


NATIONAL INSTITUTES OF HEALTH

CUMULATED INDEX MEDICUS

1997

VOLUME 38 BOOK 19

BIBLIOGRAPHY OF MEDICAL REVIEWS

I–Z

U.S. DEPARTMENT OF HEALTH
AND HUMAN SERVICES
Public Health Service
National Institutes of Health

NATIONAL LIBRARY OF MEDICINE
8600 Rockville Pike
Bethesda, MD 20894
NIH Publication Number: 98-259

ISSN: 0090-1423

Cumulated Index Medicus

© All or portions of this publication are protected against copying or other reproduction outside of the United States in accordance with the provisions of Article II of the Universal Copyright Convention.

National Library of Medicine Cataloging in Publication

Cumulated Index medicus.
Vol. 1 (Jan.-Dec. 1960)-
--Chicago : American Medical Association ; Washington, D.C. : Supt. of Docs., U.S. G.P.O. [distributor], 1961-
v.

Vols. for 1971-1978 issued as DHEW publication ; no. (NIH) 72-259, etc.; for 1979- as NIH publication ; no. 80-259, etc.
Annual cumulation of the monthly issues of Index medicus.
Continues: Quarterly cumulative Index medicus.
Issues for 1967- include Bibliography of medical reviews.
Vols. for 1965- issued by the National Library of Medicine.

1. Bibliography of Medicine 2. Medicine - indexes I. American Medical Association II. National Library of Medicine (U.S.). III. Bibliography of medical reviews IV. Index medicus V. Series: DHEW publication ; no. (NIH) 72-259, etc. VI. Series: NIH publication ; no. 80-259, etc.

ISSN 0090-1423 = Cumulated Index medicus.

ZW 1 I384



This book is printed on acid-free paper for permanence.

Use of funds for printing this periodical has been approved by the Director of the Office of Management and Budget through September 30, 1998.

For sale by the U.S. Government Printing Office
Superintendent of Documents, Mail Stop: SSOP, Washington, DC 20402-9328
ISBN 0-16-049542-3

CUMULATED INDEX MEDICUS 1997

CONTENTS

BOOK 1

Preface v
Index Medicus Citation Format vii
Introduction viii
Materials Indexed viii
The Indexing Operation viii
Subject Headings viii
Subject Heading Changes ix
Arrangement ix
Subject Section ix
Author Section xi
Bibliography of Medical Reviews xi
Access to Articles Cited xii
Interlibrary Loan Policy xii
Other Resources xiv
National Network of Libraries of Medicine xiv
International MEDLARS/MEDLINE Centers xv

MEDICAL SUBJECT HEADINGS (Contents) I-3
Medical Subject Headings 1

JOURNALS INDEXED Abbreviation Listing 1429
Full Title Listing 1529

BOOK 2 Subject Index **A-Ars** 1609

BOOK 3 Subject Index **Art-Cas** 3447

BOOK 4 Subject Index **Cat-De** 5280

BOOK 5 Subject Index **Df-Fil** 7174

BOOK 6 Subject Index **Fim-His** 9065

BOOK 7 Subject Index **Hit-Lh** 10920

BOOK 8 Subject Index **Li-Mu** 12782

BOOK 9 Subject Index **Mv-Pep** 14625

BOOK 10 Subject Index **Per-Rea** 16435

BOOK 11 Subject Index **Reb-St** 18189

BOOK 12 Subject Index **Su-Z** 20080

BOOK 13 Author Index **A-Dif** 21921

BOOK 14 Author Index **Dig-Jeq** 23938

BOOK 15 Author Index **Jer-Mor** 25951

BOOK 16 Author Index **Mos-She** 27971

BOOK 17 Author Index **Shf-Z** 29991

BOOK 18 Bibliography of Medical Reviews **A-H** 1

BOOK 19 Bibliography of Medical Reviews **I-Z** 1177

24(12):904–7 (13 ref.) (Eng. Abstr.) **(Fre)**
[What role should hysterectomy play in benign uterine lesions?] Cosson M, et al. **Contracept Fertil Sex** 1997 Feb; 25(2):112–9 (42 ref.) (Eng. Abstr.) **(Fre)**
[Dare to perform the surgery vaginally! Vagina hysterectomy is to be prefered when there is no indication for the abdominal intervention] Ottosen C. **Lakartidningen** 1997 Jun 4;94(23):2183–6 (115 ref.) **(Swe)**

ADVERSE EFFECTS

Complications of hysterectomy. Hill DJ.
Baillieres Clin Obstet Gynaecol 1997 Mar;11(1):181–97 (70 ref.)
Bladder, bowel and sexual function after hysterectomy for benign conditions. Thakar R, et al.
Br J Obstet Gynaecol 1997 Sep;104(9):983–7 (41 ref.)
Use of the omental J-flap for prevention of postoperative complications following radical abdominal hysterectomy: report of 140 cases and literature review. Patsner B, et al. **Gynecol Oncol** 1997 Jun;65(3):405–7 (16 ref.)
Omental herniation through a 5-mm laparoscopic cannula site. Toub DB, et al. **J Am Assoc Gynecol Laparosc** 1994 Aug;1(4 Pt 1):413–4 (4 ref.)

ECONOMICS

Laparoscopic and abdominal hysterectomy: a cost comparison [see comments] Tsaltas J, et al. **Med J Aust** 1997 Feb 17;166(4):205–7 (23 ref.) Comment in: Med J Aust 1997 Feb 17;166(4):172–3. Comment in: Med J Aust 1997 Aug 4;167(3):170; discussion 170–1.

METHODS

Laparoscopic radical hysterectomy for cervical cancer. Canis M, et al. **Baillieres Clin Obstet Gynaecol** 1995 Dec; 9(4):675–89 (20 ref.)
Total abdominal hysterectomy. Cliby WA.
Baillieres Clin Obstet Gynaecol 1997 Mar;11(1):77–94 (15 ref.)
Comparison of hysterectomy techniques and cost-benefit analysis. Garry R. **Baillieres Clin Obstet Gynaecol** 1997 Mar;11(1):137–48 (13 ref.)
Laparoscopic anatomy and dissection of the pelvis. Kadar N. **Baillieres Clin Obstet Gynaecol** 1997 Mar;11(1):37–60 (8 ref.)
Radical hysterectomy. Webb MJ.
Baillieres Clin Obstet Gynaecol 1997 Mar;11(1):149–66 (28 ref.)
Laparoscopic hysterectomy. Wood C, et al.
Baillieres Clin Obstet Gynaecol 1997 Mar;11(1):111–36 (62 ref.)
Laparoscopic management of gynecological malignancies. Kadar N. **Curr Opin Obstet Gynecol** 1997 Aug;9(4):247–55 (52 ref.)
Endoscopic surgery: yes, but ... [editorial; comment] Magos AL. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):243–5 (19 ref.) Comment on: Curr Opin Obstet Gynecol 1996 Aug;8(4):281–9.
Hysteroscopic management of menstrual disorders: a review of 395 patients. Cravello L, et al.
Eur J Obstet Gynecol Reprod Biol 1996 Aug;67(2):163–7 (24 ref.)
Fertility after hysteroscopic myomectomy. Ubaldi F, et al. **Hum Reprod Update** 1995 Jan;1(1):81–90 (77 ref.)
Laparoscopic and abdominal hysterectomy: a cost comparison [see comments] Tsaltas J, et al. **Med J Aust** 1997 Feb 17;166(4):205–7 (23 ref.) Comment in: Med J Aust 1997 Feb 17;166(4):172–3. Comment in: Med J Aust 1997 Aug 4;167(3):170; discussion 170–1.
Supracervical hysterectomy: ... a time for reappraisal. Munro MG. **Obstet Gynecol** 1997 Jan;89(1):133–9 (50 ref.)
[Endometrial cancer: total simple hysterectomy or radical hysterectomy? Abdominal or vaginal route?] Elhage A, et al. **Contracept Fertil Sex** 1996 Nov;24(11):830–3 (18 ref.) (Eng. Abstr.) **(Fre)**
[Endoscopic cancer surgery--uterine and ovarian cancer] Tsubata K, et al. **Gan To Kagaku Ryoho** 1997 Mar; 24(5):551–5 (7 ref.) (Eng. Abstr.) **(Jpn)**

PSYCHOLOGY

Hysterectomy: social and psychosexual aspects. Ryan MM. **Baillieres Clin Obstet Gynaecol** 1997 Mar;11(1):23–36 (56 ref.)

TRENDS

Radical hysterectomy: current management guidelines. Helmkamp BF, et al. **Am J Obstet Gynecol** 1997 Aug; 177(2):372–4 (17 ref.)

HYSTERECTOMY, VAGINAL

Surgical management of carcinoma of the cervical stump. A case report. Maseela T, et al. **Eur J Gynaecol Oncol** 1996;17(5):381–3 (9 ref.)
Laparoscopic hysterectomy [editorial; comment] [see comments] Hall BA. **Med J Aust** 1997 Feb 17;166(4):172–3 (13 ref.) Comment on: Med J Aust 1997 Feb 17;166(4):205–7. Comment in: Med J Aust 1997 Aug 4;167(3):171.
Which route for hysterectomy? Evidence-based outcomes guide selection. Kovac SR. **Postgrad Med** 1997 Sep; 102(3):153–8 (16 ref.)
[Dare to perform the surgery vaginally! Vagina hysterectomy is to be prefered when there is no indication for the abdominal intervention] Ottosen C. **Lakartidningen** 1997 Jun 4;94(23):2183–6 (115 ref.) **(Swe)**

ADVERSE EFFECTS

Port site metastasis after laparoscopic-assisted vaginal hysterectomy for endometrial cancer: possible mechanisms and prevention. Wang PH, et al. **Gynecol Oncol** 1997 Jul; 66(1):151–5 (26 ref.)
Complications and recovery from laparoscopy-assisted vaginal hysterectomy compared with abdominal and vaginal hysterectomy [see comments] Meikle SF, et al. **Obstet Gynecol** 1997 Feb;89(2):304–11 (39 ref.) Comment in: Obstet Gynecol 1997 Jun;89(6):1050–1.

METHODS

Vaginal hysterectomy. Kovac SR.
Baillieres Clin Obstet Gynaecol 1997 Mar;11(1):95–110 (46 ref.)

STANDARDS

Laparoscopically assisted vaginal hysterectomy. A review of current issues. Young W, et al.
Int J Technol Assess Health Care 1997 Spring;13(2):368–79 (77 ref.)

HYSTERIA

Current concepts of hysteria. Merskey H.
Br J Hosp Med 1994 Jan 19–Feb 1;51(1–2):11–4 (19 ref.)

HYSTERIA, CONVERSION see **CONVERSION DISORDER**

HYSTERIA, DISSOCIATIVE see **DISSOCIATIVE DISORDERS**

HYSTERICAL NEUROSES see **HYSTERIA**

HYSTEROSALPINGOGRAPHY

The role of hysterosalpingography in the evaluation of infertility. Stovall DW. **Am Fam Physician** 1997 Feb 1; 55(2):621–8 (13 ref.)

HYSTEROSCOPY

see related
HYSTEROSALPINGOGRAPHY

Hysteroscopy or ultrasound? al-Azzawi F.
Curr Opin Obstet Gynecol 1996 Aug;8(4):246–9 (21 ref.)
Fluid balance during hysteroscopic surgery. Istre O.
Curr Opin Obstet Gynecol 1997 Aug;9(4):219–25 (68 ref.)
Uterine surgery by operative hysteroscopy. Bacskó G.
Eur J Obstet Gynecol Reprod Biol 1997 Feb;71(2):219–22 (21 ref.)
Update on transcervical sterilization. Neuwirth RS.
Int J Gynaecol Obstet 1995 Dec;51 Suppl 1:S23–8 (35 ref.)
Transcervical quinacrine sterilization: clinical experience. Sokal DC, et al. **Int J Gynaecol Obstet** 1995 Dec;51 Suppl 1:S57–69 (50 ref.)

ADVERSE EFFECTS

Anaphylactic shock during hysteroscopy using Hyskon solution: case report and review of adverse reactions and their treatment. Perlitz Y, et al. **Gynecol Obstet Invest** 1996; 41(1):67–9 (21 ref.)
Complications of hysteroscopy-their cause, prevention, and correction [see comments] Loffer FD.
J Am Assoc Gynecol Laparosc 1995 Nov;3(1):11–26 (139 ref.) Comment in: J Am Assoc Gynecol Laparosc 1995 Nov;3(1):1–2.
[Carbon dioxide embolism during hysteroscopy followed by transient blindness] Ghimouz A, et al.
Ann Fr Anesth Reanim 1996;15(2):192–5 (20 ref.) (Eng. Abstr.) **(Fre)**

INSTRUMENTATION

New methods for transcervical cannulation of the fallopian tube. Kerin JF. **Int J Gynaecol Obstet** 1995 Dec;51 Suppl 1:S29–39 (39 ref.)
Possibilities and limits of operative hysteroscopy: an update on transcervical resectoscopic uterine surgery. Brandner P, et al. **Int Surg** 1996 Jul-Sep;81(3):259–65 (66 ref.)
Eight years' experience performing procedures with flexible hysteroscopes. Marty R, et al.
J Am Assoc Gynecol Laparosc 1995 Nov;3(1):113–8 (24 ref.)

METHODS

Myomectomies by endo-uterine resection. Hallez JP.
Curr Opin Obstet Gynecol 1996 Aug;8(4):250–6 (33 ref.)
Endometrial ablation by hysteroscopic instillation of hot saline solution. Goldrath MH, et al.
J Am Assoc Gynecol Laparosc 1997 Feb;4(2):235–40 (13 ref.)
The use of low-viscosity fluids for hysteroscopy [see comments] Shirk GJ, et al.
J Am Assoc Gynecol Laparosc 1994 Nov;2(1):11–21 (69 ref.) Comment in: J Am Assoc Gynecol Laparosc 1994 Nov;2(1):1–2.
[Hysteroscopic treatment of uterine synechias. A report of 102 cases] Rogé P, et al.
J Gynecol Obstet Biol Reprod (Paris) 1996;25(1):33–40 (22 ref.) (Eng. Abstr.) **(Fre)**
[Pharmacological preparation of the endometrium in surgical hysteroscopy] Primiero FM, et al. **Clin Ter** 1996 May; 147(5):245–51 (43 ref.) (Eng. Abstr.) **(Ita)**

STANDARDS

[Can microcolpohysteroscopy be used to screen cervical lesions?] Hamou J, et al. **Contracept Fertil Sex** 1997 May; 25(5):358–62 (17 ref.) **(Fre)**

UTILIZATION

Gynecologic laparoscopy and hysteroscopy in a day clinic: trends and perspectives. Gallinat A, et al.
J Am Assoc Gynecol Laparosc 1994 Feb;1(2):103–10 (25 ref.)

HYSTRIX see **RODENTIA**

I BLOOD-GROUP SYSTEM

IMMUNOLOGY

Carbohydrate recognition by Mycoplasma pneumoniae and pathologic consequences. Feizi T, et al.
Am J Respir Crit Care Med 1996 Oct;154(4 Pt 2):S133–6 (34 ref.)

I-CELL DISEASE see **MUCOLIPIDOSIS**

IA ANTIGENS see **HISTOCOMPATIBILITY ANTIGENS CLASS II**

IA-LIKE ANTIGENS see **HISTOCOMPATIBILITY ANTIGENS CLASS II**

IA-LIKE ANTIGENS, HUMAN see **HLA-D ANTIGENS**

IAP PERTUSSIS TOXIN see **PERTUSSIS TOXINS**

IATROGENIC DISEASE

see related
DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT

Iatrogenic coronary septal artery-to-right ventricular fistula complicating percutaneous transluminal coronary angioplasty with spontaneous resolution. Youssef M, et al.
Am Heart J 1997 Feb;133(2):260–2 (9 ref.)
Antibiotic-induced iatrogenic hemobilia. Huilgol VR, et al.
Am J Gastroenterol 1997 Apr;92(4):706–7 (11 ref.)
Acquired hallux varus. Donley BG. **Foot Ankle Int** 1997 Sep; 18(9):586–92 (32 ref.)
Iatrogenic facial nerve injury: the role of facial nerve monitoring. Prass RL. **Otolaryngol Clin North Am** 1996 Apr;29(2):265–75 (22 ref.)
Iatrogenic lymphoproliferative disorders in nontransplantation settings. Kamel OW.
Semin Diagn Pathol 1997 Feb;14(1):27–34 (28 ref.)
[Surgical treatment of iatrogenic stenoses of the ureter. Apropos of 17 cases] Koutani A, et al. **J Urol (Paris)** 1996; 102(4):145–9 (41 ref.) (Eng. Abstr.) **(Fre)**
[Hodgkin's disease. Long-term complications of radiotherapy] Cosset JM, et al. **Presse Med** 1997 Jul 5; 26(23):1107–12 (31 ref.) **(Fre)**
[An unusual complication of anterograde endopyelotomy: ureteral intussusception (a case report)] el Khader K, et al. **Prog Urol** 1997 Apr;7(2):273–6 (14 ref.) (Eng. Abstr.) **(Fre)**
[Immunosuppression--a tightrope walk between iatrogenic harm and therapy] Berchtold P, et al.
Schweiz Med Wochenschr 1996 Sep 21;126(38):1603–9 (19 ref.) (Eng. Abstr.) **(Ger)**
[Risk-free homeopathy?] Ernst E.
Schweiz Med Wochenschr 1996 Oct 5;126(40):1677–9 (22 ref.) (Eng. Abstr.) **(Ger)**
[Nerve injuries during dental and orthodontic interventions. Their causes, incidence, sequelae and legal assessment] Hardt N, et al. **Schweiz Monatsschr Zahnmed** 1996; 106(1):31–44 (41 ref.) **(Ger, Fre)**
[Errors in trauma team work] Hirshberg A, et al.
Harefuah 1996 Dec 1;131(11):506–7 (9 ref.) **(Heb)**
[Acute iatrogenic myopathy during treatment of status asthmaticus. Our experience and review of the literature] Pacini D, et al. **Minerva Anestesiol** 1997 Mar;63(3):81–91 (45 ref.) (Eng. Abstr.) **(Ita)**

PREVENTION & CONTROL

Complications of distal first metatarsal osteotomies. Hanft J. **Clin Podiatr Med Surg** 1996 Jul;13(3):355–65 (21 ref.)
Iatrogenic deformities of the first ray. Yu GV, et al.
Clin Podiatr Med Surg 1996 Jul;13(3):367–422 (69 ref.)

VETERINARY

Medical management of iatrogenic rents in the wall of the feline urinary bladder. Osborne CA, et al.

IATROGENIC DISEASE

Vet Clin North Am Small Anim Pract 1996 May; 26(3):551–62 (6 ref.)

IBDV see **INFECTIOUS BURSAL DISEASE VIRUS**

IBOGAINE

Assessment of neurotoxicity from potential medications for drug abuse: ibogaine testing and brain imaging. Vocci FJ, et al. **Ann N Y Acad Sci** 1997 May 30;820:29–39; discussion 39–40 (42 ref.)

PHARMACOLOGY

Ibogaine and cocaine abuse: pharmacological interactions at dopamine and serotonin receptors. Sershen H, et al. **Brain Res Bull** 1997;42(3):161–8 (77 ref.)

IBOTENIC ACID

PHARMACOLOGY

Developmental spectrum of the excitotoxic cascade induced by ibotenate: a model of hypoxic insults in fetuses and neonates. Gressens P, et al. **Neuropathol Appl Neurobiol** 1996 Dec;22(6):498–502 (22 ref.)

IBR-IPV VIRUS see **HERPESVIRUS 1, BOVINE**

IBUPROFEN

ADMINISTRATION & DOSAGE

[Focus on the safety of ibuprofen at the analgesic-antipyretic dose] Moore N, et al. **Therapie** 1996 Jul–Aug;51(4):458–63 (13 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Ibuprofen and paracetamol: relative safety in non-prescription dosages. Rainsford KD, et al. **J Pharm Pharmacol** 1997 Apr;49(4):345–76 (234 ref.)

[Focus on the safety of ibuprofen at the analgesic-antipyretic dose] Moore N, et al. **Therapie** 1996 Jul–Aug;51(4):458–63 (13 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Pharmacodynamics and pharmacokinetics of the profens: enantioselectivity, clinical implications, and special reference to S(+)-ibuprofen. Evans AM. **J Clin Pharmacol** 1996 Dec;36(12 Suppl):7S–15S (54 ref.)

THERAPEUTIC USE

Experimental evaluation of the analgesic effect of ibuprofen on primary and secondary hyperalgesia. Petersen KL, et al. **Pain** 1997 Apr;70(2–3):167–74 (50 ref.)

ICAM-1 see **INTERCELLULAR ADHESION MOLECULE-1**

ICE

The nature and evolution of interstellar ices. Chiar JE. **Orig Life Evol Biosph** 1997 Jun;27(1–3):79–100 (95 ref.)

ICE SKATING see **SKATING**

ICHTHYOSIS

Acute lymphoblastic leukemia in a child with the CHIME neuroectodermal dysplasia syndrome. Schnur RE, et al. **Am J Med Genet** 1997 Oct 3;72(1):24–9 (13 ref.)

COMPLICATIONS

Psoriasis, ichthyosis, and porphyria. Steiner G, et al. **Int Ophthalmol Clin** 1997 Spring;37(2):41–61 (71 ref.)

DIAGNOSIS

[Keratotic neurocutaneous syndromes] Tercedor J, et al. **Rev Neurol** 1997 Sep;25 Suppl 3:S238–42 (34 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Inherited ichthyoses: a review of the histology of the skin. Scheimberg I, et al. **Pediatr Pathol Lab Med** 1996 May–Jun; 16(3):359–78 (86 ref.)

PATHOLOGY

Pityriasis rotunda. Pinto GM, et al. **Cutis** 1996 Dec; 58(6):406–8 (20 ref.)

Keratitis, ichthyosis, and deafness (KID syndrome): review of the literature and proposal of a new terminology [see comments] Caceres-Rios H, et al. **Pediatr Dermatol** 1996 Mar–Apr;13(2):105–13 (68 ref.) Comment in: Pediatr Dermatol 1996 Mar–Apr;13(2):154–7.

Inherited ichthyoses: a review of the histology of the skin. Scheimberg I, et al. **Pediatr Pathol Lab Med** 1996 May–Jun; 16(3):359–78 (86 ref.)

THERAPY

[The value of oil baths for adjuvant basic therapy of inflammatory dermatoses with dry, barrier-disrupted skin] Melnik B, et al. **Hautarzt** 1996 Sep;47(9):665–72 (62 ref.) (Eng. Abstr.) **(Ger)**

ICI-46474 see **TAMOXIFEN**

ICI-66082 see **ATENOLOL**

ICOSAHEDRAL CYTOPLASMIC DEOXYRIBOVIRUSES see **IRIDOVIRIDAE**

ICRF-159 see **RAZOXANE**

ICSH see **LH**

ICSH RECEPTORS see **RECEPTORS, LH**

ICTALURIDAE

IMMUNOLOGY

Fish immunology: the utility of immortalized lymphoid cells--a mini review. Clem LW, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):137–44 (29 ref.)

ICTALURUS see **ICTALURIDAE**

ICTERUS see **JAUNDICE**

ICTERUS GRAVIS NEONATORUM see **ERYTHROBLASTOSIS, FETAL**

IDARUBICIN

ADMINISTRATION & DOSAGE

[Oral idarubicin in treatment of advanced breast carcinoma] Kerpel-Fronius S, et al. **Zentralbl Gynakol** 1996; 118(10):587–9 (5 ref.) (Eng. Abstr.) **(Ger)**

[Antileukemic agents--new drugs and attempts of rational administration] Ueda T. **Rinsho Ketsueki** 1996 Aug; 37(8):635–9 (16 ref.) **(Jpn)**

PHARMACOLOGY

Oral idarubicin. A review of its pharmacological properties and clinical efficacy in the treatment of haematological malignancies and advanced breast cancer. Buckley MM, et al. **Drugs Aging** 1997 Jul;11(1):61–86 (125 ref.)

Idarubicin: a brief overview on pharmacology and clinical use. Borchmann P, et al. **Int J Clin Pharmacol Ther** 1997 Feb;35(2):80–3 (30 ref.)

THERAPEUTIC USE

Oral idarubicin. A review of its pharmacological properties and clinical efficacy in the treatment of haematological malignancies and advanced breast cancer. Buckley MM, et al. **Drugs Aging** 1997 Jul;11(1):61–86 (125 ref.)

Idarubicin: a brief overview on pharmacology and clinical use. Borchmann P, et al. **Int J Clin Pharmacol Ther** 1997 Feb;35(2):80–3 (30 ref.)

A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan. Tamura K. **Semin Hematol** 1996 Oct;33(4 Suppl 3):2–11 (21 ref.)

IDDM see **DIABETES MELLITUS, INSULIN-DEPENDENT**

IDENTIFICATION (PSYCHOLOGY)

Patterns of life: intertwining identity and cognition. Varela FJ. **Brain Cogn** 1997 Jun;34(1):72–87 (14 ref.)

The role of mania in the genesis of dangerous delusional misidentification. Silva JA, et al. **J Forensic Sci** 1997 Jul; 42(4):670–4 (39 ref.)

IDENTIFICATION, SOCIAL see **SOCIAL IDENTIFICATION**

IDIOCY see **MENTAL RETARDATION**

IDIOPATHIC HYPERCATABOLIC HYPOPROTEINEMIA see **PROTEIN-LOSING ENTEROPATHIES**

IDIOPATHIC HYPEREOSINOPHILIC SYNDROME see **HYPEREOSINOPHILIC SYNDROME**

IDIOPATHIC HYPERTROPHIC SUBAORTIC STENOSIS see **CARDIOMYOPATHY, HYPERTROPHIC**

IDIOPATHIC HYPERTROPHIC SUBVALVULAR STENOSIS see **CARDIOMYOPATHY, HYPERTROPHIC**

IDIOPATHIC INTRACRANIAL HYPERTENSION see **PSEUDOTUMOR CEREBRI**

IDIOPATHIC THROMBOCYTOPENIC PURPURA see **PURPURA, THROMBOCYTOPENIC, IDIOPATHIC**

IDIOTYPES, IMMUNOGLOBULIN see **IMMUNOGLOBULIN IDIOTYPES**

IDOXURIDINE

DIAGNOSTIC USE

Radiolabeled nucleoside analogs in cancer diagnosis and therapy. Kassis AI, et al. **Q J Nucl Med** 1996 Sep; 40(3):301–19 (93 ref.)

THERAPEUTIC USE

Radiolabeled nucleoside analogs in cancer diagnosis and therapy. Kassis AI, et al. **Q J Nucl Med** 1996 Sep; 40(3):301–19 (93 ref.)

IGA

Molecular biology and vaccine aspects of bacterial immunoglobulin A1 proteases. Lomholt H. **APMIS Suppl** 1996;62:5–28 (125 ref.)

ANALYSIS

Linear IgA disease in a patient with bladder carcinoma. Ródenas JM, et al. **Br J Dermatol** 1997 Feb;136(2):257–9 (26 ref.)

Solitary IgA myeloma of the foot. A case report and review of the literature. Khoddami M, et al. **J Am Podiatr Med Assoc** 1997 May;87(5):233–7 (24 ref.)

BIOSYNTHESIS

Origin and structure of pathogenic IgA in IgA nephropathy. Allen A, et al. **Biochem Soc Trans** 1997 May;25(2):486–90 (34 ref.)

Mucosal immunoglobulins and their contribution to defence mechanisms: an overview. Mestecky J, et al. **Biochem Soc Trans** 1997 May;25(2):457–62 (52 ref.)

[Immune mechanism of mucous membrane and mucous membrane vaccines: Expression of level 1 and 2 Th2-type cytokine and IgA immune response] Kiyono H. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):690 (0 ref.) **(Jpn)**

BLOOD

Recurrence of immunoglobulin A nephropathy with immunoglobulin A antineutrophil cytoplasmic antibodies following renal transplantation. Martin SJ, et al. **Am J Kidney Dis** 1997 Jan;29(1):125–31 (29 ref.)

Detection of IgA anti-P30 (SAG1) antibodies in acquired and congenital toxoplasmosis. Decoster A. **Curr Top Microbiol Immunol** 1996;219:199–207 (54 ref.)

CHEMISTRY

Origin and structure of pathogenic IgA in IgA nephropathy. Allen A, et al. **Biochem Soc Trans** 1997 May;25(2):486–90 (34 ref.)

Immunoglobulin A--alpha-1-antitrypsin complex in rheumatic diseases. Łącki JK, et al. **Mater Med Pol** 1996 Oct–Dec;28(4):138–40 (21 ref.)

IMMUNOLOGY

Structure and function in IgA. Hexham JM, et al. **Chem Immunol** 1997;65:73–87 (113 ref.)

IgA nephropathy--a disorder of IgA production? Feehally J. **QJM** 1997 Jun;90(6):387–90 (25 ref.)

IgA nephropathy--human disease and animal model. Endo Y. **Ren Fail** 1997 May;19(3):347–71 (193 ref.)

Yin and Yang of mucosal immunology. Mayer L. **Transplant Proc** 1996 Oct;28(5):2435–7 (22 ref.)

METABOLISM

Structure and function of human IgA Fc receptors (Fc alpha R). Morton HC, et al. **Crit Rev Immunol** 1996;16(4):423–40 (155 ref.)

PHARMACOLOGY

Structure and function in IgA. Hexham JM, et al. **Chem Immunol** 1997;65:73–87 (113 ref.)

PHYSIOLOGY

IgA antibody as a non-inflammatory regulator of immunity. Russell MW, et al. **Biochem Soc Trans** 1997 May; 25(2):466–70 (45 ref.)

Complement in IgA immune-complex-induced neutrophil activation. Zhang W, et al. **Biochem Soc Trans** 1997 May; 25(2):462–6 (28 ref.)

IGA DEFICIENCY

COMPLICATIONS

IgA deficiency and SLE: prevalence in a clinic population and a review of the literature. Rankin EC, et al. **Lupus** 1997;6(4):390–4 (37 ref.)

DIAGNOSIS

[Primary thrombocythemia in a female carrier of IgA deficiency] Guzzini F, et al. **Recenti Prog Med** 1996 Oct;

87(10):476–9 (20 ref.) (Eng. Abstr.) **(Ita)**

EPIDEMIOLOGY

IgA deficiency and SLE: prevalence in a clinic population and a review of the literature. Rankin EC, et al. **Lupus** 1997;6(4):390–4 (37 ref.)

ETIOLOGY

IgA deficiency. Burrows PD, et al. **Adv Immunol** 1997; 65:245–76 (350 ref.)

IGA, EXOCRINE see **IGA, SECRETORY**

IGA GLOMERULONEPHRITIS see **GLOMERULONEPHRITIS, IGA**

IGA NEPHROPATHY see **GLOMERULONEPHRITIS, IGA**

IGA, SECRETORY

[Molecular aspects of secretory IgA (S-IgA) in gut-associated lymphoid tissues] Moro I, et al. **Nippon Rinsho** 1996 Apr;54(4):1155–61 (21 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

B-1 cells and their reactivity with the murine intestinal microflora. Kroese FG, et al. **Semin Immunol** 1996 Feb; 8(1):11–8 (52 ref.)

THERAPEUTIC USE

Recombinant secretory IgA for immune intervention against mucosal pathogens. Corthésy B. **Biochem Soc Trans** 1997 May;25(2):471–5 (27 ref.)

IGD

ANALYSIS

[Hyperimmunoglobulinemia D—a new periodic syndrome with features simulating familial Mediterranean fever] Livneh A, et al. **Harefuah** 1996 Oct;131(7–8):283–4 (18 ref.) **(Heb)**

BLOOD

Temporal artery involvement revealing AL amyloidosis and IgD monoclonal gammopathy. Rodon P, et al. **J Rheumatol** 1996 Jan;23(1):189–90 (17 ref.)

[The hyper-IgD syndrome] Drenth JP, et al. **Dtsch Med Wochenschr** 1996 Oct 18;121(42):1299–300 (13 ref.) **(Ger)**

IGE

see related
RECEPTORS, IGE

IgE lambda monoclonal gammopathy and amyloidosis. Jako JM, et al. **Int Arch Allergy Immunol** 1997 Apr;112(4):415–21 (49 ref.)

ANALYSIS

Immunological outcome measures. Björkstén B. **Eur Respir J Suppl** 1996 Apr;21:22s–27s (26 ref.)

Renaturation of blotted allergens increases the sensitivity of specific IgE detection. Muro MD, et al. **J Investig Allergol Clin Immunol** 1996 May-Jun;6(3):166–71 (36 ref.)

Diagnostic reliability considerations of specific IgE determination. Sanz ML, et al. **J Investig Allergol Clin Immunol** 1996 May-Jun;6(3):152–61 (36 ref.)

BIOSYNTHESIS

Allergen dose dependent cytokine production regulates specific IgE and IgG antibody production. Blaser K. **Adv Exp Med Biol** 1996;409:295–303 (16 ref.)

Regulation of human IgE synthesis. Bonnefoy JY, et al. **Ann N Y Acad Sci** 1996 Oct 31;796:59–71 (91 ref.)

Regulation of the expression of distinct human secreted IgE proteins produced by alternative RNA splicing. Saxon A, et al. **Biochem Soc Trans** 1997 May;25(2):383–7 (14 ref.)

Pairs of surface molecules involved in human IgE regulation: CD23–CD21 and CD40–CD40L. Bonnefoy JY, et al. **Eur Respir J Suppl** 1996 Aug;22:63s–66s (48 ref.)

Modulation of the human IgE response. de Vries JE, et al. **Eur Respir J Suppl** 1996 Aug;22:58s–62s (35 ref.)

Role of IL-4 in persistent IgE formation. Savelkoul HF, et al. **Eur Respir J Suppl** 1996 Aug;22:67s–71s (32 ref.)

Involvement of nuclear factor-kappa B activation in IgE synthesis in human B cells. Yanagihara Y, et al. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 2):S224–9 (38 ref.)

Molecular regulation of human IgE synthesis. Worm M, et al. **J Mol Med** 1997 Jun;75(6):440–7 (68 ref.)

[Molecular mechanisms for immunoglobulin class switching and IgE production] Shimizu A. **Nippon Rinsho** 1996 Feb; 54(2):440–5 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Regulation of Ige synthesis and cytokines in selected allergic diseases] Michałkiewicz J, et al. **Pediatr Pol** 1996 Jan; 71(1):47–56 (38 ref.) (Eng. Abstr.) **(Pol)**

[Genetic factors and environmental factors regulating synthesis of immunoglobulin E] Dziedziczko A, et al. **Pneumonol Alergol Pol** 1997;65(1–2):113–22 (39 ref.) **(Pol)**

[The discovery of IgE and its importance for allergologists] Johansson SG. **Nord Med** 1997 Apr;112(4):115–8 (15 ref.) (Eng. Abstr.) **(Swe)**

BLOOD

[Pathogenetic significance of IgE-binding epitopes allergens (published erratum appears in Pneumologie 1996 Dec;50(12):938)] Bufe A, et al. **Pneumologie** 1996 Sep; 50(9):625–31 (55 ref.) **(Ger)**

[Summer-type hypersensitivity pneumonitis in a patient with a positive skin test (15 minutes) for Trichosporon mucoides and a high serum IgE level] Nakajima M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Oct; 34(10):1168–73 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Blood eosinophilia and immunoglobulin E: the characteristics of their regulation in helminthiases and allergic diseases (editorial)] Ozeretskovskaia NN. **Med Parazitol (Mosk)** 1997 Apr-Jun;(2):3–9 (96 ref.) (Eng. Abstr.) **(Rus)**

DIAGNOSTIC USE

Some limitations in the use of specific IgE in the diagnosis of food hypersensitivity. Bindslev-Jensen C, et al. **Monogr Allergy** 1996;32:216–20 (6 ref.)

GENETICS

Mapping the genes for IgE production and allergy. Marsh DG. **Adv Exp Med Biol** 1996;409:43–53 (49 ref.)

Immunogenetics of human IgE. Snow RE, et al. **Hum Antibodies Hybridomas** 1996;7(4):157–66 (55 ref.)

[Genetic factors and environmental factors regulating synthesis of immunoglobulin E] Dziedziczko A, et al. **Pneumonol Alergol Pol** 1997;65(1–2):113–22 (39 ref.) **(Pol)**

HISTORY

Discovery and development of IgE assays. Johansson SG. **Clin Exp Allergy** 1997 May;27 Suppl 1:60–3 (15 ref.)

IMMUNOLOGY

Anti-idiotypic antibodies in the treatment of allergies. Hébert J, et al. **Adv Exp Med Biol** 1996;409:431–7 (39 ref.)

Is vaccination against IgE possible? Hellman L. **Adv Exp Med Biol** 1996;409:337–42 (18 ref.)

Controversial issues and possible answers on the antigen-specific regulation of the IgE antibody response. Ishizaka K, et al. **Adv Exp Med Biol** 1996;409:317–25 (23 ref.)

Peanut hypersensitivity. IgE binding characteristics of a recombinant Ara h I protein. Stanley JS, et al. **Adv Exp Med Biol** 1996;409:213–6 (13 ref.)

The roles of CD40 and CD23 in IgE regulation. Yasui T, et al. **Adv Exp Med Biol** 1996;409:349–54 (28 ref.)

Nasal polyps and immunoglobulin E (IgE). Settipane GA. **Allergy Asthma Proc** 1996 Sep-Oct;17(5):269–73 (28 ref.)

Antigen-mediated IGE receptor aggregation and signaling: a window on cell surface structure and dynamics. Holowka D, et al. **Annu Rev Biophys Biomol Struct** 1996;25:79–112 (149 ref.)

The basis of IgE responses to specific antigenic determinants in helminthiasis. Lobos E. **Chem Immunol** 1997;66:1–25 (126 ref.)

Latex allergy. Wooding LG, et al. **Compr Ther** 1996 Jun; 22(6):384–92 (30 ref.)

Anti-IgE and anti-Fc epsilon RI autoantibodies in clinical allergy. Fiebiger E, et al. **Curr Opin Immunol** 1996 Dec; 8(6):784–9 (40 ref.)

Atopy and the ectopic immune response. Aalberse RC. **Immunol Cell Biol** 1996 Apr;74(2):201–5 (36 ref.)

IgE, allergies and helminth parasites: a new perspective on an old conundrum. Bell RG. **Immunol Cell Biol** 1996 Aug; 74(4):337–45 (81 ref.)

Antigen presentation in allergic sensitization. Mudde GC, et al. **Immunol Cell Biol** 1996 Apr;74(2):167–73 (52 ref.)

Anti-IgE in allergic sensitization. Stadler BM, et al. **Immunol Cell Biol** 1996 Apr;74(2):195–200 (51 ref.)

Complement and Fc-receptors in regulation of the antibody response. Heyman B. **Immunol Lett** 1996 Dec;54(2–3):195–9 (68 ref.)

Regulation of IgE synthesis. Lessons from the study of IgE transgenic and CD23-deficient mice. Lamers MC, et al. **Immunol Rev** 1995 Dec;148:71–95 (74 ref.)

IgE-mediated allergen presentation via Fc epsilon RI on antigen-presenting cells. Stingl G, et al. **Int Arch Allergy Immunol** 1997 May-Jul;113(1–3):24–9 (46 ref.)

Diagnostic reliability considerations of specific IgE determination. Sanz ML, et al. **J Investig Allergol Clin Immunol** 1996 May-Jun;6(3):152–61 (36 ref.)

Oral desensitization with cow's milk in IgE-mediated cow's milk allergy. Contraí Bahna SL. **Monogr Allergy** 1996; 32:233–5 (17 ref.)

Some limitations in the use of specific IgE in the diagnosis of food hypersensitivity. Bindslev-Jensen C, et al. **Monogr Allergy** 1996;32:216–20 (6 ref.)

Oral desensitization with cow's milk in cow's milk allergy. Pro! Wüthrich B. **Monogr Allergy** 1996;32:236–40 (10 ref.)

METABOLISM

Structure-based design of peptides that inhibit IgE binding to its high-affinity receptor Fc epsilon RI. McDonnell JM, et al. **Biochem Soc Trans** 1997 May;25(2):387–92 (34 ref.)

[Mechanism and regulation of IgE production in allergy] Kurasawa K, et al. **Nippon Rinsho** 1996 Feb;54(2):434–9 (22 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

The low-affinity receptor for IgE (Fc epsilon RII or CD23) as a therapeutic target. Conrad DH, et al. **Biochem Soc Trans** 1997 May;25(2):393–7 (28 ref.)

Regulation of IgE and cytokine production by cAMP: implications for extrinsic asthma. Fedyk ER, et al. **Clin Immunol Immunopathol** 1996 Nov;81(2):101–13 (112 ref.)

IGE-MEDIATED HYPERSENSITIVITY see **HYPERSENSITIVITY, IMMEDIATE**

IGE RECEPTORS see **RECEPTORS, IGE**

IGF-BINDING PROTEIN 1 see **INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN 1**

IGF-BINDING PROTEIN 2 see **INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 2**

IGF-BINDING PROTEIN 3 see **INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3**

IGF-BINDING PROTEIN 4 see **INSULIN LIKE GROWTH-FACTOR-BINDING PROTEIN 4**

IGF-BINDING PROTEIN 5 see **INSULIN-LIKE GROWTH-FACTOR-BINDING-PROTEIN 5**

IGF-BINDING PROTEINS see **INSULIN-LIKE GROWTH-FACTOR-BINDING PROTEINS**

IGF-I see **INSULIN-LIKE GROWTH FACTOR I**

IGF-I RECEPTORS see **RECEPTORS, INSULIN-LIKE-GROWTH FACTOR I**

IGF-II see **INSULIN-LIKE GROWTH FACTOR II**

IGF-II RECEPTORS see **RECEPTORS, INSULIN-LIKE-GROWTH-FACTOR II**

IGFBP see **INSULIN-LIKE GROWTH-FACTOR-BINDING PROTEINS**

IGFBP-1 see **INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN 1**

IGFBP-2 see **INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 2**

IGFBP-3 see **INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3**

IGFBP-4 see **INSULIN LIKE GROWTH-FACTOR-BINDING PROTEIN 4**

IGFBP-5 see **INSULIN-LIKE GROWTH-FACTOR-BINDING-PROTEIN 5**

IGG

see related
RECEPTORS, IGG

Advances in the treatment of plasma cell diseases. Comenzo RL. **Hosp Pract (Off Ed)** 1996 Aug 15;31(8):67–70, 73–4, 79–84 passim (11 ref.)

[Induction of biological activities by chemically modified subfragments from human serum IgG and their application to development of medicine] Mimura T. **Yakugaku Zasshi** 1996 May;116(5):374–87 (43 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

Pemphigoid nodularis: a report of three cases and review of the literature. Cliff S, et al. **Br J Dermatol** 1997 Mar; 136(3):398–401 (14 ref.)

IgG subclasses in neurological disorders. Losy J, et al. **Neurol Neurochir Pol** 1996;30 Suppl 2:17–24 (16 ref.)

[A "not-so-benign" monoclonal gammopathy! Corneal deposits of immunoglobulins (letter)] Duarte F, et al. **Ann Med Interne (Paris)** 1996;147(6):453–5 (12 ref.) **(Fre)**

BIOSYNTHESIS

Allergen dose dependent cytokine production regulates specific IgE and IgG antibody production. Blaser K.

Adv Exp Med Biol 1996;409:295–303 (16 ref.)
Unique site of IgG2a and rheumatoid factor production in MRL/lpr mice. Jacobson BA, et al. **Immunol Rev** 1997 Apr;156:103–10 (65 ref.)
SCID–hu–PBL: a model for making human antibodies? Ifversen P, et al. **Semin Immunol** 1996 Aug;8(4):243–8 (51 ref.)

BLOOD

Amyotrophic lateral sclerosis and antibodies to voltage–gated calcium channels—new doubts [editorial; comment] Vincent A, et al. **Ann Neurol** 1996 Nov;40(5):691–3 (15 ref.) Comment on: Ann Neurol 1996 Nov;40(5):695–700. Comment on: Ann Neurol 1996 Nov;40(5):701–6.
Anti–alpha–galactoside antibody of the human plasma. Appukuttan PS. **Indian J Biochem Biophys** 1996 Jun; 33(3):159–63 (37 ref.)
Lyme borreliosis—problems of serological diagnosis. Hofmann H. **Infection** 1996 Nov–Dec;24(6):470–2 (8 ref.)
Autoimmune hemolytic anemia with warm antibodies complicated with an intercurrent attack of hemolysis with cold agglutinins in a case of Waldenström disease. Gologan R, et al. **Rom J Intern Med** 1996 Jan–Jun;34(1–2):149–54 (30 ref.)

CHEMISTRY

T cell receptor biochemistry, repertoire selection and general features of TCR and Ig structure. Davis MM, et al. **Ciba Found Symp** 1997;204:94–100; discussion 100–4 (21 ref.)

CLASSIFICATION

IgG subclasses of human autoantibodies. Maran R, et al. **Ann Med Interne (Paris)** 1997;148(1):29–38 (113 ref.)
Significance of aPL IgG subclasses. Sammaritano LR. **Lupus** 1996 Oct;5(5):436–9 (19 ref.)

DIAGNOSTIC USE

Specific IgG antibodies as markers of adverse reactions to foods. Marinkovich V. **Monogr Allergy** 1996;32:221–5 (7 ref.)
Specific IgG antibodies as markers of adverse reactions to food. Contra! Wüthrich B. **Monogr Allergy** 1996;32:226–7 (10 ref.)

IMMUNOLOGY

IgG subclasses and chronic bacterial infection. Subclass antibodies and the clinical course of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. Pressler T. **APMIS Suppl** 1996;66:1–41 (192 ref.)
IgG effector mechanisms. Clark MR. **Chem Immunol** 1997; 65:88–110 (89 ref.)
Monoclonal corneal gammopathy: topographic considerations. Sekundo W, et al. **Ger J Ophthalmol** 1996 Sep;5(5):262–7 (29 ref.)
Complement and Fc–receptors in regulation of the antibody response. Heyman B. **Immunol Lett** 1996 Dec;54(2–3):195–9 (68 ref.)
Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG [published erratum appears in Immunol Res 1997;16(2):215] Junghans RP. **Immunol Res** 1997 Feb; 16(1):29–57 (108 ref.)
Are IgG antibody avidity assays useful in the diagnosis of infectious diseases? A review. Gutiérrez J, et al. **Microbios** 1996;87(351):113–21 (40 ref.)
Specific IgG antibodies as markers of adverse reactions to foods. Marinkovich V. **Monogr Allergy** 1996;32:221–5 (7 ref.)
[The diagnostic value of IgG galactosylation in rheumatoid arthritis] Kelemen J, et al. **Orv Hetil** 1997 Jun 15; 138(24):1577–8 (25 ref.) (Eng. Abstr.) **(Hun)**

METABOLISM

Human placental Fc gamma–binding proteins in the maternofetal transfer of IgG. Kristoffersen EK. **APMIS Suppl** 1996;64:5–36 (375 ref.)
New functions of the MHC class I–related Fc receptor, FcRn. Simister NE, et al. **Biochem Soc Trans** 1997 May; 25(2):481–6 (70 ref.)

PHARMACOLOGY

IgG effector mechanisms. Clark MR. **Chem Immunol** 1997; 65:88–110 (89 ref.)

PHYSIOLOGY

Heparin–induced thrombocytopenia: IgG–mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin–induced thrombocytopenia. Warkentin TE. **Transfus Med Rev** 1996 Oct;10(4):249–58 (41 ref.)

IGG RECEPTORS see **RECEPTORS, IGG**

IGM

Schnitzler's syndrome: report of a new case and a review of the literature. Puddu P, et al. **Clin Exp Rheumatol** 1997 Jan–Feb;15(1):91–5 (32 ref.)
[Attempt at preventing hyperacute xenogenic rejection by isotopic suppression of IgM in the recipient] Pitre J, et al. **Ann Chir** 1996;50(7):524–31 (37 ref.) (Eng. Abstr.) **(Fre)**
[Peripheral neuropathies associated with IgM monoclonal gammopathy: clinical and electrophysiological aspects] Léger JM, et al. **Rev Neurol (Paris)** 1996 May;152(5):394–9 (37 ref.) (Eng. Abstr.) **(Fre)**
[Treatment of peripheral neuropathies associated with IgM anti–myelin monoclonal gammopathy] Mariette X, et al. **Rev Neurol (Paris)** 1996 May;152(5):413–6 (23 ref.) (Eng. Abstr.) **(Fre)**
[Role of LFA–1/ICAM–1–dependent cell adhesion in CD40–mediated inhibition of anti–IgM antibody–induced B–cell death] Sumimoto S, et al. **Nippon Rinsho** 1996 Jul; 54(7):1779–83 (12 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Pairs of surface molecules involved in human IgE regulation: CD23–CD21 and CD40–CD40L. Bonnefoy JY, et al. **Eur Respir J Suppl** 1996 Aug;22:63s–66s (48 ref.)

BLOOD

Lyme borreliosis—problems of serological diagnosis. Hofmann H. **Infection** 1996 Nov–Dec;24(6):470–2 (8 ref.)
[Sporadic cases of hemolytic uremic syndrome and hemorrhagic colitis with serum IgM antibodies to lipopolysaccharides of enterohemorrhagic Escherichia coli O157] Shiomi M, et al. **Nippon Rinsho** 1997 Mar; 55(3):686–92 (20 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Role of antibody signaling in inducing tumor dormancy. Uhr JW, et al. **Adv Exp Med Biol** 1996;406:69–74 (32 ref.)
Complement and Fc–receptors in regulation of the antibody response. Heyman B. **Immunol Lett** 1996 Dec;54(2–3):195–9 (68 ref.)
Neuropathy associated with "benign" anti–myelin–associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases. Ellie E, et al. **J Neurol** 1996 Jan; 243(1):34–43 (43 ref.)

METABOLISM

Morphological changes at paranodes in IgM paraproteinaemic neuropathy. Jacobs JM. **Microsc Res Tech** 1996 Aug 15;34(6):544–53 (59 ref.)

PHYSIOLOGY

IgM–mediated B cell apoptosis. Mayumi M, et al. **Crit Rev Immunol** 1995;15(3–4):255–69 (148 ref.)

IKE PHAGE see **INOVIRUS**

IL–1 see **INTERLEUKIN–1**

IL–1 RECEPTORS see **RECEPTORS, INTERLEUKIN–1**

IL–2 see **INTERLEUKIN–2**

IL–2 RECEPTORS see **RECEPTORS, INTERLEUKIN–2**

IL–3 see **INTERLEUKIN–3**

IL–3 RECEPTORS see **RECEPTORS, INTERLEUKIN–3**

IL–4 see **INTERLEUKIN–4**

IL–5 see **INTERLEUKIN–5**

IL–6 see **INTERLEUKIN–6**

IL–7 see **INTERLEUKIN–7**

IL–8 see **INTERLEUKIN–8**

IL–9 see **INTERLEUKIN–9**

IL–10 see **INTERLEUKIN–10**

IL–11 see **INTERLEUKIN–11**

IL–12 see **INTERLEUKIN–12**

IL–13 see **INTERLEUKIN–13**

IL–15 see **INTERLEUKIN–15**

IL–16 see **INTERLEUKIN–16**

ILEAL CONDUIT see **URINARY DIVERSION**

ILEAL DISEASES

DIAGNOSIS

Perforation of terminal ileum diverticulitis: a case report and literature review. Krummen DM, et al. **Am Surg** 1996 Nov; 62(11):939–40 (18 ref.)
[Stenosis of the terminal ileum. Endometriosis as the differential diagnosis of Crohn's disease] Körber J, et al. **Dtsch Med Wochenschr** 1997 Jul 25;122(30):926–9 (26 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

An unusual case of small bowel obstruction. Verstocken A, et al. **Acta Chir Belg** 1996 Jul–Aug;96(4):168–9 (23 ref.)
Intussusception in an adult secondary to an inverted Meckel's diverticulum. Steinwald PM, et al. **Am Surg** 1996 Nov; 62(11):889–94 (20 ref.)
Acute small bowel obstruction caused by endometriosis. Martín–Duce A, et al. **Eur J Surg** 1996 Sep;162(9):747–9 (41 ref.)
Strangulation ileus resulting from encasement of a loop of the small intestine by the great omentum, caused by abnormal adhesion. Kimura H, et al. **J Gastroenterol** 1996 Oct;31(5):714–6 (8 ref.)
Ileal perforation caused by congenital or perinatal cytomegalovirus infection [see comments] Huang YC, et al. **J Pediatr** 1996 Dec;129(6):931–4 (17 ref.) Comment in: J Pediatr 1997 Jul;131(1 Pt 1):168–70.
An endoscopic diagnosis of appendicular intussusception in chronic appendicitis. Nyam DC, et al. **Singapore Med J** 1997 Mar;38(3):131 (10 ref.)
[A case of eosinophilic enteritis with repeated perforation of the ileum] Ikenaga M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Sep;93(9):661–5 (12 ref.) **(Jpn)**

MICROBIOLOGY

Intussusception associated with Yersinia pseudotuberculosis infection. Koo JW, et al. **Acta Paediatr** 1996 Oct; 85(10):1253–5 (12 ref.)

PATHOLOGY

Myoepithelial hamartoma of the small bowel: report of a case. Tanaka N, et al. **Surg Today** 1996;26(12):1010–3 (12 ref.)

ULTRASONOGRAPHY

Intussusception of vermiform appendix. A case report and review of the literature. Kegelaers B, et al. **Acta Chir Belg** 1996 Nov–Dec;96(6):287–90, (22 ref.)

ILEAL NEOPLASMS

Concurrent colonic adenocarcinoma and two ileal carcinoids in a 72–year–old male. Tse V, et al. **Aust N Z J Surg** 1997 Oct;67(10):739–41 (10 ref.)

COMPLICATIONS

Colonic variceal bleeding in a patient with mesenteric venous obstruction due to an ileal carcinoid tumour. Miao YM, et al. **Eur J Gastroenterol Hepatol** 1996 Nov;8(11):1133–5 (13 ref.)
Clinics in diagnostic imaging (16). Lower gastrointestinal bleeding caused by ileal tumour. Au VW, et al. **Singapore Med J** 1996 Aug;37(4):434–7 (10 ref.)
Leiomyosarcoma originating in Meckel's diverticulum: report of a case and a review of 59 cases in the English literature. Shimizu N, et al. **Surg Today** 1997;27(6):546–9 (35 ref.)
[Edema caused by retroperitoneal and tricuspid fibrosis with sclerodermatous cutaneous involvement disclosing carcinoid tumor. Apropos of a case and review of the literature] Morand JJ, et al. **Rev Med Interne** 1997; 18(5):388–95 (61 ref.) (Eng. Abstr.) **(Fre)**
[Carcinoid tumor in Meckel's diverticulum: case presentation and review of the literature] Sutter PM, et al. **Schweiz Med Wochenschr Suppl** 1997;89:20S–24S (37 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Malignant intestinal schwannoma: a case report and a review of the literature in Japan. Nozu T, et al. **Intern Med** 1995 Nov;34(11):1101–5 (19 ref.)
Polyps and polypoid lesions of the jejunum and ileum. Clinical aspects. Levine BA, et al. **Surg Oncol Clin N Am** 1996 Jul;5(3):609–19 (59 ref.)
Lymphangiomas of the ileum: a report of two cases and a review of the literature. Uncu H, et al. **Surg Today** 1997; 27(6):542–5 (25 ref.)
[Hodgkin's disease of the ileum and a review of the cases in Japan] Takayanagi N, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jul;93(7):475–80 (19 ref.) **(Jpn)**

EPIDEMIOLOGY

Case report: a case of primary ileal carcinoma in a young woman and a review of the Japanese literature. Horiuchi A, et al. **J Gastroenterol Hepatol** 1997 Apr;12(4):349–51 (6 ref.)

ETIOLOGY

Primary intestinal Hodgkin's disease complicating ileal Crohn's disease. Kelly MD, et al. **Aust N Z J Surg** 1997 Jul;67(7):485–9 (38 ref.)
Malignant stromal tumor consistent with fibrosarcoma arising

from Meckel's diverticulum. Clinicopathological study of an incidentally discovered tumor and review of the literature. Calderale SM, et al. **Tumori** 1997 May-Jun; 83(3):703-8 (66 ref.)

SECONDARY

An unusual case of laryngeal carcinoma metastasizing to the small intestine. Yoshihara T, et al. **J Laryngol Otol** 1997 Jun;111(6):575-7 (15 ref.)

[Intestinal metastases of bronchopulmonary cancer. Apropos of a case] Kabwa L, et al. **J Chir (Paris)** 1996 Sep; 133(6):290-3 (14 ref.) (Eng. Abstr.) **(Fre)**

[Multiple jejuno-ileal metastasis of malignant schwannoma from the leg. Report of a case presenting anemia symptoms and review of the literature] Crespi C, et al. **Minerva Chir** 1996 Oct;51(10):829-33 (12 ref.) (Eng. Abstr.) **(Ita)**

[Two cases of melanoma metastasis. Description and review of the literature] Zanon C, et al. **Minerva Chir** 1996 Nov; 51(11):979-82 (8 ref.) (Eng. Abstr.) **(Ita)**

ILEAL RESERVOIRS see **PROCTOCOLECTOMY, RESTORATIVE**

ILEITIS

MICROBIOLOGY

Infectious ileocecitis caused by Yersinia, Campylobacter, and Salmonella: clinical, radiological and US findings. Puylaert JB, et al. **Eur Radiol** 1997;7(1):3-9 (42 ref.)

PARASITOLOGY

Eosinophilic ileitis with perforation caused by Angiostrongylus (Parastrongylus) costaricensis. A case study and review. Wu SS, et al. **Arch Pathol Lab Med** 1997 Sep;121(9):989-91 (15 ref.)

PATHOLOGY

Cytomegalovirus enteritis in a nonimmunocompromised host: usefulness of polymerase chain reaction by using paraffin-embedded biopsy specimen for the diagnosis. Yoshida M, et al. **Gastrointest Endosc** 1996 Oct;44(4):482-5 (19 ref.)

ILEITIS, REGIONAL see **CROHN DISEASE**

ILEITIS, TERMINAL see **CROHN DISEASE**

ILEOANAL POUCHES see **PROCTOCOLECTOMY, RESTORATIVE**

ILEOCECAL VALVE

Adult intussusception. A case report. Hamdi M, et al. **Acta Chir Belg** 1996 Nov-Dec;96(6):284-6 (18 ref.)

PATHOLOGY

Segmental xanthomatosis of the ileocecal valve with anatomic and functional obstruction. Goodman MD. **Arch Pathol Lab Med** 1997 Jan;121(1):75-8 (22 ref.)

ILEOCOLITIS see **CROHN DISEASE**

ILEOJEJUNAL BYPASS see **JEJUNOILEAL BYPASS**

ILEOSTOMY

Ileal pouch arthritis: a case report. ter Borg EJ, et al. **Eur J Gastroenterol Hepatol** 1996 Oct;8(10):957-9 (7 ref.)

[Ileostomy--cecal fistula--colostomy--which is the most suitable fecal diversion method with reference to technique, function, complications and reversal?] Köckerling F, et al. **Zentralbl Chir** 1997;122(1):34-8 (23 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Ileoanal anastomosis with pelvic pouch: short review. Gullberg K, et al. **Neth J Med** 1996 Feb;48(2):77-9 (24 ref.)

ILEUM

see related
ILEOSTOMY

Jejunoileal diverticula. Chow DC, et al. **Gastroenterologist** 1997 Mar;5(1):78-84 (74 ref.)

ABNORMALITIES

Anorectal malformation with ileal atresia. Asabe K, et al. **Pediatr Surg Int** 1997 Apr;12(4):302-4 (9 ref.)

SURGERY

Surveillance of familial adenomatous polyposis patients after ileorectal anastomosis or ileoanal pouch anastomosis. Tytgat GNJ. **Gastrointest Endosc Clin N Am** 1997 Jan; 7(1):111-27 (55 ref.)

[A case of adenocarcinoma of the reconstructed bladder following ileocystoplasty] Ishida T, et al. **Nippon Hinyokika Gakkai Zasshi** 1997 Mar;88(3):439-42 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Choice of the method of restoration of intestinal continuity after removal of the ileocecal region] Poĭda AI, et al. **Klin Khir** 1996;(10):45-7 (29 ref.) **(Rus)**

TRANSPLANTATION

Laplace's law and the risks and prevention of bladder rupture after enterocystoplasty and bladder autoaugmentation. Chancellor MB, et al. **Neurourol Urodyn** 1996;15(3):223-33 (19 ref.)

Management of complete ureteral replacement. Experiences and review of the literature. Schoeneich G, et al. **Scand J Urol Nephrol** 1997 Aug;31(4):383-8 (29 ref.)

ILEUS see **INTESTINAL OBSTRUCTION**

ILIAC ARTERY

Dynamic obstruction of the external iliac artery in endurance athletes and its relationship to endothelial function: the case of a long distance runner. Wright IA, et al. **Br J Sports Med** 1997 Jun;31(2):156-8 (10 ref.)

Internal iliac artery embolization in the management of pelvic bleeding [editorial; comment] Wells I. **Clin Radiol** 1996 Dec;51(12):825-7 (22 ref.) Comment on: Clin Radiol 1996 Dec;51(12):865-8.

Current controversies in the management of aortoiliac occlusive disease. Brewster DC. **J Vasc Surg** 1997 Feb; 25(2):365-79 (152 ref.)

Bilateral iliac artery aneurysms and pancake kidney: a case report. Eckes D, et al. **J Vasc Surg** 1997 May;25(5):927-30 (18 ref.)

Autologous vein-covered stent for the endovascular management of an iliac artery-ureteral fistula: case report and review of the literature. Kerns DB, et al. **J Vasc Surg** 1996 Oct;24(4):680-6 (46 ref.)

Aortoiliac occlusive disease. Schneider JR. **Semin Vasc Surg** 1995 Dec;8(4):277-83 (39 ref.)

[Early stent-induced thrombosis in the pelvic circulation: a complication in APC resistance] Lenglinger FX, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Mar;166(3):260-2 (11 ref.) **(Ger)**

ABNORMALITIES

Conservatively treated pelvic arteriovenous malformation: noninvasive sonographic monitoring during subsequent pregnancy. Zanetta G, et al. **J Clin Ultrasound** 1997 Sep; 25(7):401-4 (15 ref.)

INJURIES

Isolated common iliac artery occlusion secondary to atherosclerotic plaque rupture from blunt abdominal trauma: case report and review of the literature. Tsai FC, et al. **J Trauma** 1997 Jan;42(1):133-6 (18 ref.)

Vascular injury during lumbar disc surgery. Report of two cases; a review of the literature. Sağdiç K, et al. **Vasa** 1996; 25(4):378-81 (21 ref.)

RADIOGRAPHY

Diagnosis and management of ureteroiliac artery fistula: value of provocative arteriography followed by common iliac artery embolization and extraanatomic arterial bypass grafting. Vandersteen DR, et al. **J Urol** 1997 Sep;158(3 Pt 1):754-8 (31 ref.)

SURGERY

The role of aortic, iliac and femoropopliteal endarterectomy in vascular surgery today. Van Sterkenburg SM, et al. **Eur J Surg** 1995 Nov;161(11):783-9 (68 ref.)

Coital injury requiring internal iliac artery ligation. Sivalingam N, et al. **Singapore Med J** 1996 Oct;37(5):547-8 (7 ref.)

[Surgical treatment of aorto-iliac occlusive disease] Okadome K, et al. **Nippon Geka Gakkai Zasshi** 1996 Jul;97(7):545-50 (18 ref.) (Eng. Abstr.) **(Jpn)**

ILIAC VEIN

Failure patterns of cryopreserved vein grafts in liver transplantation. Kuang AA, et al. **Transplantation** 1996 Sep 27;62(6):742-7 (21 ref.)

Portal vein thrombosis and stenosis in pediatric liver transplantation. Millis JM, et al. **Transplantation** 1996 Sep 27;62(6):748-54 (24 ref.)

[Synovial cyst of the hip: a rare cause of iliac vein compression] De Smedt M, et al. **Acta Orthop Belg** 1996 Dec;62(4):238-40 (5 ref.) (Eng. Abstr.) **(Fre)**

[Ilio-femoral vein thrombosis treated with tissue plasminogen activator in a pregnant woman] Grand A, et al. **Ann Cardiol Angeiol (Paris)** 1996 Nov;45(9):517-22 (14 ref.) (Eng. Abstr.) **(Fre)**

[Successful lysis of iliofemoral and inferior vena cava thrombi in heparin-induced type-II thrombocytopenia] Emig U, et al. **Dtsch Med Wochenschr** 1997 Aug 1;122(31-32):965-8 (25 ref.) (Eng. Abstr.) **(Ger)**

ABNORMALITIES

Conservatively treated pelvic arteriovenous malformation: noninvasive sonographic monitoring during subsequent pregnancy. Zanetta G, et al. **J Clin Ultrasound** 1997 Sep; 25(7):401-4 (15 ref.)

[Technical options of renal transplant in the absence of a viable ilio-caval venous circuit. Presentation of a case and review of the literature] Lledo García E, et al. **Actas Urol Esp** 1996 Jun;20(6):577-81 (22 ref.) (Eng. Abstr.) **(Spa)**

[Bilateral pulmonary thromboembolism secondary to a double malformation of the iliac veins (letter)] Mata J, et al. **Med Clin (Barc)** 1997 Feb 1;108(4):159 (8 ref.) **(Spa)**

INJURIES

Clinics in diagnostic imaging (23). Traumatic rupture of the left iliac vein. Ram SP, et al. **Singapore Med J** 1997 Mar; 38(3):134-5 (5 ref.)

RADIOGRAPHY

Clinics in diagnostic imaging (23). Traumatic rupture of the left iliac vein. Ram SP, et al. **Singapore Med J** 1997 Mar; 38(3):134-5 (5 ref.)

SURGERY

[Impalement injury of the colon, iliac vein and sacrum--a rare combination in penetrating abdominal trauma. A case report] Funke M, et al. **Chirurg** 1996 Nov;67(11):1184-7 (27 ref.) (Eng. Abstr.) **(Ger)**

ILIUM

TRANSPLANTATION

Complications associated with harvesting autogenous iliac bone graft. Fowler BL, et al. **Am J Orthop** 1995 Dec; 24(12):895-903 (39 ref.)

Use of demineralized bone matrix in hindfoot arthrodesis. Michelson JD, et al. **Clin Orthop** 1996 Apr;(325):203-8 (24 ref.)

Superior gluteal artery injury during iliac bone grafting for spinal fusion. A case report and literature review. Lim EV, et al. **Spine** 1996 Oct 15;21(20):2376-8 (10 ref.)

ILIZAROV TECHNIQUE

Limb-lengthening, skeletal reconstruction, and bone transport with the Ilizarov method. Aronson J. **J Bone Joint Surg Am** 1997 Aug;79(8):1243-58 (180 ref.)

ILLICIT DRUG TESTING see **SUBSTANCE ABUSE DETECTION**

ILLICIT DRUGS see **STREET DRUGS**

ILLITERACY see **EDUCATIONAL STATUS**

ILLNESS BEHAVIOR see **SICK ROLE**

ILLUMINATING GAS POISONING see **CARBON MONOXIDE POISONING**

ILLUMINATION see **LIGHTING**

ILLUSIONS

Positive illusions and coping with adversity. Taylor SE, et al. **J Pers** 1996 Dec;64(4):873-98 (80 ref.)

ILLUSTRATION, MEDICAL see **MEDICAL ILLUSTRATION**

IMAGE ANALYSIS, COMPUTER-ASSISTED see **IMAGE PROCESSING, COMPUTER-ASSISTED**

IMAGE CYTOMETRY

Quality assurance issues in DNA image cytometry. Marchevsky A, et al. **Cytometry** 1996 Jun 15;26(2):101-7 (46 ref.)

The contribution of image cytometry and artificial intelligence-related methods of numerical data analysis for adipose tumor histopathologic classification. Goldschmidt D, et al. **Lab Invest** 1996 Sep;75(3):295-306 (62 ref.)

INSTRUMENTATION

Laser scanning cytometry in pathology of solid tumors. A review. Gorczyca W, et al. **Acta Cytol** 1997 Jan-Feb; 41(1):98-108 (74 ref.)

Slide-based laser scanning cytometry. Kamentsky LA, et al. **Acta Cytol** 1997 Jan-Feb;41(1):123-43 (34 ref.)

METHODS

Basic strategies for valid cytometry using image analysis. Jonker A, et al. **Histochem J** 1997 May;29(5):347-64 (46 ref.)

Errors and pitfalls in diagnostic cytology: new techniques applied to cytopathology. Ross JS. **Monogr Pathol** 1997; (39):94-117 (75 ref.)

IMAGE ENHANCEMENT

see related
RADIOGRAPHIC IMAGE ENHANCEMENT
SUBTRACTION TECHNIQUE

Spatial resolution enhancement through time gated measurements. Sölkner G, et al. **Adv Exp Med Biol** 1997; 413:75–83 (22 ref.)

Signal sources in bold contrast fMRI. Turner R. **Adv Exp Med Biol** 1997;413:19–25 (31 ref.)

Contrast-enhanced MRI of the breast: accuracy, value, controversies, solutions. Heywang-Köbrunner SH, et al. **Eur J Radiol** 1997 Feb;24(2):94–108 (73 ref.)

Colonic chromoscopy. A new perspective on polyps and flat adenomas. Kim CY, et al. **Gastrointest Endosc Clin N Am** 1997 Jul;7(3):423–37 (67 ref.)

Clinical experience with sonographic contrast agents. Melany ML, et al. **Semin Ultrasound CT MR** 1997 Feb;18(1):3–12 (40 ref.)

[Development and experimental use of receptor-specific MR contrast media] Reimer P, et al. **Radiologe** 1996 Feb; 36(2):153–63 (77 ref.) (Eng. Abstr.) **(Ger)**

[Software for image processing and its practical use] Matsumoto S. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):936–42 (13 ref.) **(Jpn)**

INSTRUMENTATION

Technology and principles of tomographic image-guided interventions and surgery. Melzer A, et al. **Surg Endosc** 1997 Sep;11(9):946–56 (25 ref.)

METHODS

New avenues in 3-D computerised (stereopathological) imaging of breast cancer (review). Davies JD, et al. **Anticancer Res** 1996 Nov–Dec;16(6C):3971–81 (96 ref.)

Dermoscopy (epiluminescence microscopy) of pigmented skin lesions. Current status and evolving trends. Argenyi ZB. **Dermatol Clin** 1997 Jan;15(1):79–95 (43 ref.)

High-resolution MR imaging of the eye and orbit. Hosten N, et al. **Front Radiat Ther Oncol** 1997;30:8–19 (37 ref.)

Methods in quantitative image analysis. Oberholzer M, et al. **Histochem Cell Biol** 1996 May;105(5):333–55 (58 ref.)

Quantitative analysis of cardiovascular MR images. van der Geest RJ, et al. **Int J Card Imaging** 1997 Jun;13(3):247–58 (39 ref.)

Narrow Band Imaging and fluorescence and its role in wound pattern documentation. Schneider RE, et al. **J Biol Photogr** 1996 Jul;64(3):67–75 (74 ref.)

Iron oxide-enhanced MR lymphography: the evaluation of cervical lymph node metastases in head and neck cancer. Anzai Y, et al. **J Magn Reson Imaging** 1997 Jan–Feb; 7(1):75–81 (41 ref.)

Use of gadolinium chelates in MR imaging of the spine. Bradley WG. **J Magn Reson Imaging** 1997 Jan–Feb; 7(1):38–46 (24 ref.)

Assessing tumor angiogenesis using macromolecular MR imaging contrast media. Brasch R, et al. **J Magn Reson Imaging** 1997 Jan–Feb;7(1):68–74 (40 ref.)

Water diffusion and exchange as they influence contrast enhancement. Donahue KM, et al. **J Magn Reson Imaging** 1997 Jan–Feb;7(1):102–10 (47 ref.)

Assessment of tumor microcirculation: a new role of dynamic contrast MR imaging. Griebel J, et al. **J Magn Reson Imaging** 1997 Jan–Feb;7(1):111–9 (73 ref.)

Phase-derivative analysis in MR angiography: reduced Venc dependency and improved vessel wall detection in laminar and disturbed flow. Hoogeveen RM, et al. **J Magn Reson Imaging** 1997 Mar–Apr;7(2):321–30 (32 ref.)

Contrast agents for MR imaging of the liver. Low RN. **J Magn Reson Imaging** 1997 Jan–Feb;7(1):56–67 (76 ref.)

Application of contrast agents in the evaluation of stroke: conventional MR and echo-planar MR imaging. Maeda M, et al. **J Magn Reson Imaging** 1997 Jan–Feb;7(1):23–8 (24 ref.)

Effects of contrast dose, delayed imaging, and magnetization transfer saturation on gadolinium-enhanced MR imaging of brain lesions. Mathews VP, et al. **J Magn Reson Imaging** 1997 Jan–Feb;7(1):14–22 (38 ref.)

Physiologic measurements by contrast-enhanced MR imaging: expectations and limitations. Roberts TP. **J Magn Reson Imaging** 1997 Jan–Feb;7(1):82–90 (60 ref.)

Principles of contrast enhancement in the evaluation of brain diseases: an overview. Runge VM, et al. **J Magn Reson Imaging** 1997 Jan–Feb;7(1):5–13 (24 ref.)

Contrast-enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple sclerosis. Simon JH. **J Magn Reson Imaging** 1997 Jan–Feb; 7(1):29–37 (74 ref.)

Contrast agents in functional MR imaging. Sorensen AG, et al. **J Magn Reson Imaging** 1997 Jan–Feb;7(1):47–55 (24 ref.)

Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. Tofts PS. **J Magn Reson Imaging** 1997 Jan–Feb; 7(1):91–101 (56 ref.)

Echo-planar FLAIR imaging in evaluation of intracranial lesions. Simonson TM, et al. **Radiographics** 1996 May; 16(3):575–84 (14 ref.)

[The measurement of the coronary flow by the phase contrast method (cine PC, Fastcard PC)] Harada M, et al. **Nippon Rinsho** 1997 Jul;55(7):1828–32 (10 ref.) (Eng. Abstr.) **(Jpn)**

[T2*-contrast perfusion study--principles, theory and clinical utility in evaluating cerebral hemodynamics] Ida M, et al. **Nippon Rinsho** 1997 Jul;55(7):1719–25 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Myocardial wall motion analysis with phase shift imaging: cine phase contrast technique] Kawamitsu H, et al. **Nippon Rinsho** 1997 Jul;55(7):1794–9 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Technical progress of three dimensional cinematic MR imaging and functional images] Kinosada Y. **Nippon Rinsho** 1997 Jul;55(7):1648–54 (3 ref.) **(Jpn)**

[Historical developments and present status of rapid NMR imaging] Kose K. **Nippon Rinsho** 1997 Jul;55(7):1633–7 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Advances in high speed MR imaging for the functional assessment of cardiovascular system] Matsuda T. **Nippon Rinsho** 1997 Jul;55(7):1789–93 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Estimation of left ventricular wall motion and viability by SPAMM tagging cine MRI] Miura T, et al. **Nippon Rinsho** 1997 Jul;55(7):1811–5 (4 ref.) (Eng. Abstr.) **(Jpn)**

[Assessment of coronary flow reserve using fast phase contrast cine MR imaging] Sakuma H, et al. **Nippon Rinsho** 1997 Jul;55(7):1833–8 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Theory and clinical application of functional MRI: 3D-functional brain mapping] Tanaka C, et al. **Nippon Rinsho** 1997 Jul;55(7):1660–5 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Technical aspects of fast, ultra-fast MR imaging] Tsukamoto T. **Nippon Rinsho** 1997 Jul;55(7):1638–42 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical efficacy of three-dimensional chemical shift imaging (3D-CSI)--a study of 3D-CSI in the human heart and its clinical perspectives for the future] Yabe T, et al. **Nippon Rinsho** 1997 Jul;55(7):1839–43 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Diffusion MRI for evaluating cerebrovascular disease] Minematsu K, et al. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1575–7 (10 ref.) (Eng. Abstr.) **(Jpn)**

IMAGE INTERPRETATION, COMPUTER-ASSISTED

Automatic border detection and three-dimensional reconstruction with echocardiography. Legget ME, et al. **Crit Care Clin** 1996 Apr;12(2):471–96 (101 ref.)

Computer-assisted reading of mammograms. Karssemeijer N, et al. **Eur Radiol** 1997;7(5):743–8 (33 ref.)

INSTRUMENTATION

Laser scanning cytometry in pathology of solid tumors. A review. Gorczyca W, et al. **Acta Cytol** 1997 Jan–Feb; 41(1):98–108 (74 ref.)

Slide-based laser scanning cytometry. Kamentsky LA, et al. **Acta Cytol** 1997 Jan–Feb;41(1):123–43 (34 ref.)

Automated rescreening in cervical cytology. Mathematical models for evaluating overall process sensitivity, specificity and cost. Kaminsky FC, et al. **Acta Cytol** 1997 Jan–Feb; 41(1):209–23 (35 ref.)

Clinical validation of interactive cytologic screening. Automating the search, not the interpretation. Mango LJ. **Acta Cytol** 1997 Jan–Feb;41(1):93–7 (15 ref.)

IMAGE PROCESSING, COMPUTER-ASSISTED

Spatial resolution enhancement through time gated measurements. Sölkner G, et al. **Adv Exp Med Biol** 1997; 413:75–83 (22 ref.)

Computer-assisted intraoperative navigation during skull base surgery. Carrau RL, et al. **Am J Otolaryngol** 1996 Mar–Apr;17(2):95–101 (20 ref.)

Dermatofibrosarcoma protuberans (DFSP): growth characteristics based on tumor modeling and a review of cases treated with Mohs micrographic surgery. Haycox CL, et al. **Ann Plast Surg** 1997 Mar;38(3):246–51 (32 ref.)

A model of the translational apparatus based on a three-dimensional reconstruction of the Escherichia coli ribosome. Frank J, et al. **Biochem Cell Biol** 1995 Nov–Dec; 73(11–12):757–65 (38 ref.)

Getting closer to an understanding of the three-dimensional structure of ribosomal RNA. Mueller F, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):767–73 (40 ref.)

Clinical implementation of electronic portal imaging: correction strategies and set-up errors. De Neve W, et al. **Bull Cancer Radiother** 1996;83(4):401–5 (33 ref.)

Computational and numerical methods for bioelectric field problems. Johnson CR. **Crit Rev Biomed Eng** 1997; 25(1):1–81 (251 ref.)

Subjective pitfalls in HRCT interpretation. Gruden JF, et al. **Crit Rev Diagn Imaging** 1996 Oct;37(5):349–434 (32 ref.)

Advanced imaging methods. Matteson SR, et al. **Crit Rev Oral Biol Med** 1996;7(4):346–95 (224 ref.)

Ribosomes: protein synthesis in slow motion. Moore PB. **Curr Biol** 1997 Mar 1;7(3):R179–81 (10 ref.)

Three-dimensional contrast-enhanced magnetic resonance angiography of the thoracic vasculature. Leung DA, et al. **Eur Radiol** 1997;7(7):981–9 (28 ref.)

Knowledge-based image analysis in the precursors of prostatic adenocarcinoma. Bartels PH, et al. **Eur Urol** 1996; 30(2):234–42 (17 ref.)

Computed tomographic colography and virtual colonoscopy. Ahlquist DA, et al. **Gastrointest Endosc Clin N Am** 1997 Jul;7(3):439–52 (47 ref.)

Basic strategies for valid cytometry using image analysis. Jonker A, et al. **Histochem J** 1997 May;29(5):347–64 (46 ref.)

Multishot rosette trajectories for spectrally selective MR imaging. Noll DC. **IEEE Trans Med Imaging** 1997 Aug; 16(4):372–7 (18 ref.)

The significance of computer-assisted semen analysis (CASA) for diagnosis in andrology and fertility prognosis. Krause W. **Int J Androl** 1995 Dec;18 Suppl 2:32–5 (14 ref.)

Computer-aided 3-D reconstruction of serially sectioned mouse embryos: its use in integrating anatomical organization. Kaufman MH, et al. **Int J Dev Biol** 1997 Apr; 41(2):223–33 (15 ref.)

Understanding and using DICOM, the data interchange standard for biomedical imaging [see comments] Bidgood WD Jr, et al. **J Am Med Inform Assoc** 1997 May–Jun; 4(3):199–212 (21 ref.) Comment in: J Am Med Inform Assoc 1997 May–Jun;4(3):252–3.

The Digital Anatomist distributed framework and its applications to knowledge-based medical imaging [see comments] Brinkley JF, et al. **J Am Med Inform Assoc** 1997 May–Jun;4(3):165–83 (55 ref.) Comment in: J Am Med Inform Assoc 1997 May–Jun;4(3):252–3.

The use of medical images in planning and delivery of radiation therapy. Kalet IJ, et al. **J Am Med Inform Assoc** 1997 Sep–Oct;4(5):327–39 (38 ref.)

Medical image databases: a content-based retrieval approach [see comments] Tagare HD, et al. **J Am Med Inform Assoc** 1997 May–Jun;4(3):184–98 (37 ref.) Comment in: J Am Med Inform Assoc 1997 May–Jun;4(3):252–3.

Understanding Fourier space and filter selection. Zubal IG, et al. **J Nucl Cardiol** 1997 May–Jun;4(3):234–43 (39 ref.)

Functional imaging of the airways. Goldin JG, et al. **J Thorac Imaging** 1997 Jan;12(1):29–37 (56 ref.)

Volumetric (helical/spiral) CT (VCT) of the airways. Naidich DP, et al. **J Thorac Imaging** 1997 Jan;12(1):11–28 (43 ref.)

The role of computed tomographic angiography in the assessment of intracranial vascular disease. Tampieri D, et al. **Neuroimaging Clin N Am** 1996 Aug;6(3):759–67 (14 ref.)

A general concept of spiral volumetric CT and a newly developed, post-processing method designated as CT-endoscopy. Kobayashi H. **Nippon Ika Daigaku Zasshi** 1996 Feb;63(1):9–21 (23 ref.)

Use of maximum intensity projections in CT angiography: a basic review. Prokop M, et al. **Radiographics** 1997 Mar–Apr;17(2):433–51 (26 ref.)

Computed radiography: its impact on radiographers. Cesar LJ. **Radiol Technol** 1997 Jan–Feb;68(3):225–32 (7 ref.)

Technical pitfalls in image acquisition, processing, and display. Forstrom LA, et al. **Semin Nucl Med** 1996 Oct; 26(4):278–94 (44 ref.)

[Strategy for remote diagnosis and the image bank. A specific application for telepathology for hematology (editorial)] Flandrin G. **Ann Pathol** 1996;16(3):155–8 (14 ref.) **(Fre)**

[Three-dimensional echocardiography. Principles and applications] Hagège A, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11):1405–11 (27 ref.) (Eng. Abstr.) **(Fre)**

[A comparative study of hormone receptors in breast cancer with quantitative immunocytochemistry and biochemistry] Marcot I, et al. **Bull Cancer** 1997 Jun;84(6):613–8 (27 ref.) (Eng. Abstr.) **(Fre)**

[Volume rendering technique in 3D vascular imaging] Marcus C, et al. **J Radiol** 1997 Jul;78(7):481–4 (11 ref.) (Eng. Abstr.) **(Fre)**

[Digital image processing in orthodontics] Tourné L. **Rev Belge Med Dent** 1996;51(4):239–56 (62 ref.) (Eng. Abstr.) **(Fre)**

[MR mammography: current status and indications] Umschaden HW, et al. **Acta Med Austriaca** 1997; 24(2):39–45 (32 ref.) (Eng. Abstr.) **(Ger)**

[Digital image processing in rhinologic education and graduate education] Keerl R, et al. **Eur Arch Otorhinolaryngol Suppl** 1996;1:297–315 (68 ref.) **(Ger)**

[Structural magnetic resonance tomography in diagnosis and research of Alzheimer type dementia] Hampel H, et al. **Nervenarzt** 1997 May;68(5):365–78 (108 ref.) (Eng. Abstr.) **(Ger)**

[Tracheobronchomegaly--Mounier-Kuhn syndrome--case report and review of the literature] Wiesner B, et al. **Pneumologie** 1997 Mar;51(3):291–5 (31 ref.) (Eng. Abstr.) **(Ger)**

[Possibilities of abdominal tumor volumetry] Helmberger H, et al. **Rontgenpraxis** 1997 Jan;50(1):11–7 (55 ref.) **(Ger)**

[Clinical aspects and therapy of degenerative joint diseases] Puhl W, et al. **Rontgenpraxis** 1997 Jun;50(6):142–9 (87 ref.) **(Ger)**

[Digital filing system for medical image data] Mitani M, et al. **Rinsho Byori** 1997 May;45(5):447–55 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Record and preservation of ultrasound images and computer-assistant analysis--estimation of digital filing system and texture analysis] Taniguchi N, et al. **Rinsho Byori** 1997 May;45(5):442–6 (5 ref.) (Eng. Abstr.)

(Jpn)
[Methods of bioimaging and their principles] Arai T. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):911–4 (0 ref.) (Jpn)
[Analysis of chromosome organization and dynamics by three-dimensional fluorescence microscopy] Hiraoka Y, et al. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(15 Suppl):2165–73 (13 ref.) (Jpn)
[Visualization of neural excitation] Iijima T, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1100–5 (12 ref.) (Jpn)
[Low light level imaging] Kamiya K. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1154–7 (4 ref.) (Jpn)
[Software for image processing and its practical use] Matsumoto S. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):936–42 (13 ref.) (Jpn)
[Computer technology for bioimaging] Minamitani H. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):932–5 (5 ref.) (Jpn)
[Image technology and modern network system] Ono S. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):949–55 (0 ref.) (Jpn)
[Digital image processing: fundamental techniques and applications in biological research] Cordova F, et al. **Arch Biol Med Exp (Santiago)** 1986;19(3–4):359–73 (6 ref.) (Eng. Abstr.) (Spa)

INSTRUMENTATION

Laser scanning cytometry in pathology of solid tumors. A review. Gorczyca W, et al. **Acta Cytol** 1997 Jan–Feb; 41(1):98–108 (74 ref.)
Utility of the TracCell system in mapping Papanicolaou-stained cytologic material. Grohs DH, et al. **Acta Cytol** 1997 Jan–Feb;41(1):144–52 (20 ref.)
Slide-based laser scanning cytometry. Kamentsky LA, et al. **Acta Cytol** 1997 Jan–Feb;41(1):123–43 (34 ref.)
Automated rescreening in cervical cytology. Mathematical models for evaluating overall process sensitivity, specificity and cost. Kaminsky FC, et al. **Acta Cytol** 1997 Jan–Feb; 41(1):209–23 (35 ref.)
Clinical validation of interactive cytologic screening. Automating the search, not the interpretation. Mango LJ. **Acta Cytol** 1997 Jan–Feb;41(1):93–7 (15 ref.)
Virtual reality: an assistive technology in neurological rehabilitation. Rose FD, et al. **Curr Opin Neurol** 1996 Dec; 9(6):461–7 (53 ref.)
The value of quantitative myocardial perfusion imaging with positron emission tomography in coronary artery disease. Wijns W, et al. **Herz** 1997 Apr;22(2):87–95 (58 ref.)
The potentials of virtual environments in the education and training of people with learning disabilities. Cromby JJ, et al. **J Intellect Disabil Res** 1996 Dec;40 (Pt 6):489–501 (80 ref.)
[Applications of modern image data processing in clinico-rhinologic research] Weber R, et al. **Eur Arch Otorhinolaryngol Suppl** 1996;1:271–96 (332 ref.) (Ger)
[New developments in parameter-oriented roentgen densitometry perfusion analysis within the scope of heart catheter studies] Haude M, et al. **Herz** 1997 Apr;22(2):72–86 (76 ref.) (Eng. Abstr.) (Ger)
[Dynamic 3-dimensional reconstruction of the heart using multiplanar transesophageal echocardiography] Hofmann T, et al. **Herz** 1997 Jun;22(3):176–8 (8 ref.) (Ger)
[Computer-assisted orthopedic surgery. From pedicle screw insertion to further applications] Berlemann U, et al. **Orthopade** 1997 May;26(5):463–9 (34 ref.) (Eng. Abstr.) (Ger)
[Methodological approaches to quantitative evaluation of microcirculation in tissues with dynamic magnetic resonance tomography] Brix G, et al. **Radiologe** 1997 Jun; 37(6):470–80 (47 ref.) (Eng. Abstr.) (Ger)
[Determining heart muscle perfusion by magnetic resonance tomography progressing to clinical application] Fischer SE, et al. **Radiologe** 1997 May;37(5):366–71 (30 ref.) (Eng. Abstr.) (Ger)
[Electronic documentation of findings and image in ultrasound diagnosis] Kuhn K. **Radiologe** 1996 Jan; 36(1):47–50 (15 ref.) (Eng. Abstr.) (Ger)
[Ultrasound diagnosis of the transplanted kidney] Mutze S, et al. **Radiologe** 1996 Jan;36(1):31–7 (49 ref.) (Eng. Abstr.) (Ger)
[New developments in ultrasound diagnosis: 3-dimensional ultrasound] Nitsch CD, et al. **Rontgenpraxis** 1997 Aug; 50(8):247–52 (9 ref.) (Ger)
[CT-angiography for diagnostic assessment of intracranial vascular aneurysms] Koch C, et al. **Wien Med Wochenschr** 1997;147(7–8):163–71 (59 ref.) (Eng. Abstr.) (Ger)
[Imaging for realtime analysis system] Suzuki M, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1158–62 (5 ref.) (Jpn)

METHODS

Image postprocessing and contrast agents in clinical MR imaging--an introductory overview. Rinck PA, et al. **Acta Radiol Suppl** 1997;412:7–19 (57 ref.)
Three-dimensional autoradiographic image-processing strategies for the study of brain injury and plasticity. Ginsberg MD, et al. **Adv Neurol** 1997;73:239–50 (24 ref.)
Digital imaging in anatomic pathology. O'Brien MJ, et al. **Am J Clin Pathol** 1996 Oct;106(4 Suppl 1):S25–32 (15 ref.)
Automation of the Papanicolaou smear: a technology assessment perspective. Linder J. **Arch Pathol Lab Med** 1997 Mar;121(3):282–6 (30 ref.)
Quantitative radiography in osteoarthritis: computerized measurement of radiographic knee and hip joint space. Conrozier T, et al. **Baillieres Clin Rheumatol** 1996 Aug; 10(3):429–33 (13 ref.)
Imaging techniques: picture the world with kaleidoscope dyes. Paddock SW. **Curr Biol** 1997 Mar 1;7(3):R182–5 (30 ref.)
Methods in quantitative image analysis. Oberholzer M, et al. **Histochem Cell Biol** 1996 May;105(5):333–55 (58 ref.)
A novel volumetric feature extraction technique with applications to MR images. Ashton EA, et al. **IEEE Trans Med Imaging** 1997 Aug;16(4):365–71 (23 ref.)
Learning-based ventricle detection from cardiac MR and CT images. Weng J, et al. **IEEE Trans Med Imaging** 1997 Aug; 16(4):378–91 (36 ref.)
Automatic visual to tactile translation--Part I: Human factors, access methods, and image manipulation. Way TP, et al. **IEEE Trans Rehabil Eng** 1997 Mar;5(1):81–94 (90 ref.)
A marker-free method for tracking human lower limb segments based on model matching. Persson T. **Int J Biomed Comput** 1996 Apr;41(2):87–97 (10 ref.)
Computerized graphic imaging for three-dimensional representation: general principles and applications to embryo/fetal development. Machin GA, et al. **Int Rev Exp Pathol** 1996;36:1–30 (87 ref.)
Ultrasound biomicroscopy of the anterior segment. Liebmann JM, et al. **J Am Optom Assoc** 1996 Aug;67(8):469–79 (42 ref.)
Corneal topography: a review of terms and concepts. Roberts C. **J Cataract Refract Surg** 1996 Jun;22(5):624–9 (11 ref.)
The clinical value of three-dimensional intravascular ultrasound imaging. Reid DB, et al. **J Endovasc Surg** 1995 Nov;2(4):356–64 (16 ref.)
Computer-assisted analysis of single-cell behavior. Cammer M, et al. **Methods Mol Biol** 1997;75:459–81 (4 ref.)
Diagnosis of congenital malformations using two-dimensional and three-dimensional ultrasonography. Chan L, et al. **Obstet Gynecol Clin North Am** 1997 Mar; 24(1):49–69 (25 ref.)
The three-dimensional structure of the connective tissue in the lamina cribrosa of the human optic nerve head. Birch M, et al. **Ophthalmologica** 1997;211(3):183–91 (24 ref.)
Optical imaging in medicine: II. Modelling and reconstruction. Arridge SR, et al. **Phys Med Biol** 1997 May; 42(5):841–53 (50 ref.)
Coherent detection techniques in optical imaging of tissues. Chan KP, et al. **Phys Med Biol** 1997 May;42(5):855–67 (40 ref.)
Current approaches to analogue instrumentation design in electrical impedance tomography. Boone KG, et al. **Physiol Meas** 1996 Nov;17(4):229–47 (47 ref.)
High-resolution icosahedral reconstruction: fulfilling the promise of cryo-electron microscopy. Mancini EJ, et al. **Structure** 1997 Jun 15;5(6):741–50 (81 ref.)
Nearly real-time visualization of arbitrary two-dimensional sections from three-dimensional acquisition. Capineri L, et al. **Ultrasound Med Biol** 1996;22(3):319–28 (8 ref.)
[Three-dimensional analysis of chromosomes by a computerized fluorescence microscope system] Haraguchi T, et al. **Nippon Rinsho** 1996 Sep;54(9):2574–82 (6 ref.) (Eng. Abstr.) (Jpn)
[High resolution mapping of genes by imaging methods using the interna] Fukui K, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(6):881–7 (22 ref.) (Jpn)
[3-D softwares and their practice] Sakai T, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):943–8 (10 ref.) (Jpn)
[Ultrasound diagnosis: current opportunities in diagnosis of gallbladder pathology] Lemeshko ZA. **Klin Med (Mosk)** 1997;75(5):18–20 (0 ref.) (Rus)

UTILIZATION

[Cervical smears. Contribution of automated screening] Ziol M, et al. **Ann Pathol** 1996 Nov;16(5):351–5 (26 ref.) (Fre)

IMAGE RECONSTRUCTION see **IMAGE PROCESSING, COMPUTER-ASSISTED**

IMAGERY (PSYCHOTHERAPY)

On knowing how to do things: a theory of motor imagery. Annett J. **Brain Res Cogn Brain Res** 1996 Mar;3(2):65–9 (17 ref.)
Planning, preparation, execution, and imagery of volitional action. Deecke L. **Brain Res Cogn Brain Res** 1996 Mar; 3(2):59–64 (51 ref.)
Mental imagery as the adaptationist views it. Pani JR. **Conscious Cogn** 1996 Sep;5(3):288–326 (235 ref.)
[The imagery of geometrical figures in psychiatry] Marchais P. **Ann Med Psychol (Paris)** 1996 Jun;154(4):266–70; discussion 270–1 (10 ref.) (Eng. Abstr.) (Fre)

METHODS

Analysis of recent literature concerning relaxation and imagery interventions for cancer pain. Wallace KG. **Cancer Nurs** 1997 Apr;20(2):79–87 (45 ref.)
Imagery and hypnosis in the treatment of cancer patients. Spiegel D, et al. **Oncology (Huntingt)** 1997 Aug; 11(8):1179–89; discussion 1189–95 (63 ref.)

IMAGERY, GUIDED see **IMAGERY (PSYCHOTHERAPY)**

IMAGINATION

see related
IMAGERY (PSYCHOTHERAPY)

The role of inhibition in the hierarchical gating of executed and imagined movements. Berthoz A. **Brain Res Cogn Brain Res** 1996 Mar;3(2):101–13 (112 ref.)
Traumatic intrusive imagery as an emotional memory phenomenon: a review of research and explanatory information processing theories. vanOyen Witvliet C. **Clin Psychol Rev** 1997;17(5):509–36 (150 ref.)
How much work can a quale do? [comment] Banks WP. **Conscious Cogn** 1996 Sep;5(3):368–80 (36 ref.) Comment on: Conscious Cogn 1996 Sep;5(3):327–58.
Imagery, creativity, and emergent structure. Finke RA. **Conscious Cogn** 1996 Sep;5(3):381–93 (58 ref.)
Ways of knowing [comment] Hardcastle VG. **Conscious Cogn** 1996 Sep;5(3):359–67 (15 ref.) Comment on: Conscious Cogn 1996 Sep;5(3):327–58.
The importance of a consideration of qualia to imagery and cognition [see comments] Hubbard TL. **Conscious Cogn** 1996 Sep;5(3):327–58 (100 ref.) Comment in: Conscious Cogn 1996 Sep;5(3):359–67. Comment in: Conscious Cogn 1996 Sep;5(3):368–80.
The relationship between joint attention and pretend play in autism. Charman T. **Dev Psychopathol** 1997 Winter; 9(1):1–16 (110 ref.)
Mental time travel and the evolution of the human mind. Suddendorf T, et al. **Genet Soc Gen Psychol Monogr** 1997 May;123(2):133–67 (190 ref.)
Death themes in anorexia nervosa: dimensions for a reply to Jackson et al. Warren B. **Int J Eat Disord** 1997 Nov; 22(3):223–9 (22 ref.)
Imagery in human classical conditioning. Dadds MR, et al. **Psychol Bull** 1997 Jul;122(1):89–103 (90 ref.)

PHYSIOLOGY

The neurophysiological basis of motor imagery. Decety J. **Behav Brain Res** 1996 May;77(1–2):45–52 (60 ref.)
Mental rotation and the right hemisphere. Corballis MC. **Brain Lang** 1997 Mar;57(1):100–21 (104 ref.)
Do imagined and executed actions share the same neural substrate? Decety J. **Brain Res Cogn Brain Res** 1996 Mar; 3(2):87–93 (57 ref.)
Is "sudden illumination" the result of the activation of a creative center at the human brain? Rodriguez-Fernandez JL. **Perspect Biol Med** 1996 Winter;39(2):207–307 (149 ref.)

IMAGING, DIAGNOSTIC see **DIAGNOSTIC IMAGING**

IMAGING, MEDICAL see **DIAGNOSTIC IMAGING**

IMAGING TECHNIQUES see **DIAGNOSTIC IMAGING**

IMIDAZOLES

The clinical pharmacology of losartan in Japanese subjects and patients. Nakashima M, et al. **Blood Press Suppl** 1996; 2:62–6 (13 ref.)
[Molecular biology of angiotensin II receptor and clinical application of the antagonist] Hiwada K. **Nippon Naika Gakkai Zasshi** 1994 Jan 10;83(1):143–8 (15 ref.) (Jpn)

ADVERSE EFFECTS

Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension. Mallion JM, et al. **Blood Press Suppl** 1996; 2:82–6 (14 ref.)
Side effect profiles of new antipsychotic agents. Casey DE. **J Clin Psychiatry** 1996;57 Suppl 11:40–5; discussion 46–52 (30 ref.)
Commentary: do angiotensin II receptor antagonists regress left ventricular hypertrophy? Lip GY. **J Hum Hypertens** 1996 Nov;10(11):725–7 (28 ref.)

ANALYSIS

Identification of new mutagenic heterocyclic amines and quantification of known heterocyclic amines. Wakabayashi K, et al. **Princess Takamatsu Symp** 1995;23:39–49 (31 ref.)

ANTAGONISTS & INHIBITORS

[Imidazoline receptors and use of drug blocking receptors II] Lada W. **Pol Merkuriusz Lek** 1996 Aug;1(2):124–5 (10 ref.) (Eng. Abstr.) (Pol)

ECONOMICS

Medical and cost-economy aspects of modern antihypertensive therapy--with special reference to 2 years

IMIDAZOLES

of clinical experience with losartan. Hansson L. **Blood Press Suppl** 1997;1:52–5 (27 ref.)

HISTORY

Historical development of losartan (DuP 753) and angiotensin II receptor subtypes. Wong PC, et al. **Blood Press Suppl** 1996;3:11–4 (29 ref.)

METABOLISM

Imidazoline binding sites and signal transduction pathways. Musgrave IF, et al. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov;23(10–11):990–4 (35 ref.)

Metabolism of the food carcinogen 2–amino–1–methyl–6–phenylimidazo[4,5–b]pyridine (PhIP) in the rat and other rodents. Alexander J, et al. **Princess Takamatsu Symp** 1995;23:113–22 (35 ref.)

Enzymatic studies of the activation of heterocyclic food mutagens in man. Boobis AR, et al. **Princess Takamatsu Symp** 1995;23:134–44 (38 ref.)

Systemic exposure to dietary heterocyclic amines in man. Davies DS, et al. **Princess Takamatsu Symp** 1995;23:190–6 (30 ref.)

Assessment of the DNA adduction and pharmacokinetics of PhIP and MeIOx in rodents at doses approximating human exposure using the technique of accelerator mass spectrometry (AMS) and 32P–postlabeling. Turteltaub KW, et al. **Princess Takamatsu Symp** 1995;23:93–102 (30 ref.)

PHARMACOKINETICS

Exposure to and activation of dietary heterocyclic amines in humans. Lynch AM, et al. **Crit Rev Oncol Hematol** 1995 Nov;21(1–3):19–31 (124 ref.)

PHARMACOLOGY

Angiotensin II receptor antagonists: the prototype losartan. Schaefer KL, et al. **Ann Pharmacother** 1996 Jun; 30(6):625–36 (81 ref.)

The diversified pharmacology of angiotensin II–receptor blockade. Timmermans PB, et al. **Blood Press Suppl** 1996; 2:53–61 (112 ref.)

Medetomidine sedation in dogs and cats: a review of its pharmacology, antagonism and dose [see comments] Cullen LK. **Br Vet J** 1996 Sep;152(5):519–35 (88 ref.) Comment in: Br Vet J 1996 Sep;152(5):493–5.

Pathologic consequences of increased angiotensin II activity. Ferrario CM, et al. **Cardiovasc Drugs Ther** 1996 Nov; 10(5):511–8 (100 ref.)

Imidazoline binding sites and signal transduction pathways. Musgrave IF, et al. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov;23(10–11):990–4 (35 ref.)

Psychopharmacology of imidazoline and alpha 2–adrenergic receptors: implications for depression. Piletz JE, et al. **Crit Rev Neurobiol** 1994;9(1):29–66 (300 ref.)

Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Goa KL, et al. **Drugs** 1996 May;51(5):820–45 (138 ref.)

Pharmacology of moxonidine, an I1–imidazoline receptor agonist. Ziegler D, et al. **J Cardiovasc Pharmacol** 1996;27 Suppl 3:S26–37 (52 ref.)

Imidazoline receptor agonist drugs: a new approach to the treatment of systemic hypertension. Yu A, et al. **J Clin Pharmacol** 1996 Feb;36(2):98–111 (100 ref.)

The I1–imidazoline receptor: from binding site to therapeutic target in cardiovascular disease. Ernsberger P, et al. **J Hypertens Suppl** 1997 Jan;15(1):S9–23 (102 ref.)

[Antifungal resistance in opportunistic pathogenic fungi (II). Imidazoles and triazoles] Martínez–Suárez JV, et al. **Enferm Infecc Microbiol Clin** 1996 Oct;14(8):490–8 (79 ref.) **(Spa)**

THERAPEUTIC USE

The use of lexipafant in the treatment of acute pancreatitis. McKay C, et al. **Adv Exp Med Biol** 1996;416:365–70 (34 ref.)

Use of azoles for systemic antifungal therapy. Kauffman CA, et al. **Adv Pharmacol** 1997;39:143–89 (340 ref.)

Nilutamide: an antiandrogen for the treatment of prostate cancer. Dole EJ, et al. **Ann Pharmacother** 1997 Jan; 31(1):65–75 (64 ref.)

Angiotensin II receptor inhibition. A new therapeutic principle. Messerli FH, et al. **Arch Intern Med** 1996 Sep 23;156(17):1957–65 (100 ref.)

Angiotensin II antagonism: a new avenue of hypertension management. Gavras H. **Blood Press Suppl** 1997;1:42–6 (24 ref.)

The clinical efficacy and tolerability of the angiotensin II–receptor antagonist losartan in Japanese patients with hypertension. Ogihara T, et al. **Blood Press Suppl** 1996; 2:78–81 (9 ref.)

The angiotensin II type 1 receptor blocker losartan in clinical practice: a review. Gavras HP, et al. **Clin Ther** 1996 Nov–Dec;18(6):1058–67; discussion 1057 (10 ref.)

Aldose reductase inhibitors: the end of an era or the need for different trial designs? Pfeifer MA, et al. **Diabetes** 1997 Sep;46 Suppl 2:S82–9 (59 ref.)

A risk–benefit assessment of losartan potassium in the treatment of hypertension. Burrell LM. **Drug Saf** 1997 Jan; 16(1):56–65 (33 ref.)

Moxonidine for hypertension. **Drug Ther Bull** 1997 May; 35(5):33–6 (16 ref.)

Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Goa KL, et al. **Drugs** 1996 May;51(5):820–45 (138 ref.)

Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. Tamminga CA, et al. **Int Clin Psychopharmacol** 1997 Feb;12 Suppl 1:S29–35 (7 ref.)

Effective antihypertensive therapy: blood pressure control with moxonidine. Prichard BN, et al. **J Cardiovasc Pharmacol** 1996;27 Suppl 3:S38–48 (40 ref.)

Losartan: first of a new class of angiotensin antagonists for the management of hypertension. Carr AA, et al. **J Clin Pharmacol** 1996 Jan;36(1):3–12 (34 ref.)

Considerations in the treatment of insulin resistance and related disorders with a new sympatholytic agent. Lithell HO. **J Hypertens Suppl** 1997 Jan;15(1):S39–42 (30 ref.)

The use of moxonidine in the treatment of hypertension. Prichard BN, et al. **J Hypertens Suppl** 1997 Jan; 15(1):S47–55 (50 ref.)

[Review of the latest treatments of vulvovaginal mycoses: role of fenticonazole nitrate (Lomexin) in their treatment] Cohen J. **Contracept Fertil Sex** 1997 May;25(5):396–403 (35 ref.) (Eng. Abstr.) **(Fre)**

The medicine of the month. Losartan (Cozaar)] Scheen AJ. **Rev Med Liege** 1997 May;52(5):367–9 (8 ref.) **(Fre)**

[Losartan, an angiotensin II receptor blocker: a new trend in cardiovascular chemotherapy] Krasnikova TL. **Klin Med (Mosk)** 1996;74(3):17–21 (38 ref.) **(Rus)**

TOXICITY

Heterocyclic amines: evaluation of their role in diet associated human cancer. Gooderham NJ, et al. **Br J Clin Pharmacol** 1996 Jul;42(1):91–8 (56 ref.)

Genetic changes induced by heterocyclic amines. Nagao M, et al. **Mutat Res** 1997 May 12;376(1–2):161–7 (43 ref.)

IMIDAZOLIDINETHIONE see **ETHYLENETHIOUREA**

IMIDOBENZYLE see **IMIPRAMINE**

IMINES

PHARMACOLOGY

Acetaminophen, N–acetyl–benzo–quinoneimine, and apoptosis [comment] Luft FC. **J Mol Med** 1997 Jul; 75(7):465–6 (8 ref.) Comment on: J Mol Med 1997 Jul;75(7):522–7.

IMINO ACIDS

DIAGNOSTIC USE

The rim sign in hepatic abscess: case report and review of the literature. McDonald KL, et al. **J Nucl Med** 1997 Aug; 38(8):1282–3 (7 ref.)

IMIPEMIDE see **IMIPENEM**

IMIPENEM

THERAPEUTIC USE

Empirical treatment of febrile neutropenia: evolution of current therapeutic approaches. Hathorn JW, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S256–65 (72 ref.)

[Severe orbital cellulitis: therapeutic results in 9 patients and review of the literature] Asensi V, et al. **Enferm Infecc Microbiol Clin** 1996 Apr;14(4):250–4 (24 ref.) (Eng. Abstr.) **(Spa)**

IMIPRAMINE

ADVERSE EFFECTS

Death of two subjects due to imipramine and desipramine metabolite accumulation during chronic therapy: a review of the literature and possible mechanisms. Swanson JR, et al. **J Forensic Sci** 1997 Mar;42(2):335–9 (40 ref.)

THERAPEUTIC USE

[Drug therapy of enuresis] von Gontard A, et al. **Z Kinder Jugenpsychiatr** 1996 Mar;24(1):18–33 (65 ref.) **(Ger)**

IMITATIVE BEHAVIOR

Input and learning processes in first language acquisition. Moerk EL. **Adv Child Dev Behav** 1996;26:181–228 (275 ref.)

IMIZIN see **IMIPRAMINE**

IMMEDIATE–EARLY GENES see **GENES, IMMEDIATE–EARLY**

IMMEDIATE–EARLY PROTEINS

GENETICS

Functional roles of immediate early proteins encoded by the human cytomegalovirus UL36–38, UL115–119, TRS1/IRS1 and US3 loci. Colberg–Poley AM. **Intervirology** 1996;39(5–6):350–60 (78 ref.)

Regulation of human cytomegalovirus immediate–early gene expression. Meier JL, et al. **Intervirology** 1996; 39(5–6):331–42 (114 ref.)

Activation and regulation of human cytomegalovirus early genes. Spector DH. **Intervirology** 1996;39(5–6):361–77 (107 ref.)

The human cytomegalovirus major immediate–early gene. Stenberg RM. **Intervirology** 1996;39(5–6):343–9 (56 ref.)

IMMEDIATE RECALL see **MEMORY, SHORT–TERM**

IMMERSION

see related
DIVING
DROWNING

IMMIGRATION see **EMIGRATION AND IMMIGRATION**

IMMOBILIZATION

Entrapment, extrication and immobilization. Mahoney PF, et al. **Eur J Emerg Med** 1996 Dec;3(4):244–6 (16 ref.)

A review of spinal immobilization techniques. De Lorenzo RA. **J Emerg Med** 1996 Sep–Oct;14(5):603–13 (91 ref.)

ADVERSE EFFECTS

Deep venous thrombosis and pulmonary embolism following cast immobilization of the lower extremity. Nesheiwat F, et al. **J Foot Ankle Surg** 1996 Nov–Dec;35(6):590–4; discussion 602 (24 ref.)

[The immobilization syndrome] Dénes Z. **Orv Hetil** 1996 Aug 11;137(32):1739–43 (36 ref.) (Eng. Abstr.) **(Hun)**

PHYSIOLOGY

Anesthesia for North American cervids Caulkett NA. **Can Vet J** 1997 Jun;38(6):389–90 (3 ref.)

IMMOBILIZED CELLS see **CELLS, IMMOBILIZED**

IMMOBILIZED ENZYMES see **ENZYMES, IMMOBILIZED**

IMMOTILE CILIA SYNDROME see **CILIARY MOTILITY DISORDERS**

IMMUNE–ASSOCIATED ANTIGENS see **HISTOCOMPATIBILITY ANTIGENS CLASS II**

IMMUNE–ASSOCIATED ANTIGENS, HUMAN see **HLA–D ANTIGENS**

IMMUNE COMPLEX see **ANTIGEN–ANTIBODY COMPLEX**

IMMUNE COMPLEX DISEASES

[Immune complex mediated tubulo–interstitial nephritis] Ehara T, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):284–6 (7 ref.) **(Jpn)**

DIAGNOSIS

[Antigens and antibodies in circulating immune complex. Intensive diagnosis of symptoms difficult to interpret] Lefvert AK. **Lakartidningen** 1997 Feb 26;94(9):719–20 (4 ref.) **(Swe)**

ETIOLOGY

Complement synthesis in the injured kidney: does it have a role in immune complex glomerulonephritis? [comment] Sacks SH, et al. **J Am Soc Nephrol** 1996 Nov;7(11):2314–9 (56 ref.) Comment on: J Am Soc Nephrol 1996 Nov;7(11):2428–33.

GENETICS

[Molecular pathogenesis of experimental membraneous glomerulonephritis (Heymann nephritis)] Kerjaschki D. **Pathologe** 1996 Jul;17(4):262–8 (45 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Atheroarteritis: a combined immunological and lipid imbalance. Wissler RW, et al. **Int J Cardiol** 1997 Aug;54 Suppl:S37–49 (126 ref.)

Complement and immune complexes. Schifferli JA. **Res Immunol** 1996 Feb;147(2):109–10 (10 ref.)

[Nephrology update—IV. Rapidly progressing glomerulonephritis] Fünfstück R, et al. **Med Klin** 1996 Oct 15;91(10):632–9 (120 ref.) **(Ger)**

PATHOLOGY

Complement and immune complexes. Schifferli JA. **Res Immunol** 1996 Feb;147(2):109–10 (16 ref.)

IMMUNE GLOBULIN, RH see **RHO(D) IMMUNE GLOBULIN**

IMMUNE GLOBULINS see **IMMUNOGLOBULINS**

IMMUNE MONITORING see **MONITORING, IMMUNOLOGIC**

IMMUNE RESPONSE ANTIGENS see **HISTOCOMPATIBILITY ANTIGENS CLASS II**

IMMUNE-RESPONSE ANTIGENS, HUMAN see **HLA-D ANTIGENS**

IMMUNE-RESPONSE-ASSOCIATED ANTIGENS see **HISTOCOMPATIBILITY ANTIGENS CLASS II**

IMMUNE RESPONSE-ASSOCIATED ANTIGENS, HUMAN see **HLA-D ANTIGENS**

IMMUNE RESPONSE GENES see **GENES, MHC CLASS II**

IMMUNE RESPONSE, MUCOSAL see **IMMUNITY, MUCOSAL**

IMMUNE RNA MANIPULATION see **IMMUNOTHERAPY, ACTIVE**

IMMUNE SERA

see related
IMMUNIZATION, PASSIVE

IMMUNE SYSTEM

Contemplations on the evolution of pro- and eukaryotic mono(ADP-ribosyl) transferases in the context of the immune system. Howard JC. **Adv Exp Med Biol** 1997; 419:453–8 (31 ref.)

The immune system following bone marrow transplantation. Ross DW. **Arch Pathol Lab Med** 1996 Sep;120(9):885–6 (6 ref.)

Molecular evolution of the vertebrate immune system. Hughes AL, et al. **Bioessays** 1997 Sep;19(9):777–86 (71 ref.)

Immunity, components of the immune system and immune response. Röllinghoff M. **Biologicals** 1997 Jun;25(2):165–8 (3 ref.)

Cytokines and immuno-endocrine factors in recurrent miscarriage. Lim KJ, et al. **Hum Reprod Update** 1996 Nov-Dec;2(6):469–81 (152 ref.)

Chance encounters and organized rendezvous. Goodnow CC. **Immunol Rev** 1997 Apr;156:5–10 (20 ref.)

Granulocyte-macrophage colony-stimulating factor and the immune system. Tarr PE. **Med Oncol** 1996 Sep; 13(3):133–40 (101 ref.)

[Catalytic antibodies: generation of a new class of protein catalysts exploiting the immune system] Fujii I. **Yakugaku Zasshi** 1996 Aug;116(8):606–21 (26 ref.) (Eng. Abstr.) **(Jpn)**

ANATOMY & HISTOLOGY

The structure and function of the avian immune system. Sharma JM. **Acta Vet Hung** 1997;45(3):229–38 (47 ref.)

CHEMISTRY

Lectin–carbohydrate interaction in the immune system. Ni Y, et al. **Vet Immunol Immunopathol** 1996 Dec; 55(1–3):205–23 (135 ref.)

CYTOLOGY

VIP modulation of immune cell functions. De la Fuente M, et al. **Adv Neuroimmunol** 1996;6(1):75–91 (132 ref.)

Bcl-x and the regulation of survival in the immune system. Behrens TW, et al. **Immunol Res** 1997;16(2):149–60 (72 ref.)

Beta-endorphin in the immune system: a role at last? Panerai AE, et al. **Immunol Today** 1997 Jul;18(7):317–9 (32 ref.)

The lost chord: microchimerism and allograft survival. Starzl TE, et al. **Immunol Today** 1996 Dec;17(12):577–84; discussion 588 (78 ref.)

[Programmed cell death and apoptosis: their significance for the development and functioning of the immune system] Pevnitskiĭ LA. **Vestn Ross Akad Med Nauk** 1996;(6):43–50 (97 ref.) **(Rus)**

DRUG EFFECTS

HIV-1 neuropathogenesis and abused drugs: current reviews, problems, and solutions. Shapshak P, et al. **Adv Exp Med Biol** 1996;402:171–86 (122 ref.)

VIP modulation of immune cell functions. De la Fuente M, et al. **Adv Neuroimmunol** 1996;6(1):75–91 (132 ref.)

Immunoregulatory role of neurotransmitters. Qiu Y, et al. **Adv Neuroimmunol** 1996;6(3):223–31 (51 ref.)

A brief review of immunomodulation caused by acute administration of ethanol: involvement of neuroendocrine pathways. Pruett SB, et al. **Alcohol Alcohol Suppl** 1994; 2:431–7 (44 ref.)

Recent studies on the effects of fetal alcohol exposure on the endocrine and immune systems. Weinberg J. **Alcohol Alcohol Suppl** 1994;2:401–9 (96 ref.)

Immune regulation by cannabinoid compounds through the inhibition of the cyclic AMP signaling cascade and altered gene expression. Kaminski NE. **Biochem Pharmacol** 1996 Oct 25;52(8):1133–40 (61 ref.)

The pharmacology, metabolism, and chemistry of clofazimine. O'Connor R, et al. **Drug Metab Rev** 1995; 27(4):591–614 (152 ref.)

Organochlorine-associated immunosuppression in prefledgling Caspian terns and herring gulls from the Great Lakes: an ecoepidemiological study. Grasman KA, et al. **Environ Health Perspect** 1996 Aug;104 Suppl 4:829–42 (92 ref.)

Immunotoxicity of pesticides: perspectives and trends. Banerjee BD, et al. **Indian J Exp Biol** 1996 Aug; 34(8):723–33 (45 ref.)

Clinical immunotoxicity of antirheumatic drugs. Bálint G, et al. **Inflamm Res** 1996 Dec;45 Suppl 2:S91–5 (70 ref.)

Pathology of toxic effects on the immune system. Gopinath C. **Inflamm Res** 1996 Dec;45 Suppl 2:S74–8 (14 ref.)

Cytokine-induced cytotoxic function expressed by lymphocytes of the innate immune system: distinguishing characteristics of NK and LAK based on functional and molecular markers. Frederick M, et al. **J Interferon Cytokine Res** 1997 Aug;17(8):435–47 (124 ref.)

Cytotoxic drugs, programmed cell death, and the immune system: defining new roles in an old play [editorial] Debatin KM. **J Natl Cancer Inst** 1997 Jun 4;89(11):750–1 (17 ref.)

Effects of mercury on the immune system. Pollard KM, et al. **Met Ions Biol Syst** 1997;34:421–40 (100 ref.)

Effects of opioids on the immune system. Roy S, et al. **Neurochem Res** 1996 Nov;21(11):1375–86 (71 ref.)

Immunotoxicology of opioids, inhalants, and other drugs of abuse. House RV, et al. **NIDA Res Monogr** 1997; 173:175–200 (51 ref.)

Effects of fatty acids and dietary lipids on cells of the immune system. Calder PC. **Proc Nutr Soc** 1996 Mar;55(1B):127–50 (127 ref.)

The effects of tachykinins on inflammatory and immune cells. Maggi CA. **Regul Pept** 1997 Jun 18;70(2–3):75–90 (198 ref.)

Immunotoxicology: clinical consequences. Luster MI. **Toxicol Ind Health** 1996 May-Aug;12(3–4):533–5 (5 ref.)

[Cyclosporin in ophthalmology] Malchuk DIu. **Antibiot Khimioter** 1997;42(7):25–9 (95 ref.) **(Rus)**

[Effect of contemporary chemotherapeutic drugs on phagocyte activity and the immune response] Nikitin AV, et al. **Antibiot Khimioter** 1996;41(7–8):49–56 (14 ref.) **(Rus)**

[Immunotoxicity assessment in the preclinical study of biologically active compounds] Uteshev BS, et al. **Eksp Klin Farmakol** 1996 May-Jun;59(3):3–8 (71 ref.) (Eng. Abstr.) **(Rus)**

EMBRYOLOGY

The role of the fetal immune system in the pathogenesis of RhD-hemolytic disease of newborns. Gurevich P, et al. **Hum Antibodies** 1997;8(2):76–89 (120 ref.)

GROWTH & DEVELOPMENT

The role of Ets transcription factors in the development and function of the mammalian immune system. Bassuk AG, et al. **Adv Immunol** 1997;64:65–104 (273 ref.)

Do milk-borne cytokines and hormones influence neonatal immune cell function? Ellis LA, et al. **J Nutr** 1997 May; 127(5 Suppl):985S–988S (30 ref.)

The maturation of the immune system. Hanson LA, et al. **Monogr Allergy** 1996;32:10–5 (23 ref.)

Development of immune functions related to allergic mechanisms in young children. Koning H, et al. **Pediatr Res** 1996 Sep;40(3):363–75 (202 ref.)

IMMUNOLOGY

Prolactin, growth hormone, and insulin-like growth factor-I in the immune system. Kooijman R, et al. **Adv Immunol** 1996;63:377–454 (364 ref.)

Functional and molecular characterization of VIP receptors and signal transduction in human and rodent immune systems. Calvo JR, et al. **Adv Neuroimmunol** 1996; 6(1):39–47 (52 ref.)

Sixteenth Gaddum Memorial Lecture December 1996. Neuroimmune interactions: the role of cytokines. Rothwell NJ. **Br J Pharmacol** 1997 Jul;121(5):841–7 (62 ref.)

Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Zinkernagel RM, et al. **Immunol Rev** 1997 Apr;156:199–209 (84 ref.)

How the immune system works and why it causes autoimmune diseases. Adams D. **Immunol Today** 1996 Jul; 17(7):300–2 (25 ref.)

The lost chord: microchimerism and allograft survival. Starzl TE, et al. **Immunol Today** 1996 Dec;17(12):577–84; discussion 588 (78 ref.)

Searching for genes involved in the pathogenesis of primary immunodeficiency diseases: lessons from mouse knockouts. Kokron CM, et al. **J Clin Immunol** 1997 Mar;17(2):109–26 (236 ref.)

Exercise and immunity: a review with emphasis on the horse. Hines MT, et al. **J Vet Intern Med** 1996 Sep-Oct; 10(5):280–9 (122 ref.)

Interactions between magnesium and vitamin D: possible implications in the immune system. McCoy H, et al. **Magnes Res** 1996 Oct;9(3):185–203 (196 ref.)

Cytokines and cell regulation. Fridman WH, et al. **Mol Aspects Med** 1997 Feb;18(1):3–90 (250 ref.)

Dendritic cells in immune response induction. Marland G, et al. **Stem Cells** 1996 Sep;14(5):501–7 (41 ref.)

The immune system of ectothermic vertebrates. Flajnik MF. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):145–50 (33 ref.)

[Heart surgery, cardiopulmonary bypass, and organic inflammatory response. Part II: changes in leukocytes, arachidonic acid derivatives, and hormones] Parolari A, et al. **G Ital Cardiol** 1996 May;26(5):545–61 (153 ref.) (Eng. Abstr.) **(Ita)**

[The immunomodulating effect of noise (a review of the literature)] Grishina TI, et al. **Med Tr Prom Ekol** 1997; (3):26–9 (31 ref.) **(Rus)**

[Nondrug methods for correcting the immune system in the rehabilitative treatment of patients with a history of viral hepatitides] Belichenko TA. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Sep-Oct;(5):46–9 (57 ref.) **(Rus)**

[The immune system and the defense of the gastric mucosal barrier] Serrano Aulló MT, et al. **Gastroenterol Hepatol** 1997 May;20 Suppl 2:44–9 (37 ref.) **(Spa)**

[The current concepts of the influence of lactobacilli on the immune system of the human body] Kostiuk OP, et al. **Fiziol Zh** 1997;43(3–4):106–15 (51 ref.) (Eng. Abstr.) **(Ukr)**

METABOLISM

A purinergic hypothesis for immunomodulation. Di Virgilio F, et al. **Ital J Biochem** 1996 Dec;45(4):195–203 (42 ref.)

Interactions between magnesium and vitamin D: possible implications in the immune system. McCoy H, et al. **Magnes Res** 1996 Oct;9(3):185–203 (196 ref.)

PATHOLOGY

The effects of tachykinins on inflammatory and immune cells. Maggi CA. **Regul Pept** 1997 Jun 18;70(2–3):75–90 (198 ref.)

Detrimental effect of bovine leukemia virus (BLV) on the immunological state of cattle. Trainin Z, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):293–302 (34 ref.)

PHYSIOLOGY

Nutritional metabolic diseases of poultry and disorders of the biological antioxidant defence system. Mézes M, et al. **Acta Vet Hung** 1997;45(3):349–60 (55 ref.)

The structure and function of the avian immune system. Sharma JM. **Acta Vet Hung** 1997;45(3):229–38 (47 ref.)

Morphine affects the brain-immune axis by modulating an interleukin-1 beta dependent pathway. Chang SL, et al. **Adv Exp Med Biol** 1996;402:35–42 (34 ref.)

The role of Ets transcription factors in the development and function of the mammalian immune system. Bassuk AG, et al. **Adv Immunol** 1997;64:65–104 (273 ref.)

Immune mechanisms of long-term graft acceptance. Hutchinson IV. **Adv Nephrol Necker Hosp** 1996;25:17–38 (38 ref.)

Role of nitric oxide in cell-mediated tumor cytotoxicity. Cifone MG, et al. **Adv Neuroimmunol** 1995;5(4):443–61 (145 ref.)

Interdependence of the endocrine and immune systems. Dardenne M, et al. **Adv Neuroimmunol** 1996;6(4):297–307 (73 ref.)

Expression of vasoactive intestinal peptide in lymphocytes: a possible endogenous role in the regulation of the immune system. Leceta J, et al. **Adv Neuroimmunol** 1996;6(1):29–36 (35 ref.)

Aging, immunity and neuroendocrine hormones. Mosley RL. **Adv Neuroimmunol** 1996;6(4):419–32 (117 ref.)

Death and dying in the immune system. Ucker DS. **Adv Pharmacol** 1997;41:179–218 (317 ref.)

Exercise, immunity and aging. Venjatraman JT, et al. **Aging (Milano)** 1997 Feb-Apr;9(1–2):42–56 (122 ref.)

Nutrition and the immune system: an introduction. Chandra RK. **Am J Clin Nutr** 1997 Aug;66(2):460S–463S (15 ref.)

The relationship between the immune and endocrine systems. Chryssikopoulos A. **Ann N Y Acad Sci** 1997 Jun 17; 816:83–93 (66 ref.)

Immune modulation of the hypothalamic-pituitary-adrenal axis. Cytokines and gases in the hypothalamus. Grossman A, et al. **Ann N Y Acad Sci** 1997 Aug 14;823:225–33 (17 ref.)

Heparan sulfate in immune responses. Selvan RS, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:127–39 (106 ref.)

The immune system as a supersystem. Tada T. **Annu Rev Immunol** 1997;15:1–13 (16 ref.)

The immune effects of neuropeptides. Berczi I, et al. **Baillieres Clin Rheumatol** 1996 May;10(2):227–57 (217 ref.)

The three-way interactions between the hypothalamic-pituitary-adrenal and gonadal axes and the immune system. Torpy DJ, et al. **Baillieres Clin Rheumatol** 1996 May;10(2):181–98 (102 ref.)

How cells instruct the immune system to carry out their elimination. Fernandez-Borja M, et al. **Biochem Soc Trans** 1996 Nov;24(4):1039–43 (38 ref.)

Functional interpretation of the organization of mammalian

adipose tissue: its relationship to the immune system. Pond CM. **Biochem Soc Trans** 1996 May;24(2):393–400 (25 ref.)

DNA methylation: regulation of gene expression and role in the immune system. Mostoslavsky R, et al. **Biochim Biophys Acta** 1997 Aug 8;1333(1):F29–50 (217 ref.)

The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions. McEwen BS, et al. **Brain Res Brain Res Rev** 1997 Feb;23(1–2):79–133 (485 ref.)

Interactions between sleep, other body rhythms, immune responses, and exercise. Shephard RJ, et al. **Can J Appl Physiol** 1997 Apr;22(2):95–116 (219 ref.)

Immunoglobulins and the regulation of autoimmunity through the immune network. Lacroix-Desmazes S, et al. **Clin Exp Rheumatol** 1996 May–Jun;14 Suppl 15:S9–15 (31 ref.)

A simple systems approach to neural–immune communication. Clatworthy AL. **Comp Biochem Physiol A Physiol** 1996 Sep;115(1):1–10 (77 ref.)

Hormones, lymphohemopoietic cytokines and the neuroimmune axis. Johnson RW, et al. **Comp Biochem Physiol A Physiol** 1997 Mar;116(3):183–201 (210 ref.)

Opioid and opiate immunoregulatory processes. Stefano GB, et al. **Crit Rev Immunol** 1996;16(2):109–44 (258 ref.)

Assessment of immune mediator expression levels in biological fluids and cells: a critical appraisal. Patarca R, et al. **Crit Rev Oncog** 1995;6(2):117–49 (289 ref.)

Danger – pathogen on the premises! Immunological tolerance. Janeway CA Jr, et al. **Curr Biol** 1996 May 1; 6(5):519–22 (20 ref.)

Lymphocyte activation and effector functions. How signals are integrated in the immune system. Nussenzweig M, et al. **Curr Opin Immunol** 1997 Jun;9(3):293–5 (0 ref.)

Apoptosis and the maintenance of homoeostasis in the immune system. Osborne BA. **Curr Opin Immunol** 1996 Apr;8(2):245–54 (89 ref.)

Immunomodulatory function of major histocompatibility complex-derived peptides. Murphy B, et al. **Curr Opin Nephrol Hypertens** 1996 May;5(3):262–8 (58 ref.)

Immunosenescence revisited. Does it have any clinical significance? Voets AJ, et al. **Drugs Aging** 1997 Jul; 11(1):1–6 (84 ref.)

Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Ben-Jonathan N, et al. **Endocr Rev** 1996 Dec;17(6):639–69 (368 ref.)

Sympathoadrenal system and immune system in the regulation of adrenocortical function. Ehrhart-Bornstein M, et al. **Eur J Endocrinol** 1996 Jul;135(1):19–26 (133 ref.)

Essential fatty acids, immune function, and exercise. König D, et al. **Exerc Immunol Rev** 1997;3:1–31 (236 ref.)

Melatonin and the immune system. Liebmann PM, et al. **Int Arch Allergy Immunol** 1997 Mar;112(3):203–11 (110 ref.)

Tumor recognition by the cellular immune system: new aspects of tumor immunology. Maeurer MJ, et al. **Int Rev Immunol** 1997;14(2–3):97–132 (155 ref.)

Nutrition and the immune system: a review of nutrient-nutrient interactions. Kubena KS, et al. **J Am Diet Assoc** 1996 Nov;96(11):1156–64; quiz 1165–6 (90 ref.)

Regulation of metabolism and growth during immune challenge: an overview of cytokine function. Spurlock ME. **J Anim Sci** 1997 Jul;75(7):1773–83 (90 ref.)

Immune response to heavy exertion. Nieman DC. **J Appl Physiol** 1997 May;82(5):1385–94 (91 ref.)

Proceedings of the 1st annual meeting of the Cardiopulmonary Bypass Consensus Panel. Napa Valley, California, October 19–21, 1994. **J Cardiovasc Pharmacol** 1996;27 Suppl 1:v–vii, S1–70 (0 ref.)

Fidelity assurance mechanisms of the brain with special reference to its immunogenic CNS compartment: their role in aging and aging-associated neurological disease. Blumenthal HT. **J Gerontol A Biol Sci Med Sci** 1997 Jan; 52(1):B1–9 (96 ref.)

Zinc modulation of immune function: specificity and mechanism of interaction [editorial; comment] Cunningham-Rundles S. **J Lab Clin Med** 1996 Jul; 128(1):9–11 (31 ref.) Comment on: J Lab Clin Med 1996 Jul;128(1):51–60.

CRH and the immune system. Karalis K, et al. **J Neuroimmunol** 1997 Feb;72(2):131–6 (87 ref.)

The immune-neuro-endocrine interactions. Tomaszewska D, et al. **J Physiol Pharmacol** 1997 Jun;48(2):139–58 (100 ref.)

TGF-beta and the endothelium during immune injury. Pintavorn P, et al. **Kidney Int** 1997 May;51(5):1401–12 (193 ref.)

Genetic control of immune responsiveness, aging and tumor incidence. Doria G, et al. **Mech Ageing Dev** 1997 Jun; 96(1–3):1–13 (50 ref.)

Behavioral-neuroendocrine-immunologic interactions in myocardial infarction. Goodkin K, et al. **Med Hypotheses** 1997 Mar;48(3):209–14 (45 ref.)

Neuroendocrine and immune system responses with spaceflights. Tipton CM, et al. **Med Sci Sports Exerc** 1996 Aug;28(8):988–98 (78 ref.)

Immunomodulation by proteolytic enzymes [editorial] Lehmann PV. **Nephrol Dial Transplant** 1996 Jun; 11(6):952–5 (12 ref.)

Interactions between adipose tissue and the immune system. Pond CM. **Proc Nutr Soc** 1996 Mar;55(1B):111–26 (61 ref.)

Molecular actions of prolactin in the immune system. Yu-Lee LY. **Proc Soc Exp Biol Med** 1997 May;215(1):35–52 (292 ref.)

Immaturity, ageing and oral tolerance. Vaz N, et al. **Scand J Immunol** 1997 Sep;46(3):225–9 (75 ref.)

Is cancer dangerous to the immune system? Fuchs EJ, et al. **Semin Immunol** 1996 Oct;8(5):271–80 (46 ref.)

The role of the Bcl-2 family of apoptosis regulatory proteins in the immune system. Hawkins CJ, et al. **Semin Immunol** 1997 Feb;9(1):25–33 (93 ref.)

Chromosomal duplication and the emergence of the adaptive immune system. Kasahara M, et al. **Trends Genet** 1997 Mar; 13(3):90–2 (22 ref.)

T-cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms. Gold R, et al. **Trends Neurosci** 1997 Sep;20(9):399–404 (64 ref.)

[Cell death and lupus] Fournié G. **Ann Med Interne (Paris)** 1996;147(7):472–9 (63 ref.) (Eng. Abstr.) **(Fre)**

[Genetic anomalies of the human immune system] Fischer A. **Bull Acad Natl Med** 1997 May;181(5):899–916; discussion 916–8 (54 ref.) (Eng. Abstr.) **(Fre)**

[Neuro-immuno-cutaneous system (NICS)] Misery L. **Pathol Biol (Paris)** 1996 Dec;44(10):867–74 (86 ref.) (Eng. Abstr.) **(Fre)**

[Apoptosis in the immune system: murder or suicide] Krammer PH. **Pharm Unserer Zeit** 1996 Nov;25(6):306–10 (29 ref.) **(Ger)**

[Aging and immunity] Hosokawa T. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):602–4 (11 ref.) **(Jpn)**

[Interactions between neuron, immune, and endocrine systems] Yoshida S, et al. **No To Shinkei** 1996 Aug; 48(8):703–10 (48 ref.) **(Jpn)**

[The influence of psychological factors on the immune system and immunological diseases] Kjeldsen-Kragh J. **Tidsskr Nor Laegeforen** 1996 Oct 30;116(26):3102–7 (34 ref.) (Eng. Abstr.) **(Nor)**

[Immuno-physiological and hematological aspects of flight certification examination] Goranchuk VV, et al. **Aviakosm Ekolog Med** 1996;30(1):54–7 (12 ref.) (Eng. Abstr.) **(Rus)**

[Is the immune system our sixth sense? Relation between the immune and neuroendocrine systems] Ferenčík M, et al. **Bratisl Lek Listy** 1997 Apr;98(4):187–98 (84 ref.) (Eng. Abstr.) **(Slo)**

[The transcendence of prolactin and its relation to the immune response] Sandoval C, et al. **Ginecol Obstet Mex** 1997 Apr;65:148–51 (26 ref.) (Eng. Abstr.) **(Spa)**

[Endogenous opioid peptides and the immune system] Peramo F, et al. **Rev Esp Anestesiol Reanim** 1997 Apr; 44(4):150–3 (43 ref.) (Eng. Abstr.) **(Spa)**

[The formation of immune system function in early postnatal ontogeny] Baieva OV. **Fiziol Zh** 1997;43(3–4):116–29 (85 ref.) (Eng. Abstr.) **(Ukr)**

PHYSIOPATHOLOGY

Biocompatibility of peritoneal dialysis solutions and host defense. Topley N. **Adv Ren Replace Ther** 1996 Oct; 3(4):309–11 (8 ref.)

The neuroendocrine immunology of rheumatoid arthritis . Chikanza IC. **Baillieres Clin Rheumatol** 1996 May; 10(2):273–93 (59 ref.)

Lymphocytes, cytokines, inflammation, and immune trafficking. Tsokos GC, et al. **Curr Opin Rheumatol** 1997 Sep;9(5):380–6 (57 ref.)

Immunologic evaluation of the child with recurrent otitis media. Church JA. **Ear Nose Throat J** 1997 Jan;76(1):31–4, 42 (21 ref.)

Do immune system changes have a role in hypertension? Fu ML. **J Hypertens** 1995 Nov;13(11):1259–65 (68 ref.)

The dendritic cell in clinical immunology: the AIDS example. Steinman RM. **J Lab Clin Med** 1996 Dec; 128(6):531–5 (18 ref.)

Postganglionic cholinergic dysautonomia with incomplete recovery: a clinical, neurophysiological and immunological case study. Baron R, et al. **J Neurol** 1996 Jan;243(1):18–24 (46 ref.)

Viruses and autoimmune disease [editorial] Vaughan JH. **J Rheumatol** 1996 Nov;23(11):1831–3 (24 ref.)

Granulomas in murine schistosomiasis mansoni have a somatostatin immunoregulatory circuit. Elliott DE, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):88–90 (37 ref.)

Emotions and disease: from balance of humors to balance of molecules. Sternberg EM. **Nat Med** 1997 Mar;3(3):264–7 (45 ref.)

RADIATION EFFECTS

Molecular aspects of UVB-induced immunosuppression. Garssen J, et al. **Arch Toxicol Suppl** 1997;19:97–109 (60 ref.)

UV-induced cutaneous photobiology. Beissert S, et al. **Crit Rev Biochem Mol Biol** 1996 Dec;31(5–6):381–404 (150 ref.)

[Changes in the immune system of the victims of the action of the factors in the accident at the Chernobyl Atomic Electric Power Station. Their manifestations, nature and the possible sequelae] Iarilin AA, et al. **Radiats Biol Radioecol** 1996 Jul–Aug;36(4):587–600 (60 ref.) (Eng. Abstr.) **(Rus)**

VIROLOGY

Viral diseases of the immune system and strategies to control infectious bursal disease by vaccination. Lütticken D. **Acta Vet Hung** 1997;45(3):239–49 (37 ref.)

Detrimental effect of bovine leukemia virus (BLV) on the immunological state of cattle. Trainin Z, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):293–302 (34 ref.)

IMMUNE TOLERANCE

see related
GRAFT VS HOST DISEASE
IMMUNOCOMPROMISED HOST
IMMUNOSUPPRESSION

Tolerance and intolerance to factor VIII: a clinical perspective. Briët E. **Adv Exp Med Biol** 1995;386:193–9 (32 ref.)

Immune tolerance to Factor VIII: the international registry data. Mariani G, et al. **Adv Exp Med Biol** 1995;386:201–8 (19 ref.)

Multiple mechanisms of immunologic tolerance: novel approaches for unresponsiveness. Scott DW. **Adv Exp Med Biol** 1995;386:209–20 (52 ref.)

Nasal tolerance to dominant and subdominant epitopes of collagen type II and protection against collagen-induced arthritis. Staines NA, et al. **Biochem Soc Trans** 1997 May; 25(2):661–4 (32 ref.)

Effect of blood transfusion on postoperative immunocompetence [editorial] Wheatley T, et al. **Br J Anaesth** 1997 May;78(5):489–92 (64 ref.)

Immunological responses to thermal injury. Sparkes BG. **Burns** 1997 Mar;23(2):106–13 (83 ref.)

Suppression of cell-mediated immunity due to immune deviation. Zhang Y. **Chin Med J (Engl)** 1996 Oct; 109(10):739–42 (5 ref.)

Cytokine regulation of immune responses and further reflections on self–non–self discrimination. **Ciba Found Symp** 1997;204:187–9 (0 ref.)

Glimpses into the balance between immunity and self-tolerance. Goodnow CC. **Ciba Found Symp** 1997; 204:190–202; discussion 202–7 (25 ref.)

Dendritic cells and tolerance induction. Steptoe RJ, et al. **Clin Exp Immunol** 1996 Sep;105(3):397–402 (91 ref.)

Mechanisms of oral tolerance. Garside P, et al. **Crit Rev Immunol** 1997;17(2):119–37 (130 ref.)

Immunologic tolerance. Sarzotti M. **Curr Opin Hematol** 1997 Jan;4(1):48–52 (49 ref.)

Mechanisms underlying T-cell tolerance. Kruisbeek AM, et al. **Curr Opin Immunol** 1996 Apr;8(2):233–44 (111 ref.)

Induction of tolerance by intrathymic inoculation of alloantigen. Naji A. **Curr Opin Immunol** 1996 Oct; 8(5):704–9 (60 ref.)

Chimerism and central tolerance. Sykes M. **Curr Opin Immunol** 1996 Oct;8(5):694–703 (84 ref.)

Peripheral tolerance to alloantigen: strategies for the future. Wood KJ. **Eur J Immunogenet** 1993 Oct;20(5):439–49 (69 ref.)

Tick modulation of host cytokines. Wikel SK. **Exp Parasitol** 1996 Nov;84(2):304–9 (23 ref.)

Effect of major histocompatibility complex matching on the development of tolerance to primarily vascularized renal allografts: a study in miniature swine. Gianello PR, et al. **Hum Immunol** 1996 Sep 15;50(1):1–10 (51 ref.)

Chimerism and tolerance: from freemartin cattle and neonatal mice to humans. Jankowski RA, et al. **Hum Immunol** 1997 Feb;52(2):155–61 (52 ref.)

Immune privilege, T-cell tolerance, and tissue-restricted autoimmunity. Streilein JW, et al. **Hum Immunol** 1997 Feb; 52(2):138–43 (29 ref.)

Induced tolerance and chimaerism in human fetuses using coelocentesis: a medical opportunity to avert genetic disease? Edwards RG, et al. **Hum Reprod Update** 1995 Jul; 1(4):419–27 (70 ref.)

Regulatory mechanisms of antitumor T cell responses in the tumor-bearing state. Fujiwara H, et al. **Immunol Res** 1995; 14(4):271–91 (109 ref.)

Induction of Th2 cell tolerance to a soluble antigen by blockade of the LFA-1-dependent pathway prevents allergic inflammation. Iwamoto I, et al. **Immunol Res** 1995; 14(4):263–70 (36 ref.)

Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8. Cobbold SP, et al. **Immunol Rev** 1996 Feb;149:5–33 (109 ref.)

Pancreatic islet allograft immunity and tolerance: the two-signal hypothesis revisited. Gill RG, et al. **Immunol Rev** 1996 Feb;149:75–96 (94 ref.)

Evidence for a thymus-dependent form of tolerance that is not based on elimination or anergy of reactive T cells. Le Douarin N, et al. **Immunol Rev** 1996 Feb;149:35–53 (67 ref.)

A model for developmentally acquired thymus-dependent tolerance to central and peripheral antigens. Modigliani Y, et al. **Immunol Rev** 1996 Feb;149:155–20 (58 ref.)

Specificity, tolerance and developmental regulation of natural killer cells defined by expression of class I-specific Ly49 receptors. Raulet DH, et al. **Immunol Rev** 1997 Feb; 155:41–52 (46 ref.)

Double negative (CD4–CD8– alpha beta+) T cells which promote tolerance induction and regulate autoimmunity.

Strober S, et al. **Immunol Rev** 1996 Feb;149:217–30 (26 ref.)
Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Weiner HL. **Immunol Today** 1997 Jul; 18(7):335–43 (143 ref.)
Oral tolerance in experimental animals. Telemo E, et al. **Int Arch Allergy Immunol** 1997 May–Jul;113(1–3):219–23 (42 ref.)
The role of T cells in the regulation of B cell tolerance. Fazekas de St. Groth B, et al. **Int Rev Immunol** 1997; 15(1–2):73–99 (77 ref.)
B–cell activation versus tolerance––the central role of immunoglobulin receptor engagement and T–cell help. Fulcher DA, et al. **Int Rev Immunol** 1997;15(1–2):33–52 (22 ref.)
Structure of HLA molecules and immunosuppressive effects of HLA derived peptides. Krensky AM, et al. **Int Rev Immunol** 1996;13(3):173–85 (56 ref.)
Cell death and the immune response: a lesson from the privileged. Ferguson TA, et al. **J Clin Immunol** 1997 Jan; 17(1):1–10 (51 ref.)
Is CTLA–4 a master switch for peripheral T cell tolerance? Bluestone JA. **J Immunol** 1997 Mar 1;158(5):1989–93 (37 ref.)
Reversal of tumor–induced immunosuppression: a new approach to cancer therapy [see comments] Wojtowicz–Praga S. **J Immunother** 1997 May;20(3):165–77 (146 ref.) Comment in: J Immunother 1997 May;20(3):178–9.
Viewing AIDS from a glycobiological perspective: potential linkages to the human fetoembryonic defence system hypothesis. Clark GF, et al. **Mol Hum Reprod** 1997 Jan; 3(1):5–13 (75 ref.)
The role of cell migration and microchimerism in the induction of tolerance after solid organ transplantation. Jindal RM, et al. **Postgrad Med J** 1997 Mar;73(857):146–50 (39 ref.)
The mother–child union: the case of missing–self and protection of the fetus [comment] Yokoyama WM. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):5998–6000 (52 ref.) Comment on: Proc Natl Acad Sci U S A 1997 May 13;94(10):5249–54.
The influence of two distinct alloresponse pathways on the design of peptide–based strategies for allograft tolerance. Benichou G, et al. **Res Immunol** 1996 Jul–Aug; 147(6):377–87 (50 ref.)
The immune–suppressive nature of pain. Page GG, et al. **Semin Oncol Nurs** 1997 Feb;13(1):10–5 (50 ref.)
Thymic selection and tolerance. Kisielow P, et al. **Transplant Proc** 1996 Dec;28(6):3429–30 (34 ref.)
Balancing the immune system for tolerance: a case for regulatory CD4 cells. Field EH, et al. **Transplantation** 1997 Jul 15;64(1):1–7 (86 ref.)
Manipulation of cytokine networks in transplantation: false hope or realistic opportunity for tolerance? Nickerson P, et al. **Transplantation** 1997 Feb 27;63(4):489–94 (71 ref.)
Suppression of T–cell immunity after measles infection: is the puzzle solved? Salmi AA. **Trends Microbiol** 1997 Mar; 5(3):85–6 (12 ref.)
Induction of immune tolerance, the future of the Registry. Ewing NP. **Vox Sang** 1996;70 Suppl 1:47–51 (43 ref.)
Immunologic tolerance in renal transplantation. Shoskes DA. **World J Urol** 1996;14(4):218–24 (90 ref.)
[Mixed chimerism and immune tolerance induction by low–stress pretreatment before kidney transplantation in monkeys] Kawai T, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):670–4 (6 ref.) **(Jpn)**
[Breakdown of B cell–tolerance and its genetic control] Hirose S. **Nippon Rinsho** 1997 Jun;55(6):1450–4 (19 ref.) (Eng. Abstr.) **(Jpn)**
[T cell tolerance and autoimmune disease] Kobayashi S. **Nippon Rinsho** 1997 Jun;55(6):1345–50 (25 ref.) (Eng. Abstr.) **(Jpn)**
[Application of oral tolerance to the treatment of autoimmune diseases––active suppression and bystander suppression] Matsui M. **Nippon Rinsho** 1997 Jun;55(6):1537–42 (25 ref.) (Eng. Abstr.) **(Jpn)**
[Mechanisms for B cell tolerance and their defects in systemic autoimmune diseases] Tsubata T. **Nippon Rinsho** 1997 Jun; 55(6):1351–5 (18 ref.) (Eng. Abstr.) **(Jpn)**
[The mechanisms of oral tolerance] Yamamoto M, et al. **Nippon Rinsho** 1997 Jun;55(6):1444–9 (23 ref.) (Eng. Abstr.) **(Jpn)**
[Measles virus infection and immunosuppression] Yanagi Y. **Uirusu** 1995 Dec;45(2):117–23 (29 ref.) **(Jpn)**

DRUG EFFECTS

Cyclophosphamide–induced immunological tolerance: an overview. Mayumi H, et al. **Immunobiology** 1996 Jul; 195(2):129–39 (74 ref.)

IMMUNOLOGY

Interactions between dietary proteins and the human system: implications for oral tolerance and food–related diseases. Barbeau WE. **Adv Exp Med Biol** 1997;415:183–93 (47 ref.)
Changes in the immune system during and after spaceflight. Taylor GR, et al. **Adv Space Biol Med** 1997;6:1–32 (92 ref.)
Will tolerance become a clinical reality? Aradhye S, et al. **Am J Med Sci** 1997 May;313(5):310–4 (40 ref.)
Immune suppression and Th1/Th2 balance in pregnancy revisited: a (very) personal tribute to Tom Wegmann. Chaouat G, et al. **Am J Reprod Immunol** 1997 Jun; 37(6):427–34 (23 ref.)
Natural autoantibodies, tolerance, and autoimmunity. Dighiero G. **Ann N Y Acad Sci** 1997 Apr 5;815:182–92 (86 ref.)
Oral tolerance: elucidation of mechanisms and application to treatment of autoimmune diseases. Fowler E, et al. **Biopolymers** 1997;43(4):323–35 (99 ref.)
Hematopoietic cell transplantation for the induction of allo– and xenotolerance. Sykes M. **Clin Transplant** 1996 Aug; 10(4):357–63 (48 ref.)
Immunology: why the baby isn't thrown out.... Simpson E. **Curr Biol** 1996 Jan 1;6(1):43–4 (6 ref.)
Use of isolated immature–stage B cells to understand negative selection and tolerance induction at the molecular level. Norvell A, et al. **Immunol Res** 1996;15(3):191–207 (71 ref.)
Chimerism and transplantation tolerance: cause and effect. Wood K, et al. **Immunol Today** 1996 Dec;17(12):584–7; discussion 588 (35 ref.)
Tolerance and chronic rejection. Sayegh MH, et al. **Kidney Int Suppl** 1997 Mar;58:S11–4 (32 ref.)
Immaturity, ageing and oral tolerance. Vaz N, et al. **Scand J Immunol** 1997 Sep;46(3):225–9 (75 ref.)
[Clonal deletion and clonal anergy as the mechanism of self–tolerance induction] Ota H, et al. **Nippon Rinsho** 1997 Jun;55(6):1331–6 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Posttransfusion immunosuppression] Shevchenko IuL, et al. **Voen Med Zh** 1996 Oct;317(10):22–5 (19 ref.) **(Rus)**

PHYSIOLOGY

The role of cytokines in ultraviolet–B induced immunosuppression. Boonstra A, et al. **Eur Cytokine Netw** 1997 Jun;8(2):117–23 (60 ref.)
The role of B7–1/B7–2:CD28/CLTA–4 pathways in the prevention of anergy, induction of productive immunity and down–regulation of the immune response. Boussiotis VA, et al. **Immunol Rev** 1996 Oct;153:5–26 (170 ref.)
Exercise–induced immunomodulation––possible roles of neuroendocrine and metabolic factors. Pedersen BK, et al. **Int J Sports Med** 1997 Mar;18 Suppl 1:S2–7 (51 ref.)
Exercise, immunology and upper respiratory tract infections. Peters EM. **Int J Sports Med** 1997 Mar;18 Suppl 1:S69–77 (101 ref.)
Clonal deletion as a mechanism of transplantation tolerance. Nikolic B, et al. **J Heart Lung Transplant** 1996 Dec; 15(12):1171–8 (72 ref.)
Modulation of T–helper cell populations: potential mechanisms of respiratory hypersensitivity and immune suppression. Selgrade MK, et al. **Toxicol Appl Pharmacol** 1997 Jul;145(1):218–29 (102 ref.)

RADIATION EFFECTS

The role of cytokines in ultraviolet–B induced immunosuppression. Boonstra A, et al. **Eur Cytokine Netw** 1997 Jun;8(2):117–23 (60 ref.)
The role of DNA damage and repair in ultraviolet B radiation–induced immunomodulation: relevance for human photocarcinogenesis. Krutmann J, et al. **Photochem Photobiol** 1996 Apr;63(4):394–6 (27 ref.)
Chromophore for UV–induced immunosuppression: urocanic acid. Norval M. **Photochem Photobiol** 1996 Apr; 63(4):386–90 (42 ref.)
Chromophore for UV–induced immunosuppression: DNA. Vink AA, et al. **Photochem Photobiol** 1996 Apr;63(4):383–6 (27 ref.)
[Ultraviolet light, skin urocanic acid and immune tolerance (editorial)] Laihia J, et al. **Duodecim** 1995;111(10):905–6 (17 ref.) **(Fin)**

IMMUNITY

see related
IMMUNOLOGIC TECHNIQUES
TUMOR ESCAPE

Immunological response in laparoscopic surgery. Smit MJ, et al. **Acta Gastroenterol Belg** 1996 Oct–Dec;59(4):245–7 (14 ref.)
Contemporary concepts of immunological function. Mackay IR. **Alcohol Alcohol Suppl** 1994;2:413–23 (32 ref.)
Immunomodulation by blood transfusion: an evolving scientific and clinical challenge. Blumberg N, et al. **Am J Med** 1996 Sep;101(3):299–308 (9 ref.)
The immune response to prolonged cardiorespiratory exercise. Nieman DC. **Am J Sports Med** 1996;24(6 Suppl):S98–103 (79 ref.)
Balancing immunity, autoimmunity, and self–tolerance. Goodnow CC. **Ann N Y Acad Sci** 1997 Apr 5;815:55–66 (27 ref.)
Immunity to lantibiotics. Saris PE, et al. **Antonie Van Leeuwenhoek** 1996 Feb;69(2):151–9 (49 ref.)
The role of dendritic cells in cutaneous immunity. Lappin MB, et al. **Arch Dermatol Res** 1996 Mar;288(3):109–21 (138 ref.)
Collectins: collectors of microorganisms for the innate immune system. Lu J. **Bioessays** 1997 Jun;19(6):509–18 (79 ref.)
Immunity, components of the immune system and immune response. Röllinghoff M. **Biologicals** 1997 Jun;25(2):165–8 (3 ref.)
Immunological reconstitution after bone marrow transplantation. Porta F, et al. **Bone Marrow Transplant** 1996 Nov;18 Suppl 2:148–50 (12 ref.)
Female sex hormones and the immune system. Chao TC. **Chang Keng I Hsueh** 1996 Mar;19(1):95–106 (149 ref.)
Immune recognition, control of infections and vaccination strategies. **Ciba Found Symp** 1997;204:142–7 (4 ref.)
Glimpses into the balance between immunity and self–tolerance. Goodnow CC. **Ciba Found Symp** 1997; 204:190–202; discussion 202–7 (25 ref.)
Immunology and immunity studied with viruses. Zinkernagel RM. **Ciba Found Symp** 1997;204:105–25; discussion 125–9 (168 ref.)
Gonadal steroids and immunity. Olsen NJ, et al. **Endocr Rev** 1996 Aug;17(4):369–84 (163 ref.)
Impaired immunity in harbour seals (Phoca vitulina) exposed to bioaccumulated environmental contaminants: review of a long–term feeding study. de Swart RL, et al. **Environ Health Perspect** 1996 Aug;104 Suppl 4:823–8 (34 ref.)
Heavy exercise, nutrition and immune function: is there a connection? Shephard RJ, et al. **Int J Sports Med** 1995 Nov;16(8):491–7 (102 ref.)
Immune deviation in relation to ocular immune privilege. Streilein JW, et al. **J Immunol** 1997 Apr 15;158(8):3557–60 (44 ref.)
Successful immunosenescence and the remodelling of immune responses with ageing. Franceschi C, et al. **Nephrol Dial Transplant** 1996;11 Suppl 9:18–25 (91 ref.)
Diet, age, and the immune system. Bradley J, et al. **Nutr Rev** 1996 Nov;54(11 Pt 2):S43–50 (19 ref.)
Regulation of lipid metabolism by cytokines during host defense. Grunfeld C, et al. **Nutrition** 1996 Jan;12(1 Suppl):S24–6 (26 ref.)
Earthworm immunity. Cooper EL. **Prog Mol Subcell Biol** 1996;15:10–45 (201 ref.)
Molecular aspects of immune reactions in Echinodermata. Matranga V. **Prog Mol Subcell Biol** 1996;15:235–47 (65 ref.)
Clotting and immune defense in Limulidae. Muta T, et al. **Prog Mol Subcell Biol** 1996;15:154–89 (155 ref.)
Seasonal changes in immune function. Nelson RJ, et al. **Q Rev Biol** 1996 Dec;71(4):511–48 (270 ref.)
Immune regulatory role of nitric oxide within the central nervous system. Dugas N, et al. **Res Immunol** 1995 Nov–Dec;146(9):707–10 (27 ref.)
The transfusion immunomodulation theory: the Th1/Th2 paradigm and an analogy with pregnancy as a unifying mechanism. Blumberg N, et al. **Semin Hematol** 1996 Oct; 33(4):329–40 (66 ref.)
Radioiodine and the immune system. DeGroot LJ. **Thyroid** 1997 Apr;7(2):259–64 (21 ref.)
Antioxidant vitamins and human immune responses. Bendich A. **Vitam Horm** 1996;52:35–62 (104 ref.)
[Immunoregulatory functions of Fc receptors] Takai T. **Seikagaku** 1997 Jun;69(6):394–409 (74 ref.) **(Jpn)**
[Gram–negative virulent bacterial lipopolysaccharide: role in infection and immunity] Vorobév AA, et al. **Vestn Ross Akad Med Nauk** 1997;(3):10–3 (35 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Restoration of aging reduced immunity is possible with immunomodulators and is applicable to cancer treatment and prevention [editorial] Mathé G, et al. **Biomed Pharmacother** 1997;51(5):193–9 (58 ref.)
Does fluoridation harm immune function? Challacombe SJ. **Community Dent Health** 1996 Sep;13 Suppl 2:69–71 (15 ref.)
Impaired immunity in harbour seals (Phoca vitulina) exposed to bioaccumulated environmental contaminants: review of a long–term feeding study. de Swart RL, et al. **Environ Health Perspect** 1996 Aug;104 Suppl 4:823–8 (34 ref.)
Immunotoxicology of the liver: adverse reactions to drugs. Beaune PH, et al. **J Hepatol** 1997;26 Suppl 2:37–42 (45 ref.)
Schiff base forming drugs: mechanisms of immune potentiation and therapeutic potential. Chen H, et al. **J Mol Med** 1996 Sep;74(9):497–504 (61 ref.)
Melatonin and the immune–hematopoietic system therapeutic and adverse pharmacological correlates. Maestroni GJ, et al. **Neuroimmunomodulation** 1996 Nov–Dec;3(6):325–32 (66 ref.)
Effect of glutamine on immune function in the surgical patient. O'Riordain MG, et al. **Nutrition** 1996 Nov–Dec; 12(11–12 Suppl):S82–4 (14 ref.)
Immunomodulation and epidural anesthesia and analgesia. de Leon–Casasola OA. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):24–5 (16 ref.)
[Mechanism of action and clinical effectiveness of immunomodulator glucosaminylmuramyl dipeptide (licopide)] Ivanov VT, et al. **Klin Med (Mosk)** 1997; 75(3):11–5 (45 ref.) **(Rus)**

GENETICS

The use of embryo genotyping in the propagation of genes involved in the immune response. Saberivand A, et al. **Immunol Cell Biol** 1996 Apr;74(2):109–20 (124 ref.)
The NF–kappa B/Rel and I kappa B gene families: mediators of immune response and inflammation. Wulczyn FG, et al. **J Mol Med** 1996 Dec;74(12):749–69 (252 ref.)
Jaw, adaptive immunity and phylogeny of vertebrate antibody VH gene family. Andersson E, et al. **Res Immunol** 1996 May;147(4):233–40 (65 ref.)

IMMUNITY

IMMUNOLOGY

Maturation of the immune response. Milstein C, et al. **Adv Protein Chem** 1996;49:451–85 (143 ref.)

Immune function. Fleisher TA. **Pediatr Rev** 1997 Oct; 18(10):351–6 (0 ref.)

Jaw, adaptive immunity and phylogeny of vertebrate antibody VH gene family. Andersson E, et al. **Res Immunol** 1996 May;147(4):233–40 (65 ref.)

PHYSIOLOGY

Nutrition and immunity in the elderly: modification of immune responses with nutritional treatments. Lesourd BM. **Am J Clin Nutr** 1997 Aug;66(2):478S–484S (88 ref.)

Synergism of nutrition, infection, and immunity: an overview. Scrimshaw NS, et al. **Am J Clin Nutr** 1997 Aug; 66(2):464S–477S (231 ref.)

Cytokines and the immune response. Van der Meide PH, et al. **Biotherapy** 1996;8(3–4):243–9 (54 ref.)

Immunomodulatory effect of immunoglobulins. Wolf HM, et al. **Clin Exp Rheumatol** 1996 May–Jun;14 Suppl 15:S17–25 (88 ref.)

The great balancing acts. The pregnant woman, placenta, fetus, and infectious agents. Nahmias AJ, et al. **Clin Perinatol** 1997 Jun;24(2):497–521 (104 ref.)

Role of nitric oxide in immune-mediated diseases [editorial] Cook HT, et al. **Clin Sci (Colch)** 1996 Oct;91(4):375–84 (111 ref.)

Immune abnormality in relation to nonimmune diseases in SAM mice. Hosono M, et al. **Exp Gerontol** 1997 Jan–Apr; 32(1–2):181–95 (49 ref.)

Immunity in athletes. Mackinnon LT. **Int J Sports Med** 1997 Mar;18 Suppl 1:S62–8 (54 ref.)

Fighting, fleeing and having fun: the immunology of physical activity. Nehlsen–Cannarella S, et al. **Int J Sports Med** 1997 Mar;18 Suppl 1:S8–21 (152 ref.)

Exercise immunology: practical applications. Nieman DC. **Int J Sports Med** 1997 Mar;18 Suppl 1:S91–100 (129 ref.)

Psychological stress, exercise and immunity. Perna FM, et al. **Int J Sports Med** 1997 Mar;18 Suppl 1:S78–83 (68 ref.)

Immune and inflammatory mechanisms in the pathogenesis of atherosclerosis. Hansson GK. **J Atheroscler Thromb** 1994;1 Suppl 1:S6–9 (42 ref.)

Immunity in athletes. Pedersen BK, et al. **J Sports Med Phys Fitness** 1996 Dec;36(4):236–45 (97 ref.)

Role of nucleosides and nucleotides in the immune system, gut reparation after injury, and brain function. Yamamoto S, et al. **Nutrition** 1997 Apr;13(4):372–4 (15 ref.)

Impact of physical activity and sport on the immune system. Shepard RJ, et al. **Rev Environ Health** 1996 Jul–Sep; 11(3):133–47 (98 ref.)

The brain's immune system. Streit WJ, et al. **Sci Am** 1995 Nov;273(5):54–5, 58–61 (3 ref.)

[Endocrine regulation of the immune response. Prolactin and its function] Durán Chávez C, et al. **Rev Alerg** 1993 Mar–Apr;40(2):27–32 (57 ref.) (Eng. Abstr.) **(Spa)**

[Endogenous opioid peptides and the immune system] Peramo F, et al. **Rev Esp Anestesiol Reanim** 1997 Apr; 44(4):150–3 (43 ref.) (Eng. Abstr.) **(Spa)**

RADIATION EFFECTS

Photoimmunology of non-melanoma skin cancer. Streilein JW. **Cancer Surv** 1996;26:207–17 (40 ref.)

IMMUNITY, ACTIVE

see related

IMMUNOTHERAPY

Modulation of protective and pathological immunity in mycobacterial infections. Ottenhoff TH, et al. **Int Arch Allergy Immunol** 1997 Aug;113(4):400–8 (70 ref.)

Immune responses to infectious diseases: an evolutionary perspective. Yang KD, et al. **Pediatr Infect Dis J** 1996 Apr;15(4):355–64 (55 ref.)

Complement: instructing the acquired immune system through the CD21/CD19 complex. Dempsey PW, et al. **Res Immunol** 1996 Feb;147(2):71–5; discussion 119–20 (34 ref.)

The cellular and molecular basis of immunity against mycobacterial diseases. Colston MJ. **Soc Appl Bacteriol Symp Ser** 1996;25:33S–39S (56 ref.)

IMMUNITY, CELLULAR

see related

HYPERSENSITIVITY, DELAYED

B7-mediated costimulation and the immune response. Schultze J, et al. **Blood Rev** 1996 Jun;10(2):111–27 (107 ref.)

Cell surface expression of heat shock proteins and the immune response. Multhoff G, et al. **Cell Stress Chaperones** 1996 Sep;1(3):167–76 (90 ref.)

Suppression of cell-mediated immunity due to immune deviation. Zhang Y. **Chin Med J (Engl)** 1996 Oct; 109(10):739–42 (5 ref.)

Cellular immunity in cutaneous and genital HPV infections. Malejczyk J, et al. **Clin Dermatol** 1997 Mar–Apr; 15(2):261–74 (131 ref.)

Echinococcosis. Dixon JB. **Comp Immunol Microbiol Infect Dis** 1997 Jan;20(1):87–94 (40 ref.)

Lung lymphocytes: origin, biological functions, and laboratory techniques for their study in immune-mediated pulmonary disorders. Semenzato G, et al. **Crit Rev Clin Lab Sci** 1996 Oct;33(5):423–55 (93 ref.)

Cell death in the regulation of immune responses. Winoto A. **Curr Opin Immunol** 1997 Jun;9(3):365–70 (79 ref.)

Regulation of host cell function by glycosylphosphatidylinositols of the parasitic protozoa. Schofield L, et al. **Immunol Cell Biol** 1996 Dec;74(6):555–63 (103 ref.)

Identification and function of host defense cells by flow cytometry. Stewart CC. **Immunol Invest** 1997 Jan–Feb; 26(1–2):83–9 (6 ref.)

The many roles of CD40 in cell-mediated inflammatory responses. Stout RD, et al. **Immunol Today** 1996 Oct; 17(10):487–92 (59 ref.)

Antiviral immunity. Zinkernagel RM, et al. **Immunol Today** 1997 Jun;18(6):258–60 (17 ref.)

T cell immunity in malaria. Kabilan L. **Indian J Med Res** 1997 Aug;106:130–48 (96 ref.)

Dendritic cells: from ignored cells to major players in T-cell-mediated immunity. Schuler G, et al. **Int Arch Allergy Immunol** 1997 Apr;112(4):317–22 (47 ref.)

Cellular immune responses to HTLV-I: immunopathogenic role in HTLV-I-associated neurologic disease. Jacobson S. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S100–6 (46 ref.)

Cellular immune reactions directed against Toxoplasma gondii with special emphasis on the central nervous system. Däubener W, et al. **Med Microbiol Immunol (Berl)** 1997 Mar;185(4):195–206 (133 ref.)

T cells in murine lupus: propagation and regulation of disease. Peng SL, et al. **Mol Biol Rep** 1996;23(3–4):247–51 (60 ref.)

Apoptosis of mature T lymphocytes: putative role in the regulation of cellular immune responses and in the pathogenesis of HIV infection. Kabelitz D, et al. **Prog Mol Subcell Biol** 1996;16:58–71 (80 ref.)

The spectrum of African Kaposi's sarcoma: is it consequential upon diverse immunological responses? Matondo P, et al. **Scand J Infect Dis** 1996;28(3):225–30 (51 ref.)

CTL effector functions. Henkart PA. **Semin Immunol** 1997 Apr;9(2):85–6 (10 ref.)

Effect of alpha-interferons on immune function. Herberman RB. **Semin Oncol** 1997 Jun;24(3 Suppl 9):S9-78–S9-80 (11 ref.)

The cellular and molecular basis of immunity against mycobacterial diseases. Colston MJ. **Soc Appl Bacteriol Symp Ser** 1996;25:33S–39S (56 ref.)

Rethinking immunosuppression in terms of the redundant and nonredundant steps in the immune response. Halloran PF. **Transplant Proc** 1996 Dec;28(6 Suppl 1):11–8 (95 ref.)

How do macrophages distinguish the living from the dead? Cheers C, et al. **Trends Microbiol** 1996 Nov;4(11):453–5 (28 ref.)

[Commemorative lecture of receiving Imamura Memorial Prize. Analysis of cellular immunity against tuberculosis in man with special reference to tuberculous pleurisy and cytokines] Shimokata K. **Kekkaku** 1996 Oct;71(10):591–6 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Strategy to overcome AIDS by cell-mediated immunity] Suglmoto M, et al. **Nippon Saikingaku Zasshi** 1996 Feb; 51(2):559–69 (28 ref.) **(Jpn)**

[Changes of humoral and cellular immunity in schizophrenia] Wojtanowska M, et al. **Psychiatr Pol** 1996 Sep–Oct; 30(5):783–99 (83 ref.) (Eng. Abstr.) **(Pol)**

DRUG EFFECTS

Fumonisin B1-immunological effects. The influence of FB1 on the early stage of immune response. Martinova EA. **Adv Exp Med Biol** 1996;391:331–42 (70 ref.)

The role of cyclic AMP and oxygen intermediates in the inhibition of cellular immunity in cancer. Uotila P. **Cancer Immunol Immunother** 1996 Sep;43(1):1–9 (118 ref.)

[Biological activity of tin and immunity] Arakawa Y. **Sangyo Eiseigaku Zasshi** 1997 Jan;39(1):1–20 (176 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Upregulation of Fas ligand by simian immunodeficiency virus – a nef–arious mechanism of immune evasion? Johnson RP. **J Exp Med** 1997 Jul 7;186(1):1–5 (50 ref.)

IMMUNOLOGY

Varicella-zoster virus: aspects of pathogenesis and host response to natural infection and varicella vaccine. Arvin AM, et al. **Adv Virus Res** 1996;46:263–309 (75 ref.)

T cell-mediated destruction of bovine leukemia virus-infected peripheral lymphocytes by bovine leukemia virus env-vaccinia recombinant vaccine. Ohishi K, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):393–8 (18 ref.)

Cellular immune recognition and the biological role of major transplantation antigens. Zinkernagel RM. **Biosci Rep** 1997 Apr;17(2):91–111 (116 ref.)

Visualizing immune responses in vivo. McHeyzer-Williams MG. **Curr Opin Immunol** 1996 Jun;8(3):321–6 (60 ref.)

Cellular immunity: the final paradigm? Attfield DC. **Immunol Cell Biol** 1997 Feb;75(1):96–101 (31 ref.)

The cell-mediated immune response against lymphocytic choriomeningitis virus in beta 2-microglobulin deficient mice. Quinn DG, et al. **Immunol Rev** 1995 Dec;148:151–69 (95 ref.)

[Immunologic fetal and neonatal immaturity: influence on the clinical course of HIV-1 infection in children] Ortigão-de-Sampaio MB, et al. **Rev Assoc Med Bras** 1997 Jan–Mar;43(1):29–34 (62 ref.) (Eng. Abstr.) **(Por)**

[New vaccines and the immune response (I). Immunologic memory. Humoral response versus cellular response] Villarrubia VG, et al. **Med Clin (Barc)** 1996 Jun 22; 107(4):146–54 (93 ref.) **(Spa)**

PHYSIOLOGY

Interleukin-12: a pivotal regulator of cell-mediated immunity. Gately MK, et al. **Cancer Treat Res** 1995; 80:341–66 (102 ref.)

Cellular and humoral autoimmunity in insulin-dependent diabetes mellitus. Scherbaum WA, et al. **Exp Clin Endocrinol Diabetes** 1995;103 Suppl 2:88–94 (68 ref.)

The acute immune response to exercise: what does it mean? Gabriel H, et al. **Int J Sports Med** 1997 Mar;18 Suppl 1:S28–45 (79 ref.)

Exercise immunology and neutrophils. Smith JA. **Int J Sports Med** 1997 Mar;18 Suppl 1:S46–55 (67 ref.)

Immunobiology of childhood tuberculosis: a window on the ontogeny of cellular immunity. Smith S, et al. **J Pediatr** 1997 Jul;131(1 Pt 1):16–26 (132 ref.)

RADIATION EFFECTS

Cell-mediated immunosuppressive mechanisms induced by UV radiation. Cooper KD. **Photochem Photobiol** 1996 Apr; 63(4):400–6 (120 ref.)

[The immunomodulating effects of low-intensity laser radiation] Konchugova TV, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1997 Jan–Feb;(1):42–5 (51 ref.) **(Rus)**

IMMUNITY, HUMORAL see **ANTIBODY FORMATION**

IMMUNITY, MATERNALLY-ACQUIRED

see related

IMMUNIZATION, PASSIVE

Ontogeny of human natural and acquired immunity. Adinolfi M. **Curr Top Microbiol Immunol** 1997;222:67–102 (262 ref.)

Transfer of maternal leukocytes to the infant by human milk. Goldman AS, et al. **Curr Top Microbiol Immunol** 1997; 222:205–13 (60 ref.)

IMMUNITY, MUCOSAL

see related

IGA, SECRETORY

In defense of mucosal surfaces. Regulation and manipulation of the mucosal immune system. Elson CO. **Adv Exp Med Biol** 1997;412:373–85 (68 ref.)

Antigen sampling across epithelial barriers and induction of mucosal immune responses. Neutra MR, et al. **Annu Rev Immunol** 1996;14:275–300 (148 ref.)

Mucosal receptors and T- and B-cell immunity. Lehner T, et al. **Antibiot Chemother** 1996;48:21–9 (48 ref.)

Lactic acid bacteria as vaccine delivery vehicles. Wells JM, et al. **Antonie Van Leeuwenhoek** 1996 Oct;70(2–4):317–30 (51 ref.)

Gram-positive commensal bacteria for mucosal vaccine delivery. Fischetti VA, et al. **Curr Opin Biotechnol** 1996 Dec;7(6):659–66 (95 ref.)

Paneth cell defensins: endogenous peptide components of intestinal host defense. Ouellette AJ, et al. **FASEB J** 1996 Sep;10(11):1280–9 (58 ref.)

The anatomical basis of intestinal immunity. Mowat AM, et al. **Immunol Rev** 1997 Apr;156:145–66 (277 ref.)

Antigen presentation of mucosal pathogens: the players and the rules. Reyes VE, et al. **Int Arch Allergy Immunol** 1997 Feb;112(2):103–14 (98 ref.)

The importance of mucosal immunology to problems in human reproduction. Anderson DJ. **J Reprod Immunol** 1996 Aug;31(1–2):3–19 (75 ref.)

Immune responses to mucosal infection: the Helicobacter pylori paradigm. Ferrero RL. **Res Immunol** 1997 Feb; 148(2):91–107 (117 ref.)

A gut reaction: lymphoepithelial communication in the intestine [comment] [see comments] Shanahan F. **Science** 1997 Mar 28;275(5308):1897–8 (11 ref.) Comment on: Science 1997 Mar 28;275(5308):1937–9. Comment in: Science 1997 Mar 28;275(5308):1897–8.

Immunopathology of human inflammatory bowel disease. Brandtzaeg P, et al. **Springer Semin Immunopathol** 1997; 18(4):555–89 (218 ref.)

The intestinal epithelial cell: immunological aspects. Christ AD, et al. **Springer Semin Immunopathol** 1997;18(4):449–61 (108 ref.)

The immunopathology of M cells. Davis IC, et al. **Springer Semin Immunopathol** 1997;18(4):421–48 (257 ref.)

A T cell/B cell/epithelial cell internet for mucosal inflammation and immunity. Fujihashi K, et al. **Springer Semin Immunopathol** 1997;18(4):477–94 (113 ref.)

On the front lines: intraepithelial lymphocytes as primary effectors of intestinal immunity. Lefrançois L, et al. **Springer Semin Immunopathol** 1997;18(4):463–75 (83 ref.)

Immunopathology of human immunodeficiency virus infection in the gastrointestinal tract. Schneider T, et al.

Springer Semin Immunopathol 1997;18(4):515–33 (124 ref.)
Immunopathology of gluten-sensitive enteropathy. Scott H, et al. **Springer Semin Immunopathol** 1997;18(4):535–53 (102 ref.)
[Chronic inflammation of mucous membranes: integration of immunity and regeneration] Zinov'ev AS, et al. **Arkh Patol** 1997 May–Jun;59(3):18–24 (50 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Fimbriae-mediated adherence induces mucosal inflammation and bacterial clearance. Consequences for anti-adhesion therapy. Connell H, et al. **Adv Exp Med Biol** 1996; 408:73–80 (43 ref.)
Major pathways of mucosal immunity and inflammation: cell activation, cytokine production and the role of bacterial factors. James SP, et al. **Aliment Pharmacol Ther** 1996;10 Suppl 2:1–9 (52 ref.)
Regulation of immune responses of the intestinal mucosa. Abreu-Martin MT, et al. **Crit Rev Immunol** 1996; 16(3):277–309 (231 ref.)
Genetic approaches to the study of cytokine regulation of mucosal immunity. Ramsay AJ. **Immunol Cell Biol** 1995 Dec;73(6):484–8 (42 ref.)
M cells and the pathogenesis of mucosal and systemic infections. Siebers A, et al. **Trends Microbiol** 1996 Jan; 4(1):22–9 (60 ref.)

PHYSIOLOGY

Ontogeny of mucosal immunity--environmental and behavioral influences. Husband AJ, et al. **Brain Behav Immun** 1996 Sep;10(3):188–204 (123 ref.)
European Commission COST/STD Initiative. Report of the expert panel VI. Concerted efforts in the field of mucosal immunology. Holmgren J, et al. **Vaccine** 1996 May; 14(7):644–64 (30 ref.)

IMMUNITY, NATURAL

An innate view of gamma delta T cells. Boismenu R, et al. **Curr Opin Immunol** 1997 Feb;9(1):57–63 (73 ref.)
The collectins in innate immunity. Epstein J, et al. **Curr Opin Immunol** 1996 Feb;8(1):29–35 (58 ref.)
Innate immunity in higher insects. Hoffmann JA, et al. **Curr Opin Immunol** 1996 Feb;8(1):8–13 (56 ref.)
The role of hemolymph coagulation in innate immunity. Muta T, et al. **Curr Opin Immunol** 1996 Feb;8(1):41–7 (48 ref.)
Scavenger receptors in innate immunity. Pearson AM. **Curr Opin Immunol** 1996 Feb;8(1):20–8 (92 ref.)
Immunity to eukaryotic parasites in vector insects. Richman A, et al. **Curr Opin Immunol** 1996 Feb;8(1):14–9 (49 ref.)
Role of natural killer cells in innate resistance to protozoan infections. Scharton-Kersten TM, et al. **Curr Opin Immunol** 1997 Feb;9(1):44–51 (86 ref.)
Effects of nutritional antioxidants and other dietary constituents on coxsackievirus-induced myocarditis. Beck MA, et al. **Curr Top Microbiol Immunol** 1997;223:81–96 (50 ref.)
Child development: vulnerability and resilience. Engle PL, et al. **Soc Sci Med** 1996 Sep;43(5):621–35 (112 ref.)
Resistance to intracellular infections: comparative genomic analysis of Nramp. Cellier M, et al. **Trends Genet** 1996 Jun; 12(6):201–4 (20 ref.)
[Host defense against mycobacterial infections--new strategies for combatting multidrug-resistant mycobacterial diseases] Kobayashi K. **Nippon Saikingaku Zasshi** 1997 Apr; 52(2):485–91 (15 ref.) **(Jpn)**
[General pathology of trace element deficiency] Zhavoronkov AA, et al. **Arkh Patol** 1997 Mar–Apr; 59(2):8–11 (24 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Interleukin 6 in diseases: cause or cure? Scholz W. **Immunopharmacology** 1996 Mar;31(2–3):131–50 (224 ref.)

GENETICS

Molecular genetics of the natural killer gene complex and innate immunity. Yokoyama WM, et al. **Biochem Soc Trans** 1997 May;25(2):691–5 (50 ref.)
Genetics of infectious disease resistance. Hill AV. **Curr Opin Genet Dev** 1996 Jun;6(3):348–53 (51 ref.)
Signal transduction in plant immunity. Shirasu K, et al. **Curr Opin Immunol** 1996 Feb;8(1):3–7 (55 ref.)
Immunogenetics of disease resistance in fish: a comparative approach. Wiegertjes GF, et al. **Dev Comp Immunol** 1996 Nov–Dec;20(6):365–81 (110 ref.)
How adaptive antibodies facilitate the evolution of natural antibodies. Anderson RW. **Immunol Cell Biol** 1996 Jun; 74(3):286–91 (49 ref.)
The natural killer gene complex: a genetic basis for understanding natural killer cell function and innate immunity. Brown MG, et al. **Immunol Rev** 1997 Feb; 155:53–65 (135 ref.)
An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. Krieg AM. **J Lab Clin Med** 1996 Aug;128(2):128–33 (37 ref.)
Recognition of bacterial avirulence proteins occurs inside the plant cell: a general phenomenon in resistance to bacterial diseases? Bonas U, et al. **Plant J** 1997 Jul;12(1):1–7 (40 ref.)
Schizophrenia, rheumatoid arthritis and natural resistance genes. Rubinstein G. **Schizophr Res** 1997 Jun 20; 25(3):177–81 (40 ref.)
Molecular intimacy between proteins specifying plant–pathogen recognition. Parker JE, et al. **Trends Biochem Sci** 1997 Aug;22(8):291–6 (49 ref.)
Genetic analysis of coevolution between plants and their natural enemies. Rausher MD. **Trends Genet** 1996 Jun; 12(6):212–7 (56 ref.)

IMMUNOLOGY

Innate pathways that control acquired immunity [editorial] Bendelac A, et al. **Curr Opin Immunol** 1997 Feb;9(1):1–3 (8 ref.)
Immunity to infection [editorial] Bloom B, et al. **Curr Opin Immunol** 1996 Aug;8(4):465–6 (0 ref.)
Innate immunity: impact on the adaptive immune response. Medzhitov R, et al. **Curr Opin Immunol** 1997 Feb;9(1):4–9 (40 ref.)
Immunogenetics of disease resistance in fish: a comparative approach. Wiegertjes GF, et al. **Dev Comp Immunol** 1996 Nov–Dec;20(6):365–81 (110 ref.)

PHYSIOLOGY

Signalling pathways: a common theme in plants and animals? Wilson I, et al. **Curr Biol** 1997 Mar 1;7(3):R175–8 (10 ref.)
[The role of allosteric RNase L in interferon-induced defence system of the cell] Wierzbicki A. **Postepy Biochem** 1995; 41(4):257–66 (68 ref.) **(Pol)**
[The periodic action of cold and body resistance] Barbarash NA. **Usp Fiziol Nauk** 1996 Oct–Dec;27(4):116–32 (101 ref.) (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Risk assessment for the harmful effects of immunotoxic agents on the immunological resistance to infectious diseases: ultraviolet light as an example. Van Loveren H, et al. **Toxicology** 1997 Apr 11;119(1):59–64 (19 ref.)

IMMUNITY, NON-SPECIFIC see **IMMUNITY, NATURAL**

IMMUNIZATION

Immunizations: current recommendations. Adkins SB 3rd. **Am Fam Physician** 1997 Sep 1;56(3):865–74 (39 ref.)
Pertussis antigens that abrogate bacterial adherence and elicit immunity. Brennan MJ, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 2):S145–9 (34 ref.)
Systemic and mucosal protective immunity to pneumococcal surface protein A. Briles DE, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:118–26 (42 ref.)
Prevention of group B Streptococcus infection in neonates. Logsdon BA, et al. **Ann Pharmacother** 1997 Jul–Aug; 31(7–8):897–906 (68 ref.)
Sensitization and enhanced allergen responsiveness. Wardlaw AJ, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 3:56–9 (0 ref.)
Neonatal jaundice, animal-induced injuries and disease, and immunizations. Gerson WT. **Curr Opin Pediatr** 1997 Aug; 9(4):447–55 (45 ref.)
Research priorities for the WHO Global Programme for Vaccines and Immunization. Lambert PH. **Dev Biol Stand** 1996;87:45–9 (0 ref.)
Enteric immunization: promises and challenges. Brown WR. **Dig Dis** 1996 May–Jun;14(3):192–200 (41 ref.)
Immunizations and travel. Thanassi WT, et al. **Emerg Med Clin North Am** 1997 Feb;15(1):43–70 (30 ref.)
The attitude against immunisation within some branches of complementary medicine. Ernst E. **Eur J Pediatr** 1997 Jul; 156(7):513–5 (32 ref.)
Therapeutic immunization against Helicobacter infection [editorial; comment] Lee A. **Gastroenterology** 1996 Jun; 110(6):2003–6 (31 ref.) Comment on: Gastroenterology 1996 Jun;110(6):1770–5.
Immunologic responses following respiratory sensitization to house dust mite allergens in mice. O'Brien R, et al. **Immunol Cell Biol** 1996 Apr;74(2):174–9 (23 ref.)
Anti-IgE in allergic sensitization. Stadler BM, et al. **Immunol Cell Biol** 1996 Apr;74(2):195–200 (51 ref.)
DNA vaccines, cyberspace and self-help programs. Whalen RG. **Intervirology** 1996;39(1–2):120–5 (21 ref.)
Anti-hepatitis A virus (HAV) vaccination: guidelines for an immunization strategy in Italy. Workshop Consensus Conference--Rome, May 2–3, 1995 [published erratum appears in Ital J Gastroenterol 1996 Jul–Aug;28(6):368] **Ital J Gastroenterol** 1996 Apr;28(3):181–4 (0 ref.)
Vaccination against Helicobacter pylori. Lee A. **J Gastroenterol** 1996 Nov;31 Suppl 9:69–74 (50 ref.)
Hepatitis and hepatitis immunisation. Feely M. **J R Soc Health** 1997 Feb;117(1):41–6 (42 ref.)
Adoptive immunotherapy of malignant glioma using tumor-sensitized T lymphocytes. Merchant RE, et al. **Neurol Res** 1997 Apr;19(2):145–52 (11 ref.)
Secondary prevention of allergic disease: an adjunct to primary prevention. Zeiger RS. **Pediatr Allergy Immunol** 1995 Aug;6(3):127–38 (61 ref.)
Prevention of Helicobacter pylori infection. Lee A. **Scand J Gastroenterol Suppl** 1996;215:11–5 (23 ref.)
New approaches to mucosal immunization. Langermann S. **Semin Gastrointest Dis** 1996 Jan;7(1):12–8 (67 ref.)
Immunoprophylactic intervention in chemical toxicity and carcinogenicity. Silbart LK, et al. **Vet Hum Toxicol** 1997 Feb;39(1):37–43 (72 ref.)
Kidney transplantation in highly sensitized patients: reappraisal of etiology, evaluation, and management protocols. Indudhara R, et al. **World J Urol** 1996; 14(4):206–17 (145 ref.)
[Vaccinations: the necessary and the desirable] Matter L. **Schweiz Med Wochenschr** 1997 Mar 8;127(10):377–81 (29 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Inflammatory joint disease after immunizations. A report of two cases. Ferrazzi V, et al. **Rev Rhum Engl Ed** 1997 Apr; 64(4):227–32 (34 ref.)

METHODS

Pertussis in the 1990s: diagnosis, treatment, and prevention. Pasternack MS. **Curr Clin Top Infect Dis** 1997;17:24–36 (38 ref.)
Developments in immunization practices and strategies: implications for vaccine stability. Plotkin SA, et al. **Dev Biol Stand** 1996;87:85–94 (18 ref.)
Epidemiologic methods in immunization programs. Chen RT, et al. **Epidemiol Rev** 1996;18(2):99–117 (173 ref.)
Tetanus and diphtheria immunization/prophylaxis adults and older adults. **Nurse Pract** 1997 Mar;22(3):116, 119–20 (11 ref.)
DNA immunization. Hassett DE, et al. **Trends Microbiol** 1996 Aug;4(8):307–12 (43 ref.)
Immunization against diphtheria with special emphasis on immunization of adults [see comments] Galazka AM, et al. **Vaccine** 1996 Jun;14(9):845–57 (96 ref.) Comment in: Vaccine 1997 Mar;15(4):459–60.
Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. West DJ, et al. **Vaccine** 1996 Aug; 14(11):1019–27 (78 ref.)
[Nonparenteral immunization methods against smallpox] Vorob'ev AA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Sep–Oct; (5):117–21 (31 ref.) **(Rus)**

STANDARDS

Analytic aspects of the standardization of allergenic extracts. van Ree R. **Allergy** 1997 Aug;52(8):795–805 (167 ref.)
Adult vaccinations: a short review. Long J, et al. **Cleve Clin J Med** 1997 Jun;64(6):311–7 (23 ref.)
New Australian immunisation guidelines. **Commun Dis Intell** 1997 Mar 20;21(6):78–9 (0 ref.)

TRENDS

Developments in childhood immunization. Reuman PD, et al. **Curr Probl Pediatr** 1996 Apr;26(4):107–37 (322 ref.)
Immunization: celebrating the past and injecting the future. Stanwell-Smith R. **J R Soc Med** 1996 Sep;89(9):509–13 (3 ref.)
Childhood immunizations--1996. Hodes DS. **Mt Sinai J Med** 1996 Oct–Nov;63(5–6):413–9 (48 ref.)
Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. West DJ, et al. **Vaccine** 1996 Aug; 14(11):1019–27 (78 ref.)

UTILIZATION

Adult immunizations: how are we doing? Eickhoff TC. **Hosp Pract (Off Ed)** 1996 Nov 15;31(11):107–8, 111–2, 115–7, passim (12 ref.)

VETERINARY

Viral diseases of the immune system and strategies to control infectious bursal disease by vaccination. Lütticken D. **Acta Vet Hung** 1997;45(3):239–49 (37 ref.)
Immunization with bacterial antigens: infections with streptococci and related organisms. Bercovier H, et al. **Dev Biol Stand** 1997;90:153–60 (25 ref.)
Immunization with bacterial antigens: Flavobacterium and Flexibacter infections. Bernardet JF. **Dev Biol Stand** 1997; 90:179–88 (46 ref.)
Immunization with viral antigens: infectious pancreatic necrosis. Christie KE. **Dev Biol Stand** 1997;90:191–9 (54 ref.)
Immunization with viral antigens: viral diseases of carp and catfish. Dixon P. **Dev Biol Stand** 1997;90:221–32 (31 ref.)
Immunization with bacterial antigens: furunculosis. Ellis AE. **Dev Biol Stand** 1997;90:107–16 (60 ref.)
Immunization with bacterial antigens: bacterial kidney disease. Kaattari SL, et al. **Dev Biol Stand** 1997;90:145–52 (40 ref.)
Immunization with viral antigens: viral haemorrhagic septicaemia. Lorenzen N, et al. **Dev Biol Stand** 1997; 90:201–9 (37 ref.)
Immunization with bacterial antigens: pasteurellosis. Romalde JL, et al. **Dev Biol Stand** 1997;90:167–77 (42 ref.)
Immunization with bacterial antigens: piscirickettsiosis. Smith PA, et al. **Dev Biol Stand** 1997;90:161–6 (12 ref.)
Immunization with bacterial antigens: yersiniosis. Stevenson RM. **Dev Biol Stand** 1997;90:117–24 (41 ref.)

IMMUNIZATION

Immunization with bacterial antigens: edwardsiellosis. Thune RL, et al. **Dev Biol Stand** 1997;90:125–34 (46 ref.)
Experience with veterinary vaccines in warm climates. Tulasne JJ, et al. **Dev Biol Stand** 1996;87:33–42 (20 ref.)
Immunization with viral antigens: infectious haematopoietic necrosis. Winton JR. **Dev Biol Stand** 1997;90:211–20 (35 ref.)
Immunization against parasitic diseases of fish. Woo PT. **Dev Biol Stand** 1997;90:233–41 (62 ref.)

IMMUNIZATION, ACTIVE see **VACCINATION**

IMMUNIZATION, BOOSTER see **IMMUNIZATION, SECONDARY**

IMMUNIZATION, PASSIVE

Progressive multifocal leukoencephalopathy: clinical and MR response to treatment. Garrels K, et al. **AJNR Am J Neuroradiol** 1996 Mar;17(3):597–600 (18 ref.)
Immune reconstitution for HIV disease. Bridges SH. **Antibiot Chemother** 1996;48:233–9 (21 ref.)
Evaluation of protective immunity to HIV–1 in human PBL–SCID mice. Mosier DE. **Antibiot Chemother** 1996; 48:125–30 (15 ref.)
A critical review of antidotal immunotherapy for low molecular weight toxins. Current antidotes and perspectives. Baud FJ, et al. **Arch Toxicol Suppl** 1997; 19:271–87 (45 ref.)
Recombinant secretory IgA for immune intervention against mucosal pathogens. Corthésy B. **Biochem Soc Trans** 1997 May;25(2):471–5 (27 ref.)
Hepatitis A: epidemiology and prevention. Feinstone SM. **Eur J Gastroenterol Hepatol** 1996 Apr;8(4):300–5 (67 ref.)
Immunisation against hepatitis A––active or passive? Iwarson S. **Infection** 1996 Jan–Feb;24(1):2–4 (15 ref.)
Applications of molecular biology and biotechnology: antibody therapy of sepsis. Wheeler AP, et al. **J Crit Care** 1996 Jun;11(2):77–94 (102 ref.)
Monitoring of cancer patients undergoing active or passive immunotherapy. Salgaller ML. **J Immunother** 1997 Jan; 20(1):1–14 (113 ref.)
Passive protection against diarrheal disease. Davidson GP. **J Pediatr Gastroenterol Nutr** 1996 Oct;23(3):207–12 (65 ref.)
From butterflies to babies. Clarke CA. **J R Nav Med Serv** 1997;82(3):232–8 (8 ref.)
Prevention of respiratory syncytial virus infection in high risk infants: consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulin. Meissner HC, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1059–68 (51 ref.)
Defining antibody protection against HIV–1 transmission in Hu–PBL–SCID mice. Koup RA, et al. **Semin Immunol** 1996 Aug;8(4):263–8 (52 ref.)
Appropriate therapeutic use of immunoglobulin. Stiehm ER. **Transfus Med Rev** 1996 Jul;10(3):203–21 (76 ref.)
Cytomegalovirus infection in seromismatched lung transplant recipients with and without prophylaxis with CMV immunoglobulin. Kathawalla SA, et al. **Transplant Proc** 1996 Dec;28(6 Suppl 2):16 (2 ref.)
Cytomegalovirus hyperimmune gammaglobulin downregulates in vitro T–cell responses. Yadin O, et al. **Transplant Proc** 1996 Dec;28(6 Suppl 2):7–8 (2 ref.)
[Preventive vaccination for viral hepatitis] Jilg W. **Z Gastroenterol** 1997 Jul;35(7):585–90 (18 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Use of intravenous immunoglobulin to prevent or treat infections in persons with immune deficiency. Lee ML, et al. **Annu Rev Med** 1997;48:93–102 (112 ref.)
Evaluation and management of recurrent spontaneous abortion. Daya S. **Curr Opin Obstet Gynecol** 1996 Jun; 8(3):188–92 (22 ref.)
Alternative treatments in the patient with intractable asthma. Spector SL. **Curr Opin Pulm Med** 1997 Jan;3(1):23–9 (64 ref.)
Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. Rosenberg SA. **J Natl Cancer Inst** 1996 Nov 20; 88(22):1635–44 (61 ref.)

STANDARDS

[Does breast feeding compromise the efficacy of sero–vaccination of infants borne to mothers who are chronic carriers of hepatitis B antigens Soulié JC, et al. **Contracept Fertil Sex** 1997 May;25(5):I–V (39 ref.) **(Fre)**

VETERINARY

Human intravenous immunoglobulin therapy. Scott–Moncrieff JC, et al. **Semin Vet Med Surg (Small Anim)** 1997 Aug;12(3):178–85 (56 ref.)

IMMUNIZATION PROGRAMS

Status and future of vaccines for adults. Grabenstein JD. **Am J Health Syst Pharm** 1997 Feb 15;54(4):379–87 (83 ref.)
Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis Prevention Board [see comments] Van Damme P, et al. **BMJ** 1997 Apr 5;314(7086):1033–6 (18 ref.) Comment in: BMJ 1997 Apr 5;314(7086):1036–7. Comment in: BMJ 1997 Jul 12;315(7100):121. Comment in: BMJ 1997 Jul 12;315(7100):121–2.
Update on vaccination guidelines. Nye FJ, et al. **Br J Hosp Med** 1997 Apr 2–15;57(7):313–8 (19 ref.)
Varicella–zoster virus vaccine. White CJ. **Clin Infect Dis** 1997 May;24(5):753–61; quiz 762–3 (82 ref.)
Acellular pertussis vaccines: the next step. Halperin SA. **Dev Biol Stand** 1997;89:363–5 (0 ref.)
The eradication of poliomyelitis in Egypt: critical factors affecting progress to date. Aylward RB, et al. **J Infect Dis** 1997 Feb;175 Suppl 1:S56–61 (18 ref.)
National immunization days: state of the art. Birmingham ME, et al. **J Infect Dis** 1997 Feb;175 Suppl 1:S183–8 (39 ref.)
Eradication of wild poliovirus from the Americas: acute flaccid paralysis surveillance, 1988–1995. de Quadros CA, et al. **J Infect Dis** 1997 Feb;175 Suppl 1:S37–42 (22 ref.)
Progress toward global polio eradication. Hull HF, et al. **J Infect Dis** 1997 Feb;175 Suppl 1:S4–9 (37 ref.)
Overview of poliomyelitis in the African Region and current regional plan of action. Okwo–Bele JM, et al. **J Infect Dis** 1997 Feb;175 Suppl 1:S10–5 (20 ref.)
Yellow fever: a decade of reemergence. Robertson SE, et al. **JAMA** 1996 Oct 9;276(14):1157–62 (62 ref.)
"Love's labours lost": failure to implement mass vaccination against group A meningococcal meningitis in sub–Saharan Africa. Robbins JB, et al. **Lancet** 1997 Sep 20; 350(9081):880–2 (41 ref.)

LEGISLATION & JURISPRUDENCE

Good performance of vaccination by education. Peltola H. **Biologicals** 1997 Jun;25(2):237–9 (9 ref.)

ORGANIZATION & ADMINISTRATION

National immunization days: experience in Latin America. Olivé JM, et al. **J Infect Dis** 1997 Feb;175 Suppl 1:S189–93 (21 ref.)

STATISTICS & NUMERICAL DATA

The impact of immunization control activities on measles outbreaks in middle and low income countries. Aylward RB, et al. **Int J Epidemiol** 1997 Jun;26(3):662–9 (68 ref.)

IMMUNIZATION SCHEDULE

Immunization of adolescents [see comments] Averhoff FM, et al. **Am Fam Physician** 1997 Jan;55(1):159–67 (30 ref.) Comment in: Am Fam Physician 1997 Jan;55(1):31, 35–6.
Adult vaccinations: a short review. Long J, et al. **Cleve Clin J Med** 1997 Jun;64(6):311–7 (23 ref.)
New Australian immunisation guidelines. **Commun Dis Intell** 1997 Mar 20;21(6):78–9 (0 ref.)
Adult immunizations. Gardner P, et al. **Compr Ther** 1996 Jul;22(7):440–8 (62 ref.)
Neonatal immunization [editorial] Isaacs D. **Curr Opin Pediatr** 1997 Feb;9(1):5–8 (24 ref.)
Immunization: protecting older patients from infectious disease [see comments] Plichta AM. **Geriatrics** 1996 Sep; 51(9):47–52; quiz 53 (22 ref.) Comment in: Geriatrics 1996 Dec;51(12): 12, 14.
Hepatitis B: recommendations for children/adolescents [see comments] **Nurse Pract** 1996 Sep;21(9):108, 111–3 (12 ref.) Comment in: Nurse Pract 1996 Dec;21(12 Pt 1):13.
Hepatitis B immunization/prophylaxis: recommendations for adults/older adults. **Nurse Pract** 1996 Dec;21(12 Pt 1):64, 67–70 (8 ref.)
Combination vaccines and immunization visits. Plotkin SA, et al. **Pediatr Infect Dis J** 1996 Feb;15(2):103–5 (33 ref.)

IMMUNIZATION, SECONDARY

Hepatitis B vaccine: current issues. Zannolli R, et al. **Ann Pharmacother** 1997 Sep;31(9):1059–67 (60 ref.)
Booster policy for adults. Marth E. **Biologicals** 1997 Jun; 25(2):199–203 (24 ref.)

IMMUNOACTIVATORS see **ADJUVANTS, IMMUNOLOGIC**

IMMUNOADJUVANTS see **ADJUVANTS, IMMUNOLOGIC**

IMMUNOADSORBENT TECHNIQUES see **IMMUNOSORBENT TECHNIQUES**

IMMUNOADSORBENTS see **IMMUNOSORBENTS**

IMMUNOASSAY

Environmental immunoassays and other bioanalytical methods: overview and update. Sherry J. **Chemosphere** 1997 Mar–Apr;34(5–7):1011–25 (87 ref.)
Immunoprocedures for detecting human chorionic gonadotropin: clinical aspects and doping control. Stenman UH, et al. **Clin Chem** 1997 Jul;43(7):1293–8 (46 ref.)
Factors modifying growth hormone estimates in immunoassays. Fisker S, et al. **Horm Res** 1996; 46(4–5):183–7 (35 ref.)

HISTORY

Discovery and development of IgE assays. Johansson SG. **Clin Exp Allergy** 1997 May;27 Suppl 1:60–3 (15 ref.)

METHODS

Immunochemical methods for fumonisins. Chu FS. **Adv Exp Med Biol** 1996;392:122–33 (68 ref.)
Discovery and development of IgE assays. Johansson SG. **Clin Exp Allergy** 1997 May;27 Suppl 1:60–3 (15 ref.)
Interest of epitopic dissection in immunoanalysis of proteins and peptides: review of theoretical and practical aspects. Niccoli P, et al. **Eur J Clin Chem Clin Biochem** 1996 Sep; 34(9):741–8 (19 ref.)
Immunodiagnosis of schistosomiasis. Tsang VC, et al. **Immunol Invest** 1997 Jan–Feb;26(1–2):175–88 (27 ref.)
Kallikrein and kallikrein–like proteinases: purification and determination by chromatographic and electrophoretic methods. Raspi G. **J Chromatogr B Biomed Appl** 1996 Sep 20;684(1–2):265–87 (251 ref.)
Clinical use of sensitive assays for thyroid–stimulating hormone. Masters PA, et al. **J Gen Intern Med** 1996 Feb; 11(2):115–27 (102 ref.)
Liposomes and immunoassays. Rongen HA, et al. **J Immunol Methods** 1997 May 26;204(2):105–33 (155 ref.)
Preparation and properties of anti–biotin antibodies. Kohen F, et al. **Methods Enzymol** 1997;279:451–63 (19 ref.)
Autoantibodies in conventional toxicity testing. Verdier F, et al. **Toxicology** 1997 Apr 11;119(1):51–8 (33 ref.)
[Analytical problems in the determination of tumor markers] Bohuon C, et al. **Nucl Med Biol** 1994 Apr;21(3):477–82 (12 ref.) **(Fre)**
[Future prospects of emergency laboratory tests––problems of immunoserologic tests] Obana Y, et al. **Rinsho Byori** 1996 Oct;44(10):956–61 (18 ref.) (Eng. Abstr.) **(Jpn)**
[Molecular diagnostics: sequence or signal amplification?] Słomski R, et al. **Postepy Biochem** 1995;41(4):220–9 (17 ref.) **(Pol)**

STANDARDS

Some comments on progress in the standardization of immunoassays for prostate–specific antigen. Stamey TA. **Br J Urol** 1997 Mar;79 Suppl 1:49–52 (17 ref.)
Use and evaluation of leucocyte monoclonal antibodies in the diagnostic laboratory: a review. Reilly JT. **Clin Lab Haematol** 1996 Mar;18(1):1–5 (19 ref.)
Why do immunoassays for tumour markers give differing results?––a view from the UK National External Quality Assessment Schemes. Sturgeon CM, et al. **Eur J Clin Chem Clin Biochem** 1996 Sep;34(9):755–9 (10 ref.)

TRENDS

Recent advances in multiple antigen peptides. Tam JP. **J Immunol Methods** 1996 Sep 13;196(1):17–32 (107 ref.)
Immunoassay: recent developments and future directions. Ekins R. **Nucl Med Biol** 1994 Apr;21(3):495–521 (33 ref.)
Issues with introducing new immunotoxicology methods into the safety assessment of pharmaceuticals. Dean JH. **Toxicology** 1997 Apr 11;119(1):95–101 (4 ref.)
The popliteal lymph node assay in 1996. Descotes J, et al. **Toxicology** 1997 Apr 11;119(1):45–9 (21 ref.)

IMMUNOASSAY, ENZYME see **IMMUNOENZYME TECHNIQUES**

IMMUNOBLASTIC LYMPHADENOPATHY

COMPLICATIONS

Rheumatic manifestations of dysproteinemias and lymphoproliferative disorders. Duna GF, et al. **Rheum Dis Clin North Am** 1996 Feb;22(1):39–51 (107 ref.)

IMMUNOBLOTTING

see related
IMMUNOCHEMISTRY

METHODS

Identification of cytokine–regulated proteins in normal and malignant cells by the combination of two–dimensional polyacrylamide gel electrophoresis, mass spectrometry, Edman degradation and immunoblotting and approaches to the analysis of their functional roles. Epstein LB, et al. **Electrophoresis** 1996 Nov;17(11):1655–70 (75 ref.)

IMMUNOCHEMISTRY

see related
IMMUNOBLOTTING
IMMUNOLOGIC TECHNIQUES

METHODS

Microbeads, magnets, and magic: the enchanting science of immunochemistry. Bertholf RL, et al. **Ann Clin Lab Sci** 1996 Sep–Oct;26(5):377–88 (8 ref.)

IMMUNOCOMPETENCE

Primary cryptococcal cellulitis caused by Cryptococcus neoformans var. gattii in an immunocompetent host. Hamann ID, et al. **Australas J Dermatol** 1997 Feb; 38(1):29–32 (24 ref.)

Severe cytomegalovirus infection in immunocompetent patients. Eddleston M, et al. **Clin Infect Dis** 1997 Jan; 24(1):52–6 (59 ref.)

Immunological reconstitution following bone marrow transplantation. Parkman R, et al. **Immunol Rev** 1997 Jun; 157:73–8 (54 ref.)

Subcutaneous phaeohyphomycosis: infection with pigmented fungi. Soomro IN, et al. **JPMA J Pak Med Assoc** 1996 Jul;46(7):156–8 (9 ref.)

Early determinants of immunocompetence. Hanson LA, et al. **Nutr Rev** 1997 Jan;55(1 Pt 2):S12–7; discussion S18–20 (45 ref.)

Host defense against nontuberculous mycobacterial infections. Holland SM. **Semin Respir Infect** 1996 Dec; 11(4):217–30 (104 ref.)

[Cytomegalovirus encephalitis in an immunocompetent adult] Donnet A, et al. **Rev Neurol (Paris)** 1996 Oct;152(10):640–1 (9 ref.) (Eng. Abstr.) **(Fre)**

[Cervical lymphadenitis in an immunocompetent patient: Mycobacterium gordonae as the cause?] Fleisch F, et al. **Dtsch Med Wochenschr** 1997 Jan 17;122(3):51–3 (11 ref.) (Eng. Abstr.) **(Ger)**

[Interstitial pulmonitis due to the cytomegalovirus in an immunocompetent adolescent: treatment with ganciclovir] Pellegrini G, et al. **Pediatr Med Chir** 1996 May–Jun; 18(3):315–7 (19 ref.) (Eng. Abstr.) **(Ita)**

[The immunocompetent structures of the skin and their role in the development of primary skin lymphomas (editorial)] Vavilov AM, et al. **Arkh Patol** 1996 Nov–Dec;58(6):7–12 (52 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

The relevance of opioids and opioid receptors on immunocompetence and immune homeostasis. Carr DJ, et al. **Proc Soc Exp Biol Med** 1996 Dec;213(3):248–57 (97 ref.)

IMMUNOLOGY

Exercise, immunity, and infection. Calabrese LH, et al. **J Am Osteopath Assoc** 1996 Mar;96(3):166–76 (137 ref.)

PHYSIOLOGY

The central nervous system as an immunocompetent organ: role of glial cells in antigen presentation. Shrikant P, et al. **J Immunol** 1996 Sep 1;157(5):1819–22 (69 ref.)

[Glutamine: effects on the immune system, protein balance and intestinal functions (see comments)] Roth E, et al. **Wien Klin Wochenschr** 1996;108(21):669–76 (59 ref.) (Eng. Abstr.) Comment in: Wien Klin Wochenschr 1996;108(21):667–8. **(Ger)**

RADIATION EFFECTS

[Impact of low-energy laser irradiation on the immunological nonspecific responsiveness in patients with tuberculosis] Litvinov VI, et al. **Probl Tuberk** 1997;(4):58–60 (75 ref.) **(Rus)**

IMMUNOCOMPROMISED HOST

Environmental ecology of Cryptosporidium and public health implications. Rose JB. **Annu Rev Public Health** 1997; 18:135–61 (109 ref.)

Vaccination of the immunocompromised patient. Loutan L. **Biologicals** 1997 Jun;25(2):231–6 (29 ref.)

Angiosarcoma of the scalp associated with renal transplantation. Kibe Y, et al. **Br J Dermatol** 1997 May; 136(5):752–6 (24 ref.)

Toxoplasma gondii and ocular toxoplasmosis: pathogenesis. Pavesio CE, et al. **Br J Ophthalmol** 1996 Dec; 80(12):1099–107 (143 ref.)

Fungal infections. Chimelli L, et al. **Brain Pathol** 1997 Jan; 7(1):613–27 (90 ref.)

HPV infections and immunosuppression. Bouwes Bavinck JN, et al. **Clin Dermatol** 1997 May–Jun;15(3):427–37 (155 ref.)

Oerskovia xanthineolytica bacteremia in an immunocompromised host: case report and review. Maguire JD, et al. **Clin Infect Dis** 1996 Mar;22(3):554–6 (11 ref.)

Radionuclide imaging of infection in the immunocompromised host. Rubin RH, et al. **Clin Infect Dis** 1996 Mar;22(3):414–23 (38 ref.)

DNA analysis in the study of fungal infections in the immunocompromised host. Zervos MJ, et al. **Clin Lab Med** 1996 Mar;16(1):73–88 (62 ref.)

Antifungal prophylaxis during neutropenia and immunodeficiency. Lortholary O, et al. **Clin Microbiol Rev** 1997 Jul;10(3):477–504 (390 ref.)

Recent advances in the management of opportunistic fungal infections. Sanchez JL, et al. **Compr Ther** 1996 Nov; 22(11):703–12 (85 ref.)

Pseudomonas aeruginosa: assessment of risk from drinking water. Hardalo C, et al. **Crit Rev Microbiol** 1997; 23(1):47–75 (179 ref.)

Pulmonary fungal infections in immunocompromised children. Shenep JL, et al. **Curr Opin Pediatr** 1997 Jun; 9(3):213–8 (34 ref.)

Respiratory illness in HIV-negative immunocompromised patients. Tietjen PA, et al. **Curr Opin Pulm Med** 1997 Mar; 3(2):125–30 (28 ref.)

Fungal infections in immunocompromised individuals. Conant MA. **Dermatol Clin** 1996 Jan;14(1):155–62 (30 ref.)

Zygomycosis. Elgart ML. **Dermatol Clin** 1996 Jan; 14(1):141–146 (24 ref.)

Tinea incognito: an update on Majocchi granuloma. Elgart ML. **Dermatol Clin** 1996 Jan;14(1):51–55 (18 ref.)

Fungal disease in the immunocompromised host. Myskowski PL, et al. **Dermatol Clin** 1997 Apr;15(2):295–305 (64 ref.)

Cutaneous amebiasis in an Iranian immunodeficient alcoholic: immunochemical and histological study [letter] Loschiavo F, et al. **Dermatology** 1997;194(4):370–1 (16 ref.)

Modifications of the microflora of the oral cavity arising during immunosuppressive chemotherapy. Sixou JL, et al. **Eur J Cancer B Oral Oncol** 1996 Sep;32B(5):306–10 (35 ref.)

Parasitic diseases in immunocompromised hosts. Cryptosporidiosis, isosporiasis, and strongyloidiasis. Heyworth MF. **Gastroenterol Clin North Am** 1996 Sep; 25(3):691–707 (116 ref.)

Prevention of fungal infections in hematology patients. Philpott-Howard J. **Infect Control Hosp Epidemiol** 1996 Aug;17(8):545–51 (68 ref.)

Fever in the neutropenic host. Chanock SJ, et al. **Infect Dis Clin North Am** 1996 Dec;10(4):777–96 (115 ref.)

The varicella vaccine. Clinical trials in immunocompromised individuals. Gershon AA, et al. **Infect Dis Clin North Am** 1996 Sep;10(3):583–94 (47 ref.)

Monocyte deactivation--rationale for a new therapeutic strategy in sepsis. Volk HD, et al. **Intensive Care Med** 1996 Oct;22 Suppl 4:S474–81 (24 ref.)

Fulminant septicemic syndrome of Bacillus cereus in a leukemic patient. Akiyama N, et al. **Intern Med** 1997 Mar; 36(3):221–6 (15 ref.)

Dental considerations in asplenic patients. De Rossi SS, et al. **J Am Dent Assoc** 1996 Sep;127(9):1359–63 (40 ref.)

Herpes zoster ophthalmicus and the immunocompromised host: a case report and review. McPherson RE. **J Am Optom Assoc** 1997 Aug;68(8):527–38 (49 ref.)

Current therapeutic approaches to cryptosporidiosis in immunocompromised patients. Hoepelman AI. **J Antimicrob Chemother** 1996 May;37(5):871–80 (71 ref.)

The importance of in-vitro susceptibility testing in the management of compromised hosts. Venditti M, et al. **J Chemother** 1997 May;9 Suppl 1:116–22 (23 ref.)

Successful treatment of molluscum contagiosum in the immunosuppressed adult with topical injection of streptococcal preparation OK-432. Inui S, et al. **J Dermatol** 1996 Sep;23(9):628–30 (19 ref.)

Subcutaneous phaeohypomycosis caused by Scytalidium dimidiatum in the foot of an immunosuppressed host. Rockett MS, et al. **J Foot Ankle Surg** 1996 Jul–Aug; 35(4):350–4 (25 ref.)

Emerging fungal infections in cancer patients. Krcmery V Jr. **J Hosp Infect** 1996 Jun;33(2):109–17 (50 ref.)

Penicillium marneffei infection in a non-HIV infected child. Kwan EY, et al. **J Paediatr Child Health** 1997 Jun; 33(3):267–71 (34 ref.)

Treatment of fungal and other opportunistic infections in immunocompromised patients. Wade JC. **Leukemia** 1997 May;11 Suppl 4:S38–9 (7 ref.)

Chryseobacterium meningosepticum: an emerging pathogen among immunocompromised adults. Report of 6 cases and literature review. Bloch KC, et al. **Medicine (Baltimore)** 1997 Jan;76(1):30–41 (84 ref.)

Invasive pneumococcal disease in the immunocompromised host. Janoff EN, et al. **Microb Drug Resist** 1997 Fall; 3(3):215–32 (192 ref.)

Guillain-Barré syndrome in immunocompromised patients: a report of three patients and review of the literature. Qureshi AI, et al. **Muscle Nerve** 1997 Aug;20(8):1002–7 (44 ref.)

Opportunistic infections of the eye in immunocompromised patients. Guembel HO, et al. **Ophthalmologica** 1997;211 Suppl 1:53–61 (55 ref.)

Oral pathoses caused by Candida albicans during chemotherapy: update on development mechanisms. Bunetel L, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Aug;82(2):161–5 (59 ref.)

Candida albicans infection of prosthetic joints. Cardinal E, et al. **Orthopedics** 1996 Mar;19(3):247–51 (34 ref.)

Respiratory problems in the immune-compromised host. Schauer U. **Pediatr Allergy Immunol** 1996;7(9 Suppl):82–5 (33 ref.)

Empyema and bloodstream infection caused by Burkholderia gladioli in a patient with cystic fibrosis after lung transplantation. Khan SU, et al. **Pediatr Infect Dis J** 1996 Jul;15(7):637–9 (14 ref.)

Two case reports and review of vascular catheter-associated bacteremia caused by nontuberculous Mycobacterium species. Rodgers GL, et al. **Pediatr Infect Dis J** 1996 Mar; 15(3):260–4 (50 ref.)

Aplastic anemia in a cardiac transplant recipient. Thio K, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1139, 1141–2 (11 ref.)

The immunocompromised host. Smith S, et al. **Pediatr Rev** 1996 Dec;17(12):435–40 (5 ref.)

Lethal disseminated Fusarium infection with sinus involvement in the immunocompromised host: case report and review of the literature. Rombaux P, et al. **Rhinology** 1996 Dec;34(4):237–41 (27 ref.)

Brain abscesses due to Geotrichum candidum. Kasantikul V, et al. **Southeast Asian J Trop Med Public Health** 1995 Dec; 26(4):805–7 (9 ref.)

Gastrointestinal problems in the immunocompromised host. A review for surgeons. Scott-Conner CEH, et al. **Surg Endosc** 1996 Oct;10(10):959–64 (48 ref.)

[Vaccinations in immunosuppressed patients] Bouchaud O. **Ann Med Interne (Paris)** 1997;148(3):272–9 (41 ref.) (Eng. Abstr.) **(Fre)**

[Prevention of parasitic infections (excluding toxoplasmosis) in immunocompromised patients] Hennequin C. **Ann Med Interne (Paris)** 1997;148(3):240–5 (44 ref.) (Eng. Abstr.) **(Fre)**

[Prevention of infections in immunosuppressed patients: prevention of post-transfusion infections] Joly V. **Ann Med Interne (Paris)** 1997;148(3):268–71 (20 ref.) (Eng. Abstr.) **(Fre)**

[Prevention of atypical mycobacterium infections in immunocompromised patients] Meynard JL. **Ann Med Interne (Paris)** 1997;148(3):230–4 (38 ref.) (Eng. Abstr.) **(Fre)**

[Prevention of toxoplasmosis in immunocompromised patients] Morlat P, et al. **Ann Med Interne (Paris)** 1997; 148(3):235–9 (32 ref.) (Eng. Abstr.) **(Fre)**

[Prevention of tuberculosis in immunocompromised patients] Perronne C. **Ann Med Interne (Paris)** 1997;148(3):226–9 (15 ref.) (Eng. Abstr.) **(Fre)**

[Prevention of bacterial infections in immunocompromised hosts, excluding HIV infection and mycobacterium infections] Raguin G. **Ann Med Interne (Paris)** 1997; 148(3):218–25 (84 ref.) (Eng. Abstr.) **(Fre)**

[Primary and secondary prevention of cytomegalovirus infections in immunocompromised patients] Salmon-Céron D. **Ann Med Interne (Paris)** 1997;148(3):246–54 (62 ref.) (Eng. Abstr.) **(Fre)**

[Malnutrition and immunodeficiency in children] Leke L, et al. **Arch Pediatr** 1996 Jul;3(7):705–13 (57 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of varicella] Balfour HH. **Presse Med** 1997 Jan; 26 Suppl 1:2–3 (2 ref.) **(Fre)**

[Central nervous system infections in patients with malignant diseases] Carpentier AF, et al. **Rev Neurol (Paris)** 1996 Oct; 152(10):587–601 (115 ref.) (Eng. Abstr.) **(Fre)**

[Surgery in immunosuppressed patients with emergency or elective indications] Lang H, et al. **Chirurg** 1997 Jul; 68(7):675–80 (26 ref.) (Eng. Abstr.) **(Ger)**

[Perioperative managements for postoperative severe infections in compromised host] Yokoyama T, et al. **Nippon Geka Gakkai Zasshi** 1996 Dec;97(12):1060–5 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Virus-related neurological disorders complicating in compromised hosts] Kimura S. **Nippon Rinsho** 1997 Apr; 55(4):949–53 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Infection in the elderly--as an immunocompromised host with undernutrition] Toba K. **Nippon Ronen Igakkai Zasshi** 1997 Feb;34(2):106–9 (10 ref.) **(Jpn)**

[Fungal infections in patients with solid tumors and other immunodepressed patients] Muñoz García-Paredes P, et al. **Rev Clin Esp** 1997 Apr;197 Suppl 1:35–43 (81 ref.) **(Spa)**

DRUG EFFECTS

Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review [see comments] Hatala R, et al. **Clin Infect Dis** 1997 May; 24(5):810–5 (37 ref.) Comment in: Clin Infect Dis 1997 May;24(5):816–9. Comment in: Clin Infect Dis 1997 May;24(5):820–3.

IMMUNOLOGY

Immune deficiency in glycogen storage disease type 1B. Garty BZ, et al. **Isr J Med Sci** 1996 Dec;32(12):1276–81 (40 ref.)

IMMUNOCONJUGATES

THERAPEUTIC USE

Vehicles, chelators, and radionuclides: choosing the "building blocks" of an effective therapeutic radioimmunoconjugate. Schubiger PA, et al. **Bioconjug Chem** 1996 Mar–Apr; 7(2):165–79 (98 ref.)

Are immunoconjugates useful for therapy with autoimmune diseases? Wu M. **Int J Immunopharmacol** 1997 Feb; 19(2):83–93 (56 ref.)

IMMUNOCONTRACEPTION see **CONTRACEPTION, IMMUNOLOGIC**

IMMUNOCYTOCHEMISTRY see **IMMUNOHISTOCHEMISTRY**

IMMUNODEFICIENCY, COMMON VARIABLE see **COMMON VARIABLE IMMUNODEFICIENCY**

IMMUNODEFICIENCY, SEVERE COMBINED see **SEVERE COMBINED IMMUNODEFICIENCY**

IMMUNODEFICIENCY SYNDROME, ACQUIRED see **ACQUIRED IMMUNODEFICIENCY SYNDROME**

IMMUNODEFICIENCY VIRUS, BOVINE

Natural and experimental bovine immunodeficiency virus infection in cattle. Snider TG, et al. **Vet Clin North Am Food Anim Pract** 1997 Mar;13(1):151–76 (94 ref.)

METABOLISM

New features in RNA recognition: a Tat–TAR complex. Wemmer DE. **Chem Biol** 1996 Jan;3(1):17–9 (12 ref.)

How Tat targets TAR: structure of the BIV peptide–RNA complex. Greenbaum NL. **Structure** 1996 Jan 15;4(1):5–9 (18 ref.)

IMMUNODEFICIENCY VIRUS, FELINE

FIV infection of the domestic cat: an animal model for AIDS. Willett BJ, et al. **Immunol Today** 1997 Apr;18(4):182–9 (105 ref.)

IMMUNOLOGY

The relevance of feline retroviruses to the development of vaccines against HIV. Jarrett O. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):385–7 (23 ref.)

Vaccination of cats with recombinant envelope glycoprotein of feline immunodeficiency virus: decreased viral load after challenge infection. Lutz H, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):431–3 (17 ref.)

Perspectives on FIV vaccine development. Elyar JS, et al. **Vaccine** 1997 Aug–Sep;15(12–13):1437–44 (59 ref.)

ISOLATION & PURIFICATION

FIV, FeLV, and FIPV: interpretation and misinterpretation of serological test results. Barr MC. **Semin Vet Med Surg (Small Anim)** 1996 Aug;11(3):144–53 (34 ref.)

PATHOGENICITY

Co-infection of Toxoplasma gondii with other pathogens: pathogenicity and chemotherapy in animal models. Lacroix C, et al. **Curr Top Microbiol Immunol** 1996;219:223–33 (33 ref.)

PHYSIOLOGY

Targeting antiviral nucleotide analogues to macrophages. Magnani M, et al. **J Leukoc Biol** 1997 Jul;62(1):133–7 (32 ref.)

IMMUNODIAGNOSIS see **IMMUNOLOGIC TESTS**

IMMUNODOMINANT EPITOPES

BLOOD

The dominant and the cryptic T cell repertoire to myelin basic protein in the Lewis rat. Mor F, et al. **J Neurosci Res** 1996 Sep 15;45(6):670–9 (60 ref.)

GENETICS

Spatial structure and insertion capacity of immunodominant region of hepatitis B core antigen. Borisova G, et al. **Intervirology** 1996;39(1–2):16–22 (23 ref.)

IMMUNOLOGY

Multiplicity of uses of monoclonal antibodies that define papillomavirus linear immunodominant epitopes. Jenson AB, et al. **Immunol Res** 1997 Feb;16(1):115–9 (22 ref.)

Lowering the tone: mechanisms of immunodominance among epitopes with low affinity for MHC [see comments] Fairchild PJ, et al. **Immunol Today** 1996 Feb;17(2):80–85 (51 ref.) Comment in: Immunol Today 1997 Feb;18(2):97–8.

Delineation of immunodominant epitopes of human T-lymphotropic virus types I and II and their usefulness in developing serologic assays for detection of antibodies to HTLV-I and HTLV-II. Lal RB. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S170–8 (56 ref.)

Multiple sclerosis: an altered immune response or an altered stress response? van Noort JM. **J Mol Med** 1996 Jun; 74(6):285–96 (49 ref.)

Immunodominant autoepitopes. Mechanisms of autoantibody induction in autoimmune diseases?] Dörner T, et al. **Dtsch Med Wochenschr** 1996 Oct 11;121(41):1267–70 (18 ref.) **(Ger)**

IMMUNOELECTROBLOTTING see **IMMUNOBLOTTING**

IMMUNOELECTRON MICROSCOPY see **MICROSCOPY, IMMUNOELECTRON**

IMMUNOELECTROOSMOPHORESIS see **COUNTERIMMUNOELECTROPHORESIS**

IMMUNOELECTROPHORESIS

see related **BLOOD PROTEIN ELECTROPHORESIS**

IMMUNOELECTROPHORESIS, COUNTERCURRENT see **COUNTERIMMUNOELECTROPHORESIS**

IMMUNOELECTROPHORESIS, CROSSOVER see **COUNTERIMMUNOELECTROPHORESIS**

IMMUNOENZYME TECHNIQUES

Genetic and antigenic diversity of human caliciviruses (HuCVs) using RT-PCR and new EIAs. Jiang X, et al. **Arch Virol Suppl** 1996;12:251–62 (36 ref.)

Combined immunocytochemistry and PRINS DNA synthesis for simultaneous detection of phenotypic and genomic parameters in cells. Speel EJ, et al. **Methods Mol Biol** 1997; 71:53–9 (15 ref.)

[A sensitive two-site (sandwich) enzyme immunoassay system for measuring nerve growth factor (NGF)] Furukawa S. **Nippon Yakurigaku Zasshi** 1997 May; 109(5):235–41 (16 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOFLUORESCENCE ANTIBODY TEST, INDIRECT see **FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT**

IMMUNOFLUORESCENCE MICROSCOPY see **MICROSCOPY, FLUORESCENCE**

IMMUNOFLUORESCENCE TECHNIQUE see **FLUORESCENT ANTIBODY TECHNIQUE**

IMMUNOFLUORESCENCE TECHNIQUE, INDIRECT see **FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT**

IMMUNOGENETICS

Immunogenetics in liver disease. Donaldson PT. **Baillieres Clin Gastroenterol** 1996 Sep;10(3):533–49 (68 ref.)

[Identification of T cell epitopes by reverse immunogenetics] Takiguchi M. **Nippon Rinsho** 1996 Dec;54(12):3379–88 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Progress and prospects of tuberculosis immunology and immunogenetics] Litvinov VI, et al. **Probl Tuberk** 1996; (6):14–8 (41 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOGENS, SYNTHETIC see **VACCINES, SYNTHETIC**

IMMUNOGLOBULIN ALLOTYPES

ANALYSIS

Immunoglobulin allotypes (GM and KM) and their interactions with HLA antigens in autoimmune diseases: a review. Dugoujon JM, et al. **Autoimmunity** 1995; 22(4):245–60 (176 ref.)

METABOLISM

Immunoglobulin allotypes (GM and KM) and their interactions with HLA antigens in autoimmune diseases: a review. Dugoujon JM, et al. **Autoimmunity** 1995; 22(4):245–60 (176 ref.)

IMMUNOGLOBULIN CLASS SWITCHING

Immunoglobulin class switching. Stavnezer J. **Curr Opin Immunol** 1996 Apr;8(2):199–205 (71 ref.)

Affinity maturation and class switching. Wabl M, et al. **Curr Opin Immunol** 1996 Feb;8(1):89–92 (27 ref.)

Biochemical studies of class switch recombination. Jessberger R, et al. **Curr Top Microbiol Immunol** 1996;217:191–202 (30 ref.)

Molecular mechanisms governing reading frame choice of immunoglobulin diversity genes. Raaphorst FM, et al. **Immunol Today** 1997 Jan;18(1):37–43 (58 ref.)

GENETICS

Developmental and molecular regulation of immunoglobulin class switch recombination. Lorenz M, et al. **Curr Top Microbiol Immunol** 1996;217:151–69 (80 ref.)

The immunoglobulin class switch: beyond "accessibility". Snapper CM, et al. **Immunity** 1997 Mar;6(3):217–23 (87 ref.)

IMMUNOLOGY

Antibody class switching. Stavnezer J. **Adv Immunol** 1996; 61:79–146 (298 ref.)

Pairs of surface molecules involved in human IgE regulation: CD23–CD21 and CD40–CD40L. Bonnefoy JY, et al. **Eur Respir J Suppl** 1996 Aug;22:63s–66s (48 ref.)

IMMUNOGLOBULIN CONSTANT REGION

GENETICS

The VH and CH immunoglobulin genes of swine: implications for repertoire development. Butler JE, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):7–17 (20 ref.)

IMMUNOLOGY

Chemical engineering at the antibody hinge. Stevenson GT. **Chem Immunol** 1997;65:57–72 (25 ref.)

IMMUNOGLOBULIN ENHANCER-BINDING PROTEIN see **NF-KAPPA B**

IMMUNOGLOBULIN FRAGMENTS

BIOSYNTHESIS

Phage display of combinatorial antibody libraries. Rader C, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):503–8 (47 ref.)

CHEMISTRY

New protein engineering approaches to multivalent and bispecific antibody fragments. Plückthun A, et al. **Immunotechnology** 1997 Jun;3(2):83–105 (174 ref.)

GENETICS

Inhibition of signaling from Type 1 receptor tyrosine kinases via intracellular expression of single-chain antibodies. Beerli RR, et al. **Breast Cancer Res Treat** 1996;38(1):11–7 (32 ref.)

THERAPEUTIC USE

Single-chain Fv antibodies for targeting cancer therapy. Begent RH, et al. **Biochem Soc Trans** 1997 May;25(2):715–7 (16 ref.)

IMMUNOGLOBULIN GENES see **GENES, IMMUNOGLOBULIN**

IMMUNOGLOBULIN GM ALLOTYPES

ANALYSIS

Immunoglobulin allotypes (GM and KM) and their interactions with HLA antigens in autoimmune diseases: a review. Dugoujon JM, et al. **Autoimmunity** 1995; 22(4):245–60 (176 ref.)

METABOLISM

Immunoglobulin allotypes (GM and KM) and their interactions with HLA antigens in autoimmune diseases: a review. Dugoujon JM, et al. **Autoimmunity** 1995; 22(4):245–60 (176 ref.)

IMMUNOGLOBULIN IDIOTYPES

IMMUNOLOGY

Induction of autoimmunity. A role for the idiotypic network. Shoenfeld Y, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:342–9 (26 ref.)

Idiotype manipulation for autoimmune diseases: where are we going? Zouali M, et al. **Autoimmunity** 1996;24(1):55–63 (72 ref.)

T and B cell recognition of idiotypes of anti-DNA autoantibodies. Gavalchin J, et al. **Lupus** 1997;6(3):337–43 (52 ref.)

IMMUNOGLOBULIN ISOTYPES

BIOSYNTHESIS

Differentiation of B cells in the bovine. Role of cytokines in immunoglobulin isotype expression. Estes DM. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):61–7 (23 ref.)

IMMUNOLOGY

IgG effector mechanisms. Clark MR. **Chem Immunol** 1997; 65:88–110 (89 ref.)

PHARMACOLOGY

IgG effector mechanisms. Clark MR. **Chem Immunol** 1997; 65:88–110 (89 ref.)

IMMUNOGLOBULIN JOINING REGION

see related **GENES, IMMUNOGLOBULIN**

GENETICS

Somatic hypermutation: Another piece in the hypermutation puzzle. Winter DB, et al. **Curr Biol** 1995 Dec 1;5(12):1345–6 (14 ref.)

IMMUNOLOGY

V(D)J recombination pathology. Schwarz K, et al. **Adv Immunol** 1996;61:285–326 (281 ref.)

IMMUNOGLOBULIN-PRODUCING CELLS see **ANTIBODY-PRODUCING CELLS**

IMMUNOGLOBULIN-SECRETING CELLS see **ANTIBODY-PRODUCING CELLS**

IMMUNOGLOBULIN SWITCH REGION

GENETICS

[Molecular mechanisms for immunoglobulin class switching and IgE production] Shimizu A. **Nippon Rinsho** 1996 Feb; 54(2):440–5 (18 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOGLOBULIN THERAPY see **IMMUNIZATION, PASSIVE**

IMMUNOGLOBULIN VARIABLE REGION

see related
BINDING SITES, ANTIBODY

The primary antibody repertoire of normal, immunodeficient and autoimmune mice is characterized by differences in V gene expression. Kaushik A, et al. **Res Immunol** 1996 Jan;147(1):9–26 (48 ref.)

ANALYSIS

Primary localized amyloidosis of the eyelid: two cases of immunoglobulin light chain–derived proteins, subtype lambda V respectively lambda VI. Olsen KE, et al. **Clin Exp Immunol** 1996 Nov;106(2):362–6 (27 ref.)

BIOSYNTHESIS

Somatic diversification of antibody responses. Zheng B, et al. **J Clin Immunol** 1996 Jan;16(1):1–11 (129 ref.)

VH gene expression in CD5 positive and CD5 negative B cell chronic lymphoid malignancies. Maloum K, et al. **Leuk Lymphoma** 1997 Feb;24(5–6):437–48 (114 ref.)

GENETICS

Immunoglobulin heavy chain variable region gene usage in human autoimmune diseases. Pascual V, et al. **Adv Exp Med Biol** 1995;386:133–9 (24 ref.)

Somatic mutation and CDR3 length of immunoglobulin lambda variable region genes in the synovium of patients with rheumatoid arthritis. Mageed RA, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:319–23 (4 ref.)

Nonrandom features of the human immunoglobulin variable region gene repertoire expressed in response to HIV-1. Zouali M. **Appl Biochem Biotechnol** 1996 Oct–Nov; 61(1–2):149–55 (31 ref.)

Somatic hypermutation: Another piece in the hypermutation puzzle. Winter DB, et al. **Curr Biol** 1995 Dec 1;5(12):1345–6 (14 ref.)

Somatic hypermutability. Wabl M, et al. **Curr Top Microbiol Immunol** 1996;217:203–19 (90 ref.)

The immunoglobulin class switch: beyond "accessibility". Snapper CM, et al. **Immunity** 1997 Mar;6(3):217–23 (87 ref.)

Rearrangement/hypermutation/gene conversion: when, where and why? Weill JC, et al. **Immunol Today** 1996 Feb; 17(2):92–7 (37 ref.)

Somatic diversification of antibody responses. Zheng B, et al. **J Clin Immunol** 1996 Jan;16(1):1–11 (129 ref.)

Generation of diversity in mammalian gut-associated lymphoid tissues: restricted V gene usage does not preclude complex V gene organization. Reynaud CA, et al. **J Immunol** 1997 Oct 1;159(7):3093–5 (18 ref.)

VH gene expression in CD5 positive and CD5 negative B cell chronic lymphoid malignancies. Maloum K, et al. **Leuk Lymphoma** 1997 Feb;24(5–6):437–48 (114 ref.)

Jaw, adaptive immunity and phylogeny of vertebrate antibody VH gene family. Andersson E, et al. **Res Immunol** 1996 May;147(4):233–40 (65 ref.)

Evolution and somatic learning in V-region genes. Perelson AS, et al. **Res Immunol** 1996 May;147(4):202–8 (8 ref.)

V-gene usage and N-region insertions in B-1a, B-1b and conventional B cells. Kantor AB. **Semin Immunol** 1996 Feb; 8(1):29–35 (73 ref.)

IMMUNOLOGY

Variable (V) region–mediated control of autoreactivity to factor VIII. Kazatchkine MD, et al. **Adv Exp Med Biol** 1995;386:223–8 (20 ref.)

V(D)J recombination pathology. Schwarz K, et al. **Adv Immunol** 1996;61:285–326 (281 ref.)

The leukemic cells of chronic lymphocytic leukemia patients with autoimmune hemolytic anemia produce isotype-switched immunoglobulins that are preferentially encoded by the 51p1 and DP-50 VH genes. Efremov DG, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:443–7 (9 ref.)

METABOLISM

Ig VH–dependent interaction between immunoglobulins and CD4. Lenert P, et al. **Int Rev Immunol** 1997;14(4):351–62 (44 ref.)

Staphylococcal protein A binding to VH3 encoded immunoglobulins. Potter KN, et al. **Int Rev Immunol** 1997; 14(4):291–308 (55 ref.)

IMMUNOGLOBULINS

see related
PARAPROTEINEMIAS

[Cell adhesion proteins in the nervous system: immunoglobulin superfamily--structure, function and involvement in neurological diseases] Yazaki T, et al. **No To Hattatsu** 1996 Nov;28(6):475–83 (26 ref.) (Eng. Abstr.) **(Jpn)**

[Telencephalin, a dendrite-associated cell adhesion molecule with brain segment-specific expression] Mori K, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):555–60 (13 ref.) **(Jpn)**

ANALYSIS

[Rationale for a trial of prevention of perinatal transmission of hepatitis C via specific immunoglobulins] Soulié JC. **Transfus Clin Biol** 1997;4(2):213–9 (46 ref.) (Eng. Abstr.) **(Fre)**

BIOSYNTHESIS

Vasoactive intestinal peptide differentially modulates human immunoglobulin production. Kimata H. **Adv Neuroimmunol** 1996;6(1):107–15 (28 ref.)

Engineering novel antibody molecules. Sensel MG, et al. **Chem Immunol** 1997;65:129–58 (80 ref.)

A comparison of the performance in vitro of precision cut tissue slices and suspensions of human spleen with special reference to immunoglobulin and cytokine production. James K, et al. **Hum Antibodies Hybridomas** 1996; 7(4):138–50 (30 ref.)

BLOOD

Direct immunofluorescence in lupus erythematosus (LE). Isfer RS, et al. **Rev Paul Med** 1996 Mar–Apr;114(2):1141–7 (19 ref.)

CHEMISTRY

Cell–adhesion proteins of the immunoglobulin superfamily in the nervous system. Uyemura K, et al. **Essays Biochem** 1996;31:37–48 (30 ref.)

Peptide secondary structure mimetics: applications to vaccines and pharmaceuticals. Qabar M, et al. **Farmaco** 1996 Feb;51(2):87–96 (77 ref.)

[Immunoglobulin superfamily] Kato K. **Rinsho Byori** 1996 Sep;Suppl 102:11–5 (7 ref.) **(Jpn)**

CLASSIFICATION

Immunoglobulin class switching. Stavnezer J. **Curr Opin Immunol** 1996 Apr;8(2):199–205 (71 ref.)

DEFICIENCY

Immunoglobulin deficient mice generated by gene targeting as models for studying the immune response. Bot A. **Int Rev Immunol** 1996;13(4):327–40 (95 ref.)

DRUG EFFECTS

Vasoactive intestinal peptide differentially modulates human immunoglobulin production. Kimata H. **Adv Neuroimmunol** 1996;6(1):107–15 (28 ref.)

Anti–adhesion therapy. Cornejo CJ, et al. **Adv Pharmacol** 1997;39:99–142 (200 ref.)

GENETICS

Immunoglobulin class switching. Stavnezer J. **Curr Opin Immunol** 1996 Apr;8(2):199–205 (71 ref.)

Factors influencing the preimmune antibody repertoire. Kraj P. **Folia Biol (Praha)** 1997;43(2):53–61 (125 ref.)

Emergence of the immunoglobulin family: conservation in protein sequence and plasticity in gene organization. Marchalonis JJ, et al. **Glycobiology** 1996 Oct;6(7):657–63 (60 ref.)

Immunoglobulin evolution, 30 years on. Steiner LA. **Glycobiology** 1996 Oct;6(7):649–56 (90 ref.)

The evolutionary origins of immunoglobulins and T-cell receptors: possibilities and probabilities. Langman RE. **Res Immunol** 1996 May;147(4):214–7 (2 ref.)

Occam's Razor, invertebrate allorecognition and Ig superfamily evolution. Mokady O. **Res Immunol** 1996 May; 147(4):241–6 (20 ref.)

The origin of immunoglobulins and T-cell receptors is likely to be the cell death sensor of macrophages. Ohno S. **Res Immunol** 1996 May;147(4):247–52 (12 ref.)

IMMUNOLOGY

Anti-red blood cell immunoglobulin transgenic mice. An experimental model of autoimmune hemolytic anemia. Nisitani S, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:246–52 (21 ref.)

Glycosylation of antibody molecules: structural and functional significance. Jefferis R, et al. **Chem Immunol** 1997;65:111–28 (63 ref.)

Surface expression of CD28 single chain Fv for costimulation by tumor cells. Winberg G, et al. **Immunol Rev** 1996 Oct; 153:209–23 (19 ref.)

[Immunoglobulin superfamily] Kato K. **Rinsho Byori** 1996 Sep;Suppl 102:11–5 (7 ref.) **(Jpn)**

[Acute rheumatic fever and rheumatic heart disease: immunological studies] Speranskii AI, et al. **Vestn Ross Akad Med Nauk** 1996;(11):44–50 (17 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Catalytic antibodies. Driggers EM, et al. **Adv Protein Chem** 1996;49:261–87 (74 ref.)

Glycosylation of antibody molecules: structural and functional significance. Jefferis R, et al. **Chem Immunol** 1997;65:111–28 (63 ref.)

The Sialoadhesins--a family of sialic acid–dependent cellular recognition molecules within the immunoglobulin superfamily. Kelm S, et al. **Glycoconj J** 1996 Dec; 13(6):913–26 (114 ref.)

Specificity and function of immunoglobulin superfamily NK cell inhibitory and stimulatory receptors. Colonna M. **Immunol Rev** 1997 Feb;155:127–33 (55 ref.)

Axonal molecules of the immunoglobulin superfamily bearing a GPI anchor: their role in controlling neurite outgrowth. Faivre-Sarrailh C, et al. **Mol Cell Neurosci** 1997; 9(2):109–15 (51 ref.)

PHARMACOLOGY

Oral delivery of antibodies. Future pharmacokinetic trends. Reilly RM, et al. **Clin Pharmacokinet** 1997 Apr; 32(4):313–23 (53 ref.)

PHYSIOLOGY

Fc receptors and their interactions with immunoglobulins. Raghavan M, et al. **Ann Rev Cell Dev Biol** 1996;12:181–220 (158 ref.)

Functional resemblance between the Ig-related NK cell receptors specific for HLA class I molecules and the CD94 C-type lectin. López-Botet M, et al. **Chem Immunol** 1996; 64:116–34 (60 ref.)

The role of immunoproteins in the survival of liposomes in the circulation. Devine DV, et al. **Crit Rev Ther Drug Carrier Syst** 1997;14(2):105–31 (146 ref.)

Structure/function relationships of axon-associated adhesion receptors of the immunoglobulin superfamily. Brümmendorf T, et al. **Curr Opin Neurobiol** 1996 Oct; 6(5):584–93 (80 ref.)

Cell–adhesion proteins of the immunoglobulin superfamily in the nervous system. Uyemura K, et al. **Essays Biochem** 1996;31:37–48 (30 ref.)

B-cell activation versus tolerance—the central role of immunoglobulin receptor engagement and T-cell help. Fulcher DA, et al. **Int Rev Immunol** 1997;15(1–2):33–52 (22 ref.)

Axonal molecules of the immunoglobulin superfamily bearing a GPI anchor: their role in controlling neurite outgrowth. Faivre-Sarrailh C, et al. **Mol Cell Neurosci** 1997; 9(2):109–15 (51 ref.)

IMMUNOGLOBULINS, FAB

ADMINISTRATION & DOSAGE

Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Kleiman NS. **Am J Cardiol** 1997 Aug 18; 80(4A):29B–33B (17 ref.)

BIOSYNTHESIS

Chemical engineering at the antibody hinge. Stevenson GT. **Chem Immunol** 1997;65:57–72 (25 ref.)

CHEMISTRY

Formulation development of an antifibrin monoclonal antibody radiopharmaceutical. Kamat MS, et al. **Pharm Biotechnol** 1996;9:343–64 (18 ref.)

[Antibody engineering and gene therapy in cancer] Hinoda Y, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Oct; 19(5):453–9 (17 ref.) **(Jpn)**

DIAGNOSTIC USE

Cancer imaging with radiolabeled antibodies: new advances with technetium-99m-labeled monoclonal antibody Fab' fragments, especially CEA-Scan and prospects for therapy. Goldenberg DM, et al. **J Nucl Med Technol** 1997 Mar; 25(1):18–23; quiz 34 (46 ref.)

IMMUNOLOGY

Chemical engineering at the antibody hinge. Stevenson GT. **Chem Immunol** 1997;65:57–72 (25 ref.)

ISOLATION & PURIFICATION

The FAB classification for acute myeloid leukaemia—is it outdated? Segeren CM, et al. **Neth J Med** 1996 Sep; 49(3):126–31 (53 ref.)

IMMUNOGLOBULINS, FAB

THERAPEUTIC USE

Restenosis: is there a pharmacologic fix in the pipeline? Keiser JA, et al. **Adv Pharmacol** 1997;39:313–51 (250 ref.)

Use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Parmar R, et al. **Am J Med Sci** 1997 Jul; 314(1):31–6 (22 ref.)

ABCIXIMAB: a new antiaggregant used in angioplasty. Genetta TB, et al. **Ann Pharmacother** 1996 Mar;30(3):251–7 (28 ref.)

A critical review of antidotal immunotherapy for low molecular weight toxins. Current antidotes and perspectives. Baud FJ, et al. **Arch Toxicol Suppl** 1997; 19:271–87 (45 ref.)

The anti-GPIIb–IIIa agents: fundamental and clinical aspects. Coller BS, et al. **Haemostasis** 1996 Oct;26 Suppl 4:285–93 (36 ref.)

IIb/IIIa platelet inhibitors in the management of coronary artery disease. Talley JD. **J Ark Med Soc** 1996 Oct; 93(5):237–9 (8 ref.)

Clinical trials update [news] Kayser SR. **Prog Cardiovasc Nurs** 1997 Spring;12(2):30–3, 44 (10 ref.)

GPIIb/IIIa antagonists: pathophysiologic and therapeutic insights from studies of c7E3 Fab. Coller BS. **Thromb Haemost** 1997 Jul;78(1):730–5 (42 ref.)

[Modern "antiplatelet agents" in unstable angina] Vahanian A, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1521–6 (27 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOGLOBULINS, FC

see related
RECEPTORS, FC

GENETICS

Non–HLA genes and the susceptibility to insulin dependent diabetes: the role of the CTLA-4 gene. Pozzilli P, et al. **Acta Diabetol** 1996 Dec;33(4):250–2 (20 ref.)

IMMUNOLOGY

Regulation of T cell activation by CD28 and CTLA4. Noel PJ, et al. **Adv Exp Med Biol** 1996;406:209–17 (27 ref.)

IMMUNOGLOBULINS, HEAVY-CHAIN

BIOSYNTHESIS

VH gene expression in CD5 positive and CD5 negative B cell chronic lymphoid malignancies. Maloum K, et al. **Leuk Lymphoma** 1997 Feb;24(5–6):437–48 (114 ref.)

GENETICS

Immunoglobulin heavy chain variable region gene usage in human autoimmune diseases. Pascual V, et al. **Adv Exp Med Biol** 1995;386:133–9 (24 ref.)

Organization of the human immunoglobulin heavy-chain locus. Matsuda F, et al. **Adv Immunol** 1996;62:1–29 (79 ref.)

PCR-based alternative for diagnosis of immunoglobulin heavy chain gene rearrangement: principles, practice, and polemics. Diaz-Cano S. **Diagn Mol Pathol** 1996 Mar; 5(1):3–9 (34 ref.)

Minimal residual disease detection in B-cell malignancies by assessing IgH rearrangement. Maloum K, et al. **Hematol Cell Ther** 1997 Jun;39(3):119–24 (52 ref.)

VH gene expression in CD5 positive and CD5 negative B cell chronic lymphoid malignancies. Maloum K, et al. **Leuk Lymphoma** 1997 Feb;24(5–6):437–48 (114 ref.)

Genetic control of DNA antibody production: focus on the heavy chain. Tsao B, et al. **Lupus** 1997;6(3):310–4 (21 ref.)

Jaw, adaptive immunity and phylogeny of vertebrate antibody VH gene family. Andersson E, et al. **Res Immunol** 1996 May;147(4):233–40 (65 ref.)

The VH and CH immunoglobulin genes of swine: implications for repertoire development. Butler JE, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):7–17 (20 ref.)

ISOLATION & PURIFICATION

PCR-based alternative for diagnosis of immunoglobulin heavy chain gene rearrangement: principles, practice, and polemics. Diaz-Cano S. **Diagn Mol Pathol** 1996 Mar; 5(1):3–9 (34 ref.)

METABOLISM

Ig VH-dependent interaction between immunoglobulins and CD4. Lenert P, et al. **Int Rev Immunol** 1997;14(4):351–62 (44 ref.)

Staphylococcal protein A binding to VH3 encoded immunoglobulins. Potter KN, et al. **Int Rev Immunol** 1997; 14(4):291–308 (55 ref.)

IMMUNOGLOBULINS, INTRAVENOUS

Prophylaxis for severe respiratory syncytial virus disease [news] Kupecz D. **Nurse Pract** 1996 Sep;21(9):116–8 (8 ref.)

[Reality and clinical application of immunoglobulin preparations] Miyara T, et al. **Nippon Naika Gakkai Zasshi** 1996 Jun 10;85(6):824–8 (8 ref.) **(Jpn)**

[Aiming serotherapy of HUS–IVIG, serum lipoprotein and C3] Nishioka K, et al. **Nippon Rinsho** 1997 Mar; 55(3):758–62 (34 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Intravenous immunoglobulin treatment of pregnant patients with unexplained recurrent abortions. Raziel A, et al. **Hum Reprod** 1996 Apr;11(4):711–5 (64 ref.)

The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders. van der Meché FG, et al. **Muscle Nerve** 1997 Feb;20(2):136–47 (93 ref.)

Intravenous immunoglobulin in rheumatic disease. Klassen LW, et al. **Rheum Dis Clin North Am** 1996 Feb;22(1):155–73 (95 ref.)

ADVERSE EFFECTS

Acute renal failure following immunoglobulin therapy. Ahsan N, et al. **Am J Nephrol** 1996;16(6):532–6 (29 ref.)

Safety and side effects of i.v. immunoglobulin therapy. Nydegger UE. **Clin Exp Rheumatol** 1996 May–Jun;14 Suppl 15:S53–7 (20 ref.)

Adverse effects of intravenous immunoglobulin therapy. Ryan ME, et al. **Clin Pediatr (Phila)** 1996 Jan;35(1):23–31 (62 ref.)

Gammagard and reported hepatitis C virus episodes. Gomperts ED. **Clin Ther** 1996;18 Suppl B:3–8 (14 ref.)

Intravenous immunoglobulin and hepatitis C virus: an overview of transmission episodes with emphasis on manufacturing data. Yap PL. **Clin Ther** 1996;18 Suppl B:43–58 (56 ref.)

[Acute kidney failure secondary to intravenous immunoglobulin administration. 4 cases and review of the literature] Decocq G, et al. **Therapie** 1996 Sep–Oct; 51(5):516–26 (26 ref.) (Eng. Abstr.) **(Fre)**

HISTORY

Immunoglobulins in autoimmunity: history and mechanisms of action. Dwyer JM. **Clin Exp Rheumatol** 1996 May–Jun; 14 Suppl 15:S3–7 (0 ref.)

IMMUNOLOGY

Immunomodulatory effect of immunoglobulins. Wolf HM, et al. **Clin Exp Rheumatol** 1996 May–Jun;14 Suppl 15:S17–25 (88 ref.)

PHARMACOLOGY

High-dose intravenous therapy with 7S immunoglobulins in autoimmune endocrine ophthalmopathy. Seppel T, et al. **Clin Exp Rheumatol** 1996 May–Jun;14 Suppl 15:S109–14 (31 ref.)

Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. Ballow M. **J Allergy Clin Immunol** 1997 Aug;100(2):151–7 (70 ref.)

PHYSIOLOGY

Immunoglobulins in autoimmunity: history and mechanisms of action. Dwyer JM. **Clin Exp Rheumatol** 1996 May–Jun; 14 Suppl 15:S3–7 (0 ref.)

Immunoglobulins and the regulation of autoimmunity through the immune network. Lacroix-Desmazes S, et al. **Clin Exp Rheumatol** 1996 May–Jun;14 Suppl 15:S9–15 (31 ref.)

THERAPEUTIC USE

Current perspectives on the use of intravenous immunoglobulin. Dickler HB, et al. **Adv Intern Med** 1996; 41:641–80 (152 ref.)

Adjunctive treatment of streptococcal toxic shock syndrome using intravenous immunoglobulin: case report and review. Perez CM, et al. **Am J Med** 1997 Jan;102(1):111–3 (15 ref.)

Clinical uses of intravenous immunoglobulin in pregnancy. Clark AL, et al. **Am J Obstet Gynecol** 1997 Jan;176(1 Pt 1):241–53 (156 ref.)

Immunotherapy for recurrent pregnancy loss: analysis of results from clinical trials. Coulam CB, et al. **Am J Reprod Immunol** 1996 Apr;35(4):352–9 (67 ref.)

Current management of asthma patients with corticosteroid resistance. Busse WW, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 2):S70–2; discussion S72–3 (16 ref.)

Intravenous immune globulin therapy for neurologic diseases. Dalakas MC. **Ann Intern Med** 1997 May 1;126(9):721–30 (97 ref.)

Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients. Dickinson BI, et al. **Ann Pharmacother** 1996 Dec;30(12):1452–64 (35 ref.)

Intravenous immune globulin for inducing remissions in systemic lupus erythematosus. Heyneman CA, et al. **Ann Pharmacother** 1997 Feb;31(2):242–4 (27 ref.)

Respiratory syncytial virus immune globulin intravenous. Wandstrat TL. **Ann Pharmacother** 1997 Jan;31(1):83–8 (36 ref.)

High dose intravenous immunoglobulin therapy for rheumatic diseases: clinical relevance and personal experience. De Vita S, et al. **Clin Exp Rheumatol** 1996 May–Jun;14 Suppl 15:S85–92 (77 ref.)

Immunoglobulins in children with autoimmune diabetes mellitus. Heinze E. **Clin Exp Rheumatol** 1996 May–Jun;14 Suppl 15:S99–102 (16 ref.)

Experience with immunoglobulins in thyroid autoimmunity. Lecomte P, et al. **Clin Exp Rheumatol** 1996 May–Jun;14 Suppl 15:S103–7 (5 ref.)

Immunomodulatory effect of immunoglobulins. Wolf HM, et al. **Clin Exp Rheumatol** 1996 May–Jun;14 Suppl 15:S17–25 (88 ref.)

The evaluation of suspected immune deficiency by the primary care physician. Infante AJ, et al. **Compr Ther** 1997 Feb;23(2):89–94 (2 ref.)

New treatments for multiple sclerosis: a clinical perspective. Thompson AJ, et al. **Curr Opin Neurol** 1996 Jun; 9(3):187–98 (82 ref.)

The use of intravenous immunoglobulins in the treatment of neuromuscular disorders. Voltz R, et al. **Curr Opin Neurol** 1996 Oct;9(5):360–6 (72 ref.)

Risks and benefits of intravenous immunoglobulin treatment in children. Fasano MB. **Curr Opin Pediatr** 1995 Dec; 7(6):688–94 (65 ref.)

Are intravenous immunoglobulin infusions beneficial in the treatment of inflammatory myopathies? [editorial; comment] Sakane T. **Intern Med** 1996 Aug;35(8):598–9 (9 ref.) Comment on: Intern Med 1996 Aug;35(8):663–7.

Sepsis and polyspecific intravenous immunoglobulins. Nydegger UE. **J Clin Apheresis** 1997;12(2):93–9 (41 ref.)

The use of self infused intravenous immunoglobulin home therapy in the treatment of acquired chronic demyelinating neuropathies. Sewell WA, et al. **J Neurol Neurosurg Psychiatry** 1997 Jul;63(1):106–9 (18 ref.)

Chronic inflammatory demyelinating polyneuropathy. Smith H, et al. **J R Army Med Corps** 1994 Jun;140(2):90–2 (18 ref.)

Intravenous immunoglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis--the Israeli experience. MS Study Group. Achiron A, et al. **Mult Scler** 1997 Apr;3(2):142–4 (21 ref.)

Intravenous immunoglobulin treatment in multifocal motor neuropathy and other chronic immune-mediated neuropathies. Comi G, et al. **Mult Scler** 1997 Apr;3(2):93–7 (53 ref.)

Modulation of autoimmune responses by intravenous immunoglobulin (IVIg). Kaveri S, et al. **Mult Scler** 1997 Apr;3(2):121–8 (60 ref.)

Immunomodulation and remyelination: two aspects of human polyclonal immunoglobulin treatment in immune mediated neuropathies? van Schaik IN, et al. **Mult Scler** 1997 Apr; 3(2):98–104 (91 ref.)

Intravenous immune globulin in the management of severe Rh D hemolytic disease. Porter TF, et al. **Obstet Gynecol Surv** 1997 Mar;52(3):193–7 (19 ref.)

Prevention of respiratory syncytial virus infection in high risk infants: consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulin. Meissner HC, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1059–68 (51 ref.)

Human intravenous immunoglobulin in primary and secondary antibody deficiencies. Stiehm ER. **Pediatr Infect Dis J** 1997 Jul;16(7):696–707 (113 ref.)

New peptide and protein drugs. Vermeij P, et al. **Pharm World Sci** 1996 Jun;18(3):87–93 (81 ref.)

Human intravenous immunoglobulin therapy. Scott-Moncrieff JC, et al. **Semin Vet Med Surg (Small Anim)** 1997 Aug;12(3):178–85 (56 ref.)

The use of allogeneic leukocytes or i.v. IgG for the treatment of patients with recurrent spontaneous abortions. Clark DA, et al. **Transfus Med Rev** 1997 Apr;11(2):85–94 (50 ref.)

[A case of atypical Miller-Fisher syndrome treated with intravenous immunoglobulins (letter)] Auzou P, et al. **Ann Med Interne (Paris)** 1996;147(6):458–9 (12 ref.) **(Fre)**

[Respective indications of plasma exchange and high-dose immunoglobulins in polyradiculoneuritis and myasthenia gravis] Raphaël JC, et al. **Presse Med** 1996 Oct 19; 25(31):1516–22 (31 ref.) (Eng. Abstr.) **(Fre)**

[Regulation of autoreactivity by the idiotypic network and therapeutic modulation of autoimmunity by polyvalent intravenous immunoglobulins (IgIV)] Lacroix-Desmazes S, et al. **Rev Neurol (Paris)** 1996 May;152(5):349–54 (40 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of autoimmune neuromuscular diseases with intravenous immunoglobulins] Illa I, et al. **Rev Neurol** 1997 Feb;25(138):263–6 (21 ref.) **(Spa)**

IMMUNOGLOBULINS, J-CHAIN

ANALYSIS

Immunoglobulin J chain. An early differentiation marker of human B cells. Mestecky J, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:111–3 (9 ref.)

IMMUNOGLOBULINS, KAPPA-CHAIN

GENETICS

The lambda B cell repertoire of kappa-deficient mice. Sanchez P, et al. **Int Rev Immunol** 1996;13(4):357–68 (53 ref.)

IMMUNOGLOBULINS, LAMBDA-CHAIN

ANALYSIS

Primary localized amyloidosis of the eyelid: two cases of immunoglobulin light chain-derived proteins, subtype lambda V respectively lambda VI. Olsen KE, et al. **Clin Exp Immunol** 1996 Nov;106(2):362–6 (27 ref.)

GENETICS

Somatic mutation and CDR3 length of immunoglobulin lambda variable region genes in the synovium of patients with rheumatoid arthritis. Mageed RA, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:319–23 (4 ref.)

PHYSIOLOGY

The lambda B cell repertoire of kappa-deficient mice. Sanchez P, et al. **Int Rev Immunol** 1996;13(4):357–68 (53 ref.)

IMMUNOGLOBULINS, LIGHT-CHAIN

IgE lambda monoclonal gammopathy and amyloidosis. Jako JM, et al. **Int Arch Allergy Immunol** 1997 Apr;112(4):415–21 (49 ref.)

BLOOD

[The clinical significance of free light-chain immunoglobulins] Kamaeva OI, et al. **Ter Arkh** 1996; 68(2):78–81 (29 ref.) **(Rus)**

IMMUNOLOGY

Surrogate light chain in B cell development. Karasuyama H, et al. **Adv Immunol** 1996;63:1–41 (178 ref.)

DNA antibodies focus on the light chain. Diamond B, et al. **Lupus** 1997;6(3):315–6 (2 ref.)

METABOLISM

Toward understanding the molecular pathogenesis of monoclonal immunoglobulin light-chain deposition [editorial] Bellotti V, et al. **Nephrol Dial Transplant** 1996 Sep;11(9):1708–11 (18 ref.)

PHYSIOLOGY

The surrogate light chain in mouse B-cell development. Rolink A, et al. **Int Rev Immunol** 1996;13(4):341–56 (41 ref.)

IMMUNOGLOBULINS, SURFACE

Immune responses: tails to teach a B cell. Nussenzweig MC. **Curr Biol** 1997 Jun 1;7(6):R355–7 (11 ref.)

IMMUNOLOGY

Negative signaling in B cells by surface immunoglobulins. Mayumi M, et al. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 2):S238–47 (102 ref.)

PHARMACOLOGY

Negative signaling in B cells by surface immunoglobulins. Mayumi M, et al. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 2):S238–47 (102 ref.)

IMMUNOGLOBULINS, THYROID-STIMULATING

see related
GRAVES' DISEASE
RECEPTORS, THYROTROPIN

IMMUNOLOGY

[Diagnostic value of thyroid antibodies] Toldy E, et al. **Orv Hetil** 1996 Sep 22;137(38):2075–80 (30 ref.) (Eng. Abstr.) **(Hun)**

IMMUNOGOLD-SILVER TECHNIQUES see **IMMUNOHISTOCHEMISTRY**

IMMUNOGOLD TECHNIQUES see **IMMUNOHISTOCHEMISTRY**

IMMUNOHISTOCHEMISTRY

Use of immunocytochemistry in the diagnosis of metastatic carcinoma. Matthews P, et al. **Ann Med** 1996 Aug; 28(4):297–300 (48 ref.)

Immunohistochemistry. Wittekind C, et al. **Digestion** 1997;58 Suppl 1:79–81 (6 ref.)

Reasons underlying discrepancies in results between immunohistochemistry and molecular biology. Kopolovic J, et al. **Eur J Histochem** 1996;40(3):177–80 (32 ref.)

Improved immuno double labelling for cell and structural biology. Koeck PJ, et al. **Micron** 1996 Apr;27(2):157–65 (124 ref.)

Immunohistochemistry: a prognostic as well as diagnostic tool? Mehregan D, et al. **Semin Cutan Med Surg** 1996 Dec; 15(4):317–25 (85 ref.)

[Antigen retrieval: its significance and drawbacks in immunohistochemistry] Ezaki T. **Kaibogaku Zasshi** 1996 Dec;71(6):615–28 (53 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Versatility of immunohistochemical reactions: comprehensive survey of detection systems. Mokrý J. **Acta Medica (Hradec Kralove)** 1996;39(4):129–40 (25 ref.)

Microwaves in diagnostic immunohistochemistry. Leong AS. **Eur J Morphol** 1996 Dec;34(5):381–3 (8 ref.)

Immunogold labeling of yeast cells: an efficient tool for the study of protein targeting and morphological alterations due to overexpression and inactivation of genes. Binder M, et al. **Histochem Cell Biol** 1996 Jul;106(1):115–30 (58 ref.)

Contributions of the immunogold technique to investigation of the biology of peroxisomes. Fahimi HD, et al. **Histochem Cell Biol** 1996 Jul;106(1):105–14 (54 ref.)

Immunogold labeling in scanning electron microscopy. Hermann R, et al. **Histochem Cell Biol** 1996 Jul;106(1):31–9 (62 ref.)

Immunogold silver staining for light microscopy. Lackie PM. **Histochem Cell Biol** 1996 Jul;106(1):9–17 (35 ref.)

Immunogold labelling of neuroendocrine peptides with special reference to antibody specificity and multiple staining techniques. Larsson LI. **Histochem Cell Biol** 1996 Jul;106(1):93–103 (73 ref.)

Improving structural integrity of cryosections for immunogold labeling. Liou W, et al. **Histochem Cell Biol** 1996 Jul;106(1):41–58 (59 ref.)

Applications of immunogold and lectin-gold labeling in tumor research and diagnosis. Roth J, et al. **Histochem Cell Biol** 1996 Jul;106(1):131–48 (117 ref.)

Protein glycosylation in the endoplasmic reticulum and the Golgi apparatus and cell type-specificity of cell surface glycoconjugate expression: analysis by the protein A-gold and lectin-gold techniques. Roth J. **Histochem Cell Biol** 1996 Jul;106(1):79–92 (130 ref.)

Freeze-fracture immunogold labeling. Torrisi MR, et al. **Histochem Cell Biol** 1996 Jul;106(1):19–30 (45 ref.)

Antigen retrieval, signal amplification and intensification in immunohistochemistry. Werner M, et al. **Histochem Cell Biol** 1996 Apr;105(4):253–60 (56 ref.)

Antigen retrieval immunohistochemistry: past, present, and future. Shi SR, et al. **J Histochem Cytochem** 1997 Mar; 45(3):327–43 (167 ref.)

Immunocytochemical methods for investigating receptor localization. Fonseca MI, et al. **Methods Mol Biol** 1997; 83:91–106 (16 ref.)

Errors and pitfalls in diagnostic cytology: new techniques applied to cytopathology. Ross JS. **Monogr Pathol** 1997; (39):94–117 (75 ref.)

The use of immunohistochemistry for evaluating the liver. Hall WC, et al. **Toxicol Pathol** 1996 Jan-Feb;24(1):4–12 (107 ref.)

Immunohistochemistry for light microscopy in safety evaluation of therapeutic agents: an overview. Burnett R, et al. **Toxicology** 1997 Apr 11;119(1):83–93 (38 ref.)

[Immunocytochemistry with epitope tagging] Iida H. **Nippon Rinsho** 1996 Mar;54(3):731–6 (7 ref.) (Eng. Abstr.) **(Jpn)**

STANDARDS

MIB-1 (Ki-67) immunostaining of breast cancer cells in cytologic smears. Dalquen P, et al. **Acta Cytol** 1997 Mar-Apr;41(2):229–37 (44 ref.)

HIERanarchy: the state of the art in immunohistochemistry [editorial] Swanson PE. **Am J Clin Pathol** 1997 Feb; 107(2):139–40 (14 ref.)

The status of immunohistochemical studies in lymphoma diagnosis. Taylor CR. **Biotech Histochem** 1997 Mar; 72(2):62–77 (57 ref.)

TRENDS

The silver anniversary of gold: 25 years of the colloidal gold marker system for immunocytochemistry and histochemistry. Roth J. **Histochem Cell Biol** 1996 Jul; 106(1):1–8 (90 ref.)

IMMUNOHISTOCYTOCHEMISTRY see **IMMUNOHISTOCHEMISTRY**

IMMUNOLABELING TECHNIQUES see **IMMUNOHISTOCHEMISTRY**

IMMUNOLOGIC ACCESSORY CELLS see **ANTIGEN-PRESENTING CELLS**

IMMUNOLOGIC CAPPING

see related
IMMUNOGLOBULINS, SURFACE

Antigen-mediated IGE receptor aggregation and signaling: a window on cell surface structure and dynamics. Holowka D, et al. **Annu Rev Biophys Biomol Struct** 1996;25:79–112 (149 ref.)

IMMUNOLOGIC COMPETENCE see **IMMUNOCOMPETENCE**

IMMUNOLOGIC DEFICIENCY SYNDROME, ACQUIRED see **ACQUIRED IMMUNODEFICIENCY SYNDROME**

IMMUNOLOGIC DEFICIENCY SYNDROMES

see related
IMMUNOCOMPROMISED HOST

Immunodeficiency as a component of recognizable syndromes. Ming JE, et al. **Am J Med Genet** 1996 Dec 30;66(4):378–98 (151 ref.)

Primary immunodeficiency diseases. Report of a WHO scientific group. **Clin Exp Immunol** 1997 Aug;109 Suppl 1:1–28 (0 ref.)

Immunodeficiency in the adult patient. Gutierrez MG, et al. **Compr Ther** 1997 Jul;23(7):446–54 (15 ref.)

Immunodeficiencies and possibilities of their modulation. Hána I. **Folia Biol (Praha)** 1996;42(1–2):61–5 (27 ref.)

The immunocompromised host. Smith S, et al. **Pediatr Rev** 1996 Dec;17(12):435–40 (5 ref.)

[Primary immunodeficiencies. I. Classification and new etiopathogenic findings] Litzman J. **Cas Lek Cesk** 1996 Sep 11;135(17):548–51 (10 ref.) (Eng. Abstr.) **(Cze)**

[Microcephaly with chromosomal instability and immunodeficiency--Nijmegen syndrome] Chrzanowska KH. **Pediatr Pol** 1996 Mar;71(3):223–34 (44 ref.) (Eng. Abstr.) **(Pol)**

COMPLICATIONS

Varicella vaccine in immunocompromised patients. Cat LK, et al. **Ann Pharmacother** 1996 Feb;30(2):181–4 (16 ref.)

Immunodeficient states and associated rheumatic manifestations. Stein CM. **Curr Opin Rheumatol** 1996 Jan; 8(1):52–6 (26 ref.)

Adult immunodeficiency and rheumatic disease. Itescu S. **Rheum Dis Clin North Am** 1996 Feb;22(1):53–73 (67 ref.)

Lymphoproliferative disorders associated with congenital immunodeficiencies. Elenitoba-Johnson KS, et al. **Semin Diagn Pathol** 1997 Feb;14(1):35–47 (75 ref.)

CONGENITAL

Lymphoproliferative disorders associated with congenital immunodeficiencies. Elenitoba-Johnson KS, et al. **Semin Diagn Pathol** 1997 Feb;14(1):35–47 (75 ref.)

DIAGNOSIS

Evaluating the child with recurrent infections. Wheeler JG. **Am Fam Physician** 1996 Nov 15;54(7):2276–82, 2285–6 (11 ref.)

Common problems in the diagnosis of immunodeficiency in children. Crago SS, et al. **Monaldi Arch Chest Dis** 1995 Dec;50(6):453–8 (21 ref.)

DRUG THERAPY

[The concept of immunocorrection in multifactor immunodeficiency states, infectious and cancerous diseases] Kuznetsov VP, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Sep–Oct; (5):104–10 (60 ref.) **(Rus)**

ENZYMOLOGY

Immunodeficiencies caused by genetic defects in protein kinases. Notarangelo LD. **Curr Opin Immunol** 1996 Aug; 8(4):448–53 (56 ref.)

ETIOLOGY

Immunosuppressive retroviral peptides: immunopathological implications for immunosuppressive influences of retroviral infections. Haraguchi S, et al. **J Leukoc Biol** 1997 Jun; 61(6):654–66 (161 ref.)

The mechanisms involved in the impairment of hematopoiesis after autologous bone marrow transplantation. Domenech J, et al. **Leuk Lymphoma** 1997 Jan;24(3–4):239–56 (126 ref.)

GENETICS

Naturally occurring primary deficiencies of the immune system. Fischer A, et al. **Annu Rev Immunol** 1997;15:93–124 (192 ref.)

Major histocompatibility complex class II deficiency: a clinical review. Elhasid R, et al. **Blood Rev** 1996 Dec; 10(4):242–8 (39 ref.)

Inherited disorders of lymphocyte development and function [editorial] Fischer A. **Curr Opin Immunol** 1996 Aug; 8(4):445–7 (15 ref.)

Immunodeficiencies caused by genetic defects in protein kinases. Notarangelo LD. **Curr Opin Immunol** 1996 Aug; 8(4):448–53 (56 ref.)

Lessons from human genetic variants in the study of B-cell differentiation. Satterthwaite AB, et al. **Curr Opin Immunol** 1996 Aug;8(4):454–8 (67 ref.)

Ataxia-telangiectasia and the ATM gene: linking neurodegeneration, immunodeficiency, and cancer to cell cycle checkpoints. Shiloh Y, et al. **J Clin Immunol** 1996 Sep;16(5):254–60 (95 ref.)

Nijmegen breakage syndrome. van der Burgt I, et al. **J Med Genet** 1996 Feb;33(2):153–6 (25 ref.)

Recent advances in the genetics of primary immunodeficiency syndromes. Shyur SD, et al.

J Pediatr 1996 Jul;129(1):8–24 (164 ref.)

[Gene therapy for hereditary immunodeficiencies] Fischer A, et al. **C R Seances Soc Biol Fil** 1996;190(1):77–93 (54 ref.) (Eng. Abstr.) **(Fre)**

[Albinism, thrombopathy, ceroid storage disease--Hermansky-Pudlak syndrome. Overview and description with immunodeficiency] Berz F, et al. **Klin Padiatr** 1996 Mar-Apr;208(2):83–7 (50 ref.) (Eng. Abstr.) **(Ger)**

[Dyskeratosis congenita. Genetic hematologic-immunologic systemic disease with pancytopenia] Sölder B, et al. **Klin Padiatr** 1996 Nov-Dec;208(6):344–9 (50 ref.) (Eng. Abstr.) **(Ger)**

[Molecular genetics of X-linked primary immunodeficiencies: advances in diagnosis and prevention] Carbonara A, et al. **Ann Ital Med Int** 1996 Jul-Sep;11(3):180–6 (55 ref.) (Eng. Abstr.) **(Ita)**

IMMUNOLOGY

Evaluation of the potentially immunodeficient patient. Fleisher TA. **Adv Intern Med** 1996;41:1–30 (80 ref.)

Major histocompatibility complex class II deficiency: a clinical review. Elhasid R, et al. **Blood Rev** 1996 Dec; 10(4):242–8 (39 ref.)

Regulation of human B cell growth and differentiation: lessons from the primary immunodeficiencies. Callard RE, et al. **Chem Immunol** 1997;67:114–32 (102 ref.)

Development and function of T lymphocytes and natural killer cells after bone marrow transplantation of severely immunodeficient mice. Wang B, et al. **Immunol Rev** 1997 Jun;157:53–60 (50 ref.)

Superantigens as virulence factors in autoimmunity and immunodeficiency diseases. Soos JM, et al. **Med Hypotheses** 1997 Mar;48(3):253–9 (52 ref.)

[Immunological effects of erythrocyte and leukocyte transfusion. Work Group Blood Group Serology of the Medical Advisory Commission of the College for Blood Transfusion of the Netherlands Red Cross] Brand A, et al. **Ned Tijdschr Geneeskd** 1997 Jan 18;141(3):136–40 (36 ref.) (Eng. Abstr.) **(Dut)**

[Diseases of the lung and respiratory tract in disorders of immunodeficiency in childhood and adolescence] Roesler J, et al. **Pneumologie** 1996 Nov;50(11):745–51 (37 ref.) **(Ger)**

[Susceptibility to infection] Cerny A. **Schweiz Med Wochenschr** 1997 Mar 1;127(9):360–6 (23 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Inherited disorders of lymphocyte development and function [editorial] Fischer A. **Curr Opin Immunol** 1996 Aug; 8(4):445–7 (15 ref.)

Lessons from human genetic variants in the study of B-cell differentiation. Satterthwaite AB, et al. **Curr Opin Immunol** 1996 Aug;8(4):454–8 (67 ref.)

Development and function of T lymphocytes and natural killer cells after bone marrow transplantation of severely immunodeficient mice. Wang B, et al. **Immunol Rev** 1997 Jun;157:53–60 (50 ref.)

PHYSIOPATHOLOGY

Mulvihill-Smith progeria-like syndrome: a further report with delineation of phenotype, immunologic deficits, and novel observation of fibroblast abnormalities. de Silva DC, et al. **Am J Med Genet** 1997 Mar 3;69(1):56–64 (12 ref.)

Immunodeficiency and its relation to lymphoid and other malignancies. Tossing G. **Ann Hematol** 1996 Oct; 73(4):163–7 (13 ref.)

THERAPY

Gene therapy of primary immunodeficiencies. Fischer A, et al. **Adv Nephrol Necker Hosp** 1997;26:107–20 (54 ref.)

Bone marrow transplantation in immunodeficiency diseases. Friedrich W. **Ann Med** 1996 Apr;28(2):115–9 (35 ref.)

Use of intravenous immunoglobulin to prevent or treat infections in persons with immune deficiency. Lee ML, et al. **Annu Rev Med** 1997;48:93–102 (112 ref.)

Gene therapy for primary immunodeficiency. Thrasher AJ, et al. **Biochem Soc Trans** 1997 May;25(2):537–40 (16 ref.)

Preclinical investigations that subserve efforts to employ bone marrow transplantation for rheumatoid or autoimmune diseases. Good RA, et al. **J Rheumatol Suppl** 1997 May; 48:5–12 (73 ref.)

Human intravenous immunoglobulin in primary and secondary antibody deficiencies. Stiehm ER. **Pediatr Infect Dis J** 1997 Jul;16(7):696–707 (113 ref.)

[Primary immunodeficiencies. II. Current therapeutic possibilities] Litzman J. **Cas Lek Cesk** 1996 Sep 11; 135(17):552–4 (20 ref.) (Eng. Abstr.) **(Cze)**

[Gene therapy for hereditary immunodeficiencies] Fischer A, et al. **C R Seances Soc Biol Fil** 1996;190(1):77–93 (54 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Bovine immunodeficiency virus: facts and questions. Belloc C, et al. **Vet Res** 1996;27(4–5):395–402 (49 ref.)

[Congenital immune deficiency diseases] Kraft W. **Tierarztl Prax** 1996 Dec;24(6):529–31 (8 ref.) **(Ger)**

VIROLOGY

Immunosuppressive retroviral peptides: immunopathological implications for immunosuppressive influences of retroviral infections. Haraguchi S, et al. **J Leukoc Biol** 1997 Jun; 61(6):654–66 (161 ref.)

IMMUNOLOGIC DISEASES

Immunologic dysfunction in cancer. Kavanaugh DY, et al. **Hematol Oncol Clin North Am** 1996 Aug;10(4):927–51 (234 ref.)

CHEMICALLY INDUCED

An analytical review of silicone immunology [see comments] Marcus DM. **Arthritis Rheum** 1996 Oct;39(10):1619–26 (75 ref.) Comment in: Arthritis Rheum 1996 Oct;39(10):1615–8.

COMPLICATIONS

Infectious arthritis and immune dysfunction [editorial] Schoen RT. **Curr Opin Rheumatol** 1996 Jul;8(4):317–21 (15 ref.)

Immunological disorders in C virus chronic hepatitis. Cosserat J, et al. **Nephrol Dial Transplant** 1996;11 Suppl 4:31–5 (26 ref.)

Clinical aspects of glucocorticoid sensitivity. Lamberts SW, et al. **Steroids** 1996 Apr;61(4):157–60 (37 ref.)

DIAGNOSIS

Major technological advances affecting clinical and diagnostic immunology. Sever JL. **Clin Diagn Lab Immunol** 1997 Jan;4(1):1–3 (5 ref.)

The evaluation of suspected immune deficiency by the primary care physician. Infante AJ, et al. **Compr Ther** 1997 Feb;23(2):89–94 (2 ref.)

[Circulating cell adhesion molecules: diagnostic-prognostic significance] Matysiak W. **Pol Arch Med Wewn** 1995 Oct; 94(4):367–74 (45 ref.) **(Pol)**

DRUG THERAPY

Cyclosporin in less common immune-mediated skin diseases. Ruzicka T. **Br J Dermatol** 1996 Sep;135 Suppl 48:40–2 (20 ref.)

Isoenzymes of protein kinase C: differential involvement in apoptosis and pathogenesis. Deacon EM, et al. **Mol Pathol** 1997 Jun;50(3):124–31 (140 ref.)

GENETICS

Non-classical-MHC genetics of immunological disease in man and mouse. The key role of pro-inflammatory cytokine genes. Daser A, et al. **Cytokine** 1996 Aug; 8(8):593–7 (43 ref.)

IMMUNOLOGY

Xid and Xid-like immunodeficiencies from a signaling point of view. Tarakhovsky A. **Curr Opin Immunol** 1997 Jun; 9(3):319–23 (50 ref.)

Identification and function of host defense cells by flow cytometry. Stewart CC. **Immunol Invest** 1997 Jan-Feb; 26(1–2):83–9 (6 ref.)

Do holes in the T-cell repertoire have a center-surround regulatory structure? A rationale for the bifurcation of the Th1 and Th2 pathways of differentiation. Mannie MD. **Med Hypotheses** 1997 Mar;48(3):261–5 (56 ref.)

Somatostatin receptor expression in clinical immunology. van Hagen PM. **Metabolism** 1996 Aug;45(8 Suppl 1):86–7 (10 ref.)

METABOLISM

Role of nitric oxide in immune-mediated diseases [editorial] Cook HT, et al. **Clin Sci (Colch)** 1996 Oct;91(4):375–84 (111 ref.)

Transcription factors in immune-mediated disease. Peltz G. **Curr Opin Biotechnol** 1997 Aug;8(4):467–73 (60 ref.)

PATHOLOGY

Biliary epithelial cells: innocent victims or active participants in immune-mediated liver disease? [editorial; comment] Adams DH. **J Lab Clin Med** 1996 Dec;128(6):528–30 (27 ref.) Comment on: J Lab Clin Med 1996 Dec;128(6):536–44.

PREVENTION & CONTROL

[Immuno-hemolytic transfusion reactions. IV. Analysis, risks and prevention] Tissier AM, et al. **Transfus Clin Biol** 1996; 3(3):167–80 (148 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

[The influence of psychological factors on the immune system and immunological diseases] Kjeldsen-Kragh J. **Tidsskr Nor Laegeforen** 1996 Oct 30;116(26):3102–7 (34 ref.) (Eng. Abstr.) **(Nor)**

THERAPY

Lymphocytapheresis. Takenaka Y. **Artif Organs** 1996 Aug; 20(8):914–6 (10 ref.)

Gene therapy for hematopoietic and immune disorders. Kohn DB. **Bone Marrow Transplant** 1996 Dec;18 Suppl 3:S55–8 (23 ref.)

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders. Current practice in Europe in 1996 and proposals for an operational classification. Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation (EBMT). Schmitz N, et al. **Bone Marrow Transplant** 1996 Apr;17(4):471–7 (52 ref.)

[Immunomodulators and some aspects of their clinical use] Khaitov RM, et al. **Klin Med (Mosk)** 1996;74(8):7–12 (16 ref.) **(Rus)**

VETERINARY

Therapeutic plasmapheresis. Bartges JW. **Semin Vet Med Surg (Small Anim)** 1997 Aug;12(3):170–7 (85 ref.)

Glucocorticosteroids as immunosuppressive agents. Cohn LA. **Semin Vet Med Surg (Small Anim)** 1997 Aug; 12(3):150–6 (49 ref.)

Immunosuppression--an overview. Miller E. **Semin Vet Med Surg (Small Anim)** 1997 Aug;12(3):144–9 (43 ref.)

The use of danazol in the therapy of immune-mediated disease of dogs. Miller E. **Semin Vet Med Surg (Small Anim)** 1997 Aug;12(3):167–9 (24 ref.)

The use of cytotoxic agents in the treatment of immune-mediated diseases of dogs and cats. Miller E. **Semin Vet Med Surg (Small Anim)** 1997 Aug;12(3):157–60 (22 ref.)

Immunodiagnostic assays. Swiderski CE, et al. **Vet Clin North Am Equine Pract** 1995 Dec;11(3):455–89 (112 ref.)

IMMUNOLOGIC ENHANCEMENT OF GRAFTS see **GRAFT ENHANCEMENT, IMMUNOLOGIC**

IMMUNOLOGIC MARKERS see **BIOLOGICAL MARKERS**

IMMUNOLOGIC MEMORY

On immunological memory. Zinkernagel RM, et al. **Annu Rev Immunol** 1996;14:333–67 (157 ref.)

Immune responses: tails to teach a B cell. Nussenzweig MC. **Curr Biol** 1997 Jun 1;7(6):R355–7 (11 ref.)

Generation of T-cell memory. Beverley PC. **Curr Opin Immunol** 1996 Jun;8(3):327–30 (42 ref.)

Development of B-cell memory and effector function. Lane P. **Curr Opin Immunol** 1996 Jun;8(3):331–5 (45 ref.)

Immunological memory. Sprent J. **Curr Opin Immunol** 1997 Jun;9(3):371–9 (96 ref.)

Establishment and persistence of virus-specific CD4+ and CD8+ T cell memory. Doherty PC, et al. **Immunol Rev** 1996 Apr;150:23–44 (85 ref.)

B-T lymphocyte interactions in the generation and survival of memory cells. Gray D, et al. **Immunol Rev** 1996 Apr; 150:45–61 (65 ref.)

In vitro analysis of the generation and propagation of memory B cells. Klinman NR. **Immunol Rev** 1996 Apr; 150:91–111 (85 ref.)

On T cell memory: arguments for antigen dependence. Kündig TM, et al. **Immunol Rev** 1996 Apr;150:63–90 (100 ref.)

Enumeration and characterization of memory cells in the TH compartment. McHeyzer-Williams MG, et al. **Immunol Rev** 1996 Apr;150:5–21 (45 ref.)

Aspects of cytotoxic T cell memory. Müllbacher A, et al. **Immunol Rev** 1996 Apr;150:113–27 (70 ref.)

From naive to memory T cells. Swain SL, et al. **Immunol Rev** 1996 Apr;150:143–67 (100 ref.)

Viruses and T cell turnover: evidence for bystander proliferation. Tough DF, et al. **Immunol Rev** 1996 Apr; 150:129–42 (50 ref.)

CD4+ CD7- T cells: a separate subpopulation of memory T cells? Reinhold U, et al. **J Clin Immunol** 1997 Jul; 17(4):265–71 (36 ref.)

Do effector and memory T helper cells also need B7 ligand costimulatory signals? Gause WC, et al. **J Immunol** 1997 Aug 1;159(3):1055–8 (49 ref.)

Differential roles for IL-12 in the maintenance of immune responses in infectious versus autoimmune disease. Seder RA, et al. **J Immunol** 1996 Oct 1;157(7):2745–8 (24 ref.)

Observations on memory B-cell development. Gray D, et al. **Semin Immunol** 1997 Aug;9(4):249–54 (51 ref.)

The cellular origins of memory B cells. Klinman NR. **Semin Immunol** 1997 Aug;9(4):241–7 (55 ref.)

Regulation of B-cell commitment to plasma cells or to memory B cells. Liu YJ, et al. **Semin Immunol** 1997 Aug; 9(4):235–40 (56 ref.)

DRUG EFFECTS

Activity of IL12 as adjuvant in promoting Th1 and Th2 recall responses. Wolf SF, et al. **Res Immunol** 1995 Sep-Oct; 146(7–8):486–9 (26 ref.)

IMMUNOLOGY

HLA-class I-specific inhibitory receptors of NK type on a subset of human T cells. Mingari MC, et al. **Chem Immunol** 1996;64:135–45 (51 ref.)

Viral immunity: interferons jog old T-cell memories. Gray D. **Curr Biol** 1996 Oct 1;6(10):1254-5 (9 ref.)
Primary and secondary immune responses to Listeria monocytogenes. Harty JT, et al. **Curr Opin Immunol** 1996 Aug;8(4):526-30 (47 ref.)
Reactivity and specificity of CD8+ T cells in mice with defects in the MHC class I antigen-presenting pathway. Ljunggren HG, et al. **Immunol Rev** 1996 Jun;151:123-48 (89 ref.)
Factors controlling the turnover of T memory cells. Sprent J, et al. **Immunol Rev** 1997 Apr;156:79-85 (57 ref.)
Sentinel function of broadly reactive human gamma delta T cells. De Libero G. **Immunol Today** 1997 Jan;18(1):22-6 (37 ref.)
Cytokines, tumour-cell death and immunogenicity: a question of choice. Musiani P, et al. **Immunol Today** 1997 Jan; 18(1):32-6 (38 ref.)
Do human cancers express shared protective antigens? or the necessity of remembrance of things past. Srivastava PK. **Semin Immunol** 1996 Oct;8(5):295-302 (47 ref.)
Targeting of peripheral blood T lymphocytes. Bolhuis RL, et al. **Springer Semin Immunopathol** 1996;18(2):211-26 (123 ref.)
Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. West DJ, et al. **Vaccine** 1996 Aug; 14(11):1019-27 (78 ref.)
[New vaccines and the immune response (I). Immunologic memory. Humoral response versus cellular response] Villarrubia VG, et al. **Med Clin (Barc)** 1996 Jun 22; 107(4):146-54 (93 ref.) **(Spa)**

PHYSIOLOGY

Role of CD26 for CD4 memory T cell function and activation. Dong RP, et al. **Hum Cell** 1996 Sep;9(3):153-62 (47 ref.)
T cells and memory lapses. Sprent J. **Trends Microbiol** 1997 Jul;5(7):259-60; discussion 260-1 (19 ref.)

IMMUNOLOGIC MONITORING see **MONITORING, IMMUNOLOGIC**

IMMUNOLOGIC RECEPTORS see **RECEPTORS, IMMUNOLOGIC**

IMMUNOLOGIC STIMULATION see **IMMUNIZATION**

IMMUNOLOGIC SUPPRESSOR FACTORS see **SUPPRESSOR FACTORS, IMMUNOLOGIC**

IMMUNOLOGIC SURVEILLANCE

AIDS: decline and fall of immune surveillance? [see comments] Feinberg MB, et al. **Curr Biol** 1997 Mar 1; 7(3):R136-40 (10 ref.) Comment in: Curr Biol 1997 Jul 1;7(7):R403-5.
Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Garrido F, et al. **Immunol Today** 1997 Feb;18(2):89-95 (67 ref.)
Viruses use stealth technology to escape from the host immune system. Wiertz EJ, et al. **Mol Med Today** 1997 Mar;3(3):116-23 (52 ref.)
Is cancer dangerous to the immune system? Fuchs EJ, et al. **Semin Immunol** 1996 Oct;8(5):271-80 (46 ref.)
[Function of Pit cells and physiopathology] Shiratori Y. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):704-7 (0 ref.) **(Jpn)**

IMMUNOLOGY

Sentinel function of broadly reactive human gamma delta T cells. De Libero G. **Immunol Today** 1997 Jan;18(1):22-6 (37 ref.)
Cytokines, tumour-cell death and immunogenicity: a question of choice. Musiani P, et al. **Immunol Today** 1997 Jan; 18(1):32-6 (38 ref.)
Do human cancers express shared protective antigens? or the necessity of remembrance of things past. Srivastava PK. **Semin Immunol** 1996 Oct;8(5):295-302 (47 ref.)

PHYSIOLOGY

Immune surveillance of the oral cavity and lymphocyte migration: relevance for alcohol abusers. Chiappelli F, et al. **Lymphology** 1995 Dec;28(4):196-207 (52 ref.)

IMMUNOLOGIC TECHNIQUES

see related
BLOOD GROUPING AND CROSSMATCHING
IMMUNOLOGIC TESTS
IMMUNOTHERAPY
SERODIAGNOSIS

Immunoisolation: at a turning point. Lanza RP, et al. **Immunol Today** 1997 Mar;18(3):135-9 (30 ref.)
Clinical connections: assays and assignment. Bell DA, et al. **Lupus** 1997;6(3):305-6 (15 ref.)
Immunodissection of the connective tissue matrix in human skin. Keene DR, et al. **Microsc Res Tech** 1997 Aug 15; 38(4):394-406 (110 ref.)
Reverse immunogenetics: from HLA-disease associations to vaccine candidates. Davenport MP, et al. **Mol Med Today** 1996 Jan;2(1):38-45 (25 ref.)
Might laboratory tests other than RAST help in diagnosing food allergy? Ventura A, et al. **Pediatr Allergy Immunol** 1995;6 Suppl 8:44-8 (70 ref.)
[Identification of T cell epitopes by reverse immunogenetics] Takiguchi M. **Nippon Rinsho** 1996 Dec;54(12):3379-88 (17 ref.) (Eng. Abstr.) **(Jpn)**
[An efficient, antigen-saving, labor-saving, and time-saving technique for making monoclonal antibodies with enlarged rat lymph nodes] Sado Y, et al. **Seikagaku** 1997 Feb; 69(2):128-31 (6 ref.) **(Jpn)**
[The immunology laboratory in malignant blood diseases] López Berges MC, et al. **Sangre (Barc)** 1996 Aug; 41(4):281-8 (44 ref.) **(Spa)**

INSTRUMENTATION

Immunology and the confocal microscope. Ojcius DM, et al. **Res Immunol** 1996 Mar-Apr;147(3):175-88 (40 ref.)

TRENDS

Advances in immunochemical detection of microorganisms. Hock B. **Ann Biol Clin (Paris)** 1996;54(6):243-52 (24 ref.)
Major technological advances affecting clinical and diagnostic immunology. Sever JL. **Clin Diagn Lab Immunol** 1997 Jan;4(1):1-3 (5 ref.)

IMMUNOLOGIC TESTS

Predictive testing in contact dermatitis. Allergic contact dermatitis. Andersen KL, et al. **Clin Dermatol** 1997 Jul-Aug;15(4):645-54 (81 ref.)
Pulmonary perspective: immunology in diagnosis and treatment of lung cancer. Weynants P, et al. **Eur Respir J** 1997 Aug;10(8):1703-19 (212 ref.)
[Should hepatitis C be screened? Hepatitis C: screening tools] Lunel F. **Gastroenterol Clin Biol** 1997;21(1 Pt 2):S11-24 (86 ref.) **(Fre)**
[Immunologic diagnosis of central nervous system viral infection] Arasaki K. **Nippon Rinsho** 1997 Apr;55(4):828-32 (10 ref.) (Eng. Abstr.) **(Jpn)**

ECONOMICS

Autoantibody screening for infertility: explaining the unexplained? Hatasaka HH, et al. **J Reprod Immunol** 1997 Sep;34(2):137-53 (30 ref.)

METHODS

Current trends in the diagnosis and management of cystic hydatid disease of the liver. Dhar P, et al. **J Commun Dis** 1996 Dec;28(4):221-30 (45 ref.)
[An improved phagocytic plaque method using gram-negative bacilli] Tomiya Y, et al. **Nippon Saikingaku Zasshi** 1996 Oct;51(4):1049-53 (6 ref.) (Eng. Abstr.) **(Jpn)**

STATISTICS & NUMERICAL DATA

[Characteristics of immunologic test values in the elderly] Rink L, et al. **Z Gerontol Geriatr** 1997 May-Jun;30(3):220-5 (22 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Immunodiagnostic assays. Swiderski CE, et al. **Vet Clin North Am Equine Pract** 1995 Dec;11(3):455-89 (112 ref.)

IMMUNOLOGICAL MODELS see **MODELS, IMMUNOLOGICAL**

IMMUNOLOGY see **ALLERGY AND IMMUNOLOGY**

IMMUNOLOGY, TRANSPLANTATION see **TRANSPLANTATION IMMUNOLOGY**

IMMUNOMODULATORS see **ADJUVANTS, IMMUNOLOGIC**

IMMUNOPEROXIDASE TECHNIQUES see **IMMUNOENZYME TECHNIQUES**

IMMUNOPHENOTYPING

Flow cytometric immunophenotyping of non-Hodgkin's lymphomas and related disorders. Tbakhi A, et al. **Cytometry** 1996 Oct 1;25(2):113-24 (90 ref.)
Immunophenotypic characterization of acute leukemias and chronic lymphoproliferative disorders: practical recommendations and classifications. Garand R, et al. **Hematol Cell Ther** 1996 Dec;38(6):471-86 (162 ref.)
Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Garrido F, et al. **Immunol Today** 1997 Feb;18(2):89-95 (67 ref.)

METHODS

Evolution of leukocyte immunophenotyping as influenced by the HIV/AIDS pandemic: a short history of the development of gating strategies for CD4+ T-cell enumeration. Mandy FF, et al. **Cytometry** 1997 Aug 15; 30(4):157-65 (31 ref.)
Fine-needle aspiration of lymph nodes: use of flow cytometry immunophenotyping. Cha I, et al. **Pathology (Phila)** 1996; 4(2):337-64 (50 ref.)
[Immunophenotyping in the diagnosis of non-Hodgkin lymphomas: a literature review] Rauh S, et al. **Bull Soc Sci Med Grand Duche Luxemb** 1996;133(2):27-33 (28 ref.) **(Fre)**

STANDARDS

Towards standardization in immunophenotyping hematological malignancies. How can we improve the reproducibility and comparability of flow cytometric results? Working Group on Leukemia Immunophenotyping. Lanza F. **Eur J Histochem** 1996;40 Suppl 1:7-14 (43 ref.)

IMMUNOPOTENTIATORS see **ADJUVANTS, IMMUNOLOGIC**

IMMUNOPROLIFERATIVE DISORDERS

COMPLICATIONS

[Triclonal gammopathy and malignant immunoproliferative syndrome] Grosbois B, et al. **Rev Med Interne** 1997; 18(6):470-3 (25 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOPROLIFERATIVE SMALL INTESTINAL DISEASE

DRUG THERAPY

Five-year results of the treatment of 23 patients with immunoproliferative small intestinal disease: a Turkish experience. Akbulut H, et al. **Cancer** 1997 Jul 1;80(1):8-14 (19 ref.)

IMMUNORADIOMETRIC ASSAY

Heterogeneity of human prolactin. Influence on immunoassays (RIA and IRMA). Claustrat B, et al. **Nucl Med Biol** 1994 Apr;21(3):331-5 (30 ref.)

IMMUNOSCINTIGRAPHY, RADIOLABELED see **RADIOIMMUNODETECTION**

IMMUNOSORBENT TECHNIQUES

Transplantation of CD34+ hematopoietic progenitor cells [see comments] Berenson RJ, et al. **Cancer Invest** 1996; 14(6):589-96 (79 ref.) Comment in: Cancer Invest 1996;14(6):640-1.
Removal of autoantibodies in dilated cardiomyopathy by immunoadsorption. Wallukat G, et al. **Int J Cardiol** 1996 May;54(2):191-5 (24 ref.)
Review of conformation-specific affinity purification methods for plasma vitamin K-dependent proteins. Yan SB. **J Mol Recognit** 1996 May-Jun;9(3):211-8 (62 ref.)
[The clinical use of protein-A immunoadsorption] Aksenov VA. **Ter Arkh** 1996;68(11):83-5 (35 ref.) **(Rus)**

IMMUNOSORBENTS

see related
ENZYME-LINKED IMMUNOSORBENT ASSAY

DIAGNOSTIC USE

[Magnetically controlled immobilized systems in the microbiological monitoring of natural foci and environmental objects for the presence of the causative agents of dangerous infectious diseases] Efremenko VI. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Mar-Apr; (2):102-6 (50 ref.) **(Rus)**

THERAPEUTIC USE

Current status in extracorporeal immunomodulation: immune disorders. Bosch T. **Artif Organs** 1996 Aug;20(8):902-5 (22 ref.)
Lymphocytapheresis. Takenaka Y. **Artif Organs** 1996 Aug; 20(8):914-6 (10 ref.)

IMMUNOSTIMULANTS see **ADJUVANTS, IMMUNOLOGIC**

IMMUNOSTIMULATING COMPLEXES see **ISCOMS**

IMMUNOSTIMULATION see **IMMUNIZATION**

IMMUNOSUPPRESSED HOST see **IMMUNOCOMPROMISED HOST**

IMMUNOSUPPRESSION

see related
ANTILYMPHOCYTE SERUM
IMMUNE TOLERANCE
IMMUNOCOMPROMISED HOST

In vivo pharmacological effects of ciclosporin and some analogues. Borel JF, et al. **Adv Pharmacol** 1996;35:115-246 (714 ref.)
Medical marijuana and its use by the immunocompromised.

McPartland JM, et al. **Altern Ther Health Med** 1997 May; 3(3):39–45 (101 ref.)

Pharmacology of immunosuppressive medications used in renal diseases and transplantation. de Mattos AM, et al. **Am J Kidney Dis** 1996 Nov;28(5):631–67 (333 ref.)

Immunomodulation in transplantation with photopheresis. Barr ML. **Artif Organs** 1996 Aug;20(8):971–3 (12 ref.)

Liver transplantation in children: advances in patient selection, technique and immunosuppression. Emond JC. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1997 Jul–Aug;38(4):249–54 (20 ref.)

Implications of the Myocarditis Treatment Trial for clinical practice. Brown CA, et al. **Curr Opin Cardiol** 1996 May; 11(3):332–6 (14 ref.)

Immunosuppressive and immunomodulatory treatment for myocarditis. Maisch B, et al. **Curr Opin Cardiol** 1996 May; 11(3):310–24 (126 ref.)

Immunology of liver transplantation: clinical management aspects. Shah V, et al. **Gastroenterologist** 1997 Jun; 5(2):137–47 (71 ref.)

The significance of immune suppression in normal self tolerance. McCullagh P. **Immunol Rev** 1996 Feb;149:127–53 (63 ref.)

Immunosuppression in renal transplantation. Bonomini V, et al. **Int J Artif Organs** 1997 Feb;20(2):73–5 (15 ref.)

Systemic immunosuppression in the treatment of posterior uveitis. Wakefield D, et al. **Int Ophthalmol Clin** 1995 Summer;35(3):107–22 (23 ref.)

In vivo immunosuppressive mechanisms. Halloran PF, et al. **J Heart Lung Transplant** 1996 Oct;15(10):959–71 (96 ref.)

Immunosuppression after liver transplantation. Lucey MR. **J Hepatol** 1996 Apr;24(4):503–5 (15 ref.)

On viruses, sex, and motherhood. Villareal LP. **J Virol** 1997 Feb;71(2):859–65 (88 ref.)

Neuroimmunomodulation in immune privilege: role of neuropeptides in ocular immunosuppression. Taylor AW. **Neuroimmunomodulation** 1996 Jul–Aug;3(4):195–204 (101 ref.)

The evolution and future of immunosuppression in renal transplantation. Goral S, et al. **Semin Nephrol** 1997 Jul; 17(4):364–72 (70 ref.)

Immunosuppression in human tumor–host interaction: role of cytokines and alterations in signal–transducing molecules. Kiessling R, et al. **Springer Semin Immunopathol** 1996;18(2):227–42 (100 ref.)

The three fates of immunosuppression in the next millenium: selectivity, synergy, and specificity [editorial] Kahan BD. **Transpl Int** 1996;9(6):527–34 (61 ref.)

Immunosuppression and immunomodulation of experimental models of systemic lupus erythematosus and antiphospholipid syndrome. Shoenfeld Y, et al. **Transplant Proc** 1996 Dec;28(6):3096–8 (33 ref.)

Measuring transplant patients' compliance with immunosuppressive therapy. De Geest S, et al. **West J Nurs Res** 1996 Oct;18(5):595–605 (45 ref.)

[Cyclophosphamide–induced immunological tolerance: an overview] Mayumi H. **Nippon Geka Gakkai Zasshi** 1996 Dec;97(12):1097–108 (101 ref.) (Eng. Abstr.) **(Jpn)**

[Biological activity of tin and immunity] Arakawa Y. **Sangyo Eiseigaku Zasshi** 1997 Jan;39(1):1–20 (176 ref.) (Eng. Abstr.) **(Jpn)**

[Rejection and immunosuppression] Charco R, et al. **Gastroenterol Hepatol** 1996 Oct;19(8):419–26 (24 ref.) **(Spa)**

ADVERSE EFFECTS

Short term immunosuppressive therapy and long–term immunoregulation: promises and problems. Isaacs J, et al. **Br J Ophthalmol** 1996 Dec;80(12):1035–6 (14 ref.)

Lymphoproliferative disorders in organ transplant recipients. Vanrenterghem Y. **Eur Radiol** 1997;7(5):665–7 (14 ref.)

Microchimerism and graft tolerance: cause or effect? [comment] Adams DH, et al. **Lancet** 1997 May 10; 349(9062):1336–7 (10 ref.) Comment on: Lancet 1997 May 10;349(9062):1358–60.

Post–transplantation lymphoproliferative disease. Savage P, et al. **QJM** 1997 Aug;90(8):497–503 (57 ref.)

Acute diverticulitis in heart transplant recipients. Detry O, et al. **Transpl Int** 1996;9(4):376–9 (22 ref.)

Carcinoma of the lung after heart transplantation. Goldstein DJ, et al. **Transplantation** 1996 Sep 27;62(6):772–5 (18 ref.)

[Pneumocystis carinii pneumonia in patients with a solid organ transplant: a report of 5 cases (see comments)] Ruiz Ruiz J, et al. **Rev Clin Esp** 1997 Jan;197(1):31–4 (59 ref.) (Eng. Abstr.) Comment in: Rev Clin Esp 1997 Jan;197(1):1–3. **(Spa)**

METHODS

The low–affinity receptor for IgE (Fc epsilon RII or CD23) as a therapeutic target. Conrad DH, et al. **Biochem Soc Trans** 1997 May;25(2):393–7 (28 ref.)

Early indicators of immunotoxicity: development of molecular biological test batteries. Vandebriel RJ, et al. **Hum Exp Toxicol** 1996 Mar;15 Suppl 1:S1, S2–10 (10 ref.)

Rationale and mechanisms of immunosuppression. Salomon DR. **Kidney Int Suppl** 1997 Mar;58:S48–50 (23 ref.)

BMT for severe autoimmune diseases: an idea whose time has come. Burt RK. **Oncology (Huntingt)** 1997 Jul; 11(7):1001–14; 1017, discussion 1018–24 (88 ref.)

Biological immunosuppressants: the way to clinical transplantation tolerance. Chatenoud L. **Transplant Proc** 1997 Feb–Mar;29(1–2):51–5 (44 ref.)

Immunosuppression in xenotransplantation. Hammer C. **Transplant Proc** 1996 Dec;28(6):3017–20 (71 ref.)

Antirejection strategy in small bowel transplantation. Wood RF. **Transplant Proc** 1996 Oct;28(5):2491–3 (39 ref.)

[Immunosuppression in organ transplantation. New substances and therapeutic approaches] Wonigeit K. **Internist (Berl)** 1996 Mar;37(3):229–39 (62 ref.) **(Ger)**

[The treatment of serious autoimmune diseases. Immune ablation integrated with hematopoietic stem cells (editorial)] Marmont AM. **Recenti Prog Med** 1996 Oct; 87(10):480–6 (90 ref.) **(Ita)**

[New trends in immunosuppressive therapy in patients with kidney transplants] Savić M, et al. **Srp Arh Celok Lek** 1997 Mar–Apr;125(3–4):99–105 (105 ref.) (Eng. Abstr.) **(Scc)**

TRENDS

Rethinking immunosuppression in terms of the redundant and nonredundant steps in the immune response. Halloran PF. **Transplant Proc** 1996 Dec;28(6 Suppl 1):11–8 (95 ref.)

VETERINARY

Immunosuppression––an overview. Miller E. **Semin Vet Med Surg (Small Anim)** 1997 Aug;12(3):144–9 (43 ref.)

IMMUNOSUPPRESSION (PHYSIOLOGY) see **IMMUNE TOLERANCE**

IMMUNOSUPPRESSIVE AGENTS

see related

ANTILYMPHOCYTE SERUM

In vivo immunosuppressive mechanisms. Halloran PF, et al. **J Heart Lung Transplant** 1996 Oct;15(10):959–71 (96 ref.)

Mycophenolate mofetil. Lipsky JJ. **Lancet** 1996 Nov 16; 348(9038):1357–9 (28 ref.)

The three fates of immunosuppression in the next millenium: selectivity, synergy, and specificity [editorial] Kahan BD. **Transpl Int** 1996;9(6):527–34 (61 ref.)

[Mycophenolate mofetil. A new immunosuppressive agent in transplantation therapy] Pedersen EB. **Ugeskr Laeger** 1997 Jul 21;159(30):4664–8 (24 ref.) **(Dan)**

[Tacrolimus (FK506): clinical, pharmacological and analytical aspects] Brunet M. **Med Clin (Barc)** 1997 Jun 14;109(3):98–106 (121 ref.) **(Spa)**

ADMINISTRATION & DOSAGE

A new microemulsion formulation of cyclosporin: pharmacokinetic and clinical features. Friman S, et al. **Clin Pharmacokinet** 1996 Mar;30(3):181–93 (50 ref.)

The use of other drugs to allow a lower dosage of cyclosporin to be used. Therapeutic and pharmacoeconomic considerations. Jones TE. **Clin Pharmacokinet** 1997 May; 32(5):357–67 (100 ref.)

Target concentration strategy for cyclosporin monitoring. Morris RG. **Clin Pharmacokinet** 1997 Mar;32(3):175–9 (18 ref.)

Microemulsion technology in the reformulation of cyclosporine: the reason behind the pharmacokinetic properties of Neoral. Ritschel WA. **Clin Transplant** 1996 Aug;10(4):364–73 (38 ref.)

Side–effects of intravenous cyclophosphamide pulse therapy. Martin F, et al. **Lupus** 1997;6(3):254–7 (16 ref.)

Immunosuppressive protocols for renal transplantation. Ponticelli C, et al. **Nephrol Dial Transplant** 1997;12 Suppl 1:45–50 (59 ref.)

Malignant tumours after renal transplantation. Fahlenkamp D, et al. **Scand J Urol Nephrol** 1996 Oct;30(5):357–62 (34 ref.)

[Anti–inflammatory and anti–allergic oral vaccines?] Lomholt HB, et al. **Ugeskr Laeger** 1996 Sep 16; 158(38):5273–6 (40 ref.) (Eng. Abstr.) **(Dan)**

[Aggressive therapy of highly active systemic lupus erythematosus] Graninger W. **Acta Med Austriaca** 1996; 23(4):129–33 (70 ref.) (Eng. Abstr.) **(Ger)**

[Cyclosporin–A therapy in autoimmune diseases] Patakfalvi A. **Orv Hetil** 1996 Sep 1;137(35):1921–7 (50 ref.) (Eng. Abstr.) **(Hun)**

[Treatment of acute a steroid–resistant ulcerative colitis with continuous venous infusion of cyclosporine] Rosselli M, et al. **Recenti Prog Med** 1996 Sep;87(9):416–21 (14 ref.) (Eng. Abstr.) **(Ita)**

[Mixed connective tissue disease: progress in diagnosis and treatment. III. Treatment. 2. Timing for the start of the therapy with adrenocorticosteroids and immunosuppressive agents and methods of their administration] Tanaka H. **Nippon Naika Gakkai Zasshi** 1996 Aug 10;85(8):1233–6 (5 ref.) **(Jpn)**

[Mycophenolate mofetil––a new immunosuppressive agent] Bergan S, et al. **Tidsskr Nor Laegeforen** 1996 Aug 30; 116(20):2439–41 (10 ref.) (Eng. Abstr.) **(Nor)**

ADVERSE EFFECTS

Neurophysiologic evaluation of cyclosporine toxicity associated with bone marrow transplantation [corrected and republished article originally printed in Acta Neurol Scand 1995 Nov;92(5):423–9] Edwards LL, et al. **Acta Neurol Scand** 1996 Nov;94(5):358–64 (22 ref.)

An overview of the adverse reactions to adrenal corticosteroids. Frauman AG. **Adverse Drug React Toxicol Rev** 1996 Nov;15(4):203–6 (12 ref.)

Sympathetic neural mechanisms of cyclosporine–induced hypertension. Sander M, et al. **Am J Hypertens** 1996 Nov; 9(11):121S–138S (197 ref.)

Cyclosporine–associated thrombotic microangiopathy/hemolytic uremic syndrome following kidney and kidney–pancreas transplantation [see comments] Young BA, et al. **Am J Kidney Dis** 1996 Oct;28(4):561–71 (62 ref.) Comment in: Am J Kidney Dis 1997 May;29(5):813–4.

Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Lynch JP 3rd, et al. **Am J Respir Crit Care Med** 1997 Feb;155(2):395–420 (353 ref.)

Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Malik SW, et al. **Am J Respir Crit Care Med** 1996 Dec;154(6 Pt 1):1851–6 (20 ref.)

Potentiation of nephrotoxicity by H2–antagonists in patients receiving cyclosporine. Lewis SM, et al. **Ann Pharmacother** 1997 Mar;31(3):363–5 (20 ref.)

Short term immunosuppressive therapy and long–term immunoregulation: promises and problems. Isaacs J, et al. **Br J Ophthalmol** 1996 Dec;80(12):1035–6 (14 ref.)

Arterial hypertension in renal transplantation. Sandrini S, et al. **Contrib Nephrol** 1996;119:16–25 (61 ref.)

Pathophysiology and treatment of lipid perturbation after cardiac transplantation. Ballantyne CM, et al. **Curr Opin Cardiol** 1997 Mar;12(2):153–60 (79 ref.)

Adenocarcinoma of the mouth in a patient with psoriasis under short–term cyclosporine therapy [letter] Yamamoto T, et al. **Dermatology** 1996;193(1):72–3 (9 ref.)

Post–transplant diabetes mellitus. The role of immunosuppression. Jindal RM, et al. **Drug Saf** 1997 Apr; 16(4):242–57 (126 ref.)

Clinically significant drug interactions with new immunosuppressive agents. Mignat C. **Drug Saf** 1997 Apr; 16(4):267–78 (62 ref.)

Preliminary risk–benefit assessment of mycophenolate mofetil in transplant rejection. Simmons WD, et al. **Drug Saf** 1997 Aug;17(2):75–92 (68 ref.)

Complications of cyclophosphamide therapy. Langford CA. **Eur Arch Otorhinolaryngol** 1997;254(2):65–72 (64 ref.)

Hepatotoxicity of transplant immunosuppressive agents. Kowdley KV, et al. **Gastroenterol Clin North Am** 1995 Dec;24(4):991–1001 (40 ref.)

Insights into chronic cyclosporine nephrotoxicity. Bennett WM. **Int J Clin Pharmacol Ther** 1996 Nov;34(11):515–9 (39 ref.)

Late onset bone marrow transplant nephropathy. Oyama Y, et al. **Intern Med** 1996 Jun;35(6):489–93 (23 ref.)

Progressive multifocal leukoencephalopathy during cyclosporine treatment. A case report. Gentile S, et al. **Ital J Neurol Sci** 1996 Oct;17(5):363–6 (20 ref.)

Post–transplantation bone disease: the role of immunosuppressive agents and the skeleton. Epstein S. **J Bone Miner Res** 1996 Jan;11(1):1–7 (73 ref.)

Cortical blindness secondary to cyclosporine after orthotopic heart transplantation: a case report and review of the literature. Drachman BM, et al. **J Heart Lung Transplant** 1996 Nov;15(11):1158–64 (38 ref.)

Oral lesions in organ transplant patients. Seymour RA, et al. **J Oral Pathol Med** 1997 Aug;26(7):297–304 (99 ref.)

Listeria monocytogenes joint infection in a patient with psoriatic arthritis [letter] Marangos MN, et al. **J Rheumatol** 1996 Nov;23(11):2005–6 (3 ref.)

Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Bennett WM, et al. **Kidney Int** 1996 Oct;50(4):1089–100 (152 ref.)

Interactions involving cyclosporine A, interleukin–6, and Epstein–Barr virus lead to the promotion of B–cell lymphoproliferative disease. Tanner JE, et al. **Leuk Lymphoma** 1996 May;21(5–6):379–90 (77 ref.)

Cyclosporin A–associated hypertension––pathomechanisms and clinical consequences [editorial] Haas M, et al. **Nephrol Dial Transplant** 1997 Mar;12(3):395–8 (49 ref.)

Severe and prolonged jaundice in a lupus nephritis patient treated with cyclophosphamide. Moroni G, et al. **Nephrol Dial Transplant** 1997 Apr;12(4):793–6 (15 ref.)

Renal transplantation and skin diseases: review of the literature and results of a 5–year follow–up of 285 patients. Barba A, et al. **Nephron** 1996;73(2):131–6 (40 ref.)

Cyclosporine neurotoxicity. Hauben M. **Pharmacotherapy** 1996 Jul–Aug;16(4):576–83 (62 ref.)

Leucocytoclastic vasculitis in a patient with azathioprine hypersensitivity. Beckett CG, et al. **Postgrad Med J** 1996 Jul;72(849):437–8 (6 ref.)

Mechanisms of acute and chronic nephrotoxicity from immunosuppressive drugs. Bennett WM. **Ren Fail** 1996 May;18(3):453–60 (57 ref.)

Drug nephrotoxicity: an overview. Bennett WM. **Ren Fail** 1997 Mar;19(2):221–4 (28 ref.)

Drug–induced rheumatic disorders. Bannwarth B. **Rev Rhum Engl Ed** 1996 Nov;63(10):639–47 (125 ref.)

Infectious complications of immunosuppressive therapy in patients with rheumatic diseases. Segal BH, et al. **Rheum Dis Clin North Am** 1997 May;23(2):219–37 (93 ref.)

Nephrotoxicity of immunosuppressive drugs: experimental and clinical observations. Andoh TF, et al.

Semin Nephrol 1997 Jan;17(1):34–45 (128 ref.)

Cyclosporine nephropathy: pathophysiology and clinical impact. Shihab FS. **Semin Nephrol** 1996 Nov;16(6):536–47 (101 ref.)

Immunosuppressant therapy during gestation. Little BB. **Semin Perinatol** 1997 Apr;21(2):143–8 (52 ref.)

Immunotoxicology: clinical consequences. Luster MI. **Toxicol Ind Health** 1996 May–Aug;12(3–4):533–5 (5 ref.)

A critical review of immunosuppressive regimens. Morris PJ. **Transplant Proc** 1996 Dec;28(6 Suppl 1):37–40 (29 ref.)

[Immunosuppression--a tightrope walk between iatrogenic harm and therapy] Berchtold P, et al. **Schweiz Med Wochenschr** 1996 Sep 21;126(38):1603–9 (19 ref.) (Eng. Abstr.) **(Ger)**

[Manifestation of neuro-Behçet disease in cyclosporin A therapy] Meusser S, et al. **Z Rheumatol** 1997 Jan–Feb; 56(1):31–9 (37 ref.) (Eng. Abstr.) **(Ger)**

[Gingival hypertrophy due to cyclosporine. A review of the literature] Vescovi P, et al. **Minerva Stomatol** 1996 Nov; 45(11):523–32 (46 ref.) (Eng. Abstr.) **(Ita)**

[Cyclosporine nephrotoxicity (chronic arteriolopathy, glomerulopathy)] Matsushima H, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):553–5 (20 ref.) **(Jpn)**

[Cyclosporine-induced hypertrophic gingivitis] Petrikas AZh, et al. **Stomatologiia (Mosk)** 1996;75(4):12–3 (12 ref.) **(Rus)**

CHEMISTRY

Protein–drug complexes important for immunoregulation and organ transplantation. Navia MA. **Curr Opin Struct Biol** 1996 Dec;6(6):838–47 (48 ref.)

Immunoreceptor tyrosine-based inhibition motifs. Vivier E, et al. **Immunol Today** 1997 Jun;18(6):286–91 (52 ref.)

ECONOMICS

Pharmacoeconomics of Neoral, a new formulation of cyclosporine, in renal transplantation. Abella I. **Transplant Proc** 1996 Dec;28(6):3131–4 (21 ref.)

IMMUNOLOGY

Immunopharmacology of rapamycin. Abraham RT, et al. **Annu Rev Immunol** 1996;14:483–510 (135 ref.)

Granulocyte–macrophage colony-stimulating factor overrides the immunosuppressive function of corticosteroids on rat pulmonary dendritic cells. Lim TK, et al. **Stem Cells** 1996 May;14(3):292–9 (62 ref.)

Retrovirus and filovirus "immunosuppressive motif" and the evolution of virus pathogenicity in HIV–1, HIV–2, and Ebola viruses. Becker Y. **Virus Genes** 1995;11(2–3):191–5 (28 ref.)

METABOLISM

Protein–drug complexes important for immunoregulation and organ transplantation. Navia MA. **Curr Opin Struct Biol** 1996 Dec;6(6):838–47 (48 ref.)

Steroid receptor interactions with heat shock protein and immunophilin chaperones. Pratt WB, et al. **Endocr Rev** 1997 Jun;18(3):306–60 (698 ref.)

The role of B7–1/B7–2:CD28/CLTA–4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response. Boussiotis VA, et al. **Immunol Rev** 1996 Oct;153:5–26 (170 ref.)

The role of CTLA–4 in the regulation and initiation of T-cell responses. Chambers CA, et al. **Immunol Rev** 1996 Oct; 153:27–46 (90 ref.)

The complexities of T-cell co-stimulation: CD28 and beyond. Sperling AI, et al. **Immunol Rev** 1996 Oct; 153:155–82 (100 ref.)

CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model. Van Gool SW, et al. **Immunol Rev** 1996 Oct;153:47–83 (150 ref.)

CTLA–4, a negative regulator of T-lymphocyte activation. Waterhouse P, et al. **Immunol Rev** 1996 Oct;153:183–207 (130 ref.)

PHARMACOKINETICS

Clinically significant drug interactions with cyclosporin. An update [see comments] Campana C, et al. **Clin Pharmacokinet** 1996 Feb;30(2):141–79 (367 ref.) Comment in: Clin Pharmacokinet 1997 Feb;32(2):173–4.

Cyclosporin pharmacokinetics in paediatric transplant recipients. Cooney GF, et al. **Clin Pharmacokinet** 1997 Jun; 32(6):481–95 (81 ref.)

A new microemulsion formulation of cyclosporin: pharmacokinetic and clinical features. Friman S, et al. **Clin Pharmacokinet** 1996 Mar;30(3):181–93 (50 ref.)

The clinical pharmacokinetics of cladribine. Liliemark J. **Clin Pharmacokinet** 1997 Feb;32(2):120–31 (67 ref.)

The use of therapeutic drug monitoring to optimise immunosuppressive therapy. Tsunoda SM, et al. **Clin Pharmacokinet** 1996 Feb;30(2):107–40 (310 ref.)

Microemulsion technology in the reformulation of cyclosporine: the reason behind the pharmacokinetic properties of Neoral. Ritschel WA. **Clin Transplant** 1996 Aug;10(4):364–73 (38 ref.)

Mechanisms of action of new immunosuppressive drugs. Morris RE. **Kidney Int Suppl** 1996 Jan;53:S26–38 (145 ref.)

PHARMACOLOGY

Dual effects of allergen–mPEG conjugates. Induction of immunological suppression and inactivation of sensitized mast cells. Sehon AH, et al. **Adv Exp Med Biol** 1996; 409:177–84 (17 ref.)

NF–kappa B as a frequent target for immunosuppressive and anti–inflammatory molecules. Baeuerle PA, et al. **Adv Immunol** 1997;65:111–37 (105 ref.)

In vivo pharmacological effects of ciclosporin and some analogues. Borel JF, et al. **Adv Pharmacol** 1996;35:115–246 (714 ref.)

The effects of immunosuppressive agents on cytokines. Elson CO. **Aliment Pharmacol Ther** 1996;10 Suppl 2:100–5; discussion 106 (27 ref.)

Mycophenolate mofetil: a unique immunosuppressive agent. Hood KA, et al. **Am J Health Syst Pharm** 1997 Feb 1; 54(3):285–94 (43 ref.)

Pharmacology of immunosuppressive medications used in renal diseases and transplantation. de Mattos AM, et al. **Am J Kidney Dis** 1996 Nov;28(5):631–67 (333 ref.)

Molecular mechanisms of immunosuppression and anti–inflammatory activities by glucocorticoids. Didonato JA, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 2):S11–5 (35 ref.)

Immunosuppressants, immunophilins, and the nervous system [editorial] Dawson TM. **Ann Neurol** 1996 Oct;40(4):559–60 (18 ref.)

Immunopharmacology of rapamycin. Abraham RT, et al. **Annu Rev Immunol** 1996;14:483–510 (135 ref.)

Thalidomide as an anti–TNF–alpha inhibitor: implications for clinical use. Klausner JD, et al. **Clin Immunol Immunopathol** 1996 Dec;81(3):219–23 (35 ref.)

Transcription–modulating drugs: mechanism and selectivity. Cai W, et al. **Curr Opin Biotechnol** 1996 Dec;7(6):608–15 (86 ref.)

Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Brazelton TR, et al. **Curr Opin Immunol** 1996 Oct; 8(5):710–20 (74 ref.)

Switching between cyclosporin formulations. What are the risks? Olyaei AJ, et al. **Drug Saf** 1997 Jun;16(6):366–73 (44 ref.)

Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Wilde MI, et al. **Drugs** 1996 May;51(5):865–94 (214 ref.)

Organochlorine–associated immunosuppression in prefledgling Caspian terns and herring gulls from the Great Lakes: an ecoepidemiological study. Grasman KA, et al. **Environ Health Perspect** 1996 Aug;104 Suppl 4:829–42 (92 ref.)

Synthetic peptides derived from human MHC class I sequences delay allograft rejection in rodents and inhibit cell–mediated cytotoxicity in vivo and in vitro. Cuturi MC, et al. **Immunol Rev** 1996 Dec;154:5–20 (56 ref.)

Immunosuppressive retroviral peptides: immunopathological implications for immunosuppressive influences of retroviral infections. Haraguchi S, et al. **J Leukoc Biol** 1997 Jun; 61(6):654–66 (161 ref.)

New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis. Arnon R, et al. **J Neurol** 1996 Apr;243(4 Suppl 1):S8–13 (28 ref.)

The effect of immunosuppressive drugs on T cell signalling pathways: non–redundant steps in the T cell response. Halloran PF. **Kidney Blood Press Res** 1996;19(3–4):174–6 (19 ref.)

HLA–derived peptides as novel immunosuppressives [editorial] Krensky AM, et al. **Nephrol Dial Transplant** 1997 May;12(5):865–8 (12 ref.)

The use of leflunomide in transplantation immunology. Waer M. **Transpl Immunol** 1996 Sep;4(3):181–5 (49 ref.)

A critical review of immunosuppressive regimens. Morris PJ. **Transplant Proc** 1996 Dec;28(6 Suppl 1):37–40 (29 ref.)

Update on preclinical and clinical experience with mycophenolate mofetil. Sollinger HW. **Transplant Proc** 1996 Dec;28(6 Suppl 1):24–9 (66 ref.)

Pharmacodynamic monitoring of immunosuppressive drugs. Yatscoff RW, et al. **Transplant Proc** 1996 Dec;28(6):3013–5 (16 ref.)

[Value of protecting mitochondrial functions during treatment with cyclosporin A] Simon N, et al. **Therapie** 1997 Mar–Apr;52(2):151–4 (30 ref.) (Eng. Abstr.) **(Fre)**

[Transplantation immunology and immunosuppressive drug] Suzuki S. **Nippon Geka Gakkai Zasshi** 1996 Nov; 97(11):964–9 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Cyclosporine as drug resistance modifiers; mechanism and clinical investigation] Hama S, et al. **Nippon Rinsho** 1997 May;55(5):1103–10 (46 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Discovery, development, and clinical trial strategies for immunosuppressive agents. Kahan BD. **Adv Nephrol Necker Hosp** 1996;25:63–89 (98 ref.)

Review article: the management of primary sclerosing cholangitis. Mitchell SA, et al. **Aliment Pharmacol Ther** 1997 Feb;11(1):33–43 (43 ref.)

An update on new immunosuppressive drugs undergoing preclinical and clinical trials: potential applications in organ transplantation. First MR. **Am J Kidney Dis** 1997 Feb; 29(2):303–17 (138 ref.)

Immunosuppressive agents in clinical trials in transplantation. Halloran PF. **Am J Med Sci** 1997 May;313(5):283–8 (39 ref.)

Leflunomide and malononitrilamides. Silva Júnior HT, et al. **Am J Med Sci** 1997 May;313(5):289–301 (101 ref.)

Current management of asthma patients with corticosteroid resistance. Busse WW, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 2):S70–2; discussion S72–3 (16 ref.)

Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Lynch JP 3rd, et al. **Am J Respir Crit Care Med** 1997 Feb;155(2):395–420 (353 ref.)

Antithymocyte immunoglobulin in severe aplastic anemia and bone marrow transplantation. Colby C, et al. **Ann Pharmacother** 1996 Oct;30(10):1164–74 (76 ref.)

Monitoring antithymocyte globulin in renal transplantation. Clark K. **Ann R Coll Surg Engl** 1996 Nov;78(6):536–40 (22 ref.)

Extracorporeal immunomodulation relevant to organ substitutions. Agishi T. **Artif Organs** 1996 Aug;20(8):917–21 (18 ref.)

15–Deoxyspergualin: a newly developed immunosuppressive agent and its mechanism of action and clinical effect: a review. Japan Collaborative Transplant Study Group for NKT–01. Amemiya H. **Artif Organs** 1996 Aug;20(8):832–5 (21 ref.)

Lamotrigine–induced toxic epidermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and immunosuppressive management. Sullivan JR, et al. **Australas J Dermatol** 1996 Nov;37(4):208–12 (32 ref.)

Fusidic acid and insulin–dependent diabetes mellitus. Nicoletti F, et al. **Autoimmunity** 1996;24(3):187–97 (45 ref.)

Safety of corticosteroids and immunosuppressive agents in ulcerative colitis. Connell WR, et al. **Baillieres Clin Gastroenterol** 1997 Mar;11(1):111–28 (124 ref.)

What is the most effective treatment of children with severe aplastic anemia who lack a matched sibling donor? Johnson FL. **Bone Marrow Transplant** 1996 Dec;18 Suppl 3:S39–44 (66 ref.)

Immunosuppressive treatment in asthma. Kon OM, et al. **Br J Hosp Med** 1997 Apr 16–May 6;57(8):383–6 (20 ref.)

The use of cyclosporin A microemulsion in rheumatoid arthritis: conclusions of an international review. Panayi GS, et al. **Br J Rheumatol** 1997 Jul;36(7):808–11 (5 ref.)

Copolymer 1: from basic research to clinical application. Teitelbaum D, et al. **Cell Mol Life Sci** 1997 Jan;53(1):24–8 (22 ref.)

Review of immunosuppression for lung transplantation. Novel drugs, new uses for conventional immunosuppressants, and alternative strategies. Hausen B, et al. **Clin Chest Med** 1997 Jun;18(2):353–66 (125 ref.)

Tacrolimus (FK506): the pros and cons of its use as an immunosuppressant in pediatric liver transplantation. Cox KL, et al. **Clin Invest Med** 1996 Oct;19(5):389–92 (15 ref.)

A review of clinical experience with the novel immunosuppressive drug mycophenolate mofetil in renal transplantation. Behrend M. **Clin Nephrol** 1996 May; 45(5):336–41 (13 ref.)

Nephrotic syndrome associated with chronic lymphocytic leukemia resistant to immunosuppressive drugs: remission obtained by splenectomy [see comments] Halimi JM, et al. **Clin Nephrol** 1996 Apr;45(4):273–6 (19 ref.) Comment in: Clin Nephrol 1997 Feb;47(2):131–3.

Experimental and clinical experience with the use of tacrolimus (FK506) in kidney transplantation. Wagner K, et al. **Clin Nephrol** 1996 May;45(5):332–5 (17 ref.)

Review of transplantation--1996. Halloran PF, et al. **Clin Transpl** 1996;:291–319 (294 ref.)

The superiority of tacrolimus in renal transplant recipients -- the Pittsburgh experience. Shapiro R, et al. **Clin Transpl** 1995;:199–205 (51 ref.)

The use of tacrolimus and mycophenolate mofetil after cardiac transplantation. Taylor DO. **Curr Opin Cardiol** 1997 Mar;12(2):161–5 (33 ref.)

Mycophenolate mofetil in kidney transplantation. Lui SL, et al. **Curr Opin Nephrol Hypertens** 1996 Nov;5(6):508–13 (54 ref.)

Alternative treatments in the patient with intractable asthma. Spector SL. **Curr Opin Pulm Med** 1997 Jan;3(1):23–9 (64 ref.)

Chronic immunosuppressive therapy for systemic vasculitis. Langford CA. **Curr Opin Rheumatol** 1997 Jan;9(1):41–7 (52 ref.)

Immunosuppressive drug treatment. McCune J, et al. **Curr Opin Rheumatol** 1997 May;9(3):191–9 (45 ref.)

Immunosuppressive drug therapy. McCune WJ. **Curr Opin Rheumatol** 1996 May;8(3):183–7 (25 ref.)

Update on therapy for refractory dermatomyositis and polymyositis. Villalba L, et al. **Curr Opin Rheumatol** 1996 Nov;8(6):544–51 (61 ref.)

Indeterminate cell histiocytosis treated successfully with 2–chlorodeoxyadenosine. Daoud MS, et al. **Cutis** 1997 Jan; 59(1):27–31; quiz 32 (24 ref.)

Failure of combination therapy with acitretin and cyclosporin A in 3 patients with erythrodermic psoriasis [letter] Kuijpers AL, et al. **Dermatology** 1997;194(1):88–90 (11 ref.)

Immunosuppressive therapy for chronic inflammatory bowel disease. Schölmerich J. **Digestion** 1997;58 Suppl 1:94–7 (6 ref.)

Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Simmons WD, et al. **Drug Saf** 1997 Aug;17(2):75–92 (68 ref.)
Newer versus older treatments for relapsing-remitting multiple sclerosis. Weinstock-Guttman B, et al. **Drug Saf** 1996 Feb;14(2):121–30 (22 ref.)
Mycophenolate mofetil for the transplanted kidney? **Drug Ther Bull** 1997 May;35(5):38–40 (9 ref.)
Systemic lupus erythematosus. **Drug Ther Bull** 1996 Mar; 34(3):20–3 (23 ref.)
Recognition and optimum management of myocarditis. Caforio AL, et al. **Drugs** 1996 Oct;52(4):515–25 (98 ref.)
Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Wilde MI, et al. **Drugs** 1996 May;51(5):865–94 (214 ref.)
Current and future therapies for myasthenia gravis. Yi Q, et al. **Drugs Aging** 1997 Aug;11(2):132–9 (61 ref.)
Immunomodulation as asthma therapy: where do we stand? Barnes PJ. **Eur Respir J Suppl** 1996 Aug;22:154s–159s (48 ref.)
Adverse and beneficial immunological effects of purine nucleoside analogues. Dighiero G. **Hematol Cell Ther** 1996 Dec;38 Suppl 2:S75–81 (98 ref.)
Clinical experience with fludarabine in hemato-oncology. Keating MJ, et al. **Hematol Cell Ther** 1996 Dec;38 Suppl 2:S83–91 (61 ref.)
FK506 in the treatment of inflammatory skin disease: promises and perspectives. Michel G, et al. **Immunol Today** 1996 Mar;17(3):106–8 (17 ref.)
Immunosuppression in renal transplantation. Bonomini V, et al. **Int J Artif Organs** 1997 Feb;20(2):73–5 (15 ref.)
Cyclosporin A mouthwash in the treatment of oral lichen planus. Jungell P, et al. **Int J Oral Maxillofac Surg** 1996 Feb;25(1):60–2 (20 ref.)
Tacrolimus: immunosuppression following liver and kidney transplant. Clark W. **J Clin Pharm Ther** 1996 Jun; 21(3):135–41 (19 ref.)
New immunosuppressive drugs in organ transplantation. Hughes SE, et al. **J Clin Pharmacol** 1996 Dec; 36(12):1081–92 (140 ref.)
Medical management of ectopic pregnancy--the role of methotrexate. Ander DS, et al. **J Emerg Med** 1997 Mar-Apr;15(2):177–82 (33 ref.)
Inhibition of endothelial cell function: should this be a main goal of immunosuppressive strategies? [editorial; comment] Bach FH. **J Heart Lung Transplant** 1997 May;16(5):493–5 (16 ref.) Comment on: J Heart Lung Transplant 1997 May;16(5):484–92.
Medical treatment for inflammatory bowel disease--refinements and new modalities [editorial] Löfberg R. **J Intern Med** 1997 Jan;241(1):1–4 (24 ref.)
Treatment of idiopathic nephrotic syndrome with cyclosporine A. Meyrier A. **J Nephrol** 1997 Jan-Feb; 10(1):14–24 (76 ref.)
Cop 1 as a candidate drug for multiple sclerosis. Teitelbaum D, et al. **J Neural Transm Suppl** 1997;49:85–91 (29 ref.)
A review of the clinical efficacy profile of copolymer 1: new U.S. phase III trial data. Johnson KP. **J Neurol** 1996 Apr; 243(4 Suppl 1):S3–7 (15 ref.)
Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases [see comments] Mouy R, et al. **J Pediatr** 1996 Nov; 129(5):750–4 (22 ref.) Comment in: J Pediatr 1996 Nov;129(5):630–2. Comment in: J Pediatr 1997 Jun;130(6):1012.
Immunosuppression in organ transplantation. Oka T, et al. **Jpn J Pharmacol** 1996 Jun;71(2):89–100 (48 ref.)
Dilemma of focal segmental glomerular sclerosis. Cortes L, et al. **Kidney Int Suppl** 1996 Jan;53:S57–63 (71 ref.)
Cyclosporine in the therapy of steroid-resistant idiopathic nephrotic syndrome. Niaudet P, et al. **Kidney Int Suppl** 1997 Mar;58:S85–90 (66 ref.)
Rationale and mechanisms of immunosuppression. Salomon DR. **Kidney Int Suppl** 1997 Mar;58:S48–50 (23 ref.)
Aspects concerning busulfan pharmacokinetics and bioavailability. Hassan M, et al. **Leuk Lymphoma** 1996 Aug; 22(5-6):395–407 (130 ref.)
The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease. Schultz KR, et al. **Leuk Lymphoma** 1997 Jan;24(3-4):201–10 (59 ref.)
Rational clinical immunotherapy for multiple sclerosis. Hunter SF, et al. **Mayo Clin Proc** 1997 Aug;72(8):765–80 (120 ref.)
Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Jayne DR, et al. **Mayo Clin Proc** 1997 Aug;72(8):737–47 (63 ref.)
Medical management and complications in the lung transplant recipient. Midthun DE, et al. **Mayo Clin Proc** 1997 Feb;72(2):175–84 (45 ref.)
Treatment of inflammatory neuropathy. Hughes RA, et al. **Mult Scler** 1997 Apr;3(2):88–92 (51 ref.)
The use of tolerance for transplantation across xenogeneic barriers. Greenstein JL, et al. **Nat Biotechnol** 1997 Mar; 15(3):235–8 (57 ref.)
New immunologically non-specific immunosuppressive agents dictate changes in standard protocols for renal transplant management. Helderman JH. **Nephrol Dial Transplant** 1997;12 Suppl 1:51–4 (9 ref.)
Focal segmental glomerular sclerosis. To treat or not to treat? 1. It is worthwhile to give the adult patient with nephrotic syndrome the benefit of an adequate therapeutic trial? Ponticelli C. **Nephrol Dial Transplant** 1995 Dec; 10(12):2351–4 (26 ref.)
New insights into therapy with monoclonal antibodies in allograft transplantation. Schena FP. **Nephrol Dial Transplant** 1997;12 Suppl 1:55–8 (29 ref.)
The use of Mycophenolate Mofetil (Cellcept) in renal transplantation [clinical conference] Vanrenterghem Y. **Nephron** 1997;76(4):392–9 (31 ref.)
Refractory IBD: medical management. Tremaine WJ. **Neth J Med** 1997 Feb;50(2):S12–4 (12 ref.)
Immunosuppressive drugs and pregnancy. Esplin MS, et al. **Obstet Gynecol Clin North Am** 1997 Sep;24(3):601–16 (94 ref.)
Immunopharmacologic therapy in renal transplantation. Shoker AS. **Pharmacotherapy** 1996 Jul-Aug;16(4):562–75 (151 ref.)
A new immunosuppressant: tacrolimus. James DG. **Postgrad Med J** 1996 Oct;72(852):586 (3 ref.)
ANCA-associated vasculitis: diagnosis and treatment in the elderly. Parry R, et al. **Postgrad Med J** 1996 Jul; 72(849):423–6 (16 ref.)
Therapeutic applications of cytokines for immunostimulation and immunosuppression: an update. Cardi G, et al. **Prog Drug Res** 1996;47:211–50 (256 ref.)
Immunosuppressive therapy in liver transplantation: principles and practice. Ascher NL. **Prog Liver Dis** 1995; 13:381–95 (98 ref.)
Use of cyclosporine A in the treatment of refractory nephrotic syndrome in adults. Meyrier A. **Ren Fail** 1996 Sep;18(5):775–84 (42 ref.)
Immunosuppressive drug use during pregnancy. Ramsey-Goldman R, et al. **Rheum Dis Clin North Am** 1997 Feb;23(1):149–67 (133 ref.)
Cyclosporine, FK-506, rapamycin, and other immunomodulators. Yocum DE. **Rheum Dis Clin North Am** 1996 Feb;22(1):133–54 (161 ref.)
Immunosuppressive therapy is always required for the treatment of limited Wegener's granulomatosis. Hoffman GS. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct; 13(3):249–52 (35 ref.)
Clinical pharmacology in gastroenterology: development of new forms of treatment of inflammatory bowel disease. Brynskov J, et al. **Scand J Gastroenterol Suppl** 1996; 216:175–80 (48 ref.)
The use of methotrexate, colchicine, and other immunomodulatory drugs in the treatment of primary biliary cirrhosis. Kaplan MM. **Semin Liver Dis** 1997 May; 17(2):129–36 (57 ref.)
The evolution and future of immunosuppression in renal transplantation. Goral S, et al. **Semin Nephrol** 1997 Jul; 17(4):364–72 (70 ref.)
Cyclosporine in glomerular disease. Mowry JA, et al. **Semin Nephrol** 1996 Nov;16(6):548–54 (61 ref.)
Glucocorticosteroids as immunosuppressive agents. Cohn LA. **Semin Vet Med Surg (Small Anim)** 1997 Aug; 12(3):150–6 (49 ref.)
Immunosuppression--an overview. Miller E. **Semin Vet Med Surg (Small Anim)** 1997 Aug;12(3):144–9 (43 ref.)
Cyclosporine and tacrolimus. Vaden SL. **Semin Vet Med Surg (Small Anim)** 1997 Aug;12(3):161–6 (26 ref.)
Pharmacoeconomics of Neoral, a new formulation of cyclosporine, in renal transplantation. Abella I. **Transplant Proc** 1996 Dec;28(6):3131–4 (21 ref.)
Immunosuppressive drugs and pregnancy: experimental and clinical data. Albengres E, et al. **Transplant Proc** 1997 Aug; 29(5):2461–6 (14 ref.)
Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis. Bartlett RR, et al. **Transplant Proc** 1996 Dec;28(6):3074–8 (28 ref.)
Tacrolimus (FK506) is superior to cyclosporine in liver transplantation. Busuttil RW, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):534–8 (12 ref.)
Biological immunosuppressants: the way to clinical transplantation tolerance. Chatenoud L. **Transplant Proc** 1997 Feb-Mar;29(1-2):51–5 (44 ref.)
Sirolimus: a new agent for clinical renal transplantation. Kahan BD. **Transplant Proc** 1997 Feb-Mar;29(1-2):48–50 (23 ref.)
Tacrolimus (FK-506) in kidney transplantation. Shapiro R. **Transplant Proc** 1997 Feb-Mar;29(1-2):45–7 (46 ref.)
Rescue therapy with mycophenolate mofetil. Mycophenolate Mofetil Renal Refractory Rejection Study Group. Tomlanovich SJ. **Transplant Proc** 1996 Dec;28(6 Suppl 1):34–6 (33 ref.)
Pharmacodynamic monitoring of immunosuppressive drugs. Yatscoff RW, et al. **Transplant Proc** 1996 Dec;28(6):3013–5 (16 ref.)
The role of mycophenolate mofetil in clinical renal transplantation. Hodge EE. **World J Urol** 1996;14(4):249–55 (26 ref.)
Kidney transplantation in highly sensitized patients: reappraisal of etiology, evaluation, and management protocols. Indudhara R, et al. **World J Urol** 1996; 14(4):206–17 (145 ref.)
The use of tacrolimus in renal transplantation. Jordan ML, et al. **World J Urol** 1996;14(4):239–42 (12 ref.)
[Immunosuppressive and immunomodulator treatment of severe systemic lupus] Guillevin L. **Ann Med Interne (Paris)** 1996;147(7):498–505 (74 ref.) (Eng. Abstr.) **(Fre)**
[Cyclosporin in the treatment of chronic diseases of the liver (excluding transplantation)] Di Martino V, et al. **Gastroenterol Clin Biol** 1997;21(5):400–11 (112 ref.) **(Fre)**
[Systemic therapy of psoriasis] Altmeyer P, et al. **Dtsch Med Wochenschr** 1996 Dec 20;121(51-52):1605–7 (14 ref.) **(Ger)**
[Causal therapy of multiple sclerosis] Pöhlau D, et al. **Dtsch Med Wochenschr** 1996 Nov 8;121(45):1407–14 (44 ref.) **(Ger)**
[Kidney transplantation. Indications, results, pre- and postoperative care] Brunkhorst R, et al. **Internist (Berl)** 1996 Mar;37(3):264–71 (13 ref.) **(Ger)**
[Immunosuppression in therapy of glomerulonephritis] Grabensee B, et al. **Internist (Berl)** 1997 Jun;38(6):562–73 (34 ref.) **(Ger)**
[Conventional immunosuppression of chronic inflammatory systemic diseases] Gross WL, et al. **Internist (Berl)** 1997 Jun;38(6):520–31 (62 ref.) **(Ger)**
[Cyclosporin A in inflammatory rheumatic diseases] Gross WL, et al. **Internist (Berl)** 1996 Jan;37(1):91–7 (61 ref.) **(Ger)**
[Cyclosporin in treatment of glomerular diseases] Krieter DH, et al. **Internist (Berl)** 1996 Jan;37(1):84–8 (34 ref.) **(Ger)**
[Etiopathogenetic differentiation of inflammatory cardiomyopathy. Immunosuppression and immunomodulation] Kühl U, et al. **Internist (Berl)** 1997 Jun;38(6):590–601 (105 ref.) **(Ger)**
[Immunosuppressive therapeutic modalities in chronic polyarthritis] Lorenz HM, et al. **Internist (Berl)** 1997 Jun; 38(6):532–40 (32 ref.) **(Ger)**
[Immunosuppressive therapy in interstitial lung diseases and immunologically-induced pneumonitis] Müller-Quernheim J, et al. **Internist (Berl)** 1997 Jun;38(6):553–61 (31 ref.) **(Ger)**
[General principles of immunosuppressive therapy of diseases of rheumatic origin] Peter HH. **Internist (Berl)** 1997 Jun; 38(6):514–9 (20 ref.) **(Ger)**
[Cyclosporin in transplantation management--especially after kidney transplantation] Quellhorst E. **Internist (Berl)** 1996 Jan;37(1):88–90 (90 ref.) **(Ger)**
[Immunosuppressive therapy of autoimmune liver diseases] Rambusch EG, et al. **Internist (Berl)** 1997 Jun;38(6):574–81 (51 ref.) **(Ger)**
[Indications for immunosuppressive therapy of chronic inflammatory bowel diseases] Schölmerich J. **Internist (Berl)** 1997 Jun;38(6):582–9 (30 ref.) **(Ger)**
[Immunosuppression in organ transplantation. New substances and therapeutic approaches] Wonigeit K. **Internist (Berl)** 1996 Mar;37(3):229–39 (62 ref.) **(Ger)**
[Basic principles in treatment of endophthalmitis] Kain HL. **Klin Monatsbl Augenheilkd** 1997 May;210(5):274–88 (62 ref.) (Eng. Abstr.) **(Ger)**
[Immunosuppression--a tightrope walk between iatrogenic harm and therapy] Berchtold P, et al. **Schweiz Med Wochenschr** 1996 Sep 21;126(38):1603–9 (19 ref.) (Eng. Abstr.) **(Ger)**
[New therapeutic possibilities in chronic inflammatory bowel diseases] Zeitz M. **Schweiz Rundsch Med Prax** 1997 Jun 18;86(25-26):1071–4 (8 ref.) (Eng. Abstr.) **(Ger)**
[A refractory case of adult-onset Still's disease] Nishio J, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1997 Jun; 20(3):191–8 (28 ref.) (Eng. Abstr.) **(Jpn)**
[Present status and problems in clinical application of tacrolimus(FK506)] Teraoka S, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):689 (0 ref.) **(Jpn)**
[Changes of serum GBV-C RNA levels under administration of interferon and cyclosporine for patients with GBV infected hepatitis] Fujikawa H, et al. **Nippon Rinsho** 1997 Mar;55(3):591–6 (26 ref.) (Eng. Abstr.) **(Jpn)**
[Kidneys involvement in multiple myeloma. Therapeutic issues] Gordeev AV, et al. **Klin Med (Mosk)** 1997; 75(8):60–2 (3 ref.) **(Rus)**
[Methotrexate in the treatment of inflammatory intestinal diseases] Diaz Blasco J, et al. **Rev Esp Enferm Dig** 1997 May;89(5):385–90 (67 ref.) **(Spa)**

TOXICITY

Isolated glomeruli and cultured mesangial cells as in vitro models to study immunosuppressive agents. Potier M, et al. **Cell Biol Toxicol** 1996 Dec;12(4-6):263–70 (36 ref.)
Differential effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin, bis(tri-n-butyltin) oxide and cyclosporine on thymus histophysiology. De Waal EJ, et al. **Crit Rev Toxicol** 1997 Jul;27(4):381–430 (460 ref.)
Pathology of toxic effects on the immune system. Gopinath C. **Inflamm Res** 1996 Dec;45 Suppl 2:S74–8 (14 ref.)
[Immunotoxicity assessment in the preclinical study of biologically active compounds] Uteshev BS, et al. **Eksp Klin Farmakol** 1996 May-Jun;59(3):3–8 (71 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOSURVEILLANCE see **MONITORING, IMMUNOLOGIC**

IMMUNOTHERAPY

Identification of the genes encoding cancer antigens:

implications for cancer immunotherapy. Rosenberg SA, et al. **Adv Cancer Res** 1996;70:145–77 (156 ref.)

Production of recombinant allergens and their application for immunotherapy. Okumura Y. **Adv Exp Med Biol** 1996; 409:163–71 (6 ref.)

Advantages and disadvantages of recombinant allergens and peptides for specific immunotherapy. Schou C. **Adv Exp Med Biol** 1996;409:137–40 (13 ref.)

Therapeutic vaccines. A pandoric prospect. Spier RE. **Adv Exp Med Biol** 1996;397:183–9 (7 ref.)

Recombinant allergens for immunotherapy. Thomas WR. **Adv Exp Med Biol** 1996;409:85–93 (78 ref.)

Soluble cytokine receptors: their roles in immunoregulation, disease, and therapy. Fernandez-Botran R, et al. **Adv Immunol** 1996;63:269–336 (325 ref.)

Current status of immunotherapy for allergies and anaphylactic reactions. Norman PS. **Adv Intern Med** 1996; 41:681–713 (129 ref.)

Targeted tumor cytotoxicity mediated by intracellular single-chain anti-oncogene antibodies. Curiel DT. **Adv Pharmacol** 1997;40:51–84 (76 ref.)

Immunoliposomes for cancer treatment. Park JW, et al. **Adv Pharmacol** 1997;40:399–435 (135 ref.)

Cytokine gene transduction in the immunotherapy of cancer. Parmiani G, et al. **Adv Pharmacol** 1997;40:259–307 (235 ref.)

Gene therapy approaches to enhance antitumor immunity. Shawler DL, et al. **Adv Pharmacol** 1997;40:309–37 (82 ref.)

Immune-based therapies in HIV infection: recent developments. Emery S, et al. **AIDS** 1996;10 Suppl A:S159–63 (38 ref.)

Specific immunotherapy in asthma: reflexions of an "old" allergist. The need for more clinical works. Panzani RC. **Allergol Immunopathol (Madr)** 1997 Jan-Feb;25(1):52–7 (18 ref.)

Implication of abnormal human trophoblast karyotype for the evidence-based approach to the understanding, investigation, and treatment of recurrent spontaneous abortion. The Recurrent Miscarriage Immunotherapy Trialists Group [editorial] Clark DA, et al. **Am J Reprod Immunol** 1996 May;35(5):495–8 (28 ref.)

The current status of therapeutic HPV vaccine. van Driel WJ, et al. **Ann Med** 1996 Dec;28(6):471–7 (72 ref.)

Basic aspects of neuroimmunology as they relate to immunotherapeutic targets: present and future prospects. Dalakas MC. **Ann Neurol** 1995 May;37 Suppl 1:S2–13 (91 ref.)

Myasthenia gravis: immunological mechanisms and immunotherapy. Lewis RA, et al. **Ann Neurol** 1995 May; 37 Suppl 1:S51–62 (109 ref.)

Treatment of Hodgkin's disease with bispecific antibodies. Hartmann F, et al. **Ann Oncol** 1996;7 Suppl 4:143–6 (17 ref.)

Getting to the source: dendritic cells as therapeutic reagents for the treatment of patients with cancer [editorial; comment] Lotze MT. **Ann Surg** 1997 Jul;226(1):1–5 (48 ref.) Comment on: Ann Surg 1997 Jul;226(1):6–16.

Strategies for immune intervention in visceral leishmaniasis. Kaye PM, et al. **Ann Trop Med Parasitol** 1995 Dec;89 Suppl 1:75–81 (37 ref.)

Cancer immunotherapy: hopes and pitfalls: a review. Ben-Efraim S. **Anticancer Res** 1996 Sep-Oct; 16(5B):3235–40 (53 ref.)

TNF blockade in rheumatoid arthritis: implications for therapy and pathogenesis. Maini RN, et al. **APMIS** 1997 Apr;105(4):257–63 (34 ref.)

Medical treatments for abnormal eye movements: pharmacological, optical and immunological strategies. Averbuch-Heller L, et al. **Aust N Z J Ophthalmol** 1997 Feb;25(1):7–13 (36 ref.)

Treatment and prognostic factors in acute myeloid leukaemia. Rowe JM, et al. **Baillieres Clin Haematol** 1996 Mar; 9(1):87–105 (114 ref.)

Single-chain Fv antibodies for targeting cancer therapy. Begent RH, et al. **Biochem Soc Trans** 1997 May;25(2):715–7 (16 ref.)

Pathogenesis and treatment of virus-induced autoimmune diabetes: novel insights gained from the RIP-LCMV transgenic mouse model. von Herrath MG, et al. **Biochem Soc Trans** 1997 May;25(2):630–5 (55 ref.)

Clinical significance of autologous tumor killing (ATK) activity and its induction therapy in human cancer. Uchida A. **Biotherapy** 1994;8(2):113–22 (53 ref.)

Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Hohlfeld R. **Brain** 1997 May;120 (Pt 5):865–916 (372 ref.)

Current immunotherapy for melanoma. Newton Bishop JA. **Cancer Surv** 1996;26:321–33 (54 ref.)

The role of immunotherapy in urologic malignancies. Abubakr YA, et al. **Cancer Treat Res** 1996;88:235–48 (86 ref.)

Intraperitoneal immunotherapy of cancer: a review of options for treatment. van Ravenswaay Claasen HH, et al. **Cancer Treat Res** 1996;82:13–40 (194 ref.)

Post-bone marrow transplant use of immunotherapy. Verma UN, et al. **Cancer Treat Res** 1997;77:27–55 (158 ref.)

TH2 cells in allergic inflammation: a target of immunotherapy. Lord CJ, et al. **Clin Exp Allergy** 1996 Jul; 26(7):756–65 (105 ref.)

Rescue of DMARD failures by means of monoclonal antibodies or biological agents. Kalden JR. **Clin Exp Rheumatol** 1997 May-Jun;15 Suppl 17:S91–8 (42 ref.)

The treatment of metastatic melanoma with chemotherapy and biologics [see comments] Atkins MB. **Curr Opin Oncol** 1997 Mar;9(2):205–13 (71 ref.) Comment in: Curr Opin Oncol 1997 Mar;9(2):175–7.

Immunotherapy for non-Hodgkin's lymphoma. Longo DL. **Curr Opin Oncol** 1996 Sep;8(5):353–9 (46 ref.)

Adjuvant therapy for melanoma [see comments] Sondak VK, et al. **Curr Opin Oncol** 1997 Mar;9(2):189–204 (119 ref.) Comment in: Curr Opin Oncol 1997 Mar;9(2):175–7.

The role of immunotherapy in pediatric allergic disease. Hedlin G. **Curr Opin Pediatr** 1995 Dec;7(6):676–82 (43 ref.)

Immunopharmacology. Terezhalmy GT, et al. **Dent Clin North Am** 1996 Jul;40(3):685–707 (45 ref.)

Recent advances in the treatment of psoriasis. Guzzo C. **Dermatol Clin** 1997 Jan;15(1):59–68 (76 ref.)

New strategies in oral immunotherapy for diabetes prevention. Muir A, et al. **Diabetes Metab Rev** 1996 Apr; 12(1):1–14 (109 ref.)

Asthma: an important disease to Otolaryngologists--part III: anti-inflammatory therapy. Gordon BR. **Ear Nose Throat J** 1996 Apr;75(4):216–24 (49 ref.)

Trends in immunotherapy of fungal infections. Kullberg BJ. **Eur J Clin Microbiol Infect Dis** 1997 Jan;16(1):51–5 (31 ref.)

Pulmonary perspective: immunology in diagnosis and treatment of lung cancer. Weynants P, et al. **Eur Respir J** 1997 Aug;10(8):1703–19 (212 ref.)

A review of clinical studies of bropirimine immunotherapy of carcinoma in situ of the bladder and upper urinary tract. Sarosdy MF. **Eur Urol** 1997;31 Suppl 1:20–6 (36 ref.)

Regional immunotherapy for liver metastases and the potential of TNF alpha in hepatic perfusion from laboratory to the clinic. Eggermont AM. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1371–8 (56 ref.)

Pre- and/or post-operative immunochemotherapy for advanced digestive cancer. Saji S, et al. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:239–49 (14 ref.)

Immunobiology and immunotherapeutic implications of syngeneic/autologous graft-versus-host disease. Hess AD, et al. **Immunol Rev** 1997 Jun;157:111–23 (102 ref.)

Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies. Deo YM, et al. **Immunol Today** 1997 Mar;18(3):127–35 (57 ref.)

Immunotherapy of leprosy. Katoch K. **Indian J Lepr** 1996 Oct-Dec;68(4):349–61 (75 ref.)

Immunotherapy for Behçet's disease. Mochizuki M. **Int Rev Immunol** 1997;14(1):49–66 (63 ref.)

The promiscuous IL-2/IL-15 receptor: a target for immunotherapy of HTLV-I-associated disorders. Waldmann TA. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S179–85 (43 ref.)

Cellular and molecular analyses of major histocompatibility complex (MHC) restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy. Schendel DJ, et al. **J Mol Med** 1997 Jun;75(6):400–13 (119 ref.)

Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis and their application for new therapeutic strategies. Martin R. **J Neural Transm Suppl** 1997;49:53–67 (96 ref.)

Immune modulation strategies in T cell mediated autoimmune diseases-relevance to IDDM. Mathieson PW. **J Pediatr Endocrinol Metab** 1996 Mar;9 Suppl 1:133–8 (26 ref.)

Initial experience combining methotrexate with biologic agents for treating rheumatoid arthritis. Moreland LW. **J Rheumatol Suppl** 1996 Mar;44:78–83 (74 ref.)

Novel immunotherapeutic strategies using MHC derived peptides. Sayegh MH, et al. **Kidney Int Suppl** 1996 Jan; 53:S13–20 (53 ref.)

Idiotype-specific T cells in multiple myeloma: targets for an immunotherapeutic intervention? Yi Q, et al. **Med Oncol** 1996 Mar;13(1):1–7 (70 ref.)

Melanosomal proteins as melanoma-specific immune targets. Sakai C, et al. **Melanoma Res** 1997 Apr;7(2):83–95 (130 ref.)

Biological properties of dendritic cells: implications to their use in the treatment of cancer. van Schooten WC, et al. **Mol Med Today** 1997 Jun;3(6):254–60 (44 ref.)

Selective immunomodulation in patients with inflammatory bowel disease--future therapy or reality? van Hogezand RA, et al. **Neth J Med** 1996 Feb;48(2):64–7 (21 ref.)

Alternative therapies for children with brain stem gliomas: immunotherapy and gene therapy. Packer RJ. **Pediatr Neurosurg** 1996;24(4):217–22 (21 ref.)

Tumor vascular endothelium: barrier or target in tumor directed drug delivery and immunotherapy. Molema G, et al. **Pharm Res** 1997 Jan;14(1):2–10 (68 ref.)

Cytokine gene-modified vaccines in the therapy of cancer. Bubenik J. **Pharmacol Ther** 1996;69(1):1–14 (208 ref.)

Allergic rhinitis. Options for pharmacotherapy and immunotherapy. Ferguson BJ. **Postgrad Med** 1997 May; 101(5):117–20, 123–6, 131 (15 ref.)

Immunotherapy for brain diseases and mental illnesses. Singh VK. **Prog Drug Res** 1997;48:129–46 (100 ref.)

Epstein-Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma. Ambinder RF, et al. **Semin Cancer Biol** 1996 Aug;7(4):217–26 (69 ref.)

New insights into the immunopathology of chronic inflammatory bowel disease. Ehrhardt RO. **Semin Gastrointest Dis** 1996 Jul;7(3):144–50 (43 ref.)

Harnessing self-reactivity in cancer immunotherapy. Schoenberger SP, et al. **Semin Immunol** 1996 Oct;8(5):303–9 (44 ref.)

Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach. Slovin SF, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 14):41–8 (61 ref.)

Biologic therapy of melanoma with cytokines and lymphocytes. Bear HD, et al. **Semin Surg Oncol** 1996 Nov-Dec;12(6):436–45 (63 ref.)

Immunotherapy of bladder cancer. Nseyo UO, et al. **Semin Surg Oncol** 1997 Sep-Oct;13(5):342–9 (76 ref.)

Tumor antigens and tumor vaccines: peptides as immunogens. Slingluff CL Jr. **Semin Surg Oncol** 1996 Nov-Dec; 12(6):446–53 (89 ref.)

Immunotherapy and gene therapy. Gitlitz BJ, et al. **Semin Urol Oncol** 1996 Nov;14(4):237–43 (51 ref.)

Novel approaches to the treatment of sepsis: lessons learned and future directions. Cross A. **Shock** 1996;6 Suppl 1:S71–4 (19 ref.)

Immunotherapy with Mycobacterium vaccae and the treatment of tuberculosis. Stanford JL, et al. **Soc Appl Bacteriol Symp Ser** 1996;25:81S–86S (30 ref.)

Experimental immunotherapies for multiple sclerosis. Martin R, et al. **Springer Semin Immunopathol** 1996;18(1):1–24 (163 ref.)

The use of allogeneic leukocytes or i.v. IgG for the treatment of patients with recurrent spontaneous abortions. Clark DA, et al. **Transfus Med Rev** 1997 Apr;11(2):85–94 (50 ref.)

Cytokine-based immunomodulation of autoimmune diseases: an overview. Bach JF. **Transplant Proc** 1996 Dec; 28(6):3023–5 (40 ref.)

Immunosuppression and immunomodulation of experimental models of systemic lupus erythematosus and antiphospholipid syndrome. Shoenfeld Y, et al. **Transplant Proc** 1996 Dec;28(6):3096–8 (33 ref.)

European Commission COST/STD Initiative. Report of the expert panel IV. A common European network for clinical trials. Moxon ER, et al. **Vaccine** 1996 May;14(7):624–43 (7 ref.)

[Chemotherapy and immunotherapy of metastatic malignant melanomas] Benhammouda A, et al. **Presse Med** 1996 Nov 16;25(35):1690–7 (80 ref.) (Eng. Abstr.) **(Fre)**

[Immunotherapy in the treatment of cancers] Tartour E, et al. **Presse Med** 1996 Nov 16;25(35):1717–22 (35 ref.) (Eng. Abstr.) **(Fre)**

[Causal therapy of multiple sclerosis] Pöhlau D, et al. **Dtsch Med Wochenschr** 1996 Nov 8;121(45):1407–14 (44 ref.) **(Ger)**

[Treatment of malignant melanoma: recent advances and perspectives] Saida T. **Gan To Kagaku Ryoho** 1997 Jan; 24(1):10–5 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Therapy of patients with head and neck neoplasms using cytotoxic T lymphocytes] IshikawaT, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):621–4 (10 ref.) **(Jpn)**

[Steroid therapy and immunotherapy of patients with collagen diseases] Yoshizaki K, et al. **Nippon Naika Gakkai Zasshi** 1996 Nov 10;85(11):1895–901 (5 ref.) **(Jpn)**

[Host defense against mycobacterial infections--new strategies for combatting multidrug-resistant mycobacterial diseases] Kobayashi K. **Nippon Saikingaku Zasshi** 1997 Apr; 52(2):485–91 (15 ref.) **(Jpn)**

[Immunotherapy of multiple sclerosis: the use of magnetic resonance imaging in the evaluation of clinical trials] Ozawa K, et al. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1501–3 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Multiple sclerosis: update on current therapies] Sato T. **Rinsho Shinkeigaku** 1995 Dec;35(12):1505–7 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Value of selected parameters for monitoring efficacy of specific immunotherapy in allergic disorders] Cichocka-Jarosz E. **Przegl Lek** 1996;53(10):739–43 (35 ref.) (Eng. Abstr.) **(Pol)**

[Immunotherapy of sepsis: myth or reality?] Vinnitskii LI, et al. **Anesteziol Reanimatol** 1997 May-Jun;(3):89–97 (143 ref.) **(Rus)**

[Immunocytotherapy. A novel direction in fetal tissue transplantation] Kulakov VI, et al. **Biull Eksp Biol Med** 1994 Apr;117(4):412–5 (22 ref.) **(Rus)**

[Meningococcal infection: should we vaccinate?] Casado Flores J. **An Esp Pediatr** 1997 Mar;46(3):221–3 (27 ref.) **(Spa)**

ADVERSE EFFECTS

Mycobacterial sepsis following intravesical instillation of bacillus Calmette-Guérin. Garyfallou GT. **Acad Emerg Med** 1996 Feb;3(2):157–60 (12 ref.)

Specific immunotherapy (SIT) in children. Cantani AD, et al. **Allergy** 1996 May;51(5):365–6 (16 ref.)

Risk management in allergen immunotherapy. Greineder DK. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 3):S330–4 (24 ref.)

Antibodies to interferon in patients undergoing IFN therapy: an update. Antonelli G. **J Biol Regul Homeost Agents** 1995 Oct-Dec;9(4):123–31 (84 ref.)

METHODS

Gene transfer of suicide genes for the treatment of malignant

gliomas: efficacy, limitations, and perspectives for a combined immunotherapy. Benedetti S, et al. **Acta Neurochir Suppl (Wien)** 1997;68:100–4 (23 ref.)

HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Disis ML, et al. **Adv Cancer Res** 1997;71:343–71 (105 ref.)

Specific immunotherapy (SIT) in children. Cantani AD, et al. **Allergy** 1996 May;51(5):365–6 (16 ref.)

Immunotherapy of metastatic renal cell cancer. Goey SH, et al. **Ann Oncol** 1996 Nov;7(9):887–900 (253 ref.)

The use of biologics in the treatment of rheumatoid arthritis (RA)—the good news and the bad news. McQueen FM. **Aust N Z J Med** 1997 Apr;27(2):175–84 (43 ref.)

Use of peptides to selectively modulate CD4+ T-cell responses. Hetzel C, et al. **Biochem Soc Trans** 1997 May; 25(2):398–403 (49 ref.)

The role of immunotherapy for urological tumours. Hrouda D, et al. **Br J Urol** 1997 Mar;79(3):307–16 (100 ref.)

Novel costimulators in the immune gene therapy of cancer. Galea-Lauri J, et al. **Cancer Gene Ther** 1996 May–Jun; 3(3):202–14 (133 ref.)

Making the most of mucin: a novel target for tumor immunotherapy. Barratt-Boyes SM. **Cancer Immunol Immunother** 1996 Nov;43(3):142–51 (65 ref.)

Gene-modified tumor cells as cellular vaccine. Baskar S. **Cancer Immunol Immunother** 1996 Nov;43(3):165–73 (96 ref.)

Carbohydrate antigens as targets for active specific immunotherapy. Ragupathi G. **Cancer Immunol Immunother** 1996 Nov;43(3):152–7 (61 ref.)

Oncogene products represent potential targets of tumor vaccines. Tuttle TM. **Cancer Immunol Immunother** 1996 Nov;43(3):135–41 (62 ref.)

The biological therapy of acute and chronic leukemia. Caron PC, et al. **Cancer Invest** 1997;15(4):342–52 (108 ref.)

Immunotherapy I: Cyclosine gene transfer strategies. Colombo MP, et al. **Cancer Metastasis Rev** 1996 Sep; 15(3):317–28 (72 ref.)

Immunotherapy II: Antigens, receptors and costimulation. Searle PF, et al. **Cancer Metastasis Rev** 1996 Sep; 15(3):329–49 (103 ref.)

Immunotherapy III: Combinatorial molecular immunotherapy—a synthesis and suggestions. Vile RG, et al. **Cancer Metastasis Rev** 1996 Sep;15(3):351–64 (101 ref.)

Chimeric T-cell receptors: highly specific tools to target cytotoxic T-lymphocytes to tumour cells. Abken H, et al. **Cancer Treat Rev** 1997 Mar;23(2):97–112 (42 ref.)

Antibodies against HIV-1 from phage display libraries: mapping of an immune response and progress towards antiviral immunotherapy. Parren PW, et al. **Chem Immunol** 1997;65:18–56 (163 ref.)

Granulocyte colony-stimulating factor and modulation of inflammatory cells in sepsis. Nelson S, et al. **Clin Chest Med** 1996 Jun;17(2):319–32 (122 ref.)

Immunotherapy for sepsis. Ralston DR, et al. **Clin Chest Med** 1996 Jun;17(2):307–17 (104 ref.)

Treatment regimens for patients with toxoplasmic encephalitis. Fung HB, et al. **Clin Ther** 1996 Nov–Dec; 18(6):1037–56; discussion 1036 (67 ref.)

Autoimmune pathogenesis of multiple sclerosis: role of autoreactive T lymphocytes and new immunotherapeutic strategies. Stinissen P, et al. **Crit Rev Immunol** 1997; 17(1):33–75 (357 ref.)

Assessment of immune mediator expression levels in biological fluids and cells: a critical appraisal. Patarca R, et al. **Crit Rev Oncog** 1995;6(2):117–49 (289 ref.)

Genetic immunization: a new era in vaccines and immune therapeutics. Chattergoon M, et al. **FASEB J** 1997 Aug; 11(10):753–63 (42 ref.)

Future directions for the treatment of colorectal carcinoma. Eck SL. **Hematol Oncol Clin North Am** 1997 Aug; 11(4):795–810 (74 ref.)

Oral cytokine administration. Rollwagen FM, et al. **Immunol Today** 1996 Dec;17(12):548–50 (15 ref.)

Intravesical therapy of bladder cancer: an immunotherapy success story. Morales A. **Int J Urol** 1996 Sep;3(5):329–33 (30 ref.)

VCAM-1/alpha 4-integrin adhesion pathway: therapeutic target for allergic inflammatory disorders. Foster CA. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 2):S270–7 (86 ref.)

Risk management in allergen immunotherapy. Greineder DK. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 3):S330–4 (24 ref.)

Reversal of tumor-induced immunosuppression: a new approach to cancer therapy [see comments] Wojtowicz-Praga S. **J Immunother** 1997 May;20(3):165–77 (146 ref.) Comment in: J Immunother 1997 May;20(3):178–9.

Bacterial immunotherapy in bronchial asthma. Oehling A. **J Investig Allergol Clin Immunol** 1997 Jan–Feb;7(1):14–9 (33 ref.)

Alternative routes for allergen-specific immunotherapy. Passalacqua G, et al. **J Investig Allergol Clin Immunol** 1996 Mar–Apr;6(2):81–7 (69 ref.)

Gene-based strategies for the immunotherapy of cancer. Tüting T, et al. **J Mol Med** 1997 Jul;75(7):478–91 (142 ref.)

Danger versus tolerance: paradigms for future studies of tumor-specific cytotoxic T lymphocytes [editorial; comment] Fenton RG, et al. **J Natl Cancer Inst** 1997 Feb 19;89(4):272–5 (28 ref.) Comment on: J Natl Cancer Inst 1997 Feb 19;89(4):293–300.

Rational clinical immunotherapy for multiple sclerosis. Hunter SF, et al. **Mayo Clin Proc** 1997 Aug;72(8):765–80 (120 ref.)

Granulocyte-macrophage colony-stimulating factor as an adjuvant in tumor immunotherapy. Fagerberg J. **Med Oncol** 1996 Sep;13(3):155–60 (52 ref.)

p53 as a target for anti-cancer immunotherapy. Chen HL, et al. **Mol Med Today** 1997 Apr;3(4):160–7 (48 ref.)

Local immune responses in ocular virus infection and their implications for future immunotherapy. Hayashi K. **Ophthalmologica** 1997;211 Suppl 1:45–52 (98 ref.)

Advances in the therapy for sepsis in children. Anderson MR, et al. **Pediatr Clin North Am** 1997 Feb;44(1):179–205 (67 ref.)

Genetic approaches to cancer immunotherapy. Blankenstein T, et al. **Rev Physiol Biochem Pharmacol** 1996;129:1–49 (168 ref.)

Biological principles and clinical development of prostate cancer gene therapy. Sanda MG. **Semin Urol Oncol** 1997 Feb;15(1):43–55 (77 ref.)

Immunological gene therapy approaches for malignant melanoma. 1. Tumor-immunological background. Bonnekoh B, et al. **Skin Pharmacol** 1997;10(2):49–62 (86 ref.)

Immunological gene therapy approaches for malignant melanoma. 2. Preclinical studies and clinical strategies. Bonnekoh B, et al. **Skin Pharmacol** 1997;10(3):105–25 (93 ref.)

Immunotherapy of malignant melanoma. Leong SP. **Surg Clin North Am** 1996 Dec;76(6):1355–81 (165 ref.)

Immunomodulation by HLA class I-derived peptides. Krensky AM, et al. **Transplant Proc** 1996 Dec;28(6):3026–8 (14 ref.)

[Anti-inflammatory and anti-allergic oral vaccines?] Lomholt HB, et al. **Ugeskr Laeger** 1996 Sep 16; 158(38):5273–6 (40 ref.) (Eng. Abstr.) **(Dan)**

[Specific immunotherapy of respiratory allergies] Michel FB, et al. **Presse Med** 1997 Apr 12;26(12):567–71 (35 ref.) **(Fre)**

[Immunotherapy strategies in lymphoma] Engert A, et al. **Internist (Berl)** 1997 Feb;38(2):150–6 (45 ref.) **(Ger)**

[Is there a reliable immunotherapy in infection?] Grimminger F, et al. **Internist (Berl)** 1997 Jun;38(6):541–52 (40 ref.) **(Ger)**

[Immunotherapy of metastatic renal cell carcinoma. Is clinical use justified in view of outcome, side effects and costs?] Oberneder R, et al. **Urologe A** 1997 Mar;36(2):130–7 (56 ref.) (Eng. Abstr.) **(Ger)**

[The role of interleukin-2—based immunotherapy in hematological malignancies] Ackerstein A, et al. **Harefuah** 1996 May 1;130(9):613–7 (45 ref.) **(Heb)**

[A new look at the history of tumor immunotherapy—for its fruitful future through overcoming the widespread cynicism] Takeuchi S. **Hum Cell** 1996 Mar;9(1):1–10 (41 ref.) (Eng. Abstr.) **(Jpn)**

[Immunomodulators and some aspects of their clinical use] Khaitov RM, et al. **Klin Med (Mosk)** 1996;74(8):7–12 (16 ref.) **(Rus)**

[Current issues in immunotherapy of tumors in the context of macrophage reaction to tissue damage fixed through evolution] Okulov VB. **Vopr Onkol** 1997;43(1):102–6 (33 ref.) **(Rus)**

[Desensitizing treatment in bronchial asthma] Duce Gracia F, et al. **Arch Bronconeumol** 1996 Oct;32(8):414–20 (57 ref.) **(Spa)**

[A scientist's day-dream or future reality? Specific immunotherapy against cancer] Kiessling R, et al. **Lakartidningen** 1997 Apr 23;94(17):1595–600 (20 ref.) **(Swe)**

TRENDS

Prospects and advances in hormonal immunomodulatory therapy. Jorgensen C, et al. **Baillieres Clin Rheumatol** 1996 May;10(2):379–92 (84 ref.)

Current and future therapies for myasthenia gravis. Yi Q, et al. **Drugs Aging** 1997 Aug;11(2):132–9 (61 ref.)

Recent advances in graft-versus-host disease (GVHD) prevention. Blazar BR, et al. **Immunol Rev** 1997 Jun; 157:79–109 (314 ref.)

Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. Mackall CL, et al. **Immunol Rev** 1997 Jun; 157:61–72 (68 ref.)

Indirect T-cell allorecognition: perspectives for peptide-based therapy in transplantation. Benichou G, et al. **Immunol Today** 1997 Feb;18(2):67–71 (34 ref.)

IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease. Röcken M, et al. **Immunol Today** 1996 May;17(5):225–31 (80 ref.)

Immunotherapy in neuromuscular disorders: current and future strategies. Drachman DB. **Muscle Nerve** 1996 Oct; 19(10):1239–51 (69 ref.)

VETERINARY

Genetic immunotherapy for cancer. Elmslie RE, et al. **Semin Vet Med Surg (Small Anim)** 1997 Aug;12(3):193–205 (93 ref.)

Vaccine adjuvants. Macy DW. **Semin Vet Med Surg (Small Anim)** 1997 Aug;12(3):206–11 (42 ref.)

Immunotherapy and cytokines. Van Kampen KR. **Semin Vet Med Surg (Small Anim)** 1997 Aug;12(3):186–92 (25 ref.)

Chemoimmunotherapy of canine lymphoma with adjuvant canine monoclonal antibody 231. Jeglum KA. **Vet Clin North Am Small Anim Pract** 1996 Jan;26(1):73–85 (19 ref.)

Canine osteosarcoma: amputation and chemoimmunotherapy. MacEwen EG, et al. **Vet Clin North Am Small Anim Pract** 1996 Jan;26(1):123–33 (50 ref.)

IMMUNOTHERAPY, ACTIVE

Active specific immunotherapy in hepatic metastasis. Schlag PM, et al. **Ann Ital Chir** 1996 Nov–Dec;67(6):783–91 (108 ref.)

The development of therapeutic vaccines of the management of malignant melanoma. Dalgleish AG, et al. **Cancer Surv** 1996;26:289–319 (158 ref.)

Breast cancer immunotherapy: current status and future prospects. Apostolopoulos V, et al. **Immunol Cell Biol** 1996 Oct;74(5):457–64 (41 ref.)

The neglected role of type I interferon in the T-cell response: implications for its clinical use. Belardelli F, et al. **Immunol Today** 1996 Aug;17(8):369–72 (50 ref.)

Monitoring of cancer patients undergoing active or passive immunotherapy. Salgaller ML. **J Immunother** 1997 Jan; 20(1):1–14 (113 ref.)

Update on active specific immunotherapy with melanoma vaccines. Conforti AM, et al. **J Surg Oncol** 1997 Sep; 66(1):55–64 (93 ref.)

Cancer vaccines. Durrant LG, et al. **QJM** 1996 Sep; 89(9):645–51 (40 ref.)

IL12 as an adjuvant for vaccines designed to prevent infection and immunopathology by schistosomes. Wynn TA, et al. **Res Immunol** 1995 Sep–Oct;146(7–8):582–90 (59 ref.)

Epitope selection and development of peptide based vaccines to treat cancer. Celis E, et al. **Semin Cancer Biol** 1995 Dec; 6(6):329–36 (52 ref.)

Augmenting the immunogenicity of carbohydrate tumor antigens. Livingston PO. **Semin Cancer Biol** 1995 Dec; 6(6):357–66 (56 ref.)

[Cancer vaccine therapy using peptides derived from tumor-rejection antigens] Akiyoshi T. **Gan To Kagaku Ryoho** 1997 Mar;24(5):511–9 (38 ref.) (Eng. Abstr.) **(Jpn)**

[T cell vaccination—induction of anti-idiotypic immune response against TCR and shift of Th1/Th2 balance] Kakimoto K, et al. **Nippon Rinsho** 1997 Jun;55(6):1512–8 (18 ref.) (Eng. Abstr.) **(Jpn)**

[TCR peptide vaccination for autoimmune diseases: involvement of T-T interaction between autoimmune T cells presenting TCR peptide and CD4–CD8– regulatory T cells] Yamamura T. **Nippon Rinsho** 1997 Jun; 55(6):1519–24 (14 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

The sting challenge test in Hymenoptera venom allergy. Position paper of the Subcommittee on Insect Venom Allergy of the European Academy of Allergology and Clinical Immunology. Ruëff F, et al. **Allergy** 1996 Apr; 51(4):216–25 (79 ref.)

Autoimmune T cells in myasthenia gravis: heterogeneity and potential for specific immunotargeting. Hawke S, et al. **Immunol Today** 1996 Jul;17(7):307–11 (32 ref.)

Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines. Jaffee EM, et al. **Methods** 1997 Jun;12(2):143–53 (50 ref.)

Role of interleukin-12 (IL12) as an anti-tumour agent: experimental biology and clinical application. Zitvogel L, et al. **Res Immunol** 1995 Sep–Oct;146(7–8):628–38 (29 ref.)

Histamine in cancer immunotherapy. Hellstrand K, et al. **Scand J Clin Lab Invest** 1997 May;57(3):193–202 (55 ref.)

Genetically engineered superantigens in experimental tumor therapy. Antonsson P, et al. **Springer Semin Immunopathol** 1996;17(4):397–410 (34 ref.)

TRENDS

Immunotoxins: an update. Thrush GR, et al. **Annu Rev Immunol** 1996;14:49–71 (167 ref.)

IMMUNOTHERAPY, ADOPTIVE

Adoptive immunotherapy post bone-marrow transplantation. Perry AR, et al. **Blood Rev** 1996 Dec;10(4):237–41 (24 ref.)

Adoptive CD8+ T-cell immunotherapy of AIDS patients with Kaposi's sarcoma. Patarca R, et al. **Crit Rev Oncog** 1995;6(3–6):179–234 (685 ref.)

Current status of adoptive immunotherapy of cancer. Chang AE, et al. **Crit Rev Oncol Hematol** 1996 Apr;22(3):213–28 (115 ref.)

Donor lymphocyte infusions. Giralt SA, et al. **Curr Opin Oncol** 1996 Mar;8(2):96–102 (61 ref.)

Adoptive immunotherapy with donor lymphocyte transfusions. Kolb HJ, et al. **Curr Opin Oncol** 1997 Mar; 9(2):139–45 (53 ref.)

Immune therapy with macrophages: present status and critical requirements for implementation. Bartoleyns J, et al. **Immunobiology** 1996 Oct;195(4–5):550–62 (50 ref.)

Adoptive cell therapy with donor lymphocytes for EBV-associated lymphomas developing after allogeneic marrow transplants. O'Reilly RJ, et al. **Important Adv Oncol** 1996;:149-66 (172 ref.)
Human tumor antigens recognized by T lymphocytes: implications for cancer therapy. Wang RF, et al. **J Leukoc Biol** 1996 Sep;60(3):296-309 (120 ref.)
Adoptive immunotherapy for Epstein-Barr virus-related lymphoma. Smith CA, et al. **Leuk Lymphoma** 1996 Oct; 23(3-4):213-20 (31 ref.)
Adoptive immunotherapy of malignant glioma using tumor-sensitized T lymphocytes. Merchant RE, et al. **Neurol Res** 1997 Apr;19(2):145-52 (11 ref.)
Cytotoxic lymphocytes: redirecting the cell-mediated immune response for the therapy of cancer. Kershaw MH, et al. **Ther Immunol** 1995 Jun;2(3):173-81 (80 ref.)
[Adoptive immunotherapy for pancreatic cancer, using MUC1 specific CTL] Masaki Y, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1679-80 (3 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Therapy with cultured T cells: principles revisited. Cheever MA, et al. **Immunol Rev** 1997 Jun;157:177-94 (56 ref.)
Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloid leukemia. Falkenburg JH, et al. **Immunol Rev** 1997 Jun;157:223-30 (71 ref.)
Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Heslop HE, et al. **Immunol Rev** 1997 Jun;157:217-22 (39 ref.)
Cellular immunotherapy and autologous transplantation for hematologic malignancy. Margolin KA, et al. **Immunol Rev** 1997 Jun;157:231-40 (83 ref.)
Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. O'Reilly RJ, et al. **Immunol Rev** 1997 Jun;157:195-216 (186 ref.)
Specific cytotoxic T lymphocytes in gene therapy. Altenschmidt U, et al. **J Mol Med** 1997 Apr;75(4):259-66 (76 ref.)
The T-body approach: potential for cancer immunotherapy. Eshhar Z, et al. **Springer Semin Immunopathol** 1996; 18(2):199-209 (31 ref.)
[Adoptive immune therapy using EBV-specific CTL] Kuzushima K, et al. **Nippon Rinsho** 1997 Feb;55(2):473-8 (17 ref.) (Eng. Abstr.) **(Jpn)**

TRENDS

Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Goulmy E. **Immunol Rev** 1997 Jun;157:125-40 (165 ref.)

IMMUNOTHERAPY, ALLERGEN see **DESENSITIZATION, IMMUNOLOGIC**

IMMUNOTHERAPY, PASSIVE see **IMMUNIZATION, PASSIVE**

IMMUNOTOXINS

Recent advances in the uses and applications of ribosome-inactivating proteins from plants. Girbés T, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 Jun;42(4):461-71 (122 ref.)
Perspectives on immunotoxicity regulatory guidelines. Harling RJ. **Inflamm Res** 1996 Dec;45 Suppl 2:S69-73 (14 ref.)
Antigen-specific agents in development. Sznol M, et al. **Semin Oncol** 1997 Apr;24(2):173-86 (120 ref.)
Genetic engineering of immunotoxins. Chandler JC, et al. **Semin Pediatr Surg** 1996 Aug;5(3):206-11 (30 ref.)

PHARMACOLOGY

Preclinical testing of an anti-erbB-2 recombinant toxin. King CR, et al. **Breast Cancer Res Treat** 1996;38(1):19-25 (17 ref.)
Alterations in fetal thymic and liver hematopoietic cells as indicators of exposure to developmental immunotoxicants. Holladay SD, et al. **Environ Health Perspect** 1996 Aug;104 Suppl 4:809-13 (34 ref.)
Immunotoxins for the treatment of B-cell lymphomas. Ghetie MA, et al. **Mol Med** 1997 Jul;3(7):420-7 (43 ref.)
[Targeted action proteins as potential drugs] Anisimova VA, et al. **Vestn Ross Akad Med Nauk** 1997;(6):52-9 (88 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Development of immunotoxins for potential clinical use in Hodgkin's disease. Barth S, et al. **Ann Oncol** 1996;7 Suppl 4:135-41 (58 ref.)
The emerging role of immunotoxins in leukemia and lymphoma. Winkler U, et al. **Ann Oncol** 1997;8 Suppl 1:139-46 (46 ref.)
Immunotoxins: an update. Thrush GR, et al. **Annu Rev Immunol** 1996;14:49-71 (167 ref.)
Therapeutic potential of anti-HIV immunotoxins. Pincus SH. **Antiviral Res** 1996 Dec;33(1):1-9 (39 ref.)
Enhancement of immunotoxin activity using chemical and biological reagents. Wu M. **Br J Cancer** 1997;75(9):1347-55 (51 ref.)
Recombinant immunotoxins. Pastan I, et al. **Breast Cancer Res Treat** 1996;38(1):3-9 (25 ref.)
Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Nichols J, et al. **Eur J Cancer** 1997 Jan;33 Suppl 1:S34-6 (27 ref.)
Monoclonal antibody-conjugated immunotherapy of cancer. Imai K, et al. **Int Rev Immunol** 1997;14(2-3):213-27 (31 ref.)
Immunotoxins for the treatment of B-cell lymphomas. Ghetie MA, et al. **Mol Med** 1997 Jul;3(7):420-7 (43 ref.)
Immunotoxin therapy. Hall WA. **Neurosurg Clin N Am** 1996 Jul;7(3):537-46 (28 ref.)
[A new strategy for treating small cell lung cancer] Ueda R, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec; 34 Suppl:111-4 (7 ref.) (Eng. Abstr.) **(Jpn)**

TOXICITY

The popliteal lymph node assay in mice: screening of drugs and other chemicals for immunotoxic hazard. Goebel C, et al. **Inflamm Res** 1996 Dec;45 Suppl 2:S85-90 (50 ref.)
Pathology of toxic effects on the immune system. Gopinath C. **Inflamm Res** 1996 Dec;45 Suppl 2:S74-8 (14 ref.)
Immunolesion by 192IgG-saporin of rat basal forebrain cholinergic system: a useful tool to produce cortical cholinergic dysfunction. Schliebs R, et al. **Prog Brain Res** 1996;109:253-64 (57 ref.)

IMP DEHYDROGENASE

ANTAGONISTS & INHIBITORS

NAD-analogues as potential anticancer agents: conformational restrictions as basis for selectivity. Pankiewicz KW, et al. **Acta Biochim Pol** 1996;43(1):183-93 (72 ref.)
A review of clinical experience with the novel immunosuppressive drug mycophenolate mofetil in renal transplantation. Behrend M. **Clin Nephrol** 1996 May; 45(5):336-41 (13 ref.)
IMP dehydrogenase as a target of antitumor and antiviral chemotherapy. Franchetti P, et al. **Farmaco** 1996 Jul; 51(7):457-69 (141 ref.)

METABOLISM

Inosine monophosphate dehydrogenase expression: transcriptional regulation of the type I and type II genes. Zimmermann A, et al. **Adv Enzyme Regul** 1996;36:75-84 (26 ref.)

PHYSIOLOGY

[Role of IMP dehydrogenase on cell differentiation] Tsutani H. **Rinsho Ketsueki** 1996 Sep;37(9):755-9 (15 ref.) **(Jpn)**

IMP NUCLEOTIDASE see **5'-NUCLEOTIDASE**

IMP PHOSPHATASE see **5'-NUCLEOTIDASE**

IMP PYROPHOSPHORYLASE see **HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE**

IMPEDANCE see **ELECTRIC IMPEDANCE**

IMPEDANCE TESTS, ACOUSTIC see **ACOUSTIC IMPEDANCE TESTS**

IMPEDANCE, TRANSTHORACIC see **CARDIOGRAPHY, IMPEDANCE**

IMPETIGO

MICROBIOLOGY

[Causative agent of impetigo: staphylococcal exfoliative toxin and regulation of the toxin production in Staphylococcus aureus] Sakurai S. **Nippon Saikingaku Zasshi** 1996 Aug; 51(3):813-22 (15 ref.) **(Jpn)**

IMPETIGO CONTAGIOSA see **IMPETIGO**

IMPLANT, COCHLEAR see **COCHLEAR IMPLANT**

IMPLANT, MIDDLE EAR see **OSSICULAR REPLACEMENT PROSTHESIS**

IMPLANT RADIOTHERAPY see **BRACHYTHERAPY**

IMPLANT-SUPPORTED DENTAL PROSTHESIS see **DENTAL PROSTHESIS, IMPLANT-SUPPORTED**

IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS see **DEFIBRILLATORS, IMPLANTABLE**

IMPLANTABLE CATHETERS see **CATHETERS, INDWELLING**

IMPLANTABLE DEFIBRILLATORS see **DEFIBRILLATORS, IMPLANTABLE**

IMPLANTABLE INFUSION PUMPS see **INFUSION PUMPS, IMPLANTABLE**

IMPLANTATION, BLASTOCYST see **OVUM IMPLANTATION**

IMPLANTS, ARTIFICIAL

see related
BIOCOMPATIBLE MATERIALS
BIOFILMS

Postpneumonectomy interatrial right-to-left shunt: successful percutaneous treatment. Godart F, et al. **Ann Thorac Surg** 1997 Sep;64(3):834-6 (7 ref.)
Absorbable polyglycolide devices in trauma and bone surgery. Ashammakhi N, et al. **Biomaterials** 1997 Jan; 18(1):3-9 (101 ref.)
Toward development of an implantable tissue engineered liver. Davis MW, et al. **Biomaterials** 1996 Feb;17(3):365-72 (74 ref.)
Studies and applications of NiTi shape memory alloys in the medical field in China. Dai K, et al. **Biomed Mater Eng** 1996;6(4):233-40 (40 ref.)
Microrough surface of metallic biomaterials: a literature review. Wen X, et al. **Biomed Mater Eng** 1996;6(3):173-89 (97 ref.)
Revision of failed prosthetic anterior cruciate ligament reconstruction. Greis PE, et al. **Clin Orthop** 1996 Apr; (325):78-90 (34 ref.)
Intervertebral disc prosthesis. Results and prospects for the year 2000. Lemaire JP, et al. **Clin Orthop** 1997 Apr; (337):64-76 (66 ref.)
Digital implant arthroplasty. Sgarlato TE, et al. **Clin Podiatr Med Surg** 1996 Apr;13(2):255-62 (12 ref.)
The role of implant surface characteristics in the healing of bone. Kieswetter K, et al. **Crit Rev Oral Biol Med** 1996; 7(4):329-45 (121 ref.)
Orthopedic implants: a guide to radiographic analysis. Goitz HT, et al. **Curr Probl Diagn Radiol** 1996 Jul-Aug; 25(4):109-68 (43 ref.)
Preclinical evaluation of Seprafilm bioresorbable membrane. Burns JW, et al. **Eur J Surg Suppl** 1997;(577):40-8 (21 ref.)
Arthrodesis of the first metatarsophalangeal joint to salvage failed silicone implant arthroplasty. Hecht PJ, et al. **Foot Ankle Int** 1997 Jul;18(7):383-90 (63 ref.)
Bioresorbable implants: applications in orthopaedic surgery. Blasier RD, et al. **Instr Course Lect** 1997;46:531-46 (64 ref.)
Intrastromal corneal ring technology. Krueger RR, et al. **Int Ophthalmol Clin** 1996 Fall;36(4):89-106 (20 ref.)
Electrosurgery and cardiac devices. Riordan AT, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 1):250-5 (40 ref.)
Recent developments of collagen-based materials for medical applications and drug delivery systems. Rao KP. **J Biomater Sci Polym Ed** 1995;7(7):623-45 (67 ref.)
Materials and design of spinal implants--a review. Martz EO, et al. **J Biomed Mater Res** 1997 Fall;38(3):267-88 (130 ref.)
Collagen-based devices for soft tissue repair. Pachence JM. **J Biomed Mater Res** 1996 Spring;33(1):35-40 (65 ref.)
Total hip arthroplasty with hydroxyapatite-coated prostheses. Jaffe WL, et al. **J Bone Joint Surg Am** 1996 Dec;78(12):1918-34 (187 ref.)
Coralline hydroxyapatite: a bone graft alternative in foot and ankle surgery. Rahimi F, et al. **J Foot Ankle Surg** 1997 May-Jun;36(3):192-203; discussion 255-6 (27 ref.)
Electrical stimulation to restore respiration. Creasey G, et al. **J Rehabil Res Dev** 1996 Apr;33(2):123-32 (40 ref.)
Challenges to clinical deployment of upper limb neuroprostheses. Triolo R, et al. **J Rehabil Res Dev** 1996 Apr;33(2):111-22 (19 ref.)
Hemorrhagic complications in association with silastic dural substitute: pediatric and adult case reports with a review of the literature. Robertson SC, et al. **Neurosurgery** 1997 Jan;40(1):201-5; discussion 205-6 (28 ref.)
Evisceration with hydroxyapatite implant. Surgical technique and review of 31 case reports. Kostick DA, et al. **Ophthalmology** 1995 Oct;102(10):1542-8; discussion 1548-9 (33 ref.)
Temporomandibular joint devices: treatment factors and outcomes. Wolford LM. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jan;83(1):143-9 (149 ref.)
Titanium-anchored prostheses in otology. Burton MJ, et al. **Otolaryngol Clin North Am** 1996 Apr;29(2):301-10 (32 ref.)
State of the art on the development of the implantable hearing device for partial hearing loss. Maniglia AJ. **Otolaryngol Clin North Am** 1996 Apr;29(2):225-43 (41 ref.)
Use of hydroxyapatite for reconstruction after surgical removal of intraosseous hemangioma in the zygomatic bone. Hirano S, et al. **Plast Reconstr Surg** 1997 Jul; 100(1):86-90 (18 ref.)
Aspects of immunoprotection of islets. van Schilfgaarde R, et al. **Transplant Proc** 1996 Dec;28(6):3516-7 (11 ref.)
Enhanced limb salvage for peripheral vascular disease with the use of spinal cord stimulation. Huber SJ, et al. **W V Med J** 1996 Mar-Apr;92(2):89-91 (14 ref.)
[Advances in the experimental studies of hydroxylapatite-based composites] Hou W, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1995 Jul;11(4):304-6 (24 ref.) **(Chi)**
[The intrastromal corneal ring (KeraVision Ring, ICR, ICRS). A modern method for correcting minor myopia] Grabner G, et al. **Wien Med Wochenschr** 1997; 147(12-13):309-21 (45 ref.) (Eng. Abstr.) **(Ger)**
[Implantable bone conduction hearing aids] Matschke RG.

IMPLANTS, ARTIFICIAL

Wien Med Wochenschr 1997;147(10):239–43 (17 ref.) (Eng. Abstr.) **(Ger)**

[Forum: Clips and coils in aneurysm treatment] Spetzger U, et al. **Wien Med Wochenschr** 1997;147(7–8):172–7 (62 ref.) (Eng. Abstr.) **(Ger)**

[Implants in urology] Huschke T, et al. **Z Arztl Fortbild (Jena)** 1997 Jan;90(8):725–31 (0 ref.) (Eng. Abstr.) **(Ger)**

[Is It possible to accomplish artificial heart within 10 years] Takano H. **Kyobu Geka** 1997 Jan;50(1):13–6 (14 ref.) **(Jpn)**

[Comparative characteristic of synthetic materials using for forming motion-support stump] Filatova IA, et al. **Vestn Oftalmol** 1996 Jul–Aug;112(3):33–5 (55 ref.) **(Rus)**

ADVERSE EFFECTS

Severe hemolysis following partial coil-occlusion of patent ductus arteriosus. Henry G, et al. **Cathet Cardiovasc Diagn** 1996 Dec;39(4):410–2 (8 ref.)

Allergy to silicone: is it real? Finegold I. **Compr Ther** 1996 Jun;22(6):393–8 (36 ref.)

Infection after open reduction and internal fixation with dynamic compression plates--clinical and experimental data. Arens S, et al. **Injury** 1996;27 Suppl 3:SC27–33 (29 ref.)

The influence of the chemical composition and surface of the implant on infection. Cordero J, et al. **Injury** 1996;27 Suppl 3:SC34–7 (28 ref.)

Relevance, pathogenicity and virulence of microorganisms in implant related infections. Printzen G. **Injury** 1996;27 Suppl 3:SC9–15 (37 ref.)

Metal implants and surface reactions. Steinemann SG. **Injury** 1996;27 Suppl 3:SC16–22 (22 ref.)

Implantable materials and infection. Williams DF. **Injury** 1996;27 Suppl 3:SC1–4 (9 ref.)

Osteolysis caused by polymethylmethacrylate (PMMA). Eftekhar NS. **Instr Course Lect** 1994;43:263–75 (53 ref.)

Complications of hydroxyapatite orbital implants. A review of 100 consecutive cases and a comparison of Dexon mesh (polyglycolic acid) with scleral wrapping. Oestreicher JH, et al. **Ophthalmology** 1997 Feb;104(2):324–9 (20 ref.)

MICROBIOLOGY

Host–bacteria interactions in foreign body infections. François P, et al. **Infect Control Hosp Epidemiol** 1996 Aug; 17(8):514–20 (63 ref.)

SUPPLY & DISTRIBUTION

The medical device directives and their impact on the development and manufacturing of medical implants. Crisp S. **Proc Inst Mech Eng [H]** 1996;210(4):233–9 (17 ref.)

IMPLANTS, BREAST see **BREAST IMPLANTS**

IMPLANTS, DENTAL see **DENTAL IMPLANTS**

IMPOTENCE

[Impotence: doctor's dream, patient's nightmare] Bar-On E, et al. **Harefuah** 1997 Apr 15;132(8):573–8 (39 ref.) **(Heb)**

DIAGNOSIS

Nitric oxide donor, linsidomine chlorhydrate (SIN-1), in the diagnosis and treatment of erectile dysfunction: critical appraisal and review of the literature. Wegner HE, et al. **Int Urol Nephrol** 1995;27(5):621–8 (29 ref.)

DRUG THERAPY

Drugs for the treatment of impotence. Garcia-Reboll L, et al. **Drugs Aging** 1997 Aug;11(2):140–51 (98 ref.)

Oral treatments for erectile dysfunction. Riley A. **Int J STD AIDS** 1996;7 Suppl 3:16–8 (12 ref.)

Nitric oxide donor, linsidomine chlorhydrate (SIN-1), in the diagnosis and treatment of erectile dysfunction: critical appraisal and review of the literature. Wegner HE, et al. **Int Urol Nephrol** 1995;27(5):621–8 (29 ref.)

Pharmacotherapy in erectile dysfunction agents for self-injection programs and alternative application models. Hedlund H, et al. **Scand J Urol Nephrol Suppl** 1996; 179:129–38 (78 ref.)

Intracavernous pharmacotherapy. Truss MC, et al. **World J Urol** 1997;15(1):71–7 (109 ref.)

[Is an auto-injector useful in the treatment of erectile insufficiency using intracavernous injection?] Amar E, et al. **Prog Urol** 1997 Jun;7(3):377–83 (12 ref.) (Eng. Abstr.) **(Fre)**

[Treatment per os of disorders of erection] Giuliano F. **Prog Urol** 1997 Feb;7(1):108–9 (15 ref.) **(Fre)**

[Treatment of erectile disorders with androgens: When? How?] Tostain J, et al. **Prog Urol** 1997 Apr;7(2):314–9 (18 ref.) (Eng. Abstr.) **(Fre)**

[Intracavernous injections and new medical treatments of impotence] Virag R. **Rev Med Interne** 1997;18 Suppl 1:31s–35s (13 ref.) (Eng. Abstr.) **(Fre)**

[Pharmacological therapy in erectile dysfunction--current standards and new viewpoint] Schultheiss D, et al. **Wien Med Wochenschr** 1997;147(4–5):102–4 (33 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

The aetiology and management of erectile, ejaculatory, and fertility problems in men with diabetes mellitus. Dunsmuir WD, et al. **Diabet Med** 1996 Aug;13(8):700–8 (96 ref.)

Diabetic sexual dysfunction. Hakim LS, et al. **Endocrinol Metab Clin North Am** 1996 Jun;25(2):379–400 (133 ref.)

Autonomic nervous system disorders and erectile dysfunction. Mathias CJ. **Int J STD AIDS** 1996;7 Suppl 3:5–8 (4 ref.)

[Treatment of erectile disorders with androgens: When? How?] Tostain J, et al. **Prog Urol** 1997 Apr;7(2):314–9 (18 ref.) (Eng. Abstr.) **(Fre)**

[Andrological data on male sexuality in the elderly] Andrianne R. **Rev Med Liege** 1997 Apr;52(4):221–3 (0 ref.) **(Fre)**

[Impotence in diabetic men] Gruenwald I, et al. **Harefuah** 1996 Dec 1;131(11):516–9 (24 ref.) **(Heb)**

PHYSIOPATHOLOGY

Clinical aspects of erectile dysfunction. Dinsmore WW. **Int J STD AIDS** 1996;7 Suppl 3:2–4 (3 ref.)

Neurological testing in erectile dysfunction. Diemont WL, et al. **J Androl** 1997 Jul–Aug;18(4):345–50 (38 ref.)

Evaluation of erectile dysfunction and sleep-related erections [see comments] Moore CA, et al. **J Psychosom Res** 1997 Jun;42(6):531–9 (32 ref.) Comment in: J Psychosom Res 1997 Jun;42(6):515–6.

Cardiovascular disease and sleep-related erections [see comments] Rosen RC, et al. **J Psychosom Res** 1997 Jun; 42(6):517–30 (25 ref.) Comment in: J Psychosom Res 1997 Jun;42(6):515–6.

Sexual functioning after multimodality treatment for disseminated nonseminomatous testicular germ cell tumor. van Basten JP, et al. **J Urol** 1997 Oct;158(4):1411–6 (47 ref.)

[Assessment of sensory thresholds of the penile dorsal nerve as screening technique for neurologic lesion in impotence] Salinas Casado J, et al. **Arch Esp Urol** 1997 Mar; 50(2):173–82 (20 ref.) (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Psychological management of erectile dysfunction and related disorders. O'Donoghue F. **Int J STD AIDS** 1996; 7 Suppl 3:9–12 (3 ref.)

Psychological subtypes of erectile dysfunction: results of statistically analyses and clinical practice. Hartmann U. **World J Urol** 1997;15(1):56–64 (12 ref.)

[Psychological aspects of erectile dysfunction] Seikowski K. **Wien Med Wochenschr** 1997;147(4–5):105–8 (24 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

[Surgical treatments of erectile impotence] Sarramon JP, et al. **Rev Med Interne** 1997;18 Suppl 1:36s–40s (31 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Impotence and its non-surgical management. Riley AJ, et al. **Br J Clin Pract** 1997 Mar;51(2):99–103, 105 (47 ref.)

Organic erectile dysfunction. Lewis RW. **Curr Ther Endocrinol Metab** 1997;6:366–70 (9 ref.)

The aetiology and management of erectile, ejaculatory, and fertility problems in men with diabetes mellitus. Dunsmuir WD, et al. **Diabet Med** 1996 Aug;13(8):700–8 (96 ref.)

Advances in the treatment of organic erectile dysfunction. Kim ED, et al. **Hosp Pract (Off Ed)** 1997 Apr 15; 32(4):101–4, 107–8, 113–4 passim (0 ref.)

Psychological management of erectile dysfunction and related disorders. O'Donoghue F. **Int J STD AIDS** 1996; 7 Suppl 3:9–12 (3 ref.)

External vacuum therapy for erectile dysfunction: use and results. Lewis RW, et al. **World J Urol** 1997;15(1):78–82 (23 ref.)

[Sexuality--an important factor for quality of life. Who should treat erectile dysfunction?] Hedelin H, et al. **Lakartidningen** 1997 Jul 9;94(28–29):2548–52 (5 ref.) **(Swe)**

IMPOTENCE, ARTERIOGENIC see **IMPOTENCE, VASCULOGENIC**

IMPOTENCE, VASCULOGENIC

DIAGNOSIS

[Diagnostic methods and therapeutic options in vasculogenic impotence] Pannone A, et al. **Minerva Chir** 1997 Jan–Feb; 52(1–2):75–92 (76 ref.) (Eng. Abstr.) **(Ita)**

[Radioisotope penography] Shirai M. **Nippon Rinsho** 1997 Apr;55 Suppl 2:390–2 (10 ref.) **(Jpn)**

DRUG THERAPY

Evidence and results obtained with a new trans-epidermal barrier (T.E.B.) drug in the medical treatment of vascular impotence. Curri SB, et al. **Boll Chim Farm** 1996 May; 135(5):316–34 (49 ref.)

PHYSIOPATHOLOGY

Evaluation of erectile dysfunction and sleep-related erections [see comments] Moore CA, et al. **J Psychosom Res** 1997 Jun;42(6):531–9 (32 ref.) Comment in: J Psychosom Res 1997 Jun;42(6):515–6.

Cardiovascular disease and sleep-related erections [see comments] Rosen RC, et al. **J Psychosom Res** 1997 Jun; 42(6):517–30 (25 ref.) Comment in: J Psychosom Res 1997 Jun;42(6):515–6.

[Drug treatment of sexual disorders in men (see comments)] Slob AK, et al. **Ned Tijdschr Geneeskd** 1996 Oct 12; 140(41):2029–32 (33 ref.) Comment in: Ned Tijdschr Geneeskd 1996 Dec 14;140(50):2528. **(Dut)**

RADIOGRAPHY

Radiologic evaluation of penile arterial anatomy in arteriogenic impotence. Wahl SI, et al. **Int J Impot Res** 1997 Jun;9(2):93–7 (23 ref.)

SURGERY

Vascular surgery for impotence: a review. DePalma RG. **Int J Impot Res** 1997 Jun;9(2):61–7 (76 ref.)

Has the efficacy of penile arterial by-pass surgery in the treatment of arteriogenic erectile dysfunction been determined? Vickers KE, et al. **Int J Impot Res** 1996 Dec; 8(4):247–51; discussion 251–3 (24 ref.)

THERAPY

[Diagnostic methods and therapeutic options in vasculogenic impotence] Pannone A, et al. **Minerva Chir** 1997 Jan–Feb; 52(1–2):75–92 (76 ref.) (Eng. Abstr.) **(Ita)**

ULTRASONOGRAPHY

Ultrasound evaluation of the penis for assessment of impotence. Connolly JA, et al. **J Clin Ultrasound** 1996 Oct; 24(8):481–6 (31 ref.)

IMPOTENCE, VENOGENIC see **IMPOTENCE, VASCULOGENIC**

IMPULSE CONTROL DISORDERS

see related
PARAPHILIAS
SUBSTANCE USE DISORDERS

Medical approaches to gambling issues--I: The medical condition. Miller MM. **Wis Med J** 1996 Sep;95(9):623–34 (34 ref.)

COMPLICATIONS

Schizophrenia and kleptomania: a case report--a biological link? Chong SA. **Ann Acad Med Singapore** 1995 Nov; 24(6):860–2 (23 ref.)

EPIDEMIOLOGY

Are impulse-control disorders related to bipolar disorder? McElroy SL, et al. **Compr Psychiatry** 1996 Jul–Aug; 37(4):229–40 (98 ref.)

PSYCHOLOGY

Phenomenology and psychopathology of uncontrolled buying. Lejoyeux M, et al. **Am J Psychiatry** 1996 Dec; 153(12):1524–9 (25 ref.)

[Impulsiveness and impulse control. On the psychological and psychopathological conceptualization] Herpertz S, et al. **Nervenarzt** 1997 Mar;68(3):171–83 (106 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Medical approaches to gambling issues--I: The medical condition. Miller MM. **Wis Med J** 1996 Sep;95(9):623–34 (34 ref.)

Medical approaches to gambling issues--II: The medical response. Miller MM. **Wis Med J** 1996 Sep;95(9):635–42 (60 ref.)

IMPULSE-RIDDEN PERSONALITY see **PERSONALITY DISORDERS**

IMPULSIVE BEHAVIOR

ETIOLOGY

MAOA deficiency and abnormal behaviour: perspectives on an association. Brunner HG. **Ciba Found Symp** 1996; 194:155–64; discussion 164–7 (39 ref.)

GENETICS

Direct analysis of candidate genes in impulsive behaviours. Goldman D, et al. **Ciba Found Symp** 1996;194:139–52; discussion 152–4 (73 ref.)

PHYSIOPATHOLOGY

The psychobiological model for impulsive unsocialized sensation seeking: a comparative approach. Zuckerman M. **Neuropsychobiology** 1996;34(3):125–9 (32 ref.)

PSYCHOLOGY

The psychobiological model for impulsive unsocialized sensation seeking: a comparative approach. Zuckerman M. **Neuropsychobiology** 1996;34(3):125–9 (32 ref.)

[Impulsiveness and impulse control. On the psychological and psychopathological conceptualization] Herpertz S, et al. **Nervenarzt** 1997 Mar;68(3):171–83 (106 ref.) (Eng. Abstr.) **(Ger)**

IN-HOSPITAL MORTALITY see **HOSPITAL MORTALITY**

IN SITU HYBRIDIZATION

Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part III. Proliferation in normal, injured and diseased tissue, growth factors, differentiation, DNA replication sites and in situ hybridization. Dolbeare F. **Histochem J** 1996 Aug;28(8):531–75 (539 ref.)

Detection of viral infections by in situ PCR: theoretical considerations and possible value in diagnostic pathology. Nuovo GJ. **J Clin Lab Anal** 1996;10(6):335–49 (30 ref.)

In situ hybridization: a new tool in molecular medicine. Charuruks N, et al. **J Med Assoc Thai** 1996 Jun; 79(6):374–81 (37 ref.)

mRNA in situ hybridization to in vitro cultured cells. Raap AK, et al. **Methods Mol Biol** 1997;75:367–75 (32 ref.)

Polymerase chain reaction and in situ hybridization: applications in toxicological pathology. Malarkey DE, et al. **Toxicol Pathol** 1996 Jan–Feb;24(1):13–23 (109 ref.)

[Detecting hepatitis C virus RNA by in situ hybridization: a critical analysis] Negro F, et al. **Gastroenterol Clin Biol** 1997;21(2):93–7 (58 ref.) **(Fre)**

[Recent molecular histochemistry and its application from localization to gene hunting] Kiyama H. **Nippon Rinsho** 1996 Feb;54(2):309–15 (6 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Lipopolysaccharide's role in the association of Salmonella cells to the mouse intestine studied by ribosomal in situ hybridization. Krogfelt KA, et al. **Adv Exp Med Biol** 1996; 408:123–8 (25 ref.)

An overview of immunological and genetic methods for detecting swine coronaviruses, transmissible gastroenteritis virus, and porcine respiratory coronavirus in tissues. Sirinarumitr T, et al. **Adv Exp Med Biol** 1997;412:37–46 (46 ref.)

In situ amplification in cytological preparations. O'Leary JJ, et al. **Cytopathology** 1997 Jun;8(3):148–60 (24 ref.)

RNA molecules lighting up under the microscope. Dirks RW. **Histochem Cell Biol** 1996 Aug;106(2):151–66 (104 ref.)

Non-isotopic electron microscope in situ hybridization for studying the functional sub-compartmentalization of the cell nucleus. Puvion-Dutilleul F, et al. **Histochem Cell Biol** 1996 Jul;106(1):59–78 (111 ref.)

Cytochemical detection systems for in situ hybridization, and the combination with immunocytochemistry, 'who is still afraid of red, green and blue?' Speel EJ, et al. **Histochem J** 1995 Nov;27(11):833–58 (212 ref.)

Detection of chromosome instability of tissue fields at risk: in situ hybridization. Hittelman WN, et al. **J Cell Biochem Suppl** 1996;25:57–62 (19 ref.)

In situ hybridization: methods and applications. Jin L, et al. **J Clin Lab Anal** 1997;11(1):2–9 (53 ref.)

Chromosome-specific PRINS. Charlieu JP, et al. **Methods Mol Biol** 1997;71:7–12 (11 ref.)

In situ PCR amplification of intracellular mRNA. Chen RH, et al. **Methods Mol Biol** 1997;71:123–32 (20 ref.)

Flow cytometry analysis of an in situ PCR for the detection of human immunodeficiency virus type-1 (HIV-1) proviral DNA. Gibellini DE, et al. **Methods Mol Biol** 1997; 71:113–22 (23 ref.)

Reverse transcriptase PCR in situ on cryopreserved tissue sections. Hendler FJ, et al. **Methods Mol Biol** 1997; 71:99–111 (9 ref.)

In situ PCR. An overview. Long AA, et al. **Methods Mol Biol** 1997;71:141–61 (82 ref.)

In situ hybridization. Mak JC, et al. **Methods Mol Biol** 1997; 83:81–9 (17 ref.)

In situ PCR to cells and to wax sections. An alternative to in situ hybridization for the detection of low copies of human papillomavirus and cytomegalovirus DNA. Mougin C, et al. **Methods Mol Biol** 1997;71:77–97 (44 ref.)

Bright-field microscopic detection of oligonucleotide PRINS-labeled DNA in chromosome preparations. Speel EJ, et al. **Methods Mol Biol** 1997;71:13–22 (21 ref.)

Direct in situ single-copy (DISC)-PCR. Troyer DL, et al. **Methods Mol Biol** 1997;71:71–6 (17 ref.)

Localized in situ amplification (LISA). PCR amplification of nucleic acid sequences in tissue sections. Tsongalis GJ. **Methods Mol Biol** 1997;71:133–9 (15 ref.)

Interphase cytogenetic analysis of solid tumors by non-isotopic DNA in situ hybridization. Alers JC, et al. **Prog Histochem Cytochem** 1996;31(3):1–133 (748 ref.)

[DNA subtraction in situ hybridization—new approaches of detecting genetic defects in surgical pathology specimens] Sasano H, et al. **Nippon Rinsho** 1996 Apr;54(4):944–8 (4 ref.) (Eng. Abstr.) **(Jpn)**

IN SITU HYBRIDIZATION, FLUORESCENCE

Primitive neuroectodermal tumor of the kidney confirmed by fluorescence in situ hybridization. Sheaff M, et al. **Am J Surg Pathol** 1997 Apr;21(4):461–8 (20 ref.)

Translocation t(10;11) involving the MLL gene in acute myeloid leukemia. Importance of fluorescence in situ hybridization (FISH) analysis. Berger R, et al. **Ann Genet** 1996;39(3):147–51 (39 ref.)

FISH technology in chromosome and genome research. Heng HH, et al. **Bioessays** 1997 Jan;19(1):75–84 (80 ref.)

Applications of fluorescence in situ hybridization techniques in cytopathology. Wolman SR. **Cancer** 1997 Aug 25; 81(4):193–7 (21 ref.)

Potential markers of aggressiveness in prostatic intraepithelial neoplasia detected by fluorescence in situ hybridization. Qian J, et al. **Eur Urol** 1996;30(2):177–84 (49 ref.)

Detection of numerical aberrations in hematologic neoplasias by fluorescence in situ hybridization. Cuneo A, et al. **Haematologica** 1997 Jan–Feb;82(1):85–90 (61 ref.)

Fluorescent in situ hybridization (FISH) for DNA probes in the interphase and metaphase stages of the cell cycle. Cannizzaro LA, et al. **Methods Mol Biol** 1997;75:313–22 (20 ref.)

Nomenclature systems for FISH-painted chromosome aberrations. Savage JR, et al. **Mutat Res** 1996 Nov; 366(2):153–61 (11 ref.)

FISHing among myeloproliferative disorders. Najfeld V. **Semin Hematol** 1997 Jan;34(1):55–63 (80 ref.)

[CGH (comparative genomic hybridization)] Sakamoto M, et al. **Nippon Rinsho** 1996 Apr;54(4):933–43 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Chromosome analysis and FISH method] Eguchi M, et al. **Rinsho Byori** 1996 Jun;44(6):541–7 (5 ref.) (Eng. Abstr.) **(Jpn)**

[The perspective on chromosomal painting (FISH)] Sasaki K. **Rinsho Byori** 1996 Feb;44(2):133–7 (2 ref.) (Eng. Abstr.) **(Jpn)**

[Applications of FISH method for diagnosis and pathophysiologic analysis in hematopoietic neoplasias] Kamada N. **Rinsho Ketsueki** 1996 Jun;37(6):467–71 (8 ref.) **(Jpn)**

[Recent progress in the analysis of the intranuclear organization of the animal cell genome by FISH] Okumura K. **Seikagaku** 1997 May;69(5):335–9 (15 ref.) **(Jpn)**

[Applications of fluorescence in situ hybridization in the study of hematologic neoplasms] Hernández JM, et al. **Sangre (Barc)** 1996 Aug;41(4):305–9 (38 ref.) **(Spa)**

METHODS

Multilocus FISH analysis [editorial; comment] Pagon RA. **Am J Hum Genet** 1997 Jul;61(1):16–7 (2 ref.) Comment on: Am J Hum Genet 1997 Jul;61(1):51–9.

Current applications of molecular cytogenetic technologies. Mark HF, et al. **Ann Clin Lab Sci** 1997 Jan–Feb;27(1):47–56 (53 ref.)

High-resolution fluorescence in situ hybridization: a new approach in genome mapping. Palotie A, et al. **Ann Med** 1996 Apr;28(2):101–6 (54 ref.)

Molecular cytogenetics of prostate cancer. Koivisto PA. **Crit Rev Oncog** 1996;7(3–4):143–50 (67 ref.)

Genetic probes in cytology: principles and applications. Wolman SR, et al. **Diagn Cytopathol** 1995 Dec;13(5):429–35 (13 ref.)

Fluorescence in situ hybridization (FISH) in cytogenetics of leukemia. Michalová K. **Folia Biol (Praha)** 1996; 42(6):311–4 (13 ref.)

RNA molecules lighting up under the microscope. Dirks RW. **Histochem Cell Biol** 1996 Aug;106(2):151–66 (104 ref.)

Oligonucleotide PRINS DNA synthesis. Gosden JR, et al. **Methods Mol Biol** 1997;71:1–6 (9 ref.)

Multiple sequential oligonucleotide primed in situ DNA syntheses (MULTI-PRINS). Gosden JR, et al. **Methods Mol Biol** 1997;71:39–44 (4 ref.)

Chromosomal PRINS DNA labeling combined with indirect immunocytochemistry. Mitchell AR. **Methods Mol Biol** 1997;71:61–70 (12 ref.)

Analysis of sperm aneuploidy by PRINS. Pellestor F, et al. **Methods Mol Biol** 1997;71:23–9 (12 ref.)

Oligonucleotide PRINS DNA synthesis on extended chromatin preparations. Shibasaki Y, et al. **Methods Mol Biol** 1997;71:45–51 (13 ref.)

Combined immunocytochemistry and PRINS DNA synthesis for simultaneous detection of phenotypic and genomic parameters in cells. Speel EJ, et al. **Methods Mol Biol** 1997; 71:53–9 (15 ref.)

PRINS DNA synthesis on frozen tissue sections. Speel EJ, et al. **Methods Mol Biol** 1997;71:31–7 (13 ref.)

Detection of chromosomes and estimation of aneuploidy in human spermatozoa using fluorescence in-situ hybridization. Downie SE, et al. **Mol Hum Reprod** 1997 Jul;3(7):585–98 (108 ref.)

Visual mapping by high resolution FISH. Heiskanen M, et al. **Trends Genet** 1996 Oct;12(10):379–82 (27 ref.)

[Comparative genomic hybridization. A screening method in genetic tumor diagnosis] Petersen I, et al. **Pathologe** 1996 Sep;17(5):333–41 (19 ref.) (Eng. Abstr.) **(Ger)**

[Application of high resolution FISH to genome analysis and cancer genetics] Inazawa J, et al. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(15 Suppl):2182–90 (21 ref.) **(Jpn)**

[The latest achievements of radiation cytogenetics in connection with the discovery of the method for the fluorescence hybridization in situ of the metaphase chromosomes of man and experimental animals using DNA probes (FISH)] Pilinskaia MA. **Tsitol Genet** 1996 Jul–Aug; 30(4):70–85 (74 ref.) (Eng. Abstr.) **(Rus)**

INADEQUATE PERSONALITY see **PERSONALITY DISORDERS**

INAPPROPRIATE ADH SYNDROME

CHEMICALLY INDUCED

Association of SIADH with selective serotonin reuptake inhibitors. Woo MH, et al. **Ann Pharmacother** 1997 Jan; 31(1):108–10 (32 ref.)

Fluoxetine and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) [see comments] Burke D, et al. **Aust N Z J Psychiatry** 1996 Apr;30(2):295–8 (13 ref.) Comment in: Aust N Z J Psychiatry 1997 Apr;31(2):306–7.

Drug-induced syndrome of inappropriate antidiuretic hormone secretion. Causes, diagnosis and management. Chan TY. **Drugs Aging** 1997 Jul;11(1):27–44 (211 ref.)

Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature. Bradley ME, et al. **Pharmacotherapy** 1996 Jul–Aug;16(4):680–3 (24 ref.)

DIAGNOSIS

SIADH and other hyponatremic disorders: diagnosis and therapeutic problems. Saito T. **Nippon Jinzo Gakkai Shi** 1996 Oct;38(10):429–34 (22 ref.)

[Progress in diagnosis and treatment of kidney diseases. IV. Abnormalities of renal tubular functions. 2. Inappropriate ADH syndrome] Saito T. **Nippon Naika Gakkai Zasshi** 1996 Oct 10;85(10):1705–10 (5 ref.) **(Jpn)**

DRUG THERAPY

[Progress in diagnosis and treatment of kidney diseases. IV. Abnormalities of renal tubular functions. 2. Inappropriate ADH syndrome] Saito T. **Nippon Naika Gakkai Zasshi** 1996 Oct 10;85(10):1705–10 (5 ref.) **(Jpn)**

ETIOLOGY

Cerebral salt wasting syndrome. Uygun MA, et al. **Neurosurg Rev** 1996;19(3):193–6 (10 ref.)

[Severe and unexpected occurrence of water-electrolyte disorders in the postoperative period] Nesa S, et al. **Acta Urol Belg** 1997 Jun;65(2):71–5 (11 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

An expanded view of SIADH, hyponatremia and hypouricemia [editorial] Maesaka JK. **Clin Nephrol** 1996 Aug;46(2):79–83 (26 ref.)

PHYSIOPATHOLOGY

Association of SIADH with selective serotonin reuptake inhibitors. Woo MH, et al. **Ann Pharmacother** 1997 Jan; 31(1):108–10 (32 ref.)

THERAPY

Association of SIADH with selective serotonin reuptake inhibitors. Woo MH, et al. **Ann Pharmacother** 1997 Jan; 31(1):108–10 (32 ref.)

Inappropriate antidiuretic hormone secretion. Miller M. **Curr Ther Endocrinol Metab** 1997;6:206–9 (16 ref.)

SIADH and other hyponatremic disorders: diagnosis and therapeutic problems. Saito T. **Nippon Jinzo Gakkai Shi** 1996 Oct;38(10):429–34 (22 ref.)

INBORN ERRORS OF METABOLISM see **METABOLISM, INBORN ERRORS**

INBREEDING

see related
CONSANGUINITY

INCENTIVE PLANS, PHYSICIAN see **PHYSICIAN INCENTIVE PLANS**

INCENTIVES see **MOTIVATION**

INCEST

PSYCHOLOGY

No more mother blaming: a feminist nursing perspective on the mother's role in father-daughter incest. Ehrmin JT. **Arch Psychiatr Nurs** 1996 Aug;10(4):252–60 (53 ref.)

An additional facet of the incest taboo: a protection of the mating-strategy template. Immerman RS, et al. **J Genet Psychol** 1997 Jun;158(2):151–64 (100 ref.)

INCIDENCE

[Prevalence and incidence. These (almost) unknowns] De

INCIDENCE

Amici D. **Minerva Anestesiol** 1996 Oct;62(10):343–8 (11 ref.) (Eng. Abstr.) **(Ita)**

INCIDENCE STUDIES see **COHORT STUDIES**

INCIDENT REPORTING, HOSPITAL see **RISK MANAGEMENT**

INCINERATION

LEGISLATION & JURISPRUDENCE

Health effects from hazardous waste incineration facilities: five case studies. Pleus RC, et al. **Toxicol Ind Health** 1996 Mar–Apr;12(2):277–87 (23 ref.)

INCIPIENT SCHIZOPHRENIA see **SCHIZOTYPAL PERSONALITY DISORDER**

INCISOR

Correction of deep overbite in adults. Nanda R.
Dent Clin North Am 1997 Jan;41(1):67–87 (14 ref.)

ABNORMALITIES

A central tubercle on the lingual surface of the upper lateral incisor: report of a case. Fukuta Y, et al.
J Nihon Univ Sch Dent 1997 Jun;39(2):86–8 (17 ref.)

CYTOLOGY

Apoptosis (programmed cell death) of transitional ameloblasts and MHC class II expression in rat incisors. Nishikawa S, et al. **Kaibogaku Zasshi** 1996 Dec; 71(6):597–603 (22 ref.)

INCLUSION BODIES

CHEMISTRY

Inclusion bodies and purification of proteins in biologically active forms. Mukhopadhyay A.
Adv Biochem Eng Biotechnol 1997;56:61–109 (160 ref.)
Hirano bodies and Alzheimer's disease. Mitake S, et al.
Kao Hsiung I Hsueh Ko Hsueh Tsa Chih 1997 Jan; 13(1):10–8 (63 ref.)

IMMUNOLOGY

[Usefulness of immunocytochemistry in the identification of Mallory bodies. Theoretical analysis about their formation] Siegmund I, et al. **Rev Med Chil** 1996 Oct;124(10):1193–9 (23 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Inclusion bodies and purification of proteins in biologically active forms. Mukhopadhyay A.
Adv Biochem Eng Biotechnol 1997;56:61–109 (160 ref.)
Origins and functions of the chlamydial inclusion. Hackstadt T, et al. **Trends Microbiol** 1997 Jul;5(7):288–93 (46 ref.)

PATHOLOGY

Intracytoplasmic chromophobe inclusion bodies in an anaplastic meningioma. Saito A, et al.
Acta Neuropathol (Berl) 1997 Apr;93(4):421–5 (9 ref.)
Gestational psittacosis: case report and literature review. Hyde SR, et al. **Mod Pathol** 1997 Jun;10(6):602–7 (16 ref.)
[Sporadic juvenile amyotrophic lateral sclerosis with neuronal basophil inclusion bodies—a nosologic entity?] Schmidbauer M, et al. **Wien Med Wochenschr** 1996; 146(9–10):201–2 (12 ref.) (Eng. Abstr.) **(Ger)**
[Glial cytoskeletal abnormality in neurodegenerative diseases: multiple system atrophy] Mizusawa H. **No To Shinkei** 1996 Oct;48(10):915–24 (55 ref.) **(Jpn)**
[Cytoplasmic inclusion bodies: a study in several diseases and a review of the literature] Scola RH, et al.
Arq Neuropsiquiatr 1996 Jun;54(2):245–59 (62 ref.) (Eng. Abstr.) **(Por)**

ULTRASTRUCTURE

Intranuclear dense bodies after metal intoxication: a review of ultrastructural and microanalytical findings. Boulahdour H, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 May; 42(3):421–9 (43 ref.)
Rabies: interactions between neurons and viruses. A review of the history of Negri inclusion bodies. Kristensson K, et al. **Neuropathol Appl Neurobiol** 1996 Jun;22(3):179–87 (30 ref.)

INCLUSION DISEASE see **CYTOMEGALOVIRUS INFECTIONS**

INCOME

Estimating the indirect cost of illness: an assessment of the forgone earnings approach. Glied S.
Am J Public Health 1996 Dec;86(12):1723–8 (14 ref.)
The class analysis of poverty: a response to Tony Novak [comment] Wright EO. **Int J Health Serv** 1996;26(2):371–9 (6 ref.) Comment on: Int J Health Serv 1995;25(1):85–100.
Comment on: Int J Health Serv 1996;26(1):187–95.
Going for the gold: the redistributive agenda behind market-based health care reform [see comments] Evans RG. **J Health Polit Policy Law** 1997 Apr;22(2):427–65 (46 ref.) Comment in: J Health Polit Policy Law 1997 Apr;22(2):467–73. Comment in: J Health Polit Policy Law 1997 Apr;22(2):475–96.

STATISTICS & NUMERICAL DATA

Earnings and schooling: an overview of economic research based on the Australian Twin Register. Miller P, et al.
Acta Genet Med Gemellol (Roma) 1996;45(4):417–29 (19 ref.)
Pension benefits among the aged: conflicting measures, unequal distributions. Woods JR. **Soc Secur Bull** 1996 Fall; 59(3):3–30 (30 ref.)

TRENDS

Income dynamics and health. Duncan GJ.
Int J Health Serv 1996;26(3):419–44 (57 ref.)

INCOMPETENCY, MENTAL see **MENTAL COMPETENCY**

INCOMPLETE VIRUSES see **DEFECTIVE VIRUSES**

INCONTINENTIA PIGMENTI

Incontinentia pigmenti. Francis JS, et al.
Semin Cutan Med Surg 1997 Mar;16(1):54–60 (59 ref.)
[Incontinentia pigmenti] Sasaki M.
Ryoikibetsu Shokogun Shirizu 1996;(15):323–5 (9 ref.) **(Jpn)**

DIAGNOSIS

Eosinophilic and neutrophilic spongiosis: clues to the diagnosis of immunobullous diseases and other inflammatory disorders. Machado-Pinto J, et al.
Semin Cutan Med Surg 1996 Dec;15(4):308–16 (45 ref.)

PATHOLOGY

Linear and whorled nevoid hypermelanosis versus incontinentia pigmenti: is pigmentary incontinence really a distinctive feature? Delaporte E, et al. **Dermatology** 1996; 192(1):70–2 (17 ref.)

INCONTINENTIA PIGMENTI ACHROMIANS see **PIGMENTATION DISORDERS**

INCUBATORS

STANDARDS

Modeling incubation temperature: the effects of incubator design, embryonic development, and egg size. French NA.
Poult Sci 1997 Jan;76(1):124–33 (52 ref.)

VETERINARY

Avian models in developmental biology. Dieterlen-Lièvre F. **Poult Sci** 1997 Jan;76(1):78–82 (44 ref.)

INDANS

THERAPEUTIC USE

Donepezil. Bryson HM, et al. **Drugs Aging** 1997 Mar; 10(3):234–9; discussion 240–1 (26 ref.)

INDEPENDENT LIVING see **ACTIVITIES OF DAILY LIVING**

INDEXING see **ABSTRACTING AND INDEXING**

INDIANS, NORTH AMERICAN

American Indian families and home care: macro social and cultural considerations. Kramer BJ. **Alaska Med** 1995 Oct–Dec;37(4):139–41 (41 ref.)
Anonymous HIV testing in the Canadian aboriginal population [see comments] Tseng AL.
Can Fam Physician 1996 Sep;42:1734–40 (21 ref.) Comment in: Can Fam Physician 1996 Dec;42:2341–2, 2344.
Aboriginal health [see comments] MacMillan HL, et al.
Can Med Assoc J 1996 Dec 1;155(11):1569–78 (85 ref.) Comment in: Can Med Assoc J 1996 Dec 1;155(11):1581–3.
Understanding and countering racism with first nations children in out-of-home care. Palmer S, et al.
Child Welfare 1996 Nov–Dec;75(6):709–25 (20 ref.)
Plasma lipids and lipoprotein concentrations among American Indians: comparison with the US population. Robbins DC, et al. **Curr Opin Lipidol** 1996 Aug;7(4):188–95 (41 ref.)
Impaired glucose tolerance in Pima Indians. Lillioja S.
Diabet Med 1996 Sep;13(9 Suppl 6):S127–32 (15 ref.)
Diabetes prevention in American Indians and Alaska Natives: where are we in 1994? Gohdes D, et al.
Diabetes Res Clin Pract 1996 Oct;34 Suppl:S95–100 (38 ref.)
An analysis of the food plants and drug plants of native North America. Moerman DE. **J Ethnopharmacol** 1996 May; 52(1):1–22 (69 ref.)
Assessing American Indian families [see comments] Seideman RY, et al. **MCN Am J Matern Child Nurs** 1996 Nov–Dec; 21(6):274–9 (38 ref.) Comment in: MCN Am J Matern Child Nurs 1997 Mar–Apr;22(2):72, 104.
American Indians and Alaska Natives—overview of the population. Rhoades ER. **Public Health Rep** 1996;111 Suppl 2:49–50 (9 ref.)
Clinical and pathological course of renal disease in non-insulin-dependent diabetes mellitus: the Pima Indian experience. Nelson RG, et al. **Semin Nephrol** 1997 Mar; 17(2):124–31 (33 ref.)

GENETICS

Distribution of four founding mtDNA haplogroups among Native North Americans. Lorenz JG, et al.
Am J Phys Anthropol 1996 Nov;101(3):307–23 (43 ref.)

INDIANS, SOUTH AMERICAN

Ritual and medicinal plants of the Ese'ejas of the Amazonian rainforest (Madre de Dios, Perú). Desmarchelier C, et al.
J Ethnopharmacol 1996 May;52(1):45–51 (20 ref.)
[Infection by hepatitis virus among the indigenous populations of South America: a review of the problem] Echevarría JM, et al. **Invest Clin** 1996 Sep;37(3):191–200 (22 ref.) (Eng. Abstr.) **(Spa)**

HISTORY

[Pre-Columbian paleopathology] Allison MJ.
Arch Biol Med Exp (Santiago) 1987;20(1):21–30 (8 ref.) **(Spa)**

INDICATORS AND REAGENTS

see related
CHELATING AGENTS
DYES
REAGENT KITS, DIAGNOSTIC
Screening for protein purification: is there an optimum adsorbent for every protein? Scopes RK.
J Mol Recognit 1996 Sep–Dec;9(5–6):305–8 (17 ref.)
[Practical use of luminogenic reagents specific for guanine-containing compounds] Kai M.
Tanpakushitsu Kakusan Koso 1997 Apr;42(5):777–83 (16 ref.) **(Jpn)**

CHEMISTRY

Analysis of derivatized peptides using high-performance liquid chromatography and capillary electrophoresis. De Antonis KM, et al. **Adv Chromatogr** 1997;37:425–52 (52 ref.)

INDIGENCY see **POVERTY**

INDIGENCY, MEDICAL see **MEDICAL INDIGENCY**

INDIGENT CARE see **MEDICAL INDIGENCY**

INDIGO CARMINE

DIAGNOSTIC USE

[Indigocarmine test] Kawabe K. **Nippon Rinsho** 1997 Apr;55 Suppl 2:608–9 (1 ref.) **(Jpn)**

INDIGOTINDISULFONATE SODIUM see **INDIGO CARMINE**

INDINAVIR

PHARMACOLOGY

HIV protease inhibitors. Carr A, et al. **AIDS** 1996;10 Suppl A:S151–7 (51 ref.)
Indinavir: a pharmacologic and clinical review of a new HIV protease inhibitor. Lacy MK, et al. **Conn Med** 1996 Dec; 60(12):723–7 (20 ref.)

INDIUM RADIOISOTOPES

DIAGNOSTIC USE

Enhanced bilateral somatostatin receptor expression in mediastinal lymph nodes ("chimney sign") in occult metastatic medullary thyroid cancer: a typical site of tumour manifestation? Behr TM, et al. **Eur J Nucl Med** 1997 Feb;24(2):184–91 (20 ref.)
Radiolabeled somatostatin analog scintigraphy in oncology and immune diseases: an overview. Kwekkeboom DJ, et al. **Eur Radiol** 1997;7(7):1103–9 (37 ref.)
Antimyosin antibody imaging in clinical myocarditis and cardiomyopathy: principle and application. Matsumori A, et al. **Int J Cardiol** 1996 May;54(2):183–90 (33 ref.)

INDIVIDUAL DIFFERENCES see **INDIVIDUALITY**

INDIVIDUALITY

A person-oriented approach in research on developmental psychopathology. Bergman LR, et al. **Dev Psychopathol** 1997 Spring;9(2):291–319 (120 ref.)
Neural regulation of viscera elicited by individual

interpretations of life experiences. Wolf S. **Integr Physiol Behav Sci** 1997 Apr-Jun;32(2):109-12 (14 ref.)

More theory-driven and less diagnosis-based behavior therapy. Eifert GH. **J Behav Ther Exp Psychiatry** 1996 Jun;27(2):75-86 (50 ref.)

Individualizing therapy, customizing clinical science. Evans IM. **J Behav Ther Exp Psychiatry** 1996 Jun;27(2):99-105 (24 ref.)

How can behavior therapy treat the same disorder with different techniques and different disorders with the same technique? [see comments] Gavino A, et al. **J Behav Ther Exp Psychiatry** 1996 Jun;27(2):107-17 (50 ref.) Comment in: J Behav Ther Exp Psychiatry 1996 Sep;27(3):311-2.

Tailor-made and standardized therapy: complementary tasks in behavior therapy. A contrarian view. Schulte D. **J Behav Ther Exp Psychiatry** 1996 Jun;27(2):119-26 (31 ref.)

Individual bioequivalence--a regulatory update [see comments] Chen ML. **J Biopharm Stat** 1997 Mar;7(1):5-11 (16 ref.) Comment in: J Biopharm Stat 1997 Mar;7(1):13-6.

Some issues for the consideration of individual bioequivalence. Endrenyi L. **J Biopharm Stat** 1997 Mar;7(1):35-9 (18 ref.)

Discussion of individual bioequivalence by M.-L. Chen. Gould AL. **J Biopharm Stat** 1997 Mar;7(1):23-9 (22 ref.)

Commentary on individual bioequivalence by M.-L. Chen [comment] Hauck WW, et al. **J Biopharm Stat** 1997 Mar;7(1):13-6 (12 ref.) Comment on: J Biopharm Stat 1997 Mar;7(1):5-11.

Some thoughts on individual bioequivalence. Liu J, et al. **J Biopharm Stat** 1997 Mar;7(1):41-8 (9 ref.)

Individual bioequivalence--a European perspective. Steinijans VW, et al. **J Biopharm Stat** 1997 Mar;7(1):31-4 (16 ref.)

A comment on so-called individual criteria of bioequivalence. Wellek S. **J Biopharm Stat** 1997 Mar;7(1):17-21 (14 ref.)

Analysis of affiliation-related traits in terms of the PAD Temperament Model. Mehrabian A. **J Psychol** 1997 Jan;131(1):101-17 (42 ref.)

Cloninger's tridimensional theory of personality and psychopathology: applications to substance use disorders. Howard MO, et al. **J Stud Alcohol** 1997 Jan;58(1):48-66 (55 ref.)

Formation and realization of individual experience. Alexandrov YuI, et al. **Neurosci Behav Physiol** 1997 Jul-Aug;27(4):441-54 (63 ref.)

Biochemical correlates of individual behavior. Gulyaeva NV, et al. **Neurosci Behav Physiol** 1997 Jul-Aug;27(4):462-9 (50 ref.)

Models of the self: self-construals and gender [see comments] Cross SE, et al. **Psychol Bull** 1997 Jul;122(1):5-37 (475 ref.) Comment in: Psychol Bull 1997 Jul;122(1):38-44; discussion 51-5. Comment in: Psychol Bull 1997 Jul;122(1):45-50; discussion 51-5.

Ecogenetics: from ecology to health. Nebert DW, et al. **Toxicol Ind Health** 1997 Mar-Jun;13(2-3):163-92 (59 ref.)

[HLA polymorphism: the origin of individual response in immunity] Takata H, et al. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(15 Suppl):2355-68 (49 ref.) **(Jpn)**

[Patterns in the shaping and realization of individual experience] Aleksandrov IuI, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 Mar-Apr;47(2):243-60 (63 ref.) (Eng. Abstr.) **(Rus)**

[The biochemical correlates of the individual typological characteristics of rat behavior] Guliaeva NV, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 Mar-Apr;47(2):329-38 (50 ref.) (Eng. Abstr.) **(Rus)**

INDIVIDUATION

A third individuation: immigration, identity, and the psychoanalytic process. Akhtar S. **J Am Psychoanal Assoc** 1995;43(4):1051-84 (145 ref.)

The analytic initiation: the effect of the archetype of initiation on the personal unconscious. Sullivan M. **J Anal Psychol** 1996 Oct;41(4):509-27 (13 ref.)

Formation and realization of individual experience. Alexandrov YuI, et al. **Neurosci Behav Physiol** 1997 Jul-Aug;27(4):441-54 (63 ref.)

[The contribution of fathers to the individuation process in adolescence] Shulman S. **Prax Kinderpsychol Kinderpsychiatr** 1997 May-Jun;46(5):321-37 (41 ref.) (Eng. Abstr.) **(Ger)**

[Patterns in the shaping and realization of individual experience] Aleksandrov IuI, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 Mar-Apr;47(2):243-60 (63 ref.) (Eng. Abstr.) **(Rus)**

INDOCYANINE GREEN

DIAGNOSTIC USE

[Indocyanine green and sulfobromophthalein tests] Sato T. **Nippon Rinsho** 1997 Apr;55 Suppl 2:177-9 (0 ref.) **(Jpn)**

INDOLEACETIC ACIDS

METABOLISM

Bacterial biosynthesis of indole-3-acetic acid. Patten CL, et al. **Can J Microbiol** 1996 Mar;42(3):207-20 (104 ref.)

The excessive production of indole-3-acetic acid and its significance in studies of the biosynthesis of this regulator of plant growth and development. Kawaguchi M, et al. **Plant Cell Physiol** 1996 Dec;37(8):1043-8 (56 ref.)

INDOLEAMINE 2,3-DIOXYGENASE see **TRYPTOPHAN OXYGENASE**

INDOLES

Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. Balfour JA, et al. **Drugs** 1997 Aug;54(2):273-98 (86 ref.)

ADVERSE EFFECTS

Perindopril-induced acute pancreatitis. Gallego-Rojo FJ, et al. **Dig Dis Sci** 1997 Aug;42(8):1789-91 (13 ref.)

Perindopril-associated pneumonitis. Benard A, et al. **Eur Respir J** 1996 Jun;9(6):1314-6 (10 ref.)

Side effect profiles of new antipsychotic agents. Casey DE. **J Clin Psychiatry** 1996;57 Suppl 11:40-5; discussion 46-52 (30 ref.)

Safety profile of the combination of verapamil and trandolapril. Holzgreve H. **J Hypertens Suppl** 1997 Mar;15(2):S51-3 (4 ref.)

CHEMICAL SYNTHESIS

[Highlights from 43 years of chemistry of naturally occurring nitrogen-containing heterocycles. (1). Syntheses and structure determinations of benzo[a]quinolizidine-type and indolo[2,3-a]quinolizidine-type alkaloids isolated from several plants] Fujii T. **Yakugaku Zasshi** 1996 May;116(5):335-54 (76 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Indole alkaloids and other constituents from the plant Securidaca longipedunculata fres. Wróbel JT, et al. **Adv Exp Med Biol** 1996;398:685-9 (7 ref.)

METABOLISM

Antioxidant properties of indole-3-pyruvic acid. Politi V, et al. **Adv Exp Med Biol** 1996;398:291-8 (38 ref.)

Interactions of procarcinogenic heterocyclic amines and indolocarbazoles with the dioxin receptor. Kleman M, et al. **Biol Chem** 1996 Nov;377(11):741-62 (270 ref.)

PHARMACOLOGY

Antioxidant properties of indole-3-pyruvic acid. Politi V, et al. **Adv Exp Med Biol** 1996;398:291-8 (38 ref.)

Pharmacology of the neurotransmitter release enhancer linopirdine (DuP 996), and insights into its mechanism of action. Aiken SP, et al. **Adv Pharmacol** 1996;35:349-84 (84 ref.)

Angiotensin-converting enzyme inhibitors and atherosclerosis: relevance of animal models to human disease. Fennessy PA, et al. **Clin Exp Pharmacol Physiol** 1996 Aug;23(8):S30-2 (14 ref.)

Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia. Plosker GL, et al. **Drugs** 1996 Mar;51(3):433-59 (130 ref.)

Effects of tenidap on intracellular signal transduction and the induction of proinflammatory cytokines: a review. Bondeson J. **Gen Pharmacol** 1996 Sep;27(6):943-56 (68 ref.)

Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9. Smitskamp-Wilms E, et al. **Gen Pharmacol** 1996 Apr;27(3):421-9 (88 ref.)

THERAPEUTIC USE

Current concepts in the management of hypercholesterolemia with an update on fluvastatin. Introduction. Cohen JD. **Am J Cardiol** 1996 Sep 26;78(6A):1-3 (26 ref.)

A review of current clinical findings with fluvastatin. Garnett WR. **Am J Cardiol** 1996 Sep 26;78(6A):20-5 (18 ref.)

Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal [see comments] Pedersen TR, et al. **Drug Saf** 1996 Jan;14(1):11-24 (94 ref.) Comment in: Drug Saf 1996 Jan;14(1):8-10.

Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia. Plosker GL, et al. **Drugs** 1996 Mar;51(3):433-59 (130 ref.)

Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. Tamminga CA, et al. **Int Clin Psychopharmacol** 1997 Feb;12 Suppl 1:S29-35 (7 ref.)

Treatment with verapamil and trandolapril in patients with congestive heart failure and myocardial infarction. The Danish Verapamil Infarction Trial (DAVIT Study Group). Hansen JF, et al. **J Hypertens Suppl** 1997 Mar;15(2):S119-22 (32 ref.)

Preclinical considerations and results with the combination of verapamil and trandolapril: blood pressure reduction and beyond. Kirchengast M. **J Hypertens Suppl** 1997 Mar;15(2):S27-33 (41 ref.)

Blood pressure control after acute stroke. Lees KR, et al. **J Hypertens Suppl** 1996 Dec;14(6):S35-8 (22 ref.)

Pharmacologic profile of ropinirole: a nonergoline dopamine agonist. Tulloch IF. **Neurology** 1997 Jul;49(1 Suppl 1):S58-62 (35 ref.)

INDOMETHACIN

ADMINISTRATION & DOSAGE

Inhibition of posterior capsule opacification by an intraocular-lens-bound sustained drug delivery system: an experimental animal study and literature review. Tetz MR, et al. **J Cataract Refract Surg** 1996 Oct;22(8):1070-8 (49 ref.)

Routine indomethacin prophylaxis: has the time come? [comment] Bada HS. **Pediatrics** 1996 Oct;98(4 Pt 1):784-5 (41 ref.) Comment on: Pediatrics 1996 Oct;98(4 Pt 1):714-8.

PHARMACOLOGY

Effects of indomethacin and local prostaglandin E2 on fracture healing in rabbits. Keller J. **Dan Med Bull** 1996 Sep;43(4):317-29 (177 ref.)

THERAPEUTIC USE

Emergency treatment of lithium-induced diabetes insipidus with nonsteroidal anti-inflammatory drugs. Lam SS, et al. **Ren Fail** 1997 Jan;19(1):183-8 (29 ref.)

INDOOR AIR POLLUTION see **AIR POLLUTION, INDOOR**

INDOOR AIR QUALITY see **AIR POLLUTION, INDOOR**

INDRI see **STREPSIRHINI**

INDRIIDAE see **STREPSIRHINI**

INDUCER CELLS see **T-LYMPHOCYTES, HELPER-INDUCER**

INDUSTRIAL ARTS see **TECHNOLOGY**

INDUSTRIAL HEALTH see **OCCUPATIONAL HEALTH**

INDUSTRIAL HYGIENE see **OCCUPATIONAL HEALTH**

INDUSTRIAL MEDICINE see **OCCUPATIONAL MEDICINE**

INDUSTRIAL MICROBIOLOGY

see related
GENETIC ENGINEERING

Microbial xylanolytic enzyme system: properties and applications. Bajpai P. **Adv Appl Microbiol** 1997;43:141-94 (266 ref.)

Old and new synthetic capacities of baker's yeast. D'Arrigo P, et al. **Adv Appl Microbiol** 1997;44:81-123 (110 ref.)

Biologically active fungal metabolites. Pearce C. **Adv Appl Microbiol** 1997;44:1-80 (200 ref.)

Biotechnology of lactic acid bacteria with special reference to bacteriophage resistance. Daly C, et al. **Antonie Van Leeuwenhoek** 1996 Oct;70(2-4):99-110 (118 ref.)

Genetic constitution of industrial yeast. Benítez T, et al. **Microbiologia** 1996 Sep;12(3):371-84 (41 ref.)

Recombinant Acremonium chrysogenum strains for the industrial production of cephalosporin. Díez B, et al. **Microbiologia** 1996 Sep;12(3):359-70 (58 ref.)

METHODS

Biotransformation for L-ephedrine production. Rogers PL, et al. **Adv Biochem Eng Biotechnol** 1997;56:33-59 (53 ref.)

Engineering antibiotic producers to overcome the limitations of classical strain improvement programs. Lal R, et al. **Crit Rev Microbiol** 1996;22(4):201-55 (222 ref.)

Merits of secretion of heterologous proteins from industrial microorganisms. Quax WJ. **Folia Microbiol (Praha)** 1997;42(2):99-103 (11 ref.)

INDUSTRIAL NURSING see **OCCUPATIONAL HEALTH NURSING**

INDUSTRIAL OILS

ANALYSIS

N-nitroso compounds in cosmetics, household commodities and cutting fluids. Eisenbrand G, et al. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:41-6 (31 ref.)

INDUSTRIAL WASTE

Microbiology and biodegradation of resin acids in pulp mill effluents: a minireview. Liss SN, et al. **Can J Microbiol** 1997 Jul;43(7):599-611 (100 ref.)

ANALYSIS

The longevity of minewater pollution: a basis for

decision-making. Younger PL. **Sci Total Environ** 1997 Feb 24;194-195:457-66 (26 ref.)

INDUSTRIALIZED COUNTRIES see **DEVELOPED COUNTRIES**

INDUSTRY

see related
COMMERCE
OCCUPATIONAL DISEASES
OCCUPATIONAL MEDICINE
WORKPLACE

Health effects of working in pulp and paper mills: exposure, obstructive airways diseases, hypersensitivity reactions, and cardiovascular diseases. Torén K, et al. **Am J Ind Med** 1996 Feb;29(2):111-22 (75 ref.)

Health effects of working in pulp and paper mills: malignant diseases [see comments] Torén K, et al. **Am J Ind Med** 1996 Feb;29(2):123-30 (48 ref.) Comment in: Am J Ind Med 1996 Nov;30(5):641.

Turning lipases into industrial biocatalysts. Bosley J. **Biochem Soc Trans** 1997 Feb;25(1):174-8 (25 ref.)

Effects of physical exertion on task performance in modern manufacturing: a taxonomy, a review, and a model. Mozrall JR, et al. **Ergonomics** 1996 Oct;39(10):1179-213 (100 ref.)

The chlorine controversy. Cap AP. **Int Arch Occup Environ Health** 1996;68(6):455-8 (19 ref.)

The role of industry in international animal agriculture. Peel CJ. **J Anim Sci** 1996 Jun;74(6):1382-5 (4 ref.)

Perspectives on Canadian field studies examining the potential of pulp and paper mill effluent to affect fish reproduction. Kovacs TG, et al. **J Toxicol Environ Health** 1997 Jul;51(4):305-52 (77 ref.)

Developing industrial-governmental-academic partnerships to address micronutrient malnutrition. Darnton-Hill I. **Nutr Rev** 1997 Mar;55(3):76-81 (24 ref.)

Sleep in Korea: a developmental perspective. Jeong DU. **Psychiatry Clin Neurosci** 1995 May;49(2):115-7 (5 ref.)

Power of one: nurses and tobacco control. Gallagher J, et al. **Semin Oncol Nurs** 1996 Nov;12(4):270-5 (14 ref.)

Alcohol and the workplace. Henderson M, et al. **WHO Reg Publ Eur Ser** 1996;67:1-100 (233 ref.)

[Hygienic aspects of health of children living in areas with developed gas chemical industries (review)] Savin VP, et al. **Gig Sanit** 1996 Jul-Aug;(4):24-7 (45 ref.) **(Rus)**

ECONOMICS

Impact of exporting dependence on livestock production systems, industry structure, and research. Macmillan KL, et al. **J Anim Sci** 1997 Feb;75(2):522-32 (25 ref.)

Defining total corporate health and safety costs--significance and impact. Review and recommendations. Brady W, et al. **J Occup Environ Med** 1997 Mar;39(3):224-31 (23 ref.)

LEGISLATION & JURISPRUDENCE

Cosmetic industry. Year in review: 1995/1996. Barker MO. **Am J Contact Dermat** 1996 Dec;7(4):251-3 (0 ref.)

Partnerships to protect. VanderMeer D. **Environ Health Perspect** 1996 Nov;104(11):1158-60 (0 ref.)

Injury, death, and the deregulation fetish: the politics of occupational safety regulation in U.K. manufacturing industries. Tombs S. **Int J Health Serv** 1996;26(2):309-29 (73 ref.)

Breaking through the tobacco industry's smoke screen: state lawsuits for reimbursement of medical expenses. Meade KE. **J Leg Med** 1996 Mar;17(1):113-41 (311 ref.)

TRENDS

Breaking through the glass ceiling: an industrial perspective. Harlander SK. **J Anim Sci** 1996 Nov;74(11):2849-54 (10 ref.)

INFANT

Breast-feeding and maternal drug use. Bailey B, et al. **Pediatr Clin North Am** 1997 Feb;44(1):41-54 (48 ref.)

INFANT BEHAVIOR

Conceptualizing genetic influences on early behavioral development. Goldsmith HH, et al. **Acta Paediatr Suppl** 1997 Jul;422:54-9 (25 ref.)

Offspring-induced nurturance: animal-human parallels. Stern JM. **Dev Psychobiol** 1997 Jul;31(1):19-37 (114 ref.)

INFANT CARE

see related
CHILD CARE
INTENSIVE CARE, NEONATAL

Principles and practice of parenteral nutrition in the neonatal period. Yu VY. **Acta Med Port** 1997 Feb-Mar; 10(2-3):185-96 (200 ref.)

Neonatal immunization [editorial] Isaacs D. **Curr Opin Pediatr** 1997 Feb;9(1):5-8 (24 ref.)

Report of the Pregnancy and Neonatal Care Group. Brown CJ, et al. **Diabet Med** 1996 Sep;13(9 Suppl 4):S43-53 (31 ref.)

Mothers' help seeking as care initiated in a social context. Pridham KF. **Image J Nurs Sch** 1997 Spring;29(1):65-70 (39 ref.)

Developmental aspects of kangaroo care. Ludington-Hoe SM, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Oct; 25(8):691-703 (78 ref.)

[Infant care practices and sudden infant death: a transcultural comparison (editorial)] Messer J, et al. **Arch Pediatr** 1997 Jan;4(1):3-7 (27 ref.) **(Fre)**

METHODS

Taking care of the preterm infant. Staines J, et al. **Practitioner** 1996 Oct;240(1567):592-6 (0 ref.)

[Kangaroo method and care] Vaivre-Douret L, et al. **Arch Pediatr** 1996 Dec;3(12):1262-9 (35 ref.) (Eng. Abstr.) **(Fre)**

INFANT DEVELOPMENT see **CHILD DEVELOPMENT**

INFANT FOOD

Lipid supply for infants with special needs. Koletzko B. **Eur J Med Res** 1997 Feb 21;2(2):69-73 (55 ref.)

Meeting lipid needs of infants with allergy and gastrointestinal diseases. Moran JR, et al. **Eur J Med Res** 1997 Feb 21;2(2):84-7 (15 ref.)

Rationale for the introduction of long chain polyunsaturated fatty acids and for concomitant increase in the level of vitamin E in infant formulas. Bendich A, et al. **Int J Vitam Nutr Res** 1997;67(4):213-31 (98 ref.)

Infants diets and insulin-dependent diabetes: evaluating the "cows' milk hypothesis" and a role for anti-bovine serum albumin immunity. Atkinson MA, et al. **J Am Coll Nutr** 1997 Aug;16(4):334-40 (56 ref.)

The role of modified food starches in baby food. Lanciers S, et al. **J La State Med Soc** 1997 Jun;149(6):211-4 (20 ref.)

Should infant formulas be supplemented with bioactive components and conditionally essential nutrients present in human milk? Hamosh M. **J Nutr** 1997 May;127(5 Suppl):971S-974S (38 ref.)

Which milk for the preterm infant? Tudehope DI, et al. **J Paediatr Child Health** 1996 Aug;32(4):275-7 (12 ref.)

Use of infant formulas in preventing or postponing atopic manifestations [editorial; comment] Kerner JA Jr. **J Pediatr Gastroenterol Nutr** 1997 Apr;24(4):442-6 (38 ref.) Comment on: J Pediatr Gastroenterol Nutr 1997 Apr;24(4):380-8.

Infant formulas: practical answers for common questions. Tigges BB. **Nurse Pract** 1997 Aug;22(8):70, 73, 77-80 passim (57 ref.)

Strategies for the prevention of iron deficiency: iron in infant formulas and baby foods. Ziegler EE, et al. **Nutr Rev** 1996 Nov;54(11 Pt 1):348-54 (32 ref.)

Complementary feeding in developing countries: factors affecting energy intake. Brown KH. **Proc Nutr Soc** 1997 Mar;56(1A):139-48 (50 ref.)

Weaning in Britain: practice, policy and problems. Wharton BA. **Proc Nutr Soc** 1997 Mar;56(1A):105-19 (48 ref.)

Limits for pesticide residues in infant foods: a safety-based proposal. Schilter B, et al. **Regul Toxicol Pharmacol** 1996 Oct;24(2 Pt 1):126-40 (96 ref.)

[Protein requirements of healthy infants and children. Comité de nutrition de la Société française de Pediatrie] **Arch Pediatr** 1997 Apr;4(4):373-82 (48 ref.) (Eng. Abstr.) **(Fre)**

[How can food supplementation to young children be improved?] Gerbouin-Rérolle P. **Sante** 1996 Jul-Aug; 6(4):229-35 (31 ref.) (Eng. Abstr.) **(Fre)**

[The effect of energy density and viscosity of porridges on the energy intake of infants] Trèche S. **Sante** 1996 Jul-Aug; 6(4):237-43 (31 ref.) (Eng. Abstr.) **(Fre)**

ANALYSIS

Protein and nonprotein nitrogen components in human milk, bovine milk, and infant formula: quantitative and qualitative aspects in infant nutrition. Rudloff S, et al. **J Pediatr Gastroenterol Nutr** 1997 Mar;24(3):328-44 (191 ref.)

The use of modular nutrients in pediatrics [published erratum appears in JPEN J Parenter Enteral Nutr 1996 Jul-Aug;20(4):305] [see comments] Davis A, et al. **JPEN J Parenter Enteral Nutr** 1996 May-Jun;20(3):228-36 (65 ref.) Comment in: JPEN J Parenter Enteral Nutr 1997 Mar-Apr;21(2):118.

[Past and present status in the design of infant formulas] Ronayne de Ferrer PA. **Arch Latinoam Nutr** 1995 Dec; 45(4):265-73 (67 ref.) (Eng. Abstr.) **(Spa)**

INFANT HEALTH see **INFANT WELFARE**

INFANT HEALTH SERVICES see **CHILD HEALTH SERVICES**

INFANT, LOW BIRTH WEIGHT

Early intervention for low-birth-weight premature infants: what can we achieve? McCarton CM, et al. **Ann Med** 1996 Jun;28(3):221-5 (47 ref.)

Parenteral nutrition in low-birth-weight infants. Heird WC, et al. **Annu Rev Nutr** 1996;16:471-99 (115 ref.)

Our strength for tomorrow: valuing our children. Levitt C, et al. **Can Fam Physician** 1997 Sep;43:1585-94 (30 ref.) **(Eng, Fre)**

From how small is too small to how much is too much. Ethical issues at the limits of neonatal viability. Peabody JL, et al. **Clin Perinatol** 1996 Sep;23(3):473-89 (75 ref.)

The problem of low birthweight, the cost and possibilities of prevention. Wynn M, et al. **Nutr Health** 1997; 11(3):159-84 (70 ref.)

Long-term perspective on premature infant outcome and contemporary intervention issues. Bennett FC, et al. **Semin Perinatol** 1997 Jun;21(3):190-201 (49 ref.)

[Birth defects. A public health problem in Mexico] Jurado-García E, et al. **Gac Med Mex** 1996 Mar-Apr; 132(2):141-82 (38 ref.) **(Spa)**

BLOOD

Practical issues in neonatal transfusion practice. Strauss RG. **Am J Clin Pathol** 1997 Apr;107(4 Suppl 1):S57-63 (32 ref.)

PSYCHOLOGY

[Kangaroo method and care] Vaivre-Douret L, et al. **Arch Pediatr** 1996 Dec;3(12):1262-9 (35 ref.) (Eng. Abstr.) **(Fre)**

INFANT MORTALITY

see related
FETAL DEATH

Stillbirths and rate of neonatal deaths in 76,761 postterm pregnancies in Sweden, 1982-1991: a register study. Ingemarsson I, et al. **Acta Obstet Gynecol Scand** 1997 Aug; 76(7):658-62 (23 ref.)

Reduction of maternal and perinatal mortality in rural and peri-urban settings: what works? Kwast BE. **Eur J Obstet Gynecol Reprod Biol** 1996 Oct;69(1):47-53 (22 ref.)

The outcome of multiple pregnancy. Doyle P. **Hum Reprod** 1996 Dec;11 Suppl 4:110-7; discussion 118-20 (32 ref.)

A review of perinatal autopsy rates worldwide, 1960s to 1990s [see comments] Khong TY. **Paediatr Perinat Epidemiol** 1996 Jan;10(1):97-105; discussion 106-9 (67 ref.) Comment in: Paediatr Perinat Epidemiol 1996 Jul;10(3):363-4.

Reproduction: a global nutritional challenge. Goldberg GR. **Proc Nutr Soc** 1997 Mar;56(1B):319-33 (58 ref.)

Child survival: physical vulnerability and resilience in adversity in the European past and the contemporary Third World. Caldwell P. **Soc Sci Med** 1996 Sep;43(5):609-19 (65 ref.)

Disease ecology and a reformist alternative: the case of infant mortality. Gesler WM, et al. **Soc Sci Med** 1997 Mar; 44(5):657-71 (106 ref.)

INFANT, NEWBORN

see related
ANIMALS, NEWBORN

Parental discretion in refusal of treatment for newborns. A real but limited right. Paris JJ, et al. **Clin Perinatol** 1996 Sep;23(3):573-81 (21 ref.)

Neonatal immunization [editorial] Isaacs D. **Curr Opin Pediatr** 1997 Feb;9(1):5-8 (24 ref.)

Skin care of the normal newborn. Liou LW, et al. **Cutis** 1997 Apr;59(4):171-4 (43 ref.)

Influences of the intrauterine metabolic environment on adult disease: what may we infer from size at birth? Purdy LP, et al. **Diabetologia** 1996 Sep;39(9):1126-30 (46 ref.)

The measurement of neonates. Wales JK, et al. **Horm Res** 1997;48 Suppl 1:2-10 (20 ref.)

Euthanasia in relation to newborn babies--a comparative study of the legal and ethical issues (II). Moor S. **Med Law** 1996;15(3):537-69 (108 ref.)

BLOOD

Antithrombin deficiency in special clinical syndromes--Part I: neonatal and pediatric/physiologic deficiency: extracorporeal membrane oxygenation. Shapiro A. **Semin Hematol** 1995 Oct;32(4 Suppl 2):33-6 (10 ref.)

GROWTH & DEVELOPMENT

Is milk-borne insulin-like growth factor-I essential for neonatal development? Burrin DG. **J Nutr** 1997 May;127(5 Suppl):975S-979S (47 ref.)

Development of the newborn GI tract and its relation to colostrum/milk intake: a review. Xu RJ. **Reprod Fertil Dev** 1996;8(1):35-48 (123 ref.)

IMMUNOLOGY

Do milk-borne cytokines and hormones influence neonatal immune cell function? Ellis LA, et al. **J Nutr** 1997 May; 127(5 Suppl):985S-988S (30 ref.)

[Rationale for a trial of prevention of perinatal transmission of hepatitis C via specific immunoglobulins] Soulié JC. **Transfus Clin Biol** 1997;4(2):213-9 (46 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Neonatal insulin secretion: implications for the programming of metabolic homeostasis. Aynsley-Green A, et al. **Acta Paediatr Jpn** 1997 Apr;39 Suppl 1:S21-5 (31 ref.)

Clinical pharmacokinetics of sedatives in neonates. Jacqz-Aigrain E, et al. **Clin Pharmacokinet** 1996 Dec; 31(6):423–43 (131 ref.)
Effects of milk and milk components on calcium, magnesium, and trace element absorption during infancy. Lönnerdal B. **Physiol Rev** 1997 Jul;77(3):643–69 (243 ref.)

PHYSIOLOGY

The role of prostaglandin receptors in regulating cerebral blood flow in the perinatal period. Chemtob S, et al. **Acta Paediatr** 1996 May;85(5):517–24 (107 ref.)
Long-term effects of intrauterine growth retardation. Kjellmer I, et al. **Acta Paediatr Suppl** 1997 Jul;422:83–4 (11 ref.)
Mechanisms of carotid chemoreceptor resetting after birth. In vitro studies. Carroll JL, et al. **Adv Exp Med Biol** 1996; 410:73–7 (19 ref.)
Fat digestion in the neonate. Manson WG, et al. **Arch Dis Child Fetal Neonatal Ed** 1997 May;76(3):F206–11 (49 ref.)
The infant cry: what can it tell us? Corwin MJ, et al. **Curr Probl Pediatr** 1996 Oct;26(9):325–34 (61 ref.)
Noninvasive brain monitoring with near infrared spectroscopy in newborn infants. Skov L. **Dan Med Bull** 1996 Jun;43(3):277–84 (100 ref.)
The evolution of clinical nutrition in the critical care of the neonate. Cotter R. **Equine Vet J Suppl** 1988 Sep;(5):17–8 (16 ref.)
Nutrition, temperature and homeostasis during perinatal development. Symonds ME, et al. **Exp Physiol** 1995 Nov; 80(6):907–40 (155 ref.)
Body temperature regulation in the newborn infant: interaction with sleep and clinical implications. Bach V, et al. **Neurophysiol Clin** 1996;26(6):379–402 (147 ref.)
Evoked potentials as predictors of outcome in neonatal intensive care unit survivors: review of the literature. Majnemer A, et al. **Pediatr Neurol** 1996 Apr;14(3):189–95 (75 ref.)
Neurophysiological assessment of brain function and maturation: I. A measure of brain adaptation in high risk infants. Scher MS. **Pediatr Neurol** 1997 Apr;16(3):191–8 (100 ref.)
Cerebral oxygenation and haemodynamics in the foetus and newborn infant. Wyatt JS. **Philos Trans R Soc Lond B Biol Sci** 1997 Jun 29; 352(1354):697–700 (30 ref.)

PSYCHOLOGY

Offspring-induced nurturance: animal-human parallels. Stern JM. **Dev Psychobiol** 1997 Jul;31(1):19–37 (114 ref.)
Pain in the newborn, a possible new starting point. McIntosh N. **Eur J Pediatr** 1997 Mar;156(3):173–7 (75 ref.)

URINE

Urea production in normal breast-fed infants measured with primed/intermittent oral doses of [15N, 15N]urea. Steinbrecher HA, et al. **Acta Paediatr** 1996 Jun; 85(6):656–62 (30 ref.)

INFANT, NEWBORN, DISEASES

see related
ABNORMALITIES

Screening for Wilms' tumor in children with high-risk congenital syndromes: considerations for an intervention trial. DeBaun MR, et al. **Med Pediatr Oncol** 1996 Nov; 27(5):415–21 (38 ref.)
Neonatal lupus syndromes. Tseng CE, et al. **Rheum Dis Clin North Am** 1997 Feb;23(1):31–54 (122 ref.)

CHEMICALLY INDUCED

The developmental toxicity of the H1 histamine antagonists. Lione A, et al. **Reprod Toxicol** 1996 Jul–Aug;10(4):247–55 (97 ref.)

DIAGNOSIS

Use of the laboratory in prediction of outcome in the high-risk newborn. Synnes AR. **Clin Chem** 1997 Jan; 43(1):243–8 (16 ref.)
Noma neonatorum. Prajapati NC, et al. **Indian Pediatr** 1995 Sep;32(9):1019–21 (9 ref.)
Neonatal dermatologic challenges. Johr RH, et al. **Pediatr Rev** 1997 Mar;18(3):86–94 (7 ref.)
[Intestinal emergencies in newborn infants] Brzezinska R. **Radiologe** 1997 Jun;37(6):432–8 (25 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

A review of teicoplanin in the treatment of serious neonatal infections. Fanos V, et al. **Eur J Pediatr** 1997 Jun; 156(6):423–7 (33 ref.)
Experimental and clinical effects of magnesium infusion in the treatment of neonatal pulmonary hypertension. Patole SK, et al. **Magnes Res** 1995 Dec;8(4):373–88 (160 ref.)

EPIDEMIOLOGY

Neonatology in the 'Pearl of the East'. Ng PC, et al. **J Paediatr Child Health** 1996 Oct;32(5):362–7 (47 ref.)

ETIOLOGY

Obstetric and perinatal outcome in pregnancies after assisted reproduction. Tanbo T, et al. **Curr Opin Obstet Gynecol** 1996 Jun;8(3):193–8 (43 ref.)
Management of Salmonella infections during pregnancy and puerperium. van der Klooster JM, et al. **Neth J Med** 1997 Aug;51(2):83–6 (24 ref.)
Role of the placenta in perinatal pathology (revisited). Altshuler G. **Pediatr Pathol Lab Med** 1996 Mar–Apr; 16(2):207–33 (101 ref.)

GENETICS

Three inherited disorders of calcium sensing. Pollak MR, et al. **Medicine (Baltimore)** 1996 May;75(3):115–23 (43 ref.)

METABOLISM

Distinctive aspects of metabolism and nutrition in infancy. Wharton BA, et al. **Clin Biochem** 1996 Oct;29(5):419–28 (22 ref.)

PATHOLOGY

Developmental neuropathology and impact of perinatal brain damage. II: white matter lesions of the neocortex. Marín-Padilla M. **J Neuropathol Exp Neurol** 1997 Mar; 56(3):219–35 (52 ref.)
Cytokines and perinatal brain injury. Silverstein FS, et al. **Neurochem Int** 1997 Apr–May;30(4–5):375–83 (56 ref.)
Neonatal acute hemorrhagic edema of childhood: case report and review of the English-language literature. Cunningham BB, et al. **Pediatr Dermatol** 1996 Jan–Feb;13(1):39–44 (10 ref.)
Role of the placenta in perinatal pathology (revisited). Altshuler G. **Pediatr Pathol Lab Med** 1996 Mar–Apr; 16(2):207–33 (101 ref.)

PREVENTION & CONTROL

Scientific basis for the content of routine antenatal care. II. Power to eliminate or alleviate adverse newborn outcomes; some special conditions and examinations. Bergsjø P, et al. **Acta Obstet Gynecol Scand** 1997 Jan;76(1):15–25 (82 ref.)

RADIOGRAPHY

Imaging the neonatal chest. Gibson AT, et al. **Clin Radiol** 1997 Mar;52(3):172–86 (139 ref.)

THERAPY

Mechanical ventilation of the newborn. An overview. Mammel MC, et al. **Clin Chest Med** 1996 Sep;17(3):603–13 (45 ref.)
The present and future role of gene therapy in the newborn. Tanswell AK, et al. **Curr Opin Pediatr** 1997 Apr;9(2):141–5 (30 ref.)
Current status of inhaled nitric oxide therapy in the perinatal period. Mupanemunda RH. **Early Hum Dev** 1997 Feb 20; 47(3):247–62 (72 ref.)
New modalities for treating neonatal infection. Bedford-Russell AR. **Eur J Pediatr** 1996 Aug;155 Suppl 2:S21–4 (23 ref.)
Gene therapy for newborns. Kohn DB, et al. **FASEB J** 1997 Jul;11(8):635–9 (20 ref.)
[Management of drug addict pregnant women and their children] Lejeune C, et al. **Arch Pediatr** 1997 Mar; 4(3):263–70 (71 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

[Ultrasonic screening of neonates] Jójárt G, et al. **Orv Hetil** 1996 Mar 24;137(12):623–7 (50 ref.) (Eng. Abstr.) **(Hun)**
[Cerebral Doppler ultrasonography in newborn infants] Luciano R, et al. **Rays** 1995 Oct–Dec;20(4):377–405 (104 ref.) (Eng. Abstr.) **(Ita)**

INFANT, NEWBORN, INTENSIVE CARE see **INTENSIVE CARE, NEONATAL**

INFANT, NEWBORN, SCREENING see **NEONATAL SCREENING**

INFANT NUTRITION

see related
CHILD NUTRITION
MILK
MILK, HUMAN

Infant feeding in the first year of age: composition and nutritional influence of the diet. Bellmonte G, et al. **Ann Ist Super Sanita** 1995;31(4):427–34 (57 ref.)
Artificial feeding: progresses and problems. Piacentini GL, et al. **Ann Ist Super Sanita** 1995;31(4):411–8 (10 ref.)
Advances in infant nutrition. Rubino A, et al. **Ann Ist Super Sanita** 1995;31(4):403–9 (39 ref.)
Assessing the effect of disease on nutrition of the preterm infant. Hay WW Jr. **Clin Biochem** 1996 Oct;29(5):399–417 (182 ref.)
Distinctive aspects of metabolism and nutrition in infancy. Wharton BA, et al. **Clin Biochem** 1996 Oct;29(5):419–28 (22 ref.)
Lipids in infant nutrition and their impact on later development. Lanting CI, et al. **Curr Opin Lipidol** 1996 Feb;7(1):43–7 (29 ref.)
Physical growth, infant nutrition, breastfeeding, and general nutrition. Rider E, et al. **Curr Opin Pediatr** 1996 Jun; 8(3):293–7 (26 ref.)
Infant nutrition: implication for somatic growth, adult onset diseases, and oral health. Sonis A, et al. **Curr Opin Pediatr** 1997 Jun;9(3):289–97 (53 ref.)
Nutritional management of the disabled child: the role of percutaneous endoscopic gastrostomy. Eltumi M, et al. **Dev Med Child Neurol** 1997 Jan;39(1):66–8 (33 ref.)
The evolution of clinical nutrition in the critical care of the neonate. Cotter R. **Equine Vet J Suppl** 1988 Sep;(5):17–8 (16 ref.)
Fruit juice consumption by infants and children: a review. Dennison BA. **J Am Coll Nutr** 1996 Oct;15(5 Suppl):4S–11S (36 ref.)
Which milk for the preterm infant? Tudehope DI, et al. **J Paediatr Child Health** 1996 Aug;32(4):275–7 (12 ref.)
Protein and nonprotein nitrogen components in human milk, bovine milk, and infant formula: quantitative and qualitative aspects in infant nutrition. Rudloff S, et al. **J Pediatr Gastroenterol Nutr** 1997 Mar;24(3):328–44 (191 ref.)
Prevention of food allergy and atopic disease. Zeiger RS. **J R Soc Med** 1997;90 Suppl 30:21–33 (90 ref.)
Dietary guidelines for infants: a timely reminder. Glinsmann WH, et al. **Nutr Rev** 1996 Feb;54(2 Pt 1):50–7 (39 ref.)
Weaning in Britain: practice, policy and problems. Wharton BA. **Proc Nutr Soc** 1997 Mar;56(1A):105–19 (48 ref.)
[The effect of energy density and viscosity of porridges on the energy intake of infants] Trèche S. **Sante** 1996 Jul–Aug; 6(4):237–43 (31 ref.) (Eng. Abstr.) **(Fre)**
[Nutritional needs of the preterm infant after hospital discharge] Zuppa AA, et al. **Minerva Pediatr** 1997 Mar; 49(3):79–88 (45 ref.) (Eng. Abstr.) **(Ita)**
[Long-term effect of nutrition in early infancy] Kolaček S, et al. **Lijec Vjesn** 1996 Mar–Apr;118(3–4):80–3 (64 ref.) (Eng. Abstr.) **(Scr)**

INFANT NUTRITION DISORDERS

see related
CHILD NUTRITION DISORDERS

COMPLICATIONS

What should obstetricians be doing about the Barker hypothesis? Fraser R Sr, et al. **Br J Obstet Gynaecol** 1997 Jun;104(6):645–7 (16 ref.)

INFANT, PREMATURE

Effectiveness of individualized neurodevelopmental care in the newborn intensive care unit (NICU). Als H, et al. **Acta Paediatr Suppl** 1996 Oct;416:21–30 (60 ref.)
Use of antenatal corticosteroids for fetal maturation in preterm infants. Anyaegbunam WI, et al. **Am Fam Physician** 1997 Sep 15;56(4):1093–6 (13 ref.)
Metabolic bone disease of prematurity. Backström MC, et al. **Ann Med** 1996 Aug;28(4):275–82 (73 ref.)
Early intervention for low-birth-weight premature infants: what can we achieve? McCarton CM, et al. **Ann Med** 1996 Jun;28(3):221–5 (47 ref.)
Parenting the prematurely born child. Holditch-Davis D, et al. **Annu Rev Nurs Res** 1997;15:3–34 (92 ref.)
Moebius syndrome: report of case. Lin KJ, et al. **ASDC J Dent Child** 1997 Jan–Feb;64(1):64–7 (24 ref.)
Surfactant therapy in the USA: trials and current routines. Soll RF. **Biol Neonate** 1997;71 Suppl 1:1–7 (39 ref.)
Nutrition and cognitive function. Gordon N. **Brain Dev** 1997 Apr;19(3):165–70 (44 ref.)
Our strength for tomorrow: valuing our children. Levitt C, et al. **Can Fam Physician** 1997 Sep;43:1585–94 (30 ref.) **(Eng, Fre)**
Neurodevelopmental outcome of hydrocephalus following intra-/periventricular hemorrhage in preterm infants: short- and long-term results. Resch B, et al. **Childs Nerv Syst** 1996 Jan;12(1):27–33 (48 ref.)
Assessing the effect of disease on nutrition of the preterm infant. Hay WW Jr. **Clin Biochem** 1996 Oct;29(5):399–417 (182 ref.)
Prediction of prematurity. Goepfert AR, et al. **Curr Opin Obstet Gynecol** 1996 Dec;8(6):417–27 (137 ref.)
Intraventricular hemorrhage in the preterm infant [published erratum appears in Early Hum Dev 1996 Jul 5;45(1–2):169] Vohr B, et al. **Early Hum Dev** 1996 Jan 5;44(1):1–16 (110 ref.)
Oxygen toxicity, free radicals and antioxidants in human disease: biochemical implications in atherosclerosis and the problems of premature neonates. Rice-Evans CA, et al. **Essays Biochem** 1995;29:39–63 (25 ref.)
Congenital bilateral agenesis of diaphragm: report of a case. Wang SM, et al. **Eur J Pediatr** 1997 Jul;156(7):572–4 (9 ref.)
Ureaplasma urealyticum colonization, prematurity and bronchopulmonary dysplasia. van Waarde WM, et al. **Eur Respir J** 1997 Apr;10(4):886–90 (26 ref.)
The measurement of neonates. Wales JK, et al. **Horm Res** 1997;48 Suppl 1:2–10 (20 ref.)
A family medicine approach to the premature infant [see comments] Dresden SM. **J Am Board Fam Pract** 1997 Mar–Apr;10(2):117–24 (28 ref.) Comment in: J Am Board Fam Pract 1997 Jul–Aug;10(4):310.

INFANT, PREMATURE

Acquired subglottic cysts in the low birth weight, pre-term infant. Tierney PA, et al. **J Laryngol Otol** 1997 May; 111(5):478-81 (17 ref.)
Coexisting left congenital diaphragmatic hernia and esophageal atresia with tracheoesophageal fistula: successful management in a premature neonate. Sapin E, et al. **J Pediatr Surg** 1996 Jul;31(7):989-91 (20 ref.)
Antenatal hormone therapy for improving the outcome of the preterm infant. Ballard RA, et al. **J Perinatol** 1996 Sep-Oct;16(5):390-6 (47 ref.)
Vancomycin cerebrospinal fluid concentrations after intravenous administration in premature infants. Reiter PD, et al. **J Perinatol** 1996 Sep-Oct;16(5):331-5 (14 ref.)
Abdominal lymphangioma in a preterm infant. Salvador A, et al. **J Perinatol** 1996 Jul-Aug;16(4):305-8 (9 ref.)
Preterm birth, cerebral palsy and magnesium [news] Goldenberg RL, et al. **Nat Med** 1997 Feb;3(2):146-7 (10 ref.)
Prevention of respiratory syncytial virus infection in high risk infants: consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulin. Meissner HC, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1059-68 (51 ref.)
The outcomes of very low birth weight infants: are we asking the right questions? McCormick MC. **Pediatrics** 1997 Jun; 99(6):869-76 (89 ref.)
Taking care of the preterm infant. Staines J, et al. **Practitioner** 1996 Oct;240(1567):592-6 (0 ref.)
The role of relationship-based developmentally supportive newborn intensive care in strengthening outcome of preterm infants. Als H, et al. **Semin Perinatol** 1997 Jun; 21(3):178-89 (84 ref.)
Parenting the prematurely born child: pathways of influence. Miles MS, et al. **Semin Perinatol** 1997 Jun;21(3):254-66 (105 ref.)
Priorities in neonatal care in developing countries. Ho NK. **Singapore Med J** 1996 Aug;37(4):424-7 (36 ref.)
Perinatal social work and the family of the newborn intensive care infant. Bachman DH, et al. **Soc Work Health Care** 1997;24(3-4):21-37 (15 ref.)
Neonatal Torulopsis glabrata fungemia. Reich JD, et al. **South Med J** 1997 Feb;90(2):246-8 (15 ref.)
[Vaccination of premature infants] Kristensen K, et al. **Ugeskr Laeger** 1996 Nov 4;158(45):6421-3 (20 ref.) (Eng. Abstr.) **(Dan)**
[Glucocorticoid-induced hypertrophic cardiomyopathy in premature infants: apropos of 4 cases] Boeuf B, et al. **Arch Pediatr** 1997 Feb;4(2):152-7 (18 ref.) (Eng. Abstr.) **(Fre)**
[Liquid ventilation: a new mode of ventilation in neonatology?] Hamon I. **Arch Pediatr** 1997 Feb;4(2):176-80 (20 ref.) (Eng. Abstr.) **(Fre)**
[Hydroelectrolytic requirements during the first week of life in premature infants weighing less than 1000 g. Physiopathology and recommendations] Yaseen H, et al. **Arch Pediatr** 1997 Jun;4(6):555-60 (43 ref.) (Eng. Abstr.) **(Fre)**
[Nutritional needs of the preterm infant after hospital discharge] Zuppa AA, et al. **Minerva Pediatr** 1997 Mar; 49(3):79-88 (45 ref.) (Eng. Abstr.) **(Ita)**

BLOOD

Practical issues in neonatal transfusion practice. Strauss RG. **Am J Clin Pathol** 1997 Apr;107(4 Suppl 1):S57-63 (32 ref.)
The hypothyroxinemia [corrected] of prematurity [editorial; comment] [published erratum appears in J Clin Endocrinol Metab 1997Jul;82(7):2191] Fisher DA. **J Clin Endocrinol Metab** 1997 Jun;82(6):1701-3 (25 ref.)
Comment on: J Clin Endocrinol Metab 1997 Jun;82(6):1704-12.

GROWTH & DEVELOPMENT

Respiratory morbidity in preschool children born prematurely. Relationship to adverse neonatal events. Greenough A, et al. **Acta Paediatr** 1996 Jul;85(7):772-7 (46 ref.)
Effects of preterm birth on oral growth and development. Seow WK. **Aust Dent J** 1997 Apr;42(2):85-91 (33 ref.)
Neonatal gut development and postnatal adaptation. Veereman-Wauters G. **Eur J Pediatr** 1996 Aug; 155(8):627-32 (55 ref.)
Which milk for the preterm infant? Tudehope DI, et al. **J Paediatr Child Health** 1996 Aug;32(4):275-7 (12 ref.)
Supplemental stimulation of premature infants: a treatment model. Dieter JN, et al. **J Pediatr Psychol** 1997 Jun; 22(3):281-95 (77 ref.)

METABOLISM

Effects of milk and milk components on calcium, magnesium, and trace element absorption during infancy. Lönnerdal B. **Physiol Rev** 1997 Jul;77(3):643-69 (243 ref.)

PHYSIOLOGY

Pharmacokinetics and renal function in preterm infants. van den Anker JN. **Acta Paediatr** 1996 Dec;85(12):1393-9 (58 ref.)
Multidisciplinary research of multimodal stimulation of premature infants: an integrated review of the literature. Mueller CR. **Matern Child Nurs J** 1996 Jan-Mar; 24(1):18-31 (31 ref.)
Neurophysiological assessment of brain function and maturation. II. A measure of brain dysmaturity in healthy preterm neonates. Scher MS. **Pediatr Neurol** 1997 May; 16(4):287-95 (36 ref.)
[Anatomical route of pain in premature newborn infants] Hamon I. **Arch Pediatr** 1996 Oct;3(10):1006-12 (27 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Supplemental stimulation of premature infants: a treatment model. Dieter JN, et al. **J Pediatr Psychol** 1997 Jun; 22(3):281-95 (77 ref.)
Behavioral effects of prematurity. Chapieski ML, et al. **Semin Perinatol** 1997 Jun;21(3):221-39 (109 ref.)

INFANT, PREMATURE, DISEASES

Fungal endocarditis in premature infants: case report and review. Mayayo E, et al. **Clin Infect Dis** 1996 Feb; 22(2):366-8 (16 ref.)
Neonatal systemic candidiasis. McDonnell M, et al. **J Paediatr Child Health** 1995 Dec;31(6):490-2 (20 ref.)
Antenatal-onset infantile cortical hyperostosis and nonimmune hydrops. Herman TE. **J Perinatol** 1996 Mar-Apr;16(2 Pt 1):137-9 (13 ref.)
Outcome of the extremely low birth weight infants (less than 999 grams): what messages are we getting? Ho NK. **Singapore Med J** 1995 Oct;36(5):527-31 (41 ref.)

DIAGNOSIS

Neurological assessment of the preterm infant. de Vries LS. **Acta Paediatr** 1996 Jul;85(7):765-71 (89 ref.)
Prediction of prematurity. Goepfert AR, et al. **Curr Opin Obstet Gynecol** 1996 Dec;8(6):417-27 (137 ref.)
Ventriculomegaly, delayed myelination, white matter hypoplasia, and "periventricular" leukomalacia: how are they related? Leviton A, et al. **Pediatr Neurol** 1996 Sep; 15(2):127-36 (163 ref.)

DRUG THERAPY

Control of cerebral and ocular blood flow autoregulation in neonates. Hardy P, et al. **Pediatr Clin North Am** 1997 Feb;44(1):137-52 (129 ref.)

EPIDEMIOLOGY

Respiratory morbidity in preschool children born prematurely. Relationship to adverse neonatal events. Greenough A, et al. **Acta Paediatr** 1996 Jul;85(7):772-7 (46 ref.)

ETIOLOGY

Neonatal hyponatremia associated with congenital hypothyroidism. Chelimsky G, et al. **Clin Pediatr (Phila)** 1997 Mar;36(3):177-80 (17 ref.)
A review of evidence for a role of magnesium and possibly copper deficiency in necrotizing enterocolitis. Caddell JL. **Magnes Res** 1996 Mar;9(1):55-66 (106 ref.)

PHYSIOPATHOLOGY

Etiology and pathogenesis of attention-deficit hyperactivity disorder (ADHD): significance of prematurity and perinatal hypoxic-haemodynamic encephalopathy. Lou HC. **Acta Paediatr** 1996 Nov;85(11):1266-71 (52 ref.)
Assessing the effect of disease on nutrition of the preterm infant. Hay WW Jr. **Clin Biochem** 1996 Oct;29(5):399-417 (182 ref.)
Cytokines in chronic lung disease of prematurity. Kotecha S. **Eur J Pediatr** 1996 Aug;155 Suppl 2:S14-7 (29 ref.)
The role of erythropoietin in the anemia of prematurity. Doyle JJ. **Semin Perinatol** 1997 Feb;21(1):20-7 (50 ref.)

PREVENTION & CONTROL

Haemopoietic colony stimulating factors for preterm neonates. Carr R, et al. **Arch Dis Child Fetal Neonatal Ed** 1997 Mar;76(2):F128-33 (89 ref.)
General obstetrics--prevention: the perinatal medicine of the future [editorial] Queenan JT. **Curr Opin Obstet Gynecol** 1996 Dec;8(6):391-3 (16 ref.)
Antenatal hormone therapy for improving the outcome of the preterm infant. Ballard RA, et al. **J Perinatol** 1996 Sep-Oct;16(5):390-6 (47 ref.)
Routine indomethacin prophylaxis: has the time come? [comment] Bada HS. **Pediatrics** 1996 Oct;98(4 Pt 1):784-5 (41 ref.) Comment on: Pediatrics 1996 Oct;98(4 Pt 1):714-8.

SURGERY

Perinatal intussusception in premature infants. Mooney DP, et al. **J Pediatr Surg** 1996 May;31(5):695-7 (12 ref.)
Coexisting left congenital diaphragmatic hernia and esophageal atresia with tracheoesophageal fistula: successful management in a premature neonate. Sapin E, et al. **J Pediatr Surg** 1996 Jul;31(7):989-91 (20 ref.)
Outcome, cost analysis, and long-term follow-up in preterm infants with massive grade IV germinal matrix hemorrhage and progressive hydrocephalus. Pikus HJ, et al. **Neurosurgery** 1997 May;40(5):983-8; discussion 988-9 (36 ref.)
Use of spinal or continuous caudal anesthesia for inguinal hernia repair in premature infants: are there advantages? Broadman LM. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):108-13 (27 ref.)

THERAPY

Initial treatment of preterm infants--continuous positive airway pressure or ventilation? Lundstrøm KE. **Eur J Pediatr** 1996 Aug;155 Suppl 2:S25-9 (34 ref.)
Long-term perspective on premature infant outcome and contemporary intervention issues. Bennett FC, et al. **Semin Perinatol** 1997 Jun;21(3):190-201 (49 ref.)
Medical outcomes in preterm infants. Dusick AM. **Semin Perinatol** 1997 Jun;21(3):164-77 (74 ref.)
Red blood cell transfusions for preterm infants: the role of evidence-based medicine. Hume H. **Semin Perinatol** 1997 Feb;21(1):8-19 (67 ref.)

ULTRASONOGRAPHY

[Cerebral Doppler ultrasonography in newborn infants] Luciano R, et al. **Rays** 1995 Oct-Dec;20(4):377-405 (104 ref.) (Eng. Abstr.) **(Ita)**

INFANT PSYCHOLOGY see **CHILD PSYCHOLOGY**

INFANT, SMALL FOR GESTATIONAL AGE

Stable isotopes and bioelectrical impedance for measuring body composition in infants born small for gestational age. Davies PS. **Horm Res** 1997;48 Suppl 1:50-5 (30 ref.)
Growth hormone treatment in short children born small for gestational age: from controversy towards consensus. Ranke MB, et al. **Horm Res** 1997;48 Suppl 1:72-4 (8 ref.)
Small-for-gestational-age infants and antenatal prediction of outcome. Roth S. **Ultrasound Obstet Gynecol** 1996 Sep; 8(3):149-51 (16 ref.)

PHYSIOLOGY

Born small for gestational age: consequences for growth. Karlberg J, et al. **Acta Paediatr Suppl** 1996 Oct;417:8-13; discussion 14 (30 ref.)
Long-term effects of intrauterine growth retardation. Kjellmer I, et al. **Acta Paediatr Suppl** 1997 Jul;422:83-4 (11 ref.)

INFANT, VERY LOW BIRTH WEIGHT

Coffin-Siris syndrome: a case of an extremely low birthweight infant with severe kyphoscoliosis. Suzumura H, et al. **Acta Paediatr Jpn** 1996 Oct;38(5):537-40 (5 ref.)
Unusual misplacement sites of percutaneous central venous lines in the very low birth weight neonate. Lussky RC, et al. **Am J Perinatol** 1997 Feb;14(2):63-7 (14 ref.)
Assessing the effect of disease on nutrition of the preterm infant. Hay WW Jr. **Clin Biochem** 1996 Oct;29(5):399-417 (182 ref.)
Individualized developmental care for very low-birth-weight infants: a critical review. Lotas MJ, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Oct;25(8):681-7 (27 ref.)
The outcomes of very low birth weight infants: are we asking the right questions? McCormick MC. **Pediatrics** 1997 Jun; 99(6):869-76 (89 ref.)
School age outcome in low birth weight preterm infants. Leonard CH, et al. **Semin Perinatol** 1997 Jun;21(3):240-53 (52 ref.)
Neuropsychological and functional outcomes of very low birth weight infants. Vohr BR, et al. **Semin Perinatol** 1997 Jun;21(3):202-20 (106 ref.)
Outcome of the extremely low birth weight infants (less than 999 grams): what messages are we getting? Ho NK. **Singapore Med J** 1995 Oct;36(5):527-31 (41 ref.)
[Hydroelectrolytic requirements during the first week of life in premature infants weighing less than 1000 g. Physiopathology and recommendations] Yaseen H, et al. **Arch Pediatr** 1997 Jun;4(6):555-60 (43 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

[Kangaroo method and care] Vaivre-Douret L, et al. **Arch Pediatr** 1996 Dec;3(12):1262-9 (35 ref.) (Eng. Abstr.) **(Fre)**

INFANT WELFARE

Breastfeeding and health in the Western world [see comments] Campbell C. **Br J Gen Pract** 1996 Oct; 46(411):613-7 (66 ref.) Comment in: Br J Gen Pract 1997 Jan;47(414):54. Comment in: Br J Gen Pract 1997 Apr;47(417):254-5.
Our strength for tomorrow: valuing our children. Levitt C, et al. **Can Fam Physician** 1997 Sep;43:1585-94 (30 ref.) **(Eng, Fre)**

INFANTICIDE

PSYCHOLOGY

Antisocial personality by proxy: the Norton-Sims syndrome. Stawar TL. **J Psychol** 1997 Jan;131(1):5-19 (46 ref.)

INFANTILE CORTICAL HYPEROSTOSIS see **HYPEROSTOSIS, CORTICAL, CONGENITAL**

INFANTILE PARALYSIS see **POLIOMYELITIS**

INFANTILE REFSUM DISEASE see **PEROXISOMAL DISORDERS**

INFANTILE SPINAL MUSCULAR ATROPHY see **WERDNIG-HOFFMANN DISEASE**

INFANTILISM, GENITAL see **HYPOGONADISM**

INFANTILISM, SEXUAL see **HYPOGONADISM**

INFARCTION

see related
MYOCARDIAL INFARCTION
SPLENIC INFARCTION

Segmental hemorrhagic infarction of testicle. Baratelli GM, et al. **J Urol** 1996 Oct;156(4):1442 (3 ref.)

[Renal infarction, infarcted kidney] Hisada Y, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):309–11 (11 ref.) **(Jpn)**

DIAGNOSIS

Recurrent small bowel infarction associated with antithrombin deficiency. Golino A, et al. **Am J Gastroenterol** 1997 Feb;92(2):323–5 (14 ref.)

Residents' corner. Answer to case of the month #46. Torsion and infarction of the greater omentum. Garant M, et al. **Can Assoc Radiol J** 1997 Apr;48(2):130–2 (6 ref.)

Nonocclusive mesenteric infarction in continuous ambulatory peritoneal dialysis. Korzets Z, et al. **Nephron** 1996; 74(2):415–8 (15 ref.)

ETIOLOGY

Diabetic muscle infarction [see comments] Umpierrez GE, et al. **Am J Med** 1996 Sep;101(3):245–50 (15 ref.) Comment in: Am J Med 1997 Aug;103(2):171–2.

Liver-spleen infarcts following transcatheter chemoembolization: a case report and review of the literature on adverse effects. Cohen SE, et al. **Dig Dis Sci** 1997 May;42(5):938–43 (29 ref.)

Livedo reticularis, rhabdomyolysis, massive intestinal infarction, and death after carbon dioxide arteriography. Rundback JH, et al. **J Vasc Surg** 1997 Aug;26(2):337–40 (13 ref.)

RADIONUCLIDE IMAGING

Scintigraphy and ultrasonography in differentiating osteomyelitis from bone infarction in sickle cell disease. Rifai A, et al. **Acta Radiol** 1997 Jan;38(1):139–43 (12 ref.)

ULTRASONOGRAPHY

Scintigraphy and ultrasonography in differentiating osteomyelitis from bone infarction in sickle cell disease. Rifai A, et al. **Acta Radiol** 1997 Jan;38(1):139–43 (12 ref.)

INFECTION

see related
ANTI-INFECTIVE AGENTS

Abdominal contamination, infection and sepsis: a continuum. Schein M, et al. **Br J Surg** 1997 Feb;84(2):269–72 (49 ref.)

Infection in childhood and neurological diseases in adult life. Martyn CN. **Br Med Bull** 1997 Jan;53(1):24–39 (35 ref.)

Infections in the elderly. Crossley KB, et al. **Clin Infect Dis** 1996 Feb;22(2):209–15 (11 ref.)

Neonatal infections. Bhutta ZA. **Curr Opin Pediatr** 1997 Apr; 9(2):133–40 (85 ref.)

Space-occupying and life-threatening infections of the head, neck, and thorax. Gradon JD. **Infect Dis Clin North Am** 1996 Dec;10(4):857–78 (105 ref.)

Infectious diseases. Forward to the past. Nath I. **Lancet** 1996 Dec 21–28;348 Suppl 2:sII11 (5 ref.)

Diagnosis and tranosis and treatment of ENT infections. Bates G, et al. **Practitioner** 1996 May;240(1562):336–40 (14 ref.)

[Future trend in research for infectious diseases] Shimizu K. **Kansenshogaku Zasshi** 1997 Apr;71(4):293–8 (0 ref.) **(Jpn)**

CLASSIFICATION

Granulomatous infections: etiology and classification. Zumla A, et al. **Clin Infect Dis** 1996 Jul;23(1):146–58 (133 ref.)

COMPLICATIONS

Are all diseases infectious? Lorber B. **Ann Intern Med** 1996 Nov 15;125(10):844–51 (65 ref.)

Infectious agents and environmental factors in lymphoid malignancies. Toren A, et al. **Blood Rev** 1996 Jun; 10(2):89–94 (63 ref.)

Infections in childhood and pregnancy as a cause of adult disease--methods and examples. Hall AJ, et al. **Br Med Bull** 1997 Jan;53(1):10–23 (33 ref.)

Cancer and infection: estimates of the attributable fraction in 1990. Pisani P, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Jun;6(6):387–400 (157 ref.)

Fever without apparent source on clinical examination, lower respiratory infections in children, other infectious diseases, and acute gastroenteritis and diarrhea of infancy and early childhood. McCarthy PL, et al. **Curr Opin Pediatr** 1997 Feb;9(1):105–26 (155 ref.)

Potential infectious agents in the induction of arthritides. Krause A, et al. **Curr Opin Rheumatol** 1996 May;8(3):203–9 (65 ref.)

Infectious complications in diabetic patients. File TM Jr, et al. **Curr Ther Endocrinol Metab** 1997;6:491–5 (9 ref.)

Pulmonary infiltrates in the cancer patient. New approaches to an old problem. Bergen GA, et al. **Infect Dis Clin North Am** 1996 Jun;10(2):297–325 (140 ref.)

Risk factors for infectious complication in patients with systemic lupus erythematosus [editorial; comment] Aotsuka S. **Intern Med** 1996 Aug;35(8):593–4 (10 ref.) Comment on: Intern Med 1996 Aug;35(8):629–36.

Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? [see comments] Vallance P, et al. **Lancet** 1997 May 10;349(9062):1391–2 (30 ref.) Comment in: Lancet 1997 Jul 26;350(9073):293. Comment in: Lancet 1997 Jul 26;350(9073):293–4.

Importance of adequate vitamin A status during iron supplementation. Ribaya-Mercado JD. **Nutr Rev** 1997 Aug; 55(8):306–7 (13 ref.)

Infectious agents and atherosclerotic vascular disease. Cook PJ, et al. **QJM** 1996 Oct;89(10):727–35 (127 ref.)

Infections and Wegener's granulomatosis--a cause and effect relationship? George J, et al. **QJM** 1997 May;90(5):367–73 (63 ref.)

The evaluation of infection and pulmonary maturity in women with premature rupture of the membranes. Beazley D, et al. **Semin Perinatol** 1996 Oct;20(5):409–17 (83 ref.)

[Vasculitis in infectious diseases] Somer T, et al. **Duodecim** 1995;111(10):964–70 (34 ref.) **(Fin)**

[Infectious diseases as a cause and risk factor for cerebrovascular ischemia] Grau AJ, et al. **Nervenarzt** 1996 Aug;67(8):639–49 (117 ref.) (Eng. Abstr.) **(Ger)**

[Infections and vasculitis] Glück T, et al. **Z Rheumatol** 1997 May-Jun;56(3):105–13 (80 ref.) (Eng. Abstr.) **(Ger)**

[Acute postinfectious glomerulonephritis] Oshima S, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):108–12 (16 ref.) **(Jpn)**

[Post-infectious demyelinating diseases] Medina-Malo C, et al. **Rev Neurol** 1997 Jun;25(142):906–12 (41 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Approach to adult patients with recurrent infections. Avery RK, et al. **Cleve Clin J Med** 1997 May;64(5):249–57 (21 ref.)

Prophylaxis post-transplant. The role of monitoring surveillance bronchoscopy and antimicrobials. Corris PA. **Clin Chest Med** 1997 Jun;18(2):311–8 (38 ref.)

Detection of infection or infectious agents by use of cytologic and histologic stains. Woods GL, et al. **Clin Microbiol Rev** 1996 Jul;9(3):382–404 (205 ref.)

Special considerations for the clinical microbiology laboratory in the diagnosis of infections in the cancer patient. Sandin RL, et al. **Infect Dis Clin North Am** 1996 Jun;10(2):413–30 (41 ref.)

The possibilities and limitations of nucleic acid amplification technology in diagnostic microbiology. Vaneechoutte M, et al. **J Med Microbiol** 1997 Mar;46(3):188–94 (63 ref.)

Inflammatory and infectious lesions of the neck. Ginsberg LE. **Semin Ultrasound CT MR** 1997 Jun;18(3):205–19 (47 ref.)

[Future prospects of emergency laboratory tests--problems of immunoserologic tests] Obana Y, et al. **Rinsho Byori** 1996 Oct;44(10):956–61 (18 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Review article: the therapy of gastrointestinal infections associated with the acquired immunodeficiency syndrome. Wilcox CM, et al. **Aliment Pharmacol Ther** 1997 Jun; 11(3):425–43 (186 ref.)

Sequential antibiotic therapy. Mandell LA. **Neth J Med** 1997 Mar;50(3):93–6 (31 ref.)

Intravenous-to-oral antibiotic switch therapy. A cost-effective approach. Cunha BA. **Postgrad Med** 1997 Apr;101(4):111–2, 115–8, 122–3 passim (13 ref.)

New uses for older antibiotics. The 'rediscovery' of four beneficial and cost-effective antimicrobials. Cunha BA. **Postgrad Med** 1997 Apr;101(4):68–70, 73–4, 79–80 passim (19 ref.)

EPIDEMIOLOGY

Infections associated with international travel: recent developments and global trends. Tornieporth NG, et al. **Adv Intern Med** 1996;41:119–64 (162 ref.)

Emerging infectious diseases: a challenge to all [see comments] Strausbaugh LJ. **Am Fam Physician** 1997 Jan; 55(1):111–7 (25 ref.) Comment in: Am Fam Physician 1997 Jan;55(1):36, 38.

Update in infectious diseases [see comments] Bartlett JG. **Ann Intern Med** 1997 Jan 1;126(1):48–56 (18 ref.) Comment in: Ann Intern Med 1997 Jul 15;127(2):165.

The global impact of neonatal infection. Stoll BJ. **Clin Perinatol** 1997 Mar;24(1):1–21 (175 ref.)

Blood transfusion and infection after colorectal cancer surgery. Vamvakas EC, et al. **Transfusion** 1996 Nov-Dec; 36(11–12):1000–8 (50 ref.)

[Infectious morbidity in technogenic environmental pollution] Savilov ED, et al. **Vestn Ross Akad Med Nauk** 1996;(8):37–40 (20 ref.) (Eng. Abstr.) **(Rus)**

[Risk factors and chronology of infection in solid organ transplantation] Gavaldà J, et al. **Enferm Infecc Microbiol Clin** 1997 May;15 Suppl 2:3–11 (123 ref.) **(Spa)**

ETIOLOGY

Intravascular catheter related bloodstream infection: epidemiology, pathogenesis and prevention. Van Wijngaerden E, et al. **Acta Clin Belg** 1997;52(1):9–18 (87 ref.)

Epidemiological perspective on infections in chronic dialysis patients. Bloembergen WE, et al. **Adv Ren Replace Ther** 1996 Jul;3(3):201–7 (35 ref.)

Evaluating the child with recurrent infections. Wheeler JG. **Am Fam Physician** 1996 Nov 15;54(7):2276–82, 2285–6 (11 ref.)

Occupationally acquired infections in health care workers. Part I. Sepkowitz KA. **Ann Intern Med** 1996 Nov 15; 125(10):826–34 (202 ref.)

Integrated management of childhood infections and malnutrition: a global initiative. Campbell H, et al. **Arch Dis Child** 1996 Dec;75(6):468–71 (28 ref.)

Approach to adult patients with recurrent infections. Avery RK, et al. **Cleve Clin J Med** 1997 May;64(5):249–57 (21 ref.)

Infections in lung transplant recipients. Chaparro C, et al. **Clin Chest Med** 1997 Jun;18(2):339–51 (68 ref.)

Granulomatous infections: etiology and classification. Zumla A, et al. **Clin Infect Dis** 1996 Jul;23(1):146–58 (133 ref.)

Catheter-related complications of cancer therapy. Greene JN. **Infect Dis Clin North Am** 1996 Jun;10(2):255–95 (175 ref.)

Overwhelming postsplenectomy infection. Lynch AM, et al. **Infect Dis Clin North Am** 1996 Dec;10(4):693–707 (107 ref.)

Exercise, immunity, and infection. Calabrese LH, et al. **J Am Osteopath Assoc** 1996 Mar;96(3):166–76 (137 ref.)

Side-effects of intravenous cyclophosphamide pulse therapy. Martin F, et al. **Lupus** 1997;6(3):254–7 (16 ref.)

Are granulocyte inhibitory proteins contributing to enhanced susceptibility to infections in uraemia? Haag-Weber M, et al. **Nephrol Dial Transplant** 1996;11 Suppl 2:98–100 (20 ref.)

Current approach to exit-site infections in patients on peritoneal dialysis. Twardowski ZJ, et al. **Nephrol Dial Transplant** 1997 Jun;12(6):1284–95 (46 ref.)

Infections associated with biliary drains. Yu JL, et al. **Scand J Gastroenterol** 1996 Jul;31(7):625–30 (89 ref.)

[Central nervous system infections in patients with malignant diseases] Carpentier AF, et al. **Rev Neurol (Paris)** 1996 Oct; 152(10):587–601 (115 ref.) (Eng. Abstr.) **(Fre)**

[Infections from intravascular catheterization] Bach IA, et al. **Anaesthesist** 1996 Nov;45(11):1111–26 (21 ref.) **(Ger)**

[A fatal case of overwhelming postsplenectomy infection syndrome developing 10 years after splenectomy] Urata Y, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1997 Jun; 20(3):184–90 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Infection and adhesion molecules] Kobayashi K. **Rinsho Byori** 1996 Sep;Suppl 102:191–7 (19 ref.) **(Jpn)**

[Infectious morbidity in technogenic environmental pollution] Savilov ED, et al. **Vestn Ross Akad Med Nauk** 1996;(8):37–40 (20 ref.) (Eng. Abstr.) **(Rus)**

[Infection in the patient undergoing bone marrow transplantation] Carratalá J, et al. **Enferm Infecc Microbiol Clin** 1997 May;15 Suppl 2:51–6 (90 ref.) **(Spa)**

GENETICS

Infection ... by the new genetics. Jepson AP. **J Infect** 1996 Jul;33(1):1–5 (51 ref.)

IMMUNOLOGY

Synergism of nutrition, infection, and immunity: an overview. Scrimshaw NS, et al. **Am J Clin Nutr** 1997 Aug; 66(2):464S–477S (231 ref.)

Leucocyte adhesion molecules in host defence against infection. Brown EJ, et al. **Ann Med** 1996 Jun;28(3):201–8 (67 ref.)

ELISPOT for detecting antibody-secreting cells in response to infections and vaccination. Arvilommi H. **APMIS** 1996 Jun;104(6):401–10 (70 ref.)

The great balancing acts. The pregnant woman, placenta, fetus, and infectious agents. Nahmias AJ, et al. **Clin Perinatol** 1997 Jun;24(2):497–521 (104 ref.)

Cytokines acting on or secreted by macrophages during intracellular infection (IL-10, IL-12, IFN-gamma). Trinchieri G. **Curr Opin Immunol** 1997 Feb;9(1):17–23 (69 ref.)

Interleukin 15: a potential player during the innate immune response to infection. Carson WE, et al. **Exp Parasitol** 1996 Nov;84(2):291–4 (19 ref.)

How are NK cell responses regulated during infection? Hunter CA. **Exp Parasitol** 1996 Dec;84(3):444–8 (45 ref.)

Oligoclonality of CD8+ T cells in health and disease: aging, infection, or immune regulation? Batliwalla F, et al.

Hum Immunol 1996 Jun-Jul;48(1-2):68-76 (37 ref.)
Th1-Th2: reliable paradigm or dangerous dogma? Allen JE, et al. **Immunol Today** 1997 Aug;18(8):387-92 (73 ref.)
Current and future clinical applications of interferon-gamma in host antimicrobial defense. Murray HW. **Intensive Care Med** 1996 Oct;22 Suppl 4:S456-61 (21 ref.)
Exercise, immunity, and infection. Calabrese LH, et al. **J Am Osteopath Assoc** 1996 Mar;96(3):166-76 (137 ref.)
Common infections, idiotypic dysregulation, autoantibody spread and induction of autoimmune diseases. Shoenfeld Y. **J Autoimmun** 1996 Apr;9(2):235-9 (39 ref.)
Differential roles for IL-12 in the maintenance of immune responses in infectious versus autoimmune disease. Seder RA, et al. **J Immunol** 1996 Oct 1;157(7):2745-8 (24 ref.)
Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. Reiser H, et al. **N Engl J Med** 1996 Oct 31;335(18):1369-77 (69 ref.)
Immune responses to infectious diseases: an evolutionary perspective. Yang KD, et al. **Pediatr Infect Dis J** 1996 Apr;15(4):355-64 (55 ref.)
Psychological stress, neuroimmunomodulation, and susceptibility to infectious diseases in animals and man: a review. Biondi M, et al. **Psychother Psychosom** 1997; 66(1):3-26 (271 ref.)
[Susceptibility to infection] Cerny A. **Schweiz Med Wochenschr** 1997 Mar 1;127(9):360-6 (23 ref.) (Eng. Abstr.) **(Ger)**
[Cytokine-mediated biological response to severe infections in surgical patients] Aikawa N, et al. **Nippon Geka Gakkai Zasshi** 1996 Dec;97(12):1054-9 (36 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Iron and infection [editorial] Boelaert JR. **Acta Clin Belg** 1996;51(4):213-21 (54 ref.)
Cytokines acting on or secreted by macrophages during intracellular infection (IL-10, IL-12, IFN-gamma). Trinchieri G. **Curr Opin Immunol** 1997 Feb;9(1):17-23 (69 ref.)
Infection, autoimmunity and autoimmune disease. Feige U, et al. **EXS** 1996;77:359-73 (69 ref.)
Membrane-protein traffic in pathogen-infected cells. Joiner KA. **J Clin Invest** 1997 Apr 15;99(8):1814-7 (5 ref.)
Iron, anemia, and infection. Walter T, et al. **Nutr Rev** 1997 Apr;55(4):111-24 (89 ref.)

MICROBIOLOGY

Emerging infectious diseases: a challenge to all [see comments] Strausbaugh LJ. **Am Fam Physician** 1997 Jan; 55(1):111-7 (25 ref.) Comment in: Am Fam Physician 1997 Jan;55(1):36, 38.
Deep neck infections. Marra S, et al. **Am J Otolaryngol** 1996 Sep-Oct;17(5):287-98 (15 ref.)
Role of microbial proteases in pathogenesis. Maeda H. **Microbiol Immunol** 1996;40(10):685-99 (81 ref.)
Emerging infections and newly-recognised pathogens. Relman DA. **Neth J Med** 1997 May;50(5):216-20 (14 ref.)

NURSING

Nursing interventions related to peritoneal catheter exit-site infections. Prowant BF. **Adv Ren Replace Ther** 1996 Jul; 3(3):228-31 (32 ref.)
Nursing interventions related to vascular access infections. Thomas-Hawkins C. **Adv Ren Replace Ther** 1996 Jul; 3(3):218-21 (56 ref.)

PATHOLOGY

Diabetic foot infections. Frykberg RG, et al. **Diabetes Metab Rev** 1996 Oct;12(3):255-70 (94 ref.)

PHYSIOPATHOLOGY

Mechanism of hepatocellular dysfunction during hyperdynamic sepsis. Wang P, et al. **Am J Physiol** 1996 May;270(5 Pt 2):R927-38 (126 ref.)
The emerging role of MIF in septic shock and infection. Bernhagen J, et al. **Biotherapy** 1994;8(2):123-7 (35 ref.)
M cells as portals of infection: clinical and pathophysiological aspects. Fujimura Y, et al. **Infect Agents Dis** 1996 Jun; 5(3):144-56 (108 ref.)
Psychological stress, exercise and immunity. Perna FM, et al. **Int J Sports Med** 1997 Mar;18 Suppl 1:S78-83 (68 ref.)
[Cardiac contractile dysfunction in response to surgical stress including trauma, hemorrhage, and infection] Suzuki K, et al. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):745-51 (20 ref.) (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE IMAGING

Radionuclide imaging of infection in the immunocompromised host. Rubin RH, et al. **Clin Infect Dis** 1996 Mar;22(3):414-23 (38 ref.)

THERAPY

Update in infectious diseases. Bartlett JG. **Ann Intern Med** 1997 Aug 1;127(3):217-24 (15 ref.)
Infectious complications in diabetic patients. File TM Jr, et al. **Curr Ther Endocrinol Metab** 1997;6:491-5 (9 ref.)
Interleukin-12: potential clinical applications in the treatment and prevention of infectious diseases. Gately MK, et al. **Drugs** 1996;52 Suppl 2:18-25; discussion 25-6 (49 ref.)
New modalities for treating neonatal infection. Bedford-Russell AR. **Eur J Pediatr** 1996 Aug;155 Suppl 2:S21-4 (23 ref.)
Current and future clinical applications of interferon-gamma in host antimicrobial defense. Murray HW. **Intensive Care Med** 1996 Oct;22 Suppl 4:S456-61 (21 ref.)

TRANSMISSION

Transfusion-transmitted infections: update. Menitove JE. **Semin Hematol** 1996 Oct;33(4):290-301 (80 ref.)

INFECTION CONTROL

Needleless and sharp-free anaesthesia. Tomkins DP, et al. **Anaesth Intensive Care** 1996 Apr;24(2):164-8 (17 ref.)
Update in infectious diseases. Bartlett JG. **Ann Intern Med** 1997 Aug 1;127(3):217-24 (15 ref.)
Update in infectious diseases [see comments] Bartlett JG. **Ann Intern Med** 1997 Jan 1;126(1):48-56 (18 ref.) Comment in: Ann Intern Med 1997 Jul 15;127(2):165.
The epidemiology of methicillin-resistant Staphylococcus aureus: surgical relevance 20 years on. McDonald M. **Aust N Z J Surg** 1997 Oct;67(10):682-5 (32 ref.)
Hospital infection control practices for tuberculosis. Davis YM, et al. **Clin Chest Med** 1997 Mar;18(1):19-33 (43 ref.)
Lung volume equipment and infection control. ERS/ATS Workshop Report Series. European Respiratory Society/American Thoracic Society. Clausen JL. **Eur Respir J** 1997 Aug;10(8):1928-32 (28 ref.)
Preventing staphylococcal infections by eradicating nasal carriage of Staphylococcus aureus: proceeding with caution [editorial; comment] Boyce JM. **Infect Control Hosp Epidemiol** 1996 Dec;17(12):775-9 (50 ref.) Comment on: Infect Control Hosp Epidemiol 1996 Dec;17(12):780-5. Comment on: Infect Control Hosp Epidemiol 1996 Dec;17(12):786-92. Comment on: Infect Control Hosp Epidemiol 1996 Dec;17(12):813-6.
How to limit the spread of Creutzfeldt-Jakob disease. Dormont D. **Infect Control Hosp Epidemiol** 1996 Aug; 17(8):521-8 (71 ref.)
Nosocomial infection caused by antibiotic-resistant organisms in the intensive-care unit. Flaherty JP, et al. **Infect Control Hosp Epidemiol** 1996 Apr;17(4):236-48 (158 ref.)
Preventing the emergence of multidrug-resistant microorganisms through antimicrobial use controls: the complexity of the problem. Jarvis WR. **Infect Control Hosp Epidemiol** 1996 Aug;17(8):490-5 (27 ref.)
Emerging infectious diseases in the institutional setting: another hot zone. Ostroff SM. **Infect Control Hosp Epidemiol** 1996 Aug;17(8):484-9 (63 ref.)
Prevention of fungal infections in hematology patients. Philpott-Howard J. **Infect Control Hosp Epidemiol** 1996 Aug;17(8):545-51 (68 ref.)
Basics of surveillance--an overview. Pottinger JM, et al. **Infect Control Hosp Epidemiol** 1997 Jul;18(7):513-27 (27 ref.)
AIDS, emergency operations, and infection control. Wittmann MM, et al. **Infect Control Hosp Epidemiol** 1996 Aug;17(8):532-8 (23 ref.)
Infection control challenges in child-care centers. Churchill RB, et al. **Infect Dis Clin North Am** 1997 Jun;11(2):347-65 (110 ref.)
Control of antimicrobial resistance in the health care system. McGowan JE Jr, et al. **Infect Dis Clin North Am** 1997 Jun;11(2):297-311 (68 ref.)
Control of biologic hazards. Stave GM. **Occup Med** 1996 Jan-Mar;11(1):79-85 (9 ref.)
Prophylactic neonatal surgery and infectious diseases. Weiss GN. **Pediatr Infect Dis J** 1997 Aug;16(8):727-34 (91 ref.)
Protecting travelers against infections: immunizations and other preventive strategies. Blair JE. **Postgrad Med** 1996 Dec;100(6):159-62, 165-6, 169-72 (5 ref.)
European Commission COST/STD Initiative. Report of the expert panel X. Animals models for vaccines to prevent infectious diseases. Mäkelä H, et al. **Vaccine** 1996 May; 14(7):717-31 (8 ref.)
[The prevention of infection in oral medicine] Vassal S, et al. **Rev Stomatol Chir Maxillofac** 1997 Sep;98(3):216-9 (19 ref.) **(Fre)**
[Pre-transplant evaluation of the donor and recipient. Recommendations for surveillance and control of infection after transplantation] Cisneros JM, et al. **Enferm Infecc Microbiol Clin** 1997 May;15 Suppl 2:98-103 (68 ref.) **(Spa)**

ECONOMICS

Selected aspects of the socioeconomic impact of nosocomial infections: morbidity, mortality, cost, and prevention. Jarvis WR. **Infect Control Hosp Epidemiol** 1996 Aug;17(8):552-7 (27 ref.)

METHODS

Guideline for prevention of intravascular device-related infections. Part II. Recommendations for the prevention of nosocomial intravascular device-related infections. Hospital Infection Control Practices Advisory Committee. **Am J Infect Control** 1996 Aug;24(4):277-93 (434 ref.)
Guideline for prevention of intravascular device-related infections. Part I. Intravascular device-related infections: an overview. The Hospital Infection Control Practices Advisory Committee. Pearson ML. **Am J Infect Control** 1996 Aug;24(4):262-77 (434 ref.)
Selective decontamination of the digestive tract in intensive care patients. van Saene HK, et al. **Br J Hosp Med** 1995 Dec 13-1996 Jan 16;54(11):558-61 (21 ref.)
Infections in lung transplant recipients. Chaparro C, et al. **Clin Chest Med** 1997 Jun;18(2):339-51 (68 ref.)
Treatment and control of colonization in the prevention of nosocomial infections. Boyce JM. **Infect Control Hosp Epidemiol** 1996 Apr;17(4):256-61 (80 ref.)
The challenge of postoperative infections: does the surgeon make a difference? Holzheimer RG, et al. **Infect Control Hosp Epidemiol** 1997 Jun;18(6):449-56 (97 ref.)
Tuberculosis control in health care. Pugliese G, et al. **Infect Control Hosp Epidemiol** 1996 Dec;17(12):819-27 (25 ref.)
Surveillance for infections associated with vascular catheters. Sherertz RJ. **Infect Control Hosp Epidemiol** 1996 Nov; 17(11):746-52 (41 ref.)
Management of healthcare workers with pharyngitis or suspected streptococcal infections. Weber DJ, et al. **Infect Control Hosp Epidemiol** 1996 Nov;17(11):753-61 (95 ref.)
Vancomycin-resistant enterococcus. Detection, epidemiology, and control measures. Boyce JM. **Infect Dis Clin North Am** 1997 Jun;11(2):367-84 (95 ref.)
Infection control in ambulatory care. Nafziger DA, et al. **Infect Dis Clin North Am** 1997 Jun;11(2):279-96 (81 ref.)
Prevention of infections in bone marrow transplant recipients. Serody JS, et al. **Infect Dis Clin North Am** 1997 Jun; 11(2):459-77 (71 ref.)
Role of molecular epidemiology in infection control. Weber S, et al. **Infect Dis Clin North Am** 1997 Jun;11(2):257-78 (59 ref.)
Selective decontamination of the digestive tract: 13 years on, what it is and what it is not. Baxby D, et al. **Intensive Care Med** 1996 Jul;22(7):699-706 (44 ref.)
Prevention of sepsis in total joint arthroplasty. An YH, et al. **J Hosp Infect** 1996 Jun;33(2):93-108 (135 ref.)
Protecting the patient and the environment--new aspects and challenges in hospital infection control. Daschner FD, et al. **J Hosp Infect** 1997 May;36(1):7-15 (30 ref.)
Methicillin-resistant Staphylococcus aureus (MRSA)--a re-appraisal of control measures in the light of changing circumstances. Humphreys H, et al. **J Hosp Infect** 1997 Jul;36(3):167-70 (20 ref.)
How to classify infections in intensive care units--the carrier state, a criterion whose time has come? van Saene HK, et al. **J Hosp Infect** 1996 May;33(1):1-12 (32 ref.)
Infectious complications: prevention and strategies for their control. Greenfield E, et al. **Nurs Clin North Am** 1997 Jun; 32(2):297-309 (24 ref.)
Worldwide prevention of vertical human immunodeficiency virus (HIV) transmission. van Vliet A, et al. **Obstet Gynecol Surv** 1997 May;52(5):301-9 (87 ref.)
Bite wounds. Early treatment and prophylaxis against infectious complications. Presutti RJ. **Postgrad Med** 1997 Apr;101(4):243-4, 246-52, 254 (10 ref.)
[Prevention of acquired pneumonia during artificial ventilation (excluding the use of anti-infectious agents)] Fagon JY, et al. **Rev Mal Respir** 1997 Jan;14(1):13-9 (43 ref.) (Eng. Abstr.) **(Fre)**
[Infection prevention in the patient undergoing hematopoietic stem cell transplantation] Baro J, et al. **Enferm Infecc Microbiol Clin** 1997 May;15 Suppl 2:90-7 (80 ref.) **(Spa)**
[Prevention of infection in recipients of solid organ transplants] Lumbreras C, et al. **Enferm Infecc Microbiol Clin** 1997 May;15 Suppl 2:77-89 (155 ref.) **(Spa)**

ORGANIZATION & ADMINISTRATION

Process surveillance: an epidemiologic challenge for all health care organizations. Baker OG. **Am J Infect Control** 1997 Apr;25(2):96-101 (34 ref.)
International Federation of Infection Control: the first 10 years. Hambraeus A, et al. **Am J Infect Control** 1997 Aug; 25(4):297-302 (16 ref.)
Surveillance of surgical site infections in alternative settings: exploring the current options. Manian FA. **Am J Infect Control** 1997 Apr;25(2):102-5 (20 ref.)
A global perspective on the past, present, and future of nosocomial infection prevention and control [editorial] Soule BM, et al. **Am J Infect Control** 1997 Aug;25(4):289-93 (25 ref.)
The expanding role of healthcare epidemiology--home and long-term care [editorial; comment] Garrett DO, et al. **Infect Control Hosp Epidemiol** 1996 Nov;17(11):714-7 (16 ref.) Comment on: Infect Control Hosp Epidemiol 1996 Nov;17(11):721-5. Comment on: Infect Control Hosp Epidemiol 1996 Nov;17(11):726-31.
Microcomputers in hospital epidemiology. Reagan DR. **Infect Control Hosp Epidemiol** 1997 Jun;18(6):440-8 (37 ref.)

TRENDS

[Future trend in research for infectious diseases] Shimizu K.

Kansenshogaku Zasshi 1997 Apr;71(4):293–8 (0 ref.) **(Jpn)**

INFECTION CONTROL, DENTAL

METHODS

Decontamination of dental unit water systems: a review of current recommendations. Fayle SA, et al. **Br Dent J** 1996 Nov 23;181(10):369–72 (26 ref.)

INFECTIOUS ANEMIA VIRUS, EQUINE

IMMUNOLOGY

Characterization of protective and enhancing immune responses to equine infectious anemia virus resulting from experimental vaccines. Montelaro RC, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):413–5 (22 ref.)

INFECTIOUS ARTERITIS VIRUS, EQUINE see **ARTERITIS VIRUS, EQUINE**

INFECTIOUS BOVINE RHINOTRACHEITIS

IMMUNOLOGY

Advances in the development and evaluation of bovine herpesvirus 1 vaccines. van Oirschot JT, et al. **Vet Microbiol** 1996 Nov;53(1–2):43–54 (60 ref.)

INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS see **HERPESVIRUS 1, BOVINE**

INFECTIOUS BURSAL AGENT see **INFECTIOUS BURSAL DISEASE VIRUS**

INFECTIOUS BURSAL DISEASE VIRUS

History of infectious bursal disease in the U.S.A.—the first two decades. Lasher HN, et al. **Avian Dis** 1997 Jan–Mar; 41(1):11–9 (54 ref.)

IMMUNOLOGY

Infectious bursal disease virus: a review of molecular basis for variations in antigenicity and virulence. Nagarajan MM, et al. **Can J Vet Res** 1997 Apr;61(2):81–8 (75 ref.)

PATHOGENICITY

Infectious bursal disease virus: a review of molecular basis for variations in antigenicity and virulence. Nagarajan MM, et al. **Can J Vet Res** 1997 Apr;61(2):81–8 (75 ref.)

INFECTIOUS DISEASE CONTACT TRACING see **CONTACT TRACING**

INFECTIOUS DISEASE REPORTING see **DISEASE NOTIFICATION**

INFECTIOUS DISEASES see **COMMUNICABLE DISEASES**

INFECTIOUS HUMAN WART VIRUS see **PAPILLOMAVIRUS, HUMAN**

INFECTIOUS MONONUCLEOSIS

COMPLICATIONS

Epstein–Barr virus–associated hemophagocytic syndrome and fatal infectious mononucleosis. Okano M, et al. **Am J Hematol** 1996 Oct;53(2):111–5 (38 ref.)

Epstein–Barr virus–induced infectious mononucleosis complicated by acute renal failure: case report and review. Mayer HB, et al. **Clin Infect Dis** 1996 Jun;22(6):1009–18 (62 ref.)

Cerebellitis as an uncommon complication of infectious mononucleosis. de Fraiture DM, et al. **Neth J Med** 1997 Aug;51(2):79–82 (13 ref.)

Epstein–Barr virus infection associated with interstitial nephritis and chronic fatigue. López–Navidad A, et al. **Scand J Infect Dis** 1996;28(2):185–7 (20 ref.)

[Liver dysfunction induced by Epstein–Barr virus infectious mononucleosis] Furman E, et al. **Harefuah** 1997 May 15; 132(10):724–5 (11 ref.) **(Heb)**

[A case of severe thrombocytopenia in infectious mononucleosis] Zipper FC, et al. **Clin Ter** 1996 Oct; 147(10):529–33 (18 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Clinical and immunological considerations in Epstein–Barr virus–associated diseases. Andersson J. **Scand J Infect Dis Suppl** 1996;100:72–82 (36 ref.)

Diagnosis of Epstein–Barr virus–related diseases. Linde A. **Scand J Infect Dis Suppl** 1996;100:83–8 (46 ref.)

Two brothers in a Malaysian family with X–linked lymphoproliferative disease—a case report. Hany A, et al. **Singapore Med J** 1996 Jun;37(3):325–7 (8 ref.)

DRUG THERAPY

Cephalexin rash in infectious mononucleosis. McCloskey GL, et al. **Cutis** 1997 May;59(5):251–4 (43 ref.)

RADIOGRAPHY

Infectious mononucleosis with pulmonary consolidation. Miyake H, et al. **J Thorac Imaging** 1996 Spring;11(2):158–60 (7 ref.)

THERAPY

Clinical and immunological considerations in Epstein–Barr virus–associated diseases. Andersson J. **Scand J Infect Dis Suppl** 1996;100:72–82 (36 ref.)

INFECTIOUS MONONUCLEOSIS–LIKE SYNDROME, CHRONIC see **FATIGUE SYNDROME, CHRONIC**

INFECTIOUS MONONUCLEOSIS VIRUS see **HERPESVIRUS 4, HUMAN**

INFECTIOUS PANCREATIC NECROSIS VIRUS

IMMUNOLOGY

Immunization with viral antigens: infectious pancreatic necrosis. Christie KE. **Dev Biol Stand** 1997;90:191–9 (54 ref.)

INFECTIOUS PERITONITIS VIRUS, FELINE

ISOLATION & PURIFICATION

FIV, FeLV, and FIPV: interpretation and misinterpretation of serological test results. Barr MC. **Semin Vet Med Surg (Small Anim)** 1996 Aug;11(3):144–53 (34 ref.)

INFECTIOUS PUSTULAR VULVOVAGINITIS VIRUS see **HERPESVIRUS 1, BOVINE**

INFERIOR COLLICULUS

[Colliculus hemorrhage] Bolzani W, et al. **Rev Neurol (Paris)** 1996 Aug–Sep;152(8–9):548–51 (8 ref.) (Eng. Abstr.) **(Fre)**

INFERIOR VENA CAVA FILTERS see **VENA CAVA FILTERS**

INFERTILITY

Infertility in the 1990s: from basic investigation to advanced treatment. Toledo AA, et al. **J Med Assoc Ga** 1997 Sep; 86(3):202–5 (5 ref.)

Occupational reproductive hazards. Paul M. **Lancet** 1997 May 10;349(9062):1385–8 (0 ref.)

Molecular medical approaches for alleviating infertility and understanding assisted reproductive technologies. Sutovsky P, et al. **Proc Assoc Am Physicians** 1996 Nov;108(6):432–43 (84 ref.)

BLOOD

Reproductive effects of maternal metabolic disorders: implications for pediatrics and obstetrics. Levy HL. **Turk J Pediatr** 1996 Jul–Sep;38(3):335–44 (36 ref.)

DIAGNOSIS

Infertility services in a managed care environment. Bates GW, et al. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):300–4 (16 ref.)

Managed care of infertility. Hull MG. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):305–13 (68 ref.)

Infertility revisited: the state of the art today and tomorrow. The ESHRE Capri Workshop. European Society for Human Reproduction and Embryology. **Hum Reprod** 1996 Aug;11(8):1779–807 (254 ref.)

The significance of computer–assisted semen analysis (CASA) for diagnosis in andrology and fertility prognosis. Krause W. **Int J Androl** 1995 Dec;18 Suppl 2:32–5 (14 ref.)

ETIOLOGY

Assisted conception and immunological infertility. Cimino C, et al. **Acta Eur Fertil** 1995 Jan–Feb;26(1):13–20 (46 ref.)

Does cigarette smoking impair natural or assisted fecundity? Hughes EG, et al. **Fertil Steril** 1996 Nov;66(5):679–89 (71 ref.)

Cystic fibrosis and infertility caused by congenital bilateral absence of the vas deferens and related clinical entities. Lissens W, et al. **Hum Reprod** 1996 Dec;11 Suppl 4:55–78; discussion 79–80 (89 ref.)

GENETICS

Genetic aspects of human infertility. Vogt PH. **Int J Androl** 1995 Dec;18 Suppl 2:3–6 (12 ref.)

Induced mouse chromosomal rearrangements as tools for identifying critical developmental genes and pathways. Culiat CT, et al. **Reprod Toxicol** 1997 Mar–Jun; 11(2–3):345–51 (58 ref.)

IMMUNOLOGY

Assisted conception and immunological infertility. Cimino C, et al. **Acta Eur Fertil** 1995 Jan–Feb;26(1):13–20 (46 ref.)

Assisted reproductive technologies and immune infertility. Bustillo M, et al. **Am J Reprod Immunol** 1996 Mar; 35(3):205–10 (38 ref.)

PHYSIOPATHOLOGY

Nutritional infertility: the role of the interconnected hypothalamic neuropeptide Y–galanin–opioid network. Kalra SP, et al. **Front Neuroendocrinol** 1996 Oct; 17(4):371–401 (219 ref.)

PSYCHOLOGY

Infertility and assisted reproductive technology: the role of the perinatal social worker. Greenfeld DA. **Soc Work Health Care** 1997;24(3–4):39–46 (12 ref.)

REHABILITATION

[Cryopreservation of embryos—used for treatment of infertility by means of assisted reproductive techniques (ART)] Wołczyński S. **Ginekol Pol** 1996 May;67(5):270–3 (20 ref.) (Eng. Abstr.) **(Pol)**

THERAPY

Management of involuntary childlessness [see comments] Himmel W, et al. **Br J Gen Pract** 1997 Feb;47(415):111–8 (166 ref.) Comment in: Br J Gen Pract 1997 Feb;47(415):69–70. Comment in: Br J Gen Pract 1997 Jun;47(419):404.

Managed health care's approach to infertility. Cohen A. **Clin Obstet Gynecol** 1997 Jun;40(2):420–6 (5 ref.)

Infertility services in a managed care environment. Bates GW, et al. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):300–4 (16 ref.)

Managed care of infertility. Hull MG. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):305–13 (68 ref.)

Obstetric and perinatal outcome in pregnancies after assisted reproduction. Tanbo T, et al. **Curr Opin Obstet Gynecol** 1996 Jun;8(3):193–8 (43 ref.)

Infertility revisited: the state of the art today and tomorrow. The ESHRE Capri Workshop. European Society for Human Reproduction and Embryology. **Hum Reprod** 1996 Aug;11(8):1779–807 (254 ref.)

Application of in–vitro fertilization in (almost) fertile couples should, and can, be avoided. te Velde ER, et al. **Int J Androl** 1995 Dec;18 Suppl 2:91–3 (10 ref.)

Current status of assisted reproductive technology in Asia and Oceania. Chang YS, et al. **J Obstet Gynaecol Res** 1996 Aug;22(4):305–30 (0 ref.)

[Oocyte maturation. From animal experiments to human reproduction techniques] Lefèvre B. **Contracept Fertil Sex** 1996 Jul–Aug;24(7–8):559–63 (34 ref.) (Eng. Abstr.) **(Fre)**

[Recent data on the treatment of unexplained infertility with clomiphene citrate, intrauterine insemination, and in vitro fertilization] Sitti–Amina AA, et al. **Contracept Fertil Sex** 1997 Feb;25(2):95–100 (15 ref.) **(Fre)**

[Modern fertilization techniques] Glander HJ. **Fortschr Med** 1996 Sep 30;114(27):333–6 (12 ref.) (Eng. Abstr.) **(Ger)**

[The achievements of medical embryology and the successes in treating infertility] Nikitin AI. **Morfologiia** 1996; 110(5):7–14 (28 ref.) (Eng. Abstr.) **(Rus)**

ULTRASONOGRAPHY

Ultrasound–guided transvaginal procedures. Timor–Tritsch IE, et al. **Curr Opin Obstet Gynecol** 1996 Jun;8(3):200–10 (79 ref.)

INFERTILITY AGENTS see **FERTILITY AGENTS**

INFERTILITY AGENTS, FEMALE see **FERTILITY AGENTS, FEMALE**

INFERTILITY, FEMALE

The impact of parity, infertility and treatment with fertility drugs on the risk of ovarian cancer. A survey. Mosgaard BJ, et al. **Acta Obstet Gynecol Scand** 1997 Feb;76(2):89–95 (28 ref.)

Infertility risks associated with postponing pregnancy. Hasty LA, et al. **J Med Assoc Ga** 1997 Sep;86(3):228–9 (5 ref.)

Endometriosis and infertility: new concepts. Ryan IP, et al. **Obstet Gynecol Surv** 1997 Jun;52(6):365–71 (57 ref.)

COMPLICATIONS

The infertile patient with hydrosalpinges—IVF with or without salpingectomy? Andersen AN, et al. **Hum Reprod** 1996 Oct;11(10):2081–4 (21 ref.)

The link between female infertility and cancer: epidemiology and possible aetiologies. Meirow D, et al. **Hum Reprod Update** 1996 Jan–Feb;2(1):63–75 (114 ref.)

INFERTILITY, FEMALE

DIAGNOSIS

[Prognostic role of age and base hormonal levels in infertility treatment] Rongières-Bertrand C, et al. **Contracept Fertil Sex** 1997 Mar;25(3):202–5 (23 ref.) **(Fre)**

EPIDEMIOLOGY

Life-style factors and female infertility. Buck GM, et al. **Epidemiology** 1997 Jul;8(4):435–41 (59 ref.)

ETIOLOGY

The role of hysterosalpingography in the evaluation of infertility. Stovall DW. **Am Fam Physician** 1997 Feb 1; 55(2):621–8 (13 ref.)

Polycystic ovary syndrome: clinical aspects. Conway GS. **Baillieres Clin Endocrinol Metab** 1996 Apr;10(2):263–79 (55 ref.)

Gynecologic issues in pediatric oncology. Jones KP. **Clin Obstet Gynecol** 1997 Mar;40(1):200–9 (21 ref.)

Pathology of female infertility. Honoré LH. **Curr Opin Obstet Gynecol** 1997 Feb;9(1):37–43 (77 ref.)

The role of salpingoscopy and falloposcopy in infertility. Marana R, et al. **Curr Opin Obstet Gynecol** 1996 Aug; 8(4):257–60 (17 ref.)

Counselling HIV patients pursuing infertility investigation and treatment [comment] Rizk B, et al. **Hum Reprod** 1997 Mar;12(3):415–6 (6 ref.) Comment on: Hum Reprod 1996 Dec;11(12):2793–6.

The "cons" of laparoscopic myomectomy in women who may reproduce in the future. Nezhat C. **Int J Fertil Menopausal Stud** 1996 May–Jun;41(3):280–3 (15 ref.)

Bilateral atresia of the proximal ampullary segment of the fallopian tubes. Kozlowski D, et al. **J Am Assoc Gynecol Laparosc** 1995 Nov;3(1):99–101 (7 ref.)

Ovarian drilling in infertile women with polycystic ovary syndrome. Rose BI. **J Am Assoc Gynecol Laparosc** 1996 May;3(3):461–8 (44 ref.)

Autoantibody screening for infertility: explaining the unexplained? Hatasaka HH, et al. **J Reprod Immunol** 1997 Sep;34(2):137–53 (30 ref.)

[Fallopian tube endoscopy in 1996] Dechaud H, et al. **Contracept Fertil Sex** 1996 Jul–Aug;24(7–8):543–8 (10 ref.) (Eng. Abstr.) **(Fre)**

[Infertility and small myoma: role of myomectomy] Fernandez H. **Contracept Fertil Sex** 1997 May;25(5):348–9 (12 ref.) **(Fre)**

[Results and indications of laparoscopic distal tuboplasty] Lavergne N, et al. **Contracept Fertil Sex** 1996 Jan; 24(1):41–8 (29 ref.) (Eng. Abstr.) **(Fre)**

[Role of surgery in the treatment of infertility due to polycystic ovaries] Pauthier S, et al. **Contracept Fertil Sex** 1996 Nov;24(11):825–9 (31 ref.) (Eng. Abstr.) **(Fre)**

[Distal tubal surgery: a critical review of 104 laparoscopic distal tuboplasties] Filippini F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(5):471–8 (31 ref.) (Eng. Abstr.) **(Fre)**

[Uterine and tubal-peritoneal factors in infertility: comparison of radiologic and endoscopic techniques] Valentini AL, et al. **Radiol Med (Torino)** 1996 Nov; 92(5):514–9 (43 ref.) **(Ita)**

[In an infertile woman, does the presence of one or several myomas of less than three cm in diameter justify a myomectomy?] Lopes P. **Contracept Fertil Sex** 1997 May; 25(5):350–1 (6 ref.) **(Spa)**

GENETICS

Clinical manifestations of genetic defects affecting gonadotrophins and their receptors. Conway GS. **Clin Endocrinol (Oxf)** 1996 Dec;45(6):657–63 (41 ref.)

The molecular genetics of the zona pellucida: mouse mutations and infertility. Rankin T, et al. **Mol Hum Reprod** 1996 Nov;2(11):889–94 (56 ref.)

IMMUNOLOGY

Autoimmunity and reproduction. Geva E, et al. **Fertil Steril** 1997 Apr;67(4):599–611 (100 ref.)

Antiphospholipid antibodies and reproductive failure: what they do and what they do not do; how to, and how not to treat! Gleicher N. **Hum Reprod** 1997 Jan;12(1):13–6 (34 ref.)

Autoantibodies and infertility: a review of the literature. Van Voorhis BJ, et al. **J Reprod Immunol** 1997 Jul;33(3):239–56 (56 ref.)

[Immunologic response against spermatozoa in the human genital tract] Domagala A, et al. **Ginekol Pol** 1996 Jun; 67(6):304–8 (26 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

[Uses of nitric oxide in obstetrics and gynecology] He W, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Feb; 31(2):119–21 (23 ref.) **(Chi)**

PARASITOLOGY

[Genital bilharziasis and female infertility. Review of the literature and three case reports] Morice P, et al. **Contracept Fertil Sex** 1996 Jan;24(1):56–61 (25 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

["Doctor shopping" in fertility medicine] Strauss B. **Arch Gynecol Obstet** 1996;259 Suppl 1:S24–32 (25 ref.) **(Ger)**

RADIOGRAPHY

The role of hysterosalpingography in the evaluation of infertility. Stovall DW. **Am Fam Physician** 1997 Feb 1; 55(2):621–8 (13 ref.)

SURGERY

Laparoscopic procedures for treatment of infertility related to polycystic ovarian syndrome. Cohen J. **Hum Reprod Update** 1996 Jul–Aug;2(4):337–44 (55 ref.)

Fertility after hysteroscopic myomectomy. Ubaldi F, et al. **Hum Reprod Update** 1995 Jan;1(1):81–90 (77 ref.)

Laparoscopic treatment is better than medical treatment for minimal or mild endometriosis. Adamsor GD. **Int J Fertil Menopausal Stud** 1996 Jul–Aug;41(4):396–9 (9 ref.)

[Tubal sterility: fertilization in vitro or surgery?] Pouly JL, et al. **Contracept Fertil Sex** 1997 Apr;25(4):I–IV (22 ref.) **(Fre)**

[Andrologic/gynecologic microsurgery and fertilization in vitro: complementary approaches?] Schoysman R, et al. **Contracept Fertil Sex** 1997 Apr;25(4):306–12 (30 ref.) (Eng. Abstr.) **(Fre)**

[A case of myomectomy for infertility and a following twin pregnancy associated with hyperthyroidism] Berlingieri D, et al. **Minerva Ginecol** 1996 Dec;48(12):545–52 (20 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Assisted conception following poor ovarian response to gonadotrophin stimulation. Keay SD, et al. **Br J Obstet Gynaecol** 1997 May;104(5):521–7 (78 ref.)

The case against new reproductive technologies in developing countries [see comments] Okonofua FE. **Br J Obstet Gynaecol** 1996 Oct;103(10):957–62 (37 ref.) Comment in: Br J Obstet Gynaecol 1997 Mar;104(3):385. Comment in: Br J Obstet Gynaecol 1997 Aug;104(8):969; discussion 969–70. Comment in: Br J Obstet Gynaecol 1997 Aug;104(8):970.

Infertility and subsequent pregnancy. Hoxsey R, et al. **Clin Perinatol** 1997 Jun;24(2):321–42 (95 ref.)

Endometriosis: medical and surgical intervention. Falcone T, et al. **Curr Opin Obstet Gynecol** 1996 Jun;8(3):178–83 (40 ref.)

Infertility treatment in women over 40 years of age. Feinman MA. **Curr Opin Obstet Gynecol** 1997 Jun;9(3):165–8 (21 ref.)

Infertility in women. Ben-Ozer S, et al. **Curr Ther Endocrinol Metab** 1997;6:228–34 (12 ref.)

Occult ovarian failure. Healy DL. **Curr Ther Endocrinol Metab** 1997;6:226–7 (6 ref.)

Laparoscopic treatment of symptomatic endometriosis. Pouly JL, et al. **Hum Reprod** 1996 Nov;11 Suppl 3:67–88 (88 ref.)

Counselling HIV patients pursuing infertility investigation and treatment [comment] Rizk B, et al. **Hum Reprod** 1997 Mar;12(3):415–6 (6 ref.) Comment on: Hum Reprod 1996 Dec;11(12):2793–6.

Medical treatment of infertility associated with minimal to mild endometriosis. Barbieri RL. **Int J Fertil Menopausal Stud** 1996 Jul–Aug;41(4):393–5 (14 ref.)

The evolution of new agents for ovulation induction. Gast MJ. **Semin Reprod Endocrinol** 1996 Nov;14(4):375–89 (79 ref.)

Evaluation and treatment of low responders. Scott RT Jr. **Semin Reprod Endocrinol** 1996 Nov;14(4):317–37 (63 ref.)

Ovulation induction in the ovulatory woman. Silverberg KM. **Semin Reprod Endocrinol** 1996 Nov;14(4):339–44 (28 ref.)

[The value of recombinant gonadotropins in treatment of infertility] Breckwoldt M, et al. **Zentralbl Gynakol** 1996; 118(3):176–8 (11 ref.) **(Ger)**

ULTRASONOGRAPHY

Advances in the use of ultrasound in infertility management. Zaidi J, et al. **Curr Opin Obstet Gynecol** 1996 Jun;8(3):161–5 (40 ref.)

VETERINARY

Gamete intrafallopian transfer. Carnevale EM. **Vet Clin North Am Equine Pract** 1996 Apr;12(1):47–60 (40 ref.)

INFERTILITY, MALE

Contribution of andrological factors to sterility. Krause W. **Andrologia** 1996;28 Suppl 1:15–7 (9 ref.)

Approaches for obtaining sperm in patients with male factor infertility. Cha KY, et al. **Fertil Steril** 1997 Jun;67(6):985–95 (86 ref.)

Approaching the next millennium: how should we manage andrology diagnosis in the intracytoplasmic sperm injection era? [editorial] Oehninger S, et al. **Fertil Steril** 1997 Mar; 67(3):434–6 (15 ref.)

Human semen analysis. Comhaire F, et al. **Hum Reprod Update** 1995 Jul;1(4):343–62 (59 ref.)

Male infertility [see comments] de Kretser DM. **Lancet** 1997 Mar 15;349(9054):787–90 (50 ref.) Comment in: Lancet 1997 May 10;349(9062):1400.

[A case of congenital ejaculatory duct obstruction] Saito K, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Dec; 87(12):1331–4 (24 ref.) (Eng. Abstr.) **(Jpn)**

CHEMICALLY INDUCED

Fertility after chemotherapy for testicular germ cell cancer. Pont J, et al. **Fertil Steril** 1997 Jul;68(1):1–5 (45 ref.)

Clinical approaches to male infertility with a case report of possible nifedipine-induced sperm dysfunction. Enders G. **J Am Board Fam Pract** 1997 Mar–Apr;10(2):131–6 (27 ref.)

DIAGNOSIS

Consensus workshop on advanced diagnostic andrology techniques. ESHRE (European Society of Human Reproduction and Embryology) Andrology Special Interest Group. **Hum Reprod** 1996 Jul;11(7):1463–79 (117 ref.)

Consensus workshop on advanced diagnostic andrology techniques [letter] Comhaire F. **Hum Reprod** 1997 Apr; 12(4):872 (2 ref.)

Advantages of strict (Tygerberg) criteria for evaluation of sperm morphology. Menkveld R, et al. **Int J Androl** 1995 Dec;18 Suppl 2:36–42 (43 ref.)

Molecular approaches to the diagnosis of male infertility. Jeremias J, et al. **Mol Hum Reprod** 1996 Mar;2(3):195–202 (60 ref.)

[CLinical examination of the infertile man in 1996] Adjiman M. **Contracept Fertil Sex** 1996 Oct;24(10):739–41 (10 ref.) **(Fre)**

[Which genetic tests in infertile men?] Jalbert P. **Contracept Fertil Sex** 1996 Jul–Aug;24(7–8):585–8 (17 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Treatment of male infertility with growth hormone. Ng SC, et al. **Clin Sci (Colch)** 1996 Sep;91(3):254–5 (18 ref.)

EPIDEMIOLOGY

Do men become infertile after having sexually transmitted urethritis? An epidemiologic examination. Ness RB, et al. **Fertil Steril** 1997 Aug;68(2):205–13 (73 ref.)

ETIOLOGY

Fertility and environmental pollutants with reference to male fecundity. Bonde JP. **Arctic Med Res** 1996;55 Suppl 1:35–7 (17 ref.)

Varicocele: indications for treatment. Comhaire F, et al. **Int J Androl** 1995 Dec;18 Suppl 2:67–71 (36 ref.)

Role of oxidative stress and antioxidants in male infertility. Sikka SC, et al. **J Androl** 1995 Nov–Dec;16(6):464–81 (16 ref.)

Identifying environmental risk to male reproductive function by occupational sperm studies: logistics and design options. Bonde JP, et al. **Occup Environ Med** 1996 Aug;53(8):511–9 (56 ref.)

What are the chances of infertility and should sperm be banked? Ohl DA, et al. **Semin Urol Oncol** 1996 Feb; 14(1):36–44 (80 ref.)

Is assisted reproduction the optimal treatment for varicocele-associated male infertility? A cost-effectiveness analysis. Schlegel PN. **Urology** 1997 Jan;49(1):83–90 (52 ref.)

Effect of diabetes mellitus upon male reproductive function. Sexton WJ, et al. **Urology** 1997 Apr;49(4):508–13 (45 ref.)

Role of reactive oxygen species in male infertility. Sharma RK, et al. **Urology** 1996 Dec;48(6):835–50 (154 ref.)

[Testicular ectopy in children. Current practical attitude] Allouch G. **J Urol (Paris)** 1996;102(3):99–101 (6 ref.) (Eng. Abstr.) **(Fre)**

[Prevention of sterility in spinal cord injured men] Tollon C, et al. **Prog Urol** 1997 Apr;7(2):203–8 (43 ref.) (Eng. Abstr.) **(Fre)**

[Andrologic diagnosis today] Haidl G. **Fortschr Med** 1996 Dec 10;114(34):465–9 (22 ref.) (Eng. Abstr.) **(Ger)**

[Cancer and male infertility] Botchan A, et al. **Harefuah** 1996 Jun 2;130(11):761–4 (45 ref.) **(Heb)**

[A case of 47XYY syndrome presenting with male infertility] Murakami J, et al. **Hinyokika Kiyo** 1997 Jun;43(6):433–6 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Environmental factors which impair male fertility] Indulski JA, et al. **Med Pr** 1997;48(1):85–92 (40 ref.) (Eng. Abstr.) **(Pol)**

[Male sterility. Preconditioning factors] Pérez y Pérez F. **An R Acad Nac Med (Madr)** 1997;114(1):105–26; discussion 126–7 (31 ref.) **(Spa)**

[Testicular microlithiasis associated with infertility] González Sánchez FJ, et al. **Arch Esp Urol** 1997 Jan–Feb;50(1):71–4 (12 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Genetic causes of male infertility. Wieacker P, et al. **Andrologia** 1997 Mar–Apr;29(2):63–9 (52 ref.)

The molecular genetics of male infertility. Elliott DJ, et al. **Bioessays** 1997 Sep;19(9):801–9 (73 ref.)

Chromosomal anomalies as a predisposing factor for male infertility. Wiland E, et al. **Folia Histochem Cytobiol** 1997; 35(2):55–62 (59 ref.)

Cytogenetics of infertile men. Van Assche E, et al. **Hum Reprod** 1996 Dec;11 Suppl 4:1–24; discussion 25–6 (114 ref.)
The genetics of male infertility [see comments] Mak V, et al. **J Urol** 1996 Oct;156(4):1245–56; discussion 1256–7 (181 ref.) Comment in: J Urol 1997 Aug;158(2):550–1.
The molecular genetics of male infertility. Meschede D, et al. **Mol Hum Reprod** 1997 May;3(5):419–30 (159 ref.)
RNA-binding proteins and human male infertility. Cooke HJ, et al. **Trends Genet** 1997 Mar;13(3):87–9 (30 ref.)
Hybrid sterility in the mouse [published erratum appears in Trends Genet 1997 Jan;13(1):42] Forejt J. **Trends Genet** 1996 Oct;12(10):412–7 (51 ref.)
[Which genetic tests in infertile men?] Jalbert P. **Contracept Fertil Sex** 1996 Jul–Aug;24(7–8):585–8 (17 ref.) (Eng. Abstr.) **(Fre)**
[Is infertility hereditary?] Plachot M. **Contracept Fertil Sex** 1997 Mar;25(3):194–5 (3 ref.) **(Fre)**

IMMUNOLOGY

Molecular approaches to the diagnosis of male infertility. Jeremias J, et al. **Mol Hum Reprod** 1996 Mar;2(3):195–202 (60 ref.)
[Immunologic response against spermatozoa in the human genital tract] Domagala A, et al. **Ginekol Pol** 1996 Jun; 67(6):304–8 (26 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Role of reactive oxygen species in male infertility. Sharma RK, et al. **Urology** 1996 Dec;48(6):835–50 (154 ref.)

MICROBIOLOGY

Do men become infertile after having sexually transmitted urethritis? An epidemiologic examination. Ness RB, et al. **Fertil Steril** 1997 Aug;68(2):205–13 (73 ref.)

PHYSIOPATHOLOGY

Role of oxidative stress and antioxidants in male infertility. Sikka SC, et al. **J Androl** 1995 Nov–Dec;16(6):464–81 (16 ref.)
[Prolactin and male infertility—unsolved enigma] Bar-On E, et al. **Harefuah** 1996 May 1;130(9):617–21 (46 ref.) **(Heb)**

PREVENTION & CONTROL

[Prevention of sterility in spinal cord injured men] Tollon C, et al. **Prog Urol** 1997 Apr;7(2):203–8 (43 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Microsurgical epididymal sperm aspiration: review of techniques, preoperative considerations, and results. Girardi SK, et al. **J Androl** 1996 Jan–Feb;17(1):5–9 (13 ref.)
[Andrologic/gynecologic microsurgery and fertilization in vitro: complementary approaches?] Schoysman R, et al. **Contracept Fertil Sex** 1997 Apr;25(4):306–12 (30 ref.) (Eng. Abstr.) **(Fre)**
[Surgical therapy of obstructive azoospermia: microsurgery] Fenice O, et al. **Arch Ital Urol Androl** 1996 Dec; 68(5):379–88 (29 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

The implications of a paternally derived centrosome during human fertilization: consequences for reproduction and the treatment of male factor infertility. Navara CS, et al. **Am J Reprod Immunol** 1997 Jan;37(1):39–49 (42 ref.)
Male infertility treatment in the light of evidence-based medicine. Leifke E, et al. **Andrologia** 1996;28 Suppl 1:23–30 (55 ref.)
Update on micromanipulation techniques for assisted conception. Ng SC, et al. **Curr Opin Obstet Gynecol** 1996 Jun;8(3):171–7 (73 ref.)
Male infertility of undetermined etiology. Baker HW. **Curr Ther Endocrinol Metab** 1997;6:359–63 (4 ref.)
Is there still a place for intra-uterine insemination as a treatment for male subfertility? A review. Cohlen BJ, et al. **Int J Androl** 1995 Dec;18 Suppl 2:72–5 (30 ref.)
Statement on intra-uterine insemination. Comhaire F, et al. **Int J Androl** 1995 Dec;18 Suppl 2:76–7 (7 ref.)
New approaches to male infertility: IVF and microinjection. Diedrich K, et al. **Int J Androl** 1995 Dec;18 Suppl 2:78–80 (11 ref.)
Survey of medical therapy in andrology. Schill WB. **Int J Androl** 1995 Dec;18 Suppl 2:56–62 (50 ref.)
Recent concepts in the management of male infertility. Namiki M. **Int J Urol** 1996 Jul;3(4):249–55 (104 ref.)
Clinical review 87: In vitro fertilization for male factor infertility. Schlegel PN, et al. **J Clin Endocrinol Metab** 1997 Mar;82(3):709–16 (69 ref.)
Intracytoplasmic sperm injection for treatment of the infertile male. Kim ED, et al. **Tex Med** 1997 Jul;93(7):50–6 (41 ref.)
[Progresses in andrology in China, 1996] Cao J. **Chung Hua I Hsueh Tsa Chih** 1996 Dec;76(12):923–4 (0 ref.) **(Chi)**
[Micro-insemination with intracytoplasmic sperm injection] Andersen AG, et al. **Ugeskr Laeger** 1996 Nov 18; 158(47):6747–51 (31 ref.) (Eng. Abstr.) **(Dan)**
[Intra-uterine inseminations with hyperstimulation in male infertility] Delépine B, et al. **Contracept Fertil Sex** 1996 Dec;24(12):891–6 (21 ref.) (Eng. Abstr.) **(Fre)**
[Intracytoplasmic injection of spermatozoa] Olivennes F, et al. **Presse Med** 1996 Nov 2;25(33):1599–603 (25 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Clinical relevance of scrotal and transrectal ultrasonography in andrological patients. Behre HM, et al. **Int J Androl** 1995 Dec;18 Suppl 2:27–31 (19 ref.)
Role of ultrasound in the assessment of male infertility. Kim ED, et al. **J Clin Ultrasound** 1996 Oct;24(8):437–53 (46 ref.)

VETERINARY

GnRH therapy for subfertile stallions. Brinsko SP. **Vet Clin North Am Equine Pract** 1996 Apr;12(1):149–60 (50 ref.)
The significance to bull fertility of morphologically abnormal sperm. Johnson WH. **Vet Clin North Am Food Anim Pract** 1997 Jul;13(2):255–70 (30 ref.)
Genetic causes of bull infertility. Steffen D. **Vet Clin North Am Food Anim Pract** 1997 Jul;13(2):243–53 (43 ref.)
Common causes of infertility in the bull. Van Camp SD. **Vet Clin North Am Food Anim Pract** 1997 Jul;13(2):203–31 (30 ref.)
[The intracytoplasmatic spermatozoa injection—the way out of the "male fertility crisis"?] Michelmann HW. **DTW Dtsch Tierarztl Wochenschr** 1996 Oct;103(10):384–6 (14 ref.) (Eng. Abstr.) **(Ger)**

INFIBULATION see **CIRCUMCISION, FEMALE**

INFLAMMATION

see related
ACUTE-PHASE REACTION
ANTI-INFLAMMATORY AGENTS

Induction of cyclo-oxygenase and nitric oxide synthase in inflammation. Appleton I, et al. **Adv Pharmacol** 1996; 35:27–78 (329 ref.)
The codependence of angiogenesis and chronic inflammation. Jackson JR, et al. **FASEB J** 1997 May;11(6):457–65 (61 ref.)
Platelets and inflammation: role of platelet-derived growth factor, adhesion molecules and histamine. Mannaioni PF, et al. **Inflamm Res** 1997 Jan;46(1):4–18 (119 ref.)
The inflammatory response to cardiopulmonary bypass. Hill GE. **Int Anesthesiol Clin** 1996 Spring;34(2):95–108 (106 ref.)
The human inflammatory response. Levy JH. **J Cardiovasc Pharmacol** 1996;27 Suppl 1:S31–7 (24 ref.)
Recruitment of inflammatory cells into lung: roles of cytokines, adhesion molecules, and complement. Ward PA. **J Lab Clin Med** 1997 Apr;129(4):400–4 (24 ref.)
Inflammatory reactions induced by pretransplant conditioning—an alternative target for modulation of acute GvHD and complications following allogeneic bone marrow transplantation? Holler E, et al. **Leuk Lymphoma** 1997 Apr;25(3–4):217–24 (35 ref.)
Nitric oxide as antiinflammatory agent. Granger DN, et al. **Methods Enzymol** 1996;269:434–42 (26 ref.)
Chronic inflammatory diseases. Iversen OJ, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Mar;13(1):66–9 (24 ref.)
Cytokines and intestinal inflammation. Fiocchi C. **Transplant Proc** 1996 Oct;28(5):2442–3 (11 ref.)
[The acute inflammatory response. Mechanisms and therapeutic possibilities] Pedersen JL, et al. **Ugeskr Laeger** 1996 Oct 7;158(41):5754–61 (37 ref.) (Eng. Abstr.) **(Dan)**
[Result of biological response to surgical stress] Yuge T. **Masui** 1996 Dec;45 Suppl:S44–8 (14 ref.) **(Jpn)**
[Pharmacology in regulation of newly inducted functional molecules] Oishi S, et al. **Nippon Yakurigaku Zasshi** 1996 Sep;108(3):104–7 (10 ref.) **(Jpn)**

BLOOD

Corticosteroid-binding globulin during inflammation and burn injury: nutritional modulation and clinical implications. Garrel DR. **Horm Res** 1996;45(3–5):245–51 (54 ref.)
Fibrinolytic and inflammatory markers for arterial occlusion: the evolving epidemiology of thrombosis and hemostasis. Ridker PM. **Thromb Haemost** 1997 Jul;78(1):53–9 (86 ref.)

CHEMICALLY INDUCED

Proinflammatory cytokines, nutritional support, and the cachexia syndrome: interactions and therapeutic options. Moldawer LL, et al. **Cancer** 1997 May 1;79(9):1828–39 (119 ref.)
Chemical-induced inflammation and inflammatory diseases. Parke DV, et al. **Int J Occup Med Environ Health** 1996; 9(3):211–7 (24 ref.)
Interferon-alpha and its effects on the cytokine cascade: a pro- and anti-inflammatory cytokine. Tilg H, et al. **Leuk Lymphoma** 1996 Sep;23(1–2):55–60 (73 ref.)
Particles, inflammation and respiratory tract carcinogenesis. Borm PJ, et al. **Toxicol Lett** 1996 Nov;88(1–3):109–13 (16 ref.)

COMPLICATIONS

Natural remission in inflammatory polyarthritis: issues of definition and prediction [see comments] Harrison BJ, et al. **Br J Rheumatol** 1996 Nov;35(11):1096–100 (21 ref.) Comment in: Br J Rheumatol 1996 Nov;35(11):1039–40.
The inflammatory basis of asthma and its implications for drug treatment. Holgate ST. **Clin Exp Allergy** 1996 Jun; 26 Suppl 4:1–4 (28 ref.)
Immune and inflammatory mechanisms in the pathogenesis of atherosclerosis. Hansson GK. **J Atheroscler Thromb** 1994;1 Suppl 1:S6–9 (42 ref.)
Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? [see comments] Vallance P, et al. **Lancet** 1997 May 10;349(9062):1391–2 (30 ref.) Comment in: Lancet 1997 Jul 26;350(9073):293. Comment in: Lancet 1997 Jul 26;350(9073):293–4.
The role of inflammation in the development of allograft coronary disease. Miller LW. **Transplant Proc** 1997 Sep; 29(6):2583–4 (18 ref.)

DIAGNOSIS

Inflammatory and infectious lesions of the neck. Ginsberg LE. **Semin Ultrasound CT MR** 1997 Jun;18(3):205–19 (47 ref.)
[Methods of evaluating airway inflammation] Mita S, et al. **Nippon Rinsho** 1996 Nov;54(11):2898–902 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Tumor and inflammation markers in diagnosis of serous pleural exudate] Trubnikov GA, et al. **Klin Med (Mosk)** 1997;75(6):15–20 (53 ref.) **(Rus)**

DRUG THERAPY

Allergic rhinitis and inflammation: the effect of nasal corticosteroid therapy. Fokkens WJ, et al. **Allergy** 1997; 52(36 Suppl):29–32 (23 ref.)
Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. Ballow M. **J Allergy Clin Immunol** 1997 Aug;100(2):151–7 (70 ref.)
Therapeutic applications of anti-cytokine strategies. Poole S. **Mol Psychiatry** 1997 Mar;2(2):137–8 (20 ref.)
Treatment of airways inflammation in asthma. Djukanović R. **Monaldi Arch Chest Dis** 1996 Dec;51(6):475–8 (26 ref.)
Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: a current appraisal. Breitner JC. **Neurobiol Aging** 1996 Sep–Oct;17(5):789–94 (93 ref.)
Antidepressant drugs and experimental inflammation. Bianchi M, et al. **Pharmacol Res** 1996 Apr–May;33(4–5):235–8 (36 ref.)
Mucolytic and mucokinetic therapy. Wills PJ, et al. **Pulm Pharmacol** 1996 Aug;9(4):197–204 (93 ref.)
Influence of high-dose antithrombin concentrate therapy on the release of cellular proteinases, cytokines, and soluble adhesion molecules in acute inflammation. Jochum M. **Semin Hematol** 1995 Oct;32(4 Suppl 2):19–32 (8 ref.)
[Bronchial asthma as an inflammation and the use of inhaled steroid] Kaneko F, et al. **Nippon Rinsho** 1996 Nov; 54(11):2962–8 (18 ref.) (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

Sounding the alarm: protein kinase cascades activated by stress and inflammation. Kyriakis JM, et al. **J Biol Chem** 1996 Oct 4;271(40):24313–6 (78 ref.)
Interactions of nitric oxide with cyclooxygenase: in vitro, ex vivo, and in vivo studies. Salvemini D, et al. **Methods Enzymol** 1996;269:12–25 (40 ref.)
[Role of type II secreted phospholipase A2 in inflammatory processes] Jacques C, et al. **C R Seances Soc Biol Fil** 1996; 190(4):437–43 (40 ref.) (Eng. Abstr.) **(Fre)**
[Phospholipase A2 and inflammation] Murakami M, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Dec;19(6):561–3 (10 ref.) **(Jpn)**

ETIOLOGY

The systemic inflammatory response to cardiopulmonary bypass: pathophysiological, therapeutic, and pharmacological considerations. Hall RI, et al. **Anesth Analg** 1997 Oct;85(4):766–82 (161 ref.)
Hypothesis: iron chelation plays a vital role in neutrophilic inflammation. Ghio AJ, et al. **Biometals** 1997 Apr; 10(2):135–42 (88 ref.)
Neurogenic inflammation: with additional discussion of central and perceptual integration of nonneurogenic inflammation. Bascom R, et al. **Environ Health Perspect** 1997 Mar;105 Suppl 2:531–7 (43 ref.)
Chemical toxicity and reactive oxygen species. Parke DV, et al. **Int J Occup Med Environ Health** 1996;9(4):331–40 (45 ref.)
Potential role of tachykinins in inflammatory diseases. Canning BJ. **J Allergy Clin Immunol** 1997 May;99(5):579–82 (30 ref.)
The inflammatory response and extracorporeal circulation. Royston D. **J Cardiothorac Vasc Anesth** 1997 May; 11(3):341–54 (150 ref.)
Amplification of the inflammatory response: adhesion molecules associated with platelet/white cell responses. Rinder C, et al. **J Cardiovasc Pharmacol** 1996;27 Suppl 1:S6–12 (41 ref.)
Taurine and inflammation—a new approach to an old problem? [letter] Stapleton PP, et al. **J Leukoc Biol** 1997 Feb;61(2):231–2 (19 ref.)

INFLAMMATION

Inflammation and metastases. Nowacki MP, et al. **Med Hypotheses** 1996 Sep;47(3):193–6 (47 ref.)
Inflammation, free radicals, and antioxidants. Conner EM, et al. **Nutrition** 1996 Apr;12(4):274–7 (40 ref.)
Mechanisms of airway inflammation in cystic fibrosis. Döring G. **Pediatr Allergy Immunol** 1996;7(9 Suppl):63–6 (31 ref.)
The influence of biomaterials on inflammatory responses to cardiopulmonary bypass. Courtney JM, et al. **Perfusion** 1996 May;11(3):220–8 (93 ref.)
Blood contact activation: pathophysiological effects and therapeutic approaches. Hornick P, et al. **Perfusion** 1996 Jan;11(1):3–19 (143 ref.)
Systemic inflammatory response and the splanchnic bed in cardiopulmonary bypass. Ohri SK. **Perfusion** 1996 May; 11(3):200–12 (68 ref.)
Systemic inflammatory responses to surgery with cardiopulmonary bypass. Royston D. **Perfusion** 1996 May; 11(3):177–89 (81 ref.)
The systemic inflammatory response to cardiopulmonary bypass and the brain. Smith PL. **Perfusion** 1996 May; 11(3):196–9 (15 ref.)
The history of the concept of inflammatory responses to cardiopulmonary bypass. Utley JR. **Perfusion** 1996 May; 11(3):190–5 (46 ref.)
Evidence for the presence of chronic inflammation during peritoneal dialysis: therapeutic implications. Breborowicz A, et al. **Perit Dial Int** 1997;17 Suppl 2:S37–41 (55 ref.)
Inflammation: patterns and new concepts. Huerre MR, et al. **Res Immunol** 1996 Sep;147(7):417–34 (33 ref.)
Mast cells as potent inflammatory cells. Dumitrașcu D. **Rom J Intern Med** 1996 Jul–Dec;34(3–4):159–72 (30 ref.)
[Acute pancreatitis: inflammatory response of the body] Jakab L. **Orv Hetil** 1996 Sep 29;137(39):2141–7 (49 ref.) (Eng. Abstr.) **(Hun)**
[The roles of adhesion molecules, cytokines, and chemokines in eosinophil activation during allergic inflammation] Chihara J. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec; 34 Suppl:116–20 (28 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

The NF-kappa B/Rel and I kappa B gene families: mediators of immune response and inflammation. Wulczyn FG, et al. **J Mol Med** 1996 Dec;74(12):749–69 (252 ref.)
Cytokines as genetic modifying factors in immune and inflammatory diseases. Cox A, et al. **J Pediatr Endocrinol Metab** 1996 Mar;9 Suppl 1:129–32 (28 ref.)

IMMUNOLOGY

Fimbriae-mediated adherence induces mucosal inflammation and bacterial clearance. Consequences for anti-adhesion therapy. Connell H, et al. **Adv Exp Med Biol** 1996; 408:73–80 (43 ref.)
Role of interleukin-4 in the development of allergic airway inflammation and airway hyperresponsiveness. Wills-Karp M, et al. **Adv Exp Med Biol** 1996;409:343–7 (37 ref.)
Platelets and inflammation. Klinger MH. **Anat Embryol (Berl)** 1997 Jul;196(1):1–11 (135 ref.)
Neuroendocrine immune responses to inflammation: the concept of the neuroendocrine immune loop. Chikanza IC, et al. **Baillieres Clin Rheumatol** 1996 May;10(2):199–225 (135 ref.)
T-lymphocyte-fibroblast interactions. Crowston JG, et al. **Biochem Soc Trans** 1997 May;25(2):529–31 (14 ref.)
Neuroimmune mechanisms in health and disease: 2. Disease. Anisman H, et al. **Can Med Assoc J** 1996 Oct 15; 155(8):1075–82 (63 ref.)
Leukocyte-endothelial cell interactions evoked by mast cells. Kubes P, et al. **Cardiovasc Res** 1996 Oct;32(4):699–708 (85 ref.)
Molecular mechanisms of leukocyte recruitment in the inflammatory process. Ley K. **Cardiovasc Res** 1996 Oct; 32(4):733–42 (129 ref.)
Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Lucey DR, et al. **Clin Microbiol Rev** 1996 Oct;9(4):532–62 (432 ref.)
Lymphocyte-fibroblast interactions. Murakami S, et al. **Crit Rev Oral Biol Med** 1997;8(1):40–50 (93 ref.)
Chemokines in immune-mediated inflammation of the central nervous system. Ransohoff RM, et al. **Cytokine Growth Factor Rev** 1996 Jun;7(1):35–46 (85 ref.)
Role of complement in inflammation and injury in the nervous system. Morgan BP, et al. **Exp Clin Immunogenet** 1997;14(1):19–23 (22 ref.)
Endogenous control and modulation of inflammation. Ferenčik M, et al. **Folia Biol (Praha)** 1996;42(1–2):47–55 (64 ref.)
NK cell proliferation and inflammation. Warren HS. **Immunol Cell Biol** 1996 Oct;74(5):473–80 (120 ref.)
Eosinophils and eosinophil-associated cytokines in allergic inflammation. Kay AB, et al. **Int Arch Allergy Immunol** 1997 May–Jul;113(1–3):196–9 (26 ref.)
The role of chemokines in inflammation. Proost P, et al. **Int J Clin Lab Res** 1996;26(4):211–23 (116 ref.)
Chemokines in allergic inflammation. Alam R. **J Allergy Clin Immunol** 1997 Mar;99(3):273–7 (8 ref.)
The inflammatory response to cardiopulmonary bypass. Miller BE, et al. **J Cardiothorac Vasc Anesth** 1997 May; 11(3):355–66 (149 ref.)
Serine protease inhibition prevents both cellular and humoral responses to cardiopulmonary bypass. Royston D. **J Cardiovasc Pharmacol** 1996;27 Suppl 1:S42–9 (60 ref.)
The utility of transgenic mouse models in the study of cutaneous immunology and inflammation. Kupper TS. **J Dermatol** 1996 Nov;23(11):741–5 (26 ref.)
A newly recognized pathway for the negative regulation of mast cell-dependent hypersensitivity and inflammation mediated by an endogenous cell surface receptor of the gp49 family. Katz HR, et al. **J Immunol** 1997 Jun 1; 158(11):5065–70 (32 ref.)
Mechanisms of inflammation and leukocyte activation. Ali H, et al. **Med Clin North Am** 1997 Jan;81(1):1–28 (89 ref.)
Interleukin 8 as a novel target for intervention therapy in acute inflammatory diseases. Harada A, et al. **Mol Med Today** 1996 Nov;2(11):482–9 (30 ref.)
Chemokine receptors: gateways to inflammation and infection. Premack BA, et al. **Nat Med** 1996 Nov; 2(11):1174–8 (39 ref.)
Molecular aspects of inflammatory and immune responses in Alzheimer's disease. Kalaria RN, et al. **Neurobiol Aging** 1996 Sep–Oct;17(5):687–93 (76 ref.)
The effects of tachykinins on inflammatory and immune cells. Maggi CA. **Regul Pept** 1997 Jun 18;70(2–3):75–90 (198 ref.)
Immunobiology of eosinophils in allergy and inflammation. Capron M, et al. **Res Immunol** 1997 Jan;148(1):29–33 (38 ref.)
Granulocyte clearance by apoptosis in the resolution of inflammation. Savill J, et al. **Semin Cell Biol** 1995 Dec; 6(6):385–93 (72 ref.)
[The role of perinuclear antineutrophil granulocytes cytoplasmic antibodies in the diagnosis of vasculitis and chronic inflammatory diseases (see comments)] Franssen CF, et al. **Ned Tijdschr Geneeskd** 1996 Oct 19; 140(42):2076–82 (66 ref.) Comment in: Ned Tijdschr Geneeskd 1997 Jan 4;141(1):63–4. **(Dut)**
[Immuno-neuro-endocrine network] Imura H. **Rinsho Byori** 1997 Jun;45(6):505–10 (12 ref.) **(Jpn)**
[Chronic inflammation of mucous membranes: integration of immunity and regeneration] Zinov'ev AS, et al. **Arkh Patol** 1997 May–Jun;59(3):18–24 (50 ref.) (Eng. Abstr.) **(Rus)**
[Atherogenesis and immune inflammation] Nagornev VA. **Biull Eksp Biol Med** 1996 Jul;122(7):4–8 (27 ref.) **(Rus)**
[Complement in inflammation] Porcel-Pérez JM, et al. **Rev Clin Esp** 1996 Mar;196 Spec No:13–8 (71 ref.) **(Spa)**

METABOLISM

PAF response to inflammatory and non-inflammatory stimuli. Saito K. **Adv Exp Med Biol** 1996;416:213–6 (11 ref.)
Antioxidants, redox-regulated transcription factors, and inflammation. Winyard PG, et al. **Adv Pharmacol** 1997; 38:403–21 (103 ref.)
Eosinophil-derived cytokines in allergic inflammation and asthma. Moqbel R. **Ann N Y Acad Sci** 1996 Oct 31; 796:209–17 (41 ref.)
Biochemistry of inflammatory processes and vascular injury. Role of neutrophils: a review. Belova LA. **Biochemistry (Mosc)** 1997 Jun;62(6):563–70 (38 ref.)
Protein kinase cascades activated by stress and inflammatory cytokines. Kyriakis JM, et al. **Bioessays** 1996 Jul; 18(7):567–77 (70 ref.)
Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. Reutelingsperger CP, et al. **Cell Mol Life Sci** 1997 Jun; 53(6):527–32 (58 ref.)
Lipoxins: putative braking signals in host defense, inflammation and hypersensitivity. Brady HR, et al. **Curr Opin Nephrol Hypertens** 1996 Jan;5(1):20–7 (57 ref.)
Inflammation in AIDS and the role of the macrophage in brain pathology. Achim CL, et al. **Curr Opin Neurol** 1996 Jun;9(3):221–5 (52 ref.)
The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Aderka D. **Cytokine Growth Factor Rev** 1996 Oct;7(3):231–40 (106 ref.)
Corticotropin-releasing factor in antinociception and inflammation. Schäfer M, et al. **Eur J Pharmacol** 1997 Mar 26;323(1):1–10 (152 ref.)
Stress proteins in inflammation. Polla BS, et al. **EXS** 1996; 77:375–91 (84 ref.)
The role of inflammation in atherosclerosis. Blum A, et al. **Isr J Med Sci** 1996 Nov;32(11):1059–65 (79 ref.)
Local expression of inflammatory cytokines in human atherosclerotic plaques. Wilcox JN, et al. **J Atheroscler Thromb** 1994;1 Suppl 1:S10–3 (22 ref.)
Reactive oxygen species and antioxidants in inflammatory diseases. Chapple IL. **J Clin Periodontol** 1997 May; 24(5):287–96 (103 ref.)
Lymphotoxin: from chronic inflammation to lymphoid organs. Sacca R, et al. **J Inflamm** 1995–96;47(1–2):81–4 (14 ref.)
Nitric oxide and inflammation: the answer is blowing in the wind. Lundberg JO, et al. **Nat Med** 1997 Jan;3(1):30–1 (19 ref.)
Evolutionary perspectives on amyloid and inflammatory features of Alzheimer disease. Finch CE, et al. **Neurobiol Aging** 1996 Sep–Oct;17(5):809–15 (131 ref.)
Molecular aspects of inflammatory and immune responses in Alzheimer's disease. Kalaria RN, et al. **Neurobiol Aging** 1996 Sep–Oct;17(5):687–93 (76 ref.)
Inflammation, free radicals, and antioxidants. Conner EM, et al. **Nutrition** 1996 Apr;12(4):274–7 (40 ref.)
Upregulation of tachykinin receptors in chronic airway inflammation. McDonald DM. **Pulm Pharmacol** 1995 Aug–Oct;8(4–5):203–5 (15 ref.)
Ca2+, a regulator of the inflammatory response--the good, the bad, and the possibilities [editorial; comment] Hotchkiss RS, et al. **Shock** 1997 Apr;7(4):308–10 (15 ref.) Comment on: Shock 1997 Apr;7(4):304–7.

PATHOLOGY

Cytokine expression and cell activation in inflammatory arthritis. Ivashkiv LB. **Adv Immunol** 1996;63:337–76 (190 ref.)
Alveolar type II cells at the crossroad of inflammation, fibrogenesis, and neoplasia [comment] Saffiotti U. **Am J Pathol** 1996 Nov;149(5):1423–6 (29 ref.) Comment on: Am J Pathol 1996 Nov;149(5):1627–38.
Apoptosis as a trigger of inflammation in Shigella-induced cell death. Guichon A, et al. **Biochem Soc Trans** 1996 Nov; 24(4):1051–4 (26 ref.)
Programmed cell death (apoptosis) and the resolution of systemic inflammation. Marshall JC, et al. **Can J Surg** 1997 Jun;40(3):169–74 (25 ref.)
Late-phase inflammation: influence on morbidity. Charlesworth EN. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 3):S291–7 (59 ref.)
Apoptosis in resolution of inflammation. Savill J. **J Leukoc Biol** 1997 Apr;61(4):375–80 (58 ref.)
Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: a current appraisal. Breitner JC. **Neurobiol Aging** 1996 Sep–Oct;17(5):789–94 (93 ref.)
Evolutionary perspectives on amyloid and inflammatory features of Alzheimer disease. Finch CE, et al. **Neurobiol Aging** 1996 Sep–Oct;17(5):809–15 (131 ref.)
Inflammatory mechanisms and anti-inflammatory therapy in Alzheimer's disease [editorial] O'Banion MK, et al. **Neurobiol Aging** 1996 Sep–Oct;17(5):669–71 (38 ref.)
Inflammatory mechanisms in neurodegeneration and Alzheimer's disease: the role of the complement system. Pasinetti GM. **Neurobiol Aging** 1996 Sep–Oct;17(5):707–16 (157 ref.)
Inflammation and Alzheimer's disease pathogenesis. Rogers J, et al. **Neurobiol Aging** 1996 Sep–Oct;17(5):681–6 (100 ref.)
The effects of tachykinins on inflammatory and immune cells. Maggi CA. **Regul Pept** 1997 Jun 18;70(2–3):75–90 (198 ref.)
The role of inflammatory cells and their proteases in extravascular fibrinolysis. Heiden M, et al. **Semin Thromb Hemost** 1996;22(6):497–501 (68 ref.)
T-cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms. Gold R, et al. **Trends Neurosci** 1997 Sep;20(9):399–404 (64 ref.)
[Inflammation in asthma] **J Pharm Belg** 1997 May–Jun; 52(3):129–30 (0 ref.) **(Fre)**

PHYSIOPATHOLOGY

Neurogenic inflammation. A model for studying efferent actions of sensory nerves. McDonald DM, et al. **Adv Exp Med Biol** 1996;410:453–62 (68 ref.)
Inflammatory reactions at the blood–endothelial interface in acute stroke. Hallenbeck JM. **Adv Neurol** 1996;71:281–97; discussion 297–300 (151 ref.)
Endogenous interleukin-10 in inflammatory disorders: regulatory roles and pharmacological modulation. Goldman M, et al. **Ann N Y Acad Sci** 1996 Oct 31; 796:282–93 (96 ref.)
Multiple organ failure, multiple organ dysfunction syndrome, and systemic inflammatory response syndrome. Why no magic bullets? Baue AE. **Arch Surg** 1997 Jul;132(7):703–7 (42 ref.)
Expression of extracellular matrix molecules, proliferation markers and cyclin-dependent kinase inhibitors in inflamed tissues. Chilosi M, et al. **Biochem Soc Trans** 1997 May; 25(2):524–8 (29 ref.)
Human leucocyte heparan sulphate proteoglycans and their roles in inflammation. Jackson DG. **Biochem Soc Trans** 1997 Feb;25(1):220–4 (23 ref.)
Molecular mechanisms underlying the actions of the pro-inflammatory cytokine interleukin 1. Royal Irish Academy Medal Lecture. O'Neill LA. **Biochem Soc Trans** 1997 Feb;25(1):295–302 (50 ref.)
Cytokines and the immune response. Van der Meide PH, et al. **Biotherapy** 1996;8(3–4):243–9 (54 ref.)
Anti-adhesion molecule and nitric oxide protection strategies in ischemic stroke. Chopp M, et al. **Curr Opin Neurol** 1996 Feb;9(1):68–72 (42 ref.)
MIF re-discovered: pituitary hormone and glucocorticoid-induced regulator of cytokine production. Bucala R. **Cytokine Growth Factor Rev** 1996 Jun;7(1):19–24 (31 ref.)
Chemokine-leukocyte interactions. The voodoo that they do so well. Taub DD. **Cytokine Growth Factor Rev** 1996 Dec; 7(4):355–76 (162 ref.)
Resolving the nitric oxide paradox in acute tissue damage [editorial] Billiar TR, et al. **Gastroenterology** 1997 Oct; 113(4):1405–7 (13 ref.)
Inflammation and Alzheimer's disease: mechanisms and therapeutic strategies. Aisen PS. **Gerontology** 1997; 43(1–2):143–9 (63 ref.)
Late-phase inflammation: influence on morbidity.

Charlesworth EN. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 3):S291–7 (59 ref.)

In vivo, in vitro, and molecular aspects of interleukin–8 and the interleukin–8 receptors. Hoch RC, et al. **J Lab Clin Med** 1996 Aug;128(2):134–45 (97 ref.)

Nuclear factor–kappa–B/steroid hormone receptor interactions as a functional basis of anti–inflammatory action of steroids in reproductive organs. van der Burg B, et al. **Mol Hum Reprod** 1996 Jun;2(6):433–8 (57 ref.)

Selectins, T–cell rolling and inflammation. Rossiter H, et al. **Mol Med Today** 1997 May;3(5):214–22 (49 ref.)

Primary afferents and inflammatory hyperexcitability [editorial; comment] Ren K. **Pain** 1996 Sep;67(1):1–2 (15 ref.) Comment on: Pain 1996 Sep;67(1):97–106.

Vascular endothelial adhesion molecules and tissue inflammation. Malik AB, et al. **Pharmacol Rev** 1996 Jun; 48(2):213–29 (135 ref.)

Signal transduction in nociceptive afferent neurons in inflammatory conditions. Bevan S. **Prog Brain Res** 1996; 113:201–13 (54 ref.)

The polymodal receptor: bio–warning and defense system. Kumazawa T. **Prog Brain Res** 1996;113:3–18 (129 ref.)

Neurogenic inflammation caused by cutaneous polymodal receptors. Lynn B. **Prog Brain Res** 1996;113:361–8 (43 ref.)

Sympathetic modulation of cutaneous polymodal receptors in chronically inflamed and diabetic rats. Sato J, et al. **Prog Brain Res** 1996;113:153–9 (41 ref.)

Neurophysiology of chronic inflammatory pain: electrophysiological recordings from spinal cord neurons in rats with prolonged acute and chronic unilateral inflammation at the ankle. Schaible HG, et al. **Prog Brain Res** 1996;110:167–76 (56 ref.)

On the role of tachykinins and calcitonin gene–related peptide in the spinal mechanisms of nociception and in the induction and maintenance of inflammation–evoked hyperexcitability in spinal cord neurons (with special reference to nociception in joints). Schaible HG. **Prog Brain Res** 1996;113:423–41 (152 ref.)

Nitric oxide production in human inflammatory processes. Dugas B, et al. **Res Immunol** 1995 Nov–Dec;146(9):661–3 (0 ref.)

Nitric oxide, a vital poison inside the immune and inflammatory network. Dugas B, et al. **Res Immunol** 1995 Nov–Dec;146(9):664–70 (45 ref.)

Inflammation: patterns and new concepts. Huerre MR, et al. **Res Immunol** 1996 Sep;147(7):417–34 (33 ref.)

The pathophysiological role of peroxynitrite in shock, inflammation, and ischemia–reperfusion injury. Szabó C. **Shock** 1996 Aug;6(2):79–88 (162 ref.)

Molecular mechanisms of early inflammation. McIntyre TM, et al. **Thromb Haemost** 1997 Jul;78(1):302–5 (30 ref.)

Apoptosis as a proinflammatory event: what can we learn from bacteria–induced cell death? Zychlinsky A, et al. **Trends Microbiol** 1997 May;5(5):201–4 (42 ref.)

[Importance of in vivo and in vitro studies of leukotrienes. Application to the particular instance of aspirin] Sainte–Laudy J. **Allerg Immunol (Paris)** 1997 Feb; 29(2):28–35 (65 ref.) (Eng. Abstr.) **(Fre)**

[Biological rhythm, inflammation and non–steroidal anti–inflammatory agents] Bureau JP, et al. **Pathol Biol (Paris)** 1996 Sep;44(7):610–7 (30 ref.) (Eng. Abstr.) **(Fre)**

[Nitrogen monoxide. Mediator or marker of chronic inflammation?] Stichtenoth DO. **Internist (Berl)** 1997 May; 38(5):420–6 (49 ref.) **(Ger)**

[Inflammation and unstable angina] Leibovitz E, et al. **Harefuah** 1996 May 1;130(9):635–8 (38 ref.) **(Heb)**

[Adhesion molecules and their role in the inflammatory process] Ravid A, et al. **Harefuah** 1996 Nov 15; 131(10):413–7 (40 ref.) **(Heb)**

[Immuno–neuro–endocrine network] Imura H. **Rinsho Byori** 1997 Jun;45(6):505–10 (12 ref.) **(Jpn)**

[Cytokine network involved in inflammatory reactions] Mukaida N. **Rinsho Byori** 1997 Jun;45(6):513–8 (11 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Anti–inflammatory actions of the neuroimmunomodulator alpha–MSH. Lipton JM, et al. **Immunol Today** 1997 Mar; 18(3):140–5 (39 ref.)

Serine protease inhibition prevents both cellular and humoral responses to cardiopulmonary bypass. Royston D. **J Cardiovasc Pharmacol** 1996;27 Suppl 1:S42–9 (60 ref.)

Leucocyte depletion in cardiothoracic surgery. Allen SM. **Perfusion** 1996 May;11(3):270–7 (59 ref.)

RADIONUCLIDE IMAGING

Radiopharmaceuticals for the study of inflammatory processes: a review. Chianelli M, et al. **Nucl Med Commun** 1997 May;18(5):437–55 (136 ref.)

The choice of an appropriate agent for imaging inflammation [editorial] [see comments] Peters AM. **Nucl Med Commun** 1996 Jun;17(6):455–8 (29 ref.) Comment in: Nucl Med Commun 1996 Nov;17(11):999.

[Scintigraphy with radiogallium in oncologic and non–oncologic diseases. State of the art and main indications] Gasparini M, et al. **Radiol Med (Torino)** 1996 Dec;92(6):770–7 (47 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

IL–10: a potential therapy for allergic inflammation? Pretolani M, et al. **Immunol Today** 1997 Jun;18(6):277–80 (47 ref.)

[Severe inflammatory disease in children. Rationale for corticosteroid immunomodulating therapy: pathogenic therapy] Moggi C, et al. **Pediatr Med Chir** 1996 Jul–Aug; 18(4):395–401 (31 ref.) (Eng. Abstr.) **(Ita)**

[Status and outlook for the use of physico–chemical methods in the treatment of pyo–inflammatory processes] Vasina TA. **Antibiot Khimioter** 1996 Apr;41(4):54–64 (100 ref.) **(Rus)**

VETERINARY

Nutritional modification of inflammatory diseases. Schoenherr WD, et al. **Semin Vet Med Surg (Small Anim)** 1997 Aug;12(3):212–22 (72 ref.)

The potential role of inflammation in the development of postvaccinal sarcomas in cats. Macy DW, et al. **Vet Clin North Am Small Anim Pract** 1996 Jan;26(1):103–9 (36 ref.)

INFLAMMATION MEDIATORS

Mechanisms of pleural liquid formation in pleural inflammation. Marchi E, et al. **Curr Opin Pulm Med** 1997 Jul;3(4):305–9 (22 ref.)

The mechanisms of action of disease–modifying antirheumatic drugs: a review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines. Bondeson J. **Gen Pharmacol** 1997 Aug;29(2):127–50 (287 ref.)

Markers of acute airway inflammation. Vignola AM, et al. **Monaldi Arch Chest Dis** 1997 Feb;52(1):83–5 (39 ref.)

Inflammatory mediators in gastrointestinal defense and injury. Wallace JL, et al. **Proc Soc Exp Biol Med** 1997 Mar;214(3):192–203 (139 ref.)

Mediators of inflammation in chronic inflammatory bowel disease. Nielsen OH, et al. **Scand J Gastroenterol Suppl** 1996;216:149–59 (63 ref.)

[Mediator aspects of the inflammatory process] Shubich MG, et al. **Arkh Patol** 1997 Mar–Apr;59(2):3–8 (50 ref.) (Eng. Abstr.) **(Rus)**

ANALYSIS

Early detection and markers of sepsis. Parsons PE, et al. **Clin Chest Med** 1996 Jun;17(2):199–212 (125 ref.)

ANTAGONISTS & INHIBITORS

[Mediators and antagonists in therapy of multiple trauma. Reliable outcome or wishful thinking?] Gebhard F. **Unfallchirurg** 1997 Apr;100(4):324–8 (43 ref.) (Eng. Abstr.) **(Ger)**

BLOOD

[Use of inflammatory protein in asthma diagnosis] Metso T, et al. **Duodecim** 1995;111(16):1616–22 (27 ref.) **(Fin)**

CHEMISTRY

Ectodomain interactions of leukocyte integrins and pro–inflammatory GPI–linked membrane proteins. Petty HR, et al. **J Pharm Biomed Anal** 1997 Jun;15(9–10):1405–16 (94 ref.)

IMMUNOLOGY

Sepsis: a new hypothesis for pathogenesis of the disease process. Bone RC, et al. **Chest** 1997 Jul;112(1):235–43 (57 ref.)

Hypothesis: a possible role for mast cells and their inflammatory mediators in the pathogenesis of autoimmune encephalomyelitis. Bebo BF Jr, et al. **J Neurosci Res** 1996 Aug 15;45(4):340–8 (55 ref.)

Molecular aspects of inflammatory and immune responses in Alzheimer's disease. Kalaria RN, et al. **Neurobiol Aging** 1996 Sep–Oct;17(5):687–93 (76 ref.)

METABOLISM

Inflammatory markers in childhood asthma. Kristjánsson S, et al. **Ann Med** 1996 Oct;28(5):395–9 (43 ref.)

Interactions of migrating T lymphocytes, inflammatory mediators, and the extracellular matrix. Lider O, et al. **Crit Rev Immunol** 1995;15(3–4):271–83 (85 ref.)

Bacterial–induced release of inflammatory mediators by bronchial epithelial cells. Khair OA, et al. **Eur Respir J** 1996 Sep;9(9):1913–22 (91 ref.)

Cytokine–inducing components of periodontopathogenic bacteria. Wilson M, et al. **J Periodontal Res** 1996 Aug; 31(6):393–407 (117 ref.)

Molecular aspects of inflammatory and immune responses in Alzheimer's disease. Kalaria RN, et al. **Neurobiol Aging** 1996 Sep–Oct;17(5):687–93 (76 ref.)

Alterations in transcriptional regulation of proinflammatory and immunoregulatory cytokine expression by hemorrhage, injury, and critical illness. Abraham E. **New Horiz** 1996 May;4(2):184–93 (98 ref.)

Cytokines, growth factors, and other inflammatory mediators in glomerulonephritis. Papayianni A. **Ren Fail** 1996 Sep; 18(5):725–40 (137 ref.)

Circulating mediators in acute pancreatitis as predictors of severity. Larvin M. **Scand J Gastroenterol Suppl** 1996; 219:16–9 (15 ref.)

Interleukins in acute pancreatitis. Schölmerich J. **Scand J Gastroenterol Suppl** 1996;219:37–42 (28 ref.)

[Cell biology of bronchial asthma: interesting new methods. Intracellular determination of cytokines in T–cells and basic proteins in eosinophilic granulocytes using flow cytometry] Krug N, et al. **Pneumologie** 1997 Apr;51(4):381–5 (26 ref.) (Eng. Abstr.) **(Ger)**

[Pharmacology in regulation of newly inducted functional molecules] Oishi S, et al. **Nippon Yakurigaku Zasshi** 1996 Sep;108(3):104–7 (10 ref.) **(Jpn)**

[Neutrophil activation by bacterial endotoxins] Klink M, et al. **Postepy Hig Med Dosw** 1996;50(4):333–50 (80 ref.) (Eng. Abstr.) **(Pol)**

PHARMACOLOGY

Control of transcriptional activation of the lipopolysaccharide binding protein (LBP) gene by proinflammatory cytokines. Kirchning C, et al. **Cytokines Cell Mol Ther** 1997 Mar;3(1):59–62 (33 ref.)

PHYSIOLOGY

Posttraumatic multiple–organ dysfunction syndrome: role of mediators in systemic inflammation and subsequent organ failure. Pastores SM, et al. **Acad Emerg Med** 1996 Jun; 3(6):611–22 (150 ref.)

Molecular mechanisms regulating nitric oxide biosynthesis: role of xenobiotics in epithelial inflammation. Heck DE. **Adv Exp Med Biol** 1996;387:171–6 (40 ref.)

Inflammatory mediators, cytokines, and adhesion molecules in pulmonary inflammation and injury. Lukacs NW, et al. **Adv Immunol** 1996;62:257–304 (227 ref.)

Septic shock. Shenep JL. **Adv Pediatr Infect Dis** 1996; 12:209–41 (162 ref.)

Interactions of migrating T lymphocytes, inflammatory mediators, and the extracellular matrix. Lider O, et al. **Crit Rev Immunol** 1995;15(3–4):271–83 (85 ref.)

The many roles of CD40 in cell–mediated inflammatory responses. Stout RD, et al. **Immunol Today** 1996 Oct; 17(10):487–92 (59 ref.)

Immune modulation and sepsis. Karzai W, et al. **Int J Clin Pract** 1997 Jun;51(4):232–7 (62 ref.)

Asthma as an inflammatory disease: implications for management. Dolen WK. **J Am Board Fam Pract** 1996 May–Jun;9(3):182–90 (75 ref.)

Lymphocyte subsets and adhesion molecules in cutaneous inflammation induced by inflammatory agonists: correlation between E–selectin and gamma delta TcR+ lymphocytes. Whyte A, et al. **Lab Invest** 1996 Sep;75(3):439–49 (52 ref.)

The blood–brain barrier in neuroinflammatory diseases. de Vries HE, et al. **Pharmacol Rev** 1997 Jun;49(2):143–55 (154 ref.)

Modification of nociceptor responses by inflammatory mediators and second messengers implicated in their action—a study in canine testicular polymodal receptors. Mizumura K, et al. **Prog Brain Res** 1996;113:115–41 (149 ref.)

Cellular mechanisms of inflammatory mediators acting on vagal sensory nerve excitability. Weinreich D. **Pulm Pharmacol** 1995 Aug–Oct;8(4–5):173–9 (5 ref.)

Mediators of mucosal inflammation: implications for therapy. van Dullemen H, et al. **Scand J Gastroenterol Suppl** 1997; 223:92–8 (108 ref.)

Inflammatory cytokines in animal health and disease. Murtaugh MP, et al. **Vet Immunol Immunopathol** 1996 Nov; 54(1–4):45–55 (65 ref.)

[The acute inflammatory response. Mechanisms and therapeutic possibilities] Pedersen JL, et al. **Ugeskr Laeger** 1996 Oct 7;158(41):5754–61 (37 ref.) (Eng. Abstr.) **(Dan)**

THERAPEUTIC USE

Antipsoriatic and proinflammatory action of anthralin. Implications for the role of oxygen radicals. Müller K. **Biochem Pharmacol** 1997 May 9;53(9):1215–21 (69 ref.)

INFLAMMATORY BOWEL DISEASES

Pregnancy and nursing. Burakoff R, et al. **Gastroenterol Clin North Am** 1995 Sep;24(3):689–98 (48 ref.)

Tumor necrosis factor (TNF) in inflammatory bowel disease: gene polymorphisms, animal models, and potential for anti–TNF therapy. Stokkers PC, et al. **J Inflamm** 1995–96; 47(1–2):97–103 (54 ref.)

Nutritional considerations and management of the child with inflammatory bowel disease. Oliva MM, et al. **Nutrition** 1996 Mar;12(3):151–8 (76 ref.)

Inflammatory bowel disease in children and adolescents. Winesett M. **Pediatr Ann** 1997 Apr;26(4):227–34 (20 ref.)

Immunogenetics of cytokines. Relevance for future research on inflammatory bowel disease. Koutroubakis I, et al. **Scand J Gastroenterol** 1995 Dec;30(12):1139–46 (98 ref.)

Role of animal models for the pathogenesis and treatment of inflammatory bowel disease. Dieleman LA, et al. **Scand J Gastroenterol Suppl** 1997;223:99–104 (99 ref.)

Inflammatory bowel disease: a new assessment. Gitnick G. **Scand J Gastroenterol Suppl** 1996;220:83–6 (26 ref.)

Future aspects on inflammatory bowel disease. Järnerot G. **Scand J Gastroenterol Suppl** 1996;220:87–90 (37 ref.)

New insights into the immunopathology of chronic

inflammatory bowel disease. Ehrhardt RO. **Semin Gastrointest Dis** 1996 Jul;7(3):144–50 (43 ref.)

BLOOD

Review article: platelets in inflammatory bowel disease—pathogenetic role and therapeutic implications. Collins CE, et al. **Aliment Pharmacol Ther** 1997 Apr; 11(2):237–47 (120 ref.)

COMPLICATIONS

The role of gut inflammation in the pathogenesis of spondyloarthropathies. Mielants H, et al. **Acta Clin Belg** 1996;51(5):340–9 (60 ref.)

Primary sclerosing cholangitis in Japanese patients: association with inflammatory bowel disease. Okada H, et al. **Acta Med Okayama** 1996 Oct;50(5):227–35 (146 ref.)

Dairy sensitivity, lactose malabsorption, and elimination diets in inflammatory bowel disease. Mishkin S. **Am J Clin Nutr** 1997 Feb;65(2):564–7 (54 ref.)

Hepatobiliary disease in inflammatory bowel disease. Balan V, et al. **Gastroenterol Clin North Am** 1995 Sep; 24(3):647–69 (112 ref.)

Inflammatory bowel disease and cancer. Itzkowitz SH. **Gastroenterol Clin North Am** 1997 Mar;26(1):129–39 (48 ref.)

Extraintestinal considerations in inflammatory bowel disease. Levine JB, et al. **Gastroenterol Clin North Am** 1995 Sep; 24(3):633–46 (66 ref.)

Association between inflammatory bowel disease and sarcoidosis. Report of two cases and review of the literature. Fries W, et al. **Scand J Gastroenterol** 1995 Dec; 30(12):1221–3 (35 ref.)

Colorectal cancer in idiopathic inflammatory bowel disease. Harpaz N, et al. **Semin Diagn Pathol** 1996 Nov;13(4):339–57 (188 ref.)

[Osteopathia in chronic inflammatory intestinal disease] Neef B, et al. **Dtsch Med Wochenschr** 1997 Feb 14;122(7):195–9 (33 ref.) **(Ger)**

[Inflammatory bowel disease] Iizuka B, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):398–405 (55 ref.) **(Jpn)**

[Hepatobiliary complications in chronic intestinal inflammatory disease] Bertrán X, et al. **Gastroenterol Hepatol** 1996 Jan;19(1):10–5 (68 ref.) **(Spa)**

[Skin manifestations of chronic intestinal inflammatory disease] Ferrándiz C. **Gastroenterol Hepatol** 1996 Jan; 19(1):16–20 (21 ref.) **(Spa)**

[Thromboembolic complications in inflammatory bowel disease] Suárez Crespo JF, et al. **Gastroenterol Hepatol** 1997 Apr;20(4):180–3 (30 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Transient radiological and colonoscopic features of inflammatory bowel disease in a patient with severe Salmonella gastroenteritis. Dagash M, et al. **Am J Gastroenterol** 1997 Feb;92(2):349–51 (6 ref.)

Chronic inflammatory bowel disease: uniformity or diversity of impact in Europe [comment] Langman MJ. **Eur J Gastroenterol Hepatol** 1997 Apr;9(4):331–2 (0 ref.) Comment on: Eur J Gastroenterol Hepatol 1997 Apr;9(4):353–9.

Inflammatory bowel disease in the pediatric patient. Grand RJ, et al. **Gastroenterol Clin North Am** 1995 Sep; 24(3):613–32 (52 ref.)

Diverticular disease and chronic idiopathic inflammatory bowel disease: associations and masquerades. Shepherd NA. **Gut** 1996 Jun;38(6):801–2 (30 ref.)

Problems in diagnosis of IBD in children. Büller HA. **Neth J Med** 1997 Feb;50(2):S8–11 (7 ref.)

[Thrombocytopenia, arthritis and enteropathy: a casual association or the expression of a unique entity?] Alpigiani MG, et al. **Pediatr Med Chir** 1996 Nov–Dec;18(6):583–4 (10 ref.) (Eng. Abstr.) **(Ita)**

[Inflammatory bowel disease activity index: clinical and laboratory indicators] Dichi I, et al. **Arq Gastroenterol** 1995 Jul–Sep;32(3):121–30 (75 ref.) (Eng. Abstr.) **(Por)**

DIET THERAPY

Dairy sensitivity, lactose malabsorption, and elimination diets in inflammatory bowel disease. Mishkin S. **Am J Clin Nutr** 1997 Feb;65(2):564–7 (54 ref.)

DRUG THERAPY

Immunosuppressive therapy for chronic inflammatory bowel disease. Schölmerich J. **Digestion** 1997;58 Suppl 1:94–7 (6 ref.)

Inflammatory bowel disease management. Some thoughts on future drug developments. Rhodes J, et al. **Drugs** 1997 Feb; 53(2):189–94 (36 ref.)

Inflammatory bowel disease in the elderly. Practical treatment guidelines. Akerkar GA, et al. **Drugs Aging** 1997 Mar;10(3):199–208 (55 ref.)

Medical management of specific clinical presentations. Bitton A, et al. **Gastroenterol Clin North Am** 1995 Sep; 24(3):541–58 (67 ref.)

Conventional drug therapy in inflammatory bowel disease. Griffin MG, et al. **Gastroenterol Clin North Am** 1995 Sep; 24(3):509–21 (89 ref.)

New therapeutic approaches. Hanauer SB, et al. **Gastroenterol Clin North Am** 1995 Sep;24(3):523–40 (166 ref.)

Medical treatment for inflammatory bowel disease—refinements and new modalities [editorial] Löfberg R. **J Intern Med** 1997 Jan;241(1):1–4 (24 ref.)

Budesonide in inflammatory bowel disease. Lamers CB, et al. **Neth J Med** 1996 Feb;48(2):60–3 (16 ref.)

Refractory IBD: medical management. Tremaine WJ. **Neth J Med** 1997 Feb;50(2):S12–4 (12 ref.)

Newer treatments for inflammatory bowel disease. Stotland BR, et al. **Prim Care** 1996 Sep;23(3):577–608 (145 ref.)

Factor XIII in chronic inflammatory bowel diseases. Lorenz R, et al. **Semin Thromb Hemost** 1996;22(5):451–5 (33 ref.)

[Side effects of 5-aminosalicylic acid] Marteau P, et al. **Gastroenterol Clin Biol** 1997;21(5):377–86 (118 ref.) **(Fre)**

[The treatment of inflammatory intestinal diseases with preparations of 5-aminosalicylic acid] Frolkis AV. **Ter Arkh** 1996;68(2):75–7 (49 ref.) **(Rus)**

[Methotrexate in the treatment of inflammatory intestinal diseases] Díaz Blasco J, et al. **Rev Esp Enferm Dig** 1997 May;89(5):385–90 (67 ref.) **(Spa)**

EPIDEMIOLOGY

Epidemiology of inflammatory bowel disease. Lashner BA. **Gastroenterol Clin North Am** 1995 Sep;24(3):467–74 (52 ref.)

Epidemiology of inflammatory bowel disease in different ethnic and religious groups: limitations and aetiological clues. Probert CS, et al. **Int J Colorectal Dis** 1996;11(1):25–8 (29 ref.)

ETIOLOGY

Tumour necrosis factor and inflammatory bowel disease. Armstrong AM, et al. **Br J Surg** 1997 Aug;84(8):1051–8 (89 ref.)

Cytomegalovirus infection masquerading as an ulcerative colitis flare-up: case report and review of the literature. Begos DG, et al. **Yale J Biol Med** 1996 Jul–Aug;69(4):323–8 (21 ref.)

[Smoking and inflammatory bowel disease: an epidemiological case-control study] Martins Júnior EV, et al. **Arq Gastroenterol** 1996 Apr–Jun;33(2):74–8 (49 ref.) (Eng. Abstr.) **(Por)**

GENETICS

Lessons from genetic models of inflammatory bowel disease. Podolsky DK. **Acta Gastroenterol Belg** 1997 Apr–Jun; 60(2):163–5 (20 ref.)

Oxidant–regulation of gene expression in the chronically inflamed intestine. Jourd'heuil D, et al. **Keio J Med** 1997 Mar;46(1):10–5 (58 ref.)

Familial occurrence and inheritance studies in inflammatory bowel disease. Binder V, et al. **Neth J Med** 1996 Feb; 48(2):53–6 (17 ref.)

IMMUNOLOGY

The immune system in inflammatory bowel disease. Fiocchi C. **Acta Gastroenterol Belg** 1997 Apr–Jun;60(2):156–62 (122 ref.)

Lessons from genetic models of inflammatory bowel disease. Podolsky DK. **Acta Gastroenterol Belg** 1997 Apr–Jun; 60(2):163–5 (20 ref.)

Major pathways of mucosal immunity and inflammation: cell activation, cytokine production and the role of bacterial factors. James SP, et al. **Aliment Pharmacol Ther** 1996;10 Suppl 2:1–9 (52 ref.)

Role of the neuroendocrine system in cytokine pathways in inflammatory bowel disease. Ottaway CA. **Aliment Pharmacol Ther** 1996;10 Suppl 2:10–5 (55 ref.)

Pathogenic role of gut inflammation in the spondyloarthropathies. Gaston JS. **Curr Opin Rheumatol** 1997 Jul;9(4):302–7 (62 ref.)

Pathogenesis of inflammatory bowel disease. Zeitz M. **Digestion** 1997;58 Suppl 1:59–61 (25 ref.)

Alterations of the mucosal immune system in inflammatory bowel disease. MacDermott RP. **J Gastroenterol** 1996 Dec; 31(6):907–16 (84 ref.)

Protective and pathogenic roles of cytokines in inflammatory bowel diseases. Neurath MF, et al. **J Investig Med** 1996 Dec;44(9):516–21 (58 ref.)

Immunopathology of human inflammatory bowel disease. Brandtzaeg P, et al. **Springer Semin Immunopathol** 1997; 18(4):555–89 (218 ref.)

[The role of cell adhesion molecules in inflammatory bowel disease and colorectal cancer] Pedersen G, et al. **Ugeskr Laeger** 1997 Aug 18;159(34):5077–84 (40 ref.) (Eng. Abstr.) **(Dan)**

METABOLISM

Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease. Cominelli F, et al. **Aliment Pharmacol Ther** 1996;10 Suppl 2:49–53; discussion 54 (39 ref.)

Major pathways of mucosal immunity and inflammation: cell activation, cytokine production and the role of bacterial factors. James SP, et al. **Aliment Pharmacol Ther** 1996;10 Suppl 2:1–9 (52 ref.)

Pro-inflammatory cytokines in inflammatory bowel disease. McAlindon ME, et al. **Aliment Pharmacol Ther** 1996;10 Suppl 2:72–4 (28 ref.)

Role of the neuroendocrine system in cytokine pathways in inflammatory bowel disease. Ottaway CA. **Aliment Pharmacol Ther** 1996;10 Suppl 2:10–5 (55 ref.)

Eicosanoids and inflammatory bowel disease. Yang VW. **Gastroenterol Clin North Am** 1996 Jun;25(2):317–32 (78 ref.)

Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease [published erratum appears in Gastroenterology 1997 Aug;113(2):732] Rugtveit J, et al. **Gastroenterology** 1997 May;112(5):1493–505 (78 ref.)

Mucus glycoproteins and their role in colorectal disease. Corfield AP, et al. **J Pathol** 1996 Sep;180(1):8–17 (110 ref.)

Oxidant–regulation of gene expression in the chronically inflamed intestine. Jourd'heuil D, et al. **Keio J Med** 1997 Mar;46(1):10–5 (58 ref.)

MICROBIOLOGY

Chronic health effects of microbial foodborne disease. Bunning VK, et al. **World Health Stat Q** 1997;50(1–2):51–6 (45 ref.)

PATHOLOGY

Similarities and dissimilarities between asthma and inflammatory bowel diseases. Collins SM. **Aliment Pharmacol Ther** 1996;10 Suppl 2:25–31 (51 ref.)

Carcinoid tumor and inflammatory bowel disease: a study of eleven cases and review of the literature. Greenstein AJ, et al. **Am J Gastroenterol** 1997 Apr;92(4):682–5 (37 ref.)

PHYSIOPATHOLOGY

Human colonic microvascular endothelial cells is a model of inflammatory bowel disease. Welton ML. **Am J Surg** 1997 Sep;174(3):247–50 (40 ref.)

Role of cell adhesion molecules in inflammatory bowel diseases. Vainer B. **Scand J Gastroenterol** 1997 May; 32(5):401–10 (122 ref.)

Mediators of mucosal inflammation: implications for therapy. van Dullemen H, et al. **Scand J Gastroenterol Suppl** 1997; 223:92–8 (108 ref.)

[Role of nitric oxide in maintaining the mucosal integrity and in inflammatory gastrointestinal diseases] Lamarque D, et al. **Gastroenterol Clin Biol** 1996;20(12):1085–98 (213 ref.) **(Fre)**

[Assessment of clinical activity in chronic intestinal inflammatory disease: activity indexes] González-Huix F. **Gastroenterol Hepatol** 1996 Jan;19(1):1–9 (72 ref.) **(Spa)**

PSYCHOLOGY

Psychosocial factors in inflammatory bowel disease. Talal AH, et al. **Gastroenterol Clin North Am** 1995 Sep; 24(3):699–716 (64 ref.)

SURGERY

[Video-laparoscopic colorectal surgery: critical review of our experience with mixed gasless pneumo-peritoneal method (editorial)] Tenchini P, et al. **G Chir** 1997 Jun–Jul; 18(6–7):325–30 (12 ref.) **(Ita)**

[Critical evaluation of the surgical treatment of chronic intestinal inflammatory disease] Martí Ragué J, et al. **Gastroenterol Hepatol** 1996 Jan;19(1):33–9 (39 ref.) **(Spa)**

THERAPY

Nutritional considerations in inflammatory bowel diseases. Kelly DG, et al. **Gastroenterol Clin North Am** 1995 Sep; 24(3):597–611 (89 ref.)

New therapeutic approaches in inflammatory bowel disease. Hodgson HJ. **Neth J Med** 1997 Feb;50(2):S15–8 (22 ref.)

How do we treat patients with inflammatory bowel disease in adolescence? Taminiau JA, et al. **Neth J Med** 1996 Feb; 48(2):57–9 (6 ref.)

Selective immunomodulation in patients with inflammatory bowel disease—future therapy or reality? van Hogezand RA, et al. **Neth J Med** 1996 Feb;48(2):64–7 (21 ref.)

Treatment of inflammatory bowel disease. Mascarenhas MR, et al. **Pediatr Rev** 1997 Mar;18(3):95–8 (6 ref.)

Biofeedback, relaxation training, and cognitive behaviour modification as treatments for lower functional gastrointestinal disorders. Bassotti G, et al. **QJM** 1997 Aug; 90(8):545–50 (69 ref.)

New therapies for inflammatory bowel disease: an update on chimeric anti-TNF alpha antibodies and IL-10 therapy. van Hogezand RA, et al. **Scand J Gastroenterol Suppl** 1997; 223:105–7 (105 ref.)

INFLAMMATORY RESPONSE SYNDROME, SYSTEMIC see **SEPSIS SYNDROME**

INFLUENZA

Influenza. More than mom and chicken soup. Bergen GA, et al. **J Fla Med Assoc** 1996 Jan;83(1):19–22 (21 ref.)

COMPLICATIONS

[Neurological outcome associated with influenza viral infection] Kamimura N, et al. **Nippon Rinsho** 1997 Apr; 55(4):880–5 (22 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Antivirals for pandemic influenza. Hayden FG.

J Infect Dis 1997 Aug;176 Suppl 1:S56–61 (59 ref.)

EPIDEMIOLOGY

Influenza: problem in Poland as elsewhere. Magdzik W, et al. **Arch Immunol Ther Exp (Warsz)** 1996;44(5–6):385–8 (12 ref.)
Emerging infections: pandemic influenza. Glezen WP. **Epidemiol Rev** 1996;18(1):64–76 (83 ref.)
Perspectives on pandemics: a research agenda. Kilbourne ED. **J Infect Dis** 1997 Aug;176 Suppl 1:S29–31 (23 ref.)
[The threat of an influenza pandemic (editorial)] Pyhälä R. **Duodecim** 1995;111(10):901–2, 905 (17 ref.) **(Fin)**
[Ecology of influenza viruses: are we prepared for the emergence of the next pandemic of influenza] Kida H. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(2):145–53 (30 ref.) **(Jpn)**

PREVENTION & CONTROL

Synthetic recombinant vaccine induces anti-influenza long-term immunity and cross-strain protection. Arnon R, et al. **Adv Exp Med Biol** 1996;397:23–9 (15 ref.)
DNA vaccines. Robinson HL, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):455–7 (27 ref.)
Influenza immunization. Glück R. **Biologicals** 1997 Jun; 25(2):221–5 (22 ref.)
Cold-adapted live attenuated influenza vaccines developed in Russia: can they contribute to meeting the needs for influenza control in other countries? Kendal AP. **Eur J Epidemiol** 1997 Jul;13(5):591–609 (18 ref.)
Use of antivirals in influenza in the elderly: prophylaxis and therapy. Nicholson KG. **Gerontology** 1996;42(5):280–9 (55 ref.)
Influenza vaccination for all elderly. Wijma G, et al. **Gerontology** 1996;42(5):270–3 (18 ref.)
Adult immunizations: how are we doing? Eickhoff TC. **Hosp Pract (Off Ed)** 1996 Nov 15;31(11):107–8, 111–2, 115–7, passim (12 ref.)
Influenza, influenza vaccine, and amantadine/rimantadine. Zimmerman RK, et al. **J Fam Pract** 1997 Aug;45(2):107–22; quiz 123–4 (44 ref.)
Improvement of inactivated influenza virus vaccines. Couch RB, et al. **J Infect Dis** 1997 Aug;176 Suppl 1:S38–44 (49 ref.)
Prospects for pandemic influenza control with currently available vaccines and antivirals. Monto AS. **J Infect Dis** 1997 Aug;176 Suppl 1:S32–7 (25 ref.)
Does influenza immunisation cause exacerbations of chronic airflow obstruction or asthma? Watson JM, et al. **Thorax** 1997 Feb;52(2):190–4 (51 ref.)
[Ecology of influenza viruses: are we prepared for the emergence of the next pandemic of influenza] Kida H. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(2):145–53 (30 ref.) **(Jpn)**
[The status of vaccinal prophylaxis against influenza today] Bichurina MA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Nov–Dec; (6):104–8 (49 ref.) **(Rus)**

THERAPY

Neuraminidase inhibitors as potential anti-influenza drugs. Bamford MJ. **J Enzyme Inhib** 1996;10(1):1–16 (86 ref.)

TRANSMISSION

[Influenza: interspecies transmissions and viral rearrangement] Manuguerra JC, et al. **Bull Acad Natl Med** 1997 Mar 18;181(3):421–30 (13 ref.) (Eng. Abstr.) **(Fre)**
[Influenza, a special form of zoonosis] Rott R. **Berl Munch Tierarztl Wochenschr** 1997 Jul–Aug; 110(7–8):241–6 (19 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

[Influenza, a special form of zoonosis] Rott R. **Berl Munch Tierarztl Wochenschr** 1997 Jul–Aug; 110(7–8):241–6 (19 ref.) (Eng. Abstr.) **(Ger)**
[Iscom (Immuno Stimulating Complex)-vaccine of equine influenza virus--transmission electron microscopic investigation and literature review] Brügmann M, et al. **DTW Dtsch Tierarztl Wochenschr** 1997 Jun;104(6):196–202 (61 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

Comments on some new viruses associated with old diseases in China. Zhu J. **Chin Med J (Engl)** 1996 Jan;109(1):5–10 (31 ref.)

INFLUENZA A VIRUS

[Evolution and epidemiology of influenza A viruses] Nakajima S, et al. **Nippon Rinsho** 1996 Oct;54(10):2839–47 (13 ref.) (Eng. Abstr.) **(Jpn)**

INFLUENZA A VIRUS, HUMAN

GENETICS

Mutations in the hemagglutinin and matrix genes of a virulent influenza virus variant, A/FM/1/47-MA, control different stages in pathogenesis. Smeenk CA, et al. **Virus Res** 1996 Oct;44(2):79–95 (44 ref.)

IMMUNOLOGY

[The status of vaccinal prophylaxis against influenza today] Bichurina MA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Nov–Dec; (6):104–8 (49 ref.) **(Rus)**

PATHOGENICITY

Neurovirulence of influenza A virus. Ward AC. **J Neurovirol** 1996 Jun;2(3):139–51 (150 ref.)
Mutations in the hemagglutinin and matrix genes of a virulent influenza virus variant, A/FM/1/47-MA, control different stages in pathogenesis. Smeenk CA, et al. **Virus Res** 1996 Oct;44(2):79–95 (44 ref.)

INFLUENZA B VIRUS

PHYSIOLOGY

Do Vpu and Vpr of human immunodeficiency virus type 1 and NB of influenza B virus have ion channel activities in the viral life cycles? Lamb RA, et al. **Virology** 1997 Mar 3;229(1):1–11 (127 ref.)

INFLUENZA VACCINE

Synthetic recombinant vaccine induces anti-influenza long-term immunity and cross-strain protection. Arnon R, et al. **Adv Exp Med Biol** 1996;397:23–9 (15 ref.)
Influenza, influenza vaccine, and amantadine/rimantadine. Zimmerman RK, et al. **J Fam Pract** 1997 Aug;45(2):107–22; quiz 123–4 (44 ref.)
[Iscom (Immuno Stimulating Complex)-vaccine of equine influenza virus--transmission electron microscopic investigation and literature review] Brügmann M, et al. **DTW Dtsch Tierarztl Wochenschr** 1997 Jun;104(6):196–202 (61 ref.) (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

Influenza vaccination for all elderly. Wijma G, et al. **Gerontology** 1996;42(5):270–3 (18 ref.)

ADVERSE EFFECTS

Microscopic polyangiitis after influenza vaccination. Kelsall JT, et al. **J Rheumatol** 1997 Jun;24(6):1198–202 (15 ref.)
Does influenza immunisation cause exacerbations of chronic airflow obstruction or asthma? Watson JM, et al. **Thorax** 1997 Feb;52(2):190–4 (51 ref.)

IMMUNOLOGY

Development of an adjuvant to enhance the immune response to influenza vaccine in the elderly. Martin JT. **Biologicals** 1997 Jun;25(2):209–13 (12 ref.)
Improvement of inactivated influenza virus vaccines. Couch RB, et al. **J Infect Dis** 1997 Aug;176 Suppl 1:S38–44 (49 ref.)
Prospects for pandemic influenza control with currently available vaccines and antivirals. Monto AS. **J Infect Dis** 1997 Aug;176 Suppl 1:S32–7 (25 ref.)
Development of novel influenza virus vaccines and vectors. Palese P, et al. **J Infect Dis** 1997 Aug;176 Suppl 1:S45–9 (16 ref.)
[The status of vaccinal prophylaxis against influenza today] Bichurina MA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Nov–Dec; (6):104–8 (49 ref.) **(Rus)**

STANDARDS

Cold-adapted live attenuated influenza vaccines developed in Russia: can they contribute to meeting the needs for influenza control in other countries? Kendal AP. **Eur J Epidemiol** 1997 Jul;13(5):591–609 (18 ref.)

THERAPEUTIC USE

Influenza immunization. Glück R. **Biologicals** 1997 Jun; 25(2):221–5 (22 ref.)

INFLUENZA VIRUS, EQUINE see **INFLUENZA A VIRUS**

INFLUENZA VIRUS TYPE A, HUMAN see **INFLUENZA A VIRUS, HUMAN**

INFLUENZA VIRUSES see **ORTHOMYXOVIRIDAE**

INFLUENZA VIRUSES TYPE A see **INFLUENZA A VIRUS**

INFLUENZA VIRUSES TYPE B see **INFLUENZA B VIRUS**

INFORMATION CENTERS

Getting research into practice. Bouchier IA. **Health Bull (Edinb)** 1997 Jan;55(1):62–7 (14 ref.)

INFORMATION DISPLAY see **DATA DISPLAY**

INFORMATION DISSEMINATION see **INFORMATION SERVICES**

INFORMATION MANAGEMENT

EDUCATION

Outreach activities of the National Library of Medicine: a five-year review. Wallingford KT, et al. **Bull Med Libr Assoc** 1996 Apr;84(2 Suppl):1–60 (0 ref.)
Managing and communicating information in a new era. Crandall S, et al. **Fam Med** 1997 Apr;29(4):270–4 (46 ref.)

INFORMATION PROCESSING, AUTOMATIC see **AUTOMATIC DATA PROCESSING**

INFORMATION PROCESSING, HUMAN see **MENTAL PROCESSES**

INFORMATION RETRIEVAL see **INFORMATION STORAGE AND RETRIEVAL**

INFORMATION RETRIEVAL SYSTEMS see **INFORMATION SYSTEMS**

INFORMATION SCIENCE

TRENDS

The changing face of health information and health information work: a conceptual framework. Bradley J. **Bull Med Libr Assoc** 1996 Jan;84(1):1–10 (40 ref.)

INFORMATION SERVICES

Enhancing clinical teaching with information technologies: what can we do right now? Sandroni S. **Acad Med** 1997 Sep;72(9):770–4 (17 ref.)
Consumer involvement in nutritional issues: the role of information. Vaandrager HW, et al. **Am J Clin Nutr** 1997 Jun;65(6 Suppl):1980S–1984S (21 ref.)
Media choice in nutrition education of general practitioners. van Woerkum CM. **Am J Clin Nutr** 1997 Jun;65(6 Suppl):2013S–2015S (9 ref.)
CDC and ATSDR electronic information resources for health officers [see comments] Friede A, et al. **Am J Infect Control** 1996 Dec;24(6):440–54 (9 ref.) Comment in: Am J Infect Control 1996 Dec;24(6):417–20.
Nutri-action analysis as' a research strategy to improve nutrition information, education and communication interventions in Asia. Smitasiri S, et al. **Biomed Environ Sci** 1996 Sep;9(2–3):290–5 (13 ref.)
Medical software and information technology transfer methods. Schertzer RM. **Can J Ophthalmol** 1996 Feb; 31(1):45–50 (11 ref.)
Dissemination and utilization of health promotion and disease prevention knowledge: theory, research and experience. Green LW, et al. **Can J Public Health** 1996 Nov–Dec;87 Suppl 2:S11–7 (80 ref.)
What information do consumers want and need? Edgman-Levitan S, et al. **Health Aff (Millwood)** 1996 Winter;15(4):42–56 (20 ref.)
EUR-ASSESS Project Subgroup Report on Dissemination and Impact. Granados A, et al. **Int J Technol Assess Health Care** 1997 Spring;13(2):220–86 (120 ref.)
The World Wide Web: a review of an emerging internet-based technology for the distribution of biomedical information. Lowe HJ, et al. **J Am Med Inform Assoc** 1996 Jan–Feb;3(1):1–14 (82 ref.)
Sources of information on women's and infants' health. Lee MA. **J Nurse Midwifery** 1996 Sep–Oct;41(5):393–400 (63 ref.)
Trials of providing costing information to general practitioners: a systematic review. Beilby JJ, et al. **Med J Aust** 1997 Jul 21;167(2):89–92 (34 ref.)
Informing consumer decisions in health care: implications from decision-making research. Hibbard JH, et al. **Milbank Q** 1997;75(3):395–414 (31 ref.)
The use of computers in cancer pain management. Frandsen JL. **Semin Oncol Nurs** 1997 Feb;13(1):49–56 (21 ref.)
[The Internet and its incorporation into the health sector] Linger C, et al. **Rev Panam Salud Publica** 1997 Apr; 1(4):315–23 (104 ref.) (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

[New communication media for ophthalmology] Spallek G, et al. **Ophthalmologe** 1996 Oct;93(5):596–603 (15 ref.) (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

Developing issues under the Massachusetts 'Physician Profile' Act. Donohue JP. **Am J Law Med** 1997; 23(1):115–58 (367 ref.)

STATISTICS & NUMERICAL DATA

Outreach activities of the National Library of Medicine: a five-year review. Wallingford KT, et al. **Bull Med Libr Assoc** 1996 Apr;84(2 Suppl):1–60 (0 ref.)

TRENDS

A practical guide to patient education and information giving.

Hill J. **Baillieres Clin Rheumatol** 1997 Feb;11(1):109–27 (53 ref.)

INFORMATION STORAGE AND RETRIEVAL

Information retrieval for patient care. Gardner M. **BMJ** 1997 Mar 29;314(7085):950–3 (20 ref.)

Genitourinary medicine and The Internet No. 4. Lau RK. **Genitourin Med** 1997 Feb;73(1):73–4 (0 ref.)

Searching for the evidence. Palmer J, et al. **Genitourin Med** 1997 Feb;73(1):70–2 (8 ref.)

An industrial process view of information delivery to support clinical decision making: implications for systems design and process measures. Elson RB, et al. **J Am Med Inform Assoc** 1997 Jul–Aug;4(4):266–78 (95 ref.)

The World Wide Web: a review of an emerging internet–based technology for the distribution of biomedical information. Lowe HJ, et al. **J Am Med Inform Assoc** 1996 Jan–Feb;3(1):1–14 (82 ref.)

Medical image databases: a content–based retrieval approach [see comments] Tagare HD, et al. **J Am Med Inform Assoc** 1997 May–Jun;4(3):184–98 (37 ref.) Comment in: J Am Med Inform Assoc 1997 May–Jun;4(3):252–3.

Information retrieval in digital libraries: bringing search to the net. Schatz BR. **Science** 1997 Jan 17;275(5298):327–34 (48 ref.)

INFORMATION SYSTEMS

Enhancing clinical teaching with information technologies: what can we do right now? Sandroni S. **Acad Med** 1997 Sep;72(9):770–4 (17 ref.)

Postacute neurorehabilitation: roles and responsibilities within a national information system. Evans RW. **Arch Phys Med Rehabil** 1997 Aug;78(8 Suppl 4):S17–25 (38 ref.)

Information retrieval for patient care. Gardner M. **BMJ** 1997 Mar 29;314(7085):950–3 (20 ref.)

Informatics applications in blood banking. Kern DA, et al. **Clin Lab Med** 1996 Dec;16(4):947–60 (42 ref.)

The use of claims databases for outcomes research: rationale, challenges, and strategies. Motheral BR, et al. **Clin Ther** 1997 Mar–Apr;19(2):346–66 (74 ref.)

Description of patients undergoing high risk angioplasty. Analyses of various databases. Kleiman NS. **Eur Heart J** 1995 Nov;16 Suppl L:30–5 (50 ref.)

Information technology in the health care industry. Prochazka EJ, et al. **Hawaii Med J** 1997 Jun;56(6):144–8 (32 ref.)

Microcomputers in hospital epidemiology. Reagan DR. **Infect Control Hosp Epidemiol** 1997 Jun;18(6):440–8 (37 ref.)

Serious technology assessment for health care information technology. Cushman R. **J Am Med Inform Assoc** 1997 Jul–Aug;4(4):259–65 (31 ref.)

The chemokine information source: identification and characterization of novel chemokines using the WorldWideWeb and expressed sequence tag databases. Wells TN, et al. **J Leukoc Biol** 1997 May;61(5):545–50 (16 ref.)

Are separate normal data files required for quantitative pharmacologic stress radionuclide myocardial perfusion imaging? Wackers FJ. **J Nucl Cardiol** 1996 Nov–Dec;3(6 Pt 2):S31–40 (18 ref.)

The use of mapping in public health and planning health services. Gordon A, et al. **J Public Health Med** 1997 Jun; 19(2):139–47 (8 ref.)

Classification systems in nursing: formalizing nursing knowledge and implications for nursing information systems. Goossen WT, et al. **Methods Inf Med** 1996 Mar; 35(1):59–71 (65 ref.)

Molecular linguistics: extracting information from gene and protein sequences [comment] Botstein D, et al. **Proc Natl Acad Sci U S A** 1997 May 27;94(11):5506–7 (13 ref.) Comment on: Proc Natl Acad Sci U S A 1997 May 27;94(11):5831–6.

Dementia drug development: use of information systems to harmonize global drug development. Whitehouse PJ, et al. **Psychopharmacol Bull** 1997;33(1):129–33 (19 ref.)

Geographical information systems and tropical diseases. Openshaw S. **Trans R Soc Trop Med Hyg** 1996 Jul–Aug; 90(4):337–9 (14 ref.)

Communications: technology transfer in the developed world. Murrell KD. **Vet Parasitol** 1996 Aug;64(1–2):107–20 (19 ref.)

[NIHS information and computing infrastructure (NICI)] Nakata K, et al. **Eisei Shikenjo Hokoku** 1996;(114):53–61 (8 ref.) (Eng. Abstr.) **(Jpn)**

[An international exchange and dissemination of chemical safety information on the Internet] Ohtake C, et al. **Eisei Shikenjo Hokoku** 1996;(114):76–83 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Important points and references for the description of hazard information in MSDS] Yamamoto M, et al. **Eisei Shikenjo Hokoku** 1994;(112):138–42 (6 ref.) (Eng. Abstr.) **(Jpn)**

ORGANIZATION & ADMINISTRATION

The barriers and benefits of nursing information systems. Bowles KH. **Comput Nurs** 1997 Jul–Aug;15(4):191–6; quiz 197–8 (42 ref.)

The Digital Anatomist distributed framework and its applications to knowledge–based medical imaging [see comments] Brinkley JF, et al. **J Am Med Inform Assoc** 1997 May–Jun;4(3):165–83 (55 ref.) Comment in: J Am Med Inform Assoc 1997 May–Jun;4(3):252–3.

STANDARDS

Evaluating the impact of health care information systems. Anderson JG, et al. **Int J Technol Assess Health Care** 1997 Spring;13(2):380–93 (42 ref.)

Understanding and using DICOM, the data interchange standard for biomedical imaging [see comments] Bidgood WD Jr, et al. **J Am Med Inform Assoc** 1997 May–Jun; 4(3):199–212 (21 ref.) Comment in: J Am Med Inform Assoc 1997 May–Jun;4(3):252–3.

TRENDS

[Health information systems: the network of epidemiological surveillance and primary care. The current situation] Mirón Canelo JA, et al. **Aten Primaria** 1997 Apr 15;19(6):323–7 (26 ref.) **(Spa)**

INFORMED CONSENT

see related
HUMAN EXPERIMENTATION
TRUTH DISCLOSURE

Caring about risks. Are severely depressed patients competent to consent to research? [see comments] Elliott C. **Arch Gen Psychiatry** 1997 Feb;54(2):113–6 (29 ref.) Comment in: Arch Gen Psychiatry 1997 Feb;54(2):117–20. Comment in: Arch Gen Psychiatry 1997 Feb;54(2):121–3.

Legal and ethical myths about informed consent. Meisel A, et al. **Arch Intern Med** 1996 Dec 9–23;156(22):2521–6 (18 ref.)

Testing for HIV without specific consent: a short review. Magnusson RS. **Aust N Z J Public Health** 1996 Feb; 20(1):57–60 (33 ref.)

Ethical concerns about relapse studies [see comments] Shamoo AE, et al. **Camb Q Healthc Ethics** 1996 Summer; 5(3):373–86 (51 ref.) Comment in: Camb Q Healthc Ethics 1997 Spring;6(2):233–4.

Bioethics for clinicians: 3. Capacity. Etchells E, et al. **Can Med Assoc J** 1996 Sep 15;155(6):657–61 (29 ref.)

Ethics of resuscitation. Hook CC, et al. **Crit Care Clin** 1996 Jan;12(1):135–48 (53 ref.)

Informed consent in epidemiologic studies involving genetic markers. Hunter D, et al. **Epidemiology** 1997 Sep;8(5):596–9 (9 ref.)

Psychological aspects of organ donation: a critical review and synthesis of individual and next–of–kin donation decisions. Radecki CM, et al. **Health Psychol** 1997 Mar; 16(2):183–95 (158 ref.)

Contraceptive methods: potential for abuse. Benagiano G, et al. **Int J Gynaecol Obstet** 1997 Jan;56(1):39–46 (23 ref.)

The rights of psychiatric patients in the light of the principles announced by the United Nations: a recognition of the right to consent to treatment? Gendreau C. **Int J Law Psychiatry** 1997 Spring;20(2):259–78 (77 ref.)

Informed consent for research purposes in intensive care patients in Europe––part I. An official statement of the European Society of Intensive Care Medicine. Working Group on Ethics. Lemaire F, et al. **Intensive Care Med** 1997 Mar;23(3):338–41 (0 ref.)

Adolescents as research subjects without permission of their parents or guardians: ethical considerations. Levine RJ. **J Adolesc Health** 1995 Nov;17(5):287–97 (23 ref.)

A concept analysis of consent. Brennan M. **J Adv Nurs** 1997 Mar;25(3):477–84 (37 ref.)

Compromised consent: deficiencies in the consent process for genetic testing. Andrews LB. **J Am Med Womens Assoc** 1997 Winter;52(1):39–42, 44 (34 ref.)

Involving children and adolescents in medical decision making: developmental and clinical considerations. McCabe MA. **J Pediatr Psychol** 1996 Aug;21(4):505–16 (48 ref.)

Genetic testing for susceptibility to adult–onset cancer. The process and content of informed consent. Geller G, et al. **JAMA** 1997 May 14;277(18):1467–74 (122 ref.)

Preventing harm in resuscitation medicine. Ardagh M. **N Z Med J** 1997 Apr 11;110(1041):113–5 (28 ref.)

[Explanation and agreement (informed consent) in clinical practice] Vollmann I, et al. **Dtsch Med Wochenschr** 1997 Jul 4;122(27):870–3 (52 ref.) **(Ger)**

[Preoperative evaluation of patients and informed consent] Inada E. **Masui** 1996 Dec;45 Suppl:S137–8 (8 ref.) **(Jpn)**

[Informed consent of the esophageal cancer] Kodama M, et al. **Nippon Geka Gakkai Zasshi** 1996 Jun;97(6):409–15 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Lung cancer: Progress in diagnosis and treatment. III. Treatment and prognosis: 1. Overview on treatment of lung cancer––therapeutic plans for lung cancer and associated informed consent] Eguchi K. **Nippon Naika Gakkai Zasshi** 1997 Jan 10;86(1):65–72 (5 ref.) **(Jpn)**

[Informed consent for cancer patients and their family] Yamawaki S. **Nippon Seikeigeka Gakkai Zasshi** 1996 Sep; 70(9):553–8 (12 ref.) **(Jpn)**

LEGISLATION & JURISPRUDENCE

Practical issues in informed consent for transfusion. Sazama K. **Am J Clin Pathol** 1997 Apr;107(4 Suppl 1):S72–4 (8 ref.)

Legal and ethical considerations of informed consent. Pape T. **AORN J** 1997 Jun;65(6):1122–7 (42 ref.)

Report disclaimers and informed expectations about Papanicolaou smears: an Australian view. Mitchell H. **Arch Pathol Lab Med** 1997 Mar;121(3):327–30 (8 ref.)

Informed consent by children and adolescents to psychiatric treatment. Batten DA. **Aust N Z J Psychiatry** 1996 Oct; 30(5):623–9; discussion 630–2 (24 ref.)

Ethical research with the developmentally disabled. Weisstub DN, et al. **Can J Psychiatry** 1997 Jun;42(5):492–6 (31 ref.)

Legal issues in blood banking. Elements of informed consent. Sherman LA. **Clin Lab Med** 1996 Dec;16(4):931–46 (42 ref.)

Treatment decisions for patients without surrogates: rethinking policies for a vulnerable population [see comments] Miller TE, et al. **J Am Geriatr Soc** 1997 Mar; 45(3):369–74 (35 ref.) Comment in: J Am Geriatr Soc 1997 Mar;45(3):375–7.

Better to lay it out on the table rather than do it behind the curtain: hospitals need to obtain consent before using newly deceased patients to teach resuscitation procedures. Kerns AF. **J Contemp Health Law Policy** 1997 Spring; 13(2):581–612 (197 ref.)

Human experimentation. Protecting patient autonomy through informed consent. Tuthill KA. **J Leg Med** 1997 Jun;18(2):221–50 (180 ref.)

Legislating to preserve women's autonomy during pregnancy. Feitshans IL. **Med Law** 1995;14(5–6):397–412 (40 ref.)

Informed consent and disclosure in the physician–patient relationship: expanding obligations for physicians in the United States. LeBlang TR. **Med Law** 1995;14(5–6):429–44 (46 ref.)

Informed consent: putting risks into perspective. Singh AD, et al. **Surv Ophthalmol** 1997 Jul–Aug;42(1):83–6 (10 ref.)

Genetic research, adolescents, and informed consent. Weir RF, et al. **Theor Med** 1995 Dec;16(4):347–73 (78 ref.)

[Consent and patient education in anesthesia. Legal principles and forensic consequences] Biermann E. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jul; 32(7):427–52 (108 ref.) **(Ger)**

[Legal implications, patient education responsibilities for referring and treating physicians] Ulsenheimer K. **Z Kardiol** 1996 Aug;85(8):529–36 (29 ref.) **(Ger)**

[The responsibility of the emergency service physician and patient consent to treatment and hospitalization] Wiernikowski A, et al. **Przegl Lek** 1997;54(6):449–51 (11 ref.) (Eng. Abstr.) **(Pol)**

INFRARED RAYS

Prevention of the adverse health effects of cold by using infrared heaters. Anttonen H, et al. **Aretic Med Res** 1995; 54 Suppl 2:55–9 (9 ref.)

[Novel utilization of antibiotics––a finding method of damaged parts in bacteria] Sawai J, et al. **Nippon Saikingaku Zasshi** 1996 Feb;51(2):589–99 (15 ref.) **(Jpn)**

INFRARED SPECTROPHOTOMETRY see **SPECTROPHOTOMETRY, INFRARED**

INFRATENTORIAL NEOPLASMS

SECONDARY

Cervical carcinoma metastatic to the brain. Robinson JB, et al. **Gynecol Oncol** 1997 Aug;66(2):324–6 (32 ref.)

SURGERY

Cervical carcinoma metastatic to the brain. Robinson JB, et al. **Gynecol Oncol** 1997 Aug;66(2):324–6 (32 ref.)

INFUNDIBULAR NUCLEUS see **ARCUATE NUCLEUS**

INFUSION PUMPS

Pulse–spray thrombolysis in acutely obstructed coronary artery in critical situations. Saito T, et al. **Cathet Cardiovasc Diagn** 1997 Jan;40(1):101–8 (23 ref.)

Food and drug administration regulations and computer–controlled infusion pumps. Bazaral MG, et al. **Int Anesthesiol Clin** 1995 Summer;33(3):45–63 (42 ref.)

Infusion rate control algorithms for pharmacokinetic model–driven drug infusion devices. Jacobs JR. **Int Anesthesiol Clin** 1995 Summer;33(3):65–82 (20 ref.)

Computer–controlled infusions in anesthesia. Kenny GN, et al. **Int Anesthesiol Clin** 1995 Summer;33(3):101–9 (17 ref.)

Protein delivery with infusion pumps. Bremer U, et al. **Pharm Biotechnol** 1997;10:239–54 (12 ref.)

Home infusion therapy. Gorski LA, et al. **Semin Oncol Nurs** 1996 Aug;12(3):193–201 (30 ref.)

[Validation of a new interactive software monitoring a controlled–flow infusion pump for cisplatin dosage regimen adjustment] Cupissol D, et al. **Bull Cancer** 1996 Aug; 83(8):664–76 (36 ref.) (Eng. Abstr.) **(Fre)**

INFUSION PUMPS, EXTERNAL see **INFUSION PUMPS**

INFUSION PUMPS, IMPLANTABLE

Managing chronic neuropathic pain with implanted anesthetic reservoirs. Monsivais JJ, et al. **Hand Clin** 1996 Nov;12(4):781–6 (8 ref.)

Biocompatibility issues of implantable drug delivery systems. Park H, et al. **Pharm Res** 1996 Dec;13(12):1770–6 (58 ref.)

ADVERSE EFFECTS

Intrathecal granuloma after implantation of a morphine pump: case report and review of the literature. Bejjani GK, et al. **Surg Neurol** 1997 Sep;48(3):288–91 (23 ref.)

INFUSION THERAPY, HOME see **HOME INFUSION THERAPY**

INFUSIONS, INTRA-ARTERIAL

[Hepatic metastases of colorectal cancers: intra-arterial chemotherapy. Value and indications] Rougier P, et al. **Presse Med** 1996 Nov 16;25(35):1683–8 (32 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Regional chemotherapy with blood filtration for non resectable liver metastases. Taton G. **Acta Chir Belg** 1997 Apr;97(2):60–4 (26 ref.)

INFUSIONS, INTRA-OSSEOUS see **INFUSIONS, INTRAOSSEOUS**

INFUSIONS, INTRAOSSEOUS

INSTRUMENTATION

Hypertonic saline dextran (HSD) and intraosseous vascular access for the treatment of haemorrhagic hypotension in the far-forward combat arena. Dubick MA, et al. **Ann Acad Med Singapore** 1997 Jan;26(1):64–9 (48 ref.)

INFUSIONS, INTRAVENOUS

see related
IMMUNOGLOBULINS, INTRAVENOUS

Outpatient parenteral antimicrobial–drug therapy. Gilbert DN, et al. **N Engl J Med** 1997 Sep 18;337(12):829–38 (89 ref.)

ADVERSE EFFECTS

[Venous catheterization can cause infusion thrombophlebitis. Study of the literature on its causes and occurrence] Adolfsson A, et al. **Lakartidningen** 1996 Nov 27; 93(48):4398, 4403–4 (17 ref.) **(Swe)**

INFUSIONS, PARENTERAL

see related
FLUID THERAPY
HOME INFUSION THERAPY

Phospholipid–rich particles in commercial parenteral fat emulsions. An overview. Bach AC, et al. **Prog Lipid Res** 1996;35(2):133–53 (232 ref.)

ADVERSE EFFECTS

Distribution of intraperitoneal chemotherapy into the pleural cavity. Vaccarello L, et al. **Obstet Gynecol** 1994 Oct;84(4 Pt 2):714–7 (14 ref.)

METHODS

Safe, simple subcutaneous fluid administration. Farrand S, et al. **Br J Hosp Med** 1996 Jun 5–18;55(11):690–2 (5 ref.)

Therapeutic interventions for oligohydramnios: amnioinfusion and maternal hydration. Kilpatrick SJ. **Clin Obstet Gynecol** 1997 Jun;40(2):328–36 (39 ref.)

INFUSIONS, REGIONAL ARTERIAL see **INFUSIONS, INTRA-ARTERIAL**

INFUSORS see **INFUSION PUMPS**

INGUINAL CANAL

EMBRYOLOGY

The genitofemoral nerve may link testicular inguinoscrotal descent with congenital inguinal hernia. Clarnette TD, et al. **Aust N Z J Surg** 1996 Sep;66(9):612–7 (66 ref.)

PATHOLOGY

Primary extrarenal Wilms' tumor in the inguinal canal: case report and review of the literature. Arkovitz MS, et al. **J Pediatr Surg** 1996 Jul;31(7):957–9 (15 ref.)

INGUINAL HERNIA see **HERNIA, INGUINAL**

INHALATION ANESTHETICS see **ANESTHETICS, INHALATION**

INHALATION BURNS see **BURNS, INHALATION**

INHALATION DEVICES see **NEBULIZERS AND VAPORIZERS**

INHALATION DRUG ADMINISTRATION see **ADMINISTRATION, INHALATION**

INHALATION INJURY, SMOKE see **SMOKE INHALATION INJURY**

INHALATION OF DRUGS see **ADMINISTRATION, INHALATION**

INHALATION PROVOCATION TESTS see **BRONCHIAL PROVOCATION TESTS**

INHALATION THERAPY see **RESPIRATORY THERAPY**

INHALATORS see **NEBULIZERS AND VAPORIZERS**

INHALERS see **NEBULIZERS AND VAPORIZERS**

INHALING see **ASPIRATION**

INHIBIN

Inhibins and activins: roles in clinical practice. Wallace EM, et al. **Br J Obstet Gynaecol** 1996 Oct;103(10):945–56 (151 ref.)

[Inhibin and activin] Abe Y, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Aug; 48(8):708–20 (55 ref.) **(Jpn)**

[Activin: diversity of functions and signal transduction] Sugino H, et al. **Seikagaku** 1996 Aug;68(8):1405–28 (110 ref.) **(Jpn)**

BLOOD

Immunoreactive inhibin, müllerian inhibitory substance, and activin as biochemical markers for juvenile granulosa cell tumors. Silverman LA, et al. **J Pediatr** 1996 Dec; 129(6):918–21 (20 ref.)

METABOLISM

Activin and follistatin as local regulators in the human ovary. Peng C, et al. **Biol Signals** 1996 Mar–Apr;5(2):81–9 (51 ref.)

Follistatins and alpha 2–macroglobulin are soluble binding proteins for inhibin and activin. Mather JP. **Horm Res** 1996; 45(3–5):207–10 (29 ref.)

PHARMACOLOGY

Activin treated urodele ectoderm: a model experimental system for cardiogenesis. Ariizumi T, et al. **Int J Dev Biol** 1996 Aug;40(4):715–8 (19 ref.)

PHYSIOLOGY

Editorial: inhibin in the male––progress at last [editorial] Burger HG, et al. **Endocrinology** 1997 Apr;138(4):1361–2 (23 ref.)

Inhibin, activin, and follistatin in reproductive medicine. Halvorson LM, et al. **Fertil Steril** 1996 Mar;65(3):459–69 (110 ref.)

Roles of inhibins, activins, and follistatin in the female reproductive system. Knight PG. **Front Neuroendocrinol** 1996 Oct;17(4):476–509 (231 ref.)

Inhibin in the male. De Kretser DM, et al. **J Androl** 1996 May–Jun;17(3):179–82 (16 ref.)

Inhibin, activin and follistatin in the human placenta––a new family of regulatory proteins. Petraglia F. **Placenta** 1997 Jan;18(1):3–8 (57 ref.)

Inhibins, activins, and follistatins: the saga continues. DePaolo LV. **Proc Soc Exp Biol Med** 1997 Apr; 214(4):328–39 (136 ref.)

Activins, inhibins, and follistatins: further thoughts on a growing family of regulators. Mather JP, et al. **Proc Soc Exp Biol Med** 1997 Jul;215(3):209–22 (175 ref.)

Activins and activin receptors in cell growth. Ying SY, et al. **Proc Soc Exp Biol Med** 1997 Feb;214(2):114–22 (114 ref.)

[Family of inhibins and activins: from endocrine to paracrine action] Pigny P, et al. **Ann Endocrinol (Paris)** 1996; 57(5):385–94 (82 ref.) (Eng. Abstr.) **(Fre)**

[Embryonic induction and role of activins during early amphibian development] Asashima M, et al. **Hum Cell** 1996 Dec;9(4):277–82 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Activin A induces apoptotic cell death of myeloma cells] Yamato K, et al. **Rinsho Ketsueki** 1996 Jul;37(7):564–73 (18 ref.) **(Jpn)**

INHIBITION (PSYCHOLOGY)

Contributions of inhibitory mechanisms to unified theory in neuroscience and psychology. Clark JM. **Brain Cogn** 1996 Feb;30(1):127–52 (104 ref.)

Life span changes in electrophysiological measures of inhibition. Dustman RE, et al. **Brain Cogn** 1996 Feb; 30(1):109–26 (70 ref.)

Inhibitory mechanisms of neural and cognitive control: applications to selective attention and sequential action. Houghton G, et al. **Brain Cogn** 1996 Feb;30(1):20–43 (91 ref.)

Inhibition and attention deficit hyperactivity disorder. Quay HC. **J Abnorm Child Psychol** 1997 Feb;25(1):7–13 (34 ref.)

Mechanism of disinhibition after brain lesions. Starkstein SE, et al. **J Nerv Ment Dis** 1997 Feb;185(2):108–14 (36 ref.)

Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Barkley RA. **Psychol Bull** 1997 Jan;121(1):65–94 (400 ref.)

Parental investment theory and gender differences in the evolution of inhibition mechanisms. Bjorklund DF, et al. **Psychol Bull** 1996 Sep;120(2):163–88 (200 ref.)

INHIBITION, NEURAL see **NEURAL INHIBITION**

INITIATOR CODON see **CODON, INITIATOR**

INJECTIONS

[Amnioinfusion: indications and results] Luton D, et al. **Presse Med** 1996 Dec 7;25(38):1881–4 (30 ref.) (Eng. Abstr.) **(Fre)**

INJECTIONS, EPIDURAL

see related
ANESTHESIA, EPIDURAL

INJECTIONS, INTRA-ARTICULAR

METHODS

Facet joint injections. Gunzburg R, et al. **Bull Hosp Jt Dis** 1996;55(4):173–5 (22 ref.)

INJECTIONS, INTRALESIONAL

METHODS

Injection techniques and use in the treatment of sports injuries. Scott WA. **Sports Med** 1996 Dec;22(6):406–16 (64 ref.)

INJECTIONS, INTRAMUSCULAR

ADVERSE EFFECTS

Livedo–like dermatitis (Nicolau's syndrome): a review of three cases. Ruffieux P, et al. **Dermatology** 1996; 193(4):368–71 (16 ref.)

Non–invasive and quantitative evaluation of post–injection muscle damage by pharmacokinetic analysis of creatine kinase release. Lefebvre HP, et al. **Vet Res** 1996; 27(4–5):343–61 (44 ref.)

INJECTIONS, INTRAVENOUS

Poly(ethylene glycol)–coated nanospheres: potential carriers for intravenous drug administration. Gref R, et al. **Pharm Biotechnol** 1997;10:167–98 (100 ref.)

ECONOMICS

[Value of the use of the oral route versus the injectable route for fluoroquinolones. Pharmacoeconomic incidence and bibliographical study] Douet C, et al. **Therapie** 1996 Jul–Aug;51(4):464–75 (115 ref.) (Eng. Abstr.) **(Fre)**

INJECTIONS, SCLEROSING see **SCLEROSING SOLUTIONS**

INJECTIONS, SPINAL

see related
ANESTHESIA, EPIDURAL
ANESTHESIA, SPINAL

INJURIES see **WOUNDS AND INJURIES**

INJURIES, MULTIPLE see **MULTIPLE TRAUMA**

INJURIES, NONPENETRATING see **WOUNDS, NONPENETRATING**

INK

Printing processes and printing inks. **IARC Monogr Eval Carcinog Risks Hum** 1996;65:33–147 (272 ref.)

INLAY CASTING WAX

CHEMISTRY

Pattern waxes and inaccuracies in fixed and removable partial denture castings. Diwan R, et al. **J Prosthet Dent** 1997 May;77(5):553–5 (20 ref.)

INLAYS

Direct–indirect resin restoration: a case report of acceptable compromise. Liebenberg WH. **J Can Dent Assoc** 1997 Apr; 63(4):265–72 (55 ref.)

INNATE BEHAVIOR see **INSTINCT**

INNOMINATE ARTERY

INNOMINATE ARTERY see **BRACHIOCEPHALIC TRUNK**

INNOVATION DIFFUSION see **DIFFUSION OF INNOVATION**

INOCULATION LYMPHORETICULOSIS see **CAT-SCRATCH DISEASE**

INORGANIC CHEMISTRY see **CHEMISTRY, INORGANIC**

INOSINATE PHOSPHATASE see **5'-NUCLEOTIDASE**

INOSINE

ANALOGS & DERIVATIVES

Enzymatic conversion of adenosine to inosine and to N1-methylinosine in transfer RNAs: a review. Grosjean H, et al. **Biochimie** 1996;78(6):488-501 (98 ref.)

METABOLISM

Enzymatic conversion of adenosine to inosine and to N1-methylinosine in transfer RNAs: a review. Grosjean H, et al. **Biochimie** 1996;78(6):488-501 (98 ref.)

INOSINE PHOSPHORYLASE see **PURINE-NUCLEOSIDE PHOSPHORYLASE**

INOSINE TRIPHOSPHATE

ANALOGS & DERIVATIVES

Random mutagenesis by using mixtures of dNTP and dITP in PCR. Kuipers OP. **Methods Mol Biol** 1996;57:351-6 (9 ref.)

INOSINIC ACID DEHYDROGENASE see **IMP DEHYDROGENASE**

INOSITOL

METABOLISM

[Inositol treatment in medicine] Levine J, et al. **Harefuah** 1996 May 1;130(9):630-4 (36 ref.) **(Heb)**

PHYSIOLOGY

["Inositol" signal transduction in yeast] Nikawa J. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1680-7 (36 ref.) **(Jpn)**

THERAPEUTIC USE

Inositol prevents expression of a genetic model of neural tube defects in mice. **Nutr Rev** 1997 May;55(5):176-7 (9 ref.)

[Inositol treatment in medicine] Levine J, et al. **Harefuah** 1996 May 1;130(9):630-4 (36 ref.) **(Heb)**

INOSITOL HEXAPHOSPHATE see **PHYTIC ACID**

INOSITOL PHOSPHATES

[Biologically active myo-inositol phosphates] Stepanov AE, et al. **Bioorg Khim** 1996 Oct-Nov;22(10-11):737-44 (92 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Inositol phosphates - whither bound? Intracellular signalling. Irvine R, et al. **Curr Biol** 1996 May 1;6(5):537-40 (17 ref.)

Biochemistry and genetics of inositol phosphate metabolism in Dictyostelium. van Haastert PJ, et al. **FEBS Lett** 1997 Jun 23;410(1):39-43 (41 ref.)

SHIP, a new player in cytokine-induced signalling. Liu L, et al. **Leukemia** 1997 Feb;11(2):181-4 (38 ref.)

PHYSIOLOGY

The function of inositol high polyphosphate binding proteins. Fukuda M, et al. **Bioessays** 1997 Jul;19(7):593-603 (85 ref.)

Cell signalling by inositol phosphoglycans from different species. Varela-Nieto I, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Oct; 115(2):223-41 (204 ref.)

INOSITOL PHOSPHOGLYCERIDES see **PHOSPHATIDYLINOSITOLS**

INOSITOL 1,4,5-TRIPHOSPHATE see **INOSITOL 1,4,5-TRISPHOSPHATE**

INOSITOL 1,4,5-TRISPHOSPHATE

BIOSYNTHESIS

Structure and function of inositol 1,4,5-trisphosphate receptor. Yoshida Y, et al. **Jpn J Pharmacol** 1997 Jun; 74(2):125-37 (119 ref.)

METABOLISM

Elementary events of InsP3-induced Ca2+ liberation in Xenopus oocytes: hot spots, puffs and blips. Parker I, et al. **Cell Calcium** 1996 Aug;20(2):105-21 (44 ref.)

Inositol 1,4,5-trisphosphate receptors and calcium signaling. Michikawa T, et al. **Crit Rev Neurobiol** 1996;10(1):39-55 (117 ref.)

Inositol trisphosphate/Ca2+ as messengers of bradykinin B2 and muscarinic acetylcholine m1-m4 receptors in neuroblastoma-derived hybrid cells. Noda M, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1-3):175-85 (44 ref.)

Regulation of the myo-inositol and betaine cotransporters by tonicity. Handler JS, et al. **Kidney Int** 1996 Jun; 49(6):1682-3 (21 ref.)

Regulation of calcium spiking in mammalian oocytes through a combination of inositol trisphosphate-dependent entry and release. Berridge MJ. **Mol Hum Reprod** 1996 Jun; 2(6):386-8 (25 ref.)

A hierarchical concept of cellular and subcellular Ca(2+)-signalling. Lipp P, et al. **Prog Biophys Mol Biol** 1996;65(3):265-96 (100 ref.)

PHYSIOLOGY

Intracellular Ca2+ release by InsP3 in cerebellar Purkinje neurones. Ogden D, et al. **Acta Physiol Scand** 1996 Jul; 157(3):381-94 (40 ref.)

The 1996 Massry Prize. Inositol trisphosphate and calcium: two interacting second messengers. Berridge MJ. **Am J Nephrol** 1997;17(1):1-11 (94 ref.)

Structure and function of inositol 1,4,5-trisphosphate receptor. Mikoshiba K, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:178-97 (65 ref.)

The InsP3 receptor and intracellular Ca2+ signaling. Mikoshiba K. **Curr Opin Neurobiol** 1997 Jun;7(3):339-45 (70 ref.)

Inositol (1,4,5)-trisphosphate receptors: functional properties, modulation, and role in calcium wave propagation. Bezprozvanny I. **Soc Gen Physiol Ser** 1996;51:75-86 (55 ref.)

Functional properties of inositol 1,4,5-trisphosphate receptor and Ca2+ signaling. Iino M. **Soc Gen Physiol Ser** 1996; 51:67-73 (29 ref.)

Inositol 1,4,5-trisphosphate receptor activation and nuclear envelope assembly. Wilson KL, et al. **Soc Gen Physiol Ser** 1996;51:189-93 (14 ref.)

[G proteins-phosphoinositide pathways in hypertension] Hu SJ, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan;27(1):31-6 (18 ref.) (Eng. Abstr.) **(Chi)**

INOTROPIC AGENTS, POSITIVE CARDIAC see **CARDIOTONIC AGENTS**

INOTROPISM see **MUSCLE CONTRACTION**

INOTROPISM, CARDIAC see **MYOCARDIAL CONTRACTION**

INOVIRUS

Phage presentation. Hill HR, et al. **Mol Microbiol** 1996 May; 20(4):685-92 (51 ref.)

INPATIENTS

Recognizing bedside rationing: clear cases and tough calls [see comments] Ubel PA, et al. **Ann Intern Med** 1997 Jan 1;126(1):74-80 (28 ref.) Comment in: Ann Intern Med 1997 Jun 1;126(11):921; discussion 921-2.

Inpatient management of acute leukemia. Kalaycio M. **Cleve Clin J Med** 1997 Jul-Aug;64(7):385-9 (56 ref.)

Meaningful linkage practices: challenges and opportunities. Boyer CA. **New Dir Ment Health Serv** 1997 Spring; (73):87-101 (54 ref.)

[Patients leaving psychiatric hospitals without permission] Naveh S, et al. **Harefuah** 1996 May 15;130(10):699-701 (15 ref.) **(Heb)**

INSANITY DEFENSE

A Malay crosscultural worldview and forensic review of amok. Hatta SM. **Aust N Z J Psychiatry** 1996 Aug; 30(4):505-10 (30 ref.)

Myths, realities, and the political world: the anthropology of insanity defense attitudes [see comments] Perlin ML. **Bull Am Acad Psychiatry Law** 1996;24(1):5-26 (138 ref.) Comment in: Bull Am Acad Psychiatry Law 1996;24(3):423-6. Comment in: Bull Am Acad Psychiatry Law 1996;24(3):426-7.

The reformulated defence of insanity in the Australian Criminal Code Act 1995 (Cth). McSherry B. **Int J Law Psychiatry** 1997 Spring;20(2):183-97 (29 ref.)

Violence of psychotic patients: how much responsibility can be attributed? Nedopil N. **Int J Law Psychiatry** 1997 Spring;20(2):243-7 (15 ref.)

Asking the impossible: the negligence liability of the mentally ill. Goldstein EJ. **J Contemp Health Law Policy** 1995 Fall; 12(1):67-92 (184 ref.)

Conditional release: court-ordered outpatient treatment for insanity acquittees. Stafford KP, et al. **New Dir Ment Health Serv** 1997 Fall;(75):61-72 (11 ref.)

[Testimony of the psychiatric expert from the viewpoint of the criminal judge] Schmitt B. **Arch Kriminol** 1996 Jul-Aug;198(1-2):38-54 (68 ref.) **(Ger)**

INSECT BITES AND STINGS

Selection of biting sites by mosquitoes. de Jong R, et al. **Ciba Found Symp** 1996;200:89-100; discussion 101-8 (41 ref.)

COMPLICATIONS

Anaphylaxis and stinging insect reactions. Dykewicz MS. **Compr Ther** 1996 Sep;22(9):579-85 (9 ref.)

Papular urticaria in children. Howard R, et al. **Pediatr Dermatol** 1996 May-Jun;13(3):246-9 (15 ref.)

[Myocardial infarction following a bee sting. Apropos of a case and review of the literature] Massing JL, et al. **Ann Cardiol Angeiol (Paris)** 1997 May-Jun;46(5-6):311-5 (11 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Hymenoptera immunotherapy [editorial] Mosbech H. **Allergy** 1997 Jan;52(1):1-3 (17 ref.)

The sting challenge test in Hymenoptera venom allergy. Position paper of the Subcommittee on Insect Venom Allergy of the European Academy of Allergology and Clinical Immunology. Ruëff F, et al. **Allergy** 1996 Apr; 51(4):216-25 (79 ref.)

Stinging insect hypersensitivity in children. Graft DF. **Curr Opin Pediatr** 1996 Dec;8(6):597-600 (23 ref.)

PREVENTION & CONTROL

Insect repellents: an overview. Brown M, et al. **J Am Acad Dermatol** 1997 Feb;36(2 Pt 1):243-9 (35 ref.)

Insect repellents. What really works? Mafong EA, et al. **Postgrad Med** 1997 Aug;102(2):63, 68-9, 74 (26 ref.)

THERAPY

Hymenoptera immunotherapy [editorial] Mosbech H. **Allergy** 1997 Jan;52(1):1-3 (17 ref.)

The sting challenge test in Hymenoptera venom allergy. Position paper of the Subcommittee on Insect Venom Allergy of the European Academy of Allergology and Clinical Immunology. Ruëff F, et al. **Allergy** 1996 Apr; 51(4):216-25 (79 ref.)

INSECT CONTROL

see related
INSECTICIDE RESISTANCE
PEST CONTROL, BIOLOGICAL

The biology, ecology, and management of the cat flea. Rust MK, et al. **Annu Rev Entomol** 1997;42:451-73 (172 ref.)

Vector insects and their control. Lehane MJ. **Ciba Found Symp** 1996;200:8-16; discussion 16-21, 46-7 (37 ref.)

METHODS

The USDA Forest Service pesticide spray behavior and application development program--an overview. Barry JW. **J Am Mosq Control Assoc** 1996 Jun;12(2 Pt 2):342-52 (88 ref.)

An operational perspective on measuring aerosol cloud dynamics. Burkett DA, et al. **J Am Mosq Control Assoc** 1996 Jun;12(2 Pt 2):380-3 (4 ref.)

Overview of meteorological measurements for aerial spray modeling. Rafferty JE, et al. **J Am Mosq Control Assoc** 1996 Jun;12(2 Pt 2):364-7 (7 ref.)

An introduction to aerial spray modeling with FSCBG. Forest Service Cramer-Barry-Grim. Teske ME. **J Am Mosq Control Assoc** 1996 Jun;12(2 Pt 2):353-8 (47 ref.)

Breeding habitats of vector sandflies and their control in India. Sivagnaname N, et al. **J Commun Dis** 1997 Jun; 29(2):153-9 (57 ref.)

Future perspectives on insect pest management: engineering the pest. Pfeifer TA, et al. **J Invertebr Pathol** 1996 Mar; 67(2):109-19 (81 ref.)

INSECT GENES see **GENES, INSECT**

INSECT GROWTH REGULATORS see **JUVENILE HORMONES**

INSECT HORMONES

CHEMISTRY

Allatostatins: diversity in structure and function of an insect neuropeptide family. Bendena WG, et al. **Ann N Y Acad Sci** 1997 Apr 24;814:53-66 (56 ref.)

Structures, assays and receptors for locust adipokinetic hormones. Goldsworthy GJ, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 Aug; 117(4):483-96 (136 ref.)

GENETICS

Insect storage proteins: gene families and receptors. Haunerland NH. **Insect Biochem Mol Biol** 1996 Sep-Oct; 26(8-9):755-65 (60 ref.)

Tudor domains in proteins that interact with RNA. Ponting CP. **Trends Biochem Sci** 1997 Feb;22(2):51-2 (17 ref.)

METABOLISM

The multiple role of the pheromone-binding protein in olfactory transduction. Ziegelberger G. **Ciba Found Symp** 1996;200:267-75; discussion 275-80 (41 ref.)
Structures, assays and receptors for locust adipokinetic hormones. Goldsworthy GJ, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 Aug; 117(4):483-96 (136 ref.)
Pattern formation: The link between ovary and embryo. Stein D. **Curr Biol** 1995 Dec 1;5(12):1360-3 (16 ref.)
Insect storage proteins: gene families and receptors. Haunerland NH. **Insect Biochem Mol Biol** 1996 Sep-Oct; 26(8-9):755-65 (60 ref.)
Thrombin inhibitors of bloodsucking animals. Dodt J, et al. **Semin Thromb Hemost** 1996;22(2):203-8 (44 ref.)

PHYSIOLOGY

Allatostatins: diversity in structure and function of an insect neuropeptide family. Bendena WG, et al. **Ann N Y Acad Sci** 1997 Apr 24;814:53-66 (56 ref.)
Eclosion hormone action on the nervous system. Intracellular messengers and sites of action. Morton DB. **Ann N Y Acad Sci** 1997 Apr 24;814:40-50 (48 ref.)
Insect physiology: the emerging story of ecdysis. Hesterlee S, et al. **Curr Biol** 1996 Jun 1;6(6):648-50 (9 ref.)
Cell culture approaches to understanding the actions of steroid hormones on the insect nervous system. Levine RB, et al. **Dev Neurosci** 1996;18(1-2):73-86 (72 ref.)
Steroid receptors and nervous system metamorphosis in insects. Truman JW. **Dev Neurosci** 1996;18(1-2):87-101 (41 ref.)
The roles of engrailed. Hidalgo A. **Trends Genet** 1996 Jan; 12(1):1-4 (25 ref.)
Files on steroids--Drosophila metamorphosis and the mechanisms of steroid hormone action. Thummel CS. **Trends Genet** 1996 Aug;12(8):306-10 (48 ref.)
Engrailed and retinotectal topography. Rétaux S, et al. **Trends Neurosci** 1996 Dec;19(12):542-6 (56 ref.)
The revolution in insect neuropeptides illustrated by the adipokinetic hormone/red pigment-concentrating hormone family of peptides. Gäde G. **Z Naturforsch [C]** 1996 Sep-Oct;51(9-10):607-17 (86 ref.)

INSECT PARVOVIRUSES see **DENSOVIRUS**

INSECT PROTEINS

CHEMISTRY

Structure and functions of channel-forming peptides: magainins, cecropins, melittin and alamethicin. Bechinger B. **J Membr Biol** 1997 Apr 1;156(3):197-211 (262 ref.)

GENETICS

Carcinogenesis: a balance between beta-catenin and APC. Gumbiner BM. **Curr Biol** 1997 Jul 1;7(7):R443-6 (26 ref.)
Partners in time. Circadian rhythms. Van Gelder RN, et al. **Curr Biol** 1996 Mar 1;6(3):244-6 (16 ref.)
Functions of mammalian Polycomb group and trithorax group related genes. Gould A. **Curr Opin Genet Dev** 1997 Aug;7(4):488-94 (61 ref.)
Expression and function of Enhancer of split bHLH proteins during Drosophila neurogenesis. Bray SJ. **Perspect Dev Neurobiol** 1997;4(4):313-23 (65 ref.)
The fascination of the Drosophila NMJ. Brunner A, et al. **Trends Genet** 1997 Mar;13(3):85-7 (19 ref.)
Chromatin-silencing mechanisms in Drosophila maintain patterns of gene expression. Pirrotta V. **Trends Genet** 1997 Aug;13(8):314-8 (49 ref.)

METABOLISM

Armadillo and dTCF: a marriage made in the nucleus. Cavallo R, et al. **Curr Opin Genet Dev** 1997 Aug; 7(4):459-66 (68 ref.)
PcG complexes and chromatin silencing. Pirrotta V. **Curr Opin Genet Dev** 1997 Apr;7(2):249-58 (69 ref.)

PHYSIOLOGY

Catching a Gli-mpse of Hedgehog. Ruiz i Altaba A. **Cell** 1997 Jul 25;90(2):193-6 (20 ref.)
Cell migration: don't tread on me. Doren MV, et al. **Curr Biol** 1997 Mar 1;7(3):R148-50 (13 ref.)
Limb morphogenesis: connections between patterning and growth. Serrano N, et al. **Curr Biol** 1997 Mar 1; 7(3):R186-95 (52 ref.)
Hedgehog signaling in Drosophila eye and limb development - conserved machinery, divergent roles? Burke R, et al. **Curr Opin Neurobiol** 1997 Feb;7(1):55-61 (65 ref.)
CNS midline development in Drosophila. Hummel T, et al. **Perspect Dev Neurobiol** 1997;4(4):357-68 (87 ref.)
Diverse roles for the Notch receptor in the development of D. melanogaster. Young MW, et al. **Perspect Dev Neurobiol** 1997;4(4):345-55 (77 ref.)
Tumor suppressor genes and signal transduction in Drosophila. Woods DF, et al. **Princess Takamatsu Symp** 1994;24:1-13 (69 ref.)
The world according to hedgehog. Hammerschmidt M, et al. **Trends Genet** 1997 Jan;13(1):14-21 (93 ref.)

INSECT REPELLENTS

Insect repellents. What really works? Mafong EA, et al. **Postgrad Med** 1997 Aug;102(2):63, 68-9, 74 (26 ref.)

ADVERSE EFFECTS

Neurological effects associated with use of the insect repellent N,N-diethyl-m-toluamide (DEET) [see comments] Osimitz TG, et al. **J Toxicol Clin Toxicol** 1997; 35(5):435-41 (47 ref.) Comment in: J Toxicol Clin Toxicol 1997 ;35(5):443-5.

THERAPEUTIC USE

Insect repellents: an overview. Brown M, et al. **J Am Acad Dermatol** 1997 Feb;36(2 Pt 1):243-9 (35 ref.)

INSECT STRUCTURAL GENES see **GENES, STRUCTURAL, INSECT**

INSECT VECTORS

Vector insects and their control. Lehane MJ. **Ciba Found Symp** 1996;200:8-16; discussion 16-21, 46-7 (37 ref.)
Biological control of malaria vectors. Das PK, et al. **Indian J Med Res** 1997 Aug;106:174-97 (225 ref.)
Urban malaria vector biology. Hati AK. **Indian J Med Res** 1997 Aug;106:149-63 (111 ref.)
The medical importance of cockroaches. Baumholtz MA, et al. **Int J Dermatol** 1997 Feb;36(2):90-6 (19 ref.)
Black fly (Diptera:Simuliidae) salivary secretions: importance in vector competence and disease. Cupp EW, et al. **J Med Entomol** 1997 Mar;34(2):87-94 (76 ref.)
Biological variation in Anopheles darlingi Root. Charlwood JD. **Mem Inst Oswaldo Cruz** 1996 Jul-Aug;91(4):391-8 (80 ref.)
The biology of malarial parasite in the mosquito--a review. Simonetti AB. **Mem Inst Oswaldo Cruz** 1996 Sep-Oct; 91(5):519-41 (277 ref.)
Application of deltamethrin-impregnated bednets for mosquito and malaria control in Yunnan, China. Zhang Z, et al. **Southeast Asian J Trop Med Public Health** 1996 Jun;27(2):367-71 (14 ref.)
[Dengue and its vectors in Brazil] Dégallier N, et al. **Bull Soc Pathol Exot** 1996;89(2):128-35; discussion 136 (95 ref.) (Eng. Abstr.) **(Fre)**
[The risk of urban yellow fever outbreaks in Brazil by dengue vectors. Aedes aegypti and Aedes albopictus] Mondet B, et al. **Bull Soc Pathol Exot** 1996;89(2):107-13; discussion 114 (11 ref.) (Eng. Abstr.) **(Fre)**
[Problems posed by the spread of Aedes albopictus] Rodhain F. **Bull Soc Pathol Exot** 1996;89(2):137-40; discussion 140-1 (0 ref.) (Eng. Abstr.) **(Fre)**
[The concept of medical entomology: the determination of the effect of arthropods on human health] Rasnitsyn SP. **Izv Akad Nauk Ser Biol** 1996 Jul-Aug;(4):437-45 (87 ref.) (Eng. Abstr.) **(Rus)**

CLASSIFICATION

Systematics of mosquito disease vectors (Diptera, Culicidae): impact of molecular biology and cladistic analysis. Munstermann LE, et al. **Annu Rev Entomol** 1997;42:351-69 (109 ref.)

IMMUNOLOGY

Immunity to eukaryotic parasites in vector insects. Richman A, et al. **Curr Opin Immunol** 1996 Feb;8(1):14-9 (49 ref.)

PARASITOLOGY

Immunity to eukaryotic parasites in vector insects. Richman A, et al. **Curr Opin Immunol** 1996 Feb;8(1):14-9 (49 ref.)

PHYSIOLOGY

Breeding habitats of vector sandflies and their control in India. Sivagnaname N, et al. **J Commun Dis** 1997 Jun; 29(2):153-9 (57 ref.)

VIROLOGY

Aedes albopictus in the United States: ten-year presence and public health implications. Moore CG, et al. **Emerg Infect Dis** 1997 Jul-Sep;3(3):329-34 (28 ref.)

INSECT VIRUSES

The Tetraviridae. Hanzlik TN, et al. **Adv Virus Res** 1997; 48:101-68 (190 ref.)

INSECTICIDE RESISTANCE

Application of deltamethrin-impregnated bednets for mosquito and malaria control in Yunnan, China. Zhang Z, et al. **Southeast Asian J Trop Med Public Health** 1996 Jun;27(2):367-71 (14 ref.)

GENETICS

Insecticide resistance genes in mosquitoes: their mutations, migration, and selection in field populations. Pasteur N, et al. **J Hered** 1996 Nov-Dec;87(6):444-9 (52 ref.)

INSECTICIDES

see related
CHOLINESTERASE INHIBITORS

Saponins from Medicago Spp.: chemical characterization and biological activity against insects. Tava A, et al. **Adv Exp Med Biol** 1996;405:97-109 (42 ref.)
Can house dust mite-triggered atopic dermatitis be alleviated using acaricides? Cameron MM. **Br J Dermatol** 1997 Jul; 137(1):1-8 (93 ref.)
The USDA Forest Service pesticide spray behavior and application development program--an overview. Barry JW. **J Am Mosq Control Assoc** 1996 Jun;12(2 Pt 2):342-52 (88 ref.)
A review of ultralow-volume aerial sprays of insecticide for mosquito control. Mount GA, et al. **J Am Mosq Control Assoc** 1996 Dec;12(4):601-18 (78 ref.)

ADMINISTRATION & DOSAGE

Scabies. Peterson CM, et al. **Pediatr Ann** 1996 Feb; 25(2):97-100 (13 ref.)

ADVERSE EFFECTS

A risk-benefit assessment of agents used in the treatment of scabies. Elgart ML. **Drug Saf** 1996 Jun;14(6):386-93 (44 ref.)
[Parasite control and its effect on the environment] Liebisch A. **DTW Dtsch Tierarztl Wochenschr** 1996 Jul; 103(7):268-73 (20 ref.) (Eng. Abstr.) **(Ger)**

ANALYSIS

Annual variation of insecticides in precipitation in rural Japan. Kawata K, et al. **Bull Environ Contam Toxicol** 1996 Dec;57(6):853-8 (15 ref.)

ISOLATION & PURIFICATION

Prospects for altering host range for baculovirus bioinsecticides. Thiem SM. **Curr Opin Biotechnol** 1997 Jun; 8(3):317-22 (58 ref.)

METABOLISM

Molecular aspects of pesticide degradation by microorganisms. Kumar S, et al. **Crit Rev Microbiol** 1996; 22(1):1-26 (129 ref.)

PHARMACOLOGY

The insecticidal proteins of Bacillus thuringiensis. Kumar PA, et al. **Adv Appl Microbiol** 1996;42:1-43 (311 ref.)
The utility of strains of morphological group II Bacillus. Singer S. **Adv Appl Microbiol** 1996;42:219-61 (65 ref.)
Probing the mechanism of action of Bacillus thuringiensis insecticidal proteins by site-directed mutagenesis--a minireview. Dean DH, et al. **Gene** 1996 Nov 7;179(1):111-7 (25 ref.)
[Resistance of insects to insecticides. Molecular mechanisms and epidemiology] Bergé JB, et al. **C R Seances Soc Biol Fil** 1996;190(4):445-54 (34 ref.) (Eng. Abstr.) **(Fre)**

POISONING

Four cases of amitraz poisoning in humans. Kennel O, et al. **Vet Hum Toxicol** 1996 Feb;38(1):28-30 (26 ref.)

THERAPEUTIC USE

A risk-benefit assessment of agents used in the treatment of scabies. Elgart ML. **Drug Saf** 1996 Jun;14(6):386-93 (44 ref.)
Anopheline species complexes & malaria control. Subbarao SK, et al. **Indian J Med Res** 1997 Aug;106:164-73 (41 ref.)
Crusted scabies associated with systemic lupus erythematosus: response to benzyl benzoate therapy. Chutimunt N. **J Med Assoc Thai** 1996 Jan;79(1):65-8 (10 ref.)

TOXICITY

Community structure and dynamics in desert ecosystems: potential implications for insecticide risk assessment. van der Valk HC. **Arch Environ Contam Toxicol** 1997 Jan; 32(1):11-21 (74 ref.)
Insecticide resistance genes in mosquitoes: their mutations, migration, and selection in field populations. Pasteur N, et al. **J Hered** 1996 Nov-Dec;87(6):444-9 (52 ref.)
Basic toxicology of pesticides. Costa LG. **Occup Med** 1997 Apr-Jun;12(2):251-68 (50 ref.)
Neuronal ion channels as the target sites of insecticides. Narahashi T. **Pharmacol Toxicol** 1996 Jul;79(1):1-14 (146 ref.)

INSECTICIDES, BOTANICAL

Application of deltamethrin-impregnated bednets for mosquito and malaria control in Yunnan, China. Zhang Z, et al. **Southeast Asian J Trop Med Public Health** 1996 Jun;27(2):367-71 (14 ref.)

ANALYSIS

Chromatographic methods for the determination of pyrethrin and pyrethroid pesticide residues in crops, foods and

INSECTICIDES, BOTANICAL

environmental samples. Chen ZM, et al. **J Chromatogr A** 1996 Nov 22;754(1-2):367-95 (226 ref.)

CHEMISTRY

Interaction of synthetic pyrethroids with micro-organisms: a review. Johri AK, et al. **Microbios** 1997; 89(360-361):151-6 (35 ref.)

PHARMACOLOGY

Review: mosquito nets and insecticides for net treatment: a discussion of existing and potential distribution systems in Africa. Lines J. **Trop Med Int Health** 1996 Oct; 1(5):616-32 (54 ref.)

TOXICITY

Interaction of synthetic pyrethroids with micro-organisms: a review. Johri AK, et al. **Microbios** 1997; 89(360-361):151-6 (35 ref.)

INSECTICIDES, CARBAMATE

ADVERSE EFFECTS

Thermoregulatory aspects of environmental exposure to anticholinesterase agents. Gordon CJ. **Rev Environ Health** 1996 Jul-Sep;11(3):101-17 (72 ref.)

ANALYSIS

Recent advances in the residue analysis of N-methylcarbamate pesticides. Yang SS, et al. **J Chromatogr A** 1996 Nov 22;754(1-2):3-16 (117 ref.)

POISONING

Diagnosis and treatment of organophosphate and carbamate intoxication. Wagner SL. **Occup Med** 1997 Apr-Jun; 12(2):239-49 (44 ref.)

Fatal human poisonings in northern Greece: 1990-1995. Tsoukali H, et al. **Vet Hum Toxicol** 1996 Oct;38(5):366-7 (5 ref.)

INSECTICIDES, ORGANOCHLORINE

ADVERSE EFFECTS

The human health effects of DDT (dichlorodiphenyltrichloroethane) and PCBS (polychlorinated biphenyls) and an overview of organochlorines in public health. Longnecker MP, et al. **Annu Rev Public Health** 1997;18:211-44 (127 ref.)

Organochlorine exposure and risk for breast cancer. Safe SH, et al. **Prog Clin Biol Res** 1997;396:133-45 (63 ref.)

ANALYSIS

Chromatographic techniques in the analysis of organochlorine pesticide residues. Mukherjee I, et al. **J Chromatogr A** 1996 Nov 22;754(1-2):33-42 (87 ref.)

Analytical methods for the determination of organochlorine compounds. Application to environmental samples in the Slovak Republic. Veningerová M, et al. **J Chromatogr A** 1997 Jul 11;774(1-2):333-47 (52 ref.)

Organochlorine insecticide residues in African Fauna: 1971-1995. Wiktelius S, et al. **Rev Environ Contam Toxicol** 1997;151:1-37 (100 ref.)

BLOOD

An overview of some reproductive toxicology studies conducted at Health Canada. Foster WG, et al. **Toxicol Ind Health** 1996 May-Aug;12(3-4):447-59 (77 ref.)

METABOLISM

Genetic manipulations of microorganisms for the degradation of hexachlorocyclohexane. Johri AK, et al. **FEMS Microbiol Rev** 1996 Dec;19(2):69-84 (184 ref.)

TOXICITY

Methoxychlor as a model for environmental estrogens. Cummings AM. **Crit Rev Toxicol** 1997 Jul;27(4):367-79 (75 ref.)

INSECTICIDES, ORGANOPHOSPHATE

see related
CHOLINESTERASE INHIBITORS

ADVERSE EFFECTS

Thermoregulatory aspects of environmental exposure to anticholinesterase agents. Gordon CJ. **Rev Environ Health** 1996 Jul-Sep;11(3):101-17 (72 ref.)

POISONING

Diagnosis and treatment of organophosphate and carbamate intoxication. Wagner SL. **Occup Med** 1997 Apr-Jun; 12(2):239-49 (44 ref.)

Fatal human poisonings in northern Greece: 1990-1995. Tsoukali H, et al. **Vet Hum Toxicol** 1996 Oct;38(5):366-7 (5 ref.)

[Carbamate and organophosphate poisoning] Peduto VA, et al. **Minerva Anestesiol** 1996 Jan-Feb;62(1-2):33-54 (116 ref.) (Eng. Abstr.) **(Ita)**

TOXICITY

Neuropathy target esterase (NTE): molecular characterisation and cellular localisation. Glynn P. **Arch Toxicol Suppl** 1997;19:325-9 (10 ref.)

The concept and target of promotion of axonopathies. Lotti M. **Arch Toxicol Suppl** 1997;19:331-6 (45 ref.)

Cell culture models of interspecies selectivity to organophosphorous insecticides. Veronesi B, et al. **Neurotoxicology** 1997;18(1):283-97 (85 ref.)

INSECTICIDES, ORGANOPHOSPHATE, ANTAGONISTS see **CHOLINESTERASE REACTIVATORS**

INSECTICIDES, ORGANOTHIOPHOSPHATE

POISONING

[Fatal food poisoning by parathion] Laynez Bretones F, et al. **Med Clin (Barc)** 1997 Feb 15;108(6):224-5 (17 ref.) (Eng. Abstr.) **(Spa)**

INSECTICIDES, ORGANOTHIOPHOSPHATE, ANTAGONISTS see **CHOLINESTERASE REACTIVATORS**

INSECTS

Production of heterologous proteins using the baculovirus/insect expression system. Griffiths CM, et al. **Methods Mol Biol** 1997;75:427-40 (18 ref.)

ANATOMY & HISTOLOGY

The evolution of insect wings and their sensory apparatus. Dickinson MH, et al. **Brain Behav Evol** 1997 Jul;50(1):13-24 (70 ref.)

CHEMISTRY

Serine proteinase inhibitors from insect hemolymph. Polanowski A, et al. **Acta Biochim Pol** 1996;43(3):445-53 (42 ref.)

The explosion of structural information on insect neuropeptides. Gäde G. **Fortschr Chem Org Naturst** 1997; 71:1-128 (494 ref.)

What can we learn from prostaglandins and related eicosanoids in insects? Stanley-Samuelson DW, et al. **Insect Biochem Mol Biol** 1996 Mar;26(3):223-34 (101 ref.)

Insect neuropeptide proctolin and its analogues. An overview of the present literature. Konopińska D. **J Pept Res** 1997 Jun;49(6):457-66 (56 ref.)

DRUG EFFECTS

[Resistance of insects to insecticides. Molecular mechanisms and epidemiology] Bergé JB, et al. **C R Seances Soc Biol Fil** 1996;190(4):445-54 (34 ref.) (Eng. Abstr.) **(Fre)**

EMBRYOLOGY

Common ground plans in early brain development in mice and flies. Arendt D, et al. **Bioessays** 1996 Mar;18(3):255-9 (64 ref.)

The development and evolution of polyembryonic insects. Strand MR, et al. **Curr Top Dev Biol** 1997;35:121-59 (158 ref.)

ENZYMOLOGY

Cytochrome P-450 in plant/insect interactions: geraniol 10-hydroxylase and the biosynthesis of iridoid monoterpenoids. Hallahan DL, et al. **Drug Metabol Drug Interact** 1995;12(3-4):369-82 (44 ref.)

Biochemical properties of insect and crustacean proteasomes. Mykles DL. **Mol Biol Rep** 1997 Mar;24(1-2):133-8 (34 ref.)

GENETICS

Transposable elements and gene transformation in non-drosophilid insects. O'Brochta DA, et al. **Insect Biochem Mol Biol** 1996 Sep-Oct;26(8-9):739-53 (96 ref.)

IMMUNOLOGY

Biological mediators of insect immunity. Gillespie JP, et al. **Annu Rev Entomol** 1997;42:611-43 (230 ref.)

Innate immunity in higher insects. Hoffmann JA, et al. **Curr Opin Immunol** 1996 Feb;8(1):8-13 (56 ref.)

Inducible humoral immune defense responses in insects. Karp RD. **Prog Mol Subcell Biol** 1996;15:67-87 (94 ref.)

METABOLISM

The role of cardenolides in a crucifer-insect relationship. Renwick JA. **Adv Exp Med Biol** 1996;405:111-21 (52 ref.)

Molecular characteristics of mammalian and insect amino acid transporters: implications for amino acid homeostasis. Castagna M, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):269-86 (200 ref.)

MICROBIOLOGY

Non-cultivable microorganisms from symbiotic associations of insects and other hosts. Baumann P, et al. **Antonie Van Leeuwenhoek** 1997 Jul;72(1):39-48 (68 ref.)

PHYSIOLOGY

The evolution of insect flight: implications for the evolution of the nervous system. Edwards JS. **Brain Behav Evol** 1997 Jul;50(1):8-12 (26 ref.)

Central mechanisms of pheromone information processing. Mustaparta H. **Chem Senses** 1996 Apr;21(2):269-75 (34 ref.)

Odour plumes and odour-mediated flight in insects. Cardé RT. **Ciba Found Symp** 1996;200:54-66; discussion 66-70 (46 ref.)

Coding mechanisms in insect olfaction. Mustaparta H. **Ciba Found Symp** 1996;200:149-57 (51 ref.)

Insect visual perception: complex abilities of simple nervous systems. Giurfa M, et al. **Curr Opin Neurobiol** 1997 Aug; 7(4):505-13 (46 ref.)

Cell culture approaches to understanding the actions of steroid hormones on the insect nervous system. Levine RB, et al. **Dev Neurosci** 1996;18(1-2):73-86 (72 ref.)

Steroid receptors and nervous system metamorphosis in insects. Truman JW. **Dev Neurosci** 1996;18(1-2):87-101 (41 ref.)

Control of circulation in insects. Miller TA. **Gen Pharmacol** 1997 Jul;29(1):23-38 (55 ref.)

Perireceptor events in olfaction. Pelosi P. **J Neurobiol** 1996 May;30(1):3-19 (99 ref.)

Genetic approaches to the study of memory in insects. Lopatina NG, et al. **Neurosci Behav Physiol** 1997 May-Jun; 27(3):250-3 (12 ref.)

Insect neurotransmission: neurotransmitters and their receptors. Osborne RH. **Pharmacol Ther** 1996;69(2):117-42 (429 ref.)

The role of cytochrome P450 monooxygenases in plant-insect interactions. Schuler MA. **Plant Physiol** 1996 Dec;112(4):1411-9 (47 ref.)

The nitric oxide system in insects. Müller U. **Prog Neurobiol** 1997 Feb;51(3):363-81 (146 ref.)

Neuropeptides, amines and amino acids in an elementary insect ganglion: functional and chemical anatomy of the unfused abdominal ganglion. Nässel DR. **Prog Neurobiol** 1996 Mar-Apr;48(4-5):325-420 (360 ref.)

Development of the insect stomatogastric nervous system. Hartenstein V. **Trends Neurosci** 1997 Sep;20(9):421-7 (21 ref.)

ULTRASTRUCTURE

Structure and function of insect olfactory sensilla. Steinbrecht RA. **Ciba Found Symp** 1996;200:158-74; discussion 174-7 (67 ref.)

INSEMINATION, ARTIFICIAL

see related
FERTILIZATION IN VITRO
SEMEN PRESERVATION

Is there still a place for intra-uterine insemination as a treatment for male subfertility? A review. Cohlen BJ, et al. **Int J Androl** 1995 Dec;18 Suppl 2:72-5 (30 ref.)

[Artificial insemination in the AIDS era] Paz G, et al. **Harefuah** 1996 Oct;131(7-8):252-4 (23 ref.) **(Heb)**

ADVERSE EFFECTS

[Pelvic infection following intrauterine insemination: is it rare?] Lavie O, et al. **Harefuah** 1996 Jun 2;130(11):757-60 (31 ref.) **(Heb)**

METHODS

Assisted conception and immunological infertility. Cimino C, et al. **Acta Eur Fertil** 1995 Jan-Feb;26(1):13-20 (46 ref.)

Assisted reproductive technologies and immune infertility. Bustillo M, et al. **Am J Reprod Immunol** 1996 Mar; 35(3):205-10 (38 ref.)

Statement on intra-uterine insemination. Comhaire F, et al. **Int J Androl** 1995 Dec;18 Suppl 2:76-7 (7 ref.)

New approaches to male infertility: IVF and microinjection. Diedrich K, et al. **Int J Androl** 1995 Dec;18 Suppl 2:78-80 (11 ref.)

[Recent data on the treatment of unexplained infertility with clomiphene citrate, intrauterine insemination, and in vitro fertilization] Sitti-Amina AA, et al. **Contracept Fertil Sex** 1997 Feb;25(2):95-100 (15 ref.) **(Fre)**

VETERINARY

Biotechnological advances in goat reproduction. Amoah EA, et al. **J Anim Sci** 1997 Feb;75(2):578-85 (74 ref.)

[Separation techniques ro achieve vital and reproduction competent equine spermatozoa populations--a survey] Sieme H, et al. **DTW Dtsch Tierarztl Wochenschr** 1997 Aug; 104(8):298-302 (61 ref.) (Eng. Abstr.) **(Ger)**

INSEMINATION, ARTIFICIAL, HETEROLOGOUS

PSYCHOLOGY

Donor insemination, the impact on family and child development. Brewaeys A.
J Psychosom Obstet Gynaecol 1996 Mar;17(1):1–13 (62 ref.)
Donor insemination: the gifting and selling of semen. Daniels KR, et al. **Soc Sci Med** 1996 Jun;42(11):1521–36 (96 ref.)

INSEMINATION, ARTIFICIAL, HOMOLOGOUS

METHODS

[Micro-insemination with intracytoplasmic sperm injection] Andersen AG, et al. **Ugeskr Laeger** 1996 Nov 18; 158(47):6747–51 (31 ref.) (Eng. Abstr.) **(Dan)**
[Medically assisted reproduction with immature spermatozoa. Clinical examination and surgical technics] Schoysman R, et al. **Acta Urol Belg** 1997 Jun;65(2):21–6 (32 ref.) (Eng. Abstr.) **(Fre)**
[Intra-uterine inseminations with hyperstimulation in male infertility] Delépine B, et al. **Contracept Fertil Sex** 1996 Dec;24(12):891–6 (21 ref.) (Eng. Abstr.) **(Fre)**
[Physiology of human gamete interaction] Wolf JP, et al. **Contracept Fertil Sex** 1997 Jan;25(1):69–78 (20 ref.) (Eng. Abstr.) **(Fre)**

INSEMINATION, ARTIFICIAL, HUMAN DONOR see **INSEMINATION, ARTIFICIAL, HETEROLOGOUS**

INSEMINATION, ARTIFICIAL, HUSBAND see **INSEMINATION, ARTIFICIAL, HOMOLOGOUS**

INSERTION ELEMENTS, DNA see **DNA INSERTION ELEMENTS**

INSERTION SEQUENCE see **DNA INSERTION ELEMENTS**

INSERTION SEQUENCE ELEMENTS see **DNA INSERTION ELEMENTS**

INSERTIONAL ACTIVATION see **MUTAGENESIS, INSERTIONAL**

INSERTIONAL MUTAGENESIS see **MUTAGENESIS, INSERTIONAL**

INSERVICE TRAINING

[Performance capacity of elderly workers--internal and external influencing factors] Dittmann-Kohli F, et al.
Z Gerontol Geriatr 1996 Sep-Oct;29(5):323–7 (47 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

Demand for post-qualifying professional education in the health care sector in England. Calpin-Davies PJ.
J Adv Nurs 1996 Oct;24(4):800–9 (33 ref.)

INSOMNIA

Insomnia. Spielman AJ, et al. **Neurol Clin** 1996 Aug; 14(3):513–43 (34 ref.)

DRUG THERAPY

Zolpidem: distinct from triazolam? Lobo BL, et al.
Ann Pharmacother 1997 May;31(5):625–32 (52 ref.)
Polysomnographic effects of hypnotic drugs. A review. Parrino L, et al. **Psychopharmacology (Berl)** 1996 Jul; 126(1):1–16 (131 ref.)
[Use of antidepressants in sleep disorders: practical considerations] Touchon J. **Encephale** 1995 Dec;21 Spec No 7:41–7 (24 ref.) (Eng. Abstr.) **(Fre)**
[Concepts in pharmacotherapy of insomnia] Jordan W, et al. **Internist (Berl)** 1996 May;37(5):490–9 (75 ref.) **(Ger)**
[Sleeping pills and their use] Askenasy JJ. **Harefuah** 1996 May 1;130(9):639–40 (16 ref.) **(Heb)**

ETIOLOGY

Anxiety disorders and insomnia in geriatric patients. Folks DG, et al. **Psychiatr Clin North Am** 1997 Mar;20(1):137–64 (109 ref.)
Sleep disorders in Chinese culture: experiences from a study of insomnia in Taiwan. Lee YJ.
Psychiatry Clin Neurosci 1995 May;49(2):103–6 (9 ref.)
The etiology and management of insomnia. Bond T, et al.
Va Med Q 1996 Fall;123(4):254–5 (7 ref.)
[Agrypnia (organic insomnia)] Autret A, et al.
Neurophysiol Clin 1995;25(6):360–6 (37 ref.) (Eng. Abstr.) **(Fre)**
[Sleep and depression] Voderholzer U, et al.
Internist (Berl) 1996 May;37(5):483–9 (26 ref.) **(Ger)**

PSYCHOLOGY

Sleep disorders in Chinese culture: experiences from a study of insomnia in Taiwan. Lee YJ.
Psychiatry Clin Neurosci 1995 May;49(2):103–6 (9 ref.)
[Sleep disorders in prison] Bourgeois D. **Encephale** 1997 May-Jun;23(3):180–3 (11 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Management of insomnia [see comments] Kupfer DJ, et al. **N Engl J Med** 1997 Jan 30;336(5):341–6 (50 ref.) Comment in: N Engl J Med 1997 Jun 26;336(26):1919.
Treatment of insomnia. Getting to the root of sleeping problems. Pary R, et al. **Postgrad Med** 1996 Nov; 100(5):195–8, 201–10 (27 ref.)
Acupuncture treatment for insomnia and acupuncture analgesia. Lin Y. **Psychiatry Clin Neurosci** 1995 May; 49(2):119–20 (17 ref.)
The etiology and management of insomnia. Bond T, et al. **Va Med Q** 1996 Fall;123(4):254–5 (7 ref.)
[Psychological, psychotherapeutic and other non-pharmacologic forms of therapy in treatment of insomnia. Position of the "Insomnia" Study Group of the German Society of Sleep Research and Sleep Medicine] Hajak G, et al. **Fortschr Neurol Psychiatr** 1997 Mar; 65(3):133–44 (144 ref.) (Eng. Abstr.) **(Ger)**

INSOMNIA, FATAL FAMILIAL see **PRION DISEASES**

1,4,5-INSP3 see **INOSITOL 1,4,5-TRISPHOSPHATE**

INSPIRATORY CAPACITY

Tension-time index of inspiratory muscles in children [editorial; comment] Gaultier C. **Pediatr Pulmonol** 1997 May;23(5):327–9 (18 ref.) Comment on: Pediatr Pulmonol 1997 May;23(5):336–43.

INSPIRATORY POSITIVE-PRESSURE BREATHING see **INTERMITTENT POSITIVE-PRESSURE BREATHING**

INSPIRATORY POSITIVE-PRESSURE VENTILATION see **INTERMITTENT POSITIVE-PRESSURE VENTILATION**

INSTABILITY, JOINT see **JOINT INSTABILITY**

INSTILLATION, RECTAL see **ADMINISTRATION, RECTAL**

INSTINCT

see related
LIBIDO
Synaptic mechanisms in invertebrate pattern generation. Cropper EC, et al. **Curr Opin Neurobiol** 1996 Dec; 6(6):833–41 (48 ref.)
Intrinsic neuromodulation: altering neuronal circuits from within. Katz PS, et al. **Trends Neurosci** 1996 Feb; 19(2):54–61 (72 ref.)

INSTITUTES see **ACADEMIES AND INSTITUTES**

INSTITUTIONAL ETHICS COMMITTEES see **ETHICS COMMITTEES**

INSTITUTIONAL LIABILITY see **LIABILITY, LEGAL**

INSTITUTIONAL PERSONNEL LICENSURE see **LICENSURE**

INSTITUTIONAL POLICY see **ORGANIZATIONAL POLICY**

INSTITUTIONAL REVIEW BOARD see **PROFESSIONAL STAFF COMMITTEES**

INSTITUTIONALIZATION

see related
CHILD, INSTITUTIONALIZED
DEINSTITUTIONALIZATION
HOSPITALIZATION
[Family and social aspects in dementia] Bermejo F, et al. **Med Clin (Barc)** 1997 Jun 21;109(4):140–6 (173 ref.) **(Spa)**

INSTITUTIONALIZED CHILD see **CHILD, INSTITUTIONALIZED**

INSTRUCTIONAL MODELS see **MODELS, EDUCATIONAL**

INSTRUCTIONAL TECHNOLOGY see **EDUCATIONAL TECHNOLOGY**

INSTRUMENTAL LEARNING see **CONDITIONING, OPERANT**

INSUFFLATION ANESTHESIA see **ANESTHESIA, INHALATION**

INSULA OF REIL see **CEREBRAL CORTEX**

INSULIN

see related
HYPERINSULINEMIA
HYPERINSULINISM
RECEPTORS, INSULIN
Mechanisms of inhibition of insulin release. Sharp GW.
Am J Physiol 1996 Dec;271(6 Pt 1):C1781–99 (135 ref.)
Diabetes mellitus and impaired pancreatic beta-cell proliferation. Sjöholm A. **J Intern Med** 1996 Mar; 239(3):211–20 (87 ref.)
Insulin analogues. Barnett AH, et al. **Lancet** 1997 Jan 4; 349(9044):47–51 (39 ref.)
[Tertiary structure and functional sites of bombyxin, an insect insulin-like peptide: comparison with those of insulin] Nagata K, et al. **Tanpakushitsu Kakusan Koso** 1996 Aug; 41(10):1485–96 (54 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Combinations sulfonylurea and insulin therapy in diabetes mellitus. Kabadi UM, et al. **Compr Ther** 1995 Dec; 21(12):731–6 (51 ref.)
Insulin preparations--time to rationalise. **Drug Ther Bull** 1996 Feb;34(2):11–4 (11 ref.)
Effects of intra-arterial infusion of insulin on control of forearm vascular resistance in normotensive and hypertensive subjects. Imaizumi T. **Hypertens Res** 1996 Jun;19 Suppl 1:S47–50 (19 ref.)
Controlling blood glucose: insights from an engineering control systems perspective. Worthington DR.
Med Inf (Lond) 1997 Jan-Mar;22(1):5–19 (28 ref.)
Insulin formulation and delivery. Brange J, et al.
Pharm Biotechnol 1997;10:343–409 (500 ref.)
Insulin iontophoresis. Sage BH Jr. **Pharm Biotechnol** 1997; 10:319–41 (30 ref.)
Insulin therapy in type II diabetes: who needs it, how much of it, and for how long? Skyler JS. **Postgrad Med** 1997 Feb;101(2):85–90, 92–4, 96 (0 ref.)
[Adaptation of insulin therapy in the evening and/or at bedtime. Experience of night hospitalization] Bennis D, et al. **Journ Annu Diabetol Hotel Dieu** 1996;:233–47 (21 ref.) **(Fre)**
[Insulin therapy and sports] Aigner A.
Wien Med Wochenschr 1997;147(9):222–5 (22 ref.) (Eng. Abstr.) **(Ger)**
[Insulin therapy in type II diabetes] Beyer J, et al.
Wien Med Wochenschr 1997;147(9):211–6 (25 ref.) (Eng. Abstr.) **(Ger)**
[Insulin therapy: basic principles and strategy] Waldhäusl W.
Wien Med Wochenschr 1997;147(9):200–2, 204–5 (25 ref.) (Eng. Abstr.) **(Ger)**
[Insulin therapy of type I diabetes] Willms B.
Wien Med Wochenschr 1997;147(9):206–10 (13 ref.) (Eng. Abstr.) **(Ger)**
[The changeover to insulin U100. Clinical and pharmacoeconomic suggestions (editorial)] Costa B.
Med Clin (Barc) 1996 Apr 6;106(13):495–7 (25 ref.) **(Spa)**

ADVERSE EFFECTS

Insulin--adverse reactions and clinical problems. Davidson J, et al. **Adverse Drug React Toxicol Rev** 1996 Jun; 15(2):79–91 (85 ref.)
Insulin allergy and insulin resistance. Lebovitz HE.
Curr Ther Endocrinol Metab 1997;6:500–4 (7 ref.)
Insulin therapy and its shortcomings - the need for new approaches. Whitehouse FW. **Diabet Med** 1997 Jun;14 Suppl 2:S5–8 (29 ref.)
Studies in hypoglycaemia in children with insulin-dependent diabetes mellitus. Amiel SA. **Horm Res** 1996;45(6):285–90 (56 ref.)
[Risks and side effects of intensified insulin therapy] Honegger R, et al. **Wien Med Wochenschr** 1997; 147(9):226–30 (10 ref.) (Eng. Abstr.) **(Ger)**
[Hypoglycemia--a problem in insulin therapy?] Otto-Buczkowska E, et al. **Przegl Lek** 1996;53(6):497–500 (38 ref.) (Eng. Abstr.) **(Pol)**

ANALOGS & DERIVATIVES

Insulin lispro: its role in the treatment of diabetes mellitus. Campbell RK, et al. **Ann Pharmacother** 1996 Nov; 30(11):1263–71 (50 ref.)
Insulin lispro. Holleman F, et al. **N Engl J Med** 1997 Jul 17;337(3):176–83 (84 ref.)
Benefits of lispro insulin: control of postprandial glucose levels is within reach. Bohannon NJ. **Postgrad Med** 1997 Feb;101(2):73–6, 79–80 (25 ref.)
Insulin analogues: new agents for improving glycemic control. White JR Jr, et al. **Postgrad Med** 1997 Feb; 101(2):58–60, 63–5, 70 (14 ref.)
[Insulin analogs and new antidiabetic agents. Prospects in diabetes therapy] Gallwitz B, et al. **Internist (Berl)** 1997 Jun;38(6):617–24; discussion 624 (71 ref.) **(Ger)**

BIOSYNTHESIS

Genetic engineering of insulin expression in nonislet cells: implications for beta-cell replacement therapy for insulin-dependent diabetes mellitus. Lipes MA, et al.
Acta Diabetol 1997 Mar;34(1):2–5 (22 ref.)
Regulation of insulin gene transcription by nutrients.

Docherty K, et al. **Biochem Soc Trans** 1996 May; 24(2):368–72 (35 ref.)

BLOOD

Posttranslational effects of protein kinase C and insulin on red cell membrane phosphorylation and cation heteroexchange in hypertension. Semplicini A, et al. **Blood Press Suppl** 1996;1:55–8 (25 ref.)

Insulin resistance in polycystic ovary syndrome. Prelevic GM. **Curr Opin Obstet Gynecol** 1997 Jun;9(3):193–201 (99 ref.)

Impaired glucose tolerance in Pima Indians. Lillioja S. **Diabet Med** 1996 Sep;13(9 Suppl 6):S127–32 (15 ref.)

[The intestinal hormone glucagon-like peptide 1 (GLP-1): from experiment to the clinic] Göke B, et al. **Z Gastroenterol** 1997 Apr;35(4):285–94 (62 ref.) (Eng. Abstr.) **(Ger)**

CHEMISTRY

Representing primary electrophoretic data in the 1/time domain: comparison to representations in the time domain. Mammen M, et al. **Anal Chem** 1997 Jun 1;69(11):2165–70 (16 ref.)

Toward understanding insulin fibrillation. Brange J, et al. **J Pharm Sci** 1997 May;86(5):517–25 (78 ref.)

The chemistry of peroxovanadium compounds relevant to insulin mimesis. Shaver A, et al. **Mol Cell Biochem** 1995 Dec 6–20;153(1–2):5–15 (84 ref.)

DEFICIENCY

Insulin deficiency vs insulin resistance in NIDDM: concluding remarks by a 'biased' observer. Cerasi E. **Diabet Med** 1996 Sep;13(9 Suppl 6):S161–4 (45 ref.)

Classification of diabetes on the basis of etiologies versus degree of insulin deficiency. Kuzuya T, et al. **Diabetes Care** 1997 Feb;20(2):219–20 (13 ref.)

DIAGNOSTIC USE

[Insulin-induced hypoglycemia test] Horiba N, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:275–8 (3 ref.) **(Jpn)**

[Insulin induced hypoglycemic test] Inoue K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:219–22 (9 ref.) **(Jpn)**

ECONOMICS

[The changeover to insulin U100. Clinical and pharmacoeconomic suggestions (editorial)] Costa B. **Med Clin (Barc)** 1996 Apr 6;106(13):495–7 (25 ref.) **(Spa)**

GENETICS

Genetic engineering of insulin expression in nonislet cells: implications for beta-cell replacement therapy for insulin-dependent diabetes mellitus. Lipes MA, et al. **Acta Diabetol** 1997 Mar;34(1):2–5 (22 ref.)

Pathogenesis and treatment of virus-induced autoimmune diabetes: novel insights gained from the RIP-LCMV transgenic mouse model. von Herrath MG, et al. **Biochem Soc Trans** 1997 May;25(2):630–5 (55 ref.)

Gene therapy for diabetes mellitus [editorial] Docherty K. **Clin Sci (Colch)** 1997 Apr;92(4):321–30 (69 ref.)

Regulation of gene expression by insulin. O'Brien RM, et al. **Physiol Rev** 1996 Oct;76(4):1109–61 (622 ref.)

[1997 Maurice Dérot. Transcriptional regulation of the insulin gene: a step toward gene therapy of diabetes] Cerasi E, et al. **Journ Annu Diabetol Hotel Dieu** 1997;:299–304 (15 ref.) **(Fre)**

[Effects of hyperglycemia in the transmission of the insulin message] Hauguel-de Mouzon S, et al. **Journ Annu Diabetol Hotel Dieu** 1996;:145–56 (85 ref.) **(Fre)**

IMMUNOLOGY

Using transgenic mouse models to dissect the pathogenesis of virus-induced autoimmune disorders of the islets of Langerhans and the central nervous system. von Herrath MG, et al. **Immunol Rev** 1996 Aug;152:111–43 (190 ref.)

METABOLISM

Protein metabolism in diabetes mellitus. Abu-Lebdeh HS, et al. **Baillieres Clin Endocrinol Metab** 1996 Oct; 10(4):589–601 (59 ref.)

Postmenopausal hormone replacement therapy and insulin metabolism: effects of route of administration and implications for heart disease and diabetes risk. Godsland IF, et al. **Br J Clin Pract Symp Suppl** 1996 Sep;86:1–5 (43 ref.)

Actions of insulin on the mammalian heart: metabolism, pathology and biochemical mechanisms. Brownsey RW, et al. **Cardiovasc Res** 1997 Apr;34(1):3–24 (263 ref.)

New insights into the role and mechanism of glycogen synthase activation by insulin. Lawrence JC Jr, et al. **Diabetes** 1997 Apr;46(4):541–7 (63 ref.)

Dietary fats and insulin action. Storlien LH, et al. **Diabetologia** 1996 Jun;39(6):621–31 (106 ref.)

Signal transduction mechanism of insulin and insulin-like growth factor-1. Kadowaki T, et al. **Endocr J** 1996 Oct; 43 Suppl:S33–41 (47 ref.)

PDK1, one of the missing links in insulin signal transduction? Cohen P, et al. **FEBS Lett** 1997 Jun 23;410(1):3–10 (71 ref.)

Is leptin an insulin counter-regulatory hormone? Remesar X, et al. **FEBS Lett** 1997 Jan 27;402(1):9–11 (46 ref.)

Insulin exposure and aging theory. Parr T. **Gerontology** 1997; 43(3):182–200 (165 ref.)

Is there evidence for phospho-oligosaccharides as insulin mediators? Field MC. **Glycobiology** 1997 Mar;7(2):161–8 (65 ref.)

Adaptation of islets of Langerhans to pregnancy: beta-cell growth, enhanced insulin secretion and the role of lactogenic hormones. Sorenson RL, et al. **Horm Metab Res** 1997 Jun;29(6):301–7 (59 ref.)

Insulin internalization and other signaling pathways in the pleiotropic effects of insulin. Smith RM, et al. **Int Rev Cytol** 1997;173:243–80 (139 ref.)

The role of phosphoinositide 3-kinase in insulin signalling. Shepherd PR, et al. **J Mol Endocrinol** 1996 Dec; 17(3):175–84 (92 ref.)

Peroxovanadium compounds: biological actions and mechanism of insulin-mimesis. Bevan AP, et al. **Mol Cell Biochem** 1995 Dec 6–20;153(1–2):49–58 (52 ref.)

Facilitative glucose transporters in ruminants. Hocquette JF, et al. **Proc Nutr Soc** 1996 Mar;55(1B):221–36 (70 ref.)

Hormonal regulation of the insulin-responsive glucose transporter, GLUT4: some recent advances. Livingstone C, et al. **Proc Nutr Soc** 1996 Mar;55(1B):179–90 (54 ref.)

Insulin-sensitive phospholipid signaling systems and glucose transport: an update. Farese RV. **Proc Soc Exp Biol Med** 1996 Oct;213(1):1–12 (103 ref.)

A novel DNA/protein complex interacts with the insulin-like growth factor binding protein-1 (IGFBP-1) insulin response sequence and is required for maximal effects of insulin and glucocorticoids on promoter function. Unterman T, et al. **Prog Growth Factor Res** 1995; 6(2-4):119–29 (26 ref.)

[The insulin transduction system] Mitev V. **Mol Med (Sofia)** 1996;1(2):4–8 (21 ref.) (Eng. Abstr.) **(Bul)**

[Anti-atherosclerotic action of angiotensin converting enzyme II. Effect on metabolism of kinin, free radical reaction, sensitivity to insulin and lipid metabolism] Stajszczyk M, et al. **Postepy Hig Med Dosw** 1996; 50(6):635–47 (71 ref.) (Eng. Abstr.) **(Pol)**

PHARMACOKINETICS

[Problems in creating insulin preparations with increased stability against proteolysis] Valuev LI, et al. **Prikl Biokhim Mikrobiol** 1996 Jul-Aug;32(4):371–81 (60 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Compartmentalization of protein traffic in insulin-sensitive cells. Kandror KV, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):E1–14 (134 ref.)

Cell volume and the metabolic actions of insulin. Zhande R, et al. **Biochem Cell Biol** 1996;74(4):513–22 (79 ref.)

Glycogen synthase: activation by insulin and effect of transgenic overexpression in skeletal muscle. Lawrence JC Jr, et al. **Biochem Soc Trans** 1997 Feb;25(1):14–9 (42 ref.)

Trafficking, targeting and translocation of the insulin-responsive glucose transporter, GLUT4, in adipocytes. Rice JE, et al. **Biochem Soc Trans** 1996 May; 24(2):540–6 (47 ref.)

The crosstalk between insulin and the sympathetic nervous system: possible implications in the pathogenesis of essential hypertension. Lembo G, et al. **Blood Press Suppl** 1996; 1:38–42 (43 ref.)

Cell death, survival and proliferation in Tetrahymena thermophila. Effects of insulin, sodium nitroprusside, 8-Bromo cyclic GMP, NG-methyl-L-arginine and methylene blue. Christensen ST, et al. **Cell Biol Int** 1996 Oct;20(10):653–66 (78 ref.)

Regulation of mesangial chloride channels by insulin and glucose: role in diabetic nephropathy. Ling BN. **Clin Exp Pharmacol Physiol** 1996 Jan;23(1):89–94 (42 ref.)

Insulin and the vasculature—old actors, new roles. Baron AD. **J Investig Med** 1996 Oct;44(8):406–12 (32 ref.)

Modulation of insulin action by vanadate: evidence of a role for phosphotyrosine phosphatase activity to alter cellular signaling. Fantus IG, et al. **Mol Cell Biochem** 1995 Dec 6–20;153(1–2):103–12 (76 ref.)

Regulation of gene expression by insulin. O'Brien RM, et al. **Physiol Rev** 1996 Oct;76(4):1109–61 (622 ref.)

New concepts in extracellular signaling for insulin action: the single gateway hypothesis. Bergman RN. **Recent Prog Horm Res** 1997;52:359–85; discussion 385–7 (68 ref.)

PHYSIOLOGY

Insulin receptor/IRS-1/PI 3-kinase signaling system in corticosteroid-induced insulin resistance. Folli F, et al. **Acta Diabetol** 1996 Sep;33(3):185–92 (82 ref.)

In vitro insulinomimetic [corrected] effects of GLP-1 in liver, muscle and fat [published erratum appears in Acta Physiol Scand 1996 Nov;158(3):297] Valverde I, et al. **Acta Physiol Scand** 1996 Jul;157(3):359–60 (11 ref.)

Multiple signaling pathways involved in the metabolic effects of insulin. Moule SK, et al. **Am J Cardiol** 1997 Aug 4; 80(3A):41A–49A (62 ref.)

Endocrine and nutritional modulation of glucose disposal and storage in muscle. Holness MJ, et al. **Biochem Soc Trans** 1997 Feb;25(1):1–7 (23 ref.)

Autoregulation of endogenous glucose production in man. Tappy L, et al. **Biochem Soc Trans** 1997 Feb;25(1):11–3 (22 ref.)

Regulation of gene expression by insulin: analysis in single living cells. Tavaré JM, et al. **Biochem Soc Trans** 1996 May; 24(2):378–84 (33 ref.)

Insulin second messengers. Strålfors P. **Bioessays** 1997 Apr; 19(4):327–35 (79 ref.)

The IRS-signalling system during insulin and cytokine action. Yenush L, et al. **Bioessays** 1997 Jun;19(6):491–500 (81 ref.)

Does insulin have a role in hypertension? Bursztyn M. **Blood Press Suppl** 1996;1:64–6 (30 ref.)

Metabolic disturbances in subjects predisposed for hypertension. Endre T, et al. **Blood Press Suppl** 1996;1:10–3 (40 ref.)

Insulin and the sympathetic nervous system in the pathophysiology of hypertension. Landsberg L. **Blood Press Suppl** 1996;1:25–9 (46 ref.)

Nutrition, hormones, and breast cancer: is insulin the missing link? [see comments] Kaaks R. **Cancer Causes Control** 1996 Nov;7(6):605–25 (355 ref.) Comment in: Cancer Causes Control 1996 Nov;7(6):569–71.

Insulin and hypertension: a causal relationship? Bhanot S, et al. **Cardiovasc Res** 1996 Feb;31(2):212–21 (134 ref.)

Involvement of a pertussis-toxin sensitive G protein in the induction of gene expression by insulin. Butler AP, et al. **Cell Signal** 1996 Nov;8(7):475–80 (47 ref.)

Relationship between insulin and hemodialysis-associated hypotension. Kahn AM, et al. **Curr Opin Nephrol Hypertens** 1997 Jan;6(1):1–5 (47 ref.)

Role of PI 3-kinase and SH-PTP2 in insulin action. Kasuga M. **Diabet Med** 1996 Sep;13(9 Suppl 6):S87–9 (23 ref.)

Gastric emptying in type 2 diabetes: quick or slow? Smith U. **Diabet Med** 1996 Sep;13(9 Suppl 5):S31–3 (22 ref.)

Lilly lecture 1995. Glucose transport: pivotal step in insulin action. Kahn BB. **Diabetes** 1996 Nov;45(11):1644–54 (63 ref.)

Regulation of in vivo ketogenesis: role of free fatty acids and control by epinephrine, thyroid hormones, insulin and glucagon. Beylot M. **Diabetes Metab** 1996 Oct; 22(5):299–304 (44 ref.)

Insulin and insulin-like growth factor-I: their role as risk factors in the development of diabetic cardiovascular disease. Göke B, et al. **Diabetes Res Clin Pract** 1996 Feb; 30 Suppl:93–106 (102 ref.)

The pancreatic beta-cell as a fuel sensor: an electrophysiologist's viewpoint. Rorsman P. **Diabetologia** 1997 May;40(5):487–95 (56 ref.)

Insulin as a growth factor. Menon RK, et al. **Endocrinol Metab Clin North Am** 1996 Sep;25(3):633–47 (47 ref.)

Protein anabolic action of insulin, growth hormone and insulin-like growth factor I. Russell-Jones DL, et al. **Eur J Endocrinol** 1996 Dec;135(6):631–42 (144 ref.)

Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology [clinical conference] Sowers JR. **Hypertension** 1997 Mar;29(3):691–9 (157 ref.)

Alterations of fracture healing in the diabetic condition. Kagel EM, et al. **Iowa Orthop J** 1996;16:147–52 (33 ref.)

The influence of female sex steroids on glucose metabolism and insulin action. Godsland IF. **J Intern Med Suppl** 1996; 738:1–60 (307 ref.)

The significance of intracellular insulin to insulin action. Duckworth WC, et al. **J Investig Med** 1997 Feb;45(2):20–7 (64 ref.)

In vitro maturation of buffalo oocytes: role of insulin and its interaction with gonadotrophins. Totey SM, et al. **J Reprod Fertil Suppl** 1996;50:113–9 (45 ref.)

Insulin exposure controls the rate of mammalian aging. Parr T. **Mech Ageing Dev** 1996 Jul 5;88(1–2):75–82 (45 ref.)

Up-regulation of IGF binding protein-1 as an anticarcinogenic strategy: relevance to caloric restriction, exercise, and insulin sensitivity. McCarty MF. **Med Hypotheses** 1997 Apr;48(4):297–308 (153 ref.)

The early intracellular signaling pathway for the insulin/insulin-like growth factor receptor family in the mammalian central nervous system. Folli F, et al. **Mol Neurobiol** 1996 Oct;13(2):155–83 (162 ref.)

Modulation of insulin secretion by feeding behavior and physical activity: possible beneficial effects on obese and aged rats. Carpinelli AR, et al. **Neurosci Biobehav Rev** 1996 Summer;20(2):183–8 (64 ref.)

Insulin-stimulated glucose disposal: does adipose play a role? Frost SC. **Nutr Rev** 1996 Oct;54(10):329–31 (37 ref.)

Insulin, the renin-angiotensin-aldosterone system and blood pressure. Tait JF, et al. **Perspect Biol Med** 1997 Winter; 40(2):246–59 (64 ref.)

[Insulin, steroids and steroidogenesis] Svačina S, et al. **Cesk Fysiol** 1997 Jun;46(2):51–6 (41 ref.) (Eng. Abstr.) **(Cze)**

[Current achievements in the study of the signal mechanisms of the action of insulin and related peptides] Pertseva MN, et al. **Zh Evol Biokhim Fiziol** 1996 May-Jun;32(3):318–40 (109 ref.) **(Rus)**

[Insulin as vasoactive hormone. Significance for diabetes, obesity and hypertension] Lind L, et al. **Lakartidningen** 1997 Aug 6;94(32–33):2730–2 (47 ref.) **(Swe)**

SECRETION

Effects of prolonged glucose stimulation on pancreatic beta cells: from increased sensitivity to desensitization. Purrello F, et al. **Acta Diabetol** 1996 Dec;33(4):253–6 (18 ref.)

Neonatal insulin secretion: implications for the programming of metabolic homeostasis. Aynsley-Green A, et al. **Acta Paediatr Jpn** 1997 Apr;39 Suppl 1:S21–5 (31 ref.)

Regulation of insulin secretion by phospholipase C. Zawalich WS, et al. **Am J Physiol** 1996 Sep;271(3 Pt 1):E409–16 (64 ref.)

PACAP/VIP receptors in pancreatic beta-cells: their roles in insulin secretion. Inagaki N, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:44–51; discussion 52–3 (23 ref.)

Enhancement of glucose-induced insulin secretion in transgenic mice overexpressing human VIP gene in pancreatic beta cells. Kato I, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:232–42; discussion 242–3 (28 ref.)

Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome. Holte J. **Baillieres Clin Endocrinol Metab** 1996 Apr;10(2):221–47 (145 ref.)

Pancreatic B-cells as mediators of metabolic effects of regulatory peptides. Flatt PR. **Biochem Soc Trans** 1996 May;24(2):570–5 (33 ref.)

Insulin secretion and its modulation by antiarrhythmic and sulfonylurea drugs. Horie M, et al. **Cardiovasc Res** 1997 Apr;34(1):69–72 (42 ref.)

Essential biochemical design features of the fuel-sensing system in pancreatic beta-cells. Matschinsky FM, et al. **Chem Biol** 1997 Apr;4(4):249–57 (34 ref.)

In vivo glucose metabolism, insulin secretion and, insulin action in Europids with non-insulin-dependent diabetes mellitus (NIDDM) and their first-degree relatives. Beck-Nielsen H, et al. **Diabet Med** 1996 Sep;13(9 Suppl 6):S78–84 (17 ref.)

Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166. Kikuchi M. **Diabet Med** 1996 Sep;13(9 Suppl 6):S151–5 (15 ref.)

Oscillatory insulin secretion: a variable phenotypic marker. Matthews DR. **Diabet Med** 1996 Sep;13(9 Suppl 6):S53–8 (15 ref.)

Oral antidiabetic drugs: an overview. Melander A. **Diabet Med** 1996 Sep;13(9 Suppl 6):S143–7 (28 ref.)

Normal physiology and phenotypic characterization of beta-cell function in subjects at risk for non-insulin-dependent diabetes mellitus. Porte D Jr. **Diabet Med** 1996 Sep;13(9 Suppl 6):S25–32 (32 ref.)

Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications. Scheen AJ, et al. **Diabetes Metab** 1996 Dec;22(6):397–406 (103 ref.)

Role of potassium channels in the modulation of insulin release [comment] Smits P. **Diabetologia** 1996 Jul; 39(7):865–7 (17 ref.) Comment on: Diabetologia 1996 Jul;39(7):861–4.

Hyper- and hypoinsulinemia in type-2 diabetes: what may be wrong in the secretory mechanism of the B-cell. Ammon HP. **Exp Clin Endocrinol Diabetes** 1997;105 Suppl 2:43–7 (22 ref.)

Gene therapy of diabetes mellitus--aims, methods and future prospects. Tiedge M, et al. **Exp Clin Endocrinol Diabetes** 1995;103 Suppl 2:46–55 (77 ref.)

Long-term antidiabetic activity of vanadyl after treatment withdrawal: restoration of insulin secretion? Cros GH, et al. **Mol Cell Biochem** 1995 Dec 6-20;153(1-2):191–5 (13 ref.)

A physico-chemical perspective of plant polysaccharides in relation to glucose absorption, insulin secretion and the entero-insular axis. Ellis PR, et al. **Proc Nutr Soc** 1996 Nov;55(3):881–98 (76 ref.)

Pancreatic B-cell dysfunction and glucose toxicity in non-insulin-dependent diabetes. Flatt PR, et al. **Proc Nutr Soc** 1997 Mar;56(1B):243–62 (75 ref.)

The effect of age on insulin resistance and secretion: a review. Muller DC, et al. **Semin Nephrol** 1996 Jul;16(4):289–98 (79 ref.)

[Role of intercellular communication via gap junctions in insulin secretion] Meda P. **Ann Endocrinol (Paris)** 1996; 57(6):481–3 (15 ref.) (Eng. Abstr.) **(Fre)**

[Glucotoxicity and insulin secretion. An excessively reductionistic formulation] Portha B, et al. **Journ Annu Diabetol Hotel Dieu** 1996;:121–31 (31 ref.) **(Fre)**

[Insulin secretion--assay method and its significance] Emoto M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:418–22 (6 ref.) **(Jpn)**

[Tolbutamide, glucagon, leucine and arginine tolerance test] Hosaka T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:423–7 (10 ref.) **(Jpn)**

[Insulin release kinetics and insulin sensitivity in impaired glucose tolerance] Kikuchi M. **Nippon Rinsho** 1996 Oct; 54(10):2658–66 (44 ref.) (Eng. Abstr.) **(Jpn)**

[Electrophysiological studies of insulin secretion, physiology and pathophysiology] Rorsman P. **Nord Med** 1997 May; 112(5):164–8 (14 ref.) (Eng. Abstr.) **(Swe)**

THERAPEUTIC USE

Metformin and insulin: is there a role for combination therapy? Daniel JR, et al. **Ann Pharmacother** 1997 Apr; 31(4):474–80 (19 ref.)

Vanadium salts as insulin substitutes: mechanisms of action, a scientific and therapeutic tool in diabetes mellitus research. Sekar N, et al. **Crit Rev Biochem Mol Biol** 1996 Dec;31(5–6):339–59 (134 ref.)

Insulin-dependent diabetes mellitus in adults. Levandoski LA, et al. **Curr Ther Endocrinol Metab** 1997;6:418–30 (6 ref.)

Insulin therapy and its shortcomings – the need for new approaches. Whitehouse FW. **Diabet Med** 1997 Jun;14 Suppl 2:S5–8 (29 ref.)

To bridge science and patient care in diabetes [published erratum appears in Diabetologia 1996 Sep;39(9):1130] Berger M. **Diabetologia** 1996 Jul;39(7):749–57 (85 ref.)

Guidelines for the management of insulin-dependent diabetes mellitus in pregnancy. Steel JM, et al. **Drugs** 1996 Jul; 52(1):60–70 (61 ref.)

Advances in the treatment of diabetes mellitus in the elderly. Development of insulin analogues. Hoogwerf BJ, et al. **Drugs Aging** 1996 Dec;9(6):438–48 (65 ref.)

Combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routine. Riddle MC. **Horm Metab Res** 1996 Sep;28(9):430–3 (30 ref.)

Treatment of prediabetic patients with insulin: experience and future. European Prediabetes Study Group. Carel JC, et al. **Horm Res** 1996;45 Suppl 1:44–7 (19 ref.)

Therapeutic problems in type II diabetic patients developing insulin requirement. Leutenegger M, et al. **J Diabetes Complications** 1996 Sep-Oct;10(5):255–60 (31 ref.)

Implications and results of the Diabetes Control and Complications Trial. Tamborlane WV, et al. **Pediatr Clin North Am** 1997 Apr;44(2):285–300 (37 ref.)

Can insulin therapy delay or prevent insulin-dependent diabetes mellitus? Kakka R, et al. **Pharmacotherapy** 1997 Jan-Feb;17(1):38–44 (21 ref.)

Insulin analogues: new agents for improving glycemic control. White JR Jr, et al. **Postgrad Med** 1997 Feb; 101(2):58–60, 63–5, 70 (14 ref.)

Driving and diabetics on insulin therapy. Distiller LA, et al. **S Afr Med J** 1996 Aug;86(8 Suppl):1018–20 (15 ref.)

[Insulin therapy during pregnancy: how far and how intensified?] Bringer J, et al. **Journ Annu Diabetol Hotel Dieu** 1997;:81–93 (37 ref.) **(Fre)**

[Insulin sparing and metabolic control with metformin-insulin combination] Isnard F. **Journ Annu Diabetol Hotel Dieu** 1997;:305–25 (90 ref.) **(Fre)**

[Alternative to insulin therapy: diet and physical exercise] Jovanovic-Peterson L. **Journ Annu Diabetol Hotel Dieu** 1997;:95–124 (135 ref.) **(Fre)**

[For and against intensive insulin therapy] Czyżyk A. **Pol Arch Med Wewn** 1997;97 Spec No:7–12 (22 ref.) **(Pol)**

INSULIN ANTIBODIES

BLOOD

Combined antibody screening for improved prediction of IDDM--modern strategies. Roll U, et al. **Exp Clin Endocrinol Diabetes** 1997;105(1):1–14 (41 ref.)

INSULIN INFUSION SYSTEMS

Understanding continuous subcutaneous insulin infusion therapy. Savinetti-Rose B, et al. **Am J Nurs** 1997 Mar; 97(3):42–8; quiz 48–9 (11 ref.)

Diabetes treatment with implantable delivery devices. Impressed or unimpressed? [editorial] Ratner RE. **ASAIO J** 1997 May-Jun;43(3):125–6 (11 ref.)

Management of diabetes with glucose sensors and implantable insulin pumps. From the dream of the 60s to the realities of the 90s. Selam JL. **ASAIO J** 1997 May-Jun;43(3):137–42 (69 ref.)

[Medical engineering complexes for automated insulin therapy of diabetes] Bobylev VM, et al. **Med Tekh** 1997 Mar-Apr;(2):41–3 (6 ref.) (Eng. Abstr.) **(Rus)**

INSULIN-LIKE GROWTH FACTOR I

see related
RECEPTORS, INSULIN-LIKE-GROWTH FACTOR I

ADVERSE EFFECTS

Unlabeled milk from cows treated with biosynthetic growth hormones: a case of regulatory abdication. Epstein SS. **Int J Health Serv** 1996;26(1):173–85 (66 ref.)

ANALOGS & DERIVATIVES

Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I. Ballard FJ, et al. **Int J Biochem Cell Biol** 1996 Oct;28(10):1085–7 (12 ref.)

Further characterisation of an IGF-I enhancing antibody: actions on IGF-I-induced hypoglycaemia and interaction with the analogue LR3IGF-I. Pell JM, et al. **Prog Growth Factor Res** 1995;6(2–4):367–75 (23 ref.)

In vivo actions of IGF analogues with poor affinities for IGFBPs: metabolic and growth effects in pigs of different ages and GH responsiveness. Walton PE, et al. **Prog Growth Factor Res** 1995;6(2–4):385–95 (13 ref.)

ANALYSIS

Unlabeled milk from cows treated with biosynthetic growth hormones: a case of regulatory abdication. Epstein SS. **Int J Health Serv** 1996;26(1):173–85 (66 ref.)

BIOSYNTHESIS

IGF-I and IGF-II: expression and function in the endocrine pancreas. Fehmann HC, et al. **Exp Clin Endocrinol Diabetes** 1995;103 Suppl 2:37–41 (38 ref.)

IMMUNOLOGY

Further characterisation of an IGF-I enhancing antibody: actions on IGF-I-induced hypoglycaemia and interaction with the analogue LR3IGF-I. Pell JM, et al. **Prog Growth Factor Res** 1995;6(2–4):367–75 (23 ref.)

ISOLATION & PURIFICATION

Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I. Ballard FJ, et al. **Int J Biochem Cell Biol** 1996 Oct;28(10):1085–7 (12 ref.)

METABOLISM

Metabolic actions of growth hormone: direct and indirect. Berneis K, et al. **Baillieres Clin Endocrinol Metab** 1996 Jul; 10(3):337–52 (78 ref.)

Insulin-like growth factor bioactivity and its modification in growth hormone resistant states. Donaghy AJ, et al. **Baillieres Clin Endocrinol Metab** 1996 Jul;10(3):421–46 (101 ref.)

Insulin-like growth factor-1 and myocyte growth: the danger of a dogma part II. Induced myocardial growth: pathologic hypertrophy [see comments] Anversa P, et al. **Cardiovasc Res** 1996 Sep;32(3):484–95 (109 ref.) Comment in: Cardiovasc Res 1996 Sep;32(3):482–3.

Signal transduction mechanism of insulin and insulin-like growth factor-1. Kadowaki T, et al. **Endocr J** 1996 Oct; 43 Suppl:S33–41 (47 ref.)

Growth hormone and insulin-like growth factors in critical illness. Gibson FA, et al. **Intensive Care Med** 1997 Apr; 23(4):369–78 (84 ref.)

Nutritional regulation of IGF-I and IGFBPs. Underwood LE. **J Pediatr Endocrinol Metab** 1996 Jun;9 Suppl 3:303–12 (42 ref.)

The hypothalamo-pituitary-growth hormone insulin-like growth factor 1 axis in children with chronic renal failure. Rees L, et al. **Kidney Int Suppl** 1996 Jan;53:S109–14 (16 ref.)

Derangements of the somatotropic hormone axis in chronic renal failure. Tönshoff B, et al. **Kidney Int Suppl** 1997 Mar; 58:S106–13 (66 ref.)

Insulin-like growth factor-I and insulin-like growth factor-binding proteins in the nephrotic syndrome. Feld SM, et al. **Pediatr Nephrol** 1996 Jun;10(3):355–8 (23 ref.)

Clinical information on serum IGFBP-3 levels and IGFBP-3 proteolytic activity in childhood. Hasegawa Y, et al. **Prog Growth Factor Res** 1995;6(2–4):457–63 (19 ref.)

Growth factors and bone formation in osteoporosis: roles for IGF-I and TGF-beta. Marie P. **Rev Rhum Engl Ed** 1997 Jan;64(1):44–53 (95 ref.)

[Growth hormone, IGF and bone metabolism in adults] Bonjour JP, et al. **Ann Endocrinol (Paris)** 1996;57(3):147–9 (36 ref.) **(Fre)**

PHARMACOLOGY

Interaction between insulin-like growth factor I, growth hormone, parathyroid hormone, 1 alpha,25-dihydroxyvitamin D3 and steroids on epiphyseal chondrocytes [see comments] Klaus G, et al. **Acta Paediatr Suppl** 1996 Oct;417:69–71 (28 ref.) Comment in: Acta Paediatr Suppl 1996 Oct;417 :80.

Control of insulin-like growth factor (IGF) action by regulation of IGF-I receptor expression. Roberts CT Jr. **Endocr J** 1996 Oct;43 Suppl:S49–55 (50 ref.)

Neurotrophic factors in the treatment of neurotoxicity: an overview. Apfel SC. **Neurotoxicology** 1996 Fall-Winter; 17(3–4):839–44 (29 ref.)

Metabolic effects of recombinant human insulin-like growth factor-I in humans: comparison with recombinant human growth hormone. Mauras N, et al. **Pediatr Nephrol** 1996 Jun;10(3):318–23 (70 ref.)

Rediscovering an old friend, IGF-I: potential use in the treatment of neurodegenerative diseases. Doré S, et al. **Trends Neurosci** 1997 Aug;20(8):326–31 (64 ref.)

[Regulation of uterine cellular proliferation with estrogens and growth factors] Alvarez-Rodríguez C, et al. **Ginecol Obstet Mex** 1996 Sep;64:406–10 (35 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Insulin like growth factors and their importance in pediatrics. Philipps AF. **Acta Paediatr Sin** 1996 Jan-Feb;37(1):1–10 (94 ref.)

The potential role of insulin-like growth factors in skeletal muscle regeneration. MacGregor J, et al. **Can J Appl Physiol** 1996 Aug;21(4):236–50 (35 ref.)

INSULIN-LIKE GROWTH FACTOR I

Big babies and infant leukemia: a role for insulin-like growth factor-1? Ross JA, et al. **Cancer Causes Control** 1996 Sep; 7(5):553-9 (66 ref.)

Insulin-like growth factor-1 and myocyte growth: the danger of a dogma. Part I. Postnatal myocardial development: normal growth [see comments] Anversa P, et al. **Cardiovasc Res** 1996 Aug;32(2):219-25 (57 ref.) Comment in: Cardiovasc Res 1996 Aug;32(2):217-8.

Insulin-like growth factor binding proteins and their role in controlling IGF actions. Clemmons DR. **Cytokine Growth Factor Rev** 1997 Mar;8(1):45-62 (153 ref.)

Insulin-like growth factor I: physiology, metabolic effects and clinical uses. Froesch ER, et al. **Diabetes Metab Rev** 1996 Oct;12(3):195-215 (117 ref.)

Insulin and insulin-like growth factor-I: their role as risk factors in the development of diabetic cardiovascular disease. Göke B, et al. **Diabetes Res Clin Pract** 1996 Feb; 30 Suppl:93-106 (102 ref.)

Insulin-like growth factors in poultry. McMurtry JP, et al. **Domest Anim Endocrinol** 1997 Jul;14(4):199-229 (242 ref.)

The somatogenic hormones and insulin-like growth factor-1: stimulators of lymphopoiesis and immune function. Clark R. **Endocr Rev** 1997 Apr;18(2):157-79 (287 ref.)

Decreased sensitivity to insulin-like growth factor I as a cause of growth failure in Turner's syndrome? [comment] Kiess W, et al. **Eur J Clin Invest** 1997 Jul;27(7):548-9 (14 ref.) Comment on: Eur J Clin Invest 1997 Jul;27(7):543-7.

Protein anabolic action of insulin, growth hormone and insulin-like growth factor I. Russell-Jones DL, et al. **Eur J Endocrinol** 1996 Dec;135(6):631-42 (144 ref.)

IGF-I and IGF-II: expression and function in the endocrine pancreas. Fehmann HC, et al. **Exp Clin Endocrinol Diabetes** 1995;103 Suppl 2:37-41 (38 ref.)

Articular cartilage destruction in experimental inflammatory arthritis: insulin-like growth factor-1 regulation of proteoglycan metabolism in chondrocytes. Verschure PJ, et al. **Histochem J** 1996 Dec;28(12):835-57 (263 ref.)

The role of insulin-like growth factors and their binding proteins in tumor hypoglycemia. Baxter RC. **Horm Res** 1996;46(4-5):195-201 (41 ref.)

Growth hormone, insulin-like growth factor-I and lipid metabolism: interactions with sex steroids. Björntorp P. **Horm Res** 1996;46(4-5):188-91 (12 ref.)

Growth hormone insulin-like growth factor I axis in insulin-dependent diabetes mellitus. Dunger DB, et al. **Horm Res** 1996 Jul;46(1):2-6 (49 ref.)

Interaction of the signalling pathways of insulin-like growth factor-I and sex steroids in the neuroendocrine hypothalamus. García-Segura LM, et al. **Horm Res** 1996; 46(4-5):160-4 (58 ref.)

Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology [clinical conference] Sowers JR. **Hypertension** 1997 Mar;29(3):691-9 (157 ref.)

The role of insulin-like and basic fibroblast growth factors on ischemic and infarcted myocardium: a mini review. Scheinowitz M, et al. **Int J Cardiol** 1997 Mar;59(1):1-5 (43 ref.)

The insulin-like growth factor and epidermal growth factor families in mammary cell growth in ruminants: action and interaction with hormones. Forsyth IA. **J Dairy Sci** 1996 Jun;79(6):1085-96 (84 ref.)

Is milk-borne insulin-like growth factor-I essential for neonatal development? Burrin DG. **J Nutr** 1997 May;127(5 Suppl):975S-979S (47 ref.)

Human aging and the GH-IGF-I axis. Ghigo E, et al. **J Pediatr Endocrinol Metab** 1996 Jun;9 Suppl 3:271-8 (74 ref.)

Autocrine/paracrine control of renal phosphate transport. Friedlander G, et al. **Kidney Int Suppl** 1996 Dec;57:S148-53 (73 ref.)

Growth hormone and insulin-like growth factor in non-uremic acidosis and uremic acidosis. Kuemmerle N, et al. **Kidney Int Suppl** 1997 Mar;58:S102-5 (39 ref.)

Somatostatin, growth hormone, insulin-like growth factor-1, and diabetes: friends or foes? Orskov H. **Metabolism** 1996 Aug;45(8 Suppl 1):91-5 (67 ref.)

Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. Le Roith D. **N Engl J Med** 1997 Feb 27;336(9):633-40 (41 ref.)

Control of the thymic microenvironment by growth hormone/insulin-like growth factor-I-mediated circuits. Savino W, et al. **Neuroimmunomodulation** 1995 Nov-Dec; 2(6):313-8 (38 ref.)

Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Stewart CE, et al. **Physiol Rev** 1996 Oct;76(4):1005-26 (232 ref.)

Physiological regulation of the human growth hormone (GH)-insulin-like growth factor type I (IGF-I) axis: predominant impact of age, obesity, gonadal function, and sleep. Veldhuis JD, et al. **Sleep** 1996 Dec;19(10 Suppl):S221-4 (17 ref.)

SECRETION

Growth hormone- and growth-hormone-releasing hormone-producing tumors. Shimon I, et al. **Cancer Treat Res** 1997;89:1-24 (78 ref.)

Growth hormone therapy in elderly people: an age-delaying drug? Bouillanne O, et al. **Fundam Clin Pharmacol** 1996; 10(5):416-30 (168 ref.)

THERAPEUTIC USE

Treatment of growth hormone insensitivity syndrome (GHIS) with insulin-like growth factor (IGF-I). Ranke MB. **Baillieres Clin Endocrinol Metab** 1996 Jul;10(3):401-10 (28 ref.)

Growth hormone and IGF-I therapy in the hypercatabolic patient. Wolf SE, et al. **Baillieres Clin Endocrinol Metab** 1996 Jul;10(3):447-63 (75 ref.)

Current and potential therapeutic uses of growth hormone and insulin-like growth factor I. Hintz RL. **Endocrinol Metab Clin North Am** 1996 Sep;25(3):759-73 (75 ref.)

The rationale for the use of recombinant human growth hormone and insulin-like growth factor-I for catabolic conditions in humans. Haymond MW, et al. **Horm Res** 1996; 46(4-5):202-7 (28 ref.)

Use of human recombinant growth hormone and human recombinant insulin-like growth factor-I in patients with human immunodeficiency virus infection. Hirschfeld S. **Horm Res** 1996;46(4-5):215-21 (105 ref.)

Growth hormone and insulin-like growth factors in critical illness. Gibson FA, et al. **Intensive Care Med** 1997 Apr; 23(4):369-78 (84 ref.)

Effects of growth hormone and insulin-like growth factor I on renal growth and function. Hammerman MR, et al. **J Pediatr** 1997 Jul;131(1 Pt 2):S17-9 (16 ref.)

Does recombinant human insulin-like growth factor I have a role in the treatment of type I (insulin dependent) diabetes during puberty? Dunger DB, et al. **J Pediatr Endocrinol Metab** 1995 Oct-Dec;8(4):237-42 (51 ref.)

Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. Le Roith D. **N Engl J Med** 1997 Feb 27;336(9):633-40 (41 ref.)

INSULIN-LIKE GROWTH FACTOR II

see related
RECEPTORS, INSULIN-LIKE-GROWTH-FACTOR II

BIOSYNTHESIS

High-molecular weight IGF-2 expression in a haemangiopericytoma associated with hypoglycaemia. Höög A, et al. **APMIS** 1997 Jun;105(6):469-82 (58 ref.)

IGF-I and IGF-II: expression and function in the endocrine pancreas. Fehmann HC, et al. **Exp Clin Endocrinol Diabetes** 1995;103 Suppl 2:37-41 (38 ref.)

GENETICS

[Altered genomic imprinting in the IGF2 and H19 genes in human lung cancer] Kondo M, et al. **Nippon Rinsho** 1996 Feb;54(2):492-6 (15 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Derangements of the somatotropic hormone axis in chronic renal failure. Tönshoff B, et al. **Kidney Int Suppl** 1997 Mar; 58:S106-13 (66 ref.)

PHARMACOLOGY

Control of insulin-like growth factor (IGF) action by regulation of IGF-I receptor expression. Roberts CT Jr. **Endocr J** 1996 Oct;43 Suppl:S49-55 (50 ref.)

PHYSIOLOGY

Insulin like growth factors and their importance in pediatrics. Philipps AF. **Acta Paediatr Sin** 1996 Jan-Feb;37(1):1-10 (94 ref.)

The potential role of insulin-like growth factors in skeletal muscle regeneration. MacGregor J, et al. **Can J Appl Physiol** 1996 Aug;21(4):236-50 (35 ref.)

Insulin-like growth factor binding proteins and their role in controlling IGF actions. Clemmons DR. **Cytokine Growth Factor Rev** 1997 Mar;8(1):45-62 (153 ref.)

Insulin-like growth factors in poultry. McMurtry JP, et al. **Domest Anim Endocrinol** 1997 Jul;14(4):199-229 (242 ref.)

IGF-I and IGF-II: expression and function in the endocrine pancreas. Fehmann HC, et al. **Exp Clin Endocrinol Diabetes** 1995;103 Suppl 2:37-41 (38 ref.)

The role of insulin-like growth factors and their binding proteins in tumor hypoglycemia. Baxter RC. **Horm Res** 1996;46(4-5):195-201 (41 ref.)

The role of insulin-like and basic fibroblast growth factors on ischemic and infarcted myocardium: a mini review. Scheinowitz M, et al. **Int J Cardiol** 1997 Mar;59(1):1-5 (43 ref.)

The insulin-like growth factor and epidermal growth factor families in mammary cell growth in ruminants: action and interaction with hormones. Forsyth IA. **J Dairy Sci** 1996 Jun;79(6):1085-96 (84 ref.)

Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. Le Roith D. **N Engl J Med** 1997 Feb 27;336(9):633-40 (41 ref.)

Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Stewart CE, et al. **Physiol Rev** 1996 Oct;76(4):1005-26 (232 ref.)

INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN 1

BIOSYNTHESIS

Up-regulation of IGF binding protein-1 as an anticarcinogenic strategy: relevance to caloric restriction, exercise, and insulin sensitivity. McCarty MF. **Med Hypotheses** 1997 Apr;48(4):297-308 (153 ref.)

GENETICS

Dexamethasone stimulation of rat insulin-like growth factor binding protein-1 (IGFBP-1) promoter activity involves the interaction of multiple transcription factors. Suh DS, et al. **Prog Growth Factor Res** 1995;6(2-4):131-40 (18 ref.)

METABOLISM

A novel DNA/protein complex interacts with the insulin-like growth factor binding protein-1 (IGFBP-1) insulin response sequence and is required for maximal effects of insulin and glucocorticoids on promoter function. Unterman T, et al. **Prog Growth Factor Res** 1995; 6(2-4):119-29 (26 ref.)

PHYSIOLOGY

Human insulin-like growth factor binding protein-1 (hIGFBP-1) transgenic mice: insights into hIGFBP-1 regulation and actions. D'Ercole AJ, et al. **Prog Growth Factor Res** 1995;6(2-4):417-23 (20 ref.)

Phenotypic manifestations of insulin-like growth factor binding protein-1 (IGFBP-1) and IGFBP-3 overexpression in transgenic mice. Murphy LJ, et al. **Prog Growth Factor Res** 1995;6(2-4):425-32 (14 ref.)

SECRETION

Regulation of IGFBP-1 in humans. Brismar K, et al. **Prog Growth Factor Res** 1995;6(2-4):449-56 (33 ref.)

INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 2

GENETICS

Genetic ablation of IGFBP-2 suggests functional redundancy in the IGFBP family. Pintar JE, et al. **Prog Growth Factor Res** 1995;6(2-4):437-45 (45 ref.)

INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3

BIOSYNTHESIS

Regulation of IGFBP-3 expression in breast cancer cells and uterus by estradiol and antiestrogens: correlations with effects on proliferation: a review. Hung H, et al. **Prog Growth Factor Res** 1995;6(2-4):495-501 (33 ref.)

Cellular localization and hormonal regulation of biosynthesis of insulin-like growth factor binding proteins and of the acid-labile subunit within rat liver. Scharf JG, et al. **Prog Growth Factor Res** 1995;6(2-4):175-80 (23 ref.)

CHEMISTRY

A 3-dimensional model for the insulin-like growth factor binding proteins (IGFBPs); supporting evidence using the structural determinants of the IGF binding site on IGFBP-3. Spencer EM, et al. **Prog Growth Factor Res** 1995;6(2-4):209-14 (4 ref.)

METABOLISM

Serum proteolysis of IGFBP-3. Bang P. **Prog Growth Factor Res** 1995;6(2-4):285-92 (21 ref.)

Clinical information on serum IGFBP-3 levels and IGFBP-3 proteolytic activity in childhood. Hasegawa Y, et al. **Prog Growth Factor Res** 1995;6(2-4):457-63 (19 ref.)

Formation of 150-kDa binary complexes of insulin-like growth factor binding protein-3 and the acid-labile subunit in vitro and in vivo. Lee CY, et al. **Prog Growth Factor Res** 1995;6(2-4):241-51 (12 ref.)

PHARMACOLOGY

Antiproliferative actions of insulin-like growth factor binding protein (IGFBP)-3 in human breast cancer cells. Oh Y, et al. **Prog Growth Factor Res** 1995;6(2-4):503-12 (42 ref.)

PHYSIOLOGY

Phenotypic manifestations of insulin-like growth factor binding protein-1 (IGFBP-1) and IGFBP-3 overexpression in transgenic mice. Murphy LJ, et al. **Prog Growth Factor Res** 1995;6(2-4):425-32 (14 ref.)

INSULIN LIKE GROWTH-FACTOR-BINDING PROTEIN 4

METABOLISM

Age-related changes in IGFBP-4 and IGFBP-5 levels in

human serum and bone: implications for bone loss with aging. Mohan S, et al. **Prog Growth Factor Res** 1995; 6(2–4):465–73 (27 ref.)

INSULIN-LIKE GROWTH-FACTOR-BINDING-PROTEIN 5

METABOLISM

Insulin-like growth factor binding protein proteolysis in bone cell models. Conover CA. **Prog Growth Factor Res** 1995; 6(2–4):301–9 (13 ref.)

Age-related changes in IGFBP-4 and IGFBP-5 levels in human serum and bone: implications for bone loss with aging. Mohan S, et al. **Prog Growth Factor Res** 1995; 6(2–4):465–73 (27 ref.)

INSULIN-LIKE GROWTH-FACTOR-BINDING PROTEINS

BLOOD

Nutritional regulation of the growth hormone and insulin-like growth factor-binding proteins. Ketelslegers JM, et al. **Horm Res** 1996;45(3–5):252–7 (48 ref.)

Insulin-like growth factor (IGF)-binding proteins in serum--do they have additional roles besides modulating the endocrine IGF actions? [editorial] Mohan S, et al. **J Clin Endocrinol Metab** 1996 Nov;81(11):3817–20 (34 ref.)

Derangements of the somatotropic hormone axis in chronic renal failure. Tönshoff B, et al. **Kidney Int Suppl** 1997 Mar; 58:S106–13 (66 ref.)

Insulin-like growth factor-I and insulin-like growth factor-binding proteins in the nephrotic syndrome. Feld SM, et al. **Pediatr Nephrol** 1996 Jun;10(3):355–8 (23 ref.)

CHEMISTRY

A 3-dimensional model for the insulin-like growth factor binding proteins (IGFBPs); supporting evidence using the structural determinants of the IGF binding site on IGFBP-3. Spencer EM, et al. **Prog Growth Factor Res** 1995;6(2–4):209–14 (4 ref.)

METABOLISM

Insulin-like growth factor bioactivity and its modification in growth hormone resistant states. Donaghy AJ, et al. **Baillieres Clin Endocrinol Metab** 1996 Jul;10(3):421–46 (101 ref.)

Nutritional regulation of IGF-I and IGFBPs. Underwood LE. **J Pediatr Endocrinol Metab** 1996 Jun;9 Suppl 3:303–12 (42 ref.)

Phosphorylation of insulin-like growth factor binding proteins. Coverley JA, et al. **Mol Cell Endocrinol** 1997 Apr 4;128(1–2):1–5 (25 ref.)

IGFs and their binding proteins. Gourmelen M, et al. **Nucl Med Biol** 1994 Apr;21(3):297–302 (20 ref.)

Proteolysis of IGFBPs by cathepsin D in vitro and in cathepsin D-deficient mice. Braulke T, et al. **Prog Growth Factor Res** 1995;6(2–4):265–71 (20 ref.)

Insulin-like growth factors (IGF) and IGF binding proteins in children with chronic renal failure. Tönshoff B, et al. **Prog Growth Factor Res** 1995;6(2–4):481–91 (49 ref.)

PHYSIOLOGY

Insulin-like growth factor binding proteins and their role in controlling IGF actions. Clemmons DR. **Cytokine Growth Factor Rev** 1997 Mar;8(1):45–62 (153 ref.)

Regulation and physiological role of insulin-like growth factor binding proteins. Conover CA. **Endocr J** 1996 Oct; 43 Suppl:S43–8 (36 ref.)

The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action. Collett-Solberg PF, et al. **Endocrinol Metab Clin North Am** 1996 Sep;25(3):591–614 (114 ref.)

Insulin-like growth factors and their receptors in growth. D'Ercole AJ. **Endocrinol Metab Clin North Am** 1996 Sep; 25(3):573–90 (44 ref.)

The role of insulin-like growth factors and their binding proteins in tumor hypoglycemia. Baxter RC. **Horm Res** 1996;46(4–5):195–201 (41 ref.)

Insulin-like growth factor-binding proteins and ovarian folliculogenesis. Monget P, et al. **Horm Res** 1996; 45(3–5):211–7 (35 ref.)

Genetic approaches to the function of insulin-like growth factor-binding proteins during rodent development. Pintar JE, et al. **Horm Res** 1996;45(3–5):172–7 (60 ref.)

Insulin-like growth factor binding proteins (IGFBPs): physiological and clinical implications. Binoux M. **J Pediatr Endocrinol Metab** 1996 Jun;9 Suppl 3:285–8 (39 ref.)

Insulin-like growth factor binding proteins as growth inhibitors in children with chronic renal failure. Powell DR, et al. **Pediatr Nephrol** 1996 Jun;10(3):343–7 (45 ref.)

Role of insulin-like growth factor binding proteins in the control of IGF actions. Clemmons DR, et al. **Prog Growth Factor Res** 1995;6(2–4):357–66 (23 ref.)

Circulating and ovarian IGF binding proteins: potential roles in normo-ovulatory cycles and in polycystic ovarian syndrome. Giudice LC, et al. **Prog Growth Factor Res** 1995; 6(2–4):397–408 (48 ref.)

The annals of IGF binding proteins: into the next millennium. Hintz RL. **Prog Growth Factor Res** 1995;6(2–4):79–89 (55 ref.)

Cell migration: interactions among integrins, IGFs and IGFBPs. Jones JI, et al. **Prog Growth Factor Res** 1995; 6(2–4):319–27 (25 ref.)

Does an IGF-binding protein (IGFBP) present in involuting rat mammary gland regulate apoptosis? Tonner E, et al. **Prog Growth Factor Res** 1995;6(2–4):409–14 (21 ref.)

In vivo actions of IGF analogues with poor affinities for IGFBPs: metabolic and growth effects in pigs of different ages and GH responsiveness. Walton PE, et al. **Prog Growth Factor Res** 1995;6(2–4):385–95 (13 ref.)

Insulin-like growth factor binding proteins: do they play a role in polycystic ovary syndrome? Cataldo NA. **Semin Reprod Endocrinol** 1997 May;15(2):123–36 (143 ref.)

INSULIN-LIKE GROWTH FACTORS see **SOMATOMEDINS**

INSULIN RECEPTORS see **RECEPTORS, INSULIN**

INSULIN RESISTANCE

Insulin resistance in non-insulin-dependent diabetes mellitus. A review. Alzaid AA. **Acta Diabetol** 1996 Jul;33(2):87–99 (198 ref.)

Insulin--adverse reactions and clinical problems. Davidson J, et al. **Adverse Drug React Toxicol Rev** 1996 Jun; 15(2):79–91 (85 ref.)

Hyperinsulinemia, insulin resistance, and the treatment of hypertension. Lithell HO. **Am J Hypertens** 1996 Nov; 9(11):150S–154S (28 ref.)

Insulin resistance and salt sensitivity. A renal hemodynamic abnormality? Weir MR. **Am J Hypertens** 1996 Dec;9(12 Pt 2):193S–199S (74 ref.)

Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Haffner SM, et al. **Am J Med** 1997 Aug;103(2):152–62 (106 ref.)

Cardiovascular risk factors and the prediabetic syndrome. Haffner SM. **Ann Med** 1996 Aug;28(4):363–70 (121 ref.)

Insulin resistance [published erratum appears in BMJ 1997 Jan 11;314(7074):134] Krentz AJ. **BMJ** 1996 Nov 30; 313(7069):1385–9 (67 ref.)

Nutrition and breast cancer risk: can an effect via insulin resistance be demonstrated? Stoll BA. **Breast Cancer Res Treat** 1996;38(3):239–46 (58 ref.)

Insulin and hypertensive cardiovascular disease. Kotchen TA, et al. **Curr Opin Cardiol** 1996 Sep;11(5):483–9 (80 ref.)

Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes. Austin MA, et al. **Curr Opin Lipidol** 1996 Jun;7(3):167–71 (28 ref.)

Free fatty acids, insulin resistance and lipoprotein metabolism. Laws A. **Curr Opin Lipidol** 1996 Jun; 7(3):172–7 (98 ref.)

The central role of dietary fat, not carbohydrate, in the insulin resistance syndrome. Purnell JQ, et al. **Curr Opin Lipidol** 1997 Feb;8(1):17–22 (71 ref.)

Do high carbohydrate diets prevent the development or attenuate the manifestations (or both) of syndrome X? A viewpoint strongly against. Reaven GM. **Curr Opin Lipidol** 1997 Feb;8(1):23–7 (42 ref.)

Insulin resistance in polycystic ovary syndrome. Prelevic GM. **Curr Opin Obstet Gynecol** 1997 Jun;9(3):193–201 (99 ref.)

In vivo glucose metabolism, insulin secretion and, insulin action in Europids with non-insulin-dependent diabetes mellitus (NIDDM) and their first-degree relatives. Beck-Nielsen H, et al. **Diabet Med** 1996 Sep;13(9 Suppl 6):S78–84 (17 ref.)

Toward an integrated phenotype in pre-NIDDM. Bergman RN, et al. **Diabet Med** 1996 Sep;13(9 Suppl 6):S67–77 (37 ref.)

Insulin deficiency vs insulin resistance in NIDDM: concluding remarks by a 'biased' observer. Cerasi E. **Diabet Med** 1996 Sep;13(9 Suppl 6):S161–4 (45 ref.)

Effects of troglitazone on insulin sensitivity. Henry RR. **Diabet Med** 1996 Sep;13(9 Suppl 6):S148–50 (9 ref.)

Impaired glucose tolerance in Pima Indians. Lillioja S. **Diabet Med** 1996 Sep;13(9 Suppl 6):S127–32 (15 ref.)

Role of fatty acids in the pathogenesis of insulin resistance and NIDDM [published erratum appears in Diabetes 1997 Mar;46(3):536] Boden G. **Diabetes** 1997 Jan;46(1):3–10 (74 ref.)

Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Saltiel AR, et al. **Diabetes** 1996 Dec; 45(12):1661–9 (53 ref.)

Insulin-resistance syndrome and cardiovascular complications of non-insulin-dependent diabetes mellitus. Fontbonne A. **Diabetes Metab** 1996 Oct;22(5):305–13 (102 ref.)

Insulin resistance as a programmed response to fetal undernutrition [see comments] Phillips DI. **Diabetologia** 1996 Sep;39(9):1119–22 (40 ref.) Comment in: Diabetologia 1996 Sep;39(9):1123–5.

Relationships among microalbuminuria, insulin resistance and renal-cardiac complications in insulin dependent and non insulin dependent diabetes. Nosadini R, et al. **Exp Clin Endocrinol Diabetes** 1997;105 Suppl 2:1–7 (72 ref.)

Reversible insulin resistance in non-insulin-dependent diabetes mellitus. Karam JH. **Horm Metab Res** 1996 Sep; 28(9):440–4 (24 ref.)

Sex hormone-binding protein, hyperinsulinemia, insulin resistance and noninsulin-dependent diabetes. Haffner SM. **Horm Res** 1996;45(3–5):233–7 (45 ref.)

Insulin resistance and hypertension in Japanese. Iimura O. **Hypertens Res** 1996 Jun;19 Suppl 1:S1–8 (90 ref.)

The deadly quartet and the insulin resistance syndrome: an historical overview. Kaplan NM. **Hypertens Res** 1996 Jun; 19 Suppl 1:S9–11 (17 ref.)

Insulin resistance seen in non-insulin dependent diabetes mellitus and hypertension. Kawamori R. **Hypertens Res** 1996 Jun;19 Suppl 1:S61–4 (6 ref.)

Obesity and the insulin resistance syndrome. Landsberg L. **Hypertens Res** 1996 Jun;19 Suppl 1:S51–5 (38 ref.)

Antihypertensive treatment in insulin resistant patients. Lithell HO, et al. **Hypertens Res** 1996 Jun;19 Suppl 1:S75–9 (30 ref.)

Insulin resistance and diabetes mellitus. DeFronzo RA, et al. **J Diabetes Complications** 1996 Sep-Oct;10(5):243–5 (28 ref.)

Diabetes and syndrome X in hypertension--population aspects. Nilsson P. **J Hum Hypertens** 1996 Feb;10 Suppl 1:S81–4 (32 ref.)

Epidemiology of hypertension and insulin resistance syndrome. Haffner SM. **J Hypertens Suppl** 1997 Jan; 15(1):S25–30 (88 ref.)

Considerations in the treatment of insulin resistance and related disorders with a new sympatholytic agent. Lithell HO. **J Hypertens Suppl** 1997 Jan;15(1):S39–42 (30 ref.)

Mechanisms of insulin resistance leading to hypertension: what we can learn from experimental models. Sechi LA, et al. **J Investig Med** 1997 Jun;45(5):238–51 (175 ref.)

Dietary and lifestyle factors contributing to insulin resistance. Bell PM. **Proc Nutr Soc** 1997 Mar;56(1B):263–72 (90 ref.)

The effect of age on insulin resistance and secretion: a review. Muller DC, et al. **Semin Nephrol** 1996 Jul;16(4):289–98 (79 ref.)

Adrenal androgens, insulin resistance, and cardiovascular disease. Casson PR, et al. **Semin Reprod Endocrinol** 1996 Feb;14(1):29–34 (54 ref.)

Metabolic aspects of polycystic ovary syndrome. Wild RA. **Semin Reprod Endocrinol** 1997 May;15(2):105–10 (26 ref.)

[TNF-alpha: molecular tie between obesity and insulin resistance] Peraldi P, et al. **Journ Annu Diabetol Hotel Dieu** 1997;:149–59 (52 ref.) **(Fre)**

[Syndrome X--insulin resistance and common metabolic disorders] Geffel D, et al. **Harefuah** 1996 Oct; 131(7–8):275–9 (34 ref.) **(Heb)**

[Diabetes mellitus and insulin resistance] Yoshimi T. **Nippon Naika Gakkai Zasshi** 1997 Mar 10;86(3):434–8 (24 ref.) **(Jpn)**

[Insulin release kinetics and insulin sensitivity in impaired glucose tolerance] Kikuchi M. **Nippon Rinsho** 1996 Oct; 54(10):2658–66 (44 ref.) (Eng. Abstr.) **(Jpn)**

[Assessment of insulin resistance by hyperinsulinemic euglycemic clamp] Maegawa H. **Nippon Rinsho** 1997 Mar; 55 Suppl 1:248–51 (12 ref.) **(Jpn)**

[Assessment of insulin resistance by minimal model analysis] Takahashi Y, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:252–5 (9 ref.) **(Jpn)**

[Obesity and insulin resistance syndrome] Tokunaga K, et al. **Nippon Rinsho** 1996 Oct;54(10):2679–86 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Hyperuricemia and insulin resistance] Wasada T, et al. **Nippon Rinsho** 1996 Dec;54(12):3293–6 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Leptin and its biological and clinical significance. Is leptin and insulin resistance in the X-5H hormonal metabolic syndrome a parallel or causally-linked phenomenon?] Hrnčiar J. **Vnitr Lek** 1997 Feb;43(2):120–4 (21 ref.) (Eng. Abstr.) **(Slo)**

PHYSIOLOGY

Insulin receptor/IRS-1/PI 3-kinase signaling system in corticosteroid-induced insulin resistance. Folli F, et al. **Acta Diabetol** 1996 Sep;33(3):185–92 (82 ref.)

Insulin like growth factors and their importance in pediatrics. Philipps AF. **Acta Paediatr Sin** 1996 Jan-Feb;37(1):1–10 (94 ref.)

Hypertension, diabetes mellitus, and insulin resistance: the role of intracellular magnesium [see comments] Paolisso G, et al. **Am J Hypertens** 1997 Mar;10(3):346–55 (74 ref.) Comment in: Am J Hypertens 1997 Mar;10(3):368–70.

Hyperinsulinaemia, insulin resistance, microalbuminuria and the risk of coronary heart disease. Yudkin JS. **Ann Med** 1996 Oct;28(5):433–8 (40 ref.)

Does insulin have a role in hypertension? Bursztyn M. **Blood Press Suppl** 1996;1:64–6 (30 ref.)

Molecular mechanisms of insulin resistance in arterial hypertension. Sechi LA, et al. **Blood Press Suppl** 1996; 1:47–54 (64 ref.)

Salt sensitivity and insulin resistance: Is there a link? Sharma AM, et al. **Blood Press Suppl** 1996;1:59–63 (33 ref.)

The insulin resistance syndrome. Smolar EN. **Compr Ther** 1997 Apr;23(4):237–43 (45 ref.)

Hypertension, dyslipidemia, and insulin resistance: links in a chain or spokes on a wheel? Hopkins PN, et al. **Curr Opin Lipidol** 1996 Aug;7(4):241–53 (103 ref.)

INSULIN RESISTANCE

Insulin resistance and coronary heart disease. Laakso M. **Curr Opin Lipidol** 1996 Aug;7(4):217–26 (102 ref.)
Insulin allergy and insulin resistance. Lebovitz HE. **Curr Ther Endocrinol Metab** 1997;6:500–4 (7 ref.)
Clinical significance of insulin resistance. Bell PM. **Diabet Med** 1996 Jun;13(6):504–9 (86 ref.)
From sand rats to diabetic patients: is non–insulin–dependent diabetes mellitus a disease of the beta cell? Cerasi E, et al. **Diabetes Metab** 1997 Mar;23 Suppl 2:47–51 (44 ref.)
Insulin resistance in central to the burden of diabetes. Ferrannini E. **Diabetes Metab Rev** 1997 Jun;13(2):81–6 (27 ref.)
Insulin resistance is not central to the burden of diabetes. Home PD. **Diabetes Metab Rev** 1997 Jun;13(2):87–92 (38 ref.)
Cardiovascular syndromes X, endothelial dysfunction and insulin resistance. Goodfellow J, et al. **Diabetes Res Clin Pract** 1996 Jul;31 Suppl:S163–71 (34 ref.)
Exercise and the metabolic syndrome. Eriksson J, et al. **Diabetologia** 1997 Feb;40(2):125–35 (163 ref.)
Visceral obesity, insulin resistance, and dyslipidemia: contribution of endurance exercise training to the treatment of the plurimetabolic syndrome. Després JP. **Exerc Sport Sci Rev** 1997;25:271–300 (125 ref.)
The metabolic syndrome: from inherited survival trait to a health care problem. Colagiuri S, et al. **Exp Clin Endocrinol Diabetes** 1997;105 Suppl 2:54–60 (83 ref.)
High plasma interleukin–2: a potential cause of insulin resistance. Penttinen J. **Med Hypotheses** 1995 Dec; 45(6):614–6 (30 ref.)
Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. DeFronzo RA. **Neth J Med** 1997 May; 50(5):191–7 (14 ref.)
PAI–1, obesity, insulin resistance and risk of cardiovascular events. Juhan–Vague I, et al. **Thromb Haemost** 1997 Jul; 78(1):656–60 (56 ref.)
[Insulin resistance, arterial hypertension and cardiovascular prevention. Therapeutic implications] Chamontin B, et al. **Presse Med** 1997 Apr 26;26(14):671–7 (51 ref.) **(Fre)**
[Insulin resistance—possible causes and effects] Bornkessel B. **Med Monatsschr Pharm** 1996 Mar;19(3):81–4 (2 ref.) **(Ger)**
[Prognostic aspects of metabolic syndrome. Is the "good living" syndrome regarded seriously enough in general insurance medicine practice?] Regenauer A. **Versicherungsmedizin** 1996 Oct 1;48(5):161–9 (49 ref.) (Eng. Abstr.) **(Ger)**
[Metabolic syndrome] Wirth A, et al. **Versicherungsmedizin** 1996 Dec 1;48(6):193–9 (16 ref.) (Eng. Abstr.) **(Ger)**
[Amylin as an additional possible pathogenic factor in NIDDM and the insulin resistance syndrome] Hrnčiar J. **Vnitr Lek** 1996 Aug;42(8):557–60 (21 ref.) (Eng. Abstr.) **(Slo)**
[Insulin resistance, calcium cell metabolism, and essential arterial hypertension. Role of skeletal muscle] Sánchez M, et al. **Med Clin (Barc)** 1996 Jun 15;107(3):102–6 (62 ref.) **(Spa)**

INSULINOMA

DIAGNOSIS

Gastrointestinal endocrine tumours. Insulinoma. Grant CS. **Baillieres Clin Gastroenterol** 1996 Dec;10(4):645–71 (75 ref.)
Use of calcium provocative test in the diagnosis of gastroenteropancreatic endocrine tumors. Vezzadini C, et al. **Panminerva Med** 1996 Dec;38(4):255–8 (14 ref.)
[Topical diagnosis of insulinomas] Egorov AV, et al. **Khirurgiia (Mosk)** 1996;(3):71–4 (70 ref.) **(Rus)**

EPIDEMIOLOGY

Insulinoma and other islet–cell tumors. Service FJ. **Cancer Treat Res** 1997;89:335–46 (43 ref.)

PATHOLOGY

Gastrointestinal endocrine cancers and nodal metastasis: biologic significance and therapeutic implications. Peplinski GR, et al. **Surg Oncol Clin N Am** 1996 Jan;5(1):159–71 (101 ref.)

SURGERY

[Special diagnostic and therapeutic aspects of insulinoma] Röher HD, et al. **Chirurg** 1997 Feb;68(2):116–21 (25 ref.) (Eng. Abstr.) **(Ger)**

INSULOMA see **INSULINOMA**

INSURANCE

Insurance underwriting in the genetic era. Pokorski RJ. **Am J Hum Genet** 1997 Jan;60(1):205–16 (67 ref.)

INSURANCE, ACCIDENT

LEGISLATION & JURISPRUDENCE

[Comments on the revision of the Königstein instructional pamphlet (see comments)] Plath P. **HNO** 1996 Aug; 44(8):431–9 (11 ref.) (Eng. Abstr.) Comment in: HNO 1997 May;45(5):356–8; discussion 358–9. **(Ger)**
[Femur head necrosis in the adult. Diagnosis, therapy, legal aspects for insurance medicine] Vogel HJ, et al. **Versicherungsmedizin** 1997 Jun 1;49(3):82–5 (26 ref.) (Eng. Abstr.) **(Ger)**

INSURANCE AUDIT see **INSURANCE CLAIM REVIEW**

INSURANCE CARRIERS

Insurance underwriting in the genetic era. Pokorski RJ. **Am J Hum Genet** 1997 Jan;60(1):205–16 (67 ref.)

ECONOMICS

Insolvency risk in health carriers: innovation, competition, and public protection. Akula JL. **Health Aff (Millwood)** 1997 Jan–Feb;16(1):9–33 (14 ref.)

LEGISLATION & JURISPRUDENCE

Insurance regulation of providers that bear risk. Overbay A, et al. **Am J Law Med** 1996;22(2–3):361–87 (0 ref.)

INSURANCE CASE MANAGEMENT see **MANAGED CARE PROGRAMS**

INSURANCE CLAIM REVIEW

LEGISLATION & JURISPRUDENCE

Refusing to pay for health care—Part III (of III): Avoiding third–party payer liability. Ross EJ. **Prog Cardiovasc Nurs** 1996 Summer;11(3):41–5 (35 ref.)

INSURANCE CLAIMS PROCESSING see **INSURANCE CLAIM REVIEW**

INSURANCE COVERAGE

Health care coverage for children who are on and off welfare. Moffitt RA, et al. **Future Child** 1997 Spring; 7(1):87–98 (20 ref.)
EUR–ASSESS Project Subgroup Report on Coverage. Cranovsky R, et al. **Int J Technol Assess Health Care** 1997 Spring;13(2):287–332 (69 ref.)

HISTORY

Putting the brakes on drive–through deliveries. Seaman S. **J Contemp Health Law Policy** 1997 Spring;13(2):497–521 (214 ref.)

LEGISLATION & JURISPRUDENCE

Sex, lies, and health insurance: employer–provided health insurance coverage of abortion and infertility services and the ADA. Millsap D. **Am J Law Med** 1996;22(1):51–84 (309 ref.)
What is the method to their "madness?" Experimental treatment exclusions in health insurance policies. Lahr JG. **J Contemp Health Law Policy** 1997 Spring;13(2):613–36 (175 ref.)
Putting the brakes on drive–through deliveries. Seaman S. **J Contemp Health Law Policy** 1997 Spring;13(2):497–521 (214 ref.)

TRENDS

Medical necessity in Canadian health policy: four meanings and ... a funeral? Charles C, et al. **Milbank Q** 1997; 75(3):365–94 (93 ref.)

INSURANCE, HEALTH

see related
MEDICALLY UNINSURED
PHYSICIAN'S PRACTICE PATTERNS

Consumer health plan choice: current knowledge and future directions. Scanlon DP, et al. **Annu Rev Public Health** 1997; 18:507–28 (62 ref.)
Health care coverage for children who are on and off welfare. Moffitt RA, et al. **Future Child** 1997 Spring; 7(1):87–98 (20 ref.)
What information do consumers want and need? Edgman–Levitan S, et al. **Health Aff (Millwood)** 1996 Winter;15(4):42–56 (20 ref.)
EUR–ASSESS Project Subgroup Report on Coverage. Cranovsky R, et al. **Int J Technol Assess Health Care** 1997 Spring;13(2):287–332 (69 ref.)
Market–oriented health care reforms: trends and future options. van de Ven WP. **Soc Sci Med** 1996 Sep; 43(5):655–66 (40 ref.)

ECONOMICS

Health insurance and child support. Meyer DR. **Health Aff (Millwood)** 1997 Mar–Apr;16(2):207–17 (18 ref.)

LEGISLATION & JURISPRUDENCE

Genetic predispositions, prophylactic treatments and private health insurance: nothing is better than a good pair of genes. Glazier AK. **Am J Law Med** 1997;23(1):45–68 (149 ref.)
Speaking of personal responsibility and individual accountability.... Keigher SM. **Health Soc Work** 1996 Nov; 21(4):304–11 (9 ref.)
Genetic discrimination and health insurance: a call for legislative action. Rothenberg KH. **J Am Med Womens Assoc** 1997 Winter;52(1):43–4 (16 ref.)
What is the method to their "madness?" Experimental treatment exclusions in health insurance policies. Lahr JG. **J Contemp Health Law Policy** 1997 Spring;13(2):613–36 (175 ref.)
The politics of "Drive–through deliveries": putting early postpartum discharge on the legislative agenda. Declercq E, et al. **Milbank Q** 1997;75(2):175–202 (69 ref.)

STANDARDS

Consumer surveys of health plan performance: a comparison of content and approach and a look to the future. Allen HM Jr, et al. **Jt Comm J Qual Improv** 1996 Dec; 22(12):775–94 (26 ref.)

STATISTICS & NUMERICAL DATA

Medicaid and private insurance: evidence and implications [see comments] Cutler DM, et al. **Health Aff (Millwood)** 1997 Jan–Feb;16(1):194–200 (13 ref.) Comment in: Health Aff (Millwood) 1997 Jan–Feb;16(1):201–3. Comment in: Health Aff (Millwood) 1997 Jan–Feb;16(1):204–6.

INSURANCE, HEALTH, CATASTROPHIC see **INSURANCE, MAJOR MEDICAL**

INSURANCE, HEALTH, FOR AGED AND DISABLED see **MEDICARE**

INSURANCE, HEALTH, REIMBURSEMENT

Medical necessity: making sense out of nonsense. Hein K. **J Am Board Fam Pract** 1997 May–Jun;10(3):222–6 (11 ref.)
Whose outcomes. Patients, providers, or payers? Kleinpell RM. **Nurs Clin North Am** 1997 Sep;32(3):513–20 (21 ref.)

LEGISLATION & JURISPRUDENCE

Groping for the reins: ERISA, HMO malpractice, and enterprise liability. Kilcullen JK. **Am J Law Med** 1996; 22(1):7–50 (414 ref.)
Insurance regulation of providers that bear risk. Overbay A, et al. **Am J Law Med** 1996;22(2–3):361–87 (0 ref.)
Refusing to pay for health care—Part III (of III): Avoiding third–party payer liability. Ross EJ. **Prog Cardiovasc Nurs** 1996 Summer;11(3):41–5 (35 ref.)
Refusing to pay for health care—Part II (of III): Emerging trends in third–party payer liability. Ross EJ. **Prog Cardiovasc Nurs** 1996 Spring;11(2):40–5 (57 ref.)

STATISTICS & NUMERICAL DATA

Cost minimization analysis of various treatment options for surgical stage I endometrial carcinoma. Konski AA, et al. **Int J Radiat Oncol Biol Phys** 1997 Jan 15;37(2):367–73 (33 ref.)

INSURANCE, LIABILITY

Liability issues with the Papanicolaou smear: an insurance industry perspective. Scott MD. **Arch Pathol Lab Med** 1997 Mar;121(3):239–40 (0 ref.)
Do you have nursing professional liability insurance?—Part I. Byrd CM. **Prog Cardiovasc Nurs** 1997 Spring;12(2):37–9 (7 ref.)

LEGISLATION & JURISPRUDENCE

The search for the elusive electronic medical record system—medical liability, the missing factor. Grams RR, et al. **J Med Syst** 1997 Feb;21(1):1–10 (5 ref.)

INSURANCE, LIFE

[Prognostic aspects of metabolic syndrome. Is the "good living" syndrome regarded seriously enough in general insurance medicine practice?] Regenauer A. **Versicherungsmedizin** 1996 Oct 1;48(5):161–9 (49 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

Review article: insurance risks for patients with ulcerative colitis or Crohn's disease. Travis SP. **Aliment Pharmacol Ther** 1997 Feb;11(1):51–9 (23 ref.)

INSURANCE, LONG–TERM CARE

LEGISLATION & JURISPRUDENCE

[Determining the extent of nursing care need according to the nursing care insurance law in an interdisciplinary comparison] Cappell E. **Z Gerontol Geriatr** 1996 Nov–Dec; 29(6):418–25 (28 ref.) (Eng. Abstr.) **(Ger)**

INSURANCE, MAJOR MEDICAL

ECONOMICS

How will medical savings accounts affect medical spending? Ozanne L. **Inquiry** 1996 Fall;33(3):225–36 (10 ref.)

INSURANCE, NURSING SERVICES

LEGISLATION & JURISPRUDENCE

[Determining the extent of nursing care need according to the nursing care insurance law in an interdisciplinary comparison] Cappell E. **Z Gerontol Geriatr** 1996 Nov–Dec; 29(6):418–25 (28 ref.) (Eng. Abstr.) **(Ger)**

INSURANCE SELECTION BIAS

Genetic predispositions, prophylactic treatments and private health insurance: nothing is better than a good pair of genes. Glazier AK. **Am J Law Med** 1997;23(1):45–68 (149 ref.)

The private insurance industry's tactics against suspected homosexuals: redlining based on occupation, residence and marital status. Li KC. **Am J Law Med** 1996;22(4):477–502 (202 ref.)

INSURANCE STATUS see **INSURANCE COVERAGE**

INSURERS see **INSURANCE CARRIERS**

INTEGRAL MEMBRANE PROTEINS see **MEMBRANE PROTEINS**

INTEGRASE

CHEMISTRY

The cis–trans paradox of integrase [see comments] Jayaram M. **Science** 1997 Apr 4;276(5309):49–51 (22 ref.) Comment in: Science 1997 Apr 4;276(5309):126–31.

GENETICS

How knockout mouse lines will be used to study the role of drug–metabolizing enzymes and their receptors during reproduction and development, and in environmental toxicity, cancer, and oxidative stress. Nebert DW, et al. **Biochem Pharmacol** 1997 Feb 7;53(3):249–54 (44 ref.)

Conditional gene targeting. Rajewsky K, et al. **J Clin Invest** 1996;98(11 Suppl):S51–3 (30 ref.)

[Modification of gene targeting method for functional analysis of the target gene in vivo] Shibata H, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(4):460–5 (2 ref.) (Eng. Abstr.) **(Jpn)**

INTEGRASE INHIBITORS, HIV see **HIV INTEGRASE INHIBITORS**

INTEGRATED DELIVERY SYSTEMS see **DELIVERY OF HEALTH CARE, INTEGRATED**

INTEGRATED HEALTH CARE SYSTEMS see **DELIVERY OF HEALTH CARE, INTEGRATED**

INTEGRATION, PROPHAGE see **LYSOGENY**

INTEGRATION, PROVIRUS see **VIRUS INTEGRATION**

INTEGRATION, VIRUS see **VIRUS INTEGRATION**

INTEGRIN ALPHA–5 BETA–1 see **RECEPTORS, FIBRONECTIN**

INTEGRIN ALPHA–IIB BETA–3 see **PLATELET GLYCOPROTEIN GPIIB–IIIA COMPLEX**

INTEGRIN ALPHA–M BETA–2 see **MACROPHAGE–1 ANTIGEN**

INTEGRIN ALPHA–V BETA–3 see **RECEPTORS, VITRONECTIN**

INTEGRIN BETA–1 SUBUNIT see **ANTIGENS, CD29**

INTEGRIN BETA 2 SUBUNIT see **ANTIGENS, CD18**

INTEGRINS

see related
ANTIGENS, CD18
ANTIGENS, CD29
CELL ADHESION MOLECULES

BIOSYNTHESIS

Thalidomide may impede cell migration in primates by down–regulating integrin beta–chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis. McCarty MF. **Med Hypotheses** 1997 Aug; 49(2):123–31 (108 ref.)

BLOOD

Platelet receptors for collagen. Moroi M, et al. **Thromb Haemost** 1997 Jul;78(1):439–44 (48 ref.)

CHEMISTRY

Structure and function of the mucosal T–cell integrin alpha E beta 7. Kilshaw PJ, et al. **Biochem Soc Trans** 1997 May; 25(2):433–9 (48 ref.)

Emerging paradigms of integrin ligand binding and activation. Sugimori T, et al. **Kidney Int** 1997 May; 51(5):1454–62 (135 ref.)

[Adhesion molecules and cancer metastasis] Ota I, et al. **Rinsho Byori** 1997 Jun;45(6):528–33 (12 ref.) (Eng. Abstr.) **(Jpn)**

DEFICIENCY

Bovine leukocyte adhesion deficiency: a brief overview of a modern disease and its implications. Gerardi AS. **Acta Vet Hung** 1996;44(1):1–8 (18 ref.)

DRUG EFFECTS

Anti–adhesion therapy. Cornejo CJ, et al. **Adv Pharmacol** 1997;39:99–142 (200 ref.)

GENETICS

Multiple roles for integrins during development. Beauvais–Jouneau A, et al. **Biol Cell** 1997 Mar;89(1):5–11 (47 ref.)

Genetic analyses of integrin function in mice. Fässler R, et al. **Curr Opin Cell Biol** 1996 Oct;8(5):641–6 (47 ref.)

Targeted mutations in cell adhesion genes: what have we learned from them? Hynes RO. **Dev Biol** 1996 Dec 15; 180(2):402–12 (89 ref.)

Targeted mutations in integrins and their ligands: their implications for vascular biology. Hynes RO, et al. **Thromb Haemost** 1997 Jul;78(1):83–7 (40 ref.)

IMMUNOLOGY

Integrins and cancer. Varner JA, et al. **Curr Opin Cell Biol** 1996 Oct;8(5):724–30 (77 ref.)

Where the outside meets the inside: integrins as activators and targets of signal transduction cascades. Brown E, et al. **Immunol Lett** 1996 Dec;54(2–3):189–93 (35 ref.)

Getting integrins into shape: recent insights into how integrin activity is regulated by conformational changes. Mould AP. **J Cell Sci** 1996 Nov;109 (Pt 11):2613–8 (56 ref.)

Granulocyte adhesion molecules––structure/function relationships. Dransfield I. **Semin Cell Biol** 1995 Dec; 6(6):337–44 (49 ref.)

[Vascular immune reactions in arteritis and atherosclerosis. Receptors for endothelial adhesion] Hansson G. **Lakartidningen** 1997 Mar 5;94(10):852–4 (20 ref.) **(Swe)**

METABOLISM

Ligand binding and affinity modulation of integrins. Tozer EC, et al. **Biochem Cell Biol** 1996;74(6):785–98 (140 ref.)

Understanding the molecular basis of cell migration; implications for clinical therapy in multiple sclerosis. Milner R. **Clin Sci (Colch)** 1997 Feb;92(2):113–22 (57 ref.)

Integrin cytoplasmic interactions and bidirectional transmembrane signalling. Dedhar S, et al. **Curr Opin Cell Biol** 1996 Oct;8(5):657–69 (86 ref.)

Genetic analyses of integrin function in mice. Fässler R, et al. **Curr Opin Cell Biol** 1996 Oct;8(5):641–6 (47 ref.)

Integrin activation: the link between ligand binding and signal transduction. Humphries MJ. **Curr Opin Cell Biol** 1996 Oct; 8(5):632–40 (59 ref.)

Integrin–ligand interactions: scratching the surface. Kanazashi SI, et al. **Curr Opin Hematol** 1997 Jan;4(1):67–74 (86 ref.)

Targeted mutations in cell adhesion genes: what have we learned from them? Hynes RO. **Dev Biol** 1996 Dec 15; 180(2):402–12 (89 ref.)

The cell adhesion molecule L1: species– and cell–type–dependent multiple binding mechanisms. Kadmon G, et al. **Differentiation** 1997 Feb;61(3):143–50 (43 ref.)

The role of alpha 4 integrins in lung pathophysiology. Lobb RR, et al. **Eur Respir J Suppl** 1996 Aug;22:104s–108s (34 ref.)

Roles of integrins in fibronectin matrix assembly. Wu C. **Histol Histopathol** 1997 Jan;12(1):233–40 (76 ref.)

Fibronectin and integrins interactions. Mohri H. **J Investig Med** 1996 Oct;44(8):429–41 (157 ref.)

Protein kinase mediators of integrin signal transduction. Hannigan GE, et al. **J Mol Med** 1997 Jan;75(1):35–44 (116 ref.)

Topography and biological role of integrins in human skin. Marchisio PC, et al. **Microsc Res Tech** 1997 Aug 15; 38(4):353–60 (80 ref.)

The regulation of expression of integrin receptors. Kim LT, et al. **Proc Soc Exp Biol Med** 1997 Feb;214(2):123–31 (118 ref.)

Molecular mechanisms for focal adhesion assembly through regulation of protein–protein interactions. Gilmore AP, et al. **Structure** 1996 Jun 15;4(6):647–51 (35 ref.)

Molecular crosstalk between adhesion receptors and proteolytic cascades in vascular remodelling. Preissner KT, et al. **Thromb Haemost** 1997 Jul;78(1):88–95 (114 ref.)

Modulation of cell adhesion during epithelial restitution in the gastrointestinal tract. Pignatelli M. **Yale J Biol Med** 1996 Mar–Apr;69(2):131–5 (38 ref.)

[Integrins and cadherins: two superfamilies of adhesive receptors] Gulino D, et al. **Ann Endocrinol (Paris)** 1996; 57(3):139–46 (32 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Expression and function of integrins on hematopoietic progenitor cells. Coulombel L, et al. **Acta Haematol** 1997; 97(1–2):13–21 (92 ref.)

Expression and function of adhesion receptors in acute myelogenous leukemia: parallels with normal erythroid and myeloid progenitors. Liesveld JL. **Acta Haematol** 1997; 97(1–2):53–62 (108 ref.)

Homing and trafficking of hemopoietic progenitor cells. Papayannopoulou T, et al. **Acta Haematol** 1997; 97(1–2):97–104 (73 ref.)

Adhesive proteins and the hematogenous spread of cancer. Tuszynski GP, et al. **Acta Haematol** 1997;97(1–2):29–39 (100 ref.)

Integrin–mediated regulation of hematopoiesis: do BCR/ABL–induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors? Verfaillie CM, et al. **Acta Haematol** 1997; 97(1–2):40–52 (160 ref.)

Adhesive interactions in hemopoiesis. Wilson JG. **Acta Haematol** 1997;97(1–2):6–12 (97 ref.)

Cellular adhesion molecules: regulation and functional significance in the pathogenesis of liver diseases. Jaeschke H. **Am J Physiol** 1997 Sep;273(3 Pt 1):G602–11 (131 ref.)

Integrins: role in cell adhesion and communication. Gille J, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:93–106 (87 ref.)

Pathophysiologic role of alpha 4 integrins in the lung. Lobb RR, et al. **Ann N Y Acad Sci** 1996 Oct 31;796:113–23 (47 ref.)

RGD and other recognition sequences for integrins. Ruoslahti E. **Ann Rev Cell Dev Biol** 1996;12:697–715 (103 ref.)

The integrin alpha 6 beta 4 and the biology of carcinoma. Rabinovitz I, et al. **Biochem Cell Biol** 1996;74(6):811–21 (112 ref.)

Structure and function of the mucosal T–cell integrin alpha E beta 7. Kilshaw PJ, et al. **Biochem Soc Trans** 1997 May; 25(2):433–9 (48 ref.)

Cooperation between soluble factors and integrin–mediated cell anchorage in the control of cell growth and differentiation. Juliano R. **Bioessays** 1996 Nov;18(11):911–7 (77 ref.)

Integrin–mediated calcium signaling and regulation of cell adhesion by intracellular calcium. Sjaastad MD, et al. **Bioessays** 1997 Jan;19(1):47–55 (83 ref.)

Adhesion molecules in reproduction. Klentzeris LD. **Br J Obstet Gynaecol** 1997 Apr;104(4):401–9 (53 ref.)

Regulation of the actin cytoskeleton, integrins and cell growth by the Rho family of small GTPases. Hotchin NA, et al. **Cancer Surv** 1996;27:311–22 (73 ref.)

Integrins, angiogenesis and vascular cell survival. Strömblad S, et al. **Chem Biol** 1996 Nov;3(11):881–5 (36 ref.)

Integrins and disease [editorial] Hillis GS, et al. **Clin Sci (Colch)** 1996 Dec;91(6):639–50 (100 ref.)

Structure/function relationships of axon–associated adhesion receptors of the immunoglobulin superfamily. Brümmendorf T, et al. **Curr Opin Neurobiol** 1996 Oct; 6(5):584–93 (80 ref.)

The regulation of growth and intracellular signaling by integrins. Meredith JE Jr, et al. **Endocr Rev** 1996 Jun; 17(3):207–20 (199 ref.)

Role of integrins in angiogenesis. Brooks PC. **Eur J Cancer** 1996 Dec;32A(14):2423–9 (67 ref.)

The role of alpha 4 integrins in lung pathophysiology. Lobb RR, et al. **Eur Respir J Suppl** 1996 Aug;22:104s–108s (34 ref.)

Cell adhesion receptors and gap junctions in normal and neoplastic transformed thyrocytes. Pötter E, et al. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 4:24–8 (34 ref.)

The role of vascular cell integrins alpha v beta 3 and alpha v beta 5 in angiogenesis. Varner JA. **EXS** 1997;79:361–90 (243 ref.)

Integrins and reproductive physiology: expression and modulation in fertilization, embryogenesis, and implantation. Sueoka K, et al. **Fertil Steril** 1997 May; 67(5):799–811 (100 ref.)

Integrins in cell adhesion and signaling. Akiyama SK. **Hum Cell** 1996 Sep;9(3):181–6 (51 ref.)

Role of the PS integrins in Drosophila development. Brower DL, et al. **Immunol Cell Biol** 1995 Dec;73(6):558–64 (34 ref.)

Integrins as promiscuous signal transduction devices. Petty HR, et al. **Immunol Today** 1996 May;17(5):209–12 (23 ref.)

Regulating integrin–mediated adhesion: one more function for PI 3–kinase? Shimizu Y, et al. **Immunol Today** 1996 Dec;17(12):565–73 (82 ref.)

Integrins––new frontier in cancer biology. Chatterjee A. **Indian J Exp Biol** 1996 Oct;34(10):923–6 (45 ref.)

Signal transduction in cell–matrix interactions. Guan JL, et al. **Int Rev Cytol** 1996;168:81–121 (244 ref.)

Inside–out signaling through integrins. Faull RJ, et al. **J Am Soc Nephrol** 1996 Aug;7(8):1091–7 (81 ref.)

Extracellular matrix components and integrins in the control of arterial smooth muscle cell structure and function. Hedin

INTEGRINS

U. **J Atheroscler Thromb** 1994;1 Suppl 1:S39–46 (13 ref.)
Initiation of white cell activation during cardiopulmonary bypass: cytokines and receptors. Cameron D. **J Cardiovasc Pharmacol** 1996;27 Suppl 1:S1–5 (12 ref.)
Integrin-dependent signal transduction. Lafrenie RM, et al. **J Cell Biochem** 1996 Jun 15;61(4):543–53 (69 ref.)
Regulation of leukocyte integrin function: affinity vs. avidity. Stewart M, et al. **J Cell Biochem** 1996 Jun 15;61(4):554–61 (54 ref.)
Signal transduction by the alpha 6 beta 4 integrin: charting the path between laminin binding and nuclear events. Giancotti FG. **J Cell Sci** 1996 Jun;109 (Pt 6):1165–72 (84 ref.)
Cell adhesion and angiogenesis. Bischoff J. **J Clin Invest** 1997 Feb 1;99(3):373–6 (27 ref.)
Cell adhesion in vascular biology. New insights into integrin-ligand interaction. Loftus JC, et al. **J Clin Invest** 1997 May 15;99(10):2302–6 (34 ref.)
Integrins and vascular extracellular matrix assembly. Ruoslahti E, et al. **J Clin Invest** 1997 Mar 15;99(6):1149–52 (37 ref.)
Perspectives series: cell adhesion in vascular biology. Integrin signaling in vascular biology. Shattil SJ, et al. **J Clin Invest** 1997 Jul 1;100(1):1–5 (77 ref.)
Pathophysiology of CML: do defects in integrin function contribute to the premature circulation and massive expansion of the BCR/ABL positive clone? Verfaillie CM, et al. **J Lab Clin Med** 1997 Jun;129(6):584–91 (52 ref.)
Signaling mechanisms and the activation of leukocyte integrins. Newton RA, et al. **J Leukoc Biol** 1997 Apr; 61(4):422–6 (54 ref.)
Integrin signaling in leukocytes: lessons from the alpha6beta1 integrin. Wei J, et al. **J Leukoc Biol** 1997 Apr;61(4):397–407 (119 ref.)
Integrins: expression, modulation, and signaling in fertilization, embryogenesis and implantation. Yoshimura Y. **Keio J Med** 1997 Mar;46(1):16–24 (75 ref.)
The solid state environment orchestrates embryonic development and tissue remodeling. Damsky CH, et al. **Kidney Int** 1997 May;51(5):1427–33 (45 ref.)
Leukocyte migration in immune complex glomerulonephritis: role of adhesion receptors. Lefkowith JB. **Kidney Int** 1997 May;51(5):1469–75 (54 ref.)
Integrins and laminins in tissue remodeling. Quaranta V, et al. **Kidney Int** 1997 May;51(5):1441–6 (60 ref.)
Integrins as signaling molecules and targets for tumor therapy. Ruoslahti E. **Kidney Int** 1997 May;51(5):1413–7 (44 ref.)
Modulation of cell proliferation by the integrin cytoplasmic domain. Zheng DQ, et al. **Kidney Int** 1997 May; 51(5):1434–40 (80 ref.)
VLA-4-mediated interactions between normal human hematopoietic progenitors and stromal cells. Oostendorp RA, et al. **Leuk Lymphoma** 1997 Feb;24(5–6):423–35 (94 ref.)
Topography and biological role of integrins in human skin. Marchisio PC, et al. **Microsc Res Tech** 1997 Aug 15; 38(4):353–60 (80 ref.)
Integrins and human reproduction. Bronson RA, et al. **Mol Hum Reprod** 1996 Mar;2(3):153–68 (160 ref.)
Integrin adhesion receptors: structure, function and implications for biomedicine. Newham P, et al. **Mol Med Today** 1996 Jul;2(7):304–13 (40 ref.)
Role of laminin and integrin interactions in growth cone guidance. McKerracher L, et al. **Mol Neurobiol** 1996 Apr; 12(2):95–116 (157 ref.)
Integrin receptors, the cytoskeleton, and glomerular cell function. Schnaper HW. **Pediatr Nephrol** 1996 Aug; 10(4):523–8 (11 ref.)
Intracellular mechanisms of axon growth induction by CAMs and integrins: some unresolved issues. Bixby JL, et al. **Perspect Dev Neurobiol** 1996;4(2–3):147–56 (79 ref.)
A structural basis for bidirectional integrin signalling. Filardo EJ, et al. **Princess Takamatsu Symp** 1994;24:106–17 (54 ref.)
Integrin signals and tumor growth control. Juliano RL. **Princess Takamatsu Symp** 1994;24:118–24 (33 ref.)
Cell adhesion and tumor metastasis. Ruoslahti E. **Princess Takamatsu Symp** 1994;24:99–105 (36 ref.)
Cell migration: interactions among integrins, IGFs and IGFBPs. Jones JI, et al. **Prog Growth Factor Res** 1995; 6(2–4):319–27 (25 ref.)
Extracellular matrix components and integrins in relationship to human intestinal epithelial cell differentiation. Beaulieu JF. **Prog Histochem Cytochem** 1997;31(4):1–78 (380 ref.)
Adhesion receptors in malignant transformation and dissemination of gastrointestinal tumors. Streit M, et al. **Recent Results Cancer Res** 1996;142:19–50 (141 ref.)
Signaling through G proteins in platelets: to the integrins and beyond. Brass LF, et al. **Thromb Haemost** 1997 Jul; 78(1):581–9 (98 ref.)
Integrins: possible functions in the adult CNS [see comments] Jones LS. **Trends Neurosci** 1996 Feb;19(2):68–72 (85 ref.) Comment in: Trends Neurosci 1996 Jun;19(6):228.
[Role of integrins in ocular physiology and diseases] Goldschild M, et al. **J Fr Ophtalmol** 1997;20(4):311–25 (100 ref.) **(Fre)**
[The methods of analysis of signal transduction through adhesion molecules] Hamasaki K, et al. **Rinsho Byori** 1996 Sep;Suppl 102:147–52 (12 ref.) **(Jpn)**
[Integrin family] Irie A, et al. **Rinsho Byori** 1996 Sep;Suppl 102:16–23 (20 ref.) **(Jpn)**
[Signal transduction via adhesion molecules] Nojima Y. **Rinsho Byori** 1996 Sep;Suppl 102:90–6 (23 ref.) **(Jpn)**
[Adhesion molecules and cancer metastasis] Ota I, et al. **Rinsho Byori** 1997 Jun;45(6):528–33 (12 ref.) (Eng. Abstr.) **(Jpn)**

INTELLECTUAL PROPERTY

Academic research: policies and practice. Bertha SL. **J Ethnopharmacol** 1996 Apr;51(1–3):59–73 (7 ref.)
The position of intellectual property rights in drug discovery and development from natural products. Boyd MR. **J Ethnopharmacol** 1996 Apr;51(1–3):17–25; discussion 25–7 (12 ref.)
Juridical and sociocultural problems on the definition of a law concerning property, usage and access to genetic resources in Colombia. Calle R. **J Ethnopharmacol** 1996 Apr;51(1–3):127–42; discussion 142–6 (3 ref.)
Interests and policies of the state of Sarawak, Malaysia regarding intellectual property rights for plant derived drugs. Chung FJ. **J Ethnopharmacol** 1996 Apr; 51(1–3):201–4 (1 ref.)
Biodiversity prospecting in Nigeria: seeking equity and reciprocity in intellectual property rights through partnership arrangements and capacity building. Iwu MM. **J Ethnopharmacol** 1996 Apr;51(1–3):209–19 (4 ref.)
Biological diversity, indigenous knowledge, drug discovery and intellectual property rights: creating reciprocity and maintaining relationships. King SR, et al. **J Ethnopharmacol** 1996 Apr;51(1–3):45–57 (25 ref.)
Tanzania's policy on biodiversity prospecting and drug discovery programs. Mahunnah RL, et al. **J Ethnopharmacol** 1996 Apr;51(1–3):221–8 (13 ref.)
Legal issues in sharing the benefits of biodiversity prospecting. Mays TD, et al. **J Ethnopharmacol** 1996 Apr; 51(1–3):93–102; discussion 102–9 (14 ref.)
Gene co-ops and the biotrade: translating genetic resource rights into sustainable development. Reid WV. **J Ethnopharmacol** 1996 Apr;51(1–3):75–92 (21 ref.)
[Intellectual property rights in Costa Rica in the light of the Biodiversity Convention] Salazar R, et al. **J Ethnopharmacol** 1996 Apr;51(1–3):177–93 (12 ref.) (Eng. Abstr.) **(Spa)**

INTELLIGENCE

Developing brain and breastfeeding. Banapurmath CR, et al. **Indian Pediatr** 1996 Jan;33(1):35–8 (33 ref.)
The importance of intelligence in western societies. Brand CR. **J Biosoc Sci** 1996 Oct;28(4):387–404 (85 ref.)
Reductionism and intelligence: the case of inspection time. Deary IJ. **J Biosoc Sci** 1996 Oct;28(4):405–23 (80 ref.)
Group differences: is the good society impossible? Flynn JR. **J Biosoc Sci** 1996 Oct;28(4):573–85 (24 ref.)
The smoking addiction of pregnant women and the consequences on their offspring's intellectual development. Frydman M. **J Environ Pathol Toxicol Oncol** 1996; 15(2–4):169–72 (11 ref.)
Intelligence, personality, and interests: evidence for overlapping traits. Ackerman PL, et al. **Psychol Bull** 1997 Mar;121(2):219–45 (210 ref.)
[Intelligence and intelligence tests] Dittrich P. **Cas Lek Cesk** 1996 Oct 23;135(20):647–52 (22 ref.) (Eng. Abstr.) **(Cze)**

GENETICS

Molecular genetic research on IQ: can it be done? Should it be done? Daniels J, et al. **J Biosoc Sci** 1996 Oct; 28(4):491–507 (37 ref.)
What genetic research on intelligence tells us about the environment. Plomin R, et al. **J Biosoc Sci** 1996 Oct; 28(4):587–606 (64 ref.)

PHYSIOLOGY

Underestimating the rat's intelligence. Davis H. **Brain Res Cogn Brain Res** 1996 Jun;3(3–4):291–8 (57 ref.)
Investigating cognitive abilities in animals: unrealized potential. Thomas RK. **Brain Res Cogn Brain Res** 1996 Jun;3(3–4):157–66 (20 ref.)
Sex differences and IQ. Mackintosh NJ. **J Biosoc Sci** 1996 Oct;28(4):559–71 (45 ref.)
Intelligence is not just mental speed. Rabbitt P. **J Biosoc Sci** 1996 Oct;28(4):425–49 (72 ref.)
G explained. Anderson B. **Med Hypotheses** 1995 Dec; 45(6):602–4 (27 ref.)
Neuroscience and human intelligence differences. Deary IJ, et al. **Trends Neurosci** 1997 Aug;20(8):365–71 (82 ref.)

INTELLIGENCE TESTS

Developmental assessment tests: scope and limitations [editorial] Chaudhari S. **Indian Pediatr** 1996 Jul;33(7):541–5 (19 ref.)
Sex differences and IQ. Mackintosh NJ. **J Biosoc Sci** 1996 Oct;28(4):559–71 (45 ref.)
[Intelligence and intelligence tests] Dittrich P. **Cas Lek Cesk** 1996 Oct 23;135(20):647–52 (22 ref.) (Eng. Abstr.) **(Cze)**

STANDARDS

Either a paradigm shift or no mental measurement: the nonscience and the nonsense of The Bell Curve. Hilliard AG 3rd. **Cult Divers Ment Health** 1996;2(1):1–20 (37 ref.)

STATISTICS & NUMERICAL DATA

Bio-ecological approach to cognitive assessment. Armour-Thomas E, et al. **Cult Divers Ment Health** 1997; 3(2):131–44 (15 ref.)
The cognitive assessment of limited-English-proficient children: current problems and practical recommendations. Lopez MC, et al. **Cult Divers Ment Health** 1997;3(2):117–30 (65 ref.)

INTENSIVE CARE

see related
CRITICAL CARE

The use of muscle relaxants in the intensive care unit. Booij LH. **Acta Anaesthesiol Belg** 1997;48(1):35–44 (98 ref.)
Dialysis support in the pediatric intensive care unit. Parekh RS, et al. **Adv Ren Replace Ther** 1996 Oct;3(4):326–36 (46 ref.)
Induced hypothermia in intensive care medicine. Bernard S. **Anaesth Intensive Care** 1996 Jun;24(3):382–8 (104 ref.)
Seizures. Bleck TP. **Baillieres Clin Neurol** 1996 Oct; 5(3):565–76 (29 ref.)
Infections. Bolton CF. **Baillieres Clin Neurol** 1996 Oct; 5(3):599–626 (57 ref.)
The neurological consultation and neurological syndromes in the intensive care unit [see comments] Bolton CF, et al. **Baillieres Clin Neurol** 1996 Oct;5(3):447–75 (57 ref.) Comment in: Baillieres Clin Neurol 1996 Oct;5(3):645–71.
Severe stroke. Brandt T, et al. **Baillieres Clin Neurol** 1996 Oct;5(3):515–41 (94 ref.)
Metabolic encephalopathies. Chen R, et al. **Baillieres Clin Neurol** 1996 Oct;5(3):577–98 (64 ref.)
Subarachnoid haemorrhage. diPierro CG, et al. **Baillieres Clin Neurol** 1996 Oct;5(3):543–63 (37 ref.)
Management of Guillain-Barré syndrome (GBS). Hahn AF. **Baillieres Clin Neurol** 1996 Oct;5(3):627–44 (99 ref.)
Central nervous system trauma. Statham PF, et al. **Baillieres Clin Neurol** 1996 Oct;5(3):497–514 (51 ref.)
Ethics. Young GB. **Baillieres Clin Neurol** 1996 Oct; 5(3):673–84 (36 ref.)
The respiratory system. Zifko U, et al. **Baillieres Clin Neurol** 1996 Oct;5(3):477–95 (69 ref.)
Neuromuscular disorders in critical illness [comment] Zochodne DW, et al. **Baillieres Clin Neurol** 1996 Oct; 5(3):645–71 (111 ref.) Comment on: Baillieres Clin Neurol 1996 Oct;5(3):447–75.
Selective decontamination of the digestive tract in intensive care patients. van Saene HK, et al. **Br J Hosp Med** 1995 Dec 13–1996 Jan 16;54(11):558–61 (21 ref.)
Movement disorders associated with withdrawal from high-dose intravenous haloperidol therapy in delirious ICU patients. Riker RR, et al. **Chest** 1997 Jun;111(6):1778–81 (29 ref.)
Clinical applications of cerebral monitoring. Langford RM. **Comput Methods Programs Biomed** 1996 Oct;51(1–2):29–33 (12 ref.)
ICU scoring systems allow prediction of patient outcomes and comparison of ICU performance. Becker RB, et al. **Crit Care Clin** 1996 Jul;12(3):503–14 (53 ref.)
Does gastric tonometry work? No. Benjamin E, et al. **Crit Care Clin** 1996 Jul;12(3):587–601 (77 ref.)
Does gastric tonometry work? Yes. Brown SD, et al. **Crit Care Clin** 1996 Jul;12(3):569–85 (72 ref.)
Ethically based medical decision making in the intensive care unit: residency teaching strategies. Crausman RS, et al. **Crit Care Clin** 1996 Jan;12(1):71–84 (54 ref.)
Does pulmonary artery catheter use change outcome? Yes. Del Guercio LR. **Crit Care Clin** 1996 Jul;12(3):553–7 (14 ref.)
Does increasing oxygen delivery improve outcome? Yes. Kelly KM. **Crit Care Clin** 1996 Jul;12(3):635–44 (42 ref.)
Do pulmonary artery catheters improve patient outcome? No. Leibowitz AB. **Crit Care Clin** 1996 Jul;12(3):559–68 (39 ref.)
Nutrition support is not beneficial and can be harmful in critically ill patients. Marino PL, et al. **Crit Care Clin** 1996 Jul;12(3):667–76 (47 ref.)
Does increasing oxygen delivery improve outcome in the critically ill? No. Ronco JJ, et al. **Crit Care Clin** 1996 Jul; 12(3):645–59 (47 ref.)
Early nutritional support in critical illness is important. Sax HC. **Crit Care Clin** 1996 Jul;12(3):661–6 (17 ref.)
ICU scoring systems do not allow prediction of patient outcomes or comparison of ICU performance. Sherck JP, et al. **Crit Care Clin** 1996 Jul;12(3):515–23 (41 ref.)
Spiritual issues and bioethics in the intensive care unit: the role of the chaplain. Wagner JT, et al. **Crit Care Clin** 1996 Jan;12(1):15–27 (09 ref.)
Predicting survival in the intensive care unit. Hunt JP, et al. **Curr Probl Surg** 1997 Jul;34(7):527–99 (188 ref.)
Newborn intensive care--success, failure and opportunities. Stahlman MT. **Equine Vet J Suppl** 1988 Sep;(5):1–4; discussion 5 (39 ref.)
Neuromuscular conditions in the intensive care unit [editorial; comment] Bolton CF. **Intensive Care Med** 1996 Sep; 22(9):841–3 (15 ref.) Comment on: Intensive Care Med 1996 Sep;22(9):849–55. Comment on: Intensive Care Med 1996 Sep;22(9):856–61. Comment on: Intensive Care Med 1996 Sep;22(9):862–6.
Aspergillosis in the ICU: the glass half-empty? [editorial;

comment] Crawford SW. **Intensive Care Med** 1996 Dec; 22(12):1291–3 (16 ref.) Comment on: Intensive Care Med 1996 Dec;22(12):1315–22.

Informed consent for research purposes in intensive care patients in Europe—part I. An official statement of the European Society of Intensive Care Medicine. Working Group on Ethics. Lemaire F, et al. **Intensive Care Med** 1997 Mar;23(3):338–41 (0 ref.)

Anti-inflammatory therapies: application of molecular biology techniques in intensive care medicine. Liu M, et al. **Intensive Care Med** 1997 Jul;23(7):718–31 (127 ref.)

Severe community-acquired pneumonia: what do we need to know to effectively manage patients? [editorial; comment] Niederman MS. **Intensive Care Med** 1996 Dec; 22(12):1285–7 (10 ref.) Comment on: Intensive Care Med 1996 Dec;22(12):1294–300.

Tissue hypoxia. How to detect, how to correct, how to prevent? Richard C. **Intensive Care Med** 1996 Nov; 22(11):1250–7 (34 ref.)

Diagnostic and therapeutic implications of transesophageal echocardiography in medical ICU patients with unexplained shock, hypoxemia, or suspected endocarditis. Slama MA, et al. **Intensive Care Med** 1996 Sep;22(9):916–22 (24 ref.)

Worldwide similarities and differences in the foregoing of life-sustaining treatments [editorial; comment] Sprung CL, et al. **Intensive Care Med** 1996 Oct;22(10):1003–5 (37 ref.) Comment on: Intensive Care Med 1996 Oct;22(10):1015–9. Comment on: Intensive Care Med 1996 Oct;22(10):1020–5.

Recall in the sedated ICU patient. Cheng EY. **J Clin Anesth** 1996 Dec;8(8):675–8 (30 ref.)

Tissue hypoxia: how to detect, how to correct, how to prevent? Third European Consensus Conference in Intensive Care Medicine. Organized by the Société de Réanimation de Langue Française, Cosponsored by the American Thoracic Society and the European Society of Intensive Care Medicine. **J Crit Care** 1997 Mar;12(1):39–47 (34 ref.)

Lower respiratory tract infections in the intensive care unit: consequences of antibiotic resistance for choice of antibiotic. Lode H, et al. **Microb Drug Resist** 1995 Summer; 1(2):163–7 (33 ref.)

Problems with resistance in pediatric intensive care. Toltzis P, et al. **New Horiz** 1996 Aug;4(3):353–60 (74 ref.)

Recent developments in lipid emulsions: relevance to intensive care. Carpentier YA, et al. **Nutrition** 1997 Sep; 13(9 Suppl):73S–78S (54 ref.)

Parenteral glutamine supply in intensive care patients. Griffiths RD, et al. **Nutrition** 1996 Nov–Dec;12(11–12 Suppl):S73–5 (22 ref.)

Advanced cardiac life support controversy: where do antiarrhythmic agents fit in? [published erratum appears in Pharmacotherapy 1997 May–Jun;17(3):634] Chow MS. **Pharmacotherapy** 1997 Mar–Apr;17(2 Pt 2):84S–88S; discussion 89S–91S (36 ref.)

Nondepolarizing neuromuscular blocking drugs in the intensive care unit: a clinical review. Reeves ST, et al. **South Med J** 1997 Aug;90(8):769–74 (47 ref.)

[The pathophysiological and intensive care-resuscitation aspects of septic shock] Vasilev D, et al. **Khirurgiia (Sofiia)** 1996;49(4):9–11 (24 ref.) (Eng. Abstr.) **(Bul)**

[Consensus conference. Use of human albumin solutions in surgical anesthesia and surgical intensive care of adults. Saint-Mandé, France, 15 December 1995] **Ann Fr Anesth Reanim** 1996;15(4):407–568 (0 ref.) **(Fre)**

[Sedation in intensive care units. Indications and techniques] Martin C, et al. **Presse Med** 1996 Oct 19;25(31):1479–90 (38 ref.) (Eng. Abstr.) **(Fre)**

[Gastroduodenal ulcers in intensive care units] Raynard B, et al. **Presse Med** 1996 Oct 19;25(31):1448–52 (28 ref.) (Eng. Abstr.) **(Fre)**

[Intensive care in lung and heart-lung transplantation] Bastien O, et al. **Rev Mal Respir** 1996 Nov;13(5 Suppl):S23–9 (34 ref.) (Eng. Abstr.) **(Fre)**

[Fibroscopic bronchoscopy in intensive care] Marquette CH, et al. **Rev Mal Respir** 1997 Apr;14(2):101–11 (41 ref.) (Eng. Abstr.) **(Fre)**

[Imaging procedures in intensive care medicine. II. Techniques, indications, diagnostic signs] Bankier AA, et al. **Anaesthesist** 1996 Sep;45(9):869–80 (18 ref.) **(Ger)**

[Prolonged muscle weakness in intensive care patients with special attention to the so-called intensive care polyneuromyopathy] Hinder F, et al. **Anaesthesist** 1997 Mar;46(3):211–9 (49 ref.) (Eng. Abstr.) **(Ger)**

[Ethics in intensive medicine] List WF. **Anaesthesist** 1997 Apr;46(4):261–6 (14 ref.) (Eng. Abstr.) **(Ger)**

[Transesophageal echocardiography in anesthesia and intensive care. The diagnostic importance of transesophageal echocardiography] Loick HM, et al. **Anaesthesist** 1997 Jun;46(6):504–14 (123 ref.) (Eng. Abstr.) **(Ger)**

[Prognostic scores in intensive care] Unertl K, et al. **Anaesthesist** 1997 Jun;46(6):471–80 (64 ref.) (Eng. Abstr.) **(Ger)**

[Risks and side effects of diagnostic bronchoalveolar lavage in ventilated patients] Zimmermann P, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Mar; 32(3):169–74 (62 ref.) (Eng. Abstr.) **(Ger)**

[Monitoring of emergency and intensive care patients: simple diagnostic aids] Spreng DE, et al. **Schweiz Arch Tierheilkd** 1996;138(11):537–45 (18 ref.) (Eng. Abstr.) **(Ger)**

[Noninvasive ventilation in intensive care] Jolliet P, et al. **Schweiz Med Wochenschr** 1997 Jan 25;127(4):107–21 (85 ref.) (Eng. Abstr.) **(Ger)**

[Experience of an intermediate respiratory intensive therapy in the treatment of prolonged weaning from mechanical ventilation] Vitacca M, et al. **Minerva Anestesiol** 1996 Mar; 62(3):57–64 (23 ref.) (Eng. Abstr.) **(Ita)**

[Thermoregulatory research in the field of anesthesia and intensive care: a review] Ozaki M. **Masui** 1996 Jul; 45(7):804–12 (45 ref.) (Eng. Abstr.) **(Jpn)**

[Intensive therapy in diabetic ketoacidotic coma] Dolina OA, et al. **Anesteziol Reanimatol** 1995 Nov–Dec;(6):41–6 (37 ref.) **(Rus)**

METHODS

Head injuries in children and adults. Mansfield RT. **Crit Care Clin** 1997 Jul;13(3):611–28 (105 ref.)

Pain management in the pediatric intensive care unit. Chambliss CR, et al. **Curr Opin Pediatr** 1997 Jun; 9(3):246–53 (54 ref.)

Bedside burr hole for intracranial pressure monitoring performed by intensive care physicians. A 5-year experience. Bochicchio M, et al. **Intensive Care Med** 1996 Oct;22(10):1070–4 (24 ref.)

Nebuliser therapy in the intensive care unit. O'Doherty MJ, et al. **Thorax** 1997 Apr;52 Suppl 2:S56–9 (46 ref.)

[Imaging in intensive care medicine. I. Techniques, indications, diagnostic signs] Bankier AA, et al. **Anaesthesist** 1996 Aug;45(8):769–86 (0 ref.) **(Ger)**

[The intensive treatment of multiple myeloma with support from hematopoietic progenitors] Paz-Ares L, et al. **Med Clin (Barc)** 1997 Feb 15;108(6):226–9 (37 ref.) **(Spa)**

ORGANIZATION & ADMINISTRATION

Intensive care in Australia and New Zealand. No nonsense "down under". Dobb GJ. **Crit Care Clin** 1997 Apr; 13(2):299–316 (18 ref.)

PSYCHOLOGY

Drugs for amnesia in the ICU. Wagner BK, et al. **Am J Crit Care** 1997 May;6(3):192–201; quiz 202–3 (145 ref.)

STANDARDS

The ethics of providing intensive care in managed care organizations. Danis M, et al. **New Horiz** 1997 Feb; 5(1):85–93 (39 ref.)

INTENSIVE CARE, NEONATAL

Neonatal and pediatric critical care: ethical decision making. Cooper R, et al. **Crit Care Clin** 1996 Jan;12(1):149–64 (53 ref.)

Serratia marcescens infections in neonatal departments: description of an outbreak and review of the literature. van Ogtrop ML, et al. **J Hosp Infect** 1997 Jun;36(2):95–103 (22 ref.)

End-of-life decisions in Dutch neonatal intensive care units [editorial; comment] Moskop JC. **J Pediatr** 1996 Nov; 129(5):627–30 (49 ref.) Comment on: J Pediatr 1996 Nov;129(5):661–6.

Evoked potentials as predictors of outcome in neonatal intensive care unit survivors: review of the literature. Majnemer A, et al. **Pediatr Neurol** 1996 Apr;14(3):189–95 (75 ref.)

The role of relationship-based developmentally supportive newborn intensive care in strengthening outcome of preterm infants. Als H, et al. **Semin Perinatol** 1997 Jun; 21(3):178–89 (84 ref.)

Medical outcomes in preterm infants. Dusick AM. **Semin Perinatol** 1997 Jun;21(3):164–77 (74 ref.)

Parenting the prematurely born child: pathways of influence. Miles MS, et al. **Semin Perinatol** 1997 Jun;21(3):254–66 (105 ref.)

Priorities in neonatal care in developing countries. Ho NK. **Singapore Med J** 1996 Aug;37(4):424–7 (36 ref.)

Perinatal social work and the family of the newborn intensive care infant. Bachman DH, et al. **Soc Work Health Care** 1997;24(3–4):21–37 (15 ref.)

LEGISLATION & JURISPRUDENCE

Expert testimony, legal reasoning, and justice. The case for adopting a data-based standard of care in allegations of medical negligence in the NICU. Meadow W, et al. **Clin Perinatol** 1996 Sep;23(3):583–95 (32 ref.)

Euthanasia in relation to newborn babies—a comparative study of the legal and ethical issues (I). Moor S. **Med Law** 1996;15(2):295–317 (108 ref.)

The uncertain 'best interests' of neonates: decision making in the neonatal intensive care unit. Shewchuk TR. **Med Law** 1995;14(5–6):331–58 (128 ref.)

METHODS

Neurological assessment of the preterm infant. de Vries LS. **Acta Paediatr** 1996 Jul;85(7):765–71 (89 ref.)

Effectiveness of individualized neurodevelopmental care in the newborn intensive care unit (NICU). Als H, et al. **Acta Paediatr Suppl** 1996 Oct;416:21–30 (60 ref.)

Individualized developmental care for very low-birth-weight infants: a critical review. Lotas MJ, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Oct;25(8):681–7 (27 ref.)

Supplemental stimulation of premature infants: a treatment model. Dieter JN, et al. **J Pediatr Psychol** 1997 Jun; 22(3):281–95 (77 ref.)

TRENDS

Advances in neonatal conventional ventilation. Sinha SK, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 Sep; 75(2):F135–40 (25 ref.)

INTENSIVE CARE, SURGICAL see **INTENSIVE CARE**

INTENSIVE CARE UNITS

Nutrition in the critical care settings of renal diseases. Moore LW, et al. **Adv Ren Replace Ther** 1996 Jul;3(3):250–60 (32 ref.)

The approach to anticoagulation in patients treated with extracorporeal therapy in the intensive care unit. Ward DM. **Adv Ren Replace Ther** 1997 Apr;4(2):160–73 (134 ref.)

Use of dopamine in the ICU. Hope, hype, belief and facts. Girbes AR, et al. **Clin Exp Hypertens** 1997 Jan–Feb; 19(1–2):191–9 (20 ref.)

Chest radiography in the ICU. Henschke CI, et al. **Clin Imaging** 1997 Mar–Apr;21(2):90–103 (51 ref.)

Transcranial Doppler ultrasonography in the neurocritical care unit. Manno EM. **Crit Care Clin** 1997 Jan;13(1):79–104 (87 ref.)

Ethics in the intensive care unit. Creating an ethical environment. Nelson RM. **Crit Care Clin** 1997 Jul; 13(3):691–701 (28 ref.)

Common nutritional issues in pediatric and adult critical care medicine. Schears GJ, et al. **Crit Care Clin** 1997 Jul; 13(3):669–90 (195 ref.)

Acute renal failure in infants, children and adults. Stewart CL, et al. **Crit Care Clin** 1997 Jul;13(3):575–90 (122 ref.)

Analyzing intensive care unit length of stay data: problems and possible solutions. Weissman C. **Crit Care Med** 1997 Sep;25(9):1594–600 (46 ref.)

Chest imaging in the intensive care unit. Tocino I. **Eur J Radiol** 1996 Aug;23(1):46–57 (50 ref.)

The experiences of families with a relative in the intensive care unit. Jamerson PA, et al. **Heart Lung** 1996 Nov–Dec; 25(6):467–74 (36 ref.)

Nurses and physicians evaluate their intensive care experiences. Laubach W, et al. **Heart Lung** 1996 Nov–Dec; 25(6):475–82 (32 ref.)

Magnitude and prevention of nosocomial infections in the intensive care unit. Fridkin SK, et al. **Infect Dis Clin North Am** 1997 Jun;11(2):479–96 (59 ref.)

How to classify infections in intensive care units—the carrier state, a criterion whose time has come? van Saene HK, et al. **J Hosp Infect** 1996 May;33(1):1–12 (32 ref.)

Causes of edema in the intensive care unit. Koomans HA, et al. **Kidney Int Suppl** 1997 Jun;59:S105–10 (102 ref.)

A review of stress ulcer prophylaxis in the neurosurgical intensive care unit. Lu WY, et al. **Neurosurgery** 1997 Aug; 41(2):416–25; discussion 425–6 (150 ref.)

A model of the transmission of antibiotic-resistant bacteria in the intensive care unit. Barza M. **New Horiz** 1996 Aug; 4(3):333–7 (29 ref.)

Could invasive diagnostic techniques for ventilator-associated pneumonia be associated with reduced antibiotic usage in the ICU? Brun-Buisson C. **New Horiz** 1996 Aug;4(3):345–52 (58 ref.)

Resistance to antifungal agents in the critical care setting: problems and perspectives. Martins MD, et al. **New Horiz** 1996 Aug;4(3):338–44 (37 ref.)

Vancomycin-resistant Enterococcus faecium infections in the ICU and quinupristin/dalfopristin. Zervos M. **New Horiz** 1996 Aug;4(3):385–92 (38 ref.)

Muscle mass, survival, and the elderly ICU patient. Griffiths RD. **Nutrition** 1996 Jun;12(6):456–8 (28 ref.)

Neuromuscular transmission and its pharmacological blockade. Part 4: Use of relaxants in paediatric and elderly patients, in obstetrics, and in the intensive care unit. Booij LH. **Pharm World Sci** 1997 Feb;19(1):45–52 (11 ref.)

Pitfalls in the prediction of renal function in the intensive care unit. A review. Wells M, et al. **S Afr J Surg** 1997 Feb;35(1):16–9 (26 ref.)

Dysphagia in neurologic patients in the intensive care unit. Langmore SE. **Semin Neurol** 1996 Dec;16(4):329–40 (144 ref.)

[Hospital rehabilitation of patients with severe brain injuries. II: Prognosis and effect of early intensive, specialized rehabilitation] Jørgensen HS. **Ugeskr Laeger** 1997 Jun 23; 159(26):4093–8 (28 ref.) (Eng. Abstr.) **(Dan)**

[The simplest methods for controlling patient status in resuscitation and intensive therapy units] Zolotokrylina ES, et al. **Anesteziol Reanimatol** 1996 Sep–Oct;(5):81–6 (30 ref.) (Eng. Abstr.) **(Rus)**

[Fungal infection in patients admitted to the intensive care unit] León Gil C, et al. **Rev Clin Esp** 1997 Apr;197 Suppl 1:17–28 (86 ref.) **(Spa)**

ECONOMICS

Psychiatric intensive care in acute psychosis. Hyde CE, et

al. **Int Clin Psychopharmacol** 1996 May;11 Suppl 2:61–5 (31 ref.)
Economic implications of the timing of do–not–resuscitate orders for ICU patients. Bock KR, et al. **New Horiz** 1997 Feb;5(1):51–5 (29 ref.)
[Cost–analyses of intensive care units] Gyldmark M. **Ugeskr Laeger** 1996 Sep 30;158(40):5600–5 (23 ref.) (Eng. Abstr.) **(Dan)**

ORGANIZATION & ADMINISTRATION

High dependency units: role and need [editorial] Bodenham AR, et al. **Br J Hosp Med** 1996 Sep 4–17;56(5):192–3 (8 ref.)
Critical care in the United States. Who are we and how did we get here? Calvin JE, et al. **Crit Care Clin** 1997 Apr; 13(2):363–76 (36 ref.)
Does a full–time, 24–hour intensivist improve care and efficiency? Carlson RW, et al. **Crit Care Clin** 1996 Jul; 12(3):525–51 (63 ref.)
Intensive care in Australia and New Zealand. No nonsense "down under". Dobb GJ. **Crit Care Clin** 1997 Apr; 13(2):299–316 (18 ref.)
Critical care. A specialty without frontiers. Fisher MM. **Crit Care Clin** 1997 Apr;13(2):235–43 (16 ref.)
Critical care in Africa. North to south and the future with special reference to southern Africa. Lipman J, et al. **Crit Care Clin** 1997 Apr;13(2):255–65 (38 ref.)
Critical care in East Asia. Little dragons and sleeping giants. Mustafa I, et al. **Crit Care Clin** 1997 Apr;13(2):287–98 (17 ref.)
Critical care in Canada. The North American difference. Sibbald WJ, et al. **Crit Care Clin** 1997 Apr;13(2):347–62 (13 ref.)
Critical care in South America. The new tradition. Terzi RG, et al. **Crit Care Clin** 1997 Apr;13(2):377–87 (8 ref.)
Critical care in India. Udwadia FE, et al. **Crit Care Clin** 1997 Apr;13(2):317–29 (11 ref.)
Critical care in Europe. Vincent JL, et al. **Crit Care Clin** 1997 Apr;13(2):245–54 (14 ref.)
Critical care in Japan and Korea. The market of excellence. Yoshiya I, et al. **Crit Care Clin** 1997 Apr;13(2):267–85 (11 ref.)
Environments that support ethical practice. Rushton CH, et al. **New Horiz** 1997 Feb;5(1):20–9 (55 ref.)

STANDARDS

International perspectives on ethics in critical care. Nyman DJ, et al. **Crit Care Clin** 1997 Apr;13(2):409–15 (36 ref.)
Ethical allocation of ICU resources: a view from the USA. Osborne M, et al. **Intensive Care Med** 1996 Oct; 22(10):1010–4 (49 ref.)
Health professional decision–making in the ICU: a review of the evidence. Cook DJ. **New Horiz** 1997 Feb;5(1):15–9 (46 ref.)
Ethics of allocating intensive care unit resources. Lanken PN, et al. **New Horiz** 1997 Feb;5(1):38–50 (45 ref.)

STATISTICS & NUMERICAL DATA

Severity of illness scoring systems to adjust nosocomial infection rates: a review and commentary. Keita–Perse O, et al. **Am J Infect Control** 1996 Dec;24(6):429–34 (20 ref.)

TRENDS

Acute dialysis and continuous renal replacement: the emergence of new technology involving the nephrologist in the intensive care setting. Yagi N, et al. **Semin Nephrol** 1997 Jul;17(4):306–20 (126 ref.)

UTILIZATION

International comparisons of critical care outcome and resource consumption. Angus DC, et al. **Crit Care Clin** 1997 Apr;13(2):389–407 (85 ref.)
Prognoses of seriously ill hospitalized patients on the days before death: implications for patient care and public policy. Lynn J, et al. **New Horiz** 1997 Feb;5(1):56–61 (10 ref.)

INTENSIVE CARE UNITS, NEONATAL

Outbreaks of infection in neonatal intensive care units (NICU) [letter; comment] Damjanovic V, et al. **J Hosp Infect** 1997 Mar;35(3):237–44 (19 ref.) Comment on: J Hosp Infect 1996 Jun;33(2):145–51.

ORGANIZATION & ADMINISTRATION

Evolution of neonatal and pediatric critical care in India. Vidyasagar D, et al. **Crit Care Clin** 1997 Apr;13(2):331–46 (31 ref.)

INTENSIVE CARE UNITS, PEDIATRIC

Nutritional support of the pediatric intensive care unit patient. Cañete A, et al. **Curr Opin Pediatr** 1996 Jun; 8(3):248–55 (31 ref.)

STANDARDS

Ethical controversies in pediatric critical care. Burns JP, et al. **New Horiz** 1997 Feb;5(1):72–84 (65 ref.)

TRENDS

[Facts and fancy in intensive care. A good example: septic shock (editorial)] Devictor D. **Arch Pediatr** 1996 Sep; 3(9):841–4 (23 ref.) **(Fre)**

INTERAGENCY RELATIONS see **INTERINSTITUTIONAL RELATIONS**

INTERCALATED NEURONS see **INTERNEURONS**

INTERCALATING AGENTS

PHARMACOLOGY

DNA modifying agents as tools for studying chromatin structure. Millard JT. **Biochimie** 1996;78(10):803–16 (174 ref.)
[Sanguinarine and ellipticine cytotoxic alkaloids isolated from well–known antitumor plants. Intracellular targets of their action] Faddeeva MD, et al. **Tsitologiia** 1997; 39(2–3):181–208 (156 ref.) (Eng. Abstr.) **(Rus)**

INTERCELLULAR ADHESION MOLECULE–1

BIOSYNTHESIS

The significance of adhesion molecules in nephrology. Burkhardt K, et al. **Artif Organs** 1996 May;20(5):433–6 (27 ref.)
Vascular endothelial adhesion molecules and tissue inflammation. Malik AB, et al. **Pharmacol Rev** 1996 Jun; 48(2):213–29 (135 ref.)

IMMUNOLOGY

Molecular events in allergic inflammation: experimental models and possible modulation. Canonica GW, et al. **Allergy** 1997;52(34 Suppl):25–30 (46 ref.)
Intercellular adhesion molecule–1. van de Stolpe A, et al. **J Mol Med** 1996 Jan;74(1):13–33 (317 ref.)

METABOLISM

[CpG motif in DNA from immune complexes of SLE patients augments expression of intercellular adhesion molecule–1 on endothelial cells] Miyata M, et al. **Rinsho Byori** 1996 Dec;44(12):1125–31 (31 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

ICAM–1 as a potential target for treatments blocking the host response in stroke. Lindsherg PJ. **Keio J Med** 1996 Sep;45(3):254–61; discussion 261–2 (39 ref.)
Neutrophil emigration in the lungs. Doerschuk CM, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:141–5 (21 ref.)
[ICAM–1 and allergic inflammation] Canonica GW. **Allerg Immunol (Paris)** 1997 Mar;29(3):77–9; discussion 84 (17 ref.) (Eng. Abstr.) **(Fre)**
[The roles of adhesion molecules, cytokines, and chemokines in eosinophil activation during allergic inflammation] Chihara J. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec; 34 Suppl:116–20 (28 ref.) (Eng. Abstr.) **(Jpn)**
[Role of LFA–1/ICAM–1–dependent cell adhesion in CD40–mediated inhibition of anti–IgM antibody–induced B–cell death] Sumimoto S, et al. **Nippon Rinsho** 1996 Jul; 54(7):1779–83 (12 ref.) (Eng. Abstr.) **(Jpn)**
[The roles of adhesion molecules, cytokines and chemokines in relation to eosinophil activation in allergic inflammation] Chihara J. **Rinsho Byori** 1996 Dec;44(12):1147–51 (11 ref.) (Eng. Abstr.) **(Jpn)**

INTERCELLULAR ADHESION MOLECULES see **CELL ADHESION MOLECULES**

INTERCELLULAR JUNCTIONS

The cellular Internet: on–line with connexins. Bruzzone R, et al. **Bioessays** 1996 Sep;18(9):709–18 (75 ref.)
Carbohydrate recognition systems: functional triads in cell–cell interactions. Crocker PR, et al. **Curr Opin Struct Biol** 1996 Oct;6(5):679–91 (98 ref.)
Plant intercellular communication via plasmodesmata. McLean BG, et al. **Plant Cell** 1997 Jul;9(7):1043–54 (120 ref.)

CHEMISTRY

Functional studies of the protein 4.1 family of junctional proteins in Drosophila. Fehon RG, et al. **Soc Gen Physiol Ser** 1997;52:149–59 (38 ref.)

PHYSIOLOGY

Endothelial permeability for macromolecules. Mechanistic aspects of pathophysiological modulation. van Hinsbergh WM. **Arterioscler Thromb Vasc Biol** 1997 Jun;17(6):1018–23 (61 ref.)
Cell contact–dependent signaling. Fagotto F, et al. **Dev Biol** 1996 Dec 15;180(2):445–54 (89 ref.)
Junction genetics. Bryant PJ. **Dev Genet** 1997;20(2):75–90 (203 ref.)
Adhesive proteins at endothelial cell–to–cell junctions and leukocyte extravasation. Dejana E, et al. **Haemostasis** 1996 Oct;26 Suppl 4:210–9 (54 ref.)
The desmosome and the syndesmos: cell junctions in normal development and in malignancy. Franke WW, et al. **Princess Takamatsu Symp** 1994;24:14–27 (62 ref.)
Possible involvement of adherens junction plaque proteins in tumorigenesis and metastasis. Tsukita S, et al. **Princess Takamatsu Symp** 1994;24:38–50 (69 ref.)

INTERCELLULAR SPACE see **EXTRACELLULAR SPACE**

INTERCOSTAL MUSCLES

Traumatic transdiaphragmatic intercostal hernia secondary to coughing: case report and review of the literature. Rogers FB, et al. **J Trauma** 1996 Nov;41(5):902–3 (3 ref.)

INTERCRINES see **CHEMOKINES**

INTERDENTAL PAPILLA see **GINGIVA**

INTERDIGITATING CELLS see **DENDRITIC CELLS**

INTERDISCIPLINARY HEALTH TEAM see **PATIENT CARE TEAM**

INTERFACE, USER COMPUTER see **USER–COMPUTER INTERFACE**

INTERFASCICULAR OLIGODENDROGLIA see **OLIGODENDROGLIA**

INTERFEROMETRY

METHODS

Implantable hearing device performance measured by laser Doppler interferometry. Gan RZ, et al. **Ear Nose Throat J** 1997 May;76(5):297–9, 302, 305–9 (27 ref.)

INTERFEROMETRY, MICROSCOPIC see **MICROSCOPY, INTERFERENCE**

INTERFERON ALFA see **INTERFERON–ALPHA**

INTERFERON ALFA–2A

ADVERSE EFFECTS

Alpha–interferon induced severe pneumonitis [letter] Wolf Y, et al. **J Toxicol Clin Toxicol** 1997;35(1):113–4 (5 ref.)

THERAPEUTIC USE

We are very spoiled [editorial; comment] Fine SL, et al. **Arch Ophthalmol** 1997 Jul;115(7):915–6 (11 ref.) Comment on: Arch Ophthalmol 1997 Jul;115(7):865–72.
Interferon alfa–2a. Williams CD, et al. **Br J Hosp Med** 1997 May 7–20;57(9):436–9 (10 ref.)
Antibodies to interferon–alpha in treated cancer patients: incidence and significance. McKenna RM, et al. **J Interferon Cytokine Res** 1997 Mar;17(3):141–3 (25 ref.)
Interferon treatment of chronic hepatitis C with cirrhosis. Cooksley WG. **J Viral Hepat** 1997;4 Suppl 1:85–8 (15 ref.)

INTERFERON ALFA–2B

IMMUNOLOGY

The incidence and clinical significance of antibodies to interferon–a in patients with solid tumors. Oberg K, et al. **Biotherapy** 1997;10(1):1–5 (21 ref.)

PHARMACOLOGY

Induction of interleukin–1 and interleukin–1 receptor antagonist. Dinarello CA. **Semin Oncol** 1997 Jun;24(3 Suppl 9):S9–81–S9–93 (117 ref.)

THERAPEUTIC USE

Antibodies to interferon–alpha in treated cancer patients: incidence and significance. McKenna RM, et al. **J Interferon Cytokine Res** 1997 Mar;17(3):141–3 (25 ref.)
Interferon treatment of chronic hepatitis C with cirrhosis. Cooksley WG. **J Viral Hepat** 1997;4 Suppl 1:85–8 (15 ref.)
Cyclic interferon alpha treatment in metastatic renal cell carcinoma: results of a phase II study and review of the literature. Hofmockel G, et al. **Urol Int** 1997;58(1):8–12 (34 ref.)
[Melanoma: a new interferon is coming ... handle with care!] Négrier S. **Bull Cancer** 1997 Apr;84(4):435–7 (22 ref.) **(Fre)**
[The treatment of chronic hepatitis C with interferon in patients infected with the human immunodeficiency virus. The Spanish Group for the Study of Viral Hepatitis in HIV+ Patients] Soriano V, et al. **Med Clin (Barc)** 1996 Apr 6;106(13):486–90 (64 ref.) (Eng. Abstr.) **(Spa)**
[Treatment with interferon alfa–2b in patients with chronic hepatitis caused by hepatitis C virus: predictive factors for the response, relapse and early development to cirrhosis after treatment] Pérez Roldán F, et al.

Rev Esp Enferm Dig 1996 Sep;88(9):609–15 (23 ref.) (Eng. Abstr.) **(Spa)**

INTERFERON ALFA-2C see **INTERFERON ALFA, RECOMBINANT**

INTERFERON ALFA, RECOMBINANT

[Recombinant probiotics: problems and prospects of their use for medicine and veterinary practice] Sorokulova IB, et al. **Vestn Ross Akad Med Nauk** 1997;(3):46–9 (15 ref.) (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

Autoantibodies before, during and after administration of recombinant interferon-alpha for chronic viral hepatitis. Lopes EP, et al. **Rev Inst Med Trop Sao Paulo** 1995 Sep–Oct;37(5):455–60 (23 ref.)

ADVERSE EFFECTS

Interferon-alpha induces renal dysfunction and injury. Phillips TM. **Curr Opin Nephrol Hypertens** 1996 Jul; 5(4):380–3 (39 ref.)

CHEMISTRY

Three-dimensional models of interferon-alpha subtypes IFN-con1, IFN-alpha8, andIFN-alpha1 derived from the crystal structure of IFN-alpha2b. Walter MR. **Semin Oncol** 1997 Jun;24(3 Suppl 9):S9–52–S9–62 (33 ref.)

PHARMACOLOGY

Biologic activities of natural and synthetic type I interferons. Pfeffer LM. **Semin Oncol** 1997 Jun;24(3 Suppl 9):S9–63–S9–69 (44 ref.)

THERAPEUTIC USE

Interferon alfa in the treatment of chronic viral hepatitis B and C. Woo MH, et al. **Ann Pharmacother** 1997 Mar; 31(3):330–7 (59 ref.)

Interferon therapy for chronic hepatitis C. Davis GL. **Baillieres Clin Gastroenterol** 1996 Jul;10(2):289–98 (78 ref.)

Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group. Keeffe EB, et al. **Hepatology** 1997 Sep;26(3 Suppl 1):101S–107S (28 ref.)

Interferon-alpha for viral hepatitis. Jonas MM. **J Pediatr Gastroenterol Nutr** 1996 Aug;23(2):93–106 (149 ref.)

Interferon treatment in polycythaemia vera. Reilly JT, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:143–8 (64 ref.)

Treatment of HCV liver disease by recombinant interferon alpha. Bailly F, et al. **Nephrol Dial Transplant** 1996;11 Suppl 4:56–7 (11 ref.)

Interferon-alpha in childhood haematological malignancies. Simkó R, et al. **Postgrad Med J** 1996 Dec;72(854):709–13 (58 ref.)

Adjuvant application of interferons. el Kassas H, et al. **Semin Oncol** 1996 Dec;23(6):737–43 (35 ref.)

Increasing effectiveness of interferon-alpha for malignancies. Lindner DJ, et al. **Semin Oncol** 1997 Jun;24(3 Suppl 9):S9–99–S9–104 (26 ref.)

[Prevention and treatment of hepatitis C] Poupon R, et al. **Bull Acad Natl Med** 1996 Jun–Jul;180(6):1279–89; discussion 1289–92 (45 ref.) (Eng. Abstr.) **(Fre)**

[Diagnosis and therapy of chronic viral hepatitis] Heintges T, et al. **Z Gastroenterol** 1996 Jul;34(7):446–56 (127 ref.) (Eng. Abstr.) **(Ger)**

[The successful use of recombinant alfa-2 interferon in HBV-associated glomerulonephritis in a child] Fedorchenko SV, et al. **Ter Arkh** 1996;68(2):69–70 (9 ref.) **(Rus)**

INTERFERON-ALPHA

ADMINISTRATION & DOSAGE

Natural human interferon alpha may act differently when given parenterally or orally to patients chronically infected with hepatitis B virus. Georgiades JA. **Arch Immunol Ther Exp (Warsz)** 1996;44(1):11–22 (47 ref.)

Cutaneous ulcerations resulting from intramuscular injections of interferon alfa [letter; comment] Konohana A, et al. **J Am Acad Dermatol** 1996 Nov;35(5 Pt 1):788–9 (9 ref.) Comment on: J Am Acad Dermatol 1995 Sep;33(3):393–410; quiz 410–2.

Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. Legha SS. **Semin Oncol** 1997 Feb;24(1 Suppl 4):S39–43 (25 ref.)

[How should hepatitis C be treated? Treatment of hepatitis C with interferon] Marcellin P. **Gastroenterol Clin Biol** 1997;21(1 Pt 2):S81–8 (44 ref.) **(Fre)**

[Therapy of hepatitis C] Alscher DM, et al. **Med Klin** 1997 Mar 15;92(3):147–61 (127 ref.) (Eng. Abstr.) **(Ger)**

[Recent progress in therapy for chronic myelogenous leukemia] Urabe A. **Gan To Kagaku Ryoho** 1997 Jul; 24(9):1066–73 (30 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Development of arthritis and hypothyroidism during alpha-interferon therapy for chronic hepatitis C. Pittau E, et al. **Clin Exp Rheumatol** 1997 Jul–Aug;15(4):415–9 (25 ref.)

Interferon-alpha induces renal dysfunction and injury. Phillips TM. **Curr Opin Nephrol Hypertens** 1996 Jul; 5(4):380–3 (39 ref.)

Side effects of alpha interferon in chronic hepatitis C. Dusheiko G. **Hepatology** 1997 Sep;26(3 Suppl 1):112S–121S (112 ref.)

Interferon alfa-associated retinopathy. Chambers RB, et al. **J Am Osteopath Assoc** 1997 Jan;97(1):43–5 (12 ref.)

Second malignancy in hairy cell leukaemia: no evidence of increased incidence after treatment with interferon alpha. Pawson R, et al. **Leuk Lymphoma** 1996 Jun;22(1–2):103–6 (13 ref.)

Acute renal failure and nephrotic syndrome with alpha interferon therapy. Dimitrov Y, et al. **Nephrol Dial Transplant** 1997 Jan;12(1):200–3 (23 ref.)

[Psoriasis induced by interferon-alpha. Apropos of a case (letter)] Nguyen C, et al. **Ann Med Interne (Paris)** 1996; 147(7):519–21 (15 ref.) **(Fre)**

[How should hepatitis C be monitored? Monitoring of treated hepatitis C] Larrey D. **Gastroenterol Clin Biol** 1997;21(1 Pt 2):S99–110 (124 ref.) **(Fre)**

[A case of myasthenia gravis which developed myasthenic crisis after alpha-interferon therapy for chronic hepatitis C] Konishi T. **Rinsho Shinkeigaku** 1996 Aug;36(8):980–5 (14 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Interferons alpha/beta and their receptors: place in the hierarchy of cytokines. Zav'Yalov VP, et al. **APMIS** 1997 Mar;105(3):161–86 (220 ref.)

IMMUNOLOGY

Antibodies to interferon in patients undergoing IFN therapy: an update. Antonelli G. **J Biol Regul Homeost Agents** 1995 Oct–Dec;9(4):123–31 (84 ref.)

Natural autoantibodies to interferons. Meager A. **J Interferon Cytokine Res** 1997 Jul;17 Suppl 1:S51–3 (26 ref.)

ISOLATION & PURIFICATION

The human interferon-alpha species and hybrid proteins. Pestka S. **Semin Oncol** 1997 Jun;24(3 Suppl 9):S9–4–S9–17 (106 ref.)

PHARMACOLOGY

New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Tilg H. **Gastroenterology** 1997 Mar;112(3):1017–21 (24 ref.)

Interferon-alpha, Bcl-2 expression and apoptosis in B-cell chronic lymphocytic leukemia. Jewell AP. **Leuk Lymphoma** 1996 Mar;21(1–2):43–7 (48 ref.)

Influence of interferon-alpha on cytokine expression by the bone marrow microenvironment--impact on treatment of myeloproliferative disorders. Peschel C, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:129–34 (77 ref.)

Effect of alpha-interferons on immune function. Herberman RB. **Semin Oncol** 1997 Jun;24(3 Suppl 9):S9–78–S9–80 (11 ref.)

Biologic activities of natural and synthetic type I interferons. Pfeffer LM. **Semin Oncol** 1997 Jun;24(3 Suppl 9):S9–63–S9–69 (44 ref.)

PHYSIOLOGY

Regulatory cytokines in inflammatory bowel disease. Pallone F, et al. **Aliment Pharmacol Ther** 1996;10 Suppl 2:75–9; discussion 80 (41 ref.)

Interferons alpha/beta and their receptors: place in the hierarchy of cytokines. Zav'Yalov VP, et al. **APMIS** 1997 Mar;105(3):161–86 (220 ref.)

THERAPEUTIC USE

Progressive multifocal leukoencephalopathy: clinical and MR response to treatment. Garrels K, et al. **AJNR Am J Neuroradiol** 1996 Mar;17(3):597–600 (18 ref.)

Interferon therapy for chronic hepatitis C. Davis GL. **Baillieres Clin Gastroenterol** 1996 Jul;10(2):289–98 (78 ref.)

New drugs in essential thrombocythemia and polycythemia vera. Tefferi A, et al. **Blood Rev** 1997 Mar;11(1):1–7 (87 ref.)

Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Bukowski RM. **Cancer** 1997 Oct 1;80(7):1198–220 (222 ref.)

Hepatitis C virus infection: clinical aspects and treatment with interferon alfa. Jonas MM. **Clin Ther** 1996;18 Suppl B:110–25 (127 ref.)

Thymus-derived peptides in the treatment of viral chronic hepatitis [see comments] Naylor PH, et al. **Dig Dis** 1996 Nov–Dec;14(6):362–70 (41 ref.) Comment in: Dig Dis 1996 Nov–Dec;14(6):331–3.

Cytokine therapy for hematological malignancies. Ezaki K, et al. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:182–94 (50 ref.)

Therapy of hepatitis C: re-treatment with alpha interferon. Alberti A, et al. **Hepatology** 1997 Sep;26(3 Suppl 1):137S–142S (26 ref.)

Therapy of hepatitis C: interferon alfa-n1 trials. Farrell GC. **Hepatology** 1997 Sep;26(3 Suppl 1):96S–100S (24 ref.)

Therapy of hepatitis C: alpha interferon and ribavirin. Reichard O, et al. **Hepatology** 1997 Sep;26(3 Suppl 1):108S–111S (29 ref.)

Treatment of "problematic" hepatitis C patients. Colombo M. **Ital J Gastroenterol** 1996 Sep;28(7):393–5 (24 ref.)

Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients. Bazarbachi A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S186–90 (16 ref.)

Antibodies to interferon in patients undergoing IFN therapy: an update. Antonelli G. **J Biol Regul Homeost Agents** 1995 Oct–Dec;9(4):123–31 (84 ref.)

Current strategies for the treatment of CLL. Montserrat E, et al. **Leuk Lymphoma** 1996 Oct;22 Suppl 2:65–8 (17 ref.)

Practical guidelines for the management of chronic myelogenous leukemia with interferon alpha. O'Brien S, et al. **Leuk Lymphoma** 1996 Oct;23(3–4):247–52 (24 ref.)

Interferon-alpha and its effects on the cytokine cascade: a pro- and anti-inflammatory cytokine. Tilg H, et al. **Leuk Lymphoma** 1996 Sep;23(1–2):55–60 (73 ref.)

The treatment of chronic viral hepatitis. Hoofnagle JH, et al. **N Engl J Med** 1997 Jan 30;336(5):347–56 (106 ref.)

The role of adoptive immunotherapy in solid cancers. Kruit WH, et al. **Neth J Med** 1997 Feb;50(2):47–68 (270 ref.)

The role of interferon alfa in the treatment of metastatic melanoma. Legha SS. **Semin Oncol** 1997 Feb;24(1 Suppl 4):S24–31 (35 ref.)

[Factors of response to treatment with interferon-alpha in patients with chronic hepatitis C. Therapeutic perspectives] Marcellin P, et al. **Gastroenterol Clin Biol** 1995 Dec; 19(12):991–1000 (86 ref.) **(Fre)**

[Should hepatitis C be treated? Which biological tests are useful before deciding or refuting a treatment with interferon-alpha in patients with chronic hepatitis C?] Pawlotsky JM. **Gastroenterol Clin Biol** 1997;21(1 Pt 2):S41–50 (85 ref.) **(Fre)**

[Monitoring of treated or non-treated chronic viral hepatitis C. 2: Criteria of efficacy and monitoring of treatment with interferon-alpha] Payen JL. **Gastroenterol Clin Biol** 1997; 21(1 Pt 2):S175–89 (276 ref.) **(Fre)**

[Results of treatment of hepatitis C with interferon alone or combined with other drugs] Serfaty L. **Gastroenterol Clin Biol** 1997;21(1 Pt 2):S154–66 (136 ref.) **(Fre)**

[Pathogenesis and alpha-2 interferon treatment of chronic hepatitis B] Pirotte J. **Rev Med Liege** 1996 Aug; 51(8):514–21 (38 ref.) **(Fre)**

[Interferon-alpha in chronic myeloid leukemia] Hehlmann R. **Fortschr Med** 1997 Mar 30;115(9):30–4, 37–8 (20 ref.) (Eng. Abstr.) **(Ger)**

[Use of ursodeoxycholic acid in treatment of chronic hepatitis C] Warunek W, et al. **Folia Med Cracov** 1996; 37(1–2):97–100 (17 ref.) (Eng. Abstr.) **(Pol)**

[Alpha-interferon in present-day treatment of myeloma] Demina EA, et al. **Gematol Transfuziol** 1996 Mar–Apr; 41(2):32–6 (70 ref.) **(Rus)**

[Treatment of multiple sclerosis with interferons] Nogales-Gaete J, et al. **Rev Med Chil** 1996 May; 124(5):597–604 (38 ref.) (Eng. Abstr.) **(Spa)**

INTERFERON-BETA

ADMINISTRATION & DOSAGE

[Interferon-beta 1a in therapy of relapsing-remitting multiple sclerosis] Hartung HP, et al. **Nervenarzt** 1997 Jun; 68(6):525–7 (13 ref.) **(Ger)**

CHEMISTRY

Interferons alpha/beta and their receptors: place in the hierarchy of cytokines. Zav'Yalov VP, et al. **APMIS** 1997 Mar;105(3):161–86 (220 ref.)

Interferon- beta-1b (Betaseron): A model for hydrophobic therapeutic proteins. Lin LS, et al. **Pharm Biotechnol** 1996; 9:275–301 (62 ref.)

GENETICS

[Development of an anti-HIV gene therapy based on the antiviral properties of beta interferon] De Maeyer E, et al. **Transfus Clin Biol** 1997;4(3):281–6 (13 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Interferons alpha/beta and their receptors: place in the hierarchy of cytokines. Zav'Yalov VP, et al. **APMIS** 1997 Mar;105(3):161–86 (220 ref.)

Interleukin-1beta-mediated beta-cell inhibition in vivo. Bach LW. **Dan Med Bull** 1996 Feb;43(1):39–57 (282 ref.)

THERAPEUTIC USE

Interferon beta: the current position. Boothman BR. **Br J Hosp Med** 1997 Mar 19–Apr 1;57(6):277–80 (10 ref.)

Interferon beta in multiple sclerosis. Arnason BG. **Clin Immunol Immunopathol** 1996 Oct;81(1):1–11 (101 ref.)

Newer versus older treatments for relapsing-remitting multiple sclerosis. Weinstock-Guttman B, et al. **Drug Saf** 1996 Feb;14(2):121–30 (22 ref.)

Interferon beta-1B--hope or hype? **Drug Ther Bull** 1996 Feb; 34(2):9–11 (17 ref.)

INTERFERON-BETA

Italian Neurological Society Consensus Conference. New therapies in multiple sclerosis: beta-interferon. **Ital J Neurol Sci** 1996 Apr;17(2):175–8 (0 ref.)
Therapeutic advances: beta-interferon for multiple sclerosis. Clark W. **J Clin Pharm Ther** 1996 Aug;21(4):195–9 (27 ref.)
Role of interferons in demyelinating diseases. Arnason BG, et al. **J Neural Transm Suppl** 1997;49:117–23 (23 ref.)
Role of interferons in demyelinating disease. Johnson KP. **J Neural Transm Suppl** 1997;49:111–5 (13 ref.)
Alternative therapies for children with brain stem gliomas: immunotherapy and gene therapy. Packer RJ. **Pediatr Neurosurg** 1996;24(4):217–22 (21 ref.)
Interferon- beta-1b (Betaseron): A model for hydrophobic therapeutic proteins. Lin LS, et al. **Pharm Biotechnol** 1996; 9:275–301 (62 ref.)
Mechanisms of action of interferon-beta in multiple sclerosis. Arnason BG, et al. **Springer Semin Immunopathol** 1996; 18(1):125–48 (163 ref.)
Beta-interferon and multiple sclerosis. Hall GL, et al. **Trends Neurosci** 1997 Feb;20(2):63–7 (66 ref.)
[Interferon-beta-1b treatment of disseminated sclerosis] Sørensen S. **Ugeskr Laeger** 1997 Feb 3;159(6):779–84 (30 ref.) **(Dan)**
[Clinical testing of the treatment effect of interferon-beta Ia and Ib in multiple sclerosis] de Haan RJ, et al. **Ned Tijdschr Geneeskd** 1996 Nov 2;140(44):2168–71 (24 ref.) **(Dut)**
[Treatment of multiple sclerosis with interferons] Nogales-Gaete J, et al. **Rev Med Chil** 1996 May; 124(5):597–604 (38 ref.) (Eng. Abstr.) **(Spa)**

INTERFERON, FIBROBLAST see **INTERFERON-BETA**

INTERFERON-GAMMA see **INTERFERON TYPE II**

INTERFERON GAMMA-1B see **INTERFERON-GAMMA, RECOMBINANT**

INTERFERON GAMMA-2A see **INTERFERON-GAMMA, RECOMBINANT**

INTERFERON-GAMMA, RECOMBINANT

GENETICS

Islet regeneration in IFNgamma transgenic mice. Jones EM, et al. **Horm Metab Res** 1997 Jun;29(6):308–10 (32 ref.)

INTERFERON, IMMUNE see **INTERFERON TYPE II**

INTERFERON INDUCERS

see related
ANTINEOPLASTIC AGENTS
ANTIVIRAL AGENTS

INTERFERON, LEUKOCYTE see **INTERFERON-ALPHA**

INTERFERON, LYMPHOBLAST see **INTERFERON-ALPHA**

INTERFERON RECEPTORS see **RECEPTORS, INTERFERON**

INTERFERON TYPE I

CHEMISTRY

Structure-activity of type I interferons. Viscomi GC. **Biotherapy** 1997;10(1):59–86 (126 ref.)
Elucidation of the basic three-dimensional structure of type I interferons and its functional and evolutionary implications. Mitsui Y, et al. **J Interferon Cytokine Res** 1997 Jun;17(6):319–26 (40 ref.)

GENETICS

Type I interferon genes and proteins. Díaz MO, et al. **Biotherapy** 1996;8(3–4):157–62 (31 ref.)

IMMUNOLOGY

Placental interferons. Bazer FW, et al. **Am J Reprod Immunol** 1996 Apr;35(4):297–308 (109 ref.)
Viral immunity: interferons jog old T-cell memories. Gray D. **Curr Biol** 1996 Oct 1;6(10):1254–5 (9 ref.)
Natural autoantibodies to interferons. Meager A. **J Interferon Cytokine Res** 1997 Jul;17 Suppl 1:S51–3 (26 ref.)

METABOLISM

Type I interferon genes and proteins. Díaz MO, et al. **Biotherapy** 1996;8(3–4):157–62 (31 ref.)

PHARMACOLOGY

The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. Blatt LM, et al. **J Interferon Cytokine Res** 1996 Jul;16(7):489–99 (64 ref.)

PHYSIOLOGY

Interferon tau: a novel pregnancy recognition signal. Bazer FW, et al. **Am J Reprod Immunol** 1997 Jun;37(6):412–20 (53 ref.)
The neglected role of type I interferon in the T-cell response: implications for its clinical use. Belardelli F, et al. **Immunol Today** 1996 Aug;17(8):369–72 (50 ref.)
tau-Interferon: pregnancy recognition signal in ruminants. Spencer TE, et al. **Proc Soc Exp Biol Med** 1996 Dec; 213(3):215–29 (110 ref.)
New and atypical families of type I interferons in mammals: comparative functions, structures, and evolutionary relationships. Roberts RM, et al. **Prog Nucleic Acid Res Mol Biol** 1997;56:287–325 (164 ref.)
Recent developments and potentialities for reducing embryo mortality in ruminants: the role of IFN-tau and other cytokines in early pregnancy. Martal J, et al. **Reprod Fertil Dev** 1997;9(3):355–80 (250 ref.)
The role of type I interferons in the differentiation and function of Th1 and Th2 cells. de Waal Malefyt R. **Semin Oncol** 1997 Jun;24(3 Suppl 9):S9–94–S9–98 (55 ref.)

THERAPEUTIC USE

The neglected role of type I interferon in the T-cell response: implications for its clinical use. Belardelli F, et al. **Immunol Today** 1996 Aug;17(8):369–72 (50 ref.)

INTERFERON TYPE I, RECOMBINANT see **INTERFERON ALFA, RECOMBINANT**

INTERFERON TYPE II

ADMINISTRATION & DOSAGE

Successful treatment of cutaneous leishmaniasis using systemic interferon-gamma. Kolde G, et al. **Dermatology** 1996;192(1):56–60 (17 ref.)
Isolated limb perfusion for malignant melanoma. Alexander HR Jr, et al. **Semin Surg Oncol** 1996 Nov-Dec;12(6):416–28 (85 ref.)

ANALYSIS

The 1996 Moyer Award. Effects of endotoxin on the Th1/Th2 response in humans. Zimmer S, et al. **J Burn Care Rehabil** 1996 Nov-Dec;17(6 Pt 1):491–6 (39 ref.)

BIOSYNTHESIS

Synthesis of type 1 (IFN gamma) and type 2 (IL-4, IL-5, and IL-10) cytokines by human eosinophils. Lamkhioued B, et al. **Ann N Y Acad Sci** 1996 Oct 31;796:203–8 (22 ref.)
Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation. Strober W, et al. **Immunol Today** 1997 Feb;18(2):61–4 (11 ref.)

GENETICS

Regulation of interferon-gamma gene expression. Young HA. **J Interferon Cytokine Res** 1996 Aug;16(8):563–8 (26 ref.)
Molecular regulation of cytokine gene expression: interferon-gamma as a model system. Young HA, et al. **Prog Nucleic Acid Res Mol Biol** 1997;56:109–27 (82 ref.)

IMMUNOLOGY

Allergen dose dependent cytokine production regulates specific IgE and IgG antibody production. Blaser K. **Adv Exp Med Biol** 1996;409:295–303 (16 ref.)
Natural antibodies to interferon-gamma. Caruso A, et al. **Biotherapy** 1997;10(1):29–37 (21 ref.)
Potential therapeutic use of antibodies directed towards HuIFN-gamma. Froyen G, et al. **Biotherapy** 1997; 10(1):49–57 (102 ref.)
Lymphocytes, cytokines, inflammation, and immune trafficking. Tsokos GC. **Curr Opin Rheumatol** 1996 Sep; 8(5):395–402 (74 ref.)
Interferon-gamma in autoimmunity. Billiau A. **Cytokine Growth Factor Rev** 1996 Jun;7(1):25–34 (106 ref.)
Current and future clinical applications of interferon-gamma in host antimicrobial defense. Murray HW. **Intensive Care Med** 1996 Oct;22 Suppl 4:S456–61 (21 ref.)

METABOLISM

TH1/TH2 cytokine profile in celiac disease. Karban A, et al. **Isr J Med Sci** 1997 Mar;33(3):209–14 (49 ref.)

PHARMACOLOGY

Proposed role of a gamma-interferon inducible proteasome-regulator in antigen presentation. Realini CA, et al. **Adv Exp Med Biol** 1996;389:51–61 (40 ref.)
GAS elements: a few nucleotides with a major impact on cytokine-induced gene expression. Decker T, et al. **J Interferon Cytokine Res** 1997 Mar;17(3):121–34 (166 ref.)

PHYSIOLOGY

Interferon-gamma: biology and role in pathogenesis. Billiau A. **Adv Immunol** 1996;62:61–130 (374 ref.)
Regulatory cytokines in inflammatory bowel disease. Pallone F, et al. **Aliment Pharmacol Ther** 1996;10 Suppl 2:75–9; discussion 80 (41 ref.)
Cellular and molecular mechanisms underlying IL-12-induced tumor regression. Fujiwara H, et al. **Ann N Y Acad Sci** 1996 Oct 31;795:294–309 (47 ref.)
Cellular responses to interferon-gamma. Boehm U, et al. **Annu Rev Immunol** 1997;15:749–95 (282 ref.)
Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation. Strober W, et al. **Immunol Today** 1997 Feb;18(2):61–4 (11 ref.)
Interferon-gamma as a regulator of squamous differentiation. Saunders N, et al. **J Dermatol Sci** 1996 Nov;13(2):98–106 (23 ref.)
Role of interferons in demyelinating diseases. Arnason BG, et al. **J Neural Transm Suppl** 1997;49:117–23 (23 ref.)
Does human toxoplasmosis involve an imbalance in T1/T2 cytokines? Gómez Marín JE, et al. **Med Hypotheses** 1997 Feb;48(2):161–9 (72 ref.)
The effects of interferon-gamma on the central nervous system. Popko B, et al. **Mol Neurobiol** 1997 Feb-Apr; 14(1-2):19–35 (135 ref.)
[Commemorative lecture of receiving Imamura Memorial Prize. Analysis of cellular immunity against tuberculosis in man with special reference to tuberculous pleurisy and cytokines] Shimokata K. **Kekkaku** 1996 Oct;71(10):591–6 (7 ref.) (Eng. Abstr.) **(Jpn)**
[The role of interferon-gamma and interleukin-4 in the pathogenesis of atopic diseases] Boznański A. **Pol Merkuriusz Lek** 1996 Jul;1(1):63–5 (39 ref.) (Eng. Abstr.) **(Pol)**

SECRETION

Modulation of T-cell cytokine secretion by accessory cell-derived products. Hilkens CM, et al. **Eur Respir J Suppl** 1996 Aug;22:90s–94s (33 ref.)

THERAPEUTIC USE

The role of nebulized IFN-gamma in the modulation of allergic responses. Lack G, et al. **Adv Exp Med Biol** 1996; 409:17–23 (15 ref.)
Recombinant cytokine treatment for scleroderma. Can the antifibrotic potential of interferon-gamma be realized clinically? [editorial; comment] Varga J. **Arch Dermatol** 1997 May;133(5):637–42 (42 ref.) Comment on: Arch Dermatol 1997 May;133(5):609–13.
Current and future clinical applications of interferon-gamma in host antimicrobial defense. Murray HW. **Intensive Care Med** 1996 Oct;22 Suppl 4:S456–61 (21 ref.)
Gamma interferon in the treatment of Kala-azar and other forms of Leishmaniasis. Sundar S, et al. **J Assoc Physicians India** 1995 May;43(5):348–50 (31 ref.)
[Treatment of multiple sclerosis with interferons] Nogales-Gaete J, et al. **Rev Med Chil** 1996 May; 124(5):597–604 (38 ref.) (Eng. Abstr.) **(Spa)**

INTERFERON TYPE II, RECOMBINANT see **INTERFERON-GAMMA, RECOMBINANT**

INTERFERONS

see related
RECEPTORS, INTERFERON

Biology and therapeutic uses of myeloid hematopoietic growth factors and interferons [see comments] Lau AS, et al. **Pediatr Infect Dis J** 1996 Jul;15(7):563–75 (96 ref.) Comment in: Pediatr Infect Dis J 1997 Feb;16(2):260.
[Interferon] Tanaka H. **Gan To Kagaku Ryoho** 1997 Sep; 24(11):1471–6 (51 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Oral application of cytokines. Georgiades JA, et al. **Biotherapy** 1996;8(3–4):205–12 (44 ref.)

ADVERSE EFFECTS

Interferon-induced vitiligo in a patient with chronic viral hepatitis C infection. Simsek H, et al. **Dermatology** 1996; 193(1):65–6 (11 ref.)
Drug-induced rheumatic disorders. Bannwarth B. **Rev Rhum Engl Ed** 1996 Nov;63(10):639–47 (125 ref.)
[Interferon therapy and autoimmunity] Fritzsch J, et al. **Med Klin** 1997 May 15;92(5):265–72 (102 ref.) (Eng. Abstr.) **(Ger)**

BIOSYNTHESIS

Induction of interferons-induced genes. Samuel CE, et al. **Biotherapy** 1996;8(3-4):183–7 (30 ref.)

GENETICS

Induction of interferons-induced genes. Samuel CE, et al. **Biotherapy** 1996;8(3-4):183–7 (30 ref.)

IMMUNOLOGY

Interferon antibodies in patients with infectious diseases. Anti-interferon antibodies. Antonelli G, et al. **Biotherapy** 1997;10(1):7–14 (50 ref.)
The expression of potency of neutralizing antibodies for interferons and other cytokines. Grossberg SE, et al. **Biotherapy** 1997;10(1):93–8 (18 ref.)
In vivo development of antibody to interferons: an update to 1996. Antonelli G. **J Interferon Cytokine Res** 1997 Jul;

17 Suppl 1:S39–46 (74 ref.)

METABOLISM

Virus proteins that bind cytokines, chemokines or interferons. Smith GL. **Curr Opin Immunol** 1996 Aug;8(4):467–71 (47 ref.)

Interacting pathways of interferon signaling. Williams BR, et al. **Semin Oncol** 1997 Jun;24(3 Suppl 9):S9-70–S9-77 (85 ref.)

PHARMACOKINETICS

[Design of topically resorptive interferon drugs] Shchekanova SM, et al. **Vestn Ross Akad Med Nauk** 1996; (9):30–3 (48 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Interferon and hormone sensitivity of endocrine-related tumors. Sica G, et al. **Anticancer Drugs** 1996 Feb; 7(2):150–60 (80 ref.)

Oral application of cytokines. Georgiades JA, et al. **Biotherapy** 1996;8(3–4):205–12 (44 ref.)

Interferons and the tumor cell. Strander H, et al. **Biotherapy** 1996;8(3–4):213–8 (54 ref.)

ISGF3 gamma p48, a specificity switch for interferon activated transcription factors. Bluyssen AR, et al. **Cytokine Growth Factor Rev** 1996 Jun;7(1):11–7 (54 ref.)

Wherefore interferon? Gresser I. **J Leukoc Biol** 1997 May; 61(5):567–74 (109 ref.)

Therapies for advanced colorectal cancer: the role of interferon and leucovorin. Macdonald JS. **Tumori** 1997 Jan–Feb;83(1 Suppl):S67–9 (21 ref.)

[Anti-fibrotic effects of interferons. Mechanisms of action and therapeutic prospects] Pilette C, et al. **Gastroenterol Clin Biol** 1997;21(6–7):466–71 (40 ref.) **(Fre)**

PHYSIOLOGY

IRF-1: the transcription factor linking the interferon response and oncogenesis. Taniguchi T, et al. **Biochim Biophys Acta** 1997 Aug 8;1333(1):M9–17 (58 ref.)

Biological effects of the interferons and other cytokines. Friedman RM, et al. **Biotherapy** 1996;8(3–4):189–98 (53 ref.)

Interferon signal transduction. Larner A, et al. **Biotherapy** 1996;8(3–4):175–81 (60 ref.)

Factors inhibiting IFN activity. Schellekens H, et al. **Biotherapy** 1996;8(3–4):199–204 (0 ref.)

IRF-1 and IRF-2 as regulators of the interferon system and cell growth. Taniguchi T. **Indian J Biochem Biophys** 1995 Oct;32(5):235–9 (33 ref.)

The PKR protein kinase--an interferon-inducible regulator of cell growth and differentiation. Samuel CE, et al. **Int J Hematol** 1997 Apr;65(3):227–37 (89 ref.)

Cytokine research: the interferon paradigm. Morris A, et al. **J Clin Pathol** 1997 Aug;50(8):635–9 (46 ref.)

Interferons and other cytokines in bacterial infections. Degré M. **J Interferon Cytokine Res** 1996 Jun;16(6):417–26 (43 ref.)

Reflections on the years in interferon research. Pitha PM. **J Interferon Cytokine Res** 1997 Apr;17(4):181–4 (27 ref.)

HIN-200: a novel family of IFN-inducible nuclear proteins expressed in leukocytes. Dawson MJ, et al. **J Leukoc Biol** 1996 Sep;60(3):310–6 (47 ref.)

Wherefore interferon? Gresser I. **J Leukoc Biol** 1997 May; 61(5):567–74 (109 ref.)

Analysis of cytokine profiles in patients with human papillomavirus-associated neoplasms [editorial; comment] Wu TC, et al. **J Natl Cancer Inst** 1997 Feb 5;89(3):185–7 (33 ref.) Comment on: J Natl Cancer Inst 1997 Feb 5;89(3):245–50.

Hypertrophic scars, keloids, and contractures. The cellular and molecular basis for therapy. Tredget EE, et al. **Surg Clin North Am** 1997 Jun;77(3):701–30 (160 ref.)

[The role of allosteric RNase L in interferon-induced defence system of the cell] Wierzbicki A. **Postepy Biochem** 1995; 41(4):257–66 (68 ref.) **(Pol)**

[Mechanisms of transcriptional regulation of interferon-induced genes: description in the IIG-TRRD information system] Anan'ko EA, et al. **Mol Biol (Mosk)** 1997 Jul–Aug;31(4):701–13 (98 ref.) **(Rus)**

THERAPEUTIC USE

Biological and monoclonal antibody therapy for high-grade gliomas. Hoang-Xuan K, et al. **Baillieres Clin Neurol** 1996 Jun;5(2):395–411 (98 ref.)

The role of interferon in the therapy of malignant lymphoma. McLaughlin P. **Biomed Pharmacother** 1996;50(3–4):140–8 (60 ref.)

Immunomodulation following chemotherapy. Obadina M, et al. **Breast Cancer Res Treat** 1996;38(1):41–8 (44 ref.)

The treatment of disseminated malignant melanoma with special reference to the role of interferons, vinca alkaloids and tamoxifen. Bezwoda WR. **Cancer Treat Rev** 1997 Jan; 23(1):17–34 (144 ref.)

Interferon and other therapies for hepatitis B and hepatitis C infections. Rothstein KD, et al. **Clin Lab Med** 1996 Jun; 16(2):465–91 (154 ref.)

Treatment of chronic hepatitis C. Nelson DR, et al. **Compr Ther** 1997 Apr;23(4):269–76 (29 ref.)

New treatments for multiple sclerosis: a clinical perspective. Thompson AJ, et al. **Curr Opin Neurol** 1996 Jun; 9(3):187–98 (82 ref.)

Interferons in melanoma. Agarwala SS, et al. **Curr Opin Oncol** 1996 Mar;8(2):167–74 (57 ref.)

A practical guide to the use of interferons in the management of hepatitis virus infections. Saracco G, et al. **Drugs** 1997 Jan;53(1):74–85 (74 ref.)

Retinoid-interferon therapy of solid tumors. Lippman SM, et al. **Int J Cancer** 1997 Feb 7;70(4):481–3 (27 ref.)

In vivo development of antibody to interferons: an update to 1996. Antonelli G. **J Interferon Cytokine Res** 1997 Jul; 17 Suppl 1:S39–46 (74 ref.)

Why do so many cancer patients fail to respond to interferon therapy? Einhorn S, et al. **J Interferon Cytokine Res** 1996 Apr;16(4):275–81 (83 ref.)

Interferons in precancer and cancer prevention: where are we? Tanneberger S, et al. **J Interferon Cytokine Res** 1996 May;16(5):339–46 (113 ref.)

Clinical relevance of hepatitis C virus quasispecies. Enomoto N, et al. **J Viral Hepat** 1995;2(6):267–72 (27 ref.)

Interferon treatment of cirrhotic patients with chronic hepatitis C. Idilman R, et al. **J Viral Hepat** 1997 Mar; 4(2):81–91 (75 ref.)

Treatment of chronic hepatitis C: another therapeutic option. Trepo C, et al. **Nephrol Dial Transplant** 1996;11 Suppl 4:62–4 (9 ref.)

Interferon in viral liver diseases: pharmacological aspects. da Silva LC, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1996 Sep–Oct;51(5):211–6 (33 ref.)

Biologic therapy of melanoma with cytokines and lymphocytes. Bear HD, et al. **Semin Surg Oncol** 1996 Nov–Dec;12(6):436–45 (63 ref.)

[Treatment of chronic viral hepatitis B and C] Stránský J. **Vnitr Lek** 1997 Jan;43(1):41–4 (12 ref.) **(Cze)**

[Treatment of carcinoid tumors of the digestive tract] Votte A, et al. **Gastroenterol Clin Biol** 1995 Dec;19(12):1031–42 (122 ref.) **(Fre)**

[Cellular growth factors in the treatment of bronchogenic cancers] Pujol JL, et al. **Rev Mal Respir** 1996;13(4):335–8 (17 ref.) **(Fre)**

[The therapy of hepatitis C in the failure of interferon] Hermann R, et al. **Dtsch Med Wochenschr** 1997 Aug 22; 122(34–35):1049–54 (55 ref.) **(Ger)**

[Causal therapy of multiple sclerosis] Pöhlau D, et al. **Dtsch Med Wochenschr** 1996 Nov 8;121(45):1407–14 (44 ref.) **(Ger)**

[Outcomes research in therapy of chronic hepatitis C] Niederau C, et al. **Internist (Berl)** 1996 Dec;37(12):1225–36 (40 ref.) **(Ger)**

[Interferon treatment for age-related macular degeneration] Loewenstein A, et al. **Harefuah** 1997 Feb 16;132(4):275–9 (44 ref.) **(Heb)**

[Optimal antiviral therapy of chronic hepatitis caused by hepatitis C virus] Cooreman MP, et al. **Orv Hetil** 1997 Jun 1;138(22 Suppl 1):1476–82 (51 ref.) (Eng. Abstr.) **(Hun)**

[Cryoglobulinemia in chronic liver diseases: cause or consequence?] Csepregi A, et al. **Orv Hetil** 1997 Mar 16; 138(11):651–6 (46 ref.) (Eng. Abstr.) **(Hun)**

[Clinical use of interferon] Lauta VM. **Clin Ter** 1996 Jul–Aug; 147(7–8):345–51 (25 ref.) (Eng. Abstr.) **(Ita)**

[Changes of serum GBV-C RNA levels under administration of interferon and cyclosporine for patients with GBV infected hepatitis] Fujikawa H, et al. **Nippon Rinsho** 1997 Mar;55(3):591–6 (26 ref.) (Eng. Abstr.) **(Jpn)**

[Interferons in the treatment of chronic viral hepatitides] Podymova SD, et al. **Ter Arkh** 1996;68(11):74–7 (52 ref.) **(Rus)**

[Interferons in multiple sclerosis] Tintoré M. **Rev Neurol** 1997 Feb;25(138):267–9 (7 ref.) **(Spa)**

INTERGENERATIONAL RELATIONS

Intergenerational equity: an exploration of the 'fair innings' argument. Williams A. **Health Econ** 1997 Mar–Apr; 6(2):117–32 (28 ref.)

Custodial grandparenting: new roles for middle-aged and older adults. Emick MA, et al. **Int J Aging Hum Dev** 1996; 43(2):135–54 (92 ref.)

Cultural aspects of ageing: gender and inter-generational issues. Jefferys M. **Soc Sci Med** 1996 Sep;43(5):681–7 (36 ref.)

"Things were different then": countertransference issues for younger female therapists working with older female clients. Levine L. **Soc Work Health Care** 1996;22(4):73–88 (20 ref.)

INTERINSTITUTIONAL RELATIONS

Collaborating across organizational boundaries to improve the quality of care. Plsek PE. **Am J Infect Control** 1997 Apr;25(2):85–95 (18 ref.)

Perspectives on the place of environmental health and protection in public health and public health agencies. Kotchian S. **Annu Rev Public Health** 1997;18:245–59 (36 ref.)

A research note about military-civilian humanitarianism: more questions than answers. Weiss TG. **Disasters** 1997 Jun;21(2):95–117 (116 ref.)

Tacit collusion among hospitals in price competitive markets. Mobley LR. **Health Econ** 1996 May–Jun;5(3):183–93 (43 ref.)

New federalism and intergovernmental fiscal relationships: the implications for health policy [see comments] Anton TJ. **J Health Polit Policy Law** 1997 Jun;22(3):691–720 (38 ref.) Comment in: J Health Polit Policy Law 1997 Jun;22(3):879–96. Comment in: J Health Polit Policy Law 1997 Jun;22(3):897–906.

Challenges and opportunities in establishing a Latino health research center in a majority academic institution. Giachello AL. **J Med Syst** 1996 Oct;20(5):351–76 (14 ref.)

Working with education reporters to advocate for comprehensive school health education. Sofalvi AJ, et al. **J Sch Health** 1997 May;67(5):185–6 (19 ref.)

Posttraumatic stress, mental health professionals, and the clergy: a need for collaboration, training, and research. Weaver AJ, et al. **J Trauma Stress** 1996 Oct;9(4):847–56 (54 ref.)

The public sector-private sector interface: current issues, future trends. Surles RC, et al. **New Dir Ment Health Serv** 1996 Winter;(72):71–9 (8 ref.)

Managed care and the public health challenge of TB. Halverson PK, et al. **Public Health Rep** 1997 Jan–Feb; 112(1):22–8 (14 ref.)

The changing roles of health care personnel in health and health care management. Hunter DJ. **Soc Sci Med** 1996 Sep;43(5):799–808 (31 ref.)

[Collaboration between non-governmental organizations and governments for health sector reform] Dickson K. **Rev Panam Salud Publica** 1997 Apr;1(4):324–9 (9 ref.) (Eng. Abstr.) **(Spa)**

INTERIOR DESIGN AND FURNISHINGS

STANDARDS

Making our offices universally accessible: guidelines for physicians [see comments] Jones KE, et al. **Can Med Assoc J** 1997 Mar 1;156(5):647–56 (64 ref.) Comment in: Can Med Assoc J 1997 Mar 1;156(5):657–9.

INTERIOR FURNISHINGS see **INTERIOR DESIGN AND FURNISHINGS**

INTERLEUKIN-1

see related
RECEPTORS, INTERLEUKIN-1

[Processing and release of interleukin-1] Watanabe N, et al. **Seikagaku** 1996 Oct;68(10):1638–41 (16 ref.) **(Jpn)**

BIOSYNTHESIS

Induction of interleukin-1 and glucocorticoid hormones by HIV promotes viral replication and links human chromosome 2 to AIDS pathogenesis: genetic mechanisms and therapeutic implications. Corley PA. **Med Hypotheses** 1997 May;48(5):415–21 (73 ref.)

Induction of interleukin-1 and interleukin-1 receptor antagonist. Dinarello CA. **Semin Oncol** 1997 Jun;24(3 Suppl 9):S9-81–S9-93 (117 ref.)

CHEMISTRY

The chemokine superfamily: crosstalk with the IL-1 system. Mantovani A, et al. **Immunobiology** 1996 Oct; 195(4–5):522–49 (163 ref.)

IMMUNOLOGY

The chemokine superfamily: crosstalk with the IL-1 system. Mantovani A, et al. **Immunobiology** 1996 Oct; 195(4–5):522–49 (163 ref.)

Immune cytokine regulation of sympathetic ganglion response to injury. Jonakait GM, et al. **Neuroimmunomodulation** 1995 Jul–Aug;2(4):236–40 (37 ref.)

METABOLISM

Morphine affects the brain-immune axis by modulating an interleukin-1 beta dependent pathway. Chang SL, et al. **Adv Exp Med Biol** 1996;402:35–42 (34 ref.)

Benzene-induced bone marrow cell depression caused by inhibition of the conversion of pre-interleukins-1alpha and -1beta to active cytokines by hydroquinone, a biological reactive metabolite of benzene. Niculescu R, et al. **Adv Exp Med Biol** 1996;387:329–37 (30 ref.)

Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease. Cominelli F, et al. **Aliment Pharmacol Ther** 1996;10 Suppl 2:49–53; discussion 54 (39 ref.)

TSG-6: an IL-1/TNF-inducible protein with anti-inflammatory activity. Wisniewski HG, et al. **Cytokine Growth Factor Rev** 1997 Jun;8(2):143–56 (135 ref.)

Dual expression of p80 type I and p68 type II interleukin-1 receptors on anterior pituitary cells synthesizing growth hormone. French RA, et al. **Endocrinology** 1996 Sep; 137(9):4027–36 (84 ref.)

The interleukin-1 receptor complex and interleukin-1 signal transduction. Martin MU, et al. **Eur Cytokine Netw** 1997 Mar;8(1):5–17 (65 ref.)

Interleukin-1 in renal fibrosis. Nikolic-Paterson DJ, et al. **Kidney Int Suppl** 1996 May;54:S88–90 (26 ref.)

Interleukin-1 receptor antagonism. Nikolic-Paterson DJ, et al. **Semin Nephrol** 1996 Nov;16(6):583–90 (38 ref.)

INTERLEUKIN-1

PHARMACOLOGY

Molecular mechanisms underlying the actions of the pro-inflammatory cytokine interleukin 1. Royal Irish Academy Medal Lecture. O'Neill LA. **Biochem Soc Trans** 1997 Feb;25(1):295–302 (50 ref.)

Upregulation of enzymatic activity by interleukin-1 in osteoarthritis. Chevalier X. **Biomed Pharmacother** 1997; 51(2):58–62 (34 ref.)

Interleukin-1, nitric oxide and reactive astrocytes. Lee SC, et al. **Brain Behav Immun** 1995 Dec;9(4):345–54 (48 ref.)

PHYSIOLOGY

IL1 beta impairs relational but not procedural rodent learning in a water maze task. Gibertini M. **Adv Exp Med Biol** 1996; 402:207–17 (53 ref.)

Immune modulators in the context of the ovulatory process: a role for interleukin-1. Adashi EY. **Am J Reprod Immunol** 1996 Mar;35(3):190–4 (49 ref.)

The interleukin-1 system and human implantation. Simón C, et al. **Am J Reprod Immunol** 1997 Jan;37(1):64–72 (51 ref.)

Review: cytokine involvement in ovarian processes. Terranova PF, et al. **Am J Reprod Immunol** 1997 Jan; 37(1):50–63 (121 ref.)

Heatstroke-induced cerebral ischemia and neuronal damage. Involvement of cytokines and monoamines. Lin MT. **Ann N Y Acad Sci** 1997 Mar 15;813:572–80 (54 ref.)

Molecular mechanisms underlying the actions of the pro-inflammatory cytokine interleukin 1. Royal Irish Academy Medal Lecture. O'Neill LA. **Biochem Soc Trans** 1997 Feb;25(1):295–302 (50 ref.)

Interleukin-1 and its inhibitors: implications for disease biology and therapy. Estrov Z, et al. **Cancer Treat Res** 1995;80:51–82 (279 ref.)

Factors affecting IL-1-mediated collagen metabolism by fibroblasts and the pathogenesis of periodontal disease: a review of the literature. Havemose-Poulsen A, et al. **Crit Rev Oral Biol Med** 1997;8(2):217–36 (206 ref.)

The role of interleukin-1 in the pathogenesis of IDDM. Mandrup-Poulsen T. **Diabetologia** 1996 Sep;39(9):1005–29 (316 ref.)

Negative regulators of the interleukin-1 system: receptor antagonists and a decoy receptor. Mantovani A, et al. **Int J Clin Lab Res** 1996;26(1):7–14 (78 ref.)

Interleukin-1 beta: a common cause of Alzheimer's disease and diabetes mellitus. Holden RJ, et al. **Med Hypotheses** 1995 Dec;45(6):559–71 (108 ref.)

Neuropathogenesis of HIV-1 infection: interactions between interleukin-1 and transforming growth factor-beta 1. Vitković L. **Mol Psychiatry** 1997 Mar;2(2):111–2 (16 ref.)

Brain–periphery connections: do they play a role in mediating the effect of centrally injected interleukin-1 beta on gonadal function? Turnbull A, et al. **Neuroimmunomodulation** 1995 Jul–Aug;2(4):224–35 (79 ref.)

[Production of IL-1 ra and its biological significance in experimental arthritis of rabbits] Matsukawa A, et al. **Nippon Seikeigeka Gakkai Zasshi** 1996 Nov;70(11):751–8 (11 ref.) **(Jpn)**

THERAPEUTIC USE

Monocyte deactivation--rationale for a new therapeutic strategy in sepsis. Volk HD, et al. **Intensive Care Med** 1996 Oct;22 Suppl 4:S474–81 (24 ref.)

Interleukin 1 trials in cancer patients: a review of the toxicity, antitumor and hematopoietic effects. Veltri S, et al. **Stem Cells** 1996 Mar;14(2):164–76 (58 ref.)

INTERLEUKIN-1 RECEPTORS see **RECEPTORS, INTERLEUKIN-1**

INTERLEUKIN-2

see related
RECEPTORS, INTERLEUKIN-2

ADMINISTRATION & DOSAGE

Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. Legha SS. **Semin Oncol** 1997 Feb;24(1 Suppl 4):S39–43 (25 ref.)

ADVERSE EFFECTS

Colosplenic fistula in a patient treated with interleukin-2 for malignant melanoma. Chun ES, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):674–6 (8 ref.)

BIOSYNTHESIS

The effect of age on the expression of interleukin-2. Pahlavani MA, et al. **Mech Ageing Dev** 1996 Aug 29; 89(3):125–54 (188 ref.)

BLOOD

High plasma interleukin-2: a potential cause of insulin resistance. Penttinen J. **Med Hypotheses** 1995 Dec; 45(6):614–6 (30 ref.)

DEFICIENCY

Interleukin-2 deficient mice: a new model to study autoimmunity and self-tolerance. Horak I, et al. **Immunol Rev** 1995 Dec;148:35–44 (29 ref.)

IMMUNOLOGY

Lessons from immunological, biochemical, and molecular pathways of the activation mediated by IL-2 and IL-4. Rebollo A, et al. **Adv Immunol** 1996;63:127–96 (646 ref.)

Natural antibodies to IL-2. Balsari A, et al. **Biotherapy** 1997; 10(1):25–8 (12 ref.)

Treatment-induced antibodies to interleukin-2. Prümmer O. **Biotherapy** 1997;10(1):15–24 (66 ref.)

Interleukin-2 deficient mice: a new model to study autoimmunity and self-tolerance. Horak I, et al. **Immunol Rev** 1995 Dec;148:35–44 (29 ref.)

Interleukin 2 and its receptors: recent advances and new immunological functions [see comments] Thèze J, et al. **Immunol Today** 1996 Oct;17(10):481–6 (39 ref.) Comment in: Immunol Today 1997 May;18(5):254.

The immune system in severe ovarian hyperstimulation syndrome. Orvieto R, et al. **Isr J Med Sci** 1996 Dec; 32(12):1180–2 (15 ref.)

METABOLISM

Cytokines: shared receptors, distinct functions. DiSanto JP. **Curr Biol** 1997 Jul 1;7(7):R424–6 (17 ref.)

PHARMACOLOGY

Lessons from immunological, biochemical, and molecular pathways of the activation mediated by IL-2 and IL-4. Rebollo A, et al. **Adv Immunol** 1996;63:127–96 (646 ref.)

Hormones and lupus: defective dehydroepiandrosterone activity induces impaired interleukin-2 activity of T lymphocytes in patients with systemic lupus erythematosus. Suzuki N, et al. **Ann Med Interne (Paris)** 1996;147(4):248–52 (37 ref.)

Application of differential display to isolate novel genes in interleukin-2-induced adult respiratory distress syndrome. Neville LF, et al. **Ann N Y Acad Sci** 1996 Oct 31;796:257–71 (52 ref.)

Cytokine-induced cytotoxic function expressed by lymphocytes of the innate immune system: distinguishing characteristics of NK and LAK based on functional and molecular markers. Frederick M, et al. **J Interferon Cytokine Res** 1997 Aug;17(8):435–47 (124 ref.)

PHYSIOLOGY

Signal transduction by interleukin-12 and interleukin-2. A comparison and contrast. Bacon CM, et al. **Ann N Y Acad Sci** 1996 Oct 31;795:41–59 (106 ref.)

Interleukin-2 as a neuroregulatory cytokine. Hanisch UK, et al. **Brain Res Brain Res Rev** 1995 Nov;21(3):246–84 (469 ref.)

Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency. Johnston JA, et al. **J Leukoc Biol** 1996 Oct;60(4):441–52 (153 ref.)

Promotion of interleukin-2 activity as a strategy for 'rejuvenating' geriatric immune function. McCarty MF. **Med Hypotheses** 1997 Jan;48(1):47–54 (120 ref.)

[Commemorative lecture of receiving Imamura Memorial Prize. Analysis of cellular immunity against tuberculosis in man with special reference to tuberculous pleurisy and cytokines] Shimokata K. **Kekkaku** 1996 Oct;71(10):591–6 (7 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Immunomodulation following chemotherapy. Obadina M, et al. **Breast Cancer Res Treat** 1996;38(1):41–8 (44 ref.)

Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Bukowski RM. **Cancer** 1997 Oct 1;80(7):1198–220 (222 ref.)

The role of immunotherapy in urologic malignancies. Abubakr YA, et al. **Cancer Treat Res** 1996;88:235–48 (86 ref.)

Interleukin-2: its rationale and role in the treatment of patients with cancer. Rubin JT. **Cancer Treat Res** 1995; 80:83–105 (188 ref.)

Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Nichols J, et al. **Eur J Cancer** 1997 Jan;33 Suppl 1:S34–6 (27 ref.)

Locoregional IL-2 immunotherapy of bladder cancer. Santoni A, et al. **Immunopharmacol Immunotoxicol** 1997 Feb;19(1):1–13 (31 ref.)

Role of interleukin-2 in human hematological malignancies. Toren A, et al. **Med Oncol** 1995 Sep;12(3):177–86 (94 ref.)

The role of adoptive immunotherapy in solid cancers. Kruit WH, et al. **Neth J Med** 1997 Feb;50(2):47–68 (270 ref.)

Treatment of malignant melanoma with interleukin-2. Philip PA, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 4):S32–8 (64 ref.)

Biologic therapy of melanoma with cytokines and lymphocytes. Bear HD, et al. **Semin Surg Oncol** 1996 Nov–Dec;12(6):436–45 (63 ref.)

[The role of interleukin-2--based immunotherapy in hematological malignancies] Ackerstein A, et al. **Harefuah** 1996 May 1;130(9):613–7 (45 ref.) **(Heb)**

INTERLEUKIN-2 RECEPTORS see **RECEPTORS, INTERLEUKIN-2**

INTERLEUKIN-3

see related
RECEPTORS, INTERLEUKIN-3

[Interleukine-3: a multifunctional cytokine] Arock M. **Ann Pharm Fr** 1996;54(4):162–76 (59 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Interleukin-3 and its receptor. Lindemann A, et al. **Cancer Treat Res** 1995;80:107–42 (283 ref.)

INTERLEUKIN-3 RECEPTORS see **RECEPTORS, INTERLEUKIN-3**

INTERLEUKIN-4

see related
HISTOCOMPATIBILITY ANTIGENS CLASS II

BIOSYNTHESIS

Synthesis of type 1 (IFN gamma) and type 2 (IL-4, IL-5, and IL-10) cytokines by human eosinophils. Lamkhioued B, et al. **Ann N Y Acad Sci** 1996 Oct 31;796:203–8 (22 ref.)

Dissociation of production of interleukin-4 and interleukin-5. Sewell WA, et al. **Immunol Cell Biol** 1996 Jun;74(3):274–7 (27 ref.)

The function of costimulatory molecules and the development of IL-4-producing T cells. Gause WC, et al. **Immunol Today** 1997 Mar;18(3):115–20 (47 ref.)

GENETICS

Genetics of atopy and asthma: promoter-based candidate gene studies for IL-4. Rosenwasser LJ. **Int Arch Allergy Immunol** 1997 May–Jul;113(1–3):61–4 (19 ref.)

IMMUNOLOGY

Allergen dose dependent cytokine production regulates specific IgE and IgG antibody production. Blaser K. **Adv Exp Med Biol** 1996;409:295–303 (16 ref.)

Role of interleukin-4 in the development of allergic airway inflammation and airway hyperresponsiveness. Wills-Karp M, et al. **Adv Exp Med Biol** 1996;409:343–7 (37 ref.)

Lessons from immunological, biochemical, and molecular pathways of the activation mediated by IL-2 and IL-4. Rebollo A, et al. **Adv Immunol** 1996;63:127–96 (646 ref.)

Source of IL-4 able to induce the development of TH2-like cells. Ricci M, et al. **Clin Exp Allergy** 1997 May; 27(5):488–500 (118 ref.)

Functions of IL-4 and control of its expression. Brown MA, et al. **Crit Rev Immunol** 1997;17(1):1–32 (257 ref.)

Role of IL-4 in persistent IgE formation. Savelkoul HF, et al. **Eur Respir J Suppl** 1996 Aug;22:67s–71s (32 ref.)

IL-4 in schistosomiasis. Pearce EJ, et al. **Exp Parasitol** 1996 Nov;84(2):295–9 (47 ref.)

Immune responses of IL-4, IL-5, IL-6 deficient mice. Kopf M, et al. **Immunol Rev** 1995 Dec;148:45–69 (116 ref.)

IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease. Röcken M, et al. **Immunol Today** 1996 May;17(5):225–31 (80 ref.)

METABOLISM

Source of IL-4 able to induce the development of TH2-like cells. Ricci M, et al. **Clin Exp Allergy** 1997 May; 27(5):488–500 (118 ref.)

STAT6: its role in interleukin 4-mediated biological functions. Takeda K, et al. **J Mol Med** 1997 May; 75(5):317–26 (120 ref.)

PHARMACOLOGY

Lessons from immunological, biochemical, and molecular pathways of the activation mediated by IL-2 and IL-4. Rebollo A, et al. **Adv Immunol** 1996;63:127–96 (646 ref.)

Safety evaluation of recombinant human interleukin-4. I. Preclinical studies. Leach MW, et al. **Clin Immunol Immunopathol** 1997 Apr;83(1):8–11 (38 ref.)

Tumor necrosis factor-alpha and interleukin 4 in myeloma cell precursor differentiation. Sawamura M, et al. **Leuk Lymphoma** 1996 Mar;21(1–2):31–6 (45 ref.)

PHYSIOLOGY

Interleukin 4 and interleukin 13: same response, different receptors. Callard RE, et al. **Biochem Soc Trans** 1997 May; 25(2):451–5 (44 ref.)

Structure and function of interleukin-4 and its receptor. Puri RK. **Cancer Treat Res** 1995;80:143–85 (318 ref.)

Interleukin 4: signalling mechanisms and control of T cell differentiation. Paul WE. **Ciba Found Symp** 1997; 204:208–16; discussion 216–9 (40 ref.)

Functions of IL-4 and control of its expression. Brown MA, et al. **Crit Rev Immunol** 1997;17(1):1–32 (257 ref.)

Role of IL-4 in persistent IgE formation. Savelkoul HF, et al. **Eur Respir J Suppl** 1996 Aug;22:67s–71s (32 ref.)

Dissociation of production of interleukin-4 and interleukin-5. Sewell WA, et al. **Immunol Cell Biol** 1996 Jun;74(3):274–7 (27 ref.)

Interleukin-4 and its receptor: essential mediators of the allergic response. Ryan JJ. **J Allergy Clin Immunol** 1997 Jan;99(1 Pt 1):1–5 (8 ref.)

IL-4 as a key factor influencing the development of allergen-specific Th2-like cells in atopic individuals. Ricci

M, et al. **J Investig Allergol Clin Immunol** 1997 May-Jun; 7(3):144–50 (63 ref.)

Tumor necrosis factor-alpha and interleukin 4 in myeloma cell precursor differentiation. Sawamura M, et al. **Leuk Lymphoma** 1996 Mar;21(1-2):31–6 (45 ref.)

[The signal transduction mechanism of IL-4 in X-linked severe combined immunodeficiency patients] Izuhara K. **Rinsho Ketsueki** 1997 Mar;38(3):186–8 (8 ref.) **(Jpn)**

[The role of interferon-gamma and interleukin-4 in the pathogenesis of atopic diseases] Boznański A. **Pol Merkuriusz Lek** 1996 Jul;1(1):63–5 (39 ref.) (Eng. Abstr.) **(Pol)**

SECRETION

Modulation of T-cell cytokine secretion by accessory cell-derived products. Hilkens CM, et al. **Eur Respir J Suppl** 1996 Aug;22:90s–94s (33 ref.)

STANDARDS

Safety evaluation of recombinant human interleukin-4. I. Preclinical studies. Leach MW, et al. **Clin Immunol Immunopathol** 1997 Apr;83(1):8–11 (38 ref.)

THERAPEUTIC USE

IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease. Röcken M, et al. **Immunol Today** 1996 May;17(5):225–31 (80 ref.)

[IL-4 and tumor immunity] Nogawa S. **Fukuoka Igaku Zasshi** 1996 Jan;87(1):8–13 (45 ref.) **(Jpn)**

INTERLEUKIN-5

Th2-type cytokines, hypereosinophilia, and interleukin-5 in HIV disease. Paganelli R, et al. **Allergy** 1997 Jan; 52(1):110–1 (9 ref.)

ANTAGONISTS & INHIBITORS

Inhibition of interleukin-5 with a monoclonal antibody attenuates allergic inflammation. Danzig M, et al. **Allergy** 1997 Aug;52(8):787–94 (102 ref.)

BIOSYNTHESIS

Enhanced production and gene expression of IL-5 in bronchial asthma. Possible management of atopic diseases with IL-5 specific gene transcription inhibitor. Mori A, et al. **Adv Exp Med Biol** 1996;409:439–50 (36 ref.)

Synthesis of type 1 (IFN gamma) and type 2 (IL-4, IL-5, and IL-10) cytokines by human eosinophils. Lamkhioued B, et al. **Ann N Y Acad Sci** 1996 Oct 31;796:203–8 (22 ref.)

Dissociation of production of interleukin-4 and interleukin-5. Sewell WA, et al. **Immunol Cell Biol** 1996 Jun;74(3):274–7 (27 ref.)

[Treatment of atopic diseases by controlling IL-5 production] Mori A, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Dec;19(6):598–601 (13 ref.) **(Jpn)**

GENETICS

How is expression of the interleukin-5 gene regulated? Karlen S, et al. **Immunol Cell Biol** 1996 Apr;74(2):218–23 (57 ref.)

IMMUNOLOGY

Immune responses of IL-4, IL-5, IL-6 deficient mice. Kopf M, et al. **Immunol Rev** 1995 Dec;148:45–69 (116 ref.)

METABOLISM

Interleukin 5 interactions with soluble and cell surface forms of its receptor. Li J, et al. **J Mol Recognit** 1996 Sep-Dec; 9(5-6):347–55 (60 ref.)

PHYSIOLOGY

Interleukin-5: an overview. Takatsu K. **Cancer Treat Res** 1995;80:187–208 (97 ref.)

Dissociation of production of interleukin-4 and interleukin-5. Sewell WA, et al. **Immunol Cell Biol** 1996 Jun;74(3):274–7 (27 ref.)

SECRETION

Modulation of T-cell cytokine secretion by accessory cell-derived products. Hilkens CM, et al. **Eur Respir J Suppl** 1996 Aug;22:90s–94s (33 ref.)

INTERLEUKIN-6

see related
PLASMACYTOMA

ADVERSE EFFECTS

Interleukin 6 in diseases: cause or cure? Scholz W. **Immunopharmacology** 1996 Mar;31(2-3):131–50 (224 ref.)

ANALOGS & DERIVATIVES

Cytokines in neuronal development. Jonakait GM. **Adv Pharmacol** 1997;37:35–67 (369 ref.)

BIOSYNTHESIS

Hypoxia-induced modulation of endothelial cell properties: regulation of barrier function and expression of interleukin-6. Yan SF, et al. **Kidney Int** 1997 Feb; 51(2):419–25 (26 ref.)

The expression of IL-6 and its related genes in acute leukemia. Sugiyama H, et al. **Leuk Lymphoma** 1996 Mar; 21(1-2):49–52 (42 ref.)

Interactions involving cyclosporine A, interleukin-6, and Epstein-Barr virus lead to the promotion of B-cell lymphoproliferative disease. Tanner JE, et al. **Leuk Lymphoma** 1996 May;21(5-6):379–90 (77 ref.)

BLOOD

Interleukin-6-type cytokines in vivo: regulated bioavailability. Sehgal PB. **Proc Soc Exp Biol Med** 1996 Dec;213(3):238–47 (73 ref.)

CHEMISTRY

Interleukin-6: structure-function relationships. Simpson RJ, et al. **Protein Sci** 1997 May;6(5):929–55 (338 ref.)

GENETICS

[Effects of in vivo instillation of genes coding for cytokines on pulmonary fibrosis] Hayashi S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:190–4 (19 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Gp130 and the interleukin-6 family of cytokines. Taga T, et al. **Annu Rev Immunol** 1997;15:797–819 (130 ref.)

Targeted disruption of the IL-6 related genes: gp130 and NF-IL-6. Akira S, et al. **Immunol Rev** 1995 Dec; 148:221–53 (135 ref.)

Immune responses of IL-4, IL-5, IL-6 deficient mice. Kopf M, et al. **Immunol Rev** 1995 Dec;148:45–69 (116 ref.)

IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Tilg H, et al. **Immunol Today** 1997 Sep; 18(9):428–32 (53 ref.)

IL-6 cytokine family and signal transduction: a model of the cytokine system. Hibi M, et al. **J Mol Med** 1996 Jan; 74(1):1–12 (168 ref.)

METABOLISM

The signal transducer gp130 is shared by interleukin-6 family of haematopoietic and neurotrophic cytokines. Taga T. **Ann Med** 1997 Feb;29(1):63–72 (88 ref.)

Cytokines in the hypophysis: a comparative look at interleukin-6 in the porcine anterior pituitary gland. Abraham EJ, et al. **Comp Biochem Physiol A Physiol** 1997 Mar;116(3):203–7 (30 ref.)

PHYSIOLOGY

Cytokines in neuronal development. Jonakait GM. **Adv Pharmacol** 1997;37:35–67 (369 ref.)

Interleukin-6 and megakaryocytopoiesis: an update. Baatout S. **Ann Hematol** 1996 Oct;73(4):157–62 (90 ref.)

Interleukin-6 in the injured patient. Marker of injury or mediator of inflammation? Biffl WL, et al. **Ann Surg** 1996 Nov;224(5):647–64 (256 ref.)

Interleukin-6: a comprehensive review. Lotz M. **Cancer Treat Res** 1995;80:209–33 (139 ref.)

Interleukin-6: biologic properties and role in lymphoproliferative disorders. Seymour JF, et al. **Cancer Treat Res** 1996;84:167–206 (231 ref.)

Myeloma biology and therapy. Present status and future developments. Nishimoto N, et al. **Hematol Oncol Clin North Am** 1997 Feb;11(1):159–72 (85 ref.)

Regulation of oligodendrocyte cell survival and differentiation by ciliary neurotrophic factor, leukemia inhibitory factor, oncostatin M, and interleukin-6. Vos JP, et al. **Perspect Dev Neurobiol** 1996;4(1):39–52 (133 ref.)

Interleukin-6 (IL-6)--a molecule with both beneficial and destructive potentials. Gadient RA, et al. **Prog Neurobiol** 1997 Aug;52(5):379–90 (155 ref.)

Interleukin-6: structure-function relationships. Simpson RJ, et al. **Protein Sci** 1997 May;6(5):929–55 (338 ref.)

[Similarity and synergy of trauma and sepsis: role of tumor necrosis factor-alpha and interleukin-6 (see comments)] Tang GJ. **Acta Anaesthesiol Sin** 1996 Sep;34(3):141–9 (46 ref.) (Eng. Abstr.) Comment in: Acta Anaesthesiol Sin 1996 Sep;34(3):i. **(Chi)**

[Factors regulating the function of adhesion molecules] Tagawa S, et al. **Rinsho Byori** 1996 Sep;Suppl 102:60–8 (12 ref.) **(Jpn)**

[gp-130 related cytokines in mechanisms of myeloma cell growth] Fukutoku M, et al. **Rinsho Ketsueki** 1997 Apr; 38(4):262–5 (13 ref.) **(Jpn)**

THERAPEUTIC USE

Interleukin 6 in diseases: cause or cure? Scholz W. **Immunopharmacology** 1996 Mar;31(2-3):131–50 (224 ref.)

Potential use of recombinant human interleukin-6 in clinical oncology. Veldhuis GJ, et al. **Leuk Lymphoma** 1996 Feb; 20(5-6):373–9 (61 ref.)

INTERLEUKIN-7

METABOLISM

IL-7 receptor and VDJ recombination: trophic versus mechanistic actions. Candéias S, et al. **Immunity** 1997 May; 6(5):501–8 (104 ref.)

PHYSIOLOGY

Interleukin-7. Biology and implications for dermatology. Möller P, et al. **Exp Dermatol** 1996 Jun;5(3):129–37 (91 ref.)

THERAPEUTIC USE

Interleukin-7. Biology and implications for dermatology. Möller P, et al. **Exp Dermatol** 1996 Jun;5(3):129–37 (91 ref.)

INTERLEUKIN-8

see related
NEUTROPHIL ACTIVATION

IMMUNOLOGY

Interleukin 8 as a novel target for intervention therapy in acute inflammatory diseases. Harada A, et al. **Mol Med Today** 1996 Nov;2(11):482–9 (30 ref.)

PHYSIOLOGY

In vivo, in vitro, and molecular aspects of interleukin-8 and the interleukin-8 receptors. Hoch RC, et al. **J Lab Clin Med** 1996 Aug;128(2):134–45 (97 ref.)

[Activation of neutrophil by cytokines] Yamagoe S, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1086–91 (13 ref.) **(Jpn)**

INTERLEUKIN-9

PHYSIOLOGY

Interleukin-9: structural characteristics and biologic properties. Renauld JC. **Cancer Treat Res** 1995;80:287–303 (60 ref.)

INTERLEUKIN-10

BIOSYNTHESIS

Synthesis of type 1 (IFN gamma) and type 2 (IL-4, IL-5, and IL-10) cytokines by human eosinophils. Lamkhioued B, et al. **Ann N Y Acad Sci** 1996 Oct 31;796:203–8 (22 ref.)

IMMUNOLOGY

Lymphocytes, cytokines, inflammation, and immune trafficking. Tsokos GC. **Curr Opin Rheumatol** 1996 Sep; 8(5):395–402 (74 ref.)

The paradoxical effects of interleukin 10 in the immunoregulation of autoimmune diabetes. Balasa B, et al. **J Autoimmun** 1996 Apr;9(2):283–6 (34 ref.)

Studies with IL-10-/- mice: an overview. Rennick DM, et al. **J Leukoc Biol** 1997 Apr;61(4):389–96 (49 ref.)

PHYSIOLOGY

Immune suppression and Th1/Th2 balance in pregnancy revisited: a (very) personal tribute to Tom Wegmann. Chaouat G, et al. **Am J Reprod Immunol** 1997 Jun; 37(6):427–34 (23 ref.)

Endogenous interleukin-10 in inflammatory disorders: regulatory roles and pharmacological modulation. Goldman M, et al. **Ann N Y Acad Sci** 1996 Oct 31; 796:282–93 (96 ref.)

THERAPEUTIC USE

IL-10: a potential therapy for allergic inflammation? Pretolani M, et al. **Immunol Today** 1997 Jun;18(6):277–80 (47 ref.)

New therapies for inflammatory bowel disease: an update on chimeric anti-TNF alpha antibodies and IL-10 therapy. van Hogezand RA, et al. **Scand J Gastroenterol Suppl** 1997; 223:105–7 (105 ref.)

INTERLEUKIN-11

Interleukin-11: review of molecular, cell biology, and clinical use. Du X, et al. **Blood** 1997 Jun 1;89(11):3897–908 (168 ref.)

INTERLEUKIN-12

see related
IMMUNITY, CELLULAR

Function and clinical use of interleukin-12. Trinchieri G. **Curr Opin Hematol** 1997 Jan;4(1):59–66 (78 ref.)

[Interleukin-12--polyfunctional cytokine] Aharon-Maor A, et al. **Harefuah** 1996 Dec 1;131(11):501–5 (50 ref.) **(Heb)**

INTERLEUKIN-12

BIOSYNTHESIS

Regulation of interleukin-12 production. Ma X, et al. **Ann N Y Acad Sci** 1996 Oct 31;795:13-25 (43 ref.)

Production of interleukin-12. Ma X, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):432-8 (36 ref.)

Macrophage production of IL12 is a critical link between the innate and specific immune responses to Listeria. Tripp CS, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):515-20 (32 ref.)

GENETICS

Genetic control of interleukin 12 responsiveness: implications for disease pathogenesis. Gorham JD, et al. **J Mol Med** 1997 Jul;75(7):502-11 (100 ref.)

Role of interleukin-12 (IL12) as an anti-tumour agent: experimental biology and clinical application. Zitvogel L, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):628-38 (29 ref.)

IMMUNOLOGY

Regulation of interleukin-12 signalling during T helper phenotype development. Jacobson NG, et al. **Adv Exp Med Biol** 1996;409:61-73 (31 ref.)

Development of an antipathology vaccine for schistosomiasis. Wynn TA. **Ann N Y Acad Sci** 1996 Oct 25;797:191-5 (27 ref.)

Interleukin-12, an emerging anti-tumour cytokine. Hiscox S, et al. **In Vivo** 1997 Mar-Apr;11(2):125-32 (97 ref.)

IL12 in acute viral infectious disease. Biron CA, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):590-600 (37 ref.)

Interleukin-12 and malaria. Crutcher JM, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):552-9 (42 ref.)

The role of IL12 in toxoplasmosis. Hunter CA, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):546-52 (44 ref.)

IL12 and the human immune response to mycobacteria. Modlin RL, et al. **Res Immunol** 1995 Sep-Oct; 146(7-8):526-31 (43 ref.)

IL12 in Candida albicans infections. Romani L, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):532-8 (31 ref.)

METABOLISM

Regulation of interleukin-12 signal transduction during T helper phenotype development. Jacobson NG, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):446-56 (23 ref.)

IL12 receptors and receptor antagonists. Presky DH, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):439-45 (21 ref.)

PHARMACOLOGY

IL12, a direct stimulator and indirect inhibitor of haematopoiesis. Jacobsen SE. **Res Immunol** 1995 Sep-Oct; 146(7-8):506-14 (34 ref.)

The effects of IL12 on B-cell subset function. Metzger DW, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):499-505 (32 ref.)

Interleukin-12: a proinflammatory cytokine with immunoregulatory functions [editorial] Trinchieri G, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):423-31 (42 ref.)

PHYSIOLOGY

Regulatory cytokines in inflammatory bowel disease. Pallone F, et al. **Aliment Pharmacol Ther** 1996;10 Suppl 2:75-9; discussion 80 (41 ref.)

The role of IL-12 in the pathogenesis of Th1 cell-mediated autoimmune diseases. Adorini L, et al. **Ann N Y Acad Sci** 1996 Oct 31;795:208-15 (46 ref.)

Signal transduction by interleukin-12 and interleukin-2. A comparison and contrast. Bacon CM, et al. **Ann N Y Acad Sci** 1996 Oct 31;795:41-59 (106 ref.)

Cellular and molecular mechanisms underlying IL-12-induced tumor regression. Fujiwara H, et al. **Ann N Y Acad Sci** 1996 Oct 31;795:294-309 (47 ref.)

Interleukin 12: cellular and molecular immunology of an important regulatory cytokine. Introduction. Lotze MT. **Ann N Y Acad Sci** 1996 Oct 31;795:xiii-xix (38 ref.)

Interleukin-12: a pivotal regulator of cell-mediated immunity. Gately MK, et al. **Cancer Treat Res** 1995; 80:341-66 (102 ref.)

Role of interleukin-12 in human Th1 response. Trinchieri G. **Chem Immunol** 1996;63:14-29 (79 ref.)

Modulation of T-cell cytokine secretion by accessory cell-derived products. Hilkens CM, et al. **Eur Respir J Suppl** 1996 Aug;22:90s-94s (33 ref.)

IL-12: a key cytokine in immune regulation. Lamont AG, et al. **Immunol Today** 1996 May;17(5):214-7 (0 ref.)

Differential roles for IL-12 in the maintenance of immune responses in infectious versus autoimmune disease. Seder RA, et al. **J Immunol** 1996 Oct 1;157(7):2745-8 (24 ref.)

The role of endogenous IL12 in the induction of Th1-cell-mediated autoimmune diseases. Adorini L, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):645-51 (51 ref.)

Interleukin-12 in the pathogenesis and therapy of HIV disease. Chehimi J, et al. **Res Immunol** 1995 Sep-Oct; 146(7-8):605-14 (61 ref.)

Role of IL12 in HIV disease/AIDS. Chougnet C, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):615-22 (54 ref.)

Influence of IL12 on the maturation of human naive T cells. Delespesse G, et al. **Res Immunol** 1995 Sep-Oct; 146(7-8):461-6 (25 ref.)

Interleukin-12 in murine leishmaniasis--match, flame or fuel? Fowell DJ, et al. **Res Immunol** 1995 Sep-Oct; 146(7-8):566-75 (47 ref.)

The influence of IL12 on the development of Th1 and Th2 cells and its adjuvant effect for humoral immune responses. Germann T, et al. **Res Immunol** 1995 Sep-Oct; 146(7-8):481-6 (40 ref.)

Role of IL12 in MAIDS. Giese NA, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):600-5 (25 ref.)

Immunoregulation of murine leishmaniasis by interleukin-12. Heinzel FP, et al. **Res Immunol** 1995 Sep-Oct; 146(7-8):575-81 (34 ref.)

The role of IL12 in modulating an established Th2 response in experimental leishmaniasis. Hondowicz B, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):560-5 (21 ref.)

The role of macrophage- and dendritic cell-derived IL12 in Th1 phenotype development. O'Garra A, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):466-72 (50 ref.)

The role of IL12 in helper T-cell differentiation. Perez VL, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):477-80 (17 ref.)

Role of IL12 in the development of human Th1 type cells. Romagnani S, et al. **Res Immunol** 1995 Sep-Oct; 146(7-8):452-60 (22 ref.)

Role of IL12 in induction of cell-mediated immunity to Toxoplasma gondii [published erratum appears in Res Immunol 1996 Feb;147(2):121] Scharton-Kersten T, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):539-45 (29 ref.)

Interleukin-12 and its role in cutaneous sensitization. Schwarz T. **Res Immunol** 1995 Sep-Oct;146(7-8):494-9 (38 ref.)

The role of IL12 in the regulation of Th1 and Th2 differentiation. Seder RA. **Res Immunol** 1995 Sep-Oct; 146(7-8):473-6 (31 ref.)

Activity of IL12 as adjuvant in promoting Th1 and Th2 recall responses. Wolf SF, et al. **Res Immunol** 1995 Sep-Oct; 146(7-8):486-9 (26 ref.)

THERAPEUTIC USE

Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials. Lotze MT, et al. **Ann N Y Acad Sci** 1996 Oct 31;795:440-54 (41 ref.)

Interleukin-12: potential clinical applications in the treatment and prevention of infectious diseases. Gately MK, et al. **Drugs** 1996;52 Suppl 2:18-25; discussion 25-6 (49 ref.)

Interleukin-12, an emerging anti-tumour cytokine. Hiscox S, et al. **In Vivo** 1997 Mar-Apr;11(2):125-32 (97 ref.)

Interleukin-12 as an inducer of cytotoxic effectors in anti-tumor immunity. Kumagai K, et al. **Int Rev Immunol** 1997;14(2-3):229-56 (107 ref.)

Interleukin-12: potential clinical applications in the treatment of chronic viral hepatitis. Gately MK. **J Viral Hepat** 1997; 4 Suppl 1:33-9 (48 ref.)

Role of IL12 as an anti-tumour agent: current status and future directions. Brunda MJ. **Res Immunol** 1995 Sep-Oct; 146(7-8):622-28 (29 ref.)

Interleukin-12 in the pathogenesis and therapy of HIV disease. Chehimi J, et al. **Res Immunol** 1995 Sep-Oct; 146(7-8):605-14 (61 ref.)

A sequence of cellular and molecular events involved in IL12-induced tumour regression. Fujiwara H, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):638-44 (25 ref.)

IL12 as an adjuvant for vaccines designed to prevent infection and immunopathology by schistosomes. Wynn TA, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):582-90 (59 ref.)

Role of interleukin-12 (IL12) as an anti-tumour agent: experimental biology and clinical application. Zitvogel L, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):628-38 (29 ref.)

[Antineoplastic effects of interleukin-12] Fujiwara H, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):611-5 (10 ref.) **(Jpn)**

INTERLEUKIN-13

CHEMISTRY

Molecular and biological characteristics of interleukin-13. de Vries JE. **Chem Immunol** 1996;63:204-18 (65 ref.)

GENETICS

Molecular and biological characteristics of interleukin-13. de Vries JE. **Chem Immunol** 1996;63:204-18 (65 ref.)

PHYSIOLOGY

Interleukin 4 and interleukin 13: same response, different receptors. Callard RE, et al. **Biochem Soc Trans** 1997 May; 25(2):451-5 (44 ref.)

Interleukin-13: characterization and biologic properties. McKenzie AN, et al. **Cancer Treat Res** 1995;80:367-78 (43 ref.)

INTERLEUKIN-15

CHEMISTRY

Characterization of interleukin-15 (IL-15) and the IL-15 receptor complex. Kennedy MK, et al. **J Clin Immunol** 1996 May;16(3):134-43 (56 ref.)

IMMUNOLOGY

Interleukin 15: a potential player during the innate immune response to infection. Carson WE, et al. **Exp Parasitol** 1996 Nov;84(2):291-4 (19 ref.)

Unconventional T-cell activation by IL-15 in rheumatoid arthritis [news; comment] Carson DA. **Nat Med** 1997 Feb; 3(2):148-9 (8 ref.) Comment on: Nat Med 1997 Feb;3(2):189-95.

METABOLISM

Cytokines: shared receptors, distinct functions. DiSanto JP. **Curr Biol** 1997 Jul 1;7(7):R424-6 (17 ref.)

Characterization of interleukin-15 (IL-15) and the IL-15 receptor complex. Kennedy MK, et al. **J Clin Immunol** 1996 May;16(3):134-43 (56 ref.)

PHYSIOLOGY

Interleukin 15. Cosman D, et al. **Biochem Soc Trans** 1997 May;25(2):371-4 (30 ref.)

Ontogeny of NK cells and the bone marrow microenvironment: where does IL15 fit in? Puzanov IJ, et al. **Res Immunol** 1997 Mar-Apr;148(3):195-201 (46 ref.)

INTERLEUKIN-16

PHYSIOLOGY

Interleukin 16 and its function as a CD4 ligand. Center DM, et al. **Immunol Today** 1996 Oct;17(10):476-81 (45 ref.)

INTERLEUKIN RECEPTORS see **RECEPTORS, INTERLEUKIN**

INTERLEUKINS

BIOSYNTHESIS

Pro-inflammatory cytokines in inflammatory bowel disease. McAlindon ME, et al. **Aliment Pharmacol Ther** 1996;10 Suppl 2:72-4 (28 ref.)

Inhibiting inflammatory cytokines. Kluth DC, et al. **Semin Nephrol** 1996 Nov;16(6):576-82 (60 ref.)

BLOOD

Circulating cytokine concentrations and outcome prediction in intensive care unit patients: still the tip of the iceberg? [editorial; comment] Matuschak GM. **Crit Care Med** 1996 Nov;24(11):1769-71 (33 ref.) Comment on: Crit Care Med 1996 Nov;24(11):1775-81.

METABOLISM

TH1/TH2 cytokine profile in celiac disease. Karban A, et al. **Isr J Med Sci** 1997 Mar;33(3):209-14 (49 ref.)

Interleukins in acute pancreatitis. Schölmerich J. **Scand J Gastroenterol Suppl** 1996;219:37-42 (28 ref.)

PHYSIOLOGY

Interleukins and cerebral ischaemia. Rothwell NJ, et al. **Int Rev Neurobiol** 1997;40:281-98 (90 ref.)

Analysis of cytokine profiles in patients with human papillomavirus-associated neoplasms [editorial; comment] Wu TC, et al. **J Natl Cancer Inst** 1997 Feb 5;89(3):185-7 (33 ref.) Comment on: J Natl Cancer Inst 1997 Feb 5;89(3):245-50.

Does human toxoplasmosis involve an imbalance in T1/T2 cytokines? Gómez Marín JE, et al. **Med Hypotheses** 1997 Feb;48(2):161-9 (72 ref.)

Interleukins involved in the pathogenesis of chronic airway inflammation. Lasky JA, et al. **Res Immunol** 1997 Jan; 148(1):39-47 (90 ref.)

[Cooperation of proinflammatory interleukins in a cytokine rete in patients with septic syndrome] Modzelewski B. **Pol Merkuriusz Lek** 1996 Oct;1(4):284-6 (35 ref.) **(Pol)**

THERAPEUTIC USE

Cytokine gene-modified vaccines in the therapy of cancer. Bubenik J. **Pharmacol Ther** 1996;69(1):1-14 (208 ref.)

INTERMEDIATE FILAMENT PROTEINS

Intermediate filament proteins. Quinlan R, et al. **Protein Profile** 1995;2(8):795-952 (6308 ref.)

[Neuronal intermediate filament proteins] Bousquet O, et al. **C R Seances Soc Biol Fil** 1996;190(2-3):269-87 (105 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Phosphorylation-dependent control of structures of intermediate filaments: a novel approach using site- and phosphorylation state-specific antibodies. Inagaki M, et al. **J Biochem (Tokyo)** 1997 Mar;121(3):407-14 (113 ref.)

GENETICS

The cytoskeleton and disease: genetic disorders of intermediate filaments. Fuchs E. **Annu Rev Genet** 1996; 30:197-231 (184 ref.)

Plectin and human genetic disorders of the skin and muscle. The paradigm of epidermolysis bullosa with muscular dystrophy. Uitto J, et al. **Exp Dermatol** 1996 Oct; 5(5):237-46 (71 ref.)

Intermediate filaments and gene regulation. Traub P. **Physiol Chem Phys Med NMR** 1995;27(4):377-400 (142 ref.)

METABOLISM

Dynamic organisation of intermediate filaments and associated proteins during the cell cycle. Foisner R. **Bioessays** 1997 Apr;19(4):297–305 (70 ref.)

Implications of intermediate filament protein phosphorylation. Ku NO, et al. **Cancer Metastasis Rev** 1996 Dec;15(4):429–44 (140 ref.)

Epidermal structural proteins in skin disorders. Manabe M, et al. **J Dermatol Sci** 1997 Sep;15(3):143–65 (167 ref.)

Poly(ADP-ribosyl)ation and nuclear matrix/intermediate filament proteins in renal carcinogenesis. Vamvakas S, et al. **Recent Results Cancer Res** 1997;143:195–208 (60 ref.)

Intermediate filament linker proteins. Fuchs E, et al. **Soc Gen Physiol Ser** 1997;52:141–8 (39 ref.)

Specificity of desmosomal plaque protein interactions with intermediate filaments: keeping adhesive junctions segregated. Green KJ, et al. **Soc Gen Physiol Ser** 1997; 52:123–39 (84 ref.)

[Visualization of site-specific phosphorylation of intermediate filaments during the cell cycle] Takai Y, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1920–6 (27 ref.) **(Jpn)**

PHYSIOLOGY

Intermediate filaments in the nervous system: implications in cancer. Ho CL, et al. **Cancer Metastasis Rev** 1996 Dec; 15(4):483–97 (119 ref.)

Intermediate filaments as dynamic structures. Klymkowsky MW. **Cancer Metastasis Rev** 1996 Dec;15(4):417–28 (171 ref.)

INTERMEDIATE FILAMENTS

GENETICS

Transgenic mice carrying chimeric or mutated type III intermediate filament (IF) genes. Bloemendal H, et al. **Cell Mol Life Sci** 1997 Jan;53(1):1–12 (67 ref.)

METABOLISM

Dynamic organisation of intermediate filaments and associated proteins during the cell cycle. Foisner R. **Bioessays** 1997 Apr;19(4):297–305 (70 ref.)

Intermediate filament expression in prostate cancer. Nagle RB. **Cancer Metastasis Rev** 1996 Dec;15(4):473–82 (88 ref.)

Two-dimensional gel analysis of glandular keratin intermediate filament phosphorylation. Liao J, et al. **Electrophoresis** 1996 Nov;17(11):1671–6 (67 ref.)

Intermediate filament proteins of the liver: emerging disease association and functions. Omary MB, et al. **Hepatology** 1997 May;25(5):1043–8 (67 ref.)

PATHOLOGY

Intermediate filament aggregates in mitoses of primary cutaneous neuroendocrine (Merkel cell) carcinoma. Alvarez-Gago T, et al. **Histopathology** 1996 Apr; 28(4):349–55 (30 ref.)

Role of glial filaments in cells and tumors of glial origin: a review. Rutka JT, et al. **J Neurosurg** 1997 Sep; 87(3):420–30 (122 ref.)

PHYSIOLOGY

Neuronal intermediate filaments. Lee MK, et al. **Annu Rev Neurosci** 1996;19:187–217 (229 ref.)

Multiple drug resistance and intermediate filaments. Cress AE, et al. **Cancer Metastasis Rev** 1996 Dec;15(4):499–506 (32 ref.)

Role of intermediate filaments in migration, invasion and metastasis. Hendrix MJ, et al. **Cancer Metastasis Rev** 1996 Dec;15(4):507–25 (105 ref.)

Intermediate filaments. Hendrix MJ. **Cancer Metastasis Rev** 1996 Dec;15(4):413–6 (33 ref.)

Intermediate filaments in the nervous system: implications in cancer. Ho CL, et al. **Cancer Metastasis Rev** 1996 Dec; 15(4):483–97 (119 ref.)

Intermediate filaments as dynamic structures. Klymkowsky MW. **Cancer Metastasis Rev** 1996 Dec;15(4):417–28 (171 ref.)

Intermediate filaments and cytoplasmic networking: new connections and more functions. Chou YH, et al. **Curr Opin Cell Biol** 1997 Feb;9(1):49–53 (32 ref.)

Roles of microfilaments and intermediate filaments in adrenal steroidogenesis. Hall PF, et al. **Microsc Res Tech** 1997 Mar 15;36(6):463–79 (108 ref.)

Intermediate filaments and gene regulation. Traub P. **Physiol Chem Phys Med NMR** 1995;27(4):377–400 (142 ref.)

INTERMEDINS see **MSH**

INTERMETATARSAL JOINT see **TARSAL JOINT**

INTERMITTENT CLAUDICATION

[Intermittent claudication] Ishimaru S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):444–6 (12 ref.) **(Jpn)**

DIAGNOSIS

Spinal stenosis and neurogenic claudication. Porter RW. **Spine** 1996 Sep 1;21(17):2046–52 (12 ref.)

DRUG THERAPY

Clinical experience with pentoxifylline. Labs KH, et al. **Atherosclerosis** 1997 Jun;131 Suppl:S37–9 (15 ref.)

ETIOLOGY

Dynamic obstruction of the external iliac artery in endurance athletes and its relationship to endothelial function: the case of a long distance runner. Wright IA, et al. **Br J Sports Med** 1997 Jun;31(2):156–8 (10 ref.)

Spinal stenosis and neurogenic claudication. Porter RW. **Spine** 1996 Sep 1;21(17):2046–52 (12 ref.)

PSYCHOLOGY

The relationship between descriptive and valuational quality-of-life measures in patients with intermittent claudication. Bosch JL, et al. **Med Decis Making** 1996 Jul–Sep;16(3):217–25 (29 ref.)

THERAPY

Quality of life assessment in peripheral arterial disease. Hiatt WR. **Atherosclerosis** 1997 Jun;131 Suppl:S35–6 (7 ref.)

The relationship between descriptive and valuational quality-of-life measures in patients with intermittent claudication. Bosch JL, et al. **Med Decis Making** 1996 Jul–Sep;16(3):217–25 (29 ref.)

INTERMITTENT POSITIVE-PRESSURE BREATHING

METHODS

Pediatric noninvasive nasal ventilation. Birnkrant DJ, et al. **J Child Neurol** 1997 Jun;12(4):231–6 (31 ref.)

INTERMITTENT POSITIVE-PRESSURE VENTILATION

[Recommendations of Bavarian Muscle Centers of the German Neuromuscular Disease Society for home ventilation of neuromuscular diseases of adult patients] Winterholler M, et al. **Nervenarzt** 1997 Apr;68(4):351–7 (23 ref.) (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

Ventilators in the operating room. Eisenkraft JB, et al. **Int Anesthesiol Clin** 1997 Winter;35(1):87–108 (25 ref.)

METHODS

A guide to noninvasive intermittent ventilatory support. Knebel A, et al. **Heart Lung** 1997 Jul–Aug;26(4):307–16 (24 ref.)

Non-invasive ventilation. Spence D. **Postgrad Med J** 1996 Sep;72(851):532–4 (6 ref.)

INTERNAL-EXTERNAL CONTROL

Controlling ourselves, controlling our world. Psychology's role in understanding positive and negative consequences of seeking and gaining control. Shapiro DH Jr, et al. **Am Psychol** 1996 Dec;51(12):1213–30 (330 ref.)

Self and self-control. Rachlin H. **Ann N Y Acad Sci** 1997 Jun 18;818:84–97 (06 ref.)

Racism and the mental health of African Americans: the role of self and system blame. Neighbors HW, et al. **Ethn Dis** 1996 Winter-Spring;6(1–2):167–75 (53 ref.)

Fundamental analysis in research on well-being: distress and the sense of control. Mirowsky J, et al. **Gerontologist** 1996 Oct;36(5):584–94 (26 ref.)

A guide to constructs of control. Skinner EA. **J Pers Soc Psychol** 1996 Sep;71(3):549–70 (120 ref.)

Coping with job loss: an attributional model. Thomson NF. **J Psychol** 1997 Jan;131(1):73–80 (26 ref.)

Ethical issues relative to autonomy and personal control in independent and cognitively impaired elders. Rice VH, et al. **Nurs Outlook** 1997 Jan–Feb;45(1):27–34 (34 ref.)

A stitch in time: self-regulation and proactive coping. Aspinwall LG, et al. **Psychol Bull** 1997 May;121(3):417–36 (175 ref.)

Complaints and complaining: functions, antecedents, and consequences. Kowalski RM. **Psychol Bull** 1996 Mar; 119(2):179–96 (169 ref.)

Some conceptual considerations on the sense of coherence. Geyer S. **Soc Sci Med** 1997 Jun;44(12):1771–9 (59 ref.)

INTERNAL FIXATORS

Spinal instrumentation in the management of adolescent scoliosis. Bridwell KH. **Clin Orthop** 1997 Feb;(335):64–72 (29 ref.)

ADVERSE EFFECTS

Neurological complications in segmental spinal instrumentation: analysis of 750 patients. Cervellati S, et al. **Eur Spine J** 1996;5(3):161–6 (25 ref.)

INTERNAL MAMMARY ARTERY IMPLANTATION see **MYOCARDIAL REVASCULARIZATION**

INTERNAL MEDICINE

The role of prognosis in clinical decision making. Christakis NA, et al. **J Gen Intern Med** 1996 Jul;11(7):422–5 (19 ref.)

General internal medicine update. Information clinicians and teachers need to know. Sheffield JV, et al. **J Gen Intern Med** 1996 Oct;11(10):613–21 (61 ref.)

EDUCATION

Internal medicine residency training and outcomes [see comments] Griffith CH 3rd, et al. **J Gen Intern Med** 1997 Jun;12(6):390–6 (53 ref.) Comment in: J Gen Intern Med 1997 Jun;12(6):399–400.

METHODS

[Internal medicine aspects of diabetic care] Tatoń J. **Pol Merkuriusz Lek** 1997 Jan;2(7):61–5 (12 ref.) **(Pol)**

TRENDS

Update in general internal medicine. Sheffield JV, et al. **Ann Intern Med** 1997 Jul 1;127(1):43–51 (21 ref.)

INTERNATIONAL AGENCIES

Cruel wars and safe havens: humanitarian aid in Liberia 1989–1996. Outram Q. **Disasters** 1997 Sep;21(3):189–205 (60 ref.)

Epidemiology of occupational carcinogens and mutagens. Ruder AM. **Occup Med** 1996 Jul–Sep;11(3):487–512 (103 ref.)

ORGANIZATION & ADMINISTRATION

International Federation of Infection Control: the first 10 years. Hambraeus A, et al. **Am J Infect Control** 1997 Aug; 25(4):297–302 (16 ref.)

Establishment of microbiological safety criteria for foods in international trade. International Commission on Microbiological Specifications for Foods. **World Health Stat Q** 1997;50(1–2):119–23 (2 ref.)

INTERNATIONAL COOPERATION

see related
CONGRESSES

Food and nutrition surveillance: an international overview. Jerome NW, et al. **Am J Clin Nutr** 1997 Apr;65(4 Suppl):1198S–1202S (11 ref.)

INFOODS: the international network of food data systems. Scrimshaw NS. **Am J Clin Nutr** 1997 Apr;65(4 Suppl):1190S–1193S (17 ref.)

A global perspective on the past, present, and future of nosocomial infection prevention and control [editorial] Soule BM, et al. **Am J Infect Control** 1997 Aug;25(4):289–93 (25 ref.)

Concepts of marine specimen banking. Rossbach M, et al. **Chemosphere** 1997 May;34(9–10):1997–2010 (39 ref.)

Proposal for a revised international standard series of patch tests. Lachapelle JM, et al. **Contact Dermatitis** 1997 Mar; 36(3):121–3 (8 ref.)

Guidelines for international collaborative research. Rosser WW, et al. **Fam Pract** 1997 Aug;14(4):330–4 (14 ref.)

Nursing science in the global community. Ketefian S, et al. **Image J Nurs Sch** 1997 Spring;29(1):11–5 (27 ref.)

EUR-ASSESS Project Subgroup Report on Coverage. Cranovsky R, et al. **Int J Technol Assess Health Care** 1997 Spring;13(2):287–332 (69 ref.)

EUR-ASSESS Project Subgroup Report on Dissemination and Impact. Granados A, et al. **Int J Technol Assess Health Care** 1997 Spring;13(2):220–86 (120 ref.)

Priority setting for health technology assessment. Theoretical considerations and practical approaches. Priority setting Subgroup of the EUR-ASSESS Project. Henshall C, et al. **Int J Technol Assess Health Care** 1997 Spring; 13(2):144–85 (43 ref.)

EUR-ASSESS Project Subgroup report on Methodology. Methodological guidance for the conduct of health technology assessment. Liberati A, et al. **Int J Technol Assess Health Care** 1997 Spring;13(2):186–219 (55 ref.)

Japan/United States collaboration in international HIV prevention and care. Brown T, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 2:S68–80 (18 ref.)

International HIV and AIDS prevention: Japan/United States collaboration. Umenai T, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 2:S58–67 (6 ref.)

Global linkages in animal agriculture: new opportunities for United States agricultural universities. Johnson WL. **J Anim Sci** 1996 Jun;74(6):1386–94 (13 ref.)

Juridical and sociocultural problems on the definition of a law concerning property, usage and access to genetic resources in Colombia. Calle R. **J Ethnopharmacol** 1996 Apr;51(1–3):127–42; discussion 142–6 (3 ref.)

Medicinal plant genetic resources and international cooperation: the Brazilian perspective. Elisabetsky E, et al. **J Ethnopharmacol** 1996 Apr;51(1–3):111–9; discussion 119–20 (19 ref.)

Biological diversity, indigenous knowledge, drug discovery and intellectual property rights: creating reciprocity and

INTERNATIONAL COOPERATION

maintaining relationships. King SR, et al. **J Ethnopharmacol** 1996 Apr;51(1–3):45–57 (25 ref.)

Legal issues in sharing the benefits of biodiversity prospecting. Mays TD, et al. **J Ethnopharmacol** 1996 Apr; 51(1–3):93–102; discussion 102–9 (14 ref.)

Research, valorization and exploitation of biological resources for medicinal purposes in the Malagasy Republic (Madagascar). Randimbivololona F. **J Ethnopharmacol** 1996 Apr;51(1–3):195–200 (10 ref.)

Quality management for health care in the Middle East and north Africa: professional cooperation as part of the peace process. Habib J, et al. **Jt Comm J Qual Improv** 1997 Jan; 23(1):65–8 (0 ref.)

Public mental health. III: Hatred and reconciliation. Curle A. **Med Confl Surviv** 1997 Jan–Mar;13(1):37–47 (2 ref.)

A proposal for the training of regional medical experts. Johnson DE. **Mil Med** 1997 Aug;162(8):533–6 (11 ref.)

Codex Alimentarius. Pothisiri P, et al. **Nutr Rev** 1996 Nov; 54(11 Pt 2):S149–51 (4 ref.)

Regulatory and legal aspects of functional foods: an international perspective. Randell A, et al. **Nutr Rev** 1996 Nov;54(11 Pt 2):S152–5 (0 ref.)

Testing and risk assessment strategies: international perspectives. Koëter HB. **Reprod Toxicol** 1997 Mar–Jun; 11(2–3):453–6 (4 ref.)

Paediatric life support. An advisory statement by the Paediatric Life Support Working Group of the International Liaison Committee on Resuscitation. Nadkarni V, et al. **Resuscitation** 1997 Apr;34(2):115–27 (69 ref.)

Current status of trade in cultured shrimps. Chen SN. **Rev Sci Tech** 1996 Jun;15(2):517–21 (8 ref.)

Overview of the current international trade in ornamental fish, with special reference to Singapore. Cheong L. **Rev Sci Tech** 1996 Jun;15(2):445–81 (4 ref.)

The World Trade Organisation agreement on the application of sanitary and phytosanitary measures. Chillaud T. **Rev Sci Tech** 1996 Jun;15(2):733–51 (6 ref.) **(Eng, Fre)**

Characteristics of the current international trade in ornamental fish, with special reference to the European Union. Davenport KE. **Rev Sci Tech** 1996 Jun;15(2):435–43 (6 ref.)

International trade in live molluscs: perspective from the Americas. Elston RA. **Rev Sci Tech** 1996 Jun;15(2):483–90 (6 ref.)

Movement of pathogens with the international trade of live fish: problems and solutions. Hedrick RP. **Rev Sci Tech** 1996 Jun;15(2):523–31 (29 ref.)

Characteristics of current international trade of live salmonid eggs. Jansen M, et al. **Rev Sci Tech** 1996 Jun;15(2):423–33 (20 ref.)

International efforts in cancer pain relief. Coyne PJ. **Semin Oncol Nurs** 1997 Feb;13(1):57–62 (29 ref.)

Establishment of microbiological safety criteria for foods in international trade. International Commission on Microbiological Specifications for Foods. **World Health Stat Q** 1997;50(1–2):119–23 (2 ref.)

[International research programs and training of researchers] Helander E, et al. **Duodecim** 1995;111(19):1872–6 (0 ref.) **(Fin)**

[International trade in bivalve mollusks and the current situation in France and in Europe] Le Borgne Y. **Rev Sci Tech** 1996 Jun;15(2):491–8 (6 ref.) (Eng. Abstr.) **(Fre)**

[International trade in living penaeid shrimp between countries in the Pacific and the Atlantic areas and in Europe] Michel A. **Rev Sci Tech** 1996 Jun;15(2):499–515 (35 ref.) (Eng. Abstr.) **(Fre)**

[Concise International Chemical Assessment Document (CICAD): a new chemical safety series in IPCS, internationalizing national reviews] Sekizawa J. **Eisei Shikenjo Hokoku** 1996;(114):89–94 (3 ref.) (Eng. Abstr.) **(Jpn)**

[Preparation of International Chemical Safety Cards (ICSC) and their translation into Japanese] Yamamoto M, et al. **Eisei Shikenjo Hokoku** 1994;(112):143–6 (3 ref.) (Eng. Abstr.) **(Jpn)**

[International guidelines for the clinical evaluation of anti-infective drugs] Sagawa K. **Jpn J Antibiot** 1997 Jan; 50(1):87–106 (7 ref.) **(Jpn)**

[Global health care: seeking a new paradigm of health care for all] Wakai S. **No Shinkei Geka** 1997 Apr;25(4):299–306 (45 ref.) **(Jpn)**

[Intellectual property rights in Costa Rica in the light of the Biodiversity Convention] Salazar R, et al. **J Ethnopharmacol** 1996 Apr;51(1–3):177–93 (12 ref.) (Eng. Abstr.) **(Spa)**

INTERNATIONAL EDUCATIONAL EXCHANGE

see related

FOREIGN MEDICAL GRADUATES

Would it work for us? Learning from quality improvement in Europe and beyond. Ovretveit J. **Jt Comm J Qual Improv** 1997 Jan;23(1):7–22 (91 ref.)

[Asian educational exchange in thoracic surgery] Oishi K. **Kyobu Geka** 1997 Jan;50(1):45–7 (0 ref.) **(Jpn)**

INTERNATIONAL HEALTH PROBLEMS see **WORLD HEALTH**

INTERNET see **COMPUTER COMMUNICATION NETWORKS**

INTERNEURONS

PHYSIOLOGY

How do nerve cells compute? Dendritic integration in fly visual interneurones. Borst A. **Acta Physiol Scand** 1996 Jul; 157(3):403–7 (10 ref.)

Lamprey spinal interneurons and their roles in swimming activity. Buchanan JT. **Brain Behav Evol** 1996;48(5):287–96 (49 ref.)

On the translation of directional motor cortical commands to activation of muscles via spinal interneuronal systems. Georgopoulos AP. **Brain Res Cogn Brain Res** 1996 Mar; 3(2):151–5 (23 ref.)

Functions for interneuronal nets in the hippocampus. Buzsáki G. **Can J Physiol Pharmacol** 1997 May;75(5):508–15 (72 ref.)

Inhibitory control of GABAergic interneurons in the hippocampus. Freund TF, et al. **Can J Physiol Pharmacol** 1997 May;75(5):479–87 (69 ref.)

Synaptic plasticity in hippocampal interneurons? A commentary. McBain CJ, et al. **Can J Physiol Pharmacol** 1997 May;75(5):488–94 (47 ref.)

Do GABAA and GABAB inhibitory postsynaptic responses originate from distinct interneurons in the hippocampus? Nurse S, et al. **Can J Physiol Pharmacol** 1997 May; 75(5):520–5 (59 ref.)

Interneurons of the hippocampus. Freund TF, et al. **Hippocampus** 1996;6(4):347–470 (757 ref.)

The neuronal network for locomotion in the lamprey spinal cord: evidence for the involvement of commissural interneurons. Buchanan JT, et al. **J Physiol Paris** 1995; 89(4–6):221–33 (54 ref.)

Spinal interneurons and preganglionic neurons in sacral autonomic reflex pathways. deGroat WC, et al. **Prog Brain Res** 1996;107:97–111 (90 ref.)

Neurotrophins and activity-dependent plasticity of cortical interneurons. Marty S, et al. **Trends Neurosci** 1997 May; 20(5):198–202 (68 ref.)

[Volume transmission as a means of interneuronal interaction in the striatum] Saul'skaia NB. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 Mar–Apr; 47(2):362–73 (52 ref.) (Eng. Abstr.) **(Rus)**

INTERNSHIP AND RESIDENCY

In the realm of ideas: the advent of advanced surgery of the human cerebrum and neurosurgical education. Apuzzo ML. **Acta Neurochir Suppl (Wien)** 1997;69:145–50 (29 ref.)

Rapid sequence intubation in adults with elevated intracranial pressure: a survey of emergency medicine residency programs [see comments] Silber SH. **Am J Emerg Med** 1997 May;15(3):263–7 (71 ref.) Comment in: Am J Emerg Med 1997 May;15(3):321.

Ethically based medical decision making in the intensive care unit: residency teaching strategies. Crausman RS, et al. **Crit Care Clin** 1996 Jan;12(1):71–84 (54 ref.)

Ethnocultural factors in the development of an Asian American psychiatrist. Chung H, et al. **Cult Divers Ment Health** 1996;2(2):99–106 (12 ref.)

Administrative and health policy training for residents. Bischof RO, et al. **Hosp Pract (Off Ed)** 1996 Aug 15; 31(8):93–4, 99–100 (17 ref.)

Education in accident and emergency medicine for senior house officers: review and recommendations. Rodenberg H. **J Accid Emerg Med** 1996 Jul;13(4):238–42 (15 ref.)

Internal medicine residency training and outcomes [see comments] Griffith CH 3rd, et al. **J Gen Intern Med** 1997 Jun;12(6):390–6 (53 ref.) Comment in: J Gen Intern Med 1997 Jun;12(6):399–400.

Oral presentations for surgical meetings. Edwards MJ, et al. **J Surg Res** 1997 Feb 15;68(1):87–90 (4 ref.)

Accreditation of residency training in the US. Armbruster JS. **Postgrad Med J** 1996 Jul;72(849):391–4 (0 ref.)

METHODS

The community health center and family practice residency training [see comments] Prislin MD, et al. **Fam Med** 1996 Oct;28(9):624–8 (20 ref.) Comment in: Fam Med 1996 Oct;28(9):616–7.

ORGANIZATION & ADMINISTRATION

Clinical training opportunities for Thai medical graduates in the United States. Nuchprayoon I. **J Med Assoc Thai** 1996 Oct;79(10):667–75 (10 ref.)

STANDARDS

House physicians. Accountabilities and possibilities. La Puma J. **Arch Intern Med** 1996 Dec 9–23;156(22):2529–33 (24 ref.)

STATISTICS & NUMERICAL DATA

What are the facts concerning the number of residency positions in Canada? [editorial] [see comments] Dauphinee D, et al. **Can Med Assoc J** 1997 Mar 1;156(5):665–7 (2 ref.) Comment in: CMAJ 1997 Jul 15;157(2):134, 136; discussion 139. Comment in: CMAJ 1997 Jul 15;157(2):136; discussion 139. Comment in: CMAJ 1997 Jul 15;157(2):136, 138; discussion 139. Comment in: CMAJ 1997 Jul 15;157(2):138.

TRENDS

The clinician–educator—present and future roles. Branch WT, et al. **J Gen Intern Med** 1997 Apr;12 Suppl 2:S1–4 (24 ref.)

INTERNSHIP, DENTAL see **INTERNSHIP AND RESIDENCY**

INTERNUCLEOSOMAL DNA FRAGMENTATION see **DNA FRAGMENTATION**

INTEROBSERVER VARIATION see **OBSERVER VARIATION**

INTERPERSONAL RELATIONS

Social ties and health: the benefits of social integration. Seeman TE. **Ann Epidemiol** 1996 Sep;6(5):442–51 (69 ref.)

Social behavior in autism. Grossman JB, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:440–54 (120 ref.)

An overview of depression-prone personality traits and the role of interpersonal sensitivity. Boyce P, et al. **Aust N Z J Psychiatry** 1996 Feb;30(1):90–103 (99 ref.)

Procedures as dialogical sequences: a revised version of the fundamental concept in cognitive analytic therapy. Leiman M. **Br J Med Psychol** 1997 Jun;70 (Pt 2):193–207 (30 ref.)

Signs and voices: joining a conversation in progress. Stiles WB. **Br J Med Psychol** 1997 Jun;70 (Pt 2):169–76 (35 ref.)

The problem: shiftwork. Costa G. **Chronobiol Int** 1997 Mar; 14(2):89–98 (42 ref.)

Aggression from a developmental perspective: genes, environments and interactions. Cairns RB. **Ciba Found Symp** 1996;194:45–56; discussion 57–60 (31 ref.)

Suicide: how to survive as a survivor? Grad OT. **Crisis** 1996; 17(3):136–42 (38 ref.)

Information exchange in the disaster zone: interaction between aid workers and recipients in south Sudan. Jok JM. **Disasters** 1996 Sep;20(3):206–15 (6 ref.)

Social relationships in later life: a review of the research literature [editorial] Phillipson C. **Int J Geriatr Psychiatry** 1997 May;12(5):505–12 (61 ref.)

Idealization and disillusionment in the dramas of Henrik Ibsen. Rotenberg CT, et al. **J Am Acad Psychoanal** 1996 Spring;24(1):137–61 (24 ref.)

All my buddies was male: relationship issues of women with addictions. Henderson D, et al. **J Obstet Gynecol Neonatal Nurs** 1997 Jul–Aug;26(4):469–76 (41 ref.)

The interactional context of problem-, emotion-, and relationship-focused coping: the role of the big five personality factors. O'Brien TB, et al. **J Pers** 1996 Dec; 64(4):775–813 (100 ref.)

Prospects for the assessment of normal and abnormal interpersonal behavior. Wiggins JS, et al. **J Pers Assess** 1997 Feb;68(1):110–26 (92 ref.)

Developing an ethical basis for student-teacher interaction. Wehrwein T. **J Prof Nurs** 1996 Sep–Oct;12(5):297–302 (25 ref.)

Dynamic-system analysis of opponent relationships in collective actions in soccer. Grehaigne JF, et al. **J Sports Sci** 1997 Apr;15(2):137–49 (26 ref.)

Naturalistic observation of children with autism: evidence for intersubjectivity. Toomey J, et al. **New Dir Child Dev** 1995 Fall;(69):75–89 (28 ref.)

The mutual interactions of culture and emotion. Markus H, et al. **Psychiatr Serv** 1996 Mar;47(3):225–6 (9 ref.)

Autism from an intersubjective perspective. Roser K, et al. **Psychoanal Rev** 1996 Jun;83(3):305–23 (28 ref.)

An integrative framework for explaining reactions to decisions: interactive effects of outcomes and procedures. Brockner J, et al. **Psychol Bull** 1996 Sep;120(2):189–208 (73 ref.)

Social consequences of experiential openness. McCrae RR. **Psychol Bull** 1996 Nov;120(3):323–37 (143 ref.)

Infants' perception of expressive behaviors: differentiation of multimodal information. Walker-Andrews AS. **Psychol Bull** 1997 May;121(3):437–56 (215 ref.)

Psychological well-being: meaning, measurement, and implications for psychotherapy research. Ryff CD, et al. **Psychother Psychosom** 1996;65(1):14–23 (56 ref.)

Discourse behaviors in older adults. Shadden BB. **Semin Speech Lang** 1997 May;18(2):143–56; quiz 156–7 (90 ref.)

INTERPHASE

Interphase cytogenetics and pathology: a tool for diagnosis and research. Wolfe KQ, et al. **J Pathol** 1997 Apr; 181(4):359–61 (38 ref.)

GENETICS

Mutation in resting cells: the role of endogenous DNA damage. Bridges BA. **Cancer Surv** 1996;28:155–67 (47 ref.)

PHYSIOLOGY

Microtubule dynamics: treadmilling comes around again. Waterman-Storer CM, et al. **Curr Biol** 1997 Jun 1; 7(6):R369–72 (19 ref.)

Role of alternate sigma factors in starvation protein synthesis—novel mechanisms of catabolite repression. Matin A. **Res Microbiol** 1996 Jul–Sep;147(6–7):494–505 (73

ref.)

INTERPLANETARY DUST see **COSMIC DUST**

INTERPROFESSIONAL RELATIONS

Behavioral science activities at the Centers for Disease Control and Prevention. A selected overview of exemplary programs. Galavotti C, et al. **Am Psychol** 1997 Feb; 52(2):154–66 (100 ref.)

Shared care: a review of the literature. Hampson JP, et al. **Fam Pract** 1996 Jun;13(3):264–79 (230 ref.)

Values in health care professional socialization: implications for geriatric education in interdisciplinary teamwork. Clark PG. **Gerontologist** 1997 Aug;37(4):441–51 (80 ref.)

The integration of clinical and experimental work. Covino NA. **Int J Clin Exp Hypn** 1997 Apr;45(2):109–25 (70 ref.)

The politics of collaboration as viewed through the lens of a collaborative nursing research project. Beattie J, et al. **J Adv Nurs** 1996 Oct;24(4):682–7 (26 ref.)

Nursing research: our world not theirs? Mulhall A. **J Adv Nurs** 1997 May;25(5):969–76 (63 ref.)

Liaison mental health nursing: origins, definition and prospects. Roberts D. **J Adv Nurs** 1997 Jan;25(1):101–8 (60 ref.)

Relationships between primary care physicians and consultants in managed care. Brett AS. **J Clin Ethics** 1997 Spring;8(1):60–5 (13 ref.)

A manual on manners and courtesies for the shared care of patients. Stoeckle JD, et al. **J Clin Ethics** 1997 Spring; 8(1):22–33 (19 ref.)

Physicians' collaboration with chaplains: difficulties and benefits. Thiel MM, et al. **J Clin Ethics** 1997 Spring; 8(1):94–103 (23 ref.)

Characteristics of materials distributed by drug companies. An evaluation of appropriateness [see comments] Stryer D, et al. **J Gen Intern Med** 1996 Oct;11(10):575–83 (81 ref.) Comment in: J Gen Intern Med 1996 Oct;11(10):635–6. Comment in: J Gen Intern Med 1996 Oct;11(10):637–9. Comment in: J Gen Intern Med 1996 Oct;11(10):640–1. Comment in: J Gen Intern Med 1996 Oct;11(10):642–4.

Multiple authorship: issues and recommendations. Erlen JA, et al. **J Prof Nurs** 1997 Jul–Aug;13(4):262–70 (23 ref.)

Quality management for health care in the Middle East and north Africa: professional cooperation as part of the peace process. Habib J, et al. **Jt Comm J Qual Improv** 1997 Jan; 23(1):65–8 (0 ref.)

Guiding dialogue in the transformation of teacher–student relationships. Gaines S, et al. **Nurs Outlook** 1996 May–Jun; 44(3):124–8 (14 ref.)

Collaborative care between nurse practitioners and primary care physicians. Arcangelo V, et al. **Prim Care** 1996 Mar; 23(1):103–13 (15 ref.)

Supervision as an analytic experience. Pegeron JP. **Psychoanal Q** 1996 Oct;65(4):693–710 (26 ref.)

[Psychopathology and cognitive neurosciences: theoretical conflicts and experimental paradigms] Jouvent R, et al. **Encephale** 1997 Jun;23 Spec No 3:9–14 (30 ref.) (Eng. Abstr.) **(Fre)**

[Medical expert assessment in civil and criminal law—legal evaluation of medical expert opinion] Schlund GH. **Z Arztl Fortbild (Jena)** 1996 Nov;90(7):596–602 (37 ref.) (Eng. Abstr.) **(Ger)**

INTERSEXUALITY see **HERMAPHRODITISM**

INTERSTELLAR DUST see **COSMIC DUST**

INTERSTITIAL CELL-STIMULATING HORMONE see **LH**

INTERSTITIAL CELL TUMOR see **LEYDIG CELL TUMOR**

INTERSTITIAL CYSTITIS see **CYSTITIS, INTERSTITIAL**

INTERSTITIAL FLUID see **EXTRACELLULAR SPACE**

INTERSTITIAL LUNG DISEASES see **LUNG DISEASES, INTERSTITIAL**

INTERSTITIAL NEPHRITIS see **NEPHRITIS, INTERSTITIAL**

INTERTARSAL JOINT see **TARSAL JOINT**

INTERTROCHANTERIC FRACTURES see **HIP FRACTURES**

INTERVENING SEQUENCES see **INTRONS**

INTERVENTION STUDIES

Design and conduct of occupational injury intervention studies: a review of evaluation strategies. Zwerling C, et al. **Am J Ind Med** 1997 Aug;32(2):164–79 (105 ref.)

Design issues addressed in published evaluations of adolescent HIV-risk reduction interventions: a review [see comments] Stanton B, et al. **J Adolesc Health** 1996 Jun; 18(6):387–96 (61 ref.) Comment in: J Adolesc Health 1996 Jun;18(6):379.

Nevada's elderly: nutrition screening, risk, and interventions. Wilson D, et al. **Nutr Rev** 1996 Jan;54(1 Pt 2):S45–7 (12 ref.)

INTERVERTEBRAL DISK

see related
DISKECTOMY

The current treatment of cervical disc rupture. Roberts MP, et al. **Conn Med** 1996 Jul;60(7):395–8 (23 ref.)

[Septic arthritis of posterior lumbar facet joint] Ben Hamouda M, et al. **J Radiol** 1997 May;78(5):373–6 (10 ref.) (Eng. Abstr.) **(Fre)**

[Thoracic spondylotic myelopathies. Apropos of 4 new cases] Stecken J, et al. **Neurochirurgie** 1996;42(3):147–52 (40 ref.) (Eng. Abstr.) **(Fre)**

INJURIES

The disc at risk in athletes: perspectives on operative and nonoperative care. Young JL, et al. **Med Sci Sports Exerc** 1997 Jul;29(7 Suppl):S222–32 (74 ref.)

PATHOLOGY

Imaging findings in patients with failed back surgery syndrome. Van Goethem JW, et al. **J Belge Radiol** 1997 Apr;80(2):81–4 (19 ref.)

The radiologic assessment for a lumbar disc herniation. Herzog RJ. **Spine** 1996 Dec 15;21(24 Suppl):19S–38S (90 ref.)

PHYSIOLOGY

Influence of varying muscle forces on lumbar intradiscal pressure: an in vitro study. Wilke HJ, et al. **J Biomech** 1996 Apr;29(4):549–55 (39 ref.)

Is the nucleus pulposus a solid or a fluid? Mechanical behaviors of the nucleus pulposus of the human intervertebral disc. Iatridis JC, et al. **Spine** 1996 May 15; 21(10):1174–84 (68 ref.)

PHYSIOPATHOLOGY

Distinguish the specific from non-specific low back pain. Hanley EN Jr. **Bull Hosp Jt Dis** 1996;55(4):195–6 (23 ref.)

Epidemiology and pathogenesis of non-specific low back pain: what does the epidemiology tell us? Riihimäki H. **Bull Hosp Jt Dis** 1996;55(4):197–8 (14 ref.)

RADIOGRAPHY

Complications of cervical discography: findings in a large series. Guyer RD, et al. **J Spinal Disord** 1997 Apr; 10(2):95–101 (14 ref.)

SURGERY

The artificial disc: theory, design and materials. Bao QB, et al. **Biomaterials** 1996 Jun;17(12):1157–67 (107 ref.)

Intervertebral disc prosthesis. Results and prospects for the year 2000. Lemaire JP, et al. **Clin Orthop** 1997 Apr; (337):64–76 (66 ref.)

Operative treatment of degenerative cervical disk disease. Heller JG, et al. **J South Orthop Assoc** 1996 Fall; 5(3):188–206 (44 ref.)

Persistent serratus anterior paralysis after fracture of an anterior cervical bone graft. Smith MD, et al. **Orthopedics** 1996 Jul;19(7):611–3 (16 ref.)

History and current status of percutaneous arthroscopic disc surgery. Kambin P, et al. **Spine** 1996 Dec 15;21(24 Suppl):57S–61S (54 ref.)

Lumbar disc disease with discogenic pain. What surgical treatment is most effective? Nachemson A, et al. **Spine** 1996 Aug 1;21(15):1835–8 (21 ref.)

ULTRASTRUCTURE

Is the nucleus pulposus a solid or a fluid? Mechanical behaviors of the nucleus pulposus of the human intervertebral disc. Iatridis JC, et al. **Spine** 1996 May 15; 21(10):1174–84 (68 ref.)

INTERVERTEBRAL DISK CHEMOLYSIS

see related
CHYMOPAPAIN

Lumbar chymopapain nucleolysis. Javid MJ, et al. **Neurosurg Clin N Am** 1996 Jan;7(1):17–27 (50 ref.)

Update on chemonucleolysis. Brown MD. **Spine** 1996 Dec 15;21(24 Suppl):62S–68S (50 ref.)

METHODS

Is there a future for percutaneous intradiscal therapy? Maroon JC, et al. **Clin Neurosurg** 1996;43:239–51 (49 ref.)

INTERVERTEBRAL DISK DISPLACEMENT

see related
INTERVERTEBRAL DISK CHEMOLYSIS
SCIATICA

The current treatment of cervical disc rupture. Roberts MP, et al. **Conn Med** 1996 Jul;60(7):395–8 (23 ref.)

Three-level thoracic disc herniation: case report and review of the literature. Korovessis PG, et al. **Eur Spine J** 1997; 6(1):74–6 (22 ref.)

COMPLICATIONS

Steps in the management of low back pain [see comments] Kuritzky L. **Hosp Pract (Off Ed)** 1996 Aug 15;31(8):109–24; discussion 124, 130 (5 ref.) Comment in: Hosp Pract (Off Ed) 1997 Mar 15;32(3):41.

Large osteoarthritic bone cyst of the facet joint causing low back pain and sciatica. Shirado O, et al. **Orthopedics** 1997 May;20(5):472–5 (13 ref.)

Neurophysiologic tests in diagnosis of nerve root compression caused by disc herniation. Dvořák J. **Spine** 1996 Dec 15;21(24 Suppl):39S–44S (33 ref.)

[Acute lumbar disk displacement with nerve root compression. Indications for peridural steroid injection] Schlumpf U, et al. **Schweiz Rundsch Med Prax** 1997 Feb 18;86(8):292–5 (29 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Osteoid osteoma of the vertebral body with extension across the intervertebral disc. Hurtgen KL, et al. **J Manipulative Physiol Ther** 1996 Feb;19(2):118–23 (31 ref.)

Herniated intervertebral disc without pain. Gorman WF, et al. **J Okla State Med Assoc** 1997 May–Jun;90(5):185–90 (38 ref.)

History and physical examination in patients with herniated lumbar discs. Andersson GB, et al. **Spine** 1996 Dec 15;21(24 Suppl):10S–18S (25 ref.)

Consensus summary of the diagnosis and treatment of lumbar disc herniation. Andersson GB, et al. **Spine** 1996 Dec 15; 21(24 Suppl):75S–78S (0 ref.)

Intraradicular, intervertebral disc herniation. A case report. Finkel HZ. **Spine** 1997 May 1;22(9):1028–9 (8 ref.)

Late displacement of a fracture dislocation at the lumbosacral junction. A case study. Steinitz DK, et al. **Spine** 1997 May 1;22(9):1024–7 (9 ref.)

[Consensus on diagnosis and treatment of the lumbosacral radicular syndrome. Dutch Society for Neurology] Stam J. **Ned Tijdschr Geneeskd** 1996 Dec 28;140(52):2621–7 (31 ref.) (Eng. Abstr.) **(Dut)**

DRUG THERAPY

Update on chemonucleolysis. Brown MD. **Spine** 1996 Dec 15;21(24 Suppl):62S–68S (50 ref.)

ETIOLOGY

Natural history and nonoperative treatment of lumbar disc herniation. Saal JA. **Spine** 1996 Dec 15;21(24 Suppl):2S–9S (45 ref.)

PATHOLOGY

Magnetic resonance imaging and clinical follow-up: study of 27 patients receiving chiropractic care for cervical and lumbar disc herniations. BenEliyahu DJ. **J Manipulative Physiol Ther** 1996 Nov–Dec;19(9):597–606 (58 ref.)

PHYSIOPATHOLOGY

[Biomechanics of lumbar instability] Krismer M, et al. **Orthopade** 1997 Jun;26(6):516–20 (37 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Automated percutaneous nucleotomy: restricted indications based on CT scan appearance. Castro WH, et al. **Neurosurg Clin N Am** 1996 Jan;7(1):43–7 (24 ref.)

Radiologic case study. Symptomatic, calcified extruded disk of the thoracic spine. Falbo SE, et al. **Orthopedics** 1997 Jan;20(1):84, 76 (8 ref.)

The radiologic assessment for a lumbar disc herniation. Herzog RJ. **Spine** 1996 Dec 15;21(24 Suppl):19S–38S (90 ref.)

SURGERY

The far lateral approach to lumbar disc herniations. Porchet F, et al. **Adv Tech Stand Neurosurg** 1997;23:249–74 (50 ref.)

Lumbar discectomy microdiscectomy: "the gold standard". Apostolides PJ, et al. **Clin Neurosurg** 1996;43:228–38 (41 ref.)

The case for posterior lumbar interbody fusion. Branch CL Jr. **Clin Neurosurg** 1996;43:252–67 (62 ref.)

Arthroscopic discectomy of the lumbar spine. Kambin P, et al. **Clin Orthop** 1997 Apr;(337):49–57 (54 ref.)

Controversies in low back pain: the surgical approach. Hanley EN Jr, et al. **Instr Course Lect** 1994;43:415–23 (56 ref.)

Indications for laser surgery in the treatment of degenerative disk disease of the lumbar spine. Simpson JM. **J South Orthop Assoc** 1996 Fall;5(3):174–80 (38 ref.)

Automated percutaneous nucleotomy: restricted indications based on CT scan appearance. Castro WH, et al. **Neurosurg Clin N Am** 1996 Jan;7(1):43–7 (24 ref.)

Stereotactic lumbar microdiscectomy. Koutrouvelis PG, et al. **Neurosurg Clin N Am** 1996 Jan;7(1):49–57 (14 ref.)

Transforaminal endoscopic microdiscectomy. Mathews HH. **Neurosurg Clin N Am** 1996 Jan;7(1):59–63 (23 ref.)

Automated percutaneous discectomy. Quigley MR, et al. **Neurosurg Clin N Am** 1996 Jan;7(1):29–35 (27 ref.)
Percutaneous laser discectomy. Quigley MR. **Neurosurg Clin N Am** 1996 Jan;7(1):37–42 (17 ref.)
Percutaneous endoscopic thoracic discectomy. Regan JJ. **Neurosurg Clin N Am** 1996 Jan;7(1):87–98 (43 ref.)
Causes of failed back surgery syndrome [editorial] Goupille P. **Rev Rhum Engl Ed** 1996 Apr;63(4):235–9 (40 ref.)
History and current status of percutaneous arthroscopic disc surgery. Kambin P, et al. **Spine** 1996 Dec 15;21(24 Suppl):57S–61S (54 ref.)
Focus issue on lumbar disc herniation: macro– and microdiscectomy. McCulloch JA. **Spine** 1996 Dec 15;21(24 Suppl):45S–56S (105 ref.)
Minimally invasive disc surgery. Nucleotomy versus fragmentectomy. Onik GM, et al. **Spine** 1997 Apr 1; 22(7):827–8; discussion 828–30 (6 ref.)
Results of surgery compared with conservative management for lumbar disc herniations. Postacchini F. **Spine** 1996 Jun 1;21(11):1383–7 (19 ref.)
Image–guided minimally invasive therapy. Seibel RM. **Surg Endosc** 1997 Feb;11(2):154–62 (38 ref.)
Vascular injury during lumbar disc surgery. Report of two cases; a review of the literature. Sağdiç K, et al. **Vasa** 1996; 25(4):378–81 (21 ref.)
[Vascular complications during surgery of lumbar disk herniation. Apropos of 3 personal cases and 37 cases from a national investigation] Mercier P, et al. **Neurochirurgie** 1996;42(4–5):202–8 (16 ref.) (Eng. Abstr.) **(Fre)**
[Minimally invasive approach and surgical procedures in the lumbar spine] Ogon M, et al. **Orthopade** 1997 Jun; 26(6):553–61 (49 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Randomized controlled trials in industrial low back pain relating to return to work. Part 2. Discogenic low back pain. Scheer SJ, et al. **Arch Phys Med Rehabil** 1996 Nov; 77(11):1189–97 (79 ref.)
Magnetic resonance imaging and clinical follow–up: study of 27 patients receiving chiropractic care for cervical and lumbar disc herniations. BenEliyahu DJ. **J Manipulative Physiol Ther** 1996 Nov–Dec;19(9):597–606 (58 ref.)
Lumbar chymopapain nucleolysis. Javid MJ, et al. **Neurosurg Clin N Am** 1996 Jan;7(1):17–27 (50 ref.)
Consensus summary of the diagnosis and treatment of lumbar disc herniation. Andersson GB, et al. **Spine** 1996 Dec 15; 21(24 Suppl):75S–78S (0 ref.)
Results of surgery compared with conservative management for lumbar disc herniations. Postacchini F. **Spine** 1996 Jun 1;21(11):1383–7 (19 ref.)
Natural history and nonoperative treatment of lumbar disc herniation. Saal JA. **Spine** 1996 Dec 15;21(24 Suppl):2S–9S (45 ref.)
[Consensus on diagnosis and treatment of the lumbosacral radicular syndrome. Dutch Society for Neurology] Stam J. **Ned Tijdschr Geneeskd** 1996 Dec 28;140(52):2621–7 (31 ref.) (Eng. Abstr.) **(Dut)**
[The conservative treatment for lumbar disc herniation] Maruo S. **Nippon Seikeigeka Gakkai Zasshi** 1996 Oct; 70(10):673–84 (40 ref.) **(Jpn)**

INTERVIEW, PSYCHOLOGICAL

Motivational interviewing: research, practice, and puzzles. Miller WR. **Addict Behav** 1996 Nov–Dec;21(6):835–42 (35 ref.)
Annotation: communication strategies for deaf children. Gregory S, et al. **J Child Psychol Psychiatry** 1996 Nov; 37(8):895–905 (95 ref.)

INTERVIEWS

Computer–assisted self–interviewing: a multimedia approach to dietary assessment. Kohlmeier L, et al. **Am J Clin Nutr** 1997 Apr;65(4 Suppl):1275S–1281S (32 ref.)
The validity of self–reported drug use in survey research: an overview and critique of research methods. Harrison L. **NIDA Res Monogr** 1997;167:17–36 (41 ref.)
Mode of interview and reporting of sensitive issues: design and implementation of audio computer–assisted self–interviewing. Lessler JT, et al. **NIDA Res Monogr** 1997;167:366–82 (27 ref.)
Hearing the patient's 'voice': toward a social poetics in diagnostic interviews. Katz AM, et al. **Soc Sci Med** 1996 Sep;43(6):919–31 (32 ref.)
[Qualitative methods in empirical health research. Focused group interview and participant observation] Maunsbach M, et al. **Nord Med** 1997 Apr;112(4):126–8 (15 ref.) **(Dan)**

METHODS

A review of recently published qualitative research in general practice. More methodological questions than answers? Hoddinott P, et al. **Fam Pract** 1997 Aug;14(4):313–9 (33 ref.)
Research interviewing. Plant H. **Palliat Med** 1996 Oct; 10(4):339–41 (16 ref.)

INTESTINAL ABSORPTION

see related

MALABSORPTION SYNDROMES

Molecular biology of Na+ absorption. Barbry P, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):G571–85 (155 ref.)
Physiological regulation of gastric emptying and glucose absorption. Macdonald IA. **Diabet Med** 1996 Sep;13(9 Suppl 5):S11–5 (12 ref.)
Decelerating gastric emptying: therapeutic possibilities in type 2 diabetes. Phillips WT, et al. **Diabet Med** 1996 Sep; 13(9 Suppl 5):S44–8 (13 ref.)
Absorption of beta–carotene and other carotenoids in humans and animal models. van Vliet T. **Eur J Clin Nutr** 1996 Jul;50 Suppl 3:S32–7 (59 ref.)
Impaired absorption of oral levodopa: a major cause for response fluctuations in Parkinson's disease. Djaldetti R, et al. **Isr J Med Sci** 1996 Dec;32(12):1224–7 (26 ref.)
Control of iron absorption. Anderson GJ. **J Gastroenterol Hepatol** 1996 Nov;11(11):1030–2 (5 ref.)
Current concepts in intestinal peptide absorption. Fricker G, et al. **J Pept Sci** 1996 Jul–Aug;2(4):195–211 (209 ref.)
We may not measure the correct intestinal wall permeability coefficient of drugs: alternative absorptive clearance concept [see comments] Chiou WL. **J Pharmacokinet Biopharm** 1995 Jun;23(3):323–31 (42 ref.) Comment in: J Pharmacokinet Biopharm 1995 Jun;23(3):333–7.
The oral absorption of micro– and nanoparticulates: neither exceptional nor unusual. Florence AT. **Pharm Res** 1997 Mar;14(3):259–66 (88 ref.)
Gastrointestinal drug absorption: is it time to consider heterogeneity as well as homogeneity? Macheras P, et al. **Pharm Res** 1997 Jul;14(7):842–7 (48 ref.)
Carrier–mediated intestinal transport of drugs. Tsuji A, et al. **Pharm Res** 1996 Jul;13(7):963–77 (110 ref.)
Experimental studies of intestinal ion and water transport. Holtug K, et al. **Scand J Gastroenterol Suppl** 1996; 216:95–110 (176 ref.)
Clinical implications of the sugar absorption test: intestinal permeability test to assess mucosal barrier function. Uil JJ, et al. **Scand J Gastroenterol Suppl** 1997;223:70–8 (75 ref.)
Alterations in intestinal transport of oxalate in disease states. Hatch M, et al. **Scanning Microsc** 1995;9(4):1121–6; discussion 1126 (43 ref.)
Dietary oxalate and its intestinal absorption. Holmes RP, et al. **Scanning Microsc** 1995;9(4):1109–18; discussion 1118–20 (53 ref.)
Intestinal water and electrolyte absorption and secretion. Chang EB. **Transplant Proc** 1996 Oct;28(5):2679–82 (3 ref.)
Motility and absorption in the transplanted gut. Sarr MG. **Transplant Proc** 1996 Oct;28(5):2535–8 (30 ref.)
[Intestinal permeability] Montalto M, et al. **Recenti Prog Med** 1997 Mar;88(3):140–7 (53 ref.) (Eng. Abstr.) **(Ita)**
[Absorption and secretion mechanism of water and electrolytes in intestines] Hanai H, et al. **Nippon Naika Gakkai Zasshi** 1996 Jul 10;85(7):1034–41 (7 ref.) **(Jpn)**
[Digestion and absorption mechanism of carbohydrates and proteins in intestines] Takeda E, et al. **Nippon Naika Gakkai Zasshi** 1996 Jul 10;85(7):1029–33 (5 ref.) **(Jpn)**
[Absorption test of protein] Nakamura T. **Nippon Rinsho** 1997 Apr;55 Suppl 2:109–10 (3 ref.) **(Jpn)**
[Absorption test of fat] Nakamura T. **Nippon Rinsho** 1997 Apr;55 Suppl 2:111–2 (3 ref.) **(Jpn)**
[d–xylose absorption test] Nakamura T. **Nippon Rinsho** 1997 Apr;55 Suppl 2:115–6 (8 ref.) **(Jpn)**

DRUG EFFECTS

Inhibitory effect of oleanene–type triterpene oligoglycosides on ethanol absorption: the structure–activity relationships. Yoshikawa M, et al. **Adv Exp Med Biol** 1996;404:207–18 (40 ref.)
Interactions between drugs and nutrients. Tschanz C, et al. **Adv Pharmacol** 1996;35:1–26 (57 ref.)
Olestra: assessing its potential to interact with drugs in the gastrointestinal tract. Goldman P. **Clin Pharmacol Ther** 1997 Jun;61(6):613–8 (39 ref.)
Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. Charman WN, et al. **J Pharm Sci** 1997 Mar;86(3):269–82 (263 ref.)
Strategies for delivery of peptides utilizing absorption–enhancing agents. Fix JA. **J Pharm Sci** 1996 Dec;85(12):1282–5 (10 ref.)

PHYSIOLOGY

A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: advantages and limitations of the Caco–2 model. Delie F, et al. **Crit Rev Ther Drug Carrier Syst** 1997;14(3):221–86 (282 ref.)
Mechanisms of intestinal calcium absorption and availability of dietary calcium in pigs. Kaune R. **DTW Dtsch Tierarztl Wochenschr** 1996 Jun;103(6):215–8 (28 ref.)
Mechanisms of intestinal phosphorus absorption and availability of dietary phosphorus in pigs. Schröder B, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Jun; 103(6):209–14 (87 ref.)
The influence of food on the absorption and metabolism of drugs: an update [see comments] Williams L, et al. **Eur J Drug Metab Pharmacokinet** 1996 Jul–Sep; 21(3):201–11 (82 ref.) Comment in: Eur J Drug Metab Pharmacokinet 1997 Jan–Mar;22(1):85–6.
Small–intestinal absorption of cadmium and the significance of mucosal metallothionein. Elsenhans B, et al. **Hum Exp Toxicol** 1997 Aug;16(8):429–34 (28 ref.)
Kinetic analysis of the intestinal iron absorption process in situ. The potential of vascularly autoperfused intestinal loops. Hunder G, et al. **Hum Exp Toxicol** 1997 Aug; 16(8):425–8 (17 ref.)
The assessment of doses and effects from intakes of radioactive particles. Harrison JD, et al. **J Anat** 1996 Dec; 189 (Pt 3):521–30 (23 ref.)
Nanoparticles and microparticles for drug and vaccine delivery. Kreuter J. **J Anat** 1996 Dec;189 (Pt 3):503–5 (24 ref.)
The intestinal uptake of particles and the implications for drug and antigen delivery. O'Hagan DT. **J Anat** 1996 Dec; 189 (Pt 3):477–82 (38 ref.)
Particle uptake and translocation across epithelial membranes. Thomas NW, et al. **J Anat** 1996 Dec;189 (Pt 3):487–90 (17 ref.)
Mathematical modeling of digestion and nutrient absorption in pigs. Bastianelli D, et al. **J Anim Sci** 1996 Aug; 74(8):1873–87 (86 ref.)
Peptide regulation of intestinal glucose absorption. Bird AR, et al. **J Anim Sci** 1996 Oct;74(10):2523–40 (267 ref.)
Intestinal rings and isolated intestinal mucosal cells. Fix JA. **Pharm Biotechnol** 1996;8:51–66 (36 ref.)
Models of drug absorption in situ and in conscious animals. Griffiths R, et al. **Pharm Biotechnol** 1996;8:67–84 (30 ref.)
Cultured intestinal epithelial cell models. Hidalgo IJ. **Pharm Biotechnol** 1996;8:35–50 (32 ref.)
Methods for evaluating intestinal permeability and metabolism in vitro. Smith PL. **Pharm Biotechnol** 1996; 8:13–34 (89 ref.)
[Glutamine: effects on the immune system, protein balance and intestinal functions (see comments)] Roth E, et al. **Wien Klin Wochenschr** 1996;108(21):669–76 (59 ref.) (Eng. Abstr.) Comment in: Wien Klin Wochenschr 1996 ;108(21):667–8. **(Ger)**
[Biological activity of a carrier molecule–iron complex: probable mechanisms of intestinal absorption] Curri SB. **Boll Chim Farm** 1996 Apr;135(4):248–58 (21 ref.) (Eng. Abstr.) **(Ita)**

INTESTINAL ATRESIA

COMPLICATIONS

Anorectal malformation with ileal atresia. Asabe K, et al. **Pediatr Surg Int** 1997 Apr;12(4):302–4 (9 ref.)

SURGERY

Congenital multiple intestinal atresia successfully treated with multiple anastomoses in a premature neonate: report of a case. Hasegawa T, et al. **Surg Today** 1996;26(10):849–51 (17 ref.)

INTESTINAL BYPASS see **JEJUNOILEAL BYPASS**

INTESTINAL DISEASES

Biochemical tests in diseases of the intestinal tract: their contributions to diagnosis, management, and understanding the pathophysiology of specific disease states. Abdelshaheed NN, et al. **Crit Rev Clin Lab Sci** 1997 Apr; 34(2):141–223 (357 ref.)

CHEMICALLY INDUCED

Lisinopril–induced isolated visceral angioedema: review of ACE–inhibitor–induced small bowel angioedema. Abdelmalek MF, et al. **Dig Dis Sci** 1997 Apr;42(4):847–50 (15 ref.)
[Non–gastroduodenal digestive toxicity of non–steroidal anti–inflammatory agents] Lesur G. **Presse Med** 1996 Oct 12;25(30):1376–80 (25 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Rare causes of occult small intestinal bleeding, including aortoenteric fistulas, small bowel tumors, and small bowel ulcers. Bashir RM, et al. **Gastrointest Endosc Clin N Am** 1996 Oct;6(4):709–38 (238 ref.)
Enteropathies associated with protracted diarrhea of infancy: clinicopathological features, cellular and molecular mechanisms. Cutz E, et al. **Pediatr Pathol Lab Med** 1997 May–Jun;17(3):335–68 (77 ref.)

DIAGNOSIS

Enteroscopy with enteroclysis. Aliperti G, et al. **Gastrointest Endosc Clin N Am** 1996 Oct;6(4):803–10 (32 ref.)
Intraoperative enteroscopy. Indications and techniques. Cave DR, et al. **Gastrointest Endosc Clin N Am** 1996 Oct; 6(4):793–802 (47 ref.)
Sonde enteroscopy. Technique, depth of insertion, and yield of lesions. Gostout CJ. **Gastrointest Endosc Clin N Am** 1996

Oct;6(4):777–92 (22 ref.)
Push enteroscopy. Technique, depth, and yield of insertion. Wilmer A, et al. **Gastrointest Endosc Clin N Am** 1996 Oct; 6(4):759–76 (73 ref.)
[Hydrogen test (H2) in the air expired for the diagnosis of small bowel bacterial overgrowth] Marcelino RT, et al. **Arq Gastroenterol** 1995 Oct–Dec;32(4):191–8 (73 ref.) (Eng. Abstr.) **(Por)**

DRUG THERAPY

[Ciprofloxacin in the treatment of intestinal infections of bacterial etiology] Sidorenko SV. **Antibiot Khimioter** 1997; 42(6):26–33 (60 ref.) **(Rus)**

ENZYMOLOGY

[The digestive barrier functions of the enzymatic systems of the normal small intestine and in pathology] Timofeeva NM. **Vestn Ross Akad Med Nauk** 1996;(1):37–41 (24 ref.) (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Effects of transition on bowel diseases in sub–Saharan Africans. Walker AR, et al.
Eur J Gastroenterol Hepatol 1997 Feb;9(2):207–10 (57 ref.)
[Infectious disease in Kenya––epidemiological study of diarrhoeal disease in children] Aihara M. **Rinsho Byori** 1997 May;45(5):421–6 (6 ref.) (Eng. Abstr.) **(Jpn)**
[Gastrointestinal tuberculosis] Miagkova LP.
Klin Med (Mosk) 1997;75(8):9–12 (15 ref.) **(Rus)**

ETIOLOGY

Bladder, bowel and sexual function after hysterectomy for benign conditions. Thakar R, et al.
Br J Obstet Gynaecol 1997 Sep;104(9):983–7 (41 ref.)
Small bowel review––Part II. Thomson AB, et al.
Can J Gastroenterol 1997 Mar;11(2):159–65 (84 ref.)
Mechanisms of adhesion development and effects on wound healing. Holmdahl L. **Eur J Surg Suppl** 1997;(579):7–9 (11 ref.)
External strangulation of the small bowel following injury to inguinoscrotal hernia. Chaloner EJ, et al. **Injury** 1997 Jan;28(1):69–70 (4 ref.)
Evisceration after enterocele repair: a rare complication of vaginal surgery. Virtanen HS, et al.
Int Urogynecol J Pelvic Floor Dysfunct 1996;7(6):344–7 (27 ref.)
Pathogenesis of enteric infection by Campylobacter. Ketley JM. **Microbiology** 1997 Jan;143 (Pt 1):5–21 (80 ref.)
[Enteral clostridial infections caused by Clostridium perfringens type A (the pathogenic aspects)] Bakulin IN. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Mar–Apr; (2):106–13 (42 ref.) **(Rus)**

GENETICS

The genetic basis of primary disorders of intestinal fat transport. Levy E. **Clin Invest Med** 1996 Oct;19(5):317–24 (75 ref.)

IMMUNOLOGY

Neuro–immune pathobiology of infectious enteric disease. Argenzio RA. **Adv Exp Med Biol** 1997;412:21–9 (55 ref.)

METABOLISM

The genetic basis of primary disorders of intestinal fat transport. Levy E. **Clin Invest Med** 1996 Oct;19(5):317–24 (75 ref.)

MICROBIOLOGY

Virus–receptor interactions in the enteric tract. Virus–receptor interactions. Holmes KV, et al.
Adv Exp Med Biol 1997;412:125–33 (49 ref.)
Interactions between the enteric pathogen and the host. An assortment of bacterial lectins and a set of glycoconjugate receptors. Mouricout M. **Adv Exp Med Biol** 1997; 412:109–23 (88 ref.)
[Pathogenic intestinal bacteria: adhesion and invasion] Paerregaard A. **Ugeskr Laeger** 1997 Mar 3;159(10):1417–22 (39 ref.) (Eng. Abstr.) **(Dan)**
[Pathogenicity of fungi in the intestines––current status of the discussion] Scheurlen M. **Fortschr Med** 1996 Sep 20; 114(26):319–21 (20 ref.) (Eng. Abstr.) **(Ger)**
[Clinical pictures of orointestinal candidiasis. Fiction or reality?] Knoke M. **Mycoses** 1996;39 Suppl 1:40–3 (22 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Comparative histopathology of intestinal infections. Moon HW. **Adv Exp Med Biol** 1997;412:1–19 (70 ref.)
The pathology of fibrosing colonopathy of cystic fibrosis: a study of 12 cases and review of the literature. Pawel BR, et al. **Hum Pathol** 1997 Apr;28(4):395–9 (25 ref.)
The role of apoptosis in intestinal disease. Watson AJ.
J Gastroenterol 1997 Jun;32(3):414–23 (100 ref.)
Variant Hirschsprung's disease. Puri P. **J Pediatr Surg** 1997 Feb;32(2):149–57 (52 ref.)

PHYSIOPATHOLOGY

Neuro–immune pathobiology of infectious enteric disease. Argenzio RA. **Adv Exp Med Biol** 1997;412:21–9 (55 ref.)
Adaptation of intestinal nutrient transport in health and disease. Part I. Thomson AB, et al. **Dig Dis Sci** 1997 Mar; 42(3):453–69 (254 ref.)
Adaptation of intestinal nutrient transport in health and disease. Part II. Thomson AB, et al. **Dig Dis Sci** 1997 Mar; 42(3):470–88 (271 ref.)
Can the intestine adapt to a changing environment? [editorial; comment] Thompson JS. **Gastroenterology** 1997 Oct; 113(4):1402–5 (32 ref.) Comment on: Gastroenterology 1997 Oct;113(4):1074–81.
Neurological complications of enteric disease [see comments] Wills A, et al. **Gut** 1996 Oct;39(4):501–4 (71 ref.) Comment in: Gut 1997 Jul;41(1):133.
Changes in gene structure and regulation of E–cadherin during epithelial development, differentiation, and disease. Jankowski JA, et al. **Prog Nucleic Acid Res Mol Biol** 1997; 57:187–215 (192 ref.)
Primary and secondary disorders to gut muscle and nerve. Kamm MA. **Scand J Gastroenterol Suppl** 1996;220:91–3 (17 ref.)
Functional disorders of the small intestine. Kellow JE, et al. **Semin Gastrointest Dis** 1996 Oct;7(4):208–16 (32 ref.)

PREVENTION & CONTROL

Enteric immunization: promises and challenges. Brown WR. **Dig Dis** 1996 May–Jun;14(3):192–200 (41 ref.)
[Prophylaxis of infectious intestinal diseases before leaving for underdeveloped countries] Sakaue Y. **Rinsho Byori** 1997 May;45(5):415–20 (0 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Radiographic imaging of small bowel disease. Newman J. **Radiol Technol** 1997 Jul–Aug;68(6):491–504; quiz 505–8 (24 ref.)

SURGERY

Short–bowel syndrome. Medical aspects and prospects of intestinal transplantation. Pirenne J. **Acta Chir Belg** 1996 Jul–Aug;96(4):150–4 (27 ref.)
The unique challenge of small intestinal transpiantation. Woodward JM, et al. **Br J Hosp Med** 1996 Sep 18–Oct 1;56(6):285–90 (25 ref.)
Can the intestine adapt to a changing environment? [editorial; comment] Thompson JS. **Gastroenterology** 1997 Oct; 113(4):1402–5 (32 ref.) Comment on: Gastroenterology 1997 Oct;113(4):1074–81.
The surgical management of aortoenteric fistulas. Montgomery RS, et al. **Surg Clin North Am** 1996 Oct; 76(5):1147–57 (54 ref.)
[Ileostomy––cecal fistula––colostomy––which is the most suitable fecal diversion method with reference to technique, function, complications and reversal?] Köckerling F, et al. **Zentralbl Chir** 1997;122(1):34–8 (23 ref.) (Eng. Abstr.) **(Ger)**
[Sciatic hernia: report of a case and review of the literature] Guzmán–Valdivia–Gómez G, et al. **Gac Med Mex** 1996 Jan–Feb;132(1):85–7 (4 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Management of lower gastrointestinal tract dysfunction. Corazziari E, et al. **Semin Neurol** 1996 Sep;16(3):289–96 (72 ref.)
[The concept of an ecological approach to the therapy of intestinal infections] Potievskii EG, et al.
Zh Mikrobiol Epidemiol Immunobiol 1997 Mar–Apr; (2):98–101 (23 ref.) **(Rus)**

ULTRASONOGRAPHY

[The ultrasonic diagnosis of tumorous diseases of the stomach and intestines] al–Abbas B, et al.
Vestn Khir Im I I Grek 1995;154(4–6):132–4 (41 ref.) **(Rus)**

INTESTINAL DISEASES, PARASITIC

Human enteric infection with Ancylostoma caninum: hookworms reappraised in the light of a "new" zoonosis. Prociv P, et al. **Acta Trop** 1996 Sep;62(1):23–44 (105 ref.)
Gut Coccidia–– Isospora, Cryptosporidium, Cyclospora and Sarcocystis. Ackers JP. **Semin Gastrointest Dis** 1997 Jan; 8(1):33–44 (166 ref.)

COMPLICATIONS

[A case of severe malnutrition due to Ascaris lumbricoides infestation in a boy] Castiglione N, et al.
Pediatr Med Chir 1996 Nov–Dec;18(6):615–7 (8 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Laboratory diagnosis of Cyclospora infections. Eberhard ML, et al. **Arch Pathol Lab Med** 1997 Aug;121(8):792–7 (21 ref.)
The approach to stool examination for parasites. Koontz F, et al. **Gastroenterol Clin North Am** 1996 Sep;25(3):435–49 (33 ref.)
Intestinal microsporidiosis. Croft SL, et al.
Semin Gastrointest Dis 1997 Jan;8(1):45–55 (70 ref.)
[Intestinal and systemic infections caused by Microsporidia] Weber R, et al. **Internist (Berl)** 1996 Sep;37(9):912–8 (22 ref.) **(Ger)**
[Intestinal helminthiasis––general practice problem of the gastroenterologist] Volkheimer G. **Z Gastroenterol** 1996 Sep;34(9):534–41 (2 ref.) (Eng. Abstr.) **(Ger)**
[A case of asymptomatic colonic anisakiasis revealed by chance and treated by colonoscopy] Yoshikawa I, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Nov;93(11):837–40 (22 ref.) **(Jpn)**

EPIDEMIOLOGY

Intestinal geohelminthiasis in the developing world [published erratum appears in Natl Med J India 1997 May–Jun;10(3):153] Ananthakrishnan S, et al.
Natl Med J India 1997 Mar–Apr;10(2):67–71 (74 ref.)
[Intestinal geohelminthosis in man and domestic animals in the riverside sections of the Valdivia River Basin, Chile] Torres P, et al. **Bol Chil Parasitol** 1995 Jul–Dec; 50(3–4):57–66 (82 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Enteric helminth infection: immunopathology and resistance during intestinal nematode infection. Grencis RK.
Chem Immunol 1997;66:41–61 (106 ref.)

PARASITOLOGY

[Intestinal parasitic diseases] Saito O, et al.
Nippon Naika Gakkai Zasshi 1996 Jul 10;85(7):1114–20 (5 ref.) **(Jpn)**

PREVENTION & CONTROL

[Prophylaxis of infectious intestinal diseases before leaving for underdeveloped countries] Sakaue Y. **Rinsho Byori** 1997 May;45(5):415–20 (0 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

[Intestinal schistosomiasis, a facultative precancerous condition? Review of the literature with reference to Schistosoma japonicum associated rectum carcinoma] Jatzko G, et al. **Chirurg** 1997 Jul;68(7):727–31 (24 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[A case of asymptomatic colonic anisakiasis revealed by chance and treated by colonoscopy] Yoshikawa I, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Nov;93(11):837–40 (22 ref.) **(Jpn)**

VETERINARY

Prospects for development of genetic markers for resistance to gastrointestinal parasite infection in sheep. Beh KJ, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):879–97 (149 ref.)
Feasibility and implications of breeding sheep for resilience to nematode challenge. Bisset SA, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):857–68 (38 ref.)
Nutrition and parasite interaction. Coop RL, et al.
Int J Parasitol 1996 Aug–Sep;26(8–9):951–62 (89 ref.)
Nutritional enhancement of parasite control in small ruminant production systems in developing countries of South–East Asia and the Pacific. Knox M, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):963–70 (44 ref.)
Prospects for the immunological control of ruminant gastrointestinal nematodes: natural immunity, can it be harnessed? Miller HR. **Int J Parasitol** 1996 Aug–Sep; 26(8–9):801–11 (87 ref.)
Controlling internal parasites in grazing ruminants without recourse to anthelmintics: approaches, experiences and prospects. Niezen JH, et al. **Int J Parasitol** 1996 Aug–Sep; 26(8–9):983–92 (35 ref.)
Prospects of breeding small ruminants for resistance to internal parasites. Woolaston RR, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):845–55 (63 ref.)
[Genetic aspects of sheep resistance to gastrointestinal nematode infections] Doligalska M. **Wiad Parazytol** 1995; 41(4):405–11 (42 ref.) (Eng. Abstr.) **(Pol)**

INTESTINAL EPITHELIUM see **INTESTINAL MUCOSA**

INTESTINAL FISTULA

CHEMICALLY INDUCED

Colosplenic fistula in a patient treated with interleukin–2 for malignant melanoma. Chun ES, et al.
J Comput Assist Tomogr 1997 Jul–Aug;21(4):674–6 (8 ref.)

CLASSIFICATION

Classification and pathophysiology of enterocutaneous fistulas. Berry SM, et al. **Surg Clin North Am** 1996 Oct; 76(5):1009–18 (54 ref.)

COMPLICATIONS

Infected abdominal aortic aneurysm associated with a psoas abscess, aorto–duodenal and sigmoid fistulas. Case report and review of the literature. Louagie YA, et al.
Acta Chir Belg 1997 Jan–Feb;97(1):39–43 (22 ref.)
Unilateral lower limb hypertrophic osteoarthropathy due to aortic graft infection and aortoenteric fistula. Martínez JI,

et al. **Eur J Vasc Endovasc Surg** 1996 Nov;12(4):497–500 (23 ref.)
Surgical management and treatment of sepsis associated with gastrointestinal fistulas. Rolandelli R, et al. **Surg Clin North Am** 1996 Oct;76(5):1111–22 (19 ref.)

DIAGNOSIS

[Biliodigestive fistulae. Apropos 2 cases with opposite symptomatology] Picucci L, et al. **Minerva Chir** 1997 Apr; 52(4):439–47 (34 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Small bowel fistulae in Degos' disease: a case report and literature review. Atchabahian A, et al. **Am J Gastroenterol** 1996 Oct;91(10):2208–11 (57 ref.)
Salpingocolonic fistula secondary to diverticulitis. Hain JM, et al. **Am Surg** 1996 Dec;62(12):984–6 (22 ref.)
Bouveret's syndrome: case report and review of the literature. Frattaroli FM, et al. **Hepatogastroenterology** 1997 Jul–Aug;44(16):1019–22 (79 ref.)
Colovesical fistula caused by chronic chicken bone perforation. Khan MS, et al. **Ir J Med Sci** 1996 Jan–Mar; 165(1):51–2 (19 ref.)
Enteric fistulas and necrotizing enterocolitis. Stringer MD, et al. **J Pediatr Surg** 1996 Sep;31(9):1268–71 (15 ref.)
Local recurrence of renal cell carcinoma causing duodenal–inferior vena caval fistula: case report and review of the literature. Benjamin DS, et al. **Urology** 1996 Oct; 48(4):636–8 (16 ref.)
[Malignant duodenal fistulae of colonic origin (clinical case)] Spay G, et al. **Chirurgie** 1996;121(4):269–72 (24 ref.) (Eng. Abstr.) **(Fre)**
[Internal appendicular–organic fistulae––a complication of acute appendicitis] Bokhan KL. **Vestn Khir Im I I Grek** 1997;156(2):137–9 (28 ref.) **(Rus)**

PHYSIOPATHOLOGY

Classification and pathophysiology of enterocutaneous fistulas. Berry SM, et al. **Surg Clin North Am** 1996 Oct; 76(5):1009–18 (54 ref.)

RADIOGRAPHY

Radiologic investigation and treatment of gastrointestinal fistulas. Thomas HA. **Surg Clin North Am** 1996 Oct; 76(5):1081–94 (46 ref.)

SURGERY

Factors influencing outcome in patients with gastrointestinal fistula. Campos AC, et al. **Surg Clin North Am** 1996 Oct; 76(5):1191–8 (37 ref.)
Colonic fistulas. Lavery IC. **Surg Clin North Am** 1996 Oct; 76(5):1183–90 (11 ref.)
Radiologic investigation and treatment of gastrointestinal fistulas. Thomas HA. **Surg Clin North Am** 1996 Oct; 76(5):1081–94 (46 ref.)

THERAPY

General management of gastrointestinal fistulas. Recognition, stabilization, and correction of fluid and electrolyte imbalances. Foster CE 3rd, et al. **Surg Clin North Am** 1996 Oct;76(5):1019–33 (60 ref.)
Nutritional management of patients with gastrointestinal fistulas. Meguid MM, et al. **Surg Clin North Am** 1996 Oct; 76(5):1035–80 (114 ref.)
Small bowel fistulas. Tassiopoulos AK, et al. **Surg Clin North Am** 1996 Oct;76(5):1175–81 (18 ref.)

INTESTINAL HORMONE RECEPTORS see **RECEPTORS, GASTROINTESTINAL HORMONE**

INTESTINAL HORMONES see **GASTROINTESTINAL HORMONES**

INTESTINAL MOTILITY see **GASTROINTESTINAL MOTILITY**

INTESTINAL MUCOSA

see related
INTESTINAL SECRETIONS

Enteric bacterial toxins: mechanisms of action and linkage to intestinal secretion. Sears CL, et al. **Microbiol Rev** 1996 Mar;60(1):167–215 (588 ref.)
[Gastrointestinal mucus] Paerregaard A. **Ugeskr Laeger** 1996 Sep 23;158(39):5423–7 (40 ref.) (Eng. Abstr.) **(Dan)**

ANATOMY & HISTOLOGY

The anatomical basis of intestinal immunity. Mowat AM, et al. **Immunol Rev** 1997 Apr;156:145–66 (277 ref.)
[Intestinal intercellular tight junctions. I. Structure and molecular mechanisms of regulation] Stein J, et al. **Z Gastroenterol** 1997 Mar;35(3):205–20 (117 ref.) (Eng. Abstr.) **(Ger)**

BLOOD SUPPLY

Gut dysfunction in critically ill patients: a review of the literature. Stechmiller JK, et al. **Am J Crit Care** 1997 May; 6(3):204–9 (66 ref.)
Rapid monitoring of gastrointestinal intraluminal PCO2 as an end–organ perfusion index [editorial; comment] Tao W, et al. **Crit Care Med** 1997 Sep;25(9):1458–9 (28 ref.) Comment on: Crit Care Med 1997 Sep;25(9):1575–8.
Hormonal therapy for bleeding gastrointestinal mucosal vascular abnormalities: a promising alternative. Marshall JK, et al. **Eur J Gastroenterol Hepatol** 1997 May;9(5):521–5 (60 ref.)

CYTOLOGY

T cell development within the intestinal mucosa: clues to a novel immune–endocrine network? Klein JR. **Adv Neuroimmunol** 1996;6(4):397–405 (43 ref.)
Epithelial cell growth and differentiation. I. Intestinal growth factors. Drucker DJ. **Am J Physiol** 1997 Jul;273(1 Pt 1):G3–6 (13 ref.)
Epithelial cell growth and differentiation. II. Intestinal apoptosis. Potten CS. **Am J Physiol** 1997 Aug;273(2 Pt 1):G253–7 (16 ref.)
Circadian cell kinetics in humans. Aspects related to cancer chemotherapy. Smaaland R, et al. **In Vivo** 1995 Nov–Dec; 9(6):529–37 (91 ref.)
Extracellular matrix components and integrins in relationship to human intestinal epithelial cell differentiation. Beaulieu JF. **Prog Histochem Cytochem** 1997;31(4):1–78 (380 ref.)
Regulation and significance of apoptosis in the stem cells of the gastrointestinal epithelium. Potten CS, et al. **Stem Cells** 1997;15(2):82–93 (96 ref.)
The life and times of an intestinal M cell. Savidge TC. **Trends Microbiol** 1996 Aug;4(8):301–6 (50 ref.)

DRUG EFFECTS

Selective decontamination of the digestive tract in intensive care patients. van Saene HK, et al. **Br J Hosp Med** 1995 Dec 13–1996 Jan 16;54(11):558–61 (21 ref.)
Insights into opioid action in the intestinal tract. De Luca A, et al. **Pharmacol Ther** 1996;69(2):103–15 (164 ref.)
Peptic activity and gastroduodenal mucosal damage. Raufman JP. **Yale J Biol Med** 1996 Jan–Feb;69(1):85–90 (27 ref.)

ENZYMOLOGY

Small–intestinal absorption of cadmium and the significance of mucosal metallothionein. Elsenhans B, et al. **Hum Exp Toxicol** 1997 Aug;16(8):429–34 (28 ref.)

IMMUNOLOGY

T cell development within the intestinal mucosa: clues to a novel immune–endocrine network? Klein JR. **Adv Neuroimmunol** 1996;6(4):397–405 (43 ref.)
Dynamic regulation of intestinal immunity by hormones of the hypothalamus–pituitary–thyroid axis. Wang J. **Adv Neuroimmunol** 1996;6(4):407–17 (51 ref.)
Mucosal allergy: role of mast cells and eosinophil granulocytes in the gut. Bischoff SC. **Baillieres Clin Gastroenterol** 1996 Sep;10(3):443–59 (79 ref.)
Special features of the intestinal lymphocytic system. Köhne G, et al. **Baillieres Clin Gastroenterol** 1996 Sep;10(3):427–42 (82 ref.)
Regulation of immune responses of the intestinal mucosa. Abreu–Martin MT, et al. **Crit Rev Immunol** 1996; 16(3):277–309 (231 ref.)
Mechanisms of oral tolerance. Garside P, et al. **Crit Rev Immunol** 1997;17(2):119–37 (130 ref.)
The mucosal adjuvant activities of ADP–ribosylating bacterial enterotoxins. Snider DP. **Crit Rev Immunol** 1995; 15(3–4):317–48 (276 ref.)
Pathogenesis of inflammatory bowel disease. Zeitz M. **Digestion** 1997;58 Suppl 1:59–61 (25 ref.)
Advances in mucosal immunology. McGowan I, et al. **Gastroenterol Clin North Am** 1997 Jun;26(2):145–73 (213 ref.)
The anatomical basis of intestinal immunity. Mowat AM, et al. **Immunol Rev** 1997 Apr;156:145–66 (277 ref.)
Mucosal T cells and mast cells share common adhesion receptors. Smith TJ, et al. **Immunol Today** 1996 Feb; 17(2):60–3 (53 ref.)
Reciprocal IFN–gamma and TGF–beta responses regulate the occurrence of mucosal inflammation. Strober W, et al. **Immunol Today** 1997 Feb;18(2):61–4 (11 ref.)
Alterations of the mucosal immune system in inflammatory bowel disease. MacDermott RP. **J Gastroenterol** 1996 Dec; 31(6):907–16 (84 ref.)
Mucosal immunology and models of mucosal HIV infection. Griffin GE, et al. **Mem Inst Oswaldo Cruz** 1996 May–Jun; 91(3):367–9 (9 ref.)
Microflora–associated defense stimulating factors. Pulverer G, et al. **Scand J Gastroenterol Suppl** 1997;222:107–11 (41 ref.)
A gut reaction: lymphoepithelial communication in the intestine [comment] [see comments] Shanahan F. **Science** 1997 Mar 28;275(5308):1897–8 (11 ref.) Comment on: Science 1997 Mar 28;275(5308):1937–9. Comment in: Science 1997 Mar 28;275(5308):1897–8.
Mucosal immune responses to intestinal bacterial pathogens. Bloom PD, et al. **Semin Gastrointest Dis** 1996 Jul; 7(3):151–66 (125 ref.)
T–cell responses to enteric antigens. Hurst SD, et al. **Semin Gastrointest Dis** 1996 Jul;7(3):118–23 (45 ref.)
New approaches to mucosal immunization. Langermann S. **Semin Gastrointest Dis** 1996 Jan;7(1):12–8 (67 ref.)
The immunologic aspects of human immunodeficiency virus infection in the gastrointestinal tract. Schneider T, et al. **Semin Gastrointest Dis** 1996 Jan;7(1):19–29 (108 ref.)
Basic and clinical overview of the mucosal immune system. Toy LS, et al. **Semin Gastrointest Dis** 1996 Jan;7(1):2–11 (125 ref.)
Immunopathology of human inflammatory bowel disease. Brandtzaeg P, et al. **Springer Semin Immunopathol** 1997; 18(4):555–89 (218 ref.)
The intestinal epithelial cell: immunological aspects. Christ AD, et al. **Springer Semin Immunopathol** 1997;18(4):449–61 (108 ref.)
On the front lines: intraepithelial lymphocytes as primary effectors of intestinal immunity. Lefrançois L, et al. **Springer Semin Immunopathol** 1997;18(4):463–75 (83 ref.)
Immunopathology of human immunodeficiency virus infection in the gastrointestinal tract. Schneider T, et al. **Springer Semin Immunopathol** 1997;18(4):515–33 (124 ref.)
Immunopathology of gluten–sensitive enteropathy. Scott H, et al. **Springer Semin Immunopathol** 1997;18(4):535–53 (102 ref.)
Cytokines and intestinal inflammation. Fiocchi C. **Transplant Proc** 1996 Oct;28(5):2442–3 (11 ref.)
Yin and Yang of mucosal immunology. Mayer L. **Transplant Proc** 1996 Oct;28(5):2435–7 (22 ref.)
Exogenous nucleotides and gastrointestinal immunity. Walker WA. **Transplant Proc** 1996 Oct;28(5):2438–41 (22 ref.)
The life and times of an intestinal M cell. Savidge TC. **Trends Microbiol** 1996 Aug;4(8):301–6 (50 ref.)
M cells and the pathogenesis of mucosal and systemic infections. Siebers A, et al. **Trends Microbiol** 1996 Jan; 4(1):22–9 (60 ref.)
Mucosal mast cells and the allergic response against nematode parasites. Miller HR. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):331–6 (28 ref.)
Immune responses towards intestinal bacteria––current concepts and future perspectives. Duchmann R, et al. **Z Gastroenterol** 1997 May;35(5):337–46 (78 ref.)
[Physiopathology of mucous–membrane immunity system and neuroendocrine regulation] Nakura H, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):694 (0 ref.) **(Jpn)**
[Molecular biological characterization of intestinal intraepithelial lymphocytes and their receptors] Nagura H, et al. **Nippon Rinsho** 1996 Apr;54(4):1162–9 (23 ref.) (Eng. Abstr.) **(Jpn)**

INJURIES

Epithelial migration in the colon: filling in the gaps [editorial] Wilson AJ, et al. **Clin Sci (Colch)** 1997 Aug;93(2):97–108 (103 ref.)
Colonic injury after ESWL of renal calculi [letter] Etzkorn KP, et al. **Gastrointest Endosc** 1996 Oct;44(4):511–2 (3 ref.)

METABOLISM

Bowditch lecture. Integrated regulation of intestinal epithelial transport: intercellular and intracellular pathways. Barrett KE. **Am J Physiol** 1997 Apr;272(4 Pt 1):C1069–76 (40 ref.)
Nutrient regulation of intestinal sugar–transporter expression. Shirazi–Beechey SP, et al. **Biochem Soc Trans** 1996 May; 24(2):389–92 (18 ref.)
Renal and intestinal autocrine monoaminergic systems: dopamine versus 5–hydroxytryptamine. Vieira–Coelho MA, et al. **Clin Exp Hypertens** 1997 Jan–Feb;19(1–2):43–58 (22 ref.)
Does gastric tonometry work? No. Benjamin E, et al. **Crit Care Clin** 1996 Jul;12(3):587–601 (77 ref.)
Does gastric tonometry work? Yes. Brown SD, et al. **Crit Care Clin** 1996 Jul;12(3):569–85 (72 ref.)
Tonometry. A review of clinical studies. Taylor DE, et al. **Crit Care Clin** 1996 Oct;12(4):1007–18 (46 ref.)
The roles of excessive gastro–oesophageal reflux, disordered oesophageal motility and decreased mucosal sensitivity in the pathogenesis of Barrett's oesophagus. Niemantsverdriet EC, et al. **Eur J Gastroenterol Hepatol** 1997 May;9(5):515–9 (41 ref.)
Rolling in the clover: trefoil factor family (TFF)–domain peptides, cell migration and cancer. Wright NA, et al. **FEBS Lett** 1997 May 19;408(2):121–3 (20 ref.)
Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease [published erratum appears in Gastroenterology 1997 Aug;113(2):732] Rugtveit J, et al. **Gastroenterology** 1997 May;112(5):1493–505 (78 ref.)
Hydrogen sulphide: a bacterial toxin in ulcerative colitis? Pitcher MC, et al. **Gut** 1996 Jul;39(1):1–4 (86 ref.)
Kinetic analysis of the intestinal iron absorption process in situ. The potential of vascularly autoperfused intestinal loops. Hunder G, et al. **Hum Exp Toxicol** 1997 Aug; 16(8):425–8 (17 ref.)
Gastrointestinal tonometry: a monitor of regional dysoxia. Gutierrez G, et al. **New Horiz** 1996 Nov;4(4):413–9 (52 ref.)
Intestinal rings and isolated intestinal mucosal cells. Fix JA. **Pharm Biotechnol** 1996;8:51–66 (36 ref.)
[Intestinal permeability] Montalto M, et al. **Recenti Prog Med** 1997 Mar;88(3):140–7 (53 ref.) (Eng. Abstr.) **(Ita)**

MICROBIOLOGY

Epithelial cell growth and differentiation. III. Promoting diversity in the intestine: conversations between the microflora, epithelium, and diffuse GALT. Gordon JI, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):G565–70 (29 ref.)

Enteropathogenic E. coli exploitation of host epithelial cells. Finlay BB, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:26–31 (51 ref.)

Clinical uses of probiotics for stabilizing the gut mucosal barrier: successful strains and future challenges. Salminen S, et al. **Antonie Van Leeuwenhoek** 1996 Oct;70(2–4):347–58 (90 ref.)

Selective decontamination of the digestive tract in intensive care patients. van Saene HK, et al. **Br J Hosp Med** 1995 Dec 13–1996 Jan 16;54(11):558–61 (21 ref.)

Paving the way for pathogens? Schauer DB. **Curr Biol** 1997 Feb 1;7(2):R75–7 (10 ref.)

Epithelial cells as sensors for microbial infection. Kagnoff MF, et al. **J Clin Invest** 1997 Jul 1;100(1):6–10 (26 ref.)

Microflora-associated defense stimulating factors. Pulverer G, et al. **Scand J Gastroenterol Suppl** 1997;222:107–11 (41 ref.)

Colonization and translocation of intestinal bacterial flora. Wells CL. **Transplant Proc** 1996 Oct;28(5):2653–6 (78 ref.)

PARASITOLOGY

Mucosal mast cells and the allergic response against nematode parasites. Miller HR.
Vet Immunol Immunopathol 1996 Nov;54(1–4):331–6 (28 ref.)

PATHOLOGY

Ulcerative colitis: an epithelial disease? Gibson PR.
Baillieres Clin Gastroenterol 1997 Mar;11(1):17–33 (84 ref.)

Sonde enteroscopy. Technique, depth of insertion, and yield of lesions. Gostout CJ. **Gastrointest Endosc Clin N Am** 1996 Oct;6(4):777–92 (22 ref.)

Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation. Strober W, et al. **Immunol Today** 1997 Feb;18(2):61–4 (11 ref.)

Molecular aspects of mucosal repair: a summary [comment] Moss SF, et al. **Yale J Biol Med** 1996 Mar–Apr;69(2):155–8 (7 ref.) Comment on: Yale J Biol Med 1996 Mar–Apr;69(2):105–18. Comment on: Yale J Biol Med 1996 Mar–Apr;69(2):119–29.

Modulation of cell adhesion during epithelial restitution in the gastrointestinal tract. Pignatelli M. **Yale J Biol Med** 1996 Mar–Apr;69(2):131–5 (38 ref.)

Peptic activity and gastroduodenal mucosal damage. Raufman JP. **Yale J Biol Med** 1996 Jan–Feb;69(1):85–90 (27 ref.)

[The problem of regeneration of the gastrointestinal tract mucosa in erosive-ulcerous lesions] Potkhin PP, et al.
Arkh Patol 1997 Mar–Apr;59(2):68–71 (47 ref.) (Eng. Abstr.) **(Rus)**

[Erosive lesions of gastroduodenal mucosa: etiology, pathogenesis, clinical features, treatment] Maev IV, et al.
Klin Med (Mosk) 1997;75(6):57–61 (40 ref.) **(Rus)**

PHYSIOLOGY

Do intestinal villi secrete? Jodal M, et al.
Acta Physiol Scand 1996 Oct;158(2):115–8 (35 ref.)

A critical role for nitric oxide in intestinal barrier function and dysfunction. Alican I, et al. **Am J Physiol** 1996 Feb; 270(2 Pt 1):G225–37 (106 ref.)

Molecular biology of Na+ absorption. Barbry P, et al.
Am J Physiol 1997 Sep;273(3 Pt 1):G571–85 (155 ref.)

Epithelial cell growth and differentiation. I. Intestinal growth factors. Drucker DJ. **Am J Physiol** 1997 Jul;273(1 Pt 1):G3–6 (13 ref.)

Epithelial cell growth and differentiation. III. Promoting diversity in the intestine: conversations between the microflora, epithelium, and diffuse GALT. Gordon JI, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):G565–70 (29 ref.)

Epithelial cell growth and differentiation. II. Intestinal apoptosis. Potten CS. **Am J Physiol** 1997 Aug;273(2 Pt 1):G253–7 (16 ref.)

Regulation of the mucosal epithelial barrier. Göke M, et al.
Baillieres Clin Gastroenterol 1996 Sep;10(3):393–405 (89 ref.)

Mucosal protection through active intestinal secretion: neural and paracrine modulation by 5-hydroxytryptamine. Brown DR. **Behav Brain Res** 1996;73(1–2):193–7 (54 ref.)

Cooperative modulation of gastrointestinal mucosal defence by prostaglandins and nitric oxide. Wallace JL.
Clin Invest Med 1996 Oct;19(5):346–51 (52 ref.)

Epithelial cells as sensors for microbial infection. Kagnoff MF, et al. **J Clin Invest** 1997 Jul 1;100(1):6–10 (26 ref.)

Healing the epithelium: solving the problem from two sides. Podolsky DK. **J Gastroenterol** 1997 Feb;32(1):122–6 (33 ref.)

Role of supplementation of a nucleic acid solution on the intestinal mucosa under total parenteral nutrition. Tsujinaka T, et al. **Nutrition** 1997 Apr;13(4):369–71 (9 ref.)

Peptic ulcer pathophysiology: acid, bicarbonate, and mucosal function. Højgaard L, et al.
Scand J Gastroenterol Suppl 1996;216:10–5 (62 ref.)

Clinical implications of the sugar absorption test: intestinal permeability test to assess mucosal barrier function. Uil JJ, et al. **Scand J Gastroenterol Suppl** 1997;223:70–8 (75 ref.)

Intestinal water and electrolyte absorption and secretion. Chang EB. **Transplant Proc** 1996 Oct;28(5):2679–82 (3 ref.)

Motility and absorption in the transplanted gut. Sarr MG.
Transplant Proc 1996 Oct;28(5):2535–8 (30 ref.)

Molecular aspects of mucosal repair: a summary [comment] Moss SF, et al. **Yale J Biol Med** 1996 Mar–Apr;69(2):155–8 (7 ref.) Comment on: Yale J Biol Med 1996 Mar–Apr;69(2):105–18. Comment on: Yale J Biol Med 1996 Mar–Apr;69(2):119–29.

[Role of nitric oxide in maintaining the mucosal integrity and in inflammatory gastrointestinal diseases] Lamarque D, et al. **Gastroenterol Clin Biol** 1996;20(12):1085–98 (213 ref.) **(Fre)**

[The role of natural growth stimulators in regulation of regeneration processes in small intestinal epithelium after irradiation] Dziekiewicz M. **Przegl Lek** 1996;53(8):610–3 (21 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

A critical role for nitric oxide in intestinal barrier function and dysfunction. Alican I, et al. **Am J Physiol** 1996 Feb; 270(2 Pt 1):G225–37 (106 ref.)

Intestinal epithelial barrier dysfunction in Crohn's disease. Ma TY. **Proc Soc Exp Biol Med** 1997 Apr;214(4):318–27 (87 ref.)

[Physiopathology of mucous-membrane immunity system and neuroendocrine regulation] Nakura H, et al.
Nihon Rinsho Meneki Gakkai Kaishi 1995 Dec;18(6):694 (0 ref.) **(Jpn)**

SECRETION

Do intestinal villi secrete? Jodal M, et al.
Acta Physiol Scand 1996 Oct;158(2):115–8 (35 ref.)

The intestine, an endocrine organ. Schmidt WE.
Digestion 1997;58 Suppl 1:56–8 (16 ref.)

Rice inhibits intestinal secretions. Goldberg ED, et al.
Nutr Rev 1996 Jan;54(1 Pt 1):36–7 (8 ref.)

Recent aspects of the regulation of intestinal mucus secretion. Laboisse C, et al. **Proc Nutr Soc** 1996 Mar;55(1B):259–64 (18 ref.)

Brain-gut interaction. Gué M, et al. **Semin Neurol** 1996 Sep; 16(3):235–43 (83 ref.)

SURGERY

Endoscopic mucosal resection. Shim CS.
J Korean Med Sci 1996 Dec;11(6):457–66 (33 ref.)

TRANSPLANTATION

Intestinal water and electrolyte absorption and secretion. Chang EB. **Transplant Proc** 1996 Oct;28(5):2679–82 (3 ref.)

Colonization and translocation of intestinal bacterial flora. Wells CL. **Transplant Proc** 1996 Oct;28(5):2653–6 (78 ref.)

ULTRASTRUCTURE

Adaptive remodelling of intestinal epithelium assessed using stereology: correlation of single cell and whole organ data with nutrient transport. Mayhew TM.
Histol Histopathol 1996 Jul;11(3):729–41 (101 ref.)

INTESTINAL NEOPLASMS

An overview of adenocarcinoma of the small intestine. Neugut AI, et al. **Oncology (Huntingt)** 1997 Apr; 11(4):529–36; discussion 545, 549–50 (62 ref.)

[Primary malignant T-cell lymphoma of large intestine] Furubayashi T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Apr;94(4):278–83 (20 ref.) **(Jpn)**

COMPLICATIONS

Rare causes of occult small intestinal bleeding, including aortoenteric fistulas, small bowel tumors, and small bowel ulcers. Bashir RM, et al.
Gastrointest Endosc Clin N Am 1996 Oct;6(4):709–38 (238 ref.)

Solitary intestinal fibromatosis: a rare cause of intestinal perforation in neonates. Al-Salem AH, et al.
Pediatr Surg Int 1997 Jul;12(5–6):437–40 (13 ref.)

DIAGNOSIS

Approaches to the diagnosis of gut neuroendocrine tumors: the last word (today). Modlin IM, et al.
Gastroenterology 1997 Feb;112(2):583–90 (23 ref.)

Economic aspects of endoscopic screening for intestinal precancerous conditions. Sonnenberg A, et al.
Gastrointest Endosc Clin N Am 1997 Jan;7(1):165–84 (19 ref.)

[Primary lymphoma of the small intestine. A clinical case report and review of the literature] Bonaccorso R, et al.
Minerva Chir 1997 May;52(5):643–7 (13 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Octreotide in malignant intestinal obstruction. Pandha HS, et al. **Anticancer Drugs** 1996 Jan;7 Suppl 1:5–10 (23 ref.)

ECONOMICS

Economic aspects of endoscopic screening for intestinal precancerous conditions. Sonnenberg A, et al.
Gastrointest Endosc Clin N Am 1997 Jan;7(1):165–84 (19 ref.)

EPIDEMIOLOGY

Increased incidence of second malignancies associated with small bowel adenocarcinoma. Ripley D, et al.
Can J Gastroenterol 1997 Jan–Feb;11(1):65–8 (16 ref.)

Primary intestinal lymphoma: clinical and therapeutic features of 32 patients. Zinzani PL, et al.
Haematologica 1997 May–Jun;82(3):305–8 (27 ref.)

ETIOLOGY

Early development of adenocarcinoma in a young woman following augmentation cystoplasty for undiversion. Carr LK, et al. **J Urol** 1997 Jun;157(6):2255–6 (3 ref.)

The Min mouse: a genetic model for intestinal carcinogenesis. Thompson MB. **Toxicol Pathol** 1997 May–Jun;25(3):329–32 (31 ref.)

GENETICS

Studies of neoplasia in the Min mouse. Shoemaker AR, et al. **Biochim Biophys Acta** 1997 Apr 18;1332(2):F25–48 (202 ref.)

Molecular genetics of small bowel cancer. Arber N, et al.
Cancer Epidemiol Biomarkers Prev 1997 Sep;6(9):745–8 (57 ref.)

Manipulation of the mouse germline in the study of Min-induced neoplasia. Bilger A, et al.
Semin Cancer Biol 1996 Oct;7(5):249–60 (118 ref.)

The Min mouse: a genetic model for intestinal carcinogenesis. Thompson MB. **Toxicol Pathol** 1997 May–Jun;25(3):329–32 (31 ref.)

PATHOLOGY

Interdigitating reticulum-cell sarcoma of the intestine: a case report and review of the literature. Banner B, et al.
Diagn Cytopathol 1997 Sep;17(3):216–22 (23 ref.)

Rare causes of occult small intestinal bleeding, including aortoenteric fistulas, small bowel tumors, and small bowel ulcers. Bashir RM, et al.
Gastrointest Endosc Clin N Am 1996 Oct;6(4):709–38 (238 ref.)

Small bowel cancer. Imaging features and staging. Buckley JA, et al. **Radiol Clin North Am** 1997 Mar;35(2):381–402 (31 ref.)

Small bowel cancer. Clinical and pathologic features. Gore RM. **Radiol Clin North Am** 1997 Mar;35(2):351–60 (83 ref.)

Clear cell tumors of the alimentary tract and abdominal cavity. Ritter JH, et al. **Semin Diagn Pathol** 1997 Aug; 14(3):213–9 (42 ref.)

[Bone metaplasia in adenomatous intestinal polyp. Report of a case and review of the literature] Cavazza A, et al.
Pathologica 1996 Dec;88(6):511–3 (17 ref.) (Eng. Abstr.) **(Ita)**

RADIOGRAPHY

Imaging of primary small intestinal tumours by enteroclysis and CT with pathological correlation. Gourtsoyiannis N, et al. **Eur Radiol** 1997;7(5):625–42 (50 ref.)

Small bowel cancer. Imaging features and staging. Buckley JA, et al. **Radiol Clin North Am** 1997 Mar;35(2):381–402 (31 ref.)

Small bowel cancer. Radiologic diagnosis. Maglinte DT, et al. **Radiol Clin North Am** 1997 Mar;35(2):361–80 (50 ref.)

SURGERY

Surgical management for carcinoid tumors of small bowel, appendix, colon, and rectum. Stinner B, et al.
World J Surg 1996 Feb;20(2):183–8 (26 ref.)

[Treatment of tumors of the small intestine. Clinical results of 31 years/review of the literature] Sarkar MR, et al.
Leber Magen Darm 1996 Jul;26(4):204–6, 209–14 (0 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Tumours of the intestine. Takahashi M, et al.
IARC Sci Publ 1996;(126):137–47 (29 ref.)

INTESTINAL OBSTRUCTION

COMPLICATIONS

Transverse colon volvulus and associated Chilaiditi's syndrome: case report and literature review. Plorde JJ, et al. **Am J Gastroenterol** 1996 Dec;91(12):2613–6 (14 ref.)

CONGENITAL

[Intestinal emergencies in newborn infants] Brzezinska R.
Radiologe 1997 Jun;37(6):432–8 (25 ref.) (Eng. Abstr.) **(Ger)**

[Volvulus in childhood] Peitz HG. **Radiologe** 1997 Jun; 37(6):439–45 (30 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Eosinophilic colitis presenting as a left-sided colocolonic intussusception with secondary large bowel obstruction: an uncommon entity with a rare presentation. Box JC, et al. **Am Surg** 1997 Aug;63(8):741–3 (16 ref.)

INTESTINAL OBSTRUCTION

DRUG THERAPY

Octreotide in malignant intestinal obstruction. Pandha HS, et al. **Anticancer Drugs** 1996 Jan;7 Suppl 1:5–10 (23 ref.)

[Acute reversible pan–dysautonomia: effect of erythromycin on gastrointestinal involvement] Lagasse JP, et al. **Gastroenterol Clin Biol** 1997;21(4):331–4 (12 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

An unusual case of small bowel obstruction. Verstocken A, et al. **Acta Chir Belg** 1996 Jul–Aug;96(4):168–9 (23 ref.)

Small bowel obstruction secondary to enterolith impaction complicating jejunal diverticulitis. Harris LM, et al. **Am J Gastroenterol** 1997 Sep;92(9):1538–40 (16 ref.)

Delayed gastric emptying and postoperative ileus after nongastric abdominal surgery: part II. Resnick J, et al. **Am J Gastroenterol** 1997 Jun;92(6):934–40 (69 ref.)

Segmental xanthomatosis of the ileocecal valve with anatomic and functional obstruction. Goodman MD. **Arch Pathol Lab Med** 1997 Jan;121(1):75–8 (22 ref.)

Acute small bowel obstruction caused by endometriosis. Martín–Duce A, et al. **Eur J Surg** 1996 Sep;162(9):747–9 (41 ref.)

The clinical significance of adhesions: focus on intestinal obstruction. Ellis H. **Eur J Surg Suppl** 1997;(577):5–9 (29 ref.)

Gastric volvulus: an old disease process with some new twists. Schaefer DC, et al. **Gastroenterologist** 1997 Mar; 5(1):41–5 (19 ref.)

Congenital caecal cystic duplication presenting with caecal volvulus in an elderly woman. Choong CK, et al. **Int J Colorectal Dis** 1997;12(4):256–8 (27 ref.)

Strangulation ileus resulting from encasement of a loop of the small intestine by the great omentum, caused by abnormal adhesion. Kimura H, et al. **J Gastroenterol** 1996 Oct;31(5):714–6 (8 ref.)

Intestinal stricture following seat belt injury in children. Lynch JM, et al. **J Pediatr Surg** 1996 Oct;31(10):1354–7 (13 ref.)

Colonic volvulus: a rare presentation of Hirschsprung's disease. Sarioğlu A, et al. **J Pediatr Surg** 1997 Jan; 32(1):117–8 (10 ref.)

Abdominal cocoon in a male: rare cause of intestinal obstruction. Wig JD, et al. **Trop Gastroenterol** 1995 Oct–Dec;16(4):31–3 (15 ref.)

[Incarcerated hernia following laparoscopic surgery. A complication to be avoided. Case presentation and literature review] Esteve C, et al. **Rev Med Suisse Romande** 1997 Jan;117(1):25–8 (23 ref.) (Eng. Abstr.) **(Fre)**

[Cholelithic intestinal obstruction] Bokhan KL. **Vestn Khir Im I I Grek** 1996;155(4):110–2 (22 ref.) **(Rus)**

[Intestinal obstruction as late presentation of traumatic diaphragmatic hernia: report of a case and review of the literature] Vásquez JC, et al. **Rev Gastroenterol Peru** 1996 May–Aug;16(2):158–61 (21 ref.) (Eng. Abstr.) **(Spa)**

[A case of isolated jejunal ulcer and review of the literature] Schmulson Wasserman MJ, et al. **Rev Invest Clin** 1995 Nov–Dec;47(6):477–80 (16 ref.) (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

The role of radiology in the diagnosis of small-bowel obstruction. Maglinte DD, et al. **AJR Am J Roentgenol** 1997 May;168(5):1171–80 (71 ref.)

Clinics in diagnostic imaging (13). Congenital duodenal obstruction. Chan KL, et al. **Singapore Med J** 1996 Jun; 37(3):308–10 (10 ref.)

[The computed tomographic picture of deep gallstone ileus] Rieger J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Feb;166(2):164–6 (10 ref.) **(Ger)**

SURGERY

Cecal volvulus in pregnancy. Case report and review of literature. John H, et al. **Arch Gynecol Obstet** 1996; 258(3):161–4 (18 ref.)

Pulmonary aspiration complicating intraoperative small-bowel decompression: a case report and literature review. Phillips I, et al. **Can J Surg** 1996 Dec;39(6):495–8 (32 ref.)

The management of patients with advanced cancer (II). Heys SD, et al. **Eur J Surg Oncol** 1997 Jun;23(3):257–63 (69 ref.)

Self-expandable nitinol coil stent for management of colonic obstruction due to a malignant anastomotic stricture. Bashir RM, et al. **Gastrointest Endosc** 1996 Oct;44(4):497–501 (44 ref.)

Neuroleptic malignant syndrome: case report and review. Dykstra TJ, et al. **J Am Osteopath Assoc** 1997 Jun; 97(6):355–7 (10 ref.)

[Immediate resection–anastomosis after intra–operative colonic irrigation in cancer of the left colon with obstruction] Rohr S, et al. **J Chir (Paris)** 1996 Jul; 133(5):195–200 (36 ref.) (Eng. Abstr.) **(Fre)**

[Volvulus of the right colon. Plea for right hemicolectomy. Apropos of a series of 23 cases] Tuech JJ, et al. **J Chir (Paris)** 1996 Sep;133(6):267–9 (14 ref.) (Eng. Abstr.) **(Fre)**

[Late results of Childs–Phillips mesenteric plication for therapy and prevention of small intestine ileus] Sclabas G, et al. **Chirurg** 1997 Jul;68(7):693–9 (32 ref.) (Eng. Abstr.) **(Ger)**

[Annular pancreas. Report of a case and review of the literature] Jotz GP, et al. **Arq Gastroenterol** 1996 Jan–Mar; 33(1):29–31 (13 ref.) (Eng. Abstr.) **(Por)**

[The use of the laser in the surgical treatment of acute intestinal obstruction and the prevention of adhesive disease] Kalish IuI, et al. **Khirurgiia (Mosk)** 1996;(6):103–8 (123 ref.) **(Rus)**

THERAPY

Medical management of intestinal obstruction in terminal care. Frank C. **Can Fam Physician** 1997 Feb;43:259–65 (29 ref.)

Peroral insertion techniques of self–expanding metal stents for malignant gastric outlet and duodenal stenoses. Maetani I, et al. **Gastrointest Endosc** 1996 Oct;44(4):468–71 (12 ref.)

Integrating medical and surgical treatments in gastrointestinal, genitourinary, and biliary obstruction in patients with cancer. Fainsinger RL. **Hematol Oncol Clin North Am** 1996 Feb;10(1):173–88 (115 ref.)

Long–term results of endoureterotomy for benign ureteral and ureteroenteric strictures. Wolf JS Jr, et al. **J Urol** 1997 Sep;158(3 Pt 1):759–64 (28 ref.)

[Treatment of stenoses of the gastrointestinal tract] Grund KE. **Schweiz Rundsch Med Prax** 1997 Jul 16; 86(29–30):1154–9 (9 ref.) (Eng. Abstr.) **(Ger)**

[Intestinal obstruction in cancer patients. Palliative treatment] Costa I, et al. **Acta Med Port** 1997 May;10(5):381–5 (30 ref.) (Eng. Abstr.) **(Por)**

INTESTINAL PERFORATION

COMPLICATIONS

Severe abdominal pain and thrombocytopenia—typical symptoms of occult jejunal diverticulum perforation? Klee FE, et al. **J Gastroenterol** 1997 Apr;32(2):246–50 (62 ref.)

Churg–Strauss syndrome with intestinal perforation. Khan JA, et al. **JPMA J Pak Med Assoc** 1996 May;46(5):109–10 (13 ref.)

DIAGNOSIS

Perforated diverticulum of the transverse colon. Yamamoto M, et al. **Am J Gastroenterol** 1997 Sep;92(9):1567–9 (11 ref.)

Stercoral perforation of the colon: case report and review of the literature. Dubinsky I. **J Emerg Med** 1996 May–Jun; 14(3):323–5 (10 ref.)

ETIOLOGY

Malignant B–cell lymphoma in an infant with severe combined immunodeficiency with short–limbed skeletal dysplasia. van den Berg H, et al. **Acta Paediatr** 1997 Jul; 86(7):778–80 (10 ref.)

Duodenal perforation by a Greenfield filter: endoscopic diagnosis. Bianchini AU, et al. **Am J Gastroenterol** 1997 Apr;92(4):686–7 (26 ref.)

Perforated appendicitis within an inguinal hernia: case report and review of the literature. Lyass S, et al. **Am J Gastroenterol** 1997 Apr;92(4):700–2 (10 ref.)

Perforation of terminal ileum diverticulitis: a case report and literature review. Krummen DM, et al. **Am Surg** 1996 Nov; 62(11):939–40 (18 ref.)

Intestinal perforation after suction lipoplasty: a case report and review of the literature. Talmor M, et al. **Ann Plast Surg** 1997 Feb;38(2):169–72 (20 ref.)

Perforation of the jejunum secondary to AIDS–related gastrointestinal Kaposi's sarcoma. Yoshida EM, et al. **Can J Gastroenterol** 1997 Jan–Feb;11(1):38–40 (15 ref.)

Bay leaf perforation of Meckel's diverticulum [letter] Bell CD, et al. **Can J Surg** 1997 Apr;40(2):146–7 (9 ref.)

Colonoscopic perforations. Etiology, diagnosis, and management. Damore LJ 2nd, et al. **Dis Colon Rectum** 1996 Nov;39(11):1308–14 (38 ref.)

Colovesical fistula caused by chronic chicken bone perforation. Khan MS, et al. **Ir J Med Sci** 1996 Jan–Mar; 165(1):51–2 (19 ref.)

Perforation of the sigmoid colon by hydrostatic pressure of a public water fountain. Farbin S, et al. **J Emerg Med** 1996 Nov–Dec;14(6):703–6 (30 ref.)

Ileal perforation caused by congenital or perinatal cytomegalovirus infection [see comments] Huang YC, et al. **J Pediatr** 1996 Dec;129(6):931–4 (17 ref.) Comment in: J Pediatr 1997 Jul;131(1 Pt 1):168–70.

Appendiceal perforation: a potentially lethal initial mode of presentation of Hirschsprung's disease. Sarioğlu A, et al. **J Pediatr Surg** 1997 Jan;32(1):123–4 (11 ref.)

Solitary intestinal fibromatosis: a rare cause of intestinal perforation in neonates. Al–Salem AH, et al. **Pediatr Surg Int** 1997 Jul;12(5–6):437–40 (13 ref.)

Perforated cecal adenocarcinoma presenting as a thigh abscess. Mann GN, et al. **South Med J** 1997 Sep; 90(9):949–51 (7 ref.)

Laparoscopic closure for perforation of the sigmoid colon by endoscopic linear stapler. Hayashi K, et al. **Surg Laparosc Endosc** 1996 Oct;6(5):411–3 (13 ref.)

[Colonic perforations complicating colonoscopy. Apropos of 15 consecutive cases observed over 16 years] Ettersperger L, et al. **Gastroenterol Clin Biol** 1995 Dec;19(12):1018–22 (35 ref.) (Eng. Abstr.) **(Fre)**

[The penetration of a bile duct metal stent into the duodenal bulb as a late complication of combined stent/radiotherapy in Klatskin's tumor] Wingen M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Jan;166(1):75–7 (10 ref.) **(Ger)**

[Perforations in Crohn's ileitis and their consequences in the natural history of the disease] Tonelli P. **Ann Ital Chir** 1995 Sep–Oct;66(5):695–708 (31 ref.) (Eng. Abstr.) **(Ita)**

[A case of eosinophilic enteritis with repeated perforation of the ileum] Ikenaga M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Sep;93(9):661–5 (12 ref.) **(Jpn)**

[A case of jejunal malignant lymphoma resulting in perforation 2 years after transcatheter arterial embolization for hepatocellular carcinoma] Yokohama A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Aug;93(8):578–82 (21 ref.) **(Jpn)**

[Perforation of the intestine by a peritoneal tube 10 years after a ventriculo–peritoneal shunt] Kin S, et al. **No Shinkei Geka** 1997 Jun;25(6):573–5 (14 ref.) (Eng. Abstr.) **(Jpn)**

PARASITOLOGY

Eosinophilic ileitis with perforation caused by Angiostrongylus (Parastrongylus) costaricensis. A case study and review. Wu SS, et al. **Arch Pathol Lab Med** 1997 Sep;121(9):989–91 (15 ref.)

RADIOGRAPHY

[The computed tomographic demonstration of duodenal perforation caused by a fish bone] Völk M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Aug;167(2):198–200 (10 ref.) **(Ger)**

INTESTINAL POLYPS

Colorectal polyps and their relationship to cancer. Kim EC, et al. **Gastroenterol Clin North Am** 1997 Mar;26(1):1–17 (56 ref.)

Benign colorectal polyps. Endoscopic surveillance guidelines and effects on colorectal cancer risk. Lum DF, et al. **Surg Oncol Clin N Am** 1996 Jul;5(3):621–32 (54 ref.)

COMPLICATIONS

Adult T–cell leukemia with multiple lymphomatous polyposis of the gastrointestinal tract. Itsuno M, et al. **Endoscopy** 1995 Nov;27(9):700–3 (24 ref.)

Inflammatory cloacogenic polyp: an unrecognized cause of hematochezia and tenesmus in childhood. Poon KK, et al. **J Pediatr** 1997 Feb;130(2):327–9 (13 ref.)

DIAGNOSIS

Diagnosis and management of gastroduodenal polyps. Burke CA, et al. **Surg Oncol Clin N Am** 1996 Jul;5(3):589–607 (69 ref.)

The clinical features of the hereditary and nonhereditary polyposis syndromes. Kuwada SK, et al. **Surg Oncol Clin N Am** 1996 Jul;5(3):553–67 (77 ref.)

Polyps and polypoid lesions of the jejunum and ileum. Clinical aspects. Levine BA, et al. **Surg Oncol Clin N Am** 1996 Jul;5(3):609–19 (59 ref.)

DRUG THERAPY

[A high CEA level in a case of Cronkhite–Canada syndrome, showing decrease by prednisolone treatment] Fukazawa M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Aug; 94(8):543–8 (18 ref.) **(Jpn)**

EPIDEMIOLOGY

Epidemiology of gastrointestinal polyps. Jacobson JS, et al. **Surg Oncol Clin N Am** 1996 Jul;5(3):531–44 (115 ref.)

ETIOLOGY

[Secondary lymphomatous polyposis of the gastrointestinal tract in patients with nodal lymphomas] Bányai A, et al. **Orv Hetil** 1996 Jul 21;137(29):1591–5 (19 ref.) (Eng. Abstr.) **(Hun)**

GENETICS

Familial polyposis syndromes. Advances in molecular genetic characterization. Powell SM. **Surg Oncol Clin N Am** 1996 Jul;5(3):569–87 (104 ref.)

PATHOLOGY

Hyperplastic polyposis of the large bowel. Three cases and a review of the literature. Jørgensen H, et al. **Scand J Gastroenterol** 1996 Aug;31(8):825–30 (41 ref.)

Pathology neoplastic and non–neoplastic. Graeme–Cook F. **Surg Oncol Clin N Am** 1996 Jul;5(3):487–512 (31 ref.)

Endoscopic management of malignant colorectal polyps. Kafka NJ, et al. **Surg Oncol Clin N Am** 1996 Jul;5(3):633–61 (158 ref.)

PREVENTION & CONTROL

Screening programs in the population at large and in high–risk groups. Lush DT. **Surg Oncol Clin N Am** 1996 Jul;5(3):545–52 (35 ref.)

SURGERY

Management of colorectal polyps. Markowitz AJ, et al. **CA Cancer J Clin** 1997 Mar–Apr;47(2):93–112 (101 ref.)

Endoscopic management of malignant colorectal polyps. Kafka NJ, et al. **Surg Oncol Clin N Am** 1996 Jul;5(3):633–61 (158 ref.)

Complications of endoscopic polypectomy. Vernava AM 3rd, et al. **Surg Oncol Clin N Am** 1996 Jul;5(3):663–73 (50 ref.)

[Cronkhite–Canada syndrome. Epidemiology, symptoms, morphology and therapy based on a case report and literature review] Zügel N, et al. **Chirurg** 1997 Jul; 68(7):710–4 (44 ref.) (Eng. Abstr.) **(Ger)**

INTESTINAL PSEUDO-OBSTRUCTION

Primary and secondary disorders to gut muscle and nerve. Kamm MA. **Scand J Gastroenterol Suppl** 1996;220:91–3 (17 ref.)

CONGENITAL

Segmental dilatation of the jejunum. Mir E, et al. **Acta Paediatr Jpn** 1996 Feb;38(1):69–71 (18 ref.)

DIAGNOSIS

Diagnosis and treatment of chronic intestinal pseudo–obstruction in children: report of consensus workshop [see comments] Rudolph CD, et al. **J Pediatr Gastroenterol Nutr** 1997 Jan;24(1):102–12 (170 ref.) Comment in: J Pediatr Gastroenterol Nutr 1997 Jan;24(1):100–1.

DRUG THERAPY

Management of gastrointestinal motility disorders. A practical guide to drug selection and appropriate ancillary measures. Malagelada JR, et al. **Drugs** 1996 Oct; 52(4):494–506 (96 ref.)

ETIOLOGY

Massive secretory diarrhea and pseudo–obstruction as the initial presentation of Crohn's disease. Carethers JM, et al. **J Clin Gastroenterol** 1996 Jul;23(1):55–9 (26 ref.)

IMMUNOLOGY

Autoantibody–associated sensory neuronopathy and intestinal pseudo–obstruction without detectable neoplasia. Briellmann RS, et al. **Eur Neurol** 1996;36(6):369–73 (26 ref.)

METABOLISM

Deficiency of c–kit+ cells in patients with a myopathic form of chronic idiopathic intestinal pseudo–obstruction. Isozaki K, et al. **Am J Gastroenterol** 1997 Feb;92(2):332–4 (18 ref.)

PATHOLOGY

Deficiency of c–kit+ cells in patients with a myopathic form of chronic idiopathic intestinal pseudo–obstruction. Isozaki K, et al. **Am J Gastroenterol** 1997 Feb;92(2):332–4 (18 ref.)

PHYSIOPATHOLOGY

Delayed gastric emptying and postoperative ileus after nongastric abdominal surgery: part I. Resnick J, et al. **Am J Gastroenterol** 1997 May;92(5):751–62 (130 ref.)

THERAPY

Diagnosis and treatment of chronic intestinal pseudo–obstruction in children: report of consensus workshop [see comments] Rudolph CD, et al. **J Pediatr Gastroenterol Nutr** 1997 Jan;24(1):102–12 (170 ref.) Comment in: J Pediatr Gastroenterol Nutr 1997 Jan;24(1):100–1.

INTESTINAL SECRETIONS

see related
GASTROINTESTINAL HORMONES

Effects of parenteral nutrients on gastrointestinal motility and secretion. Masclee AA, et al. **Scand J Gastroenterol Suppl** 1996;218:50–5 (81 ref.)

INTESTINE, LARGE

[Cholelithic intestinal obstruction] Bokhan KL. **Vestn Khir Im I I Grek** 1996;155(4):110–2 (22 ref.) **(Rus)**

BLOOD SUPPLY

The arterial vascularization of the large intestine. Anatomical and radiological study. Bertelli L, et al. **Surg Radiol Anat** 1996;18 Suppl 1:A1–6, S1–59 (682 ref.)

[Intramural vascular system of the large intestine of mammals. A study of the literature] Wille KH, et al. **Anat Histol Embryol** 1997 Jun;26(2):85–91 (49 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Lipopolysaccharide's role in the association of Salmonella cells to the mouse intestine studied by ribosomal in situ hybridization. Krogfelt KA, et al. **Adv Exp Med Biol** 1996; 408:123–8 (25 ref.)

Substrates for fermentation in the large bowel. Johnson IT. **Biochem Soc Trans** 1996 Aug;24(3):824–8 (36 ref.)

PATHOLOGY

Endometriosis of the bowel with lymph node involvement. A report of three cases and review of the literature. Insabato L, et al. **Pathol Res Pract** 1996 Sep;192(9):957–61; discussion 962 (16 ref.)

PHYSIOLOGY

Epithelial cell growth and differentiation. I. Intestinal growth factors. Drucker DJ. **Am J Physiol** 1997 Jul;273(1 Pt 1):G3–6 (13 ref.)

INTESTINE, SMALL

Obscure gastrointestinal bleeding: role of small bowel enteroscopy. Portwood GL, et al. **J S C Med Assoc** 1997 Feb;93(2):51–6 (49 ref.)

An overview of adenocarcinoma of the small intestine. Neugut AI, et al. **Oncology (Huntingt)** 1997 Apr; 11(4):529–36; discussion 545, 549–50 (62 ref.)

[Complicated intestinal tuberculosis of the mesenteric root] Wagner JB, et al. **Dtsch Med Wochenschr** 1997 May 16; 122(20):643–7 (25 ref.) (Eng. Abstr.) **(Ger)**

[Primary lymphoma of the small intestine. A clinical case report and review of the literature] Bonaccorso R, et al. **Minerva Chir** 1997 May;52(5):643–7 (13 ref.) (Eng. Abstr.) **(Ita)**

[Cholelithic intestinal obstruction] Bokhan KL. **Vestn Khir Im I I Grek** 1996;155(4):110–2 (22 ref.) **(Rus)**

ABNORMALITIES

Enteric duplication in the adult, derived from the foregut, midgut and hindgut: presentation, patterns and literature review. Hackam DJ, et al. **Can J Surg** 1997 Apr; 40(2):129–33 (21 ref.)

[A case of preduodenal portal vein diagnosed concomitantly with malrotation of the intestine] Kito Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Aug;94(8):538–42 (10 ref.) **(Jpn)**

BLOOD SUPPLY

Recurrent small bowel infarction associated with antithrombin deficiency. Golino A, et al. **Am J Gastroenterol** 1997 Feb;92(2):323–5 (14 ref.)

Mesenteric ischemia secondary to cocaine abuse: case reports and literature review. Sudhakar CB, et al. **Am J Gastroenterol** 1997 Jun;92(6):1053–4 (12 ref.)

Hereditary hemorrhagic telangiectasia and other intestinal vascular anomalies. Korzenik JR. **Gastroenterologist** 1996 Sep;4(3):203–10 (75 ref.)

A rapidly progressive ischemic enteropathy with malabsorption syndrome. Case report. Cicchinelli M, et al. **Minerva Gastroenterol Dietol** 1996 Jun;42(2):103–5 (11 ref.)

[Visceral varix] Sakurai T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):547–9 (9 ref.) **(Jpn)**

CHEMISTRY

Molecular genetics of small bowel cancer. Arber N, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Sep;6(9):745–8 (57 ref.)

CYTOLOGY

Cholecystokinin cells. Liddle RA. **Annu Rev Physiol** 1997; 59:221–42 (118 ref.)

Identification of the interstitial cells of Cajal. Komuro T, et al. **Histol Histopathol** 1996 Jul;11(3):769–86 (75 ref.)

DRUG EFFECTS

Bile acid transport systems as pharmaceutical targets. Kramer W, et al. **Eur J Clin Invest** 1996 Sep;26(9):715–32 (89 ref.)

EMBRYOLOGY

Neonatal gut development and postnatal adaptation. Veereman–Wauters G. **Eur J Pediatr** 1996 Aug; 155(8):627–32 (55 ref.)

ENZYMOLOGY

[Molecular biological aspects of brush border membrane hydrolases and brush border membrane] Miura S, et al. **Nippon Rinsho** 1996 Apr;54(4):1130–6 (23 ref.) (Eng. Abstr.) **(Jpn)**

[The digestive barrier functions of the enzymatic systems of the normal small intestine and in pathology] Timofeeva NM. **Vestn Ross Akad Med Nauk** 1996;(1):37–41 (24 ref.) (Eng. Abstr.) **(Rus)**

GROWTH & DEVELOPMENT

Neonatal gut development and postnatal adaptation. Veereman–Wauters G. **Eur J Pediatr** 1996 Aug; 155(8):627–32 (55 ref.)

IMMUNOLOGY

CD1d: outside–in antigen presentation in the intestinal epithelium? [editorial; comment] Blumberg RS, et al. **Clin Exp Immunol** 1997 Aug;109(2):223–5 (37 ref.) Comment on: Clin Exp Immunol 1997 Aug;109(2):317–20.

INJURIES

Intestinal perforation after suction lipoplasty: a case report and review of the literature. Talmor M, et al. **Ann Plast Surg** 1997 Feb;38(2):169–72 (20 ref.)

Evisceration after laparoscopic sterilization. Lopez A, et al. **J Am Assoc Gynecol Laparosc** 1995 Nov;3(1):109–11 (11 ref.)

INNERVATION

Experimental basis for realistic large–scale computer simulation of the enteric nervous system. Furness JB, et al. **Clin Exp Pharmacol Physiol** 1996 Sep;23(9):786–92 (27 ref.)

METABOLISM

Cholecystokinin cells. Liddle RA. **Annu Rev Physiol** 1997; 59:221–42 (118 ref.)

Small–intestinal absorption of cadmium and the significance of mucosal metallothionein. Elsenhans B, et al. **Hum Exp Toxicol** 1997 Aug;16(8):429–34 (28 ref.)

Kinetic analysis of the intestinal iron absorption process in situ. The potential of vascularly autoperfused intestinal loops. Hunder G, et al. **Hum Exp Toxicol** 1997 Aug; 16(8):425–8 (17 ref.)

Hyperglycemia and intestinal and renal glucose transport: implications for diabetic renal injury [editorial] Debnam ES, et al. **Kidney Int** 1996 Oct;50(4):1101–9 (108 ref.)

Cellular and molecular aspects of fat metabolism in the small intestine. Besnard P, et al. **Proc Nutr Soc** 1996 Mar; 55(1B):19–37 (99 ref.)

Intestinal sodium–dependent D–glucose co–transporter: dietary regulation. Shirazi–Beechey SP. **Proc Nutr Soc** 1996 Mar;55(1B):167–78 (44 ref.)

MICROBIOLOGY

The small intestine as the origin of bacteremia in acute diffuse peritonitis. Peregudov SI, et al. **Nutr Hosp** 1996 Nov–Dec; 11(6):317–20 (8 ref.)

Colonization and translocation of intestinal bacterial flora. Wells CL. **Transplant Proc** 1996 Oct;28(5):2653–6 (78 ref.)

[Hydrogen test (H2) in the air expired for the diagnosis of small bowel bacterial overgrowth] Marcelino RT, et al. **Arq Gastroenterol** 1995 Oct–Dec;32(4):191–8 (73 ref.) (Eng. Abstr.) **(Por)**

PATHOLOGY

Sclerosing encapsulating peritonitis associated with continuous ambulatory peritoneal dialysis: surgical management. Smith L, et al. **Am J Kidney Dis** 1997 Mar; 29(3):456–60 (17 ref.)

CT evaluation of the acute abdomen: bowel pathology spectrum of disease. Johnson GL, et al. **Crit Rev Diagn Imaging** 1996 Aug;37(3):163–90 (8 ref.)

Small bowel tumors: an overview. O'Riordan BG, et al. **Dig Dis** 1996 Jul–Aug;14(4):245–57 (41 ref.)

Imaging of primary small intestinal tumours by enteroclysis and CT with pathological correlation. Gourtsoyiannis N, et al. **Eur Radiol** 1997;7(5):625–42 (50 ref.)

Small bowel cancer. Imaging features and staging. Buckley JA, et al. **Radiol Clin North Am** 1997 Mar;35(2):381–402 (31 ref.)

Small bowel cancer. Clinical and pathologic features. Gore RM. **Radiol Clin North Am** 1997 Mar;35(2):351–60 (83 ref.)

Transplantation–induced injuries of the intestinal muscularis and its innervation: from preservation to chronic rejection. Bauer AJ. **Transplant Proc** 1996 Oct;28(5):2539–41 (11 ref.)

PHYSIOLOGY

Epithelial cell growth and differentiation. I. Intestinal growth factors. Drucker DJ. **Am J Physiol** 1997 Jul;273(1 Pt 1):G3–6 (13 ref.)

Physiological regulation of gastric emptying and glucose absorption. Macdonald IA. **Diabet Med** 1996 Sep;13(9 Suppl 5):S11–5 (12 ref.)

Intestinal water and electrolyte absorption and secretion. Chang EB. **Transplant Proc** 1996 Oct;28(5):2679–82 (3 ref.)

Motility and absorption in the transplanted gut. Sarr MG. **Transplant Proc** 1996 Oct;28(5):2535–8 (30 ref.)

[The role of natural growth stimulators in regulation of regeneration processes in small intestinal epithelium after irradiation] Dziekiewicz M. **Przegl Lek** 1996;53(8):610–3 (21 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

Small bowel review—Part II. Thomson AB, et al. **Can J Gastroenterol** 1997 Mar;11(2):159–65 (84 ref.)

Small bowel review—Part I. Thomson AB, et al. **Can J Gastroenterol** 1997 Jan–Feb;11(1):49–56 (89 ref.)

Gastric emptying in type 2 diabetes: quick or slow? Smith U. **Diabet Med** 1996 Sep;13(9 Suppl 5):S31–3 (22 ref.)

Intestinal adaptation to nutritional stress. Raul F, et al. **Proc Nutr Soc** 1996 Mar;55(1B):279–89 (74 ref.)

Functional disorders of the small intestine. Kellow JE, et

al. **Semin Gastrointest Dis** 1996 Oct;7(4):208–16 (32 ref.)

RADIOGRAPHY

Enteroscopy with enteroclysis. Aliperti G, et al. **Gastrointest Endosc Clin N Am** 1996 Oct;6(4):803–10 (32 ref.)

Small bowel cancer. Imaging features and staging. Buckley JA, et al. **Radiol Clin North Am** 1997 Mar;35(2):381–402 (31 ref.)

Small bowel cancer. Radiologic diagnosis. Maglinte DT, et al. **Radiol Clin North Am** 1997 Mar;35(2):361–80 (50 ref.)

Radiographic imaging of small bowel disease. Newman J. **Radiol Technol** 1997 Jul–Aug;68(6):491–504; quiz 505–8 (24 ref.)

[The computed tomographic picture of deep gallstone ileus] Rieger J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Feb;166(2):164–6 (10 ref.) **(Ger)**

SURGERY

Surgical management for carcinoid tumors of small bowel, appendix, colon, and rectum. Stinner B, et al. **World J Surg** 1996 Feb;20(2):183–8 (26 ref.)

[Treatment of tumors of the small intestine. Clinical results of 31 years/review of the literature] Sarkar MR, et al. **Leber Magen Darm** 1996 Jul;26(4):204–6, 209–14 (0 ref.) (Eng. Abstr.) **(Ger)**

TRANSPLANTATION

The unique challenge of small intestinal transplantation. Woodward JM, et al. **Br J Hosp Med** 1996 Sep 18–Oct 1;56(6):285–90 (25 ref.)

Infections due to dematiaceous fungi in organ transplant recipients: case report and review. Singh N, et al. **Clin Infect Dis** 1997 Mar;24(3):369–74 (35 ref.)

Small intestinal transplantation: reflections on an evolving approach to intestinal failure [editorial; comment] Quigley EM. **Gastroenterology** 1996 Jun;110(6):2009–12 (30 ref.) Comment on: Gastroenterology 1996 Jun;110(6):1820–34.

Transplantation-induced injuries of the intestinal muscularis and its innervation: from preservation to chronic rejection. Bauer AJ. **Transplant Proc** 1996 Oct;28(5):2539–41 (11 ref.)

Intestinal water and electrolyte absorption and secretion. Chang EB. **Transplant Proc** 1996 Oct;28(5):2679–82 (3 ref.)

Small bowel and pancreas transplantation. Pollard S. **Transplant Proc** 1997 Sep;29(6):2721–2 (0 ref.)

Motility and absorption in the transplanted gut. Sarr MG. **Transplant Proc** 1996 Oct;28(5):2535–8 (30 ref.)

Experimental basis for intestinal transplantation. Sonnino RE. **Transplant Proc** 1997 May;29(3):1795–7 (53 ref.)

Colonization and translocation of intestinal bacterial flora. Wells CL. **Transplant Proc** 1996 Oct;28(5):2653–6 (78 ref.)

Antirejection strategy in small bowel transplantation. Wood RF. **Transplant Proc** 1996 Oct;28(5):2491–3 (39 ref.)

[Small intestine transplantation in the human--clinical studies] Więckowski J, et al. **Wiad Lek** 1994 Nov–Dec; 47(21–24):859–64 (30 ref.) (Eng. Abstr.) **(Pol)**

INTESTINES

see related

GASTROENTEROSTOMY

Bowel as a kidney substitute in renal failure. Friedman EA. **Am J Kidney Dis** 1996 Dec;28(6):943–50 (68 ref.)

ABNORMALITIES

Intestinal malrotation in a child with cardio-facio-cutaneous syndrome. McDaniel CH, et al. **Am J Med Genet** 1997 Jun 13;70(3):284–6 (30 ref.)

Reversed midgut rotation in a neonate: case report with a brief review of the literature. Valioulis I, et al. **J Pediatr Surg** 1997 Apr;32(4):643–5 (27 ref.)

ANATOMY & HISTOLOGY

Glutamine: is it a conditionally required nutrient for the human gastrointestinal system?[see comments] Buchman AL. **J Am Coll Nutr** 1996 Jun;15(3):199–205 (76 ref.) Comment in: J Am Coll Nutr 1996 Jun;15(3):195–6.

[The structure and histotopography of the gastroenteropancreatic endocrine system in teleost fish] Shirkina NI. **Morfologiia** 1995;108(3):78–83 (66 ref.) **(Rus)**

BLOOD SUPPLY

Neural reflexes controlling intestinal microcirculation. Vanner S, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):G223–30 (66 ref.)

Intestinal migrating motor complexes and blood flow: what is the link? Fioramonti J, et al. **Eur J Gastroenterol Hepatol** 1996 Aug;8(8):765–7 (18 ref.)

Livedo reticularis, rhabdomyolysis, massive intestinal infarction, and death after carbon dioxide arteriography. Rundback JH, et al. **J Vasc Surg** 1997 Aug;26(2):337–40 (13 ref.)

[Laparoscopic second-look in acute intestinal ischemia] Tola M, et al. **Minerva Chir** 1997 May;52(5):527–30 (11 ref.) (Eng. Abstr.) **(Ita)**

[Intestinal reperfusion: the physiopathological fundamentals of its therapeutic prospects] Rodríguez García JI, et al. **Rev Esp Enferm Dig** 1997 Jan;89(1):39–45 (74 ref.) **(Spa)**

[The current state of the diagnosis and treatment of acute mesenteric ischemia] Loba MM, et al. **Klin Khir** 1996; (7):40–3 (49 ref.) **(Ukr)**

CYTOLOGY

Epithelial cell migration in the intestine. Heath JP. **Cell Biol Int** 1996 Feb;20(2):139–46 (43 ref.)

The centenary of the problem of the interstitial cells of Cajal. Kobayashi S. **Kaibogaku Zasshi** 1996 Dec;71(6):629–37 (32 ref.)

Cultured intestinal epithelial cell models. Hidalgo IJ. **Pharm Biotechnol** 1996;8:35–50 (32 ref.)

DRUG EFFECTS

Review article: older systemic and newer topical glucocorticosteroids and the gastrointestinal tract. Thiesen A, et al. **Aliment Pharmacol Ther** 1996 Aug;10(4):487–96 (111 ref.)

PAF and the digestive tract. A review. Izzo AA. **J Pharm Pharmacol** 1996 Nov;48(11):1103–11 (118 ref.)

The osmotic and intrinsic mechanisms of the pharmacological laxative action of oral high doses of magnesium sulphate. Importance of the release of digestive polypeptides and nitric oxide. Izzo AA, et al. **Magnes Res** 1996 Jun; 9(2):133–8 (35 ref.)

EMBRYOLOGY

Genes and lineages in the formation of the enteric nervous system. Gershon MD. **Curr Opin Neurobiol** 1997 Feb; 7(1):101–9 (81 ref.)

Biphasic intestinal development in amphibians: embryogenesis and remodeling during metamorphosis. Shi YB, et al. **Curr Top Dev Biol** 1996;32:205–35 (117 ref.)

GROWTH & DEVELOPMENT

Importance of milk and diet on the ontogeny and adaptation of the intestine. Perin NM, et al. **J Pediatr Gastroenterol Nutr** 1997 Apr;24(4):419–25 (76 ref.)

IMMUNOLOGY

In defense of mucosal surfaces. Regulation and manipulation of the mucosal immune system. Elson CO. **Adv Exp Med Biol** 1997;412:373–85 (68 ref.)

Antigen presentation in the intestine. Panja A, et al. **Baillieres Clin Gastroenterol** 1996 Sep;10(3):407–25 (94 ref.)

Antigens with application toward immune control of blood-feeding parasitic nematodes. Jasmer DP, et al. **Br Vet J** 1995 May;152(3):251–68 (89 ref.)

Avian gut-associated lymphoid tissues and intestinal immune responses to Eimeria parasites. Lillehoj HS, et al. **Clin Microbiol Rev** 1996 Jul;9(3):349–60 (118 ref.)

Paneth cell defensins: endogenous peptide components of intestinal host defense. Ouellette AJ, et al. **FASEB J** 1996 Sep;10(11):1280–9 (58 ref.)

Oral tolerance in experimental animals. Telemo E, et al. **Int Arch Allergy Immunol** 1997 May–Jul;113(1–3):219–23 (42 ref.)

Intestinal involvement in atopic disease. Isolauri E. **J R Soc Med** 1997;90 Suppl 30:15–20 (50 ref.)

Immunological mechanisms of the gut. Hanson LA, et al. **Pediatr Allergy Immunol** 1995;6 Suppl 8:7–12 (58 ref.)

Cytokines and intestinal inflammation. Fiocchi C. **Transplant Proc** 1996 Oct;28(5):2442–3 (11 ref.)

INNERVATION

Genes and lineages in the formation of the enteric nervous system. Gershon MD. **Curr Opin Neurobiol** 1997 Feb; 7(1):101–9 (81 ref.)

The centenary of the problem of the interstitial cells of Cajal. Kobayashi S. **Kaibogaku Zasshi** 1996 Dec;71(6):629–37 (32 ref.)

METABOLISM

Glucose transporters in the regulation of intestinal, renal, and liver glucose fluxes. Thorens B. **Am J Physiol** 1996 Apr; 270(4 Pt 1):G541–53 (130 ref.)

Peptide transporters in the intestine and the kidney. Leibach FH, et al. **Annu Rev Nutr** 1996;16:99–119 (119 ref.)

Signal transduction in gastrointestinal smooth muscle. Makhlouf GM, et al. **Cell Signal** 1997 May–Jun; 9(3–4):269–76 (92 ref.)

Nutrients and intestinal adaptation. Thomson AB, et al. **Clin Invest Med** 1996 Oct;19(5):331–45 (140 ref.)

The oligopeptide transporter (Pept-1) in human intestine: biology and function. Adibi SA. **Gastroenterology** 1997 Jul; 113(1):332–40 (55 ref.)

The regulation of intestinal metabolism and its impact on whole animal energetics. Cant JP, et al. **J Anim Sci** 1996 Oct;74(10):2541–53 (98 ref.)

Control of synthesis and secretion of intestinal apolipoprotein A-IV by lipid. Kalogeris TJ, et al. **J Nutr** 1997 Mar; 127(3):537S–543S (87 ref.)

We may not measure the correct intestinal wall permeability coefficient of drugs: alternative absorptive clearance concept [see comments] Chiou WL. **J Pharmacokinet Biopharm** 1995 Jun;23(3):323–31 (42 ref.) Comment in: J Pharmacokinet Biopharm 1995 Jun;23(3):333–7.

Multiple targets for endothelin-1 in human intestine. Montrose MH. **J Physiol (Lond)** 1997 Mar 1;499 (Pt 2):289 (5 ref.)

Intestinal rings and isolated intestinal mucosal cells. Fix JA. **Pharm Biotechnol** 1996;8:51–66 (36 ref.)

Cultured intestinal epithelial cell models. Hidalgo IJ. **Pharm Biotechnol** 1996;8:35–50 (32 ref.)

Model systems for intestinal lymphatic transport studies. Porter CJ, et al. **Pharm Biotechnol** 1996;8:85–102 (22 ref.)

Methods for evaluating intestinal permeability and metabolism in vitro. Smith PL. **Pharm Biotechnol** 1996; 8:13–34 (89 ref.)

Tachykinins in the gut. Part I. Expression, release and motor function. Holzer P, et al. **Pharmacol Ther** 1997; 73(3):173–217 (504 ref.)

Regulation of intestinal sugar transport. Ferraris RP, et al. **Physiol Rev** 1997 Jan;77(1):257–302 (299 ref.)

Differential regulation of the fructose transporters GLUT2 and GLUT5 in the intestinal cell line Caco-2. Brot-Laroche E. **Proc Nutr Soc** 1996 Mar;55(1B):201–8 (28 ref.)

[Intestinal permeability] Montalto M, et al. **Recenti Prog Med** 1997 Mar;88(3):140–7 (53 ref.) (Eng. Abstr.) **(Ita)**

[Absorption and secretion mechanism of water and electrolytes in intestines] Hanai H, et al. **Nippon Naika Gakkai Zasshi** 1996 Jul 10;85(7):1034–41 (7 ref.) **(Jpn)**

[Absorptive mechanism of vitamins, lipids and bile acid] Miura S, et al. **Nippon Naika Gakkai Zasshi** 1996 Jul 10; 85(7):1042–7 (5 ref.) **(Jpn)**

[Digestion and absorption mechanism of carbohydrates and proteins in intestines] Takeda E, et al. **Nippon Naika Gakkai Zasshi** 1996 Jul 10;85(7):1029–33 (5 ref.) **(Jpn)**

[The mechanisms of urate transport in the kidney and the intestine] Sekine T, et al. **Nippon Rinsho** 1996 Dec; 54(12):3237–42 (17 ref.) (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

Interactions between the enteric pathogen and the host. An assortment of bacterial lectins and a set of glycoconjugate receptors. Mouricout M. **Adv Exp Med Biol** 1997; 412:109–23 (88 ref.)

Paving the way for pathogens? Schauer DB. **Curr Biol** 1997 Feb 1;7(2):R75–7 (10 ref.)

Lactulose and combination therapy of hepatic encephalopathy: the role of the intestinal microflora. Weber FL Jr. **Dig Dis** 1996;14 Suppl 1:53–63 (71 ref.)

Intestinal flora and endogenous vitamin synthesis. Hill MJ. **Eur J Cancer Prev** 1997 Mar;6 Suppl 1:S43–5 (10 ref.)

N-nitrosation at non-gastric sites. Hill MJ. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:105–8 (12 ref.)

The relationship between gut-derived bacteria and the development of the multiple organ dysfunction syndrome. Nieuwenhuijzen GA, et al. **J Anat** 1996 Dec;189 (Pt 3):537–48 (165 ref.)

Taxonomical changes in intestinal (faecal) enterococci and streptococci: consequences on their use as indicators of faecal contamination in drinking water. Leclerc H, et al. **J Appl Bacteriol** 1996 Nov;81(5):459–66 (97 ref.)

Antimicrobial treatment of periodontal diseases disturbs the human ecology: a review. Edlund C, et al. **J Chemother** 1996 Oct;8(5):331–41 (65 ref.)

The impact of mercury released from dental "silver" fillings on antibiotic resistances in the primate oral and intestinal bacterial flora. Liebert CA, et al. **Met Ions Biol Syst** 1997; 34:441–60 (69 ref.)

Trauma, shock, and gut translocation. Deitch EA, et al. **New Horiz** 1996 May;4(2):289–99 (61 ref.)

Principles of ex ovo competitive exclusion and in ovo administration of Lactobacillus reuteri. Edens FW, et al. **Poult Sci** 1997 Jan;76(1):179–96 (120 ref.)

B-1 cells and their reactivity with the murine intestinal microflora. Kroese FG, et al. **Semin Immunol** 1996 Feb; 8(1):11–8 (52 ref.)

[Pathogenic intestinal bacteria: adhesion and invasion] Paerregaard A. **Ugeskr Laeger** 1997 Mar 3;159(10):1417–22 (39 ref.) (Eng. Abstr.) **(Dan)**

[Intraabdominal polymicrobial infection due to antimicrobial resistant anaerobes] Watanabe K, et al. **Nippon Geka Gakkai Zasshi** 1996 Dec;97(12):1036–41 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Intestinal bacterial translocation] Llovet JM, et al. **Gastroenterol Hepatol** 1996 Aug–Sep;19(7):374–82 (110 ref.) **(Spa)**

PATHOLOGY

Intestinal physiology and pathology in gene-targeted mouse models of cystic fibrosis. Grubb BR, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):G258–66 (76 ref.)

Sclerosing encapsulating peritonitis after intraperitoneal use of povidone iodine. Keating JP, et al. **Aust N Z J Surg** 1997 Oct;67(10):742–4 (19 ref.)

Intestinal metaplasia is not a strong risk factor for bladder cancer: study of 53 cases with long-term follow-up. Corica FA, et al. **Urology** 1997 Sep;50(3):427–31 (29 ref.)

[Systemic amyloidosis associated with common variable hypogammaglobulinemia and intestinal lymphoid nodular

hyperplasia] Sánchez-Pobre P, et al. **Gastroenterol Hepatol** 1996 Aug-Sep;19(7):351-5 (38 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Cell-cell and cell-ECM interactions in epithelial apoptosis and cell renewal during frog intestinal development. Shi YB. **Cell Biochem Biophys** 1995;27(3):179-202 (85 ref.)

Biphasic intestinal development in amphibians: embryogenesis and remodeling during metamorphosis. Shi YB, et al. **Curr Top Dev Biol** 1996;32:205-35 (117 ref.)

Adaptation of intestinal nutrient transport in health and disease. Part I. Thomson AB, et al. **Dig Dis Sci** 1997 Mar; 42(3):453-69 (254 ref.)

Adaptation of intestinal nutrient transport in health and disease. Part II. Thomson AB, et al. **Dig Dis Sci** 1997 Mar; 42(3):470-88 (271 ref.)

The intestine, an endocrine organ. Schmidt WE. **Digestion** 1997;58 Suppl 1:56-8 (16 ref.)

Intestinal migrating motor complexes and blood flow: what is the link? Fioramonti J, et al. **Eur J Gastroenterol Hepatol** 1996 Aug;8(8):765-7 (18 ref.)

Glutamine: is it a conditionally required nutrient for the human gastrointestinal system?[see comments] Buchman AL. **J Am Coll Nutr** 1996 Jun;15(3):199-205 (76 ref.) Comment in: J Am Coll Nutr 1996 Jun;15(3):195-6.

Intestinal effects of milkborne growth factors in neonates of agricultural importance. Odle J, et al. **J Anim Sci** 1996 Oct;74(10):2509-22 (120 ref.)

Glutamine: an essential amino acid for the gut. van der Hulst RR, et al. **Nutrition** 1996 Nov-Dec;12(11-12 Suppl):S78-81 (22 ref.)

Role of nucleosides and nucleotides in the immune system, gut reparation after injury, and brain function. Yamamoto S, et al. **Nutrition** 1997 Apr;13(4):372-4 (15 ref.)

Belching, bloating, and flatulence. How to help patients who have troublesome abdominal gas. Rao SS. **Postgrad Med** 1997 Apr;101(4):263-9, 275-8 (23 ref.)

PHYSIOPATHOLOGY

Intestinal physiology and pathology in gene-targeted mouse models of cystic fibrosis. Grubb BR, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):G258-66 (76 ref.)

Effect of psychoneural factors on intestinal epithelial function. Berin MC, et al. **Can J Gastroenterol** 1997 May-Jun;11(4):353-7 (29 ref.)

Intestinal gas in children [editorial] Hyams JS. **Curr Opin Pediatr** 1996 Oct;8(5):467-70 (28 ref.)

A review of evidence for a role of magnesium and possibly copper deficiency in necrotizing enterocolitis. Caddell JL. **Magnes Res** 1996 Mar;9(1):55-66 (106 ref.)

Clinical intestinal gas syndromes. Clearfield HR. **Prim Care** 1996 Sep;23(3):621-8 (19 ref.)

Primary and secondary disorders to gut muscle and nerve. Kamm MA. **Scand J Gastroenterol Suppl** 1996;220:91-3 (17 ref.)

[Orthotopic bladder replacement: I. Physiopathology of orthotopic bladder replacement with intestine] Errando Smet C, et al. **Arch Esp Urol** 1997 Mar;50(2):109-13 (24 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Standardization of terminology and assessment of functional characteristics of intestinal urinary reservoirs. Thüroff JW, et al. **Neurourol Urodyn** 1996;15(5):499-511 (6 ref.)

[Clinical evaluation of factor XIII for postoperative stomal leakage and fistulae after gastrointestinal surgery] Ishibiki K. **Rinsho Byori** 1997 Feb;Suppl 104:17-24 (7 ref.) **(Jpn)**

[The use of the mechanical suture in surgery on the stomach and intestines] Mel'nik VM, et al. **Klin Khir** 1996;(9):37-40 (65 ref.) **(Rus)**

[Characteristics of several types of manual intestinal sutures] Mel'nik VM, et al. **Klin Khir** 1996;(8):34-7 (71 ref.) **(Rus)**

[Choice of the method of restoration of intestinal continuity after removal of the ileocecal region] Poída AI, et al. **Klin Khir** 1996;(10):45-7 (29 ref.) **(Rus)**

TRANSPLANTATION

Current status of home parenteral nutrition in the United States. Howard L, et al. **Transplant Proc** 1996 Oct; 28(5):2691-5 (6 ref.)

Yin and Yang of mucosal immunology. Mayer L. **Transplant Proc** 1996 Oct;28(5):2435-7 (22 ref.)

Current perspectives of transplantation immunology via the intestine. Starzl TE. **Transplant Proc** 1996 Oct;28(5):2430-2 (32 ref.)

ULTRASTRUCTURE

Membrane vesicles. Proulx P. **Adv Food Nutr Res** 1996; 40:197-206 (23 ref.)

INTOXICATION see **POISONING**

INTOXICATION, ALCOHOLIC see **ALCOHOLIC INTOXICATION**

INTRA-ABDOMINAL INFUSIONS see **INFUSIONS, PARENTERAL**

INTRA-AORTIC BALLOON PUMPING

The continuing evolution of mechanical ventricular assistance. Argenziano M, et al. **Curr Probl Surg** 1997 Apr; 34(4):317-86 (220 ref.)

[Mechanical myocardial support systems 1997: an overview of inta-aortic balloon counterpulsation to implantable left ventricular support systems] Hammel D, et al. **Anaesthesist** 1997 May;46(5):408-18 (66 ref.) (Eng. Abstr.) **(Ger)**

[Clinical application and management of assisted circulation in the treatment of cardiogenic shock] Kodama K, et al. **Nippon Naika Gakkai Zasshi** 1996 Jan 10;85(1):82-7 (10 ref.) **(Jpn)**

ADVERSE EFFECTS

Paraplegia complicating intraaortic balloon pumping [letter] Hurlé A, et al. **Ann Thorac Surg** 1997 Apr;63(4):1217-8 (5 ref.)

INSTRUMENTATION

Mechanical support--benefits and risks [editorial] Scheld HH. **Thorac Cardiovasc Surg** 1997 Feb;45(1):1-5 (32 ref.)

[Shock] Okada M. **Ryoikibetsu Shokogun Shirizu** 1996; (12):67-77 (15 ref.) **(Jpn)**

INTRA-ARTERIAL LINES see **CATHETERS, INDWELLING**

INTRACELLULAR ADHESION MOLECULES see **CELL ADHESION MOLECULES**

INTRACELLULAR FLUID

CHEMISTRY

Swelling-activated organic osmolyte channels. Kirk K. **J Membr Biol** 1997 Jul 1;158(1):1-16 (132 ref.)

IMMUNOLOGY

Interaction of natural killer cells with extracellular matrix induces early intracellular signalling events and enhances cytotoxic functions. Palmieri G, et al. **Nat Immun** 1996-97; 15(2-3):147-53 (50 ref.)

CD8+ T cells in intracellular bacterial infections of mice. White DW, et al. **Res Immunol** 1996 Oct-Dec; 147(8-9):519-24 (48 ref.)

METABOLISM

The regulation of intracellular pH in the diabetic myocardium. Feuvray D. **Cardiovasc Res** 1997 Apr; 34(1):48-54 (50 ref.)

Regulation of intracellular Ca2+ in the heart during diabetes. Pierce GN, et al. **Cardiovasc Res** 1997 Apr;34(1):41-7 (99 ref.)

Intracellular calcium levels are unchanged in the diabetic heart. Yu JZ, et al. **Cardiovasc Res** 1997 Apr;34(1):91-8 (74 ref.)

Abnormal mechanical function in diabetes: relation to myocardial calcium handling. Schaffer SW, et al. **Coron Artery Dis** 1996 Feb;7(2):109-15 (51 ref.)

Control of the renal microcirculation: cellular and integrative perspectives. Casellas D, et al. **Curr Opin Nephrol Hypertens** 1996 Jan;5(1):57-63 (52 ref.)

Regulation of the intracellular calcium concentration in epithelial cells. Leipziger J, et al. **Kidney Blood Press Res** 1996;19(3-4):148-50 (21 ref.)

MICROBIOLOGY

CD8+ T cells in intracellular bacterial infections of mice. White DW, et al. **Res Immunol** 1996 Oct-Dec; 147(8-9):519-24 (48 ref.)

PHYSIOLOGY

Volume expansion-sensing outward-rectifier Cl- channel: fresh start to the molecular identity and volume sensor. Okada Y. **Am J Physiol** 1997 Sep;273(3 Pt 1):C755-89 (332 ref.)

INTRACELLULAR MEMBRANES

CHEMISTRY

Topogenesis of inner membrane proteins of mitochondria. Stuart RA, et al. **Trends Biochem Sci** 1996 Jul;21(7):261-7 (40 ref.)

METABOLISM

Intracellular calcium-release channels: regulators of cell life and death. Marks AR. **Am J Physiol** 1997 Feb;272(2 Pt 2):H597-605 (103 ref.)

Protein transport across the eukaryotic endoplasmic reticulum and bacterial inner membranes. Rapoport TA, et al. **Annu Rev Biochem** 1996;65:271-303 (234 ref.)

Intracellular free calcium and its modulation. Traina G. **Arch Ital Biol** 1996 Oct;134(4):323-39 (70 ref.)

Recognition of a transmembrane domain: another role for the ribosome? [comment] Siegel V. **Cell** 1997 Jul 11; 90(1):5-8 (19 ref.) Comment on: Cell 1997 Jul 11;90(1):31-41.

Microtubule motor complexes moving membranous organelles. Sheetz MP. **Cell Struct Funct** 1996 Oct; 21(5):369-73 (31 ref.)

Contact sites and transport in mitochondria. Moynagh PN. **Essays Biochem** 1995;30:1-14 (35 ref.)

Extra-and intracellular transport of retinoids: a reappraisal. Siegenthaler G. **Horm Res** 1996;45(3-5):122-7 (30 ref.)

Membrane dynamics at the endoplasmic reticulum-Golgi interface. Bannykh SI, et al. **J Cell Biol** 1997 Jul 14; 138(1):1-4 (40 ref.)

Current concepts of hepatic uptake, intracellular transport and biliary secretion of bile acids: physiological basis and pathophysiological changes in cholestatic liver dysfunction. Azer SA, et al. **J Gastroenterol Hepatol** 1996 Apr; 11(4):396-407 (154 ref.)

Do intracellular organelles have any role in transport of bile acids by hepatocytes? Erlinger S. **J Hepatol** 1996;24 Suppl 1:88-93 (33 ref.)

Protein translocation across the membrane of the endoplasmic reticulum. Wilkinson BM, et al. **J Membr Biol** 1997 Feb 1;155(3):189-97 (109 ref.)

Cytochrome P450 metabolites of arachidonic acid as intracellular signaling molecules in vascular tissue. Harder DR, et al. **J Vasc Res** 1997 May-Jun;34(3):237-43 (35 ref.)

Changes in intracellular Ca2+ concentration produced by the alteration of intracellular pH in rat parotid acinar cells. Nishiguchi H, et al. **Jpn J Physiol** 1997 Feb;47(1):41-9 (32 ref.)

Retroactive motors. Schnapp BJ. **Neuron** 1997 Apr; 18(4):523-6 (24 ref.)

Intracellular protein transport to the thyrocyte plasma membrane: potential implications for thyroid physiology. Arvan P, et al. **Thyroid** 1997 Feb;7(1):89-105 (293 ref.)

PHYSIOLOGY

Bowditch lecture. Integrated regulation of intestinal epithelial transport: intercellular and intracellular pathways. Barrett KE. **Am J Physiol** 1997 Apr;272(4 Pt 1):C1069-76 (40 ref.)

Mechanism of formation of post Golgi vesicles from TGN membranes: Arf-dependent coat assembly and PKC-regulated vesicle scission. Sabatini DD, et al. **Biocell** 1996 Dec;20(3):287-300 (104 ref.)

Caveolae, DIGs, and the dynamics of sphingolipid-cholesterol microdomains. Harder T, et al. **Curr Opin Cell Biol** 1997 Aug;9(4):534-42 (75 ref.)

SNAREs and NSF in targeted membrane fusion. Hay JC, et al. **Curr Opin Cell Biol** 1997 Aug;9(4):505-12 (70 ref.)

COPII and secretory cargo capture into transport vesicles. Kuehn MJ, et al. **Curr Opin Cell Biol** 1997 Aug;9(4):477-83 (57 ref.)

The diversity of Rab proteins in vesicle transport. Novick P, et al. **Curr Opin Cell Biol** 1997 Aug;9(4):496-504 (78 ref.)

The role of lipid signaling in constitutive membrane traffic. Roth MG, et al. **Curr Opin Cell Biol** 1997 Aug;9(4):519-26 (64 ref.)

Biogenesis of COPI-coated transport vesicles. Nickel W, et al. **FEBS Lett** 1997 Aug 25;413(3):395-400 (77 ref.)

Intracellular mechanisms of axon growth induction by CAMs and integrins: some unresolved issues. Bixby JL, et al. **Perspect Dev Neurobiol** 1996;4(2-3):147-56 (79 ref.)

[The vacuolar apparatus and membrane fusion in the cell] Bulychev AG, et al. **Tsitologiia** 1996;38(10):1001-35 (280 ref.) (Eng. Abstr.) **(Rus)**

INTRACELLULAR SECOND MESSENGERS see **SECOND MESSENGER SYSTEMS**

INTRACEREBRAL PRESSURE see **INTRACRANIAL PRESSURE**

INTRACISTERNAL A-PARTICLE GENES see **GENES, INTRACISTERNAL A-PARTICLE**

INTRACRANIAL ANEURYSM see **CEREBRAL ANEURYSM**

INTRACRANIAL ARTERIOVENOUS MALFORMATIONS see **CEREBRAL ARTERIOVENOUS MALFORMATIONS**

INTRACRANIAL HYPERTENSION, BENIGN see **PSEUDOTUMOR CEREBRI**

INTRACRANIAL PRESSURE

see related
PSEUDOTUMOR CEREBRI

Rapid sequence intubation in adults with elevated intracranial pressure: a survey of emergency medicine residency programs [see comments] Silber SH. **Am J Emerg Med** 1997 May;15(3):263-7 (71 ref.) Comment in: Am J Emerg Med 1997 May;15(3):321.

Hemispheric strokes: clinical or surgical management? Intracranial pressure monitoring of a case and review of the literature. Carvalho GA, et al. **Arq Neuropsiquiatr** 1995 Dec;53(4):821-4 (26 ref.)

Headache caused by raised intracranial pressure and intracranial hypotension. Ramadan NM. **Curr Opin Neurol** 1996 Jun;9(3):214-8 (53 ref.)

Bedside burr hole for intracranial pressure monitoring

performed by intensive care physicians. A 5-year experience. Bochicchio M, et al. **Intensive Care Med** 1996 Oct;22(10):1070–4 (24 ref.)
Indications for intracranial pressure monitoring. Brain Trauma Foundation. **J Neurotrauma** 1996 Nov; 13(11):667–79 (52 ref.)
Intracranial pressure treatment threshold. Brain Trauma Foundation. **J Neurotrauma** 1996 Nov;13(11):681–3 (7 ref.)
Recommendations for intracranial pressure monitoring technology. Brain Trauma Foundation. **J Neurotrauma** 1996 Nov;13(11):685–92 (35 ref.)
Guidelines for cerebral perfusion pressure. Brain Trauma Foundation. **J Neurotrauma** 1996 Nov;13(11):693–7 (35 ref.)
The use of mannitol in severe head injury. Brain Trauma Foundation. **J Neurotrauma** 1996 Nov;13(11):705–9 (43 ref.)
The role of glucocorticoids in the treatment of severe head injury. Brain Trauma Foundation. **J Neurotrauma** 1996 Nov;13(11):715–8 (19 ref.)
Physiologic principles for volume regulation of a tissue enclosed in a rigid shell with application to the injured brain. Grände PO, et al. **J Trauma** 1997 May;42(5 Suppl):S23–31 (34 ref.)
Therapy of patients with head injuries: key parameters for management. Prough DS, et al. **J Trauma** 1997 May;42(5 Suppl):S10–8 (78 ref.)
Increased intracranial pressure and the cerebrospinal fluid spaces. Smith RR, et al. **Semin Ultrasound CT MR** 1996 Jun;17(3):206–20 (24 ref.)
[Fulminant liver insufficiency and the possible role of intracranial pressure monitoring, also in children] Plötz FB, et al. **Ned Tijdschr Geneeskd** 1996 Nov 16;140(46):2274–6 (28 ref.) **(Dut)**
[Spontaneous intracranial hypotension syndrome] Ben Amor S, et al. **Rev Neurol (Paris)** 1996 Oct;152(10):611–4 (24 ref.) (Eng. Abstr.) **(Fre)**
[Management of increased intracranial pressure in metastatic brain tumor] Muragaki Y, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(3):297–302 (7 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

[Hypertonic solutions and intracranial pressure] Favre JB, et al. **Schweiz Med Wochenschr** 1996 Sep 28; 126(39):1635–43 (41 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Hydrocephalus and chronically increased intracranial pressure in achondroplasia. Erdinçler P, et al. **Childs Nerv Syst** 1997 Jun;13(6):345–8 (15 ref.)
[Value of electroneurophysiological monitoring on the intensive care unit] Engelhardt W. **Zentralbl Neurochir** 1997;58(1):36–42 (23 ref.) **(Ger)**
[Monitoring cerebral perfusion pressure] Jantzen JP. **Zentralbl Neurochir** 1997;58(1):32–5 (31 ref.) **(Ger)**

INTRAMEDULLARY NAILING see **FRACTURE FIXATION, INTRAMEDULLARY**

INTRAOBSERVER VARIATION see **OBSERVER VARIATION**

INTRAOCULAR PRESSURE

see related
GLAUCOMA
OCULAR HYPERTENSION
OCULAR HYPOTENSION

Intraocular pressure and circulation at the disc in glaucoma. Hitchings RA. **Acta Ophthalmol Scand Suppl** 1997; (220):15–20; discussion 20–2 (63 ref.)
Glaucomatous optic nerve cupping as an optic neuropathy. Anderson DR, et al. **Clin Neurosci** 1997;4(5):274–8 (37 ref.)
Proper outcome measurements regarding glaucoma: the inadequacy of using intraocular pressure alone. Spaeth GL. **Eur J Ophthalmol** 1996 Apr–Jun;6(2):101–5 (35 ref.)
Impact of intraocular pressure on venous outflow from the globe: a hypothesis regarding IOP-dependent vascular damage in normal-tension and hypertensive glaucoma. Bito LZ. **J Glaucoma** 1996 Apr;5(2):127–34 (40 ref.)
Target pressure in glaucoma therapy. Jampel HD. **J Glaucoma** 1997 Apr;6(2):133–8 (16 ref.)
Management of chronic hypotony after glaucoma filtration surgery. Liebmann JM, et al. **J Glaucoma** 1996 Jun; 5(3):210–20 (127 ref.)
Resuturing the scleral flap leads to resolution of hypotony maculopathy. Schwartz GF, et al. **J Glaucoma** 1996 Aug; 5(4):246–51 (50 ref.)
Ocular outflow facility with emphasis on neuronal regulation of intraocular smooth muscles. Suzuki R. **J Smooth Muscle Res** 1996 Dec;32(6):229–47 (82 ref.)

DRUG EFFECTS

Prostaglandins and cholinomimetics [editorial; comment] Kaufman PL. **Arch Ophthalmol** 1997 Jul;115(7):911–3 (41 ref.) Comment on: Arch Ophthalmol 1997 Jul;115(7):857–61.
Initial clinical studies with prostaglandins and their analogues. Camras CB, et al. **Surv Ophthalmol** 1997 Feb; 41 Suppl 2:S61–8 (52 ref.)
Reduced intraocular pressure and increased ocular perfusion pressure in normal tension glaucoma: a review of short-term studies with three dose regimens of latanoprost treatment. Greve EL, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S89–92 (18 ref.)
The additive intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents. Hoyng PF, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S93–8 (43 ref.)
Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow. Mishima HK, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S139–44 (26 ref.)
Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids. Resul B, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S47–52 (16 ref.)
Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Walters TR. **Surv Ophthalmol** 1996 Nov;41 Suppl 1:S19–26 (26 ref.)
[Local carbonic anhydrase inhibitor dorzolamide: development and properties] Pfeiffer N. **Ophthalmologe** 1996 Feb;93(1):103–18 (9 ref.) **(Ger)**

PHYSIOLOGY

Do beta-adrenoceptors and serotonin 5-HT1A receptors have similar functions in the control of intraocular pressure in the rabbit? Osborne NN, et al. **Ophthalmologica** 1996; 210(5):308–14 (40 ref.)
[Primary chronic open angle glaucoma--are there vascular risk factors?] Drance SM. **Klin Monatsbl Augenheilkd** 1996 Jun;208(6):A9–13 (58 ref.) **(Ger)**

INTRAOPERATIVE CARE

Intraoperative autologous blood donation preserves red cell mass but does not decrease postoperative bleeding. Helm RE, et al. **Ann Thorac Surg** 1996 Nov;62(5):1431–41 (25 ref.)
Intraoperative cytology: promise, practice, and problems. Silverberg SG. **Diagn Cytopathol** 1995 Dec;13(5):386–7 (7 ref.)
Echocaridography for the anesthesiologist. Sarier KK, et al. **Int Anesthesiol Clin** 1996 Summer;34(3):57–77 (41 ref.)
Operative and postoperative evaluation and management in the elderly. Abyad A. **Middle East J Anesthesiol** 1995 Oct; 13(3):291–306 (33 ref.)
Laparoscopic staging and intraoperative ultrasonography for liver tumor management. Ravikumar TS. **Surg Oncol Clin N Am** 1996 Apr;5(2):271–82 (36 ref.)
Intraoperative ultrasonography and other techniques for segmental resections. Takayama T, et al. **Surg Oncol Clin N Am** 1996 Apr;5(2):261–9 (16 ref.)
[Intraoperative sonography. Intraoperative sonographic position finding for the surgical removal of a residual root from the sublingual space] Ludwig A, et al. **Schweiz Monatsschr Zahnmed** 1997;107(5):398–404 (6 ref.) **(Ger, Fre)**
[Preoperative evaluation of aged patients] Meguro K, et al. **Masui** 1996 Dec;45 Suppl:S143–6 (5 ref.) **(Jpn)**
[Intraoperative fluid therapy] Ogawa R. **Masui** 1996 Dec;45 Suppl:S199–207 (15 ref.) **(Jpn)**
[Perioperative care of patients with heart dysfunction] Soto S. **Masui** 1996 Dec;45 Suppl:S128–33 (12 ref.) **(Jpn)**
[Anesthesia and intraoperative care of patients with heart dysfunction] Ueda N, et al. **Masui** 1996 Dec;45 Suppl:S114–21 (24 ref.) **(Jpn)**
[Intraoperative management of patients with esophageal neoplasms] Ando N, et al. **Nippon Geka Gakkai Zasshi** 1996 Jun;97(6):427–31 (7 ref.) **(Jpn)**
[Intraoperative fluid infusion and blood transfusion in patients of esophageal cancer] Endo Y, et al. **Nippon Geka Gakkai Zasshi** 1996 Jun;97(6):416–20 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Surgical procedures and intra-operative management to prevent postoperative complications following resection of esophageal cancer] Fujita H. **Nippon Geka Gakkai Zasshi** 1996 Jun;97(6):421–6 (0 ref.) (Eng. Abstr.) **(Jpn)**
[Care of esophageal cancer patients with diabetes mellitus--preoperative management and treatment] Shimada Y, et al. **Nippon Geka Gakkai Zasshi** 1996 Jun; 97(6):404–8 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Studies on intraoperative cardiac mapping] Watanabe S, et al. **Rinsho Kyobu Geka** 1989 Jun;9(3):229–37 (24 ref.) (Eng. Abstr.) **(Jpn)**
[The use of intravascular laser irradiation of the blood in surgery] Ismailov DA, et al. **Vestn Khir Im I I Grek** 1995; 154(4–6):128–31 (59 ref.) **(Rus)**

ADVERSE EFFECTS

Inadvertent intraoperative myelography with Hypaque: case report and discussion. Killeffer JA, et al. **Surg Neurol** 1997 Jul;48(1):70–3 (23 ref.)

METHODS

Perioperative management of lung volume reduction patients. Keller CA, et al. **Clin Chest Med** 1997 Jun;18(2):285–300 (39 ref.)
Preparation and intraoperative management of the pediatric patient. Hata T. **Pediatr Ann** 1997 Aug;26(8):471–81; quiz 501–3 (28 ref.)
Perisurgical use of epoetin alfa in orthopedic surgery patients. Adamson J. **Semin Hematol** 1997 Apr;33(2 Suppl 2):55–8; discussion 59 (11 ref.)
Practice policies for surgical red blood cell transfusion: surgical transfusion policies. Spence RK. **Semin Hematol** 1996 Jan;33(1 Suppl 1):19–22 (42 ref.)
[Indications and role of albumin for vascular loading in the operating room] Gérard JL, et al. **Ann Fr Anesth Reanim** 1996;15(4):481–90 (69 ref.) (Eng. Abstr.) **(Fre)**
[Echo-guided drainage of pararenal and pelvic fluid accumulations: technique, indications, and results] Porena M, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):19–26 (8 ref.) (Eng. Abstr.) **(Ita)**

TRENDS

Lymphoid lesions. Burke JS. **Pathology (Phila)** 1996; 3(2):503–12 (32 ref.)
Urinary tract and male genital system. Coulson WF. **Pathology (Phila)** 1996;3(2):493–502 (17 ref.)
Liver. Ferrell LD, et al. **Pathology (Phila)** 1996;3(2):367–78 (36 ref.)
Gastrointestinal tract. Goidstein NS, et al. **Pathology (Phila)** 1996;3(2):349–65 (65 ref.)
Soft tissue. Kempson RL. **Pathology (Phila)** 1996;3(2):545–53 (11 ref.)
Lung. Lombard CM. **Pathology (Phila)** 1996;3(2):321–38 (16 ref.)
The female genital tract. Longacre TA, et al. **Pathology (Phila)** 1996;3(2):427–92 (26 ref.)
The mediastinum. Marchevsky A. **Pathology (Phila)** 1996; 3(2):339–48 (19 ref.)
Upper aerodigestive tract. Ranchod M. **Pathology (Phila)** 1996;3(2):299–304 (5 ref.)
Salivary gland. Ranchod M. **Pathology (Phila)** 1996; 3(2):305–19 (12 ref.)
Intraoperative consultation: introduction and general principles. Ranchod M. **Pathology (Phila)** 1996;3(2):259–71 (7 ref.)
Technical aspects of intraoperative diagnosis. Ranchod M. **Pathology (Phila)** 1996;3(2):273–84 (4 ref.)
Parathyroid gland. Ranchod M. **Pathology (Phila)** 1996; 3(2):405–16 (28 ref.)
The pancreas and peripancreatic area. Ranchod M, et al. **Pathology (Phila)** 1996;3(2):379–87 (20 ref.)
Thyroid gland. Ranchod M. **Pathology (Phila)** 1996; 3(2):389–403 (24 ref.)
Bone. Ranchod M, et al. **Pathology (Phila)** 1996;3(2):535–44 (11 ref.)
Skin. Smoller BR, et al. **Pathology (Phila)** 1996;3(2):285–98 (15 ref.)
Central nervous system. Vinters HV, et al. **Pathology (Phila)** 1996;3(2):513–34 (39 ref.)
Breast. Weidner N, et al. **Pathology (Phila)** 1996;3(2):417–26 (23 ref.)

INTRAOPERATIVE COMPLICATIONS

Don't cry over spilled stones? Complications of gallstones spilled during laparoscopic cholecystectomy: case report and literature review [see comments] Patterson EJ, et al. **Can J Surg** 1997 Aug;40(4):300–4 (35 ref.) Comment in: Can J Surg 1997 Aug;40(4):249–50.
Selected complications of radial keratotomy, photorefractive keratectomy, and laser in situ keratomileusis. Filatov V, et al. **Int Ophthalmol Clin** 1997 Winter;37(1):123–48 (96 ref.)
The neurologic implications of diabetic hyperglycemia during surgical procedures at increased risk for brain ischemia. Sieber FE. **J Clin Anesth** 1997 Jun;9(4):334–40 (69 ref.)
Surgical complications of lung transplantation in children. Huddleston CB. **Semin Thorac Cardiovasc Surg** 1996 Jul; 8(3):296–304 (41 ref.)
Superior gluteal artery injury during iliac bone grafting for spinal fusion. A case report and literature review. Lim EV, et al. **Spine** 1996 Oct 15;21(20):2376–8 (10 ref.)
Clinical manifestations of lost gallstones after laparoscopic cholecystectomy: a case report with review of the literature. Läuffer JM, et al. **Surg Laparosc Endosc** 1997 Apr;7(2):103–12 (69 ref.)
[Perioperative care of patients with heart dysfunction--influence of epidural anesthesia] Shibata K, et al. **Masui** 1996 Dec;45 Suppl:S122–7 (18 ref.) **(Jpn)**
[Intraoperative management of patients with esophageal neoplasms] Ando N, et al. **Nippon Geka Gakkai Zasshi** 1996 Jun;97(6):427–31 (7 ref.) **(Jpn)**

BLOOD

Thromboelastography for the assessment of hypercoagulability during general surgery. Arcelus JI, et al. **Semin Thromb Hemost** 1995;21 Suppl 4:21–6 (62 ref.)

CHEMICALLY INDUCED

Cardiopulmonary compromise after use of topical and submucosal alpha-agonists: possible added complication by the use of beta-blocker therapy. Kalyanaraman M, et al. **Otolaryngol Head Neck Surg** 1997 Jul;117(1):56–61 (32 ref.)
[Surgery in patients treated with anticoagulation during emergency and elective interventions] Encke A. **Chirurg** 1997 Jul;68(7):670–4 (11 ref.) (Eng. Abstr.) **(Ger)**
[Allergic reactions during anesthesia] Escolano F, et al. **Rev Esp Anestesiol Reanim** 1996 Jan;43(1):17–26 (56 ref.)

(Eng. Abstr.) **(Spa)**

DIAGNOSIS

Detection of intraoperative myocardial ischemia. Perrino AC Jr, et al. **Int Anesthesiol Clin** 1996 Summer;34(3):37–56 (67 ref.)

EPIDEMIOLOGY

Venous air embolism during operative hysteroscopy [see comments] Brooks PG. **J Am Assoc Gynecol Laparosc** 1997 May;4(3):399–402 (10 ref.) Comment in: J Am Assoc Gynecol Laparosc 1997 May;4(3):291–2.

Effects of regional anesthesia on perioperative outcome. Atanassoff PG. **J Clin Anesth** 1996 Sep;8(6):446–55 (106 ref.)

Complications of major operative laparoscopy. A review of 452 cases. Saidi MH, et al. **J Reprod Med** 1996 Jul; 41(7):471–6 (29 ref.)

Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Ciric I, et al. **Neurosurgery** 1997 Feb; 40(2):225–36; discussion 236–7 (101 ref.)

ETIOLOGY

Intestinal perforation after suction lipoplasty: a case report and review of the literature. Talmor M, et al. **Ann Plast Surg** 1997 Feb;38(2):169–72 (20 ref.)

Airway closure and intraoperative hypoxaemia: twenty–five years later. Wahba RM. **Can J Anaesth** 1996 Nov; 43(11):1144–9 (32 ref.)

Cardiac arrest after esmolol administration: a review of acute beta–blocker toxicity. Litman RS, et al. **J Am Osteopath Assoc** 1996 Oct;96(10):616–8 (27 ref.)

Asystole after inadvertent intubation of the orbit. Green JG, et al. **J Oral Maxillofac Surg** 1997 Aug;55(8):856–9 (43 ref.)

Perioperative considerations in a newly described subtype of congenital long QT syndrome. Joseph–Reynolds AM, et al. **Paediatr Anaesth** 1997;7(3):237–41 (25 ref.)

Ventricular laceration and cardiac tamponade during laparoscopic Nissen fundoplication. Firoozmand E, et al. **Surg Laparosc Endosc** 1996 Oct;6(5):394–7 (10 ref.)

Laparoscopic complications in markedly obese urologic patients (a multi–institutional review). Mendoza D, et al. **Urology** 1996 Oct;48(4):562–7 (30 ref.)

[Damage due to patient positioning in anesthesia and surgical medicine (1)] Ullrich W, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jan; 32(1):4–20 (0 ref.) (Eng. Abstr.) **(Ger)**

[Errors and risks in oncologic laparoscopic surgery] Köckerling F, et al. **Chirurg** 1997 Mar;68(3):215–24 (39 ref.) (Eng. Abstr.) **(Ger)**

[Acute iatrogenic myopathy during treatment of status asthmaticus. Our experience and review of the literature] Pacini D, et al. **Minerva Anestesiol** 1997 Mar;63(3):81–91 (45 ref.) (Eng. Abstr.) **(Ita)**

IMMUNOLOGY

[Surgery in immunosuppressed patients with emergency or elective indications] Lang H, et al. **Chirurg** 1997 Jul; 68(7):675–80 (26 ref.) (Eng. Abstr.) **(Ger)**

MORTALITY

[Risk assessment] Bartels H, et al. **Chirurg** 1997 Jul; 68(7):654–61 (56 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Ureteral injuries during gynecologic procedures. Mariotti G, et al. **Minerva Urol Nefrol** 1997 Jun;49(2):95–8 (23 ref.)

[Tumor embolism with fatal cerebral infarct in pneumonectomy. Case report and review of the literature] Zürcher M, et al. **Chirurg** 1996 Sep;67(9):959–62 (37 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Malignant hyperthermia in a 3–month–old infant: a case report. Pennington GP, et al. **J Med Assoc Ga** 1996 Sep; 85(3):162–3 (10 ref.)

PREVENTION & CONTROL

Intravenous agents and intraoperative neuroprotection. Beyond barbiturates. Cheng MA, et al. **Crit Care Clin** 1997 Jan;13(1):185–99 (90 ref.)

Hypothermia–associated protection from ischemic brain injury: implications for patient management. Wass CT, et al. **Int Anesthesiol Clin** 1996 Fall;34(4):95–111 (76 ref.)

Perioperative pain management. Levy BS, et al. **J Am Assoc Gynecol Laparosc** 1995 Aug;2(4):381–7 (24 ref.)

[Positioning trauma in anesthesia and surgical intensive care medicine (2)] Kienzle F, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Feb; 32(2):72–86 (204 ref.) (Eng. Abstr.) **(Ger)**

[Are high risk patients candidates for minimally invasive surgery with CO2 pneumoperitoneum? Viewpoint from anesthesiology] Schulte–Steinberg H, et al. **Chirurg** 1996 Jan;67(1):72–6 (33 ref.) (Eng. Abstr.) **(Ger)**

[The patient with respiratory problems] Senninger N, et al. **Chirurg** 1997 Jul;68(7):662–9 (58 ref.) (Eng. Abstr.) **(Ger)**

[Viscoelastic substances in cataract surgery. Principles and current overview] Hessemer V, et al. **Klin Monatsbl Augenheilkd** 1996 Aug–Sep;209(2–3):55–61 (77 ref.) (Eng. Abstr.) **(Ger)**

[Cataract operation during therapy with anticoagulants. Principles, perioperative procedure, complications and recommendations] Dick B, et al. **Ophthalmologe** 1997 May; 94(5):372–84 (28 ref.) **(Ger)**

[Anesthesiologic preparation for urologic operations. II: Procedure in concomitant diseases] Wilhelm W, et al. **Urologe A** 1996 Nov;35(6):497–510 (10 ref.) **(Ger)**

[Human error in the anesthesiological field. Up to what point is it possible to speak of prevention?] De Amici D, et al. **Epidemiol Prev** 1997 Jan–Mar;21(1):19–29 (51 ref.) (Eng. Abstr.) **(Ita)**

[Preoperative evaluation of aged patients] Meguro K, et al. **Masui** 1996 Dec;45 Suppl:S143–6 (5 ref.) **(Jpn)**

[Radical neck dissection and the possibility of complications: surgical technique] Kurnatowski P, et al. **Otolaryngol Pol** 1996;50(4):383–93 (8 ref.) (Eng. Abstr.) **(Pol)**

SURGERY

Asymptomatic right atrial aneurysm: fortuitous finding and resection. Zeebregts CJ, et al. **Eur J Cardiothorac Surg** 1997 Mar;11(3):591–3 (8 ref.)

Consultation section. How would you handle a tear in the posterior capsule, detected at the end of phacoemulsification, with the cortex intact and no vitreous loss? [see comments] **J Cataract Refract Surg** 1997 Jan–Feb; 23(1):12–8 (9 ref.) Comment in: J Cataract Refract Surg 1997 May;23(4):462.

Re: Circumcision: successful glanular reconstruction and survival following traumatic amputation [letter; comment] Van Howe RS. **J Urol** 1997 Aug;158(2):550 (16 ref.) Comment on: J Urol 1996 Aug;156(2 Pt 2):842–4.

[Perforation of the cervical esophagus after ventral fusion of the cervical spine. Defect coverage by muscle–plasty with the sternocleidomastoid muscle: case report and review of the literature] Lamesch P, et al. **Chirurg** 1997 May;68(5):543–7 (30 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Pulmonary aspiration complicating intraoperative small–bowel decompression: a case report and literature review. Phillips I, et al. **Can J Surg** 1996 Dec;39(6):495–8 (32 ref.)

Intravascular ultrasound: a guide for management of complications during intervention? Görge G, et al. **Eur Heart J** 1995 Nov;16 Suppl L:86–92 (57 ref.)

Management of perioperative arrhythmias. Feeley TW. **J Cardiothorac Vasc Anesth** 1997 Apr;11(2 Suppl 1):10–5; discussion 24–5 (36 ref.)

Venous air embolism: a review. Palmon SC, et al. **J Clin Anesth** 1997 May;9(3):251–7 (51 ref.)

Conservative management of colon injury following percutaneous renal surgery. Gerspach JM, et al. **Urology** 1997 Jun;49(6):831–6 (14 ref.)

[Intra– and postoperative catheter epidural analgesia. Combination of epidural analgesia and general anesthesia] Seeling W, et al. **Anaesthesist** 1997 Mar;46(3):237–52 (13 ref.) **(Ger)**

[Anesthetic managements for pericardiectomy of three patients with constrictive pericarditis] Kurokawa S, et al. **Masui** 1997 Apr;46(4):515–20 (8 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Coronary artery flow monitoring: the value of intravascular Doppler for detection of complications after interventions. Anderson HV, et al. **Eur Heart J** 1995 Nov;16 Suppl L:93–6 (20 ref.)

VETERINARY

Anaesthetic problems caused by diaphragmatic hernia in the horse: a review of four cases. Clutton RE, et al. **Equine Vet J Suppl** 1992 Feb;(11):30–3 (30 ref.)

INTRAOPERATIVE MONITORING

Computer–assisted intraoperative navigation during skull base surgery. Carrau RL, et al. **Am J Otolaryngol** 1996 Mar–Apr;17(2):95–101 (20 ref.)

Intraoperative automated ST segment analysis: a reliable black box? Yang H. **Can J Anaesth** 1996 Oct; 43(10):1041–51 (71 ref.)

Monitoring of hemostasis in cardiac surgical patients: impact of point–of–care testing on blood loss and transfusion outcomes. Despotis GJ, et al. **Clin Chem** 1997 Sep; 43(9):1684–96 (153 ref.)

Innovations in minimalism: intraoperative MRI. Alexander E 3rd, et al. **Clin Neurosurg** 1996;43:338–52 (34 ref.)

Minimalism through intraoperative functional mapping. Berger MS. **Clin Neurosurg** 1996;43:324–37 (17 ref.)

Intraoperative cranial navigation. Maciunas RJ. **Clin Neurosurg** 1996;43:353–81 (21 ref.)

Intraoperative enteroscopy. Indications and techniques. Cave DR, et al. **Gastrointest Endosc Clin N Am** 1996 Oct; 6(4):793–802 (47 ref.)

Monitoring for cerebrovascular surgery. Bloom MJ, et al. **Int Anesthesiol Clin** 1996 Summer;34(3):137–47 (56 ref.)

Assessment of sedation, analgesia, and neuromuscular blockade in the perioperative period. Habibi S, et al. **Int Anesthesiol Clin** 1996 Summer;34(3):215–41 (68 ref.)

Methods for monitoring hemostasis during and following cardiac surgery. Huffman SM, et al. **Int Anesthesiol Clin** 1996 Spring;34(2):123–39 (34 ref.)

The monitoring of mechanically ventilated patients. Kirby RR. **Int Anesthesiol Clin** 1997 Winter;35(1):65–86 (61 ref.)

Intraoperative neurophysiological monitoring. Lopez JR. **Int Anesthesiol Clin** 1996 Fall;34(4):33–54 (92 ref.)

Detection of intraoperative myocardial ischemia. Perrino AC Jr, et al. **Int Anesthesiol Clin** 1996 Summer;34(3):37–56 (67 ref.)

Echocaridography for the anesthesiologist. Sarier KK, et al. **Int Anesthesiol Clin** 1996 Summer;34(3):57–77 (41 ref.)

Temperature monitoring. Young CC, et al. **Int Anesthesiol Clin** 1996 Summer;34(3):149–74 (50 ref.)

Intraoperative color–flow duplex ultrasonography following carotid endarterectomy. Hallett JW Jr, et al. **Neurosurg Clin N Am** 1996 Oct;7(4):733–40 (11 ref.)

Intraoperative use of somatosensory evoked potentials for brain monitoring during carotid surgery. Horsch S, et al. **Neurosurg Clin N Am** 1996 Oct;7(4):693–702 (16 ref.)

Intraoperative use of transcranial Doppler ultrasonography. Lam AM, et al. **Neurosurg Clin N Am** 1996 Oct;7(4):709–22 (82 ref.)

Intraoperative use of electroencephalography as an assessment of cerebral blood flow. McGrail KM. **Neurosurg Clin N Am** 1996 Oct;7(4):685–92 (52 ref.)

Management of vestibular schwannomas (acoustic neuromas): the value of neurophysiology for evaluation and prediction of auditory function in 420 cases. Matthies C, et al. **Neurosurgery** 1997 May;40(5):919–29; discussion 929–30 (44 ref.)

Iatrogenic facial nerve injury: the role of facial nerve monitoring. Prass RL. **Otolaryngol Clin North Am** 1996 Apr;29(2):265–75 (22 ref.)

Cerebral monitoring during cardiopulmonary bypass. Ali MI, et al. **Perfusion** 1996 Jul;11(4):299–312 (43 ref.)

[Spinal cord monitoring during spinal surgery] Hu J, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1996 Feb; 18(1):72–5 (30 ref.) **(Chi)**

[Blood gas analysis] Boemke W, et al. **Anaesthesist** 1996 Mar; 45(3):289–310 (18 ref.) **(Ger)**

[Monitoring intraoperative awareness. Vegetative signs, isolated forearm technique, electroencephalogram, and acute evoked potentials] Schwender D, et al. **Anaesthesist** 1996 Aug;45(8):708–21 (66 ref.) (Eng. Abstr.) **(Ger)**

[Are high risk patients candidates for minimally invasive surgery with CO2 pneumoperitoneum? Viewpoint from anesthesiology] Schulte–Steinberg H, et al. **Chirurg** 1996 Jan;67(1):72–6 (33 ref.) (Eng. Abstr.) **(Ger)**

[Does multi–vessel disease of brain supplying arteries modify the procedure in carotid operations?] Kogel H. **Zentralbl Chir** 1996;121(12):1049–53 (34 ref.) (Eng. Abstr.) **(Ger)**

[Intraoperative monitoring during anesthesia in children] Miyasaka K. **Masui** 1996 Dec;45 Suppl:S6–13 (18 ref.) **(Jpn)**

[Intraoperative monitoring of respiratory function] Suwa K. **Masui** 1996 Dec;45 Suppl:S187–91 (2 ref.) **(Jpn)**

[Electrophysiological intraoperative monitoring in the surgery of brain stem lesions] Sekiya T, et al. **No Shinkei Geka** 1996 Apr;24(4):311–20 (57 ref.) **(Jpn)**

[Radical neck dissection and the possibility of complications: surgical technique] Kurnatowski P, et al. **Otolaryngol Pol** 1996;50(4):383–93 (8 ref.) (Eng. Abstr.) **(Pol)**

METHODS

Patients' memories of events during general anaesthesia. Bailey AR, et al. **Anaesthesia** 1997 May;52(5):460–76 (102 ref.)

Visual evoked potentials in endoscopic and anterior skull base surgery: a review. Jones NS. **J Laryngol Otol** 1997 Jun; 111(6):513–6 (33 ref.)

Thromboelastography in liver transplantation. Kang Y. **Semin Thromb Hemost** 1995;21 Suppl 4:34–44 (46 ref.)

Preoperative evaluation and intraoperative management of patients with chronic renal failure undergoing vascular procedures. Morrison DE. **Semin Vasc Surg** 1996 Sep; 9(3):166–71 (16 ref.)

[Muscle relaxants. New substances and neuromuscular monitoring] Diefenbach C, et al. **Anaesthesist** 1997 Jan; 46(1):3–13 (79 ref.) (Eng. Abstr.) **(Ger)**

INTRAOPERATIVE PERIOD

Clinical applications of cerebral monitoring. Langford RM. **Comput Methods Programs Biomed** 1996 Oct;51(1–2):29–33 (12 ref.)

INTRAOSSEOUS GANGLION see **BONE CYSTS**

INTRAPERITONEAL INFUSIONS see **INFUSIONS, PARENTERAL**

INTRAUTERINE CROSS-TRANSFUSION see **FETOFETAL TRANSFUSION**

INTRAUTERINE DEVICES

Fertility control by emergency contraception. Glasier A. **Adv Contracept** 1996 Sep;12(3):167–72 (17 ref.)

Modern intra-uterine devices. Odlind V. **Baillieres Clin Obstet Gynaecol** 1996 Apr;10(1):55–67 (50 ref.)

Intrauterine devices. Mishell DR Jr. **Curr Ther Endocrinol Metab** 1997;6:285–92 (6 ref.)

Reappearance of the intrauterine device: a 'user-friendly' contraceptive. Kaunitz AM. **Int J Fertil Womens Med** 1997 Mar–Apr;42(2):120–7 (22 ref.)

Emergency contraception: the nurse's role in providing postcoital options. Lindberg CE. **J Obstet Gynecol Neonatal Nurs** 1997 Mar–Apr; 26(2):145–52 (24 ref.)

Mechanisms of action of intrauterine devices. Ortiz ME, et al. **Obstet Gynecol Surv** 1996 Dec;51(12 Suppl):S42–51 (82 ref.)

[Progresses in family planning in China, 1996] Wu Y. **Chung Hua I Hsueh Tsa Chih** 1996 Dec;76(12):919–20 (0 ref.) **(Chi)**

ADVERSE EFFECTS

Intrauterine devices and pelvic inflammatory disease: evolving perspectives on the data. Burkman RT. **Obstet Gynecol Surv** 1996 Dec;51(12 Suppl):S35–41 (46 ref.)

TRENDS

The IUD in evolution. Westhoff C. **Obstet Gynecol Surv** 1996 Dec;51(12 Suppl):S20–4 (23 ref.)

INTRAUTERINE DEVICES, COPPER

The levonorgestrel-releasing intrauterine device: a wider role than contraception. Coleman M, et al. **Aust N Z J Obstet Gynaecol** 1997 May;37(2):195–201 (68 ref.)

STANDARDS

[Intrauterine copper contraceptive implants] Van Kets H, et al. **Contracept Fertil Sex** 1996 Dec;24(12):908–11 (21 ref.) (Eng. Abstr.) **(Fre)**

INTRAUTERINE DEVICES, MEDICATED

The levonorgestrel-releasing intrauterine device: a wider role than contraception. Coleman M, et al. **Aust N Z J Obstet Gynaecol** 1997 May;37(2):195–201 (68 ref.)

Gynaecological aspects of the levonorgestrel-releasing intrauterine system [see comments] Sturridge F, et al. **Br J Obstet Gynaecol** 1997 Mar;104(3):285–9 (36 ref.) Comment in: Br J Obstet Gynaecol 1997 Mar;104(3):viii.

Implantable hormonal and emergency contraception. Cullins VE, et al. **Curr Opin Obstet Gynecol** 1997 Jun;9(3):169–74 (44 ref.)

Progestin-releasing intrauterine devices. Toivonen J, et al. **Curr Ther Endocrinol Metab** 1997;6:281–5 (7 ref.)

A risk-benefit assessment of the levonorgestrel-releasing intrauterine system. Sturridge F, et al. **Drug Saf** 1996 Dec; 15(6):430–40 (66 ref.)

INTRAUTERINE DIAGNOSIS see **PRENATAL DIAGNOSIS**

INTRAUTERINE GROWTH RETARDATION see **FETAL GROWTH RETARDATION**

INTRAVENOUS ANESTHETICS see **ANESTHETICS, INTRAVENOUS**

INTRAVENOUS DRIP see **INFUSIONS, INTRAVENOUS**

INTRAVENOUS DRUG ABUSE see **SUBSTANCE ABUSE, INTRAVENOUS**

INTRAVENOUS DRUG DELIVERY SYSTEMS see **INFUSION PUMPS**

INTRAVENOUS FEEDING see **PARENTERAL NUTRITION**

INTRAVENOUS HYPERALIMENTATION see **PARENTERAL NUTRITION, TOTAL**

INTRAVENOUS IMMUNOGLOBULINS see **IMMUNOGLOBULINS, INTRAVENOUS**

INTRAVENOUS INFUSIONS see **INFUSIONS, INTRAVENOUS**

INTRONS

Novel intron-encoded small nucleolar RNAs with long sequence complementarities to mature rRNAs involved in ribosome biogenesis. Bachellerie JP, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):835–43 (30 ref.)

Intron-dependent enzymatic formation of modified nucleosides in eukaryotic tRNAs: a review. Grosjean H, et al. **Biochimie** 1997 May;79(5):293–302 (74 ref.)

A difficult phase for introns-early. Molecular evolution. Hurst LD, et al. **Curr Biol** 1996 May 1;6(5):533–6 (22 ref.)

RNA splicing: unexpected spliceosome diversity. Kreivi JP, et al. **Curr Biol** 1996 Jul 1;6(7):802–5 (9 ref.)

Introns and gene evolution. de Souza SJ, et al. **Genes Cells** 1996 Jun;1(6):493–505 (84 ref.)

Regulation of expression of the alpha 1 (I) collagen gene: a critical appraisal of the role of the first intron [see comments] Bornstein P. **Matrix Biol** 1996 Apr;15(1):3–10 (54 ref.) Comment in: Matrix Biol 1996 Jul;15(2):62–3; discussion 70. Comment in: Matrix Biol 1996 Jul;15(2):64; discussion 70. Comment in: Matrix Biol 1996 Jul;15(2):65; discussion 70. Comment in: Matrix Biol 1996 Jul;15(2):66–7; discussion 70. Comment in: Matrix Biol 1996 Jul;15(2):68–9; discussion 70.

Arabidopsis intron mutations and pre-mRNA splicing. Brown JW. **Plant J** 1996 Nov;10(5):771–80 (73 ref.)

Secrets of RNA folding revealed. Price S, et al. **Structure** 1996 Oct 15;4(10):1129–32 (30 ref.)

Archaeal introns: splicing, intercellular mobility and evolution. Lykke-Andersen J, et al. **Trends Biochem Sci** 1997 Sep;22(9):326–31 (36 ref.)

RNA editing, introns and evolution. Herbert A. **Trends Genet** 1996 Jan;12(1):6–9 (23 ref.)

GENETICS

Group II introns: elaborate ribozymes. Jacquier A. **Biochimie** 1996;78(6):474–87 (77 ref.)

PHYSIOLOGY

Transposition: mobile introns get into line. Grivell LA. **Curr Biol** 1996 Jan 1;6(1):48–51 (20 ref.)

INTUBATION

see related
CHEST TUBES

ADVERSE EFFECTS

Delayed presentation of esophageal perforation as a result of overtube placement. Dinning JP, et al. **J Clin Gastroenterol** 1997 Jun;24(4):250–2 (12 ref.)

PSYCHOLOGY

[Communication with intubated patients] Ben-Ami-Lozover S, et al. **Harefuah** 1996 Jun 16;130(12):806–10, 880 (40 ref.) (Eng. Abstr.) **(Heb)**

INTUBATION, ENDOTRACHEAL see **INTUBATION, INTRATRACHEAL**

INTUBATION, INTRATRACHEAL

Airway managements of patients with maxillofacial trauma [published erratum appears in Acta Anaesthesiol Sin 1997 Mar;35(1):59] King HK. **Acta Anaesthesiol Sin** 1996 Dec; 34(4):213–20 (51 ref.)

Airway management in neuroanaesthesia. Spiekermann BF, et al. **Can J Anaesth** 1996 Aug;43(8):820–34 (93 ref.)

Intubation of critically ill patients. Blosser SA, et al. **Clin Chest Med** 1996 Sep;17(3):355–78 (182 ref.)

Difficult intubation in paediatrics. Frei FJ, et al. **Paediatr Anaesth** 1996;6(4):251–63 (166 ref.)

[Airway management of the multiple trauma patient] Ben-Abraham R, et al. **Harefuah** 1997 Jun 15; 132(12):897–902 (35 ref.) **(Heb)**

ADVERSE EFFECTS

Bacteraemia during direct laryngoscopy and endotracheal intubation: a study using a multiple culture, large volume technique. Goldstein S, et al. **Anaesth Intensive Care** 1997 Jun;25(3):239–44 (25 ref.)

Dental injuries during general anaesthesia [see comments] Chadwick RG, et al. **Br Dent J** 1996 Apr 6;180(7):255–8 (21 ref.) Comment in: Br Dent J 1996 Jul 6;181(1):11.

Postintubation tracheal stenosis. Grillo HC, et al. **Chest Surg Clin N Am** 1996 Nov;6(4):725–31 (14 ref.)

Intracranial placement of a nasotracheal tube after facial fracture: a rare complication [see comments] Marlow TJ, et al. **J Emerg Med** 1997 Mar–Apr;15(2):187–91 (12 ref.) Comment in: J Emerg Med 1997 Mar–Apr;15(2):243–4.

Contribution of endotracheal tubes to the pathogenesis of ventilator-associated pneumonia. Koerner RJ. **J Hosp Infect** 1997 Feb;35(2):83–9 (24 ref.)

Acquired subglottic cysts in the low birth weight, pre-term infant. Tierney PA, et al. **J Laryngol Otol** 1997 May; 111(5):478–81 (17 ref.)

Asystole after inadvertent intubation of the orbit. Green JG, et al. **J Oral Maxillofac Surg** 1997 Aug;55(8):856–9 (43 ref.)

Obstructive atelectasis associated with nasotracheal intubation: a case report. Vikari CA, et al. **J Oral Maxillofac Surg** 1997 Sep;55(9):992–6 (15 ref.)

Factors influencing acquired upper airway obstruction in newborn infants receiving assisted ventilation because of respiratory failure: an overview. da Silva OP. **J Perinatol** 1996 Jul–Aug;16(4):272–5 (35 ref.)

Post intubation tracheal stenosis. Grillo HC, et al. **Semin Thorac Cardiovasc Surg** 1996 Oct;8(4):370–80 (16 ref.)

[The difficult intubation] Kleemann PP. **Anaesthesist** 1996 Dec;45(12):1248–67 (11 ref.) **(Ger)**

[Conservative treatment of 2 tracheal lesions secondary to anesthetic intubation] Buitrago LJ, et al. **Arch Bronconeumol** 1997 Mar;33(3):151–3 (16 ref.) (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

The use of paraglossal straight blade laryngoscopy in difficult tracheal intubation. Henderson JJ. **Anaesthesia** 1997 Jun; 52(6):552–60 (75 ref.)

Airway exchange catheters for safe extubation: the clinical and scientific details that make the concept work [editorial; comment] Benumof JL. **Chest** 1997 Jun;111(6):1483–6 (19 ref.) Comment on: Chest 1997 Jun;111(6):1660–5.

[Endoscopy of the respiratory tract in childhood] Nicolai T. **Fortschr Med** 1996 Sep 20;114(26):322–6 (17 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Prediction of difficult intubation. Randell T. **Acta Anaesthesiol Scand** 1996 Sep;40(8 Pt 2):1016–23 (28 ref.)

Rapid sequence intubation in adults with elevated intracranial pressure: a survey of emergency medicine residency programs [see comments] Silber SH. **Am J Emerg Med** 1997 May;15(3):263–7 (71 ref.) Comment in: Am J Emerg Med 1997 May;15(3):321.

A review of etomidate for rapid sequence intubation in the emergency department. Bergen JM, et al. **J Emerg Med** 1997 Mar–Apr;15(2):221–30 (162 ref.)

Emergency airway management. Hamilton PH, et al. **Mt Sinai J Med** 1997 Sep–Oct;64(4–5):292–301 (52 ref.)

[Prophylaxis and treatment of aspiration syndrome and complications of artificial lung ventilation with endotracheal laser therapy] Chesnov VS, et al. **Anesteziol Reanimatol** 1996 Jul–Aug;(4):78–9 (3 ref.) **(Rus)**

[New techniques for laryngoscopy and tracheal intubation] Ariño-Irujo JJ, et al. **Rev Esp Anestesiol Reanim** 1997 Jun–Jul;44(6):223–9, 249 (57 ref.) **(Spa)**

[Evaluation and management of the difficult airway (see comments)] Rodrigo MP, et al. **Rev Esp Anestesiol Reanim** 1996 Jan;43(1):34–41 (25 ref.) Comment in: Rev Esp Anestesiol Reanim 1997 Apr;44(4):167–9. **(Spa)**

INTUITION

Heuristics, servants to intuition, in clinical decision-making. Cioffi J. **J Adv Nurs** 1997 Jul;26(1):203–8 (48 ref.)

Intuition and rational decision-making in professional thinking: a false dichotomy? Easen P, et al. **J Adv Nurs** 1996 Oct;24(4):667–73 (28 ref.)

Intuition: a critical review of the research and rhetoric. King L, et al. **J Adv Nurs** 1997 Jul;26(1):194–202 (41 ref.)

[Diagnostic process in internal medicine: decision analysis or intuition?] Speich R. **Schweiz Med Wochenschr** 1997 Aug 5;127(31–32):1263–79 (100 ref.) (Eng. Abstr.) **(Ger)**

[The use of intuition--conceptual aspects and clinical significance] Shemesh-Kigli R. **Harefuah** 1997 Jun 15; 132(12):878–83 (34 ref.) **(Heb)**

INTUSSUSCEPTION

CONGENITAL

Perinatal intussusception in premature infants. Mooney DP, et al. **J Pediatr Surg** 1996 May;31(5):695–7 (12 ref.)

DIAGNOSIS

Eosinophilic colitis presenting as a left-sided colocolonic intussusception with secondary large bowel obstruction: an uncommon entity with a rare presentation. Box JC, et al. **Am Surg** 1997 Aug;63(8):741–3 (16 ref.)

ETIOLOGY

Intussusception in an adult secondary to an inverted Meckel's diverticulum. Steinwald PM, et al. **Am Surg** 1996 Nov; 62(11):889–94 (20 ref.)

An endoscopic diagnosis of appendicular intussusception in chronic appendicitis. Nyam DC, et al. **Singapore Med J** 1997 Mar;38(3):131 (10 ref.)

Isolated colonic neurofibroma manifested by massive lower gastrointestinal bleeding and intussusception. Abramson LP, et al. **South Med J** 1997 Sep;90(9):952–4 (9 ref.)

[Intestinal invagination caused by colonic lipoma] Cirino E, et al. **Minerva Chir** 1996 Sep;51(9):717–23 (33 ref.) (Eng. Abstr.) **(Ita)**

MICROBIOLOGY

Intussusception associated with Yersinia pseudotuberculosis infection. Koo JW, et al. **Acta Paediatr** 1996 Oct; 85(10):1253–5 (12 ref.)

RADIOGRAPHY

[The computed tomographic finding of sigmoid-rectal invagination and the radiological-macropathological correlation] Rodekohr S, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997

Jan;166(1):78–80 (10 ref.) **(Ger)**

SURGERY

Adult intussusception. A case report. Hamdi M, et al. **Acta Chir Belg** 1996 Nov–Dec;96(6):284–6 (18 ref.)
Perineal repair of colorectoanal intussusception. Report of a case and review of the literature. Zainea GG, et al. **Dis Colon Rectum** 1996 Dec;39(12):1434–7 (9 ref.)

ULTRASONOGRAPHY

Intussusception of vermiform appendix. A case report and review of the literature. Kegelaers B, et al. **Acta Chir Belg** 1996 Nov–Dec;96(6):287–90 (22 ref.)
[Invagination] Rohrschneider W. **Radiologe** 1997 Jun; 37(6):446–53 (45 ref.) (Eng. Abstr.) **(Ger)**

INUITS see **ESKIMOS**

INVASIVE MOLE see **HYDATIDIFORM MOLE, INVASIVE**

INVASIVENESS, NEOPLASM see **NEOPLASM INVASIVENESS**

INVENTORIES, HOSPITAL

TRENDS

Can a hospital be like a supermarket? Better data will provide cost controls, efficiencies, and income streams. Fox KA. **J Health Care Finance** 1997 Spring;23(3):44–8 (6 ref.)

INVERSE PCR see **POLYMERASE CHAIN REACTION**

INVERSION (GENETICS)

Molecular genetics of inversion 16 leukemia: implications for leukemogenesis. Claxton DF, et al. **Cancer Treat Res** 1996; 84:1–18 (62 ref.)
Two brothers with multiple congenital anomalies and mental retardation due to disomy (X)(q12–>q13.3) inherited from the mother. Apacik C, et al. **Clin Genet** 1996 Aug; 50(2):63–73 (23 ref.)
Partial deletion of 18p and partial duplication of 18q caused by a paternal pericentric inversion. Israëls T, et al. **Clin Genet** 1996 Dec;50(6):520–4 (17 ref.)
Pericentric inversions of chromosome 4: report of a new family and review of the literature. Villa A, et al. **Clin Genet** 1995 Nov;48(5):255–60 (31 ref.)
Chromosome 16 inversion in acute myelogenous leukemias with bone marrow eosinophilia [editorial] Ueda R. **Intern Med** 1996 Apr;35(4):241–2 (12 ref.)
The biological significance of the multidrug resistance gene MRP in inversion 16 leukemias. Kuss BJ, et al. **Leuk Lymphoma** 1996 Feb;20(5–6):357–64 (34 ref.)
[Hemophilia A and inversion in the factor VIII gene] Inaba H, et al. **Rinsho Byori** 1997 Feb;Suppl 104:99–106 (16 ref.) **(Jpn)**

INVERTEBRATE GANGLIA see **GANGLIA, INVERTEBRATE**

INVERTEBRATE HORMONES

ANALYSIS

Nematode FMRFamide-related peptide (FaRP)-systems: occurrence, distribution and physiology. Maule AG, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):927–36 (50 ref.)

CHEMISTRY

Structure and distribution of mini-titins. Vibert P, et al. **Adv Biophys** 1996;33:199–209 (37 ref.)

GENETICS

Occurrence and diversity of neuropeptides from the crustacean hyperglycemic hormone family in arthropods. A short review. Soyez D. **Ann N Y Acad Sci** 1997 Apr 24;814:319–23 (28 ref.)

PHYSIOLOGY

Peptidergic neurohormonal control systems in invertebrates. Nässel DR. **Curr Opin Neurobiol** 1996 Dec;6(6):842–50 (69 ref.)

INVERTEBRATE PHOTORECEPTORS see **PHOTORECEPTORS, INVERTEBRATE**

INVERTEBRATES

Convergent evolution in invertebrates. Moore J, et al. **Biol Rev Camb Philos Soc** 1997 Feb;72(1):1–60 (340 ref.)

EMBRYOLOGY

Set-aside cells in maximal indirect development: evolutionary and developmental significance. Peterson KJ, et al. **Bioessays** 1997 Jul;19(7):623–31 (39 ref.)

ENZYMOLOGY

Release of nitric oxide from astroglial cells: a key mechanism in neuroimmune disorders. Mollace V, et al. **Adv Neuroimmunol** 1995;5(4):421–30 (33 ref.)
The prophenoloxidase activating system and associated proteins in invertebrates. Johansson MW, et al. **Prog Mol Subcell Biol** 1996;15:46–66 (142 ref.)

GENETICS

Genetic influences on aging. Johnson TE. **Exp Gerontol** 1997 Jan–Apr;32(1–2):11–22 (83 ref.)
Evolutionary origins and maintenance of redundant gene expression during metazoan development. Cooke J, et al. **Trends Genet** 1997 Sep;13(9):360–4 (44 ref.)

GROWTH & DEVELOPMENT

Literature review and analysis of biological complexity in model stream ecosystems: influence of size and experimental design. Belanger SE. **Ecotoxicol Environ Saf** 1997 Feb;36(1):1–16 (187 ref.)

IMMUNOLOGY

The role of hemolymph coagulation in innate immunity. Muta T, et al. **Curr Opin Immunol** 1996 Feb;8(1):41–7 (48 ref.)
The invertebrate phagocytic immunocyte: clues to a common evolution of immune and neuroendocrine systems. Ottaviani E, et al. **Immunol Today** 1997 Apr;18(4):169–74 (55 ref.)
Immune function of alpha 2-macroglobulin in invertebrates. Armstrong PB, et al. **Prog Mol Subcell Biol** 1996;15:101–30 (193 ref.)
The prophenoloxidase activating system and associated proteins in invertebrates. Johansson MW, et al. **Prog Mol Subcell Biol** 1996;15:46–66 (142 ref.)
Humoral factors in marine invertebrates. Leclerc M. **Prog Mol Subcell Biol** 1996;15:1–9 (70 ref.)
Blood clotting in invertebrates. Srimal S. **Prog Mol Subcell Biol** 1996;15:88–100 (106 ref.)
Occam's Razor, invertebrate allorecognition and Ig superfamily evolution. Mokady O. **Res Immunol** 1996 May; 147(4):241–6 (20 ref.)

METABOLISM

Intracellular fatty acid-binding proteins: putting lower vertebrates in perspective. Londraville RL. **Braz J Med Biol Res** 1996 Jun;29(6):707–20 (109 ref.)
Iodine metabolism and thyroid-related functions in organisms lacking thyroid follicles: are thyroid hormones also vitamins? Eales JG. **Proc Soc Exp Biol Med** 1997 Apr; 214(4):302–17 (195 ref.)

PHYSIOLOGY

Serotonergic modulation of behaviour: a phylogenetic overview. Weiger WA. **Biol Rev Camb Philos Soc** 1997 Feb;72(1):61–95 (172 ref.)
Synaptic mechanisms in invertebrate pattern generation. Cropper EC, et al. **Curr Opin Neurobiol** 1996 Dec; 6(6):833–41 (48 ref.)
Peptidergic neurohormonal control systems in invertebrates. Nässel DR. **Curr Opin Neurobiol** 1996 Dec;6(6):842–50 (69 ref.)
Invertebrate presynaptic inhibition and motor control. Clarac F, et al. **Exp Brain Res** 1996 Nov;112(2):163–80 (112 ref.)
Olfactory information processing in the brain: encoding chemical and temporal features of odors. Christensen TA, et al. **J Neurobiol** 1996 May;30(1):82–91 (68 ref.)
Genetic analysis of cholinergic nerve terminal function in invertebrates. Baylis HA, et al. **J Neurocytol** 1996 Dec; 25(12):747–62 (100 ref.)
Reinforcement concept in investigations on simple nervous systems. Balaban PM. **Neurosci Behav Physiol** 1997 Jul–Aug;27(4):435–40 (15 ref.)
Immune function of alpha 2-macroglobulin in invertebrates. Armstrong PB, et al. **Prog Mol Subcell Biol** 1996;15:101–30 (193 ref.)
Blood clotting in invertebrates. Srimal S. **Prog Mol Subcell Biol** 1996;15:88–100 (106 ref.)
Animal lectins as cell surface receptors: current status for invertebrate species. Vasta GR, et al. **Prog Mol Subcell Biol** 1996;17:158–82 (137 ref.)
The neuroimmunology of stress from invertebrates to man [published erratum appears in Prog Neurobiol 1996 Jun;49(3):285] Ottaviani E, et al. **Prog Neurobiol** 1996 Mar–Apr;48(4–5):421–40 (103 ref.)
Signalling from neurones to glial cells in invertebrates. Coles JA, et al. **Trends Neurosci** 1996 Aug;19(8):358–62 (35 ref.)
[The concept of reinforcement in research on simple nervous systems] Baladan PM. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 Mar–Apr; 47(2):280–5 (13 ref.) (Eng. Abstr.) **(Rus)**

INVERTED REPEAT SEQUENCE see **REPETITIVE SEQUENCES, NUCLEIC ACID**

INVESTIGATIONAL NEW DRUGS see **DRUGS, INVESTIGATIONAL**

INVOLUNTARY COMMITMENT see **COMMITMENT OF MENTALLY ILL**

IODAMOEBIASIS see **AMEBIASIS**

IODIDE PEROXIDASE

Thyroid peroxidase: experimental and clinical integration. Ohtaki S, et al. **Endocr J** 1996 Feb;43(1):1–14 (119 ref.)
The deiodinase family of selenoproteins. St Germain DL, et al. **Thyroid** 1997 Aug;7(4):655–68 (178 ref.)

CHEMISTRY

Update on the human iodothyronine selenodeiodinases, the enzymes regulating the activation and inactivation of thyroid hormone. Larsen PR. **Biochem Soc Trans** 1997 May;25(2):588–92 (35 ref.)

IMMUNOLOGY

Molecular analysis of the antibody response to thyroglobulin and thyroid peroxidase. McIntosh RS, et al. **Thyroid** 1997 Jun;7(3):471–87 (90 ref.)

METABOLISM

Update on the human iodothyronine selenodeiodinases, the enzymes regulating the activation and inactivation of thyroid hormone. Larsen PR. **Biochem Soc Trans** 1997 May;25(2):588–92 (35 ref.)
Thyroid carcinoma: interrelationships between local thyroid hormone metabolism by the type I 5'-deiodinase and the expression of thyroid hormone receptors and other thyroid-specific (de-)differentiation markers. Köhrle J. **Curr Top Pathol** 1997;91:83–116 (230 ref.)

IODINASE see **IODIDE PEROXIDASE**

IODINATED HYDROCARBONS see **HYDROCARBONS, IODINATED**

IODINE

Iodine-induced thyroiditis in the non-obese diabetic (NOD) mouse—more questions than answers. Scherbaum WA. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 3:20–3 (7 ref.)
[Renal toxicity of iodine contrast media. Mechanisms and prevention] Deray G, et al. **Presse Med** 1997 Feb 15; 26(4):190–4 (26 ref.) **(Fre)**

ADMINISTRATION & DOSAGE

Control of efficiency and results, and adverse effects of excess iodine administration on thyroid function. Koutras DA. **Ann Endocrinol (Paris)** 1996;57(6):463–9 (55 ref.)
[Current views on the importance of iodine for animals] Herzig I, et al. **Vet Med (Praha)** 1996 Dec;41(12):379–86 (83 ref.) (Eng. Abstr.) **(Cze)**
[Iodine intake in Denmark] Pedersen KM, et al. **Ugeskr Laeger** 1997 Apr 7;159(15):2201–6 (40 ref.) (Eng. Abstr.) **(Dan)**

ADVERSE EFFECTS

Control of efficiency and results, and adverse effects of excess iodine administration on thyroid function. Koutras DA. **Ann Endocrinol (Paris)** 1996;57(6):463–9 (55 ref.)
[Risk of hyperthyroidism in examinations with contrast media] Hehrmann R, et al. **Aktuelle Radiol** 1996 Sep; 6(5):243–8 (16 ref.) (Eng. Abstr.) **(Ger)**

DEFICIENCY

Maternal and fetal impact of chronic iodine deficiency. Glinoer D. **Clin Obstet Gynecol** 1997 Mar;40(1):102–16 (23 ref.)
A ten year review of the iodine deficiency disorders program of the People's Republic of China. Wang J, et al. **J Public Health Policy** 1997;18(2):219–41 (57 ref.)
Teratogen update: iodine deficiency, a community teratogen. Hollowell JG Jr, et al. **Teratology** 1997 Jun;55(6):389–405 (102 ref.)

METABOLISM

Iodolactones and iodoaldehydes—mediators of iodine in thyroid autoregulation. Dugrillon A. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 4:41–5 (21 ref.)
Iodine metabolism and thyroid-related functions in organisms lacking thyroid follicles: are thyroid hormones also vitamins? Eales JG. **Proc Soc Exp Biol Med** 1997 Apr; 214(4):302–17 (195 ref.)
Iodine metabolism and thyroid physiology: current concepts. Cavalieri RR. **Thyroid** 1997 Apr;7(2):177–81 (30 ref.)

PHARMACOKINETICS

Bioavailability of iodine. Hurrell RF. **Eur J Clin Nutr** 1997 Jan;51 Suppl 1:S9–12 (39 ref.)

PHARMACOLOGY

Iodine-induced thyroid inhibition and cell necrosis: two consequences of the same free-radical mediated mechanism? Denef JF, et al. **Mol Cell Endocrinol** 1996 Jul 23;121(1):101–3 (22 ref.)

THERAPEUTIC USE

Childhood primary hypothyroidism and endemic cretinism. Dussault JH. **Curr Ther Endocrinol Metab** 1997;6:107–9 (4

ref.)
Endemic goiter. Trimarchi F, et al.
Curr Ther Endocrinol Metab 1997;6:101–7 (9 ref.)
[Protection of the thyroid in children and fetuses in case of nuclear accident] Vernis M, et al. **Arch Pediatr** 1997 May; 4(5):473–9 (29 ref.) (Eng. Abstr.) **(Fre)**

IODINE COMPOUNDS

METABOLISM

Iodolactones and iodoaldehydes—mediators of iodine in thyroid autoregulation. Dugrillon A.
Exp Clin Endocrinol Diabetes 1996;104 Suppl 4:41–5 (21 ref.)

IODINE RADIOISOTOPES

Radioiodine and the immune system. DeGroot LJ.
Thyroid 1997 Apr;7(2):259–64 (21 ref.)

ADMINISTRATION & DOSAGE

Radioiodine dispensing and usage in a centralized hospital nuclear pharmacy. Hung JC. **Thyroid** 1997 Apr;7(2):289–94 (31 ref.)
Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Maxon HR, et al. **Thyroid** 1997 Apr; 7(2):183–7 (26 ref.)
Radiation dose to patients and relatives incident to 131I therapy. Zanzonico PB. **Thyroid** 1997 Apr;7(2):199–204 (20 ref.)

ADVERSE EFFECTS

Radioiodine and the immune system. DeGroot LJ.
Thyroid 1997 Apr;7(2):259–64 (21 ref.)
Late consequences of radioiodine for diagnosis and therapy in Sweden. Hall P, et al. **Thyroid** 1997 Apr;7(2):205–8 (15 ref.)
Radioiodine treatment, ablation, and ophthalmopathy: a balanced perspective. Tallstedt L, et al. **Thyroid** 1997 Apr; 7(2):241–5 (22 ref.)
[131 iodine: medical use. Carcinogenic and genetic effects] Schlumberger M, et al. **Ann Endocrinol (Paris)** 1996; 57(3):166–76 (48 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSTIC USE

False-positive radioiodine uptake in the abdomen and the pelvis: radioiodine retention in the kidneys and review of the literature. Bakheet SM, et al. **Clin Nucl Med** 1996 Dec; 21(12):932–7 (25 ref.)
Iodine-123 labelled radiopharmaceuticals and single-photon emission tomography: a natural liaison. Bourguignon MH, et al. **Eur J Nucl Med** 1997 Mar;24(3):331–44 (106 ref.)
IBZM- and CIT-SPECT of the dopaminergic system in parkinsonism. Tissingh G, et al. **J Neural Transm Suppl** 1997;50:31–7 (38 ref.)
Radiolabeled nucleoside analogs in cancer diagnosis and therapy. Kassis AI, et al. **Q J Nucl Med** 1996 Sep; 40(3):301–19 (93 ref.)
Pharmacokinetics of radioiodinated fatty acid myocardial imaging agents in animal models and human studies. Knapp FF Jr, et al. **Q J Nucl Med** 1996 Sep;40(3):252–69 (97 ref.)
Clinical use of metaiodobenzylguanidine imaging in cardiology. Merlet P, et al. **Q J Nucl Med** 1995 Dec;39(4 Suppl 1):29–39 (79 ref.)
The current status of meta-iodobenzylguanidine and related agents for the diagnosis of neuro-endocrine tumors. Shapiro B, et al. **Q J Nucl Med** 1995 Dec;39(4 Suppl 1):3–8 (60 ref.)
Malignant paraganglioma of the prostate: case report, depiction by meta-iodobenzylguanidine scintigraphy and review of the literature. Shapiro B, et al.
Q J Nucl Med 1997 Mar;41(1):36–41 (37 ref.)
Nuclear imaging in the management of thyroid carcinoma. Cavalieri RR. **Thyroid** 1996 Oct;6(5):485–92 (55 ref.)
Percent 131I uptake and post-therapy 131I scans: their role in the management of thyroid cancer. Reynolds JC.
Thyroid 1997 Apr;7(2):281–4 (13 ref.)
[Value of cardiac scintigraphy with I123 meta-iodobenzylguanidine in congestive heart failure. A review] Agostini D, et al. **Ann Cardiol Angeiol (Paris)** 1997 May-Jun;46(5–6):293–302 (50 ref.) (Eng. Abstr.) **(Fre)**
[131 iodine and differentiated thyroid cancers] Delisle MJ, et al. **Ann Endocrinol (Paris)** 1996;57(3):186–93 (30 ref.) (Eng. Abstr.) **(Fre)**
[Evaluation of benzodiazepine receptor in the cerebral cortex of Parkinson's disease using 123I-iomazenil SPECT] Kawabata K, et al. **Nippon Rinsho** 1997 Jan;55(1):244–8 (21 ref.) (Eng. Abstr.) **(Jpn)**
[Gordon test] Sato T. **Nippon Rinsho** 1997 Apr;55 Suppl 2:117–9 (4 ref.) **(Jpn)**

PHARMACOKINETICS

Percent 131I uptake and post-therapy 131I scans: their role in the management of thyroid cancer. Reynolds JC.
Thyroid 1997 Apr;7(2):281–4 (13 ref.)
Radiation dose to patients and relatives incident to 131I therapy. Zanzonico PB. **Thyroid** 1997 Apr;7(2):199–204 (20 ref.)

STANDARDS

Standards for radioiodines. Coursey BM. **Thyroid** 1997 Apr; 7(2):285–8 (11 ref.)

THERAPEUTIC USE

131I-MIBG therapy of neural crest tumours (review). Troncone L, et al. **Anticancer Res** 1997 May-Jun; 17(3B):1823–31 (84 ref.)
Targeted radiotherapy using Auger electron emitters. O'Donoghue JA, et al. **Phys Med Biol** 1996 Oct; 41(10):1973–92 (81 ref.)
Radiolabeled nucleoside analogs in cancer diagnosis and therapy. Kassis AI, et al. **Q J Nucl Med** 1996 Sep; 40(3):301–19 (93 ref.)
The changing role of radioiodine in the management of differentiated thyroid cancer. Reynolds JC, et al.
Semin Nucl Med 1997 Apr;27(2):152–64 (67 ref.)
Controversies related to the medical and surgical management of hyperthyroidism in children. Waldhausen JH. **Semin Pediatr Surg** 1997 Aug;6(3):121–7 (37 ref.)
131I therapy for pediatric thyroid cancer. Yeh SD, et al. **Semin Pediatr Surg** 1997 Aug;6(3):128–33 (49 ref.)
Regulations and policies on radioiodine 131I therapy in Europe. Beckers C. **Thyroid** 1997 Apr;7(2):221–4 (9 ref.)
Nuclear imaging in the management of thyroid carcinoma. Cavalieri RR. **Thyroid** 1996 Oct;6(5):485–92 (55 ref.)
Radioiodine for nontoxic multinodular goiter. Huysmans D, et al. **Thyroid** 1997 Apr;7(2):235–9 (22 ref.)
Use of radioiodine in the management of hyperthyroidism in the UK: development of guidelines. Lazarus JH, et al. **Thyroid** 1997 Apr;7(2):229–31 (14 ref.)
Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Maxon HR, et al. **Thyroid** 1997 Apr; 7(2):183–7 (26 ref.)
131I therapy for elevated thyroglobulin levels. Schlumberger M, et al. **Thyroid** 1997 Apr;7(2):273–6 (10 ref.)
Radioiodine treatment, ablation, and ophthalmopathy: a balanced perspective. Tallstedt L, et al. **Thyroid** 1997 Apr; 7(2):241–5 (22 ref.)
Regulations for radioiodine therapy in the United States: current status and the process of change. Vetter RJ.
Thyroid 1997 Apr;7(2):209–11 (9 ref.)
Radioiodine therapy for Graves' disease: case selection and restrictions recommended to patients in North America. Wartofsky L. **Thyroid** 1997 Apr;7(2):213–6 (24 ref.)
[131 iodine and differentiated thyroid cancers] Delisle MJ, et al. **Ann Endocrinol (Paris)** 1996;57(3):186–93 (30 ref.) (Eng. Abstr.) **(Fre)**
[131 iodine for the initial treatment of thyroid cancer] Delisle MJ, et al. **Ann Endocrinol (Paris)** 1997;58(3):197–203 (43 ref.) (Eng. Abstr.) **(Fre)**
[Radioiodine therapy and radioiodine after-care in differentiated thyroid gland carcinomas] Börner AR, et al. **Zentralbl Chir** 1997;122(4):274–85 (80 ref.) (Eng. Abstr.) **(Ger)**
[Radioiodine therapy of Basedow's disease—is there a therapeutic standard?] Moser E. **Zentralbl Chir** 1997; 122(4):227–30 (15 ref.) (Eng. Abstr.) **(Ger)**
[Radioiodine therapy in differentiated thyroid gland carcinoma] Schicha H, et al. **Zentralbl Chir** 1997; 122(4):266–73 (44 ref.) (Eng. Abstr.) **(Ger)**
[Therapeutic possibilities in metastatic pheochromocytoma] Vierhapper H, et al. **Zentralbl Chir** 1997;122(6):494–7 (28 ref.) (Eng. Abstr.) **(Ger)**
[Is radioiodine ablation of residual thyroid tissue indicated after an operation for differentiated thyroid cancer?] Chebotareva ED, et al. **Lik Sprava** 1997 Jan-Feb;(1):118–22 (18 ref.) **(Rus)**

IODIZED OIL

ADMINISTRATION & DOSAGE

Chemoembolization for hepatocellular carcinoma. Nakamura H. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1390–1 (6 ref.)
Treatment of unresectable hepatocellular carcinoma: targeted therapies using iodized oil. Bhattacharya S, et al.
Princess Takamatsu Symp 1995;25:253–64 (63 ref.)

PHARMACOKINETICS

[A case of liver metastasis from so-called hepatoid adenocarcinoma of stomach with lipiodol accumulation] Ueda H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Feb; 93(2):120–5 (14 ref.) **(Jpn)**

THERAPEUTIC USE

[Is there a place for arterial chemoembolization of the liver in the treatment for hepatocellular carcinoma? (editorial)] Trinchet JC, et al. **Gastroenterol Clin Biol** 1995 Dec; 19(12):967–9 (24 ref.) **(Fre)**
[Lipiodol with and without Gelfoam in primary liver tumors. Plasma levels of Mitoxantrone and clinical results] Civalleri D, et al. **G Chir** 1997 Jun-Jul;18(6–7):362–7 (36 ref.) (Eng. Abstr.) **(Ita)**

IODOBENZENES

DIAGNOSTIC USE

Clinical use of metaiodobenzylguanidine imaging in cardiology. Merlet P, et al. **Q J Nucl Med** 1995 Dec;39(4 Suppl 1):29–39 (79 ref.)
The current status of meta-iodobenzylguanidine and related agents for the diagnosis of neuro-endocrine tumors. Shapiro B, et al. **Q J Nucl Med** 1995 Dec;39(4 Suppl 1):3–8 (60 ref.)
Malignant paraganglioma of the prostate: case report, depiction by meta-iodobenzylguanidine scintigraphy and review of the literature. Shapiro B, et al.
Q J Nucl Med 1997 Mar;41(1):36–41 (37 ref.)
[Value of cardiac scintigraphy with I123 meta-iodobenzylguanidine in congestive heart failure. A review] Agostini D, et al. **Ann Cardiol Angeiol (Paris)** 1997 May-Jun;46(5–6):293–302 (50 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

131I-MIBG therapy of neural crest tumours (review). Troncone L, et al. **Anticancer Res** 1997 May-Jun; 17(3B):1823–31 (84 ref.)
[Therapeutic possibilities in metastatic pheochromocytoma] Vierhapper H, et al. **Zentralbl Chir** 1997;122(6):494–7 (28 ref.) (Eng. Abstr.) **(Ger)**

IODODEOXYURIDINE see **IDOXURIDINE**

5-IODO-2'-DEOXYURIDINE see **IDOXURIDINE**

IODOPHORS

see related
ANTI-INFECTIVE AGENTS, LOCAL

IODOTHYRONINE DEIODINASE see **IODIDE PEROXIDASE**

IODOTHYRONINE 5'-DEIODINASE see **IODIDE PEROXIDASE**

IODOTYROSINE DEIODASE see **IODIDE PEROXIDASE**

ION CHANNEL GATING

The role of inhibition in the hierarchical gating of executed and imagined movements. Berthoz A.
Brain Res Cogn Brain Res 1996 Mar;3(2):101–13 (112 ref.)
P2X receptors: a third major class of ligand-gated ion channels. North RA. **Ciba Found Symp** 1996;198:91–105; discussion 105–9 (76 ref.)
Receptor-regulated ion channels. Jan LY, et al.
Curr Opin Cell Biol 1997 Apr;9(2):155–60 (60 ref.)
Calcium permeability of glutamate-gated channels in the central nervous system. Burnashev N.
Curr Opin Neurobiol 1996 Jun;6(3):311–7 (57 ref.)
Calmodulin regulation of cyclic-nucleotide-gated channels. Molday RS. **Curr Opin Neurobiol** 1996 Aug;6(4):445–52 (59 ref.)
P2X receptors: an emerging channel family. Buell G, et al.
Eur J Neurosci 1996 Oct;8(10):2221–8 (47 ref.)
K+ channel opening: a new drug principle in cardiovascular medicine [see comments] Nielsen-Kudsk JE, et al.
Heart 1996 Aug;76(2):109–16 (51 ref.) Comment in: Heart 1997 May;77(5):487.
Modulation of amino acid-gated ion channels by protein phosphorylation. Moss SJ, et al. **Int Rev Neurobiol** 1996; 39:1–52 (183 ref.)
Transmitter modulation of neuronal calcium channels. Jones SW, et al. **J Membr Biol** 1997 Jan 1;155(1):1–10 (97 ref.)
Ionic mechanisms of the cardiac pacemaker potential. Noma A. **Jpn Heart J** 1996 Sep;37(5):673–82 (29 ref.)
Molecular diversity of cyclic nucleotide-gated cation channels. Biel M, et al.
Naunyn Schmiedebergs Arch Pharmacol 1995 Dec; 353(1):1–10 (100 ref.)
The acetylcholine receptor ligand-gated channel as a molecular target of disease and therapeutic agents. Barrantes FJ. **Neurochem Res** 1997 Apr;22(4):391–400 (68 ref.)

DRUG EFFECTS

Is there a therapeutic future for "potassium channel openers"? [editorial] Lawson K. **Clin Sci (Colch)** 1996 Dec; 91(6):651–63 (111 ref.)
Antisense oligonucleotides induce functional deletion of ligand gated ion channels in cultured neurons and brain explants. Brussaard AB. **J Neurosci Methods** 1997 Jan; 71(1):55–64 (21 ref.)
Mechanisms of action of antiarrhythmic drugs: from ion channel blockage to arrhythmia termination. Grant AO. **Pacing Clin Electrophysiol** 1997 Feb;20(2 Pt 2):432–44 (65 ref.)
A Ca2+ release mechanism gated by the novel pyridine nucleotide, NAADP. Genazzani AA, et al.
Trends Pharmacol Sci 1997 Apr;18(4):108–10 (22 ref.)

GENETICS

Hypokalemic periodic paralysis: an autosomal dominant muscle disorder caused by mutations in a voltage-gated calcium channel. Lapie P, et al. **Neuromuscul Disord** 1997 Jun;7(4):234–40 (68 ref.)

PHYSIOLOGY

Gap junction channel gating and permselectivity: their roles in co-ordinated tissue function. Brink PR. **Clin Exp Pharmacol Physiol** 1996 Dec;23(12):1041-6 (38 ref.)

Where are the gates in gap junction channels? Dahl G. **Clin Exp Pharmacol Physiol** 1996 Dec;23(12):1047-52 (51 ref.)

Molecular physiology of gap junction channels. Spray DC. **Clin Exp Pharmacol Physiol** 1996 Dec;23(12):1038-40 (21 ref.)

Kinetochore function: molecular motors, switches and gates. Yen TJ, et al. **Curr Opin Cell Biol** 1996 Jun;8(3):381-8 (47 ref.)

Effects of nitric oxide on glutamate-gated channels and other ionic channels. Fagni L, et al. **J Chem Neuroanat** 1996 Jun; 10(3-4):231-40 (55 ref.)

Cooperativity in cyclic nucleotide-gated ion channels [comment] Pugh EN Jr. **J Gen Physiol** 1996 Feb; 107(2):165-7 (20 ref.) Comment on: J Gen Physiol 1996 Feb;107(2):169-81.

Gap junctions as electrical synapses. Bennett MV. **J Neurocytol** 1997 Jun;26(6):349-66 (98 ref.)

Pathophysiological functions of ATP-sensitive K+ channels in myocardial ischemia. Hiraoka M. **Jpn Heart J** 1997 May; 38(3):297-315 (116 ref.)

Two aspects of the inward rectification mechanism. Effects of cytoplasmic blockers and extracellular K+ on the inward rectifier K+ channel. Kubo Y. **Jpn Heart J** 1996 Sep;37(5):631-41 (25 ref.)

Periodic paralysis and voltage-gated ion channels [editorial] Fontaine B, et al. **Kidney Int** 1996 Jan;49(1):9-18 (107 ref.)

Organic osmolyte channels: transport characteristics and regulation. Goldstein L, et al. **Kidney Int** 1996 Jun; 49(6):1690-4 (24 ref.)

The electroneutral Na(+)-(K+)-Cl- cotransport family. Hebert SC, et al. **Kidney Int** 1996 Jun;49(6):1638-41 (6 ref.)

Single channel properties of a volume sensitive anion channel: lessons from noise analysis. Jackson PS, et al. **Kidney Int** 1996 Jun;49(6):1695-9 (26 ref.)

The modulation of calcium currents by the activation of mGluRs. Functional implications. Stefani A, et al. **Mol Neurobiol** 1996 Aug;13(1):81-95 (81 ref.)

Functional and molecular analysis of glutamate-gated channels by patch-clamp and RT-PCR at the single cell level. Audinat E, et al. **Neurochem Int** 1996 Feb; 28(2):119-36 (49 ref.)

Molecular biology and electrophysiology of glutamate-gated chloride channels of invertebrates. Cully DF, et al. **Parasitology** 1996;113 Suppl:S191-200 (64 ref.)

Molecular pathophysiology of voltage-gated ion channels. Lehmann-Horn F, et al. **Rev Physiol Biochem Pharmacol** 1996;128:195-268 (310 ref.)

Membrane bioelectrogenesis and ionic channel activity simulation under drug action. Pennec JP, et al. **Rom J Physiol** 1995 Jan-Dec;32(1-4):3-10 (20 ref.)

Mechanical transduction by ion channels: how forces reach the channel. Sachs F. **Soc Gen Physiol Ser** 1997;52:209-18 (52 ref.)

Voltage-gated Na+ channels in glia: properties and possible functions. Sontheimer H, et al. **Trends Neurosci** 1996 Aug; 19(8):325-31 (67 ref.)

The transmitter-gated channels: a range of receptor types and structures. Barnard EA. **Trends Pharmacol Sci** 1996 Sep;17(9):305-9 (38 ref.)

GABAc receptors: relatively simple transmitter -gated ion channels? Johnston GA. **Trends Pharmacol Sci** 1996 Sep; 17(9):319-23 (30 ref.)

ION CHANNELS

see related
ION CHANNEL GATING
ION PUMPS

The roles of tryptophan residues in the structure, function, and folding of the gramicidin transmembrane ion channel. Wallace BA. **Adv Exp Med Biol** 1996;398:607-14 (29 ref.)

Water channels and urea transporters. Wintour EM. **Clin Exp Pharmacol Physiol** 1997 Jan;24(1):1-9 (78 ref.)

Penetrating insights into pore formation [news] Hughson FM. **Nat Struct Biol** 1997 Feb;4(2):89-92 (28 ref.)

The aquaporin family of water channels in kidney. Agre P, et al. **Nephrologie** 1996;17(7):409-15 (64 ref.)

[Periodic palsies and myotonias are ion channel diseases (editorial)] Fontaine B, et al. **Rev Neurol (Paris)** 1996 Oct; 152(10):579-86 (39 ref.) **(Fre)**

[Non-selective cation channel] Kawahara K. **Nippon Rinsho** 1996 Mar;54(3):679-84 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Artificial models of transport proteins in membrane] Kobuke Y. **Nippon Rinsho** 1996 Mar;54(3):737-43 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Receptor diseases and their evaluation methods] Miyachi Y, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:435-43 (7 ref.) **(Jpn)**

[Channel structure and functioning based on octagonal structure model] Sato C, et al. **Nippon Rinsho** 1996 Mar; 54(3):744-56 (26 ref.) (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Similarity of neuronal cell injury and death in AIDS dementia and focal cerebral ischemia: potential treatment with NMDA open-channel blockers and nitric oxide-related species. Lipton SA. **Brain Pathol** 1996 Oct;6(4):507-17 (117 ref.)

Modulation and block of ion channels: a new biology of polyamines. Williams K. **Cell Signal** 1997 Jan;9(1):1-13 (148 ref.)

BIOSYNTHESIS

Do aquaporins have a role in nocturnal enuresis? Frøkiaer J, et al. **Scand J Urol Nephrol Suppl** 1997;183:31-2 (10 ref.)

CHEMISTRY

Molecular and functional diversity of the NMDA receptor channel. Mishina M, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:136-52 (43 ref.)

Engineering the gramicidin channel. Koeppe RE 2nd, et al. **Annu Rev Biophys Biomol Struct** 1996;25:231-58 (126 ref.)

Structure and function of cyclic nucleotide-gated channels. Zagotta WN, et al. **Annu Rev Neurosci** 1996;19:235-63 (137 ref.)

Towards an understanding of the structural and functional properties of MscL, a mechanosensitive channel in bacteria. Blount P, et al. **Biol Cell** 1996;87(1-2):1-8 (58 ref.)

Molecular physiology of gap junction channels. Spray DC. **Clin Exp Pharmacol Physiol** 1996 Dec;23(12):1038-40 (21 ref.)

Channel-forming toxins: tales of transformation. Gouaux E. **Curr Opin Struct Biol** 1997 Aug;7(4):566-73 (63 ref.)

P2X receptors: an emerging channel family. Buell G, et al. **Eur J Neurosci** 1996 Oct;8(10):2221-8 (47 ref.)

Gramicidin channels--a solvable membrane "protein" folding problem. Andersen OS, et al. **Indian J Biochem Biophys** 1996 Oct;33(5):331-42 (79 ref.)

Developing three-dimensional models of ion channel proteins. Guy HR, et al. **Ion Channels** 1996;4:1-40 (135 ref.)

Transmembrane auxiliary subunits of voltage-dependent ion channels. Gurnett CA, et al. **J Biol Chem** 1996 Nov 8; 271(45):27975-8 (52 ref.)

Structure and functions of channel-forming peptides: magainins, cecropins, melittin and alamethicin. Bechinger B. **J Membr Biol** 1997 Apr 1;156(3):197-211 (262 ref.)

Ion channels: structural basis for function and disease. Goldstein SA. **Semin Perinatol** 1996 Dec;20(6):520-30 (86 ref.)

DRUG EFFECTS

Some actions of taurine on ionic currents of myocardial cells and myometrial cells. Sperelakis N, et al. **Adv Exp Med Biol** 1996;403:275-84 (18 ref.)

Calcium permeability of glutamate-gated channels in the central nervous system. Burnashev N. **Curr Opin Neurobiol** 1996 Jun;6(3):311-7 (57 ref.)

Activation of ion channels by acetylcholine: two contrasting transduction pathways. Lester HA. **Harvey Lect** 1995-96; 91:79-98 (40 ref.)

Gramicidin channels--a solvable membrane "protein" folding problem. Andersen OS, et al. **Indian J Biochem Biophys** 1996 Oct;33(5):331-42 (79 ref.)

Effects of ethanol on ion channels. Crews FT, et al. **Int Rev Neurobiol** 1996;39:283-367 (520 ref.)

Effects of mercurials on ligand- and voltage-gated ion channels: a review. Sirois JE, et al. **Neurotoxicology** 1996 Spring;17(1):63-84 (140 ref.)

Mechanisms of action of antiarrhythmic drugs: from ion channel blockage to arrhythmia termination. Grant AO. **Pacing Clin Electrophysiol** 1997 Feb;20(2 Pt 2):432-44 (65 ref.)

The pharmacology of mechanogated membrane ion channels. Hamill OP, et al. **Pharmacol Rev** 1996 Jun;48(2):231-52 (257 ref.)

Membrane bioelectrogenesis and ionic channel activity simulation under drug action. Pennec JP, et al. **Rom J Physiol** 1995 Jan-Dec;32(1-4):3-10 (20 ref.)

Ionic effects of the Alzheimer's disease beta-amyloid precursor protein and its metabolic fragments. Fraser SP, et al. **Trends Neurosci** 1997 Feb;20(2):67-72 (91 ref.)

[Possible applications of the "patch-clamp" method in anesthesiologic research; comment] Bräu ME, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Nov; 31(9):537-42 (21 ref.) (Eng. Abstr.) Comment on: Anasthesiol Intensivmed Notfallmed Schmer 1996 Nov;31(9):535-6. **(Ger)**

GENETICS

Mechanosensitive channels of Escherichia coli: the MscL gene, protein, and activities. Sukharev SI, et al. **Annu Rev Physiol** 1997;59:633-57 (94 ref.)

Genes that control lung liquid. Giles F. Filley Lecture. Barker PM. **Chest** 1997 Jun;111(6 Suppl):105S-110S (38 ref.)

Pathophysiology of ion channel mutations. Keating MT, et al. **Curr Opin Genet Dev** 1996 Jun;6(3):326-33 (53 ref.)

Molecular and cellular defects in nephrogenic diabetes insipidus. Knoers NV, et al. **Curr Opin Nephrol Hypertens** 1996 Jul;5(4):353-8 (43 ref.)

Physiology and pathophysiology of aquaporins. Mulders SM, et al. **Eur J Clin Invest** 1996 Dec;26(12):1041-50 (84 ref.)

Phenotype variation and newcomers in ion channel disorders. Bulman DE. **Hum Mol Genet** 1997;6(10):1679-85 (84 ref.)

Antisense oligonucleotides induce functional deletion of ligand gated ion channels in cultured neurons and brain explants. Brussaard AB. **J Neurosci Methods** 1997 Jan; 71(1):55-64 (21 ref.)

Methods for transient expression of hetero-oligomeric ligand-gated ion channels. Lüddens H, et al. **Methods Mol Biol** 1997;83:55-63 (25 ref.)

Ion channels--basic science and clinical disease [see comments] Ackerman MJ, et al. **N Engl J Med** 1997 May 29;336(22):1575-86 (67 ref.) Comment in: N Engl J Med 1997 May 29;336(22):1599-600.

Channelopathies: ion channel disorders of muscle as a paradigm for paroxysmal disorders of the nervous system. Ptáček LJ. **Neuromuscul Disord** 1997 Jun;7(4):250-5 (56 ref.)

Ion channels, the QT interval, and arrhythmias. Wilde AA, et al. **Pacing Clin Electrophysiol** 1997 Aug;20(8 Pt 2):2048-51 (12 ref.)

Channelopathies: the nondystrophic myotonias and periodic paralyses. Lehmann-Horn F, et al. **Semin Pediatr Neurol** 1996 Jun;3(2):122-39 (114 ref.)

IMMUNOLOGY

Autoimmunity to ion-channels and other proteins in paraneoplastic disorders. Lang B, et al. **Curr Opin Immunol** 1996 Dec;8(6):865-71 (55 ref.)

METABOLISM

Regulation of ion channels in smooth muscles by calcium. Carl A, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):C9-34 (266 ref.)

Role of ion channels in aqueous humor formation. Jacob TJ, et al. **Am J Physiol** 1996 Sep;271(3 Pt 1):C703-20 (166 ref.)

Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin. Knepper MA. **Am J Physiol** 1997 Jan;272(1 Pt 2):F3-12 (59 ref.)

Cytoplasmic ATP-dependent regulation of ion transporters and channels: mechanisms and messengers. Hilgemann DW. **Annu Rev Physiol** 1997;59:193-220 (166 ref.)

Interactions of polyamines with ion channels. Williams K. **Biochem J** 1997 Jul 15;325 (Pt 2):289-97 (104 ref.)

Membrane pores--from biology to track-etched membranes. Bashford CL. **Biosci Rep** 1995 Dec;15(6):553-65 (49 ref.)

Differential electrophysiology of repolarisation from clone to clinic. Coronel R, et al. **Cardiovasc Res** 1997 Mar; 33(3):503-17 (30 ref.)

A role for the anion exchanger AE1 (band 3 protein) in cell volume regulation. Garcia-Romeu F, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 Nov;42(7):985-94 (29 ref.)

Band 3 in cell volume regulation in fish erythrocytes. Perlman DF, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 Nov;42(7):975-84 (31 ref.)

Transduction mechanisms of P2Z purinoceptors. Wiley JS, et al. **Ciba Found Symp** 1996;198:149-60; discussion 160-5 (52 ref.)

Cell-volume regulation: P-glycoprotein--a cautionary tale. Wine JJ, et al. **Curr Biol** 1996 Nov 1;6(11):1410-2 (28 ref.)

Receptor-regulated ion channels. Jan LY, et al. **Curr Opin Cell Biol** 1997 Apr;9(2):155-60 (60 ref.)

Calcium permeability of glutamate-gated channels in the central nervous system. Burnashev N. **Curr Opin Neurobiol** 1996 Jun;6(3):311-7 (57 ref.)

Interaction of ion channels and receptors with PDZ domain proteins. Kornau HC, et al. **Curr Opin Neurobiol** 1997 Jun; 7(3):368-73 (35 ref.)

Calmodulin regulation of cyclic-nucleotide-gated channels. Molday RS. **Curr Opin Neurobiol** 1996 Aug;6(4):445-52 (59 ref.)

Characterization of ion channels in stimulus-secretion coupling in pancreatic islets. Ammälä C, et al. **Digestion** 1997;58 Suppl 2:81-5 (21 ref.)

What causes ion channel proteins to fluctuate open and closed? Liebovitch LS, et al. **Int J Neural Syst** 1996 Sep; 7(4):321-31 (16 ref.)

Anion channels of the inner membrane of mammalian and yeast mitochondria. Ballarin C, et al. **J Bioenerg Biomembr** 1996 Apr;28(2):125-30 (30 ref.)

Characterization and function of the mitochondrial outer membrane peptide-sensitive channel. Henry JP, et al. **J Bioenerg Biomembr** 1996 Apr;28(2):101-8 (31 ref.)

Perspectives on the mitochondrial multiple conductance channel. Kinnally KW, et al. **J Bioenerg Biomembr** 1996 Apr;28(2):115-23 (72 ref.)

Mitochondrial channels revisited. Mannella CA. **J Bioenerg Biomembr** 1996 Apr;28(2):89-91 (42 ref.)

Is there VDAC in cell compartments other than the mitochondria? Yu WH, et al. **J Bioenerg Biomembr** 1996 Apr;28(2):93-100 (49 ref.)

Single channel seeks permeant ion for brief but intimate relationship. Yellen G. **J Gen Physiol** 1997 Aug;110(2):83-5 (21 ref.)

Regulation of epithelial ion channels by the cystic fibrosis transmembrane conductance regulator. Greger R, et al. **J Mol Med** 1996 Sep;74(9):527-34 (79 ref.)

Periodic paralysis and voltage-gated ion channels [editorial] Fontaine B, et al. **Kidney Int** 1996 Jan;49(1):9-18 (107 ref.)

Oxygen sensing by ion channels. López-Barneo J, et al. **Kidney Int** 1997 Feb;51(2):454-61 (43 ref.)

ION CHANNELS

Endothelial vasoregulation and mechanosensitive ion channels in hypertension [editorial] Hoyer J. **Nephrol Dial Transplant** 1997 Jan;12(1):6–8 (24 ref.)
NMDA receptors: from genes to channels. Sucher NJ, et al. **Trends Pharmacol Sci** 1996 Oct;17(10):348–55 (67 ref.)
[Molecular structure and expression of ion channels in the heart] Isomoto S, et al. **Nippon Rinsho** 1996 Aug; 54(8):2056–65 (24 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Ion channel associated proteins. Sheng M, et al. **Curr Opin Neurobiol** 1996 Oct;6(5):602–8 (63 ref.)

PHYSIOLOGY

Aquaporins: from physiology to nephrogenic diabetes insipidus. Knoers N, et al. **Adv Nephrol Necker Hosp** 1996; 25:257–73 (73 ref.)
Ionic channels in corneal endothelium. Rae JL, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):C975–89 (66 ref.)
Molecular and functional diversity of the NMDA receptor channel. Mishina M, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:136–52 (43 ref.)
Structure and function of cyclic nucleotide–gated channels. Zagotta WN, et al. **Annu Rev Neurosci** 1996;19:235–63 (137 ref.)
Ion channels in vascular endothelium. Nilius B, et al. **Annu Rev Physiol** 1997;59:145–70 (197 ref.)
Mechanosensitive channels of Escherichia coli: the MscL gene, protein, and activities. Sukharev SI, et al. **Annu Rev Physiol** 1997;59:633–57 (94 ref.)
Stretch–sensitive ion channels of neuronal growth cones. Pellegrino M, et al. **Arch Ital Biol** 1997 Sep;135(4):319–29 (62 ref.)
Towards an understanding of the structural and functional properties of MscL, a mechanosensitive channel in bacteria. Blount P, et al. **Biol Cell** 1996;87(1–2):1–8 (58 ref.)
Why do cyclic nucleotide–gated channels have the jitters? [comment] Karpen JW. **Biophys J** 1997 Mar;72(3):986–8 (9 ref.) Comment on: Biophys J 1997 Mar;72(3):1165–81.
A list of vertebrate cardiac ionic currents nomenclature, properties, function and cloned equivalents. Boyett MR, et al. **Cardiovasc Res** 1996 Sep;32(3):455–81 (259 ref.)
The roles of ion channels in an inherited heart disease: molecular genetics of the long QT syndrome. Kass RS, et al. **Cardiovasc Res** 1996 Sep;32(3):443–54 (146 ref.)
Modulation and block of ion channels: a new biology of polyamines. Williams K. **Cell Signal** 1997 Jan;9(1):1–13 (148 ref.)
Gap junction channel gating and permselectivity: their roles in co–ordinated tissue function. Brink PR. **Clin Exp Pharmacol Physiol** 1996 Dec;23(12):1041–6 (38 ref.)
Where are the gates in gap junction channels? Dahl G. **Clin Exp Pharmacol Physiol** 1996 Dec;23(12):1047–52 (51 ref.)
Molecular physiology of gap junction channels. Spray DC. **Clin Exp Pharmacol Physiol** 1996 Dec;23(12):1038–40 (21 ref.)
Modeling of cardiac electrophysiological mechanisms: from action potential genesis to its propagation in myocardium. Bardou AL, et al. **Crit Rev Biomed Eng** 1996; 24(2–3):141–221 (113 ref.)
Using fractals and nonlinear dynamics to determine the physical properties of ion channel proteins. Liebovitch LS, et al. **Crit Rev Neurobiol** 1996;10(2):169–87 (53 ref.)
Regulation of aquaporin–2 water channel trafficking by vasopressin. Knepper MA, et al. **Curr Opin Cell Biol** 1997 Aug;9(4):560–4 (46 ref.)
Role of aquaporins in water balance disorders. Knepper MA, et al. **Curr Opin Nephrol Hypertens** 1997 Jul;6(4):367–71 (31 ref.)
Interaction of ion channels and receptors with PDZ domain proteins. Kornau HC, et al. **Curr Opin Neurobiol** 1997 Jun; 7(3):368–73 (35 ref.)
The roles of trp and calcium in regulating photoreceptor function in Drosophila. Minke B, et al. **Curr Opin Neurobiol** 1996 Aug;6(4):459–66 (67 ref.)
Regulation of excitatory and inhibitory neurotransmitter–gated ion channels by protein phosphorylation. Smart TG. **Curr Opin Neurobiol** 1997 Jun; 7(3):358–67 (72 ref.)
Channels in transporters. Sonders MS, et al. **Curr Opin Neurobiol** 1996 Jun;6(3):294–302 (59 ref.)
Cyclic nucleotide gated channels as regulators of CNS development and plasticity. Zufall F, et al. **Curr Opin Neurobiol** 1997 Jun;7(3):404–12 (73 ref.)
Ion channels: key elements in gamete signaling. Darszon A, et al. **Curr Top Dev Biol** 1996;34:117–67 (448 ref.)
Physiology and pathophysiology of aquaporins. Mulders SM, et al. **Eur J Clin Invest** 1996 Dec;26(12):1041–50 (84 ref.)
G protein regulation of alveolar ion channels: implications for lung fluid transport. Kemp PJ, et al. **Exp Physiol** 1996 May;81(3):493–504 (35 ref.)
Electrophysiology of ion channels of the heart. Ravens U, et al. **Fundam Clin Pharmacol** 1996;10(4):321–8 (28 ref.)
Spontaneous signalling in small central neurons: mechanisms and roles of spike–amplitude and spike–interval fluctuations. Arhem P, et al. **Int J Neural Syst** 1996 Sep; 7(4):369–76 (39 ref.)
The biogenesis, traffic, and function of the cystic fibrosis transmembrane conductance regulator. Jilling T, et al. **Int Rev Cytol** 1997;172:193–241 (173 ref.)
Ion channels and membrane receptors in follicle–enclosed Xenopus oocytes. Arellano RO, et al. **Ion Channels** 1996; 4:203–59 (130 ref.)
VDAC, a channel in the outer mitochondrial membrane. Colombini M, et al. **Ion Channels** 1996;4:169–202 (75 ref.)
Single–channel studies in molluscan neurons. Fejtl M, et al. **Ion Channels** 1996;4:333–76 (130 ref.)
Ion channels in plasma membrane signal transduction. Catterall WA. **J Bioenerg Biomembr** 1996 Jun;28(3):217–8 (3 ref.)
The life cycle of a connexin: gap junction formation, removal, and degradation. Laird DW. **J Bioenerg Biomembr** 1996 Aug;28(4):311–8 (54 ref.)
Molecular mechanisms of cyclic nucleotide–gated channels. Zagotta WN. **J Bioenerg Biomembr** 1996 Jun;28(3):269–78 (92 ref.)
Effects of nitric oxide on glutamate–gated channels and other ionic channels. Fagni L, et al. **J Chem Neuroanat** 1996 Jun; 10(3–4):231–40 (55 ref.)
Cooperativity in cyclic nucleotide–gated ion channels [comment] Pugh EN Jr. **J Gen Physiol** 1996 Feb; 107(2):165–7 (20 ref.) Comment on: J Gen Physiol 1996 Feb;107(2):169–81.
Swelling–activated organic osmolyte channels. Kirk K. **J Membr Biol** 1997 Jul 1;158(1):1–16 (132 ref.)
Stretch–activated ion channels in the heart. Hu H, et al. **J Mol Cell Cardiol** 1997 Jun;29(6):1511–23 (145 ref.)
Model experiments on squid axons and NG108–15 mouse neuroblastoma x rat glioma hybrid cells. Schmitt H, et al. **J Physiol Paris** 1995;89(4–6):181–93 (61 ref.)
Functions of cardiac ion channels under normal and pathological conditions. Hiraoka M, et al. **Jpn Heart J** 1996 Sep;37(5):693–707 (81 ref.)
Ion channels in neuroglial cells. Oh Y. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1997 Jan;13(1):1–9 (53 ref.)
Organic osmolyte channels: transport characteristics and regulation. Goldstein L, et al. **Kidney Int** 1996 Jun; 49(6):1690–4 (24 ref.)
Single channel properties of a volume sensitive anion channel: lessons from noise analysis. Jackson PS, et al. **Kidney Int** 1996 Jun;49(6):1695–9 (26 ref.)
Renal aquaporins. Knepper MA, et al. **Kidney Int** 1996 Jun; 49(6):1712–7 (47 ref.)
The aquaporin family of water channels in kidney: an update on physiology and pathophysiology of aquaporin–2. Nielsen S, et al. **Kidney Int** 1996 Jun;49(6):1718–23 (43 ref.)
Nephrology. The year of the pores. Schieppati A, et al. **Lancet** 1996 Dec 21–28;348 Suppl 2:sII13 (5 ref.)
The aquaporin family of water channel proteins in clinical medicine. Lee MD, et al. **Medicine (Baltimore)** 1997 May; 76(3):141–56 (186 ref.)
Synaptic targeting of ionotropic neurotransmitter receptors. Kirsch J, et al. **Mol Cell Neurosci** 1996;8(2–3):93–8 (50 ref.)
Double identity for proteins of the Bcl–2 family. Reed JC. **Nature** 1997 Jun 19;387(6635):773–6 (40 ref.)
Molecular diversity of cyclic nucleotide–gated cation channels. Biel M, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Dec; 353(1):1–10 (100 ref.)
Molecular mechanisms of microglial activation. B. Voltage– and purinoceptor–operated channels in microglia. Illes P, et al. **Neurochem Int** 1996 Jul;29(1):13–24 (63 ref.)
The acetylcholine receptor ligand–gated channel as a molecular target of disease and therapeutic agents. Barrantes FJ. **Neurochem Res** 1997 Apr;22(4):391–400 (68 ref.)
Scentsational ion channels. Firestein S. **Neuron** 1996 Nov; 17(5):803–6 (20 ref.)
Listening to neurotransmitter transporters. Lester HA, et al. **Neuron** 1996 Nov;17(5):807–10 (22 ref.)
PDZs and receptor/channel clustering: rounding up the latest suspects [comment] Sheng M. **Neuron** 1996 Oct;17(4):575–8 (19 ref.) Comment on: Neuron 1996 Oct;17(4):759–67.
Ion channels: structural basis for function and disease. Goldstein SA. **Semin Perinatol** 1996 Dec;20(6):520–30 (86 ref.)
Mitochondrial inner membrane channels in yeast and mammals. Ballarin C, et al. **Soc Gen Physiol Ser** 1996; 51:155–71 (51 ref.)
Structure and function of the yeast outer mitochondrial membrane channel, VDAC. Forte M, et al. **Soc Gen Physiol Ser** 1996;51:145–54 (19 ref.)
Regulation of store–operated calcium currents in mast cells. Parekh AB, et al. **Soc Gen Physiol Ser** 1996;51:231–9 (18 ref.)
Mechanical transduction by ion channels: how forces reach the channel. Sachs F. **Soc Gen Physiol Ser** 1997;52:209–18 (52 ref.)
Nuclear ion channels and regulation of the nuclear pore. Stehno–Bittel L, et al. **Soc Gen Physiol Ser** 1996;51:195–207 (36 ref.)
MscL: a mechanosensitive channel in Escherichia coli. Sukharev SI, et al. **Soc Gen Physiol Ser** 1996;51:133–41 (34 ref.)
Oxygen–sensing by ion channels and the regulation of cellular functions. López–Barneo J. **Trends Neurosci** 1996 Oct; 19(10):435–40 (46 ref.)
Calcineurin regulation of synaptic function: from ion channels to transmitter release and gene transcription. Yakel JL. **Trends Pharmacol Sci** 1997 Apr;18(4):124–34 (63 ref.)
Do Vpu and Vpr of human immunodeficiency virus type 1 and NB of influenza B virus have ion channel activities in the viral life cycles? Lamb RA, et al. **Virology** 1997 Mar 3;229(1):1–11 (127 ref.)
Tubule electrophysiology: from single channels back to the renal epithelium. Boulpaep EL. **Wien Klin Wochenschr** 1997 Jun 27;109(12–13):489–92 (18 ref.)
Multiple types of ion channels in cavernous smooth muscle. Noack T, et al. **World J Urol** 1997;15(1):45–9 (12 ref.)
[The molecular biology studies of water channels] Li XJ, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan;27(1):19–24 (22 ref.) (Eng. Abstr.) **(Chi)**
[Contractile force and myocardial ischemia––electrical and ionic mechanisms] Köppel H, et al. **Acta Med Austriaca** 1997;24(3):114–21 (98 ref.) (Eng. Abstr.) **(Ger)**
[Electrophysiology of cardiac ion channels] Hirano Y, et al. **Nippon Rinsho** 1996 Aug;54(8):2050–5 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Transport of water through biological membranes] Nałęcz KA. **Postepy Biochem** 1996;42(2):161–7 (73 ref.) **(Pol)**

ION CHANNELS, CALCIUM see **CALCIUM CHANNELS**

ION CHANNELS, CHLORIDE see **CHLORIDE CHANNELS**

ION CHANNELS, POTASSIUM see **POTASSIUM CHANNELS**

ION CHANNELS, SODIUM see **SODIUM CHANNELS**

ION COTRANSPORT see **ION TRANSPORT**

ION EXCHANGE, INTRACELLULAR see **ION TRANSPORT**

ION EXCHANGE RESINS

see related
CHROMATOGRAPHY, ION EXCHANGE

[Separation of DNA fragments by high–performance ion–exchanger] Yamasaki Y. **Tanpakushitsu Kakusan Koso** 1996 Dec;41(16):2593–6 (11 ref.) **(Jpn)**

ION PUMPS

METABOLISM

Ion pumps in epithelial cells: sorting, stabilization, and polarity. Caplan MJ. **Am J Physiol** 1997 Jun;272(6 Pt 1):G1304–13 (73 ref.)
Bacterial resistances to toxic metal ions––a review. Silver S. **Gene** 1996 Nov 7;179(1):9–19 (70 ref.)

ION–SELECTIVE ELECTRODES

Role of magnesium in patho–physiological processes and the clinical utility of magnesium ion selective electrodes. Altura BM, et al. **Scand J Clin Lab Invest Suppl** 1996;224:211–34 (127 ref.)
Electric potential measured, concentration reported: how to get mmols from mV. Lewenstam A. **Scand J Clin Lab Invest Suppl** 1996;224:135–9 (6 ref.)

STANDARDS

International consensus on the standardization of sodium and potassium measurements by ion–selective electrodes in undiluted samples. Külpmann WR, et al. **Scand J Clin Lab Invest Suppl** 1996;224:145–60 (6 ref.)
A problem associated with the use of a calomel reference electrode in an ISE analytical system. Vitiello JD, et al. **Scand J Clin Lab Invest Suppl** 1996;224:165–71 (4 ref.)

ION TRANSPORT

see related
ANTIPORTERS
ION PUMPS

Band 3 protein: physiology, function and structure. Hamasaki N, et al. **Cell Mol Biol (Noisy–le–grand)** 1996 Nov; 42(7):1025–39 (57 ref.)
Changes in ionic fluxes during cerebral ischaemia. Kristián T, et al. **Int Rev Neurobiol** 1997;40:27–45 (67 ref.)
Renal transporters for organic anions and organic cations. Structural requirements for substrates. Ullrich KJ. **J Membr Biol** 1997 Jul 15;158(2):95–107 (89 ref.)

PHYSIOLOGY

Regulation of ionic conductances and gene expression by hypoxia in an oxygen sensitive cell line. Millhorn DE, et al. **Adv Exp Med Biol** 1996;410:135–42 (17 ref.)
Introduction to medical physiology: cellular membranes and transmembrane transport of solutes and water [published erratum appears in Am J Physiol 1997 Jun;272(6 Pt 3):following table of contents] Benos DJ. **Am J Physiol** 1996 Dec;271(6 Pt 3):S2–9 (27 ref.)
Placental transfer of inorganic ions and water. Stulc J. **Physiol Rev** 1997 Jul;77(3):805–36 (297 ref.)
Molecular physiology of vertebrate Na+/H+ exchangers.

Wakabayashi S, et al. **Physiol Rev** 1997 Jan;77(1):51–74 (310 ref.)

Ion-exchange gel regulates neurotransmitter release through the exocytotic fusion pore. Marszalek P, et al. **Soc Gen Physiol Ser** 1996;51:211–22 (39 ref.)

Ion exchangers mediating NaCl transport in the proximal tubule. Aronson PS. **Wien Klin Wochenschr** 1997 Jun 27; 109(12–13):435–40 (58 ref.)

IONIC STRENGTH see **OSMOLAR CONCENTRATION**

IONOPHORES

see related
UNCOUPLING AGENTS

METABOLISM

From kinetics and thermodynamics of GABAA receptor binding to ionophore function. Maksay G. **Neurochem Int** 1996 Oct;29(4):361–70 (65 ref.)

IONS

A possible role of cold-induced ionic stress in cold-induced cell death. Aslanidi KB, et al. **Membr Cell Biol** 1997; 11(1):57–76 (47 ref.)

Applications of the ion-pair concept to hydrophilic substances with special emphasis on peptides. Quintanar-Guerrero D, et al. **Pharm Res** 1997 Feb; 14(2):119–27 (53 ref.)

IONTOPHORESIS

Insulin iontophoresis. Sage BH Jr. **Pharm Biotechnol** 1997; 10:319–41 (30 ref.)

IOPAMIDOL

ANALOGS & DERIVATIVES

New non-ionic contrast: effects on the cardiovascular system. Pagny JY, et al. **Eur J Radiol** 1996 Nov;23 Suppl 1:S2–5 (23 ref.)

Safety profile of new non-ionic contrast media: renal tolerance. Stacul F, et al. **Eur J Radiol** 1996 Nov;23 Suppl 1:S6–9 (23 ref.)

IPNV see **INFECTIOUS PANCREATIC NECROSIS VIRUS**

IPPB see **INTERMITTENT POSITIVE-PRESSURE BREATHING**

IPPV see **INTERMITTENT POSITIVE-PRESSURE VENTILATION**

IPRATROPIUM

THERAPEUTIC USE

Ipratropium bromide (Atrovent) nasal spray. A new treatment for rhinorrhea [news] Pfister SM. **Nurse Pract** 1996 Jul;21(7):104, 107–8 (8 ref.)

IPROVERATRIL see **VERAPAMIL**

IPSID see **IMMUNOPROLIFERATIVE SMALL INTESTINAL DISEASE**

IR GENES see **GENES, MHC CLASS II**

IRIDIUM RADIOISOTOPES

THERAPEUTIC USE

The role of brachytherapy in the treatment and control of central bronchial carcinoma. Macha HN, et al. **Monaldi Arch Chest Dis** 1996 Aug;51(4):325–8 (23 ref.)

[Iridium 192 brachytherapy of supra-tentorial high grade glioma recurring in irradiated areas: technique and preliminary results of the Pitié-Salpêtrière hospital group] Boisserie G, et al. **Bull Cancer Radiother** 1996;83(3):144–52 (20 ref.) (Eng. Abstr.) **(Fre)**

IRIDOCYCLITIS

COMPLICATIONS

Psoriatic arthritis and hypopyon-iridocyclitis. Possible mechanism of the association of psoriasis and anterior uveitis. Iijima S, et al. **Dermatology** 1996;193(4):295–9 (24 ref.)

DIAGNOSIS

Psoriatic arthritis and hypopyon-iridocyclitis. Possible mechanism of the association of psoriasis and anterior uveitis. Iijima S, et al. **Dermatology** 1996;193(4):295–9 (24 ref.)

IRIDOVIRIDAE

PHYSIOLOGY

Southern hemisphere mollusc diseases and an overview of associated risk assessment problems. Hine PM. **Rev Sci Tech** 1996 Jun;15(2):563–77 (77 ref.)

Appearance and spread of diseases among bivalve molluscs in the northern hemisphere in relation to international trade. Renault T. **Rev Sci Tech** 1996 Jun;15(2):551–61 (40 ref.)

IRIDOVIRUS

The iridoviruses. Williams T. **Adv Virus Res** 1996;46:345–412 (268 ref.)

PATHOGENICITY

[Iridovirus infection in fish] Nakajima K. **Uirusu** 1996 Jun; 46(1):61–6 (26 ref.) **(Jpn)**

IRIS

ABNORMALITIES

New autosomal recessive multiple congenital abnormalities/mental retardation syndrome with craniofacial dysmorphism absent corpus callosum, iris colobomas and connective tissue dysplasia. Temtamy SA, et al. **Clin Dysmorphol** 1996 Jul;5(3):231–40 (31 ref.)

BLOOD SUPPLY

Iris fluorescein angiography in clinical practice. Brancato R, et al. **Surv Ophthalmol** 1997 Jul-Aug;42(1):41–70 (417 ref.)

PATHOLOGY

A unification hypothesis of pigment dispersion syndrome. Ritch R. **Trans Am Ophthalmol Soc** 1996;94:381–405; discussion 405–9 (118 ref.)

SURGERY

Laser iridotomy. Liebmann JM, et al. **Ophthalmic Surg Lasers** 1996 Mar;27(3):209–27 (211 ref.)

Should patients with anatomically narrow angles have prophylactic iridectomy? Wilensky JT, et al. **Surv Ophthalmol** 1996 Jul-Aug;41(1):31–6 (35 ref.)

ULTRASTRUCTURE

The color of the human eye: a review of morphologic correlates and of some conditions that affect iridial pigmentation. Imesch PD, et al. **Surv Ophthalmol** 1997 Feb; 41 Suppl 2:S117–23 (46 ref.)

IRIS DISEASES

CHEMICALLY INDUCED

Prostaglandins: a new approach to glaucoma management with a new, intriguing side effect. Bito LZ. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S1–14 (74 ref.)

DIAGNOSIS

Iris fluorescein angiography in clinical practice. Brancato R, et al. **Surv Ophthalmol** 1997 Jul-Aug;42(1):41–70 (417 ref.)

METABOLISM

The color of the human eye: a review of morphologic correlates and of some conditions that affect iridial pigmentation. Imesch PD, et al. **Surv Ophthalmol** 1997 Feb; 41 Suppl 2:S117–23 (46 ref.)

IRIS NEOPLASMS

PATHOLOGY

Adenocarcinoma of the iris pigment epithelium. Spraul CW, et al. **Arch Ophthalmol** 1996 Dec;114(12):1512–7 (35 ref.)

Plasmacytoma of the eye and orbit. Adkins JW, et al. **Int Ophthalmol** 1996–97;20(6):339–43 (11 ref.)

SECONDARY

[Iris metastases. Apropos of 4 cases] Mouriaux F, et al. **J Fr Ophtalmol** 1997;20(1):37–41 (17 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Intraocular melanomata in the horse. Barnett KC, et al. **Equine Vet J Suppl** 1990 Sep;(10):76–82 (27 ref.)

IRON

see related
FERRIC COMPOUNDS
FERRITIN
FERROUS COMPOUNDS
HEMOSIDERIN
HEMOSIDEROSIS
SIDEROSIS
TRANSFERRIN

ADMINISTRATION & DOSAGE

Daily versus weekly: how many iron pills do pregnant women need? [see comments] Galloway R, et al. **Nutr Rev** 1996 Oct;54(10):318–23 (33 ref.) Comment in: Nutr Rev 1997 Apr;55(4):141–2.

Strategies for the prevention of iron deficiency: iron in infant formulas and baby foods. Ziegler EE, et al. **Nutr Rev** 1996 Nov;54(11 Pt 1):348–54 (32 ref.)

Iron deficiency anemia. When is parenteral therapy warranted? Swain RA, et al. **Postgrad Med** 1996 Nov; 100(5):181–2, 185, 188–93 (15 ref.)

[New aspects on preventive iron supplementation in normal pregnancy] Haram K, et al. **Tidsskr Nor Laegeforen** 1997 Mar 10;117(7):966–9 (32 ref.) (Eng. Abstr.) **(Nor)**

ADVERSE EFFECTS

The iron hypothesis--does iron cause atherosclerosis? Meyers DG. **Clin Cardiol** 1996 Dec;19(12):925–9 (41 ref.)

Iron versus cholesterol--response to dissent by Weintraub et al. Sullivan JL. **J Clin Epidemiol** 1996 Dec; 49(12):1359–62 (20 ref.)

Iron versus cholesterol--perspectives on the iron and heart disease debate. Sullivan JL. **J Clin Epidemiol** 1996 Dec; 49(12):1345–52 (51 ref.)

Effects of positive iron status at a cellular level. McCord JM. **Nutr Rev** 1996 Mar;54(3):85–8 (41 ref.)

Importance of adequate vitamin A status during iron supplementation. Ribaya-Mercado JD. **Nutr Rev** 1997 Aug; 55(8):306–7 (13 ref.)

Iron and heart disease: the epidemiologic data. Sempos CT, et al. **Nutr Rev** 1996 Mar;54(3):73–84 (99 ref.)

Does occupational exposure to iron promote infection? Palmer K, et al. **Occup Environ Med** 1997 Aug;54(8):529–34 (52 ref.)

ANALYSIS

Model complexes of di-iron sites in methane mono-oxygenase and ribonucleotide reductase: structure and reactivity. Fontecave M, et al. **Biochem Soc Trans** 1997 Feb;25(1):65–9 (36 ref.)

BLOOD

Iron management in end-stage renal disease. Fishbane S, et al. **Am J Kidney Dis** 1997 Mar;29(3):319–33 (104 ref.)

The laboratory assessment of iron status--an update. Worwood M. **Clin Chim Acta** 1997 Mar 18;259(1–2):3–23 (80 ref.)

[Iron homeostasis in preoperative autologous blood donation] Weisbach V, et al. **Infusionsther Transfusionsmed** 1996 Jun; 23(3):161–70 (84 ref.) (Eng. Abstr.) **(Ger)**

CHEMISTRY

[Biological activity of a carrier molecule-iron complex: probable mechanisms of intestinal absorption] Curri SB. **Boll Chim Farm** 1996 Apr;135(4):248–58 (21 ref.) (Eng. Abstr.) **(Ita)**

DEFICIENCY

Erythropoietin and iron [see comments] Sunder-Plassmann G, et al. **Clin Nephrol** 1997 Mar;47(3):141–57 (236 ref.) Comment in: Clin Nephrol 1997 Jun;47(6):408.

Iron metabolism: a comprehensive review. Beard JL, et al. **Nutr Rev** 1996 Oct;54(10):295–317 (277 ref.)

Strategies of the Pan American Health Organization/World Health Organization for the control of iron deficiency in Latin America. Freire WB. **Nutr Rev** 1997 Jun;55(6):183–8 (15 ref.)

Preventing iron deficiency through food fortification. Hurrell RF. **Nutr Rev** 1997 Jun;55(6):210–22 (97 ref.)

Strategies for the prevention of iron deficiency through foods in the household. Layrisse M, et al. **Nutr Rev** 1997 Jun; 55(6):233–9 (42 ref.)

Preventing iron deficiency in infants and preschool children in Argentina. O'Donnell AM, et al. **Nutr Rev** 1997 Jun; 55(6):189–94 (22 ref.)

Hookworm control as a strategy to prevent iron deficiency. Stoltzfus RJ, et al. **Nutr Rev** 1997 Jun;55(6):223–32 (54 ref.)

Iron supplementation for the control of iron deficiency in populations at risk. Viteri FE. **Nutr Rev** 1997 Jun; 55(6):195–209 (74 ref.)

Micronutrients: effects of variation in [Hb] and iron deficiency on physical performance. Ekblom B. **World Rev Nutr Diet** 1997;82:122–30 (64 ref.)

[Iron deficiency as a risk factor during the perinatal period] Zdziennicki A, et al. **Ginekol Pol** 1996 Jun;67(6):301–3 (14 ref.) (Eng. Abstr.) **(Pol)**

[Benefits and dangers connected with clinical use of microelements] Martyka Z, et al. **Przegl Lek** 1995; 52(12):599–602 (25 ref.) (Eng. Abstr.) **(Pol)**

[Relationship of vitamins and microelements and their role in the prevention of iron deficiencies (review)] Nasolodin VV, et al. **Gig Sanit** 1996 Nov-Dec;(6):26–9 (41 ref.) **(Rus)**

IMMUNOLOGY

Iron, anemia, and infection. Walter T, et al. **Nutr Rev** 1997 Apr;55(4):111–24 (89 ref.)

IRON

METABOLISM

Iron and infection [editorial] Boelaert JR. **Acta Clin Belg** 1996;51(4):213–21 (54 ref.)
Iron status and risk of cardiovascular disease. Corti MC, et al. **Ann Epidemiol** 1997 Jan;7(1):62–8 (48 ref.)
Comparative nutrition of iron and copper. Winzerling JJ, et al. **Annu Rev Nutr** 1997;17:501–26 (165 ref.)
Response of Neisseria meningitidis to iron limitation. Pettersson A, et al. **Antonie Van Leeuwenhoek** 1997 Feb; 71(1–2):129–36 (34 ref.)
The role of nitric oxide in the regulation of cellular iron metabolism. Domachowske JB. **Biochem Mol Med** 1997 Feb;60(1):1–7 (59 ref.)
Studies on non–haem ferrous–dependent oxygenases and oxidases. Barlow JN, et al. **Biochem Soc Trans** 1997 Feb; 25(1):86–90 (30 ref.)
Ribonucleotide reductase, lipoxygenase and the intracellular low–molecular–weight iron pool. Cooper CE, et al. **Biochem Soc Trans** 1997 Feb;25(1):75–80 (25 ref.)
The iron form of methane mono–oxygenase and its mode of action. Dalton H, et al. **Biochem Soc Trans** 1997 Feb; 25(1):69–74 (27 ref.)
Pumping iron: does bacterioferritin contain a redox–driven iron pump? Thomson AJ, et al. **Biochem Soc Trans** 1997 Feb;25(1):96–101 (16 ref.)
Hepatic iron deposition in human disease and animal models. Halliday JW, et al. **Biometals** 1996 Apr;9(2):205–9 (23 ref.)
Iron withholding: a defense against viral infections. Weinberg ED. **Biometals** 1996 Oct;9(4):393–9 (46 ref.)
Tissue–specific regulation of iron metabolism and heme synthesis: distinct control mechanisms in erythroid cells [see comments] Ponka P. **Blood** 1997 Jan 1;89(1):1–25 (311 ref.) Comment in: Blood 1997 Jul 1;90(1):473–4.
Assessment of iron status. Baynes RD. **Clin Biochem** 1996 Jun;29(3):209–15 (35 ref.)
Molecular mechanisms of iron transport. Gutierrez JA, et al. **Crit Rev Eukaryot Gene Expr** 1996;6(1):1–14 (144 ref.)
Molecular biology of iron and zinc uptake in eukaryotes. Eide D. **Curr Opin Cell Biol** 1997 Aug;9(4):573–7 (28 ref.)
Regulation of iron metabolism in eukaryotes. Rouault T, et al. **Curr Top Cell Regul** 1997;35:1–19 (88 ref.)
The impact of oxidative stress on eukaryotic iron metabolism. Rouault TA, et al. **EXS** 1996;77:183–97 (58 ref.)
Iron depletion and virulence in Staphylococcus aureus. Trivier D, et al. **FEMS Microbiol Lett** 1996 Aug 1; 141(2–3):117–27 (51 ref.)
How does superoxide dismutase protect against tumor necrosis factor: a hypothesis informed by effect of superoxide on "free" iron. Liochev SI, et al. **Free Radic Biol Med** 1997;23(4):668–71 (46 ref.)
Iron homeostasis, oxidative stress, and DNA damage. Meneghini R. **Free Radic Biol Med** 1997;23(5):783–92 (74 ref.)
Iron overload in light of the identification of a haemochromatosis gene. Hollán S. **Haematologia (Budap)** 1997;28(3):109–16 (23 ref.)
Iron deprivation and cancer: a view beginning with studies of monoclonal antibodies against the transferrin receptor. Kemp JD. **Histol Histopathol** 1997 Jan;12(1):291–6 (52 ref.)
Serum ferritin in Danes: studies of iron status from infancy to old age, during blood donation and pregnancy. Milman N. **Int J Hematol** 1996 Feb;63(2):103–35 (151 ref.)
Iron and liver: current concepts in the pathogenesis and management of chronic liver diseases. Guptan RC, et al. **J Assoc Physicians India** 1996 Mar;44(3):198–202 (46 ref.)
Control of iron absorption. Anderson GJ. **J Gastroenterol Hepatol** 1996 Nov;11(11):1030–2 (5 ref.)
Contributions of the Brisbane Liver Group to knowledge of iron metabolism. Bothwell TH. **J Gastroenterol Hepatol** 1996 Nov;11(11):1025–7 (9 ref.)
Alcohol and iron: one glass of red or more? Fletcher LM. **J Gastroenterol Hepatol** 1996 Nov;11(11):1039–41 (6 ref.)
Cellular iron processing. Morgan EH. **J Gastroenterol Hepatol** 1996 Nov;11(11):1027–30 (6 ref.)
Transport of iron in the blood–brain–cerebrospinal fluid system. Bradbury MW. **J Neurochem** 1997 Aug; 69(2):443–54 (121 ref.)
Signal transduction and transcriptional and posttranscriptional control of iron–regulated genes in bacteria. Crosa JH. **Microbiol Mol Biol Rev** 1997 Sep; 61(3):319–36 (178 ref.)
Hemoglobin catabolism and iron utilization by malaria parasites. Rosenthal PJ, et al. **Mol Biochem Parasitol** 1996 Dec 20;83(2):131–9 (77 ref.)
Molecular biology of iron acquisition in Saccharomyces cerevisiae. Askwith CC, et al. **Mol Microbiol** 1996 Apr; 20(1):27–34 (54 ref.)
Aluminium toxicity: its relationship with bone and iron metabolism. Cannata Andia JB. **Nephrol Dial Transplant** 1996;11 Suppl 3:69–73 (75 ref.)
Iron metabolism: a comprehensive review. Beard JL, et al. **Nutr Rev** 1996 Oct;54(10):295–317 (277 ref.)
Discovery of the hemochromatosis gene will require rethinking the regulation of iron metabolism. Fleet JC. **Nutr Rev** 1996 Sep;54(9):285–7 (6 ref.)
Influence of disease on iron status. Worwood M. **Proc Nutr Soc** 1997 Mar;56(1B):409–19 (37 ref.)
Iron–sulfur clusters: nature's modular, multipurpose structures. Beinert H, et al. **Science** 1997 Aug 1; 277(5326):653–9 (78 ref.)
Erythropoietin, iron metabolism, and red blood cell production. Adamson J. **Semin Hematol** 1996 Apr;33(2 Suppl 2):5–7; discussion 8–9 (9 ref.)
Iron–sulfur clusters as biosensors of oxidants and iron [published erratum appears in Trends Biochem Sci 1996 Jul;21(7):246] [see comments] Rouault TA, et al. **Trends Biochem Sci** 1996 May;21(5):174–7 (48 ref.) Comment in: Trends Biochem Sci 1996 Aug;21(8):282–3.
The role of iron in plant host–pathogen interactions. Expert D, et al. **Trends Microbiol** 1996 Jun;4(6):232–7 (44 ref.)
[Advances in the study of mechanism of iron uptake and some related etiology] Qian Z, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Oct;76(10):792–4 (19 ref.) **(Chi)**
[Ferrokinetics] Takahashi Y, et al. **Nippon Rinsho** 1997 Mar; 55 Suppl 1:75–83 (4 ref.) **(Jpn)**
[Iron uptake mechanisms of pathogenic bacteria] Yamamoto S, et al. **Nippon Saikingaku Zasshi** 1996 Feb;51(2):523–47 (210 ref.) **(Jpn)**

PHARMACOKINETICS

Bioavailability of iron. Hurrell RF. **Eur J Clin Nutr** 1997 Jan;51 Suppl 1:S4–8 (59 ref.)
Iron, copper, and zinc absorption and turnover; the use of stable isotopes. Aggett PJ. **Eur J Pediatr** 1997 Aug;156 Suppl 1:S29–34 (27 ref.)
Kinetic analysis of the intestinal iron absorption process in situ. The potential of vascularly autoperfused intestinal loops. Hunder G, et al. **Hum Exp Toxicol** 1997 Aug; 16(8):425–8 (17 ref.)
Interaction of iron with other nutrients. Lynch SR. **Nutr Rev** 1997 Apr;55(4):102–10 (92 ref.)

PHARMACOLOGY

Oxidative DNA damage induced by dioxetanes, photosensitizing ketones, and photo–fenton reagents. Adam W, et al. **Recent Results Cancer Res** 1997;143:21–34 (40 ref.)

PHYSIOLOGY

Iron and thermoregulation: a review. Brigham D, et al. **Crit Rev Food Sci Nutr** 1996 Dec;36(8):747–63 (91 ref.)
Relationship of iron to oligodendrocytes and myelination. Connor JR, et al. **Glia** 1996 Jun;17(2):83–93 (92 ref.)
Iron and chronic viral hepatitis. Bonkovsky HL, et al. **Hepatology** 1997 Mar;25(3):759–68 (118 ref.)
The Lactobacillus anomaly: total iron abstinence. Weinberg ED. **Perspect Biol Med** 1997 Summer;40(4):578–83 (27 ref.)
Interaction between iron–regulatory proteins and their RNA target sequences, iron–responsive elements. Henderson BR, et al. **Prog Mol Subcell Biol** 1997;18:117–39 (115 ref.)
Mechanisms for posttranscriptional regulation by iron–responsive elements and iron regulatory proteins. Muckenthaler M, et al. **Prog Mol Subcell Biol** 1997; 18:93–115 (100 ref.)
[The importance of iron in humans] Friedmann B, et al. **Cas Lek Cesk** 1997 Jun 12;136(12):386–91 (17 ref.) (Eng. Abstr.) **(Cze)**

POISONING

Acute iron poisoning. McGuigan MA. **Pediatr Ann** 1996 Jan; 25(1):33–8 (36 ref.)

THERAPEUTIC USE

Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin–treated patients. Drüeke TB, et al. **Clin Nephrol** 1997 Jul;48(1):1–8 (69 ref.)
Erythropoietin and iron [see comments] Sunder–Plassmann G, et al. **Clin Nephrol** 1997 Mar;47(3):141–57 (236 ref.) Comment in: Clin Nephrol 1997 Jun;47(6):408.
Iron deficiency and educational deficiency. Pollitt E. **Nutr Rev** 1997 Apr;55(4):133–41 (12 ref.)
Importance of adequate vitamin A status during iron supplementation. Ribaya–Mercado JD. **Nutr Rev** 1997 Aug; 55(8):306–7 (13 ref.)

TOXICITY

Iron–induced carcinogenesis: the role of redox regulation. Toyokuni S. **Free Radic Biol Med** 1996;20(4):553–66 (178 ref.)
Formation, prevention, and repair of DNA damage by iron/hydrogen peroxide. Henle ES, et al. **J Biol Chem** 1997 Aug 1;272(31):19095–8 (82 ref.)
Iron–induced tissue damage and cancer: the role of reactive oxygen species–free radicals. Okada S. **Pathol Int** 1996 May;46(5):311–32 (109 ref.)

IRON CHELATES

PHARMACOLOGY

Potential use of iron chelators against oxidative damage. Galey JB. **Adv Pharmacol** 1997;38:167–203 (141 ref.)
Hypothesis: iron chelation plays a vital role in neutrophilic inflammation. Ghio AJ, et al. **Biometals** 1997 Apr; 10(2):135–42 (88 ref.)

THERAPEUTIC USE

The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders. Gassen M, et al. **Pharmacol Toxicol** 1997 Apr;80(4):159–66 (76 ref.)

IRON–DEFICIENCY ANEMIA see **ANEMIA, IRON–DEFICIENCY**

IRON, DIETARY

Iron and liver: current concepts in the pathogenesis and management of chronic liver diseases. Guptan RC, et al. **J Assoc Physicians India** 1996 Mar;44(3):198–202 (46 ref.)

ADMINISTRATION & DOSAGE

A new procedure to fortify fluid milk and dairy products with high–bioavailable ferrous sulfate. Boccio JR, et al. **Nutr Rev** 1997 Jun;55(6):240–6 (21 ref.)

THERAPEUTIC USE

Preventing iron deficiency through food fortification. Hurrell RF. **Nutr Rev** 1997 Jun;55(6):210–22 (97 ref.)
Strategies for the prevention of iron deficiency through foods in the household. Layrisse M, et al. **Nutr Rev** 1997 Jun; 55(6):233–9 (42 ref.)
Iron supplementation for the control of iron deficiency in populations at risk. Viteri FE. **Nutr Rev** 1997 Jun; 55(6):195–209 (74 ref.)

IRON OVERLOAD

COMPLICATIONS

Hyperlipidemia versus iron overload and coronary artery disease: yet more arguments on the cholesterol debate. Weintraub WS, et al. **J Clin Epidemiol** 1996 Dec; 49(12):1353–8 (55 ref.)
Iron overload and liver fibrosis. Arthur MJ. **J Gastroenterol Hepatol** 1996 Dec;11(12):1124–9 (67 ref.)
Does occupational exposure to iron promote infection? Palmer K, et al. **Occup Environ Med** 1997 Aug;54(8):529–34 (52 ref.)

DIAGNOSIS

MR imaging of diffuse liver disease. Hepatic fat and iron. Siegelman ES. **Magn Reson Imaging Clin N Am** 1997 May; 5(2):347–65 (104 ref.)

DRUG THERAPY

Oral iron chelation with deferiprone. Diav–Citrin O, et al. **Pediatr Clin North Am** 1997 Feb;44(1):235–47 (75 ref.)

IRON PROTEINS, NON–HEME see **NONHEME IRON PROTEINS**

IRON–SULFUR PROTEIN REDUCTASE see **FERREDOXIN–NADP REDUCTASE**

IRON–SULFUR PROTEINS

Iron regulatory proteins 1 and 2. Henderson BR. **Bioessays** 1996 Sep;18(9):739–46 (57 ref.)

CHEMISTRY

[Rieske protein—a component of transmembrane cytochrome complexes] Gubernator B, et al. **Postepy Biochem** 1997; 43(1):41–50 (90 ref.) **(Pol)**

METABOLISM

Superoxide–driven aconitase FE–S center cycling. Gardner PR. **Biosci Rep** 1997 Feb;17(1):33–42 (65 ref.)
The role of the 'Rieske' iron sulfur protein in the hydroquinone oxidation (Q(P)) site of the cytochrome bc1 complex. The 'proton–gated affinity change' mechanism. Link TA. **FEBS Lett** 1997 Jul 28;412(2):257–64 (38 ref.)
The role of iron–sulfur clusters in in vivo hydroxyl radical production. Liochev SL. **Free Radic Res** 1996 Nov; 25(5):369–84 (131 ref.)
Interaction between iron–regulatory proteins and their RNA target sequences, iron–responsive elements. Henderson BR, et al. **Prog Mol Subcell Biol** 1997;18:117–39 (115 ref.)
Iron–sulfur clusters: nature's modular, multipurpose structures. Beinert H, et al. **Science** 1997 Aug 1; 277(5326):653–9 (78 ref.)
Redox signal transduction via iron–sulfur clusters in the SoxR transcription activator. Hidalgo E, et al. **Trends Biochem Sci** 1997 Jun;22(6):207–10 (37 ref.)
[Rieske protein—a component of transmembrane cytochrome complexes] Gubernator B, et al. **Postepy Biochem** 1997; 43(1):41–50 (90 ref.) **(Pol)**

PHYSIOLOGY

Iron–sulfur clusters as biosensors of oxidants and iron [published erratum appears in Trends Biochem Sci 1996 Jul;21(7):246] [see comments] Rouault TA, et al. **Trends Biochem Sci** 1996 May;21(5):174–7 (48 ref.) Comment in: Trends Biochem Sci 1996 Aug;21(8):282–3.

IRRADIATION, HALF–BODY see **HEMIBODY IRRADIATION**

IRRADIATION, HEMIBODY see **HEMIBODY IRRADIATION**

IRRIGATION

Irrigating fluids in endoscopic surgery. Hahn RG. **Br J Urol** 1997 May;79(5):669–80 (130 ref.)

[Uptake of the irrigating fluid during surgical endoscopy. Measure the absorption by ethanol indication] Hahn R. **Lakartidningen** 1997 Feb 5;94(6):440–3 (33 ref.) **(Swe)**

ADVERSE EFFECTS

Transurethral resection of the prostate (TURP) syndrome: a review of the pathophysiology and management. Gravenstein D. **Anesth Analg** 1997 Feb;84(2):438–46 (97 ref.)

Fluid balance during hysteroscopic surgery. Istre O. **Curr Opin Obstet Gynecol** 1997 Aug;9(4):219–25 (68 ref.)

[Urologic irrigation solutions are not safe. Serious adverse effects are documented] Hahn R. **Lakartidningen** 1997 Feb 5;94(6):437–8 (32 ref.) **(Swe)**

METHODS

Bimanual irrigation/aspiration. Brauweiler P. **J Cataract Refract Surg** 1996 Oct;22(8):1013–6 (7 ref.)

[Immediate resection-anastomosis after intra-operative colonic irrigation in cancer of the left colon with obstruction] Rohr S, et al. **J Chir (Paris)** 1996 Jul; 133(5):195–200 (36 ref.) (Eng. Abstr.) **(Fre)**

IRRITABLE BOWEL SYNDROME see **COLONIC DISEASES, FUNCTIONAL**

IRRITANT DERMATITIS see **DERMATITIS, IRRITANT**

IRRITANTS

ADVERSE EFFECTS

Allergen–irritant interaction and the role of corticosteroids. Davies RJ, et al. **Allergy** 1997;52(38 Suppl):59–65 (30 ref.)

Detergent and skin irritation. Effendy I, et al. **Clin Dermatol** 1996 Jan–Feb;14(1):15–21 (82 ref.)

Prevention by exposure assessment. Flyvholm MA. **Curr Probl Dermatol** 1996;25:97–105 (29 ref.)

The spectrum of irritancy and application of bioengineering techniques. Serup J. **Curr Probl Dermatol** 1995;23:131–43 (26 ref.)

Prevention of surfactant–induced irritant contact dermatitis. Wilhelm KP. **Curr Probl Dermatol** 1996;25:78–85 (21 ref.)

Role of exposure to inhalant irritants and infections for the development of allergic diseases. Björkstén B. **Pediatr Allergy Immunol** 1996;7(9 Suppl):111–6 (37 ref.)

The use of nasal lavage for objective measurement of irritant–induced nasal inflammation. Peden DB. **Regul Toxicol Pharmacol** 1996 Aug;24(1 Pt 2):S76–8 (23 ref.)

The use of cluster significance analysis to identify asymmetric QSAR data sets in toxicology. An example with eye irritation data. Cronin MT. **SAR QSAR Environ Res** 1996; 5(3):167–75 (23 ref.)

PHARMACOKINETICS

Moisturizers in the prevention of contact dermatitis. Hannuksela M. **Curr Probl Dermatol** 1996;25:214–20 (31 ref.)

PHARMACOLOGY

Transcutaneous electrical resistance: application in predicting skin corrosives. Lewis RW, et al. **Curr Probl Dermatol** 1995; 23:243–55 (15 ref.)

TOXICITY

Practical application of non–whole animal alternatives: summary of IRAG workshop on eye irritation testing. Interagency Regulatory Alternatives Group. Bradlaw J, et al. **Food Chem Toxicol** 1997 Jan;35(1):175–8 (0 ref.)

Statistical planning and analysis considerations in the evaluation of in vitro alternatives to whole animal use for eye irritation testing. Feder P, et al. **Food Chem Toxicol** 1997 Jan;35(1):167–74 (6 ref.)

IS ELEMENTS see **DNA INSERTION ELEMENTS**

ISAACS' SYNDROME see **FASCICULATION**

ISCHEMIA

Chronic lower extremity ischemia. Welch HJ. **Compr Ther** 1997 Aug;23(8):534–8 (2 ref.)

Acute mesenteric ischemia. McKinsey JF, et al. **Surg Clin North Am** 1997 Apr;77(2):307–18 (29 ref.)

[Pneumatic tourniquets in orthopedics] Estebe JP, et al. **Ann Fr Anesth Reanim** 1996;15(2):162–78 (211 ref.) (Eng. Abstr.) **(Fre)**

[Circadian patterns of ischemic events] Cafagna D, et al. **Minerva Med** 1996 Oct;87(10):455–64 (95 ref.) (Eng. Abstr.) **(Ita)**

[Ischemia in existing diseases and efficacy of the treatment agents] Higuchi M, et al. **Nippon Yakurigaku Zasshi** 1996 Sep;108(3):108–10 (6 ref.) **(Jpn)**

CHEMICALLY INDUCED

Acute mesenteric ischaemia associated with 5–FU, cisplatin and vincristine chemotherapy. Allerton R. **Clin Oncol (R Coll Radiol)** 1996;8(2):116–7 (15 ref.)

CLASSIFICATION

Critical and subcritical ischaemia. Wolfe JH, et al. **Eur J Vasc Endovasc Surg** 1997 Jun;13(6):578–82 (27 ref.)

Pathophysiological classification of human spinal cord ischemia. Castro–Moure F, et al. **J Spinal Cord Med** 1997 Jan;20(1):74–87 (178 ref.)

[The retinochoroidal ischemia syndrome. Its classification, etiopathogenesis and clinical aspects] Munteanu G. **Oftalmologia** 1996 Jul–Sep;40(3):241–8 (24 ref.) (Eng. Abstr.) **(Rum)**

COMPLICATIONS

Anterior ischemic optic neuropathy. Hayreh SS. **Clin Neurosci** 1997;4(5):251–63 (48 ref.)

Leaky urothelium and/or vesical ischemia enable urinary potassium to cause idiopathic urgency/frequency syndrome and urge incontinence. Hohlbrugger G. **Int Urogynecol J Pelvic Floor Dysfunct** 1996;7(5):242–55 (94 ref.)

[Acute vertigo caused by ischemia of the postero–inferior cerebellar artery or PICA. Apropos of 2 cases] Duclos JY, et al. **Rev Laryngol Otol Rhinol (Bord)** 1997; 118(2):119–24 (18 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Biological basis for PCO2 as a detector of ischemia. Tønnessen TI. **Acta Anaesthesiol Scand** 1997 Jun; 41(6):659–69 (79 ref.)

The application of magnetic resonance techniques to the evaluation of the patient with sickle–cell disease. Terk MR, et al. **Biomed Instrum Technol** 1996 Jul–Aug;30(4):349–53 (12 ref.)

The rationale and utility of neurophysiological investigations in clinical monitoring for brain and spinal cord ischaemia during surgery and intensive care. Prior P. **Comput Methods Programs Biomed** 1996 Oct;51(1–2):13–27 (101 ref.)

Does gastric tonometry work? No. Benjamin E, et al. **Crit Care Clin** 1996 Jul;12(3):587–601 (77 ref.)

A rapidly progressive ischemic enteropathy with malabsorption syndrome. Case report. Cicchinelli M, et al. **Minerva Gastroenterol Dietol** 1996 Jun;42(2):103–5 (11 ref.)

MR angiography of abdominal ischemia. Li KC. **Semin Ultrasound CT MR** 1996 Aug;17(4):352–9 (35 ref.)

History of mesenteric ischemia. The evolution of a diagnosis and management. Boley SJ, et al. **Surg Clin North Am** 1997 Apr;77(2):275–88 (90 ref.)

Chronic mesenteric ischemia. Clinical presentation and diagnosis. Moawad J, et al. **Surg Clin North Am** 1997 Apr; 77(2):357–69 (35 ref.)

Limb salvage in peripheral vascular trauma. Adebo O. **West Afr J Med** 1996 Jul–Sep;15(3):139–42 (33 ref.)

[Radiology and geriatrics: limits between normal values and pathology exemplified by conventional thoracic roentgen image, cerebral CT and MRI and pelvic–leg angiography] Osterheider MA. **Z Gerontol Geriatr** 1997 May–Jun; 30(3):226–34 (17 ref.) (Eng. Abstr.) **(Ger)**

[The current state of the diagnosis and treatment of acute mesenteric ischemia] Loba MM, et al. **Klin Khir** 1996; (7):40–3 (49 ref.) **(Ukr)**

DRUG THERAPY

Defibrotide as a possible anti–ischemic drug. Coccheri S, et al. **Semin Thromb Hemost** 1996;22 Suppl 1:9–14 (42 ref.)

ETIOLOGY

Mesenteric ischemia secondary to cocaine abuse: case reports and literature review. Sudhakar CB, et al. **Am J Gastroenterol** 1997 Jun;92(6):1053–4 (12 ref.)

Atherosclerotic ischemic renal disease. Greco BA, et al. **Am J Kidney Dis** 1997 Feb;29(2):167–87 (144 ref.)

'Trash foot' following operations involving the abdominal aorta. Kuhan G, et al. **Aust N Z J Surg** 1997 Jan;67(1):21–4 (14 ref.)

Evaluation of the white finger risk prediction model in ISO 5349 suggests need for prospective studies. Gemne G, et al. **Cent Eur J Public Health** 1996 May;4(2):137–9 (23 ref.)

Vascular disease of the lower extremities in diabetes mellitus. LoGerfo FW, et al. **Endocrinol Metab Clin North Am** 1996 Jun;25(2):439–45 (27 ref.)

Horton giant cell arteritis of the legs. Report of a case. Amatucci G, et al. **J Cardiovasc Surg (Torino)** 1997 Jun; 38(3):309–12 (14 ref.)

Role of cross talk between superoxide and NO in the energy metabolism and pathogenesis of vasogenic tissue injury. Inoue M. **J Toxicol Sci** 1996 Dec;21(5):289 (0 ref.)

Isolated stab wound to the artery of Adamkiewicz: case report and review of the literature. Rogers FB, et al. **J Trauma** 1997 Sep;43(3):549–51 (18 ref.)

Leukocytes, cell adhesion molecules and ischemic acute renal failure. Rabb H, et al. **Kidney Int** 1997 May;51(5):1463–8 (31 ref.)

Unusual causes of mesenteric ischemia. Krupski WC, et al. **Surg Clin North Am** 1997 Apr;77(2):471–502 (80 ref.)

["Saint Anthony's fire:" ergotamine–induced vascular spasms as the cause of acute ischemic syndrome] Rosenkranz S, et al. **Dtsch Med Wochenschr** 1997 Apr 4;122(14):450–4 (51 ref.) **(Ger)**

[Ischemic complications of accidental intra–arterial injection in drug addicts] Haj–Yahia S, et al. **Harefuah** 1996 Sep; 131(5–6):178–80 (33 ref.) **(Heb)**

IMMUNOLOGY

Gut dysfunction in critically ill patients: a review of the literature. Stechmiller JK, et al. **Am J Crit Care** 1997 May; 6(3):204–9 (66 ref.)

METABOLISM

Calcium handling by hippocampal neurons under physiologic and pathologic conditions. Erecinska M, et al. **Adv Neurol** 1996;71:119–36 (176 ref.)

Rapid monitoring of gastrointestinal intraluminal PCO2 as an end–organ perfusion index [editorial; comment] Tao W, et al. **Crit Care Med** 1997 Sep;25(9):1458–9 (28 ref.) Comment on: Crit Care Med 1997 Sep;25(9):1575–8.

Metabolic and clonogenic consequences of ischaemia reperfusion insult in solid tumours. Parkins CS, et al. **Exp Physiol** 1997 Mar;82(2):361–8 (22 ref.)

Regulation of thermotolerance and ischemic tolerance. Nagata K. **EXS** 1996;77:467–81 (51 ref.)

Role of cross talk between superoxide and NO in the energy metabolism and pathogenesis of vasogenic tissue injury. Inoue M. **J Toxicol Sci** 1996 Dec;21(5):289 (0 ref.)

PATHOLOGY

Endothelial damage caused by ischemia and reperfusion and different ventilatory strategies in the lung. Moore TM, et al. **Chin J Physiol** 1996;39(2):65–81 (132 ref.)

PHYSIOPATHOLOGY

Graded restriction of blood flow in exercising leg muscles: a human model. Bjurstedt H, et al. **Adv Exp Med Biol** 1995; 381:147–56 (32 ref.)

Hemodynamic factors in acute renal failure. Conger J. **Adv Ren Replace Ther** 1997 Apr;4(2 Suppl 1):25–37 (99 ref.)

Renal stress response and acute renal failure. Safirstein R. **Adv Ren Replace Ther** 1997 Apr;4(2 Suppl 1):38–42 (25 ref.)

Putting the actin cytoskeleton into perspective: pathophysiology of ischemic alterations. Molitoris BA. **Am J Physiol** 1997 Apr;272(4 Pt 2):F430–3 (28 ref.)

Relationships of the circadian rhythms of thrombotic, ischemic, hemorrhagic, and arrhythmic events to blood pressure rhythms. Manfredini R, et al. **Ann N Y Acad Sci** 1996 Aug 15;783:141–58 (183 ref.)

Endothelial damage caused by ischemia and reperfusion and different ventilatory strategies in the lung. Moore TM, et al. **Chin J Physiol** 1996;39(2):65–81 (132 ref.)

Ischemic optic neuropathy: models for mechanism of disease. Potarazu SV. **Clin Neurosci** 1997;4(5):264–9 (22 ref.)

Ischemic renal failure. Zucchelli P, et al. **Contrib Nephrol** 1996;119:59–66 (45 ref.)

Ischaemic renal injury. Alcázar JM, et al. **Curr Opin Nephrol Hypertens** 1997 Mar;6(2):157–65 (105 ref.)

Endothelin in ischemic acute renal failure. Hunley TE, et al. **Curr Opin Nephrol Hypertens** 1997 Jul;6(4):394–400 (76 ref.)

Ischemic conditioning of the stomach may reduce the incidence of esophagogastric anastomotic leaks complicating esophagectomy: a hypothesis. Urschel JD. **Dis Esophagus** 1997 Jul;10(3):217–9 (23 ref.)

Metabolic and clonogenic consequences of ischaemia reperfusion insult in solid tumours. Parkins CS, et al. **Exp Physiol** 1997 Mar;82(2):361–8 (22 ref.)

Mechanisms of postischemic injury in skeletal muscle: intervention strategies. Rubin BB, et al. **J Appl Physiol** 1996 Feb;80(2):369–87 (220 ref.)

The microvascular cell and ischemia–reperfusion injury. Verrier E. **J Cardiovasc Pharmacol** 1996;27 Suppl 1:S26–30 (20 ref.)

Leukocyte responses to hypoxic/ischemic conditions. Scannell G. **New Horiz** 1996 May;4(2):179–83 (27 ref.)

The pathophysiological role of peroxynitrite in shock, inflammation, and ischemia–reperfusion injury. Szabó C. **Shock** 1996 Aug;6(2):79–88 (162 ref.)

[What is the role of the sympathetic nervous system in digital vasospasms?] Gasser P. **Schweiz Rundsch Med Prax** 1996 Oct 15;85(42):1320–3 (31 ref.) (Eng. Abstr.) **(Ger)**

[The basic patterns of the ischemic and reperfusion changes in the tissues of the ischemic extremity and in the whole body] Tsapenko MV. **Klin Khir** 1996;(9):44–9 (49 ref.) **(Ukr)**

RADIOGRAPHY

CT findings in ischaemic hepatic failure due to intra–arterial embolisation: a case report. Catalano O. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Jan;166(1):81–3 (18 ref.)

ISCHEMIA

SURGERY

Treatment of thromboembolic complications of fulminant meningococcal septic shock. Mele JA 3rd, et al. **Ann Plast Surg** 1997 Mar;38(3):283–90 (29 ref.)

Upper extremity arterial bypass distal to the wrist. Dalman RL. **Ann Vasc Surg** 1997 Sep;11(5):550–7 (55 ref.)

Kidney salvage in a case of ruptured renal artery aneurysm: case report and literature review. Schorn B, et al. **Cardiovasc Surg** 1997 Feb;5(1):134–6 (21 ref.)

Management of severe ischemia of the upper extremity. Pederson WC. **Clin Plast Surg** 1997 Jan;24(1):107–20 (56 ref.)

Management of vasospastic disorders of the hand. Troum SJ, et al. **Clin Plast Surg** 1997 Jan;24(1):121–32 (50 ref.)

Horton giant cell arteritis of the legs. Report of a case. Amatucci G, et al. **J Cardiovasc Surg (Torino)** 1997 Jun; 38(3):309–12 (14 ref.)

History of mesenteric ischemia. The evolution of a diagnosis and management. Boley SJ, et al. **Surg Clin North Am** 1997 Apr;77(2):275–88 (90 ref.)

[Reduction of amputation incidence and mortality following prolonged ischemia of the lower limbs. Value of a controlled reperfusion?] Defraigne JO, et al. **Rev Med Liege** 1996 Aug;51(8):534–44 (57 ref.) **(Fre)**

[CT-guided neurolysis. Status of the technique and current results] Schneider B, et al. **Radiologe** 1996 Sep;36(9):692–9 (24 ref.) (Eng. Abstr.) **(Ger)**

[Distal popliteal bypass in the diabetic patient. Clinical case] Cavallini M, et al. **Minerva Chir** 1996 Jul–Aug; 51(7–8):589–95 (23 ref.) (Eng. Abstr.) **(Ita)**

[Laparoscopic second-look in acute intestinal ischemia] Tola M, et al. **Minerva Chir** 1997 May;52(5):527–30 (11 ref.) (Eng. Abstr.) **(Ita)**

[Critical limb ischemia] Iwai T. **Nippon Geka Gakkai Zasshi** 1996 Jul;97(7):486–91 (13 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Angiogenic gene therapy. A leg to stand on? [editorial; comment] Fox JC, et al. **Circulation** 1996 Dec 15; 94(12):3065–6 (11 ref.) Comment on: Circulation 1996 Dec 15;94(12):3281–90.

A little VEGF goes a long way. Therapeutic angiogenesis by direct injection of vascular endothelial growth factor-encoding plasmid DNA [editorial; comment] Majesky MW. **Circulation** 1996 Dec 15;94(12):3062–4 (17 ref.) Comment on: Circulation 1996 Dec 15;94(12):3281–90.

Critical and subcritical ischaemia. Wolfe JH, et al. **Eur J Vasc Endovasc Surg** 1997 Jun;13(6):578–82 (27 ref.)

Gene therapy with angiogenic factors: a new potential approach to the treatment of ischemic diseases. Safi J Jr, et al. **J Mol Cell Cardiol** 1997 Sep;29(9):2311–25 (128 ref.)

Limb salvage in peripheral vascular trauma. Adebo O. **West Afr J Med** 1996 Jul–Sep;15(3):139–42 (33 ref.)

[Peripheral arterial occlusive disease. Diagnosis and modern conservative therapy] Zinnagl N. **Hautarzt** 1996 Jan; 47(1):70–8 (11 ref.) **(Ger)**

[Intestinal reperfusion: the physiopathological fundamentals of its therapeutic prospects] Rodríguez García JI, et al. **Rev Esp Enferm Dig** 1997 Jan;89(1):39–45 (74 ref.) **(Spa)**

ISCHEMIA, MYOCARDIAL see **MYOCARDIAL ISCHEMIA**

ISCHEMIA-REPERFUSION INJURY see **REPERFUSION INJURY**

ISCHEMIC COLITIS see **COLITIS, ISCHEMIC**

ISCHEMIC HEART DISEASE see **MYOCARDIAL ISCHEMIA**

ISCHEMIC OPTIC NEUROPATHY see **OPTIC NEUROPATHY, ISCHEMIC**

ISCHEMIC PRECONDITIONING

Protection against ischemic-reperfusion injury of skeletal muscle: role of ischemic preconditioning and adenosine pretreatment. Lee HT, et al. **J Reconstr Microsurg** 1996 Aug;12(6):383–8 (39 ref.)

Mechanisms of ischemic preconditioning. Ishida T, et al. **Shock** 1997 Aug;8(2):86–94 (117 ref.)

ISCHEMIC PRECONDITIONING, MYOCARDIAL

Bradykinin and endothelial-cardiac myocyte interactions in ischemic preconditioning. Parratt JR, et al. **Am J Cardiol** 1997 Aug 4;80(3A):124A–131A (49 ref.)

Cardioprotection induced by ischemic preconditioning in the mammalian heart: effects on arrhythmogenesis. Lukas A, et al. **Can J Physiol Pharmacol** 1997 Apr;75(4):316–25 (102 ref.)

Controversies in preconditioning. de Jong JW, et al. **Cardiovasc Drugs Ther** 1997 Jan;10(6):767–73 (62 ref.)

Does protein kinase C play a pivotal role in the mechanisms of ischemic preconditioning? Gho BC, et al. **Cardiovasc Drugs Ther** 1997 Jan;10(6):775–86 (83 ref.)

Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration. Engler RL, et al. **Circulation** 1996 Nov 1;94(9):2297–301 (66 ref.)

Ischemic preconditioning: clinical relevance and investigative studies. Schlaifer JD, et al. **Clin Cardiol** 1997 Jul; 20(7):602–6 (24 ref.)

Myocardial preconditioning. What have we learned? Sumeray MS, et al. **Eur Heart J** 1997 Jan;18 Suppl A:A8–14 (83 ref.)

Ischaemic preconditioning and cardiac surgery. Alkhulaifi AM, et al. **Eur J Cardiothorac Surg** 1996;10(9):792–8 (46 ref.)

Ischemic preconditioning against infarction: its mechanism and clinical implications. Miura T, et al. **EXS** 1996; 76:365–82 (63 ref.)

Delayed protection of the ischemic heart--from pathophysiology to therapeutic applications. Richard V, et al. **Fundam Clin Pharmacol** 1996;10(5):409–15 (84 ref.)

Myocardial stunning, hibernation, and ischemic preconditioning. Vroom MB, et al. **J Cardiothorac Vasc Anesth** 1996 Oct;10(6):789–99 (131 ref.)

Myocardial, neural and vascular aspects of ischemic preconditioning. Losano G, et al. **Life Sci** 1996; 59(15):1185–92 (61 ref.)

Salvage of jeopardized myocardium by ischemic preconditioning: is the quest over? Strasser R, et al. **Mol Cell Biochem** 1996 Jul–Aug;160–161:209–15 (31 ref.)

[Ischemic preconditioning: the potentials and limits of the analysis and use of endogenous myocardial protection in man] Heidland UE, et al. **Dtsch Med Wochenschr** 1997 Jan 17;122(3):65–70 (46 ref.) **(Ger)**

[The role of adenosine in "ischemic preconditioning"] Schaper W, et al. **Z Kardiol** 1996;85 Suppl 6:185–90 (34 ref.) (Eng. Abstr.) **(Ger)**

[Myocardial protection from ischemic damage: effects of preconditioning and pharmacologic activation of KATP channels] Galiè N, et al. **Cardiologia** 1995 Dec;40(12 Suppl 1):77–82 (23 ref.) **(Ita)**

[Clinical relevance of ischemic preconditioning] Tomai F, et al. **Cardiologia** 1997 Jul;42(7):693–9 (58 ref.) **(Ita)**

[Mechanisms of ischemic preconditioning: relation with ischemia-reperfusion injury] Gattullo D, et al. **G Ital Cardiol** 1997 Mar;27(3):288–96 (66 ref.) (Eng. Abstr.) **(Ita)**

ISCHIUM

ABNORMALITIES

Minimally united ischiopagus twins: infraumbilical union with cloacal anomalies. Spencer R. **J Pediatr Surg** 1996 Nov; 31(11):1538–45 (25 ref.)

ISCOMS

see related
SAPONINS

[Iscom (Immuno Stimulating Complex)-vaccine of equine influenza virus--transmission electron microscopic investigation and literature review] Brügmann M, et al. **DTW Dtsch Tierarztl Wochenschr** 1997 Jun;104(6):196–202 (61 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

ISCOMs (immunostimulating complexes): the first decade. Barr IG, et al. **Immunol Cell Biol** 1996 Feb;74(1):8–25 (152 ref.)

ISLAM

see related
ARABS

Issues in forensic psychiatry in Islamic jurisprudence. Chaleby KS. **Bull Am Acad Psychiatry Law** 1996; 24(1):117–24 (21 ref.)

Ramadan fasting--effects on health and disease. Malik GM, et al. **J Assoc Physicians India** 1996 May;44(5):332–4 (15 ref.)

Minisymposium. Definition of death, organ donation and interruption of treatment of Islam. Hassaballah AM. **Nephrol Dial Transplant** 1996 Jun;11(6):964–5 (10 ref.)

[Sexuality and religions] Chaix-Durand G, et al. **Contracept Fertil Sex** 1997 Mar;25(3):I–XIII (26 ref.) **(Fre)**

ISLAND FLAPS see **SURGICAL FLAPS**

ISLANDS OF LANGERHANS see **ISLETS OF LANGERHANS**

ISLET-ACTIVATING PROTEIN see **PERTUSSIS TOXINS**

ISLET CELL TUMOR see **ADENOMA, ISLET CELL**

ISLET CELL TUMOR, MALIGNANT see **CARCINOMA, ISLET CELL**

ISLET CELL TUMOR, ULCEROGENIC see **ZOLLINGER-ELLISON SYNDROME**

ISLETS OF LANGERHANS

CYTOLOGY

Cell death mediators in autoimmune diabetes--no shortage of suspects. Benoist C, et al. **Cell** 1997 Apr 4;89(1):1–3 (16 ref.)

Collagenase and human islet isolation. Johnson PR, et al. **Cell Transplant** 1996 Jul–Aug;5(4):437–52 (189 ref.)

Applications of confocal and fluorescence microscopy. Pedley KC. **Digestion** 1997;58 Suppl 2:62–8 (31 ref.)

Pancreatic development and maturation of the islet B cell. Studies of pluripotent islet cultures. Madsen OD, et al. **Eur J Biochem** 1996 Dec 15;242(3):435–45 (125 ref.)

Diabetes mellitus and impaired pancreatic beta-cell proliferation. Sjöholm A. **J Intern Med** 1996 Mar; 239(3):211–20 (87 ref.)

Insulin-dependent diabetes mellitus: the hypothesis of molecular mimicry between islet cell antigens and microorganisms. Maclaren NK, et al. **Mol Med Today** 1997 Feb;3(2):76–83 (37 ref.)

DRUG EFFECTS

Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells. Kramer W, et al. **Horm Metab Res** 1996 Sep;28(9):464–8 (36 ref.)

Factors determining the glucose sensitivity and glucose responsiveness of pancreatic beta cells. Schuit FC. **Horm Res** 1996;46(3):99–106 (80 ref.)

Pancreatic B-cell dysfunction and glucose toxicity in non-insulin-dependent diabetes. Flatt PR, et al. **Proc Nutr Soc** 1997 Mar;56(1B):243–62 (75 ref.)

EMBRYOLOGY

[Transplantation of cultured Langerhans cells of fetal pancreas in the treatment of insulin-dependent diabetes mellitus] Skaletskiĭ NN, et al. **Biull Eksp Biol Med** 1994 Apr;117(4):356–63 (80 ref.) **(Rus)**

ENZYMOLOGY

Regulation of overexpressed hexokinases in liver and islet cells. Newgard CB, et al. **Biochem Soc Trans** 1997 Feb; 25(1):118–22 (26 ref.)

The harmony of the spheres: inducible nitric oxide synthase and related genes in pancreatic beta cells. Eizirik DL, et al. **Diabetologia** 1996 Aug;39(8):875–90 (166 ref.)

Hyperexpression of GAD in the islets may be relevant but is it sufficient to induce autoimmune insulitis? [comment] Pozzilli P, et al. **Diabetologia** 1997 Mar;40(3):357–61 (28 ref.) Comment on: Diabetologia 1997 Mar;40(3):352–6.

GROWTH & DEVELOPMENT

Induction of pancreatic islet neogenesis. Vinik A, et al. **Horm Metab Res** 1997 Jun;29(6):278–93 (165 ref.)

IMMUNOLOGY

Pathogenesis and treatment of virus-induced autoimmune diabetes: novel insights gained from the RIP-LCMV transgenic mouse model. von Herrath MG, et al. **Biochem Soc Trans** 1997 May;25(2):630–5 (55 ref.)

The immune response to islets in experimental diabetes and insulin-dependent diabetes mellitus. Wegmann DR. **Curr Opin Immunol** 1996 Dec;8(6):860–4 (39 ref.)

Protein tyrosine phosphatase-like proteins: link with IDDM. Pietropaolo M, et al. **Diabetes Care** 1997 Feb;20(2):208–14 (42 ref.)

Islet cell autoimmunity in women with gestational diabetes and risk of progression to insulin-dependent diabetes mellitus. Mauricio D, et al. **Diabetes Metab Rev** 1996 Dec; 12(4):275–85 (66 ref.)

The role of interleukin-1 in the pathogenesis of IDDM. Mandrup-Poulsen T. **Diabetologia** 1996 Sep;39(9):1005–29 (316 ref.)

Hyperexpression of GAD in the islets may be relevant but is it sufficient to induce autoimmune insulitis? [comment] Pozzilli P, et al. **Diabetologia** 1997 Mar;40(3):357–61 (28 ref.) Comment on: Diabetologia 1997 Mar;40(3):352–6.

Islet cell autoantigens in type 1 diabetes. Christie MR. **Eur J Clin Invest** 1996 Oct;26(10):827–38 (81 ref.)

Macrophages in islet destruction in autoimmune diabetes mellitus. Burkart V, et al. **Immunobiology** 1996 Oct; 195(4–5):601–13 (49 ref.)

Using transgenic mouse models to dissect the pathogenesis of virus-induced autoimmune disorders of the islets of Langerhans and the central nervous system. von Herrath MG, et al. **Immunol Rev** 1996 Aug;152:111–43 (190 ref.)

Autoimmune diabetes: the role of the islets of Langerhans. Homo-Delarche F, et al. **Immunol Today** 1996 Oct; 17(10):456–60 (92 ref.)

Insulin-dependent diabetes mellitus: the hypothesis of molecular mimicry between islet cell antigens and microorganisms. Maclaren NK, et al. **Mol Med Today** 1997 Feb;3(2):76–83 (37 ref.)

[Analysis of the mechanism of the development of insulin-dependent diabetes mellitus and an attempt to prevent its onset by the functional T cell molecules] Yokono K, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Dec;19(6):618–21 (4 ref.) **(Jpn)**

METABOLISM

Molecular mechanism underlying glucagon-like peptide 1 induced calcium mobilization from internal stores in insulin-secreting beta TC3 cells. Gromada J, et al. **Acta Physiol Scand** 1996 Jul;157(3):349-51 (7 ref.)

Mechanisms of inhibition of insulin release. Sharp GW. **Am J Physiol** 1996 Dec;271(6 Pt 1):C1781-99 (135 ref.)

Regulation of insulin secretion by phospholipase C. Zawalich WS, et al. **Am J Physiol** 1996 Sep;271(3 Pt 1):E409-16 (64 ref.)

Endoprotease regulation of miniglucagon production. Bataille D, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:1-8; discussion 8-9 (12 ref.)

Essential biochemical design features of the fuel-sensing system in pancreatic beta-cells. Matschinsky FM, et al. **Chem Biol** 1997 Apr;4(4):249-57 (34 ref.)

Is GLUT2 required for glucose sensing? Schuit FC. **Diabetologia** 1997 Jan;40(1):104-11 (67 ref.)

Are there kinetic advantages of GLUT2 in pancreatic glucose sensing? Sweet IR, et al. **Diabetologia** 1997 Jan;40(1):112-9 (16 ref.)

Characterization of ion channels in stimulus-secretion coupling in pancreatic islets. Ammälä C, et al. **Digestion** 1997;58 Suppl 2:81-5 (21 ref.)

IGF-I and IGF-II: expression and function in the endocrine pancreas. Fehmann HC, et al. **Exp Clin Endocrinol Diabetes** 1995;103 Suppl 2:37-41 (38 ref.)

Regulation of islet hormone gene expression by incretin hormones. Fehmann HC, et al. **Exp Clin Endocrinol Diabetes** 1995;103 Suppl 2:56-65 (60 ref.)

Neurotrophin and neurotrophin receptors in islet cells. Scharfmann R. **Horm Metab Res** 1997 Jun;29(6):294-6 (13 ref.)

Transgenic overproduction of islet amyloid polypeptide (amylin) is not sufficient for islet amyloid formation. Verchere CB, et al. **Horm Metab Res** 1997 Jun;29(6):311-6 (33 ref.)

Pancreatic B-cell dysfunction and glucose toxicity in non-insulin-dependent diabetes. Flatt PR, et al. **Proc Nutr Soc** 1997 Mar;56(1B):243-62 (75 ref.)

MICROBIOLOGY

The role of enteroviral infections in the development of IDDM: limitations of current approaches. Graves PM, et al. **Diabetes** 1997 Feb;46(2):161-8 (59 ref.)

PATHOLOGY

Islet pathology of non-insulin-dependent diabetes mellitus (NIDDM). Westermark P. **Diabet Med** 1996 Sep;13(9 Suppl 6):S46-8 (23 ref.)

Macrophages in islet destruction in autoimmune diabetes mellitus. Burkart V, et al. **Immunobiology** 1996 Oct; 195(4-5):601-13 (49 ref.)

Autoimmune diabetes: the role of the islets of Langerhans. Homo-Delarche F, et al. **Immunol Today** 1996 Oct; 17(10):456-60 (92 ref.)

[Etiology and pathogenesis of insulin-dependent diabetes mellitus] Klöppel G, et al. **Verh Dtsch Ges Pathol** 1996; 80:93-103 (67 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Regulation, perturbation, and correction of metabolic events in pancreatic islets. Malaisse WJ. **Acta Diabetol** 1996 Sep; 33(3):173-9 (52 ref.)

Effects of prolonged glucose stimulation on pancreatic beta cells: from increased sensitivity to desensitization. Purrello F, et al. **Acta Diabetol** 1996 Dec;33(4):253-6 (18 ref.)

Contributions of modeling to understanding stimulus-secretion coupling in pancreatic beta-cells. Sherman A. **Am J Physiol** 1996 Aug;271(2 Pt 1):E362-72 (70 ref.)

PACAP/VIP receptors in pancreatic beta-cells: their roles in insulin secretion. Inagaki N, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:44-51; discussion 52-3 (23 ref.)

Enhancement of glucose-induced insulin secretion in transgenic mice overexpressing human VIP gene in pancreatic beta cells. Kato I, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:232-42; discussion 242-3 (28 ref.)

Signal transduction of PACAP and GLP-1 in pancreatic beta cells. Leech CA, et al. **Ann N Y Acad Sci** 1996 Dec 26; 805:81-92; discussion 92-3 (44 ref.)

Pancreatic beta-cell receptors and G proteins coupled to adenylyl cyclase. Marie JC, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:122-31; discussion 132 (61 ref.)

Regulation of insulin gene transcription by nutrients. Docherty K, et al. **Biochem Soc Trans** 1996 May; 24(2):368-72 (35 ref.)

Pancreatic B-cells as mediators of metabolic effects of regulatory peptides. Flatt PR. **Biochem Soc Trans** 1996 May;24(2):570-5 (33 ref.)

Gap junction involvement in secretion: the pancreas experience. Meda P. **Clin Exp Pharmacol Physiol** 1996 Dec; 23(12):1053-7 (42 ref.)

Interleukin-1beta-mediated beta-cell inhibition in vivo. Bach LW. **Dan Med Bull** 1996 Feb;43(1):39-57 (282 ref.)

Toward an integrated phenotype in pre-NIDDM. Bergman RN, et al. **Diabet Med** 1996 Sep;13(9 Suppl 6):S67-77 (37 ref.)

Beta-cell behavior during the prediabetic stage. Part I. Beta-cell pathophysiology. Homo-Delarche F. **Diabetes Metab** 1997 Jun;23(3):181-94 (123 ref.)

Induction of beta-cell neogenesis by islet injury. Teitelman G. **Diabetes Metab Rev** 1996 Jul;12(2):91-102 (45 ref.)

The pancreatic beta-cell as a fuel sensor: an electrophysiologist's viewpoint. Rorsman P. **Diabetologia** 1997 May;40(5):487-95 (56 ref.)

Role of potassium channels in the modulation of insulin release [comment] Smits P. **Diabetologia** 1996 Jul; 39(7):865-7 (17 ref.) Comment on: Diabetologia 1996 Jul;39(7):861-4.

Protein kinase C signalling in pancreatic beta-cells: cellular and molecular approaches. Persaud SJ. **Digestion** 1997;58 Suppl 2:86-92 (32 ref.)

IGF-I and IGF-II: expression and function in the endocrine pancreas. Fehmann HC, et al. **Exp Clin Endocrinol Diabetes** 1995;103 Suppl 2:37-41 (38 ref.)

Application of molecular genetics to the study of beta-cell function and diabetes mellitus. Poller WC. **Exp Clin Endocrinol Diabetes** 1995;103 Suppl 2:15-22 (81 ref.)

Peptide hormone regulation of islet cells. D'Alessio D. **Horm Metab Res** 1997 Jun;29(6):297-300 (32 ref.)

Islet regeneration in IFNgamma transgenic mice. Jones EM, et al. **Horm Metab Res** 1997 Jun;29(6):308-10 (32 ref.)

Transcription factors contributing to the pancreatic beta-cell phenotype. Madsen OD, et al. **Horm Metab Res** 1997 Jun; 29(6):265-70 (60 ref.)

Adaptation of islets of Langerhans to pregnancy: beta-cell growth, enhanced insulin secretion and the role of lactogenic hormones. Sorenson RL, et al. **Horm Metab Res** 1997 Jun;29(6):301-7 (59 ref.)

Molecular mechanisms of beta-cell destruction in IDDM: the role of nicotinamide. Gale EA. **Horm Res** 1996;45 Suppl 1:39-43 (22 ref.)

The beta cell transcription factors and development of the pancreas. Sander M, et al. **J Mol Med** 1997 May; 75(5):327-40 (129 ref.)

Role of selected peptides in the vagal regulation of gastric motor and endocrine pancreatic function. Krowicki ZK. **J Physiol Pharmacol** 1996 Sep;47(3):399-409 (55 ref.)

The intrinsic rhythmicity of spike-burst generation in pancreatic beta-cells and intercellular interaction within an islet. Kitasato H, et al. **Jpn J Physiol** 1996 Oct; 46(5):363-73 (71 ref.)

PHYSIOPATHOLOGY

Pharmacology of the endocrine pancreas, adrenal cortex, and female reproductive organ. Huber MA, et al. **Dent Clin North Am** 1996 Jul;40(3):753-77 (118 ref.)

From sand rats to diabetic patients: is non-insulin-dependent diabetes mellitus a disease of the beta cell? Cerasi E, et al. **Diabetes Metab** 1997 Mar;23 Suppl 2:47-51 (44 ref.)

[Amylin/IAPP (islet amyloid polypeptide)--physiology and clinical significance] Ludvik B. **Wien Klin Wochenschr** 1997 Jun 6;109(11):379-83 (41 ref.) (Eng. Abstr.) **(Ger)**

SECRETION

Genetic engineering of insulin expression in nonislet cells: implications for beta-cell replacement therapy for insulin-dependent diabetes mellitus. Lipes MA, et al. **Acta Diabetol** 1997 Mar;34(1):2-5 (22 ref.)

Contributions of modeling to understanding stimulus-secretion coupling in pancreatic beta-cells. Sherman A. **Am J Physiol** 1996 Aug;271(2 Pt 1):E362-72 (70 ref.)

Insulin secretion and its modulation by antiarrhythmic and sulfonylurea drugs. Horie M, et al. **Cardiovasc Res** 1997 Apr;34(1):69-72 (42 ref.)

Gap junction involvement in secretion: the pancreas experience. Meda P. **Clin Exp Pharmacol Physiol** 1996 Dec; 23(12):1053-7 (42 ref.)

Oscillatory insulin secretion: a variable phenotypic marker. Matthews DR. **Diabet Med** 1996 Sep;13(9 Suppl 6):S53-8 (15 ref.)

Normal physiology and phenotypic characterization of beta-cell function in subjects at risk for non-insulin-dependent diabetes mellitus. Porte D Jr. **Diabet Med** 1996 Sep;13(9 Suppl 6):S25-32 (32 ref.)

Hyper- and hypoinsulinemia in type-2 diabetes: what may be wrong in the secretory mechanism of the B-cell. Ammon HP. **Exp Clin Endocrinol Diabetes** 1997;105 Suppl 2:43-7 (22 ref.)

[Insulin secretion--assay method and its significance] Emoto M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:418-22 (6 ref.) **(Jpn)**

[Tolbutamide, glucagon, leucine and arginine tolerance test] Hosaka T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:423-7 (10 ref.) **(Jpn)**

ISLETS OF LANGERHANS TRANSPLANTATION

Scientific and political impediments to successful islet transplantation. Weir GC, et al. **Diabetes** 1997 Aug; 48(8):1247-56 (110 ref.)

Perspectives in pancreatic and islet cell transplantation for the therapy of IDDM. Calafiore R. **Diabetes Care** 1997 May;20(5):889-96 (62 ref.)

Islet cell transplantation: beyond the paradigms. Kenyon NS, et al. **Diabetes Metab Rev** 1996 Dec;12(4):361-72 (70 ref.)

Islet transplantation: an update. Sutherland DE, et al. **Diabetes Metab Rev** 1996 Jul;12(2):137-50 (120 ref.)

Islet transplantation in immunoseparating membranes for treatment of insulin-dependent diabetes mellitus. Zekorn T, et al. **Exp Clin Endocrinol Diabetes** 1995;103 Suppl 2:136-9 (20 ref.)

Pancreas and islet transplantation: current progresses, problems and perspectives. Secchi A, et al. **Horm Metab Res** 1997 Jan;29(1):1-8 (45 ref.)

Pancreatic islet allograft immunity and tolerance: the two-signal hypothesis revisited. Gill RG, et al. **Immunol Rev** 1996 Feb;149:75-96 (94 ref.)

New approaches for control of anti-self-reactivity in type 1 diabetes and transplantation of pancreatic islets. Slavin S, et al. **Transplant Proc** 1997 Jun;29(4):1929-31 (15 ref.)

[Islet cell and pancreas transplantation in diabetes: status 1996] Bretzel RG. **Ther Umsch** 1996 Dec;53(12):889-901 (51 ref.) (Eng. Abstr.) **(Ger)**

[Transplantation of human fetal tissues--a promising method of treatment of diabetes mellitus] Malaitsev VV, et al. **Biull Eksp Biol Med** 1994 Apr;117(4):350-5 (55 ref.) **(Rus)**

[Transplantation of cultured Langerhans cells of fetal pancreas in the treatment of insulin-dependent diabetes mellitus] Skaletskii NN, et al. **Biull Eksp Biol Med** 1994 Apr;117(4):356-63 (80 ref.) **(Rus)**

IMMUNOLOGY

Aspects of immunoprotection of islets. van Schilfgaarde R, et al. **Transplant Proc** 1996 Dec;28(6):3516-7 (11 ref.)

METHODS

Aspects of immunoprotection of islets. van Schilfgaarde R, et al. **Transplant Proc** 1996 Dec;28(6):3516-7 (11 ref.)

[Pancreas transplantation--between experiment and clinical method] Klempnauer J, et al. **Internist (Berl)** 1996 Mar; 37(3):289-94 (23 ref.) **(Ger)**

[Current aspects of islet cell transplantation] Schrezenmeir J, et al. **Med Klin** 1996 Feb 15;91 Suppl 1:19-24 (31 ref.) **(Ger)**

PATHOLOGY

Prevention of type I diabetes and recurrent beta-cell destruction of transplanted islets. Slover RH, et al. **Endocr Rev** 1997 Apr;18(2):241-58 (259 ref.)

PHYSIOLOGY

Islet cell transplantation in diabetes mellitus--from bench to bedside. Bretzel RG, et al. **Exp Clin Endocrinol Diabetes** 1995;103 Suppl 2:143-59 (113 ref.)

ISOANTIBODIES

see related
BLOOD GROUPS

BLOOD

Female alloimmunization with antibodies known to cause hemolytic disease. Geifman-Holtzman O, et al. **Obstet Gynecol** 1997 Feb;89(2):272-5 (18 ref.)

DIAGNOSTIC USE

Advances in the use of monoclonal antibodies for blood group testing. Rouger P, et al. **Transfus Clin Biol** 1997 Jul; 4(4):345-9 (14 ref.)

IMMUNOLOGY

Antibodies to von Willebrand factor in von Willebrand disease. Mannucci PM, et al. **Adv Exp Med Biol** 1995; 386:87-92 (23 ref.)

Epitope specificity and functional characterization of factor VIII inhibitors. Scandella D, et al. **Adv Exp Med Biol** 1995; 386:47-63 (20 ref.)

Inhibitors in congenital haemophilia. Brettler DB. **Baillieres Clin Haematol** 1996 Jun;9(2):319-29 (46 ref.)

Acquired inhibitors. Cohen AJ, et al. **Baillieres Clin Haematol** 1996 Jun;9(2):331-54 (100 ref.)

The role of the fetal immune system in the pathogenesis of RhD-hemolytic disease of newborns. Gurevich P, et al. **Hum Antibodies** 1997;8(2):76-89 (120 ref.)

Networked alloimmunity: a brief reexamination of some basic concepts in transplantation immunobiology. Orosz CG. **J Heart Lung Transplant** 1996 Nov;15(11):1063-8 (12 ref.)

Prenatal diagnosis and management of neonatal alloimmune thrombocytopenia. Johnson JA, et al. **Semin Perinatol** 1997 Feb;21(1):45-52 (32 ref.)

Management of fetal and neonatal alloimmune thrombocytopenia. Kaplan C, et al. **Transfus Med Rev** 1996 Jul;10(3):233-40 (63 ref.)

Delineating physiological (natural) autoreactivity from pathological autoimmunity. Kazatchkine MD. **Vox Sang** 1996;70 Suppl 1:24-9 (16 ref.)

The treatment of factor VIII inhibitors--a general overview. White GC, et al. **Vox Sang** 1996;70 Suppl 1:19-23 (10 ref.)

ISOANTIGENS

ISOANTIGENS

see related
BLOOD GROUPS
Peripheral tolerance to alloantigen: strategies for the future. Wood KJ. **Eur J Immunogenet** 1993 Oct;20(5):439–49 (69 ref.)

ADMINISTRATION & DOSAGE
Induction of tolerance by intrathymic inoculation of alloantigen. Naji A. **Curr Opin Immunol** 1996 Oct; 8(5):704–9 (60 ref.)

ANALYSIS
Antigen–independent determinants of late renal allograft outcome: the role of renal mass. Mackenzie HS, et al. **Curr Opin Nephrol Hypertens** 1996 Jul;5(4):289–96 (88 ref.)

BLOOD
Individual prostate–specific antigen (PSA) forms as prostate tumor markers. Becker C, et al. **Clin Chim Acta** 1997 Jan 3;257(1):117–32 (87 ref.)
Molecular basis of Kell blood group phenotypes. Lee S. **Vox Sang** 1997;73(1):1–11 (72 ref.)

GENETICS
Occam's Razor, invertebrate allorecognition and Ig superfamily evolution. Mokady O. **Res Immunol** 1996 May; 147(4):241–6 (20 ref.)

IMMUNOLOGY
Sperm antigens and their use in the development of an immunocontraceptive. Diekman AB, et al. **Am J Reprod Immunol** 1997 Jan;37(1):111–7 (74 ref.)
Allorecognition by murine natural killer cells: studies with bone marrow transplants and lysis of T lymphoblasts. Liu J, et al. **Chem Immunol** 1996;64:164–80 (23 ref.)
Induction of tolerance to cardiac allografts. Wood KJ. **Curr Opin Cardiol** 1996 Mar;11(2):208–13 (32 ref.)
Signal minus 1: a key factor in immunological tolerance to tissue–specific self antigens? Parish CR. **Immunol Cell Biol** 1996 Jun;74(3):278–85 (50 ref.)
The role of peptide specificity in MHC class I–restricted allogeneic responses. Frelinger JA, et al. **Immunol Rev** 1996 Dec;154:45–58 (48 ref.)
Allorecognition by murine natural killer cells: lysis of T–lymphoblasts and rejection of bone–marrow grafts. George T, et al. **Immunol Rev** 1997 Feb;155:29–40 (53 ref.)
Indirect T cell recognition in allograft rejection. Bradley JA. **Int Rev Immunol** 1996;13(3):245–55 (85 ref.)
T cell receptor (TCR) repertoire in alloimmune responses. Finn OJ, et al. **Int Rev Immunol** 1996;13(3):187–207 (131 ref.)
Role of indirect allorecognition in allograft rejection. Sayegh MH, et al. **Int Rev Immunol** 1996;13(3):221–9 (43 ref.)
Networked alloimmunity: a brief reexamination of some basic concepts in transplantation immunobiology. Orosz CG. **J Heart Lung Transplant** 1996 Nov;15(11):1063–8 (12 ref.)
Role of the CD28:B7 costimulatory interaction in alloimmune responses. Akalin E, et al. **Kidney Int Suppl** 1997 Mar; 58:S8–10 (21 ref.)
Female alloimmunization with antibodies known to cause hemolytic disease. Geifman–Holtzman O, et al. **Obstet Gynecol** 1997 Feb;89(2):272–5 (18 ref.)
The influence of two distinct alloresponse pathways on the design of peptide–based strategies for allograft tolerance. Benichou G, et al. **Res Immunol** 1996 Jul–Aug; 147(6):377–87 (50 ref.)
Alloimmunization and platelet transfusion. McFarland JG. **Semin Hematol** 1996 Oct;33(4):315–28 (132 ref.)
[Immunology of the fetal–maternal relationship] González NC, et al. **Rev Alerg Mex** 1996 Jan–Feb;43(1):18–22 (49 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM
Heterogeneity of mouse brain macrophages in alloantigen presentation to naive CD8+ T cells as revealed by a panel of microglial cell lines. Askew D, et al. **Immunobiology** 1996 Oct;195(4–5):417–30 (56 ref.)

ISOASPARTIC ACID see **ASPARTIC ACID**

ISOCITRATE DEHYDROGENASE

CHEMISTRY
Control by phosphorylation. Johnson LN, et al. **Curr Opin Struct Biol** 1996 Dec;6(6):762–9 (36 ref.)
Intermediate trapping and laue X–ray diffraction: potential for enzyme mechanism, dynamics, and inhibitor screening. Stoddard BL. **Pharmacol Ther** 1996;70(3):215–56 (95 ref.)

METABOLISM
Chemical arrows for enzymatic targets. Colman RF. **FASEB J** 1997 Mar;11(4):217–26 (27 ref.)

ISOCITRATE HYDRO–LYASE see **ACONITATE HYDRATASE**

ISOCYANATES

ADVERSE EFFECTS
Death due to asthma at workplace in a diphenylmethane diisocyanate–sensitized subject. Carino M, et al. **Respiration** 1997;64(1):111–3 (16 ref.)

ISOCYANIDES see **CYANIDES**

ISOELECTRIC FOCUSING

METHODS
Isoelectric focusing in immobilized pH gradients: recent analytical and preparative developments. Righetti PG, et al. **Anal Biochem** 1997 Apr 5;247(1):1–10 (82 ref.)
Capillary isoelectric focusing of proteins. Pritchett TJ. **Electrophoresis** 1996 Jul;17(7):1195–201 (51 ref.)

ISOENZYMES

Protein kinase C isoenzymes: regulation and function. Blobe GC, et al. **Cancer Surv** 1996;27:213–48 (190 ref.)
Selective inhibitors of cyclooxygenase–2. Potential in elderly patients. Davies NM, et al. **Drugs Aging** 1996 Dec; 9(6):406–17 (124 ref.)
The 11 beta–hydroxysteroid dehydrogenase enzymes: perspectives and paradoxes. Krozowski Z. **Endocr Res** 1996 Nov;22(4):781–90 (25 ref.)
Prostaglandin endoperoxide H synthases (cyclooxygenases)–1 and –2. Smith WL, et al. **J Biol Chem** 1996 Dec 27;271(52):33157–60 (75 ref.)
[Protein tyrosine phosphatases in the neural system] Mizuno K, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):446–52 (35 ref.) **(Jpn)**

ANALYSIS
Retinal protein kinase C. Wood JP, et al. **Neurochem Int** 1997 Feb;30(2):119–36 (146 ref.)

ANTAGONISTS & INHIBITORS
Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC–alpha and C–raf kinase. Henry SP, et al. **Anticancer Drug Des** 1997 Jul;12(5):409–20 (38 ref.)
Antisense oligonucleotide inhibitors of isozymes of protein kinase C: in vitro and in vivo activity, and clinical development as anti–cancer therapeutics. McGraw K, et al. **Anticancer Drug Des** 1997 Jul;12(5):315–26 (42 ref.)
Antisense–protein kinase A: a single–gene–based therapeutic approach. Cho–Chung YS, et al. **Antisense Nucleic Acid Drug Dev** 1997 Jun;7(3):217–23 (20 ref.)
Feedback inhibition of dihydrodipicolinate synthase enzymes by L–lysine. Blickling S, et al. **Biol Chem** 1997 Mar–Apr; 378(3–4):207–10 (25 ref.)
IMP dehydrogenase as a target of antitumor and antiviral chemotherapy. Franchetti P, et al. **Farmaco** 1996 Jul; 51(7):457–69 (141 ref.)
Inhibition of human cytochrome P450–3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies. Greenblatt DJ, et al. **J Clin Pharmacol** 1996 Sep;36(9):792–8 (51 ref.)
Phosphodiesterase inhibitors: knockout drops? Raeburn D, et al. **J Pharm Pharmacol** 1997 May;49 Suppl 3:19–24 (22 ref.)
Phosphodiesterase (PDE)4 inhibitors: anti–inflammatory drugs of the future? Teixeira MM, et al. **Trends Pharmacol Sci** 1997 May;18(5):164–71 (101 ref.)

BIOSYNTHESIS
Hexokinase II gene: structure, regulation and promoter organization. Printz RL, et al. **Biochem Soc Trans** 1997 Feb;25(1):107–12 (44 ref.)
Time for integration of predictive factors for selection of breast cancer patients who need postoperative radiation therapy? [editorial; comment] Bergh J. **J Natl Cancer Inst** 1997 May 7;89(9):605–7 (31 ref.) Comment on: J Natl Cancer Inst 1997 May 7;89(9):639–45.
COX–1 and COX–2 tissue expression: implications and predictions. Crofford LJ. **J Rheumatol** 1997 Jul;24 Suppl 49:15–9 (40 ref.)
Antiphospholipid antibodies, eicosanoids and expression of endothelial cyclooxygenase–2. Carreras LO, et al. **Lupus** 1996 Oct;5(5):494–7 (46 ref.)

BLOOD
The clinical value of lactate dehydrogenase in serum: a quantitative review. Huijgen HJ, et al. **Eur J Clin Chem Clin Biochem** 1997 Aug;35(8):569–79 (89 ref.)

CHEMISTRY
Prostaglandin endoperoxide H synthases–1 and –2. Smith WL, et al. **Adv Immunol** 1996;62:167–215 (221 ref.)
Insights into acylphosphatase structure and catalytic mechanism. Stefani M, et al. **Cell Mol Life Sci** 1997 Feb; 53(2):141–51 (88 ref.)
Deciphering isozyme function: exploring cell biology with chemistry in the post–genomic era. Crews CM. **Chem Biol** 1996 Dec;3(12):961–5 (31 ref.)
Nongenetic variation, genetic–environmental interactions and altered gene expression. II. Disease, parasite and pollution effects. Poly WJ. **Comp Biochem Physiol B Biochem Mol Biol** 1997 May; 117(1):61–74 (202 ref.)
Phospholipase C–gamma1: regulation of enzyme function and role in growth factor–dependent signal transduction. Kamat A, et al. **Cytokine Growth Factor Rev** 1997 Jun; 8(2):109–17 (86 ref.)
Tyrosine hydroxylase: human isoforms, structure and regulation in physiology and pathology. Nagatsu T. **Essays Biochem** 1995;30:15–35 (45 ref.)
Tropomyosin isoforms in nonmuscle cells. Lin JJ, et al. **Int Rev Cytol** 1997;170:1–38 (275 ref.)
Genetic analysis of nitric oxide synthase isoforms: targeted mutation in mice. Huang PL, et al. **J Mol Med** 1996 Aug; 74(8):415–21 (41 ref.)
Structure and function of the Na,K pump: ten years of molecular biology. Pressley TA. **Miner Electrolyte Metab** 1996;22(5–6):264–71 (63 ref.)

DRUG EFFECTS
Review article: COX–II inhibitors––a new generation of safer NSAIDs? Donnelly MT, et al. **Aliment Pharmacol Ther** 1997 Apr;11(2):227–36 (92 ref.)
Cyclooxygenase–2 inhibitors: a new class of anti–inflammatory agents that spare the gastrointestinal tract. Masferrer JL, et al. **Gastroenterol Clin North Am** 1996 Jun;25(2):363–72 (35 ref.)
Modulation of the cytochrome P450 system as a mechanism of chemoprotection. Wolf CR, et al. **IARC Sci Publ** 1996; (139):165–73 (24 ref.)
Pain management in osteoarthritis: the role of COX–2 inhibitors. Lane NE. **J Rheumatol** 1997 Jul;24 Suppl 49:20–4 (30 ref.)
Outcome of specific COX–2 inhibition in rheumatoid arthritis. Lipsky PE, et al. **J Rheumatol** 1997 Jul;24 Suppl 49:9–14 (21 ref.)
Differentiating among nonsteroidal antiinflammatory drugs by pharmacokinetic and pharmacodynamic profiles. Fenner H. **Semin Arthritis Rheum** 1997 Jun;26(6 Suppl 1):28–33 (14 ref.)
Meloxicam: selective COX–2 inhibition in clinical practice. Furst DE. **Semin Arthritis Rheum** 1997 Jun;26(6 Suppl 1):21–7 (24 ref.)
Cyclooxygenase–2 inhibitors: a new approach to the therapy of ocular inflammation. Masferrer JL, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S35–40 (43 ref.)

GENETICS
Novel members of mammalian kexin family proteases, pace 4C, pace 4D, PC 7A and PC 7B. Matsuda Y, et al. **Adv Exp Med Biol** 1996;389:63–71 (15 ref.)
Prostacyclin and nitric oxide–related gene transfer in preventing arterial thrombosis and restenosis. Wu KK. **Agents Actions Suppl** 1997;48:107–23 (35 ref.)
Hexokinase II gene: structure, regulation and promoter organization. Printz RL, et al. **Biochem Soc Trans** 1997 Feb;25(1):107–12 (44 ref.)
Deciphering isozyme function: exploring cell biology with chemistry in the post–genomic era. Crews CM. **Chem Biol** 1996 Dec;3(12):961–5 (31 ref.)
Influence of pharmacogenetics on drug disposition and response. Eichelbaum M, et al. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov;23(10–11):983–5 (21 ref.)
The potential for isoenzyme–selective modulation of protein kinase C. Hofmann J. **FASEB J** 1997 Jul;11(8):649–69 (256 ref.)
The cytochrome P450 4 (CYP4) family. Simpson AE. **Gen Pharmacol** 1997 Mar;28(3):351–9 (115 ref.)
Interpatient variability: genetic predisposition and other genetic factors. West WL, et al. **J Clin Pharmacol** 1997 Jul;37(7):635–48 (76 ref.)
Granzymes: a variety of serine protease specificities encoded by genetically distinct subfamilies. Smyth MJ, et al. **J Leukoc Biol** 1996 Nov;60(5):555–62 (107 ref.)
Tartrate–resistant acid phosphatase: gene structure and function. Fleckenstein E, et al. **Leukemia** 1997 Jan; 11(1):10–3 (39 ref.)
Molecular genetics of yeast TCA cycle isozymes. McAlister–Henn L, et al. **Prog Nucleic Acid Res Mol Biol** 1997;57:317–39 (89 ref.)
Disruption of cyclooxygenase genes in mice. Mahler JF, et al. **Toxicol Pathol** 1996 Nov–Dec;24(6):717–9 (6 ref.)
[Diverse structures of diacylglycerol kinase gene family] Sakane F. **Seikagaku** 1997 Mar;69(3):176–81 (15 ref.) **(Jpn)**
[Molecular cloning of ADH7 encoding human class IV (sigma) ADH and its clinical significance] Yokoyama H, et al. **Tanpakushitsu Kakusan Koso** 1997 Jan;42(1):42–9 (49 ref.) **(Jpn)**

METABOLISM
New alcohol dehydrogenases for the synthesis of chiral compounds. Hummel W. **Adv Biochem Eng Biotechnol** 1997;58:145–84 (252 ref.)
Inositol lipid cycle and autonomous nuclear signalling. Cocco

L, et al. **Adv Enzyme Regul** 1996;36:101–14 (32 ref.)
Alcohol dehydrogenases: a family of isozymes with differential functions. Holmes RS. **Alcohol Alcohol Suppl** 1994;2:127–30 (43 ref.)
Kinetic behaviour of vertebrate hexokinases with emphasis on hexokinase D (IV). Cárdenas ML. **Biochem Soc Trans** 1997 Feb;25(1):131–5 (53 ref.)
Hexokinase expression in liver preneoplasia and neoplasia. Mayer D, et al. **Biochem Soc Trans** 1997 Feb;25(1):122–7 (32 ref.)
An introduction to the isoenzymes of mammalian hexokinase types I–III. Wilson JE. **Biochem Soc Trans** 1997 Feb; 25(1):103–7 (49 ref.)
Influence of pharmacogenetics on drug disposition and response. Eichelbaum M, et al. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov;23(10–11):983–5 (21 ref.)
Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Preskorn SH. **Clin Pharmacokinet** 1997;32 Suppl 1:1–21 (143 ref.)
Kinase connections on the cellular intranet. Signalling pathways. Pelech SL. **Curr Biol** 1996 May 1;6(5):551–4 (19 ref.)
'Hot spots' of creatine kinase localization in brain: cerebellum, hippocampus and choroid plexus. Kaldis P, et al. **Dev Neurosci** 1996;18(5–6):542–54 (75 ref.)
Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Rendic S, et al. **Drug Metab Rev** 1997 Feb–May; 29(1–2):413–580 (295 ref.)
11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. White PC, et al. **Endocr Rev** 1997 Feb;18(1):135–56 (209 ref.)
Zonation of cytochrome P450 expression, drug metabolism and toxicity in liver. Lindros KO. **Gen Pharmacol** 1997 Feb;28(2):191–6 (50 ref.)
Regulation of phosphoinositide-specific phospholipase C isozymes. Rhee SG, et al. **J Biol Chem** 1997 Jun 13; 272(24):15045–8 (50 ref.)
Use of probe drugs as predictors of drug metabolism in humans. Kivistö KT, et al. **J Clin Pharmacol** 1997 Jan;37(1 Suppl):40S–48S (54 ref.)
Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part I. Harvey AT, et al. **J Clin Psychopharmacol** 1996 Aug;16(4):273–85 (130 ref.)
PAF and PAF acetylhydrolase in the nervous system. Hattori M, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):99–102 (9 ref.)
Na,K-pump expression and distribution in the nephron. Farman N. **Miner Electrolyte Metab** 1996;22(5–6):272–8 (36 ref.)
Glycogen phosphorylase isoenzyme BB in diagnosis of myocardial ischaemic injury and infarction. Krause EG, et al. **Mol Cell Biochem** 1996 Jul–Aug;160–161:289–95 (29 ref.)
Regulation of ICE activity and ICE isoforms by LPS. Tingsborg S, et al. **Mol Psychiatry** 1997 Mar;2(2):122–4 (10 ref.)
Independent prostanoid biosynthetic systems associated with prostaglandin endoperoxide synthases-1 and -2. Smith WL, et al. **Thromb Haemost** 1997 Jul;78(1):627–30 (63 ref.)
G16 as a universal G protein adapter: implications for agonist screening strategies. Milligan G, et al. **Trends Pharmacol Sci** 1996 Jul;17(7):235–7 (26 ref.)
[Pulmonary nitric oxide synthase isoform expression and their functional significance] Munakata M. **Nippon Rinsho** 1996 Feb;54(2):358–63 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Phosphatidylinositol-specific phospholipase C isozymes and regulation of their activity] Pawełczyk T. **Postepy Biochem** 1996;42(3):290–8 (151 ref.) **(Pol)**

PHARMACOLOGY

Clinical implications of antidepressant pharmacokinetics and pharmacogenetics. Cohen LJ, et al. **Ann Pharmacother** 1996 Dec;30(12):1471–80 (90 ref.)

PHYSIOLOGY

Carbonic anhydrase and the heart. Swenson ER. **Cardiologia** 1997 May;42(5):453–62 (97 ref.)
Regulatory functions of phospholipase A2. Murakami M, et al. **Crit Rev Immunol** 1997;17(3–4):225–83 (436 ref.)
Physiological regulation of blood pressure and kidney function by guanylyl cyclase isoforms. Kishimoto I, et al. **Curr Opin Nephrol Hypertens** 1997 Jan;6(1):58–63 (46 ref.)
Phospholipase C-gamma1: regulation of enzyme function and role in growth factor-dependent signal transduction. Kamat A, et al. **Cytokine Growth Factor Rev** 1997 Jun; 8(2):109–17 (86 ref.)
Cyclooxygenase 2 and wound healing in the stomach [editorial; comment] Stenson WF. **Gastroenterology** 1997 Feb;112(2):645–8 (32 ref.) Comment on: Gastroenterology 1997 Feb;112(2):387–97.
New directions in cyclooxygenase research and their implications for NSAID-gastropathy. Flower RJ. **Ital J Gastroenterol** 1996 Dec;28 Suppl 4:23–7 (26 ref.)
The discovery and function of COX-2. Needleman P, et al. **J Rheumatol** 1997 Jul;24 Suppl 49:6–8 (23 ref.)
Tartrate-resistant acid phosphatase: gene structure and function. Fleckenstein E, et al. **Leukemia** 1997 Jan; 11(1):10–3 (39 ref.)
Renal H,K-ATPase: structure, function and regulation. Kone BC. **Miner Electrolyte Metab** 1996;22(5–6):349–65 (102 ref.)
Isoenzymes of protein kinase C: differential involvement in apoptosis and pathogenesis. Deacon EM, et al. **Mol Pathol** 1997 Jun;50(3):124–31 (140 ref.)
Cyclooxygenase 1 and 2 in rheumatic disease: implications for nonsteroidal anti-inflammatory drug therapy. Spangler RS. **Semin Arthritis Rheum** 1996 Aug;26(1):435–46 (79 ref.)
[Selective cyclooxygenase-2 (COX-2) inhibitor. Progress in rheumatoid therapy?] Reuss-Borst M. **Internist (Berl)** 1997 Mar;38(3):266–71 (35 ref.) **(Ger)**
[Cyclooxygenase-1 and cyclooxygenase-2] Yamamoto K, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Dec; 19(6):564–7 (14 ref.) **(Jpn)**
[Pulmonary nitric oxide synthase isoform expression and their functional significance] Munakata M. **Nippon Rinsho** 1996 Feb;54(2):358–63 (22 ref.) (Eng. Abstr.) **(Jpn)**

ISOEPHEDRINE see **EPHEDRINE**

ISOETRETIN see **ACITRETIN**

ISOFLAVONES

PHARMACOLOGY

Inhibition of protein tyrosine phosphorylation in endothelial cells: relationship to antiproliferative action of genistein. Koroma BM, et al. **Biochem Soc Trans** 1997 Feb; 25(1):35–40 (37 ref.)

ISOFLURANE

ADVERSE EFFECTS

Massive hepatic necrosis and death following repeated isoflurane exposure: case report and review of the literature. Gelven PL, et al. **Am J Forensic Med Pathol** 1996 Mar;17(1):61–4 (12 ref.)
Isoflurane hepatotoxicity: a case report and review of the literature. Sinha A, et al. **Am J Gastroenterol** 1996 Nov; 91(11):2406–9 (12 ref.)

ANALOGS & DERIVATIVES

Desflurane and sevoflurane are valuable additions to the practice of neuroanesthesiology: pro. Baker KZ. **J Neurosurg Anesthesiol** 1997 Jan;9(1):66–8 (24 ref.)
The new inhalational anesthetics desflurane and sevoflurane are valuable additions to the practice of neuroanesthesia: con. Tempelhoff R. **J Neurosurg Anesthesiol** 1997 Jan; 9(1):69–71 (19 ref.)
[Critical evaluation of the new inhalational anesthetics desflurane and sevoflurane] Scholz J, et al. **Anaesthesiol Reanim** 1997;22(1):15–20 (39 ref.) (Eng. Abstr.) **(Ger)**
[New inhalation anesthetics] Conzen P, et al. **Anaesthesist** 1996 Aug;45(8):674–93 (82 ref.) (Eng. Abstr.) **(Ger)**

ISOGRAFT see **TRANSPLANTATION, ISOGENEIC**

ISOHEMAGGLUTININS see **HEMAGGLUTININS**

ISOHEXANES see **HEXANES**

ISOIMMUNIZATION, RHESUS see **RH ISOIMMUNIZATION**

ISOLATION, PATIENT see **PATIENT ISOLATION**

ISOLATION PERFUSION THERAPY see **PERFUSION, REGIONAL**

ISOLATION, SOCIAL see **SOCIAL ISOLATION**

ISOMERASES

CHEMISTRY

Protein disulfide isomerase: a multifunctional protein of the endoplasmic reticulum. Luz JM, et al. **EXS** 1996;77:97–117 (138 ref.)

DEFICIENCY

Peroxisomal bifunctional enzyme deficiency: serial neurophysiological examinations of a case. Akaboshi S, et al. **Brain Dev** 1997 Jun;19(4):295–9 (24 ref.)

GENETICS

Glutathione-independent prostaglandin D synthase as a lead molecule for designing new functional proteins. Toh H, et al. **Protein Eng** 1996 Dec;9(12):1067–82 (51 ref.)

METABOLISM

Stereochemical aspects of fatty acid oxidation: hydroperoxide isomerases. Hamberg M. **Acta Chem Scand** 1996 Mar; 50(3):219–24 (33 ref.)
Biogenesis of the bundle-forming pilus of enteropathogenic Escherichia coli: reconstitution of fimbriae in recombinant E. coli and role of DsbA in pilin stability--a review. Donnenberg MS, et al. **Gene** 1997 Jun 11;192(1):33–8 (62 ref.)

PHYSIOLOGY

Prostaglandin D synthase (beta-trace protein): a molecular clock to trace the origin of REM sleep? Sri Kantha S. **Med Hypotheses** 1997 May;48(5):411–2 (21 ref.)

ISOMETRIC CONTRACTION

PHYSIOLOGY

Force and the motor cortex. Ashe J. **Behav Brain Res** 1997 Jun;86(1):1–15 (75 ref.)
Measurement of isometric elbow and shoulder moments: position-dependent strength of posterior deltoid-to-triceps muscle tendon transfer in tetraplegia. Kirsch RF, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):403–9 (10 ref.)
The role of resistance training in patients with cardiac disease. McCartney N, et al. **J Cardiovasc Risk** 1996 Apr;3(2):160–6 (50 ref.)
Measurement of muscle strength and power. Bassey EJ. **Muscle Nerve Suppl** 1997;5:S44–6 (14 ref.)

ISOMETRIC EXERCISE see **EXERCISE**

ISONIAZID

ADMINISTRATION & DOSAGE

Short-course chemoprophylaxis for tuberculosis. Bishai WR, et al. **Clin Chest Med** 1997 Mar;18(1):115–22 (56 ref.)

ADVERSE EFFECTS

[Fulminant hepatitis during the therapy for tuberculous meningitis] Garavelli PL. **Recenti Prog Med** 1996 Dec; 87(12):597 (8 ref.) **(Ita)**

PHARMACOLOGY

Life without KatG. Zhang Y. **Trends Microbiol** 1996 Nov; 4(11):415–6 (15 ref.)

POISONING

Intentional overdosage with isoniazid: case report and review of literature. Tai DY, et al. **Singapore Med J** 1996 Apr; 37(2):222–5 (44 ref.)

THERAPEUTIC USE

Mycobacterium szulgai infection of the lung: case report and review of an unusual pathogen. Benator DA, et al. **Am J Med Sci** 1997 Jun;313(6):346–51 (25 ref.)
Mantoux (tuberculosis) testing. Evaluation of guidelines for testing in Canadian institutions. Thomas RE. **Can Fam Physician** 1997 May;43:933–8 (40 ref.)
Epidemiology, control and treatment of multidrug-resistant tuberculosis. Chaulet P, et al. **Drugs** 1996;52 Suppl 2:103–7; discussion 107–8 (17 ref.)
[Primary chemoprevention of tuberculosis in HIV-infected patients in non-industrialized countries] Anglaret X, et al. **Sante** 1997 Mar–Apr;7(2):89–94 (38 ref.) (Eng. Abstr.) **(Fre)**

ISONICOTINIC ACID HYDRAZIDE see **ISONIAZID**

ISOPRENALINE see **ISOPROTERENOL**

ISOPRENOID PHOSPHATE SUGARS see **POLYISOPRENYL PHOSPHATE SUGARS**

ISOPRENOID PHOSPHATES see **POLYISOPRENYL PHOSPHATES**

ISOPRENYLATION see **PROTEIN ISOPRENYLATION**

ISOPROPANOL see **ALCOHOL, PROPYL**

ISOPROPYL ALCOHOL see **ALCOHOL, PROPYL**

ISOPROPYLARTERENOL see **ISOPROTERENOL**

N-ISOPROPYLATROPINE see **IPRATROPIUM**

ISOPROTERENOL

DIAGNOSTIC USE

[Comparative data of tilt test with or without isoproterenol in investigation of unexplained unconsciousness and syncope] Raybaud F, et al. **Arch Mal Coeur Vaiss** 1996 Sep;89(9):1145–51 (32 ref.) (Eng. Abstr.) **(Fre)**
[Pharmacological test] Hirayama M, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:491–3 (8 ref.) **(Jpn)**

ISOQUINOLINES

Mivacurium in infants and children. Goudsouzian NG. **Paediatr Anaesth** 1997;7(3):183–90 (53 ref.)
[Mivacurium in pediatric anesthesia] Hofmockel VR, et al. **Anaesthesiol Reanim** 1996;21(1):11–3 (25 ref.) (Eng. Abstr.) **(Ger)**

ISOQUINOLINES

[New muscle relaxants. Update on mivacurium, rocuronium and cis-atracurium] Fuchs-Buder T. **Anaesthesist** 1997 Apr;46(4):350-9 (17 ref.) **(Ger)**

ADMINISTRATION & DOSAGE

[New muscle relaxants] Diefenbach C, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Feb; 31(1):2-8 (57 ref.) (Eng. Abstr.) **(Ger)**

CHEMISTRY

beta-Phenylethylamines and the isoquinoline alkaloids. Bentley KW. **Nat Prod Rep** 1997 Aug;14(4):387-411 (462 ref.)

METABOLISM

Tetrahydroisoquinolines and alcoholism: where are we today? Myers RD. **Alcohol Clin Exp Res** 1996 May; 20(3):498-500 (11 ref.)

PHARMACOLOGY

Nelfinavir. Perry CM, et al. **Drugs** 1997 Jul;54(1):81-7; discussion 88 (30 ref.)

beta-Phenylethylamines and the isoquinoline alkaloids. Bentley KW. **Nat Prod Rep** 1997 Aug;14(4):387-411 (462 ref.)

[The clinical pharmacology of mivacurium] Diefenbach C, et al. **Anaesthesist** 1997 May;46(5):385-8 (25 ref.) (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Aldose reductase inhibitors: the end of an era or the need for different trial designs? Pfeifer MA, et al. **Diabetes** 1997 Sep;46 Suppl 2:S82-9 (59 ref.)

TOXICITY

Preclinical toxicology studies with the angiotensin-converting enzyme inhibitor quinapril hydrochloride (Accupril). McGuire EJ, et al. **J Toxicol Sci** 1996 Nov;21(4):207-14 (21 ref.)

Genetic changes induced by heterocyclic amines. Nagao M, et al. **Mutat Res** 1997 May 12;376(1-2):161-7 (43 ref.)

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE

ANALOGS & DERIVATIVES

Molecular and cellular pharmacology of a calcium/calmodulin-dependent protein kinase II (CaM kinase II) inhibitor, KN-62, and proposal of CaM kinase phosphorylation cascades. Hidaka H, et al. **Adv Pharmacol** 1996;36:193-219 (84 ref.)

ISOSORBIDE DINITRATE

ANALOGS & DERIVATIVES

Achieving sustained improvement in myocardial perfusion: role of isosorbide mononitrate. Lewin HC, et al. **Am J Cardiol** 1997 Jun 26;79(12B):31-5 (50 ref.)

NO-donors and angina pectoris: more than just symptomatic treatment? Cleophas TJ, et al. **Neth J Med** 1997 Apr; 50(4):180-3 (24 ref.)

ISOSPORA

PATHOGENICITY

Biology of Isospora spp. from humans, nonhuman primates, and domestic animals. Lindsay DS, et al. **Clin Microbiol Rev** 1997 Jan;10(1):19-34 (193 ref.)

Gut Coccidia-- Isospora, Cryptosporidium, Cyclospora and Sarcocystis. Ackers JP. **Semin Gastrointest Dis** 1997 Jan; 8(1):33-44 (166 ref.)

ISOTACHOPHORESIS see **ELECTROPHORESIS**

ISOTHIOCYANATES

METABOLISM

Allosteric effects in stilbenedisulfonate binding to band 3 protein (AE1). Salhany JM. **Cell Mol Biol (Noisy-le-grand)** 1996 Nov;42(7):1065-96 (107 ref.)

PHARMACOLOGY

Chemoprotection against cancer by isothiocyanates and glucosinolates. Talalay P, et al. **Biochem Soc Trans** 1996 Aug;24(3):806-10 (35 ref.)

Approaches to chemoprevention of lung cancer based on carcinogens in tobacco smoke. Hecht SS. **Environ Health Perspect** 1997 Jun;105 Suppl 4:955-63 (87 ref.)

THERAPEUTIC USE

Chemoprevention of lung cancer by isothiocyanates. Hecht SS. **Adv Exp Med Biol** 1996;401:1-11 (34 ref.)

Isothiocyanates as inhibitors of esophageal cancer. Stoner GD, et al. **Adv Exp Med Biol** 1996;401:13-23 (31 ref.)

ISOTOPE LABELING

Isotopic methods for probing organization of cellular metabolism. Sherry AD, et al. **Cell Biochem Funct** 1996 Dec;14(4):259-68 (34 ref.)

Synthesis of isotopically labelled retinal. Structural and functional studies at the atomic level of the chromophore in visual pigments. Lugtenburg J. **Eur J Clin Nutr** 1996 Jul;50 Suppl 3:S17-20 (18 ref.)

Safety of stable isotope use. Koletzko B, et al. **Eur J Pediatr** 1997 Aug;156 Suppl 1:S12-7 (49 ref.)

Preparation of radiolabeled gangliosides. Sonnino S, et al. **Glycobiology** 1996 Jul;6(5):479-87 (45 ref.)

Physical activity levels from a meta-analysis of doubly labeled water studies for validating energy intake as measured by dietary assessment. Black AE. **Nutr Rev** 1996 Jun;54(6):170-4 (28 ref.)

METHODS

Iron, copper, and zinc absorption and turnover; the use of stable isotopes. Aggett PJ. **Eur J Pediatr** 1997 Aug;156 Suppl 1:S29-34 (27 ref.)

Stable isotopes in biosciences, their measurement and models for amino acid metabolism. Bier DM. **Eur J Pediatr** 1997 Aug;156 Suppl 1:S2-8 (31 ref.)

Protein turnover in critically ill children. Bodamer OA, et al. **Eur J Pediatr** 1997 Aug;156 Suppl 1:S59-61 (16 ref.)

Studies of apolipoprotein B-100 metabolism using radiotracers and stable isotopes. Demant T, et al. **Eur J Pediatr** 1997 Aug;156 Suppl 1:S75-7 (9 ref.)

New insights into lipid and fatty acid metabolism via stable isotopes. Demmelmair H, et al. **Eur J Pediatr** 1997 Aug; 156 Suppl 1:S70-4 (20 ref.)

Stable isotope studies in propionic and methylmalonic acidaemia. Leonard JV. **Eur J Pediatr** 1997 Aug;156 Suppl 1:S67-9 (19 ref.)

Bedside measurement of pulmonary capillary permeability in patients with acute lung injury. What have we learned? [editorial] Rocker GM. **Intensive Care Med** 1996 Jul; 22(7):619-21 (19 ref.)

ISOTOPES

Stable isotopes and mass isotopomer study of fatty acid and cholesterol synthesis. A review of the MIDA approach. Lee WN. **Adv Exp Med Biol** 1996;399:95-114 (31 ref.)

Applications of mass isotopomer analysis to nutrition research. Brunengraber H, et al. **Annu Rev Nutr** 1997; 17:559-96 (135 ref.)

Stable light isotope biogeochemistry of hydrothermal systems. Des Marais DJ. **Ciba Found Symp** 1996;202:83-94; discussion 94-8 (41 ref.)

Safety of stable isotope use. Koletzko B, et al. **Eur J Pediatr** 1997 Aug;156 Suppl 1:S12-7 (49 ref.)

Use of stable isotopically labeled tracers for studies of metabolic kinetics: an overview. Patterson BW. **Metabolism** 1997 Mar;46(3):322-9 (35 ref.)

[Stable isotopes in nutrition research] de Santiago S, et al. **Arch Latinoam Nutr** 1995 Mar;45(1):6-11 (28 ref.) (Eng. Abstr.) **(Spa)**

ISOTRETINOIN

ADVERSE EFFECTS

How to ensure fetal safety when mothers use isotretinoin (Accutane). Koren G, et al. **Can Fam Physician** 1997 Feb; 43:216-9 (4 ref.)

THERAPEUTIC USE

Juvenile nodulocystic acne responding to systemic isotretinoin [letter] Horne HL, et al. **Br J Dermatol** 1997 May;136(5):796-7 (7 ref.)

Use of antioxidant supplements in the treatment of human oral leukoplakia. Kaugars GE, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Jan;81(1):5-14 (126 ref.)

TOXICITY

Retinoic acid embryopathy: case report and review of literature. Coberly S, et al. **Pediatr Pathol Lab Med** 1996 Sep-Oct;16(5):823-36 (24 ref.)

ISOTYPE SWITCHING see **IMMUNOGLOBULIN CLASS SWITCHING**

ISOXAZOLES

[Research and development of zonisamide, a new type of antiepileptic drug] Shimizu M, et al. **Yakugaku Zasshi** 1996 Jul;116(7):533-47 (55 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOKINETICS

The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Perucca E, et al. **Clin Pharmacokinet** 1996 Jul;31(1):29-46 (120 ref.)

PHARMACOLOGY

The use of leflunomide in transplantation immunology. Waer M. **Transpl Immunol** 1996 Sep;4(3):181-5 (49 ref.)

THERAPEUTIC USE

Leflunomide and malononitrilamides. Silva Júnior HT, et al. **Am J Med Sci** 1997 May;313(5):289-301 (101 ref.)

Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis. Bartlett RR, et al. **Transplant Proc** 1996 Dec;28(6):3074-8 (28 ref.)

ISOZYMES see **ISOENZYMES**

ITAI-ITAI see **CADMIUM POISONING**

ITCHING see **PRURITUS**

ITO SYNDROME see **PIGMENTATION DISORDERS**

ITP see **INOSINE TRIPHOSPHATE**

ITRACONAZOLE

ADMINISTRATION & DOSAGE

Treatment of onychomycosis and tinea pedis with intermittent itraconazole therapy. Del Rosso JQ. **J Am Osteopath Assoc** 1996 Oct;96(10):607-9 (19 ref.)

PHARMACOKINETICS

Antifungal prophylaxis with itraconazole in neutropenic patients: pharmacological, microbiological and clinical aspects. Glasmacher A, et al. **Mycoses** 1996 Jul-Aug; 39(7-8):249-58 (117 ref.)

PHARMACOLOGY

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards [see comments] Rex JH, et al. **Clin Infect Dis** 1997 Feb; 24(2):235-47 (123 ref.) Comment in: Clin Infect Dis 1997 Feb;24(2):248-9.

THERAPEUTIC USE

The role of azole antifungal agents for systemic antifungal therapy. Lee YP, et al. **Cleve Clin J Med** 1997 Feb; 64(2):99-106 (67 ref.)

Treatment of cerebral Aspergillosis with itraconazole: do high doses improve the prognosis? [see comments] Sánchez C, et al. **Clin Infect Dis** 1995 Dec;21(6):1485-7 (12 ref.) Comment in: Clin Infect Dis 1996 Nov;23(5):1196-7.

Corneal chromoblastomycosis. Barton K, et al. **Cornea** 1997 Mar;16(2):235-9 (18 ref.)

Onychomycosis--treatment, relapse and re-infection. Hull PR. **Dermatology** 1997;194 Suppl 1:7-9 (18 ref.)

First report of mycetoma caused by Arthrographis kalrae: successful treatment with itraconazole. Degavre B, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):318-20 (15 ref.)

Susceptibility testing of fungi and correlation with clinical outcome. Ghannoum MA. **J Chemother** 1997 May;9 Suppl 1:19-24 (49 ref.)

Antifungal prophylaxis with itraconazole in neutropenic patients: pharmacological, microbiological and clinical aspects. Glasmacher A, et al. **Mycoses** 1996 Jul-Aug; 39(7-8):249-58 (117 ref.)

Cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. Zeind CS, et al. **Pharmacotherapy** 1996 Jul-Aug;16(4):547-61 (127 ref.)

Nosocomial cerebral aspergillosis: a report of 3 cases. Darras-Joly C, et al. **Scand J Infect Dis** 1996;28(3):317-9 (28 ref.)

IUDR see **IDOXURIDINE**

IUGR see **FETAL GROWTH RETARDATION**

IVERMECTIN

ANALOGS & DERIVATIVES

Evolution of a specific fluorogenic derivatization of ivermectin for bioanalytical applications. A review. Fink DW, et al. **Analyst** 1996 Nov;121(11):1533-7 (12 ref.)

Avermectins and milbemycins. McKellar QA, et al. **J Vet Pharmacol Ther** 1996 Oct;19(5):331-51 (223 ref.)

[Biosynthesis of avermectins: physiological and technological aspects] Mironov VA, et al. **Antibiot Khimioter** 1997; 42(3):31-6 (24 ref.) **(Rus)**

THERAPEUTIC USE

Treatment of onchocerciasis. Van Laethem Y, et al. **Drugs** 1996 Dec;52(6):861-9 (51 ref.)

[Ivermectin and tropical dermatoses] Caumes E. **Bull Soc Pathol Exot** 1997;90(1):37-8 (17 ref.) (Eng. Abstr.) **(Fre)**

IVIG see **IMMUNOGLOBULINS, INTRAVENOUS**

IXODES

The history of the cattle tick Boophilus microplus in Australia and achievements in its control. Angus BM. **Int J Parasitol** 1996 Dec;26(12):1341–55 (163 ref.)

[Early summer meningoencephalitis and Lyme borreliosis. Tick-borne diseases] **Med Monatsschr Pharm** 1997 May; 20(5):126–32 (2 ref.) **(Ger)**

[Ixodid tick-borne borrelioses—a new group of human diseases] Korenberg EI, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Jul–Aug; (4):104–8 (59 ref.) **(Rus)**

MICROBIOLOGY

Fatal attraction or how do we get tick bites? Kahl O. **Infection** 1996 Sep–Oct;24(5):394–5 (5 ref.)

Arthropod- and host-specific gene expression by Borrelia burgdorferi. de Silva AM, et al. **J Clin Invest** 1997 Feb 1;99(3):377–9 (11 ref.)

Lyme borreliosis in the southern United States: a review. Oliver JH Jr. **J Parasitol** 1996 Dec;82(6):926–35 (134 ref.)

PHYSIOLOGY

[The place of ixodid ticks (Ixodidae) in forest ecosystems] Balashov IuS. **Parazitologiia** 1996 May–Jun;30(3):193–204 (50 ref.) (Eng. Abstr.) **(Rus)**

IXODES DAMMINI see **IXODES**

IXODES RICINUS see **IXODES**

IXODES SCAPULARIS see **IXODES**

J CHAINS see **IMMUNOGLOBULINS, J-CHAIN**

J-POUCH see **PROCTOCOLECTOMY, RESTORATIVE**

JAAGSIEKTE see **PULMONARY ADENOMATOSIS, OVINE**

JACKKNIFE SEIZURES see **SPASMS, INFANTILE**

JACKSONIAN SEIZURE see **EPILEPSY, PARTIAL**

JACOBSON'S ORGAN see **VOMERONASAL ORGAN**

JAKOB-CREUTZFELDT SYNDROME see **CREUTZFELDT-JAKOB SYNDROME**

JAMESTOWN CANYON VIRUS see **CALIFORNIA GROUP VIRUSES**

JANSKY-BIELSCHOWSKY DISEASE see **NEURONAL CEROID-LIPOFUSCINOSIS**

JAPANESE AMERICANS see **ASIAN AMERICANS**

JAPANESE MONKEY see **MACACA**

JAPANESE QUAIL see **COTURNIX**

JAUNDICE

CHEMICALLY INDUCED

Severe and prolonged jaundice in a lupus nephritis patient treated with cyclophosphamide. Moroni G, et al. **Nephrol Dial Transplant** 1997 Apr;12(4):793–6 (15 ref.)

DIAGNOSIS

Computer-assisted diagnosis in gastroenterology. Malchow-Møller A, et al. **Scand J Gastroenterol Suppl** 1996;216:225–33 (63 ref.)

[Jaundice: differential diagnosis] Takikawa H, et al. **Nippon Naika Gakkai Zasshi** 1997 Apr 10;86(4):538–43 (4 ref.) **(Jpn)**

ETIOLOGY

[Liver cirrhosis and jaundice] Arakawa Y, et al. **Nippon Naika Gakkai Zasshi** 1997 Apr 10;86(4):551–6 (5 ref.) **(Jpn)**

[Idiopathic biliary liver cirrhosis, primary sclerosing cholangitis, and jaundice] Oda M, et al. **Nippon Naika Gakkai Zasshi** 1997 Apr 10;86(4):565–73 (5 ref.) **(Jpn)**

[Drug-induced hepatic dysfunction and jaundice] Onji M. **Nippon Naika Gakkai Zasshi** 1997 Apr 10;86(4):557–64 (16 ref.) **(Jpn)**

[Acute hepatitis, fulminant hepatitis, and jaundice] Yoshiba M. **Nippon Naika Gakkai Zasshi** 1997 Apr 10;86(4):544–50 (5 ref.) **(Jpn)**

[III. Barriers in breastfeeding: hyperbilirubinemia] Mikiel-Kostyra K. **Pediatr Pol** 1996 Mar;71(3):275–8 (19 ref.) (Eng. Abstr.) **(Pol)**

JAUNDICE, CHOLESTATIC see **CHOLESTASIS**

JAUNDICE, CHOLESTATIC, EXTRAHEPATIC see **BILE DUCT OBSTRUCTION, EXTRAHEPATIC**

JAUNDICE, CHOLESTATIC, INTRAHEPATIC see **CHOLESTASIS, INTRAHEPATIC**

JAUNDICE, CHRONIC IDIOPATHIC

METABOLISM

The canalicular multispecific organic anion transporter and conjugated hyperbilirubinemia in rat and man. Paulusma CC, et al. **J Mol Med** 1997 Jun;75(6):420–8 (106 ref.)

JAUNDICE, HEMOLYTIC see **ANEMIA, HEMOLYTIC**

JAUNDICE, MECHANICAL see **CHOLESTASIS**

JAUNDICE, NEONATAL

Bilirubin metabolism and kernicterus. Gourley GR. **Adv Pediatr** 1997;44:173–229 (346 ref.)

Neonatal jaundice, animal-induced injuries and disease, and immunizations. Gerson WT. **Curr Opin Pediatr** 1997 Aug; 9(4):447–55 (45 ref.)

Animal-induced injuries and disease, neonatal jaundice, immunizations, and viral infections. Gerson WT. **Curr Opin Pediatr** 1996 Aug;8(4):417–25 (69 ref.)

Evaluation of neonatal jaundice: monitoring the transition in bilirubin metabolism. Stevenson DK, et al. **J Perinatol** 1996 May–Jun;16(3 Pt 2):S62–7 (20 ref.)

DIAGNOSIS

Transcutaneous bilirubinometry: its role in the assessment of neonatal jaundice. Dai J, et al. **Clin Biochem** 1997 Feb; 30(1):1–9 (67 ref.)

Criteria for treatment of neonatal jaundice. Bratlid D. **J Perinatol** 1996 May–Jun;16(3 Pt 2):S83–8 (32 ref.)

DRUG THERAPY

Control of bilirubin production by synthetic heme analogs: pharmacologic and toxicologic considerations. Drummond GS, et al. **J Perinatol** 1996 May–Jun;16(3 Pt 2):S72–9 (36 ref.)

Traditional Chinese medicine and treatment of neonatal jaundice. Ho NK. **Singapore Med J** 1996 Dec;37(6):645–51 (88 ref.)

PREVENTION & CONTROL

Can severe neonatal jaundice be prevented by neonatal screening for glucose-6-phosphate dehydrogenase deficiency?—a review of evidence. Chuu WM, et al. **Acta Paediatr Sin** 1996 Sep–Oct;37(5):333–41 (66 ref.)

PSYCHOLOGY

[Hyperbilirubinemia in full-term neonates: sequelae for long-term development better than expected. Ad-hoc Commission Hyperbilirubinemia and Phototherapy of the Section Neonatology of the Netherlands Society for Pediatrics] Brand PL, et al. **Ned Tijdschr Geneeskd** 1997 Jan 18;141(3):144–7 (38 ref.) (Eng. Abstr.) **(Dut)**

THERAPY

Jaundice in the healthy term neonate: when is treatment indicated? Bland HE. **Curr Probl Pediatr** 1996 Nov–Dec; 26(10):355–63 (40 ref.)

Criteria for treatment of neonatal jaundice. Bratlid D. **J Perinatol** 1996 May–Jun;16(3 Pt 2):S83–8 (32 ref.)

Progress in phototherapy. de Araújo MC, et al. **Rev Paul Med** 1996 Mar–Apr;114(2):1134–40 (33 ref.)

JAUNDICE, OBSTRUCTIVE see **CHOLESTASIS**

JAUNDICE, OBSTRUCTIVE, EXTRAHEPATIC see **BILE DUCT OBSTRUCTION, EXTRAHEPATIC**

JAUNDICE, OBSTRUCTIVE, INTRAHEPATIC see **CHOLESTASIS, INTRAHEPATIC**

JAUNDICE, SPIROCHETAL see **WEIL'S DISEASE**

JAW

see related
TEMPOROMANDIBULAR JOINT

IMMUNOLOGY

Jaw, adaptive immunity and phylogeny of vertebrate antibody VH gene family. Andersson E, et al. **Res Immunol** 1996 May;147(4):233–40 (65 ref.)

PHYSIOLOGY

Modeling the mechanical behavior of the jaws and their related structures by finite element (FE) analysis. Korioth TW, et al. **Crit Rev Oral Biol Med** 1997;8(1):90–104 (158 ref.)

Re-examining jaw regeneration in urodeles: what have we learnt? Ferretti P. **Int J Dev Biol** 1996 Aug;40(4):807–11 (30 ref.)

Encoding of tooth loads by human periodontal afferents and their role in jaw motor control. Trulsson M, et al. **Prog Neurobiol** 1996 Jun;49(3):267–84 (89 ref.)

SURGERY

Surgical-orthodontic correction of adult facial deformities. Blanchaert R, et al. **Dent Clin North Am** 1996 Oct; 40(4):945–59 (26 ref.)

Perioperative morbidity in maxillofacial orthopaedic surgery: a retrospective study. Van de Perre JP, et al. **J Craniomaxillofac Surg** 1996 Oct;24(5):263–70 (123 ref.)

Facial growth and the need for orthognathic surgery after cleft palate repair: literature review and report of 28 cases. DeLuke DM, et al. **J Oral Maxillofac Surg** 1997 Jul; 55(7):694–7; discussion 697–8 (20 ref.)

[Experimental research in maxillofacial surgery] Ferri J, et al. **Rev Stomatol Chir Maxillofac** 1997 Sep;98(3):179–82 (19 ref.) **(Fre)**

JAW ABNORMALITIES

GENETICS

[Autosomal chromosomes and anomalies of the oromaxillofacial area] Giacchetti D, et al. **Minerva Stomatol** 1996 Apr;45(4):157–67 (52 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Heminasal aplasia: a case report and review of the literature of the last 25 years. van Kempen AA, et al. **Clin Dysmorphol** 1997 Apr;6(2):147–52 (32 ref.)

JAW CYSTS

PATHOLOGY

New developments in selected cysts of the jaws. Daley TED, et al. **J Can Dent Assoc** 1997 Jul–Aug;63(7):526–7, 530–2 (34 ref.)

JAW DISEASES

CHEMICALLY INDUCED

Minocycline-induced intraoral pharmacogenic pigmentation: case reports and review of the literature. Westbury LW, et al. **J Periodontol** 1997 Jan;68(1):84–91 (78 ref.)

COMPLICATIONS

The role of osteopenia in oral bone loss and periodontal disease. Wactawski-Wende J, et al. **J Periodontol** 1996 Oct; 67(10 Suppl):1076–84 (108 ref.)

ETIOLOGY

Anatomical considerations in the diagnosis and management of acute maxillofacial bacterial infections. Bridgeman A, et al. **Aust Dent J** 1996 Aug;41(4):238–45 (33 ref.)

[Brown tumor of the jaws] Tarello F, et al. **Minerva Stomatol** 1996 Oct;45(10):465–70 (17 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Oral manifestations of sarcoidosis. Blinder D, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Apr;83(4):458–61 (53 ref.)

RADIOGRAPHY

Panoramic radiography in dental diagnostics. Molander B. **Swed Dent J Suppl** 1996;119:1–26 (169 ref.)

SURGERY

[Paget disease of the jaws. Review of the subject. Clinical-therapeutic considerations] Russo A, et al. **Minerva Stomatol** 1996 Jul–Aug;45(7–8):349–54 (12 ref.) (Eng. Abstr.) **(Ita)**

JAW, EDENTULOUS

REHABILITATION

The implant-supported prosthesis for the edentulous arch: design considerations. Sadowsky SJ. **J Prosthet Dent** 1997 Jul;78(1):28–33 (41 ref.)

JAW NEOPLASMS

COMPLICATIONS

[Oral candidiasis following radiotherapy for neoplasms of the oromaxillofacial area] Tartaro GP, et al. **Minerva Stomatol** 1996 Oct;45(10):451–4 (9 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Ameloblastoma. Cytologic findings and literature review. Mathew S, et al. **Acta Cytol** 1997 Jul–Aug;41(4):955–60 (15 ref.)

Some current concepts on the pathology of ameloblastomas. Gardner DG. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Dec;82(6):660–9 (34 ref.)

Clear cell tumors of the salivary glands, jaws, and oral

JAW NEOPLASMS

mucosa. Maiorano E, et al. **Semin Diagn Pathol** 1997 Aug; 14(3):203–12 (80 ref.)

SURGERY

[Enteral nutrition in maxillofacial oncology] Garau V, et al. **Minerva Stomatol** 1997 Jul–Aug;46(7–8):415–22 (29 ref.) (Eng. Abstr.) **(Ita)**

JC VIRUS see **POLYOMAVIRUS HOMINIS 2**

JE PROTEIN see **MONOCYTE CHEMOATTRACTANT PROTEIN-1**

JEALOUSY

Morbid jealousy as a variant of obsessive–compulsive disorder. Parker G, et al. **Aust N Z J Psychiatry** 1997 Feb; 31(1):133–8 (16 ref.)

JEHOVAH'S WITNESSES see **CHRISTIANITY**

JEJUNAL DISEASES

Small bowel obstruction secondary to enterolith impaction complicating jejunal diverticulitis. Harris LM, et al. **Am J Gastroenterol** 1997 Sep;92(9):1538–40 (16 ref.)

Crohn's disease of the upper gastrointestinal tract. Wagtmans MJ, et al. **Neth J Med** 1997 Feb;50(2):S2–7 (58 ref.)

COMPLICATIONS

Severe abdominal pain and thrombocytopenia––typical symptoms of occult jejunal diverticulum perforation? Klee FE, et al. **J Gastroenterol** 1997 Apr;32(2):246–50 (62 ref.)

[Gastrointestinal hemorrhage and diverticula of the jejunum––presentation of a case report and review of the literature] Greco B, et al. **Swiss Surg** 1997;3(3):104–6 (11 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Melanosis jejuni. Banai J, et al. **Gastrointest Endosc** 1997 May;45(5):432–4 (23 ref.)

Jejunal angiodysplasia confirmed by intravascular injection technique in vitro. Report of a case and review of the literature. Koga H, et al. **J Clin Gastroenterol** 1996 Sep; 23(2):139–44 (71 ref.)

[A case of isolated jejunal ulcer and review of the literature] Schmulson Wasserman MJ, et al. **Rev Invest Clin** 1995 Nov–Dec;47(6):477–80 (16 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Small bowel fistulae in Degos' disease: a case report and literature review. Atchabahian A, et al. **Am J Gastroenterol** 1996 Oct;91(10):2208–11 (57 ref.)

Perforation of the jejunum secondary to AIDS–related gastrointestinal Kaposi's sarcoma. Yoshida EM, et al. **Can J Gastroenterol** 1997 Jan–Feb;11(1):38–40 (15 ref.)

Intestinal stricture following seat belt injury in children. Lynch JM, et al. **J Pediatr Surg** 1996 Oct;31(10):1354–7 (13 ref.)

RADIOGRAPHY

Jejunal angiodysplasia confirmed by intravascular injection technique in vitro. Report of a case and review of the literature. Koga H, et al. **J Clin Gastroenterol** 1996 Sep; 23(2):139–44 (71 ref.)

JEJUNAL NEOPLASMS

Primary adenocarcinoma of the angle of Treitz. Case report and review of the literature. Fronticelli CM, et al. **Arch Surg** 1996 Oct;131(10):1109–11 (8 ref.)

Small bowel tumors: an overview. O'Riordan BG, et al. **Dig Dis** 1996 Jul–Aug;14(4):245–57 (41 ref.)

Extramedullary plasmacytoma of the jejunum. Tsuruda T, et al. **Intern Med** 1996 May;35(5):422–6 (15 ref.)

COMPLICATIONS

[A case of jejunal malignant lymphoma resulting in perforation 2 years after transcatheter arterial embolization for hepatocellular carcinoma] Yokohama A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Aug;93(8):578–82 (21 ref.) **(Jpn)**

CONGENITAL

Fetiform teratoma arising from a tubular intestinal duplication. A probable cause of ruptured exomphalos. Barker GM, et al. **Pediatr Surg Int** 1997 Feb;12(2–3):204–5 (7 ref.)

DIAGNOSIS

Polyps and polypoid lesions of the jejunum and ileum. Clinical aspects. Levine BA, et al. **Surg Oncol Clin N Am** 1996 Jul;5(3):609–19 (59 ref.)

PATHOLOGY

Sarcomatoid carcinoma of the small intestine. Lam KY, et al. **Aust N Z J Surg** 1996 Sep;66(9):636–9 (15 ref.)

Case report: Krukenberg tumours arising from a primary duodenojejunal adenocarcinoma. Loke TK, et al. **Clin Radiol** 1997 Feb;52(2):154–5 (12 ref.)

SECONDARY

[Multiple jejuno–ileal metastasis of malignant schwannoma from the leg. Report of a case presenting anemia symptoms and review of the literature] Crespi C, et al. **Minerva Chir** 1996 Oct;51(10):829–33 (12 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Pediatric intestinal leiomyosarcomas: case report and review of the literature. Kennedy AP Jr, et al. **J Pediatr Surg** 1997 Aug;32(8):1234–6 (25 ref.)

JEJUNOILEAL BYPASS

[Plastic surgery in the treatment of the outcome of intestinal bypass for obesity: a clinical case report] Bernardi C, et al. **G Chir** 1996 Nov–Dec;17(11–12):602–6 (15 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

Calcium carbonate as a constipating agent––a myth of centuries revisited. Caspary WF. **Eur J Gastroenterol Hepatol** 1996 Jun;8(6):545–7 (24 ref.)

JEJUNOSTOMY

[Motility deficits in Roux–loop gastrojejunal reconstruction after the surgical treatment of reflux diseases (the Roux stasis syndrome)] Mateş IN, et al. **Chirurgia (Bucur)** 1997 May–Jun;92(3):187–98 (50 ref.) (Eng. Abstr.) **(Rum)**

METHODS

Direct button percutaneous endoscopic jejunostomy: successful placement in a patient with severe malnutrition and previous gastric resection. Dumot JA, et al. **Gastrointest Endosc** 1997 Jan;45(1):92–4 (14 ref.)

[Enteral jejunostomy prevents malnutrition. The method is safe and practical even for home care] Elgadi A, et al. **Lakartidningen** 1997 Jan 29;94(5):324–6 (20 ref.) **(Swe)**

JEJUNUM

see related
JEJUNOSTOMY

Jejunoileal diverticula. Chow DC, et al. **Gastroenterologist** 1997 Mar;5(1):78–84 (74 ref.)

Churg–Strauss syndrome with intestinal perforation. Khan JA, et al. **JPMA J Pak Med Assoc** 1996 May;46(5):109–10 (13 ref.)

ABNORMALITIES

Segmental dilatation of the jejunum. Mir E, et al. **Acta Paediatr Jpn** 1996 Feb;38(1):69–71 (18 ref.)

Fetiform teratoma arising from a tubular intestinal duplication. A probable cause of ruptured exomphalos. Barker GM, et al. **Pediatr Surg Int** 1997 Feb;12(2–3):204–5 (7 ref.)

Congenital multiple intestinal atresia successfully treated with multiple anastomoses in a premature neonate: report of a case. Hasegawa T, et al. **Surg Today** 1996;26(10):849–51 (17 ref.)

BLOOD SUPPLY

Case report: successful treatment of bleeding jejunal varices using mesoportal recanalization and stent placement: report of a case and review of the literature. Stafford Johnson DB, et al. **Clin Radiol** 1997 Jul;52(7):562–5 (17 ref.)

Enteroscopic diagnosis of bleeding jejunal phlebectasia: a case report and review of literature. Kumar P, et al. **Gastrointest Endosc** 1997 Aug;46(2):185–7 (13 ref.)

GROWTH & DEVELOPMENT

Sialic acid––marker of development and differentiation. Kraml J, et al. **Sb Lek** 1994;95(4):271–75 (33 ref.)

INJURIES

Intestinal stricture following seat belt injury in children. Lynch JM, et al. **J Pediatr Surg** 1996 Oct;31(10):1354–7 (13 ref.)

METABOLISM

Sialic acid––marker of development and differentiation. Kraml J, et al. **Sb Lek** 1994;95(4):271–75 (33 ref.)

SURGERY

Jejunum or stomach for the pancreatic anastomosis after pancreaticoduodenectomy. Warshaw AL. **HPB Surg** 1997; 10(3):191–3 (4 ref.)

Congenital multiple intestinal atresia successfully treated with multiple anastomoses in a premature neonate: report of a case. Hasegawa T, et al. **Surg Today** 1996;26(10):849–51 (17 ref.)

[Complications of two types of pancreatic anastomosis after pancreaticoduodenectomy] Andivot T, et al. **Ann Chir** 1996;50(6):431–7 (37 ref.) (Eng. Abstr.) **(Fre)**

TRANSPLANTATION

Autotransplanted jejunum in head and neck cancer. Kornfehl J. **Eur J Cancer B Oral Oncol** 1994 Jan;30B(1):16–22 (96 ref.)

JELLYFISH

Worldwide deaths and severe envenomation from jellyfish stings. Fenner PJ, et al. **Med J Aust** 1996 Dec 2–16; 165(11–12):658–61 (32 ref.)

GROWTH & DEVELOPMENT

Checkpoints in the life–cycle of Cassiopea spp.: control of metagenesis and metamorphosis in a tropical jellyfish. Hofmann DK, et al. **Int J Dev Biol** 1996 Feb;40(1):331–8 (43 ref.)

JELLYFISH VENOMS see **CNIDARIAN VENOMS**

JERVELL–LANGE NIELSEN SYNDROME see **LONG QT SYNDROME**

JEWS

see related
JUDAISM

Diet and disease––the Israeli paradox: possible dangers of a high omega–6 polyunsaturated fatty acid diet. Yam D, et al. **Isr J Med Sci** 1996 Nov;32(11):1134–43 (135 ref.)

Familial Creutzfeldt–Jakob disease. Codon 200 prion disease in Libyan Jews. Meiner Z, et al. **Medicine (Baltimore)** 1997 Jul;76(4):227–37 (86 ref.)

Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families [see comments] Tonin P, et al. **Nat Med** 1996 Nov;2(11):1179–83 (25 ref.) Comment in: Nat Med 1996 Nov;2(11):1162.

JIMSONWEED see **STRAMONIUM**

JOB APPLICATION

How to get a job in medicine: 1. Scriven P. **Br J Hosp Med** 1996 May 1–14;55(9):546–8 (0 ref.)

Obtaining a faculty position in academic emergency medicine. Simon HK, et al. **Pediatr Emerg Care** 1997 Apr; 13(2):130–3 (9 ref.)

JOB DESCRIPTION

The physician executive: role in the adaptation of American medicine. Schneller ES, et al. **Health Care Manage Rev** 1997 Spring;22(2):90–6 (46 ref.)

Models of differentiated practice and specialization in community nursing: a review of the literature. Jansen PG, et al. **J Adv Nurs** 1996 Nov;24(5):968–80 (89 ref.)

The concept of the specialist community nurse. Kelly A. **J Adv Nurs** 1996 Jul;24(1):42–52 (51 ref.)

The emergency nurse practitioner role in major accident and emergency departments: professional issues and the research agenda. Tye CC. **J Adv Nurs** 1997 Aug; 26(2):364–70 (54 ref.)

The nurse's role as patient advocate: obligation or imposition? Willard C. **J Adv Nurs** 1996 Jul;24(1):60–6 (30 ref.)

The role of the clinical research coordinator in multicenter clinical trials. Pelke S, et al. **J Obstet Gynecol Neonatal Nurs** 1997 May–Jun; 26(3):279–85 (14 ref.)

Conducting a comprehensive school health program. Resnicow K, et al. **J Sch Health** 1996 Feb;66(2):59–63 (19 ref.)

Justifying nurse practitioner existence: hard facts to hard figures [see comments] Buppert CK. **Nurse Pract** 1995 Aug; 20(8):43–4, 46–8 (12 ref.) Comment in: Nurse Pract 1996 Jan;21(1):6. Comment in: Nurse Pract 1996 Jan;21(1):6, 9.

The role of nursing in primary health care. Campbell S. **WHO Reg Publ Eur Ser** 1997;74:209–39 (59 ref.)

JOB LADDERS see **CAREER MOBILITY**

JOB SATISFACTION

Career satisfaction and clinician–educators. The rewards and challenges of teaching. The Society of General Internal Medicine Career Satisfaction Study Group. Gerrity MS, et al. **J Gen Intern Med** 1997 Apr;12 Suppl 2:S90–7 (55 ref.)

Unrelieved job stress can lead to burnout. Clarke S, et al. **Radiol Technol** 1996 Nov–Dec;68(2):159–60 (9 ref.)

JOB'S SYNDROME

[Abnormality of immunoglobulin (hyperimmunoglobulinemia E syndrome)] Sugiyama H. **Ryoikibetsu Shokogun Shirizu** 1996;(15):155–7 (6 ref.) **(Jpn)**

JOHNE'S DISEASE see **PARATUBERCULOSIS**

JOINING REGION, IG see **IMMUNOGLOBULIN JOINING REGION**

JOINT CAPSULE

DRUG EFFECTS

Facet joint injections. Gunzburg R, et al. **Bull Hosp Jt Dis** 1996;55(4):173–5 (22 ref.)

PHYSIOLOGY

The joint capsule and joint laxity in dogs with hip dysplasia [see comments] Madsen JS. **J Am Vet Med Assoc** 1997 May 15;210(10):1463–5 (26 ref.) Comment in: J Am Vet Med Assoc 1997 May 15;210(10):1417–8.

A scientific basis for the biologic regeneration of synovial joints. Luyten FP. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jan;83(1):167–9 (169 ref.)

JOINT COMMISSION ON ACCREDITATION OF HEALTHCARE ORGANIZATIONS

The benefits of continuous performance measurement. Nadzam DM, et al. **Nurs Clin North Am** 1997 Sep; 32(3):543–59 (13 ref.)

JOINT COMMISSION ON ACCREDITATION OF HOSPITALS see **JOINT COMMISSION ON ACCREDITATION OF HEALTHCARE ORGANIZATIONS**

JOINT DEFORMITIES, ACQUIRED

DIAGNOSIS

Genu varum and genu valgum in children. Greene WB. **Instr Course Lect** 1994;43:151–9 (35 ref.)

SURGERY

Surgical techniques and the management of fixed deformities in total knee arthroplasty. Delfico AJ, et al. **Am J Knee Surg** 1996 Spring;9(2):83–90 (24 ref.)

THERAPY

Genu varum and genu valgum in children. Greene WB. **Instr Course Lect** 1994;43:151–9 (35 ref.)

Rotational problems in children. Staheli LT. **Instr Course Lect** 1994;43:199–209 (91 ref.)

JOINT DISEASES

Arthroscopy of the knee. Satku K, et al. **Ann Acad Med Singapore** 1996 Sep;25(5):703–7 (29 ref.)

Sarcoid arthropathy. Totemchokchyakarn K, et al. **Bull Rheum Dis** 1997 May;46(3):3–5 (5 ref.)

Diagnostic and classification criteria, clinical and functional assessment, and therapeutic advances for spondyloarthropathies. Olivieri I, et al. **Curr Opin Rheumatol** 1997 Jul;9(4):284–90 (85 ref.)

Ulnar drift [editorial] Flatt AE. **J Hand Ther** 1996 Oct–Dec; 9(4):282–92 (24 ref.)

COMPLICATIONS

Bruck syndrome (osteogenesis imperfecta with congenital joint contractures): review and report on the first North American case. McPherson E, et al. **Am J Med Genet** 1997 May 2;70(1):28–31 (4 ref.)

The spectrum of osteoarticular and soft tissue changes in patients with human immunodeficiency virus (HIV) infection. Tehranzadeh J, et al. **Crit Rev Diagn Imaging** 1996 Sep;37(4):305–47 (43 ref.)

Osteoarticular manifestations of congenital insensitivity to pain with anhydrosis. Szöke G, et al. **Int Orthop** 1996; 20(2):107–10 (22 ref.)

Three common causes of childhood hip pain. Koop S, et al. **Pediatr Clin North Am** 1996 Oct;43(5):1053–66 (23 ref.)

Four new cases of collagenous colitis with joint symptoms. Soulier C, et al. **Rev Rhum Engl Ed** 1996 Oct;63(9):593–9 (49 ref.)

DIAGNOSIS

MR arthrography: a review of current technique and applications. Helgason JW, et al. **AJR Am J Roentgenol** 1997 Jun;168(6):1473–80 (50 ref.)

Massive proximal femoral osteoarticular allograft. Bohm P, et al. **Arch Orthop Trauma Surg** 1996;115(2):100–3 (23 ref.)

Diagnostic and quantitative arthroscopy: quantitative arthroscopy. Ayral X. **Baillieres Clin Rheumatol** 1996 Aug; 10(3):477–94 (28 ref.)

Diagnostic radiography in rheumatoid arthritis: benefits and limitations. Bohndorf K, et al. **Baillieres Clin Rheumatol** 1996 Aug;10(3):399–407 (17 ref.)

Synovial fluid cell analysis. Dougados M. **Baillieres Clin Rheumatol** 1996 Aug;10(3):519–34 (29 ref.)

MR imaging. Peterfy CG. **Baillieres Clin Rheumatol** 1996 Nov;10(4):635–78 (53 ref.)

Percutaneous needle biopsy and synovial histology. Saaibi DL, et al. **Baillieres Clin Rheumatol** 1996 Aug;10(3):535–54 (118 ref.)

Salmonella braenderup sacroiliac osteomyelitis in a nonsickle cell patient: case report. Hunt BK, et al. **Bull Hosp Jt Dis** 1996;55(2):86–7 (9 ref.)

Imaging of articular pathology: MRI, CT, arthrography. Berquist TH. **Clin Anat** 1997;10(1):1–13 (35 ref.)

Magnetic resonance imaging of the musculoskeletal system. Part 5. The wrist. Siegel S, et al. **Clin Orthop** 1996 Nov; (332):281–300 (35 ref.)

Evaluation of the patient presenting with a painful wrist. Young VL, et al. **Clin Plast Surg** 1996 Jul;23(3):361–8 (12 ref.)

Radiologic interpretation of vacuum phenomena. Balkissoon AR. **Crit Rev Diagn Imaging** 1996 Oct;37(5):435–60 (25 ref.)

Wrist disorders: what should we be looking for with imaging techniques? Berquist TH. **J Hand Ther** 1996 Apr–Jun; 9(2):108–13 (22 ref.)

Aneurysmal bone cyst involving the distal phalanx of a child. Katz MA, et al. **Orthopedics** 1997 May;20(5):463–6 (23 ref.)

Pediatric knee. Clinical assessment and common disorders. Davids JR. **Pediatr Clin North Am** 1996 Oct;43(5):1067–90 (67 ref.)

Indirect MR arthrography: techniques and applications. Vahlensieck M, et al. **Semin Ultrasound CT MR** 1997 Aug; 18(4):302–6 (9 ref.)

[MRI of the joints] Haltiala T, et al. **Duodecim** 1995; 111(16):1553–64 (21 ref.) **(Fin)**

[Clinical, radiologic and other examinations in diagnosis of knee joint changes] Kotela I. **Przegl Lek** 1996;53(3):181–4 (20 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Facet joint injections. Gunzburg R, et al. **Bull Hosp Jt Dis** 1996;55(4):173–5 (22 ref.)

Metalloproteinase inhibitors and the prevention of connective tissue breakdown. Cawston TE. **Pharmacol Ther** 1996; 70(3):163–82 (278 ref.)

EPIDEMIOLOGY

Predisposing factors to spondyloarthropathies. Brown M, et al. **Curr Opin Rheumatol** 1997 Jul;9(4):308–14 (91 ref.)

ETIOLOGY

Connective tissue and joint disease in diabetes mellitus. Rosenbloom AL, et al. **Endocrinol Metab Clin North Am** 1996 Jun;25(2):473–83 (47 ref.)

The stiff total knee replacement: causes, treatment, and prevention. Johanson NA. **Instr Course Lect** 1997;46:191–5 (28 ref.)

Limited joint mobility in children with type 1 diabetes mellitus. A critical review. Verrotti A, et al. **J Pediatr Endocrinol Metab** 1996 Jan–Feb;9(1):3–8 (43 ref.)

Joint disorders in cystic fibrosis. Turner MA, et al. **J R Soc Med** 1997;90 Suppl 31:13–20 (60 ref.)

Microscopic polyangiitis after influenza vaccination. Kelsall JT, et al. **J Rheumatol** 1997 Jun;24(6):1198–202 (15 ref.)

New aspects in the pathogenesis of dialysis-related amyloidosis: role of beta 2-microglobulin modified with advanced glycation end products in bone and joint destruction. Miyata T, et al. **Nephrol Dial Transplant** 1996; 11 Suppl 2:140–3 (17 ref.)

Heterotopic ossification in neuromuscular disorders. Botte MJ, et al. **Orthopedics** 1997 Apr;20(4):335–41; quiz 342–3 (68 ref.)

Joint manifestations in myelodysplastic syndromes. A report of three cases presenting as polymyalgia rheumatica. Berthelot JM, et al. **Rev Rhum Engl Ed** 1997 Feb; 64(2):95–100 (35 ref.)

Occupation as a risk factor for knee disorders. Jensen LK, et al. **Scand J Work Environ Health** 1996 Jun;22(3):165–75 (72 ref.)

[Changes in the locomotor system in gastrointestinal diseases] Zulkarneev RA. **Khirurgiia (Mosk)** 1997;(4):74–7 (83 ref.) **(Rus)**

GENETICS

Predisposing factors to spondyloarthropathies. Brown M, et al. **Curr Opin Rheumatol** 1997 Jul;9(4):308–14 (91 ref.)

IMMUNOLOGY

Pathogenic role of gut inflammation in the spondyloarthropathies. Gaston JS. **Curr Opin Rheumatol** 1997 Jul;9(4):302–7 (62 ref.)

MICROBIOLOGY

Clinical, bacteriological, and serological aspects of Klebsiella infections and their spondylarthropathic sequelae. Sahly H, et al. **Clin Diagn Lab Immunol** 1997 Jul;4(4):393–9 (104 ref.)

Septic bone and joint infections. Hedstrom SA. **Curr Opin Rheumatol** 1997 Jul;9(4):317–20 (11 ref.)

Septic arthritis. Pioro MH, et al. **Rheum Dis Clin North Am** 1997 May;23(2):239–58 (102 ref.)

PATHOLOGY

The articular polymodal nociceptor in health and disease. Schmidt RF. **Prog Brain Res** 1996;113:53–81 (111 ref.)

[A case of a combination of sarcoidosis and myeloma] Kamaeva OI, et al. **Ter Arkh** 1995;67(12):57–9 (19 ref.) **(Rus)**

PHYSIOPATHOLOGY

Spondyloarthropathies [editorial] Khan MA. **Curr Opin Rheumatol** 1997 Jul;9(4):281–3 (4 ref.)

Pathophysiology of joint pain. Perrot S, et al. **Rev Rhum Engl Ed** 1996 Jul–Sep;63(7–8):485–92 (88 ref.)

PREVENTION & CONTROL

[Examination methods for the prevention of traumatic and nontraumatic osteoarthropathies related to flying activity] Rotondo G. **Riv Med Aeronaut Spaz** 1975 Oct–Dec; 38(4):375–91 (25 ref.) (Eng. Abstr.) **(Ita)**

RADIOGRAPHY

Imaging in clinical trials. Bird HA. **Baillieres Clin Rheumatol** 1996 Nov;10(4):699–709 (61 ref.)

CT scans and arthro-CT scans. Drape JL, et al. **Baillieres Clin Rheumatol** 1996 Nov;10(4):615–34 (13 ref.)

Interventional radiology techniques in musculoskeletal disease. Gibbon WW. **Baillieres Clin Rheumatol** 1996 Nov; 10(4):711–27 (22 ref.)

RADIONUCLIDE IMAGING

Isotope imaging. Ryan PJ, et al. **Baillieres Clin Rheumatol** 1996 Nov;10(4):589–613 (54 ref.)

REHABILITATION

Anterior-inferior capsular length insufficiency in the painful shoulder. Hjelm R, et al. **J Orthop Sports Phys Ther** 1996 Mar;23(3):216–22 (14 ref.)

Basic protocols of rehabilitation for the ankle, knee, hip, and shoulder. Torburn L. **Prim Care** 1996 Jun;23(2):389–403 (24 ref.)

SURGERY

Arthroscopy in hand surgery. Jones KJ. **Clin Plast Surg** 1996 Jul;23(3):463–76 (30 ref.)

Current status of wrist arthrodesis and wrist arthroplasty. Murray PM. **Clin Plast Surg** 1996 Jul;23(3):385–94 (63 ref.)

Aneurysmal bone cyst involving the distal phalanx of a child. Katz MA, et al. **Orthopedics** 1997 May;20(5):463–6 (23 ref.)

Current concepts in the treatment of articular cartilage defects. Minas T, et al. **Orthopedics** 1997 Jun;20(6):525–38 (41 ref.)

[What treatment expectations does the elderly patient have from surgery and what can surgery achieve? From the viewpoint of joint surgery] Pfister U. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:439–43 (9 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Interventional radiology techniques in musculoskeletal disease. Gibbon WW. **Baillieres Clin Rheumatol** 1996 Nov; 10(4):711–27 (22 ref.)

Splinting the wrist: mobilization and protection. Schultz-Johnson K. **J Hand Ther** 1996 Apr–Jun; 9(2):165–77 (54 ref.)

[Shock waves in orthopedics] Haupt G. **Urologe A** 1997 May; 36(3):233–8 (48 ref.) (Eng. Abstr.) **(Ger)**

JOINT INSTABILITY

What happens in the motion segment? Panjabi MM. **Bull Hosp Jt Dis** 1996;55(3):149–53 (14 ref.)

Desbuquois syndrome in an Arab Bedouin family. al-Gazeli LI, et al. **Clin Genet** 1996 Oct;50(4):255–9 (13 ref.)

Joint hypermobility syndromes. Raff ML, et al. **Curr Opin Rheumatol** 1996 Sep;8(5):459–66 (81 ref.)

The natural progression of scaphoid instability. Watson HK, et al. **Hand Clin** 1997 Feb;13(1):39–49 (16 ref.)

Nontraumatic glenohumeral instability and coracoacromial impingement in swimmers. Bak K. **Scand J Med Sci Sports** 1996 Jun;6(3):132–44 (76 ref.)

COMPLICATIONS

Lumbar spine instability: outcome and randomized controlled trials. Nachemson AL. **Bull Hosp Jt Dis** 1996;55(3):166 (11 ref.)

Comparison of neurologic deficits with atlanto-dens intervals in patients with Down syndrome. Ferguson RL, et al. **J Spinal Disord** 1997 Jun;10(3):246–52 (30 ref.)

DIAGNOSIS

Screening of children with Down syndrome for atlantoaxial (C1–2) instability: another contentious health question. Taylor TK, et al. **Med J Aust** 1996 Oct 21;165(8):448–50 (20 ref.)

MR arthrography of the glenohumeral joint. Stoller DW. **Radiol Clin North Am** 1997 Jan;35(1):97–116 (47 ref.)

Evaluation of shoulder laxity. McFarland EG, et al. **Sports Med** 1996 Oct;22(4):264–72 (38 ref.)

[Diagnostic imaging of instability of the shoulder joint] Funke M, et al. **Radiologe** 1996 Dec;36(12):951–9 (59 ref.) (Eng. Abstr.) **(Ger)**

[Diagnostic imaging of ankle joint instability] Schäfer D, et al. **Sportverletz Sportschaden** 1996 Sep;10(3):55–7 (30 ref.) (Eng. Abstr.) **(Ger)**

JOINT INSTABILITY

ETIOLOGY

Extensor mechanism problems in total knee arthroplasty. Dennis DA. **Instr Course Lect** 1997;46:171–80 (119 ref.)

Complications of type I coronoid fractures in competitive athletes: report of two cases and review of the literature. Liu SH, et al. **J Shoulder Elbow Surg** 1996 May–Jun; 5(3):223–7 (18 ref.)

[Arthroscopic aspects and chronologic outcome of lesions of the labro–ligament complex in post–traumatic antero–inferior instability of the shoulder. A prospective study of 91 cases] Gleyze P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(4):288–98 (46 ref.) (Eng. Abstr.) **(Fre)**

[Knee instability in sportsmen due to anterior cruciate ligament tear] Soudry M, et al. **Harefuah** 1996 Jun 16; 130(12):863–7 (42 ref.) **(Heb)**

PHYSIOPATHOLOGY

The mysteries of segmental instability. Szpalski M. **Bull Hosp Jt Dis** 1996;55(3):147–8 (10 ref.)

Proprioception and joint stability. Jerosch J, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;4(3):171–9 (106 ref.)

Evaluation of shoulder laxity. McFarland EG, et al. **Sports Med** 1996 Oct;22(4):264–72 (38 ref.)

[Biomechanics of lumbar instability] Krismer M, et al. **Orthopade** 1997 Jun;26(6):516–20 (37 ref.) (Eng. Abstr.) **(Ger)**

[Biomechanics of the ligaments of the unstable ankle joint] Hintermann B. **Sportverletz Sportschaden** 1996 Sep; 10(3):48–54 (64 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Traumatic peroneal tendon instability [see comments] Mason RB, et al. **Am J Sports Med** 1996 Sep–Oct;24(5):652–8 (30 ref.) Comment in: Am J Sports Med 1997 Jul–Aug;25(4):587.

Arthroscopic stabilization of the ankle. Kashuk KB, et al. **Clin Podiatr Med Surg** 1997 Jul;14(3):459–78 (38 ref.)

Arthroscopic Bankart repair. Shea KP. **Clin Sports Med** 1996 Oct;15(4):737–51 (37 ref.)

The treatment of wrist instability. Garcia–Elias M. **J Bone Joint Surg Br** 1997 Jul;79(4):684–90 (51 ref.)

Management of carpal instabilities. Wright TW, et al. **J Hand Ther** 1996 Apr–Jun;9(2):148–56 (37 ref.)

Different patterns of meniscal tears in acute anterior cruciate ligament (ACL) ruptures and in chronic ACL–deficient knees. Classification, staging and timing of treatment. Cipolla M, et al. **Knee Surg Sports Traumatol Arthrosc** 1995; 3(3):130–4 (15 ref.)

Anatomic endoscopic ACL reconstruction with autogenous patellar tendon graft. Clancy WG Jr. **Orthopedics** 1997 May;20(5):397, 399–400 (5 ref.)

[Scapho–capitate fracture. Apropos of a case, review of the literature] Boisgard S, et al. **Ann Chir Main Memb Super** 1996;15(3):181–8 (21 ref.) (Eng. Abstr.) **(Fre)**

[Functional disorders of the foot after tenodeses: is the method still currently acceptable?] Becker HP, et al. **Sportverletz Sportschaden** 1996 Dec;10(4):94–9 (47 ref.) (Eng. Abstr.) **(Ger)**

[The unstable upper ankle joint. Treatment of acute ligament rupture—a review of the literature] Sommer CJ. **Sportverletz Sportschaden** 1996 Dec;10(4):76–8 (34 ref.) (Eng. Abstr.) **(Ger)**

[Arthroscopic therapy of the unstable shoulder joint—acceptance and critical considerations] Jerosch J. **Z Orthop Ihre Grenzgeb** 1997 Jan–Feb;135(1):79–83 (40 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

The joint capsule and joint laxity in dogs with hip dysplasia [see comments] Madsen JS. **J Am Vet Med Assoc** 1997 May 15;210(10):1463–5 (26 ref.) Comment in: J Am Vet Med Assoc 1997 May 15;210(10):1417–8.

Surgical conditions of the cervical spine. Tomlinson J. **Semin Vet Med Surg (Small Anim)** 1996 Nov;11(4):225–34 (28 ref.)

[Hip dysplasia in dogs—a new radiologic technique for the recognition of loose hip joints] Flückiger M, et al. **Schweiz Arch Tierheilkd** 1997;139(4):183–5 (0 ref.) **(Ger)**

JOINT LOOSE BODIES

SURGERY

Arthroscopic excision of intra–articular ossifications. A case report and review of the literature. Rooney RC, et al. **Am J Orthop** 1996 Jun;25(6):437–40 (7 ref.)

JOINT PROSTHESIS

The elbow joint and its total arthroplasty. Part II. Finite element study. Lewis G, et al. **Biomed Mater Eng** 1996; 6(5):367–77 (25 ref.)

The elbow joint and its total arthroplasty. Part I. A state–of–the–art review. Lewis G. **Biomed Mater Eng** 1996; 6(5):353–65 (42 ref.)

Cellular basis for failure of joint prosthesis. Mohanty M. **Biomed Mater Eng** 1996;6(3):165–72 (24 ref.)

Digital implant arthroplasty. Sgarlato TE, et al. **Clin Podiatr Med Surg** 1996 Apr;13(2):255–62 (12 ref.)

MR imaging of soft tissues adjacent to orthopaedic hardware: techniques to minimize susceptibility artefact. Eustace S, et al. **Clin Radiol** 1997 Aug;52(8):589–94 (9 ref.)

Orthopaedic challenges in an aging population. Goldberg VM, et al. **Instr Course Lect** 1997;46:417–22 (24 ref.)

Complications of humeral head replacement for proximal humeral fractures. Muldoon MP, et al. **Instr Course Lect** 1997;46:15–24 (40 ref.)

The current status of hydroxyapatite coating of prostheses [editorial] Søballe K, et al. **J Bone Joint Surg Br** 1996 Sep; 78(5):689–91 (39 ref.)

Total shoulder arthroplasty. James WC 3rd, et al. **J S C Med Assoc** 1996 Oct;92(10):426–31 (15 ref.)

Indications for glenoid resurfacing in shoulder arthroplasty. Rodosky MW, et al. **J Shoulder Elbow Surg** 1996 May–Jun; 5(3):231–48 (107 ref.)

Temporomandibular joint devices: treatment factors and outcomes. Wolford LM. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jan;83(1):143–9 (149 ref.)

Biological reaction to debris in relation to joint prostheses. Revell PA, et al. **Proc Inst Mech Eng [H]** 1997; 211(2):187–97 (90 ref.)

[Current problems and future trends of polymeric biomaterials for orthopaedic surgery] Ikada Y. **Nippon Seikeigeka Gakkai Zasshi** 1996 Jan;70(1):28–39 (28 ref.) **(Jpn)**

ADVERSE EFFECTS

Current concepts in orthopaedic biomaterials and implant fixation. Friedman RJ, et al. **Instr Course Lect** 1994; 43:233–55 (193 ref.)

Prevention of deep periprosthetic joint infection. Hanssen AD, et al. **Instr Course Lect** 1997;46:555–67 (132 ref.)

Prevention of sepsis in total joint arthroplasty. An YH, et al. **J Hosp Infect** 1996 Jun;33(2):93–108 (135 ref.)

Failed implants and multiple operations. Milam SB. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jan;83(1):156–62 (103 ref.)

Synovitis and silicone joint implants: a summary of reported cases. Foliart DE. **Plast Reconstr Surg** 1997 Jan; 99(1):245–52 (59 ref.)

METHODS

Arthroplasty for arthritis and rotator cuff deficiency. Collins DN, et al. **Orthop Clin North Am** 1997 Apr;28(2):225–39 (59 ref.)

REHABILITATION

Sports after total joint replacement. Cirincione RJ. **Md Med J** 1996 Aug;45(8):644–7 (12 ref.)

STANDARDS

Total joint replacement: on innovation, ambition, courage, irony and morsellized bone, of course. Huiskes R. **Iowa Orthop J** 1997;17:130–3 (0 ref.)

Biomechanics and design of shoulder arthroplasty. McCullagh PJ. **Proc Inst Mech Eng [H]** 1995;209(4):207–13 (23 ref.)

JOINT PURCHASING see **GROUP PURCHASING**

JOINT TUBERCULOSIS see **TUBERCULOSIS, OSTEOARTICULAR**

JOINT VENTURES, HOSPITAL–PHYSICIAN see **HOSPITAL–PHYSICIAN JOINT VENTURES**

JOINTS

see related
ARTHROGRAPHY
ARTHROPLASTY
ARTHROSCOPY

Malignant giant cell tumor of the tendon sheaths and joints (malignant pigmented villonodular synovitis). Bertoni F, et al. **Am J Surg Pathol** 1997 Feb;21(2):153–63 (14 ref.)

To splint or not to splint—past philosophy and present practice: Part I. Richard R, et al. **J Burn Care Rehabil** 1996 Sep–Oct;17(5):444–53 (112 ref.)

DRUG EFFECTS

Effects of cyclosporin on joint damage in rheumatoid arthritis. The Italian Rheumatologists Study Group on Rheumatoid Arthritis. Ferraccioli GF, et al. **Clin Exp Rheumatol** 1997 May–Jun;15 Suppl 17:S83–9 (32 ref.)

IMMUNOLOGY

T–cell reactivity to human HSP60 in oligo–articular juvenile chronic arthritis is associated with a favorable prognosis and the generation of regulatory cytokines in the inflamed joint. Prakken AB, et al. **Immunol Lett** 1997 Jun 1; 57(1–3):139–42 (20 ref.)

INJURIES

Orthopaedic challenges in an aging population. Goldberg VM, et al. **Instr Course Lect** 1997;46:417–22 (24 ref.)

Proprioception and joint stability. Jerosch J, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;4(3):171–9 (106 ref.)

MR imaging of injuries to the small joints. Horton MG, et al. **Radiol Clin North Am** 1997 May;35(3):671–700 (111 ref.)

Acute and chronic avulsive injuries. el–Khoury GY, et al. **Radiol Clin North Am** 1997 May;35(3):747–66 (42 ref.)

Indirect MR arthrography: techniques and applications. Vahlensieck M, et al. **Semin Ultrasound CT MR** 1997 Aug; 18(4):302–6 (9 ref.)

[New developments in joint surgery] Lobenhoffer P, et al. **Orthopade** 1997 May;26(5):422–36 (76 ref.) (Eng. Abstr.) **(Ger)**

[Periarticular fractures of the upper and lower extremity. I: ABC classification using the AO principle] Arand M, et al. **Rontgenpraxis** 1997 Jun;50(6):168–74 (16 ref.) **(Ger)**

[Periarticular fractures of the upper and lower extremity. II: Therapeutic principle] Arand M, et al. **Rontgenpraxis** 1997 Jun;50(6):175–81 (19 ref.) **(Ger)**

[Periarticular fractures—what should be observed?] Hald HJ. **Rontgenpraxis** 1997 Jun;50(6):158–67 (41 ref.) **(Ger)**

INNERVATION

The articular polymodal nociceptor in health and disease. Schmidt RF. **Prog Brain Res** 1996;113:53–81 (111 ref.)

Pathophysiology of joint pain. Perrot S, et al. **Rev Rhum Engl Ed** 1996 Jul–Sep;63(7–8):485–92 (88 ref.)

PATHOLOGY

The arthropathy of fibroblastic rheumatism. Romas E, et al. **Arthritis Rheum** 1997 Jan;40(1):183–7 (16 ref.)

Joint destruction in rheumatoid arthritis: biological bases. Kingsley G, et al. **Clin Exp Rheumatol** 1997 May–Jun;15 Suppl 17:S3–14 (103 ref.)

Cellular pathways of joint destruction. Müller–Ladner U, et al. **Curr Opin Rheumatol** 1997 May;9(3):213–20 (76 ref.)

Lessons for joint destruction from animal models. van den Berg WB. **Curr Opin Rheumatol** 1997 May;9(3):221–8 (71 ref.)

Optimizing joint imaging: MR imaging techniques. Adam G, et al. **Eur Radiol** 1996;6(6):882–9 (55 ref.)

MR arthrography: is it worthwhile? Palmer WE. **Top Magn Reson Imaging** 1996 Feb;8(1):24–43 (50 ref.)

Osteoarthritis. Joint anatomy, physiology, and pathobiology. Johnston SA. **Vet Clin North Am Small Anim Pract** 1997 Jul;27(4):699–723 (102 ref.)

[MRI of the joints] Haltiala T, et al. **Duodecim** 1995; 111(16):1553–64 (21 ref.) **(Fin)**

[The pathogenesis of joint destruction in chronic polyarthritis] Mohr W. **Radiologe** 1996 Aug;36(8):593–9 (40 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Effects of age on the biomechanics and physiology of gait. Judge JO, et al. **Clin Geriatr Med** 1996 Nov;12(4):659–78 (45 ref.)

Proprioception and joint stability. Jerosch J, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;4(3):171–9 (106 ref.)

[Dynamic joint control training as neuromuscular coordination] Ihara H. **Nippon Seikeigeka Gakkai Zasshi** 1996 Sep;70(9):583–93 (30 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Joint assessment in rheumatoid arthritis. Scott DL, et al. **Br J Rheumatol** 1996 Sep;35 Suppl 2:14–8 (34 ref.)

Cellular pathways of joint destruction. Müller–Ladner U, et al. **Curr Opin Rheumatol** 1997 May;9(3):213–20 (76 ref.)

Skeletal malalignments of the lower quarter: correlated and compensatory motions and postures. Riegger–Krugh C, et al. **J Orthop Sports Phys Ther** 1996 Feb;23(2):164–70 (45 ref.)

Osteoarthritis. Joint anatomy, physiology, and pathobiology. Johnston SA. **Vet Clin North Am Small Anim Pract** 1997 Jul;27(4):699–723 (102 ref.)

[Hip joint congenital dysplasia, examination, treatment, ultrasound assessment in newborns and infants according to Graf] Pyka P, et al. **Pediatr Pol** 1996 Jun;71(6):543–7 (24 ref.) **(Pol)**

SURGERY

Total joint replacement and golf. Mallon WJ, et al. **Clin Sports Med** 1996 Jan;15(1):179–90 (32 ref.)

ULTRASONOGRAPHY

[Hip joint congenital dysplasia, examination, treatment, ultrasound assessment in newborns and infants according to Graf] Pyka P, et al. **Pediatr Pol** 1996 Jun;71(6):543–7 (24 ref.) **(Pol)**

JOSEPH AZOREAN DISEASE see **MACHADO–JOSEPH DISEASE**

JOSEPH DISEASE see **MACHADO–JOSEPH DISEASE**

JOURNALISM

Medical scientists and health news reporting: a case of miscommunication. Shuchman M, et al.

Ann Intern Med 1997 Jun 15;126(12):976–82 (67 ref.)
Evidence-based approach to the medical literature. Fletcher RH, et al. **J Gen Intern Med** 1997 Apr;12 Suppl 2:S5–14 (22 ref.)
The Journal of Human Hypertension: looking back over 10 years of research and thinking of the future [editorial] Beevers DG, et al. **J Hum Hypertens** 1997 Jan;11(1):1–5 (36 ref.)

JOURNALS see **PERIODICALS**

JUDAISM

see related
JEWS

Halachic perspective on involuntary psychiatric care of the mentally ill. Cohen DA, et al. **Med Law** 1995;14(5–6):463–9 (32 ref.)
Involuntary confinement for tuberculosis control: the Jewish view. Rosner F. **Mt Sinai J Med** 1996 Jan;63(1):44–8 (27 ref.)
[Sexuality and religions] Chaix-Durand G, et al. **Contracept Fertil Sex** 1997 Mar;25(3):I–XIII (26 ref.) **(Fre)**

JUDGMENT

Reflective learning: a teaching strategy for critical thinking. Baker CR. **J Nurs Educ** 1996 Jan;35(1):19–22 (14 ref.)
Issues in measuring critical thinking: meeting the challenge. Rane-Szostak D, et al. **J Nurs Educ** 1996 Jan;35(1):5–11 (41 ref.)
The psychology of good judgment: frequency formats and simple algorithms [see comments] Gigerenzer G. **Med Decis Making** 1996 Jul–Sep;16(3):273–80 (32 ref.)
Comment in: Med Decis Making 1997 Apr–Jun;17(2):233.
How convergence of research paradigms can improve research on diagnostic judgment. Hammond KR. **Med Decis Making** 1996 Jul–Sep;16(3):281–7 (30 ref.)
Externalizing the critical thinking in knowledge development and clinical judgment. Facione NC, et al. **Nurs Outlook** 1996 May–Jun;44(3):129–36 (19 ref.)
Can phronesis save the life of medical ethics? Beresford EB. **Theor Med** 1996 Sep;17(3):209–24 (42 ref.)
"Don't think zebras": uncertainty, interpretation, and the place of paradox in clinical education. Hunter K. **Theor Med** 1996 Sep;17(3):225–41 (19 ref.)

JUDO see **MARTIAL ARTS**

JUGAL BONE see **ZYGOMA**

JUGULAR VEINS

Aberrant external jugular vein phlebectasia with tongue pain. Stofman GM, et al. **Am J Otolaryngol** 1997 Mar–Apr;18(2):148–50 (8 ref.)
You are asked to place a dialysis access catheter in a patient. What is your preferred access site, and why? Trerotola SO. **J Vasc Interv Radiol** 1997 Jan–Feb;8(1 Pt 1):75–6 (10 ref.)
Congenital internal jugular venous aneurysm: diagnosis and treatment. Bosshardt TL, et al. **Mil Med** 1996 Apr;161(4):246–7 (10 ref.)
Jugular bulb oximetry for the monitoring of cerebral blood flow and metabolism. Mayberg TS, et al. **Neurosurg Clin N Am** 1996 Oct;7(4):755–65 (71 ref.)

ABNORMALITIES

Combined endovascular and surgical treatment in vertebral arteriovenous fistula. A case report. Nakstad PH, et al. **Acta Radiol** 1997 Jan;38(1):25–9 (19 ref.)

ANATOMY & HISTOLOGY

Phase-derivative analysis in MR angiography: reduced Venc dependency and improved vessel wall detection in laminar and disturbed flow. Hoogeveen RM, et al. **J Magn Reson Imaging** 1997 Mar–Apr;7(2):321–30 (32 ref.)

METABOLISM

Monitoring of cerebral hemodynamics with jugular bulb catheters. Feldman Z, et al. **Crit Care Clin** 1997 Jan;13(1):51–77 (76 ref.)

PHYSIOPATHOLOGY

Internal jugular phlebectasia. al-Dousary S. **Int J Pediatr Otorhinolaryngol** 1997 Jan 3;38(3):273–80 (10 ref.)

JUN B PROTEINS see **PROTO-ONCOGENE PROTEINS C-JUN**

JUN D PROTEINS see **PROTO-ONCOGENE PROTEINS C-JUN**

JUN GENES see **GENES, JUN**

JUN PROTO-ONCOGENE PROTEINS see **PROTO-ONCOGENE PROTEINS C-JUN**

JUNCTIONAL ECTOPIC TACHYCARDIA see **TACHYCARDIA, ECTOPIC JUNCTIONAL**

JUNGIAN THEORY

The analytic initiation: the effect of the archetype of initiation on the personal unconscious. Sullivan M. **J Anal Psychol** 1996 Oct;41(4):509–27 (13 ref.)

JURISPRUDENCE

see related
FORENSIC DENTISTRY
FORENSIC MEDICINE

Liability issues in the treatment of patients with rheumatic diseases. Gibofsky A. **Am J Med** 1997 Jan 27;102(1A):40S–42S (04 ref.)
Guidelines for experts reviewing Papanicolaou smear litigation cases. Frable WJ. **Arch Pathol Lab Med** 1997 Mar;121(3):331–4 (12 ref.)
Professional responsibility in elder law: a synthesis of preventive law and therapeutic jurisprudence. Stolle DP. **Behav Sci Law** 1996 Autumn;14(4):459–78 (0 ref.)
Occupational stress and the law: some current issues for employers. Howard GS. **Br J Hosp Med** 1996 May 1–14;55(9):563–6 (9 ref.)
The judicial response to HIV/AIDS. Kirby M. **Int J STD AIDS** 1997 Apr;8(4):265–71 (35 ref.)
Canine legislation: can dogs get a fair shake in court? Burt MR. **J Am Vet Med Assoc** 1997 Apr 15;210(8):1139–42 (19 ref.)
Drawing the line: issues of boundary and the homosexual law reform bill campaign in New Zealand (Aotearoa), 1985–86. Atmore C. **J Homosex** 1995;30(1):23–52 (47 ref.)
Medical examiner variability. Hinchcliffe R. **J Laryngol Otol** 1997 Jan;111(1):8–14 (25 ref.)
Hereditary cancer litigation: a status report. Severin MJ. **Oncology (Huntingt)** 1996 Feb;10(2):211–4; discussion 217 (15 ref.)
Legal and societal issues facing survivors of childhood cancer. Monaco GP, et al. **Pediatr Clin North Am** 1997 Aug;44(4):1043–58 (27 ref.)
[The surgeon, the expert, the judge] Vayre P. **Bull Acad Natl Med** 1996 Dec;180(9):2149–58; discussion 2158–61 (11 ref.) (Eng. Abstr.) **(Fre)**

JURISPRUDENCE, PSYCHIATRIC see **FORENSIC PSYCHIATRY**

JUVENILE DELINQUENCY

The impact of exposure to crime and violence on urban youth. Berman SL, et al. **Am J Orthopsychiatry** 1996 Jul;66(3):329–36 (29 ref.)

CLASSIFICATION

Severe conduct disorder--some key issues [see comments] Werry JS. **Can J Psychiatry** 1997 Aug;42(6):577–83 (37 ref.)
Comment in: Can J Psychiatry 1997 Aug;42(6):561–2.

LEGISLATION & JURISPRUDENCE

The juvenile court: analysis and recommendations. Stevenson CS, et al. **Future Child** 1996 Winter;6(3):4–28 (109 ref.)

PREVENTION & CONTROL

Using qualitative data to inform public policy: evaluating "choose to de-fuse". Levine IS, et al. **Am J Orthopsychiatry** 1996 Jul;66(3):363–77 (34 ref.)
Juvenile homicide in America: how can we stop the killing? Heide KM. **Behav Sci Law** 1997 Spring;15(2):203–20 (96 ref.)
Long-term effects of early childhood programs on social outcomes and delinquency. Yoshikawa H. **Future Child** 1995 Winter;5(3):51–75 (83 ref.)
The prevention of delinquency, with particular reference to violent crime. Shepherd JP, et al. **Med Sci Law** 1996 Oct;36(4):331–6 (69 ref.)

PSYCHOLOGY

Adolescent homicide and family pathology: implications for research and treatment with adolescents. Crespi TD, et al. **Adolescence** 1996 Summer;31(122):353–67 (40 ref.)
A critique of social bonding and control theory of delinquency using the principles of Psychology of Mind. Kelley TM. **Adolescence** 1996 Summer;31(122):321–37 (31 ref.)
Juvenile homicide in America: how can we stop the killing? Heide KM. **Behav Sci Law** 1997 Spring;15(2):203–20 (96 ref.)
Clinical evaluations for transfer of juveniles to criminal court: current practices and future research. Kruh IP, et al. **Behav Sci Law** 1997 Spring;15(2):151–65 (93 ref.)
The relationship of attention deficit hyperactivity disorder and conduct disorder to juvenile delinquency: legal implications. Foley HA, et al. **Bull Am Acad Psychiatry Law** 1996;24(3):333–45 (44 ref.)

REHABILITATION

Developing delinquent youths: a reintegrative model for rehabilitation and a new role for the juvenile justice system. Bazemore G, et al. **Child Welfare** 1997 Sep–Oct;76(5):665–716 (91 ref.)
Problems among youths entering the juvenile justice system, their service needs and innovative approaches to address them. Dembo R. **Subst Use Misuse** 1996 Jan;31(1):81–94 (100 ref.)

STATISTICS & NUMERICAL DATA

Learning disabilities, crime, delinquency, and special education placement. Winters CA. **Adolescence** 1997 Summer;32(126):451–62 (40 ref.)
Social factors leading to juvenile delinquency. Sakuta T. **Keio J Med** 1996 Dec;45(4):287–95 (109 ref.)

JUVENILE HORMONES

PHYSIOLOGY

Juvenile hormone in adult eusocial Hymenoptera: gonadotropin and behavioral pacemaker. Robinson GE, et al. **Arch Insect Biochem Physiol** 1997;35(4):559–83 (116 ref.)
Juvenile hormone, behavioral maturation, and brain structure in the honey bee. Fahrbach SE, et al. **Dev Neurosci** 1996;18(1–2):102–14 (121 ref.)
Numb diverts notch pathway off the tramtrack. Campos-Ortega JA. **Neuron** 1996 Jul;17(1):1–4 (18 ref.)
Control of daughter cell fates during asymmetric division: interaction of Numb and Notch. Guo M, et al. **Neuron** 1996 Jul;17(1):27–41 (84 ref.)

JUXTAGLOMERULAR APPARATUS

see related
BARTTER'S DISEASE
RENIN

BLOOD SUPPLY

Contractile properties of afferent and efferent arterioles. Ito S, et al. **Clin Exp Pharmacol Physiol** 1997 Jul;24(7):532–5 (30 ref.)

CYTOLOGY

Cell-specific protein and gene expression in the juxtaglomerular apparatus. Barajas L. **Clin Exp Pharmacol Physiol** 1997 Jul;24(7):520–6 (74 ref.)
Role of mesangial cells in macula densa to afferent arteriole information transfer. Goligorsky MS, et al. **Clin Exp Pharmacol Physiol** 1997 Jul;24(7):527–31 (44 ref.)
Membrane and secretory properties of renal juxtaglomerular granular cells. Kurtz A. **Clin Exp Pharmacol Physiol** 1997 Jul;24(7):536–40 (57 ref.)

METABOLISM

Characteristics of membrane transport processes of macula densa cells. Bell PD, et al. **Clin Exp Pharmacol Physiol** 1997 Jul;24(7):541–7 (59 ref.)
Regulation of renin synthesis in the juxtaglomerular cells. Della Bruna R, et al. **Curr Opin Nephrol Hypertens** 1996 Jan;5(1):16–9 (33 ref.)

PHYSIOLOGY

Whys and wherefores of juxtaglomerular apparatus function. Briggs JP, et al. **Kidney Int** 1996 Jun;49(6):1724–6 (29 ref.)
Nitric oxide in the juxtaglomerular apparatus. Ito S, et al. **Kidney Int Suppl** 1996 Jun;55:S6–8 (34 ref.)

PHYSIOPATHOLOGY

Kidney and hypertension: role of the juxtaglomerular apparatus. Ito S. **Tohoku J Exp Med** 1997 Apr;181(4):411–29 (58 ref.)

RADIOGRAPHY

CT of pancreatitis with renal and juxtarenal manifestations. Farman J, et al. **Clin Imaging** 1997 May–Jun;21(3):183–8 (9 ref.)

K CELLS see **KILLER CELLS**

KAINATE RECEPTORS see **RECEPTORS, KAINIC ACID**

KAINIC ACID

see related
RECEPTORS, KAINIC ACID

PHARMACOLOGY

Molecular dissection of corticosteroid action in the rat hippocampus. Application of the differential display techniques. Vreugdenhil E, et al. **J Mol Neurosci** 1996 Summer;7(2):135–46 (40 ref.)

KAINIC ACID RECEPTORS see **RECEPTORS, KAINIC ACID**

KALA-AZAR see **LEISHMANIASIS, VISCERAL**

KALLIKREIN

see related
COAGULANTS

KALLIKREIN

ANALYSIS

Kallikrein and kallikrein-like proteinases: purification and determination by chromatographic and electrophoretic methods. Raspi G. **J Chromatogr B Biomed Appl** 1996 Sep 20;684(1-2):265-87 (251 ref.)

Prostate-specific human kallikrein (hK2) as a novel marker for prostate cancer. Young CY, et al. **Prostate Suppl** 1996; 7:17-24 (41 ref.)

ANTAGONISTS & INHIBITORS

Tissue kallikrein inhibitors in mammals. Chao J, et al. **Immunopharmacology** 1996 May;32(1-3):67-72 (44 ref.)

DRUG EFFECTS

Tissue kallikrein inhibitors in mammals. Chao J, et al. **Immunopharmacology** 1996 May;32(1-3):67-72 (44 ref.)

GENETICS

Prostate-specific antigen: molecular forms and the human kallikrein gene family. Lilja H. **Br J Urol** 1997 Mar;79 Suppl 1:44-8 (41 ref.)

ISOLATION & PURIFICATION

Kallikrein and kallikrein-like proteinases: purification and determination by chromatographic and electrophoretic methods. Raspi G. **J Chromatogr B Biomed Appl** 1996 Sep 20;684(1-2):265-87 (251 ref.)

METABOLISM

Pivotal role of renal kallikrein-kinin system in the development of hypertension and approaches to new drugs based on this relationship. Katori M, et al. **Jpn J Pharmacol** 1996 Feb;70(2):95-128 (247 ref.)

PHARMACOLOGY

Long-term infusion of kallikrein attenuates renal injury in Dahl salt-sensitive rats. Uehara Y, et al. **Am J Hypertens** 1997 May;10(5 Pt 2):83S-88S (23 ref.)

THERAPEUTIC USE

New experimental evidence for a role of tissue kallikrein in hypertension. Chao J, et al. **Nephrol Dial Transplant** 1997 Aug;12(8):1569-74 (57 ref.)

KALLIKREIN-KININ SYSTEM

The kallikrein-kinin system in post-myocardial infarction cardiac remodeling. Wollert KC, et al. **Am J Cardiol** 1997 Aug 4;80(3A):158A-161A (45 ref.)

DRUG EFFECTS

Radiographic contrast media and the coagulation and complement systems. Hoffmeister HM, et al. **Invest Radiol** 1996 Sep;31(9):591-5 (44 ref.)

PHYSIOLOGY

The kallikrein/kinin system and kinin antagonists in trauma. Rodell TC. **Immunopharmacology** 1996 Jun;33(1-3):279-83 (9 ref.)

Antihypertensive and cardioprotective effects after angiotensin-converting enzyme inhibition: role of kinins. Tschöpe C, et al. **J Card Fail** 1997 Jun;3(2):133-48 (192 ref.)

KALLIKREIN-TRYPSIN INACTIVATOR see **APROTININ**

KALLMANN SYNDROME

DIAGNOSIS

The neuroradiology of Kallmann's syndrome: a genotypic and phenotypic analysis [published erratum appears in J Clin Endocrinol Metab 1996 Oct;81(10):3614] Quinton R, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):3010-7 (58 ref.)

[The Kallmann syndrome: a review and clinical report] Pandurski F. **Akush Ginekol (Sofiia)** 1996;35(3):44-6 (27 ref.) **(Bul)**

GENETICS

The neuroradiology of Kallmann's syndrome: a genotypic and phenotypic analysis [published erratum appears in J Clin Endocrinol Metab 1996 Oct;81(10):3614] Quinton R, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):3010-7 (58 ref.)

[Molecular bases of neurosensory deficits in man] Petit C. **Ann Med Interne (Paris)** 1996;147(6):449-52 (13 ref.) **(Fre)**

KAMPO see **MEDICINE, CHINESE TRADITIONAL**

KANDINSKY SYNDROME see **ORGANIC MENTAL DISORDERS, PSYCHOTIC**

KANGAROOS

PHYSIOLOGY

The uterine environment in early pregnancy in the tammar wallaby. Shaw G. **Reprod Fertil Dev** 1996;8(4):811-8 (66 ref.)

KANNER'S SYNDROME see **AUTISM, INFANTILE**

KANPO see **MEDICINE, CHINESE TRADITIONAL**

KAOLIN-CEPHALIN COAGULATION TIME see **PARTIAL THROMBOPLASTIN TIME**

KAPOSI'S DISEASE see **XERODERMA PIGMENTOSUM**

KAPOSI'S SARCOMA see **SARCOMA, KAPOSI'S**

KAPOSI'S SARCOMA-ASSOCIATED HERPESVIRUS see **HERPESVIRUS, KAPOSI'S SARCOMA-ASSOCIATED**

KAPPA ALLOTYPES see **IMMUNOGLOBULIN ALLOTYPES**

KAPPA B ENHANCER BINDING PROTEIN see **NF-KAPPA B**

KAPPA IMMUNOGLOBULINS see **IMMUNOGLOBULINS, KAPPA-CHAIN**

KAPPA RECEPTORS see **RECEPTORS, OPIOID, KAPPA**

KARATE see **MARTIAL ARTS**

KARTAGENER'S SYNDROME

[Kartagener syndrome] Tsukahara M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):271-2 (22 ref.) **(Jpn)**

COMPLICATIONS

[An unusual case of Kartagener's syndrome associated with rheumatoid arthritis] Porawska W, et al. **Pol Arch Med Wewn** 1996 Dec;96(6):577-80 (13 ref.) (Eng. Abstr.) **(Pol)**

KARTAGENER'S TRIAD see **KARTAGENER'S SYNDROME**

KARYOKINESIS see **MITOSIS**

KARYOTYPING

[Value and limits of transabdominal cytogenetic amniocenteses during the first trimester of pregnancy] Irion O, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(5):500-4 (17 ref.) (Eng. Abstr.) **(Fre)**

[Comparative gene mapping and human karyotype evolution] Hirai M, et al. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(15 Suppl):2441-9 (39 ref.) **(Jpn)**

METHODS

Karyotyping of yeast strains by pulsed-field gel electrophoresis. Johnston JR. **Methods Mol Biol** 1996; 53:69-78 (30 ref.)

KATZ ADJUSTMENT SCALES see **PSYCHIATRIC STATUS RATING SCALES**

KAWASAKI DISEASE see **MUCOCUTANEOUS LYMPH NODE SYNDROME**

KEARNS-SAYRE-SHY-DAROFF SYNDROME see **KEARNS SYNDROME**

KEARNS SYNDROME

DIAGNOSIS

[The Kearns-Sayre syndrome] Mal'mberg SA, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1997;97(8):53-7 (18 ref.) **(Rus)**

GENETICS

Hypoparathyroidism and deafness associated with pleioplasmic large scale rearrangements of the mitochondrial DNA: a clinical and molecular genetic study of four children with Kearns-Sayre syndrome. Wilichowski E, et al. **Pediatr Res** 1997 Feb;41(2):193-200 (47 ref.)

[Kearns-Sayre syndrome: encephalomyopathy caused by deletion of mitochondrial DNA] Lewczuk A, et al. **Pol Arch Med Wewn** 1996 Dec;96(6):597-604 (40 ref.) **(Pol)**

[Rearrangement of the mitochondrial DNA in Kearns-Sayre syndrome: is it necessary to differentiate deletions from duplications or polymerization?] Barrientos A, et al. **Neurologia** 1996 Aug-Sep;11(7):257-60 (10 ref.) **(Spa)**

KELL BLOOD-GROUP SYSTEM

ANALYSIS

Detection of Kell blood groups: molecular methods in the diagnostic laboratory. Murphy MT, et al. **Blood Rev** 1997 Mar;11(1):8-15 (60 ref.)

GENETICS

Detection of Kell blood groups: molecular methods in the diagnostic laboratory. Murphy MT, et al. **Blood Rev** 1997 Mar;11(1):8-15 (60 ref.)

Molecular basis of Kell blood group phenotypes. Lee S. **Vox Sang** 1997;73(1):1-11 (72 ref.)

KELOID

see related
CICATRIX, HYPERTROPHIC

PATHOLOGY

The 1996 Lindberg Award. Calcium antagonists alter cell shape and induce procollagenase synthesis in keloid and normal human dermal fibroblasts. Doong H, et al. **J Burn Care Rehabil** 1996 Nov-Dec;17(6 Pt 1):497-514 (19 ref.)

SURGERY

Laser treatment of hypertrophic scars, keloids, and striae. Alster TS. **Dermatol Clin** 1997 Jul;15(3):419-29 (86 ref.)

THERAPY

Hypertrophic scars, keloids, and contractures. The cellular and molecular basis for therapy. Tredget EE, et al. **Surg Clin North Am** 1997 Jun;77(3):701-30 (160 ref.)

[Modern treatment of keloids] Djoković R, et al. **Srp Arh Celok Lek** 1997 May-Jun;125(5-6):176-80 (38 ref.) (Eng. Abstr.) **(Scc)**

KERATECTOMY, EXCIMER LASER see **KERATECTOMY, PHOTOREFRACTIVE, EXCIMER LASER**

KERATECTOMY, EXCIMER LASER PHOTOREFRACTIVE see **KERATECTOMY, PHOTOREFRACTIVE, EXCIMER LASER**

KERATECTOMY, PHOTOREFRACTIVE, EXCIMER LASER

Photorefractive keratectomy (PRK) in the military aviator: an aeromedical perspective. Ivan DJ, et al. **Aviat Space Environ Med** 1996 Aug;67(8):770-6 (44 ref.)

Corneal nerve recovery after photorefractive keratectomy and laser in situ keratomileusis. Latvala T, et al. **Int Ophthalmol Clin** 1996 Fall;36(4):21-7 (38 ref.)

Excimer laser phototherapeutic keratectomy. Rapuano CJ. **Int Ophthalmol Clin** 1996 Fall;36(4):127-36 (11 ref.)

Photorefractive keratectomy for myopia of -8.00 to -24.00 diopters. Goes FJ. **J Refract Surg** 1996 Jan-Feb;12(1):91-7 (14 ref.)

Eye dominance in excimer laser photorefractive keratectomy. Hashim AA. **J Refract Surg** 1997 Aug;13(5 Suppl):S461-2 (5 ref.)

Eye infections after refractive keratotomy. Jain S, et al. **J Refract Surg** 1996 Jan-Feb;12(1):148-55 (49 ref.)

Prevalence of myopia in adults: implications for refractive surgeons [see comments] McCarty CA, et al. **J Refract Surg** 1997 May-Jun;13(3):229-34 (41 ref.) Comment in: J Refract Surg 1997 May-Jun;13(3):213-5.

Excimer laser phototherapeutic keratectomy: clinical and surgical aspects. Thompson VM. **Ophthalmic Surg Lasers** 1995 Sep-Oct;26(5):461-72 (31 ref.)

[Excimer laser method for correction of vision disorders. A chance for life without eyeglasses?] Huber I. **Med Monatsschr Pharm** 1996 Dec;19(12):365-70 (15 ref.) **(Ger)**

[Refractive laser surgery of the cornea] Kaminski S, et al. **Wien Med Wochenschr** 1997;147(12-13):302-7 (48 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Complications of photorefractive keratectomy. Edmison DR. **Int Ophthalmol Clin** 1997 Winter;37(1):83-94 (24 ref.)

Selected complications of radial keratotomy, photorefractive keratectomy, and laser in situ keratomileusis. Filatov V, et al. **Int Ophthalmol Clin** 1997 Winter;37(1):123-48 (96 ref.)

Problems of refraction after photorefractive keratectomy. Siow KL, et al. **J Am Optom Assoc** 1996 Dec;67(12):755-61 (7 ref.)

Macular hemorrhage after excimer laser photorefractive keratectomy. Loewenstein A, et al. **J Cataract Refract Surg** 1997 Jun;23(5):808-10 (8 ref.)

METHODS

Phototherapeutic keratectomy for superficial corneal disorders. Gallo JP, et al. **Int Ophthalmol Clin** 1997 Winter;

37(1):155–70 (53 ref.)
Methods for calculating the requisite phototherapeutic ablation for corneal scars and surface irregularities. Rowsey JJ. **Int Ophthalmol Clin** 1996 Fall;36(4):137–40 (0 ref.)
A comparison of modern incisional keratotomy and photorefractive keratectomy. Shapiro DR. **Int Ophthalmol Clin** 1997 Winter;37(1):65–81 (56 ref.)
Corneal modulators and their use in excimer laser phototherapeutic keratectomy. Stevens SX, et al. **Int Ophthalmol Clin** 1996 Fall;36(4):119–25 (22 ref.)
Bilateral photorefractive keratectomy with intentional unilateral undercorrection performed on an aircraft pilot [editorial; comment] Mader TH. **J Cataract Refract Surg** 1997 Mar;23(2):145–7 (22 ref.) Comment on: J Cataract Refract Surg 1997 Mar;23(2):294–6.
Refractive surgery, optical aberrations, and visual performance [see comments] Applegate RA, et al. **J Refract Surg** 1997 May–Jun;13(3):295–9 (17 ref.) Comment in: J Refract Surg 1997 May–Jun;13(3):213–5.
Excimer laser photorefractive keratectomy for high myopia: four-year experience with a multiple zone technique. Piovella M, et al. **Ophthalmology** 1997 Oct;104(10):1554–65 (33 ref.)
[Myopia surgery] Waked N. **J Med Liban** 1996;44(2):86–9 (13 ref.) **(Fre)**

KERATIN

Human keratin diseases: hereditary fragility of specific epithelial tissues. Corden LD, et al. **Exp Dermatol** 1996 Dec;5(6):297–307 (102 ref.)

ANALYSIS

Signet-ring carcinoma of the prostate. Leong FJ, et al. **Pathol Res Pract** 1996 Dec;192(12):1232–8; discussion 1239–41 (30 ref.)

BIOSYNTHESIS

Epidermal differentiation and keratin gene expression. Fuchs E. **Princess Takamatsu Symp** 1994;24:290–302 (63 ref.)

CHEMISTRY

Protein chains in hair and epidermal keratin IF: structural features and spatial arrangements. Parry DA. **EXS** 1997; 78:177–207 (122 ref.)

GENETICS

Genetic approaches to understanding the keratinopathies. Bale SJ, et al. **Adv Dermatol** 1997;12:99–113; discussion 114 (63 ref.)
Hair keratinization in health and disease. Jones LN, et al. **Dermatol Clin** 1996 Oct;14(4):633–50 (104 ref.)
The role of keratin proteins and their genes in the growth, structure and properties of hair. Powell BC, et al. **EXS** 1997;78:59–148 (284 ref.)
[Molecular diagnostic detection of circulating tumor cells and their prognostic implications] Nakanishi H, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(3):257–65 (33 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Is psoriasis induced by streptococcal superantigens and maintained by M-protein-specific T cells that cross-react with keratin? Valdimarsson H, et al. **Clin Exp Immunol** 1997 Jan;107 Suppl 1:21–4 (28 ref.)

METABOLISM

Keratin biochemistry. Albers KM. **Clin Dermatol** 1996 Jul–Aug;14(4):309–20 (108 ref.)
Two-dimensional gel analysis of glandular keratin intermediate filament phosphorylation. Liao J, et al. **Electrophoresis** 1996 Nov;17(11):1671–6 (67 ref.)
Human epidermal keratinocyte: keratinization processes. Blumenberg M, et al. **EXS** 1997;78:1–29 (99 ref.)
The role of keratin proteins and their genes in the growth, structure and properties of hair. Powell BC, et al. **EXS** 1997;78:59–148 (284 ref.)
Intermediate filament proteins of the liver: emerging disease association and functions. Omary MB, et al. **Hepatology** 1997 May;25(5):1043–8 (67 ref.)

PHYSIOLOGY

Oncogenic regulation and function of keratins 8 and 18. Oshima RG, et al. **Cancer Metastasis Rev** 1996 Dec; 15(4):445–71 (221 ref.)

KERATINOCYTES

Keratinocyte gene transfer and gene therapy. Garlick JA, et al. **Crit Rev Oral Biol Med** 1996;7(3):204–21 (138 ref.)

CYTOLOGY

The growth fraction of normal human epidermis. Heenen M, et al. **Dermatology** 1997;194(4):313–7 (31 ref.)
Interferon-gamma as a regulator of squamous differentiation. Saunders N, et al. **J Dermatol Sci** 1996 Nov;13(2):98–106 (23 ref.)
Ultraviolet light-induced keratinocyte apoptosis: a potential mechanism for the induction of skin lesions and autoantibody production in LE. Casciola-Rosen L, et al. **Lupus** 1997;6(2):175–80 (52 ref.)
Keratinocyte culture. Barlow Y, et al. **Methods Mol Biol** 1997;75:117–29 (7 ref.)
Human pilosebaceous culture. Kealey T, et al. **Methods Mol Biol** 1997;75:101–15 (20 ref.)
The epidermal keratinocyte as a model for the study of gene regulation and cell differentiation. Eckert RL, et al. **Physiol Rev** 1997 Apr;77(2):397–424 (298 ref.)

METABOLISM

Keratinocytes and cytokine/growth factors. Feliciani C, et al. **Crit Rev Oral Biol Med** 1996;7(4):300–18 (185 ref.)
Human epidermal keratinocyte: keratinization processes. Blumenberg M, et al. **EXS** 1997;78:1–29 (99 ref.)
Epidermal differentiation and keratin gene expression. Fuchs E. **Princess Takamatsu Symp** 1994;24:290–302 (63 ref.)
Cytokine-mediated communication by keratinocytes and Langerhans cells with dendritic epidermal T cells. Takashima A, et al. **Semin Immunol** 1996 Dec;8(6):333–9 (87 ref.)

PATHOLOGY

Signal transduction in normal and neoplastic keratinocytes. Dlugosz AA. **J Dermatol** 1996 Nov;23(11):751–5 (40 ref.)

PHYSIOLOGY

Towards a molecular definition of keratinocyte activation after acute injury to stratified epithelia. Coulombe PA. **Biochem Biophys Res Commun** 1997 Jul 18;236(2):231–8 (96 ref.)
Hair keratinization in health and disease. Jones LN, et al. **Dermatol Clin** 1996 Oct;14(4):633–50 (104 ref.)
The genetic basis of human keratinocyte immortalisation in squamous cell carcinoma development: the role of telomerase reactivation. Parkinson EK, et al. **Eur J Cancer** 1997 Apr;33(5):727–34 (81 ref.)
Transcription factor regulation of epidermal keratinocyte gene expression. Eckert RL, et al. **Mol Biol Rep** 1996; 23(1):59–70 (175 ref.)
The epidermal keratinocyte as a model for the study of gene regulation and cell differentiation. Eckert RL, et al. **Physiol Rev** 1997 Apr;77(2):397–424 (298 ref.)

KERATITIS

CHEMICALLY INDUCED

Fusarium keratitis following the use of topical antibiotic-corticosteroid therapy in traumatised eyes. Wong TY, et al. **Ann Acad Med Singapore** 1996 Nov;25(6):862–5 (19 ref.)

COMPLICATIONS

Hailey-Hailey disease with acrokeratosis verruciformis Hopf [letter] Yakis G, et al. **Acta Derm Venereol** 1996 Mar; 76(2):157 (4 ref.)

DIAGNOSIS

[Diagnosis and therapy of fungal keratitis--a review] Behrens-Baumann W. **Klin Monatsbl Augenheilkd** 1997 May;210(5):aA10–3 (51 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Common ocular infections. A prescriber's guide. Donahue SP, et al. **Drugs** 1996 Oct;52(4):526–40 (66 ref.)

EPIDEMIOLOGY

Contact lens-related microbial keratitis: Part I: Epidemiology. Liesegang TJ. **Cornea** 1997 Mar; 16(2):125–31 (54 ref.)

ETIOLOGY

[Contact lenses. Infections and hygiene] Brewitt H. **Ophthalmologe** 1997 May;94(5):311–6 (53 ref.) (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

The role of Serratia marcescens in soft contact lens associated ocular infections. A review. Parment PA. **Acta Ophthalmol Scand** 1997 Feb;75(1):67–71 (77 ref.)
Contact lens-related microbial keratitis: Part I: Epidemiology. Liesegang TJ. **Cornea** 1997 Mar; 16(2):125–31 (54 ref.)
Fungal keratitis. Abad JC, et al. **Int Ophthalmol Clin** 1996 Summer;36(3):1–15 (70 ref.)

PATHOLOGY

Keratitis, ichthyosis, and deafness (KID syndrome): review of the literature and proposal of a new terminology [see comments] Caceres-Rios H, et al. **Pediatr Dermatol** 1996 Mar–Apr;13(2):105–13 (68 ref.) Comment in: Pediatr Dermatol 1996 Mar–Apr;13(2):154–7.

KERATITIS, ACANTHAMOEBA see **ACANTHAMOEBA KERATITIS**

KERATITIS, HERPETIC

DRUG THERAPY

Medical management of herpes simplex ocular infections. Lee SY, et al. **Int Ophthalmol Clin** 1996 Spring;36(2):85–97 (42 ref.)
Treatment of herpetic keratitis with acyclovir: benefits and problems. Ohashi Y. **Ophthalmologica** 1997;211 Suppl 1:29–32 (26 ref.)

ETIOLOGY

Immunity causing blindness: five different paths to herpes stromal keratitis. Streilein JW, et al. **Immunol Today** 1997 Sep;18(9):443–9 (51 ref.)
Herpesvirus infections of the anterior segment. Chang EJ, et al. **Int Ophthalmol Clin** 1996 Summer;36(3):17–28 (31 ref.)

KERATITIS, ULCERATIVE see **CORNEAL ULCER**

KERATOACANTHOMA

DIAGNOSIS

Multiple painful keratoacanthomas. Frank TL, et al. **Int J Dermatol** 1996 Sep;35(9):648–50 (24 ref.)
[Keratoacanthoma of the eyelid area. Problems and risks in diagnosis and therapy] Hintschich CR, et al. **Klin Monatsbl Augenheilkd** 1997 Apr;210(4):219–24 (58 ref.) (Eng. Abstr.) **(Ger)**
[Recurrent palpebral keratoacanthoma] Cernea P, et al. **Oftalmologia** 1997;41(1):26–7 (9 ref.) (Eng. Abstr.) **(Rum)**

DRUG THERAPY

Aggressive giant keratoacanthoma of the face treated with intramuscular methotrexate and triamcinolone acetonide. Santoso-Pham JC, et al. **Cutis** 1997 Jun;59(6):329–32 (26 ref.)

PATHOLOGY

Conjunctival keratoacanthoma. Schellini SA, et al. **Acta Ophthalmol Scand** 1997 Jun;75(3):335–7 (22 ref.)

KERATOCONJUNCTIVITIS

IMMUNOLOGY

The eosinophil and the eye. Bonini S, et al. **Allergy** 1997;52(34 Suppl):44–7 (25 ref.)

PHYSIOPATHOLOGY

[Main mechanisms of kerato-conjunctival inflammation] Becquet F, et al. **J Fr Ophtalmol** 1997;20(1):71–84 (68 ref.) **(Fre)**

KERATOCONJUNCTIVITIS SICCA

ETIOLOGY

[The eye and hepatitis C] Tahri H, et al. **J Fr Ophtalmol** 1997;20(6):453–5 (23 ref.) (Eng. Abstr.) **(Fre)**

KERATOCONJUNCTIVITIS, VERNAL see **CONJUNCTIVITIS, ALLERGIC**

KERATOCONUS

Keratoconus: diagnosis and treatment. Nordan LT. **Int Ophthalmol Clin** 1997 Winter;37(1):51–63 (0 ref.)

DIAGNOSIS

Keratoconus in two pairs of identical twins. Bechara SJ, et al. **Cornea** 1996 Jan;15(1):90–3 (22 ref.)

PATHOLOGY

Biomicroscopic signs and disease severity in keratoconus. Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study Group. Zadnik K, et al. **Cornea** 1996 Mar; 15(2):139–46 (46 ref.)

KERATOCYSTS see **ODONTOGENIC CYSTS**

KERATODERMA BLENNORRHAGICUM see **KERATOSIS**

KERATODERMA, PALMOPLANTAR

[Mal de Meleda] Ochiai T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):337–8 (11 ref.) **(Jpn)**

CLASSIFICATION

Frontiers in keratodermas: pushing the envelope. Christiano AM. **Trends Genet** 1997 Jun;13(6):227–33 (45 ref.)

COMPLICATIONS

Primary digital clubbing associated with palmoplantar

KERATODERMA, PALMOPLANTAR

keratoderma. Barraud-Klenovsek MM, et al. **Dermatology** 1997;194(3):302-5 (15 ref.)
Hereditary painful callosities with associated features. Cambiaghi S, et al. **Dermatology** 1996;193(1):47-9 (15 ref.)

CONGENITAL

Olmsted syndrome: report of a new case. Frias-Iniesta J, et al. **Br J Dermatol** 1997 Jun;136(6):935-8 (15 ref.)

DIAGNOSIS

Acrokeratoelastoidosis. Dyall-Smith D. **Australas J Dermatol** 1996 Nov;37(4):213-4 (6 ref.)

GENETICS

Frontiers in keratodermas: pushing the envelope. Christiano AM. **Trends Genet** 1997 Jun;13(6):227-33 (45 ref.)

PATHOLOGY

Meleda disease: report of two cases investigated by electron microscopy. Frenk E, et al. **Dermatology** 1996; 193(4):358-61 (13 ref.)

KERATOLYTIC AGENTS

ADVERSE EFFECTS

How to ensure fetal safety when mothers use isotretinoin (Accutane). Koren G, et al. **Can Fam Physician** 1997 Feb; 43:216-9 (4 ref.)

PHARMACOKINETICS

Clinical pharmacokinetics of tretinoin. Regazzi MB, et al. **Clin Pharmacokinet** 1997 May;32(5):382-402 (111 ref.)

THERAPEUTIC USE

Juvenile nodulocystic acne responding to systemic isotretinoin [letter] Horne HL, et al. **Br J Dermatol** 1997 May;136(5):796-7 (7 ref.)
Necrobiosis lipoidica treated with topical tretinoin. Heymann WR. **Cutis** 1996 Jul;58(1):53-4 (8 ref.)
Topical retinoic acid (tretinoin) for photoaging: conceptions and misperceptions. Kligman AM. **Cutis** 1996 Mar; 57(3):142-4 (11 ref.)
Treatment of photodamage with topical tretinoin: an overview. Gilchrest BA. **J Am Acad Dermatol** 1997 Mar; 36(3 Pt 2):S27-36 (29 ref.)

TOXICITY

Tretinoin: a review of the nonclinical developmental toxicology experience. Kochhar DM, et al. **J Am Acad Dermatol** 1997 Mar;36(3 Pt 2):S47-59 (49 ref.)

KERATOMA see **KERATOSIS**

KERATOPLASTY see **CORNEAL TRANSPLANTATION**

KERATOPLASTY, LAMELLAR see **CORNEAL TRANSPLANTATION**

KERATOPLASTY, PENETRATING

Corneal chromoblastomycosis. Barton K, et al. **Cornea** 1997 Mar;16(2):235-9 (18 ref.)
[Disinfection of human donor corneas during preparation and preservation] Hagenah M, et al. **Klin Monatsbl Augenheilkd** 1996 Jul;209(1):1-6; discussion 1 (58 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Surgical correction of refractive errors after penetrating keratoplasty. Hardten DR, et al. **Int Ophthalmol Clin** 1997 Winter;37(1):1-35 (118 ref.)

METHODS

Tampa trephine penetrating keratoplasty: a tissue-tab technique for corneal transplantation. The Tampa Trephine Study Group. Rowsey JJ. **Int Ophthalmol Clin** 1996 Fall; 36(4):141-52 (12 ref.)

KERATOSIS

CHEMICALLY INDUCED

Arsenic and the skin. Schwartz RA. **Int J Dermatol** 1997 Apr;36(4):241-50 (144 ref.)

COMPLICATIONS

Pityriasis rubra pilaris and focal acantholytic dyskeratosis. Cowen P, et al. **Australas J Dermatol** 1997 Feb;38(1):40-1 (5 ref.)
Multiple dermatofibromas accompanied by eruptive benign keratoses in a patient with systemic lupus erythematosus. Kuniyuki S, et al. **J Dermatol** 1996 Sep;23(9):619-22 (14 ref.)

DIAGNOSIS

Keratotic lesions of the foot. DeLauro TM. **Clin Podiatr Med Surg** 1996 Jan;13(1):73-84 (9 ref.)

PATHOLOGY

Epithelial migration in keratosis obturans. Corbridge RJ, et al. **Am J Otolaryngol** 1996 Nov-Dec;17(6):411-4 (12 ref.)
Benign persistent papular acantholytic and dyskeratotic eruption with features of warty dyskeratoma [letter] Urbani CE, et al. **Australas J Dermatol** 1996 Nov;37(4):225-6 (13 ref.)
Cutaneous horn: a brief review and report of a case. Thappa DM, et al. **J Dermatol** 1997 Jan;24(1):34-7 (17 ref.)

SURGERY

Cutaneous facial resurfacing with the carbon dioxide laser. Biesman BS. **Ophthalmic Surg Lasers** 1996 Aug; 27(8):685-98 (62 ref.)

THERAPY

Therapeutic perspectives in actinic and other keratoses. Schwartz RA. **Int J Dermatol** 1996 Aug;35(8):533-8 (124 ref.)

KERATOSIS BLENNORRHAGICA see **KERATOSIS**

KERATOSIS FOLLICULARIS

DRUG THERAPY

Oral contraceptives in the treatment of Darier-White disease--a case report and review of the literature. Oostenbrink JH, et al. **Clin Exp Dermatol** 1996 Nov; 21(6):442-4 (16 ref.)

GENETICS

Localized Darier disease. Implications for genetic studies. O'Malley MP, et al. **Arch Dermatol** 1997 Sep;133(9):1134-8 (46 ref.)

KERATOSIS PALMARIS ET PLANTARIS see **KERATODERMA, PALMOPLANTAR**

KERATOSIS, PALMOPLANTAR see **KERATODERMA, PALMOPLANTAR**

KERATOSIS, SEBORRHEIC

COMPLICATIONS

Malignancy arising in seborrheic keratosis: a report of two cases. Yap WM, et al. **Ann Acad Med Singapore** 1997 Mar; 26(2):235-7 (15 ref.)

KERATOTOMY, RADIAL

ADVERSE EFFECTS

Selected complications of radial keratotomy, photorefractive keratectomy, and laser in situ keratomileusis. Filatov V, et al. **Int Ophthalmol Clin** 1997 Winter;37(1):123-48 (96 ref.)
[Complications of radial keratotomy and their treatments] Wu G, et al. **Chung Hua Yen Ko Tsa Chih** 1995 Jul; 31(4):299-301 (16 ref.) **(Chi)**

METHODS

Corneal coupling principles. Rowsey JJ, et al. **Int Ophthalmol Clin** 1996 Fall;36(4):29-38 (26 ref.)
A comparison of modern incisional keratotomy and photorefractive keratectomy. Shapiro DR. **Int Ophthalmol Clin** 1997 Winter;37(1):65-81 (56 ref.)
Refractive surgery, optical aberrations, and visual performance [see comments] Applegate RA, et al. **J Refract Surg** 1997 May-Jun;13(3):295-9 (17 ref.) Comment in: J Refract Surg 1997 May-Jun;13(3):213-5.
20/20--how close must we get? [see comments] Werblin TP. **J Refract Surg** 1997 May-Jun;13(3):300-1 (3 ref.) Comment in: J Refract Surg 1997 May-Jun;13(3):213-5.
[Myopia surgery] Waked N. **J Med Liban** 1996;44(2):86-9 (13 ref.) **(Fre)**

KERNICTERUS

Bilirubin metabolism and kernicterus. Gourley GR. **Adv Pediatr** 1997;44:173-229 (346 ref.)

KETAMINE

[New intravenous anesthetics. Remifentanil, S(+)-ketamine, eltanolone and target controlled infusion] Albrecht S, et al. **Anaesthesist** 1996 Dec;45(12):1129-41 (85 ref.) (Eng. Abstr.) **(Ger)**
[Recovery and psychomimetic reactions following S-(+)-ketamine] Engelhardt W. **Anaesthesist** 1997 Mar;46 Suppl 1:S38-42 (20 ref.) (Eng. Abstr.) **(Ger)**
[Clinical significance of S-(+)-ketamine] Hempelmann G, et al. **Anaesthesist** 1997 Mar;46 Suppl 1:S3-7 (26 ref.) (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

Continuous ketamine infusion for the treatment of refractory asthma in a mechanically ventilated infant: case report and review of the pediatric literature. Nehama J, et al. **Pediatr Emerg Care** 1996 Aug;12(4):294-7 (20 ref.)

ADVERSE EFFECTS

[S-(+)-Ketamine and circulation] Zielmann S, et al. **Anaesthesist** 1997 Mar;46 Suppl 1:S43-6 (15 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

[Endocrine reactions following S-(+)-ketamine] Adams HA. **Anaesthesist** 1997 Mar;46 Suppl 1:S30-7 (33 ref.) (Eng. Abstr.) **(Ger)**
[Effects of ketamine on CNS-function] Detsch O, et al. **Anaesthesist** 1997 Mar;46 Suppl 1:S20-9 (98 ref.) (Eng. Abstr.) **(Ger)**
[Mechanisms of action of ketamine] Kress HG. **Anaesthesist** 1997 Mar;46 Suppl 1:S8-19 (120 ref.) (Eng. Abstr.) **(Ger)**
[Neuroprotection by ketamine at the cellular level] Pfenninger E, et al. **Anaesthesist** 1997 Mar;46 Suppl 1:S47-54 (64 ref.) (Eng. Abstr.) **(Ger)**
[The mechanisms of action of ketamine] Tarakanov AV, et al. **Eksp Klin Farmakol** 1996 Nov-Dec;59(6):56-61 (95 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

Ketamine and its use in the pig. Recommendations of the Consensus meeting on Ketamine Anaesthesia in Pigs, Bergen 1994. Ketamine Consensus Working Group. Boschert K, et al. **Lab Anim** 1996 Jul;30(3):209-19 (28 ref.)

THERAPEUTIC USE

Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. Krupitsky EM, et al. **J Psychoactive Drugs** 1997 Apr-Jun;29(2):165-83 (55 ref.)
Ketamine in cancer pain: an update. Mercadante S. **Palliat Med** 1996 Jul;10(3):225-30 (35 ref.)
[Ketamine and neuroprotection. Clinical outlook] Fitzal S. **Anaesthesist** 1997 Mar;46 Suppl 1:S65-70 (48 ref.) (Eng. Abstr.) **(Ger)**
[Effect of ketamine on global cerebral ischemia] Kempski O, et al. **Anaesthesist** 1997 Mar;46 Suppl 1:S61-4 (35 ref.) (Eng. Abstr.) **(Ger)**
[Ketamine racemate and S-(+)-ketamine. Cerebrovascular effects and neuroprotection following focal ischemia] Werner C, et al. **Anaesthesist** 1997 Mar;46 Suppl 1:S55-60 (25 ref.) (Eng. Abstr.) **(Ger)**

3-KETO-5-ALPHA-STEROID DELTA-4-DEHYDROGENASE see **TESTOSTERONE 5-ALPHA-REDUCTASE**

KETOACIDOSIS, DIABETIC see **DIABETIC KETOACIDOSIS**

3-KETOACYL COA THIOLASE see **ACETYL COA ACYLTRANSFERASE**

KETOCONAZOLE

ADVERSE EFFECTS

Strategic proposals to avoid drug interactions during drug development: a lesson from a terfenadine-related drug interaction. Ishizaki T. **J Toxicol Sci** 1996 Dec;21(5):301-3 (15 ref.)
Ketoconazole-induced adrenal crisis in a patient with metastatic prostatic adenocarcinoma: case report and review of the literature. Sarver RG, et al. **Urology** 1997 May;49(5):781-5 (27 ref.)

THERAPEUTIC USE

The role of azole antifungal agents for systemic antifungal therapy. Lee YP, et al. **Cleve Clin J Med** 1997 Feb; 64(2):99-106 (67 ref.)
The use of other drugs to allow a lower dosage of cyclosporin to be used. Therapeutic and pharmacoeconomic considerations. Jones TE. **Clin Pharmacokinet** 1997 May; 32(5):357-67 (100 ref.)

KETOGLUTARATE DEHYDROGENASE COMPLEX

DEFICIENCY

Inborn errors of the Krebs cycle: a group of unusual mitochondrial diseases in human. Rustin P, et al. **Biochim Biophys Acta** 1997 Aug 22;1361(2):185-97 (35 ref.)

KETONE BODIES

BIOSYNTHESIS

A review of the newer antiepileptic drugs and the ketogenic diet. Barron TF, et al. **Clin Pediatr (Phila)** 1997 Sep; 36(9):513-21 (61 ref.)

METABOLISM

The ketogenic diet: 1997. Swink TD, et al. **Adv Pediatr** 1997; 44:297-329 (80 ref.)

Regulation of in vivo ketogenesis: role of free fatty acids and control by epinephrine, thyroid hormones, insulin and glucagon. Beylot M. **Diabetes Metab** 1996 Oct; 22(5):299–304 (44 ref.)
New aspects of ketone bodies in energy metabolism of dairy cows: a review. Holtenius P, et al.
Zentralbl Veterinarmed A 1996 Dec;43(10):579–87 (43 ref.)

KETONE OXIDOREDUCTASES

CHEMISTRY

Lipoylation of acyltransferase components of 2-oxo acid dehydrogenase complexes. Quinn J. **Methods Enzymol** 1997;279:193–202 (25 ref.)

IMMUNOLOGY

Biochemistry and autoimmune response to the 2-oxoacid dehydrogenase complexes in primary biliary cirrhosis. Bassendine MF, et al. **Semin Liver Dis** 1997 Feb;17(1):49–60 (99 ref.)

METABOLISM

Lipoate addition to acyltransferases of alpha-keto acid dehydrogenase complexes and H-protein of glycine cleavage system. Fujiwara K, et al. **Methods Enzymol** 1997; 279:184–93 (23 ref.)

KETONES

PHARMACOLOGY

Oxidative DNA damage induced by dioxetanes, photosensitizing ketones, and photo-fenton reagents. Adam W, et al. **Recent Results Cancer Res** 1997;143:21–34 (40 ref.)

TOXICITY

The relevance of axonal swellings and atrophy to gamma-diketone neurotoxicity: a forum position paper [see comments] LoPachin RM, et al. **Neurotoxicology** 1997; 18(1):7–22 (107 ref.) Comment in: Neurotoxicology 1997 ;18(1):23–4; discussion 37–40. Comment in: Neurotoxicology 1997 ;18(1):25–8; discussion 37–40. Comment in: Neurotoxicology 1997 ;18(1):29–30; discussion 37–10. Comment in: Neurotoxicology 1997 ;18(1):31–2; discussion 37–40. Comment in: Neurotoxicology 1997 ;18(1):33–6; discussion 37–40.
Neurofilamentous swellings and axonal atrophy are of unclear significance to diketone toxicity: commentary on forum position paper [comment] Sickles DW.
Neurotoxicology 1997;18(1):33–6; discussion 37–40 (15 ref.) Comment on: Neurotoxicology 1997 ;18(1):7–22.

6-KETO-PGF1 ALPHA see **6-KETOPROSTAGLANDIN F1 ALPHA**

KETOPROFEN

CHEMISTRY

Chirality: a major issue in veterinary pharmacology. Landoni MF, et al. **J Vet Pharmacol Ther** 1996 Feb;19(1):82–4 (17 ref.)

THERAPEUTIC USE

Preclinical and clinical development of dexketoprofen. Mauleón D, et al. **Drugs** 1996;52 Suppl 5:24–45; discussion 45–6 (163 ref.)

6-KETOPROSTAGLANDIN F1 ALPHA

BLOOD

[Research on plasma TXA2, PGI2 levels, blood stasis syndrome and promoting blood circulation] Li H.
Chung Kuo Chung Hsi I Chieh Ho Tsa Chih 1995 Nov; 15(11):701–4 (30 ref.) **(Chi)**

KETOQUINOLINES see **QUINOLONES**

KETOSIS, DIABETIC see **DIABETIC KETOACIDOSIS**

3-KETOSTEROID ISOMERASES see **STEROID ISOMERASES**

3-KETOTHIOLASE see **ACETYL COA ACYLTRANSFERASE**

KETOTIFEN

THERAPEUTIC USE

[Inhibitor of chemical mediator release] Fujimura M.
Nippon Rinsho 1996 Nov;54(11):3029–33 (8 ref.) (Eng. Abstr.) **(Jpn)**

KI-67 ANTIGEN

ANALYSIS

MIB-1 (Ki-67) immunostaining of breast cancer cells in cytologic smears. Dalquen P, et al. **Acta Cytol** 1997 Mar-Apr;41(2):229–37 (44 ref.)
Esophageal carcinoma metastatic centrally to the mandible: a case report with implication of cell proliferating marker Ki-67. Koyama T, et al. **J Oral Maxillofac Surg** 1997 Jun; 55(6):640–5 (16 ref.)
Clinical significance of Ki-67 staining index in acoustic neurinoma. Yokoyama M, et al.
Neurol Med Chir (Tokyo) 1996 Oct;36(10):698–702; discussion 702–3 (27 ref.)
[Ki-67, marker of proliferation] Guinebretière JM, et al.
Ann Pathol 1997 Mar;17(1):25–30 (57 ref.) **(Fre)**

BIOSYNTHESIS

p53, proliferating cell nuclear antigen, and Ki-67 expression in extrauterine leiomyosarcomas. O'Reilly PE, et al.
Mod Pathol 1997 Feb;10(2):91–7 (28 ref.)

KI-1 ANTIGENS see **ANTIGENS, CD30**

KI-1 LARGE-CELL LYMPHOMA see **LYMPHOMA, LARGE-CELL, KI-1**

KI-1 LYMPHOMA see **LYMPHOMA, LARGE-CELL, KI-1**

KI-1-POSITIVE ANAPLASTIC LARGE-CELL LYMPHOMA see **LYMPHOMA, LARGE-CELL, KI-1**

KI-RAS GENES see **GENES, RAS**

KICKBACKS see **FRAUD**

KIDNAPPING see **CRIME**

KIDNEY

see related
DIURESIS
NEPHRECTOMY
RENAL CIRCULATION

Cytokines: the kidney as a model for their role in tissue injury and repair [editorial] Isbel NM, et al. **Aust N Z J Med** 1996 Oct;26(5):636–9 (25 ref.)
Angiotensin II receptors and renal hemodynamics and function. Ichikawa I. **Blood Press Suppl** 1996;2:19–21 (7 ref.)

ABNORMALITIES

A primary carcinoid tumor of the kidney: a case report and review of the literature. Kurl S, et al. **Abdom Imaging** 1996 Sep-Oct;21(5):464–7 (24 ref.)
Further arguments for non-fortuitous association of Potter sequence with XYY males. Rudnik-Schöneborn S, et al. **Ann Genet** 1996;39(1):43–6 (12 ref.)
Fetal and neonatal nephrology. Guillery EN.
Curr Opin Pediatr 1997 Apr;9(2):148–53 (77 ref.)
Problems of abdominal aortic aneurysm associated with horseshoe kidney. Artioukh DY, et al.
Eur J Vasc Endovasc Surg 1997 Jul;14(1):75–8 (12 ref.)
Genetic manipulation of the embryonic kidney. Woolf AS.
Exp Nephrol 1997 Mar-Apr;5(2):152–6 (32 ref.)
Congenital ectopic vas deferens inserting into the bladder with ipsilateral renal agenesis. Delakas D, et al.
Int Urol Nephrol 1996;28(5):701–7 (13 ref.)
Laparascopic excision of pelvic kidney with single vaginal ectopic ureter. Moores D, et al. **J Pediatr Surg** 1997 Apr; 32(4):634–5 (12 ref.)
Accessory scrotum and anorectal malformation associated with "pseudo" prune belly in a neonate. Shoshany G, et al. **J Perinatol** 1996 May-Jun;16(3 Pt 1):224–6 (25 ref.)
Locally advanced rectal cancer with a pelvic kidney complicating adjuvant radiation therapy. Bokhari MB, et al. **J Surg Oncol** 1996 Sep;63(1):57–60 (14 ref.)
Horseshoe kidney is associated with an increased relative risk of primary renal carcinoid tumor. Krishnan B, et al. **J Urol** 1997 Jun;157(6):2059–66 (42 ref.)
Management of ectopic ureters: experience with the upper tract approach. Plaire JC, et al. **J Urol** 1997 Sep;158(3 Pt 2):1245–7 (11 ref.)
Cystic dysplasia of the rete testis: a benign congenital lesion associated with ipsilateral urological anomalies. Wojcik LJ, et al. **J Urol** 1997 Aug;158(2):600–4 (14 ref.)
Bilateral iliac artery aneurysms and pancake kidney: a case report. Eckes D, et al. **J Vasc Surg** 1997 May;25(5):927–30 (18 ref.)
Genetics of human kidney malformations. Winyard P, et al.
Nephrol Dial Transplant 1996 Jun;11(6):976–8 (10 ref.)
Molecular bases of human kidney malformations. Woolf AS.
Pediatr Nephrol 1997 Jun;11(3):373–6 (12 ref.)
Nephrogenic rests and renal abnormalities in Brachmann-de Lange syndrome. Charles AK, et al.
Pediatr Pathol Lab Med 1997 Mar-Apr;17(2):209–19 (35 ref.)
Aortic reconstruction in patients with horseshoe or ectopic kidneys. de Virgilio C, et al. **Semin Vasc Surg** 1996 Sep; 9(3):245–52 (12 ref.)
Abdominal aortic aneurysm and congenital pelvic kidney. A rare association. Glock Y, et al. **Tex Heart Inst J** 1997; 24(2):131–3 (5 ref.)
Ureteral duplication with lower pole ectopia to the vas: a case report of an exception to the Weigert-Meyer law. Slaughenhoupt BL, et al. **Urology** 1997 Feb;49(2):269–71 (3 ref.)
[Seminal vesicle cyst and ipsilateral kidney failure. Report of 2 cases and review of the literature] Zurkirchen MA, et al. **Urologe A** 1996 Nov;35(6):490–4 (15 ref.) (Eng. Abstr.) **(Ger)**
[Retroperitoneal mucinous cystadenocarcinoma associated with horseshoe kidney: a case report] Takayama H, et al.
Hinyokika Kiyo 1996 Aug;42(8):573–6 (8 ref.) (Eng. Abstr.) **(Jpn)**
[A case of renal pelvic cancer associated with giant hydronephrosis of a horseshoe kidney] Tsuru N, et al.
Hinyokika Kiyo 1997 Mar;43(3):223–6 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Renal dysplasia] Asaka M, et al.
Ryoikibetsu Shokogun Shirizu 1997;(16 Pt 1):442–5 (17 ref.) **(Jpn)**
[Segmental renal hypoplasia (Ask-Upmark kidney)] Inaba S.
Ryoikibetsu Shokogun Shirizu 1997;(16 Pt 1):397–9 (18 ref.) **(Jpn)**
[Ectopic kidney, renal ectopy] Kawamura T.
Ryoikibetsu Shokogun Shirizu 1997;(16 Pt 1):347–51 (7 ref.) **(Jpn)**
[Malrotated kidney] Kawamura T.
Ryoikibetsu Shokogun Shirizu 1997;(16 Pt 1):352–3 (6 ref.) **(Jpn)**
[Supernumerary kidney] Kawamura T.
Ryoikibetsu Shokogun Shirizu 1997;(16 Pt 1):354 (2 ref.) **(Jpn)**
[Renal agenesis, renal dysplasia, renal aplasia, renal hypoplasia, oligomeganephronia] Kawamura T.
Ryoikibetsu Shokogun Shirizu 1997;(16 Pt 1):358–70 (49 ref.) **(Jpn)**
[Fused kidney--anomalies of renal fusion (lobulated kidney)] Kawamura T. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):371–6 (13 ref.) **(Jpn)**
[Renal retinal dysplasia] Tomosugi N, et al.
Ryoikibetsu Shokogun Shirizu 1997;(16 Pt 1):381–4 (20 ref.) **(Jpn)**
[Multicystic renal dysplasia: changes in the contralateral urinary tract] Navascues del Río JA, et al.
Actas Urol Esp 1996 Jun;20(6):564–8; discussion 568–9 (17 ref.) (Eng. Abstr.) **(Spa)**
[Disk kidney. Report of a case] Pérez García FJ, et al.
Actas Urol Esp 1996 Nov-Dec;20(10):907–11 (16 ref.) (Eng. Abstr.) **(Spa)**

BLOOD SUPPLY

Hemodynamic factors in acute renal failure. Conger J.
Adv Ren Replace Ther 1997 Apr;4(2 Suppl 1):25–37 (99 ref.)
Atherosclerotic ischemic renal disease. Greco BA, et al.
Am J Kidney Dis 1997 Feb;29(2):167–87 (144 ref.)
Putting the actin cytoskeleton into perspective: pathophysiology of ischemic alterations. Molitoris BA.
Am J Physiol 1997 Apr;272(4 Pt 2):F430–3 (28 ref.)
Kidney salvage in a case of ruptured renal artery aneurysm: case report and literature review. Schorn B, et al.
Cardiovasc Surg 1997 Feb;5(1):134–6 (21 ref.)
A 'BOLD' new approach to renal oxygen economy [editorial; comment] Kone BC. **Circulation** 1996 Dec 15;94(12):3067–8 (17 ref.) Comment on: Circulation 1996 Dec 15;94(12):3271–5.
Ischemic renal failure. Zucchelli P, et al. **Contrib Nephrol** 1996;119:59–66 (45 ref.)
Ischaemic renal injury. Alcázar JM, et al.
Curr Opin Nephrol Hypertens 1997 Mar;6(2):157–65 (105 ref.)
Control of the renal microcirculation: cellular and integrative perspectives. Casellas D, et al.
Curr Opin Nephrol Hypertens 1996 Jan;5(1):57–63 (52 ref.)
Endothelin in ischemic acute renal failure. Hunley TE, et al. **Curr Opin Nephrol Hypertens** 1997 Jul;6(4):394–400 (76 ref.)
Interactions between arterial pressure and sodium excretion. Navar LG, et al. **Curr Opin Nephrol Hypertens** 1996 Jan; 5(1):64–71 (89 ref.)
Radiographic evaluation of the renal vasculature. Textor SC, et al. **Curr Opin Nephrol Hypertens** 1996 Nov;5(6):541–51 (61 ref.)
Effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist, and an endothelin receptor antagonist on renal afferent arteriolar structure. Skov K, et al.
Hypertension 1996 Sep;28(3):464–71 (62 ref.)
ANCA small-vessel vasculitis. Falk RJ, et al.
J Am Soc Nephrol 1997 Feb;8(2):314–22 (31 ref.)
Importance of nitric oxide in the control of renal hemodynamics. Baylis C, et al. **Kidney Int** 1996 Jun; 49(6):1727–31 (36 ref.)
Nephroangiosclerosis and hypertension: things are not as simple as you might think [editorial] Meyrier A, et al.
Nephrol Dial Transplant 1996 Nov;11(11):2116–20 (34 ref.)
Classification, pathogenesis, and treatment of systemic vasculitis. Griffith ME, et al. **Ren Fail** 1996 Sep; 18(5):785–802 (119 ref.)
Methods of renal blood flow measurement. Young LS, et

al. **Urol Res** 1996;24(3):149–60 (85 ref.)
[Renal varices. X-ray computed tomographic diagnosis and treatment by embolization] Lenoir S, et al. **J Radiol** 1997 Jan;78(1):69–72 (13 ref.) (Eng. Abstr.) **(Fre)**
[Ultrasound diagnosis of the transplanted kidney] Mutze S, et al. **Radiologe** 1996 Jan;36(1):31–7 (49 ref.) (Eng. Abstr.) **(Ger)**
[Renal infarction, infarcted kidney] Hisada Y, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):309–11 (11 ref.) **(Jpn)**
[Cyclosporine nephrotoxicity (chronic arteriolopathy, glomerulopathy)] Matsushima H, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):553–5 (20 ref.) **(Jpn)**
[Renal vasculitis. Early discovery is significant for prognosis] Westberg G. **Lakartidningen** 1997 Mar 5;94(10):857–60 (11 ref.) **(Swe)**

CHEMISTRY

Molecular characterization of chloride channels in the kidney. Uchida S, et al. **Exp Nephrol** 1996 May–Jun; 4(3):135–8 (20 ref.)
Vasopressin receptors in health and disease. Bichet DG. **Kidney Int** 1996 Jun;49(6):1706–11 (33 ref.)
The aquaporin family of water channels in kidney: an update on physiology and pathophysiology of aquaporin-2. Nielsen S, et al. **Kidney Int** 1996 Jun;49(6):1718–23 (43 ref.)

CYTOLOGY

A new role for the stromal cells in kidney development. Bard J. **Bioessays** 1996 Sep;18(9):705–7 (15 ref.)
The erythropoietin-producing cells. Maxwell PH, et al. **Exp Nephrol** 1996 Nov–Dec;4(6):309–13 (22 ref.)
Tandem scanning confocal microscopic imaging of the living kidney. Andrews P. **Int Rev Exp Pathol** 1996;36:131–43 (19 ref.)
Optical studies of intracellular pH in kidney cells in vitro. Hamm LL, et al. **Int Rev Exp Pathol** 1996;36:161–73 (52 ref.)
Coordinate regulation of organic osmolytes in renal cells. Burg MB. **Kidney Int** 1996 Jun;49(6):1684–5 (20 ref.)
Primary kidney cells. Taub M. **Methods Mol Biol** 1997; 75:153–61 (19 ref.)

DRUG EFFECTS

Systemic complications of nonsteroidal anti-inflammatory drug use. Palmer BF, et al. **Adv Intern Med** 1996;41:605–39 (153 ref.)
Is ochratoxin a nephrotoxic in human beings? Godin M, et al. **Adv Nephrol Necker Hosp** 1997;26:181–206 (123 ref.)
Potentiation of nephrotoxicity by H2-antagonists in patients receiving cyclosporine. Lewis SM, et al. **Ann Pharmacother** 1997 Mar;31(3):363–5 (20 ref.)
Renal effects of calcium antagonists with special reference to manidipine hydrochloride. Rodicio JL. **Blood Press Suppl** 1996;5:10–5 (36 ref.)
Effects of antihypertensive drugs on various aspects of renal function. de Leeuw PW, et al. **Cardiovasc Drugs Ther** 1997 Jan;10(6):803–8 (27 ref.)
Current status of putative imidazoline (I1) receptors and renal mechanisms in relation to their antihypertensive therapeutic potential. Evans RG. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov;23(10–11):845–54 (90 ref.)
Structural changes in the renal vasculature in the spontaneously hypertensive rat: no effect of angiotensin II blockade. Kett MM, et al. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S132–5 (35 ref.)
Clinically significant drug interactions with cyclosporin. An update [see comments] Campana C, et al. **Clin Pharmacokinet** 1996 Feb;30(2):141–79 (367 ref.) Comment in: Clin Pharmacokinet 1997 Feb;32(2):173–4.
Cell biology of aminoglycoside nephrotoxicity: newer aspects. Molitoris BA. **Curr Opin Nephrol Hypertens** 1997 Jul;6(4):384–8 (22 ref.)
Interferon-alpha induces renal dysfunction and injury. Phillips TM. **Curr Opin Nephrol Hypertens** 1996 Jul; 5(4):380–3 (39 ref.)
ACE inhibitors and the kidney. A risk–benefit assessment. Navis G, et al. **Drug Saf** 1996 Sep;15(3):200–11 (110 ref.)
Aspects of contrast media nephrotoxicity. Morcos SK, et al. **Eur J Radiol** 1996 Nov;23(3):178–84 (59 ref.)
Safety profile of new non-ionic contrast media: renal tolerance. Stacul F, et al. **Eur J Radiol** 1996 Nov;23 Suppl 1:S6–9 (23 ref.)
Renal effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibition in healthy subjects. Burnier M, et al. **Exp Nephrol** 1996;4 Suppl 1:41–6 (41 ref.)
Experience with antisense oligodeoxynucleotides in renal cells. Ganz MB, et al. **Exp Nephrol** 1997 May–Jun; 5(3):175–9 (14 ref.)
The renoprotective action of angiotensin-converting enzyme inhibitors in diabetes. Ruggenenti P, et al. **Exp Nephrol** 1996;4 Suppl 1:53–60 (42 ref.)
From converting enzyme inhibition to angiotensin II receptor blockade: new insight on angiotensin II receptor subtypes in the kidney. Wolf G, et al. **Exp Nephrol** 1996;4 Suppl 1:8–19 (133 ref.)
Use of phosphonocarboxylic acids as inhibitors of sodium-phosphate cotransport. Loghman-Adham M. **Gen Pharmacol** 1996 Mar;27(2):305–12 (92 ref.)
Development and validation of new screening tests for nephrotoxic effects. Price RG, et al. **Hum Exp Toxicol** 1996 Mar;15 Suppl 1:S10–9 (44 ref.)
Sympathetic and cardiorenal actions of leptin. Haynes WG, et al. **Hypertension** 1997 Sep;30(3 Pt 2):619–23 (45 ref.)
Posttransplant erythrocytosis: a model for the investigation of the pharmacological control of renal erythropoietin production? Gleiter CH. **Int J Clin Pharmacol Ther** 1996 Nov;34(11):489–92 (32 ref.)
Drug induced renal disease. Jha V, et al. **J Assoc Physicians India** 1995 Jun;43(6):407–21 (83 ref.)
Nephrotoxicities of nonsteroidal anti-inflammatory drugs. Wen SF. **J Formos Med Assoc** 1997 Mar;96(3):157–71 (155 ref.)
Renal protection in diabetes: an emerging role for calcium antagonists. Parving HH, et al. **J Hypertens Suppl** 1996 Nov;14(4):S21–5 (54 ref.)
Does antihypertensive therapy protect the kidney in essential hypertension? Rodicio JL. **J Hypertens Suppl** 1996 Sep; 14(2):S69–75; discussion S75–6 (60 ref.)
Assessing renal effects and renal protection. Rodicio JL, et al. **J Hypertens Suppl** 1995 Dec;13(4):S19–25 (80 ref.)
Effects of growth hormone and insulin-like growth factor I on renal growth and function. Hammerman MR, et al. **J Pediatr** 1997 Jul;131(1 Pt 2):S17–9 (16 ref.)
Renal toxicodynamics of ochratoxin A: a pathophysiological approach. Gekle M, et al. **Kidney Blood Press Res** 1996; 19(5):225–35 (74 ref.)
Drug-induced nephrotoxicity. Choudhury D, et al. **Med Clin North Am** 1997 May;81(3):705–17 (66 ref.)
Are angiotensin II receptor blockers superior to angiotensin converting enzyme inhibitors with regard to their renoprotective effect? [editorial] Geiger H. **Nephrol Dial Transplant** 1997 Apr;12(4):640–2 (15 ref.)
Nonsteroidal anti-inflammatory drugs (NSAIDs) and the kidney [editorial] Pugliese F, et al. **Nephrol Dial Transplant** 1997 Mar;12(3):386–8 (17 ref.)
Urography into the 21st century: new contrast media, renal handling, imaging characteristics, and nephrotoxicity. Katzberg RW. **Radiology** 1997 Aug;204(2):297–312 (163 ref.)
Trichloroethylene cancer risk: simplified calculation of PBPK-based MCLs for cytotoxic end points. Bogen KT, et al. **Regul Toxicol Pharmacol** 1997 Feb;25(1):26–42 (121 ref.)
Hazard assessment of germanium supplements. Tao SH, et al. **Regul Toxicol Pharmacol** 1997 Jun;25(3):211–9 (62 ref.)
Drug nephrotoxicity: an overview. Bennett WM. **Ren Fail** 1997 Mar;19(2):221–4 (28 ref.)
Mechanisms of acute and chronic nephrotoxicity from immunosuppressive drugs. Bennett WM. **Ren Fail** 1996 May;18(3):453–60 (57 ref.)
Biomonitoring of early effects on the kidney or the lung. Bernard A, et al. **Sci Total Environ** 1997 Jun 20; 199(1–2):205–11 (10 ref.)
Nephrotoxicity of immunosuppressive drugs: experimental and clinical observations. Andoh TF, et al. **Semin Nephrol** 1997 Jan;17(1):34–45 (128 ref.)
Renal toxicities of antineoplastic drugs and bone marrow transplantation. Berns JS, et al. **Semin Nephrol** 1997 Jan; 17(1):54–66 (167 ref.)
Contrast media-associated nephrotoxicity. Rudnick MR, et al. **Semin Nephrol** 1997 Jan;17(1):15–26 (150 ref.)
Aminoglycoside nephrotoxicity. Swan SK. **Semin Nephrol** 1997 Jan;17(1):27–33 (83 ref.)
Renal failure related to angiotensin-converting enzyme inhibitors. Textor SC. **Semin Nephrol** 1997 Jan;17(1):67–76 (49 ref.)
Occupational and environmental renal disease. Wedeen RP. **Semin Nephrol** 1997 Jan;17(1):46–53 (35 ref.)
Pathogenetic mechanisms in nephrotoxic acute renal failure. Zager RA. **Semin Nephrol** 1997 Jan;17(1):3–14 (97 ref.)
[Nephrotoxicity of cytostatic drugs. Pathogenesis, prevention, therapy] Tesař V, et al. **Cas Lek Cesk** 1997 Apr 2;136(7):205–9 (63 ref.) (Eng. Abstr.) **(Cze)**
[The kidney in children under chemotherapy] Cachat F, et al. **Rev Med Suisse Romande** 1996 Dec;116(12):985–93 (33 ref.) (Eng. Abstr.) **(Fre)**
[Nephrotoxin-induced tubulointerstitial nephropathies] Kliem V, et al. **Internist (Berl)** 1996 Nov;37(11):1116–28 (96 ref.) **(Ger)**
[ACE inhibitors and the kidney] Hörl WH. **Wien Med Wochenschr** 1996;146(11):231–4; discussion 234–5 (27 ref.) (Eng. Abstr.) **(Ger)**
[Renal side effects of angiotensin converting enzyme inhibitors] Schmidt A, et al. **Wien Med Wochenschr** 1996; 146(16):454–6 (28 ref.) (Eng. Abstr.) **(Ger)**
[Cytokines and renal injury] Amoroso A, et al. **Minerva Urol Nefrol** 1996 Dec;48(4):169–76 (37 ref.) (Eng. Abstr.) **(Ita)**
[Aminoglycosides, risk factors and neonatal kidney] Khoory BJ, et al. **Pediatr Med Chir** 1996 Sep–Oct;18(5):495–9 (38 ref.) (Eng. Abstr.) **(Ita)**
[The effect of vasoactive preparations on kidney functional status in patients with chronic glomerulonephritis and kidney failure] Kolesnyk MO, et al. **Lik Sprava** 1996 Jul–Sep;(7–9):18–21 (30 ref.) **(Ukr)**

EMBRYOLOGY

Genetic control of kidney development. Dressler GR. **Adv Nephrol Necker Hosp** 1997;26:1–17 (86 ref.)
Inductive tissue interactions, cell signaling, and the control of kidney organogenesis. Vainio S, et al. **Cell** 1997 Sep 19;90(6):975–8 (19 ref.)
Genetics of kidney development. Ekblom P. **Curr Opin Nephrol Hypertens** 1996 May;5(3):282–7 (37 ref.)
Model systems for the study of kidney development: use of the pronephros in the analysis of organ induction and patterning. Vize PD, et al. **Dev Biol** 1997 Aug 15; 188(2):189–204 (111 ref.)
Dystroglycan and laminins: glycoconjugates involved in branching epithelial morphogenesis. Durbeej M, et al. **Exp Lung Res** 1997 Mar–Apr;23(2):109–18 (43 ref.)
Genetic manipulation of the embryonic kidney. Woolf AS. **Exp Nephrol** 1997 Mar–Apr;5(2):152–6 (32 ref.)
Role of extracellular matrix, growth factors and proto-oncogenes in metanephric development. Kanwar YS, et al. **Kidney Int** 1997 Sep;52(3):589–606 (240 ref.)
The molecular basis of embryonic kidney development. Lechner MS, et al. **Mech Dev** 1997 Mar;62(2):105–20 (120 ref.)
Pax-2, kidney development, and oncogenesis. Dressler GR. **Med Pediatr Oncol** 1996 Nov;27(5):440–4 (34 ref.)
Gene targeting in kidney development. Kreidberg JA. **Med Pediatr Oncol** 1996 Nov;27(5):445–52 (76 ref.)
Angiotensin mediated interaction of fetal kidney and placenta in the control of fetal arterial pressure and its role in hydrops fetalis. Faber JJ, et al. **Placenta** 1997 May; 18(4):313–26 (43 ref.)

ENZYMOLOGY

Physiological regulation of blood pressure and kidney function by guanylyl cyclase isoforms. Kishimoto I, et al. **Curr Opin Nephrol Hypertens** 1997 Jan;6(1):58–63 (46 ref.)
The cytochrome P450 4 (CYP4) family. Simpson AE. **Gen Pharmacol** 1997 Mar;28(3):351–9 (115 ref.)
Immunocytochemical localization of the vacuolar H(+)-ATPase pump in the kidney. Bastani B. **Histol Histopathol** 1997 Jul;12(3):769–79 (55 ref.)
Immunocytochemistry of renal H-ATPase. Bastani B, et al. **Miner Electrolyte Metab** 1996;22(5–6):382–95 (73 ref.)
Renal H,K-ATPase: structure, function and regulation. Kone BC. **Miner Electrolyte Metab** 1996;22(5–6):349–65 (102 ref.)
The renal adenosine triphosphatases: functional integration and clinical significance. Laski ME, et al. **Miner Electrolyte Metab** 1996;22(5–6):410–22 (95 ref.)
Direct regulation of the Na,K pump by signal transduction mechanisms. Middleton JP. **Miner Electrolyte Metab** 1996; 22(5–6):293–302 (84 ref.)
The regulation of 3 beta-hydroxysteroid dehydrogenase expression. Mason JI, et al. **Steroids** 1997 Jan;62(1):164–8 (41 ref.)
[Molecular and functional diversity of NA,K-ATPase and renal H,K-ATPases] Jaisser F. **Nephrologie** 1996; 17(7):401–8 (43 ref.) (Eng. Abstr.) **(Fre)**

GROWTH & DEVELOPMENT

Apoptosis in the mammalian kidney: incidence, effectors, and molecular control in normal development and disease states. Buttyan R, et al. **Adv Pharmacol** 1997;41:369–81 (58 ref.)
Genetics of kidney development. Ekblom P. **Curr Opin Nephrol Hypertens** 1996 May;5(3):282–7 (37 ref.)
Roles of growth factors in renal development. Woolf AS, et al. **Curr Opin Nephrol Hypertens** 1997 Jan;6(1):10–4 (55 ref.)
Aging and the kidney. Epstein M. **J Am Soc Nephrol** 1996 Aug;7(8):1106–22 (135 ref.)
Transgenic animal models as tools for studying renal developmental physiology. Davisson RL, et al. **Pediatr Nephrol** 1996 Dec;10(6):798–803 (58 ref.)
Nitric oxide in the developing kidney. Solhaug MJ, et al. **Pediatr Nephrol** 1996 Aug;10(4):529–39 (91 ref.)

IMMUNOLOGY

Autoantibodies against components of renal basement membrane. Hellmark T, et al. **Adv Nephrol Necker Hosp** 1997;26:291–302 (41 ref.)
The nephritogenic immune response. Fitzsimons MM, et al. **Curr Opin Nephrol Hypertens** 1997 May;6(3):267–75 (75 ref.)

INJURIES

Experimental glomerulosclerosis: Defektheilung of the kidney. Schiller B, et al. **Artif Organs** 1996 May; 20(5):445–50 (50 ref.)
Mechanisms of injury in progressive renal disease. Anderson S. **Exp Nephrol** 1996;4 Suppl 1:34–40 (44 ref.)
MRI and CT in blunt renal trauma: an update. Leppäniemi A, et al. **Semin Ultrasound CT MR** 1997 Apr;18(2):129–35 (25 ref.)
[Diagnostic and therapeutic approach to kidney injuries] Bianchi G, et al. **G Chir** 1997 May;18(5):308–12 (39 ref.) (Eng. Abstr.) **(Ita)**
[Renal injury in childhood] Rengo M, et al. **G Chir** 1997 Jun–Jul;18(6–7):359–61 (22 ref.) (Eng. Abstr.) **(Ita)**
[Hypertension following renal trauma] Nomura G. **Ryoikibetsu Shokogun Shirizu** 1996;(12):83–6 (11 ref.) **(Jpn)**
[Renal traumatism: diagnostic protocol and therapeutic indications] Monserrat Monfort JJ, et al. **Actas Urol Esp** 1996 Jun;20(6):534–43 (18 ref.) (Eng. Abstr.)

(Spa)

INNERVATION

[Renal neuroadrenergic effects. Part I. Renal ischemia caused by sympathetic stimulation and risk factors of cadaver donor] García Matilla F, et al. **Actas Urol Esp** 1997 Mar; 21(3):236–41 (38 ref.) (Eng. Abstr.) (Spa)

METABOLISM

The kidney as a target for biological reactive metabolites: linking metabolism to toxicity. Monks TJ, et al. **Adv Exp Med Biol** 1996;387:203–12 (72 ref.)

The renal epithelial sodium channel: new insights in understanding hypertension. Rossier BC. **Adv Nephrol Necker Hosp** 1996;25:275–86 (38 ref.)

Mechanisms of abnormal renal sodium handling in obesity hypertension. Hall JE. **Am J Hypertens** 1997 May;10(5 Pt 2):49S–55S (48 ref.)

Renal P450 metabolites of arachidonic acid and the development of hypertension in Dahl salt-sensitive rats. Roman RJ, et al. **Am J Hypertens** 1997 May;10(5 Pt 2):63S–67S (33 ref.)

Renal assimilation of oligopeptides: physiological mechanisms and metabolic importance. Adibi SA. **Am J Physiol** 1997 May;272(5 Pt 1):E723–36 (92 ref.)

Glucose transporters in the regulation of intestinal, renal, and liver glucose fluxes. Thorens B. **Am J Physiol** 1996 Apr; 270(4 Pt 1):G541–53 (130 ref.)

Peptide transporters in the intestine and the kidney. Leibach FH, et al. **Annu Rev Nutr** 1996;16:99–119 (119 ref.)

Renal K+ channels: structure and function. Wang W, et al. **Annu Rev Physiol** 1997;59:413–36 (139 ref.)

Role of the b(o,+)-like amino acid-transport system in the renal reabsorption of cystine and dibasic amino acids. Palacín M, et al. **Biochem Soc Trans** 1996 Aug;24(3):856–63 (53 ref.)

Renal dopamine receptors: mechanisms of action and developmental aspects. Cheung PY, et al. **Cardiovasc Res** 1996 Jan;31(1):2–6 (54 ref.)

Light microscope autoradiography of peripheral dopamine receptor subtypes. Amenta F. **Clin Exp Hypertens** 1997 Jan–Feb;19(1–2):27–41 (30 ref.)

Renal transport of drugs: specificity and molecular mechanisms. Somogyi A. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov;23(10–11):986–9 (22 ref.)

Intrarenal localization of nitric oxide synthase isoforms and soluble guanylyl cyclase. Star RA. **Clin Exp Pharmacol Physiol** 1997 Aug;24(8):607–10 (39 ref.)

Angiotensin receptors and development: the kidney. Alcorn D, et al. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S88–92 (55 ref.)

Growth promoter-induced inhibition of proteolytic activities in cultured kidney cells: potential impact in diabetic nephropathy. Ling H, et al. **Clin Nephrol** 1996 Oct; 46(4):260–2 (32 ref.)

Nitric oxide and blood pressure: effects of nitric oxide deficiency. Baylis C, et al. **Curr Opin Nephrol Hypertens** 1996 Jan;5(1):80–8 (109 ref.)

Renal responses to antagonism of the renin–angiotensin system. Braam B, et al. **Curr Opin Nephrol Hypertens** 1996 Jan;5(1):89–96 (69 ref.)

Mineral metabolism [editorial] Drüeke TB, et al. **Curr Opin Nephrol Hypertens** 1997 Jul;6(4):305–7 (28 ref.)

Erythropoietin production in liver and kidneys. Eckardt KU. **Curr Opin Nephrol Hypertens** 1996 Jan;5(1):28–34 (79 ref.)

The scent of an ion: calcium-sensing and its roles in health and disease. Hebert SC, et al. **Curr Opin Nephrol Hypertens** 1996 Jan;5(1):45–53 (79 ref.)

Chloride channels in renal epithelial cells. Reeves WB, et al. **Curr Opin Nephrol Hypertens** 1996 Sep;5(5):406–10 (44 ref.)

Mammalian urea transporters. Shayakul C, et al. **Curr Opin Nephrol Hypertens** 1996 Sep;5(5):401–5 (21 ref.)

Peripheral metabolism of parathyroid hormone. Studies with isolated perfused kidneys and livers from normal and uremic rats. Daugaard H. **Dan Med Bull** 1996 Jun; 43(3):203–15 (143 ref.)

Renal glucose production and utilization: new aspects in humans. Stumvoll M, et al. **Diabetologia** 1997 Jul; 40(7):749–57 (89 ref.)

Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity. Matzke GR, et al. **Drug Saf** 1997 Mar;16(3):205–31 (236 ref.)

The erythropoietin-producing cells. Maxwell PH, et al. **Exp Nephrol** 1996 Nov–Dec;4(6):309–13 (22 ref.)

From converting enzyme inhibition to angiotensin II receptor blockade: new insight on angiotensin II receptor subtypes in the kidney. Wolf G, et al. **Exp Nephrol** 1996;4 Suppl 1:8–19 (133 ref.)

Posttransplant erythrocytosis: a model for the investigation of the pharmacological control of renal erythropoietin production? Gleiter CH. **Int J Clin Pharmacol Ther** 1996 Nov;34(11):489–92 (32 ref.)

Renal tolerance of nonionic dimers [see comments] Deray G, et al. **Invest Radiol** 1996 Jun;31(6):372–7 (27 ref.) Comment in: Invest Radiol 1997 Jun;32(6):368–70.

Functional and molecular aspects of renal prostaglandin receptors [see comments] Breyer MD, et al. **J Am Soc Nephrol** 1996 Jan;7(1):8–17 (87 ref.) Comment in: J Am Soc Nephrol 1996 Aug;7(8):1245–6.

A cloned Ca(2+)-sensing receptor: a mediator of direct effects of extracellular Ca2+ on renal function? Brown EM, et al. **J Am Soc Nephrol** 1995 Dec;6(6):1530–40 (99 ref.)

1996 Homer Smith Award Lecture. Cum grano salis: the epithelial sodium channel and the control of blood pressure. Rossier BC. **J Am Soc Nephrol** 1997 Jun;8(6):980–92 (81 ref.)

Sodium and the kidney in essential hypertension. de Wardener HE. **J Hum Hypertens** 1996 Oct;10(10):645–8 (65 ref.)

Genetic determinants and renal mechanisms in essential hypertension. Manunta P, et al. **J Hum Hypertens** 1996 Oct;10(10):649–56 (75 ref.)

Renal transporters for organic anions and organic cations. Structural requirements for substrates. Ullrich KJ. **J Membr Biol** 1997 Jul 15;158(2):95–107 (89 ref.)

Does primary salt wasting occur in 11-beta-hydroxylase deficiency? Singer-Granick C, et al. **J Pediatr Endocrinol Metab** 1995 Oct–Dec;8(4):275–80 (21 ref.)

The role of renal dopaminergic activity in the pathophysiology of essential hypertension. Iimura O. **Jpn Heart J** 1996 Nov;37(6):815–28 (100 ref.)

Pivotal role of renal kallikrein–kinin system in the development of hypertension and approaches to new drugs based on this relationship. Katori M, et al. **Jpn J Pharmacol** 1996 Feb;70(2):95–128 (247 ref.)

Regulation of the intracellular calcium concentration in epithelial cells. Leipziger J, et al. **Kidney Blood Press Res** 1996;19(3–4):148–50 (21 ref.)

Comparative aspects of renal urate transport. Dantzler WH. **Kidney Int** 1996 Jun;49(6):1549–51 (15 ref.)

Hyperglycemia and intestinal and renal glucose transport: implications for diabetic renal injury [editorial] Debnam ES, et al. **Kidney Int** 1996 Oct;50(4):1101–9 (108 ref.)

Oxygen and renal metabolism. Epstein FH. **Kidney Int** 1997 Feb;51(2):381–5 (30 ref.)

Extracellular calcium-sensing receptor: implications for calcium and magnesium handling in the kidney. Hebert SC. **Kidney Int** 1996 Dec;50(6):2129–39 (97 ref.)

Heterogeneities and profiles of oxygen pressure in brain and kidney as examples of the pO2 distribution in the living tissue. Lübbers DW, et al. **Kidney Int** 1997 Feb;51(2):372–80 (40 ref.)

Sites of erythropoietin production. Maxwell PH, et al. **Kidney Int** 1997 Feb;51(2):393–401 (57 ref.)

Protein glycation in the kidney: role in diabetes and aging. Vlassara H. **Kidney Int** 1996 Jun;49(6):1795–804 (69 ref.)

Kidney, salt, and hypertension: how and why. Kurokawa K. **Kidney Int Suppl** 1996 Jun;55:S46–51 (27 ref.)

Ammonium transport and the role of the Na,K-ATPase. Wall SM. **Miner Electrolyte Metab** 1996;22(5–6):311–7 (43 ref.)

The Na-(K)-Cl cotransporter family in the mammalian kidney: molecular identification and function(s). Delpire E, et al. **Nephrol Dial Transplant** 1996 Oct;11(10):1967–73 (34 ref.)

Expression of Na(+)-H+ exchanger isoforms in the kidney--implications for renal function and disease [editorial] Rutherford PA. **Nephrol Dial Transplant** 1996 Sep;11(9):1711–3 (18 ref.)

Trafficking of lysosomal membrane proteins in polarized kidney cells. Hunziker W, et al. **Nephrologie** 1996; 17(7):347–50 (22 ref.)

Renal acid excretion in early infancy. Manz F, et al. **Pediatr Nephrol** 1997 Apr;11(2):231–43 (102 ref.)

Renal excretion of endothelin in children. Máttyus I, et al. **Pediatr Nephrol** 1997 Aug;11(4):513–21 (92 ref.)

A molecular view of proximal tubular inorganic phosphate (Pi) reabsorption and of its regulation. Murer H, et al. **Pflugers Arch** 1997 Feb;433(4):379–89 (107 ref.)

Isolated renal brush border and basolateral membrane vesicles and cultured renal cells. Gutierrez MM, et al. **Pharm Biotechnol** 1996;8:193–210 (31 ref.)

Use of an isolated perfused kidney to assess renal clearance of drugs: information obtained in steady-state and non-steady-state experimental systems. Okudaira N, et al. **Pharm Biotechnol** 1996;8:211–38 (58 ref.)

Renal drug transport: a review. Bendayan R. **Pharmacotherapy** 1996 Nov–Dec;16(6):971–85 (165 ref.)

Interaction of urinary crystals with renal epithelial cells in the pathogenesis of nephrolithiasis. Lieske JC, et al. **Semin Nephrol** 1996 Sep;16(5):458–73 (73 ref.)

Thrombin stimulation of renal cells. Rondeau E, et al. **Semin Thromb Hemost** 1996;22(2):135–8 (25 ref.)

[Regulation and physiopathology of phosphate transport] Friedlander G. **Nephrologie** 1996;17(7):371–5 (35 ref.) (Eng. Abstr.) (Fre)

[The mechanisms of urate transport in the kidney and the intestine] Sekine T, et al. **Nippon Rinsho** 1996 Dec; 54(12):3237–42 (17 ref.) (Eng. Abstr.) (Jpn)

[Osmolytes and osmoregulation in renal cells] Więckowski MR, et al. **Postepy Biochem** 1996;42(2):167–77 (76 ref.) (Pol)

PATHOLOGY

Nonimmunologic factors involved in long-term renal allograft deterioration. Fellström BC, et al. **Adv Nephrol Necker Hosp** 1996;25:51–62 (63 ref.)

Chronic rejection: is allograft destruction an inevitable phenomenon? Kreis H, et al. **Adv Nephrol Necker Hosp** 1996;25:3–15 (44 ref.)

The implication of renin-angiotensin system on renal injury seen in Dahl salt-sensitive rats. Hirawa N, et al. **Am J Hypertens** 1997 May;10(5 Pt 2):102S–106S (19 ref.)

Long-term infusion of kallikrein attenuates renal injury in Dahl salt-sensitive rats. Uehara Y, et al. **Am J Hypertens** 1997 May;10(5 Pt 2):83S–88S (23 ref.)

Fine-needle aspiration of the adult kidney. Renshaw AA, et al. **Cancer** 1997 Apr 25;81(2):71–88 (154 ref.)

Managing lupus nephritis: algorithms for conservative use of renal biopsy. Salach RH, et al. **Cleve Clin J Med** 1996 Mar–Apr;63(2):106–15 (43 ref.)

Renal involvement in primary vasculitides. Sinico RA, et al. **Clin Rev Allergy Immunol** 1997 Spring;15(1):65–72 (28 ref.)

Nephrotoxicity of antiviral therapies. Becker BN, et al. **Curr Opin Nephrol Hypertens** 1996 Jul;5(4):375–9 (44 ref.)

Lessons from kidney biopsies. Osterby R. **Diabetes Metab Rev** 1996 Oct;12(3):151–74 (121 ref.)

Renal hypertrophy and kidney disease in diabetes. Rabkin R, et al. **Diabetes Metab Rev** 1996 Oct;12(3):217–41 (268 ref.)

Transdifferentiation: a new angle on renal fibrosis. Strutz F, et al. **Exp Nephrol** 1996 Sep–Oct;4(5):267–70 (32 ref.)

Renal fibrosis: insights into pathogenesis and treatment. el Nahas AM, et al. **Int J Biochem Cell Biol** 1997 Jan; 29(1):55–62 (67 ref.)

Growth factors and apoptosis in neonatal ureteral obstruction. Chevalier RL. **J Am Soc Nephrol** 1996 Aug; 7(8):1098–105 (54 ref.)

Molecular insights into renal interstitial fibrosis [editorial] Eddy AA. **J Am Soc Nephrol** 1996 Dec;7(12):2495–508 (158 ref.)

Lobar dysmorphism of the kidney: report of two cases and review of the literature. Zwirewich CV, et al. **J Comput Assist Tomogr** 1997 Sep–Oct;21(5):742–4 (4 ref.)

TGF-beta in kidney fibrosis: a target for gene therapy. Border WA, et al. **Kidney Int** 1997 May;51(5):1388–96 (40 ref.)

The renal allograft biopsy. Colvin RB. **Kidney Int** 1996 Sep; 50(3):1069–82 (137 ref.)

Possible pathogenesis of renal fibrosis. Okada H, et al. **Kidney Int Suppl** 1996 May;54:S37–8 (23 ref.)

In vitro formation of cysts derived from a rat model of autosomal dominant polycystic kidney disease. Pey R, et al. **Nephrol Dial Transplant** 1996;11 Suppl 6:58–61 (31 ref.)

Interstitial nephritis. Dhillon S, et al. **Postgrad Med J** 1997 Mar;73(857):151–5 (33 ref.)

Glutathione-dependent bioactivation and renal toxicity of xenobiotics. Dekant W. **Recent Results Cancer Res** 1997; 143:77–87 (83 ref.)

Poly(ADP-ribosyl)ation and nuclear matrix/intermediate filament proteins in renal carcinogenesis. Vamvakas S, et al. **Recent Results Cancer Res** 1997;143:195–208 (60 ref.)

The role of the kidney biopsy in the treatment of lupus nephritis. Kashgarian M. **Ren Fail** 1996 Sep;18(5):765–73 (44 ref.)

Reduction of liver mass due to malnutrition in rats. Correlation with emaciation of animals and size of organs not inserted in the portal system. Miguel Parra O, et al. **Rev Paul Med** 1995 May–Jun;113(3):903–9 (53 ref.)

Candidal renal papillary necrosis: report of a case and review. Chiew YF. **Singapore Med J** 1996 Feb;37(1):119–21 (14 ref.)

Percutaneous needle biopsy of the kidney. Indications, applications, technique, and complications. Osborne CA, et al. **Vet Clin North Am Small Anim Pract** 1996 Nov; 26(6):1461–504 (23 ref.)

[Kidney involvement in progressive scleroderma] Blumenstein M, et al. **Dtsch Med Wochenschr** 1997 Feb 14;122(7):200–4 (22 ref.) (Ger)

[Renal pathology of VTEC related HUS] Shigematsu H. **Nippon Rinsho** 1997 Mar;55(3):721–5 (20 ref.) (Eng. Abstr.) (Jpn)

PHYSIOLOGY

Genetic and nongenetic determinants of salt sensitivity and blood pressure. Cowley AW Jr. **Am J Clin Nutr** 1997 Feb; 65(2 Suppl):587S–593S (50 ref.)

The role of the cytochrome P450-dependent metabolites of arachidonic acid in blood pressure regulation and renal function: a review. Rahman M, et al. **Am J Hypertens** 1997 Mar;10(3):356–65 (104 ref.)

Endothelins in the normal and diseased kidney. Kohan DE. **Am J Kidney Dis** 1997 Jan;29(1):2–26 (260 ref.)

Growth factors and the kidney: regulation of epithelial cell movement and morphogenesis. Cantley LG. **Am J Physiol** 1996 Dec;271(6 Pt 2):F1103–13 (95 ref.)

Cellular and molecular mechanisms of renal peptide transport. Daniel H, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):F1–8 (72 ref.)

Biosynthesis and homeostatic roles of nitric oxide in the normal kidney. Kone BC, et al. **Am J Physiol** 1997 May; 272(5 Pt 2):F561–78 (222 ref.)

Putting the actin cytoskeleton into perspective: pathophysiology of ischemic alterations. Molitoris BA. **Am J Physiol** 1997 Apr;272(4 Pt 2):F430–3 (28 ref.)

Nitric oxide and the immature kidney. Ballèvre L, et al. **Biol Neonate** 1996;70(1):1–14 (96 ref.)

The potential role of nitric oxide in angiotensin II-receptor blockade. Cachofeiro V, et al. **Blood Press Suppl** 1996; 2:29–35 (49 ref.)

Calcium-receptor-regulated parathyroid and renal function. Brown EM, et al. **Bone** 1997 Apr;20(4):303–9 (50 ref.)

KIDNEY

Role of nitric oxide in the control of glomerular microcirculation. Ito S, et al. **Clin Exp Pharmacol Physiol** 1997 Aug;24(8):578–81 (18 ref.)

Mineral metabolism: new aspects and perspectives [editorial] Drüeke TB. **Curr Opin Nephrol Hypertens** 1996 Jul; 5(4):297–9 (16 ref.)

Regulation of renal phosphate handling: recent findings. Friedlander G. **Curr Opin Nephrol Hypertens** 1996 Jul; 5(4):316–20 (29 ref.)

A reappraisal of aldosterone effects on the kidney: new insights provided by epithelial sodium channel cloning. Gründer S, et al. **Curr Opin Nephrol Hypertens** 1997 Jan; 6(1):35–9 (50 ref.)

Physiological regulation of blood pressure and kidney function by guanylyl cyclase isoforms. Kishimoto I, et al. **Curr Opin Nephrol Hypertens** 1997 Jan;6(1):58–63 (46 ref.)

Ularitide: from renal natriuretic peptide to clinical trials. Meyer M, et al. **Curr Opin Nephrol Hypertens** 1996 Jul; 5(4):364–8 (40 ref.)

Growth hormone, the insulin-like growth factor system, and the kidney. Feld S, et al. **Endocr Rev** 1996 Oct;17(5):423–80 (725 ref.)

Renal effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibition in healthy subjects. Burnier M, et al. **Exp Nephrol** 1996;4 Suppl 1:41–6 (41 ref.)

The intrarenal renin-angiotensin system: a paracrine system for the local control of renal function separate from the systemic axis. Harris RC, et al. **Exp Nephrol** 1996;4 Suppl 1:2–7 (66 ref.)

Mechanical stress-cell function relationships in renal cells [editorial] Harris RC, et al. **Exp Nephrol** 1997 Jul–Aug; 5(4):263–70 (85 ref.)

alpha-Adrenergic regulation of human renal function. Michel MC, et al. **Fundam Clin Pharmacol** 1996;10(6):493–503 (108 ref.)

Renal function monitoring. Garwood S, et al. **Int Anesthesiol Clin** 1996 Summer;34(3):175–94 (87 ref.)

Optical studies of intracellular pH in kidney cells in vitro. Hamm LL, et al. **Int Rev Exp Pathol** 1996;36:161–73 (52 ref.)

Cellular and molecular mechanisms of renal phosphate transport. Tenenhouse HS. **J Bone Miner Res** 1997 Feb; 12(2):159–64 (64 ref.)

Changes in renal sympathetic nerve activities in the regulation of body fluid balance with special reference to central neuropeptides in conscious rats. Kannan H. **Jpn J Physiol** 1996 Apr;46(2):111–22 (107 ref.)

Antisense and the kidney. Oberbauer R, et al. **Kidney Blood Press Res** 1996;19(5):221–4 (19 ref.)

Direct and indirect cost of urea excretion. Bankir L, et al. **Kidney Int** 1996 Jun;49(6):1598–607 (68 ref.)

Importance of nitric oxide in the control of renal hemodynamics. Baylis C, et al. **Kidney Int** 1996 Jun; 49(6):1727–31 (36 ref.)

Vasopressin receptors in health and disease. Bichet DG. **Kidney Int** 1996 Jun;49(6):1706–11 (33 ref.)

Renal effects of angiotensin II receptor blockade in normotensive subjects. Burnier M, et al. **Kidney Int** 1996 Jun;49(6):1787–90 (32 ref.)

Cellular and molecular events in the action of antidiuretic hormone. Hays RM. **Kidney Int** 1996 Jun;49(6):1700–5 (30 ref.)

Renal brush border membrane Na/Pi-cotransport: molecular aspects in PTH-dependent and dietary regulation. Murer H, et al. **Kidney Int** 1996 Jun;49(6):1769–73 (44 ref.)

Evolutionary aspects of renal function. Natochin YV. **Kidney Int** 1996 Jun;49(6):1539–42 (22 ref.)

Plasma cAMP: a hepatorenal link influencing proximal reabsorption and renal hemodynamics? Bankir L, et al. **Kidney Int Suppl** 1997 Jun;59:S50–6 (60 ref.)

Nephrology. The year of the pores. Schieppati A, et al. **Lancet** 1996 Dec 21–28;348 Suppl 2:sII13 (5 ref.)

The kidney in blood pressure regulation and development of hypertension. Navar LG. **Med Clin North Am** 1997 Sep; 81(5):1165–98 (179 ref.)

Nitric oxide (NO) in renal physiology and pathophysiology [editorial] Baylis C, et al. **Nephrol Dial Transplant** 1996 Oct;11(10):1955–7 (13 ref.)

Amylin—its role in the kidney [editorial] Cooper ME, et al. **Nephrol Dial Transplant** 1997 Jan;12(1):8–10 (17 ref.)

Renal haemodynamics in the elderly. Fliser D, et al. **Nephrol Dial Transplant** 1996;11 Suppl 9:2–8 (92 ref.)

Transgenic animal models as tools for studying renal developmental physiology. Davisson RL, et al. **Pediatr Nephrol** 1996 Dec;10(6):798–803 (58 ref.)

Nitric oxide in the developing kidney. Solhaug MJ, et al. **Pediatr Nephrol** 1996 Aug;10(4):529–39 (91 ref.)

Plasticity of renal epithelial cells: the way a potassium channel supports migration. Schwab A, et al. **Pflugers Arch** 1996;432(3 Suppl):R87–93 (42 ref.)

Neural control of renal function. DiBona GF, et al. **Physiol Rev** 1997 Jan;77(1):75–197 (1736 ref.)

Inflammatory cells in renal regeneration. Ghielli M, et al. **Ren Fail** 1996 May;18(3):355–75 (106 ref.)

Pitfalls in the prediction of renal function in the intensive care unit. A review. Wells M, et al. **S Afr J Surg** 1997 Feb;35(1):16–9 (26 ref.)

The relative influence of delayed graft function and acute rejection on renal transplant survival. Nicholson ML, et al. **Transpl Int** 1996;9(4):415–9 (29 ref.)

[Kidney and nitric oxide] Dimitrov Y, et al. **Nephrologie** 1997; 18(2):41–6 (42 ref.) (Eng. Abstr.) **(Fre)**

[Role of nitric oxide in the regulation of arterial pressure and renal function] Dussaule JC, et al. **Presse Med** 1996 Nov 23;25(36):1789–93 (22 ref.) (Eng. Abstr.) **(Fre)**

[Quantitative analysis in nuclear nephrourology: clearance, uptake and transit time] Itoh K. **Kaku Igaku** 1997 Jan; 34(1):53–8 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Nitric oxide in renal physiology and pathology] Markov KhM. **Vestn Ross Akad Med Nauk** 1996;(7):73–8 (61 ref.) **(Rus)**

PHYSIOPATHOLOGY

Pharmacokinetics and renal function in preterm infants. van den Anker JN. **Acta Paediatr** 1996 Dec;85(12):1393–9 (58 ref.)

Growth factors and cytokines in acute renal failure. Harris RC. **Adv Ren Replace Ther** 1997 Apr;4(2 Suppl 1):43–53 (139 ref.)

Protecting the residual renal function: which drugs of choice? Bretzel RG. **Am J Hypertens** 1997 Jul;10(7 Pt 2):159S–166S (75 ref.)

Nitric oxide, the kidney, and hypertension. Lahera V, et al. **Am J Hypertens** 1997 Jan;10(1):129–40 (101 ref.)

Epithelial cell polarity and disease. Wilson PD. **Am J Physiol** 1997 Apr;272(4 Pt 2):F434–42 (47 ref.)

Principles of drug administration in renal insufficiency. Lam YW, et al. **Clin Pharmacokinet** 1997 Jan;32(1):30–57 (118 ref.)

Is deterioration of renal function in essential hypertension predictable? Campese VM, et al. **Contrib Nephrol** 1996; 119:83–90 (35 ref.)

Mechanisms and management of renal dysfunction in heart failure. Anand IS, et al. **Curr Opin Cardiol** 1997 May; 12(3):251–8 (93 ref.)

Proteinuria and progression of renal disease: therapeutic implications. Gansevoort RT, et al. **Curr Opin Nephrol Hypertens** 1997 Mar;6(2):133–40 (55 ref.)

Endothelin in ischemic acute renal failure. Hunley TE, et al. **Curr Opin Nephrol Hypertens** 1997 Jul;6(4):394–400 (76 ref.)

Renal implications of arterial hypertension. Ruilope LM. **Curr Opin Nephrol Hypertens** 1997 Mar;6(2):152–6 (50 ref.)

Renal considerations, dialysis, and ultrafiltration during cardiopulmonary bypass. Sutton RG. **Int Anesthesiol Clin** 1996 Spring;34(2):165–76 (42 ref.)

Renal dysfunction in patients with sarcoidosis [editorial; comment] Sato A. **Intern Med** 1996 Jul;35(7):523–4 (13 ref.) Comment on: Intern Med 1996 Jul;35(7):579–82.

Antihypertensive therapy and renal function. Mimran A. **J Cardiovasc Pharmacol** 1996;27 Suppl 3:S19–25 (47 ref.)

Sodium and the kidney in essential hypertension. de Wardener HE. **J Hum Hypertens** 1996 Oct;10(10):645–8 (65 ref.)

Central role of the kidney and abnormal fluid volume control in hypertension. Hall JE, et al. **J Hum Hypertens** 1996 Oct; 10(10):633–9 (23 ref.)

Genetic determinants and renal mechanisms in essential hypertension. Manunta P, et al. **J Hum Hypertens** 1996 Oct;10(10):649–56 (75 ref.)

Altered myogenic responsiveness of the renal microvasculature in experimental hypertension. Hayashi K, et al. **J Hypertens** 1996 Dec;14(12):1387–401 (155 ref.)

Prevention and treatment of late graft dysfunction. van der Woude FJ. **Kidney Blood Press Res** 1997;20(3):170–2 (23 ref.)

Renal mechanisms of genetic hypertension: from the molecular level to the intact organism. Cusi D, et al. **Kidney Int** 1996 Jun;49(6):1754–9 (62 ref.)

Protein glycation in the kidney: role in diabetes and aging. Vlassara H. **Kidney Int** 1996 Jun;49(6):1795–804 (69 ref.)

Residual renal function, peritoneal transport characteristics and dialysis adequacy in peritoneal dialysis. Heimbürger O. **Kidney Int Suppl** 1996 Nov;56:S47–55 (111 ref.)

Kidney, salt, and hypertension: how and why. Kurokawa K. **Kidney Int Suppl** 1996 Jun;55:S46–51 (27 ref.)

Renal function in pediatric liver transplant patients. McDiarmid SV. **Kidney Int Suppl** 1996 Jan;53:S77–84 (121 ref.)

Nephrology. The year of the pores. Schieppati A, et al. **Lancet** 1996 Dec 21–28;348 Suppl 2:sII13 (5 ref.)

Hyponatremia and hypernatremia. Fried LF, et al. **Med Clin North Am** 1997 May;81(3):585–609 (120 ref.)

Hypokalemia and hyperkalemia. Mandal AK. **Med Clin North Am** 1997 May;81(3):611–39 (37 ref.)

Nitric oxide (NO) in renal physiology and pathophysiology [editorial] Baylis C, et al. **Nephrol Dial Transplant** 1996 Oct;11(10):1955–7 (13 ref.)

Tony Raine Memorial Lecture. Hypertension and the kidney: culprit and victim. Koomans HA, et al. **Nephrol Dial Transplant** 1996 Oct;11(10):1961–6 (110 ref.)

Renal involvement in mitochondrial cytopathies [see comments] Niaudet P, et al. **Pediatr Nephrol** 1996 Jun; 10(3):368–73 (81 ref.) Comment in: Pediatr Nephrol 1997 Jun;11(3):386.

The impact of residual renal function on the adequacy of peritoneal dialysis. Lameire N, et al. **Perit Dial Int** 1997; 17 Suppl 2:S102–10 (73 ref.)

Factors affecting peritoneal efficiency in different treatment schedules. Nolph KD. **Perit Dial Int** 1997;17 Suppl 2:S98–101 (19 ref.)

Acceleration of recovery in acute renal failure: from cellular mechanisms of tubular repair to innovative targeted therapies. Abbate M, et al. **Ren Fail** 1996 May;18(3):377–88 (68 ref.)

Kidney and hypertension: role of the juxtaglomerular apparatus. Ito S. **Tohoku J Exp Med** 1997 Apr; 181(4):411–29 (58 ref.)

[Normal kidney function and acute and chronic kidney function disorders] Kallerhoff M. **Urologe A** 1996 Jul; 35(4):345–54 (13 ref.) **(Ger)**

[The renal dopaminergic system and arterial hypertension] Pestana M, et al. **Rev Port Cardiol** 1996 Dec;15(12):893–902 (66 ref.) **(Por)**

[Multiple myeloma and the kidneys] Kamaeva OI. **Ter Arkh** 1997;69(6):73–5 (26 ref.) **(Rus)**

RADIOGRAPHY

Review article: the quantification of renal function with enhanced computed tomography. Blomley MJ, et al. **Br J Radiol** 1996 Nov;69(827):989–95 (40 ref.)

Uroscopy in the 21st century: high-field NMR spectroscopy. Neild GH, et al. **Nephrol Dial Transplant** 1997 Mar; 12(3):404–17 (37 ref.)

Helical CT for detection and characterization of renal masses. Yuh BI, et al. **Semin Ultrasound CT MR** 1997 Apr; 18(2):82–90 (20 ref.)

Radiologic evaluation of small and indeterminant renal masses. Curry NS, et al. **Urol Clin North Am** 1997 Aug; 24(3):493–505 (56 ref.)

[Patchy renal vasoconstriction] Ishikawa I. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):293–6 (20 ref.) **(Jpn)**

RADIONUCLIDE IMAGING

False-positive radioiodine uptake in the abdomen and the pelvis: radioiodine retention in the kidneys and review of the literature. Bakheet SM, et al. **Clin Nucl Med** 1996 Dec; 21(12):932–7 (25 ref.)

The evaluation of acute pyelonephritis and renal scarring with technetium 99m-dimercaptosuccinic acid renal scintigraphy: evolving concepts and future directions. Rushton HG. **Pediatr Nephrol** 1997 Feb;11(1):108–20 (102 ref.)

MRI and CT in blunt renal trauma: an update. Leppäniemi A, et al. **Semin Ultrasound CT MR** 1997 Apr;18(2):129–35 (25 ref.)

Helical CT for detection and characterization of renal masses. Yuh BI, et al. **Semin Ultrasound CT MR** 1997 Apr; 18(2):82–90 (20 ref.)

[99m technetium-dimercaptosuccinic acid renal scan in urinary tract infection in infancy and childhood] Aladjem M, et al. **Harefuah** 1997 Jun 1;132(11):796–8 (25 ref.) **(Heb)**

[Evaluation of renal function by SPECT] Nakagawa T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:638–41 (7 ref.) **(Jpn)**

SECRETION

Renin secretion in Lyon hypertensive rats. Julien C, et al. **Clin Exp Hypertens** 1997 Jul–Aug;19(5–6):699–711 (26 ref.)

Renal secretion of organic anions and cations. Pritchard JB, et al. **Kidney Int** 1996 Jun;49(6):1649–54 (29 ref.)

SURGERY

Management of ectopic ureters: experience with the upper tract approach. Plaire JC, et al. **J Urol** 1997 Sep;158(3 Pt 2):1245–7 (11 ref.)

[Retroperitoneal mucinous cystadenocarcinoma associated with horseshoe kidney: a case report] Takayama H, et al. **Hinyokika Kiyo** 1996 Aug;42(8):573–6 (8 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Ultrasonic imaging of microscopic structures in living organs. Insana MF. **Int Rev Exp Pathol** 1996;36:73–92 (18 ref.)

Doppler ultrasound of the kidney. Platt JF. **Semin Ultrasound CT MR** 1997 Feb;18(1):22–32 (81 ref.)

ULTRASTRUCTURE

The physical chemical basis for preserving cell structure for electron microscopy at the molecular level and available preparatory methods. Sjöstrand FS. **J Submicrosc Cytol Pathol** 1997 Apr;29(2):157–72 (27 ref.)

Viewing the renal epithelium with the atomic force microscope. Oberleithner H, et al. **Kidney Blood Press Res** 1996;19(3–4):142–7 (38 ref.)

KIDNEY, ARTIFICIAL

Acute renal failure: role of dialysis membrane biocompatibility. Pascual M, et al. **Annu Rev Med** 1997; 48:467–76 (39 ref.)

Characterization of molecular transport in artificial kidneys. Leypoldt JK, et al. **Artif Organs** 1996 May;20(5):381–9 (37 ref.)

Membrane biocompatibility in the treatment of acute renal failure: what is the evidence in 1996? Jacobs C. **Nephrol Dial Transplant** 1997 Jan;12(1):38–42 (32 ref.)

Different types of dialyzer membranes: does the bio(in)compatibility matter in the treatment of ARF? Vanholder R, et al. **Ren Fail** 1996 May;18(3):471–9 (42 ref.)

Prospects for a bioartificial kidney. Woods JD, et al. **Semin Nephrol** 1997 Jul;17(4):381–6 (25 ref.)

KIDNEY-BRUSH-BORDER NEUTRAL PROTEINASE see **NEPRILYSIN**

KIDNEY CALCULI

Renal calculi in pregnancy. Gorton E, et al. **Br J Urol** 1997 Jul;80 Suppl 1:4–9 (39 ref.)

Interaction of urinary crystals with renal epithelial cells in the pathogenesis of nephrolithiasis. Lieske JC, et al. **Semin Nephrol** 1996 Sep;16(5):458–73 (73 ref.)

Staghorn calculi. Segura JW. **Urol Clin North Am** 1997 Feb; 24(1):71–80 (28 ref.)

CHEMICALLY INDUCED

Adverse effects of high-calcium diets in humans. Whiting SJ, et al. **Nutr Rev** 1997 Jan;55(1 Pt 1):1–9 (62 ref.)

CHEMISTRY

Clinical approach to adults. Monk RD. **Semin Nephrol** 1996 Sep;16(5):375–88 (71 ref.)

COMPLICATIONS

[Unusual association of transitional cell carcinoma in the upper urinary tract, with contralateral renal metastasis and renal lithiasis of long clinical course] Cuesta Presedo JM, et al. **Actas Urol Esp** 1997 Jan;21(1):60–3 (15 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Patient evaluation. Laboratory and imaging studies. Begun FP, et al. **Urol Clin North Am** 1997 Feb;24(1):97–116 (41 ref.)

DRUG THERAPY

Southwestern Internal Medicine Conference: medical management of nephrolithiasis--a new, simplified approach for general practice. Pak CY. **Am J Med Sci** 1997 Apr; 313(4):215–9 (29 ref.)

Prospective therapeutic studies in nephrolithiasis. Ackermann DK. **World J Urol** 1997;15(3):172–5 (29 ref.)

ETIOLOGY

Genetic versus environmental factors in renal stone disease. Jaeger P. **Curr Opin Nephrol Hypertens** 1996 Jul;5(4):342–6 (35 ref.)

Properties and function of nephrocalcin: mechanism of kidney stone inhibition or promotion. Nakagawa Y. **Keio J Med** 1997 Mar;46(1):1–9 (21 ref.)

Glycosaminoglycans, proteins, and stone formation: adult themes and child's play. Ryall RL. **Pediatr Nephrol** 1996 Oct;10(5):656–66 (134 ref.)

Uric acid–related nephrolithiasis. Low RK, et al. **Urol Clin North Am** 1997 Feb;24(1):135–48 (69 ref.)

Animal models of kidney stone formation: an analysis. Khan SR. **World J Urol** 1997;15(4):236–43 (52 ref.)

The role of the papilla in idiopathic calcium oxalate nephrolithiasis. Krautschick A, et al. **World J Urol** 1997; 15(4):213–8 (59 ref.)

Cell cultures and nephrolithiasis. Verkoelen CF, et al. **World J Urol** 1997;15(4):229–35 (84 ref.)

[Hyperoxaluria and renal calculi] Buño Soto A, et al. **Arch Esp Urol** 1996 Sep;49(7):707–26 (172 ref.) (Eng. Abstr.) **(Spa)**

[Urinary lithiasis in transplanted kidney] Lancina Martín JA, et al. **Arch Esp Urol** 1997 Mar;50(2):141–50 (60 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Genetic versus environmental factors in renal stone disease. Jaeger P. **Curr Opin Nephrol Hypertens** 1996 Jul;5(4):342–6 (35 ref.)

METABOLISM

Oxalate transport and calcium oxalate renal stone disease [editorial] Verkoelen CF, et al. **Urol Res** 1996;24(4):183–91 (77 ref.)

PHYSIOPATHOLOGY

New insights into the pathophysiology and treatment of nephrolithiasis: new research venues. Coe FL, et al. **J Bone Miner Res** 1997 Apr;12(4):522–33 (112 ref.)

Nephrolithiasis: how it happens and what to do about it. Trivedi BK. **Postgrad Med** 1996 Dec;100(6):63–7, 71–2, 77–8 (12 ref.)

PREVENTION & CONTROL

Properties and function of nephrocalcin: mechanism of kidney stone inhibition or promotion. Nakagawa Y. **Keio J Med** 1997 Mar;46(1):1–9 (21 ref.)

[Thiazide diuretics and calcium metabolism: role in renal lithiasis and osteoporosis] Suárez Fernández C, et al. **An Med Interna** 1996 Aug;13(8):401–6 (52 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Nephrolithiasis. Pak CY. **Curr Ther Endocrinol Metab** 1997; 6:572–6 (3 ref.)

Colonic injury after ESWL of renal calculi [letter] Etzkorn KP, et al. **Gastrointest Endosc** 1996 Oct;44(4):511–2 (3 ref.)

New insights into the pathophysiology and treatment of nephrolithiasis: new research venues. Coe FL, et al. **J Bone Miner Res** 1997 Apr;12(4):522–33 (112 ref.)

Medical management of nephrolithiasis. Saklayen MG. **Med Clin North Am** 1997 May;81(3):785–99 (56 ref.)

Nephrolithiasis: how it happens and what to do about it. Trivedi BK. **Postgrad Med** 1996 Dec;100(6):63–7, 71–2, 77–8 (12 ref.)

Clinical approach to adults. Monk RD. **Semin Nephrol** 1996 Sep;16(5):375–88 (71 ref.)

Management of calyceal calculi. Cohen TD, et al. **Urol Clin North Am** 1997 Feb;24(1):81–96 (85 ref.)

Medical therapy, calcium oxalate urolithiasis. Ruml LA, et al. **Urol Clin North Am** 1997 Feb;24(1):117–33 (148 ref.)

Sandwich therapy. Streem SB. **Urol Clin North Am** 1997 Feb;24(1):213–23 (33 ref.)

Treatment options in struvite stones. Wang LP, et al. **Urol Clin North Am** 1997 Feb;24(1):149–62 (149 ref.)

Percutaneous nephrostolithotomy. What is its role in 1997? Wolf JS Jr, et al. **Urol Clin North Am** 1997 Feb;24(1):43–58 (64 ref.)

[Percutaneous therapy of kidney calculi. Current status] Kaldenbach U, et al. **Med Monatsschr Pharm** 1997 Apr; 20(4):90–7 (62 ref.) **(Ger)**

[Extracorporeal shockwave lithotripsy today--an assessment of current status] Chaussy C, et al. **Urologe A** 1997 May; 36(3):194–9 (82 ref.) (Eng. Abstr.) **(Ger)**

[Extracorporeal shockwave lithotripsy in childhood] Schultz-Lampel D, et al. **Urologe A** 1997 May;36(3):200–8 (81 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Time reversal focusing applied to lithotripsy. Thomas JL, et al. **Ultrason Imaging** 1996 Apr;18(2):106–21 (9 ref.)

KIDNEY CALICES

Management of calyceal calculi. Cohen TD, et al. **Urol Clin North Am** 1997 Feb;24(1):81–96 (85 ref.)

Staghorn calculi. Segura JW. **Urol Clin North Am** 1997 Feb; 24(1):71–80 (28 ref.)

Sandwich therapy. Streem SB. **Urol Clin North Am** 1997 Feb;24(1):213–23 (33 ref.)

[Pericalyceal cyst, parapelvic cyst] Kubodera S, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):439–40 (10 ref.) **(Jpn)**

[Pericalyceal lymphangiectasia] Kubodera S, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):441 (4 ref.) **(Jpn)**

[Calyceal diverticulum] Maezawa H, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):437–8 (15 ref.) **(Jpn)**

ABNORMALITIES

[Megacalycosis] Kobayashi K. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):355–7 (12 ref.) **(Jpn)**

[Hydrocalycosis] Orikasa S. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):385–6 (4 ref.) **(Jpn)**

[Extrarenal calyces: extrarenal collecting system] Orikasa S. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):380 (1 ref.) **(Jpn)**

KIDNEY CIRCULATION see **RENAL CIRCULATION**

KIDNEY COLLECTING DUCTS see **KIDNEY TUBULES, COLLECTING**

KIDNEY CONCENTRATING ABILITY

PHYSIOLOGY

Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin. Knepper MA. **Am J Physiol** 1997 Jan;272(1 Pt 2):F3–12 (59 ref.)

Current concepts of the countercurrent multiplication system. Sands JM, et al. **Kidney Int Suppl** 1996 Dec;57:S93–9 (109 ref.)

KIDNEY CORTEX

PATHOLOGY

Phenotypic features of cortical interstitial cells potentially important in fibrosis. Alpers CE, et al. **Kidney Int Suppl** 1996 May;54:S28–31 (37 ref.)

RADIONUCLIDE IMAGING

Renal cortical scintigraphy: effect on medical decision making in childhood urinary tract infection [editorial; comment] Strife CF, et al. **J Pediatr** 1996 Dec;129(6):785–7 (18 ref.) Comment on: J Pediatr 1996 Dec;129(6):815–20.

KIDNEY CORTEX NECROSIS

[Renal cortical necrosis] Kijima Y. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):34–7 (13 ref.) **(Jpn)**

KIDNEY, CYSTIC

[Cystic kidney disease--genetics, pathogenesis and clinical aspects in children] Popović-Rolović M, et al. **Srp Arh Celok Lek** 1996;124 Suppl 1:222–8 (24 ref.) (Eng. Abstr.) **(Scc)**

CLASSIFICATION

[Simple renal cysts, localized cystic disease, and multilocular renal cysts] Asaka M, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):433–6 (20 ref.) **(Jpn)**

[Renal cystic disease] Ishikawa I. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):446–50 (17 ref.) **(Jpn)**

COMPLICATIONS

Renal cell carcinoma in a giant renal cyst. A case report and review of the literature. Ulker V, et al. **Int Urol Nephrol** 1996;28(2):141–4 (11 ref.)

[Hemorrhagic renal cyst] Muraoka K, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):422–4 (18 ref.) **(Jpn)**

[Renal tumor with acquired cystic disease of the kidney] Tanabe N, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):459–62 (18 ref.) **(Jpn)**

CONGENITAL

[Miranda syndrome] Kudo M. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):410–4 (20 ref.) **(Jpn)**

DIAGNOSIS

Renal cysts, renal cancer and von Hippel-Lindau disease [editorial] Neumann HP, et al. **Kidney Int** 1997 Jan; 51(1):16–26 (94 ref.)

Renal cysts and cystic neoplasms. Miller MA, et al. **Magn Reson Imaging Clin N Am** 1997 Feb;5(1):49–66 (29 ref.)

Spectrum of glomerulocystic kidneys: a case report and review of the literature. Dedeoglu IO, et al. **Pediatr Pathol Lab Med** 1996 Nov-Dec;16(6):941–9 (24 ref.)

Current concepts and controversies in imaging of renal cystic diseases. Levine E, et al. **Urol Clin North Am** 1997 Aug; 24(3):523–43 (108 ref.)

DRUG THERAPY

[Study on the sclerosing agent for the treatment of simple renal cysts] Akiyama H, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Dec;87(12):1277–80 (18 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Cystic kidney diseases. Griffin MD, et al. **Curr Opin Nephrol Hypertens** 1997 May;6(3):276–83 (65 ref.)

[Acquired renal cystic disease] Ishikawa I. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):418–21 (16 ref.) **(Jpn)**

GENETICS

Further arguments for non-fortuitous association of Potter sequence with XYY males. Rudnik-Schöneborn S, et al. **Ann Genet** 1996;39(1):43–6 (12 ref.)

PATHOLOGY

Multicystic nephroma: report of a case with fine-needle aspiration findings. Hughes JH, et al. **Diagn Cytopathol** 1996 Feb;14(1):60–3 (9 ref.)

Multilocular renal cyst associated with testicular epidermoid cyst. Radhi JM, et al. **Histopathology** 1996 Oct;29(4):377–9 (4 ref.)

Hyperdiploidy and trisomy 12 in the cystic partially differentiated nephroblastoma. de Chadarévian JP, et al. **Hum Pathol** 1996 Sep;27(9):980–1 (5 ref.)

Spectrum of glomerulocystic kidneys: a case report and review of the literature. Dedeoglu IO, et al. **Pediatr Pathol Lab Med** 1996 Nov-Dec;16(6):941–9 (24 ref.)

Cystic renal lymphangiectasia: a distinctive clinicopathologic entity in the pediatric age group. Simonton SC, et al. **Pediatr Pathol Lab Med** 1997 Mar-Apr;17(2):293–301 (26 ref.)

[Transitional cell carcinoma of the renal pelvis with cystic formation: a case report] Fukuoka A, et al. **Hinyokika Kiyo** 1996 Oct;42(10):739–42 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Multilocular cystic nephroma, multilocular renal cyst] Komatsu H, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):509–11 (10 ref.) **(Jpn)**

KIDNEY, CYSTIC

RADIOGRAPHY

Radiologic evaluation of small and indeterminant renal masses. Curry NS, et al. **Urol Clin North Am** 1997 Aug; 24(3):493–505 (56 ref.)

SURGERY

Laparoscopic ablation of peripelvic renal cysts. Hoenig DM, et al. **J Urol** 1997 Oct;158(4):1345–8 (16 ref.)

KIDNEY DISEASES

Pregnancy complicated by chronic renal disease. Jones DC. **Clin Perinatol** 1997 Jun;24(2):483–96 (38 ref.)

Advantages and shortcomings of experimental models of immune-mediated glomerular and tubulointerstitial diseases [editorial] De Heer E, et al. **Exp Nephrol** 1996 Jul–Aug; 4(4):193–200 (116 ref.)

Drug induced renal disease. Jha V, et al. **J Assoc Physicians India** 1995 Jun;43(6):407–21 (83 ref.)

The renal risks of smoking. Orth SR, et al. **Kidney Int** 1997 Jun;51(6):1669–77 (154 ref.)

Renal disease in the elderly: distinctive disorders, tailored treatments. Ali H. **Postgrad Med** 1996 Dec;100(6):44–8, 53–4, 57 (25 ref.)

Paraneoplastic syndromes of the kidney. Maesaka JK, et al. **Semin Oncol** 1997 Jun;24(3):373–81 (81 ref.)

BLOOD

Role of complement in glomerular injury. Feucht HE. **Kidney Blood Press Res** 1996;19(5):290–9 (77 ref.)

CHEMICALLY INDUCED

Toxicity of nonsteroidal anti-inflammatory drugs in the elderly: is advanced age a risk factor? Solomon DH, et al. **Am J Med** 1997 Feb;102(2):208–15 (97 ref.)

Nonnarcotic analgesics: prevalence and estimated economic impact of toxicities [see comments] McGoldrick MD, et al. **Ann Pharmacother** 1997 Feb;31(2):221–7 (50 ref.) Comment in: Ann Pharmacother 1997 Feb;31(2):245–8.

Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review [see comments] Hatala R, et al. **Clin Infect Dis** 1997 May; 24(5):810–5 (37 ref.) Comment in: Clin Infect Dis 1997 May;24(5):816–9. Comment in: Clin Infect Dis 1997 May;24(5):820–3.

Analgesics and chronic renal disease. Klag MJ, et al. **Curr Opin Nephrol Hypertens** 1996 May;5(3):236–41 (42 ref.)

Toxic nephropathies. Springate JE. **Curr Opin Pediatr** 1997 Apr;9(2):166–9 (45 ref.)

Role of metallothionein in cadmium-induced hepatotoxicity and nephrotoxicity. Klaassen CD, et al. **Drug Metab Rev** 1997 Feb–May;29(1–2):79–102 (66 ref.)

Aspects of contrast media nephrotoxicity. Morcos SK, et al. **Eur J Radiol** 1996 Nov;23(3):178–84 (59 ref.)

Safety profile of new non-ionic contrast media: renal tolerance. Stacul F, et al. **Eur J Radiol** 1996 Nov;23 Suppl 1:S6–9 (23 ref.)

Adaptation to the nephrotoxicity of heme proteins. Nath KA. **Exp Nephrol** 1996 May–Jun;4(3):139–43 (27 ref.)

Nephrotoxicity of ochratoxin A. Pleština R. **Food Addit Contam** 1996;13 Suppl:49–50 (9 ref.)

Insights into chronic cyclosporine nephrotoxicity. Bennett WM. **Int J Clin Pharmacol Ther** 1996 Nov;34(11):515–9 (39 ref.)

Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Bennett WM, et al. **Kidney Int** 1996 Oct;50(4):1089–100 (152 ref.)

Drug-induced nephrotoxicity. Choudhury D, et al. **Med Clin North Am** 1997 May;81(3):705–17 (66 ref.)

Renal complications in HIV disease. Rao TK. **Med Clin North Am** 1996 Nov;80(6):1437–51 (61 ref.)

Drug-induced nephrotoxicity: the crucial role of risk factors. Thatte L, et al. **Postgrad Med** 1996 Dec;100(6):83–4, 87–8, 91 passim (26 ref.)

Mechanisms of acute and chronic nephrotoxicity from immunosuppressive drugs. Bennett WM. **Ren Fail** 1996 May;18(3):453–60 (57 ref.)

Cyclosporine nephropathy: pathophysiology and clinical impact. Shihab FS. **Semin Nephrol** 1996 Nov;16(6):536–47 (101 ref.)

Occupational and environmental renal disease. Wedeen RP. **Semin Nephrol** 1997 Jan;17(1):46–53 (35 ref.)

[Renal toxicity of iodine contrast media. Mechanisms and prevention] Deray G, et al. **Presse Med** 1997 Feb 15; 26(4):190–4 (26 ref.) **(Fre)**

[Diuretic associated renal diseases] Fukunaga M, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):588–91 (14 ref.) **(Jpn)**

[Nephropathy induced by stimulants and narcotics (heroin, amphetamine, etc)] Hashimoto K, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):526–8 (9 ref.) **(Jpn)**

[Nephropathy induced by anticonvulsants] Hashimoto K, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):536–8 (6 ref.) **(Jpn)**

[Lithium-induced renal disease] Horio M, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):584–7 (13 ref.) **(Jpn)**

[Renal complications of anti-hypertensive drugs] Kaname S, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):531–5 (11 ref.) **(Jpn)**

[Cyclosporine nephrotoxicity (chronic arteriolopathy, glomerulopathy)] Matsushima H, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):553–5 (20 ref.) **(Jpn)**

[Nephropathy induced by non-drug chemical agents] Miyazaki K, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):577–9 (15 ref.) **(Jpn)**

[Antimicrobial nephrotoxicity] Nakahama H. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):547–9 (7 ref.) **(Jpn)**

[Nephrotoxicity of antineoplastic agents (antibiotics)] Nakahama H. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):539–41 (9 ref.) **(Jpn)**

[D-penicillamine nephropathy] Ohno I. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):523–5 (17 ref.) **(Jpn)**

[Ciprofloxacin nephropathy, acyclovir nephropathy] Ohno I. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):556–9 (18 ref.) **(Jpn)**

[Nephrotoxicity of non steroidal anti-inflammatory drugs (NSAID)] Ozono Y, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):574–6 (9 ref.) **(Jpn)**

[Toxic nephropathy] Shibasaki T. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):567–70 (5 ref.) **(Jpn)**

[Sulfonamide nephropathy] Shibasaki T. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):550–2 (4 ref.) **(Jpn)**

[Nephrotoxicity of antineoplastic drugs] Suzuki T, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):542–6 (26 ref.) **(Jpn)**

[Contrast nephropathy] Tsuchida H, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):563–6 (13 ref.) **(Jpn)**

[Gold nephropathy] Ujiie K, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):529–30 (4 ref.) **(Jpn)**

[Drug-induced renal disorders in patients with rheumatoid arthritis] Nakano M, et al. **Ryumachi** 1996 Oct;36(5):775–82 (40 ref.) **(Jpn)**

[Biomarkers in diagnosis of kidney diseases caused by chemical toxins] Lutz W, et al. **Med Pr** 1997;48(2):205–13 (20 ref.) (Eng. Abstr.) **(Pol)**

[Nephrotoxicity of contrast media--etiopathogenesis and methods of prevention] Kolonko A, et al. **Postepy Hig Med Dosw** 1996;50(3):245–63 (62 ref.) (Eng. Abstr.) **(Pol)**

COMPLICATIONS

Hypertension with identifiable cause. Secondary hypertension. Liu L. **Chin Med J (Engl)** 1996 Dec; 109(12):909–18 (36 ref.)

Hypercholesterolemia and progressive kidney disease: the role of macrophages and macrophage-derived products. Ricardo SD, et al. **Contrib Nephrol** 1997;120:197–209 (51 ref.)

Invasive versus non-invasive diagnosis of renal bone disease. Fournier A, et al. **Curr Opin Nephrol Hypertens** 1997 Jul; 6(4):333–48 (70 ref.)

Rheumatologic manifestations of renal disease. Ferrari R. **Curr Opin Rheumatol** 1996 Jan;8(1):71–6 (13 ref.)

Renal complications in HIV disease. Rao TK. **Med Clin North Am** 1996 Nov;80(6):1437–51 (61 ref.)

Calcitriol in the management of secondary hyperparathyroidism of renal failure. Daisley-Kydd RE, et al. **Pharmacotherapy** 1996 Jul–Aug;16(4):619–30 (64 ref.)

Hyperfiltration nephropathy as a cause of late graft loss in renal transplantation. Modlin C, et al. **World J Urol** 1996; 14(4):256–64 (86 ref.)

[Preoperative management-cardiac, pulmonary, and renal dysfunction] Murata A, et al. **Nippon Geka Gakkai Zasshi** 1996 Jun;97(6):398–403 (4 ref.) (Eng. Abstr.) **(Jpn)**

[Idiopathic tubular proteinuria (Dent's disease)] Igarashi T. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):670–3 (17 ref.) **(Jpn)**

[Systemic lupus erythematosus with renal involvement: progress in research on pathogenesis, diagnosis and treatment] Klinger M. **Pol Arch Med Wewn** 1997 Mar; 97(3):287–93 (26 ref.) **(Pol)**

[Secondary hyperlipoproteinemias] Duława J. **Wiad Lek** 1996;49(7–12):166–72 (0 ref.) (Eng. Abstr.) **(Pol)**

[Organic nephropathies in patients with liver diseases] Amoedo ML, et al. **Gastroenterol Hepatol** 1996 Mar; 19(3):167–77 (129 ref.) **(Spa)**

CONGENITAL

Fetal and neonatal nephrology. Guillery EN. **Curr Opin Pediatr** 1997 Apr;9(2):148–53 (77 ref.)

Congenital oligonephropathy: The fetal flaw in essential hypertension? Mackenzie HS, et al. **Kidney Int Suppl** 1996 Jun;55:S30–4 (71 ref.)

[Juvenile nephronophthisis-medullary cystic disease (JN-MCD) complex] Kobayashi S, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):403–5 (8 ref.) **(Jpn)**

DIAGNOSIS

Predictive ability of creatinine clearance estimate models in pediatric bone marrow transplant patients. Jacobson P, et al. **Bone Marrow Transplant** 1997 Mar;19(5):481–5 (15 ref.)

Invasive versus non-invasive diagnosis of renal bone disease. Fournier A, et al. **Curr Opin Nephrol Hypertens** 1997 Jul; 6(4):333–48 (70 ref.)

Traumatic autonephrectomy due to explosion: a case report and literature review. Donat R, et al. **Int Urol Nephrol** 1996;28(6):743–6 (10 ref.)

Lobar dysmorphism of the kidney: report of two cases and review of the literature. Zwirewich CV, et al. **J Comput Assist Tomogr** 1997 Sep–Oct;21(5):742–4 (4 ref.)

Current status of DNA diagnosis for hereditary nephropathies. Zerres K, et al. **Kidney Blood Press Res** 1996;19(3–4):209–14 (15 ref.)

MR imaging of renal function. Bennett HF, et al. **Magn Reson Imaging Clin N Am** 1997 Feb;5(1):107–26 (58 ref.)

Diagnosis and management of glomerular diseases. Jennette JC, et al. **Med Clin North Am** 1997 May;81(3):653–77 (87 ref.)

Diagnostic imaging in pediatric AIDS. Haller JO, et al. **Pediatr Clin North Am** 1997 Jun;44(3):721–40 (64 ref.)

Candidal renal papillary necrosis: report of a case and review. Chiew YF. **Singapore Med J** 1996 Feb;37(1):119–21 (14 ref.)

[Renal endometriosis. Report of a case] Rousselot F, et al. **Prog Urol** 1996 Dec;6(6):936–9 (21 ref.) (Eng. Abstr.) **(Fre)**

[Renal manifestations of viral diseases] Péchère-Bertschi A, et al. **Schweiz Rundsch Med Prax** 1997 Jul 30; 86(31–32):1204–8 (15 ref.) (Eng. Abstr.) **(Fre)**

[Specific infections of the kidney] Hirose T. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):254–7 (6 ref.) **(Jpn)**

[Renal pseudotumor] Sakurai Y, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):478–80 (14 ref.) **(Jpn)**

[Biomarkers in diagnosis of kidney diseases caused by chemical toxins] Lutz W, et al. **Med Pr** 1997;48(2):205–13 (20 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Pharmacology of immunosuppressive medications used in renal diseases and transplantation. de Mattos AM, et al. **Am J Kidney Dis** 1996 Nov;28(5):631–67 (333 ref.)

Impact of renin-angiotensin system blockade on structure and function of glomerular membrane components in animal models of kidney disease. Remuzzi A, et al. **Exp Nephrol** 1996;4 Suppl 1:27–33 (57 ref.)

Progression of renal disease--can it be reversed? The role of calcium channel blockers and angiotensin-converting enzyme inhibitors. Boner G. **Isr J Med Sci** 1996 Dec; 32(12):1217–21 (42 ref.)

Impact of antihypertensive therapy on progression of experimental renal disease. Dworkin LD. **J Hum Hypertens** 1996 Oct;10(10):663–8 (20 ref.)

Treatment and prevention of target organ damage. Padmavati S. **J Hum Hypertens** 1996 Feb;10 Suppl 1:S85–7 (10 ref.)

Treatment of hypertension. Fogo A, et al. **Semin Nephrol** 1996 Nov;16(6):555–66 (114 ref.)

[Kidneys involvement in multiple myeloma. Therapeutic issues] Gordeev AV, et al. **Klin Med (Mosk)** 1997; 75(8):60–2 (3 ref.) **(Rus)**

EMBRYOLOGY

Genetic manipulation of the embryonic kidney. Woolf AS. **Exp Nephrol** 1997 Mar–Apr;5(2):152–6 (32 ref.)

ENZYMOLOGY

The role of angiotensin I-converting enzyme gene polymorphism in renal disease. Schmidt S, et al. **Curr Opin Nephrol Hypertens** 1996 Nov;5(6):552–5 (26 ref.)

Matrix metalloproteinases (MMPs) in renal fibrosis. Norman JT, et al. **Kidney Int Suppl** 1996 May;54:S61–3 (9 ref.)

The renal adenosine triphosphatases: functional integration and clinical significance. Laski ME, et al. **Miner Electrolyte Metab** 1996;22(5–6):410–22 (95 ref.)

EPIDEMIOLOGY

Vascular nephropathies and nephrosclerosis: epidemiology and pathophysiology. Meyrier A, et al. **Adv Nephrol Necker Hosp** 1997;26:207–45 (261 ref.)

The role of blood pressure as a risk factor for renal disease: a review of the epidemiologic evidence. Whelton PK, et al. **J Hum Hypertens** 1996 Oct;10(10):683–9 (44 ref.)

Epidemiology of pediatric kidney diseases. Wyatt RJ, et al. **Pediatr Ann** 1996 May;25(5):288–96 (75 ref.)

ETHNOLOGY

Renal problems in black South African children. Thomson PD. **Pediatr Nephrol** 1997 Aug;11(4):508–12 (45 ref.)

ETIOLOGY

Cytokines: the kidney as a model for their role in tissue injury and repair [editorial] Isbel NM, et al. **Aust N Z J Med** 1996 Oct;26(5):636–9 (25 ref.)

Renal manifestations of tuberous sclerosis complex. O'Hagan

AR, et al. **Clin Pediatr (Phila)** 1996 Oct;35(10):483–9 (71 ref.)

Renal involvement in primary vasculitides. Sinico RA, et al. **Clin Rev Allergy Immunol** 1997 Spring;15(1):65–72 (28 ref.)

Lead and the kidney: nephropathy, hypertension, and gout. Perazella MA. **Conn Med** 1996 Sep;60(9):521–6 (30 ref.)

Cholesterol as a predictor of progression in nondiabetic chronic renal disease. Greco BA, et al. **Contrib Nephrol** 1997;120:48–61 (57 ref.)

Atherogenic lipoproteins and human disease: extending concepts beyond the heart to the kidney. Kamanna VS, et al. **Curr Opin Nephrol Hypertens** 1997 May;6(3):205–11 (57 ref.)

The sympathetic nervous system in hypertension and renal disease. Saruta T, et al. **Curr Opin Nephrol Hypertens** 1996 Jan;5(1):72–9 (45 ref.)

Hypertension and renal dysfunction. Zucchelli P, et al. **Curr Opin Nephrol Hypertens** 1996 Jan;5(1):97–101 (46 ref.)

Use of urinary beta-2-microglobulin to predict severe renal damage in fetal obstructive uropathy. Freedman AL, et al. **Fetal Diagn Ther** 1997 Jan–Feb;12(1):1–6 (29 ref.)

Bone marrow transplant nephropathy: a case report and review of the literature. Cruz DN, et al. **J Am Soc Nephrol** 1997 Jan;8(1):166–73 (26 ref.)

HIV infection and the kidney. D'Agati V, et al. **J Am Soc Nephrol** 1997 Jan;8(1):138–52 (114 ref.)

Impact of antihypertensive therapy on progression of experimental renal disease. Dworkin LD. **J Hum Hypertens** 1996 Oct;10(10):663–8 (20 ref.)

Blood pressure and renal function: therapeutic implications [editorial] Ruilope LM, et al. **J Hypertens** 1996 Nov; 14(11):1259–63 (54 ref.)

Hypertension and renal disease: role of microalbuminuria. Janssen WM, et al. **J Hypertens Suppl** 1996 Dec; 14(5):S173–7 (42 ref.)

The renal consequences of arterial hypertension. Mountokalakis TD. **Kidney Int** 1997 May;51(5):1639–53 (109 ref.)

Endothelin in renal pathophysiology: from experimental to therapeutic application. Rabelink TJ, et al. **Kidney Int** 1996 Dec;50(6):1827–33 (115 ref.)

Chemokines and renal disease. Schlöndorff D, et al. **Kidney Int** 1997 Mar;51(3):610–21 (122 ref.)

Renal abscess: an illustrative case and review of the literature. Rinder MR. **Md Med J** 1996 Oct;45(10):839–43 (27 ref.)

Vesicoureteric reflux and reflux nephropathy: the Christchurch contribution. Bailey RR, et al. **N Z Med J** 1997 Jul 25;110(1048):266–9 (53 ref.)

The kidney in tuberous sclerosis: manifestations and molecular genetic mechanisms. Sampson JR. **Nephrol Dial Transplant** 1996;11 Suppl 6:34–7 (40 ref.)

Sleep-related breathing disturbances: their pathogenesis and potential interest to the nephrologist. Silverberg DS, et al. **Nephrol Dial Transplant** 1997 Apr;12(4):680–3 (37 ref.)

Tubular dysfunction following kidney transplantation [editorial] Heering P, et al. **Nephron** 1996;74(3):501–11 (67 ref.)

Polyunsaturated fatty acids and renal disease. Lefkowith JB, et al. **Proc Soc Exp Biol Med** 1996 Oct;213(1):13–23 (103 ref.)

Adhesion molecules in renal diseases. Müller GA, et al. **Ren Fail** 1996 Sep;18(5):711–24 (81 ref.)

Pathogenetic and clinical aspects of the renal involvement in hemorrhagic fever with renal syndrome. Settergren B, et al. **Ren Fail** 1997 Jan;19(1):1–14 (108 ref.)

Scleroderma renal crisis. Steen VD. **Rheum Dis Clin North Am** 1996 Nov;22(4):861–78 (72 ref.)

Clinical and pathological course of renal disease in non-insulin-dependent diabetes mellitus: the Pima Indian experience. Nelson RG, et al. **Semin Nephrol** 1997 Mar; 17(2):124–31 (33 ref.)

Atheroembolic renal disease. Saleem S, et al. **Semin Nephrol** 1996 Jul;16(4):309–18 (70 ref.)

Renocolic fistula as a complication to xanthogranulomatous pyelonephritis. Majeed HA, et al. **Singapore Med J** 1997 Mar;38(3):116–9 (17 ref.)

Hepatitis virus and kidney. Praditpornsilpa K, et al. **Singapore Med J** 1996 Dec;37(6):639–44 (53 ref.)

Abnormal lipid metabolism and renal disorders. Saito T. **Tohoku J Exp Med** 1997 Mar;181(3):321–37 (56 ref.)

[Vasculitis attacking the kidneys] Grönhagen-Riska C, et al. **Duodecim** 1995;111(15):1442–51 (54 ref.) **(Fin)**

[Renal involvement in essential arterial hypertension] Bobrie G. **Presse Med** 1997 May 24;26(17):821–4 (18 ref.) (Eng. Abstr.) **(Fre)**

[Nephropathies and arterial hypertension] Bobrie G. **Presse Med** 1997 May 24;26(17):825–30 (27 ref.) (Eng. Abstr.) **(Fre)**

[Renal involvement in HIV-1 infection] Nochy D. **Presse Med** 1997 Feb 1;26(2):91–5 (23 ref.) **(Fre)**

[Kidney involvement in progressive scleroderma] Blumenstein M, et al. **Dtsch Med Wochenschr** 1997 Feb 14;122(7):200–4 (22 ref.) **(Ger)**

[A case of renal cell carcinoma presenting as spontaneous renal rupture] Tsuji H, et al. **Hinyokika Kiyo** 1996 Jul; 42(7):517–20 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Kidney and complement regulatory factors] Matsuo S. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):643–6 (14 ref.) **(Jpn)**

[Progress in diagnosis and treatment of renal diseases. II. nephropathies associated with systemic diseases. 3. Amyloidosis] Gejo F. **Nippon Naika Gakkai Zasshi** 1996 Oct 10;85(10):1663–7 (7 ref.) **(Jpn)**

[Mixed connective tissue disease: progress in diagnosis and treatment. III. Treatment. 3. Clinical aspects and treatment of specific conditions. 3) Renal lesions] Takasaki Y. **Nippon Naika Gakkai Zasshi** 1996 Aug 10;85(8):1254–8 (6 ref.) **(Jpn)**

[Role of apoptosis in renal injury] Sugiyama H, et al. **Nippon Rinsho** 1996 Jul;54(7):1975–81 (35 ref.) (Eng. Abstr.) **(Jpn)**

[Role of the renin-angiotensin system in cardiovascular and renal diseases] Kim S. **Nippon Yakurigaku Zasshi** 1997 May; 109(5):223–33 (41 ref.) (Eng. Abstr.) **(Jpn)**

[Renal necrotizing vasculitis] Hiromura K. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):301–4 (18 ref.) **(Jpn)**

[Potassium-losing nephropathy] Noguchi Y, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):641–5 (9 ref.) **(Jpn)**

[Reflux nephropathy in vesico-ureteral reflux (VUR)] Shigematsu H. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):275–7 (19 ref.) **(Jpn)**

[Renal dysfunction caused by animal poisons (snake venoms, bite and punctured poisoning)] Suda M, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):571–3 (16 ref.) **(Jpn)**

[Wunderlich's syndrome: report of 3 cases] Ara Goñi MA, et al. **Actas Urol Esp** 1997 Feb;21(2):158–62 (17 ref.) (Eng. Abstr.) **(Spa)**

[Renal hematoma as a result of internal ureteral catheterization] Lujan Galán M, et al. **Actas Urol Esp** 1997 Apr;21(4):427–9 (6 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Biology and genetics of inherited renal tubular disorders [editorial] van't Hoff WG. **Exp Nephrol** 1996 Sep–Oct; 4(5):253–62 (71 ref.)

Molecular genetics of renal diseases. Saito A, et al. **Intern Med** 1997 Feb;36(2):81–6 (73 ref.)

Current status of DNA diagnosis for hereditary nephropathies. Zerres K, et al. **Kidney Blood Press Res** 1996;19(3–4):209–14 (15 ref.)

Polymorphisms of the renin-angiotensin system genes in progressive renal diseases [editorial] Yoshida H, et al. **Kidney Int** 1996 Sep;50(3):732–44 (137 ref.)

Angiotensin I-converting enzyme insertion/deletion polymorphism: potential significance in nephrology. Kitamura H, et al. **Kidney Int Suppl** 1996 Jun;55:S101–3 (21 ref.)

Hereditary disorders of the glomerular basement membrane. Smeets HJ, et al. **Pediatr Nephrol** 1996 Dec;10(6):779–88 (101 ref.)

The year 1995–1996 in review: genetically re-engineering clinical nephrology. Trachtman H. **Pediatr Nephrol** 1997 Jun;11(3):377–81 (27 ref.)

Molecular bases of human kidney malformations. Woolf AS. **Pediatr Nephrol** 1997 Jun;11(3):373–6 (12 ref.)

[Pathogenetic importance of gene polymorphisms in the renin-angiotensin system] Chudek J, et al. **Pol Arch Med Wewn** 1996 Oct;96(4):369–77 (79 ref.) **(Pol)**

IMMUNOLOGY

The nephritogenic immune response. Fitzsimons MM, et al. **Curr Opin Nephrol Hypertens** 1997 May;6(3):267–75 (75 ref.)

[The complement system in kidney diseases] Cesano G, et al. **Minerva Med** 1997 May;88(5):197–203 (16 ref.) (Eng. Abstr.) **(Ita)**

[Complement in kidney diseases] Cosio FG, et al. **Rev Clin Esp** 1996 Mar;196 Spec No:36–43 (77 ref.) **(Spa)**

METABOLISM

The kidney as a target for biological reactive metabolites: linking metabolism to toxicity. Monks TJ, et al. **Adv Exp Med Biol** 1996;387:203–12 (72 ref.)

The significance of adhesion molecules in nephrology. Burkhardt K, et al. **Artif Organs** 1996 May;20(5):433–6 (27 ref.)

Pharmacokinetics of opioids in renal dysfunction. Davies G, et al. **Clin Pharmacokinet** 1996 Dec;31(6):410–22 (93 ref.)

The role of oxidatively modified lipoproteins in lipid nephropathy. Gröne HJ, et al. **Contrib Nephrol** 1997; 120:160–75 (96 ref.)

Isoprenoids, Ras and proliferative glomerular disease. O'Donnell MP, et al. **Contrib Nephrol** 1997;120:219–27 (35 ref.)

Adhesion molecules in renal disease. Bonventre JV, et al. **Curr Opin Nephrol Hypertens** 1996 May;5(3):254–61 (62 ref.)

Atherogenic lipoproteins and human disease: extending concepts beyond the heart to the kidney. Kamanna VS, et al. **Curr Opin Nephrol Hypertens** 1997 May;6(3):205–11 (57 ref.)

Chloride channels in renal epithelial cells. Reeves WB, et al. **Curr Opin Nephrol Hypertens** 1996 Sep;5(5):406–10 (44 ref.)

Role of chemokines in glomerular diseases. Banas B, et al. **Kidney Blood Press Res** 1996;19(5):270–80 (89 ref.)

The kidney in mitochondrial cytopathies [editorial] Niaudet P, et al. **Kidney Int** 1997 Apr;51(4):1000–7 (100 ref.)

Primary renal abnormalities in hereditary hypertension. Woolfson RG, et al. **Kidney Int** 1996 Sep;50(3):717–31 (231 ref.)

Molecular analysis of human glomerular disease. Esposito C, et al. **Kidney Int Suppl** 1996 Jan;53:S21–5 (31 ref.)

Interleukin-1 in renal fibrosis. Nikolic-Paterson DJ, et al. **Kidney Int Suppl** 1996 May;54:S88–90 (26 ref.)

Expression of receptors for advanced glycation end-products in occlusive vascular and renal disease. Bierhaus A, et al. **Nephrol Dial Transplant** 1996;11 Suppl 5:87–90 (32 ref.)

The impact of disease states as a modifying factor for nutrition toxicity. Russell RM. **Nutr Rev** 1997 Feb; 55(2):50–3 (18 ref.)

Abnormal lipid metabolism and renal disorders. Saito T. **Tohoku J Exp Med** 1997 Mar;181(3):321–37 (56 ref.)

[Metabolic disorder of purine nucleotide in patients with renal disease] Hosoya T, et al. **Nippon Rinsho** 1996 Dec; 54(12):3354–9 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Sodium-losing nephropathy] Terano T, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):674–7 (4 ref.) **(Jpn)**

[Lipoprotein glomerulopathy] Watanabe T, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):219–22 (19 ref.) **(Jpn)**

PARASITOLOGY

Hydatid cysts of the kidney, seminal vesicle and gluteus muscle. Pasaoglu E, et al. **Australas Radiol** 1997 Aug; 41(3):297–9 (12 ref.)

PATHOLOGY

Apoptosis in the mammalian kidney: incidence, effectors, and molecular control in normal development and disease states. Buttyan R, et al. **Adv Pharmacol** 1997;41:369–81 (58 ref.)

Mechanisms of apoptosis and its potential role in renal tubular epithelial cell injury. Lieberthal W, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):F477–88 (126 ref.)

Fine-needle aspiration of the adult kidney. Renshaw AA, et al. **Cancer** 1997 Apr 25;81(2):71–88 (154 ref.)

Atheromatous embolism. Faraggiana T, et al. **Contrib Nephrol** 1996;119:67–73 (18 ref.)

'Benign' essential hypertension and kidney damage: a histopathologist's view. Howie AJ. **J Hum Hypertens** 1996 Oct;10(10):691–4 (25 ref.)

The interstitium in renal disease [editorial] Becker GJ, et al. **J Intern Med** 1997 Aug;242(2):93–7 (62 ref.)

Role of angiotensin II in glomerular injury: lessons from experimental and clinical studies. Hilgers KF, et al. **Kidney Blood Press Res** 1996;19(5):254–62 (112 ref.)

Apoptosis and renal scarring. Savill J, et al. **Kidney Int Suppl** 1996 May;54:S14–7 (57 ref.)

Hereditary disorders of the glomerular basement membrane. Smeets HJ, et al. **Pediatr Nephrol** 1996 Dec;10(6):779–88 (101 ref.)

Nephrogenic rests and renal abnormalities in Brachmann-de Lange syndrome. Charles AK, et al. **Pediatr Pathol Lab Med** 1997 Mar–Apr;17(2):209–19 (35 ref.)

[Fibrillary glomerulopathy. Amyloidosis and non-amyloidosis] Wullbrand A, et al. **Dtsch Med Wochenschr** 1997 Mar 7;122(10):302–8 (71 ref.) **(Ger)**

[Fetal uropathies: anatomo-pathologic background] Caruso G, et al. **Arch Ital Urol Androl** 1997 Jun;69(3):201–8 (13 ref.) (Eng. Abstr.) **(Ita)**

[Liposarcoma, lipoma and lipomatosis of the kidney] Fujioka T, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):488–90 (15 ref.) **(Jpn)**

[Multilocular cystic nephroma, multilocular renal cyst] Komatsu H, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):509–11 (10 ref.) **(Jpn)**

[Renal diseases with glomerular hypertrophy] Okada K. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):158–61 (18 ref.) **(Jpn)**

[A case of a combination of sarcoidosis and myeloma] Kamaeva OI, et al. **Ter Arkh** 1995;67(12):57–9 (19 ref.) **(Rus)**

PHYSIOPATHOLOGY

Endothelins in the normal and diseased kidney. Kohan DE. **Am J Kidney Dis** 1997 Jan;29(1):2–26 (260 ref.)

Nitric oxide in renal health and disease. Kone BC. **Am J Kidney Dis** 1997 Sep;30(3):311–33 (217 ref.)

Potential role of chemokines in human renal disease. Stahl RA. **Am J Kidney Dis** 1997 Sep;30(3):xlix–li (0 ref.)

Evidence for a role of nitric oxide in hypertension and in renal disease in man. Noris M, et al. **Contrib Nephrol** 1996; 119:8–15 (15 ref.)

Mineral metabolism: new aspects and perspectives [editorial] Drüeke TB. **Curr Opin Nephrol Hypertens** 1996 Jul; 5(4):297–9 (16 ref.)

Involvement of complement components in renal disease. Johnson RJ. **Curr Opin Nephrol Hypertens** 1997 Mar; 6(2):120–7 (51 ref.)

Renal implications of arterial hypertension. Ruilope LM. **Curr Opin Nephrol Hypertens** 1997 Mar;6(2):152–6 (50 ref.)

What role does apoptosis play in progression of renal disease? Savill J, et al. **Curr Opin Nephrol Hypertens** 1996 Jul; 5(4):369–74 (62 ref.)

KIDNEY DISEASES

Kidney damage in 'benign' essential hypertension [see comments] Whelton PK, et al.
Curr Opin Nephrol Hypertens 1997 Mar;6(2):177–83 (36 ref.) Comment in: Curr Opin Nephrol Hypertens 1997 Mar;6(2):167–8.

The paracrine endothelin system: pathophysiology and implications in clinical medicine. Hocher B, et al.
Eur J Clin Chem Clin Biochem 1997 Mar;35(3):175–89 (157 ref.)

Na+/H+ exchanger subtypes in the renal tubule: function and regulation in physiology and disease. Paillard M.
Exp Nephrol 1997 Jul–Aug;5(4):277–84 (59 ref.)

Biology and genetics of inherited renal tubular disorders [editorial] van't Hoff WG. **Exp Nephrol** 1996 Sep–Oct; 4(5):253–62 (71 ref.)

Angiotensin in progressive renal diseases: theory and practice [editorial] Matsusaka T, et al. **J Am Soc Nephrol** 1996 Oct; 7(10):2025–43 (245 ref.)

Ambulatory blood pressure monitoring: coming of age in nephrology. Townsend RR, et al. **J Am Soc Nephrol** 1996 Nov;7(11):2279–87 (47 ref.)

Interactions between renal tubules and interstitium. Howie AJ, et al. **J Clin Pathol** 1996 Oct;49(10):783–6 (26 ref.)

The interstitium in renal disease [editorial] Becker GJ, et al. **J Intern Med** 1997 Aug;242(2):93–7 (62 ref.)

Vasopressin receptors in health and disease. Bichet DG.
Kidney Int 1996 Jun;49(6):1706–11 (33 ref.)

The hyperfiltration theory: a paradigm shift in nephrology. Brenner BM, et al. **Kidney Int** 1996 Jun;49(6):1774–7 (55 ref.)

Role of dietary protein and blood pressure in the progression of renal disease. Klahr S. **Kidney Int** 1996 Jun;49(6):1783–6 (18 ref.)

Understanding the nature of renal disease progression. Remuzzi G, et al. **Kidney Int** 1997 Jan;51(1):2–15 (168 ref.)

Endocrine disturbances of calcium metabolism in uremia: renal causes and systemic consequences. Ritz E, et al.
Kidney Int 1996 Jun;49(6):1765–8 (39 ref.)

Proteoglycans: their possible role in renal fibrosis. Davies M, et al. **Kidney Int Suppl** 1996 May;54:S55–60 (46 ref.)

Endothelins and kidney diseases [editorial] Brown M, et al. **Nephron** 1996;72(3):375–82 (94 ref.)

Tubular dysfunction following kidney transplantation [editorial] Heering P, et al. **Nephron** 1996;74(3):501–11 (67 ref.)

Pathophysiology of the vascular wall: the role of nitric oxide in renal disease. Raij L, et al.
Prostaglandins Leukot Essent Fatty Acids 1996 Jan; 54(1):53–8 (83 ref.)

[Antihypertensive treatment in the nephropathic patient] Andreucci VE, et al. **Cardiologia** 1996 May;41 Suppl 1:25–9 (19 ref.) **(Ita)**

[Nitric oxide in renal physiology and pathology] Markov KhM. **Vestn Ross Akad Med Nauk** 1996;(7):73–8 (61 ref.) **(Rus)**

[The role of thromboxane in the pathogenesis of nephropathies] Dzúrik R, et al. **Vnitr Lek** 1996 Nov; 42(11):784–8 (46 ref.) (Eng. Abstr.) **(Slo)**

PREVENTION & CONTROL

Role of nutrition in prevention of the progression of renal disease. Maroni BJ, et al. **Annu Rev Nutr** 1997;17:435–55 (71 ref.)

Reducing chemotherapy-associated toxicity in elderly cancer patients. Zagonel V, et al. **Cancer Treat Rev** 1996 May; 22(3):223–44 (135 ref.)

Proteinuria and progression of renal disease: therapeutic implications. Gansevoort RT, et al.
Curr Opin Nephrol Hypertens 1997 Mar;6(2):133–40 (55 ref.)

Treatment and prevention of target organ damage. Padmavati S. **J Hum Hypertens** 1996 Feb;10 Suppl 1:S85–7 (10 ref.)

Concomitant diseases in elderly hypertensives: the position of nicardipine. Zannad F. **J Hypertens Suppl** 1996 Oct; 14(3):S37–40 (34 ref.)

Will angiotensin II receptor antagonists be renoprotective in humans? Ichikawa I. **Kidney Int** 1996 Aug;50(2):684–92 (53 ref.)

Prevention of progression of renal fibrosis: how far are we? Müller GA, et al. **Kidney Int Suppl** 1996 May;54:S75–82 (114 ref.)

Prevention of progression of nephropathy. Klahr S.
Nephrol Dial Transplant 1997;12 Suppl 2:63–6 (24 ref.)

[Clinical use of Amifostine (WR-2721) as a preparation protecting healthy tissues from the cytotoxic effects of chemotherapy and radiation therapy] Wrembel-Wargocka J, et al. **Przegl Lek** 1996;53(11):820–5 (15 ref.) (Eng. Abstr.) **(Pol)**

RADIOGRAPHY

Fatal reaction from inadvertent intrathecal entry of ionic contrast medium during a nephrogram. Sahjpaul RL, et al. **Acta Neuropathol (Berl)** 1997 Jan;93(1):101–3 (11 ref.)

CT of pancreatitis with renal and juxtarenal manifestations. Farman J, et al. **Clin Imaging** 1997 May–Jun;21(3):183–8 (9 ref.)

Radiologic assessment of renal masses: implications for patient care. Davidson AJ, et al. **Radiology** 1997 Feb; 202(2):297–305 (97 ref.)

Delayed CT in acute renal infection. Dalla-Palma L, et al. **Semin Ultrasound CT MR** 1997 Apr;18(2):122–8 (12 ref.)

RADIONUCLIDE IMAGING

The true clinical significance of renography in nephro-urology. Woolfson RG, et al. **Eur J Nucl Med** 1997 May;24(5):557–70 (199 ref.)

SURGERY

The evaluation of living renal transplant donors: clinical practice guidelines. Ad Hoc Clinical Practice Guidelines Subcommittee of the Patient Care and Education Committee of the American Society of Transplant Physicians. Kasiske BL, et al. **J Am Soc Nephrol** 1996 Nov; 7(11):2288–313 (259 ref.)

[Renal transplantation in patients over 60 years of age. An increasing clinical reality] Tommasi GV, et al.
Minerva Urol Nefrol 1997 Mar;49(1):29–31 (15 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Gene therapy for kidney disease. Sukhatme VP.
Adv Nephrol Necker Hosp 1997;26:73–80 (33 ref.)

Central venous catheters for maintenance hemodialysis: a cautionary approach. Swartz RD, et al.
Adv Ren Replace Ther 1997 Jul;4(3):275–84 (86 ref.)

Molecular therapy for renal diseases. Lipkowitz MS, et al. **Am J Kidney Dis** 1996 Oct;28(4):475–92 (169 ref.)

Quantification of hemodialysis: analysis of methods and the relevance to patient outcome. Clark WR, et al.
Blood Purif 1997;15(2):92–111 (73 ref.)

Measuring effectiveness and outcomes of interventions for renal disease. Powe NR. **Curr Opin Nephrol Hypertens** 1996 May;5(3):230–5 (37 ref.)

Gene transfer into the glomerulus by the hemagglutinating virus of Japan-liposome method. Imai E, et al.
Exp Nephrol 1997 Mar–Apr;5(2):112–7 (30 ref.)

Genetic manipulation of the kidney: round one. Kitamura M. **Exp Nephrol** 1997 Mar–Apr;5(2):109–11 (51 ref.)

Gene expression in kidney using transgenic approaches. Kopp JB. **Exp Nephrol** 1997 Mar–Apr;5(2):157–67 (50 ref.)

Liposome-mediated gene transfer into the tubules. Lien YH, et al. **Exp Nephrol** 1997 Mar–Apr;5(2):132–6 (22 ref.)

Gene transfer into kidney tubules and vasculature by adenoviral vectors. Sukhatme VP, et al. **Exp Nephrol** 1997 Mar–Apr;5(2):137–43 (20 ref.)

Diagnosis and management of glomerular diseases. Jennette JC, et al. **Med Clin North Am** 1997 May;81(3):653–77 (87 ref.)

Delayed referral for dialysis [editorial] Eadington DW.
Nephrol Dial Transplant 1996 Nov;11(11):2124–6 (10 ref.)

New strategies for peritoneal dialysis fluids. Gokal R.
Nephrol Dial Transplant 1997;12 Suppl 1:74–7 (39 ref.)

The costs of dialysis in Italy. Piccoli G, et al.
Nephrol Dial Transplant 1997;12 Suppl 1:33–44 (46 ref.)

Peritoneal dialysis and haemodialysis: are they comparable? Prichard SS. **Nephrol Dial Transplant** 1997;12 Suppl 1:65–7 (18 ref.)

Adequacy of peritoneal dialysis is more than Kt/V. Ronco C. **Nephrol Dial Transplant** 1997;12 Suppl 1:68–73 (10 ref.)

Clinical and therapeutic aspects of renal amyloidosis. Schena FP, et al. **Nephrol Dial Transplant** 1996;11 Suppl 9:63–8 (27 ref.)

Bone marrow transplantation as a strategy for the treatment of autoimmune-linked renal diseases. Ikehara S.
Ren Fail 1996 Jan;18(1):1–18 (44 ref.)

Optimizing disease management in the next 25 years. Glassock RJ. **Semin Nephrol** 1997 Jul;17(4):387–90 (17 ref.)

Dietary L-arginine in renal disease. Peters H, et al.
Semin Nephrol 1996 Nov;16(6):567–75 (64 ref.)

Update on interventional uroradiology. Dyer RB, et al.
Urol Clin North Am 1997 Aug;24(3):623–52 (128 ref.)

[Active treatment of renal disease in Finland] Stenman S, et al. **Duodecim** 1995;111(15):1497–504 (17 ref.) **(Fin)**

[How to manage suspected renal disease] Takala J, et al.
Duodecim 1995;111(15):1411–8 (20 ref.) **(Fin)**

[Chemokines and anti-chemokine therapy in kidney diseases] Yokoyama H. **Nippon Naika Gakkai Zasshi** 1997 Apr 10; 86(4):689–94 (10 ref.) **(Jpn)**

[Hyperbaric oxygenation in uronephrology] Zadoev SA, et al. **Urol Nefrol (Mosk)** 1997 May–Jun;(3):52–5 (70 ref.) **(Rus)**

ULTRASONOGRAPHY

Renovascular disease: Doppler ultrasound. Hélénon O, et al.
Semin Ultrasound CT MR 1997 Apr;18(2):136–46 (27 ref.)

Doppler ultrasound of the kidney. Platt JF.
Semin Ultrasound CT MR 1997 Feb;18(1):22–32 (81 ref.)

URINE

Use of urinary beta-2-microglobulin to predict severe renal damage in fetal obstructive uropathy. Freedman AL, et al. **Fetal Diagn Ther** 1997 Jan–Feb;12(1):1–6 (29 ref.)

VETERINARY

Immunization with bacterial antigens: bacterial kidney disease. Kaattari SL, et al. **Dev Biol Stand** 1997;90:145–52 (40 ref.)

The role of omega-3 fatty acids in renal disorders. Plotnick AN. **J Am Vet Med Assoc** 1996 Sep 1;209(5):906–10 (55 ref.)

Hypertension and renal disease. Bartges JW, et al.
Vet Clin North Am Small Anim Pract 1996 Nov; 26(6):1331–45 (68 ref.)

Hypercalcemia and renal failure. Etiology, pathophysiology, diagnosis, and treatment. Kruger JM, et al.
Vet Clin North Am Small Anim Pract 1996 Nov; 26(6):1417–45 (121 ref.)

Congenital renal diseases. Lees GE.
Vet Clin North Am Small Anim Pract 1996 Nov; 26(6):1379–99 (84 ref.)

Importance of clinical trials in evaluating therapy of renal diseases. Polzin DJ.
Vet Clin North Am Small Anim Pract 1996 Nov; 26(6):1519–25 (8 ref.)

Management of postrenal azotemia. Polzin DJ, et al.
Vet Clin North Am Small Anim Pract 1996 May; 26(3):507–13 (4 ref.)

Diagnostic imaging strategies in small animal nephrology. Rivers BJ, et al. **Vet Clin North Am Small Anim Pract** 1996 Nov;26(6):1505–17 (35 ref.)

KIDNEY FAILURE

Glomerular hyperfiltration in essential hypertension: cause or consequence? Schmieder RE. **Contrib Nephrol** 1996; 119:91–7 (19 ref.)

Renal failure in the vascular patient. Naude G, et al.
Semin Vasc Surg 1996 Sep;9(3):266–74 (76 ref.)

BLOOD

Severe hyperphosphatemia following phosphate administration for bowel preparation in patients with renal failure: two cases and a review of the literature. Fine A, et al. **Am J Kidney Dis** 1997 Jan;29(1):103–5 (11 ref.)

Combined measurements of ionized calcium and intact parathyroid hormone in blood. Rudnicki PM.
Dan Med Bull 1996 Feb;43(1):58–67 (188 ref.)

CHEMICALLY INDUCED

Does antihypertensive therapy protect the kidney in essential hypertension? Rodicio JL. **J Hypertens Suppl** 1996 Sep; 14(2):S69–75; discussion S75–6 (60 ref.)

Nephrotoxicity of immunosuppressive drugs: experimental and clinical observations. Andoh TF, et al.
Semin Nephrol 1997 Jan;17(1):34–45 (128 ref.)

Aminoglycoside nephrotoxicity. Swan SK. **Semin Nephrol** 1997 Jan;17(1):27–33 (83 ref.)

Renal failure related to angiotensin-converting enzyme inhibitors. Textor SC. **Semin Nephrol** 1997 Jan;17(1):67–76 (49 ref.)

COMPLICATIONS

[Uremic arthritis] Ogawa H, et al.
Ryoikibetsu Shokogun Shirizu 1997;(16 Pt 1):42–7 (20 ref.) **(Jpn)**

[Uremic syndrome] Shirasaki A, et al.
Ryoikibetsu Shokogun Shirizu 1997;(16 Pt 1):38–41 (6 ref.) **(Jpn)**

DIET THERAPY

Nutrition in renal disease. Mallat SG. **J Med Liban** 1997; 45(2):90–2 (25 ref.)

DRUG THERAPY

Principles of drug administration in renal insufficiency. Lam YW, et al. **Clin Pharmacokinet** 1997 Jan;32(1):30–57 (118 ref.)

Treatment of renal failure and blood pressure. Silverman M, et al. **Curr Opin Nephrol Hypertens** 1997 May;6(3):237–42 (55 ref.)

Angiotensin converting enzyme inhibitors, calcium channel blockers, and their combination in the treatment of glomerular disease. Ritz E, et al. **J Hypertens Suppl** 1997 Mar;15(2):S21–6 (44 ref.)

ENZYMOLOGY

Pathogenesis of dyslipoproteinemia in renal insufficiency: the role of lipoprotein lipase and hepatic lipase. Arnadóttir M. **Scand J Clin Lab Invest** 1997 Feb;57(1):1–11 (97 ref.)

EPIDEMIOLOGY

Renal insufficiency in the neonatal period. Hentschel R, et al. **Clin Nephrol** 1996 Jul;46(1):54–8 (11 ref.)

[An epidemiologic approach for the prevention of renal insufficiency] Simon P. **Nephrologie** 1996;17(5):283–8 (60 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Does non-malignant essential hypertension cause renal damage? A clinician's view. Beevers DG, et al.
J Hum Hypertens 1996 Oct;10(10):695–9 (16 ref.)

Recent data on hypertension and progressive renal disease. Zucchelli P, et al. **J Hum Hypertens** 1996 Oct; 10(10):679–82 (20 ref.)

Renal failure from mitochondrial cytopathies. Buemi M, et al. **Nephron** 1997;76(3):249–53 (23 ref.)

Outcome of renal transplantation in systemic lupus erythematosus. Stone JH, et al. **Semin Arthritis Rheum** 1997 Aug;27(1):17–26 (36 ref.)

Renal toxicities of antineoplastic drugs and bone marrow

transplantation. Berns JS, et al. **Semin Nephrol** 1997 Jan; 17(1):54–66 (167 ref.)

[Urological emergency for cancer patients] Ozono S, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(3):292–6 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Acute renal failure following surgical insult] Hirasawa H, et al. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):765–70 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Renal failure caused by the ingestion of poisonous mushrooms] Koyama K. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):580–3 (10 ref.) **(Jpn)**

METABOLISM

Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. Harrower AD. **Clin Pharmacokinet** 1996 Aug;31(2):111–9 (52 ref.)

Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity. Matzke GR, et al. **Drug Saf** 1997 Mar;16(3):205–31 (236 ref.)

PATHOLOGY

A 51–year–old woman with nephrotic syndrome, hematuria, and renal insufficiency. Fogo A, et al. **Am J Kidney Dis** 1997 May;29(5):806–10 (30 ref.)

PHYSIOPATHOLOGY

Water, electrolyte and acid base disturbances in renal insufficiency. Physiological and pathophysiological significance of cell volume. Busch GL, et al. **Clin Nephrol** 1996 Oct;46(4):270–3 (50 ref.)

Treatment of renal failure and blood pressure. Silverman M, et al. **Curr Opin Nephrol Hypertens** 1997 May;6(3):237–42 (55 ref.)

Endothelial function and the kidney. An emerging target for cardiovascular therapy. Rabelink TJ, et al. **Drugs** 1997;53 Suppl 1:11–9 (63 ref.)

Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Tominaga Y, et al. **Semin Surg Oncol** 1997 Mar–Apr;13(2):78–86 (68 ref.)

PREVENTION & CONTROL

Diabetic nephropathy: strategies for preventing renal failure. Salem JK, et al. **Cleve Clin J Med** 1996 Oct;63(6):331–8 (48 ref.)

[An epidemiologic approach for the prevention of renal insufficiency] Simon P. **Nephrologie** 1996;17(5):283–8 (60 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Outcome of renal transplantation in systemic lupus erythematosus. Stone JH, et al. **Semin Arthritis Rheum** 1997 Aug;27(1):17–26 (36 ref.)

THERAPY

Characterization of molecular transport in artificial kidneys. Leypoldt JK, et al. **Artif Organs** 1996 May;20(5):381–9 (37 ref.)

Adequacy of peritoneal dialysis. Blake PG. **Curr Opin Nephrol Hypertens** 1996 Nov;5(6):492–6 (41 ref.)

Measuring the adequacy of peritoneal dialysis: is there a link with nutrition and outcome? Gokal R. **Curr Opin Nephrol Hypertens** 1996 Nov;5(6):521–6 (58 ref.)

Recipient evaluation, preparation, and care in pediatric transplantation: the University of Minnesota protocols. Matas AJ, et al. **Kidney Int Suppl** 1996 Jan;53:S99–102 (12 ref.)

Update in nephrology. Maher MJ, et al. **Med Health R I** 1996 Mar;79(3):110–12 (13 ref.)

The dialysis patient today. Davison AM. **Nephrol Dial Transplant** 1995;10 Suppl 10:2–6 (17 ref.)

The 'first-use syndrome' revisited: a dialysis centre's perspective. Ing TS, et al. **Nephrol Dial Transplant** 1995; 10 Suppl 10:39–44 (66 ref.)

Implications of cytokine measurements during in vitro and clinical haemodialysis. Pereira BJ. **Nephrol Dial Transplant** 1995;10 Suppl 10:18–26 (112 ref.)

Acute dialysis and continuous renal replacement: the emergence of new technology involving the nephrologist in the intensive care setting. Yagi N, et al. **Semin Nephrol** 1997 Jul;17(4):306–20 (126 ref.)

[Systemic inflammatory reactions to extracorporeal therapy measures (I): Hemodialysis and hemofiltration] Schlee H, et al. **Wien Klin Wochenschr** 1997 May 9;109(9):301–11 (78 ref.) (Eng. Abstr.) **(Ger)**

[Acute renal failure following surgical insult] Hirasawa H, et al. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):765–70 (17 ref.) (Eng. Abstr.) **(Jpn)**

VETERINARY

Role of hemodialysis in the management of dogs and cats with renal failure. Cowgill LD, et al. **Vet Clin North Am Small Anim Pract** 1996 Nov; 26(6):1347–78 (64 ref.)

KIDNEY FAILURE, ACUTE

see related
ANURIA

HEMODIALYSIS

Acute renal failure in infants, children and adults. Stewart CL, et al. **Crit Care Clin** 1997 Jul;13(3):575–90 (122 ref.)

Acute renal failure in general surgery. Slapak M. **J R Soc Med** 1996;89 Suppl 29:13–5 (8 ref.)

Hepatorenal failure. Davison AM. **Nephrol Dial Transplant** 1996;11 Suppl 8:24–31 (55 ref.)

ARF in the 1990s: prevention and accelerated recovery. Eliahou HE, et al. **Ren Fail** 1996 May;18(3):323–32 (33 ref.)

As fiduciaries physicians hold in trust: life, death, and money—and least of those is money. Kjellstrand CM. **Ren Fail** 1996 May;18(3):417–23 (32 ref.)

[Renal failure in the elderly] Kitamoto K. **Nippon Ronen Igakkai Zasshi** 1996 Sep;33(9):657–61 (14 ref.) **(Jpn)**

CHEMICALLY INDUCED

Oxidant mechanisms in toxic acute renal failure. Baliga R, et al. **Am J Kidney Dis** 1997 Mar;29(3):465–77 (84 ref.)

Propylene glycol–induced proximal renal tubular cell injury. Yorgin PD, et al. **Am J Kidney Dis** 1997 Jul;30(1):134–9 (57 ref.)

Adverse effects of bisphosphonates. A comparative review. Adami S, et al. **Drug Saf** 1996 Mar;14(3):158–70 (105 ref.)

Nonsteroidal anti–inflammatory drugs and acute renal failure in the elderly. A risk–benefit assessment. Ailabouni W, et al. **Drugs Aging** 1996 Nov;9(5):341–51 (74 ref.)

Management of acute renal failure in the elderly. Treatment options. Mandal AK, et al. **Drugs Aging** 1996 Oct; 9(4):226–50 (82 ref.)

MDMA induced hyperthermia: report of a fatality and review of current therapy. Dar KJ, et al. **Intensive Care Med** 1996 Sep;22(9):995–6 (13 ref.)

Severe acute renal failure due to bromate intoxication: report of a case and discussion of management guidelines based on a review of the literature. De Vriese A, et al. **Nephrol Dial Transplant** 1997 Jan;12(1):204–9 (29 ref.)

Urography into the 21st century: new contrast media, renal handling, imaging characteristics, and nephrotoxicity. Katzberg RW. **Radiology** 1997 Aug;204(2):297–312 (163 ref.)

Drug nephrotoxicity: an overview. Bennett WM. **Ren Fail** 1997 Mar;19(2):221–4 (28 ref.)

Contrast media–associated nephrotoxicity. Rudnick MR, et al. **Semin Nephrol** 1997 Jan;17(1):15–26 (150 ref.)

Pathogenetic mechanisms in nephrotoxic acute renal failure. Zager RA. **Semin Nephrol** 1997 Jan;17(1):3–14 (97 ref.)

[Acute kidney failure secondary to intravenous immunoglobulin administration. 4 cases and review of the literature] Decocq G, et al. **Therapie** 1996 Sep–Oct; 51(5):516–26 (26 ref.) (Eng. Abstr.) **(Fre)**

[Contrast media–associated nephropathy—pathogenesis and prevention] Erley CM, et al. **Aktuelle Radiol** 1997 Jul; 7(4):189–92 (20 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Nutrition in acute renal failure patients. Ikizler TA, et al. **Adv Ren Replace Ther** 1997 Apr;4(2 Suppl 1):54–63 (67 ref.)

Epstein–Barr virus–induced infectious mononucleosis complicated by acute renal failure: case report and review. Mayer HB, et al. **Clin Infect Dis** 1996 Jun;22(6):1009–18 (62 ref.)

Hyperkalemia: therapeutic options in acute and chronic renal failure. Kemper MJ, et al. **Clin Nephrol** 1996 Jul;46(1):67–9 (15 ref.)

A case of Sjögren's syndrome associated with Sweet's syndrome. Osawa H, et al. **Clin Rheumatol** 1997 Jan; 16(1):101–5 (16 ref.)

Acute renal failure in multiple–organ dysfunction syndrome. Kierdorf HP, et al. **Kidney Blood Press Res** 1997; 20(3):164–6 (21 ref.)

Renal complications in HIV disease. Rao TK. **Med Clin North Am** 1996 Nov;80(6):1437–51 (61 ref.)

Management of peripheral arterial disease in patients with end–stage renal failure. Koskas F, et al. **Nephrol Dial Transplant** 1997 Mar;12(3):604–7 (9 ref.)

Acute renal failure in non–fulminant hepatitis A [see comments] Lin CC, et al. **Nephrol Dial Transplant** 1996 Oct;11(10):2061–6 (32 ref.) Comment in: Nephrol Dial Transplant 1997 Jul;12(7):1543–4.

DIAGNOSIS

Epstein–Barr virus–induced infectious mononucleosis complicated by acute renal failure: case report and review. Mayer HB, et al. **Clin Infect Dis** 1996 Jun;22(6):1009–18 (62 ref.)

[Hantavirus–induced acute renal failure] Zeier M, et al. **Internist (Berl)** 1996 Nov;37(11):1092–5 (17 ref.) **(Ger)**

[Progress in diagnosis and treatment of kidney diseases. V. Renal failure and kidney transplantation. 1. Acute renal failure] Hishida A. **Nippon Naika Gakkai Zasshi** 1996 Oct 10;85(10):1711–6 (5 ref.) **(Jpn)**

DIET THERAPY

Nutrition in acute renal failure. Riella MC. **Ren Fail** 1997 Mar;19(2):237–52 (79 ref.)

DRUG THERAPY

Basic aspects of vasorelaxant and bronchodilating peptides in clinical use: urodilatin (INN: Ularitide), VIP, and PACAP. Meyer M, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:443–61; discussion 461–3 (104 ref.)

The use of dopamine in acute renal failure [letter] Harper L, et al. **Clin Nephrol** 1997 May;47(5):347–9 (29 ref.)

Is renal dose dopamine protective or therapeutic? Yes. Carcoana OV, et al. **Crit Care Clin** 1996 Jul;12(3):677–85 (54 ref.)

Is renal dose dopamine protective or therapeutic? No. Cottee DB, et al. **Crit Care Clin** 1996 Jul;12(3):687–95 (51 ref.)

Can we further slow down the progression to end–stage renal disease in diabetic hypertensive patients? Bretzel RG. **J Hypertens Suppl** 1997 Mar;15(2):S83–8 (74 ref.)

Effects of growth hormone and insulin–like growth factor I on renal growth and function. Hammerman MR, et al. **J Pediatr** 1997 Jul;131(1 Pt 2):S17–9 (16 ref.)

"Renal–dose" dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. Denton MD, et al. **Kidney Int** 1996 Jul;50(1):4–14 (79 ref.)

Therapeutic potential of RGD peptides in acute renal injury. Goligorsky MS, et al. **Kidney Int** 1997 May;51(5):1487–92 (48 ref.)

The role of platelet–activating factor and the effect of PAF blocking receptors on the outcome of ARF. López–Novoa JM, et al. **Ren Fail** 1996 May;18(3):489–99 (83 ref.)

Lactulose and renal failure. Vogt B, et al. **Scand J Gastroenterol Suppl** 1997;222:100–1 (17 ref.)

[Low dosage dopamine improves kidney function: current status of knowledge and evaluation of a controversial topic] Kindgen–Milles D, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jun; 32(6):333–42 (85 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Acute renal failure in leptospirosis. Abdulkader RC. **Ren Fail** 1997 Mar;19(2):191–8 (34 ref.)

Pathophysiology, causes, and prognosis of acute renal failure in the elderly. Lameire N, et al. **Ren Fail** 1996 May; 18(3):333–46 (65 ref.)

ETIOLOGY

Adhesion molecules and acute renal failure. Bonventre JV, et al. **Adv Nephrol Necker Hosp** 1996;25:159–76 (65 ref.)

Acute renal failure in the pediatric patient. Mendley SR, et al. **Adv Ren Replace Ther** 1997 Apr;4(2 Suppl 1):93–101 (29 ref.)

Acute renal failure following immunoglobulin therapy. Ahsan N, et al. **Am J Nephrol** 1996;16(6):532–6 (29 ref.)

Acute renal failure in idiopathic nephrotic syndrome. Loghman–Adham M, et al. **Clin Nephrol** 1997 Feb; 47(2):76–80 (29 ref.)

Can we further slow down the progression to end–stage renal disease in diabetic hypertensive patients? Bretzel RG. **J Hypertens Suppl** 1997 Mar;15(2):S83–8 (74 ref.)

Renal disease. II. Malaria and acute renal failure. Day NP, et al. **J R Coll Physicians Lond** 1997 Mar–Apr;31(2):146–8 (16 ref.)

Leukocytes, cell adhesion molecules and ischemic acute renal failure. Rabb H, et al. **Kidney Int** 1997 May;51(5):1463–8 (31 ref.)

Atypical metastasis from prostatic carcinoma. Report of a case of renal metastasis and literature review. Galindo Gallego M, et al. **Minerva Urol Nefrol** 1996 Dec; 48(4):183–7 (27 ref.)

Acute renal failure and nephrotic syndrome with alpha interferon therapy. Dimitrov Y, et al. **Nephrol Dial Transplant** 1997 Jan;12(1):200–3 (23 ref.)

Endothelin: what role in acute contrast nephropathy? [editorial] Gross P, et al. **Nephrol Dial Transplant** 1996 Sep; 11(9):1716–8 (12 ref.)

Role of growth factors in acute renal failure [editorial] Wang S, et al. **Nephrol Dial Transplant** 1997 Aug;12(8):1560–3 (17 ref.)

Rapidly progressive T cell lymphoma presenting as acute renal failure: case report and review of the literature. Neuhauser TS, et al. **Pediatr Pathol Lab Med** 1997 May–Jun;17(3):449–60 (47 ref.)

Acute renal failure in leptospirosis. Abdulkader RC. **Ren Fail** 1997 Mar;19(2):191–8 (34 ref.)

Posttransplant acute renal failure. Bennett WM. **Ren Fail** 1997 Mar;19(2):225–6 (12 ref.)

The role of the calcium–dependent enzymes nitric oxide synthase and calpain in hypoxia–induced proximal tubule injury. Edelstein CL, et al. **Ren Fail** 1996 May;18(3):501–11 (73 ref.)

The role of platelet–activating factor and the effect of PAF blocking receptors on the outcome of ARF. López–Novoa JM, et al. **Ren Fail** 1996 May;18(3):489–99 (83 ref.)

Acute renal failure complicating nonfulminant hepatitis A. McCann UG 2nd, et al. **West J Med** 1996 Nov; 165(5):308–10 (32 ref.)

[Acute obstructive renal failure and scrotal complete hernia of the bladder. Apropos of a case, review of the literature] Mianné D, et al. **J Chir (Paris)** 1996;133(9–10):459–61 (14 ref.) (Eng. Abstr.) **(Fre)**

[Creatinine of 250 micro mol/l: what should be done?] Wahl C, et al. **Schweiz Rundsch Med Prax** 1997 May 14; 86(20):861–4 (7 ref.) (Eng. Abstr.) **(Ger)**

[A case of toxic shock syndrome (TSS) induced by methicillin–resistant staphylococcus aureus (MRSA)

presenting as acute renal failure with disseminated intravascular coagulation] Fukuuchi F, et al. **Nippon Jinzo Gakkai Shi** 1996 Jan;38(1):27–32 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Hyperuricemia and the kidney] Ichida K, et al. **Nippon Rinsho** 1996 Dec;54(12):3277–82 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Acute renal failure in glomerulonephritis and nephrotic syndrome] Furuya R, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):121–3 (14 ref.) **(Jpn)**

[Acute renal failure] Honda N. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):9–12 (7 ref.) **(Jpn)**

[Patchy renal vasoconstriction] Ishikawa I. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):293–6 (20 ref.) **(Jpn)**

[Rhabdomyolysis and acute kidney failure] Rosa EC, et al. **Rev Assoc Med Bras** 1996 Jan–Mar;42(1):39–45 (71 ref.) **(Por)**

METABOLISM

Oxidant mechanisms in toxic acute renal failure. Baliga R, et al. **Am J Kidney Dis** 1997 Mar;29(3):465–77 (84 ref.)

Mechanisms causing loss of muscle in acute uremia. Mitch WE. **Ren Fail** 1996 May;18(3):389–94 (36 ref.)

PATHOLOGY

Pathology of acute renal failure: structure/function correlations. Racusen LC. **Adv Ren Replace Ther** 1997 Apr; 4(2 Suppl 1):3–16 (101 ref.)

Propylene glycol–induced proximal renal tubular cell injury. Yorgin PD, et al. **Am J Kidney Dis** 1997 Jul;30(1):134–9 (57 ref.)

The nature of renal cell injury. Edelstein CL, et al. **Kidney Int** 1997 May;51(5):1341–51 (149 ref.)

PHYSIOPATHOLOGY

Hemodynamic factors in acute renal failure. Conger J. **Adv Ren Replace Ther** 1997 Apr;4(2 Suppl 1):25–37 (99 ref.)

Growth factors and cytokines in acute renal failure. Harris RC. **Adv Ren Replace Ther** 1997 Apr;4(2 Suppl 1):43–53 (139 ref.)

Renal stress response and acute renal failure. Safirstein R. **Adv Ren Replace Ther** 1997 Apr;4(2 Suppl 1):38–42 (25 ref.)

Endothelin in ischemic acute renal failure. Hunley TE, et al. **Curr Opin Nephrol Hypertens** 1997 Jul;6(4):394–400 (76 ref.)

Sodium balance in renal failure. Shemin D, et al. **Curr Opin Nephrol Hypertens** 1997 Mar;6(2):128–32 (39 ref.)

Role of adenosine in tubuloglomerular feedback and acute renal failure. Osswald H, et al. **J Auton Pharmacol** 1996 Dec;16(6):377–80 (34 ref.)

Endothelin and nitric oxide in hepatorenal syndrome: a balance reset. Epstein M, et al. **J Nephrol** 1997 May–Jun; 10(3):120–35 (158 ref.)

Intradialytic renal haemodynamics—potential consequences for the management of the patient with acute renal failure [editorial] Manns M, et al. **Nephrol Dial Transplant** 1997 May;12(5):870–2 (18 ref.)

Nitric oxide and acute renal failure [editorial] [see comments] Peer G, et al. **Nephron** 1996;73(3):375–81 (82 ref.) Comment in: Nephron 1997;76(1):121.

Acceleration of recovery in acute renal failure: from cellular mechanisms of tubular repair to innovative targeted therapies. Abbate M, et al. **Ren Fail** 1996 May;18(3):377–88 (68 ref.)

Glomerular hemodynamics in acute renal failure. Boim MA, et al. **Ren Fail** 1997 Mar;19(2):209–12 (17 ref.)

The role of calcium in the pathogenesis of acute renal failure. Edelstein CL, et al. **Ren Fail** 1997 Mar;19(2):199–207 (73 ref.)

Inflammatory cells in renal regeneration. Ghielli M, et al. **Ren Fail** 1996 May;18(3):355–75 (106 ref.)

[Uremia: pathophysiologic sequelae and indications for kidney replacement therapy] Jakob SM, et al. **Schweiz Med Wochenschr** 1997 Jun 21;127(25):1077–81 (20 ref.) (Eng. Abstr.) **(Ger)**

[Normal kidney function and acute and chronic kidney function disorders] Kallerhoff M. **Urologe A** 1996 Jul; 35(4):345–54 (13 ref.) **(Ger)**

[Acute on chronic renal failure] Higuchi C, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):5–8 (13 ref.) **(Jpn)**

PREVENTION & CONTROL

Prevention of cis-platinum nephrotoxicity in a high-risk patient. Donadio C, et al. **Ren Fail** 1996 Jul;18(4):691–5 (9 ref.)

Therapeutic strategies in the prevention of acute renal failure. García RE. **Ren Fail** 1997 Mar;19(2):231–5 (23 ref.)

Management and prevention of acute renal failure in solid organ transplantation. Morales JM. **Ren Fail** 1996 May; 18(3):481–8 (25 ref.)

[Renal protective effects of calcium antagonists] Musialik D, et al. **Pol Merkuriusz Lek** 1996 Oct;1(4):266–70 (50 ref.) (Eng. Abstr.) **(Pol)**

THERAPY

Dialysis prescription and kinetics in acute renal failure. Clark WR, et al. **Adv Ren Replace Ther** 1997 Apr;4(2 Suppl 1):64–71 (44 ref.)

The use of biocompatible dialysis membranes in acute renal failure. Himmelfarb J, et al. **Adv Ren Replace Ther** 1997 Apr;4(2 Suppl 1):72–80 (86 ref.)

Continuous renal replacement therapies in the acute renal failure setting: current concepts. Mehta RL. **Adv Ren Replace Ther** 1997 Apr;4(2 Suppl 1):81–92 (92 ref.)

Acute renal failure in the pediatric patient. Mendley SR, et al. **Adv Ren Replace Ther** 1997 Apr;4(2 Suppl 1):93–101 (29 ref.)

Nutrition in the critical care settings of renal diseases. Moore LW, et al. **Adv Ren Replace Ther** 1996 Jul;3(3):250–60 (32 ref.)

Transport characteristics of the slow therapies: implications for achieving adequacy of dialysis in acute renal failure. Sigler MH. **Adv Ren Replace Ther** 1997 Jan;4(1):68–80 (38 ref.)

Acute renal failure in the 21st century: recommendations for management and outcomes assessment. DuBose TD Jr, et al. **Am J Kidney Dis** 1997 May;29(5):793–9 (31 ref.)

Inconsequence of membrane choice in acute renal failure? Mujais SK, et al. **Artif Organs** 1996 May;20(5):454–5 (10 ref.)

New treatments for acute renal failure: growth factors and beyond [editorial] Hammerman MR. **Curr Opin Nephrol Hypertens** 1997 Jan;6(1):7–9 (15 ref.)

Renal replacement therapy in acute renal failure. McCarthy JT. **Curr Opin Nephrol Hypertens** 1996 Nov;5(6):480–4 (38 ref.)

ARF–continuing controversies [editorial] Shaldon S. **Int J Artif Organs** 1996 Aug;19(8):446–7 (14 ref.)

Continuous hemofiltration in the treatment of acute renal failure [see comments] Forni LG, et al. **N Engl J Med** 1997 May 1;336(18):1303–9 (28 ref.) Comment in: N Engl J Med 1997 Sep 4;337(10):712–3; discussion 713–4. Comment in: N Engl J Med 1997 Sep 4;337(10):713; discussion 713–4.

Severe acute renal failure due to bromate intoxication: report of a case and discussion of management guidelines based on a review of the literature. De Vriese A, et al. **Nephrol Dial Transplant** 1997 Jan;12(1):204–9 (29 ref.)

Membrane biocompatibility in the treatment of acute renal failure: what is the evidence in 1996? Jacobs C. **Nephrol Dial Transplant** 1997 Jan;12(1):38–42 (32 ref.)

Monitoring of blood volume during haemodialysis treatment of acute renal and multiple organ failures. Katzarski KS. **Nephrol Dial Transplant** 1996;11 Suppl 8:20–3 (46 ref.)

Intradialytic renal haemodynamics—potential consequences for the management of the patient with acute renal failure [editorial] Manns M, et al. **Nephrol Dial Transplant** 1997 May;12(5):870–2 (18 ref.)

Acceleration of recovery in acute renal failure: from cellular mechanisms of tubular repair to innovative targeted therapies. Abbate M, et al. **Ren Fail** 1996 May;18(3):377–88 (68 ref.)

The treatment of patients with ARF and MOSF: a framework for a discussion on ethical issues. Abel F. **Ren Fail** 1996 May;18(3):409–16 (11 ref.)

Management and prevention of acute renal failure in solid organ transplantation. Morales JM. **Ren Fail** 1996 May; 18(3):481–8 (25 ref.)

Acute renal failure in patients with kidney transplant: continuous versus intermittent renal replacement therapy. Ronco C, et al. **Ren Fail** 1996 May;18(3):461–70 (36 ref.)

Can hemodialysis technique modify the hypercatabolic state? Sunder-Plassmann G, et al. **Ren Fail** 1996 May; 18(3):395–404 (70 ref.)

Different types of dialyzer membranes: does the bio(in)compatibility matter in the treatment of ARF? Vanholder R, et al. **Ren Fail** 1996 May;18(3):471–9 (42 ref.)

Should continuous renal replacement therapy be used for 'non-renal' indications in critically ill patients with shock? van Bommel EF. **Resuscitation** 1997 Jan;33(3):257–70 (124 ref.)

Acute renal failure in the aged. Macías-Núñez JF, et al. **Semin Nephrol** 1996 Jul;16(4):330–8 (48 ref.)

[Acute renal failure in hospitalized patients] Ruokonen E, et al. **Duodecim** 1995;111(15):1471–7 (23 ref.) **(Fin)**

[Choice of renal replacement therapy] Favre H. **Schweiz Med Wochenschr** 1997 Jun 21;127(25):1082–7 (19 ref.) (Eng. Abstr.) **(Fre)**

[Continuous "high flux" dialysis: an effective renal replacement therapy for intensive care patients] Ronco C, et al. **Zentralbl Chir** 1997;122(5):378–82 (30 ref.) (Eng. Abstr.) **(Ger)**

[Progress in diagnosis and treatment of kidney diseases. V. Renal failure and kidney transplantation. 1. Acute renal failure] Hishida A. **Nippon Naika Gakkai Zasshi** 1996 Oct 10;85(10):1711–6 (5 ref.) **(Jpn)**

[A case of the successful use of protein A adsorption in a patient with acute kidney failure in rapidly progressing lupus glomerulonephritis] Aksenov VA, et al. **Ter Arkh** 1997;69(2):66–8 (14 ref.) **(Rus)**

URINE

Rhabdomyolysis and myohemoglobinuric acute renal failure [editorial] Zager RA. **Kidney Int** 1996 Feb;49(2):314–26 (148 ref.)

[Acute renal failure in hospitalized patients] Ruokonen E, et al. **Duodecim** 1995;111(15):1471–7 (23 ref.) **(Fin)**

KIDNEY FAILURE, CHRONIC

see related
HEMODIALYSIS
UREMIA

Pregnancy complicated by chronic renal disease. Jones DC. **Clin Perinatol** 1997 Jun;24(2):483–96 (38 ref.)

Is deterioration of renal function in essential hypertension predictable? Campese VM, et al. **Contrib Nephrol** 1996; 119:83–90 (35 ref.)

Pharmacologic considerations in the dental management of the patient with disorders of the renal system. Naylor GD, et al. **Dent Clin North Am** 1996 Jul;40(3):665–83 (51 ref.)

Renal syndromes in diabetes. Friedman EA. **Endocrinol Metab Clin North Am** 1996 Jun;25(2):293–324 (172 ref.)

[Renal failure in the elderly] Kitamoto K. **Nippon Ronen Igakkai Zasshi** 1996 Sep;33(9):657–61 (14 ref.) **(Jpn)**

[Chronic renal insufficiency] Kováč A, et al. **Vnitr Lek** 1996 Jul;42(7):503–6 (11 ref.) (Eng. Abstr.) **(Slo)**

[Chronic end-stage kidney failure in Mexico] Hernández-Llamas G, et al. **Gac Med Mex** 1995 Jul–Aug; 131(4):459–63 (14 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

Interpreting glycosylated hemoglobin in diabetic patients on peritoneal dialysis. Tzamaloukas AH. **Adv Perit Dial** 1996; 12:171–5 (40 ref.)

Iron management in end-stage renal disease. Fishbane S, et al. **Am J Kidney Dis** 1997 Mar;29(3):319–33 (104 ref.)

Assessing erythropoiesis and the effect of erythropoietin therapy in renal disease by reticulocyte counting. Pradella M, et al. **Clin Lab Haematol** 1996 Dec;18 Suppl 1:35–7 (19 ref.)

Hyperhomocysteinaemia and end stage renal disease. Gupta A, et al. **J Nephrol** 1997 Mar–Apr;10(2):77–84 (59 ref.)

Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Bostom AG, et al. **Kidney Int** 1997 Jul;52(1):10–20 (112 ref.)

Homocysteinemia and vascular disease in end-stage renal disease. Dennis VW, et al. **Kidney Int Suppl** 1996 Dec; 57:S11–7 (59 ref.)

Growth hormone binding protein and free growth hormone in chronic renal failure. Baumann G. **Pediatr Nephrol** 1996 Jun;10(3):328–30 (32 ref.)

CHEMICALLY INDUCED

Analgesics and chronic renal disease. Klag MJ, et al. **Curr Opin Nephrol Hypertens** 1996 May;5(3):236–41 (42 ref.)

[What is reliable in prevention of contrast medium–induced nephropathy?] Friedrichsohn CB, et al. **Med Klin** 1997 Jun 15;92(6):329–34 (72 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Cardiovascular complications in end-stage renal disease and hemodialysis patients. Kes P, et al. **Acta Med Croatica** 1996; 50(4–5):199–208 (95 ref.)

Clinical considerations in hemodialysis access infection. Albers FJ. **Adv Ren Replace Ther** 1996 Jul;3(3):208–17 (46 ref.)

Epidemiological perspective on infections in chronic dialysis patients. Bloembergen WE, et al. **Adv Ren Replace Ther** 1996 Jul;3(3):201–7 (35 ref.)

Ischemic heart disease in patients with end-stage renal disease. Fellner SK, et al. **Adv Ren Replace Ther** 1996 Jul; 3(3):240–9 (38 ref.)

Peer resource consulting: redesigning a new future. Kapron K, et al. **Adv Ren Replace Ther** 1997 Jul;4(3):267–74 (24 ref.)

Peritoneal catheter exit-site and tunnel infections. Piraino B. **Adv Ren Replace Ther** 1996 Jul;3(3):222–7 (56 ref.)

Nursing interventions related to peritoneal catheter exit-site infections. Prowant BF. **Adv Ren Replace Ther** 1996 Jul; 3(3):228–31 (32 ref.)

Nursing interventions related to peritonitis. Prowant BF. **Adv Ren Replace Ther** 1996 Jul;3(3):237–9 (9 ref.)

Patients with HIV infection and end-stage renal disease. Schoenfeld P, et al. **Adv Ren Replace Ther** 1996 Oct; 3(4):287–92 (27 ref.)

Nursing interventions related to vascular access infections. Thomas-Hawkins C. **Adv Ren Replace Ther** 1996 Jul; 3(3):218–21 (56 ref.)

Peritonitis in peritoneal dialysis patients: an overview. Tzamaloukas AH. **Adv Ren Replace Ther** 1996 Jul; 3(3):232–6 (24 ref.)

Serum ferritin and other iron indices in adult Nigerians with chronic renal failure—review of management of anaemia. Oluboyede OA, et al. **Afr J Med Med Sci** 1995 Sep; 24(3):231–7 (52 ref.)

McCollum Award Lecture, 1996: protein-energy malnutrition in maintenance dialysis patients. Kopple JD. **Am J Clin Nutr** 1997 May;65(5):1544–57 (134 ref.)

Calciphylaxis in a patient with Crohn's disease in the absence of end-stage renal disease. Barri YM, et al.

Am J Kidney Dis 1997 May;29(5):773–6 (34 ref.)

Coronary revascularization in patients on dialysis. What treatment option should we choose? Cruz DN, et al. **ASAIO J** 1996 May–Jun;42(3):139–41 (91 ref.)

Metabolic acidosis and nutrition in dialysis patients. Bergström J. **Blood Purif** 1995 Nov–Dec;13(6):361–7 (26 ref.)

Treatment of hypertension in renal failure patients: when do we overtreat? When do we undertreat? Rosansky SJ. **Blood Purif** 1996;14(4):315–20 (19 ref.)

Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients. Drüeke TB, et al. **Clin Nephrol** 1997 Jul;48(1):1–8 (69 ref.)

Hyperkalemia: therapeutic options in acute and chronic renal failure. Kemper MJ, et al. **Clin Nephrol** 1996 Jul;46(1):67–9 (15 ref.)

Myocardial hypertrophy in chronic renal failure: a multifactorial, reversible alteration. Cannella G, et al. **Contrib Nephrol** 1996;119:135–40 (14 ref.)

Volume-dependent factors in hypertension in chronic renal failure. Dal Canton A, et al. **Contrib Nephrol** 1996; 119:26–30 (20 ref.)

Arterial hypertension and mortality in dialysis patients. RPDT Working Group. Quarello F, et al. **Contrib Nephrol** 1996;119:141–6 (18 ref.)

Growth hormone as a new treatment modality for short children with chronic renal failure. The German Study Group for Growth Hormone Treatment in Chronic Renal Failure. Mehls O, et al. **Horm Res** 1996;46(4–5):230–5 (54 ref.)

Calciphylaxis in chronic renal failure. Budisavljevic MN, et al. **J Am Soc Nephrol** 1996 Jul;7(7):978–82 (18 ref.)

Diagnosis and management of coronary artery disease in patients with end-stage renal disease on hemodialysis. de Lemos JA, et al. **J Am Soc Nephrol** 1996 Oct;7(10):2044–54 (96 ref.)

Considerations for the treatment of secondary hyperparathyroidism in renal failure. Felsenfeld AJ. **J Am Soc Nephrol** 1997 Jun;8(6):993–1004 (48 ref.)

Growth hormone treatment in children before and after renal transplantation. Hokken-Koelega AC. **J Pediatr Endocrinol Metab** 1996 Jun;9 Suppl 3:359–64 (41 ref.)

Dyslipidemia in chronic renal failure patients [editorial] Almeida AF, et al. **J Postgrad Med** 1994 Apr–Jun; 40(2):52–4 (26 ref.)

Renal disease. II. The clinical impact of recombinant human erythropoietin. Muirhead N. **J R Coll Physicians Lond** 1997 Mar–Apr;31(2):125–30 (39 ref.)

Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure [editorial] Erslev AJ, et al. **Kidney Int** 1997 Mar;51(3):622–30 (93 ref.)

Nutrition in end-stage renal disease. Ikizler TA, et al. **Kidney Int** 1996 Aug;50(2):343–57 (182 ref.)

Atherosclerosis and arteriosclerosis in chronic renal failure [editorial] London GM, et al. **Kidney Int** 1997 Jun; 51(6):1678–95 (196 ref.)

Bone disease in patients receiving growth hormone. Watkins SL. **Kidney Int Suppl** 1996 Jan;53:S126–7 (17 ref.)

Neurotoxicity associated with acyclovir in end stage renal failure. Kitching AR, et al. **N Z Med J** 1997 May 9; 110(1043):167–9 (19 ref.)

The patient with end-stage renal failure and ascites. Franz M, et al. **Nephrol Dial Transplant** 1997 May;12(5):1070–8 (58 ref.)

Ultrasonographic intervention of parathyroid hyperplasia in chronic dialysis patients: a theoretical approach. Fukagawa M, et al. **Nephrol Dial Transplant** 1996;11 Suppl 3:125–9 (32 ref.)

Are cardiac troponins reliable serodiagnositic markers of cardiac ischaemia in end-stage renal disease? [editorial] Haller C, et al. **Nephrol Dial Transplant** 1996 Jun; 11(6):941–4 (16 ref.)

Should hyperlipidaemia in dialysis patients be treated? [editorial] Wheeler DC. **Nephrol Dial Transplant** 1997 Jan; 12(1):19–21 (10 ref.)

Nutritional markers and survival in maintenance dialysis patients [editorial] Pollock CA, et al. **Nephron** 1996; 74(4):625–41 (176 ref.)

Malnutrition in patients with end-stage renal disease: diagnosis, pathophysiology and treatment. Kooman JP, et al. **Neth J Med** 1997 Mar;50(3):120–32 (100 ref.)

Calcitriol administration in end-stage renal disease: intravenous or oral? Quarles LD, et al. **Pediatr Nephrol** 1996 Jun;10(3):331–6 (42 ref.)

Anemia, hypertension, and myocardial dysfunction in end-stage renal disease. Venkatesan J, et al. **Semin Nephrol** 1997 Jul;17(4):257–69 (125 ref.)

Results of revascularization for peripheral arterial insufficiency in chronic renal failure patients. Donayre CE. **Semin Vasc Surg** 1996 Sep;9(3):253–61 (34 ref.)

Infrainguinal bypass in end-stage renal disease: when is it justified? Isiklar MH, et al. **Semin Vasc Surg** 1997 Mar; 10(1):42–8 (45 ref.)

Cutaneous gangrene secondary to metastatic calcification in end stage renal failure--a case report. Tan HH, et al. **Singapore Med J** 1996 Aug;37(4):438–40 (12 ref.)

Parathyroid carcinoma in patients with chronic renal failure on maintenance hemodialysis. Miki H, et al. **Surgery** 1996 Nov;120(5):897–901 (10 ref.)

[Anemia in chronic renal failure and erythropoietin] Rosenlöf K. **Duodecim** 1995;111(15):1489–95 (37 ref.) **(Fin)**

[Diastolic dysfunction in chronic renal failure patients under hemodialysis] Douchet MP, et al. **Ann Cardiol Angeiol (Paris)** 1996 Dec;45(10):589–92 (15 ref.) (Eng. Abstr.) **(Fre)**

[Role of phosphorus in hyperparathyroidism secondary to non-dialysed adult chronic renal insufficiency] Combe C, et al. **Nephrologie** 1996;17(3):149–56 (68 ref.) (Eng. Abstr.) **(Fre)**

[Malnutrition in chronic renal insufficiency] Aparicio M, et al. **Presse Med** 1997 Mar 15;26(8):389–95 (25 ref.) **(Fre)**

[Coronary heart disease in patients with end-stage kidney failure] Leschke M, et al. **Dtsch Med Wochenschr** 1997 Aug 1;122(31–32):976–82 (57 ref.) **(Ger)**

[Therapy with antibiotics in renal failure] Anding K, et al. **Med Klin** 1996 Nov 15;91(11):698–702 (42 ref.) **(Ger)**

[Increased cancer incidence in terminal kidney failure: potential pathogenetic mechanisms] Vamvakas S, et al. **Schweiz Med Wochenschr** 1997 Apr 5;127(14):597–604 (100 ref.) (Eng. Abstr.) **(Ger)**

[Combined heart-kidney transplantation in pediatric age] Caione P, et al. **Minerva Pediatr** 1996 Oct;48(10):451–5 (21 ref.) (Eng. Abstr.) **(Ita)**

[Glucose intolerance in chronic renal failure] Matsushita Y, et al. **Nippon Rinsho** 1996 Oct;54(10):2715–8 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Renal dwarfism] Ito K, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):21–3 (14 ref.) **(Jpn)**

[Uremic cardiomyopathy] Shigematsu Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):189–92 (12 ref.) **(Jpn)**

[Uremic myopathy] Wanic-Kossowska M. **Pol Arch Med Wewn** 1996 Jun;95(6):578–84 (39 ref.) **(Pol)**

[Conditions and consequences of cardiac alterations in patients with end-stage renal disease on maintenance hemodialysis] Zabicka H. **Postepy Hig Med Dosw** 1996; 50(3):277–91 (100 ref.) (Eng. Abstr.) **(Pol)**

[Aortic valve prosthesis and the plication of a dissecting aneurysm of the ascending aorta in a patient with infectious endocarditis against a background of chronic kidney failure and its management by regular hemodialysis] Uglov FG, et al. **Vestn Khir Im I I Grek** 1996;155(2):9–14 (28 ref.) (Eng. Abstr.) **(Rus)**

DIAGNOSIS

The hemodialysis patient: object of diagnosis or part of the treatment team? Burnell MS. **Adv Ren Replace Ther** 1997 Apr;4(2):145–51 (22 ref.)

Use of the medical differential diagnosis to achieve optimal end-stage renal disease outcomes. Rodriguez RA. **Adv Ren Replace Ther** 1997 Apr;4(2):97–111 (102 ref.)

Bone disease in moderate renal failure: cause, nature and prevention. Bushinsky DA. **Annu Rev Med** 1997;48:167–76 (46 ref.)

Kidney disease: jade, dialysis or transplantation? [editorial] Barakat AJ. **J Med Liban** 1996;44(4):184–6 (5 ref.)

The hyperparathyroidism of chronic renal failure: a disorder of growth. Parfitt AM. **Kidney Int** 1997 Jul;52(1):3–9 (90 ref.)

[Diabetic nephropathy and pregnancy] Schröder W, et al. **Z Geburtshilfe Neonatol** 1997 May–Jun;201(3):75–81 (88 ref.) (Eng. Abstr.) **(Ger)**

[Progress in diagnosis and treatment of kidney diseases. V. Renal failure and kidney transplantation. 2. chronic renal failure] Horio M, et al. **Nippon Naika Gakkai Zasshi** 1996 Oct 10;85(10):1717–22 (5 ref.) **(Jpn)**

DIET THERAPY

Nutrition and chronic renal disease in children. Chan W. **Acta Paediatr Sin** 1996 Jul–Aug;37(4):244–7 (26 ref.)

Adaptation of African-American cultural and food preferences in end-stage renal disease diets. Patel C, et al. **Adv Ren Replace Ther** 1997 Jan;4(1):30–9 (14 ref.)

Is there still a role for a diet very low in protein, with or without supplements, in the management of patients with end-stage renal failure? Klahr S. **Curr Opin Nephrol Hypertens** 1996 Jul;5(4):384–7 (16 ref.)

Diet in chronic renal failure. Shendurnikar N, et al. **Indian Pediatr** 1995 Oct;32(10):1120–3 (14 ref.)

DRUG THERAPY

Clinical trials in progression of chronic renal failure. Striker GE, et al. **Adv Intern Med** 1997;42:555–95 (53 ref.)

1995 update of the working group reports on chronic renal failure and renovascular hypertension. National High Blood Pressure Education Program Working Group. **Arch Intern Med** 1996 Sep 23;156(17):1938–47 (98 ref.)

Appropriate hematocrit levels of erythropoietin supplementary therapy in end-stage renal failure complicated by coronary artery disease. Nagao K, et al. **Can J Cardiol** 1997 Aug;13(8):747–53 (23 ref.)

Assessing erythropoiesis and the effect of erythropoietin therapy in renal disease by reticulocyte counting. Pradella M, et al. **Clin Lab Haematol** 1996 Dec;18 Suppl 1:35–7 (19 ref.)

Erythropoietin and iron [see comments] Sunder-Plassmann G, et al. **Clin Nephrol** 1997 Mar;47(3):141–57 (236 ref.) Comment in: Clin Nephrol 1997 Jun;47(6):408.

The use of growth factors to increase glomerular filtration rate in chronic renal failure patients. Miller SB, et al. **Curr Opin Nephrol Hypertens** 1997 Jul;6(4):401–4 (30 ref.)

Prognostic value of the short-term antiproteinuric response to ACE inhibition for prediction of GFR decline in patients with nondiabetic renal disease. Wapstra FH, et al. **Exp Nephrol** 1996;4 Suppl 1:47–52 (48 ref.)

Metoclopramide in a patient with renal failure may be an increased risk of neuroleptic malignant syndrome [letter] Fujita Y, et al. **Intensive Care Med** 1996 Jul;22(7):717 (5 ref.)

The treatment of hypertension in diabetic nephropathy. Lewis EJ. **J Hum Hypertens** 1996 Oct;10(10):675–7 (5 ref.)

Effects of growth hormone and insulin-like growth factor I on renal growth and function. Hammerman MR, et al. **J Pediatr** 1997 Jul;131(1 Pt 2):S17–9 (16 ref.)

Erythropoietin in chronic renal failure. Valderrábano F. **Kidney Int** 1996 Oct;50(4):1373–91 (169 ref.)

Physiologic role and diuretic efficacy of atrial natriuretic peptide in health and chronic renal disease. Conte G, et al. **Kidney Int Suppl** 1997 Jun;59:S28–32 (21 ref.)

Recombinant human growth hormone in children with chronic renal insufficiency--clinical update: 1995. Fine RN. **Kidney Int Suppl** 1996 Jan;53:S115–8 (22 ref.)

Use of diuretics in chronic renal failure. Suki WN. **Kidney Int Suppl** 1997 Jun;59:S33–5 (19 ref.)

Long-term use of recombinant human growth hormone in children with chronic renal insufficiency. Yadin O, et al. **Kidney Int Suppl** 1997 Mar;58:S114–7 (30 ref.)

Ace inhibition in chronic renal failure: a step forward [editorial] [see comments] Mann JF. **Nephrol Dial Transplant** 1996 Jun;11(6):932–3 (15 ref.) Comment in: Nephrol Dial Transplant 1997 Jan;12(1):234–5.

Recombinant erythropoietin: 10 years of clinical experience. Valderrábano F. **Nephrol Dial Transplant** 1997;12 Suppl 1:2–9 (74 ref.)

Verapamil deleterious effects in chronic renal failure. Váquez C, et al. **Nephron** 1996;72(3):461–4 (11 ref.)

Lactulose and renal failure. Vogt B, et al. **Scand J Gastroenterol Suppl** 1997;222:100–1 (17 ref.)

[Survey on experimental studies on traditional Chinese medicine treatment of chronic renal failure] Wang L, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Jan; 16(1):58–60 (26 ref.) **(Chi)**

[The influence of antihypertensive treatment on progression of chronic nephropathy] Petersen LJ, et al. **Ugeskr Laeger** 1997 Jul 28;159(31):4745–51 (32 ref.) (Eng. Abstr.) **(Dan)**

[Diuretic therapy in chronic kidney failure] Risler T, et al. **Dtsch Med Wochenschr** 1996 Nov 15;121(46):1435–9 (26 ref.) **(Ger)**

[Diuretics in renal failure] Ritz E. **Wien Med Wochenschr** 1996;146(16):443–6 (9 ref.) (Eng. Abstr.) **(Ger)**

[The effect of vasoactive preparations on kidney functional status in patients with chronic glomerulonephritis and kidney failure] Kolesnyk MO, et al. **Lik Sprava** 1996 Jul–Sep;(7–9):18–21 (30 ref.) **(Ukr)**

EPIDEMIOLOGY

End-stage renal disease: why aren't improvements in hypertension treatment reducing the risk? Jaimes E, et al. **Curr Opin Cardiol** 1996 Sep;11(5):471–6 (63 ref.)

Nephropathy in type II diabetes. Ritz E. **Exp Clin Endocrinol Diabetes** 1997;105 Suppl 2:80–2 (19 ref.)

End-stage renal disease in China. Li L. **Kidney Int** 1996 Jan; 49(1):287–301 (81 ref.)

Future evolution of the ESRD patient population--a perspective for the year 2000. Molzahn M. **Nephrol Dial Transplant** 1996;11 Suppl 8:59–62 (20 ref.)

ETHNOLOGY

Diabetes and hypertension in Britain's ethnic minorities: implications for the future of renal services [see comments] Raleigh VS. **BMJ** 1997 Jan 18;314(7075):209–13 (33 ref.) Comment in: BMJ 1997 May 17;314(7092):1486.

Are we missing an epidemic of HIV-associated nephropathy? Winston JA, et al. **J Am Soc Nephrol** 1996 Jan;7(1):1–7 (57 ref.)

ETIOLOGY

Clinical trials in progression of chronic renal failure. Striker GE, et al. **Adv Intern Med** 1997;42:555–95 (53 ref.)

End-stage renal failure from mushroom poisoning with Cortinarius orellanus: report of four cases and review of the literature. Horn S, et al. **Am J Kidney Dis** 1997 Aug; 30(2):282–6 (16 ref.)

Cholesterol emboli: a common cause of renal failure. Vidt DG. **Annu Rev Med** 1997;48:375–85 (44 ref.)

Cholesterol as a predictor of progression in nondiabetic chronic renal disease. Greco BA, et al. **Contrib Nephrol** 1997;120:48–61 (57 ref.)

Ischemic renal failure. Zucchelli P, et al. **Contrib Nephrol** 1996;119:59–66 (45 ref.)

Ischaemic renal injury. Alcázar JM, et al. **Curr Opin Nephrol Hypertens** 1997 Mar;6(2):157–65 (105 ref.)

Further trends in the etiology of end-stage renal disease in African-Americans. Coresh J, et al. **Curr Opin Nephrol Hypertens** 1997 May;6(3):243–9 (52 ref.)

End-stage renal disease in NIDDM: a consequence of

microangiopathy alone? Raine AE, et al. **Diabetologia** 1996 Dec;39(12):1673–5 (16 ref.)

Aplasia of the cerebellar vermis associated with chronic renal disease. A report of six cases and a review of the literature. Keuth B, et al. **Eur J Pediatr** 1996 Nov;155(11):963–7 (29 ref.)

Mechanisms of injury in progressive renal disease. Anderson S. **Exp Nephrol** 1996;4 Suppl 1:34–40 (44 ref.)

Renal failure in sickle cell anemia. Wong WY, et al. **Hematol Oncol Clin North Am** 1996 Dec;10(6):1321–31 (69 ref.)

Late onset bone marrow transplant nephropathy. Oyama Y, et al. **Intern Med** 1996 Jun;35(6):489–93 (23 ref.)

The renal tubule in the progression of chronic renal failure. Palmer BF. **J Investig Med** 1997 Aug;45(6):346–61 (172 ref.)

Significance of postglomerular capillaries in the pathogenesis of chronic renal failure. Bohle A, et al. **Kidney Blood Press Res** 1996;19(3–4):191–5 (30 ref.)

Arterial stiffness in hypertensive subjects with or without end-stage renal disease. Safar ME, et al. **Kidney Blood Press Res** 1997;20(2):82–9 (56 ref.)

Diabetic nephropathy. Lapuz MH. **Med Clin North Am** 1997 May;81(3):679–88 (49 ref.)

Enteric hyperoxaluria and renal failure associated with lymphangiectasia. Allen A, et al. **Nephrol Dial Transplant** 1997 Apr;12(4):802–6 (25 ref.)

Progressive renal failure--inability of podocytes to replicate and the consequences for development of glomerulosclerosis. Kriz W. **Nephrol Dial Transplant** 1996 Sep;11(9):1738–42 (16 ref.)

An improved understanding of the causes of end-stage renal disease. Young EW. **Semin Nephrol** 1997 May;17(3):170–5 (38 ref.)

[Prognosis of prenatal uropathies: should fetal urine tests be continued?] Bensman A. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(5):510–4 (28 ref.) (Eng. Abstr.) **(Fre)**

[The Churg-Strauss syndrome with cerebral seizures and terminal kidney failure] Terjung B, et al. **Dtsch Med Wochenschr** 1997 Jul 4;122(27):853–8 (22 ref.) (Eng. Abstr.) **(Ger)**

[Update nephrology-I. Etiology and possibilities for modifying the progression of chronic renal failure] Stein G, et al. **Med Klin** 1996 Feb 15;91(2):76–81 (0 ref.) **(Ger)**

[Current issues in the diagnosis and therapy of diabetic nephropathy] de Châtel R, et al. **Orv Hetil** 1997 Jan 26; 138(4):187–93 (70 ref.) (Eng. Abstr.) **(Hun)**

GENETICS

[Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) with chronic renal failure: report of mother-child cases] Ihara M, et al. **Rinsho Shinkeigaku** 1996 Sep;36(9):1069–73 (13 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Derangements of protein metabolism in chronic renal failure. Kaysen GA, et al. **Blood Purif** 1996;14(5):373–81 (68 ref.)

Erythropoietin dysregulation in renal failure and research on IgA nephropathy. Tan CC. **Clin Sci (Colch)** 1996 Sep; 91(3):258–60 (18 ref.)

Lipid abnormalities in progressive renal insufficiency. Attman PO, et al. **Contrib Nephrol** 1997;120:1–10 (35 ref.)

Membrane protein damage and methylation reactions in chronic renal failure [editorial] Perna AF, et al. **Kidney Int** 1996 Aug;50(2):358–66 (94 ref.)

The hypothalamo-pituitary-growth hormone insulin-like growth factor 1 axis in children with chronic renal failure. Rees L, et al. **Kidney Int Suppl** 1996 Jan;53:S109–14 (16 ref.)

Is testing for growth hormone release necessary? Wilson DM. **Kidney Int Suppl** 1996 Jan;53:s123–5 (20 ref.)

New insights into the regulation of parathyroid hormone synthesis and secretion in chronic renal failure. Silver J, et al. **Nephrol Dial Transplant** 1996;11 Suppl 3:2–5 (30 ref.)

Influence of chronic liver disease and chronic renal failure on nutrient metabolism and undernutrition [editorial] Cano N, et al. **Nutrition** 1997 Apr;13(4):381–3 (74 ref.)

Abnormal skeletal response to parathyroid hormone and the expression of its receptor in chronic uremia. Drüeke TB. **Pediatr Nephrol** 1996 Jun;10(3):348–50 (23 ref.)

Insulin-like growth factors (IGF) and IGF binding proteins in children with chronic renal failure. Tönshoff B, et al. **Prog Growth Factor Res** 1995;6(2–4):481–91 (49 ref.)

Alterations in intestinal transport of oxaiate in disease states. Hatch M, et al. **Scanning Microsc** 1995;9(4):1121–6; discussion 1126 (43 ref.)

[Vitamin disturbances in chronic renal insufficiency. I. Water soluble vitamins] Pietrzak I. **Przegl Lek** 1995;52(10):522–5 (20 ref.) (Eng. Abstr.) **(Pol)**

MORTALITY

Cardiovascular factors influencing survival in dialysis patients. Alpert MA. **Adv Perit Dial** 1996;12:110–9 (57 ref.)

Is peritoneal dialysis the preferred modality in the diabetic patient? Kraus MA, et al. **Adv Perit Dial** 1996;12:89–92 (10 ref.)

Comparison of long-term survival between hemodialysis and peritoneal dialysis. Maiorca R, et al. **Adv Perit Dial** 1996; 12:79–88 (34 ref.)

Survival with end-stage renal failure in the 1990s [editorial] Schwab SJ, et al. **Curr Opin Nephrol Hypertens** 1996 Nov; 5(6):477–9 (19 ref.)

PATHOLOGY

Imaging of the parathyroid in chronic renal failure: diagnostic and therapeutic aspects. Fukagawa M, et al. **Curr Opin Nephrol Hypertens** 1997 Jul;6(4):349–55 (74 ref.)

Evolving role of the podocyte in chronic renal failure. Kriz W. **Kidney Blood Press Res** 1997;20(3):180–3 (21 ref.)

Pathogenesis of chronic renal failure in the primary glomerulopathies, renal vasculopathies, and chronic interstitial nephritides. Bohle A, et al. **Kidney Int Suppl** 1996 May;54:S2–9 (44 ref.)

[Apoptosis in uremic complication] Matsumoto Y, et al. **Rinsho Byori** 1997 Jul;45(7):638–42 (12 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Maintenance of employment on dialysis. Rasgon S, et al. **Adv Ren Replace Ther** 1997 Apr;4(2):152–9 (26 ref.)

Use of bioelectrical impedance analysis measurements in the clinical management of patients undergoing dialysis. Kushner RF, et al. **Am J Clin Nutr** 1996 Sep;64(3 Suppl):503S–509S (58 ref.)

Molecular basis for the management of secondary hyperparathyroidism in chronic renal failure. Fukagawa M, et al. **Artif Organs** 1995 Dec;19(12):1210–4 (25 ref.)

Assessment of the nutritional state of dialysis patients. Kerr PG, et al. **Blood Purif** 1996;14(5):382–7 (25 ref.)

Oral vitamin D or calcium carbonate in the prevention of renal bone disease? Argilés A, et al. **Curr Opin Nephrol Hypertens** 1996 Jul;5(4):329–36 (53 ref.)

Mineral metabolism: new aspects and perspectives [editorial] Drüeke TB. **Curr Opin Nephrol Hypertens** 1996 Jul; 5(4):297–9 (16 ref.)

The use of growth factors to increase glomerular filtration rate in chronic renal failure patients. Miller SB, et al. **Curr Opin Nephrol Hypertens** 1997 Jul;6(4):401–4 (30 ref.)

Sodium balance in renal failure. Shemin D, et al. **Curr Opin Nephrol Hypertens** 1997 Mar;6(2):128–32 (39 ref.)

Kidney damage in 'benign' essential hypertension [see comments] Whelton PK, et al. **Curr Opin Nephrol Hypertens** 1997 Mar;6(2):177–83 (36 ref.) Comment in: Curr Opin Nephrol Hypertens 1997 Mar;6(2):167–8.

Prognostic value of the short-term antiproteinuric response to ACE inhibition for prediction of GFR decline in patients with nondiabetic renal disease. Wapstra FH, et al. **Exp Nephrol** 1996;4 Suppl 1:47–52 (48 ref.)

Hypertension in the dialysis population: no easy answers [editorial] Salem MM. **Int J Artif Organs** 1996 Dec; 19(12):693–4 (15 ref.)

Adaptation to changes in dietary phosphorus intake in health and in renal failure. Loghman-Adham M. **J Lab Clin Med** 1997 Feb;129(2):176–88 (153 ref.)

Effects of renal failure on the growth hormone-insulin-like growth factor axis. Powell DR. **J Pediatr** 1997 Jul;131(1 Pt 2):S13–6 (21 ref.)

Evolving role of the podocyte in chronic renal failure. Kriz W. **Kidney Blood Press Res** 1997;20(3):180–3 (21 ref.)

Residual renal function, peritoneal transport characteristics and dialysis adequacy in peritoneal dialysis. Heimbürger O. **Kidney Int Suppl** 1996 Nov;56:S47–55 (111 ref.)

Derangements of the somatotropic hormone axis in chronic renal failure. Tönshoff B, et al. **Kidney Int Suppl** 1997 Mar; 58:S106–13 (66 ref.)

Pathophysiology of advanced glycation end-products in renal failure. Miyata T, et al. **Nephrol Dial Transplant** 1996; 11 Suppl 5:27–30 (23 ref.)

Growth retardation in children with chronic renal insufficiency [editorial] Fine RN. **Nephron** 1997;76(2):125–9 (45 ref.)

Abnormal skeletal response to parathyroid hormone and the expression of its receptor in chronic uremia. Drüeke TB. **Pediatr Nephrol** 1996 Jun;10(3):348–50 (23 ref.)

Insulin-like growth factor binding proteins as growth inhibitors in children with chronic renal failure. Powell DR, et al. **Pediatr Nephrol** 1996 Jun;10(3):343–7 (45 ref.)

The impact of residual renal function on the adequacy of peritoneal dialysis. Lameire N, et al. **Perit Dial Int** 1997; 17 Suppl 2:S102–10 (73 ref.)

Physical working capacity in uremic patients. Clyne N. **Scand J Urol Nephrol** 1996 Aug;30(4):247–52 (31 ref.)

Pathogenesis and medical treatment of secondary hyperparathyroidism. Fukagawa M, et al. **Semin Surg Oncol** 1997 Mar-Apr;13(2):73–7 (36 ref.)

Lipids and progressive renal failure. Keane WF. **Wien Klin Wochenschr** 1996;108(14):420–4 (44 ref.)

[Why does renal insufficiency progress? (editorial)] Grönhagen-Riska C, et al. **Duodecim** 1995;111(15):1389–93 (15 ref.) **(Fin)**

[Accumulation of AGE (advanced glycosylation end-products) in the aging process, in diabetes mellitus and in chronic renal failure] Wisotzky J, et al. **Med Klin** 1996 Jul 15;91(7):454–7 (45 ref.) **(Ger)**

[Normal kidney function and acute and chronic kidney function disorders] Kallerhoff M. **Urologe A** 1996 Jul; 35(4):345–54 (13 ref.) **(Ger)**

[Renal infantilism] Ito K. **Ryoikibetsu Shokogun Shirizu** 1997; (16 Pt 1):27–9 (3 ref.) **(Jpn)**

[Cardiovascular system function in patients with chronic kidney failure on hemodialysis] Rzhevskaia ON, et al. **Urol Nefrol (Mosk)** 1997 Mar-Apr;(2):45–51 (159 ref.) **(Rus)**

PREVENTION & CONTROL

The effect of blood pressure reduction on end stage renal disease. Jamerson K. **Am J Hypertens** 1996 Aug; 9(8):60s–64s (22 ref.)

Treatment of diabetic nephropathy in its early stages. Deferrari G, et al. **Diabetes Metab Rev** 1997 Mar; 13(1):51–61 (85 ref.)

Prevention of diabetic nephropathy. Materson BJ, et al. **Hosp Pract (Off Ed)** 1997 Feb 15;32(2):129–34, 139–40 (12 ref.)

Titrating for antiproteinuric effect: the clue to renoprotection? Navis G, et al. **J Hum Hypertens** 1996 Oct; 10(10):669–73 (47 ref.)

End-stage renal disease. Measures to prevent it or slow its progression [published erratum appears in Postgrad Med 1997 Jul;102(1):36] Hood VL, et al. **Postgrad Med** 1996 Nov;100(5):163–6, 171–6 (26 ref.)

The benefits of ACE inhibitors and calcium antagonists in slowing progressive renal failure: focus on fixed-dose combination antihypertensive therapy. Epstein M. **Ren Fail** 1996 Nov;18(6):813–32 (101 ref.)

[The significance of diagnosing microalbuminuria and microglobulinuria in diabetes mellitus and arterial hypertension] Kasprowicz B, et al. **Przegl Lek** 1997; 54(3):180–4 (70 ref.) (Eng. Abstr.) **(Pol)**

PSYCHOLOGY

Family support and survival among African-American end-stage renal disease patients. Holder B. **Adv Ren Replace Ther** 1997 Jan;4(1):13–21 (33 ref.)

Psychosocial problem assessment and end-stage renal disease patient outcomes. Vourlekis BS, et al. **Adv Ren Replace Ther** 1997 Apr;4(2):136–44 (18 ref.)

Lessons from psychosocial studies of chronic renal failure. Postlethwaite RJ, et al. **Arch Dis Child** 1996 Nov; 75(5):455–9 (26 ref.)

A review of health-related quality-of-life measures used in end-stage renal disease. Edgell ET, et al. **Clin Ther** 1996 Sep-Oct;18(5):887–938 (129 ref.)

RADIOGRAPHY

[Metastatic pulmonary calcification as a rare complication of terminal kidney failure: the x-ray and CT findings] Reuter M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Nov;165(5):493–5 (13 ref.) **(Ger)**

REHABILITATION

Meaningful rehabilitation of the end-stage renal disease patient. Thornton TA, et al. **Semin Nephrol** 1997 May; 17(3):246–52 (20 ref.)

[Chronic renal failure in childhood] Michalk DV. **Z Arztl Fortbild Qualitatssich** 1997 Jun;91(3):227–32 (11 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Growth hormone treatment in children before and after renal transplantation. Hokken-Koelega AC. **J Pediatr Endocrinol Metab** 1996 Jun;9 Suppl 3:359–64 (41 ref.)

Surgery for renal hyperparathyroidism--experience of 640 cases. Takagi H, et al. **Nagoya J Med Sci** 1997 Mar; 60(1–2):15–22 (32 ref.)

Renal transplantation in the older end stage renal disease patient. Becker BN, et al. **Semin Nephrol** 1996 Jul; 16(4):353–62 (61 ref.)

Preoperative evaluation and intraoperative management of patients with chronic renal failure undergoing vascular procedures. Morrison DE. **Semin Vasc Surg** 1996 Sep; 9(3):166–71 (16 ref.)

[Surgery in chronically dialysed kidney failure patients] **Prog Urol** 1996 Oct;6(5):687–712 (147 ref.) **(Fre)**

[Surgical aspects of chronic kidney failure and transplantation. The donor] **Prog Urol** 1996 Oct;6(5):713–52 (370 ref.) **(Fre)**

[Surgical aspects of chronic kidney failure and transplantation. Transplantation] **Prog Urol** 1996 Oct; 6(5):753–69 (88 ref.) **(Fre)**

[Kidney transplantation. Indications, results, pre- and postoperative care] Brunkhorst R, et al. **Internist (Berl)** 1996 Mar;37(3):264–71 (13 ref.) **(Ger)**

[Kidney transplantation in the child] Leumann E. **Schweiz Med Wochenschr** 1997 Jun 14;127(24):1039–43 (12 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Adequacy of treatment for end-stage renal disease in the United States. Lundin AP, et al. **Adv Intern Med** 1996; 41:323–63 (94 ref.)

The hemodialysis patient: object of diagnosis or part of the treatment team? Burnell MS. **Adv Ren Replace Ther** 1997 Apr;4(2):145–51 (22 ref.)

Grams to milliequivalents: a concise guide to adjusting hemodialysate composition. Carlsen DB, et al. **Adv Ren Replace Ther** 1996 Jul;3(3):261–5 (2 ref.)

Dialysis prescription and kinetics in acute renal failure. Clark WR, et al. **Adv Ren Replace Ther** 1997 Apr;4(2 Suppl 1):64–71 (44 ref.)

Withdrawal from dialysis: a review with an emphasis on the black experience. Leggat JE Jr, et al. **Adv Ren Replace Ther** 1997 Jan;4(1):22–9 (44 ref.)

Making decisions about end-stage renal disease treatment: a review of theories and issues. Pfettscher SA. **Adv Ren Replace Ther** 1997 Jan;4(1):81–8 (62 ref.)

African-Americans on maintenance dialysis: a review of racial differences in incidence, treatment, and survival. Price DA, et al. **Adv Ren Replace Ther** 1997 Jan;4(1):3–12 (42 ref.)

Maintenance of employment on dialysis. Rasgon S, et al. **Adv Ren Replace Ther** 1997 Apr;4(2):152–9 (26 ref.)

Use of the medical differential diagnosis to achieve optimal end-stage renal disease outcomes. Rodriguez RA. **Adv Ren Replace Ther** 1997 Apr;4(2):97–111 (102 ref.)

Use of bioelectrical impedance analysis measurements in the clinical management of patients undergoing dialysis. Kushner RF, et al. **Am J Clin Nutr** 1996 Sep;64(3 Suppl):503S–509S (58 ref.)

Bowel as a kidney substitute in renal failure. Friedman EA. **Am J Kidney Dis** 1996 Dec;28(6):943–50 (68 ref.)

Clinical outcome relative to the dose of dialysis is not what you think: the fallacy of the mean [editorial] Gotch FA, et al. **Am J Kidney Dis** 1997 Jul;30(1):1–15 (32 ref.)

Tumoral calcinosis in patients on hemodialysis. Case report and review of the literature. Pečovnik-Balon B, et al. **Am J Nephrol** 1997;17(1):93–5 (16 ref.)

Automated peritoneal dialysis: new implications for pharmacists. Brophy DF, et al. **Ann Pharmacother** 1997 Jun;31(6):756–64 (47 ref.)

Acute renal failure: role of dialysis membrane biocompatibility. Pascual M, et al. **Annu Rev Med** 1997; 48:467–76 (39 ref.)

Peritoneal dialysis for patients with diabetes and end-stage renal disease: sorting out the biases? [editorial] Finkelstein FO, et al. **ASAIO J** 1996 Jan-Feb;42(1):1–3 (24 ref.)

ESRD modality selection into the 21st century: the importance of non medical factors. Nissenson AR, et al. **ASAIO J** 1997 May-Jun;43(3):143–50 (25 ref.)

Use of intraperitoneal pressure, ultrafiltration and purification dwell times for individual peritoneal dialysis prescription in children. Fischbach M, et al. **Clin Nephrol** 1996 Jul; 46(1):14–6 (11 ref.)

Screening for cardiovascular disease in dialysis patients. Murphy SW, et al. **Curr Opin Nephrol Hypertens** 1996 Nov; 5(6):532–40 (76 ref.)

Do potassium deficient diets and K+ removal by dialysis contribute to the cardiovascular morbidity and mortality of patients with end stage renal disease? [editorial] Dolson GM. **Int J Artif Organs** 1997 Mar;20(3):134–5 (15 ref.)

Making long-term peritoneal dialysis possible [editorial] Dombros NV, et al. **Int J Artif Organs** 1997 Mar; 20(3):129–33 (24 ref.)

Peritoneal dialysis access [editorial] Eklund BH. **Int J Artif Organs** 1996 Jul;19(7):381–3 (30 ref.)

The concept of "dry weight" in maintenance hemodialysis: flaws in clinical application [editorial] Ifudu O. **Int J Artif Organs** 1996 Jul;19(7):384–6 (22 ref.)

Recovery from "end-stage" renal disease [editorial] Quérin S. **Int J Artif Organs** 1996 May;19(5):263–4 (17 ref.)

Upper extremity musculoskeletal manifestations of dialysis-associated amyloidosis. Fitzpatrick DC, et al. **Iowa Orthop J** 1996;16:135–8 (28 ref.)

Diagnosis and management of coronary artery disease in patients with end-stage renal disease on hemodialysis. de Lemos JA, et al. **J Am Soc Nephrol** 1996 Oct;7(10):2044–54 (96 ref.)

Kidney disease: jade, dialysis or transplantation? [editorial] Barakat AJ. **J Med Liban** 1996;44(4):184–6 (5 ref.)

Progressive renal failure. el Nahas AM, et al. **J R Coll Physicians Lond** 1997 Jan-Feb;31(1):27–31 (33 ref.)

Management of oxalosis. Broyer M, et al. **Kidney Int Suppl** 1996 Jan;53:S93–8 (29 ref.)

Residual renal function, peritoneal transport characteristics and dialysis adequacy in peritoneal dialysis. Heimbürger O. **Kidney Int Suppl** 1996 Nov;56:S47–55 (111 ref.)

Testing for growth hormone release is not necessary prior to treatment of children with chronic renal insufficiency with recombinant human growth hormone. Kohaut EC, et al. **Kidney Int Suppl** 1996 Jan;53:S119–22 (26 ref.)

Skeletal response to intermittent calcitriol therapy in secondary hyperparathyroidism. Salusky IB, et al. **Kidney Int Suppl** 1996 Jan;53:S135–9 (45 ref.)

Nondialysis management of chronic renal failure. Malhotra D, et al. **Med Clin North Am** 1997 May;81(3):749–66 (66 ref.)

beta 2-microglobulin and amyloidosis: who is at risk? Davison AM. **Nephrol Dial Transplant** 1995;10 Suppl 10:48–51 (22 ref.)

The costs of dialysis in the USA. Garella S. **Nephrol Dial Transplant** 1997;12 Suppl 1:10–21 (44 ref.)

Renal replacement therapy in the elderly: an old problem with young solutions [editorial] Ismail N. **Nephrol Dial Transplant** 1997 May;12(5):873–6 (31 ref.)

The costs of dialysis treatments for patients with end-stage renal disease in France. Jacobs C. **Nephrol Dial Transplant** 1997;12 Suppl 1:29–32 (5 ref.)

New indicators to evaluate bacteriological quality of the dialysis fluid and the associated inflammatory response in ESRD patients. Krautzig S, et al. **Nephrol Dial Transplant** 1996;11 Suppl 2:87–91 (29 ref.)

The costs of renal services in Britain. Mallick NP. **Nephrol Dial Transplant** 1997;12 Suppl 1:25–8 (0 ref.)

Growth hormone treatment of short children with chronic renal failure before and after renal transplantation: rationale and recent results. Mehls O, et al. **Nephrol Dial Transplant** 1996 Sep;11(9):1747–50 (39 ref.)

The costs of dialysis in Canada. Prichard SS. **Nephrol Dial Transplant** 1997;12 Suppl 1:22–4 (2 ref.)

Should hyperlipidaemia in dialysis patients be treated? [editorial] Wheeler DC. **Nephrol Dial Transplant** 1997 Jan; 12(1):19–21 (10 ref.)

Nonocclusive mesenteric infarction in continuous ambulatory peritoneal dialysis. Korzets Z, et al. **Nephron** 1996; 74(2):415–8 (15 ref.)

Long-term outcomes of peritoneal dialysis. Cancarini GC, et al. **Perit Dial Int** 1997;17 Suppl 2:S115–8 (16 ref.)

Erythropoietin 1997: a brief update. Gahl GM, et al. **Perit Dial Int** 1997;17 Suppl 2:S84–90 (75 ref.)

Peritoneal dialysis is a real clinical option. Giangrande AC, et al. **Perit Dial Int** 1997;17 Suppl 2:S149–54 (25 ref.)

The impact of residual renal function on the adequacy of peritoneal dialysis. Lameire N, et al. **Perit Dial Int** 1997; 17 Suppl 2:S102–10 (73 ref.)

Plasticizers in renal failure: aspects of metabolism and toxicity. Mettang T, et al. **Perit Dial Int** 1997;17 Suppl 2:S31–6 (34 ref.)

Factors affecting peritoneal efficiency in different treatment schedules. Nolph KD. **Perit Dial Int** 1997;17 Suppl 2:S98–101 (19 ref.)

Integration of peritoneal dialysis in active uremia treatment. Ronco C, et al. **Perit Dial Int** 1997;17 Suppl 2:S155–60 (9 ref.)

End-stage renal disease. Measures to prevent it or slow its progression [published erratum appears in Postgrad Med 1997 Jul;102(1):36] Hood VL, et al. **Postgrad Med** 1996 Nov;100(5):163–6, 171–6 (26 ref.)

Tumoral calcinosis in hemodialysis patients. A review of three cases. Franco M, et al. **Rev Rhum Engl Ed** 1997 Jan; 64(1):59–62 (19 ref.)

Options for renal replacement therapy: special considerations. Becker BN, et al. **Semin Nephrol** 1997 May;17(3):176–87 (71 ref.)

Optimizing the treatment of the dialysis patient: a painful lesson. Depner TA. **Semin Nephrol** 1997 Jul;17(4):285–97 (103 ref.)

Optimizing end-stage renal disease therapy for the patient with diabetes mellitus. Friedlander MA, et al. **Semin Nephrol** 1997 Jul;17(4):331–45 (107 ref.)

A 1990s perspective of hepatitis C, human immunodeficiency virus, and tuberculosis infections in dialysis patients. Murthy BV, et al. **Semin Nephrol** 1997 Jul;17(4):346–63 (185 ref.)

End-stage renal disease. Parker T, et al. **Semin Nephrol** 1997 Jul;17(4):253–6 (0 ref.)

End-stage renal disease: a proving ground for quality improvement in health care. Rutherford WE, et al. **Semin Nephrol** 1997 May;17(3):218–25 (28 ref.)

The dialysis facility of the future: the financial and social environment. Steinman TI. **Semin Nephrol** 1997 Jul; 17(4):298–305 (24 ref.)

Parathyroid carcinoma in patients with chronic renal failure on maintenance hemodialysis. Miki H, et al. **Surgery** 1996 Nov;120(5):897–901 (10 ref.)

[Treatment of chronic renal insufficiency] Saha H, et al. **Duodecim** 1995;111(15):1479–87 (32 ref.) **(Fin)**

[Active treatment of renal disease in Finland] Stenman S, et al. **Duodecim** 1995;111(15):1497–504 (17 ref.) **(Fin)**

[Progress in diagnosis and treatment of kidney diseases. V. Renal failure and kidney transplantation. 2. chronic renal failure] Horio M, et al. **Nippon Naika Gakkai Zasshi** 1996 Oct 10;85(10):1717–22 (5 ref.) **(Jpn)**

[Hemodialysis] Maeda K. **Nippon Naika Gakkai Zasshi** 1997 Mar 10;86(3):506–9 (3 ref.) **(Jpn)**

[Chronic renal failure] Mochizuki T, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):80–4 (16 ref.) **(Jpn)**

[Viral hepatitis type B and C in patients with chronic renal failure treated with dialysis] Niemczyk S. **Pol Arch Med Wewn** 1996 Nov;96(5):484–9 (37 ref.) **(Pol)**

[Peritoneum as a dialysis membrane. II. Pathology] Grzybowski A, et al. **Przegl Lek** 1997;54(1):52–61 (114 ref.) (Eng. Abstr.) **(Pol)**

[Aluminum toxicity in patients with chronic renal failure] Wanic-Kossowska M, et al. **Przegl Lek** 1995;52(12):603–5 (32 ref.) **(Pol)**

[Cardiovascular system function in patients with chronic kidney failure on hemodialysis] Rzhevskaia ON, et al. **Urol Nefrol (Mosk)** 1997 Mar-Apr;(2):45–51 (159 ref.) **(Rus)**

[Prescription of hemodialysis in patients with chronic renal insufficiency] **Gac Med Mex** 1994 Jul-Aug;130(4):269–71 (0 ref.) **(Spa)**

[Replacement treatment of chronic renal insufficiency. Current perspectives (editorial)] Ortuño Mirete J. **Rev Clin Esp** 1997 May;197(5):306–16 (97 ref.) **(Spa)**

VETERINARY

Does modifying dietary lipids influence the progression of renal failure? Brown SA, et al. **Vet Clin North Am Small Anim Pract** 1996 Nov; 26(6):1277–85 (26 ref.)

What role does dietary protein restriction play in the management of chronic renal failure in dogs? Devaux C, et al. **Vet Clin North Am Small Anim Pract** 1996 Nov; 26(6):1247–67 (44 ref.)

Prevention of acute renal failure. Grauer GF. **Vet Clin North Am Small Anim Pract** 1996 Nov; 26(6):1447–59 (88 ref.)

Benefits of calcitriol therapy and serum phosphorus control in dogs and cats with chronic renal failure. Both are essential to prevent of suppress toxic hyperparathyroidism. Nagode LA, et al. **Vet Clin North Am Small Anim Pract** 1996 Nov; 26(6):1293–330 (236 ref.)

Diet therapy guidelines for cats with chronic renal failure. Polzin DJ, et al. **Vet Clin North Am Small Anim Pract** 1996 Nov;26(6):1269–75 (24 ref.)

Pathophysiology and management of progressive renal disease. Brown SA, et al. **Vet J** 1997 Sep;154(2):93–109 (97 ref.)

KIDNEY FUNCTION TESTS

Replacing renal function with gastrointestinal nitrogen extraction [editorial] Friedman EA. **ASAIO J** 1996 Nov-Dec;42(6):929–31 (35 ref.)

Predictive ability of creatinine clearance estimate models in pediatric bone marrow transplant patients. Jacobson P, et al. **Bone Marrow Transplant** 1997 Mar;19(5):481–5 (15 ref.)

Recovery from "end-stage" renal disease [editorial] Quérin S. **Int J Artif Organs** 1996 May;19(5):263–4 (17 ref.)

MR imaging of renal function. Bennett HF, et al. **Magn Reson Imaging Clin N Am** 1997 Feb;5(1):107–26 (58 ref.)

[Normal kidney function and acute and chronic kidney function disorders] Kallerhoff M. **Urologe A** 1996 Jul; 35(4):345–54 (13 ref.) **(Ger)**

METHODS

Review article: the quantification of renal function with enhanced computed tomography. Blomley MJ, et al. **Br J Radiol** 1996 Nov;69(827):989–95 (40 ref.)

[Renal acidification test] Akakura K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:631–3 (10 ref.) **(Jpn)**

[Selectivity index] Kakuta S, et al. **Nippon Rinsho** 1997 Apr; 55 Suppl 2:610–3 (8 ref.) **(Jpn)**

[Indigocarmine test] Kawabe K. **Nippon Rinsho** 1997 Apr;55 Suppl 2:608–9 (1 ref.) **(Jpn)**

[Phenolsulfonphthalein test] Kimura M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:605–7 (3 ref.) **(Jpn)**

[The measurement of renal plasma flow] Nagai T. **Nippon Rinsho** 1997 Apr;55 Suppl 2:597–600 (6 ref.) **(Jpn)**

[Evaluation of renal function by SPECT] Nakagawa T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:638–41 (7 ref.) **(Jpn)**

[Concentration test and dilution test] Ogawa Y, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:614–6 (3 ref.) **(Jpn)**

[beta 2-microglobulin clearance] Okubo M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:620–3 (9 ref.) **(Jpn)**

[Osmolar clearance] Yonemura K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:617–9 (5 ref.) **(Jpn)**

STATISTICS & NUMERICAL DATA

[The kidneys in aging] Niederstadt C, et al. **Z Gerontol Geriatr** 1997 May-Jun;30(3):200–7 (44 ref.) (Eng. Abstr.) **(Ger)**

KIDNEY GLOMERULUS

see related
GLOMERULAR FILTRATION RATE
RENAL BLOOD FLOW, EFFECTIVE
RENAL PLASMA FLOW, EFFECTIVE

Gene transfer into the glomerulus by the hemagglutinating virus of Japan-liposome method. Imai E, et al. **Exp Nephrol** 1997 Mar-Apr;5(2):112–7 (30 ref.)

Lipoprotein glomerulopathy: a new role for apolipoprotein E? [editorial; comment] Karet FE, et al. **J Am Soc Nephrol** 1997 May;8(5):840–2 (21 ref.) Comment on: J Am Soc Nephrol 1997 May;8(5):820–3.

Structural and functional changes in diabetic glomerulopathy. Schleicher E, et al. **Kidney Blood Press Res** 1996; 19(5):305–15 (54 ref.)

Diagnosis and management of glomerular diseases. Jennette JC, et al. **Med Clin North Am** 1997 May;81(3):653–77 (87 ref.)

ABNORMALITIES

[Congenital glomerulosclerosis] Yokota N, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):171–4 (7 ref.) **(Jpn)**

BLOOD SUPPLY

Haemodynamically mediated glomerular injury: the end of a 15-year-old controversy? Zatz R.

Curr Opin Nephrol Hypertens 1996 Nov;5(6):468–75 (81 ref.)

Significance of postglomerular capillaries in the pathogenesis of chronic renal failure. Bohle A, et al. **Kidney Blood Press Res** 1996;19(3–4):191–5 (30 ref.)

[Selective permeability of the glomerular filtration barrier in man] Petitjean P, et al. **Nephrologie** 1996;17(2):113–6 (9 ref.) (Eng. Abstr.) **(Fre)**

CYTOLOGY

Biology of glomerular cells in culture. Ardaillou R. **Cell Biol Toxicol** 1996 Dec;12(4–6):257–61 (6 ref.)

Isolated glomeruli and cultured mesangial cells as in vitro models to study immunosuppressive agents. Potier M, et al. **Cell Biol Toxicol** 1996 Dec;12(4–6):263–70 (36 ref.)

Cell culture of podocytes. Mundel P, et al. **Exp Nephrol** 1996 Sep–Oct;4(5):263–6 (36 ref.)

Cell biology of kidney glomerulus. Ohno S, et al. **Int Rev Cytol** 1996;166:181–230 (163 ref.)

New aspects of podocyte cell biology. Mundel P, et al. **Kidney Blood Press Res** 1997;20(3):173–6 (20 ref.)

Assessment of podocyte function. Pavenstädt H. **Kidney Blood Press Res** 1997;20(3):177–9 (14 ref.)

DRUG EFFECTS

Isolated glomeruli and cultured mesangial cells as in vitro models to study immunosuppressive agents. Potier M, et al. **Cell Biol Toxicol** 1996 Dec;12(4–6):263–70 (36 ref.)

Impact of renin–angiotensin system blockade on structure and function of glomerular membrane components in animal models of kidney disease. Remuzzi A, et al. **Exp Nephrol** 1996;4 Suppl 1:27–33 (57 ref.)

Treatment of hypertension. Fogo A, et al. **Semin Nephrol** 1996 Nov;16(6):555–66 (114 ref.)

Dietary L–arginine in renal disease. Peters H, et al. **Semin Nephrol** 1996 Nov;16(6):567–75 (64 ref.)

IMMUNOLOGY

Anti–GBM antibodies in Goodpasture syndrome; anatomy of an epitope [editorial] Hellmark T, et al. **Nephrol Dial Transplant** 1997 Apr;12(4):646–8 (10 ref.)

INJURIES

Transforming growth factor–beta in human glomerular injury. Peters H, et al. **Curr Opin Nephrol Hypertens** 1997 Jul;6(4):389–93 (27 ref.)

METABOLISM

Lipoxins: putative braking signals in host defense, inflammation and hypersensitivity. Brady HR, et al. **Curr Opin Nephrol Hypertens** 1996 Jan;5(1):20–7 (57 ref.)

Gene delivery into the glomerulus via mesangial cell vectors. Kitamura M. **Exp Nephrol** 1997 Mar–Apr;5(2):118–25 (40 ref.)

Complement synthesis in the injured kidney: does it have a role in immune complex glomerulonephritis? [comment] Sacks SH, et al. **J Am Soc Nephrol** 1996 Nov;7(11):2314–9 (56 ref.) Comment on: J Am Soc Nephrol 1996 Nov;7(11):2428–33.

Role of chemokines in glomerular diseases. Banas B, et al. **Kidney Blood Press Res** 1996;19(5):270–80 (89 ref.)

Stability and leakiness: opposing challenges to the glomerulus. Kriz W, et al. **Kidney Int** 1996 Jun;49(6):1570–4 (31 ref.)

The glomerular basement membrane charge–selectivity barrier: an oversimplified concept? [editorial] Goode NP, et al. **Nephrol Dial Transplant** 1996 Sep;11(9):1714–6 (24 ref.)

[Lipoprotein glomerulopathy] Watanabe T, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):219–22 (19 ref.) **(Jpn)**

PATHOLOGY

Glomerular changes in normo– and microalbuminuric patients with long–standing insulin–dependent diabetes mellitus. Fioretto P, et al. **Adv Nephrol Necker Hosp** 1997;26:247–63 (60 ref.)

Experimental glomerulosclerosis: Defektheilung of the kidney. Schiller B, et al. **Artif Organs** 1996 May;20(5):445–50 (50 ref.)

Isoprenoids, Ras and proliferative glomerular disease. O'Donnell MP, et al. **Contrib Nephrol** 1997;120:219–27 (35 ref.)

Role of complement in glomerular injury. Feucht HE. **Kidney Blood Press Res** 1996;19(5):290–9 (77 ref.)

Role of angiotensin II in glomerular injury: lessons from experimental and clinical studies. Hilgers KF, et al. **Kidney Blood Press Res** 1996;19(5):254–62 (112 ref.)

A frequent pathway to glomerulosclerosis: deterioration of tuft architecture–podocyte damage–segmental sclerosis. Kriz W, et al. **Kidney Blood Press Res** 1996;19(5):245–53 (33 ref.)

Evolving role of the podocyte in chronic renal failure. Kriz W. **Kidney Blood Press Res** 1997;20(3):180–3 (21 ref.)

T cell involvement in glomerular injury. Merkel F, et al. **Kidney Blood Press Res** 1996;19(5):298–304 (69 ref.)

Cytokines and glomerular injury. Ostendorf T, et al. **Kidney Blood Press Res** 1996;19(5):281–9 (138 ref.)

Reactive oxygen species and glomerular injury. Rohrmoser MM, et al. **Kidney Blood Press Res** 1996;19(5):263–9 (82 ref.)

Mechanism of fluid secretion common to aglomerular and glomerular kidneys. Beyenbach KW, et al. **Kidney Int** 1996 Jun;49(6):1543–8 (9 ref.)

Phenotypic modulation of renal cells during experimental and clinical renal scarring. el Nahas AM, et al. **Kidney Int Suppl** 1996 May;54:S23–7 (52 ref.)

Glomerular involvement in type II diabetes – is it all diabetic glomerulosclerosis? [editorial] Cordonnier D. **Nephrol Dial Transplant** 1996 Jun;11(6):936–8 (18 ref.)

Hereditary disorders of the glomerular basement membrane. Smeets HJ, et al. **Pediatr Nephrol** 1996 Dec;10(6):779–88 (101 ref.)

A renal biopsy in essential for the management of ANCA–positive patients with glomerulonephritis. Falk RJ, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct;13(3):230–1 (13 ref.)

A renal biopsy is essential for the management of ANCA–positive patients with glomerulonephritis: the contra–view. Niles JL. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct;13(3):232–4 (10 ref.)

Newer glomerular diseases. Abt AB, et al. **Semin Nephrol** 1996 Nov;16(6):501–10 (51 ref.)

Clinical and pathological course of renal disease in non–insulin–dependent diabetes mellitus: the Pima Indian experience. Nelson RG, et al. **Semin Nephrol** 1997 Mar;17(2):124–31 (33 ref.)

[Fibrillary glomerulopathy. Amyloidosis and non–amyloidosis] Wullbrand A, et al. **Dtsch Med Wochenschr** 1997 Mar 7;122(10):302–8 (71 ref.) **(Ger)**

[Glomerulocystic kidney] Kanozawa K, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):154–7 (17 ref.) **(Jpn)**

[Glomerular lipidosis] Kasahara N, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):162–6 (14 ref.) **(Jpn)**

[Glomerular fibrosis] Kitazawa K, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):150–3 (2 ref.) **(Jpn)**

[Glomerular capillary endotheliosis] Monma N, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):144–6 (13 ref.) **(Jpn)**

[Benign familial hematuria (thin basement membrane disease)] Nagasawa T, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):223–6 (13 ref.) **(Jpn)**

[Renal diseases with glomerular hypertrophy] Okada K. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):158–61 (18 ref.) **(Jpn)**

PHYSIOLOGY

Biology of glomerular cells in culture. Ardaillou R. **Cell Biol Toxicol** 1996 Dec;12(4–6):257–61 (6 ref.)

Extracellular ATP regulates glomerular endothelial cell function. Pavenstädt H, et al. **J Auton Pharmacol** 1996 Dec;16(6):389–91 (20 ref.)

Assessment of podocyte function. Pavenstädt H. **Kidney Blood Press Res** 1997;20(3):177–9 (14 ref.)

Mechanism of fluid secretion common to aglomerular and glomerular kidneys. Beyenbach KW, et al. **Kidney Int** 1996 Jun;49(6):1543–8 (9 ref.)

Roles of the mesangium in glomerular function. Schlöndorff D. **Kidney Int** 1996 Jun;49(6):1583–5 (28 ref.)

Integrin receptors, the cytoskeleton, and glomerular cell function. Schnaper HW. **Pediatr Nephrol** 1996 Aug;10(4):523–8 (11 ref.)

Controversies on glomerular filtration from Ludwig to the present. Steinhausen M, et al. **Pflugers Arch** 1996;432(3 Suppl):R73–81 (79 ref.)

The aging glomerulus. Baylis C, et al. **Semin Nephrol** 1996 Jul;16(4):265–76 (106 ref.)

PHYSIOPATHOLOGY

Proteinuria as a consequence of altered glomerular permselectivity—clinical implications. Oberbauer R, et al. **Clin Nephrol** 1996 Dec;46(6):357–61 (29 ref.)

Evolving role of the podocyte in chronic renal failure. Kriz W. **Kidney Blood Press Res** 1997;20(3):180–3 (21 ref.)

Potential role of lipids in the progression of glomerular diseases. Olbricht CJ. **Kidney Blood Press Res** 1997;20(3):188–9 (27 ref.)

Glomerular hemodynamics in acute renal failure. Boim MA, et al. **Ren Fail** 1997 Mar;19(2):209–12 (17 ref.)

Inhibiting inflammatory cytokines. Kluth DC, et al. **Semin Nephrol** 1996 Nov;16(6):576–82 (60 ref.)

KIDNEY INSUFFICIENCY see **KIDNEY FAILURE**

KIDNEY INSUFFICIENCY, ACUTE see **KIDNEY FAILURE, ACUTE**

KIDNEY INSUFFICIENCY, CHRONIC see **KIDNEY FAILURE, CHRONIC**

KIDNEY MEDULLA

[Renomedullary interstitial cell tumor, renal medullary fibroma] Nonomura A. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):495–7 (10 ref.) **(Jpn)**

ABNORMALITIES

[Unipapillary kidney, multipapillary kidney] Kawamura T. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):396 (5 ref.) **(Jpn)**

CYTOLOGY

Kidney cell survival in high tonicity. Handler JS, et al. **Comp Biochem Physiol A Physiol** 1997 Jul;117(3):301–6 (54 ref.)

METABOLISM

Kidney cell survival in high tonicity. Handler JS, et al. **Comp Biochem Physiol A Physiol** 1997 Jul;117(3):301–6 (54 ref.)

Regulation of the myo–inositol and betaine cotransporters by tonicity. Handler JS, et al. **Kidney Int** 1996 Jun;49(6):1682–3 (21 ref.)

Active urea transport in the rat inner medullary collecting duct: functional characterization and initial expression cloning. Sands JM, et al. **Kidney Int** 1996 Jun;49(6):1611–4 (41 ref.)

PHYSIOLOGY

Role of the renal medulla in volume and arterial pressure regulation. Cowley AW Jr. **Am J Physiol** 1997 Jul;273(1 Pt 2):R1–15 (109 ref.)

Urea transporters in kidney and erythrocytes. Sands JM, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):F321–39 (163 ref.)

Osmoregulation in the renal papilla: membranes, messengers and molecules. Kinne RK, et al. **Kidney Int** 1996 Jun;49(6):1686–9 (29 ref.)

Current concepts of the countercurrent multiplication system. Sands JM, et al. **Kidney Int Suppl** 1996 Dec;57:S93–9 (109 ref.)

The mechanism of urine concentration in the inner medulla. Oh MS, et al. **Nephron** 1997;75(4):384–93 (27 ref.)

PHYSIOPATHOLOGY

The role of the papilla in idiopathic calcium oxalate nephrolithiasis. Krautschick A, et al. **World J Urol** 1997;15(4):213–8 (59 ref.)

SECRETION

Evidence for a renomedullary vasodepressor hormone. Thomas CJ, et al. **Clin Exp Pharmacol Physiol** 1996 Sep;23(9):777–85 (69 ref.)

KIDNEY NEOPLASMS

Renal cell carcinoma after therapy for neuroblastoma. Donnelly LF, et al. **AJR Am J Roentgenol** 1996 Oct;167(4):915–7 (8 ref.)

Renal cell carcinoma. Savage PD. **Curr Opin Oncol** 1996 May;8(3):247–51 (53 ref.)

Renal cell carcinoma. Motzer RJ, et al. **Curr Probl Cancer** 1997 Jul–Aug;21(4):185–232 (254 ref.)

Two synchronous primary tumors of the ovary and kidney: a case report. Balat O, et al. **Eur J Gynaecol Oncol** 1996;17(4):257–9 (9 ref.)

Renal cell carcinoma—diagnosis and treatment: state of the art. Bono AV, et al. **Eur Urol** 1997;31 Suppl 1:47–55 (46 ref.)

Wilms' tumor in an adult: a case report and review of the literature. Butler D, et al. **J Ky Med Assoc** 1997 May;95(5):191–6 (23 ref.)

Current issues in the diagnosis and management of Wilms' tumor. Paulino AC. **Oncology (Huntingt)** 1996 Oct;10(10):1553–65; discussion 1565–71 (90 ref.)

Primary carcinoid of the kidney. Sahin A, et al. **Scand J Urol Nephrol** 1996 Aug;30(4):325–7 (9 ref.)

Role of surgery in patients with metastatic renal cell carcinoma. Flanigan RC. **Semin Urol Oncol** 1996 Nov;14(4):227–9 (18 ref.)

Renal cell carcinoma: basic biology and clinical behavior. Franklin JR, et al. **Semin Urol Oncol** 1996 Nov;14(4):208–15 (64 ref.)

Primary renal lymphoma. Case report and review of the literature. Saito S. **Urol Int** 1996;56(3):192–5 (17 ref.)

Primary osteosarcoma of the spermatic cord with synchronous bilateral renal cell carcinoma. Beiswanger JC, et al. **Urology** 1997 Jun;49(6):957–9 (14 ref.)

[Renal pelvic tumor (transitional cell carcinoma, squamous cell carcinoma, adenocarcinoma, etc.)] Matsuki K, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):466–70 (15 ref.) **(Jpn)**

[Renal oncocytoma] Nakamura H. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):471–3 (15 ref.) **(Jpn)**

[WAGR syndrome] Teraoka M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):227–8 (14 ref.) **(Jpn)**

[Renal leiomyoma and renal leiomyosarcoma] Uozumi J, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):501–4 (17 ref.) **(Jpn)**

[Nephroblastoma] Yokomori K. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):474–7 (16 ref.) **(Jpn)**

[Synchronous multiple renal carcinoma. Review of the literature and report of a new case] Borrego Hernando J, et al. **Arch Esp Urol** 1996 Sep;49(7):760–3 (20 ref.) (Eng.

Abstr.) **(Spa)**

[Hemangiopericytoma of the renal sinus. Report of a case and review of the literature] Carcamo Valor P, et al. **Arch Esp Urol** 1996 Nov;49(9):944–9 (25 ref.) (Eng. Abstr.) **(Spa)**

[Inverted carcinoma of kidney pelvis coexisting with transitional cell carcinoma of the bladder. A therapeutic alternative] Díaz Calleja E, et al. **Arch Esp Urol** 1997 Mar; 50(2):189–92 (9 ref.) (Eng. Abstr.) **(Spa)**

[Chronic myelomonocytic leukemia and renal carcinoma: a rare association (letter)] Fernández-Escribano M, et al. **Sangre (Barc)** 1997 Feb;42(1):88–9 (5 ref.) **(Spa)**

BLOOD

[Sedimentation rate and renal cancer] Iversen OH, et al. **Tidsskr Nor Laegeforen** 1997 Jun 30;117(17):2493–6 (8 ref.) (Eng. Abstr.) **(Nor)**

BLOOD SUPPLY

[Correlation of neovascularization and vascular endothelial growth factor in human renal cell carcinoma] Sato K, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(4):389–94 (17 ref.) (Eng. Abstr.) **(Jpn)**

CHEMICALLY INDUCED

Carcinogenicity and kinetic aspects of ochratoxin A. Schlatter C, et al. **Food Addit Contam** 1996;13 Suppl:43–4 (6 ref.)

d-limonene mechanistic data and risk assessment: absolute species-specific cytotoxicity, enhanced cell proliferation, and tumor promotion. Whysner J, et al. **Pharmacol Ther** 1996;71(1–2):127–36 (44 ref.)

Poly(ADP-ribosyl)ation and nuclear matrix/intermediate filament proteins in renal carcinogenesis. Vamvakas S, et al. **Recent Results Cancer Res** 1997;143:195–208 (60 ref.)

COMPLICATIONS

Wilms' tumour presenting as a pulmonary embolism. Ceelen W, et al. **Acta Chir Belg** 1997 Jun;97(3):148–50 (12 ref.)

Bilateral renal cell carcinoma in autosomal dominant polycystic kidney disease. A case report and literature review. Soderdahl DW, et al. **Am J Nephrol** 1997; 17(1):96–9 (24 ref.)

Prognostic relevance of intracaval neoplastic extension for patients with renal cell cancer. Kuczyk MA, et al. **Br J Urol** 1997 Jul;80(1):18–24 (27 ref.)

Wilms tumor associated with polycythemia: case report and review of the literature. Lal A, et al. **J Pediatr Hematol Oncol** 1997 May-Jun;19(3):263–5 (19 ref.)

Xanthogranulomatous pyelonephritis associated with transitional cell carcinoma of the renal pelvis. Val-Bernal JF, et al. **Urol Int** 1996;57(4):240–5 (34 ref.)

Local recurrence of renal cell carcinoma causing duodenal-inferior vena caval fistula: case report and review of the literature. Benjamin DS, et al. **Urology** 1996 Oct; 48(4):636–8 (16 ref.)

[Adenocarcinoma of the kidney associated with polycystic kidney treated by conservative surgery (apropos of a case)] el Khader K, et al. **Prog Urol** 1997 Jun;7(3):464–7 (20 ref.) (Eng. Abstr.) **(Fre)**

[Renal angiolipoma associated with bilateral double ureter. A clinical case] Verna C, et al. **Minerva Urol Nefrol** 1997 Mar;49(1):39–44 (28 ref.) (Eng. Abstr.) **(Ita)**

[Bilateral renal cell carcinoma with extension into the vena cava associated with von Hippel-Lindau disease: a case report and review of the literature] Minamide M, et al. **Hinyokika Kiyo** 1996 May;42(5):361–4 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Renal angiomyolipoma and renal cell carcinoma associated with tuberous sclerosis: a case report] Sugimoto M, et al. **Hinyokika Kiyo** 1997 Jan;43(1):33–5 (14 ref.) (Eng. Abstr.) **(Jpn)**

[A case of renal cell carcinoma presenting as spontaneous renal rupture] Tsuji H, et al. **Hinyokika Kiyo** 1996 Jul; 42(7):517–20 (17 ref.) (Eng. Abstr.) **(Jpn)**

[A case of renal pelvic cancer associated with giant hydronephrosis of a horseshoe kidney] Tsuru N, et al. **Hinyokika Kiyo** 1997 Mar;43(3):223–6 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Renal cell carcinoma associated with renal artery aneurysm] Yazawa K, et al. **Hinyokika Kiyo** 1997 May;43(5):343–5 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Renal tumor with acquired cystic disease of the kidney] Tanabe N, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):459–62 (18 ref.) **(Jpn)**

[Embolism of the small branches of the pulmonary artery in x-ray endovascular occlusion of the renal vessels in cancer] Iurin AG. **Arkh Patol** 1996 Nov-Dec;58(6):62–4 (9 ref.) (Eng. Abstr.) **(Rus)**

[Dermatomyositis and small cell tumor of the kidney] Benages Pamies J, et al. **Actas Urol Esp** 1997 Jan; 21(1):67–70 (8 ref.) (Eng. Abstr.) **(Spa)**

[Unusual association of transitional cell carcinoma in the upper urinary tract, with contralateral renal metastasis and renal lithiasis of long clinical course] Cuesta Presedo JM, et al. **Actas Urol Esp** 1997 Jan;21(1):60–3 (15 ref.) (Eng. Abstr.) **(Spa)**

CONGENITAL

Atypical mesoblastic nephroma. A potentially malignant variant of congenital mesoblastic nephroma. Review of literature & report of four cases. Sane SY, et al. **Indian J Cancer** 1996 Mar;33(1):6–11 (26 ref.)

DIAGNOSIS

A primary carcinoid tumor of the kidney: a case report and review of the literature. Kurl S, et al. **Abdom Imaging** 1996 Sep-Oct;21(5):464–7 (24 ref.)

Endoscopic brush cytology of the upper urinary tract. Evaluation of its efficacy and potential limitations in diagnosis. Dodd LG, et al. **Acta Cytol** 1997 Mar-Apr; 41(2):377–84 (45 ref.)

Molecular differential diagnosis of renal carcinoma: from microscopes to microsatellites [comment] Steiner G, et al. **Am J Pathol** 1996 Dec;149(6):1791–5 (30 ref.) Comment on: Am J Pathol 1996 Dec;149(6):2081–8.

Primitive neuroectodermal tumor of the kidney confirmed by fluorescence in situ hybridization. Sheaff M, et al. **Am J Surg Pathol** 1997 Apr;21(4):461–8 (20 ref.)

Renal cell carcinoma: current prognostic factors. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Gelb AB. **Cancer** 1997 Sep 1;80(5):981–6 (68 ref.)

A case of renal cell carcinoma associated with synchronous contralateral renal pelvic cancer and bladder tumor. Ando M, et al. **Int J Urol** 1996 Jul;3(4):310–2 (8 ref.)

Small cell carcinoma of the kidney: case report. Kitamura M, et al. **Int J Urol** 1997 Jul;4(4):422–4 (13 ref.)

Acute cholecystitis or metastatic renal cell carcinoma? a diagnostic dilemma. Finkelstein LH, et al. **J Am Osteopath Assoc** 1996 May;96(5):314–5 (15 ref.)

Renal medullary carcinoma: a recently described highly aggressive renal tumor in young black patients. Herring JC, et al. **J Urol** 1997 Jun;157(6):2246–7 (2 ref.)

Re: Is contralateral exploration of the kidney necessary in patients with Wilms tumor? [letter; comment] Paulino AC. **J Urol** 1997 Jun;157(6):2265 (6 ref.) Comment on: J Urol 1996 Aug;156(2 Pt 2):693–5.

Renal cysts, renal cancer and von Hippel-Lindau disease [editorial] Neumann HP, et al. **Kidney Int** 1997 Jan; 51(1):16–26 (94 ref.)

MR imaging of renal and adrenal masses in children. Bilal MM, et al. **Magn Reson Imaging Clin N Am** 1997 Feb; 5(1):179–97 (74 ref.)

Renal MR angiography. Borrello JA. **Magn Reson Imaging Clin N Am** 1997 Feb;5(1):83–93 (49 ref.)

Detection and staging of renal cancer. Choyke PL. **Magn Reson Imaging Clin N Am** 1997 Feb;5(1):29–47 (50 ref.)

Renal cysts and cystic neoplasms. Miller MA, et al. **Magn Reson Imaging Clin N Am** 1997 Feb;5(1):49–66 (29 ref.)

Renal masses: urologic management. Ornstein DK, et al. **Magn Reson Imaging Clin N Am** 1997 Feb;5(1):1–12 (85 ref.)

MR imaging in the evaluation of small (< or =3.0 cm) renal masses. Rofsky NM, et al. **Magn Reson Imaging Clin N Am** 1997 Feb;5(1):67–81 (54 ref.)

The kidney: radiologic-pathologic correlation. Wagner BJ. **Magn Reson Imaging Clin N Am** 1997 Feb;5(1):13–28 (42 ref.)

Errors and pitfalls in diagnostic cytology of abdominal organs. Silverman JF. **Monogr Pathol** 1997;(39):147–70 (107 ref.)

Renal cell carcinoma in adolescents. A case report and review of the literature. Fiori E, et al. **Panminerva Med** 1996 Jun;38(2):121–8 (114 ref.)

Wilms' tumor. Petruzzi MJ, et al. **Pediatr Clin North Am** 1997 Aug;44(4):939–52 (75 ref.)

Pediatric renal neoplasms. Strouse PJ. **Radiol Clin North Am** 1996 Nov;34(6):1081–100 (76 ref.)

Focal xanthogranulomatous pyelonephritis presenting as renal tumour in children. Case report with a review of the literature. Marteinsson VT, et al. **Scand J Urol Nephrol** 1996 Jun;30(3):235–9 (32 ref.)

Imaging of angiomyolipomas. Lemaitre L, et al. **Semin Ultrasound CT MR** 1997 Apr;18(2):100–14 (70 ref.)

The diagnosis and management of small (< or = 3 cm) renal neoplasms: a commentary. Wills JS. **Semin Ultrasound CT MR** 1997 Apr;18(2):75–81 (55 ref.)

Imaging work-up: is it renal carcinoma and is it operable? Barbaric ZL. **Semin Urol Oncol** 1996 Nov;14(4):196–202 (31 ref.)

Paraneoplastic manifestations of renal cell carcinoma. Gold PJ, et al. **Semin Urol Oncol** 1996 Nov;14(4):216–22 (46 ref.)

[The synchronous occurrence of acute myeloid leukemia and kidney carcinoma] Bohle W, et al. **Dtsch Med Wochenschr** 1997 Jun 6;122(23):743–6 (15 ref.) (Eng. Abstr.) **(Ger)**

[Mesonephric tumor, mesonephric carcinoma] Asano T, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):512–5 (10 ref.) **(Jpn)**

[Renal angiomyolipoma] Kikuchi K. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):481–3 (13 ref.) **(Jpn)**

[Benign and malignant renal tumors] Matsuki K, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):491–4 (10 ref.) **(Jpn)**

[Renal adenoma] Takahashi S, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):498–500 (19 ref.) **(Jpn)**

[Renal cell carcinoma] Watanabe H, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):484–7 (20 ref.) **(Jpn)**

[Renal-cell carcinoma and polycystic disease in an adult] Caballero Alcántara J, et al. **Actas Urol Esp** 1997 Apr; 21(4):410–4 (17 ref.) (Eng. Abstr.) **(Spa)**

[Renal adenocarcinoma in a girl 13 years old] Varo Solís C, et al. **Actas Urol Esp** 1997 Apr;21(4):398–401 (12 ref.) (Eng. Abstr.) **(Spa)**

[Incidental versus clinical renal adenocarcinoma: comparative study (1970–1994)] Vega Vega A, et al. **Actas Urol Esp** 1996 Jul-Aug;20(7):605–13 (29 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Retinoid-interferon therapy of solid tumors. Lippman SM, et al. **Int J Cancer** 1997 Feb 7;70(4):481–3 (27 ref.)

Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma. Walther MM, et al. **World J Urol** 1996;14 Suppl 1:S2–7 (49 ref.)

[The role of etoposide therapy in urogenital cancer] Kawai K, et al. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1929–35 (36 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Nutrition and renal cell cancer. Wolk A, et al. **Cancer Causes Control** 1996 Jan;7(1):5–18 (96 ref.)

Renal cell carcinoma. Long GD. **Curr Opin Oncol** 1997 May; 9(3):301–6 (45 ref.)

Mucinous adenocarcinoma of the renal pelvis in natives of India. Terris MK, et al. **Urol Int** 1997;58(2):121–3 (21 ref.)

ETIOLOGY

Renal manifestations of tuberous sclerosis complex. O'Hagan AR, et al. **Clin Pediatr (Phila)** 1996 Oct;35(10):483–9 (71 ref.)

Hormone-associated cancer: mechanistic similarities between human breast cancer and estrogen-induced kidney carcinogenesis in hamsters. Liehr JG. **Environ Health Perspect** 1997 Apr;105 Suppl 3:565–9 (54 ref.)

Renal cell carcinoma in a giant renal cyst. A case report and review of the literature. Ulker V, et al. **Int Urol Nephrol** 1996;28(2):141–4 (11 ref.)

Horseshoe kidney is associated with an increased relative risk of primary renal carcinoid tumor. Krishnan B, et al. **J Urol** 1997 Jun;157(6):2059–66 (42 ref.)

GENETICS

Molecular differential diagnosis of renal carcinoma: from microscopes to microsatellites [comment] Steiner G, et al. **Am J Pathol** 1996 Dec;149(6):1791–5 (30 ref.) Comment on: Am J Pathol 1996 Dec;149(6):2081–8.

Atypical presentation of Denys-Drash syndrome in a female with a novel Wt1 gene mutation. Machin GA. **Birth Defects Orig Artic Ser** 1996;30(1):269–86 (29 ref.)

Inherited renal cell carcinoma. Maher ER. **Br J Urol** 1996 Oct;78(4):542–5 (45 ref.)

Involvement of the chromosomal region 11q13 in renal oncocytoma: case report and literature review. Neuhaus C, et al. **Cancer Genet Cytogenet** 1997 Apr;94(2):95–8 (20 ref.)

Genetics of renal tumours. Fleming S. **Cancer Metastasis Rev** 1997 Jun;16(1–2):127–40 (144 ref.)

A clinical overview of WT1 gene mutations. Little M, et al. **Hum Mutat** 1997;9(3):209–25 (118 ref.)

Pax-2, kidney development, and oncogenesis. Dressler GR. **Med Pediatr Oncol** 1996 Nov;27(5):440–4 (34 ref.)

Multiple genetic abnormalities of 11p15 in Wilms' tumor. Feinberg AP. **Med Pediatr Oncol** 1996 Nov;27(5):484–9 (61 ref.)

An overview of the clinical and molecular genetics of Wilms' tumor. Grundy P, et al. **Med Pediatr Oncol** 1996 Nov; 27(5):394–7 (53 ref.)

Gene targeting in kidney development. Kreidberg JA. **Med Pediatr Oncol** 1996 Nov;27(5):445–52 (76 ref.)

Role of genomic imprinting in Wilms' tumour and overgrowth disorders. Reeve AE. **Med Pediatr Oncol** 1996 Nov;27(5):470–5 (50 ref.)

Beck-Wiedemann syndrome and Wilms' tumour. Ward A. **Mol Hum Reprod** 1997 Feb;3(2):157–68 (184 ref.)

Molecular genetics of human renal cell tumours. Kovacs G. **Nephrol Dial Transplant** 1996;11 Suppl 6:62–5 (20 ref.)

Molecular genetics of renal cell carcinoma. Wagner JR, et al. **Semin Urol Oncol** 1996 Nov;14(4):244–9 (60 ref.)

[Molecular genetics of Wilm's tumor] Kaplinsky C, et al. **Harefuah** 1997 May 15;132(10):706–10 (42 ref.) **(Heb)**

[Genetic events and molecular biology of Wilms' tumor] Navajas Gutiérrez A, et al. **An Esp Pediatr** 1997 Feb; 46(2):105–8 (39 ref.) **(Spa)**

METABOLISM

Growth factors and renal cancer: characterization and therapeutic implications. Mydlo JH. **World J Urol** 1995; 13(6):356–63 (57 ref.)

KIDNEY NEOPLASMS

PATHOLOGY

Spontaneous regression of metastatic renal cancer. Case report and literature review. Lokich J. **Am J Clin Oncol** 1997 Aug;20(4):416–8 (34 ref.)

Primary primitive neuroectodermal tumor of the kidney. Case report and review of the literature. Furman J, et al. **Am J Clin Pathol** 1996 Sep;106(3):339–44 (41 ref.)

Solitary metastatic tumors to the pancreas: a case report and review of the literature [see comments] Robbins EG 2nd, et al. **Am J Gastroenterol** 1996 Nov;91(11):2414–7 (37 ref.) Comment in: Am J Gastroenterol 1997 May;92(5):914–5.

Renal carcinoma with a solitary synchronous contralateral adrenal metastasis: a case report. Sapienza P, et al. **Anticancer Res** 1997 Jan–Feb;17(1B):743–7 (13 ref.)

Osteoclastoma–like giant cell tumor of the renal pelvis associated with papillary transitional cell carcinoma. Molinié V, et al. **Arch Pathol Lab Med** 1997 Feb; 121(2):162–6 (28 ref.)

Renal cell carcinoma with cavitoatrial extension: case report and review of the literature. López Candales A, et al. **Bol Asoc Med P R** 1996 Apr–Jun;88(4–6):42–5 (27 ref.)

Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin–2. Bukowski RM. **Cancer** 1997 Oct 1;80(7):1198–220 (222 ref.)

Grading of renal cell carcinoma: Workgroup No. 2. Union Internationale Contre le Cancer and the American Joint Committee on Cancer (AJCC). Medeiros LJ, et al. **Cancer** 1997 Sep 1;80(5):990–1 (0 ref.)

Aggressive variants of chromophobe renal cell carcinoma. Renshaw AA, et al. **Cancer** 1996 Oct 15;78(8):1756–61 (24 ref.)

Cytodifferentiation of a Wilms' tumor pulmonary metastasis: theoretic and clinical implications. Seemayer TA, et al. **Cancer** 1997 Apr 15;79(8):1629–34 (20 ref.)

New developments in the pathology of Wilms tumor. Beckwith JB. **Cancer Invest** 1997;15(2):153–62 (31 ref.)

Renal cell carcinoma metastatic to the thumb: a case report and review of subungual metastases from all primary sites. Vine JE, et al. **Clin Exp Dermatol** 1996 Sep;21(5):377–80 (11 ref.)

Multicystic nephroma: report of a case with fine–needle aspiration findings. Hughes JH, et al. **Diagn Cytopathol** 1996 Feb;14(1):60–3 (9 ref.)

Renal clear cell carcinoma appearing as a left neck mass. Boggess MA, et al. **Ear Nose Throat J** 1996 Sep; 75(9):620–22 (13 ref.)

Coexisting non–functioning pheochromocytoma and renal oncocytoma: a case report and review of the literature. Daskalopoulos G, et al. **Eur J Radiol** 1996 Sep;23(2):138–42 (22 ref.)

Coexistence of renal cell carcinoma and renal angiomyolipoma developing in a kidney: a case report. Tsuboniwa N, et al. **Hinyokika Kiyo** 1997 Feb;43(2):131–5 (30 ref.)

Rhabdoid tumour of the kidney: a clinicopathological study of 22 patients from the International Society of Paediatric Oncology (SIOP) nephroblastoma file. Vujanić GM, et al. **Histopathology** 1996 Apr;28(4):333–40 (20 ref.)

Hyperdiploidy and trisomy 12 in the cystic partially differentiated nephroblastoma. de Chadarévian JP, et al. **Hum Pathol** 1996 Sep;27(9):980–1 (5 ref.)

Atypical mesoblastic nephroma. A potentially malignant variant of congenital mesoblastic nephroma. Review of literature & report of four cases. Sane SY, et al. **Indian J Cancer** 1996 Mar;33(1):6–11 (26 ref.)

Renal cell carcinoma in a child: case report and brief review of literature. Sharma MC, et al. **Indian J Cancer** 1995 Jun; 32(2):85–8 (18 ref.)

Renal angiosarcoma: a case report. Hiratsuka Y, et al. **Int J Urol** 1997 Jan;4(1):90–3 (22 ref.)

An unusual case of Bellini duct carcinoma. Anjum MI, et al. **Int Urol Nephrol** 1996;28(5):695–8 (6 ref.)

Report of 337 patients with renal cell carcinoma emphasizing 110 with stage IV disease and review of the literature. Guinan P, et al. **J Surg Oncol** 1997 Apr;64(4):295–8 (22 ref.)

Laparoscopic adrenalectomy for solitary metachronous contralateral adrenal metastasis from renal cell carcinoma. Elashry OM, et al. **J Urol** 1997 Apr;157(4):1217–22 (37 ref.)

Bellini duct carcinoma: a case report. Natsume O, et al. **Jpn J Clin Oncol** 1997 Apr;27(2):107–10 (18 ref.)

Renal cell carcinoma of the spindle cell type with metastasis to the pancreas: a case report. Zhao B, et al. **Jpn J Clin Oncol** 1997 Feb;27(1):58–61 (34 ref.)

Histological analysis of aggressiveness and responsiveness in Wilms' tumor. Beckwith JB, et al. **Med Pediatr Oncol** 1996 Nov;27(5):422–8 (20 ref.)

Late recurrence of clear cell sarcoma of the kidney. Kusumakumary P, et al. **Med Pediatr Oncol** 1997 May; 28(5):355–7 (12 ref.)

Intragraft angiotropic large–cell lymphoma of T cell–type in a long–term renal allograft recipient [see comments] Ghorbani RP, et al. **Mod Pathol** 1996 Jun;9(6):671–6 (43 ref.) Comment in: Mod Pathol 1996 Nov;9(11):1089–90.

An incidental finding—bilateral multifocal renal oncocytoma. Bender BU, et al. **Nephrol Dial Transplant** 1997 May; 12(5):1034–6 (27 ref.)

Primary carcinoid tumor of the kidney with special reference to its histogenesis. Takeshima Y, et al. **Pathol Int** 1996 Nov; 46(11):894–900 (37 ref.)

Sarcomatoid transitional cell carcinoma of the renal pelvis. A report of five cases with clinical, pathological, immunohistochemical and DNA ploidy analysis. Lopez–Beltran A, et al. **Pathol Res Pract** 1996 Dec; 192(12):1218–24 (27 ref.)

Dedifferentiated cystic nephroma with malignant mesenchymoma as the dedifferentiated component. Faria PA, et al. **Pediatr Pathol Lab Med** 1996 Nov–Dec; 16(6):1003–11 (21 ref.)

Survival of patients with renal cell carcinoma invading the inferior vena cava. Mattos RM, et al. **Semin Urol Oncol** 1996 Nov;14(4):223–6 (15 ref.)

Natural history of renal cell carcinoma. Paulson DF. **Semin Urol Oncol** 1996 Nov;14(4):203–7 (16 ref.)

Imaging approach to staging of renal cell carcinoma. Bechtold RE, et al. **Urol Clin North Am** 1997 Aug; 24(3):507–22 (60 ref.)

Fibroepithelial polyp in the renal pelvis. Nakamoto T, et al. **Urol Int** 1996;56(1):48–51 (17 ref.)

Gallbladder metastasis of renal cell carcinoma. A case report and review of the literature. Sparwasser C, et al. **Urol Int** 1997;58(4):257–8 (8 ref.)

Transitional cell carcinoma of the kidney with tumor thrombus into the vena cava. Williams JH, et al. **Urology** 1996 Dec;48(6):932–5 (14 ref.)

Biology of metastasis and its clinical implications: renal–cell cancer. Ulchaker JC, et al. **World J Urol** 1996;14(3):175–81 (58 ref.)

[Mesoblastic nephroma in adults. Apropos of a case and review of the literature] Bouvier R, et al. **Arch Anat Cytol Pathol** 1996;44(1):37–41 (17 ref.) (Eng. Abstr.) **(Fre)**

[Intraluminal metastasis of the common bile duct from renal carcinoma] Hakami F, et al. **Prog Urol** 1996 Jun;6(3):436–8 (9 ref.) (Eng. Abstr.) **(Fre)**

[Kidney cancer and pancreatic metastases. Report of 3 cases] Masson J, et al. **Prog Urol** 1996 Jun;6(3):443–6 (17 ref.) (Eng. Abstr.) **(Fre)**

[Carcinoma–in–carcinoma metastasis. In situ DNA quantification and immunohistochemical diagnosis] Sperb RA, et al. **Pathologe** 1996 Sep;17(5):385–90 (39 ref.) (Eng. Abstr.) **(Ger)**

[Transitional cell carcinoma of the renal pelvis with cystic formation: a case report] Fukuoka A, et al. **Hinyokika Kiyo** 1996 Oct;42(10):739–42 (13 ref.) (Eng. Abstr.) **(Jpn)**

[A case report of primary renal carcinoid tumor] Kubota Y, et al. **Hinyokika Kiyo** 1996 Sep;42(9):671–5 (14 ref.) (Eng. Abstr.) **(Jpn)**

[A case of spontaneous rupture of renal leiomyosarcoma] Kyuno H, et al. **Hinyokika Kiyo** 1996 Aug;42(8):583–6 (9 ref.) (Eng. Abstr.) **(Jpn)**

[A case report of renal cell carcinoma with bilateral adrenal metastases] Miyamoto S, et al. **Hinyokika Kiyo** 1997 Feb; 43(2):127–30 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Bellini duct carcinoma of the kidney: a case report] Sue Y, et al. **Hinyokika Kiyo** 1997 Mar;43(3):213–6 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Prognostic factors in patients with non–metastatic renal cell carcinoma] Inomiya H, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Sep;87(9):1099–104 (27 ref.) (Eng. Abstr.) **(Jpn)**

[Renal cell carcinoma—clinicopathological characteristics and future aspects] Onishi T. **Nippon Hinyokika Gakkai Zasshi** 1997 Jan;88(1):1–23 (208 ref.) **(Jpn)**

[Gallbladder metastasis from renal cell carcinoma—a report of a case] Uchiyama T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Jan;94(1):68–72 (14 ref.) **(Jpn)**

[Liposarcoma, lipoma and lipomatosis of the kidney] Fujioka T, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):488–90 (15 ref.) **(Jpn)**

[Chromophobe renal cell carcinoma] Kuroda N, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):456–8 (16 ref.) **(Jpn)**

[Clear cell sarcoma of the kidney] Nakamura H. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):463–5 (20 ref.) **(Jpn)**

[Renomedullary interstitial cell tumor, renal medullary fibroma] Nonomura A. **Ryoikibetsu Shokogun Shirizu** 1997; (16 Pt 1):495–7 (10 ref.) **(Jpn)**

[Von Recklinghausen's disease: experimental models and comparative aspects] Turusov VS, et al. **Arkh Patol** 1996 Sep–Oct;58(5):3–13 (52 ref.) (Eng. Abstr.) **(Rus)**

[To radiation diagnosis of renal cancer with solitary metastasis into bone system] Chekunova EV, et al. **Vestn Rentgenol Radiol** 1997 Jan–Feb;(1):35–8 (18 ref.) **(Rus)**

[Malignant fibrohistiocytoma of the renal capsule. Report of a case and review of the literature] Gutiérrez Mínguez E, et al. **Actas Urol Esp** 1996 Sep;20(8):744–5 (10 ref.) (Eng. Abstr.) **(Spa)**

[Subcutaneous metastasis as the first manifestation of kidney cancer dissemination] Martínez Sarmiento M, et al. **Actas Urol Esp** 1997 Apr;21(4):402–5 (21 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Molecular prognostic factor in renal cell carcinoma. Shimazui T, et al. **Semin Urol Oncol** 1996 Nov;14(4):250–5 (62 ref.)

[Juxtaglomerular cell tumor] Kihara I. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):516–9 (16 ref.) **(Jpn)**

PREVENTION & CONTROL

Clinical research priorities in renal cell carcinoma: renal cell carcinoma chemoprevention strategies including target populations, proposed agents, and clinical trial designs—Workgroup No. 6. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Hanash KA, et al. **Cancer** 1997 Sep 1; 80(5):999–1001 (14 ref.)

Screening for Wilms' tumor in children with high–risk congenital syndromes: considerations for an intervention trial. DeBaun MR, et al. **Med Pediatr Oncol** 1996 Nov; 27(5):415–21 (38 ref.)

RADIOGRAPHY

Renal angiosarcoma: a case report. Hiratsuka Y, et al. **Int J Urol** 1997 Jan;4(1):90–3 (22 ref.)

Contralateral adrenal metastasis in renal cell cancer. Dieckmann KP, et al. **Scand J Urol Nephrol** 1996 Apr; 30(2):139–43 (34 ref.)

Incidentally detected renal angiomyolipoma with tumour thrombus into the inferior vena cava. Rubio–Briones J, et al. **Scand J Urol Nephrol** 1997 Apr;31(2):189–91 (14 ref.)

Computed tomography of renal metastases. Ferrozzi F, et al. **Semin Ultrasound CT MR** 1997 Apr;18(2):115–21 (31 ref.)

Radiologic evaluation of small and indeterminant renal masses. Curry NS, et al. **Urol Clin North Am** 1997 Aug; 24(3):493–505 (56 ref.)

[To radiation diagnosis of renal cancer with solitary metastasis into bone system] Chekunova EV, et al. **Vestn Rentgenol Radiol** 1997 Jan–Feb;(1):35–8 (18 ref.) **(Rus)**

[Present day radiation diagnosis of renal tumors and cysts] Vlasov PV, et al. **Vestn Rentgenol Radiol** 1997 May–Jun; (3):35–47 (62 ref.) (Eng. Abstr.) **(Rus)**

RADIOTHERAPY

Radiotherapy in Wilms' tumour. Thomas PR. **Ann Acad Med Singapore** 1996 May;25(3):425–8 (21 ref.)

SECONDARY

Computed tomography of renal metastases. Ferrozzi F, et al. **Semin Ultrasound CT MR** 1997 Apr;18(2):115–21 (31 ref.)

[Carcinoma–in–carcinoma metastasis. In situ DNA quantification and immunohistochemical diagnosis] Sperb RA, et al. **Pathologe** 1996 Sep;17(5):385–90 (39 ref.) (Eng. Abstr.) **(Ger)**

[Multiple metastases of malignant cutaneous melanoma into the upper urinary tract] Török P, et al. **Orv Hetil** 1997 Feb 2;138(5):285–7 (13 ref.) (Eng. Abstr.) **(Hun)**

[Novel metastasis model of human lung cancer cells representing different histological types in SCID mice depleted of NK cells] Yano S, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(4):489–94 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Metastatic renal tumor originating from esophageal cancer: report of 2 cases] Miyoshi Y, et al. **Hinyokika Kiyo** 1997 May;43(5):347–50 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Kidney involvement in trophoblastic disease (chorionepithelioma)] Timoshenko NI, et al. **Ter Arkh** 1995; 67(12):59–61 (6 ref.) (Eng. Abstr.) **(Rus)**

SECRETION

Comments on different states of secretory autonomy of juxtaglomerular cell tumors of the kidney [editorial] Kihara I. **Intern Med** 1996 Apr;35(4):239–40 (13 ref.)

SURGERY

Surgery for the urinary tract cancer. Lukkarinen O. **Ann Chir Gynaecol** 1996;85(3):202–6 (47 ref.)

Conservative surgery for renal cell carcinoma. Terrone C, et al. **Ann Urol (Paris)** 1997;31(3):137–44 (55 ref.)

Current surgical management of Wilms' tumor. Haase GM. **Curr Opin Pediatr** 1996 Jun;8(3):268–75 (65 ref.)

Imaging work–up: is it renal carcinoma and is it operable? Barbaric ZL. **Semin Urol Oncol** 1996 Nov;14(4):196–202 (31 ref.)

Nephron–sparing surgery for renal cell carcinoma. Griffin JH, et al. **Tech Urol** 1996 Spring;2(1):43–7 (14 ref.)

Fibroepithelial polyp of the renal pelvis: nephron–sparing surgery after false–positive biopsy for transitional cell carcinoma. Brady JD, et al. **Urology** 1997 Mar;49(3):460–4 (32 ref.)

Partial nephrectomy for pediatric renal cell carcinoma: an unusual case presentation. Manion S, et al. **Urology** 1997 Mar;49(3):465–8 (9 ref.)

[Renal oncocytoma: nephrectomy or tumorectomy? Description of five cases and review of the literature] Gabellon S, et al. **Ann Urol (Paris)** 1997;31(3):131–6 (32 ref.) (Eng. Abstr.) **(Fre)**

[Synchronous bilateral renal cell carcinoma. Renal transplantation after nephrectomy] Lobbedez T, et al. **Presse Med** 1997 Feb 1;26(2):66–9 (12 ref.) (Eng. Abstr.) **(Fre)**

[Status of organ preserving surgery in renal cell carcinoma] Brkovic D, et al. **Urologe A** 1997 Mar;36(2):103–8 (33 ref.)

(Eng. Abstr.) **(Ger)**

[Rational diagnosis and surgical therapy of renal cell carcinoma with tumor thrombosis in the vena cava] Piechota HJ, et al. **Urologe A** 1997 Jan;36(1):54–63 (47 ref.) (Eng. Abstr.) **(Ger)**

[Nephron sparing surgery for renal cell carcinoma] Faris G, et al. **Harefuah** 1996 Nov 15;131(10):438–40 (17 ref.) **(Heb)**

[Conservative treatment of renal cell carcinoma: framework, incidence and classification] Del Nero A, et al. **Arch Ital Urol Androl** 1997 Apr;69(2):81–6 (31 ref.) (Eng. Abstr.) **(Ita)**

[Laparoscopic surgery for renal carcinomas] Suzuki K, et al. **Gan To Kagaku Ryoho** 1997 Mar;24(5):544–50 (23 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Prevention and treatment of renal carcinoma: new genetic strategies. Junien C, et al. **Adv Nephrol Necker Hosp** 1997; 26:81–106 (130 ref.)

Immunotherapy of metastatic renal cell cancer. Goey SH, et al. **Ann Oncol** 1996 Nov;7(9):887–900 (253 ref.)

Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Bukowski RM. **Cancer** 1997 Oct 1;80(7):1198–220 (222 ref.)

Renal, bladder, and prostate cancers: gene therapy. Carducci MA, et al. **Cancer Treat Res** 1996;88:219–34 (66 ref.)

Clinical practice guidelines: renal cell carcinoma. Bukowski RM, et al. **Cleve Clin J Med** 1997;64 Suppl 1:SI1–44; quiz SI45–7 (291 ref.)

Wilms' tumour. Green DM. **Eur J Cancer** 1997 Mar; 33(3):409–18; discussion 19–20 (130 ref.)

Cellular and molecular analyses of major histocompatibility complex (MHC) restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy. Schendel DJ, et al. **J Mol Med** 1997 Jun;75(6):400–13 (119 ref.)

The role of adoptive immunotherapy in solid cancers. Kruit WH, et al. **Neth J Med** 1997 Feb;50(2):47–68 (270 ref.)

Wilms' tumor. Petruzzi MJ, et al. **Pediatr Clin North Am** 1997 Aug;44(4):939–52 (75 ref.)

Nephroblastoma. Haase GM, et al. **Semin Pediatr Surg** 1997 Feb;6(1):11–6 (50 ref.)

Immunotherapy and gene therapy. Gitlitz BJ, et al. **Semin Urol Oncol** 1996 Nov;14(4):237–43 (51 ref.)

Cyclic interferon alpha treatment in metastatic renal cell carcinoma: results of a phase II study and review of the literature. Hofmockel G, et al. **Urol Int** 1997;58(1):8–12 (34 ref.)

Upper-tract transitional cell carcinoma. Tawfiek ER, et al. **Urology** 1997 Sep;50(3):321–9 (87 ref.)

Growth factors and renal cancer: characterization and therapeutic implications. Mydlo JH. **World J Urol** 1995; 13(6):356–63 (57 ref.)

[Renal cell carcinoma--a current review] Schmid HP, et al. **Schweiz Rundsch Med Prax** 1997 May 14;86(20):837–43 (54 ref.) (Eng. Abstr.) **(Ger)**

[Immunotherapy of metastatic renal cell carcinoma. Is clinical use justified in view of outcome, side effects and costs?] Oberneder R, et al. **Urologe A** 1997 Mar;36(2):130–7 (56 ref.) (Eng. Abstr.) **(Ger)**

[Benign and malignant renal tumors] Matsuki K, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):491–4 (10 ref.) **(Jpn)**

[Experience in treating Nephroblastomas] Lebedev VI, et al. **Vestn Ross Akad Med Nauk** 1996;(10):13–7 (10 ref.) (Eng. Abstr.) **(Rus)**

ULTRASONOGRAPHY

Prenatal ultrasound characterization of the suprarenal mass: distinction between neuroblastoma and subdiaphragmatic extralobar pulmonary sequestration. Curtis MR, et al. **J Ultrasound Med** 1997 Feb;16(2):75–83 (69 ref.)

VETERINARY

Tumours of the urinary bladder, renal pelvis, ureter and urethra. Fukushima S, et al. **IARC Sci Publ** 1996; (126):243–59 (39 ref.)

Tumours of the kidney. Tsuda H, et al. **IARC Sci Publ** 1996; (126):223–42 (119 ref.)

KIDNEY PAPILLA see **KIDNEY MEDULLA**

KIDNEY PAPILLARY NECROSIS

[Renal papillary necrosis] Kijima Y. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):30–3 (13 ref.) **(Jpn)**

RADIONUCLIDE IMAGING

The evaluation of acute pyelonephritis and renal scarring with technetium 99m-dimercaptosuccinic acid renal scintigraphy: evolving concepts and future directions. Rushton HG. **Pediatr Nephrol** 1997 Feb;11(1):108–20 (102 ref.)

KIDNEY PELVIS

A case of renal cell carcinoma associated with synchronous contralateral renal pelvic cancer and bladder tumor. Ando M, et al. **Int J Urol** 1996 Jul;3(4):310–2 (8 ref.)

Percutaneous treatment of transitional cell carcinoma of the upper urinary tract. Okada H, et al. **Int J Urol** 1997 Mar; 4(2):130–3 (15 ref.)

Imaging for ureteropelvic junction obstruction in adults. Wolf JS Jr, et al. **J Endourol** 1996 Apr;10(2):93–104 (88 ref.)

Vesicoureteral reflux and ureteropelvic junction obstruction: association, treatment options and outcome. Bomalaski MD, et al. **J Urol** 1997 Mar;157(3):969–74 (21 ref.)

Sarcomatoid transitional cell carcinoma of the renal pelvis. A report of five cases with clinical, pathological, immunohistochemical and DNA ploidy analysis. Lopez-Beltran A, et al. **Pathol Res Pract** 1996 Dec; 192(12):1218–24 (27 ref.)

Fibroepithelial polyp of the renal pelvis: nephron-sparing surgery after false-positive biopsy for transitional cell carcinoma. Brady JD, et al. **Urology** 1997 Mar;49(3):460–4 (32 ref.)

[Parietal calcifications of the kidney pelvis in Corynebacterium urealyticum urinary infection] Maciejewski C, et al. **J Radiol** 1996 Aug;77(8):571–3 (12 ref.) (Eng. Abstr.) **(Fre)**

[Pericalyceal cyst, parapelvic cyst] Kubodera S, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):439–40 (10 ref.) **(Jpn)**

[Pyelocaliceal diverticuli] Chesa Ponce N. **Actas Urol Esp** 1997 Mar;21(3):180–6 (29 ref.) (Eng. Abstr.) **(Spa)**

[Inverted carcinoma of kidney pelvis coexisting with transitional cell carcinoma of the bladder. A therapeutic alternative] Díaz Calleja E, et al. **Arch Esp Urol** 1997 Mar; 50(2):189–92 (9 ref.) (Eng. Abstr.) **(Spa)**

ABNORMALITIES

[Duplicated renal pelvis, triplicated renal pelvis, bifid pelvis] Nishi M, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):377–9 (11 ref.) **(Jpn)**

PATHOLOGY

Fibroepithelial polyp in the renal pelvis. Nakamoto T, et al. **Urol Int** 1996;56(1):48–51 (17 ref.)

PHYSIOPATHOLOGY

Physiology and evaluation of ureteropelvic junction obstruction. Anderson KR, et al. **J Endourol** 1996 Apr; 10(2):87–91 (40 ref.)

SURGERY

Complications of endopyelotomy. Bellman GC. **J Endourol** 1996 Apr;10(2):177–81 (18 ref.)

Crossing vessels at the ureteropelvic junction: do they influence endopyelotomy outcome? Gupta M, et al. **J Endourol** 1996 Apr;10(2):183–7 (39 ref.)

Acucise endopyelotomy: evolution of a less-invasive technology. Nakada SY, et al. **J Endourol** 1996 Apr; 10(2):133–9 (30 ref.)

[An unusual complication of anterograde endopyelotomy: ureteral intussusception (a case report)] el Khader K, et al. **Prog Urol** 1997 Apr;7(2):273–6 (14 ref.) (Eng. Abstr.) **(Fre)**

KIDNEY, POLYCYSTIC

[Renal dysplasia] Asaka M, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):442–5 (17 ref.) **(Jpn)**

[Meckel syndrome] Yoshida K, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):406–9 (3 ref.) **(Jpn)**

CLASSIFICATION

[Renal cystic disease] Ishikawa I. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):446–50 (17 ref.) **(Jpn)**

COMPLICATIONS

Complications of polycystic kidney disease. Watson ML. **Kidney Int** 1997 Jan;51(1):353–65 (68 ref.)

[Adenocarcinoma of the kidney associated with polycystic kidney treated by conservative surgery (apropos of a case)] el Khader K, et al. **Prog Urol** 1997 Jun;7(3):464–7 (20 ref.) (Eng. Abstr.) **(Fre)**

[Juvenile nephronophthisis-medullary cystic disease (JN-MCD) complex] Kobayashi S, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):403–5 (8 ref.) **(Jpn)**

[Multicystic renal dysplasia: changes in the contralateral urinary tract] Navascues del Rio JA, et al. **Actas Urol Esp** 1996 Jun;20(6):564–8; discussion 568–9 (17 ref.) (Eng. Abstr.) **(Spa)**

CONGENITAL

[Congenital diverticula of the ureter] Machmouchi M, et al. **J Med Liban** 1996;44(4):227–9 (8 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Clinics in diagnostic imaging (18). Multilocular cystic nephroma. Chan KL, et al. **Singapore Med J** 1996 Oct; 37(5):536–40 (10 ref.)

ETIOLOGY

Renal manifestations of tuberous sclerosis complex. O'Hagan AR, et al. **Clin Pediatr (Phila)** 1996 Oct;35(10):483–9 (71 ref.)

Recent advances in the understanding of polycystic kidney disease. Bacallao RL, et al. **Curr Opin Nephrol Hypertens** 1997 Jul;6(4):377–83 (44 ref.)

Polycystic kidney disease: an unrecognized emerging infectious disease? Miller-Hjelle MA, et al. **Emerg Infect Dis** 1997 Apr-Jun;3(2):113–27 (85 ref.)

GENETICS

Multicystic kidney in siblings. Moazin MS, et al. **J Pediatr Surg** 1997 Jan;32(1):119–20 (6 ref.)

[Hereditary renal diseases and their genetic diagnosis (editorial)] Kääriäinen H, et al. **Duodecim** 1995; 111(15):1398–400 (10 ref.) **(Fin)**

[Progress in diagnosis and treatment of renal diseases. III. Hereditary nephropathies and others. 1. Polycystic kidney] Higashihara E. **Nippon Naika Gakkai Zasshi** 1996 Oct 10; 85(10):1674–80 (34 ref.) **(Jpn)**

[Polycystic kidney disease] Horie S. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):425–9 (24 ref.) **(Jpn)**

PATHOLOGY

Dedifferentiated cystic nephroma with malignant mesenchymoma as the dedifferentiated component. Faria PA, et al. **Pediatr Pathol Lab Med** 1996 Nov-Dec; 16(6):1003–11 (21 ref.)

[Glomerulocystic kidney] Kanozawa K, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):154–7 (17 ref.) **(Jpn)**

RADIOGRAPHY

[Present day radiation diagnosis of renal tumors and cysts] Vlasov PV, et al. **Vestn Rentgenol Radiol** 1997 May-Jun; (3):35–47 (62 ref.) (Eng. Abstr.) **(Rus)**

SECRETION

Mechanisms of fluid secretion by polycystic epithelia. Sullivan LP, et al. **Kidney Int** 1996 Jun;49(6):1586–91 (26 ref.)

ULTRASONOGRAPHY

[Meckel syndrome. Update on a recurrent case] Calmelet P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997; 26(4):435–41 (35 ref.) (Eng. Abstr.) **(Fre)**

[Congenital adenomatoid cystic malformation of the lung and renal polycystosis. A fetal case report and review of the literature] Jamet F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(2):193–6 (11 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Murine models of polycystic kidney disease. Schieren G, et al. **Nephrol Dial Transplant** 1996;11 Suppl 6:38–45 (77 ref.)

KIDNEY, POLYCYSTIC, AUTOSOMAL DOMINANT

The etiology, pathogenesis, and treatment of autosomal dominant polycystic kidney disease: recent advances. Grantham JJ. **Am J Kidney Dis** 1996 Dec;28(6):788–803 (105 ref.)

Autosomal recessive polycystic kidney disease. Zerres K, et al. **Nephrol Dial Transplant** 1996;11 Suppl 6:29–33 (35 ref.)

[Autosomal dominant polycystic kidney disease (ADPKD)] Shoji K. **Ryoikibetsu Shokogun Shirizu** 1996;(15):480–2 (19 ref.) **(Jpn)**

COMPLICATIONS

Extrarenal manifestations in autosomal dominant polycystic kidney disease. Chauveau D, et al. **Adv Nephrol Necker Hosp** 1997;26:265–89 (100 ref.)

Bilateral renal cell carcinoma in autosomal dominant polycystic kidney disease. A case report and literature review. Soderdahl DW, et al. **Am J Nephrol** 1997; 17(1):96–9 (24 ref.)

Extrarenal manifestations of ADPKD. Perrone RD. **Kidney Int** 1997 Jun;51(6):2022–36 (126 ref.)

DIAGNOSIS

Spectrum of glomerulocystic kidneys: a case report and review of the literature. Dedeoglu IO, et al. **Pediatr Pathol Lab Med** 1996 Nov-Dec;16(6):941–9 (24 ref.)

[Renal-cell carcinoma and polycystic disease in an adult] Caballero Alcántara J, et al. **Actas Urol Esp** 1997 Apr; 21(4):410–4 (17 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Advances in polycystic kidney disease. Schneider MC. **Mol Med Today** 1996 Feb;2(2):70–5 (32 ref.)

Polycystic kidney disease: huge kidneys, huge problems, huge progress. Grantham JJ. **Trans Am Clin Climatol Assoc** 1996; 108:165–70; discussion 170–2 (21 ref.)

KIDNEY, POLYCYSTIC, AUTOSOMAL DOMINANT

GENETICS

The long walk toward the PKD1 gene. The European PKD1 Consortium. Roelfsema JH, et al. **Adv Nephrol Necker Hosp** 1996;25:131–45 (46 ref.)

Renal disease. II. The polycystic kidney disease 1 (PKD–1) gene: an important clue in the study of renal cyst formation. Ong AC. **J R Coll Physicians Lond** 1997 Mar–Apr; 31(2):141–6 (16 ref.)

PATHOLOGY

In vitro formation of cysts derived from a rat model of autosomal dominant polycystic kidney disease. Pey R, et al. **Nephrol Dial Transplant** 1996;11 Suppl 6:58–61 (31 ref.)

Spectrum of glomerulocystic kidneys: a case report and review of the literature. Dedeoglu IO, et al. **Pediatr Pathol Lab Med** 1996 Nov–Dec;16(6):941–9 (24 ref.)

PHYSIOPATHOLOGY

Epithelial cell polarity and disease. Wilson PD. **Am J Physiol** 1997 Apr;272(4 Pt 2):F434–42 (47 ref.)

THERAPY

Outcome of renal replacement therapy in autosomal dominant polycystic kidney disease. Pirson Y, et al. **Nephrol Dial Transplant** 1996;11 Suppl 6:24–8 (31 ref.)

Autosomal dominant polycystic kidney disease--the patient on renal replacement therapy. Zeier M, et al. **Nephrol Dial Transplant** 1996;11 Suppl 6:18–20 (17 ref.)

VETERINARY

Rat models of autosomal dominant polycystic kidney disease. Gretz N, et al. **Nephrol Dial Transplant** 1996;11 Suppl 6:46–51 (33 ref.)

KIDNEY, POLYCYSTIC, AUTOSOMAL RECESSIVE

GENETICS

Autosomal recessive polycystic kidney disease: clinical features and genetics. Zerres K, et al. **Adv Nephrol Necker Hosp** 1996;25:147–57 (34 ref.)

PHYSIOPATHOLOGY

Autosomal recessive polycystic kidney disease: clinical features and genetics. Zerres K, et al. **Adv Nephrol Necker Hosp** 1996;25:147–57 (34 ref.)

KIDNEY REPLACEMENT THERAPY see **RENAL REPLACEMENT THERAPY**

KIDNEY, SPONGE

[Medullary sponge kidney] Chikaraishi T, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):415–7 (11 ref.) **(Jpn)**

COMPLICATIONS

Medullary sponge kidney associated with congenital hemihypertrophy. Indridason OS, et al. **J Am Soc Nephrol** 1996 Aug;7(8):1123–30 (29 ref.)

KIDNEY STONES see **KIDNEY CALCULI**

KIDNEY TRANSPLANTATION

Relapse of focal segmental glomerulosclerosis after kidney transplantation. Dantal J, et al. **Adv Nephrol Necker Hosp** 1996;25:91–106 (95 ref.)

Nonimmunologic factors involved in long–term renal allograft deterioration. Fellström BC, et al. **Adv Nephrol Necker Hosp** 1996;25:51–62 (63 ref.)

Acute kidney rejection: is there a consensus? Guttmann RD. **Adv Nephrol Necker Hosp** 1997;26:165–70 (15 ref.)

Chronic rejection: is allograft destruction an inevitable phenomenon? Kreis H, et al. **Adv Nephrol Necker Hosp** 1996;25:3–15 (44 ref.)

Potential involvement of growth factors in the proliferation of arteriolar smooth muscle cells during chronic graft rejection. Vuillemin T, et al. **Adv Nephrol Necker Hosp** 1996;25:39–49 (26 ref.)

The infant with primary hyperoxaluria and oxalosis: from diagnosis to multiorgan transplantation. Bunchman TE, et al. **Adv Ren Replace Ther** 1996 Oct;3(4):315–25 (31 ref.)

Pharmacology of immunosuppressive medications used in renal diseases and transplantation. de Mattos AM, et al. **Am J Kidney Dis** 1996 Nov;28(5):631–67 (333 ref.)

Pulmonary mucormycosis in diabetic renal allograft recipients. Latif S, et al. **Am J Kidney Dis** 1997 Mar; 29(3):461–4 (26 ref.)

Polyomavirus–induced interstitial nephritis in two renal transplant recipients: case reports and review of the literature. Mathur VS, et al. **Am J Kidney Dis** 1997 May; 29(5):754–8 (9 ref.)

Cyclosporine–associated thrombotic microangiopathy/hemolytic uremic syndrome following kidney and kidney–pancreas transplantation [see comments] Young BA, et al. **Am J Kidney Dis** 1996 Oct;28(4):561–71 (62 ref.) Comment in: Am J Kidney Dis 1997 May;29(5):813–4.

Successful pregnancy after combined renal–pancreas transplantation: a case report and literature review. Skannal DG, et al. **Am J Perinatol** 1996 Aug;13(6):383–7 (21 ref.)

Abdominal aortic aneurysectomy after kidney transplantation: case report and review of the literature. Ierardi RP, et al. **Am Surg** 1996 Nov;62(11):961–6 (30 ref.)

Monitoring antithymocyte globulin in renal transplantation. Clark K. **Ann R Coll Surg Engl** 1996 Nov;78(6):536–40 (22 ref.)

Liver–kidney transplantation for Budd–Chiari syndrome. Ronk LL, et al. **AORN J** 1996 Aug;64(2):196–201, 203–6 (27 ref.)

Renal transplantation: progress and prospects. Hillebrand GF, et al. **Artif Organs** 1996 May;20(5):403–7 (18 ref.)

Factors affecting renal allograft survival in African Americans. Gaston RS. **Blood Purif** 1996;14(4):327–33 (42 ref.)

High incidence of porokeratosis in renal transplant recipients. Herranz P, et al. **Br J Dermatol** 1997 Feb;136(2):176–9 (28 ref.)

Pregnancy and renal transplantation. Davison JM, et al. **Br J Urol** 1997 Jul;80 Suppl 1:29–32 (25 ref.)

Organ transplantation. Xia S. **Chin Med J (Engl)** 1996 Jan; 109(1):29–31 (0 ref.)

Toxoplasmosis in kidney transplant recipients: report of six cases and review. Renoult E, et al. **Clin Infect Dis** 1997 Apr;24(4):625–34 (43 ref.)

A review of clinical experience with the novel immunosuppressive drug mycophenolate mofetil in renal transplantation. Behrend M. **Clin Nephrol** 1996 May; 45(5):336–41 (13 ref.)

Experimental and clinical experience with the use of tacrolimus (FK506) in kidney transplantation. Wagner K, et al. **Clin Nephrol** 1996 May;45(5):332–5 (17 ref.)

Pure red cell aplasia due to parvovirus B19 infection in solid organ transplantation. Ahsan N, et al. **Clin Transplant** 1997 Aug;11(4):265–70 (26 ref.)

The effect of HMG–CoA reductase inhibitors on chronic allograft rejection. Katznelson S. **Contrib Nephrol** 1997; 120:97–104 (50 ref.)

Hepatitis C in dialysis and transplantation. Diego JM, et al. **Curr Opin Nephrol Hypertens** 1996 Nov;5(6):497–503 (94 ref.)

Mycophenolate mofetil in kidney transplantation. Lui SL, et al. **Curr Opin Nephrol Hypertens** 1996 Nov;5(6):508–13 (54 ref.)

Should hepatitis C positive donors be accepted for renal transplantation? Morales JM, et al. **Curr Opin Nephrol Hypertens** 1996 May;5(3):199–201 (40 ref.)

Update on the status of pancreas–kidney transplantation. Pelletier RP, et al. **Curr Opin Nephrol Hypertens** 1996 Nov; 5(6):504–7 (30 ref.)

Mycophenolate mofetil for the transplanted kidney? **Drug Ther Bull** 1997 May;35(5):38–40 (9 ref.)

The evaluation of living renal transplant donors: clinical practice guidelines. Ad Hoc Clinical Practice Guidelines Subcommittee of the Patient Care and Education Committee of the American Society of Transplant Physicians. Kasiske BL, et al. **J Am Soc Nephrol** 1996 Nov; 7(11):2288–313 (259 ref.)

Reversal of acute renal allograft rejection by extracorporeal photopheresis: a case presentation and review of the literature. Wolfe JT, et al. **J Clin Apheresis** 1996;11(1):36–41 (26 ref.)

A case of disseminated superficial actinic porokeratosis subsequent to renal transplantation. Matsushita S, et al. **J Dermatol** 1997 Feb;24(2):110–2 (12 ref.)

Nephrarious goings on. Kidney sales and moral arguments [see comments] Richards JR. **J Med Philos** 1996 Aug; 21(4):375–416 (15 ref.) Comment in: J Med Philos 1996 Aug;21(4):357–73.

Recurrence of the original disease in pediatric renal transplantation. Baqi N, et al. **J Nephrol** 1997 Mar–Apr; 10(2):85–92 (96 ref.)

Growth hormone is safe in children after renal transplantation. Benfield MR, et al. **J Pediatr** 1997 Jul;131(1 Pt 2):S28–31 (26 ref.)

Growth hormone is not safe for children with renal transplants. Friedman AL. **J Pediatr** 1997 Jul;131(1 Pt 2):S25–7 (38 ref.)

Results of renal transplantation in patients with Schistosoma infection. Barrou B, et al. **J Urol** 1997 Apr;157(4):1232–5; discussion 1235–6 (17 ref.)

Hyperparathyroidism and bone loss in renal graft recipients. Ittel TH, et al. **Kidney Blood Press Res** 1997;20(3):157–62 (72 ref.)

New approaches for the prevention of early graft rejection. Kahan BD. **Kidney Blood Press Res** 1997;20(3):167–9 (20 ref.)

Prevention and treatment of late graft dysfunction. van der Woude FJ. **Kidney Blood Press Res** 1997;20(3):170–2 (23 ref.)

The renal allograft biopsy. Colvin RB. **Kidney Int** 1996 Sep; 50(3):1069–82 (137 ref.)

The past, present, and future of renal xenotransplantation. Hancock WW. **Kidney Int** 1997 Mar;51(3):932–44 (59 ref.)

Acyclovir prophylaxis for cytomegalovirus disease in high–risk renal transplant recipients: is it effective? Goral S, et al. **Kidney Int Suppl** 1996 Dec;57:S62–5 (22 ref.)

Recipient evaluation, preparation, and care in pediatric transplantation: the University of Minnesota protocols. Matas AJ, et al. **Kidney Int Suppl** 1996 Jan;53:S99–102 (12 ref.)

Primary care of patients with renal transplants. Peddi VR, et al. **Med Clin North Am** 1997 May;81(3):767–84 (41 ref.)

Intragraft angiotropic large–cell lymphoma of T cell–type in a long–term renal allograft recipient [see comments] Ghorbani RP, et al. **Mod Pathol** 1996 Jun;9(6):671–6 (43 ref.) Comment in: Mod Pathol 1996 Nov;9(11):1089–90.

Surgery for renal hyperparathyroidism--experience of 640 cases. Takagi H, et al. **Nagoya J Med Sci** 1997 Mar; 60(1–2):15–22 (32 ref.)

Adhesion molecules and the mechanisms of kidney rejection [editorial] de Bustillo EM, et al. **Nephrol Dial Transplant** 1996 Jun;11(6):949–52 (34 ref.)

New immunologically non–specific immunosuppressive agents dictate changes in standard protocols for renal transplant management. Helderman JH. **Nephrol Dial Transplant** 1997;12 Suppl 1:51–4 (9 ref.)

Growth hormone treatment of short children with chronic renal failure before and after renal transplantation: rationale and recent results. Mehls O, et al. **Nephrol Dial Transplant** 1996 Sep;11(9):1747–50 (39 ref.)

How to manage the dialysis patient with chronic viral hepatitis who is considered for renal transplantation [editorial] Paparella M, et al. **Nephrol Dial Transplant** 1996 Nov;11(11):2122–4 (10 ref.)

Xenotransplantation: problems and prospects. Perico N, et al. **Nephrol Dial Transplant** 1997;12 Suppl 1:59–64 (52 ref.)

Hepatitis C infection in renal transplant patients: new insights and unanswered questions. Pirson Y, et al. **Nephrol Dial Transplant** 1996;11 Suppl 4:42–5 (23 ref.)

Immunosuppressive protocols for renal transplantation. Ponticelli C, et al. **Nephrol Dial Transplant** 1997;12 Suppl 1:45–50 (59 ref.)

New insights into therapy with monoclonal antibodies in allograft transplantation. Schena FP. **Nephrol Dial Transplant** 1997;12 Suppl 1:55–8 (29 ref.)

The management of the failed renal allograft [editorial] Vanrenterghem Y, et al. **Nephrol Dial Transplant** 1996 Jun; 11(6):955–7 (17 ref.)

The role of platelet–activating factor antagonists in the prophylaxis of posttransplant acute tubular necrosis. Grinyó JM, et al. **Ren Fail** 1996 May;18(3):445–51 (45 ref.)

Acute renal failure in patients with kidney transplant: continuous versus intermittent renal replacement therapy. Ronco C, et al. **Ren Fail** 1996 May;18(3):461–70 (36 ref.)

Outcome of renal transplantation in systemic lupus erythematosus. Stone JH, et al. **Semin Arthritis Rheum** 1997 Aug;27(1):17–26 (36 ref.)

Renal transplantation in the older end stage renal disease patient. Becker BN, et al. **Semin Nephrol** 1996 Jul; 16(4):353–62 (61 ref.)

Expanding the donor pool. First MR. **Semin Nephrol** 1997 Jul;17(4):373–80 (59 ref.)

Nonfatal gastric mucormycosis in a renal transplant recipient. Martinez EJ, et al. **South Med J** 1997 Mar;90(3):341–4 (39 ref.)

The relative influence of delayed graft function and acute rejection on renal transplant survival. Nicholson ML, et al. **Transpl Int** 1996;9(4):415–9 (29 ref.)

Prevention of reperfusion–induced, free radical–mediated acute endothelial injury by superoxide dismutase as an effective tool to delay/prevent chronic renal allograft failure: a review. Land W, et al. **Transplant Proc** 1997 Sep; 29(6):2567–8 (7 ref.)

Current issues in renal transplantation. Moore R. **Transplant Proc** 1997 Sep;29(6):2714–5 (6 ref.)

Kidney transplantation from living–related donors. Stryjecka–Rowińska D, et al. **Transplant Proc** 1996 Dec; 28(6):3576–7 (6 ref.)

Issues facing transplantation in the United Kingdom. Wood RF, et al. **Transplant Proc** 1997 Sep;29(6):2731–4 (0 ref.)

Renal transplantation in multiple myeloma. Case report and review of the literature [published erratum appears in Transplantation 1997 Mar 27;63(6):916] Dagher F, et al. **Transplantation** 1996 Dec 15;62(11):1577–80 (24 ref.)

The role of mycophenolate mofetil in clinical renal transplantation. Hodge EE. **World J Urol** 1996;14(4):249–55 (26 ref.)

Kidney transplantation in highly sensitized patients: reappraisal of etiology, evaluation, and management protocols. Indudhara R, et al. **World J Urol** 1996; 14(4):206–17 (145 ref.)

The use of tacrolimus in renal transplantation. Jordan ML, et al. **World J Urol** 1996;14(4):239–42 (12 ref.)

Kidney transplantation in Saudi Arabia: a unique experience. Al–Khudair WK, et al. **World J Urol** 1996;14(4):268–71 (17 ref.)

Hyperfiltration nephropathy as a cause of late graft loss in renal transplantation. Modlin C, et al. **World J Urol** 1996; 14(4):256–64 (86 ref.)

Immunologic tolerance in renal transplantation. Shoskes DA. **World J Urol** 1996;14(4):218–24 (90 ref.)

Contemporary criteria for cadaveric organ donation in renal transplantation: the need for better selection parameters. Taylor RJ, et al. **World J Urol** 1996;14(4):225–9 (23 ref.)

[Progresses in organ transplantation in China, 1996] Chen S, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Dec; 76(12):913–4 (0 ref.) **(Chi)**

[Synchronous bilateral renal cell carcinoma. Renal

transplantation after nephrectomy] Lobbedez T, et al. **Presse Med** 1997 Feb 1;26(2):66–9 (12 ref.) (Eng. Abstr.) **(Fre)**

[The results of kidney transplantation] **Prog Urol** 1996 Oct; 6(5):801–11 (86 ref.) (Eng. Abstr.) **(Fre)**

[The combined grafts of the kidney and another organ] **Prog Urol** 1996 Oct;6(5):813–30 (157 ref.) **(Fre)**

[Surgical aspects of chronic kidney failure and transplantation. The donor] **Prog Urol** 1996 Oct;6(5):713–52 (370 ref.) **(Fre)**

[Surgery in chronically dialysed kidney failure patients] **Prog Urol** 1996 Oct;6(5):687–712 (147 ref.) **(Fre)**

[Combined heart–kidney transplantation in pediatric age] Caione P, et al. **Minerva Pediatr** 1996 Oct;48(10):451–5 (21 ref.) (Eng. Abstr.) **(Ita)**

[Renal transplantation in patients over 60 years of age. An increasing clinical reality] Tommasi GV, et al. **Minerva Urol Nefrol** 1997 Mar;49(1):29–31 (15 ref.) (Eng. Abstr.) **(Ita)**

[Mixed chimerism and immune tolerance induction by low–stress pretreatment before kidney transplantation in monkeys] Kawai T, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):670–4 (6 ref.) **(Jpn)**

[Organ transplantation. 4. Renal transplantation] Yasumura T, et al. **Nippon Geka Gakkai Zasshi** 1996 Nov;97(11):970–7 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Progress in diagnosis and treatment of kidney diseases. V. Renal failure and kidney transplantation. 3. Rejection reaction following kidney transplantation] Sakai K, et al. **Nippon Naika Gakkai Zasshi** 1996 Oct 10;85(10):1723–7 (6 ref.) **(Jpn)**

[Hypertension after renal transplantation] Kokado Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):78–82 (11 ref.) **(Jpn)**

[Xanthogranulomatous pyelonephritis in renal allograft. Report of a case and review of the literature] Cozar JM, et al. **Actas Urol Esp** 1996 Jul–Aug;20(7):664–8 (14 ref.) (Eng. Abstr.) **(Spa)**

[Renal neuroadrenergic effects. Part I. Renal ischemia caused by sympathetic stimulation and risk factors of cadaver donor] García Matilla F, et al. **Actas Urol Esp** 1997 Mar; 21(3):236–41 (38 ref.) (Eng. Abstr.) **(Spa)**

[Vascular prosthesis in kidney transplantation] Alvarez Castelo LM, et al. **Arch Esp Urol** 1997 Apr;50(3):275–82 (15 ref.) (Eng. Abstr.) **(Spa)**

[Is there an age limit for cadaveric kidney donors currently?] Cofán Pujol F, et al. **Arch Esp Urol** 1996 Dec; 49(10):1013–20 (61 ref.) (Eng. Abstr.) **(Spa)**

[Infections in kidney and pancreas transplantation] Casanova D, et al. **Enferm Infecc Microbiol Clin** 1997 May;15 Suppl 2:104–11 (44 ref.) **(Spa)**

[Replacement treatment of chronic renal insufficiency. Current perspectives (editorial)] Ortuño Mirete J. **Rev Clin Esp** 1997 May;197(5):306–16 (97 ref.) **(Spa)**

ADVERSE EFFECTS

Hodgkin's disease following solid organ transplantation. Bierman PJ, et al. **Ann Oncol** 1996 Mar;7(3):265–70 (30 ref.)

Angiosarcoma of the scalp associated with renal transplantation. Kibe Y, et al. **Br J Dermatol** 1997 May; 136(5):752–6 (24 ref.)

Management of recurrent nephrotic syndrome after kidney transplantation in children. Cochat P, et al. **Clin Nephrol** 1996 Jul;46(1):17–20 (27 ref.)

Arterial hypertension in renal transplantation. Sandrini S, et al. **Contrib Nephrol** 1996;119:16–25 (61 ref.)

Posttransplant erythrocytosis: a model for the investigation of the pharmacological control of renal erythropoietin production? Gleiter CH. **Int J Clin Pharmacol Ther** 1996 Nov;34(11):489–92 (32 ref.)

Incidence and consequences of post–transplantation lymphoproliferative disorders. Boubenider S, et al. **J Nephrol** 1997 May–Jun;10(3):136–45 (106 ref.)

Growth hormone treatment in children before and after renal transplantation. Hokken–Koelega AC. **J Pediatr Endocrinol Metab** 1996 Jun;9 Suppl 3:359–64 (41 ref.)

Hepatitis C virus infection in dialysis and renal transplantation. Pereira BJ, et al. **Kidney Int** 1997 Apr; 51(4):981–99 (273 ref.)

Acute rejection of renal allografts: mechanistic insights and therapeutic options. Suthanthiran M. **Kidney Int** 1997 Apr; 51(4):1289–304 (182 ref.)

Metabolic abnormalities in renal transplant recipients. Risk factors and predictors of chronic graft dysfunction? [editorial] Dimény E, et al. **Nephrol Dial Transplant** 1997 Jan;12(1):21–4 (25 ref.)

Renal transplantation and skin diseases: review of the literature and results of a 5–year follow–up of 285 patients. Barba A, et al. **Nephron** 1996;73(2):131–6 (40 ref.)

Tubular dysfunction following kidney transplantation [editorial] Heering P, et al. **Nephron** 1996;74(3):501–11 (67 ref.)

Bacterial infections after renal transplantation. Schmaldienst S, et al. **Nephron** 1997;75(2):140–53 (101 ref.)

Posttransplant acute renal failure. Bennett WM. **Ren Fail** 1997 Mar;19(2):225–6 (12 ref.)

Risk factors and prognosis of posttransplant acute tubular necrosis. de Oliveira AF, et al. **Ren Fail** 1997 Mar; 19(2):267–9 (17 ref.)

Malignant tumours after renal transplantation. Fahlenkamp D, et al. **Scand J Urol Nephrol** 1996 Oct;30(5):357–62 (34 ref.)

Chronic rejection and graft arteriosclerosis: 4 years after the Alexis Carrel proposal on diagnostic criteria. Paul LC, et al. **Transplant Proc** 1997 Sep;29(6):2628–9 (28 ref.)

Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Aguado JM, et al. **Transplantation** 1997 May 15; 63(9):1278–86 (22 ref.)

Treatment of hyperlipidemia in renal transplant recipients. Arnadottir M, et al. **Transplantation** 1997 Feb 15; 63(3):339–45 (89 ref.)

Recurrent glomerulonephritis following renal transplantation. Kotanko P, et al. **Transplantation** 1997 Apr 27;63(8):1045–52 (77 ref.)

Virus infection and cancer risk in transplant recipients. McGregor JM, et al. **Trends Microbiol** 1996 Jan;4(1):2–3 (14 ref.)

[Angiosarcoma arising from an arterio–venous fistula in a renal transplant recipient. An unusual complication] Medioni LD, et al. **Ann Pathol** 1996;16(3):200–2 (19 ref.) (Eng. Abstr.) **(Fre)**

[Hepatotropic virus and renal transplantation] Pol S, et al. **Gastroenterol Clin Biol** 1996;20(12):1058–65 (107 ref.) **(Fre)**

[Complications of kidney transplantation] **Prog Urol** 1996 Oct;6(5):771–99 (222 ref.) **(Fre)**

[Lung pathology in heart, liver and kidney transplantation in adults] Martel S, et al. **Rev Mal Respir** 1996 Nov;13(5 Suppl):S57–70 (178 ref.) (Eng. Abstr.) **(Fre)**

[Hypertension after kidney transplantation] Lenz T, et al. **Dtsch Med Wochenschr** 1996 Nov 15;121(46):1440–5 (45 ref.) **(Ger)**

[Lymphocele after renal transplantation: therapeutic controversies in the age of laparoscopy] Lledó García E, et al. **Actas Urol Esp** 1996 Jul–Aug;20(7):648–54 (36 ref.) (Eng. Abstr.) **(Spa)**

[Renal transplantectomy] Fernández Aparicio T, et al. **Arch Esp Urol** 1996 Dec;49(10):1079–91 (45 ref.) (Eng. Abstr.) **(Spa)**

[Urinary lithiasis in transplanted kidney] Lancina Martín JA, et al. **Arch Esp Urol** 1997 Mar;50(2):141–50 (60 ref.) (Eng. Abstr.) **(Spa)**

[Surgical treatment of obstructive disease of the transplanted kidney] Montañés Medina P, et al. **Arch Esp Urol** 1996 Dec;49(10):1071–8 (28 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

Pharmacoeconomics of Neoral, a new formulation of cyclosporine, in renal transplantation. Abella I. **Transplant Proc** 1996 Dec;28(6):3131–4 (21 ref.)

IMMUNOLOGY

Recurrence of immunoglobulin A nephropathy with immunoglobulin A antineutrophil cytoplasmic antibodies following renal transplantation. Martin SJ, et al. **Am J Kidney Dis** 1997 Jan;29(1):125–31 (29 ref.)

Studies evaluating high–dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients. Dickinson BI, et al. **Ann Pharmacother** 1996 Dec;30(12):1452–64 (35 ref.)

Acute kidney graft rejection morphology and immunology. Andersen CB. **APMIS Suppl** 1997;67:1–35 (233 ref.)

15–Deoxyspergualin: a newly developed immunosuppressive agent and its mechanism of action and clinical effect: a review. Japan Collaborative Transplant Study Group for NKT–01. Amemiya H. **Artif Organs** 1996 Aug;20(8):832–5 (21 ref.)

Role of lipids in chronic renal allograft rejection. Swan SK. **Contrib Nephrol** 1997;120:62–7 (34 ref.)

Evaluation of the transplant recipient and donor: molecular approach to tissue typing, flow cytometry and alternative approaches to distributing organs. Takemoto SK, et al. **Curr Opin Nephrol Hypertens** 1997 May;6(3):299–303 (39 ref.)

Effect of major histocompatibility complex matching on the development of tolerance to primarily vascularized renal allografts: a study in miniature swine. Gianello PR, et al. **Hum Immunol** 1996 Sep 15;50(1):1–10 (51 ref.)

Immunosuppression in renal transplantation. Bonomini V, et al. **Int J Artif Organs** 1997 Feb;20(2):73–5 (15 ref.)

Tacrolimus: immunosuppression following liver and kidney transplant. Clark W. **J Clin Pharm Ther** 1996 Jun; 21(3):135–41 (19 ref.)

Subcutaneous phaeohypomycosis caused by Scytalidium dimidiatum in the foot of an immunosuppressed host. Rockett MS, et al. **J Foot Ankle Surg** 1996 Jul–Aug; 35(4):350–4 (25 ref.)

Immunomodulation in experimental and clinical nephrology using chimeric proteins. Kunzendorf U, et al. **Kidney Blood Press Res** 1996;19(3–4):201–4 (39 ref.)

The humoral immune response towards HLA class II determinants in renal transplantation [editorial] Feucht HE, et al. **Kidney Int** 1996 Nov;50(5):1464–75 (103 ref.)

Adhesion molecules and rejection of renal allografts. Solez K, et al. **Kidney Int** 1997 May;51(5):1476–80 (49 ref.)

The problem of chronic rejection: influence of leukocyte–endothelial interactions. Briscoe DM, et al. **Kidney Int Suppl** 1997 Mar;58:S22–7 (101 ref.)

Hyperacute xenograft rejection as an immunologic barrier to xenotransplantation. Daniels LJ, et al. **Kidney Int Suppl** 1997 Mar;58:S28–35 (72 ref.)

Tolerance and chronic rejection. Sayegh MH, et al. **Kidney Int Suppl** 1997 Mar;58:S11–4 (32 ref.)

Novel immunotherapeutic strategies using MHC derived peptides. Sayegh MH, et al. **Kidney Int Suppl** 1996 Jan; 53:S13–20 (53 ref.)

The use of Mycophenolate Mofetil (Cellcept) in renal transplantation [clinical conference] Vanrenterghem Y. **Nephron** 1997;76(4):392–9 (31 ref.)

Immunopharmacologic therapy in renal transplantation. Shoker AS. **Pharmacotherapy** 1996 Jul–Aug;16(4):562–75 (151 ref.)

Treatment of acute rejection. Thiel G, et al. **Ren Fail** 1996 May;18(3):433–43 (27 ref.)

The evolution and future of immunosuppression in renal transplantation. Goral S, et al. **Semin Nephrol** 1997 Jul; 17(4):364–72 (70 ref.)

Immunological and hemodynamic mechanisms in chronic renal allograft rejection. Paul LC, et al. **Transpl Immunol** 1996 Mar;4(1):39–42 (27 ref.)

Pharmacoeconomics of Neoral, a new formulation of cyclosporine, in renal transplantation. Abella I. **Transplant Proc** 1996 Dec;28(6):3131–4 (21 ref.)

The "injury response": a concept linking nonspecific injury, acute rejection, and long–term transplant outcomes. Halloran PF, et al. **Transplant Proc** 1997 Feb–Mar; 29(1–2):79–81 (22 ref.)

Sirolimus: a new agent for clinical renal transplantation. Kahan BD. **Transplant Proc** 1997 Feb–Mar;29(1–2):48–50 (23 ref.)

Antibody and complement in graft rejection. Sanfilippo F, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):179–80 (26 ref.)

Tacrolimus (FK–506) in kidney transplantation. Shapiro R. **Transplant Proc** 1997 Feb–Mar;29(1–2):45–7 (46 ref.)

[Cyclosporin in transplantation management—especially after kidney transplantation] Quellhorst E. **Internist (Berl)** 1996 Jan;37(1):88–90 (90 ref.) **(Ger)**

[New trends in immunosuppressive therapy in patients with kidney transplants] Savić M, et al. **Srp Arh Celok Lek** 1997 Mar–Apr;125(3–4):99–105 (105 ref.) (Eng. Abstr.) **(Scc)**

METHODS

The superiority of tacrolimus in renal transplant recipients — the Pittsburgh experience. Shapiro R, et al. **Clin Transpl** 1995;:199–205 (51 ref.)

The prospects for xenotransplantation of the kidney. Platt JL. **Curr Opin Nephrol Hypertens** 1997 May;6(3):284–91 (88 ref.)

Development of renal transplantation as an art and science. Otieno LS. **East Afr Med J** 1996 Oct;73(10):683–7 (43 ref.)

Prospects for a bioartificial kidney. Woods JD, et al. **Semin Nephrol** 1997 Jul;17(4):381–6 (25 ref.)

[Surgical aspects of chronic kidney failure and transplantation. Transplantation] **Prog Urol** 1996 Oct; 6(5):753–69 (88 ref.) **(Fre)**

[Surgical technics of kidney transplantation] Benoit G. **Prog Urol** 1996 Aug–Sep;6(4):594–604 (51 ref.) (Eng. Abstr.) **(Fre)**

[Kidney transplantation. Indications, results, pre– and postoperative care] Brunkhorst R, et al. **Internist (Berl)** 1996 Mar;37(3):264–71 (13 ref.) **(Ger)**

[Kidney transplantation in the child] Leumann E. **Schweiz Med Wochenschr** 1997 Jun 14;127(24):1039–43 (12 ref.) (Eng. Abstr.) **(Ger)**

[Selected aspects of organ transplantation] Sułowicz W. **Przegl Lek** 1996;53(3):124–6 (9 ref.) (Eng. Abstr.) **(Pol)**

[Technical options of renal transplant in the absence of a viable ilio–caval venous circuit. Presentation of a case and review of the literature] Lledo García E, et al. **Actas Urol Esp** 1996 Jun;20(6):577–81 (22 ref.) (Eng. Abstr.) **(Spa)**

[Surgical aspects of renal transplantation] Robles JE, et al. **Rev Med Univ Navarra** 1994 Oct–Dec;38(4):201–6 (44 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Acute kidney graft rejection morphology and immunology. Andersen CB. **APMIS Suppl** 1997;67:1–35 (233 ref.)

Mechanisms of action of new immunosuppressive drugs. Morris RE. **Kidney Int Suppl** 1996 Jan;53:S26–38 (145 ref.)

[Interstitial changes in kidney transplants] Schindler R, et al. **Internist (Berl)** 1996 Nov;37(11):1152–8 (61 ref.) **(Ger)**

[Ultrasound diagnosis of the transplanted kidney] Mutze S, et al. **Radiologe** 1996 Jan;36(1):31–7 (49 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Antigen–independent determinants of late renal allograft outcome: the role of renal mass. Mackenzie HS, et al. **Curr Opin Nephrol Hypertens** 1996 Jul;5(4):289–96 (88 ref.)

Pathophysiology of reduced glomerular filtration rate in delayed graft function. Scandling JD, et al. **Curr Opin Nephrol Hypertens** 1997 Jul;6(4):405–9 (53 ref.)

The importance of the kidney in primary hypertension: insights from cross–transplantation. Rettig R, et al. **J Hum Hypertens** 1996 Oct;10(10):641–4 (31 ref.)

KIDNEY TRANSPLANTATION

Intragraft expression of T-cell activation genes in human renal allograft rejection. Pavlakis M, et al. **Kidney Int Suppl** 1996 Jan;53:S7-12 (49 ref.)

Pathogenesis of primary hypertension--lessons from renal transplantation studies. Uber A, et al. **Kidney Int Suppl** 1996 Jun;55:S42-5 (28 ref.)

Does dialysis-related amyloidosis regress after transplantation? [editorial] Jadoul M, et al. **Nephrol Dial Transplant** 1997 Apr;12(4):655-7 (14 ref.)

Urine cytology: an underused method to diagnose acute renal allograft rejection. Corey HE. **Pediatr Nephrol** 1997 Apr; 11(2):226-30 (62 ref.)

[Pregnancy in women undergoing a kidney transplant. Our experience and a review of the literature] Tommasi GV, et al. **Minerva Ginecol** 1996 Dec;48(12):553-6 (10 ref.) (Eng. Abstr.) **(Ita)**

STANDARDS

[Commercial kidney transplantation in the "third world." Risks, ethical-moralistic questions and urgently required consequences] Daul AE, et al. **Dtsch Med Wochenschr** 1996 Oct 25;121(43):1341-4 (18 ref.) **(Ger)**

STATISTICS & NUMERICAL DATA

[Kidney donation by the elderly--an emergency solution?] Waleczek H, et al. **Chirurg** 1996 Sep;67(9):907-14 (48 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

Organ transplantation in Taiwan. Lee CJ. **Artif Organs** 1996 Dec;20(12):1270-3 (10 ref.)

Development of renal transplantation as an art and science. Otieno LS. **East Afr Med J** 1996 Oct;73(10):683-7 (43 ref.)

Transplantation in the 21st century. Morris PJ. **Kidney Int Suppl** 1997 Mar;58:S51-5 (28 ref.)

[The future of kidney and pancreas transplantation] **Prog Urol** 1996 Oct;6(5):831-41 (64 ref.) **(Fre)**

VETERINARY

Principles of renal transplantation in the dog: A review. Németh T, et al. **Acta Vet Hung** 1997;45(2):213-26 (36 ref.)

KIDNEY TUBULAR NECROSIS, ACUTE

[Acute tubular necrosis] Miyaji T, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):13-6 (3 ref.) **(Jpn)**

ETIOLOGY

Risk factors and prognosis of posttransplant acute tubular necrosis. de Oliveira AF, et al. **Ren Fail** 1997 Mar; 19(2):267-9 (17 ref.)

PATHOLOGY

The "injury response": a concept linking nonspecific injury, acute rejection, and long-term transplant outcomes. Halloran PF, et al. **Transplant Proc** 1997 Feb-Mar; 29(1-2):79-81 (22 ref.)

PHYSIOPATHOLOGY

Recent advances in understanding mechanisms of renal tubular injury. Ueda N, et al. **Adv Ren Replace Ther** 1997 Apr;4(2 Suppl 1):17-24 (13 ref.)

PREVENTION & CONTROL

Prevention of experimental acute tubular necrosis: current clinical applications and perspectives. Verbeke M, et al. **Adv Nephrol Necker Hosp** 1996;25:177-216 (233 ref.)

The role of platelet-activating factor antagonists in the prophylaxis of posttransplant acute tubular necrosis. Grinyó JM, et al. **Ren Fail** 1996 May;18(3):445-51 (45 ref.)

KIDNEY TUBULES

BLOOD SUPPLY

Renal stress response and acute renal failure. Safirstein R. **Adv Ren Replace Ther** 1997 Apr;4(2 Suppl 1):38-42 (25 ref.)

CHEMISTRY

Renal aquaporins. Knepper MA, et al. **Kidney Int** 1996 Jun; 49(6):1712-7 (47 ref.)

CYTOLOGY

Improved differentiation of renal tubular epithelium in vitro: potential for tissue engineering. Minuth WW, et al. **Exp Nephrol** 1997 Jan-Feb;5(1):10-7 (43 ref.)

Cellular mechanisms for bi-directional regulation of tubular sodium reabsorption. Aperia A, et al. **Kidney Int** 1996 Jun; 49(6):1743-7 (44 ref.)

Cell cultures and nephrolithiasis. Verkoelen CF, et al. **World J Urol** 1997;15(4):229-35 (84 ref.)

DRUG EFFECTS

Advantages and limitations of the use of isolated kidney tubules in pharmacotoxicology. Chauvin MF, et al. **Cell Biol Toxicol** 1996 Dec;12(4-6):283-7 (27 ref.)

Regulation of renal tubular sodium transport by angiotensin II and atrial natriuretic factor. Harris PJ, et al. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S112-8 (74 ref.)

Mechanism of action of diuretics. Bleich M, et al. **Kidney Int Suppl** 1997 Jun;59:S11-5 (50 ref.)

EMBRYOLOGY

Mesenchyme to epithelium transition during development of the mammalian kidney tubule. Davies JA. **Acta Anat (Basel)** 1996;156(3):187-201 (121 ref.)

ENZYMOLOGY

Biochemical mechanisms and regulation of hydrogen transport in renal tubules. Eiam-Ong S, et al. **Miner Electrolyte Metab** 1996;22(5-6):366-81 (237 ref.)

Corticosteroid regulation of renal Na,K-ATPase. Verrey F, et al. **Miner Electrolyte Metab** 1996;22(5-6):279-92 (99 ref.)

IMMUNOLOGY

[Antitubular basement membrane antibody nephritis] Ueda S, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):137-9 (17 ref.) **(Jpn)**

METABOLISM

Advantages and limitations of the use of isolated kidney tubules in pharmacotoxicology. Chauvin MF, et al. **Cell Biol Toxicol** 1996 Dec;12(4-6):283-7 (27 ref.)

Renal and intestinal autocrine monoaminergic systems: dopamine versus 5-hydroxytryptamine. Vieira-Coelho MA, et al. **Clin Exp Hypertens** 1997 Jan-Feb;19(1-2):43-58 (22 ref.)

Molecular regulation of renal phosphate transport. Levi M, et al. **J Membr Biol** 1996 Nov;154(1):1-9 (73 ref.)

Potassium transport and potassium channels in the kidney tubules. Kawahara K, et al. **Jpn J Physiol** 1997 Feb; 47(1):1-10 (99 ref.)

Cellular mechanisms for bi-directional regulation of tubular sodium reabsorption. Aperia A, et al. **Kidney Int** 1996 Jun; 49(6):1743-7 (44 ref.)

ATP-sensitive K+ channels in the kidney. Quast U. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Aug-Sep; 354(3):213-25 (136 ref.)

Cellular mechanisms in renal tubular transport of divalent inorganic anions. Murer H, et al. **Nephrologie** 1996; 17(7):365-9 (33 ref.)

The mechanisms of renal tubule electrolyte and water absorption, 100 years after Carl Ludwig. Greger R. **Pflugers Arch** 1996;432(3 Suppl):R82-6 (31 ref.)

[Molecular aspects of Na+/H+ exchange in the renal tubule: localization and adaptation to the acid-base state] Borensztein P, et al. **Nephrologie** 1996;17(7):377-81 (21 ref.) (Eng. Abstr.) **(Fre)**

[Fractional tubular reabsorption of phosphate] Akatsu T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:310-2 (9 ref.) **(Jpn)**

[Renal glucosuria] Fujinaka H, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):663-5 (13 ref.) **(Jpn)**

[Idiopathic tubular proteinuria (Dent's disease)] Igarashi T. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):670-3 (17 ref.) **(Jpn)**

[Bartter's syndrome, Gitelman's syndrome] Shibagaki Y, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):595-600 (21 ref.) **(Jpn)**

[Renal hypouricemia (idiopathic, secondary)] Tofuku Y. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):660-2 (16 ref.) **(Jpn)**

PATHOLOGY

Pathology of acute renal failure: structure/function correlations. Racusen LC. **Adv Ren Replace Ther** 1997 Apr; 4(2 Suppl 1):3-16 (101 ref.)

Mechanisms of apoptosis and its potential role in renal tubular epithelial cell injury. Lieberthal W, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):F477-88 (126 ref.)

The renal tubule in the progression of chronic renal failure. Palmer BF. **J Investig Med** 1997 Aug;45(6):346-61 (172 ref.)

The nature of renal cell injury. Edelstein CL, et al. **Kidney Int** 1997 May;51(5):1341-51 (149 ref.)

Significance of tubulointerstitial changes in diabetic renal disease. Ziyadeh FN. **Kidney Int Suppl** 1996 May;54:S10-3 (57 ref.)

PHYSIOLOGY

Liposome-mediated gene transfer into the tubules. Lien YH, et al. **Exp Nephrol** 1997 Mar-Apr;5(2):132-6 (22 ref.)

Na+/H+ exchanger subtypes in the renal tubule: function and regulation in physiology and disease. Paillard M. **Exp Nephrol** 1997 Jul-Aug;5(4):277-84 (59 ref.)

Gene transfer into kidney tubules and vasculature by adenoviral vectors. Sukhatme VP, et al. **Exp Nephrol** 1997 Mar-Apr;5(2):137-43 (20 ref.)

Interactions between renal tubules and interstitium. Howie AJ, et al. **J Clin Pathol** 1996 Oct;49(10):783-6 (26 ref.)

Physiological and pathophysiological role of the epithelial sodium channel in the control of blood pressure. Hummler E, et al. **Kidney Blood Press Res** 1996;19(3-4):160-5 (49 ref.)

Potassium transport: from clearance to channels and pumps. Giebisch G, et al. **Kidney Int** 1996 Jun;49(6):1624-31 (30 ref.)

Transcriptional responses to tubule challenges. Gullans SR, et al. **Kidney Int** 1996 Jun;49(6):1678-81 (19 ref.)

Tubule electrophysiology: from single channels back to the renal epithelium. Boulpaep EL. **Wien Klin Wochenschr** 1997 Jun 27;109(12-13):489-92 (18 ref.)

PHYSIOPATHOLOGY

Biology and genetics of inherited renal tubular disorders [editorial] van't Hoff WG. **Exp Nephrol** 1996 Sep-Oct; 4(5):253-62 (71 ref.)

Role of adenosine in tubuloglomerular feedback and acute renal failure. Osswald H, et al. **J Auton Pharmacol** 1996 Dec;16(6):377-80 (34 ref.)

Tubular dysfunction following kidney transplantation [editorial] Heering P, et al. **Nephron** 1996;74(3):501-11 (67 ref.)

Acceleration of recovery in acute renal failure: from cellular mechanisms of tubular repair to innovative targeted therapies. Abbate M, et al. **Ren Fail** 1996 May;18(3):377-88 (68 ref.)

Animal models of kidney stone formation: an analysis. Khan SR. **World J Urol** 1997;15(4):236-43 (52 ref.)

KIDNEY TUBULES, COLLECTING

Bellini duct carcinoma: a case report. Natsume O, et al. **Jpn J Clin Oncol** 1997 Apr;27(2):107-10 (18 ref.)

[Bellini duct carcinoma of the kidney: a case report] Sue Y, et al. **Hinyokika Kiyo** 1997 Mar;43(3):213-6 (20 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Active urea transport in the rat inner medullary collecting duct: functional characterization and initial expression cloning. Sands JM, et al. **Kidney Int** 1996 Jun;49(6):1611-4 (41 ref.)

[Pathological aspects of water transport in the collecting ducts] Bichet DG. **Nephrologie** 1996;17(7):417-22 (17 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

An unusual case of Bellini duct carcinoma. Anjum MI, et al. **Int Urol Nephrol** 1996;28(5):695-8 (6 ref.)

PHYSIOLOGY

Regulation of aquaporin-2 water channel trafficking by vasopressin. Knepper MA, et al. **Curr Opin Cell Biol** 1997 Aug;9(4):560-4 (46 ref.)

KIDNEY TUBULES, DISTAL

METABOLISM

Interaction of urinary crystals with renal epithelial cells in the pathogenesis of nephrolithiasis. Lieske JC, et al. **Semin Nephrol** 1996 Sep;16(5):458-73 (73 ref.)

PHYSIOLOGY

Distal urinary acidification from Homer Smith to the present. Gluck SL, et al. **Kidney Int** 1996 Jun;49(6):1660-4 (57 ref.)

Structure and function of the low conductance KATP channel, ROMK. Hebert SC, et al. **Wien Klin Wochenschr** 1997 Jun 27;109(12-13):471-6 (46 ref.)

PHYSIOPATHOLOGY

New insights into the pathogenesis of distal renal tubular acidosis. Bastani B, et al. **Miner Electrolyte Metab** 1996; 22(5-6):396-409 (133 ref.)

[Type I renal tubular acidosis (type I RTA)] Nakayama H, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):621-3 (0 ref.) **(Jpn)**

KIDNEY TUBULES, PROXIMAL

The role of the calcium-dependent enzymes nitric oxide synthase and calpain in hypoxia-induced proximal tubule injury. Edelstein CL, et al. **Ren Fail** 1996 May;18(3):501-11 (73 ref.)

CHEMISTRY

Biochemical heterogeneity of arginine metabolism along kidney proximal tubules. Morel F, et al. **Kidney Int** 1996 Jun;49(6):1608-10 (14 ref.)

CYTOLOGY

On the mechanism of bicarbonate exit from renal proximal tubular cells. Seki G, et al. **Kidney Int** 1996 Jun; 49(6):1671-7 (22 ref.)

DRUG EFFECTS

Propylene glycol-induced proximal renal tubular cell injury. Yorgin PD, et al. **Am J Kidney Dis** 1997 Jul;30(1):134-9 (57 ref.)

INJURIES

Role of nitric oxide and superoxide balance in hypoxia-reoxygenation proximal tubular injury. Yaqoob M, et al. **Nephrol Dial Transplant** 1996 Sep;11(9):1738-42 (34 ref.)

Role of nitric oxide and superoxide balance in hypoxia-reoxygenation proximal tubular injury. Yaqoob M, et al. **Nephrol Dial Transplant** 1996 Sep;11(9):1743-6 (34 ref.)

METABOLISM

Mechanisms of chloride transport in the proximal tubule. Aronson PS, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):F179-92 (102 ref.)

Regulation of sodium transport by endogenous dopamine production in proximal tubular and OK cells. Baines AD, et al. **Clin Exp Hypertens** 1997 Jan-Feb;19(1-2):87-91 (14 ref.)

Dopamine-1 receptor G-protein coupling and the involvement of phospholipase A2 in dopamine-1 receptor mediated cellular signaling mechanisms in the proximal tubules of SHR. Hussain T, et al. **Clin Exp Hypertens** 1997 Jan-Feb;19(1-2):131-40 (31 ref.)

Hormone, growth factor, and vitamin handling by proximal tubule cells. Christensen EI, et al. **Curr Opin Nephrol Hypertens** 1997 Jan;6(1):20-7 (134 ref.)

Acute and chronic mechanisms for regulating proximal tubule angiotensin II receptor expression. Harris RC, et al. **J Am Soc Nephrol** 1997 Feb;8(2):306-13 (86 ref.)

The renal electrogenic Na+:HCO-3 cotransporter. Boron VF, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):263-8 (24 ref.)

Molecular mechanisms in the regulation of renal proximal tubular Na/phosphate cotransport. Murer H, et al. **Kidney Blood Press Res** 1996;19(3-4):151-4 (27 ref.)

Function and dysfunction of renal transport molecules: lessons from electrophysiology. Waldegger S, et al. **Kidney Blood Press Res** 1996;19(3-4):155-9 (40 ref.)

Role of ion exchangers in mediating NaCl transport in the proximal tubule. Aronson PS. **Kidney Int** 1996 Jun; 49(6):1665-70 (58 ref.)

Biochemical heterogeneity of arginine metabolism along kidney proximal tubules. Morel F, et al. **Kidney Int** 1996 Jun;49(6):1608-10 (14 ref.)

Plasma cAMP: a hepatorenal link influencing proximal reabsorption and renal hemodynamics? Bankir L, et al. **Kidney Int Suppl** 1997 Jun;59:S50-6 (60 ref.)

Autocrine/paracrine control of renal phosphate transport. Friedlander G, et al. **Kidney Int Suppl** 1996 Dec;57:S148-53 (73 ref.)

Role of nitric oxide and superoxide balance in hypoxia-reoxygenation proximal tubular injury. Yaqoob M, et al. **Nephrol Dial Transplant** 1996 Sep;11(9):1738-42 (34 ref.)

Role of nitric oxide and superoxide balance in hypoxia-reoxygenation proximal tubular injury. Yaqoob M, et al. **Nephrol Dial Transplant** 1996 Sep;11(9):1743-6 (34 ref.)

The role of calcium in the pathogenesis of acute renal failure. Edelstein CL, et al. **Ren Fail** 1997 Mar;19(2):199-207 (73 ref.)

[Endocytosis and receptors: molecular and physiological aspects] Verroust PJ, et al. **Nephrologie** 1996;17(7):359-64 (49 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Propylene glycol-induced proximal renal tubular cell injury. Yorgin PD, et al. **Am J Kidney Dis** 1997 Jul;30(1):134-9 (57 ref.)

Surface membrane polarity of proximal tubular cells: alterations as a basis for malfunction. Molitoris BA, et al. **Kidney Int** 1996 Jun;49(6):1592-7 (36 ref.)

PHYSIOLOGY

Control of proximal tubular apical Na/Pi cotransport. Murer H, et al. **Exp Nephrol** 1996 Jul-Aug;4(4):201-4 (23 ref.)

On the mechanism of bicarbonate exit from renal proximal tubular cells. Seki G, et al. **Kidney Int** 1996 Jun; 49(6):1671-7 (22 ref.)

Ion exchangers mediating NaCl transport in the proximal tubule. Aronson PS. **Wien Klin Wochenschr** 1997 Jun 27; 109(12-13):435-40 (58 ref.)

The electrogenic Na/HCO3 cotransporter. Boron WF, et al. **Wien Klin Wochenschr** 1997 Jun 27;109(12-13):445-56 (70 ref.)

PHYSIOPATHOLOGY

Role of endothelin in the development of glomerulosclerosis. Remuzzi G. **Kidney Blood Press Res** 1996;19(3-4):182-3 (7 ref.)

Surface membrane polarity of proximal tubular cells: alterations as a basis for malfunction. Molitoris BA, et al. **Kidney Int** 1996 Jun;49(6):1592-7 (36 ref.)

[Type II (proximal) renal tubular acidosis] Tashima Y, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):624-8 (9 ref.) **(Jpn)**

KIENBOECK'S DISEASE see **OSTEOCHONDRITIS**

KILLED VACCINES see **VACCINES, INACTIVATED**

KILLER CELLS

see related
ANTIBODY-DEPENDENT CELL CYTOTOXICITY

IMMUNOLOGY

Activated T cells and cytokine-induced CD3+CD56+ killer cells. Schmidt-Wolf GD, et al. **Ann Hematol** 1997 Feb; 74(2):51-6 (49 ref.)

[Antibody-dependent cell-mediated cytotoxicity] Mukaida N. **Nippon Rinsho** 1997 Mar;55 Suppl 1:193-5 (12 ref.) **(Jpn)**

KILLER CELLS, LYMPHOKINE-ACTIVATED

see related
IMMUNOTHERAPY, ADOPTIVE
INTERLEUKIN-2

DRUG EFFECTS

Cytokine-induced cytotoxic function expressed by lymphocytes of the innate immune system: distinguishing characteristics of NK and LAK based on functional and molecular markers. Frederick M, et al. **J Interferon Cytokine Res** 1997 Aug;17(8):435-47 (124 ref.)

PHYSIOLOGY

Activated T cells and cytokine-induced CD3+CD56+ killer cells. Schmidt-Wolf GD, et al. **Ann Hematol** 1997 Feb; 74(2):51-6 (49 ref.)

TRANSPLANTATION

Pre- and/or post-operative immunochemotherapy for advanced digestive cancer. Saji S, et al. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:239-49 (14 ref.)

KILLER CELLS, NATURAL

Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Chan JK, et al. **Blood** 1997 Jun 15;89(12):4501-13 (84 ref.)

Aggressive primary natural killer cell lymphoma of the caecum: a case report and literature review. Lei KI, et al. **Clin Oncol (R Coll Radiol)** 1997;9(3):191-4 (23 ref.)

Avian natural killer cells. Göbel TW, et al. **Curr Top Microbiol Immunol** 1996;212:107-17 (72 ref.)

How to recognize a foreign submarine. Kärre K. **Immunol Rev** 1997 Feb;155:5-9 (31 ref.)

[Extra thymus gland differentiation of IEL and role of liver] Abo T. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec; 18(6):695-700 (13 ref.) **(Jpn)**

CHEMISTRY

Natural killer cell receptors specific for MHC class I molecules [published erratum appears in Curr Opin Immunol 1996 Jun;8(3):419] Colonna M. **Curr Opin Immunol** 1996 Feb;8(1):101-7 (60 ref.)

Domain organization and sequence relationship of killer cell inhibitory receptors. Salter RD, et al. **Immunol Rev** 1997 Feb;155:175-82 (39 ref.)

Polymorphism and domain variability of human killer cell inhibitory receptors. Selvakumar A, et al. **Immunol Rev** 1997 Feb;155:183-96 (57 ref.)

Ontogeny of NK cells and the bone marrow microenvironment: where does IL15 fit in? Puzanov IJ, et al. **Res Immunol** 1997 Mar-Apr;148(3):195-201 (46 ref.)

CYTOLOGY

Cytokines: shared receptors, distinct functions. DiSanto JP. **Curr Biol** 1997 Jul 1;7(7):R424-6 (17 ref.)

Specificity, tolerance and developmental regulation of natural killer cells defined by expression of class I-specific Ly49 receptors. Raulet DH, et al. **Immunol Rev** 1997 Feb; 155:41-52 (46 ref.)

Ontogeny of NK cells and the bone marrow microenvironment: where does IL15 fit in? Puzanov IJ, et al. **Res Immunol** 1997 Mar-Apr;148(3):195-201 (46 ref.)

DRUG EFFECTS

Factors involved in modulation of NK cell activity by ethanol consumption. Blank SE, et al. **Alcohol Alcohol Suppl** 1994;2:439-45 (27 ref.)

Mistletoe therapy for human cancer: the role of the natural killer cells. Schink M. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S47-51 (50 ref.)

Cytokine-induced cytotoxic function expressed by lymphocytes of the innate immune system: distinguishing characteristics of NK and LAK based on functional and molecular markers. Frederick M, et al. **J Interferon Cytokine Res** 1997 Aug;17(8):435-47 (124 ref.)

ENZYMOLOGY

Granzymes: a variety of serine protease specificities encoded by genetically distinct subfamilies. Smyth MJ, et al. **J Leukoc Biol** 1996 Nov;60(5):555-62 (107 ref.)

IMMUNOLOGY

Factors involved in modulation of NK cell activity by ethanol consumption. Blank SE, et al. **Alcohol Alcohol Suppl** 1994;2:439-45 (27 ref.)

Immune suppression and Th1/Th2 balance in pregnancy revisited: a (very) personal tribute to Tom Wegmann. Chaouat G, et al. **Am J Reprod Immunol** 1997 Jun; 37(6):427-34 (23 ref.)

Functions of human decidual NK cells. King A, et al. **Am J Reprod Immunol** 1996 Mar;35(3):258-60 (28 ref.)

Mouse CD1-specific NK1 T cells: development, specificity, and function. Bendelac A, et al. **Annu Rev Immunol** 1997; 15:535-62 (116 ref.)

Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Kägi D, et al. **Annu Rev Immunol** 1996;14:207-32 (157 ref.)

Natural killer cell regulation during viral infection. Biron CA. **Biochem Soc Trans** 1997 May;25(2):687-90 (33 ref.)

Role of natural killer and NK1+ T-cells in regulating cell-mediated immunity during Toxoplasma gondii infection. Denkers EY, et al. **Biochem Soc Trans** 1997 May; 25(2):699-703 (43 ref.)

Development and function of natural killer 1+ T-cells. MacDonald HR. **Biochem Soc Trans** 1997 May;25(2):696-9 (41 ref.)

Molecular genetics of the natural killer gene complex and innate immunity. Yokoyama WM, et al. **Biochem Soc Trans** 1997 May;25(2):691-5 (50 ref.)

Clinical significance of autologous tumor killing (ATK) activity and its induction therapy in human cancer. Uchida A. **Biotherapy** 1994;8(2):113-22 (53 ref.)

Molecular mechanisms in cell-mediated cytotoxicity. Moretta A. **Cell** 1997 Jul 11;90(1):13-8 (49 ref.)

Signal transduction during NK cell activation. Bonnema JD, et al. **Chem Immunol** 1996;64:28-43 (102 ref.)

Allorecognition by murine natural killer cells: studies with bone marrow transplants and lysis of T lymphoblasts. Liu J, et al. **Chem Immunol** 1996;64:164-80 (23 ref.)

HLA-class I-specific inhibitory receptors of NK type on a subset of human T cells. Mingari MC, et al. **Chem Immunol** 1996;64:135-45 (51 ref.)

Inhibitory and activatory receptors for HLA class I molecules in human natural killer cells. Moretta A, et al. **Chem Immunol** 1996;64:77-87 (50 ref.)

Role of the major histocompatibility complex class I regions in rat natural killer cell allograft responses in vivo and in vitro. Rolstad B. **Chem Immunol** 1996;64:59-76 (65 ref.)

Natural killer cells in MHC class I deficient mice. Salcedo M, et al. **Chem Immunol** 1996;64:44-58 (51 ref.)

NK cells and CTL: opposite sides of the same coin. Valiante NM, et al. **Chem Immunol** 1996;64:146-63 (81 ref.)

MHC class I-dependent and -independent NK cell specificity. Yokoyama WM, et al. **Chem Immunol** 1996; 64:1-18 (88 ref.)

Major histocompatibility complex (MHC) class I recognition by natural killer cells. Döhring C, et al. **Crit Rev Immunol** 1997;17(3-4):285-99 (129 ref.)

Turning off natural killers. Innate immunity. Imboden J. **Curr Biol** 1996 Sep 1;6(9):1070-2 (10 ref.)

Activation and function of natural killer cell responses during viral infections. Biron CA. **Curr Opin Immunol** 1997 Feb; 9(1):24-34 (91 ref.)

Role of murine NK cells and their receptors in hybrid resistance. Kumar V, et al. **Curr Opin Immunol** 1997 Feb; 9(1):52-6 (39 ref.)

Natural killer cell receptors. Long EO, et al. **Curr Opin Immunol** 1997 Jun;9(3):344-50 (69 ref.)

Recognition events that inhibit and activate natural killer cells. Raulet DH. **Curr Opin Immunol** 1996 Jun;8(3):372-7 (55 ref.)

Role of natural killer cells in innate resistance to protozoan infections. Scharton-Kersten TM, et al. **Curr Opin Immunol** 1997 Feb;9(1):44-51 (86 ref.)

Inter-relationship among macrophages, natural killer cells and neutrophils in early stages of Listeria resistance. Unanue ER. **Curr Opin Immunol** 1997 Feb;9(1):35-43 (114 ref.)

Interleukin 15: a potential player during the innate immune response to infection. Carson WE, et al. **Exp Parasitol** 1996 Nov;84(2):291-4 (19 ref.)

How are NK cell responses regulated during infection? Hunter CA. **Exp Parasitol** 1996 Dec;84(3):444-8 (45 ref.)

Natural killer cells: from no receptors to too many. Lanier LL. **Immunity** 1997 Apr;6(4):371-8 (109 ref.)

NK cell proliferation and inflammation. Warren HS. **Immunol Cell Biol** 1996 Oct;74(5):473-80 (120 ref.)

Murine natural killer cell differentiation: past, present, and future. Moore TA, et al. **Immunol Res** 1996;15(2):151-62 (94 ref.)

Signal transduction by human NK cell MHC-recognizing receptors. Binstadt BA, et al. **Immunol Rev** 1997 Feb; 155:197-203 (70 ref.)

Allorecognition by murine natural killer cells: lysis of T-lymphoblasts and rejection of bone-marrow grafts. George T, et al. **Immunol Rev** 1997 Feb;155:29-40 (53 ref.)

Host MHC class I gene control of NK-cell specificity in the mouse. Höglund P, et al. **Immunol Rev** 1997 Feb; 155:11-28 (86 ref.)

The potential role of NK cells in the separation of graft-versus-tumor effects from graft-versus-host disease after allogeneic bone marrow transplantation. Murphy WJ,

et al. **Immunol Rev** 1997 Jun;157:167–76 (83 ref.)
Transduction of cytotoxic signals in natural killer cells: a general model of fine tuning between activatory and inhibitory pathways in lymphocytes. Renard V, et al. **Immunol Rev** 1997 Feb;155:205–21 (153 ref.)
Human NK cells: their ligands, receptors and functions. Reyburn H, et al. **Immunol Rev** 1997 Feb;155:119–25 (70 ref.)
Positive and negative MHC class I recognition by rat NK cells. Rolstad B, et al. **Immunol Rev** 1997 Feb;155:91–104 (72 ref.)
Polymorphism and domain variability of human killer cell inhibitory receptors. Selvakumar A, et al. **Immunol Rev** 1997 Feb;155:183–96 (57 ref.)
Development and function of T lymphocytes and natural killer cells after bone marrow transplantation of severely immunodeficient mice. Wang B, et al. **Immunol Rev** 1997 Jun;157:53–60 (50 ref.)
NK cells and reproduction. King A, et al. **Immunol Today** 1997 Feb;18(2):64–6 (15 ref.)
Inhibitory MHC class I receptors on NK cells and T cells [see comments] Lanier LL, et al. **Immunol Today** 1996 Feb; 17(2):86–91 (52 ref.) Comment in: Immunol Today 1997 Mar;18(3):146.
The molecular basis of natural killer (NK) cell recognition and function. Moretta L, et al. **J Clin Immunol** 1996 Sep; 16(5):243–53 (69 ref.)
Receptors that turn on and turn off natural killer cells. Chong AS. **J Heart Lung Transplant** 1996 Jul;15(7):675–83 (71 ref.)
MCP-1 and CCR2 in HIV infection: regulation of agonist and receptor expression. Sozzani S, et al. **J Leukoc Biol** 1997 Jul;62(1):30–3 (23 ref.)
Aggressive natural killer (NK) cell lymphoma: report of a pediatric case and review of the literature. Ohnuma K, et al. **Leuk Lymphoma** 1997 Apr;25(3–4):387–92 (7 ref.)
Chronic lymphatic leukemias of T and NK cell type. Kingreen D, et al. **Leukemia** 1997 Apr;11 Suppl 2:S46–9 (36 ref.)
Uterine natural killer cells: insights into lineage relationships and functions from studies of pregnancies in mutant and transgenic mice. Croy BA, et al. **Nat Immun** 1996–97; 15(1):22–33 (69 ref.)
Uterine natural killer cells in species with epitheliochorial placentation. Engelhardt H, et al. **Nat Immun** 1996–97; 15(1):53–69 (95 ref.)
Uterine natural killer cells during pregnancy in rodents. Head JR. **Nat Immun** 1996–97;15(1):7–21 (79 ref.)
Human uterine natural killer cells. King A, et al. **Nat Immun** 1996–97;15(1):41–52 (60 ref.)
Viewpoint: signal transduction during natural killer cell activation. Leibson P. **Nat Immun** 1995;14(3):117–22 (38 ref.)
Interaction of natural killer cells with extracellular matrix induces early intracellular signalling events and enhances cytotoxic functions. Palmieri G, et al. **Nat Immun** 1996–97; 15(2–3):147–53 (50 ref.)
Natural killer cells in the nonpregnant murine uterus. Pollack SB, et al. **Nat Immun** 1996–97;15(1):34–40 (33 ref.)
Migratory functions of natural killer cells. Somersalo K. **Nat Immun** 1996–97;15(2–3):117–33 (170 ref.)
Divergent signal transduction pathways and effects on natural killer cell functions induced by interaction of Fc receptors with physiologic ligands or antireceptor antibodies. Sulica A, et al. **Nat Immun** 1995;14(3):123–33 (58 ref.)
Granulated lymphocytes of pregnancy. Whitelaw PF, et al. **Placenta** 1996 Nov;17(8):533–43 (112 ref.)
Neuroimmunomodulation: a brief review. Can conditioning of natural killer cell activity reverse cancer and/or aging? Spector NH. **Regul Toxicol Pharmacol** 1996 Aug;24(1 Pt 2):S32–8 (46 ref.)
Role for NK-cell-associated Fas ligand in cell-mediated cytotoxicity and apoptosis. Eischen CM, et al. **Res Immunol** 1997 Mar–Apr;148(3):164–9 (43 ref.)
NKRP1A and p40 molecules are involved in regulation of activation and maturation of human NK cells. Poggi A, et al. **Res Immunol** 1997 Mar–Apr;148(3):179–84 (34 ref.)
The role of natural killer cells in allograft responses to MHC antigens in the rat. Rolstad B, et al. **Res Immunol** 1997 Mar–Apr;148(3):159–64 (42 ref.)
Macrophages, NK cells and neutrophils in the cytokine loop of Listeria resistance. Unanue ER. **Res Immunol** 1996 Oct–Dec;147(8–9):499–505 (55 ref.)
The killer cell inhibitory receptor genomic region on human chromosome 19q13.4. Dupont B, et al. **Tissue Antigens** 1997 Jun;49(6):557–63 (43 ref.)
NK-lysin, structure and function of a novel effector molecule of porcine T and NK cells. Andersson M, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):123–6 (11 ref.)
[Albinism, thrombopathy, ceroid storage disease--Hermansky-Pudlak syndrome. Overview and description with immunodeficiency] Berz F, et al. **Klin Padiatr** 1996 Mar–Apr;208(2):83–7 (50 ref.) (Eng. Abstr.) **(Ger)**
[Function of Pit cells and physiopathology] Shiratori Y. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):704–7 (0 ref.) **(Jpn)**
[Activity of natural killer (NK) cells] Abo T. **Nippon Rinsho** 1997 Mar;55 Suppl 1:189–92 (15 ref.) **(Jpn)**
[Clinical characteristics of Epstein-Barr virus-associated natural killer cell lymphoma/leukemia] Kawa K. **Nippon Rinsho** 1997 Feb;55(2):424–8 (8 ref.) (Eng. Abstr.) **(Jpn)**
[Polyclonal and clonal proliferation of large granular lymphocytes] Kowal M, et al. **Pol Arch Med Wewn** 1995 Oct;94(4):349–57 (31 ref.) **(Pol)**
[Trace elements and natural killer activity] Zhavoronkov AA, et al. **Arkh Patol** 1996 Nov–Dec;58(6):65–70 (59 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Receptors for HLA class-I molecules in human natural killer cells. Moretta A, et al. **Annu Rev Immunol** 1996;14:619–48 (127 ref.)
Molecular structures of HLA-specific human NK cell receptors. Cantoni C, et al. **Chem Immunol** 1996;64:88–103 (70 ref.)
NKB1: a killer cell inhibitory receptor for class I HLA-B allotypes. D'Andrea A, et al. **Chem Immunol** 1996; 64:104–15 (44 ref.)
Functional resemblance between the Ig-related NK cell receptors specific for HLA class I molecules and the CD94 C-type lectin. López-Botet M, et al. **Chem Immunol** 1996; 64:116–34 (60 ref.)
Inhibitory and activatory receptors for HLA class I molecules in human natural killer cells. Moretta A, et al. **Chem Immunol** 1996;64:77–87 (50 ref.)
Natural killer cell receptors and MHC class I interactions. Lanier LL. **Curr Opin Immunol** 1997 Feb;9(1):126–31 (63 ref.)
Killer cell inhibitory receptor interactions with HLA class I molecules: implications for alloreactivity and transplantation. Young NT, et al. **Hum Immunol** 1997 Jan; 52(1):1–11 (109 ref.)
Natural killer cells: from no receptors to too many. Lanier LL. **Immunity** 1997 Apr;6(4):371–8 (109 ref.)
The CD94/NKG2 C-type lectin receptor complex: involvement in NK cell-mediated recognition of HLA class I molecules. López-Botet M, et al. **Immunol Res** 1997; 16(2):175–85 (50 ref.)
Signal transduction by human NK cell MHC-recognizing receptors. Binstadt BA, et al. **Immunol Rev** 1997 Feb; 155:197–203 (70 ref.)
The natural killer gene complex: a genetic basis for understanding natural killer cell function and innate immunity. Brown MG, et al. **Immunol Rev** 1997 Feb; 155:53–65 (135 ref.)
Specificity and function of immunoglobulin superfamily NK cell inhibitory and stimulatory receptors. Colonna M. **Immunol Rev** 1997 Feb;155:127–33 (55 ref.)
Arousal and inhibition of human NK cells. Lanier LL, et al. **Immunol Rev** 1997 Feb;155:145–54 (98 ref.)
Killer cell inhibitory receptors: diversity, specificity, and function. Long EO, et al. **Immunol Rev** 1997 Feb; 155:135–44 (51 ref.)
Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes. Moretta A, et al. **Immunol Rev** 1997 Feb;155:105–17 (92 ref.)
Specificity, tolerance and developmental regulation of natural killer cells defined by expression of class I-specific Ly49 receptors. Raulet DH, et al. **Immunol Rev** 1997 Feb; 155:41–52 (46 ref.)
Transduction of cytotoxic signals in natural killer cells: a general model of fine tuning between activatory and inhibitory pathways in lymphocytes. Renard V, et al. **Immunol Rev** 1997 Feb;155:205–21 (153 ref.)
Human NK cells: their ligands, receptors and functions. Reyburn H, et al. **Immunol Rev** 1997 Feb;155:119–25 (70 ref.)
Positive and negative MHC class I recognition by rat NK cells. Rolstad B, et al. **Immunol Rev** 1997 Feb;155:91–104 (72 ref.)
Divergent functions of lectin-like receptors on NK cells. Ryan JC, et al. **Immunol Rev** 1997 Feb;155:79–89 (70 ref.)
Killer cell receptors: keeping pace with MHC class I evolution. Valiante NM, et al. **Immunol Rev** 1997 Feb; 155:155–64 (51 ref.)
NK-cell receptors and recognition of MHC class I molecules. López-Botet M, et al. **Immunol Today** 1996 May; 17(5):212–4 (4 ref.)
HLA class-I-specific NK receptors belong to two distinct molecular families and display inhibitory or activating function. Cantoni C, et al. **Res Immunol** 1997 Mar–Apr; 148(3):146–50 (28 ref.)
Immunoglobulin superfamily inhibitory receptors: from natural killer cells to antigen-presenting cells. Colonna M. **Res Immunol** 1997 Mar–Apr;148(3):169–71 (33 ref.)
The CD94/NKG2C-type lectin receptor complex in recognition of HLA class I molecules. López-Botet M, et al. **Res Immunol** 1997 Mar–Apr;148(3):155–9 (30 ref.)
NK receptors and signalling. Palmieri G, et al. **Res Immunol** 1997 Mar–Apr;148(3):184–90 (55 ref.)
Events in the adaptation of natural killer cell receptors to MHC class I polymorphisms. Parham P. **Res Immunol** 1997 Mar–Apr;148(3):190–4 (19 ref.)
NKRP1A and p40 molecules are involved in regulation of activation and maturation of human NK cells. Poggi A, et al. **Res Immunol** 1997 Mar–Apr;148(3):179–84 (34 ref.)

PATHOLOGY

Classification of T-cell and NK-cell neoplasms based on the REAL classification. Jaffe ES, et al. **Ann Oncol** 1997;8 Suppl 2:17–24 (77 ref.)
Development and function of T lymphocytes and natural killer cells after bone marrow transplantation of severely immunodeficient mice. Wang B, et al. **Immunol Rev** 1997 Jun;157:53–60 (50 ref.)
Aggressive natural killer (NK) cell lymphoma: report of a pediatric case and review of the literature. Ohnuma K, et al. **Leuk Lymphoma** 1997 Apr;25(3–4):387–92 (7 ref.)

PHYSIOLOGY

Signal transduction during natural killer cell activation: inside the mind of a killer. Leibson PJ. **Immunity** 1997 Jun; 6(6):655–61 (117 ref.)
Immune regulation: a critical link between NK cells and CTLs. Kos FJ, et al. **Immunol Today** 1996 Apr;17(4):174–6 (31 ref.)
The role of natural killer cells in viral infections. See DM, et al. **Scand J Immunol** 1997 Sep;46(3):217–24 (98 ref.)
Granulysin, a new human cytolytic granule-associated protein with possible involvement in cell-mediated cytotoxicity. Peña SV, et al. **Semin Immunol** 1997 Apr; 9(2):117–25 (50 ref.)

VIROLOGY

[Epstein-Barr virus (EBV)-positive NK cell line YT, and ALL/LBL of NK-lineage] Tani A, et al. **Rinsho Byori** 1996 Oct;44(10):936–43 (28 ref.) (Eng. Abstr.) **(Jpn)**

KILLER PHENOTYPE see **PHENOTYPE**

KIMURA DISEASE see **ANGIOLYMPHOID HYPERPLASIA WITH EOSINOPHILIA**

KINASES see **PHOSPHOTRANSFERASES**

KINDLING (NEUROLOGY)

[Neuromechanisms for intractable epilepsy: a review of the studies on the kindling model of epilepsy] Sato M. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1997 Feb; 17(1):31–4 (9 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Neuropeptides-immunoreactivity and their mRNA expression in kindling: functional implications for limbic epileptogenesis. Schwarzer C, et al. **Brain Res Brain Res Rev** 1996 Jun;22(1):27–50 (120 ref.)

PATHOLOGY

Astrocytes in kindling: relevance to epileptogenesis. Khurgel M, et al. **Epilepsy Res** 1996 Dec;26(1):163–75 (72 ref.)

PHYSIOLOGY

Hoigne's syndrome, kindling, and panic disorder. Araszkiewicz A, et al. **Depress Anxiety** 1996–97;4(3):139–43 (45 ref.)
Testing the neural sensitization and kindling hypothesis for illness from low levels of environmental chemicals. Bell IR, et al. **Environ Health Perspect** 1997 Mar;105 Suppl 2:539–47 (103 ref.)
Transition between two types of epileptic seizures in developing rats as a sign of progressive epileptogenesis. Mareš P, et al. **Epilepsy Res Suppl** 1996;12:75–8 (30 ref.)
A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures. Post RM, et al. **Mol Neurobiol** 1996 Aug; 13(1):33–60 (132 ref.)
The role of the piriform cortex in kindling. Löscher W, et al. **Prog Neurobiol** 1996 Dec;50(5–6):427–81 (245 ref.)

KINESIN

CHEMISTRY

Myosin and kinesin: mother and child reunited. Hackney DD. **Chem Biol** 1996 Jul;3(7):525–8 (20 ref.)
The structure of microtubule-motor complexes. Amos LA, et al. **Curr Opin Cell Biol** 1997 Feb;9(1):4–11 (52 ref.)
Kinesin and NCD, two structural cousins of myosin. Sellers JR. **J Muscle Res Cell Motil** 1996 Apr;17(2):173–5 (23 ref.)

GENETICS

The bimC family of kinesins: essential bipolar mitotic motors driving centrosome separation. Kashina AS, et al. **Biochim Biophys Acta** 1997 Jul 24;1357(3):257–71 (49 ref.)

METABOLISM

The molecular mechanism of organelle transport along microtubules: the identification and characterization of KIFs (kinesin superfamily proteins). Hirokawa N. **Cell Struct Funct** 1996 Oct;21(5):357–67 (36 ref.)
Molecular motors: single-molecule mechanics. Simmons R. **Curr Biol** 1996 Apr 1;6(4):392–4 (17 ref.)
Cytoskeleton: a catastrophic kinesin. Waters JC, et al. **Curr Biol** 1996 Apr 1;6(4):361–3 (13 ref.)
Motors and membrane traffic. Goodson HV, et al. **Curr Opin Cell Biol** 1997 Feb;9(1):18–28 (97 ref.)
Motoring to the finish: kinesin and dynein work together

to orient the yeast mitotic spindle [comment] Stearns T. **J Cell Biol** 1997 Sep 8;138(5):957-60 (23 ref.) Comment on: J Cell Biol 1997 Sep 8;138(5):1023-40. Comment on: J Cell Biol 1997 Sep 8;138(5):1041-53.

PHYSIOLOGY

Kinesin proteins: a phylum of motors for microtubule-based motility. Moore JD, et al. **Bioessays** 1996 Mar;18(3):207-19 (78 ref.)

Motors involved in spindle assembly and chromosome segregation. Vernos I, et al. **Curr Opin Cell Biol** 1996 Feb; 8(1):4-9 (45 ref.)

Kinetochore function: molecular motors, switches and gates. Yen TJ, et al. **Curr Opin Cell Biol** 1996 Jun;8(3):381-8 (47 ref.)

Retroactive motors. Schnapp BJ. **Neuron** 1997 Apr; 18(4):523-6 (24 ref.)

KINESTHESIS

A comparison of the self-awareness and kinesthetic-visual matching theories of self-recognition: autistic children and others. Mitchell RW. **Ann N Y Acad Sci** 1997 Jun 18; 818:38-62 (111 ref.)

PHYSIOLOGY

[Left hand clumsiness due to disturbance of kinesthesia after damage to the dorsal column of the high cervical cord] Hashimoto R, et al. **Rinsho Shinkeigaku** 1997 Apr; 37(4):319-25 (22 ref.) (Eng. Abstr.) **(Jpn)**

KINETICS

Molecular interaction analysis in ligand design using mass transport, kinetic and thermodynamic methods. Doyle ML, et al. **J Mol Recognit** 1996 Mar-Apr;9(2):65-74 (33 ref.)

KINETICS, DRUG see **PHARMACOKINETICS**

KINETOCHORES

CHEMISTRY

Kinetochore function: molecular motors, switches and gates. Yen TJ, et al. **Curr Opin Cell Biol** 1996 Jun;8(3):381-8 (47 ref.)

METABOLISM

How cells get the right chromosomes. Nicklas RB. **Science** 1997 Jan 31;275(5300):632-7 (45 ref.)

PHYSIOLOGY

Kinetochore function: molecular motors, switches and gates. Yen TJ, et al. **Curr Opin Cell Biol** 1996 Jun;8(3):381-8 (47 ref.)

ULTRASTRUCTURE

Traction fibre: toward a "tensegral" model of the spindle. Pickett-Heaps JD, et al. **Cell Motil Cytoskeleton** 1997; 37(1):1-6 (32 ref.)

KINETOPLAST DNA see **DNA, KINETOPLAST**

KINETOPLAST DNA MAXICIRCLES see **DNA, KINETOPLAST**

KINETOPLAST DNA MINICIRCLES see **DNA, KINETOPLAST**

KINETOPLASTIDA

CYTOLOGY

Comparative morphology of kinetoplastids. Frolov AO, et al. **Tsitologiia** 1995;37(11):1072-96 (107 ref.)

GENETICS

RNA editing in kinetoplastid protozoa. Stuart K, et al. **Microbiol Mol Biol Rev** 1997 Mar;61(1):105-20 (114 ref.)

The genomic organization of guide RNA genes in kinetoplastid protozoa: several conundrums and their solutions. Simpson L. **Mol Biochem Parasitol** 1997 Jun; 86(2):133-41 (39 ref.)

Cell and genome coevolution: facultative anaerobiosis, glycosomes and kinetoplastan RNA editing. Cavalier-Smith T. **Trends Genet** 1997 Jan;13(1):6-9 (30 ref.)

METABOLISM

Kinetoplastid glucose transporters. Tetaud E, et al. **Biochem J** 1997 Aug 1;325 (Pt 3):569-80 (103 ref.)

RNA editing in kinetoplastid protozoa. Stuart K, et al. **Microbiol Mol Biol Rev** 1997 Mar;61(1):105-20 (114 ref.)

KINGELLA KINGAE

ISOLATION & PURIFICATION

Kingella kingae: an emerging cause of invasive infections in young children. Yagupsky P, et al. **Clin Infect Dis** 1997 May;24(5):860-6 (80 ref.)

KININASE II see **PEPTIDYL-DIPEPTIDASE A**

KININASE II INHIBITORS see **ANGIOTENSIN-CONVERTING ENZYME INHIBITORS**

KININOGENASE see **KALLIKREIN**

KININOGENS

DEFICIENCY

The brown Norway rats and the kinin system. Damas J. **Peptides** 1996;17(5):859-72 (183 ref.)

IMMUNOLOGY

Non beta 2-glycoprotein I cofactors for antiphospholipid antibodies. Galli M. **Lupus** 1996 Oct;5(5):388-92 (42 ref.)

METABOLISM

Inhibitory and antiadhesive properties of human kininogens. Colman RW. **Immunopharmacology** 1996 May;32(1-3):9-18 (24 ref.)

Pivotal role of renal kallikrein-kinin system in the development of hypertension and approaches to new drugs based on this relationship. Katori M, et al. **Jpn J Pharmacol** 1996 Feb;70(2):95-128 (247 ref.)

PHARMACOLOGY

Inhibitory and antiadhesive properties of human kininogens. Colman RW. **Immunopharmacology** 1996 May;32(1-3):9-18 (24 ref.)

Leu271-Glu292 in kininogens blocks thrombin-induced aggregation. Colman RW, et al. **Immunopharmacology** 1996 May;32(1-3):80-1 (3 ref.)

PHYSIOLOGY

Contact activation: a revision. Schmaier AH. **Thromb Haemost** 1997 Jul;78(1):101-7 (65 ref.)

[Cell adhesion and high molecular weight kininogen] Asakura S. **Rinsho Byori** 1997 Feb;Suppl 104:7-16 (15 ref.) **(Jpn)**

KININOGENS, HIGH MOLECULAR WEIGHT see **KININOGENS**

KININOGENS, LOW MOLECULAR WEIGHT see **KININOGENS**

KININS

ANTAGONISTS & INHIBITORS

The kallikrein/kinin system and kinin antagonists in trauma. Rodell TC. **Immunopharmacology** 1996 Jun;33(1-3):279-83 (9 ref.)

Tachykinin and kinin receptor antagonists: therapeutic perspectives in allergic airway disease. Bertrand C, et al. **Trends Pharmacol Sci** 1996 Jul;17(7):255-9 (58 ref.)

DRUG EFFECTS

[Anti-atherosclerotic action of angiotensin converting enzyme II. Effect on metabolism of kinin, free radical reaction, sensitivity to insulin and lipid metabolism] Stajszczyk M, et al. **Postepy Hig Med Dosw** 1996; 50(6):635-47 (71 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Role of kinins in myocardial ischemia. Linz W, et al. **EXS** 1996;76:231-41 (60 ref.)

Kinins in the cardiovascular system. Schölkens BA. **Immunopharmacology** 1996 Jun;33(1-3):209-16 (49 ref.)

Antihypertensive and cardioprotective effects after angiotensin-converting enzyme inhibition: role of kinins. Tschöpe C, et al. **J Card Fail** 1997 Jun;3(2):133-48 (192 ref.)

The brown Norway rats and the kinin system. Damas J. **Peptides** 1996;17(5):859-72 (183 ref.)

KINKY HAIR SYNDROME

Menkes disease: recent advances and new insights into copper metabolism. Tümer Z, et al. **Ann Med** 1996 Apr;28(2):121-9 (63 ref.)

GENETICS

Menkes disease: recent advances and new aspects. Tümer Z, et al. **J Med Genet** 1997 Apr;34(4):265-74 (102 ref.)

METABOLISM

Copper transport and its alterations in Menkes and Wilson diseases. DiDonato M, et al. **Biochim Biophys Acta** 1997 Feb 27;1360(1):3-16 (125 ref.)

KIT PROTO-ONCOGENE PROTEINS see **PROTO-ONCOGENE PROTEINS C-KIT**

KLATSKIN'S TUMOR

COMPLICATIONS

[The penetration of a bile duct metal stent into the duodenal bulb as a late complication of combined stent/radiotherapy in Klatskin's tumor] Wingen M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Jan;166(1):75-7 (10 ref.) **(Ger)**

SURGERY

[Malignant tumors of the hepatic bifurcation--results of surgical therapy and prognostic factors] Beckurts KT, et al. **Chirurg** 1997 Apr;68(4):378-84 (37 ref.) (Eng. Abstr.) **(Ger)**

KLEBSIELLA

IMMUNOLOGY

Molecular mimicry: the geographical distribution of immune responses to Klebsiella in ankylosing spondylitis and its relevance to therapy. Ebringer A, et al. **Clin Rheumatol** 1996 Jan;15 Suppl 1:57-61 (24 ref.)

KLEBSIELLA AEROGENES see **KLEBSIELLA PNEUMONIAE**

KLEBSIELLA INFECTIONS

[Emphysematous cystitis: a case report] Nakayama T, et al. **Hinyokika Kiyo** 1996 May;42(5):381-3 (14 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Bacterial pericarditis and cardiac tamponade in patients infected with human immunodeficiency virus type 1: case report and review. Scerpella EG, et al. **Clin Infect Dis** 1995 Dec;21(6):1518-9 (4 ref.)

Afebrile spontaneous pneumopyopericardium. Tsai WC, et al. **Int J Cardiol** 1996 Apr 19;54(1):69-72 (6 ref.)

DIAGNOSIS

Clinical, bacteriological, and serological aspects of Klebsiella infections and their spondylarthropathic sequelae. Sahly H, et al. **Clin Diagn Lab Immunol** 1997 Jul;4(4):393-9 (104 ref.)

KLEBSIELLA PNEUMONIAE

Bacterial pericarditis and cardiac tamponade in patients infected with human immunodeficiency virus type 1: case report and review. Scerpella EG, et al. **Clin Infect Dis** 1995 Dec;21(6):1518-9 (4 ref.)

ISOLATION & PURIFICATION

Clinical, bacteriological, and serological aspects of Klebsiella infections and their spondylarthropathic sequelae. Sahly H, et al. **Clin Diagn Lab Immunol** 1997 Jul;4(4):393-9 (104 ref.)

Afebrile spontaneous pneumopyopericardium. Tsai WC, et al. **Int J Cardiol** 1996 Apr 19;54(1):69-72 (6 ref.)

KLEIN-WAARDENBURG SYNDROME see **WAARDENBURG'S SYNDROME**

KLENOW FRAGMENT see **DNA POLYMERASE I**

KLEPTOMANIA see **IMPULSE CONTROL DISORDERS**

KLINEFELTER'S SYNDROME

COMPLICATIONS

Leg ulcers in Klinefelter's syndrome--further evidence for an involvement of plasminogen activator inhibitor-1. Zollner TM, et al. **Br J Dermatol** 1997 Mar;136(3):341-4 (23 ref.)

GENETICS

Intracranial malignant germ cell tumor and the Klinefelter syndrome. Case report and review of the literature. Prall JA, et al. **Pediatr Neurosurg** 1995;23(4):219-24 (33 ref.)

PHYSIOPATHOLOGY

The impact of oestradiol on ages at onset in schizophrenia reevaluated through Klinefelter syndrome [letter] Pinabel F, et al. **Schizophr Res** 1997 Feb 28;23(3):269-70 (5 ref.)

KLIPPEL-FEIL SYNDROME

[Klippel-Feil syndrome] Shiozawa Z. **Ryoikibetsu Shokogun Shirizu** 1996;(15):273-4 (5 ref.) **(Jpn)**

KLIPPEL-TRENAUNAY DISEASE see **KLIPPEL-TRENAUNAY-WEBER SYNDROME**

KLIPPEL-TRENAUNAY-WEBER SYNDROME

[Klippel-Weber syndrome] Fujita M.
Ryoikibetsu Shokogun Shirizu 1996;(14):423-5 (11 ref.) **(Jpn)**

COMPLICATIONS

[Klippel-Trenaunay-type congenital angiodysplasia syndrome; medical and psychological aspects (see comments)] van der Ploeg MN, et al.
Ned Tijdschr Geneeskd 1996 Dec 14;140(50):2502-5 (29 ref.)
Comment in: Ned Tijdschr Geneeskd 1997 Mar 29;141(13):650-1. **(Dut)**

KLORAMFENIKOL see **CHLORAMPHENICOL**

KLUYVEROMYCES

GENETICS

Application of yeasts in gene expression studies: a comparison of Saccharomyces cerevisiae, Hansenula polymorpha and Kluyveromyces lactis -- a review. Gellissen G, et al.
Gene 1997 Apr 29;190(1):87-97 (94 ref.)

PHYSIOLOGY

Nystatin-rhodamine B assay for estimating activity of killer toxin from Kluyveromyces lactis. Palková Z, et al.
Methods Mol Biol 1996;53:325-9 (5 ref.)

KNEE

Reliability and validity of clinical outcome measurements of osteoarthritis of the hip and knee--a review of the literature. Sun Y, et al. **Clin Rheumatol** 1997 Mar; 16(2):185-98 (65 ref.)

ABNORMALITIES

A case of popliteal pterygium treated along with nerve expansion. Maral T, et al. **Plast Reconstr Surg** 1997 Jul; 100(1):91-5 (15 ref.)

PATHOLOGY

Magnetic resonance imaging (MRI) of the knee: a pattern approach for evaluating bone marrow edema. Yu JS, et al. **Crit Rev Diagn Imaging** 1996 Sep;37(4):261-303 (51 ref.)

PHYSIOPATHOLOGY

Anterior knee pain in adolescents and young adults [see comments] Johnson RP. **Curr Opin Rheumatol** 1997 Mar; 9(2):159-64 (20 ref.) Comment in: Curr Opin Rheumatol 1997 Mar;9(2):133-43.

SURGERY

Pain relief from intra-articular morphine after knee surgery: a qualitative systematic review. Kalso E, et al. **Pain** 1997 Jun;71(2):127-34 (47 ref.)
[Postoperative analgesia after surgery of the knee] Fletcher D. **Cah Anesthesiol** 1996;44(3):253-9 (74 ref.) (Eng. Abstr.) **(Fre)**

KNEE INJURIES

Common athletic knee injuries. Fadale PD, et al.
Clin Sports Med 1997 Jul;16(3):479-99 (67 ref.)
Occupational knee injuries. Westrich GH, et al.
Orthop Clin North Am 1996 Oct;27(4):805-14 (25 ref.)
Swimming injuries. An overview. McMaster WC.
Sports Med 1996 Nov;22(5):332-6 (26 ref.)

COMPLICATIONS

Traumatic popliteal artery thrombosis and compartment syndrome of the leg following blunt trauma to the knee: a discussion of treatment and complications. Seybold EA, et al. **J Orthop Trauma** 1996;10(2):138-41 (21 ref.)

DIAGNOSIS

MR imaging before arthroscopy in knee joint disorders? [see comments] Rappeport ED, et al. **Acta Radiol** 1996 Sep; 37(5):602-9 (44 ref.) Comment in: Acta Radiol 1996 Sep;37(5):601.
The posterior cruciate ligament: a review. Duri ZA, et al. **Am J Knee Surg** 1997 Summer;10(3):149-64; discussion 164-5 (91 ref.)
Anterior knee pain in the military population. Chang PC, et al. **Ann Acad Med Singapore** 1997 Jan;26(1):60-3 (12 ref.)
A prospective study comparing the accuracy of the clinical diagnosis of meniscus tear with magnetic resonance imaging and its effect on clinical outcome [see comments] Miller GK. **Arthroscopy** 1996 Aug;12(4):406-13 (42 ref.)
Comment in: Arthroscopy 1997 Apr;13(2):271-5; discussion 276-7, 279-80. Comment in: Arthroscopy 1997 Apr;13(2):275-6; discussion 277-80.
Anterior knee pain: a review. Cutbill JW, et al.
Clin J Sport Med 1997 Jan;7(1):40-5 (77 ref.)
The dislocated knee. Schenck RC Jr. **Instr Course Lect** 1994; 43:127-36 (39 ref.)
Imaging of skeletal and soft tissue injuries in and around the knee. Walker CW, et al. **Radiol Clin North Am** 1997 May; 35(3):631-53 (61 ref.)
[Meniscus lesions] Wirth CJ, et al. **Orthopade** 1997 Feb; 26(2):191-208 (74 ref.) **(Ger)**

ETIOLOGY

Delayed articular cartilage slough: two cases resulting from holmium:YAG laser damage to normal articular cartilage and a review of the literature. Thal R, et al.
Arthroscopy 1996 Feb;12(1):92-4 (8 ref.)
Spontaneous rupture of the anterior cruciate ligament after anabolic steroids. Freeman BJ, et al. **Br J Sports Med** 1995 Dec;29(4):274-5 (8 ref.)
ACL injury patterns in women. Traina SM, et al.
Orthopedics 1997 Jun;20(6):545-9; quiz 550-1 (28 ref.)

PHYSIOPATHOLOGY

The knee as a biologic transmission with an envelope of function: a theory. Dye SF. **Clin Orthop** 1996 Apr; (325):10-8 (10 ref.)
Functional adaptations in patients with ACL-deficient knees. Hurwitz DE, et al. **Exerc Sport Sci Rev** 1997;25:1-20 (43 ref.)
Biomechanics of knee ligament healing, repair and reconstruction. Woo SL, et al. **J Biomech** 1997 May; 30(5):431-9 (68 ref.)

REHABILITATION

Functional knee braces and dynamic performance: a review. Kramer JF, et al. **Clin J Sport Med** 1997 Jan;7(1):32-9 (17 ref.)
Rehabilitation after meniscal repair. Shelbourne KD, et al. **Clin Sports Med** 1996 Jul;15(3):595-612 (36 ref.)
Anterior cruciate ligament injury rehabilitation in athletes. Biomechanical considerations. Beynnon BD, et al.
Sports Med 1996 Jul;22(1):54-64 (45 ref.)
Rehabilitation of injuries in competitive swimmers. Kenal KA, et al. **Sports Med** 1996 Nov;22(5):337-47 (28 ref.)
Rehabilitation programmes following arthroscopic meniscectomy in athletes. Wheatley WB, et al.
Sports Med 1996 Jun;21(6):447-56 (22 ref.)

SURGERY

Treatment of complex injuries involving the posterior cruciate and posterolateral ligaments of the knee [see comments] Noyes FR, et al. **Am J Knee Surg** 1996 Fall; 9(4):200-14 (74 ref.) Comment in: Am J Knee Surg 1996 Fall;9(4):171.
Bilateral spontaneous patellar tendon rupture. Schwartzberg RS, et al. **Am J Orthop** 1996 May;25(5):369-72 (36 ref.)
The role of pedicled or free fibular grafts in knee arthrodesis. Hallock GG. **Ann Plast Surg** 1997 Jul;39(1):60-3 (14 ref.)
Destruction of a cyropreserved meniscal allograft: a case for acute rejection. Hamlet W, et al. **Arthroscopy** 1997 Aug; 13(4):517-21 (34 ref.)
Arthroscopic medial meniscal repair in the athlete. DeHaven KE, et al. **Clin Sports Med** 1997 Jan;16(1):69-86 (49 ref.)
Meniscal repair. Where do we go from here? Kollias SL, et al. **Clin Sports Med** 1996 Jul;15(3):621-30 (48 ref.)
Allograft meniscus transplantation. Kuhn JE, et al.
Clin Sports Med 1996 Jul;15(3):537-6 (109 ref.)
Arthroscopic all-inside meniscus repair. Reigel CA, et al. **Clin Sports Med** 1996 Jul;15(3):483-98 (22 ref.)
Meniscal repair using the outside-to-inside technique. Rodeo SA, et al. **Clin Sports Med** 1996 Jul;15(3):469-81 (44 ref.)
The management of meniscal tears in the ACL-deficient knee. Schmitz MA, et al. **Clin Sports Med** 1996 Jul; 15(3):573-93 (142 ref.)
Arthroscopic posterior cruciate ligament reconstruction. Schulte KR, et al. **Clin Sports Med** 1997 Jan;16(1):145-56 (22 ref.)
Meniscus replacement. Stone KR. **Clin Sports Med** 1996 Jul; 15(3):557-71 (63 ref.)
Use of lasers for meniscal repair. Vangsness CT Jr.
Clin Sports Med 1996 Jul;15(3):531-5 (43 ref.)
Arthroscopic anterior cruciate ligament reconstruction. Veltri DM. **Clin Sports Med** 1997 Jan;16(1):123-44 (56 ref.)
Computer assisted knee surgery: diagnostics and planning of knee surgery. Sati M, et al. **Comput Aided Surg** 1997; 2(2):108-23 (49 ref.)
Biomechanics of knee ligament healing, repair and reconstruction. Woo SL, et al. **J Biomech** 1997 May; 30(5):431-9 (68 ref.)
Avulsion of the patellar ligament with combined fracture luxation of the proximal tibial epiphysis: case report and review of the literature. Perez Carro L.
J Orthop Trauma 1996;10(5):355-8 (8 ref.)
Different patterns of meniscal tears in acute anterior cruciate ligament (ACL) ruptures and in chronic ACL-deficient knees. Classification, staging and timing of treatment. Cipolla M, et al. **Knee Surg Sports Traumatol Arthrosc** 1995; 3(3):130-4 (15 ref.)
Timing of surgery in anterior cruciate ligament-injured knees. Shelbourne KD, et al.
Knee Surg Sports Traumatol Arthrosc 1995;3(3):148-56 (22 ref.)
[Meniscus lesions] Wirth CJ, et al. **Orthopade** 1997 Feb; 26(2):191-208 (74 ref.) **(Ger)**
[Acute and chronic knee ligament injuries] Hertel P.
Unfallchirurg 1996 Sep;99(9):686-700; quiz 699 (15 ref.) **(Ger)**
[Tibial plateau fractures] Hertel P. **Unfallchirurg** 1997 Jul; 100(7):508-23 (28 ref.) (Eng. Abstr.) **(Ger)**
[Distal femoral fractures. Transarticular reconstruction, percutaneous plate osteosynthesis and retrograde nailing] Krettek C, et al. **Unfallchirurg** 1996 Jan;99(1):2-10 (20 ref.) (Eng. Abstr.) **(Ger)**
[Complex trauma of the knee joint. Diagnosis--management--therapeutic principles] Krettek C, et al. **Unfallchirurg** 1996 Sep;99(9):616-27 (56 ref.) (Eng. Abstr.) **(Ger)**
[Development of replacement meniscus of autogenous tissue] Metak G, et al. **Unfallchirurg** 1996 Jul;99(7):477-86 (36 ref.) (Eng. Abstr.) **(Ger)**
[Fractures of the distal femur] Rüter A, et al.
Unfallchirurg 1996 Jul;99(7):510-9 (8 ref.) **(Ger)**

THERAPY

Anterior knee pain: a review. Cutbill JW, et al.
Clin J Sport Med 1997 Jan;7(1):40-5 (77 ref.)
The dislocated knee. Schenck RC Jr. **Instr Course Lect** 1994; 43:127-36 (39 ref.)
Patellofemoral malalignment. Goldberg B. **Pediatr Ann** 1997 Jan;26(1):32-5 (39 ref.)

ULTRASONOGRAPHY

Ultrasonography of the knee. Brys P, et al.
J Belge Radiol 1996 Aug;79(4):155-9 (19 ref.)
[Sonography of the knee extensor system] Gruber G.
Ultraschall Med 1996 Oct;17(5):206-11 (16 ref.) (Eng. Abstr.) **(Ger)**
[Standardized ultrasound study of the knee joint] Gruber G, et al. **Ultraschall Med** 1997 Apr;18(2):52-61 (6 ref.) (Eng. Abstr.) **(Ger)**

KNEE JOINT

Surgical techniques and the management of fixed deformities in total knee arthroplasty. Delfico AJ, et al.
Am J Knee Surg 1996 Spring;9(2):83-90 (24 ref.)
Classification of articular cartilage lesions of the knee at arthroscopy. Lewandrowski KU, et al. **Am J Knee Surg** 1996 Summer;9(3):121-8 (33 ref.)
Synovial chondromatosis: a case study and brief review. Coles MJ, et al. **Am J Orthop** 1997 Jan;26(1):37-40 (13 ref.)
Arthroscopic excision of intra-articular ossifications. A case report and review of the literature. Rooney RC, et al.
Am J Orthop 1996 Jun;25(6):437-40 (7 ref.)
Patellofemoral pain syndrome. A critical review of the clinical trials on nonoperative therapy. Arroll B, et al.
Am J Sports Med 1997 Mar-Apr;25(2):207-12 (32 ref.)
Observations on the microenvironmental nature of cartilage degradation in rheumatoid arthritis. Woolley DE, et al.
Ann Rheum Dis 1997 Mar;56(3):151-61 (57 ref.)
Pyrophosphate arthropathy in the knees of elderly persons. Handy JR. **Arch Intern Med** 1996 Nov 25;156(21):2426-32 (89 ref.)
Paraarticular osteochondroma of the knee: report of 2 cases and review of the literature. Reith JD, et al.
Clin Orthop 1997 Jan;(334):225-32 (17 ref.)
Synovial plicae of the knee. Controversies and review. Dupont JY. **Clin Sports Med** 1997 Jan;16(1):87-122 (86 ref.)
Genu varum and genu valgum in children. Greene WB.
Instr Course Lect 1994;43:151-9 (35 ref.)
Anterior knee pain syndromes in the adolescent. Stanitski CL. **Instr Course Lect** 1994;43:211-20 (77 ref.)
Arthroscopic debridement versus arthroplasty in the osteoarthritic knee. Jackson RW, et al. **J Arthroplasty** 1997 Jun;12(4):465-9; discussion 469-70 (13 ref.)
Static and dynamic balance responses in persons with bilateral knee osteoarthritis. Wegener L, et al.
J Orthop Sports Phys Ther 1997 Jan;25(1):13-8 (50 ref.)
Irreducible fracture dislocation of the knee. Pugh KJ, et al.
J Orthop Trauma 1996;10(5):359-62 (25 ref.)
Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. Bellamy N, et al. **J Rheumatol** 1997 Apr;24(4):799-802 (6 ref.)
Pediatric knee. Clinical assessment and common disorders. Davids JR. **Pediatr Clin North Am** 1996 Oct;43(5):1067-90 (67 ref.)
Occupation as a risk factor for knee disorders. Jensen LK, et al. **Scand J Work Environ Health** 1996 Jun;22(3):165-75 (72 ref.)
A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the knee, with an emphasis on trial methodology. Towheed TE, et al.
Semin Arthritis Rheum 1997 Apr;26(5):755-70 (103 ref.)
Anserine bursitis: a brief review. Handy JR.
South Med J 1997 Apr;90(4):376-7 (11 ref.)
Osteoarthritis in elderly knees. Handy JR. **South Med J** 1996 Nov;89(11):1031-5 (40 ref.)
[Malignant synovial "chondromatosis" or chondrosarcomatous transformation of synovial chondromatosis of the knee?] Bascoulergue G, et al.
Bull Cancer 1996 Nov;83(11):951-6 (11 ref.) (Eng. Abstr.) **(Fre)**
[Compression of the peroneal nerve by a synovial cyst in a 7-year-oldchild] Gayet LE, et al.
Rev Chir Orthop Reparatrice Appar Mot 1996;82(8):762-6

(17 ref.) (Eng. Abstr.) **(Fre)**

[Primary chronic polyarthritis of the knee joint] Rand T, et al. **Radiologe** 1996 Aug;36(8):617–23 (16 ref.) (Eng. Abstr.) **(Ger)**

[Incidence and prevalence of cox- and gonarthrosis in the general population] Sun Y, et al. **Z Orthop Ihre Grenzgeb** 1997 May–Jun;135(3):184–92 (49 ref.) (Eng. Abstr.) **(Ger)**

[Clinical, radiologic and other examinations in diagnosis of knee joint changes] Kotela I. **Przegl Lek** 1996;53(3):181–4 (20 ref.) (Eng. Abstr.) **(Pol)**

[Conservative treatment of degenerative changes in the knee joint] Kotela I. **Przegl Lek** 1996;53(3):185–7 (17 ref.) (Eng. Abstr.) **(Pol)**

[Combination of two diseases of knee joint] Mochul'skii AS, et al. **Vestn Rentgenol Radiol** 1997 Jul–Aug;(4):36–7 (6 ref.) **(Rus)**

ANATOMY & HISTOLOGY

Ultrasonography of the knee. Brys P, et al. **J Belge Radiol** 1996 Aug;79(4):155–9 (19 ref.)

MR imaging of the knee ligaments and the postoperative knee. Irizarry JM, et al. **Radiol Clin North Am** 1997 Jan; 35(1):45–76 (80 ref.)

PATHOLOGY

MR imaging before arthroscopy in knee joint disorders? [see comments] Rappeport ED, et al. **Acta Radiol** 1996 Sep; 37(5):602–9 (44 ref.) Comment in: Acta Radiol 1996 Sep;37(5):601.

Osteoarthrosis of the knee and physical load from occupation. Vingård E. **Ann Rheum Dis** 1996 Sep;55(9):677–9 (23 ref.)

Magnetic resonance imaging (MRI) of the knee: a pattern approach for evaluating bone marrow edema. Yu JS, et al. **Crit Rev Diagn Imaging** 1996 Sep;37(4):261–303 (51 ref.)

Synovial metastasis: diagnosis by fine-needle aspiration cytologic investigation. Thompson KS, et al. **Diagn Cytopathol** 1996 Nov;15(4):334–7 (18 ref.)

Synovial hemangioma of the knee. Price NJ, et al. **J Pediatr Orthop** 1997 Jan–Feb;17(1):74–7 (21 ref.)

Cartilage and subchondral bone interaction in osteoarthrosis of human knee joint: a histological and histomorphometric study. Matsui H, et al. **Microsc Res Tech** 1997 May 15; 37(4):333–42 (22 ref.)

MR imaging of the knee menisci. Rubin DA. **Radiol Clin North Am** 1997 Jan;35(1):21–44 (79 ref.)

Pseudotumor and arthropathy in the knees of a hemophiliac. Gaary E, et al. **Skeletal Radiol** 1996 Jan;25(1):85–7 (18 ref.)

MR of the postoperative knee. Tuite MJ, et al. **Top Magn Reson Imaging** 1996 Feb;8(1):2–14 (51 ref.)

[MRT in tuberculous gonarthritis in childhood] Staatz G, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Aug;167(2):210–2 (10 ref.) **(Ger)**

[Pathogenesis and pathologic anatomy of degenerative knee joint disease] Kotela I. **Przegl Lek** 1996;53(3):178–80 (19 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

The knee as a biologic transmission with an envelope of function: a theory. Dye SF. **Clin Orthop** 1996 Apr; (325):10–8 (10 ref.)

Detection of knee unlock during stance by accelerometry. Veltink PH, et al. **IEEE Trans Rehabil Eng** 1996 Dec; 4(4):395–402 (21 ref.)

A finite element analysis of the load transfer between an above-knee residual limb and its prosthetic socket—roles of interface friction and distal-end boundary conditions. Zhang M, et al. **IEEE Trans Rehabil Eng** 1996 Dec; 4(4):337–46 (45 ref.)

Biomechanics of knee ligaments: basic concepts and clinical application. Fu FH, et al. **Instr Course Lect** 1994;43:137–48 (97 ref.)

Biomechanical studies of the remodeling of knee joint tendons and ligaments. Hayashi K. **J Biomech** 1996 Jun; 29(6):707–16 (55 ref.)

PHYSIOPATHOLOGY

Functional knee braces and dynamic performance: a review. Kramer JF, et al. **Clin J Sport Med** 1997 Jan;7(1):32–9 (17 ref.)

Extensor mechanism problems in total knee arthroplasty. Dennis DA. **Instr Course Lect** 1997;46:171–80 (119 ref.)

The stiff total knee replacement: causes, treatment, and prevention. Johanson NA. **Instr Course Lect** 1997;46:191–5 (28 ref.)

Reflex sympathetic dystrophy and pain dysfunction in the lower extremity. Lindenfeld TN, et al. **Instr Course Lect** 1997;46:261–8 (51 ref.)

Basic science and conservative care of patellofemoral dysfunction: a review of the literature. Banovetz JM, et al. **Iowa Orthop J** 1996;16:88–96 (63 ref.)

Patellofemoral pain syndrome: diagnosis and management. Papagelopoulos PJ, et al. **Orthopedics** 1997 Feb; 20(2):148–57; quiz 158–9 (76 ref.)

Fractures in children treated with radiotherapy for soft tissue sarcoma. Wall JE, et al. **Orthopedics** 1996 Aug;19(8):657–64 (24 ref.)

Osteoarthritis in ankle and knee joints. Huch K, et al. **Semin Arthritis Rheum** 1997 Feb;26(4):667–74 (67 ref.)

RADIOGRAPHY

Definitions of osteoarthritis in the knee and hand. Jacobson LT. **Ann Rheum Dis** 1996 Sep;55(9):656–8 (23 ref.)

Quantitative radiography in osteoarthritis: computerized measurement of radiographic knee and hip joint space. Conrozier T, et al. **Baillieres Clin Rheumatol** 1996 Aug; 10(3):429–33 (13 ref.)

Plain radiography in the evaluation of knee osteoarthritis. Mazzuca S. **Curr Opin Rheumatol** 1997 May;9(3):263–7 (36 ref.)

Reliability of radiographic grading of osteoarthritis of the hip and knee. Sun Y, et al. **Scand J Rheumatol** 1997; 26(3):155–65 (38 ref.)

RADIONUCLIDE IMAGING

The use of scintigraphy to detect increased osseous metabolic activity about the knee. Dye SF, et al. **Instr Course Lect** 1994;43:453–69 (73 ref.)

SURGERY

Arthroscopy of the knee. Satku K, et al. **Ann Acad Med Singapore** 1996 Sep;25(5):703–7 (29 ref.)

Introduction to the basics of arthroscopy of the knee. Cautilli R Jr. **Clin Sports Med** 1997 Jan;16(1):1–16 (23 ref.)

Open or arthroscopic lateral release. Indications, techniques, and rehabilitation. Ford DH, et al. **Clin Sports Med** 1997 Jan;16(1):29–49 (55 ref.)

Arthroscopic treatment of the degenerative knee in older athletes. Goldman RT, et al. **Clin Sports Med** 1997 Jan; 16(1):51–68 (45 ref.)

Arthroscopy of the patellofemoral joint. Pidoriano AJ, et al. **Clin Sports Med** 1997 Jan;16(1):17–28 (30 ref.)

Surgical exposure in revision total knee arthroplasty. Whiteside LA. **Instr Course Lect** 1997;46:221–5 (8 ref.)

Treatment of adolescent Blount disease by asymmetric physeal distraction. de Pablos J, et al. **J Pediatr Orthop** 1997 Jan–Feb;17(1):54–8 (30 ref.)

[Postoperative analgesia after surgery of the knee] Fletcher D. **Cah Anesthesiol** 1996;44(3):253–9 (74 ref.) (Eng. Abstr.) **(Fre)**

[Twenty-eight years' treatments using high tibial osteotomy with development of Y-blade plate and postoperative repair of degenerated cartilage in the osteoarthritic knee] Koshino T. **Nippon Seikeigeka Gakkai Zasshi** 1996 Dec; 70(12):817–25 (29 ref.) **(Jpn)**

ULTRASONOGRAPHY

Sonography of tendons: patterns of disease. van Holsbeeck M, et al. **Instr Course Lect** 1994;43:475–81 (20 ref.)

Ultrasonography of the knee. Brys P, et al. **J Belge Radiol** 1996 Aug;79(4):155–9 (19 ref.)

[Sonography of the knee extensor system] Gruber G. **Ultraschall Med** 1996 Oct;17(5):206–11 (16 ref.) (Eng. Abstr.) **(Ger)**

[Standardized ultrasound study of the knee joint] Gruber G, et al. **Ultraschall Med** 1997 Apr;18(2):52–61 (6 ref.) (Eng. Abstr.) **(Ger)**

KNEE MEDIAL COLLATERAL LIGAMENT see **MEDIAL COLLATERAL LIGAMENT, KNEE**

KNEE PROSTHESIS

Revision total knee arthroplasty due to aseptic failure. Bostrom MP, et al. **Am J Knee Surg** 1996 Spring;9(2):91–8 (28 ref.)

Total knee arthroplasty. What have we learned? Scuderi GR, et al. **Am J Knee Surg** 1996 Spring;9(2):73–5 (18 ref.)

Prosthetic selection in total knee arthroplasty. Vince KG. **Am J Knee Surg** 1996 Spring;9(2):76–82 (54 ref.)

Polyethylene wear and osteolysis following total knee replacement. Ayers DC. **Instr Course Lect** 1997;46:205–13 (31 ref.)

Surgical exposure in revision total knee arthroplasty. Whiteside LA. **Instr Course Lect** 1997;46:221–5 (8 ref.)

Polyethylene wear in total hip and knee arthroplasties. Lewis G. **J Biomed Mater Res** 1997 Spring;38(1):55–75 (118 ref.)

Infected total knee arthroplasty: review. Berman AT, et al. **Orthopedics** 1997 Jun;20(6):563–6 (17 ref.)

[Knee joint endoprostheses] Zambelli PY, et al. **Ther Umsch** 1996 Oct;53(10):797–805 (47 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Infection of a total knee arthroplasty by Candida parapsilosis. A case report of successful treatment by joint reimplantation with a literature review. Hennessy MJ. **Am J Knee Surg** 1996 Summer;9(3):133–6 (15 ref.)

Diagnosis and management of the infected total knee arthroplasty. Simmons TD, et al. **Am J Knee Surg** 1996 Spring;9(2):99–106 (77 ref.)

Polyethylene wear and osteolysis following total knee replacement. Ayers DC. **Instr Course Lect** 1997;46:205–13 (31 ref.)

Supracondylar fracture of the distal femur proximal to a total knee replacement. Ayers DC. **Instr Course Lect** 1997; 46:197–203 (23 ref.)

Extensor mechanism problems in total knee arthroplasty. Dennis DA. **Instr Course Lect** 1997;46:171–80 (119 ref.)

Wound complications in total knee arthroplasty. Dennis DA. **Instr Course Lect** 1997;46:165–9 (69 ref.)

The management of bone defects in revision total knee arthroplasty. Engh GA, et al. **Instr Course Lect** 1997; 46:227–36 (26 ref.)

Neurovascular complications following total knee replacement: causes, treatment, and prevention. Johanson NA. **Instr Course Lect** 1997;46:181–4 (15 ref.)

The stiff total knee replacement: causes, treatment, and prevention. Johanson NA. **Instr Course Lect** 1997;46:191–5 (28 ref.)

Thromboembolic disease. Pellegrini VD Jr. **Instr Course Lect** 1997;46:185–9 (34 ref.)

Management of the patient with an infected knee arthroplasty. Pellegrini VD Jr. **Instr Course Lect** 1997; 46:215–9 (29 ref.)

Oerskovia xanthineolytica infection of a prosthetic joint: case report and review. Harrington RD, et al. **J Clin Microbiol** 1996 Jul;34(7):1821–4 (18 ref.)

Metallosis mimicking infection in a cemented total knee replacement. Huo MH, et al. **Orthopedics** 1997 May; 20(5):466–70 (18 ref.)

Establishing a universal protocol for deep vein thrombosis following orthopedic surgery: total knee arthroplasty. Sculco TP. **Orthopedics** 1996 Aug;19 Suppl:6–8 (22 ref.)

INSTRUMENTATION

Which primary total knee replacement? A review of currently available TKR in the United Kingdom. Liow RY, et al. **Ann R Coll Surg Engl** 1997 Sep;79(5):335–40 (35 ref.)

METHODS

Surgical techniques and the management of fixed deformities in total knee arthroplasty. Delfico AJ, et al. **Am J Knee Surg** 1996 Spring;9(2):83–90 (24 ref.)

The use of bone graft for managing bone defects in complex total knee arthroplasty. Rosenberg AG. **Am J Knee Surg** 1997 Winter;10(1):42–8 (15 ref.)

KNEE REPLACEMENT, TOTAL see **KNEE PROSTHESIS**

KNOCKOUT MICE see **MICE, KNOCKOUT**

KNOWLEDGE

Bakhtin, nursing narratives, and dialogical consciousness. Bowers R, et al. **ANS Adv Nurs Sci** 1997 Mar;19(3):70–7 (28 ref.)

Questioning science: how knowledge is socially constructed. Thorogood N. **Br Dent J** 1997 Sep 13;183(5):152–5 (38 ref.)

Nursing science in the global community. Ketefian S, et al. **Image J Nurs Sch** 1997 Spring;29(1):11–5 (27 ref.)

Social epistemology, gender and nursing theory. Cash K. **Int J Nurs Stud** 1997 Apr;34(2):137–43 (27 ref.)

The postmodernist hoax and its effects on nursing. Kermode S, et al. **Int J Nurs Stud** 1996 Aug;33(4):375–84 (36 ref.)

Developing the nurse as a knowledge worker in health--learning the artistry of practice. Antrobus S. **J Adv Nurs** 1997 Apr;25(4):829–35 (27 ref.)

Scientific knowledge in medicine: a new clinical epistemology? Marshall T. **J Eval Clin Pract** 1997 Apr; 3(2):133–8 (16 ref.)

Externalizing the critical thinking in knowledge development and clinical judgment. Facione NC, et al. **Nurs Outlook** 1996 May–Jun;44(3):129–36 (19 ref.)

Determining the effect that consultation–liaison psychiatry in primary care has on family physicians' psychiatric knowledge and practice. Carr VJ, et al. **Psychosomatics** 1997 May–Jun;38(3):217–29 (51 ref.)

"Don't think zebras": uncertainty, interpretation, and the place of paradox in clinical education. Hunter K. **Theor Med** 1996 Sep;17(3):225–41 (19 ref.)

[Antinomies and epistemological "sutures" between the socio-biological and the collective-individual characteristics within the field of social epidemiology] de Melo-Filho DA. **Rev Saude Publica** 1996 Aug;30(4):383–91 (22 ref.) (Eng. Abstr.) **(Por)**

KNOWLEDGE ACQUISITION (COMPUTER) see **ARTIFICIAL INTELLIGENCE**

KNOWLEDGE, ATTITUDES, PRACTICE

The effects of HIV counseling and testing on risk-related practices and help-seeking behavior. Wolitski RJ, et al. **AIDS Educ Prev** 1997 Jun;9(3 Suppl):52–67 (45 ref.)

Dietary surveillance for states and communities. Byers T, et al. **Am J Clin Nutr** 1997 Apr;65(4 Suppl):1210S–1214S (22 ref.)

Drug interactions among the elderly [news] Liaw ST. **Aust Fam Physician** 1997 Apr;26(4):355–7 (29 ref.)

Attitudes and access: advancing the rights of people with disabilities [editorial; comment] Peat M. **Can Med Assoc J** 1997 Mar 1;156(5):657–9 (8 ref.) Comment on: Can Med Assoc J 1997 .Mar 1;156(5):647–56.

The patient and family adjustment to chronic disease in the home. Medalie JH. **Disabil Rehabil** 1997 Apr;19(4):163–70 (9 ref.)

KNOWLEDGE, ATTITUDES, PRACTICE

Understanding the impact of effective teenage pregnancy prevention programs. Frost JJ, et al. **Fam Plann Perspect** 1995 Sep–Oct;27(5):188–95 (13 ref.)

Age, socioeconomic status, and exercise self–efficacy [see comments] Clark DO. **Gerontologist** 1996 Apr;36(2):157–64 (53 ref.) Comment in: Gerontologist 1996 Apr;36(2):145–6. Comment in: Gerontologist 1996 Apr;36(2):174–7.

Clinicians teaching orthopaedics: effective strategies. Meals RA, et al. **Instr Course Lect** 1997;46:583–94 (38 ref.)

Research communication media: creating an outstanding impression with abstracts, poster exhibits, and slides. Russell JA, et al. **Instr Course Lect** 1994;43:625–37 (29 ref.)

The politics of sex research and constructions of female sexuality: what relevance to sexual health work with young women? Few C. **J Adv Nurs** 1997 Mar;25(3):615–25 (95 ref.)

HIV/AIDS risk in heterosexual college students. A review of a decade of literature. Lewis JE, et al. **J Am Coll Health** 1997 Jan;45(4):147–58 (76 ref.)

What if Osler were one of us? Inpatient teaching today. Ende J. **J Gen Intern Med** 1997 Apr;12 Suppl 2:S41–8 (38 ref.)

HIV–infected competitive athletes. What are the risks? What precautions should be taken? Feller A, et al. **J Gen Intern Med** 1997 Apr;12(4):243–6 (30 ref.)

Why African Americans may not be participating in clinical trials. Harris Y, et al. **J Natl Med Assoc** 1996 Oct; 88(10):630–4 (19 ref.)

Nurses' knowledge of pain assessment and management: how much progress have we made? McCaffery M, et al. **J Pain Symptom Manage** 1997 Sep;14(3):175–88 (39 ref.)

Attitudes and beliefs about medication and pain management in children. McGrath PJ, et al. **J Palliat Care** 1996 Autumn; 12(3):46–50 (22 ref.)

Attitudes to Papanicolaou smears. Conway K. **J Psychosom Obstet Gynaecol** 1996 Dec;17(4):189–94 (45 ref.)

Bridging student health risks and academic achievement through comprehensive school health programs. Symons CW, et al. **J Sch Health** 1997 Aug;67(6):220–7 (73 ref.)

Studying knowledge, culture, and behavior in applied medical anthropology [see comments] Pelto PJ, et al. **Med Anthropol Q** 1997 Jun;11(2):147–63 (29 ref.) Comment in: Med Anthropol Q 1997 Jun;11(2):252–5.

Negotiating relevance: belief, knowledge, and practice in international health projects [see comments] Yoder PS. **Med Anthropol Q** 1997 Jun;11(2):131–46 (54 ref.) Comment in: Med Anthropol Q 1997 Jun;11(2):252–5.

Privileged knowledge and mothers' "perceptions": the case of breast–feeding and insufficient milk in Bangladesh. Zeitlyn S, et al. **Med Anthropol Q** 1997 Mar;11(1):56–68 (17 ref.)

Helping heart attack victims to save their own lives [editorial; comment] Langton PE, et al. **Med J Aust** 1997 Mar 3; 166(5):228–9 (9 ref.) Comment on: Med J Aust 1997 Mar 3;166(5):233–6.

Militarism: a psychosocial disease. Coulter NA. **Med War** 1992 Jan–Mar;8(1):7–17 (15 ref.)

Medical education––addressing the needs of the dying child. Charlton R. **Palliat Med** 1996 Jul;10(3):240–6 (79 ref.)

Meeting unmet need: new strategies. Robey B, et al. **Popul Rep J** 1996 Sep;(43):1–35 (247 ref.)

Sleep disorders in Chinese culture: experiences from a study of insomnia in Taiwan. Lee YJ. **Psychiatry Clin Neurosci** 1995 May;49(2):103–6 (9 ref.)

Group education for rheumatoid arthritis patients. Taal E, et al. **Semin Arthritis Rheum** 1997 Jun;26(6):805–16 (56 ref.)

Lymphatic filariasis and the women of India. Bandyopadhyay L. **Soc Sci Med** 1996 May;42(10):1401–10 (33 ref.)

STDS in women attending family planning clinics: a case study in Addis Ababa. Duncan ME, et al. **Soc Sci Med** 1997 Feb;44(4):441–54 (101 ref.)

Changing patterns of pharmaceutical practice in the United States. Vuckovic N, et al. **Soc Sci Med** 1997 May; 44(9):1285–302 (126 ref.)

Do family planning programs affect fertility preferences? A literature review. Freedman R. **Stud Fam Plann** 1997 Mar; 28(1):1–13 (55 ref.)

[Breast feeding promotion program implementation: 1992–1994] Mikiel–Kostyra K. **Pediatr Pol** 1996 Jan; 71(1):65–7 (10 ref.) **(Pol)**

[Knowledge and opinions of physicians on acquired immunodeficiency syndrome] González López E. **Med Clin (Barc)** 1996 Nov 16;107(17):664–8 (85 ref.) **(Spa)**

KNOWLEDGE BASES (COMPUTER) see **ARTIFICIAL INTELLIGENCE**

KNOWLEDGE OF RESULTS (PSYCHOLOGY)

Use of effective feedback to facilitate adult learning. Sachdeva AK. **J Cancer Educ** 1996 Summer;11(2):106–18 (53 ref.)

KNOWLEDGE REPRESENTATION (COMPUTER) see **ARTIFICIAL INTELLIGENCE**

KOCK POUCH see **PROCTOCOLECTOMY, RESTORATIVE**

KOEHLER'S DISEASE see **OSTEOCHONDRITIS**

KOLMOGOROV–SMIRNOV TEST see **STATISTICS, NONPARAMETRIC**

KORO

COMPLICATIONS

Genital pain associated with genital retraction: a case of Koro syndrome. Wilson S, et al. **J Pain Symptom Manage** 1997 Mar;13(3):176–8 (8 ref.)

ETHNOLOGY

[Koro: cultural heritage from Southeast Asia] Kesomaa M, et al. **Duodecim** 1995;111(12):1093–5 (17 ref.) **(Fin)**

KORSAKOFF PSYCHOSIS see **ALCOHOL AMNESTIC DISORDER**

KORSAKOFF SYNDROME see **ALCOHOL AMNESTIC DISORDER**

KRABBE'S DISEASE see **LEUKODYSTROPHY, GLOBOID CELL**

KRAUROSIS PENIS see **BALANITIS**

KRAUROSIS VULVAE

DIAGNOSIS

Lichen sclerosus: early diagnosis is the key to treatment. Hall D. **Nurse Pract** 1996 Dec;21(12 Pt 1):57–8, 61–2 (16 ref.)

PATHOLOGY

Chronic white plaque of the vulva in postmenopausal women. Inazumi T, et al. **J Dermatol** 1996 Sep;23(9):635–8 (6 ref.)

KRAUSE'S END BULBS see **MECHANORECEPTORS**

KREBS CYCLE see **CITRIC ACID CYCLE**

KRILL see **CRUSTACEA**

KRINGLES

PHYSIOLOGY

Roles of kringle domain–containing serine proteases in epithelial–mesenchymal transitions during embryonic development. Théry C, et al. **Acta Anat (Basel)** 1996; 156(3):162–72 (101 ref.)

KRUKENBERG TUMOR

ETIOLOGY

Krukenberg syndrome as a natural manifestation of tumor cell entrapment. Sugarbaker PH, et al. **Cancer Treat Res** 1996;82:163–91 (85 ref.)

SECONDARY

Case report: Krukenberg tumours arising from a primary duodenojejunal adenocarcinoma. Loke TK, et al. **Clin Radiol** 1997 Feb;52(2):154–5 (12 ref.)

KRUSKAL–WALLIS H STATISTIC see **STATISTICS, NONPARAMETRIC**

KRYPTON

DIAGNOSTIC USE

[Regional evaluation of ventilation by RI] Kawakami K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:42–4 (3 ref.) **(Jpn)**

KSHV see **HERPESVIRUS, KAPOSI'S SARCOMA–ASSOCIATED**

KUFS DISEASE see **NEURONAL CEROID–LIPOFUSCINOSIS**

KUNG FU see **MARTIAL ARTS**

KUNITZ PANCREATIC TRYPSIN INHIBITOR see **APROTININ**

KUPFFER CELLS

IMMUNOLOGY

[Hepatic macrophages and virus] Steffan AM. **Pathol Biol (Paris)** 1997 Feb;45(2):169–83 (59 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Cell volume signalling, osmolytes and liver function. Häussinger D, et al. **Digestion** 1997;58 Suppl 1:21–3 (17 ref.)

PHYSIOLOGY

Role of Kupffer cells, endotoxin and free radicals in hepatotoxicity due to prolonged alcohol consumption: studies in female and male rats. Thurman RG, et al. **J Nutr** 1997 May;127(5 Suppl):903S–906S (30 ref.)

[Role of Kupffer cells in liver diseases] Yamamoto H, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):701–3 (5 ref.) **(Jpn)**

KURU

[Dementias by prions: a new pathogenic paradigm] López de Munain A. **Rev Neurol** 1997 Jul;25 Suppl 1:S55–62 (136 ref.) **(Spa)**

ETIOLOGY

[Prions and infantile pathology] Nigro N, et al. **Minerva Pediatr** 1996 May;48(5):221–3 (8 ref.) (Eng. Abstr.) **(Ita)**

TRANSMISSION

[Kuru] Mori S. **Nippon Rinsho** 1997 Apr;55(4):987–92 (16 ref.) (Eng. Abstr.) **(Jpn)**

KWASHIORKOR

PHYSIOPATHOLOGY

[Malnutrition and the heart (hypoproteinemia, kwashiorkor)] Komine T, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (15):36–8 (13 ref.) **(Jpn)**

KYASANUR FOREST DISEASE VIRUS see **ENCEPHALITIS VIRUSES, TICK–BORNE**

KYNURENINE

ANALOGS & DERIVATIVES

Kynurenine hydroxylase and kynureninase inhibitors as tools to study the role of kynurenine metabolites in the central nervous system. Moroni F, et al. **Adv Exp Med Biol** 1996; 398:203–10 (22 ref.)

Endogenous kynurenine derivatives and pain. Weil–Fugazza J. **Adv Exp Med Biol** 1996;398:83–7 (27 ref.)

METABOLISM

The kynurenine pathway and neurologic disease. Therapeutic strategies. Heyes MP. **Adv Exp Med Biol** 1996;398:125–9 (23 ref.)

Kynurenine pathway enzymes in brain. Properties of enzymes and regulation of quinolinic acid synthesis. Saito K, et al. **Adv Exp Med Biol** 1996;398:485–92 (42 ref.)

PHARMACOLOGY

Kynurenine hydroxylase and kynureninase inhibitors as tools to study the role of kynurenine metabolites in the central nervous system. Moroni F, et al. **Adv Exp Med Biol** 1996; 398:203–10 (22 ref.)

PHYSIOLOGY

Kynurenines and anxiety. Lapin IP. **Adv Exp Med Biol** 1996; 398:191–4 (18 ref.)

Basic mechanisms of kynurenine actions in the central nervous system. Stone TW, et al. **Adv Exp Med Biol** 1996; 398:195–201 (37 ref.)

Endogenous kynurenine derivatives and pain. Weil–Fugazza J. **Adv Exp Med Biol** 1996;398:83–7 (27 ref.)

KYPHOSIS

COMPLICATIONS

Lumbar spinal stenosis: indications for arthrodesis and spinal instrumentation. Herkowitz HN. **Instr Course Lect** 1994; 43:425–33 (35 ref.)

CONGENITAL

Coffin–Siris syndrome: a case of an extremely low birthweight infant with severe kyphoscoliosis. Suzumura H, et al. **Acta Paediatr Jpn** 1996 Oct;38(5):537–40 (5 ref.)

DIAGNOSIS

Idiopathic scoliosis and kyphosis. Pizzutillo PD. **Instr Course Lect** 1994;43:185–91 (10 ref.)

ETIOLOGY

Dystrophic kyphoscoliosis in neurofibromatosis type I: a report of two cases and review of the literature. Vandenbroucke J, et al. **Eur Spine J** 1997;6(4):273–7 (15 ref.)

SURGERY

Neurological complications in segmental spinal instrumentation: analysis of 750 patients. Cervellati S, et al. **Eur Spine J** 1996;5(3):161–6 (25 ref.)

THERAPY

Idiopathic scoliosis and kyphosis. Pizzutillo PD. **Instr Course Lect** 1994;43:185–91 (10 ref.)

L3T4 ANTIGENS see **ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE**

L FORMS

ISOLATION & PURIFICATION

Bacterial L-forms research in China. Huang G, et al. **Chin Med J (Engl)** 1996 Jan;109(1):18–20 (0 ref.)

PATHOGENICITY

Bacterial persistence and expression of disease. Domingue GJ Sr, et al. **Clin Microbiol Rev** 1997 Apr;10(2):320–44 (185 ref.)

L-MYC GENES see **GENES, MYC**

L-MYC PROTEINS see **PROTO-ONCOGENE PROTEINS C-MYC**

L SELECTIN see **L-SELECTIN**

LABELING, DRUG see **DRUG LABELING**

LABELING, FOOD see **FOOD LABELING**

LABELING, PRODUCT see **PRODUCT LABELING**

LABETALOL

THERAPEUTIC USE

Successful management of acute aortic dissection in a heart transplant recipient. Defraigne JO, et al. **Acta Chir Belg** 1997 Jun;97(3):141–4 (15 ref.)

LABOR

see related
FETAL MONITORING
OXYTOCICS
TRIAL OF LABOR

Intrathecal narcotics for labor analgesia. Stephens MB, et al. **Am Fam Physician** 1997 Aug;56(2):463–70 (27 ref.)

Active management of labor. Peaceman AM, et al. **Am J Obstet Gynecol** 1996 Aug;175(2):363–8 (28 ref.)

Intrapartum fetal monitoring. Permezel M. **Aust Fam Physician** 1997 Mar;26(3):255–7, 260–1 (10 ref.)

Intrapartum care. Chua S, et al. **Aust N Z J Obstet Gynaecol** 1997 Feb;37(1):25–35 (82 ref.)

Preliminary risk-benefit analysis of ropivacaine in labour and following surgery. Cederholm I. **Drug Saf** 1997 Jun; 16(6):391–402 (60 ref.)

Dead babies and the birth of desire: maternal erotic transferences and countertransferences. Wrye HK. **J Am Acad Psychoanal** 1996 Spring;24(1):75–94 (14 ref.)

Intrathecal analgesia for labor. Wildman KM, et al. **J Fam Pract** 1997 Jun;44(6):535–40 (16 ref.)

Pain management for labor and delivery in the 90s. James CF. **J Fla Med Assoc** 1997 Jan;84(1):28–36 (19 ref.)

Childbirth education in the 1990s and beyond. Zwelling E. **J Obstet Gynecol Neonatal Nurs** 1996 Jun;25(5):425–32 (49 ref.)

Controversies: prelabor rupture of the membranes at term: the case for expectant management. Keirse MJ, et al. **J Perinat Med** 1996;24(6):563–72 (46 ref.)

Fetal pulse oximetry during labor: issues and recommendations for clinical use. Saling E. **J Perinat Med** 1996;24(5):467–78 (25 ref.)

Premature rupture of the membranes in term patients. Duff P. **Semin Perinatol** 1996 Oct;20(5):401–8 (41 ref.)

[The role of citokinesin the parturition] Terao T. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Aug; 48(8):742–50 (22 ref.) **(Jpn)**

DRUG EFFECTS

The prevention of post partum haemorrhage: optimising routine management of the third stage of labour. Prendiville WJ. **Eur J Obstet Gynecol Reprod Biol** 1996 Oct; 69(1):19–24 (22 ref.)

ETHNOLOGY

Cultural competence in the care of abused women. Campbell JC, et al. **J Nurse Midwifery** 1996 Nov-Dec;41(6):457–62 (22 ref.)

METABOLISM

Oncofetal fibronectin: new insight into the physiology of implantation and labor. Dunn PA, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Nov-Dec; 25(9):753–7 (24 ref.)

PHYSIOLOGY

Role of platelet-activating factor in parturition. Narahara H, et al. **Adv Exp Med Biol** 1996;416:269–75 (41 ref.)

A speculative review of parturition in the mare. Thorburn GD. **Equine Vet J Suppl** 1993 Apr;(14):41–9 (72 ref.)

Sonographic assessment of cervical changes during pregnancy and delivery: current concepts. Maymon R, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Aug; 67(2):149–55 (46 ref.)

Acute pain and the obstetric patient: recent developments in analgesia for labor and delivery. Ward ME. **Int Anesthesiol Clin** 1997 Spring;35(2):83–103 (115 ref.)

Physiological changes at parturition and their relationship to metabolic disorders. Goff JP, et al. **J Dairy Sci** 1997 Jul;80(7):1260–8 (69 ref.)

Nuclear factor-kappa-B/steroid hormone receptor interactions as a functional basis of anti-inflammatory action of steroids in reproductive organs. van der Burg B, et al. **Mol Hum Reprod** 1996 Jun;2(6):433–8 (57 ref.)

PSYCHOLOGY

Post-traumatic stress disorder after childbirth: the phenomenon of traumatic birth. Reynolds JL. **Can Med Assoc J** 1997 Mar 15;156(6):831–5 (32 ref.)

LABOR COMPLICATIONS

Obstetric complications and rheumatic disease. Johnson MJ. **Rheum Dis Clin North Am** 1997 Feb;23(1):169–82 (50 ref.)

Acute gastric aspiration: prevention and treatment. Rowe TF. **Semin Perinatol** 1997 Aug;21(4):313–9 (45 ref.)

[Cord prolapse. Review of the literature. A series of 50 cases] Dufour P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(8):841–5 (20 ref.) (Eng. Abstr.) **(Fre)**

[Fetal macrosomia: diagnosis and management in labor] Aschkenazi S, et al. **Harefuah** 1997 Feb 2;132(3):198–204 (37 ref.) **(Heb)**

CHEMICALLY INDUCED

[Maternal complications from tocolytic treatment with beta-mimetics. Three cases of pulmonary edema] Hourdequin P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(5):528–32 (21 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Postpartum obturator nerve syndrome: case report and review of the nerve compression syndrome during pregnancy and delivery] Lindner A, et al. **Zentralbl Gynakol** 1997;119(3):93–9 (43 ref.) (Eng. Abstr.) **(Ger)**

[Amniotic fluid embolism in trial of labor. A case report] D'Addato F, et al. **Minerva Ginecol** 1997 May;49(5):217–20 (16 ref.) (Eng. Abstr.) **(Ita)**

EPIDEMIOLOGY

Birth trauma. A five-year review of incidence and associated perinatal factors. Perlow JH, et al. **J Reprod Med** 1996 Oct;41(10):754–60 (22 ref.)

ETIOLOGY

Occult obstetric trauma and anal incontinence. Sultan AH, et al. **Eur J Gastroenterol Hepatol** 1997 May;9(5):423–7 (32 ref.)

Peripartum pubic symphysis separation: a case series and review of the literature. Snow RE, et al. **Obstet Gynecol Surv** 1997 Jul;52(7):438–43 (21 ref.)

RADIOGRAPHY

Disruption of the pelvic ring during spontaneous childbirth. A case report. Pennig D, et al. **J Bone Joint Surg Br** 1997 May;79(3):438–40 (8 ref.)

SURGERY

[Pelvic floor reconstruction after traumatic childbirth damage] Franz HB, et al. **Zentralbl Chir** 1996;121(8):688–91 (20 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Transcutaneous electrical nerve stimulation in labour pain: a systematic review. Carroll D, et al. **Br J Obstet Gynaecol** 1997 Feb;104(2):169–75 (20 ref.)

[Vaginal delivery in multiple pregnancy--a plea for spontaneous delivery] Hohlfeld P, et al. **Arch Gynecol Obstet** 1996;259 Suppl 1:S137–46 (58 ref.) **(Fre)**

[Obstetric perspectives: consensus of the gynecology department of the University of Liège. Document of the 3rd cycle studies, October 96] Biquet G, et al. **Rev Med Liege** 1997 Mar;52(3):142–8 (0 ref.) **(Fre)**

[Clinical aspects and therapy of amniotic fluid embolism. Illustration based on a case report] Bussen S, et al. **Z Geburtshilfe Neonatol** 1997 May-Jun;201(3):95–8 (50 ref.) (Eng. Abstr.) **(Ger)**

LABOR, INDUCED

see related
OXYTOCICS

Managing post-term pregnancy. **Drug Ther Bull** 1997 Mar; 35(3):17–8 (19 ref.)

Chemotherapeutic induction of labour. A rational approach. Xenakis EM, et al. **Drugs** 1997 Jul;54(1):61–8 (71 ref.)

Controversies: premature rupture of membranes at term--no advantage of delaying induction > 24 hours. Ingemarsson I. **J Perinat Med** 1996;24(6):573–9 (19 ref.)

Induced early delivery of a fetus with hypoplastic left heart: a moral choice when neither surgery nor abortion is an acceptable option. Paris JJ, et al. **J Perinatol** 1997 Jul-Aug; 17(4):314–7 (22 ref.)

[Induced labor. Consensus development conference. National College of French Obstetricians and Gynecologists. Paris, 29-30 November 1995] **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(1 Suppl):1–4 (0 ref.) **(Fre)**

METHODS

Methods of cervical ripening and labor induction. Summers L. **J Nurse Midwifery** 1997 Mar-Apr;42(2):71–85 (130 ref.)

Ripening of the unfavorable cervix with extraamniotic catheter balloon: clinical experience and review. Sherman DJ, et al. **Obstet Gynecol Surv** 1996 Oct;51(10):621–7 (24 ref.)

[Prostaglandin-induced labor--is the prostaglandin E2 vaginal gel a "new" alternative?] Rath W, et al. **Geburtshilfe Frauenheilkd** 1996 Oct;56(10):536–41 (23 ref.) (Eng. Abstr.) **(Ger)**

LABOR MIGRATION see **TRANSIENTS AND MIGRANTS**

LABOR ONSET

Onset and forces of term labor. Ulmsten U. **Acta Obstet Gynecol Scand** 1997 Jul;76(6):499–514 (172 ref.)

LABOR, PREMATURE

see related
INFANT, PREMATURE
TOCOLYTIC AGENTS

Should intravenous hydration be the first line of defense with threatened preterm labor? A critical review of the literature. Freda MC, et al. **J Perinatol** 1996 Sep-Oct; 16(5):385–9 (15 ref.)

Rudimentary uterine horn pregnancy. A case report on surviving twins delivered eight days apart. Nahum GG. **J Reprod Med** 1997 Aug;42(8):525–32 (30 ref.)

[New perspectives for an old problem: premature labor] Barrón Vallejo J, et al. **Ginecol Obstet Mex** 1997 Aug; 65:326–31 (34 ref.) (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

The effect of cocaine on myometrial contractile activity: basic mechanisms. Monga M. **Semin Perinatol** 1996 Apr; 20(2):140–6 (45 ref.)

DIAGNOSIS

The diagnostic accuracy of cervico-vaginal fetal fibronectin in predicting preterm delivery: an overview. Chien PF, et al. **Br J Obstet Gynaecol** 1997 Apr;104(4):436–44 (54 ref.)

Prediction of prematurity. Goepfert AR, et al. **Curr Opin Obstet Gynecol** 1996 Dec;8(6):417–27 (137 ref.)

Preterm labor and preterm premature rupture of the membranes. Diagnosis and management. Mercer BM, et al. **Infect Dis Clin North Am** 1997 Mar;11(1):177–201 (151 ref.)

Use of fetal fibronectin in clinical practice. Ascarelli MH, et al. **Obstet Gynecol Surv** 1997 Apr;52(4 Suppl):S1–12 (32 ref.)

[Uterine activity and premature delivery. Review of the literature] Vercoustre L. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(2):131–6 (30 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Nitric oxide and the myometrium. Norman J. **Pharmacol Ther** 1996;70(2):91–100 (70 ref.)

ENZYMOLOGY

The possible role of sodium-potassium adenosine triphosphatase in preterm labour. Du Toit PJ, et al. **Med Hypotheses** 1996 Sep;47(3):197–8 (11 ref.)

EPIDEMIOLOGY

Physical activity and the risk of preterm labor: an epidemiological review and synthesis of recent literature. Dye TD, et al. **Semin Perinatol** 1996 Aug;20(4):334–9 (28 ref.)

ETIOLOGY

Pre-term pre-labour amniorrhexis. Carroll S, et al. **Curr Opin Obstet Gynecol** 1996 Dec;8(6):441–8 (34 ref.)

Pathogenesis of preterm labor and preterm premature rupture of membranes associated with intraamniotic infection. Gomez R, et al. **Infect Dis Clin North Am** 1997 Mar; 11(1):135–76 (220 ref.)

Motor vehicle crashes, pregnancy loss and preterm labor [see comments] Pearlman MD. **Int J Gynaecol Obstet** 1997 May; 57(2):127–32 (17 ref.) Comment in: Int J Gynaecol Obstet 1997 May;57(2):123.

LABOR, PREMATURE

The possible role of sodium-potassium adenosine triphosphatase in preterm labour. Du Toit PJ, et al. **Med Hypotheses** 1996 Sep;47(3):197-8 (11 ref.)

A critical review of the relationship between gestational weight gain and preterm delivery. Carmichael SL, et al. **Obstet Gynecol** 1997 May;89(5 Pt 2):865-73 (64 ref.)

Physical activity and the risk of preterm labor: an epidemiological review and synthesis of recent literature. Dye TD, et al. **Semin Perinatol** 1996 Aug;20(4):334-9 (28 ref.)

[Premature labor and intrauterine infection] Egarter C, et al. **Geburtshilfe Frauenheilkd** 1996 Sep;56(9):M138-40 (15 ref.) **(Ger)**

[Bacterial vaginosis and preterm labor] Bar-David J, et al. **Harefuah** 1997 Jun 15;132(12):871-5 (50 ref.) **(Heb)**

[Causes of premature birth and its prevention] Terao T. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Aug;48(8):660-5 (0 ref.) **(Jpn)**

MICROBIOLOGY

The relationship between bacterial vaginosis and preterm birth. A review. Chaim W, et al. **Arch Gynecol Obstet** 1997; 259(2):51-8 (44 ref.)

NURSING

The nursing management of women experiencing preterm labor: clinical guidelines and why they are needed. Jones DP, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Sep; 25(7):569-92 (56 ref.)

PHYSIOPATHOLOGY

[Uterine activity and premature delivery. Review of the literature] Vercoustre L. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(2):131-6 (30 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Use of antibiotics to prevent preterm birth. Gibbs RS, et al. **Am J Obstet Gynecol** 1997 Aug;177(2):375-80 (35 ref.)

Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. Steele RW. **Clin Pediatr (Phila)** 1996 Jul;35(7):378-9 (0 ref.)

Infection and prematurity: evidence-based approaches. McGregor JA, et al. **Curr Opin Obstet Gynecol** 1996 Dec; 8(6):428-32 (42 ref.)

ACOG committee opinion. Home uterine activity monitoring. Number 172, May 1996 (replaces number 115, September 1992). Committee on Obstetric Practice. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1996 Jul;54(1):71-7 (32 ref.)

Prevention of prematurity. Hobel CJ. **Pediatr Ann** 1996 Apr; 25(4):188; 191-8 (72 ref.)

[Causes of premature birth and its prevention] Terao T. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Aug;48(8):660-5 (0 ref.) **(Jpn)**

LABOR PRESENTATION

see related
DELIVERY
VERSION, FETAL

LABOR PRESENTATION, BREECH see **BREECH PRESENTATION**

LABOR, SECOND STAGE see **LABOR STAGE, SECOND**

LABOR STAGE, SECOND

PHYSIOLOGY

A second look at the second stage of labor [see comments] Roberts J, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Jun; 25(5):415-23 (70 ref.) Comment in: J Obstet Gynecol Neonatal Nurs 1997 Jan-Feb;26(1):15.

LABOR UNIONS

A strategic response to the occupational health establishment. Sass R. **Int J Health Serv** 1996;26(2):355-70 (11 ref.)

ORGANIZATION & ADMINISTRATION

Organized labor and health reform: union interests and the Clinton plan. Weil LA. **J Public Health Policy** 1997; 18(1):30-48 (81 ref.)

LABORATORIES

see related
TECHNOLOGY, MEDICAL LABORATORY

Clinically relevant, cost-effective clinical microbiology. Strategies to decrease unnecessary testing. Wilson ML. **Am J Clin Pathol** 1997 Feb;107(2):154-67 (68 ref.)

Decision-making laboratory computer systems as essential tools for achievement of total quality. Blick KE. **Clin Chem** 1997 May;43(5):908-12 (8 ref.)

Thoughts on quality-control systems: a laboratorian's perspective. Cembrowski GS. **Clin Chem** 1997 May; 43(5):886-92 (33 ref.)

Mycobacteriology laboratory. Heifets L. **Clin Chest Med** 1997 Mar;18(1):35-53 (68 ref.)

The mycobacteriology laboratory. Past, present, and future. Heifets LB. **Clin Lab Med** 1996 Sep;16(3):513-25 (32 ref.)

Special considerations for the clinical microbiology laboratory in the diagnosis of infections in the cancer patient. Sandin RL, et al. **Infect Dis Clin North Am** 1996 Jun;10(2):413-30 (41 ref.)

Role of the microbiology laboratory in monitoring and identifying resistance: use of molecular biology. Pfaller MA, et al. **New Horiz** 1996 Aug;4(3):361-9 (31 ref.)

The use of the psychological laboratory to study sensitive survey topics. Willis GB. **NIDA Res Monogr** 1997; 167:416-38 (55 ref.)

[The immunology laboratory in malignant blood diseases] López Berges MC, et al. **Sangre (Barc)** 1996 Aug; 41(4):281-8 (44 ref.) **(Spa)**

ECONOMICS

The impact of managed care on genetic testing laboratories in the United States. Mark HF, et al. **Cytobios** 1996; 88(352):43-52 (8 ref.)

HISTORY

Poultry vaccine laboratories in the United States: a historical perspective. Hitchner SB. **Avian Dis** 1996 Apr-Jun; 40(2):255-65 (10 ref.)

LEGISLATION & JURISPRUDENCE

An overview of consumer protection act--remedial aspects in laboratory services. Thergaonkar A, et al. **Indian J Pathol Microbiol** 1996 Jul;39(3):237-50 (39 ref.)

Microbiology testing and the pediatrician's office. Rogers WO, et al. **Pediatr Infect Dis J** 1997 Apr;16(4):339-45 (13 ref.)

STANDARDS

Standards of laboratory practice: evaluation of fetal lung maturity. National Academy of Clinical Biochemistry. Ashwood ER. **Clin Chem** 1997 Jan;43(1):211-4 (21 ref.)

A laboratorian's perspective on evaluation and implementation of new laboratory tests. O'Kane DJ, et al. **Clin Chem** 1997 Sep;43(9):1771-80 (61 ref.)

Clinical mycobacteriology. Work flow and optional protocols for laboratories in industrialized countries. Della-Latta P. **Clin Lab Med** 1996 Sep;16(3):677-95 (76 ref.)

Tuberculosis bacteriology laboratory services and incremental protocols for developing countries. Laszlo A. **Clin Lab Med** 1996 Sep;16(3):697-716 (59 ref.)

Biosafety in the clinical mycobacteriology laboratory. Richmond JY, et al. **Clin Lab Med** 1996 Sep;16(3):527-50 (38 ref.)

Clinical mycobacteriology. Activities and recommendations by the association of state and territorial public health laboratory directors. Warren NG, et al. **Clin Lab Med** 1996 Sep;16(3):731-43 (24 ref.)

Quality assurance in the mycobacteriology laboratory. Quality control, quality improvement, and proficiency testing. Woods GL, et al. **Clin Lab Med** 1996 Sep; 16(3):657-75 (45 ref.)

Office laboratory procedures, office economics, patient and parent education, and urinary tract infection. Ey JL, et al. **Curr Opin Pediatr** 1996 Dec;8(6):639-49 (78 ref.)

Proposed guidelines for the internal quality control of analytical results in the medical laboratory. Petersen PH, et al. **Eur J Clin Chem Clin Biochem** 1996 Dec; 34(12):983-99 (48 ref.)

The role of the microbiology laboratory in the investigation of child sexual abuse. Dyson C, et al. **J Med Microbiol** 1996 Nov;45(5):313-8 (51 ref.)

Practical computer validation for pharmaceutical laboratories. McDowall RD. **J Pharm Biomed Anal** 1995 Dec;14(1-2):13-22 (20 ref.)

A procedure for assessing a contract testing facility: one sponsor's perspective. Twitty MM, et al. **Qual Assur** 1997 Jan-Mar;5(1):61-8 (4 ref.)

STATISTICS & NUMERICAL DATA

Automated selection of statistical quality-control procedures to assure meeting clinical or analytical quality requirements. Westgard JO, et al. **Clin Chem** 1997 Feb;43(2):400-3 (32 ref.)

TRENDS

Robotics and the changing face of the clinical laboratory [see comments] Boyd JC, et al. **Clin Chem** 1996 Dec; 42(12):1901-10 (30 ref.) Comment in: Clin Chem 1996 Dec;42(12):1899-900.

LABORATORIES, HOSPITAL

Effective use of the clinical microbiology laboratory for diagnosing diarrheal diseases. Hines J, et al. **Clin Infect Dis** 1996 Dec;23(6):1292-301 (81 ref.)

MANPOWER

Stress echocardiography: personnel and technical equipment. Ketteler T, et al. **Eur Heart J** 1997 Jun;18 Suppl D:D43-8 (25 ref.)

STANDARDS

Practical approaches to improve laboratory performance and transfusion safety. Galel SA, et al. **Am J Clin Pathol** 1997 Apr;107(4 Suppl 1):S43-9 (19 ref.)

Guidelines for internal peer review in the cardiac catheterization laboratory. Laboratory Performance Standards Committee, Society for Cardiac Angiography and Interventions. Heupler FA Jr, et al. **Cathet Cardiovasc Diagn** 1997 Jan;40(1):21-32 (74 ref.)

LABORATORY ANIMAL SCIENCE

STANDARDS

Health care for research animals is essential and affordable. Jacoby RO, et al. **FASEB J** 1997 Jul;11(8):609-14 (6 ref.)

LABORATORY ANIMALS see **ANIMALS, LABORATORY**

LABORATORY DIAGNOSIS see **DIAGNOSIS, LABORATORY**

LABORATORY INFORMATION SYSTEMS see **CLINICAL LABORATORY INFORMATION SYSTEMS**

LABORATORY MARKERS see **BIOLOGICAL MARKERS**

LABORATORY PERSONNEL

STANDARDS

Stress echocardiography: personnel and technical equipment. Ketteler T, et al. **Eur Heart J** 1997 Jun;18 Suppl D:D43-8 (25 ref.)

LABORATORY TECHNICIANS see **LABORATORY PERSONNEL**

LABYRINTH

see related
ENDOLYMPH

Value of fat suppression magnetic resonance imaging in the diagnosis of lipomas of the internal auditory canal. Hara A, et al. **Ann Otol Rhinol Laryngol** 1997 Apr;106(4):343-7 (27 ref.)

ABNORMALITIES

Congenital deformities of the inner ear: classification and aspects regarding cochlear implant surgery. Marangos N, et al. **Adv Otorhinolaryngol** 1997;52:52-6 (7 ref.)

Cochlear implants in children with congenital inner ear malformations. Luntz M, et al. **Arch Otolaryngol Head Neck Surg** 1997 Sep;123(9):974-7 (22 ref.)

The LAURA multichannel cochlear implant in a true Mondini dysplasia. Janssens S, et al. **Eur Arch Otorhinolaryngol** 1996;253(4-5):301-4 (12 ref.)

Isolated congenital internal auditory canal atresia with normal facial nerve function. Yates JA, et al. **Int J Pediatr Otorhinolaryngol** 1997 Jul 18;41(1):1-8 (5 ref.)

Cochlear implantation in common cavity malformations using a transmastoid labyrinthotomy approach. McElveen JT Jr, et al. **Laryngoscope** 1997 Aug;107(8):1032-6 (11 ref.)

Congenital malformation of the inner ear and recurrent meningitis. A case report. Hultcrantz M, et al. **ORL J Otorhinolaryngol Relat Spec** 1996 Nov-Dec; 58(6):333-7 (8 ref.)

ANATOMY & HISTOLOGY

On the role played by ontogenetic remodeling and functional transformation in the evolution of terrestrial hearing. Fritzsch B. **Brain Behav Evol** 1997 Jul;50(1):38-49 (75 ref.)

BLOOD SUPPLY

Abnormality of the labyrinthine artery and its topographical relation to the abducent nerve. Melling M, et al. **Acta Anat (Basel)** 1996;156(2):151-4 (38 ref.)

Aneurysm of the internal auditory artery: our experience and review of the literature. Banczerowski P, et al. **Acta Neurochir (Wien)** 1996;138(10):1157-62 (39 ref.)

CYTOLOGY

Cell fate specification in the inner ear. Fekete DM. **Curr Opin Neurobiol** 1996 Aug;6(4):533-41 (59 ref.)

DRUG EFFECTS

Very high-dose streptomycin labyrinthectomy. Sataloff RT, et al. **Ear Nose Throat J** 1996 Apr;75(4):239-43 (20 ref.)

Molecular and clinical implications of loop diuretic ototoxicity. Ikeda K, et al. **Hear Res** 1997 May;107(1-2):1-8 (96 ref.)

Dexamethasone perfusion of the labyrinth plus intravenous dexamethasone for Ménière's disease. Shea JJ Jr, et al. **Otolaryngol Clin North Am** 1996 Apr;29(2):353-8 (24 ref.)

EMBRYOLOGY

Cell fate specification in the inner ear. Fekete DM.

Curr Opin Neurobiol 1996 Aug;6(4):533-41 (59 ref.)

GROWTH & DEVELOPMENT

The role of neurotrophic factors in regulating the development of inner ear innervation. Fritzsch B, et al. **Trends Neurosci** 1997 Apr;20(4):159-64 (59 ref.)

INNERVATION

Balance and equilibrium, II: The retrovestibular neural pathway. Swartz JD, et al. **AJNR Am J Neuroradiol** 1996 Jun-Jul;17(6):1187-90 (9 ref.)

The role of neurotrophic factors in regulating the development of inner ear innervation. Fritzsch B, et al. **Trends Neurosci** 1997 Apr;20(4):159-64 (59 ref.)

METABOLISM

Role of the ISK protein in the IminK channel complex. Busch AE, et al. **Trends Pharmacol Sci** 1997 Jan;18(1):26-9 (48 ref.)

PATHOLOGY

Lipomas of the internal auditory canal. Singh SP, et al. **Arch Pathol Lab Med** 1996 Jul;120(7):681-3 (12 ref.)

Magnetic resonance imaging assessment of labyrinthine pathology. Marsot-Dupuch K, et al. **Eur Radiol** 1996; 6(5):621-30 (28 ref.)

PHYSIOLOGY

Strategies for clinical and experimental interventions for repair and regeneration in the inner ear. Raphael Y. **Adv Neurol** 1997;72:163-9 (50 ref.)

LABYRINTH DISEASES

DIAGNOSIS

MRI evidence of labyrinthine and eighth-nerve bundle involvement in mumps virus sudden deafness and vertigo. Comacchio F, et al. **ORL J Otorhinolaryngol Relat Spec** 1996 Nov-Dec; 58(6):295-7 (18 ref.)

[Imaging of the labyrinth and vestibular nerve. Clinical significance for differential diagnosis of vestibular diseases] Jäger L, et al. **Nervenarzt** 1997 Jun;68(6):443-58 (42 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Update on idiopathic perilymphatic fistulas. Kohut RI, et al. **Otolaryngol Clin North Am** 1996 Apr;29(2):343-52 (15 ref.)

SURGERY

Laser applications in inner ear surgery. Anthony PF. **Otolaryngol Clin North Am** 1996 Dec;29(6):1031-48 (26 ref.)

THERAPY

Strategies for clinical and experimental interventions for repair and regeneration in the inner ear. Raphael Y. **Adv Neurol** 1997;72:163-9 (50 ref.)

LABYRINTHITIS

ETIOLOGY

Mumps labyrinthitis, endolymphatic hydrops and sudden deafness in succession in the same ear. Hydén D. **ORL J Otorhinolaryngol Relat Spec** 1996 Nov-Dec; 58(6):338-42 (9 ref.)

VETERINARY

Otitis media and interna and temporohyoid osteoarthropathy. Blythe LL. **Vet Clin North Am Equine Pract** 1997 Apr; 13(1):21-42 (24 ref.)

LAC OPERON

Lac repressor-operator complex. Kercher MA, et al. **Curr Opin Struct Biol** 1997 Feb;7(1):76-85 (97 ref.)

GENETICS

Genome organization, natural genetic engineering and adaptive mutation. Shapiro JA. **Trends Genet** 1997 Mar; 13(3):98-104 (68 ref.)

LAC REPRESSORS see **REPRESSOR PROTEINS**

LACHESIS see **VIPERIDAE**

LACRIMAL APPARATUS

see related
DACRYOCYSTORHINOSTOMY
TEARS

Fibrous histiocytoma of the lacrimal sac. Choi G, et al. **Head Neck** 1997 Jan;19(1):72-5 (23 ref.)

INJURIES

Dog bite-induced canalicular lacerations: a review of 17 cases. Slonim CB. **Ophthal Plast Reconstr Surg** 1996 Sep; 12(3):218-22 (23 ref.)

PATHOLOGY

Normal anatomy and lesions of the lacrimal sac and duct: evaluated by dacryocystography, computed tomography, and MR imaging. Weber AL, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):199-217 (122 ref.)

PHYSIOLOGY

[Evaluation of lacrimal function] Tamura N, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:462-5 (12 ref.) **(Jpn)**

SURGERY

Current treatment of post-traumatic deformities. Residual orbital, adnexal, and soft-tissue abnormalities. Spinelli HM, et al. **Clin Plast Surg** 1997 Jul;24(3):519-30 (47 ref.)

LACRIMAL APPARATUS DISEASES

DIAGNOSIS

Benign and malignant tumors of the orbital cavity including the lacrimal gland. Warner MA, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):123-42 (109 ref.)

Normal anatomy and lesions of the lacrimal sac and duct: evaluated by dacryocystography, computed tomography, and MR imaging. Weber AL, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):199-217 (122 ref.)

Nasolacrimal drainage system cyst in an adult. Yamasoba T, et al. **ORL J Otorhinolaryngol Relat Spec** 1996 Nov-Dec;58(6):311-4 (8 ref.)

ETIOLOGY

Canalicular stenosis in the course of primary herpes simplex infection [letter] Jager GV, et al. **Br J Ophthalmol** 1997 Apr;81(4):332 (8 ref.)

PATHOLOGY

Tumors arising in the palpebral lobe of the lacrimal gland. Vangveeravong S, et al. **Ophthalmology** 1996 Oct; 103(10):1606-12 (38 ref.)

[Oncocytoma of the caruncle. Anatomo-clinical study apropos of a case] Girard B, et al. **J Fr Ophtalmol** 1996; 19(10):619-22 (23 ref.) (Eng. Abstr.) **(Fre)**

LACRIMAL DUCT OBSTRUCTION

CONGENITAL

Managing congenital lacrimal obstruction in general practice. Young JD, et al. **BMJ** 1997 Aug 2;315(7103):293-6 (29 ref.)

PHYSIOPATHOLOGY

Tearing: lacrimal obstructions. Sakol PJ. **Pa Med** 1996 Mar; 99 Suppl:99-104 (22 ref.)

SURGERY

Dacryocystocele in an adult: endoscopic management. Bhaya M, et al. **Am J Otolaryngol** 1997 Mar-Apr;18(2):131-4 (24 ref.)

THERAPY

Managing congenital lacrimal obstruction in general practice. Young JD, et al. **BMJ** 1997 Aug 2;315(7103):293-6 (29 ref.)

LACRIMAL GLAND see **LACRIMAL APPARATUS**

LACROSSE see **RACQUET SPORTS**

LACTALBUMIN

CHEMISTRY

Thermal unfolding of beta-lactoglobulin, alpha-lactalbumin, and bovine serum albumin. A thermodynamic approach. Relkin P. **Crit Rev Food Sci Nutr** 1996 Jul;36(6):565-601 (180 ref.)

LACTAMS

PHARMACOLOGY

[Mini review: a factor enhanced the antibacterial effect of beta-lactams on methicillin-resistant Staphylococcus aureus] Tajima Y. **Rinsho Byori** 1996 Nov;44(11):1093-9 (6 ref.) (Eng. Abstr.) **(Jpn)**

LACTASES see **BETA-GALACTOSIDASE**

LACTATE see **LACTIC ACID**

LACTATE DEHYDROGENASE

Methods for the separation of lactate dehydrogenases and clinical significance of the enzyme. Kopperschläger G, et al. **J Chromatogr B Biomed Appl** 1996 Sep 20; 684(1-2):25-49 (154 ref.)

BLOOD

The clinical value of lactate dehydrogenase in serum: a quantitative review. Huijgen HJ, et al. **Eur J Clin Chem Clin Biochem** 1997 Aug;35(8):569-79 (89 ref.)

Clinical and biological significance of serum tumor markers in adult T-cell leukemia. Sadamori N. **Leuk Lymphoma** 1996 Aug;22(5-6):415-9 (59 ref.)

METABOLISM

Biochemical adjustments to hypoxia by Amazon cichlids. Almeida-Val VM, et al. **Braz J Med Biol Res** 1995 Nov-Dec;28(11-12):1257-63 (27 ref.)

Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Drent M, et al. **Eur Respir J** 1996 Aug;9(8):1736-42 (60 ref.)

The fructose diphosphate/phosphate regulation of carbohydrate metabolism in low G + C gram-positive anaerobes. Russell JB, et al. **Res Microbiol** 1996 Jul-Sep; 147(6-7):528-35 (82 ref.)

LACTATES

BLOOD

Dangerous curves. A perspective on exercise, lactate, and the anaerobic threshold. Myers J, et al. **Chest** 1997 Mar; 111(3):787-95 (105 ref.)

METABOLISM

Replenishment of muscle glycogen after high-intensity exercise: a role for intramuscular lactate glyconeogenesis? Palmer TN, et al. **Biochem Soc Trans** 1997 Feb;25(1):25-30 (43 ref.)

LACTATION

see related
BREAST FEEDING
COLOSTRUM
MILK
MILK, HUMAN

Dermatologic drugs, pregnancy, and lactation. A conservative guide. Reed BR. **Arch Dermatol** 1997 Jul; 133(7):894-8 (38 ref.)

Lipid metabolism in the lactating mammary gland. Barber MC, et al. **Biochim Biophys Acta** 1997 Aug 16; 1347(2-3):101-26 (257 ref.)

Dermatologic drug use during pregnancy and lactation. Reed BR. **Dermatol Clin** 1997 Jan;15(1):197-206 (112 ref.)

Pregnancy and nursing. Burakoff R, et al. **Gastroenterol Clin North Am** 1995 Sep;24(3):689-98 (48 ref.)

Consensus statement. Lactational amenorrhea method for family planning. **J Nurse Midwifery** 1996 Sep-Oct; 41(5):405-6 (00 ref.)

Significance of lipid consumption during lactation. Ortiz-Olaya N, et al. **Rev Invest Clin** 1996 Nov-Dec; 48(6):473-8 (40 ref.)

[Breast feeding as family planning in a global perspective] Bøhler E. **Tidsskr Nor Laegeforen** 1997 Feb 20;117(5):701-4 (46 ref.) (Eng. Abstr.) **(Nor)**

DRUG EFFECTS

Drug therapy in the nursing mother. Dillon AE, et al. **Obstet Gynecol Clin North Am** 1997 Sep;24(3):675-96 (47 ref.)

[Ciprofloxacin treatment for pregnant or lactating women and children?] Aizenstein O, et al. **Harefuah** 1997 Feb 16; 132(4):283-8 (41 ref.) **(Heb)**

METABOLISM

Reproduction: a global nutritional challenge. Goldberg GR. **Proc Nutr Soc** 1997 Mar;56(1B):319-33 (58 ref.)

Protein metabolism during lactation. Jessop NS. **Proc Nutr Soc** 1997 Mar;56(1A):169-75 (22 ref.)

Adipose tissue metabolism during lactation: where do we go from here? McNamara JP. **Proc Nutr Soc** 1997 Mar; 56(1A):149-67 (72 ref.)

Mammary-tissue amino acid transport systems. Shennan DB, et al. **Proc Nutr Soc** 1997 Mar;56(1A):177-91 (64 ref.)

[Metabolic host-tumor relationships during perinatal phase] Argilés JM, et al. **Med Clin (Barc)** 1997 Jun 28; 109(5):186-94 (52 ref.) **(Spa)**

PHYSIOLOGY

Breastfeeding: physiological, endocrine and behavioural adaptations caused by oxytocin and local neurogenic activity in the nipple and mammary gland. Uvnäs-Moberg K, et al. **Acta Paediatr** 1996 May;85(5):525-30 (43 ref.)

The use of lactational amenorrhea as a fertility regulating method. Rivera R. **Adv Contracept** 1996 Sep;12(3):179-85 (10 ref.)

LACTATION

Integrative functions of lactational hormones in social behavior and stress management. Carter CS, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:164–74 (78 ref.)

Oxytocin control of maternal behavior. Regulation by sex steroids and offspring stimuli. Pedersen CA. **Ann N Y Acad Sci** 1997 Jan 15;807:126–45 (65 ref.)

Energy and protein requirements during lactation. Dewey KG. **Annu Rev Nutr** 1997;17:19–36 (49 ref.)

Nutrition during lactation. Hamosh M. **Bibl Nutr Dieta** 1996; (53):23–36 (48 ref.)

Parathyroid hormone–related protein and its role in pregnancy, lactation, and neonatal growth and development [comment] Cooper CW. **Eur J Endocrinol** 1997 May;136(5):465–6 (13 ref.) Comment on: Eur J Endocrinol 1997 May;136(5):546–51.

The interplay of feeding and genetics on heifer rearing and first lactation milk yield: a review. Lee AJ. **J Anim Sci** 1997 Mar;75(3):846–51 (23 ref.)

Cellular defense mechanisms in the udder and lactation of goats. Paape MJ, et al. **J Anim Sci** 1997 Feb;75(2):556–65 (81 ref.)

Influence of prepubertal feeding level on milk yield potential of dairy heifers: a review. Sejrsen K, et al. **J Anim Sci** 1997 Mar;75(3):828–35 (63 ref.)

Pregnancy and lactation as risk factors for subsequent bone loss and osteoporosis. Sowers M. **J Bone Miner Res** 1996 Aug;11(8):1052–60 (90 ref.)

Breastfeeding update. 2: Clinical lactation management. Powers NG, et al. **Pediatr Rev** 1997 May;18(5):147–61 (9 ref.)

Mathematical modelling of nitrogen flow in growing pigs and lactating sows. Pettigrew JE. **Proc Nutr Soc** 1997 Jul; 56(2):645–56 (27 ref.)

Nutritional control of amino acid supply to the mammary gland during lactation in the pig. Trottier NL. **Proc Nutr Soc** 1997 Jul;56(2):581–91 (39 ref.)

Enduring effects of infant feeding experiences on adult blood pressure. Myers MM. **Psychosom Med** 1996 Nov–Dec; 58(6):612–21 (45 ref.)

[Hypercalcemia induced by lactation in 2 patients with treated hypoparathyroidism] Cathébras P, et al. **Rev Med Interne** 1996;17(8):675–6 (10 ref.) (Eng. Abstr.) **(Fre)**

LACTATION DISORDERS

see related

GALACTORRHEA

Too much of a good thing. Maternal and infant hyperlactation syndromes. Livingstone V. **Can Fam Physician** 1996 Jan;42:89–99 (20 ref.)

PSYCHOLOGY

Privileged knowledge and mothers' "perceptions": the case of breast–feeding and insufficient milk in Bangladesh. Zeitlyn S, et al. **Med Anthropol Q** 1997 Mar;11(1):56–68 (17 ref.)

LACTATION, PROLONGED see **LACTATION**

LACTIC ACID

Sensory aspects of host location in mosquitoes. Bowen MF. **Ciba Found Symp** 1996;200:197–208; discussion 208–11, 226–32 (41 ref.)

ADMINISTRATION & DOSAGE

Medium–depth chemical peeling. Otley CC, et al. **Semin Cutan Med Surg** 1996 Sep;15(3):145–54 (23 ref.)

BIOSYNTHESIS

Microbiological production of lactic acid. Litchfield JH. **Adv Appl Microbiol** 1996;42:45–95 (253 ref.)

Short–chain carboxylic–acid–stimulated, PMN–mediated gingival inflammation. Niederman R, et al. **Crit Rev Oral Biol Med** 1997;8(3):269–90 (144 ref.)

BLOOD

Fetal monitoring with lactate. Nordström L, et al. **Baillieres Clin Obstet Gynaecol** 1996 Jun;10(2):225–42 (93 ref.)

Lactate during exercise at high altitude. Kayser B. **Eur J Appl Physiol** 1996;74(3):195–205 (51 ref.)

Lactate metabolism and regional lactate exchange after cardiac surgery. Takala J, et al. **New Horiz** 1996 Nov; 4(4):483–92 (43 ref.)

Elevations in blood lactate: overview of use in critical care. Toffaletti J. **Scand J Clin Lab Invest Suppl** 1996;224:107–10 (9 ref.)

Use of blood lactate measurements for prediction of exercise performance and for control of training. Recommendations for long–distance running. Billat LV. **Sports Med** 1996 Sep; 22(3):157–75 (138 ref.)

METABOLISM

Lactate transport in heart in relation to myocardial ischemia. Halestrap AP, et al. **Am J Cardiol** 1997 Aug 4; 80(3A):17A–25A (56 ref.)

Biotechnology of lactic acid bacteria with special reference to bacteriophage resistance. Daly C, et al. **Antonie Van Leeuwenhoek** 1996 Oct;70(2–4):99–110 (118 ref.)

Genomic organization of lactic acid bacteria. Davidson BE, et al. **Antonie Van Leeuwenhoek** 1996 Oct;70(2–4):161–83 (153 ref.)

Metabolic engineering of sugar catabolism in lactic acid bacteria. de Vos WM. **Antonie Van Leeuwenhoek** 1996 Oct; 70(2–4):223–42 (132 ref.)

Lytic systems in lactic acid bacteria and their bacteriophages. Gasson MJ. **Antonie Van Leeuwenhoek** 1996 Oct; 70(2–4):147–59 (63 ref.)

The role of transport processes in survival of lactic acid bacteria. Energy transduction and multidrug resistance. Konings WN, et al. **Antonie Van Leeuwenhoek** 1997 Feb; 71(1–2):117–28 (65 ref.)

Biosynthesis of bacteriocins in lactic acid bacteria. Nes IF, et al. **Antonie Van Leeuwenhoek** 1996 Oct;70(2–4):113–28 (82 ref.)

Biopreservation by lactic acid bacteria. Stiles ME. **Antonie Van Leeuwenhoek** 1996 Oct;70(2–4):331–45 (132 ref.)

Barriers to application of genetically modified lactic acid bacteria. Verrips CT, et al. **Antonie Van Leeuwenhoek** 1996 Oct;70(2–4):299–316 (44 ref.)

Lactic acid bacteria as vaccine delivery vehicles. Wells JM, et al. **Antonie Van Leeuwenhoek** 1996 Oct;70(2–4):317–30 (51 ref.)

Antifungal attributes of lactic acid bacteria--a review. Batish VK, et al. **Crit Rev Biotechnol** 1997;17(3):209–25 (61 ref.)

Injectable microcapsules prepared with biodegradable poly(alpha–hydroxy) acids for prolonged release of drugs. Ogawa Y. **J Biomater Sci Polym Ed** 1997;8(5):391–409 (85 ref.)

D–lactic acidosis: turning sugar into acids in the gastrointestinal tract. Halperin ML, et al. **Kidney Int** 1996 Jan;49(1):1–8 (75 ref.)

Buffers: bicarbonate, lactate and pyruvate. Feriani M. **Kidney Int Suppl** 1996 Nov;56:S75–80 (61 ref.)

The fructose diphosphate/phosphate regulation of carbohydrate metabolism in low G + C gram–positive anaerobes. Russell JB, et al. **Res Microbiol** 1996 Jul–Sep; 147(6–7):528–35 (82 ref.)

THERAPEUTIC USE

Cosmetic use of alpha–hydroxy acids. Vidt DG, et al. **Cleve Clin J Med** 1997 Jun;64(6):327–9 (11 ref.)

LACTIC ACIDOSIS see **ACIDOSIS, LACTIC**

LACTIC CYTOCHROME REDUCTASE see **LACTATE DEHYDROGENASE**

LACTOBACILLUS

Lactobacillus bacteremia: description of the clinical course in adult patients without endocarditis. Antony SJ, et al. **Clin Infect Dis** 1996 Oct;23(4):773–8 (25 ref.)

Functional dairy foods with Lactobacillus strain GG. Salminen S. **Nutr Rev** 1996 Nov;54(11 Pt 2):S99–101 (32 ref.)

CHEMISTRY

Enterococcus faecalis cytolysin and lactocin S of Lactobacillus sake. Gilmore MS, et al. **Antonie Van Leeuwenhoek** 1996 Feb;69(2):129–38 (35 ref.)

Purification of bacteriocins of lactic acid bacteria: problems and pointers. Carolissen–Mackay V, et al. **Int J Food Microbiol** 1997 Jan;34(1):1–16 (65 ref.)

CLASSIFICATION

Lactic acid bacteria of foods and their current taxonomy. Stiles ME, et al. **Int J Food Microbiol** 1997 Apr 29; 36(1):1–29 (167 ref.)

GENETICS

Genomic organization of lactic acid bacteria. Davidson BE, et al. **Antonie Van Leeuwenhoek** 1996 Oct;70(2–4):161–83 (153 ref.)

Inducible gene expression and environmentally regulated genes in lactic acid bacteria. Kok J. **Antonie Van Leeuwenhoek** 1996 Oct;70(2–4):129–45 (77 ref.)

Barriers to application of genetically modified lactic acid bacteria. Verrips CT, et al. **Antonie Van Leeuwenhoek** 1996 Oct;70(2–4):299–316 (44 ref.)

Plasmids in Lactobacillus. Wang TT, et al. **Crit Rev Biotechnol** 1997;17(3):227–72 (188 ref.)

GROWTH & DEVELOPMENT

The Lactobacillus anomaly: total iron abstinence. Weinberg ED. **Perspect Biol Med** 1997 Summer;40(4):578–83 (27 ref.)

[Criteria for selection of lactobacilli for probiotic use] Nemcová R. **Vet Med (Praha)** 1997 Jan;42(1):19–27 (84 ref.) (Eng. Abstr.) **(Slo)**

IMMUNOLOGY

[The current concepts of the influence of lactobacilli on the immune system of the human body] Kostiuk OP, et al. **Fiziol Zh** 1997;43(3–4):106–15 (51 ref.) (Eng. Abstr.) **(Ukr)**

ISOLATION & PURIFICATION

Selective detection, enumeration and identification of potentially probiotic Lactobacillus and Bifidobacterium species in mixed bacterial populations. Charteris WP, et al. **Int J Food Microbiol** 1997 Mar 18;35(1):1–27 (301 ref.)

Principles of ex ovo competitive exclusion and in ovo administration of Lactobacillus reuteri. Edens FW, et al. **Poult Sci** 1997 Jan;76(1):179–96 (120 ref.)

METABOLISM

Metabolic engineering of sugar catabolism in lactic acid bacteria. de Vos WM. **Antonie Van Leeuwenhoek** 1996 Oct; 70(2–4):223–42 (132 ref.)

The role of transport processes in survival of lactic acid bacteria. Energy transduction and multidrug resistance. Konings WN, et al. **Antonie Van Leeuwenhoek** 1997 Feb; 71(1–2):117–28 (65 ref.)

The proteolytic systems of lactic acid bacteria. Kunji ER, et al. **Antonie Van Leeuwenhoek** 1996 Oct;70(2–4):187–221 (186 ref.)

Biosynthesis of bacteriocins in lactic acid bacteria. Nes IF, et al. **Antonie Van Leeuwenhoek** 1996 Oct;70(2–4):113–28 (82 ref.)

Biopreservation by lactic acid bacteria. Stiles ME. **Antonie Van Leeuwenhoek** 1996 Oct;70(2–4):331–45 (132 ref.)

Bacteriocins of Lactobacillus plantarum strains from fermented foods. Olasupo NA. **Folia Microbiol (Praha)** 1996;41(2):130–6 (25 ref.)

Regulation of carbohydrate transport in Lactococcus and Lactobacillus. Ye J. **Res Microbiol** 1996 Jul–Sep; 147(6–7):523–7 (31 ref.)

PHYSIOLOGY

Lytic systems in lactic acid bacteria and their bacteriophages. Gasson MJ. **Antonie Van Leeuwenhoek** 1996 Oct; 70(2–4):147–59 (63 ref.)

Principles of ex ovo competitive exclusion and in ovo administration of Lactobacillus reuteri. Edens FW, et al. **Poult Sci** 1997 Jan;76(1):179–96 (120 ref.)

VIROLOGY

Biotechnology of lactic acid bacteria with special reference to bacteriophage resistance. Daly C, et al. **Antonie Van Leeuwenhoek** 1996 Oct;70(2–4):99–110 (118 ref.)

LACTOBACILLUS ACIDOPHILUS

GROWTH & DEVELOPMENT

Lactulose, lactic acid bacteria, intestinal microecology and mucosal protection. Salminen S, et al. **Scand J Gastroenterol Suppl** 1997;222:45–8 (19 ref.)

LACTOBACILLUS CASEI

GENETICS

The dlt operon in the biosynthesis of D–alanyl–lipoteichoic acid in Lactobacillus casei. Neuhaus FC, et al. **Microb Drug Resist** 1996 Spring;2(1):77–84 (44 ref.)

ISOLATION & PURIFICATION

Lactobacillus casei infection in an AIDS patient [letter] Abgrall S, et al. **Eur J Clin Microbiol Infect Dis** 1997 Feb; 16(2):180–2 (7 ref.)

METABOLISM

The dlt operon in the biosynthesis of D–alanyl–lipoteichoic acid in Lactobacillus casei. Neuhaus FC, et al. **Microb Drug Resist** 1996 Spring;2(1):77–84 (44 ref.)

LACTOCOCCUS

CHEMISTRY

Purification of bacteriocins of lactic acid bacteria: problems and pointers. Carolissen–Mackay V, et al. **Int J Food Microbiol** 1997 Jan;34(1):1–16 (65 ref.)

METABOLISM

The proteolytic systems of lactic acid bacteria. Kunji ER, et al. **Antonie Van Leeuwenhoek** 1996 Oct;70(2–4):187–221 (186 ref.)

Diacetyl formation by lactic bacteria. Escamilla–Hurtado ML, et al. **Rev Latinoam Microbiol** 1996 Apr–Jun; 38(2):129–37 (48 ref.)

LACTOCOCCUS LACTIS

GENETICS

Inducible gene expression and environmentally regulated genes in lactic acid bacteria. Kok J. **Antonie Van Leeuwenhoek** 1996 Oct;70(2–4):129–45 (77 ref.)

Progress in the development of Lactococcus lactis as a recombinant mucosal vaccine delivery system. Norton PM, et al. **Folia Microbiol (Praha)** 1995;40(3):225–30 (10 ref.)

Genetic determinants for the biosynthesis of nisin, a

bacteriocin produced by Lactococcus lactis. Rodríguez JM, et al. **Microbiologia** 1996 Mar;12(1):61–74 (45 ref.)

IMMUNOLOGY

Progress in the development of Lactococcus lactis as a recombinant mucosal vaccine delivery system. Norton PM, et al. **Folia Microbiol (Praha)** 1995;40(3):225–30 (10 ref.)

METABOLISM

Physiology of pyruvate metabolism in Lactococcus lactis. Cocaign-Bousquet M, et al. **Antonie Van Leeuwenhoek** 1996 Oct;70(2–4):253–67 (87 ref.)

The role of transport processes in survival of lactic acid bacteria. Energy transduction and multidrug resistance. Konings WN, et al. **Antonie Van Leeuwenhoek** 1997 Feb; 71(1–2):117–28 (65 ref.)

Casein and peptide degradation in lactic acid bacteria. Mierau I, et al. **Biotechnol Genet Eng Rev** 1997;14:279–301 (125 ref.)

Regulation of carbohydrate transport in Lactococcus and Lactobacillus. Ye J. **Res Microbiol** 1996 Jul–Sep; 147(6–7):523–7 (31 ref.)

PHYSIOLOGY

Lactococcus lactis and stress. Rallu F, et al. **Antonie Van Leeuwenhoek** 1996 Oct;70(2–4):243–51 (61 ref.)

LACTOFERRIN

BIOSYNTHESIS

Commercial production of lactoferrin, a multifunctional iron-binding glycoprotein. Ward PP, et al. **Biotechnol Genet Eng Rev** 1997;14:303–19 (114 ref.)

LACTOGEN HORMONE, PLACENTAL see **PLACENTAL LACTOGEN**

LACTOGENIC HORMONE, PITUITARY see **PROLACTIN**

LACTOGLOBULINS

CHEMISTRY

Thermal unfolding of beta-lactoglobulin, alpha-lactalbumin, and bovine serum albumin. A thermodynamic approach. Relkin P. **Crit Rev Food Sci Nutr** 1996 Jul;36(6):565–601 (180 ref.)

LACTONES

CHEMISTRY

Acetogenins from Annonaceae. Cavé A, et al. **Fortschr Chem Org Naturst** 1997;70:81–288 (245 ref.)

METABOLISM

Production of lactones and peroxisomal beta-oxidation in yeasts. Endrizzi A, et al. **Crit Rev Biotechnol** 1996; 16(4):301–29 (195 ref.)

Iodolactones and iodoaldehydes—mediators of iodine in thyroid autoregulation. Dugrillon A. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 4:41–5 (21 ref.)

PHARMACOLOGY

Mode of action of orlistat. Guerciolini R. **Int J Obes Relat Metab Disord** 1997 Jun;21 Suppl 3:S12–23 (42 ref.)

Bryostatin 1: differentiating agent from the depths [comment] Stone RM. **Leuk Res** 1997 May;21(5):399–401 (32 ref.) Comment on: Leuk Res 1997 May;21(5):391–7.

[Morphological reversion of tumor cells by histone deacetylase inhibitors and radicicol] Yoshida M, et al. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1512–8 (34 ref.) (Eng. Abstr.) **(Jpn)**

LACTOSE

ADMINISTRATION & DOSAGE

A toxicological review of lactose to support clinical administration by inhalation. Baldrick P, et al. **Food Chem Toxicol** 1997 Jul;35(7):719–33 (95 ref.)

ADVERSE EFFECTS

Diet does not ensure normal development in galactosemia [see comments] Widhalm K, et al. **J Am Coll Nutr** 1997 Jun;16(3):204–8 (51 ref.) Comment in: J Am Coll Nutr 1997 Jun;16(3):190–1.

METABOLISM

Phylogenetic analysis of the evolution of lactose digestion in adults. Holden C, et al. **Hum Biol** 1997 Oct;69(5):605–28 (108 ref.)

TOXICITY

A toxicological review of lactose to support clinical administration by inhalation. Baldrick P, et al. **Food Chem Toxicol** 1997 Jul;35(7):719–33 (95 ref.)

Low digestible carbohydrates (polyols and lactose): significance of adrenal medullary proliferative lesions in the rat. Lynch BS, et al. **Regul Toxicol Pharmacol** 1996 Jun;23(3):256–97 (279 ref.)

LACTOSE INTOLERANCE

Lactose intolerance in childhood [editorial] Bhutta ZA. **JPMA J Pak Med Assoc** 1996 Oct;46(10):216–7 (31 ref.)

[Milk intolerance] Nakamura T. **Nippon Naika Gakkai Zasshi** 1996 Jul 10;85(7):1079–84 (5 ref.) **(Jpn)**

[Lactose and its implications in gastroenterology. Nutrition and food sciences] Solomons NW. **Rev Invest Clin** 1996 Nov;48 Suppl:1–13 (60 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Lactose intolerance. Diagnosis and dietary treatment with milk substitutes. Talhouk RS, et al. **J Med Liban** 1996; 44(1):36–40 (51 ref.)

DIET THERAPY

Review article: the treatment of lactose intolerance. Suarez FL, et al. **Aliment Pharmacol Ther** 1995 Dec;9(6):589–97 (49 ref.)

Lactose intolerance. Diagnosis and dietary treatment with milk substitutes. Talhouk RS, et al. **J Med Liban** 1996; 44(1):36–40 (51 ref.)

EPIDEMIOLOGY

[Poor digestion of lactose. Its definition, prevalence in Mexico, and its implications in milk consumption] López P, et al. **Rev Invest Clin** 1996 Nov;48 Suppl:15–22 (47 ref.) (Eng. Abstr.) **(Spa)**

[Lactose intolerance. Its definition, its prevalence in Mexico, and its implications in milk consumption] Palma M, et al. **Rev Invest Clin** 1996 Nov;48 Suppl:25–31 (22 ref.) (Eng. Abstr.) **(Spa)**

[Secondary lactase deficiency in children and its epidemiologic implications] Vega Franco L. **Rev Invest Clin** 1996 Nov;48 Suppl:33–43 (50 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Dairy sensitivity, lactose malabsorption, and elimination diets in inflammatory bowel disease. Mishkin S. **Am J Clin Nutr** 1997 Feb;65(2):564–7 (54 ref.)

Gastrointestinal disorders due to cow's milk consumption. Barnard J. **Pediatr Ann** 1997 Apr;26(4):244–50 (19 ref.)

GENETICS

[Heredity of poor digestion of lactose] Lisker R. **Rev Invest Clin** 1996 Nov;48 Suppl:23–4 (12 ref.) (Eng. Abstr.) **(Spa)**

LACTOSE TOLERANCE TEST

[Lactose tolerance test] Nakamura T. **Nippon Rinsho** 1997 Apr;55 Suppl 2:107–8 (7 ref.) **(Jpn)**

LACTULOSE

DIAGNOSTIC USE

Clinical implications of the sugar absorption test: intestinal permeability test to assess mucosal barrier function. Uil JJ, et al. **Scand J Gastroenterol Suppl** 1997;223:70–8 (75 ref.)

PHARMACOLOGY

Lactulose, disaccharides and colonic flora. Clinical consequences. Clausen MR, et al. **Drugs** 1997 Jun; 53(6):930–42 (71 ref.)

Lactulose, lactic acid bacteria, intestinal microecology and mucosal protection. Salminen S, et al. **Scand J Gastroenterol Suppl** 1997;222:45–8 (19 ref.)

Effect of lactulose and fiber-rich diets on bile in relation to gallstone disease: an update. VanBerge-Henegouwen GP, et al. **Scand J Gastroenterol Suppl** 1997;222:68–71 (35 ref.)

Effects of lactulose on nitrogen metabolism. Weber FL Jr. **Scand J Gastroenterol Suppl** 1997;222:83–7 (42 ref.)

THERAPEUTIC USE

Lactulose and combination therapy of hepatic encephalopathy: the role of the intestinal microflora. Weber FL Jr. **Dig Dis** 1996;14 Suppl 1:53–63 (71 ref.)

A clinical hepatologist's predictions about non-absorbed carbohydrates for the early twenty-first century. Conn HO. **Scand J Gastroenterol Suppl** 1997;222:88–92 (51 ref.)

Lactulose and renal failure. Vogt B, et al. **Scand J Gastroenterol Suppl** 1997;222:100–1 (17 ref.)

LACUNAR DEMENTIA see **DEMENTIA, MULTI-INFARCT**

LACZ GENES see **LAC OPERON**

LAFORA DISEASE see **EPILEPSY, MYOCLONIC**

LAGOMORPHA

Syphilis in European brown hares (Lepus europaeus). Lumeij JT. **Vet Q** 1996;18 Suppl 3:S151–2 (8 ref.)

LAGOTHRIX see **CEBIDAE**

LAK CELLS see **KILLER CELLS, LYMPHOKINE-ACTIVATED**

LAKI-LORAND FACTOR see **FACTOR XIII**

LAMBDA IMMUNOGLOBULINS see **IMMUNOGLOBULINS, LAMBDA-CHAIN**

LAMBDA PHAGE see **BACTERIOPHAGE LAMBDA**

LAMBERT-EATON MYASTHENIC SYNDROME

Lambert-Eaton myasthenic syndrome: clinical diagnosis, immune-mediated mechanisms, and update on therapies. Sanders DB. **Ann Neurol** 1995 May;37 Suppl 1:S63–73 (58 ref.)

COMPLICATIONS

Acute ventilatory failure in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine. Smith AG, et al. **Neurology** 1996 Apr;46(4):1143–5 (15 ref.)

DIAGNOSIS

[Lambert-Eaton syndrome] Osterhage J, et al. **Med Klin** 1996 Aug 15;91(8):526–30 (34 ref.) **(Ger)**

DRUG THERAPY

3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome. Molgó J, et al. **Pflugers Arch** 1996;431(6 Suppl 2):R295–6 (25 ref.)

LAMBLIA see **GIARDIA**

LAMBLIA INTESTINALIS see **GIARDIA LAMBLIA**

LAMBLIASIS see **GIARDIASIS**

LAMENESS, ANIMAL

A clinical perspective on lameness originating in the carpus. Bramlage LR, et al. **Equine Vet J Suppl** 1988 Sep;(6):12–8 (13 ref.)

Laminitis in the dairy cow: a cell biological approach. Hendry KA, et al. **J Dairy Res** 1997 Aug;64(3):475–86 (65 ref.)

PHYSIOPATHOLOGY

Instrumentation and techniques in locomotion and lameness. Clayton HM. **Vet Clin North Am Equine Pract** 1996 Aug; 12(2):337–50 (31 ref.)

Kinetic and kinematic gait analysis and the assessment of lameness in the dog. DeCamp CE. **Vet Clin North Am Small Anim Pract** 1997 Jul;27(4):825–40 (42 ref.)

LAMINAR AIR-FLOW AREAS see **ENVIRONMENT, CONTROLLED**

LAMINECTOMY

Role of peridural fibrosis in the failed back: a review. Robertson JT. **Eur Spine J** 1996;5 Suppl 1:S2–6 (22 ref.)

METHODS

Spinal stenosis: indications for laminectomy. Garfin SR, et al. **Instr Course Lect** 1994;43:411–4 (24 ref.)

[The dorsal approach in degeneratively changed cervical spine] Yonenobu K, et al. **Orthopade** 1996 Nov;25(6):533–41 (34 ref.) (Eng. Abstr.) **(Ger)**

LAMININ

see related
RECEPTORS, LAMININ

BIOSYNTHESIS

Laminins in the adult and aged brain. Jucker M, et al. **Mol Chem Neuropathol** 1996 May–Aug;28(1–3):209–18 (44 ref.)

CHEMISTRY

Macromolecular organization of basement membranes. Timpl R. **Curr Opin Cell Biol** 1996 Oct;8(5):618–24 (60 ref.)

Domains of laminin. Engvall E, et al. **J Cell Biochem** 1996 Jun 15;61(4):493–501 (51 ref.)

The functions of laminins: lessons from in vivo studies. Ryan MC, et al. **Matrix Biol** 1996 Dec;15(6):369–81 (74 ref.)

LAMININ

DEFICIENCY

Peripheral nerve involvement in merosin-deficient congenital muscular dystrophy and dy mouse. Matsumura K, et al. **Neuromuscul Disord** 1997 Jan;7(1):7-12 (50 ref.)

GENETICS

Merosin/laminin-2 and muscular dystrophy. Wewer UM, et al. **Neuromuscul Disord** 1996 Dec;6(6):409-18 (69 ref.)

Molecular variants of fibronectin and laminin: structure, physiological occurrence and histopathological aspects. Kosmehl H, et al. **Virchows Arch** 1996 Dec;429(6):311-22 (132 ref.)

METABOLISM

Dystroglycan and laminins: glycoconjugates involved in branching epithelial morphogenesis. Durbeej M, et al. **Exp Lung Res** 1997 Mar-Apr;23(2):109-18 (43 ref.)

Laminins in lung development. Schuger L. **Exp Lung Res** 1997 Mar-Apr;23(2):119-29 (57 ref.)

Signal transduction by the alpha 6 beta 4 integrin: charting the path between laminin binding and nuclear events. Giancotti FG. **J Cell Sci** 1996 Jun;109 (Pt 6):1165-72 (84 ref.)

Molecular variants of fibronectin and laminin: structure, physiological occurrence and histopathological aspects. Kosmehl H, et al. **Virchows Arch** 1996 Dec;429(6):311-22 (132 ref.)

PHARMACOKINETICS

Matrigel: a useful tool to study endothelial differentiation. Baatout S, et al. **Rom J Intern Med** 1996 Jul-Dec; 34(3-4):263-9 (51 ref.)

PHYSIOLOGY

Endothelial differentiation using Matrigel (review). Baatout S. **Anticancer Res** 1997 Jan-Feb;17(1A):451-5 (65 ref.)

Laminin and the mechanism of neuronal outgrowth. Luckenbill-Edds L. **Brain Res Brain Res Rev** 1997 Feb; 23(1-2):1-27 (98 ref.)

Agrin, laminin beta 2 (s-laminin) and ARIA: their role in neuromuscular development. Ruegg MA. **Curr Opin Neurobiol** 1996 Feb;6(1):97-103 (58 ref.)

Regulation of capillary formation by laminin and other components of the extracellular matrix. Grant DS, et al. **EXS** 1997;79:317-33 (64 ref.)

The laminins. Malinda KM, et al. **Int J Biochem Cell Biol** 1996 Sep;28(9):957-9 (6 ref.)

Neuronal laminins and their cellular receptors. Powell SK, et al. **Int J Biochem Cell Biol** 1997 Mar;29(3):401-14 (133 ref.)

Integrins and laminins in tissue remodeling. Quaranta V, et al. **Kidney Int** 1997 May;51(5):1441-6 (60 ref.)

The functions of laminins: lessons from in vivo studies. Ryan MC, et al. **Matrix Biol** 1996 Dec;15(6):369-81 (74 ref.)

Role of laminin and integrin interactions in growth cone guidance. McKerracher L, et al. **Mol Neurobiol** 1996 Apr; 12(2):95-116 (157 ref.)

[Mechanism of laminin chain assembly] Nomizu M, et al. **Tanpakushitsu Kakusan Koso** 1996 Dec;41(16):2542-51 (42 ref.) **(Jpn)**

LAMININ RECEPTORS see **RECEPTORS, LAMININ**

LAMIVUDINE

PHARMACOLOGY

Newer nucleosides: lamivudine and stavudine. Katlama C, et al. **AIDS** 1996;10 Suppl A:S135-43 (58 ref.)

Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Perry CM, et al. **Drugs** 1997 Apr;53(4):657-80 (114 ref.)

THERAPEUTIC USE

Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Perry CM, et al. **Drugs** 1997 Apr;53(4):657-80 (114 ref.)

Lamivudine. Porche DJ. **J Assoc Nurses AIDS Care** 1996 May-Jun;7(3):51-3 (3 ref.)

Wheel keeps turning for antiviral combination chemotherapy. Coen DM. **Trends Microbiol** 1996 Feb;4(2):51-2 (14 ref.)

LAMPREYS

ANATOMY & HISTOLOGY

Lamprey spinal interneurons and their roles in swimming activity. Buchanan JT. **Brain Behav Evol** 1996;48(5):287-96 (49 ref.)

Retinopetal projections in lampreys. Vesselkin NP, et al. **Brain Behav Evol** 1996;48(5):277-86 (96 ref.)

The brains of lampreys and hagfishes: characteristics, characters, and comparisons. Wicht H. **Brain Behav Evol** 1996;48(5):248-61 (86 ref.)

Review of larval and postlarval eye ultrastructure in the lamprey (Cyclostomata) with special emphasis on Geotria australis (Gray). Meyer-Rochow VB, et al. **Microsc Res Tech** 1996 Dec 15;35(6):431-44 (95 ref.)

PHYSIOLOGY

Feeding and breathing in lampreys. Rovainen CM. **Brain Behav Evol** 1996;48(5):297-305 (67 ref.)

LANADIGENIN see **DIGOXIGENIN**

LANDAU-KLEFFNER SYNDROME

The Landau-Kleffner syndrome: increased understanding. Gordon N. **Brain Dev** 1997 Jul;19(5):311-6 (51 ref.)

PSYCHOLOGY

Acquired epileptiform aphasia. Tuchman RF. **Semin Pediatr Neurol** 1997 Jun;4(2):93-101 (74 ref.)

LANGAT VIRUS see **ENCEPHALITIS VIRUSES, TICK-BORNE**

LANGERHANS-CELL GRANULOMATOSIS see **HISTIOCYTOSIS, LANGERHANS-CELL**

LANGERHANS CELLS

IMMUNOLOGY

"HIV-peplotion vaccine"--a novel approach to protection against AIDS by transepithelial transport of viral peptides to Langerhans cells for long-term antiviral CTL response. (A review). Becker Y. **Acta Microbiol Immunol Hung** 1996; 43(1):1-17 (83 ref.)

Epidermal cytokines and the induction of allergic and non-allergic contact dermatitis. Kimber I, et al. **Arch Toxicol Suppl** 1997;19:229-38 (60 ref.)

Cadherins and Langerhans cell immunobiology. Udey MC. **Clin Exp Immunol** 1997 Jan;107 Suppl 1:6-8 (32 ref.)

[Langerhans cells and the immunological function of the skin] Buianova AV. **Lik Sprava** 1996 Mar-Apr;(3-4):24-7 (34 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Cytokine-mediated communication by keratinocytes and Langerhans cells with dendritic epidermal T cells. Takashima A, et al. **Semin Immunol** 1996 Dec;8(6):333-9 (87 ref.)

PHYSIOLOGY

Transfer of antivirals to skin Langerhans cells--a novel approach to anti-HIV treatment by "antiviral peplotion". Becker Y. **Acta Biochim Pol** 1996;43(1):175-81 (30 ref.)

Langerhans cells may trigger the psoriatic disease process via production of nitric oxide. Morhenn VB. **Immunol Today** 1997 Sep;18(9):433-6 (53 ref.)

Fc epsilon RI on human epidermal Langerhans cells: an old receptor with new structure and functions. Bieber T. **Int Arch Allergy Immunol** 1997 May-Jul;113(1-3):30-4 (28 ref.)

[The functional morphology of the Langerhans cells in the female reproductive tract] Bykov VL. **Morfologiia** 1997; 111(2):7-16 (109 ref.) (Eng. Abstr.) **(Rus)**

LANGUAGE

see related
MULTILINGUALISM
SIGN LANGUAGE

Recovery of language after brain damage. Karbe H, et al. **Adv Neurol** 1997;73:347-58 (46 ref.)

Audio-vocal learning in budgerigars. Hall WS, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:352-67 (58 ref.)

Brain, language and the origin of human mental functions. Maturana H, et al. **Biol Res** 1995;28(1):15-26 (13 ref.)

Does cognition in the disconnected right hemisphere require right hemisphere possession of language? Bogen JE. **Brain Lang** 1997 Mar;57(1):12-21 (72 ref.)

Modularity of language reconsidered. Levy Y. **Brain Lang** 1996 Nov;55(2):240-63 (63 ref.)

Activation without selection: parallel right hemisphere roles in language and intentional movement? Richards L, et al. **Brain Lang** 1997 Mar;57(1):151-78 (140 ref.)

Neuroanatomy of language processing studied with functional MRI. Binder JR. **Clin Neurosci** 1997;4(2):87-94 (112 ref.)

PET activation and language. Chertkow H, et al. **Clin Neurosci** 1997;4(2):78-86 (69 ref.)

Neurophysiological aspects of language processing. Friederici AD. **Clin Neurosci** 1997;4(2):64-72 (76 ref.)

What words are telling us about the brain. Raichle ME. **Cold Spring Harb Symp Quant Biol** 1996;61:9-14 (25 ref.)

The neural system of language: structure and development. Nobre AC, et al. **Curr Opin Neurobiol** 1997 Apr;7(2):262-8 (58 ref.)

New standardized visual acuity charts in Hindi and Gujarati. Khamar BM, et al. **Indian J Ophthalmol** 1996 Sep; 44(3):161-4 (4 ref.)

A new case of atypical cerebral dominance. Posteraro L, et al. **Ital J Neurol Sci** 1996 Jun;17(3):237-40 (19 ref.)

Listeners do hear sounds, not tongues. Fowler CA. **J Acoust Soc Am** 1996 Mar;99(3):1730-41 (77 ref.)

Humans, information and science. Jones P. **J Adv Nurs** 1996 Sep;24(3):591-8 (23 ref.)

Mind, brain, machine: language. Forrest DV. **J Am Acad Psychoanal** 1996 Fall;24(3):409-30 (51 ref.)

In defense of an onset-rime syllable structure for English. Treiman R, et al. **Lang Speech** 1995 Apr-Jun;38 (Pt 2):127-42 (32 ref.)

The noninvasive identification of language function. Neuroimaging and rapid transcranial magnetic stimulation. Gaillard WD, et al. **Neurosurg Clin N Am** 1997 Jul; 8(3):321-35 (100 ref.)

High-frequency brain activity: its possible role in attention, perception and language processing. Pulvermüller F, et al. **Prog Neurobiol** 1997 Aug;52(5):427-45 (130 ref.)

Views on how the electrical activity that the brain generates reflects the functions of different language structures. Kutas M. **Psychophysiology** 1997 Jul;34(4):383-98 (37 ref.)

Optimality: from neural networks to universal grammar. Prince A, et al. **Science** 1997 Mar 14;275(5306):1604-10 (18 ref.)

Electrophysiological studies of language and language impairment. Mills DL, et al. **Semin Pediatr Neurol** 1997 Jun;4(2):125-34 (27 ref.)

Language dominance in the cerebral hemispheres. Hamani C. **Surg Neurol** 1997 Jan;47(1):81-3 (20 ref.)

Schizophrenia as failure of hemispheric dominance for language. Crow TJ. **Trends Neurosci** 1997 Aug; 20(8):339-43 (67 ref.)

[Illegal drug use by secondary school children in Belgium: north-south differences] Navarro FJ, et al. **Rev Epidemiol Sante Publique** 1996 Oct;44(5):395-406 (41 ref.) (Eng. Abstr.) **(Fre)**

[Preparation of International Chemical Safety Cards (ICSC) and their translation into Japanese] Yamamoto M, et al. **Eisei Shikenjo Hokoku** 1994;(112):143-6 (3 ref.) (Eng. Abstr.) **(Jpn)**

[Brain structures of reading Japanese words with functional MRI] Makabe T, et al. **Nippon Rinsho** 1997 Jul; 55(7):1699-705 (29 ref.) (Eng. Abstr.) **(Jpn)**

LANGUAGE COMPREHENSION TESTS see **LANGUAGE TESTS**

LANGUAGE DELAY see **LANGUAGE DEVELOPMENT DISORDERS**

LANGUAGE DEVELOPMENT

see related
SPEECH

Preparing to read: the foundations of literacy. Bialystok E. **Adv Child Dev Behav** 1996;26:1-34 (140 ref.)

Input and learning processes in first language acquisition. Moerk EL. **Adv Child Dev Behav** 1996;26:181-228 (275 ref.)

Language acquisition: the acquisition of linguistic structure in normal and special populations. McDonald JL. **Annu Rev Psychol** 1997;48:215-41 (105 ref.)

The anatomical substrates for language and hemispheric specialization. Aboitiz F, et al. **Biol Res** 1995;28(1):45-50 (31 ref.)

What language reveals about children's categories of personhood. Budwig N, et al. **New Dir Child Dev** 1995 Fall;(69):21-32 (25 ref.)

Language acquisition and use: learning and applying probabilistic constraints. Seidenberg MS. **Science** 1997 Mar 14;275(5306):1599-603 (46 ref.)

Normal language acquisition. Rescorla L, et al. **Semin Pediatr Neurol** 1997 Jun;4(2):70-6 (67 ref.)

LANGUAGE DEVELOPMENT DISORDERS

DIAGNOSIS

Hearing, speech, language, and vestibular disorders in the fetal alcohol syndrome: a literature review. Church MW, et al. **Alcohol Clin Exp Res** 1997 May;21(3):495-512 (163 ref.)

Language acquisition: the acquisition of linguistic structure in normal and special populations. McDonald JL. **Annu Rev Psychol** 1997;48:215-41 (105 ref.)

ETIOLOGY

Language development in children with congenital strokes. Nass R. **Semin Pediatr Neurol** 1997 Jun;4(2):109-16 (59 ref.)

PATHOLOGY

Evidence from imaging on the relationship between brain structure and developmental language disorders. Semrud-Clikeman M. **Semin Pediatr Neurol** 1997 Jun; 4(2):117-24 (53 ref.)

PHYSIOPATHOLOGY

A theory of neurolinguistic development. Locke JL. **Brain Lang** 1997 Jun 15;58(2):265-326 (405 ref.)

[Neurobiological findings in children with specific language development disorders] von Suchodoletz W. **Z Kinder Jugenpsychiatr** 1997 Mar;25(1):35-45 (45 ref.) **(Ger)**

PSYCHOLOGY

Psychiatric aspects of hearing impairments. Hindley P. **J Child Psychol Psychiatry** 1997 Jan;38(1):101-17 (120 ref.)

Developmental language disorders. Hall NE.
Semin Pediatr Neurol 1997 Jun;4(2):77–85 (49 ref.)
Language disorders in children with autism. Rapin I, et al.
Semin Pediatr Neurol 1997 Jun;4(2):86–92 (31 ref.)

REHABILITATION

[Combined verbal and sign language for promoting communication development in non-verbal or or pre-verbal children and adolescents with mental retardation] Wilken E. **Rehabilitation (Stuttg)** 1996 Nov; 35(4):228–32 (11 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Evaluating intervention for language impaired children: a review of the literature. Law J. **Eur J Disord Commun** 1997;32(2 Spec No):1–14 (56 ref.)
Remediation of children with developmental language disorders. Dunn M. **Semin Pediatr Neurol** 1997 Jun; 4(2):135–42 (22 ref.)

LANGUAGE DISORDERS

see related
SPEECH DISORDERS

COMPLICATIONS

Tourette syndrome. Coprolalia and other coprophenomena. Singer C. **Neurol Clin** 1997 May;15(2):299–308 (49 ref.)

DIAGNOSIS

Practitioner review: developmental language disorders: a clinical update. Rapin I. **J Child Psychol Psychiatry** 1996 Sep;37(6):643–55 (108 ref.)
Cognition, language, and speech in amyotrophic lateral sclerosis: a review. Strong MJ, et al.
J Clin Exp Neuropsychol 1996 Apr;18(2):291–303 (70 ref.)
Adults with language-learning disabilities: new challenges and changing perspectives. Kleinman SN, et al.
Semin Speech Lang 1996 Aug;17(3):201–15; quiz 215–6 (102 ref.)
[Language and aphasias] Porta-Etessam J, et al.
Rev Neurol 1997 Aug;25(144):1269–77 (47 ref.) (Eng. Abstr.) **(Spa)**
[Language disorders: is EEG clinically useful?] Tuchman RF.
Rev Neurol 1997 May;25(141):744–9 (60 ref.) **(Spa)**

ETIOLOGY

Connectionist modeling of the recovery of language functions following brain damage. Harley TA. **Brain Lang** 1996 Jan; 52(1):7–24 (71 ref.)
Age-related effects on speech fluency. Caruso AJ, et al.
Semin Speech Lang 1997 May;18(2):171–9; quiz 179–80 (50 ref.)

PHYSIOPATHOLOGY

Electrophysiological studies of language and language impairment. Mills DL, et al. **Semin Pediatr Neurol** 1997 Jun;4(2):125–34 (27 ref.)

PSYCHOLOGY

Agrammatism in aphasiology. Goodglass H. **Clin Neurosci** 1997;4(2):51–6 (41 ref.)
Symbolic play of children with language impairment: a critical review. Casby MW. **J Speech Lang Hear Res** 1997 Jun;40(3):468–79 (73 ref.)

REHABILITATION

Connectionist modeling of the recovery of language functions following brain damage. Harley TA. **Brain Lang** 1996 Jan; 52(1):7–24 (71 ref.)

LANGUAGE PATHOLOGY see **SPEECH-LANGUAGE PATHOLOGY**

LANGUAGE TESTS

Neuropsychologic assessment in surgical treatment of epilepsy. Trenerry MR. **Mayo Clin Proc** 1996 Dec; 71(12):1196–200 (58 ref.)

LANGUAGE THERAPY

METHODS

Evaluating intervention for language impaired children: a review of the literature. Law J. **Eur J Disord Commun** 1997;32(2 Spec No):1–14 (56 ref.)

TRENDS

Recent advances in speech and language therapy. Appleton J, et al. **Br J Hosp Med** 1996 May 1–14;55(9):582–5 (19 ref.)

LANGUAGE TRAINING see **LANGUAGE THERAPY**

LANOLIN

The lanolin paradox. Wolf R. **Dermatology** 1996; 192(3):198–202 (44 ref.)

LANSING VIRUS see **POLIOVIRUSES, HUMAN 1–3**

LANTHANIDES see **METALS, RARE EARTH**

LANUGO see **HAIR**

LAPAROSCOPIC CHOLECYSTECTOMY see **CHOLECYSTECTOMY, LAPAROSCOPIC**

LAPAROSCOPIC SURGERY see **SURGERY, LAPAROSCOPIC**

LAPAROSCOPY

The role of laparoscopy in blunt abdominal trauma. Leppäniemi AK, et al. **Ann Med** 1996 Dec;28(6):483–9 (52 ref.)
Laparoscopy in the management of gastric adenocarcinoma. Burke EC, et al. **Ann Surg** 1997 Mar;225(3):262–7 (9 ref.)
The role of salpingoscopy and falloposcopy in infertility. Marana R, et al. **Curr Opin Obstet Gynecol** 1996 Aug; 8(4):257–60 (17 ref.)
Laparoscopic common bile duct exploration: a review. Ferzli GS, et al. **J Laparoendosc Surg** 1996 Dec;6(6):413–9 (36 ref.)
Laparoscopic ultrasonography for staging of gastrointestinal malignancy. Gouma DJ, et al.
Scand J Gastroenterol Suppl 1996;218:43–9 (19 ref.)
Laparoscopic diagnosis of gallbladder agenesis. Singh B, et al. **Surg Laparosc Endosc** 1997 Apr;7(2):129–32 (30 ref.)
Laparoscopic staging and intraoperative ultrasonography for liver tumor management. Ravikumar TS.
Surg Oncol Clin N Am 1996 Apr;5(2):271–82 (36 ref.)
[Value of diagnostic laparoscopy in abdominal trauma] Röthlin M, et al. **Unfallchirurg** 1997 Jul;100(7):595–600 (60 ref.) **(Ger)**
[The non-palpable testis: modern diagnostic and therapeutic approaches] Battaglino F, et al. **Pediatr Med Chir** 1996 Jul–Aug;18(4):407–10 (27 ref.) (Eng. Abstr.) **(Ita)**
[Diagnosis of liver disease on laparoscopy: special reference to type B and C hepatitis] Sugaya H, et al.
Nippon Shokakibyo Gakkai Zasshi 1996 Nov;93(11):783–8 (58 ref.) **(Jpn)**

ADVERSE EFFECTS

Port site metastasis after laparoscopic-assisted vaginal hysterectomy for endometrial cancer: possible mechanisms and prevention. Wang PH, et al. **Gynecol Oncol** 1997 Jul; 66(1):151–5 (26 ref.)
Implantation metastasis of ovarian cancer after third-look laparoscopy. Gungor M, et al.
JPMA J Pak Med Assoc 1996 May;46(5):111–2 (6 ref.)

ECONOMICS

Clinical economics review: the health-care economic implications of minimal access gastrointestinal surgery. Guillou PJ, et al. **Aliment Pharmacol Ther** 1996 Oct; 10(5):707–13 (32 ref.)
Clinical economics review: the management of gallstone disease. Hussaini SH. **Aliment Pharmacol Ther** 1996 Oct; 10(5):699–705 (63 ref.)

METHODS

Diagnostic laparoscopy by physicians: we should do it. Haydon GH, et al. **QJM** 1997 Apr;90(4):297–304 (40 ref.)
The acute abdomen in the pregnant patient. Is there a role for laparoscopy? Gurbuz AT, et al. **Surg Endosc** 1997 Feb; 11(2):98–102 (33 ref.)
Laparoscopic transdiaphragmatic diagnostic pericardial window in the hemodynamically stable patient with penetrating chest trauma. A brief report. McMahon DJ, et al. **Surg Endosc** 1997 May;11(5):474–5 (9 ref.)
[Celioscopic digestive surgery: from the explosion to a critical reflexion] Napolitano C, et al. **Ann Ital Chir** 1996 Jul–Aug;67(4):479–84; discussion 484–5 (40 ref.) (Eng. Abstr.) **(Ita)**

STANDARDS

[Peritoneal tuberculosis. Value of laparoscopy] Kasia JM, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997; 26(4):367–73 (26 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Instrumentation and techniques for laparoscopic and thoracoscopic surgery in the horse. Hendrickson DA, et al. **Vet Clin North Am Equine Pract** 1996 Aug;12(2):235–59 (27 ref.)

LAPAROTOMY

Endoscopic polypectomy under laparotomy throughout the alimentary tract for a patient with blue rubber bleb nevus syndrome. Shimada S, et al. **Gastrointest Endosc** 1997 May; 45(5):423–7 (25 ref.)
The potential for improved abdominal procedures and approaches for tubal occlusion. Steele SJ.
Int J Gynaecol Obstet 1995 Dec;51 Suppl 1:S17–22 (18 ref.)
[Negative second-look laparatomy in ovarian cancers. Survival analysis and prognostic factors from 64 cases treated at the Gustave Roussy Institute] Pautier P, et al. **Bull Cancer** 1997 Feb;84(2):147–54 (37 ref.) (Eng. Abstr.) **(Fre)**

METHODS

New concepts in trauma. Burch JM. **Am J Surg** 1997 Jan; 173(1):44–6; discussion 47–8 (11 ref.)
A fifteen-year review of female sterilization by minilaparotomy under local anesthesia in Kenya. Ruminjo JK, et al. **Contraception** 1997 Apr;55(4):249–60 (45 ref.)
Endometriosis: medical and surgical intervention. Falcone T, et al. **Curr Opin Obstet Gynecol** 1996 Jun;8(3):178–83 (40 ref.)
Abdominal incisions from creation to closure. Nygaard IE, et al. **Obstet Gynecol Surv** 1996 Jul;51(7):429–36 (63 ref.)
Physiologic rationale for abbreviated laparotomy. Burch JM, et al. **Surg Clin North Am** 1997 Aug;77(4):779–82 (11 ref.)
Laparoscopy in gynaecological cancer. Vinatier D, et al.
Surg Oncol 1996 Oct–Dec;5(5–6):211–20 (48 ref.)

LARVA MIGRANS

DIAGNOSIS

Cutaneous myiasis due to Dermatobia hominis in Japan. Taniguchi Y, et al. **J Dermatol** 1996 Feb;23(2):125–8 (18 ref.)

LARVA MIGRANS, CUTANEOUS see **LARVA MIGRANS**

LARVA MIGRANS, OCULAR see **LARVA MIGRANS**

LARVA MIGRANS, VISCERAL

Dirofilaria, visceral larva migrans, and tropical pulmonary eosinophilia. Chitkara RK, et al. **Semin Respir Infect** 1997 Jun;12(2):138–48 (78 ref.)

COMPLICATIONS

[Toxocariasis syndrome as a cause of hypereosinophilia] Dmoch A, et al. **Przegl Lek** 1995;52(12):610–1 (20 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Human toxocariasis and the visceral larva migrans syndrome: correlative immunopathology. Kayes SG.
Chem Immunol 1997;66:99–124 (140 ref.)

PARASITOLOGY

[Toxocara canis (Nematoda) and toxocariasis of animals and humans] Okulewicz A, et al. **Wiad Parazytol** 1997; 43(1):3–25 (70 ref.) (Eng. Abstr.) **(Pol)**

LARYNGEAL CARTILAGES

PATHOLOGY

Laryngeal necrosis after combined chemotherapy and radiation therapy. Miyaguchi M, et al. **J Laryngol Otol** 1997 Aug;111(8):763–5 (13 ref.)

LARYNGEAL DISEASES

Laryngopharyngeal reflux: a modern day "great masquerader". Hawkins BL. **J Ky Med Assoc** 1997 Sep; 95(9):379–85 (19 ref.)

COMPLICATIONS

Coexistent asthma and functional upper airway obstruction. Case reports and review of the literature. Elshami AA, et al. **Chest** 1996 Nov;110(5):1358–61 (16 ref.)
Wegener's granulomatosis, acute laryngotracheal airway obstruction and death in a 17-year-old female: case report and review of the literature. Matt BH.
Int J Pediatr Otorhinolaryngol 1996 Oct;37(2):163–72 (19 ref.)

CONGENITAL

Stridor in the neonate: laryngomalacia. Thurmond M, et al.
J La State Med Soc 1996 Sep;148(9):375–8 (15 ref.)
[Variants and early symptoms of congenital diseases of larynx and trachea] Chireshkin DG, et al.
Vestn Otorinolaringol 1996 Sep–Oct;(5):13–8 (28 ref.) (Eng. Abstr.) **(Rus)**

DIAGNOSIS

The management of lumps in the neck. Fife DG.
Br J Hosp Med 1997 May 21–Jun 3;57(10):522–6 (16 ref.)
Laryngeal manifestations of gastroesophageal reflux disease: endoscopic appearance and management. Young JL, et al.
Gastrointest Endosc 1996 Mar;43(3):225–30 (28 ref.)
Laryngeal radionecrosis versus recurrent cancer. McGuirt WF. **Otolaryngol Clin North Am** 1997 Apr;30(2):243–50 (19 ref.)
Vocal cord dysfunction presenting as acute asthma in a pediatric patient. Poirier MP, et al. **Pediatr Emerg Care** 1996 Jun;12(3):213–4 (14 ref.)
[Differential hoarseness diagnosis. Etiology, diagnosis, therapy] Grevers G. **Fortschr Med** 1997 Jun 20;115(17):26, 29–34 (7 ref.) **(Ger)**

LARYNGEAL DISEASES

[Variants and early symptoms of congenital diseases of larynx and trachea] Chireshkin DG, et al. **Vestn Otorinolaringol** 1996 Sep-Oct;(5):13-8 (28 ref.) (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

[An attempt to identify an increased incidence of occupational laryngeal diseases in teachers] Wośkowiak G. **Med Pr** 1996;47(5):519-22 (14 ref.) (Eng. Abstr.) **(Pol)**

ETIOLOGY

Acquired subglottic cysts in the low birth weight, pre-term infant. Tierney PA, et al. **J Laryngol Otol** 1997 May; 111(5):478-81 (17 ref.)

PHYSIOPATHOLOGY

Vocal cord dysfunction presenting as acute asthma in a pediatric patient. Poirier MP, et al. **Pediatr Emerg Care** 1996 Jun;12(3):213-4 (14 ref.)

PREVENTION & CONTROL

[Prevention and treatment of suppuration caused by neck trauma] Fominykh TI. **Vestn Otorinolaringol** 1996 Sep-Oct; (5):46-7 (4 ref.) (Eng. Abstr.) **(Rus)**

SURGERY

Laser applications in adult laryngeal surgery. Courey MS, et al. **Otolaryngol Clin North Am** 1996 Dec;29(6):973-86 (40 ref.)

Laser applications in pediatric laryngeal surgery. Werkhaven J. **Otolaryngol Clin North Am** 1996 Dec;29(6):1005-10 (16 ref.)

LARYNGEAL MASK AIRWAY see **LARYNGEAL MASKS**

LARYNGEAL MASKS

The laryngeal mask airway: potential applications in neonatal health care. Brimacombe J, et al. **J Obstet Gynecol Neonatal Nurs** 1997 Mar-Apr;26(2):171-8 (67 ref.)

Use of the laryngeal mask airway in oral and maxillofacial surgery. Bennett J, et al. **J Oral Maxillofac Surg** 1996 Nov; 54(11):1346-51 (38 ref.)

The laryngeal mask airway: a review for the emergency physician. Tobias JD. **Pediatr Emerg Care** 1996 Oct; 12(5):370-3 (25 ref.)

LARYNGEAL MUCOSA

Ventricular dysphonia: a case of false vocal fold mucosal traveling wave. Nasri S, et al. **Am J Otolaryngol** 1996 Nov-Dec;17(6):427-31 (12 ref.)

LARYNGEAL NEOPLASMS

Human papillomavirus and cancers of the upper aerodigestive tract: a review of epidemiological and experimental evidence. Franceschi S, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Jul;5(7):567-75 (104 ref.)

Contrasting strategic approaches to the management of subglottic hemangiomas. Froehlich P, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jul;36(2):137-46 (30 ref.)

Recurrent respiratory papillomatosis. Bauman NM, et al. **Pediatr Clin North Am** 1996 Dec;43(6):1385-401 (103 ref.)

CONGENITAL

Infantile subglottic hemangioma: a review and presentation of two cases of surgical excision. Phipps CD, et al. **Int J Pediatr Otorhinolaryngol** 1997 Jul 18;41(1):71-9 (20 ref.)

DIAGNOSIS

Subglottic nerve sheath tumor in a pediatric patient: case report and literature review. Pulli RS, et al. **Head Neck** 1997 Aug;19(5):440-4 (21 ref.)

Giant cell tumor of the larynx: case report and review of the literature. Werner JA, et al. **Head Neck** 1997 Mar; 19(2):153-7 (31 ref.)

Management of nonepidermoid cancer of the larynx. Browne JD. **Otolaryngol Clin North Am** 1997 Apr;30(2):215-29 (42 ref.)

Laryngeal cancer in children and adolescents. McGuirt WF Jr, et al. **Otolaryngol Clin North Am** 1997 Apr;30(2):207-14 (33 ref.)

The psychosocial impact of the diagnosis and treatment of laryngeal cancer. McQuellon RP, et al. **Otolaryngol Clin North Am** 1997 Apr;30(2):231-41 (44 ref.)

Imaging of laryngeal cancer. Williams DW 3rd. **Otolaryngol Clin North Am** 1997 Feb;30(1):35-58 (51 ref.)

[Leiomyosarcoma of the larynx. Review of the literature apropos of a case] Samlali R, et al. **Bull Cancer** 1996 Oct; 83(10):882-5 (29 ref.) (Eng. Abstr.) **(Fre)**

[Chondroma and chondrosarcoma of the larynx: apropos of 4 cases] Verhulst J, et al. **Rev Laryngol Otol Rhinol (Bord)** 1996;117(3):183-8 (24 ref.) (Eng. Abstr.) **(Fre)**

[The role of imaging technics in assessing laryngeal neoplasms] Melone A, et al. **Clin Ter** 1996 Dec; 147(12):673-9 (18 ref.) (Eng. Abstr.) **(Ita)**

[Diagnosis of laryngeal cancer] Szmeja Z, et al. **Otolaryngol Pol** 1995;49(5):395-409 (53 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

[Photochemotherapy in the treatment of carcinoma of the vocal cords of early stage (Tis, T1)] Delbove H, et al. **Ann Otolaryngol Chir Cervicofac** 1996;113(3):155-61 (29 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Nutrition and laryngeal cancer. Riboli E, et al. **Cancer Causes Control** 1996 Jan;7(1):147-56 (28 ref.)

Epidemiology of laryngeal cancer. Cattaruzza MS, et al. **Eur J Cancer B Oral Oncol** 1996 Sep;32B(5):293-305 (100 ref.)

ETIOLOGY

Postirradiation laryngeal osteosarcoma: case report and literature review. Sheen TS, et al. **Head Neck** 1997 Jan; 19(1):57-62 (36 ref.)

Some etio-pathogenetic factors in laryngeal carcinogenesis. Sugár J, et al. **J Environ Pathol Toxicol Oncol** 1996; 15(2-4):195-9 (26 ref.)

The etiology and pathogenesis of laryngeal carcinoma. Koufman JA, et al. **Otolaryngol Clin North Am** 1997 Feb; 30(1):1-19 (120 ref.)

GENETICS

[Detection of human papillomavirus gene sequences in laryngeal tumors and premalignant changes by polymerase chain reaction] Czeglédy J, et al. **Orv Hetil** 1997 Jul 27; 138(30):1891-5 (28 ref.) (Eng. Abstr.) **(Hun)**

PATHOLOGY

Laryngeal involvement in multiple symmetric lipomatosis: the role of computed tomography in diagnosis. Borges A, et al. **Am J Otolaryngol** 1997 Mar-Apr;18(2):127-30 (12 ref.)

Malignant fibrous histiocytomas of the larynx--report of two cases. Soh KB, et al. **Ann Acad Med Singapore** 1996 Nov; 25(6):878-81 (25 ref.)

Clinicopathological consultation. Lymphoepithelial carcinoma of the larynx hypopharynx, and trachea. Ferlito A, et al. **Ann Otol Rhinol Laryngol** 1997 May;106(5):437-44 (111 ref.)

Squamous neoplastic component in unconventional squamous cell carcinomas of the larynx. Ferlito A, et al. **Ann Otol Rhinol Laryngol** 1996 Nov;105(11):926-32 (34 ref.)

Kaposi's sarcoma of the larynx. Schiff NF, et al. **Ann Otol Rhinol Laryngol** 1997 Jul;106(7 Pt 1):563-7 (18 ref.)

Laryngeal chondroma: a benign process with long-term clinical implications. Chiu LD, et al. **Ear Nose Throat J** 1996 Aug;75(8):540-2, 544-9 (50 ref.)

Subglottic paraganglioma. Peterson KL, et al. **Head Neck** 1997 Jan;19(1):54-6 (8 ref.)

Lymphoepithelial carcinoma of the larynx and hypopharynx: study of eight cases with relationship to Epstein-Barr virus and p53 gene alterations, and review of the literature. MacMillan C, et al. **Hum Pathol** 1996 Nov;27(11):1172-9 (44 ref.)

Basaloid-squamous carcinoma. A distinct histopathological entity. Singh ZN, et al. **Indian J Cancer** 1996 Jun; 33(2):86-91 (19 ref.)

Quintuple cancers: report of a case with triple cancers in the head and neck. Martin-Granizo R, et al. **J Craniomaxillofac Surg** 1997 Jun;25(3):153-7 (34 ref.)

A rare case of laryngeal myxoma. Tsunoda K, et al. **J Laryngol Otol** 1997 Mar;111(3):271-3 (6 ref.)

An unusual case of laryngeal carcinoma metastasizing to the small intestine. Yoshihara T, et al. **J Laryngol Otol** 1997 Jun;111(6):575-7 (15 ref.)

Schwannoma of the larynx: two case reports and review of the literature. al-Otieschan AT, et al. **J Otolaryngol** 1996 Dec;25(6):412-5 (21 ref.)

Tumour recurrence or treatment sequelae following radiotherapy for larynx cancer [see comments] O'Brien PC. **J Surg Oncol** 1996 Oct;63(2):130-5 (49 ref.) Comment in: J Surg Oncol 1997 Mar;64(3):248.

Management of nonepidermoid cancer of the larynx. Browne JD. **Otolaryngol Clin North Am** 1997 Apr;30(2):215-29 (42 ref.)

Histopathology and pathologic prognostic indicators. Cappellari JO. **Otolaryngol Clin North Am** 1997 Apr; 30(2):251-68 (95 ref.)

[Lymphatic drainage of the larynx--effect on therapeutic decision in larynx carcinoma] Hagen R. **HNO** 1996 Feb; 44(2):55-60 (36 ref.) **(Ger)**

[Laryngeal malignant schwannoma in a 9-year-old boy: report of a clinical case] Dvornik G, et al. **Pathologica** 1996 Dec;88(6):519-21 (10 ref.) (Eng. Abstr.) **(Ita)**

[Diagnosis of laryngeal cancer] Szmeja Z, et al. **Otolaryngol Pol** 1995;49(5):395-409 (53 ref.) (Eng. Abstr.) **(Pol)**

PSYCHOLOGY

The psychosocial impact of the diagnosis and treatment of laryngeal cancer. McQuellon RP, et al. **Otolaryngol Clin North Am** 1997 Apr;30(2):231-41 (44 ref.)

RADIOGRAPHY

Laryngeal involvement in multiple symmetric lipomatosis: the role of computed tomography in diagnosis. Borges A, et al. **Am J Otolaryngol** 1997 Mar-Apr;18(2):127-30 (12 ref.)

Diagnosis of subglottic hemangioma by chest CT. Chetty A, et al. **Pediatr Pulmonol** 1997 Jun;23(6):464-7 (6 ref.)

RADIOTHERAPY

Neck failure in T2N0 squamous cell carcinoma of the true vocal cords: the Fox Chase experience and review of the literature. Fein DA, et al. **Am J Clin Oncol** 1997 Apr; 20(2):154-7 (17 ref.)

Altered fractionated radiation therapy for head and neck carcinomas--A Massachusetts General Hospital experience. Wang CC. **Ann Acad Med Singapore** 1996 May; 25(3):335-40 (21 ref.)

Free gastro-omental flap reconstruction of the complex, irradiated pharyngeal wound. Carlson GW, et al. **Head Neck** 1997 Jan;19(1):68-71 (11 ref.)

Tumour recurrence or treatment sequelae following radiotherapy for larynx cancer [see comments] O'Brien PC. **J Surg Oncol** 1996 Oct;63(2):130-5 (49 ref.) Comment in: J Surg Oncol 1997 Mar;64(3):248.

Laryngeal radionecrosis versus recurrent cancer. McGuirt WF. **Otolaryngol Clin North Am** 1997 Apr;30(2):243-50 (19 ref.)

Radiotherapy for carcinoma of the supraglottis. Mendenhall WM, et al. **Otolaryngol Clin North Am** 1997 Feb; 30(1):145-61 (35 ref.)

Definitive radiation management for carcinoma of the glottic larynx. Moose BD, et al. **Otolaryngol Clin North Am** 1997 Feb;30(1):131-43 (66 ref.)

Speech outcomes after laryngeal cancer management. Simpson CB, et al. **Otolaryngol Clin North Am** 1997 Apr; 30(2):189-205 (71 ref.)

Management of complications resulting from laryngeal cancer treatment. Weissler MC. **Otolaryngol Clin North Am** 1997 Apr;30(2):269-78 (16 ref.)

[External radiotherapy in early stage squamous cell carcinoma of the supraglottic larynx. Report of 28 cases] Caliceti U, et al. **Acta Otorhinolaryngol Ital** 1996 Feb; 16(1):35-9 (28 ref.) (Eng. Abstr.) **(Ita)**

[Early stages of laryngeal cancer (I-II stage) and therapeutic options: case report and review of literature] Margarino G, et al. **Acta Otorhinolaryngol Ital** 1996 Feb;16(1):40-6 (50 ref.) (Eng. Abstr.) **(Ita)**

[The role of the gap in radiotherapy in the treatment of patients with laryngeal cancer] Milecki P, et al. **Otolaryngol Pol** 1996;50(5):548-54 (32 ref.) (Eng. Abstr.) **(Pol)**

SECONDARY

Laryngeal carcinoma nodal metastases and their management. Schuller DE, et al. **Otolaryngol Clin North Am** 1997 Apr;30(2):167-77 (34 ref.)

SURGERY

Benign pleomorphic adenoma of the larynx: report of a case and review and analysis of 20 additional cases in the literature. Dubey SP, et al. **Ear Nose Throat J** 1997 Aug; 76(8):548-50, 552, 554-7 (27 ref.)

Subglottic paraganglioma. Peterson KL, et al. **Head Neck** 1997 Jan;19(1):54-6 (8 ref.)

Subglottic nerve sheath tumor in a pediatric patient: case report and literature review. Pulli RS, et al. **Head Neck** 1997 Aug;19(5):440-4 (21 ref.)

Laryngeal chondrosarcomas: the Mayo Clinic experience. Kozelsky TF, et al. **J Surg Oncol** 1997 Aug;65(4):269-73 (31 ref.)

Speech rehabilitation after treatment of laryngeal carcinoma. Blalock D. **Otolaryngol Clin North Am** 1997 Apr; 30(2):179-88 (20 ref.)

Endoscopic surgical management of glottic laryngeal cancer. Davis RK. **Otolaryngol Clin North Am** 1997 Feb; 30(1):79-86 (16 ref.)

Organ preservation therapy for advanced-stage laryngeal carcinoma. Hoffman HT, et al. **Otolaryngol Clin North Am** 1997 Feb;30(1):113-30 (41 ref.)

Management of advanced-stage laryngeal cancer. Levine PA, et al. **Otolaryngol Clin North Am** 1997 Feb; 30(1):101-12 (24 ref.)

Open surgical management of early glottic carcinoma. Osguthorpe JD, et al. **Otolaryngol Clin North Am** 1997 Feb;30(1):87-99 (42 ref.)

Speech outcomes after laryngeal cancer management. Simpson CB, et al. **Otolaryngol Clin North Am** 1997 Apr; 30(2):189-205 (71 ref.)

Management of complications resulting from laryngeal cancer treatment. Weissler MC. **Otolaryngol Clin North Am** 1997 Apr;30(2):269-78 (16 ref.)

Surgical management of early supraglottic cancer. Zeitels SM. **Otolaryngol Clin North Am** 1997 Feb;30(1):59-78 (70 ref.)

[Horizontal subglottic laryngectomy in treating cancers of

the laryngeal vestibule and vallecula. Apropos of 65 cases] Godey B, et al. **Ann Otolaryngol Chir Cervicofac** 1996; 113(7–8):412–8 (19 ref.) (Eng. Abstr.) **(Fre)**

[Laryngectomies and pharyngo–laryngectomies with tracheo–laryngo–pharyngeal shunt of Pearson type. Technique, indications and preliminary results] Laccourreye O, et al. **Ann Otolaryngol Chir Cervicofac** 1996;113(5):261–8 (34 ref.) (Eng. Abstr.) **(Fre)**

[The treatment of juvenile laryngeal papillomatosis with argon plasma coagulation] Bergler W, et al. **Dtsch Med Wochenschr** 1997 Aug 22;122(34–35):1033–6 (19 ref.) (Eng. Abstr.) **(Ger)**

[Sequelae of total laryngectomy with special reference to rehabilitation of the voice and lower airways] Ackerstaff AH, et al. **HNO** 1997 Feb;45(2):97–104 (26 ref.) **(Ger)**

[Laryngeal cancer treatment concept in metastases (see comments)] Hagen R. **HNO** 1997 Jul;45(7):512–8 (8 ref.) (Eng. Abstr.) Comment in: HNO 1997 Jul;45(7):493–4. **(Ger)**

[Early stages of laryngeal cancer (I–II stage) and therapeutic options: case report and review of literature] Margarino G, et al. **Acta Otorhinolaryngol Ital** 1996 Feb;16(1):40–6 (50 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Multidisciplinary management controversies in laryngeal cancer. Goh C, et al. **Ann Acad Med Singapore** 1996 May; 25(3):405–12 (54 ref.)

Current status of larynx preservation trials. Lefebvre JL, et al. **Curr Opin Oncol** 1996 May;8(3):209–14 (55 ref.)

[Laryngeal cancer and conservative treatment. Place of combined radiotherapy chemotherapy and modified fractionation radiotherapy] Brunin F, et al. **Bull Cancer** 1997 Feb;84(2):191–8 (43 ref.) (Eng. Abstr.) **(Fre)**

ULTRASTRUCTURE

[The anterior commissure of the larynx in the subperichondral functional surgery of the glottic plane: critical evaluation on the basis of a serial section study in normal and neoplastic laryngeal specimens] Carluccio F, et al. **Acta Otorhinolaryngol Ital** 1996 Apr;16(2):122–8 (29 ref.) (Eng. Abstr.) **(Ita)**

VIROLOGY

Some etio–pathogenetic factors in laryngeal carcinogenesis. Sugár J, et al. **J Environ Pathol Toxicol Oncol** 1996; 15(2–4):195–9 (26 ref.)

[High–risk HPV types in oral and laryngeal papilloma and leukoplakia] Arndt O, et al. **Laryngorhinootologie** 1997 Mar; 76(3):142–9 (58 ref.) (Eng. Abstr.) **(Ger)**

LARYNGEAL NERVE, SUPERIOR see **LARYNGEAL NERVES**

LARYNGEAL NERVES

PHYSIOLOGY

Laryngeal evoked brainstem responses in humans: a preliminary study. Yin SS, et al. **Laryngoscope** 1997 Sep; 107(9):1261–6 (26 ref.)

Role of the larynx in cough. Sant'Ambrogio G. **Pulm Pharmacol** 1996 Oct–Dec;9(5–6):379–82 (16 ref.)

LARYNGEAL PARALYSIS see **VOCAL CORD PARALYSIS**

LARYNGEAL PERICHONDRITIS see **LARYNGEAL DISEASES**

LARYNGEAL PROSTHESIS see **LARYNX, ARTIFICIAL**

LARYNGEAL STENOSIS see **LARYNGOSTENOSIS**

LARYNGECTOMY

see related
LARYNX, ARTIFICIAL
SPEECH, ALARYNGEAL

Laryngeal framework surgery (thyroplasty) [editorial] Harries ML. **J Laryngol Otol** 1997 Feb;111(2):103–5 (14 ref.)

[Horizontal subglottic laryngectomy in treating cancers of the laryngeal vestibule and vallecula. Apropos of 65 cases] Godey B, et al. **Ann Otolaryngol Chir Cervicofac** 1996; 113(7–8):412–8 (19 ref.) (Eng. Abstr.) **(Fre)**

[Dysphagia in amyotrophic lateral sclerosis––the mechanism and managements] Tayama N. **Rinsho Shinkeigaku** 1995 Dec;35(12):1557–9 (7 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Current status of larynx preservation trials. Lefebvre JL, et al. **Curr Opin Oncol** 1996 May;8(3):209–14 (55 ref.)

Preservation of the larynx after resection of a carcinoma of the posterior wall of the hypopharynx: versatility of a free flap patch graft. Nakatsuka T, et al. **Head Neck** 1997 Mar; 19(2):137–42 (18 ref.)

Organ preservation therapy for advanced–stage laryngeal carcinoma. Hoffman HT, et al. **Otolaryngol Clin North Am** 1997 Feb;30(1):113–30 (41 ref.)

[Laryngectomies and pharyngo–laryngectomies with tracheo–laryngo–pharyngeal shunt of Pearson type. Technique, indications and preliminary results] Laccourreye O, et al. **Ann Otolaryngol Chir Cervicofac** 1996;113(5):261–8 (34 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

The psychosocial impact of the diagnosis and treatment of laryngeal cancer. McQuellon RP, et al. **Otolaryngol Clin North Am** 1997 Apr;30(2):231–41 (44 ref.)

REHABILITATION

The role of the speech and language therapist in voice restoration after laryngectomy [editorial] Perry A. **J Laryngol Otol** 1997 Jan;111(1):4–7 (33 ref.)

Speech rehabilitation after treatment of laryngeal carcinoma. Blalock D. **Otolaryngol Clin North Am** 1997 Apr; 30(2):179–88 (20 ref.)

Speech outcomes after laryngeal cancer management. Simpson CB, et al. **Otolaryngol Clin North Am** 1997 Apr; 30(2):189–205 (71 ref.)

[Sequelae of total laryngectomy with special reference to rehabilitation of the voice and lower airways] Ackerstaff AH, et al. **HNO** 1997 Feb;45(2):97–104 (26 ref.) **(Ger)**

LARYNGISMUS

COMPLICATIONS

Acute pulmonary oedema complicating laryngospasm. Ingrams D, et al. **J Laryngol Otol** 1997 May;111(5):482–4 (13 ref.)

LARYNGITIS

Supraglottic airway infections. Millan SB, et al. **Prim Care** 1996 Dec;23(4):741–58 (106 ref.)

CHEMICALLY INDUCED

Occupational laryngitis caused by formaldehyde: a case report. Roto P, et al. **Am J Ind Med** 1996 Mar;29(3):275–77 (13 ref.)

DIAGNOSIS

Infraglottic and bronchial infections. Uba A. **Prim Care** 1996 Dec;23(4):759–91 (182 ref.)

DRUG THERAPY

Recent advances in the treatment of bronchiolitis and laryngitis. Klassen TP. **Pediatr Clin North Am** 1997 Feb; 44(1):249–61 (64 ref.)

THERAPY

Infraglottic and bronchial infections. Uba A. **Prim Care** 1996 Dec;23(4):759–91 (182 ref.)

LARYNGOPHARYNX see **HYPOPHARYNX**

LARYNGOSCOPY

Safe and effective topical application dose of lidocaine for surgery with laryngomicroscopy. Kotaki H, et al. **Clin Pharmacol Ther** 1996 Aug;60(2):229–35 (15 ref.)

Laryngeal manifestations of gastroesophageal reflux disease: endoscopic appearance and management. Young JL, et al. **Gastrointest Endosc** 1996 Mar;43(3):225–30 (28 ref.)

Airway endoscopy in the interdisciplinary management of acute epiglottitis. Damm M, et al. **Int J Pediatr Otorhinolaryngol** 1996 Dec 5;38(1):41–51 (17 ref.)

Endoscopic surgical management of glottic laryngeal cancer. Davis RK. **Otolaryngol Clin North Am** 1997 Feb; 30(1):79–86 (16 ref.)

ADVERSE EFFECTS

Bacteraemia during direct laryngoscopy and endotracheal intubation: a study using a multiple culture, large volume technique. Goldstein S, et al. **Anaesth Intensive Care** 1997 Jun;25(3):239–44 (25 ref.)

INSTRUMENTATION

The use of paraglossal straight blade laryngoscopy in difficult tracheal intubation. Henderson JJ. **Anaesthesia** 1997 Jun; 52(6):552–60 (75 ref.)

METHODS

[New techniques for laryngoscopy and tracheal intubation] Ariño–Irujo JJ, et al. **Rev Esp Anestesiol Reanim** 1997 Jun–Jul;44(6):223–9, 249 (57 ref.) **(Spa)**

LARYNGOSPASM see **LARYNGISMUS**

LARYNGOSTENOSIS

DIAGNOSIS

Assessment and management of laryngotracheal stenosis. Lesperance MM, et al. **Pediatr Clin North Am** 1996 Dec; 43(6):1413–27 (36 ref.)

ETIOLOGY

Subglottic stenosis in Wegener's granulomatosis limited to the head and neck region. Yumoto E, et al. **Ear Nose Throat J** 1997 Aug;76(8):571–4 (15 ref.)

High tracheostomy and other errors––revisited. Bennett JD. **J Laryngol Otol** 1996 Nov;110(11):1003–7 (31 ref.)

SURGERY

Management of idiopathic tracheal stenosis. Grillo HC. **Chest Surg Clin N Am** 1996 Nov;6(4):811–8 (5 ref.)

Pediatric tracheal problems. Grillo HC. **Chest Surg Clin N Am** 1996 Nov;6(4):693–700 (29 ref.)

Technique of management of subglottic stenosis. Pearson FG. **Chest Surg Clin N Am** 1996 Nov;6(4):683–92 (12 ref.)

Assessment and management of laryngotracheal stenosis. Lesperance MM, et al. **Pediatr Clin North Am** 1996 Dec; 43(6):1413–27 (36 ref.)

Subglottic resection with primary tracheal anastomosis: including synchronous laryngotracheal reconstructions. Pearson FG, et al. **Semin Thorac Cardiovasc Surg** 1996 Oct; 8(4):381–91 (19 ref.)

LARYNX

see related
LARYNGECTOMY
LARYNGOSCOPY

An unusual foreign body in the larynx: a case report. Bhat NA, et al. **J Laryngol Otol** 1996 Dec;110(12):1164–5 (7 ref.)

Prevention and management of aerodigestive foreign body injuries in childhood. Reilly JS, et al. **Pediatr Clin North Am** 1996 Dec;43(6):1403–11 (13 ref.)

ABNORMALITIES

[Variants and early symptoms of congenital diseases of larynx and trachea] Chireshkin DG, et al. **Vestn Otorinolaringol** 1996 Sep–Oct;(5):13–8 (28 ref.) (Eng. Abstr.) **(Rus)**

ANATOMY & HISTOLOGY

[The voice of the child, morphological evolution of the larynx and its acoustic consequences] Woisard V, et al. **Rev Laryngol Otol Rhinol (Bord)** 1996;117(4):313–7 (18 ref.) (Eng. Abstr.) **(Fre)**

INJURIES

Laryngotracheal trauma. Chagnon FP, et al. **Chest Surg Clin N Am** 1996 Nov;6(4):733–48 (39 ref.)

Computed tomographic evaluation of laryngotracheal trauma. Lupetin AR. **Curr Probl Diagn Radiol** 1997 Jul–Aug;26(4):185–206 (38 ref.)

PATHOLOGY

Clinicopathological consultation. Lymphoepithelial carcinoma of the larynx hypopharynx, and trachea. Ferlito A, et al. **Ann Otol Rhinol Laryngol** 1997 May;106(5):437–44 (111 ref.)

Laryngeal chondroma: a benign process with long–term clinical implications. Chiu LD, et al. **Ear Nose Throat J** 1996 Aug;75(8):540–2, 544–9 (50 ref.)

Schwannoma of the larynx: two case reports and review of the literature. al–Otieschan AT, et al. **J Otolaryngol** 1996 Dec;25(6):412–5 (21 ref.)

Management of nonepidermoid cancer of the larynx. Browne JD. **Otolaryngol Clin North Am** 1997 Apr;30(2):215–29 (42 ref.)

Organ preservation therapy for advanced–stage laryngeal carcinoma. Hoffman HT, et al. **Otolaryngol Clin North Am** 1997 Feb;30(1):113–30 (41 ref.)

Laryngeal cancer in children and adolescents. McGuirt WF Jr, et al. **Otolaryngol Clin North Am** 1997 Apr;30(2):207–14 (33 ref.)

Laryngeal carcinoma nodal metastases and their management. Schuller DE, et al. **Otolaryngol Clin North Am** 1997 Apr;30(2):167–77 (34 ref.)

[The role of imaging technics in assessing laryngeal neoplasms] Melone A, et al. **Clin Ter** 1996 Dec; 147(12):673–9 (18 ref.) (Eng. Abstr.) **(Ita)**

[Diagnosis of laryngeal cancer] Szmeja Z, et al. **Otolaryngol Pol** 1995;49(5):395–409 (53 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Upper airway influences on breathing. Sant'Ambrogio G. **Adv Exp Med Biol** 1995;381:37–46 (26 ref.)

Laryngeal neurophysiology and its clinical uses. Woodson GE. **Head Neck** 1996 Jan–Feb;18(1):78–86 (60 ref.)

Laryngeal evoked brainstem responses in humans: a preliminary study. Yin SS, et al. **Laryngoscope** 1997 Sep; 107(9):1261–6 (26 ref.)

Role of the larynx in cough. Sant'Ambrogio G. **Pulm Pharmacol** 1996 Oct–Dec;9(5–6):379–82 (16 ref.)

PHYSIOPATHOLOGY

Recurrent laryngeal papillomatosis. Retrospective analysis of 95 patients and review of the literature [editorial] Mahnke CG, et al. **Otolaryngol Pol** 1996;50(6):567–78 (61 ref.)

LARYNX

RADIATION EFFECTS

Tumour recurrence or treatment sequelae following radiotherapy for larynx cancer [see comments] O'Brien PC. **J Surg Oncol** 1996 Oct;63(2):130–5 (49 ref.) Comment in: J Surg Oncol 1997 Mar;64(3):248.

[Early stages of laryngeal cancer (I–II stage) and therapeutic options: case report and review of literature] Margarino G, et al. **Acta Otorhinolaryngol Ital** 1996 Feb;16(1):40–6 (50 ref.) (Eng. Abstr.) **(Ita)**

[The role of the gap in radiotherapy in the treatment of patients with laryngeal cancer] Milecki P, et al. **Otolaryngol Pol** 1996;50(5):548–54 (32 ref.) (Eng. Abstr.) **(Pol)**

RADIOGRAPHY

Laryngeal foreign body: an unusual complication of percutaneous tracheostomy. Kumar BN, et al. **J Laryngol Otol** 1997 Jul;111(7):652–3 (13 ref.)

[The role of imaging technics in assessing laryngeal neoplasms] Melone A, et al. **Clin Ter** 1996 Dec; 147(12):673–9 (18 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Laryngotracheal trauma. Chagnon FP, et al. **Chest Surg Clin N Am** 1996 Nov;6(4):733–48 (39 ref.)

Current status of larynx preservation trials. Lefebvre JL, et al. **Curr Opin Oncol** 1996 May;8(3):209–14 (55 ref.)

Type III–IV laryngotracheoesophageal cleft: report of a successfully treated case. Pinlong E, et al. **Int J Pediatr Otorhinolaryngol** 1996 Aug;36(3):253–62 (15 ref.)

Speech rehabilitation after treatment of laryngeal carcinoma. Blalock D. **Otolaryngol Clin North Am** 1997 Apr; 30(2):179–88 (20 ref.)

[Early stages of laryngeal cancer (I–II stage) and therapeutic options: case report and review of literature] Margarino G, et al. **Acta Otorhinolaryngol Ital** 1996 Feb;16(1):40–6 (50 ref.) (Eng. Abstr.) **(Ita)**

LARYNX, ARTIFICIAL

see related
SPEECH, ALARYNGEAL

Laryngeal framework surgery (thyroplasty) [editorial] Harries ML. **J Laryngol Otol** 1997 Feb;111(2):103–5 (14 ref.)

The role of the speech and language therapist in voice restoration after laryngectomy [editorial] Perry A. **J Laryngol Otol** 1997 Jan;111(1):4–7 (33 ref.)

LASER ANGIOPLASTY see **ANGIOPLASTY, LASER**

LASER-ASSISTED BALLOON ANGIOPLASTY see **ANGIOPLASTY, BALLOON, LASER-ASSISTED**

LASER COAGULATION

The peril of the pilot study [editorial; comment] Ferris FL 3rd, et al. **Arch Ophthalmol** 1996 Dec;114(12):1506–7 (10 ref.) Comment on: Arch Ophthalmol 1996 Dec;114(12):1456–64.

The medical necessity for treatment of port-wine stains. McClean K, et al. **Dermatol Surg** 1997 Aug;23(8):663–7 (22 ref.)

Lasers, optical systems and safety in ophthalmology: a review. Fankhauser F, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Aug;234(8):473–87 (56 ref.)

Laser photocoagulation of diabetic macular edema. Akduman L, et al. **Ophthalmic Surg Lasers** 1997 May;28(5):387–408 (76 ref.)

Long-term results of noncontact transscleral neodymium:YAG cyclophotocoagulation. Dickens CJ, et al. **Ophthalmology** 1995 Dec;102(12):1777–81 (24 ref.)

Genitourinary reconstructive surgery utilizing laser tissue welding [published erratum appears in Tech Urol 1995 Winter;1(4):227] Uzzo RG, et al. **Tech Urol** 1995 Summer; 1(2):55–61 (41 ref.)

[Dermatological laser treatment. A review of therapeutic possibilities and equipment] Haedersdal M, et al. **Ugeskr Laeger** 1997 May 26;159(22):3376–82 (40 ref.) (Eng. Abstr.) **(Dan)**

[Is it possible to treat age-related macular degeneration? (editorial)] Immonen I. **Duodecim** 1995;111(12):1083–5 (14 ref.) **(Fin)**

INSTRUMENTATION

Interstitial laser thermotherapy in neurosurgery: a review. Menovsky T, et al. **Acta Neurochir (Wien)** 1996; 138(9):1019–26 (49 ref.)

METHODS

Therapeutic modalities for treatment of peptic ulcer bleeding. Lee JG, et al. **Gastroenterologist** 1997 Mar;5(1):26–40 (97 ref.)

Laser photoablation of ileal reservoir adenomas. Geller A, et al. **Gastrointest Endosc** 1996 Oct;44(4):473–7 (57 ref.)

Treatment of central retinal vein occlusion. Baumal CR, et al. **Ophthalmic Surg Lasers** 1997 Jul;28(7):590–600 (81 ref.)

Techniques of coagulation laser prostatectomy for narrow divergence angle fibers. Milam DF. **Tech Urol** 1996 Spring; 2(1):34–9 (20 ref.)

[Laser thermocoagulation of adenoma of the prostate using an interstitial approach] Muschter R, et al. **Ann Urol (Paris)** 1997;31(1):27–37 (56 ref.) (Eng. Abstr.) **(Fre)**

LASER DESORPTION-IONIZATION MASS SPECTROMETRY, MATRIX-ASSISTED see **SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION**

LASER-DOPPLER FLOWMETRY

Application of laser Doppler flowmetry in neurosurgery. Arbit E, et al. **Neurosurg Clin N Am** 1996 Oct;7(4):741–8 (45 ref.)

[Measurement of gastric mucosal blood flow] Kashimura H, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:103–6 (10 ref.) **(Jpn)**

[Measurement of retinal circulation] Konno S, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:446–9 (14 ref.) **(Jpn)**

[Measurement of retinal blood flow by laser Doppler method] Ogasawara H, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:454–7 (15 ref.) **(Jpn)**

[Laser Doppler flowmetry--a new promising technique for assessment of the microcirculation] Szulkowska E, et al. **Pol Tyg Lek** 1996 Mar;51(10–13):179–81 (32 ref.) (Eng. Abstr.) **(Pol)**

METHODS

Implantable hearing device performance measured by laser Doppler interferometry. Gan RZ, et al. **Ear Nose Throat J** 1997 May;76(5):297–9, 302, 305–9 (27 ref.)

LASER-DOPPLER VELOCIMETRY see **LASER-DOPPLER FLOWMETRY**

LASER-INDUCED SHOCKWAVE LITHOTRIPSY see **LITHOTRIPSY, LASER**

LASER KNIFE see **LASER SURGERY**

LASER LITHOTRIPSY see **LITHOTRIPSY, LASER**

LASER SCALPEL see **LASER SURGERY**

LASER SCANNING CONFOCAL MICROSCOPY see **MICROSCOPY, CONFOCAL**

LASER SURGERY

Microendoscopic transoral CO2-laser resection of an extensive nasopharyngeal and oral teratoma. Gunkel AR, et al. **Am J Otolaryngol** 1997 Mar–Apr;18(2):140–4 (14 ref.)

A review of the use of the neodymium YAG laser in oral and maxillofacial surgery. Bradley PF. **Br J Oral Maxillofac Surg** 1997 Feb;35(1):26–35 (20 ref.)

Holmium laser sclerostomy. Saheb NE. **Can J Ophthalmol** 1996 Aug;31(5):267–8 (16 ref.)

Plaque removal and thrombus dissolution with the photoacoustic energy of pulsed-wave lasers-biotissue interactions and their clinical manifestations. Topaz O. **Cardiology** 1996 Sep–Oct;87(5):384–91 (77 ref.)

Use of lasers for meniscal repair. Vangsness CT Jr. **Clin Sports Med** 1996 Jul;15(3):531–5 (43 ref.)

Transmyocardial laser revascularization. Frazier OH, et al. **Curr Opin Cardiol** 1996 Nov;11(6):564–7 (15 ref.)

Laser treatment of hypertrophic scars, keloids, and striae. Alster TS. **Dermatol Clin** 1997 Jul;15(3):419–29 (86 ref.)

Laser resurfacing of rhytides. Fitzpatrick RE. **Dermatol Clin** 1997 Jul;15(3):431–47 (56 ref.)

Laser treatment of port-wine stains and hemangiomas. Garden JM, et al. **Dermatol Clin** 1997 Jul;15(3):373–83 (47 ref.)

Laser treatment of pigmented lesions. Goldberg DJ. **Dermatol Clin** 1997 Jul;15(3):397–407 (43 ref.)

Laser hair transplantation. Grevelink JM. **Dermatol Clin** 1997 Jul;15(3):479–86 (14 ref.)

What is new in cutaneous laser research. Grossman MC. **Dermatol Clin** 1997 Jan;15(1):1–8 (58 ref.)

Laser treatment of warts and other epidermal and dermal lesions. Hruza GJ. **Dermatol Clin** 1997 Jul;15(3):487–506 (129 ref.)

Histology of laser resurfacing. Kauvar AN, et al. **Dermatol Clin** 1997 Jul;15(3):459–67 (64 ref.)

Laser treatment of tattoos. Kilmer SL. **Dermatol Clin** 1997 Jul;15(3):409–17 (50 ref.)

Advances in dermatologic surgery. Perez M. **Dermatol Clin** 1997 Jan;15(1):9–18 (61 ref.)

Laser resurfacing of atrophic scars. West TB. **Dermatol Clin** 1997 Jul;15(3):449–57 (45 ref.)

Laser-assisted hair removal. Wheeland RG. **Dermatol Clin** 1997 Jul;15(3):469–77 (50 ref.)

Dermatologic laser surgery. A review. Alster TS, et al. **Dermatol Surg** 1996 Sep;22(9):797–805 (125 ref.)

Argon laser and Gherini-Causse Endo-Otoprobe in otologic surgery. Vincent R, et al. **Ear Nose Throat J** 1996 Dec; 75(12):770, 773–8, 780 (22 ref.)

Surgical technique for laser-assisted in situ keratomileusis. Duplessie M. **Int Ophthalmol Clin** 1996 Fall;36(4):45–51 (7 ref.)

Review of intrastromal photorefractive keratectomy with the neodymium-yttrium lithium fluoride laser. Gimbel HV, et al. **Int Ophthalmol Clin** 1997 Winter;37(1):95–102 (16 ref.)

Corneal nerve recovery after photorefractive keratectomy and laser in situ keratomileusis. Latvala T, et al. **Int Ophthalmol Clin** 1996 Fall;36(4):21–7 (38 ref.)

Corneal wound healing in laser in situ keratomileusis. Rocha G, et al. **Int Ophthalmol Clin** 1996 Fall;36(4):9–20 (41 ref.)

Myopic laser-assisted keratomileusis: an overview of published results. Sánchez-Thorin JC, et al. **Int Ophthalmol Clin** 1996 Fall;36(4):53–63 (20 ref.)

Advances in lamellar corneal refractive surgery. Slade SG, et al. **Int Ophthalmol Clin** 1997 Winter;37(1):103–22 (91 ref.)

LASIK for correction of hyperopia and hyperopia with astigmatism. Suarez E, et al. **Int Ophthalmol Clin** 1996 Fall; 36(4):65–72 (9 ref.)

Laser medicine in dermatology. Anderson RR. **J Dermatol** 1996 Nov;23(11):778–82 (17 ref.)

Lasers in periodontics. **J Periodontol** 1996 Aug;67(8):826–30 (79 ref.)

Indications for laser surgery in the treatment of degenerative disk disease of the lumbar spine. Simpson JM. **J South Orthop Assoc** 1996 Fall;5(3):174–80 (38 ref.)

Lasers: reflections on their evolution. Aronoff BL. **J Surg Oncol** 1997 Jan;64(1):84–92 (24 ref.)

Percutaneous laser discectomy. Quigley MR. **Neurosurg Clin N Am** 1996 Jan;7(1):37–42 (17 ref.)

Laser(-assisted) nerve repair. A review. Menovsky T, et al. **Neurosurg Rev** 1995;18(4):225–35 (67 ref.)

Successful surgical treatment of intraorbital arteriovenous malformations: case report. Hieu PD, et al. **Neurosurgery** 1997 Mar;40(3):626–31 (14 ref.)

Laser iridotomy. Liebmann JM, et al. **Ophthalmic Surg Lasers** 1996 Mar;27(3):209–27 (211 ref.)

Transcanalicular neodymium: YAG laser for revision of dacryocystorhinostomy. Patel BC, et al. **Ophthalmology** 1997 Jul;104(7):1191–7 (41 ref.)

Laser treatment of macular disease. Bass SJ, et al. **Optom Clin** 1996;5(1):161–73 (20 ref.)

Laser applications in inner ear surgery. Anthony PF. **Otolaryngol Clin North Am** 1996 Dec;29(6):1031–48 (26 ref.)

Use of the laser in the oral cavity. Burkey MD BB, et al. **Otolaryngol Clin North Am** 1996 Dec;29(6):949–61 (37 ref.)

Laser applications in adult laryngeal surgery. Courey MS, et al. **Otolaryngol Clin North Am** 1996 Dec;29(6):973–86 (40 ref.)

Image guidance with laser applications. Fried MP, et al. **Otolaryngol Clin North Am** 1996 Dec;29(6):1063–78 (45 ref.)

Laser decompression of the facial nerve. Kelly JH, et al. **Otolaryngol Clin North Am** 1996 Dec;29(6):1049–61 (32 ref.)

Laser utilization in the oral pharynx. Rathfoot CJ, et al. **Otolaryngol Clin North Am** 1996 Dec;29(6):963–72 (13 ref.)

Laser use in the paranasal sinuses. Rathfoot CJ, et al. **Otolaryngol Clin North Am** 1996 Dec;29(6):943–8 (13 ref.)

Laser applications in the tracheobronchial tree. Rebeiz EE, et al. **Otolaryngol Clin North Am** 1996 Dec;29(6):987–1003 (52 ref.)

Laser applications in otolaryngology. Conclusion and future outlook. Reinisch L, et al. **Otolaryngol Clin North Am** 1996 Dec;29(6):1079–85 (27 ref.)

Laser physics and tissue interactions. Reinisch L. **Otolaryngol Clin North Am** 1996 Dec;29(6):893–914 (42 ref.)

Cutaneous applications of lasers. Ries WR, et al. **Otolaryngol Clin North Am** 1996 Dec;29(6):915–29 (45 ref.)

Lasers in surgery for chronic ear disease. Saeed SR, et al. **Otolaryngol Clin North Am** 1996 Apr;29(2):245–56 (25 ref.)

Laser applications in ossicular surgery. Vernick MD DM. **Otolaryngol Clin North Am** 1996 Dec;29(6):931–41 (22 ref.)

Laser applications in pediatric laryngeal surgery. Werkhaven J. **Otolaryngol Clin North Am** 1996 Dec;29(6):1005–10 (16 ref.)

Lasers in plastic surgery: current practice. Achauer BM. **Plast Reconstr Surg** 1997 Apr;99(5):1442–50 (43 ref.)

The place of laser resurfacing within the range of medical and surgical skin resurfacing techniques. Roenigk HH Jr. **Semin Cutan Med Surg** 1996 Sep;15(3):208–13 (13 ref.)

Should patients with anatomically narrow angles have prophylactic iridectomy? Wilensky JT, et al. **Surv Ophthalmol** 1996 Jul–Aug;41(1):31–6 (35 ref.)

Laser prostatectomy is a safer, better operation than electrovaporization of the prostate [editorial] Kabalin JN. **Urology** 1997 Feb;49(2):160–5 (70 ref.)

[Use of CO2 laser in endoscopic treatment of Zenker's pharyngo-esophageal diverticula. Experience apropos of 33 cases] Hamoir M, et al. **Ann Otolaryngol Chir Cervicofac** 1997;114(1–2):7–12 (30 ref.) (Eng. Abstr.) **(Fre)**

[Indications for transmyocardial laser therapy] Maisch B, et al. **Z Kardiol** 1996;85 Suppl 6:269–79 (51 ref.) (Eng. Abstr.) **(Ger)**

[The use of the laser in the surgical treatment of acute intestinal obstruction and the prevention of adhesive disease] Kalish IuI, et al. **Khirurgiia (Mosk)** 1996;(6):103–8 (123 ref.) **(Rus)**

[Laser surgery] Klimov SV. **Klin Khir** 1996;(4):50–5 (0 ref.)

(Rus)
[The endoscopic treatment of urethral strictures and stones by using the Ho:YAG laser] Dondukov TsV, et al. **Urol Nefrol (Mosk)** 1997 Jan-Feb;(1):44-8 (109 ref.) (Rus)

ADVERSE EFFECTS

Pitfalls and complications of esophageal prosthesis, laser therapy, and dilation. Reed CE. **Chest Surg Clin N Am** 1997 Aug;7(3):623-36 (63 ref.)
Complications of laser surgery. Nanni C. **Dermatol Clin** 1997 Jul;15(3):521-34 (84 ref.)
Nonlinear absorption: intraocular microsurgery and laser lithotripsy. Vogel A. **Phys Med Biol** 1997 May; 42(5):895-912 (90 ref.)
Complications of resurfacing. Ragland HP, et al. **Semin Cutan Med Surg** 1996 Sep;15(3):200-7 (23 ref.)

INSTRUMENTATION

Experimental and clinical standards, and evolution of lasers in neurosurgery. Devaux BC, et al. **Acta Neurochir (Wien)** 1996;138(10):1135-47 (72 ref.)
Endoscopic Nd:YAG laser treatment of inoperable lower gastrointestinal cancer. Tai LS, et al. **Ann Acad Med Singapore** 1996 Sep;25(5):712-6 (39 ref.)
[Q-switched ruby laser in dermatologic therapy. Use and indications] Michel S, et al. **Hautarzt** 1997 Jul;48(7):462-70 (81 ref.) (Eng. Abstr.) (Ger)

METHODS

Aesthetic skin resurfacing with the high-energy ultrapulsed CO2 laser. Weinstein C, et al. **Clin Plast Surg** 1997 Apr; 24(2):379-405 (157 ref.)
Laser treatment of acquired vascular lesions. Ross BS, et al. **Dermatol Clin** 1997 Jul;15(3):385-96 (67 ref.)
Lasers in the treatment of benign prostatic obstruction: past, present, and future. te Slaa E, et al. **Eur Urol** 1996; 30(1):1-10 (51 ref.)
Millisecond CO2 laser skin resurfacing. Khan JA. **Int Ophthalmol Clin** 1997 Summer;37(3):29-68 (24 ref.)
Midinfrared photorefractive surgery: technical standards and clinical aspects. Mrochen M, et al. **Int Ophthalmol Clin** 1996 Fall;36(4):73-7 (12 ref.)
Refractive surgery for myopic and hyperopic astigmatism. Thompson V. **Int Ophthalmol Clin** 1997 Winter;37(1):37-49 (16 ref.)
The surgical treatment of snoring [see comments] Harries PG, et al. **J Laryngol Otol** 1996 Dec;110(12):1103-4 (9 ref.) Comment in: J Laryngol Otol 1997 Jun;111(6):598.
Surgery and laser therapy. Lawrence CM. **J R Coll Physicians Lond** 1997 Jul-Aug;31(4):369-73 (25 ref.)
Laparoscopic presacral neurectomy utilizing contact-tip Nd: YAG laser. Carter JE. **Keio J Med** 1996 Dec;45(4):332-5 (11 ref.)
Cutaneous facial resurfacing with the carbon dioxide laser. Biesman BS. **Ophthalmic Surg Lasers** 1996 Aug; 27(8):685-98 (62 ref.)
Histology of high-energy pulsed CO2 laser resurfacing. Alster TS, et al. **Semin Cutan Med Surg** 1996 Sep; 15(3):189-93 (11 ref.)
Combining surgical methods for skin resurfacing. Coleman WP 3rd, et al. **Semin Cutan Med Surg** 1996 Sep;15(3):194-9 (11 ref.)
Laser skin resurfacing. Dover JS, et al. **Semin Cutan Med Surg** 1996 Sep;15(3):177-88 (66 ref.)
Preoperative anesthesia and postoperative considerations in laser resurfacing. Fitzpatrick RE, et al. **Semin Cutan Med Surg** 1996 Sep;15(3):170-6 (11 ref.)
Successful treatment of a rectal anastomotic stenosis by transanal endoscopic microsurgery (TEM) using the contact Nd:YAG laser. Kato K, et al. **Surg Endosc** 1997 May;11(5):485-7 (11 ref.)
[Excimer laser treatment in corneal surgery] Tuunanen T, et al. **Duodecim** 1995;111(13):1202-8 (21 ref.) (Fin)
[The use of lasers in surgical orthopedics. A current review] Schmolke S, et al. **Orthopade** 1997 Mar;26(3):267-72 (25 ref.) (Eng. Abstr.) (Ger)
[Transmyocardial laser revascularization--morphologic, pathophysiologic and historical principles of indirect revascularization of the heart muscle] Moosdorf R, et al. **Z Kardiol** 1997 Mar;86(3):149-64 (130 ref.) (Eng. Abstr.) (Ger)
[Laser treatment of benign prostatic hyperplasia] Ogreid P, et al. **Nord Med** 1997 Mar;112(3):89-92 (15 ref.) (Eng. Abstr.) (Nor)

VETERINARY

Instrumentation and techniques for carbon dioxide lasers in equine general surgery. Palmer SE. **Vet Clin North Am Equine Pract** 1996 Aug;12(2):397-414 (14 ref.)
Instrumentation and techniques in transendoscopic upper respiratory tract laser surgery. Tulleners E. **Vet Clin North Am Equine Pract** 1996 Aug;12(2):373-95 (19 ref.)
[Application possibilities of laser surgery in veterinary medicine. 3: Literature review and some case reports] Weigand K, et al. **Tierarztl Prax** 1997 Jul;25(4):289-302 (73 ref.) (Eng. Abstr.) (Ger)
[Possibilities for the us of laser surgery in veterinary medicine. Part 2: Effects of laser beams on tissue] Weigand K, et al. **Tierarztl Prax** 1996 Aug;24(4):331-6 (14 ref.) (Eng. Abstr.) (Ger)

LASERS

see related

HOLOGRAPHY

Basic laser principles. Herd RM, et al. **Dermatol Clin** 1997 Jul;15(3):355-72 (55 ref.)
Future perspectives in gastroenterology: laser. Riemann JF. **Digestion** 1997;58 Suppl 1:101-3 (21 ref.)
Stress-wave-induced injury to retinal pigment epithelium cells in vitro. Douki T, et al. **Lasers Surg Med** 1996; 19(3):249-59 (33 ref.)
Laser physics and tissue interactions. Reinisch L. **Otolaryngol Clin North Am** 1996 Dec;29(6):893-914 (42 ref.)
The scanning laser ophthalmoscope. Sharp PF, et al. **Phys Med Biol** 1997 May;42(5):951-66 (80 ref.)
Laser light delivery systems for medical applications. Verdaasdonk RM, et al. **Phys Med Biol** 1997 May; 42(5):869-94 (75 ref.)
Optical trapping and manipulation of neutral particles using lasers. Ashkin A. **Proc Natl Acad Sci U S A** 1997 May 13;94(10):4853-60 (155 ref.)
Interstitial laser thermotherapy: developments in the treatment of small deep-seated brain tumors. Menovsky T, et al. **Surg Neurol** 1996 Dec;46(6):568-71; discussion 571-2 (36 ref.)
[The effect of laser radiation on biological tissue] Kaczmarek S, et al. **Wiad Lek** 1994 Nov-Dec;47(21-24):868-80 (20 ref.) (Pol)
[A comparative analysis of the biological action of microwaves and laser radiation] Zubkova SM. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Nov-Dec; (6):31-4 (16 ref.) (Eng. Abstr.) (Rus)

ADVERSE EFFECTS

Delayed articular cartilage slough: two cases resulting from holmium:YAG laser damage to normal articular cartilage and a review of the literature. Thal R, et al. **Arthroscopy** 1996 Feb;12(1):92-4 (8 ref.)
[Possibilities for the us of laser surgery in veterinary medicine. Part 2: Effects of laser beams on tissue] Weigand K, et al. **Tierarztl Prax** 1996 Aug;24(4):331-6 (14 ref.) (Eng. Abstr.) (Ger)

DIAGNOSTIC USE

[Laser fluorescence spectroscopy in cardiology: the problems and outlook] Zalesskiĭ VM, et al. **Lik Sprava** 1995 Sep-Dec;(9-12):7-10 (32 ref.) (Ukr)

THERAPEUTIC USE

New concepts in pain management and in the application of low-power laser for relief of cervicothoracic pain syndromes [editorial] Lee G, et al. **Am Heart J** 1996 Dec; 132(6):1329-34 (27 ref.)
Potential preventive and therapeutic hard-tissue applications of CO2, Nd:YAG and argon lasers in dentistry: a review. Gonzalez CD, et al. **ASDC J Dent Child** 1996 May-Jun; 63(3):196-207 (109 ref.)
Transmyocardial laser revascularization: an anesthetic perspective. Grocott HP, et al. **J Cardiothorac Vasc Anesth** 1997 Apr;11(2):206-10 (28 ref.)
Biostimulation of wound healing by low-energy laser irradiation. A review. Conlan MJ, et al. **J Clin Periodontol** 1996 May;23(5):492-6 (36 ref.)
Lasers: reflections on their evolution. Aronoff BL. **J Surg Oncol** 1997 Jan;64(1):84-92 (24 ref.)
The concept of laser phototherapy. Castro DJ, et al. **Otolaryngol Clin North Am** 1996 Dec;29(6):1011-29 (84 ref.)
[Progresses in laser medicine in China, 1996] Xu S. **Chung Hua I Hsueh Tsa Chih** 1996 Dec;76(12):939-40 (0 ref.) (Chi)
[Endoscopic treatment of early gastric cancer with laser and laserthermia using Nd : YAG laser] Otsuka S. **Nippon Rinsho** 1996 May;54(5):1326-31 (17 ref.) (Eng. Abstr.) (Jpn)
[Prophylaxis and treatment of aspiration syndrome and complications of artificial lung ventilation with endotracheal laser therapy] Chesnov VS, et al. **Anesteziol Reanimatol** 1996 Jul-Aug;(4):78-9 (3 ref.) (Rus)
[Clinical implications of high blood viscosity and its reduction bu photo-hemotherapy] Karandashov VI, et al. **Klin Med (Mosk)** 1997;75(8):19-23 (37 ref.) (Eng. Abstr.) (Rus)
[Impact of low-energy laser irradiation on the immunological nonspecific responsiveness in patients with tuberculosis] Litvinov VI, et al. **Probl Tuberk** 1997;(4):58-60 (75 ref.) (Rus)
[Laser physiotherapy of stomatological diseases] Prokhonchukov AA, et al. **Stomatologiia (Mosk)** 1995; 74(6):23-31 (21 ref.) (Eng. Abstr.) (Rus)
[The use of intravascular laser irradiation of the blood in surgery] Ismailov DA, et al. **Vestn Khir Im I I Grek** 1995; 154(4-6):128-31 (59 ref.) (Rus)
[The immunomodulating effects of low-intensity laser radiation] Konchugova TV, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1997 Jan-Feb;(1):42-5 (51 ref.) (Rus)
[Treatment of prostate benign hyperplasia (BPH) with visually controlled laser, assessment at 2 years, and anatomopathologic findings] Laguna MP, et al. **Actas Urol Esp** 1996 Sep;20(8):681-8 (23 ref.) (Eng. Abstr.) (Spa)
[Argon laser treatment of urethral angioma. Report of the first case] Borrego Hernando J, et al. **Arch Esp Urol** 1996 Oct;49(8):859-61 (12 ref.) (Eng. Abstr.) (Spa)

LASSITUDE see **FATIGUE**

LATE GENE TRANSCRIPTION see **TRANSCRIPTION, GENETIC**

LATE PROMOTERS see **PROMOTER REGIONS (GENETICS)**

LATENT SCHIZOPHRENIA see **SCHIZOTYPAL PERSONALITY DISORDER**

LATERAL BULBAR SYNDROME see **WALLENBERG'S SYNDROME**

LATERAL CYST see **PERIODONTAL CYST**

LATERAL GENICULATE BODY see **GENICULATE BODIES**

LATERAL HYPOTHALAMIC AREA see **HYPOTHALAMIC AREA, LATERAL**

LATERAL HYPOTHALAMIC NUCLEUS see **HYPOTHALAMIC AREA, LATERAL**

LATERAL LIGAMENT, ANKLE

INJURIES

[The unstable upper ankle joint. Treatment of acute ligament rupture--a review of the literature] Sommer CJ. **Sportverletz Sportschaden** 1996 Dec;10(4):76-8 (34 ref.) (Eng. Abstr.) (Ger)
[Magnetic resonance tomography (MRI) of ligament injuries of the upper ankle joint] Zanetti M, et al. **Sportverletz Sportschaden** 1996 Sep;10(3):58-62 (23 ref.) (Eng. Abstr.) (Ger)

LATERAL LIGAMENTS see **COLLATERAL LIGAMENTS**

LATERAL MENISCI see **MENISCI, TIBIAL**

LATERAL SCLEROSIS see **AMYOTROPHIC LATERAL SCLEROSIS**

LATERALITY

Crossed aphasia. Functional brain imaging with PET or SPECT. Bakar M, et al. **Arch Neurol** 1996 Oct; 53(10):1026-32 (36 ref.)
Information processing and symmetry-breaking in memory evolutive systems. Ehresmann AC, et al. **Biosystems** 1997; 43(1):25-40 (19 ref.)
Clinical and research contributions of the intracarotid amobarbital procedure to neuropsychology. Jones-Gotman M, et al. **Brain Cogn** 1997 Feb;33(1):1-6 (20 ref.)
Crossed aphasia and related anomalies of cerebral organization: case reports and a genetic hypothesis. Alexander MP, et al. **Brain Lang** 1996 Nov;55(2):213-39 (120 ref.)
Does cognition in the disconnected right hemisphere require right hemisphere possession of language? Bogen JE. **Brain Lang** 1997 Mar;57(1):12-21 (72 ref.)
Can the right hemisphere speak? Code C. **Brain Lang** 1997 Mar;57(1):38-59 (85 ref.)
Neuropsychiatric manifestations of right hemisphere lesions. Cummings JL. **Brain Lang** 1997 Mar;57(1):22-37 (85 ref.)
Behavioral and electrophysiological indices of voicing-cue discrimination: laterality patterns and development. Simos PG, et al. **Brain Lang** 1997 Mar;57(1):122-50 (84 ref.)
Rags to riches: our increasing appreciation of cognitive and communicative abilities of the human right cerebral hemisphere. Van Lancker D. **Brain Lang** 1997 Mar; 57(1):1-11 (136 ref.)
Neuropsychological evaluation in epilepsy surgery. Loring DW. **Epilepsia** 1997;38 Suppl 4:S18-23 (35 ref.)
A question of foot dominance. Gabbard C, et al. **J Gen Psychol** 1996 Oct;123(4):289-96 (33 ref.)
Mania following left hemisphere injury. Lim LC. **Singapore Med J** 1996 Aug;37(4):448-50 (18 ref.)
Language dominance in the cerebral hemispheres. Hamani C. **Surg Neurol** 1997 Jan;47(1):81-3 (20 ref.)
[Ontogenesis of lateralities. A review and attempted interpretation] Gaillard F. **Arch Pediatr** 1996 Jul; 3(7):714-22 (30 ref.) (Eng. Abstr.) (Fre)
[Left hand clumsiness due to disturbance of kinesthesia after damage to the dorsal column of the high cervical cord] Hashimoto R, et al. **Rinsho Shinkeigaku** 1997 Apr; 37(4):319-25 (22 ref.) (Eng. Abstr.) (Jpn)

LATERALITY

GENETICS

A single locus, RGHT, specifies preference for hand utilization in humans. Klar AJ. **Cold Spring Harb Symp Quant Biol** 1996;61:59–65 (28 ref.)

Handedness and speech: a critical reappraisal of the role of genetic and environmental factors in the cerebral lateralization of function. Provins KA. **Psychol Rev** 1997 Jul;104(3):554–71 (310 ref.)

[Laterality in twins] Reiss M. **Z Morphol Anthropol** 1996 Sep; 81(2):141–55 (79 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Unilateral facial pain and lung cancer. Shakespeare TP, et al. **Australas Radiol** 1996 Feb;40(1):45–6 (14 ref.)

Hemispheric asymmetry of movement. Haaland KY, et al. **Curr Opin Neurobiol** 1996 Dec;6(6):796–800 (34 ref.)

On the structure and function of the tectofugal visual pathway in laterally eyed birds. Bischof HJ, et al. **Eur J Morphol** 1997 Oct;35(4):246–54 (72 ref.)

Neuroendocrine asymmetry. Gerendai I, et al. **Front Neuroendocrinol** 1997 Jul;18(3):354–81 (154 ref.)

The hand and the eye. Filan SL, et al. **J Hand Surg [Br]** 1997 Jun;22(3):293–8 (48 ref.)

Eye dominance in excimer laser photorefractive keratectomy. Hashim AA. **J Refract Surg** 1997 Aug;13(5 Suppl):S461–2 (5 ref.)

Models of orientation and ocular dominance columns in the visual cortex: a critical comparison. Erwin E, et al. **Neural Comput** 1995 May;7(3):425–68 (83 ref.)

High level object recognition without an anterior inferior temporal lobe. Biederman I, et al. **Neuropsychologia** 1997 Mar;35(3):271–87 (64 ref.)

Avian visual lateralization: a review. Güntürkün O. **Neuroreport** 1997 Apr 14;8(6):iii–xi (93 ref.)

Laterality and types of dyslexia. Annett M. **Neurosci Biobehav Rev** 1996 Winter;20(4):631–6 (32 ref.)

Lateralization of brain mechanisms underlying automatic and controlled forms of spatial orienting of attention. Gainotti G. **Neurosci Biobehav Rev** 1996 Winter;20(4):617–22 (48 ref.)

Diencephalic asymmetries. Harris JA, et al. **Neurosci Biobehav Rev** 1996 Winter;20(4):637–43 (51 ref.)

Developmental asymmetries in experimental animals. Polani PE. **Neurosci Biobehav Rev** 1996 Winter;20(4):645–9 (50 ref.)

The concept of transcortical cell assemblies: a key to the understanding of cortical lateralization and interhemispheric interaction. Pulvermüller F, et al. **Neurosci Biobehav Rev** 1996 Winter;20(4):557–66 (53 ref.)

Cellular, morphometric, ontogenetic and connectional substrates of anatomical asymmetry. Rosen GD. **Neurosci Biobehav Rev** 1996 Winter;20(4):607–15 (72 ref.)

Structure, functional and cerebral asymmetry: in vivo morphometry of the planum temporale. Steinmetz H. **Neurosci Biobehav Rev** 1996 Winter;20(4):587–91 (49 ref.)

Lateral asymmetries in infancy: implications for the development of the hemispheres. Trevarthen C. **Neurosci Biobehav Rev** 1996 Winter;20(4):571–86 (148 ref.)

Unilateral containment of retinal axons by tectal glia: a possible role for sulfated proteoglycans. Jhaveri S, et al. **Prog Brain Res** 1996;108:135–48 (104 ref.)

Hemispheric specialization for emotions, affective aspects of language and communication and the cognitive control of display behaviors in humans. Ross ED. **Prog Brain Res** 1996;107:583–94 (131 ref.)

[Technical aspects of studying motor asymmetry] Reiss M. **Wien Med Wochenschr** 1997;147(11):275–8 (22 ref.) (Eng. Abstr.) **(Ger)**

LATEX

ADVERSE EFFECTS

Latex allergy. Senst BL, et al. **Am J Health Syst Pharm** 1997 May 1;54(9):1071–5 (20 ref.)

Latex sensitivity in children with spina bifida: implications for occupational therapy practitioners. Scoggin AE, et al. **Am J Occup Ther** 1997 Jul–Aug;51(7):608–11 (21 ref.)

Managing latex allergy in patients and health care workers. Melton AL. **Cleve Clin J Med** 1997 Feb;64(2):76–82 (60 ref.)

Latex allergy. Wooding LG, et al. **Compr Ther** 1996 Jun; 22(6):384–92 (30 ref.)

The diagnosis and management of health personnel allergic to natural rubber latex gloves. Part II. Fisher AA. **Cutis** 1997 Apr;59(4):168–70 (17 ref.)

Type I allergies to latex and the aeroallergenic problem. Heese A, et al. **Eur J Surg Suppl** 1997;(579):19–22 (14 ref.)

Latex allergies in dentistry: recognition and recommendations. Roy A, et al. **J Can Dent Assoc** 1997 Apr;63(4):297–300 (13 ref.)

Current perspectives on latex allergy [see comments] Landwehr LP, et al. **J Pediatr** 1996 Mar;128(3):305–12 (63 ref.) Comment in: J Pediatr 1996 Nov;129(5):771–2.

[Update on the latex allergy topic] Heese A, et al. **Hautarzt** 1996 Nov;47(11):817–24 (40 ref.) (Eng. Abstr.) **(Ger)**

[Latex: an allergological emergency? An update and outlook] La Grutta S, et al. **Pediatr Med Chir** 1996 Nov–Dec; 18(6):545–8 (24 ref.) (Eng. Abstr.) **(Ita)**

[Clinical and experimental aspect of latex allergy] Akasawa A. **Arerugi** 1997 Apr;46(4):349–53 (11 ref.) **(Jpn)**

[Occupational immediate allergy to latex. I. Introduction, epidemiology and clinical findings] Palczyński C, et al. **Med Pr** 1997;48(3):317–23 (15 ref.) (Eng. Abstr.) **(Pol)**

[Allergy to latex. Clinical manifestation, diagnosis and treatment] Obojski A, et al. **Pol Arch Med Wewn** 1997 Feb; 97(2):182–8 (40 ref.) **(Pol)**

IMMUNOLOGY

Cooccurrence of latex and fruit allergies. Freeman GL. **Allergy Asthma Proc** 1997 Mar–Apr;18(2):85–8 (30 ref.)

Hypersensitivity of the vascular endothelium to latex balloon catheter. Obrand DI, et al. **Ann Vasc Surg** 1997 Sep; 11(5):536–9 (28 ref.)

Latex hypersensitivity in children. Cahaly RJ, et al. **Curr Opin Pediatr** 1995 Dec;7(6):671–5 (29 ref.)

[Latex allergy] Jensen VB, et al. **Ugeskr Laeger** 1997 May 19;159(21):3129–33 (40 ref.) (Eng. Abstr.) **(Dan)**

[Clinical and experimental aspect of latex allergy] Akasawa A. **Arerugi** 1997 Apr;46(4):349–53 (11 ref.) **(Jpn)**

LATEX RUBBER see **RUBBER**

LATHYRUS see **LEGUMES**

LATINOS see **HISPANIC AMERICANS**

LATRODECTUS MACTANS see **BLACK WIDOW SPIDER**

LATS RECEPTORS see **RECEPTORS, THYROID HORMONE**

LAUGHTER

Pathological laughing and crying. Dark FL, et al. **Aust N Z J Psychiatry** 1996 Aug;30(4):472–9 (46 ref.)

Humor and laughter in palliative care. Dean RA. **J Palliat Care** 1997 Spring;13(1):34–9 (29 ref.)

LAUNDRY SERVICE, HOSPITAL

see related
BEDDING AND LINENS

LAURENCE-MOON-BIEDL SYNDROME

[Laurence–Moon–Biedl syndrome] Kurihara M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):275–7 (4 ref.) **(Jpn)**

PSYCHOLOGY

[Mental disorders in (Laurence Moon)–Bardet–Biedl syndrome] Biéder J, et al. **Ann Med Psychol (Paris)** 1996 Jun;154(4):264–5 (22 ref.) **(Fre)**

LAV-2 see **HIV-2**

LAV ANTIBODIES see **HIV ANTIBODIES**

LAV ANTIGENS see **HIV ANTIGENS**

LAV-HTLV-III see **HIV**

LAVAGE see **IRRIGATION**

LAW ENFORCEMENT OFFICERS see **POLICE**

LAXATIVES see **CATHARTICS**

LAXITY, JOINT see **JOINT INSTABILITY**

LAYING-ON-OF-HANDS see **THERAPEUTIC TOUCH**

LCF FACTOR see **INTERLEUKIN-16**

LCM VIRUSES see **LYMPHOCYTIC CHORIOMENINGITIS VIRUS**

LDL CHOLESTEROL see **LIPOPROTEINS, LDL CHOLESTEROL**

LDL RECEPTORS see **RECEPTORS, LDL**

LE CELLS see **NEUTROPHILS**

LE(X) ANTIGEN see **ANTIGENS, CD15**

LEAD

[Ecologic significance and hygienic regulation of lead and cadmium in various media (literature review)] Egorov IuL, et al. **Med Tr Prom Ekol** 1996;(10):18–25 (55 ref.) **(Rus)**

ADVERSE EFFECTS

Lead exposure in Latin America and the Caribbean. Lead Research Group of the Pan-American Health Organization. Romieu I, et al. **Environ Health Perspect** 1997 Apr;105(4):398–405 (47 ref.)

Public health implications of environmental exposure to cadmium and lead: an overview of epidemiological studies in Belgium. Working Groups. Staessen JA, et al. **J Cardiovasc Risk** 1996 Feb;3(1):26–41 (155 ref.)

PCBs and behavioral impairment: are there lessons we can learn from lead? Rice DC. **Neurotoxicol Teratol** 1996 May–Jun;18(3):229–32; discussion 271–6 (28 ref.)

Effects of low level lead exposure on cognitive function in children: a review of behavioral, neuropsychological and biological evidence. Banks EC, et al. **Neurotoxicology** 1997; 18(1):237–81 (295 ref.)

[The influence of lead on neutrophils] Hrycek A, et al. **Wiad Lek** 1996;49(7–12):103–6 (13 ref.) (Eng. Abstr.) **(Pol)**

ANALYSIS

Is placenta a good indicator of cadmium and lead exposure? Lagerkvist BI, et al. **Arch Environ Health** 1996 Sep–Oct; 51(5):389–94 (16 ref.)

Assessment of Polish population exposure to lead and cadmium with special emphasis to the Katowice Province on the basis of metal concentrations in environmental compartments. Gzyl J. **Cent Eur J Public Health** 1997 Jun; 5(2):93–6 (21 ref.)

Too easily lead? Health effects of gasoline additives. Menkes DB, et al. **Environ Health Perspect** 1997 Mar;105(3):270–3 (42 ref.)

[The anthropogenic lead burden and its risks] Schümann K, et al. **Pharm Unserer Zeit** 1997 May;26(3):143–51 (43 ref.) **(Ger)**

METABOLISM

Bone lead as a risk factor for hypertension in men. Fleet JC. **Nutr Rev** 1996 Jun;54(6):180–2 (3 ref.)

PHARMACOKINETICS

[The influence of lead on fetal development] Nowak-Węgrzyn A, et al. **Przegl Lek** 1996;53(10):744–9 (29 ref.) (Eng. Abstr.) **(Pol)**

TOXICITY

Repeated acquisition and the assessment of centrally acting compounds. Cohn J, et al. **Brain Res Cogn Brain Res** 1996 Jun;3(3–4):183–91 (60 ref.)

Response of higher plants to lead contaminated environment. Singh RP, et al. **Chemosphere** 1997 Jun;34(11):2467–93 (147 ref.)

Results of lead research: prenatal exposure and neurological consequences. Goyer RA. **Environ Health Perspect** 1996 Oct;104(10):1050–4 (53 ref.)

Lead and neurobehavioral development in gulls: a model for understanding effects in the laboratory and the field. Burger J, et al. **Neurotoxicology** 1997;18(2):495–506 (57 ref.)

Inorganic lead as a developmental neurotoxicant: some basic issues and the Düsseldorf experience. Winneke G. **Neurotoxicology** 1996 Fall–Winter;17(3–4):565–80 (91 ref.)

[Lipid peroxidation as a toxic mode of action for lead and cadmium] Skoczyńska A. **Med Pr** 1997;48(2):197–203 (55 ref.) (Eng. Abstr.) **(Pol)**

LEAD POISONING

Lead and the kidney: nephropathy, hypertension, and gout. Perazella MA. **Conn Med** 1996 Sep;60(9):521–6 (30 ref.)

[The influence of lead on fetal development] Nowak-Węgrzyn A, et al. **Przegl Lek** 1996;53(10):744–9 (29 ref.) (Eng. Abstr.) **(Pol)**

BLOOD

Blood lead levels in children in south central Los Angeles. Rothenberg SJ, et al. **Arch Environ Health** 1996 Sep–Oct; 51(5):383–8 (25 ref.)

COMPLICATIONS

Neurobehavioral aspects of lead neurotoxicity in children. Winneke G, et al. **Cent Eur J Public Health** 1997 Jun; 5(2):65–9 (41 ref.)

Lead and cancer—association or causation? [editorial] Vainio H. **Scand J Work Environ Health** 1997 Feb;23(1):1–3 (24 ref.)

[Lead—an etiologic factor in vascular disease: main evidence (lecture)] Zerbino DD, et al. **Arkh Patol** 1997 Jan–Feb; 59(1):9–12 (49 ref.) (Eng. Abstr.) **(Rus)**

DIAGNOSIS

Lead poisoning in children. Berlin CM Jr. **Curr Opin Pediatr** 1997 Apr;9(2):173–7 (23 ref.)

[Ecologic significance and hygienic regulation of lead and cadmium in various media (literature review)] Egorov IuL, et al. **Med Tr Prom Ekol** 1996;(10):18–25 (55 ref.) **(Rus)**

EPIDEMIOLOGY

Leaded gasoline abuse: the role of tetraethyl lead. Tenenbein M. **Hum Exp Toxicol** 1997 Apr;16(4):217–22 (44 ref.)

ETIOLOGY

Blood lead levels in children in south central Los Angeles. Rothenberg SJ, et al. **Arch Environ Health** 1996 Sep–Oct; 51(5):383–8 (25 ref.)

Lead exposure in Latin America and the Caribbean. Lead

Research Group of the Pan-American Health Organization. Romieu I, et al. **Environ Health Perspect** 1997 Apr;105(4):398–405 (47 ref.)

METABOLISM

Oxidative stress in acute intermittent porphyria and lead poisoning may be triggered by 5-aminolevulinic acid. Bechara EJ. **Braz J Med Biol Res** 1996 Jul;29(7):841–51 (78 ref.)

PHYSIOPATHOLOGY

[The anthropogenic lead burden and its risks] Schümann K, et al. **Pharm Unserer Zeit** 1997 May;26(3):143–51 (43 ref.) **(Ger)**

PREVENTION & CONTROL

Preventing lead poisoning in children. Silbergeld EK. **Annu Rev Public Health** 1997;18:187–210 (78 ref.)

Exposure to lead and human health in the Czech Republic. Bláha K, et al. **Cent Eur J Public Health** 1996 Dec; 4(4):233–41 (73 ref.)

Lead poisoning: the implications of current biomedical knowledge for public policy. Silbergeld EK. **Md Med J** 1996 Mar;45(3):209–17 (38 ref.)

PSYCHOLOGY

Behavioral effects of lead: commonalities between experimental and epidemiologic data. Rice DC. **Environ Health Perspect** 1996 Apr;104 Suppl 2:337–51 (119 ref.)

VETERINARY

Lead toxicosis in 2 horses: similarity to equine degenerative lower motor neuron disease. Sojka JE, et al. **J Vet Intern Med** 1996 Nov–Dec;10(6):420–3 (22 ref.)

Lead and zinc intoxication in zoological medicine: a review. Mautino M. **J Zoo Wildl Med** 1997 Mar;28(1):28–35 (73 ref.)

LEADER SIGNAL PEPTIDES see **SIGNAL PEPTIDES**

LEADERSHIP

Leadership and organizational skills in academic medicine. Bogdewic SP, et al. **Fam Med** 1997 Apr;29(4):262–5 (47 ref.)

Strategic leadership: a view from quantum and chaos theories. McDaniel RR Jr. **Health Care Manage Rev** 1997 Winter;22(1):21–37 (74 ref.)

Accountability for health care: a white paper on leadership and management for the U.S. health care system. Schneller ES. **Health Care Manage Rev** 1997 Winter;22(1):38–48; discussion 49–57 (27 ref.)

Women in the new world order: where old values command new respect. Finn SC. **J Am Diet Assoc** 1997 May; 97(5):475–80 (43 ref.)

An osteopathic prescription for medical education reform: Part 2. Specialty mix and community integration. Ross-Lee B, et al. **J Am Osteopath Assoc** 1997 Aug;97(8):463–8 (18 ref.)

Translating ideas into actions: entrepreneurial leadership in state health care reforms [see comments] Oliver TR, et al. **J Health Polit Policy Law** 1997 Jun;22(3):721–88 (98 ref.) Comment in: J Health Polit Policy Law 1997 Jun;22(3):879–96. Comment in: J Health Polit Policy Law 1997 Jun;22(3):897–906.

Developing tomorrow's integrated community health systems: a leadership challenge for public health and primary care. Welton WE, et al. **Milbank Q** 1997; 75(2):261–88 (15 ref.)

LEARNED HELPLESSNESS see **HELPLESSNESS, LEARNED**

LEARNING

Fetal memory: does it exit? What does it do? Hepper PG. **Acta Paediatr Suppl** 1996 Oct;416:16–20 (59 ref.)

The interaction of knowledge, aptitude, and strategies in children's memory performance. Bjorklund DF, et al. **Adv Child Dev Behav** 1996;26:59–89 (98 ref.)

Essential practices as adults read to meet the needs of deaf or hard of hearing students. Luetke-Stahlman B, et al. **Am Ann Deaf** 1996 Oct;141(4):309–20 (176 ref.)

Early learning and the social bond. Keverne EB, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:329–39 (32 ref.)

Neural correlates of sensitive periods in avian song learning. Nordeen KW. **Ann N Y Acad Sci** 1997 Jan 15;807:386–400 (109 ref.)

Critical periods in childhood learning. Sylva K. **Br Med Bull** 1997 Jan;53(1):185–97 (40 ref.)

The frontal cortex-basal ganglia system in primates. Wise SP, et al. **Crit Rev Neurobiol** 1996;10(3–4):317–56 (443 ref.)

Functional screening and complex traits: human 21q22.2 sequences affecting learning in mice. Smith DJ, et al. **Hum Mol Genet** 1997;6(10):1729–33 (38 ref.)

Constructing meaning in the learning experience: the role of alternative theoretical frameworks. Lauder W. **J Adv Nurs** 1996 Jul;24(1):91–7 (50 ref.)

Annotation: computers for learning: psychological perspectives. Light P. **J Child Psychol Psychiatry** 1997 Jul; 38(5):497–504 (69 ref.)

Reflective learning: a teaching strategy for critical thinking. Baker CR. **J Nurs Educ** 1996 Jan;35(1):19–22 (14 ref.)

Reverse learning and the physiological basis of eye movement desensitization. Hassard A. **Med Hypotheses** 1996 Oct; 47(4):277–82 (45 ref.)

Contract learning, clinical learning and clinicians. Parsell G, et al. **Postgrad Med J** 1996 May;72(847):284–9 (29 ref.)

Activation of c-fos in the brain. Herrera DG, et al. **Prog Neurobiol** 1996 Oct;50(2–3):83–107 (265 ref.)

A neural substrate of prediction and reward. Schultz W, et al. **Science** 1997 Mar 14;275(5306):1593–9 (37 ref.)

Language acquisition and use: learning and applying probabilistic constraints. Seidenberg MS. **Science** 1997 Mar 14;275(5306):1599–603 (46 ref.)

Machine learning paradigms for pattern recognition and image understanding. Caelli T, et al. **Spat Vis** 1996; 10(1):87–103 (23 ref.)

Using learning theory in animal behavior therapy practice. Mills DS. **Vet Clin North Am Small Anim Pract** 1997 May; 27(3):617–35 (38 ref.)

[Gene expression controlled by neural activity] Tsuda M, et al. **Tanpakushitsu Kakusan Koso** 1997 Mar;42(4):632–42 (68 ref.) **(Jpn)**

[Lifelong learning--how do physicians learn?] Pedersen OB, et al. **Tidsskr Nor Laegeforen** 1996 Sep 20;116(22):2684–8 (35 ref.) (Eng. Abstr.) **(Nor)**

DRUG EFFECTS

Neuropeptides in learning and memory processes. de Wied D. **Behav Brain Res** 1997 Feb;83(1–2):83–90 (76 ref.)

Repeated acquisition and the assessment of centrally acting compounds. Cohn J, et al. **Brain Res Cogn Brain Res** 1996 Jun;3(3–4):183–91 (60 ref.)

Animal models in cognitive behavioural pharmacology: an overview. D'Mello GD, et al. **Brain Res Cogn Brain Res** 1996 Jun;3(3–4):345–52 (25 ref.)

Investigations of hypesthesia: using anesthetics to explore relationships between consciousness, learning, and memory. Andrade J. **Conscious Cogn** 1996 Dec;5(4):562–80 (42 ref.)

Nootropics: preclinical results in the light of clinical effects; comparison with tacrine. Mondadori C. **Crit Rev Neurobiol** 1996;10(3–4):357–70 (85 ref.)

The effects of prenatal cocaine exposure on subsequent learning in the rat. Riley EP, et al. **NIDA Res Monogr** 1996;164:53–77 (13 ref.)

Long-term effects of developmental exposure to cocaine on learned and unlearned behaviors. Vorhees CV. **NIDA Res Monogr** 1996;164:3–52 (61 ref.)

A pharmacological analysis of serotonergic receptors: effects of their activation of blockade in learning. Meneses A, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Feb; 21(2):273–96 (121 ref.)

PHYSIOLOGY

Effect of training and environment on brain morphology and behavior. Schrott LM. **Acta Paediatr Suppl** 1997 Jul; 422:45–7 (38 ref.)

Metabotropic glutamate receptors in hippocampal long-term potentiation and learning and memory. Riedel G, et al. **Acta Physiol Scand** 1996 May;157(1):1–19 (125 ref.)

Some functions of primary auditory cortex in learning and memory formation. Scheich H, et al. **Adv Neurol** 1997; 73:179–93 (33 ref.)

Learning and memory during general anesthesia: an update. Ghoneim MM, et al. **Anesthesiology** 1997 Aug; 87(2):387–410 (152 ref.)

Developmental plasticity in neural circuits for a learned behavior. Bottjer SW, et al. **Annu Rev Neurosci** 1997; 20:459–81 (91 ref.)

Molecular genetic analysis of synaptic plasticity, activity-dependent neural development, learning, and memory in the mammalian brain. Chen C, et al. **Annu Rev Neurosci** 1997;20:157–84 (149 ref.)

Learning and memory in honeybees: from behavior to neural substrates. Menzel R, et al. **Annu Rev Neurosci** 1996; 19:379–404 (204 ref.)

Psychobiological models of hippocampal function in learning and memory. Gluck MA, et al. **Annu Rev Psychol** 1997; 48:481–514 (110 ref.)

Neurobiological principles of learning and memory. Brunelli M, et al. **Arch Ital Biol** 1997 Jan;135(1):15–36 (69 ref.)

Neuropeptides in learning and memory processes. de Wied D. **Behav Brain Res** 1997 Feb;83(1–2):83–90 (76 ref.)

Selecting a model system for neurobiological studies of learning and memory. Eisenstein EM. **Behav Brain Res** 1997 Jan;82(2):121–32 (56 ref.)

The tuberomammillary nucleus projections in the control of learning, memory and reinforcement processes: evidence for an inhibitory role. Huston JP, et al. **Behav Brain Res** 1997 Feb;83(1–2):97–105 (58 ref.)

Acetylcholine: a neurotransmitter for learning and memory? Blokland A. **Brain Res Brain Res Rev** 1995 Nov; 21(3):285–300 (135 ref.)

Possible confounding influence of strain, age and gender on cognitive performance in rats. Andrews JS. **Brain Res Cogn Brain Res** 1996 Jun;3(3–4):251–67 (193 ref.)

Repeated acquisition and the assessment of centrally acting compounds. Cohn J, et al. **Brain Res Cogn Brain Res** 1996 Jun;3(3–4):183–91 (60 ref.)

Underestimating the rat's intelligence. Davis H. **Brain Res Cogn Brain Res** 1996 Jun;3(3–4):291–8 (57 ref.)

Cognitive function in mammals: the evolutionary perspective. Macphail EM. **Brain Res Cogn Brain Res** 1996 Jun; 3(3–4):279–90 (58 ref.)

Attention and stimulus processing in the rat. Muir JL. **Brain Res Cogn Brain Res** 1996 Jun;3(3–4):215–25 (77 ref.)

Measurement of cognitive function: relating rodent performance with human minds. Steckler T, et al. **Brain Res Cogn Brain Res** 1996 Jun;3(3–4):299–308 (90 ref.)

Investigating cognitive abilities in animals: unrealized potential. Thomas RK. **Brain Res Cogn Brain Res** 1996 Jun;3(3–4):157–66 (20 ref.)

Spatial learning and memory: the beginning of a dream [comment] Stevens CF. **Cell** 1996 Dec 27;87(7):1147–8 (10 ref.) Comment on: Cell 1996 Dec 27;87(7):1317–26. Comment on: Cell 1996 Dec 27;87(7):1327–38. Comment on: Cell 1996 Dec 27;87(7):1339–49. Comment on: Cell 1996 Dec 27;87(7):1351–61.

Injury- and use-related plasticity in the primary sensory cortex of adult mammals: possible relationship to perceptual learning. Irvine DR, et al. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov;23(10–11):939–47 (56 ref.)

Synaptic plasticity: the basis of particular types of learning. Goda Y, et al. **Curr Biol** 1996 Apr 1;6(4):375–8 (12 ref.)

Perceptual learning: insight in sight. Walsh V, et al. **Curr Biol** 1997 Apr 1;7(4):R249–51 (11 ref.)

LTP, NMDA, genes and learning. Cain DP. **Curr Opin Neurobiol** 1997 Apr;7(2):235–42 (75 ref.)

Learning perceptual skills: behavioral probes into adult cortical plasticity. Karni A, et al. **Curr Opin Neurobiol** 1997 Aug;7(4):530–5 (71 ref.)

Memory in utero? [see comments] Hepper PG. **Dev Med Child Neurol** 1997 May;39(5):343–6 (60 ref.) Comment in: Dev Med Child Neurol 1997 May;39(5):285.

Nigrostriatal dopamine system may contribute to behavioral learning through providing reinforcement signals to the striatum. Kimura M, et al. **Eur Neurol** 1997;38 Suppl 1:11–7 (33 ref.)

LTP and spatial learning--where to next? Jeffery KJ. **Hippocampus** 1997;7(1):95–110 (105 ref.)

Fetal alcohol syndrome: early olfactory learning as a model system to study neurobehavioral deficits. Kirstein CL, et al. **Int J Neurosci** 1997 Jan;89(1–2):119–32 (128 ref.)

Endogenous opioid regulation of hippocampal function. Simmons ML, et al. **Int Rev Neurobiol** 1996;39:145–96 (241 ref.)

Vision, learning and dyslexia. A joint organizational policy statement of the American Academy of Optometry and the American Optometric Association. **J Am Optom Assoc** 1997 May;68(5):284–6 (29 ref.)

Using aversion learning techniques to assess the mental state, suffering, and welfare of farm animals. Rushen J. **J Anim Sci** 1996 Aug;74(8):1990–5 (35 ref.)

A framework for mesencephalic dopamine systems based on predictive Hebbian learning. Montague PR, et al. **J Neurosci** 1996 Mar 1;16(5):1936–47 (52 ref.)

The nucleus accumbens and learning and memory. Setlow B. **J Neurosci Res** 1997 Sep 1;49(5):515–21 (56 ref.)

Does Hebbian synaptic plasticity explain learning-induced sensory plasticity in adult mammals? Edeline JM. **J Physiol Paris** 1996;90(3–4):271–6 (52 ref.)

Plasticity of the hippocampal-prefrontal cortex synapses. Jay TM, et al. **J Physiol Paris** 1996;90(5–6):361–6 (19 ref.)

Behavioral, neural and cellular components underlying olfactory learning in the honeybee. Menzel R, et al. **J Physiol Paris** 1996;90(5–6):395–8 (36 ref.)

The role of neuropeptides in learning and memory: possible mechanisms. Shen Y, et al. **Med Hypotheses** 1995 Dec; 45(6):529–38 (80 ref.)

Neurochemical modulation of the hippocampus in learning, remembering and forgetting in primates. Ridley RM, et al. **Neurodegeneration** 1996 Dec;5(4):467–71 (27 ref.)

Consolidation: fragility on the road to the engram. Dudai Y. **Neuron** 1996 Sep;17(3):367–70 (20 ref.)

Roles of cerebellar cortex and nuclei in motor learning: contradictions or clues? Mauk MD. **Neuron** 1997 Mar; 18(3):343–6 (21 ref.)

Neurobiological basis of motor learning in mammals. Asanuma H, et al. **Neuroreport** 1997 Mar 3;8(4):i–vi (59 ref.)

Contribution of frontostriatal function to sequence learning in Parkinson's disease: evidence for dissociable systems. Dominey PF, et al. **Neuroreport** 1997 Mar 24;8(5):iii–ix (48 ref.)

Genetic aspects of the mechanisms of learning. Ponomarenko VV, et al. **Neurosci Behav Physiol** 1997 May–Jun; 27(3):245–9 (20 ref.)

Motivation and reinforcement in the systemic mechanisms of behavior: dynamic reinforcement engrams. Sudakov KV. **Neurosci Behav Physiol** 1996 Sep–Dec;26(5):445–53 (40 ref.)

Behavioral consequences of intracerebral vasopressin and oxytocin: focus on learning and memory. Engelmann M, et al. **Neurosci Biobehav Rev** 1996 Autumn;20(3):341–58 (219 ref.)

Astrocyte-neuron interaction during one-trial aversive learning in the neonate chick. Hertz L, et al. **Neurosci Biobehav Rev** 1996 Autumn;20(3):537–51 (96 ref.)

Complex roles of glutamate in the Gibbs-Ng model of one-trial aversive learning in the new-born chick. Ng KT, et al. **Neurosci Biobehav Rev** 1997 Jan;21(1):45–54 (76 ref.)

LEARNING

Locating reward cue at response manipulandum (CAM) induces symptoms of drug abuse. Tomie A. **Neurosci Biobehav Rev** 1996 Autumn;20(3):505–35 (576 ref.)

Attention to action. Passingham RE. **Philos Trans R Soc Lond B Biol Sci** 1996 Oct 29; 351(1346):1473–9 (28 ref.)

Toward a molecular definition of long-term memory storage. Bailey CH, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13445–52 (69 ref.)

A synaptic basis for memory storage in the cerebral cortex. Bear MF. **Proc Natl Acad Sci U S A** 1996 Nov 26; 93(24):13453–9 (59 ref.)

Structure and function of declarative and nondeclarative memory systems. Squire LR, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13515–22 (66 ref.)

Discovery of genes involved with learning and memory: an experimental synthesis of Hirschian and Benzerian perspectives. Tully T. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13460–7 (77 ref.)

Neural mechanisms of mammalian olfactory learning. Brennan PA, et al. **Prog Neurobiol** 1997 Mar;51(4):457–81 (160 ref.)

Long-term potentiation: a good model for learning and memory? Hölscher C. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Jan; 21(1):47–68 (69 ref.)

Protein kinase C, learning and memory: a circular determinism between physiology and behaviour [see comments] Noguès X. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Apr; 21(3):507–29 (68 ref.) Comment in: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):373–8.

Comparing the role of metabotropic glutamate receptors in long-term potentiation and in learning and memory. Riedel G, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Jul;20(5):761–89 (118 ref.)

Learning-induced alterations in hippocampal PKC-immunoreactivity: a review and hypothesis of its functional significance [see comments] Van der Zee EA, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Apr;21(3):531–72 (144 ref.) Comment in: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):373–8.

Historical review of research on protein kinase C in learning and memory [see comments] Van der Zee EA, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Apr; 21(3):379–406 (117 ref.) Comment in: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):373–8.

Neuropeptide modulation of learning and memory processes. Feany MB. **Rev Neurosci** 1996 Apr–Jun;7(2):151–64 (123 ref.)

Nitric oxide in learning and memory. Jachimowicz A, et al. **Rocz Akad Med Bialymst** 1996;41(2):161–75 (81 ref.)

Visual learning in the perception of texture: simple and contingent aftereffects of texture density. Durgin FH, et al. **Spat Vis** 1996;9(4):423–74 (127 ref.)

The neural basis of associative reward learning in honeybees. Hammer M. **Trends Neurosci** 1997 Jun;20(6):245–52 (58 ref.)

LEARNING DISORDERS

see related
DYSLEXIA

Adults with severe reading and learning difficulties: a challenge for the family physician. Kelly MS, et al. **J Am Board Fam Pract** 1997 May–Jun;10(3):199–205 (34 ref.)

CHEMICALLY INDUCED

Test methods for predicting tardive toxicity of therapeutic drugs using laboratory animals. Ando K. **J Toxicol Sci** 1996 Feb;21(1):105–7 (5 ref.)

DIAGNOSIS

Epilepsy or stereotypy? Diagnostic issues in learning disabilities. Paul A. **Seizure** 1997 Apr;6(2):111–20 (42 ref.)

Adults with language-learning disabilities: new challenges and changing perspectives. Kleinman SN, et al. **Semin Speech Lang** 1996 Aug;17(3):201–15; quiz 215–6 (102 ref.)

Neuropsychological assessment of developmental learning disabilities in adults. Vincent LC. **Semin Speech Lang** 1996 Aug;17(3):183–200 (110 ref.)

DRUG THERAPY

[Neuropharmacological effects of sigma receptor ligands: anxiolytic, anti-amnesic and neuroprotective effects] Amano M, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Jun; 16(3):73–84 (103 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Learning disabilities, crime, delinquency, and special education placement. Winters CA. **Adolescence** 1997 Summer;32(126):451–62 (40 ref.)

The overlap of attention deficit hyperactivity disorder with other common mental disorders. Hazell P. **J Paediatr Child Health** 1997 Apr;33(2):131–7 (60 ref.)

ETIOLOGY

Learning impairment and allergic rhinitis. Simons FE. **Allergy Asthma Proc** 1996 Jul–Aug;17(4):185–9. (35 ref.)

GENETICS

The recognition and investigation of X-linked learning disability syndromes. Feldman EJ. **J Intellect Disabil Res** 1996 Oct;40 (Pt 5):400–11 (77 ref.)

PATHOLOGY

Hippocampal degeneration inducing impairment of learning in rats: model of dementia? Ishikawa K, et al. **Behav Brain Res** 1997 Feb;83(1–2):39–44 (26 ref.)

Neuropathological studies on strains of senescence-accelerated mice (SAM) with age-related deficits in learning and memory. Kawamata T, et al. **Exp Gerontol** 1997 Jan–Apr;32(1–2):161–9 (45 ref.)

PHYSIOPATHOLOGY

Specific learning disabilities: a neuropsychological perspective. Ardila A. **Int J Neurosci** 1997 Feb; 89(3–4):189–205 (94 ref.)

Neurobiology of learning disabilities. Chase CH. **Semin Speech Lang** 1996 Aug;17(3):173–81 (32 ref.)

PREVENTION & CONTROL

Long-term outcomes of early childhood programs: analysis and recommendations. Gomby DS, et al. **Future Child** 1995 Winter;5(3):6–24 (60 ref.)

PSYCHOLOGY

Specific learning disabilities: a neuropsychological perspective. Ardila A. **Int J Neurosci** 1997 Feb; 89(3–4):189–205 (94 ref.)

LEBER'S OPTIC ATROPHY see **OPTIC ATROPHY, HEREDITARY**

LEBISTES see **POECILIA**

LECAM-1 see **L-SELECTIN**

LECAM-2 see **E-SELECTIN**

LECAM-3 see **P-SELECTIN**

LECITHIN ACYLTRANSFERASE DEFICIENCY

GENETICS

The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. Kuivenhoven JA, et al. **J Lipid Res** 1997 Feb;38(2):191–205 (102 ref.)

LECITHINASE A1 see **PHOSPHOLIPASES A**

LECITHINASE A2 see **PHOSPHOLIPASES A**

LECITHINASE C see **PHOSPHOLIPASE C**

LECITHINASE D see **PHOSPHOLIPASE D**

LECITHINASES see **PHOSPHOLIPASES**

LECITHINS see **PHOSPHATIDYLCHOLINES**

LECTIN, CASTOR BEAN see **RICIN**

LECTIN RECEPTORS see **RECEPTORS, MITOGEN**

LECTIN, RICINUS see **RICIN**

LECTINS

see related
RECEPTORS, MITOGEN

[Complement-activating lectin, RaRF--from molecular structure to clinical issues] Kawakami M. **Nippon Saikingaku Zasshi** 1996 Aug;51(3):717–36 (107 ref.) **(Jpn)**

CHEMISTRY

Animal lectins. Gabius HJ. **Eur J Biochem** 1997 Feb 1; 243(3):543–76 (500 ref.)

Protein glycosylation in the endoplasmic reticulum and the Golgi apparatus and cell type-specificity of cell surface glycoconjugate expression: analysis by the protein A-gold and lectin-gold techniques. Roth J. **Histochem Cell Biol** 1996 Jul;106(1):79–92 (130 ref.)

Applications of immunogold and lectin-gold labeling in tumor research and diagnosis. Roth J, et al. **Histochem Cell Biol** 1996 Jul;106(1):131–48 (117 ref.)

Galectins: a family of animal lectins that decipher glycocodes. Kasai K, et al. **J Biochem (Tokyo)** 1996 Jan;119(1):1–8 (57 ref.)

Modular organization of carbohydrate recognition domains in animal lectins. Kishore U, et al. **Matrix Biol** 1997 Mar; 15(8–9):583–92 (63 ref.)

Making a fitting choice: common aspects of sugar-binding sites in plant and animal lectins. Drickamer K. **Structure** 1997 Apr 15;5(4):465–8 (30 ref.)

Lectin-carbohydrate interaction in the immune system. Ni Y, et al. **Vet Immunol Immunopathol** 1996 Dec; 55(1–3):205–23 (135 ref.)

[Glycoconjugates on the basis of polyacrylamide--tools for studying lectins, antibodies, and glycosyltransferases in glycobiology, cytochemistry, and histochemistry] Bovin NV. **Bioorg Khim** 1996 Sep;22(9):643–63 (81 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Inhibition of bacterial adhesion and infections by lectin blocking. Beuth J, et al. **Adv Exp Med Biol** 1996;408:51–6 (46 ref.)

Towards anti-Pseudomonas aeruginosa adhesion therapy. Gilboa-Garber N. **Adv Exp Med Biol** 1996;408:39–50 (63 ref.)

Induction of anti-mistletoe lectin antibodies in relation to different mistletoe-extracts. Stein GM, et al. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S57–9 (10 ref.)

Mannose-binding lectin: the pluripotent molecule of the innate immune system. Turner MW. **Immunol Today** 1996 Nov;17(11):532–40 (76 ref.)

The lectin pathway. Matsushita M, et al. **Res Immunol** 1996 Feb;147(2):115–8 (21 ref.)

Lectin-carbohydrate interaction in the immune system. Ni Y, et al. **Vet Immunol Immunopathol** 1996 Dec; 55(1–3):205–23 (135 ref.)

ISOLATION & PURIFICATION

[Structural analysis of defense molecules found in large and small granules in hemocytes of horseshoe crab] Kawabata S. **Seikagaku** 1996 Sep;68(9):1523–36 (63 ref.) **(Jpn)**

METABOLISM

The role of lectins in recognition and adhesion of the mycoparasitic fungus Trichoderma spp. to its host. Inbar J, et al. **Adv Exp Med Biol** 1996;408:229–31 (7 ref.)

Carbohydrate-lectin interactions in infectious disease. Sharon N. **Adv Exp Med Biol** 1996;408:1–8 (20 ref.)

Structural basis of lectin-carbohydrate recognition. Weis WI, et al. **Annu Rev Biochem** 1996;65:441–73 (84 ref.)

Concepts of tumor lectinology. Gabius HJ. **Cancer Invest** 1997;15(5):454–64 (129 ref.)

Sialic acids as ligands in recognition phenomena. Varki A. **FASEB J** 1997 Mar;11(4):248–55 (100 ref.)

Structure and function of the CD94 C-type lectin receptor complex involved in recognition of HLA class I molecules. López-Botet M, et al. **Immunol Rev** 1997 Feb;155:165–74 (74 ref.)

The lectin pathway of the complement system. Matsushita M. **Microbiol Immunol** 1996;40(12):887–93 (67 ref.)

The CD94/NKG2C-type lectin receptor complex in recognition of HLA class I molecules. López-Botet M, et al. **Res Immunol** 1997 Mar–Apr;148(3):155–9 (30 ref.)

[Lectin pathway and pathophysiology] Mastsushita m. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):627–30 (20 ref.) **(Jpn)**

[Soluble beta-galactoside-binding lectins] Fink NE. **Acta Physiol Pharmacol Ther Latinoam** 1996;46(1):1–10 (61 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Clinical relevance of immunoactive mistletoe lectin-I. Beuth J. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S53–5 (19 ref.)

Differences in the apoptosis-inducing properties of Viscum album L. extracts. Büssing A, et al. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S9–14 (30 ref.)

Modulation of cytotoxicity and enhancement of cytokine release induced by Viscum album L. extracts or mistletoe lectins. Ribéreau-Gayon G, et al. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S3–8 (20 ref.)

The lectin pathway of complement activation. Turner MW. **Res Immunol** 1996 Feb;147(2):110–5 (33 ref.)

PHYSIOLOGY

Functional resemblance between the Ig-related NK cell receptors specific for HLA class I molecules and the CD94 C-type lectin. López-Botet M, et al. **Chem Immunol** 1996; 64:116–34 (60 ref.)

Lectins and biocontrol. Inbar J, et al. **Crit Rev Biotechnol** 1997;17(1):1–20 (126 ref.)

Lectins--proteins with a sweet tooth: functions in cell recognition. Sharon N, et al. **Essays Biochem** 1995;30:59–75 (24 ref.)

Lectin activities of cytokines and growth factors: function and implications for pathology. Zanetta JP, et al. **Histol Histopathol** 1996 Oct;11(4):1101–8 (67 ref.)

Divergent functions of lectin-like receptors on NK cells. Ryan JC, et al. **Immunol Rev** 1997 Feb;155:79–89 (70 ref.)

Galectins: a family of animal lectins that decipher glycocodes. Kasai K, et al. **J Biochem (Tokyo)** 1996 Jan;119(1):1–8 (57 ref.)

Animal lectins as cell surface receptors: current status for

invertebrate species. Vasta GR, et al. **Prog Mol Subcell Biol** 1996;17:158–82 (137 ref.)
[Lectin pathway and pathophysiology] Mastsushita m. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):627–30 (20 ref.) **(Jpn)**

THERAPEUTIC USE

Purpurins and benzochlorins as sensitizers for photodynamic therapy. Garbo GM. **J Photochem Photobiol B** 1996 Jul; 34(2–3):109–16 (64 ref.)

LEECHES

Clinical use of leeches in reconstructive surgery. Daane S, et al. **Am J Orthop** 1997 Aug;26(8):528–32 (36 ref.)
Medicinal leeches: ancient therapy is a source of biotech drugs. Piascik P. **J Am Pharm Assoc (Wash)** 1997 May–Jun; NS37(3):285–6 (0 ref.)

ANATOMY & HISTOLOGY

The role of the leech in medical therapeutics. Eldor A, et al. **Blood Rev** 1996 Dec;10(4):201–9 (108 ref.)

EMBRYOLOGY

Developmental control of cell division in leech embryos. Bissen ST. **Bioessays** 1997 Mar;19(3):201–7 (52 ref.)

PHYSIOLOGY

The role of the leech in medical therapeutics. Eldor A, et al. **Blood Rev** 1996 Dec;10(4):201–9 (108 ref.)
Thrombin inhibitors of bloodsucking animals. Dodt J, et al. **Semin Thromb Hemost** 1996;22(2):203–8 (44 ref.)

LEFT HEART SYNDROME, HYPOPLASTIC see **HYPOPLASTIC LEFT HEART SYNDROME**

LEFT VENTRICULAR DYSFUNCTION see **VENTRICULAR DYSFUNCTION, LEFT**

LEFT VENTRICULAR FUNCTION see **VENTRICULAR FUNCTION, LEFT**

LEFT VENTRICULAR HYPERTROPHY see **HYPERTROPHY, LEFT VENTRICULAR**

LEG

see related
HINDLIMB

Frequency and duration of remission after isolated limb perfusion for melanoma. Thompson JF, et al. **Arch Surg** 1997 Aug;132(8):903–7 (23 ref.)
Tumor-induced hypercalcemia in a patient with extensive soft tissue sarcoma: effects of bisphosphonate therapy and surgery. Oleffe V, et al. **J Surg Oncol** 1996 Oct;63(2):125–9 (25 ref.)
Isolated limb perfusion for malignant melanoma. Alexander HR Jr, et al. **Semin Surg Oncol** 1996 Nov–Dec;12(6):416–28 (85 ref.)
[Rotational deformities of the lower limbs in children] Lokiec F, et al. **Harefuah** 1996 Jun 2;130(11):770–4 (31 ref.) **(Heb)**
[Multiple jejuno–ileal metastasis of malignant schwannoma from the leg. Report of a case presenting anemia symptoms and review of the literature] Crespi C, et al. **Minerva Chir** 1996 Oct;51(10):829–33 (12 ref.) (Eng. Abstr.) **(Ita)**

ABNORMALITIES

Evaluation and management of in-toe gait in the neurologically intact child. Volpe RG. **Clin Podiatr Med Surg** 1997 Jan;14(1):57–85 (101 ref.)

BLOOD SUPPLY

Graded restriction of blood flow in exercising leg muscles: a human model. Bjurstedt H, et al. **Adv Exp Med Biol** 1995; 381:147–56 (32 ref.)
Lower extremity arterial disease in sports. Abraham P, et al. **Am J Sports Med** 1997 Jul–Aug;25(4):581–4 (40 ref.)
Treatment of thromboembolic complications of fulminant meningococcal septic shock. Mele JA 3rd, et al. **Ann Plast Surg** 1997 Mar;38(3):283–90 (29 ref.)
Blood flow measurements in lower limb arteries using duplex ultrasound. Hussain ST. **Ann R Coll Surg Engl** 1997 Sep; 79(5):323–30 (25 ref.)
'Trash foot' following operations involving the abdominal aorta. Kuhan G, et al. **Aust N Z J Surg** 1997 Jan;67(1):21–4 (14 ref.)
Colour flow duplex imaging of occlusive arterial disease of the lower limb. Pemberton M, et al. **Br J Surg** 1997 Jul; 84(7):912–9 (100 ref.)
Minimally invasive surgery for perforator vein incompetence. Saharay M, et al. **Cardiovasc Surg** 1996 Dec;4(6):701–5 (58 ref.)
Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Weitz JI, et al. **Circulation** 1996 Dec 1;94(11):3026–49 (294 ref.)
Chronic lower extremity ischemia. Welch HJ. **Compr Ther** 1997 Aug;23(8):534–8 (2 ref.)
Vascular disease of the lower extremities in diabetes mellitus. LoGerfo FW, et al. **Endocrinol Metab Clin North Am** 1996 Jun;25(2):439–45 (27 ref.)
Pelvic lipoma causing venous obstruction syndrome. Acheson A, et al. **Eur J Vasc Endovasc Surg** 1997 Aug; 14(2):149–50 (6 ref.)
Problems related to the definition of "distal" bypass and "secondary" patency rates. A paper for debate. Panayiotopoulos YP, et al. **Eur J Vasc Endovasc Surg** 1996 Nov;12(4):464–70 (37 ref.)
Critical and subcritical ischaemia. Wolfe JH, et al. **Eur J Vasc Endovasc Surg** 1997 Jun;13(6):578–82 (27 ref.)
Horton giant cell arteritis of the legs. Report of a case. Amatucci G, et al. **J Cardiovasc Surg (Torino)** 1997 Jun; 38(3):309–12 (14 ref.)
Chronic venous insufficiency and venous ulceration. Alguire PC, et al. **J Gen Intern Med** 1997 Jun;12(6):374–83 (112 ref.)
Comparison of streptokinase and urokinase in local thrombolysis of peripheral arterial occlusions for lower limb salvage. Dubé M, et al. **J Vasc Interv Radiol** 1996 Jul–Aug;7(4):587–93 (25 ref.)
The assessment of acute calf pain. Banerjee A. **Postgrad Med J** 1997 Feb;73(856):86–8 (29 ref.)
Duplex sonography of lower extremity arteries. Zierler RE, et al. **Semin Ultrasound CT MR** 1997 Feb;18(1):39–56 (67 ref.)
Infrainguinal bypass in end-stage renal disease: when is it justified? Isiklar MH, et al. **Semin Vasc Surg** 1997 Mar; 10(1):42–8 (45 ref.)
[Peripheral artery aneurysms. I. Aneurysms of the lower limbs] Defraigne JO, et al. **Rev Med Liege** 1996 Dec; 51(12):771–81 (31 ref.) **(Fre)**
[Reduction of amputation incidence and mortality following prolonged ischemia of the lower limbs. Value of a controlled reperfusion?] Defraigne JO, et al. **Rev Med Liege** 1996 Aug;51(8):534–44 (57 ref.) **(Fre)**
[Chronic occlusive arteriopathy of the lower limbs: therapeutic approach] Hayoz D. **Schweiz Med Wochenschr** 1997 Mar 29;127(13):549–53 (21 ref.) (Eng. Abstr.) **(Fre)**
[MR angiography of the pelvic–leg blood vessels: current status and perspectives] Vosshenrich R, et al. **Aktuelle Radiol** 1997 Jan;7(1):14–8 (24 ref.) (Eng. Abstr.) **(Ger)**
[Peripheral arterial occlusive disease. Diagnosis and modern conservative therapy] Zinnagl N. **Hautarzt** 1996 Jan; 47(1):70–8 (11 ref.) **(Ger)**
[CT-guided neurolysis. Status of the technique and current results] Schneider B, et al. **Radiologe** 1996 Sep;36(9):692–9 (24 ref.) (Eng. Abstr.) **(Ger)**
[Radiology and geriatrics: limits between normal values and pathology exemplified by conventional thoracic roentgen image, cerebral CT and MRI and pelvic–leg angiography] Osterheider MA. **Z Gerontol Geriatr** 1997 May–Jun; 30(3):226–34 (17 ref.) (Eng. Abstr.) **(Ger)**
[Distal popliteal bypass in the diabetic patient. Clinical case] Cavallini M, et al. **Minerva Chir** 1996 Jul–Aug; 51(7–8):589–95 (23 ref.) (Eng. Abstr.) **(Ita)**
[The "pedrada" ("coup–de–fouet") syndrome. A possibility to be considered in acute leg pain] Toscano F, et al. **Minerva Chir** 1997 Apr;52(4):489–91 (12 ref.) (Eng. Abstr.) **(Ita)**
[Critical limb ischemia] Iwai T. **Nippon Geka Gakkai Zasshi** 1996 Jul;97(7):486–91 (13 ref.) (Eng. Abstr.) **(Jpn)**
[The basic patterns of the ischemic and reperfusion changes in the tissues of the ischemic extremity and in the whole body] Tsapenko MV. **Klin Khir** 1996;(9):44–9 (49 ref.) **(Ukr)**

GROWTH & DEVELOPMENT

Short-term measurements of linear growth in early life: infant knemometry. Michaelsen KF. **Acta Paediatr** 1997 Jun; 86(6):551–3 (27 ref.)

INNERVATION

[Distal nerve compression of the leg. Clinical and electrophysiologic study] Mabin D. **Neurophysiol Clin** 1997; 27(1):9–24 (113 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Dedicated extremity MR imaging. An emerging technology. Peterfy CG, et al. **Radiol Clin North Am** 1997 Jan; 35(1):1–20 (32 ref.)

PHYSIOLOGY

A marker-free method for tracking human lower limb segments based on model matching. Persson T. **Int J Biomed Comput** 1996 Apr;41(2):87–97 (10 ref.)

PHYSIOPATHOLOGY

FES standing: control by handle reactions of leg muscle stimulation (CHRELMS). Donaldson N de N, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):280–4 (12 ref.)

SURGERY

Daily functioning of the lower extremity amputee: an overview of the literature. Pernot HF, et al. **Clin Rehabil** 1997 May;11(2):93–106 (71 ref.)
Current concepts: amputation surgery in peripheral vascular disease. Pinzur MS. **Instr Course Lect** 1997;46:501–9 (24 ref.)
Rehabilitation of the older lower limb amputee: a brief review. Cutson TM, et al. **J Am Geriatr Soc** 1996 Nov; 44(11):1388–93 (60 ref.)
Massive prostheses for malignant bone tumours of the limbs. Cannon SR. **J Bone Joint Surg Br** 1997 May;79(3):497–506 (20 ref.)
The distally based medial gastrocnemius flap: case report and anatomic study. Atchabahian A, et al. **Plast Reconstr Surg** 1996 Dec;98(7):1253–7 (10 ref.)
Reconstruction of the lower extremity after ablative resection for cancer. Walton RL, et al. **Surg Oncol Clin N Am** 1997 Jan;6(1):133–76 (102 ref.)
[Quality of life after orthopedic surgery of the lower limbs. A new approach] Guillemin F, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(6):549–56 (27 ref.) (Eng. Abstr.) **(Fre)**

LEG DERMATOSES

DIAGNOSIS

Multiple painful keratoacanthomas. Frank TL, et al. **Int J Dermatol** 1996 Sep;35(9):648–50 (24 ref.)

PATHOLOGY

Skin disorders of the lower extremity in adults as reported in the current literature. Black JR, et al. **Clin Podiatr Med Surg** 1996 Jan;13(1):109–17 (38 ref.)

LEG INJURIES

Lower leg, foot, and ankle injuries in young athletes. Stanish WD. **Clin Podiatr Med Surg** 1997 Jul;14(3):559–78 (71 ref.)
Leg injuries. Blue JM, et al. **Clin Sports Med** 1997 Jul; 16(3):467–78 (37 ref.)
Stress injury to bone in the female athlete. Nattiv A, et al. **Clin Sports Med** 1997 Apr;16(2):197–224 (131 ref.)

CLASSIFICATION

[Periarticular fractures of the upper and lower extremity. I: ABC classification using the AO principle] Arand M, et al. **Rontgenpraxis** 1997 Jun;50(6):168–74 (16 ref.) **(Ger)**

COMPLICATIONS

Case report: post-traumatic cerebral fat embolism: CT and MR findings. Report of two cases and review of the literature. Chrysikopoulos H, et al. **Clin Radiol** 1996 Oct; 51(10):728–32 (27 ref.)
Escherichia vulneris in a Danish soccer wound. Jepsen CF, et al. **Scand J Infect Dis** 1997;29(3):313–4 (6 ref.)
[Lower limb injury and Sudeck's syndrome] Kotela I. **Przegl Lek** 1996;53(6):501–3 (19 ref.) (Eng. Abstr.) **(Pol)**

DIAGNOSIS

The use of MR imaging in the assessment and clinical management of stress reactions of bone in high-performance athletes. Arendt EA, et al. **Clin Sports Med** 1997 Apr;16(2):291–306 (15 ref.)
Imaging of stress injuries to bone. Radiography, scintigraphy, and MR imaging. Deutsch AL, et al. **Clin Sports Med** 1997 Apr;16(2):275–90 (29 ref.)
Advanced imaging in orthopaedics: current pitfalls and new applications. Potter HG, et al. **Instr Course Lect** 1997; 46:521–9 (38 ref.)
Management of common pediatric fractures. England SP, et al. **Pediatr Clin North Am** 1996 Oct;43(5):991–1012 (12 ref.)
MR imaging of acute orthopedic trauma to the extremities. Eustace S. **Radiol Clin North Am** 1997 May;35(3):615–29 (68 ref.)
Role of MR imaging in acute injuries to the appendicular skeleton. Ohashi K, et al. **Radiol Clin North Am** 1997 May; 35(3):591–613 (166 ref.)

ETIOLOGY

Stress fractures in the pediatric athlete. Coady CM, et al. **Clin Sports Med** 1997 Apr;16(2):225–38 (43 ref.)
Footwear and stress fractures. Frey C. **Clin Sports Med** 1997 Apr;16(2):249–57 (31 ref.)
Does running exercise cause osteoarthritis? Lahr DD. **Md Med J** 1996 Aug;45(8):641–4 (18 ref.)
The anti-personnel land mine epidemic: a case report and review of the literature [see comments] Gondring WH. **Mil Med** 1996 Dec;161(12):760–2 (6 ref.) Comment in: Mil Med 1997 Apr;162(4):i.

SURGERY

[Quality of life after orthopedic surgery of the lower limbs. A new approach] Guillemin F, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(6):549–56 (27 ref.) (Eng. Abstr.) **(Fre)**
[Periarticular fractures of the upper and lower extremity. II: Therapeutic principle] Arand M, et al. **Rontgenpraxis** 1997 Jun;50(6):175–81 (19 ref.) **(Ger)**
[Covering soft tissue defects] Kinzl L, et al. **Unfallchirurg** 1996 Oct;99(10):714–26 (29 ref.) (Eng. Abstr.) **(Ger)**

LEG INJURIES

THERAPY

Hamstring injuries. Current trends in treatment and prevention. Kujala UM, et al. **Sports Med** 1997 Jun; 23(6):397–404 (41 ref.)

LEG LENGTH INEQUALITY

see related
BONE LENGTHENING

Leg lengthening and bone transport in children. Hill RA, et al. **Br J Hosp Med** 1997 Apr 16–May 6;57(8):399–404 (15 ref.)

[Anisomelia. Clinical consequences and treatment] Steen H, et al. **Tidsskr Nor Laegeforen** 1997 Apr 30;117(11):1595–600 (78 ref.) (Eng. Abstr.) **(Nor)**

CONGENITAL

Medullary sponge kidney associated with congenital hemihypertrophy. Indridason OS, et al.
J Am Soc Nephrol 1996 Aug;7(8):1123–30 (29 ref.)

SURGERY

Callotasis lengthening: a review of some technical aspects. Maffulli N. **Bull Hosp Jt Dis** 1996;54(4):249–54 (85 ref.)

THERAPY

Patient management during limb lengthening. Green SA.
Instr Course Lect 1997;46:547–54 (7 ref.)

LEG ULCER

[Venous leg ulcer] Hamilton Jakobsen B, et al.
Ugeskr Laeger 1997 May 5;159(19):2836–40 (40 ref.) (Eng. Abstr.) **(Dan)**

DRUG THERAPY

Optimal management of chronic leg ulcers in the elderly. Goodfield M. **Drugs Aging** 1997 May;10(5):341–8 (25 ref.)

Factor XIII in ulcerative leg disease: background and preliminary clinical results. Wozniak G, et al.
Semin Thromb Hemost 1996;22(5):445–50 (43 ref.)

ETIOLOGY

Leg ulcers in Klinefelter's syndrome--further evidence for an involvement of plasminogen activator inhibitor-1. Zollner TM, et al. **Br J Dermatol** 1997 Mar;136(3):341–4 (23 ref.)

Leg ulcers in sickle cell disease. Eckman JR.
Hematol Oncol Clin North Am 1996 Dec;10(6):1333–44 (74 ref.)

NURSING

The management of the client with a leg ulcer: precarious nursing practice. Husband LL. **J Adv Nurs** 1996 Jul; 24(1):53–9 (32 ref.)

SURGERY

Split-thickness skin grafting for lower extremity ulcerations. Kirsner RS, et al. **Dermatol Surg** 1997 Feb;23(2):85–91; quiz 92–3 (59 ref.)

THERAPY

Chronic wounds. Eaglstein WH, et al.
Surg Clin North Am 1997 Jun;77(3):689–700 (54 ref.)

LEGAL GUARDIANS

Informed consent by children and adolescents to psychiatric treatment. Batten DA. **Aust N Z J Psychiatry** 1996 Oct; 30(5):623–9; discussion 630–2 (24 ref.)

Genetic testing in children. Clayton EW. **J Med Philos** 1997 Jun;22(3):233–51 (29 ref.)

Adolescent parents and medical decision-making. De Ville K. **J Med Philos** 1997 Jun;22(3):253–70 (52 ref.)

Parenting and the best interests of minors. Downie RS, et al. **J Med Philos** 1997 Jun;22(3):219–31 (9 ref.)

LEGISLATION & JURISPRUDENCE

Treatment decisions for patients without surrogates: rethinking policies for a vulnerable population [see comments] Miller TE, et al. **J Am Geriatr Soc** 1997 Mar; 45(3):369–74 (35 ref.) Comment in: J Am Geriatr Soc 1997 Mar;45(3):375–7.

LEGAL MEDICINE see **FORENSIC MEDICINE**

LEGG-PERTHES DISEASE

CLASSIFICATION

[Remarks on classification of Perthes disease] Synder M, et al. **Chir Narzadow Ruchu Ortop Pol** 1997;62(2):115–21 (29 ref.) (Eng. Abstr.) **(Pol)**

DIAGNOSIS

[Perthes disease] Krauspe R, et al. **Orthopade** 1997 Mar; 26(3):289–302 (46 ref.) **(Ger)**

ETIOLOGY

[Perthes' disease] Ishii Y.
Nippon Seikeigeka Gakkai Zasshi 1996 May;70(5):285–95 (30 ref.) **(Jpn)**

LEGIONELLA

CLASSIFICATION

Antigenic and genetic characterization of Legionella proteins: contributions to taxonomy, diagnosis and pathogenesis. Bangsborg JM. **APMIS Suppl** 1997;70:1–53 (450 ref.)

GENETICS

Antigenic and genetic characterization of Legionella proteins: contributions to taxonomy, diagnosis and pathogenesis. Bangsborg JM. **APMIS Suppl** 1997;70:1–53 (450 ref.)

IMMUNOLOGY

Antigenic and genetic characterization of Legionella proteins: contributions to taxonomy, diagnosis and pathogenesis. Bangsborg JM. **APMIS Suppl** 1997;70:1–53 (450 ref.)

PATHOGENICITY

The molecular ecology of legionellae. Fields BS.
Trends Microbiol 1996 Jul;4(7):286–90 (62 ref.)

LEGIONELLA PNEUMOPHILA

Cannabinoids and immunity to Legionella pneumophila infection. Klein TW, et al. **Adv Exp Med Biol** 1996; 402:103–9 (20 ref.)

ISOLATION & PURIFICATION

Spontaneous rupture of the spleen associated with pneumonia. Domingo P, et al.
Eur J Clin Microbiol Infect Dis 1996 Sep;15(9):733–6 (20 ref.)

PATHOGENICITY

Legionella pneumophila invasion of mononuclear phagocytes. Shuman HA, et al.
Curr Top Microbiol Immunol 1996;209:99–112 (64 ref.)

[Virulent factors of Legionella pneumophila and their uses in molecular epidemiology] Lu XH, et al.
Chung Hua Liu Hsing Ping Hsueh Tsa Chih 1995 Dec; 16(6):372–4 (15 ref.) **(Chi)**

LEGIONELLA PNEUMOPHILA INFECTIONS see **LEGIONNAIRES' DISEASE**

LEGIONELLACEAE

CLASSIFICATION

Legionella-like amebal pathogens--phylogenetic status and possible role in respiratory disease. Adeleke A, et al.
Emerg Infect Dis 1996 Jul–Sep;2(3):225–30 (35 ref.)

LEGIONELLOSIS

DIAGNOSIS

[Diagnosis of infections with Legionella species] Putzker M, et al. **Dtsch Med Wochenschr** 1996 Dec 20; 121(51–52):1608–15 (58 ref.) **(Ger)**

ETIOLOGY

Antigenic and genetic characterization of Legionella proteins: contributions to taxonomy, diagnosis and pathogenesis. Bangsborg JM. **APMIS Suppl** 1997;70:1–53 (450 ref.)

PREVENTION & CONTROL

[Legionella infection in occupational and environmental health] Fujii J, et al. **Sangyo Ika Daigaku Zasshi** 1996 Mar 1;18(1):61–76 (16 ref.) (Eng. Abstr.) **(Jpn)**

LEGIONNAIRES' DISEASE

Legionellosis. Stout JE, et al. **N Engl J Med** 1997 Sep 4; 337(10):682–7 (87 ref.)

COMPLICATIONS

Spontaneous rupture of the spleen associated with pneumonia. Domingo P, et al.
Eur J Clin Microbiol Infect Dis 1996 Sep;15(9):733–6 (20 ref.)

DIAGNOSIS

Legionnaire's disease during pregnancy: a case presentation and review of the literature. Eisenberg VH, et al.
Eur J Obstet Gynecol Reprod Biol 1997 Mar;72(1):15–8 (25 ref.)

Diagnosis and chemotherapy of Legionnaires' disease [editorial; comment] Hoepelman IM. **Neth J Med** 1996 Nov;49(5):185–8 (18 ref.) Comment on: Neth J Med 1996 Nov;49(5):196–201. Comment on: Neth J Med 1996 Nov;49(5):202–4.

[Neurologic and psychiatric symptoms of legionella infection. Case report and overview of the clinical spectrum] Plaschke M, et al. **Nervenarzt** 1997 Apr;68(4):342–5 (30 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Diagnosis and chemotherapy of Legionnaires' disease [editorial; comment] Hoepelman IM. **Neth J Med** 1996 Nov;49(5):185–8 (18 ref.) Comment on: Neth J Med 1996 Nov;49(5):196–201. Comment on: Neth J Med 1996 Nov;49(5):202–4.

EPIDEMIOLOGY

Perspectives in fatal epidemics. Butler JC, et al.
Infect Dis Clin North Am 1996 Dec;10(4):917–37 (75 ref.)

[Virulent factors of Legionella pneumophila and their uses in molecular epidemiology] Lu XH, et al.
Chung Hua Liu Hsing Ping Hsueh Tsa Chih 1995 Dec; 16(6):372–4 (15 ref.) **(Chi)**

IMMUNOLOGY

Cannabinoids and immunity to Legionella pneumophila infection. Klein TW, et al. **Adv Exp Med Biol** 1996; 402:103–9 (20 ref.)

PREVENTION & CONTROL

[Legionella infection in occupational and environmental health] Fujii J, et al. **Sangyo Ika Daigaku Zasshi** 1996 Mar 1;18(1):61–76 (16 ref.) (Eng. Abstr.) **(Jpn)**

LEGISLATION

see related
LICENSURE

Bicycle helmet laws: a current perspective. Borgialli DA. **J Am Osteopath Assoc** 1997 Jul;97(7):399–402 (25 ref.)

A ten-year review of the effect of OBRA-87 on psychotropic prescribing practices in an academic nursing home. Lantz MS, et al. **Psychiatr Serv** 1996 Sep;47(9):951–5 (34 ref.)

[Legal aspects of epilepsy and coexisting psychiatric disorders] Diez-Cuervo A. **Rev Neurol** 1997 Mar; 25(139):435–47 (26 ref.) (Eng. Abstr.) **(Spa)**

LEGISLATION, DRUG

Two UK Government proposals bearing on drug safety [editorial] Griffin JP. **Adverse Drug React Toxicol Rev** 1997 Mar;16(1):1–7 (10 ref.)

Exposure to mixtures of chemical substances: is there a need for regulations? Van Zorge JA. **Food Chem Toxicol** 1996 Nov–Dec;34(11–12):1033–6 (5 ref.)

Perspectives on immunotoxicity regulatory guidelines. Harling RJ. **Inflamm Res** 1996 Dec;45 Suppl 2:S69–73 (14 ref.)

Human hallucinogenic drug research: regulatory, clinical, and scientific issues. Strassman RJ. **NIDA Res Monogr** 1994;146:92–123 (90 ref.)

LEGISLATION, FOOD

Regulatory aspects of fumonisins with respect to animal feed. Animal derived residues in foods. Miller MA, et al.
Adv Exp Med Biol 1996;392:363–8 (4 ref.)

Regulatory aspects of fumonisins in the United States. Troxell TC. **Adv Exp Med Biol** 1996;392:355–61 (4 ref.)

Regulatory aspects of the introduction of new macronutrient substitutes. Rulis AM, et al. **Ann N Y Acad Sci** 1997 May 23;819:22–8 (0 ref.)

Food control systems in Canada. Smith TM, et al.
Crit Rev Food Sci Nutr 1997 Apr;37(3):229–51 (19 ref.)

Perspectives on immunotoxicity regulatory guidelines. Harling RJ. **Inflamm Res** 1996 Dec;45 Suppl 2:S69–73 (14 ref.)

Raising food hygiene standards--could customer power and the new laws hold the key? Leach JC. **J R Soc Health** 1996 Dec;116(6):351–5 (36 ref.)

Legal aspects of functional foods: the situation in China. Kan X. **Nutr Rev** 1996 Nov;54(11 Pt 2):S162–6 (16 ref.)

The Eastern consumer viewpoint: the experience in Japan. Kojima K. **Nutr Rev** 1996 Nov;54(11 Pt 2):S186–8 (0 ref.)

Regulatory status of functional foods in Singapore. Kuan CH. **Nutr Rev** 1996 Nov;54(11 Pt 2):S168 (0 ref.)

Regulatory aspects of functional foods in Nigeria. Osuide GE. **Nutr Rev** 1996 Nov;54(11 Pt 2):S167 (0 ref.)

Functional foods--the future: how to regulate these foods. Pascal G. **Nutr Rev** 1996 Nov;54(11 Pt 2):S199–201 (8 ref.)

Regulatory and legal aspects of functional foods: the Australian perspective. Preston C, et al. **Nutr Rev** 1996 Nov;54(11 Pt 2):S156–61 (5 ref.)

Regulatory and legal aspects of functional foods: an international perspective. Randell A, et al. **Nutr Rev** 1996 Nov;54(11 Pt 2):S152–5 (0 ref.)

LEGISLATION, MEDICAL

Respect for the patient's integrity and self-determination--an ethical imperative called upon in the Swedish Health and

Medical Care Act. Margareta A. **Med Law** 1996; 15(2):189–93 (9 ref.)
Legal and societal issues facing survivors of childhood cancer. Monaco GP, et al. **Pediatr Clin North Am** 1997 Aug;44(4):1043–58 (27 ref.)
Regulations and policies on radioiodine 131I therapy in Europe. Beckers C. **Thyroid** 1997 Apr;7(2):221–4 (9 ref.)
Regulations for radioiodine therapy in the United States: current status and the process of change. Vetter RJ. **Thyroid** 1997 Apr;7(2):209–11 (9 ref.)
[Ethical–judicial aspects of postoperative patient support] Ulsenheimer K. **Anaesthesist** 1997 Apr;46(4):343–7 (35 ref.) **(Ger)**
[Reuse of disposable equipment. Medicolegal viewpoint] Fallani M, et al. **Minerva Cardioangiol** 1996 May; 44(5):263–73 (40 ref.) (Eng. Abstr.) **(Ita)**

LEGISLATION, PHARMACY

FDA regulatory reform. Beatrice M. **Curr Opin Biotechnol** 1997 Jun;8(3):370–8 (22 ref.)
Vaccines: current regulatory issues. Kenimer JG. **Curr Opin Biotechnol** 1997 Jun;8(3):357–60 (15 ref.)
Regulatory affairs biopharmaceuticals regulation––progress and challenges [editorial] Lambert K. **Curr Opin Biotechnol** 1997 Jun;8(3):347–9 (8 ref.)
Potential influence of international harmonization of pharmaceutical regulations on biopharmaceutical development. Lubiniecki AS. **Curr Opin Biotechnol** 1997 Jun;8(3):350–6 (30 ref.)

LEGISLATION, VETERINARY

Canine legislation: can dogs get a fair shake in court? Burt MR. **J Am Vet Med Assoc** 1997 Apr 15;210(8):1139–42 (19 ref.)
Chilean legislation for the control of diseases of aquatic species. Campos Larraín MC, et al. **Rev Sci Tech** 1996 Jun; 15(2):675–86 (16 ref.)
Finfish health protection regulations in Canada. Carey TG. **Rev Sci Tech** 1996 Jun;15(2):647–58 (6 ref.)
The World Trade Organisation agreement on the application of sanitary and phytosanitary measures. Chillaud T. **Rev Sci Tech** 1996 Jun;15(2):733–51 (6 ref.) **(Eng, Fre)**
Animal health and the trade in aquatic animals within and to the European Union. Daelman W. **Rev Sci Tech** 1996 Jun;15(2):711–22 (6 ref.)
Quarantine of aquatic animals in Australia. Doyle KA, et al. **Rev Sci Tech** 1996 Jun;15(2):659–73 (25 ref.)
National legislation in Great Britain for the control of fish diseases. Hill BJ. **Rev Sci Tech** 1996 Jun;15(2):633–45 (20 ref.)
Synopsis of freshwater aquaculture legislation in Germany since national reunification. Schlotfeldt HJ. **Rev Sci Tech** 1996 Jun;15(2):687–701 (8 ref.)

LEGUMES

see related
PLANTS, EDIBLE
[Pharmacology of Sophora flavescense and its clinical uses] Niu KZ. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Nov;15(11):698–700 (16 ref.) **(Chi)**

CHEMISTRY

Triterpene and steroid saponins isolated from two Melilotus species. Khodakov GV, et al. **Adv Exp Med Biol** 1996; 405:211–22 (17 ref.)
Bioactive saponins from solanaceous and leguminous plants. Nohara T, et al. **Adv Exp Med Biol** 1996;404:263–76 (22 ref.)

ENZYMOLOGY

Protein proteinase inhibitors in legume seeds––overview. Birk Y. **Arch Latinoam Nutr** 1996 Dec;44(4 Suppl 1):26S–30S (47 ref.)

MICROBIOLOGY

The genetic and biochemical basis for nodulation of legumes by rhizobia. Pueppke SG. **Crit Rev Biotechnol** 1996; 16(1):1–51 (435 ref.)
Nodulation: finding the lost common denominator. Peters NK. **Curr Biol** 1997 Apr 1;7(4):R223–6 (22 ref.)
Biogenesis of the peribacteroid membrane in root nodules. Verma DP, et al. **Trends Microbiol** 1996 Sep;4(9):364–8 (40 ref.)

LEIGH DISEASE

GENETICS

Hereditary polioencephalomyelopathy of the Australian cattle dog. Brenner O, et al. **Acta Neuropathol (Berl)** 1997 Jul;94(1):54–66 (42 ref.)

VETERINARY

Hereditary polioencephalomyelopathy of the Australian cattle dog. Brenner O, et al. **Acta Neuropathol (Berl)** 1997 Jul;94(1):54–66 (42 ref.)

LEIOMYOBLASTOMA see **LEIOMYOMA,**

EPITHELIOID

LEIOMYOMA

[Renal leiomyoma and renal leiomyosarcoma] Uozumi J, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):501–4 (17 ref.) **(Jpn)**

CHEMISTRY

Immunohistological detection of estrogen and progesterone receptors in multiple and well differentiated leiomyomatous lung tumors in women with uterine leiomyomas (so–called benign metastasizing leiomyomas). A report on 5 cases. Jautzke G, et al. **Pathol Res Pract** 1996 Mar;192(3):215–23 (77 ref.)

COMPLICATIONS

Leiomyoma–related bleeding: a classic hypothesis updated for the molecular era. Stewart EA, et al. **Hum Reprod Update** 1996 Jul–Aug;2(4):295–306 (94 ref.)
Giant uterine fibromyoma producing secondary polycythemia. Clark CL, et al. **Obstet Gynecol** 1994 Oct; 84(4 Pt 2):722–4 (10 ref.)
[Unusual cause of gastric bleeding: leiomyoma] Alberti P, et al. **Minerva Chir** 1996 Oct;51(10):779–83 (22 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Leiomyoma of the female urethra and bladder: report of twenty–three patients and review of the literature. Cornella JL, et al. **Am J Obstet Gynecol** 1997 Jun;176(6):1278–85 (24 ref.)
The relevance of abnormal motility patterns in intra–mural oesophageal leiomyomata. Amer KM, et al. **Eur J Cardiothorac Surg** 1996;10(8):634–40 (12 ref.)
Solitary fibrous tumor of the meninges. Case report and review of the literature. Prayson RA, et al. **J Neurosurg** 1997 Jun;86(6):1049–52 (21 ref.)
Uterine myomas in adolescents: case reports and a review of the literature. Fields KR, et al. **J Pediatr Adolesc Gynecol** 1996 Nov;9(4):195–8 (14 ref.)
Zygomatic leiomyoma. Case report. Robiony M, et al. **Minerva Stomatol** 1996 Dec;45(12):593–7 (17 ref.)
[A large symptomatic gastric leiomyoma. A case report and considerations of the treatment possibilities] Falsitta M, et al. **Minerva Chir** 1997 Apr;52(4):461–4 (7 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

GnRH agonists and uterine leiomyomas. Broekmans FJ. **Hum Reprod** 1996 Nov;11 Suppl 3:3–25 (145 ref.)
GnRH analogues in the treatment of uterine fibroids. Golan A. **Hum Reprod** 1996 Nov;11 Suppl 3:33–41 (31 ref.)
Blood flow changes in the uterus induced by treatment with GnRH analogues. Shaw RW. **Hum Reprod** 1996 Nov;11 Suppl 3:27–32 (10 ref.)
GnRH agonists before surgery for uterine leiomyomas. A review [see comments] Crosignani PG, et al. **J Reprod Med** 1996 Jun;41(6):415–21 (38 ref.) Comment in: J Reprod Med 1997 Apr;42(4):253.

GENETICS

Leiomyoma of uterus in a patient with ring chromosome 12: case presentation and literature review. Hajianpour MJ, et al. **Am J Med Genet** 1996 May 17;63(2):335–9 (12 ref.)
Smooth muscle neoplasms of the uterus. Tiltman AJ. **Curr Opin Obstet Gynecol** 1997 Feb;9(1):48–51 (26 ref.)

METABOLISM

[Uterine fibromas and the hormonal pattern: the therapeutic considerations] De Leo V, et al. **Minerva Ginecol** 1996 Dec; 48(12):533–8 (35 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Vaginal leiomyoma––a case report with review of the literature. Sharma D, et al. **Cent Afr J Med** 1995 Dec; 41(12):403–5 (10 ref.)
Leiomyoma of the oral cavity: a light microscopic and immunohistochemical study with review of the literature from 1884 to 1992. Baden E, et al. **Eur J Cancer B Oral Oncol** 1994 Jan;30B(1):1–7 (101 ref.)
Plexiform leiomyoma of the esophagus: a peculiar gross variant simulating plexiform neurofibroma. Higa S, et al. **J Gastroenterol** 1996 Feb;31(1):100–4 (8 ref.)
Leiomyoma of the mandible: a rapid growing case with immunohistochemical and electron microscopic observations. Katou F, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jul;84(1):45–50 (23 ref.)
[Symplastic leiomyoma combined with focal adenocarcinoma of the endometrium] Veselinova T, et al. **Akush Ginekol (Sofiia)** 1996;35(3):47–9 (6 ref.) (Eng. Abstr.) **(Bul)**
[Uterine leiomyosarcomas: a surprising pathology. Review of the literature. Six case reports] Durand–Réville M, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(7):710–5 (19 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Growth factors and cytokines in uterine leiomyomas. Andersen J. **Semin Reprod Endocrinol** 1996 Aug; 14(3):269–82 (123 ref.)

SURGERY

Myomectomies by endo–uterine resection. Hallez JP. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):250–6 (33 ref.)
Endoscopic surgery: yes, but ... [editorial; comment] Magos AL. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):243–5 (19 ref.) Comment on: Curr Opin Obstet Gynecol 1996 Aug;8(4):281–9.
Laparoscopic myomectomy today. Fibroids: management and treatment: the state of the art. Donnez J, et al. **Hum Reprod** 1996 Sep;11(9):1837–40 (38 ref.)
Fertility after hysteroscopic myomectomy. Ubaldi F, et al. **Hum Reprod Update** 1995 Jan;1(1):81–90 (77 ref.)
The role of laparoscopy in myomectomy. Hasson HM. **Int J Fertil Menopausal Stud** 1996 May–Jun;41(3):276–9 (21 ref.)
The "cons" of laparoscopic myomectomy in women who may reproduce in the future. Nezhat C. **Int J Fertil Menopausal Stud** 1996 May–Jun;41(3):280–3 (15 ref.)
Regression of uterine low–grade smooth–muscle tumors metastatic to the lung after oophorectomy. Abu–Rustum NR, et al. **Obstet Gynecol** 1997 May;89(5 Pt 2):850–2 (13 ref.)
[Infertility and small myoma: role of myomectomy] Fernandez H. **Contracept Fertil Sex** 1997 May;25(5):348–9 (12 ref.) **(Fre)**
[Fibrous tumors localized in the pleura] Biancari F, et al. **G Chir** 1996 Aug–Sep;17(8–9):437–43 (57 ref.) (Eng. Abstr.) **(Ita)**
[A case of myomectomy for infertility and a following twin pregnancy associated with hyperthyroidism] Berlingieri D, et al. **Minerva Ginecol** 1996 Dec;48(12):545–52 (20 ref.) (Eng. Abstr.) **(Ita)**
[A case of leiomyoma of the posterior mediastinum] Nakamura M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Nov;44(11):2082–6 (14 ref.) (Eng. Abstr.) **(Jpn)**
[In an infertile woman, does the presence of one or several myomas of less than three cm in diameter justify a myomectomy?] Lopes P. **Contracept Fertil Sex** 1997 May; 25(5):350–1 (6 ref.) **(Spa)**

THERAPY

The levonorgestrel–releasing intrauterine device: a wider role than contraception. Coleman M, et al. **Aust N Z J Obstet Gynaecol** 1997 May;37(2):195–201 (68 ref.)
Uterine myomas in adolescents: case reports and a review of the literature. Fields KR, et al. **J Pediatr Adolesc Gynecol** 1996 Nov;9(4):195–8 (14 ref.)
Rodent model of reproductive tract leiomyomata: characterization and use in preclinical therapeutic studies. Howe SR, et al. **Prog Clin Biol Res** 1997;396:205–15 (29 ref.)
[The development of conservative treatment in uterine myoma] Nikolov A, et al. **Akush Ginekol (Sofiia)** 1996; 35(1–2):51–3 (14 ref.) **(Bul)**

LEIOMYOMA, EPITHELIOID

DIAGNOSIS

Leiomyoblastoma of the duodenum presenting with exsanguinating haemorrhage [see comments] Sawant PD, et al. **J Assoc Physicians India** 1995 Jun;43(6):432–3 (16 ref.) Comment in: J Assoc Physicians India 1996 Mar;44(3):226.

LEIOMYOMA, VASCULAR see **ANGIOMYOMA**

LEIOMYOMATOSIS

[Intravenous leiomyomatosis of uterine origin with cardiac extension. A case report and review of the literature] Tribondeau P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(2):187–92 (33 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Diffuse peritoneal leiomyomatosis. A clinical case report] Borsellino G, et al. **Minerva Ginecol** 1997 Jan–Feb; 49(1–2):53–7 (28 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

Familial leiomyomata. Vellanki LS, et al. **Cutis** 1996 Jul; 58(1):80–2 (9 ref.)

PATHOLOGY

Breast cancer metastatic to uterine leiomyoma: a case report. Sugiyama T, et al. **J Obstet Gynaecol** 1995 Aug; 21(4):349–55 (21 ref.)
[A case of multiple pulmonary leiomyomatous hamartoma] Ohno K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 May;44(5):723–8 (27 ref.) (Eng. Abstr.) **(Jpn)**

LEIOMYOSARCOMA

Leiomyosarcoma of urinary bladder: personal experience in 3 cases over a 10-year period. De Berardinis E, et al. **Arch Ital Urol Androl** 1997 Feb;69 Suppl 1:73–80 (33 ref.)

Leiomyosarcoma of the oesophagus: a case report and literature review of leiomyosarcoma. Visioli A, et al. **Australas Radiol** 1997 May;41(2):160–5 (36 ref.)

Perineal and perirectal sarcomas: report of two cases. Kessler KJ, et al. **Dis Colon Rectum** 1996 Apr;39(4):468–72 (27 ref.)

Stage IIIC ovarian leiomyosarcoma in a premenopausal woman with multiple recurrences: prolonged survival with surgical therapy. Rasmussen CC, et al. **Gynecol Oncol** 1997 Sep;66(3):519–25 (21 ref.)

Leiomyosarcoma of the renal vein. Brandes SB, et al. **J Surg Oncol** 1996 Nov;63(3):195–200 (26 ref.)

'Spontaneous' regression of advanced leiomyosarcoma of the urinary bladder. Lei KI, et al. **Oncology** 1997 Jan–Feb; 54(1):19–22 (20 ref.)

[Primary pulmonary artery sarcoma (e.g. spindle cell sarcoma of the pulmonary artery, pulmonary artery leiomyosarcoma)] Miyahara Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):598–600 (16 ref.) **(Jpn)**

[Renal leiomyoma and renal leiomyosarcoma] Uozumi J, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):501–4 (17 ref.) **(Jpn)**

COMPLICATIONS

Death due to a leiomyosarcoma of the pulmonary artery. Marchetti D, et al. **Am J Forensic Med Pathol** 1996 Dec; 17(4):315–8 (21 ref.)

Leiomyosarcoma originating in Meckel's diverticulum: report of a case and a review of 59 cases in the English literature. Shimizu N, et al. **Surg Today** 1997;27(6):546–9 (35 ref.)

[Microangiopathic hemolytic anemia associated with uterine sarcoma: report of a case. Review of the literature] Tsatsaris V, et al. **Rev Med Interne** 1996;17(9):749–53 (23 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Leiomyosarcoma of the female breast: report of two new cases and a review of the literature. Falconieri G, et al. **Am J Clin Pathol** 1997 Jul;108(1):19–25 (28 ref.)

Primary leiomyosarcoma of the mandible. Laccourreye O, et al. **Am J Otolaryngol** 1996 Nov–Dec;17(6):415–9 (22 ref.)

Diagnostic imaging of primary hepatic leiomyosarcoma: a case report. Civardi G, et al. **Ital J Gastroenterol** 1996 Feb–Mar;28(2):98–101 (10 ref.)

Leiomyosarcoma of the nasal cavity. Case report and literature review. Lippert BM, et al. **ORL J Otorhinolaryngol Relat Spec** 1996 Mar–Apr; 58(2):115–20 (49 ref.)

Leiomyosarcoma of the colon presenting as acute suppurative peritonitis. Iwasa K, et al. **Surg Today** 1997;27(4):337–44 (44 ref.)

Primary leiomyosarcoma arising in the lesser sac: report of a case. Kimura H, et al. **Surg Today** 1997;27(7):672–5 (10 ref.)

[Leiomyosarcoma of the larynx. Review of the literature apropos of a case] Samlali R, et al. **Bull Cancer** 1996 Oct; 83(10):882–5 (29 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Leiomyosarcoma occurring in the ligamentum teres of the liver: a case report and a review of seven reported cases. Yamaguchi J, et al. **Hepatogastroenterology** 1996 Jul–Aug; 43(10):1051–6 (13 ref.)

ETIOLOGY

Radiation-induced sarcoma following curative radiotherapy for testicular seminoma: case report and brief review of the literature. Stein ME, et al. **Tumori** 1997 May–Jun; 83(3):721–3 (14 ref.)

METABOLISM

p53, proliferating cell nuclear antigen, and Ki-67 expression in extrauterine leiomyosarcomas. O'Reilly PE, et al. **Mod Pathol** 1997 Feb;10(2):91–7 (28 ref.)

PATHOLOGY

Primary leiomyosarcoma of bone: report of seven cases and review of the literature. Khoddami M, et al. **Arch Pathol Lab Med** 1996 Jul;120(7):671–5 (21 ref.)

Primary leiomyosarcoma of the skin. Wargon O. **Australas J Dermatol** 1997 Feb;38(1):26–8 (6 ref.)

Primary leiomyosarcoma affecting the ankle joint. Delsmann BM, et al. **Foot Ankle Int** 1996 Jul;17(7):420–4 (31 ref.)

Multiple leiomyosarcoma of the stomach. Colovic RB, et al. **Hepatogastroenterology** 1997 Mar–Apr;44(14):610–2 (4 ref.)

Inflammatory pseudotumour of the liver with malignant transformation. Report of two cases. Zavaglia C, et al. **Ital J Gastroenterol** 1996 Apr;28(3):152–9 (43 ref.)

Leiomyosarcoma with osteoclast-like giant cells of the spermatic cord. A case report and review of the literature. Konety BR, et al. **Urol Int** 1996;56(4):259–62 (14 ref.)

[Uterine leiomyosarcomas: a surprising pathology. Review of the literature. Six case reports] Durand-Réville M, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(7):710–5 (19 ref.) (Eng. Abstr.) **(Fre)**

[A case of spontaneous rupture of renal leiomyosarcoma] Kyuno H, et al. **Hinyokika Kiyo** 1996 Aug;42(8):583–6 (9 ref.) (Eng. Abstr.) **(Jpn)**

[A case of leiomyosarcoma of the pancreas] Tanaka Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Sep; 93(9):676–80 (10 ref.) **(Jpn)**

RADIOGRAPHY

[Retroperitoneal leiomyosarcoma: case report and literature review] Baraké H, et al. **Rev Med Brux** 1996 Dec; 17(6):384–8 (19 ref.) (Eng. Abstr.) **(Fre)**

RADIOTHERAPY

[Uterine sarcoma treated by surgery and postoperative radiation therapy. Patterns of relapse, prognostic factors and role of radiation therapy] Coquard R, et al. **Bull Cancer** 1997 Jun;84(6):625–9 (29 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

Leiomyosarcoma of the inferior vena cava: a clinicopathologic review and report of three cases. Kulaylat MN, et al. **J Surg Oncol** 1997 Jul;65(3):205–17 (95 ref.)

Regression of uterine low-grade smooth-muscle tumors metastatic to the lung after oophorectomy. Abu-Rustum NR, et al. **Obstet Gynecol** 1997 May;89(5 Pt 2):850–2 (13 ref.)

SURGERY

Leiomyosarcoma of the left atrium: a case report. Kuo CS, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1997 Feb; 59(2):136–40 (18 ref.)

Primary cardiac leiomyosarcoma: seven-year survival with combined surgical and adjuvant therapy. Pessotto R, et al. **Int J Cardiol** 1997 Jun 27;60(1):91–4 (15 ref.)

Treatment of haemorrhage following rupture of aortic leiomyosarcoma. Survival for 4.2 years. Testini M, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6):593–6 (16 ref.)

Pediatric intestinal leiomyosarcomas: case report and review of the literature. Kennedy AP Jr, et al. **J Pediatr Surg** 1997 Aug;32(8):1234–6 (25 ref.)

Infantile intestinal leiomyosarcoma: surgical resection (without adjuvant therapy) for cure. Simpson BB, et al. **J Pediatr Surg** 1996 Nov;31(11):1577–80 (22 ref.)

Regression of uterine low-grade smooth-muscle tumors metastatic to the lung after oophorectomy. Abu-Rustum NR, et al. **Obstet Gynecol** 1997 May;89(5 Pt 2):850–2 (13 ref.)

Primary leiomyosarcoma of the thyroid gland. Ozaki O, et al. **Surg Today** 1997;27(2):177–80 (13 ref.)

[Uterine sarcoma treated by surgery and postoperative radiation therapy. Patterns of relapse, prognostic factors and role of radiation therapy] Coquard R, et al. **Bull Cancer** 1997 Jun;84(6):625–9 (29 ref.) (Eng. Abstr.) **(Fre)**

[Leiomyosarcoma of the vagina: a rare case] Hachi H, et al. **Bull Cancer** 1997 Feb;84(2):215–7 (11 ref.) (Eng. Abstr.) **(Fre)**

[Leiomyosarcoma of the spermatic cord. A case report with review of the literature] Wiebel T, et al. **Urologe A** 1996 Jan;35(1):54–6 (21 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Rodent model of reproductive tract leiomyomata: characterization and use in preclinical therapeutic studies. Howe SR, et al. **Prog Clin Biol Res** 1997;396:205–15 (29 ref.)

LEIOMYOSARCOMA, EPITHELIOID see **LEIOMYOSARCOMA**

LEIOMYOSARCOMA, MYXOID see **LEIOMYOSARCOMA**

LEISHMANIA

CLASSIFICATION

Monoclonal antibodies for the identification of New World Leishmania species. Grimaldi G, et al. **Mem Inst Oswaldo Cruz** 1996 Jan–Feb;91(1):37–42 (37 ref.)

GENETICS

From population to genome: ecogenetics of Leishmania (Viannia) braziliensis and L. (V.) peruviana [published erratum appears in Ann Trop Med Parasitol 1996 Jun;90(3):351] Dujardin JC, et al. **Ann Trop Med Parasitol** 1995 Dec;89 Suppl 1:45–53 (29 ref.)

Molecular biology. Cruz AK, et al. **Clin Dermatol** 1996 Sep–Oct;14(5):533–40 (87 ref.)

Unravelling the Leishmania genome. Ivens AC, et al. **Curr Opin Genet Dev** 1996 Dec;6(6):704–10 (67 ref.)

IMMUNOLOGY

Vaccines against leishmaniasis. Modabber F. **Ann Trop Med Parasitol** 1995 Dec;89 Suppl 1:83–8 (24 ref.)

Leishmaniasis: Immunological and clinical aspects and vaccines in Venezuela. Convit J. **Clin Dermatol** 1996 Sep–Oct;14(5):479–87 (15 ref.)

Vaccine for prophylaxis and immunotherapy, Brazil. Genaro O, et al. **Clin Dermatol** 1996 Sep–Oct;14(5):503–12 (43 ref.)

Invasion, control and persistence of Leishmania parasites. Bogdan C, et al. **Curr Opin Immunol** 1996 Aug;8(4):517–25 (64 ref.)

ISOLATION & PURIFICATION

DNA-based methods in the detection of Leishmania parasites: field applications and practicalities. Wilson SM. **Ann Trop Med Parasitol** 1995 Dec;89 Suppl 1:95–100 (25 ref.)

PATHOGENICITY

Invasion, control and persistence of Leishmania parasites. Bogdan C, et al. **Curr Opin Immunol** 1996 Aug;8(4):517–25 (64 ref.)

PHYSIOLOGY

Parasite-host relationships: in-situ study of Leishmania spp. in resistant and susceptible mice. Bosque F, et al. **Ann Trop Med Parasitol** 1995 Dec;89 Suppl 1:19–22 (16 ref.)

LEISHMANIA BRAZILIENSIS

[Leishmania (Viannia) braziliensis Vianna, 1911 in French Guiana. Clinical, therapeutic and epidemiological considerations in the ninth human diagnosed case] Raccurt CP, et al. **Bull Soc Pathol Exot** 1996;89(5):341–4 (29 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

From population to genome: ecogenetics of Leishmania (Viannia) braziliensis and L. (V.) peruviana [published erratum appears in Ann Trop Med Parasitol 1996 Jun;90(3):351] Dujardin JC, et al. **Ann Trop Med Parasitol** 1995 Dec;89 Suppl 1:45–53 (29 ref.)

LEISHMANIA BRAZILIENSIS BRAZILIENSIS see **LEISHMANIA BRAZILIENSIS**

LEISHMANIA DONOVANI

Macronodular hepatic granulomas due to visceral leishmaniasis in an AIDS patient: imaging findings. Canalias J, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):677–9 (13 ref.)

Visceral leishmaniasis with special reference to Egypt (review and comment). Morsy TA. **J Egypt Soc Parasitol** 1997 Aug;27(2):373–96 (134 ref.)

[Visceral leishmaniasis with an unusually long incubation time] Matzdorff AC, et al. **Dtsch Med Wochenschr** 1997 Jul 11;122(28–29):890–4 (15 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Identification of genes mediating lipophosphoglycan biosynthesis by functional complementation of Leishmania donovani mutants. Beverley SM, et al. **Ann Trop Med Parasitol** 1995 Dec;89 Suppl 1:11–17 (33 ref.)

LEISHMANIA DONOVANI CHAGASI see **LEISHMANIA INFANTUM**

LEISHMANIA DONOVANI INFANTUM see **LEISHMANIA INFANTUM**

LEISHMANIA INFANTUM

AIDS and Leishmania infantum. New approaches for a new epidemiological problem. Alvar J, et al. **Clin Dermatol** 1996 Sep–Oct;14(5):541–6 (31 ref.)

Visceral leishmaniasis with special reference to Egypt (review and comment). Morsy TA. **J Egypt Soc Parasitol** 1997 Aug;27(2):373–96 (134 ref.)

LEISHMANIA (LEISHMANIA) see **LEISHMANIA**

LEISHMANIA (LEISHMANIA) DONOVANI see **LEISHMANIA DONOVANI**

LEISHMANIA (LEISHMANIA) INFANTUM see **LEISHMANIA INFANTUM**

LEISHMANIA (LEISHMANIA) MAJOR see **LEISHMANIA MAJOR**

LEISHMANIA (LEISHMANIA) MEXICANA see **LEISHMANIA MEXICANA**

LEISHMANIA MAJOR

CYTOLOGY

Effects of osmotic stress on metabolism, shape, and amino

acid content of Leishmania. Blum JJ. **Biol Cell** 1996; 87(1-2):9-16 (63 ref.)

GENETICS

Parasite genome analysis. A global map of the Leishmania major genome: prelude to genomic sequencing. Ivens AC, et al. **Trans R Soc Trop Med Hyg** 1997 Mar-Apr; 91(2):111-5 (37 ref.)

IMMUNOLOGY

Th cell development and regulation in experimental cutaneous leishmaniasis. Scott P. **Chem Immunol** 1996; 63:98-114 (72 ref.)

Immunology of murine leishmaniasis. McSorley S, et al. **Clin Dermatol** 1996 Sep-Oct;14(5):451-64 (165 ref.)

Interleukin-12 in murine leishmaniasis--match, flame or fuel? Fowell DJ, et al. **Res Immunol** 1995 Sep-Oct; 146(7-8):566-75 (47 ref.)

Immunoregulation of murine leishmaniasis by interleukin-12. Heinzel FP, et al. **Res Immunol** 1995 Sep-Oct; 146(7-8):575-81 (34 ref.)

LEISHMANIA MEXICANA

ENZYMOLOGY

The rational design of trypanocidal drugs: selective inhibition of the glyceraldehyde-3-phosphate dehydrogenase in Trypanosomatidae. Callens M, et al. **Ann Trop Med Parasitol** 1995 Dec;89 Suppl 1:23-30 (25 ref.)

LEISHMANIA MEXICANA AMAZONENSIS see **LEISHMANIA MEXICANA**

LEISHMANIA MEXICANA MEXICANA see **LEISHMANIA MEXICANA**

LEISHMANIA TROPICA MAJOR see **LEISHMANIA MAJOR**

LEISHMANIA (VIANNIA) see **LEISHMANIA**

LEISHMANIA (VIANNIA) BRAZILIENSIS see **LEISHMANIA BRAZILIENSIS**

LEISHMANIASIS

Experimental models for leishmaniasis and for testing anti-leishmanial vaccines. Hommel M, et al. **Ann Trop Med Parasitol** 1995 Dec;89 Suppl 1:55-73 (142 ref.)

Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Berman JD. **Clin Infect Dis** 1997 Apr;24(4):684-703 (169 ref.)

Clinical spectrum of Leishmaniasis. Pearson RD, et al. **Clin Infect Dis** 1996 Jan;22(1):1-13 (52 ref.)

COMPLICATIONS

Leishmania and human immunodeficiency virus coinfection: the first 10 years. Alvar J, et al. **Clin Microbiol Rev** 1997 Apr;10(2):298-319 (304 ref.)

DIAGNOSIS

DNA-based methods in the detection of Leishmania parasites: field applications and practicalities. Wilson SM. **Ann Trop Med Parasitol** 1995 Dec;89 Suppl 1:95-100 (25 ref.)

DRUG THERAPY

New developments in the chemotherapy of leishmaniasis. Chance ML. **Ann Trop Med Parasitol** 1995 Dec;89 Suppl 1:37-43 (39 ref.)

Liposomes as drug delivery system in leishmaniasis. Kshirsagar NA, et al. **J Assoc Physicians India** 1995 Jan; 43(1):46-8 (16 ref.)

IMMUNOLOGY

Cytokine networks with infection: mycobacterial infections, leishmaniasis, human immunodeficiency virus infection, and sepsis. DiPiro JT. **Pharmacotherapy** 1997 Mar-Apr; 17(2):205-23 (175 ref.)

The role of IL12 in modulating an established Th2 response in experimental leishmaniasis. Hondowicz B, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):560-5 (21 ref.)

METABOLISM

Possible roles of nitric oxide and peroxynitrite in murine leishmaniasis. Augusto O, et al. **Braz J Med Biol Res** 1996 Jul;29(7):853-62 (55 ref.)

PREVENTION & CONTROL

Vaccines against leishmaniasis. Modabber F. **Ann Trop Med Parasitol** 1995 Dec;89 Suppl 1:83-8 (24 ref.)

Leishmaniasis reservoirs and their significance in control. Ashford RW. **Clin Dermatol** 1996 Sep-Oct;14(5):523-32 (41 ref.)

Leishmaniasis. Public health aspects and control. Desjeux P. **Clin Dermatol** 1996 Sep-Oct;14(5):417-23 (21 ref.)

Invasion, control and persistence of Leishmania parasites. Bogdan C, et al. **Curr Opin Immunol** 1996 Aug;8(4):517-25 (64 ref.)

THERAPY

Gamma interferon in the treatment of Kala-azar and other forms of Leishmaniasis. Sundar S, et al. **J Assoc Physicians India** 1995 May;43(5):348-50 (31 ref.)

TRANSMISSION

Spread of lymphatic filariasis, re-emergence of leishmaniasis & threat of babesiosis in India. Dhanda V, et al. **Indian J Med Res** 1996 Jan;103:46-54 (70 ref.)

LEISHMANIASIS, AMERICAN see **LEISHMANIASIS, CUTANEOUS**

LEISHMANIASIS, CUTANEOUS

Old World cutaneous leishmaniasis. Samady JA, et al. **Int J Dermatol** 1997 Mar;36(3):161-6 (64 ref.)

DIAGNOSIS

Diagnosis of leishmaniasis. Reed SG. **Clin Dermatol** 1996 Sep-Oct;14(5):471-8 (42 ref.)

EPIDEMIOLOGY

Leishmaniasis in Texas: epidemiology and clinical aspects of human cases. McHugh CP, et al. **Am J Trop Med Hyg** 1996 Nov;55(5):547-55 (49 ref.)

[Visceral and cutaneous leishmaniases in the north. Retrospective study of cases diagnosed in the Rabta Hospital of Tunis] Belhadj S, et al. **Bull Soc Pathol Exot** 1996;89(4):269-73 (14 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Leishmaniasis in Texas: epidemiology and clinical aspects of human cases. McHugh CP, et al. **Am J Trop Med Hyg** 1996 Nov;55(5):547-55 (49 ref.)

Tegumentary leishmaniasis in childhood. Bittencourt AL, et al. **Pediatr Dermatol** 1996 Nov-Dec;13(6):455-63 (58 ref.)

Interleukin-12 in murine leishmaniasis--match, flame or fuel? Fowell DJ, et al. **Res Immunol** 1995 Sep-Oct; 146(7-8):566-75 (47 ref.)

IMMUNOLOGY

Th cell development and regulation in experimental cutaneous leishmaniasis. Scott P. **Chem Immunol** 1996; 63:98-114 (72 ref.)

Leishmaniasis: Immunological and clinical aspects and vaccines in Venezuela. Convit J. **Clin Dermatol** 1996 Sep-Oct;14(5):479-87 (15 ref.)

Immunology of murine leishmaniasis. McSorley S, et al. **Clin Dermatol** 1996 Sep-Oct;14(5):451-64 (165 ref.)

Cutaneous leishmaniasis: a model for analysis of the immunoregulation by accessory cells. Moll H, et al. **Med Microbiol Immunol (Berl)** 1996 Feb;184(4):163-8 (54 ref.)

Interleukin-12 in murine leishmaniasis--match, flame or fuel? Fowell DJ, et al. **Res Immunol** 1995 Sep-Oct; 146(7-8):566-75 (47 ref.)

Immunoregulation of murine leishmaniasis by interleukin-12. Heinzel FP, et al. **Res Immunol** 1995 Sep-Oct; 146(7-8):575-81 (34 ref.)

PARASITOLOGY

[Leishmania (Viannia) braziliensis Vianna, 1911 in French Guiana. Clinical, therapeutic and epidemiological considerations in the ninth human diagnosed case] Raccurt CP, et al. **Bull Soc Pathol Exot** 1996;89(5):341-4 (29 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Cutaneous leishmaniasis: clinical aspect. Dowlati Y. **Clin Dermatol** 1996 Sep-Oct;14(5):425-31 (10 ref.)

Mononuclear phagocytes and dendritic leukocytes in the skin. Milon G, et al. **Clin Dermatol** 1996 Sep-Oct;14(5):465-70 (65 ref.)

Successful treatment of cutaneous leishmaniasis using systemic interferon-gamma. Kolde G, et al. **Dermatology** 1996;192(1):56-60 (17 ref.)

[Diffuse cutaneous leishmaniasis and acquired immunodeficiency syndrome in a Senegalese patient] Ndiaye PB, et al. **Bull Soc Pathol Exot** 1996;89(4):282-6 (22 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Natural history, clinical evolution, and the host-parasite interaction in New World cutaneous Leishmaniasis. Weigle K, et al. **Clin Dermatol** 1996 Sep-Oct;14(5):433-50 (161 ref.)

PREVENTION & CONTROL

Vaccine for prophylaxis and immunotherapy, Brazil. Genaro O, et al. **Clin Dermatol** 1996 Sep-Oct;14(5):503-12 (43 ref.)

THERAPY

Treatment of cutaneous leishmaniasis (Old World). Dowlati Y. **Clin Dermatol** 1996 Sep-Oct;14(5):513-7 (28 ref.)

Successful treatment of cutaneous leishmaniasis using systemic interferon-gamma. Kolde G, et al. **Dermatology** 1996;192(1):56-60 (17 ref.)

LEISHMANIASIS, NEW WORLD see **LEISHMANIASIS, CUTANEOUS**

LEISHMANIASIS, OLD WORLD see **LEISHMANIASIS, CUTANEOUS**

LEISHMANIASIS, VISCERAL

Kala-azar comes to New York. Parkas V, et al. **Arch Intern Med** 1997 Apr 28;157(8):921-3 (20 ref.)

DIAGNOSIS

Macronodular hepatic granulomas due to visceral leishmaniasis in an AIDS patient: imaging findings. Canalias J, et al. **J Comput Assist Tomogr** 1997 Jul-Aug;21(4):677-9 (13 ref.)

[Visceral leishmaniasis with an unusually long incubation time] Matzdorff AC, et al. **Dtsch Med Wochenschr** 1997 Jul 11;122(28-29):890-4 (15 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

AIDS and Leishmania infantum. New approaches for a new epidemiological problem. Alvar J, et al. **Clin Dermatol** 1996 Sep-Oct;14(5):541-6 (31 ref.)

[Visceral and cutaneous leishmaniases in the north. Retrospective study of cases diagnosed in the Rabta Hospital of Tunis] Belhadj S, et al. **Bull Soc Pathol Exot** 1996;89(4):269-73 (14 ref.) (Eng. Abstr.) **(Fre)**

PARASITOLOGY

Visceral leishmaniasis. Wilson ME, et al. **Gastroenterol Clin North Am** 1996 Sep;25(3):535-51 (132 ref.)

[Progresses in tropical diseases and parasitosis in China, 1996] Zheng J. **Chung Hua I Hsueh Tsa Chih** 1996 Dec; 76(12):898-9 (0 ref.) **(Chi)**

PHYSIOPATHOLOGY

Visceral leishmaniasis with special reference to Egypt (review and comment). Morsy TA. **J Egypt Soc Parasitol** 1997 Aug;27(2):373-96 (134 ref.)

THERAPY

Strategies for immune intervention in visceral leishmaniasis. Kaye PM, et al. **Ann Trop Med Parasitol** 1995 Dec;89 Suppl 1:75-81 (37 ref.)

Gamma interferon in the treatment of Kala-azar and other forms of Leishmaniasis. Sundar S, et al. **J Assoc Physicians India** 1995 May;43(5):348-50 (31 ref.)

TRANSMISSION

Breeding habitats of vector sandflies and their control in India. Sivagnaname N, et al. **J Commun Dis** 1997 Jun; 29(2):153-9 (57 ref.)

LEISURE ACTIVITIES

Work and leisure: transcending the dichotomy. Primeau LA. **Am J Occup Ther** 1996 Jul-Aug;50(7):569-77 (61 ref.)

Physical activity at leisure and risk of osteoarthritis. Lane NE. **Ann Rheum Dis** 1996 Sep;55(9):682-4 (23 ref.)

The role of leisure in stroke rehabilitation. Parker CJ, et al. **Disabil Rehabil** 1997 Jan;19(1):1-5 (40 ref.)

LELYSTAD VIRUS see **SWINE INFERTILITY AND RESPIRATORY SYNDROME VIRUS**

LEMURIFORMES see **STREPSIRHINI**

LEMUROIDEA see **STREPSIRHINI**

LENGTH OF LIFE see **LONGEVITY**

LENGTH OF STAY

Early release following cardiac surgery. Keon WJ, et al. **Curr Opin Cardiol** 1996 Nov;11(6):599-602 (20 ref.)

Putting the brakes on drive-through deliveries. Seaman S. **J Contemp Health Law Policy** 1997 Spring;13(2):497-521 (214 ref.)

[Explanatory factors of length of stay at the diagnosis-related group 129: common pneumonia and pleurisy, aged over 69 and/or associated co-morbidities] Vergnenegre A, et al. **Rev Pneumol Clin** 1996;52(4):245-52 (28 ref.) (Eng. Abstr.) **(Fre)**

LEGISLATION & JURISPRUDENCE

The politics of "Drive-through deliveries": putting early postpartum discharge on the legislative agenda. Declercq E, et al. **Milbank Q** 1997;75(2):175-202 (69 ref.)

LENGTH OF STAY

STATISTICS & NUMERICAL DATA

Analyzing intensive care unit length of stay data: problems and possible solutions. Weissman C. **Crit Care Med** 1997 Sep;25(9):1594–600 (46 ref.)

LENS CAPSULE, CRYSTALLINE

DRUG EFFECTS

Inhibition of posterior capsule opacification by an intraocular-lens-bound sustained drug delivery system: an experimental animal study and literature review. Tetz MR, et al. **J Cataract Refract Surg** 1996 Oct;22(8):1070–8 (49 ref.)

INJURIES

Consultation section. How would you handle a tear in the posterior capsule, detected at the end of phacoemulsification, with the cortex intact and no vitreous loss? [see comments] **J Cataract Refract Surg** 1997 Jan–Feb; 23(1):12–8 (9 ref.) Comment in: J Cataract Refract Surg 1997 May;23(4):462.

SURGERY

Consultation section. How would you handle a tear in the posterior capsule, detected at the end of phacoemulsification, with the cortex intact and no vitreous loss? [see comments] **J Cataract Refract Surg** 1997 Jan–Feb; 23(1):12–8 (9 ref.) Comment in: J Cataract Refract Surg 1997 May;23(4):462.

LENS, CRYSTALLINE

The current status of phakic intraocular lenses. Zaldivar R, et al. **Int Ophthalmol Clin** 1996 Fall;36(4):107–11 (5 ref.)

ANATOMY & HISTOLOGY

A simple view of age-related changes in the shape of the lens of the human eye. Wyatt HJ, et al. **Eye** 1995;9 (Pt 6):772–5 (27 ref.)

EMBRYOLOGY

Cellular and molecular features of lens differentiation: a review of recent advances. Wride MA. **Differentiation** 1996 Dec;61(2):77–93 (226 ref.)

Lens induction in axolotls: comparison with inductive signaling mechanisms in Xenopus laevis. Servetnick MD, et al. **Int J Dev Biol** 1996 Aug;40(4):755–61 (36 ref.)

[Involvement of SOX proteins in activation of crystallin genes and lens development] Kamachi Y. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1113–23 (32 ref.) **(Jpn)**

METABOLISM

[The characteristics of crystalline lens metabolism] Preda M. **Oftalmologia** 1997;41(1):8–11 (9 ref.) (Eng. Abstr.) **(Rum)**

PHYSIOLOGY

Cellular and molecular features of lens differentiation: a review of recent advances. Wride MA. **Differentiation** 1996 Dec;61(2):77–93 (226 ref.)

The role of chloride in the lens of the eye. Zhang JJ, et al. **Exp Physiol** 1997 Mar;82(2):245–59 (60 ref.)

PHYSIOPATHOLOGY

Cataract as a protein condensation disease: the Proctor Lecture. Benedek GB. **Invest Ophthalmol Vis Sci** 1997 Sep; 38(10):1911–21 (55 ref.)

RADIATION EFFECTS

Use of subjective and nonsubjective methodologies to evaluate lens radiation damage in exposed populations—an overview. Worgul BV, et al. **Radiat Environ Biophys** 1996 Aug;35(3):137–44 (58 ref.)

SURGERY

Considering corneal and lenticular techniques of refractive surgery [editorial; comment] Rosen ES. **J Cataract Refract Surg** 1997 Jun;23(5):689–91 (13 ref.) Comment on: J Cataract Refract Surg 1997 Jun;23(5):731–5.

Clear lensectomy and implantation of a low-power posterior chamber intraocular lens for correction of high myopia: a four-year follow-up. Colin J, et al. **Ophthalmology** 1997 Jan;104(1):73–7; discussion 77–8 (9 ref.)

LENS DISLOCATION see **LENS SUBLUXATION**

LENS IMPLANTATION, INTRAOCULAR see **LENSES, INTRAOCULAR**

LENS OPACITIES see **CATARACT**

LENS PROTEINS see **CRYSTALLINS**

LENS SUBLUXATION

COMPLICATIONS

[Retinal detachment and posterior lens luxation. Value of liquid perfluorocarbons] Nacef L, et al. **J Fr Ophtalmol** 1996;19(6–7):432–4 (10 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

[Biomechanical characteristics of interactions between the drainage and accommodation regulatory systems of the eye in health and in contusion sens subluxation] Volkov VV, et al. **Vestn Oftalmol** 1997 May–Jun;113(3):5–7 (21 ref.) (Eng. Abstr.) **(Rus)**

LENSES, CONTACT see **CONTACT LENSES**

LENSES, CONTACT, HYDROPHILIC see **CONTACT LENSES, HYDROPHILIC**

LENSES, INTRAOCULAR

The current status of phakic intraocular lenses. Zaldivar R, et al. **Int Ophthalmol Clin** 1996 Fall;36(4):107–11 (5 ref.)

Bimanual irrigation/aspiration. Brauweiler P. **J Cataract Refract Surg** 1996 Oct;22(8):1013–6 (7 ref.)

Inhibition of posterior capsule opacification by an intraocular-lens-bound sustained drug delivery system: an experimental animal study and literature review. Tetz MR, et al. **J Cataract Refract Surg** 1996 Oct;22(8):1070–8 (49 ref.)

Intraocular lens implants: a biocompatibility review. Beasley AM, et al. **J Invest Surg** 1996 Nov–Dec;9(6):399–413 (88 ref.)

Clear lensectomy and implantation of a low-power posterior chamber intraocular lens for correction of high myopia: a four-year follow-up. Colin J, et al. **Ophthalmology** 1997 Jan;104(1):73–7; discussion 77–8 (9 ref.)

Fluorescein angiographic evaluation of the effect of latanoprost treatment on blood-retinal barrier integrity: a review of studies conducted on pseudophakic glaucoma patients and on phakic and aphakic monkeys. Hoyng PF, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S83–8 (33 ref.)

[Infectious complications of cataract-implant surgery] Galand A, et al. **Bull Soc Belge Ophtalmol** 1996;260:67–9 (10 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

The significance of inflammatory reactions following cataract extraction and intraocular lens implantation [editorial] Miyake K. **J Cataract Refract Surg** 1996;22 Suppl 1:759–63 (46 ref.)

LENTICULAR NUCLEUS see **CORPUS STRIATUM**

LENTIFORM NUCLEUS see **CORPUS STRIATUM**

LENTIGINOSIS see **LENTIGO**

LENTIGINOSIS, PERIORAL see **PEUTZ-JEGHERS SYNDROME**

LENTIGO

COMPLICATIONS

Bilateral segmental neurofibromatosis with partial unilateral lentiginosis. Wong SS. **Br J Dermatol** 1997 Mar; 136(3):380–3 (32 ref.)

CONGENITAL

[LEOPARD syndrome] Tsukahara M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):278–80 (17 ref.) **(Jpn)**

LENTIGO, MALIGNANT see **HUTCHINSON'S MELANOTIC FRECKLE**

LENTILS see **LEGUMES**

LENTINUS see **POLYPORACEAE**

LENTIVIRINAE see **LENTIVIRUS**

LENTIVIRUS

CLASSIFICATION

Bovine immunodeficiency virus: facts and questions. Belloc C, et al. **Vet Res** 1996;27(4–5):395–402 (49 ref.)

GENETICS

The complexities of viral genome analysis: the primate lentiviruses. McClure MA. **Curr Opin Genet Dev** 1996 Dec; 6(6):749–56 (59 ref.)

LENTIVIRUS INFECTIONS

Co-infection of Toxoplasma gondii with other pathogens: pathogenicity and chemotherapy in animal models. Lacroix C, et al. **Curr Top Microbiol Immunol** 1996;219:223–33 (33 ref.)

IMMUNOLOGY

Vaccination of cats with recombinant envelope glycoprotein of feline immunodeficiency virus: decreased viral load after challenge infection. Lutz H, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):431–3 (17 ref.)

PREVENTION & CONTROL

Replication in goats in vivo of caprine arthritis-encephalitis virus deleted in vif or tat genes: possible use of these deletion mutants as live vaccines. Harmache A, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):409–11 (9 ref.)

The relevance of feline retroviruses to the development of vaccines against HIV. Jarrett O. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):385–7 (23 ref.)

Evaluation of vaccines for ovine lentivirus infection. Perk K, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20; 12(5):425–6 (19 ref.)

DNA vaccines. Robinson HL, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):455–7 (27 ref.)

VETERINARY

Risk factors for transmission and methods for control of caprine arthritis-encephalitis virus infection. Rowe JD, et al. **Vet Clin North Am Food Anim Pract** 1997 Mar; 13(1):35–53 (69 ref.)

Natural and experimental bovine immunodeficiency virus infection in cattle. Snider TG, et al. **Vet Clin North Am Food Anim Pract** 1997 Mar;13(1):151–76 (94 ref.)

Bovine immunodeficiency virus: facts and questions. Belloc C, et al. **Vet Res** 1996;27(4–5):395–402 (49 ref.)

VIROLOGY

Vaccination of cats with recombinant envelope glycoprotein of feline immunodeficiency virus: decreased viral load after challenge infection. Lutz H, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):431–3 (17 ref.)

LENTIVIRUSES, OVINE-CAPRINE

GENETICS

Molecular characterization of field isolates of lentiviruses of small ruminants. Leroux C, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):427–9 (27 ref.)

IMMUNOLOGY

Evaluation of vaccines for ovine lentivirus infection. Perk K, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20; 12(5):425–6 (19 ref.)

LENTIVIRUSES, SIMIAN see **SIV**

LEON VIRUS see **POLIOVIRUSES, HUMAN 1–3**

LEPIDOPTERA

VIROLOGY

The Tetraviridae. Hanzlik TN, et al. **Adv Virus Res** 1997; 48:101–68 (190 ref.)

Nucleopolyhedrovirus interactions with their insect hosts. Volkman LE. **Adv Virus Res** 1997;48:313–48 (170 ref.)

LEPROSTATIC AGENTS

ADVERSE EFFECTS

Dapsone agranulocytosis in a leprosy patient. Hiran S, et al. **Lepr Rev** 1994 Sep;65(3):279–81 (14 ref.)

PHARMACOLOGY

The pharmacology, metabolism, and chemistry of clofazimine. O'Connor R, et al. **Drug Metab Rev** 1995; 27(4):591–614 (152 ref.)

THERAPEUTIC USE

Multidrug therapeutic challenges in leprosy. Jain S, et al. **Int J Dermatol** 1997 Jul;36(7):493–6 (48 ref.)

Needed research in chemotherapy of leprosy related to the individual patient. Jacobson RR. **Int J Lepr Other Mycobact Dis** 1996 Dec;64(4 Suppl):S16–20 (10 ref.)

Chemotherapy of leprosy: progress since the Orlando Congress, and prospects for the future. Ji B, et al. **Int J Lepr Other Mycobact Dis** 1996 Dec;64(4 Suppl):S80–8; discussion S88–90 (10 ref.)

The management of erythema nodosum leprosum: current and future options [editorial] Lockwood DN. **Lepr Rev** 1996 Dec;67(4):253–9 (57 ref.)

Practical problems in the management of leprosy. Ramesh

V, et al. **Lepr Rev** 1996 Dec;67(4):330–6 (42 ref.)
Hansen's disease (leprosy). Wariyar B. **Nebr Med J** 1996 May; 81(5):147–8 (8 ref.)

LEPROSY

see related
LEPROSTATIC AGENTS

CLASSIFICATION

[Contemporary problems in the epidemiology and clinical pathology of leprosy] Kocięcka W. **Wiad Parazytol** 1995; 41(4):373–90 (41 ref.) (Eng. Abstr.) **(Pol)**

COMPLICATIONS

Prevention of blindness in leprosy: an overview of the relevant clinical and programme-planning issues. Lewallen S. **Ann Trop Med Parasitol** 1997 Jun;91(4):341–8 (15 ref.)
Leprosy disabilities: magnitude of the problem.
Indian J Lepr 1996 Oct–Dec;68(4):335–44 (28 ref.)
Concomitant occurrence of leprosy, cutaneous tuberculosis and pulmonary tuberculosis--a case report [letter] Inamadar AC, et al. **Lepr Rev** 1994 Sep;65(3):282–4 (8 ref.)
[Simplification and codification of treatment for leprous plantar ulcers] Grauwin MY, et al. **Acta Leprol** 1997; 10(3):165–8 (12 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Bangkok Workshop on Leprosy Research. Research needs related to epidemiology and control: subclinical infection. Gupte MD. **Int J Lepr Other Mycobact Dis** 1996 Dec;64(4 Suppl):S29–36; discussion S36–7 (43 ref.)
The contribution of serological tests to leprosy control. Klatser PR, et al. **Int J Lepr Other Mycobact Dis** 1996 Dec;64(4 Suppl):S63–6; discussion S66–7 (21 ref.)
Bangkok Workshop on Leprosy Research. Diagnosis, classification and prognosis. Talhari S.
Int J Lepr Other Mycobact Dis 1996 Dec;64(4 Suppl):S13–4; discussion S14–5 (6 ref.)
Hansen's disease (leprosy). Wariyar B. **Nebr Med J** 1996 May; 81(5):147–8 (8 ref.)
[Leprosy differential diagnosis in 1996] Mahé A.
Acta Leprol 1996;10(2):69–77 (16 ref.) (Eng. Abstr.) **(Fre)**
[Current aspects of leprosy] Sticht-Groh V, et al.
Hautarzt 1997 May;48(5):297–302 (32 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Multidrug therapeutic challenges in leprosy. Jain S, et al. **Int J Dermatol** 1997 Jul;36(7):493–6 (48 ref.)
Needed research in chemotherapy of leprosy related to the individual patient. Jacobson RR.
Int J Lepr Other Mycobact Dis 1996 Dec;64(4 Suppl):S16–20 (10 ref.)
Chemotherapy of leprosy: progress since the Orlando Congress, and prospects for the future. Ji B, et al.
Int J Lepr Other Mycobact Dis 1996 Dec;64(4 Suppl):S80–8; discussion S88–90 (10 ref.)
Bangkok Workshop on Leprosy Research. Treatment of reactions and nerve damage. Naafs B.
Int J Lepr Other Mycobact Dis 1996 Dec;64(4 Suppl):S21–8 (34 ref.)
Dapsone agranulocytosis in a leprosy patient. Hiran S, et al. **Lepr Rev** 1994 Sep;65(3):279–81 (14 ref.)
Practical problems in the management of leprosy. Ramesh V, et al. **Lepr Rev** 1996 Dec;67(4):330–6 (42 ref.)

EPIDEMIOLOGY

Nerve abscess in children and adults leprosy patients: analysis of 145 cases and review of the literature. Salafia A, et al. **Acta Leprol** 1996;10(1):45–50 (40 ref.)
The epidemiology of Mycobacterium leprae: recent insight. van Beers SM, et al. **FEMS Microbiol Lett** 1996 Mar 1; 136(3):221–30 (49 ref.)
Bangkok Workshop on Leprosy Research. Predicting trends. Lechat MF. **Int J Lepr Other Mycobact Dis** 1996 Dec;64(4 Suppl):S38–42; discussion S42–3 (7 ref.)
[Contemporary problems in the epidemiology and clinical pathology of leprosy] Kocięcka W. **Wiad Parazytol** 1995; 41(4):373–90 (41 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

[The genetic susceptibility to leprosy in humans] Lagrange PH, et al. **Acta Leprol** 1996;10(1):11–27 (68 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

The role of inflammatory cytokines in the tissue injury of leprosy. Sarno EN, et al.
Int J Lepr Other Mycobact Dis 1996 Dec;64(4 Suppl):S69–73; discussion S73–4 (26 ref.)
Humoral immunity in Hansen's disease. Cossermelli-Messina W, et al. **Rev Paul Med** 1995 Jul–Aug;113(4):929–34 (86 ref.)
The cellular and molecular basis of immunity against mycobacterial diseases. Colston MJ.
Soc Appl Bacteriol Symp Ser 1996;25:33S–39S (56 ref.)

MICROBIOLOGY

Mycobacterial virulence factors. Gordon S, et al.
Soc Appl Bacteriol Symp Ser 1996;25:10S–22S (120 ref.)

PATHOLOGY

[Anatomopathologic study of five cases of leprosy in HIV seropositive patients] Faye O, et al. **Acta Leprol** 1996; 10(2):93–9 (22 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

On the criteria for basic elimination of leprosy. He DX, et al. **Indian J Lepr** 1996 Oct–Dec;68(4):345–7 (0 ref.)
Immunoprophylaxis against leprosy; the case for improved vaccines against leprosy. Britton WJ.
Int J Lepr Other Mycobact Dis 1996 Dec;64(4 Suppl):S77–9 (12 ref.)
Primary prevention of leprosy. Fine PE.
Int J Lepr Other Mycobact Dis 1996 Dec;64(4 Suppl):S44–9 (22 ref.)
Vaccination against leprosy--the view from 1996 [editorial] Fine PE, et al. **Lepr Rev** 1996 Dec;67(4):249–52 (18 ref.)
Leprosy control program in Thailand. Duangajna P.
Nippon Rai Gakkai Zasshi 1996 Jul;65(2):88–93 (6 ref.)

REHABILITATION

Stigma and socio-economic reintegration of leprosy sufferers in Nigeria. Awofeso N. **Acta Leprol** 1996;10(2):89–91 (12 ref.)
Bangkok Workshop on Leprosy Research. Research needs related to disabilities and rehabilitation. Smith WC, et al.
Int J Lepr Other Mycobact Dis 1996 Dec;64(4 Suppl):S52–4; discussion S54–5 (12 ref.)

THERAPY

Pregnancy in patients with Hansen disease. Lyde CB.
Arch Dermatol 1997 May;133(5):623–7 (13 ref.)
Immunotherapy of leprosy. Katoch K. **Indian J Lepr** 1996 Oct–Dec;68(4):349–61 (75 ref.)

LEPROSY, CUTANEOUS see **LEPROSY, LEPROMATOUS**

LEPROSY, LEPROMATOUS

DRUG THERAPY

Bangkok Workshop on Leprosy Research. Treatment of reactions and nerve damage. Naafs B.
Int J Lepr Other Mycobact Dis 1996 Dec;64(4 Suppl):S21–8 (34 ref.)
The management of erythema nodosum leprosum: current and future options [editorial] Lockwood DN. **Lepr Rev** 1996 Dec;67(4):253–9 (57 ref.)

PHYSIOPATHOLOGY

The management of erythema nodosum leprosum: current and future options [editorial] Lockwood DN. **Lepr Rev** 1996 Dec;67(4):253–9 (57 ref.)

LEPROSY, MACULAR see **LEPROSY, TUBERCULOID**

LEPROSY, NEURAL see **LEPROSY, TUBERCULOID**

LEPROSY, NODULAR see **LEPROSY, LEPROMATOUS**

LEPROSY, TUBERCULOID

IMMUNOLOGY

Tuberculoid leprosy--one phenomenon with many perceptions. Porichha D. **Indian J Lepr** 1997 Apr–Jun; 69(2):183–8 (25 ref.)

LEPTOMENINGEAL CYSTS see **ARACHNOID CYSTS**

LEPTOSPIRA

Leptospirosis in wild animals. Hartskeerl RA, et al.
Vet Q 1996;18 Suppl 3:S149–50 (12 ref.)

ISOLATION & PURIFICATION

Bacterial L-forms research in China. Huang G, et al.
Chin Med J (Engl) 1996 Jan;109(1):18–20 (0 ref.)

LEPTOSPIRA ICTEROHAEMORRHAGIAE see **LEPTOSPIRA INTERROGANS**

LEPTOSPIRA INTERROGANS

GENETICS

[The molecular genetic and biological aspects of the ecology of pathogenic Leptospira (Leptospira interrogans)] Anan'ina IuV. **Zh Mikrobiol Epidemiol Immunobiol** 1996 May-Jun;(3):19–21 (27 ref.) (Eng. Abstr.) **(Rus)**

PATHOGENICITY

[The molecular genetic and biological aspects of the ecology of pathogenic Leptospira (Leptospira interrogans)] Anan'ina IuV. **Zh Mikrobiol Epidemiol Immunobiol** 1996 May-Jun;(3):19–21 (27 ref.) (Eng. Abstr.) **(Rus)**

LEPTOSPIROSIS

Leptospiral pneumonia. Hill MK, et al.
Semin Respir Infect 1997 Mar;12(1):44–9 (42 ref.)

COMPLICATIONS

Acute renal failure in leptospirosis. Abdulkader RC.
Ren Fail 1997 Mar;19(2):191–8 (34 ref.)

ETIOLOGY

[The results of the study of the pathogenesis and pathophysiology of the leptospiral infectious process and its clinical manifestations] Pupkevich-Diamant IaS.
Zh Mikrobiol Epidemiol Immunobiol 1996 Jan–Feb; (1):100–4 (47 ref.) **(Rus)**

VETERINARY

Diagnosis of leptospirosis: a reemerging disease of companion animals. Bolin CA. **Semin Vet Med Surg (Small Anim)** 1996 Aug;11(3):166–71 (33 ref.)
Leptospirosis in wild animals. Hartskeerl RA, et al.
Vet Q 1996;18 Suppl 3:S149–50 (12 ref.)

LEPTOSPIROSIS, ICTEROHEMORRHAGIC see **WEIL'S DISEASE**

LEPTOTHRIX see **GRAM-NEGATIVE AEROBIC BACTERIA**

LERICHE'S SYNDROME

[Leriche syndrome] Sugimura S.
Ryoikibetsu Shokogun Shirizu 1996;(14):426–8 (9 ref.) **(Jpn)**

LESBIANISM see **HOMOSEXUALITY, FEMALE**

LESCH-NYHAN SYNDROME

[Complete and partial deficiency of HPRT] Ogasawara N. **Nippon Rinsho** 1996 Dec;54(12):3315–20 (21 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[The genetic diagnosis of hypoxanthine-guanine phosphoribosyltransferase (HGPRT) deficiency. A study of 12 cases] Torres Jiménez R, et al. **Med Clin (Barc)** 1997 Mar 8;108(9):344–8 (24 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

The recognition of Lesch-Nyhan syndrome as an inborn error of purine metabolism. Nyhan WL.
J Inherit Metab Dis 1997 Jun;20(2):171–8 (16 ref.)

LESS-DEVELOPED COUNTRIES see **DEVELOPING COUNTRIES**

LET see **LINEAR ENERGY TRANSFER**

LETHAL MIDLINE GRANULOMA see **GRANULOMA, LETHAL MIDLINE**

LETHARGY see **SLEEP STAGES**

LETS PROTEINS see **FIBRONECTINS**

LEU ANTIGENS see **ANTIGENS, DIFFERENTIATION**

LEU ANTIGENS, B-LYMPHOCYTE see **ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE**

LEU ANTIGENS, T-LYMPHOCYTE see **ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE**

LEU-2 ANTIGENS see **ANTIGENS, CD8**

LEU-CAM RECEPTOR FAMILY see **RECEPTORS, LEUKOCYTE-ADHESION**

LEU-M1 ANTIGENS see **ANTIGENS, CD15**

LEU-M5 ANTIGENS see **ANTIGEN P150,95**

LEUCINE

ANALOGS & DERIVATIVES

Lexipafant (BB-882), a potent PAF antagonist in acute pancreatitis. Curtis LD. **Adv Exp Med Biol** 1996;416:361–3 (16 ref.)
The use of lexipafant in the treatment of acute pancreatitis. McKay C, et al. **Adv Exp Med Biol** 1996;416:365–70 (34 ref.)

ANALYSIS

Biochemical and molecular basis of Bernard-Soulier syndrome: a review. de la Salle C, et al.

LEUCINE

Nouv Rev Fr Hematol 1995;37(4):215–22 (58 ref.)

DIAGNOSTIC USE

[Insulin secretion—assay method and its significance] Emoto M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:418–22 (6 ref.) **(Jpn)**

[Tolbutamide, glucagon, leucine and arginine tolerance test] Hosaka T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:423–7 (10 ref.) **(Jpn)**

PHARMACOLOGY

Leu271–Glu292 in kininogens blocks thrombin-induced aggregation. Colman RW, et al. **Immunopharmacology** 1996 May;32(1–3):80–1 (3 ref.)

LEUCINE ZIPPERS

Evidence to suggest that expression of MITF induces melanocyte differentiation and haploinsufficiency of MITF causes Waardenburg syndrome type 2A. Tachibana M. **Pigment Cell Res** 1997 Feb–Apr;10(1–2):25–33 (33 ref.)

Do basic region-leucine zipper proteins bend their DNA targets ... does it matter? [comment] Hagerman PJ. **Proc Natl Acad Sci U S A** 1996 Sep 17;93(19):9993–6 (45 ref.) Comment on: Proc Natl Acad Sci U S A 1996 Sep 17;93(19):10117–22.

LEUCOHARMINE see **HARMINE**

LEUCOMYCINS

METABOLISM

Specific targeting of protein–DNA complexes by DNA-reactive drugs (+)-CC-1065 and pluramycins. Henderson D, et al. **J Mol Recognit** 1996 Mar–Apr; 9(2):75–87 (59 ref.)

LEUCONOSTOC

Leuconostoc bacteremia in an infant with short-gut syndrome: case report and literature review. Dhodapkar KM, et al. **Mayo Clin Proc** 1996 Dec;71(12):1171–4 (24 ref.)

METABOLISM

The role of transport processes in survival of lactic acid bacteria. Energy transduction and multidrug resistance. Konings WN, et al. **Antonie Van Leeuwenhoek** 1997 Feb; 71(1–2):117–28 (65 ref.)

Diacetyl formation by lactic bacteria. Escamilla-Hurtado ML, et al. **Rev Latinoam Microbiol** 1996 Apr–Jun; 38(2):129–37 (48 ref.)

LEUCOTOMY see **PSYCHOSURGERY**

LEUCOVORIN

ADMINISTRATION & DOSAGE

A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Machover D. **Cancer** 1997 Oct 1;80(7):1179–87 (47 ref.)

PHARMACOLOGY

Therapies for advanced colorectal cancer: the role of interferon and leucovorin. Macdonald JS. **Tumori** 1997 Jan–Feb;83(1 Suppl):S67–9 (21 ref.)

THERAPEUTIC USE

Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival. Zaniboni A. **J Clin Oncol** 1997 Jun; 15(6):2432–41 (59 ref.)

Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin. Klaassen U, et al. **J Infus Chemother** 1996 Summer;6(3):127–32 (34 ref.)

[Methotrexate-leucovorin rescue therapy: pharmacological characteristics and clinical effective use] Fujimoto T. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1901–6 (6 ref.) (Eng. Abstr.) **(Jpn)**

LEUKAPHERESIS

METHODS

Peripheral blood stem cell harvesting and CD34-positive cell selection. Shpall EJ, et al. **Cancer Treat Res** 1997;77:143–57 (65 ref.)

Safety of large-volume leukapheresis for collection of peripheral blood progenitor cells. Reik RA, et al. **J Clin Apheresis** 1997;12(1):10–3 (16 ref.)

Purging of tumor cells from leukapheresis products: experimental and clinical aspects. Kvalheim G, et al. **J Hematother** 1996 Aug;5(4):427–36 (31 ref.)

Principles of counting low numbers of leukocytes in leukoreduced blood components. Dzik S. **Transfus Med Rev** 1997 Jan;11(1):44–55 (56 ref.)

STANDARDS

Lymphocytapheresis. Takenaka Y. **Artif Organs** 1996 Aug; 20(8):914–6 (10 ref.)

LEUKEMIA

see related

LEUKEMIC INFILTRATION

Principles of graft-vs.-leukemia reactivity. Truitt RL, et al. **Biol Blood Marrow Transplant** 1995 Dec;1(2):61–8 (71 ref.)

ABC of clinical haematology. The acute leukaemias. Liesner RJ, et al. **BMJ** 1997 Mar 8;314(7082):733–6 (0 ref.)

Graft-versus-host disease and graft-versus-leukemia. Michallet M. **Hematol Cell Ther** 1996 Oct;38(5):459–60 (15 ref.)

Human factor-dependent leukemia cell lines. Tohyama K. **Int J Hematol** 1997 Jun;65(4):309–17 (70 ref.)

Comparative research on leukemia and related diseases: an introduction to a scientific approach. Hehlmann R, et al. **J Mol Med** 1997 Jul;75(7):528–38 (156 ref.)

[Molecular mechanisms of acute leukemias] Hirai H. **Rinsho Ketsueki** 1997 Mar;38(3):166–71 (20 ref.) **(Jpn)**

[Minimal residual disease in acute leukemias. Optimal method of detection] Deptała A, et al. **Pol Arch Med Wewn** 1996 Jun;95(6):585–94 (35 ref.) **(Pol)**

BLOOD

Apoptosis in normal and neoplastic hematopoiesis. Yoshida Y, et al. **Crit Rev Oncol Hematol** 1996 Nov;24(3):185–211 (273 ref.)

Serum levels of adhesion molecules and cytokines in patients with acute leukaemia. Bruserud O, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):423–30 (45 ref.)

Antithrombin deficiency in special clinical syndromes--Part II: hematologic malignancies and bone marrow transplantation. Haire WD. **Semin Hematol** 1995 Oct;32(4 Suppl 2):56–60 (8 ref.)

[Various factors determining direction of differentiation in leukemic cells] Sasaki R. **Rinsho Ketsueki** 1996 Sep; 37(9):751–4 (7 ref.) **(Jpn)**

[Role of IMP dehydrogenase on cell differentiation] Tsutani H. **Rinsho Ketsueki** 1996 Sep;37(9):755–9 (15 ref.) **(Jpn)**

CHEMICALLY INDUCED

Toxicology and epidemiology of 1,3-butadiene. Himmelstein MW, et al. **Crit Rev Toxicol** 1997 Jan;27(1):1–108 (239 ref.)

Clinical features of hematopoietic malignancies and related disorders among benzene-exposed workers in China. Benzene Study Group. Linet MS, et al. **Environ Health Perspect** 1996 Dec;104 Suppl 6:1353–64 (116 ref.)

The mechanism of benzene-induced leukemia: a hypothesis and speculations on the causes of leukemia. Smith MT. **Environ Health Perspect** 1996 Dec;104 Suppl 6:1219–25 (63 ref.)

The effects of benzene and other leukaemogenic agents on haematopoietic stem and progenitor cell differentiation. Irons RD, et al. **Eur J Haematol Suppl** 1996;60:119–24 (40 ref.)

CLASSIFICATION

[Concurrence of cytochemical and immune patterns of different cell lines in cases of acute leukemia] Grignaschi VJ, et al. **Medicina (B Aires)** 1996;56(4):339–45 (14 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Inpatient management of acute leukemia. Kalaycio M. **Cleve Clin J Med** 1997 Jul–Aug;64(7):385–9 (56 ref.)

[Cardiovascular disease in leukemia] Nagoshi H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):147–50 (25 ref.) **(Jpn)**

DIAGNOSIS

Novel leukaemia markers. Micklem KJ. **Biosci Rep** 1995 Dec; 15(6):463–8 (12 ref.)

Flow cytometry: recent advances in diagnosis and monitoring of leukemia [see comments] Jennings CD, et al. **Cancer Invest** 1997;15(4):384–99 (94 ref.) Comment in: Cancer Invest 1997 ;15(4):382–3.

Flow-cytometric quantitation in chronic leukemias. Lavabre-Bertrand T. **Eur J Histochem** 1996;40 Suppl 1:33–8 (56 ref.)

Immunophenotypic characterization of acute leukemias and chronic lymphoproliferative disorders: practical recommendations and classifications. Garand R, et al. **Hematol Cell Ther** 1996 Dec;38(6):471–86 (162 ref.)

Diagnosis and classification of the acute leukemias: recent advances and controversial issues. Taylor CG, et al. **Hematopathol Mol Hematol** 1996;10(1–2):1–38 (216 ref.)

The role of magnetic resonance imaging in the diagnosis and monitoring of myelodysplastic syndromes or leukemia. Takagi S, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):443–50 (33 ref.)

[Clinical use of polymerase chain reaction in diagnosis and monitoring of malignant diseases] Jäger U, et al. **Wien Klin Wochenschr** 1996;108(20):634–9 (35 ref.) (Eng. Abstr.) **(Ger)**

[Leukemia in pediatric age] Massimo L, et al. **Minerva Pediatr** 1997 Jan–Feb;49(1–2):1–19 (73 ref.) (Eng. Abstr.) **(Ita)**

[Progress in diagnosis of leukemia] Kamada N, et al. **Rinsho Byori** 1996 Aug;44(8):736–42 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Detection of minimal residual leukemia using polymerase chain reaction method] Naoe T. **Rinsho Byori** 1996 Jun; 44(6):535–40 (3 ref.) (Eng. Abstr.) **(Jpn)**

[Applications of FISH method for diagnosis and pathophysiologic analysis in hematopoietic neoplasias] Kamada N. **Rinsho Ketsueki** 1996 Jun;37(6):467–71 (8 ref.) **(Jpn)**

DRUG THERAPY

Topoisomerases in human leukemia. Peereboom D, et al. **Adv Pharmacol** 1994;29B:33–50 (90 ref.)

Factors affecting topotecan sensitivity in human leukemia samples. Kaufmann SH, et al. **Ann N Y Acad Sci** 1996 Dec 13;803:128–42 (44 ref.)

Central nervous system relapse of lymphoid malignancies in adults: the role of high-dose chemotherapy. van Besien K, et al. **Ann Oncol** 1997 Jun;8(6):515–24 (122 ref.)

The emerging role of immunotoxins in leukemia and lymphoma. Winkler U, et al. **Ann Oncol** 1997;8 Suppl 1:139–46 (46 ref.)

Targeting c-myc in leukemia. Calabretta B, et al. **Anticancer Drug Des** 1997 Jul;12(5):373–81 (31 ref.)

Developing oligonucleotide therapeutics for human leukemia. Gewirtz AM. **Anticancer Drug Des** 1997 Jul;12(5):341–58 (54 ref.)

Multidrug resistance in leukaemia. McKenna SL, et al. **Br J Haematol** 1997 Mar;96(4):659–74 (203 ref.)

Oral idarubicin. A review of its pharmacological properties and clinical efficacy in the treatment of haematological malignancies and advanced breast cancer. Buckley MM, et al. **Drugs Aging** 1997 Jul;11(1):61–86 (125 ref.)

Perspectives on purine analogues. Cheson BD. **Hematol Cell Ther** 1996 Dec;38 Suppl 2:S109–16 (104 ref.)

Antibodies to interferon-alpha in treated cancer patients: incidence and significance. McKenna RM, et al. **J Interferon Cytokine Res** 1997 Mar;17(3):141–3 (25 ref.)

Quercetin and the growth of leukemic progenitors. Larocca LM, et al. **Leuk Lymphoma** 1996 Sep;23(1–2):49–53 (51 ref.)

Multidrug resistance in leukemias and its reversal. Malayeri R, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):451–8 (89 ref.)

Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia. Momparler RL, et al. **Leukemia** 1997 Mar;11 Suppl 1:S1–6 (57 ref.)

Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia. Momparler RL, et al. **Leukemia** 1997 Feb;11(2):175–80 (57 ref.)

Role of interleukin-2 in human hematological malignancies. Toren A, et al. **Med Oncol** 1995 Sep;12(3):177–86 (94 ref.)

A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan. Tamura K. **Semin Hematol** 1996 Oct;33(4 Suppl 3):2–11 (21 ref.)

Brain abscesses due to Geotrichum candidum. Kasantikul V, et al. **Southeast Asian J Trop Med Public Health** 1995 Dec; 26(4):805–7 (9 ref.)

[Management of hematologic malignancies during pregnancy] Maloisel F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(6):602–7 (49 ref.) (Eng. Abstr.) **(Fre)**

[High dose chemotherapy with autologous stem cell transplantation] Weissinger F, et al. **Fortschr Med** 1997 Mar 30;115(9):39–43 (20 ref.) (Eng. Abstr.) **(Ger)**

[Therapy of infections in patients with acute leukemia] Hiddemann W, et al. **Med Klin** 1997 Jul 15;92(7):406–9 (18 ref.) (Eng. Abstr.) **(Ger)**

[Antileukemic agents--new drugs and attempts of rational administration] Ueda T. **Rinsho Ketsueki** 1996 Aug; 37(8):635–9 (16 ref.) **(Jpn)**

ENZYMOLOGY

Technical improvement in determining telomerase activity in hematologic neoplasias: a possibility of single cell determination of telomerase activity. Ohyashiki K, et al. **Hum Cell** 1996 Dec;9(4):295–300 (40 ref.)

EPIDEMIOLOGY

Epidemiology of childhood leukemia. Shu XO. **Curr Opin Hematol** 1997 Jul;4(4):227–32 (61 ref.)

Etoposide in Langerhans cell histiocytosis [editorial] Gadner H. **Pediatr Hematol Oncol** 1996 Jul–Aug;13(4):309–11 (15 ref.)

Radioepidemiology in the aftermath of the nuclear program of the former Soviet Union: unique lessons to be learnt. Burkart W. **Radiat Environ Biophys** 1996 May;35(2):65–73 (19 ref.)

ETIOLOGY

Big babies and infant leukemia: a role for insulin-like growth factor-1? Ross JA, et al. **Cancer Causes Control** 1996 Sep; 7(5):553–9 (66 ref.)

The process of leukemogenesis. Irons RD, et al. **Environ Health Perspect** 1996 Dec;104 Suppl 6:1239–46 (122 ref.)

Could aplastic anaemia be considered a pre-pre-leukaemic disorder? Socié G. **Eur J Haematol Suppl** 1996;60:60–3 (39 ref.)

Aetiology of acute leukaemia. Greaves MF. **Lancet** 1997 Feb 1;349(9048):344–9 (45 ref.)

Leukaemogenesis, gene interplay, and the role of the haemopoietic environment. Lawler M. **Radiat Oncol Investig** 1997;5(3):154–7 (18 ref.)

Secondary leukaemias. Clinical and cytobiological aspects. Quaglino D, et al. **Recenti Prog Med** 1996 Oct;87(10):491–9 (46 ref.)

GENETICS

The MDR phenotype in hematologic malignancies: prognostic relevance and future perspectives. Hegewisch-Becker S, et al. **Ann Hematol** 1996 Mar; 72(3):105–17 (128 ref.)

Targeting c-myc in leukemia. Calabretta B, et al. **Anticancer Drug Des** 1997 Jul;12(5):373–81 (31 ref.)

Cytogenetic and molecular detection of genetic mutations in human tumours. Le Beau MM. **Biologicals** 1996 Sep; 24(3):189–91 (10 ref.)

Genetic alterations in leukemias and lymphomas: impressive progress and continuing complexity. Nowell PC. **Cancer Genet Cytogenet** 1997 Mar;94(1):13–9 (52 ref.)

Telomere dynamics and cytogenetic changes in human hematologic neoplasias: a working hypothesis. Ohyashiki K, et al. **Cancer Genet Cytogenet** 1997 Mar;94(1):67–72 (41 ref.)

The role of p53 in malignancy. Keith FJ, et al. **Cancer Treat Res** 1996;84:113–37 (150 ref.)

Deletion of chromosome 5 (5q–) in leukemia: current knowledge. Nagarajan L. **Cancer Treat Res** 1996;84:19–29 (31 ref.)

Bcl-2 family proteins and the regulation of programmed cell death in leukemia and lymphoma. Reed JC, et al. **Cancer Treat Res** 1996;84:31–72 (231 ref.)

BCL-2 gene rearrangements in lymphoid malignancies. Crisan D. **Clin Lab Med** 1996 Mar;16(1):23–47 (107 ref.)

A new transcription factor family associated with human leukemias. Speck NA, et al. **Crit Rev Eukaryot Gene Expr** 1995;5(3–4):337–64 (169 ref.)

Developments in cytogenetics and oncogenes in acute leukemia. Strout MP, et al. **Curr Opin Oncol** 1997 Jan; 9(1):8–17 (76 ref.)

The TEL gene contributes to the pathogenesis of myeloid and lymphoid leukemias by diverse molecular genetic mechanisms. Golub TR, et al. **Curr Top Microbiol Immunol** 1997;220:67–79 (15 ref.)

Disruption of a homolog of trithorax by 11q23 translocations: leukemogenic and transcriptional implications. Waring PM, et al. **Curr Top Microbiol Immunol** 1997;220:1–23 (135 ref.)

Telomeres and telomerase in normal and malignant haematopoietic cells. Norrback KF, et al. **Eur J Cancer** 1997 Apr;33(5):774–80 (57 ref.)

Fluorescence in situ hybridization (FISH) in cytogenetics of leukemia. Michalová K. **Folia Biol (Praha)** 1996; 42(6):311–4 (13 ref.)

The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias. Lo Coco F, et al. **Haematologica** 1997 May-Jun;82(3):364–70 (66 ref.)

Telomere crisis in leukemia. Ishikawa F. **Int J Hematol** 1997 Jun;65(4):355–64 (46 ref.)

Chromosomal abnormalities and oncogenes. Mitani K. **Int J Hematol** 1996 Feb;63(2):81–93 (74 ref.)

Molecular genetics of acute leukaemia. Sawyers CL. **Lancet** 1997 Jan 18;349(9046):196–200 (40 ref.)

c-kit Point mutation in patients with myeloproliferative disorders. Kimura A, et al. **Leuk Lymphoma** 1997 Apr; 25(3–4):281–7 (32 ref.)

Pattern of expression and their clinical implications of the GATA family, stem cell leukemia gene, and EVI1 in leukemia and myelodysplastic syndromes. Ohyashiki K, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):431–6 (47 ref.)

Role of the cyclin-dependent kinase 4 and 6 inhibitor gene family p15, p16, p18 and p19 in leukemia and lymphoma. Siebert R, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):505–20 (107 ref.)

C-kit receptors in childhood malignant lymphoblastic cells. Sykora KW, et al. **Leuk Lymphoma** 1997 Apr; 25(3–4):201–16 (94 ref.)

Overexpression of the MDM2 oncogene in leukemia and lymphoma. Watanabe T, et al. **Leuk Lymphoma** 1996 May; 21(5–6):391–7, color plates XVI following 5 (49 ref.)

The genetics of familial leukemia. Horwitz M. **Leukemia** 1997 Aug;11(8):1347–59 (205 ref.)

Leukemogenesis by the chromosomal translocations. Mitani K. **Leukemia** 1997 Apr;11 Suppl 3:294–6 (32 ref.)

Detection of minimal residual disease in multiple myeloma and acute leukaemia. Bakkus MH, et al. **Med Oncol** 1996 Jun;13(2):121–31 (88 ref.)

Molecular biology of leukemia for the clinician. Paietta E. **Med Oncol** 1995 Sep;12(3):157–66 (39 ref.)

Cytogenetic techniques for human leukemias. Swansbury GJ. **Methods Mol Biol** 1997;75:323–39 (20 ref.)

[Apoptosis and leukemia] Ma D, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Oct;34(10):709–11 (22 ref.) **(Chi)**

[Progress in understanding the development of leukemia. Consequences for the clinic] von Schilling C, et al. **Internist (Berl)** 1996 Oct;37(10):971–81 (76 ref.) **(Ger)**

[Association of congenital chromosome abnormalities and malignant diseases] Erzsébet B, et al. **Orv Hetil** 1996 Feb 4;137(5):227–31 (25 ref.) (Eng. Abstr.) **(Hun)**

IMMUNOLOGY

The immunobiology of T cell therapies for leukemias. Shlomchik WD, et al. **Acta Haematol** 1996;96(4):189–213 (145 ref.)

Towards standardization in immunophenotyping hematological malignancies. How can we improve the reproducibility and comparability of flow cytometric results? Working Group on Leukemia Immunophenotyping. Lanza F. **Eur J Histochem** 1996;40 Suppl 1:7–14 (43 ref.)

Flow-cytometric quantitation in chronic leukemias. Lavabre-Bertrand T. **Eur J Histochem** 1996;40 Suppl 1:33–8 (56 ref.)

CD10 in acute leukemias. GEIL (Groupe d'Etude Immunologique des Leucémies). Béné MC, et al. **Haematologica** 1997 Mar-Apr;82(2):205–10 (49 ref.)

Graft-versus-leukemia effect and its clinical implications. Imamura M, et al. **Leuk Lymphoma** 1996 Nov; 23(5–6):477–92 (163 ref.)

Mechanisms of the graft-versus-leukemia reaction. Barrett AJ. **Stem Cells** 1997;15(4):248–58 (106 ref.)

[Concurrence of cytochemical and immune patterns of different cell lines in cases of acute leukemia] Grignaschi VJ, et al. **Medicina (B Aires)** 1996;56(4):339–45 (14 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Use of human leukemia-lymphoma cell lines in hematological research: effects of thrombopoietin on human leukemia cell lines. Drexler HG, et al. **Hum Cell** 1996 Dec;9(4):309–16 (36 ref.)

Multidrug resistance in leukemias and its reversal. Malayeri R, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):451–8 (89 ref.)

Expression of sialosyl-T and disialosyl-T antigens in erythroid cells. Muroi K, et al. **Leuk Lymphoma** 1997 May; 25(5–6):403–14 (31 ref.)

Pattern of expression and their clinical implications of the GATA family, stem cell leukemia gene, and EVI1 in leukemia and myelodysplastic syndromes. Ohyashiki K, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):431–6 (47 ref.)

Granulocyte colony-stimulating factor receptor at various differentiation stages of normal and leukemic hematopoietic cells. Shinjo K, et al. **Leuk Lymphoma** 1997 Mar; 25(1–2):37–46 (49 ref.)

The expression of IL-6 and its related genes in acute leukemia. Sugiyama H, et al. **Leuk Lymphoma** 1996 Mar; 21(1–2):49–52 (42 ref.)

Prosomes (proteasomes) changes during differentiation are related to the type of inducer. Bureau JP, et al. **Mol Biol Rep** 1997 Mar;24(1–2):57–62 (65 ref.)

MICROBIOLOGY

[Atypical mycobacteria. Disseminated infection in patients with hematologic diseases] Vejlgaard TB, et al. **Ugeskr Laeger** 1997 Sep 1;159(36):5362–7 (40 ref.) (Eng. Abstr.) **(Dan)**

PATHOLOGY

Gene regulatory mechanisms operative on hematopoietic cells: proliferation, differentiation, and neoplasia. Calabretta B, et al. **Crit Rev Eukaryot Gene Expr** 1997;7(1–2):117–24 (36 ref.)

Immunophenotype definition of the stem/progenitor cell compartment. Implications for the identification of blast cells in acute leukemia. Moretti S, et al. **Eur J Histochem** 1996;40 Suppl 1:43–52 (59 ref.)

Flow cytometry study of cell cycle, apoptosis and drug resistance in acute leukemia. Lacombe F, et al. **Hematol Cell Ther** 1996 Dec;38(6):495–504 (52 ref.)

Fas receptor (CD95)-mediated apoptosis in leukemic cells. Komada Y, et al. **Leuk Lymphoma** 1997 Mar;25(1–2):9–21 (65 ref.)

Is PKC activation required for leukemia cell differentiation? [comment] Woloschak GE. **Leuk Res** 1997 May;21(5):411–4 (42 ref.) Comment on: Leuk Res 1997 May;21(5):403–10.

[Intraocular and orbital involvement in lymphomas and leukemias] Pe'er J. **Harefuah** 1996 Aug;131(3–4):116–20 (37 ref.) **(Heb)**

[Cytokines regulate apoptosis of leukemic cells] Handa A. **Nippon Rinsho** 1996 Jul;54(7):1797–802 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Overexpression of bcl-2 suppresses apoptotic cell death of the human leukemic cell line TF-1] Ito T, et al. **Nippon Rinsho** 1996 Jul;54(7):1815–21 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Induction of apoptosis by fibronectin via its interaction with VLA5] Sugahara H. **Nippon Rinsho** 1996 Jul;54(7):1809–14 (16 ref.) (Eng. Abstr.) **(Jpn)**

[The mechanism of apoptosis induced by anticancer agents in human leukemia cells] Yoshida A, et al. **Nippon Rinsho** 1996 Jul;54(7):1822–7 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Leukemic infiltration of the pericardium] Shibata K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):289–90 (6 ref.) **(Jpn)**

[Discovery of a novel bioactivity of gangliosides: gangliosides as differentiation-inducers for human leukemic cells and mechanism(s) of their action] Nojiri H. **Seikagaku** 1996 Aug;68(8):1429–44 (50 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Haemopoietic growth factors and leukaemogenesis. Pierce A, et al. **Biochem Soc Trans** 1997 May;25(2):366–70 (45 ref.)

Transcription factors, normal myeloid development, and leukemia. Tenen DG, et al. **Blood** 1997 Jul 15;90(2):489–519 (455 ref.)

Apoptosis in normal and neoplastic hematopoiesis. Yoshida Y, et al. **Crit Rev Oncol Hematol** 1996 Nov;24(3):185–211 (273 ref.)

Flow cytometry study of cell cycle, apoptosis and drug resistance in acute leukemia. Lacombe F, et al. **Hematol Cell Ther** 1996 Dec;38(6):495–504 (52 ref.)

Hematopoietic growth factors in leukemia. Touw IP, et al. **Pathol Res Pract** 1996 Jul;192(7):734–42 (81 ref.)

[Ocular sites of acute leukemias] Berthou C, et al. **J Fr Ophtalmol** 1996;19(6–7):470–8 (45 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Consensus conference on unrelated donor bone marrow transplantation: its use in leukaemias and allied disorders. Royal College of Physicians of Edinburgh, 29 and 30 October 1996 [letter] **Leukemia** 1997 Mar;11(3):451–2 (0 ref.)

Autologous bone marrow and peripheral blood stem cell transplantation in haematological malignancies: current status. Marcoullis G, et al. **Med Oncol** 1995 Dec; 12(4):209–18 (91 ref.)

THERAPY

The immunobiology of T cell therapies for leukemias. Shlomchik WD, et al. **Acta Haematol** 1996;96(4):189–213 (145 ref.)

The study of haemopoietic stem cells in patients: concepts, approaches and cautionary tales. Testa NG, et al. **Ann Oncol** 1996;7 Suppl 2:5–8 (24 ref.)

Ribonuclease H-mediated antisense effects in intact human leukaemia cells. Tidd DM. **Biochem Soc Trans** 1996 Aug; 24(3):619–23 (21 ref.)

The role of unrelated bone-marrow transplantation in childhood acute leukaemia. Veys P. **Blood Rev** 1996 Dec; 10(4):231–6 (38 ref.)

Current trials in acute leukaemia. Nagesh K, et al. **Br J Hosp Med** 1996 Nov 20-Dec 10;56(10):532–6 (19 ref.)

The biological therapy of acute and chronic leukemia. Caron PC, et al. **Cancer Invest** 1997;15(4):342–52 (108 ref.)

Treatment of relapse after allogeneic bone marrow transplantation. Giralt SA, et al. **Cancer Treat Res** 1996; 84:279–90 (70 ref.)

Autologous bone marrow transplantation for leukemia and lymphoma. van Besien K, et al. **Cancer Treat Res** 1996; 84:207–59 (228 ref.)

Inpatient management of acute leukemia. Kalaycio M. **Cleve Clin J Med** 1997 Jul-Aug;64(7):385–9 (56 ref.)

Consensus statement on unrelated donor BMT, 29 & 30 October 1996. Its use in leukaemias and allied disorders. Consensus Panel. **Clin Oncol (R Coll Radiol)** 1997; 9(2):132–3 (0 ref.)

Recent advances in the treatment of acute leukemia. Berman E. **Curr Opin Hematol** 1997 Jul;4(4):256–60 (28 ref.)

Central nervous system leukemia [see comments] Blaney SM, et al. **Curr Opin Oncol** 1996 Jan;8(1):13–9 (38 ref.) Comment in: Curr Opin Oncol 1996 Jan;8(1):1–2.

Treatment of adult acute leukemia. Büchner T. **Curr Opin Oncol** 1997 Jan;9(1):18–25 (61 ref.)

Adoptive immunotherapy with donor lymphocyte transfusions. Kolb HJ, et al. **Curr Opin Oncol** 1997 Mar; 9(2):139–45 (53 ref.)

Treatment of childhood leukemia. Silverman LB, et al. **Curr Opin Oncol** 1997 Jan;9(1):26–33 (74 ref.)

The potential role of amifostine (Ethyol) in haematological malignancies. Gorin NC. **Eur J Cancer** 1996;32A Suppl 4:S31–9 (22 ref.)

Antiblastic chemotherapy for haematologic malignancies and second tumours. Barillari G, et al. **Eur J Cancer Prev** 1996 Oct;5(5):402–4 (14 ref.)

Hematological malignancies. Brenner MK. **FASEB J** 1997 Jul;11(8):640–8 (39 ref.)

ACOS presentations for publication in the Japanese Journal of Cancer and Chemotherapy. Masaoka T. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:178–81 (1 ref.)

Donor leukocyte infusions for relapsed leukemia after allogeneic BMT. Mackinnon S. **Hematol Cell Ther** 1996 Oct;38(5):461–2 (5 ref.)

Unrelated donor bone marrow transplantation: its use in leukaemias and allied disorders. Consensus statement from the RCPE/Consensus Conference on Unrelated Donor BMT held on 29 and 30 October 1996 [editorial] **J Clin Pathol** 1997 Feb;50(2):91–2 (0 ref.)

The treatment of acute leukaemia. Burnett AK, et al. **Lancet** 1997 Jan 25;349(9047):270–5 (40 ref.)

Graft-versus-leukemia effect and its clinical implications. Imamura M, et al. **Leuk Lymphoma** 1996 Nov; 23(5–6):477–92 (163 ref.)

Gene therapy strategies for leukemia. Braun SE, et al. **Mol Med Today** 1997 Jan;3(1):39–46 (51 ref.)

Infectious complications of patients undergoing therapy for

acute leukemia: current status and future prospects. Chanock SJ, et al. **Semin Oncol** 1997 Feb;24(1):132–40 (65 ref.)

Mechanisms of the graft–versus–leukemia reaction. Barrett AJ. **Stem Cells** 1997;15(4):248–58 (106 ref.)

Consensus Conference on unrelated donor BMT, 29–30 October 1996: its use in leukaemias and allied disorders. Franklin IM. **Transfus Med** 1997 Mar;7(1):63–4 (0 ref.)

Consensus statement from the Consensus Conference on Unrelated–Donor Bone Marrow Transplants––29 and 30 October 1996. Their use in leukaemias and allied disorders. Franklin IM. **Vox Sang** 1997;73(1):52–3 (0 ref.)

[Diagnosis of minimal residual disease in autologous bone marrow transplantation] Jørgensen H, et al. **Nord Med** 1996 Dec;111(10):344–7 (15 ref.) (Eng. Abstr.) **(Dan)**

[Transplantation of hematopoietic stem cells] Hertenstein B, et al. **Internist (Berl)** 1996 Mar;37(3):295–303 (41 ref.) **(Ger)**

[Value of hematopoietic stem cell transplantation in treatment of leukemia] Runde V, et al. **Internist (Berl)** 1996 Oct; 37(10):1030–9 (39 ref.) **(Ger)**

[Experimental approaches] Voliotis DL, et al. **Internist (Berl)** 1996 Oct;37(10):1040–8 (84 ref.) **(Ger)**

[Transplantation of hematopoietic stem cells. I: Definitions, principle indications, complications] Link H, et al. **Med Klin** 1997 Aug 15;92(8):480–91, 505 (106 ref.) (Eng. Abstr.) **(Ger)**

[Prospects for antisense therapy of human leukemias] Maekawa T. **Hum Cell** 1996 Mar;9(1):17–24 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Present status of donor leukocyte transfusion for leukemia. Relapse after allogeneic bone marrow transplantation in Japan] Morishima Y, et al. **Rinsho Ketsueki** 1997 Jun; 38(6):476–8 (9 ref.) **(Jpn)**

[Indication of unrelated donor bone marrow transplantation for refractory leukemia] Oh H. **Rinsho Ketsueki** 1996 Aug; 37(8):671–5 (7 ref.) **(Jpn)**

[Mobilization and collection of peripheral blood stem cells] Shimazaki C, et al. **Rinsho Ketsueki** 1996 Jul;37(7):574–8 (10 ref.) **(Jpn)**

[Elimination of minimal residual leukemic cells by biological response modifiers] Yamamoto K. **Rinsho Ketsueki** 1996 Aug;37(8):666–70 (10 ref.) **(Jpn)**

[Minimal residual disease in acute leukemias––clinical significance] Deptała A, et al. **Pol Arch Med Wewn** 1997 Mar;97(3):268–74 (60 ref.) **(Pol)**

LEUKEMIA, ADULT T-CELL see **LEUKEMIA, T-CELL**

LEUKEMIA, B-CELL

GENETICS

VH gene expression in CD5 positive and CD5 negative B cell chronic lymphoid malignancies. Maloum K, et al. **Leuk Lymphoma** 1997 Feb;24(5–6):437–48 (114 ref.)

IMMUNOLOGY

Autoimmunity and B–cell malignancies. Dighiero G. **Verh Dtsch Ges Pathol** 1996;80:148–59 (105 ref.)

METABOLISM

VH gene expression in CD5 positive and CD5 negative B cell chronic lymphoid malignancies. Maloum K, et al. **Leuk Lymphoma** 1997 Feb;24(5–6):437–48 (114 ref.)

PATHOLOGY

Cellular interactions among marrow stromal and normal/neoplastic pre–B– and B–lymphoblastic cells. Patrick CW Jr, et al. **Leuk Lymphoma** 1996 Jul; 22(3–4):205–19 (117 ref.)

The role of the CD40 antigen on malignant B cells. Planken EV, et al. **Leuk Lymphoma** 1996 Jul;22(3–4):229–35 (63 ref.)

LEUKEMIA, B-CELL, ACUTE

GENETICS

Molecular cytogenetics of t(12;21) (p13;q22). Bernard OA, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):459–65 (41 ref.)

LEUKEMIA, B-CELL, CHRONIC

COMPLICATIONS

Endobronchial inflammatory pseudotumour in a patient with B–cell chronic lymphocytic leukemia and malignant pleural mesothelioma. Stappaerts I, et al. **Acta Clin Belg** 1996; 51(4):261–4 (8 ref.)

Inflammatory neuromuscular disorders associated with chronic lymphoid leukemia: evidence for clonal B cells within muscle and nerve. Creange A, et al. **J Neurol Sci** 1996 Apr;137(1):35–41 (25 ref.)

DIAGNOSIS

Chronic lymphocytic leukemia and hairy–cell leukemia–diagnosis and treatment: results of a consensus meeting of the German CLL Co–operative Group [editorial] Brittinger G, et al. **Leukemia** 1997 Apr;11 Suppl 2:S1–3 (26 ref.)

[Chronic lymphatic leukemia and hairy cell leukemia. Diagnosis and therapy] Brittinger G, et al. **Med Klin** 1997 Jun 15;92(6):309–12 (29 ref.) **(Ger)**

DRUG THERAPY

Is there a place for 2–CDA in the treatment of B–CLL? Mitterbauer M, et al. **Leukemia** 1997 Apr;11 Suppl 2:S35–7 (27 ref.)

The Scripps Clinic experience with cladribine (2–CdA) in the treatment of chronic lymphocytic leukemia. Saven A. **Semin Hematol** 1996 Jan;33(1 Suppl 1):28–33 (31 ref.)

GENETICS

Genes and chromosomes in chronic B–cell leukemia. Crossen PE. **Cancer Genet Cytogenet** 1997 Mar;94(1):44–51 (104 ref.)

Clinical correlations of immunophenotypic variations and the presence of trisomy 12 in B–cell chronic lymphocytic leukemia. Tefferi A, et al. **Cancer Genet Cytogenet** 1997 Jun;95(2):173–7 (28 ref.)

Minimal residual disease detection in B–cell malignancies by assessing IgH rearrangement. Maloum K, et al. **Hematol Cell Ther** 1997 Jun;39(3):119–24 (52 ref.)

Cytogenetic and molecular cytogenetic analysis of B cell chronic lymphocytic leukemia: specific chromosome aberrations identify prognostic subgroups of patients and point to loci of candidate genes. Döhner H, et al. **Leukemia** 1997 Apr;11 Suppl 2:S19–24 (65 ref.)

IMMUNOLOGY

Inflammatory neuromuscular disorders associated with chronic lymphoid leukemia: evidence for clonal B cells within muscle and nerve. Creange A, et al. **J Neurol Sci** 1996 Apr;137(1):35–41 (25 ref.)

Antigen receptor function in chronic lymphocytic leukemia B cells. Lankester AC, et al. **Leuk Lymphoma** 1996 Dec; 24(1–2):27–33 (22 ref.)

METABOLISM

Regulation and function of adhesion molecules in B–cell chronic lymphocytic leukaemia. Jewell AP, et al. **Acta Haematol** 1997;97(1–2):67–72 (25 ref.)

PATHOLOGY

The emergence of Hodgkin's disease in a patient with long–standing chronic lymphocytic leukemia––case report and review of the literature. Samuelsson J, et al. **Acta Oncol** 1997;36(3):351–3 (24 ref.)

B–cell chronic lymphocytic leukemia: recent progress in biology, diagnosis, and therapy. Montserrat E, et al. **Ann Oncol** 1997;8 Suppl 1:93–101 (119 ref.)

The pathology of the chronic lymphoid leukaemias. Kroft SH, et al. **Blood Rev** 1995 Dec;9(4):234–50 (120 ref.)

Peritumoral B cell infiltrate associated with chronic lymphocytic leukemia obscuring margin evaluation during Mohs micrographic surgery [letter] Humphreys TR, et al. **Dermatol Surg** 1996 Oct;22(10):894–6 (21 ref.)

What is the CLL B–lymphocyte? Dighiero G, et al. **Leuk Lymphoma** 1996 Oct;22 Suppl 2:13–39 (68 ref.)

Interferon–alpha, Bcl–2 expression and apoptosis in B–cell chronic lymphocytic leukemia. Jewell AP. **Leuk Lymphoma** 1996 Mar;21(1–2):43–7 (48 ref.)

Modulation of apoptosis with cytokines in B–cell chronic lymphocytic leukaemia. Mainou–Fowler T, et al. **Leuk Lymphoma** 1996 May;21(5–6):369–77 (126 ref.)

PHYSIOPATHOLOGY

[Cytokines and chronic B–cell lymphatic leukemia] Berrocal E, et al. **Sangre (Barc)** 1997 Feb;42(1):39–46 (103 ref.) **(Spa)**

THERAPY

B–cell chronic lymphocytic leukemia: recent progress in biology, diagnosis, and therapy. Montserrat E, et al. **Ann Oncol** 1997;8 Suppl 1:93–101 (119 ref.)

New perspectives on the approach to chronic lymphocytic leukemia. Goodman MG, et al. **Leuk Lymphoma** 1996 Jun; 22(1–2):1–10 (51 ref.)

Interferon–alpha, Bcl–2 expression and apoptosis in B–cell chronic lymphocytic leukemia. Jewell AP. **Leuk Lymphoma** 1996 Mar;21(1–2):43–7 (48 ref.)

Chronic lymphocytic leukemia and hairy–cell leukemia–diagnosis and treatment: results of a consensus meeting of the German CLL Co–operative Group [editorial] Brittinger G, et al. **Leukemia** 1997 Apr;11 Suppl 2:S1–3 (26 ref.)

Cytogenetic and molecular cytogenetic analysis of B cell chronic lymphocytic leukemia: specific chromosome aberrations identify prognostic subgroups of patients and point to loci of candidate genes. Döhner H, et al. **Leukemia** 1997 Apr;11 Suppl 2:S19–24 (65 ref.)

LEUKEMIA, BASOPHILIC, ACUTE

VETERINARY

Basophilic leukemia in a dog. Mears EA, et al. **J Vet Intern Med** 1997 Mar–Apr;11(2):92–4 (13 ref.)

LEUKEMIA, BOVINE see **ENZOOTIC BOVINE LEUKOSIS**

LEUKEMIA, EOSINOPHILIC see **HYPEREOSINOPHILIC SYNDROME**

LEUKEMIA, ERYTHROBLASTIC, ACUTE

Avian erythropoiesis and erythroleukemia: towards understanding the role of the biomolecules involved. Beug H, et al. **Biochim Biophys Acta** 1996 Dec 9;1288(3):M35–47 (92 ref.)

PATHOLOGY

[Overexpression of bcl–2 suppresses apoptosis in the human leukemia cell line TF–1] Ito T. **Rinsho Byori** 1997 Jul; 45(7):628–37 (19 ref.) (Eng. Abstr.) **(Jpn)**

VIROLOGY

Acute avian leukemia viruses as tools to study hematopoietic cell differentiation. McNagny KM, et al. **Curr Top Microbiol Immunol** 1996;212:143–62 (114 ref.)

LEUKEMIA, EXPERIMENTAL

Comparative research on leukemia and related diseases: an introduction to a scientific approach. Hehlmann R, et al. **J Mol Med** 1997 Jul;75(7):528–38 (156 ref.)

CHEMICALLY INDUCED

The effects of benzene and other leukaemogenic agents on haematopoietic stem and progenitor cell differentiation. Irons RD, et al. **Eur J Haematol Suppl** 1996;60:119–24 (40 ref.)

ETIOLOGY

Normal and leukemic human stem cells assayed in SCID mice. Dick JE. **Semin Immunol** 1996 Aug;8(4):197–206 (69 ref.)

Leukemogenesis by Moloney murine leukemia virus: a multistep process. Fan H. **Trends Microbiol** 1997 Feb; 5(2):74–82 (48 ref.)

GENETICS

The role of HOX homeobox genes in normal and leukemic hematopoiesis. Lawrence HJ, et al. **Stem Cells** 1996 May; 14(3):281–91 (99 ref.)

IMMUNOLOGY

Moloney leukemia virus–induced cell surface antigen mimicry by monoclonal antibodies. Baskin JG, et al. **Immunol Res** 1995;14(4):292–316 (96 ref.)

PHYSIOPATHOLOGY

Modelling human leukemia and lymphoma in severe combined immunodeficient (SCID) mice: practical applications. Flavell DJ. **Hematol Oncol** 1996 Jun; 14(2):67–82 (100 ref.)

PREVENTION & CONTROL

Correlates of immune protection after vaccination with attenuated live murine leukemia virus. Ruprecht RM, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):375–7 (14 ref.)

LEUKEMIA, FELINE

COMPLICATIONS

Opportunistic infections associated with retroviral infections in cats. Lappin MR. **Semin Vet Med Surg (Small Anim)** 1995 Nov;10(4):244–50 (71 ref.)

Hematologic abnormalities associated with retroviral infections in the cat. Shelton GH, et al. **Semin Vet Med Surg (Small Anim)** 1995 Nov;10(4):220–33 (86 ref.)

THERAPY

Caring for the retrovirus infected cat. McCaw D. **Semin Vet Med Surg (Small Anim)** 1995 Nov;10(4):216–219 (23 ref.)

LEUKEMIA, GRANULOCYTIC see **LEUKEMIA, MYELOID**

LEUKEMIA, GRANULOCYTIC, CHRONIC see **LEUKEMIA, MYELOID, CHRONIC**

LEUKEMIA, GRANULOCYTIC, CHRONIC-PHASE see **LEUKEMIA, MYELOID, CHRONIC-PHASE**

LEUKEMIA, HAIRY CELL

Workshop on chronic lymphocytic leukemia and hairy cell leukemia. Results of a consensus conference of the German CLL Cooperative Group. Peer–reviewed proceedings. Berlin, Germany, February 7–10, 1996. **Leukemia** 1997 Apr; 11 Suppl 2:S1–64 (0 ref.)

DIAGNOSIS

Chronic lymphocytic leukemia and hairy-cell leukemia--diagnosis and treatment: results of a consensus meeting of the German CLL Cooperative Group. Brittinger G, et al. **Ann Hematol** 1997 Jun;74(6):291-4 (29 ref.)

Chronic lymphocytic leukemia and hairy-cell leukemia-diagnosis and treatment: results of a consensus meeting of the German CLL Co-operative Group [editorial] Brittinger G, et al. **Leukemia** 1997 Apr;11 Suppl 2:S1-3 (26 ref.)

[Chronic lymphatic leukemia and hairy cell leukemia. Diagnosis and therapy] Brittinger G, et al. **Med Klin** 1997 Jun 15;92(6):309-12 (29 ref.) **(Ger)**

DRUG THERAPY

Clinical experience with 2'-deoxycoformycin. Catovsky D. **Hematol Cell Ther** 1996 Dec;38 Suppl 2:S103-7 (25 ref.)

PATHOLOGY

[Hairy cell leukemia with specific omental involvement] Volkova MA, et al. **Ter Arkh** 1996;68(7):79-82 (26 ref.) **(Rus)**

THERAPY

Second malignancy in hairy cell leukaemia: no evidence of increased incidence after treatment with interferon alpha. Pawson R, et al. **Leuk Lymphoma** 1996 Jun;22(1-2):103-6 (13 ref.)

Chronic lymphocytic leukemia and hairy-cell leukemia-diagnosis and treatment: results of a consensus meeting of the German CLL Co-operative Group [editorial] Brittinger G, et al. **Leukemia** 1997 Apr;11 Suppl 2:S1-3 (26 ref.)

LEUKEMIA L1210

DRUG THERAPY

Curative chemotherapy for acute myeloid leukemia: the development of high-dose ara-C from the laboratory to bedside. Capizzi RL. **Invest New Drugs** 1996;14(3):249-56 (34 ref.)

PATHOLOGY

[Molecular design of apoptosis inducing agents derived from bleomycin] Umezawa K, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(4):412-7 (16 ref.) (Eng. Abstr.) **(Jpn)**

LEUKEMIA, LARGE GRANULAR LYMPHOCYTIC see **LEUKEMIA, LYMPHOCYTIC**

LEUKEMIA, LYMPHOBLASTIC see **LEUKEMIA, LYMPHOCYTIC**

LEUKEMIA, LYMPHOBLASTIC, ACUTE see **LEUKEMIA, LYMPHOCYTIC, ACUTE**

LEUKEMIA, LYMPHOBLASTIC, ACUTE, L1 see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L1**

LEUKEMIA, LYMPHOBLASTIC, ACUTE, L2 see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L2**

LEUKEMIA, LYMPHOBLASTIC, ACUTE, PHILADELPHIA-POSITIVE see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L2**

LEUKEMIA, LYMPHOBLASTIC, ACUTE, T-CELL see **LEUKEMIA, T-CELL, ACUTE**

LEUKEMIA, LYMPHOBLASTIC, BURKITT-TYPE see **LEUKEMIA, B-CELL, ACUTE**

LEUKEMIA, LYMPHOBLASTIC, CHRONIC see **LEUKEMIA, LYMPHOCYTIC, CHRONIC**

LEUKEMIA, LYMPHOCYTIC

[Large granular lymphocyte leukemia] Mizuki M, et al. **Rinsho Byori** 1996 Oct;44(10):917-26 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Epstein-Barr virus (EBV)-positive NK cell line YT, and ALL/LBL of NK-lineage] Tani A, et al. **Rinsho Byori** 1996 Oct;44(10):936-43 (28 ref.) (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

The last revised "Euro-American classification" of lymphoid leukemias and non-Hodgkin's lymphomas: the same inaccuracies and inconsistencies in a chaotic complexity [editorial] Mathé G. **Biomed Pharmacother** 1996; 50(3-4):97-117 (44 ref.)

GENETICS

The non-random distribution of point mutations in leukaemia and myelodysplasia--a possible pointer to their aetiology. Parry TE. **Leuk Res** 1997 Jun;21(6):559-74 (81 ref.)

METABOLISM

Coexpression of lymphoid and myeloid markers on cell surfaces. Lefterova P, et al. **Leuk Lymphoma** 1997 Jun; 26(1-2):27-33 (68 ref.)

PATHOLOGY

Immunoperoxidase techniques in the evaluation of cutaneous lymphocytic infiltrates. Smoller BR. **Semin Cutan Med Surg** 1996 Dec;15(4):300-7 (30 ref.)

RADIOTHERAPY

Basal cell carcinoma in a girl after cobalt irradiation to the cranium for acute lymphoblastic leukemia: case report and literature review. Garcia-Silva J, et al. **Pediatr Dermatol** 1996 Jan-Feb;13(1):54-7 (13 ref.)

THERAPY

Lymphoblastic leukaemia and non-Hodgkin's lymphoma. Lilleyman JS, et al. **Br Med Bull** 1996 Oct;52(4):742-63 (95 ref.)

VIROLOGY

The human T-cell lymphotropic viruses types I/II are not involved in T prolymphocytic leukemia and large granular lymphocytic leukemia. Pawson R, et al. **Leukemia** 1997 Aug;11(8):1305-11 (34 ref.)

LEUKEMIA, LYMPHOCYTIC, ACUTE

Acute lymphoblastic leukemia in a child with the CHIME neuroectodermal dysplasia syndrome. Schnur RE, et al. **Am J Med Genet** 1997 Oct 3;72(1):24-9 (13 ref.)

Acute lymphocytic leukemia: a comprehensive review with emphasis on biology and therapy. Cortes JE, et al. **Cancer Treat Res** 1996;84:291-323 (265 ref.)

Acute leukemia in the elderly. Extermann M. **Clin Geriatr Med** 1997 May;13(2):227-44 (78 ref.)

Myelodysplasia and the leukemias. Jacobs P. **Dis Mon** 1997 Aug;43(8):505-97 (183 ref.)

BLOOD

Transfusion support in acute leukemias. Webb IJ, et al. **Semin Oncol** 1997 Feb;24(1):141-6 (72 ref.)

CLASSIFICATION

Molecular subsets and prognostic factors in acute lymphoblastic leukemia. Westbrook CA. **Leukemia** 1997 May;11 Suppl 4:S8-10 (5 ref.)

[Acute leukemia in childhood. Classification--diagnosis--therapy--prognosis] Creutzig U, et al. **Internist (Berl)** 1996 Oct;37(10):982-93 (41 ref.) **(Ger)**

COMPLICATIONS

Respiratory syncytial virus bronchiolitis in a girl undergoing chemotherapy for acute lymphoblastic leukemia: an immunologic study of local secretion. Tsutsumi H, et al. **Pediatr Infect Dis J** 1996 Jul;15(7):635-6 (12 ref.)

DIAGNOSIS

Detection of minimal residual disease in all: biology, methods, and applications. Roberts WM, et al. **Cancer Treat Res** 1996; 84:149-66 (56 ref.)

Malignant external otitis as the presentation of childhood acute lymphocytic leukemia. Pacini DL, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1132-4 (21 ref.)

[Acute lymphatic leukemia of the adult. Diagnosis, risk groups and therapy] Hoelzer D, et al. **Internist (Berl)** 1996 Oct;37(10):994-1007 (56 ref.) **(Ger)**

DRUG THERAPY

Pegaspargase: an alternative? Holle LM. **Ann Pharmacother** 1997 May;31(5):616-24 (30 ref.)

Risk-adapted treatment of adult acute lymphoblastic leukemia (ALL). Linker CA. **Leukemia** 1997 May;11 Suppl 4:S24-7 (9 ref.)

Why is age such an important independent prognostic factor in acute lymphoblastic leukemia? Perentesis JP. **Leukemia** 1997 May;11 Suppl 4:S4-7 (40 ref.)

Malignant external otitis as the presentation of childhood acute lymphocytic leukemia. Pacini DL, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1132-4 (21 ref.)

Respiratory syncytial virus bronchiolitis in a girl undergoing chemotherapy for acute lymphoblastic leukemia: an immunologic study of local secretion. Tsutsumi H, et al. **Pediatr Infect Dis J** 1996 Jul;15(7):635-6 (12 ref.)

[Neuro-cognitive sequelae during acute lymphoblastic leukemia in children (editorial)] Bader-Meunier B, et al. **Arch Pediatr** 1996 Aug;3(8):745-8 (29 ref.) **(Fre)**

[Chemotherapy of relapsed AML and ALL] Nishikawa K. **Rinsho Ketsueki** 1996 Aug;37(8):647-50 (6 ref.) **(Jpn)**

ENZYMOLOGY

Adenosine deaminase in childhood malignancy: should there be a second look? [editorial; comment] Blatt J. **Pediatr Hematol Oncol** 1996 Jul-Aug;13(4):301-3 (8 ref.) Comment on: Pediatr Hematol Oncol 1996 Jul-Aug;13(4):339-47.

GENETICS

Is genomic imprinting involved in the pathogenesis of hyperdiploid and haploid acute lymphoblastic leukemia of childhood? Haas OA. **Acta Genet Med Gemellol (Roma)** 1996;45(1-2):239-42 (18 ref.)

Dichotomy of hyperdiploid acute lymphoblastic leukemia on the basis of the distribution of gained chromosomes. Mertens F, et al. **Cancer Genet Cytogenet** 1996 Nov; 92(1):8-10 (10 ref.)

MLL fusion genes in the 11q23 acute leukemias. Downing JR, et al. **Cancer Treat Res** 1996;84:73-92 (81 ref.)

Molecular analysis of infant acute leukemia. Hilden JM, et al. **Leuk Lymphoma** 1997 Apr;25(3-4):191-9 (65 ref.)

Inactivation of cyclin-dependent kinase inhibitor genes and development of human acute leukemias. Ragione FD, et al. **Leuk Lymphoma** 1997 Mar;25(1-2):23-35 (90 ref.)

p16: at last a tumor suppressor gene involved in childhood acute lymphoblastic leukemias! [editorial] Leblanc T. **Pediatr Hematol Oncol** 1997 Mar-Apr;14(2):iii-viii (15 ref.)

[Tribulations of the p16/MTS1/CDKN2 tumor gene suppressor: a continuing saga] Larsen CJ. **Bull Cancer** 1997 Apr;84(4):427-30 (27 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Two case reports and review of vascular catheter-associated bacteremia caused by nontuberculous Mycobacterium species. Rodgers GL, et al. **Pediatr Infect Dis J** 1996 Mar; 15(3):260-4 (50 ref.)

MORTALITY

[Acute lymphoblastic leukemia in children. Progress in life expectancy] Schaison G, et al. **Presse Med** 1997 Feb 15; 26(4):178-83 (25 ref.) **(Fre)**

PATHOLOGY

The use of flow cytometry to detect minimal residual disease in acute leukemia. Campana D, et al. **Eur J Histochem** 1996; 40 Suppl 1:39-42 (19 ref.)

Lymphocytic aleukemic leukemia cutis. Taniguchi S, et al. **J Am Acad Dermatol** 1996 Nov;35(5 Pt 2):849-50 (7 ref.)

PHYSIOPATHOLOGY

Thyroid function in children treated for acute lymphoblastic leukemia. Mohn A, et al. **J Endocrinol Invest** 1997 Apr; 20(4):215-9 (25 ref.)

RADIOTHERAPY

High-dose radiation-induced meningiomas following acute lymphoblastic leukemia in children. Salvati M, et al. **Childs Nerv Syst** 1996 May;12(5):266-9 (35 ref.)

THERAPY

Adult acute leukemia. Cripe LD. **Curr Probl Cancer** 1997 Jan-Feb;21(1):1-64 (200 ref.)

The role of second bone marrow transplant using a different donor for relapsed leukemia or graft failure [letter] Lipton JH, et al. **Eur J Haematol** 1997 Feb;58(2):133-6 (27 ref.)

Graft versus leukemia (GVL) in the therapy of acute lymphoblastic leukemia (ALL). Appelbaum FR. **Leukemia** 1997 May;11 Suppl 4:S15-7 (12 ref.)

The role of allogeneic bone marrow transplantation in the treatment of high-risk acute lymphocytic leukemia in adults. Forman SJ. **Leukemia** 1997 May;11 Suppl 4:S18-9 (9 ref.)

Biologic response modifiers in acute lymphoblastic leukemia. Gribben JG, et al. **Leukemia** 1997 May;11 Suppl 4:S31-3 (16 ref.)

Use of cytokines in the treatment of acute lymphoblastic leukemia. Nemunaitis J. **Leukemia** 1997 May;11 Suppl 4:S36-7 (19 ref.)

Bone marrow transplantation in first remission. Rowe JM. **Leukemia** 1997 May;11 Suppl 4:S12-4 (23 ref.)

ALL and beyond: implications for other hematologic malignancies. Thomas ED. **Leukemia** 1997 May;11 Suppl 4:S43-5 (7 ref.)

Bone marrow transplantation for acute lymphocytic leukemia (ALL). Weisdorf DJ. **Leukemia** 1997 May;11 Suppl 4:S20-2 (13 ref.)

Treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL). Weiss MA. **Leukemia** 1997 May;11 Suppl 4:S28-30 (20 ref.)

Molecular subsets and prognostic factors in acute lymphoblastic leukemia. Westbrook CA. **Leukemia** 1997 May;11 Suppl 4:S8-10 (5 ref.)

Acute lymphoblastic leukemia. Pui CH. **Pediatr Clin North Am** 1997 Aug;44(4):831-46 (119 ref.)

[Two cases of heterologous transplantation with peripheral blood] Gómez-Almaguer D, et al. **Rev Invest Clin** 1997 Jan-Feb;49(1):41-5 (33 ref.) (Eng. Abstr.) **(Spa)**

LEUKEMIA, LYMPHOCYTIC, ACUTE, B-CELL see **LEUKEMIA, B-CELL, ACUTE**

LEUKEMIA, LYMPHOCYTIC, ACUTE, L1

Recent advances in the biology and treatment of childhood

acute lymphoblastic leukemia. Rubnitz JE, et al. **Curr Opin Hematol** 1997 Jul;4(4):233–41 (108 ref.)

COMPLICATIONS

Cutaneous mucormycosis with subsequent visceral dissemination in a child with neutropenia: a case report and review of the pediatric literature. Wirth F, et al. **J Am Acad Dermatol** 1997 Feb;36(2 Pt 2):336–41 (58 ref.)

DRUG THERAPY

Intrathecal methotrexate overdose. Lee AC, et al. **Acta Paediatr** 1997 Apr;86(4):434–7 (15 ref.)

Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia. Pieters R, et al. **Crit Rev Oncol Hematol** 1997 Jan; 25(1):11–26 (178 ref.)

Acute lymphoblastic leukaemia [see comments] Lilleyman JS. **Eur J Cancer** 1997 Jan;33(1):85–90 (66 ref.) Comment in: Eur J Cancer 1997 Jan;33(1):8–9.

Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia. Matherly LH, et al. **Leuk Lymphoma** 1996 May;21(5–6):359–68 (70 ref.)

Does pharmacokinetic variability influence the efficacy of high–dose methotrexate for the treatment of children with acute lymphoblastic leukemia: what can we learn from small studies? [comment] Evans WE, et al. **Leuk Res** 1997 May;21(5):435–7 (13 ref.) Comment on: Leuk Res 1997 May;21(5):429–34.

Why is age such an important independent prognostic factor in acute lymphoblastic leukemia? Perentesis JP. **Leukemia** 1997 May;11 Suppl 4:S4–7 (40 ref.)

[Recent advances on the treatment of acute childhood leukemia] Fujimoto T. **Gan To Kagaku Ryoho** 1997 Jul; 24(9):1059–65 (20 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Epidemiology of acute leukemia in children and adults. Sandler DP, et al. **Semin Oncol** 1997 Feb;24(1):3–16 (223 ref.)

GENETICS

Acute lymphoblastic leukemia and chromosome 21. Berger R. **Cancer Genet Cytogenet** 1997 Mar;94(1):8–12 (73 ref.)

Chromosome abnormalities in leukaemia: the 11q23 paradigm. Young BD, et al. **Cancer Surv** 1996;28:225–45 (135 ref.)

Comparison of prognostic determinants in childhood acute lymphoblastic leukaemia in negroid and Caucasian populations. Macharia WM. **East Afr Med J** 1996 Oct; 73(10):638–42 (17 ref.)

Molecular cytogenetics of t(12;21) (p13;q22). Bernard OA, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):459–65 (41 ref.)

THERAPY

Autologous versus allogeneic BMT in AML: the European experience. Report of the EBMT--Pediatric Diseases Working Party. Klingebiel T, et al. **Bone Marrow Transplant** 1996 Nov;18 Suppl 2:49–52 (12 ref.)

Which children do benefit from bone marrow transplant? The EBMT Paediatric Diseases Working Party. Niethammer D, et al. **Bone Marrow Transplant** 1996 Nov; 18 Suppl 2:43–6 (11 ref.)

Comparison of prognostic determinants in childhood acute lymphoblastic leukaemia in negroid and Caucasian populations. Macharia WM. **East Afr Med J** 1996 Oct; 73(10):638–42 (17 ref.)

Overview of clinical studies of childhood acute lymphoblastic leukemia for more than ten years by the Japanese Children's Cancer and Leukemia Study Group. Koizumi S, et al. **Pediatr Hematol Oncol** 1997 Jan–Feb; 14(1):17–28 (26 ref.)

Spindle cell carcinoma of the tongue in a long–term survivor of childhood acute lymphoblastic leukemia. Shaw MP, et al. **Pediatr Hematol Oncol** 1997 Jan–Feb;14(1):79–83 (16 ref.)

Allogeneic hematopoietic stem cell transplantation for acute leukemia. Appelbaum FR. **Semin Oncol** 1997 Feb; 24(1):114–23 (45 ref.)

[Hematopoietic stem cell transplantation for children with cancer] Ohira M. **Gan To Kagaku Ryoho** 1997 Apr; 24(6):644–9 (3 ref.) (Eng. Abstr.) **(Jpn)**

[Brief history and future prospects of treatment of childhood acute lymphocytic leukemia] Bessho F. **Rinsho Ketsueki** 1997 May;38(5):380–4 (10 ref.) **(Jpn)**

[Role of bone marrow transplantation for high risk acute lymphoblastic leukemia in children] Matsuyama T, et al. **Rinsho Ketsueki** 1997 May;38(5):406–13 (11 ref.) **(Jpn)**

VIROLOGY

Considerations on a possible viral etiology for B–precursor acute lymphoblastic leukemia of childhood. Smith M. **J Immunother** 1997 Mar;20(2):89–100 (122 ref.)

The implications for childhood leukemia of infection with adenovirus. Dorak MT. **Trends Microbiol** 1996 Feb; 4(2):60–3 (52 ref.)

LEUKEMIA, LYMPHOCYTIC, ACUTE, L2

BLOOD

Clinical and biological significance of serum tumor markers in adult T–cell leukemia. Sadamori N. **Leuk Lymphoma** 1996 Aug;22(5–6):415–9 (59 ref.)

DRUG THERAPY

Risk–adapted treatment of adult acute lymphoblastic leukemia (ALL). Linker CA. **Leukemia** 1997 May;11 Suppl 4:S24–7 (9 ref.)

Why is age such an important independent prognostic factor in acute lymphoblastic leukemia? Perentesis JP. **Leukemia** 1997 May;11 Suppl 4:S4–7 (40 ref.)

Treatment of adult acute lymphoblastic leukemia. Laport GF, et al. **Semin Oncol** 1997 Feb;24(1):70–82 (65 ref.)

GENETICS

Acute lymphoblastic leukemia and chromosome 21. Berger R. **Cancer Genet Cytogenet** 1997 Mar;94(1):8–12 (73 ref.)

METABOLISM

Beta–1–integrin expression in adult acute lymphoblastic leukemia: possible relationship with the stem cell antigen CD34. Cacciola RR, et al. **Acta Haematol** 1997; 97(1–2):63–6 (41 ref.)

PATHOLOGY

Burkitt's lymphoma–leukemia in patients treated for Hodgkin's disease. Salloum E, et al. **Cancer Invest** 1996; 14(6):527–33 (47 ref.)

Adult acute leukemia: hand mirror cell variant. Wibowo A, et al. **Hematopathol Mol Hematol** 1996;10(1–2):85–98 (47 ref.)

[Polycythemia vera progressing to acute lymphoblastic leukemia after 13 years] Arai Y, et al. **Rinsho Ketsueki** 1996 Dec;37(12):1405–9 (14 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Biology and treatment of adult acute lymphoblastic leukemia. Levitt L, et al. **West J Med** 1996 Feb;164(2):143–55 (135 ref.)

THERAPY

Allogenic bone marrow transplantation for leukemias and aplastic anemia. Tsai TW, et al. **Adv Intern Med** 1997; 42:423–51 (122 ref.)

Strategies for the treatment of recurrent acute lymphoblastic leukemia in adults. Bassan R, et al. **Haematologica** 1996 Jan–Feb;81(1):20–36 (172 ref.)

Allogeneic hematopoietic stem cell transplantation for acute leukemia. Appelbaum FR. **Semin Oncol** 1997 Feb; 24(1):114–23 (45 ref.)

LEUKEMIA, LYMPHOCYTIC, ACUTE, MIXED–CELL see **LEUKEMIA, MIXED–CELL**

LEUKEMIA, LYMPHOCYTIC, ACUTE, T–CELL see **LEUKEMIA, T–CELL, ACUTE**

LEUKEMIA, LYMPHOCYTIC, B–CELL see **LEUKEMIA, B–CELL**

LEUKEMIA, LYMPHOCYTIC, CHRONIC

ABC of clinical haematology. Malignant lymphomas and chronic lymphocytic leukaemia. Mead GM. **BMJ** 1997 Apr 12;314(7087):1103–6 (0 ref.)

Chronic lymphocytic leukemia. Kipps TJ. **Curr Opin Hematol** 1997 Jul;4(4):268–76 (120 ref.)

Chronic lymphocytic leukemia. Dighiero G, et al. **Hematol Cell Ther** 1996 Dec;38 Suppl 2:S41–61 (297 ref.)

Workshop on chronic lymphocytic leukemia and hairy cell leukemia. Results of a consensus conference of the German CLL Cooperative Group. Peer–reviewed proceedings. Berlin, Germany, February 7–10, 1996. **Leukemia** 1997 Apr; 11 Suppl 2:S1–64 (0 ref.)

COMPLICATIONS

Primary malignant tumors (lymphoma excluded) in patients with chronic lymphocytic leukemia. A series of 22 cases from a retrospective study of 248 patients. Lauvin R, et al. **Ann Med Interne (Paris)** 1996;147(6):389–92 (16 ref.)

Hypercalcemia may indicate Richter's syndrome: report of four cases and review. Beaudreuil J, et al. **Cancer** 1997 Mar 15;79(6):1211–5 (33 ref.)

Nephrotic syndrome associated with chronic lymphocytic leukemia resistant to immunosuppressive drugs: remission obtained by splenectomy [see comments] Halimi JM, et al. **Clin Nephrol** 1996 Apr;45(4):273–6 (19 ref.) Comment in: Clin Nephrol 1997 Feb;47(2):131–3.

DIAGNOSIS

Chronic lymphocytic leukemia and hairy–cell leukemia--diagnosis and treatment: results of a consensus meeting of the German CLL Cooperative Group. Brittinger G, et al. **Ann Hematol** 1997 Jun;74(6):291–4 (29 ref.)

Chronic lymphocytic leukemia and hairy–cell leukemia–diagnosis and treatment: results of a consensus meeting of the German CLL Co–operative Group [editorial] Brittinger G, et al. **Leukemia** 1997 Apr;11 Suppl 2:S1–3 (26 ref.)

DRUG THERAPY

Purine analogs in chronic lymphocytic leukemia and Waldenström's macroglobulinemia. O'Brien S, et al. **Ann Oncol** 1996;7 Suppl 6:S27–33 (53 ref.)

Clinical experience with 2'–deoxycoformycin. Catovsky D. **Hematol Cell Ther** 1996 Dec;38 Suppl 2:S103–7 (25 ref.)

Chlorambucil in chronic lymphocytic leukemia: mechanism of action. Begleiter A, et al. **Leuk Lymphoma** 1996 Oct; 23(3–4):187–201 (94 ref.)

Why do drugs work in CLL? Plunkett W, et al. **Leuk Lymphoma** 1996 Oct;22 Suppl 2:1–11 (75 ref.)

Present status of purine analogs in the therapy of chronic lymphocytic leukemias. Bergmann L. **Leukemia** 1997 Apr; 11 Suppl 2:S29–34 (77 ref.)

Purine analogs in the treatment of chronic lymphocytic leukemia. Pott C, et al. **Leukemia** 1997 Apr;11 Suppl 2:S25–8 (52 ref.)

Prophylactic strategies to meet infectious complications in fludarabine–treated CLL. Südhoff T, et al. **Leukemia** 1997 Apr;11 Suppl 2:S38–41 (38 ref.)

Current results and prospective trials of cladribine in chronic lymphocytic leukemia. Tallman MS, et al. **Semin Hematol** 1996 Jan;33(1 Suppl 1):23–7 (27 ref.)

[Treatment of chronic lymphatic leukemia] Adam Z, et al. **Vnitr Lek** 1996 Aug;42(8):573–8 (43 ref.) (Eng. Abstr.) **(Cze)**

GENETICS

Genetic abnormalities in chronic lymphocytic leukemia and their clinical and prognostic implications. Dierlamm J, et al. **Cancer Genet Cytogenet** 1997 Mar;94(1):27–35 (84 ref.)

Telomere dynamics and cytogenetic changes in human hematologic neoplasias: a working hypothesis. Ohyashiki K, et al. **Cancer Genet Cytogenet** 1997 Mar;94(1):67–72 (41 ref.)

BCL3 rearrangements and t(14;19) in chronic lymphocytic leukemia and other B–cell malignancies: a molecular and cytogenetic study. McKeithan TW, et al. **Genes Chromosomes Cancer** 1997 Sep;20(1):64–72 (38 ref.)

Cellular/cytogenetic events in CLL. Catovsky D, et al. **Leuk Lymphoma** 1996 Oct;22 Suppl 2:41–5 (9 ref.)

PATHOLOGY

The leukemic cells of chronic lymphocytic leukemia patients with autoimmune hemolytic anemia produce isotype–switched immunoglobulins that are preferentially encoded by the 51p1 and DP–50 VH genes. Efremov DG, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:443–7 (9 ref.)

Leukemic meningitis complicating early stage chronic lymphocytic leukemia. Miller K, et al. **Arch Pathol Lab Med** 1997 May;121(5):524–7 (30 ref.)

Acute liver failure due to hepatic involvement by hematologic malignancy. Shehab TM, et al. **Dig Dis Sci** 1997 Jul;42(7):1400–5 (28 ref.)

What does apoptosis mean in CLL? Binet JL, et al. **Leuk Lymphoma** 1996 Oct;22 Suppl 2:47–52 (20 ref.)

[Reactive angioendotheliomatosis in chronic lymphatic leukemia] Schmidt K, et al. **Hautarzt** 1996 Jul;47(7):550–5 (33 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Bone marrow transplantation in chronic lymphocytic leukemia and lymphomas. Pavletic ZS, et al. **Biomed Pharmacother** 1996;50(3–4):118–24 (53 ref.)

THERAPY

Bone marrow transplantation for low–grade B–cell malignancies [see comments] Gribben JG. **Curr Opin Oncol** 1997 Mar;9(2):117–21 (34 ref.) Comment in: Curr Opin Oncol 1997 Mar;9(2):115–6.

Innovative strategies for the treatment of CLL. Keating M, et al. **Leuk Lymphoma** 1996 Oct;22 Suppl 2:53–64 (15 ref.)

Current strategies for the treatment of CLL. Montserrat E, et al. **Leuk Lymphoma** 1996 Oct;22 Suppl 2:65–8 (17 ref.)

Chronic lymphocytic leukemia and hairy–cell leukemia–diagnosis and treatment: results of a consensus meeting of the German CLL Co–operative Group [editorial] Brittinger G, et al. **Leukemia** 1997 Apr;11 Suppl 2:S1–3 (26 ref.)

The role of stem cell transplantation in the treatment of chronic lymphocytic leukemia. Dreger P, et al. **Leukemia** 1997 Apr;11 Suppl 2:S42–5 (25 ref.)

Prognostic factors in chronic lymphocytic leukemia. Hallek M, et al. **Leukemia** 1997 Apr;11 Suppl 2:S4–13 (89 ref.)

First–line therapy of advanced chronic lymphocytic leukemia. Wilhelm M, et al. **Leukemia** 1997 Apr;11 Suppl 2:S14–8 (49 ref.)

[Chronic lymphatic leukemia. Progress in diagnosis and therapy] Borchmann P, et al. **Internist (Berl)** 1996 Oct; 37(10):1022–9 (51 ref.) **(Ger)**

[Treatment of chronic lymphocytic leukemia]

Niesiobędzka-Krężel J. **Pol Arch Med Wewn** 1996 Sep; 96(3):275–83 (24 ref.) **(Pol)**

LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL see **LEUKEMIA, B-CELL, CHRONIC**

LEUKEMIA, LYMPHOCYTIC, CHRONIC, T-CELL see **LEUKEMIA, T-CELL, CHRONIC**

LEUKEMIA, LYMPHOCYTIC, L3 see **LEUKEMIA, B-CELL, ACUTE**

LEUKEMIA, LYMPHOCYTIC, LARGE GRANULAR see **LEUKEMIA, LYMPHOCYTIC**

LEUKEMIA, LYMPHOCYTIC, T-CELL see **LEUKEMIA, T-CELL**

LEUKEMIA, LYMPHOID see **LEUKEMIA, LYMPHOCYTIC**

LEUKEMIA-LYMPHOMA, ADULT T-CELL see **LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED**

LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED

[Dermatologic aspects of T-cell leukemia-lymphoma in adults] Bagot M. **Ann Med Interne (Paris)** 1996; 147(8):580–1 (16 ref.) **(Fre)**

[T-cell leukemia-lymphoma in adults and other blood diseases in HTLV-I infection] Raphaël M. **Ann Med Interne (Paris)** 1996;147(8):582–5 (30 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

HTLV-I infection and adult T-cell leukemia in Brazil: an overview. de Oliveira M do S, et al. **Rev Paul Med** 1996 May-Jun;114(3):1177–85 (43 ref.)

METABOLISM

Thioredoxin/adult T-cell leukemia-derived factor (ADF) and redox regulation. Sasada T, et al. **J Toxicol Sci** 1996 Dec;21(5):285–7 (0 ref.)

[Fas antigen (CD95) expressions and apoptosis of neoplastic cells from various lymphoid malignancies including adult T-cell leukemia/lymphoma] Sasao T, et al. **Nippon Rinsho** 1996 Jul;54(7):1986–91 (23 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Vaccine against human T cell leukemia-lymphoma virus type I: progress and prospects. Bomford R, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):403–5 (34 ref.)

Attenuated poxvirus vectors as carriers in vaccines against human T cell leukemia-lymphoma virus type I. Franchini G, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20; 12(5):407–8 (21 ref.)

VIROLOGY

HTLV-I and cancers in tropical countries. Moreau JP, et al. **Eur J Cancer Prev** 1996 Oct;5(5):409–10 (8 ref.)

HAM/TSP and ATL: persistent paradoxes and new hypotheses. Xu X, et al. **J Neurovirol** 1996 Apr;2(2):60–9 (120 ref.)

LEUKEMIA-LYMPHOMA VIRUS ANTIBODIES, HUMAN T-CELL see **HTLV-BLV ANTIBODIES**

LEUKEMIA, MEGAKARYOBLASTIC, ACUTE see **LEUKEMIA, MEGAKARYOCYTIC, ACUTE**

LEUKEMIA, MEGAKARYOCYTIC see **LEUKEMIA, MEGAKARYOCYTIC, ACUTE**

LEUKEMIA, MEGAKARYOCYTIC, ACUTE

ETIOLOGY

[Werner's syndrome developing acute megakaryoblastic leukemia with der(1;7)] Yamada T, et al. **Rinsho Ketsueki** 1997 Jan;38(1):28–32 (15 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Expression of erythroid-specific genes in megakaryoblastic disorders. Ito E, et al. **Leuk Lymphoma** 1996 Nov; 23(5–6):545–50 (55 ref.)

LEUKEMIA, MIXED, B- AND T-CELL see **LEUKEMIA, MIXED-CELL**

LEUKEMIA, MIXED-CELL

CLASSIFICATION

Definition of acute biphenotypic leukemia. Matutes E, et al. **Haematologica** 1997 Jan-Feb;82(1):64–6 (10 ref.)

LEUKEMIA, MONOBLASTIC, ACUTE see **LEUKEMIA, MONOCYTIC, ACUTE**

LEUKEMIA, MONOCYTIC, ACUTE

Congenital monoblastic leukemia as a cause of third-trimester fetal loss: the role of monoclonal antibody testing. Greenbaum BH, et al. **J Perinatol** 1996 May-Jun;16(3 Pt 1):202–4 (20 ref.)

COMPLICATIONS

Hepatosplenic abscess caused by Curvularia boedijn in a patient with acute monocytic leukemia. Shigemori M, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1128–9 (11 ref.)

CONGENITAL

Spontaneous remission of congenital leukemia [see comments] Dinulos JG, et al. **J Pediatr** 1997 Aug;131(2):300–3 (17 ref.) Comment in: J Pediatr 1997 Aug;131(2):176–7.

ETIOLOGY

Secondary acute monocytic leukemia occurring during the treatment of a testicular germ cell tumor. A case report and review of the literature. Nonomura N, et al. **Urol Int** 1997;58(4):239–42 (26 ref.)

GENETICS

Translocation t(10;11) involving the MLL gene in acute myeloid leukemia. Importance of fluorescence in situ hybridization (FISH) analysis. Berger R, et al. **Ann Genet** 1996;39(3):147–51 (39 ref.)

METABOLISM

Bidirectional feedback regulation on 17 kD tumor necrosis factor (TNF) production by 26 kD membrane-bound TNF precursor. Soma IG, et al. **J Inflamm** 1995–96;47(1–2):52–60 (9 ref.)

LEUKEMIA, MONOCYTIC, CHRONIC

CONGENITAL

Spontaneous remission of congenital leukemia [see comments] Dinulos JG, et al. **J Pediatr** 1997 Aug;131(2):300–3 (17 ref.) Comment in: J Pediatr 1997 Aug;131(2):176–7.

LEUKEMIA, MYELOBLASTIC, ACUTE see **LEUKEMIA, MYELOCYTIC, ACUTE**

LEUKEMIA, MYELOCYTIC see **LEUKEMIA, MYELOID**

LEUKEMIA, MYELOCYTIC, ACUTE

Primary extramedullary leukemia of the prostate: case report and review of the literature. Quien ET, et al. **Am J Hematol** 1996 Dec;53(4):267–71 (18 ref.)

Myelodysplasia and the leukemias. Jacobs P. **Dis Mon** 1997 Aug;43(8):505–97 (183 ref.)

CLASSIFICATION

The FAB classification for acute myeloid leukaemia—is it outdated? Segeren CM, et al. **Neth J Med** 1996 Sep; 49(3):126–31 (53 ref.)

[Acute leukemia in childhood. Classification—diagnosis—therapy—prognosis] Creutzig U, et al. **Internist (Berl)** 1996 Oct;37(10):982–93 (41 ref.) **(Ger)**

COMPLICATIONS

Intrahepatic cholestasis due to systemic mastocytosis: a case report and review of literature. Safyan EL, et al. **Am J Gastroenterol** 1997 Jul;92(7):1197–200 (14 ref.)

Candida tropicalis arthritis in a patient with acute myeloid leukemia successfully treated with fluconazole: case report and review of the literature. Weers-Pothoff G, et al. **Infection** 1997 Mar-Apr;25(2):109–11 (25 ref.)

The management of acute myeloid leukaemia (AML) in human immunodeficiency virus (HIV) infection: a case report and review. Kane D, et al. **Int J STD AIDS** 1997 Apr;8(4):272–4 (13 ref.)

Fulminant septicemic syndrome of Bacillus cereus in a leukemic patient. Akiyama N, et al. **Intern Med** 1997 Mar; 36(3):221–6 (15 ref.)

Simultaneous development of Crohn's disease and myelodysplastic syndrome progressing to acute myelocytic leukemia in a patient with a normal karyotype. Tani T, et al. **J Gastroenterol** 1996 Aug;31(4):599–602 (18 ref.)

Extramedullary myeloid cell tumors in myelodysplastic-syndromes: not a true indication of impending acute myeloid leukemia. Byrd JC, et al. **Leuk Lymphoma** 1996 Mar;21(1–2):153–9 (50 ref.)

Capnocytophaga meningitis in a cancer patient. Kim JO, et al. **Pediatr Infect Dis J** 1996 Jul;15(7):636–7 (11 ref.)

Disseminated Blastoschizomyces capitatus infection in acute myeloblastic leukaemia. Report of three cases. Sanz MA, et al. **Support Care Cancer** 1996 Jul;4(4):291–3 (14 ref.)

DIAGNOSIS

Intrahepatic cholestasis due to systemic mastocytosis: a case report and review of literature. Safyan EL, et al. **Am J Gastroenterol** 1997 Jul;92(7):1197–200 (14 ref.)

DRUG THERAPY

Clinical and ethical issues in the treatment of a Jehovah's Witness with acute myeloblastic leukemia. Kerridge I, et al. **Arch Intern Med** 1997 Aug 11–25;157(15):1753–7 (26 ref.)

Design and analysis of trials of salvage therapy in acute myelogenous leukemia. Estey E, et al. **Cancer Chemother Pharmacol** 1997;40 Suppl:S9–12 (08 ref.)

Granulocytic colony-stimulating factors in the management of patients with acute myeloid leukemia. Dombret H. **Hematol Cell Ther** 1996 Jul;38(3):231–40 (92 ref.)

The management of acute myeloid leukaemia (AML) in human immunodeficiency virus (HIV) infection: a case report and review. Kane D, et al. **Int J STD AIDS** 1997 Apr;8(4):272–4 (13 ref.)

Haemopoietic growth factors, the cell cycle of acute myeloblastic leukaemia progenitors and sensitivity to cytosine arabinoside. Smith MA, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):467–72 (36 ref.)

Hematopoietic growth factors in acute leukemia. Rowe JM, et al. **Leukemia** 1997 Mar;11(3):328–41 (135 ref.)

Acute leukemia and chemotherapy: a modeling viewpoint. Afenya E. **Math Biosci** 1996 Dec;138(2):79–100 (30 ref.)

Classical multidrug resistance in acute myeloid leukaemia. Paietta E. **Med Oncol** 1997 Mar;14(1):53–60 (63 ref.)

[Recent advances on the treatment of acute childhood leukemia] Fujimoto T. **Gan To Kagaku Ryoho** 1997 Jul; 24(9):1059–65 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Progress in the treatment of adult acute myeloid leukemia] Ohno R. **Gan To Kagaku Ryoho** 1997 Jul;24(9):1053–8 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Chemotherapy of relapsed AML and ALL] Nishikawa K. **Rinsho Ketsueki** 1996 Aug;37(8):647–50 (6 ref.) **(Jpn)**

ENZYMOLOGY

Role of interleukin-1 beta converting enzyme (ICE) in acute myelogenous leukemia cell proliferation and programmed cell death. Estrov Z, et al. **Leuk Lymphoma** 1997 Feb; 24(5–6):379–91 (113 ref.)

ETIOLOGY

Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment. van Leeuwen FE. **Baillieres Clin Haematol** 1996 Mar;9(1):57–85 (115 ref.)

Eosinophilia and granulocytic dysplasia terminating in acute myeloid leukaemia after 24 years. Doordujin JK, et al. **Br J Haematol** 1996 Dec;95(3):531–4 (13 ref.)

Pre leukemic granulocytic sarcoma of vagina. A case report with review of literature. Lakshminarasimhan S, et al. **Indian J Cancer** 1996 Sep;33(3):145–8 (13 ref.)

[Three cases of secondary acute myeloid leukemia after long-term treatment with oral etoposide] Kikuta T, et al. **Rinsho Ketsueki** 1996 Nov;37(11):1276–82 (15 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Anticipation in familial leukemia [see comments] Horwitz M, et al. **Am J Hum Genet** 1996 Nov;59(5):990–8 (55 ref.) Comment in: Am J Hum Genet 1997 May;60(5):1256–7.

p190bcr/abl rearrangement in myelodysplastic syndromes: two reports and review of the literature. Lesesve JF, et al. **Br J Haematol** 1996 Nov;95(2):372–5 (34 ref.)

c-myc amplification in a preleukemia patient with trisomy 4 and double minutes: review of the unique coexistence of these two chromosome abnormalities in acute myelogenous leukemia. Reddy KS, et al. **Cancer Genet Cytogenet** 1997 Jun;95(2):206–9 (10 ref.)

Molecular genetics of inversion 16 leukemia: implications for leukemogenesis. Claxton DF, et al. **Cancer Treat Res** 1996; 84:1–18 (62 ref.)

MLL fusion genes in the 11q23 acute leukemias. Downing JR, et al. **Cancer Treat Res** 1996;84:73–92 (81 ref.)

Molecular cytogenetics of childhood acute myelogenous leukaemias. Leblanc T, et al. **Eur J Haematol** 1997 Jul; 59(1):1–13 (105 ref.)

Chromosome 16 inversion in acute myelogenous leukemias with bone marrow eosinophilia [editorial] Ueda R. **Intern Med** 1996 Apr;35(4):241–2 (12 ref.)

Significance of quantitative analysis of AML1/ETO transcripts in peripheral blood stem cells from t(8;21) acute myelogenous leukemia. Miyamoto T, et al. **Leuk Lymphoma** 1997 Mar;25(1–2):69–75 (37 ref.)

Cytokines, molecular biological abnormalities, and acute myelogenous leukemia. Preisler HD, et al. **Leuk Res** 1997 Apr;21(4):299–312 (121 ref.)

Cytosine methylation changes during normal hematopoiesis and in acute myeloid leukemia. Lübbert M, et al. **Leukemia** 1997 Mar;11 Suppl 1:S12–8 (46 ref.)

[Function of the PEBP2/CBF/AML1 genes] Satake M. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):997–1007 (35 ref.) **(Jpn)**

LEUKEMIA, MYELOCYTIC, ACUTE

IMMUNOLOGY

Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloid leukemia. Falkenburg JH, et al. **Immunol Rev** 1997 Jun;157:223–30 (71 ref.)

CD34 expression on acute myelocytic leukemia cells. Geller RB, et al. **Leuk Res** 1997 May;21(5):387–9 (15 ref.)

METABOLISM

Cytosine methylation changes during normal hematopoiesis and in acute myeloid leukemia. Lübbert M, et al. **Leukemia** 1997 Mar;11 Suppl 1:S12–8 (46 ref.)

Assays for the analysis of P-glycoprotein in acute myeloid leukemia and CD34 subsets of AML blasts. Sonneveld P, et al. **Leukemia** 1997 Jul;11(7):1160–5 (47 ref.)

PATHOLOGY

Granulocytic sarcoma of uterine cervix as presentation of acute myeloid leukemia: a case report and review of literature. Kamble R, et al. **J Obstet Gynaecol Res** 1997 Jun;23(3):261–6 (33 ref.)

Role of interleukin-1 beta converting enzyme (ICE) in acute myelogenous leukemia cell proliferation and programmed cell death. Estrov Z, et al. **Leuk Lymphoma** 1997 Feb; 24(5–6):379–91 (113 ref.)

Fas receptor (CD95)-mediated apoptosis in leukemic cells. Komada Y, et al. **Leuk Lymphoma** 1997 Mar;25(1–2):9–21 (65 ref.)

The effects of thrombopoietin on the growth of acute myeloblastic leukemia cells. Matsumura I, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):533–8 (43 ref.)

Haemopoietic growth factors, the cell cycle of acute myeloblastic leukaemia progenitors and sensitivity to cytosine arabinoside. Smith MA, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):467–72 (36 ref.)

[Growth mechanism of leukemic cells in acute myeloid leukemia] Nara N. **Rinsho Ketsueki** 1997 Apr;38(4):257–61 (20 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Stem cell renewal and determination during clonal expansion in normal and leukaemic haemopoiesis. McCulloch EA. **Cell Prolif** 1993 Sep;26(5):399–425 (240 ref.)

THERAPY

Allogenic bone marrow transplantation for leukemias and aplastic anemia. Tsai TW, et al. **Adv Intern Med** 1997; 42:423–51 (122 ref.)

Purging autologous bone marrow with monoclonal antibodies for transplantation in acute myelogenous leukemia. Hammert LC, et al. **Blood Rev** 1997 Jun; 11(2):80–90 (76 ref.)

Treatment of acute myeloblastic leukemia in adults. The GOELAM experience. Harousseau JL, et al. **Hematol Cell Ther** 1996 Oct;38(5):381–91 (38 ref.)

The EORTC trials for acute myelogenous leukemia. EORTC Leukemia Cooperative Group. European Organisation of Research and Treatment of Cancer. Zittoun R. **Hematol Cell Ther** 1996 Jul;38(3):247–52 (17 ref.)

Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloid leukemia. Falkenburg JH, et al. **Immunol Rev** 1997 Jun;157:223–30 (71 ref.)

Sclerodermatous changes of chronic graft-versus-host-disease treated with puva. Woscoff A, et al. **Int J Dermatol** 1996 Sep;35(9):656–8 (26 ref.)

[Acute myeloid leukemia] Büchner T. **Internist (Berl)** 1996 Oct;37(10):1008–12 (33 ref.) **(Ger)**

[The autotransplantation of hemopoietic progenitors in acute myeloblastic leukemia (editorial; comment)] Sierra Gil J, et al. **Med Clin (Barc)** 1997 Feb 15;108(6):221–3 (41 ref.) Comment on: Med Clin (Barc) 1997 Feb 15;108(6):201–6. **(Spa)**

[Acute myeloid leukemia. Achievements and challenges in the treatment of adults] Gruber A, et al. **Lakartidningen** 1997 Jun 25;94(26–27):2454–6, 2459–60 (34 ref.) **(Swe)**

LEUKEMIA, MYELOCYTIC, CHRONIC see **LEUKEMIA, MYELOID, CHRONIC**

LEUKEMIA, MYELOGENOUS see **LEUKEMIA, MYELOID**

LEUKEMIA, MYELOGENOUS, ACUTE see **LEUKEMIA, MYELOCYTIC, ACUTE**

LEUKEMIA, MYELOGENOUS, AGGRESSIVE-PHASE see **LEUKEMIA, MYELOID, AGGRESSIVE-PHASE**

LEUKEMIA, MYELOGENOUS, CHRONIC see **LEUKEMIA, MYELOID, CHRONIC**

LEUKEMIA, MYELOGENOUS, CHRONIC-PHASE see **LEUKEMIA, MYELOID, CHRONIC-PHASE**

LEUKEMIA, MYELOGENOUS, PH1-NEGATIVE see **LEUKEMIA, MYELOID, PHILADELPHIA-NEGATIVE**

LEUKEMIA, MYELOGENOUS, PH1-POSITIVE see **LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE**

LEUKEMIA, MYELOID

Acute leukemia in the elderly. Extermann M. **Clin Geriatr Med** 1997 May;13(2):227–44 (78 ref.)

Granulocytic sarcomas: clinical, diagnostic and therapeutical aspects. Martinelli G, et al. **Leuk Lymphoma** 1997 Jan; 24(3–4):349–53 (22 ref.)

The molecular pathogenesis of treatment-induced (secondary) leukemias: foundations for treatment and prevention. Karp JE, et al. **Semin Oncol** 1997 Feb; 24(1):103–13 (89 ref.)

[Granulocytic sarcoma as a tumor presentation of myeloid hemopathies (comment)] Tapia M, et al. **Sangre (Barc)** 1997 Feb;42(1):5–6 (14 ref.) Comment on: Sangre (Barc) 1997 Feb;42(1):73–5. Comment on: Sangre (Barc) 1997 Feb;42(1):77–80. **(Spa)**

BLOOD

Transfusion support in acute leukemias. Webb IJ, et al. **Semin Oncol** 1997 Feb;24(1):141–6 (72 ref.)

COMPLICATIONS

Paecilomyces sinusitis in an immunocompromised adult patient: case report and review. Gucalp R, et al. **Clin Infect Dis** 1996 Aug;23(2):391–3 (10 ref.)

Diabetes insipidus, acute myelogenous leukemia, and monosomy 7. Mozersky RP, et al. **J Am Osteopath Assoc** 1996 Feb;96(2):116–8 (8 ref.)

DIAGNOSIS

Diagnosis and treatment of acute myelogenous leukemia in childhood. Creutzig U. **Crit Rev Oncol Hematol** 1996 Apr; 22(3):183–96 (195 ref.)

Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count. Chan GC, et al. **Leukemia** 1997 Feb;11(2):206–11 (32 ref.)

Diagnosis and treatment of childhood acute myelogenous leukemia. Ebb DH, et al. **Pediatr Clin North Am** 1997 Aug; 44(4):847–62 (93 ref.)

[The synchronous occurrence of acute myeloid leukemia and kidney carcinoma] Bohle W, et al. **Dtsch Med Wochenschr** 1997 Jun 6;122(23):743–6 (15 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Multidrug resistance in acute myeloid leukaemia. Sonneveld P. **Baillieres Clin Haematol** 1996 Mar;9(1):185–203 (128 ref.)

Intensifying induction therapy in acute myeloid leukemia: has a new standard of care emerged? [editorial] Rowe JM, et al. **Blood** 1997 Sep 15;90(6):2121–6 (76 ref.)

Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Schiffer CA. **Blood** 1996 Nov 15;88(10):3675–85 (69 ref.)

High-dose cytosine arabinoside in the treatment of acute myeloid leukaemia. Cole N, et al. **Blood Rev** 1997 Mar; 11(1):39–45 (27 ref.)

Use of hematopoietic growth factors in the treatment of acute myelogenous leukemia. Ganser A, et al. **Curr Opin Hematol** 1997 May;4(3):191–5 (27 ref.)

Potential clinical applications of rhGM-CSF in acute myeloid leukemia based on its biologic activity and receptor interaction. Lanza F, et al. **Haematologica** 1997 Mar-Apr;82(2):239–45 (60 ref.)

Curative chemotherapy for acute myeloid leukemia: the development of high-dose ara-C from the laboratory to bedside. Capizzi RL. **Invest New Drugs** 1996;14(3):249–56 (34 ref.)

Application of myeloid growth factors in the treatment of acute myeloid leukemia. Terpstra W, et al. **Leukemia** 1997 Mar;11(3):315–27 (136 ref.)

The treatment of adult acute myeloid leukemia. Bishop JF. **Semin Oncol** 1997 Feb;24(1):57–69 (123 ref.)

[Low dose cytarabine in the treatment of acute myeloid leukemia. Apropos of 41 cases] Frikha M, et al. **Bull Cancer** 1996 Dec;83(12):996–1001 (22 ref.) (Eng. Abstr.) **(Fre)**

[Primary granulocytic sarcoma of the pancreas: efficacy of early treatment with intensive chemotherapy] Moreau P, et al. **Rev Med Interne** 1996;17(8):677–9 (12 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias". Najean Y, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:111–9 (42 ref.)

Myelodysplasia and acute myeloid leukemia occurring after autologous bone marrow transplantation for lymphoma. Traweek ST, et al. **Leuk Lymphoma** 1996 Feb; 20(5–6):365–72 (47 ref.)

Epidemiology of acute leukemia in children and adults. Sandler DP, et al. **Semin Oncol** 1997 Feb;24(1):3–16 (223 ref.)

ETIOLOGY

Myeloid leukemia after hematotoxins. Larson RA, et al. **Environ Health Perspect** 1996 Dec;104 Suppl 6:1303–7 (32 ref.)

The Charlotte Friend Memorial Lecture. The role of hematopoietic growth factors in the development and suppression of myeloid leukemias. Metcalf D. **Leukemia** 1997 Oct;11(10):1599–604 (55 ref.)

GENETICS

Molecular and cytogenetic abnormalities in acute myeloid leukaemia and myelodysplastic syndromes. de Greef GE, et al. **Baillieres Clin Haematol** 1996 Mar;9(1):1–18 (86 ref.)

Contribution of oncogenes and tumor suppressor genes to myeloid leukemia. Wolff L. **Biochim Biophys Acta** 1997 Jun 7;1332(3):F67–104 (352 ref.)

Monosomy 7 and 7q--associated with myeloid malignancy. Johnson E, et al. **Blood Rev** 1997 Mar;11(1):46–55 (127 ref.)

Robertsonian translocation as an acquired karyotypic abnormality in leukaemia. Ma SK, et al. **Br J Haematol** 1997 Jul;98(1):213–5 (12 ref.)

Chromosome abnormalities in leukaemia: the 11q23 paradigm. Young BD, et al. **Cancer Surv** 1996;28:225–45 (135 ref.)

Wilms tumor gene expression in acute myeloid leukemias. Bergmann L, et al. **Leuk Lymphoma** 1997 May; 25(5–6):435–43 (55 ref.)

Bcl-2 expression in acute myeloblastic leukaemia: relationship with autonomous growth and CD34 antigen expression. Bradbury DA, et al. **Leuk Lymphoma** 1997 Jan; 24(3–4):221–8 (48 ref.)

Molecular diagnosis and monitoring of acute myeloid leukemia. Biondi A, et al. **Leuk Res** 1996 Oct;20(10):801–7 (47 ref.)

The non-random distribution of point mutations in leukaemia and myelodysplasia--a possible pointer to their aetiology. Parry TE. **Leuk Res** 1997 Jun;21(6):559–74 (81 ref.)

Severe congenital neutropenia terminating in acute myeloid leukemia: disease progression associated with mutations in the granulocyte-colony stimulating factor receptor gene. Touw IP, et al. **Leuk Res** 1996 Aug;20(8):629–31 (20 ref.)

Molecular biology of acute myeloid leukemia. Caligiuri MA, et al. **Semin Oncol** 1997 Feb;24(1):32–44 (120 ref.)

Clinical significance of cytogenetics in acute myeloid leukemia. Mrózek K, et al. **Semin Oncol** 1997 Feb; 24(1):17–31 (93 ref.)

IMMUNOLOGY

Immunophenotyping of AML and MDS and detection of residual disease. Sanz MA, et al. **Baillieres Clin Haematol** 1996 Mar;9(1):35–55 (146 ref.)

METABOLISM

Expression and function of adhesion receptors in acute myelogenous leukemia: parallels with normal erythroid and myeloid progenitors. Liesveld JL. **Acta Haematol** 1997; 97(1–2):53–62 (108 ref.)

Wilms tumor gene expression in acute myeloid leukemias. Bergmann L, et al. **Leuk Lymphoma** 1997 May; 25(5–6):435–43 (55 ref.)

Coexpression of lymphoid and myeloid markers on cell surfaces. Lefterova P, et al. **Leuk Lymphoma** 1997 Jun; 26(1–2):27–33 (68 ref.)

PATHOLOGY

Special cytological subtypes of acute myeloid leukaemias and myelodysplastic syndromes. Castoldi G, et al. **Baillieres Clin Haematol** 1996 Mar;9(1):19–33 (55 ref.)

cAMP and 'death signals' in a myeloid leukaemia cell: from membrane receptors to nuclear responses: a review. Ruchaud S, et al. **Biochem Soc Trans** 1997 May;25(2):410–5 (56 ref.)

The use of flow cytometry to detect minimal residual disease in acute leukemia. Campana D, et al. **Eur J Histochem** 1996; 40 Suppl 1:39–42 (19 ref.)

Granulocytic sarcoma in the absence of myeloid leukemia. Sisack MJ, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):308–11 (29 ref.)

Granulocytic sarcoma of uterine cervix as presentation of acute myeloid leukemia: a case report and review of literature. Kamble R, et al. **J Obstet Gynaecol Res** 1997 Jun;23(3):261–6 (33 ref.)

Granulocytic sarcoma in acute promyelocytic leukemia [letter; comment] Benekli M, et al. **Leuk Lymphoma** 1996 Jun;22(1–2):183–6 (19 ref.) Comment on: Leuk Lymphoma 1994 Aug;14(5–6):453–6.

True histiocytic lymphoma: is it an entity? Elghetany MT. **Leukemia** 1997 May;11(5):762–4 (32 ref.)

The Charlotte Friend Memorial Lecture. The role of hematopoietic growth factors in the development and suppression of myeloid leukemias. Metcalf D. **Leukemia** 1997 Oct;11(10):1599–604 (55 ref.)

PHYSIOPATHOLOGY

Role of Bcr-Abl kinase in resistance to apoptosis. Samali A, et al. **Adv Pharmacol** 1997;41:533–52 (124 ref.)

cAMP and 'death signals' in a myeloid leukaemia cell: from membrane receptors to nuclear responses: a review. Ruchaud S, et al. **Biochem Soc Trans** 1997 May;25(2):410–5 (56 ref.)

Recent progress on the role of Axl, a receptor tyrosine kinase, in malignant transformation of myeloid leukemias. Neubauer A, et al. **Leuk Lymphoma** 1997 Mar;25(1–2):91–6 (23 ref.)

THERAPY

Treatment of the elderly patient with acute myeloid leukaemia. Löwenberg B. **Baillieres Clin Haematol** 1996 Mar;9(1):147-59 (49 ref.)

Treatment and prognostic factors in acute myeloid leukaemia. Rowe JM, et al. **Baillieres Clin Haematol** 1996 Mar; 9(1):87-105 (114 ref.)

Treatment of childhood acute myeloid leukaemia. Taub JW, et al. **Baillieres Clin Haematol** 1996 Mar;9(1):129-46 (100 ref.)

Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Anderson JE, et al. **Blood** 1997 Apr 1;89(7):2578-85 (23 ref.)

Administration of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation in children with acute myelogenous leukemia: a note of caution. Calderwood S, et al. **Bone Marrow Transplant** 1996 Jul; 18(1):87-91 (23 ref.)

The role of granulocyte- and granulocyte-macrophage-colony-stimulating factors in the treatment of acute myeloid leukaemia. Johnson PR, et al. **Br J Haematol** 1997 Apr;97(1):1-8 (48 ref.)

Acute myeloid leukaemia. Stevens RF. **Br Med Bull** 1996 Oct;52(4):764-77 (53 ref.)

Diagnosis and treatment of acute myelogenous leukemia in childhood. Creutzig U. **Crit Rev Oncol Hematol** 1996 Apr; 22(3):183-96 (195 ref.)

Adult acute leukemia. Cripe LD. **Curr Probl Cancer** 1997 Jan-Feb;21(1):1-64 (200 ref.)

Peripheral blood stem cells in acute myeloid leukemia: biology and clinical applications. Aglietta M, et al. **Haematologica** 1996 Jan-Feb;81(1):77-92 (129 ref.)

Diagnosis and treatment of childhood acute myelogenous leukemia. Ebb DH, et al. **Pediatr Clin North Am** 1997 Aug; 44(4):847-62 (93 ref.)

Allogeneic hematopoietic stem cell transplantation for acute leukemia. Appelbaum FR. **Semin Oncol** 1997 Feb; 24(1):114-23 (45 ref.)

Hematopoietic growth factors in acute myeloid leukemia: supportive and priming effects. Büchner T, et al. **Semin Oncol** 1997 Feb;24(1):124-31 (37 ref.)

Autologous bone marrow transplantation for acute myeloid leukemia. Imrie K, et al. **Stem Cells** 1996 Jan;14(1):69-78 (80 ref.)

LEUKEMIA, MYELOID, ACCELERATED-PHASE see **LEUKEMIA, MYELOID, AGGRESSIVE-PHASE**

LEUKEMIA, MYELOID, ACUTE, M1 see **LEUKEMIA, MYELOCYTIC, ACUTE**

LEUKEMIA, MYELOID, ACUTE, M2 see **LEUKEMIA, MYELOCYTIC, ACUTE**

LEUKEMIA, MYELOID, ACUTE, M3 see **LEUKEMIA, PROMYELOCYTIC, ACUTE**

LEUKEMIA, MYELOID, ACUTE, M4 see **LEUKEMIA, MYELOMONOCYTIC, ACUTE**

LEUKEMIA, MYELOID, ACUTE, M5 see **LEUKEMIA, MONOCYTIC, ACUTE**

LEUKEMIA, MYELOID, ACUTE, M6 see **LEUKEMIA, ERYTHROBLASTIC, ACUTE**

LEUKEMIA, MYELOID, ACUTE, M7 see **LEUKEMIA, MEGAKARYOCYTIC, ACUTE**

LEUKEMIA, MYELOID, AGGRESSIVE-PHASE

PATHOLOGY

[Chronic myeloid leukemia developing into a multifocal extramedullary blast crisis (see comments)] Tapia M, et al. **Sangre (Barc)** 1997 Feb;42(1):77-80 (22 ref.) (Eng. Abstr.) Comment in: Sangre (Barc) 1997 Feb;42(1):5-6. **(Spa)**

LEUKEMIA, MYELOID, CHRONIC

ABC of clinical haematology. Chronic myeloid leukaemia [published erratum appears in BMJ 1997 Mar 15;314(7083):812] Goldman J. **BMJ** 1997 Mar 1; 314(7081):657-60 (0 ref.)

Chronic myeloid leukemia. Goldman JM. **Curr Opin Hematol** 1997 Jul;4(4):277-85 (86 ref.)

Myelodysplasia and the leukemias. Jacobs P. **Dis Mon** 1997 Aug;43(8):505-97 (183 ref.)

New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia [see comments] Carella AM, et al. **Haematologica** 1997 Jul-Aug; 82(4):478-95 (176 ref.) Comment in: Haematologica 1997 Jul-Aug;82(4):385-6.

DIAGNOSIS

Clinical and biological aspects of Philadelphia-negative/BCR-negative chronic myeloid leukemia. Costello R, et al. **Leuk Lymphoma** 1997 Apr; 25(3-4):225-32 (45 ref.)

Chronic granulocytic leukemia: recent information on pathogenesis, diagnosis, and disease monitoring. Tefferi A, et al. **Mayo Clin Proc** 1997 May;72(5):445-52 (76 ref.)

DRUG THERAPY

Signal transduction-based strategies for the treatment of chronic myelogenous leukemia. Senechal K, et al. **Mol Med Today** 1996 Dec;2(12):503-9 (43 ref.)

ETIOLOGY

Chronic myelocytic leukemia following ulcerative colitis [letter] Fujisawa S, et al. **Int J Hematol** 1996 Apr; 63(3):241-2 (12 ref.)

Clinical and biological aspects of Philadelphia-negative/BCR-negative chronic myeloid leukemia. Costello R, et al. **Leuk Lymphoma** 1997 Apr; 25(3-4):225-32 (45 ref.)

GENETICS

Characterization of a complex translocation [t(4;9;22)(p16;q34;q11)] in chronic myelogenous leukemia by fluorescence in situ hybridization technique. Gudi R, et al. **Cancer Genet Cytogenet** 1996 Sep;90(2):142-5 (17 ref.)

Telomere dynamics and cytogenetic changes in human hematologic neoplasias: a working hypothesis. Ohyashiki K, et al. **Cancer Genet Cytogenet** 1997 Mar;94(1):67-72 (41 ref.)

Pathogenesis and progression of chronic myeloid leukemia. Santucci MA, et al. **Haematologica** 1996 Jan-Feb; 81(1):63-76 (64 ref.)

Chronic granulocytic leukemia: recent information on pathogenesis, diagnosis, and disease monitoring. Tefferi A, et al. **Mayo Clin Proc** 1997 May;72(5):445-52 (76 ref.)

[Chronic myeloid leukemia. Current strategies in diagnosis, therapy and follow-up] Hochhaus A, et al. **Internist (Berl)** 1996 Oct;37(10):1013-21 (30 ref.) **(Ger)**

IMMUNOLOGY

Chronic myeloid leukemia as an immunological target. Lim SH, et al. **Am J Hematol** 1997 Jan;54(1):61-7 (49 ref.)

Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloid leukemia. Falkenburg JH, et al. **Immunol Rev** 1997 Jun;157:223-30 (71 ref.)

Immunophenotypic characteristics of the blast crisis in chronic myeloid leukemia. López-Karpovitch X, et al. **Rev Invest Clin** 1997 Jan-Feb;49(1):31-6 (23 ref.)

PATHOLOGY

T-cell blast crisis in chronic myelogenous leukemia. Immunophenotypic and molecular biologic findings. Dorfman DM, et al. **Am J Clin Pathol** 1997 Feb; 107(2):168-76 (49 ref.)

Extramedullary blast transformation in a patient with chronic myelogenous leukaemia. Gebremedhin A. **Ethiop Med J** 1997 Jan;35(1):57-61 (15 ref.)

Extramedullary blast crisis in chronic myeloid leukemia. Specchia G, et al. **Leuk Res** 1996 Nov-Dec;20(11-12):905-8 (28 ref.)

Immunophenotypic characteristics of the blast crisis in chronic myeloid leukemia. López-Karpovitch X, et al. **Rev Invest Clin** 1997 Jan-Feb;49(1):31-6 (23 ref.)

PHYSIOPATHOLOGY

Chronic myelogenous leukemia: an update on the biological findings and therapeutic approaches. Ferrajoli A, et al. **Crit Rev Oncol Hematol** 1996 Apr;22(3):151-74 (253 ref.)

Pathophysiology of CML: do defects in integrin function contribute to the premature circulation and massive expansion of the BCR/ABL positive clone? Verfaillie CM, et al. **J Lab Clin Med** 1997 Jun;129(6):584-91 (52 ref.)

THERAPY

Mobilization/transplantation of Ph1-negative blood progenitor cells in chronic myelogenous leukaemia. Carella AM, et al. **Ann Oncol** 1996;7 Suppl 2:19-22 (27 ref.)

Autologous transplantation therapy for chronic myelogenous leukemia. Bhatia R, et al. **Blood** 1997 Apr 15;89(8):2623-34 (103 ref.)

Autografting for CML--overview and perspectives. Goldman JM. **Bone Marrow Transplant** 1996 May;17 Suppl 3:S71-4 (17 ref.)

Autologous stem cell transplantation for the treatment of chronic myelogenous leukemia. Bhatia R, et al. **Cancer Treat Res** 1997;77:357-74 (60 ref.)

Donor lymphocyte infusions. Giralt SA, et al. **Curr Opin Oncol** 1996 Mar;8(2):96-102 (61 ref.)

Treatment of the individual patient with chronic myelogenous leukemia [editorial; comment] **Haematologica** 1997 Jul-Aug;82(4):385-6 (8 ref.) Comment on: Haematologica 1997 Jul-Aug;82(4):478-95.

Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloid leukemia. Falkenburg JH, et al. **Immunol Rev** 1997 Jun;157:223-30 (71 ref.)

The graft-versus-leukemia effect of post-transplant donor leukocyte infusion. Johnson BD, et al. **Leuk Lymphoma** 1996 Sep;23(1-2):1-9 (65 ref.)

Multi-unit anti-BCR-ABL ribozyme therapy in chronic myelogenous leukemia. Leopold LH, et al. **Leuk Lymphoma** 1996 Aug;22(5-6):365-73 (56 ref.)

Practical guidelines for the management of chronic myelogenous leukemia with interferon alpha. O'Brien S, et al. **Leuk Lymphoma** 1996 Oct;23(3-4):247-52 (24 ref.)

[Interferon-alpha in chronic myeloid leukemia] Hehlmann R. **Fortschr Med** 1997 Mar 30;115(9):30-4, 37-8 (20 ref.) (Eng. Abstr.) **(Ger)**

[Recent progress in therapy for chronic myelogenous leukemia] Urabe A. **Gan To Kagaku Ryoho** 1997 Jul; 24(9):1066-73 (30 ref.) (Eng. Abstr.) **(Jpn)**

[Autologous hemopoietic progenitor cell transplantation in chronic myelogenous leukemia] Carreras E. **Med Clin (Barc)** 1997 Jun 28;109(5):181-5 (50 ref.) **(Spa)**

[Two cases of heterologous transplantation with peripheral blood] Gómez-Almaguer D, et al. **Rev Invest Clin** 1997 Jan-Feb;49(1):41-5 (33 ref.) (Eng. Abstr.) **(Spa)**

LEUKEMIA, MYELOID, CHRONIC-PHASE

DRUG THERAPY

Intensive combination chemotherapy in treatment of CML. Lengfelder E, et al. **Bone Marrow Transplant** 1996 May; 17 Suppl 3:S55-7 (19 ref.)

THERAPY

Cytokine therapy for hematological malignancies. Ezaki K, et al. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:182-94 (50 ref.)

LEUKEMIA, MYELOID, NAEGELI-TYPE see **LEUKEMIA, MYELOMONOCYTIC, ACUTE**

LEUKEMIA, MYELOID, PH1-NEGATIVE see **LEUKEMIA, MYELOID, PHILADELPHIA-NEGATIVE**

LEUKEMIA, MYELOID, PH1-POSITIVE see **LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE**

LEUKEMIA, MYELOID, PHILADELPHIA-NEGATIVE

see related
PHILADELPHIA CHROMOSOME

DIAGNOSIS

Clinical and biological aspects of Philadelphia-negative/BCR-negative chronic myeloid leukemia. Costello R, et al. **Leuk Lymphoma** 1997 Apr; 25(3-4):225-32 (45 ref.)

PATHOLOGY

Mobilization/transplantation of Ph1-negative blood progenitor cells in chronic myelogenous leukaemia. Carella AM, et al. **Ann Oncol** 1996;7 Suppl 2:19-22 (27 ref.)

LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE

see related
PHILADELPHIA CHROMOSOME

Biology and treatment of chronic myeloid leukemia. Jones RJ. **Curr Opin Oncol** 1997 Jan;9(1):3-7 (41 ref.)

DRUG THERAPY

Current aspects of drug therapy in Philadelphia-positive CML: correlation of tumor burden with survival. Hehlmann R, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:161-7 (42 ref.)

GENETICS

Pathogenesis and progression of chronic myeloid leukemia. Santucci MA, et al. **Haematologica** 1996 Jan-Feb; 81(1):63-76 (64 ref.)

A coiled-coil tetramerization domain of BCR-ABL is essential for the interactions of SH2-containing signal transduction molecules. Tauchi T, et al. **Hum Cell** 1996 Dec;9(4):333-6 (18 ref.)

PATHOLOGY

Integrin-mediated regulation of hematopoiesis: do BCR/ABL-induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors? Verfaillie CM, et al. **Acta Haematol** 1997; 97(1-2):40-52 (160 ref.)

New understanding of the pathogenesis of CML: a prototype of early neoplasia. Clarkson BD, et al. **Leukemia** 1997 Sep; 11(9):1404-28 (179 ref.)

Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD). Murphy S. **Thromb Haemost** 1997 Jul;78(1):622-6 (46 ref.)

THERAPY

The management of chronic myeloid leukaemia--a case

LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE

history. Sureda A, et al. **Ann Oncol** 1997 Jan;8(1):91–6 (33 ref.)

Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in children: experience of eight European Countries. The EBMT Paediatric Diseases Working Party. Dini G, et al. **Bone Marrow Transplant** 1996 Nov;18 Suppl 2:80–5 (13 ref.)

Rationalizing autotransplant strategies for chronic myeloid leukemia. Daley GQ. **Leuk Lymphoma** 1996 May; 21(5–6):353–8 (39 ref.)

[Recent progress in therapy for chronic myelogenous leukemia] Urabe A. **Gan To Kagaku Ryoho** 1997 Jul; 24(9):1066–73 (30 ref.) (Eng. Abstr.) **(Jpn)**

LEUKEMIA, MYELOID, SCHILLING-TYPE see **LEUKEMIA, MONOCYTIC, ACUTE**

LEUKEMIA, MYELOID, STABLE-PHASE see **LEUKEMIA, MYELOID, CHRONIC-PHASE**

LEUKEMIA, MYELOMONOCYTIC, ACUTE

CONGENITAL

Spontaneous remission of congenital leukemia [see comments] Dinulos JG, et al. **J Pediatr** 1997 Aug;131(2):300–3 (17 ref.) Comment in: J Pediatr 1997 Aug;131(2):176–7.

DRUG THERAPY

Tretinoin tocoferil as a possible differentiation-inducing agent against myelomonocytic leukemia. Makishima M, et al. **Leuk Lymphoma** 1997 Jun;26(1–2):43–8 (55 ref.)

GENETICS

The biological significance of the multidrug resistance gene MRP in inversion 16 leukemias. Kuss BJ, et al. **Leuk Lymphoma** 1996 Feb;20(5–6):357–64 (34 ref.)

LEUKEMIA, MYELOMONOCYTIC, CHRONIC

Juvenile myelomonocytic leukemia. Aricò M, et al. **Blood** 1997 Jul 15;90(2):479–88 (103 ref.)

[Chronic myelomonocytic leukemia and renal carcinoma: a rare association (letter)] Fernández-Escribano M, et al. **Sangre (Barc)** 1997 Feb;42(1):88–9 (5 ref.) **(Spa)**

DIAGNOSIS

Chronic myelomonocytic leukemia: from biology to therapy. Cambier N, et al. **Hematol Cell Ther** 1997 Apr;39(2):41–8 (115 ref.)

EPIDEMIOLOGY

Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Niemeyer CM, et al. **Blood** 1997 May 15; 89(10):3534–43 (68 ref.)

GENETICS

Monosomy X as a recurring sole cytogenetic abnormality associated with myelodysplastic diseases. Abruzzese E, et al. **Cancer Genet Cytogenet** 1997 Feb;93(2):140–6 (41 ref.)

METABOLISM

Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy. Emanuel PD, et al. **Mol Med Today** 1996 Nov;2(11):468–75 (40 ref.)

PATHOLOGY

Specific skin infiltration as first sign of chronic myelomonocytic leukemia with an unusual phenotype. Braga D, et al. **J Am Acad Dermatol** 1996 Nov;35(5 Pt 2):804–7 (17 ref.)

THERAPY

Chronic myelomonocytic leukemia: from biology to therapy. Cambier N, et al. **Hematol Cell Ther** 1997 Apr;39(2):41–8 (115 ref.)

LEUKEMIA, NEUTROPHILIC, CHRONIC

[Chronic neutrophilic leukemia] Gastearena J, et al. **Sangre (Barc)** 1995 Dec;40(6):499–503 (62 ref.) **(Spa)**

LEUKEMIA, NONLYMPHOBLASTIC, ACUTE see **LEUKEMIA, NONLYMPHOCYTIC, ACUTE**

LEUKEMIA, NONLYMPHOCYTIC, ACUTE

DRUG THERAPY

Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia. Dunn CJ, et al. **Drugs Aging** 1996 Aug;9(2):122–47 (132 ref.)

GENETICS

Monosomy X as a recurring sole cytogenetic abnormality associated with myelodysplastic diseases. Abruzzese E, et al. **Cancer Genet Cytogenet** 1997 Feb;93(2):140–6 (41 ref.)

Translocation t(8;16)(p11;p13) in acute non-lymphocytic leukemia: report on two new cases and review of the literature. Velloso ER, et al. **Leuk Lymphoma** 1996 Mar; 21(1–2):137–42 (33 ref.)

LEUKEMIA, PLASMA-CELL see **LEUKEMIA, PLASMACYTIC**

LEUKEMIA, PLASMACYTIC

Plasma cell leukemia. A report on 11 patients and review of the literature. Pasqualetti P, et al. **Panminerva Med** 1996 Sep;38(3):179–84 (30 ref.)

DIAGNOSIS

The medium cell sIg+, proplasmocytic lymphoma/leukemia. Positive and differential diagnosis with other B-lymphoblastoid neoplasias [editorial] Mathé G, et al. **Biomed Pharmacother** 1996;50(9):425–32 (23 ref.)

GENETICS

Non-random chromosomal rearrangements and their implications in clinical features and outcome of multiple myeloma and plasma cell leukemia. Taniwaki M, et al. **Leuk Lymphoma** 1996 Mar;21(1–2):25–30 (39 ref.)

IMMUNOLOGY

Fas/Apo-1 (CD95)-mediated and CD95-independent apoptosis of malignant plasma cells. Hata H, et al. **Leuk Lymphoma** 1996 Dec;24(1–2):35–42 (21 ref.)

LEUKEMIA, PRE-B-CELL

GENETICS

E2A-Pbx1 induces growth, blocks differentiation, and interacts with other homeodomain proteins regulating normal differentiation. Kamps MP. **Curr Top Microbiol Immunol** 1997;220:25–43 (68 ref.)

E2A-HLF chimeric transcription factors in pro-B cell acute lymphoblastic leukemia. Look AT. **Curr Top Microbiol Immunol** 1997;220:45–53 (54 ref.)

VIROLOGY

Considerations on a possible viral etiology for B-precursor acute lymphoblastic leukemia of childhood. Smith M. **J Immunother** 1997 Mar;20(2):89–100 (122 ref.)

LEUKEMIA, PROGRANULOCYTIC see **LEUKEMIA, PROMYELOCYTIC, ACUTE**

LEUKEMIA, PROLYMPHOCYTIC

Current approach to the biology and treatment of chronic lymphoid malignancies other than CLL. Catovsky D. **Hematol Cell Ther** 1996 Dec;38 Suppl 2:S63–6 (27 ref.)

GENETICS

[Oncogenesis of T-cell prolymphocytic leukemia (editorial)] Stern MH. **Pathol Biol (Paris)** 1996 Oct;44(8):689–93 (16 ref.) (Eng. Abstr.) **(Fre)**

VIROLOGY

The human T-cell lymphotropic viruses types I/II are not involved in T prolymphocytic leukemia and large granular lymphocytic leukemia. Pawson R, et al. **Leukemia** 1997 Aug;11(8):1305–11 (34 ref.)

LEUKEMIA, PROMYELOCYTIC, ACUTE

BLOOD

[Apoptosis in leukemic cell proliferation and differentiation] Terui Y, et al. **Rinsho Ketsueki** 1996 Jul;37(7):547–51 (11 ref.) **(Jpn)**

COMPLICATIONS

Tranexamic acid in oncology. Seto AH, et al. **Ann Pharmacother** 1996 Jul-Aug;30(7–8):868–70 (11 ref.)

Acute promyelocytic leukaemia in the all trans retinoic acid era. DeLoughery TG, et al. **Med Oncol** 1996 Dec; 13(4):233–40 (107 ref.)

DRUG THERAPY

Treatment of acute promyelocytic leukaemia. Fenaux P, et al. **Baillieres Clin Haematol** 1996 Mar;9(1):107–28 (103 ref.)

Rare but important adverse effects of all-trans retinoic acid in acute promyelocytic leukemia and their management. Hatake K, et al. **Int J Hematol** 1997 Jul;66(1):13–9 (46 ref.)

Retinoid resistance in leukemic cells. Kizaki M, et al. **Leuk Lymphoma** 1997 May;25(5–6):427–34 (42 ref.)

Acute promyelocytic leukaemia in the all trans retinoic acid era. DeLoughery TG, et al. **Med Oncol** 1996 Dec; 13(4):233–40 (107 ref.)

Acute promyelocytic leukemia: biology and treatment. Fenaux P, et al. **Semin Oncol** 1997 Feb;24(1):92–102 (114 ref.)

[All-trans retinoic acid therapy in acute promyelocytic leukemia--current status and prospect] Kitamura K, et al. **Rinsho Ketsueki** 1996 Sep;37(9):760–5 (15 ref.) **(Jpn)**

[Acute promyelocytic leukemia: model of differential therapy] Samochatova EV, et al. **Gematol Transfuziol** 1996 Mar-Apr;41(2):29–32 (40 ref.) **(Rus)**

ENZYMOLOGY

Leukocyte alkaline phosphatase a specific marker for the post-mitotic neutrophilic granulocyte: regulation in acute promyelocytic leukemia. Garattini E, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):493–503 (73 ref.)

ETIOLOGY

The biologic function of PML and its role in acute promyelocytic leukemia. Mu ZM, et al. **Leuk Lymphoma** 1996 Oct;23(3–4):277–85 (55 ref.)

GENETICS

The PML nuclear compartment and cancer. Doucas V, et al. **Biochim Biophys Acta** 1996 Dec 9;1288(3):M25–9 (38 ref.)

Characterisation of the PML/RAR alpha rearrangement associated with t(15;17) acute promyelocytic leukaemia. Grimwade D, et al. **Curr Top Microbiol Immunol** 1997; 220:81–112 (153 ref.)

PML, PLZF and NPM genes in the molecular pathogenesis of acute promyelocytic leukemia. Pandolfi PP. **Haematologica** 1996 Sep-Oct;81(5):472–82 (86 ref.)

Variant and masked translocations in acute promyelocytic leukemia. Brunel V, et al. **Leuk Lymphoma** 1996 Jul; 22(3–4):221–8 (68 ref.)

METABOLISM

Clinical relevance of all-trans retinoic acid pharmacokinetics and its modulation in acute promyelocytic leukemia. Lazzarino M, et al. **Leuk Lymphoma** 1996 Nov; 23(5–6):539–43 (45 ref.)

PATHOLOGY

Extramedullary acute promyelocytic leukemia [see comments] Wiernik PH, et al. **Cancer** 1996 Dec 15; 78(12):2510–4 (33 ref.) Comment in: Cancer 1997 Jun 1;79(11):2263–4. Comment in: Cancer 1997 Aug 1;80(3):518–9.

Biology and treatment of acute promyelocytic leukemia [see comments] Fenaux P, et al. **Curr Opin Oncol** 1996 Jan; 8(1):3–12 (89 ref.) Comment in: Curr Opin Oncol 1996 Jan;8(1):1–2.

Granulocytic sarcoma in acute promyelocytic leukemia [letter; comment] Benekli M, et al. **Leuk Lymphoma** 1996 Jun;22(1–2):183–6 (19 ref.) Comment on: Leuk Lymphoma 1994 Aug;14(5–6):453–6.

[Mechanisms of retinoid resistance in leukemic cells] Kizaki M, et al. **Rinsho Ketsueki** 1996 Sep;37(9):766–9 (16 ref.) **(Jpn)**

THERAPY

Biology and treatment of acute promyelocytic leukemia [see comments] Fenaux P, et al. **Curr Opin Oncol** 1996 Jan; 8(1):3–12 (89 ref.) Comment in: Curr Opin Oncol 1996 Jan;8(1):1–2.

[Progresses in hematology in China, 1996] Chen Z, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Dec;76(12):888–9 (0 ref.) **(Chi)**

LEUKEMIA, RADIATION-INDUCED

see related
NEOPLASMS, SECOND PRIMARY

EPIDEMIOLOGY

Epidemiological appraisal of studies of residential exposure to power frequency magnetic fields and adult cancers. Li CY, et al. **Occup Environ Med** 1996 Aug;53(8):505–10 (28 ref.)

ETIOLOGY

Occupational exposure to electromagnetic fields and adult leukaemia: a review of the epidemiological evidence. Feychting M. **Radiat Environ Biophys** 1996 Nov; 35(4):237–42 (32 ref.)

Magnetic fields and leukemia--risk for adults living close to power lines. Verkasalo PK. **Scand J Work Environ Health** 1996;22 Suppl 2:1–56 (145 ref.)

LEUKEMIA, T-CELL

DRUG THERAPY

Treatment with a combination of zidovudine and

alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients. Bazarbachi A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S186-90 (16 ref.)

[T-cell large granular lymphocytic leukemia associated with pure red cell aplasia, successfully treated with cyclophosphamide] Mátrai Z, et al. **Orv Hetil** 1997 Aug 17;138(33):2075-80 (45 ref.) (Eng. Abstr.) **(Hun)**

GENETICS

Transgenic mouse models for HTLV-I infection. Grossman WJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S162-9 (99 ref.)

Immunogenetics of HTLV-I/II and associated diseases. Sonoda S, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S119-23 (38 ref.)

IMMUNOLOGY

A new immunobiological view of radiation-promoted lymphomagenesis. Coggin JH Jr, et al. **Int J Radiat Biol** 1997 Jan;71(1):81-94 (14 ref.)

An HTLV-I/II vaccine: from animal models to clinical trials? de Thé G, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S191-8 (48 ref.)

[Adult T-cell leukemia and adhesion molecules] Imura A, et al. **Rinsho Byori** 1996 Sep;Suppl 102:216-21 (21 ref.) **(Jpn)**

METABOLISM

ATL and HTLV-I: in vivo cell growth of ATL cells. Uchiyama T. **J Clin Immunol** 1996 Nov;16(6):305-14 (105 ref.)

[Adult T cell leukemia (ATL)] Matsuzaki H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):135-8 (18 ref.) **(Jpn)**

PATHOLOGY

ATL and HTLV-I: in vivo cell growth of ATL cells. Uchiyama T. **J Clin Immunol** 1996 Nov;16(6):305-14 (105 ref.)

PHYSIOPATHOLOGY

[Pathophysiology of ATL from the aspect of apoptosis] Tsuda H. **Rinsho Ketsueki** 1996 Jul;37(7):558-63 (16 ref.) **(Jpn)**

THERAPY

The promiscuous IL-2/IL-15 receptor: a target for immunotherapy of HTLV-I-associated disorders. Waldmann TA. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S179-85 (43 ref.)

VIROLOGY

Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients. Bazarbachi A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S186-90 (16 ref.)

An HTLV-I/II vaccine: from animal models to clinical trials? de Thé G, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S191-8 (48 ref.)

Transgenic mouse models for HTLV-I infection. Grossman WJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S162-9 (99 ref.)

Adult T-cell leukemia in Japan. Takatsuki K, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S15-9 (38 ref.)

The promiscuous IL-2/IL-15 receptor: a target for immunotherapy of HTLV-I-associated disorders. Waldmann TA. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S179-85 (43 ref.)

LEUKEMIA, T-CELL, ACUTE

COMPLICATIONS

Adult T-cell leukemia with multiple lymphomatous polyposis of the gastrointestinal tract. Itsuno M, et al. **Endoscopy** 1995 Nov;27(9):700-3 (24 ref.)

GENETICS

Transcription factors of the bHLH and LIM families: synergistic mediators of T cell acute leukemia? Baer R, et al. **Curr Top Microbiol Immunol** 1997;220:55-65 (58 ref.)

Molecular biology of acute lymphocytic leukemia. Thandla S, et al. **Semin Oncol** 1997 Feb;24(1):45-56 (94 ref.)

PATHOLOGY

T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL). Bunn PA Jr, et al. **J Cell Biochem Suppl** 1996;24:12-23 (125 ref.)

LEUKEMIA, T-CELL, CHRONIC

IMMUNOLOGY

Chronic lymphatic leukemias of T and NK cell type. Kingreen D, et al. **Leukemia** 1997 Apr;11 Suppl 2:S46-9 (36 ref.)

PATHOLOGY

The pathology of the chronic lymphoid leukaemias. Kroft SH, et al. **Blood Rev** 1995 Dec;9(4):234-50 (120 ref.)

LEUKEMIA VIRUS ANTIBODIES, HUMAN T-CELL see **HTLV-BLV ANTIBODIES**

LEUKEMIA VIRUS, BOVINE

Experiences with the New York State Bovine Leukosis Virus Eradication and Certification Program. Brunner MA, et al. **Vet Clin North Am Food Anim Pract** 1997 Mar; 13(1):143-50 (2 ref.)

Natural transmission of bovine leukemia virus in dairy and beef cattle. Hopkins SG, et al. **Vet Clin North Am Food Anim Pract** 1997 Mar;13(1):107-28 (131 ref.)

Economics of bovine leukemia virus infection. Pelzer KD. **Vet Clin North Am Food Anim Pract** 1997 Mar;13(1):129-41 (43 ref.)

IMMUNOLOGY

T cell-mediated destruction of bovine leukemia virus-infected peripheral lymphocytes by bovine leukemia virus env-vaccinia recombinant vaccine. Ohishi K, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):393-8 (18 ref.)

Detrimental effect of bovine leukemia virus (BLV) on the immunological state of cattle. Trainin Z, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1-4):293-302 (34 ref.)

LEUKEMIA VIRUS, FELINE

Cooperating events in lymphomagenesis mediated by feline leukemia virus. Levy LS, et al. **Leukemia** 1997 Apr;11 Suppl 3:239-41 (16 ref.)

GENETICS

Viral genetic variation, AIDS, and the multistep nature of carcinogenesis: the feline leukemia virus model. Rohn JL, et al. **Leukemia** 1996 Dec;10(12):1867-9 (31 ref.)

Endogenous env elements: partners in generation of pathogenic feline leukemia viruses. Roy-Burman P. **Virus Genes** 1995;11(2-3):147-61 (107 ref.)

IMMUNOLOGY

Efficacy of an inactivated feline leukemia virus vaccine. Hoover EA, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):379-83 (53 ref.)

The relevance of feline retroviruses to the development of vaccines against HIV. Jarrett O. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):385-7 (23 ref.)

Efficacy of recombinant feline leukemia virus vaccines. Jarrett O. **AIDS Res Hum Retroviruses** 1996 Mar 20; 12(5):435-6 (14 ref.)

Feline leukaemia virus: a review of immunity and vaccination. Sparkes AH. **J Small Anim Pract** 1997 May; 38(5):187-94 (49 ref.)

The potential role and mechanisms of FeLV vaccine-induced neoplasms. Macy DW. **Semin Vet Med Surg (Small Anim)** 1995 Nov;10(4):234-7 (36 ref.)

ISOLATION & PURIFICATION

FIV, FeLV, and FIPV: interpretation and misinterpretation of serological test results. Barr MC. **Semin Vet Med Surg (Small Anim)** 1996 Aug;11(3):144-53 (34 ref.)

PATHOGENICITY

Cytopathic feline leukemia viruses cause apoptosis in hemolymphatic cells. Rojko JL, et al. **Prog Mol Subcell Biol** 1996;16:13-43 (150 ref.)

LEUKEMIA VIRUS I, HUMAN T-CELL see **HTLV-I**

LEUKEMIA VIRUS II, HUMAN T-CELL see **HTLV-II**

LEUKEMIA VIRUSES, HUMAN T-CELL see **HTLV-BLV VIRUSES**

LEUKEMIA VIRUSES, MURINE

IMMUNOLOGY

Correlates of immune protection after vaccination with attenuated live murine leukemia virus. Ruprecht RM, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):375-7 (14 ref.)

The role of the immune response in MULV-induced lymphomagenesis. Marshall DJ, et al. **Leukemia** 1996 Dec; 10(12):1860-6 (79 ref.)

PHYSIOLOGY

Targeting antiviral nucleotide analogues to macrophages. Magnani M, et al. **J Leukoc Biol** 1997 Jul;62(1):133-7 (32 ref.)

LEUKEMIC GENE EXPRESSION REGULATION see **GENE EXPRESSION REGULATION, LEUKEMIC**

LEUKEMIC INFILTRATION

Specific skin infiltration as first sign of chronic myelomonocytic leukemia with an unusual phenotype. Braga D, et al. **J Am Acad Dermatol** 1996 Nov;35(5 Pt 2):804-7 (17 ref.)

Granulocytic sarcoma of uterine cervix as presentation of acute myeloid leukemia: a case report and review of literature. Kamble R, et al. **J Obstet Gynaecol Res** 1997 Jun;23(3):261-6 (33 ref.)

[Leukemic infiltration of the pericardium] Shibata K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):289-90 (6 ref.) **(Jpn)**

PATHOLOGY

Extramedullary acute promyelocytic leukemia [see comments] Wiernik PH, et al. **Cancer** 1996 Dec 15; 78(12):2510-4 (33 ref.) Comment in: Cancer 1997 Jun 1;79(11):2263-4. Comment in: Cancer 1997 Aug 1;80(3):518-9.

Peritumoral B cell infiltrate associated with chronic lymphocytic leukemia obscuring margin evaluation during Mohs micrographic surgery [letter] Humphreys TR, et al. **Dermatol Surg** 1996 Oct;22(10):894-6 (21 ref.)

Granulocytic sarcoma in acute promyelocytic leukemia [letter; comment] Benekli M, et al. **Leuk Lymphoma** 1996 Jun;22(1-2):183-6 (19 ref.) Comment on: Leuk Lymphoma 1994 Aug;14(5-6):453-6.

Immunoperoxidase techniques in the evaluation of cutaneous lymphocytic infiltrates. Smoller BR. **Semin Cutan Med Surg** 1996 Dec;15(4):300-7 (30 ref.)

[Hairy cell leukemia with specific omental involvement] Volkova MA, et al. **Ter Arkh** 1996;68(7):79-82 (26 ref.) **(Rus)**

LEUKEMIC RETICULOENDOTHELIOSIS see **LEUKEMIA, HAIRY CELL**

LEUKEMOGENIC VIRUSES see **RETROVIRIDAE**

LEUKEMOID REACTION

COMPLICATIONS

Undifferentiated carcinoma of the nasopharynx and leukemoid reaction: report of case with literature review. Saussez S, et al. **J Laryngol Otol** 1997 Jan;111(1):66-9 (12 ref.)

LEUKOCYTAPHERESIS see **LEUKAPHERESIS**

LEUKOCYTE-ADHESION DEFICIENCY SYNDROME

Leukocyte adhesion defects. Etzioni A. **Arch Immunol Ther Exp (Warsz)** 1997;45(1):31-6 (23 ref.)

[Disorders of neutrophil function] Komiyama A. **Rinsho Ketsueki** 1996 Jun;37(6):497-501 (14 ref.) **(Jpn)**

COMPLICATIONS

[Infection and adhesion molecules] Kobayashi K. **Rinsho Byori** 1996 Sep;Suppl 102:191-7 (19 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Bovine leucocyte adhesion deficiency: a review of a modern disease and its implications. Gerardi AS. **Res Vet Sci** 1996 Nov;61(3):183-6 (18 ref.)

VETERINARY

Bovine leukocyte adhesion deficiency: a brief overview of a modern disease and its implications. Gerardi AS. **Acta Vet Hung** 1996;44(1):1-8 (18 ref.)

Bovine leucocyte adhesion deficiency: a review of a modern disease and its implications. Gerardi AS. **Res Vet Sci** 1996 Nov;61(3):183-6 (18 ref.)

LEUKOCYTE ADHESION INHIBITOR see **INTERLEUKIN-8**

LEUKOCYTE ADHESION MOLECULES see **CELL ADHESION MOLECULES**

LEUKOCYTE ADHESION PROTEIN P150,95 see **ANTIGEN P150,95**

LEUKOCYTE-ADHESION RECEPTORS

LEUKOCYTE-ADHESION RECEPTORS see **RECEPTORS, LEUKOCYTE-ADHESION**

LEUKOCYTE ANTIGENS see **HLA ANTIGENS**

LEUKOCYTE COMMON ANTIGENS see **ANTIGENS, CD45**

LEUKOCYTE COUNT

Eosinophil density: what does it mean? [editorial] Wardlaw A. **Clin Exp Allergy** 1995 Dec;25(12):1145–9 (43 ref.)

LEUKOCYTE COUNT, DIFFERENTIAL see **LEUKOCYTE COUNT**

LEUKOCYTE DIFFERENTIATION ANTIGENS, HUMAN see **ANTIGENS, CD**

LEUKOCYTE ELASTASE

ANTAGONISTS & INHIBITORS

Use of secretory leukoprotease inhibitor to augment lung antineutrophil elastase activity. Vogelmeier C, et al. **Chest** 1996 Dec;110(6 Suppl):261S–266S (58 ref.)

Therapeutic potential of neutrophil-elastase inhibition in pulmonary disease. Vender RL. **J Investig Med** 1996 Dec; 44(9):531–9 (88 ref.)

GENETICS

[Structure and expression of the human neutrophil elastase gene--regulatory mechanism and its relevance to the respiratory diseases] Yoshimura K, et al. **Nippon Rinsho** 1996 Feb;54(2):396–404 (24 ref.) (Eng. Abstr.) **(Jpn)**

LEUKOCYTE FUNCTION ASSOCIATED ANTIGEN-1 see **LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1**

LEUKOCYTE MIGRATION INHIBITION TESTS see **CELL MIGRATION INHIBITION**

LEUKOCYTE MIGRATION TEST see **CELL MIGRATION INHIBITION**

LEUKOCYTE NUMBER see **LEUKOCYTE COUNT**

LEUKOCYTE TRANSFUSION

see related
LYMPHOCYTE TRANSFUSION

Donor leukocyte infusions for relapsed leukemia after allogeneic BMT. Mackinnon S. **Hematol Cell Ther** 1996 Oct;38(5):461–2 (5 ref.)

Granulocyte transfusions. Time for a second look. Chanock SJ, et al. **Infect Dis Clin North Am** 1996 Jun;10(2):327–43 (66 ref.)

The graft-versus-leukemia effect of post-transplant donor leukocyte infusion. Johnson BD, et al. **Leuk Lymphoma** 1996 Sep;23(1–2):1–9 (65 ref.)

[Immunological effects of erythrocyte and leukocyte transfusion. Work Group Blood Group Serology of the Medical Advisory Commission of the College for Blood Transfusion of the Netherlands Red Cross] Brand A, et al. **Ned Tijdschr Geneeskd** 1997 Jan 18;141(3):136–40 (36 ref.) (Eng. Abstr.) **(Dut)**

[Present status of donor leukocyte transfusion for leukemia. Relapse after allogeneic bone marrow transplantation in Japan] Morishima Y, et al. **Rinsho Ketsueki** 1997 Jun; 38(6):476–8 (9 ref.) **(Jpn)**

LEUKOCYTES

see related
PHAGOCYTOSIS

CHEMISTRY

EGF-TM7: a novel subfamily of seven-transmembrane-region leukocyte cell-surface molecules. McKnight AJ, et al. **Immunol Today** 1996 Jun; 17(6):283–7 (32 ref.)

Ectodomain interactions of leukocyte integrins and pro-inflammatory GPI-linked membrane proteins. Petty HR, et al. **J Pharm Biomed Anal** 1997 Jun;15(9–10):1405–16 (94 ref.)

[Analysis of aromatic DNA adducts in inhabitants of Upper Silesia] Grzybowska E. **Postepy Hig Med Dosw** 1997; 51(2):185–203 (58 ref.) (Eng. Abstr.) **(Pol)**

CYTOLOGY

Leukocyte-endothelial adhesion and angiogenesis in tumors. Jain RK, et al. **Cancer Metastasis Rev** 1996 Jun; 15(2):195–204 (63 ref.)

Leukocyte adhesion--structure and function of human leukocyte beta2-integrins and their cellular ligands. Gahmberg CG, et al. **Eur J Biochem** 1997 Apr 15; 245(2):215–32 (226 ref.)

Adhesive proteins at endothelial cell-to-cell junctions and leukocyte extravasation. Dejana E, et al. **Haemostasis** 1996 Oct;26 Suppl 4:210–9 (54 ref.)

Regulation of leukocyte integrin function: affinity vs. avidity. Stewart M, et al. **J Cell Biochem** 1996 Jun 15;61(4):554–61 (54 ref.)

What do we at present know about the ALCAT test and what is lacking? Bindslev-Jensen C, et al. **Monogr Allergy** 1996;32:228–32 (5 ref.)

The hematopoietic development of dendritic cells: a distinct pathway for myeloid differentiation. Young JW, et al. **Stem Cells** 1996 Jul;14(4):376–87 (77 ref.)

DRUG EFFECTS

Anti-adhesion therapy. Cornejo CJ, et al. **Adv Pharmacol** 1997;39:99–142 (200 ref.)

ENZYMOLOGY

Leukocyte protein tyrosine kinases: potential targets for drug discovery. Bolen JB, et al. **Annu Rev Immunol** 1997; 15:371–404 (222 ref.)

Leukocyte alkaline phosphatase a specific marker for the post-mitotic neutrophilic granulocyte: regulation in acute promyelocytic leukemia. Garattini E, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):493–503 (73 ref.)

IMMUNOLOGY

Significance of the inflammatory response in brain ischemia. Hallenbeck JM. **Acta Neurochir Suppl (Wien)** 1996;66:27–31 (28 ref.)

Leukocytes, macrophages and secondary brain damage following cerebral ischemia. Tomita M, et al. **Acta Neurochir Suppl (Wien)** 1996;66:32–9 (58 ref.)

Orchestrated information transfer underlying leukocyte endothelial interactions. Ebnet K, et al. **Annu Rev Immunol** 1996;14:155–77 (132 ref.)

Use and evaluation of leucocyte monoclonal antibodies in the diagnostic laboratory: a review. Reilly JT. **Clin Lab Haematol** 1996 Mar;18(1):1–5 (19 ref.)

To stick or not to stick: the new leukocyte homing paradigm. Dunon D, et al. **Curr Opin Cell Biol** 1996 Oct;8(5):714–23 (108 ref.)

Transfer of maternal leukocytes to the infant by human milk. Goldman AS, et al. **Curr Top Microbiol Immunol** 1997; 222:205–13 (60 ref.)

Evolution of leukocyte immunophenotyping as influenced by the HIV/AIDS pandemic: a short history of the development of gating strategies for CD4+ T-cell enumeration. Mandy FF, et al. **Cytometry** 1997 Aug 15; 30(4):157–65 (31 ref.)

Leukocyte migration and activation in the lungs [editorial; comment] Martin TR. **Eur Respir J** 1997 Apr;10(4):770–1 (15 ref.) Comment on: Eur Respir J 1997 Apr;10(4):795–803.

Leukocyte migration and activation by murine chemokines. Haelens A, et al. **Immunobiology** 1996 Oct;195(4–5):499–521 (97 ref.)

Sevenspan transmembrane molecules: novel receptors involved in leukocyte adhesion. van Lier RA, et al. **Immunol Lett** 1996 Dec;54(2–3):185–7 (13 ref.)

The selectins: insights into selectin-induced intracellular signaling in leukocytes. Crockett-Torabi E, et al. **Immunol Res** 1995;14(4):237–51 (116 ref.)

Experimental antileukocyte interventions in cerebral ischemia. Härtl R, et al. **J Cereb Blood Flow Metab** 1996 Nov;16(6):1108–19 (120 ref.)

The problem of chronic rejection: influence of leukocyte-endothelial interactions. Briscoe DM, et al. **Kidney Int Suppl** 1997 Mar;58:S22–7 (101 ref.)

Mechanisms of inflammation and leukocyte activation. Ali H, et al. **Med Clin North Am** 1997 Jan;81(1):1–28 (89 ref.)

The interaction of endothelial cells with inflammatory cells in vasculitis. Savage CO. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct;13(3):214–6 (19 ref.)

Targeting of peripheral blood T lymphocytes. Bolhuis RL, et al. **Springer Semin Immunopathol** 1996;18(2):211–26 (123 ref.)

The use of allogeneic leukocytes or i.v. IgG for the treatment of patients with recurrent spontaneous abortions. Clark DA, et al. **Transfus Med Rev** 1997 Apr;11(2):85–94 (50 ref.)

[The cytotoxic function of normal leukocytes and in chronic tumorous diseases of the blood] Vozniuk VP, et al. **Lik Sprava** 1996 Mar-Apr;(3–4):9–12 (45 ref.) **(Ukr)**

METABOLISM

Nonsperm cells in human semen: with special reference to seminal leukocytes and their possible influence on fertility. Fedder J. **Arch Androl** 1996 Jan-Feb;36(1):41–65 (94 ref.)

Two selectins converge on sulphate. Leukocyte adhesion. Rosen SD, et al. **Curr Biol** 1996 Mar 1;6(3):261–4 (21 ref.)

Hypochlorous acid and its pharmacological antagonism: an update picture. Lapenna D, et al. **Gen Pharmacol** 1996 Oct; 27(7):1145–7 (30 ref.)

HIN-200: a novel family of IFN-inducible nuclear proteins expressed in leukocytes. Dawson MJ, et al. **J Leukoc Biol** 1996 Sep;60(3):310–6 (47 ref.)

[Non-enzyme cation proteins of peripheral blood leukocytes-factor of nonspecific reaction of body to injury] Priima OB. **Klin Med (Mosk)** 1997;75(2):4–6 (36 ref.) **(Rus)**

PARASITOLOGY

Theileria transformation of bovine leukocytes: a parasite model for the study of lymphoproliferation. Chaussepied M, et al. **Res Immunol** 1996 Mar-Apr;147(3):127–38 (64 ref.)

PATHOLOGY

Novel roles for E-selectin in endothelial-leukocyte adhesion. Yoshida M, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:493–7 (12 ref.)

Hematology and hemostasis in the horse: normal functions and common abnormalities. Lassen ED, et al. **Vet Clin North Am Equine Pract** 1995 Dec;11(3):351–89 (107 ref.)

[ICAM-1 and allergic inflammation] Canonica GW. **Allerg Immunol (Paris)** 1997 Mar;29(3):77–9; discussion 84 (17 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Structure and function of leukocyte chemoattractant receptors. Ye RD, et al. **Adv Pharmacol** 1997;39:221–89 (360 ref.)

Cytokine-leukocyte networks and the establishment of pregnancy. Robertson SA, et al. **Am J Reprod Immunol** 1997 Jun;37(6):438–42 (37 ref.)

Evidence for vascular tone regulation by resident or infiltrating leukocytes. Marceau F. **Biochem Pharmacol** 1996 Nov 22;52(10):1481–8 (74 ref.)

Heterogeneity of interactions mediated by membrane glycoproteins of lymphocytes. Barclay AN, et al. **Biochem Soc Trans** 1997 Feb;25(1):224–8 (15 ref.)

Human leucocyte heparan sulphate proteoglycans and their roles in inflammation. Jackson DG. **Biochem Soc Trans** 1997 Feb;25(1):220–4 (23 ref.)

Glycoconjugate cross-talk in metastatic cancer cells, leucocytes, parasites and bacteria. Leroy A, et al. **Biochem Soc Trans** 1997 Feb;25(1):228–34 (48 ref.)

Signalling and adhesive properties of the integrin leucocyte function-associated antigen 1 (LFA-1). van Kooyk Y, et al. **Biochem Soc Trans** 1997 May;25(2):515–20 (51 ref.)

Leucocyte adhesion under flow conditions: principles important in tissue engineering. Jones DA, et al. **Biomaterials** 1996 Feb;17(3):337–47 (92 ref.)

Cerebrovascular reactivity: role of endothelium/platelet/leukocyte interactions. Akopov S, et al. **Cerebrovasc Brain Metab Rev** 1996 Spring;8(1):11–94 (432 ref.)

Nitric oxide: nature's naturally occurring leukocyte inhibitor [editorial; comment] Lefer AM. **Circulation** 1997 Feb 4; 95(3):553–4 (39 ref.) Comment on: Circulation 1997 Feb 4;95(3):662–8.

Mononuclear phagocytes and dendritic leukocytes in the skin. Milon G, et al. **Clin Dermatol** 1996 Sep-Oct;14(5):465–70 (65 ref.)

Rho GTPases and leukocyte cytoskeletal regulation. Dharmawardhane S, et al. **Curr Opin Hematol** 1997 Jan; 4(1):12–8 (83 ref.)

Antimicrobial peptides of leukocytes. Ganz T, et al. **Curr Opin Hematol** 1997 Jan;4(1):53–8 (75 ref.)

Traffic of leukocytes through the maternofetal placental interface and its possible consequences. Papadogiannakis N. **Curr Top Microbiol Immunol** 1997;222:141–57 (137 ref.)

Chemokine-leukocyte interactions. The voodoo that they do so well. Taub DD. **Cytokine Growth Factor Rev** 1996 Dec; 7(4):355–76 (162 ref.)

Role of nitric oxide in regulation of leucocyte-endothelial cell interactions. Hickey MJ, et al. **Exp Physiol** 1997 Mar; 82(2):339–48 (38 ref.)

Flow cytometry assessment of leukocyte functions in vascular pathologies. Freyburger G, et al. **Hematol Cell Ther** 1996 Dec;38(6):513–26 (102 ref.)

Leukocyte migration and activation by murine chemokines. Haelens A, et al. **Immunobiology** 1996 Oct;195(4–5):499–521 (97 ref.)

Cellular polarization induced by chemokines: a mechanism for leukocyte recruitment? del Pozo MA, et al. **Immunol Today** 1996 Mar;17(3):127–31 (35 ref.)

Influence of blood cells and blood flow on venous endothelium. Dormandy JA. **Int Angiol** 1996 Jun; 15(2):119–23 (16 ref.)

Exercise-induced immunomodulation--possible roles of neuroendocrine and metabolic factors. Pedersen BK, et al. **Int J Sports Med** 1997 Mar;18 Suppl 1:S2–7 (51 ref.)

Xenotransplantation of baboon bone marrow cells: a historical review of the protocols as a possible treatment modality for HIV/AIDS. Relf MV. **J Assoc Nurses AIDS Care** 1996 Sep-Oct;7(5):27–35 (38 ref.)

Initiation of white cell activation during cardiopulmonary bypass: cytokines and receptors. Cameron D. **J Cardiovasc Pharmacol** 1996;27 Suppl 1:S1–5 (12 ref.)

Amplification of the inflammatory response: adhesion molecules associated with platelet/white cell responses. Rinder C, et al. **J Cardiovasc Pharmacol** 1996;27 Suppl 1:S6–12 (41 ref.)

Cigarettes and the wages of sn-2: oxidized species of PAF in smoking hamsters [editorial; comment] FitzGerald GA. **J Clin Invest** 1997 May 15;99(10):2300–1 (10 ref.) Comment on: J Clin Invest 1997 May 15;99(10):2358–64.

Perspectives series: cell adhesion in vascular biology. Role of PSGL-1 binding to selectins in leukocyte recruitment.

McEver RP, et al. **J Clin Invest** 1997 Aug 1;100(3):485–91 (70 ref.)
Signaling mechanisms and the activation of leukocyte integrins. Newton RA, et al. **J Leukoc Biol** 1997 Apr; 61(4):422–6 (54 ref.)
Integrin signaling in leukocytes: lessons from the alpha6beta1 integrin. Wei J, et al. **J Leukoc Biol** 1997 Apr;61(4):397–407 (119 ref.)
ICAM–1 as a potential target for treatments blocking the host response in stroke. Lindsherg PJ. **Keio J Med** 1996 Sep;45(3):254–61; discussion 261–2 (39 ref.)
Selectin ligands, leukocyte trafficking, and fucosyltransferase genes. Lowe JB. **Kidney Int** 1997 May;51(5):1418–26 (113 ref.)
Leukocytes, cell adhesion molecules and ischemic acute renal failure. Rabb H, et al. **Kidney Int** 1997 May;51(5):1463–8 (31 ref.)
Activation of inflammation and leukocyte recruitment into the peritoneal cavity. Topley N, et al. **Kidney Int Suppl** 1996 Nov;56:S17–21 (44 ref.)
Selectins, T–cell rolling and inflammation. Rossiter H, et al. **Mol Med Today** 1997 May;3(5):214–22 (49 ref.)
Leukocyte responses to hypoxic/ischemic conditions. Scannell G. **New Horiz** 1996 May;4(2):179–83 (27 ref.)
Leucocyte depletion in cardiothoracic surgery. Allen SM. **Perfusion** 1996 May;11(3):270–7 (59 ref.)
Peritoneal dialysis solution biocompatibility: inhibitory mechanisms and recent studies with bicarbonate–buffered solutions. Jörres A, et al. **Perit Dial Int** 1997;17 Suppl 2:S42–6 (53 ref.)
A massage for the journey: keeping leukocytes soft and silent [comment] von Andrian UH.
Proc Natl Acad Sci U S A 1997 May 13;94(10):4825–7 (22 ref.) Comment on: Proc Natl Acad Sci U S A 1997 May 13;94(10):5338–43.
Ischemia/reperfusion–induced leukocyte–endothelial interactions in postcapillary venules. Eppihimer MJ, et al. **Shock** 1997 Jul;8(1):16–25 (85 ref.)
Intracellular pH regulation in leukocytes: mechanisms and functional significance. Hackam DJ, et al. **Shock** 1996 Jan; 5(1):17–21 (44 ref.)
Leukocyte crosstalk at the vascular wall. Furie B, et al. **Thromb Haemost** 1997 Jul;78(1):306–9 (34 ref.)
The role of leukocyte and endothelial adhesion molecules in ischemia–reperfusion injury. Thiagarajan RR, et al. **Thromb Haemost** 1997 Jul;78(1):310–4 (35 ref.)
[Regulation of leukocyte migration by adhesion molecules] Spertini O. **Schweiz Med Wochenschr** 1996 Nov 9; 126(45):1926–34 (81 ref.) (Eng. Abstr.) **(Fre)**
[An improved phagocytic plaque method using gram–negative bacilli] Tomiya Y, et al.
Nippon Saikingaku Zasshi 1996 Oct;51(4):1049–53 (6 ref.) (Eng. Abstr.) **(Jpn)**
[Leukocyte–endothelium interaction: inflammation and gastric damage] Panés J, et al. **Gastroenterol Hepatol** 1997 May;20 Suppl 2:22–32 (129 ref.) **(Spa)**
[Adhesion molecules in the interactions of leukocytes, endothelium, and extracellular matrix (I). Structure, distribution, and biological function] Cid i Xutglà MC, et al. **Med Clin (Barc)** 1997 Mar 29;108(12):472–7 (76 ref.) **(Spa)**
[Adhesion molecules in the interactions of leukocytes, endothelium, and extracellular matrix (II). Relevance in human clinical medicine and potential therapeutic applications] Cid i Xutglà MC, et al. **Med Clin (Barc)** 1997 Apr 5;108(13):503–11 (95 ref.) **(Spa)**

SECRETION

[Importance of in vivo and in vitro studies of leukotrienes. Application to the particular instance of aspirin] Sainte–Laudy J. **Allerg Immunol (Paris)** 1997 Feb; 29(2):28–35 (65 ref.) (Eng. Abstr.) **(Fre)**

VIROLOGY

Infection of blood and bone marrow cells with the human cytomegalovirus in vivo. Meyer–König U, et al.
Leuk Lymphoma 1997 May;25(5–6):445–54 (58 ref.)
[Viral attenuation of labile blood products] Folléa G, et al. **Transfus Clin Biol** 1996;3(2):113–23 (84 ref.) (Eng. Abstr.) **(Fre)**

LEUKOCYTES, MONONUCLEAR

DRUG EFFECTS

Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Brattsand R, et al.
Aliment Pharmacol Ther 1996;10 Suppl 2:81–90; discussion 91–2 (81 ref.)
Mononuclear cells in corticosteroid–resistant asthma. Lane SJ, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 2):S49–51; discussion S52 (17 ref.)
Phenotype and engraftment potential of cytokine–mobilized peripheral blood mononuclear cells. Mielcarek M, et al. **Curr Opin Hematol** 1997 May;4(3):176–82 (80 ref.)
Inhibition of tissue factor and cytokine release. Gray E, et al. **Haemostasis** 1996;26 Suppl 1:92–5 (12 ref.)
Action of cyclosporin A on mononuclear phagocytes. Losa García JE, et al. **J Investig Allergol Clin Immunol** 1996 Jul–Aug;6(4):222–31 (97 ref.)

PHYSIOLOGY

Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Brattsand R, et al.
Aliment Pharmacol Ther 1996;10 Suppl 2:81–90; discussion 91–2 (81 ref.)
Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis? Burmester GR, et al. **Arthritis Rheum** 1997 Jan;40(1):5–18 (178 ref.)
Inflammatory cells in renal regeneration. Ghielli M, et al. **Ren Fail** 1996 May;18(3):355–75 (106 ref.)

LEUKOCYTES, POLYMORPHONUCLEAR see **NEUTROPHILS**

LEUKOCYTOPENIA see **LEUKOPENIA**

LEUKOCYTOSIS

PHYSIOPATHOLOGY

Catecholamine–induced leukocytosis: early observations, current research, and future directions. Benschop RJ, et al. **Brain Behav Immun** 1996 Jun;10(2):77–91 (103 ref.)

LEUKODYSTROPHY, GLOBOID CELL

COMPLICATIONS

[Isolated spastic paraparesis disclosing Krabbe disease in adult age] Bataillard M, et al. **Rev Neurol (Paris)** 1997 Jun; 153(5):347–50 (20 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Progressive neuronopathy in two Cairn terrier litter mates. Zaal MD, et al. **Vet Q** 1997 Mar;19(1):34–6 (15 ref.)

LEUKODYSTROPHY, METACHROMATIC

ENZYMOLOGY

[Deficiency of arylsulfatase A activity as a basis of metachromatic leucodystrophy] Lugowska A, et al. **Postepy Biochem** 1996;42(3):284–9 (59 ref.) **(Pol)**

GENETICS

[2 familial cases of metachromatic leukodystrophy of late onset] Brault JL, et al. **Rev Neurol (Paris)** 1997 Apr; 153(3):193–6 (13 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

[Cell transplantation for neuronal and muscular disorders] Kondoh T, et al. **No To Shinkei** 1997 Jun;49(6):507–15 (50 ref.) **(Jpn)**

LEUKOENCEPHALITIS, ACUTE HEMORRHAGIC

ETIOLOGY

[Neurological outcome associated with influenza viral infection] Kamimura N, et al. **Nippon Rinsho** 1997 Apr; 55(4):880–5 (22 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

[Acute Weston Hurst necrotizing hemorrhagic leukoencephalitis] Donnet A, et al. **Rev Neurol (Paris)** 1996 Dec;152(12):748–51 (10 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Acute necrotizing encephalopathy of childhood: a novel form of acute encephalopathy prevalent in Japan and Taiwan. Mizuguchi M. **Brain Dev** 1997 Mar;19(2):81–92 (82 ref.)

LEUKOENCEPHALITIS, SUBACUTE SCLEROSING see **SUBACUTE SCLEROSING PANENCEPHALITIS**

LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL

Progressive multifocal leucoencephalopathy. Dalsgaard Hansen NJ, et al. **Ital J Neurol Sci** 1996 Dec;17(6):393–9 (48 ref.)
[Mechanism of neuronal damage in AIDS] Nagashima K. **Hokkaido Igaku Zasshi** 1997 Jan;72(1):37–41 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Nervous system infections—Progressive multifocal leukoencephalopathy] Ochi H, et al.
Nippon Naika Gakkai Zasshi 1996 May 10;85(5):731–5 (5 ref.) **(Jpn)**
[Progressive multifocal leukoencephalopathy] Nagashima K, et al. **Nippon Rinsho** 1997 Apr;55(4):916–21 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Slow virus infection] Yamanouchi K. **Nippon Rinsho** 1997 Apr;55(4):795–9 (15 ref.) (Eng. Abstr.) **(Jpn)**

CHEMICALLY INDUCED

Multifocal leukoencephalopathy associated with 5–fluorouracil and levamisole adjuvant therapy for colon cancer. A report of two cases and review of the literature. The INTACC. Intergruppo Nazionale Terpia Adiuvante Colon Carcinoma. Luppi G, et al. **Ann Oncol** 1996 Apr; 7(4):412–5 (11 ref.)

COMPLICATIONS

Progressive multifocal leukoencephalopathy in HIV [editorial] Sadler M, et al. **Int J STD AIDS** 1997 Jun; 8(6):351–7 (61 ref.)

DIAGNOSIS

Progressive multifocal leukoencephalopathy: clinical and MR response to treatment. Garrels K, et al.
AJNR Am J Neuroradiol 1996 Mar;17(3):597–600 (18 ref.)
Virus–host interactions and diagnosis of human polyomavirus–associated disease. Dörries K.
Intervirology 1996;39(3):165–75 (75 ref.)

ETIOLOGY

Progressive multifocal leukoencephalopathy during cyclosporine treatment. A case report. Gentile S, et al.
Ital J Neurol Sci 1996 Oct;17(5):363–6 (20 ref.)
Progressive multifocal leukoencephalopathy: the evolution of a disease once considered rare. Berger JR, et al.
J Neurovirol 1995 Mar;1(1):5–18 (107 ref.)

GENETICS

CADASIL: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Ruchoux MM, et al. **J Neuropathol Exp Neurol** 1997 Sep;56(9):947–64 (72 ref.)
[CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy)] Chabriat H, et al. **J Mal Vasc** 1996;21(5):277–82 (37 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Progressive multifocal leukoencephalopathy: the evolution of a disease once considered rare. Berger JR, et al.
J Neurovirol 1995 Mar;1(1):5–18 (107 ref.)
[Neurological complications of patients infected by HIV–1] Abós J. **Rev Neurol** 1996 Dec;24(136):1569–76 (49 ref.) **(Spa)**

THERAPY

Progressive multifocal leukoencephalopathy: clinical and MR response to treatment. Garrels K, et al.
AJNR Am J Neuroradiol 1996 Mar;17(3):597–600 (18 ref.)

VIROLOGY

[Neurological complications of patients infected by HIV–1] Abós J. **Rev Neurol** 1996 Dec;24(136):1569–76 (49 ref.) **(Spa)**

LEUKOMA see **CORNEAL OPACITY**

LEUKOMALACIA, PERIVENTRICULAR

DIAGNOSIS

Ventriculomegaly, delayed myelination, white matter hypoplasia, and "periventricular" leukomalacia: how are they related? Leviton A, et al. **Pediatr Neurol** 1996 Sep; 15(2):127–36 (163 ref.)

PHYSIOPATHOLOGY

Periventricular leukomalacia, glial development and myelination. Takashima S, et al. **Early Hum Dev** 1995 Oct 2;43(2):177–84 (40 ref.)

ULTRASONOGRAPHY

Multicystic encephalomalacia in term infants. Frigieri G, et al. **Childs Nerv Syst** 1996 Dec;12(12):759–64 (17 ref.)
[Ultrasound diagnosis of periventricular leukomalacia] Staneva KN, et al. **Z Geburtshilfe Neonatol** 1997 Mar–Apr; 201(2):44–8 (58 ref.) (Eng. Abstr.) **(Ger)**

LEUKOPENIA

CHEMICALLY INDUCED

Mortality, major amputation rates, and leukopenia after isolated limb perfusion with phenylalanine mustard for the treatment of melanoma. Taber SW, et al.
Ann Surg Oncol 1997 Jul–Aug;4(5):440–5 (30 ref.)
Ritodrine–induced leukopenia: a case report and literature review. Wu CD, et al. **Chang Keng I Hsueh** 1996 Dec; 19(4):388–91 (7 ref.)

DIAGNOSIS

Principles of counting low numbers of leukocytes in leukoreduced blood components. Dzik S.
Transfus Med Rev 1997 Jan;11(1):44–55 (56 ref.)

LEUKOPHERESIS see **LEUKAPHERESIS**

LEUKOPLAKIA, ORAL

DIAGNOSIS

Oncogenes and growth factor receptors as diagnostic and prognostic markers in precancers and cancers of the oral mucosa. Burkhardt A. **Curr Top Pathol** 1996;90:223–39 (136 ref.)

DRUG THERAPY

Use of antioxidant supplements in the treatment of human oral leukoplakia. Kaugars GE, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Jan;81(1):5–14 (126 ref.)

VIROLOGY

[High-risk HPV types in oral and laryngeal papilloma and leukoplakia] Arndt O, et al. **Laryngorhinootologie** 1997 Mar; 76(3):142–9 (58 ref.) (Eng. Abstr.) **(Ger)**

LEUKOSARCOMA see **LEUKEMIA**

LEUKOSIS, AVIAN see **AVIAN LEUKOSIS**

LEUKOSIS, BOVINE see **ENZOOTIC BOVINE LEUKOSIS**

LEUKOSIS VIRUS, AVIAN

Avian erythropoiesis and erythroleukemia: towards understanding the role of the biomolecules involved. Beug H, et al. **Biochim Biophys Acta** 1996 Dec 9;1288(3):M35–47 (92 ref.)

Avian retroviruses. Fadly AM.
Vet Clin North Am Food Anim Pract 1997 Mar;13(1):71–85 (65 ref.)

ISOLATION & PURIFICATION

Acute avian leukemia viruses as tools to study hematopoietic cell differentiation. McNagny KM, et al.
Curr Top Microbiol Immunol 1996;212:143–62 (114 ref.)

LEUKOTAXIS see **CHEMOTAXIS, LEUKOCYTE**

LEUKOTOMY see **PSYCHOSURGERY**

LEUKOTRIENE C4

BIOSYNTHESIS

Consequences of transcellular biosynthesis of leukotriene C4 on organ function. Maclouf J, et al. **Haemostasis** 1996 Oct; 26 Suppl 4:28–36 (41 ref.)

LEUKOTRIENE D4

METABOLISM

Leukotriene activity modulation in asthma. Spector SL. **Drugs** 1997 Sep;54(3):369–84 (124 ref.)

LEUKOTRIENE RECEPTORS see **RECEPTORS, LEUKOTRIENE**

LEUKOTRIENES

see related
RECEPTORS, LEUKOTRIENE

ADVERSE EFFECTS

Leukotrienes: pathophysiologic role and therapeutic potentials in asthma. Sanico AM, et al.
Allergy Asthma Proc 1996 Nov–Dec;17(6):331–4 (41 ref.)

ANTAGONISTS & INHIBITORS

Antileukotrienes in the treatment of asthma. O'Byrne PM, et al. **Ann Intern Med** 1997 Sep 15;127(6):472–80 (109 ref.)

Anti-leukotriene agents: a new direction in asthma therapy [see comments] Nathan RA. **J Asthma** 1996;33(6):353–66 (95 ref.) Comment in: J Asthma 1996;33(6):351–2.

Pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in the management of asthma. Drazen JM. **Pharmacotherapy** 1997 Jan–Feb;17(1 Pt 2):22S–30S (58 ref.)

Anti-leukotriene intervention: is there adequate information for clinical use in asthma? Ind PW. **Respir Med** 1996 Nov; 90(10):575–86 (70 ref.)

[Progress in the study of lipoxin and leukotriene] Wu SH. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan;27(1):79–81 (10 ref.) **(Chi)**

[Clinical pharmacology of leucotriene inhibitors] Paggiaro PL, et al. **Ann Ital Med Int** 1996 Oct;11 Suppl 2:85S–89S (39 ref.) (Eng. Abstr.) **(Ita)**

[Anti-leukotriene agents: rationale for and prospects of use] Passalacqua G, et al. **Ann Ital Med Int** 1996 Oct;11 Suppl 2:93S–96S (36 ref.) (Eng. Abstr.) **(Ita)**

[Leukotrienes and asthma. Clinical and experimental experiences with leukotriene receptor antagonists and leukotriene synthesis inhibitors] Henriksen AH, et al.
Tidsskr Nor Laegeforen 1997 Feb 20;117(5):647–51 (27 ref.) (Eng. Abstr.) **(Nor)**

[New developments in the treatment of bronchial asthma: leukotriene inhibitors] Tsoï AN, et al. **Ter Arkh** 1997; 69(2):83–8 (54 ref.) **(Rus)**

BIOSYNTHESIS

Biosynthesis inhibitors for leukotrienes in bronchial asthma. Negro JM, et al. **Allergol Immunopathol (Madr)** 1997 Jul–Aug;25(4):209–16 (48 ref.)

Role of leukotrienes in asthma pathogenesis. Fabbri L, et al. **Monaldi Arch Chest Dis** 1996 Dec;51(6):548–55 (112 ref.)

IMMUNOLOGY

The role of leukotrienes in asthma and allergic rhinitis. Busse WW. **Clin Exp Allergy** 1996 Aug;26(8):868–79 (75 ref.)

METABOLISM

Analytical methods for the measurement of leukotrienes and other eicosanoids in biological samples from asthmatic subjects. Kumlin M. **J Chromatogr A** 1996 Feb 19; 725(1):29–40 (56 ref.)

Biosynthesis, metabolization and biological importance of the primary 15-lipoxygenase metabolites 15-hydro(pero)XY-5Z,8Z,11Z,13E-eicosatetraenoic acid and 13-hydro(pero)XY-9Z,11E-octadecadienoic acid. Kühn H. **Prog Lipid Res** 1996 Sep;35(3):203–26 (251 ref.)

[Role and significance of leukotrienes in liver diseases] Bao W, et al. **Chung Hua Nei Ko Tsa Chih** 1996 Jan;35(1):57–9 (12 ref.) **(Chi)**

PHARMACOLOGY

Biology and pathophysiology of leukotrienes. Denzlinger C. **Crit Rev Oncol Hematol** 1996 Jul;23(3):167–223 (832 ref.)

PHYSIOLOGY

Leukotrienes and their antagonists in allergic disorders. Negro JM, et al. **Allergol Immunopathol (Madr)** 1997 Mar–Apr;25(2):104–12 (69 ref.)

Leukotrienes in asthma. The potential therapeutic role of antileukotriene agents. Smith LJ. **Arch Intern Med** 1996 Oct 28;156(19):2181–9 (95 ref.)

Leukotrienes in the pathogenesis of asthma. O'Byrne PM. **Chest** 1997 Feb;111(2 Suppl):27S–34S (94 ref.)

The leukotrienes: mediators of chronic inflammation in asthma. Sampson AP. **Clin Exp Allergy** 1996 Sep; 26(9):995–1004 (103 ref.)

Antileukotriene agents. Tan RA, et al.
Curr Opin Pulm Med 1997 May;3(3):215–20 (46 ref.)

[Importance of in vivo and in vitro studies of leukotrienes. Application to the particular instance of aspirin] Sainte-Laudy J. **Allerg Immunol (Paris)** 1997 Feb; 29(2):28–35 (65 ref.) (Eng. Abstr.) **(Fre)**

[Leukotrienes and antagonists of leukotriene receptors] **J Pharm Belg** 1997 May–Jun;52(3):131–2 (0 ref.) **(Fre)**

[Effects of leukotrienes on bronchial secretions] Chinet T, et al. **Rev Pneumol Clin** 1997;53(2):86–90 (21 ref.) (Eng. Abstr.) **(Fre)**

[Physiopathology of asthma: what role for leukotrienes?] Lockhart A, et al. **Rev Pneumol Clin** 1997;53(3):119–27 (79 ref.) (Eng. Abstr.) **(Fre)**

[Leukotrienes: their significance in the pathogenesis of asthma] Bianco S. **Ann Ital Med Int** 1996 Oct;11 Suppl 2:90S–92S (19 ref.) (Eng. Abstr.) **(Ita)**

URINE

Measurements of leukotrienes in the urine: strategies and applications. Kumlin M. **Allergy** 1997 Feb;52(2):124–35 (100 ref.)

LEUKOVIRUSES see **RETROVIRIDAE**

LEUPROLIDE

THERAPEUTIC USE

GnRH agonists before surgery for uterine leiomyomas. A review [see comments] Crosignani PG, et al.
J Reprod Med 1996 Jun;41(6):415–21 (38 ref.) Comment in: J Reprod Med 1997 Apr;42(4):253.

LEUPRORELIN see **LEUPROLIDE**

LEUROCRISTINE see **VINCRISTINE**

LEVAMISOLE

THERAPEUTIC USE

Multifocal leukoencephalopathy associated with 5-fluorouracil and levamisole adjuvant therapy for colon cancer. A report of two cases and review of the literature. The INTACC. Intergruppo Nazionale Terpia Adiuvante Colon Carcinoma. Luppi G, et al. **Ann Oncol** 1996 Apr; 7(4):412–5 (11 ref.)

LEVARTERENOL see **NOREPINEPHRINE**

LEVEL OF HEALTH see **HEALTH STATUS**

LEVOAMPHETAMINE see **AMPHETAMINE**

LEVOCARDIA

[Levocardia with situs inversus (isolated levocardia)] Aotsuka H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):87–90 (17 ref.) **(Jpn)**

SURGERY

Intraatrial baffle repair of isolated ventricular inversion with left atrial isomerism. McElhinney DB, et al.
Ann Thorac Surg 1996 Nov;62(5):1529–32 (12 ref.)

LEVODOPA

ADMINISTRATION & DOSAGE

Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. Stocchi F, et al. **Clin Neuropharmacol** 1997 Apr;20(2):95–115 (146 ref.)

[Treatment and prognosis of juvenile parkinsonism--L-dopa responsiveness] Takubo H. **Nippon Rinsho** 1997 Jan; 55(1):101–5 (23 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Methods of managing levodopa-induced dyskinesias. Giron LT Jr, et al. **Drug Saf** 1996 Jun;14(6):365–74 (35 ref.)

Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment. Young BK, et al. **Drugs Aging** 1997 May;10(5):367–83 (153 ref.)

Management of motor fluctuations in Parkinson's disease. Koller WC. **Eur Neurol** 1996;36 Suppl 1:43–8 (48 ref.)

Gene therapy for Parkinson's disease: an approach to the prevention or palliation of levodopa-associated motor complications. Mouradian MM, et al. **Exp Neurol** 1997 Mar; 144(1):51–7 (65 ref.)

Malignant melanoma and levodopa: is there a relationship? Two new cases and a review of the literature. Pfützner W, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):332–6 (68 ref.)

Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease. Blanchet PJ, et al. **Neurosci Biobehav Rev** 1997 Jul;21(4):447–53 (80 ref.)

[Problems of long-term levodopa therapy in Parkinson's disease] Nakamura Y. **Nippon Rinsho** 1997 Jan;55(1):65–71 (26 ref.) (Eng. Abstr.) **(Jpn)**

[Psychiatric complications of L-dopa: physiopathology and treatment] Castro-García A. **Rev Neurol** 1997 Aug;25 Suppl 2:S157–62 (70 ref.) (Eng. Abstr.) **(Spa)**

[Physiopathology of the dyskinesias induced by L-dopa] Grandas F, et al. **Rev Neurol** 1997 Aug;25 Suppl 2:S151–6 (93 ref.) (Eng. Abstr.) **(Spa)**

[Drug-related motor disorders in aged people] Martí-Massó JF. **Rev Neurol** 1997 Jul;25 Suppl 1:S37–43 (35 ref.) **(Spa)**

CHEMISTRY

New strategies with dopaminergic drugs: modified formulations of levodopa and novel agonists. Goetz CG. **Exp Neurol** 1997 Mar;144(1):17–20 (45 ref.)

DIAGNOSTIC USE

[L-dopa and dopamine loading test] Azuma K, et al.
Nippon Rinsho 1997 Apr;55 Suppl 2:252–5 (7 ref.) **(Jpn)**

[L-dopa provocative test] Takeda S, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:229–33 (10 ref.) **(Jpn)**

PHARMACOKINETICS

Pharmacokinetic optimisation in the treatment of Parkinson's disease [published erratum appears in Clin Pharmacokinet 1996 Aug;31(2):110] Contin M, et al.
Clin Pharmacokinet 1996 Jun;30(6):463–81 (196 ref.)

Impaired absorption of oral levodopa: a major cause for response fluctuations in Parkinson's disease. Djaldetti R, et al. **Isr J Med Sci** 1996 Dec;32(12):1224–7 (26 ref.)

PHARMACOLOGY

Stimulation of basal and L-DOPA-induced motor activity by glutamate antagonists in animal models of Parkinson's disease. Starr MS, et al. **Neurosci Biobehav Rev** 1997 Jul; 21(4):437–46 (69 ref.)

PHYSIOLOGY

Neurobiology of L-DOPAergic systems. Misu Y, et al.
Prog Neurobiol 1996 Aug;49(5):415–54 (237 ref.)

POISONING

Is levodopa toxic? Fahn S. **Neurology** 1996 Dec;47(6 Suppl 3):S184–95 (154 ref.)

THERAPEUTIC USE

Using liquid levodopa in the treatment of Parkinson's disease. A practical guide. Kurth MC. **Drugs Aging** 1997 May; 10(5):332–40 (40 ref.)

Treatment of Parkinson's disease. Advances in the pharmacological therapy. Ghika J. **Eur Neurol** 1996;

36(6):396–9 (33 ref.)
Motor fluctuations in levodopa treatment: clinical pharmacology. Stocchi F, et al. **Eur Neurol** 1996;36 Suppl 1:38–42 (38 ref.)
Dopa-responsive dystonia: a syndrome of selective nigrostriatal dopaminergic deficiency. Jeon BS. **J Korean Med Sci** 1997 Aug;12(4):269–79 (78 ref.)
Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy. Fischer PA. **J Neural Transm Suppl** 1995;46:381–9 (29 ref.)
Role of selegiline in combination therapy of Parkinson's disease. Myllylä VV, et al. **Neurology** 1996 Dec;47(6 Suppl 3):S200–9 (145 ref.)
[Parkinson disease: interrogations and solutions] Allain H, et al. **Presse Med** 1997 Jun 7;26(19):909–15 (58 ref.) (Eng. Abstr.) **(Fre)**
[Pharmacological therapy of complicated Parkinson's disease] Jiménez-Jiménez FJ, et al. **Rev Neurol** 1997 Aug; 25 Suppl 2:S170–9 (249 ref.) (Eng. Abstr.) **(Spa)**
[Neuroprotective and neurorestorative therapy in Parkinson's disease] Jiménez-Jiménez FJ, et al. **Rev Neurol** 1997 Aug; 25 Suppl 2:S185–93 (207 ref.) (Eng. Abstr.) **(Spa)**
[Initial treatment of Parkinson's disease] Kulisevsky J, et al. **Rev Neurol** 1997 Aug;25 Suppl 2:S163–9 (42 ref.) (Eng. Abstr.) **(Spa)**

LEVOFLOXACIN see **OFLOXACIN**

LEVOMYCETIN see **CHLORAMPHENICOL**

LEVONOREPINEPHRINE see **NOREPINEPHRINE**

LEVONORGESTREL

The levonorgestrel-releasing intrauterine device: a wider role than contraception. Coleman M, et al. **Aust N Z J Obstet Gynaecol** 1997 May;37(2):195–201 (68 ref.)
[Levonorgestrel contraceptive implants. Facts and controversies of a current contraceptive method] Vasconcelos-Allende M, et al. **Ginecol Obstet Mex** 1996 Nov;64:498–502 (13 ref.) (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

Gynaecological aspects of the levonorgestrel-releasing intrauterine system [see comments] Sturridge F, et al. **Br J Obstet Gynaecol** 1997 Mar;104(3):285–9 (36 ref.) Comment in: Br J Obstet Gynaecol 1997 Mar;104(3):viii.

ADVERSE EFFECTS

The role of triphasic levonorgestrel in oral contraception: a review of metabolic and hemostatic effects. Lachnit-Fixson U. **Gynecol Endocrinol** 1996 Jun; 10(3):207–18 (48 ref.)
Use of Norplant in women with or at-risk for noninsulin-dependent diabetes. Womack J, et al. **J Nurse Midwifery** 1996 Jul-Aug;41(4):285–96 (44 ref.)

PHARMACOLOGY

Implantable hormonal and emergency contraception. Cullins VE, et al. **Curr Opin Obstet Gynecol** 1997 Jun;9(3):169–74 (44 ref.)
Progesterone receptor in Norplant endometrium. Lau TM, et al. **Hum Reprod** 1996 Oct;11 Suppl 2:90–4 (16 ref.)

LEVOTETRAMISOLE see **LEVAMISOLE**

LEVOTHYROXINE

ADVERSE EFFECTS

[Thyroid and osteoporosis] Földes J, et al. **Orv Hetil** 1996 Jun 23;137(25):1347–54 (50 ref.) (Eng. Abstr.) **(Hun)**

THERAPEUTIC USE

[Administration of high dose levothyroxine in treatment of rapid cycling bipolar disorders. Review of the literature and initial therapeutic application apropos of 6 cases] Afflelou S, et al. **Encephale** 1997 May-Jun;23(3):209–17 (20 ref.) (Eng. Abstr.) **(Fre)**
[Current status of the treatment with thyroid hormones] Laudo Pardos C, et al. **An Med Interna** 1996 Nov; 13(11):555–61 (98 ref.) (Eng. Abstr.) **(Spa)**

LEVOTHYROXINE SODIUM see **LEVOTHYROXINE**

LEVULOSE see **FRUCTOSE**

LEWANDOWSKY-LUTZ DISEASE see **EPIDERMODYSPLASIA VERRUCIFORMIS**

LEWIS BLOOD-GROUP SYSTEM

GENETICS

Advances in molecular genetics of alpha-2- and alpha-3/4-fucosyltransferases. Costache M, et al. **Transfus Clin Biol** 1997 Jul;4(4):367–82 (119 ref.)

IMMUNOLOGY

Adhesins of Staphylococcus aureus that bind Lewis(a) antigen. Relationship to sudden infant death syndrome. Blackwell CC, et al. **Adv Exp Med Biol** 1996;408:95–105 (55 ref.)

LEWIS SYSTEM see **LEWIS BLOOD-GROUP SYSTEM**

LEWIS X ANTIGEN see **ANTIGENS, CD15**

LEWY BODIES

Lewy-body dementia and responsiveness to cholinesterase inhibitors: a paradigm for heterogeneity of Alzheimer's disease? Liberini P, et al. **Trends Pharmacol Sci** 1996 Apr; 17(4):155–60 (56 ref.)

METABOLISM

The distribution of Lewy bodies in pure autonomic failure: autopsy findings and review of the literature. Hague K, et al. **Acta Neuropathol (Berl)** 1997 Aug;94(2):192–6 (16 ref.)

LEWY BODY DISEASE see **PARKINSON DISEASE**

LEYDIG CELL TUMOR

COMPLICATIONS

Spinal cord compression from metastatic Leydig's cell tumor of the testis: case report. Sawin PD, et al. **Neurosurgery** 1996 Feb;38(2):407–11 (53 ref.)
[Gynecomastia and Leydig cell tumor] Catalá Bauset M, et al. **An Med Interna** 1997 Mar;14(3):131–4 (21 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

[Renomedullary interstitial cell tumor, renal medullary fibroma] Nonomura A. **Ryoikibetsu Shokogun Shirizu** 1997; (16 Pt 1):495–7 (10 ref.) **(Jpn)**

SECONDARY

Spinal cord compression from metastatic Leydig's cell tumor of the testis: case report. Sawin PD, et al. **Neurosurgery** 1996 Feb;38(2):407–11 (53 ref.)

LEYDIG CELLS

PATHOLOGY

Leydig cell hyperplasia and adenoma formation: mechanisms and relevance to humans. Clegg ED, et al. **Reprod Toxicol** 1997 Jan-Feb;11(1):107–21 (170 ref.)

PHYSIOLOGY

Paracrine control of human Leydig cell and Sertoli cell functions. Carreau S. **Folia Histochem Cytobiol** 1996; 34(3-4):111–9 (90 ref.)
Luteinizing hormone on Leydig cell structure and function. Mendis-Handagama SM. **Histol Histopathol** 1997 Jul; 12(3):869–82 (46 ref.)

ULTRASTRUCTURE

Luteinizing hormone on Leydig cell structure and function. Mendis-Handagama SM. **Histol Histopathol** 1997 Jul; 12(3):869–82 (46 ref.)

LFA-1 see **LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1**

LFA-3 see **ANTIGENS, CD58**

LH

see related
RECEPTORS, LH

ADMINISTRATION & DOSAGE

Roles of follicle stimulating hormone and luteinizing hormone in controlled ovarian hyperstimulation. Hillier SG. **Hum Reprod** 1996 Nov;11 Suppl 3:113–21 (28 ref.)

ANALYSIS

Bioassays of gonadotropins based on cloned receptors. Christin-Maitre S, et al. **Mol Cell Endocrinol** 1996 Dec 20;125(1-2):151–9 (49 ref.)

BIOSYNTHESIS

Effects of GnRH and PACAP on gonadotropin secretion and subunit messenger RNAs. Winters SJ, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:343–52; discussion 352–4 (30 ref.)

BLOOD

Heterogeneity of plasma gonadotropins. Consequences on immunological properties of LH. Roger M, et al. **Nucl Med Biol** 1994 Apr;21(3):349–57 (30 ref.)

CHEMISTRY

Structural and functional characterisation of hFSH and hLH isoforms. Stanton PG, et al. **Mol Cell Endocrinol** 1996 Dec 20;125(1-2):133–41 (31 ref.)

DEFICIENCY

Follicular development and oocyte maturation in hypogonadotrophic women employing recombinant follicle-stimulating hormone: the role of oestradiol. Fauser BC. **Hum Reprod Update** 1997 Mar-Apr;3(2):101–8 (57 ref.)

GENETICS

Clinical assessment of human gonadotrophins produced by recombinant DNA technology. Loumaye E, et al. **Hum Reprod** 1996 Sep;11 Suppl 1:95–107; discussion 117–9 (53 ref.)
Inherited disorders of the gonadotropin hormones. Jameson JL. **Mol Cell Endocrinol** 1996 Dec 20;125(1-2):143–9 (32 ref.)

METABOLISM

Neuroendocrine mechanism mediating fasting-induced suppression of luteinizing hormone secretion in female rats. Maeda K, et al. **Acta Neurobiol Exp (Warsz)** 1996; 56(3):787–96 (43 ref.)
Neuroendocrinology of the polycystic ovary syndrome. Soule SG. **Baillieres Clin Endocrinol Metab** 1996 Apr; 10(2):205–19 (59 ref.)
The treatment of patients with polycystic ovaries undergoing IVF. Franks S. **J Assist Reprod Genet** 1997 Jan;14(1):12–4 (12 ref.)
The significance of high follicular-phase luteinizing hormone levels in the treatment of women with polycystic ovarian syndrome by in vitro fertilization. Tarlatzis BC, et al. **J Assist Reprod Genet** 1997 Jan;14(1):1–4 (22 ref.)
Novel modalities for appraising individual and coordinate pulsatile hormone secretion: the paradigm of luteinizing hormone and testosterone release in the aging male. Veldhuis JD. **Mol Psychiatry** 1997 Jan;2(1):70–80 (56 ref.)
Circadian control of reproduction in the female rat. van der Beek EM. **Prog Brain Res** 1996;111:295–320 (172 ref.)
Interaction, signal generation, signal divergence, and signal transduction of LH/CG and the receptor. Ji TH, et al. **Recent Prog Horm Res** 1997;52:431–53; discussion 454 (78 ref.)

PHARMACOLOGY

Ovarian stimulation for assisted reproduction. Meldrum DR. **Curr Opin Obstet Gynecol** 1996 Jun;8(3):166–70 (33 ref.)

PHYSIOLOGY

Potential novel roles of luteinizing hormone and human chorionic gonadotropin during early pregnancy in women. Rao CV. **Early Pregnancy** 1997 Mar;3(1):1–9 (88 ref.)
Luteinizing hormone on Leydig cell structure and function. Mendis-Handagama SM. **Histol Histopathol** 1997 Jul; 12(3):869–82 (46 ref.)
Structural and functional characterisation of hFSH and hLH isoforms. Stanton PG, et al. **Mol Cell Endocrinol** 1996 Dec 20;125(1-2):133–41 (31 ref.)

SECRETION

New concepts of the neuroendocrine regulation of gonadotropin surges in rats. Levine JE. **Biol Reprod** 1997 Feb;56(2):293–302 (104 ref.)
Gonadotroph and other clinically nonfunctioning pituitary adenomas. Snyder PJ. **Cancer Treat Res** 1997;89:57–72 (39 ref.)
Novel estrogen feedback sites associated with stress-induced suppression of luteinizing hormone secretion in female rats. Maeda K, et al. **Cell Mol Neurobiol** 1996 Jun;16(3):311–24 (32 ref.)
Effect of histone-H2A (H-H2A), platelet activating factor (PAF) and pregnancy specific protein B (PSPB) on secretion of prostaglandins E and F2 alpha (PGE; PGF2 alpha) by bovine endometrium and H-H2A on basal secretion of luteinizing hormone (LH) by bovine pituitary cells in vitro. Weems CW, et al. **Chin J Physiol** 1996; 39(3):147–54 (53 ref.)
Current concepts on ultradian rhythms of luteinizing hormone secretion in the human. Bergendahl M, et al. **Hum Reprod Update** 1996 Nov-Dec;2(6):507–18 (106 ref.)
Progestin and estrogen regulation of pulsatile LH release and development of persistent ovarian follicles in cattle. Kinder JE, et al. **J Anim Sci** 1996 Jun;74(6):1424–40 (66 ref.)
Oxytocin and the control of LH. Evans JJ. **J Endocrinol** 1996 Nov;151(2):169–74 (75 ref.)

URINE

Metabolism of hCG and hLH to multiple urinary forms. Birken S, et al. **Mol Cell Endocrinol** 1996 Dec 20; 125(1-2):121–31 (83 ref.)

LH, ALPHA SUBUNIT see **GLYCOPROTEIN HORMONES, ALPHA SUBUNIT**

LH-FSH RELEASING HORMONE see **GONADORELIN**

LH-HCG RECEPTORS see **RECEPTORS, LH**

LH RECEPTORS

LH RECEPTORS see **RECEPTORS, LH**

LH-RELEASING HORMONE see **GONADORELIN**

LHFSHRH RECEPTORS see **RECEPTORS, LHRH**

LHRH see **GONADORELIN**

LHRH RECEPTORS see **RECEPTORS, LHRH**

LI-FRAUMENI SYNDROME

see related
GENES, P53

GENETICS

Li-Fraumeni syndrome--a molecular and clinical review. Varley JM, et al. **Br J Cancer** 1997;76(1):1-14 (160 ref.)

LIABILITY, LEGAL

see related
MALPRACTICE

Medicolegal issues. An anatomic pathologist's perspective. Roth LM. **Am J Clin Pathol** 1996 Oct;106(4 Suppl 1):S18-24 (17 ref.)

Groping for the reins: ERISA, HMO malpractice, and enterprise liability. Kilcullen JK. **Am J Law Med** 1996; 22(1):7-50 (414 ref.)

An overview of professional liability in occupational therapy. Ranke BA, et al. **Am J Occup Ther** 1997 Sep;51(8):671-80 (17 ref.)

College of American Pathologists Conference XXX on quality and liability issues with the Papanicolaou smear: summation. Austin RM. **Arch Pathol Lab Med** 1997 Mar; 121(3):341-2 (21 ref.)

Quality and liability issues with the Papanicolaou smear: the problem of definition of errors and false-negative smears. Davey DD. **Arch Pathol Lab Med** 1997 Mar;121(3):267-9 (26 ref.)

Quality and liability issues with the Papanicolaou smear: lessons from the science of error prevention. Derman H. **Arch Pathol Lab Med** 1997 Mar;121(3):287-91 (16 ref.)

The gynecologist's perspective of liability and quality issues with the Papanicolaou smear. Greer BE. **Arch Pathol Lab Med** 1997 Mar;121(3):246-9 (30 ref.)

Liability issues with the Papanicolaou smear: general legal background. Kline TJ. **Arch Pathol Lab Med** 1997 Mar; 121(3):250-2 (14 ref.)

Liability issues with the Papanicolaou smear: the view of a hospital administrator at Newport Hospital, Newport, Rhode Island. Sampson AJ. **Arch Pathol Lab Med** 1997 Mar;121(3):241-5 (2 ref.)

Quality and liability issues with the Papanicolaou smear: the role of professional organizations in reform initiatives. Stanley MW. **Arch Pathol Lab Med** 1997 Mar;121(3):321-6 (10 ref.)

Liability issues with the Papanicolaou smear: a defense lawyer's perspective. Varner CD. **Arch Pathol Lab Med** 1997 Mar;121(3):315-20 (50 ref.)

Liability issues with the Papanicolaou smear: the expert witness database. Wood WS. **Arch Pathol Lab Med** 1997 Mar;121(3):335-40 (58 ref.)

Persistence is not always a virtue: tort reform, civil liability for health care, and the lack of empirical evidence. Daniels S, et al. **Behav Sci Law** 1997 Winter;15(1):3-19 (104 ref.)

Legal issues in allergy and clinical immunology. Gibofsky A. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 3):S334-8 (34 ref.)

Hazardous substance litigation in Maryland: theories of recovery and proof of causation. Gallacher I. **J Contemp Health Law Policy** 1997 Spring;13(2):423-59 (169 ref.)

Asking the impossible: the negligence liability of the mentally ill. Goldstein EJ. **J Contemp Health Law Policy** 1995 Fall; 12(1):67-92 (184 ref.)

The buck stops here: preemption of third-party claims by the false claims act. O'Neil TF 3rd, et al. **J Contemp Health Law Policy** 1995 Fall;12(1):41-65 (149 ref.)

Capitation, disease management, and physician liability. Frenkel M. **J Health Care Finance** 1997 Spring;23(3):87-90 (0 ref.)

Breaking through the tobacco industry's smoke screen: state lawsuits for reimbursement of medical expenses. Meade KE. **J Leg Med** 1996 Mar;17(1):113-41 (311 ref.)

Silicone breast implants. Can emerging medical, legal, and scientific concepts be reconciled? Snyder JW. **J Leg Med** 1997 Jun;18(2):133-220 (421 ref.)

Chiropractic liability within managed health care--implications for managed-care organizations. Sigler DC. **J Manipulative Physiol Ther** 1996 Jun;19(5):350-6 (32 ref.)

The search for the elusive electronic medical record system--medical liability, the missing factor. Grams RR, et al. **J Med Syst** 1997 Feb;21(1):1-10 (5 ref.)

Liability risks in gynaecology and obstetrics under German and Austrian law. Bernat E. **Med Law** 1995;14(5-6):413-23 (63 ref.)

Errors in cervical smears: minimizing the risk of medicolegal consequences. Greening SE. **Monogr Pathol** 1997; (39):16-39 (52 ref.)

The legal ramifications of the NCCN practice guidelines. Miller FH. **Oncology (Huntingt)** 1996 Nov;10(11 Suppl):35-9 (20 ref.)

Liability for pediatric care. Classé JG. **Optom Clin** 1996; 5(2):161-85 (66 ref.)

Refusing to pay for health care--Part II (of III): Emerging trends in third-party payer liability. Ross EJ. **Prog Cardiovasc Nurs** 1996 Spring;11(2):40-5 (57 ref.)

Refusing to pay for health care--Part III (of III): Avoiding third-party payer liability. Ross EJ. **Prog Cardiovasc Nurs** 1996 Summer;11(3):41-5 (35 ref.)

Legal issues in treating perpetrators and victims of violence. Resnick PJ, et al. **Psychiatr Clin North Am** 1997 Jun; 20(2):473-87 (74 ref.)

The consequences of knowing: ethical and legal liabilities in illicit drug research. Fitzgerald J, et al. **Soc Sci Med** 1996 Dec;43(11):1591-600 (35 ref.)

[Principles of physician's liability as it applies to the anesthetist (see comments)] Schlund GH. **Anaesthesist** 1996 Sep;45(9):789-97 (61 ref.) (Eng. Abstr.) Comment in: Anaesthesist 1997 May;46(5):462-4. Comment in: Anaesthesist 1997 Jul;46(7):627-8. **(Ger)**

[Reuse of disposable equipment. Medicolegal viewpoint] Fallani M, et al. **Minerva Cardioangiol** 1996 May; 44(5):263-73 (40 ref.) (Eng. Abstr.) **(Ita)**

LIBIDO

PHYSIOLOGY

Sexual functioning after multimodality treatment for disseminated nonseminomatous testicular germ cell tumor. van Basten JP, et al. **J Urol** 1997 Oct;158(4):1411-6 (47 ref.)

Bull libido/serving capacity. Chenoweth PJ. **Vet Clin North Am Food Anim Pract** 1997 Jul;13(2):331-44 (88 ref.)

LIBMAN-SACKS DISEASE see **LUPUS ERYTHEMATOSUS, SYSTEMIC**

LIBRARIANSHIP see **LIBRARY SCIENCE**

LIBRARIES, HEALTH SCIENCE see **LIBRARIES, MEDICAL**

LIBRARIES, MEDICAL

Characteristics of information resources preferred by primary care physicians. Thompson ML. **Bull Med Libr Assoc** 1997 Apr;85(2):187-92 (80 ref.)

[Medical databases, index books and library services] Suutarinen P. **Duodecim** 1995;111(19):1838-43 (6 ref.) **(Fin)**

LIBRARY SCIENCE

TRENDS

The changing face of health information and health information work: a conceptual framework. Bradley J. **Bull Med Libr Assoc** 1996 Jan;84(1):1-10 (40 ref.)

LIBRARY SERVICES

[Medical databases, index books and library services] Suutarinen P. **Duodecim** 1995;111(19):1838-43 (6 ref.) **(Fin)**

LICE

see related
PEDICULOSIS

METABOLISM

Toxins produced by arthropod parasites: salivary gland proteins of human body lice and venom proteins of chelonine wasps. Jones D, et al. **Toxicon** 1996 Nov-Dec; 34(11-12):1421-9 (32 ref.)

LICENSES see **LICENSURE**

LICENSURE

see related
ACCREDITATION
CERTIFICATION

Nutrition coverage on medical licensing examinations in the United States. Hark LA, et al. **Am J Clin Nutr** 1997 Feb; 65(2):568-71 (23 ref.)

Licensing, practice, and malpractice in occupational medicine. Rischitelli DG. **Occup Med** 1996 Jan-Mar; 11(1):121-35 (51 ref.)

LEGISLATION & JURISPRUDENCE

Juridical and sociocultural problems on the definition of a law concerning property, usage and access to genetic resources in Colombia. Calle R. **J Ethnopharmacol** 1996 Apr;51(1-3):127-42; discussion 142-6 (3 ref.)

Rules and regulations on the collection in Cameroon of biological materials for biological testing and drug discovery. Jato JG, et al. **J Ethnopharmacol** 1996 Apr; 51(1-3):121-5 (8 ref.)

Collection of biological materials in biodiversity prospecting in India: problems and solutions. Mehrotra BN. **J Ethnopharmacol** 1996 Apr;51(1-3):161-5 (0 ref.)

LICENSURE, HOSPITAL

Recommendations for qualification of centres implanting and following defibrillators. Study Group on Qualification of ICD Implanting Centers of the Working Groups on Arrhythmias and Cardiac Pacing of the European Society of Cardiology. Lévy S, et al. **Eur Heart J** 1996 Dec; 17(12):1796-9 (13 ref.)

LICENSURE, INSTITUTIONAL, PERSONNEL see **LICENSURE**

LICENSURE, NURSING

Computerized NCLEX-RN preparation programs. A comparative review. Billings D, et al. **Comput Nurs** 1996 Sep-Oct;14(5):272-86 (27 ref.)

Education for the nursing of children and their families: standards and guidelines for prelicensure and early professional education [published erratum appears in J Pediatr Nurs 1997 Apr;12(2):132] Pridham KF, et al. **J Pediatr Nurs** 1996 Oct;11(5):273-80 (29 ref.)

Education for entry into practice: an ethical perspective. Hess JD. **J Prof Nurs** 1996 Sep-Oct;12(5):289-96 (49 ref.)

Unlicensed assistive personnel in the perioperative setting. Micheli AJ, et al. **Nurs Clin North Am** 1997 Mar; 32(1):201-13 (24 ref.)

LEGISLATION & JURISPRUDENCE

Second licensure for advanced practice: current status. Robinson DL, et al. **Nurse Pract** 1996 Sep;21(9):71-4, 80-2, 88 (25 ref.)

TRENDS

Emerging licensing issues in Canada and the US. **Int Nurs Rev** 1996 Jul-Aug;43(4):113-20, 126 (37 ref.)

LICENSURE, PHARMACY

LEGISLATION & JURISPRUDENCE

'1996' starting the modern era of biologics regulation: FDA's elimination of establishment licensure and other changes. Gamerman GE, et al. **Biotechnol Appl Biochem** 1997 Jun; 25 (Pt 3):189-95 (31 ref.)

LICHEN PLANUS

CHEMICALLY INDUCED

Lichenoid reaction to hepatitis B vaccination. Saywell CA, et al. **Australas J Dermatol** 1997 Aug;38(3):152-4 (13 ref.)

DIAGNOSIS

[Genital erosive lichen planus] Vilmer C, et al. **Ann Dermatol Venereol** 1996;123(6-7):405-13 (70 ref.) **(Fre)**

IMMUNOLOGY

Immunologic aspects of dermal and oral lichen planus: a review. Porter SR, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Mar;83(3):358-66 (107 ref.)

PATHOLOGY

Lichenoid reaction to hepatitis B vaccination. Saywell CA, et al. **Australas J Dermatol** 1997 Aug;38(3):152-4 (13 ref.)

LICHEN PLANUS, ORAL

DIAGNOSIS

[Oral lichen planus (OLP). Therapeutic guidelines and clinical experience with 71 patients] Vescovi P, et al. **Minerva Stomatol** 1996 Nov;45(11):501-15 (38 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Cyclosporin A mouthwash in the treatment of oral lichen planus. Jungell P, et al. **Int J Oral Maxillofac Surg** 1996 Feb;25(1):60-2 (20 ref.)

ETIOLOGY

[The significance of the microflora of the oral cavity in the etiology and pathogenesis of lichen ruber planus] Rabinovich IM, et al. **Stomatologiia (Mosk)** 1997;76(2):72-5 (60 ref.) **(Rus)**

IMMUNOLOGY

Severe erosive stomatitis: association with immunological diseases? Reynaers A, et al. **Dermatology** 1997;194(4):411-5 (24 ref.)

Is there a role for tumor necrosis factor-alpha (TNF-alpha) in oral lichen planus? Sugermann PB, et al.

J Oral Pathol Med 1996 May;25(5):219–24 (81 ref.)
Immunologic aspects of dermal and oral lichen planus: a review. Porter SR, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Mar;83(3):358–66 (107 ref.)

LICHEN RUBER PLANUS see **LICHEN PLANUS**

LICHEN SCLEROSUS see **LICHEN SCLEROSUS ET ATROPHICUS**

LICHEN SCLEROSUS ET ATROPHICUS

COMPLICATIONS

Pathobiology of vulvar squamous neoplasia. Crum CP, et al. **Curr Opin Obstet Gynecol** 1997 Feb;9(1):63–9 (50 ref.)

DIAGNOSIS

Lichen sclerosus: early diagnosis is the key to treatment. Hall D. **Nurse Pract** 1996 Dec;21(12 Pt 1):57–8, 61–2 (16 ref.)

ETIOLOGY

A study of clinical and aetiological factors and possible associations of lichen sclerosus in males. Lipscombe TK, et al. **Australas J Dermatol** 1997 Aug;38(3):132–6 (26 ref.)

PATHOLOGY

Lichen sclerosus in women. Wakelin SH, et al.
Clin Dermatol 1997 Jan–Feb;15(1):155–69 (131 ref.)
Chronic white plaque of the vulva in postmenopausal women. Inazumi T, et al. **J Dermatol** 1996 Sep;23(9):635–8 (6 ref.)
Lichen sclerosus et atrophicus of the oral cavity: report of two cases. Brown AR, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Aug;84(2):165–70 (37 ref.)

LICHEN SIMPLEX CHRONICUS see **NEURODERMATITIS**

LICHENIFORM ERUPTIONS see **LICHENOID ERUPTIONS**

LICHENOID ERUPTIONS

CHEMICALLY INDUCED

Lichenoid drug eruption following the Blaschko lines. Muñoz MA, et al. **Dermatology** 1996;193(1):66–7 (10 ref.)

COMPLICATIONS

Nail lichen striatus: clinical features and long-term follow-up of five patients. Tosti A, et al. **J Am Acad Dermatol** 1997 Jun;36(6 Pt 1):908–13 (14 ref.)

LICHENS

Allergic contact dermatitis to liverworts, lichens, and mosses. Schmidt RJ. **Semin Dermatol** 1996 Jun;15(2):95–102 (86 ref.)

LICORICE see **GLYCYRRHIZA**

LIDOCAINE

[Topical anesthesia with the EMLA cream: application in pediatric urology] Xavier B, et al. **Actas Urol Esp** 1996 Nov–Dec;20(10):883–5 (15 ref.) (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

Evidence for safety margins of lignocaine local anaesthetics for peri-oral use. Cannell H. **Br Dent J** 1996 Oct 5; 181(7):243–9 (43 ref.)
Safe and effective topical application dose of lidocaine for surgery with laryngomicroscopy. Kotaki H, et al.
Clin Pharmacol Ther 1996 Aug;60(2):229–35 (15 ref.)
Use of streptomycin–lidocaine injections in the treatment of the cluster–tic syndrome. Clinical perspectives and a case report. Kreiner M. **J Craniomaxillofac Surg** 1996 Oct; 24(5):289–92 (48 ref.)

ADVERSE EFFECTS

Safe and effective topical application dose of lidocaine for surgery with laryngomicroscopy. Kotaki H, et al.
Clin Pharmacol Ther 1996 Aug;60(2):229–35 (15 ref.)

CONTRAINDICATIONS

[The systemic problems in the dental treatment of the elderly patients] Matsuura H. **Nippon Ronen Igakkai Zasshi** 1996 Jul;33(7):505–7 (0 ref.) **(Jpn)**

LIE DETECTION

The North American polygraph and psychophysiology: disinterested, uninterested, and interested perspectives. Furedy JJ. **Int J Psychophysiol** 1996 Feb–Mar; 21(2–3):97–105 (13 ref.)

LIFE

Life on Mars: a clue to life on Earth? Brack A.
Chem Biol 1997 Jan;4(1):9–12 (27 ref.)
[Natural atomic radiation and phenomenon of life] Kuzin AM. **Biull Eksp Biol Med** 1997 Apr;123(4):364–6 (28 ref.) **(Rus)**

LIFE CHANGE EVENTS

Experience Producing Drive Theory: how genes drive experience and shape personality. Bouchard TJ Jr.
Acta Paediatr Suppl 1997 Jul;422:60–4 (41 ref.)
The effects of stressful life events on depression. Kessler RC.
Annu Rev Psychol 1997;48:191–214 (133 ref.)
Toward a middle-range theory of resilience. Polk LV.
ANS Adv Nurs Sci 1997 Mar;19(3):1–13 (42 ref.)
The concept of resilience. Wolff S.
Aust N Z J Psychiatry 1995 Dec;29(4):565–74 (61 ref.)
Recent undesirable life events: their influence on subsequent psychopathology. Goodyer IM.
Eur Child Adolesc Psychiatry 1996;5 Suppl 1:33–7 (29 ref.)
Dyspepsia world-wide and the role of stress [comment] Thompson WG. **Eur J Gastroenterol Hepatol** 1997 Jan; 9(1):7–8 (4 ref.) Comment on: Eur J Gastroenterol Hepatol 1997 Jan;9(1):21–6.
Toward a definition of family resilience: integrating life-span and family perspectives. Hawley DR, et al.
Fam Process 1996 Sep;35(3):283–98 (66 ref.)
The concept of family resilience: crisis and challenge. Walsh F. **Fam Process** 1996 Sep;35(3):261–81 (112 ref.)
Stress and the life course: a paradigmatic alliance. Pearlin LI, et al. **Gerontologist** 1996 Apr;36(2):239–47 (69 ref.)
Trauma and the gut: interactions between stressful experience and intestinal function. Stam R, et al. **Gut** 1997 Jun; 40(6):704–9 (110 ref.)
Depression following a spinal cord injury. Boekamp JR, et al. **Int J Psychiatry Med** 1996;26(3):329–49 (97 ref.)
Neural regulation of viscera elicited by individual interpretations of life experiences. Wolf S.
Integr Physiol Behav Sci 1997 Apr–Jun;32(2):109–12 (14 ref.)
The trait and process of resilience. Jacelon CS.
J Adv Nurs 1997 Jan;25(1):123–9 (25 ref.)
Trauma: prevalence, impairment, service use, and cost. Solomon SD, et al. **J Clin Psychiatry** 1997;58 Suppl 9:5–11 (30 ref.)
Additive effects, but no synergistic interaction of stressful life-events and genetic loading in affective disorders. Fritze J, et al. **J Neural Transm** 1996;103(10):1221–9 (24 ref.)
Construing benefits from adversity: adaptational significance and dispositional underpinnings. Affleck G, et al.
J Pers 1996 Dec;64(4):899–922 (85 ref.)
The mismeasure of coping by checklist. Coyne JC, et al.
J Pers 1996 Dec;64(4):959–91 (70 ref.)
Coping and personality: third time's the charm? Suls J, et al. **J Pers** 1996 Dec;64(4):993–1005 (43 ref.)
Positive illusions and coping with adversity. Taylor SE, et al. **J Pers** 1996 Dec;64(4):873–98 (80 ref.)
Donor insemination, the impact on family and child development. Brewaeys A.
J Psychosom Obstet Gynaecol 1996 Mar;17(1):1–13 (62 ref.)
An existential model for promoting life change. Confronting the disease concept. Ford GG. **J Subst Abuse Treat** 1996 Mar–Apr;13(2):151–8 (35 ref.)
The Interview for Recent Life Events. Paykel ES.
Psychol Med 1997 Mar;27(2):301–10 (95 ref.)
Persistent changes in corticotropin-releasing factor systems due to early life stress: relationship to the pathophysiology of major depression and post-traumatic stress disorder. Heim C, et al. **Psychopharmacol Bull** 1997;33(2):185–92 (63 ref.)
From the lesson of Harvey Cushing to current knowledge: psychosocial aspects of endocrine disease [editorial] Sonino N. **Psychother Psychosom** 1997;66(3):113–6 (32 ref.)
Tracking of physical activity and physical fitness across the lifespan. Malina RM. **Res Q Exerc Sport** 1996 Sep;67(3 Suppl):S48–57 (64 ref.)
[Psychological factors and life change events in bipolar patients] Hardy-Baylé MC. **Encephale** 1997 Jan;23 Spec No 1:20–6 (45 ref.) (Eng. Abstr.) **(Fre)**
[Life change event--life history--life plant: psychopathologic and forensic aspects] Janzarik W.
Nervenarzt 1996 Jul;67(7):545–51 (15 ref.) (Eng. Abstr.) **(Ger)**

LIFE EXPECTANCY

see related
LONGEVITY

The geriatrician in 1996--a viewpoint from Switzerland. Michel JP, et al. **Aging (Milano)** 1996 Apr;8(2):135–40 (32 ref.)
Human senescence. Kirkwood TB. **Bioessays** 1996 Dec; 18(12):1009–16 (58 ref.)
How does hormone replacement therapy affect the longevity of women with different risk profiles? Frank J, et al.
Can Fam Physician 1997 Aug;43:1371–3 (5 ref.)
Life expectancy, comorbidity, and quality of life. A framework of reference for medical decisions. Bennahum DA, et al. **Clin Geriatr Med** 1997 Feb;13(1):33–53 (94 ref.)
Undernutrition and aging. Aihie Sayer A, et al.
Gerontology 1997;43(4):203–5 (22 ref.)
Survival beyond age 70 in relation to diet. de Groot LC, et al. **Nutr Rev** 1996 Jul;54(7):211–2 (10 ref.)
Is there a fountain of youth? A review of current life extension strategies. Bernarducci MP, et al.
Pharmacotherapy 1996 Mar–Apr;16(2):183–200 (74 ref.)
[Menopause and postmenopause. Prognostic criteria in insurance medicine] Schiefeling M. **Versicherungsmedizin** 1996 Aug 1;48(4):116–25 (62 ref.) (Eng. Abstr.) **(Ger)**
[Familial adenomatous polyposis. Problems encountered with rectum preservation in surgical treatment and life expectancy] Colombo PL, et al. **Ann Ital Chir** 1995 Sep–Oct;66(5):671–83 (67 ref.) (Eng. Abstr.) **(Ita)**

TRENDS

A theory of technophysio evolution, with some implications for forecasting population, health care costs, and pension costs [published erratum appears in Demography 1997 May;34(2):170] Fogel RW, et al. **Demography** 1997 Feb; 34(1):49–66 (119 ref.)
Changes in the age dependence of mortality and disability: cohort and other determinants. Manton KG, et al.
Demography 1997 Feb;34(1):135–57 (77 ref.)

LIFE EXPERIENCES see **LIFE CHANGE EVENTS**

LIFE SCIENCES see **BIOLOGICAL SCIENCES**

LIFE STYLE

see related
HEALTH BEHAVIOR
QUALITY OF LIFE

Predicting and coping with the consequences of stopping driving. O'Neill D. **Alzheimer Dis Assoc Disord** 1997 Jun; 11 Suppl 1:70–2 (22 ref.)
Anemia and the transition of nomadic hunter-gatherers to a sedentary life-style: follow-up study of a Kalahari community. Kent S, et al. **Am J Phys Anthropol** 1996 Mar; 99(3):455–72 (46 ref.)
Women's health initiative. Why now? What is it? What's new? Matthews KA, et al. **Am Psychol** 1997 Feb;52(2):101–16 (100 ref.)
Obesity as a risk factor for various diseases: necessity of lifestyle changes for healthy aging. Tanaka K, et al.
Appl Human Sci 1996 Jul;15(4):139–48 (76 ref.)
Human senescence. Kirkwood TB. **Bioessays** 1996 Dec; 18(12):1009–16 (58 ref.)
Obesity management by life-style strategies. Cowburn G, et al. **Br Med Bull** 1997;53(2):389–408 (92 ref.)
Social and biological pathways linking early life and adult disease. Power C, et al. **Br Med Bull** 1997 Jan;53(1):210–21 (58 ref.)
Barriers to lifestyle change, and the need to develop an integrated approach to prevention. Ockene IS, et al.
Cardiol Clin 1996 Feb;14(1):159–69 (54 ref.)
Oxidative stress associated with exercise, psychological stress and life-style factors. Møller P, et al.
Chem Biol Interact 1996 Sep 27;102(1):17–36 (171 ref.)
Stress, coping, lifestyle and hypertension: a paradigm for research, prevention and non-pharmacological management of hypertension. Beilin LJ.
Clin Exp Hypertens 1997 Jul–Aug;19(5–6):739–52 (24 ref.)
The potential for lifestyle change to influence the progression of impaired glucose tolerance to non-insulin-dependent diabetes mellitus. Bourn DM. **Diabet Med** 1996 Nov; 13(11):938–45 (55 ref.)
Life-style factors and female infertility. Buck GM, et al.
Epidemiology 1997 Jul;8(4):435–41 (59 ref.)
Angina in patients with an active lifestyle. Mittleman MA.
Eur Heart J 1996 Dec;17 Suppl G:30–5 (33 ref.)
A systematic review of the effectiveness of promoting lifestyle change in general practice. Ashenden R, et al.
Fam Pract 1997 Apr;14(2):160–76 (51 ref.)
Diet and lung cancer 20+ years later: more questions than answers? Koo LC. **Int J Cancer** 1997;Suppl 10:22–9 (82 ref.)
Position of the American Dietetic Association: weight management. **J Am Diet Assoc** 1997 Jan;97(1):71–4 (44 ref.)
Fat, caloric intake, and obesity: lifestyle risk factors for breast cancer. Greenwald P, et al. **J Am Diet Assoc** 1997 Jul;97(7 Suppl):S24–30 (76 ref.)
Life-style changes and coronary heart disease: the influence of nonpharmacologic interventions. Fair JM, et al.
J Cardiovasc Nurs 1995 Jan;9(2):12–24 (33 ref.)
Life style as a blood pressure determinant. Staessen JA, et al. **J R Soc Med** 1996 Sep;89(9):484–9 (89 ref.)
Guidelines for school and community programs to promote lifelong physical activity among young people. National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and prevention.
J Sch Health 1997 Aug;67(6):202–19 (276 ref.)
Fruits and vegetables: protective or just fellow travelers? Nestle M. **Nutr Rev** 1996 Aug;54(8):255–7 (22 ref.)
Lifestyle, fibrinolysis and lipids. Brommer EJ, et al.
Pharm World Sci 1997 Apr;19(2):82–8 (65 ref.)
Lifestyle modifications for hypertension. The many benefits are worth the effort. Zellner C, et al. **Postgrad Med** 1996 Oct;100(4):75–9, 83 (28 ref.)
Physical activity and health: atherosclerotic, metabolic, and hypertensive diseases. Bouchard C, et al.
Res Q Exerc Sport 1995 Dec;66(4):268–75 (70 ref.)

LIFE STYLE

Roles of diet and physical activity in the prevention of osteoporosis. Anderson JJ, et al. **Scand J Rheumatol Suppl** 1996;103:65–74 (43 ref.)

Finnish research project on aging workers in 1981–1992. Tuomi K, et al. **Scand J Work Environ Health** 1997;23 Suppl 1:7–11 (33 ref.)

Physical activity and risk of cardiovascular disease in middle-aged individuals. Recommendations. Rauramaa R, et al. **Sports Med** 1996 Aug;22(2):65–9 (35 ref.)

Paths to recovery from substance misuse: change of lifestyle and the role of treatment. Biomqvist J. **Subst Use Misuse** 1996 Nov;31(13):1807–52 (109 ref.)

[Injuries in elderly patients: maximal management versus minimal osteosynthesis depending on active life style and economic resources] Roesgen M. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:903–6 (6 ref.) (Eng. Abstr.) **(Ger)**

[Prognostic aspects of metabolic syndrome. Is the "good living" syndrome regarded seriously enough in general insurance medicine practice?] Regenauer A. **Versicherungsmedizin** 1996 Oct 1;48(5):161–9 (49 ref.) (Eng. Abstr.) **(Ger)**

[New special research data on over 100-year-old and older probands and problems (II)] Franke H. **Z Gerontol Geriatr** 1997 Mar–Apr;30(2):130–55 (119 ref.) (Eng. Abstr.) **(Ger)**

LIFE SUPPORT CARE

see related
RESUSCITATION ORDERS

Life support courses: are they effective? Jabbour M, et al. **Ann Emerg Med** 1996 Dec;28(6):690–8 (39 ref.)

Advanced life support for acute toxic injury (TOXALS). Baker DJ. **Eur J Emerg Med** 1996 Dec;3(4):256–62 (12 ref.)

Worldwide similarities and differences in the foregoing of life-sustaining treatments [editorial; comment] Sprung CL, et al. **Intensive Care Med** 1996 Oct;22(10):1003–5 (37 ref.) Comment on: Intensive Care Med 1996 Oct;22(10):1015–9. Comment on: Intensive Care Med 1996 Oct;22(10):1020–5.

Persistent vegetative state: important considerations for the neuroscience nurse. Ozuna J. **J Neurosci Nurs** 1996 Jun; 28(3):199–203 (20 ref.)

Advance directives: from the perspective of the patient and the physician [published erratum appears in J R Soc Med 1997 Feb;90(2):120] Johnston SC, et al. **J R Soc Med** 1996 Oct;89(10):568–70 (31 ref.)

Paediatric life support. An advisory statement by the Paediatric Life Support Working Group of the International Liaison Committee on Resuscitation. Nadkarni V, et al. **Resuscitation** 1997 Apr;34(2):115–27 (69 ref.)

ECONOMICS

[The limits of intensive care medicine] Kox WJ, et al. **Zentralbl Chir** 1996;121(7):515–20 (15 ref.) (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

[Legal limits of assisted death: exemplified by amyotrophic lateral sclerosis] Bernat E. **Wien Med Wochenschr** 1996; 146(9–10):195–8 (50 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Overcoming language barriers when teaching the Advanced Trauma Life Support course [editorial] Ali J, et al. **Eur J Surg** 1997 Jul;163(7):483–6 (14 ref.)

[Life support for homeostasis in organ donors] Stocker R, et al. **Schweiz Med Wochenschr** 1997 Jun 14; 127(24):1044–50 (30 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

Health professional decision-making in the ICU: a review of the evidence. Cook DJ. **New Horiz** 1997 Feb;5(1):15–9 (46 ref.)

Withholding and withdrawal of life support: ethical, legal, and clinical aspects. Luce JM. **New Horiz** 1997 Feb; 5(1):30–7 (28 ref.)

LIFE SUPPORT SYSTEMS

Future directions for resuscitation research. V. Ultra-advanced life support. Tisherman SA, et al. **Resuscitation** 1997 Jun;34(3):281–93 (93 ref.)

[Mechanical myocardial support systems 1997: an overview of inta-aortic balloon counterpulsation to implantable left ventricular support systems] Hammel D, et al. **Anaesthesist** 1997 May;46(5):408–18 (66 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

Timing of intracranial hemorrhage during extracorporeal life support. Biehl DA, et al. **ASAIO J** 1996 Nov–Dec; 42(6):938–41 (16 ref.)

LIFE SUPPORT SYSTEMS, REGENERATIVE see **ECOLOGICAL SYSTEMS, CLOSED**

LIFE TABLE ANALYSIS see **LIFE TABLES**

LIFE TABLE METHODS see **LIFE TABLES**

LIFE TABLE MODELS see **LIFE TABLES**

LIFE TABLES

Assessing the reliability of paleodemographic fertility estimators using simulated skeletal distributions. Paine RR, et al. **Am J Phys Anthropol** 1996 Oct;101(2):151–9 (38 ref.)

What demographers can learn from fruit fly actuarial models and biology. Carey JR. **Demography** 1997 Feb;34(1):17–30 (151 ref.)

LIFTING

ADVERSE EFFECTS

Back pain in the workplace. What you lift or how you lift matters far less than whether you lift or when [editorial] Hadler NM. **Spine** 1997 May 1;22(9):935–40 (41 ref.)

LIGAMENTS

[Dunbar's syndrome: clinical reality or physiopathologic hypothesis?] De Cecchis L, et al. **Ann Ital Chir** 1996 Jul–Aug;67(4):501–5 (28 ref.) (Eng. Abstr.) **(Ita)**

ABNORMALITIES

Thrombocytopenia in association with a wandering spleen. Moll S, et al. **Am J Hematol** 1996 Dec;53(4):259–63 (17 ref.)

Are left-sided gallbladders really located on the left side? Nagai M, et al. **Ann Surg** 1997 Mar;225(3):274–80 (32 ref.)

PATHOLOGY

[Incisional hernia after surgical laparoscopy: a case of hepatic ligament incarceration and review of the literature] Deval B, et al. **Contracept Fertil Sex** 1997 Jan;25(1):66–8 (14 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Sacrospinous vault fixation. Hogston P. **Br J Hosp Med** 1997 Jan 15–Feb 5;57(1–2):39–40 (4 ref.)

LIGAMENTS, ARTICULAR

ANATOMY & HISTOLOGY

The ligaments of the wrist. A current overview of anatomy with considerations of their potential functions. Berger RA. **Hand Clin** 1997 Feb;13(1):63–82 (25 ref.)

Current concepts: the stabilizing structures of the glenohumeral joint. Wilk KE, et al. **J Orthop Sports Phys Ther** 1997 Jun;25(6):364–79 (119 ref.)

MR imaging of the knee ligaments and the postoperative knee. Irizarry JM, et al. **Radiol Clin North Am** 1997 Jan; 35(1):45–76 (80 ref.)

MR arthrography of the rotator cuff and labral-ligamentous complex. Palmer WE. **Semin Ultrasound CT MR** 1997 Aug; 18(4):278–90 (19 ref.)

INJURIES

Current opinions in etiopathogenesis of headaches caused by cervical spine pathology. Wojczal J. **Ann Univ Mariae Curie Sklodowska [Med]** 1995;50:95–101 (16 ref.)

Arthroscopic repairs of triangular fibrocartilage complex tears. Baehser-Griffith P, et al. **AORN J** 1997 Jul; 66(1):101–2, 105–11, quiz 112, 115, 117–8 (23 ref.)

Impingement syndrome of the ankle caused by a medial meniscoid lesion. Egol KA, et al. **Arthroscopy** 1997 Aug; 13(4):522–5 (10 ref.)

Ankle ligament injuries. Renström PA, et al. **Br J Sports Med** 1997 Mar;31(1):11–20 (134 ref.)

Functional knee braces and dynamic performance: a review. Kramer JF, et al. **Clin J Sport Med** 1997 Jan;7(1):32–9 (17 ref.)

Atlanto-axial dislocation without fracture: case report of an ejection injury. Boos N, et al. **J Bone Joint Surg Br** 1997 Mar;79(2):204–5 (8 ref.)

[Possibilities of gene therapy in traumatic and degenerative articular lesions. Current status of experimental and initial clinical applications] Gerich TG, et al. **Orthopade** 1997 May;26(5):450–8 (92 ref.) (Eng. Abstr.) **(Ger)**

[New developments in joint surgery] Lobenhoffer P, et al. **Orthopade** 1997 May;26(5):422–36 (76 ref.) (Eng. Abstr.) **(Ger)**

[Biomechanics of the ligaments of the unstable ankle joint] Hintermann B. **Sportverletz Sportschaden** 1996 Sep; 10(3):48–54 (64 ref.) (Eng. Abstr.) **(Ger)**

[Diagnostic imaging of ankle joint instability] Schäfer D, et al. **Sportverletz Sportschaden** 1996 Sep;10(3):55–7 (30 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Pathological anatomy and dynamic effect of the displaced plantar plate and the importance of the integrity of the plantar plate-deep transverse metatarsal ligament tie-bar. Stainsby GD. **Ann R Coll Surg Engl** 1997 Jan;79(1):58–68 (17 ref.)

Synovial cyst and degeneration of the transverse ligament: an unusual cause of high cervical myelopathy. Case report. Fransen P, et al. **J Neurosurg** 1997 Jun;86(6):1027–30 (17 ref.)

[Arthroscopic aspects and chronologic outcome of lesions of the labro-ligament complex in post-traumatic antero-inferior instability of the shoulder. A prospective study of 91 cases] Gleyze P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(4):288–98 (46 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Biomechanics of knee ligaments: basic concepts and clinical application. Fu FH, et al. **Instr Course Lect** 1994;43:137–48 (97 ref.)

Biomechanical studies of the remodeling of knee joint tendons and ligaments. Hayashi K. **J Biomech** 1996 Jun; 29(6):707–16 (55 ref.)

PHYSIOPATHOLOGY

Evaluation of the child with ligamentous laxity. Agnew P. **Clin Podiatr Med Surg** 1997 Jan;14(1):117–30 (29 ref.)

Anterior-inferior capsular length insufficiency in the painful shoulder. Hjelm R, et al. **J Orthop Sports Phys Ther** 1996 Mar;23(3):216–22 (14 ref.)

SURGERY

Arthroscopic repairs of triangular fibrocartilage complex tears. Baehser-Griffith P, et al. **AORN J** 1997 Jul; 66(1):101–2, 105–11, quiz 112, 115, 117–8 (23 ref.)

Arthroscopic stabilization of the ankle. Kashuk KB, et al. **Clin Podiatr Med Surg** 1997 Jul;14(3):459–78 (38 ref.)

Open or arthroscopic lateral release. Indications, techniques, and rehabilitation. Ford DH, et al. **Clin Sports Med** 1997 Jan;16(1):29–49 (55 ref.)

[Acute and chronic knee ligament injuries] Hertel P. **Unfallchirurg** 1996 Sep;99(9):686–700; quiz 699 (15 ref.) **(Ger)**

ULTRASONOGRAPHY

[Sonography of the knee extensor system] Gruber G. **Ultraschall Med** 1996 Oct;17(5):206–11 (16 ref.) (Eng. Abstr.) **(Ger)**

LIGAMENTS, COLLATERAL see **COLLATERAL LIGAMENTS**

LIGAMENTS, LATERAL see **COLLATERAL LIGAMENTS**

LIGAMENTUM COLLATERALE TIBIALE see **MEDIAL COLLATERAL LIGAMENT, KNEE**

LIGAMENTUM LATERALE ARTICULATIONIS TALOCRURALIS see **LATERAL LIGAMENT, ANKLE**

LIGAMENTUM PATELLAE see **PATELLAR LIGAMENT**

LIGANDINS see **GLUTATHIONE TRANSFERASES**

LIGANDS

see related
RADIOLIGAND ASSAY
RECEPTORS, CELL SURFACE

"Small is beautiful": major modifications in DNA structure or dynamics by small substituents or ligands. Guschlbauer W. **Acta Biochim Pol** 1996;43(1):77–94 (97 ref.)

A new class of models for computing receptor–ligand binding affinities. Gilson MK, et al. **Chem Biol** 1997 Feb;4(2):87–92 (78 ref.)

Ligand function of antigenized antibodies expressing the RGD motif. Billetta R, et al. **Chem Immunol** 1997;65:159–78 (53 ref.)

Engineering minibody-like ligands by design and selection. Sollazzo M, et al. **Chem Immunol** 1997;65:1–17 (64 ref.)

P2X receptors: a third major class of ligand-gated ion channels. North RA. **Ciba Found Symp** 1996;198:91–105; discussion 105–9 (76 ref.)

Prolactin and growth hormone receptors. Goffin V, et al. **Clin Endocrinol (Oxf)** 1996 Sep;45(3):247–55 (120 ref.)

Nuclear magnetic resonance (NMR) analysis of ligand receptor interactions: the cholinergic system—a model. Fraenkel Y, et al. **Crit Rev Biochem Mol Biol** 1996; 31(4):273–301 (149 ref.)

Functions of CD40 and its ligand, gp39 (CD40L). Laman JD, et al. **Crit Rev Immunol** 1996;16(1):59–108 (220 ref.)

The multiple origins of cooperativity in binding to multi-site lattices. Sackett DL, et al. **FEBS Lett** 1996 Nov 11; 397(1):1–6 (19 ref.)

Getting integrins into shape: recent insights into how integrin activity is regulated by conformational changes. Mould AP. **J Cell Sci** 1996 Nov;109 (Pt 11):2613–8 (56 ref.)

Partial activation of foreign antigen specific T lymphocytes by a self peptide: possible roles of altered peptide ligands in regulating T lymphocyte mediated immune response. Cao W, et al. **J Mol Med** 1996 Oct;74(10):573–82 (104 ref.)

Molecular interaction analysis in ligand design using mass transport, kinetic and thermodynamic methods. Doyle ML, et al. **J Mol Recognit** 1996 Mar–Apr;9(2):65–74 (33 ref.)

Automated docking of flexible ligands: applications of AutoDock. Goodsell DS, et al. **J Mol Recognit** 1996 Jan–Feb;9(1):1–5 (23 ref.)
Energetic and entropic factors determining binding affinity in protein–ligand complexes. Klebe G, et al. **J Recept Signal Transduct Res** 1997 Jan–May; 17(1–3):459–73 (58 ref.)
Thermodynamic parameters of ligand–receptor interactions: computation and error margins [published erratum appears in J Recept Signal Transduct Res 1997 Jul;17(4):667] Pliška V. **J Recept Signal Transduct Res** 1997 Jan–May; 17(1–3):495–510 (22 ref.)
Studies of protein–ligand interactions by NMR. Craik DJ, et al. **Methods Mol Biol** 1997;60:195–232 (61 ref.)
The TNF–ligand and receptor superfamilies: controllers of immunity and the Trojan horses of autoimmune disease? Hill CM, et al. **Mol Aspects Med** 1996 Oct;17(5):455–509 (240 ref.)
Computational tools for structure–based ligand design. Böhm HJ. **Prog Biophys Mol Biol** 1996;66(3):197–210 (106 ref.)
Neuroprotective and anti–amnesic potentials of sigma (sigma) receptor ligands. Maurice T, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Jan; 21(1):69–102 (224 ref.)
Solving inconsistencies in the analysis of receptor–ligand interactions. Tuk B, et al. **Trends Pharmacol Sci** 1996 Nov; 17(11):403–9 (22 ref.)
[Analysis and characterization of ligand–receptor binding systems] Ogawa N. **Nippon Rinsho** 1997 Apr;55 Suppl 2:444–9 (14 ref.) **(Jpn)**
[The selections, selectin ligands and hemopoitic system] Miyakasa M. **Rinsho Ketsueki** 1996 Jun;37(6):502–5 (0 ref.) **(Jpn)**

LIGASES

Purification and properties of bovine and human holocarboxylase synthetases. Suzuki Y, et al. **Methods Enzymol** 1997;279:386–93 (12 ref.)

CHEMISTRY

Structure of ATP–dependent carboxylase, dethiobiotin synthase. Schneider G, et al. **Methods Enzymol** 1997; 279:376–85 (21 ref.)
Structure and mechanism of action of the vitamin K–dependent gamma–glutamyl carboxylase: recent advances from mutagenesis studies. Furie BC, et al. **Thromb Haemost** 1997 Jul;78(1):595–8 (25 ref.)

GENETICS

Characterization of the gamma–glutamyl carboxylase. Wu SM, et al. **Thromb Haemost** 1997 Jul;78(1):599–604 (31 ref.)

METABOLISM

Ligase chain reaction. Lee HH. **Biologicals** 1996 Sep; 24(3):197–9 (6 ref.)
Modulation of the surface architecture of gram–negative bacteria by the action of surface polymer:lipid A–core ligase and by determinants of polymer chain length. Whitfield C, et al. **Mol Microbiol** 1997 Feb;23(4):629–38 (36 ref.)
Biochemical and molecular studies of human methenyltetrahydrofolate synthetase. Jolivet J, et al. **Stem Cells** 1996 Jan;14(1):33–40 (55 ref.)

LIGATION, TUBAL see **STERILIZATION, TUBAL**

LIGHT

see related
LIGHTING
PHOTIC STIMULATION
PHOTOBIOLOGY
PHOTOCHEMISTRY
PHOTOCHEMOTHERAPY
PHOTOMETRY
PHOTOSENSITIVITY DISORDERS
PHOTOSYNTHESIS
PHOTOTHERAPY
SUNLIGHT
ULTRAVIOLET THERAPY

Light–harvesting complexes in oxygenic photosynthesis: diversity, control, and evolution. Grossman AR, et al. **Annu Rev Genet** 1995;29:231–88 (368 ref.)
A fundamental step–transition in retinal function at low light intensities. Morgan IG, et al. **Aust N Z J Ophthalmol** 1997 May;25 Suppl 1:S70–2 (15 ref.)
The genetics of phototransduction and circadian rhythms in Arabidopsis. Millar AJ, et al. **Bioessays** 1997 Mar; 19(3):209–14 (41 ref.)
Let there be light: signal transduction in a mammalian circadian system. Golombek DA, et al. **Braz J Med Biol Res** 1996 Jan;29(1):131–40 (77 ref.)
Plant photomorphogenesis: a green light for cryptochrome research. Whitelam G. **Curr Biol** 1995 Dec 1;5(12):1351–3 (7 ref.)
Phototransduction in transgenic mice. Lem J, et al. **Curr Opin Neurobiol** 1996 Aug;6(4):453–8 (45 ref.)
Response of the maize catalases to light. Polidoros AN, et al. **Free Radic Biol Med** 1997;23(3):497–504 (56 ref.)
Basic principles of optical radiation and some common applications in anesthesia. Gravenstein D, et al. **J Clin Monit** 1996 Nov;12(6):445–54 (75 ref.)
Dioptric power: its nature and its representation in three– and four–dimensional space [see comments] Harris WF. **Optom Vis Sci** 1997 Jun;74(6):349–66 (84 ref.) Comment in: Optom Vis Sci 1997 Jun;74(6):339–41.
Wavefronts and their propagation in astigmatic optical systems. Harris WF. **Optom Vis Sci** 1996 Sep;73(9):606–12 (31 ref.)
Light signal transduction in plants. Staub JM, et al. **Photochem Photobiol** 1996 Dec;64(6):897–905 (109 ref.)
Optical imaging in medicine: II. Modelling and reconstruction. Arridge SR, et al. **Phys Med Biol** 1997 May; 42(5):841–53 (50 ref.)
Optical imaging in medicine: I. Experimental techniques. Hebden JC, et al. **Phys Med Biol** 1997 May;42(5):825–40 (75 ref.)
Light dosimetry in vivo. Star WM. **Phys Med Biol** 1997 May; 42(5):763–87 (125 ref.)
The role of the COP/DET/FUS genes in light control of arabidopsis seedling development. Wei N, et al. **Plant Physiol** 1996 Nov;112(3):871–8 (46 ref.)
Pulsed light and pulsed electric field for foods and eggs. Dunn J. **Poult Sci** 1996 Sep;75(9):1133–6 (0 ref.)
From seed germination to flowering, light controls plant development via the pigment phytochrome. Chory J, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12066–71 (63 ref.)
A retinal dark–light switch: a review of the evidence. Morgan IG, et al. **Vis Neurosci** 1996 May–Jun;13(3):399–409 (134 ref.)
[How does, bacteriorhodopsin convert light into energy?] Kandori H, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb; 42(2):101–9 (41 ref.) **(Jpn)**
[Phytochrome: a plant sensor for environmental light conditions] Tokutomi S. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(2):121–8 (31 ref.) **(Jpn)**
[The biological role of Vavilov–Cerenkov emission] Morozov II. **Radiats Biol Radioecol** 1996 Nov–Dec; 36(6):921–5 (32 ref.) (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Optical radiation safety of medical light sources. Sliney DH. **Phys Med Biol** 1997 May;42(5):981–96 (50 ref.)
[Drugs and light] Tønnesen HH. **Tidsskr Nor Laegeforen** 1997 Jun 30;117(17):2481–3 (18 ref.) (Eng. Abstr.) **(Nor)**

LIGHT ADAPTATION see **ADAPTATION, OCULAR**

LIGHT, LUMINESCENT see **LUMINESCENCE**

LIGHT SIGNAL TRANSDUCTION see **PHOTOTRANSDUCTION**

LIGHT, VISIBLE see **LIGHT**

LIGHTING

Bright light: a countermeasure for jet lag? Samel A, et al. **Chronobiol Int** 1997 Mar;14(2):173–83 (40 ref.)
Mach bands: how many models are possible? Recent experimental findings and modeling attempts. Pessoa L. **Vision Res** 1996 Oct;36(19):3205–27 (115 ref.)

LIGHTNING INJURIES

[Lightning injuries. Mechanisms and treatment] Wanner–Olsen H, et al. **Ugeskr Laeger** 1996 Dec 9; 158(50):7210–2 (11 ref.) (Eng. Abstr.) **(Dan)**

COMPLICATIONS

Nature's high–voltage injuries: sometimes a deadly consequence. Shaw PK, et al. **Neth J Med** 1996 Oct; 49(4):153–9 (20 ref.)

DIAGNOSIS

MRI of lightning injury: early white matter changes associated with cerebral dysfunction [see comments] Milton WJ, et al. **J Okla State Med Assoc** 1996 Mar;89(3):93–4 (9 ref.) Comment in: J Okla State Med Assoc 1997 Feb;90(2):74.

LIGHTNING STROKE see **LIGHTNING INJURIES**

LIGNAC–FANCONI SYNDROME see **FANCONI SYNDROME**

LIGNANS

CHEMICAL SYNTHESIS

[Weitz' aminium salt initiated electron transfer reactions and application to the synthesis of natural products] Takeya T, et al. **Yakugaku Zasshi** 1997 Jun;117(6):353–67 (21 ref.) (Eng. Abstr.) **(Jpn)**

LIGNIN

METABOLISM

Lignin biodegradation by the ascomycete Chrysonilia sitophila. Rodríguez J, et al. **Appl Biochem Biotechnol** 1997 Feb–Mar;62(2–3):233–42 (70 ref.)
Mechanism and potential applications of bio–ligninolytic systems in a CELSS. Sarikaya A, et al. **Appl Biochem Biotechnol** 1997 Feb–Mar;62(2–3):131–49 (43 ref.)

THERAPEUTIC USE

[The enterosorbent polifepan in the treatment of organic diseases of the digestive system] Frol'kis AV. **Ter Arkh** 1997;69(2):76–80 (43 ref.) **(Rus)**

LIGNOCAINE see **LIDOCAINE**

LIKELIHOOD FUNCTIONS

Inferences for likelihood ratios in the absence of a "gold standard". Joseph L, et al. **Med Decis Making** 1996 Oct–Dec;16(4):412–7 (18 ref.)

LIMBIC SYSTEM

ABNORMALITIES

Agenesis of cerebellum associated with arrhinencephaly. Leech RW, et al. **Clin Neuropathol** 1997 Mar–Apr; 16(2):90–7 (98 ref.)
Brainstem, cerebellar and limbic neuroanatomical abnormalities in autism. Courchesne E. **Curr Opin Neurobiol** 1997 Apr;7(2):269–78 (67 ref.)

ANATOMY & HISTOLOGY

Functional anatomy of human hippocampal formation and related structures. Braak H, et al. **J Child Neurol** 1996 Jul; 11(4):265–75 (100 ref.)
The anatomical relationships of the prefrontal cortex with limbic structures and the basal ganglia. Groenewegen HJ, et al. **J Psychopharmacol (Oxf)** 1997;11(2):99–106 (100 ref.)
The limbic system. An overview of the anatomy and its development. Sitoh YY, et al. **Neuroimaging Clin N Am** 1997 Feb;7(1):1–10 (25 ref.)
Neuroimmunomodulation via limbic structures—the neuroanatomy of psychoimmunology. Haas HS, et al. **Prog Neurobiol** 1997 Feb;51(2):195–222 (426 ref.)

IMMUNOLOGY

Neuroimmunomodulation via limbic structures—the neuroanatomy of psychoimmunology. Haas HS, et al. **Prog Neurobiol** 1997 Feb;51(2):195–222 (426 ref.)

METABOLISM

Ventral tegmental area 5–HT receptors: mesolimbic dopamine release and behavioural studies. Mylecharane EJ. **Behav Brain Res** 1996;73(1–2):1–5 (37 ref.)

PATHOLOGY

Limbic circuits and monoamine receptors: dissecting the effects of antipsychotics from disease processes. Joyce JN, et al. **J Psychiatr Res** 1997 Mar–Apr;31(2):197–217 (70 ref.)
Limbic circuits and neuropsychiatric disorders. Functional anatomy and neuroimaging findings. Byrum CE, et al. **Neuroimaging Clin N Am** 1997 Feb;7(1):79–99 (105 ref.)
Neuropathology of the limbic system. Shaw CM, et al. **Neuroimaging Clin N Am** 1997 Feb;7(1):101–42 (47 ref.)

PHYSIOLOGY

Synaptic regulation of mesocorticolimbic dopamine neurons. White FJ. **Annu Rev Neurosci** 1996;19:405–36 (191 ref.)
5–HT3 and 5–HT4 receptors in terminal regions of the mesolimbic system. Kilpatrick GJ, et al. **Behav Brain Res** 1996;73(1–2):11–3 (23 ref.)
The primate temporal pole: its putative role in object recognition and memory. Nakamura K, et al. **Behav Brain Res** 1996 May;77(1–2):53–77 (290 ref.)
The antipsychotic potential of subtype–selective 5–HT receptor ligands based on interactions with mesolimbic dopamine systems. Tricklebank MD. **Behav Brain Res** 1996; 73(1–2):15–7 (25 ref.)
The limbic system: an anatomic, phylogenetic, and clinical perspective. Mega MS, et al. **J Neuropsychiatry Clin Neurosci** 1997 Summer;9(3):315–30 (101 ref.)
Somatosensory and visceral input to the hypothalamus and limbic system. Burstein R. **Prog Brain Res** 1996;107:257–67 (92 ref.)
The nucleus accumbens: gateway for limbic structures to reach the motor system? Groenewegen HJ, et al. **Prog Brain Res** 1996;107:485–511 (157 ref.)
The greater limbic system, the emotional motor system and the brain. Nieuwenhuys R. **Prog Brain Res** 1996;107:551–80 (115 ref.)
Inadequate frameworks for understanding bodily homeostasis. Blessing WW. **Trends Neurosci** 1997 Jun; 20(6):235–9 (44 ref.)

PHYSIOPATHOLOGY

Alcohol dependence: a commentary on mechanisms. Hoffman PL, et al. **Alcohol Alcohol** 1996 Jul;31(4):333–40 (60 ref.)

LIMBIC SYSTEM

Neuropeptides–immunoreactivity and their mRNA expression in kindling: functional implications for limbic epileptogenesis. Schwarzer C, et al. **Brain Res Brain Res Rev** 1996 Jun;22(1):27–50 (120 ref.)

Limbic–cortical dysregulation: a proposed model of depression. Mayberg HS. **J Neuropsychiatry Clin Neurosci** 1997 Summer;9(3):471–81 (135 ref.)

Paroxysmal limbic disorders in neuropsychiatry. Salloway S, et al. **J Neuropsychiatry Clin Neurosci** 1997 Summer; 9(3):403–19 (37 ref.)

Neuropsychiatric symptoms from the temporolimbic lobes. Trimble MR, et al. **J Neuropsychiatry Clin Neurosci** 1997 Summer;9(3):429–38 (86 ref.)

Limbic processes and the affective dimension of pain. Chapman CR. **Prog Brain Res** 1996;110:63–81 (72 ref.)

Behavioural complications of limbic epilepsy: implications for an understanding of the emotional motor system in man. Trimble M. **Prog Brain Res** 1996;107:605–16 (42 ref.)

Psychopharmacologic violence associated with cocaine abuse: kindling of a limbic dyscontrol syndrome? Davis WM. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Nov;20(8):1273–300 (143 ref.)

Stress, depression and the mesolimbic dopamine system. Cabib S, et al. **Psychopharmacology (Berl)** 1996 Dec; 128(4):331–42 (100 ref.)

[Generalization mechanisms of limbic seizures] Mori N. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1997 Feb; 17(1):25–9 (26 ref.) (Eng. Abstr.) **(Jpn)**

[Limbic–hypothalamic–pituitary–adrenal axis in depression: literature review] Twardowska K, et al. **Psychiatr Pol** 1996 Sep–Oct;30(5):741–55 (46 ref.) (Eng. Abstr.) **(Pol)**

SURGERY

Neuropsychiatric complications after temporal lobe limbic system surgery. Gabriel EM, et al. **Neuroimaging Clin N Am** 1997 Feb;7(1):155–64 (62 ref.)

LIMBS see **EXTREMITIES**

LIMBUS CORNEAE

CYTOLOGY

[Limbus stem cells and their significance for regeneration of of the corneal surface] Kruse FE. **Ophthalmologe** 1996 Oct;93(5):633–43 (32 ref.) **(Ger)**

SURGERY

Management of fibrous histiocytoma of the corneoscleral limbus: report of a case and review of the literature. Mietz H, et al. **Graefes Arch Clin Exp Ophthalmol** 1997 Feb; 235(2):87–91 (24 ref.)

LIMIT DEXTRINOSIS see **GLYCOGEN STORAGE DISEASE TYPE III**

LIMITATION OF ACTIVITY, CHRONIC see **ACTIVITIES OF DAILY LIVING**

LIMULUS see **HORSESHOE CRABS**

LIMULUS TEST

[Use of the Limulus test (LAL) to detect endotoxins] Kaca W. **Postepy Hig Med Dosw** 1996;50(5):447–57 (45 ref.) (Eng. Abstr.) **(Pol)**

METHODS

The impact of non–endotoxin LAL–reactive materials on Limulus amebocyte lysate analyses. Cooper JF, et al. **PDA J Pharm Sci Technol** 1997 Jan–Feb;51(1):2–6 (32 ref.)

[Application of a bacterial endotoxin test for parenteral drugs] Ogawa Y. **Eisei Shikenjo Hokoku** 1994;(112):209–11 (2 ref.) (Eng. Abstr.) **(Jpn)**

LINAC RADIOSURGERY see **RADIOSURGERY**

LINDANE

METABOLISM

Genetic manipulations of microorganisms for the degradation of hexachlorocyclohexane. Johri AK, et al. **FEMS Microbiol Rev** 1996 Dec;19(2):69–84 (184 ref.)

LINEAR ACCELERATOR RADIOSURGERY see **RADIOSURGERY**

LINEAR ACCELERATORS see **PARTICLE ACCELERATORS**

LINEAR ENERGY TRANSFER

[Heavy ion radiotherapy for lung cancer] Miyamoto T, et al. **Nippon Geka Gakkai Zasshi** 1997 Jan;98(1):60–7 (10 ref.) (Eng. Abstr.) **(Jpn)**

LINEAR MODELS

Opening the black box: the relationship between neural networks and linear discriminant functions. Kemp RA, et al. **Anal Cell Pathol** 1997;14(1):19–30 (14 ref.)

Measurement and analysis of unbound drug concentrations. Wright JD, et al. **Clin Pharmacokinet** 1996 Jun;30(6):445–62 (142 ref.)

Concepts, properties, and applications of linear systems to describe distribution, identify input, and control endogenous substances and drugs in biological systems. Verotta D. **Crit Rev Biomed Eng** 1996;24(2–3):73–139 (119 ref.)

LINEAR REGRESSION see **LINEAR MODELS**

LINENS see **BEDDING AND LINENS**

LINGUAL BONE see **HYOID BONE**

LINGUAL NERVE

Nerve paralysis after surgery in the submandibular triangle: review of University of Tokyo Hospital experience. Ichimura K, et al. **Head Neck** 1997 Jan;19(1):48–53 (19 ref.)

INJURIES

Trigeminal nerve injury and repair. Ruggiero SL. **N Y State Dent J** 1996 Oct;62(8):36–40 (6 ref.)

LINGUISTICS

Signs and voices: joining a conversation in progress. Stiles WB. **Br J Med Psychol** 1997 Jun;70 (Pt 2):169–76 (35 ref.)

Linguistic approaches to biological sequences. Searls DB. **Comput Appl Biosci** 1997 Aug;13(4):333–44 (49 ref.)

Optimality: from neural networks to universal grammar. Prince A, et al. **Science** 1997 Mar 14;275(5306):1604–10 (18 ref.)

Language acquisition and use: learning and applying probabilistic constraints. Seidenberg MS. **Science** 1997 Mar 14;275(5306):1599–603 (46 ref.)

About signs and symptoms: can semiotics expand the view of clinical medicine? Nessa J. **Theor Med** 1996 Dec; 17(4):363–77 (54 ref.)

LINITIS PLASTICA

PATHOLOGY

[Primary signet ring cell adenocarcinoma of the bladder. Report of 2 cases of bladder plastic linitis] González Mínguez C, et al. **Arch Esp Urol** 1996 Jun;49(5):517–20 (27 ref.) (Eng. Abstr.) **(Spa)**

SECONDARY

[Metastatic linitis plastica of the bladder] Signori GB, et al. **Arch Ital Urol Androl** 1997 Feb;69(1):69–72 (18 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Primary linitis plastica of the rectum: report of four cases and review of the literature. Murayama H, et al. **Surg Today** 1996;26(11):875–81 (22 ref.)

LINKAGE (GENETICS)

Analysis of genetic linkage and somatic loss of heterozygosity in affected pairs of first–degree relatives. Rohde K, et al. **Am J Hum Genet** 1997 Aug;61(2):418–22 (13 ref.)

How many X–linked genes for non–specific mental retardation (MRX) are there? [letter] Gedeon AK, et al. **Am J Med Genet** 1996 Jul 12;64(1):158–62 (40 ref.)

XLMR genes: update 1996. Lubs HA, et al. **Am J Med Genet** 1996 Jul 12;64(1):147–57 (105 ref.)

Study of X–linked mental retardation (XLMR): summary of 61 families in the Miami/Greenwood Study. Lubs HA, et al. **Am J Med Genet** 1996 Jul 12;64(1):169–75 (34 ref.)

Schizophrenia and chromosome 6p. Turecki G, et al. **Am J Med Genet** 1997 Apr 18;74(2):195–8 (23 ref.)

X chromosome inactivation and X–linked mental retardation. Willard HF. **Am J Med Genet** 1996 Jul 12;64(1):21–6 (53 ref.)

Genetic linkage studies for the identification of cancer–related genes. Brancolini V, et al. **Ann Ist Super Sanita** 1996;32(1):173–80 (45 ref.)

Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Conference Participants. Foster NL, et al. **Ann Neurol** 1997 Jun; 41(6):706–15 (41 ref.)

Dystrophinopathy, the expanding phenotype. Dystrophin abnormalities in X–linked dilated cardiomyopathy [editorial; comment] Beggs AH. **Circulation** 1997 May 20; 95(10):2344–7 (24 ref.) Comment on: Circulation 1997 May 20;95(10):2434–40.

Nonsyndromic X–linked mental retardation: review and mapping of MRX29 to Xp21. Häne B, et al. **Clin Genet** 1996 Oct;50(4):176–83 (49 ref.)

Molecular analysis of X–linked nephrogenic diabetes insipidus. Fujiwara TM, et al. **Eur J Endocrinol** 1996 Jun; 134(6):675–7 (12 ref.)

Affected sibpair linkage tests for multiple linked susceptibility genes. Farrall M. **Genet Epidemiol** 1997;14(2):103–15 (18 ref.)

A comprehensive map of the porcine genome. Rohrer GA, et al. **Genome Res** 1996 May;6(5):371–91 (112 ref.)

Panning for gold: genome–wide scanning for linkage in type 1 diabetes. Todd JA, et al. **Hum Mol Genet** 1996;5 Spec No:1443–8 (52 ref.)

Susceptibility loci for lupus: a guiding light from murine models? [editorial] Kotzin BL. **J Clin Invest** 1997 Feb 15; 99(4):557–8 (12 ref.)

Molecular genetics of familial spastic paraplegia: a multitude of responsible genes. Kobayashi H, et al. **J Neurol Sci** 1996 May;137(2):131–8 (40 ref.)

Genetics of human obesity: recent results from linkage studies. Bouchard C. **J Nutr** 1997 Sep;127(9):1887S–1890S (18 ref.)

Craniosynostosis in X–linked hypophosphataemic rickets. Willis FR, et al. **J Paediatr Child Health** 1997 Feb; 33(1):78–9 (12 ref.)

A paradigmatic shift in the approach to neuropsychiatric gene linkage may require an anthropogenetic perspective. Gericke GS. **Med Hypotheses** 1995 Dec;45(6):517–22 (65 ref.)

X–linked agammaglobulinemia. A clinical and molecular analysis. Ochs HD, et al. **Medicine (Baltimore)** 1996 Nov; 75(6):287–99 (134 ref.)

Software for genetic linkage analysis: an update. Bryant SP. **Mol Biotechnol** 1996 Feb;5(1):49–61 (58 ref.)

Association studies in psychiatric genetics [editorial] Owen MJ, et al. **Mol Psychiatry** 1997 Jul;2(4):270–3 (21 ref.)

X–linked malformations of neuronal migration. Dobyns WB, et al. **Neurology** 1996 Aug;47(2):331–9 (65 ref.)

Linkage map of phenotype and RFLP markers in rice. Yoshimura A, et al. **Plant Mol Biol** 1997 Sep;35(1–2):49–60 (36 ref.)

Multipoint linkage map from sperm typing data. Lien S. **Reprod Nutr Dev** 1996;36(6):637–42 (16 ref.)

Frontiers in keratodermas: pushing the envelope. Christiano AM. **Trends Genet** 1997 Jun;13(6):227–33 (45 ref.)

The genetic analysis of multiple sclerosis. Sawcer S, et al. **Trends Genet** 1997 Jun;13(6):234–9 (65 ref.)

[Molecular genetics of X–linked primary immunodeficiencies: advances in diagnosis and prevention] Carbonara A, et al. **Ann Ital Med Int** 1996 Jul–Sep;11(3):180–6 (55 ref.) (Eng. Abstr.) **(Ita)**

[Clinical characteristics and linkage analysis of autosomal recessive form of juvenile parkinsonism(AR–JP)] Saito M, et al. **Nippon Rinsho** 1997 Jan;55(1):83–8 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Cousins with X–linked recessive myotubular myopathy] Mori Y, et al. **No To Hattatsu** 1997 Jul;29(4):310–4 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Genetic analysis of responsible genes for essential hypertension] Nabika T. **Rinsho Byori** 1997 Feb; 45(2):107–11 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Mutation "outbursts" of various genes in natural populations of Drosophila melanogaster] Gershenzon SM. **Genetika** 1997 Apr;33(4):421–30 (86 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

A systematic evaluation of linkage studies in bipolar disorder. Turecki G, et al. **Acta Psychiatr Scand** 1996 May; 93(5):317–26 (85 ref.)

Linkage analysis of genetic disorders. Taylor EW, et al. **Methods Mol Biol** 1997;68:11–25 (24 ref.)

Genetic linkage and bipolar affective disorder: progress and pitfalls. Baron M. **Mol Psychiatry** 1997 May;2(3):200–10 (76 ref.)

Dissecting the genetic complexity of schizophrenia. Karayiorgou M, et al. **Mol Psychiatry** 1997 May; 2(3):211–23 (161 ref.)

Spinal muscular atrophy in childhood. Fidziańska A. **Semin Pediatr Neurol** 1996 Jun;3(2):53–8 (31 ref.)

LINKAGE DISEQUILIBRIUM

The TDT and other family–based tests for linkage disequilibrium and association [editorial] Spielman RS, et al. **Am J Hum Genet** 1996 Nov;59(5):983–9 (22 ref.)

Significance of linkage disequilibrium between the fragile X locus and its flanking markers [editorial] Chiurazzi P, et al. **Am J Med Genet** 1996 Jul 12;64(1):203–8 (50 ref.)

LINKAGE MAPPING see **CHROMOSOME MAPPING**

LINKER–INSERTION MUTAGENESIS see **MUTAGENESIS, INSERTIONAL**

LINOLEIC ACIDS

DEFICIENCY

The Canadian Society for Nutritional Sciences 1995 Young Scientist Award Lecture. Recent studies on the synthesis, beta–oxidation, and deficiency of linoleate and alpha–linolenate: are essential fatty acids more aptly named indispensable or conditionally dispensable fatty acids? Cunnane SC. **Can J Physiol Pharmacol** 1996 Jun; 74(6):629–39 (78 ref.)

METABOLISM

Biosynthesis, metabolization and biological importance of the primary 15–lipoxygenase metabolites

15-hydro(pero)XY-5Z,8Z,11Z,13E-eicosatetraenoic acid and 13-hydro(pero)XY-9Z,11E-octadecadienoic acid. Kühn H. **Prog Lipid Res** 1996 Sep;35(3):203-26 (251 ref.)

THERAPEUTIC USE

Cows' milk fat components as potential anticarcinogenic agents. Parodi PW. **J Nutr** 1997 Jun;127(6):1055-60 (71 ref.)

LINOLENIC ACID see **ALPHA-LINOLENIC ACID**

LINOLENIC ACIDS

ADVERSE EFFECTS

Dietary fatty acids--the N-6/N-3 balance and chronic elderly diseases. Excess linoleic acid and relative N-3 deficiency syndrome seen in Japan. Okuyama H, et al. **Prog Lipid Res** 1996 Dec;35(4):409-57 (491 ref.)

LIOTHYRONINE see **TRIIODOTHYRONINE**

LIP

Dermatofibrosarcoma protuberans of the upper lip: an overview and a case report. Vandeweyer E, et al. **Eur J Surg Oncol** 1997 Jun;23(3):275-7 (22 ref.)

INJURIES

Oral self-injurious behavior in the developmentally disabled: review and a case. Saemundsson SR, et al. **ASDC J Dent Child** 1997 May-Jun;64(3):205-9, 228 (42 ref.)

SURGERY

Lip augmentation with preserved fascia lata. Burres SA. **Dermatol Surg** 1997 Jun;23(6):459-62 (13 ref.)

Concepts in lip reconstruction. Hamilton MM, et al. **Otolaryngol Clin North Am** 1997 Aug;30(4):593-606 (10 ref.)

LIP DISEASES

CONGENITAL

Congenital midline sinus of the upper lip: case report and review of literature. Asahina I, et al. **Cleft Palate Craniofac J** 1997 Jan;34(1):83-5 (10 ref.)

[Congenital fistula of the lower lip. Apropos of 2 cases] Riquet-Bricard C, et al. **Rev Stomatol Chir Maxillofac** 1996; 97(4):209-16 (43 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Recurrent scarring ulcers of the oral mucosa. Sutton disease (periadenitis mucosa necrotica recurrens. Chung JY, et al. **Arch Dermatol** 1997 Sep;133(9):1162-3, 1165-6 (6 ref.)

LIP NEOPLASMS

PATHOLOGY

Epithelioid hemangiomas of the maxillofacial area. A report of three cases and a review of the literature. Martín-Granizo R, et al. **Int J Oral Maxillofac Surg** 1997 Jun;26(3):212-4 (10 ref.)

Multiple idiopathic mucosal neuromas: a minor form of multiple endocrine neoplasia type 2B or a new entity? Pujol RM, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):349-52 (22 ref.)

Trichoepithelioma with an adjacent basal cell carcinoma, transformation or collision? Wallace ML, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):343-5 (10 ref.)

Stromal bone formation in pleomorphic adenoma of minor salivary gland origin. Takeda Y, et al. **J Nihon Univ Sch Dent** 1996 Jul;38(2):102-4 (6 ref.)

SURGERY

Oncologic and reconstructive considerations in nonmelanotic skin and lip cancers. Luce EA, et al. **Surg Oncol Clin N Am** 1996 Oct;5(4):751-84 (60 ref.)

ULTRASTRUCTURE

Apocrine carcinoma of the lip: a case report including immunohistochemical and ultrastructural study, discussion of differential diagnosis, and review of the literature. Hayes MM, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Aug;82(2):193-9 (65 ref.)

LIPANTHYL see **PROCETOFEN**

LIPASE

[Chemical modification of proteins by polyethylene glycol] Uemura T, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep; 41(11):1607-13 (26 ref.) **(Jpn)**

ADVERSE EFFECTS

The pathology of fibrosing colonopathy of cystic fibrosis: a study of 12 cases and review of the literature. Pawel BR, et al. **Hum Pathol** 1997 Apr;28(4):395-9 (25 ref.)

ANTAGONISTS & INHIBITORS

Covalent inhibition of digestive lipases: an in vitro study. Gargouri Y, et al. **Biochim Biophys Acta** 1997 Jan 7; 1344(1):6-37 (131 ref.)

Mode of action of orlistat. Guerciolini R. **Int J Obes Relat Metab Disord** 1997 Jun;21 Suppl 3:S12-23 (42 ref.)

CHEMISTRY

Structure and function of pancreatic lipase and colipase. Lowe ME. **Annu Rev Nutr** 1997;17:141-58 (74 ref.)

DEFICIENCY

Naturally occurring mutations in mice affecting lipid transport and metabolism. Reue K, et al. **J Lipid Res** 1996 Jul;37(7):1387-405 (120 ref.)

GENETICS

Genetics and molecular biology of hepatic lipase. Bensadoun A, et al. **Curr Opin Lipidol** 1996 Apr;7(2):77-81 (44 ref.)

Molecular mechanisms of rat and human pancreatic triglyceride lipases. Lowe ME. **J Nutr** 1997 Apr; 127(4):549-57 (49 ref.)

Molecular pathobiology of the human lipoprotein lipase gene. Murthy V, et al. **Pharmacol Ther** 1996;70(2):101-35 (260 ref.)

[Recent data on hepatic lipase gene. Structure and functions of this enzyme] Arca-Sedda Benhizia F, et al. **Ann Biol Clin (Paris)** 1996;54(3-4):117-30 (153 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Structure and function of pancreatic lipase and colipase. Lowe ME. **Annu Rev Nutr** 1997;17:141-58 (74 ref.)

Turning lipases into industrial biocatalysts. Bosley J. **Biochem Soc Trans** 1997 Feb;25(1):174-8 (25 ref.)

Predicting the behaviour of lipases in low-water media. Halling PJ. **Biochem Soc Trans** 1997 Feb;25(1):170-4 (31 ref.)

Microbial lipases: structures, function and industrial applications. Rogalska E, et al. **Biochem Soc Trans** 1997 Feb;25(1):161-4 (34 ref.)

Regulation of lumen fat digestion: enzymic aspects. Verger R, et al. **Proc Nutr Soc** 1996 Mar;55(1B):5-18 (55 ref.)

Microbial lipases: production and applications. Ghosh PK, et al. **Sci Prog** 1996;79 (Pt 2):119-57 (35 ref.)

PHYSIOLOGY

New aspects on the role of plasma lipases in lipoprotein catabolism and atherosclerosis. Beisiegel U. **Atherosclerosis** 1996 Jul;124(1):1-8 (111 ref.)

Molecular mechanisms of rat and human pancreatic triglyceride lipases. Lowe ME. **J Nutr** 1997 Apr; 127(4):549-57 (49 ref.)

Pathogenesis of dyslipoproteinemia in renal insufficiency: the role of lipoprotein lipase and hepatic lipase. Arnadóttir M. **Scand J Clin Lab Invest** 1997 Feb;57(1):1-11 (97 ref.)

TOXICITY

Safety evaluation of lipase derived from Rhizopus oryzae: summary of toxicological data. Coenen TM, et al. **Food Chem Toxicol** 1997 Mar-Apr;35(3-4):315-22 (24 ref.)

LIPECTOMY

[Surgical treatment of lipodystrophies] De Mey A. **Rev Med Brux** 1996 Sep;17(4):240-3 (17 ref.) (Eng. Abstr.) **(Fre)**

[Suction lipectomy in surgery] Gorbunov AS, et al. **Khirurgiia (Mosk)** 1997;(4):70-3 (94 ref.) **(Rus)**

INSTRUMENTATION

Intestinal perforation after suction lipoplasty: a case report and review of the literature. Talmor M, et al. **Ann Plast Surg** 1997 Feb;38(2):169-72 (20 ref.)

METHODS

Advances in dermatologic surgery. Perez M. **Dermatol Clin** 1997 Jan;15(1):9-18 (61 ref.)

Ultrasonically assisted lipectomy in aesthetic breast surgery. Maillard GF, et al. **Plast Reconstr Surg** 1997 Jul; 100(1):238-41 (8 ref.)

The role of subcutaneous infiltration in suction-assisted lipoplasty: a review. Rohrich RJ, et al. **Plast Reconstr Surg** 1997 Feb;99(2):514-9; discussion 520-6 (46 ref.)

[Axillary node removal prepared by liposuction and assisted by endoscopy in the surgical treatment of breast cancers] Brun JL, et al. **Contracept Fertil Sex** 1997 Mar; 25(3):XIV-XVIII (9 ref.) **(Fre)**

[Superficial liposuction: a new treatment for lipodystrophies] Adant JP, et al. **Rev Med Liege** 1997;52(7):463-8 (12 ref.) **(Fre)**

LIPEMIA-CLEARING FACTOR see **LIPOPROTEIN LIPASE**

LIPID A

ANALOGS & DERIVATIVES

Pharmacologic myocardial preconditioning with monophosphoryl lipid A (MLA) reduces infarct size and stunning in dogs and rabbits. Elliott GT. **Ann N Y Acad Sci** 1996 Sep 30;793:386-99 (63 ref.)

BIOSYNTHESIS

Lipid A: target for antibacterial drugs [comment] Vaara M. **Science** 1996 Nov 8;274(5289):939-40 (12 ref.) Comment on: Science 1996 Nov 8;274(5289):980-2.

CHEMISTRY

[Chemical structure and biological activities of Porphyromonas gingivalis lipid A] Umemoto T, et al. **Nippon Saikingaku Zasshi** 1997 Apr;52(2):475-83 (15 ref.) **(Jpn)**

METABOLISM

Modulation of the surface architecture of gram-negative bacteria by the action of surface polymer:lipid A-core ligase and by determinants of polymer chain length. Whitfield C, et al. **Mol Microbiol** 1997 Feb;23(4):629-38 (36 ref.)

PHYSIOLOGY

[Chemical structure and biological activities of Porphyromonas gingivalis lipid A] Umemoto T, et al. **Nippon Saikingaku Zasshi** 1997 Apr;52(2):475-83 (15 ref.) **(Jpn)**

LIPID BILAYERS

see related

LIPOSOMES

The lateral pressure profile in membranes: a physical mechanism of general anesthesia. Cantor RS. **Biochemistry** 1997 Mar 4;36(9):2339-44 (33 ref.)

A new phase in phosphatidylcholines [comment] O'Leary TJ, et al. **Biophys J** 1996 Dec;71(6):2915-6 (9 ref.) Comment on: Biophys J 1996 Dec;71(6):3186-98.

The first living systems: a bioenergetic perspective. Deamer DW. **Microbiol Mol Biol Rev** 1997 Jun;61(2):239-61 (166 ref.)

Protein:protein interactions in the lipid bilayer (review). Harrison PT. **Mol Membr Biol** 1996 Apr-Jun;13(2):67-79 (69 ref.)

CHEMISTRY

Protein kinase C and phospholipase C: bilayer interactions and regulation. Hurley JH, et al. **Curr Opin Struct Biol** 1997 Aug;7(4):557-65 (69 ref.)

Molecular dynamics simulations of lipid bilayers. Merz KM Jr. **Curr Opin Struct Biol** 1997 Aug;7(4):511-7 (54 ref.)

Molecular dynamics simulation of hydrated phospholipid bilayers. Kothekar V. **Indian J Biochem Biophys** 1996 Dec; 33(6):431-47 (122 ref.)

Fluorescence probes for studying membrane heterogeneity. Davenport L. **Methods Enzymol** 1997;278:487-512 (91 ref.)

Has nature designed the cholesterol side chain for optimal interaction with phospholipids? Bittman R. **Subcell Biochem** 1997;28:145-71 (85 ref.)

METABOLISM

[Coupled transbilayer transport of peptides, lipids, and ions mediated by a peptide-lipid supramolecular complex pore] Matsuzaki K, et al. **Seikagaku** 1997 Feb;69(2):119-22 (14 ref.) **(Jpn)**

LIPID EMULSIONS, INTRAVENOUS see **FAT EMULSIONS, INTRAVENOUS**

LIPID METABOLISM, INBORN ERRORS

BLOOD

[Sitosterolemia] Takahashi M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):48-51 (9 ref.) **(Jpn)**

GENETICS

Fatty acid mitochondrial beta-oxidation and hypoglycaemia in children. Taroni F, et al. **Curr Opin Neurol** 1996 Dec; 9(6):477-85 (88 ref.)

Metabolic myopathies. Tein I. **Semin Pediatr Neurol** 1996 Jun;3(2):59-98 (357 ref.)

METABOLISM

Sitosterolemia. Salen G, et al. **Subcell Biochem** 1997; 28:453-76 (49 ref.)

VETERINARY

Lipid storage disease. Hänichen T, et al. **Lab Anim Sci** 1997 Jun;47(3):275-9 (13 ref.)

LIPID PEROXIDATION

High fat diet, lipid peroxidation, and pancreatic carcinogenesis. Zhang J, et al. **Adv Exp Med Biol** 1996; 399:165–72 (53 ref.)

Oxidized low density lipoproteins in atherogenesis: role of dietary modification. Reaven PD, et al. **Annu Rev Nutr** 1996;16:51–71 (94 ref.)

The generation and actions of isoprostanes. Roberts LJ 2nd, et al. **Biochim Biophys Acta** 1997 Apr 1;1345(2):121–35 (71 ref.)

Dietary antioxidants and cardioprotection--fact or fallacy? Steinbrecher UP. **Can J Physiol Pharmacol** 1997 Mar; 75(3):228–33 (66 ref.)

Dietary polyunsaturates and peroxidation of low density lipoprotein. Nenseter MS, et al. **Curr Opin Lipidol** 1996 Feb;7(1):8–13 (34 ref.)

Microvesicular steatosis and steatohepatitis: role of mitochondrial dysfunction and lipid peroxidation. Fromenty B, et al. **J Hepatol** 1997;26 Suppl 1:13–22 (54 ref.)

Biochemistry of the induction and prevention of lipoperoxidative damage in human spermatozoa. Storey BT. **Mol Hum Reprod** 1997 Mar;3(3):203–13 (91 ref.)

Free radical pathology in schizophrenia: a review. Reddy RD, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Aug;55(1–2):33–43 (137 ref.)

The role of antioxidant vitamins and enzymes in the prevention of exercise-induced muscle damage. Dekkers JC, et al. **Sports Med** 1996 Mar;21(3):213–38 (62 ref.)

Vitamins C and E and LDL oxidation. Frei B, et al. **Vitam Horm** 1996;52:1–34 (122 ref.)

[The antioxidant allowance of the body and lipid peroxidation in patients with gastric and duodenal peptic ulcers] Petrov EE. **Lik Sprava** 1996 Jul–Sep;(7–9):13–8 (50 ref.) **(Rus)**

DRUG EFFECTS

The mechanism of the hypochlorite-induced lipid peroxidation. Panasenko OM. **Biofactors** 1997;6(2):181–90 (44 ref.)

Efficacy and mechanisms of action of the cytoprotective lipid peroxidation inhibitor tirilazad mesylate in subarachnoid haemorrhage. Hall ED. **Eur J Anaesthesiol** 1996 May; 13(3):279–89 (55 ref.)

[Lipid peroxidation as a toxic mode of action for lead and cadmium] Skoczyńska A. **Med Pr** 1997;48(2):197–203 (55 ref.) (Eng. Abstr.) **(Pol)**

[Tirilazad mesylate (Freedox)--an effective inhibitor of lipid membrane peroxidation] Sániová B. **Bratisl Lek Listy** 1997 Jun;98(6):339–42 (20 ref.) (Eng. Abstr.) **(Slo)**

PHYSIOLOGY

Paradoxical influence of Ca(2+) on lipid peroxidation. Gupta M, et al. **Indian J Exp Biol** 1996 Nov;34(11):1071–6 (61 ref.)

Lipoxidation products as biomarkers of oxidative damage to proteins during lipid peroxidation reactions. Requena JR, et al. **Nephrol Dial Transplant** 1996;11 Suppl 5:48–53 (28 ref.)

Brain attack. Acute therapeutic interventions. Free radical scavengers and antioxidants. Hall ED. **Neurosurg Clin N Am** 1997 Apr;8(2):195–206 (78 ref.)

Estimation of peroxidative damage. A critical review. Esterbauer H. **Pathol Biol (Paris)** 1996 Jan;44(1):25–8 (20 ref.)

[The significance of antioxidants] Kuhl H. **Zentralbl Gynakol** 1997;119(1):1–5 (11 ref.) **(Ger)**

[Cytotoxic action of active forms of oxygen and mechanisms of development of a chronic process in the liver in liver disease] Loginov AS, et al. **Patol Fiziol Eksp Ter** 1996 Oct–Dec;(4):3–5 (20 ref.) (Eng. Abstr.) **(Rus)**

LIPID PEROXIDES

METABOLISM

Elevation of macrophage SeGSHPx gene expression prevents from its formation of foam cell and inhibits atherogenesis. Chen Y, et al. **Chin Med J (Engl)** 1996 Jan;109(1):51–4 (17 ref.)

Biosynthesis, metabolization and biological importance of the primary 15-lipoxygenase metabolites 15-hydro(pero)XY-5Z,8Z,11Z,13E-eicosatetraenoic acid and 13-hydro(pero)XY-9Z,11E-octadecadienoic acid. Kühn H. **Prog Lipid Res** 1996 Sep;35(3):203–26 (251 ref.)

PHARMACOLOGY

Oxidative DNA damage induced by dioxetanes, photosensitizing ketones, and photo-fenton reagents. Adam W, et al. **Recent Results Cancer Res** 1997;143:21–34 (40 ref.)

LIPIDOSIS see **LIPOIDOSIS**

LIPIDS

see related
FATS

Novel lipids and cancer. Isoprenoids and other phytochemicals. Elson CE. **Adv Exp Med Biol** 1996; 399:71–86 (131 ref.)

Uses of biotechnology in modifying plant lipids. Budziszewski GJ, et al. **Lipids** 1996 Jun;31(6):557–69 (121 ref.)

Significance of lipid consumption during lactation. Ortiz-Olaya N, et al. **Rev Invest Clin** 1996 Nov–Dec; 48(6):473–8 (40 ref.)

[Synthetic vectors for gene transfection] Emi N, et al. **Nippon Rinsho** 1996 Jul;54(7):1997–2002 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Protein immobilization in lipid bilayer membrane films on electrodes and their electron transfer reactions] Tominaga M, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep; 41(11):1600–6 (8 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. Cevc G. **Crit Rev Ther Drug Carrier Syst** 1996;13(3–4):257–388 (331 ref.)

Novel lipid sources in parenteral and enteral nutrition. Bistrian BR. **Proc Nutr Soc** 1997 Mar;56(1B):471–7 (40 ref.)

ADVERSE EFFECTS

Abnormal lipid metabolism and renal disorders. Saito T. **Tohoku J Exp Med** 1997 Mar;181(3):321–37 (56 ref.)

ANALYSIS

Lipid biomarkers of adherence to low fat diets. Ashley JM. **Adv Exp Med Biol** 1996;399:115–29 (83 ref.)

Bioactive lipids in foods. Calder PC. **Biochem Soc Trans** 1996 Aug;24(3):814–24 (58 ref.)

Lipid biomarkers for bacterial ecosystems: studies of cultured organisms, hydrothermal environments and ancient sediments. Summons RE, et al. **Ciba Found Symp** 1996; 202:174–93; discussion 193–4 (33 ref.)

Mapping the lipid distribution in the membranes of BHK cells (mini-review). Allan D. **Mol Membr Biol** 1996 Apr–Jun;13(2):81–4 (26 ref.)

The lipids in human milk. Jensen RG. **Prog Lipid Res** 1996 Mar;35(1):53–92 (102 ref.)

[Lipid-laden alveolar macrophages as markers of gastro-esophageal reflux in pulmonary disease in childhood] Bibi H, et al. **Harefuah** 1997 Jan 1;132(1):40–2 (31 ref.) **(Heb)**

[Absorption test of fat] Nakamura T. **Nippon Rinsho** 1997 Apr;55 Suppl 2:111–2 (3 ref.) **(Jpn)**

[The lipid and carbohydrate components of mycobacteria and the methods for their determination] Gizatulina NM. **Probl Tuberk** 1996;(4):59–62 (42 ref.) **(Rus)**

BIOSYNTHESIS

The role of peroxisomes in ether lipid synthesis. Back to the roots of PAF. van den Bosch H, et al. **Adv Exp Med Biol** 1996;416:33–40 (27 ref.)

Formation of lipids, peptides and cytokines. Monteseirín J, et al. **Allergol Immunopathol (Madr)** 1996 Sep–Oct; 24(5):211–8 (110 ref.)

Lipid biosynthesis in peroxisomes. Hajra AK, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:129–41 (51 ref.)

Mechanisms by which carbohydrates regulate expression of genes for glycolytic and lipogenic enzymes. Girard J, et al. **Annu Rev Nutr** 1997;17:325–52 (105 ref.)

Regulation of hepatic de novo lipogenesis in humans. Hellerstein MK, et al. **Annu Rev Nutr** 1996;16:523–57 (123 ref.)

Regulation of the expression of lipogenic enzyme genes by carbohydrate. Towle HC, et al. **Annu Rev Nutr** 1997; 17:405–33 (135 ref.)

Epoxy allylic carbocations as conceptual intermediates in the biogenesis of diverse marine oxylipins. Gerwick WH. **Lipids** 1996 Dec;31(12):1215–31 (73 ref.)

Regulation of lipid biosynthesis by the AMP-activated protein kinase and its role in the hepatocellular response to stress. Corton JM, et al. **Prog Liver Dis** 1996;14:69–99 (133 ref.)

Polyunsaturated fatty acids regulate lipogenic and peroxisomal gene expression by independent mechanisms. Clarke SD, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Jul; 57(1):65–9 (22 ref.)

BLOOD

Diet and serum lipid concentrations: where are we? Hegsted DM, et al. **Am J Clin Nutr** 1997 Jun;65(6):1893–6 (31 ref.)

Individual fatty acid effects on plasma lipids and lipoproteins: human studies. Kris-Etherton PM, et al. **Am J Clin Nutr** 1997 May;65(5 Suppl):1628S–1644S (50 ref.)

Fish consumption, fish oil, lipids, and coronary heart disease. Stone NJ. **Am J Clin Nutr** 1997 Apr;65(4):1083–6 (41 ref.)

Assays for thrombosis factors: relations to plasma lipids. Tracy RP. **Am J Clin Nutr** 1997 May;65(5 Suppl):1669S–1673S (43 ref.)

Lipids, risk factors and ischaemic heart disease. Castelli WP. **Atherosclerosis** 1996 Jul;124 Suppl:S1–9 (48 ref.)

Gene-diet interaction in determining plasma lipid response to dietary intervention. Ordovas JM, et al. **Atherosclerosis** 1995 Dec;118 Suppl:S11–27 (188 ref.)

Transdermal hormone replacement therapy, serum lipids and lipoproteins. Crook D, et al. **Br J Clin Pract Symp Suppl** 1996 Sep;86:17–21 (34 ref.)

Meal frequency and plasma lipids and lipoproteins. Mann J. **Br J Nutr** 1997 Apr;77 Suppl 1:S83–90 (31 ref.)

Tracing lipogenesis in humans using deuterated water. Jones PJ. **Can J Physiol Pharmacol** 1996 Jun;74(6):755–60 (35 ref.)

Trans fatty acids, plasma lipid levels, and risk of developing cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Lichtenstein AH. **Circulation** 1997 Jun 3;95(11):2588–90 (23 ref.)

Fiber, lipids, and coronary heart disease. A statement for healthcare professionals from the Nutrition Committee, American Heart Association. Van Horn L. **Circulation** 1997 Jun 17;95(12):2701–4 (53 ref.)

Role of lipids in progressive renal disease: insights from the analbuminemic rat. Joles JA, et al. **Contrib Nephrol** 1997; 120:120–31 (79 ref.)

Role of lipids in chronic renal allograft rejection. Swan SK. **Contrib Nephrol** 1997;120:62–7 (34 ref.)

The new thinking on lipids and coronary artery disease. Superko HR. **Curr Opin Cardiol** 1997 Mar;12(2):180–7 (65 ref.)

Hypertension, dyslipidemia, and insulin resistance: links in a chain or spokes on a wheel? Hopkins PN, et al. **Curr Opin Lipidol** 1996 Aug;7(4):241–53 (103 ref.)

Trials of the effects of drugs and hormones on lipids and lipoproteins. Mann WA, et al. **Curr Opin Lipidol** 1995 Dec; 6(6):354–9 (52 ref.)

Trials of lipid-lowering therapy in secondary prevention of coronary heart disease. Olsson AG, et al. **Curr Opin Lipidol** 1995 Dec;6(6):369–73 (20 ref.)

Soy protein and serum lipids. Potter SM. **Curr Opin Lipidol** 1996 Aug;7(4):260–4 (32 ref.)

Plasma lipids and lipoprotein concentrations among American Indians: comparison with the US population. Robbins DC, et al. **Curr Opin Lipidol** 1996 Aug;7(4):188–95 (41 ref.)

Selection of appropriate type and intensity of lipid-lowering therapy. Tikkanen MJ. **Curr Opin Lipidol** 1995 Dec; 6(6):360–4 (39 ref.)

Role of elevated lipids in diabetic cardiomyopathy. McNeill JH. **Diabetes Res Clin Pract** 1996 Jul;31 Suppl:S67–71 (26 ref.)

Atheroarteritis: a combined immunological and lipid imbalance. Wissler RW, et al. **Int J Cardiol** 1997 Aug;54 Suppl:S37–49 (126 ref.)

Dietary trans-monounsaturated fatty acids negatively impact plasma lipids in humans: critical review of the evidence [see comments] Khosla P, et al. **J Am Coll Nutr** 1996 Aug; 15(4):325–39 (111 ref.) Comment in: J Am Coll Nutr 1996 Aug;15(4):321–2.

The effect of dietary fat, antioxidants, and pro-oxidants on blood lipids, lipoproteins, and atherosclerosis. Kwiterovich PO Jr. **J Am Diet Assoc** 1997 Jul;97(7 Suppl):S31–41 (75 ref.)

Secondary prevention of heart disease amongst patients with lipid abnormalities: practice and trends in the United States. Brown BG, et al. **J Intern Med** 1997 Apr;241(4):283–94 (62 ref.)

Modifications in plasma lipoprotein concentration and lipid composition regulate the biological activity of hydrophobic drugs. Wasan KM. **J Pharmacol Toxicol Methods** 1996 Sep; 36(1):1–11 (68 ref.)

Estrogens, progestins and lipid metabolism. Tikkanen MJ. **Maturitas** 1996 May;23 Suppl:S51–5 (24 ref.)

Pathogenesis of atherosclerosis. Ylä-Herttuala S, et al. **Maturitas** 1996 May;23 Suppl:S47–9 (13 ref.)

Lipids and lipoproteins in women. O'Brien T, et al. **Mayo Clin Proc** 1997 Mar;72(3):235–44 (106 ref.)

Status of lipids as a risk factor for stroke. Gorelick PB, et al. **Neuroepidemiology** 1997;16(3):107–15 (65 ref.)

Postprandial lipid metabolism: an overview. Havel RJ. **Proc Nutr Soc** 1997 Jul;56(2):659–66 (50 ref.)

Apolipoprotein B-48 as a marker for chylomicrons and their remnants: studies in the postprandial state. Isherwood SG, et al. **Proc Nutr Soc** 1997 Mar;56(1B):497–505 (53 ref.)

Postprandial lipid metabolism in relation to coronary heart disease. Karpe F. **Proc Nutr Soc** 1997 Jul;56(2):671–8 (47 ref.)

Postprandial lipid metabolism and thrombosis. Miller GJ. **Proc Nutr Soc** 1997 Jul;56(2):739–44 (38 ref.)

Postprandial lipid metabolism: effects of dietary fatty acids. Williams CM. **Proc Nutr Soc** 1997 Jul;56(2):679–92 (53 ref.)

The influence of dietary fat on postprandial lipaemia and factor VII coagulant activity in human subjects. Yahia N, et al. **Proc Nutr Soc** 1997 Mar;56(1B):489–96 (41 ref.)

Nutritional and metabolic aspects of postprandial lipemia. Lairon D. **Reprod Nutr Dev** 1996;36(4):345–55 (46 ref.)

Coagulation factor VII, dietary fat and blood lipids: a review. Mennen LI, et al. **Thromb Haemost** 1996 Oct;76(4):492–9 (92 ref.)

Lipids and progressive renal failure. Keane WF. **Wien Klin Wochenschr** 1996;108(14):420–4 (44 ref.)

Effects of antihypertensive therapy on glucose and lipid metabolism. Zehetgruber M, et al. **Wien Klin Wochenschr** 1996 Dec 27;108(24):775–80 (61 ref.)

Mechanisms controlling lipemic responses to dietary lipids. Kushwaha RS, et al. **World Rev Nutr Diet** 1997;80:82–125 (252 ref.)

[Hyperlipidemia in pregnancy] Dejager S, et al.

Presse Med 1996 Nov 30;25(37):1839–45 (34 ref.) (Eng. Abstr.) **(Fre)**

[Goals and practical implementation of lipid therapy in coronary heart disease] Beil FU, et al. **Herz** 1997 Jun; 22(3):134–40 (40 ref.) (Eng. Abstr.) **(Ger)**

[Alcohol, lipid metabolism and coronary heart disease] Schneider J, et al. **Herz** 1996 Aug;21(4):217–26 (66 ref.) (Eng. Abstr.) **(Ger)**

[Diuretics and diabetes mellitus] Teuscher AU. **Wien Med Wochenschr** 1996;146(16):439–42 (45 ref.) (Eng. Abstr.) **(Ger)**

[Lipid, apoprotein and fibrinogen levels in the blood of male patients following myocardial infarct and the effect of diet on these parameters in ischemic heart disease] Márk L, et al. **Orv Hetil** 1996 Nov 3;137(44):2447–50 (40 ref.) (Eng. Abstr.) **(Hun)**

[Angina pectoris: the lipid profile and clinical practice] Diogo AN. **Acta Med Port** 1997 Apr;10(4):293–8 (25 ref.) (Eng. Abstr.) **(Por)**

[Apo E: blood lipids, ischemic cardiopathy and Alzheimer's disease] Lahoz C, et al. **Med Clin (Barc)** 1997 May 31; 109(1):31–6 (82 ref.) **(Spa)**

CHEMISTRY

Lateral forces acting between particles in liquid films or lipid membranes. Kralchevsky PA. **Adv Biophys** 1997;34:25–39 (74 ref.)

On the importance of hydroxyl groups in the polar head-group of nonionic surfactants and membrane lipids. Shinoda K, et al. **Adv Colloid Interface Sci** 1996 Feb 8; 64:253–71 (25 ref.)

Lipid modifications of G-protein–coupled receptor kinases. Inglese J, et al. **Biochem Soc Trans** 1996 Aug;24(3):714–7 (33 ref.)

Epoxy allylic carbocations as conceptual intermediates in the biogenesis of diverse marine oxylipins. Gerwick WH. **Lipids** 1996 Dec;31(12):1215–31 (73 ref.)

Mapping the lipid distribution in the membranes of BHK cells (mini–review). Allan D. **Mol Membr Biol** 1996 Apr–Jun;13(2):81–4 (26 ref.)

[Model systems based on the lipid–porphyrin assemblies and lipoproteins in biochemical studies] Pikuz SS, et al. **Bioorg Khim** 1996 Oct–Nov;22(10–11):725–36 (69 ref.) (Eng. Abstr.) **(Rus)**

DEFICIENCY

Polyunsaturated fatty acid deficiency in liver diseases: pathophysiological and clinical significance. Cabré E, et al. **Nutrition** 1996 Jul–Aug;12(7–8):542–8 (81 ref.)

GENETICS

Biochemistry and molecular genetics of cell–wall lipid biosynthesis in mycobacteria. Kolattukudy PE, et al. **Mol Microbiol** 1997 Apr;24(2):263–70 (30 ref.)

[The genetic bases of the lipid metabolic disorders in atherosclerosis] Tseliko VI. **Tsitol Genet** 1996 Mar–Apr; 30(2):74–82 (56 ref.) (Eng. Abstr.) **(Ukr)**

ISOLATION & PURIFICATION

Lipid apheresis: from a heroic treatment to routine clinical practice. Bosch T. **Artif Organs** 1996 May;20(5):414–9 (29 ref.)

METABOLISM

Regulation of lipogenic enzyme expression by glucose in liver and adipose tissue: a review of the potential cellular and molecular mechanisms. Foufelle F, et al. **Adv Enzyme Regul** 1996;36:199–226 (91 ref.)

Regulation of carbohydrate and fat metabolism during and after exercise. Holloszy JO, et al. **Annu Rev Nutr** 1996; 16:121–38 (87 ref.)

The pulmonary lipofibroblast (lipid interstitial cell) and its contributions to alveolar development. McGowan SE, et al. **Annu Rev Physiol** 1997;59:43–62 (87 ref.)

Lipids and atherogenesis in diabetes mellitus. Betteridge DJ. **Atherosclerosis** 1996 Jul;124 Suppl:S43–7 (42 ref.)

Metabolic actions of growth hormone: direct and indirect. Berneis K, et al. **Baillieres Clin Endocrinol Metab** 1996 Jul; 10(3):337–52 (78 ref.)

The role of substrates in the regulation of protein metabolism. Tessari P, et al. **Baillieres Clin Endocrinol Metab** 1996 Oct; 10(4):511–32 (125 ref.)

Oestrogens and postprandial lipid metabolism. Westerveld HT, et al. **Biochem Soc Trans** 1997 Feb;25(1):45–9 (48 ref.)

Lipid metabolism in the lactating mammary gland. Barber MC, et al. **Biochim Biophys Acta** 1997 Aug 16; 1347(2–3):101–26 (257 ref.)

Microsomal triglyceride transfer protein. Wetterau JR, et al. **Biochim Biophys Acta** 1997 Apr 1;1345(2):136–50 (74 ref.)

Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators of lipid metabolism. Latruffe N, et al. **Biochimie** 1997 Feb–Mar; 79(2–3):81–94 (162 ref.)

Lipid structure and Ca(2+)-ATPase function. Lee AG, et al. **Biosci Rep** 1995 Oct;15(5):289–98 (50 ref.)

Sepsis and fat metabolism. Samra JS, et al. **Br J Surg** 1996 Sep;83(9):1186–96 (234 ref.)

Non-bilayer lipids and biological fusion intermediates. Chernomordik L. **Chem Phys Lipids** 1996 Jul 15; 81(2):203–13 (87 ref.)

Risk factors, endothelial cell turnover and lipid transport in atherogenesis. Lin SJ. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Nov; 58(5):309–16 (55 ref.)

The effects of detergents on hydration and skin surface lipids. Thune P. **Clin Dermatol** 1996 Jan–Feb;14(1):29–33 (33 ref.)

Lipid abnormalities in progressive renal insufficiency. Attman PO, et al. **Contrib Nephrol** 1997;120:1–10 (35 ref.)

Peroxisome proliferator–activated receptor gamma and the control of adipogenesis. Brun RP, et al. **Curr Opin Lipidol** 1997 Aug;8(4):212–8 (55 ref.)

Lipids in infant nutrition and their impact on later development. Lanting CI, et al. **Curr Opin Lipidol** 1996 Feb;7(1):43–7 (29 ref.)

Lipid metabolism [editorial] Poisson JP. **Curr Opin Lipidol** 1997 Apr;8(2):U20–1 (5 ref.)

The menopause and lipid metabolism: strategies for cardiovascular disease prevention. Soma MR, et al. **Curr Opin Lipidol** 1997 Aug;8(4):229–35 (52 ref.)

In vivo studies of intrahepatic metabolic pathways. Beylot M, et al. **Diabetes Metab** 1997 Jun;23(3):251–7 (54 ref.)

Winter stress syndrome: an important consideration for hazard assessment of aquatic pollutants. Lemly AD. **Ecotoxicol Environ Saf** 1996 Aug;34(3):223–7 (22 ref.)

Regulation of protein kinase C: a tale of lipids and proteins. Quest AF. **Enzyme Protein** 1996;49(5–6):231–61 (242 ref.)

Lipid requirements in infants with digestive diseases with references to short bowel syndrome. Goulet O. **Eur J Med Res** 1997 Feb 21;2(2):79–83 (26 ref.)

Lipid supply for infants with special needs. Koletzko B. **Eur J Med Res** 1997 Feb 21;2(2):69–73 (55 ref.)

Meeting lipid needs of infants with allergy and gastrointestinal diseases. Moran JR, et al. **Eur J Med Res** 1997 Feb 21;2(2):84–7 (15 ref.)

New insights into lipid and fatty acid metabolism via stable isotopes. Demmelmair H, et al. **Eur J Pediatr** 1997 Aug; 156 Suppl 1:S70–4 (20 ref.)

Lipid and lipoprotein modification by advanced glycosylation end–products: role in atherosclerosis. Bucala R. **Exp Physiol** 1997 Mar;82(2):327–37 (38 ref.)

Lipid metabolism in the ischemic and reperfused heart. van der Vusse GJ, et al. **EXS** 1996;76:175–90 (53 ref.)

Integral lipids of hair and stratum corneum. Wertz PW. **EXS** 1997;78:227–37 (51 ref.)

Hepatic canalicular membrane 1: The role of mdr2 P-glycoprotein in hepatobiliary lipid transport. Elferink RP, et al. **FASEB J** 1997 Jan;11(1):19–28 (59 ref.)

The cytochrome P450 4 (CYP4) family. Simpson AE. **Gen Pharmacol** 1997 Mar;28(3):351–9 (115 ref.)

The role of the lipid matrix in the biosynthesis of dolichyl-linked oligosaccharides. Schutzbach JS. **Glycoconj J** 1997 Feb;14(2):175–82 (77 ref.)

Growth hormone, insulin–like growth factor–I and lipid metabolism: interactions with sex steroids. Björntorp P. **Horm Res** 1996;46(4–5):188–91 (12 ref.)

Acyltransferases and transacylases involved in fatty acid remodeling of phospholipids and metabolism of bioactive lipids in mammalian cells. Yamashita A, et al. **J Biochem (Tokyo)** 1997 Jul;122(1):1–16 (149 ref.)

The stratum corneum revisited. Elias PM. **J Dermatol** 1996 Nov;23(11):756–8 (77 ref.)

Research prospects with benfluorex. Ravel D, et al. **J Diabetes Complications** 1996 Sep–Oct;10(5):246–54 (56 ref.)

Metabolic effects of antihypertensive drugs. Suter PM, et al. **J Hypertens Suppl** 1995 Dec;13(4):S11–7 (74 ref.)

Cytosolic phospholipase A2 (cPLA2) and lipid mediator release in the brain. Kramer RM, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):3–7 (14 ref.)

Production and function of lipid second messengers in proliferating and differentiated neuroblastoma cells. Lang D, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):349–59 (38 ref.)

N–arachidonoylethanolamine (anandamide), an endogenous cannabinoid receptor ligand, and related lipid molecules in the nervous tissues. Sugiura T, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):51–6 (20 ref.)

Naturally occurring mutations in mice affecting lipid transport and metabolism. Reue K, et al. **J Lipid Res** 1996 Jul;37(7):1387–405 (120 ref.)

Morphology of lipid alterations in the epidermis: a review. Menon G, et al. **Microsc Res Tech** 1997 May 1;37(3):180–92 (180 ref.)

Biochemistry and molecular genetics of cell–wall lipid biosynthesis in mycobacteria. Kolattukudy PE, et al. **Mol Microbiol** 1997 Apr;24(2):263–70 (30 ref.)

Lipid metabolism in photoreceptor membranes: regulation and mechanisms. Giusto NM, et al. **Neurochem Res** 1997 Apr;22(4):445–53 (58 ref.)

Regulation of lipid metabolism by cytokines during host defense. Grunfeld C, et al. **Nutrition** 1996 Jan;12(1 Suppl):S24–6 (26 ref.)

Intralobular innervation and lipocyte contractility in the liver. Ueno T, et al. **Nutrition** 1997 Feb;13(2):141–8 (83 ref.)

Tear film lipid layer formation: implications for contact lens wear. Korb DR, et al. **Optom Vis Sci** 1996 Mar;73(3):189–92 (38 ref.)

Developmental aspects of lipid metabolism. Koldovský O, et al. **Physiol Res** 1995;44(6):353–6 (40 ref.)

The structure and biogenesis of plant oil bodies: the role of the ER membrane and the oleosin class of proteins. Napier JA, et al. **Plant Mol Biol** 1996 Aug;31(5):945–56 (68 ref.)

Lipid absorption and hepatic metabolism in ruminants. Bauchart D, et al. **Proc Nutr Soc** 1996 Mar;55(1B):39–47 (38 ref.)

Adipocyte hormone–sensitive lipase: a major regulator of lipid metabolism. Langin D, et al. **Proc Nutr Soc** 1996 Mar; 55(1B):93–109 (83 ref.)

Disposition of lipids in the postprandial state. Williams CM. **Proc Nutr Soc** 1996 Mar;55(1B):79–91 (61 ref.)

Lipids and biomineralizations. Goldberg M, et al. **Prog Histochem Cytochem** 1996;31(2):1–187 (500 ref.)

Betaine ether–linked glycerolipids: chemistry and biology. Dembitsky VM. **Prog Lipid Res** 1996 Mar;35(1):1–51 (202 ref.)

Heat stress lipids and schizophrenia. Bates PR, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Aug; 55(1–2):101–7 (66 ref.)

Lysosomal metabolism of lipids. Johnson WJ, et al. **Subcell Biochem** 1996;27:239–93 (250 ref.)

Cholesterol–sphingomyelin interactions in cells–-effects on lipid metabolism. Slotte JP. **Subcell Biochem** 1997; 28:277–93 (86 ref.)

Oxidized lipids in atherogenesis: formation, destruction and action. Berliner J, et al. **Thromb Haemost** 1997 Jul; 78(1):195–9 (34 ref.)

Abnormal lipid metabolism and renal disorders. Saito T. **Tohoku J Exp Med** 1997 Mar;181(3):321–37 (56 ref.)

[Modifications of lipids and lipoproteins due to end products of advanced glycosylation: role in atherosclerosis] Bucala R. **Journ Annu Diabetol Hotel Dieu** 1996;:133–44 (38 ref.) **(Fre)**

[Chronobiology, nutrition and metabolism] Mejean L, et al. **Pathol Biol (Paris)** 1996 Sep;44(7):603–9 (61 ref.) (Eng. Abstr.) **(Fre)**

[Absorptive mechanism of vitamins, lipids and bile acid] Miura S, et al. **Nippon Naika Gakkai Zasshi** 1996 Jul 10; 85(7):1042–7 (5 ref.) **(Jpn)**

[Biochemistry of risk factors for cardiovascular diseases in laboratory medicine] Okabe H. **Rinsho Byori** 1996 Nov; 44(11):1050–7 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Leukotriene A4 hydrolase: a bifunctional enzyme acts toward two different types of cellular compounds, lipids and peptides] Minami M, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(6):825–33 (42 ref.) **(Jpn)**

[Lipids in the cell nucleus] Bucki R, et al. **Postepy Hig Med Dosw** 1997;51(3):319–28 (53 ref.) (Eng. Abstr.) **(Pol)**

[Anti–atherosclerotic action of angiotensin converting enzyme II. Effect on metabolism of kinin, free radical reaction, sensitivity to insulin and lipid metabolism] Stajszczyk M, et al. **Postepy Hig Med Dosw** 1996; 50(6):635–47 (71 ref.) (Eng. Abstr.) **(Pol)**

[Transcriptional regulation of lipid metabolism genes: description in the TRDD database] Ignat'eva EV, et al. **Mol Biol (Mosk)** 1997 Jul–Aug;31(4):684–700 (81 ref.) **(Rus)**

[Disorders of lipid levels and metabolism as risk factors for the onset and development of cerebral arteriosclerosis and cerebral ischemia] Jovičić A, et al. **Vojnosanit Pregl** 1996 Mar–Apr;53(2):125–32 (53 ref.) **(Scr)**

PHARMACOLOGY

Non–bilayer lipids and biological fusion intermediates. Chernomordik L. **Chem Phys Lipids** 1996 Jul 15; 81(2):203–13 (87 ref.)

The effects of non–lamellar forming lipids on membrane protein–lipid interactions. Stubbs CD, et al. **Chem Phys Lipids** 1996 Jul 15;81(2):185–95 (71 ref.)

Effects of lipidic mediators on the growth of human myeloid and erythroid marrow progenitors. Dupuis F, et al. **J Lipid Mediat Cell Signal** 1997 Jul;16(3):117–25 (33 ref.)

Does modifying dietary lipids influence the progression of renal failure? Brown SA, et al. **Vet Clin North Am Small Anim Pract** 1996 Nov; 26(6):1277–85 (26 ref.)

PHYSIOLOGY

Peroxisome proliferator–activated receptors: a nuclear receptor signaling pathway in lipid physiology. Lemberger T, et al. **Ann Rev Cell Dev Biol** 1996;12:335–63 (116 ref.)

Lipid hypothesis of cardiovascular calcification [editorial; comment] Demer LL. **Circulation** 1997 Jan 21;95(2):297–8 (18 ref.) Comment on: Circulation 1997 Jan 21;95(2):479–88.

Lipids and endothelial function: effects of lipid–lowering and other therapeutic interventions. Lüscher TF, et al. **Curr Opin Lipidol** 1996 Aug;7(4):234–40 (67 ref.)

Potential role of lipids in the progression of glomerular diseases. Olbricht CJ. **Kidney Blood Press Res** 1997; 20(3):188–9 (27 ref.)

Bioactive lipids in excitatory neurotransmission and neuronal plasticity. Bazan NG, et al. **Neurochem Int** 1997 Feb; 30(2):225–31 (59 ref.)

Signal transduction and gene expression in the eye: a contemporary view of the pro–inflammatory, anti–inflammatory and modulatory roles of prostaglandins and other bioactive lipids. Bazan NG, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S23–34 (100 ref.)

[Lipids and atherosclerosis] Gmiński J. **Wiad Lek** 1996; 49(7–12):153–8 (0 ref.) (Eng. Abstr.) **(Pol)**

LIPIDS

SECRETION

Lipid secretory mechanisms in the mammalian harderian gland. Satoh Y, et al. **Microsc Res Tech** 1996 Jun 1; 34(2):104–10 (47 ref.)

THERAPEUTIC USE

Cows' milk fat components as potential anticarcinogenic agents. Parodi PW. **J Nutr** 1997 Jun;127(6):1055–60 (71 ref.)

LIPOAMIDE DEHYDROGENASE

CHEMISTRY

Dihydrolipoamide dehydrogenase: structural and mechanistic aspects. Vettakkorumakankav NN, et al. **Indian J Biochem Biophys** 1996 Jun;33(3):168–76 (64 ref.)

METABOLISM

Dihydrolipoamide dehydrogenase: structural and mechanistic aspects. Vettakkorumakankav NN, et al. **Indian J Biochem Biophys** 1996 Jun;33(3):168–76 (64 ref.)

LIPOCORTIN I see **ANNEXIN I**

LIPOCORTIN II see **ANNEXIN II**

LIPOCORTIN V see **ANNEXIN V**

LIPOCORTINS see **ANNEXINS**

LIPODYSTROPHY

PHYSIOPATHOLOGY

Generalized lipodystrophy, congenital and acquired (lipoatrophy). Seip M, et al. **Acta Paediatr Suppl** 1996 Jun; 413:2–28 (129 ref.)

SURGERY

[Surgical treatment of lipodystrophies] De Mey A. **Rev Med Brux** 1996 Sep;17(4):240–3 (17 ref.) (Eng. Abstr.) **(Fre)**

[Superficial liposuction: a new treatment for lipodystrophies] Adant JP, et al. **Rev Med Liege** 1997;52(7):463–8 (12 ref.) **(Fre)**

LIPODYSTROPHY, INTESTINAL see **WHIPPLE'S DISEASE**

LIPOFUSCIN

METABOLISM

Lipofuscin of the retinal pigment epithelium: a review. Kennedy CJ, et al. **Eye** 1995;9 (Pt 6):763–71 (72 ref.)

Biochemical basis of lipofuscin, ceroid, and age pigment–like fluorophores. Yin D. **Free Radic Biol Med** 1996; 21(6):871–88 (187 ref.)

Brain lipofuscinolysis and ceroidolysis—to be or not to be. Riga D, et al. **Gerontology** 1995;41 Suppl 2:271–81 (42 ref.)

Studies on age pigments evolving into a new theory of biological aging. Yin D. **Gerontology** 1995;41 Suppl 2:159–72 (99 ref.)

PHARMACOLOGY

Lipofuscin fluorophore inhibits lysosomal protein degradation and may cause early stages of macular degeneration. Eldred GE. **Gerontology** 1995;41 Suppl 2:15–28 (72 ref.)

LIPOIC ACID see **THIOCTIC ACID**

LIPOIDOSIS

CHEMICALLY INDUCED

Cationic amphiphilic drug-induced phospholipidosis. Halliwell WH. **Toxicol Pathol** 1997 Jan–Feb;25(1):53–60 (87 ref.)

PATHOLOGY

[Glomerular lipidosis] Kasahara N, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):162–6 (14 ref.) **(Jpn)**

VETERINARY

Nutrition and liver disease. Biourge VC. **Semin Vet Med Surg (Small Anim)** 1997 Feb;12(1):34–44 (61 ref.)

Feline hepatic lipidosis. Dimski DS. **Semin Vet Med Surg (Small Anim)** 1997 Feb;12(1):28–33 (31 ref.)

LIPOLYSIS

Lipolysis: contribution from regional fat. Jensen MD. **Annu Rev Nutr** 1997;17:127–39 (42 ref.)

PHYSIOLOGY

Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. Goldberg IJ. **J Lipid Res** 1996 Apr;37(4):693–707 (163 ref.)

[Mechanism of catecholamine-induced lipolysis in adipocytes] Okuda H. **Seikagaku** 1997 Jun;69(6):420–4 (15 ref.) **(Jpn)**

LIPOLYSIS, SUCTION see **LIPECTOMY**

LIPOMA

[Lipoma and liposarcoma of the heart] Mikouchi H. **Ryoikibetsu Shokogun Shirizu** 1996;(14):246–9 (23 ref.) **(Jpn)**

[Benign pericardial tumor (angioma, lipoma, teratoma)] Natsume T. **Ryoikibetsu Shokogun Shirizu** 1996;(14):295–6 (5 ref.) **(Jpn)**

[Epicardial lipoma] Saito D, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):230–2 (17 ref.) **(Jpn)**

COMPLICATIONS

Pelvic lipoma causing venous obstruction syndrome. Acheson A, et al. **Eur J Vasc Endovasc Surg** 1997 Aug; 14(2):149–50 (6 ref.)

[Intestinal invagination caused by colonic lipoma] Cirino E, et al. **Minerva Chir** 1996 Sep;51(9):717–23 (33 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Value of fat suppression magnetic resonance imaging in the diagnosis of lipomas of the internal auditory canal. Hara A, et al. **Ann Otol Rhinol Laryngol** 1997 Apr;106(4):343–7 (27 ref.)

Lipomas of the internal auditory canal. Singh SP, et al. **Arch Pathol Lab Med** 1996 Jul;120(7):681–3 (12 ref.)

Neural fibrolipoma of the foot: a case report. Donley BG, et al. **Foot Ankle Int** 1996 Nov;17(11):712–3 (8 ref.)

Clinical image. Lipoblastoma of the thigh: MR appearance. Katz DS, et al. **J Comput Assist Tomogr** 1996 Nov–Dec; 20(6):1002–3 (8 ref.)

Hourglass thoracic lipoma of infancy: case report and review of the literature. Solsona-Norbón B, et al. **J Pediatr Surg** 1997 May;32(5):785–6 (9 ref.)

Intraosseous lipoma of the distal femur: MRI appearance. Levin MF, et al. **Skeletal Radiol** 1996 Jan;25(1):82–4 (5 ref.)

Primary lipomatous tumors of the cardiac valves. Benvenuti LA, et al. **South Med J** 1996 Oct;89(10):1018–20 (17 ref.)

EMBRYOLOGY

Embryogenesis. Why do we need a new explanation for the emergence of spina bifida with lipoma? Catala M. **Childs Nerv Syst** 1997 Jun;13(6):336–40 (28 ref.)

EPIDEMIOLOGY

A rare case of pancreatic lipoma. Merli M, et al. **Hepatogastroenterology** 1996 May–Jun;43(9):734–6 (10 ref.)

GENETICS

Congenital lumbosacral lipomas. Pierre-Kahn A, et al. **Childs Nerv Syst** 1997 Jun;13(6):298–334; discussion 335 (199 ref.)

The cytogenetics of lipomatous tumours. Rubin BP, et al. **Histopathology** 1997 Jun;30(6):507–11 (53 ref.)

PATHOLOGY

Oral infiltrating lipomas. Bataineh AB, et al. **Br J Oral Maxillofac Surg** 1996 Dec;34(6):520–3 (20 ref.)

Clinical evaluation of cutaneous lesions of the back: spinal signatures that do not go away. Humphreys RP. **Clin Neurosurg** 1996;43:175–87 (6 ref.)

Intraosseous lipoma of the calcaneus. Greenspan A, et al. **Foot Ankle Int** 1997 Jan;18(1):53–6 (26 ref.)

Hypothalamic osteolipoma: a case report. Wittig H, et al. **Gen Diagn Pathol** 1997 Jun;142(5–6):361–4 (30 ref.)

Hibernoma of scalp: case report and review of literature. Naik R, et al. **Indian J Cancer** 1996 Jun;33(2):116–8 (13 ref.)

Pharyngeal lipoma with cartilaginous metaplasia (chondrolipoma): a case report and literature review. Nwaorgu OG, et al. **J Laryngol Otol** 1997 Jul;111(7):656–8 (11 ref.)

Giant adrenal lipoma: a report of two cases and review of literature. Lam KY, et al. **Scand J Urol Nephrol** 1997 Feb; 31(1):89–90 (5 ref.)

[Intramuscular lipoma of the head and neck. Description of a case and review of the literature] Heymans O, et al. **Rev Stomatol Chir Maxillofac** 1996;97(4):241–3 (22 ref.) (Eng. Abstr.) **(Fre)**

[A case report of cervicomediastinal lipoma] Kitami A, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):624–7 (21 ref.) (Eng. Abstr.) **(Jpn)**

[On the histogenesis and classification of fibrous, lipomatous, fibrohistiocytic and related tumors of bone and soft tissues] Hizawa K. **Nippon Seikeigeka Gakkai Zasshi** 1996 Oct; 70(10):685–95 (30 ref.) **(Jpn)**

[A case of gastric lipoma prolapsed into the duodenal bulb, which caused ball valve syndrome] Machishi H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Aug;93(8):560–4 (12 ref.) **(Jpn)**

[Liposarcoma, lipoma and lipomatosis of the kidney] Fujioka T, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):488–90 (15 ref.) **(Jpn)**

ULTRASONOGRAPHY

Sonographic detection of lipomyelomeningocele: a retrospective documentation. Chreston J, et al. **J Clin Ultrasound** 1997 Jan;25(1):50–1 (5 ref.)

LIPOMA, PLEOMORPHIC see **LIPOMA**

LIPOMATOSIS

Parotid lipomatosis. Holland AJ, et al. **J Pediatr Surg** 1996 Oct;31(10):1422–3 (18 ref.)

CHEMICALLY INDUCED

[Lipomatosis induced by corticosteroid therapy] Humblot S, et al. **Rev Med Interne** 1997;18(5):396–401 (25 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Epidural lipomatosis with lumbar radiculopathy in one obese patient. Case report and review of the literature. Qasho R, et al. **Neurosurg Rev** 1997;20(3):206–9 (28 ref.)

ETIOLOGY

A case of colonic pseudolipomatosis: a rare complication of colonoscopy? Kaassis M, et al. **Endoscopy** 1997 May; 29(4):325–7 (8 ref.)

Epidural lipomatosis not induced by corticosteroid therapy. Three cases including one in a patient with primary Cushing's disease (review of the literature). Benamou PH, et al. **Rev Rhum Engl Ed** 1996 Mar;63(3):207–12 (18 ref.)

PATHOLOGY

Macrodystrophia lipomatosa of the foot: a report of three cases and literature review. Bailey EJ, et al. **Foot Ankle Int** 1997 Feb;18(2):89–93 (17 ref.)

[Liposarcoma, lipoma and lipomatosis of the kidney] Fujioka T, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):488–90 (15 ref.) **(Jpn)**

RADIOGRAPHY

Total fat replacement of the pancreas: case report and review of the literature. Rosseel F, et al. **J Belge Radiol** 1996 Nov; 79(5):199–200 (14 ref.)

Epidural lipomatosis: case report and literature review. Hierholzer J, et al. **Neuroradiology** 1996 May;38(4):343–8 (25 ref.)

SURGERY

Idiopathic spinal epidural lipomatosis. Robertson SC, et al. **Neurosurgery** 1997 Jul;41(1):68–74; discussion 74–5 (41 ref.)

LIPOMATOSIS, MULTIPLE SYMMETRICAL

PATHOLOGY

Laryngeal involvement in multiple symmetric lipomatosis: the role of computed tomography in diagnosis. Borges A, et al. **Am J Otolaryngol** 1997 Mar–Apr;18(2):127–30 (12 ref.)

Madelung's disease: an uncommon disorder of unknown aetiology? Parmar C, et al. **Br J Oral Maxillofac Surg** 1996 Oct;34(5):467–70 (18 ref.)

RADIOGRAPHY

Laryngeal involvement in multiple symmetric lipomatosis: the role of computed tomography in diagnosis. Borges A, et al. **Am J Otolaryngol** 1997 Mar–Apr;18(2):127–30 (12 ref.)

SURGERY

[Madelung's cervicodorsal adipose hypertrophy (the Launois–Bensaude syndrome)] Constantinoiu S, et al. **Chirurgia (Bucur)** 1996 Nov–Dec;45(6):331–6 (13 ref.) (Eng. Abstr.) **(Rum)**

LIPOMATOSIS, NODULAR CIRCUMSCRIBED see **LIPOMATOSIS, MULTIPLE SYMMETRICAL**

LIPOMUCOPOLYSACCHARIDOSIS see **MUCOLIPIDOSIS**

LIPOPOLYSACCHARIDE RECEPTORS see **ANTIGENS, CD14**

LIPOPOLYSACCHARIDES

Molecular genetics and biochemistry of Yersinia lipopolysaccharide. Skurnik M, et al. **APMIS** 1996 Dec; 104(12):849–72 (100 ref.)

Bacterial products and the control of ingestive behavior:

clinical implications. Langhans W. **Nutrition** 1996 May; 12(5):303–15 (110 ref.)
Role of lipo–oligosaccharides and lipopolysaccharides in bacterial adherence [see comments] Jacques M. **Trends Microbiol** 1996 Oct;4(10):408–9 (31 ref.) Comment in: Trends Microbiol 1996 Nov;4(11):418.
[Gram–negative virulent bacterial lipopolysaccharide: role in infection and immunity] Vorobév AA, et al. **Vestn Ross Akad Med Nauk** 1997;(3):10–3 (35 ref.) (Eng. Abstr.) **(Rus)**

ANTAGONISTS & INHIBITORS

Inhibition of tissue factor and cytokine release. Gray E, et al. **Haemostasis** 1996;26 Suppl 1:92–5 (12 ref.)

BIOSYNTHESIS

Lipoteichoic acid as a target for antimicrobial action. Canepari P, et al. **Microb Drug Resist** 1996 Spring;2(1):85–9 (20 ref.)
Rhizobium symbiosis: nod factors in perspective. Long SR. **Plant Cell** 1996 Oct;8(10):1885–98 (140 ref.)

CHEMISTRY

The lipooligosaccharides of pathogenic gram–negative bacteria. Preston A, et al. **Crit Rev Microbiol** 1996; 22(3):139–80 (192 ref.)
Biochemistry and cell biology of bacterial endotoxins. Holst O, et al. **FEMS Immunol Med Microbiol** 1996 Dec 1; 16(2):83–104 (229 ref.)
Molecular mimicry of host structures by bacterial lipopolysaccharides and its contribution to disease. Moran AP, et al. **FEMS Immunol Med Microbiol** 1996 Dec 1; 16(2):105–15 (94 ref.)
Bacterial lipopolysaccharides—themes and variations. Wilkinson SG. **Prog Lipid Res** 1996 Sep;35(3):283–343 (810 ref.)
Pseudomonas aeruginosa lipopolysaccharides and pathogenesis. Goldberg JB, et al. **Trends Microbiol** 1996 Dec;4(12):490–4 (50 ref.)
[Lipopolysaccharides containing sialic acid] Gamian A. **Postepy Hig Med Dosw** 1996;50(5):459–72 (43 ref.) (Eng. Abstr.) **(Pol)**
[Proteus lipopolysaccharides] Sidorczyk Z. **Postepy Hig Med Dosw** 1996;50(5):401–17 (51 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

T–cell recognition of non–peptide antigens. Porcelli SA, et al. **Curr Opin Immunol** 1996 Aug;8(4):510–6 (50 ref.)
Lipopolysaccharide dependent cellular activation. Tobias PS, et al. **J Periodontal Res** 1997 Jan;32(1 Pt 2):99–103 (40 ref.)
[Sporadic cases of hemolytic uremic syndrome and hemorrhagic colitis with serum IgM antibodies to lipopolysaccharides of enterohemorrhagic Escherichia coli O157] Shiomi M, et al. **Nippon Rinsho** 1997 Mar; 55(3):686–92 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Pathogenesis of Guillain–Barré syndrome and Fisher's syndrome: molecular mimicry between antecedent infectious agents and components of nerve tissues] Yuki N. **Rinsho Shinkeigaku** 1995 Dec;35(12):1373–5 (10 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Lipopolysaccharide's role in the association of Salmonella cells to the mouse intestine studied by ribosomal in situ hybridization. Krogfelt KA, et al. **Adv Exp Med Biol** 1996; 408:123–8 (25 ref.)
Rhizobium lipo–chitooligosaccharide nodulation factors: signaling molecules mediating recognition and morphogenesis. Dénarié J, et al. **Annu Rev Biochem** 1996; 65:503–35 (185 ref.)
The role of lipochitooligosaccharides in root nodule organogenesis and plant cell growth. Schultze M, et al. **Curr Opin Genet Dev** 1996 Oct;6(5):631–8 (76 ref.)
Control of transcriptional activation of the lipopolysaccharide binding protein (LBP) gene by proinflammatory cytokines. Kirchning C, et al. **Cytokines Cell Mol Ther** 1997 Mar;3(1):59–62 (33 ref.)
Cytokine–inducing components of periodontopathogenic bacteria. Wilson M, et al. **J Periodontal Res** 1996 Aug; 31(6):393–407 (117 ref.)
Sialylation of neisserial lipopolysaccharide: a major influence on pathogenicity. Smith H, et al. **Microb Pathog** 1995 Dec; 19(6):365–77 (59 ref.)
Modulation of the surface architecture of gram–negative bacteria by the action of surface polymer:lipid A–core ligase and by determinants of polymer chain length. Whitfield C, et al. **Mol Microbiol** 1997 Feb;23(4):629–38 (36 ref.)
[Neutrophil activation by bacterial endotoxins] Klink M, et al. **Postepy Hig Med Dosw** 1996;50(4):333–50 (80 ref.) (Eng. Abstr.) **(Pol)**

PHARMACOLOGY

Lipopolysaccharide binding protein participation in cellular activation by LPS. Su GL, et al. **Crit Rev Immunol** 1995; 15(3–4):201–14 (97 ref.)
Cytokine induction by bacteria: beyond lipopolysaccharide. Henderson B, et al. **Cytokine** 1996 Apr;8(4):269–82 (160 ref.)
Regulation of ICE activity and ICE isoforms by LPS. Tingsborg S, et al. **Mol Psychiatry** 1997 Mar;2(2):122–4 (10 ref.)

TOXICITY

L–Selectin—a signalling receptor for lipopolysaccharide. Malhotra R, et al. **Chem Biol** 1997 Aug;4(8):543–7 (29 ref.)
Pathobiology of lipopolysaccharide. Mayeux PR. **J Toxicol Environ Health** 1997 Aug 8;51(5):415–35 (117 ref.)
Role of lipopolysaccharide and related cytokines in Helicobacter pylori infection. Pece S, et al. **Recenti Prog Med** 1997 May;88(5):237–41 (36 ref.)

LIPOPROTEIN(A)

Lipoprotein [a]. van den Ende A, et al. **Adv Clin Chem** 1996; 32:73–134 (366 ref.)
[Research progress in lipoprotein (a): aspects of biochemistry and molecular biology] Huang YT. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan;27(1):25–30 (20 ref.) (Eng. Abstr.) **(Chi)**
[Lipoprotein(a) as an athero–thrombotic risk factor: epidemiologic evidence and possible pathogenetic mechanisms] Lenzi S, et al. **G Ital Cardiol** 1996 Oct; 26(10):1203–25 (189 ref.) (Eng. Abstr.) **(Ita)**

BLOOD

Elevated levels of serum lipoprotein(a) and apolipoprotein(a) phenotype are not related to pre–eclampsia. Leerink CB, et al. **Acta Obstet Gynecol Scand** 1997 Aug;76(7):625–8 (20 ref.)
Lipoprotein Lp(a) excess and coronary heart disease [see comments] Stein JH, et al. **Arch Intern Med** 1997 Jun 9; 157(11):1170–6 (119 ref.) Comment in: Arch Intern Med 1997 Jun 9;157(11):1161–2.
Hyperlipidaemia and cardiovascular disease [editorial] Somers VK, et al. **Curr Opin Lipidol** 1996 Dec; 7(6):U193–201 (13 ref.)
Dietary trans–fatty acids and serum lipoproteins in humans. Zock PL, et al. **Curr Opin Lipidol** 1996 Feb;7(1):34–7 (22 ref.)
Coronary artery disease in Asian Indians: lessons learnt and the role of lipoprotein(a). Enas EA, et al. **Indian Heart J** 1997 Jan–Feb;49(1):25–34 (110 ref.)
Lipoprotein[a]: a predictor of atherosclerotic disease. Harris ED. **Nutr Rev** 1997 Mar;55(3):61–4 (23 ref.)
[Lipoprotein (a) as a cardiovascular risk factor in man] Schneider R, et al. **Harefuah** 1997 Jan 1;132(1):46–50 (57 ref.) **(Heb)**
[Lipoprotein(a). Its importance as an additional atherosclerosis marker] Campos E. **Acta Med Port** 1997 Jan;10(1):87–93 (67 ref.) (Eng. Abstr.) **(Por)**

CHEMISTRY

Pathophysiological implication of the structural domains of lipoprotein(a). Huby T, et al. **Atherosclerosis** 1997 Aug; 133(1):1–6 (48 ref.)
The assembly of lipoprotein Lp(a). Frank S, et al. **Eur J Clin Invest** 1996 Feb;26(2):109–14 (42 ref.)
Lipoprotein(a): structural implications for pathophysiology. Koschinsky ML, et al. **Int J Clin Lab Res** 1997;27(1):14–23 (94 ref.)

METABOLISM

Cellular binding and degradation of lipoprotein (a). Fless GM. **J Atheroscler Thromb** 1995;2 Suppl 1:S1–4 (20 ref.)

PHARMACOLOGY

Effects of lipoprotein (a) on mesangial cell biology. Greiber S, et al. **Contrib Nephrol** 1997;120:146–52 (35 ref.)

PHYSIOLOGY

Lipoprotein(a), a clinically elusive lipoprotein particle [editorial; comment] Fortmann SP, et al. **Circulation** 1997 Jan 21;95(2):295–6 (18 ref.) Comment on: Circulation 1997 Jan 21;95(2):329–34.
How often has Lp(a) evolved? Lawn RM. **Clin Genet** 1996 Apr;49(4):167–74 (61 ref.)
Lipoprotein(a) in health and disease. Kronenberg F, et al. **Crit Rev Clin Lab Sci** 1996 Dec;33(6):495–543 (238 ref.)
Lipoprotein (a) in the regulation of fibrinolysis. Edelberg JM, et al. **J Atheroscler Thromb** 1995;2 Suppl 1:S5–7 (27 ref.)

LIPOPROTEIN DEFICIENCY, HDL, FAMILIAL see **TANGIER DISEASE**

LIPOPROTEIN LDL RECEPTORS see **RECEPTORS, LDL**

LIPOPROTEIN LIPASE

GENETICS

Human lipoprotein lipase deficiency: does chronic dyslipidemia lead to increased oxidative stress and mitochondrial DNA damage in blood cells? Ven Murthy MR, et al. **Acta Biochim Pol** 1996;43(1):227–40 (51 ref.)
Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C–III genes by activating the nuclear receptor PPAR. Auwerx J, et al. **Atherosclerosis** 1996 Jul;124 Suppl:S29–37 (59 ref.)
The tissue–specific expression of lipoprotein lipase: implications for energy and lipoprotein metabolism. Zechner R. **Curr Opin Lipidol** 1997 Apr;8(2):77–88 (174 ref.)
Potential role of TNFalpha and lipoprotein lipase as candidate genes for obesity. Kern PA. **J Nutr** 1997 Sep; 127(9):1917S–1922S (43 ref.)
Molecular pathobiology of the human lipoprotein lipase gene. Murthy V, et al. **Pharmacol Ther** 1996;70(2):101–35 (260 ref.)

METABOLISM

Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. Goldberg IJ. **J Lipid Res** 1996 Apr;37(4):693–707 (163 ref.)
Lipoprotein lipase (EC 3.1.1.34) targeting of lipoproteins to receptors. Beisiegel U, et al. **Proc Nutr Soc** 1997 Jul; 56(2):731–7 (37 ref.)
Lipoprotein lipase: regulation and role in lipoprotein metabolism. Olivecrona T, et al. **Proc Nutr Soc** 1997 Jul; 56(2):723–9 (14 ref.)
[Lipoprotein lipase: properties, change in activity with age and in some noninfectious human diseases] Kovalenko IG, et al. **Vopr Med Khim** 1996 Jan–Mar;42(1):3–9 (53 ref.) **(Rus)**

PHYSIOLOGY

New aspects on the role of plasma lipases in lipoprotein catabolism and atherosclerosis. Beisiegel U. **Atherosclerosis** 1996 Jul;124(1):1–8 (111 ref.)
Potential role of TNFalpha and lipoprotein lipase as candidate genes for obesity. Kern PA. **J Nutr** 1997 Sep; 127(9):1917S–1922S (43 ref.)
Pathogenesis of dyslipoproteinemia in renal insufficiency: the role of lipoprotein lipase and hepatic lipase. Arnadóttir M. **Scand J Clin Lab Invest** 1997 Feb;57(1):1–11 (97 ref.)

LIPOPROTEIN LIPASE DEFICIENCY, FAMILIAL

GENETICS

Human lipoprotein lipase deficiency: does chronic dyslipidemia lead to increased oxidative stress and mitochondrial DNA damage in blood cells? Ven Murthy MR, et al. **Acta Biochim Pol** 1996;43(1):227–40 (51 ref.)

PHYSIOPATHOLOGY

Molecular pathobiology of the human lipoprotein lipase gene. Murthy V, et al. **Pharmacol Ther** 1996;70(2):101–35 (260 ref.)

LIPOPROTEIN RECEPTORS see **RECEPTORS, LIPOPROTEIN**

LIPOPROTEINS

see related
APOLIPOPROTEINS
HYPERLIPOPROTEINEMIA
HYPOLIPOPROTEINEMIA
PROTEOLIPIDS
RECEPTORS, LIPOPROTEIN

[Aiming serotherapy of HUS–IVIG, serum lipoprotein and C3] Nishioka K, et al. **Nippon Rinsho** 1997 Mar; 55(3):758–62 (34 ref.) **(Jpn)**
[Lipoproteins as functional associates of protein–lipid complexes (literature review)] Titov VN. **Klin Lab Diagn** 1997 Jul;(7):13–9 (52 ref.) **(Rus)**

BIOSYNTHESIS

Evolution of processes and regulators of lipoprotein synthesis: from birds to mammals. Davis RA. **J Nutr** 1997 May;127(5 Suppl):795S–800S (44 ref.)

BLOOD

Aggressive medical therapy for the prevention and treatment of coronary artery disease. Malloy MJ, et al. **Adv Intern Med** 1997;42:1–38 (113 ref.)
n–3 fatty acids and serum lipoproteins: human studies. Harris WS. **Am J Clin Nutr** 1997 May;65(5 Suppl):1645S–1654S (83 ref.)
n–3 fatty acids and serum lipoproteins: animal studies. Harris WS. **Am J Clin Nutr** 1997 May;65(5 Suppl):1611S–1616S (62 ref.)
Individual fatty acid effects on plasma lipids and lipoproteins: human studies. Kris–Etherton PM, et al. **Am J Clin Nutr** 1997 May;65(5 Suppl):1628S–1644S (50 ref.)
Effects of dietary fatty acids on lipoproteins and cardiovascular disease risk: summary. Schaefer EJ. **Am J Clin Nutr** 1997 May;65(5 Suppl):1655S–1656S (3 ref.)
Will correction of dyslipoproteinaemia reduce coronary heart disease risk in patients with non–insulin–dependent diabetes? Need for trial evidence. Pyörälä K, et al. **Ann Med** 1996 Aug;28(4):357–62 (35 ref.)
New aspects on the role of plasma lipases in lipoprotein

catabolism and atherosclerosis. Beisiegel U.
Atherosclerosis 1996 Jul;124(1):1–8 (111 ref.)

LDL receptor–independent and –dependent uptake of lipoproteins. van Berkel TJ, et al. **Atherosclerosis** 1995 Dec; 118 Suppl:S43–50 (59 ref.)

Butter, margarine and serum lipoproteins. Zock PL, et al. **Atherosclerosis** 1997 May;131(1):7–16 (72 ref.)

Trans fatty acids, lipoproteins, and coronary risk. Zock PL, et al. **Can J Physiol Pharmacol** 1997 Mar;75(3):211–6 (43 ref.)

Small genetic effects in complex diseases: a review of regulatory sequence variants in dyslipoproteinemia and atherosclerosis. Hegele RA. **Clin Biochem** 1997 Apr; 30(3):183–8 (56 ref.)

Pathophysiology and treatment of lipid perturbation after cardiac transplantation. Ballantyne CM, et al.
Curr Opin Cardiol 1997 Mar;12(2):153–60 (79 ref.)

Free fatty acids, insulin resistance and lipoprotein metabolism. Laws A. **Curr Opin Lipidol** 1996 Jun; 7(3):172–7 (98 ref.)

Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Mackness MI, et al.
Curr Opin Lipidol 1996 Apr;7(2):69–76 (59 ref.)

Trials of the effects of drugs and hormones on lipids and lipoproteins. Mann WA, et al. **Curr Opin Lipidol** 1995 Dec; 6(6):354–9 (52 ref.)

Serum lipoproteins in children and young adults: determinants and treatment strategies. Porkka KV, et al. **Curr Opin Lipidol** 1996 Aug;7(4):183–7 (44 ref.)

Plasma lipids and lipoprotein concentrations among American Indians: comparison with the US population. Robbins DC, et al. **Curr Opin Lipidol** 1996 Aug;7(4):188–95 (41 ref.)

'Normolipidemic' tendinous and tuberous xanthomatosis. Mancuso G, et al. **Dermatology** 1996;193(1):27–32 (25 ref.)

Physical activity and lipoprotein metabolism: epidemiological evidence and clinical trials. Berg A, et al.
Eur J Med Res 1997 Jun 16;2(6):259–64 (40 ref.)

Gene therapy for atherosclerosis. Rader DJ.
Int J Clin Lab Res 1997;27(1):35–43 (85 ref.)

Diet–gene interactions in human lipoprotein metabolism. Dreon DM, et al. **J Am Coll Nutr** 1997 Aug;16(4):313–24 (146 ref.)

The effect of dietary fat, antioxidants, and pro–oxidants on blood lipids, lipoproteins, and atherosclerosis. Kwiterovich PO Jr. **J Am Diet Assoc** 1997 Jul;97(7 Suppl):S31–41 (75 ref.)

Lipoprotein glomerulopathy: a new role for apolipoprotein E? [editorial; comment] Karet FE, et al.
J Am Soc Nephrol 1997 May;8(5):840–2 (21 ref.) Comment on: J Am Soc Nephrol 1997 May;8(5):820–3.

Significance of hypertriglyceridemia in the occurrence of ischemic heart disease. Matsuzawa Y.
J Atheroscler Thromb 1995;2 Suppl 1:S26–8 (0 ref.)

Dyslipidemia, morbidity, and mortality in non–insulin–dependent diabetes mellitus. Lipoproteins and coronary heart disease in non–insulin–dependent diabetes mellitus. Laakso M. **J Diabetes Complications** 1997 Mar–Apr;11(2):137–41 (31 ref.)

Modifications in plasma lipoprotein concentration and lipid composition regulate the biological activity of hydrophobic drugs. Wasan KM. **J Pharmacol Toxicol Methods** 1996 Sep; 36(1):1–11 (68 ref.)

Lipids and lipoproteins as coronary risk factors in non–insulin–dependent diabetes mellitus. Syvänne M, et al. **Lancet** 1997 Jul;350 Suppl 1:SI20–3 (34 ref.)

n–3 fatty acids and lipoproteins: comparison of results from human and animal studies. Harris WS. **Lipids** 1996 Mar; 31(3):243–52 (129 ref.)

Pathogenesis of atherosclerosis. Ylä–Herttuala S, et al.
Maturitas 1996 May;23 Suppl:S47–9 (13 ref.)

Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins. Alaupovic P.
Methods Enzymol 1996;263:32–60 (219 ref.)

Lipoproteins, lipid droplets, lysosomes, and adrenocortical steroid hormone synthesis: morphological studies. Tóth IE, et al. **Microsc Res Tech** 1997 Mar 15;36(6):480–92 (107 ref.)

Lifestyle, fibrinolysis and lipids. Brommer EJ, et al.
Pharm World Sci 1997 Apr;19(2):82–8 (65 ref.)

Effects of drugs on postprandial lipoprotein metabolism. Packard CJ. **Proc Nutr Soc** 1997 Jul;56(2):745–51 (19 ref.)

Metabolic aspects of polycystic ovary syndrome. Wild RA. **Semin Reprod Endocrinol** 1997 May;15(2):105–10 (26 ref.)

[Cardiovascular disease–related serum lipid parameters in a Hungarian subpopulation] Szépvölgyi J, et al. **Orv Hetil** 1997 Aug 10;138(32):2005–8 (33 ref.) (Eng. Abstr.) **(Hun)**

[Uremic dyslipoproteinemia] Kimura H, et al.
Ryoikibetsu Shokogun Shirizu 1997;(16 Pt 1):76–9 (18 ref.) **(Jpn)**

[Blood flow lipid transport from viewpoint of protein biochemistry] Titov VN. **Vestn Ross Akad Med Nauk** 1996; (9):3–7 (36 ref.) (Eng. Abstr.) **(Rus)**

CHEMISTRY

Merck Frosst award lecture 1995. La conference Merck Frosst 1995. Structural studies of lipoproteins and their apolipoprotein components. Ryan RO.
Biochem Cell Biol 1996;74(2):155–64 (48 ref.)

Biophysical studies of lipopeptide–membrane interactions. Epand RM. **Biopolymers** 1997;43(1):15–24 (54 ref.)

Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins. Alaupovic P.
Methods Enzymol 1996;263:32–60 (219 ref.)

DEFICIENCY

Tissue factor pathway inhibitor: clinical deficiency states. Sandset PM, et al. **Thromb Haemost** 1997 Jul;78(1):467–70 (45 ref.)

DRUG EFFECTS

The pharmacology and effectiveness of specific lipid–active drugs: estrogen/sex steroids. LaRosa JC.
Coron Artery Dis 1996 Sep;7(9):683–8 (37 ref.)

Hormone replacement therapy and coronary artery disease. Morris D. **Curr Opin Obstet Gynecol** 1996 Jun;8(3):184–7 (26 ref.)

Effects of sex steroid hormones on lipoproteins, clotting, and the arterial wall. Knopp RH, et al.
Semin Reprod Endocrinol 1996 Feb;14(1):15–27 (112 ref.)

[Desogestrel contraceptives: the perfect pill for lipids?] Laurendeau L. **Can Fam Physician** 1996 Jan;42:62–71 (32 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Candidate genes, small effects, and the prediction of atherosclerosis. Hegele RA. **Crit Rev Clin Lab Sci** 1997 Aug;34(4):343–67 (91 ref.)

Adenovirus–mediated gene transfer: strategies and applications in lipoprotein research. Gerard RD, et al.
Curr Opin Lipidol 1996 Apr;7(2):105–11 (37 ref.)

Regulatory mutations in human lipoprotein disorders and atherosclerosis. Kontula K, et al. **Curr Opin Lipidol** 1996 Apr;7(2):64–8 (28 ref.)

[A mammalian telomerase component gene TLP1] Ishikawa F, et al. **Tanpakushitsu Kakusan Koso** 1997 Jul; 42(9):1407–19 (21 ref.) **(Jpn)**

METABOLISM

Modified lipoproteins, cytokines and macrovascular disease in non–insulin–dependent diabetes mellitus. Lopes–Virella MF, et al. **Ann Med** 1996 Aug;28(4):347–54 (78 ref.)

New insights into lipid metabolism in non–insulin–dependent diabetes mellitus. Taskinen MR, et al. **Ann Med** 1996 Aug; 28(4):335–40 (35 ref.)

Near–infrared imaging and spectroscopy in stroke research: lipoprotein distribution and disease. Dempsey RJ, et al. **Ann N Y Acad Sci** 1997 May 30;820:149–69 (37 ref.)

Role of lipid synthesis, chaperone proteins and proteasomes in the assembly and secretion of apoprotein B–containing lipoproteins from cultured liver cells. Ginsberg HN.
Clin Exp Pharmacol Physiol 1997 May;24(5):A29–32 (61 ref.)

The genetic basis of primary disorders of intestinal fat transport. Levy E. **Clin Invest Med** 1996 Oct;19(5):317–24 (75 ref.)

Lipid abnormalities in progressive renal insufficiency. Attman PO, et al. **Contrib Nephrol** 1997;120:1–10 (35 ref.)

Candidate genes, small effects, and the prediction of atherosclerosis. Hegele RA. **Crit Rev Clin Lab Sci** 1997 Aug;34(4):343–67 (91 ref.)

Scavenger receptors in atherosclerosis. Freeman MW.
Curr Opin Hematol 1997 Jan;4(1):41–7 (52 ref.)

An emerging understanding of the interactions of plasma lipoproteins with the arterial wall that leads to the development of atherosclerosis [editorial] Beisiegel U, et al. **Curr Opin Lipidol** 1996 Oct;7(5):265–8 (24 ref.)

Lipoprotein alterations and atherosclerosis in the elderly. Corti MC, et al. **Curr Opin Lipidol** 1997 Aug;8(4):236–41 (47 ref.)

New insights into the regulation of lipoprotein metabolism: studies in procaryocytes, eukaryocytes, rodents, pigs, and people [editorial] Ginsberg HN, et al.
Curr Opin Lipidol 1997 Jun;8(3):127–30 (30 ref.)

Atherosclerosis: cell biology and lipoproteins [editorial] Groves PH. **Curr Opin Lipidol** 1996 Jun;7(3):U99–104 (11 ref.)

Design and analysis of lipid tracer kinetic studies. Hugh P, et al. **Curr Opin Lipidol** 1996 Jun;7(3):143–8 (41 ref.)

Lipoprotein glycation and its metabolic consequences. Lyons TJ, et al. **Curr Opin Lipidol** 1997 Jun;8(3):174–80 (69 ref.)

The vascular endothelial barrier––selective retention of lipoproteins. Nordestgaard BG. **Curr Opin Lipidol** 1996 Oct;7(5):269–73 (73 ref.)

Smoking, alcohol and lipoprotein metabolism. Porkka KV, et al. **Curr Opin Lipidol** 1996 Jun;7(3):162–6 (47 ref.)

Atherosclerosis: cell biology and lipoproteins [editorial] Tabas I. **Curr Opin Lipidol** 1997 Apr;8(2):U25–7 (16 ref.)

The tissue–specific expression of lipoprotein lipase: implications for energy and lipoprotein metabolism. Zechner R. **Curr Opin Lipidol** 1997 Apr;8(2):77–88 (174 ref.)

Atherogenic lipoproteins and human disease: extending concepts beyond the heart to the kidney. Kamanna VS, et al. **Curr Opin Nephrol Hypertens** 1997 May;6(3):205–11 (57 ref.)

Modification of lipoproteins in diabetes. Lopes–Virella MF, et al. **Diabetes Metab Rev** 1996 Apr;12(1):69–90 (180 ref.)

Triglyceride–rich lipoproteins in non–insulin–dependent diabetes mellitus: post–prandial metabolism and relation to premature atherosclerosis. De Man FH, et al.
Eur J Clin Invest 1996 Feb;26(2):89–108 (264 ref.)

Apolipoprotein function in health and disease: insights from natural mutations. Franceschini G. **Eur J Clin Invest** 1996 Sep;26(9):733–46 (109 ref.)

Studies of apolipoprotein B–100 metabolism using radiotracers and stable isotopes. Demant T, et al.
Eur J Pediatr 1997 Aug;156 Suppl 1:S75–7 (9 ref.)

Lipid and lipoprotein modification by advanced glycosylation end–products: role in atherosclerosis. Bucala R. **Exp Physiol** 1997 Mar;82(2):327–37 (38 ref.)

The roles of free radicals, peroxides and oxidized lipoproteins in second messenger system dysfunction. Czubryt MP, et al. **EXS** 1996;76:57–69 (37 ref.)

Tissue factor pathway inhibitor: regulation of its inhibitory activity by phospholipid surfaces. Lindhout T, et al.
Haemostasis 1996 Oct;26 Suppl 4:89–97 (23 ref.)

Postprandial lipoprotein metabolism in diabetes mellitus and obesity. Lewis GF. **J Atheroscler Thromb** 1995;2 Suppl 1:S34–5 (4 ref.)

Lipoprotein trafficking in vascular cells. Molecular Trojan horses and cellular saboteurs. Hajjar DP, et al.
J Biol Chem 1997 Sep 12;272(37):22975–8 (64 ref.)

Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. Goldberg IJ. **J Lipid Res** 1996 Apr;37(4):693–707 (163 ref.)

An overview of recent developments in avian lipoprotein metabolism. Elkin RG. **J Nutr** 1997 May;127(5 Suppl):793S–794S (9 ref.)

Lipoprotein metabolism and fattening in poultry. Hermier D. **J Nutr** 1997 May;127(5 Suppl):805S–808S (33 ref.)

Modulation of glomerular sclerosis and interstitial fibrosis by native and modified lipoproteins. Gröne HJ, et al.
Kidney Int Suppl 1996 May;54:S18–22 (28 ref.)

Abnormalities of lipoprotein metabolism in CAPD patients. Wheeler DC. **Kidney Int Suppl** 1996 Nov;56:S41–6 (54 ref.)

Site–specific modification of apolipoprotein B by advanced glycosylation end–products: implications for lipoprotein clearance and atherogenesis. Bucala R.
Nephrol Dial Transplant 1996;11 Suppl 5:17–9 (20 ref.)

Lipoprotein lipase (EC 3.1.1.34) targeting of lipoproteins to receptors. Beisiegel U, et al. **Proc Nutr Soc** 1997 Jul; 56(2):731–7 (37 ref.)

Lipoprotein lipase: regulation and role in lipoprotein metabolism. Olivecrona T, et al. **Proc Nutr Soc** 1997 Jul; 56(2):723–9 (14 ref.)

Lipoprotein metabolism in experimental nephrosis. Marsh JB. **Proc Soc Exp Biol Med** 1996 Nov;213(2):178–86 (78 ref.)

Hepatic lipoprotein metabolism: recent molecular insights. Cooper AD. **Prog Liver Dis** 1995;13:173–200 (173 ref.)

Lipoproteins and cellular cholesterol homeostasis. Johnson WJ, et al. **Subcell Biochem** 1997;28:235–76 (174 ref.)

[Modifications of lipids and lipoproteins due to end products of advanced glycosylation: role in atherosclerosis] Bucala R. **Journ Annu Diabetol Hotel Dieu** 1996;:133–44 (38 ref.) **(Fre)**

[Lipoprotein metabolism] Corvilain B. **Rev Med Brux** 1997 Feb;18(1):3–9 (11 ref.) (Eng. Abstr.) **(Fre)**

[Turnover of serum lipoprotein and its evaluation] Takeuchi N. **Nippon Rinsho** 1997 Mar;55 Suppl 1:262–8 (44 ref.) **(Jpn)**

[Biochemistry of risk factors for cardiovascular diseases in laboratory medicine] Okabe H. **Rinsho Byori** 1996 Nov; 44(11):1050–7 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Disorder of lipid metabolism (hyperlipidemia, disorder of lipoprotein, etc)] Kobori S, et al.
Ryoikibetsu Shokogun Shirizu 1996;(15):43–7 (8 ref.) **(Jpn)**

[Lipoprotein glomerulopathy] Watanabe T, et al.
Ryoikibetsu Shokogun Shirizu 1997;(16 Pt 1):219–22 (19 ref.) **(Jpn)**

[Transport of fatty acids in the bloodflow as the major function of lipoproteins] Titov VN. **Vopr Med Khim** 1997 Jul–Aug;43(4):195–207 (42 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Pharmacological profiling of recombinant tissue factor pathway inhibitor. Jeske W, et al.
Semin Thromb Hemost 1996;22(2):213–9 (27 ref.)

PHYSIOLOGY

Atherosclerosis and the mouse: a decade of experience. Plump A. **Ann Med** 1997 Jun;29(3):193–8 (48 ref.)

Atherosclerosis progression/regression: lipoprotein and vessel wall determinants. Kramsch DM. **Atherosclerosis** 1995 Dec;118 Suppl:S29–36 (53 ref.)

The influence of oxidized lipoproteins, oxidation products and antioxidants on the release of nitric oxide from the endothelium and the response of platelets to nitric oxide. Bruckdorfer KR, et al. **Biofactors** 1997;6(2):191–9 (49 ref.)

Role of lipoproteins in platelet activation. Zhao B.
Blood Coagul Fibrinolysis 1996 Mar;7(2):270–3 (12 ref.)

Tissue factor pathway inhibitor: from unknown coagulation inhibitor to major antithrombotic principle [see comments] Lindahl AK. **Cardiovasc Res** 1997 Feb;33(2):286–91 (44 ref.) Comment in: Cardiovasc Res 1997 Feb;33(2):284–5.

Tissue factor pathway inhibitor (TFPI)––an update. Sandset PM. **Haemostasis** 1996 Oct;26 Suppl 4:154–65 (68 ref.)

TEST–yolk media and sperm quality. Jeyendran RS, et al.
Hum Reprod Update 1995 Jan;1(1):73–9 (60 ref.)

Impact of nitric oxide on renal hemodynamics and glomerular function: modulation by atherogenic lipoproteins? Galle J, et al. **Kidney Blood Press Res** 1996;19(1):2–15 (180 ref.)

Lipoproteins in heart disease. Basile-Borgia A, et al. **Perfusion** 1996 Jul;11(4):338-45 (24 ref.)

SECRETION

Regulation of hepatic apolipoprotein-B-containing lipoprotein secretion. Pease RJ, et al. **Curr Opin Lipidol** 1996 Jun;7(3):132-8 (51 ref.)

THERAPEUTIC USE

Tissue factor pathway inhibitor: potential therapeutic applications. Bajaj MS, et al. **Thromb Haemost** 1997 Jul; 78(1):471-7 (69 ref.)

LIPOPROTEINS, HDL

Molecular disorders of cholesteryl ester transfer protein. Yamashita S, et al. **J Atheroscler Thromb** 1996;3(1):1-11 (73 ref.)

BLOOD

Lipid metabolism [editorial] Goldberg I. **Curr Opin Lipidol** 1996 Dec;7(6):U184-92 (9 ref.)

Dietary effects on plasma LDL and HDL. Mann JI. **Curr Opin Lipidol** 1997 Feb;8(1):35-8 (17 ref.)

CHEMISTRY

Structure of apo A-I high-density lipoproteins: a review. Titov VN. **Biochemistry (Mosc)** 1997 Jan;62(1):1-14 (73 ref.)

HDL heterogeneity and atherosclerosis. Tailleux A, et al. **Crit Rev Clin Lab Sci** 1996 Jun;33(3):163-201 (168 ref.)

DEFICIENCY

"Isolated" low high-density lipoprotein cholesterol. Wilt VM, et al. **Ann Pharmacother** 1997 Jan;31(1):89-97 (65 ref.)

Genetic determinants of high density lipoprotein levels. Funke H. **Curr Opin Lipidol** 1997 Jun;8(3):189-96 (62 ref.)

GENETICS

Genetic determinants of high density lipoprotein levels. Funke H. **Curr Opin Lipidol** 1997 Jun;8(3):189-96 (62 ref.)

METABOLISM

Pharmacology of apolipoprotein A-I. Andersson LO. **Curr Opin Lipidol** 1997 Aug;8(4):225-8 (18 ref.)

High density lipoprotein and lipoprotein oxidation. Banka CL. **Curr Opin Lipidol** 1996 Jun;7(3):139-42 (43 ref.)

High density lipoprotein and coronary heart disease: insights from mutations leading to low high density lipoprotein. Calabresi L, et al. **Curr Opin Lipidol** 1997 Aug;8(4):219-24 (46 ref.)

Lipid metabolism [editorial] Dominiczak MH. **Curr Opin Lipidol** 1996 Jun;7(3):U85-91 (10 ref.)

Unravelling high density lipoprotein-apolipoprotein metabolism in human mutants and animal models. Rader DJ, et al. **Curr Opin Lipidol** 1996 Jun;7(3):117-23 (74 ref.)

Scavenger receptor BI--a cell surface receptor for high density lipoprotein. Rigotti A, et al. **Curr Opin Lipidol** 1997 Jun;8(3):181-8 (113 ref.)

Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. Vega GL, et al. **Curr Opin Lipidol** 1996 Aug;7(4):209-16 (25 ref.)

PHYSIOLOGY

"Isolated" low high-density lipoprotein cholesterol. Wilt VM, et al. **Ann Pharmacother** 1997 Jan;31(1):89-97 (65 ref.)

Reverse cholesterol transport: its contribution to cholesterol catabolism in normal and disease states. Loh KC, et al. **Can J Cardiol** 1996 Oct;12(10):944-50 (58 ref.)

HDL heterogeneity and atherosclerosis. Tailleux A, et al. **Crit Rev Clin Lab Sci** 1996 Jun;33(3):163-201 (168 ref.)

Multi-functional aspects of high density lipoprotein as an anti-atherogenic lipoprotein in vivo: evidence from in vitro experiments using macrophages. Miyazaki A, et al. **J Atheroscler Thromb** 1995;2(1):30-6 (34 ref.)

[High density lipoproteins: physiological importance] Kurashvili LV. **Patol Fiziol Eksp Ter** 1997 Jul-Sep;(3):40-3 (52 ref.) **(Rus)**

LIPOPROTEINS, HDL CHOLESTEROL

see related
HYPERCHOLESTEROLEMIA
HYPERCHOLESTEROLEMIA, FAMILIAL

Genetics and molecular biology [editorial] Ochoa A, et al. **Curr Opin Lipidol** 1997 Apr;8(2):U18-9 (10 ref.)

BLOOD

"Isolated" low high-density lipoprotein cholesterol. Wilt VM, et al. **Ann Pharmacother** 1997 Jan;31(1):89-97 (65 ref.)

Dietary trans-fatty acids and serum lipoproteins in humans. Zock PL, et al. **Curr Opin Lipidol** 1996 Feb;7(1):34-7 (22 ref.)

Common genetic determinants of dyslipidemia: the hypertriglyceridemia/low-high-density lipoprotein syndrome. Galton DJ. **J Cardiovasc Pharmacol** 1995;25 Suppl 4:S35-40 (33 ref.)

High-fat, high-cholesterol diet raises plasma HDL cholesterol: studies on the mechanism of this effect. Wolf G. **Nutr Rev** 1996 Jan;54(1 Pt 1):34-5 (8 ref.)

[High triglyceride, low HDL-cholesterol and risk of coronary heart disease] Jeppesen J, et al. **Ugeskr Laeger** 1996 Nov 25;158(48):6896-901 (40 ref.) (Eng. Abstr.) **(Dan)**

METABOLISM

Theoretical considerations of what regulates low-density-lipoprotein and high-density-lipoprotein cholesterol. Dietschy JM. **Am J Clin Nutr** 1997 May;65(5 Suppl):1581S-1589S (62 ref.)

Dietary fatty acids and lipoprotein metabolism. Lichtenstein AH. **Curr Opin Lipidol** 1996 Jun;7(3):155-61 (37 ref.)

LIPOPROTEINS, LDL

see related
RECEPTORS, LDL

Molecular disorders of cholesteryl ester transfer protein. Yamashita S, et al. **J Atheroscler Thromb** 1996;3(1):1-11 (73 ref.)

BLOOD

Relationships among oxidation of low-density lipoprotein, antioxidant protection, and atherosclerosis. Esterbauer H, et al. **Adv Pharmacol** 1997;38:425-56 (150 ref.)

The atherogenic role of triglycerides and small, dense low density lipoproteins: impact of ciprofibrate therapy. Chapman MJ, et al. **Atherosclerosis** 1996 Jul;124 Suppl:S21-8 (33 ref.)

Does an acidic pH explain why low density lipoprotein is oxidised in atherosclerotic lesions? Leake DS. **Atherosclerosis** 1997 Mar 21;129(2):149-57 (100 ref.)

Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. Steinberg D. **Circulation** 1997 Feb 18;95(4):1062-71 (96 ref.)

Angiographic trials of lipid-lowering therapy: an update. Mancini GB. **Curr Opin Lipidol** 1995 Dec;6(6):379-85 (13 ref.)

Dietary effects on plasma LDL and HDL. Mann JI. **Curr Opin Lipidol** 1997 Feb;8(1):35-8 (17 ref.)

What can we learn about dense low density lipoprotein and lipoprotein particles from clinical trials? Superko HR. **Curr Opin Lipidol** 1996 Dec;7(6):363-8 (42 ref.)

Atherosclerosis: cell biology and lipoproteins [editorial] Williams KJ. **Curr Opin Lipidol** 1996 Dec;7(6):U202-8 (26 ref.)

Low-density lipoprotein subclasses: mechanisms of formation and modulation. Griffin BA. **Proc Nutr Soc** 1997 Jul; 56(2):693-702 (54 ref.)

Genetic, metabolic, and dietary influences on the atherogenic lipoprotein phenotype. Krauss RM. **World Rev Nutr Diet** 1997;80:22-43 (110 ref.)

CHEMISTRY

Practical approaches to low density lipoprotein oxidation: whys, wherefores and pitfalls. Rice-Evans C, et al. **Free Radic Res** 1996 Oct;25(4):285-311 (89 ref.)

Using peroxynitrite as oxidant with low-density lipoprotein. Patel RP, et al. **Methods Enzymol** 1996;269:375-84 (32 ref.)

[Charge heterogeneity of low density lipoproteins] Myara I, et al. **Ann Biol Clin (Paris)** 1996;54(6):229-34 (89 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

Low-density lipoprotein subclasses: mechanisms of formation and modulation. Griffin BA. **Proc Nutr Soc** 1997 Jul; 56(2):693-702 (54 ref.)

DRUG EFFECTS

Dynamics of oxidation of LDL and its inhibition by antioxidants. Niki E, et al. **Biofactors** 1997;6(2):201-8 (84 ref.)

GENETICS

Genetic factors that contribute to interindividual variations in plasma low density lipoprotein-cholesterol levels. Cohen J, et al. **Ciba Found Symp** 1996;197:194-206; discussion 206-10 (40 ref.)

Genetic, metabolic, and dietary influences on the atherogenic lipoprotein phenotype. Krauss RM. **World Rev Nutr Diet** 1997;80:22-43 (110 ref.)

IMMUNOLOGY

Endogenous and exogenous antioxidants and the generation of antigenic epitopes in oxidatively-modified LDL. Bellomo G, et al. **Biofactors** 1997;6(2):91-8 (31 ref.)

ISOLATION & PURIFICATION

Low density lipoprotein apheresis: a selective plasma separation method [editorial] Bambauer R. **Artif Organs** 1996 Apr;20(4):284-5 (6 ref.)

Heparin-induced extracorporeal low-density lipoprotein precipitation and low-density lipoprotein chemoadsorption onto dextran sulfate: a comparison. Bosch Y. **Artif Organs** 1996 Apr;20(4):328-31 (20 ref.)

Current status of low density lipoprotein-apheresis for the therapy of severe hyperlipidemia. Gordon BR, et al. **Curr Opin Lipidol** 1996 Dec;7(6):381-4 (31 ref.)

Low-density lipoprotein apheresis using the Liposorber dextran sulfate cellulose system for patients with hypercholesterolemia refractory to medical therapy. Gordon BR, et al. **J Clin Apheresis** 1996;11(3):128-31 (23 ref.)

Treatment of hypercholesterolemia with heparin-induced extracorporeal low-density lipoprotein precipitation (HELP). Lees RS, et al. **J Clin Apheresis** 1996;11(3):132-7 (37 ref.)

METABOLISM

Antioxidant effect of flavonoids. Catapano AL. **Angiology** 1997 Jan;48(1):39-44 (42 ref.)

The role of oxidized LDL in atherogenesis: immunological response and anti-phospholipid antibodies. Witztum JL, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:88-96; discussion 96-9 (27 ref.)

Oxidized low density lipoproteins in atherogenesis: role of dietary modification. Reaven PD, et al. **Annu Rev Nutr** 1996;16:51-71 (94 ref.)

Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis. Hurt-Camejo E, et al. **Arterioscler Thromb Vasc Biol** 1997 Jun;17(6):1011-7 (101 ref.)

Transfer of low density lipoprotein into the arterial wall and risk of atherosclerosis. Nielsen LB. **Atherosclerosis** 1996 Jun;123(1-2):1-15 (102 ref.)

A critical look at the evidence for the oxidation of LDL in atherogenesis. Steinberg D. **Atherosclerosis** 1997 Jun;131 Suppl:S5-7 (7 ref.)

Immunological response to oxidized LDL. Witztum JL. **Atherosclerosis** 1997 Jun;131 Suppl:S9-11 (11 ref.)

Endogenous and exogenous antioxidants and the generation of antigenic epitopes in oxidatively-modified LDL. Bellomo G, et al. **Biofactors** 1997;6(2):91-8 (31 ref.)

Pathways for oxidation of low density lipoprotein by myeloperoxidase: tyrosyl radical, reactive aldehydes, hypochlorous acid and molecular chlorine. Heinecke JW. **Biofactors** 1997;6(2):145-55 (44 ref.)

Dynamics of oxidation of LDL and its inhibition by antioxidants. Niki E, et al. **Biofactors** 1997;6(2):201-8 (84 ref.)

Is atherosclerosis exclusively a postprandial phenomenon? Mamo JC, et al. **Clin Exp Pharmacol Physiol** 1997 Mar-Apr;24(3-4):288-93 (48 ref.)

Potential role of lipids in the progression of diabetic nephropathy. Krämer-Guth A, et al. **Clin Nephrol** 1996 Oct;46(4):262-5 (27 ref.)

The role of oxidatively modified lipoproteins in lipid nephropathy. Gröne HJ, et al. **Contrib Nephrol** 1997; 120:160-75 (96 ref.)

Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes. Austin MA, et al. **Curr Opin Lipidol** 1996 Jun;7(3):167-71 (28 ref.)

High density lipoprotein and lipoprotein oxidation. Banka CL. **Curr Opin Lipidol** 1996 Jun;7(3):139-42 (43 ref.)

Lipid metabolism [editorial] Dominiczak MH. **Curr Opin Lipidol** 1996 Jun;7(3):U85-91 (10 ref.)

Oxidized lipoproteins and nitric oxide. Jessup W. **Curr Opin Lipidol** 1996 Oct;7(5):274-80 (73 ref.)

Dietary polyunsaturates and peroxidation of low density lipoprotein. Nenseter MS, et al. **Curr Opin Lipidol** 1996 Feb;7(1):8-13 (34 ref.)

Interaction of oxidized low density lipoprotein with macrophages in atherosclerosis, and the antiatherogenicity of antioxidants. Aviram M. **Eur J Clin Chem Clin Biochem** 1996 Aug;34(8):599-608 (95 ref.)

Glycated low-density lipoprotein and atherogenesis: the missing link between diabetes mellitus and hypercholesterolaemia? [editorial] Graier WF, et al. **Eur J Clin Invest** 1997 Jun;27(6):457-9 (32 ref.)

Oxidised low density lipoprotein, antioxidants and coronary atherosclerosis [editorial] Gambhir DS, et al. **Indian Heart J** 1997 Jan-Feb;49(1):19-22 (23 ref.)

Oxidized low-density lipoprotein and atherosclerosis. Devaraj S, et al. **Int J Clin Lab Res** 1996;26(3):178-84 (86 ref.)

Endocytic uptake of lysophosphatidylcholine mediated by macrophage scavenger receptor plays a major role in oxidized low density lipoprotein-induced macrophage growth. Sakai M, et al. **J Atheroscler Thromb** 1996; 2(2):81-6 (19 ref.)

Basic research in antioxidant inhibition of steps in atherogenesis. Gokce N, et al. **J Cardiovasc Risk** 1996 Aug; 3(4):352-7 (65 ref.)

Oxidative hypothesis of atherogenesis. Klatt P, et al. **J Cardiovasc Risk** 1996 Aug;3(4):346-51 (50 ref.)

Antioxidants and atherosclerotic heart disease. Diaz MN, et al. **N Engl J Med** 1997 Aug 7;337(6):408-16 (76 ref.)

The effects of oral vitamin supplementation on cardiovascular risk factors. Woodside JV, et al. **Proc Nutr Soc** 1997 Mar; 56(1B):479-88 (77 ref.)

Vitamins C and E and LDL oxidation. Frei B, et al. **Vitam Horm** 1996;52:1-34 (122 ref.)

[The role of the oxidative modification of LDL in the pathogenesis of atherosclerosis] Gudev A. **Mol Med (Sofia)** 1996;1(1):31-8 (44 ref.) **(Bul)**

[Role of oxidation of lipoproteins in the pathogenesis of atherosclerosis] Picard S. **Pathol Biol (Paris)** 1996 Jan;

LIPOPROTEINS, LDL

44(1):46–50 (35 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

The oxidation hypothesis of atherosclerosis: an update. Westhuyzen J. **Ann Clin Lab Sci** 1997 Jan–Feb;27(1):1–10 (90 ref.)

Effect of low-density lipoproteins on mesangial cell expression of monocyte chemoattractant peptides. Kamanna VS, et al. **Contrib Nephrol** 1997;120:176–90 (65 ref.)

PHYSIOLOGY

Modulation of vascular tone by low density lipoproteins: effects on L-arginine transport and nitric oxide synthesis. Jay MT, et al. **Exp Physiol** 1997 Mar;82(2):349–60 (60 ref.)

Practical approaches to low density lipoprotein oxidation: whys, wherefores and pitfalls. Rice-Evans C, et al. **Free Radic Res** 1996 Oct;25(4):285–311 (89 ref.)

The role of oxidized LDL in the atherogenic process. Witztum JL. **J Atheroscler Thromb** 1994;1(2):71–5 (32 ref.)

Low density lipoprotein oxidation and its pathobiological significance. Steinberg D. **J Biol Chem** 1997 Aug 22; 272(34):20963–6 (74 ref.)

Atherosclerosis as a microvascular disease: impaired angiogenesis mediated by suppressed basic fibroblast growth factor expression. Chen CH, et al. **Proc Assoc Am Physicians** 1997 Jul;109(4):351–61 (59 ref.)

Oxidized lipids in atherogenesis: formation, destruction and action. Berliner J, et al. **Thromb Haemost** 1997 Jul; 78(1):195–9 (34 ref.)

LIPOPROTEINS, LDL CHOLESTEROL

see related
HYPERCHOLESTEROLEMIA
HYPERCHOLESTEROLEMIA, FAMILIAL

BLOOD

Dietary fat saturation effects on low-density-lipoprotein concentrations and metabolism in various animal models. Nicolosi RJ. **Am J Clin Nutr** 1997 May;65(5 Suppl):1617S–1627S (32 ref.)

Cholesterol and coronary heart disease. The 21st century. Grundy SM. **Arch Intern Med** 1997 Jun 9;157(11):1177–84 (70 ref.)

What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease? Thompson GR. **Atherosclerosis** 1997 May;131(1):1–5 (26 ref.)

Beyond LDL cholesterol reduction [editorial] Superko HR. **Circulation** 1996 Nov 15;94(10):2351–4 (29 ref.)

Response of low density lipoprotein cholesterol levels to dietary change: contributions of different mechanisms. Fielding CJ. **Curr Opin Lipidol** 1997 Feb;8(1):39–42 (23 ref.)

Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points. Kinlay S, et al. **Curr Opin Lipidol** 1996 Dec;7(6):389–97 (104 ref.)

Dietary trans-fatty acids and serum lipoproteins in humans. Zock PL, et al. **Curr Opin Lipidol** 1996 Feb;7(1):34–7 (22 ref.)

Common genetic determinants of dyslipidemia: the hypertriglyceridemia/low-high-density lipoprotein syndrome. Galton DJ. **J Cardiovasc Pharmacol** 1995;25 Suppl 4:S35–40 (33 ref.)

LDL-cholesterol lowering and atherosclerosis--clinical benefit and possible mechanisms: an update [see comments] Kroon AA, et al. **Neth J Med** 1997 Jul;51(1):16–27 (140 ref.) Comment in: Neth J Med 1997 Jul;51(1):v–vii.

[Heparin-induced extracorporeal LDL precipitation (HELP) in therapy refractory hypercholesterolemia and coronary heart disease: effect on clinical and morphological regression of coronary sclerosis] Schuff-Werner P. **Z Kardiol** 1997;86 Suppl 1:57–64 (30 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Genetic epidemiology of dyslipidaemia and atherosclerosis. Austin MA. **Ann Med** 1996 Oct;28(5):459–63 (20 ref.)

ISOLATION & PURIFICATION

Low-density lipoprotein removal methods by membranes and future perspectives. Matsuda Y, et al. **Artif Organs** 1996 Apr;20(4):346–54 (37 ref.)

Extracorporeal removal of lipids by dextran sulfate cellulose adsorption. Olbricht CJ. **Artif Organs** 1996 Apr;20(4):332–5 (31 ref.)

METABOLISM

Theoretical considerations of what regulates low-density-lipoprotein and high-density-lipoprotein cholesterol. Dietschy JM. **Am J Clin Nutr** 1997 May;65(5 Suppl):1581S–1589S (62 ref.)

Dietary fat saturation effects on low-density-lipoprotein concentrations and metabolism in various animal models. Nicolosi RJ. **Am J Clin Nutr** 1997 May;65(5 Suppl):1617S–1627S (32 ref.)

Dietary fatty acids and lipoprotein metabolism. Lichtenstein AH. **Curr Opin Lipidol** 1996 Jun;7(3):155–61 (37 ref.)

LIPOPROTEINS, VLDL

BIOSYNTHESIS

Fatty acid regulation of very low density lipoprotein production. Lewis GF. **Curr Opin Lipidol** 1997 Jun; 8(3):146–53 (59 ref.)

Regulation of VLDL synthesis and secretion in the liver. Gruffat D, et al. **Reprod Nutr Dev** 1996;36(4):375–89 (89 ref.)

GENETICS

VLDL receptor in health and disease: interview with a receptor in avian oocytes and mammalian muscle and fat cells. Bujo H, et al. **J Atheroscler Thromb** 1996;2(2):71–5 (33 ref.)

METABOLISM

[Triglyceride turnover and it's evaluation] Oikawa S, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:278–81 (11 ref.) **(Jpn)**

PHARMACOLOGY

Remnant-like particles stimulate platelet aggregation in whole blood. Nakano T, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:480–7 (19 ref.)

SECRETION

Regulation of VLDL synthesis and secretion in the liver. Gruffat D, et al. **Reprod Nutr Dev** 1996;36(4):375–89 (89 ref.)

[Immunosuppressive substances induced by liver grafting] Kobayashi E. **Tanpakushitsu Kakusan Koso** 1997 Jul; 42(9):1420–6 (40 ref.) **(Jpn)**

LIPOSARCOMA

[Lipoma and liposarcoma of the heart] Mikouchi H. **Ryoikibetsu Shokogun Shirizu** 1996;(14):246–9 (23 ref.) **(Jpn)**

DIAGNOSIS

Liposarcoma of the retropharyngeal space: review of the literature. Prince ME, et al. **J Otolaryngol** 1997 Apr; 26(2):139–42 (20 ref.)

GENETICS

Translocations in solid tumours. Cooper CS. **Curr Opin Genet Dev** 1996 Feb;6(1):71–5 (27 ref.)

The cytogenetics of lipomatous tumours. Rubin BP, et al. **Histopathology** 1997 Jun;30(6):507–11 (53 ref.)

PATHOLOGY

Mesenteric pleomorphic liposarcoma in an adolescent. Pawel BR, et al. **Arch Pathol Lab Med** 1997 Feb;121(2):173–6 (15 ref.)

Giant pedunculated liposarcomas of the esophagus: literature review and case report. Boggi U, et al. **Hepatogastroenterology** 1997 Mar-Apr;44(14):398–407 (42 ref.)

Subdural sarcoma associated with chronic subdural hematoma. Report of two cases and review of the literature. Cinalli G, et al. **J Neurosurg** 1997 Mar;86(3):553–7 (12 ref.)

Symmetrical multifocal liposarcoma. Kulhavy M, et al. **S Afr J Surg** 1997 May;35(2):68–9 (14 ref.)

[Liposarcoma of the oral cavity: description of a case and review of the literature] Gialdini F, et al. **Acta Otorhinolaryngol Ital** 1995 Apr;15(2):112–6 (37 ref.) (Eng. Abstr.) **(Ita)**

[Liposarcoma: controversies and conceptual problems (editorial)] Dei Tos AP. **Pathologica** 1996 Dec;88(6):467–71 (31 ref.) **(Ita)**

[Liposarcoma, lipoma and lipomatosis of the kidney] Fujioka T, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):488–90 (15 ref.) **(Jpn)**

SURGERY

Primary liposarcoma of the stomach resected endoscopically. Yamamoto K, et al. **Endoscopy** 1995 Nov;27(9):711 (5 ref.)

[A case of primary anterior mediastinal liposarcoma with a heterotopic mass in the pericardium of the same histology] Kiyama H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Dec;44(12):2191–5 (14 ref.) (Eng. Abstr.) **(Jpn)**

LIPOSARCOMA, DEDIFFERENTIATED see **LIPOSARCOMA**

LIPOSARCOMA, MYXOID

GENETICS

TLS-CHOP and the role of RNA-binding proteins in oncogenic transformation. Ron D. **Curr Top Microbiol Immunol** 1997;220:131–42 (53 ref.)

PATHOLOGY

A case of liposarcoma originating in the chest wall. Urabe M, et al. **Nippon Geka Hokan** 1995 Nov 1;64(6):131–8 (20 ref.)

Myxoid liposarcoma of the scalp: case report and literature review. Herman O, et al. **Plast Reconstr Surg** 1997 Jul; 100(1):84–5 (9 ref.)

Combined myxoid liposarcoma and angiolipoma of the spermatic cord. Ikinger U, et al. **Urology** 1997 Apr; 49(4):635–7 (15 ref.)

LIPOSARCOMA, PLEOMORPHIC see **LIPOSARCOMA**

LIPOSOMES

Electron crystallography of macromolecular periodic arrays on phospholipid monolayers. Chiu W, et al. **Adv Biophys** 1997;34:161–72 (59 ref.)

Liposomes as a vehicle for drug delivery. Taylor KM, et al. **Br J Hosp Med** 1994 Jan 19–Feb 1;51(1–2):55–60 (24 ref.)

Lipidic vector systems for gene transfer. Lee RJ, et al. **Crit Rev Ther Drug Carrier Syst** 1997;14(2):173–206 (67 ref.)

The challenges of recombinant adeno-associated virus manufacturing: alternative use of adeno-associated virus plasmid/liposome complexes for gene therapy applications. Lebkowski JS, et al. **Curr Top Microbiol Immunol** 1996; 218:51–9 (11 ref.)

Cationic liposome-mediated gene transfer. Gao X, et al. **Gene Ther** 1995 Dec;2(10):710–22 (92 ref.)

Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl). Working PK, et al. **Hum Exp Toxicol** 1996 Sep;15(9):751–85 (68 ref.)

Liposomes for drug targeting in the lymphatic system. Hirnle P. **Hybridoma** 1997 Feb;16(1):127–32 (15 ref.)

Liposomes as drug delivery system in leishmaniasis. Kshirsagar NA, et al. **J Assoc Physicians India** 1995 Jan; 43(1):46–8 (16 ref.)

Affinity liposomes in vivo: factors influencing target accumulation. Torchilin VP. **J Mol Recognit** 1996 Sep-Dec;9(5–6):335–46 (54 ref.)

Pharmacokinetic considerations in the development of labeled liposomes and micelles for diagnostic imaging. Torchilin VP. **Q J Nucl Med** 1997 Jun;41(2):141–53 (64 ref.)

[Liposomes in opthalmology. Review of the literature] Desmettre T, et al. **J Fr Ophtalmol** 1996;19(11):716–31 (72 ref.) (Eng. Abstr.) **(Fre)**

[Physico-chemical characterization and application for drug carrier of soybean-derived sterols and their glucosides-containing liposomes] Maitani Y. **Yakugaku Zasshi** 1996 Dec;116(12):901–10 (28 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Immunoliposomes for cancer treatment. Park JW, et al. **Adv Pharmacol** 1997;40:399–435 (135 ref.)

Liposomes. Sharata HH, et al. **Int J Dermatol** 1996 Nov; 35(11):761–9 (75 ref.)

Liposomes and immunoassays. Rongen HA, et al. **J Immunol Methods** 1997 May 26;204(2):105–33 (155 ref.)

CHEMISTRY

The influence of protein and interfacial structure on the self-assembly of oriented protein arrays. Leckband DE. **Adv Biophys** 1997;34:173–90 (36 ref.)

Long-term expression of the human alpha1-antitrypsin gene in mice employing anionic and cationic liposome vector. Aliño SF. **Biochem Pharmacol** 1997 Jul 1;54(1):9–13 (35 ref.)

METABOLISM

The role of immunoproteins in the survival of liposomes in the circulation. Devine DV, et al. **Crit Rev Ther Drug Carrier Syst** 1997;14(2):105–31 (146 ref.)

MscL: a mechanosensitive channel in Escherichia coli. Sukharev SI, et al. **Soc Gen Physiol Ser** 1996;51:133–41 (34 ref.)

[Visualized dynamics of microtubules and liposomes] Kaneko T, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1215–20 (13 ref.) **(Jpn)**

THERAPEUTIC USE

Colloidal systems for tumor targeting. Storm G, et al. **Hybridoma** 1997 Feb;16(1):119–25 (58 ref.)

Gene therapy for central nervous system injury: the use of cationic liposomes: an invited review. Yang K, et al. **J Neurotrauma** 1997 May;14(5):281–97 (118 ref.)

LIPOSUCTION see **LIPECTOMY**

LIPOTROPIN 61-91 see **BETA-ENDORPHIN**

LIPOXIDASE see **LIPOXYGENASE**

LIPOXYGENASE

CHEMISTRY

Stereochemical aspects of fatty acid oxidation: hydroperoxide isomerases. Hamberg M. **Acta Chem Scand** 1996 Mar;

50(3):219–24 (33 ref.)
Lipoxygenases: structural principles and spectroscopy. Gaffney BJ. **Annu Rev Biophys Biomol Struct** 1996; 25:431–59 (91 ref.)

GENETICS

The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice. Funk CD. **Biochim Biophys Acta** 1996 Nov 11; 1304(1):65–84 (139 ref.)

METABOLISM

Ribonucleotide reductase, lipoxygenase and the intracellular low-molecular-weight iron pool. Cooper CE, et al. **Biochem Soc Trans** 1997 Feb;25(1):75–80 (25 ref.)
The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice. Funk CD. **Biochim Biophys Acta** 1996 Nov 11; 1304(1):65–84 (139 ref.)
Glomerulonephritis: roles for lipoxygenase pathways in pathophysiology and therapy. Badr KF. **Curr Opin Nephrol Hypertens** 1997 Mar;6(2):111–8 (75 ref.)

5-LIPOXYGENASE see **ARACHIDONATE 5-LIPOXYGENASE**

12-LIPOXYGENASE see **ARACHIDONATE 12-LIPOXYGENASE**

15-LIPOXYGENASE see **ARACHIDONATE 15-LIPOXYGENASE**

LIPOXYGENASE INHIBITORS

THERAPEUTIC USE

Biosynthesis inhibitors for leukotrienes in bronchial asthma. Negro JM, et al. **Allergol Immunopathol (Madr)** 1997 Jul-Aug;25(4):209–16 (48 ref.)
Antileukotriene therapy for asthma. Larsen JS, et al. **Am J Health Syst Pharm** 1996 Dec 1;53(23):2821–30; quiz 2877–8 (100 ref.)
Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma [see comments] Wenzel SE, et al. **Ann Pharmacother** 1996 Jul-Aug;30(7–8):858–64 (34 ref.) Comment in: Ann Pharmacother 1996 Jul-Aug;30(7–8):873–5.
Antileukotriene agents. Tan RA, et al. **Curr Opin Pulm Med** 1997 May;3(3):215–20 (46 ref.)
Pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in the management of asthma. Drazen JM. **Pharmacotherapy** 1997 Jan-Feb;17(1 Pt 2):22S–30S (58 ref.)
The use of 5-lipoxygenase inhibitors and leukotriene receptor antagonists in the treatment of chronic asthma. Sorkness CA. **Pharmacotherapy** 1997 Jan-Feb;17(1 Pt 2):50S–54S (14 ref.)
Cyclooxygenase and lipoxygenase inhibitors in cancer therapy. Ara G, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Jan; 54(1):3–16 (188 ref.)
Anti-leukotriene intervention: is there adequate information for clinical use in asthma? Ind PW. **Respir Med** 1996 Nov; 90(10):575–86 (70 ref.)

LIQUID PARAFFIN see **MINERAL OIL**

LISINOPRIL

ADVERSE EFFECTS

Lisinopril-induced isolated visceral angioedema: review of ACE-inhibitor-induced small bowel angioedema. Abdelmalek MF, et al. **Dig Dis Sci** 1997 Apr;42(4):847–50 (15 ref.)

PHARMACOLOGY

Lisinopril. A review of its pharmacology and use in the management of the complications of diabetes mellitus. Goa KL, et al. **Drugs** 1997 Jun;53(6):1081–105 (157 ref.)
Lisinopril. A review of its pharmacology and clinical efficacy in elderly patients. Langtry HD, et al. **Drugs Aging** 1997 Feb;10(2):131–66 (240 ref.)

THERAPEUTIC USE

Lisinopril. A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction. Goa KL, et al. **Drugs** 1996 Oct;52(4):564–88 (154 ref.)

LISTERIA

CHEMISTRY

Actin and cell pathogenesis. Higley S, et al. **Curr Opin Cell Biol** 1997 Feb;9(1):62–9 (63 ref.)

CLASSIFICATION

[Taxonomy of the Listeria genus and typing of L. monocytogenes] Rocourt J. **Pathol Biol (Paris)** 1996 Nov; 44(9):749–56 (104 ref.) (Eng. Abstr.) **(Fre)**

GROWTH & DEVELOPMENT

[Critical analysis of isolation, counting and identification methods of Listeria in food industry] Bind JL, et al. **Pathol Biol (Paris)** 1996 Nov;44(9):757–68 (43 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Innate versus acquired immunity in listeriosis. Brombacher F, et al. **Res Immunol** 1996 Oct-Dec;147(8–9):505–11 (53 ref.)

ISOLATION & PURIFICATION

[Critical analysis of isolation, counting and identification methods of Listeria in food industry] Bind JL, et al. **Pathol Biol (Paris)** 1996 Nov;44(9):757–68 (43 ref.) (Eng. Abstr.) **(Fre)**

PATHOGENICITY

Actin and cell pathogenesis. Higley S, et al. **Curr Opin Cell Biol** 1997 Feb;9(1):62–9 (63 ref.)
Regulation of virulence gene expression in pathogenic Listeria. Brehm K, et al. **Microbiologia** 1996 Jun; 12(2):219–36 (66 ref.)

LISTERIA INFECTIONS

COMPLICATIONS

Listeria monocytogenes joint infection in a patient with psoriatic arthritis [letter] Marangos MN, et al. **J Rheumatol** 1996 Nov;23(11):2005–6 (3 ref.)
Fatal Listeria meningitis, endocarditis and pericarditis in a patient with haemochromatosis. Manso C, et al. **Scand J Infect Dis** 1997;29(3):308–9 (14 ref.)

DRUG THERAPY

Management of listeriosis. Hof H, et al. **Clin Microbiol Rev** 1997 Apr;10(2):345–57 (144 ref.)
Listeria endocarditis: current management and patient outcome--world literature review. Spyrou N, et al. **Heart** 1997 Apr;77(4):380–3 (51 ref.)

EPIDEMIOLOGY

Health risk assessment of Listeria monocytogenes in Canada. Farber JM, et al. **Int J Food Microbiol** 1996 Jun; 30(1–2):145–56 (28 ref.)
Food poisoning, listeriosis, and febrile gastroenteritis. **Nutr Rev** 1997 Feb;55(2):57–60 (6 ref.)
Foodborne listeriosis. Rocourt J, et al. **World Health Stat Q** 1997;50(1–2):67–73 (27 ref.)

ETIOLOGY

Prolonged gastric acid suppression therapy: a significant risk factor for Listeria monocytogenes infection? [comment] Glupczynski Y. **Eur J Gastroenterol Hepatol** 1996 Nov; 8(11):1063–6 (19 ref.) Comment on: Eur J Gastroenterol Hepatol 1996 Nov;8(11):1071–4.

IMMUNOLOGY

Inter-relationship among macrophages, natural killer cells and neutrophils in early stages of Listeria resistance. Unanue ER. **Curr Opin Immunol** 1997 Feb;9(1):35–43 (114 ref.)
Innate versus acquired immunity in listeriosis. Brombacher F, et al. **Res Immunol** 1996 Oct-Dec;147(8–9):505–11 (53 ref.)
Class Ib MHC products in host immunity against Listeria monocytogenes. Kurlander RJ, et al. **Res Immunol** 1996 Oct-Dec;147(8–9):524–31 (33 ref.)
Macrophage production of IL12 is a critical link between the innate and specific immune responses to Listeria. Tripp CS, et al. **Res Immunol** 1995 Sep-Oct;146(7–8):515–20 (32 ref.)
Macrophages, NK cells and neutrophils in the cytokine loop of Listeria resistance. Unanue ER. **Res Immunol** 1996 Oct-Dec;147(8–9):499–505 (55 ref.)

MICROBIOLOGY

Listeriosis. Lorber B. **Clin Infect Dis** 1997 Jan;24(1):1–9; quiz 10–1 (125 ref.)
Molecular and genetic determinants involved in invasion of mammalian cells by Listeria monocytogenes. Dramsi S, et al. **Curr Top Microbiol Immunol** 1996;209:61–77 (91 ref.)
Regulation of virulence gene expression in pathogenic Listeria. Brehm K, et al. **Microbiologia** 1996 Jun; 12(2):219–36 (66 ref.)
The molecular mechanisms of actin-based intracellular motility by Listeria monocytogenes. Chakraborty T. **Microbiologia** 1996 Jun;12(2):237–44 (34 ref.)
The pathogenesis of infection by Listeria monocytogenes. Rouquette C, et al. **Microbiologia** 1996 Jun;12(2):245–58 (92 ref.)

TRANSMISSION

Prolonged gastric acid suppression therapy: a significant risk factor for Listeria monocytogenes infection? [comment] Glupczynski Y. **Eur J Gastroenterol Hepatol** 1996 Nov; 8(11):1063–6 (19 ref.) Comment on: Eur J Gastroenterol Hepatol 1996 Nov;8(11):1071–4.

VETERINARY

A review of Listeria monocytogenes and listeriosis [see comments] Low JC, et al. **Vet J** 1997 Jan;153(1):9–29 (272 ref.) Comment in: Vet J 1997 Jan;153(1):3–5.
[Cerebral listeriosis in cattle: literature review and retrospective analysis of individual cases] Hirsbrunner G, et al. **Tierarztl Prax** 1997 Jul;25(4):336–43 (30 ref.) (Eng. Abstr.) **(Ger)**

LISTERIA MONOCYTOGENES

Health risk assessment of Listeria monocytogenes in Canada. Farber JM, et al. **Int J Food Microbiol** 1996 Jun; 30(1–2):145–56 (28 ref.)
A review of Listeria monocytogenes and listeriosis [see comments] Low JC, et al. **Vet J** 1997 Jan;153(1):9–29 (272 ref.) Comment in: Vet J 1997 Jan;153(1):3–5.

CHEMISTRY

How the Listeria monocytogenes ActA protein converts actin polymerization into a motile force. Smith GA, et al. **Trends Microbiol** 1997 Jul;5(7):272–6 (42 ref.)

CLASSIFICATION

[Taxonomy of the Listeria genus and typing of L. monocytogenes] Rocourt J. **Pathol Biol (Paris)** 1996 Nov; 44(9):749–56 (104 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Management of listeriosis. Hof H, et al. **Clin Microbiol Rev** 1997 Apr;10(2):345–57 (144 ref.)

GROWTH & DEVELOPMENT

[Resistance of Listeria monocytogenes to physical exposure] Augustin JC. **Pathol Biol (Paris)** 1996 Nov;44(9):790–807 (94 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Listeriosis. Lorber B. **Clin Infect Dis** 1997 Jan;24(1):1–9; quiz 10–1 (125 ref.)
Antibodies to Listeria monocytogenes. Bhunia AK. **Crit Rev Microbiol** 1997;23(2):77–107 (179 ref.)
Primary and secondary immune responses to Listeria monocytogenes. Harty JT, et al. **Curr Opin Immunol** 1996 Aug;8(4):526–30 (47 ref.)
H2-M3 restricted presentation of Listeria monocytogenes antigens. Lenz LL, et al. **Immunol Rev** 1996 Jun;151:107–21 (30 ref.)
Pathogenesis and immunology of Listeria monocytogenes. Schlech WF. **Pathol Biol (Paris)** 1996 Nov;44(9):775–82 (74 ref.)

ISOLATION & PURIFICATION

Prolonged gastric acid suppression therapy: a significant risk factor for Listeria monocytogenes infection? [comment] Glupczynski Y. **Eur J Gastroenterol Hepatol** 1996 Nov; 8(11):1063–6 (19 ref.) Comment on: Eur J Gastroenterol Hepatol 1996 Nov;8(11):1071–4.

PATHOGENICITY

Listeriosis. Lorber B. **Clin Infect Dis** 1997 Jan;24(1):1–9; quiz 10–1 (125 ref.)
Common entry mechanisms. Bacterial pathogenesis. Marra A, et al. **Curr Biol** 1996 Sep 1;6(9):1084–6 (14 ref.)
Molecular and genetic determinants involved in invasion of mammalian cells by Listeria monocytogenes. Dramsi S, et al. **Curr Top Microbiol Immunol** 1996;209:61–77 (91 ref.)
The pathogenesis of infection by Listeria monocytogenes. Rouquette C, et al. **Microbiologia** 1996 Jun;12(2):245–58 (92 ref.)
Pathogenesis and immunology of Listeria monocytogenes. Schlech WF. **Pathol Biol (Paris)** 1996 Nov;44(9):775–82 (74 ref.)
Listeria monocytogenes--aspects of pathogenicity. Schwarzkopf A. **Pathol Biol (Paris)** 1996 Nov;44(9):769–74 (30 ref.)
Class Ib MHC products in host immunity against Listeria monocytogenes. Kurlander RJ, et al. **Res Immunol** 1996 Oct-Dec;147(8–9):524–31 (33 ref.)

PHYSIOLOGY

The molecular mechanisms of actin-based intracellular motility by Listeria monocytogenes. Chakraborty T. **Microbiologia** 1996 Jun;12(2):237–44 (34 ref.)
Thermal and biological treatments to control psychrotrophic pathogens. Sheldon BW, et al. **Poult Sci** 1996 Sep; 75(9):1126–32 (45 ref.)

RADIATION EFFECTS

[Resistance of Listeria monocytogenes to physical exposure] Augustin JC. **Pathol Biol (Paris)** 1996 Nov;44(9):790–807 (94 ref.) (Eng. Abstr.) **(Fre)**

LITERACY PROGRAMS see **EDUCATION**

LITERATURE

LITERATURE

see related
MEDICINE IN LITERATURE

[The phenomenon of deja vu in psychopathology and literature] Farina B, et al. **Minerva Psichiatr** 1996 Jun; 37(2):99–106 (28 ref.) (Eng. Abstr.) **(Ita)**

LITERATURE, MODERN

[Literature and psychiatry] Borgna E. **Recenti Prog Med** 1996 Dec;87(12):628–34 (26 ref.) (Eng. Abstr.) **(Ita)**

LITHIUM

ADMINISTRATION & DOSAGE

Dosing strategies and time course of response to antimanic drugs. Bowden CL. **J Clin Psychiatry** 1996;57 Suppl 13:4–9; discussion 10–2 (44 ref.)

ADVERSE EFFECTS

Irreversible lithium neurotoxicity: an overview. Kores B, et al. **Clin Neuropharmacol** 1997 Aug;20(4):283–99 (84 ref.)

Use of thyroid hormone to diminish the cognitive side effects of psychiatric treatment. Tremont G, et al. **Psychopharmacol Bull** 1997;33(2):273–80 (68 ref.)

Emergency treatment of lithium-induced diabetes insipidus with nonsteroidal anti-inflammatory drugs. Lam SS, et al. **Ren Fail** 1997 Jan;19(1):183–8 (29 ref.)

[Is lithium a teratogen?] Kučera V. **Cas Lek Cesk** 1996 Nov 20;135(22):726–8 (20 ref.) (Eng. Abstr.) **(Cze)**

[Lithium-induced renal disease] Horio M, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):584–7 (13 ref.) **(Jpn)**

ANALYSIS

Analytical strategies for the measurement of lithium in biological samples. Christian GD. **J Pharm Biomed Anal** 1996 Jun;14(8–10):899–908 (74 ref.)

PHARMACOLOGY

On the functions of lithium: the mood stabilizer. Shastry BS. **Bioessays** 1997 Mar;19(3):199–200 (25 ref.)

Regulation of signal transduction pathways by mood-stabilizing agents: implications for the delayed onset of therapeutic efficacy. Manji HK, et al. **J Clin Psychiatry** 1996;57 Suppl 13:34–46; discussion 47–8 (109 ref.)

G protein-mediated signal transduction as a target of antidepressant and antibipolar drug action: evidence from model systems. Rasenick MM, et al. **J Clin Psychiatry** 1996; 57 Suppl 13:49–55; discussion 56–8 (38 ref.)

Inositol monophosphatase inhibitors--lithium mimetics? Atack JR. **Med Res Rev** 1997 Mar;17(2):215–24 (32 ref.)

[Biological mechanisms of drug-resistant depression] Suwalska A, et al. **Psychiatr Pol** 1996 Sep–Oct;30(5):713–29 (56 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

The combat of non-compliance during prophylactic lithium treatment. Schou M. **Acta Psychiatr Scand** 1997 May; 95(5):361–3 (28 ref.)

Current therapeutic profile of lithium [comment] Gershon S, et al. **Arch Gen Psychiatry** 1997 Jan;54(1):16–20 (94 ref.) Comment on: Arch Gen Psychiatry 1997 Jan;54(1):9–13; discussion 14–5.

Unanswered questions, unknown future for one of our oldest medications [comment] Gitlin MJ, et al. **Arch Gen Psychiatry** 1997 Jan;54(1):21–3 (30 ref.) Comment on: Arch Gen Psychiatry 1997 Jan;54(1):9–13; discussion 14–5.

Forty years of lithium treatment [see comments] Schou M. **Arch Gen Psychiatry** 1997 Jan;54(1):9–13; discussion 14–5 (42 ref.) Comment in: Arch Gen Psychiatry 1997 Jan;54(1):16–20. Comment in: Arch Gen Psychiatry 1997 Jan;54(1):21–3.

Lithium therapy in the treatment of manic-depressive illness. Present status and future perspectives. A critical review. Emilien G, et al. **Arch Int Pharmacodyn Ther** 1995 Nov–Dec;330(3):251–78 (137 ref.)

The role of lithium in the affective disorders. Johnson G. **Aust N Z J Psychiatry** 1996 Dec;30(6):715–9 (19 ref.)

The diagnosis and treatment of mania in the elderly. McDonald WM, et al. **Bull Menninger Clin** 1996 Spring; 60(2):174–96 (136 ref.)

Health-economic implications of the onset of action of antimanic agents. Keck PE Jr, et al. **J Clin Psychiatry** 1996; 57 Suppl 13:13–8; discussion 19–22 (53 ref.)

Prophylactic lithium treatment of unipolar and bipolar manic-depressive illness. Schou M. **Psychopathology** 1995; 28 Suppl 1:81–5 (26 ref.)

[ssues in polypharmacotherapy: focus on major depression. Dufresne RL. **Psychopharmacol Bull** 1996;32(4):547–53 (30 ref.)

Polypharmacy in bipolar I disorder. Solomon DA, et al. **Psychopharmacol Bull** 1996;32(4):579–87 (45 ref.)

Lithium, a multi-edged sword: the past, present, and future. Jefferson JW. **Wis Med J** 1996 Apr;95(4):231–5 (27 ref.)

[Biological mechanisms of drug-resistant depression] Suwalska A, et al. **Psychiatr Pol** 1996 Sep–Oct;30(5):713–29 (56 ref.) (Eng. Abstr.) **(Pol)**

TOXICITY

Irreversible lithium neurotoxicity: an overview. Kores B, et al. **Clin Neuropharmacol** 1997 Aug;20(4):283–99 (84 ref.)

LITHIUM CARBONATE

ADVERSE EFFECTS

Lithium neurotoxicity at low therapeutic doses Hypotheses for causes and mechanism of action following a retrospective analysis of published case reports. Emilien G, et al. **Acta Neurol Belg** 1996 Dec;96(4):281–93 (76 ref.)

Chorea caused by lithium intoxication: a case report and literature review. Podskalny GD, et al. **Mov Disord** 1996 Nov;11(6):733–7 (22 ref.)

PHARMACOLOGY

Inositol monophosphatase, the putative therapeutic target for lithium. Atack JR. **Brain Res Brain Res Rev** 1996 Aug; 22(2):183–90 (60 ref.)

POISONING

Pathologic assessment of cerebellar atrophy following acute lithium intoxication. Mangano WE, et al. **Clin Neuropathol** 1997 Jan–Feb;16(1):30–3 (19 ref.)

LITHIUM CHLORIDE

PHARMACOLOGY

Transformation of lithium-treated yeast cells and the selection of auxotrophic and dominant markers. Mount RC, et al. **Methods Mol Biol** 1996;53:139–45 (19 ref.)

LITHIUM COMPOUNDS

THERAPEUTIC USE

Long term treatment of bipolar disorder [see comments] Silverstone T, et al. **Drugs** 1996 Mar;51(3):367–82 (105 ref.) Comment in: Drugs 1997 Apr;53(4):726.

[What a physician ought to know about lithium therapy] Aitio ML. **Duodecim** 1995;111(11):1013–20 (23 ref.) **(Fin)**

LITHOLAPAXY see **LITHOTRIPSY**

LITHOTRIPSY

see related
HIGH-ENERGY SHOCK WAVES

Extracorporeal shock wave lithotripsy. Zanetti G, et al. **Arch Ital Urol Androl** 1996 Sep;68(4):263–76 (113 ref.)

Extracorporeal shock wave lithotripsy. Sauerbruch T. **Digestion** 1997;58 Suppl 1:98–100 (12 ref.)

Transpapillary choledochoscopy. Bourke MJ, et al. **Gastrointest Endosc Clin N Am** 1996 Jan;6(1):235–52 (56 ref.)

Endoscopic management of difficult common bile duct stones. Lee JG, et al. **Gastrointest Endosc Clin N Am** 1996 Jan;6(1):43–55 (60 ref.)

Use of extracorporeal shock waves in the treatment of pseudarthrosis, tendinopathy and other orthopedic diseases. Haupt G. **J Urol** 1997 Jul;158(1):4–11 (151 ref.)

Advances in lithotripsy and stone disease treatment [published errata appear in Radiol Technol 1996 Sep–Oct;68(1):17 and 1997 Mar–Apr;68(4):285] Newman J. **Radiol Technol** 1996 Jul–Aug;67(6):479–96; quiz 497–500 (44 ref.)

Lithotripsy and surgery. Lingeman JE. **Semin Nephrol** 1996 Sep;16(5):487–98 (56 ref.)

Update on interventional uroradiology. Dyer RB, et al. **Urol Clin North Am** 1997 Aug;24(3):623–52 (128 ref.)

Intracorporeal lithotripsy. Instrumentation and development. Grocela JA, et al. **Urol Clin North Am** 1997 Feb;24(1):13–23 (29 ref.)

Treatment update on pediatric urolithiasis. Esen T, et al. **World J Urol** 1997;15(3):195–202 (62 ref.)

[Ureteroscopy versus in situ extracorporeal shockwave lithotripsy in the treatment of calculi of the distal ureter] Leblanc B, et al. **Prog Urol** 1996 Aug–Sep;6(4):535–8 (22 ref.) (Eng. Abstr.) **(Fre)**

[Extracorporeal shockwave lithotripsy today--an assessment of current status] Chaussy C, et al. **Urologe A** 1997 May; 36(3):194–9 (82 ref.) (Eng. Abstr.) **(Ger)**

[Shock waves in orthopedics] Haupt G. **Urologe A** 1997 May; 36(3):233–8 (48 ref.) (Eng. Abstr.) **(Ger)**

[Extracorporeal shock wave lithotripsy in urolithiasis. An update] Karlsen SJ. **Tidsskr Nor Laegeforen** 1996 Oct 10; 116(24):2889–92 (25 ref.) (Eng. Abstr.) **(Nor)**

ADVERSE EFFECTS

Endoscopic treatment of gastric outlet obstruction caused by a gallstone (Bouveret's syndrome) after extracorporeal shock-wave lithotripsy. Dumonceau JM, et al. **Endoscopy** 1997 May;29(4):319–21 (12 ref.)

Colonic injury after ESWL of renal calculi [letter] Etzkorn KP, et al. **Gastrointest Endosc** 1996 Oct;44(4):511–2 (3 ref.)

CONTRAINDICATIONS

Contemporary clinical practice of shock wave lithotripsy: a reevaluation of contraindications. Streem SB. **J Urol** 1997 Apr;157(4):1197–203 (66 ref.)

ECONOMICS

Clinical economics review: the management of gallstone disease. Hussaini SH. **Aliment Pharmacol Ther** 1996 Oct; 10(5):699–705 (63 ref.)

INSTRUMENTATION

[Current status of minimally invasive treatment methods in sialolithiasis] Iro H, et al. **HNO** 1996 Feb;44(2):78–84 (19 ref.) (Eng. Abstr.) **(Ger)**

[Percutaneous therapy of kidney calculi. Current status] Kaldenbach U, et al. **Med Monatsschr Pharm** 1997 Apr; 20(4):90–7 (62 ref.) **(Ger)**

[Extracorporeal shockwave lithotripsy in childhood] Schultz-Lampel D, et al. **Urologe A** 1997 May;36(3):200–8 (81 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Time reversal focusing applied to lithotripsy. Thomas JL, et al. **Ultrason Imaging** 1996 Apr;18(2):106–21 (9 ref.)

[Endoscopic techniques in the treatment of calculi in the upper urinary tract] Hem E. **Tidsskr Nor Laegeforen** 1996 Oct 10;116(24):2893–6 (28 ref.) (Eng. Abstr.) **(Nor)**

LITHOTRIPSY, LASER

[Ureteroscopic lithotripsy using the laser] Usaï E, et al. **Ann Urol (Paris)** 1997;31(1):49–53 (21 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Nonlinear absorption: intraocular microsurgery and laser lithotripsy. Vogel A. **Phys Med Biol** 1997 May; 42(5):895–912 (90 ref.)

INSTRUMENTATION

[Current status of minimally invasive treatment methods in sialolithiasis] Iro H, et al. **HNO** 1996 Feb;44(2):78–84 (19 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Non-invasive determination of port wine stain anatomy and physiology for optimal laser treatment strategies. van Gemert MJ, et al. **Phys Med Biol** 1997 May;42(5):937–50 (35 ref.)

LITIGATION see **JURISPRUDENCE**

LITTLE'S DISEASE see **CEREBRAL PALSY**

LIVEDO RETICULARIS see **SKIN DISEASES, VASCULAR**

LIVER

see related
HEPATECTOMY

Adenoviral vectors for hepatic gene transfer in animals. Kay MA. **Chest** 1997 Jun;111(6 Suppl):138S–142S (43 ref.)

Intermediate filament proteins of the liver: emerging disease association and functions. Omary MB, et al. **Hepatology** 1997 May;25(5):1043–8 (67 ref.)

Ontogeny and developmental regulation of heme oxygenase. Dennery PA, et al. **J Perinatol** 1996 May–Jun;16(3 Pt 2):S79–83 (32 ref.)

Contrast-enhanced MR imaging of the liver. Van Beers BE, et al. **Radiology** 1997 May;203(2):297–306 (105 ref.)

[Incisional hernia after surgical laparoscopy: a case of hepatic ligament incarceration and review of the literature] Deval B, et al. **Contracept Fertil Sex** 1997 Jan;25(1):66–8 (14 ref.) (Eng. Abstr.) **(Fre)**

ABNORMALITIES

Hepatoblastoma in a child with trisomy 18: cytogenetics, liver anomalies, and literature review. Bove KE, et al. **Pediatr Pathol Lab Med** 1996 Mar–Apr;16(2):253–62 (39 ref.)

ANATOMY & HISTOLOGY

Liver transplantation: review of the literature. Part 1: Anatomic features and current concepts. Patenaude YG, et al. **Can Assoc Radiol J** 1997 Jun;48(3):171–8 (19 ref.)

Segmental anatomy of the liver: a review and a proposal for an international working nomenclature. Fasel JH, et al. **Eur Radiol** 1996;6(6):834–7 (37 ref.)

Terminology of liver anatomy and liver resections: coming to grips with hepatic Babel. Strasberg SM. **J Am Coll Surg** 1997 Apr;184(4):413–34 (26 ref.)

In vivo hepatic magnetic resonance spectroscopy: clinical or research tool? Jalan R, et al. **J Hepatol** 1996 Sep; 25(3):414–24 (78 ref.)

BLOOD SUPPLY

Hepatic sinusoidal endothelial cell in alcoholemia and

endotoxemia. Deaciuc IV, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):607–14 (87 ref.)

Liver–spleen infarcts following transcatheter chemoembolization: a case report and review of the literature on adverse effects. Cohen SE, et al. **Dig Dis Sci** 1997 May;42(5):938–43 (29 ref.)

Stapler technique for extrahepatic vascular control during hepatic resection. Scudamore CH, et al. **J Invest Surg** 1997 Jan–Apr;10(1–2):59–61 (7 ref.)

Pathophysiology and treatment of variceal hemorrhage. Roberts LR, et al. **Mayo Clin Proc** 1996 Oct;71(10):973–83 (63 ref.)

CT findings in ischaemic hepatic failure due to intra-arterial embolisation: a case report. Catalano O. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Jan;166(1):81–3 (18 ref.)

Remodeling of hepatic microvascular responsiveness after ischemia/reperfusion. Clemens MG, et al. **Shock** 1997 Aug; 8(2):80–5 (66 ref.)

Therapeutic modulation of free radical–mediated reperfusion injury of the liver and its surgical implications. Marubayashi S, et al. **Surg Today** 1996;26(8):573–80 (97 ref.)

Sinusoidal lining cells and hepatotoxicity. Laskin DL. **Toxicol Pathol** 1996 Jan–Feb;24(1):112–8 (118 ref.)

Structure and function of sinusoidal lining cells in the liver. Wisse E, et al. **Toxicol Pathol** 1996 Jan–Feb;24(1):100–11 (111 ref.)

Failure patterns of cryopreserved vein grafts in liver transplantation. Kuang AA, et al. **Transplantation** 1996 Sep 27;62(6):742–7 (21 ref.)

Experimental methods in hepatology. Guidelines of the German Association for the Study of the Liver (GASL). Liver perfusion—technique and applications. vom Dahl S, et al. **Z Gastroenterol** 1997 Mar;35(3):221–6 (58 ref.)

[Gaseous monoxides as an endogenous modulator of organ function—application of multifunctional digital microfluorography] Suematsu M, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1075–9 (10 ref.) **(Jpn)**

[The vascular bed of the liver in cirrhoses: pathogenesis and morphogenesis] Koshkin AB. **Lik Sprava** 1996 Mar–Apr; (3–4):6–9 (22 ref.) **(Rus)**

CHEMISTRY

Adhesion molecules in normal human liver. Scoazec JY. **Hepatogastroenterology** 1996 Sep–Oct;43(11):1103–5 (12 ref.)

Purification of RNA polymerase II general transcription factors from rat liver. Conaway RC, et al. **Methods Enzymol** 1996;273:194–207 (18 ref.)

Simultaneous measurement of hundreds of liver proteins: application in assessment of liver function. Anderson NL, et al. **Toxicol Pathol** 1996 Jan–Feb;24(1):72–6 (8 ref.)

Biochemical basis of hepatocellular injury. Kedderis GL. **Toxicol Pathol** 1996 Jan–Feb;24(1):77–83 (60 ref.)

CYTOLOGY

Hepatic gene therapy for hemophilia B. Kay MA. **Adv Exp Med Biol** 1995;386:229–34 (16 ref.)

Zonation of parenchymal and nonparenchymal metabolism in liver. Jungermann K, et al. **Annu Rev Nutr** 1996; 16:179–203 (70 ref.)

Cell volume and the metabolic actions of insulin. Zhande R, et al. **Biochem Cell Biol** 1996;74(4):513–22 (79 ref.)

Toward development of an implantable tissue engineered liver. Davis MW, et al. **Biomaterials** 1996 Feb;17(3):365–72 (74 ref.)

Liver endothelial cells: participation in host response to lymphoma metastasis. Umansky V, et al. **Cancer Metastasis Rev** 1996 Jun;15(2):273–9 (54 ref.)

Cell–based therapy of acute liver failure: the extracorporeal bioartificial liver. Frémond B, et al. **Cell Biol Toxicol** 1996 Dec;12(4–6):325–9 (20 ref.)

Pluripotential liver stem cells: facultative stem cells located in the biliary tree. Alison MR, et al. **Cell Prolif** 1996 Jul; 29(7):373–402 (150 ref.)

Effect of extracellular matrix topology on cell structure, function, and physiological responsiveness: hepatocytes cultured in a sandwich configuration. Berthiaume F, et al. **FASEB J** 1996 Nov;10(13):1471–84 (62 ref.)

Perspectives of liver cell transplantation: a review. Schmidt HH, et al. **Hepatogastroenterology** 1997 Jul–Aug; 44(16):1013–8 (20 ref.)

Adhesion molecules in normal human liver. Scoazec JY. **Hepatogastroenterology** 1996 Sep–Oct;43(11):1103–5 (12 ref.)

Adhesion molecules in viral hepatitis. Volpes R. **Hepatogastroenterology** 1996 Sep–Oct;43(11):1106–8 (17 ref.)

The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Rockey D. **Hepatology** 1997 Jan;25(1):2–5 (43 ref.)

Importance of cell kinetics rhythmicity for the control of cell proliferation and carcinogenesis in rat liver (review). Barbason H, et al. **In Vivo** 1995 Nov–Dec;9(6):539–48 (33 ref.)

Hepatocyte transplantation. Habibullah CM, et al. **Indian J Gastroenterol** 1996 Jan;15(1):16–9 (31 ref.)

Consideration of potential immunological problems in the application of xenogenic hybrid liver support. Bornemann R, et al. **Int J Artif Organs** 1996 Nov;19(11):655–63 (54 ref.)

Importance of the kinetic characterization of liver cell metabolic reactions to the design of hybrid liver support devices. Catapano G, et al. **Int J Artif Organs** 1996 Nov; 19(11):670–6 (19 ref.)

Biliary epithelial cells: innocent victims or active participants in immune–mediated liver disease? [editorial; comment] Adams DH. **J Lab Clin Med** 1996 Dec;128(6):528–30 (27 ref.) Comment on: J Lab Clin Med 1996 Dec;128(6):536–44.

Percutaneous transcatheter liver cell transplantation: an emerging modality and its clinical implications. Kerr A, et al. **J Vasc Interv Radiol** 1996 Mar–Apr;7(2):169–76 (53 ref.)

Hepatic stellate cells—from the viewpoint of retinoid handling and function of the extracellular matrix. Senoo H, et al. **Kaibogaku Zasshi** 1997 Apr;72(2):79–94 (51 ref.)

Transdifferentiation of hepatic stellate cells (Ito cells) to myofibroblasts: a key event in hepatic fibrogenesis. Gressner AM. **Kidney Int Suppl** 1996 May;54:S39–45 (59 ref.)

Isolation of rat liver hepatocytes. Neufeld DS. **Methods Mol Biol** 1997;75:145–51 (6 ref.)

Application of the in vitro rat hepatocyte micronucleus assay in genetic toxicology testing. Müller–Tegethoff K, et al. **Mutat Res** 1997 Aug 1;392(1–2):125–38 (82 ref.)

Intralobular innervation and lipocyte contractility in the liver. Ueno T, et al. **Nutrition** 1997 Feb;13(2):141–8 (83 ref.)

Cultured rat hepatocytes. LeCluyse EL, et al. **Pharm Biotechnol** 1996;8:121–59 (140 ref.)

Isolated hepatocytes. Vore M, et al. **Pharm Biotechnol** 1996; 8:115–20 (6 ref.)

Possible involvement of adherens junction plaque proteins in tumorigenesis and metastasis. Tsukita S, et al. **Princess Takamatsu Symp** 1994;24:38–50 (69 ref.)

Hepatic stellate cells. Friedman SL. **Prog Liver Dis** 1996; 14:101–30 (185 ref.)

Hepatocyte transplantation: progress toward liver repopulation. Gupta S, et al. **Prog Liver Dis** 1996; 14:199–222 (110 ref.)

Regulation and functional significance of liver cell volume. Häussinger D. **Prog Liver Dis** 1996;14:29–53 (115 ref.)

Active cell death (apoptosis) in liver biology and disease. Schulte–Hermann R, et al. **Prog Liver Dis** 1995;13:1–35 (246 ref.)

Time for a consistent approach to preparing and culturing hepatocytes? Skett P, et al. **Xenobiotica** 1996 Jan;26(1):1–7 (23 ref.)

[Liver cell transplantation as somatic gene therapy] Tietge UJ, et al. **Dtsch Med Wochenschr** 1996 Oct 11; 121(41):1271–5 (49 ref.) **(Ger)**

[Extra thymus gland differentiation of IEL and role of liver] Abo T. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec; 18(6):695–700 (13 ref.) **(Jpn)**

[Characteristics of morphological differentiation of hepatocytes in ontogenesis of different animals depending on the type of nutrition] Kalashnikova MM. **Biull Eksp Biol Med** 1997 Jan;123(1):4–10 (31 ref.) **(Rus)**

[The transplantation of isolated hepatocytes] Cuervas–Mons Martínez V. **Gastroenterol Hepatol** 1997 Feb;20(2):59–64 (103 ref.) **(Spa)**

DRUG EFFECTS

Betaine, ethanol, and the liver: a review. Barak AJ, et al. **Alcohol** 1996 Jul–Aug;13(4):395–8 (27 ref.)

Susceptibility to alcohol–related liver injury. Lieber CS. **Alcohol Alcohol Suppl** 1994;2:315–26 (122 ref.)

Ethanol–induced apoptosis and oxidative stress in hepatocytes. Higuchi H, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9 Suppl):340A–346A (65 ref.)

Massive hepatic necrosis and death following repeated isoflurane exposure: case report and review of the literature. Gelven PL, et al. **Am J Forensic Med Pathol** 1996 Mar;17(1):61–4 (12 ref.)

Liver toxicity does not have to follow methotrexate therapy of patients with rheumatoid arthritis [editorial] [see comments] Kremer JM. **Am J Gastroenterol** 1997 Feb; 92(2):194–6 (29 ref.) Comment in: Am J Gastroenterol 1997 Aug;92(8):1402–3.

In vitro investigation of the molecular mechanisms of hepatotoxicity. Castell JV, et al. **Arch Toxicol Suppl** 1997; 19:313–21 (27 ref.)

Xenobiotic–induced hepatotoxicity: mechanisms of liver injury and methods of monitoring hepatic function. Sturgill MG, et al. **Clin Chem** 1997 Aug;43(8 Pt 2):1512–26 (201 ref.)

Hepatic injury associated with halogenated anaesthetics: cross–sensitization and its clinical implications. Mikatti NE, et al. **Eur J Anaesthesiol** 1997 Jan;14(1):7–14 (57 ref.)

Bile acid transport systems as pharmaceutical targets. Kramer W, et al. **Eur J Clin Invest** 1996 Sep;26(9):715–32 (89 ref.)

Drinking habits and occupational exposure to xenobiotics: a review. Bisio S, et al. **G Ital Med Lav** 1995 Jan–Nov; 17(1–6):37–40 (32 ref.)

Hepatotoxicity of drugs used in the treatment of gastrointestinal disorders. Bashir RM, et al. **Gastroenterol Clin North Am** 1995 Dec;24(4):937–67 (213 ref.)

Hepatobiliary toxicity of total parenteral nutrition in adults. Bashir RM, et al. **Gastroenterol Clin North Am** 1995 Dec; 24(4):1003–25 (187 ref.)

Hepatotoxicity of analgesics and anti–inflammatory agents. Fry SW, et al. **Gastroenterol Clin North Am** 1995 Dec; 24(4):875–905 (171 ref.)

Hepatotoxicity of anesthetics and other central nervous system drugs. Holt C, et al. **Gastroenterol Clin North Am** 1995 Dec;24(4):853–74 (165 ref.)

Hepatotoxicity of chemotherapeutic and oncologic agents. King PD, et al. **Gastroenterol Clin North Am** 1995 Dec; 24(4):969–90 (194 ref.)

Hepatotoxicity of transplant immunosuppressive agents. Kowdley KV, et al. **Gastroenterol Clin North Am** 1995 Dec;24(4):991–1001 (40 ref.)

Hepatotoxicity of anticholesterol, cardiovascular, and endocrine drugs and hormonal agents. Lahoti S, et al. **Gastroenterol Clin North Am** 1995 Dec;24(4):907–22 (111 ref.)

Hepatotoxicity of antimicrobial, antifungal, and antiparasitic agents. Reddy KR, et al. **Gastroenterol Clin North Am** 1995 Dec;24(4):923–36 (99 ref.)

Hepatotoxicity of antiviral agents. Styrt B, et al. **Gastroenterol Clin North Am** 1995 Dec;24(4):839–52 (84 ref.)

Chemical– and toxin–induced hepatotoxicity. Zimmerman HJ, et al. **Gastroenterol Clin North Am** 1995 Dec; 24(4):1027–45 (107 ref.)

Research prospects with benfluorex. Ravel D, et al. **J Diabetes Complications** 1996 Sep–Oct;10(5):246–54 (56 ref.)

Hepatotoxicity in drug development: detection, significance and solutions. Ballet F. **J Hepatol** 1997;26 Suppl 2:26–36 (67 ref.)

Use of hepatocyte cultures for the study of hepatotoxic compounds. Guillouzo A, et al. **J Hepatol** 1997;26 Suppl 2:73–80 (45 ref.)

Genetic predisposition to drug–induced hepatotoxicity. Larrey D, et al. **J Hepatol** 1997;26 Suppl 2:12–21 (74 ref.)

Molecular structure and hepatotoxicity: compared data about two closely related thiophene compounds. Mansuy D. **J Hepatol** 1997;26 Suppl 2:22–5 (11 ref.)

Initiation–promotion model for assessment of carcinogenicity: medium–term liver bioassay in rats for rapid detection of carcinogenic agents. Imaida K, et al. **J Toxicol Sci** 1996 Dec;21(5):483–7 (38 ref.)

A proposal for avoiding toxic interactions of a drug under development to estimate inhibitory ability on the drug metabolizing enzymes in human liver. Noguchi H. **J Toxicol Sci** 1996 Dec;21(5):317–21 (11 ref.)

Enhanced hepatotoxicity of acetaminophen in the alcoholic patient. Two case reports and a review of the literature. Johnston SC, et al. **Medicine (Baltimore)** 1997 May; 76(3):185–91 (40 ref.)

A review of drug–induced lysosomal disorders of the liver in man and laboratory animals. Schneider P, et al. **Microsc Res Tech** 1997 Feb 15;36(4):253–75 (145 ref.)

Trichloroethylene cancer risk: simplified calculation of PBPK–based MCLs for cytotoxic end points. Bogen KT, et al. **Regul Toxicol Pharmacol** 1997 Feb;25(1):26–42 (121 ref.)

Hazard assessment of germanium supplements. Tao SH, et al. **Regul Toxicol Pharmacol** 1997 Jun;25(3):211–9 (62 ref.)

Methotrexate update [editorial] Kremer JM. **Scand J Rheumatol** 1996;25(6):341–4 (31 ref.)

Mechanisms of liver damage. Losser MR, et al. **Semin Liver Dis** 1996 Nov;16(4):357–67 (154 ref.)

Effects of alcohol and prescription and over–the–counter drug use on liver enzyme profiles. Haley NJ. **Stat Bull Metrop Insur Co** 1995 Oct–Dec;76(4):2–9 (11 ref.)

Simultaneous measurement of hundreds of liver proteins: application in assessment of liver function. Anderson NL, et al. **Toxicol Pathol** 1996 Jan–Feb;24(1):72–6 (8 ref.)

Importance of and approaches to quantification of hepatocyte apoptosis. Goldsworthy TL, et al. **Toxicol Pathol** 1996 Jan–Feb;24(1):24–35 (47 ref.)

Biochemical basis of hepatocellular injury. Kedderis GL. **Toxicol Pathol** 1996 Jan–Feb;24(1):77–83 (60 ref.)

Sinusoidal lining cells and hepatotoxicity. Laskin DL. **Toxicol Pathol** 1996 Jan–Feb;24(1):112–8 (118 ref.)

Polymerase chain reaction and in situ hybridization: applications in toxicological pathology. Malarkey DE, et al. **Toxicol Pathol** 1996 Jan–Feb;24(1):13–23 (109 ref.)

Quantitation of multistage carcinogenesis in rat liver. Pitot HC, et al. **Toxicol Pathol** 1996 Jan–Feb;24(1):119–28 (56 ref.)

Biliary proliferation and adaptation in furan–induced rat liver injury and carcinogenesis. Sirica AE. **Toxicol Pathol** 1996 Jan–Feb;24(1):90–9 (52 ref.)

Bile acids in the assessment of hepatocellular function. Thompson MB. **Toxicol Pathol** 1996 Jan–Feb;24(1):62–71 (138 ref.)

[Hormone–mediated calcium responses of rat and human hepatocytes. Study of multicellular systems by videomicroscopy] Tordjmann T, et al. **Gastroenterol Clin Biol** 1995 Dec;19(12):980–90 (24 ref.) (Eng. Abstr.) **(Fre)**

EMBRYOLOGY

Alterations in fetal thymic and liver hematopoietic cells as indicators of exposure to developmental immunotoxicants. Holladay SD, et al. **Environ Health Perspect** 1996 Aug;104 Suppl 4:809–13 (34 ref.)

LIVER

ENZYMOLOGY

Georges Brohee Prize 1996. Major cytochrome P-450 families: implications in health and liver diseases. Horsmans Y. **Acta Gastroenterol Belg** 1997 Jan-Mar;60(1):2-10 (117 ref.)

Regulation of lipogenic enzyme expression by glucose in liver and adipose tissue: a review of the potential cellular and molecular mechanisms. Foufelle F, et al. **Adv Enzyme Regul** 1996;36:199-226 (91 ref.)

Regulation of rat ALDH-3 by hepatic protein kinases and glucocorticoids. Prough RA, et al. **Adv Exp Med Biol** 1997; 414:29-36 (18 ref.)

Betaine, ethanol, and the liver: a review. Barak AJ, et al. **Alcohol** 1996 Jul-Aug;13(4):395-8 (27 ref.)

Cytochromes P450 and UDP-glucuronosyl-transferases as hepatocellular autoantigens. Obermayer-Straub P, et al. **Baillieres Clin Gastroenterol** 1996 Sep;10(3):501-32 (139 ref.)

Tissue-specific modulation of glucocorticoid action by the 11 beta-hydroxysteroid dehydrogenases. Chapman KE, et al. **Biochem Soc Trans** 1997 May;25(2):583-7 (47 ref.)

Hexokinase expression in liver preneoplasia and neoplasia. Mayer D, et al. **Biochem Soc Trans** 1997 Feb;25(1):122-7 (32 ref.)

Regulation of overexpressed hexokinases in liver and islet cells. Newgard CB, et al. **Biochem Soc Trans** 1997 Feb; 25(1):118-22 (26 ref.)

Mild liver enzyme abnormalities: eliminating hemochromatosis as cause. Witte DL. **Clin Chem** 1997 Aug; 43(8 Pt 2):1535-8 (26 ref.)

Genetics and molecular biology of hepatic lipase. Bensadoun A, et al. **Curr Opin Lipidol** 1996 Apr;7(2):77-81 (44 ref.)

Ectonucleotidases, purine nucleoside transporter, and function of the bile canalicular plasma membrane of the hepatocyte. Che M, et al. **FASEB J** 1997 Feb;11(2):101-8 (86 ref.)

Hepatic canalicular membrane 5: Expression and localization of the conjugate export pump encoded by the MRP2 (cMRP/cMOAT) gene in liver. Keppler D, et al. **FASEB J** 1997 Jun;11(7):509-16 (39 ref.)

Hormonal regulation of hepatic enzymes involved in foreign compound metabolism. Prough RA, et al. **FASEB J** 1996 Oct;10(12):1369-77 (39 ref.)

Zonation of cytochrome P450 expression, drug metabolism and toxicity in liver. Lindros KO. **Gen Pharmacol** 1997 Feb;28(2):191-6 (50 ref.)

The cytochrome P450 4 (CYP4) family. Simpson AE. **Gen Pharmacol** 1997 Mar;28(3):351-9 (115 ref.)

Steroid UDP glucuronosyltransferases: characterization and regulation. Mackenzie PI, et al. **J Endocrinol** 1996 Sep;150 Suppl:S79-86 (52 ref.)

Role of metabolism in the activation of dehydroepiandrosterone as a peroxisome proliferator. Waxman DJ. **J Endocrinol** 1996 Sep;150 Suppl:S129-47 (140 ref.)

A proposal for avoiding toxic interactions of a drug under development to estimate inhibitory ability on the drug metabolizing enzymes in human liver. Noguchi H. **J Toxicol Sci** 1996 Dec;21(5):317-21 (11 ref.)

Phenobarbital induction of cytochrome P450 genes in primary hepatocyte and transgenic models. Omiecinski CJ. **J Toxicol Sci** 1996 Dec;21(5):279-81 (4 ref.)

Purification and characterization of glutathione-dependent dehydroascorbate reductase from rat liver. Maellaro E, et al. **Methods Enzymol** 1997;279:30-5 (13 ref.)

Human liver cocaine carboxylesterases. Bosron WF, et al. **NIDA Res Monogr** 1997;173:27-34 (22 ref.)

Strategies for the prenatal diagnosis of primary hyperoxaluria type 1. Danpure CJ, et al. **Prenat Diagn** 1996 Jul; 16(7):587-98 (36 ref.)

Pathogenesis of dyslipoproteinemia in renal insufficiency: the role of lipoprotein lipase and hepatic lipase. Arnadóttir M. **Scand J Clin Lab Invest** 1997 Feb;57(1):1-11 (97 ref.)

Effects of alcohol and prescription and over-the-counter drug use on liver enzyme profiles. Haley NJ. **Stat Bull Metrop Insur Co** 1995 Oct-Dec;76(4):2-9 (11 ref.)

The regulation of 3 beta-hydroxysteroid dehydrogenase expression. Mason JI, et al. **Steroids** 1997 Jan;62(1):164-8 (41 ref.)

Coordinate regulation of cholesterol 7 alpha-hydroxylase and HMG-CoA reductase in the liver. Björkhem I, et al. **Subcell Biochem** 1997;28:23-55 (152 ref.)

Pharmacological basis for hepatic drug metabolism in sheep. Galtier P, et al. **Vet Res** 1996;27(4-5):363-72 (30 ref.)

[Recent data on hepatic lipase gene. Structure and functions of this enzyme] Arca-Sedda Benhizia F, et al. **Ann Biol Clin (Paris)** 1996;54(3-4):117-30 (153 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Extrahepatic complement biosynthesis: where, when and why? Morgan BP, et al. **Clin Exp Immunol** 1997 Jan; 107(1):1-7 (103 ref.)

Immunotoxicology of T cell-dependent experimental liver injury. Tiegs G, et al. **Exp Toxicol Pathol** 1996 Jul; 48(5):471-6 (39 ref.)

Adhesion molecules in viral hepatitis. Volpes R. **Hepatogastroenterology** 1996 Sep-Oct;43(11):1106-8 (17 ref.)

Strange brew: T cells in the liver. Crispe IN, et al. **Immunol Today** 1996 Nov;17(11):522-5 (38 ref.)

Localization of cytochromes P450 in human tissues: implications for chemical toxicity. McKinnon RA, et al. **Pathology** 1996 May;28(2):148-55 (78 ref.)

Mechanisms of liver damage. Losser MR, et al. **Semin Liver Dis** 1996 Nov;16(4):357-67 (154 ref.)

Characteristics of the intrahepatic cytotoxic T lymphocyte response in chronic hepatitis C virus infection. Koziel MJ, et al. **Springer Semin Immunopathol** 1997;19(1):69-83 (90 ref.)

[Extra thymus gland differentiation of IEL and role of liver] Abo T. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec; 18(6):695-700 (13 ref.) **(Jpn)**

[Liver autoreaction in hepatitis virus infection] Senya M, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Dec; 19(6):614-7 (8 ref.) **(Jpn)**

INJURIES

The increasing frequency of nonoperative management of patients with liver and spleen injury. Rutledge R. **Adv Surg** 1996;30:385-415 (72 ref.)

Susceptibility to alcohol-related liver injury. Lieber CS. **Alcohol Alcohol Suppl** 1994;2:315-26 (122 ref.)

Management of retrohepatic venous injuries with atrial caval shunts. Weber S, et al. **AORN J** 1996 Sep;64(3):376-7, 380-2 (14 ref.)

Pathogenesis of liver fibrosis [editorial] Alcolado R, et al. **Clin Sci (Colch)** 1997 Feb;92(2):103-12 (121 ref.)

Immunotoxicology of T cell-dependent experimental liver injury. Tiegs G, et al. **Exp Toxicol Pathol** 1996 Jul; 48(5):471-6 (39 ref.)

Traumatic rupture of hepatic hemangioma. Hotokezaka M, et al. **J Clin Gastroenterol** 1996 Jul;23(1):69-71 (20 ref.)

Endoscopic treatment of biliary colic resulting from hemobilia after nonoperative management of blunt hepatic injury: case report and review of the literature. Clancy TE, et al. **J Trauma** 1997 Sep;43(3):527-9 (23 ref.)

Hepatic cell division and tissue repair: a key to survival after liver injury. Chanda S, et al. **Mol Med Today** 1996 Feb; 2(2):82-9 (37 ref.)

Molecular and cellular control points in pediatric liver injury and repair. Tracy TF Jr, et al. **Semin Pediatr Surg** 1996 Aug;5(3):175-81 (24 ref.)

[Liver injuries] Shakhnazarov SR. **Vestn Khir Im I I Grek** 1996;155(6):96-9 (35 ref.) **(Rus)**

INNERVATION

Role of central neural mechanisms in the regulation of hepatic glucose metabolism. Nonogaki K, et al. **Life Sci** 1997; 60(11):797-807 (101 ref.)

Neural monitoring system for circulating somatostatin in the hepatoportal area. Nakabayashi H. **Nutrition** 1997 Mar; 13(3):225-9 (17 ref.)

Intralobular innervation and lipocyte contractility in the liver. Ueno T, et al. **Nutrition** 1997 Feb;13(2):141-8 (83 ref.)

METABOLISM

In vitro insulinomimetic [corrected] effects of GLP-1 in liver, muscle and fat [published erratum appears in Acta Physiol Scand 1996 Nov;158(3):297] Valverde I, et al. **Acta Physiol Scand** 1996 Jul;157(3):359-60 (11 ref.)

Mechanism of autophagy in permeabilized hepatocytes: evidence for regulation by GTP binding proteins. Kadowaki M, et al. **Adv Exp Med Biol** 1996;389:113-9 (17 ref.)

Neuroprotective and deleterious effects of nitric oxide on focal cerebral ischemia-induced neurone death. Verrecchia C, et al. **Adv Neuroimmunol** 1995;5(4):359-78 (181 ref.)

Collagen breakdown products as markers of fibrosis and cirrhosis. Niemelä O. **Alcohol Alcohol Suppl** 1994;2:345-52 (85 ref.)

Theoretical considerations of what regulates low-density-lipoprotein and high-density-lipoprotein cholesterol. Dietschy JM. **Am J Clin Nutr** 1997 May;65(5 Suppl):1581S-1589S (62 ref.)

Glucose transporters in the regulation of intestinal, renal, and liver glucose fluxes. Thorens B. **Am J Physiol** 1996 Apr; 270(4 Pt 1):G541-53 (130 ref.)

The contribution of various organs to ammonia formation: a review of factors determining the arterial ammonia concentration [see comments] Huizenga JR, et al. **Ann Clin Biochem** 1996 Jan;33 (Pt 1):23-30 (63 ref.) Comment in: Ann Clin Biochem 1997 Mar;34 (Pt 2):210-1.

Regulation of hepatic de novo lipogenesis in humans. Hellerstein MK, et al. **Annu Rev Nutr** 1996;16:523-57 (123 ref.)

Zonation of parenchymal and nonparenchymal metabolism in liver. Jungermann K, et al. **Annu Rev Nutr** 1996; 16:179-203 (70 ref.)

Cell volume and the metabolic actions of insulin. Zhande R, et al. **Biochem Cell Biol** 1996;74(4):513-22 (79 ref.)

Binding and translocation of glucokinase in hepatocytes. Agius L, et al. **Biochem Soc Trans** 1997 Feb;25(1):145-50 (28 ref.)

Bridging the gap between glucose phosphorylation and glycogen synthesis in the liver. Guinovart JJ, et al. **Biochem Soc Trans** 1997 Feb;25(1):157-60 (21 ref.)

New insight into the regulation of liver glycogen metabolism by glucose. Stalmans W, et al. **Biochem Soc Trans** 1997 Feb;25(1):19-25 (35 ref.)

Metabolic regulation of hepatic gene expression. Towle HC, et al. **Biochem Soc Trans** 1996 May;24(2):364-8 (31 ref.)

The regulatory protein of glucokinase. van Schaftingen E, et al. **Biochem Soc Trans** 1997 Feb;25(1):136-40 (41 ref.)

Transcriptional regulation by glucose in the liver. Kahn A. **Biochimie** 1997 Feb-Mar;79(2-3):113-8 (8 ref.)

Hepatic iron deposition in human disease and animal models. Halliday JW, et al. **Biometals** 1996 Apr;9(2):205-9 (23 ref.)

Cytochrome P450 and its interactions with the heme biosynthetic pathway. De Matteis F, et al. **Can J Physiol Pharmacol** 1996 Jan;74(1):1-8 (59 ref.)

Gaseous monoxides: a new class of microvascular regulator in the liver. Suematsu M, et al. **Cardiovasc Res** 1996 Oct; 32(4):679-86 (60 ref.)

Extrahepatic complement biosynthesis: where, when and why? Morgan BP, et al. **Clin Exp Immunol** 1997 Jan; 107(1):1-7 (103 ref.)

Membrane transport as a determinant of the hepatic elimination of drugs and metabolites. Evans AM. **Clin Exp Pharmacol Physiol** 1996 Oct-Nov;23(10-11):970-4 (32 ref.)

Role of lipid synthesis, chaperone proteins and proteasomes in the assembly and secretion of apoprotein B-containing lipoproteins from cultured liver cells. Ginsberg HN. **Clin Exp Pharmacol Physiol** 1997 May;24(5):A29-32 (61 ref.)

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion. Huff MW, et al. **Curr Opin Lipidol** 1997 Jun;8(3):138-45 (74 ref.)

Fatty acid regulation of very low density lipoprotein production. Lewis GF. **Curr Opin Lipidol** 1997 Jun; 8(3):146-53 (59 ref.)

Erythropoietin production in liver and kidneys. Eckardt KU. **Curr Opin Nephrol Hypertens** 1996 Jan;5(1):28-34 (79 ref.)

Peripheral metabolism of parathyroid hormone. Studies with isolated perfused kidneys and livers from normal and uremic rats. Daugaard H. **Dan Med Bull** 1996 Jun; 43(3):203-15 (143 ref.)

In vivo studies of intrahepatic metabolic pathways. Beylot M, et al. **Diabetes Metab** 1997 Jun;23(3):251-7 (54 ref.)

Past, present, and future applications of precision-cut liver slices for in vitro xenobiotic metabolism. Ekins S. **Drug Metab Rev** 1996 Nov;28(4):591-623 (151 ref.)

Covalent binding of xenobiotics to specific proteins in the liver. Pumford NR, et al. **Drug Metab Rev** 1997 Feb-May; 29(1-2):39-57 (67 ref.)

Cholestatic properties and hepatic transport of steroid glucuronides. Vore M, et al. **Drug Metab Rev** 1997 Feb-May;29(1-2):183-203 (49 ref.)

Development of organic anion transport in the liver. Barth A, et al. **Exp Toxicol Pathol** 1996 Jul;48(5):421-32 (188 ref.)

Hepatic canalicular membrane 1: The role of mdr2 P-glycoprotein in hepatobiliary lipid transport. Elferink RP, et al. **FASEB J** 1997 Jan;11(1):19-28 (59 ref.)

Hepatic canalicular membrane. Introduction: transport across the hepatocyte canalicular membrane. Keppler D, et al. **FASEB J** 1997 Jan;11(1):15-8 (46 ref.)

Regulation of fibrinogen biosynthesis by cytokines, consequences on the vascular risk. Vasse M, et al. **Haemostasis** 1996 Oct;26 Suppl 4:331-9 (29 ref.)

Autophagic proteolysis: control and specificity. Blommaart EF, et al. **Histochem J** 1997 May;29(5):365-85 (187 ref.)

Hepatic disease, nutritional therapy, and the metabolic environment. Bauer JE. **J Am Vet Med Assoc** 1996 Dec 1;209(11):1850-4 (40 ref.)

Regulation of energy metabolism in liver. Soboll S. **J Bioenerg Biomembr** 1995 Dec;27(6):571-82 (92 ref.)

Current concepts of hepatic uptake, intracellular transport and biliary secretion of bile acids: physiological basis and pathophysiological changes in cholestatic liver dysfunction. Azer SA, et al. **J Gastroenterol Hepatol** 1996 Apr; 11(4):396-407 (154 ref.)

Contributions of the Brisbane Liver Group to knowledge of iron metabolism. Bothwell TH. **J Gastroenterol Hepatol** 1996 Nov;11(11):1025-7 (9 ref.)

Natural anticoagulants and the liver. Castelino DJ, et al. **J Gastroenterol Hepatol** 1997 Jan;12(1):77-83 (32 ref.)

Review article: new insights into the mechanisms of hepatic transport and bile secretion. Erlinger S. **J Gastroenterol Hepatol** 1996 Jun;11(6):575-9 (34 ref.)

How does copper get into bile? New insights into the mechanism(s) of hepatobiliary copper transport. Dijkstra M, et al. **J Hepatol** 1996;24 Suppl 1:109-20 (108 ref.)

Do intracellular organelles have any role in transport of bile acids by hepatocytes? Erlinger S. **J Hepatol** 1996;24 Suppl 1:88-93 (33 ref.)

Drug-induced cholestasis. Erlinger S. **J Hepatol** 1997;26 Suppl 1:1-4 (11 ref.)

Ion transport in hepatocytes: mechanisms and correlations to cell volume, hormone actions and metabolism. Graf J, et al. **J Hepatol** 1996;24 Suppl 1:53-77 (315 ref.)

Drug traffic in the hepatobiliary system. Groothuis GM, et al. **J Hepatol** 1996;24 Suppl 1:3-28 (252 ref.)

Hepatocellular transport systems: from carrier identification in membrane vesicles to cloned proteins. Meier PJ. **J Hepatol** 1996;24 Suppl 1:29-35 (65 ref.)

What we have learned about bumetanide and the concept of multispecific bile acid/drug transporters from the liver. Petzinger E, et al. **J Hepatol** 1996;24 Suppl 1:42-6 (33 ref.)

Molecular aspects of organic anion uptake in liver. Sottocasa GL, et al. **J Hepatol** 1996;24 Suppl 1:36-41 (24 ref.)

Effects of cholestasis on membrane flow and surface polarity

in hepatocytes. Stieger B, et al. **J Hepatol** 1996;24 Suppl 1:128–34 (80 ref.)
Regulation of intracellular pH in the hepatocyte. Mechanisms and physiological implications. Strazzabosco M, et al. **J Hepatol** 1996 May;24(5):631–44 (122 ref.)
Hepatobiliary elimination of certain peptide-mimicking drugs: linear hydrophobic and hydrophilic renin-inhibitors and hydrophobic cyclopeptides. Ziegler K, et al. **J Hepatol** 1996;24 Suppl 1:47–52 (22 ref.)
Secondary alterations of human hepatocellular peroxisomes. De Craemer D. **J Inherit Metab Dis** 1995;18 Suppl 1:181–213 (124 ref.)
Somatic gene therapy for phenylketonuria and other hepatic deficiencies. Eisensmith RC, et al. **J Inherit Metab Dis** 1996;19(4):412–23 (30 ref.)
Cytokines and the hepatic acute phase response. Moshage H. **J Pathol** 1997 Mar;181(3):257–66 (114 ref.)
Overview of enzymes of drug metabolism. Meyer UA. **J Pharmacokinet Biopharm** 1996 Oct;24(5):449–59 (21 ref.)
The human drug metabolizing cytochromes P450. Wrighton SA, et al. **J Pharmacokinet Biopharm** 1996 Oct;24(5):461–73 (17 ref.)
Sites of erythropoietin production. Maxwell PH, et al. **Kidney Int** 1997 Feb;51(2):393–401 (57 ref.)
Role of central neural mechanisms in the regulation of hepatic glucose metabolism. Nonogaki K, et al. **Life Sci** 1997; 60(11):797–807 (101 ref.)
Biogenesis of hepatic acute-phase response to trauma. Fouad FM, et al. **Med Hypotheses** 1996 Aug;47(2):157–77 (75 ref.)
Training enhanced hepatic gluconeogenesis: the importance for glucose homeostasis during exercise. Donovan CM, et al. **Med Sci Sports Exerc** 1997 May;29(5):628–34 (58 ref.)
Metabolism of methionine in liver disease. Mato JM, et al. **Methods Find Exp Clin Pharmacol** 1996;18 Suppl B:35–46 (87 ref.)
Intranuclear distribution, function and fate of glutathione and glutathione-S-conjugate in living rat hepatocytes studied by fluorescence microscopy. Bellomo G, et al. **Microsc Res Tech** 1997 Feb 15;36(4):243–52 (58 ref.)
Conjugation of glutathione with the reactive metabolites of 1, 1-dichloroethylene in murine lung and liver. Forkert PG. **Microsc Res Tech** 1997 Feb 15;36(4):234–42 (45 ref.)
Naked DNA transport and expression in mammalian cells. Wolff JA. **Neuromuscul Disord** 1997 Jul;7(5):314–8 (32 ref.)
The selection of suitable substrates for hepatic energy metabolism after massive hepatectomy [editorial] Jin MB, et al. **Nutrition** 1997 Apr;13(4):386–7 (6 ref.)
Influence of nutrition on liver oxidative metabolism. Jorquera F, et al. **Nutrition** 1996 Jun;12(6):442–7 (76 ref.)
Isolated perfused liver. Brouwer KL, et al. **Pharm Biotechnol** 1996;8:161–92 (140 ref.)
Cultured rat hepatocytes. LeCluyse EL, et al. **Pharm Biotechnol** 1996;8:121–59 (140 ref.)
Isolated hepatocytes. Vore M, et al. **Pharm Biotechnol** 1996; 8:115–20 (6 ref.)
Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Iwatsubo T, et al. **Pharmacol Ther** 1997;73(2):147–71 (84 ref.)
S-adenosylmethionine synthesis: molecular mechanisms and clinical implications. Mato JM, et al. **Pharmacol Ther** 1997; 73(3):265–80 (174 ref.)
Regulation of sulphation and glutathion conjugation of acetaminophen in isolated rat hepatocytes. Dalhoff K. **Pharmacol Toxicol** 1996;78 Suppl 1:1–24 (173 ref.)
Lipid absorption and hepatic metabolism in ruminants. Bauchart D, et al. **Proc Nutr Soc** 1996 Mar;55(1B):39–47 (38 ref.)
An energy sensor for control of energy intake. Friedman MI. **Proc Nutr Soc** 1997 Mar;56(1A):41–50 (51 ref.)
Liver protein and glutamine metabolism during cachexia. Hulsewé KW, et al. **Proc Nutr Soc** 1997 Jul;56(2):801–6 (23 ref.)
Regulation of hepatic nitrogen metabolism in ruminants. Lobley GE, et al. **Proc Nutr Soc** 1997 Jul;56(2):547–63 (57 ref.)
Cellular localization and hormonal regulation of biosynthesis of insulin-like growth factor binding proteins and of the acid-labile subunit within rat liver. Scharf JG, et al. **Prog Growth Factor Res** 1995;6(2-4):175–80 (23 ref.)
Dietary polyunsaturated fatty acid regulation of gene transcription. Jump DB, et al. **Prog Lipid Res** 1996 Sep; 35(3):227–41 (142 ref.)
Regulation of liver-specific gene expression. Chojkier M. **Prog Liver Dis** 1995;13:37–61 (155 ref.)
Hepatic lipoprotein metabolism: recent molecular insights. Cooper AD. **Prog Liver Dis** 1995;13:173–200 (173 ref.)
Regulation of lipid biosynthesis by the AMP-activated protein kinase and its role in the hepatocellular response to stress. Corton JM, et al. **Prog Liver Dis** 1996;14:69–99 (133 ref.)
Ethanol oxidizing enzymes: roles in alcohol metabolism and alcoholic liver disease. Crabb DW. **Prog Liver Dis** 1995; 13:151–72 (158 ref.)
Calcium signaling mechanisms in liver in health and disease. Nathanson MH, et al. **Prog Liver Dis** 1996;14:1–27 (184 ref.)
Regulation and function of the multidrug resistance genes in liver. Silverman JA, et al. **Prog Liver Dis** 1995;13:101–23 (160 ref.)
New methods for in vivo studies of hepatic metabolism. Beylot M, et al. **Reprod Nutr Dev** 1996;36(4):363–73 (51 ref.)
Regulation of VLDL synthesis and secretion in the liver. Gruffat D, et al. **Reprod Nutr Dev** 1996;36(4):375–89 (89 ref.)
Regulation of net hepatic glucose uptake: interaction of neural and pancreatic mechanisms. Moore MC, et al. **Reprod Nutr Dev** 1996;36(4):399–406 (30 ref.)
Novel pathways for elimination of cholesterol by extrahepatic formation of side-chain oxidized oxysterols. Diczfalusy U, et al. **Scand J Clin Lab Invest Suppl** 1996; 226:9–17 (18 ref.)
Characterization of membrane transport processes: lessons from the study of BSP, bilirubin, and fatty acid uptake. Berk PD, et al. **Semin Liver Dis** 1996 May;16(2):107–20 (69 ref.)
Hepatocellular transport and secretion of biliary phospholipids. Cohen DE. **Semin Liver Dis** 1996 May; 16(2):191–200 (68 ref.)
Plasma membrane and mitochondrial transport of hepatic reduced glutathione. Fernández-Checa JC, et al. **Semin Liver Dis** 1996 May;16(2):147–58 (44 ref.)
Sinusoidal (basolateral) bile salt uptake systems of hepatocytes. Hagenbuch B, et al. **Semin Liver Dis** 1996 May;16(2):129–36 (80 ref.)
Hepatocellular transport: role of ATP-binding cassette proteins. Lomri N, et al. **Semin Liver Dis** 1996 May; 16(2):201–10 (112 ref.)
Hepatic amino acid transport. Moseley RH. **Semin Liver Dis** 1996 May;16(2):137–45 (121 ref.)
Secretion of organic anions by hepatocytes: involvement of homologues of the multidrug resistance protein. Müller M, et al. **Semin Liver Dis** 1996 May;16(2):211–20 (137 ref.)
Hepatocellular sinusoidal membrane organic anion transport and transporters. Wolkoff AW. **Semin Liver Dis** 1996 May; 16(2):121–7 (43 ref.)
Intracellular transport of small hydrophobic compounds by the hepatocyte. Zucker SD, et al. **Semin Liver Dis** 1996 May;16(2):159–67 (84 ref.)
Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function. Panday VR, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 11):S11-34–S11-38 (37 ref.)
Mechanisms and (patho)physiological significance of biliary cholesterol secretion. Kuipers F, et al. **Subcell Biochem** 1997;28:295–318 (106 ref.)
Different regulation of thyroid hormone transport in liver and pituitary: its possible role in the maintenance of low T3 production during nonthyroidal illness and fasting in man. Everts ME, et al. **Thyroid** 1996 Aug;6(4):359–68 (79 ref.)
[Regulation of the expression of hepatic genes coding the enzymes of glycolysis and gluconeogenesis] Girard J. **Journ Annu Diabetol Hotel Dieu** 1996;:37–53 (91 ref.) **(Fre)**
[Circadian rhythms in hepatic biotransformation of drugs] Bélanger PM. **Pathol Biol (Paris)** 1996 Jun;44(6):564–70 (28 ref.) (Eng. Abstr.) **(Fre)**
[The diagnosis of liver diseases in the dog] Neumann S, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Oct; 103(10):422–8 (73 ref.) (Eng. Abstr.) **(Ger)**
[Nitrogen monoxide (NO) in the function of the gastrointestinal tract and the liver] Palatka K, et al. **Orv Hetil** 1997 Jun 15;138(24):1555–9 (51 ref.) (Eng. Abstr.) **(Hun)**
[Hepatic metabolism and transport of bilirubin and other organic anions] Adachi Y, et al. **Nippon Rinsho** 1996 Aug; 54(8):2276–90 (94 ref.) (Eng. Abstr.) **(Jpn)**
[The role of P-glycoprotein in the liver] Kusuhara H, et al. **Nippon Rinsho** 1997 May;55(5):1069–76 (22 ref.) (Eng. Abstr.) **(Jpn)**
[The role of genetically determined oxidation of drugs and xenobiotics in pathogenesis of neoplastic diseases] Niewiński P, et al. **Postepy Hig Med Dosw** 1996; 50(4):321–32 (55 ref.) (Eng. Abstr.) **(Pol)**
[Active forms of oxygen: cytotoxic effects and methodological approaches to laboratory control of liver lesions (literature review)] Matiushin BN, et al. **Klin Lab Diagn** 1996 Jul-Aug;(4):51–3 (17 ref.) (Eng. Abstr.) **(Rus)**
[Biochemical methods for the diagnosis of liver pathology] Titov VN. **Ter Arkh** 1993;65(2):85–9 (43 ref.) **(Rus)**

PARASITOLOGY

The malaria sporozoite's journey into the liver. Sinnis P. **Infect Agents Dis** 1996 Jun;5(3):182–9 (54 ref.)

PATHOLOGY

Liver imaging. Clinical applications and future perspectives. Rummeny EJ, et al. **Acta Radiol** 1997 Jul;38(4 Pt 2):626–30 (45 ref.)
Massive hepatic necrosis and death following repeated isoflurane exposure: case report and review of the literature. Gelven PL, et al. **Am J Forensic Med Pathol** 1996 Mar;17(1):61–4 (12 ref.)
Epithelioid hemangioendothelioma of the liver. A rare hepatic tumor. Läuffer JM, et al. **Cancer** 1996 Dec 1; 78(11):2318–27 (68 ref.)
Transjugular liver biopsy: a review of 77 biopsies using a spring-propelled cutting needle (biopsy gun). Gorriz E, et al. **Cardiovasc Intervent Radiol** 1996 Nov-Dec; 19(6):442–5 (15 ref.)
MRI of the liver. A pictorial essay. Shapiro RS, et al. **Clin Imaging** 1997 Jul-Aug;21(4):293–302 (34 ref.)
Hepatocellular injury in hepatitis B and C virus infections. Feitelson MA. **Clin Lab Med** 1996 Jun;16(2):307–24 (110 ref.)
Liver MRI with contrast enhancement. Runge VM. **Crit Rev Diagn Imaging** 1997 Jun;38(3):207–30 (29 ref.)
Nodular hematopoiesis of the liver diagnosed by fine-needle aspiration cytology. Lemos LB, et al. **Diagn Cytopathol** 1997 Jan;16(1):51–4 (40 ref.)
Ancillary studies in FNA of liver and pancreas. Silverman JF, et al. **Diagn Cytopathol** 1995 Dec;13(5):396–410 (151 ref.)
Acute liver failure due to hepatic involvement by hematologic malignancy. Shehab TM, et al. **Dig Dis Sci** 1997 Jul;42(7):1400–5 (28 ref.)
Contrast agents for MR imaging of the liver: a clinical overview. Mahfouz AE, et al. **Eur Radiol** 1997;7(4):507–13 (27 ref.)
Hepatotoxicity of herbal remedies: insights into the intricacies of plant-animal warfare and cell death [editorial; comment] Kaplowitz N. **Gastroenterology** 1997 Oct;113(4):1408–12 (19 ref.) Comment on: Gastroenterology 1997 Oct;113(4):1334–46.
The role of granulomatous phlebitis and thrombosis in the pathogenesis of cirrhosis and portal hypertension in sarcoidosis. Moreno-Merlo F, et al. **Hepatology** 1997 Sep; 26(3):554–60 (29 ref.)
The role of liver biopsy in hepatitis C. Perrillo RP. **Hepatology** 1997 Sep;26(3 Suppl 1):57S–61S (36 ref.)
Chronic hepatitis: what is activity and how should it be assessed? Scheuer PJ. **Histopathology** 1997 Feb;30(2):103–5 (19 ref.)
Inflammatory pseudotumour of the liver with malignant transformation. Report of two cases. Zavaglia C, et al. **Ital J Gastroenterol** 1996 Apr;28(3):152–9 (43 ref.)
Liver apoptosis. Feldmann G. **J Hepatol** 1997;26 Suppl 2:1–11 (117 ref.)
Various approaches to obtaining liver tissue--choosing the biopsy technique. Lebrec D. **J Hepatol** 1996;25 Suppl 1:20–4 (21 ref.)
Mechanisms of neutrophil-induced parenchymal cell injury. Jaeschke H, et al. **J Leukoc Biol** 1997 Jun;61(6):647–53 (93 ref.)
Outpatient liver biopsy in children: a medical position statement of the North American Society for Pediatric Gastroenterology and Nutrition. Fox VL, et al. **J Pediatr Gastroenterol Nutr** 1996 Oct;23(3):213–6 (20 ref.)
Imaging of pediatric liver tumors. Buetow PC, et al. **Magn Reson Imaging Clin N Am** 1997 May;5(2):397–413 (50 ref.)
MR imaging of the liver. Primary malignant neoplasms in the adult. Buetow PC, et al. **Magn Reson Imaging Clin N Am** 1997 May;5(2):289–318 (55 ref.)
Hepatic metastases. Lewis KH, et al. **Magn Reson Imaging Clin N Am** 1997 May;5(2):319–30 (54 ref.)
MR imaging of the liver. Contrast agents. Mahfouz AE, et al. **Magn Reson Imaging Clin N Am** 1997 May;5(2):223–40 (28 ref.)
Benign liver tumors. Mathieu D, et al. **Magn Reson Imaging Clin N Am** 1997 May;5(2):255–88 (71 ref.)
MR imaging of inflammatory disease of the liver. Mergo PJ, et al. **Magn Reson Imaging Clin N Am** 1997 May; 5(2):367–76 (41 ref.)
MR imaging of the liver. Cirrhosis and premalignant nodules. Ohtomo K. **Magn Reson Imaging Clin N Am** 1997 May; 5(2):331–46 (38 ref.)
MR imaging of the liver—a practical approach. Paley MR, et al. **Magn Reson Imaging Clin N Am** 1997 May; 5(2):415–29 (34 ref.)
Hepatic hemangiomas. Semelka RC, et al. **Magn Reson Imaging Clin N Am** 1997 May;5(2):241–53 (27 ref.)
MR imaging of the liver in children. Siegel MJ, et al. **Magn Reson Imaging Clin N Am** 1996 Nov;4(4):637–56 (50 ref.)
MR imaging of diffuse liver disease. Hepatic fat and iron. Siegelman ES. **Magn Reson Imaging Clin N Am** 1997 May; 5(2):347–65 (104 ref.)
MR imaging of the liver. Technique. Soyer P, et al. **Magn Reson Imaging Clin N Am** 1997 May;5(2):205–21 (78 ref.)
Vascular diseases and MR angiography of the liver. Spritzer CE. **Magn Reson Imaging Clin N Am** 1997 May;5(2):377–96 (66 ref.)
Liver. Ferrell LD, et al. **Pathology (Phila)** 1996;3(2):367–78 (36 ref.)
Fine-needle aspiration biopsy of the liver: diagnostic problems. Ljung BM, et al. **Pathology (Phila)** 1996; 4(2):365–88 (31 ref.)
Focal nodular hyperplasia of the liver: radiologic-pathologic correlation [published erratum appears in Radiographics 1997 Mar-Apr;17(2):524] Buetow PC, et al. **Radiographics** 1996 Mar;16(2):369–88 (40 ref.)
Fine-needle aspiration of the liver and pancreas: a cytology primer for radiologists. Dodd LG, et al. **Radiology** 1997 Apr;203(1):1–9 (58 ref.)
Reduction of liver mass due to malnutrition in rats. Correlation with emaciation of animals and size of organs not inserted in the portal system. Miguel Parra O, et al.

Rev Paul Med 1995 May-Jun;113(3):903-9 (53 ref.)
Nodular regenerative hyperplasia of the liver in systemic lupus erythematosus. The relationship with anticardiolipin antibody and lupus anticoagulant. Sekiya M, et al. **Scand J Rheumatol** 1997;26(3):215-7 (13 ref.)
Liver biopsy--past, present and future. Chuah SY. **Singapore Med J** 1996 Feb;37(1):86-90 (69 ref.)
Histopathology and detection of hepatitis C virus in liver. Scheuer PJ, et al. **Springer Semin Immunopathol** 1997; 19(1):27-45 (119 ref.)
Use of precision-cut liver slices as an in vitro tool for evaluating liver function. Gandolfi AJ, et al. **Toxicol Pathol** 1996 Jan-Feb;24(1):58-61 (37 ref.)
Importance of and approaches to quantification of hepatocyte apoptosis. Goldsworthy TL, et al. **Toxicol Pathol** 1996 Jan-Feb;24(1):24-35 (47 ref.)
The use of immunohistochemistry for evaluating the liver. Hall WC, et al. **Toxicol Pathol** 1996 Jan-Feb;24(1):4-12 (107 ref.)
Polymerase chain reaction and in situ hybridization: applications in toxicological pathology. Malarkey DE, et al. **Toxicol Pathol** 1996 Jan-Feb;24(1):13-23 (109 ref.)
Quantitation of multistage carcinogenesis in rat liver. Pitot HC, et al. **Toxicol Pathol** 1996 Jan-Feb;24(1):119-28 (56 ref.)
Biliary proliferation and adaptation in furan-induced rat liver injury and carcinogenesis. Sirica AE. **Toxicol Pathol** 1996 Jan-Feb;24(1):90-9 (52 ref.)
Bile acids in the assessment of hepatocellular function. Thompson MB. **Toxicol Pathol** 1996 Jan-Feb;24(1):62-71 (138 ref.)
The hepatic stellate (Ito) cell: its role in human liver disease. Hautekeete ML, et al. **Virchows Arch** 1997 Mar; 430(3):195-207 (125 ref.)
[Percutaneous puncture in hepatic echinococcosis] Stoianov G, et al. **Khirurgiia (Sofiia)** 1996;49(5):26-8 (9 ref.) (Eng. Abstr.) **(Bul)**
[Progresses in pathology in China, 1996] Fang W. **Chung Hua I Hsueh Tsa Chih** 1996 Dec;76(12):944-5 (0 ref.) **(Chi)**
[Role of guided fine needle punction in the diagnosis of deep-seated Aids-related infections. Report of a case of hepato-nodal histoplasmosis] Longchampt E, et al. **Ann Pathol** 1996 Sep;16(4):266-70 (12 ref.) (Eng. Abstr.) **(Fre)**
[Nodular regenerative hyperplasia associated with primary antiphospholipid syndrome] Cadranel JF, et al. **Gastroenterol Clin Biol** 1996;20(10):901-4 (44 ref.) (Eng. Abstr.) **(Fre)**
[Should hepatitis C be treated? Value of hepatic biopsy in the management of patients with chronic hepatitis C virus infection?] Deugnier Y. **Gastroenterol Clin Biol** 1997;21(1 Pt 2):S51-6 (41 ref.) **(Fre)**
[Fulminant or sub-fulminant hepatocellular failure caused by metastatic invasiveness of the liver: an other cause of hypoxic hepatitis?] Henrion J, et al. **Gastroenterol Clin Biol** 1996;20(6-7):535-43 (38 ref.) (Eng. Abstr.) **(Fre)**
[Focal nodular hyperplasia and spontaneous intrahepatic porto-portal communication] Mignon F, et al. **J Radiol** 1996 Dec;77(12):1233-6 (22 ref.) (Eng. Abstr.) **(Fre)**
[Consequences of cholestasis from the pathologist's viewpoint] Zimmermann A. **Schweiz Med Wochenschr** 1997 May 10;127(19):812-20 (38 ref.) (Eng. Abstr.) **(Ger)**
[The role of the pathologist in the diagnosis and monitoring of Wilson's disease] Faa G. **Pathologica** 1996 Apr; 88(2):102-10 (31 ref.) (Eng. Abstr.) **(Ita)**
[Infantile hepatic hemangioendothelioma of the liver: report of 11 cases] Presedo A, et al. **Cir Pediatr** 1996 Apr;9(2):51-4 (11 ref.) (Eng. Abstr.) **(Spa)**
[Idiopathic portal hypertension, multiple focal nodular hepatic hyperplasia, the CREST syndrome and protein S deficiency] Sánchez Manuel J, et al. **Rev Esp Enferm Dig** 1997 Jan;89(1):55-9 (30 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Thymus influences liver functions through hypothalamus-pituitary-gonad axis in rats. Li L, et al. **Adv Neuroimmunol** 1996;6(3):289-93 (19 ref.)
Cellular adhesion molecules: regulation and functional significance in the pathogenesis of liver diseases. Jaeschke H. **Am J Physiol** 1997 Sep;273(3 Pt 1):G602-11 (131 ref.)
Molecular aspects of hepatobiliary transport. Müller M, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):G1285-303 (241 ref.)
Gene transfer and disruption strategies to elucidate hepatic lipoprotein receptor functions. Herz J, et al. **Atherosclerosis** 1995 Dec;118 Suppl:S37-41 (15 ref.)
Regulation of lipogenic enzyme expression by glucose in liver and adipose tissue: is glucose 6-phosphate the signalling metabolite? Foufelle F, et al. **Biochem Soc Trans** 1996 May; 24(2):372-8 (43 ref.)
Polarised membrane traffic in hepatocytes. Wilton JC, et al. **Bioessays** 1996 Mar;18(3):229-36 (67 ref.)
Role of transcription factors in the age-dependent regulation of the androgen receptor gene in rat liver. Supakar PC, et al. **Biol Signals** 1996 May-Jun;5(3):170-9 (37 ref.)
Liver endothelial cells: participation in host response to lymphoma metastasis. Umansky V, et al. **Cancer Metastasis Rev** 1996 Jun;15(2):273-9 (54 ref.)
Artificial liver support. Sussman NL, et al. **Clin Invest Med** 1996 Oct;19(5):393-9 (36 ref.)
Cell volume signalling, osmolytes and liver function. Häussinger D, et al. **Digestion** 1997;58 Suppl 1:21-3 (17 ref.)
Ectonucleotidases, purine nucleoside transporter, and function of the bile canalicular plasma membrane of the hepatocyte. Che M, et al. **FASEB J** 1997 Feb;11(2):101-8 (86 ref.)
Gene therapy for atherosclerosis. Rader DJ. **Int J Clin Lab Res** 1997;27(1):35-43 (85 ref.)
Multiple hepatic functions of endothelin-1: physiopathological relevance. Mallat A, et al. **J Hepatol** 1996 Sep;25(3):405-13 (79 ref.)
Plasma cAMP: a hepatorenal link influencing proximal reabsorption and renal hemodynamics? Bankir L, et al. **Kidney Int Suppl** 1997 Jun;59:S50-6 (60 ref.)
Innervation of the liver: morphology and function. Tiniakos DG, et al. **Liver** 1996 Jun;16(3):151-60 (125 ref.)
Artificial liver support: the pipe dream of today should be the reality of the near future. Fouad FM, et al. **Med Hypotheses** 1996 Aug;47(2):145-55 (42 ref.)
The nerves, the liver, and the route of feeding: an integrated response to nutrient delivery [editorial] Moore MC, et al. **Nutrition** 1996 Apr;12(4):282-4 (25 ref.)
An energy sensor for control of energy intake. Friedman MI. **Proc Nutr Soc** 1997 Mar;56(1A):41-50 (51 ref.)
Control of vesicle traffic in hepatocytes. Ihrke G, et al. **Prog Liver Dis** 1995;13:63-99 (239 ref.)
Nitric oxide, hepatocytes and inflammation. Nussler AK, et al. **Res Immunol** 1995 Nov-Dec;146(9):671-77 (62 ref.)
Use of precision-cut liver slices as an in vitro tool for evaluating liver function. Gandolfi AJ, et al. **Toxicol Pathol** 1996 Jan-Feb;24(1):58-61 (37 ref.)
Structure and function of sinusoidal lining cells in the liver. Wisse E, et al. **Toxicol Pathol** 1996 Jan-Feb;24(1):100-11 (111 ref.)
[Role of the liver as a glucose sensor in the integrated response to hypoglycemia] Hamilton-Wessler M, et al. **Journ Annu Diabetol Hotel Dieu** 1996;:19-35 (44 ref.) **(Fre)**
[Role of the liver in the regulation of glucose metabolism in diabetes and chronic liver disease] Cotrozzi G, et al. **Ann Ital Med Int** 1997 Apr-Jun;12(2):84-91 (86 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Hepatic dysfunction in two sibs with Alström syndrome: case report and review of the literature. Awazu M, et al. **Am J Med Genet** 1997 Mar 3;69(1):13-6 (6 ref.)
Mechanism of hepatocellular dysfunction during hyperdynamic sepsis. Wang P, et al. **Am J Physiol** 1996 May;270(5 Pt 2):R927-38 (126 ref.)
Assessment of liver function: pre- and peritransplant evaluation. Shaked A, et al. **Clin Chem** 1997 Aug;43(8 Pt 2):1539-45 (53 ref.)
Hepatic circulation and toxicology. Lautt WW, et al. **Drug Metab Rev** 1997 Feb-May;29(1-2):369-95 (117 ref.)
Molecular pathogenesis of liver disease in alpha1-antitrypsin deficiency. Teckman JH, et al. **Hepatology** 1996 Dec; 24(6):1504-16 (142 ref.)
Multiple hepatic functions of endothelin-1: physiopathological relevance. Mallat A, et al. **J Hepatol** 1996 Sep;25(3):405-13 (79 ref.)

RADIOGRAPHY

Liver imaging. Clinical applications and future perspectives. Rummeny EJ, et al. **Acta Radiol** 1997 Jul;38(4 Pt 2):626-30 (45 ref.)
Helical/spiral computed body tomography. Brink JA, et al. **Clin Radiol** 1997 Jul;52(7):489-503 (102 ref.)
[Parameters influencing hepatic parenchyma enhancement in x-ray computed tomography after intravenous injection of iodinated contrast medium] Bonaldi VM, et al. **J Radiol** 1997 Apr;78(4):265-70 (39 ref.) (Eng. Abstr.) **(Fre)**
[Evaluation of hepatic hemodynamics on CT] Yoshie K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:169-72 (13 ref.) **(Jpn)**

SECRETION

Regulation of hepatic apolipoprotein-B-containing lipoprotein secretion. Pease RJ, et al. **Curr Opin Lipidol** 1996 Jun;7(3):132-8 (51 ref.)
Role of cholesterol in regulating apolipoprotein B secretion by the liver. Thompson GR, et al. **J Lipid Res** 1996 Mar; 37(3):439-47 (64 ref.)
Role of vesicle-mediated transport pathways in hepatocellular bile secretion. Crawford JM. **Semin Liver Dis** 1996 May;16(2):169-89 (252 ref.)
[Immunosuppressive substances induced by liver grafting] Kobayashi E. **Tanpakushitsu Kakusan Koso** 1997 Jul; 42(9):1420-6 (40 ref.) **(Jpn)**

SURGERY

Complete resection of the caudate lobe of the liver: technique and results. Bartlett D, et al. **Br J Surg** 1996 Aug; 83(8):1076-81 (24 ref.)
Terminology of liver anatomy and liver resections: coming to grips with hepatic Babel. Strasberg SM. **J Am Coll Surg** 1997 Apr;184(4):413-34 (26 ref.)
Stapler technique for extrahepatic vascular control during hepatic resection. Scudamore CH, et al. **J Invest Surg** 1997 Jan-Apr;10(1-2):59-61 (7 ref.)
Liver. Ferrell LD, et al. **Pathology (Phila)** 1996;3(2):367-78 (36 ref.)
Laparoscopic hepatobiliary surgery. Strasberg SM, et al. **Prog Liver Dis** 1995;13:349-80 (131 ref.)

ULTRASONOGRAPHY

Finite amplitude distortion and its relationship to linear derating formulae for diagnostic ultrasound systems. Christopher T, et al. **Ultrasound Med Biol** 1996; 22(8):1103-16 (36 ref.)
[Color Doppler sonography of the liver] Konno K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:165-8 (0 ref.) **(Jpn)**

ULTRASTRUCTURE

Biochemistry below 0 degrees C: nature's frozen vertebrates. Storey KB, et al. **Braz J Med Biol Res** 1996 Mar; 29(3):283-307 (92 ref.)
Secondary alterations of human hepatocellular peroxisomes. De Craemer D. **J Inherit Metab Dis** 1995;18 Suppl 1:181-213 (124 ref.)
Control of vesicle traffic in hepatocytes. Ihrke G, et al. **Prog Liver Dis** 1995;13:63-99 (239 ref.)
[Characteristics features of the ultrastructure of liver cells in various morphological types of animals and their significance] Kalashnikova MM. **Biull Eksp Biol Med** 1996 Jun;121(6):604-9 (27 ref.) **(Rus)**

VIROLOGY

Hepatotropic viruses seen by clinicians. Zielińska W, et al. **Arch Immunol Ther Exp (Warsz)** 1996;44(5-6):291-6 (27 ref.)
In situ detection of hepatitis C virus--a critical appraisal. Lau JY, et al. **J Hepatol** 1996;24(2 Suppl):43-51 (35 ref.)
Organ and species specificity of hepatitis B virus (HBV) infection: a review of literature with a special reference to preferential attachment of HBV to human hepatocytes. De Meyer S, et al. **J Viral Hepat** 1997 May;4(3):145-53 (93 ref.)
Relationship between hepatocyte proliferation and hepatitis delta virus replication in neoplastic and non-neoplastic liver tissues. Negro F, et al. **J Viral Hepat** 1997 Mar; 4(2):93-8 (26 ref.)
In vivo transfection of rat liver with hepatitis C virus cDNA using cationic liposome-mediated gene delivery. Hayashi N, et al. **Princess Takamatsu Symp** 1995;25:143-9 (22 ref.)
Histopathology and detection of hepatitis C virus in liver. Scheuer PJ, et al. **Springer Semin Immunopathol** 1997; 19(1):27-45 (119 ref.)

LIVER ABSCESS

DIAGNOSIS

MR imaging of inflammatory disease of the liver. Mergo PJ, et al. **Magn Reson Imaging Clin N Am** 1997 May; 5(2):367-76 (41 ref.)

MICROBIOLOGY

Hepatosplenic abscesses due to Brucella melitensis: report of a case involving a child and review of the literature. Vallejo JG, et al. **Clin Infect Dis** 1996 Mar;22(3):485-9 (22 ref.)
[A case of liver abscess caused by Streptococcus milleri] Nagata S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Apr;94(4):290-4 (10 ref.) **(Jpn)**

RADIONUCLIDE IMAGING

The rim sign in hepatic abscess: case report and review of the literature. McDonald KL, et al. **J Nucl Med** 1997 Aug; 38(8):1282-3 (7 ref.)

VETERINARY

Minimum inhibitory concentrations for selected antimicrobial agents against Fusobacterium necrophorum isolated from hepatic abscesses in cattle and sheep. Mateos E, et al. **J Vet Pharmacol Ther** 1997 Feb;20(1):21-3 (24 ref.)

LIVER ABSCESS, AMEBIC

DIAGNOSIS

Amebic liver abscess. Fujihara T, et al. **J Gastroenterol** 1996 Oct;31(5):659-63 (28 ref.)
[Multiple amebic liver abscess] Honein K, et al. **J Med Liban** 1996;44(1):44-7 (17 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Amebic liver abscess. Fujihara T, et al. **J Gastroenterol** 1996 Oct;31(5):659-63 (28 ref.)

EPIDEMIOLOGY

[Amebiasis and amebic liver abscess in Mexico: a present-day public health problem] Escandón Romero C, et al. **Rev Gastroenterol Mex** 1996 Oct-Dec;61(4):378-86 (18 ref.) (Eng. Abstr.) **(Spa)**

LIVER, ARTIFICIAL

Cell-based therapy of acute liver failure: the extracorporeal bioartificial liver. Frémond B, et al. **Cell Biol Toxicol** 1996 Dec;12(4–6):325–9 (20 ref.)

Importance of the kinetic characterization of liver cell metabolic reactions to the design of hybrid liver support devices. Catapano G, et al. **Int J Artif Organs** 1996 Nov; 19(11):670–6 (19 ref.)

Support of acute liver failure patients with a bioartificial liver. Watanabe FD, et al. **J Clin Apheresis** 1996;11(3):138–42 (15 ref.)

Artificial liver support: the pipe dream of today should be the reality of the near future. Fouad FM, et al. **Med Hypotheses** 1996 Aug;47(2):145–55 (42 ref.)

Artificial liver support: state of the art. Dixit V, et al. **Scand J Gastroenterol Suppl** 1996;220:101–14 (76 ref.)

Use of bioartificial and artificial liver support devices. Hughes RD, et al. **Semin Liver Dis** 1996 Nov;16(4):435–44 (61 ref.)

Bioartificial livers: the state of the art [see comments] Anand AC. **Trop Gastroenterol** 1995 Oct–Dec;17(4):202–11 (106 ref.) Comment in: Trop Gastroenterol 1996 Oct–Dec;17(4):197–8.

[Use of extracorporeal hybrid (natural–artificial) liver in the treatment of patients with fulminant hepatitis] Bojić I. **Vojnosanit Pregl** 1996 Mar–Apr;53(2):133–6 (42 ref.) **(Scr)**

ADVERSE EFFECTS

Consideration of potential immunological problems in the application of xenogenic hybrid liver support. Bornemann R, et al. **Int J Artif Organs** 1996 Nov;19(11):655–63 (54 ref.)

STANDARDS

Development of a hybrid liver support system: a review. Gerlach JC. **Int J Artif Organs** 1996 Nov;19(11):645–54 (54 ref.)

TRENDS

[Is "terminal" liver damage reversible? Value, practicality and future of bridging techniques for the liver] Gubernatis G, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996; 113:380–8 (22 ref.) **(Ger)**

LIVER CELL ADHESION MOLECULES see **CADHERINS**

LIVER CIRCULATION

see related
ENTEROHEPATIC CIRCULATION
PORTAL SYSTEM

Blood flow and liver imaging. Itai Y, et al. **Radiology** 1997 Feb;202(2):306–14 (80 ref.)

[Surgical stress and organ dysfunction: liver] Nakatani T, et al. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):752–8 (47 ref.) (Eng. Abstr.) **(Jpn)**

[Color Doppler sonography of the liver] Konno K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:165–8 (0 ref.) **(Jpn)**

[Estimation of portal flow by MR angiography] Machida K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:173–6 (9 ref.) **(Jpn)**

[Evaluation of hepatic hemodynamics on CT] Yoshie K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:169–72 (13 ref.) **(Jpn)**

[Doppler ultrasound of blood flow in the hepatic veins] Andersen K. **Tidsskr Nor Laegeforen** 1997 Apr 10; 117(9):1296–8 (32 ref.) (Eng. Abstr.) **(Nor)**

[Hepatoportal hemodynamics in liver cirrhosis with the portal hypertension syndrome] Bulanov KI. **Lik Sprava** 1996 Jan–Feb;(1–2):32–5 (40 ref.) **(Rus)**

PHYSIOLOGY

Gaseous monoxides: a new class of microvascular regulator in the liver. Suematsu M, et al. **Cardiovasc Res** 1996 Oct; 32(4):679–86 (60 ref.)

Hepatic circulation and toxicology. Lautt WW, et al. **Drug Metab Rev** 1997 Feb–May;29(1–2):369–95 (117 ref.)

LIVER CIRRHOSIS

Patients with geleophysic dysplasia are not always geleophysic. Santolaya JM, et al. **Am J Med Genet** 1997 Oct 3;72(1):85–90 (12 ref.)

Hepatic fibrogenesis. Davis BH, et al. **Clin Lab Med** 1996 Jun;16(2):361–75 (68 ref.)

The assessment of body composition in patients with cirrhosis. Morgan MY, et al. **Eur J Nucl Med** 1996 Feb; 23(2):213–25 (90 ref.)

[Liver fibrosis] Taba Shiwa S, et al. **Rev Gastroenterol Mex** 1996 Jul–Sep;61(3):263–71 (104 ref.) **(Spa)**

BLOOD

Aquaretic agents: a new potential treatment of dilutional hyponatremia in cirrhosis. Ginès P, et al. **J Hepatol** 1996 Apr;24(4):506–12 (69 ref.)

Plasma cholecystokinin and its precursors in hepatic cirrhosis. Paloheimo LI, et al. **J Hepatol** 1997 Aug;27(2):299–305 (36 ref.)

COMPLICATIONS

Esophageal motility abnormalities in cirrhotic patients before and after endoscopic variceal treatment. Fass R, et al. **Am J Gastroenterol** 1997 Jun;92(6):941–6 (53 ref.)

A rare intrahepatic portacaval tubular shunt in a patient with spastic paraparesis. Ardic S, et al. **Australas Radiol** 1997 May;41(2):181–4 (17 ref.)

Cirrhosis and pregnancy. A case report and review of the literature. Restaino A, et al. **Clin Exp Obstet Gynecol** 1996; 23(4):240–7 (24 ref.)

Treatment of hepatic encephalopathy in patients with cirrhosis of the liver. Ferenci P. **Dig Dis** 1996;14 Suppl 1:40–52 (58 ref.)

Medical prophylaxis of haemorrhage from oesophageal varices in patients with liver cirrhosis. Gross M, et al. **Eur J Gastroenterol Hepatol** 1997 Jun;9(6):603–12 (95 ref.)

Prophylactic endoscopic sclerotherapy in patients with liver cirrhosis, portal hypertension, and esophageal varices. Paquet KJ, et al. **Hepatogastroenterology** 1997 May–Jun; 44(15):625–36 (54 ref.)

[Spontaneous ascites infections] Lata J. **Vnitr Lek** 1996 Nov; 42(11):789–91 (20 ref.) (Eng. Abstr.) **(Cze)**

[Bacterial infections in patients with cirrhosis] Le Dinh T, et al. **Ann Med Interne (Paris)** 1996;147(6):413–31 (172 ref.) **(Fre)**

[What vasoactive agent should be chosen in rupture of esophageal varices in cirrhosis? (editorial)] de Parades V, et al. **Presse Med** 1997 Jul 12;26(24):1146–8 (35 ref.) (Eng. Abstr.) **(Fre)**

[Prevention and therapy of complications of liver cirrhosis: ascites, encephalopathy and malnutrition] Köllinger M, et al. **Med Klin** 1996 Feb 15;91(2):89–102 (143 ref.) **(Ger)**

[Association of pulmonary and portal hypertension] Arcangeli C, et al. **Minerva Cardioangiol** 1996 Jul–Aug; 44(7–8):343–52 (55 ref.) (Eng. Abstr.) **(Ita)**

[The superior vena cava occlusion syndrome. A case of neoplastic thrombosis due to hepatocarcinoma and cirrhosis] Zanetti PP, et al. **Minerva Chir** 1997 Apr; 52(4):455–9 (20 ref.) (Eng. Abstr.) **(Ita)**

[Liver cirrhosis and jaundice] Arakawa Y, et al. **Nippon Naika Gakkai Zasshi** 1997 Apr 10;86(4):551–6 (5 ref.) **(Jpn)**

[Cardio–circulatory abnormalities in patients with liver cirrhosis] Tabuchi H. **Ryoikibetsu Shokogun Shirizu** 1996; (15):411–4 (17 ref.) **(Jpn)**

[Risk factors for the occurrence of hemorrhage from varicose dilated esophageal veins in liver cirrhosis] Bulanov KI. **Klin Khir** 1996;(9):35–7 (30 ref.) **(Rus)**

[Hepatocellular cancer with a background of liver cirrhosis] Zhuravlev VA, et al. **Klin Med (Mosk)** 1996;74(2):2–5 (53 ref.) **(Rus)**

CONGENITAL

[A case of congenital hepatic fibrosis successfully performed by esophageal transection for esophago–gastric varices] Ogawa A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 May;94(5):356–60 (12 ref.) **(Jpn)**

DIAGNOSIS

ICG clearance in assessing cirrhotic patients with hepatocellular carcinoma for major hepatic resection. Kitano S, et al. **HPB Surg** 1997;10(3):182–3 (9 ref.)

Gastric antral vascular ectasia causing severe anemia. Toyota M, et al. **J Gastroenterol** 1996 Oct;31(5):710–3 (22 ref.)

MR imaging of the liver. Cirrhosis and premalignant nodules. Ohtomo K. **Magn Reson Imaging Clin N Am** 1997 May; 5(2):331–46 (38 ref.)

Imaging of hepatic cirrhosis. Brown JJ, et al. **Radiology** 1997 Jan;202(1):1–16 (142 ref.)

Spontaneous group B streptococcal meningitis in a patient with cirrhosis. Tung BY, et al. **West J Med** 1996 Oct; 165(4):229–30 (13 ref.)

DRUG THERAPY

Drug administration in chronic liver disease. Westphal JF, et al. **Drug Saf** 1997 Jul;17(1):47–73 (225 ref.)

Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Windmeier C, et al. **Gen Pharmacol** 1997 Aug;29(2):181–96 (195 ref.)

Interferon treatment of chronic hepatitis C with cirrhosis. Cooksley WG. **J Viral Hepat** 1997;4 Suppl 1:85–8 (15 ref.)

Interferon treatment of cirrhotic patients with chronic hepatitis C. Idilman R, et al. **J Viral Hepat** 1997 Mar; 4(2):81–91 (75 ref.)

[Anti-fibrotic effects of interferons. Mechanisms of action and therapeutic prospects] Pilette C, et al. **Gastroenterol Clin Biol** 1997;21(6–7):466–71 (40 ref.) **(Fre)**

[Aquaretic agents] Bosch–Marcé M, et al. **Gastroenterol Hepatol** 1996 Nov;19(9):472–7 (55 ref.) **(Spa)**

ETIOLOGY

Protein–calorie malnutrition and the etiology of cirrhosis [editorial; comment] McCullough AJ, et al. **Am J Gastroenterol** 1997 May;92(5):734–8 (77 ref.) Comment on: Am J Gastroenterol 1997 May;92(5):777–83.

Pathogenesis of liver fibrosis [editorial] Alcolado R, et al. **Clin Sci (Colch)** 1997 Feb;92(2):103–12 (121 ref.)

Pathogenesis of liver fibrogenesis. Strobel D, et al. **Digestion** 1997;58 Suppl 1:37–8 (3 ref.)

Copper tubings, home wells and early childhood cirrhosis. Mühlendahl KE. **Eur J Pediatr** 1996 Dec;155(12):1061–2 (21 ref.)

Tissue inhibitors of metalloproteinases in liver fibrosis. Iredale JP. **Int J Biochem Cell Biol** 1997 Jan;29(1):43–54 (108 ref.)

Iron overload and liver fibrosis. Arthur MJ. **J Gastroenterol Hepatol** 1996 Dec;11(12):1124–9 (67 ref.)

Cytokine regulation of schistosome–induced granuloma and fibrosis. Wahl SM, et al. **Kidney Int** 1997 May;51(5):1370–5 (62 ref.)

HBV and HCV chronic hepatitis and cirrhosis. Piccinino F, et al. **Res Virol** 1997 Mar–Apr;148(2):135–8 (29 ref.)

[The vascular bed of the liver in cirrhoses: pathogenesis and morphogenesis] Koshkin AB. **Lik Sprava** 1996 Mar–Apr; (3–4):6–9 (22 ref.) **(Rus)**

METABOLISM

Collagen breakdown products as markers of fibrosis and cirrhosis. Niemelä O. **Alcohol Alcohol Suppl** 1994;2:345–52 (85 ref.)

Regulation of urea synthesis by diet protein and carbohydrate in normal man and in patients with cirrhosis. Relationship to glucagon and insulin. Hamberg O. **Dan Med Bull** 1997 Jun;44(3):225–41 (220 ref.)

Energy and protein requirements of patients with chronic liver disease. Kondrup J, et al. **J Hepatol** 1997 Jul; 27(1):239–47 (74 ref.)

Pathogenesis of water and sodium retention in cirrhosis. Martin PY, et al. **Kidney Int Suppl** 1997 Jun;59:S43–9 (66 ref.)

Carnitine metabolism in chronic liver disease. Krähenbühl S. **Life Sci** 1996;59(19):1579–99 (137 ref.)

MORTALITY

Hepatic venous pressure measurement: an old test as a new prognostic marker in cirrhosis? Armonis A, et al. **Hepatology** 1997 Jan;25(1):245–8 (52 ref.)

Nutrition status predicts survival in cirrhosis. Kalman DR, et al. **Nutr Rev** 1996 Jul;54(7):217–9 (14 ref.)

PATHOLOGY

The role of granulomatous phlebitis and thrombosis in the pathogenesis of cirrhosis and portal hypertension in sarcoidosis. Moreno–Merlo F, et al. **Hepatology** 1997 Sep; 26(3):554–60 (29 ref.)

Molecular mechanisms of hepatic fibrosis and principles of therapy. Friedman SL. **J Gastroenterol** 1997 Jun; 32(3):424–30 (37 ref.)

PHYSIOPATHOLOGY

Review article: renal circulatory changes in cirrhosis--pathogenesis and therapeutic prospects. Forrest EH, et al. **Aliment Pharmacol Ther** 1996 Jun;10(3):219–31 (121 ref.)

Regulation of renal sodium and water excretion in the nephrotic syndrome and cirrhosis of the liver. Jespersen B. **Dan Med Bull** 1997 Apr;44(2):191–207 (230 ref.)

Subclinical encephalopathy. Blei AT, et al. **Dig Dis** 1996;14 Suppl 1:2–11 (42 ref.)

Closing in on the signals of hepatic fibrosis [editorial; comment] Friedman SL. **Gastroenterology** 1997 Apr; 112(4):1406–9 (32 ref.) Comment on: Gastroenterology 1997 Apr;112(4):1297–306.

Review: the controversy over the pathophysiology of ascites formation in cirrhosis. Wong F, et al. **J Gastroenterol Hepatol** 1997 Jun;12(6):437–44 (84 ref.)

Endothelins in chronic liver disease. Møller S, et al. **Scand J Clin Lab Invest** 1996 Oct;56(6):481–90 (109 ref.)

[Pathogenesis of sodium and water retention in cirrhosis of the liver] Martin PY. **Schweiz Rundsch Med Prax** 1997 Jul 30;86(31–32):1194–7 (15 ref.) (Eng. Abstr.) **(Fre)**

[Hepatopulmonary syndrome] Lotterer E, et al. **Schweiz Rundsch Med Prax** 1997 Jan 21;86(4):104–8 (30 ref.) (Eng. Abstr.) **(Ger)**

[Natural course and physiopathology of ascites in the cirrhotic patient] Bernardi M, et al. **Ann Ital Med Int** 1996 Oct;11 Suppl 2:30S–38S (113 ref.) (Eng. Abstr.) **(Ita)**

[Physiopathologic basis of medical therapy of portal hypertension in cirrhosis] Gatta A, et al. **Ann Ital Med Int** 1996 Oct;11 Suppl 2:39S–47S (93 ref.) (Eng. Abstr.) **(Ita)**

[Vasodilation in cirrhosis: is CGRP (calcitonin gene–related peptide) also among the possible mediators?] Paoletti V, et al. **Clin Ter** 1996 Oct;147(10):505–14 (34 ref.) (Eng. Abstr.) **(Ita)**

[Hemodynamic disorders due to liver cirrhosis] Garbuzenko DV. **Klin Med (Mosk)** 1996;74(2):5–7 (49 ref.) **(Rus)**

[Hepatoportal hemodynamics in liver cirrhosis with the portal hypertension syndrome] Bulanov KI. **Lik Sprava** 1996 Jan–Feb;(1–2):32–5 (40 ref.) **(Rus)**

[Intestinal bacterial translocation] Llovet JM, et al. **Gastroenterol Hepatol** 1996 Aug–Sep;19(7):374–82 (110 ref.) **(Spa)**

[Hyperaldosteronism, spironolactone and liver cirrhosis] Sort P, et al. **Gastroenterol Hepatol** 1997 Mar;20(3):151–9 (80

LIVER CIRRHOSIS

ref.) **(Spa)**

PREVENTION & CONTROL

Prevention of liver cancer and cirrhosis by vaccines. Prince AM. **Clin Lab Med** 1996 Jun;16(2):493–505 (80 ref.)

SURGERY

Hemodynamic and metabolic effects of transjugular intrahepatic portosystemic shunt (TIPS) during anesthesia for orthotopic liver transplantation. Antonini M, et al. **Transpl Int** 1996;9(4):403–7 (9 ref.)

[Surgical approach to posthepatitic cirrhotic patient today] Meriggi F, et al. **G Chir** 1996 Jun–Jul;17(6–7):370–8 (68 ref.) (Eng. Abstr.) **(Ita)**

[Prognostic criteria in the surgery of liver cirrhosis] Kalita NIa, et al. **Klin Khir** 1995;(2):39–41 (53 ref.) **(Rus)**

[The surgical treatment of diuretic-resistant ascites in liver cirrhosis] Khokhlov AV. **Vestn Khir Im I I Grek** 1996; 155(4):107–9 (44 ref.) **(Rus)**

THERAPY

Review: nutritional support for patients with cirrhosis. Fan ST. **J Gastroenterol Hepatol** 1997 Apr;12(4):282–6 (55 ref.)

[Endovascular interventions in decompensated liver cirrhosis] Bulanov KI. **Klin Khir** 1996;(4):46–9 (42 ref.) **(Rus)**

ULTRASONOGRAPHY

[Ultrasound guided puncture of the portal vein in transjugular intrahepatic portasystemic stent shunt (TIPSS)] Roeren T, et al. **Radiologe** 1996 Sep;36(9):677–82 (22 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

Patterns of progression: unpredictability and risk of decompensated cirrhosis. Tassopoulos NC. **Dig Dis Sci** 1996 Dec;41(12 Suppl):41S–48S (46 ref.)

Therapy of hepatitis C: patients with cirrhosis. Schalm SW, et al. **Hepatology** 1997 Sep;26(3 Suppl 1):128S–132S (13 ref.)

LIVER CIRRHOSIS, ALCOHOLIC

CLASSIFICATION

[Effect of fibroscopic sclerotherapy of hemorrhaging esophageal varices on survival in alcoholic liver cirrhosis (comparative retrospective study)] Kempelen I, et al. **Orv Hetil** 1996 Sep 15;137(37):2019–23 (46 ref.) (Eng. Abstr.) **(Hun)**

COMPLICATIONS

Management of portal hypertension and esophageal varices in alcoholic cirrhosis. Trevillyan J, et al. **Am Fam Physician** 1997 Apr;55(5):1851–8, 1861–2 (28 ref.)

Campylobacter jejuni peritonitis in a patient with liver cirrhosis. Vermeij CG, et al. **Eur J Gastroenterol Hepatol** 1996 Dec;8(12):1219–21 (9 ref.)

Disseminated superficial porokeratosis in a patient with chronic liver disease. Park BS, et al. **J Dermatol** 1997 Jul; 24(7):485–7 (13 ref.)

[Indications and role of albumin, plasma volume expansion excluded, in the preoperative or postoperative management of portal hypertension] Moreau R, et al. **Ann Fr Anesth Reanim** 1996;15(4):514–24 (0 ref.) (Eng. Abstr.) **(Fre)**

[Neuromeningeal cryptococcosis and alcoholic cirrhosis] Artru P, et al. **Gastroenterol Clin Biol** 1997;21(1):78–81 (29 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of a hemorrhagic duodenal varice by endoscopic sclerotherapy] Paupard T, et al. **Gastroenterol Clin Biol** 1995 Dec;19(12):1051–4 (18 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

The role of hepatitis C virus in alcoholic liver disease. Grellier LF, et al. **Alcohol Alcohol** 1997 Mar–Apr; 32(2):103–11 (58 ref.)

Marked increase in serum CA 19-9 level in patients with alcoholic cirrhosis: report of four cases. Mathurin P, et al. **Eur J Gastroenterol Hepatol** 1996 Nov;8(11):1129–31 (17 ref.)

ETIOLOGY

Protein-calorie malnutrition and the etiology of cirrhosis [editorial; comment] McCullough AJ, et al. **Am J Gastroenterol** 1997 May;92(5):734–8 (77 ref.) Comment on: Am J Gastroenterol 1997 May;92(5):777–83.

Pathogenesis and treatment of liver fibrosis in alcoholics: 1996 update. Lieber CS. **Dig Dis** 1997 Jan–Apr; 15(1–2):42–66 (175 ref.)

METABOLISM

Ethanol metabolism, cirrhosis and alcoholism. Lieber CS. **Clin Chim Acta** 1997 Jan 3;257(1):59–84 (165 ref.)

REHABILITATION

Beta-blockers revisited: picking patients with alcoholic cirrhosis who will benefit. Bay MK, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):788–90 (33 ref.)

SURGERY

Fair treatment of alcoholic patients in the context of liver transplantation. Shelton W, et al. **Alcohol Clin Exp Res** 1997 Feb;21(1):93–100 (33 ref.)

THERAPY

Management of alcoholic cirrhosis of the liver. McEwen DR. **AORN J** 1996 Aug;64(2):209–16, 218–20, 222–3 passim (64 ref.)

LIVER CIRRHOSIS, BILIARY

Primary biliary cirrhosis. Neuberger J. **Lancet** 1997 Sep 20; 350(9081):875–9 (50 ref.)

Primary biliary cirrhosis [see comments] Kaplan MM. **N Engl J Med** 1996 Nov 21;335(21):1570–80 (153 ref.) Comment in: N Engl J Med 1997 May 8;336(19):1387; discussion 1388.

Primary biliary cirrhosis–current concepts and treatment. Fock KM. **Singapore Med J** 1996 Feb;37(1):20–3 (55 ref.)

COMPLICATIONS

Primary biliary cirrhosis associated with mixed type autoimmune hemolytic anemia and sicca syndrome: a case report and review of literature. Chen CY, et al. **Am J Gastroenterol** 1997 Sep;92(9):1547–9 (21 ref.)

Hepatocellular carcinoma associated with precirrhotic primary biliary cirrhosis successfully treated by a right hepatic lobectomy: report of a case. Wakai T, et al. **Surg Today** 1996;26(9):723–6 (23 ref.)

[Hepatocellular carcinoma in asymptomatic primary biliary cirrhosis] Lucidarme D, et al. **Rev Med Interne** 1996; 17(7):568–70 (19 ref.) (Eng. Abstr.) **(Fre)**

[Arteriovenous lung fistula as a pulmonary complication of biliary cirrhosis] Kramann B, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Nov;165(5):502–4 (17 ref.) **(Ger)**

[Idiopathic biliary liver cirrhosis, primary sclerosing cholangitis, and jaundice] Oda M, et al. **Nippon Naika Gakkai Zasshi** 1997 Apr 10;86(4):565–73 (5 ref.) **(Jpn)**

[A case of intrahepatic cholangiocellular carcinoma associated with primary biliary cirrhosis] Dohmen K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 May;94(5):361–5 (19 ref.) **(Jpn)**

[A case of esophageal intramural pseudodiverticulosis complicated with primary biliary cirrhosis and mixed connective tissue disease] Iguchi Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Mar;94(3):180–5 (11 ref.) **(Jpn)**

[A case of primary biliary cirrhosis associated with fatty liver following delivery] Nakamura T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Aug;94(8):558–63 (20 ref.) **(Jpn)**

[A male case of polymyositis associated with asymptomatic primary biliary cirrhosis] Nakasho K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Sep;93(9):666–70 (16 ref.) **(Jpn)**

[An autopsy case of primary biliary cirrhosis associated with progressive systemic sclerosis--a review of reported cases in Japan] Shikuwa S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Nov;93(11):845–50 (16 ref.) **(Jpn)**

DIAGNOSIS

Hepatocellular carcinoma in primary biliary cirrhosis. Turissini SB, et al. **Am J Gastroenterol** 1997 Apr; 92(4):676–8 (26 ref.)

DRUG THERAPY

Ursodeoxycholic acid therapy in primary biliary cirrhosis. Podda M, et al. **Ital J Gastroenterol** 1996 Feb–Mar; 28(2):114–7 (21 ref.)

The use of methotrexate, colchicine, and other immunomodulatory drugs in the treatment of primary biliary cirrhosis. Kaplan MM. **Semin Liver Dis** 1997 May; 17(2):129–36 (57 ref.)

ENZYMOLOGY

Biochemistry and autoimmune response to the 2-oxoacid dehydrogenase complexes in primary biliary cirrhosis. Bassendine MF, et al. **Semin Liver Dis** 1997 Feb;17(1):49–60 (99 ref.)

EPIDEMIOLOGY

The geoepidemiology of primary biliary cirrhosis. Metcalf J, et al. **Semin Liver Dis** 1997 Feb;17(1):13–22 (36 ref.)

ETIOLOGY

Late recurrent post-transplant primary biliary cirrhosis in British Columbia. Yoshida EM, et al. **Can J Gastroenterol** 1997 Apr;11(3):229–33 (20 ref.)

GENETICS

Primary biliary cirrhosis [editorial] Jones DE, et al. **J Intern Med** 1997 May;241(5):345–8 (15 ref.)

IMMUNOLOGY

Myasthenia gravis and primary biliary cirrhosis. Common immunological features and rare coincidence. Kiechl S, et al. **Acta Neurol Scand** 1996 Apr;93(4):263–5 (21 ref.)

Immunopathology of primary biliary cirrhosis. Galperin C, et al. **Baillieres Clin Gastroenterol** 1996 Sep;10(3):461–81 (85 ref.)

T-cell autoimmunity in primary biliary cirrhosis. Jones DE. **Clin Sci (Colch)** 1996 Nov;91(5):551–8 (40 ref.)

Adhesion molecules in primary biliary cirrhosis and primary sclerosing cholangitis. Broomé U, et al. **Hepatogastroenterology** 1996 Sep–Oct;43(11):1109–12 (35 ref.)

Molecular aspects and the pathological basis of primary biliary cirrhosis. Leung PS, et al. **J Autoimmun** 1996 Apr; 9(2):119–28 (103 ref.)

Cytokines in primary biliary cirrhosis. Berg PA, et al. **Semin Liver Dis** 1997 May;17(2):115–23 (84 ref.)

Nuclear envelope protein autoantibodies in primary biliary cirrhosis. Courvalin JC, et al. **Semin Liver Dis** 1997 Feb; 17(1):79–90 (88 ref.)

Ductular expression of autoantigens in primary biliary cirrhosis. Joplin R, et al. **Semin Liver Dis** 1997 May; 17(2):97–103 (37 ref.)

Antimitochondrial antibodies in primary biliary cirrhosis. Leung PS, et al. **Semin Liver Dis** 1997 Feb;17(1):61–9 (72 ref.)

The nature of autoimmune disease. Mackay IR, et al. **Semin Liver Dis** 1997 Feb;17(1):3–11 (46 ref.)

Autoantibodies against "nuclear dots" in primary biliary cirrhosis. Szostecki C, et al. **Semin Liver Dis** 1997 Feb; 17(1):71–8 (72 ref.)

The role of T cells in primary biliary cirrhosis. Van de Water J, et al. **Semin Liver Dis** 1997 May;17(2):105–13 (60 ref.)

MORTALITY

Survival algorithms and outcome analysis in primary biliary cirrhosis. Pasha TM, et al. **Semin Liver Dis** 1997 May; 17(2):147–58 (63 ref.)

PATHOLOGY

Immunopathology of primary biliary cirrhosis. Galperin C, et al. **Baillieres Clin Gastroenterol** 1996 Sep;10(3):461–81 (85 ref.)

Late recurrent post-transplant primary biliary cirrhosis in British Columbia. Yoshida EM, et al. **Can J Gastroenterol** 1997 Apr;11(3):229–33 (20 ref.)

Histopathology of primary biliary cirrhosis with emphasis on expression of adhesion molecules. Nakanuma Y, et al. **Semin Liver Dis** 1997 Feb;17(1):35–47 (77 ref.)

PHYSIOPATHOLOGY

The potential role of dual-energy X-ray absorptiometry in the assessment of body composition in cirrhotic patients. Madden AM, et al. **Nutrition** 1997 Jan;13(1):40–5 (60 ref.)

The clinical expression of primary biliary cirrhosis. Heathcote J. **Semin Liver Dis** 1997 Feb;17(1):23–33 (86 ref.)

THERAPY

Treatment of primary biliary cirrhosis. Heathcote J. **J Gastroenterol Hepatol** 1996 Jul;11(7):605–9 (29 ref.)

Transplantation for primary biliary cirrhosis. Neuberger J. **Semin Liver Dis** 1997 May;17(2):137–46 (56 ref.)

LIVER CIRRHOSIS, EXPERIMENTAL

Animal models of liver fibrosis. Wu J, et al. **Scand J Gastroenterol** 1996 Dec;31(12):1137–43 (76 ref.)

PHYSIOPATHOLOGY

Endothelins in chronic liver disease. Møller S, et al. **Scand J Clin Lab Invest** 1996 Oct;56(6):481–90 (109 ref.)

LIVER CIRRHOSIS, OBSTRUCTIVE see **LIVER CIRRHOSIS, BILIARY**

LIVER DISEASES

Treatment of hepatic cysts in the era of laparoscopic surgery. Klingler PJ, et al. **Br J Surg** 1997 Apr;84(4):438–44 (60 ref.)

Liver injury during sepsis. Pastor CM, et al. **J Crit Care** 1995 Dec;10(4):183–97 (141 ref.)

BLOOD

Natural anticoagulants and the liver. Castelino DJ, et al. **J Gastroenterol Hepatol** 1997 Jan;12(1):77–83 (32 ref.)

CHEMICALLY INDUCED

Hepatotoxicity and -carcinogenicity of the fumonisins in rats. A review regarding mechanistic implications for establishing risk in humans. Gelderblom WC, et al. **Adv Exp Med Biol** 1996;392:279–96 (62 ref.)

Review article: methotrexate in gastroenterology--dangerous villain or simply misunderstood? Tang H, et al. **Aliment Pharmacol Ther** 1996 Dec;10(6):851–8 (64 ref.)

Nonnarcotic analgesics: prevalence and estimated economic

impact of toxicities [see comments] McGoldrick MD, et al. **Ann Pharmacother** 1997 Feb;31(2):221–7 (50 ref.) Comment in: Ann Pharmacother 1997 Feb;31(2):245–8.

Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs. Walker AM. **Arthritis Rheum** 1997 Feb;40(2):201–8 (11 ref.)

Hepatic bleeding and hemorrhagic shock following thrombolytic therapy in patients with acute myocardial infarction [letter] Gárcia-Jiménez A, et al. **Chest** 1997 Jun; 111(6):1787 (5 ref.)

Xenobiotic-induced hepatotoxicity: mechanisms of liver injury and methods of monitoring hepatic function. Sturgill MG, et al. **Clin Chem** 1997 Aug;43(8 Pt 2):1512–26 (201 ref.)

Antibacterial-induced hepatotoxicity. Incidence, prevention and management. George DK, et al. **Drug Saf** 1996 Jul; 15(1):79–85 (56 ref.)

Nonsteroidal anti-inflammatory drug-induced hepatic disorders. Incidence and prevention. Manoukian AV, et al. **Drug Saf** 1996 Jul;15(1):64–71 (59 ref.)

Tenoxicam-associated hepatic injury: a case report and review. Katsinelos P, et al. **Eur J Gastroenterol Hepatol** 1997 Apr;9(4):403–6 (24 ref.)

Regulation of hepatic glutathione metabolism and its role in hepatotoxicity. Kretzschmar M. **Exp Toxicol Pathol** 1996 Jul;48(5):439–46 (85 ref.)

Mechanisms of drug-induced liver disease. DeLeve LD, et al. **Gastroenterol Clin North Am** 1995 Dec;24(4):787–810 (119 ref.)

Genetic predisposition to drug-induced liver disease. Fontana RJ, et al. **Gastroenterol Clin North Am** 1995 Dec; 24(4):811–38 (172 ref.)

Morphologic spectrum of drug-induced hepatic disease. Ishak KG, et al. **Gastroenterol Clin North Am** 1995 Dec; 24(4):759–86 (33 ref.)

Prevention and treatment of drug-induced liver disease. Speeg KV, et al. **Gastroenterol Clin North Am** 1995 Dec; 24(4):1047–64 (192 ref.)

General aspects of drug-induced liver disease. Zimmerman HJ, et al. **Gastroenterol Clin North Am** 1995 Dec; 24(4):739–57 (54 ref.)

Fifty years of experience with propylthiouracil-associated hepatotoxicity: what have we learned? Williams KV, et al. **J Clin Endocrinol Metab** 1997 Jun;82(6):1727–33 (70 ref.)

[Spontaneous liver rupture after thrombolytic therapy with streptokinase] Hinterthaner M, et al. **Zentralbl Chir** 1997; 122(1):49–51 (20 ref.) (Eng. Abstr.) **(Ger)**

[Hepatotoxic occupational risk factors] Tomei F, et al. **Minerva Med** 1996 Dec;87(12):585–98 (96 ref.) (Eng. Abstr.) **(Ita)**

[A case of drug-induced liver injury due to bukuryo-in-go-hange-koboku-to] Yoshikubo S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Aug;94(8):564–8 (17 ref.) **(Jpn)**

COMPLICATIONS

Hepatic hydrothorax: possible etiology of recurring pleural effusion. Hahn MH, et al. **Am Fam Physician** 1997 Aug; 56(2):523–7 (09 ref.)

Spontaneous rupture of the liver in amyloidosis. Bujanda L, et al. **Am J Gastroenterol** 1997 Aug;92(8):1385–6 (8 ref.)

Hepatobiliary tract and pancreatic disorders in celiac disease. Freeman HJ. **Can J Gastroenterol** 1997 Jan–Feb;11(1):77–81 (79 ref.)

Rheumatic features of gastrointestinal tract, hepatic, and pancreatic diseases. Ramos-Remus C, et al. **Curr Opin Rheumatol** 1997 Jan;9(1):56–61 (68 ref.)

Portal hypertensive gastropathy. Trevino HH, et al. **Dig Dis** 1996 Jul–Aug;14(4):258–70 (106 ref.)

Hepatic osteodystrophy: a review. Idilman R, et al. **Hepatogastroenterology** 1997 Mar–Apr;44(14):574–81 (15 ref.)

Squamous cell carcinoma of the liver originating from a solitary non-parasitic cyst case report and review of the literature. Weimann A, et al. **HPB Surg** 1996;10(1):45–9 (24 ref.)

Treatment of a patient with an infected hepatic cyst. Purvis JR, et al. **J Fam Pract** 1996 Dec;43(6):577–80 (26 ref.)

The pathogenesis of growth failure in paediatric liver disease. Holt RI, et al. **J Hepatol** 1997 Aug;27(2):413–23 (104 ref.)

A case of pseudolymphoma of the liver with chronic hepatitis C. Kim SR, et al. **J Hepatol** 1997 Jan;26(1):209–14 (30 ref.)

Prescribing in liver disease. Reichen J. **J Hepatol** 1997;26 Suppl 1:36–40 (57 ref.)

Hepatopulmonary syndrome with progressive hypoxemia as an indication for liver transplantation: case reports and literature review. Krowka MJ, et al. **Mayo Clin Proc** 1997 Jan;72(1):44–53 (41 ref.)

Polyunsaturated fatty acid deficiency in liver diseases: pathophysiological and clinical significance. Cabré E, et al. **Nutrition** 1996 Jul–Aug;12(7–8):542–8 (81 ref.)

Hepatosplenic abscess caused by Curvularia boedijn in a patient with acute monocytic leukemia. Shigemori M, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1128–9 (11 ref.)

[Nutritional therapy in chronic hepatopathy] Caregaro L, et al. **Ann Ital Med Int** 1996 Oct–Dec;11(4):268–74 (46 ref.) (Eng. Abstr.) **(Ita)**

[Intrahepatic cholestasis in chronic liver disease] Roda E, et al. **Ann Ital Med Int** 1996 Oct;11 Suppl 2:48S–52S (53 ref.) (Eng. Abstr.) **(Ita)**

[Impaired glucose tolerance in liver and pancreas disease] Nagasaka Y, et al. **Nippon Rinsho** 1996 Oct;54(10):2720–4 (21 ref.) (Eng. Abstr.) **(Jpn)**

[HGBV-C infection in patients with chronic liver disease] Sugai Y, et al. **Nippon Rinsho** 1997 Mar;55(3):564–8 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Intravascular blood microcoagulation in liver diseases] Svintsitskiĭ AS, et al. **Lik Sprava** 1996 Jul–Sep;(7–9):8–12 (35 ref.) **(Rus)**

[Organic nephropathies in patients with liver diseases] Amoedo ML, et al. **Gastroenterol Hepatol** 1996 Mar; 19(3):167–77 (129 ref.) **(Spa)**

DIAGNOSIS

Clinical implications of studies with MnDPDP in animal models of hepatic abnormalities [see comments] Ni Y, et al. **Acta Radiol** 1997 Jul;38(4 Pt 2):724–31 (42 ref.) Comment in: Acta Radiol 1997 Jul;38(4 Pt 2):623–5.

Tumorous intrahepatic lymphoproliferative disorder in transplanted livers. Strouse PJ, et al. **AJR Am J Roentgenol** 1996 Nov;167(5):1159–62 (11 ref.)

The liver: new functional, prognostic and diagnostic tests. Tredger JM, et al. **Ann Clin Biochem** 1997 Mar;34 (Pt 2):121–41 (225 ref.)

Endoscopy. Dillon JF, et al. **Baillieres Clin Gastroenterol** 1995 Dec;9(4):745–58 (54 ref.)

Investigation of the patient with abnormal liver function tests. Noack KB, et al. **Baillieres Clin Gastroenterol** 1997 Mar; 11(1):83–95 (49 ref.)

Clinical evaluation of liver disease. Simpson KJ, et al. **Baillieres Clin Gastroenterol** 1995 Dec;9(4):639–59 (70 ref.)

Biochemical assay of serum bile acids: methods and applications. Azer SA, et al. **Br J Biomed Sci** 1997 Jun; 54(2):118–32 (151 ref.)

Molecular biological methods in diagnosis and treatment of liver diseases. Worman HJ. **Clin Chem** 1997 Aug;43(8 Pt 2):1476–86 (103 ref.)

Multivariate discriminant analysis of biochemical parameters for the differentiation of clinically confounding liver diseases. Salvatore F, et al. **Clin Chim Acta** 1997 Jan 3; 257(1):41–58 (47 ref.)

MRI of the liver. A pictorial essay. Shapiro RS, et al. **Clin Imaging** 1997 Jul–Aug;21(4):293–302 (34 ref.)

Liver MRI with contrast enhancement. Runge VM. **Crit Rev Diagn Imaging** 1997 Jun;38(3):207–30 (29 ref.)

Imaging techniques in the diagnosis of gastrointestinal and hepatic disease. Kao SC, et al. **Curr Opin Pediatr** 1996 Oct; 8(5):487–94 (119 ref.)

Breath tests: concepts, applicaticns and limitations. Rating D, et al. **Eur J Pediatr** 1997 Aug;156 Suppl 1:S18–23 (9 ref.)

Detection of chronic liver disease: costs and benefits. Quinn PG, et al. **Gastroenterologist** 1997 Mar;5(1):58–77 (107 ref.)

Inflammatory pseudotumor of the liver presenting as incidentaloma: report of a case and review of the literature. Schmid A, et al. **Hepatogastroenterology** 1996 Jul–Aug; 43(10):1009–14 (9 ref.)

Cystic mesenchymal hamartoma of the liver--a rare condition. Motiwale SS, et al. **Indian J Cancer** 1996 Sep; 33(3):157–60 (15 ref.)

Macronodular hepatic granulomas due to visceral leishmaniasis in an AIDS patient: imaging findings. Canalias J, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):677–9 (13 ref.)

Prognostic models in chronic liver disease: validity, usefulness and future role. Christensen E. **J Hepatol** 1997 Jun;26(6):1414–24 (57 ref.)

Diagnostic approach to liver enzyme elevation. Craxi A, et al. **J Hepatol** 1996;25 Suppl 1:47–51 (13 ref.)

Contrast agents for MR imaging of the liver. Low RN. **J Magn Reson Imaging** 1997 Jan–Feb;7(1):56–67 (76 ref.)

MR imaging of the liver. Contrast agents. Mahfouz AE, et al. **Magn Reson Imaging Clin N Am** 1997 May;5(2):223–40 (28 ref.)

Benign liver tumors. Mathieu D, et al. **Magn Reson Imaging Clin N Am** 1997 May;5(2):255–88 (71 ref.)

MR imaging of inflammatory disease of the liver. Mergo PJ, et al. **Magn Reson Imaging Clin N Am** 1997 May; 5(2):367–76 (41 ref.)

MR imaging of the liver. Cirrhosis and premalignant nodules. Ohtomo K. **Magn Reson Imaging Clin N Am** 1997 May; 5(2):331–46 (38 ref.)

MR imaging of the liver--a practical approach. Paley MR, et al. **Magn Reson Imaging Clin N Am** 1997 May; 5(2):415–29 (34 ref.)

MR imaging of the liver in children. Siegel MJ, et al. **Magn Reson Imaging Clin N Am** 1996 Nov;4(4):637–56 (50 ref.)

MR imaging of diffuse liver disease. Hepatic fat and iron. Siegelman ES. **Magn Reson Imaging Clin N Am** 1997 May; 5(2):347–65 (104 ref.)

MR imaging of the liver. Technique. Soyer P, et al. **Magn Reson Imaging Clin N Am** 1997 May;5(2):205–21 (78 ref.)

Clinical approach to the patient with abnormal liver test results. Kamath PS. **Mayo Clin Proc** 1996 Nov; 71(11):1089–94; quiz 1094–5 (00 ref.)

Imaging of the hepatobiliary tract. Saini S. **N Engl J Med** 1997 Jun 26;336(26):1889–94 (48 ref.)

Fine-needle aspiration biopsy of the liver: diagnostic problems. Ljung BM, et al. **Pathology (Phila)** 1996; 4(2):365–88 (31 ref.)

Diagnostic imaging in pediatric AIDS. Haller JO, et al. **Pediatr Clin North Am** 1997 Jun;44(3):721–40 (64 ref.)

Evaluation of tests used to screen patients with liver disorders. Scheig R. **Prim Care** 1996 Sep;23(3):551–60 (9 ref.)

Diagnostic laparoscopy by physicians: we should do it. Haydon GH, et al. **QJM** 1997 Apr;90(4):297–304 (40 ref.)

Acute hepatic disease. Taylor GA. **Radiol Clin North Am** 1997 Jul;35(4):799–814 (56 ref.)

Noninvasive neuroinvestigation in liver disease. Morgan MY. **Semin Liver Dis** 1996 Aug;16(3):293–314 (112 ref.)

Hepatic mesenchymal hamartoma: a case report and radiological findings. Lai FM, et al. **Singapore Med J** 1996 Apr;37(2):226–8 (19 ref.)

Inflammatory pseudotumor of the liver: report of a case and review of the literature. Uetsuji S, et al. **Surg Today** 1996; 26(7):517–21 (12 ref.)

Diagnostic criteria for degenerative, inflammatory, proliferative nonneoplastic and neoplastic liver lesions in medaka (Oryzias latipes): consensus of a National Toxicology Program Pathology Working Group. Boorman GA, et al. **Toxicol Pathol** 1997 Mar–Apr;25(2):202–10 (32 ref.)

[Liver mesenchymal hamartoma in adulthood. Report of a new case] Turlin B, et al. **Ann Pathol** 1996;16(3):192–5 (20 ref.) (Eng. Abstr.) **(Fre)**

[1996 review of the literature: liver imaging] Merkle EM, et al. **Rontgenpraxis** 1997 Mar;50(3):55–62 (50 ref.) **(Ger)**

[Primary amyloidosis of the gastrointestinal tract and liver--two case reports] Halm U, et al. **Z Gastroenterol** 1997 Feb;35(2):131–7 (35 ref.) (Eng. Abstr.) **(Ger)**

[The place of fibronectin in hepatologic diagnosis] Simon K. **Wiad Lek** 1994 Nov–Dec;47(21–24):854–8 (44 ref.) (Eng. Abstr.) **(Pol)**

[Biochemical methods for the diagnosis of liver pathology] Titov VN. **Ter Arkh** 1993;65(2):85–9 (43 ref.) **(Rus)**

[Changes in gamma-glutamyltransferase activity in diseases of the liver and biliary tract] Vŭrbanov G, et al. **Ter Arkh** 1993;65(2):82–5 (50 ref.) **(Rus)**

DIET THERAPY

Nutrition and liver disease. Corish C. **Nutr Rev** 1997 Jan;55(1 Pt 1):17–20 (24 ref.)

Nutritional considerations and management of the child with liver disease. Novy MA, et al. **Nutrition** 1997 Mar; 13(3):177–84 (77 ref.)

DRUG THERAPY

Role of oxidative stress and antioxidant therapy in alcoholic and nonalcoholic liver diseases. Lieber CS. **Adv Pharmacol** 1997;38:601–28 (188 ref.)

Prostaglandins in liver disease and liver transplantation. Ruwart MJ, et al. **Gastroenterol Clin North Am** 1996 Jun; 25(2):397–407 (66 ref.)

Indigenous drugs and liver disease. Bhatt AD, et al. **Indian J Gastroenterol** 1996 Apr;15(2):63–7 (30 ref.)

Modification of liposomes for liver targeting. Wu J, et al. **J Hepatol** 1996 Jun;24(6):757–63 (48 ref.)

Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid. Balistreri WF. **J Pediatr Gastroenterol Nutr** 1997 May;24(5):573–89 (184 ref.)

Ursodeoxycholic acid in cystic fibrosis-related liver disease: a systematic review. Cheng K, et al. **J R Soc Med** 1997; 90 Suppl 31:6–12 (32 ref.)

Ursodeoxycholic acid in the treatment of liver diseases. Saksena S, et al. **Postgrad Med J** 1997 Feb;73(856):75–80 (78 ref.)

Somatostatin and its analogues in G.I. tract, liver and pancreatic disorders. Dhar A, et al. **Trop Gastroenterol** 1995 Jul–Sep;16(3):3–7 (22 ref.)

[Cyclosporin in the treatment of chronic diseases of the liver (excluding transplantation)] Di Martino V, et al. **Gastroenterol Clin Biol** 1997;21(5):400–11 (112 ref.) **(Fre)**

[Immunosuppressive therapy of autoimmune liver diseases] Rambusch EG, et al. **Internist (Berl)** 1997 Jun;38(6):574–81 (51 ref.) **(Ger)**

[New gastroenterological prospects of ursodeoxycholic acid] Sheptulin AA. **Klin Med (Mosk)** 1996;74(4):8–10 (38 ref.) **(Rus)**

[The treatment of chronic diffuse liver diseases with chorionic gonadotropin (a review of the literature)] Usov DV, et al. **Lik Sprava** 1995 Mar–Apr;(3–4):42–6 (55 ref.) **(Rus)**

ECONOMICS

Clinical economics review: cost-effectiveness in the therapy of liver disease. Neuberger J, et al. **Aliment Pharmacol Ther** 1997 Feb;11(1):61–8 (30 ref.)

Detection of chronic liver disease: costs and benefits. Quinn PG, et al. **Gastroenterologist** 1997 Mar;5(1):58–77 (107 ref.)

ENZYMOLOGY

Georges Brohee Prize 1996. Major cytochrome P-450 families: implications in health and liver diseases. Horsmans Y. **Acta Gastroenterol Belg** 1997 Jan–Mar;60(1):2–10 (117 ref.)

Review: alpha 1-antitrypsin deficiency associated liver disease. Qu D, et al. **J Gastroenterol Hepatol** 1997 May; 12(5):404–16 (99 ref.)

[The microsomal enzyme system and liver pathology]

Posokhova EA. **Eksp Klin Farmakol** 1996 Jul–Aug; 59(4):73–9 (120 ref.) (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs. Walker AM. **Arthritis Rheum** 1997 Feb;40(2):201–8 (11 ref.)

An overview of gastrointestinal and hepatobiliary diseases in Thailand. Kullavanijaya P. **J Gastroenterol Hepatol** 1997 May;12(5):S11–2 (10 ref.)

[Retrospective and comparative study of pneumococcal bacteremia in patients with chronic hepatopathy] Ramos Rincón JM, et al. **An Med Interna** 1996 Jul;13(7):313–6 (21 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Spontaneous rupture of the liver in amyloidosis. Bujanda L, et al. **Am J Gastroenterol** 1997 Aug;92(8):1385–6 (8 ref.)

Liver penetration by a duodenal ulcer. Padda SS, et al. **Am J Gastroenterol** 1997 Feb;92(2):352–4 (12 ref.)

Spontaneous liver hematoma in pregnancy not clearly associated with preeclampsia: a case presentation and literature review. Schwartz ML, et al. **Am J Obstet Gynecol** 1997 Jun;176(6):1328–32; discussion 1332–3 (19 ref.)

Alpha-1-antitrypsin deficiency: biochemistry and clinical manifestations. Perlmutter DH. **Ann Med** 1996 Oct; 28(5):385–94 (70 ref.)

Alcohol and the liver. Hills KS, et al. **Br J Hosp Med** 1997 May 21–Jun 3;57(10):517–21 (15 ref.)

Hepatobiliary manifestations of cystic fibrosis. Colombo C, et al. **Eur J Gastroenterol Hepatol** 1996 Aug;8(8):748–54 (48 ref.)

Diagnosis and treatment of hepatic disease in patients with HIV. Poles MA, et al. **Gastroenterol Clin North Am** 1997 Jun;26(2):291–321 (170 ref.)

Hepatobiliary complications of parenteral nutrition. Gaddipati K, et al. **Gastroenterologist** 1996 Jun;4(2):98–106 (91 ref.)

Liver disease in extrahepatic malignancy. Su AY, et al. **Hematol Oncol Clin North Am** 1996 Aug;10(4):953–66 (45 ref.)

Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease. Manns MP, et al. **Hepatology** 1997 Oct; 26(4):1054–66 (147 ref.)

Helicobacter and liver disease [editorial; comment] Fox JG, et al. **Ital J Gastroenterol Hepatol** 1997 Feb;29(1):5–10 (68 ref.) Comment on: Ital J Gastroenterol Hepatol 1997 Feb;29(1):13–7.

Iron and liver: current concepts in the pathogenesis and management of chronic liver diseases. Guptan RC, et al. **J Assoc Physicians India** 1996 Mar;44(3):198–202 (46 ref.)

Some peculiarities of hepatobiliary diseases in Vietnam. Ha MV. **J Gastroenterol Hepatol** 1997 May;12(5):S15–8 (21 ref.)

Recent advances in autoimmune liver diseases. Manns MP. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):575–7 (6 ref.)

Liver disease in polyglandular autoimmune disease type one: clinicopathologic study of three patients and review of the literature. Goldstein NS, et al. **Pediatr Pathol Lab Med** 1996 Jul–Aug;16(4):625–36 (38 ref.)

Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan. Chen DS. **Princess Takamatsu Symp** 1995;25:27–32 (24 ref.)

Oxidative stress and liver disease. Kaplowitz N, et al. **Prog Liver Dis** 1996;14:131–59 (148 ref.)

Nodular regenerative hyperplasia of the liver in systemic lupus erythematosus. The relationship with anticardiolipin antibody and lupus anticoagulant. Sekiya M, et al. **Scand J Rheumatol** 1997;26(3):215–7 (13 ref.)

Mechanisms of liver damage. Losser MR, et al. **Semin Liver Dis** 1996 Nov;16(4):357–67 (154 ref.)

Inflammatory pseudotumor of the liver associated with extrahepatic infection. White JE, et al. **South Med J** 1997 Jan;90(1):23–9 (48 ref.)

[Subcapsular hematoma of the liver. Six cases and review of the literature] Matar N, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(1):89–93 (21 ref.) (Eng. Abstr.) **(Fre)**

[Liver dysfunction induced by Epstein-Barr virus infectious mononucleosis] Furman E, et al. **Harefuah** 1997 May 15; 132(10):724–5 (11 ref.) **(Heb)**

[Role of Kupffer cells in liver diseases] Yamamoto H, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):701–3 (5 ref.) **(Jpn)**

[Autoimmune liver diseases: the relation to other autoimmune pathology] Podymova SD, et al. **Ter Arkh** 1993;65(2):36–41 (41 ref.) (Eng. Abstr.) **(Rus)**

[A giant ulcer of the stomach with perforation into the liver simulating cancer] Kovalenko VL, et al. **Vestn Khir Im I I Grek** 1996;155(6):82–3 (7 ref.) **(Rus)**

[Hepatobiliary complications in chronic intestinal inflammatory disease] Bertrán X, et al. **Gastroenterol Hepatol** 1996 Jan;19(1):10–5 (68 ref.) **(Spa)**

[Hepatic changes in porphyria] Enriquez de Salamanca R. **Med Clin (Barc)** 1997 May 10;108(18):709–15 (89 ref.) **(Spa)**

GENETICS

Genetic predisposition to drug-induced liver disease. Fontana RJ, et al. **Gastroenterol Clin North Am** 1995 Dec; 24(4):811–38 (172 ref.)

Inherited liver diseases affecting the adult. Tung BY, et al. **Gastroenterologist** 1996 Dec;4(4):245–61 (168 ref.)

[Molecular biology 1996: gastroenterology and hepatology] Blum HE. **Schweiz Rundsch Med Prax** 1997 Jul 16; 86(29–30):1172–7 (44 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Autoantibodies. Czaja AJ. **Baillieres Clin Gastroenterol** 1995 Dec;9(4):723–44 (78 ref.)

Immunogenetics in liver disease. Donaldson PT. **Baillieres Clin Gastroenterol** 1996 Sep;10(3):533–49 (68 ref.)

Mechanisms of neutrophil-induced parenchymal cell injury. Jaeschke H, et al. **J Leukoc Biol** 1997 Jun;61(6):647–53 (93 ref.)

Cytochrome P450 enzymes and UDP-glucuronosyltransferases as hepatocellular autoantigens. Obermayer-Straub P, et al. **Mol Biol Rep** 1996;23(3–4):235–42 (59 ref.)

Mini-review: tumor necrosis factor (TNF) and TNF soluble receptors (TNF-sR) in liver disease and liver transplantation. Majno PE, et al. **Swiss Surg** 1995;(4):182–5 (27 ref.)

METABOLISM

Protein metabolism and liver disease. Charlton MR. **Baillieres Clin Endocrinol Metab** 1996 Oct;10(4):617–35 (110 ref.)

Biochemical abnormalities in liver disease. Hassanein T, et al. **Baillieres Clin Gastroenterol** 1995 Dec;9(4):679–88 (19 ref.)

Liver function tests. Renner EL. **Baillieres Clin Gastroenterol** 1995 Dec;9(4):661–77 (145 ref.)

Gaseous monoxides: a new class of microvascular regulator in the liver. Suematsu M, et al. **Cardiovasc Res** 1996 Oct; 32(4):679–86 (60 ref.)

Regulation of hepatic glutathione metabolism and its role in hepatotoxicity. Kretzschmar M. **Exp Toxicol Pathol** 1996 Jul;48(5):439–46 (85 ref.)

Mechanisms of drug-induced liver disease. DeLeve LD, et al. **Gastroenterol Clin North Am** 1995 Dec;24(4):787–810 (119 ref.)

Intermediate filament proteins of the liver: emerging disease association and functions. Omary MB, et al. **Hepatology** 1997 May;25(5):1043–8 (67 ref.)

Drug elimination in chronic liver diseases. Huet PM, et al. **J Hepatol** 1997;26 Suppl 2:63–72 (40 ref.)

Metabolism of methionine in liver disease. Mato JM, et al. **Methods Find Exp Clin Pharmacol** 1996;18 Suppl B:35–46 (87 ref.)

The impact of disease states as a modifying factor for nutrition toxicity. Russell RM. **Nutr Rev** 1997 Feb; 55(2):50–3 (18 ref.)

Influence of chronic liver disease and chronic renal failure on nutrient metabolism and undernutrition [editorial] Cano N, et al. **Nutrition** 1997 Apr;13(4):381–3 (74 ref.)

Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function. Panday VR, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 11):S11-34–S11-38 (37 ref.)

Effects of liver diseases on drug metabolism. Paintaud G, et al. **Therapie** 1996 Jul–Aug;51(4):384–9 (51 ref.)

[Role and significance of leukotrienes in liver diseases] Bao W, et al. **Chung Hua Nei Ko Tsa Chih** 1996 Jan;35(1):57–9 (12 ref.) **(Chi)**

[Role of the liver in the regulation of glucose metabolism in diabetes and chronic liver disease] Cotrozzi G, et al. **Ann Ital Med Int** 1997 Apr–Jun;12(2):84–91 (86 ref.) (Eng. Abstr.) **(Ita)**

[The pharmacokinetics of fluoroquinolones in different diseases] Iakovlev VP, et al. **Antibiot Khimioter** 1997; 42(1):23–9 (49 ref.) (Eng. Abstr.) **(Rus)**

[Active forms of oxygen: cytotoxic effects and methodological approaches to laboratory control of liver lesions (literature review)] Matiushin BN, et al. **Klin Lab Diagn** 1996 Jul–Aug;(4):51–3 (17 ref.) (Eng. Abstr.) **(Rus)**

MICROBIOLOGY

Gastrointestinal manifestations. Tanowitz HB, et al. **Med Clin North Am** 1996 Nov;80(6):1395–414 (128 ref.)

PATHOLOGY

Apoptosis and the gastrointestinal system. Que F, et al. **Adv Pharmacol** 1997;41:409–28 (81 ref.)

Liver biopsy. Desmet V, et al. **Baillieres Clin Gastroenterol** 1995 Dec;9(4):811–28 (115 ref.)

Ancillary studies in FNA of liver and pancreas. Silverman JF, et al. **Diagn Cytopathol** 1995 Dec;13(5):396–410 (151 ref.)

Morphologic spectrum of drug-induced hepatic disease. Ishak KG, et al. **Gastroenterol Clin North Am** 1995 Dec; 24(4):759–86 (33 ref.)

Inflammatory pseudotumour of the liver with malignant transformation. Report of two cases. Zavaglia C, et al. **Ital J Gastroenterol** 1996 Apr;28(3):152–9 (43 ref.)

Liver disease in pregnancy. Assy N, et al. **J Am Coll Surg** 1996 Dec;183(6):643–53 (116 ref.)

Apoptosis in liver disease. Galle PR. **J Hepatol** 1997 Aug; 27(2):405–12 (87 ref.)

Biliary epithelial cells: innocent victims or active participants in immune-mediated liver disease? [editorial; comment] Adams DH. **J Lab Clin Med** 1996 Dec;128(6):528–30 (27 ref.) Comment on: J Lab Clin Med 1996 Dec;128(6):536–44.

Mechanisms of neutrophil-induced parenchymal cell injury. Jaeschke H, et al. **J Leukoc Biol** 1997 Jun;61(6):647–53 (93 ref.)

Cystic endometriosis of the upper abdominal organs. Report on three cases and review of the literature. Verbeke C, et al. **Pathol Res Pract** 1996 Mar;192(3):300–4; discussion 305 (28 ref.)

Liver disease in polyglandular autoimmune disease type one: clinicopathologic study of three patients and review of the literature. Goldstein NS, et al. **Pediatr Pathol Lab Med** 1996 Jul–Aug;16(4):625–36 (38 ref.)

Active cell death (apoptosis) in liver biology and disease. Schulte-Hermann R, et al. **Prog Liver Dis** 1995;13:1–35 (246 ref.)

Molecular and cellular control points in pediatric liver injury and repair. Tracy TF Jr, et al. **Semin Pediatr Surg** 1996 Aug;5(3):175–81 (24 ref.)

Diagnostic criteria for degenerative, inflammatory, proliferative nonneoplastic and neoplastic liver lesions in medaka (Oryzias latipes): consensus of a National Toxicology Program Pathology Working Group. Boorman GA, et al. **Toxicol Pathol** 1997 Mar–Apr;25(2):202–10 (32 ref.)

The hepatic stellate (Ito) cell: its role in human liver disease. Hautekeete ML, et al. **Virchows Arch** 1997 Mar; 430(3):195–207 (125 ref.)

[Value of individual evaluation of the responsiveness of the granulocyte system in an experiment and in clinical practice] Sidel'nikova VI, et al. **Patol Fiziol Eksp Ter** 1996 Oct–Dec;(4):6–9 (40 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Neuroprotective and deleterious effects of nitric oxide on focal cerebral ischemia-induced neurone death. Verrecchia C, et al. **Adv Neuroimmunol** 1995;5(4):359–78 (181 ref.)

Cellular adhesion molecules: regulation and functional significance in the pathogenesis of liver diseases. Jaeschke H. **Am J Physiol** 1997 Sep;273(3 Pt 1):G602–11 (131 ref.)

Haemodynamic assessment. Lebrec D. **Baillieres Clin Gastroenterol** 1995 Dec;9(4):759–69 (55 ref.)

Pathogenesis and pathology of liver disease associated with alpha 1-antitrypsin deficiency. Massi G. **Chest** 1996 Dec; 110(6 Suppl):251S–255S (51 ref.)

Assessment of liver function: pre- and peritransplant evaluation. Shaked A, et al. **Clin Chem** 1997 Aug;43(8 Pt 2):1539–45 (53 ref.)

Hepatic regeneration. The role of regeneration in pathogenesis of chronic liver diseases. Bisgaard HC, et al. **Clin Lab Med** 1996 Jun;16(2):325–39 (102 ref.)

Liver regeneration in health and disease. Taub R. **Clin Lab Med** 1996 Jun;16(2):341–60 (78 ref.)

AGA technical review: malnutrition and cachexia, chronic diarrhea, and hepatobiliary disease in patients with human immunodeficiency virus infection. Wilcox CM, et al. **Gastroenterology** 1996 Dec;111(6):1724–52 (311 ref.)

Molecular pathogenesis of liver disease in alpha1-antitrypsin deficiency. Teckman JH, et al. **Hepatology** 1996 Dec; 24(6):1504–16 (142 ref.)

Endothelin and nitric oxide in hepatorenal syndrome: a balance reset. Epstein M, et al. **J Nephrol** 1997 May–Jun; 10(3):120–35 (158 ref.)

Gastrointestinal manifestations. Tanowitz HB, et al. **Med Clin North Am** 1996 Nov;80(6):1395–414 (128 ref.)

Nitric oxide, hepatocytes and inflammation. Nussler AK, et al. **Res Immunol** 1995 Nov–Dec;146(9):671–77 (62 ref.)

Mechanisms of inflammatory liver injury: adhesion molecules and cytotoxicity of neutrophils. Jaeschke H, et al. **Toxicol Appl Pharmacol** 1996 Aug;139(2):213–26 (98 ref.)

The hepatic stellate (Ito) cell: its role in human liver disease. Hautekeete ML, et al. **Virchows Arch** 1997 Mar; 430(3):195–207 (125 ref.)

[Surgical stress and organ dysfunction: liver] Nakatani T, et al. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):752–8 (47 ref.) (Eng. Abstr.) **(Jpn)**

[Cytotoxic action of active forms of oxygen and mechanisms of development of a chronic process in the liver in liver disease] Loginov AS, et al. **Patol Fiziol Eksp Ter** 1996 Oct–Dec;(4):3–5 (20 ref.) (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Prevention and treatment of drug-induced liver disease. Speeg KV, et al. **Gastroenterol Clin North Am** 1995 Dec; 24(4):1047–64 (192 ref.)

[Biomarkers of hepatotoxic effects: their usefulness in occupational medicine] Indulski JA, et al. **Med Pr** 1997; 48(2):177–87 (34 ref.) (Eng. Abstr.) **(Pol)**

PSYCHOLOGY

Psychological assessment in liver disease. Masterton G, et al. **Baillieres Clin Gastroenterol** 1995 Dec;9(4):791–809 (74 ref.)

RADIOGRAPHY

Abdominal visceral calcification in primary amyloidosis: CT findings. Jacobs JE, et al. **Abdom Imaging** 1997 Sep–Oct; 22(5):519–21 (8 ref.)

CT patterns of nodular hepatic and splenic sarcoidosis: a review of the literature. Scott GC, et al. **J Comput Assist Tomogr** 1997 May–Jun;21(3):369–72 (11 ref.)

Blood flow and liver imaging. Itai Y, et al. **Radiology** 1997 Feb;202(2):306–14 (80 ref.)

Helical biphasic contrast-enhanced CT of the liver: technique, indications, interpretation, and pitfalls. Oliver JH 3rd, et al. **Radiology** 1996 Oct;201(1):1–14 (34 ref.)

RADIONUCLIDE IMAGING

[A role of radionuclide studies for gastrointestinal and hepatobiliary diseases] Koizumi K. **Kaku Igaku** 1996 Jul; 33(7):785–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

REHABILITATION

[Gastroenterologic and hepatologic rehabilitation today—on changes in indications and contents] Zillessen E. **Z Arztl Fortbild (Jena)** 1996 Oct;90(6):487–93 (19 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Cryosurgery. Onik G. **Crit Rev Oncol Hematol** 1996 May; 23(1):1–24 (58 ref.)

Perspectives of liver cell transplantation: a review. Schmidt HH, et al. **Hepatogastroenterology** 1997 Jul–Aug; 44(16):1013–8 (20 ref.)

Two cases of spontaneous liver rupture and literature review. Cozzi PJ, et al. **HPB Surg** 1996;9(4):257–60 (15 ref.)

Liver transplantation: perspectives after 250 liver transplants at the Ochsner Clinic. Takiff H, et al. **J La State Med Soc** 1997 Jul;149(6):234–8 (0 ref.)

Hepatopulmonary syndrome with progressive hypoxemia as an indication for liver transplantation: case reports and literature review. Krowka MJ, et al. **Mayo Clin Proc** 1997 Jan;72(1):44–53 (41 ref.)

[Liver transplantation. Indications, results, pre- and postoperative care] Böker KH, et al. **Internist (Berl)** 1996 Mar;37(3):250–63 (88 ref.) **(Ger)**

[Liver transplantation: problem of timing and predictive factors] Pár A. **Orv Hetil** 1996 Oct 20;137(42 Suppl 1):2364–8 (27 ref.) (Eng. Abstr.) **(Hun)**

THERAPY

Review article: critical review of meta-analyses of randomized clinical trials in hepatogastroenterology. Auperin A, et al. **Aliment Pharmacol Ther** 1997 Apr; 11(2):215–25 (97 ref.)

Clinical economics review: cost-effectiveness in the therapy of liver disease. Neuberger J, et al. **Aliment Pharmacol Ther** 1997 Feb;11(1):61–8 (30 ref.)

Toward development of an implantable tissue engineered liver. Davis MW, et al. **Biomaterials** 1996 Feb;17(3):365–72 (74 ref.)

Molecular biological methods in diagnosis and treatment of liver diseases. Worman HJ. **Clin Chem** 1997 Aug;43(8 Pt 2):1476–86 (103 ref.)

Iron and liver: current concepts in the pathogenesis and management of chronic liver diseases. Guptan RC, et al. **J Assoc Physicians India** 1996 Mar;44(3):198–202 (46 ref.)

Treatment of a patient with an infected hepatic cyst. Purvis JR, et al. **J Fam Pract** 1996 Dec;43(6):577–80 (26 ref.)

Prognostic models in chronic liver disease: validity, usefulness and future role. Christensen E. **J Hepatol** 1997 Jun;26(6):1414–24 (57 ref.)

Update on therapy for hepatobiliary diseases. Kowdley KV. **Nurse Pract** 1996 Jul;21(7):78, 81–4, 86 (30 ref.)

Gene therapy for human liver disease. Raper SE, et al. **Prog Liver Dis** 1995;13:201–30 (135 ref.)

[Experimental methods in hepatology. Guidelines of the German Work Group for Study of the Liver. Therapy of ascites in liver diseases. German Work Group for Study of the Liver] Gerbes AL. **Z Gastroenterol** 1997 Apr; 35(4):295–300 (47 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

[Diagnosis of cystic lesions of the liver] Pelletier G. **Ann Chir** 1997;51(3):267–71 (16 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Do steroidal saponins have a role in hepatogenous photosensitization diseases of sheep? Flåøyen A. **Adv Exp Med Biol** 1996;405:395–403 (51 ref.)

Diet selection and special considerations in the management of hepatic diseases. Bauer JE. **J Am Vet Med Assoc** 1997 Mar 1;210(5):625–9 (38 ref.)

Hepatic disease, nutritional therapy, and the metabolic environment. Bauer JE. **J Am Vet Med Assoc** 1996 Dec 1;209(11):1850–4 (40 ref.)

Nutrition and liver disease. Biourge VC. **Semin Vet Med Surg (Small Anim)** 1997 Feb;12(1):34–44 (61 ref.)

Feline hepatic lipidosis. Dimski DS. **Semin Vet Med Surg (Small Anim)** 1997 Feb;12(1):28–33 (31 ref.)

Liver imaging in the cat. Penninck D, et al. **Semin Vet Med Surg (Small Anim)** 1997 Feb;12(1):10–21 (33 ref.)

Inflammatory liver disease. Weiss DJ, et al. **Semin Vet Med Surg (Small Anim)** 1997 Feb;12(1):22–7 (28 ref.)

[The diagnosis of liver diseases in the dog] Neumann S, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Oct; 103(10):422–8 (73 ref.) (Eng. Abstr.) **(Ger)**

[Possibilities and limitations of drugs to protect the liver] Schmid A, et al. **Tierarztl Prax** 1996 Dec;24(6):537–41 (26 ref.) (Eng. Abstr.) **(Ger)**

LIVER DISEASES, ALCOHOLIC

Alcohol and other chemicals in the development of hepatocellular carcinoma. Farber E. **Clin Lab Med** 1996 Jun;16(2):377–94 (80 ref.)

Medical considerations for dental care of patients with alcohol-related liver disease. Glick M. **J Am Dent Assoc** 1997 Jan;128(1):61–70 (58 ref.)

Dietary modulation of oxidative stress in alcoholic liver disease in rats. Porta EA. **J Nutr** 1997 May;127(5 Suppl):912S–915S (32 ref.)

Nutritional factors required for alcoholic liver disease in rats. Rao GA, et al. **J Nutr** 1997 May;127(5 Suppl):896S–898S (29 ref.)

DRUG THERAPY

Role of oxidative stress and antioxidant therapy in alcoholic and nonalcoholic liver diseases. Lieber CS. **Adv Pharmacol** 1997;38:601–28 (188 ref.)

ETIOLOGY

The prognosis and outcome of alcoholic liver disease. Morgan MY. **Alcohol Alcohol Suppl** 1994;2:335–43 (56 ref.)

Medical consequences of alcohol abuse: is gender a factor? Schenker S. **Alcohol Clin Exp Res** 1997 Feb;21(1):179–81 (41 ref.)

Role of Kupffer cells, endotoxin and free radicals in hepatotoxicity due to prolonged alcohol consumption: studies in female and male rats. Thurman RG, et al. **J Nutr** 1997 May;127(5 Suppl):903S–906S (30 ref.)

METABOLISM

Ethanol oxidizing enzymes: roles in alcohol metabolism and alcoholic liver disease. Crabb DW. **Prog Liver Dis** 1995; 13:151–72 (158 ref.)

[Recent progression in research on alcoholic liver disease] Yokoyama H, et al. **Nippon Rinsho** 1997 Feb;55(2):479–90 (36 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Pathological spectrum of alcoholic liver disease. Hall PD. **Alcohol Alcohol Suppl** 1994;2:303–13 (81 ref.)

[Current aspects of alcohol-induced liver damage] Parkkila S, et al. **Duodecim** 1995;111(13):1194–201 (51 ref.) **(Fin)**

PHYSIOPATHOLOGY

Cerebral dysfunction in chronic alcoholism: role of alcoholic liver disease. Butterworth RF. **Alcohol Alcohol Suppl** 1994; 2:259–65 (40 ref.)

Hepatic sinusoidal endothelial cell in alcoholemia and endotoxemia. Deaciuc IV, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):607–14 (87 ref.)

Adhesion molecules and alcoholic liver disease. Fisher N, et al. **Hepatogastroenterology** 1996 Sep–Oct;43(11):1113–6 (32 ref.)

SURGERY

[When should liver transplant be indicated in the treatment of alcoholic hepatic disease?] Mincis M, et al. **Rev Assoc Med Bras** 1996 Oct–Dec;42(4):242–4 (24 ref.) **(Por)**

THERAPY

Alcohol-related liver disease: treatment controversies. Batey RG. **Alcohol Alcohol Suppl** 1994;2:327–33 (27 ref.)

URINE

Alcohol-induced changes in urinary aminolevulinic acid and porphyrins: unrelated to liver disease. Schoenfeld N, et al. **Alcohol** 1996 Jan–Feb;13(1):59–63 (18 ref.)

VIROLOGY

Interactions between alcohol and hepatitis viruses in the liver. Brechot C, et al. **Clin Lab Med** 1996 Jun;16(2):273–87 (135 ref.)

Ethanol and hepatocellular injury. French SW. **Clin Lab Med** 1996 Jun;16(2):289–306 (110 ref.)

[Hepatitis virus and alcoholic liver disease] Parés A, et al. **Gastroenterol Hepatol** 1996 Aug–Sep;19(7):383–9 (49 ref.) **(Spa)**

LIVER DISEASES, PARASITIC

DIAGNOSIS

The approach to stool examination for parasites. Koontz F, et al. **Gastroenterol Clin North Am** 1996 Sep;25(3):435–49 (33 ref.)

MR imaging of inflammatory disease of the liver. Mergo PJ, et al. **Magn Reson Imaging Clin N Am** 1997 May; 5(2):367–76 (41 ref.)

LIVER FAILURE

Neonatal liver failure. Shneider BL. **Curr Opin Pediatr** 1996 Oct;8(5):495–501 (55 ref.)

Hepatorenal failure. Davison AM. **Nephrol Dial Transplant** 1996;11 Suppl 8:24–31 (55 ref.)

CHEMICALLY INDUCED

Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature. Sundar K, et al. **Crit Care Med** 1997 Aug;25(8):1425–30 (26 ref.)

Pemoline-associated hepatic failure: a critical analysis of the literature. Shevell M, et al. **Pediatr Neurol** 1997 Jan; 16(1):14–6 (22 ref.)

COMPLICATIONS

Severe liver impairment in a cystic fibrosis-affected child homozygous for the G542X mutation. Castaldo G, et al. **Am J Med Genet** 1997 Mar 17;69(2):155–8 (21 ref.)

Indurated plaques of mycosis fungoides in a woman with fulminant hepatic failure. Vannucci SA, et al. **Cutis** 1996 Mar;57(3):159–62 (11 ref.)

Perioperative anti-endotoxin strategies. Houdijk AP, et al. **Scand J Gastroenterol Suppl** 1997;222:93–7 (57 ref.)

PHYSIOPATHOLOGY

Cerebral circulation in liver failure: Ohm's law in force. Larsen FS. **Semin Liver Dis** 1996 Aug;16(3):281–92 (98 ref.)

SURGERY

Liver transplantation for pediatric patients: a review and update. Kleinman RE. **Acta Paediatr Sin** 1996 Mar–Apr; 37(2):81–91 (76 ref.)

Fair treatment of alcoholic patients in the context of liver transplantation. Shelton W, et al. **Alcohol Clin Exp Res** 1997 Feb;21(1):93–100 (33 ref.)

Hepatocyte transplantation. Habibullah CM, et al. **Indian J Gastroenterol** 1996 Jan;15(1):16–9 (31 ref.)

[Is "terminal" liver damage reversible? Value, practicality and future of bridging techniques for the liver] Gubernatis G, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996; 113:380–8 (22 ref.) **(Ger)**

THERAPY

Support of acute liver failure patients with a bioartificial liver. Watanabe FD, et al. **J Clin Apheresis** 1996;11(3):138–42 (15 ref.)

Liver transplantation for acute liver failure: outcome analysis. Shakil AO, et al. **J Viral Hepat** 1997;4 Suppl 1:107–10 (27 ref.)

Bioartificial livers: the state of the art [see comments] Anand AC. **Trop Gastroenterol** 1996 Oct–Dec;17(4):202–11 (106 ref.) Comment in: Trop Gastroenterol 1996 Oct–Dec;17(4):197–8.

LIVER FAILURE, ACUTE

Ammonia and glutamine metabolism during liver insufficiency: the role of kidney and brain in interorgan nitrogen exchange. Dejong CH, et al. **Scand J Gastroenterol Suppl** 1996;218:61–77 (134 ref.)

Circulatory, respiratory, cerebral, and renal derangements in acute liver failure: pathophysiology and management. Ellis A, et al. **Semin Liver Dis** 1996 Nov;16(4):379–88 (63 ref.)

The American experience with transplantation for acute liver failure. McCashland TM, et al. **Semin Liver Dis** 1996 Nov; 16(4):427–33 (63 ref.)

CHEMICALLY INDUCED

The complex interaction between ethanol and acetaminophen. Slattery JT, et al. **Clin Pharmacol Ther** 1996 Sep;60(3):241–6 (49 ref.)

Paracetamol hepatotoxicity: how to prevent. O'Grady JG. **J R Soc Med** 1997 Jul;90(7):368–70 (12 ref.)

Acute hepatic failure related to chronic acetaminophen intoxication. Luria JW, et al. **Pediatr Emerg Care** 1996 Aug; 12(4):291–3 (13 ref.)

Unusual complications of paracetamol poisoning. Jones AL, et al. **QJM** 1997 Mar;90(3):161–8 (148 ref.)

COMPLICATIONS

Hepatic encephalopathy. Mullen KD, et al. **Gastroenterologist** 1996 Sep;4(3):188–202 (185 ref.)

Hepatic encephalopathy and brain edema in acute hepatic failure: does glutamate play a role? [editorial; comment] Butterworth RF. **Hepatology** 1997 Apr;25(4):1032–4 (27

ref.) Comment on: Hepatology 1997 Apr;25(4):820-7.

ETIOLOGY

Acute liver failure due to hepatic involvement by hematologic malignancy. Shehab TM, et al. **Dig Dis Sci** 1997 Jul;42(7):1400-5 (28 ref.)

Small-cell carcinoma of the lung manifesting as acute hepatic failure [see comments] McGuire BM, et al. **Mayo Clin Proc** 1997 Feb;72(2):133-9 (43 ref.) Comment in: Mayo Clin Proc 1997 Aug;72(8):791.

Classification, etiology, and considerations of outcome in acute liver failure. Williams R. **Semin Liver Dis** 1996 Nov; 16(4):343-8 (39 ref.)

Pathogenesis of acute liver failure [see comments] O'Grady JG. **Trop Gastroenterol** 1996 Oct-Dec;17(4):199-201 (24 ref.) Comment in: Trop Gastroenterol 1996 Oct-Dec;17(4):197-8.

METABOLISM

Pathophysiological changes in cerebral circulation, oxidative metabolism and blood-brain barrier in patients with acute liver failure. Tailored cerebral oxygen utilization. Larsen FS, et al. **J Hepatol** 1997 Jul;27(1):231-8 (65 ref.)

MICROBIOLOGY

Bacterial and fungal infection in acute liver failure. Rolando N, et al. **Semin Liver Dis** 1996 Nov;16(4):389-402 (89 ref.)

PHYSIOPATHOLOGY

Pathophysiological changes in cerebral circulation, oxidative metabolism and blood-brain barrier in patients with acute liver failure. Tailored cerebral oxygen utilization. Larsen FS, et al. **J Hepatol** 1997 Jul;27(1):231-8 (65 ref.)

The management of abnormalities of hemostasis in acute liver failure. Pereira SP, et al. **Semin Liver Dis** 1996 Nov; 16(4):403-14 (193 ref.)

PREVENTION & CONTROL

Paracetamol-induced acute liver failure: prevention and management. O'Grady JG. **J Hepatol** 1997;26 Suppl 1:41-6 (45 ref.)

Paracetamol hepatotoxicity: how to prevent. O'Grady JG. **J R Soc Med** 1997 Jul;90(7):368-70 (12 ref.)

RADIOGRAPHY

CT findings in ischaemic hepatic failure due to intra-arterial embolisation: a case report. Catalano O. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Jan;166(1):81-3 (18 ref.)

SURGERY

Liver transplantation in Europe for patients with acute liver failure. Bismuth H, et al. **Semin Liver Dis** 1996 Nov; 16(4):415-25 (41 ref.)

Liver transplantation for the treatment of fulminant hepatic failure induced by the ingestion of ecstasy. Brauer RB, et al. **Transpl Int** 1997;10(3):229-33 (11 ref.)

THERAPY

Cell-based therapy of acute liver failure: the extracorporeal bioartificial liver. Frémond B, et al. **Cell Biol Toxicol** 1996 Dec;12(4-6):325-9 (20 ref.)

Development of a hybrid liver support system: a review. Gerlach JC. **Int J Artif Organs** 1996 Nov;19(11):645-54 (54 ref.)

Paracetamol-induced acute liver failure: prevention and management. O'Grady JG. **J Hepatol** 1997;26 Suppl 1:41-6 (45 ref.)

Use of bioartificial and artificial liver support devices. Hughes RD, et al. **Semin Liver Dis** 1996 Nov;16(4):435-44 (61 ref.)

Management of acute liver failure. Lee WM. **Semin Liver Dis** 1996 Nov;16(4):369-78 (76 ref.)

LIVER FAILURE, FULMINANT see **HEPATIC ENCEPHALOPATHY**

LIVER FIBROSIS see **LIVER CIRRHOSIS**

LIVER FUNCTION TESTS

The liver: new functional, prognostic and diagnostic tests. Tredger JM, et al. **Ann Clin Biochem** 1997 Mar;34 (Pt 2):121-41 (225 ref.)

Investigation of the patient with abnormal liver function tests. Noack KB, et al. **Baillieres Clin Gastroenterol** 1997 Mar; 11(1):83-95 (49 ref.)

Liver function tests. Renner EL. **Baillieres Clin Gastroenterol** 1995 Dec;9(4):661-77 (145 ref.)

Clinical chemistry and post-liver-transplant monitoring. Hickman PE, et al. **Clin Chem** 1997 Aug;43(8 Pt 2):1546-54 (67 ref.)

Assessing liver function and hyperbilirubinemia in the newborn. National Academy of Clinical Biochemistry. Rosenthal P. **Clin Chem** 1997 Jan;43(1):228-34 (61 ref.)

Assessment of liver function: pre- and peritransplant evaluation. Shaked A, et al. **Clin Chem** 1997 Aug;43(8 Pt 2):1539-45 (53 ref.)

Mild liver enzyme abnormalities: eliminating hemochromatosis as cause. Witte DL. **Clin Chem** 1997 Aug; 43(8 Pt 2):1535-8 (26 ref.)

Clinical approach to the patient with abnormal liver test results. Kamath PS. **Mayo Clin Proc** 1996 Nov; 71(11):1089-94; quiz 1094-5 (00 ref.)

Evaluation of tests used to screen patients with liver disorders. Scheig R. **Prim Care** 1996 Sep;23(3):551-60 (9 ref.)

Effects of alcohol and prescription and over-the-counter drug use on liver enzyme profiles. Haley NJ. **Stat Bull Metrop Insur Co** 1995 Oct-Dec;76(4):2-9 (11 ref.)

METHODS

Simultaneous measurement of hundreds of liver proteins: application in assessment of liver function. Anderson NL, et al. **Toxicol Pathol** 1996 Jan-Feb;24(1):72-6 (8 ref.)

Use of precision-cut liver slices as an in vitro tool for evaluating liver function. Gandolfi AJ, et al. **Toxicol Pathol** 1996 Jan-Feb;24(1):58-61 (37 ref.)

[Indocyanine green and sulfobromophthalein tests] Sato T. **Nippon Rinsho** 1997 Apr;55 Suppl 2:177-9 (0 ref.) **(Jpn)**

LIVER GLYCOGEN

BIOSYNTHESIS

Bridging the gap between glucose phosphorylation and glycogen synthesis in the liver. Guinovart JJ, et al. **Biochem Soc Trans** 1997 Feb;25(1):157-60 (21 ref.)

METABOLISM

New insight into the regulation of liver glycogen metabolism by glucose. Stalmans W, et al. **Biochem Soc Trans** 1997 Feb;25(1):19-25 (35 ref.)

LIVER MICROSOMES see **MICROSOMES, LIVER**

LIVER MITOCHONDRIA see **MITOCHONDRIA, LIVER**

LIVER NEOPLASMS

Gamma/delta T-cell hepatosplenic lymphoma: review of the literature, diagnosis by flow cytometry and concomitant autoimmune hemolytic anemia. Sallah S, et al. **Ann Hematol** 1997 Mar;74(3):139-42 (15 ref.)

Hepatocellular carcinoma. Lau WY, et al. **Br J Hosp Med** 1997 Feb 5-18;57(3):101-4 (20 ref.)

Small hepatocellular carcinoma: past, present and future. Tang Z. **Chin Med J (Engl)** 1996 Jan;109(1):21-4 (31 ref.)

Fibrolamellar hepatocellular carcinoma. Case reports and a review of the literature. Saab S, et al. **Dig Dis Sci** 1996 Oct;41(10):1981-5 (40 ref.)

Hepatocellular carcinoma. Manns MP, et al. **Digestion** 1997; 58 Suppl 1:69-75 (111 ref.)

Pathogenesis of primary hepatocellular carcinoma. Curry GW, et al. **Eur J Gastroenterol Hepatol** 1996 Sep;8(9):850-5 (120 ref.)

The medical management of hepatocellular carcinoma (HCC) in Japan: a review with implications for HCC seen in the west. Ichida T, et al. **Hepatogastroenterology** 1996 Nov-Dec;43(12):1575-83 (37 ref.)

Hepatocellular carcinoma. Johnson RC. **Hepatogastroenterology** 1997 Jan-Feb;44(13):307-12 (43 ref.)

Hepatitis C and hepatocellular carcinoma. Di Bisceglie AM. **Hepatology** 1997 Sep;26(3 Suppl 1):34S-38S (47 ref.)

Primary lymphoma of the liver in AIDS. Report of one new case and review of the literature. Scerpella EG, et al. **J Clin Gastroenterol** 1996 Jan;22(1):51-3 (20 ref.)

Primary hepatic non-Hodgkin's lymphoma in children: a case report and review of the literature. Ramos G, et al. **Med Pediatr Oncol** 1997 May;28(5):370-2 (12 ref.)

Recent developments in screening, diagnosis and surgical treatment of hepatocellular carcinoma. IJzermans JN, et al. **Scand J Gastroenterol Suppl** 1997;223:50-4 (45 ref.)

Primary epithelial hepatic malignancies: etiology, epidemiology, and outcome after subtotal and total hepatic resection. Nagorney DM, et al. **Surg Oncol Clin N Am** 1996 Apr;5(2):283-300 (121 ref.)

Hepatic hemangioma: a review. Iqbal N, et al. **Tex Med** 1997 May;93(5):48-50 (24 ref.)

Aflatoxin and liver injury. Bhat RV. **Trop Gastroenterol** 1996 Jul-Sep;17(3):153-60 (75 ref.)

BLOOD SUPPLY

Blood flow and liver imaging. Itai Y, et al. **Radiology** 1997 Feb;202(2):306-14 (80 ref.)

CHEMICALLY INDUCED

Hepatocarcinogenesis of peroxisome proliferators. Rao MS, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:573-87 (142 ref.)

Non-genotoxic hepatocarcinogenesis: suppression of apoptosis by peroxisome proliferators. Roberts RA. **Ann N Y Acad Sci** 1996 Dec 27;804:588-611 (97 ref.)

Mechanism-based risk assessment of peroxisome proliferating rodent hepatocarcinogens. Williams GM, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:554-72 (69 ref.)

Molecular biomarkers for aflatoxins: from adducts to gene mutations to human liver cancer. Groopman JD, et al. **Can J Physiol Pharmacol** 1996 Feb;74(2):203-9 (40 ref.)

Hepatocarcinogenic potential of di(2-ethylhexyl)phthalate in rodents and its implications on human risk. Huber WW, et al. **Crit Rev Toxicol** 1996 Jun;26(4):365-481 (483 ref.)

Cyproterone acetate: is it hepato- or genotoxic? Rabe T, et al. **Drug Saf** 1996 Jan;14(1):25-38 (60 ref.)

Tamoxifen and secondary tumours. An update. Wilking N, et al. **Drug Saf** 1997 Feb;16(2):104-17 (151 ref.)

Hepatocellular carcinoma p53 G > T transversions at codon 249: the fingerprint of aflatoxin exposure? Lasky T, et al. **Environ Health Perspect** 1997 Apr;105(4):392-7 (48 ref.)

Malignant hepatic tumours associated with previous exposure to Thorotrast: four cases. Lee FI, et al. **Eur J Gastroenterol Hepatol** 1996 Nov;8(11):1121-4 (22 ref.)

Methylene chloride induced mouse liver and lung tumours: an overview of the role of mechanistic studies in human safety assessment. Green T. **Hum Exp Toxicol** 1997 Jan; 16(1):3-13 (60 ref.)

The molecular mechanism of aflatoxin B1-induced liver cancer: is mitotic recombination involved? Sengstag C. **Mol Carcinog** 1997 Jul;19(3):147-52 (22 ref.)

Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Shen HM, et al. **Mutat Res** 1996 Oct;366(1):23-44 (167 ref.)

Adducts and tamoxifen. Busch H. **Semin Oncol** 1997 Feb;24(1 Suppl 1):S1-98-S1-104 (37 ref.)

Relevance of rat liver tumors to human hepatic and endometrial cancer. Guzelian PS. **Semin Oncol** 1997 Feb; 24(1 Suppl 1):S1-105-S1-21 (130 ref.)

Review of the toxicology of tamoxifen. Wogan GN. **Semin Oncol** 1997 Feb;24(1 Suppl 1):S1-87-S1-97 (36 ref.)

CLASSIFICATION

[TNM classification of liver cancer] Yamasaki S. **Gan To Kagaku Ryoho** 1997 Jul;24(9):1175-82 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Surgical classification of liver local lesions] Konstantinov BA, et al. **Khirurgiia (Mosk)** 1997;(2):18-20 (9 ref.) (Eng. Abstr.) **(Rus)**

COMPLICATIONS

Primary sinusoidal lymphoma of the liver revealed by autoimmune hemolytic anemia. Pouderoux P, et al. **Gastroenterol Clin Biol** 1997;21(6-7):514-8 (23 ref.)

Traumatic rupture of hepatic hemangioma. Hotokezaka M, et al. **J Clin Gastroenterol** 1996 Jul;23(1):69-71 (20 ref.)

Case report: primary hepatic lymphoma associated with chronic liver disease. Higuchi T, et al. **J Gastroenterol Hepatol** 1997 Mar;12(3):237-42 (90 ref.)

Small-cell carcinoma of the lung manifesting as acute hepatic failure [see comments] McGuire BM, et al. **Mayo Clin Proc** 1997 Feb;72(2):133-9 (43 ref.) Comment in: Mayo Clin Proc 1997 Aug;72(8):791.

Hepatic angiomyolipoma developing during the follow-up of ulcerative colitis: report of a case and review of the literature. Suzuki S, et al. **Surg Today** 1996;26(8):635-9 (44 ref.)

[Hemobilia disclosing very small hepatocellular carcinoma ruptured into the biliary ducts] Cajot O, et al. **Gastroenterol Clin Biol** 1997;21(5):426-9 (19 ref.) (Eng. Abstr.) **(Fre)**

[The superior vena cava occlusion syndrome. A case of neoplastic thrombosis due to hepatocarcinoma and cirrhosis] Zanetti PP, et al. **Minerva Chir** 1997 Apr; 52(4):455-9 (20 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Hepatocellular carcinoma in primary biliary cirrhosis. Turissini SB, et al. **Am J Gastroenterol** 1997 Apr; 92(4):676-8 (26 ref.)

Imaging: focus on hepatocellular carcinoma and liver transplantation. Redhead DN, et al. **Baillieres Clin Gastroenterol** 1995 Dec;9(4):771-90 (66 ref.)

MRI of the liver. A pictorial essay. Shapiro RS, et al. **Clin Imaging** 1997 Jul-Aug;21(4):293-302 (34 ref.)

The characterization of liver tumours by MRI. Robinson PJ. **Clin Radiol** 1996 Nov;51(11):749-61 (145 ref.)

Screening for hepatocellular carcinoma. Haydon GH, et al. **Eur J Gastroenterol Hepatol** 1996 Sep;8(9):856-60 (49 ref.)

Imaging of metastases to the liver. Mahfouz AE, et al. **Eur Radiol** 1996;6(5):607-14 (60 ref.)

MR imaging characteristics of hepatic tumors. Martí-Bonmatí L. **Eur Radiol** 1997;7(2):249-58 (48 ref.)

ICG clearance in assessing cirrhotic patients with hepatocellular carcinoma for major hepatic resection. Kitano S, et al. **HPB Surg** 1997;10(3):182-3 (9 ref.)

Cystic mesenchymal hamartoma of the liver--a rare condition. Motiwale SS, et al. **Indian J Cancer** 1996 Sep; 33(3):157-60 (15 ref.)

Diagnostic imaging of primary hepatic leiomyosarcoma: a case report. Civardi G, et al. **Ital J Gastroenterol** 1996 Feb-Mar;28(2):98-101 (10 ref.)

Hepatic cystic mass with a daughter cyst: a feature of mucinous cystadenoma. Verbeeck N, et al. **J Belge Radiol** 1997 Jun;80(3):113-5 (8 ref.)

Mucinous biliary cystadenoma with mesenchymal stroma: expressions of CA 19-9 and carcinoembryonic antigen in serum and cystic fluid. Lee JH, et al. **J Gastroenterol** 1996 Oct;31(5):732-6 (22 ref.)

Mixed hepatoblastoma in an adult--a case report and literature review. Ahn HJ, et al. **J Korean Med Sci** 1997 Aug;12(4):369-73 (23 ref.)

Hepatic adenomatosis in an adolescent. Gokhale R, et al.

J Pediatr Gastroenterol Nutr 1996 Nov;23(4):482–6 (24 ref.)

Imaging of pediatric liver tumors. Buetow PC, et al. **Magn Reson Imaging Clin N Am** 1997 May;5(2):397–413 (50 ref.)

MR imaging of the liver. Primary malignant neoplasms in the adult. Buetow PC, et al. **Magn Reson Imaging Clin N Am** 1997 May;5(2):289–318 (55 ref.)

Hepatic metastases. Lewis KH, et al. **Magn Reson Imaging Clin N Am** 1997 May;5(2):319–30 (54 ref.)

Benign liver tumors. Mathieu D, et al. **Magn Reson Imaging Clin N Am** 1997 May;5(2):255–88 (71 ref.)

Hepatic hemangiomas. Semelka RC, et al. **Magn Reson Imaging Clin N Am** 1997 May;5(2):241–53 (27 ref.)

Errors and pitfalls in diagnostic cytology of abdominal organs. Silverman JF. **Monogr Pathol** 1997;(39):147–70 (107 ref.)

Focal nodular hyperplasia of the liver: radiologic–pathologic correlation [published erratum appears in Radiographics 1997 Mar–Apr;17(2):524] Buetow PC, et al. **Radiographics** 1996 Mar;16(2):369–88 (40 ref.)

Clinics in diagnostic imaging (14). Cavernous haemangioma of the liver. Ooi GC, et al. **Singapore Med J** 1996 Jun; 37(3):312–4 (10 ref.)

Imaging of primary and metastatic liver tumors. Kruskal JB, et al. **Surg Oncol Clin N Am** 1996 Apr;5(2):231–60 (34 ref.)

Diagnostic criteria for degenerative, inflammatory, proliferative nonneoplastic and neoplastic liver lesions in medaka (Oryzias latipes): consensus of a National Toxicology Program Pathology Working Group. Boorman GA, et al. **Toxicol Pathol** 1997 Mar–Apr;25(2):202–10 (32 ref.)

[Hepatic angiomyolipoma simulating hepatocytic tumor. 3 cases] Arblade S, et al. **Gastroenterol Clin Biol** 1996; 20(11):1022–6 (39 ref.) (Eng. Abstr.) **(Fre)**

[Hepatic hamartoma in adults. Apropos of a case documented by MRI] Beal D, et al. **J Radiol** 1996 Dec;77(12):1229–32 (19 ref.) (Eng. Abstr.) **(Fre)**

[Diagnostic imaging of hepatocellular carcinoma] Vogl TJ, et al. **Dtsch Med Wochenschr** 1997 May 2;122(18):585–8 (13 ref.) **(Ger)**

[Inflammatory pseudotumor of the liver--rare differential diagnosis of undetermined hepatic space–occupying lesion. Case report and review of the literature] Mathiak G, et al. **Langenbecks Arch Chir** 1996;381(6):309–17 (69 ref.) (Eng. Abstr.) **(Ger)**

[1996 review of the literature: liver imaging] Merkle EM, et al. **Rontgenpraxis** 1997 Mar;50(3):55–62 (50 ref.) **(Ger)**

[Diagnosis of hepatocellular carcinoma] Allgaier HP, et al. **Schweiz Med Wochenschr** 1996 Nov 16;126(46):1975–83 (94 ref.) (Eng. Abstr.) **(Ger)**

[Diagnostic imaging of liver metastasis] Damascelli B, et al. **Ann Ital Chir** 1996 Nov–Dec;67(6):739–49 (44 ref.) (Eng. Abstr.) **(Ita)**

[Early discovery of hepatocellular carcinoma] Tanikawa K. **Nippon Naika Gakkai Zasshi** 1997 Mar 10;86(3):402–5 (9 ref.) **(Jpn)**

[Early liver cancer] Takikawa H, et al. **Nippon Rinsho** 1996 May;54(5):1380–4 (17 ref.) (Eng. Abstr.) **(Jpn)**

[A case of hepatic hemangiosarcoma in which heterogeneous MRI findings were useful for diagnosis] Oba S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Jan;94(1):49–55 (13 ref.) **(Jpn)**

[Diagnosis and surgical policy in benign lesions of liver] Malinovskii NN, et al. **Khirurgiia (Mosk)** 1997;(2):21–3 (7 ref.) (Eng. Abstr.) **(Rus)**

[Hepatocellular carcinoma. General aspects of diagnosis and treatment] Manterola C, et al. **Rev Med Chil** 1996 Apr; 124(4):469–79 (44 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Simonetti RG, et al. **Ann Oncol** 1997 Feb;8(2):117–36 (54 ref.)

Therapeutic potential of octreotide in the treatment of liver metastases. Davies N, et al. **Anticancer Drugs** 1996 Jan;7 Suppl 1:23–31 (41 ref.)

Treatment of patients with liver metastases. Fumoleau P. **Anticancer Drugs** 1996 Aug;7 Suppl 2:21–3 (24 ref.)

Is intra-arterial chemotherapy worthwhile in the treatment of patients with unresectable hepatic colorectal cancer metastases? Cohen AM, et al. **Eur J Cancer** 1996 Dec; 32A(13):2195–205 (74 ref.)

Ethanol injection for the treatment of hepatic tumours. Bartolozzi C, et al. **Eur Radiol** 1996;6(5):682–96 (99 ref.)

Aggressive high-dose intra-hepatic artery chemotherapy for unresectable hepatocellular carcinoma (HCC). Carr BI. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1379 (0 ref.)

Intraarterial infusion chemotherapy for unresectable hepatic metastases from colorectal cancer. Fujii M. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1381–4 (5 ref.)

Arterial infusion chemotherapy for peritoneal and liver metastasis in gastric cancer. Kitamura M, et al. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:45–51 (14 ref.)

Mitoxantrone, 5-FU + folinic acid, mitomycin C for regional chemotherapy of malignant liver tumors. Link KH, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1380 (0 ref.)

Chemotherapy for metastatic melanoma during pregnancy. Dipaola RS, et al. **Gynecol Oncol** 1997 Sep;66(3):526–30 (21 ref.)

Locoregional immuno-chemotherapy in liver carcinoma--present and future. Okuno K, et al. **Hepatogastroenterology** 1995 Sep–Oct;42(5):578–86 (38 ref.)

Optimal locoregional immunochemotherapy after tumor-mass reduction for advanced hepatocellular carcinoma. Yamamoto M, et al. **Hepatogastroenterology** 1995 Sep–Oct;42(5):567–77 (35 ref.)

Intra-hepatic arterial drug delivery. Blesing CH, et al. **J Drug Target** 1996;3(5):341–7 (63 ref.)

Update on hepatic intra-arterial chemotherapy. Venook AP. **Oncology (Huntingt)** 1997 Jul;11(7):947–57; discussion 961–2, 964, 970 (51 ref.)

Use of novel beta-L(–)-nucleoside analogues for treatment and prevention of chronic hepatitis B virus infection and hepatocellular carcinoma. Bridges EG, et al. **Prog Liver Dis** 1995;13:231–45 (70 ref.)

Hepatic tumors in children. Newman KD. **Semin Pediatr Surg** 1997 Feb;6(1):38–41 (30 ref.)

Theoretic and experimental aspects of regional liver infusion. August DA. **Surg Oncol Clin N Am** 1996 Apr;5(2):399–409 (36 ref.)

Clinical and preclinical trials of isolated liver perfusion for advanced liver tumors: primary liver tumors. Lowy AM, et al. **Surg Oncol Clin N Am** 1996 Apr;5(2):429–41 (18 ref.)

Isolated liver perfusion for liver metastases: pharmacokinetic advantage? Ravikumar TS, et al. **Surg Oncol Clin N Am** 1996 Apr;5(2):443–9 (22 ref.)

Regional chemotherapy approaches for primary and metastatic liver tumors. Venook AP, et al. **Surg Oncol Clin N Am** 1996 Apr;5(2):411–427 (96 ref.)

[Hepatic metastases of colorectal cancers: intra-arterial chemotherapy. Value and indications] Rougier P, et al. **Presse Med** 1996 Nov 16;25(35):1683–8 (32 ref.) (Eng. Abstr.) **(Fre)**

[Adjuvant chemotherapy following liver metastasis resection in neoplasms of the colorectum] Bajetta E, et al. **Ann Ital Chir** 1996 Nov–Dec;67(6):813–7 (25 ref.) (Eng. Abstr.) **(Ita)**

[Locoregional chemotherapy of liver metastasis from colorectal carcinoma] Zamparelli G, et al. **Ann Ital Chir** 1996 Nov–Dec;67(6):793–7 (30 ref.) (Eng. Abstr.) **(Ita)**

[Lipiodol with and without Gelfoam in primary liver tumors. Plasma levels of Mitoxantrone and clinical results] Civalleri D, et al. **G Chir** 1997 Jun–Jul;18(6–7):362–7 (36 ref.) (Eng. Abstr.) **(Ita)**

[Case of malignant pheochromocytoma with successful control of systemic metastasis with CVD chemotherapy] Minami T, et al. **Nippon Naika Gakkai Zasshi** 1996 Dec 10;85(12):2078–80 (10 ref.) **(Jpn)**

[Percutaneous ethanol injection therapy for small hepatocellular carcinoma] Otsuka S. **Nippon Rinsho** 1996 May;54(5):1347–50 (14 ref.) (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

Hexokinase expression in liver preneoplasia and neoplasia. Mayer D, et al. **Biochem Soc Trans** 1997 Feb;25(1):122–7 (32 ref.)

Telomerase in hepatocellular carcinogenesis. Ide T, et al. **Hum Cell** 1996 Dec;9(4):283–6 (2 ref.)

EPIDEMIOLOGY

Primary hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Kiszkis H. **Arch Immunol Ther Exp (Warsz)** 1996;44(5–6):315–23 (50 ref.)

The epidemiology of hepatocellular carcinoma. Johnson PJ. **Eur J Gastroenterol Hepatol** 1996 Sep;8(9):845–9 (50 ref.)

Hepatoblastoma in adult age: a report of two cases. Bortolasi L, et al. **Hepatogastroenterology** 1996 Jul–Aug; 43(10):1073–8 (21 ref.)

Leiomyosarcoma occurring in the ligamentum teres of the liver: a case report and a review of seven reported cases. Yamaguchi J, et al. **Hepatogastroenterology** 1996 Jul–Aug; 43(10):1051–6 (13 ref.)

An 18-year follow-up of primary hepatic carcinoid with carcinoid syndrome. Mehta DC, et al. **J Clin Gastroenterol** 1996 Jul;23(1):60–2 (22 ref.)

[Epidemiology of hepatocellular carcinoma in the department of Calvados] Even C, et al. **Gastroenterol Clin Biol** 1997; 21(6–7):450–8 (53 ref.) (Eng. Abstr.) **(Fre)**

[The epidemiology, risk factors and prevention of liver cancer] Ribes Puig J, et al. **Gastroenterol Hepatol** 1997 May;20(5):248–58 (94 ref.) **(Spa)**

ETIOLOGY

Hepatitis B virus X antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma. Feitelson MA, et al. **Am J Pathol** 1997 Apr; 150(4):1141–57 (164 ref.)

Primary hepatic lymphoma associated with chronic hepatitis C. Andres E, et al. **Ann Med Interne (Paris)** 1997; 148(3):280–3 (18 ref.)

Interspecies comparison of liver carcinogenesis: implications for cancer risk assessment. Grisham JW. **Carcinogenesis** 1997 Jan;18(1):59–81 (418 ref.)

Alcohol and other chemicals in the development of hepatocellular carcinoma. Farber E. **Clin Lab Med** 1996 Jun;16(2):377–94 (80 ref.)

Increasing evidence that hepatitis B virus X gene protein and p53 protein may interact in the pathogenesis of hepatocellular carcinoma. Kew MC. **Hepatology** 1997 Apr; 25(4):1037–8 (16 ref.)

Squamous cell carcinoma of the liver originating from a solitary non-parasitic cyst case report and review of the literature. Weimann A, et al. **HPB Surg** 1996;10(1):45–9 (24 ref.)

Primary liver cancer is of multifactorial origin: importance of hepatitis B virus infection and dietary aflatoxin. Saracco G. **J Gastroenterol Hepatol** 1995 Sep–Oct;10(5):604–8 (38 ref.)

Hepatitis C virus infection as a major risk factor for hepatocellular carcinoma. Caselmann WH, et al. **J Hepatol** 1996;24(2 Suppl):61–6 (65 ref.)

Hepatitis B virus transcriptional activators: mechanisms and possible role in oncogenesis. Henkler F F, et al. **J Viral Hepat** 1996 May;3(3):109–21 (129 ref.)

HCV and liver cancer: the epidemiological evidence. Bosch FX. **Princess Takamatsu Symp** 1995;25:15–25 (39 ref.)

Hepatitis B and C viruses in hepatitis B surface antigen negative hepatocellular carcinoma patients. Bréchot C, et al. **Princess Takamatsu Symp** 1995;25:199–209 (57 ref.)

Viral co-factors in liver cancer: lessons from hepatitis B virus. Butel JS, et al. **Princess Takamatsu Symp** 1995; 25:185–98 (70 ref.)

Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan. Chen DS. **Princess Takamatsu Symp** 1995;25:27–32 (24 ref.)

Hepatitis C virus infection in black patients with hepatocellular carcinoma in southern Africa. Kew MC. **Princess Takamatsu Symp** 1995;25:33–40 (26 ref.)

Molecular and genetic epidemiology of hepatocellular carcinoma: studies in China and Senegal. London WT, et al. **Princess Takamatsu Symp** 1995;25:51–60 (22 ref.)

Association of hepatitis C virus and hepatocellular carcinoma in the United States. Reid AE, et al. **Princess Takamatsu Symp** 1995;25:41–9 (29 ref.)

Hepatocarcinogenesis: hepatitis viruses and altered tumor suppressor gene function. Tabor E. **Princess Takamatsu Symp** 1995;25:151–61 (59 ref.)

Pathogenesis of hepatocellular carcinoma: sequential cellular, molecular, and metabolic changes. Bannasch P. **Prog Liver Dis** 1996;14:161–97 (254 ref.)

Liver graft-transmitted glioblastoma multiforme. A case report and experience with 13 multiorgan donors suffering from primary cerebral neoplasia [see comments] Jonas S, et al. **Transpl Int** 1996;9(4):426–9 (16 ref.) Comment in: Transpl Int 1997;10(1):83–4.

[Advances in the research on relation between sex hormones and liver cancers] Ren Z, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Sep;76(9):714–6 (19 ref.) **(Chi)**

[Hepatocellular carcinoma in asymptomatic primary biliary cirrhosis] Lucidarme D, et al. **Rev Med Interne** 1996; 17(7):568–70 (19 ref.) (Eng. Abstr.) **(Fre)**

[Regulation mechanism of specific expression of tumor marker gene during carcinogenesis] Imagawa M. **Yakugaku Zasshi** 1996 Jul;116(7):505–18 (29 ref.) (Eng. Abstr.) **(Jpn)**

[Hepatocellular cancer with a background of liver cirrhosis] Zhuravlev VA, et al. **Klin Med (Mosk)** 1996;74(2):2–5 (53 ref.) **(Rus)**

GENETICS

Hepatosplenic gamma/delta T-cell lymphoma: a report of two cases in immunocompromised patients, associated with isochromosome 7q. François A, et al. **Am J Surg Pathol** 1997 Jul;21(7):781–90 (43 ref.)

Hepatocellular carcinoma p53 G > T transversions at codon 249: the fingerprint of aflatoxin exposure? Lasky T, et al. **Environ Health Perspect** 1997 Apr;105(4):392–7 (48 ref.)

Imprinted genes in liver carcinogenesis. De Souza AT, et al. **FASEB J** 1997 Jan;11(1):60–7 (136 ref.)

Hepatoblastoma in a child with trisomy 18: cytogenetics, liver anomalies, and literature review. Bove KE, et al. **Pediatr Pathol Lab Med** 1996 Mar–Apr;16(2):253–62 (39 ref.)

[Genetic alterations associated with hepatocellular carcinoma] Boige V, et al. **Gastroenterol Clin Biol** 1997; 21(1):34–44 (132 ref.) **(Fre)**

MICROBIOLOGY

Liver tumorigenesis by Helicobacter hepaticus: considerations of mechanism. Canella KA, et al. **In Vivo** 1996 May–Jun;10(3):285–92 (70 ref.)

MORTALITY

Long-term survival after hepatic cryosurgery versus surgical resection for metastatic colorectal carcinoma: a critical review of the literature. Tandan VR, et al. **Can J Surg** 1997 Jun;40(3):175–81 (23 ref.)

Management of hepatocellular carcinoma: long-term outcome in 2639 cases. Zhou XD, et al. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:9–16 (26 ref.)

NURSING

Cryosurgical ablation of unresectable hepatic tumors [published erratum appears in AORN J 1996 Nov;64(5):686] Zuro LM, et al. **AORN J** 1996 Aug;64(2):231–6, 239–44; quiz 244–6, 248–50 (37 ref.)

LIVER NEOPLASMS

PATHOLOGY

Primary hepatic malignant tumor with rhabdoid features. A histological, immunocytochemical, and electron microscopic study of four cases and a review of the literature. Scheimberg I, et al. **Am J Surg Pathol** 1996 Nov; 20(11):1394–400 (27 ref.)

Follicular dendritic cell tumor of the liver. Evidence for an Epstein–Barr virus–related clonal proliferation of follicular dendritic cells. Shek TW, et al. **Am J Surg Pathol** 1996 Mar;20(3):313–24 (45 ref.)

Yolk sac tumor of the liver combined with hepatocellular carcinoma. Morinaga S, et al. **Arch Pathol Lab Med** 1996 Jul;120(7):687–90 (20 ref.)

Epithelioid hemangioendothelioma of the liver. A rare hepatic tumor. Läuffer JM, et al. **Cancer** 1996 Dec 1; 78(11):2318–27 (68 ref.)

Nodular hematopoiesis of the liver diagnosed by fine–needle aspiration cytology. Lemos LB, et al. **Diagn Cytopathol** 1997 Jan;16(1):51–4 (40 ref.)

Inflammatory pseudotumour of the liver with malignant transformation. Report of two cases. Zavaglia C, et al. **Ital J Gastroenterol** 1996 Apr;28(3):152–9 (43 ref.)

Case report: fibrolamellar hepatocellular carcinoma in a Japanese woman: a case report and review of Japanese cases. Hoshino H, et al. **J Gastroenterol Hepatol** 1996 Jun; 11(6):551–5 (25 ref.)

Effect of partial liver resection on tumour growth. de Jong KP, et al. **J Hepatol** 1996 Jul;25(1):109–21 (173 ref.)

Mandibular metastatic hepatocellular carcinoma: a case involving severe postbiopsy hemorrhage. Ashar A, et al. **J Oral Maxillofac Surg** 1997 Jun;55(6):547–52 (36 ref.)

Hepatocellular carcinoma metastatic to the mandibular ramus and condyle: report of a case and review of the literature. Yoshimura Y, et al. **J Oral Maxillofac Surg** 1997 Mar; 55(3):297–306 (38 ref.)

Hepatocellular carcinomas diagnosed following metastasis to the oral cavity. Report of 2 cases. Llanes F, et al. **J Periodontol** 1996 Jul;67(7):717–9 (7 ref.)

The molecular mechanism of aflatoxin B1–induced liver cancer: is mitotic recombination involved? Sengstag C. **Mol Carcinog** 1997 Jul;19(3):147–52 (22 ref.)

Apoptosis and cancer risk assessment. Goldsworthy TL, et al. **Mutat Res** 1996 Sep;365(1–3):71–90 (95 ref.)

Management of primary and metastatic tumors to the liver. Sardi A, et al. **Oncology (Huntingt)** 1996 Jun;10(6):911–25; discussion 926, 929–30 (138 ref.)

Sarcomatoid hepatocellular carcinoma with osteoclast–like giant cells: case report and immunohistochemical observations. Sasaki A, et al. **Pathol Int** 1997 May; 47(5):318–24 (30 ref.)

Preneoplastic lesions in chronic hepatitis C. Thung SN, et al. **Princess Takamatsu Symp** 1995;25:171–8 (40 ref.)

Diagnostic criteria for degenerative, inflammatory, proliferative nonneoplastic and neoplastic liver lesions in medaka (Oryzias latipes): consensus of a National Toxicology Program Pathology Working Group. Boorman GA, et al. **Toxicol Pathol** 1997 Mar–Apr;25(2):202–10 (32 ref.)

[Tumors of the liver: morphological tests] Kunstlinger F. **Ann Chir** 1997;51(2):145–51 (43 ref.) (Eng. Abstr.) **(Fre)**

[Infantile hepatic hemangioendothelioma of the liver: report of 11 cases] Presedo A, et al. **Cir Pediatr** 1996 Apr;9(2):51–4 (11 ref.) (Eng. Abstr.) **(Spa)**

[Spontaneous bacterial peritonitis and primary hepatic lymphoma in a female patient with human immunodeficiency virus infection (letter)] Sancho JM, et al. **Med Clin (Barc)** 1997 Feb 15;108(6):238 (7 ref.) **(Spa)**

PHYSIOPATHOLOGY

Importance of cell kinetics rhythmicity for the control of cell proliferation and carcinogenesis in rat liver (review). Barbason H, et al. **In Vivo** 1995 Nov–Dec;9(6):539–48 (33 ref.)

[Proliferation of peroxisomes and the hepatocarcinogenic process] Palut D. **Rocz Panstw Zakl Hig** 1997;48(1):1–11 (65 ref.) (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

Prevention of liver cancer and cirrhosis by vaccines. Prince AM. **Clin Lab Med** 1996 Jun;16(2):493–505 (80 ref.)

Chemoprevention by inducers of carcinogen detoxication enzymes. Kensler TW. **Environ Health Perspect** 1997 Jun; 105 Suppl 4:965–70 (55 ref.)

Chemoprevention of primary liver cancer. Buiatti E. **IARC Sci Publ** 1996;(136):41–3 (18 ref.)

Carcinogen–DNA and protein adducts: biomarkers for cohort selection and modifiable endpoints in chemoprevention trials. Kensler TW, et al. **J Cell Biochem Suppl** 1996;25:85–91 (30 ref.)

Hepatitis B virus, the vaccine, and the control of primary cancer of the liver. Blumberg BS. **Proc Natl Acad Sci U S A** 1997 Jul 8;94(14):7121–5 (4 ref.)

Use of novel beta–L(–)–nucleoside analogues for treatment and prevention of chronic hepatitis B virus infection and hepatocellular carcinoma. Bridges EG, et al. **Prog Liver Dis** 1995;13:231–45 (70 ref.)

[Towards a chemoprevention of hepatocellular carcinoma? (editorial)] Ganne–Carrié N, et al. **Gastroenterol Clin Biol** 1997;21(6–7):447–9 (31 ref.) **(Fre)**

[Inhibitory effect of FOY–305 on liver metastasis of the pancreatic cancer] Ohta T, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1669–72 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Early detection of hepatobiliary cancer in mass health screening] Kiyosawa K, et al. **Nippon Rinsho** 1996 May; 54(5):1425–30 (12 ref.) (Eng. Abstr.) **(Jpn)**

[The epidemiology, risk factors and prevention of liver cancer] Ribes Puig J, et al. **Gastroenterol Hepatol** 1997 May;20(5):248–58 (94 ref.) **(Spa)**

RADIOGRAPHY

CT arterial portography: technique, indications and applications. Redvanly RD, et al. **Clin Radiol** 1997 Apr; 52(4):256–68 (67 ref.)

Spontaneous rupture of a hepatic angiomyolipoma: CT findings and literature review. Guidi G, et al. **Eur Radiol** 1997;7(3):335–7 (32 ref.)

Helical biphasic contrast–enhanced CT of the liver: technique, indications, interpretation, and pitfalls. Oliver JH 3rd, et al. **Radiology** 1996 Oct;201(1):1–14 (34 ref.)

[Contrast enhanced CT] Kohno A, et al. **Nippon Rinsho** 1996 May;54(5):1249–54 (14 ref.) (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE IMAGING

[Diagnosis of hepatic angiomas and 99m–Tc labeled red cells scintigraphy] Zerbib E, et al. **J Radiol** 1996 Sep;77(9):683–5 (11 ref.) **(Fre)**

[Nuclear medicine approach for the detection and characterization of liver metastasis] Maffioli L, et al. **Ann Ital Chir** 1996 Nov–Dec;67(6):751–9 (63 ref.) (Eng. Abstr.) **(Ita)**

SECONDARY

Regional chemotherapy with blood filtration for non resectable liver metastases. Taton G. **Acta Chir Belg** 1997 Apr;97(2):60–4 (26 ref.)

Active specific immunotherapy in hepatic metastasis. Schlag PM, et al. **Ann Ital Chir** 1996 Nov–Dec;67(6):783–91 (108 ref.)

Biological prospectives to define prognosis and treatment strategies in liver metastases from colorectal cancer. Silvestrini R, et al. **Ann Ital Chir** 1996 Nov–Dec; 67(6):733–7 (36 ref.)

Surgical management of metastatic cancer in the liver. Sugarbaker PH. **Ann Ital Chir** 1996 Nov–Dec;67(6):773–82 (22 ref.)

Colorectal cancer and the liver. Taylor I. **Ann R Coll Surg Engl** 1997 Sep;79(5):315–8 (29 ref.)

Liver transplantation for metastatic neuroendocrine tumors [see comments] Lang H, et al. **Ann Surg** 1997 Apr; 225(4):347–54 (34 ref.) Comment in: Ann Surg 1997 Apr;225(4):345–6.

Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31–case French multicentric report. Le Treut YP, et al. **Ann Surg** 1997 Apr; 225(4):355–64 (33 ref.)

Therapeutic potential of octreotide in the treatment of liver metastases. Davies N, et al. **Anticancer Drugs** 1996 Jan;7 Suppl 1:23–31 (41 ref.)

Treatment of patients with liver metastases. Fumoleau P. **Anticancer Drugs** 1996 Aug;7 Suppl 2:21–3 (24 ref.)

The aetiology and management of hepatic metastases. Hugh TJ, et al. **Aust N Z J Surg** 1997 Jul;67(7):400–9 (90 ref.)

Liver endothelial cells: participation in host response to lymphoma metastasis. Umansky V, et al. **Cancer Metastasis Rev** 1996 Jun;15(2):273–9 (54 ref.)

Liver–directed therapies for gastrointestinal malignancies. McMurrick PJ, et al. **Curr Opin Oncol** 1997 Jul;9(4):367–72 (34 ref.)

Poorly–differentiated adenoid cystic carcinoma: cytologic appearance in fine–needle aspirates of distant metastases. Yu GH, et al. **Diagn Cytopathol** 1996 Nov;15(4):296–300 (27 ref.)

Is intra–arterial chemotherapy worthwhile in the treatment of patients with unresectable hepatic colorectal cancer metastases? Cohen AM, et al. **Eur J Cancer** 1996 Dec; 32A(13):2195–205 (74 ref.)

Repeat resection of recurrent hepatic metastases—improvement in prognosis? Riesener KP, et al. **Eur J Surg** 1996 Sep;162(9):709–15 (36 ref.)

Imaging of metastases to the liver. Mahfouz AE, et al. **Eur Radiol** 1996;6(5):607–14 (60 ref.)

Regional immunotherapy for liver metastases and the potential of TNF alpha in hepatic perfusion from laboratory to the clinic. Eggermont AM. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1371–8 (56 ref.)

Intraarterial infusion chemotherapy for unresectable hepatic metastases from colorectal cancer. Fujii M. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1381–4 (5 ref.)

Arterial infusion chemotherapy for peritoneal and liver metastasis in gastric cancer. Kitamura M, et al. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:45–51 (14 ref.)

Pre– and/or post–operative immunochemotherapy for advanced digestive cancer. Saji S, et al. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:239–49 (14 ref.)

Hepatic resection for metastatic gynecologic carcinomas. Chi DS, et al. **Gynecol Oncol** 1997 Jul;66(1):45–51 (18 ref.)

Liver disease in extrahepatic malignancy. Su AY, et al. **Hematol Oncol Clin North Am** 1996 Aug;10(4):953–66 (45 ref.)

The approach to the patient with single and multiple liver metastases, pulmonary metastases, and intra–abdominal metastases from colorectal carcinoma. VanderMeer TJ, et al. **Hematol Oncol Clin North Am** 1997 Aug;11(4):759–77 (78 ref.)

Adrenocorticotropin–producing pituitary carcinoma with liver metastasis. Lormeau B, et al. **J Endocrinol Invest** 1997 Apr;20(4):230–6 (23 ref.)

Alpha–fetoprotein, carcinoembryonic antigen, and carbohydrate antigen 19–9–producing gallbladder cancer. Ono T, et al. **J Gastroenterol** 1996 Oct;31(5):742–6 (14 ref.)

Pancreatic cancer and hypercalcemia associated with von Recklinghausen's disease. Yamamoto M, et al. **J Gastroenterol** 1996 Oct;31(5):728–31 (28 ref.)

The dead end of 5–fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer. Köhne CH, et al. **J Infus Chemother** 1996 Fall;6(4):206–10 (31 ref.)

Hepatic metastases. Lewis KH, et al. **Magn Reson Imaging Clin N Am** 1997 May;5(2):319–30 (54 ref.)

Small–cell carcinoma of the lung manifesting as acute hepatic failure [see comments] McGuire BM, et al. **Mayo Clin Proc** 1997 Feb;72(2):133–9 (43 ref.) Comment in: Mayo Clin Proc 1997 Aug;72(8):791.

Update on hepatic intra–arterial chemotherapy. Venook AP. **Oncology (Huntingt)** 1997 Jul;11(7):947–57; discussion 961–2, 964, 970 (51 ref.)

Treatment of colorectal cancer: hepatic metastasis. Fong Y, et al. **Semin Surg Oncol** 1996 Jul–Aug;12(4):219–52 (215 ref.)

Invasive therapy of metastatic colorectal cancer to the liver. Millikan KW, et al. **Surg Clin North Am** 1997 Feb; 77(1):27–48 (84 ref.)

Re–resection for colorectal liver metastasis. Bismuth H, et al. **Surg Oncol Clin N Am** 1996 Apr;5(2):353–64 (52 ref.)

Surgical resection of metastatic liver tumors. Kavolius J, et al. **Surg Oncol Clin N Am** 1996 Apr;5(2):337–52 (69 ref.)

Australian experience of cryoablation of liver tumors: metastases. Morris DL, et al. **Surg Oncol Clin N Am** 1996 Apr;5(2):391–7 (12 ref.)

Molecular determinants in the biology of liver metastasis. Radinsky R, et al. **Surg Oncol Clin N Am** 1996 Apr; 5(2):215–29 (74 ref.)

Isolated liver perfusion for liver metastases: pharmacokinetic advantage? Ravikumar TS, et al. **Surg Oncol Clin N Am** 1996 Apr;5(2):443–9 (22 ref.)

Resection of liver metastasis from alpha–fetoprotein–producing early gastric cancer: report of a case. Tsurumachi T, et al. **Surg Today** 1997;27(6):563–6 (11 ref.)

Liver graft–transmitted glioblastoma multiforme. A case report and experience with 13 multiorgan donors suffering from primary cerebral neoplasia [see comments] Jonas S, et al. **Transpl Int** 1996;9(4):426–9 (16 ref.) Comment in: Transpl Int 1997;10(1):83–4.

Treatment of liver metastases of carcinoid tumors. Ahlman H, et al. **World J Surg** 1996 Feb;20(2):196–202 (58 ref.)

[Fulminant or sub–fulminant hepatocellular failure caused by metastatic invasiveness of the liver: an other cause of hypoxic hepatitis?] Henrion J, et al. **Gastroenterol Clin Biol** 1996;20(6–7):535–43 (38 ref.) (Eng. Abstr.) **(Fre)**

[Diagnosis and therapy of liver metastases of neuroendocrine tumors] Lehnert T, et al. **Chirurg** 1997 Feb;68(2):122–31 (63 ref.) (Eng. Abstr.) **(Ger)**

[Repeat interventions in metastases] Seifert JK, et al. **Chirurg** 1997 Mar;68(3):247–54 (37 ref.) (Eng. Abstr.) **(Ger)**

[Adenovirus gene therapy for liver metastases of gastrointestinal tumors. Development status and future prospectives] Block A, et al. **Dtsch Med Wochenschr** 1997 May 30;122(22):728–32 (17 ref.) **(Ger)**

[Adjuvant chemotherapy following liver metastasis resection in neoplasms of the colorectum] Bajetta E, et al. **Ann Ital Chir** 1996 Nov–Dec;67(6):813–7 (25 ref.) (Eng. Abstr.) **(Ita)**

[Diagnostic imaging of liver metastasis] Damascelli B, et al. **Ann Ital Chir** 1996 Nov–Dec;67(6):739–49 (44 ref.) (Eng. Abstr.) **(Ita)**

[Nuclear medicine approach for the detection and characterization of liver metastasis] Maffioli L, et al. **Ann Ital Chir** 1996 Nov–Dec;67(6):751–9 (63 ref.) (Eng. Abstr.) **(Ita)**

[Locoregional chemotherapy of liver metastasis from colorectal carcinoma] Zamparelli G, et al. **Ann Ital Chir** 1996 Nov–Dec;67(6):793–7 (30 ref.) (Eng. Abstr.) **(Ita)**

[Inhibitory effect of FOY–305 on liver metastasis of the pancreatic cancer] Ohta T, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1669–72 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Diagnosis and therapy for metastatic liver cancer] Okuno K, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(10):1255–61 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Novel metastasis model of human lung cancer cells representing different histological types in SCID mice depleted of NK cells] Yano S, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(4):489–94 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Case of malignant pheochromocytoma with successful control of systemic metastasis with CVD chemotherapy]

Minami T, et al. **Nippon Naika Gakkai Zasshi** 1996 Dec 10;85(12):2078–80 (10 ref.) **(Jpn)**

[A case of liver metastasis from so–called hepatoid adenocarcinoma of stomach with lipiodol accumulation] Ueda H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Feb; 93(2):120–5 (14 ref.) **(Jpn)**

[Treatment of liver metastasis of endocrine tumors of the pancreas] Orozco Zepeda H. **Rev Gastroenterol Mex** 1997 Jan–Mar;62(1):50–6 (28 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

The role of cryotherapy in the management of patients with liver tumors. Ravikumar TS. **Adv Surg** 1996;30:281–91 (19 ref.)

Surgical management of metastatic cancer in the liver. Sugarbaker PH. **Ann Ital Chir** 1996 Nov–Dec;67(6):773–82 (22 ref.)

Liver transplantation for metastatic neuroendocrine tumors [see comments] Lang H, et al. **Ann Surg** 1997 Apr; 225(4):347–54 (34 ref.) Comment in: Ann Surg 1997 Apr;225(4):345–6.

Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31–case French multicentric report. Le Treut YP, et al. **Ann Surg** 1997 Apr; 225(4):355–64 (33 ref.)

Cryosurgical ablation of unresectable hepatic tumors [published erratum appears in AORN J 1996 Nov;64(5):686] Zuro LM, et al. **AORN J** 1996 Aug;64(2):231–6, 239–44; quiz 244–6, 248–50 (37 ref.)

Liver transplantation in metastatic carcinoid tumour. Coperchini ML, et al. **Aust N Z J Med** 1996 Oct; 26(5):702–4 (7 ref.)

The aetiology and management of hepatic metastases. Hugh TJ, et al. **Aust N Z J Surg** 1997 Jul;67(7):400–9 (90 ref.)

Complete resection of the caudate lobe of the liver: technique and results. Bartlett D, et al. **Br J Surg** 1996 Aug; 83(8):1076–81 (24 ref.)

Surgery for hepatoblastoma in children. Geiger JD. **Curr Opin Pediatr** 1996 Jun;8(3):276–82 (40 ref.)

Repeat resection of recurrent hepatic metastases—improvement in prognosis? Riesener KP, et al. **Eur J Surg** 1996 Sep;162(9):709–15 (36 ref.)

Hepatic resection for metastatic gynecologic carcinomas. Chi DS, et al. **Gynecol Oncol** 1997 Jul;66(1):45–51 (18 ref.)

Surgically resected primary malignant lymphoma of the liver. Taketomi A, et al. **Hepatogastroenterology** 1996 May–Jun; 43(9):651–7 (24 ref.)

Hepatobiliary cystadenomas and cystadenocarcinoma. Report of five cases. Gadzijev E, et al. **HPB Surg** 1996; 9(2):83–92 (28 ref.)

Hepatic cryotherapy for cancer: a review and critique. Morris DL. **HPB Surg** 1996;9(2):118–20 (23 ref.)

Liver tumor ablation techniques. Scudamore CH, et al. **J Invest Surg** 1997 Jul–Aug;10(4):157–64 (55 ref.)

Hepatic tumors in children. Newman KD. **Semin Pediatr Surg** 1997 Feb;6(1):38–41 (30 ref.)

Invasive therapy of metastatic colorectal cancer to the liver. Millikan KW, et al. **Surg Clin North Am** 1997 Feb; 77(1):27–48 (84 ref.)

Re–resection for colorectal liver metastasis. Bismuth H, et al. **Surg Oncol Clin N Am** 1996 Apr;5(2):353–64 (52 ref.)

Surgical resection of metastatic liver tumors. Kavolius J, et al. **Surg Oncol Clin N Am** 1996 Apr;5(2):337–52 (69 ref.)

Australian experience of cryoablation of liver tumors: metastases. Morris DL, et al. **Surg Oncol Clin N Am** 1996 Apr;5(2):391–7 (12 ref.)

Laparoscopic staging and intraoperative ultrasonography for liver tumor management. Ravikumar TS. **Surg Oncol Clin N Am** 1996 Apr;5(2):271–82 (36 ref.)

Intraoperative ultrasonography and other techniques for segmental resections. Takayama T, et al. **Surg Oncol Clin N Am** 1996 Apr;5(2):261–9 (16 ref.)

Hepatocellular carcinoma associated with precirrhotic primary biliary cirrhosis successfully treated by a right hepatic lobectomy: report of a case. Wakai T, et al. **Surg Today** 1996;26(9):723–6 (23 ref.)

Treatment of liver metastases of carcinoid tumors. Ahlman H, et al. **World J Surg** 1996 Feb;20(2):196–202 (58 ref.)

[Laparoscopic surgery of benign tumors of the liver. Apropos of 5 cases] Laporte J, et al. **J Chir (Paris)** 1996; 133(9–10):432–6 (15 ref.) (Eng. Abstr.) **(Fre)**

[Significance of diagnostic imaging for determining surgical indications in solid liver tumors] Otto G, et al. **Chirurg** 1997 Apr;68(4):334–45 (39 ref.) (Eng. Abstr.) **(Ger)**

[Liver transplantation. Indications, results, pre– and postoperative care] Böker KH, et al. **Internist (Berl)** 1996 Mar;37(3):250–63 (88 ref.) **(Ger)**

[A case of primary hepatic carcinoid. A report of its surgical resolution] Cianchi F, et al. **Minerva Chir** 1997 Apr; 52(4):433–7 (14 ref.) (Eng. Abstr.) **(Ita)**

[Percutaneous microwave coagulation therapy and endoscopic microwave coagulo–necrotic therapy for small hepatocellular carcinoma] Otsuka S. **Nippon Rinsho** 1996 May;54(5):1343–6 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Surgical classification of liver local lesions] Konstantinov BA, et al. **Khirurgiia (Mosk)** 1997;(2):18–20 (9 ref.) (Eng. Abstr.) **(Rus)**

THERAPY

Regional chemotherapy with blood filtration for non resectable liver metastases. Taton G. **Acta Chir Belg** 1997 Apr;97(2):60–4 (26 ref.)

Preoperative transcatheter arterial embolization for giant cavernous hemangioma of the liver with consumption coagulopathy. Suzuki H, et al. **Am J Gastroenterol** 1997 Apr;92(4):688–91 (29 ref.)

Nonresectional therapies for hepatocellular carcinoma. Liu CL, et al. **Am J Surg** 1997 Apr;173(4):358–65 (100 ref.)

Active specific immunotherapy in hepatic metastasis. Schlag PM, et al. **Ann Ital Chir** 1996 Nov–Dec;67(6):783–91 (108 ref.)

Chemo–embolization in the treatment of liver metastases from colorectal cancer. Cascinu S, et al. **Cancer Treat Rev** 1996 Sep;22(5):355–63 (51 ref.)

Sequential transarterial chemoembolization for unresectable advanced hepatocellular carcinoma. Jaeger HJ, et al. **Cardiovasc Intervent Radiol** 1996 Nov–Dec;19(6):388–96 (32 ref.)

Pharmacokinetic rationale for chemotherapeutic drugs combined with intra–arterial degradable starch microspheres (Spherex). Johansson CJ. **Clin Pharmacokinet** 1996 Sep;31(3):231–40 (44 ref.)

Liver–directed therapies for gastrointestinal malignancies. McMurrick PJ, et al. **Curr Opin Oncol** 1997 Jul;9(4):367–72 (34 ref.)

Liver–spleen infarcts following transcatheter chemoembolization: a case report and review of the literature on adverse effects. Cohen SE, et al. **Dig Dis Sci** 1997 May;42(5):938–43 (29 ref.)

The management of liver cell cancer. Rasmussen I, et al. **Eur J Gastroenterol Hepatol** 1996 Sep;8(9):861–7 (87 ref.)

Interventional radiology for hepatic arterial infusion chemotherapy. Arai Y. **Gan To Kagaku Ryoho** 1996 Sep; 23(11):1385–9 (8 ref.)

Regional immunotherapy for liver metastases and the potential of TNF alpha in hepatic perfusion from laboratory to the clinic. Eggermont AM. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1371–8 (56 ref.)

Chemoembolization for hepatocellular carcinoma. Nakamura H. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1390–1 (6 ref.)

Pre– and/or post–operative immunochemotherapy for advanced digestive cancer. Saji S, et al. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:239–49 (14 ref.)

Gene therapy for hepatocellular carcinoma: progress but many stones yet unturned! [editorial; comment] Schuster MJ, et al. **Gastroenterology** 1997 Feb;112(2):656–9 (22 ref.) Comment on: Gastroenterology 1997 Feb;112(2):501–10.

The approach to the patient with single and multiple liver metastases, pulmonary metastases, and intra–abdominal metastases from colorectal carcinoma. VanderMeer TJ, et al. **Hematol Oncol Clin North Am** 1997 Aug;11(4):759–77 (78 ref.)

Treatment of hepatocellular carcinoma. Bruix J. **Hepatology** 1997 Feb;25(2):259–62 (37 ref.)

Treatment of hepatocellular carcinoma. Colombo M. **J Viral Hepat** 1997;4 Suppl 1:125–30 (27 ref.)

Management of primary and metastatic tumors to the liver. Sardi A, et al. **Oncology (Huntingt)** 1996 Jun;10(6):911–25; discussion 926, 929–30 (138 ref.)

Treatment of unresectable hepatocellular carcinoma: targeted therapies using iodized oil. Bhattacharya S, et al. **Princess Takamatsu Symp** 1995;25:253–64 (63 ref.)

The present status of treatments for hepatocellular carcinoma. Tanikawa K. **Princess Takamatsu Symp** 1995;25:245–52 (13 ref.)

Spherex (degradable starch microspheres) chemo–occlusion–enhancement of tumor drug concentration and therapeutic efficacy: an overview. Håkansson L, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 6):S6–100–S6–109 (64 ref.)

Management of pediatric liver tumors. Bowman LC, et al. **Surg Oncol Clin N Am** 1996 Apr;5(2):451–9 (51 ref.)

Gene therapy for liver tumors. Panis Y, et al. **Surg Oncol Clin N Am** 1996 Apr;5(2):461–73 (63 ref.)

Interstitial therapies for liver tumors. Ravikumar TS. **Surg Oncol Clin N Am** 1996 Apr;5(2):365–77 (20 ref.)

Ablative approach for primary liver cancer: Shanghai experience. Zhou XD, et al. **Surg Oncol Clin N Am** 1996 Apr;5(2):379–90 (31 ref.)

[Is there a place for arterial chemoembolization of the liver in the treatment for hepatocellular carcinoma? (editorial)] Trinchet JC, et al. **Gastroenterol Clin Biol** 1995 Dec; 19(12):967–9 (24 ref.) **(Fre)**

[Adenovirus gene therapy for liver metastases of gastrointestinal tumors. Development status and future prospectives] Block A, et al. **Dtsch Med Wochenschr** 1997 May 30;122(22):728–32 (17 ref.) **(Ger)**

[Therapy of primary hepatocellular carcinoma] Jonas S, et al. **Dtsch Med Wochenschr** 1997 May 9;122(19):617–20 (16 ref.) **(Ger)**

[Percutaneous alcohol instillation therapy (PAI) and chemoembolization in extensive hepatocellular carcinoma] Adamus R, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Feb;166(2):173–5 (10 ref.) **(Ger)**

[Therapy of hepatocellular carcinoma] Allgaier HP, et al. **Schweiz Med Wochenschr** 1996 Nov 16;126(46):1984–94 (106 ref.) (Eng. Abstr.) **(Ger)**

[Nonsurgical therapy of focal liver lesions] Allgaier HP, et al. **Schweiz Rundsch Med Prax** 1997 Jan 21;86(4):86–90 (40 ref.) (Eng. Abstr.) **(Ger)**

[Imaging–guided therapy of primary tumors of the liver] Fuertes Guirò F, et al. **Minerva Chir** 1996 May;51(5):321–8 (88 ref.) (Eng. Abstr.) **(Ita)**

[A case of jejunal malignant lymphoma resulting in perforation 2 years after transcatheter arterial embolization for hepatocellular carcinoma] Yokohama A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Aug;93(8):578–82 (21 ref.) **(Jpn)**

[Treatment of hepatocarcinoma] Martínez Cerezo FJ, et al. **Rev Esp Enferm Dig** 1996 Oct;88(10):687–94 (64 ref.) **(Spa)**

[Treatment of liver metastasis of endocrine tumors of the pancreas] Orozco Zepeda H. **Rev Gastroenterol Mex** 1997 Jan–Mar;62(1):50–6 (28 ref.) (Eng. Abstr.) **(Spa)**

[Hepatocellular carcinoma. General aspects of diagnosis and treatment] Manterola C, et al. **Rev Med Chil** 1996 Apr; 124(4):469–79 (44 ref.) (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

[Diagnosis of cystic lesions of the liver] Pelletier G. **Ann Chir** 1997;51(3):267–71 (16 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Tumours of the liver. Moore MA, et al. **IARC Sci Publ** 1996; (126):79–108 (83 ref.)

Surgical treatment of hepatobiliary cystadenomas in cats. Trout NJ. **Semin Vet Med Surg (Small Anim)** 1997 Feb; 12(1):51–3 (21 ref.)

VIROLOGY

Hepatitis B and C viruses and primary liver cancer. Brechot C. **Baillieres Clin Gastroenterol** 1996 Jul;10(2):335–73 (237 ref.)

Hepatitis B and C viruses and hepatocellular carcinoma. Kew MC. **Clin Lab Med** 1996 Jun;16(2):395–406 (73 ref.)

Viral hepatitis and liver cancer: new opportunities for prevention. Bosch FX. **Eur J Cancer Prev** 1996 Oct; 5(5):408–9 (0 ref.)

Hepatitis C virus and hepatocellular carcinoma [editorial] Giacosa A, et al. **Eur J Cancer Prev** 1996 Dec;5(6):423–4 (5 ref.)

Hepatitis B virus transcriptional activators: mechanisms and possible role in oncogenesis. Henkler F F, et al. **J Viral Hepat** 1996 May;3(3):109–21 (129 ref.)

Relationship between hepatocyte proliferation and hepatitis delta virus replication in neoplastic and non–neoplastic liver tissues. Negro F, et al. **J Viral Hepat** 1997 Mar; 4(2):93–8 (26 ref.)

Hepatitis and cancer: genetic aspects. Olsson R. **Scand J Gastroenterol Suppl** 1996;220:115–20 (53 ref.)

Is the DNA repair system involved in hepatitis–B–virus–mediated hepatocellular carcinogenesis? Butel JS, et al. **Trends Microbiol** 1996 Mar;4(3):119–24 (55 ref.)

Hepatitis B virus–induced hepatocellular carcinoma: possible roles for HBx. Cromlish JA. **Trends Microbiol** 1996 Jul; 4(7):270–4 (61 ref.)

[Advances in the molecular pathological study of hepatitis viruses and the canceration of liver cancers] Wang L, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Dec; 24(6):393–5 (11 ref.) **(Chi)**

[Molecular biology, diagnosis and treatment of hepatocellular carcinoma] Toda G, et al. **Nippon Naika Gakkai Zasshi** 1997 Jan 10;86(1):146–53 (17 ref.) **(Jpn)**

[Detection of GBV–C RNA among non B non C hepatocellular carcinoma patients] Kitamoto M, et al. **Nippon Rinsho** 1997 Mar;55(3):583–6 (6 ref.) (Eng. Abstr.) **(Jpn)**

LIVER NEOPLASMS, EXPERIMENTAL

CHEMICALLY INDUCED

Hepatotoxicity and –carcinogenicity of the fumonisins in rats. A review regarding mechanistic implications for establishing risk in humans. Gelderblom WC, et al. **Adv Exp Med Biol** 1996;392:279–96 (62 ref.)

Hepatocarcinogenesis of peroxisome proliferators. Rao MS, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:573–87 (142 ref.)

Non–genotoxic hepatocarcinogenesis: suppression of apoptosis by peroxisome proliferators. Roberts RA. **Ann N Y Acad Sci** 1996 Dec 27;804:588–611 (97 ref.)

Mechanism–based risk assessment of peroxisome proliferating rodent hepatocarcinogens. Williams GM, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:554–72 (69 ref.)

The molecular mechanism of aflatoxin B1–induced liver cancer: is mitotic recombination involved? Sengstag C. **Mol Carcinog** 1997 Jul;19(3):147–52 (22 ref.)

A review of the hepatic tumors related to mixed–function oxidase induction in the mouse [see comments] Butler WH. **Toxicol Pathol** 1996 Jul–Aug;24(4):484–92 (54 ref.) Comment in: Toxicol Pathol 1996 Jul–Aug;24(4):507–8.

Problems in consideration of rodent hepatocarcinogenesis for regulatory purposes. Moch RW, et al. **Toxicol Pathol** 1996 Jan–Feb;24(1):138–45 (28 ref.)

Quantitation of multistage carcinogenesis in rat liver. Pitot HC, et al. **Toxicol Pathol** 1996 Jan–Feb;24(1):119–28 (56 ref.)

Biliary proliferation and adaptation in furan–induced rat liver injury and carcinogenesis. Sirica AE. **Toxicol Pathol** 1996

Jan-Feb;24(1):90-9 (52 ref.)
Emerging issues in mouse liver carcinogenesis. Ward JM, et al. **Toxicol Pathol** 1996 Jan-Feb;24(1):129-37 (87 ref.)
[Pleiotrophic peroxisome induction by hypolipidemic agents in primates and rodents] Stangl H, et al. **Wien Klin Wochenschr** 1996;108(2):40-4 (56 ref.) (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

Hexokinase expression in liver preneoplasia and neoplasia. Mayer D, et al. **Biochem Soc Trans** 1997 Feb;25(1):122-7 (32 ref.)
A review of the hepatic tumors related to mixed-function oxidase induction in the mouse [see comments] Butler WH. **Toxicol Pathol** 1996 Jul-Aug;24(4):484-92 (54 ref.) Comment in: Toxicol Pathol 1996 Jul-Aug;24(4):507-8.

GENETICS

Genetic analysis of multistage hepatocarcinogenesis. Poole TM, et al. **Prog Clin Biol Res** 1996;395:33-45 (40 ref.)

PATHOLOGY

The molecular mechanism of aflatoxin B1-induced liver cancer: is mitotic recombination involved? Sengstag C. **Mol Carcinog** 1997 Jul;19(3):147-52 (22 ref.)
Problems in consideration of rodent hepatocarcinogenesis for regulatory purposes. Moch RW, et al. **Toxicol Pathol** 1996 Jan-Feb;24(1):138-45 (28 ref.)
Quantitation of multistage carcinogenesis in rat liver. Pitot HC, et al. **Toxicol Pathol** 1996 Jan-Feb;24(1):119-28 (56 ref.)
Emerging issues in mouse liver carcinogenesis. Ward JM, et al. **Toxicol Pathol** 1996 Jan-Feb;24(1):129-37 (87 ref.)

LIVER REGENERATION

Hepatic regeneration. The role of regeneration in pathogenesis of chronic liver diseases. Bisgaard HC, et al. **Clin Lab Med** 1996 Jun;16(2):325-39 (102 ref.)
Liver regeneration in health and disease. Taub R. **Clin Lab Med** 1996 Jun;16(2):341-60 (78 ref.)
Hepatic stem cells in liver regeneration. Thorgeirsson SS. **FASEB J** 1996 Sep;10(11):1249-56 (68 ref.)
Liver regeneration: methods for monitoring and their applications. Assy N, et al. **J Hepatol** 1997 Apr; 26(4):945-52 (81 ref.)
Effect of partial liver resection on tumour growth. de Jong KP, et al. **J Hepatol** 1996 Jul;25(1):109-21 (173 ref.)
Hepatic cell division and tissue repair: a key to survival after liver injury. Chanda S, et al. **Mol Med Today** 1996 Feb; 2(2):82-9 (37 ref.)
Liver regeneration: prospects for therapy based on new technologies. Kay MA, et al. **Mol Med Today** 1997 Mar; 3(3):108-15 (49 ref.)
Nodular regenerative hyperplasia of the liver in systemic lupus erythematosus. The relationship with anticardiolipin antibody and lupus anticoagulant. Sekiya M, et al. **Scand J Rheumatol** 1997;26(3):215-7 (13 ref.)
Liver regeneration. Michalopoulos GK, et al. **Science** 1997 Apr 4;276(5309):60-6 (98 ref.)

GENETICS

[Control of growth and expression of protooncogenes in regenerating liver] Zou Y, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan;27(1):7-12 (17 ref.) (Eng. Abstr.) **(Chi)**

PHYSIOLOGY

Review: regulation of liver regeneration by pro-inflammatory cytokines. Diehl AM, et al. **J Gastroenterol Hepatol** 1996 May;11(5):466-70 (36 ref.)

LIVER TRANSPLANTATION

Liver transplantation: current status and unresolved controversies. Everson GT, et al. **Adv Intern Med** 1997; 42:505-53 (141 ref.)
The infant with primary hyperoxaluria and oxalosis: from diagnosis to multiorgan transplantation. Bunchman TE, et al. **Adv Ren Replace Ther** 1996 Oct;3(4):315-25 (31 ref.)
Tumorous intrahepatic lymphoproliferative disorder in transplanted livers. Strouse PJ, et al. **AJR Am J Roentgenol** 1996 Nov;167(5):1159-62 (11 ref.)
Liver transplantation for metastatic neuroendocrine tumors [see comments] Lang H, et al. **Ann Surg** 1997 Apr; 225(4):347-54 (34 ref.) Comment in: Ann Surg 1997 Apr;225(4):345-6.
Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Le Treut YP, et al. **Ann Surg** 1997 Apr; 225(4):355-64 (33 ref.)
Reperfusion injury after liver preservation for transplantation. Lemasters JJ, et al. **Annu Rev Pharmacol Toxicol** 1997;37:327-38 (89 ref.)
Liver-kidney transplantation for Budd-Chiari syndrome. Ronk LL, et al. **AORN J** 1996 Aug;64(2):196-201, 203-6 (27 ref.)
Liver transplantation in metastatic carcinoid tumour. Coperchini ML, et al. **Aust N Z J Med** 1996 Oct; 26(5):702-4 (7 ref.)
Liver transplantation in virus-induced chronic liver disease. Colantoni A, et al. **Baillieres Clin Gastroenterol** 1996 Jul; 10(2):375-88 (65 ref.)
Imaging: focus on hepatocellular carcinoma and liver transplantation. Redhead DN, et al. **Baillieres Clin Gastroenterol** 1995 Dec;9(4):771-90 (66 ref.)
Liver transplantation: review of the literature. Part 2: Vascular and biliary complications. Patenaude YG, et al. **Can Assoc Radiol J** 1997 Aug;48(4):231-42 (63 ref.)
Liver transplantation: review of the literature. Part 1: Anatomic features and current concepts. Patenaude YG, et al. **Can Assoc Radiol J** 1997 Jun;48(3):171-8 (19 ref.)
Hepatitis B infection and liver transplantation. Yoshida EM. **Can J Gastroenterol** 1997 Jul-Aug;11(5):462-8 (60 ref.)
Liver transplantation in children: advances in patient selection, technique and immunosuppression. Emond JC. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1997 Jul-Aug;38(4):249-54 (20 ref.)
The current status of hepatic transplantation at the University of Pittsburgh. Abu-Elmagd K, et al. **Clin Transpl** 1995; :145-70 (84 ref.)
Parvovirus B19 infection in a liver transplant recipient: case report and review in organ transplant recipients. Chang FY, et al. **Clin Transplant** 1996 Jun;10(3):243-7 (36 ref.)
Cutaneous squamous cell carcinoma metastatic to the parotid gland in a transplant patient. Christiansen TN, et al. **Clin Transplant** 1996 Dec;10(6 Pt 1):561-3 (23 ref.)
Liver transplantation for hereditary hemochromatosis. Poulos JE, et al. **Dig Dis** 1996 Sep-Oct;14(5):316-22 (19 ref.)
Management of extrahepatic biliary disease after orthotopic liver transplantation: review of the literature and results of a multicenter survey. Sossenheimer M, et al. **Endoscopy** 1996 Sep;28(7):565-71 (58 ref.)
Prostaglandins in liver disease and liver transplantation. Ruwart MJ, et al. **Gastroenterol Clin North Am** 1996 Jun; 25(2):397-407 (66 ref.)
Hepatitis C after orthotopic liver transplantation. Araya V, et al. **Gastroenterology** 1997 Feb;112(2):575-82 (47 ref.)
Bone disease after liver transplantation [see comments] Losowsky MS, et al. **Gut** 1996 Oct;39(4):505-7 (50 ref.) Comment in: Gut 1997 May;40(5):695-6.
Hepatitis C and the controversies it creates relative to liver transplantation and autoimmune hepatitis. Bayraktar Y, et al. **Hepatogastroenterology** 1996 Jul-Aug;43(10):873-81 (56 ref.)
Severe graft versus host disease following liver transplantation confirmed by PCR-HLA-B sequencing: report of a case and literature review. Sanchez-Izquierdo JA, et al. **Hepatogastroenterology** 1996 Jul-Aug; 43(10):1057-61 (17 ref.)
Review: hepatitis B and liver transplantation. Angus PW. **J Gastroenterol Hepatol** 1997 Mar;12(3):217-23 (59 ref.)
Prospects for xenotransplantation of the liver. Harland RC, et al. **J Hepatol** 1996 Aug;25(2):248-58 (98 ref.)
Preservation injury: mechanisms, prevention and consequences. Jaeschke H. **J Hepatol** 1996 Nov; 25(5):774-80 (78 ref.)
Immunosuppression after liver transplantation. Lucey MR. **J Hepatol** 1996 Apr;24(4):503-5 (15 ref.)
CMV infection of transplant recipients. Mutimer D. **J Hepatol** 1996 Aug;25(2):259-69 (77 ref.)
Liver transplantation: perspectives after 250 liver transplants at the Ochsner Clinic. Takiff H, et al. **J La State Med Soc** 1997 Jul;149(6):234-8 (0 ref.)
Hepatitis B virus and liver transplantation: concepts in antiviral prophylaxis. Grellier L, et al. **J Viral Hepat** 1997; 4 Suppl 1:111-6 (48 ref.)
Liver transplantation for acute liver failure: outcome analysis. Shakil AO, et al. **J Viral Hepat** 1997;4 Suppl 1:107-10 (27 ref.)
Morbidity and mortality of recurrent hepatitis C infection after orthotopic liver transplantation. Vierling JM, et al. **J Viral Hepat** 1997;4 Suppl 1:117-24 (53 ref.)
Artificial liver support: the pipe dream of today should be the reality of the near future. Fouad FM, et al. **Med Hypotheses** 1996 Aug;47(2):145-55 (42 ref.)
The SCID-hu mouse: an in vivo model for HIV-1 infection in humans. Bonyhadi ML, et al. **Mol Med Today** 1997 Jun; 3(6):246-53 (51 ref.)
Treatment of chronic hepatitis C: another therapeutic option. Trepo C, et al. **Nephrol Dial Transplant** 1996;11 Suppl 4:62-4 (9 ref.)
Immunosuppressive therapy in liver transplantation: principles and practice. Ascher NL. **Prog Liver Dis** 1995; 13:381-95 (98 ref.)
Management and prevention of acute renal failure in solid organ transplantation. Morales JM. **Ren Fail** 1996 May; 18(3):481-8 (25 ref.)
Spontaneous bacterial peritonitis: an indication for liver transplantation? Bac DJ. **Scand J Gastroenterol Suppl** 1996; 218:38-42 (43 ref.)
Primary sclerosing cholangitis and liver transplantation. Klompmaker IJ, et al. **Scand J Gastroenterol Suppl** 1996; 218:98-102 (42 ref.)
Liver transplantation in Europe for patients with acute liver failure. Bismuth H, et al. **Semin Liver Dis** 1996 Nov; 16(4):415-25 (41 ref.)
The American experience with transplantation for acute liver failure. McCashland TM, et al. **Semin Liver Dis** 1996 Nov; 16(4):427-33 (63 ref.)
Transplantation for primary biliary cirrhosis. Neuberger J. **Semin Liver Dis** 1997 May;17(2):137-46 (56 ref.)
Spontaneous resolution of rhodococcal pulmonary infection in a liver transplant recipient. Schilz RJ, et al. **South Med J** 1997 Aug;90(8):851-4 (33 ref.)
Therapeutic modulation of free radical-mediated reperfusion injury of the liver and its surgical implications. Marubayashi S, et al. **Surg Today** 1996;26(8):573-80 (97 ref.)
Liver transplantation for the treatment of fulminant hepatic failure induced by the ingestion of ecstasy. Brauer RB, et al. **Transpl Int** 1997;10(3):229-33 (11 ref.)
New approaches to treatment of recurrent hepatitis C virus following liver transplantation using ribavirin. Bizollon T, et al. **Transplant Proc** 1996 Oct;28(5):2842-3 (13 ref.)
Liver transplantation. Friend PJ. **Transplant Proc** 1997 Sep; 29(6):2716-8 (22 ref.)
Liver transplantation for Langerhans' cell histiocytosis--a case report and literature review. Melendez HV, et al. **Transplantation** 1996 Oct 27;62(8):1167-71 (30 ref.)
The pig as a model in liver xenotransplantation. Wolf P, et al. **Vet Res** 1997 May-Jun;28(3):217-22 (14 ref.)
[Progresses in organ transplantation in China, 1996] Chen S, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Dec; 76(12):913-4 (0 ref.) **(Chi)**
[Current indications for liver transplantation in adults] Elnakadi I, et al. **J Med Liban** 1996;44(2):80-5 (30 ref.) **(Fre)**
[Liver transplantation in adults. Indications and results] Vanlemmens C, et al. **Presse Med** 1996 Dec 14; 25(39):1952-60 (42 ref.) (Eng. Abstr.) **(Fre)**
[Liver transplantation in familial amyloid polyneuropathy. Case report and review of the literature] Krüger M, et al. **Internist (Berl)** 1997 Jul;38(7):692-700 (41 ref.) (Eng. Abstr.) **(Ger)**
[New trends in liver transplantation--lessons learned and future perspectives] Mor E, et al. **Harefuah** 1996 Dec 1; 131(11):492-7 (49 ref.) **(Heb)**
[Liver transplantation: problem of timing and predictive factors] Pár A. **Orv Hetil** 1996 Oct 20;137(42 Suppl 1):2364-8 (27 ref.) (Eng. Abstr.) **(Hun)**
[Liver transplantation. Selection criteria and risk evaluation] Petti R, et al. **Recenti Prog Med** 1997 Feb;88(2):85-9 (32 ref.) (Eng. Abstr.) **(Ita)**
[Fulminant hepatic failure and liver transplantation] Marubayashi S, et al. **Nippon Geka Gakkai Zasshi** 1997 May;98(5):516-23 (43 ref.) (Eng. Abstr.) **(Jpn)**
[Problems of living-related partial liver transplantation to adult patients] Tashiro S, et al. **Rinsho Byori** 1996 Aug; 44(8):715-25 (21 ref.) (Eng. Abstr.) **(Jpn)**
[Variable clinical manifestations of familial amyloid polyneuropathy and living related liver transplantation] Ikeda S, et al. **Rinsho Shinkeigaku** 1995 Dec;35(12):1433-5 (11 ref.) (Eng. Abstr.) **(Jpn)**
[When should liver transplant be indicated in the treatment of alcoholic hepatic disease?] Mincis M, et al. **Rev Assoc Med Bras** 1996 Oct-Dec;42(4):242-4 (24 ref.) **(Por)**
[The transplantation of isolated hepatocytes] Cuervas-Mons Martínez V. **Gastroenterol Hepatol** 1997 Feb;20(2):59-64 (103 ref.) **(Spa)**

ADVERSE EFFECTS

Hodgkin's disease following solid organ transplantation. Bierman PJ, et al. **Ann Oncol** 1996 Mar;7(3):265-70 (30 ref.)
Late recurrent post-transplant primary biliary cirrhosis in British Columbia. Yoshida EM, et al. **Can J Gastroenterol** 1997 Apr;11(3):229-33 (20 ref.)
Cytomegalovirus infection following liver transplantation: review of the literature. Kanj SS, et al. **Clin Infect Dis** 1996 Mar;22(3):537-49 (147 ref.)
Rupture of splenic artery aneurysm after liver transplantation. Jovine E, et al. **Clin Transplant** 1996 Oct;10(5):451-4 (19 ref.)
Medical problems occurring after orthotopic liver transplantation. Carson KL, et al. **Dig Dis Sci** 1997 Aug; 42(8):1666-74 (36 ref.)
Treatment for recurrent viral hepatitis after liver transplantation. Brumage LK, et al. **J Hepatol** 1997 Feb; 26(2):440-5 (19 ref.)
The bile duct in liver transplantation. Pretter PC, et al. **Semin Roentgenol** 1997 Jul;32(3):202-14 (70 ref.)
Thromboelastography and liver transplantation. Gillies BS. **Semin Thromb Hemost** 1995;21 Suppl 4:45-9 (15 ref.)
Thromboelastography in liver transplantation. Kang Y. **Semin Thromb Hemost** 1995;21 Suppl 4:34-44 (46 ref.)
Liver graft-transmitted glioblastoma multiforme. A case report and experience with 13 multiorgan donors suffering from primary cerebral neoplasia [see comments] Jonas S, et al. **Transpl Int** 1996;9(4):426-9 (16 ref.) Comment in: Transpl Int 1997;10(1):83-4.
Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Aguado JM, et al. **Transplantation** 1997 May 15; 63(9):1278-86 (22 ref.)
Candida albicans osteomyelitis in a liver transplant recipient: a case report and review of the literature. Jonnalagadda S, et al. **Transplantation** 1996 Oct 27;62(8):1182-4 (19 ref.)
[Non-surgical treatment of biliary stenoses after hepatic transplantation] Bouttier E, et al. **J Radiol** 1997 Jul; 78(7):485-9 (18 ref.) (Eng. Abstr.) **(Fre)**

[Lung pathology in heart, liver and kidney transplantation in adults] Martel S, et al. **Rev Mal Respir** 1996 Nov;13(5 Suppl):S57–70 (178 ref.) (Eng. Abstr.) **(Fre)**

ECONOMICS

Clinical economics review: liver transplantation. O'Grady JG. **Aliment Pharmacol Ther** 1997 Jun;11(3):445–51 (35 ref.)

IMMUNOLOGY

Tacrolimus (FK506): the pros and cons of its use as an immunosuppressant in pediatric liver transplantation. Cox KL, et al. **Clin Invest Med** 1996 Oct;19(5):389–92 (15 ref.)

Immunology of liver transplantation: clinical management aspects. Shah V, et al. **Gastroenterologist** 1997 Jun; 5(2):137–47 (71 ref.)

Adhesion molecules in liver transplantation. Steinhoff G, et al. **Hepatogastroenterology** 1996 Sep–Oct;43(11):1117–23 (35 ref.)

Tacrolimus: immunosuppression following liver and kidney transplant. Clark W. **J Clin Pharm Ther** 1996 Jun; 21(3):135–41 (19 ref.)

Mini-review: tumor necrosis factor (TNF) and TNF soluble receptors (TNF-sR) in liver disease and liver transplantation. Majno PE, et al. **Swiss Surg** 1995;(4):182–5 (27 ref.)

Tacrolimus (FK506) is superior to cyclosporine in liver transplantation. Busuttil RW, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):534–8 (12 ref.)

Cross-matching in liver transplantation. Donaldson PT, et al. **Transplantation** 1997 Mar 27;63(6):789–94 (65 ref.)

[Immunosuppressive substances induced by liver grafting] Kobayashi E. **Tanpakushitsu Kakusan Koso** 1997 Jul; 42(9):1420–6 (40 ref.) **(Jpn)**

[Rejection and immunosuppression] Charco R, et al. **Gastroenterol Hepatol** 1996 Oct;19(8):419–26 (24 ref.) **(Spa)**

METHODS

Liver transplantation for pediatric patients: a review and update. Kleinman RE. **Acta Paediatr Sin** 1996 Mar–Apr; 37(2):81–91 (76 ref.)

Split-liver transplantation. The Paul Brousse policy. Azoulay D, et al. **Ann Surg** 1996 Dec;224(6):737–46; discussion 746–8 (41 ref.)

In situ splitting of cadaveric livers. The ultimate expansion of a limited donor pool. Rogiers X, et al. **Ann Surg** 1996 Sep;224(3):331–9; discussion 339–41 (26 ref.)

Cell-based therapy of acute liver failure: the extracorporeal bioartificial liver. Frémond B, et al. **Cell Biol Toxicol** 1996 Dec;12(4–6):325–9 (20 ref.)

Perspectives of liver cell transplantation: a review. Schmidt HH, et al. **Hepatogastroenterology** 1997 Jul–Aug; 44(16):1013–8 (20 ref.)

Hemodynamic and metabolic effects of transjugular intrahepatic portosystemic shunt (TIPS) during anesthesia for orthotopic liver transplantation. Antonini M, et al. **Transpl Int** 1996;9(4):403–7 (9 ref.)

Failure patterns of cryopreserved vein grafts in liver transplantation. Kuang AA, et al. **Transplantation** 1996 Sep 27;62(6):742–7 (21 ref.)

Portal vein thrombosis and stenosis in pediatric liver transplantation. Millis JM, et al. **Transplantation** 1996 Sep 27;62(6):748–54 (24 ref.)

[Malignant tumors of the hepatic bifurcation—results of surgical therapy and prognostic factors] Beckurts KT, et al. **Chirurg** 1997 Apr;68(4):378–84 (37 ref.) (Eng. Abstr.) **(Ger)**

[Liver transplantation. Indications, results, pre- and postoperative care] Böker KH, et al. **Internist (Berl)** 1996 Mar;37(3):250–63 (88 ref.) **(Ger)**

[Alternatives to liver transplantation] Kupcsulik P. **Orv Hetil** 1996 Oct 20;137(42 Suppl 1):2381–7 (41 ref.) (Eng. Abstr.) **(Hun)**

PATHOLOGY

Banff schema for grading liver allograft rejection: an international consensus document. **Hepatology** 1997 Mar; 25(3):658–63 (42 ref.)

PHYSIOLOGY

Clinical chemistry and post-liver-transplant monitoring. Hickman PE, et al. **Clin Chem** 1997 Aug;43(8 Pt 2):1546–54 (67 ref.)

Assessment of liver function: pre- and peritransplant evaluation. Shaked A, et al. **Clin Chem** 1997 Aug;43(8 Pt 2):1539–45 (53 ref.)

Electroencephalographic abnormalities in liver transplant recipients: practical considerations and review. Steg RE, et al. **J Clin Neurophysiol** 1996 Jan;13(1):60–8 (30 ref.)

Renal function in pediatric liver transplant patients. McDiarmid SV. **Kidney Int Suppl** 1996 Jan;53:S77–84 (121 ref.)

Seizures after orthotopic liver transplantation. Wszolek ZK, et al. **Seizure** 1997 Feb;6(1):31–9 (33 ref.)

PSYCHOLOGY

Fair treatment of alcoholic patients in the context of liver transplantation. Shelton W, et al. **Alcohol Clin Exp Res** 1997 Feb;21(1):93–100 (33 ref.)

STANDARDS

Hepatopulmonary syndrome with progressive hypoxemia as an indication for liver transplantation: case reports and literature review. Krowka MJ, et al. **Mayo Clin Proc** 1997 Jan;72(1):44–53 (41 ref.)

TRENDS

Organ transplantation in Taiwan. Lee CJ. **Artif Organs** 1996 Dec;20(12):1270–3 (10 ref.)

[Is "terminal" liver damage reversible? Value, practicality and future of bridging techniques for the liver] Gubernatis G, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996; 113:380–8 (22 ref.) **(Ger)**

LIVESTOCK see **ANIMALS, DOMESTIC**

LIVING DONORS

Consensus Conference on unrelated donor bone-marrow transplantation. Royal College of Physicians of Edinburgh, 29–30 October 1996. **Blood Rev** 1996 Dec;10(4):210–5 (4 ref.)

Unrelated bone-marrow transplantation in adults. Huntly BJ, et al. **Blood Rev** 1996 Dec;10(4):220–30 (85 ref.)

Donor considerations in living-related donor lung transplantation. Mallory GB Jr, et al. **Clin Chest Med** 1997 Jun;18(2):239–44 (24 ref.)

Hematopoietic stem cell transplants from unrelated donors. Hansen JA, et al. **Immunol Rev** 1997 Jun;157:141–51 (68 ref.)

Factors influencing the outcome of bone marrow transplants using unrelated donors. Madrigal JA, et al. **Immunol Rev** 1997 Jun;157:153–66 (120 ref.)

The evaluation of living renal transplant donors: clinical practice guidelines. Ad Hoc Clinical Practice Guidelines Subcommittee of the Patient Care and Education Committee of the American Society of Transplant Physicians. Kasiske BL, et al. **J Am Soc Nephrol** 1996 Nov; 7(11):2288–313 (259 ref.)

Bodily integrity and the sale of human organs. Wilkinson S, et al. **J Med Ethics** 1996 Dec;22(6):334–9 (12 ref.)

Kidney transplantation from living-related donors. Stryjecka-Rowińska D, et al. **Transplant Proc** 1996 Dec; 28(6):3576–7 (6 ref.)

[Problems of living-related partial liver transplantation to adult patients] Tashiro S, et al. **Rinsho Byori** 1996 Aug; 44(8):715–25 (21 ref.) (Eng. Abstr.) **(Jpn)**

PSYCHOLOGY

Donor insemination: the gifting and selling of semen. Daniels KR, et al. **Soc Sci Med** 1996 Jun;42(11):1521–36 (96 ref.)

LIVING WILLS

see related
RIGHT TO DIE

Ethical aspects of medical decision-making in demented patients: a report from the Netherlands [see comments] Hertogh CM, et al. **Alzheimer Dis Assoc Disord** 1996 Spring;10(1):11–9 (44 ref.) Comment in: Alzheimer Dis Assoc Disord 1996 Spring;10(1):3–4.

Creating a living will. Experience at a multilevel geriatric facility. Levitt D, et al. **Can Fam Physician** 1996 Dec; 42:2413–20 (22 ref.)

Acting on a living will: a physician's dilemma. Gordon M, et al. **Can Med Assoc J** 1996 Oct 1;155(7):893–5 (29 ref.)

LEGISLATION & JURISPRUDENCE

The advance directive (or living will). Samuels A. **Med Sci Law** 1996 Jan;36(1):2–8 (22 ref.)

LIVOR MORTIS see **POSTMORTEM CHANGES**

LIZARDS

PARASITOLOGY

Malarial parasites of lizards: diversity and ecology. Schall JJ. **Adv Parasitol** 1996;37:255–333 (125 ref.)

LLAMAS see **CAMELIDS, NEW WORLD**

LMWH see **HEPARIN, LOW-MOLECULAR-WEIGHT**

LOAD-BEARING see **WEIGHT-BEARING**

LOBAR PNEUMONIA see **PNEUMONIA, LOBAR**

LOBBYING

Well-healed: inside lobbying for health care reform, Part III. **Int J Health Serv** 1996;26(1):19–46 (30 ref.)

A strategic response to the occupational health establishment. Sass R. **Int J Health Serv** 1996;26(2):355–70 (11 ref.)

Meta-analysis and public policy: opportunity for nursing impact. Conn VS, et al. **Nurs Outlook** 1996 Nov–Dec; 44(6):267–71 (29 ref.)

Power of one: nurses and tobacco control. Gallagher J, et al. **Semin Oncol Nurs** 1996 Nov;12(4):270–5 (14 ref.)

The role of nurses and midwives in government. Ralph C, et al. **WHO Reg Publ Eur Ser** 1997;74:167–90 (9 ref.)

LOBOTOMY see **PSYCHOSURGERY**

LOBSTEIN'S DISEASE see **OSTEOGENESIS IMPERFECTA**

LOBSTERS

ENZYMOLOGY

Biochemical properties of insect and crustacean proteasomes. Mykles DL. **Mol Biol Rep** 1997 Mar;24(1–2):133–8 (34 ref.)

METABOLISM

Antiport-driven sulfate secretion in an invertebrate epithelium. Gerencser GA, et al. **J Exp Zool** 1996 Jul 1; 275(4):269–76 (58 ref.)

MICROBIOLOGY

Geographical spread of bacterial and fungal diseases of crustaceans. Alderman DJ. **Rev Sci Tech** 1996 Jun; 15(2):603–32 (59 ref.)

PARASITOLOGY

Overview of "bumper car" disease—impact on the North American lobster fishery. Cawthorn RJ. **Int J Parasitol** 1997 Feb;27(2):167–72 (27 ref.)

LOCKED-IN SYNDROME see **QUADRIPLEGIA**

LOCOMOTION

see related
GAIT

Visual deficits and mobility. Evaluation and management. Maino JH. **Clin Geriatr Med** 1996 Nov;12(4):803–23 (50 ref.)

Size influences on primate locomotion and body shape, with special emphasis on the locomotion of 'small mammals'. Preuschoft H, et al. **Folia Primatol (Basel)** 1996; 66(1–4):93–112 (64 ref.)

Paraplegic locomotion: a review. Nene AV, et al. **Spinal Cord** 1996 Sep;34(9):507–24 (106 ref.)

[Acquisition of human bipedal gait from the viewpoint of the aquatic ape theory] Bender R, et al. **Anthropol Anz** 1997 Mar;55(1):1–14 (25 ref.) (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Melatonin effects on behavior: possible mediation by the central GABAergic system. Golombek DA, et al. **Neurosci Biobehav Rev** 1996 Autumn;20(3):403–12 (175 ref.)

The role of dopamine in the behavioral effects of caffeine in animals and humans. Garrett BE, et al. **Pharmacol Biochem Behav** 1997 Jul;57(3):533–41 (125 ref.)

Sensitization to the behavioral effects of cocaine: modulation by dynorphin and kappa-opioid receptor agonists. Shippenberg TS, et al. **Pharmacol Biochem Behav** 1997 Jul; 57(3):449–55 (66 ref.)

PHYSIOLOGY

Embryonic spinal cord transplants enhance locomotor performance in spinalized newborn rats. Tessler A, et al. **Adv Neurol** 1997;72:291–303 (52 ref.)

Limb morphology, bipedal gait, and the energetics of hominid locomotion. Steudel K. **Am J Phys Anthropol** 1996 Feb;99(2):345–55 (73 ref.)

Role of the cerebellum and motor cortex in the regulation of visually controlled locomotion. Armstrong DM, et al. **Can J Physiol Pharmacol** 1996 Apr;74(4):443–55 (55 ref.)

Visuomotor regulation of locomotion. Rossignol S. **Can J Physiol Pharmacol** 1996 Apr;74(4):418–25 (94 ref.)

Basic neurophysiology of primate locomotion. Mori S, et al. **Folia Primatol (Basel)** 1996;66(1–4):192–203 (51 ref.)

Functional morphological similarities in the locomotor skeleton of miocene catarrhines and platyrrhine monkeys. Rose MD. **Folia Primatol (Basel)** 1996;66(1–4):7–14 (66 ref.)

Neurochemical bases of locomotion and ethanol stimulant effects. Phillips TJ, et al. **Int Rev Neurobiol** 1996;39:243–82 (296 ref.)

The neuronal network for locomotion in the lamprey spinal cord: evidence for the involvement of commissural interneurons. Buchanan JT, et al. **J Physiol Paris** 1995; 89(4–6):221–33 (54 ref.)

Positive feedback as a general mechanism for sustaining rhythmic and non-rhythmic activity. Roberts A, et al. **J Physiol Paris** 1995;89(4–6):241–8 (33 ref.)

A review of adaptive change in musculoskeletal impedance during space flight and associated implications for postflight head movement control. McDonald PV, et al. **J Vestib Res** 1997 Mar–Jun;7(2–3):239–50 (63 ref.)

Muscle strength and rising from a chair in older adults. Alexander NB, et al. **Muscle Nerve Suppl** 1997;5:S56–9 (19 ref.)

How do the elderly negotiate stairs? Cavanagh PR, et al. **Muscle Nerve Suppl** 1997;5:S52–5 (20 ref.)

Evidence for a spinal stepping generator in man. Bussel B, et al. **Paraplegia** 1996 Feb;34(2):91–2 (24 ref.)

Locomotion in patients with spinal cord injuries. Dietz V, et al. **Phys Ther** 1997 May;77(5):508–16 (52 ref.)

Aspects of cerebellar function in relation to locomotor movements. Armstrong DM, et al. **Prog Brain Res** 1997;

LOCOMOTION

114:401–21 (84 ref.)
Biologically based artificial navigation systems: review and prospects. Trullier O, et al. **Prog Neurobiol** 1997 Apr; 51(5):483–544 (153 ref.)
Control of locomotion in the decerebrate cat. Whelan PJ. **Prog Neurobiol** 1996 Aug;49(5):481–515 (311 ref.)
Sensorimotor stimulation to improve locomotor recovery after spinal cord injury. Muir GD, et al. **Trends Neurosci** 1997 Feb;20(2):72–7 (60 ref.)
Instrumentation and techniques in locomotion and lameness. Clayton HM. **Vet Clin North Am Equine Pract** 1996 Aug; 12(2):337–50 (31 ref.)
[Retained capacity for action in brain gunshot injury. Case report and systematic examination] Karger B, et al. **Arch Kriminol** 1997 May–Jun;199(5–6):159–66 (18 ref.) (Eng. Abstr.) **(Ger)**

LOCOMOTION, CELL see **CELL MOVEMENT**

LOCUS COERULEUS

METABOLISM

Depression as a spreading neuronal adjustment disorder. Harro J, et al. **Eur Neuropsychopharmacol** 1996 Aug; 6(3):207–23 (193 ref.)

PHYSIOLOGY

Role of the locus coeruleus in emotional activation. Aston-Jones G, et al. **Prog Brain Res** 1996;107:379–402 (151 ref.)
Where is the locus in opioid withdrawal? Christie MJ, et al. **Trends Pharmacol Sci** 1997 Apr;18(4):134–40 (73 ref.)

PHYSIOPATHOLOGY

Noradrenergic mechanisms in stress and anxiety: I. Preclinical studies. Bremner JD, et al. **Synapse** 1996 May; 23(1):28–38 (138 ref.)

LOCUS OF CONTROL see **INTERNAL–EXTERNAL CONTROL**

LOCUSTS see **GRASSHOPPERS**

LOEFFLER SYNDROME see **PULMONARY EOSINOPHILIA**

LOEFFLER'S ENDOCARDITIS see **HYPEREOSINOPHILIC SYNDROME**

LOG–LINEAR MODELS see **LINEAR MODELS**

LOGIC

Temporal logics and real time expert systems. Blom JA. **Comput Methods Programs Biomed** 1996 Oct;51(1–2):35–49 (30 ref.)
Intuition and rational decision-making in professional thinking: a false dichotomy? Easen P, et al. **J Adv Nurs** 1996 Oct;24(4):667–73 (28 ref.)
Logical limits of randomized controlled trials. Sleigh JW. **J Eval Clin Pract** 1997 Apr;3(2):145–8 (5 ref.)
Politics, practical logic, and primary health care in rural Haiti. Brodwin PE. **Med Anthropol Q** 1997 Mar;11(1):69–88 (58 ref.)
Can phronesis save the life of medical ethics? Beresford EB. **Theor Med** 1996 Sep;17(3):209–24 (42 ref.)

LOGIC, FUZZY see **FUZZY LOGIC**

LOGISTIC MODELS

Use of a four parameter logistic equation and parameter sharing to evaluate animal responses to graded levels of nitrogen or amino acids. Gahl MJ, et al. **Adv Food Nutr Res** 1996;40:157–67 (20 ref.)
Advantages and disadvantages of using artificial neural networks versus logistic regression for predicting medical outcomes. Tu JV. **J Clin Epidemiol** 1996 Nov; 49(11):1225–31 (37 ref.)
Mathematical tools for demonstrating the clinical usefulness of biochemical markers. Boyd JC. **Scand J Clin Lab Invest Suppl** 1997;227:46–63 (42 ref.)
A comparison of goodness-of-fit tests for the logistic regression model. Hosmer DW, et al. **Stat Med** 1997 May 15;16(9):965–80 (24 ref.)

LOGISTIC REGRESSION see **LOGISTIC MODELS**

LOGIT MODELS see **LOGISTIC MODELS**

LONELINESS

Loneliness in elderly people: an important area for nursing research. Donaldson JM, et al. **J Adv Nurs** 1996 Nov; 24(5):952–9 (76 ref.)

LONG-ACTING THYROID STIMULATOR

see related
RECEPTORS, THYROID HORMONE

LONG-CHAIN ACYL COA see **ACYL COENZYME A**

LONG QT SYNDROME

The long QT syndromes. Bailey BP. **Aust N Z J Med** 1996 Dec;26(6):834–40 (36 ref.)
The long QT syndrome. Schwartz PJ. **Curr Probl Cardiol** 1997 Jun;22(6):297–351 (93 ref.)
Recent advances in understanding the mechanisms, diagnosis and treatment of congenital and acquired long QT syndrome. Sra J, et al. **Indian Heart J** 1996 Nov–Dec; 48(6):639–51 (67 ref.)
[Hereditary cardiac arrhythmia] Tsuji S, et al. **Nippon Rinsho** 1996 Aug;54(8):2213–9 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Jervell and Lange-Nielsen syndrome] Aoki T. **Ryoikibetsu Shokogun Shirizu** 1996;(12):188–91 (20 ref.) **(Jpn)**
[Romano-Ward syndrome] Tomita Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):211–4 (14 ref.) **(Jpn)**

CHEMICALLY INDUCED

QTc-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: a prospective evaluation and review of the literature. Tschida SJ, et al. **Pharmacotherapy** 1996 Jul–Aug; 16(4):663–74 (52 ref.)

COMPLICATIONS

When a syncopal event is more than a faint, Part I. Sharp KT. **MCN Am J Matern Child Nurs** 1997 Jan–Feb; 22(1):26–30 (17 ref.)
[Torsades de pointe with spiramycine and metiquazine therapy. Apropos of a case] Verdun F, et al. **Arch Mal Coeur Vaiss** 1997 Jan;90(1):103–6 (10 ref.) (Eng. Abstr.) **(Fre)**

CONGENITAL

Perioperative considerations in a newly described subtype of congenital long QT syndrome. Joseph-Reynolds AM, et al. **Paediatr Anaesth** 1997;7(3):237–41 (25 ref.)
[Congenital and secondary long QT syndrome] Matsuo S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):203–7 (6 ref.) **(Jpn)**

DIAGNOSIS

Will QT dispersion play a role in clinical decision-making? [editorial; comment] Surawicz B. **J Cardiovasc Electrophysiol** 1996 Aug;7(8):777–84 (48 ref.) Comment on: J Cardiovasc Electrophysiol 1996 Aug;7(8):738–59.
When a syncopal event is more than a faint, Part I. Sharp KT. **MCN Am J Matern Child Nurs** 1997 Jan–Feb; 22(1):26–30 (17 ref.)

ETIOLOGY

[Long QT syndrome] Nakajima T, et al. **Nippon Rinsho** 1996 Mar;54(3):776–81 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Congenital and secondary long QT syndrome] Matsuo S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):203–7 (6 ref.) **(Jpn)**
[QT dispersion] Bańcarz A, et al. **Przegl Lek** 1996;53(9):687–9 (18 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

The roles of ion channels in an inherited heart disease: molecular genetics of the long QT syndrome. Kass RS, et al. **Cardiovasc Res** 1996 Sep;32(3):443–54 (146 ref.)
Molecular genetics of long QT syndrome from genes to patients. Wang Q, et al. **Curr Opin Cardiol** 1997 May; 12(3):310–20 (61 ref.)
The phenotype/genotype relation and the current status of genetic screening in hypertrophic cardiomyopathy, Marfan syndrome, and the long QT syndrome. Burn J, et al. **Heart** 1997 Aug;78(2):110–6 (40 ref.)
Ion channels—basic science and clinical disease [see comments] Ackerman MJ, et al. **N Engl J Med** 1997 May 29;336(22):1575–86 (67 ref.) Comment in: N Engl J Med 1997 May 29;336(22):1599–600.
Molecular biology of the long QT syndrome: impact on management. Priori SG, et al. **Pacing Clin Electrophysiol** 1997 Aug;20(8 Pt 2):2052–7 (35 ref.)
[Familial epilepsy seizure disclosing long QT syndrome (see comments)] Moreau T, et al. **Rev Neurol (Paris)** 1996 Oct; 152(10):642–5 (10 ref.) (Eng. Abstr.) Comment in: Rev Neurol (Paris) 1997 Jun;153(5):359. **(Fre)**

NURSING

When a syncopal event is more than a faint, Part II. Sharp KT. **MCN Am J Matern Child Nurs** 1997 Mar–Apr; 22(2):80–4 (26 ref.)

PHYSIOPATHOLOGY

Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Roden DM, et al. **Circulation** 1996 Oct 15;94(8):1996–2012 (167 ref.)
Long reflections on the QT interval: the sixth annual Gordon K. Moe Lecture [see comments] James TN. **J Cardiovasc Electrophysiol** 1996 Aug;7(8):738–59 (109 ref.) Comment in: J Cardiovasc Electrophysiol 1996 Aug;7(8):777–84.
Perioperative considerations in a newly described subtype of congenital long QT syndrome. Joseph-Reynolds AM, et al. **Paediatr Anaesth** 1997;7(3):237–41 (25 ref.)

THERAPY

Clinical management of patients with the long QT syndrome: drugs, devices, and gene-specific therapy. Moss AJ. **Pacing Clin Electrophysiol** 1997 Aug;20(8 Pt 2):2058–60 (20 ref.)

LONG-TERM CARE

see related
INSURANCE, LONG-TERM CARE
Cardiopulmonary resuscitation of elderly people in long-term care [editorial] [see comments] Nazerali N. **Can Fam Physician** 1996 Dec;42:2320–2, 2330–2 (22 ref.) Comment in: Can Fam Physician 1997 Apr;43:609, 611, 613. Comment in: Can Fam Physician 1997 Apr;43:613. **(Eng, Fre)**
Risk management issues in long-term care. Weinberg AD. **Compr Ther** 1996 May;22(5):311–7 (17 ref.)
Brainstem tumors in childhood: preparing patients and families for long- and short-term care. Shiminski-Maher T. **Pediatr Neurosurg** 1996;24(5):267–71 (11 ref.)
[The quality of life for the elderly in long-term care—view point of social welfare] Ohkuni M. **Nippon Ronen Igakkai Zasshi** 1996 Jul;33(7):508–11 (0 ref.) **(Jpn)**

LEGISLATION & JURISPRUDENCE

[The Parkinson patient in expert social medicine assessment with special reference to the nursing care law] Semsch-Poppe B, et al. **Gesundheitswesen** 1996 Dec; 58(12):635–40 (18 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

The expanding role of healthcare epidemiology—home and long-term care [editorial; comment] Garrett DO, et al. **Infect Control Hosp Epidemiol** 1996 Nov;17(11):714–7 (16 ref.) Comment on: Infect Control Hosp Epidemiol 1996 Nov;17(11):721–5. Comment on: Infect Control Hosp Epidemiol 1996 Nov;17(11):726–31.
The appropriate role for the state hospital. Belcher JR, et al. **J Ment Health Adm** 1997 Winter;24(1):64–71 (63 ref.)

LONG-TERM CARE INSURANCE see **INSURANCE, LONG-TERM CARE**

LONG-TERM POTENTIATION

LTP and spatial learning—where to next? Jeffery KJ. **Hippocampus** 1997;7(1):95–110 (105 ref.)
Expression mechanisms of long-term potentiation in the hippocampus. Isaac JT, et al. **J Physiol Paris** 1996; 90(5–6):299–303 (12 ref.)
Bioactive lipids in excitatory neurotransmission and neuronal plasticity. Bazan NG, et al. **Neurochem Int** 1997 Feb; 30(2):225–31 (59 ref.)
CaM kinase II in long-term potentiation. Fukunaga K, et al. **Neurochem Int** 1996 Apr;28(4):343–58 (151 ref.)
Modulation of glutamate receptors by calcium/calmodulin-dependent protein kinase II. Soderling TR. **Neurochem Int** 1996 Apr;28(4):359–61 (27 ref.)
Neurobiological basis of motor learning in mammals. Asanuma H, et al. **Neuroreport** 1997 Mar 3;8(4):i–vi (59 ref.)
Activity-related modulation of cholinergic transmission. Collier B. **Prog Brain Res** 1996;109:243–9 (41 ref.)
[The retrograde messengers in hippocampal long-term potentiation] Hu ZA, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan;27(1):82–4 (7 ref.) **(Chi)**

DRUG EFFECTS

Cognitive enhancers and hippocampal long-term potentiation in vitro. Kaneko S, et al. **Behav Brain Res** 1997 Feb; 83(1–2):45–9 (33 ref.)

GENETICS

Messengers from the synapses to the nucleus (MSNs) that establish late phase of long-term potentiation (LTP) and long-term memory. Suzuki T. **Neurosci Res** 1996 May; 25(1):1–6 (75 ref.)

PHYSIOLOGY

Metabotropic glutamate receptors in hippocampal long-term potentiation and learning and memory. Riedel G, et al. **Acta Physiol Scand** 1996 May;157(1):1–19 (125 ref.)

Modifiable neuronal connections: an overview for psychiatrists. Jeffery KJ, et al. **Am J Psychiatry** 1997 Feb; 154(2):156–64 (35 ref.)
An alternative to the LTP orthodoxy: a plasticity–pathology continuum model. McEachern JC, et al. **Brain Res Brain Res Rev** 1996 Jun;22(1):51–92 (307 ref.)
Retrograde messengers, long-term potentiation and memory. Medina JH, et al. **Brain Res Brain Res Rev** 1995 Sep; 21(2):185–94 (113 ref.)
The hippocampus, long-term potentiation and memory. Redman S. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov; 23(10–11):961–4 (29 ref.)
Synaptic plasticity: the basis of particular types of learning. Goda Y, et al. **Curr Biol** 1996 Apr 1;6(4):375–8 (12 ref.)
Synaptic plasticity: a role for nitric oxide in LTP. Huang EP. **Curr Biol** 1997 Mar 1;7(3):R141–3 (12 ref.)
LTP, NMDA, genes and learning. Cain DP. **Curr Opin Neurobiol** 1997 Apr;7(2):235–42 (75 ref.)
LTD, LTP, and the sliding threshold for long-term synaptic plasticity. Stanton PK. **Hippocampus** 1996;6(1):35–42 (69 ref.)
Retrograde messengers and long-term potentiation: a progress report. Williams JH. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):331–9 (55 ref.)
Synapse specificity and long-term information storage. Schuman EM. **Neuron** 1997 Mar;18(3):339–42 (22 ref.)
A role of Ca2+/calmodulin-dependent protein kinase II in the induction of long-term potentiation in hippocampal CA1 area. Miyamoto E, et al. **Neurosci Res** 1996 Jan; 24(2):117–22 (34 ref.)
Metaplasticity: a new vista across the field of synaptic plasticity. Abraham WC, et al. **Prog Neurobiol** 1997 Jul; 52(4):303–23 (138 ref.)
Receptor-mediated activation of protein kinase C in hippocampal long-term potentiation: facts, problems and implications [see comments] Angenstein F, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Apr; 21(3):427–54 (113 ref.) Comment in: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):373–8.
Long-term potentiation: a good model for learning and memory? Hölscher C. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Jan; 21(1):47–68 (69 ref.)
Comparing the role of metabotropic glutamate receptors in long-term potentiation and in learning and memory. Riedel G, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Jul;20(5):761–89 (118 ref.)
[The molecular-cellular mechanisms of long-term potentiation] Emel'ianov NA, et al. **Usp Fiziol Nauk** 1996 Jul–Sep;27(3):12–30 (143 ref.) (Eng. Abstr.) **(Rus)**

LONG-TERM SURVIVORS see **SURVIVORS**

LONG TERMINAL REPEAT see **REPETITIVE SEQUENCES, NUCLEIC ACID**

LONG TERMINAL REPEAT, HIV see **HIV LONG TERMINAL REPEAT**

LONGEVITY

see related
AGED
AGED, 80 AND OVER
LIFE EXPECTANCY

Physical activity, physical fitness and longevity. Lee IM, et al. **Aging (Milano)** 1997 Feb–Apr;9(1–2):2–11 (42 ref.)
How frailty models can be used for evaluating longevity limits: taking advantage of an interdisciplinary approach. Yashin AI, et al. **Demography** 1997 Feb;34(1):31–48 (105 ref.)
Determinants of longevity: genetic, environmental and medical factors. Christensen K, et al. **J Intern Med** 1996 Dec;240(6):333–41 (79 ref.)
Landscapes of longevity: the calcium-selenium-mercury connection in cancer and heart disease. Foster HD. **Med Hypotheses** 1997 Apr;48(4):355–60 (76 ref.)
Long-term fetal programming of body composition and longevity. James WP. **Nutr Rev** 1997 Jan;55(1 Pt 2):S31–41; discussion S41–3 (55 ref.)
Effects of vegetarian diets on aging and longevity. Walter P. **Nutr Rev** 1997 Jan;55(1 Pt 2):S61–5; discussion S65–8 (49 ref.)
Physical activity and fitness for health and longevity. Paffenbarger RS Jr, et al. **Res Q Exerc Sport** 1996 Sep; 67(3 Suppl):S11–28 (68 ref.)
Physical activity, long-term CHD mortality and longevity: a review of studies over the last 30 years. Goldbourt U. **World Rev Nutr Diet** 1997;82:229–39 (21 ref.)
[New special research data on over 100-year-old and older probands and problems (II)] Franke H. **Z Gerontol Geriatr** 1997 Mar–Apr;30(2):130–55 (119 ref.) (Eng. Abstr.) **(Ger)**
[Longevity, disease, and duration of disability] Matsushita S. **Nippon Ronen Igakkai Zasshi** 1996 Dec;33(12):916–22 (32 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice? [editorial] Packer M. **J Am Coll Cardiol** 1996 Nov 1; 28(5):1323–7 (25 ref.)

GENETICS

Genes and longevity [editorial] De Benedictis G. **Aging (Milano)** 1996 Dec;8(6):367–9 (16 ref.)
Selection for maximum longevity in mice. Harrison DE, et al. **Exp Gerontol** 1997 Jan–Apr;32(1–2):65–78 (52 ref.)
Insulin exposure and aging theory. Parr T. **Gerontology** 1997; 43(3):182–200 (165 ref.)
Telomere (telomerase) hypothesis of aging and immortalization. Rao KS. **Indian J Biochem Biophys** 1996 Apr;33(2):88–92 (47 ref.)
The limit to human longevity: an approach through a stress theory of ageing. Parsons PA. **Mech Ageing Dev** 1996 Jun 25;87(3):211–8 (46 ref.)
Aging. What makes us tick? [comment] Guarente L. **Science** 1997 Feb 14;275(5302):943–4 (11 ref.) Comment on: Science 1997 Feb 14;275(5302):980–3.

PHYSIOLOGY

Comparative aging and life histories in mammals. Austad SN. **Exp Gerontol** 1997 Jan–Apr;32(1–2):23–38 (115 ref.)
Multiphasic models of survival: analysis of mortality rate change regions and the issue of finite species lifespan. Witten TM, et al. **Exp Gerontol** 1997 May–Jun;32(3):259–85 (65 ref.)
Seminars in medicine of the Beth Israel Deaconess Medical Center. Caloric intake and aging. Weindruch R, et al. **N Engl J Med** 1997 Oct 2;337(14):986–94 (69 ref.)
Is there a fountain of youth? A review of current life extension strategies. Bernarducci MP, et al. **Pharmacotherapy** 1996 Mar–Apr;16(2):183–200 (74 ref.)
[Feasibility of increasing the longevity of healthy life using rational nutrition] Potemkina NS, et al. **Fiziol Cheloveka** 1996 Sep–Oct;22(5):123–7 (45 ref.) **(Rus)**

LONGITUDINAL LIGAMENTS

see related
OSSIFICATION OF POSTERIOR LONGITUDINAL LIGAMENT

LONGITUDINAL STUDIES

Time series analysis and its relationship with longitudinal analysis. Molenaar PC. **Int J Sports Med** 1997 Jul;18 Suppl 3:S232–7 (25 ref.)

LOOP ILEOSTOMY see **ILEOSTOMY**

LOOP OF HENLE

ANATOMY & HISTOLOGY

The macula densa: recent developments. Harris RC. **J Hypertens** 1996 Jul;14(7):815–22 (103 ref.)

METABOLISM

1995 Homer W. Smith Award Lecture. Characterization of basolateral mTAL Cl- channels. Andreoli TE. **J Am Soc Nephrol** 1996 Jun;7(6):818–30 (41 ref.)
Ca2+ and Mg2+ sensor in the thick ascending limb of the loop of Henle. Di Stefano A, et al. **Kidney Blood Press Res** 1997;20(3):190–3 (23 ref.)

PHYSIOLOGY

The macula densa: recent developments. Harris RC. **J Hypertens** 1996 Jul;14(7):815–22 (103 ref.)
Ca2+ and Mg2+ sensor in the thick ascending limb of the loop of Henle. Di Stefano A, et al. **Kidney Blood Press Res** 1997;20(3):190–3 (23 ref.)

LOOSE BODIES, JOINT see **JOINT LOOSE BODIES**

LORATADINE

THERAPEUTIC USE

Loratadine in the treatment of urticaria. Monroe EW. **Clin Ther** 1997 Mar–Apr;19(2):232–42 (60 ref.)
Safety and efficacy of loratadine in urticaria. Monroe EW. **Int J Dermatol** 1996 Dec;35(12):837–41 (35 ref.)
[Airway hyperreactivity and respiratory allergy in children] **Rev Alerg Mex** 1996;43 Spec No:22–37 (73 ref.) **(Spa)**

LORAZEPAM

THERAPEUTIC USE

[Treatment of neurological complications: cerebral edema and epileptic seizures] Vivancos Mora J. **Neurologia** 1995 Dec;10 Suppl 2:23–9 (67 ref.) (Eng. Abstr.) **(Spa)**

LORR'S INPATIENT MULTIDIMENSIONAL PSYCHIATRIC RATING SCALE see **PSYCHIATRIC STATUS RATING SCALES**

LOU GEHRIG'S DISEASE see **AMYOTROPHIC LATERAL SCLEROSIS**

LOUIS-BAR SYNDROME see **ATAXIA TELANGIECTASIA**

LOUPING ILL VIRUS see **ENCEPHALITIS VIRUSES, TICK-BORNE**

LOVASTATIN

ANALOGS & DERIVATIVES

Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal [see comments] Pedersen TR, et al. **Drug Saf** 1996 Jan; 14(1):11–24 (94 ref.) Comment in: Drug Saf 1996 Jan;14(1):8–10.
Statins do more than just lower cholesterol [see comments] [published erratum appears in Lancet 1997 Jan 18;349(9046):214] Vaughan CJ, et al. **Lancet** 1996 Oct 19; 348(9034):1079–82 (29 ref.) Comment in: Lancet 1996 Dec 7;348(9041):1582. Comment in: Lancet 1996 Dec 7;348(9041):1582–3. Comment in: Lancet 1996 Dec 7;348(9041):1583.

THERAPEUTIC USE

Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal [see comments] Pedersen TR, et al. **Drug Saf** 1996 Jan; 14(1):11–24 (94 ref.) Comment in: Drug Saf 1996 Jan;14(1):8–10.

LOW BACK PAIN

see related
SCIATICA

Treatment of occupationally acquired low back pain. Daniels JM 2nd. **Am Fam Physician** 1997 Feb 1;55(2):587–96, 601–2 (21 ref.)
The McKenzie method: a general practice interpretation: the lumbar spine. Taylor MD. **Aust Fam Physician** 1996 Feb; 25(2):189–93, 196–7, 200–1 (5 ref.)
Patient educational material in the management of low back pain in primary care. Burton AK, et al. **Bull Hosp Jt Dis** 1996;55(3):138–41 (24 ref.)
Low back pain in the year 2000--"back" to the future. Nachemson AL. **Bull Hosp Jt Dis** 1996;55(3):119–21 (39 ref.)
Where does the pain come from? Rydevik BL. **Bull Hosp Jt Dis** 1996;55(4):191–4 (22 ref.)
Prevention of low back disability. Waddell G. **Bull Hosp Jt Dis** 1996;55(4):221–4 (28 ref.)
Low back pain. Kuritzky L. **Compr Ther** 1997 May; 23(5):332–6 (17 ref.)
Epidemiology, etiology, diagnostic evaluation, and treatment of low back pain [see comments] Borenstein DG. **Curr Opin Rheumatol** 1997 Mar;9(2):144–50 (35 ref.) Comment in: Curr Opin Rheumatol 1997 Mar;9(2):133–43.
Cervical and lumbar pain. Cohen ML. **Med J Aust** 1996 Nov 4;165(9):504–8 (22 ref.)
Low back and cervical spine disorders. Rainville J, et al. **Orthop Clin North Am** 1996 Oct;27(4):729–46 (80 ref.)
Chronic low back pain. Borenstein DG. **Rheum Dis Clin North Am** 1996 Aug;22(3):439–56 (66 ref.)

COMPLICATIONS

Disability resulting from occupational low back pain. Part II: What do we know about secondary prevention? A review of the scientific evidence on prevention after disability begins. Frank JW, et al. **Spine** 1996 Dec 15; 21(24):2918–29 (73 ref.)

DIAGNOSIS

Distinguish the specific from non-specific low back pain. Hanley EN Jr. **Bull Hosp Jt Dis** 1996;55(4):195–6 (23 ref.)
Steps in the management of low back pain [see comments] Kuritzky L. **Hosp Pract (Off Ed)** 1996 Aug 15;31(8):109–24; discussion 124, 130 (5 ref.) Comment in: Hosp Pract (Off Ed) 1997 Mar 15;32(3):41.
Evaluation and treatment of low back pain. Dorsher PT. **J Fla Med Assoc** 1997 Jan;84(1):24–7 (26 ref.)
Primary care management of acute low back pain. Jones AK. **Nurse Pract** 1997 Jul;22(7):50–2, 61–3, 66 passim; quiz 74–5 (18 ref.)
Patients with low back pain: how to identify the few who need extra attention [see comments] Connelly C. **Postgrad Med** 1996 Dec;100(6):143–6, 149–50, 155–6 (10 ref.) Comment in: Postgrad Med 1997 Apr;101(4):56, 58.
Low back pain. Bueff HU, et al. **Prim Care** 1996 Jun; 23(2):345–64 (16 ref.)
Truncated sciatica as the first manifestation of a fatigue fracture of the sacrum in a young male [letter] Lechevalier D, et al. **Rev Rhum Engl Ed** 1996 Jul–Sep;63(7–8):505 (11 ref.)
Oh, my aching back: evaluation and surgical treatment of lumbar spine disorders. Kirkpatrick JS. **South Med J** 1996 Oct;89(10):935–9 (19 ref.)

DRUG THERAPY

Efficacy of non-steroidal anti-inflammatory drugs for low back pain: a systematic review of randomised clinical trials. Koes BW, et al. **Ann Rheum Dis** 1997 Apr;56(4):214–23 (53 ref.)

Injections and low back pain: outcome and randomized controlled trials. Balagué F. **Bull Hosp Jt Dis** 1996; 55(4):185–90 (49 ref.)

Epidural injection for the treatment of low back pain. Moskovich R. **Bull Hosp Jt Dis** 1996;55(4):178–84 (46 ref.)

Chronic opioid analgesic therapy for chronic low back pain [see comments] Brown RL, et al. **J Am Board Fam Pract** 1996 May–Jun;9(3):191–204 (63 ref.) Comment in: J Am Board Fam Pract 1996 May–Jun;9(3):225–8. Comment in: J Am Board Fam Pract 1996 Sep–Oct;9(5):386; discussion 387–8. Comment in: J Am Board Fam Pract 1996 Sep–Oct;9(5):386–7; discussion 387–8. Comment in: J Am Board Fam Pract 1996 Sep–Oct;9(5):388; discussion 387–8. Comment in: J Am Board Fam Pract 1996 Sep–Oct;9(5):388–9; discussion 387–8.

Drug therapy for back pain. Which drugs help which patients? Deyo RA. **Spine** 1996 Dec 15;21(24):2840–9; discussion 2849–50 (63 ref.)

[Epidural glucocorticoid injection in lumbago sciatica] Ringsdal VS, et al. **Ugeskr Laeger** 1997 Sep 15; 159(38):5653–7 (40 ref.) (Eng. Abstr.) **(Dan)**

[Injection treatment of non-radicular lumbalgia] Wittenberg RH, et al. **Orthopade** 1997 Jun;26(6):544–52 (62 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

Psychological factors in disabling low back pain: causes or consequences? Simmonds MJ, et al. **Disabil Rehabil** 1996 Apr;18(4):161–8 (94 ref.)

EPIDEMIOLOGY

Design factors in epidemiologic cohort studies of work-related low back injury or pain. Kraus JF, et al. **Am J Ind Med** 1997 Aug;32(2):153–63 (50 ref.)

Epidemiology and pathogenesis of non-specific low back pain: what does the epidemiology tell us? Riihimäki H. **Bull Hosp Jt Dis** 1996;55(4):197–8 (14 ref.)

Low back pain: risk factors for chronicity. Valat JP, et al. **Rev Rhum Engl Ed** 1997 Mar;64(3):189–94 (30 ref.)

The epidemiology of low back pain in the rest of the world. A review of surveys in low- and middle-income countries [see comments] Volinn E. **Spine** 1997 Aug 1;22(15):1747–54 (55 ref.) Comment in: Spine 1997 Aug 1;22(15):1798.

ETIOLOGY

A clinician's approach to acute low back pain. Borenstein DG. **Am J Med** 1997 Jan 27;102(1A):16S–22S (20 ref.)

The piriformis syndrome [see comments] Parziale JR, et al. **Am J Orthop** 1996 Dec;25(12):819–23 (33 ref.) Comment in: Am J Orthop 1997 May;26(5):316, 318.

Back pain in the workplace. Ratti N, et al. **Br J Rheumatol** 1997 Feb;36(2):260–4 (26 ref.)

Shadows of the truth in patients with spinal pain: a review. Giles LG, et al. **Can J Psychiatry** 1997 Feb;42(1):44–8 (80 ref.)

Back pain in golf. Hosea TM, et al. **Clin Sports Med** 1996 Jan;15(1):37–53 (37 ref.)

The influence of personal variables on work-related low-back disorders and implications for future research. Dempsey PG, et al. **J Occup Environ Med** 1997 Aug; 39(8):748–59 (99 ref.)

Increased phantom limb pain as an initial symptom of spinal-neoplasia [published erratum appears in J Pain Symptom Manage 1997 Sep;14(3):135] Chang VT, et al. **J Pain Symptom Manage** 1997 Jun;13(6):362–4 (18 ref.)

The biomechanics of fast bowling in men's cricket: a review. Bartlett RM, et al. **J Sports Sci** 1996 Oct;14(5):403–24 (80 ref.)

Large osteoarthritic bone cyst of the facet joint causing low back pain and sciatica. Shirado O, et al. **Orthopedics** 1997 May;20(5):472–5 (13 ref.)

Patients with low back pain: how to identify the few who need extra attention [see comments] Connelly C. **Postgrad Med** 1996 Dec;100(6):143–6, 149–50, 155–6 (10 ref.) Comment in: Postgrad Med 1997 Apr;101(4):56, 58.

Causes of failed back surgery syndrome [editorial] Goupille P. **Rev Rhum Engl Ed** 1996 Apr;63(4):235–9 (40 ref.)

Low back pain disorders and exposure to whole-body vibration in the workplace. Bovenzi M. **Semin Perinatol** 1996 Feb;20(1):38–53 (61 ref.)

Assessment and treatment of low back pain in working pregnant women. Ostgaard HC. **Semin Perinatol** 1996 Feb; 20(1):61–9 (25 ref.)

Back pain in the workplace. What you lift or how you lift matters far less than whether you lift or when [editorial] Hadler NM. **Spine** 1997 May 1;22(9):935–40 (41 ref.)

Giant intrasacral schwannoma forming a presacral mass: a report of an unusual cause of lumbosacral radiculopathy. Turgut M, et al. **Zentralbl Neurochir** 1996;57(4):201–5 (19 ref.)

[Low back pain: critical analysis of the state of the art] Paolaggi JB. **Bull Acad Natl Med** 1996 May;180(5):1033–49; discussion 1049–52 (75 ref.) (Eng. Abstr.) **(Fre)**

[Differential sciatica pain diagnosis from the neurologic viewpoint] Lindner A, et al. **Med Klin** 1997 Jun 15; 92(6):335–43 (83 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Epidemiology and pathogenesis of non-specific low back pain: what does the epidemiology tell us? Riihimäki H. **Bull Hosp Jt Dis** 1996;55(4):197–8 (14 ref.)

The mysteries of segmental instability. Szpalski M. **Bull Hosp Jt Dis** 1996;55(3):147–8 (10 ref.)

Mechanisms of low back pain: a neurophysiologic and neuroanatomic study. Cavanaugh JM, et al. **Clin Orthop** 1997 Feb;(335):166–80 (63 ref.)

[Lumbar pain in old age] Baumgartner H. **Schweiz Rundsch Med Prax** 1996 Oct 22;85(43):1347–53 (13 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

A new trend in the study of low back pain in workplaces. Yamamoto S. **Ind Health** 1997 Apr;35(2):173–85 (120 ref.)

Work-related back pain in nurses. Hignett S. **J Adv Nurs** 1996 Jun;23(6):1238–46 (80 ref.)

Mechanical stress reduction during seated jolt/vibration exposure. Wilder DG, et al. **Semin Perinatol** 1996 Feb; 20(1):54–60 (85 ref.)

Disability resulting from occupational low back pain. Part I: What do we know about primary prevention? A review of the scientific evidence on prevention before disability begins. Frank JW, et al. **Spine** 1996 Dec 15;21(24):2908–17 (80 ref.)

[Diagnostic problems and prophylaxis of paraoccupational diseases of the spine] Iżycki J. **Med Pr** 1996;47(6):651–5 (31 ref.) (Eng. Abstr.) **(Pol)**

PSYCHOLOGY

Psychological factors in disabling low back pain: causes or consequences? Simmonds MJ, et al. **Disabil Rehabil** 1996 Apr;18(4):161–8 (94 ref.)

Screening for psychological factors in patients with low back problems: Waddell's nonorganic signs. Scalzitti DA. **Phys Ther** 1997 Mar;77(3):306–12 (36 ref.)

Educational and behavioral interventions for back pain in primary care. Turner JA. **Spine** 1996 Dec 15;21(24):2851–7; discussion 2858–9 (48 ref.)

[Psychosomatic aspects of chronic pain] Doering S, et al. **Orthopade** 1997 Jun;26(6):521–7 (19 ref.) (Eng. Abstr.) **(Ger)**

[A psychological therapy methods in chronic non-radicular backache] Söllner W, et al. **Orthopade** 1997 Jun; 26(6):535–43 (62 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Spinal radiographic findings and nonspecific low back pain. A systematic review of observational studies. van Tulder MW, et al. **Spine** 1997 Feb 15;22(4):427–34 (58 ref.)

RADIONUCLIDE IMAGING

Low back pain and nuclear medicine. Everaert H, et al. **J Belge Radiol** 1997 Jun;80(3):124–7 (15 ref.)

REHABILITATION

Industrial rehabilitation medicine. 2. Case studies in occupational low back pain. Scheer SJ, et al. **Arch Phys Med Rehabil** 1997 Mar;78(3 Suppl):S10–5 (72 ref.)

Randomized controlled trials in industrial low back pain. Part 3. Subacute/chronic pain interventions. Scheer SJ, et al. **Arch Phys Med Rehabil** 1997 Apr;78(4):414–23 (65 ref.)

Randomized controlled trials in industrial low back pain relating to return to work. Part 2. Discogenic low back pain. Scheer SJ, et al. **Arch Phys Med Rehabil** 1996 Nov; 77(11):1189–97 (79 ref.)

Exercises for the patient with low back pain: when and how. Nordin M, et al. **Bull Hosp Jt Dis** 1996;55(3):142–6 (31 ref.)

Spinal manipulation as a valid treatment for low back pain. Vernon LF. **Del Med J** 1996 Mar;68(3):175–8 (33 ref.)

Posteroanterior spinal mobilization: state of the art review and discussion. Björnsdóttir SV, et al. **Disabil Rehabil** 1997 Feb;19(2):39–46 (40 ref.)

The biopsychosocial disease consequence model in rehabilitation: model development in the Finnish 'work hardening' programme for chronic pain. Talo S, et al. **Int J Rehabil Res** 1996 Jun;19(2):93–109 (35 ref.)

Isolated lumbar strengthening in the rehabilitation of chronic low back pain. Deutsch FE. **J Manipulative Physiol Ther** 1996 Feb;19(2):124–33 (76 ref.)

Regional back pain: predicament at home, nemesis at work [editorial] [see comments] Hadler NM. **J Occup Environ Med** 1996 Oct;38(10):973–8 (54 ref.) Comment in: J Occup Environ Med 1996 Oct;38(10):979–80.

Rehabilitation of acute and subacute low back and neck pain in the work-injured patient. Hartigan C, et al. **Orthop Clin North Am** 1996 Oct;27(4):841–60 (61 ref.)

Functional restoration in chronic low back pain. Bendix T, et al. **Scand J Med Sci Sports** 1996 Apr;6(2):88–97 (57 ref.)

Physical exercise and low back pain. Campello M, et al. **Scand J Med Sci Sports** 1996 Apr;6(2):63–72 (54 ref.)

Exercise programs for subjects with low back disorders. Mälkiä E, et al. **Scand J Med Sci Sports** 1996 Apr;6(2):73–81 (103 ref.)

Clinical benefit of intensive dynamic exercises for low back pain. Manniche C. **Scand J Med Sci Sports** 1996 Apr; 6(2):82–7 (55 ref.)

An agenda for primary care research on low back pain. Borkan JM, et al. **Spine** 1996 Dec 15;21(24):2880–4 (6 ref.)

Low back pain. A primary care challenge. Deyo RA, . al. **Spine** 1996 Dec 15;21(24):2826–32 (20 ref.)

Exercises: which ones are worth trying, for which patients, and when? Faas A. **Spine** 1996 Dec 15;21(24):2874–8; discussion 2878–9 (16 ref.)

Objectification of functional improvement after nonoperative care. Flores L, et al. **Spine** 1997 Jul 15;22(14):1622–33 (128 ref.)

Spinal manipulation for low back pain. An updated systematic review of randomized clinical trials. Koes BW, et al. **Spine** 1996 Dec 15;21(24):2860–71; discussion 2872–3 (72 ref.)

Educational and behavioral interventions for back pain in primary care. Turner JA. **Spine** 1996 Dec 15;21(24):2851–7; discussion 2858–9 (48 ref.)

[Interrater studies of evaluating the reliability of somatic findings] Saur PM, et al. **Rehabilitation (Stuttg)** 1996 Aug; 35(3):150–60 (37 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

The artificial disc: theory, design and materials. Bao QB, et al. **Biomaterials** 1996 Jun;17(12):1157–67 (107 ref.)

How to fuse the lumbar spine. Fraser RD. **Bull Hosp Jt Dis** 1996;55(3):158–61 (10 ref.)

Outcome of fusion: assessment techniques and comparison of anterior fusion with posterolateral fusion. Greenough CG. **Bull Hosp Jt Dis** 1996;55(3):162–5 (14 ref.)

Lumbar spine instability: outcome and randomized controlled trials. Nachemson AL. **Bull Hosp Jt Dis** 1996;55(3):166 (11 ref.)

Controversies in low back pain: the surgical approach. Hanley EN Jr, et al. **Instr Course Lect** 1994;43:415–23 (56 ref.)

Imaging findings in patients with failed back surgery syndrome. Van Goethem JW, et al. **J Belge Radiol** 1997 Apr;80(2):81–4 (19 ref.)

Lumbar disc disease with discogenic pain. What surgical treatment is most effective? Nachemson A, et al. **Spine** 1996 Aug 1;21(15):1835–8 (21 ref.)

THERAPY

A clinician's approach to acute low back pain. Borenstein DG. **Am J Med** 1997 Jan 27;102(1A):16S–22S (20 ref.)

The McKenzie method: a general practice interpretation: the lumbar spine. Taylor MD. **Aust Fam Physician** 1996 Feb; 25(2):189–93, 196–7, 200–1 (5 ref.)

Spinal cord stimulation [editorial] Simpson BA. **Br J Neurosurg** 1997 Feb;11(1):5–11 (65 ref.)

Low back pain in children and adolescents: to treat or not? Burton AK. **Bull Hosp Jt Dis** 1996;55(3):127–9 (25 ref.)

Spinal manipulation: when, how, and who? Haldeman SD. **Bull Hosp Jt Dis** 1996;55(3):135–7 (19 ref.)

Chronic low back pain and disability: the efficacy of functional restoration. Hazard RG. **Bull Hosp Jt Dis** 1996; 55(4):213–6 (16 ref.)

Steps in the management of low back pain [see comments] Kuritzky L. **Hosp Pract (Off Ed)** 1996 Aug 15;31(8):109–24; discussion 124, 130 (5 ref.) Comment in: Hosp Pract (Off Ed) 1997 Mar 15;32(3):41.

Modern management of spinal disorders. Waddell G. **J Manipulative Physiol Ther** 1995 Nov–Dec;18(9):590–6 (14 ref.)

Scientific application of sports medicine principles for acute low back problems. The Agency for Health Care Policy and Research Low Back Guideline Panel (AHCPR, Guideline #14) [see comments] Bigos SJ, et al. **J Orthop Sports Phys Ther** 1996 Oct;24(4):192–207 (5 ref.) Comment in: J Orthop Sports Phys Ther 1997 Aug;26(2):105–8.

The disc at risk in athletes: perspectives on operative and nonoperative care. Young JL, et al. **Med Sci Sports Exerc** 1997 Jul;29(7 Suppl):S222–32 (74 ref.)

Primary care management of acute low back pain. Jones AK. **Nurse Pract** 1997 Jul;22(7):50–2, 61–3, 66 passim; quiz 74–5 (18 ref.)

Assessment and treatment of low back pain in working pregnant women. Ostgaard HC. **Semin Perinatol** 1996 Feb; 20(1):61–9 (25 ref.)

Objectification of functional improvement after nonoperative care. Flores L, et al. **Spine** 1997 Jul 15;22(14):1622–33 (128 ref.)

[Physical therapy in low back pain] Muff L, et al. **Schweiz Rundsch Med Prax** 1996 Sep 10;85(37):1116–22 (18 ref.) (Eng. Abstr.) **(Ger)**

LOW CARDIAC OUTPUT see **CARDIAC OUTPUT, LOW**

LOW-DENSITY LIPOPROTEINS see **LIPOPROTEINS, LDL**

LOW GRAVITY see **HYPOGRAVITY**

LOW-INCOME POPULATION see **POVERTY**

LOW-MOLECULAR-WEIGHT HEPARIN see **HEPARIN, LOW-MOLECULAR-WEIGHT**

LOW MOLECULAR WEIGHT NUCLEAR RNA see **RNA, SMALL NUCLEAR**

LOW-PROTEIN DIET see DIET, PROTEIN-RESTRICTED

LOW T3 AND T4 SYNDROME see EUTHYROID SICK SYNDROMES

LOW T3 SYNDROME see EUTHYROID SICK SYNDROMES

LOWE SYNDROME see OCULOCEREBRORENAL SYNDROME

LOWER EXTREMITY see LEG

LOWER NEPHRON NEPHROSIS see KIDNEY TUBULAR NECROSIS, ACUTE

LOWN-GANONG-LEVINE SYNDROME

[Lown-Ganong-Levine syndrome] Toshida N, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):196-8 (7 ref.) **(Jpn)**

LP(A) see LIPOPROTEIN(A)

LSD see LYSERGIC ACID DIETHYLAMIDE

LTC4 see LEUKOTRIENE C4

LTD4 see LEUKOTRIENE D4

LUBRICATION

Surgical glove lubricants: from toxicity to opportunity. Woods JA, et al. **J Emerg Med** 1997 Mar-Apr;15(2):209-20 (59 ref.)

LUCERNE see ALFALFA

LUCIFERASE

CHEMISTRY

Structure of bacterial luciferase. Baldwin TO, et al. **Curr Opin Struct Biol** 1995 Dec;5(6):798-809 (72 ref.)

Firefly luciferase: the structure is known, but the mystery remains. Baldwin TO. **Structure** 1996 Mar 15;4(3):223-8 (49 ref.)

METABOLISM

Structure of bacterial luciferase. Baldwin TO, et al. **Curr Opin Struct Biol** 1995 Dec;5(6):798-809 (72 ref.)

LULIBERIN see GONADORELIN

LULIBERIN RECEPTORS see RECEPTORS, LHRH

LUMBAGO see LOW BACK PAIN

LUMBAR PLEXUS see LUMBOSACRAL PLEXUS

LUMBAR PUNCTURE see SPINAL PUNCTURE

LUMBAR REGION see LUMBOSACRAL REGION

LUMBAR VERTEBRAE

Distinguish the specific from non-specific low back pain. Hanley EN Jr. **Bull Hosp Jt Dis** 1996;55(4):195-6 (23 ref.)

Primary osteosarcoma of the L2 lamina presenting as "silent" paraplegia: case report and review of the literature. Korovessis P, et al. **Eur Spine J** 1995;4(6):375-8 (18 ref.)

Exogenous lumbar spondylodiscitis following a stabwound injury and vertebral fracture. A case report and review of the literature. Schulze CJ, et al. **Eur Spine J** 1995; 4(6):357-9 (16 ref.)

Steps in the management of low back pain [see comments] Kuritzky L. **Hosp Pract (Off Ed)** 1996 Aug 15;31(8):109-24; discussion 124, 130 (5 ref.) Comment in: Hosp Pract (Off Ed) 1997 Mar 15;32(3):41.

The causes of failure of lumbar transpedicular spinal instrumentation and fusion: a prospective study. Hadjipavlou A, et al. **Int Orthop** 1996;20(1):35-42 (53 ref.)

Magnetic resonance imaging and clinical follow-up: study of 27 patients receiving chiropractic care for cervical and lumbar disc herniations. BenEliyahu DJ. **J Manipulative Physiol Ther** 1996 Nov-Dec;19(9):597-606 (58 ref.)

Increased phantom limb pain as an initial symptom of spinal-neoplasia [published erratum appears in J Pain Symptom Manage 1997 Sep;14(3):135] Chang VT, et al. **J Pain Symptom Manage** 1997 Jun;13(6):362-4 (18 ref.)

Treatment of coccidioidal spinal infection: experience in 16 cases. Herron LD, et al. **J Spinal Disord** 1997 Jun; 10(3):215-22 (11 ref.)

Solid variant of an aneurysmal bone cyst (giant cell reparative granuloma) of the 3rd lumbar vertebra. Sato K, et al. **Nagoya J Med Sci** 1996 Dec;59(3-4):159-65 (22 ref.)

Epithelioid hemangioendothelioma of the lumbar vertebral column: case report and review of literature. Ellis TS, et al. **Neurosurgery** 1996 Feb;38(2):402-7 (51 ref.)

Large osteoarthritic bone cyst of the facet joint causing low back pain and sciatica. Shirado O, et al. **Orthopedics** 1997 May;20(5):472-5 (13 ref.)

An update on orthotic devices for the lumbar spine based on a review of the literature. Calmels P, et al. **Rev Rhum Engl Ed** 1996 Apr;63(4):285-91 (52 ref.)

[Giant cell tumors of the spine. Report of a case, literature review] Laffargue P, et al. **Acta Orthop Belg** 1997 Mar; 63(1):28-34 (32 ref.) (Eng. Abstr.) **(Fre)**

[Septic arthritis of posterior lumbar facet joint] Ben Hamouda M, et al. **J Radiol** 1997 May;78(5):373-6 (10 ref.) (Eng. Abstr.) **(Fre)**

[Vascular complications during surgery of lumbar disk herniation. Apropos of 3 personal cases and 37 cases from a national investigation] Mercier P, et al. **Neurochirurgie** 1996;42(4-5):202-8 (16 ref.) (Eng. Abstr.) **(Fre)**

[Radiology of lumbar spinal canal stenosis] Hähnel S, et al. **Aktuelle Radiol** 1996 Jul;6(4):165-70 (38 ref.) (Eng. Abstr.) **(Ger)**

[Osteoporosis of the lumbar spine] Villiger PM, et al. **Schweiz Rundsch Med Prax** 1996 Oct 22;85(43):1354-9 (15 ref.) (Eng. Abstr.) **(Ger)**

[Degenerative lumbar spondylolisthesis] Eshkenazi AU, et al. **Harefuah** 1997 Feb 2;132(3):229-32 (34 ref.) **(Heb)**

[The conservative treatment for lumbar disc herniation] Maruo S. **Nippon Seikeigeka Gakkai Zasshi** 1996 Oct; 70(10):673-84 (40 ref.) **(Jpn)**

[Scoliosis of sudden evolution due to lumbar osteoblastoma] Amaral J de S, et al. **Acta Med Port** 1997 May;10(5):417-22 (16 ref.) (Eng. Abstr.) **(Por)**

ABNORMALITIES

Congenital lumbosacral lipomas. Pierre-Kahn A, et al. **Childs Nerv Syst** 1997 Jun;13(6):298-334; discussion 335 (199 ref.)

[Severe congenital thoracic-lumbar scoliosis in pregnancy. A case report and review of the literature] Restaino A, et al. **Minerva Ginecol** 1996 Dec;48(12):565-71 (29 ref.) (Eng. Abstr.) **(Ita)**

ANATOMY & HISTOLOGY

Anthropometrical and mechanical considerations in determining normal parameters for the sagittal lumbar spine. Dulhunty JA. **J Manipulative Physiol Ther** 1997 Feb; 20(2):92-102 (34 ref.)

DRUG EFFECTS

Lumbar chymopapain nucleolysis. Javid MJ, et al. **Neurosurg Clin N Am** 1996 Jan;7(1):17-27 (50 ref.)

INJURIES

Injury risk for research subjects with spina bifida occulta in a repeated impact study: a case review. Albano JP, et al. **Aviat Space Environ Med** 1996 Aug;67(8):767-9 (15 ref.)

Anterior instrumentation in the management of thoracolumbar burst fractures. Ghanayem AJ, et al. **Clin Orthop** 1997 Feb;(335):89-100 (38 ref.)

Posterior instrumentation for thoracolumbar trauma. Stambough JL. **Clin Orthop** 1997 Feb;(335):73-88 (131 ref.)

The biomechanics of low back injury: implications on current practice in industry and the clinic. McGill SM. **J Biomech** 1997 May;30(5):465-75 (50 ref.)

Emergency department approach to acute thoracolumbar spine injury. Savitsky E, et al. **J Emerg Med** 1997 Jan-Feb; 15(1):49-60 (72 ref.)

The disc at risk in athletes: perspectives on operative and nonoperative care. Young JL, et al. **Med Sci Sports Exerc** 1997 Jul;29(7 Suppl):S222-32 (74 ref.)

Thoracic and lumbar spine trauma. Brandser EA, et al. **Radiol Clin North Am** 1997 May;35(3):533-57 (77 ref.)

Osteoporotic vertebral fractures in a man under high-dose inhaled glucocorticoid therapy. A case-report with a review of the literature. Laroche M, et al. **Rev Rhum Engl Ed** 1997 Apr;64(4):267-70 (16 ref.)

The role of imaging in the diagnosis and management of thoracolumbar burst fractures: current concepts and a review of the literature. Saifuddin A, et al. **Skeletal Radiol** 1996 Oct;25(7):603-13 (49 ref.)

Traumatic spondylopelvic dissociation. A case report and literature review [see comments] Bents RT, et al. **Spine** 1996 Aug 1;21(15):1814-9 (25 ref.) Comment in: Spine 1997 Jun 1;22(11):1276.

PATHOLOGY

Abdominal aortic aneurysm with lumbar vertebral erosion in Behçet's disease. A case report and review of the literature. Roeyen G, et al. **Eur J Vasc Endovasc Surg** 1997 Feb;13(2):242-6 (40 ref.)

Imaging findings in patients with failed back surgery syndrome. Van Goethem JW, et al. **J Belge Radiol** 1997 Apr;80(2):81-4 (19 ref.)

Lumbar facet pain: biomechanics, neuroanatomy and neurophysiology. Cavanaugh JM, et al. **J Biomech** 1996 Sep;29(9):1117-29 (54 ref.)

Clinical image. Tophaceous gout of the lumbar spine: MR findings. Miller LJ, et al. **J Comput Assist Tomogr** 1996 Nov-Dec;20(6):1004-5 (7 ref.)

Candida osteomyelitis and disc space infection of the lumbar spine. Munk PL, et al. **Skeletal Radiol** 1997 Jan;26(1):42-6 (17 ref.)

Oh, my aching back: evaluation and surgical treatment of lumbar spine disorders. Kirkpatrick JS. **South Med J** 1996 Oct;89(10):935-9 (19 ref.)

Consensus summary of the diagnosis and treatment of lumbar disc herniation. Andersson GB, et al. **Spine** 1996 Dec 15; 21(24 Suppl):75S-78S (0 ref.)

Idiopathic avascular necrosis of a vertebral body. Case report and literature review. Chou LH, et al. **Spine** 1997 Aug 15;22(16):1928-32 (18 ref.)

Focus issue on lumbar disc herniation: macro- and microdiscectomy. McCulloch JA. **Spine** 1996 Dec 15;21(24 Suppl):45S-56S (105 ref.)

Natural history and nonoperative treatment of lumbar disc herniation. Saal JA. **Spine** 1996 Dec 15;21(24 Suppl):2S-9S (45 ref.)

PHYSIOLOGY

Anthropometrical and mechanical considerations in determining normal parameters for the sagittal lumbar spine. Dulhunty JA. **J Manipulative Physiol Ther** 1997 Feb; 20(2):92-102 (34 ref.)

PHYSIOPATHOLOGY

Lumbar facet pain: biomechanics, neuroanatomy and neurophysiology. Cavanaugh JM, et al. **J Biomech** 1996 Sep;29(9):1117-29 (54 ref.)

[Stenosis of the lumbar spinal canal. Pathophysiology, clinical aspects and therapy] Benini A. **Orthopade** 1997 May; 26(5):503-14 (6 ref.) **(Ger)**

[Biomechanics of lumbar instability] Krismer M, et al. **Orthopade** 1997 Jun;26(6):516-20 (37 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Lateral dual X-ray absorptiometry of the lumbar spine: current status [editorial] Jergas M, et al. **Bone** 1997 Apr; 20(4):311-4 (39 ref.)

Automated percutaneous nucleotomy: restricted indications based on CT scan appearance. Castro WH, et al. **Neurosurg Clin N Am** 1996 Jan;7(1):43-7 (24 ref.)

Chondromyxoid fibroma of the lumbar spine. Cabral CE, et al. **Skeletal Radiol** 1997 Aug;26(8):488-92 (24 ref.)

[The computed tomographic findings on the lumbar spine in systemic mastocytosis] Lugmayr H, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Feb;166(2):162-3 (7 ref.) **(Ger)**

SURGERY

The far lateral approach to lumbar disc herniations. Porchet F, et al. **Adv Tech Stand Neurosurg** 1997;23:249-74 (50 ref.)

How to fuse the lumbar spine. Fraser RD. **Bull Hosp Jt Dis** 1996;55(3):158-61 (10 ref.)

Lumbar spine instability: outcome and randomized controlled trials. Nachemson AL. **Bull Hosp Jt Dis** 1996;55(3):166 (11 ref.)

Oxygen venous embolism after the use of hydrogen peroxide during lumbar discectomy. Despond O, et al. **Can J Anaesth** 1997 Apr;44(4):410-3 (18 ref.)

Lumbar discectomy microdiscectomy: "the gold standard". Apostolides PJ, et al. **Clin Neurosurg** 1996;43:228-38 (41 ref.)

The case for posterior lumbar interbody fusion. Branch CL Jr. **Clin Neurosurg** 1996;43:252-67 (62 ref.)

Transpedicle instrumentation in the degenerative spine. Heim SE. **Clin Orthop** 1997 Apr;(337):97-110 (146 ref.)

Spinal instrumentation in the management of degenerative disorders of the lumbar spine. Sidhu KS, et al. **Clin Orthop** 1997 Feb;(335):39-53 (41 ref.)

Controversies in low back pain: the surgical approach. Hanley EN Jr, et al. **Instr Course Lect** 1994;43:415-23 (56 ref.)

Minimally invasive arthroscopic spinal surgery. Kambin P, et al. **Instr Course Lect** 1997;46:143-61 (79 ref.)

Minimally invasive endoscopic surgery of the spine. Goldstein JA, et al. **J South Orthop Assoc** 1996 Winter; 5(4):251-62 (34 ref.)

Adult spondylolisthesis treated with posterolateral lumbar fusion and pedicular instrumentation with AO DC plates. Thalgott JS, et al. **J Spinal Disord** 1997 Jun;10(3):204-8 (15 ref.)

Automated percutaneous nucleotomy: restricted indications based on CT scan appearance. Castro WH, et al. **Neurosurg Clin N Am** 1996 Jan;7(1):43-7 (24 ref.)

Stereotactic lumbar microdiscectomy. Koutrouvelis PG, et al. **Neurosurg Clin N Am** 1996 Jan;7(1):49-57 (14 ref.)

Percutaneous endoscopic lumbar spine fusion. Leu HF, et al. **Neurosurg Clin N Am** 1996 Jan;7(1):107-17 (20 ref.)

Automated percutaneous discectomy. Quigley MR, et al. **Neurosurg Clin N Am** 1996 Jan;7(1):29-35 (27 ref.)

Percutaneous laser discectomy. Quigley MR. **Neurosurg Clin N Am** 1996 Jan;7(1):37-42 (17 ref.)

Intraradicular, intervertebral disc herniation. A case report. Finkel HZ. **Spine** 1997 May 1;22(9):1028-9 (8 ref.)

Management of iatrogenic spinal stenosis complicating placement of a fusion cage. A case report. Glassman SD, et al. **Spine** 1996 Oct 15;21(20):2383-6 (16 ref.)

Controversy. Fusion of L5-S1 in adult scoliosis. Horton WC, et al. **Spine** 1996 Nov 1;21(21):2520-2 (8 ref.)

Lumbar disc disease with discogenic pain. What surgical

LUMBAR VERTEBRAE

treatment is most effective? Nachemson A, et al. **Spine** 1996 Aug 1;21(15):1835–8 (21 ref.)

Results of surgery compared with conservative management for lumbar disc herniations. Postacchini F. **Spine** 1996 Jun 1;21(11):1383–7 (19 ref.)

Vascular injury during lumbar disc surgery. Report of two cases; a review of the literature. Sağdiç K, et al. **Vasa** 1996; 25(4):378–81 (21 ref.)

[Minimally invasive approach and surgical procedures in the lumbar spine] Ogon M, et al. **Orthopade** 1997 Jun; 26(6):553–61 (49 ref.) (Eng. Abstr.) **(Ger)**

[Is instrumented pedicle fixation of the lumbar vertebrae used on too large a scale?--thoughts on indication] Schulitz KP. **Z Orthop Ihre Grenzgeb** 1996 Sep–Oct;134(5):472–6; discussion 476–8 (29 ref.) (Eng. Abstr.) **(Ger)**

LUMBOSACRAL PLEXUS

[Three-in-one block or femoral nerve block. What should be done and how?] Dupré LJ. **Ann Fr Anesth Reanim** 1996; 15(7):1099–101 (33 ref.) (Eng. Abstr.) **(Fre)**

ANATOMY & HISTOLOGY

A comparative anatomical study of muscles of the pelvic outlet and the piriformis with special reference to their innervation. Akita K. **Kaibogaku Zasshi** 1997 Feb; 72(1):9–12 (21 ref.)

PHYSIOPATHOLOGY

Lumbosacral plexus neuropathy: a case report and review of the literature. van Alfen N, et al. **Clin Neurol Neurosurg** 1997 May;99(2):138–41 (16 ref.)

LUMBOSACRAL REGION

see related
LOW BACK PAIN

Successful treatment of spinal osteosarcoma with radiation and chemotherapy. Hershey A, et al. **Orthopedics** 1996 Jul; 19(7):617–8 (7 ref.)

INJURIES

Injury risk for research subjects with spina bifida occulta in a repeated impact study: a case review. Albano JP, et al. **Aviat Space Environ Med** 1996 Aug;67(8):767–9 (15 ref.)

Traumatic spondylopelvic dissociation. A case report and literature review [see comments] Bents RT, et al. **Spine** 1996 Aug 1;21(15):1814–9 (25 ref.) Comment in: Spine 1997 Jun 1;22(11):1276.

Late displacement of a fracture dislocation at the lumbosacral junction. A case study. Steinitz DK, et al. **Spine** 1997 May 1;22(9):1024–7 (9 ref.)

LUMINESCENCE

see related
CHEMILUMINESCENCE

Oxygen dependent quenching of phosphorescence: a status report. Wilson DF, et al. **Adv Exp Med Biol** 1996;388:101–7 (38 ref.)

Lessons from a cooperative, bacterial–animal association: the Vibrio fischeri–Euprymna scolopes light organ symbiosis. Ruby EG. **Annu Rev Microbiol** 1996;50:591–624 (138 ref.)

[Recent advances of chemistry of bioluminescence] Isobe M, et al. **Seikagaku** 1996 Nov;68(11):1683–91 (54 ref.) **(Jpn)**

[Practical use of luminogenic reagents specific for guanine–containing compounds] Kai M. **Tanpakushitsu Kakusan Koso** 1997 Apr;42(5):777–83 (16 ref.) **(Jpn)**

LUMINESCENT PROTEINS

[Nuclear transport visualized by protein tagging systems including GFP] Kimata Y, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1187–92 (24 ref.) **(Jpn)**

LUMINOL

DIAGNOSTIC USE

Methods and reagents. Chemiluminescent detection methods. Hengen PN. **Trends Biochem Sci** 1997 Aug;22(8):313–4 (9 ref.)

LUMPECTOMY see **MASTECTOMY, SEGMENTAL**

LUNDBORG–UNVERRICHT SYNDROME see **EPILEPSY, MYOCLONIC**

LUNG

see related
PNEUMONECTOMY
PULMONARY CIRCULATION
RESPIRATION

Recruitment of inflammatory cells into lung: roles of cytokines, adhesion molecules, and complement. Ward PA. **J Lab Clin Med** 1997 Apr;129(4):400–4 (24 ref.)

Fractured tracheostomy tube: an overlooked foreign body. Gupta SC, et al. **J Laryngol Otol** 1996 Nov;110(11):1069–71 (14 ref.)

Ontogeny and developmental regulation of heme oxygenase. Dennery PA, et al. **J Perinatol** 1996 May–Jun;16(3 Pt 2):S79–83 (32 ref.)

ABNORMALITIES

Pulmonary agenesis: a predictor of ipsilateral malformations. Cunningham ML, et al. **Am J Med Genet** 1997 Jun 27; 70(4):391–8 (52 ref.)

Bronchopulmonary–foregut malformations: a continuum of paracrine hamartomas? Kousseff BG, et al. **Am J Med Genet** 1997 Jan 10;68(1):12–7 (92 ref.)

Pulmonary parenchymal abnormalities in congenital diaphragmatic hernia. Wilcox DT, et al. **Clin Perinatol** 1996 Dec;23(4):771–9 (36 ref.)

Unilateral pulmonary hypoplasia with bifid ureter and pelvis. Prasad R, et al. **Indian J Chest Dis Allied Sci** 1996 Jul–Sep; 38(3):205–9 (9 ref.)

Asynchronous pulmonary hyperplasia associated with tracheal atresia: pathologic and prenatal sonographic findings. Wright JR Jr, et al. **Pediatr Pathol Lab Med** 1995 Jan–Feb;15(1):81–97 (21 ref.)

Lung–angiodysplasia and von Willebrand's disease in a family with Rendu–Osler disease. A case report. Girola SS, et al. **Recenti Prog Med** 1996 Dec;87(12):589–91 (9 ref.)

Pulmonary hypoplasia presented in adulthood as a chronic respiratory failure: report of two cases. Embryology, clinical symptoms and diagnostic procedures. Mas A, et al. **Respiration** 1997;64(3):240–3 (14 ref.)

Making the most out of the least: new insights into congenital diaphragmatic hernia [editorial] Karamanoukian HL, et al. **Thorax** 1997 Mar;52(3):209–12 (68 ref.)

Spontaneous pneumothorax in a patient with an azygos lobe. Sadikot RT, et al. **Thorax** 1997 Jun;52(6):579–80; discussion 575–6 (9 ref.)

[Systemic arterial supply to the basal segments of the lung] Hamada T, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (13):308–10 (19 ref.) **(Jpn)**

ANATOMY & HISTOLOGY

The avian respiratory system: a unique model for studies of respiratory toxicosis and for monitoring air quality. Brown RE, et al. **Environ Health Perspect** 1997 Feb;105(2):188–200 (108 ref.)

BLOOD SUPPLY

Smooth muscle cell heterogeneity in pulmonary and systemic vessels. Importance in vascular disease. Frid MG, et al. **Arterioscler Thromb Vasc Biol** 1997 Jul;17(7):1203–9 (40 ref.)

Pulmonary capillaritis and alveolar hemorrhage. Update on diagnosis and management [published erratum appears in Chest 1997 Jul;112(1):300] Green RJ, et al. **Chest** 1996 Nov; 110(5):1305–16 (69 ref.)

The normal pulmonary vascular transition at birth. Dukarm RC, et al. **Clin Perinatol** 1996 Dec;23(4):711–26 (128 ref.)

Pulmonary vascular abnormalities in congenital diaphragmatic hernia. O'Toole SJ, et al. **Clin Perinatol** 1996 Dec;23(4):781–94 (70 ref.)

Bedside measurement of pulmonary capillary permeability in patients with acute lung injury. What have we learned? [editorial] Rocker GM. **Intensive Care Med** 1996 Jul; 22(7):619–21 (19 ref.)

Lung–angiodysplasia and von Willebrand's disease in a family with Rendu–Osler disease. A case report. Girola SS, et al. **Recenti Prog Med** 1996 Dec;87(12):589–91 (9 ref.)

[The significance of endothelin for physiologic and pathophysiologic processes of the lung (see comments)] Schmeck J, et al. **Anasthesiol Intensivmed Notfallmed Schmerztther** 1997 Jul; 32(7):401–8 (123 ref.) (Eng. Abstr.) Comment in: Anasthesiol Intensivmed Notfallmed Schmer 1997 Jul;32(7):397–8. **(Ger)**

[Pulmonary vasculitis: systematic aspects, pathogenesis and therapy] Kummer F, et al. **Pneumologie** 1997 Mar; 51(3):279–85 (24 ref.) **(Ger)**

[Hepatopulmonary syndrome] Lotterer E, et al. **Schweiz Rundsch Med Prax** 1997 Jan 21;86(4):104–8 (30 ref.) (Eng. Abstr.) **(Ger)**

[Systemic arterial supply to the basal segments of the lung] Hamada T, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (13):308–10 (19 ref.) **(Jpn)**

[Primary pulmonary hypertension in adults] Kriuchkova GS, et al. **Arkh Patol** 1996 May–Jun;58(3):68–75 (53 ref.) (Eng. Abstr.) **(Rus)**

CHEMISTRY

Airway smooth muscle cell culture: application to studies of airway wall remodelling and phenotype plasticity in asthma. Hirst SJ. **Eur Respir J** 1996 Apr;9(4):808–20 (107 ref.)

CYTOLOGY

Dendritic–cell regulation of lung immunity. Dupuis M, et al. **Am J Respir Cell Mol Biol** 1997 Sep;17(3):284–6 (13 ref.)

Stem cells in lung development, disease, and therapy. Mason RJ, et al. **Am J Respir Cell Mol Biol** 1997 Apr;16(4):355–63 (68 ref.)

Neuroepithelial bodies and solitary neuroendocrine cells in the lungs of amphibia. Goniakowska–Witalińska L. **Microsc Res Tech** 1997 Apr 1;37(1):13–30 (71 ref.)

Comparative histology of pulmonary neuroendocrine cell system in mammalian lungs. Scheuermann DW. **Microsc Res Tech** 1997 Apr 1;37(1):31–42 (150 ref.)

Ontogeny of neuroepithelial bodies: correlations with mitogenesis and innervation. Sorokin SP, et al. **Microsc Res Tech** 1997 Apr 1;37(1):43–61 (116 ref.)

Quantitative microscopical methods for the identification and localisation of nerves and neuroendocrine cell markers in mammalian lung. Springall DR, et al. **Microsc Res Tech** 1997 Apr 1;37(1):92–100 (40 ref.)

Paraneurons in the gills and airways of fishes. Zaccone G, et al. **Microsc Res Tech** 1997 Apr 1;37(1):4–12 (48 ref.)

Neutrophil emigration in the lungs. Doerschuk CM, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:141–5 (21 ref.)

Granulocyte–macrophage colony–stimulating factor overrides the immunosuppressive function of corticosteroids on rat pulmonary dendritic cells. Lim TK, et al. **Stem Cells** 1996 May;14(3):292–9 (62 ref.)

DRUG EFFECTS

Longitudinal studies of air pollution effects on lung function. Dockery DW, et al. **Am J Respir Crit Care Med** 1996 Dec; 154(6 Pt 2):S250–6 (50 ref.)

Mechanisms in the pathogenesis of amiodarone–induced pulmonary toxicity. Massey TE, et al. **Can J Physiol Pharmacol** 1995 Dec;73(12):1675–85 (142 ref.)

Interactions of glucocorticoids and beta 2–agonists. Adcock IM, et al. **Eur Respir J** 1996 Jan;9(1):160–8 (82 ref.)

Methotrexate update [editorial] Kremer JM. **Scand J Rheumatol** 1996;25(6):341–4 (31 ref.)

Biomonitoring of early effects on the kidney or the lung. Bernard A, et al. **Sci Total Environ** 1997 Jun 20; 199(1–2):205–11 (10 ref.)

Nitric oxide and lung surfactant. Hallman M, et al. **Semin Perinatol** 1996 Jun;20(3):173–85 (101 ref.)

Ascorbic acid. Protection of lung tissue against damage. Maritz GS. **Subcell Biochem** 1996;25:265–91 (125 ref.)

A review of the toxicology of air pollutants: toxicology of chemical mixtures. Oehme FW, et al. **Vet Hum Toxicol** 1996 Oct;38(5):371–7 (47 ref.)

[Prenatal corticotherapy and acceleration of fetal maturation. I. Experimental and pharmacological data] Lacaze–Masmonteil T. **Arch Pediatr** 1996 Nov;3(11):1111–7 (48 ref.) (Eng. Abstr.) **(Fre)**

[Prenatal corticotherapy and acceleration of fetal maturation. II. Results of clinical applications] Lacaze–Masmonteil T. **Arch Pediatr** 1996 Nov;3(11):1119–28 (75 ref.) (Eng. Abstr.) **(Fre)**

[Lipid emulsions and pulmonary function] Planas M, et al. **Nutr Hosp** 1996 May–Jun;11(3):155–9 (36 ref.) (Eng. Abstr.) **(Spa)**

EMBRYOLOGY

Possible mechanism for late gestational development of the antioxidant enzymes in the fetal rat lung. Frank L, et al. **Biol Neonate** 1996;70(2):116–27 (57 ref.)

Transcriptional control in the developing lung. The Parker B. Francis lectureship. Korfhagen TR, et al. **Chest** 1997 Jun;111(6 Suppl):83S–88S (25 ref.)

Transcriptional regulation of the surfactant protein–A gene in fetal lung. Mendelson CR, et al. **Chest** 1997 Jun;111(6 Suppl):96S–104S (32 ref.)

Coordination of genetic, epigenetic, and environmental factors in lung development, injury, and repair. Warburton D, et al. **Chest** 1997 Jun;111(6 Suppl):119S–122S (51 ref.)

Standards of laboratory practice: evaluation of fetal lung maturity. National Academy of Clinical Biochemistry. Ashwood ER. **Clin Chem** 1997 Jan;43(1):211–4 (21 ref.)

Current status of amniotic fluid tests of fetal maturity. Field NT, et al. **Clin Obstet Gynecol** 1997 Jun;40(2):366–86 (51 ref.)

The effects of mechanical forces on fetal lung growth. Kitterman JA. **Clin Perinatol** 1996 Dec;23(4):727–40 (79 ref.)

The effect of mechanical forces on in utero lung growth in congenital diaphragmatic hernia. Nobuhara KK, et al. **Clin Perinatol** 1996 Dec;23(4):741–52 (63 ref.)

Use of transgenic mice to study autocrine–paracrine signaling in lung morphogenesis and differentiation. Whitsett JA, et al. **Clin Perinatol** 1996 Dec;23(4):753–69 (54 ref.)

New insights into lung growth and development. Price WA, et al. **Curr Opin Pediatr** 1996 Jun;8(3):202–8 (35 ref.)

Dystroglycan and laminins: glycoconjugates involved in branching epithelial morphogenesis. Durbeej M, et al. **Exp Lung Res** 1997 Mar–Apr;23(2):109–18 (43 ref.)

Cell–matrix interactions in gland development in the lung. Infeld MD. **Exp Lung Res** 1997 Mar–Apr;23(2):161–9 (24 ref.)

Basement membranes and pulmonary development. Sannes PL, et al. **Exp Lung Res** 1997 Mar–Apr;23(2):101–8 (27 ref.)

Laminins in lung development. Schuger L. **Exp Lung Res** 1997 Mar–Apr;23(2):119–29 (57 ref.)

Regulation of lung expansion and lung growth before birth. Harding R, et al. **J Appl Physiol** 1996 Jul;81(1):209–24 (20 ref.)

Lung maturation. Hume R, et al. **Proc Nutr Soc** 1996 Mar;

55(1B):529–42 (70 ref.)
The evaluation of infection and pulmonary maturity in women with premature rupture of the membranes. Beazley D, et al. **Semin Perinatol** 1996 Oct;20(5):409–17 (83 ref.)
[Prenatal corticotherapy and acceleration of fetal maturation. II. Results of clinical applications] Lacaze-Masmonteil T. **Arch Pediatr** 1996 Nov;3(11):1119–28 (75 ref.) (Eng. Abstr.) **(Fre)**
[Prenatal corticotherapy and acceleration of fetal maturation. I. Experimental and pharmacological data] Lacaze-Masmonteil T. **Arch Pediatr** 1996 Nov;3(11):1111–7 (48 ref.) (Eng. Abstr.) **(Fre)**
[Prenatal lung maturation with corticosteroids--an overview] Hildebrand K, et al. **Z Geburtshilfe Neonatol** 1996 Nov-Dec;200(6):207–12 (54 ref.) (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

Of mites and men: trypsin-like proteases in the lungs. Caughey GH. **Am J Respir Cell Mol Biol** 1997 Jun; 16(6):621–8 (69 ref.)
Possible mechanism for late gestational development of the antioxidant enzymes in the fetal rat lung. Frank L, et al. **Biol Neonate** 1996;70(2):116–27 (57 ref.)
Superoxide dismutase and pulmonary oxygen toxicity. Tsan MF. **Proc Soc Exp Biol Med** 1997 Feb;214(2):107–13 (82 ref.)
[Pulmonary nitric oxide synthase isoform expression and their functional significance] Munakata M. **Nippon Rinsho** 1996 Feb;54(2):358–63 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Increased production of nitric oxide in the immediate and late asthmatic responses in guinea pigs] Uchida Y, et al. **Nippon Rinsho** 1996 Feb;54(2):364–8 (15 ref.) (Eng. Abstr.) **(Jpn)**

GROWTH & DEVELOPMENT

Bombesin-like peptides and airway repair: a recapitulation of lung development? Spurzem JR, et al. **Am J Respir Cell Mol Biol** 1997 Mar;16(3):209–11 (44 ref.)
The relationship of childhood respiratory infection to growth and decline in lung function. Britton J, et al. **Am J Respir Crit Care Med** 1996 Dec;154(6 Pt 2):S240–5 (57 ref.)
Advances in the management of respiratory failure. Accelerating lung growth. Wilson JM. **ASAIO J** 1996 May-Jun;42(3):201–3 (12 ref.)
Lung development and early origins of childhood respiratory illness. Dezateux C, et al. **Br Med Bull** 1997 Jan;53(1):40–57 (74 ref.)
Maturation of the cardiopulmonary system. Cottrill CM. **Equine Vet J Suppl** 1993 Apr;(14):26–30 (74 ref.)
Basement membranes and pulmonary development. Sannes PL, et al. **Exp Lung Res** 1997 Mar-Apr;23(2):101–8 (27 ref.)
Human lung growth: a review. Merkus PJ, et al. **Pediatr Pulmonol** 1996 Jun;21(6):383–97 (213 ref.)
Lung maturation. Hume R, et al. **Proc Nutr Soc** 1996 Mar; 55(1B):529–42 (70 ref.)
Influence of thyroid hormones and temperature on adipose tissue development and lung maturation. Symonds ME, et al. **Proc Nutr Soc** 1996 Mar;55(1B):561–9 (58 ref.)
Strategic utilization of fetal lung maturity tests. Wong SS, et al. **Scand J Clin Lab Invest** 1996 Oct;56(6):525–32 (33 ref.)

IMMUNOLOGY

The link between the nose and lung, perennial rhinitis and asthma--is it the same disease? Rowe-Jones JM. **Allergy** 1997;52(36 Suppl):20–8 (124 ref.)
Dendritic-cell regulation of lung immunity. Dupuis M, et al. **Am J Respir Cell Mol Biol** 1997 Sep;17(3):284–6 (13 ref.)
Immunologic effects of HIV in the lung. Agostini C, et al. **Clin Chest Med** 1996 Dec;17(4):633–45 (106 ref.)
Cytokines and pulmonary host defenses. Standiford TJ. **Curr Opin Pulm Med** 1997 Mar;3(2):81–8 (56 ref.)
Leukocyte migration and activation in the lungs [editorial; comment] Martin TR. **Eur Respir J** 1997 Apr;10(4):770–1 (15 ref.) Comment on: Eur Respir J 1997 Apr;10(4):795–803.
HIV and pulmonary immune responses. Agostini C, et al. **Immunol Today** 1996 Aug;17(8):359–64 (43 ref.)
Basic concepts in lung immunology. Poulter LW. **Res Immunol** 1997 Jan;148(1):8–13 (10 ref.)
Inflammatory changes in proximal and peripheral airways of asthmatic patients. Oddera S, et al. **Respir Med** 1997 Jul;91(6):323–6 (29 ref.)
"Ultimate activation" of eosinophils in vivo: lysis and release of clusters of free eosinophil granules (Cfegs). Persson CG, et al. **Thorax** 1997 Jun;52(6):569–74 (58 ref.)

INJURIES

Inflammatory mediators, cytokines, and adhesion molecules in pulmonary inflammation and injury. Lukacs NW, et al. **Adv Immunol** 1996;62:257–304 (227 ref.)
Pulmonary contusion: a collective review. Allen GS, et al. **Am Surg** 1996 Nov;62(11):895–900 (72 ref.)
Traumatic adult respiratory distress syndrome. Bass TL, et al. **Chest Surg Clin N Am** 1997 May;7(2):429–42 (71 ref.)
Trauma to the lung. Boyd AD, et al. **Chest Surg Clin N Am** 1997 May;7(2):263–84 (70 ref.)
High-inflation pressure and positive end-expiratory pressure. Injurious to the lung? No. Nelson LD. **Crit Care Clin** 1996 Jul;12(3):603–25 (110 ref.)
High-inflation pressure and positive end-expiratory pressure. Injurious to the lung? Yes. Papadakos PJ, et al. **Crit Care Clin** 1996 Jul;12(3):627–34 (29 ref.)
Pulmonary contusion: review of the clinical entity. Cohn SM. **J Trauma** 1997 May;42(5):973–9 (76 ref.)
Acute lung injury: clinical concept and experimental approaches to pathogenesis. Kanazawa M. **Keio J Med** 1996 Sep;45(3):131–9 (61 ref.)
Role of oxidant stress in the adult respiratory distress syndrome: evaluation of a novel antioxidant strategy in a porcine model of endotoxin-induced acute lung injury. Gonzalez PK, et al. **Shock** 1996;6 Suppl 1:S23–6 (54 ref.)
Ascorbic acid. Protection of lung tissue against damage. Maritz GS. **Subcell Biochem** 1996;25:265–91 (125 ref.)
Toxicology of blast overpressure. Elsayed NM. **Toxicology** 1997 Jul 25;121(1):1–15 (76 ref.)

INNERVATION

[Pulmonary vagal afferents in man] Paleček F. **Cesk Fysiol** 1997 Jun;46(2):57–63 (90 ref.) (Eng. Abstr.) **(Cze)**

METABOLISM

Salt and water transport across alveolar and distal airway epithelia in the adult lung. Matthay MA, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):L487–503 (145 ref.)
The stress response and the lung. Wong HR, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):L1–9 (94 ref.)
Posttranscriptional regulation of lung elastin production [comment] Parks WC. **Am J Respir Cell Mol Biol** 1997 Jul;17(1):1–2 (13 ref.) Comment on: Am J Respir Cell Mol Biol 1997 Jul;17(1):10–6.
Adenovirus-vector-mediated cytokine gene transfer to lung tissue. Gauldie J, et al. **Ann N Y Acad Sci** 1996 Oct 31; 796:235–44 (26 ref.)
Nitric oxide and the lung: an overview. Head CA. **Artif Organs** 1997 Jan;21(1):5–9 (26 ref.)
Concentration and second gas effects: can the accepted explanation be improved? Korman B, et al. **Br J Anaesth** 1997 May;78(5):618–25 (37 ref.)
Pharmacokinetics of inhaled drugs. Lipworth BJ. **Br J Clin Pharmacol** 1996 Dec;42(6):697–705 (55 ref.)
Genes that control lung liquid. Giles F. Filley Lecture. Barker PM. **Chest** 1997 Jun;111(6 Suppl):105S–110S (38 ref.)
The interdependence of lung antioxidants and antiprotease defense in ARDS. Gadek JE, et al. **Chest** 1996 Dec;110(6 Suppl):273S–277S (13 ref.)
The structure and function of surfactant protein-A. McCormack F. **Chest** 1997 Jun;111(6 Suppl):114S–119S (57 ref.)
Pulmonary metabolism of biogenic amines. Akber SF. **Compr Ther** 1997 Apr;23(4):254–8 (32 ref.)
Antibiotic penetration in the respiratory tract and implications for the selection of antimicrobial therapy. Honeybourne D. **Curr Opin Pulm Med** 1997 Mar;3(2):170–4 (35 ref.)
Interactions of glucocorticoids and beta 2-agonists. Adcock IM, et al. **Eur Respir J** 1996 Jan;9(1):160–8 (82 ref.)
Cellular glutathione turnover in vitro, with emphasis on type II pneumocytes. van Klaveren RJ, et al. **Eur Respir J** 1997 Jun;10(6):1392–400 (75 ref.)
Elastin in lung development. Mariani TJ, et al. **Exp Lung Res** 1997 Mar-Apr;23(2):131–45 (56 ref.)
Fibronectin and fibronectin receptors in lung development. Roman J. **Exp Lung Res** 1997 Mar-Apr;23(2):147–59 (50 ref.)
Alveolar epithelial clearance of protein. Folkesson HG, et al. **J Appl Physiol** 1996 May;80(5):1431–45 (166 ref.)
Conjugation of glutathione with the reactive metabolites of 1, 1-dichloroethylene in murine lung and liver. Forkert PG. **Microsc Res Tech** 1997 Feb 15;36(4):234–42 (45 ref.)
In situ and in vivo methods for pulmonary delivery. Eljamal M, et al. **Pharm Biotechnol** 1996;8:361–74 (30 ref.)
New concepts in the pulmonary disposition of antibiotics [see comments] Bergogne-Berezin E. **Pulm Pharmacol** 1995 Apr-Jun;8(2-3):65–81 (92 ref.) Comment in: Pulm Pharmacol 1996 Feb;9(1):63, 65.
The composition and function of reptilian pulmonary surfactant. Daniels CB, et al. **Respir Physiol** 1995 Dec; 102(2-3):121–35 (50 ref.)
Cysteinyl leukotriene receptors in the human lung: what's new? [see comments] Gorenne I, et al. **Trends Pharmacol Sci** 1996 Oct;17(10):342–5 (27 ref.) Comment in: Trends Pharmacol Sci 1997 May;18(5):148–9.

MICROBIOLOGY

Hypertrophic osteoarthropathy associated with Pneumocystis carinii pneumonia and human immunodeficiency virus infection. Gunnarsson G, et al. **Clin Infect Dis** 1996 Mar;22(3):590–1 (9 ref.)
The viability of Mycobacterium tuberculosis in formalin-fixed pulmonary autopsy tissue: review of the literature and brief report. Kappel TJ, et al. **Hum Pathol** 1996 Dec;27(12):1361–4 (34 ref.)

PARASITOLOGY

Pulmonary dirofilariasis in man: a new Italian case. Review of the European literature. Pampiglione S, et al. **Parasite** 1994 Dec;1(4):379–85 (27 ref.)

PATHOLOGY

The role of alveolar macrophages and dendritic cells in allergic airway sensitization. Jansen HM. **Allergy** 1996 May; 51(5):279–92 (138 ref.)
PCR diagnosis of viral pneumonitis from fixed-lung tissue in children. Akhtar N, et al. **Biochem Mol Med** 1996 Jun; 58(1):66–76 (35 ref.)
Endothelial damage caused by ischemia and reperfusion and different ventilatory strategies in the lung. Moore TM, et al. **Chin J Physiol** 1996;39(2):65–81 (132 ref.)
Lung lymphocytes: origin, biological functions, and laboratory techniques for their study in immune-mediated pulmonary disorders. Semenzato G, et al. **Crit Rev Clin Lab Sci** 1996 Oct;33(5):423–55 (93 ref.)
Pathology of lung cancer. Leslie KO, et al. **Curr Opin Pulm Med** 1997 Jul;3(4):252–6 (32 ref.)
Inflammatory and neoplastic processes of the lung: differential diagnosis and pitfalls in FNA biopsies. Silverman JF. **Diagn Cytopathol** 1995 Dec;13(5):448–62 (93 ref.)
Airway smooth muscle cell culture: application to studies of airway wall remodelling and phenotype plasticity in asthma. Hirst SJ. **Eur Respir J** 1996 Apr;9(4):808–20 (107 ref.)
Intravascular lymphomatosis diagnosed by transbronchial lung biopsy. Takamura K, et al. **Eur Respir J** 1997 Apr; 10(4):955–7 (13 ref.)
Mediastinoscopy, thoracoscopy, and video-assisted thoracic surgery in the diagnosis and staging of lung cancer. Mentzer SJ. **Hematol Oncol Clin North Am** 1997 Jun; 11(3):435–47 (21 ref.)
Extracellular matrix and lung inflammation. Roman J. **Immunol Res** 1996;15(2):163–78 (94 ref.)
Pulmonary neuroendocrine cell system in pediatric and adult lung disease. Gosney JR. **Microsc Res Tech** 1997 Apr 1; 37(1):107–13 (76 ref.)
The spectrum of pulmonary vasculitis. DeRemee RA. **Monaldi Arch Chest Dis** 1996 Feb;51(1):35–8 (21 ref.)
Diagnostic strategies of lung biopsy. Keller R. **Monaldi Arch Chest Dis** 1995 Dec;50(6):464–8 (37 ref.)
Errors and pitfalls in lung and pleural cytology. Linder J. **Monogr Pathol** 1997;(39):40–59 (78 ref.)
Fine-needle aspiration of the lung. Jeffrey PB. **Pathology (Phila)** 1996;4(2):439–61 (42 ref.)
Recent advances in the pulmonary pathology of human immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome (AIDS). Klassen MK, et al. **Pathology (Phila)** 1996;4(1):43–71 (149 ref.)
Low-grade B-cell lymphomas of lung and lymphomatoid granulomatosis. Koss M, et al. **Pathology (Phila)** 1996; 4(1):125–39 (48 ref.)
Lung. Lombard CM. **Pathology (Phila)** 1996;3(2):321–38 (16 ref.)
Neuroendocrine tumors of the lung. Marchevsky AM. **Pathology (Phila)** 1996;4(1):103–23 (59 ref.)
Vasculitis of the lung. Travis WD, et al. **Pathology (Phila)** 1996;4(1):23–41 (98 ref.)
Markers and mediators of inflammation in neonatal lung disease. Ozdemir A, et al. **Pediatr Pulmonol** 1997 Apr; 23(4):292–306 (153 ref.)
Osteogenesis imperfecta Type IIA and pulmonary hypoplasia with normal alveolar development. Thibeault DW, et al. **Pediatr Pulmonol** 1995 Nov;20(5):301–6 (23 ref.)
The alphabet soup revisited: the chronic interstitial pneumonias in the 1990s. McAdams HP, et al. **Radiographics** 1996 Sep;16(5):1009–33; discussion 1033–4 (78 ref.)
A lung biopsy is unnecessary in the management of ANCA-positive patients with chest-roentgenographic abnormalities. Cordier JF. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct;13(3):235–7 (17 ref.)
A lung biopsy is necessary in the management of ANCA-positive patients with chest roentgenographic abnormalities. King TE Jr. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct;13(3):238–40 (10 ref.)
Function at the junction: dynamic interactions between lung cells and extracellular matrix. Spurzem JR. **Thorax** 1996 Sep;51(9):956–8 (12 ref.)
Reactions to particles in smoke. Hill IR. **Toxicology** 1996 Dec 31;115(1-3):119–22 (17 ref.)
[MRI of the pulmonary parenchyma. Clinical value and research prospects] Berthezène Y, et al. **J Radiol** 1997 May; 78(5):347–51 (25 ref.) (Eng. Abstr.) **(Fre)**
[Invasive pneumonia diagnosis in community-acquired pneumonia (see comments)] Dalhoff K, et al. **Pneumologie** 1996 Oct;50(10):687–92 (46 ref.) Comment in: Pneumologie 1997 Feb;51(2):90–2. **(Ger)**
[The role of cytokines in pulmonary fibrosis] Ogushi F. **Nippon Ika Daigaku Zasshi** 1996 Oct;63(5):391–4 (7 ref.) **(Jpn)**

PHYSIOLOGY

The microphysiology of lung liquid clearance. Bhattacharya J. **Adv Exp Med Biol** 1995;381:95–108 (32 ref.)

Some recent advances in studies on J receptors. Paintal AS. **Adv Exp Med Biol** 1995;381:15–25 (40 ref.)
Extracellular matrix biology in the lung. Dunsmore SE, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):L3–27 (493 ref.)
Expanding the frontiers of lung biology through the creative use of alveolar epithelial cells in culture [see comments] Paine R 3rd, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):L484–6 (32 ref.) Comment in: Am J Physiol 1996 Apr;270(4 Pt 1):L483.
Ontogeny of the arterial and cardiopulmonary baroreflex during fetal and postnatal life. Segar JL. **Am J Physiol** 1997 Aug;273(2 Pt 2):R457–71 (148 ref.)
Bombesin-like peptides and airway repair: a recapitulation of lung development? Spurzem JR, et al. **Am J Respir Cell Mol Biol** 1997 Mar;16(3):209–11 (44 ref.)
The uptake of mineral particles by pulmonary epithelial cells. Churg A. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 1):1124–40 (185 ref.)
Coordination of genetic, epigenetic, and environmental factors in lung development, injury, and repair. Warburton D, et al. **Chest** 1997 Jun;111(6 Suppl):119S–122S (51 ref.)
Bioelectrical impedance techniques in medicine. Part III: Impedance imaging. Third section: medical applications. Morucci JP, et al. **Crit Rev Biomed Eng** 1996; 24(4–6):655–77 (108 ref.)
G protein regulation of alveolar ion channels: implications for lung fluid transport. Kemp PJ, et al. **Exp Physiol** 1996 May;81(3):493–504 (35 ref.)
The hemodynamic consequences of mechanical ventilation: an evolving story. Pinsky MR. **Intensive Care Med** 1997 May;23(5):493–503 (93 ref.)
Regulation of lung expansion and lung growth before birth. Harding R, et al. **J Appl Physiol** 1996 Jul;81(1):209–24 (20 ref.)
The lung and the world about it. The Tudor Edwards Lecture 1996. Seaton A. **J R Coll Physicians Lond** 1996 May–Jun;30(3):232–7 (33 ref.)
Figuring out why we breathe. Farnsworth WE. **Med Hypotheses** 1997 Mar;48(3):229–36 (54 ref.)
Pulmonary function and cardiopulmonary interactions at microgravity. Linnarsson D. **Med Sci Sports Exerc** 1996 Oct;28(10 Suppl):S14–7 (21 ref.)
Lung function and airway responsiveness in infancy. Landau LI. **Monaldi Arch Chest Dis** 1996 Aug;51(4):303–5 (23 ref.)
J'accuse!–M. LeComte de LaPlace a Prohibé le Recrutement des Alvéoles du Poumon [Can high-frequency ventilation conscript alveolar recruits and encourage re-enlistment?] [comment] Nelson NM. **Pediatrics** 1996 Dec;98(6 Pt 1):1196–7 (15 ref.) Comment on: Pediatrics 1996 Dec;98(6 Pt 1):1044–57.
The surfactant system of the lung modulates pathological processes. von Wichert P. **Pol Arch Med Wewn** 1997;97 Spec No:69–71 (24 ref.)
High resolution computed tomography (HRCT) and new perspectives in functional radiology of the lung. Sallustio G, et al. **Rays** 1997 Jan–Mar;22(1):157–82 (41 ref.) **(Eng, Ita)**
The gastrointestinal tract and the lungs. Similarities with particular emphasis on the neuroendocrine cells. Waldum HL, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Mar; 13(1):63–5 (41 ref.)
Strategic utilization of fetal lung maturity tests. Wong SS, et al. **Scand J Clin Lab Invest** 1996 Oct;56(6):525–32 (33 ref.)
[The pulmonary interstitium in the transition from a physiological state to the development of edema] Miserocchi G. **Cardiologia** 1997 Feb;42(2):163–9 (25 ref.) **(Ita)**
[Evaluation of pulmonary function by expiratory CT using helical CT] Eda S, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:45–7 (6 ref.) **(Jpn)**
[Analytical method of lung sounds] Murata A, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:80–3 (6 ref.) **(Jpn)**
[Circadian variation of lung function in health persons] Franczuk M, et al. **Pneumonol Alergol Pol** 1997; 65(1–2):96–103 (26 ref.) **(Pol)**
[The role of nitric oxide in regulating pulmonary functions] Nevzorova VA, et al. **Ter Arkh** 1997;69(3):68–73 (104 ref.) **(Rus)**

PHYSIOPATHOLOGY

The stress response and the lung. Wong HR, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):L1–9 (94 ref.)
Risk factors for accelerated decline among patients with chronic obstructive pulmonary disease. Kerstjens HA, et al. **Am J Respir Crit Care Med** 1996 Dec;154(6 Pt 2):S266–72 (34 ref.)
Longitudinal analyses of airway responsiveness and pulmonary function decline. Rijcken B, et al. **Am J Respir Crit Care Med** 1996 Dec;154(6 Pt 2):S246–9 (33 ref.)
Pathophysiologic role of alpha 4 integrins in the lung. Lobb RR, et al. **Ann N Y Acad Sci** 1996 Oct 31;796:113–23 (47 ref.)
Vasoactive intestinal peptide and nitric oxide: divergent roles in relation to tissue injury. Said SI. **Ann N Y Acad Sci** 1996 Dec 26;805:379–87; discussion 387–8 (60 ref.)
Oxidant-protease interaction in the lung. Prospects for antioxidant therapy. Buhl R, et al. **Chest** 1996 Dec;110(6 Suppl):267S–272S (57 ref.)
Endothelial damage caused by ischemia and reperfusion and different ventilatory strategies in the lung. Moore TM, et al. **Chin J Physiol** 1996;39(2):65–81 (132 ref.)
Ozone, airways and allergic airways disease. Krishna MT, et al. **Clin Exp Allergy** 1995 Dec;25(12):1150–8 (82 ref.)
Hyperinflation and respiratory muscle interaction. Decramer M. **Eur Respir J** 1997 Apr;10(4):934–41 (53 ref.)
Effect of hyperinflation on the diaphragm. De Troyer A. **Eur Respir J** 1997 Mar;10(3):708–13 (56 ref.)
Heart–lung interactions: applications in the critically ill. Fessler HE. **Eur Respir J** 1997 Jan;10(1):226–37 (105 ref.)
On the causes of lung hyperinflation during bronchoconstriction. Pellegrino R, et al. **Eur Respir J** 1997 Feb;10(2):468–75 (58 ref.)
Pulmonary hyperinflation and ventilator-dependent patients. Rossi A, et al. **Eur Respir J** 1997 Jul;10(7):1663–74 (90 ref.)
The role of alpha 4 integrins in lung pathophysiology. Lobb RR, et al. **Eur Respir J Suppl** 1996 Aug;22:104s–108s (34 ref.)
Growth factors in asthma. Vignola AM, et al. **Monaldi Arch Chest Dis** 1997 Apr;52(2):159–69 (151 ref.)
Histogenesis of the pulmonary lesions in the course of visna maedi virus-induced pneumonia. Cadoré JL, et al. **Vet Res** 1996;27(4–5):419–26 (46 ref.)
[Pathophysiology of acute lung injury] Kitamura S. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:1–7 (5 ref.) (Eng. Abstr.) **(Jpn)**
[The non-gas-exchange functions of the lungs and the role of their disorders in the development of bronchopulmonary complications] Skobel'skiĭ VB. **Anesteziol Reanimatol** 1996 May–Jun;(3):63–8 (126 ref.) **(Rus)**
[Lipid emulsions and pulmonary function] Planas M, et al. **Nutr Hosp** 1996 May–Jun;11(3):155–9 (36 ref.) (Eng. Abstr.) **(Spa)**

RADIATION EFFECTS

Radiation change in normal organs: an overview of body imaging. Libshitz HI, et al. **Eur Radiol** 1996;6(6):786–95 (82 ref.)

RADIOGRAPHY

Ground-glass opacity at CT: the ABCs. Collins J, et al. **AJR Am J Roentgenol** 1997 Aug;169(2):355–67 (85 ref.)
Sand aspiration with near-drowning. Radiographic and bronchoscopic findings [see comments] Dunagan DP, et al. **Am J Respir Crit Care Med** 1997 Jul;156(1):292–5 (15 ref.) Comment in: N Engl J Med 1997 Oct 16;337(16):1175.
Subjective pitfalls in HRCT interpretation. Gruden JF, et al. **Crit Rev Diagn Imaging** 1996 Oct;37(5):349–434 (32 ref.)
Lobar collapse: basic concepts. Proto AV. **Eur J Radiol** 1996 Aug;23(1):9–22 (28 ref.)
Lung imaging in the adult respiratory distress syndrome: current practice and new insights. Desai SR, et al. **Intensive Care Med** 1997 Jan;23(1):7–15 (101 ref.)
High resolution computed tomography of the lungs. Shetty PG, et al. **J Assoc Physicians India** 1996 Sep;44(9):621–6, 631–6 (35 ref.)
Swyer-James syndrome documented by spiral CT angiography and high resolution inspiratory and expiratory CT: an accurate single modality exploration. Ghossain MA, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):616–8 (9 ref.)
Radiographic manifestations of lobar atelectasis. Woodring JH, et al. **J Thorac Imaging** 1996 Spring;11(2):109–44 (38 ref.)
Radiographic appearance of interstitial lung disease. Glazer C. **Radiol Technol** 1997 Jul–Aug;68(6):475–80 (13 ref.)
Technical trends in functional radiology of the lung. Meduri A, et al. **Rays** 1997 Jan–Mar;22(1):14–37 (8 ref.) **(Eng, Ita)**
High resolution computed tomography (HRCT) and new perspectives in functional radiology of the lung. Sallustio G, et al. **Rays** 1997 Jan–Mar;22(1):157–82 (41 ref.) **(Eng, Ita)**
Chest radiograph and functional radiology. Sallustio G, et al. **Rays** 1997 Jan–Mar;22(1):38–50 (11 ref.) **(Eng, Ita)**
[The Swyer-James syndrome: its imaging with high-resolution computed tomography] Hansen M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Nov;165(5):499–501 (12 ref.) **(Ger)**
[What is it called? A formulation and glossary for the finding and understanding of results in HRCT of the lung] Kauczor HU, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Nov;165(5):428–37 (88 ref.) (Eng. Abstr.) **(Ger)**
[Evaluation of pulmonary function by expiratory CT using helical CT] Eda S, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:45–7 (6 ref.) **(Jpn)**

RADIONUCLIDE IMAGING

Topics in pulmonary nuclear medicine. Kawakami K. **Ann Nucl Med** 1997 May;11(2):67–73 (12 ref.)
Radionuclide assessment of pulmonary microvascular permeability. Groeneveld AB. **Eur J Nucl Med** 1997 Apr; 24(4):449–61 (103 ref.)
Pulmonary technetium-99m diethylene triamine penta-acetic acid aerosol clearance as an index of lung injury. O'Doherty MJ, et al. **Eur J Nucl Med** 1997 Jan;24(1):81–7 (48 ref.)
Ventilation-perfusion lung scanning and spiral computed tomography of the lungs: competing or complementary modalities? Robinson PJ. **Eur J Nucl Med** 1996 Nov; 23(11):1547–53 (55 ref.)
[Regional evaluation of ventilation by RI] Kawakami K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:42–4 (3 ref.) **(Jpn)**
[Pulmonary perfusion scintigraphy and ventilation perfusion scintigraphy] Kawakami K, et al. **Nippon Rinsho** 1997 Apr; 55 Suppl 2:39–41 (3 ref.) **(Jpn)**

SECRETION

Lung mucus: a clinician's view. Kim WD. **Eur Respir J** 1997 Aug;10(8):1914–7 (25 ref.)
Surfactant protein A and lamellar bodies: a homologous secretory function of peritoneum, synovium, and lung. Dobbie JW. **Perit Dial Int** 1996 Nov–Dec;16(6):574–81 (43 ref.)

SURGERY

Lung. Lombard CM. **Pathology (Phila)** 1996;3(2):321–38 (16 ref.)
[Lung volume reduction for treatment of pulmonary emphysema] Azuri Y, et al. **Harefuah** 1997 Jan 15; 132(2):104–6 (39 ref.) **(Heb)**

ULTRASONOGRAPHY

Asynchronous pulmonary hyperplasia associated with tracheal atresia: pathologic and prenatal sonographic findings. Wright JR Jr, et al. **Pediatr Pathol Lab Med** 1995 Jan–Feb;15(1):81–97 (21 ref.)
[Pulmonary echography: a method of the future in emergency medicine and resuscitation (editorial)] Lichtenstein D. **Rev Pneumol Clin** 1997;53(2):63–8 (28 ref.) **(Fre)**

VIROLOGY

HIV and pulmonary immune responses. Agostini C, et al. **Immunol Today** 1996 Aug;17(8):359–64 (43 ref.)

LUNG CAPACITIES see **LUNG VOLUME MEASUREMENTS**

LUNG CAPACITY, TOTAL see **TOTAL LUNG CAPACITY**

LUNG COMPLIANCE

[Lung compliance] Shinano H, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:70–3 (4 ref.) **(Jpn)**

LUNG DISEASES

see related
PULMONARY HEART DISEASE

Occupational lung disease. Schwartz DA, et al. **Adv Intern Med** 1997;42:269–312 (161 ref.)
HIV in children. Bye MR. **Clin Chest Med** 1996 Dec; 17(4):787–96 (132 ref.)
HIV in illicit drug users. O'Donnell AE. **Clin Chest Med** 1996 Dec;17(4):797–807 (90 ref.)
Overview of pulmonary complications. Rosen MJ. **Clin Chest Med** 1996 Dec;17(4):621–31 (79 ref.)
Approach to the patient with pulmonary disease. Vander Els NJ, et al. **Clin Chest Med** 1996 Dec;17(4):767–85 (119 ref.)
Actinomycosis and plasma cell granuloma, coincidence or coexistence: patient report and review of the literature. Dweik RA, et al. **Clin Pediatr (Phila)** 1997 Apr; 36(4):229–33 (44 ref.)
Pulmonary hemorrhage in infants and children. Dearborn DG. **Curr Opin Pediatr** 1997 Jun;9(3):219–24 (50 ref.)
Experimental research into the pathogenesis of cobalt/hard metal lung disease. Lison D, et al. **Eur Respir J** 1996 May; 9(5):1024–8 (21 ref.)
Recruitment of inflammatory cells into lung: roles of cytokines, adhesion molecules, and complement. Ward PA. **J Lab Clin Med** 1997 Apr;129(4):400–4 (24 ref.)
[Current aspects of pulmonary nocardiosis] Desfemmes-Baleyte T, et al. **Rev Mal Respir** 1996; 13(4):321–5 (25 ref.) (Eng. Abstr.) **(Fre)**

CHEMICALLY INDUCED

Mechanisms in the pathogenesis of amiodarone-induced pulmonary toxicity. Massey TE, et al. **Can J Physiol Pharmacol** 1995 Dec;73(12):1675–85 (142 ref.)
Pleuropulmonary changes induced by ergoline drugs. Pfitzenmeyer P, et al. **Eur Respir J** 1996 May;9(5):1013–9 (46 ref.)
Nitrofurantoin-induced pulmonary toxicity during pregnancy: a report of a case and review of the literature. Boggess KA, et al. **Obstet Gynecol Surv** 1996 Jun; 51(6):367–70 (19 ref.)
How energy policies affect public health. Romm JJ, et al. **Public Health Rep** 1996 Sep–Oct;111(5):390–9 (44 ref.)
A review of the toxicology of air pollutants: toxicology of chemical mixtures. Oehme FW, et al. **Vet Hum Toxicol** 1996 Oct;38(5):371–7 (47 ref.)
[Drug-induced pneumopathies accompanied by acute respiratory insufficiency] Mayaud C, et al. **Rev Mal Respir** 1996 Dec;13(6):559–74 (188 ref.) (Eng. Abstr.) **(Fre)**
[Amiodarone and the lung] Mendonça C, et al. **Rev Port Cardiol** 1996 Oct;15(10):745–51 (48 ref.) (Eng.

Abstr.) **(Por)**

[Pulmonary hemorrhage after thrombolysis in acute myocardial infarct (letter) (corrected and republished letter originally printed in An Med Interna 1996 Oct;13(10):514–5)] Rodríguez Blanco VM, et al. **An Med Interna** 1997 Apr;14(4):209 (7 ref.) **(Spa)**

CLASSIFICATION

Pulmonary vasculitis: classification, clinical features, and management. Ciaccia A, et al. **Clin Rev Allergy Immunol** 1997 Spring;15(1):73–95 (249 ref.)

COMPLICATIONS

AIDS–related airway disease. McGuinness G, et al. **AJR Am J Roentgenol** 1997 Jan;168(1):67–77 (61 ref.)

Pulmonary infiltrates in the cancer patient. New approaches to an old problem. Bergen GA, et al. **Infect Dis Clin North Am** 1996 Jun;10(2):297–325 (140 ref.)

Hepatopulmonary syndrome with progressive hypoxemia as an indication for liver transplantation: case reports and literature review. Krowka MJ, et al. **Mayo Clin Proc** 1997 Jan;72(1):44–53 (41 ref.)

Nutritional support in advanced pulmonary disease. Thomsen C. **Respir Med** 1997 May;91(5):249–54 (46 ref.)

Human immunodeficiency virus (HIV)–related pulmonary complications in pregnancy. Saade GR. **Semin Perinatol** 1997 Aug;21(4):336–50 (126 ref.)

Chest infections and syndromes in sickle cell disease of childhood. Dreyer ZE. **Semin Respir Infect** 1996 Sep; 11(3):163–72 (67 ref.)

[A case report on graft replacement of ruptured aneurysm of the arch and the descending thoracic aorta associated with dense pulmonary adhesion] Hirai M, et al. **Kyobu Geka** 1996 May;49(5):367–71 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Preoperative management–cardiac, pulmonary, and renal dysfunction] Murata A, et al. **Nippon Geka Gakkai Zasshi** 1996 Jun;97(6):398–403 (4 ref.) (Eng. Abstr.) **(Jpn)**

[Surgical risk factors: lung diseases] Kuznetsov NA. **Khirurgiia (Mosk)** 1997;(5):72–8 (64 ref.) **(Rus)**

CONGENITAL

[Progress in the surgical treatment of congenital and acquired broncho–pulmonary pathology] Pesce C, et al. **Pediatr Med Chir** 1996 Sep–Oct;18(5):451–61 (34 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

What can we learn from exercise testing beyond the detection of myocardial ischemia? Weber KT. **Clin Cardiol** 1997 Aug; 20(8):684–96 (37 ref.)

Pulmonary vasculitis: classification, clinical features, and management. Ciaccia A, et al. **Clin Rev Allergy Immunol** 1997 Spring;15(1):73–95 (249 ref.)

Hernia of the lung: a case report and review of literature. Minai OA, et al. **Conn Med** 1997 Feb;61(2):77–81 (22 ref.)

ACOG technical bulletin. Pulmonary disease in pregnancy. Number 224––June 1996. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1996 Aug;54(2):187–96 (19 ref.)

Necrosing livedo reticularis in a patient with recurrent pulmonary hemorrhage. Aronoff DM, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):300–2 (15 ref.)

Pulmonary disease. Walker PA, et al. **Med Clin North Am** 1996 Nov;80(6):1337–62 (156 ref.)

Errors and pitfalls in lung and pleural cytology. Linder J. **Monogr Pathol** 1997;(39):40–59 (78 ref.)

Fine–needle aspiration of the lung. Jeffrey PB. **Pathology (Phila)** 1996;4(2):439–61 (42 ref.)

Bone marrow transplantation in children. Imaging assessment of complications. Benya EC, et al. **Pediatr Clin North Am** 1997 Jun;44(3):741–61 (30 ref.)

Diagnostic imaging in pediatric AIDS. Haller JO, et al. **Pediatr Clin North Am** 1997 Jun;44(3):721–40 (64 ref.)

Changing trends in the pulmonary manifestations of AIDS. McGuinness G. **Radiol Clin North Am** 1997 Sep; 35(5):1029–82 (153 ref.)

Foolers: things that look like pneumonia in children. Oermann CM, et al. **Semin Respir Infect** 1996 Sep; 11(3):204–13 (31 ref.)

[MRI of the pulmonary parenchyma. Clinical value and research prospects] Berthezène Y, et al. **J Radiol** 1997 May; 78(5):347–51 (25 ref.) (Eng. Abstr.) **(Fre)**

[Magnetic resonance imaging of the thorax] Berthezène Y, et al. **Rev Mal Respir** 1997 Jan;14(1):64–6 (14 ref.) **(Fre)**

[Thoracoscopy: current diagnostic and therapeutic indications] Loddenkemper R, et al. **Pneumologie** 1996 Feb; 50(2):189–201 (130 ref.) **(Ger)**

[AIDS in children: diagnostic imaging of pulmonary and abdominal lesions. Review of the literature and personal experience] Cecconi L, et al. **Radiol Med (Torino)** 1997 May;93(5):497–503 (16 ref.) **(Ita)**

[Pulmonary actinomycosis––diagnosis and therapy based on past reports of actinomycosis] Tanaka S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec; 34(12):1380–4 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Pulmonary alveolar microlithiasis] Konovalov EP, et al. **Klin Khir** 1994;(12):31–3 (5 ref.) (Eng. Abstr.) **(Rus)**

[Anticentromere antibodies and lung disease without skin involvement] Fernández–Fernández FJ, et al. **An Med Interna** 1997 Apr;14(4):196–8 (15 ref.) (Eng. Abstr.) **(Spa)**

[Primary pulmonary nodular amyloidosis] Antolín García MT, et al. **Arch Bronconeumol** 1997 May;33(5):251–3 (24 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Lynch JP 3rd, et al. **Am J Respir Crit Care Med** 1997 Feb;155(2):395–420 (353 ref.)

Nitric oxide and the lung: an overview. Head CA. **Artif Organs** 1997 Jan;21(1):5–9 (26 ref.)

Oxidant–protease interaction in the lung. Prospects for antioxidant therapy. Buhl R, et al. **Chest** 1996 Dec;110(6 Suppl):267S–272S (57 ref.)

Pharmacology of the pulmonary diseases. Hatch CL, et al. **Dent Clin North Am** 1996 Jul;40(3):521–41 (41 ref.)

Therapeutic potential of neutrophil–elastase inhibition in pulmonary disease. Vender RL. **J Investig Med** 1996 Dec; 44(9):531–9 (88 ref.)

Drugs by inhalatory route: an overview and upcoming clinical perspectives. Melillo EM, et al. **Monaldi Arch Chest Dis** 1996 Oct;51(5):405–12 (117 ref.)

Mucolytic and mucokinetic therapy. Wills PJ, et al. **Pulm Pharmacol** 1996 Aug;9(4):197–204 (93 ref.)

Nebuliser therapy in childhood. Barry PW, et al. **Thorax** 1997 Apr;52 Suppl 2:S78–88 (127 ref.)

Secretory leukoprotease inhibitor: partnering alpha 1–proteinase inhibitor to combat pulmonary inflammation. Bingle L, et al. **Thorax** 1996 Dec;51(12):1273–4 (13 ref.)

Nebuliser therapy in the intensive care unit. O'Doherty MJ, et al. **Thorax** 1997 Apr;52 Suppl 2:S56–9 (46 ref.)

[Acetylcysteine in children with lung disorders prescribed by one–third of family physicians: no support in the literature] Duijvestijn YC, et al. **Ned Tijdschr Geneeskd** 1997 Apr 26;141(17):826–30 (20 ref.) (Eng. Abstr.) **(Dut)**

[Anti–infective treatment of acute pneumopathies in children] Le Masne A, et al. **Arch Pediatr** 1997;4(2 Suppl 2):69s–71s (33 ref.) **(Fre)**

[Antioxidants in therapy of lung diseases. Concepts and reality] Buhl R, et al. **Med Monatsschr Pharm** 1996 Oct; 19(10):287–94 (45 ref.) **(Ger)**

[A case of the "shrinking lung syndrome" in SLE––improvement with corticosteroid therapy] Kitamura Y, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Jun; 19(3):217–22 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Mechanisms of action of glucocorticoids. Application to the treatment of respiratory inflammation] Mullol J, et al. **Arch Bronconeumol** 1996 Dec;32(10):527–34 (83 ref.) **(Spa)**

[Inhalation antibiotherapy] Vendrell Relat M, et al. **Arch Bronconeumol** 1997 Jan;33(1):41–9 (94 ref.) **(Spa)**

ENZYMOLOGY

Mechanisms of cytochrome P450–mediated formation of pneumotoxic electrophiles. Yost GS. **Adv Exp Med Biol** 1996;387:221–9 (40 ref.)

Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Drent M, et al. **Eur Respir J** 1996 Aug;9(8):1736–42 (60 ref.)

Therapeutic potential of neutrophil–elastase inhibition in pulmonary disease. Vender RL. **J Investig Med** 1996 Dec; 44(9):531–9 (88 ref.)

EPIDEMIOLOGY

Toxicologists versus toxicological disasters: toxic oil syndrome, clinical aspects. Gómez de la Cámara A, et al. **Arch Toxicol Suppl** 1997;19:31–40 (40 ref.)

Epidemiology of the toxic oil syndrome. Philen RM, et al. **Arch Toxicol Suppl** 1997;19:41–52 (25 ref.)

Pulmonary complications of cancer treatment [see comments] Alberts WM. **Curr Opin Oncol** 1997 Mar;9(2):161–9 (42 ref.) Comment in: Curr Opin Oncol 1997 Mar;9(2):147–8.

Prevalence of benign esophageal disease in the Danish population, with special reference to pulmonary disease and risk factors. Andersen LI. **Dan Med Bull** 1996 Jun; 43(3):263–76 (124 ref.)

[Pulmonary complications of human immunodeficiency virus infection in sub–Saharan Africa] Domoua K, et al. **Rev Pneumol Clin** 1997;53(2):79–84 (47 ref.) (Eng. Abstr.) **(Fre)**

[Environmental and occupational diseases] Baur X, et al. **Pneumologie** 1996 Sep;50 Suppl 2:604–6 (15 ref.) **(Ger)**

[The impact of ecological pressing on tuberculosis and nonspecific lung diseases in the Astrakhan' region] Vinnik LA. **Probl Tuberk** 1997;(1):27–30 (6 ref.) (Eng. Abstr.) **(Rus)**

ETIOLOGY

Adverse effects of crystalline silica exposure. American Thoracic Society Committee of the Scientific Assembly on Environmental and Occupational Health. **Am J Respir Crit Care Med** 1997 Feb;155(2):761–8 (146 ref.)

Ventilation patterns, surfactant and lung injury. Jonson B. **Biol Neonate** 1997;71 Suppl 1:13–7 (24 ref.)

Supportive care in bone marrow transplantation: pulmonary complications. Crawford SW. **Cancer Treat Res** 1997; 77:231–54 (86 ref.)

Respiratory complications of Ehlers–Danlos syndrome type IV. Dowton SB, et al. **Clin Genet** 1996 Dec;50(6):510–4 (14 ref.)

Pulmonary complications of cancer treatment [see comments] Alberts WM. **Curr Opin Oncol** 1997 Mar;9(2):161–9 (42 ref.) Comment in: Curr Opin Oncol 1997 Mar;9(2):147–8.

Occupational lung disease and the role of peptide growth factors. Brody AR. **Curr Opin Pulm Med** 1997 May; 3(3):203–8 (37 ref.)

The role of oxygen free radicals in occupational and environmental lung diseases. Vallyathan V, et al. **Environ Health Perspect** 1997 Feb;105 Suppl 1:165–77 (147 ref.)

Thoracic complications in uremic patients and in patients undergoing dialytic treatment: state of the art. Gavelli G, et al. **Eur Radiol** 1997;7(5):708–17 (76 ref.)

Role of oxidants/antioxidants in smoking–induced lung diseases. Rahman I, et al. **Free Radic Biol Med** 1996; 21(5):669–81 (155 ref.)

Pulmonary complications. Vichinsky E, et al. **Hematol Oncol Clin North Am** 1996 Dec;10(6):1275–87 (77 ref.)

Pulmonary manifestations in von Recklinghausen's disease [editorial; comment] Miyamoto K. **Intern Med** 1997 Jun; 36(6):381 (9 ref.) Comment on: Intern Med 1997 Jun;36(6):413–6.

Pulmonary disease. Walker PA, et al. **Med Clin North Am** 1996 Nov;80(6):1337–62 (156 ref.)

Pulmonary neuroendocrine cell system in pediatric and adult lung disease. Gosney JR. **Microsc Res Tech** 1997 Apr 1; 37(1):107–13 (76 ref.)

Pulmonary effects of firefighting. Scannell CH, et al. **Occup Med** 1995 Oct–Dec;10(4):789–801 (42 ref.)

Bone marrow transplantation in children. Imaging assessment of complications. Benya EC, et al. **Pediatr Clin North Am** 1997 Jun;44(3):741–61 (30 ref.)

Pulmonary hemorrhage: an often fatal complication of Henoch–Schoenlein purpura. Paller AS, et al. **Pediatr Dermatol** 1997 Jul–Aug;14(4):299–302 (10 ref.)

Differences between studies in reported relative risks associated with smoking: an overview. van de Mheen PJ, et al. **Public Health Rep** 1996 Sep–Oct;111(5):420–6; discussion 427 (40 ref.)

Alveolar hemorrhage in patients with rheumatic disease. Dweik RA, et al. **Rheum Dis Clin North Am** 1997 May; 23(2):395–410 (67 ref.)

Scleroderma. Clinical problems. The lungs. Silver RM. **Rheum Dis Clin North Am** 1996 Nov;22(4):825–40 (95 ref.)

Chlamydia pneumoniae and chronic lung diseases. Laurila AL, et al. **Scand J Infect Dis Suppl** 1997;104:34–6 (46 ref.)

[Airborne small particles as a cause of pulmonary diseases and excessive mortality? (see comments)] Frøsig CA, et al. **Ugeskr Laeger** 1996 Oct 14;158(42):5915–9 (34 ref.) (Eng. Abstr.) Comment in: Ugeskr Laeger 1996 Dec 16;158(51):7429–30. **(Dan)**

[Lung pathology in heart, liver and kidney transplantation in adults] Martel S, et al. **Rev Mal Respir** 1996 Nov;13(5 Suppl):S57–70 (178 ref.) (Eng. Abstr.) **(Fre)**

[Lung complications of hematopoietic stem cell transplantation] Philit F, et al. **Rev Mal Respir** 1996 Nov; 13(5 Suppl):S71–84 (116 ref.) (Eng. Abstr.) **(Fre)**

[Pleuropulmonary manifestations of systemic vasculitis] Huong DL, et al. **Rev Med Interne** 1996;17(8):640–52 (129 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary vasculitis: systematic aspects, pathogenesis and therapy] Kummer F, et al. **Pneumologie** 1997 Mar; 51(3):279–85 (24 ref.) **(Ger)**

[Interventional pneumology: procedures for pulmonary hemorrhage and tumor–induced superior vena cava syndrome] Witt C, et al. **Pneumologie** 1996 Feb;50(2):202–8 (51 ref.) (Eng. Abstr.) **(Ger)**

[Are inhaled dust particles harmful for our lungs?] Brändli O. **Schweiz Med Wochenschr** 1996 Dec 14;126(50):2165–74 (50 ref.) (Eng. Abstr.) **(Ger)**

[Lipid–laden alveolar macrophages as markers of gastro–esophageal reflux in pulmonary disease in childhood] Bibi H, et al. **Harefuah** 1997 Jan 1;132(1):40–2 (31 ref.) **(Heb)**

[Pulmonary involvement in systemic lupus erythematosus] Carasso S, et al. **Harefuah** 1997 Mar 2;132(5):360–3 (35 ref.) **(Heb)**

[The role of interstitial hyaluronan in acute lung injury] Ishibashi M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Dec;33 Suppl:225–30 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Role of adhesion molecules in the development of acute lung injury] Ishii Y. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Dec;33 Suppl:239–44 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Coping with pathological changes in heart and lung in collagen diseases––pulmonary alveolar hemorrhage] Yamakido M, et al. **Nippon Naika Gakkai Zasshi** 1996 Nov 10;85(11):1845–9 (5 ref.) **(Jpn)**

[Uremic lung] Joko T, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):69–71 (16 ref.) **(Jpn)**

[Harmful effects of organic dust on the respiratory system] Milanowski J. **Pneumonol Alergol Pol** 1996;64 Suppl 1:118–29 (37 ref.) **(Pol)**

LUNG DISEASES

[Pulmonary complications during HIV infection in children] Murgoci G, et al. **Pneumoftiziologia** 1997 Jan–Mar; 46(1):39–44 (12 ref.) **(Rum)**

[The non-gas-exchange functions of the lungs and the role of their disorders in the development of bronchopulmonary complications] Skobel'skiĭ VB. **Anesteziol Reanimatol** 1996 May–Jun;(3):63–8 (126 ref.) **(Rus)**

[Pulmonary torsion of the right superior lobe: an unusual complication secondary to surgery] Galant J, et al. **Arch Bronconeumol** 1997 May;33(5):254–6 (14 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Bronchopulmonary-foregut malformations: a continuum of paracrine hamartomas? Kousseff BG, et al. **Am J Med Genet** 1997 Jan 10;68(1):12–7 (92 ref.)

IMMUNOLOGY

Immunological aspects of the toxic oil syndrome. Lahoz C, et al. **Arch Toxicol Suppl** 1997;19:65–73 (35 ref.)

Immunologic effects of HIV in the lung. Agostini C, et al. **Clin Chest Med** 1996 Dec;17(4):633–45 (106 ref.)

Th1 and Th2 responses regulate experimental lung granuloma development. Kunkel SL, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Sep:13(2):120–8 (86 ref.)

[Antineutrophilic cytoplasmic antibodies (ANCA) in respiratory pathology] Lauque D. **Rev Mal Respir** 1996 Oct;13(5):534–6 (22 ref.) **(Fre)**

METABOLISM

Inherited surfactant protein-B deficiency. Hamvas A. **Adv Pediatr** 1997;44:369–88 (65 ref.)

Role of oxidants/antioxidants in smoking-induced lung diseases. Rahman I, et al. **Free Radic Biol Med** 1996; 21(5):669–81 (155 ref.)

New concepts in the pulmonary disposition of antibiotics [see comments] Bergogne-Berezin E. **Pulm Pharmacol** 1995 Apr–Jun;8(2–3):65–81 (92 ref.) Comment in: Pulm Pharmacol 1996 Feb;9(1):63, 65.

[Post-clinical period of disease: metabolic aspects] Endakova EA, et al. **Vestn Ross Akad Med Nauk** 1997;(8):15–9 (21 ref.) (Eng. Abstr.) **(Rus)**

MICROBIOLOGY

Legionella-like amebal pathogens--phylogenetic status and possible role in respiratory disease. Adeleke A, et al. **Emerg Infect Dis** 1996 Jul–Sep;2(3):225–30 (35 ref.)

Major medical complications of lung transplantation: a pediatric perspective. Mallory GB Jr. **Semin Thorac Cardiovasc Surg** 1996 Jul;8(3):305–12 (58 ref.)

PATHOLOGY

Stem cells in lung development, disease, and therapy. Mason RJ, et al. **Am J Respir Cell Mol Biol** 1997 Apr;16(4):355–63 (68 ref.)

Computed tomography in the management of chest infections: current status. Wheeler JH, et al. **Clin Infect Dis** 1996 Aug;23(2):232–40 (28 ref.)

Inflammatory and neoplastic processes of the lung: differential diagnosis and pitfalls in FNA biopsies. Silverman JF. **Diagn Cytopathol** 1995 Dec;13(5):448–62 (93 ref.)

Efficacy and safety of unguided percutaneous fine needle aspiration cytology in peripheral lung lesions. Kushwaha SK, et al. **J Indian Med Assoc** 1996 Mar;94(3):105–7 (12 ref.)

Recent advances in the pulmonary pathology of human immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome (AIDS). Klassen MK, et al. **Pathology (Phila)** 1996;4(1):43–71 (149 ref.)

Pathology of lung transplantation. Marboe CC. **Pathology (Phila)** 1996;4(1):73–101 (50 ref.)

Vasculitis of the lung. Travis WD, et al. **Pathology (Phila)** 1996;4(1):23–41 (98 ref.)

Embolism of fetal brain tissue to the lungs and the placenta. Baergen RN, et al. **Pediatr Pathol Lab Med** 1997 Jan–Feb; 17(1):159–67 (25 ref.)

Pathology of pulmonary granulomatous vasculitis [see comments] Travis WD. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Mar;13(1):14–27 (107 ref.) Comment in: Sarcoidosis Vasc Diffuse Lung Dis 1996 Mar;13(1):13.

[Flow cytometry for extensive thoracic diagnosis] Bernhardt K. **Acta Med Austriaca** 1997;24(1):5–7 (24 ref.) (Eng. Abstr.) **(Ger)**

[A case of multiple pulmonary leiomyomatous hamartoma] Ohno K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 May;44(5):723–8 (27 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Oxidant-protease interaction in the lung. Prospects for antioxidant therapy. Buhl R, et al. **Chest** 1996 Dec;110(6 Suppl):267S–272S (57 ref.)

Cytokines in chronic lung disease of prematurity. Kotecha S. **Eur J Pediatr** 1996 Aug;155 Suppl 2:S14–7 (29 ref.)

Pulmonary disease. Walker PA, et al. **Med Clin North Am** 1996 Nov;80(6):1337–62 (156 ref.)

Physiological outcomes of lung volume reduction surgery. Russi EW. **Monaldi Arch Chest Dis** 1997 Apr;52(2):155–8 (35 ref.)

Pulmonary inflammation--a balancing act. Colten HR, et al. **N Engl J Med** 1997 Apr 10;336(15):1094–6 (3 ref.)

[Role of nitric oxide in respiratory physiology and in the physiopathology of pulmonary diseases] Dinh-Xuan AT. **Rev Mal Respir** 1996;13(4):381–8 (30 ref.) (Eng. Abstr.) **(Fre)**

[The significance of endothelin for physiologic and pathophysiologic processes of the lung (see comments)] Schmeck J, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jul; 32(7):401–8 (123 ref.) (Eng. Abstr.) Comment in: Anasthesiol Intensivmed Notfallmed Schmer 1997 Jul;32(7):397–8. **(Ger)**

[Pathophysiology of acute lung injury] Kitamura S. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:1–7 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Physiopathology of lung injury in acute pancreatitis] Alves Júnior A, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1996 Nov–Dec;51(6):232–8 (53 ref.) (Eng. Abstr.) **(Por)**

PREVENTION & CONTROL

Reducing chemotherapy-associated toxicity in elderly cancer patients. Zagonel V, et al. **Cancer Treat Rev** 1996 May; 22(3):223–44 (135 ref.)

High frequency ventilation. Ramsden CA, et al. **J Paediatr Child Health** 1997 Apr;33(2):85–7 (23 ref.)

The preservation of function: treatment of new acquisition of a pathogen [editorial; comment] Rabin HR, et al. **Pediatr Pulmonol** 1997 May;23(5):323–4 (3 ref.) Comment on: Pediatr Pulmonol 1997 May;23(5):330–5.

Something is (not) rotten in Denmark [Hamlet (not) W. Shakespeare] [editorial; comment] Schidlow DV. **Pediatr Pulmonol** 1997 May;23(5):325–6 (4 ref.) Comment on: Pediatr Pulmonol 1997 May;23(5):330–5.

Preoperative pulmonary evaluation. Identifying patients at increased risk for complications. Mohr DN, et al. **Postgrad Med** 1996 Nov;100(5):241–4, 247–8, 251–2 passim (28 ref.)

RADIOGRAPHY

Ground-glass opacity at CT: the ABCs. Collins J, et al. **AJR Am J Roentgenol** 1997 Aug;169(2):355–67 (85 ref.)

AIDS-related airway disease. McGuinness G, et al. **AJR Am J Roentgenol** 1997 Jan;168(1):67–77 (61 ref.)

Mycobacterium szulgai infection of the lung: case report and review of an unusual pathogen. Benator DA, et al. **Am J Med Sci** 1997 Jun;313(6):346–51 (25 ref.)

Spiral computed tomographic scanning and respiratory disease. Sawyer RH. **Br J Hosp Med** 1996 Jul 10–Aug 20; 56(2–3):94–8 (12 ref.)

Subjective pitfalls in HRCT interpretation. Gruden JF, et al. **Crit Rev Diagn Imaging** 1996 Oct;37(5):349–434 (32 ref.)

Radiographic patterns of pulmonary disease. Grodzin CJ, et al. **Dis Mon** 1997 Jan;43(1):1–62 (27 ref.)

Chest imaging in the intensive care unit. Tocino I. **Eur J Radiol** 1996 Aug;23(1):46–57 (50 ref.)

High resolution computed tomography of the lungs. Shetty PG, et al. **J Assoc Physicians India** 1996 Sep;44(9):621–6, 631–6 (35 ref.)

Case report. Pulmonary involvement in Niemann-Pick disease subtype B: CT findings. Ferretti GR, et al. **J Comput Assist Tomogr** 1996 Nov–Dec;20(6):990–2 (9 ref.)

Swyer-James syndrome documented by spiral CT angiography and high resolution inspiratory and expiratory CT: an accurate single modality exploration. Ghossain MA, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):616–8 (9 ref.)

Pulmonary coccidioidomycosis in Kentucky. Woodring JH, et al. **J Ky Med Assoc** 1996 Nov;94(11):490–7 (25 ref.)

Infectious mononucleosis with pulmonary consolidation. Miyake H, et al. **J Thorac Imaging** 1996 Spring;11(2):158–60 (7 ref.)

Management of solitary pulmonary nodules. How to decide when resection is required. Lillington GA. **Postgrad Med** 1997 Mar;101(3):145–50 (10 ref.)

Chest radiograph and functional radiology. Sallustio G, et al. **Rays** 1997 Jan–Mar;22(1):38–50 (11 ref.) **(Eng, Ita)**

High resolution computed tomography (HRCT) and new perspectives in functional radiology of the lung. Sallustio G, et al. **Rays** 1997 Jan–Mar;22(1):157–82 (41 ref.) **(Eng, Ita)**

[Unilateral peripheral pulmonary nodules: initial symptoms of a limited form of Wegener's disease] Dechambre S, et al. **J Belge Radiol** 1996 Aug;79(4):162–4 (9 ref.) (Eng. Abstr.) **(Fre)**

[Pleural and pulmonary changes within the scope of rheumatoid arthritis] Bankier AA, et al. **Radiologe** 1996 Aug;36(8):637–45 (61 ref.) (Eng. Abstr.) **(Ger)**

[HRCT of the lung in collagenoses] Diederich S, et al. **Radiologe** 1996 Jul;36(7):567–78 (37 ref.) (Eng. Abstr.) **(Ger)**

[Calcium in the lung or: it might not always be tuberculosis] Henk CB, et al. **Radiologe** 1996 Jul;36(7):534–42 (37 ref.) (Eng. Abstr.) **(Ger)**

[Phenomenology of pulmonary HRCT. Definitions, differential diagnosis and clinical relevance] Roos N, et al. **Radiologe** 1996 Jul;36(7):521–33 (46 ref.) (Eng. Abstr.) **(Ger)**

[Metastatic pulmonary calcification as a rare complication of terminal kidney failure: the x-ray and CT findings] Reuter M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Nov;165(5):493–5 (13 ref.) **(Ger)**

[Thoracic actinomycosis] Besznyák G, et al. **Orv Hetil** 1996 Sep 15;137(37):2041–3 (29 ref.) (Eng. Abstr.) **(Hun)**

RADIONUCLIDE IMAGING

Positron emission tomography and the lung. Hughes JM. **Br J Hosp Med** 1996 Jul 10–Aug 20;56(2–3):86–9 (11 ref.)

The role of nuclear medicine in the investigation of patients with AIDS. Prvulovich EM, et al. **Br J Hosp Med** 1996 May 1–14;55(9):549–53 (19 ref.)

Pulmonary technetium-99m diethylene triamine penta-acetic acid aerosol clearance as an index of lung injury. O'Doherty MJ, et al. **Eur J Nucl Med** 1997 Jan;24(1):81–7 (48 ref.)

Advances in pulmonary nuclear medicine. Salvatori M. **Rays** 1997 Jan–Mar;22(1):51–72 (47 ref.) **(Eng, Ita)**

REHABILITATION

Clinical applications of cardiopulmonary exercise testing. Mahler DA, et al. **J Cardiopulm Rehabil** 1996 Nov–Dec; 16(6):357–65 (44 ref.)

SURGERY

Lung transplantation. Trulock EP. **Am J Respir Crit Care Med** 1997 Mar;155(3):789–818 (398 ref.)

What's new in pediatric surgery. Schwartz MZ. **J Am Coll Surg** 1997 Feb;184(2):181–6 (35 ref.)

Hernia of the lung repaired by VATS: a case report. Brown WT, et al. **J Laparoendosc Surg** 1996 Dec;6(6):427–30 (5 ref.)

Management of solitary pulmonary nodules. How to decide when resection is required. Lillington GA. **Postgrad Med** 1997 Mar;101(3):145–50 (10 ref.)

Lung transplantation. Part I. Indications and operative management. Wood DE, et al. **West J Med** 1996 Dec; 165(6):355–63 (36 ref.)

[Lung and heart-lung transplantation] Wagner TO, et al. **Internist (Berl)** 1996 Mar;37(3):272–82 (35 ref.) **(Ger)**

[Progress in the surgical treatment of congenital and acquired broncho-pulmonary pathology] Pesce C, et al. **Pediatr Med Chir** 1996 Sep–Oct;18(5):451–61 (34 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Lung transplantation: implications for the general internist. Nunley DR, et al. **Adv Intern Med** 1996;41:497–529 (33 ref.)

Extracorporeal support of oxygenation and ventilation. Furukawa S. **Int Anesthesiol Clin** 1997 Winter;35(1):169–76 (34 ref.)

ACOG technical bulletin. Pulmonary disease in pregnancy. Number 224--June 1996. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1996 Aug;54(2):187–96 (19 ref.)

An evaluation of the use of bronchopulmonary lavage in the treatment of plutonium oxide inhalation. Dean MR. **J R Nav Med Serv** 1997;82(3):188–96 (27 ref.)

Recent advances in pulmonary medicine. Passero MA. **Med Health R I** 1996 Mar;79(3):106–9 (30 ref.)

Introduction to different approaches to intrabronchial treatment. Bolliger CT. **Monaldi Arch Chest Dis** 1996 Aug; 51(4):316–24 (63 ref.)

High frequency oscillatory ventilation in children and infants. Greenough A. **Monaldi Arch Chest Dis** 1997 Jun; 52(3):268–71 (30 ref.)

Selectins and their counter receptors: a bitter sweet attraction. Symon FA, et al. **Thorax** 1996 Nov; 51(11):1155–7 (12 ref.)

ULTRASONOGRAPHY

[Pulmonary echography: a method of the future in emergency medicine and resuscitation (editorial)] Lichtenstein D. **Rev Pneumol Clin** 1997;53(2):63–8 (28 ref.) **(Fre)**

[Endobronchial ultrasound] Becker HD, et al. **Pneumologie** 1997 Jul;51(7):620–9 (48 ref.) **(Ger)**

VIROLOGY

Viruses and other miscellaneous organisms. Wallace JM. **Clin Chest Med** 1996 Dec;17(4):745–54 (101 ref.)

LUNG DISEASES, FUNGAL

Fungal pulmonary complications. Davies SF, et al. **Clin Chest Med** 1996 Dec;17(4):725–44 (59 ref.)

Fungal pneumonias. Catanzaro A. **Curr Opin Pulm Med** 1997 Mar;3(2):146–50 (34 ref.)

Cutaneous manifestations of systemic mycoses. Body BA. **Dermatol Clin** 1996 Jan;14(1):125–35 (105 ref.)

Community-acquired fungal pneumonia in children. Maxson S, et al. **Semin Respir Infect** 1996 Sep;11(3):196–203 (18 ref.)

Cryptococcal pneumonia. Sarosi GA. **Semin Respir Infect** 1997 Mar;12(1):50–3 (26 ref.)

[Pulmonary mucormycosis: a case report and review of the literature] Escobar Sacristán JA, et al.

Arch Bronconeumol 1996 Jan;32(1):47–9 (42 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Pulmonary mucormycosis diagnosed by bronchoalveolar lavage: a case report and review of the literature. al-Abbadi MA, et al. **Pediatr Pulmonol** 1997 Mar;23(3):222–5 (14 ref.)

Thoracic coccidioidomycosis. Batra P, et al. **Semin Roentgenol** 1996 Jan;31(1):28–44 (64 ref.)

Histoplasmosis. Conces DJ Jr. **Semin Roentgenol** 1996 Jan; 31(1):14–27 (65 ref.)

Blastomycosis. Kuzo RS, et al. **Semin Roentgenol** 1996 Jan; 31(1):45–51 (26 ref.)

Aspergillosis: a disease with many faces. Miller WT. **Semin Roentgenol** 1996 Jan;31(1):52–66 (56 ref.)

Pulmonary mucormycosis. Murphy RA, et al. **Semin Roentgenol** 1996 Jan;31(1):83–7 (28 ref.)

Pulmonary cryptococcosis. Woodring JH, et al. **Semin Roentgenol** 1996 Jan;31(1):67–75 (24 ref.)

[Genetic diagnosis of aspergillosis] Murayama SY, et al. **Kekkaku** 1997 Feb;72(2):83–90 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Serological diagnosis for cryptococcosis by the detection of beta-glucan and capsular polysaccharide] Kohno S. **Rinsho Byori** 1996 Jun;44(6):524–7 (6 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

[Conversion of chronic necrotizing pulmonary aspergillosis to invasive pulmonary aspergillosis, and successful treatment with fluconazole] Hirano K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 Apr; 35(4):408–13 (13 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Pulmonary mucormycosis in diabetic renal allograft recipients. Latif S, et al. **Am J Kidney Dis** 1997 Mar; 29(3):461–4 (26 ref.)

[Aspergillus lung pathology in transplant patients] Kaiser L, et al. **Rev Mal Respir** 1996 Nov;13(5 Suppl):S93–101 (75 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary complications in diabetes mellitus] Marvisi M, et al. **Recenti Prog Med** 1996 Dec;87(12):623–7 (52 ref.) (Eng. Abstr.) **(Ita)**

[Pulmonary complications during HIV infection in children] Murgoci G, et al. **Pneumoftiziologia** 1997 Jan–Mar; 46(1):39–44 (12 ref.) **(Rum)**

IMMUNOLOGY

Pulmonary fungal infections in immunocompromised children. Shenep JL, et al. **Curr Opin Pediatr** 1997 Jun; 9(3):213–8 (34 ref.)

MICROBIOLOGY

Pulmonary mycetoma due to Candida albicans: case report and review. Shelly MA, et al. **Clin Infect Dis** 1996 Jan; 22(1):133–5 (16 ref.)

[A case of pulmonary zygomycosis caused by Cunninghamella bertholletiae] Hashiguchi K, et al. **Kansenshogaku Zasshi** 1997 Mar;71(3):264–8 (14 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

The pathology of fungal disease in the lung. Litzky LA. **Semin Roentgenol** 1996 Jan;31(1):4–13 (37 ref.)

RADIOGRAPHY

Pulmonary aspergillosis: a spectrum of disease. Broderick LS, et al. **Crit Rev Diagn Imaging** 1996 Dec;37(6):491–531 (26 ref.)

THERAPY

Chronic necrotizing pulmonary aspergillosis: approach to management. Saraceno JL, et al. **Chest** 1997 Aug; 112(2):541–8 (24 ref.)

LUNG DISEASES, INTERSTITIAL

The acute (noninfectious) interstitial lung diseases. Schwarz MI. **Compr Ther** 1996 Oct;22(10):622–30 (20 ref.)

Diffuse lung disease: a view for the future. du Bois RM. **Sarcoidosis Vasc Diffuse Lung Dis** 1997 Mar;14(1):23–30 (125 ref.)

[Idiopathic interstitial pneumonia: profiles of the subsets, and prognosis] Nagai S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:200–3 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Interstitial pneumonia] Ando T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):415–8 (11 ref.) **(Jpn)**

CHEMICALLY INDUCED

Drug-induced lung disease. Copper JA Jr. **Adv Intern Med** 1997;42:231–68 (149 ref.)

Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Malik SW, et al. **Am J Respir Crit Care Med** 1996 Dec;154(6 Pt 1):1851–6 (20 ref.)

Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease. Tomioka R, et al. **Am J Respir Crit Care Med** 1997 Mar; 155(3):1011–20 (137 ref.)

Human toxicity of cobalt-containing dust and experimental studies on the mechanism of interstitial lung disease (hard metal disease). Lison D. **Crit Rev Toxicol** 1996 Nov; 26(6):585–616 (163 ref.)

CLASSIFICATION

The alphabet soup revisited: the chronic interstitial pneumonias in the 1990s. McAdams HP, et al. **Radiographics** 1996 Sep;16(5):1009–33; discussion 1033–4 (78 ref.)

COMPLICATIONS

Lymphocytic interstitial pneumonitis and nonspecific interstitial pneumonitis. Schneider RF. **Clin Chest Med** 1996 Dec;17(4):763–6 (29 ref.)

The potential of bronchoalveolar lavage in the prognosis and treatment of connective-vascular diseases. Spertini F, et al. **Clin Exp Rheumatol** 1996 Nov–Dec;14(6):681–8 (47 ref.)

[Exertional intolerance in respiratory insufficiency: principal mechanisms] Janssens JP, et al. **Rev Med Suisse Romande** 1997 Jun;117(6):457–64 (22 ref.) **(Fre)**

DIAGNOSIS

PCR diagnosis of viral pneumonitis from fixed-lung tissue in children. Akhtar N, et al. **Biochem Mol Med** 1996 Jun; 58(1):66–76 (35 ref.)

Acute lupus pneumonitis with normal chest radiograph. Susanto I, et al. **Chest** 1997 Jun;111(6):1781–3 (9 ref.)

Diagnosis of interstitial lung disease [editorial] [see comments] Bush A. **Pediatr Pulmonol** 1996 Aug;22(2):81–2 (21 ref.) Comment in: Pediatr Pulmonol 1997 Feb;23(2):127–8.

[Diagnostic approach of chronic diffuse infiltrative diseases of the lung in non-immunosuppressed patients] Tazi A, et al. **Presse Med** 1996 Oct 12;25(30):1381–7 (10 ref.) (Eng. Abstr.) **(Fre)**

[Bronchoalveolar lavage analyses for the diagnosis of interstitial lung diseases] Kawanami O. **Nippon Ika Daigaku Zasshi** 1996 Oct;63(5):395–9 (6 ref.) **(Jpn)**

[Diagnostic significance of fine crackles in interstitial pulmonary disease] Murata A. **Nippon Ika Daigaku Zasshi** 1996 Oct;63(5):404–8 (4 ref.) **(Jpn)**

[Imaging of interstitial pulmonary diseases] Sato M. **Nippon Ika Daigaku Zasshi** 1996 Oct;63(5):400–3 (0 ref.) **(Jpn)**

[How can we monitor and treat patients with acute exacerbations of idiopathic interstitial pneumonia] Kobayashi J, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:195–9 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical usefulness of KL-6 as a serum marker of idiopathic interstitial pneumonia] Kohno N. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:186–9 (18 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Familial interstitial lung disease in children: response to chloroquine treatment in one sibling with desquamative interstitial pneumonitis [see comments] Balasubramanyan N, et al. **Pediatr Pulmonol** 1997 Jan;23(1):55–61 (33 ref.) Comment in: Pediatr Pulmonol 1997 Jan;23(1):1–7.

[Immunosuppressive therapy in interstitial lung diseases and immunologically-induced pneumonitis] Müller-Quernheim J, et al. **Internist (Berl)** 1997 Jun;38(6):553–61 (31 ref.) **(Ger)**

[Interstitial pulmonitis due to the cytomegalovirus in an immunocompetent adolescent: treatment with ganciclovir] Pellegrini G, et al. **Pediatr Med Chir** 1996 May–Jun; 18(3):315–7 (19 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease. Tomioka R, et al. **Am J Respir Crit Care Med** 1997 Mar; 155(3):1011–20 (137 ref.)

Interstitial lung disease: basic mechanisms and genetic predisposition. Lympany PA, et al. **Monaldi Arch Chest Dis** 1997 Feb;52(1):33–6 (34 ref.)

Idiopathic interstitial lung disease: anatomoradiologic pathogenesis. Chiodera P. **Rays** 1997 Jan–Mar;22(1):127–56 (59 ref.) **(Eng, Ita)**

Diffuse lung disease: product of genetic susceptibility and environmental encounters. Lympany PA, et al. **Thorax** 1997 Jan;52(1):92–4 (12 ref.)

[Course of interstitial lung diseases associated with inflammatory myopathies. Apropos of 5 cases] Tubéry M, et al. **Ann Med Interne (Paris)** 1997;148(1):2–10 (78 ref.) (Eng. Abstr.) **(Fre)**

[Chronic interstitial lung diseases in childhood—an overview] Resch B, et al. **Klin Padiatr** 1997 Mar–Apr;209(2):59–65 (80 ref.) (Eng. Abstr.) **(Ger)**

[Role of alveolar macrophages in the pathogenesis of interstitial lung diseases-MCP-1-] Suga M. **Nippon Ika Daigaku Zasshi** 1996 Oct;63(5):384–90 (5 ref.) **(Jpn)**

[Role of alveolar macrophages in the pathogenesis of idiopathic interstitial pneumonia] Suga M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:175–80 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Mixed connective tissue disease: progress in diagnosis and treatment. III. Treatment. 3. Clinical aspects of specific conditions and treatment. 3) Interstitial pulmonary lesions and serositis] Hirakata M, et al. **Nippon Naika Gakkai Zasshi** 1996 Aug 10;85(8):1248–53 (6 ref.) **(Jpn)**

[Coping with pathological changes in heart and lung in collagen diseases—dermatomyositis and interstitial pneumonia] Nawata Y. **Nippon Naika Gakkai Zasshi** 1996 Nov 10;85(11):1850–4 (8 ref.) **(Jpn)**

[Postmyocardial infarction syndrome] Shimizu M. **Ryoikibetsu Shokogun Shirizu** 1996;(12):692–5 (14 ref.) **(Jpn)**

GENETICS

Gene expression in rodent model of environmental lung disease. Hoyle GW, et al. **Ann N Y Acad Sci** 1996 Oct 31;796:162–72 (39 ref.)

Interstitial lung disease: basic mechanisms and genetic predisposition. Lympany PA, et al. **Monaldi Arch Chest Dis** 1997 Feb;52(1):33–6 (34 ref.)

[New strategies for the etiologic study of interstitial pneumonia: familial registration and sib-pair analysis] Nukiwa T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:204–7 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Idiopathic interstitial pneumonia and TNF gene restriction fragment length polymorphism] Ohe M, et al. **Nippon Rinsho** 1996 Feb;54(2):544–9 (16 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

[N-terminal peptide of type III procollagen in serum and bronchoalveolar fluid as a marker of collagen metabolism in chronic interstitial lung diseases] Siemińska A. **Przegl Lek** 1996;53(7):574–8 (45 ref.) (Eng. Abstr.) **(Pol)**

PATHOLOGY

Diagnostic strategies of lung biopsy. Keller R. **Monaldi Arch Chest Dis** 1995 Dec;50(6):464–8 (37 ref.)

Interstitial lung disease. Fleming MV, et al. **Pathology (Phila)** 1996;4(1):1–21 (113 ref.)

Idiopathic interstitial lung disease: anatomoradiologic pathogenesis. Chiodera P. **Rays** 1997 Jan–Mar;22(1):127–56 (59 ref.) **(Eng, Ita)**

[Pulmonary structural remodeling in interstitial lung disease] Fukuda Y. **Nippon Ika Daigaku Zasshi** 1996 Oct; 63(5):379–83 (13 ref.) **(Jpn)**

RADIOGRAPHY

High-resolution computed tomography in chronic infiltrative lung disease. Hansell DM. **Eur Radiol** 1996;6(6):796–800 (44 ref.)

Radiographic appearance of interstitial lung disease. Glazer C. **Radiol Technol** 1997 Jul–Aug;68(6):475–80 (13 ref.)

LUNG DISEASES, OBSTRUCTIVE

see related

AIRWAY OBSTRUCTION

Intrinsic PEEP and cardiopulmonary interaction in patients with COPD and acute ventilatory failure. Ranieri VM, et al. **Eur Respir J** 1996 Jun;9(6):1283–92 (64 ref.)

Treatment of acute bronchitis in adults without underlying lung disease [see comments] MacKay DN. **J Gen Intern Med** 1996 Sep;11(9):557–62 (48 ref.) Comment in: ACP J Club 1997 Mar–Apr;126(2):39.

Nitric oxide in chronic obstructive pulmonary disease. Barberà JA. **Monaldi Arch Chest Dis** 1996 Dec;51(6):528–32 (28 ref.)

Nutrition and outcome in chronic respiratory disease. Schols AM. **Nutrition** 1997 Feb;13(2):161–3 (34 ref.)

[Reversible broncho-obstruction (asthma and COPD) in the elderly patient. Epidemiologic, diagnostic, and therapeutic features] Leonardi R, et al. **Recenti Prog Med** 1996 Sep; 87(9):437–44 (40 ref.) (Eng. Abstr.) **(Ita)**

[Chronic obstructive pulmonary disease] Handa S. **Ryoikibetsu Shokogun Shirizu** 1996;(15):490–3 (17 ref.) **(Jpn)**

[Chronic obstructive bronchitis: clinical, diagnostic and therapeutic aspects] Ovcharenko SI. **Klin Med (Mosk)** 1997; 75(6):53–7 (0 ref.) **(Rus)**

CHEMICALLY INDUCED

Glaucoma therapy may take your breath away. Diggory P, et al. **Age Ageing** 1997 Mar;26(2):63–7 (24 ref.)

COMPLICATIONS

Management of acute respiratory failure in chronic obstructive pulmonary disease. Zuege DJ, et al. **Curr Opin Pulm Med** 1997 May;3(3):190–7 (58 ref.)

Gastrointestinal endoscopy in high-risk patients. Cappell MS. **Dig Dis** 1996 Jul–Aug;14(4):228–44 (115 ref.)

Noninvasive positive pressure ventilation in acute respiratory

failure of chronic obstructive pulmonary disease. Clark HE, et al. **Lung** 1997;175(3):143–54 (59 ref.)

Hemodynamic estimation of chronic cor pulmonale by Doppler echocardiography. Clinical value and comparison with other noninvasive imaging techniques. Zompatori M, et al. **Rays** 1997 Jan–Mar;22(1):73–93 (50 ref.) **(Eng, Ita)**

Sleep-related hypoxaemia in chronic obstructive pulmonary disease: causes, consequences and treatment. Weitzenblum E, et al. **Respiration** 1997;64(3):187–93 (42 ref.)

[Causative role of infections with viruses or atypical pathogens in acute exacerbations of chronic bronchitis less frequent than expected (see comments)] Roessingh PH, et al. **Ned Tijdschr Geneeskd** 1996 Nov 30;140(48):2406–10 (28 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1997 Feb 15;141(7):351. **(Dut)**

[Exertional intolerance in respiratory insufficiency: principal mechanisms] Janssens JP, et al.
Rev Med Suisse Romande 1997 Jun;117(6):457–64 (22 ref.) **(Fre)**

[Arrhythmias in patients with chronic pulmonary emphysema] Makino M, et al.
Ryoikibetsu Shokogun Shirizu 1996;(12):436–9 (15 ref.) **(Jpn)**

[Respiratory disorders during sleep in chronic obstructive lung disease] Togores Solivellas B, et al.
Arch Bronconeumol 1996 Jan;32(1):32–9 (78 ref.) **(Spa)**

DIAGNOSIS

Assessing lung function. Mecoy RJ. **Aust Fam Physician** 1996 Feb;25(2):153, 156–9 (1 ref.)

Evaluation and preoperative management of lung volume reduction surgery candidates. Yusen RD, et al.
Clin Chest Med 1997 Jun;18(2):199–224 (154 ref.)

Changes in peak expiratory flow in healthy subjects and in patients with obstructive lung disease. Brand PL, et al.
Eur Respir J Suppl 1997 Feb;24:69S–71S (57 ref.)

Timed walking tests of exercise capacity in chronic cardiopulmonary illness. Steele B. **J Cardiopulm Rehabil** 1996 Jan–Feb;16(1):25–33 (49 ref.)

Imaging evaluation of obstructive atelectasis. Molina PL, et al. **J Thorac Imaging** 1996 Summer;11(3):176–86 (49 ref.)

All that wheezes is not asthma. Goldman J. **Practitioner** 1997 Jan;241(1570):35–8 (6 ref.)

[Pneumologic diagnosis with model aerosols—1: Intrapulmonary morphometry. Principles and initial results of clinical research] Kohlhäufl M, et al. **Pneumologie** 1997 Jan;51(1):40–6 (41 ref.) **(Ger)**

[Chronic bronchitis] Konietzko N. **Pneumologie** 1996 Sep;50 Suppl 2:582–4 (9 ref.) **(Ger)**

[Recommendations of the Polish Pthysiopneumonologic Society for diagnosis and treatment of chronic obstructive lung diseases] **Pneumonol Alergol Pol** 1997;65 Suppl 2:3–24 (0 ref.) **(Pol)**

DIET THERAPY

COPD: using nutrition to prevent respiratory function decline. Chapman KM, et al. **Geriatrics** 1996 Dec; 51(12):37–42 (11 ref.)

[Nutritional therapy of chronic obstructive lung diseases] Narita N. **Nippon Naika Gakkai Zasshi** 1996 Sep 10; 85(9):1554–60 (11 ref.) **(Jpn)**

DRUG THERAPY

Adverse effects of corticosteroid therapy for COPD. A critical review. McEvoy CE, et al. **Chest** 1997 Mar; 111(3):732–43 (95 ref.)

The use of theophylline in chronic obstructive pulmonary disease. Pauwels R. **Clin Exp Allergy** 1996 Mar;26 Suppl 2:55–9 (33 ref.)

Changing delivery methods for obstructive lung diseases. Dolovich M. **Curr Opin Pulm Med** 1997 May;3(3):177–89 (112 ref.)

Respiratory muscle pharmacology. Decramer M.
Monaldi Arch Chest Dis 1996 Dec;51(6):499–503 (47 ref.)

Pharmacotherapy of respiratory muscles in chronic obstructive pulmonary disease. van der Heijden HF, et al.
Respir Med 1996 Oct;90(9):513–22 (101 ref.)

Ambulatory inhalation therapy in obstructive lung diseases. Roche N, et al. **Respiration** 1997;64(2):121–30 (55 ref.)

Current best practice for nebuliser treatment. British Thoracic Society Nebulizer Project Group. **Thorax** 1997 Apr;52 Suppl 2:S1–3 (0 ref.)

[Beta2 agonists and anticholinergics. Inhalation therapy in acute deterioration of asthma and chronic obstructive pulmonary disease (see comments)] Ringbaek TJ, et al.
Ugeskr Laeger 1996 Oct 14;158(42):5957–62 (40 ref.) Comment in: Ugeskr Laeger 1997 Mar 3;159(10):1470–1. **(Dan)**

[Glucocorticoids in pneumology] Criée CP, et al.
Internist (Berl) 1997 May;38(5):490–3 (10 ref.) **(Ger)**

[Aerosols. Administration systems for pulmonary administration of drugs] Holzner P.
Med Monatsschr Pharm 1997 Jul;20(7):177–90 (68 ref.) **(Ger)**

[Theophylline and selective phosphodiesterase inhibitor in therapy of obstructive respiratory tract diseases] Rabe KF, et al. **Pneumologie** 1997 Mar;51(3):303–16 (140 ref.) **(Ger)**

[Pharmacologic therapy for patients with stable chronic obstructive pulmonary disease—emphasis on inhaled agents] Nishimura K, et al.
Nippon Kyobu Shikkan Gakkai Zasshi 1996 Dec;34 Suppl:75–8 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Pathogenetic basis of treatment for chronic obstructive pulmonary disease] Kozak-Szkopek E, et al.
Pol Merkuriusz Lek 1996 Jul;1(1):56–9 (44 ref.) (Eng. Abstr.) **(Pol)**

EPIDEMIOLOGY

Chronic occupational respiratory disease. Attfield MD, et al. **Occup Med** 1996 Jul–Sep;11(3):451–65 (53 ref.)

ETIOLOGY

Health effects of working in pulp and paper mills: exposure, obstructive airways diseases, hypersensitivity reactions, and cardiovascular diseases. Torén K, et al. **Am J Ind Med** 1996 Feb;29(2):111–22 (75 ref.)

The beginnings of chronic airflow obstruction. Shaheen S. **Br Med Bull** 1997 Jan;53(1):58–70 (42 ref.)

The role of endotoxin in grain dust exposure and airway obstruction. Von Essen S. **Curr Opin Pulm Med** 1997 May; 3(3):198–202 (37 ref.)

Lung cancer and chronic obstructive pulmonary disease. Petty TL. **Hematol Oncol Clin North Am** 1997 Jun; 11(3):531–41 (19 ref.)

Pulmonary hypoplasia presented in adulthood as a chronic respiratory failure: report of two cases. Embryology, clinical symptoms and diagnostic procedures. Mas A, et al. **Respiration** 1997;64(3):240–3 (14 ref.)

Upper airway obstruction in the rheumatic diseases. Langford CA, et al. **Rheum Dis Clin North Am** 1997 May; 23(2):345–63 (125 ref.)

Occupational and chronic obstructive pulmonary disease (COPD) [see comments] Hendrick DJ. **Thorax** 1996 Sep; 51(9):947–55 (60 ref.) Comment in: Thorax 1997 Apr;52(4):399–400.

[Pulmonary problems related to aging] Weber T, et al.
Rev Med Liege 1997 Apr;52(4):245–50 (13 ref.) **(Fre)**

[Chronic bronchitis and its sequelae. Therapy—prognosis—insurance medicine aspects] Gillissen A, et al. **Versicherungsmedizin** 1996 Dec 1;48(6):200–7 (41 ref.) (Eng. Abstr.) **(Ger)**

[Pathogenetic basis of treatment for chronic obstructive pulmonary disease] Kozak-Szkopek E, et al.
Pol Merkuriusz Lek 1996 Jul;1(1):56–9 (44 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Genetic risk factors for chronic obstructive pulmonary disease. Sandford AJ, et al. **Eur Respir J** 1997 Jun; 10(6):1380–91 (140 ref.)

METABOLISM

Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Repine JE, et al.
Am J Respir Crit Care Med 1997 Aug;156(2 Pt 1):341–57 (296 ref.)

MORTALITY

Chronic obstructive pulmonary disease. Mortality and mortality reduction. Fiel SB. **Drugs** 1996;52 Suppl 2:55–60; discussion 60–1 (20 ref.)

Pulmonary failure as a cause of death in COPD. Braghiroli A, et al. **Monaldi Arch Chest Dis** 1997 Apr;52(2):170–5 (55 ref.)

Changing smoking patterns and mortality from chronic obstructive pulmonary disease. Wise RA. **Prev Med** 1997 Jul–Aug;26(4):418–21 (23 ref.)

[The patient with respiratory problems] Senninger N, et al. **Chirurg** 1997 Jul;68(7):662–9 (58 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

[Cell types of respiratory epithelium: morphology, molecular biology and clinical significance] Bals R. **Pneumologie** 1997 Feb;51(2):142–9 (79 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Risk factors for accelerated decline among patients with chronic obstructive pulmonary disease. Kerstjens HA, et al. **Am J Respir Crit Care Med** 1996 Dec;154(6 Pt 2):S266–72 (34 ref.)

Auto-positive end-expiratory pressure and dynamic hyperinflation. Ranieri VM, et al. **Clin Chest Med** 1996 Sep;17(3):379–94 (50 ref.)

Peak flow meters and spirometers in general practice.
Drug Ther Bull 1997 Jul;35(7):52–5 (20 ref.)

Effect of hyperinflation on the diaphragm. De Troyer A. **Eur Respir J** 1997 Mar;10(3):708–13 (56 ref.)

Pulmonary hyperinflation a clinical overview. Gibson GJ. **Eur Respir J** 1996 Dec;9(12):2640–9 (70 ref.)

The role of pulmonary surfactant in obstructive airways disease. Hohlfeld J, et al. **Eur Respir J** 1997 Feb; 10(2):482–91 (119 ref.)

Impact of sleep in respiratory failure. McNicholas WT.
Eur Respir J 1997 Apr;10(4):920–33 (185 ref.)

On the causes of lung hyperinflation during bronchoconstriction. Pellegrino R, et al. **Eur Respir J** 1997 Feb;10(2):468–75 (58 ref.)

Acute airway inflammation: morphology. Saetta M.
Monaldi Arch Chest Dis 1996 Dec;51(6):463–5 (22 ref.)

Tension-time index of inspiratory muscles in children [editorial; comment] Gaultier C. **Pediatr Pulmonol** 1997 May;23(5):327–9 (18 ref.) Comment on: Pediatr Pulmonol 1997 May;23(5):336–43.

Airway disease: anatomopathologic patterns and functional correlations. Mormile F, et al. **Rays** 1997 Jan–Mar; 22(1):107–26 (51 ref.) **(Eng, Ita)**

[Gastroesophageal reflux and involvement of the airways] Micklefield GH, et al. **Pneumologie** 1996 Jun;50(6):430–6 (80 ref.) **(Ger)**

[Changes in ventilatory mechanics in emphysema] Wanke T. **Wien Med Wochenschr** 1996;146(23):585–7 (14 ref.) (Eng. Abstr.) **(Ger)**

[Chronic obstructive lung disease and sleep] Bishara H.
Harefuah 1996 Jun 2;130(11):775–7 (41 ref.) **(Heb)**

[The role of neuroendocrine cells and bombesin neuropeptides in the pathogenesis of smoking related diseases, especially chronic obstructive pulmonary disease] Siemińska A, et al. **Pneumonol Alergol Pol** 1997; 65(1–2):123–8 (32 ref.) **(Pol)**

PREVENTION & CONTROL

Is screening for chronic obstructive pulmonary disease justified? Badgett RG, et al. **Prev Med** 1997 Jul–Aug; 26(4):466–72 (86 ref.)

[Role of education in the patient with chronic diseases: example of asthma and chronic obstructive lung disease] Uldry C, et al. **Rev Med Suisse Romande** 1997 May; 117(5):433–7 (28 ref.) **(Fre)**

PSYCHOLOGY

Assessing quality of life in chronic non-specific lung disease—a review of empirical studies published between 1980 and 1994. Maillé AR, et al. **Qual Life Res** 1996 Apr; 5(2):287–301 (116 ref.)

RADIOGRAPHY

Radiology of obstructive pulmonary disease. Webb WR.
AJR Am J Roentgenol 1997 Sep;169(3):637–47 (75 ref.)

[The Swyer-James syndrome: its imaging with high-resolution computed tomography] Hansen M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Nov;165(5):499–501 (12 ref.) **(Ger)**

REHABILITATION

Pulmonary rehabilitation and surgery for end-stage lung disease. Kesten S. **Clin Chest Med** 1997 Jun;18(2):173–81 (55 ref.)

Selection criteria and programmes for pulmonary rehabilitation in COPD patients. Rehabilitation and Chronic Care Scientific Group of the European Respiratory Society. Donner CF, et al. **Eur Respir J** 1997 Mar;10(3):744–57 (97 ref.)

[Inpatient pneumologic rehabilitation of adults: goals—diagnostic and therapeutic standards—research needs] Bergmann KC, et al. **Pneumologie** 1997 May; 51(5):523–32 (87 ref.) **(Ger)**

[Indications and performance of a 6 minute treadmill test in pneumology] Kirsten D, et al. **Pneumologie** 1997 Jan; 51(1):33–5 (17 ref.) (Eng. Abstr.) **(Ger)**

[Control of training intensity in rehabilitation of chronic obstructive respiratory tract diseases] Müller C, et al.
Pneumologie 1997 May;51(5):519–22 (51 ref.) **(Ger)**

[New aspects in the treatment of bronchial asthma and chronic obstructive lung diseases] Wyser C, et al.
Schweiz Med Wochenschr 1997 May 24;127(21):885–90 (27 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Pulmonary rehabilitation and surgery for end-stage lung disease. Kesten S. **Clin Chest Med** 1997 Jun;18(2):173–81 (55 ref.)

Evaluation and preoperative management of lung volume reduction surgery candidates. Yusen RD, et al.
Clin Chest Med 1997 Jun;18(2):199–224 (154 ref.)

Lung volume reduction surgery in chronic obstructive pulmonary disease. Davies L, et al. **Thorax** 1996 Aug;51 Suppl 2:S29–34 (45 ref.)

THERAPY

Domiciliary oxygen therapy. Leach RM, et al.
Br J Hosp Med 1994 Jan 19–Feb 1;51(1–2):47–54 (33 ref.)

Mechanical ventilation in obstructive lung disease. Leatherman JW. **Clin Chest Med** 1996 Sep;17(3):577–90 (83 ref.)

Auto-positive end-expiratory pressure and dynamic hyperinflation. Ranieri VM, et al. **Clin Chest Med** 1996 Sep;17(3):379–94 (50 ref.)

Management of advanced chronic obstructive pulmonary disease. Cordova FC, et al. **Compr Ther** 1997 Jun; 23(6):413–24 (48 ref.)

Considerations for mechanical ventilation in patients with obstructive airways disease. Gal TJ.
Int Anesthesiol Clin 1997 Winter;35(1):125–37 (25 ref.)

Noninvasive mechanical ventilation in acute respiratory failure. Ambrosino N. **Monaldi Arch Chest Dis** 1996 Dec; 51(6):514–8 (34 ref.)

Noninvasive mechanical ventilation in acute on chronic

respiratory failure: determinants of success and failure. Ambrosino N. **Monaldi Arch Chest Dis** 1997 Feb;52(1):73–5 (26 ref.)

Noninvasive pressure support ventilation: physiological and clinical results in patients with COPD and acute respiratory failure. Brochard L. **Monaldi Arch Chest Dis** 1997 Feb; 52(1):64–7 (20 ref.)

Negative pressure ventilation in COPD patients with acute on chronic respiratory failure. Corrado A, et al. **Monaldi Arch Chest Dis** 1997 Feb;52(1):60–3 (44 ref.)

Physiological and clinical consequences of positive end-expiratory pressure. Ganassini A, et al. **Monaldi Arch Chest Dis** 1997 Feb;52(1):68–70 (17 ref.)

Lungs at home. Petty TL. **Monaldi Arch Chest Dis** 1996 Feb; 51(1):60–3 (20 ref.)

Long-term oxygen therapy: how can maximum benefit be achieved? Ström K. **Monaldi Arch Chest Dis** 1997 Jun; 52(3):249–52 (31 ref.)

Update in mechanical ventilation. Tobin MJ. **Monaldi Arch Chest Dis** 1996 Dec;51(6):510–3 (19 ref.)

Management 1997 of chronic obstructive pulmonary disease. Working Group of the Swiss Society of Pneumology. Leuenberger P, et al. **Schweiz Med Wochenschr** 1997 May 3;127(18):766–82 (29 ref.)

Non-invasive ventilation for exacerbations of respiratory failure in chronic obstructive pulmonary disease. Wedzicha JA. **Thorax** 1996 Aug;51 Suppl 2:S35–9 (25 ref.)

[Fundamentals of hospital treatment in exacerbations of chronic obstructive lung disease] Musil J, et al. **Vnitr Lek** 1996 Oct;42(10):717–23 (48 ref.) (Eng. Abstr.) **(Cze)**

[Concepts of noninvasive ventilation] Becker HF, et al. **Internist (Berl)** 1996 May;37(5):500–10 (82 ref.) **(Ger)**

[Non-invasive ventilation in acute respiratory insufficiency] Karg O, et al. **Pneumologie** 1996 Nov;50(11):759–63 (31 ref.) (Eng. Abstr.) **(Ger)**

[Positive end-expiratory pressure (PEEP) in respirator therapy of restrictive and obstructive lung diseases] Wagner TO, et al. **Pneumologie** 1996 Mar;50(3):225–30 (33 ref.) **(Ger)**

[Inhalation therapy in chronic obstructive bronchial diseases (see comments)] Barandun J. **Schweiz Med Wochenschr** 1996 Oct 5;126(40):1693–703 (46 ref.) (Eng. Abstr.) Comment in: Schweiz Med Wochenschr 1997 Mar 8;127(10):411. **(Ger)**

[Recommendations of the Polish Pthysiopneumonologic Society for diagnosis and treatment of chronic obstructive lung diseases] **Pneumonol Alergol Pol** 1997;65 Suppl 2:3–24 (0 ref.) **(Pol)**

VETERINARY

The pathogenesis of chronic obstructive pulmonary disease of horses. Robinson NE, et al. **Br Vet J** 1995 May; 152(3):283–306 (144 ref.)

LUNG DISEASES, PARASITIC

Pulmonary toxoplasmosis. Campagna AC. **Semin Respir Infect** 1997 Jun;12(2):98–105 (47 ref.)

Dirofilaria, visceral larva migrans, and tropical pulmonary eosinophilia. Chitkara RK, et al. **Semin Respir Infect** 1997 Jun;12(2):138–48 (78 ref.)

Pulmonary paragonimiasis. Kagawa FT. **Semin Respir Infect** 1997 Jun;12(2):149–58 (59 ref.)

Pulmonary disease in selected protozoal infections. Kemper CA. **Semin Respir Infect** 1997 Jun;12(2):113–21 (60 ref.)

Pleuropulmonary amebiasis. Lyche KD, et al. **Semin Respir Infect** 1997 Jun;12(2):106–12 (37 ref.)

Cardiopulmonary manifestations of schistosomiasis. Morris W, et al. **Semin Respir Infect** 1997 Jun;12(2):159–70 (89 ref.)

Ascariasis and hookworm. Sarinas PS, et al. **Semin Respir Infect** 1997 Jun;12(2):130–7 (45 ref.)

Pulmonary manifestations of strongyloidiasis. Wehner JH, et al. **Semin Respir Infect** 1997 Jun;12(2):122–9 (79 ref.)

EPIDEMIOLOGY

Human pulmonary dirofilariasis: a review. Rodrigues-Silva R, et al. **Rev Inst Med Trop Sao Paulo** 1995 Nov–Dec; 37(6):523–30 (112 ref.)

ETIOLOGY

[Pulmonary complications during HIV infection in children] Murgoci G, et al. **Pneumoftiziologia** 1997 Jan–Mar; 46(1):39–44 (12 ref.) **(Rum)**

PARASITOLOGY

Pulmonary dirofilariasis in man: a new Italian case. Review of the European literature. Pampiglione S, et al. **Parasite** 1994 Dec;1(4):379–85 (27 ref.)

TRANSMISSION

Pulmonary toxoplasmosis after allogeneic bone marrow transplantation: case report and review. Saad R, et al. **Bone Marrow Transplant** 1996 Jul;18(1):211–2 (10 ref.)

LUNG FUNCTION TESTS see **RESPIRATORY FUNCTION TESTS**

LUNG INJURY, ACUTE see **RESPIRATORY DISTRESS SYNDROME, ADULT**

LUNG LAVAGE see **BRONCHOALVEOLAR LAVAGE**

LUNG LAVAGE FLUID see **BRONCHOALVEOLAR LAVAGE FLUID**

LUNG NEOPLASMS

see related
CARCINOMA, NON-SMALL-CELL LUNG
CARCINOMA, SMALL CELL

Lymphangioleiomyomatosis: new insights [see comments] Kalassian KG, et al. **Am J Respir Crit Care Med** 1997 Apr; 155(4):1183–6 (34 ref.) Comment in: Am J Respir Crit Care Med 1997 Aug;156(2 Pt 1):670.

Giant carcinoid tumor of the lung. Sheppard BB, et al. **Ann Thorac Surg** 1997 Mar;63(3):851–2 (7 ref.)

Update on lung cancer. Pierce R, et al. **Aust Fam Physician** 1996 Feb;25(2):177–9, 181, 184–8 (8 ref.)

Science, medicine, and the future. Lung cancer. Sethi T. **BMJ** 1997 Mar 1;314(7081):652–5 (9 ref.)

Malignant fibrous histiocytoma of the lung. Report of four cases and review of the literature. Halyard MY, et al. **Cancer** 1996 Dec 15;78(12):2492–7 (33 ref.)

Approach to the patient with pulmonary disease. Vander Els NJ, et al. **Clin Chest Med** 1996 Dec;17(4):767–85 (119 ref.)

Pulmonary complications of HIV-associated malignancies. White DA. **Clin Chest Med** 1996 Dec;17(4):755–61 (72 ref.)

Lung cancer [editorial] Lillington GA, et al. **Curr Opin Pulm Med** 1997 Jul;3(4):243–6 (24 ref.)

Intrathoracic neoplasms other than bronchogenic carcinoma. Yoneda KY, et al. **Curr Opin Pulm Med** 1997 Jul; 3(4):257–64 (76 ref.)

Remodeling of cell surface glycoproteins by N-acetylglucosaminyltransferase III gene transfection: modulation of metastatic potentials and down regulation of hepatitis B virus replication. Taniguchi N, et al. **Glycobiology** 1996 Oct;6(7):691–4 (25 ref.)

Adjuvant therapy for stage I and II non-small cell lung cancer. Dorr VJ, et al. **Hematol Oncol Clin North Am** 1997 Apr;11(2):267–78 (39 ref.)

The multimodality treatment of stage III A/B non-small cell lung cancer. The role of surgery, radiation, and chemotherapy. Lee JD, et al. **Hematol Oncol Clin North Am** 1997 Apr;11(2):279–301 (59 ref.)

New approaches to the integrated management of early lung cancer. Mulshine JL, et al. **Hematol Oncol Clin North Am** 1997 Apr;11(2):235–52 (93 ref.)

Lymphangitis carcinomatosa: a literature review. Bruce DM, et al. **J R Coll Surg Edinb** 1996 Feb;41(1):7–13 (28 ref.)

Non-small cell lung cancer: clinical value of new biological predictors. Graziano SL. **Lung Cancer** 1997 Jun;17 Suppl 1:S37–58 (118 ref.)

Lung cancer. Sellars RE, et al. **Med J Aust** 1997 Jul 21; 167(2):99–104 (24 ref.)

Future research needs in the silica, silicosis and cancer field. Goldsmith DF, et al. **Scand J Work Environ Health** 1995; 21 Suppl 2:115–7 (32 ref.)

Non-small cell lung cancer: an overview of diagnosis, staging, and treatment. Harwood KV. **Semin Oncol Nurs** 1996 Nov;12(4):285–94 (62 ref.)

[Intestinal metastases of bronchopulmonary cancer. Apropos of a case] Kabwa L, et al. **J Chir (Paris)** 1996 Sep; 133(6):290–3 (14 ref.) (Eng. Abstr.) **(Fre)**

[From pseudolymphomas to primary pulmonary lymphomas of MALT type] Cadranel J, et al. **Presse Med** 1996 Sep 28;25(28):1285–91 (30 ref.) (Eng. Abstr.) **(Fre)**

[Lymphadenectomy in bronchial carcinoma: facts and fiction] Schildberg FW, et al. **Zentralbl Chir** 1996;121(2):96–101 (21 ref.) (Eng. Abstr.) **(Ger)**

[Lymphangioleiomyoma with retroperitoneal and thoracic involvement] Barron Medrano M, et al. **An Med Interna** 1996 Feb;13(2):75–8 (38 ref.) (Eng. Abstr.) **(Spa)**

BLOOD SUPPLY

Angiogenesis in primary lung cancer and lung secondaries. Pezzella F, et al. **Eur J Cancer** 1996 Dec;32A(14):2494–500 (34 ref.)

CEREBROSPINAL FLUID

Metastasizing extraneural tumors along the CSF pathway. Lee JY, et al. **Clin Neuropathol** 1997 May–Jun;16(3):117–21 (15 ref.)

CHEMICALLY INDUCED

The 1995 Pharmacological Society of Canada Merck Frosst Award. Cellular and molecular targets in pulmonary chemical carcinogenesis: studies with aflatoxin B1. Massey TE. **Can J Physiol Pharmacol** 1996 Jun;74(6):621–8 (58 ref.)

Dose response relationship between occupational PAH exposure and lung cancer—an overview. Bolm-Audorff U. **Cent Eur J Public Health** 1996;4 Suppl:40 (42 ref.)

Interactive effects of polycyclic aromatic hydrocarbons and iron oxides particles. Epidemiological and fundamental aspects. Haguenoer JM, et al. **Cent Eur J Public Health** 1996;4 Suppl:41–5 (42 ref.)

Environmental tobacco smoke and lung cancer: a reappraisal. Nilsson R. **Ecotoxicol Environ Saf** 1996 Jun;34(1):2–17 (115 ref.)

Polycyclic aromatic hydrocarbons and cancer in man. Mastrangelo G, et al. **Environ Health Perspect** 1996 Nov; 104(11):1166–70 (33 ref.)

Molecular epidemiology of lung and breast cancer. Ambrosone CB, et al. **Eur J Cancer Prev** 1996 Oct; 5(5):391–2 (6 ref.)

Methylene chloride induced mouse liver and lung tumours: an overview of the role of mechanistic studies in human safety assessment. Green T. **Hum Exp Toxicol** 1997 Jan; 16(1):3–13 (60 ref.)

Lung cancer rates in carbon-black workers are discordant with predictions from rat bioassay data. Valberg PA, et al. **Regul Toxicol Pharmacol** 1996 Oct;24(2 Pt 1):155–70 (67 ref.)

Analysis of diesel-exhaust unit-risk estimates derived from animal bioassays. Valberg PA, et al. **Regul Toxicol Pharmacol** 1996 Aug;24(1 Pt 1):30–44 (58 ref.)

Cancer risk assessment for crystalline silica to implement California's hot spots act. Collins JF, et al. **Scand J Work Environ Health** 1995;21 Suppl 2:99–103 (35 ref.)

Policy development for compensating workers exposed to crystalline silica in Ontario, Canada. Elinson L, et al. **Scand J Work Environ Health** 1995;21 Suppl 2:111–4 (14 ref.)

Comparative cancer potency for silica from extrapolations of human and animal findings. Goldsmith DF, et al. **Scand J Work Environ Health** 1995;21 Suppl 2:104–7 (27 ref.)

Carcinogenicity assessment of selected nickel compounds. Oller AR, et al. **Toxicol Appl Pharmacol** 1997 Mar; 143(1):152–66 (120 ref.)

Chemical mixtures in atmospheric aerosols and their correlation to lung diseases and lung cancer occurence in the general population. Spurny KR. **Toxicol Lett** 1996 Nov; 88(1–3):271–7 (34 ref.)

African-American smokers and cancers of the lung and of the upper respiratory and digestive tracts. Is menthol part of the puzzle? Richardson TL. **West J Med** 1997 Mar; 166(3):189–94 (44 ref.)

[Epidemiology of lung cancer in former poison-gas workers and molecular approaches to lung cancer] Yamakido M. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:8–12 (11 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Clinical detection of lung cancer progression markers. Tockman MS. **J Cell Biochem Suppl** 1996;25:177–84 (36 ref.)

Immunohistological detection of estrogen and progesterone receptors in multiple and well differentiated leiomyomatous lung tumors in women with uterine leiomyomas (so-called benign metastasizing leiomyomas). A report on 5 cases. Jautzke G, et al. **Pathol Res Pract** 1996 Mar;192(3):215–23 (77 ref.)

CLASSIFICATION

Staging classification committee. Ginsberg R, et al. **Lung Cancer** 1997 Jun;17 Suppl 1:S11–3 (0 ref.)

COMPLICATIONS

Paraneoplastic syndromes associated with small cell lung cancer. Marchioli CC, et al. **Chest Surg Clin N Am** 1997 Feb;7(1):65–80 (99 ref.)

Paraneoplastic subacute cutaneous lupus erythematosus: report of a case associated with cancer of the lung. Brenner S, et al. **Dermatology** 1997;194(2):172–4 (12 ref.)

Hypertrophic pulmonary osteoarthropathy in pulmonary metastasis—a case report. Aderaye G. **Ethiop Med J** 1996 Oct;34(4):251–4 (13 ref.)

The management of diabetes in patients with advanced cancer. Poulson J. **J Pain Symptom Manage** 1997 Jun; 13(6):339–46 (26 ref.)

Malignant tracheo-esophageal fistula: use of esophageal endoprosthesis. Spivak F, et al. **J Surg Oncol** 1996 Sep; 63(1):65–70 (36 ref.)

Lung cancer-induced blindness. Thirkill CE. **Lung Cancer** 1996 Jun;14(2–3):253–64 (79 ref.)

Recent implications of weight loss in lung cancer management. Chlebowski RT, et al. **Nutrition** 1996 Jan;12(1 Suppl):S43–7 (61 ref.)

Pulmonary capillary hemangiomatosis as a rare cause of pulmonary hypertension. Masur Y, et al. **Pathol Res Pract** 1996 Mar;192(3):290–5; discussion 296–9 (27 ref.)

Evaluation of crystalline silica as a threshold carcinogen. Klein AK, et al. **Scand J Work Environ Health** 1995;21 Suppl 2:95–8 (40 ref.)

Superior vena cava syndrome: an oncologic complication. Stewart IE. **Semin Oncol Nurs** 1996 Nov;12(4):312–7 (21 ref.)

Palliative treatment of malignant pericardial effusion: report of two cases and a review of the literature. Sharma A, et al. **Support Care Cancer** 1996 Jul;4(4):317–9 (17 ref.)

[Anorexia associated with bronchial cancer] Jeanfaivre T, et al. **Rev Mal Respir** 1997 Apr;14(2):113–7 (38 ref.) (Eng. Abstr.) **(Fre)**

[Actinomyces meyeri disseminated actinomycosis disclosing pulmonary carcinoma] Chaumentin G, et al. **Rev Med Interne** 1997 Jul;18(7):563–5 (15 ref.) (Eng. Abstr.) **(Fre)**

CONGENITAL

Congenital pulmonary myofibroblastic tumor: a case report with cytogenetic analysis and review of the literature. Alobeid B, et al. **Am J Surg Pathol** 1997 May;21(5):610–4 (16 ref.)

DIAGNOSIS

Comparison of the sensitivity of sputum and brush cytology in the diagnosis of lung carcinomas. Sing A, et al. **Acta Cytol** 1997 Mar–Apr;41(2):399–408 (67 ref.)

Sarcomatoid carcinomas of the lung: a clinicopathologic review. Wick MR, et al. **Am J Clin Pathol** 1997 Jul; 108(1):40–53 (116 ref.)

Screening for lung cancer. Parkin DM, et al. **Cancer Treat Res** 1996;86:121–8 (33 ref.)

Screening for lung cancer. Another look; a different view [see comments] Strauss GM, et al. **Chest** 1997 Mar; 111(3):754–68 (93 ref.) Comment in: Chest 1997 Mar;111(3):532–4.

Practical issues in the management of the patient with small cell lung cancer [published erratum appears in Chest Surg Clin N Am 1997 Aug;7(3):447] Govindan R, et al. **Chest Surg Clin N Am** 1997 Feb;7(1):167–81 (74 ref.)

Differential diagnosis of small cell neuroendocrine carcinoma of the lung. Warren WH, et al. **Chest Surg Clin N Am** 1997 Feb;7(1):49–63 (45 ref.)

Diagnostic tests for lung cancer. Edell ES. **Curr Opin Pulm Med** 1997 Jul;3(4):247–51 (24 ref.)

Appropriate diagnostic evaluation. Dresler CM. **Curr Probl Cancer** 1996 May–Jun;20(3):147–56 (21 ref.)

Recent molecular advances in the approach to early lung cancer detection and intervention. Mulshine JL, et al. **Environ Health Perspect** 1997 Jun;105 Suppl 4:935–9 (26 ref.)

Staging intrathoracic non–small–cell lung cancer. Hanson JA, et al. **Eur Radiol** 1997;7(2):161–72 (167 ref.)

Pulmonary perspective: immunology in diagnosis and treatment of lung cancer. Weynants P, et al. **Eur Respir J** 1997 Aug;10(8):1703–19 (212 ref.)

Mediastinoscopy, thoracoscopy, and video–assisted thoracic surgery in the diagnosis and staging of lung cancer. Mentzer SJ. **Hematol Oncol Clin North Am** 1997 Jun; 11(3):435–47 (21 ref.)

Prognostic markers in resectable non–small cell lung cancer. Strauss GM. **Hematol Oncol Clin North Am** 1997 Jun; 11(3):409–34 (88 ref.)

Cytogenetics revealing the diagnosis in a metastatic endometrial stromal sarcoma. Pauwels P, et al. **Histopathology** 1996 Jul;29(1):84–7 (10 ref.)

Magnetic resonance imaging of pulmonary apical tumors. Freundlich IM, et al. **J Thorac Imaging** 1996 Summer; 11(3):210–22 (11 ref.)

Small–cell carcinoma of the lung manifesting as acute hepatic failure [see comments] McGuire BM, et al. **Mayo Clin Proc** 1997 Feb;72(2):133–9 (43 ref.) Comment in: Mayo Clin Proc 1997 Aug;72(8):791.

The predictive value of spirometry. Identifying patients at risk for lung cancer in the primary care setting. Petty TL. **Postgrad Med** 1997 Mar;101(3):128–30, 133–4, 140 (14 ref.)

Imaging of lung cancer: old and new. Broderick LS, et al. **Semin Oncol** 1997 Aug;24(4):411–8 (53 ref.)

Pulmonary infections mimicking cancer: a retrospective, three–year review. Rolston KV, et al. **Support Care Cancer** 1997 Mar;5(2):90–3 (29 ref.)

A case of intrapulmonary teratoma presenting with hair expectoration. Ustün MO, et al. **Thorac Cardiovasc Surg** 1996 Oct;44(5):271–3 (9 ref.)

18F–fluorodeoxyglucose PET scans in lung cancer. Hughes JM. **Thorax** 1996 Aug;51 Suppl 2:S16–22 (34 ref.)

[Diagnostic invasive procedures in the diagnosis of primary lung cancer. Diagnostic value and complications (see comments)] Almind M, et al. **Ugeskr Laeger** 1996 Dec 30; 159(1):37–40 (40 ref.) (Eng. Abstr.) Comment in: Ugeskr Laeger 1997 May 19;159(21):3190–1. **(Dan)**

[Pneumoblastoma in children. A clinical case and review of the literature] Bongo S, et al. **Bull Cancer** 1996 Oct; 83(10):877–81 (33 ref.) (Eng. Abstr.) **(Fre)**

[Carcinoembryonic antigen] Blanchon F. **Rev Mal Respir** 1997 Apr;14 Suppl 3:S30–1 (6 ref.) **(Fre)**

[Value of tumor markers for screening and diagnosis (except prognostic and surveillance values) in primary bronchial cancers] Grivaux M. **Rev Mal Respir** 1997 Apr;14 Suppl 3:S15–9 (41 ref.) **(Fre)**

[Neuron specific enolase] Milleron B. **Rev Mal Respir** 1997 Apr;14 Suppl 3:S36–7 (12 ref.) **(Fre)**

[CYFRA 21–1] Pujol JL. **Rev Mal Respir** 1997 Apr;14 Suppl 3:S31–6 (32 ref.) **(Fre)**

[Value of serial tumor markers for the detection of recurrences] Quoix E. **Rev Mal Respir** 1997 Apr;14 Suppl 3:S27–9 (32 ref.) **(Fre)**

[Which tumor markers should be used in primary bronchial cancers?] Schuller MP, et al. **Rev Mal Respir** 1997 Apr; 14 Suppl 3:S9–14 (29 ref.) **(Fre)**

[Value of serial tumor markers for determining the prognosis and predicting treatment response and survival] Souquet PJ. **Rev Mal Respir** 1997 Apr;14 Suppl 3:S20–2 (23 ref.) **(Fre)**

[Bronchial carcinoma (lung cancer)] Häussinger K, et al. **Pneumologie** 1996 Sep;50 Suppl 2:599–603 (19 ref.) **(Ger)**

[Tumor–associated prognostic parameters in non–small–cell bronchial carcinoma] Thomas M. **Pneumologie** 1997 Jul; 51(7):669–77 (117 ref.) **(Ger)**

[Lung cancer: progress in diagnosis and treatment. IV. Related topics: 1. Telomere and telomerase, new targets for diagnosis and treatment of lung cancer] Hiyama K, et al. **Nippon Naika Gakkai Zasshi** 1997 Jan 10;86(1):95–9 (5 ref.) **(Jpn)**

[Lung cancer: Progress in diagnosis and treatment. II. Diagnostic imaging: 3. Thoracic CT and MRI] Kusumoto M, et al. **Nippon Naika Gakkai Zasshi** 1997 Jan 10; 86(1):51–7 (7 ref.) **(Jpn)**

[Lung cancer: progress in diagnosis and treatment. I. Diagnosis and physiopathology: 4. Progress in the study of tumor markers] Kuwabara M, et al. **Nippon Naika Gakkai Zasshi** 1997 Jan 10;86(1):20–6 (12 ref.) **(Jpn)**

[Pulmonary complications in hematological diseases] Ichinose Y. **Rinsho Ketsueki** 1997 Mar;38(3):172–6 (5 ref.) **(Jpn)**

[Current capabilities and procedures for diagnosing lung neoplasms] Ochmański W. **Przegl Lek** 1997;54(2):126–34 (56 ref.) (Eng. Abstr.) **(Pol)**

[Difficult for diagnosis forms of lung cancer in therapeutic practice] Orlov LL, et al. **Klin Med (Mosk)** 1997;75(1):50–2 (23 ref.) **(Rus)**

[Diagnostic and prognostic significance of oncogenes in pulmonary carcinoma] Andelić G, et al. **Vojnosanit Pregl** 1996 Sep–Oct;53(5):393–7 (44 ref.) **(Scr)**

DRUG THERAPY

Chemotherapy in the treatment of non–small cell lung cancer. Hainsworth JD. **Am Fam Physician** 1997 May 1; 55(6):2265–72 (31 ref.)

Chemotherapy in non–small cell lung cancer: a review. Tan EH, et al. **Ann Acad Med Singapore** 1996 Jul;25(4):570–83 (125 ref.)

Dose–intensive therapy in lung cancer. Elias A. **Cancer Chemother Pharmacol** 1997;40 Suppl:S64–9 (78 ref.)

Importance of dose and dose intensity in the treatment of small–cell lung cancer. Murray N. **Cancer Chemother Pharmacol** 1997;40 Suppl:S58–63 (18 ref.)

Chemotherapy for small–cell lung cancer: more is not better. Saka H, et al. **Cancer Chemother Pharmacol** 1997;40 Suppl:S107–9 (21 ref.)

The role of chemotherapy in the treatment of small cell lung cancer. Shepherd FA. **Chest Surg Clin N Am** 1997 Feb; 7(1):113–33 (82 ref.)

Preoperative chemotherapy for stage IIIA non–small cell lung cancer [see comments] Rosell R, et al. **Curr Opin Oncol** 1997 Mar;9(2):149–55 (48 ref.) Comment in: Curr Opin Oncol 1997 Mar;9(2):147–8.

Locally advanced non–small cell lung cancer: the "local" issue. Movsas B. **Curr Probl Cancer** 1996 May–Jun; 20(3):197–212 (57 ref.)

Gemcitabine. A review of its pharmacology and clinical potential in non–small cell lung cancer and pancreatic cancer. Noble S, et al. **Drugs** 1997 Sep;54(3):447–72 (119 ref.)

Non–small cell lung cancer: an overview of current management. Dancey J, et al. **Eur J Cancer** 1997 Jan;33 Suppl 1:S2–7 (88 ref.)

Combination therapy with gemcitabine in non–small cell lung cancer. Mosconi AM, et al. **Eur J Cancer** 1997 Jan;33 Suppl 1:S14–7 (20 ref.)

Improving quality of life in patients with non–small cell lung cancer: research experience with gemcitabine. Thatcher N, et al. **Eur J Cancer** 1997 Jan;33 Suppl 1:S8–13 (33 ref.)

Hormonal treatment in advanced non–small cell lung cancer: fact or fiction? Vansteenkiste JF, et al. **Eur Respir J** 1996 Aug;9(8):1707–12 (48 ref.)

Preclinical studies on the broad–spectrum neuropeptide growth factor antagonist G. Jones DA, et al. **Gen Pharmacol** 1997 Feb;28(2):183–9 (22 ref.)

Optimizing chemotherapy and radiotherapy in locally advanced non–small cell lung cancer. Arriagada R. **Hematol Oncol Clin North Am** 1997 Jun;11(3):461–72 (37 ref.)

Chemotherapy for advanced non–small cell lung cancer. Herbst RS, et al. **Hematol Oncol Clin North Am** 1997 Jun; 11(3):473–517 (204 ref.)

Evaluation of in vitro chemosensitivity using human lung cancer cell lines. Kratzke RA, et al. **J Cell Biochem Suppl** 1996;24:160–4 (31 ref.)

Photodynamic therapy in lung cancer. A review. Sutedja TG, et al. **J Photochem Photobiol B** 1996 Nov; 36(2):199–204 (63 ref.)

Residual masses after chemotherapy for metastatic testicular cancer: the clinical implications of the association between retroperitoneal and pulmonary histology. Re–analysis of Histology in Testicular Cancer (ReHiT) Study Group. Steyerberg EW, et al. **J Urol** 1997 Aug;158(2):474–8 (23 ref.)

Intensity of neoadjuvant therapy in resectable non–small cell lung cancer. Green MR, et al. **Lung Cancer** 1997 Jun;17 Suppl 1:S111–9 (14 ref.)

Treatment of small cell lung cancer: the state of the art. Murray N. **Lung Cancer** 1997 Jun;17 Suppl 1:S75–89 (42 ref.)

Subacute encephalopathic toxicity of cisplatin. Verschraegen C, et al. **Lung Cancer** 1995 Dec;13(3):305–9 (13 ref.)

Chemotherapy of non–small cell lung cancer. Scagliotti GV, et al. **Monaldi Arch Chest Dis** 1997 Jun;52(3):287–95 (75 ref.)

Chemotherapy helps patients with advanced non–small cell carcinoma of the lung. Socinski MA, et al. **N C Med J** 1996 Sep–Oct;57(5):281–6 (30 ref.)

Integration of vinorelbine into chemotherapy strategies for non–small–cell lung cancer. Vokes EE. **Oncology (Huntingt)** 1995 Jun;9(6):565–74, 577; discussion 577–8, 581– (106 ref.)

Chemotherapy for advanced lung cancer. When to expect a response. Midthun DE, et al. **Postgrad Med** 1997 Mar; 101(3):187–8, 191–2, 194 passim (20 ref.)

The Fox Chase Cancer Center and Free University Hospital Investigators' Workshop and Consensus Conference on Paclitaxel. Part 1: Lung Cancer. Puerto Rico, March 12–16, 1997. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12–1–S12–162; quiz S12–163–S12–173 (0 ref.)

Defining the role of paclitaxel in lung cancer: summary of recent studies and implications for future directions. Bunn PA Jr. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12–153–S12–162 (63 ref.)

The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer. Bunn PA Jr. **Semin Oncol** 1996 Dec;23(6 Suppl 16):18–25 (34 ref.)

Combination paclitaxel and platinum in the treatment of lung cancer: US experience. Bunn PA Jr. **Semin Oncol** 1996 Dec;23(6 Suppl 15):9–15 (29 ref.)

Overview of chemotherapy for small cell lung cancer. Bunn PA Jr, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 7):S7–69–S7–74 (44 ref.)

Chemotherapy in the management of patients with inoperable non–small cell lung cancer. Carney DN. **Semin Oncol** 1996 Dec;23(6 Suppl 16):71–5 (59 ref.)

Economic value of gemcitabine in non–small cell lung cancer. Copley–Merriman C, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 10):90–8 (15 ref.)

Management strategies for recurrent non–small cell lung cancer. Fossella FV, et al. **Semin Oncol** 1997 Aug; 24(4):455–62 (54 ref.)

Efficacy of single–agent gemcitabine in advanced non–small cell lung cancer: a review. Hansen HH, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 7):S7–38–S7–41 (15 ref.)

Small cell lung cancer in the elderly patient. Johnson DH. **Semin Oncol** 1997 Aug;24(4):484–91 (65 ref.)

Single–agent activity of gemcitabine in advanced non–small cell lung cancer. Le Chevalier T. **Semin Oncol** 1996 Oct; 23(5 Suppl 10):36–42 (23 ref.)

Overview of current and future chemotherapeutic agents in non–small cell lung cancer. Natale RB. **Semin Oncol** 1997 Apr;24(2 Suppl 7):S7–29–S7–37 (59 ref.)

Chemotherapy for advanced non–small cell lung cancer: past, present, and future. Ramanathan RK, et al. **Semin Oncol** 1997 Aug;24(4):440–54 (132 ref.)

Preoperative paclitaxel plus carboplatin for patients with intermediate–risk non–small cell lung cancer. Ruckdeschel JC. **Semin Oncol** 1996 Dec;23(6 Suppl 16):62–7 (65 ref.)

High–dose therapy with carboplatin and paclitaxel in non–small cell lung cancer. Socinski MA, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12–45–S12–51 (51 ref.)

Gemcitabine: symptomatic benefit in advanced non–small cell lung cancer. Thatcher N, et al. **Semin Oncol** 1997 Jun;24(3 Suppl 8):S8–6–S8–12 (37 ref.)

Simultaneous paclitaxel and radiotherapy: initial clinical experience in lung cancer and other malignancies. Vogt HG, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12–101–S12–105 (15 ref.)

Investigations of new drugs in combination with cisplatin in stage III non–small cell lung cancer. Vokes EE, et al. **Semin Oncol** 1997 Jun;24(3 Suppl 8):S8–42–S8–45 (24 ref.)

The role of chemotherapy in the treatment of non–small cell carcinoma of the lung. Treat J, et al. **Semin Thorac Cardiovasc Surg** 1997 Jan;9(1):90–100 (43 ref.)

[Induction chemotherapy followed by concomitant combined radiotherapy and chemotherapy in stage III non–small cell bronchial carcinoma] Bouillet T, et al. **Cancer Radiother** 1997;1(2):121–31 (39 ref.) (Eng. Abstr.) **(Fre)**

[Chemotherapy of non–small–cell lung cancers] Le Chevalier T. **Presse Med** 1996 Nov 16;25(35):1699–703 (16 ref.) (Eng. Abstr.) **(Fre)**

[Small–cell lung cancer: chemotherapy strategy] Lebeau B. **Presse Med** 1996 Nov 16;25(35):1705–8 (31 ref.) (Eng. Abstr.) **(Fre)**

[New wave of chemotherapeutic agents: update in pulmonary oncology] Sculier JP. **Rev Mal Respir** 1997 Apr;14(2):154–6 (24 ref.) **(Fre)**

[Chemotherapy in elderly patients with bronchogenic cancers] Souquet PJ, et al. **Rev Mal Respir** 1996; 13(4):327–33 (55 ref.) (Eng. Abstr.) **(Fre)**

[Taxol in bronchial carcinoma] Gatzemeier U. **Med Klin** 1996 Dec 15;91 Suppl 2:1–6 (41 ref.) **(Ger)**

[Clinical use of platinum compounds and fluorinated pyrimidines for lung cancer] Kobayashi K. **Gan To Kagaku Ryoho** 1996 Nov;23(13):1747–56 (51 ref.) (Eng. Abstr.) **(Jpn)**

[Fundamental studies on the surgical adjuvant chemotherapy to support the clinical efficacies] Tsukagoshi S.

Gan To Kagaku Ryoho 1997 Aug;24(10):1213–20 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Etoposide in the treatment of small-cell lung cancer] Ueoka H. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1920–4 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Photodynamic therapy for bronchogenic carcinoma] Kato H, et al. **Nippon Geka Gakkai Zasshi** 1997 Jan;98(1):36–40 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Chemotherapy in non-small cell lung cancer] Shimokata K. **Nippon Geka Gakkai Zasshi** 1997 Jan;98(1):41–5 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Chemotherapy for non-small cell lung cancer] Shinkai T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:92–8 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Chemotherapy for small-cell lung cancer] Ueoka H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:87–91 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Lung cancer: Progress in diagnosis and treatment. III. Treatment and prognosis: 2. Progress in chemotherapy and improvement in prognosis] Kawahara M. **Nippon Naika Gakkai Zasshi** 1997 Jan 10;86(1):73–8 (16 ref.) **(Jpn)**

[Case of malignant pheochromocytoma with successful control of systemic metastasis with CVD chemotherapy] Minami T, et al. **Nippon Naika Gakkai Zasshi** 1996 Dec 10;85(12):2078–80 (10 ref.) **(Jpn)**

[Effects, possibilities and limits. Cytostatic therapy of small cell and non-small cell lung cancer] Bergman B. **Lakartidningen** 1997 Apr 30;94(18):1702, 1707–10 (17 ref.) **(Swe)**

ECONOMICS

Economic considerations in the care of lung cancer patients. Desch CE, et al. **Curr Opin Oncol** 1996 Mar;8(2):126–32 (39 ref.)

EPIDEMIOLOGY

Lung cancer and asbestos exposure: asbestosis is not necessary. Egilman D, et al. **Am J Ind Med** 1996 Oct; 30(4):398–406 (55 ref.)

Epidemiology of lung cancer. Buiatti E, et al. **Ann Ist Super Sanita** 1996;32(1):133–44 (73 ref.)

Nutrition and lung cancer. Ziegler RG, et al. **Cancer Causes Control** 1996 Jan;7(1):157–77 (161 ref.)

The molecular epidemiology of lung cancer. Spivack SD, et al. **Crit Rev Toxicol** 1997 Jul;27(4):319–65 (315 ref.)

Molecular epidemiology of lung and breast cancer. Ambrosone CB, et al. **Eur J Cancer Prev** 1996 Oct; 5(5):391–2 (6 ref.)

The epidemiology of lung cancer: review of risk factors and Spanish data. Takkouche B, et al. **Eur J Epidemiol** 1996 Aug;12(4):341–9 (99 ref.)

The epidemiology of mesothelioma in historical context. McDonald JC, et al. **Eur Respir J** 1996 Sep;9(9):1932–42 (85 ref.)

Lung cancer due to diesel soot particles in ambient air? A critical appraisal of epidemiological studies addressing this question [see comments] Stöber W, et al. **Int Arch Occup Environ Health** 1996;68 Suppl:S3–61 (292 ref.) Comment in: Int Arch Occup Environ Health 1996;68 Suppl:S1–2.

Diet and lung cancer 20+ years later: more questions than answers? Koo LC. **Int J Cancer** 1997;Suppl 10:22–9 (82 ref.)

The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Charloux A, et al. **Int J Epidemiol** 1997 Feb;26(1):14–23 (100 ref.)

Evidence for silica's neoplastic risk among workers and derivation of cancer risk assessment. Goldsmith DF. **J Expo Anal Environ Epidemiol** 1997 Jul–Sep;7(3):291–301 (46 ref.)

Aspects of the epidemiology of lung cancer in smokers and nonsmokers in the United States. Kabat GC. **Lung Cancer** 1996 Aug;15(1):1–20 (55 ref.)

Occupational and geographical factors in the epidemiology of malignant mesothelioma. Ross D, et al. **Monaldi Arch Chest Dis** 1995 Dec;50(6):459–63 (47 ref.)

Tea and cancer prevention: an evaluation of the epidemiologic literature. Kohlmeier L, et al. **Nutr Cancer** 1997;27(1):1–13 (30 ref.)

The changing cigarette. Hoffmann D, et al. **Prev Med** 1997 Jul–Aug;26(4):427–34 (57 ref.)

Mortality from tobacco in developed countries: are indirect estimates reliable? Lee PN. **Regul Toxicol Pharmacol** 1996 Aug;24(1 Pt 1):60–8 (25 ref.)

Lung cancer rates in carbon-black workers are discordant with predictions from rat bioassay data. Valberg PA, et al. **Regul Toxicol Pharmacol** 1996 Oct;24(2 Pt 1):155–70 (67 ref.)

Asbestos, asbestosis, pleural plaques and lung cancer. Hillerdal G, et al. **Scand J Work Environ Health** 1997 Apr; 23(2):93–103 (153 ref.)

Epidemiology of lung cancer: a worldwide epidemic. Valanis BG. **Semin Oncol Nurs** 1996 Nov;12(4):251–9 (51 ref.)

Carcinoma of the lung after heart transplantation. Goldstein DJ, et al. **Transplantation** 1996 Sep 27;62(6):772–5 (18 ref.)

[Environmental and occupational diseases] Baur X, et al. **Pneumologie** 1996 Sep;50 Suppl 2:604–6 (15 ref.) **(Ger)**

[Epidemiology of health problems caused by passive smoking] Schwarz B, et al. **Wien Klin Wochenschr** 1996; 108(18):565–9 (48 ref.) (Eng. Abstr.) **(Ger)**

[Molecular epidemiology and prevention of bronchopulmonary carcinoma] De Flora S. **Chir Ital** 1995; 47(3):1–12 (49 ref.) (Eng. Abstr.) **(Ita)**

[Epidemiology of lung cancer and prevention strategy in Japan] Sobue T. **Nippon Eiseigaku Zasshi** 1996 Oct; 51(3):641–7 (44 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Chrysotile asbestos is the main cause of pleural mesothelioma. Smith AH, et al. **Am J Ind Med** 1996 Sep;30(3):252–66 (113 ref.)

Basic science of small cell lung cancer. Williams CL. **Chest Surg Clin N Am** 1997 Feb;7(1):1–19 (140 ref.)

Radon and cancer. Bochicchio F. **Eur J Cancer Prev** 1996 Oct;5(5):383–4 (12 ref.)

Lung cancer and chronic obstructive pulmonary disease. Petty TL. **Hematol Oncol Clin North Am** 1997 Jun; 11(3):531–41 (19 ref.)

Consensus report. International Agency for Research on Cancer. Mechanisms of fibre carcinogenesis. **IARC Sci Publ** 1996;(140):1–9 (2 ref.)

Diet and lung cancer 20+ years later: more questions than answers? Koo LC. **Int J Cancer** 1997;Suppl 10:22–9 (82 ref.)

Laboratory studies on silica induced toxicity and relationship to carcinogenicity. Rabovsky J. **J Expo Anal Environ Epidemiol** 1997 Jul–Sep;7(3):267–78 (51 ref.)

The p53 tumour suppressor gene: a model for molecular epidemiology of human cancer. Soussi T. **Mol Med Today** 1996 Jan;2(1):32–7 (43 ref.)

Beta-carotene increases lung cancer incidence in cigarette smokers. De Luca LM, et al. **Nutr Rev** 1996 Jun; 54(6):178–80 (17 ref.)

Pleural mesothelioma and household asbestos exposure. Schneider J, et al. **Rev Environ Health** 1996 Jan–Jun; 11(1–2):65–70 (68 ref.)

Prevention of lung cancer: the key is to stop smoking. Risser NL. **Semin Oncol Nurs** 1996 Nov;12(4):260–9 (69 ref.)

Biology of lung cancer. Works CR, et al. **Semin Oncol Nurs** 1996 Nov;12(4):276–84 (90 ref.)

Asbestos exposure, asbestosis, and asbestos-attributable lung cancer [see comments] Jones RN, et al. **Thorax** 1996 Aug; 51 Suppl 2:S9–15 (41 ref.) Comment in: Thorax 1997 Mar;52(3):306.

[Passive smoking and lung cancer: a new report in perspective (see comments)] van Barneveld TA, et al. **Ned Tijdschr Geneeskd** 1997 Jan 18;141(3):132–6 (38 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1997 Mar 8;141(10):493–4. **(Dut)**

[Passive smoking and carcinogenic risk to the lung] Trédaniel J. **Bull Acad Natl Med** 1997 Apr;181(4):736–42 (18 ref.) **(Fre)**

[Pulmonary problems related to aging] Weber T, et al. **Rev Med Liege** 1997 Apr;52(4):245–50 (13 ref.) **(Fre)**

[Passive smoking, a risk factor for lung carcinoma?] Jahn O. **Wien Klin Wochenschr** 1996;108(18):570–3 (16 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Polygenic inheritance of predisposition to lung cancer. Dragani TA, et al. **Ann Ist Super Sanita** 1996;32(1):145–50 (59 ref.)

Neuroendocrine tumors of the lung. Pathology and molecular biology. Vuitch F, et al. **Chest Surg Clin N Am** 1997 Feb; 7(1):21–47 (79 ref.)

Resistance mechanisms and their regulation in lung cancer. Volm M, et al. **Crit Rev Oncog** 1996;7(3–4):227–44 (175 ref.)

Molecular events in lung carcinogenesis. Miller YE, et al. **Hematol Oncol Clin North Am** 1997 Apr;11(2):215–34 (92 ref.)

Application of molecular epidemiology to lung cancer chemoprevention. Mooney LA, et al. **J Cell Biochem Suppl** 1996;25:63–8 (33 ref.)

Regulation of nuclear oncogenes expressed in lung cancer cell lines. Sabichi AL, et al. **J Cell Biochem Suppl** 1996; 24:218–27 (31 ref.)

Retinoic acid receptor expression abnormalities in lung cancer: important clues or major obstacles? [editorial; comment] Minna JD, et al. **J Natl Cancer Inst** 1997 May 7;89(9):602–4 (42 ref.) Comment on: J Natl Cancer Inst 1997 May 7;89(9):624–9.

Molecular pathology of neoplastic lung diseases. Przygodzki RM. **Pathology (Phila)** 1996;4(1):169–89 (152 ref.)

Molecular biomarkers of occupational lung cancer. Talaska G, et al. **Yonsei Med J** 1996 Feb;37(1):1–18 (61 ref.)

[Progress in oncogenes and anti-cancer genes in lung cancer] Guo X, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Oct; 18(5):267–9 (21 ref.) **(Chi)**

[Topographic genomapping of p53 mutations in non-small cell lung cancer using in situ PCR] Ebina M, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(4):406–11 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular approach to lung cancer] Takahashi T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Dec;33 Suppl:29–32 (25 ref.) (Eng. Abstr.) **(Jpn)**

[Prospective views for molecular oncology of the lung] Ebina M, et al. **Nippon Rinsho** 1996 Feb;54(2):299–303 (24 ref.) (Eng. Abstr.) **(Jpn)**

[A detection for replication error (RER) and LOH by microsatellite analysis in human lung cancer] Hadama T, et al. **Nippon Rinsho** 1996 Feb;54(2):487–91 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Positional-cloning efforts to identify the tumor suppressor gene at 3p] Hibi K, et al. **Nippon Rinsho** 1996 Feb; 54(2):478–81 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Search for the tumor-suppressor gene(s) on chromosome 5q, which may play an important role for the progression of lung cancer] Hosoe S. **Nippon Rinsho** 1996 Feb; 54(2):482–6 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Deletion map of human chromosome 11 in lung cancers] Iizuka M, et al. **Nippon Rinsho** 1996 Feb;54(2):472–7 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Altered genomic imprinting in the IGF2 and H19 genes in human lung cancer] Kondo M, et al. **Nippon Rinsho** 1996 Feb;54(2):492–6 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Cholecystokinin-B/gastrin receptor is a novel molecular probe for human small cell lung cancer] Matsumori Y, et al. **Nippon Rinsho** 1996 Feb;54(2):507–12 (14 ref.) (Eng. Abstr.) **(Jpn)**

[p16/CDKN2/MTS1 gene abnormality in lung cancer] Ohno A. **Nippon Rinsho** 1996 Feb;54(2):503–6 (21 ref.) (Eng. Abstr.) **(Jpn)**

[p53 gene mutations in the human lung carcinoma] Saito M, et al. **Nippon Rinsho** 1996 Feb;54(2):497–502 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to lung cancer—relevance to smoking] Uematsu F. **Nippon Rinsho** 1996 Feb;54(2):513–7 (27 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Immune mechanisms and tumor dormancy. Stewart TH. **Medicina (B Aires)** 1996;56 Suppl 1:74–82 (37 ref.)

[Immunologic reactions in the course of lung cancer] Szopiński J. **Pneumonol Alergol Pol** 1997;65(5–6):391–8 (35 ref.) **(Pol)**

METABOLISM

Resistance mechanisms and their regulation in lung cancer. Volm M, et al. **Crit Rev Oncog** 1996;7(3–4):227–44 (175 ref.)

Prognostic markers in resectable non-small cell lung cancer. Strauss GM. **Hematol Oncol Clin North Am** 1997 Jun; 11(3):409–34 (88 ref.)

Involvement of signal transduction pathways in lung cancer biology. Viallet J, et al. **J Cell Biochem Suppl** 1996; 24:228–36 (53 ref.)

Regulation of VIP gene expression in general. Human lung cancer cells in particular. Davidson A, et al. **J Mol Neurosci** 1996 Summer;7(2):99–110 (77 ref.)

Retinoic acid receptor expression abnormalities in lung cancer: important clues or major obstacles? [editorial; comment] Minna JD, et al. **J Natl Cancer Inst** 1997 May 7;89(9):602–4 (42 ref.) Comment on: J Natl Cancer Inst 1997 May 7;89(9):624–9.

Alpha-fetoprotein-producing adenocarcinoma of the lung. Yoshino I, et al. **Lung Cancer** 1996 Aug;15(1):125–30 (16 ref.)

Peptides and growth factors in non-small cell lung cancer. Moody TW. **Peptides** 1996;17(3):545–55 (151 ref.)

[Neurophysins and small-cell pulmonary cancer] Pirard F, et al. **Rev Med Liege** 1997;52(1):22–6 (24 ref.) **(Fre)**

[Double primary lung cancers producing alpha-fetoprotein] Bessho T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Dec;44(12):2216–20 (11 ref.) (Eng. Abstr.) **(Jpn)**

MORTALITY

Timing of radiotherapy in asymptomatic patients with inoperable non-small cell lung cancer: a survival analysis and literature review. Ampil FL, et al. **Radiat Med** 1996 Jul–Aug;14(4):211–4 (19 ref.)

[Evaluation of survival and prognostic factors of 2,000 broncho-pulmonary cancers registered during 10 years in a multidisciplinary oncology department] Moro D, et al. **Bull Cancer** 1997 Feb;84(2):155–61 (37 ref.) (Eng. Abstr.) **(Fre)**

[Molecular biological prognostic markers in lung cancer] Abe S. **Nippon Geka Gakkai Zasshi** 1997 Jan;98(1):2–7 (35 ref.) (Eng. Abstr.) **(Jpn)**

[Prediction of lung cancer deaths and the role of lung cancer screening in Japan] Sobue T. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Dec;33 Suppl:8–12 (29 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Spontaneous retroperitoneal hemorrhage due to adrenal metastasis for non-small cell lung cancer treated by radiation therapy. Berney CR, et al. **Acta Oncol** 1997; 36(1):91–3 (25 ref.)

Metastatic pattern at autopsy in non-resectable adenocarcinoma of the lung—a study from a cohort of 259 consecutive patients treated with chemotherapy. Stenbygaard LE, et al. **Acta Oncol** 1997;36(3):301–6 (27 ref.)

Alveolar type II cells at the crossroad of inflammation, fibrogenesis, and neoplasia [comment] Saffiotti U. **Am J Pathol** 1996 Nov;149(5):1423–6 (29 ref.) Comment

on: Am J Pathol 1996 Nov;149(5):1627–38.
Congenital pulmonary myofibroblastic tumor: a case report with cytogenetic analysis and review of the literature. Alobeid B, et al. **Am J Surg Pathol** 1997 May;21(5):610–4 (16 ref.)
Primary pulmonary meningioma: report of a case and review of the literature. Lockett L, et al. **Am J Surg Pathol** 1997 Apr;21(4):453–60 (24 ref.)
Primary pulmonary meningioma. Report of a case and review of the literature. Kaleem Z, et al. **Arch Pathol Lab Med** 1997 Jun;121(6):631–6 (40 ref.)
Cytodifferentiation of a Wilms' tumor pulmonary metastasis: theoretic and clinical implications. Seemayer TA, et al. **Cancer** 1997 Apr 15;79(8):1629–34 (20 ref.)
IIB or not IIB: the current question in staging non-small cell lung cancer. Detterbeck FC, et al. **Chest** 1997 Jul; 112(1):229–34 (40 ref.)
Staging of the patient with small cell lung cancer. Darling GE. **Chest Surg Clin N Am** 1997 Feb;7(1):81–94 (54 ref.)
Is there a place for surgery in central small cell lung cancer? Kohman LJ. **Chest Surg Clin N Am** 1997 Feb;7(1):105–12 (36 ref.)
Prophylactic cranial irradiation for patients with small cell lung cancer. An enduring controversy. Wagner H Jr. **Chest Surg Clin N Am** 1997 Feb;7(1):151–66 (53 ref.)
Pathology of lung cancer. Leslie KO, et al. **Curr Opin Pulm Med** 1997 Jul;3(4):252–6 (32 ref.)
Fine-needle aspiration cytology of pleuropulmonary blastoma: case report and review of the literature. Gelven PL, et al. **Diagn Cytopathol** 1997 Apr;16(4):336–40 (29 ref.)
Inflammatory and neoplastic processes of the lung: differential diagnosis and pitfalls in FNA biopsies. Silverman JF. **Diagn Cytopathol** 1995 Dec;13(5):448–62 (93 ref.)
Aggressive osteoblastoma with focal malignant transformation and development of pulmonary metastases. A case report with a review of literature. Kunze E, et al. **Gen Diagn Pathol** 1996 May;141(5–6):377–92 (41 ref.)
Mediastinoscopy, thoracoscopy, and video-assisted thoracic surgery in the diagnosis and staging of lung cancer. Mentzer SJ. **Hematol Oncol Clin North Am** 1997 Jun; 11(3):435–47 (21 ref.)
Epithelial-myoepithelial carcinoma of the lung: immunohistochemical and ultrastructural observations and review of the literature. Wilson RW, et al. **Hum Pathol** 1997 May;28(5):631–5 (32 ref.)
Basaloid-squamous carcinoma. A distinct histopathological entity. Singh ZN, et al. **Indian J Cancer** 1996 Jun; 33(2):86–91 (19 ref.)
Clinical features of skin metastasis from lung cancer. Hidaka T, et al. **Intern Med** 1996 Jun;35(6):459–62 (13 ref.)
Spectrum of neuroendocrine differentiation in lung cancer cell lines featured by cytomorphology, markers, and their corresponding tumors. Linnoila RI. **J Cell Biochem Suppl** 1996;24:92–106 (66 ref.)
Cell culture methods for the establishment of the NCI series of lung cancer cell lines. Oie HK, et al. **J Cell Biochem Suppl** 1996;24:24–31 (22 ref.)
New air-fluid levels in bullous lung disease: a reevaluation. Richardson MS, et al. **J Natl Med Assoc** 1996 Mar; 88(3):185–7 (19 ref.)
Pretreatment minimal staging and prognostic factors for non-small cell lung cancer. Feld R, et al. **Lung Cancer** 1997 Jun;17 Suppl 1:S3–10 (34 ref.)
The current role of invasive staging in lung cancer. Van Schil P, et al. **Monaldi Arch Chest Dis** 1997 Jun;52(3):237–41 (22 ref.)
Role of thoracoscopic lymph node staging for lung and esophageal cancer. Krasna MJ. **Oncology (Huntingt)** 1996 Jun;10(6):793–802; discussion 804, 813–4 (31 ref.)
Small cell carcinoma of lung simulating pleural mesothelioma. Report of 4 cases with autopsy confirmation. Falconieri G, et al. **Pathol Res Pract** 1995 Nov; 191(11):1147–52 (17 ref.)
Pulmonary capillary hemangiomatosis as a rare cause of pulmonary hypertension. Masur Y, et al. **Pathol Res Pract** 1996 Mar;192(3):290–5; discussion 296–9 (27 ref.)
Advances in the pathologic staging of lung cancer: detection of regional and systemic occult metastases. Chaiwun B, et al. **Pathology (Phila)** 1996;4(1):155–68 (50 ref.)
Low-grade B-cell lymphomas of lung and lymphomatoid granulomatosis. Koss M, et al. **Pathology (Phila)** 1996; 4(1):125–39 (48 ref.)
Neuroendocrine tumors of the lung. Marchevsky AM. **Pathology (Phila)** 1996;4(1):103–23 (59 ref.)
Immunopathology of malignant mesothelioma. Sheibani K, et al. **Pathology (Phila)** 1996;4(1):191–212 (89 ref.)
Prophylactic cranial irradiation in small cell lung cancer: rationale, results, and recommendations. Glantz MJ, et al. **Semin Oncol** 1997 Aug;24(4):477–83 (76 ref.)
Pulmonary nodule caused by an alveolar adenoma of the lung. Böhm J, et al. **Virchows Arch** 1997 Feb;430(2):181–4 (9 ref.)
Pulmonary and thymic carcinoid tumors. Dusmet ME, et al. **World J Surg** 1996 Feb;20(2):189–95 (59 ref.)
[Primary pulmonary lymphoma] Cadranel J, et al. **Rev Mal Respir** 1997 Apr;14(2):73–92 (122 ref.) (Eng. Abstr.) **(Fre)**
[Cell cycle clock and its dysregulation in bronchopulmonary cancers] Brechot JM. **Rev Pneumol Clin** 1997;53(1):7–11 (23 ref.) (Eng. Abstr.) **(Fre)**
[Flow cytometry for extensive thoracic diagnosis] Bernhardt K. **Acta Med Austriaca** 1997;24(1):5–7 (24 ref.) (Eng. Abstr.) **(Ger)**
[Carcinoma-in-carcinoma metastasis. In situ DNA quantification and immunohistochemical diagnosis] Sperb RA, et al. **Pathologe** 1996 Sep;17(5):385–90 (39 ref.) (Eng. Abstr.) **(Ger)**
[Lymphoepithelioma-like lung carcinomas] Wöckel W, et al. **Pathologe** 1997 Mar;18(2):147–52 (15 ref.) (Eng. Abstr.) **(Ger)**
[Prognostic factors in stage I of non-small-cell bronchial carcinoma] Passlick B, et al. **Zentralbl Chir** 1996; 121(10):851–7; discussion 858–60 (62 ref.) (Eng. Abstr.) **(Ger)**
[Lymphadenectomy in bronchial carcinoma: facts and fiction] Schildberg FW, et al. **Zentralbl Chir** 1996;121(2):96–101 (21 ref.) (Eng. Abstr.) **(Ger)**
[Muscle metastasis in a patient with epidermoid carcinoma of the lung] Romano L, et al. **Radiol Med (Torino)** 1997 Mar;93(3):294–5 (11 ref.) **(Ita)**
[gamma-Glutamylcysteine synthetase and chemosensitivity] Nishio K, et al. **Gan To Kagaku Ryoho** 1997 Feb; 24(4):418–23 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Novel metastasis model of human lung cancer cells representing different histological types in SCID mice depleted of NK cells] Yano S, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(4):489–94 (8 ref.) (Eng. Abstr.) **(Jpn)**
[Metastatic tumor to the penis from lung and pancreas cancer: report of two cases] Danno S, et al. **Hinyokika Kiyo** 1997 Jan;43(1):61–3 (11 ref.) (Eng. Abstr.) **(Jpn)**
[A case of malignant hemangioendothelioma of the lung with rapid growth of pulmonary metastasis] Tatsuta M, et al. **Kyobu Geka** 1997 Apr;50(4):321–4 (5 ref.) (Eng. Abstr.) **(Jpn)**
[Primary carcinosarcoma of TE lung—a report of two cases] Matsukawa M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jul;44(7):970–7 (24 ref.) (Eng. Abstr.) **(Jpn)**
[A case of multiple pulmonary leiomyomatous hamartoma] Ohno K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 May;44(5):723–8 (27 ref.) (Eng. Abstr.) **(Jpn)**
[Lung cancer: Progress in diagnosis and treatment. I. Diagnosis and physiopathology: 5. Pathology—pathological classification and the origin of adenocarcinoma] Okamura A, et al. **Nippon Naika Gakkai Zasshi** 1997 Jan 10;86(1):27–32 (5 ref.) **(Jpn)**
[Effects of biochemical modulation chemotherapy with CDDP and 5-FU on metastatic brain tumor from lung cancer] Nakagawa H, et al. **No Shinkei Geka** 1997 Mar; 25(3):215–23 (39 ref.) (Eng. Abstr.) **(Jpn)**
[Bladder metastasis of lung adenocarcinoma] Martín-Marquina Aspiunza A, et al. **Actas Urol Esp** 1997 Apr;21(4):406–8 (6 ref.) (Eng. Abstr.) **(Spa)**
[Localized fibrous tumor in the parenchyma. Report of 2 cases, one of them multiple and bilateral] Vázquez-Pelillo JC, et al. **Arch Bronconeumol** 1996 Jan;32(1):43–6 (41 ref.) (Eng. Abstr.) **(Spa)**
[In spite of the long way to reach optimal treatment and prevention. Increased knowledge of lung cancer biology] Bergh J. **Lakartidningen** 1997 Apr 16;94(16):1489–92 (40 ref.) **(Swe)**

PHYSIOPATHOLOGY

Advances in the understanding of lung cancer. Groeger AM, et al. **Anticancer Res** 1997 Jul-Aug;17(4A):2519–22 (57 ref.)
Unilateral facial pain and lung cancer. Shakespeare TP, et al. **Australas Radiol** 1996 Feb;40(1):45–6 (14 ref.)
Remodeling of cell surface glycoproteins by N-acetylglucosaminyltransferase III gene transfection: modulation of metastatic potentials and down regulation of hepatitis B virus replication. Taniguchi N, et al. **Glycobiology** 1996 Oct;6(7):691–4 (25 ref.)
The biology of lung cancer. Carbone DP. **Semin Oncol** 1997 Aug;24(4):388–401 (181 ref.)
[Lung cancer: progress in diagnosis and treatment. I. Diagnosis and physiopathology: 1. Clinical conditions and physical findings of lung cancer] Kunikane H, et al. **Nippon Naika Gakkai Zasshi** 1997 Jan 10;86(1):4–9 (5 ref.) **(Jpn)**

PREVENTION & CONTROL

Chemoprevention of lung cancer by isothiocyanates. Hecht SS. **Adv Exp Med Biol** 1996;401:1–11 (34 ref.)
Approaches to chemoprevention of lung cancer based on carcinogens in tobacco smoke. Hecht SS. **Environ Health Perspect** 1997 Jun;105 Suppl 4:955–63 (87 ref.)
Roles of retinoids and their nuclear receptors in the development and prevention of upper aerodigestive tract cancers. Lotan R. **Environ Health Perspect** 1997 Jun;105 Suppl 4:985–8 (52 ref.)
Chemoprevention of respiratory tract cancer. Khuri FR, et al. **Hematol Oncol Clin North Am** 1997 Jun;11(3):387–408 (72 ref.)
Role of cesarean section in prevention of recurrent respiratory papillomatosis—is there one? Kosko JR, et al. **Int J Pediatr Otorhinolaryngol** 1996 Mar;35(1):31–8 (26 ref.)
Carcinogen-DNA and protein adducts: biomarkers for cohort selection and modifiable endpoints in chemoprevention trials. Kensler TW, et al. **J Cell Biochem Suppl** 1996;25:85–91 (30 ref.)
Tea and cancer prevention: an evaluation of the epidemiologic literature. Kohlmeier L, et al. **Nutr Cancer** 1997;27(1):1–13 (30 ref.)
Beta carotene and cancer: risk or protection? [editorial] Vainio H. **Scand J Work Environ Health** 1996 Jun; 22(3):161–3 (15 ref.)
Lung cancer chemoprevention and management of carcinoma in situ. Karp DD. **Semin Oncol** 1997 Aug; 24(4):402–10 (76 ref.)
Prevention of lung cancer: the key is to stop smoking. Risser NL. **Semin Oncol Nurs** 1996 Nov;12(4):260–9 (69 ref.)
[The strategic use of genetic polymorphisms in carcinogen metabolizing enzyme for prevention of cancer] Ikawa S. **Gan To Kagaku Ryoho** 1997 Feb;24(4):454–9 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Epidemiology of lung cancer and prevention strategy in Japan] Sobue T. **Nippon Eiseigaku Zasshi** 1996 Oct; 51(3):641–7 (44 ref.) (Eng. Abstr.) **(Jpn)**
[Prediction of lung cancer deaths and the role of lung cancer screening in Japan] Sobue T. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Dec;33 Suppl:8–12 (29 ref.) (Eng. Abstr.) **(Jpn)**
[Detection of early cancer by lung cancer screening] Saito Y, et al. **Nippon Rinsho** 1996 May;54(5):1410–4 (13 ref.) (Eng. Abstr.) **(Jpn)**

PSYCHOLOGY

Quality of life assessment in chemotherapy trials for non-small cell lung cancer: are theory and practice significantly different? Hopwood P. **Semin Oncol** 1996 Oct; 23(5 Suppl 10):60–4 (24 ref.)
Psychosocial issues and lung cancer: a behavioral approach. Ryan LS. **Semin Oncol Nurs** 1996 Nov;12(4):318–23 (80 ref.)

RADIOGRAPHY

Imaging of pulmonary lymphomas. Lee KS, et al. **AJR Am J Roentgenol** 1997 Feb;168(2):339–45 (44 ref.)
Lung cancer staging: the role of computed tomography and magnetic resonance imaging. Bonomo L, et al. **Eur J Radiol** 1996 Aug;23(1):35–45 (48 ref.)
Lung metastases. Herold CJ, et al. **Eur Radiol** 1996; 6(5):596–606 (72 ref.)
Imaging and medical staging of lung cancer. Shaffer K. **Hematol Oncol Clin North Am** 1997 Apr;11(2):197–213 (47 ref.)
Factors affecting the radiologic appearance of peripheral bronchogenic carcinomas. Sone S, et al. **J Thorac Imaging** 1997 Jul;12(3):159–72 (41 ref.)
The radiologic appearance of lung cancer. O'Donovan PB. **Oncology (Huntingt)** 1997 Sep;11(9):1387–402; discussion 1402–4 (47 ref.)
Management of solitary pulmonary nodules. How to decide when resection is required. Lillington GA. **Postgrad Med** 1997 Mar;101(3):145–50 (10 ref.)
[Unilateral peripheral pulmonary nodules: initial symptoms of a limited form of Wegener's disease] Dechambre S, et al. **J Belge Radiol** 1996 Aug;79(4):162–4 (9 ref.) (Eng. Abstr.) **(Fre)**
[AIDS-associated illnesses in radiologic diagnosis: overview and differential diagnosis] Rademaker J, et al. **Aktuelle Radiol** 1997 Mar;7(2):69–73 (30 ref.) **(Ger)**
[Phenomenology of pulmonary HRCT. Definitions, differential diagnosis and clinical relevance] Roos N, et al. **Radiologe** 1996 Jul;36(7):521–33 (46 ref.) (Eng. Abstr.) **(Ger)**
[Spiral computed tomography in the diagnosis and staging of bronchopulmonary carcinoma] Cittadini G Jr, et al. **Chir Ital** 1995;47(3):13–7 (24 ref.) (Eng. Abstr.) **(Ita)**
[Lung cancer: Progress in diagnosis and treatment. II. Diagnostic imaging: 1. Basis of interpretation of plain thoracic X-ray photographs] Ikezoe J. **Nippon Naika Gakkai Zasshi** 1997 Jan 10;86(1):33–8 (4 ref.) **(Jpn)**
[Lung cancer: Progress in diagnosis and treatment. II. Diagnostic imaging: 2. Plain thoracic X-ray photographs—differential diagnosis and pit falls] Niimi H, et al. **Nippon Naika Gakkai Zasshi** 1997 Jan 10;86(1):39–50 (5 ref.) **(Jpn)**
[Contrast enhanced CT] Kohno A, et al. **Nippon Rinsho** 1996 May;54(5):1249–54 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Clinical application of helical CT and thin slice CT] Moriyama N. **Nippon Rinsho** 1996 May;54(5):1241–8 (4 ref.) (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE IMAGING

[Lung cancer: Progress in diagnosis and treatment. II. Diagnostic imaging: 4. Radioisotope diagnosis of lung cancer] Imai T, et al. **Nippon Naika Gakkai Zasshi** 1997 Jan 10;86(1):58–64 (7 ref.) **(Jpn)**
[Diagnosis of early cancer with positron emission tomography] Kubota K. **Nippon Rinsho** 1996 May; 54(5):1263–7 (12 ref.) (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY

Spontaneous retroperitoneal hemorrhage due to adrenal metastasis for non-small cell lung cancer treated by radiation therapy. Berney CR, et al. **Acta Oncol** 1997;

36(1):91–3 (25 ref.)
The role of palliative thoracic radiotherapy in non-small cell lung cancer. Brundage MD, et al. **Can J Oncol** 1996 Feb; 6 Suppl 1:25–32 (24 ref.)
Dose-intensive therapy in lung cancer. Elias A. **Cancer Chemother Pharmacol** 1997;40 Suppl:S64–9 (78 ref.)
Role of radiotherapy in the treatment of small cell lung carcinoma. Williams TE, et al. **Chest Surg Clin N Am** 1997 Feb;7(1):135–49 (59 ref.)
Locally advanced non-small cell lung cancer: the "local" issue. Movsas B. **Curr Probl Cancer** 1996 May–Jun; 20(3):197–212 (57 ref.)
Optimizing chemotherapy and radiotherapy in locally advanced non-small cell lung cancer. Arriagada R. **Hematol Oncol Clin North Am** 1997 Jun;11(3):461–72 (37 ref.)
Palliative radiation therapy for non-small cell lung cancer. Baldini EH. **Hematol Oncol Clin North Am** 1997 Apr; 11(2):303–19 (63 ref.)
Radiation biology of lung cancer. Sullivan FJ, et al. **J Cell Biochem Suppl** 1996;24:152–9 (68 ref.)
Thoracic irradiation of limited small cell lung cancer: have we defined optimal dose, time, and fractionation? Wagner H Jr. **Lung Cancer** 1997 Jun;17 Suppl 1:S137–48 (28 ref.)
The role of brachytherapy in the treatment and control of central bronchial carcinoma. Macha HN, et al. **Monaldi Arch Chest Dis** 1996 Aug;51(4):325–8 (23 ref.)
Timing of radiotherapy in asymptomatic patients with inoperable non-small cell lung cancer: a survival analysis and literature review. Ampil FL, et al. **Radiat Med** 1996 Jul–Aug;14(4):211–4 (19 ref.)
Simultaneous paclitaxel and radiotherapy: initial clinical experience in lung cancer and other malignancies. Vogt HG, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12-101–S12–105 (15 ref.)
Radiation therapy for lung cancer. Hilderley LJ. **Semin Oncol Nurs** 1996 Nov;12(4):304–11 (31 ref.)
The role of radiation therapy in the management of non-small cell lung cancer. Machtay M, et al. **Semin Thorac Cardiovasc Surg** 1997 Jan;9(1):80–9 (40 ref.)
[Postoperative radiotherapy in non-small cell lung cancer. Apropos of a series of 374 cases] Baillet F, et al. **Cancer Radiother** 1997;1(2):137–42 (23 ref.) (Eng. Abstr.) **(Fre)**
[Discussion on the role of radiotherapy in non-small cell lung cancer apropos of 137 non-metastatic cases] Dessard-Diana B, et al. **Cancer Radiother** 1997;1(2):154–8 (10 ref.) (Eng. Abstr.) **(Fre)**
[Radiotherapy in locoregional treatment of inoperable non-small cell lung cancer: results from a series of 381 patients] Durdux C, et al. **Cancer Radiother** 1997;1(2):132–6 (19 ref.) (Eng. Abstr.) **(Fre)**
[Adjuvant whole-brain irradiation in small-cell bronchial carcinoma] Kiricuta IC, et al. **Strahlenther Onkol** 1996 Oct; 172(10):553–8 (33 ref.) (Eng. Abstr.) **(Ger)**
[Heavy ion radiotherapy for lung cancer] Miyamoto T, et al. **Nippon Geka Gakkai Zasshi** 1997 Jan;98(1):60–7 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Radiotherapy for non-small cell lung cancer] Sumi M, et al. **Nippon Geka Gakkai Zasshi** 1997 Jan;98(1):53–9 (39 ref.) (Eng. Abstr.) **(Jpn)**
[Recent advances in radiation therapy for non-small cell lung cancer] Morita K. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:103–6 (8 ref.) (Eng. Abstr.) **(Jpn)**
[Lung cancer: progress in diagnosis and treatment. III. Treatment and prognosis: 3. Radiotherapy] Miyamoto T. **Nippon Naika Gakkai Zasshi** 1997 Jan 10;86(1):79–87 (10 ref.) **(Jpn)**
[Is timing important in adjuvant radiotherapy?] Ramón Baeza M. **Rev Med Chil** 1996 Jul;124(7):859–64 (16 ref.) (Eng. Abstr.) **(Spa)**
[Radiotherapy of lung cancer. Optimized radiotherapy improves survival] Brodin O. **Lakartidningen** 1997 May 14; 94(20):1881–6 (25 ref.) **(Swe)**

SECONDARY

Spontaneous regression of metastatic renal cancer. Case report and literature review. Lokich J. **Am J Clin Oncol** 1997 Aug;20(4):416–8 (34 ref.)
Metastasizing placental site trophoblastic tumor: immunohistochemical and DNA analysis. 2 case reports and a review of the literature. Remadi S, et al. **Arch Gynecol Obstet** 1997;259(2):97–103 (24 ref.)
Cytodifferentiation of a Wilms' tumor pulmonary metastasis: theoretic and clinical implications. Seemayer TA, et al. **Cancer** 1997 Apr 15;79(8):1629–34 (20 ref.)
Intrathoracic neoplasms other than bronchogenic carcinoma. Yoneda KY, et al. **Curr Opin Pulm Med** 1997 Jul; 3(4):257–64 (76 ref.)
Treatment of the patient with lung metastases. Roth JA, et al. **Curr Probl Surg** 1996 Nov;33(11):881–952 (326 ref.)
Poorly-differentiated adenoid cystic carcinoma: cytologic appearance in fine-needle aspirates of distant metastases. Yu GH, et al. **Diagn Cytopathol** 1996 Nov;15(4):296–300 (27 ref.)
Hypertrophic pulmonary osteoarthropathy in pulmonary metastasis--a case report. Aderaye G. **Ethiop Med J** 1996 Oct;34(4):251–4 (13 ref.)
Surgical resection of pulmonary metastases from colorectal carcinoma. Five-year survival and main prognostic factors. Baron O, et al. **Eur J Cardiothorac Surg** 1996;10(5):347–51 (28 ref.)
Remission of recurrent cervical cancer with paclitaxel and carboplatin: a case report and review of literature. Termrungruanglert W, et al. **Eur J Gynaecol Oncol** 1996; 17(6):493–6 (21 ref.)
Lung metastases. Herold CJ, et al. **Eur Radiol** 1996; 6(5):596–606 (72 ref.)
Spontaneous metastasizing squamous cell carcinoma of the oesophagus in a Sprague Dawley rat. Deschl U, et al. **Exp Toxicol Pathol** 1997 Feb;49(1–2):123–7 (10 ref.)
Aggressive osteoblastoma with focal malignant transformation and development of pulmonary metastases. A case report with a review of literature. Kunze E, et al. **Gen Diagn Pathol** 1996 May;141(5–6):377–92 (41 ref.)
The approach to the patient with single and multiple liver metastases, pulmonary metastases, and intra-abdominal metastases from colorectal carcinoma. VanderMeer TJ, et al. **Hematol Oncol Clin North Am** 1997 Aug;11(4):759–77 (78 ref.)
Cytogenetics revealing the diagnosis in a metastatic endometrial stromal sarcoma. Pauwels P, et al. **Histopathology** 1996 Jul;29(1):84–7 (10 ref.)
Residual masses after chemotherapy for metastatic testicular cancer: the clinical implications of the association between retroperitoneal and pulmonary histology. Re-analysis of Histology in Testicular Cancer (ReHiT) Study Group. Steyerberg EW, et al. **J Urol** 1997 Aug;158(2):474–8 (23 ref.)
Metastases from metastatis: a careful examination [see comments] Langenfeld J, et al. **N J Med** 1996 May; 93(5):37–40 (18 ref.) Comment in: N J Med 1996 Jul;93(7):10.
Regression of uterine low-grade smooth-muscle tumors metastatic to the lung after oophorectomy. Abu-Rustum NR, et al. **Obstet Gynecol** 1997 May;89(5 Pt 2):850–2 (13 ref.)
Surgical management of lung metastases: selection factors and results. Dresler CM, et al. **Oncology (Huntingt)** 1996 May;10(5):649–55; discussion 655–6, 659 (52 ref.)
Immunohistological detection of estrogen and progesterone receptors in multiple and well differentiated leiomyomatous lung tumors in women with uterine leiomyomas (so-called benign metastasizing leiomyomas). A report on 5 cases. Jautzke G, et al. **Pathol Res Pract** 1996 Mar;192(3):215–23 (77 ref.)
Management of pulmonary metastases from colorectal cancer. Vigneswaran WT. **Semin Surg Oncol** 1996 Jul–Aug; 12(4):264–6 (19 ref.)
Lung metastasectomy for colorectal cancer. Pastorino U. **Tumori** 1997 Jan–Feb;83(1 Suppl):S28–30 (09 ref.)
[Malignant granular cell tumor. Report of a clinico-pathologic case] Rochaix P, et al. **Ann Pathol** 1996 Sep;16(4):292–5 (32 ref.) (Eng. Abstr.) **(Fre)**
[Repeat interventions in metastases] Seifert JK, et al. **Chirurg** 1997 Mar;68(3):247–54 (37 ref.) (Eng. Abstr.) **(Ger)**
[Surgical treatment of pulmonary metastasis from breast carcinoma. Personal contribution and considerations on the experience in the literature] Morone G, et al. **Ann Ital Chir** 1996 Nov–Dec;67(6):833–5; discussion 835–6 (23 ref.) (Eng. Abstr.) **(Ita)**
[Extraosseus osteogenic sarcoma: report of a case with atypical secondary involvement of the lung] Pezzullo L, et al. **Radiol Med (Torino)** 1997 Mar;93(3):296–8 (16 ref.) **(Ita)**
[Pulmonary metastasis from breast cancer: a case report with 19-year disease-free interval] Kamiyoshihara M, et al. **Kyobu Geka** 1997 Mar;50(3):194–6 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Case of malignant pheochromocytoma with successful control of systemic metastasis with CVD chemotherapy] Minami T, et al. **Nippon Naika Gakkai Zasshi** 1996 Dec 10;85(12):2078–80 (10 ref.) **(Jpn)**

SECRETION

Clubbing, arthralgia and haemoptysis in a patient with metastatic carcinoma of the breast [letter] Gregory RK, et al. **Ann Oncol** 1996 Sep;7(7):756–7 (4 ref.)
Pathophysiology and clinical aspects of the ectopic GH-releasing hormone syndrome. Losa M, et al. **Clin Endocrinol (Oxf)** 1997 Aug;47(2):123–35 (93 ref.)

SURGERY

The present status of surgery for lung cancer. Lacquet LK. **Acta Chir Belg** 1996 Nov–Dec;96(6):245–51 (15 ref.)
Metastasectomy for soft tissue sarcomas. Pastorino U. **Cancer Treat Res** 1997;91:65–75 (32 ref.)
Is there a place for surgery in central small cell lung cancer? Kohman LJ. **Chest Surg Clin N Am** 1997 Feb;7(1):105–12 (36 ref.)
Surgical treatment of peripheral small cell lung cancer. Urschel JD. **Chest Surg Clin N Am** 1997 Feb;7(1):95–103 (47 ref.)
Preoperative chemotherapy for stage IIIA non-small cell lung cancer [see comments] Rosell R, et al. **Curr Opin Oncol** 1997 Mar;9(2):149–55 (48 ref.) Comment in: Curr Opin Oncol 1997 Mar;9(2):147–8.
Surgical approaches in special situations. Goldberg M. **Curr Probl Cancer** 1996 May–Jun;20(3):179–96 (96 ref.)
Preoperative and postoperative care of standard and high risk surgical patients. Reilly JJ Jr. **Hematol Oncol Clin North Am** 1997 Jun;11(3):449–59 (42 ref.)
Is there a role for surgery in small-cell lung cancer? Urschel JD, et al. **J R Soc Med** 1997 Jul;90(7):387–90 (53 ref.)
Surgery for small cell lung cancer. Deslauriers J. **Lung Cancer** 1997 Jun;17 Suppl 1:S91–8 (39 ref.)
The limits of surgical resection alone for non-small cell lung cancer. Johnston MR. **Lung Cancer** 1997 Jun;17 Suppl 1:S99–102 (11 ref.)
Recent advances in lung cancer surgery in Europe. Motta G. **Lung Cancer** 1996 Dec;16(1):1–11 (27 ref.)
Regression of uterine low-grade smooth-muscle tumors metastatic to the lung after oophorectomy. Abu-Rustum NR, et al. **Obstet Gynecol** 1997 May;89(5 Pt 2):850–2 (13 ref.)
Surgical management of lung metastases: selection factors and results. Dresler CM, et al. **Oncology (Huntingt)** 1996 May;10(5):649–55; discussion 655–6, 659 (52 ref.)
Curable lung cancer. How to find it and treat it. Johnston MR. **Postgrad Med** 1997 Mar;101(3):155–6, 159–65 (13 ref.)
Management of solitary pulmonary nodules. How to decide when resection is required. Lillington GA. **Postgrad Med** 1997 Mar;101(3):145–50 (10 ref.)
Second lung cancers in patients successfully treated for lung cancer. Johnson BE, et al. **Semin Oncol** 1997 Aug; 24(4):492–9 (47 ref.)
Carinal resection for bronchogenic cancer. Dartevelle P, et al. **Semin Thorac Cardiovasc Surg** 1996 Oct;8(4):414–25 (28 ref.)
The role of surgery in the multimodality management of non-small cell lung cancer. Kaiser LR, et al. **Semin Thorac Cardiovasc Surg** 1997 Jan;9(1):60–79 (79 ref.)
Lung metastasectomy for colorectal cancer. Pastorino U. **Tumori** 1997 Jan–Feb;83(1 Suppl):S28–30 (09 ref.)
[Principles and results of systematic lymph node dissection in surgically treated bronchial carcinoma] Schirren J, et al. **Chirurg** 1996 Sep;67(9):869–76 (35 ref.) (Eng. Abstr.) **(Ger)**
[Tumor embolism with fatal cerebral infarct in pneumonectomy. Case report and review of the literature] Zürcher M, et al. **Chirurg** 1996 Sep;67(9):959–62 (37 ref.) (Eng. Abstr.) **(Ger)**
[Radical surgery and lymph node dissection in bronchial carcinoma] Schirren J, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:790–7 (8 ref.) (Eng. Abstr.) **(Ger)**
[Central bronchoplastic procedures in Hungary and their outcome (198–1993)] Hrivó A, et al. **Orv Hetil** 1996 Nov 17;137(46):2559–63 (32 ref.) (Eng. Abstr.) **(Hun)**
[Surgical treatment of pulmonary metastasis from breast carcinoma. Personal contribution and considerations on the experience in the literature] Morone G, et al. **Ann Ital Chir** 1996 Nov–Dec;67(6):833–5; discussion 835–6 (23 ref.) (Eng. Abstr.) **(Ita)**
[Carcinoma of the lung involving the thoracic wall] Sartori F, et al. **Chir Ital** 1995;47(3):24–6 (12 ref.) (Eng. Abstr.) **(Ita)**
[Video-assisted thoracic surgery for lung cancer] Shirakusa T, et al. **Gan To Kagaku Ryoho** 1997 Mar;24(5):520–4 (7 ref.) (Eng. Abstr.) **(Jpn)**
[The combined resection of left atrium for advanced lung cancer on cardiopulmonary bypass: a case report] Kugai T, et al. **Kyobu Geka** 1996 Aug;49(9):738–41 (41 ref.) (Eng. Abstr.) **(Jpn)**
[Complete Pleuropneumonectomy] Morita T, et al. **Kyobu Geka** 1996 Jul;49(8 Suppl):697–705 (90 ref.) **(Jpn)**
[A case of malignant lung fibrous histiocytoma] Sato K, et al. **Kyobu Geka** 1996 Dec;49(13):1115–8 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Extended resection for lung cancer] Tsuchiya R. **Nippon Geka Gakkai Zasshi** 1997 Jan;98(1):26–30 (18 ref.) (Eng. Abstr.) **(Jpn)**
[Video-assisted thoracoscopic surgery for a 89-year-old patient with primary lung cancer—report of a case] Kamiyoshihara M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):628–31 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Surgical treatment for small cell lung cancer] Ichinose Y. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:99–102 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Thoracoscopic surgery] Inui K, et al. **Nippon Rinsho** 1996 May;54(5):1322–5 (17 ref.) (Eng. Abstr.) **(Jpn)**
[The surgical treatment of poorly differentiated lung cancer] Shnitko SN. **Vestn Khir Im I I Grek** 1996;(1):105–7 (41 ref.) **(Rus)**
[Surgical resection of lung cancer. Supplemented with radiotherapy and chemotherapy may improve the therapeutic results] Hambraeus GM. **Lakartidningen** 1997 Apr 16;94(16):1493–7 (21 ref.) **(Swe)**

THERAPY

Recent advances in the treatment of non-small cell lung cancer. Goss GD, et al. **Anticancer Drugs** 1996 Jun; 7(4):363–85 (226 ref.)
Treatment principles in advanced non-small-cell lung cancer. Scott CL, et al. **Aust N Z J Surg** 1996 Oct; 66(10):688–93 (44 ref.)
Pulmonary blastoma: a review with special emphasis on prognosis and treatment. Larsen H, et al. **Cancer Treat Rev** 1996 May;22(3):145–60 (120 ref.)
Gene therapy for lung cancer and mesothelioma. Albelda SM. **Chest** 1997 Jun;111(6 Suppl):144S–149S (48 ref.)

Practical issues in the management of the patient with small cell lung cancer [published erratum appears in Chest Surg Clin N Am 1997 Aug;7(3):447] Govindan R, et al. **Chest Surg Clin N Am** 1997 Feb;7(1):167–81 (74 ref.)

Future directions in the therapy of small cell lung cancer. Perry MC. **Chest Surg Clin N Am** 1997 Feb;7(1):183–94 (56 ref.)

Treatment of non-small-cell lung cancer. Hadeed VA, et al. **Compr Ther** 1996 Oct;22(10):641–8 (33 ref.)

Economic considerations in the care of lung cancer patients. Desch CE, et al. **Curr Opin Oncol** 1996 Mar;8(2):126–32 (39 ref.)

Preoperative chemotherapy for stage IIIa non-small cell lung cancer. Fossella FV, et al. **Curr Opin Oncol** 1996 Mar; 8(2):106–11 (41 ref.)

Lung and mediastinum [editorial; comment] Ruckdeschel JC. **Curr Opin Oncol** 1997 Mar;9(2):147–8 (20 ref.) Comment on: Curr Opin Oncol 1997 Mar;9(2):149–55. Comment on: Curr Opin Oncol 1997 Mar;9(2):156–60. Comment on: Curr Opin Oncol 1997 Mar;9(2):161–9. Comment on: Curr Opin Oncol 1997 Mar;9(2):170–4.

Stage-directed treatment guidelines. Langer C, et al. **Curr Probl Cancer** 1996 May–Jun;20(3):157–78 (99 ref.)

Newer aspects in the diagnosis, treatment, and prevention of non-small cell lung cancer. Part II. Langer CJ, et al. **Curr Probl Cancer** 1996 Jul–Aug;20(4):217–79 (380 ref.)

Pulmonary perspective: immunology in diagnosis and treatment of lung cancer. Weynants P, et al. **Eur Respir J** 1997 Aug;10(8):1703–19 (212 ref.)

Future directions in lung cancer research and therapeutics. Elias AD. **Hematol Oncol Clin North Am** 1997 Jun; 11(3):519–27 (8 ref.)

The approach to the patient with single and multiple liver metastases, pulmonary metastases, and intra-abdominal metastases from colorectal carcinoma. VanderMeer TJ, et al. **Hematol Oncol Clin North Am** 1997 Aug;11(4):759–77 (78 ref.)

Therapeutic options for regionally advanced non-small cell lung cancer. Buccheri G, et al. **Lung Cancer** 1996 Jun; 14(2–3):281–300 (85 ref.)

Small cell lung cancer. Ihde D, et al. **Lung Cancer** 1997 Jun; 17 Suppl 1:S19–21 (0 ref.)

Post-operative adjuvant therapy for non-small-cell lung cancer. Johnson D, et al. **Lung Cancer** 1997 Jun;17 Suppl 1:S23–5 (0 ref.)

Adjuvant chemotherapy for non-small cell lung cancer. Johnson DH. **Lung Cancer** 1997 Jun;17 Suppl 1:S103–10 (36 ref.)

Concurrent treatments and induction treatments for unresectable tumors. Klastersky J, et al. **Lung Cancer** 1997 Jun;17 Suppl 1:S27–8 (0 ref.)

Induction treatment for resectable non-small-cell lung cancer. Perry MC, et al. **Lung Cancer** 1997 Jun;17 Suppl 1:S15–8 (0 ref.)

Alternatives to chemotherapy and radiotherapy as adjuvant treatment for lung cancer. Shepherd FA. **Lung Cancer** 1997 Jun;17 Suppl 1:S121–36 (45 ref.)

Recent implications of weight loss in lung cancer management. Chlebowski RT, et al. **Nutrition** 1996 Jan;12(1 Suppl):S43–7 (61 ref.)

Lung cancer: review of the ECOG experience. Eastern Cooperative Oncology Group. Schiller JH, et al. **Oncology** 1997 Sep–Oct;54(5):353–62 (71 ref.)

Management of carcinoma of the superior pulmonary sulcus. Johnson DE, et al. **Oncology (Huntingt)** 1997 Jun; 11(6):781–5; discussion 785–6 (27 ref.)

Systemic investigational therapies as adjuvants to surgery in patients with operable lung cancer. Bunn PA Jr, et al. **Semin Oncol** 1997 Jun;24(3 Suppl 8):S8–46–S8–52 (68 ref.)

Overview of the randomized phase III trials in non-small cell lung cancer in North America. Kelly K. **Semin Oncol** 1997 Jun;24(3 Suppl 8):S8–2–S8–5 (10 ref.)

Combined modality therapy of non-small cell lung cancer. Ruckdeschel JC. **Semin Oncol** 1997 Aug;24(4):429–39 (110 ref.)

Current management of small cell lung cancer. Sandler AB. **Semin Oncol** 1997 Aug;24(4):463–76 (71 ref.)

Introduction to the treatment of lung cancer. Splinter TA. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12–1–S12–5 (44 ref.)

Treatment of small cell lung cancer. Blanke CD, et al. **Semin Thorac Cardiovasc Surg** 1997 Jan;9(1):101–10 (60 ref.)

Clinical trials in lung cancer: nihilism versus enthusiasm. Spiro SG. **Thorax** 1997 Jul;52(7):598–604 (20 ref.)

[Gene therapy in lung cancer] Ran P, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Oct; 18(5):270–3 (23 ref.) **(Chi)**

[Therapy of non-small cell lung cancer] Klášterský J. **Cas Lek Cesk** 1997 Apr 2;136(7):199–204 (38 ref.) (Eng. Abstr.) **(Cze)**

[New therapeutic strategies and current research in inoperable locally advanced non small-cell lung cancers (stage IIIB)] Le Cesne A, et al. **Bull Cancer** 1997 Apr; 84(4):413–9 (45 ref.) (Eng. Abstr.) **(Fre)**

[Biological basis of combined chemo-radiotherapy. Applications to lung cancers] Mornex F, et al. **Cancer Radiother** 1997;1(1):29–41 (70 ref.) (Eng. Abstr.) **(Fre)**

[Gene therapy in oncology: applications to lung cancer] Chapiro J, et al. **Rev Mal Respir** 1996 Oct;13(5):467–76 (93 ref.) (Eng. Abstr.) **(Fre)**

[Cellular growth factors in the treatment of bronchogenic cancers] Pujol JL, et al. **Rev Mal Respir** 1996;13(4):335–8 (17 ref.) **(Fre)**

[Value of tumor markers in surveillance of primary bronchial cancers and to evaluate therapy] Sculier JP. **Rev Mal Respir** 1997 Apr;14 Suppl 3:S23–6 (29 ref.) **(Fre)**

[With reference to later intra-/extrathoracic recurrence manifestations also after so-called radical operation: when are (neo-)adjuvant measures indicated?] Dringes P. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:805–9 (20 ref.) (Eng. Abstr.) **(Ger)**

[Current status of interdisciplinary therapy of stage III non-small-cell bronchial carcinoma] Manegold C, et al. **Pneumologie** 1996 Oct;50(10):735–41 (52 ref.) **(Ger)**

[Therapeutic strategy for small cell lung cancer] Fukuoka M. **Nippon Geka Gakkai Zasshi** 1997 Jan;98(1):46–52 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Future directions of gene therapy for lung cancer] Hasegawa Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Dec; 33 Suppl:33–7 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Can improvement in therapy decrease the rate of death due to lung cancer?] Kasai T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Dec;33 Suppl:17–23 (29 ref.) (Eng. Abstr.) **(Jpn)**

[A new strategy for treating small cell lung cancer] Ueda R, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec; 34 Suppl:111–4 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Lung cancer: Progress in diagnosis and treatment. III. Treatment and prognosis: 1. Overview on treatment of lung cancer—therapeutic plans for lung cancer and associated informed consent] Eguchi K. **Nippon Naika Gakkai Zasshi** 1997 Jan 10;86(1):65–72 (5 ref.) **(Jpn)**

[Lung cancer: Progress in diagnosis and treatment. III. Therapy and prognosis: 4. For improvement of QOL—including conservative treatment (stents, VATS, laser, and intracavitary radiation)] Iioka S. **Nippon Naika Gakkai Zasshi** 1997 Jan 10;86(1):88–94 (5 ref.) **(Jpn)**

[Human gene therapy for lung cancer] Fujiwara T, et al. **Nippon Rinsho** 1997 May;55(5):1296–306 (36 ref.) (Eng. Abstr.) **(Jpn)**

[Early lung cancer] Nakayama H, et al. **Nippon Rinsho** 1996 May;54(5):1359–65 (15 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

[Endobronchial ultrasound] Becker HD, et al. **Pneumologie** 1997 Jul;51(7):620–9 (48 ref.) **(Ger)**

VETERINARY

Tumours of the lower respiratory tract. Mohr U, et al. **IARC Sci Publ** 1996;(126):189–222 (162 ref.)

VIROLOGY

Lymphoepithelioma-like carcinoma of the lung [see comments] Wöckel W, et al. **Pathol Res Pract** 1995 Nov; 191(11):1170–4 (20 ref.) Comment in: Pathol Res Pract 1995 Nov;191(11):1175–7.

LUNG PURPURA WITH NEPHRITIS see **GOODPASTURE'S SYNDROME**

LUNG TRANSPLANTATION

see related
HEART–LUNG TRANSPLANTATION

Lung transplantation: implications for the general internist. Nunley DR, et al. **Adv Intern Med** 1996;41:497–529 (33 ref.)

Radiologic issues in lung transplantation for end-stage pulmonary disease. Erasmus JJ, et al. **AJR Am J Roentgenol** 1997 Jul;169(1):69–78 (81 ref.)

Lung transplant rejection: obliterative bronchiolitis. Spector NM, et al. **Am J Crit Care** 1996 Sep;5(5):366–72 (39 ref.)

Lung transplantation. Trulock EP. **Am J Respir Crit Care Med** 1997 Mar;155(3):789–818 (398 ref.)

Anaesthesia for patients after lung transplantation. Haddow GR. **Can J Anaesth** 1997 Feb;44(2):182–97 (103 ref.)

Perioperative anaesthetic considerations for patients undergoing lung transplantation. Singh H, et al. **Can J Anaesth** 1997 Mar;44(3):284–99 (100 ref.)

Lung transplantation for alpha 1-antitrypsin deficiency emphysema. Trulock EP. **Chest** 1996 Dec;110(6 Suppl):284S–294S (37 ref.)

Donor criteria and evaluation. Frost AE. **Clin Chest Med** 1997 Jun;18(2):231–7 (22 ref.)

Donor considerations in living-related donor lung transplantation. Mallory GB Jr, et al. **Clin Chest Med** 1997 Jun;18(2):239–44 (24 ref.)

Indications. Unilateral, bilateral, heart-lung, and lobar transplant procedures. Patterson GA. **Clin Chest Med** 1997 Jun;18(2):225–30 (18 ref.)

Perioperative management in lung transplantation. Simpson KP, et al. **Clin Chest Med** 1997 Jun;18(2):277–84 (38 ref.)

Patient selection, evaluation, and preoperative management for lung transplant candidates. Smith CM. **Clin Chest Med** 1997 Jun;18(2):183–97 (123 ref.)

Pediatric lung transplantation. Stillwell PC, et al. **Clin Chest Med** 1997 Jun;18(2):405–14 (46 ref.)

Early and long-term functional outcomes in unilateral, bilateral, and living-related transplant recipients. Williams TJ, et al. **Clin Chest Med** 1997 Jun;18(2):245–57 (80 ref.)

Lung transplantation: historical perspective, current concepts, and anesthetic considerations. Bracken CA, et al. **J Cardiothorac Vasc Anesth** 1997 Apr;11(2):220–41 (167 ref.)

Management of cystic fibrosis before and after lung transplantation. Egan JJ, et al. **J R Soc Med** 1997;90 Suppl 31:47–58 (54 ref.)

Medical management and complications in the lung transplant recipient. Midthun DE, et al. **Mayo Clin Proc** 1997 Feb;72(2):175–84 (45 ref.)

Lung and heart-lung transplantation in children. Noyes BE, et al. **Pediatr Pulmonol** 1997 Jan;23(1):39–48 (57 ref.)

Pediatric lung transplantation: indications and contraindications. Kurland G. **Semin Thorac Cardiovasc Surg** 1996 Jul;8(3):277–85 (66 ref.)

Cytomegalovirus infection in seromismatched lung transplant recipients with and without prophylaxis with CMV immunoglobulin. Kathawalla SA, et al. **Transplant Proc** 1996 Dec;28(6 Suppl 2):16 (2 ref.)

Heart and lung transplantation. McLean AD, et al. **Transplant Proc** 1997 Sep;29(6):2719–20 (0 ref.)

Lung transplantation. Part II. Postoperative management and results [see comments] Wood DE, et al. **West J Med** 1997 Jan;166(1):45–55 (64 ref.) Comment in: West J Med 1997 Jan;166(1):67–8.

[Mucoviscidosis. Pulmonary transplantation] Foucaud P, et al. **Presse Med** 1997 May 3–10;26(15):733–7 (25 ref.) **(Fre)**

[Intensive care in lung and heart-lung transplantation] Bastien O, et al. **Rev Mal Respir** 1996 Nov;13(5 Suppl):S23–9 (34 ref.) (Eng. Abstr.) **(Fre)**

[Present status of lung transplantation and heart-lung transplantation] Handa M, et al. **Rinsho Kyobu Geka** 1989 Apr;9(2):117–22 (29 ref.) (Eng. Abstr.) **(Jpn)**

[Anesthesia in lung transplantation] Vicente R, et al. **Rev Esp Anestesiol Reanim** 1997 Jan;44(1):23–9 (86 ref.) **(Spa)**

[Heart-lung and lung transplantation] Herreros J. **Rev Med Univ Navarra** 1994 Oct–Dec;38(4):165–73 (38 ref.) **(Spa)**

ADVERSE EFFECTS

Infections in lung transplant recipients. Chaparro C, et al. **Clin Chest Med** 1997 Jun;18(2):339–51 (68 ref.)

Prophylaxis post-transplant. The role of monitoring surveillance bronchoscopy and antimicrobials. Corris PA. **Clin Chest Med** 1997 Jun;18(2):311–8 (38 ref.)

Obliterative bronchiolitis. Kelly K, et al. **Clin Chest Med** 1997 Jun;18(2):319–38 (156 ref.)

Acute pulmonary allograft rejection. Mechanisms, diagnosis, and management. King-Biggs MB. **Clin Chest Med** 1997 Jun;18(2):301–10 (86 ref.)

Nonpulmonary medical complications in the intermediate and long-term survivor. Maurer JR, et al. **Clin Chest Med** 1997 Jun;18(2):367–82 (114 ref.)

Posttransplantation physiologic features of the lung and obliterative bronchiolitis. Scott JP, et al. **Mayo Clin Proc** 1997 Feb;72(2):170–4 (33 ref.)

Empyema and bloodstream infection caused by Burkholderia gladioli in a patient with cystic fibrosis after lung transplantation. Khan SU, et al. **Pediatr Infect Dis J** 1996 Jul;15(7):637–9 (14 ref.)

Surgical complications of lung transplantation in children. Huddleston CB. **Semin Thorac Cardiovasc Surg** 1996 Jul; 8(3):296–304 (41 ref.)

Major medical complications of lung transplantation: a pediatric perspective. Mallory GB Jr. **Semin Thorac Cardiovasc Surg** 1996 Jul;8(3):305–12 (58 ref.)

[Endobronchial complications in lung and heart-lung transplantation] Bonnette P. **Rev Mal Respir** 1996 Nov;13(5 Suppl):S49–56 (51 ref.) (Eng. Abstr.) **(Fre)**

[Infectious complications of lung and heart-lung transplantation] Nicod LP. **Rev Mal Respir** 1996 Nov;13(5 Suppl):S41–7 (58 ref.) (Eng. Abstr.) **(Fre)**

ECONOMICS

The cost of lung transplantation and the quality of life post-transplant. Gross CR, et al. **Clin Chest Med** 1997 Jun; 18(2):391–403 (58 ref.)

IMMUNOLOGY

Review of immunosuppression for lung transplantation. Novel drugs, new uses for conventional immunosuppressants, and alternative strategies. Hausen B, et al. **Clin Chest Med** 1997 Jun;18(2):353–66 (125 ref.)

[Immunological aspects of lung transplantation] Etienne B, et al. **Rev Mal Respir** 1996 Nov;13(5 Suppl):S15–22 (120 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Revascularization of the bronchial arteries in lung transplantation: an overview. Nørgaard MA, et al. **Ann Thorac Surg** 1996 Oct;62(4):1215–21 (45 ref.)

Surgical issues in lung transplantation: options, donor selection, graft preservation, and airway healing. Daly RC, et al. **Mayo Clin Proc** 1997 Jan;72(1):79–84 (24 ref.)

Lung transplantation. Part I. Indications and operative management. Wood DE, et al. **West J Med** 1996 Dec;

165(6):355–63 (36 ref.)
[Lung transplantation] Vogelmeier C, et al. **Pneumologie** 1996 Dec;50 Suppl 3:854–9 (35 ref.) **(Ger)**
[Lung transplantation] Weder W. **Schweiz Rundsch Med Prax** 1997 Mar 18;86(12):470–5 (35 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Pathology of lung transplantation. Marboe CC. **Pathology (Phila)** 1996;4(1):73–101 (50 ref.)

PHYSIOLOGY

[Functional respiratory physiology and physiopathology of lung transplant patients] Estenne M. **Rev Mal Respir** 1996 Nov;13(5 Suppl):S5–14 (38 ref.) (Eng. Abstr.) **(Fre)**
[Graft dysfunction, acute rejection and bronchiolitis obliterans in lung and heart–lung transplantation] Sleiman C, et al. **Rev Mal Respir** 1996 Nov;13(5 Suppl):S31–40 (66 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

The cost of lung transplantation and the quality of life post–transplant. Gross CR, et al. **Clin Chest Med** 1997 Jun; 18(2):391–403 (58 ref.)

STANDARDS

Lung transplantation: selection of patients and analysis of outcome. Peters SG, et al. **Mayo Clin Proc** 1997 Jan; 72(1):85–8 (24 ref.)

TRENDS

The past, present, and future of lung transplantation. Grover FL, et al. **Am J Surg** 1997 Jun;173(6):523–33 (31 ref.)
Organ transplantation in Taiwan. Lee CJ. **Artif Organs** 1996 Dec;20(12):1270–3 (10 ref.)
[Present international status and basic approach of lung and heart–lung transplantation] Kondo T, et al. **Nippon Geka Gakkai Zasshi** 1996 Nov;97(11):997–1002 (27 ref.) (Eng. Abstr.) **(Jpn)**

LUNG VOLUME MEASUREMENTS

Measurement of lung volumes by plethysmography [see comments] Coates AL, et al. **Eur Respir J** 1997 Jun; 10(6):1415–27 (43 ref.) Comment in: Eur Respir J 1997 Jun;10(6):1205–6.

INSTRUMENTATION

Lung volume equipment and infection control. ERS/ATS Workshop Report Series. European Respiratory Society/American Thoracic Society. Clausen JL. **Eur Respir J** 1997 Aug;10(8):1928–32 (28 ref.)

METHODS

Comparison of methods of measuring static lung volumes. Kendrick AH. **Monaldi Arch Chest Dis** 1996 Oct; 51(5):431–9 (53 ref.)
[Measurements of lung volume and its subdivisions by spirography] Endo K. **Nippon Rinsho** 1997 Apr;55 Suppl 2:5–7 (2 ref.) **(Jpn)**

LUNG WATER, EXTRAVASCULAR see **EXTRAVASCULAR LUNG WATER**

LUPUS

Neonatal lupus. Buyon JP. **Curr Opin Rheumatol** 1996 Sep; 8(5):485–90 (30 ref.)

CHEMICALLY INDUCED

Minocycline related lupus. Masson C, et al. **J Rheumatol** 1996 Dec;23(12):2160–1 (7 ref.)

COMPLICATIONS

Squamous cell carcinoma arising from lupus vulgaris on an old burn scar: diagnosis by polymerase chain reaction. Hagiwara K, et al. **J Dermatol** 1996 Dec;23(12):883–9 (17 ref.)
Antiphospholipid antibody associated thrombosis: a consensus for treatment? McCrae KR. **Lupus** 1996 Dec; 5(6):560–70 (39 ref.)

IMMUNOLOGY

Macromolecular substrates for the ICE–like proteases during apoptosis. Rosen A, et al. **J Cell Biochem** 1997 Jan; 64(1):50–4 (24 ref.)
T cells in murine lupus: propagation and regulation of disease. Peng SL, et al. **Mol Biol Rep** 1996;23(3–4):247–51 (60 ref.)
Neonatal lupus: bedside to bench and back [editorial] Buyon JP. **Scand J Rheumatol** 1996;25(5):271–6 (49 ref.)

LUPUS ANTICOAGULANT see **LUPUS COAGULATION INHIBITOR**

LUPUS COAGULATION INHIBITOR

see related
ANTIPHOSPHOLIPID SYNDROME

Lupus anticoagulants and thrombosis: the role of phospholipids. Esmon NL, et al. **Haematologica** 1997 Jul–Aug;82(4):474–7 (32 ref.)

ANALYSIS

Severe bleeding due to acquired hypoprothrombinemia–lupus anticoagulant syndrome. Case report and review of literature. Vivaldi P, et al. **Haematologica** 1997 May–Jun; 82(3):345–7 (26 ref.)
Lupus anticoagulants/antiphospholipid–protein antibodies: the great imposters. Triplett DA. **Lupus** 1996 Oct; 5(5):431–5 (36 ref.)
Nodular regenerative hyperplasia of the liver in systemic lupus erythematosus. The relationship with anticardiolipin antibody and lupus anticoagulant. Sekiya M, et al. **Scand J Rheumatol** 1997;26(3):215–7 (13 ref.)

BIOSYNTHESIS

The immunogenetics of the antiphospholipid syndrome, anticardiolipin antibodies, and lupus anticoagulant. Sebastiani GD, et al. **Semin Arthritis Rheum** 1996 Jun; 25(6):414–20 (38 ref.)

BLOOD

The "lupus" circulating anticoagulant, AKA the primary antiphospholipid syndrome. Rothschild BM. **Compr Ther** 1996 Jul;22(7):420–3 (14 ref.)
Systemic lupus erythematosus with ischemic peripheral neuropathy and lupus anticoagulant: response to intravenous prostaglandin E1. Yoshikawa Y, et al. **Cutis** 1996 Dec;58(6):393–6 (8 ref.)
Antiphospholipid antibodies: predictive value of laboratory tests. Galli M, et al. **Thromb Haemost** 1997 Jul;78(1):75–8 (28 ref.)
[Antiphospholipid antibodies, lupus anticoagulant and thrombosis] Capel P. **Rev Med Brux** 1997 Jun;18(3):108–10 (18 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Mechanisms of activity of lupus anticoagulants. Rao LV. **Curr Opin Hematol** 1997 Sep;4(5):344–50 (40 ref.)

LUPUS ERYTHEMATOSUS, CHRONIC CUTANEOUS see **LUPUS ERYTHEMATOSUS, DISCOID**

LUPUS ERYTHEMATOSUS, CUTANEOUS

CLASSIFICATION

The lexicon of cutaneous lupus erythematosus—a review and personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus. Sontheimer RD. **Lupus** 1997;6(2):84–95 (90 ref.)

COMPLICATIONS

Leukocytoclastic vasculitis in subacute cutaneous lupus erythematosus: clinicopathologic study of three cases and review of the literature. Sánchez–Pérez J, et al. **Dermatology** 1996;193(3):230–5 (22 ref.)

DIAGNOSIS

Phototesting and photoprotection in LE. Walchner M, et al. **Lupus** 1997;6(2):167–74 (80 ref.)

DRUG THERAPY

Management of skin disease in lupus. Callen JP. **Bull Rheum Dis** 1997 Apr;46(2):4–7 (11 ref.)
Management of antimalarial–refractory cutaneous lupus erythematosus. Callen JP. **Lupus** 1997;6(2):203–8 (37 ref.)

ECONOMICS

Epidemiology and socioeconomic impact of skin disease in lupus erythematosus. Tebbe B, et al. **Lupus** 1997; 6(2):96–104 (121 ref.)

EPIDEMIOLOGY

Epidemiology and socioeconomic impact of skin disease in lupus erythematosus. Tebbe B, et al. **Lupus** 1997; 6(2):96–104 (121 ref.)

ETIOLOGY

Pathogenetic mechanisms and treatment of cutaneous lupus erythematosus. Werth VP, et al. **Curr Opin Rheumatol** 1997 Sep;9(5):400–9 (91 ref.)
Paraneoplastic subacute cutaneous lupus erythematosus: report of a case associated with cancer of the lung. Brenner S, et al. **Dermatology** 1997;194(2):172–4 (12 ref.)
Ultraviolet light modulation of autoantigens, epidermal cytokines and adhesion molecules as contributing factors of the pathogenesis of cutaneous LE. Bennion SD, et al. **Lupus** 1997;6(2):181–92 (116 ref.)
[New aspects on the morphology and pathogenesis of lupus erythematosus] Kerl H. **Z Hautkr** 1976 Feb 15;51(4):143–62 (0 ref.) **(Ger)**

IMMUNOLOGY

Pathology, immunopathology, and immunohistochemistry in cutaneous lupus erythematosus. David–Bajar KM, et al. **Lupus** 1997;6(2):145–57 (83 ref.)
Direct immunofluorescence in lupus erythematosus (LE). Isfer RS, et al. **Rev Paul Med** 1996 Mar–Apr;114(2):1141–7 (19 ref.)

PATHOLOGY

Nodular cutaneous lupus mucinosis: report of a case and review of previously reported cases. Kano Y, et al. **Cutis** 1996 Jun;57(6):441–4 (22 ref.)
Pathology, immunopathology, and immunohistochemistry in cutaneous lupus erythematosus. David–Bajar KM, et al. **Lupus** 1997;6(2):145–57 (83 ref.)
[New aspects on the morphology and pathogenesis of lupus erythematosus] Kerl H. **Z Hautkr** 1976 Feb 15;51(4):143–62 (0 ref.) **(Ger)**

PHYSIOPATHOLOGY

Animal models of cutaneous lupus erythematosus and lupus erythematosus photosensitivity. Furukawa F. **Lupus** 1997; 6(2):193–202 (88 ref.)

RADIOTHERAPY

Prospects for UV–A1 therapy as a treatment modality in cutaneous and systemic LE. McGrath H Jr. **Lupus** 1997; 6(2):209–17 (81 ref.)

THERAPY

Pathogenetic mechanisms and treatment of cutaneous lupus erythematosus. Werth VP, et al. **Curr Opin Rheumatol** 1997 Sep;9(5):400–9 (91 ref.)

LUPUS ERYTHEMATOSUS, CUTANEOUS, CHRONIC see **LUPUS ERYTHEMATOSUS, DISCOID**

LUPUS ERYTHEMATOSUS, CUTANEOUS, SUBACUTE see **LUPUS ERYTHEMATOSUS, CUTANEOUS**

LUPUS ERYTHEMATOSUS, DISCOID

see related
PANNICULITIS, LUPUS ERYTHEMATOSUS

CHEMICALLY INDUCED

Atenolol–induced lupus erythematosus. McGuiness M, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):298–9 (16 ref.)

COMPLICATIONS

Systemic lupus erythematosus, discoid lupus erythematosus, and progressive systemic sclerosis. Foster CS. **Int Ophthalmol Clin** 1997 Spring;37(2):93–110 (76 ref.)

DIAGNOSIS

Cutaneous lupus erythematosus during the neonatal and childhood periods. Lee LA, et al. **Lupus** 1997;6(2):132–8 (54 ref.)
[Cerebral positron emission tomographic study in systemic lupus erythematosus] Csépány T, et al. **Orv Hetil** 1997 Aug 3;138(31):1947–52 (46 ref.) (Eng. Abstr.) **(Hun)**

DRUG THERAPY

Management of skin disease in lupus. Callen JP. **Bull Rheum Dis** 1997 Apr;46(2):4–7 (11 ref.)

IMMUNOLOGY

Cutaneous diseases in adults associated with anti–Ro/SS–A autoantibody production. McCauliffe DP. **Lupus** 1997; 6(2):158–66 (100 ref.)
Direct immunofluorescence in lupus erythematosus (LE). Isfer RS, et al. **Rev Paul Med** 1996 Mar–Apr;114(2):1141–7 (19 ref.)

LUPUS ERYTHEMATOSUS DISSEMINATUS see **LUPUS ERYTHEMATOSUS, SYSTEMIC**

LUPUS ERYTHEMATOSUS PROFUNDUS see **PANNICULITIS, LUPUS ERYTHEMATOSUS**

LUPUS ERYTHEMATOSUS, SUBACUTE CUTANEOUS see **LUPUS ERYTHEMATOSUS, CUTANEOUS**

LUPUS ERYTHEMATOSUS, SYSTEMIC

see related
ANTIPHOSPHOLIPID SYNDROME
LUPUS COAGULATION INHIBITOR

Oral contraceptives in women with systemic lupus erythematosus. Buyon JP. **Ann Med Interne (Paris)** 1996; 147(4):259–64 (58 ref.)
Outpatient management of systemic lupus erythematosus. Sims GN Jr, et al. **Cleve Clin J Med** 1996 Mar–Apr; 63(2):94–100 (25 ref.)
Thrombomodulin: a new frontier in lupus research? [editorial] Cucurull E, et al. **Clin Exp Rheumatol** 1997 Jan–Feb;

15(1):1–4 (38 ref.)

Autoimmune disease in pregnancy. Systemic lupus erythematosus and antiphospholipid syndrome. Silver RM, et al. **Clin Perinatol** 1997 Jun;24(2):291–320 (240 ref.)

Pregnancy in systemic lupus erythematosus. Khamashta MA, et al. **Curr Opin Rheumatol** 1996 Sep;8(5):424–9 (74 ref.)

Systemic lupus erythematosus flares during pregnancy. Khamashta MA, et al. **Rheum Dis Clin North Am** 1997 Feb;23(1):15–30 (69 ref.)

Hopkins Lupus Pregnancy Center: 1987 to 1996. Petri M. **Rheum Dis Clin North Am** 1997 Feb;23(1):1–13 (34 ref.)

Neonatal lupus erythematosus. Silverman ED, et al. **Rheum Dis Clin North Am** 1997 Aug;23(3):599–618 (100 ref.)

Neonatal lupus syndromes. Tseng CE, et al. **Rheum Dis Clin North Am** 1997 Feb;23(1):31–54 (122 ref.)

[Progresses in rheumatology in China, 1996] Shi G. **Chung Hua I Hsueh Tsa Chih** 1996 Dec;76(12):894–5 (0 ref.) **(Chi)**

[Libman–Sacks endocarditis––a jubilee year] Afek A, et al. **Harefuah** 1997 May 15;132(10):718–9 (20 ref.) **(Heb)**

[Coping with pathological changes in nerves and blood vessels in collagen disease––CNS lupus] Hirohata S. **Nippon Naika Gakkai Zasshi** 1996 Nov 10;85(11):1816–21 (5 ref.) **(Jpn)**

[Atypical verrucous endocarditis (Libman–Sacks disease)] Murata K. **Ryoikibetsu Shokogun Shirizu** 1996;(13):483–5 (16 ref.) **(Jpn)**

[Systemic lupus erythematosus and pregnancy (analysis of 84 cases)] Cabral–Castañeda F, et al. **Ginecol Obstet Mex** 1996 Aug;64:363–7 (65 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

Lack of association between prolactin levels and clinical activity in patients with systemic lupus erythematosus [letter; comment] Mok CC, et al. **J Rheumatol** 1996 Dec; 23(12):2185–6 (3 ref.) Comment on: J Rheumatol 1996 Apr;23(4):629–32.

Okadaic acid–like toxin in systemic lupus erythematosus patients: hypothesis for toxin–induced pathology, immune dysregulation, and transactivation of herpesviruses. Mitchell TM. **Med Hypotheses** 1996 Sep;47(3):217–25 (102 ref.)

[Prolactin and autoimmune diseases] Yang X, et al. **Chung Hua Nei Ko Tsa Chih** 1996 Jan;35(1):60–2 (20 ref.) **(Chi)**

CHEMICALLY INDUCED

Drug–induced lupus [editorial; comment] Miyasaka N. **Intern Med** 1996 Jul;35(7):527–8 (6 ref.) Comment on: Intern Med 1996 Jul;35(7):587–91.

Silica–associated systemic erythematosus lupus or mineral dust lupus? Masson C, et al. **Lupus** 1997;6(1):1–3 (8 ref.)

COMPLICATIONS

Isolated persistent fetal bradycardia in complete A–V block: a conservative approach is appropriate. A case report and a review of the literature. Rabinerson D, et al. **Am J Perinatol** 1997 Jul;14(6):317–20 (17 ref.)

Systemic lupus erythematosus and pregnancy. Druzin ML, et al. **Ann Med Interne (Paris)** 1996;147(4):265–73 (124 ref.)

Osteoporosis and systemic lupus erythematosus: etiology and treatment strategies. Segal LG, et al. **Ann Med Interne (Paris)** 1996;147(4):281–9 (43 ref.)

Anti–P antibodies and neuropsychiatric lupus erythematosus. Georgescu L, et al. **Ann N Y Acad Sci** 1997 Aug 14; 823:263–9 (28 ref.)

Evaluating the neurocognitive complications of SLE. Lessons from HIV disease. Grant I, et al. **Ann N Y Acad Sci** 1997 Aug 14;823:18–43 (46 ref.)

Antiphospholipid antibodies and cerebral lupus. Harris EN, et al. **Ann N Y Acad Sci** 1997 Aug 14;823:270–8 (53 ref.)

Psychiatric and neurocognitive concomitants of systemic lupus erythematosus. Keenan PA, et al. **Ann N Y Acad Sci** 1997 Aug 14;823:69–80 (18 ref.)

Central interleukin–1 receptors as mediators of sickness. Kelley KW, et al. **Ann N Y Acad Sci** 1997 Aug 14; 823:234–46 (91 ref.)

Delayed neuronal degeneration results from endogenous glutamate excess. Possible role in NP–SLE. Volpe BT. **Ann N Y Acad Sci** 1997 Aug 14;823:185–7 (23 ref.)

Detection of cerebral ischemia in systemic lupus erythematosus by magnetic resonance techniques. Welch KM, et al. **Ann N Y Acad Sci** 1997 Aug 14;823:120–31 (27 ref.)

Human immunodeficiency virus infection in systemic lupus erythematosus. Fox RA, et al. **Arthritis Rheum** 1997 Jun; 40(6):1168–72 (22 ref.)

Invasive soft tissue infections with Streptococcus pneumoniae in patients with systemic lupus erythematosus: case report and review of the literature. Hill MD, et al. **Arthritis Rheum** 1997 Sep;40(9):1716–9 (16 ref.)

Gonococcal endocarditis in a patient with systemic lupus erythematosus. Tikly M, et al. **Br J Rheumatol** 1997 Feb; 36(2):270–2 (14 ref.)

Autoimmune thyroid disease in systemic lupus erythematosus and Sjögren's syndrome. Scofield RH. **Clin Exp Rheumatol** 1996 May–Jun;14(3):321–30 (100 ref.)

Lupus and the central nervous system. West SG. **Curr Opin Rheumatol** 1996 Sep;8(5):408–14 (46 ref.)

Systemic lupus erythematosus with ischemic peripheral neuropathy and lupus anticoagulant: response to intravenous prostaglandin E1. Yoshikawa Y, et al. **Cutis** 1996 Dec;58(6):393–6 (8 ref.)

Periarticular ectopic calcinosis probably due to 1 alpha–OH–vitamin D3 therapy, and successful treatment with bisphosphonate compound in a patient with systemic lupus erythematosus. Miyata M, et al. **Fukushima J Med Sci** 1996 Dec;42(1–2):39–46 (28 ref.)

Severe bleeding due to acquired hypoprothrombinemia–lupus anticoagulant syndrome. Case report and review of literature. Vivaldi P, et al. **Haematologica** 1997 May–Jun; 82(3):345–7 (26 ref.)

Surgery of systemic lupus erythematosus arthritis of the hand. Nalebuff EA. **Hand Clin** 1996 Aug;12(3):591–602 (23 ref.)

Systemic lupus erythematosus, discoid lupus erythematosus, and progressive systemic sclerosis. Foster CS. **Int Ophthalmol Clin** 1997 Spring;37(2):93–110 (76 ref.)

Risk factors for infectious complication in patients with systemic lupus erythematosus [editorial; comment] Aotsuka S. **Intern Med** 1996 Aug;35(8):593–4 (10 ref.) Comment on: Intern Med 1996 Aug;35(8):629–36.

Allergy and systemic lupus [editorial; comment] Kivity S. **Isr J Med Sci** 1997 Feb;33(2):150–1 (8 ref.) Comment on: Isr J Med Sci 1997 Feb;33(2):147–9.

Multiple dermatofibromas accompanied by eruptive benign keratoses in a patient with systemic lupus erythematosus. Kuniyuki S, et al. **J Dermatol** 1996 Sep;23(9):619–22 (14 ref.)

Systemic lupus erythematosus with obstructive uropathy. Case report and review. Kim HJ, et al. **J Korean Med Sci** 1995 Dec;10(6):462–9 (31 ref.)

Lupus aortitis: a case report and review of the literature. Willett WF 3rd, et al. **J La State Med Soc** 1996 Feb; 148(2):55–9 (29 ref.)

Crusted scabies associated with systemic lupus erythematosus: response to benzyl benzoate therapy. Chutimunt N. **J Med Assoc Thai** 1996 Jan;79(1):65–8 (10 ref.)

Spontaneous rupture of the spleen in a patient with systemic lupus erythematosus. Tolaymat A, et al. **J Rheumatol** 1995 Dec;22(12):2344–5 (15 ref.)

Autosplenectomy in systemic lupus erythematosus. Uthman I, et al. **J Rheumatol** 1996 Oct;23(10):1806–10 (18 ref.)

Malignant lymphoma in patients with rheumatic diseases other than Sjögren's syndrome: a clinicopathologic study of five cases and a review of the Japanese literature. Kojima M, et al. **Jpn J Clin Oncol** 1997 Apr;27(2):84–90 (43 ref.)

The concurrence of lupus and fibromyalgia: implications for diagnosis and management. Bennett R. **Lupus** 1997; 6(6):494–9 (90 ref.)

Transverse myelopathy in SLE: clinical features and functional outcomes. Chan KF, et al. **Lupus** 1996 Aug; 5(4):294–9 (13 ref.)

Vasculitis in systemic lupus erythematosus. Drenkard C, et al. **Lupus** 1997;6(3):235–42 (41 ref.)

Cutaneous manifestations of Hughes syndrome occurring in the context of lupus erythematosus. Francès C, et al. **Lupus** 1997;6(2):139–44 (57 ref.)

Acinetobacter pericarditis with tamponade in a patient with systemic lupus erythematosus. Lam SM, et al. **Lupus** 1997; 6(5):480–3 (13 ref.)

Neuropsychiatric lupus: getting beyond the barrier of the brain [editorial] Mevorach D, et al. **Lupus** 1996 Jun; 5(3):173–4 (32 ref.)

Antimalarial drugs in pregnancy––the North American experience. Parke AL, et al. **Lupus** 1996 Jun;5 Suppl 1:S67–9 (21 ref.)

Common variable immunodeficiency in a patient with systemic lupus erythematosus. Swaak AJ, et al. **Lupus** 1996 Jun;5(3):242–6 (18 ref.)

Bullous skin disease in lupus erythematosus. Yell JA, et al. **Lupus** 1997;6(2):112–21 (67 ref.)

Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome. Zamora MR, et al. **Medicine (Baltimore)** 1997 May;76(3):192–202 (58 ref.)

Central serous chorioretinopathy in patients with systemic lupus erythematosus. Cunningham ET Jr, et al. **Ophthalmology** 1996 Dec;103(12):2081–90 (84 ref.)

Histiocytic necrotizing lymphadenitis, Kikuchi–Fujimoto's disease, associated with systemic lupus erythemotosus. Martínez–Vázquez C, et al. **QJM** 1997 Aug;90(8):531–3 (19 ref.)

Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective [editorial] Petri M. **Scand J Rheumatol** 1996;25(4):191–3 (16 ref.)

Nodular regenerative hyperplasia of the liver in systemic lupus erythematosus. The relationship with anticardiolipin antibody and lupus anticoagulant. Sekiya M, et al. **Scand J Rheumatol** 1997;26(3):215–7 (13 ref.)

Systemic lupus erythematosus and multiple myeloma: a rare association. Afeltra A, et al. **Semin Arthritis Rheum** 1997 Jun;26(6):845–9 (30 ref.)

Outcome of silent lupus nephritis. Gonzalez–Crespo MR, et al. **Semin Arthritis Rheum** 1996 Aug;26(1):468–76 (73 ref.)

Outcome of renal transplantation in systemic lupus erythematosus. Stone JH, et al. **Semin Arthritis Rheum** 1997 Aug;27(1):17–26 (36 ref.)

Mitral insufficiency caused by systemic lupus erythematosus requiring valve replacement: three case reports and a review of the literature. Morin AM, et al. **Thorac Cardiovasc Surg** 1996 Dec;44(6):313–6 (25 ref.)

[Pulmonary involvement in systemic lupus erythematosus] Carasso S, et al. **Harefuah** 1997 Mar 2;132(5):360–3 (35 ref.) **(Heb)**

[A case of the "shrinking lung syndrome" in SLE––improvement with corticosteroid therapy] Kitamura Y, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Jun; 19(3):217–22 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Aortic valve replacement due to Libman–Sacks endocarditis combined with infectious endocarditis] Taniyasu N, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Aug;44(8):1193–7 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Case of systemic lupus erythematosus with protein–losing gastroenteropathy] Matsumura M, et al. **Nippon Naika Gakkai Zasshi** 1996 Jul 10;85(7):1150–3 (8 ref.) **(Jpn)**

[Hemolytic anemias observed in SLE] Ichikawa Y, et al. **Nippon Rinsho** 1996 Sep;54(9):2528–33 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Systemic lupus erythematosus] Kitamoto K. **Ryoikibetsu Shokogun Shirizu** 1996;(15):185–8 (11 ref.) **(Jpn)**

[Pericarditis in collagen vascular diseases] Matsumoto Y. **Ryoikibetsu Shokogun Shirizu** 1996;(13):511–4 (15 ref.) **(Jpn)**

[A case of Sjögren's syndrome and systemic lupus erythematosus complicated with necrotizing angiitis of the gallbladder] Suwa A, et al. **Ryumachi** 1995 Dec;35(6):904–9 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Systemic lupus erythematosus with renal involvement: progress in research on pathogenesis, diagnosis and treatment] Klinger M. **Pol Arch Med Wewn** 1997 Mar; 97(3):287–93 (26 ref.) **(Pol)**

[Systemic lupus erythematosus and the central nervous system] Rojas E, et al. **Rev Alerg** 1993 Mar–Apr;40(2):46–9 (49 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Scabies mimicking systemic lupus erythematosus. Bastian HM, et al. **Am J Med** 1997 Mar;102(3):305–6 (6 ref.)

MRI–MRS of the brain in systemic lupus erythematosus. How do we use it to understand causes of clinical signs? Tanabe J, et al. **Ann N Y Acad Sci** 1997 Aug 14;823:169–84 (53 ref.)

Acute lupus pneumonitis with normal chest radiograph. Susanto I, et al. **Chest** 1997 Jun;111(6):1781–3 (9 ref.)

Prognosis and treatment of systemic lupus erythematosus. Gladman DD. **Curr Opin Rheumatol** 1996 Sep;8(5):430–7 (60 ref.)

Systemic lupus erythematosus in childhood. Concordance in a pair of monozygotic twins for anti–dsDNA antibodies and discordance for disease expression [letter] Bustabad S, et al. **J Rheumatol** 1997 Jul;24(7):1450–1 (7 ref.)

Systemic Lupus International Collaborating Clinics conference on assessment of lupus flare and quality of life measures in SLE. Systemic Lupus International Collaborating Clinics Group. Gladman D, et al. **J Rheumatol** 1996 Nov;23(11):1953–5 (14 ref.)

Cutaneous lupus erythematosus during the neonatal and childhood periods. Lee LA, et al. **Lupus** 1997;6(2):132–8 (54 ref.)

Phototesting and photoprotection in LE. Walchner M, et al. **Lupus** 1997;6(2):167–74 (80 ref.)

Systemic lupus erythematosus. Diagnosis and treatment. Pisetsky DS, et al. **Med Clin North Am** 1997 Jan; 81(1):113–28 (47 ref.)

Systemic lupus erythematosus. Rasaratnam I, et al. **Med J Aust** 1997 Mar 3;166(5):266–70 (16 ref.)

Systemic lupus erythematosus (SLE) presenting as acute pancreatitis––a case report. Leong KP, et al. **Singapore Med J** 1996 Jun;37(3):323–4 (18 ref.)

[Antiphospholipid syndrome and psychosis] Clervoy P, et al. **Encephale** 1997 Mar–Apr;23(2):105–7 (14 ref.) (Eng. Abstr.) **(Fre)**

[Cerebral positron emission tomographic study in systemic lupus erythematosus] Csépány T, et al. **Orv Hetil** 1997 Aug 3;138(31):1947–52 (46 ref.) (Eng. Abstr.) **(Hun)**

[Clinical evaluation of immuno–serological laboratory data] Kasukawa R, et al. **Rinsho Byori** 1996 Dec;44(12):1157–63 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Hematological "masks" in systemic lupus erythematosus] Krasovskii II, et al. **Ter Arkh** 1997;69(5):58–61 (24 ref.) (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Studies of dehydroepiandrosterone (DHEA) as a therapeutic agent in systemic lupus erythematosus. Van Vollenhoven RF, et al. **Ann Med Interne (Paris)** 1996;147(4):290–6 (22 ref.)

Use of colony–stimulating factors in the treatment of neutropenia associated with collagen vascular disease. Starkebaum G. **Curr Opin Hematol** 1997 May;4(3):196–9 (46 ref.)

Systemic lupus erythematosus. **Drug Ther Bull** 1996 Mar; 34(3):20–3 (23 ref.)

Recognition and management of systemic lupus erythematosus. Schroeder JO, et al. **Drugs** 1997 Sep; 54(3):422–34 (117 ref.)

Keys to managing systemic lupus erythematosus. Roberts WN. **Hosp Pract (Off Ed)** 1997 Feb 15;32(2):113–6, 119–22, 125–6 (5 ref.)

Sex hormones in systemic lupus erythematosus: a controversy for modern times [editorial; comment] Bruce IN, et al. **J Rheumatol** 1997 Aug;24(8):1461–3 (33 ref.) Comment on: J Rheumatol 1997 Aug;24(8):1639–40.

What's new in the treatment of pediatric SLE. Silverman E. **J Rheumatol** 1996 Sep;23(9):1657–60 (16 ref.)

Dehydroepiandrosterone (DHEA) and lupus erythematosus: an update [editorial] Lahita RG. **Lupus** 1997;6(6):491–3 (18 ref.)

The efficacy of antimalarials in systemic lupus erythematosus. Nayak V, et al. **Lupus** 1996 Jun;5 Suppl 1:S23–7 (26 ref.)

Antimalarial drugs in pregnancy—the North American experience. Parke AL, et al. **Lupus** 1996 Jun;5 Suppl 1:S67–9 (21 ref.)

Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Petri M. **Lupus** 1996 Jun;5 Suppl 1:S16–22 (59 ref.)

Systemic lupus erythematosus. Rasaratnam I, et al. **Med J Aust** 1997 Mar 3;166(5):266–70 (16 ref.)

Cyclosporine, FK–506, rapamycin, and other immunomodulators. Yocum DE. **Rheum Dis Clin North Am** 1996 Feb;22(1):133–54 (161 ref.)

An overview of the treatment of childhood SLE [editorial] Silverman ED, et al. **Scand J Rheumatol** 1997;26(4):241–6 (26 ref.)

[Aggressive therapy of highly active systemic lupus erythematosus] Graninger W. **Acta Med Austriaca** 1996; 23(4):129–33 (70 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

Epidemiology and socioeconomic impact of skin disease in lupus erythematosus. Tebbe B, et al. **Lupus** 1997; 6(2):96–104 (121 ref.)

EPIDEMIOLOGY

Systemic lupus erythematosus: demographics, prognosis, and outcome. Klippel JH. **J Rheumatol Suppl** 1997 May; 48:67–71 (44 ref.)

Occasional series: lupus around the world. The Chilean experience of systemic lupus erythematosus. Massardo L, et al. **Lupus** 1996 Jun;5(3):175–7 (21 ref.)

Epidemiology and socioeconomic impact of skin disease in lupus erythematosus. Tebbe B, et al. **Lupus** 1997; 6(2):96–104 (121 ref.)

Systemic lupus erythematosus. The Singapore experience. Feng PH. **Ryumachi** 1997 Apr;37(2):140–1 (8 ref.)

Nocardiosis in systemic lupus erythematosus. Mok CC, et al. **Semin Arthritis Rheum** 1997 Feb;26(4):675–83 (63 ref.)

ETIOLOGY

Neuropsychiatric lupus and hormones. Robinson T, et al. **Ann Med Interne (Paris)** 1996;147(4):276–80 (23 ref.)

Autoantibodies: markers of disease or pathogenic? Isenberg DA. **Ann N Y Acad Sci** 1997 Aug 14;823:256–62 (20 ref.)

Apoptosis in peripheral lymphocytes in systemic lupus erythematosus: a review. Rose LM, et al. **Br J Rheumatol** 1997 Feb;36(2):158–63 (49 ref.)

Following the disease course in systemic lupus erythematosus: are serologic variables of any use? [editorial; comment] Swaak AJ, et al. **J Rheumatol** 1996 Nov; 23(11):1842–4 (12 ref.) Comment on: J Rheumatol 1996 Nov;23(11):1891–6.

Systemic lupus erythematosus: immunopathogenesis and the card game analogy. Isenberg DA. **J Rheumatol Suppl** 1997 May;48:62–6 (27 ref.)

The TNF–ligand and receptor superfamilies: controllers of immunity and the Trojan horses of autoimmune disease? Hill CM, et al. **Mol Aspects Med** 1996 Oct;17(5):455–509 (240 ref.)

Female hormone therapy and the risk of developing or exacerbating systemic lupus erythematosus or rheumatoid arthritis. Liang MH, et al. **Proc Assoc Am Physicians** 1996 Jan;108(1):25–8 (25 ref.)

Nucleosomes and lupus [editorial] Gilbert D, et al. **Rev Rhum Engl Ed** 1997 Apr;64(4):210–4 (41 ref.)

[New aspects on the morphology and pathogenesis of lupus erythematosus] Kerl H. **Z Hautkr** 1976 Feb 15;51(4):143–62 (0 ref.) **(Ger)**

[Abnormal Fas and Fas ligand expression of lymphocytes in patients with SLE] Suzuki N, et al. **Nippon Rinsho** 1996 Jul;54(7):1955–9 (18 ref.) (Eng. Abstr.) **(Jpn)**

[CpG motif in DNA from immune complexes of SLE patients augments expression of intercellular adhesion molecule–1 on endothelial cells] Miyata M, et al. **Rinsho Byori** 1996 Dec;44(12):1125–31 (31 ref.) (Eng. Abstr.) **(Jpn)**

[The pathogenesis of neonatal lupus erythematosus and Ro52] Itoh Y. **Ryumachi** 1996 Dec;36(6):884–90 (35 ref.) **(Jpn)**

[Antiphospholipid antibody syndrome in systemic lupus erythematosus] Zmonarski S, et al. **Pol Tyg Lek** 1996 May; 51(19–22):299–302 (35 ref.) (Eng. Abstr.) **(Pol)**

[Active forms of oxygen and pathogenesis of rheumatoid arthritis and systemic lupus erythematosus] Lisitsyna TA, et al. **Vestn Ross Akad Med Nauk** 1996;(12):15–20 (51 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Genetic basis of systemic lupus erythematosus. Vyse TJ, et al. **Curr Opin Immunol** 1996 Dec;8(6):843–51 (79 ref.)

Genetics of systemic lupus erythematosus. Tsao BP, et al. **Curr Opin Rheumatol** 1997 Sep;9(5):377–9 (9 ref.)

Genetic contributions to SLE. Kono DH, et al. **J Autoimmun** 1996 Aug;9(4):437–52 (182 ref.)

Susceptibility loci for lupus: a guiding light from murine models? [editorial] Kotzin BL. **J Clin Invest** 1997 Feb 15; 99(4):557–8 (12 ref.)

IMMUNOLOGY

Antinucleosome antibodies and systemic lupus erythematosus. Amoura Z, et al. **Adv Nephrol Necker Hosp** 1997;26:303–16 (66 ref.)

Clinical significance of antinuclear antibodies in systemic rheumatic diseases. Hietarinta M, et al. **Ann Med** 1996 Aug; 28(4):283–91 (84 ref.)

The roles of B cells in MRL/lpr murine lupus. Chan O, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:75–87 (64 ref.)

Nucleosome–driven autoimmune response in lupus. Pathogenic T helper cell epitopes and costimulatory signals. Datta SK, et al. **Ann N Y Acad Sci** 1997 Apr 5; 815:155–70 (168 ref.)

Anti–P antibodies and neuropsychiatric lupus erythematosus. Georgescu L, et al. **Ann N Y Acad Sci** 1997 Aug 14; 823:263–9 (28 ref.)

Autoantibodies: markers of disease or pathogenic? Isenberg DA. **Ann N Y Acad Sci** 1997 Aug 14;823:256–62 (20 ref.)

Autoantibodies to nervous system tissue in human and murine systemic lupus erythematosus. Moore PM. **Ann N Y Acad Sci** 1997 Aug 14;823:289–99 (92 ref.)

Initiation of autoimmunity to self–proteins complexed with viral antigens. Reeves WH, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:139–54 (51 ref.)

Antiendothelial cell antibodies (AECA) in systemic lupus erythematosus (SLE). D'Cruz D, et al. **Clin Rev Allergy Immunol** 1997 Spring;15(1):53–63 (54 ref.)

Autoantibodies in systemic lupus erythematosus. Alarcón–Segovia D, et al. **Curr Opin Rheumatol** 1996 Sep; 8(5):403–7 (33 ref.)

Autoantibodies in systemic lupus erythematosus. Cabral AR, et al. **Curr Opin Rheumatol** 1997 Sep;9(5):387–92 (39 ref.)

Lymphocytes, cytokines, inflammation, and immune trafficking. Tsokos GC. **Curr Opin Rheumatol** 1996 Sep; 8(5):395–402 (74 ref.)

Retroviruses and systemic lupus erythematosus. Herrmann M, et al. **Immunol Rev** 1996 Aug;152:145–56 (54 ref.)

Do naturally occurring autoantibodies participate in the constitution of the pathological B–cell repertoire in systemic lupus erythematosus? Gilbert D, et al. **J Autoimmun** 1996 Apr;9(2):247–57 (72 ref.)

Insights into the basis of systemic lupus. Steinberg AD. **J Autoimmun** 1995 Dec;8(6):771–75 (92 ref.)

T cells of lupus and molecular targets for immunotherapy. Datta SK, et al. **J Clin Immunol** 1997 Jan;17(1):11–20 (150 ref.)

Systemic lupus erythematosus in childhood. Concordance in a pair of monozygotic twins for anti–dsDNA antibodies and discordance for disease expression [letter] Bustabad S, et al. **J Rheumatol** 1997 Jul;24(7):1450–1 (7 ref.)

The nuclear compartment of living cells is not an absolute immunologically sequestered site: evidence for spontaneous intranuclear entry of lupus autoantibodies to living cells. Golan TD. **Leukemia** 1997 Jan;11(1):6–9 (52 ref.)

Clinical connections: assays and assignment. Bell DA, et al. **Lupus** 1997;6(3):305–6 (15 ref.)

Ultraviolet light–induced keratinocyte apoptosis: a potential mechanism for the induction of skin lesions and autoantibody production in LE. Casciola–Rosen L, et al. **Lupus** 1997;6(2):175–80 (52 ref.)

T helper cells driving pathogenic anti–DNA autoantibody production in lupus: nucleosomal epitopes and CD40 ligand signals. Datta SK, et al. **Lupus** 1997;6(3):333–6 (4 ref.)

DNA antibodies focus on the light chain. Diamond B, et al. **Lupus** 1997;6(3):315–6 (2 ref.)

T and B cell recognition of idiotypes of anti–DNA autoantibodies. Gavalchin J, et al. **Lupus** 1997;6(3):337–43 (52 ref.)

The role of antibodies to DNA in systemic lupus erythematosus—a review and introduction to an international workshop on DNA antibodies held in London, May 1996. Isenberg DA, et al. **Lupus** 1997; 6(3):290–304 (146 ref.)

Are DNA antibodies actually pathogenic? Naparstek Y, et al. **Lupus** 1997;6(3):307–9 (8 ref.)

IgA deficiency and SLE: prevalence in a clinic population and a review of the literature. Rankin EC, et al. **Lupus** 1997;6(4):390–4 (37 ref.)

Expression of anti–DNA antibodies. Stevenson FK, et al. **Lupus** 1997;6(3):321–3 (7 ref.)

Genetic control of DNA antibody production: focus on the heavy chain. Tsao B, et al. **Lupus** 1997;6(3):310–4 (21 ref.)

T cells specific for DNA–binding peptides. Wang M, et al. **Lupus** 1997;6(3):349–50 (7 ref.)

Molecular, metabolic and immune evidence suggest that systemic autoimmune disease is antigen–mediated. Benke PJ. **Med Hypotheses** 1996 Nov;47(5):337–46 (130 ref.)

Autoantibody to the nucleosome subunit (H2A–H2B)–DNA is an early and ubiquitous feature of lupus–like conditions. Burlingame RW, et al. **Mol Biol Rep** 1996;23(3–4):159–66 (46 ref.)

What triggers anti–dsDNA antibodies? Herrmann M, et al. **Mol Biol Rep** 1996;23(3–4):265–7 (12 ref.)

Clinical and immunological aspects of autoantibodies to RA33/hnRNP–A/B proteins—a link between RA, SLE and MCTD. Steiner G, et al. **Mol Biol Rep** 1996; 23(3–4):167–71 (29 ref.)

Guidelines for looking at the antiphospholipid antibodies in systemic lupus erythematosus. Stratta P, et al. **Nephron** 1997;76(4):400–5 (70 ref.)

Direct immunofluorescence in lupus erythematosus (LE). Isfer RS, et al. **Rev Paul Med** 1996 Mar–Apr;114(2):1141–7 (19 ref.)

Anti–lymphocyte autoantibodies in systemic lupus erythematosus. Winfield JB, et al. **Trans Am Clin Climatol Assoc** 1996;108:127–35 (35 ref.)

Autoantibodies—what do they recognize? Tan EM. **Verh Dtsch Ges Pathol** 1996;80:1–11 (29 ref.)

[Antiphospholipid antibody/cofactors. What are they? Why, when and how to search for them? Is treatment justified?] Piette JC, et al. **Ann Med Interne (Paris)** 1996;147(7):492–7 (36 ref.) (Eng. Abstr.) **(Fre)**

[Kikuchi syndrome, Hashimoto thyroiditis and lupus serology. Apropos of a case] Bousquet E, et al. **Rev Med Interne** 1996;17(10):836–8 (14 ref.) (Eng. Abstr.) **(Fre)**

[Systemic lupus erythematosus and antiphospholipid syndrome] Gröne HJ. **Verh Dtsch Ges Pathol** 1996;80:21–37 (71 ref.) (Eng. Abstr.) **(Ger)**

[Nucleosome as an autoantigen in systemic lupus erythematosus] Gruenbaum E, et al. **Harefuah** 1997 Apr 1;132(7):475–8 (29 ref.) **(Heb)**

[Thymus in systemic lupus erythematosus] Kartashova VI, et al. **Klin Med (Mosk)** 1997;75(1):24–6 (15 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Delayed neuronal degeneration results from endogenous glutamate excess. Possible role in NP–SLE. Volpe BT. **Ann N Y Acad Sci** 1997 Aug 14;823:185–7 (23 ref.)

MICROBIOLOGY

Nocardiosis in systemic lupus erythematosus. Mok CC, et al. **Semin Arthritis Rheum** 1997 Feb;26(4):675–83 (63 ref.)

PATHOLOGY

Bullous systemic lupus erythematosus—a case report and review. Tay YK, et al. **Ann Acad Med Singapore** 1995 Nov; 24(6):879–82 (14 ref.)

Multiple basaloid cell hamartoma with alopecia and autoimmune disease (systemic lupus erythematosus). Akasaka T, et al. **J Dermatol** 1996 Nov;23(11):821–4 (12 ref.)

Systemic lupus erythematosus with obstructive uropathy. Case report and review. Kim HJ, et al. **J Korean Med Sci** 1995 Dec;10(6):462–9 (31 ref.)

Placental pathology in systemic lupus erythematosus and phospholipid antibody syndrome. Salafia CM, et al. **Rheum Dis Clin North Am** 1997 Feb;23(1):85–97 (72 ref.)

[Systemic lupus erythematosus and antiphospholipid syndrome] Gröne HJ. **Pathologe** 1996 Nov;17(6):405–16 (71 ref.) (Eng. Abstr.) **(Ger)**

[Systemic lupus erythematosus and antiphospholipid syndrome] Gröne HJ. **Verh Dtsch Ges Pathol** 1996;80:21–37 (71 ref.) (Eng. Abstr.) **(Ger)**

[New aspects on the morphology and pathogenesis of lupus erythematosus] Kerl H. **Z Hautkr** 1976 Feb 15;51(4):143–62 (0 ref.) **(Ger)**

PHYSIOPATHOLOGY

Prolactin and systemic lupus erythematosus. McMurray RW. **Ann Med Interne (Paris)** 1996;147(4):253–8 (37 ref.)

Hormones and lupus: defective dehydroepiandrosterone activity induces impaired interleukin–2 activity of T lymphocytes in patients with systemic lupus erythematosus. Suzuki N, et al. **Ann Med Interne (Paris)** 1996;147(4):248–52 (37 ref.)

Cerebral lupus vasculopathy. Mechanisms and clinical relevance. Hess DC. **Ann N Y Acad Sci** 1997 Aug 14; 823:154–68 (77 ref.)

The regulation of murine lupus. Peng SL, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:128–38 (96 ref.)

Oral contraceptives and systemic lupus erythematosus. Petri M, et al. **Arthritis Rheum** 1997 May;40(5):797–803 (88 ref.)

Neuroendocrine changes in systemic lupus erythematosus and Sjögren's syndrome. Fox RA, et al. **Baillieres Clin Rheumatol** 1996 May;10(2):333–47 (86 ref.)

Endocrine aspects of paediatric rheumatic diseases. Neeck G, et al. **Baillieres Clin Rheumatol** 1996 May;10(2):349–63 (69 ref.)

Outcome in pediatric rheumatic disease. Graham TB, et al. **Curr Opin Rheumatol** 1997 Sep;9(5):434–9 (32 ref.)

Lymphocytes, cytokines, inflammation, and immune trafficking. Tsokos GC, et al. **Curr Opin Rheumatol** 1997 Sep;9(5):380–6 (57 ref.)

Lupus and the central nervous system. West SG. **Curr Opin Rheumatol** 1996 Sep;8(5):408–14 (46 ref.)

Recognition and management of systemic lupus erythematosus. Schroeder JO, et al. **Drugs** 1997 Sep; 54(3):422–34 (117 ref.)

Keys to managing systemic lupus erythematosus. Roberts WN. **Hosp Pract (Off Ed)** 1997 Feb 15;32(2):113–6, 119–22, 125–6 (5 ref.)

Lack of association between prolactin levels and clinical activity in patients with systemic lupus erythematosus [letter; comment] Mok CC, et al. **J Rheumatol** 1996 Dec;

23(12):2185–6 (3 ref.) Comment on: J Rheumatol 1996 Apr;23(4):629–32.

Systemic lupus erythematosus: demographics, prognosis, and outcome. Klippel JH. **J Rheumatol Suppl** 1997 May; 48:67–71 (44 ref.)

Systemic lupus erythematosus in males. A study of 107 Latin American patients. Molina JF, et al. **Medicine (Baltimore)** 1996 May;75(3):124–30 (72 ref.)

[Cytokines and lupus] Emilie D, et al. **Ann Med Interne (Paris)** 1996;147(7):480–4 (29 ref.) (Eng. Abstr.) **(Fre)**

[Cell death and lupus] Fournié G. **Ann Med Interne (Paris)** 1996;147(7):472–9 (63 ref.) (Eng. Abstr.) **(Fre)**

[Cytokines in systemic lupus erythematosus] Robak E, et al. **Przegl Lek** 1996;53(8):623–6 (31 ref.) (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

Immunosuppression and immunomodulation of experimental models of systemic lupus erythematosus and antiphospholipid syndrome. Shoenfeld Y, et al. **Transplant Proc** 1996 Dec;28(6):3096–8 (33 ref.)

PSYCHOLOGY

Cognition and mood in systemic lupus erythematosus. Evaluation and pathogenesis. Denburg SD, et al. **Ann N Y Acad Sci** 1997 Aug 14;823:44–59 (107 ref.)

Cognitive disorders in systemic lupus erythematosus. Epidemiologic and clinical issues. Hanly JG, et al. **Ann N Y Acad Sci** 1997 Aug 14;823:60–8 (34 ref.)

Psychiatric and neurocognitive concomitants of systemic lupus erythematosus. Keenan PA, et al. **Ann N Y Acad Sci** 1997 Aug 14;823:69–80 (18 ref.)

Neuropsychiatric systemic lupus erythematosus. Stress, stroke, and seizures. Moore PM. **Ann N Y Acad Sci** 1997 Aug 14;823:1–17 (114 ref.)

Psychological aspects of systemic lupus erythematosus: cognitive function, mood, and self-report. Denburg SD, et al. **J Rheumatol** 1997 May;24(5):998–1003 (71 ref.)

Behaviour of MRL mice: an animal model of disturbed behaviour in systemic autoimmune disease. Szechtman H, et al. **Lupus** 1997;6(3):223–9 (40 ref.)

Psychiatric aspects of rheumatology. Moran MG. **Psychiatr Clin North Am** 1996 Sep;19(3):575–87 (53 ref.)

RADIOTHERAPY

Ultraviolet irradiation in systemic lupus erythematosus: friend or foe? Cohen MR, et al. **Br J Rheumatol** 1996 Oct; 35(10):1002–7 (68 ref.)

Prospects for UV-A1 therapy as a treatment modality in cutaneous and systemic LE. McGrath H Jr. **Lupus** 1997; 6(2):209–17 (81 ref.)

SURGERY

Surgery of systemic lupus erythematosus arthritis of the hand. Nalebuff EA. **Hand Clin** 1996 Aug;12(3):591–602 (23 ref.)

THERAPY

Splenic hematopoiesis after granulocyte-colony stimulating factor therapy in a lupus patient [letter] Tsoi WC, et al. **Am J Hematol** 1996 Dec;53(4):283–4 (4 ref.)

Clinical studies for systemic lupus erythematosus. From chaos to rigor. Kunitz SC. **Ann N Y Acad Sci** 1997 Aug 14;823:308–18 (12 ref.)

Intravenous immune globulin for inducing remissions in systemic lupus erythematosus. Heyneman CA, et al. **Ann Pharmacother** 1997 Feb;31(2):242–4 (27 ref.)

New methods of treatment in an experimental murine model of systemic lupus erythematosus induced by idiotypic manipulation. Shoenfeld Y, et al. **Ann Rheum Dis** 1997 Jan; 56(1):5–11 (71 ref.)

The Lupus Plasmapheresis Study Group: rationale and updated interim report. Euler HH, et al. **Artif Organs** 1996 Apr;20(4):356–9 (33 ref.)

Prognosis and treatment of systemic lupus erythematosus. Gladman DD. **Curr Opin Rheumatol** 1996 Sep;8(5):430–7 (60 ref.)

Approaches to the management of systemic lupus erythematosus. Strand V. **Curr Opin Rheumatol** 1997 Sep; 9(5):410–20 (80 ref.)

Immunoregulatory circuits and potential treatment of connective tissue diseases. Alcocer-Varela J, et al. **Int Arch Allergy Immunol** 1996 Dec;111(4):348–54 (51 ref.)

Treatment of systemic lupus erythematosus and antiphospholipid syndrome: from experimental models to patients' bedside. Krause I, et al. **Int Arch Allergy Immunol** 1996 Dec;111(4):355–61 (51 ref.)

T cells of lupus and molecular targets for immunotherapy. Datta SK, et al. **J Clin Immunol** 1997 Jan;17(1):11–20 (150 ref.)

Hematopoietic stem cell transplantation for autoimmune diseases. Brooks PM. **J Rheumatol Suppl** 1997 May; 48:19–22 (22 ref.)

The potential role of autologous stem cell transplantation in patients with systemic lupus erythematosus. Hahn BH. **J Rheumatol Suppl** 1997 May;48:89–93 (35 ref.)

Stem cell transplantation for severe autoimmune disorders, with special reference to rheumatic diseases. Marmont AM. **J Rheumatol Suppl** 1997 May;48:13–8 (48 ref.)

The evolving role of blood and marrow transplantation for the treatment of autoimmune diseases. Sullivan KM, et al. **J Rheumatol Suppl** 1997 May;48:1–4 (59 ref.)

Obstetric management of the high-risk lupus pregnancy. Mascola MA, et al. **Rheum Dis Clin North Am** 1997 Feb; 23(1):119–32 (67 ref.)

Outcome of silent lupus nephritis. Gonzalez-Crespo MR, et al. **Semin Arthritis Rheum** 1996 Aug;26(1):468–76 (73 ref.)

[Immunosuppressive and immunomodulator treatment of severe systemic lupus] Guillevin L. **Ann Med Interne (Paris)** 1996;147(7):498–505 (74 ref.) (Eng. Abstr.) **(Fre)**

[The therapy of systemic lupus erythematosus (see comments)] Hiepe F, et al. **Dtsch Med Wochenschr** 1996 Sep 13;121(37):1129–33 (16 ref.) Comment in: Dtsch Med Wochenschr 1997 Jul 4;122(27):877. **(Ger)**

[Specific inhibition of anti-DNA antibody production by an anti-DH ribozyme] Suzuki Y, et al. **Nippon Rinsho** 1997 Jun;55(6):1557–61 (18 ref.) (Eng. Abstr.) **(Jpn)**

VETERINARY

Animal models for nervous system disease in systemic lupus erythematosus. Brey RL, et al. **Ann N Y Acad Sci** 1997 Aug 14;823:97–106 (55 ref.)

VIROLOGY

Retroviruses and systemic lupus erythematosus. Herrmann M, et al. **Immunol Rev** 1996 Aug;152:145–56 (54 ref.)

[Endogenous retroviral sequences as a factor in the pathogenesis of systemic lupus erythematosus] Walchner M, et al. **Hautarzt** 1996 Jul;47(7):502–9 (55 ref.) (Eng. Abstr.) **(Ger)**

[Systemic lupus erythematosus (SLE) and retrovirus] Sekigawa I, et al. **Nippon Rinsho** 1997 Jun;55(6):1492–7 (20 ref.) (Eng. Abstr.) **(Jpn)**

LUPUS GLOMERULONEPHRITIS see **LUPUS NEPHRITIS**

LUPUS NEPHRITIS

Lupus nephritis. Davis JC, et al. **Curr Opin Rheumatol** 1996 Sep;8(5):415–23 (85 ref.)

CHEMICALLY INDUCED

Propylthiouracil-induced diffuse proliferative lupus nephritis: review of immunological complications. Prasad GV, et al. **J Am Soc Nephrol** 1997 Jul;8(7):1205–10 (18 ref.)

COMPLICATIONS

Mesangial lupus nephritis with associated nephrotic syndrome. Stankeviciute N, et al. **J Am Soc Nephrol** 1997 Jul;8(7):1199–204 (13 ref.)

SLE nephropathy in a patient with HIV infection: case report and review of the literature. Kudva YC, et al. **J Rheumatol** 1996 Oct;23(10):1811–5 (23 ref.)

DIAGNOSIS

Membranous lupus nephritis with antineutrophil cytoplasmic antibody-associated segmental necrotizing and crescentic glomerulonephritis. Marshall S, et al. **Am J Kidney Dis** 1997 Jan;29(1):119–24 (28 ref.)

[Progress in diagnosis and treatment of renal diseases. II. nephropathies associated with systemic diseases. 2. Lupus nephritis] Nagasawa T. **Nippon Naika Gakkai Zasshi** 1996 Oct 10;85(10):1657–62 (5 ref.) **(Jpn)**

DRUG THERAPY

Cyclophosphamide in lupus nephritis [editorial] Steinberg AD, et al. **J Rheumatol** 1995 Oct;22(10):1812–5 (12 ref.)

Severe and prolonged jaundice in a lupus nephritis patient treated with cyclophosphamide. Moroni G, et al. **Nephrol Dial Transplant** 1997 Apr;12(4):793–6 (15 ref.)

Treatment of lupus nephritis. Austin HA, et al. **Semin Nephrol** 1996 Nov;16(6):527–35 (87 ref.)

[Treatment of nephritis in systemic lupus erythematodes] Ligtenberg G, et al. **Ned Tijdschr Geneeskd** 1996 Sep 28; 140(39):1941–4 (27 ref.) **(Dut)**

[Methylprednisolone pulse therapy in the early phases of lupus nephritis] Mitić I, et al. **Srp Arh Celok Lek** 1996;124 Suppl 1:67–9 (42 ref.) (Eng. Abstr.) **(Scc)**

ETIOLOGY

Nucleosomes and the pathogenesis of lupus nephritis. Berden JH, et al. **Kidney Blood Press Res** 1997;20(3):198–200 (15 ref.)

GENETICS

Genetic dissection of lupus nephritis in murine models of SLE. Wakeland EK, et al. **J Clin Immunol** 1997 Jul; 17(4):272–81 (53 ref.)

IMMUNOLOGY

Lupus nephritis: the value of biochemical and immunological monitoring of disease activity. Vangelista A, et al. **Ren Fail** 1996 Sep;18(5):755–63 (35 ref.)

PATHOLOGY

Managing lupus nephritis: algorithms for conservative use of renal biopsy. Salach RH, et al. **Cleve Clin J Med** 1996 Mar-Apr;63(2):106–15 (43 ref.)

PHYSIOPATHOLOGY

Autoimmunity against nucleosomes and lupus nephritis. Van Bruggen MC, et al. **Ann Med Interne (Paris)** 1996; 147(7):485–9 (61 ref.)

THERAPY

Management of lupus nephritis. Balow JE, et al. **Kidney Int Suppl** 1996 Jan;53:S88–92 (31 ref.)

The role of the kidney biopsy in the treatment of lupus nephritis. Kashgarian M. **Ren Fail** 1996 Sep;18(5):765–73 (44 ref.)

[Treatments of lupus nephropathies] Delahousse M. **Ann Med Interne (Paris)** 1996;147(7):507–12 (37 ref.) (Eng. Abstr.) **(Fre)**

[Progress in diagnosis and treatment of renal diseases. II. nephropathies associated with systemic diseases. 2. Lupus nephritis] Nagasawa T. **Nippon Naika Gakkai Zasshi** 1996 Oct 10;85(10):1657–62 (5 ref.) **(Jpn)**

[Lupus nephropathy--therapeutic options 1996] Matuszkiewicz-Rowińska J, et al. **Pol Arch Med Wewn** 1997 Jan;97(1):85–90 (41 ref.) **(Pol)**

[A case of the successful use of protein A adsorption in a patient with acute kidney failure in rapidly progressing lupus glomerulonephritis] Aksenov VA, et al. **Ter Arkh** 1997;69(2):66–8 (14 ref.) **(Rus)**

LUPUS PANNICULITIS see **PANNICULITIS, LUPUS ERYTHEMATOSUS**

LUPUS VULGARIS see **LUPUS**

LURCHER MICE see **MICE, NEUROLOGIC MUTANTS**

LUTEAL PHASE

PHYSIOLOGY

Luteal function--luteolysis. Messinis IE. **Ann N Y Acad Sci** 1997 Jun 17;816:151–7 (45 ref.)

LUTEINIZING HORMONE see **LH**

LUTEINIZING HORMONE, ALPHA SUBUNIT see **GLYCOPROTEIN HORMONES, ALPHA SUBUNIT**

LUTEINIZING HORMONE RECEPTORS see **RECEPTORS, LH**

LUTEINIZING HORMONE-RELEASING HORMONE see **GONADORELIN**

LUTEMBACHER'S SYNDROME

[Lutembacher's syndrome] Hoshino S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):20–1 (10 ref.) **(Jpn)**

LUTEOTROPIN see **PROLACTIN**

LUTEOVIRUS

Molecular biology of luteoviruses. Mayo MA, et al. **Adv Virus Res** 1996;46:413–60 (143 ref.)

LUTROPIN see **LH**

LUTROPIN RECEPTORS see **RECEPTORS, LH**

LUTZOMYIA see **PSYCHODIDAE**

LY ANTIGENS see **ANTIGENS, LY**

17,20-LYASE see **17 ALPHA-HYDROXYPROGESTERONE ALDOLASE**

LYASES

PHYSIOLOGY

Regulation of eukaryotic abasic endonucleases and their role in genetic stability. Demple B, et al. **Environ Health Perspect** 1997 Jun;105 Suppl 4:931–4 (25 ref.)

LYCINE see **BETAINE**

LYCOPERSICON ESCULENTUM see **TOMATOES**

LYCOREMINE see **GALANTHAMINE**

LYELL'S SYNDROME see **EPIDERMAL NECROLYSIS, TOXIC**

LYING

see related
LIE DETECTION

Symbolic aspects of confabulation following brain injury: influence of premorbid personality. Weinstein EA.

Bull Menninger Clin 1996 Summer;60(3):331–50 (39 ref.)
Provoking nonepileptic seizures: the ethics of deceptive diagnostic testing. Burack JH, et al. **Hastings Cent Rep** 1997 Jul–Aug;27(4):24–33 (25 ref.)

LYME BORRELIOSIS see **LYME DISEASE**

LYME DISEASE

Lyme neuroborreliosis in children. Christen HJ. **Ann Med** 1996 Jun;28(3):235–40 (48 ref.)
Lyme disease. Shift the paradigm! Ellenbogen C. **Arch Fam Med** 1997 Mar–Apr;6(2):191–5 (35 ref.)
Lyme borreliosis: an update. Cutler SJ. **Br J Hosp Med** 1996 Dec 11–1997 Jan 14;56(11):581–4 (13 ref.)
Myths and facts about Lyme disease. Sigal LH. **Cleve Clin J Med** 1997 Apr;64(4):203–9 (20 ref.)
Is human granulocytic ehrlichiosis a new Lyme disease? Review and comparison of clinical, laboratory, epidemiological, and some biological features. Dumler JS. **Clin Infect Dis** 1997 Jul;25 Suppl 1:S43–7 (54 ref.)
Lyme disease and ehrlichiosis. Liveris D. **Clin Podiatr Med Surg** 1996 Oct;13(4):595–634 (156 ref.)
Neonatal jaundice, animal-induced injuries and disease, and immunizations. Gerson WT. **Curr Opin Pediatr** 1997 Aug; 9(4):447–55 (45 ref.)
Lyme disease. Evans J. **Curr Opin Rheumatol** 1997 Jul; 9(4):328–36 (97 ref.)
Lyme disease. Athreya BH, et al. **Curr Probl Pediatr** 1996 Jul;26(6):189–207 (126 ref.)
[Spirochaeta! myocarditis] Shimizu K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):158–60 (16 ref.) **(Jpn)**
[Unilateral chorioretinitis as presentation form of Lyme disease (letter)] Vila N, et al. **Med Clin (Barc)** 1996 Nov 2;107(15):597 (5 ref.) **(Spa)**

CLASSIFICATION

Neurologic manifestation and classification of borreliosis. Haass A, et al. **Infection** 1996 Nov–Dec;24(6):467–9 (12 ref.)

COMPLICATIONS

Retinal vasculitis in Lyme borreliosis. Leys AM, et al. **Bull Soc Belge Ophtalmol** 1995;259:205–14 (64 ref.)
Neurologic manifestation and classification of borreliosis. Haass A, et al. **Infection** 1996 Nov–Dec;24(6):467–9 (12 ref.)
The ocular manifestations of Lyme disease. Zaidman GW. **Int Ophthalmol Clin** 1997 Spring;37(2):13–28 (49 ref.)
Cardiovascular manifestations of Lyme disease. Paparone PW. **J Am Osteopath Assoc** 1997 Mar;97(3):156–61 (31 ref.)
[The cardiac and neurological manifestations of Lyme borreliosis in congenital first-degree AV block] Stille-Siegener M, et al. **Dtsch Med Wochenschr** 1996 Oct 18;121(42):1292–6 (18 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Recognition and management of Lyme disease. Verdon ME, et al. **Am Fam Physician** 1997 Aug;56(2):427–36, 439–40 (37 ref.)
PCR in laboratory diagnosis of human Borrelia burgdorferi infections. Schmidt BL. **Clin Microbiol Rev** 1997 Jan; 10(1):185–201 (195 ref.)
Lyme disease. Evans J. **Curr Opin Rheumatol** 1996 Jul; 8(4):327–33 (78 ref.)
Differentiation of orofacial pain related to Lyme disease from other dental and facial pain disorders. Heir GM. **Dent Clin North Am** 1997 Apr;41(2):243–58 (32 ref.)
Current aspects of Lyme disease and other Borrelia burgdorferi infections. Berger BW. **Dermatol Clin** 1997 Apr;15(2):247–55 (58 ref.)
Borrelia burgdorferi infection: clinical diagnostic techniques. Coyle PK. **Immunol Invest** 1997 Jan–Feb;26(1–2):117–28 (67 ref.)
Lyme borreliosis--problems of serological diagnosis. Hofmann H. **Infection** 1996 Nov–Dec;24(6):470–2 (8 ref.)
Physician preferences in the diagnosis and treatment of Lyme disease in the United States. Ziska MH, et al. **Infection** 1996 Mar–Apr;24(2):182–6 (29 ref.)
Neuro-ophthalmic manifestations of Lyme disease. Balcer LJ, et al. **J Neuroophthalmol** 1997 Jun;17(2):108–21 (160 ref.)
Diagnosis and treatment of Lyme arthritis. Steere AC. **Med Clin North Am** 1997 Jan;81(1):179–94 (90 ref.)
Lyme borreliosis: laboratory considerations. Golightly MG. **Semin Neurol** 1997 Mar;17(1):11–7 (65 ref.)
European Union Concerted Action on Risk Assessment in Lyme Borreliosis: clinical case definitions for Lyme borreliosis. Stanek G, et al. **Wien Klin Wochenschr** 1996 Dec 13;108(23):741–7 (28 ref.)
[Lyme borreliosis yesterday, today and tomorrow] Wahlberg P. **Duodecim** 1995;111(14):1298–303 (34 ref.) **(Fin)**
[Contemporary understanding of diagnosing Lyme borreliosis] Flisiak R, et al. **Pol Arch Med Wewn** 1995 Nov; 94(5):432–5 (6 ref.) **(Pol)**

DRUG THERAPY

Recognition and management of Lyme disease. Verdon ME, et al. **Am Fam Physician** 1997 Aug;56(2):427–36, 439–40 (37 ref.)
Controversies in the use of antimicrobials for the prevention and treatment of Lyme disease. Wormser GP. **Infection** 1996 Mar–Apr;24(2):178–81 (38 ref.)
Physician preferences in the diagnosis and treatment of Lyme disease in the United States. Ziska MH, et al. **Infection** 1996 Mar–Apr;24(2):182–6 (29 ref.)

EPIDEMIOLOGY

Lyme disease. Evans J. **Curr Opin Rheumatol** 1996 Jul; 8(4):327–33 (78 ref.)
Lyme disease during pregnancy. Silver HM. **Infect Dis Clin North Am** 1997 Mar;11(1):93–7 (11 ref.)
Lyme borreliosis in the southern United States: a review. Oliver JH Jr. **J Parasitol** 1996 Dec;82(6):926–35 (134 ref.)

ETIOLOGY

Lyme disease: a review of aspects of its immunology and immunopathogenesis. Sigal LH. **Annu Rev Immunol** 1997; 15:63–92 (289 ref.)
[Platelet activating factor (PAF) and Lyme disease] Isogai E, et al. **Nippon Saikingaku Zasshi** 1996 Aug;51(3):863–9 (15 ref.) **(Jpn)**

GENETICS

Arthropod- and host-specific gene expression by Borrelia burgdorferi. de Silva AM, et al. **J Clin Invest** 1997 Feb 1;99(3):377–9 (11 ref.)

IMMUNOLOGY

Lyme disease: a review of aspects of its immunology and immunopathogenesis. Sigal LH. **Annu Rev Immunol** 1997; 15:63–92 (289 ref.)
Why is chronic Lyme borreliosis chronic? Aberer E, et al. **Clin Infect Dis** 1997 Jul;25 Suppl 1:S64–70 (61 ref.)
Immunity to Lyme disease: protection, pathology and persistence. Seiler KP, et al. **Curr Opin Immunol** 1996 Aug; 8(4):503–9 (93 ref.)
Lyme borreliosis--problems of serological diagnosis. Hofmann H. **Infection** 1996 Nov–Dec;24(6):470–2 (8 ref.)
The recombinant outer surface protein A (lipOspA) of Borrelia burgdorferi: a Lyme disease vaccine. Wallich R, et al. **Infection** 1996 Sep–Oct;24(5):396–7 (12 ref.)
Immunologic mechanisms in Lyme neuroborreliosis: the potential role of autoimmunity and molecular mimicry. Sigal LH. **Semin Neurol** 1997 Mar;17(1):63–8 (63 ref.)

MICROBIOLOGY

Genetic diversity of Borrelia of Lyme borreliosis. Postic D, et al. **Wien Klin Wochenschr** 1996 Dec 13;108(23):748–51 (33 ref.)
[Genetically strange Borrelia and conservation of genes associated with motility in Lyme disease Borrelia] Yanagihara Y, et al. **Nippon Saikingaku Zasshi** 1996 Oct; 51(4):1015–24 (14 ref.) **(Jpn)**
[Present status of Lyme borreliosis and characterization of Lyme disease Borrelia isolated in Japan] Masuzawa T. **Yakugaku Zasshi** 1997 Jun;117(6):319–38 (59 ref.) (Eng. Abstr.) **(Jpn)**

PARASITOLOGY

Ticks and Borrelia: model systems for investigating pathogen-arthropod interactions. Schwan TG. **Infect Agents Dis** 1996 Jun;5(3):167–81 (120 ref.)

PATHOLOGY

Functional brain imaging and neuropsychological testing in Lyme disease. Fallon BA, et al. **Clin Infect Dis** 1997 Jul; 25 Suppl 1:S57–63 (46 ref.)
Immunity to Lyme disease: protection, pathology and persistence. Seiler KP, et al. **Curr Opin Immunol** 1996 Aug; 8(4):503–9 (93 ref.)
Lyme neuroborreliosis in the rhesus monkey. England JD, et al. **Semin Neurol** 1997 Mar;17(1):53–6 (32 ref.)
Mechanisms of injury in Lyme neuroborreliosis. Garcia-Monco JC, et al. **Semin Neurol** 1997 Mar; 17(1):57–62 (90 ref.)
Lyme encephalopathy: a neuropsychological perspective. Kaplan RF, et al. **Semin Neurol** 1997 Mar;17(1):31–7 (42 ref.)

PHYSIOPATHOLOGY

Neuroborreliosis: central nervous system involvement. Halperin JJ. **Semin Neurol** 1997 Mar;17(1):19–24 (48 ref.)
Peripheral nervous system Lyme borreliosis. Logigian EL. **Semin Neurol** 1997 Mar;17(1):25–30 (0 ref.)
Lyme disease in children. Shapiro ED, et al. **Semin Neurol** 1997 Mar;17(1):39–44 (63 ref.)

PREVENTION & CONTROL

The outer surface protein A (OspA) of Borrelia burgdorferi: a vaccine candidate and bioactive mediator. Kramer MD, et al. **Infection** 1996 Mar–Apr;24(2):190–4 (35 ref.)
Experimental immunization against Lyme borreliosis with recombinant Osp proteins: an overview. Sadziene A, et al. **Infection** 1996 Mar–Apr;24(2):195–202 (89 ref.)
The recombinant outer surface protein A (lipOspA) of Borrelia burgdorferi: a Lyme disease vaccine. Wallich R, et al. **Infection** 1996 Sep–Oct;24(5):396–7 (12 ref.)
Immunological and molecular variability of OspA and OspC. Implications for Borrelia vaccine development. Wilske B, et al. **Infection** 1996 Mar–Apr;24(2):208–12 (32 ref.)
Lyme disease vaccine. Wormser GP. **Infection** 1996 Mar–Apr;24(2):203–7 (54 ref.)
Controversies in the use of antimicrobials for the prevention and treatment of Lyme disease. Wormser GP. **Infection** 1996 Mar–Apr;24(2):178–81 (38 ref.)
Treatment and prevention of Lyme disease, with emphasis on antimicrobial therapy for neuroborreliosis and vaccination. Wormser GP. **Semin Neurol** 1997 Mar; 17(1):45–52 (91 ref.)

PSYCHOLOGY

Functional brain imaging and neuropsychological testing in Lyme disease. Fallon BA, et al. **Clin Infect Dis** 1997 Jul; 25 Suppl 1:S57–63 (46 ref.)

THERAPY

Treatment of Lyme arthritis. Cimmino MA, et al. **Infection** 1996 Jan–Feb;24(1):91–3 (28 ref.)
Treatment and prevention of Lyme disease, with emphasis on antimicrobial therapy for neuroborreliosis and vaccination. Wormser GP. **Semin Neurol** 1997 Mar; 17(1):45–52 (91 ref.)

TRANSMISSION

Fatal attraction or how do we get tick bites? Kahl O. **Infection** 1996 Sep–Oct;24(5):394–5 (5 ref.)
Arthropod- and host-specific gene expression by Borrelia burgdorferi. de Silva AM, et al. **J Clin Invest** 1997 Feb 1;99(3):377–9 (11 ref.)
[Early summer meningoencephalitis and Lyme borreliosis. Tick-borne diseases] **Med Monatsschr Pharm** 1997 May; 20(5):126–32 (2 ref.) **(Ger)**

VETERINARY

Lyme disease: laboratory diagnosis of infected and vaccinated symptomatic dogs. Jacobson RH, et al. **Semin Vet Med Surg (Small Anim)** 1996 Aug;11(3):172–82 (37 ref.)
Do roe deer (Capreolus capreolus) spread Borrelia-infected Ixodes ricinus ticks? Rijpkema SG. **Vet Q** 1996;18 Suppl 3:S146–7 (14 ref.)

LYMNAEA

PHYSIOLOGY

In vivo neuropharmacological and in vitro laser ablation techniques as tools in the analysis of neuronal circuits underlying behavior in a molluscan model system. Kemenes G. **Gen Pharmacol** 1997 Jul;29(1):7–15 (90 ref.)

LYMPH

PHYSIOLOGY

Perireceptor events in olfaction. Pelosi P. **J Neurobiol** 1996 May;30(1):3–19 (99 ref.)

LYMPH NODE DISSECTION see **LYMPH NODE EXCISION**

LYMPH NODE EXCISION

Lymphangiectomy and treatment modalities in Merkel cell carcinoma: a report of five new cases. Vandeput JJ, et al. **Anticancer Res** 1996 Nov–Dec;16(6B):3887–93 (49 ref.)
Theoretical and empirical arguments in relation to elective lymph node dissection for melanoma. Piepkorn M, et al. **Arch Dermatol** 1997 Aug;133(8):995–1002 (110 ref.)
Breast cancer: current issues in diagnosis and treatment [see comments] Furnival CM. **Aust N Z J Surg** 1997 Jan; 67(1):47–58 (55 ref.) Comment in: Aust N Z J Surg 1997 Jul;67(7):476.
Retroperitoneal lymphadenectomy in staging and treatment of clinical stage I and II nonseminomatous testis cancer (NSGCT): the development of nerve-sparing techniques. Donohue JP. **Cancer Treat Res** 1996;88:105–19 (20 ref.)
Sentinel node dissection in the treatment of melanoma. Report of three cases and review of the literature. Cottingham T, et al. **Dermatol Surg** 1997 Feb;23(2):113–8; discussion 118–9 (33 ref.)
Primary treatment in stage II non-seminomatous germ cell tumours of the testis: a matter of scalpel or drug infusion? Culine S, et al. **Eur J Cancer** 1996 Sep;32A(10):1641–4 (31 ref.)
Is axillary lymph node dissection necessary in routine management of breast cancer? No. Cady B. **Important Adv Oncol** 1996;:251–65 (119 ref.)
Is axillary lymph node dissection necessary in the routine management of breast cancer? Yes. Moore MP, et al. **Important Adv Oncol** 1996;:245–50 (53 ref.)
Case against axillary lymphadenectomy for most patients with infiltrating breast cancer [editorial] Cady B. **J Surg Oncol** 1997 Sep;66(1):7–10 (34 ref.)
Axillary lymphadenectomy: a diagnostic and therapeutic procedure [editorial] Moore MP, et al. **J Surg Oncol** 1997 Sep;66(1):2–6 (42 ref.)

LYMPH NODE EXCISION

Role of sentinel node biopsy in the management of malignant melanoma. North JH Jr, et al. **Oncology (Huntingt)** 1996 Aug;10(8):1237–42; discussion 1242–6 (20 ref.)

Current role of retroperitoneal lymph node dissection in testicular cancer. Steele GS, et al. **Oncology (Huntingt)** 1997 May;11(5):717–29; discussion 730–37 passim (56 ref.)

Surgical management of patients with intermediate thickness melanoma: current role of elective lymph node dissection. Cole DJ, et al. **Semin Oncol** 1996 Dec;23(6):719–24 (41 ref.)

Axillary dissection: when and how radical? Morrow M. **Semin Surg Oncol** 1996 Sep–Oct;12(5):321–7 (51 ref.)

Surgical management of stage I and II melanoma patients: approach to the regional lymph node basin. Ross MI. **Semin Surg Oncol** 1996 Nov–Dec;12(6):394–401 (43 ref.)

Retroperitoneal lymphadenectomy: the traditional treatment option. Jewett MA, et al. **Semin Urol Oncol** 1996 Feb; 14(1):24–9 (16 ref.)

Role of axillary dissection in mammographically detected breast cancer. Jamali FR, et al. **Surg Oncol Clin N Am** 1997 Apr;6(2):343–58 (85 ref.)

[Axillary lymph node dissection in clinically occult breast cancer] Le Bouëdec G, et al. **Bull Cancer** 1996 Jul; 83(7):581–8 (50 ref.) (Eng. Abstr.) **(Fre)**

[Radical surgery and lymph node dissection in bronchial carcinoma] Schirren J, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:790–7 (8 ref.) (Eng. Abstr.) **(Ger)**

[Lymphadenectomy in bronchial carcinoma: facts and fiction] Schildberg FW, et al. **Zentralbl Chir** 1996;121(2):96–101 (21 ref.) (Eng. Abstr.) **(Ger)**

[Sentinal node sampling in patients with malignant melanoma] Yaniv D, et al. **Harefuah** 1997 May 15;132(10):711–3 (18 ref.) **(Heb)**

[Lymph node excision in stomach cancer and clinical comparative tests] Sakamoto J, et al. **Nippon Geka Gakkai Zasshi** 1996 Oct;97(10):926–31 (18 ref.) **(Jpn)**

[Squamous cell carcinoma of unknown origin affecting mediastinal lymph nodes] Yodonawa S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec; 34(12):1364–8 (10 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Postmastectomy pain syndromes. Kwekkeboom K. **Cancer Nurs** 1996 Feb;19(1):37–43 (24 ref.)

Predicting pelvic lymph node involvement in patients with localized prostate cancer. Ekman P. **Eur Urol** 1997;32 Suppl 3:60–4 (19 ref.)

The effect of sartorius transposition on wound morbidity following inguinal–femoral lymphadenectomy. Paley PJ, et al. **Gynecol Oncol** 1997 Feb;64(2):237–41 (20 ref.)

[Frequency of lymphedema of the upper limb after treatment of breast cancer. Risk factors. Apropos of 683 cases] Ferrandez JC, et al. **Bull Cancer** 1996 Dec;83(12):989–95 (21 ref.) (Eng. Abstr.) **(Fre)**

INSTRUMENTATION

[Lymph node excision in thyroid carcinoma] Dralle H, et al. **Chirurg** 1996 Aug;67(8):788–806 (108 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Laparoscopic pelvic and aortic lymphadenectomy. Kadar N. **Baillieres Clin Obstet Gynaecol** 1995 Dec;9(4):651–73 (24 ref.)

Laparoscopic staging of endometrial cancer. Fowler JM. **Clin Obstet Gynecol** 1996 Sep;39(3):669–85 (54 ref.)

Laparoscopic management of gynecological malignancies. Kadar N. **Curr Opin Obstet Gynecol** 1997 Aug;9(4):247–55 (52 ref.)

Surgical management of cervical lymph node metastases. Eicher SA, et al. **Curr Opin Oncol** 1996 May;8(3):215–20 (30 ref.)

Extent of resection and lymphadenectomy in early Barrett's cancer. Korst RJ, et al. **Dis Esophagus** 1997 Jul;10(3):172–8 (42 ref.)

Extent of resection and lymphadenectomy in early squamous cell esophageal cancer. Nabeya K, et al. **Dis Esophagus** 1997 Jul;10(3):159–61 (28 ref.)

The gamma-probe-guided resection of radiolabeled primary lymph nodes. Alex JC, et al. **Surg Oncol Clin N Am** 1996 Jan;5(1):33–41 (18 ref.)

[Axillary node removal prepared by liposuction and assisted by endoscopy in the surgical treatment of breast cancers] Brun JL, et al. **Contracept Fertil Sex** 1997 Mar; 25(3):XIV–XVIII (9 ref.) **(Fre)**

[Lymph node dissections in malignant melanoma] Hohenberger W, et al. **Chirurg** 1996 Aug;67(8):779–87 (24 ref.) (Eng. Abstr.) **(Ger)**

[Principles and value of lymph node excision in colorectal carcinoma] Lehnert T, et al. **Chirurg** 1996 Sep;67(9):889–99 (74 ref.) (Eng. Abstr.) **(Ger)**

[Basic principles and value of lymphadenectomy in breast carcinoma] Schildberg FW, et al. **Chirurg** 1996 Aug; 67(8):771–8 (38 ref.) (Eng. Abstr.) **(Ger)**

[Principles and results of systematic lymph node dissection in surgically treated bronchial carcinoma] Schirren J, et al. **Chirurg** 1996 Sep;67(9):869–76 (35 ref.) (Eng. Abstr.) **(Ger)**

[Principles and value of lymph node excision in tumors of the pancreatobiliary system] Schumpelick V, et al. **Chirurg** 1996 Sep;67(9):900–6 (68 ref.) (Eng. Abstr.) **(Ger)**

[Lymphadenectomy in tumors of the upper gastrointestinal tract] Siewert JR, et al. **Chirurg** 1996 Sep;67(9):877–88 (29 ref.) (Eng. Abstr.) **(Ger)**

[Current surgical therapy of breast carcinoma and subsequent requirements for histopathologic diagnosis] Schönfelder M. **Zentralbl Chir** 1997;122(2):74–8 (17 ref.) (Eng. Abstr.) **(Ger)**

MORTALITY

Extended lymph node dissection in gastrointestinal cancer. Noguchi M, et al. **J Surg Oncol** 1997 May;65(1):57–65 (86 ref.)

LYMPH NODE HYPERPLASIA, GIANT see **GIANT LYMPH NODE HYPERPLASIA**

LYMPH NODE SYNDROME, MUCOCUTANEOUS see **MUCOCUTANEOUS LYMPH NODE SYNDROME**

LYMPH NODES

see related
LYMPH NODE EXCISION
LYMPHOGRAPHY
RADICAL NECK DISSECTION

Morphology, function and pathology of follicular dendritic cells. Imai Y, et al. **Pathol Int** 1996 Nov;46(11):807–33 (127 ref.)

[Differentiated thyroid cancer revealed by cervical adenopathy] Rodier JF, et al. **Ann Endocrinol (Paris)** 1997; 58(3):268–71 (28 ref.) **(Fre)**

ANATOMY & HISTOLOGY

Cords, channels, corridors and conduits: critical architectural elements facilitating cell interactions in the lymph node cortex. Gretz JE, et al. **Immunol Rev** 1997 Apr;156:11–24 (78 ref.)

[Current data on the structural–functional organization of the lymph node] Vyrenkov IuE, et al. **Morfologiia** 1995; 108(3):84–90 (47 ref.) **(Rus)**

BLOOD SUPPLY

High endothelial venules of the rat lymph node. A review and a question: is their activity antigen specific? Sainte-Marie G, et al. **Anat Rec** 1996 Aug;245(4):593–620 (144 ref.)

CYTOLOGY

Sophisticated strategies for information encounter in the lymph node: the reticular network as a conduit of soluble information and a highway for cell traffic. Gretz JE, et al. **J Immunol** 1996 Jul 15;157(2):495–9 (55 ref.)

DRUG EFFECTS

The local lymph node assay: a viable alternative to currently accepted skin sensitization tests. Basketter DA, et al. **Food Chem Toxicol** 1996 Oct;34(10):985–97 (70 ref.)

The local lymph node assay: status of validation. Chamberlain M, et al. **Food Chem Toxicol** 1996 Oct;34(10):999–1002 (20 ref.)

The popliteal lymph node assay in mice: screening of drugs and other chemicals for immunotoxic hazard. Goebel C, et al. **Inflamm Res** 1996 Dec;45 Suppl 2:S85–90 (50 ref.)

The popliteal lymph node assay in 1996. Descotes J, et al. **Toxicology** 1997 Apr 11;119(1):45–9 (21 ref.)

IMMUNOLOGY

Lentivirus replication in lymphoid tissue: use of lymphatic cannulation to study the initial stages of infection and immunity. McConnell I, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):417–20 (18 ref.)

Regulation of lymphocyte migration into lymph nodes by high endothelial venules. Ager A. **Biochem Soc Trans** 1997 May;25(2):421–8 (46 ref.)

High-endothelial-venule ligands for L-selectin: identification and functions. Rosen SD, et al. **Biochem Soc Trans** 1997 May;25(2):428–33 (45 ref.)

Sophisticated strategies for information encounter in the lymph node: the reticular network as a conduit of soluble information and a highway for cell traffic. Gretz JE, et al. **J Immunol** 1996 Jul 15;157(2):495–9 (55 ref.)

[An efficient, antigen-saving, labor-saving, and time-saving technique for making monoclonal antibodies with enlarged rat lymph nodes] Sado Y, et al. **Seikagaku** 1997 Feb; 69(2):128–31 (6 ref.) **(Jpn)**

METABOLISM

Drug delivery to lymphatic tissue. Papisov M, et al. **Crit Rev Ther Drug Carrier Syst** 1996;13(1–2):57–84 (153 ref.)

MICROBIOLOGY

Nontuberculous mycobacterial cervical adenitis. Suskind DL, et al. **Clin Pediatr (Phila)** 1997 Jul;36(7):403–9 (28 ref.)

PATHOLOGY

Sentinel lymph node evaluation in melanoma. Brady MS, et al. **Arch Dermatol** 1997 Aug;133(8):1014–20 (32 ref.)

Pleomorphic medium-sized T-cell lymphoma following Hodgkin's disease (nodular sclerosis type). Gaulier A, et al. **Arch Pathol Lab Med** 1997 Apr;121(4):411–6 (27 ref.)

Diagnosis of axillary lymph node metastases in patients with breast cancer. Noguchi M, et al. **Breast Cancer Res Treat** 1996;40(3):283–93 (97 ref.)

Lymph node micrometastases from breast carcinoma: reviewing the dilemma. Dowlatshahi K, et al. **Cancer** 1997 Oct 1;80(7):1188–97 (55 ref.)

More rational and conservative surgical strategies for malignant melanoma using lymphatic mapping and sentinel node biopsy techniques. Reintgen D. **Curr Opin Oncol** 1996 Mar;8(2):152–8 (23 ref.)

Extranodal non-Hodgkin's lymphomas of the oral cavity. Jordan RC, et al. **Curr Top Pathol** 1996;90:125–46 (89 ref.)

Predicting pelvic lymph node involvement in patients with localized prostate cancer. Ekman P. **Eur Urol** 1997;32 Suppl 3:60–4 (19 ref.)

Therapeutic strategies for early gastric cancer. Sowa M, et al. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:18–28 (10 ref.)

Significance of lymph node sampling in epithelial carcinoma of the ovary. Carnino F, et al. **Gynecol Oncol** 1997 Jun; 65(3):467–72 (25 ref.)

Depth of invasion as a predictive factor for cervical lymph node metastasis in tongue carcinoma. Fukano H, et al. **Head Neck** 1997 May;19(3):205–10 (14 ref.)

Localized primary amyloidosis of axillary lymph nodes. Lanzafame S, et al. **Histopathology** 1996 Apr;28(4):369–71 (6 ref.)

Diagnostic exercise: sheep with enlarged lymph nodes. Rand MS. **Lab Anim Sci** 1996 Jun;46(3):335–7 (10 ref.)

Extramedullary blast crisis in chronic myeloid leukemia. Specchia G, et al. **Leuk Res** 1996 Nov–Dec;20(11–12):905–8 (28 ref.)

Pitfalls in the diagnosis of fine-needle aspiration of lymph nodes. Katz RL. **Monogr Pathol** 1997;(39):118–33 (23 ref.)

Role of thoracoscopic lymph node staging for lung and esophageal cancer. Krasna MJ. **Oncology (Huntingt)** 1996 Jun;10(6):793–802; discussion 804, 813–4 (31 ref.)

Role of sentinel node biopsy in the management of malignant melanoma. North JH Jr, et al. **Oncology (Huntingt)** 1996 Aug;10(8):1237–42; discussion 1242–6 (20 ref.)

Laryngeal carcinoma nodal metastases and their management. Schuller DE, et al. **Otolaryngol Clin North Am** 1997 Apr;30(2):167–77 (34 ref.)

Endometriosis of the bowel with lymph node involvement. A report of three cases and review of the literature. Insabato L, et al. **Pathol Res Pract** 1996 Sep;192(9):957–61; discussion 962 (16 ref.)

Fine-needle aspiration of lymph nodes: use of flow cytometry immunophenotyping. Cha I, et al. **Pathology (Phila)** 1996; 4(2):337–64 (50 ref.)

Gamma probe guided sentinel node biopsy in breast cancer. Gulec SA, et al. **Q J Nucl Med** 1997 Sep;41(3):251–61 (61 ref.)

Surgical pathology of lymph nodes in cancer staging: routine and specialized techniques. Siegel RJ. **Surg Oncol Clin N Am** 1996 Jan;5(1):25–31 (33 ref.)

[The role of sentinel node biopsy in the treatment of patients with breast carcinoma (see comments)] van de Velde CJ. **Ned Tijdschr Geneeskd** 1996 Nov 9;140(45):2223–5 (22 ref.) Comment in: Ned Tijdschr Geneeskd 1996 Nov 16;140(46):2302–3; discussion 2303–4. Comment in: Ned Tijdschr Geneeskd 1997 Jan 25;141(4):214–5. **(Dut)**

[Lymph node biopsy] Brousse N. **Ann Pathol** 1996; 16(3):219–24 (16 ref.) (Eng. Abstr.) **(Fre)**

[Role of guided fine needle punction in the diagnosis of deep-seated Aids-related infections. Report of a case of hepato-nodal histoplasmosis] Longchampt E, et al. **Ann Pathol** 1996 Sep;16(4):266–70 (12 ref.) (Eng. Abstr.) **(Fre)**

[Lymph node excision in thyroid carcinoma] Dralle H, et al. **Chirurg** 1996 Aug;67(8):788–806 (108 ref.) (Eng. Abstr.) **(Ger)**

[Lymph node dissections in malignant melanoma] Hohenberger W, et al. **Chirurg** 1996 Aug;67(8):779–87 (24 ref.) (Eng. Abstr.) **(Ger)**

[Metastatic malignant melanoma in treated non-Hodgkin's lymphoma] Falk S, et al. **Hautarzt** 1996 Sep;47(9):716–8 (21 ref.) (Eng. Abstr.) **(Ger)**

[Lymphatic drainage of the larynx--effect on therapeutic decision in larynx carcinoma] Hagen R. **HNO** 1996 Feb; 44(2):55–60 (36 ref.) **(Ger)**

[Primary salivary gland tumors in lymph nodes of the parotid gland. Report of 3 cases and review of the literature] Seifert G. **Pathologe** 1997 Mar;18(2):141–6 (54 ref.) (Eng. Abstr.) **(Ger)**

[Contrast media for magnetic resonance tomographic lymph node diagnosis (MR lymphography)] Taupitz M, et al. **Radiologe** 1996 Feb;36(2):134–40 (28 ref.) (Eng. Abstr.) **(Ger)**

[Sentinal node sampling in patients with malignant melanoma] Yaniv D, et al. **Harefuah** 1997 May 15;132(10):711–3 (18 ref.) **(Heb)**

RADIONUCLIDE IMAGING

False tumor-positive lymph nodes in radioimmunodiagnosis

and radioimmunoguided surgery: etiologic mechanisms. Cornelius EA, et al. **J Surg Oncol** 1996 Sep;63(1):23–35 (53 ref.)

Lymphoscintigraphy, the sentinel node concept, and the intraoperative gamma probe in melanoma, breast cancer, and other potential cancers. Alazraki NP, et al. **Semin Nucl Med** 1997 Jan;27(1):55–67 (51 ref.)

The role of lymphoscintigraphy and sentinel node mapping in assessing patient risk in melanoma. Essner R. **Semin Oncol** 1997 Feb;24(1 Suppl 4):S8-10 (15 ref.)

SURGERY

Laparoscopic pelvic and aortic lymphadenectomy. Kadar N. **Baillieres Clin Obstet Gynaecol** 1995 Dec;9(4):651–73 (24 ref.)

What is the appropriate management of early stage cervical cancer (International Federation of Gynecology and Obstetrics stages I and IIA), surgical assessment of lymph nodes, and role of therapeutic resection of lymph nodes involved with cancer? Moore DH, et al. **J Natl Cancer Inst Monogr** 1996;(21):43–6 (40 ref.)

ULTRASONOGRAPHY

[Rosai–Dorfman lymphadenopathy, a rare reactive lymphoproliferative disease. How valid are ultrasound morphologic criteria in lymph node involvement?] Grötz KA, et al. **Ultraschall Med** 1997 Apr;18(2):72–9 (44 ref.) (Eng. Abstr.) **(Ger)**

[Ultrasound morphology of peripheral lymph nodes] Abolmaali N, et al. **Z Arztl Fortbild Qualitatssich** 1997 Jul; 91(4):355–60 (11 ref.) (Eng. Abstr.) **(Ger)**

LYMPHADENECTOMY see **LYMPH NODE EXCISION**

LYMPHADENITIS

COMPLICATIONS

Histiocytic necrotizing lymphadenitis, Kikuchi–Fujimoto's disease, associated with systemic lupus erythemotosus. Martínez-Vázquez C, et al. **QJM** 1997 Aug;90(8):531–3 (19 ref.)

DIAGNOSIS

[Cervical lymphadenitis in an immunocompetent patient: Mycobacterium gordonae as the cause?] Fleisch F, et al. **Dtsch Med Wochenschr** 1997 Jan 17;122(3):51–3 (11 ref.) (Eng. Abstr.) **(Ger)**

[Adenophlegmons of the neck area. A case report and review of the literature] Solazzo L, et al. **Minerva Stomatol** 1996 Oct;45(10):471–5 (10 ref.) (Eng. Abstr.) **(Ita)**

[Kikuchi's disease. A rare cause of fever, lymphadenopathies and polyarthritis] Moraes MF, et al. **Acta Med Port** 1997 Jan;10(1):103–6 (27 ref.) (Eng. Abstr.) **(Por)**

ETIOLOGY

Human lymphadenitis due to Corynebacterium pseudotuberculosis: report of ten cases from Australia and review. Peel MM, et al. **Clin Infect Dis** 1997 Feb; 24(2):185–91 (26 ref.)

Ulceroglandular lymphadenopathy due to Rickettsia conorii in Italy [letter] Castagnola E, et al. **Eur J Clin Microbiol Infect Dis** 1996 Sep;15(9):766–7 (5 ref.)

IMMUNOLOGY

[Kikuchi syndrome, Hashimoto thyroiditis and lupus serology. Apropos of a case] Bousquet E, et al. **Rev Med Interne** 1996;17(10):836–8 (14 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Nontuberculous mycobacterial cervical adenitis. Suskind DL, et al. **Clin Pediatr (Phila)** 1997 Jul;36(7):403–9 (28 ref.)

PATHOLOGY

[A case of Kikuchi disease. Review of the literature] Bequignon A, et al. **Ann Otolaryngol Chir Cervicofac** 1996; 113(4):233–6 (14 ref.) (Eng. Abstr.) **(Fre)**

[Kikuchi–Fujimoto necrotizing histiocytic lymphadenitis: apropos of 2 cases and review of the literature] Sire S, et al. **Rev Med Interne** 1996;17(10):842–5 (24 ref.) (Eng. Abstr.) **(Fre)**

[Necrotizing histiocytic lymphadenitis: Kikuchi's disease (letter)] Mosquera Lozano D, et al. **An Med Interna** 1996 Feb;13(2):97 (9 ref.) **(Spa)**

[Necrotizing histiocytic lymphadenitis (Kikuchi–Fujimoto disease): contribution of 2 cases] Torres Martínez M, et al. **Rev Clin Esp** 1996 Oct;196(10):706–9 (27 ref.) (Eng. Abstr.) **(Spa)**

LYMPHADENITIS, TUBERCULOUS see **TUBERCULOSIS, LYMPH NODE**

LYMPHADENOPATHY-ASSOCIATED ANTIBODIES see **HIV ANTIBODIES**

LYMPHADENOPATHY-ASSOCIATED ANTIGENS see **HIV ANTIGENS**

LYMPHADENOPATHY-ASSOCIATED VIRUS see **HIV**

LYMPHADENOPATHY, IMMUNOBLASTIC see **IMMUNOBLASTIC LYMPHADENOPATHY**

LYMPHADENOPATHY SYNDROME see **AIDS-RELATED COMPLEX**

LYMPHANGIECTASIS

[Pericalyceal lymphangiectasia] Kubodera S, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):441 (4 ref.) **(Jpn)**

CONGENITAL

[Anomalies of umbilical vein in the fetus. A case report and review of the literature] Tordjeman N, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(5):495–9 (18 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Acquired lymphangiectasis following mastectomy and radiation therapy—report of a case and review of the literature. Giannelli V, et al. **Cutis** 1996 Oct;58(4):276–8 (11 ref.)

ETIOLOGY

Acquired lymphangiectasis following mastectomy and radiation therapy—report of a case and review of the literature. Giannelli V, et al. **Cutis** 1996 Oct;58(4):276–8 (11 ref.)

PATHOLOGY

Cystic renal lymphangiectasia: a distinctive clinicopathologic entity in the pediatric age group. Simonton SC, et al. **Pediatr Pathol Lab Med** 1997 Mar–Apr;17(2):293–301 (26 ref.)

LYMPHANGIECTASIS, INTESTINAL

COMPLICATIONS

Enteric hyperoxaluria and renal failure associated with lymphangiectasia. Allen A, et al. **Nephrol Dial Transplant** 1997 Apr;12(4):802–6 (25 ref.)

LYMPHANGIOENDOTHELIOMA see **LYMPHANGIOMA**

LYMPHANGIOGRAPHY see **LYMPHOGRAPHY**

LYMPHANGIOLEIOMYOMA see **LYMPHANGIOMYOMA**

LYMPHANGIOMA

[Lymphangioma] Ogita S. **Ryoikibetsu Shokogun Shirizu** 1996;(15):629–31 (12 ref.) **(Jpn)**

[Pericardiac lymphangioma] Takahashi M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):268–9 (8 ref.) **(Jpn)**

COMPLICATIONS

A case of Cobb syndrome associated with lymphangioma circumscriptum. Shim JH, et al. **Dermatology** 1996; 193(1):45–7 (11 ref.)

DIAGNOSIS

Intrapericardial lymphangioma presenting as neonatal cardiac tamponade. Daubeney PE, et al. **Pediatr Cardiol** 1996 Mar–Apr;17(2):129–31 (12 ref.)

PATHOLOGY

Lymphangioma-like variant of Kaposi's sarcoma: clinicopathologic study of seven cases with review of the literature. Cossu S, et al. **Am J Dermatopathol** 1997 Feb; 19(1):16–22 (25 ref.)

[Enormous lingual lymphangioma] Beziat JL, et al. **Rev Stomatol Chir Maxillofac** 1997 Aug;98(2):76–80 (19 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

[A case of mediastinal lymphangioma] Takahashi Y, et al. **Rinsho Kyobu Geka** 1988 Apr;8(2):195–9 (17 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Abdominal lymphangioma in a preterm infant. Salvador A, et al. **J Perinatol** 1996 Jul–Aug;16(4):305–8 (9 ref.)

LYMPHANGIOMA, CAVERNOUS see **LYMPHANGIOMA**

LYMPHANGIOMA, CYSTIC

[Cystic lymphangioma of the spermatic cord. Report of a new case] Jung JL, et al. **Prog Urol** 1996 Dec;6(6):948–9 (6 ref.) (Eng. Abstr.) **(Fre)**

[Cystic lymphangioma of the adrenal gland in adults. Review of the literature and report of a new case] Alapont Pérez FM, et al. **Actas Urol Esp** 1996 Sep;20(8):739–42 (12 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Cystic lymphangioma of the transverse colon: report of a case and review of the literature. Young TH, et al. **Abdom Imaging** 1996 Sep–Oct;21(5):415–7 (26 ref.)

Scrotal cystic lymphangioma: the misdiagnosed scrotal mass. Hurwitz RS, et al. **J Urol** 1997 Sep;158(3 Pt 2):1182–5 (8 ref.)

Lymphangiomas of the ileum: a report of two cases and a review of the literature. Uncu H, et al. **Surg Today** 1997; 27(6):542–5 (25 ref.)

ETIOLOGY

Etiology, prognosis and management of nuchal cystic hygroma: 25 new cases and literature review. Descamps P, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Jan; 71(1):3–10 (112 ref.)

PATHOLOGY

Giant mediastinal lymphangioma in a neonate: report of a case. Takamatsu H, et al. **Surg Today** 1996;26(7):527–31 (24 ref.)

SURGERY

Arachnoid cysts associated with subdural hematomas and hygromas: analysis of 16 cases, long-term follow-up, and review of the literature. Parsch CS, et al. **Neurosurgery** 1997 Mar;40(3):483–90 (66 ref.)

THERAPY

Etiology, prognosis and management of nuchal cystic hygroma: 25 new cases and literature review. Descamps P, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Jan; 71(1):3–10 (112 ref.)

LYMPHANGIOMYOMA

[Lymphangioleiomyoma with retroperitoneal and thoracic involvement] Barron Medrano M, et al. **An Med Interna** 1996 Feb;13(2):75–8 (38 ref.) (Eng. Abstr.) **(Spa)**

LYMPHANGIOMYOMATOSIS

Lymphangioleiomyomatosis: new insights [see comments] Kalassian KG, et al. **Am J Respir Crit Care Med** 1997 Apr; 155(4):1183–6 (34 ref.) Comment in: Am J Respir Crit Care Med 1997 Aug;156(2 Pt 1):670.

PATHOLOGY

Lymphangioleiomyomatosis of the uterus simulating high-stage endometrial stromal sarcoma. Longacre TA, et al. **Gynecol Oncol** 1996 Dec;63(3):404–10 (39 ref.)

LYMPHANGITIS

Lymphangitis carcinomatosa: a literature review. Bruce DM, et al. **J R Coll Surg Edinb** 1996 Feb;41(1):7–13 (28 ref.)

[Lymphangitis] Katoh I, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):626–8 (11 ref.) **(Jpn)**

COMPLICATIONS

Granulomatous lymphangitis of the penile skin as a cause of penile swelling in children. Mor Y, et al. **J Urol** 1997 Aug;158(2):591–2 (12 ref.)

LYMPHAPHERESIS see **LEUKAPHERESIS**

LYMPHATIC CAPILLARIES see **LYMPHATIC SYSTEM**

LYMPHATIC CYST see **LYMPHOCELE**

LYMPHATIC DISEASES

see related
CHYLOTHORAX
LEUKEMIA, LYMPHOCYTIC
LYMPHOMA

DIAGNOSIS

Pitfalls in the diagnosis of fine-needle aspiration of lymph nodes. Katz RL. **Monogr Pathol** 1997;(39):118–33 (23 ref.)

Fine-needle aspiration of lymph nodes: use of flow cytometry immunophenotyping. Cha I, et al. **Pathology (Phila)** 1996; 4(2):337–64 (50 ref.)

Imaging of cervical lymphadenopathy. Kaji AV, et al. **Semin Ultrasound CT MR** 1997 Jun;18(3):220–49 (56 ref.)

DRUG THERAPY

Drug delivery to lymphatic tissue. Papisov M, et al. **Crit Rev Ther Drug Carrier Syst** 1996;13(1–2):57–84 (153 ref.)

LYMPHATIC DISEASES

ETIOLOGY

Polytetrafluoroethylene giant granuloma and adenopathy: long-term complications following subureteral polytetrafluoroethylene injection for the treatment of vesicoureteral reflux in children. Aragona F, et al. **J Urol** 1997 Oct;158(4):1539–42 (41 ref.)

[Differentiated thyroid cancer revealed by cervical adenopathy] Rodier JF, et al. **Ann Endocrinol (Paris)** 1997; 58(3):268–71 (28 ref.) **(Fre)**

[Differential diagnosis of lymphadenopathies] Bogomolov BP. **Klin Med (Mosk)** 1996;74(5):4–9 (00 ref.) **(Rus)**

PARASITOLOGY

Lymphatic filariasis in immigrants from developing countries. Cunningham NM. **Am Fam Physician** 1997 Mar; 55(4):1199–204 (10 ref.)

PATHOLOGY

Cervical lymphadenopathy in the eastern province of Saudi Arabia. Al-Sohaibani MO. **East Afr Med J** 1996 Aug; 73(8):533–7 (43 ref.)

Localized primary amyloidosis of axillary lymph nodes. Lanzafame S, et al. **Histopathology** 1996 Apr;28(4):369–71 (6 ref.)

[A case of a combination of sarcoidosis and myeloma] Kamaeva OI, et al. **Ter Arkh** 1995;67(12):57–9 (19 ref.) **(Rus)**

PHYSIOPATHOLOGY

Lymphangiogenesis: mechanisms, significance and clinical implications. Witte MH, et al. **EXS** 1997;79:65–112 (172 ref.)

SURGERY

[The potentials for the surgical treatment of intrathoracic sarcoidosis complicated by chronic pleurisy] Duzhii ID, et al. **Lik Sprava** 1996 Jul–Sep;(7–9):168–70 (12 ref.) (Eng. Abstr.) **(Rus)**

LYMPHATIC ENDOTHELIUM see **ENDOTHELIUM, LYMPHATIC**

LYMPHATIC FILARIASIS see **ELEPHANTIASIS, FILARIAL**

LYMPHATIC IRRADIATION

Neck failure in T2N0 squamous cell carcinoma of the true vocal cords: the Fox Chase experience and review of the literature. Fein DA, et al. **Am J Clin Oncol** 1997 Apr; 20(2):154–7 (17 ref.)

Delivery after bone marrow transplantation with total lymphoid irradiation for severe aplastic anemia. Ashida T, et al. **Int J Hematol** 1996 Oct;64(3–4):279–81 (14 ref.)

LYMPHATIC METASTASIS

Surgical management of cervical lymph node metastases. Eicher SA, et al. **Curr Opin Oncol** 1996 May;8(3):215–20 (30 ref.)

[Metastatic cervical adenopathies of unknown primary site. Long-term course] Percodani J, et al. **Ann Otolaryngol Chir Cervicofac** 1996;113(4):212–8 (23 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Lymph node micrometastases from breast carcinoma: reviewing the dilemma. Dowlatshahi K, et al. **Cancer** 1997 Oct 1;80(7):1188–97 (55 ref.)

Is axillary lymph node dissection necessary in routine management of breast cancer? No. Cady B. **Important Adv Oncol** 1996;:251–65 (119 ref.)

Is axillary lymph node dissection necessary in the routine management of breast cancer? Yes. Moore MP, et al. **Important Adv Oncol** 1996;:245–50 (53 ref.)

Imaging of cervical lymphadenopathy. Kaji AV, et al. **Semin Ultrasound CT MR** 1997 Jun;18(3):220–49 (56 ref.)

[Endometrial cancer: progress in the evaluation of locoregional extension by imaging techniques] Buthiau D, et al. **Contracept Fertil Sex** 1996 Oct;24(10):757–61 (38 ref.) (Eng. Abstr.) **(Fre)**

[Contrast media for magnetic resonance tomographic lymph node diagnosis (MR lymphography)] Taupitz M, et al. **Radiologe** 1996 Feb;36(2):134–40 (28 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Apoptosis of T lymphoma cells and its inhibition by monoclonal antibodies against cell surface adhesion molecules. Tsuruo T, et al. **Princess Takamatsu Symp** 1994; 24:91–8 (18 ref.)

Colon cancer nodal metastasis: biologic significance and therapeutic considerations. Daneker GW Jr, et al. **Surg Oncol Clin N Am** 1996 Jan;5(1):173–89 (69 ref.)

The biologic and clinical significance of lymphatic metastases in breast cancer. Foster RS Jr. **Surg Oncol Clin N Am** 1996 Jan;5(1):79–104 (142 ref.)

Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Grebe SK, et al. **Surg Oncol Clin N Am** 1996 Jan;5(1):43–63 (114 ref.)

Gastric cancer nodal metastases: biologic significance and therapeutic considerations. Hundahl SA. **Surg Oncol Clin N Am** 1996 Jan;5(1):129–44 (72 ref.)

Nodal metastases in rectal cancer: the role of surgery in outcome. MacFarlane JK. **Surg Oncol Clin N Am** 1996 Jan;5(1):191–202 (41 ref.)

Gastrointestinal endocrine cancers and nodal metastasis: biologic significance and therapeutic implications. Peplinski GR, et al. **Surg Oncol Clin N Am** 1996 Jan;5(1):159–71 (101 ref.)

Soft tissue sarcoma nodal metastases: biologic significance and therapeutic considerations. Skinner KA, et al. **Surg Oncol Clin N Am** 1996 Jan;5(1):121–7 (14 ref.)

Pancreatic nodal metastases: biologic significance and therapeutic considerations. Yeo CJ, et al. **Surg Oncol Clin N Am** 1996 Jan;5(1):145–57 (37 ref.)

[Squamous cell carcinoma of unknown origin affecting mediastinal lymph nodes] Yodonawa S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec; 34(12):1364–8 (10 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

The pathobiology of metastasis within the lymphatic system. Weiss L. **Surg Oncol Clin N Am** 1996 Jan;5(1):15–24 (29 ref.)

PREVENTION & CONTROL

Is prophylactic neck irradiation indicated in patients with squamous cell carcinoma of the maxillary sinus? Paulino AC, et al. **Int J Radiat Oncol Biol Phys** 1997 Sep 1; 39(2):283–9 (25 ref.)

RADIONUCLIDE IMAGING

Enhanced bilateral somatostatin receptor expression in mediastinal lymph nodes ("chimney sign") in occult metastatic medullary thyroid cancer: a typical site of tumour manifestation? Behr TM, et al. **Eur J Nucl Med** 1997 Feb;24(2):184–91 (20 ref.)

Melanoma nodal metastases: biologic significance and therapeutic considerations. Reintgen D. **Surg Oncol Clin N Am** 1996 Jan;5(1):105–20 (24 ref.)

LYMPHATIC RADIATION THERAPY see **LYMPHATIC IRRADIATION**

LYMPHATIC SARCOMA see **LYMPHOMA, DIFFUSE**

LYMPHATIC SYSTEM

see related **LYMPHOGRAPHY**

ANATOMY & HISTOLOGY

Lymphatic system of the pancreas. O'Morchoe CC. **Microsc Res Tech** 1997 Jun 1–15;37(5–6):456–77 (95 ref.)

Advanced colloid-based systems for efficient delivery of drugs and diagnostic agents to the lymphatic tissues. Moghimi SM, et al. **Prog Biophys Mol Biol** 1996; 65(3):221–49 (180 ref.)

General anatomy of the lymphatic system. Foster RS Jr. **Surg Oncol Clin N Am** 1996 Jan;5(1):1–13 (38 ref.)

BLOOD SUPPLY

The morphofunctional organization of lymphatic vascular periphery. Comparini L, et al. **Ital J Anat Embryol** 1996 Oct–Dec;101(4):81–139 (113 ref.)

DRUG EFFECTS

A lymphatic function of Daflon 500 mg. Labrid C. **Int Angiol** 1995 Sep;14(3 Suppl 1):36–8 (11 ref.)

IMMUNOLOGY

The XI AIDS conference and HIV-1 lymphopathy. Shields JW. **Lymphology** 1997 Sep;30(3):137–54 (70 ref.)

METABOLISM

Liposomes for drug targeting in the lymphatic system. Hirnle P. **Hybridoma** 1997 Feb;16(1):127–32 (15 ref.)

Model systems for intestinal lymphatic transport studies. Porter CJ, et al. **Pharm Biotechnol** 1996;8:85–102 (22 ref.)

Advanced colloid-based systems for efficient delivery of drugs and diagnostic agents to the lymphatic tissues. Moghimi SM, et al. **Prog Biophys Mol Biol** 1996; 65(3):221–49 (180 ref.)

PATHOLOGY

Cutaneous lymphocytic vasculitis: a definition, a review, and a proposed classification. Carlson JA, et al. **Semin Diagn Pathol** 1996 Feb;13(1):72–90 (57 ref.)

[Lymphatic drainage of the larynx--effect on therapeutic decision in larynx carcinoma] Hagen R. **HNO** 1996 Feb; 44(2):55–60 (36 ref.) **(Ger)**

PHYSIOLOGY

Lymphangiogenesis: mechanisms, significance and clinical implications. Witte MH, et al. **EXS** 1997;79:65–112 (172 ref.)

The morphofunctional organization of lymphatic vascular periphery. Comparini L, et al. **Ital J Anat Embryol** 1996 Oct–Dec;101(4):81–139 (113 ref.)

Update on osteopathic medical concepts and the lymphatic system. Degenhardt BF, et al. **J Am Osteopath Assoc** 1996 Feb;96(2):97–100 (31 ref.)

Disruption of cytokine signaling in lymphoid development: unique contributions of the common cytokine gamma chain and the Jak3 kinase. Eynon EE, et al. **J Interferon Cytokine Res** 1996 Sep;16(9):677–84 (32 ref.)

Pathophysiology of hydrops fetalis. Apkon M. **Semin Perinatol** 1995 Dec;19(6):437–46 (44 ref.)

RADIATION EFFECTS

[Cellular mechanisms of functional disorders of the lymphatic system in high-dose radiotherapy] Chukhlovin AB, et al. **Vopr Onkol** 1997;43(2):231–7 (58 ref.) **(Rus)**

LYMPHEDEMA

[Lymphedema] Katoh I, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):632–6 (21 ref.) **(Jpn)**

COMPLICATIONS

Squamous cell carcinoma arising in chronic lymphoedema. Lister RK, et al. **Br J Dermatol** 1997 Mar;136(3):384–7 (19 ref.)

DIAGNOSIS

Lymphedema praecox seen as isolated unilateral arm involvement: case report and review of the literature. Harel L, et al. **J Pediatr** 1997 Mar;130(3):492–4 (14 ref.)

ETIOLOGY

Lymphedema due to chronic penile strangulation: a case report. Tanabe N, et al. **J Dermatol** 1996 Sep;23(9):648–51 (15 ref.)

[Frequency of lymphedema of the upper limb after treatment of breast cancer. Risk factors. Apropos of 683 cases] Ferrandez JC, et al. **Bull Cancer** 1996 Dec;83(12):989–95 (21 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Pericentric inversions of chromosome 4: report of a new family and review of the literature. Villa A, et al. **Clin Genet** 1995 Nov;48(5):255–60 (31 ref.)

PHYSIOPATHOLOGY

[Heavy legs, venular microangiopathy and stasis acrodermatitis] Piérard GE. **Rev Med Liege** 1996 Aug; 51(8):510–3 (22 ref.) **(Fre)**

LYMPHOBLAST TRANSFORMATION see **LYMPHOCYTE TRANSFORMATION**

LYMPHOBLASTIC LARGE-CELL LYMPHOMA see **LYMPHOMA, LYMPHOBLASTIC**

LYMPHOBLASTIC LEUKEMIA see **LEUKEMIA, LYMPHOCYTIC**

LYMPHOBLASTIC LEUKEMIA, ACUTE see **LEUKEMIA, LYMPHOCYTIC, ACUTE**

LYMPHOBLASTIC LEUKEMIA, ACUTE, ADULT see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L2**

LYMPHOBLASTIC LEUKEMIA, ACUTE, CHILDHOOD see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L1**

LYMPHOBLASTIC LEUKEMIA, ACUTE, L1 see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L1**

LYMPHOBLASTIC LEUKEMIA, ACUTE, L2 see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L2**

LYMPHOBLASTIC LEUKEMIA, ACUTE, T-CELL see **LEUKEMIA, T-CELL, ACUTE**

LYMPHOBLASTIC LEUKEMIA, CHRONIC see **LEUKEMIA, LYMPHOCYTIC, CHRONIC**

LYMPHOBLASTIC LYMPHOMA see **LYMPHOMA, LYMPHOBLASTIC**

LYMPHOBLASTIC LYMPHOSARCOMA, DIFFUSE see **LYMPHOMA, LYMPHOBLASTIC**

LYMPHOCELE

DIAGNOSIS

Presentation and management of lymphatic cyst of the colon: report of a case. Poulos JE, et al. **Dis Colon Rectum** 1997 Mar;40(3):366–9 (23 ref.)

SURGERY

Presentation and management of lymphatic cyst of the colon:

report of a case. Poulos JE, et al. **Dis Colon Rectum** 1997 Mar;40(3):366–9 (23 ref.)
[Lymphocele after renal transplantation: therapeutic controversies in the age of laparoscopy] Lledó García E, et al. **Actas Urol Esp** 1996 Jul–Aug;20(7):648–54 (36 ref.) (Eng. Abstr.) **(Spa)**

LYMPHOCYSTIVIRUS see **IRIDOVIRIDAE**

LYMPHOCYTAPHERESIS see **LEUKAPHERESIS**

LYMPHOCYTE-ACTIVATING FACTOR see **INTERLEUKIN-1**

LYMPHOCYTE ACTIVATION see **LYMPHOCYTE TRANSFORMATION**

T-LYMPHOCYTE ANTIGEN RECEPTOR GAMMA-CHAIN GENE REARRANGEMENT see **GENE REARRANGEMENT, GAMMA-CHAIN T-CELL ANTIGEN RECEPTOR**

LYMPHOCYTE CHEMOATTRACTANT FACTOR see **INTERLEUKIN-16**

LYMPHOCYTE COOPERATION

Molecular mechanisms involved in T-B interactions. Lane P. **Chem Immunol** 1997;67:1–13 (65 ref.)
Development of B-cell memory and effector function. Lane P. **Curr Opin Immunol** 1996 Jun;8(3):331–5 (45 ref.)
Visualizing immune responses in vivo. McHeyzer-Williams MG. **Curr Opin Immunol** 1996 Jun;8(3):321–6 (60 ref.)
T helper cells driving pathogenic anti-DNA autoantibody production in lupus: nucleosomal epitopes and CD40 ligand signals. Datta SK, et al. **Lupus** 1997;6(3):333–6 (4 ref.)

IMMUNOLOGY

Immune response to mouse mammary tumour virus. Luther SA, et al. **Curr Opin Immunol** 1996 Aug;8(4):498–502 (24 ref.)
Soluble, antigen-specific T-cell proteins: T-cell–based humoral immunity? Cone RE, et al. **Immunol Today** 1996 Jul;17(7):318–22 (53 ref.)

LYMPHOCYTE COUNT

METHODS

Enumeration and characterization of memory cells in the TH compartment. McHeyzer-Williams MG, et al. **Immunol Rev** 1996 Apr;150:5–21 (45 ref.)

LYMPHOCYTE COUNT, CD4 see **CD4 LYMPHOCYTE COUNT**

T4 LYMPHOCYTE COUNT see **CD4 LYMPHOCYTE COUNT**

B-LYMPHOCYTE DIFFERENTIATION ANTIGENS see **ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE**

T-LYMPHOCYTE DIFFERENTIATION ANTIGENS see **ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE**

B-LYMPHOCYTE EPITOPES see **EPITOPES, B-LYMPHOCYTE**

T-LYMPHOCYTE EPITOPES see **EPITOPES, T-LYMPHOCYTE**

LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1

BIOSYNTHESIS

CD11c integrin gene promoter activity during myeloid differentiation. Córbi AL, et al. **Leuk Lymphoma** 1997 May; 25(5–6):415–25 (67 ref.)

CHEMISTRY

Signalling and adhesive properties of the integrin leucocyte function-associated antigen 1 (LFA-1). van Kooyk Y, et al. **Biochem Soc Trans** 1997 May;25(2):515–20 (51 ref.)

GENETICS

CD11c integrin gene promoter activity during myeloid differentiation. Córbi AL, et al. **Leuk Lymphoma** 1997 May; 25(5–6):415–25 (67 ref.)

PHYSIOLOGY

Signalling and adhesive properties of the integrin leucocyte function-associated antigen 1 (LFA-1). van Kooyk Y, et al. **Biochem Soc Trans** 1997 May;25(2):515–20 (51 ref.)

LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN-3 see **ANTIGENS, CD58**

B-LYMPHOCYTE GENE REARRANGEMENT see **GENE REARRANGEMENT, B-LYMPHOCYTE**

T-LYMPHOCYTE GENE REARRANGEMENT see **GENE REARRANGEMENT, T-LYMPHOCYTE**

B-LYMPHOCYTE HEAVY CHAIN GENE REARRANGEMENT see **GENE REARRANGEMENT, B-LYMPHOCYTE, HEAVY CHAIN**

LYMPHOCYTE HOMING RECEPTORS see **RECEPTORS, LYMPHOCYTE HOMING**

LYMPHOCYTE IMMUNOPHENOTYPING see **IMMUNOPHENOTYPING**

LYMPHOCYTE MEDIATORS see **LYMPHOKINES**

LYMPHOCYTE MITOGENIC FACTOR see **INTERLEUKIN-2**

B-LYMPHOCYTE MU CHAIN GENE REARRANGEMENT see **GENE REARRANGEMENT, B-LYMPHOCYTE, HEAVY CHAIN**

LYMPHOCYTE STIMULATION see **LYMPHOCYTE TRANSFORMATION**

LYMPHOCYTE SUBPOPULATIONS see **LYMPHOCYTE SUBSETS**

LYMPHOCYTE SUBSETS

see related
IMMUNOPHENOTYPING

IMMUNOLOGY

The acute immune response to exercise: what does it mean? Gabriel H, et al. **Int J Sports Med** 1997 Mar;18 Suppl 1:S28–45 (79 ref.)
Aging, immunity, and cardiopulmonary bypass surgery: adding insult to injury [editorial; comment] Peterson PK. **J Lab Clin Med** 1997 Jun;129(6):578–9 (9 ref.) Comment on: J Lab Clin Med 1997 Jun;129(6):592–602.
Lymphocyte subsets in experimental bronchopulmonary inflammation and hyperresponsiveness. Coyle AJ, et al. **Res Immunol** 1997 Jan;148(1):13–8 (44 ref.)

METABOLISM

Regulation of interferon-gamma gene expression. Young HA. **J Interferon Cytokine Res** 1996 Aug;16(8):563–8 (26 ref.)

PATHOLOGY

Cellular components and features of immune response in abdominal aortic aneurysms. Pearce WH, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:175–85 (45 ref.)
Lymphocyte subsets and adhesion molecules in cutaneous inflammation induced by inflammatory agonists: correlation between E-selectin and gamma delta TcR+ lymphocytes. Whyte A, et al. **Lab Invest** 1996 Sep;75(3):439–49 (52 ref.)

B-LYMPHOCYTE SUBSETS

CYTOLOGY

Germinal center development. Liu YJ, et al. **Immunol Rev** 1997 Apr;156:111–26 (138 ref.)

IMMUNOLOGY

In vitro analysis of the generation and propagation of memory B cells. Klinman NR. **Immunol Rev** 1996 Apr; 150:91–111 (85 ref.)
Bar Mitzvah for B-1 cells: how will they grow up? [comment] Tarakhovsky A. **J Exp Med** 1997 Mar 17; 185(6):981–4 (48 ref.) Comment on: J Exp Med 1997 Mar 17;185(6):1035–42.
The effects of IL12 on B-cell subset function. Metzger DW, et al. **Res Immunol** 1995 Sep–Oct;146(7–8):499–505 (32 ref.)

METABOLISM

Production of cytokines by human B cells in health and disease. Pistoia V. **Immunol Today** 1997 Jul;18(7):343–50 (81 ref.)

PHYSIOLOGY

What do chronic B cell malignancies teach us about B cell subsets? Pritsch O, et al. **Chem Immunol** 1997;67:85–101 (114 ref.)
Distinctive developmental origins and specificities of the CD5+ B-cell subset. Hardy RR, et al. **Semin Immunol** 1996 Feb;8(1):37–44 (39 ref.)

T-LYMPHOCYTE SUBSETS

T-cells and macrophages in HIV disease. McGrath MS. **Clin Rev Allergy Immunol** 1996–97 Winter;14(4):359–66 (48 ref.)
[Analysis of T cell subsets with monoclonal antibodies] Homma T, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:159–65 (15 ref.) **(Jpn)**

CYTOLOGY

The role of adhesion and costimulation molecules in graft-versus-host disease. Schlegel PG. **Acta Haematol** 1997;97(1–2):105–17 (191 ref.)
Events that regulate differentiation of alpha beta TCR+ and gamma delta TCR+ T cells from a common precursor. Kang J, et al. **Semin Immunol** 1997 Jun;9(3):171–9 (60 ref.)

DRUG EFFECTS

Stimulation of the specific immune system by mistletoe extracts. Fischer S, et al. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S33–7 (32 ref.)

IMMUNOLOGY

Mouse CD1-specific NK1 T cells: development, specificity, and function. Bendelac A, et al. **Annu Rev Immunol** 1997; 15:535–62 (116 ref.)
Recognition by gamma/delta T cells. Chien YH, et al. **Annu Rev Immunol** 1996;14:511–32 (75 ref.)
Manipulation of the Th1/Th2 cell balance: an approach to treat human autoimmune diseases? Adorini L, et al. **Autoimmunity** 1996;23(1):53–68 (131 ref.)
Role of natural killer and NK1+ T-cells in regulating cell-mediated immunity during Toxoplasma gondii infection. Denkers EY, et al. **Biochem Soc Trans** 1997 May; 25(2):699–703 (43 ref.)
Role of CD4+CD8- thymocytes in the prevention of autoimmune diabetes. Seddon B, et al. **Biochem Soc Trans** 1997 May;25(2):620–4 (16 ref.)
Graft-versus-host disease: the viewpoint from the donor T cell. Chao NJ. **Biol Blood Marrow Transplant** 1997 Apr; 3(1):1–10 (82 ref.)
HLA-class I-specific inhibitory receptors of NK type on a subset of human T cells. Mingari MC, et al. **Chem Immunol** 1996;64:135–45 (51 ref.)
T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Wingren AG, et al. **Crit Rev Immunol** 1995;15(3–4):235–53 (97 ref.)
Cell-mediated immune system regulation in periodontal diseases. Mathur A, et al. **Crit Rev Oral Biol Med** 1997; 8(1):76–89 (104 ref.)
T-cell subsets: recruiting the right kind of help. Lichtman AH, et al. **Curr Biol** 1997 Apr 1;7(4):R242–4 (10 ref.)
An innate view of gamma delta T cells. Boismenu R, et al. **Curr Opin Immunol** 1997 Feb;9(1):57–63 (73 ref.)
T cell clonal anergy. Schwartz RH. **Curr Opin Immunol** 1997 Jun;9(3):351–7 (44 ref.)
Characterization of human T cell clones specific for Toxoplasma gondii. Pistoia V, et al. **Curr Top Microbiol Immunol** 1996;219:165–73 (29 ref.)
T cell subsets in immunologically-mediated glomerulonephritis. van Alderwegen IE, et al. **Histol Histopathol** 1997 Jan;12(1):241–50 (93 ref.)
Sentinel function of broadly reactive human gamma delta T cells. De Libero G. **Immunol Today** 1997 Jan;18(1):22–6 (37 ref.)
T-cell regeneration: all repertoires are not created equal. Mackall CL, et al. **Immunol Today** 1997 May;18(5):245–51 (69 ref.)
Mouse NK1.1+ T cells: a new family of T cells. Vicari AP, et al. **Immunol Today** 1996 Feb;17(2):71–6 (76 ref.)
Gamma delta T cells: their immunobiology and role in malaria infections. Rzepczyk CM, et al. **Int J Parasitol** 1997 Feb;27(2):191–200 (74 ref.)
CD4+ CD7- T cells: a separate subpopulation of memory T cells? Reinhold U, et al. **J Clin Immunol** 1997 Jul; 17(4):265–71 (36 ref.)
T cells specific for DNA-binding peptides. Wang M, et al. **Lupus** 1997;6(3):349–50 (7 ref.)
Gamma delta T cells in bacterial infections. Ferrick DA, et al. **Res Immunol** 1996 Oct-Dec;147(8–9):532–41 (74 ref.)
Human gamma delta T cells in tuberculosis. Poquet Y, et al. **Res Immunol** 1996 Oct-Dec;147(8–9):542–9 (52 ref.)
T-cell receptor alpha beta and gamma delta T cells in rat and human skin—are they equivalent? Elbe A, et al. **Semin Immunol** 1996 Dec;8(6):341–9 (82 ref.)
Events that regulate differentiation of alpha beta TCR+ and gamma delta TCR+ T cells from a common precursor. Kang J, et al. **Semin Immunol** 1997 Jun;9(3):171–9 (60 ref.)
Thymic development of V gamma 3 cells. Leclercq G, et al. **Semin Immunol** 1996 Dec;8(6):315–21 (63 ref.)
Functions of CD8 T-cell subsets secreting different cytokine patterns. Mosmann TR, et al. **Semin Immunol** 1997 Apr; 9(2):87–92 (26 ref.)
Cytokines in primary biliary cirrhosis. Berg PA, et al. **Semin Liver Dis** 1997 May;17(2):115–23 (84 ref.)
[Immunopathology of malaria: emergence of a new T-lymphocyte reactivity] Behr C. **C R Seances Soc Biol Fil** 1996;190(4):357–68 (67 ref.) (Eng. Abstr.) **(Fre)**
[Local immune response to surgical stress] Hosokawa T. **Masui** 1996 Dec;45 Suppl:S31–7 (27 ref.) **(Jpn)**
[Polyclonal and clonal proliferation of large granular lymphocytes] Kowal M, et al. **Pol Arch Med Wewn** 1995 Oct;94(4):349–57 (31 ref.) **(Pol)**
[Superantigens and their behavior in the immune response] López H, et al. **Rev Alerg Mex** 1996 Jan–Feb;43(1):13–7 (40 ref.) (Eng. Abstr.) **(Spa)**

T-LYMPHOCYTE SUBSETS

METABOLISM

An innate view of gamma delta T cells. Boismenu R, et al. **Curr Opin Immunol** 1997 Feb;9(1):57–63 (73 ref.)

Molecular and cellular biology of dendritic epidermal T cells. Boismenu R, et al. **Semin Immunol** 1996 Dec;8(6):323–31 (58 ref.)

Origin and development of the gamma delta T–cell system in sheep: a critical role for the thymus in the generation of TcR diversity and tissue tropism. Cahill RN, et al. **Semin Immunol** 1996 Dec;8(6):351–60 (61 ref.)

Cytokine–mediated communication by keratinocytes and Langerhans cells with dendritic epidermal T cells. Takashima A, et al. **Semin Immunol** 1996 Dec;8(6):333–9 (87 ref.)

MICROBIOLOGY

Biological role of Th cell subsets in candidiasis. Romani L, et al. **Chem Immunol** 1996;63:115–37 (124 ref.)

PHYSIOLOGY

Differentiation and functions of T cell subsets. Mosmann TR, et al. **Ciba Found Symp** 1997;204:148–54; discussion 154–8 (13 ref.)

Contribution of 65–kDa heat shock protein induced by gamma and delta T cells to protection against Toxoplasma gondii infection. Himeno K, et al. **Immunol Res** 1996; 15(3):258–64 (25 ref.)

Cytokines: communication molecules that influence the process of disease. Splitter G. **Jpn J Vet Res** 1997 May; 45(1):3–12 (64 ref.)

LYMPHOCYTE SUBTYPING see **IMMUNOPHENOTYPING**

LYMPHOCYTE TRANSFORMATION

Antigen analogs as therapeutic agents. Alexander J, et al. **Adv Exp Med Biol** 1995;386:109–18 (24 ref.)

T–cell blast crisis in chronic myelogenous leukemia. Immunophenotypic and molecular biologic findings. Dorfman DM, et al. **Am J Clin Pathol** 1997 Feb; 107(2):168–76 (49 ref.)

CD28/B7 system of T cell costimulation. Lenschow DJ, et al. **Annu Rev Immunol** 1996;14:233–58 (117 ref.)

CD28 co–receptor signal transduction in T–cell activation. Blair PJ, et al. **Biochem Soc Trans** 1997 May;25(2):651–7 (57 ref.)

T–lymphocyte activation and regulation in the central nervous system. Sedgwick JD. **Biochem Soc Trans** 1997 May;25(2):673–9 (36 ref.)

B7–mediated costimulation and the immune response. Schultze J, et al. **Blood Rev** 1996 Jun;10(2):111–27 (107 ref.)

Gene–modified tumor cells as cellular vaccine. Baskar S. **Cancer Immunol Immunother** 1996 Nov;43(3):165–73 (96 ref.)

Signal transduction during NK cell activation. Bonnema JD, et al. **Chem Immunol** 1996;64:28–43 (102 ref.)

Source of IL–4 able to induce the development of TH2–like cells. Ricci M, et al. **Clin Exp Allergy** 1997 May; 27(5):488–500 (118 ref.)

Lymphocyte activation in health and disease. Berridge MJ. **Crit Rev Immunol** 1997;17(2):155–78 (155 ref.)

Accessory molecule and costimulation requirements for CD4 T cell response. Croft M, et al. **Crit Rev Immunol** 1997; 17(1):89–118 (159 ref.)

T cell activation pathways: B7, LFA–3, and ICAM–1 shape unique T cell profiles. Wingren AG, et al. **Crit Rev Immunol** 1995;15(3–4):235–53 (97 ref.)

Activation and function of natural killer cell responses during viral infections. Biron CA. **Curr Opin Immunol** 1997 Feb; 9(1):24–34 (91 ref.)

Activation of B lymphocytes: integrating signals from CD19, CD22 and Fc gamma RIIb1. Doody GM, et al. **Curr Opin Immunol** 1996 Jun;8(3):378–82 (47 ref.)

Development of B–cell memory and effector function. Lane P. **Curr Opin Immunol** 1996 Jun;8(3):331–5 (45 ref.)

Costimulation and autoimmunity. Tivol EA, et al. **Curr Opin Immunol** 1996 Dec;8(6):822–30 (66 ref.)

Extramedullary blast transformation in a patient with chronic myelogenous leukaemia. Gebremedhin A. **Ethiop Med J** 1997 Jan;35(1):57–61 (15 ref.)

Modulation of T–cell cytokine secretion by accessory cell–derived products. Hilkens CM, et al. **Eur Respir J Suppl** 1996 Aug;22:90s–94s (33 ref.)

Making the T cell receptor go the distance: a topological view of T cell activation. Shaw AS, et al. **Immunity** 1997 Apr;6(4):361–9 (58 ref.)

The role of dendritic cells in T cell activation. Ni K, et al. **Immunol Cell Biol** 1997 Jun;75(3):223–30 (117 ref.)

Accessory molecule regulation of naive CD4 T cell activation. Dubey C, et al. **Immunol Res** 1996;15(2):114–25 (68 ref.)

Involvement of CD80 in the generation of CD4+ cytotoxic T cells. Mauri D, et al. **Immunol Res** 1996;15(2):126–40 (112 ref.)

The role of CTLA–4 in the regulation and initiation of T–cell responses. Chambers CA, et al. **Immunol Rev** 1996 Oct; 153:27–46 (90 ref.)

Specificity and function of immunoglobulin superfamily NK cell inhibitory and stimulatory receptors. Colonna M. **Immunol Rev** 1997 Feb;155:127–33 (55 ref.)

Allorecognition by murine natural killer cells: lysis of T–lymphoblasts and rejection of bone–marrow grafts. George T, et al. **Immunol Rev** 1997 Feb;155:29–40 (53 ref.)

The role of CD40 ligand in costimulation and T–cell activation. Grewal IS, et al. **Immunol Rev** 1996 Oct; 153:85–106 (100 ref.)

Arousal and inhibition of human NK cells. Lanier LL, et al. **Immunol Rev** 1997 Feb;155:145–54 (98 ref.)

Enumeration and characterization of memory cells in the TH compartment. McHeyzer–Williams MG, et al. **Immunol Rev** 1996 Apr;150:5–21 (45 ref.)

Pathways of T–cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. Mackall CL, et al. **Immunol Rev** 1997 Jun; 157:61–72 (68 ref.)

Transduction of cytotoxic signals in natural killer cells: a general model of fine tuning between activatory and inhibitory pathways in lymphocytes. Renard V, et al. **Immunol Rev** 1997 Feb;155:205–21 (153 ref.)

The complexities of T–cell co–stimulation: CD28 and beyond. Sperling AI, et al. **Immunol Rev** 1996 Oct; 153:155–82 (100 ref.)

From naive to memory T cells. Swain SL, et al. **Immunol Rev** 1996 Apr;150:143–67 (100 ref.)

CD80, CD86 and CD40 provide accessory signals in a multiple–step T–cell activation model. Van Gool SW, et al. **Immunol Rev** 1996 Oct;153:47–83 (150 ref.)

CTLA–4, a negative regulator of T–lymphocyte activation. Waterhouse P, et al. **Immunol Rev** 1996 Oct;153:183–207 (130 ref.)

Cellular environments and apoptosis: tissue microenvironments control activated T–cell death. Akbar AN, et al. **Immunol Today** 1997 Feb;18(2):72–6 (43 ref.)

A central role of CD40 ligand in the regulation of CD4+ T–cell responses. Grewal IS, et al. **Immunol Today** 1996 Sep;17(9):410–4 (41 ref.)

PI 3–kinase: a pivotal pathway in T–cell activation? Ward SG, et al. **Immunol Today** 1996 Apr;17(4):187–97 (116 ref.)

Lymphocyte activation in allergic reactions elicited by small–molecular–weight compounds. Merk HF, et al. **Int Arch Allergy Immunol** 1997 May–Jul;113(1–3):173–6 (22 ref.)

B–cell activation versus tolerance––the central role of immunoglobulin receptor engagement and T–cell help. Fulcher DA, et al. **Int Rev Immunol** 1997;15(1–2):33–52 (22 ref.)

The importance of efficacy and partial agonism in evaluating models of B lymphocyte activation. Hodgkin PD, et al. **Int Rev Immunol** 1997;15(1–2):101–27 (26 ref.)

Understanding the mechanisms of sustained signaling and T cell activation [comment] Lanzavecchia A. **J Exp Med** 1997 May 19;185(10):1717–9 (20 ref.) Comment on: J Exp Med 1997 May 19;185(10):1803–13. Comment on: J Exp Med 1997 May 19;185(10):1815–25. Comment on: J Exp Med 1997 May 19;185(10):1859–64.

Sites of B lymphocyte selection, activation, and tolerance in spleen. Liu YJ. **J Exp Med** 1997 Aug 29;186(5):625–9 (42 ref.)

Is CTLA–4 a master switch for peripheral T cell tolerance? Bluestone JA. **J Immunol** 1997 Mar 1;158(5):1989–93 (37 ref.)

Do effector and memory T helper cells also need B7 ligand costimulatory signals? Gause WC, et al. **J Immunol** 1997 Aug 1;159(3):1055–8 (49 ref.)

T helper cell activation and human retroviral pathogenesis. Copeland KF, et al. **Microbiol Rev** 1996 Dec;60(4):722–42 (370 ref.)

Viewpoint: signal transduction during natural killer cell activation. Leibson P. **Nat Immun** 1995;14(3):117–22 (38 ref.)

Divergent signal transduction pathways and effects on natural killer cell functions induced by interaction of Fc receptors with physiologic ligands or antireceptor antibodies. Sulica A, et al. **Nat Immun** 1995;14(3):123–33 (58 ref.)

New molecular aspects of chronic uraemia and dialysis–related immunocompetent cell activation. Descamps–Latscha B, et al. **Nephrol Dial Transplant** 1996; 11 Suppl 2:121–4 (23 ref.)

Inhibitory and activatory receptors for MHC class I molecules. Cambiaggi A, et al. **Res Immunol** 1997 Mar–Apr;148(3):172–9 (53 ref.)

Regulation of interleukin–12 signal transduction during T helper phenotype development. Jacobson NG, et al. **Res Immunol** 1995 Sep–Oct;146(7–8):446–56 (23 ref.)

NKRP1A and p40 molecules are involved in regulation of activation and maturation of human NK cells. Poggi A, et al. **Res Immunol** 1997 Mar–Apr;148(3):179–84 (34 ref.)

HIV1 Nef: the Machiavelli of cellular activation. Greenway A, et al. **Res Virol** 1997 Jan–Feb;148(1):58–64 (51 ref.)

B–cell development and differentiation. Duchosal MA. **Semin Hematol** 1997 Jan;34(1 Suppl 1):2–12 (146 ref.)

Variant TCR ligands: new insights into the molecular basis of antigen–dependent signal transduction and T–cell activation. Madrenas J, et al. **Semin Immunol** 1996 Apr; 8(2):83–101 (99 ref.)

Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Krieg AM. **Trends Microbiol** 1996 Feb; 4(2):73–6 (35 ref.)

[Lymphocyte blastogenesis] Sugiura S, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:176–9 (2 ref.) **(Jpn)**

DRUG EFFECTS

Altered peptide ligand–induced partial T cell activation: molecular mechanisms and role in T cell biology. Sloan–Lancaster J, et al. **Annu Rev Immunol** 1996;14:1–27 (81 ref.)

Significance of the blood beryllium lymphocyte proliferation test. Newman LS. **Environ Health Perspect** 1996 Oct;104 Suppl 5:953–6 (28 ref.)

The neglected role of type I interferon in the T–cell response: implications for its clinical use. Belardelli F, et al. **Immunol Today** 1996 Aug;17(8):369–72 (50 ref.)

Covalent chemical events in immune induction: fundamental and therapeutic aspects [see comments] Rhodes J. **Immunol Today** 1996 Sep;17(9):436–41 (44 ref.) Comment in: Immunol Today 1997 Jul;18(7):362.

The responses of mature T cells are not necessarily antagonized by their positively selecting peptide. Ignatowicz L, et al. **J Immunol** 1996 Sep 1;157(5):1827–31 (33 ref.)

The effect of endogenous altered peptide ligands on peripheral T–cell responses. Vidal K, et al. **Semin Immunol** 1996 Apr;8(2):117–22 (44 ref.)

GENETICS

Lessons from immunological, biochemical, and molecular pathways of the activation mediated by IL–2 and IL–4. Rebollo A, et al. **Adv Immunol** 1996;63:127–96 (646 ref.)

Regulation of gene expression at early stages of B–cell and T–cell differentiation. Fitzsimmons D, et al. **Curr Opin Immunol** 1996 Apr;8(2):166–74 (64 ref.)

Gene targeting reveals a hierarchy of transcription factors regulating specification of lymphoid cell fates. Singh H. **Curr Opin Immunol** 1996 Apr;8(2):160–5 (40 ref.)

[Regulatory mechanisms of lymphocyte proliferation: roles of Spa–1 gene] Minato N. **Hum Cell** 1996 Mar;9(1):11–6 (7 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Regulation of T cell activation by CD28 and CTLA4. Noel PJ, et al. **Adv Exp Med Biol** 1996;406:209–17 (27 ref.)

Lessons from immunological, biochemical, and molecular pathways of the activation mediated by IL–2 and IL–4. Rebollo A, et al. **Adv Immunol** 1996;63:127–96 (646 ref.)

Activation and proliferation of lymphocytes and other mammalian cells in microgravity. Cogoli A, et al. **Adv Space Biol Med** 1997;6:33–79 (76 ref.)

Major pathways of mucosal immunity and inflammation: cell activation, cytokine production and the role of bacterial factors. James SP, et al. **Aliment Pharmacol Ther** 1996;10 Suppl 2:1–9 (52 ref.)

Co–stimulation in T cell responses. Chambers CA, et al. **Curr Opin Immunol** 1997 Jun;9(3):396–404 (83 ref.)

Regulation of gene expression at early stages of B–cell and T–cell differentiation. Fitzsimmons D, et al. **Curr Opin Immunol** 1996 Apr;8(2):166–74 (64 ref.)

Interactions of TCRs with MHC–peptide complexes: a quantitative basis for mechanistic models. Margulies DH. **Curr Opin Immunol** 1997 Jun;9(3):390–5 (56 ref.)

Role of phosphatases in lymphocyte activation. Neel BG. **Curr Opin Immunol** 1997 Jun;9(3):405–20 (124 ref.)

Recognition events that inhibit and activate natural killer cells. Raulet DH. **Curr Opin Immunol** 1996 Jun;8(3):372–7 (55 ref.)

ITIMs and ITAMs. The Yin and Yang of antigen and Fc receptor–linked signaling machinery. Isakov N. **Immunol Res** 1997 Feb;16(1):85–100 (112 ref.)

Murine natural killer cell differentiation: past, present, and future. Moore TA, et al. **Immunol Res** 1996;15(2):151–62 (94 ref.)

B–cell activation by superstimulatory influenza virus hemagglutinin: a pathogenesis for autoimmunity? Cash E, et al. **Immunol Rev** 1996 Aug;152:67–88 (116 ref.)

Epstein–Barr virus infection of T cells: implications for altered T–lymphocyte activation, repertoire development and autoimmunity. Dreyfus DH, et al. **Immunol Rev** 1996 Aug;152:89–110 (67 ref.)

Cytotoxic T–lymphocyte (CTL) responses against acute or chronic myeloid leukemia. Falkenburg JH, et al. **Immunol Rev** 1997 Jun;157:223–30 (71 ref.)

Use of adoptive transfer of T–cell–antigen–receptor–transgenic T cell for the study of T–cell activation in vivo. Pape KA, et al. **Immunol Rev** 1997 Apr;156:67–78 (59 ref.)

Transcriptional control of lymphoid development: lessons from gene targeting. Clevers HC, et al. **Immunol Today** 1996 Jul;17(7):336–43 (59 ref.)

T–cell regeneration: all repertoires are not created equal. Mackall CL, et al. **Immunol Today** 1997 May;18(5):245–51 (69 ref.)

HTLV–I–induced T–cell activation. Buckle GJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S107–13 (68 ref.)

Partial activation of foreign antigen specific T lymphocytes by a self peptide: possible roles of altered peptide ligands in regulating T lymphocyte mediated immune response. Cao W, et al. **J Mol Med** 1996 Oct;74(10):573–82 (104 ref.)

The maturation of the immune system. Hanson LA, et al. **Monogr Allergy** 1996;32:10–5 (23 ref.)

Unconventional T–cell activation by IL–15 in rheumatoid arthritis [news; comment] Carson DA. **Nat Med** 1997 Feb; 3(2):148–9 (8 ref.) Comment on: Nat Med 1997 Feb;3(2

):189–95.
Theileria transformation of bovine leukocytes: a parasite model for the study of lymphoproliferation. Chaussepied M, et al. **Res Immunol** 1996 Mar–Apr;147(3):127–38 (64 ref.)
[Immunopathology of malaria: emergence of a new T-lymphocyte reactivity] Behr C.
C R Seances Soc Biol Fil 1996;190(4):357–68 (67 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Mechanisms of leukocyte activation in the circulation. Schmid-Schönbein GW, et al. **Atherosclerosis** 1997 Jun;131 Suppl:S23–5 (15 ref.)
Signaling events in T lymphocytes leading to cellular activation or programmed cell death. Musci MA, et al. **Clin Immunol Immunopathol** 1997 Jun;83(3):205–22 (197 ref.)
The complexity of signaling pathways activated by the BCR. DeFranco AL. **Curr Opin Immunol** 1997 Jun;9(3):296–308 (120 ref.)
Lymphocyte activation and effector functions. How signals are integrated in the immune system. Nussenzweig M, et al. **Curr Opin Immunol** 1997 Jun;9(3):293–5 (0 ref.)
Lymphocyte proliferation in response to exercise. Nielsen HB, et al. **Eur J Appl Physiol** 1997;75(5):375–9 (32 ref.)
Role of CD26 for CD4 memory T cell function and activation. Dong RP, et al. **Hum Cell** 1996 Sep;9(3):153–62 (47 ref.)
Immunoreceptor tyrosine-based inhibition motifs. Vivier E, et al. **Immunol Today** 1997 Jun;18(6):286–91 (52 ref.)
Signaling mechanisms and the activation of leukocyte integrins. Newton RA, et al. **J Leukoc Biol** 1997 Apr; 61(4):422–6 (54 ref.)
Do superantigens play a role in lymphoproliferation? Amariglio N, et al. **Leuk Lymphoma** 1996 Jul; 22(3–4):237–43 (44 ref.)
Antigen analogs as tools to study T-cell activation function and activation. Sette A, et al. **Semin Immunol** 1996 Apr; 8(2):103–8 (29 ref.)
[Activation of T-lymphocytes in Crohn disease and in ulcerative hemorrhagic rectocolitis. Therapeutic implications] Voiglio E, et al. **Pathol Biol (Paris)** 1996 Apr; 44(4):287–92 (44 ref.) (Eng. Abstr.) **(Fre)**
[The TRAF family protein-mediated B cell proliferation signal and the mechanism of LMP1-induced B cell transformation] Inoue J. **Nippon Rinsho** 1997 Feb; 55(2):299–304 (18 ref.) (Eng. Abstr.) **(Jpn)**

LYMPHOCYTE TRANSFUSION

Donor lymphocyte infusions. Giralt SA, et al.
Curr Opin Oncol 1996 Mar;8(2):96–102 (61 ref.)
Adoptive immunotherapy with donor lymphocyte transfusions. Kolb HJ, et al. **Curr Opin Oncol** 1997 Mar; 9(2):139–45 (53 ref.)

LYMPHOCYTES

see related
ANTILYMPHOCYTE SERUM
Lung lymphocytes: origin, biological functions, and laboratory techniques for their study in immune-mediated pulmonary disorders. Semenzato G, et al.
Crit Rev Clin Lab Sci 1996 Oct;33(5):423–55 (93 ref.)
[Collagenous and lymphocytic colitis] Díaz Blasco J, et al. **Med Clin (Barc)** 1997 May 24;108(20):791–6 (83 ref.) **(Spa)**

CHEMISTRY

Characterization of the VIP receptor from SUP T1 lymphoblasts. Robberecht P, et al. **Adv Neuroimmunol** 1996; 6(1):49–57 (58 ref.)

CYTOLOGY

The role of the Ikaros gene in lymphocyte development and homeostasis. Georgopoulos K, et al. **Annu Rev Immunol** 1997;15:155–76 (51 ref.)
Germinal centers: a second childhood for lymphocytes. Tarlinton D. **Curr Biol** 1997 Mar 1;7(3):R155–9 (25 ref.)
Developmental regulation of V(D)J recombination and lymphocyte differentiation. Willerford DM, et al.
Curr Opin Genet Dev 1996 Oct;6(5):603–9 (62 ref.)
Aspects of lymphocyte developmental biology. von Boehmer H. **Immunol Today** 1997 Jun;18(6):260–2 (38 ref.)
Cytokine regulation of early lymphohematopoietic development. Hirayama F, et al. **Stem Cells** 1996 Jul; 14(4):369–75 (41 ref.)

DRUG EFFECTS

Chemokines and lymphocyte biology. Hedrick JA, et al.
Curr Opin Immunol 1996 Jun;8(3):343–7 (38 ref.)

ENZYMOLOGY

Protein tyrosine phosphatase roles in the regulation of lymphocyte signaling. Pani G, et al.
Clin Immunol Immunopathol 1997 Jul;84(1):1–16 (110 ref.)

IMMUNOLOGY

Regulation of lymphoid apoptosis by Bcl-2 and Bcl-XL. Nuñez G, et al. **Adv Exp Med Biol** 1996;406:75–82 (36 ref.)
Mechanisms for recognition and phagocytosis of apoptotic lymphocytes by macrophages. Schlegel RA, et al.
Adv Exp Med Biol 1996;406:21–8 (26 ref.)
Analysis of gene function in lymphocytes by RAG-2-deficient blastocyst complementation. Chen J.
Adv Immunol 1996;62:31–59 (104 ref.)
How do lymphocytes know where to go: current concepts and enigmas of lymphocyte homing. Salmi M, et al.
Adv Immunol 1997;64:139–218 (568 ref.)
Immunomodulation of peripheral lymphocytes by hormones of the hypothalamus-pituitary-thyroid axis. Kruger TE.
Adv Neuroimmunol 1996;6(4):387–95 (63 ref.)
Activation and proliferation of lymphocytes and other mammalian cells in microgravity. Cogoli A, et al.
Adv Space Biol Med 1997;6:33–79 (76 ref.)
Special features of the intestinal lymphocytic system. Köhne G, et al. **Baillieres Clin Gastroenterol** 1996 Sep;10(3):427–42 (82 ref.)
Heterogeneity of interactions mediated by membrane glycoproteins of lymphocytes. Barclay AN, et al.
Biochem Soc Trans 1997 Feb;25(1):224–8 (15 ref.)
Pathogenesis and treatment of virus-induced autoimmune diabetes: novel insights gained from the RIP-LCMV transgenic mouse model. von Herrath MG, et al.
Biochem Soc Trans 1997 May;25(2):630–5 (55 ref.)
Lymphocyte targeting of the central nervous system: a review of afferent and efferent CNS-immune pathways. Weller RO, et al. **Brain Pathol** 1996 Jul;6(3):275–88 (81 ref.)
Lymphocyte adhesion molecules in autoimmune rheumatic diseases: basic issues and clinical expectations. Sfikakis PP, et al. **Clin Exp Rheumatol** 1995 Nov–Dec;13(6):763–77 (108 ref.)
Protein tyrosine phosphatase roles in the regulation of lymphocyte signaling. Pani G, et al.
Clin Immunol Immunopathol 1997 Jul;84(1):1–16 (110 ref.)
Regulation of immune responses of the intestinal mucosa. Abreu-Martin MT, et al. **Crit Rev Immunol** 1996; 16(3):277–309 (231 ref.)
Developmental regulation of V(D)J recombination and lymphocyte differentiation. Willerford DM, et al.
Curr Opin Genet Dev 1996 Oct;6(5):603–9 (62 ref.)
Inherited disorders of lymphocyte development and function [editorial] Fischer A. **Curr Opin Immunol** 1996 Aug; 8(4):445–7 (15 ref.)
Chemokines and lymphocyte biology. Hedrick JA, et al.
Curr Opin Immunol 1996 Jun;8(3):343–7 (38 ref.)
The use of dominant-negative mutations to elucidate signal transduction pathways in lymphocytes. Perlmutter RM, et al. **Curr Opin Immunol** 1996 Apr;8(2):285–90 (48 ref.)
rag-1 and rag-2: biochemistry and protein interactions. Schatz DG, et al. **Curr Top Microbiol Immunol** 1996; 217:11–29 (27 ref.)
Lymphocytes from site of disease indicate probable microbiological etiology of "infective-immune" diseases such as rheumatoid arthritis. Ford DK, et al.
Infect Agents Dis 1996 Oct;5(4):223–30 (62 ref.)
Human decidual leukocytes do not proliferate in response to either extravillous trophoblast or allogeneic peripheral blood lymphocytes. King A, et al. **J Reprod Immunol** 1996 Feb;30(1):67–74 (20 ref.)
Lymphocyte-mediated cytolysis and disease. Liu CC, et al. **N Engl J Med** 1996 Nov 28;335(22):1651–9 (101 ref.)
Inflammation in EAE: role of chemokine/cytokine expression by resident and infiltrating cells. Eng LF, et al. **Neurochem Res** 1996 Apr;21(4):511–25 (133 ref.)
Virus-lymphoid cell interactions [comment] Oldstone MB. **Proc Natl Acad Sci U S A** 1996 Nov 12;93(23):12756–8 (48 ref.) Comment on: Proc Natl Acad Sci U S A 1996 Nov 12;93(23):13125–30. Comment on: Proc Natl Acad Sci U S A 1996 Nov 12;93(23):13194–9.
The hu-PBL-SCID mouse in human lymphocyte function and lymphomagenesis studies: achievements and caveats. Amadori A, et al. **Semin Immunol** 1996 Aug;8(4):249–54 (50 ref.)
Portrait of an executioner: the molecular mechanism of FAS/APO-1-induced apoptosis. Chinnaiyan AM, et al.
Semin Immunol 1997 Feb;9(1):69–76 (84 ref.)
Essential and perilous: V(D)J recombination and DNA damage checkpoints in lymphocyte precursors. Danska JS, et al. **Semin Immunol** 1997 Jun;9(3):199–206 (81 ref.)
Lymphocyte-specific genomic instability and risk of lymphoid malignancy. Kirsch IR, et al. **Semin Immunol** 1997 Jun;9(3):207–15 (96 ref.)
The molecular regulation of lymphocyte apoptosis. Lenardo MJ. **Semin Immunol** 1997 Feb;9(1):1–5 (33 ref.)
The CD95 system and the death of a lymphocyte. Matiba B, et al. **Semin Immunol** 1997 Feb;9(1):59–68 (108 ref.)
The huPBL-SCID mouse as a means to examine human immune function in vivo. Murphy WJ, et al.
Semin Immunol 1996 Aug;8(4):233–41 (69 ref.)
Immune dysfunction in murine polymicrobial sepsis: mediators, macrophages, lymphocytes and apoptosis. Ayala A, et al. **Shock** 1996;6 Suppl 1:S27–38 (134 ref.)
On the front lines: intraepithelial lymphocytes as primary effectors of intestinal immunity. Lefrançois L, et al.
Springer Semin Immunopathol 1997;18(4):463–75 (83 ref.)
Constitutive and inflammatory lymphocyte trafficking. Binns RM, et al. **Vet Immunol Immunopathol** 1996 Nov; 54(1–4):97–104 (39 ref.)
Fish immunology: the utility of immortalized lymphoid cells--a mini review. Clem LW, et al.
Vet Immunol Immunopathol 1996 Nov;54(1–4):137–44 (29 ref.)
[Lymphocyte blastogenesis] Sugiura S, et al.
Nippon Rinsho 1997 Mar;55 Suppl 1:176–9 (2 ref.) **(Jpn)**
[Bile acids and immune regulation] Tanaka H, et al.
Nippon Shokakibyo Gakkai Zasshi 1996 Oct;93(10):693–9 (49 ref.) **(Jpn)**
[Regulation of expression of the surface structure of the lymphocyte membrane by purine compounds in health and in disease] Poriadin GV, et al. **Patol Fiziol Eksp Ter** 1997 Jan-Mar;(1):42–5 (82 ref.) **(Rus)**
[Immune response of lymphocytes: new concepts] Titova NG. **Vestn Ross Akad Med Nauk** 1996;(5):18–24 (50 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

How do lymphocytes know where to go: current concepts and enigmas of lymphocyte homing. Salmi M, et al.
Adv Immunol 1997;64:139–218 (568 ref.)
Expression of vasoactive intestinal peptide in lymphocytes: a possible endogenous role in the regulation of the immune system. Leceta J, et al. **Adv Neuroimmunol** 1996;6(1):29–36 (35 ref.)
Acute induction and priming for cytokine production in lymphocytes. Trinchieri G, et al.
Cytokine Growth Factor Rev 1996 Aug;7(2):123–32 (57 ref.)
C-kit receptors in childhood malignant lymphoblastic cells. Sykora KW, et al. **Leuk Lymphoma** 1997 Apr; 25(3–4):201–16 (94 ref.)
Immune responses to adenovirus vectors in the nervous system. Wood MJ, et al. **Trends Neurosci** 1996 Nov; 19(11):497–501 (47 ref.)
[Abnormal Fas and Fas ligand expression of lymphocytes in patients with SLE] Suzuki N, et al. **Nippon Rinsho** 1996 Jul;54(7):1955–9 (18 ref.) (Eng. Abstr.) **(Jpn)**

PARASITOLOGY

The same but different: the biology of Theileria sporozoite entry into bovine cells. Shaw MK. **Int J Parasitol** 1997 May;27(5):457–74 (121 ref.)

PATHOLOGY

Lymphocyte predominant Hodgkin's disease--a workshop report. European Task Force on Lymphoma. Sextro M, et al. **Ann Oncol** 1996;7 Suppl 4:61–5 (0 ref.)
Inherited disorders of lymphocyte development and function [editorial] Fischer A. **Curr Opin Immunol** 1996 Aug; 8(4):445–7 (15 ref.)
Lymphocytic adenohypophysitis and lymphocytic infundibuloneurohypophysitis. Hashimoto K, et al.
Endocr J 1997 Feb;44(1):1–10 (107 ref.)
Spontaneous resolution of a pituitary mass: probable lymphocytic hypophysitis. Menon PS, et al.
J Assoc Physicians India 1996 Sep;44(9):653–5 (20 ref.)
Lymphoplasmacyte-rich meningioma with clinical resemblance to inflammatory pseudotumor. Report of two cases. Yamaki T, et al. **J Neurosurg** 1997 May;86(5):898–904 (22 ref.)
C-kit receptors in childhood malignant lymphoblastic cells. Sykora KW, et al. **Leuk Lymphoma** 1997 Apr; 25(3–4):201–16 (94 ref.)
Lymphocytic and granulomatous hypophysitis: experience with nine cases. Honegger J, et al. **Neurosurgery** 1997 Apr; 40(4):713–22; discussion 722–3 (41 ref.)
Cutaneous lymphocytic vasculitis: a definition, a review, and a proposed classification. Carlson JA, et al.
Semin Diagn Pathol 1996 Feb;13(1):72–90 (57 ref.)

PHYSIOLOGY

High endothelial venules: lymphocyte traffic control and controlled traffic. Kraal G, et al. **Adv Immunol** 1997; 65:347–95 (263 ref.)
High-endothelial-venule ligands for L-selectin: identification and functions. Rosen SD, et al. **Biochem Soc Trans** 1997 May;25(2):428–33 (45 ref.)
Hormones, lymphohemopoietic cytokines and the neuroimmune axis. Johnson RW, et al.
Comp Biochem Physiol A Physiol 1997 Mar;116(3):183–201 (210 ref.)
Lymphocytes, cytokines, inflammation, and immune trafficking. Tsokos GC, et al. **Curr Opin Rheumatol** 1997 Sep;9(5):380–6 (57 ref.)
The Carl Prausnitz Memorial Lecture. The development of lymphocytes. Melchers F. **Int Arch Allergy Immunol** 1997 May-Jul;113(1–3):11–3 (19 ref.)
Cellular and molecular analysis of lymphoid development using Rag-deficient mice. Spanopoulou E.
Int Rev Immunol 1996;13(4):257–88 (216 ref.)
Immune surveillance of the oral cavity and lymphocyte migration: relevance for alcohol abusers. Chiappelli F, et al. **Lymphology** 1995 Dec;28(4):196–207 (52 ref.)
[Redox regulation of cellular signaling] Suzuki Y.
Seikagaku 1997 Mar;69(3):187–91 (15 ref.) **(Jpn)**

RADIATION EFFECTS

Adaptive response to ionizing radiation in human lymphocytes: the problem of scoring aberrations in cells irradiated during asynchronous growth. Wojcik A, et al.
Mutat Res 1996 Nov;366(2):137–43 (20 ref.)

LYMPHOCYTES

Is there reliable experimental evidence for a chromosomal "fingerprint" of exposure to densely ionizing radiation? [comment] Bauchinger M, et al. **Radiat Res** 1997 Apr; 147(4):506–10 (33 ref.) Comment on: Radiat Res 1994 Oct;140(1):134–42. Comment on: Radiat Res 1996 Apr;145(4):501–7. Comment on: Radiat Res 1996 Oct;146(4):479–82.

[Action of ionizing radiation on the functional activity of lymphoid cells] Osapchenko LI. **Ukr Biokhim Zh** 1996 Jul–Aug;68(4):55–63 (78 ref.) (Eng. Abstr.) **(Rus)**

VIROLOGY

Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes. Aquaro S, et al. **J Leukoc Biol** 1997 Jul;62(1):138–43 (39 ref.)

Virus–lymphoid cell interactions [comment] Oldstone MB. **Proc Natl Acad Sci U S A** 1996 Nov 12;93(23):12756–8 (48 ref.) Comment on: Proc Natl Acad Sci U S A 1996 Nov 12;93(23):13125–30. Comment on: Proc Natl Acad Sci U S A 1996 Nov 12;93(23):13194–9.

Cytopathic feline leukemia viruses cause apoptosis in hemolymphatic cells. Rojko JL, et al. **Prog Mol Subcell Biol** 1996;16:13–43 (150 ref.)

B-LYMPHOCYTES

see related
GERMINAL CENTER
LYMPHOCYTE COOPERATION

Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Krieg AM. **Trends Microbiol** 1996 Feb; 4(2):73–6 (35 ref.)

[RP105 and B cell apoptosis] Miura Y, et al. **Nippon Rinsho** 1996 Jul;54(7):1784–9 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Role of LFA-1/ICAM-1-dependent cell adhesion in CD40-mediated inhibition of anti-IgM antibody-induced B-cell death] Sumimoto S, et al. **Nippon Rinsho** 1996 Jul; 54(7):1779–83 (12 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Antigen receptor signaling gives lymphocytes a long life [comment] Neuberger MS. **Cell** 1997 Sep 19;90(6):971–3 (8 ref.) Comment on: Cell 1997 Sep 19;90(6):1073–83.

Biochemistry of antigen receptor signaling in mature and developing B lymphocytes. Bireland ML, et al. **Crit Rev Immunol** 1997;17(3–4):353–85 (228 ref.)

CYTOLOGY

Surrogate light chain in B cell development. Karasuyama H, et al. **Adv Immunol** 1996;63:1–41 (178 ref.)

B lymphocyte development and transcription regulation in vivo. Opstelten D. **Adv Immunol** 1996;63:197–268 (308 ref.)

Fas-dependent and Fas-independent mechanisms for selection of the mature human B cell repertoire. Defrance T, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:67–74 (20 ref.)

Mutually dependent T and B cell responses in germinal centers. Gulbranson-Judge A, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:199–210 (42 ref.)

B lymphocyte developmental lineages. Hayakawa K, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:15–29 (59 ref.)

Immunoglobulin J chain. An early differentiation marker of human B cells. Mestecky J, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:111–3 (9 ref.)

Control of the sizes and contents of precursor B cell repertoires in bone marrow. Melchers F. **Ciba Found Symp** 1997;204:172–82; discussion 182–6 (24 ref.)

Signalling in lymphocyte development. Owen MJ, et al. **Curr Opin Immunol** 1996 Apr;8(2):191–8 (64 ref.)

Lymphocyte development [editorial] Storb U, et al. **Curr Opin Immunol** 1996 Apr;8(2):155–9 (28 ref.)

Differentiation and apoptosis of human germinal center B-lymphocytes. Choi YS. **Immunol Res** 1997;16(2):161–74 (105 ref.)

B cells and their fate in health and disease. Caligaris-Cappio F, et al. **Immunol Today** 1996 May;17(5):206–8 (17 ref.)

B cell development in mice. Kearney JF, et al. **Int Rev Immunol** 1997;15(3–4):207–41 (168 ref.)

Human B cell biology. Kipps TJ. **Int Rev Immunol** 1997; 15(3–4):243–64 (95 ref.)

B lymphocyte development in the rabbit. Knight KL, et al. **Int Rev Immunol** 1997;15(3–4):129–63 (108 ref.)

Avian B cell development. Masteller EL, et al. **Int Rev Immunol** 1997;15(3–4):185–206 (82 ref.)

Cellular interactions among marrow stromal and normal/neoplastic pre-B- and B-lymphoblastic cells. Patrick CW Jr, et al. **Leuk Lymphoma** 1996 Jul; 22(3–4):205–19 (117 ref.)

Separation and maintenance of primary T- and B-lymphocytes. Kinchington D, et al. **Methods Mol Biol** 1997;75:91–100 (6 ref.)

Long-term B-lymphoid cultures from murine bone marrow establishment and cloning by using stromal cell line AC 6.21. Whitlock CA, et al. **Methods Mol Biol** 1997;75:231–48 (13 ref.)

Cytokines involved in B-cell differentiation and their sites of action. Takatsu K. **Proc Soc Exp Biol Med** 1997 Jun; 215(2):121–33 (171 ref.)

B-cell development and differentiation. Duchosal MA. **Semin Hematol** 1997 Jan;34(1 Suppl 1):2–12 (146 ref.)

Key differentiation steps in normal B cells and in myeloma cells. Zubler RH. **Semin Hematol** 1997 Jan;34(1 Suppl 1):13–22 (52 ref.)

Observations on memory B-cell development. Gray D, et al. **Semin Immunol** 1997 Aug;9(4):249–54 (51 ref.)

Distinctive characteristics of germinal center B cells. Han S, et al. **Semin Immunol** 1997 Aug;9(4):255–60 (54 ref.)

The cellular origins of memory B cells. Klinman NR. **Semin Immunol** 1997 Aug;9(4):241–7 (55 ref.)

Regulation of B-cell commitment to plasma cells or to memory B cells. Liu YJ, et al. **Semin Immunol** 1997 Aug; 9(4):235–40 (56 ref.)

[Pax-5, a transcription factor controlling B cell differentiation] Kudo A. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1058–66 (25 ref.) **(Jpn)**

DRUG EFFECTS

Negative signaling in B cells by surface immunoglobulins. Mayumi M, et al. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 2):S238–47 (102 ref.)

New perspectives on the approach to chronic lymphocytic leukemia. Goodman MG, et al. **Leuk Lymphoma** 1996 Jun; 22(1–2):1–10 (51 ref.)

Modulation of apoptosis with cytokines in B-cell chronic lymphocytic leukaemia. Mainou-Fowler T, et al. **Leuk Lymphoma** 1996 May;21(5–6):369–77 (126 ref.)

ENZYMOLOGY

Genetic analysis of tyrosine kinase function in B cell development. Satterthwaite A, et al. **Annu Rev Immunol** 1996;14:131–54 (167 ref.)

IMMUNOLOGY

Regulation of B cell apoptosis. Ashman RF, et al. **Adv Exp Med Biol** 1996;406:145–54 (21 ref.)

B-cell epitopes: fact and fiction. Benjamin DC. **Adv Exp Med Biol** 1995;386:95–108 (30 ref.)

Signals for survival and apoptosis in normal and neoplastic B lymphocytes. Gordon J, et al. **Adv Exp Med Biol** 1996; 406:139–44 (10 ref.)

Generation and regulation of B cell autoreactivity arising in the periphery. Kuo P, et al. **Adv Exp Med Biol** 1996; 406:167–76 (71 ref.)

Role of the CD28–B7 costimulatory pathways in T cell-dependent B cell responses. Hathcock KS, et al. **Adv Immunol** 1996;62:131–66 (152 ref.)

CD40–CD40 ligand: a multifunctional receptor–ligand pair. Van Kooten C, et al. **Adv Immunol** 1996;61:1–77 (371 ref.)

Positive and negative selection of human B lymphocytes in vitro. Banchereau J, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:237–45 (30 ref.)

The roles of B cells in MRL/lpr murine lupus. Chan O, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:75–87 (64 ref.)

Phenotypic and functional characterization of human tonsillar subepithelial (SE) B cells. Dono M, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:171–81 (31 ref.)

Unique site of autoantibody production in Fas-deficient mice. Jacobson BA, et al. **Ann N Y Acad Sci** 1997 Apr 5; 815:218–29 (43 ref.)

Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86. Lane P. **Ann N Y Acad Sci** 1997 Apr 5;815:392–400 (40 ref.)

The role of autoreactivity in B cell selection. Stollar BD, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:30–9 (91 ref.)

Normal and malignant B-cell development with special reference to Hodgkin's disease. Rajewsky K, et al. **Ann Oncol** 1997;8 Suppl 2:79–81 (21 ref.)

Neutralizing antiviral B cell responses. Bachmann MF, et al. **Annu Rev Immunol** 1997;15:235–70 (175 ref.)

Genetic analysis of tyrosine kinase function in B cell development. Satterthwaite A, et al. **Annu Rev Immunol** 1996;14:131–54 (167 ref.)

CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Tedder TF, et al. **Annu Rev Immunol** 1997;15:481–504 (98 ref.)

Mucosal receptors and T- and B-cell immunity. Lehner T, et al. **Antibiot Chemother** 1996;48:21–9 (48 ref.)

Ulcerative colitis: an immunological disease? Radford-Smith G. **Baillieres Clin Gastroenterol** 1997 Mar;11(1):35–52 (88 ref.)

The role of Fas/FasL interactions in the regulation of B cell function. Jacobson BA, et al. **Behring Inst Mitt** 1996 Oct; (97):185–99 (44 ref.)

FasL/Fas and TNF/TNFR interactions in the regulation of immune responses and disease. Lynch DH, et al. **Behring Inst Mitt** 1996 Oct;(97):175–84 (36 ref.)

Origin and structure of pathogenic IgA in IgA nephropathy. Allen A, et al. **Biochem Soc Trans** 1997 May;25(2):486–90 (34 ref.)

Interleukin 4 and interleukin 13: same response, different receptors. Callard RE, et al. **Biochem Soc Trans** 1997 May; 25(2):451–5 (44 ref.)

Positive and negative signal co-operativity in the immune system: the BCR, Fc gamma RIIB, CR2 paradigm. Cambier JC. **Biochem Soc Trans** 1997 May;25(2):441–5 (21 ref.)

Molecular mechanisms regulating B-cell negative selection. Monroe JG. **Biochem Soc Trans** 1997 May;25(2):643–7 (25 ref.)

Antigen receptor signaling gives lymphocytes a long life [comment] Neuberger MS. **Cell** 1997 Sep 19;90(6):971–3 (8 ref.) Comment on: Cell 1997 Sep 19;90(6):1073–83.

Glimpses into the balance between immunity and self-tolerance. Goodnow CC. **Ciba Found Symp** 1997; 204:190–202; discussion 202–7 (25 ref.)

B lymphocyte physiology: the beginning and the end. Nossal GJ. **Ciba Found Symp** 1997;204:220–30; discussion 230–1 (29 ref.)

Immunology and immunity studied with viruses. Zinkernagel RM. **Ciba Found Symp** 1997;204:105–25; discussion 125–9 (168 ref.)

B-lymphocytes and autoantibody profiles in HIV disease. Ng VL. **Clin Rev Allergy Immunol** 1996–97 Winter; 14(4):367–84 (77 ref.)

IgM-mediated B cell apoptosis. Mayumi M, et al. **Crit Rev Immunol** 1995;15(3–4):255–69 (148 ref.)

Structural aspects of signal transduction in B-cells. Vihinen M, et al. **Crit Rev Immunol** 1996;16(3):251–75 (254 ref.)

Immune responses: tails to teach a B cell. Nussenzweig MC. **Curr Biol** 1997 Jun 1;7(6):R355–7 (11 ref.)

Activation of B lymphocytes: integrating signals from CD19, CD22 and Fc gamma RIIb1. Doody GM, et al. **Curr Opin Immunol** 1996 Jun;8(3):378–82 (47 ref.)

Regulation of gene expression at early stages of B-cell and T-cell differentiation. Fitzsimmons D, et al. **Curr Opin Immunol** 1996 Apr;8(2):166–74 (64 ref.)

Molecular mechanisms in B cell antigen receptor signaling. Kurosaki T. **Curr Opin Immunol** 1997 Jun;9(3):309–18 (84 ref.)

Development of B-cell memory and effector function. Lane P. **Curr Opin Immunol** 1996 Jun;8(3):331–5 (45 ref.)

Immune response to mouse mammary tumour virus. Luther SA, et al. **Curr Opin Immunol** 1996 Aug;8(4):498–502 (24 ref.)

Co-receptors of B lymphocytes. O'Rourke L, et al. **Curr Opin Immunol** 1997 Jun;9(3):324–9 (65 ref.)

Signals and susceptibility to programmed death in b cells. Rothstein TL. **Curr Opin Immunol** 1996 Jun;8(3):362–71 (133 ref.)

Immunological memory. Sprent J. **Curr Opin Immunol** 1997 Jun;9(3):371–9 (96 ref.)

Xid and Xid-like immunodeficiencies from a signaling point of view. Tarakhovsky A. **Curr Opin Immunol** 1997 Jun; 9(3):319–23 (50 ref.)

Functions of CD40 on B cells, dendritic cells and other cells. van Kooten C, et al. **Curr Opin Immunol** 1997 Jun; 9(3):330–7 (64 ref.)

Role of Fas-mediated cell death in the regulation of immune responses. van Parijs L, et al. **Curr Opin Immunol** 1996 Jun;8(3):355–61 (70 ref.)

Regulation of recombination activating gene expression during lymphocyte development. Grawunder U, et al. **Curr Top Microbiol Immunol** 1996;217:31–43 (60 ref.)

Developmental and molecular regulation of immunoglobulin class switch recombination. Lorenz M, et al. **Curr Top Microbiol Immunol** 1996;217:151–69 (80 ref.)

Evidence for phenotypic heterogeneity among B cells emigrating from the bursa of fabricius: a reflection of functional diversity? Paramithiotis E, et al. **Curr Top Microbiol Immunol** 1996;212:29–36 (12 ref.)

The somatogenic hormones and insulin-like growth factor-1: stimulators of lymphopoiesis and immune function. Clark R. **Endocr Rev** 1997 Apr;18(2):157–79 (287 ref.)

Factors influencing the preimmune antibody repertoire. Kraj P. **Folia Biol (Praha)** 1997;43(2):53–61 (125 ref.)

Development and induction of the immune response--status 1995. Sterzl J. **Folia Biol (Praha)** 1996;42(1–2):27–40 (60 ref.)

Immune activation by bacterial DNA: a new genetic code. Pisetsky DS. **Immunity** 1996 Oct;5(4):303–10 (70 ref.)

Use of isolated immature-stage B cells to understand negative selection and tolerance induction at the molecular level. Norvell A, et al. **Immunol Res** 1996;15(3):191–207 (71 ref.)

Fas expression and apoptosis in human B cells. Schattner E, et al. **Immunol Res** 1996;15(3):246–57 (82 ref.)

B-cell activation by superstimulatory influenza virus hemagglutinin: a pathogenesis for autoimmunity? Cash E, et al. **Immunol Rev** 1996 Aug;152:67–88 (116 ref.)

Signaling thresholds and interclonal competition in preimmune B-cell selection. Cyster JG. **Immunol Rev** 1997 Apr;156:87–101 (142 ref.)

B-T lymphocyte interactions in the generation and survival of memory cells. Gray D, et al. **Immunol Rev** 1996 Apr; 150:45–61 (65 ref.)

In vitro analysis of the generation and propagation of memory B cells. Klinman NR. **Immunol Rev** 1996 Apr; 150:91–111 (85 ref.)

Regulation of signalling through B-lymphocyte antigen receptors by cell-cell interaction molecules. Law CL, et al. **Immunol Rev** 1996 Oct;153:123–54 (200 ref.)

The changing preference of T and B cells for partners as T-dependent antibody responses develop. MacLennan IC, et al. **Immunol Rev** 1997 Apr;156:53–66 (95 ref.)

Follicular dendritic cells and presentation of antigen and costimulatory signals to B cells. Tew JG, et al. **Immunol Rev** 1997 Apr;156:39–52 (83 ref.)

The B/macrophage cell: an elusive link between CD5+ B lymphocytes and macrophages. Borrello MA, et al. **Immunol Today** 1996 Oct;17(10):471–5 (36 ref.)

To 'B' or not to 'B' a germinal center? Kosco-Vilbois MH, et al. **Immunol Today** 1997 May;18(5):225–30 (47 ref.)

B-cell superantigens. Silverman GJ. **Immunol Today** 1997

Aug;18(8):379–86 (59 ref.)
Negative signaling in B cells: SHIP Grbs Shc. Tridandapani S, et al. **Immunol Today** 1997 Sep;18(9):424–7 (48 ref.)
Rearrangement/hypermutation/gene conversion: when, where and why? Weill JC, et al. **Immunol Today** 1996 Feb; 17(2):92–7 (37 ref.)
Follicular dendritic cells and germinal centers. Liu YJ, et al. **Int Rev Cytol** 1996;166:139–79 (205 ref.)
B cell superantigens: potential modifiers of the normal human B cell repertoire. Domiati-Saad R, et al. **Int Rev Immunol** 1997;14(4):309–24 (62 ref.)
The role of T cells in the regulation of B cell tolerance. Fazekas de St. Groth B, et al. **Int Rev Immunol** 1997; 15(1–2):73–99 (77 ref.)
B-cell activation versus tolerance--the central role of immunoglobulin receptor engagement and T-cell help. Fulcher DA, et al. **Int Rev Immunol** 1997;15(1–2):33–52 (22 ref.)
The importance of efficacy and partial agonism in evaluating models of B lymphocyte activation. Hodgkin PD, et al. **Int Rev Immunol** 1997;15(1–2):101–27 (26 ref.)
B cell superantigens in HIV–1 infection. Müller S, et al. **Int Rev Immunol** 1997;14(4):339–49 (52 ref.)
B-cell superantigens: molecular and cellular implications. Silverman GJ, et al. **Int Rev Immunol** 1997;14(4):259–90 (108 ref.)
Apoptosis and the B cell response to antigen. Tarlinton DM, et al. **Int Rev Immunol** 1997;15(1–2):53–71 (38 ref.)
HIV–1 gp120: a novel viral B cell superantigen. Townsley-Fuchs J, et al. **Int Rev Immunol** 1997; 14(4):325–38 (59 ref.)
Negative signaling in B cells by surface immunoglobulins. Mayumi M, et al. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 2):S238–47 (102 ref.)
Do naturally occurring autoantibodies participate in the constitution of the pathological B-cell repertoire in systemic lupus erythematosus? Gilbert D, et al. **J Autoimmun** 1996 Apr;9(2):247–57 (72 ref.)
Can receptor editing play an important role in normal B-cell development? Nemazee D. **J Autoimmun** 1996 Apr; 9(2):259–61 (26 ref.)
Sites of B lymphocyte selection, activation, and tolerance in spleen. Liu YJ. **J Exp Med** 1997 Aug 29;186(5):625–9 (42 ref.)
When do microbes stimulate rheumatoid factor? [comment] Posnett DN, et al. **J Exp Med** 1997 May 19;185(10):1721–3 (26 ref.) Comment on: J Exp Med 1997 May 19;185(10):1785–92.
In vivo immunosuppressive mechanisms. Halloran PF, et al. **J Heart Lung Transplant** 1996 Oct;15(10):959–71 (96 ref.)
Effects of CD40 stimulation in the prevention of human EBV–lymphomagenesis. Funakoshi S, et al. **Leuk Lymphoma** 1997 Jan;24(3–4):187–99 (32 ref.)
Circulating clonotypic B cells in the biology of multiple myeloma: speculations on the origin of myeloma. Pilarski LM, et al. **Leuk Lymphoma** 1996 Aug;22(5–6):375–83 (56 ref.)
T and B cell recognition of idiotypes of anti–DNA autoantibodies. Gavalchin J, et al. **Lupus** 1997;6(3):337–43 (52 ref.)
Acquired immune deficiency syndrome caused by hyperimmunity. Chigira M. **Med Hypotheses** 1996 Jun; 46(6):489–98 (139 ref.)
Can epitope-focused vaccines select advantageous immune responses? Delves PJ, et al. **Mol Med Today** 1997 Feb; 3(2):55–60 (14 ref.)
B-cell activation and development within chronically inflamed synovium in rheumatoid and reactive arthritis. Berek C, et al. **Semin Immunol** 1997 Aug;9(4):261–8 (38 ref.)
Observations on memory B-cell development. Gray D, et al. **Semin Immunol** 1997 Aug;9(4):249–54 (51 ref.)
Distinctive characteristics of germinal center B cells. Han S, et al. **Semin Immunol** 1997 Aug;9(4):255–60 (54 ref.)
SCID–hu–PBL: a model for making human antibodies? Ifversen P, et al. **Semin Immunol** 1996 Aug;8(4):243–8 (51 ref.)
V-gene usage and N-region insertions in B–1a, B–1b and conventional B cells. Kantor AB. **Semin Immunol** 1996 Feb; 8(1):29–35 (73 ref.)
The cellular origins of memory B cells. Klinman NR. **Semin Immunol** 1997 Aug;9(4):241–7 (55 ref.)
B–1 cells and their reactivity with the murine intestinal microflora. Kroese FG, et al. **Semin Immunol** 1996 Feb; 8(1):11–8 (52 ref.)
Regulation of B-cell commitment to plasma cells or to memory B cells. Liu YJ, et al. **Semin Immunol** 1997 Aug; 9(4):235–40 (56 ref.)
Immune response decisions at the single cell level. McHeyzer-Williams MG. **Semin Immunol** 1997 Aug; 9(4):219–27 (66 ref.)
Memory B-cell clones and the diversity of their members. MacLennan ICM, et al. **Semin Immunol** 1997 Aug; 9(4):229–34 (49 ref.)
Human T-and B-cell functions in SCID–hu mice. Roncarolo MG, et al. **Semin Immunol** 1996 Aug;8(4):207–13 (38 ref.)
A T cell/B cell/epithelial cell internet for mucosal inflammation and immunity. Fujihashi K, et al. **Springer Semin Immunopathol** 1997;18(4):477–94 (113 ref.)
Superantigens related to B cell hyperplasia. Ponzio NM, et al. **Springer Semin Immunopathol** 1996;17(4):285–306 (159 ref.)
Regulation of Epstein–Barr virus latency by latent membrane protein 2. Longnecker R, et al. **Trends Microbiol** 1996 Jan; 4(1):38–42 (59 ref.)
Autoimmunity and B–cell malignancies. Dighiero G. **Verh Dtsch Ges Pathol** 1996;80:148–59 (105 ref.)
Differentiation of B cells in the bovine. Role of cytokines in immunoglobulin isotype expression. Estes DM. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):61–7 (23 ref.)
Restricted B–cell responses to microbial challenge of the respiratory tract. Walker J, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):197–204 (28 ref.)
[Immune response of fishes with respect to phylogenetic aspects] Ahne W. **Tierarztl Prax** 1996 Feb;24(1):88–95 (27 ref.) (Eng. Abstr.) **(Ger)**
[Intra–articular B–cells in the pathogenesis of rheumatoid arthritis] Krenn V, et al. **Verh Dtsch Ges Pathol** 1996; 80:58–66 (35 ref.) (Eng. Abstr.) **(Ger)**
[CD5 positive b–lymphocytes in autoimmunity: possible role in Graves' disease] Afeltra A, et al. **Riv Eur Sci Med Farmacol** 1995 Sep–Oct;17(5):167–74 (64 ref.) (Eng. Abstr.) **(Ita)**
[Abnormality in B cell apoptosis in mice with spontaneous systemic autoimmune disease] Tsubata T. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Dec;19(6):603–4 (10 ref.) **(Jpn)**
[Breakdown of B cell–tolerance and its genetic control] Hirose S. **Nippon Rinsho** 1997 Jun;55(6):1450–4 (19 ref.) (Eng. Abstr.) **(Jpn)**
[The TRAF family protein–mediated B cell proliferation signal and the mechanism of LMP1–induced B cell transformation] Inoue J. **Nippon Rinsho** 1997 Feb; 55(2):299–304 (18 ref.) (Eng. Abstr.) **(Jpn)**
[Immunoglobulin heavy chain variable region(VH) genes in B cell clones producing anti–colon antibodies in ulcerative colitis] Inoue N, et al. **Nippon Rinsho** 1996 Apr; 54(4):1176–81 (27 ref.) (Eng. Abstr.) **(Jpn)**
[B cell function and its evaluation] Itoh C, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:166–71 (17 ref.) **(Jpn)**
[Analysis of B cell autoepitopes and mechanisms for autoantibody production in autoimmune diseases] Kato T. **Nippon Rinsho** 1997 Jun;55(6):1462–7 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Mechanisms for B cell tolerance and their defects in systemic autoimmune diseases] Tsubata T. **Nippon Rinsho** 1997 Jun; 55(6):1351–5 (18 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Surrogate light chain in B cell development. Karasuyama H, et al. **Adv Immunol** 1996;63:1–41 (178 ref.)
Analysis of CD40–CD40 ligand interactions in the regulation of human B cell function. Lipsky PE, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:372–83 (34 ref.)
Tuning antigen receptor signaling by CD22: integrating cues from antigens and the microenvironment. Cyster JG, et al. **Immunity** 1997 May;6(5):509–17 (72 ref.)
Fas expression and apoptosis in human B cells. Schattner E, et al. **Immunol Res** 1996;15(3):246–57 (82 ref.)
Involvement of nuclear factor–kappa B activation in IgE synthesis in human B cells. Yanagihara Y, et al. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 2):S224–9 (38 ref.)

MICROBIOLOGY

EBV–B cell interactions: immortalization, rescue from apoptosis, tumorigenicity (a short review). Klein G. **Acta Microbiol Immunol Hung** 1996;43(2–3):97–105 (37 ref.)

PATHOLOGY

Lessons from human genetic variants in the study of B–cell differentiation. Satterthwaite AB, et al. **Curr Opin Immunol** 1996 Aug;8(4):454–8 (67 ref.)
E2A–Pbx1 induces growth, blocks differentiation, and interacts with other homeodomain proteins regulating normal differentiation. Kamps MP. **Curr Top Microbiol Immunol** 1997;220:25–43 (68 ref.)
E2A–HLF chimeric transcription factors in pro–B cell acute lymphoblastic leukemia. Look AT. **Curr Top Microbiol Immunol** 1997;220:45–53 (54 ref.)
Peritumoral B cell infiltrate associated with chronic lymphocytic leukemia obscuring margin evaluation during Mohs micrographic surgery [letter] Humphreys TR, et al. **Dermatol Surg** 1996 Oct;22(10):894–6 (21 ref.)
Lymphocytic mastitis and fibrosis of the breast in long–standing insulin–dependent diabetics. A histopathologic study on diabetic mastopathy and report of ten cases. Hunfeld KP, et al. **Gen Diagn Pathol** 1997 Jul;143(1):49–58 (39 ref.)
Minimal residual disease detection in B–cell malignancies by assessing IgH rearrangement. Maloum K, et al. **Hematol Cell Ther** 1997 Jun;39(3):119–24 (52 ref.)
Malignant lymphomas with a follicular growth pattern. Isaacson PG. **Histopathology** 1996 Jun;28(6):487–95 (37 ref.)
B cells and their fate in health and disease. Caligaris–Cappio F, et al. **Immunol Today** 1996 May;17(5):206–8 (17 ref.)
The role of the CD40 antigen on malignant B cells. Planken EV, et al. **Leuk Lymphoma** 1996 Jul;22(3–4):229–35 (63 ref.)
Interactions involving cyclosporine A, interleukin–6, and Epstein–Barr virus lead to the promotion of B–cell lymphoproliferative disease. Tanner JE, et al. **Leuk Lymphoma** 1996 May;21(5–6):379–90 (77 ref.)
Superantigens related to B cell hyperplasia. Ponzio NM, et al. **Springer Semin Immunopathol** 1996;17(4):285–306 (159 ref.)

PHYSIOLOGY

Regulation of lymphocyte migration into lymph nodes by high endothelial venules. Ager A. **Biochem Soc Trans** 1997 May;25(2):421–8 (46 ref.)
B cell populations: the multiple myeloma model. Caligaris–Cappio F, et al. **Chem Immunol** 1997;67:102–13 (75 ref.)
Regulation of human B cell growth and differentiation: lessons from the primary immunodeficiencies. Callard RE, et al. **Chem Immunol** 1997;67:114–32 (102 ref.)
T cells in the selection of germinal center B cells. Casamayor–Palleja M, et al. **Chem Immunol** 1997;67:27–44 (54 ref.)
Subepithelial B cells of the human tonsil. Dono M, et al. **Chem Immunol** 1997;67:58–69 (28 ref.)
Molecular mechanisms involved in T–B interactions. Lane P. **Chem Immunol** 1997;67:1–13 (65 ref.)
Tracing antigen–driven B cell development in humans. Liu YJ. **Chem Immunol** 1997;67:14–26 (53 ref.)
The complexity of signaling pathways activated by the BCR. DeFranco AL. **Curr Opin Immunol** 1997 Jun;9(3):296–308 (120 ref.)
Signalling in lymphocyte development. Owen MJ, et al. **Curr Opin Immunol** 1996 Apr;8(2):191–8 (64 ref.)
Current concepts in chicken B cell development. Funk PE, et al. **Curr Top Microbiol Immunol** 1996;212:17–28 (51 ref.)
Human B–cell progenitors and bone marrow microenvironment. Campana D, et al. **Hum Cell** 1996 Dec; 9(4):317–22 (30 ref.)
B–cell development in the mouse. Rolink A, et al. **Immunol Lett** 1996 Dec;54(2–3):157–61 (58 ref.)
Immunoglobulin deficient mice generated by gene targeting as models for studying the immune response. Bot A. **Int Rev Immunol** 1996;13(4):327–40 (95 ref.)
CD40: a pivotal receptor in the determination of life/death decisions in B lymphocytes. Klaus GG, et al. **Int Rev Immunol** 1997;15(1–2):5–31 (95 ref.)
The surrogate light chain in mouse B–cell development. Rolink A, et al. **Int Rev Immunol** 1996;13(4):341–56 (41 ref.)
The lambda B cell repertoire of kappa–deficient mice. Sanchez P, et al. **Int Rev Immunol** 1996;13(4):357–68 (53 ref.)
What is the CLL B–lymphocyte? Dighiero G, et al. **Leuk Lymphoma** 1996 Oct;22 Suppl 2:13–39 (68 ref.)
Generation and function of natural self–reactive B lymphocytes. Chen X, et al. **Semin Immunol** 1996 Feb; 8(1):19–27 (59 ref.)
Anti–red blood cell autoantibody transgenic mice: murine model of autoimmune hemolytic anemia. Murakami M, et al. **Semin Immunol** 1996 Feb;8(1):3–9 (43 ref.)
B–1 cells: unique origins and functions. Stall AM, et al. **Semin Immunol** 1996 Feb;8(1):45–59 (82 ref.)
[Molecular mechanism of apoptosis operated in the immune system] Tadakuma T. **Nippon Rinsho** 1997 Jun; 55(6):1337–44 (23 ref.) (Eng. Abstr.) **(Jpn)**
[Regulatory mechanisms for B lymphocyte apoptosis] Tsubata T. **Seikagaku** 1997 May;69(5):299–310 (59 ref.) **(Jpn)**

VIROLOGY

[The mechanisms of Epstein–Barr virus activation in B cells] Sairenji T. **Nippon Rinsho** 1997 Feb;55(2):316–20 (12 ref.) (Eng. Abstr.) **(Jpn)**

T-LYMPHOCYTES

see related
IMMUNITY, CELLULAR
LYMPHOCYTE COOPERATION

How useful are T cell clones in investigating allergy? [editorial] Frew AJ. **Clin Exp Allergy** 1995 Dec; 25(12):1143–4 (20 ref.)
T–cell gene therapy. Hege KM, et al. **Curr Opin Biotechnol** 1996 Dec;7(6):629–34 (53 ref.)
[Extra thymus gland differentiation of IEL and role of liver] Abo T. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec; 18(6):695–700 (13 ref.) **(Jpn)**
[Programmed thymic T cell death and negative selection via Fas and TCR/CD3 complex] Kishi S. **Nippon Rinsho** 1996 Jul;54(7):1760–7 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Molecular biological characterization of intestinal intraepithelial lymphocytes and their receptors] Nagura H, et al. **Nippon Rinsho** 1996 Apr;54(4):1162–9 (23 ref.) (Eng. Abstr.) **(Jpn)**
[NGFI–B/nur77 family involved in T–cell apoptosis] Okabe T, et al. **Nippon Rinsho** 1996 Jul;54(7):1768–72 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Cell adhesion molecules on lymphocytes and their role on signal transduction] Munakata Y. **Rinsho Byori** 1996 Dec; 44(12):1152–6 (0 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Lessons from immunological, biochemical, and molecular pathways of the activation mediated by IL–2 and IL–4. Rebollo A, et al. **Adv Immunol** 1996;63:127–96 (646 ref.)

Biophysical studies of T-cell receptors and their ligands. Fremont DH, et al. **Curr Opin Immunol** 1996 Feb; 8(1):93-100 (80 ref.)

Needles in haystacks: identifying specific peptide antigens for T cells. Shastri N. **Curr Opin Immunol** 1996 Apr; 8(2):271-7 (56 ref.)

T-cell epitope determination. Walden P. **Curr Opin Immunol** 1996 Feb;8(1):68-74 (60 ref.)

Biophysical and structural studies of TCRs and ligands: implications for T cell signaling. Ward ES, et al. **Curr Opin Immunol** 1997 Feb;9(1):97-106 (59 ref.)

Cellular and biochemical requirements for thymocyte negative selection. Page DM, et al. **Semin Immunol** 1996 Apr;8(2):69-82 (140 ref.)

CYTOLOGY

T cell development within the intestinal mucosa: clues to a novel immune-endocrine network? Klein JR. **Adv Neuroimmunol** 1996;6(4):397-405 (43 ref.)

Mutually dependent T and B cell responses in germinal centers. Gulbranson-Judge A, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:199-210 (42 ref.)

Cellular interactions in thymocyte development. Anderson G, et al. **Annu Rev Immunol** 1996;14:73-99 (155 ref.)

The Michael Mason Prize Essay 1996. Role of adhesion mechanisms in the pathogenesis of chronic synovitis. Pitzalis C. **Br J Rheumatol** 1996 Dec;35(12):1198-215 (108 ref.)

The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Weller M, et al. **Brain Res Brain Res Rev** 1995 Sep;21(2):128-51 (254 ref.)

Interleukin 4: signalling mechanisms and control of T cell differentiation. Paul WE. **Ciba Found Symp** 1997; 204:208-16; discussion 216-9 (40 ref.)

Multiple effects of cyclosporin A on the thymus in relation to T-cell development and autoimmunity. Damoiseaux JG, et al. **Clin Immunol Immunopathol** 1997 Mar;82(3):197-202 (41 ref.)

Signaling events in T lymphocytes leading to cellular activation or programmed cell death. Musci MA, et al. **Clin Immunol Immunopathol** 1997 Jun;83(3):205-22 (197 ref.)

Drug delivery to lymphatic tissue. Papisov M, et al. **Crit Rev Ther Drug Carrier Syst** 1996;13(1-2):57-84 (153 ref.)

Cytokines: shared receptors, distinct functions. DiSanto JP. **Curr Biol** 1997 Jul 1;7(7):R424-6 (17 ref.)

The DNA-dependent protein kinase: a matter of life and (cell) death. McConnell K, et al. **Curr Opin Cell Biol** 1996 Jun;8(3):325-30 (54 ref.)

Signalling in lymphocyte development. Owen MJ, et al. **Curr Opin Immunol** 1996 Apr;8(2):191-8 (64 ref.)

Lymphocyte development [editorial] Storb U, et al. **Curr Opin Immunol** 1996 Apr;8(2):155-9 (28 ref.)

Regulation of thymocyte development from immature progenitors. Zúñiga-Pflücker JC, et al. **Curr Opin Immunol** 1996 Apr;8(2):215-24 (96 ref.)

Dendritic cells in the T-cell areas of lymphoid organs. Steinman RM, et al. **Immunol Rev** 1997 Apr;156:25-37 (132 ref.)

Replicative senescence of T cells: does the Hayflick Limit lead to immune exhaustion? Effros RB, et al. **Immunol Today** 1997 Sep;18(9):450-4 (47 ref.)

Apoptosis mediated by the TNF-related cytokine and receptor families. Ware CF, et al. **J Cell Biochem** 1996 Jan;60(1):47-55 (48 ref.)

Cytokine flow cytometry: understanding cytokine biology at the single-cell level. Prussin C. **J Clin Immunol** 1997 May;17(3):195-204 (28 ref.)

Polymyositis in a patient with thymoma and T cell lymphocytosis. Cranney A, et al. **J Rheumatol** 1997 Jul; 24(7):1413-6 (19 ref.)

Thymic and extrathymic T cell development. Leclercq G, et al. **Leukemia** 1996 Dec;10(12):1853-9 (59 ref.)

Separation and maintenance of primary T- and B-lymphocytes. Kinchington D, et al. **Methods Mol Biol** 1997;75:91-100 (6 ref.)

Control of the thymic microenvironment by growth hormone/insulin-like growth factor-I-mediated circuits. Savino W, et al. **Neuroimmunomodulation** 1995 Nov-Dec; 2(6):313-8 (38 ref.)

Influence of IL12 on the maturation of human naive T cells. Delespesse G, et al. **Res Immunol** 1995 Sep-Oct; 146(7-8):461-6 (25 ref.)

Cross-talk between the T cell antigen receptor and the glucocorticoid receptor regulates thymocyte development. Ashwell JD, et al. **Stem Cells** 1996 Sep;14(5):490-500 (58 ref.)

Regulation of T cell apoptosis via T cell receptors and steroid receptors. Iwata M, et al. **Stem Cells** 1996 Nov;14(6):632-41 (66 ref.)

[Cell differentiation process of extra-thymus gland T lymphocytes] Abo T. **Nippon Naika Gakkai Zasshi** 1996 Nov 10;85(11):1948-51 (12 ref.) **(Jpn)**

[Function of the PEBP2/CBF/AML1 genes] Satake M. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):997-1007 (35 ref.) **(Jpn)**

DRUG EFFECTS

Lessons from immunological, biochemical, and molecular pathways of the activation mediated by IL-2 and IL-4. Rebollo A, et al. **Adv Immunol** 1996;63:127-96 (646 ref.)

Glucocorticoid-resistant asthma. T-lymphocyte defects. Corrigan CJ. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 2):S53-5; discussion S55-7 (20 ref.)

15-Deoxyspergualin: a newly developed immunosuppressive agent and its mechanism of action and clinical effect: a review. Japan Collaborative Transplant Study Group for NKT-01. Amemiya H. **Artif Organs** 1996 Aug;20(8):832-5 (21 ref.)

Current status in extracorporeal immunomodulation: immune disorders. Bosch T. **Artif Organs** 1996 Aug;20(8):902-5 (22 ref.)

ENZYMOLOGY

Molecular cloning and characterization of the T-cell mono(ADP-ribosyl)transferase RT6. Relationships to other mADPRTs and possible functions. Thiele HG, et al. **Adv Exp Med Biol** 1997;419:109-20 (82 ref.)

Protein tyrosine phosphatases in T-cell development, apoptosis and signalling. Frearson JA, et al. **Immunol Today** 1996 Aug;17(8):385-91 (57 ref.)

IMMUNOLOGY

The immunobiology of T cell therapies for leukemias. Shlomchik WD, et al. **Acta Haematol** 1996;96(4):189-213 (145 ref.)

Allergen dose dependent cytokine production regulates specific IgE and IgG antibody production. Blaser K. **Adv Exp Med Biol** 1996;409:295-303 (16 ref.)

Cell cycle control of T cell apoptosis induced by activation through the T cell antigen receptor. Chalupny NJ, et al. **Adv Exp Med Biol** 1996;406:57-67 (31 ref.)

The T cell marker RT6 in a rat model of autoimmune diabetes. Greiner DL, et al. **Adv Exp Med Biol** 1997; 419:209-16 (42 ref.)

Murine animal models to study the central role of T cells in immediate-type hypersensitivity responses. Herz U, et al. **Adv Exp Med Biol** 1996;409:25-32 (20 ref.)

The role of accessory cell products in the regulation of T cell cytokine production. Kapsenberg ML, et al. **Adv Exp Med Biol** 1996;409:305-8 (15 ref.)

Regulation of T cell activation by CD28 and CTLA4. Noel PJ, et al. **Adv Exp Med Biol** 1996;406:209-17 (27 ref.)

Effects on mouse thymocyte biology: a mini-overview with some new evidence. Ou DW, et al. **Adv Exp Med Biol** 1996;402:157-63 (22 ref.)

The thymus and T cell death. Sprent J, et al. **Adv Exp Med Biol** 1996;406:191-8 (35 ref.)

Immunomodulation with T cell reactive peptides. Wallner BP, et al. **Adv Exp Med Biol** 1996;409:231-40 (47 ref.)

Peptide induced anergy of human allergen-specific T cells. Yssel H, et al. **Adv Exp Med Biol** 1996;409:405-10 (30 ref.)

Role of the CD28-B7 costimulatory pathways in T cell-dependent B cell responses. Hathcock KS, et al. **Adv Immunol** 1996;62:131-66 (152 ref.)

Interleukin-2 receptor signaling mechanisms. Karnitz LM, et al. **Adv Immunol** 1996;61:147-99 (255 ref.)

T cell development within the intestinal mucosa: clues to a novel immune-endocrine network? Klein JR. **Adv Neuroimmunol** 1996;6(4):397-405 (43 ref.)

Apoptosis in AIDS. Badley AD, et al. **Adv Pharmacol** 1997; 41:271-94 (154 ref.)

Mouse mammary tumor virus and the immune system. Ross SR. **Adv Pharmacol** 1997;39:21-46 (95 ref.)

T-cell repertoire and HIV infection: facts and perspectives [editorial] Cossarizza A. **AIDS** 1997 Jul 15;11(9):1075-88 (169 ref.)

HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. Moore JP, et al. **AIDS** 1995;9 Suppl A:S117-36 (271 ref.)

T cell-mediated destruction of bovine leukemia virus-infected peripheral lymphocytes by bovine leukemia virus env-vaccinia recombinant vaccine. Ohishi K, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):393-8 (18 ref.)

Cytokine regulation of experimental intestinal inflammation in genetically engineered and T-lymphocyte reconstituted rodents. Sartor RB. **Aliment Pharmacol Ther** 1996;10 Suppl 2:36-42; discussion 43-4 (32 ref.)

Chronic myeloid leukemia as an immunological target. Lim SH, et al. **Am J Hematol** 1997 Jan;54(1):61-7 (49 ref.)

Immunodystrophism, T cells, cytokines, and pregnancy failure. Raghupathy R, et al. **Am J Reprod Immunol** 1996 Apr;35(4):291-6 (58 ref.)

Cellular and molecular mechanisms underlying IL-12-induced tumor regression. Fujiwara H, et al. **Ann N Y Acad Sci** 1996 Oct 31;795:294-309 (47 ref.)

Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86. Lane P. **Ann N Y Acad Sci** 1997 Apr 5;815:392-400 (40 ref.)

New knowledge about T-cell cytotoxicity. Cerottini JC, et al. **Ann Oncol** 1997;8 Suppl 2:75-8 (20 ref.)

Strategies for immune intervention in visceral leishmaniasis. Kaye PM, et al. **Ann Trop Med Parasitol** 1995 Dec;89 Suppl 1:75-81 (37 ref.)

CD28/B7 system of T cell costimulation. Lenschow DJ, et al. **Annu Rev Immunol** 1996;14:233-58 (117 ref.)

Early T lymphocyte progenitors. Shortman K, et al. **Annu Rev Immunol** 1996;14:29-47 (85 ref.)

Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Sloan-Lancaster J, et al. **Annu Rev Immunol** 1996;14:1-27 (81 ref.)

The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. Sugamura K, et al. **Annu Rev Immunol** 1996;14:179-205 (120 ref.)

Structure and function of the pre-T cell receptor. von Boehmer H, et al. **Annu Rev Immunol** 1997;15:433-52 (53 ref.)

Mucosal receptors and T- and B-cell immunity. Lehner T, et al. **Antibiot Chemother** 1996;48:21-9 (48 ref.)

Ulcerative colitis: an immunological disease? Radford-Smith G. **Baillieres Clin Gastroenterol** 1997 Mar;11(1):35-52 (88 ref.)

FasL/Fas and TNF/TNFR interactions in the regulation of immune responses and disease. Lynch DH, et al. **Behring Inst Mitt** 1996 Oct;(97):175-84 (36 ref.)

CD95 (APO-1/Fas) and its ligand in the mouse immune system. Mariani SM, et al. **Behring Inst Mitt** 1996 Oct; (97):12-23 (77 ref.)

Regulation of thymocyte development by glucocorticoids. Vacchio MS, et al. **Behring Inst Mitt** 1996 Oct;(97):24-31 (21 ref.)

CD28: a signalling perspective. Ward SG. **Biochem J** 1996 Sep 1;318 (Pt 2):361-77 (222 ref.)

Fine specificity of myelin basic protein reactive T-cells: implications for T-cell receptor antagonism. Anderton SM, et al. **Biochem Soc Trans** 1997 May;25(2):659-61 (14 ref.)

Natural killer cell regulation during viral infection. Biron CA. **Biochem Soc Trans** 1997 May;25(2):687-90 (33 ref.)

CD28 co-receptor signal transduction in T-cell activation. Blair PJ, et al. **Biochem Soc Trans** 1997 May;25(2):651-7 (57 ref.)

Heterogeneity and immunotherapy of specific T-cells in myasthenia gravis. Bond A, et al. **Biochem Soc Trans** 1997 May;25(2):665-70 (44 ref.)

Tyrosine phosphatases in T-cell development and signalling. Conroy LA, et al. **Biochem Soc Trans** 1997 May; 25(2):445-51 (41 ref.)

Interleukin 15. Cosman D, et al. **Biochem Soc Trans** 1997 May;25(2):371-4 (30 ref.)

Antigens recognized by T-lymphocytes on human tumours. Coulie PG, et al. **Biochem Soc Trans** 1997 May;25(2):544-8 (40 ref.)

Structure and function of the mucosal T-cell integrin alpha E beta 7. Kilshaw PJ, et al. **Biochem Soc Trans** 1997 May; 25(2):433-9 (48 ref.)

T-lymphocyte activation and regulation in the central nervous system. Sedgwick JD. **Biochem Soc Trans** 1997 May;25(2):673-9 (36 ref.)

T-cells with two T-cell receptors: are they important in autoimmunity? Stockinger B, et al. **Biochem Soc Trans** 1997 May;25(2):617-20 (22 ref.)

T-cells in the pathogenesis of rheumatoid arthritis villains or accomplices? Kinne RW, et al. **Biochim Biophys Acta** 1997 Apr 12;1360(2):109-41 (360 ref.)

Changes in the aging immune system. Grubeck-Loebenstein B. **Biologicals** 1997 Jun;25(2):205-8 (23 ref.)

Clinical significance of autologous tumor killing (ATK) activity and its induction therapy in human cancer. Uchida A. **Biotherapy** 1994;8(2):113-22 (53 ref.)

B7-mediated costimulation and the immune response. Schultze J, et al. **Blood Rev** 1996 Jun;10(2):111-27 (107 ref.)

T-cell receptor in Sjögren's syndrome. Sumida T, et al. **Br J Rheumatol** 1997 Jun;36(6):622-9 (52 ref.)

Using immunological techniques to determine the effect of nutrition on T-cell function. Field CJ. **Can J Physiol Pharmacol** 1996 Jun;74(6):769-77 (64 ref.)

Novel costimulators in the immune gene therapy of cancer. Galea-Lauri J, et al. **Cancer Gene Ther** 1996 May-Jun; 3(3):202-14 (133 ref.)

T cell signalling through CD73. Resta R, et al. **Cell Signal** 1997 Feb;9(2):131-9 (92 ref.)

T cells as orchestrators of the asthmatic response. Kay AB. **Ciba Found Symp** 1997;206:56-67; discussion 67-70, 106-10 (50 ref.)

Dendritic cells and T lymphocytes: developmental and functional interactions. Shortman K, et al. **Ciba Found Symp** 1997;204:130-8; discussion 138-41 (20 ref.)

Immunology and immunity studied with viruses. Zinkernagel RM. **Ciba Found Symp** 1997;204:105-25; discussion 125-9 (168 ref.)

Is psoriasis induced by streptococcal superantigens and maintained by M-protein-specific T cells that cross-react with keratin? Valdimarsson H, et al. **Clin Exp Immunol** 1997 Jan;107 Suppl 1:21-4 (28 ref.)

Multiple effects of cyclosporin A on the thymus in relation to T-cell development and autoimmunity. Damoiseaux JG, et al. **Clin Immunol Immunopathol** 1997 Mar;82(3):197-202 (41 ref.)

Signaling events in T lymphocytes leading to cellular activation or programmed cell death. Musci MA, et al. **Clin Immunol Immunopathol** 1997 Jun;83(3):205-22 (197 ref.)

T-cell autoimmunity in primary biliary cirrhosis. Jones DE. **Clin Sci (Colch)** 1996 Nov;91(5):551-8 (40 ref.)

Lymphocyte activation in health and disease. Berridge MJ. **Crit Rev Immunol** 1997;17(2):155-78 (155 ref.)

Functions of IL-4 and control of its expression. Brown MA, et al. **Crit Rev Immunol** 1997;17(1):1-32 (257 ref.)
The role of T cells in Kawasaki disease. de Inocencio J, et al. **Crit Rev Immunol** 1995;15(3-4):349-57 (54 ref.)
T lymphocyte migration: the influence of interactions via adhesion molecules, the T cell receptor, and cytokines. Hauzenberger D, et al. **Crit Rev Immunol** 1995; 15(3-4):285-316 (310 ref.)
Interactions of migrating T lymphocytes, inflammatory mediators, and the extracellular matrix. Lider O, et al. **Crit Rev Immunol** 1995;15(3-4):271-83 (85 ref.)
Autoimmune pathogenesis of multiple sclerosis: role of autoreactive T lymphocytes and new immunotherapeutic strategies. Stinissen P, et al. **Crit Rev Immunol** 1997; 17(1):33-75 (357 ref.)
T lymphocytes and their cytokines in human immunodeficiency virus (HIV) infection: implications for associated neoplasias. Jassoy C, et al. **Crit Rev Oncog** 1995; 6(3-6):275-89 (143 ref.)
T-cell receptors: is the repertoire inherently MHC-specific? Janeway CA, et al. **Curr Biol** 1997 May 1;7(5):R299-300 (11 ref.)
T-cell costimulation: T cells themselves call the shots. Owens T. **Curr Biol** 1996 Jan 1;6(1):32-7 (21 ref.)
T-call development: is notch a key player in lineage decisions? von Boehmer H. **Curr Biol** 1997 May 1; 7(5):R308-10 (13 ref.)
Immunologic tolerance. Sarzotti M. **Curr Opin Hematol** 1997 Jan;4(1):48-52 (49 ref.)
Generation of T-cell memory. Beverley PC. **Curr Opin Immunol** 1996 Jun;8(3):327-30 (42 ref.)
Co-stimulation in T cell responses. Chambers CA, et al. **Curr Opin Immunol** 1997 Jun;9(3):396-404 (83 ref.)
Regulation of gene expression at early stages of B-cell and T-cell differentiation. Fitzsimmons D, et al. **Curr Opin Immunol** 1996 Apr;8(2):166-74 (64 ref.)
Mechanisms underlying T-cell tolerance. Kruisbeek AM, et al. **Curr Opin Immunol** 1996 Apr;8(2):233-44 (111 ref.)
Immune response to mouse mammary tumour virus. Luther SA, et al. **Curr Opin Immunol** 1996 Aug;8(4):498-502 (24 ref.)
Interactions of TCRs with MHC-peptide complexes: a quantitative basis for mechanistic models. Margulies DH. **Curr Opin Immunol** 1997 Jun;9(3):390-5 (56 ref.)
T cell selection and autoimmunity: flexibility and tuning. Ohashi PS. **Curr Opin Immunol** 1996 Dec;8(6):808-14 (62 ref.)
T-cell recognition of non-peptide antigens. Porcelli SA, et al. **Curr Opin Immunol** 1996 Aug;8(4):510-6 (50 ref.)
Human tumor antigens recognized by T cells. Robbins PF, et al. **Curr Opin Immunol** 1996 Oct;8(5):628-36 (81 ref.)
Needles in haystacks: identifying specific peptide antigens for T cells. Shastri N. **Curr Opin Immunol** 1996 Apr; 8(2):271-7 (56 ref.)
TCR zeta chain in T cell development and selection. Shores EW, et al. **Curr Opin Immunol** 1997 Jun;9(3):380-9 (96 ref.)
Immunological memory. Sprent J. **Curr Opin Immunol** 1997 Jun;9(3):371-9 (96 ref.)
Role of Fas-mediated cell death in the regulation of immune responses. van Parijs L, et al. **Curr Opin Immunol** 1996 Jun;8(3):355-61 (70 ref.)
Cell death in the regulation of immune responses. Winoto A. **Curr Opin Immunol** 1997 Jun;9(3):365-70 (79 ref.)
Pathways leading to cell death in T cells. Wong B, et al. **Curr Opin Immunol** 1997 Jun;9(3):358-64 (69 ref.)
Lymphocytes, cytokines, inflammation, and immune trafficking. Tsokos GC. **Curr Opin Rheumatol** 1996 Sep; 8(5):395-402 (74 ref.)
Maternal T cell reactivity in pregnancy? Chaouat G, et al. **Curr Top Microbiol Immunol** 1997;222:103-26 (198 ref.)
T cell receptors and T cell development. Chen CH, et al. **Curr Top Microbiol Immunol** 1996;212:37-53 (88 ref.)
T cell migration during ontogeny and T cell repertoire generation. Dunon D, et al. **Curr Top Microbiol Immunol** 1996;212:79-93 (45 ref.)
Chicken gamma delta T cells. Sanchez-Garcia FJ, et al. **Curr Top Microbiol Immunol** 1996;212:55-69 (79 ref.)
Roles of T cells in coxsackievirus B-induced disease. Schwimmbeck PL, et al. **Curr Top Microbiol Immunol** 1997; 223:283-303 (90 ref.)
The immunology of Eta-1/osteopontin. Weber GF, et al. **Cytokine Growth Factor Rev** 1996 Oct;7(3):241-8 (50 ref.)
Mechanisms influencing the selection of T cell epitopes by MHC class II molecules. Mouritsen S. **Dan Med Bull** 1997 Apr;44(2):125-39 (170 ref.)
Diabetogenic T-cell clones. Haskins K, et al. **Diabetes** 1996 Oct;45(10):1299-305 (49 ref.)
The role of interleukin-1 in the pathogenesis of IDDM. Mandrup-Poulsen T. **Diabetologia** 1996 Sep;39(9):1005-29 (316 ref.)
Pathogenesis of inflammatory bowel disease. Zeitz M. **Digestion** 1997;58 Suppl 1:59-61 (25 ref.)
The somatogenic hormones and insulin-like growth factor-1: stimulators of lymphopoiesis and immune function. Clark R. **Endocr Rev** 1997 Apr;18(2):157-79 (287 ref.)
Altered peptide ligands: prospects for immune intervention in autoimmune disease. Fairchild PJ. **Eur J Immunogenet** 1997 Apr;24(2):155-67 (65 ref.)
T-cell/eosinophil interactions in the induction of asthma. Corrigan CJ, et al. **Eur Respir J Suppl** 1996 Aug;22:72s-78s (79 ref.)
Genetically modified tumour vaccines carrying inserted genes for immunoregulatory molecules. Bubeník J. **Folia Biol (Praha)** 1996;42(6):295-304 (114 ref.)
Development and induction of the immune response--status 1995. Sterzl J. **Folia Biol (Praha)** 1996;42(1-2):27-40 (60 ref.)
T cell autoimmunity to glutamic acid decarboxylase in human insulin-dependent diabetes mellitus. Lohmann T, et al. **Horm Metab Res** 1996 Jul;28(7):357-60 (29 ref.)
Epitope context and reshaping of activated T helper cell repertoire. De Berardinis P, et al. **Hum Immunol** 1997 May; 54(2):189-93 (40 ref.)
Minor histocompatibility antigens: from T cell recognition to peptide identification [editorial] Goulmy E. **Hum Immunol** 1997 Apr 15;54(1):8-14 (63 ref.)
Parameters affecting the immunogenicity of recombinant T cell epitopes inserted into hybrid proteins. Lo-Man R, et al. **Hum Immunol** 1997 May;54(2):180-8 (75 ref.)
Antigen processing differences among APC. Schneider SC, et al. **Hum Immunol** 1997 May;54(2):148-58 (72 ref.)
MHC class II-dependent peptide antigen versus superantigen presentation to T cells. Shoukry NH, et al. **Hum Immunol** 1997 May;54(2):194-201 (60 ref.)
Immune privilege, T-cell tolerance, and tissue-restricted autoimmunity. Streilein JW, et al. **Hum Immunol** 1997 Feb; 52(2):138-43 (29 ref.)
In thymic selection, peptide diversity gives and takes away. Bevan MJ. **Immunity** 1997 Aug;7(2):175-8 (16 ref.)
Making the T cell receptor go the distance: a topological view of T cell activation. Shaw AS, et al. **Immunity** 1997 Apr;6(4):361-9 (58 ref.)
The role of dendritic cells in T cell activation. Ni K, et al. **Immunol Cell Biol** 1997 Jun;75(3):223-30 (117 ref.)
T-cell reactivity to human HSP60 in oligo-articular juvenile chronic arthritis is associated with a favorable prognosis and the generation of regulatory cytokines in the inflamed joint. Prakken AB, et al. **Immunol Lett** 1997 Jun 1; 57(1-3):139-42 (20 ref.)
Self determinant selection and acquisition of the autoimmune T cell repertoire. Benichou G, et al. **Immunol Res** 1996; 15(3):234-45 (46 ref.)
T-cell recognition of self peptides as tumor rejection antigens. Kawakami Y, et al. **Immunol Res** 1996; 15(3):179-90 (51 ref.)
Skin-homing T cells in human cutaneous allergic inflammation. Santamaria Babi LF, et al. **Immunol Res** 1995;14(4):317-24 (43 ref.)
The role of CTLA-4 in the regulation and initiation of T-cell responses. Chambers CA, et al. **Immunol Rev** 1996 Oct; 153:27-46 (90 ref.)
Epstein-Barr virus infection of T cells: implications for altered T-lymphocyte activation, repertoire development and autoimmunity. Dreyfus DH, et al. **Immunol Rev** 1996 Aug;152:89-110 (67 ref.)
Allorecognition by murine natural killer cells: lysis of T-lymphoblasts and rejection of bone-marrow grafts. George T, et al. **Immunol Rev** 1997 Feb;155:29-40 (53 ref.)
B-T lymphocyte interactions in the generation and survival of memory cells. Gray D, et al. **Immunol Rev** 1996 Apr; 150:45-61 (65 ref.)
The role of CD2 as a regulator of human T-cell cytokine production. Holter W, et al. **Immunol Rev** 1996 Oct; 153:107-22 (70 ref.)
Alloreactivity, antigen recognition and T-cell selection: three diverse T-cell recognition problems with a common solution. Joyce S, et al. **Immunol Rev** 1996 Dec;154:59-103 (251 ref.)
Evidence for a thymus-dependent form of tolerance that is not based on elimination or anergy of reactive T cells. Le Douarin N, et al. **Immunol Rev** 1996 Feb;149:35-53 (67 ref.)
The changing preference of T and B cells for partners as T-dependent antibody responses develop. MacLennan IC, et al. **Immunol Rev** 1997 Apr;156:53-66 (95 ref.)
T-lymphocyte development and function in gene-targeted mutant mice. Mittrücker HW, et al. **Immunol Rev** 1995 Dec; 148:115-50 (185 ref.)
Use of adoptive transfer of T-cell-antigen-receptor-transgenic T cell for the study of T-cell activation in vivo. Pape KA, et al. **Immunol Rev** 1997 Apr;156:67-78 (59 ref.)
The role of endogenous peptides in the direct pathway of alloreactivity to human MHC class II molecules expressed on CHO cells. Pawelec G, et al. **Immunol Rev** 1996 Dec; 154:155-73 (53 ref.)
Immune deviation--the third dimension of nondeletional T cell tolerance. Röcken M, et al. **Immunol Rev** 1996 Feb; 149:175-94 (104 ref.)
The complexities of T-cell co-stimulation: CD28 and beyond. Sperling AI, et al. **Immunol Rev** 1996 Oct; 153:155-82 (100 ref.)
Factors controlling the turnover of T memory cells. Sprent J, et al. **Immunol Rev** 1997 Apr;156:79-85 (57 ref.)
Double negative (CD4-CD8- alpha beta+) T cells which promote tolerance induction and regulate autoimmunity. Strober S, et al. **Immunol Rev** 1996 Feb;149:217-30 (26 ref.)
From naive to memory T cells. Swain SL, et al. **Immunol Rev** 1996 Apr;150:143-67 (100 ref.)
Early T-cell development in CD3-deficient mice. Tanaka Y, et al. **Immunol Rev** 1995 Dec;148:171-99 (89 ref.)
Viruses and T cell turnover: evidence for bystander proliferation. Tough DF, et al. **Immunol Rev** 1996 Apr; 150:129-42 (50 ref.)
(Altered) self peptides and the regulation of self reactivity in the peripheral T cell pool. Van Eden W, et al. **Immunol Rev** 1996 Feb;149:55-73 (44 ref.)
CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model. Van Gool SW, et al. **Immunol Rev** 1996 Oct;153:47-83 (150 ref.)
Development and function of T lymphocytes and natural killer cells after bone marrow transplantation of severely immunodeficient mice. Wang B, et al. **Immunol Rev** 1997 Jun;157:53-60 (50 ref.)
CTLA-4, a negative regulator of T-lymphocyte activation. Waterhouse P, et al. **Immunol Rev** 1996 Oct;153:183-207 (130 ref.)
The shaping of the brain-specific T lymphocyte repertoire in the thymus. Wekerle H, et al. **Immunol Rev** 1996 Feb; 149:231-43 (35 ref.)
Cellular environments and apoptosis: tissue microenvironments control activated T-cell death. Akbar AN, et al. **Immunol Today** 1997 Feb;18(2):72-6 (43 ref.)
The neglected role of type I interferon in the T-cell response: implications for its clinical use. Belardelli F, et al. **Immunol Today** 1996 Aug;17(8):369-72 (50 ref.)
Indirect T-cell allorecognition: perspectives for peptide-based therapy in transplantation. Benichou G, et al. **Immunol Today** 1997 Feb;18(2):67-71 (34 ref.)
Soluble, antigen-specific T-cell proteins: T-cell-based humoral immunity? Cone RE, et al. **Immunol Today** 1996 Jul;17(7):318-22 (53 ref.)
Strange brew: T cells in the liver. Crispe IN, et al. **Immunol Today** 1996 Nov;17(11):522-5 (38 ref.)
Replicative senescence of T cells: does the Hayflick Limit lead to immune exhaustion? Effros RB, et al. **Immunol Today** 1997 Sep;18(9):450-4 (47 ref.)
Lowering the tone: mechanisms of immunodominance among epitopes with low affinity for MHC [see comments] Fairchild PJ, et al. **Immunol Today** 1996 Feb;17(2):80-85 (51 ref.) Comment in: Immunol Today 1997 Feb;18(2):97-8.
The function of costimulatory molecules and the development of IL-4-producing T cells. Gause WC, et al. **Immunol Today** 1997 Mar;18(3):115-20 (47 ref.)
Autoimmune T cells in myasthenia gravis: heterogeneity and potential for specific immunotargeting. Hawke S, et al. **Immunol Today** 1996 Jul;17(7):307-11 (32 ref.)
Uncovered: the family relationship of a T-cell-membrane protein and bacterial toxins. Koch-Nolte F, et al. **Immunol Today** 1996 Sep;17(9):402-5 (30 ref.)
The role of Grb2-associated proteins in T-cell activation. Koretzky GA. **Immunol Today** 1997 Aug;18(8):401-6 (48 ref.)
Inhibitory MHC class I receptors on NK cells and T cells [see comments] Lanier LL, et al. **Immunol Today** 1996 Feb; 17(2):86-91 (52 ref.) Comment in: Immunol Today 1997 Mar;18(3):146.
Alterations in T cells of cancer-bearers: whence specificity? Levey DL, et al. **Immunol Today** 1996 Aug;17(8):365-8 (39 ref.)
The thymic repertoire of neuroendocrine self-antigens: physiological implications in T-cell life and death. Martens H, et al. **Immunol Today** 1996 Jul;17(7):312-7 (44 ref.)
Mucosal T cells and mast cells share common adhesion receptors. Smith TJ, et al. **Immunol Today** 1996 Feb; 17(2):60-3 (53 ref.)
T-cell responses to allergens: epitope-specificity and clinical relevance. van Neerven RJ, et al. **Immunol Today** 1996 Nov;17(11):526-32 (77 ref.)
Mouse NK1.1+ T cells: a new family of T cells. Vicari AP, et al. **Immunol Today** 1996 Feb;17(2):71-6 (76 ref.)
PI 3-kinase: a pivotal pathway in T-cell activation? Ward SG, et al. **Immunol Today** 1996 Apr;17(4):187-97 (116 ref.)
The agonist-antagonist balance in positive selection. Williams O, et al. **Immunol Today** 1997 Mar;18(3):121-6 (70 ref.)
T cell immunity in malaria. Kabilan L. **Indian J Med Res** 1997 Aug;106:130-48 (96 ref.)
Dendritic cells: from ignored cells to major players in T-cell-mediated immunity. Schuler G, et al. **Int Arch Allergy Immunol** 1997 Apr;112(4):317-22 (47 ref.)
T-cell recognition of melanoma antigens and its therapeutic applications. Castelli C, et al. **Int J Clin Lab Res** 1997; 27(2):103-10 (46 ref.)
Tumor antigens recognized by T lymphocytes. Van den Eynde BJ, et al. **Int J Clin Lab Res** 1997;27(2):81-6 (56 ref.)
Effects of food restriction in military training on T-lymphocyte responses. Kramer TR, et al. **Int J Sports Med** 1997 Mar;18 Suppl 1:S84-90 (18 ref.)
The contribution of peptides to T cell allorecognition and allograft rejection. Benichou G, et al. **Int Rev Immunol** 1996;13(3):231-43 (60 ref.)
Indirect T cell recognition in allograft rejection. Bradley JA. **Int Rev Immunol** 1996;13(3):245-55 (85 ref.)
T cell receptor (TCR) repertoire in alloimmune responses. Finn OJ, et al. **Int Rev Immunol** 1996;13(3):187-207 (131 ref.)
Hyperreactivity of neutrophils and abnormal T cell homeostasis: a new insight for pathogenesis of Behçet's disease. Yamashita N. **Int Rev Immunol** 1997;14(1):11-9 (33 ref.)
Significance of antigen-specific T cell clones in collagen diseases: analyses with a novel T cell clonality evaluation system. Yamamoto K. **Intern Med** 1997 Apr;36(4):242-7 (29 ref.)

T-LYMPHOCYTES

HTLV-I-induced T-cell activation. Buckle GJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S107-13 (68 ref.)

The role of the thymus in the control of autoimmunity. Heath VL, et al. **J Autoimmun** 1996 Apr;9(2):241-6 (32 ref.)

Influence and fate of T lymphocytes in autoimmunity. Miller JF. **J Autoimmun** 1996 Apr;9(2):301-4 (11 ref.)

T cell-mediated maintenance of natural self-tolerance: its breakdown as a possible cause of various autoimmune diseases. Sakaguchi S, et al. **J Autoimmun** 1996 Apr; 9(2):211-20 (58 ref.)

Role of T cell derived cytokines in HIV infection. Maggi E, et al. **J Biol Regul Homeost Agents** 1995 Apr-Jun; 9(2):37-41 (33 ref.)

T cells of lupus and molecular targets for immunotherapy. Datta SK, et al. **J Clin Immunol** 1997 Jan;17(1):11-20 (150 ref.)

CD1 presentation of microbial nonpeptide antigens to T cells. Jullien D, et al. **J Clin Invest** 1997 May 1;99(9):2071-4 (13 ref.)

Molecular mimicry and T cell-mediated autoimmune disease [comment] Barnaba V, et al. **J Exp Med** 1997 May 5; 185(9):1529-31 (29 ref.) Comment on: J Exp Med 1997 May 5;185(9):1651-9.

Understanding the mechanisms of sustained signaling and T cell activation [comment] Lanzavecchia A. **J Exp Med** 1997 May 19;185(10):1717-9 (20 ref.) Comment on: J Exp Med 1997 May 19;185(10):1803-13. Comment on: J Exp Med 1997 May 19;185(10):1815-25. Comment on: J Exp Med 1997 May 19;185(10):1859-64.

In vivo immunosuppressive mechanisms. Halloran PF, et al. **J Heart Lung Transplant** 1996 Oct;15(10):959-71 (96 ref.)

Is CTLA-4 a master switch for peripheral T cell tolerance? Bluestone JA. **J Immunol** 1997 Mar 1;158(5):1989-93 (37 ref.)

The CD28-B7 costimulatory pathway and its role in autoimmune disease. Daikh D, et al. **J Leukoc Biol** 1997 Aug;62(2):156-62 (80 ref.)

A continuing enigma: the role of cells of macrophage lineage in the development of HIV disease. Perno CF, et al. **J Leukoc Biol** 1997 Jul;62(1):1-3 (22 ref.)

Partial activation of foreign antigen specific T lymphocytes by a self peptide: possible roles of altered peptide ligands in regulating T lymphocyte mediated immune response. Cao W, et al. **J Mol Med** 1996 Oct;74(10):573-82 (104 ref.)

Antibacterial vaccines: impact of antigen handling and immune response. Kaufmann SH. **J Mol Med** 1997 May; 75(5):360-3 (17 ref.)

T cell vaccination: clinical application in autoimmune diseases. Zhang J, et al. **J Mol Med** 1996 Nov;74(11):653-62 (43 ref.)

The dominant and the cryptic T cell repertoire to myelin basic protein in the Lewis rat. Mor F, et al. **J Neurosci Res** 1996 Sep 15;45(6):670-9 (60 ref.)

Concept of autoimmunity following spinal cord injury: possible roles for T lymphocytes in the traumatized central nervous system. Popovich PG, et al. **J Neurosci Res** 1996 Aug 15;45(4):349-63 (120 ref.)

Vaccination with autoreactive T cell clones in multiple sclerosis: overview of immunological and clinical data. Stinissen P, et al. **J Neurosci Res** 1996 Aug 15;45(4):500-11 (75 ref.)

Immune modulation strategies in T cell mediated autoimmune diseases-relevance to IDDM. Mathieson PW. **J Pediatr Endocrinol Metab** 1996 Mar;9 Suppl 1:133-8 (26 ref.)

HLA-DR restrictive supertypes dominate promiscuous T cell recognition: association of multiple HLA-DR molecules with susceptibility to autoimmune diseases. Ou D, et al. **J Rheumatol** 1997 Feb;24(2):253-61 (73 ref.)

T cell involvement in glomerular injury. Merkel F, et al. **Kidney Blood Press Res** 1996;19(5):298-304 (69 ref.)

Biologic response modifiers in acute lymphoblastic leukemia. Gribben JG, et al. **Leukemia** 1997 May;11 Suppl 4:S31-3 (16 ref.)

Chronic lymphatic leukemias of T and NK cell type. Kingreen D, et al. **Leukemia** 1997 Apr;11 Suppl 2:S46-9 (36 ref.)

Thymocyte development in vitro: implications for studies of ageing and thymic involution. Montecino-Rodriguez E, et al. **Mech Ageing Dev** 1997 Feb;93(1-3):47-57 (63 ref.)

The T cell in the ageing individual. Pawelec G, et al. **Mech Ageing Dev** 1997 Feb;93(1-3):35-45 (51 ref.)

Acquired immune deficiency syndrome caused by hyperimmunity. Chigira M. **Med Hypotheses** 1996 Jun; 46(6):489-98 (139 ref.)

Do holes in the T-cell repertoire have a center-surround regulatory structure? A rationale for the bifurcation of the Th1 and Th2 pathways of differentiation. Mannie MD. **Med Hypotheses** 1997 Mar;48(3):261-5 (56 ref.)

The post-activation refractory phase: a mechanism to measure antigenic complexity and ensure self-tolerance among mature peripheral T lymphocytes. Mannie MD. **Med Hypotheses** 1996 Dec;47(6):467-70 (37 ref.)

Idiotype-specific T cells in multiple myeloma: targets for an immunotherapeutic intervention? Yi Q, et al. **Med Oncol** 1996 Mar;13(1):1-7 (70 ref.)

T cells in murine lupus: propagation and regulation of disease. Peng SL, et al. **Mol Biol Rep** 1996;23(3-4):247-51 (60 ref.)

Immune-activation model in Alzheimer disease. Singh VK. **Mol Chem Neuropathol** 1996 May-Aug;28(1-3):105-11 (26 ref.)

Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines? Coulie PG. **Mol Med Today** 1997 Jun;3(6):261-8 (39 ref.)

Can epitope-focused vaccines select advantageous immune responses? Delves PJ, et al. **Mol Med Today** 1997 Feb; 3(2):55-60 (14 ref.)

Biological properties of dendritic cells: implications to their use in the treatment of cancer. van Schooten WC, et al. **Mol Med Today** 1997 Jun;3(6):254-60 (44 ref.)

T-cell response to milk proteins in atopic and nonatopic donors. Parronchi P, et al. **Monogr Allergy** 1996;32:121-9 (30 ref.)

Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. Reiser H, et al. **N Engl J Med** 1996 Oct 31;335(18):1369-77 (69 ref.)

Indictment of the microglia as the villain in multiple sclerosis. Sriram S, et al. **Neurology** 1997 Feb;48(2):464-70 (69 ref.)

Fas-ligand: privilege and peril [see comments] Green DR, et al. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):5986-90 (37 ref.) Comment in: Proc Natl Acad Sci U S A 1997 Apr 15;94(8):3914-9. Comment in: Proc Natl Acad Sci U S A 1997 Apr 15;94(8):3943-7.

Transplantation tolerance: fooling mother nature [comment] Suthanthiran M. **Proc Natl Acad Sci U S A** 1996 Oct 29; 93(22):12072-5 (56 ref.) Comment on: Proc Natl Acad Sci U S A 1996 Oct 29;93(22):12439-44.

Autoreactive T-cell clones from the nonobese diabetic mouse. Bergman B, et al. **Proc Soc Exp Biol Med** 1997 Jan;214(1):41-8 (53 ref.)

The influence of two distinct alloresponse pathways on the design of peptide-based strategies for allograft tolerance. Benichou G, et al. **Res Immunol** 1996 Jul-Aug; 147(6):377-87 (50 ref.)

The CD1-restricted T-cell response to mycobacteria. Moody DB, et al. **Res Immunol** 1996 Oct-Dec;147(8-9):550-9 (31 ref.)

The role of HIV1 Nef in T-cell activation: Nef impairs induction of Th1 cytokines and interacts with the Src family tyrosine kinase Lck. Collette Y, et al. **Res Virol** 1997 Jan-Feb;148(1):52-8 (44 ref.)

HIV1 Nef: the Machiavelli of cellular activation. Greenway A, et al. **Res Virol** 1997 Jan-Feb;148(1):58-64 (51 ref.)

Biologic agents for the treatment of rheumatoid arthritis. Strand V, et al. **Rheum Dis Clin North Am** 1996 Feb; 22(1):117-32 (56 ref.)

The interaction of endothelial cells with inflammatory cells in vasculitis. Savage CO. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct;13(3):214-6 (19 ref.)

The pathogenic role of T lymphocytes in vasculitis. Weyand CM, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct; 13(3):217-20 (9 ref.)

A gut reaction: lymphoepithelial communication in the intestine [comment] [see comments] Shanahan F. **Science** 1997 Mar 28;275(5308):1897-8 (11 ref.) Comment on: Science 1997 Mar 28;275(5308):1937-9. Comment in: Science 1997 Mar 28;275(5308):1897-8.

Epstein-Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma. Ambinder RF, et al. **Semin Cancer Biol** 1996 Aug;7(4):217-26 (69 ref.)

Functional cloning of genes involved in T-cell receptor-induced programmed cell death. D'Adamio L, et al. **Semin Immunol** 1997 Feb;9(1):17-23 (61 ref.)

The nature of the peptide/MHC ligand involved in positive selection. Hogquist KA, et al. **Semin Immunol** 1996 Apr; 8(2):63-8 (31 ref.)

Responses of T cells to ligands for the T-cell receptor. Janeway CA Jr, et al. **Semin Immunol** 1996 Apr; 8(2):108-115 (28 ref.)

Variant TCR ligands: new insights into the molecular basis of antigen-dependent signal transduction and T-cell activation. Madrenas J, et al. **Semin Immunol** 1996 Apr; 8(2):83-101 (99 ref.)

Cellular and biochemical requirements for thymocyte negative selection. Page DM, et al. **Semin Immunol** 1996 Apr;8(2):69-82 (140 ref.)

Human T-and B-cell functions in SCID-hu mice. Roncarolo MG, et al. **Semin Immunol** 1996 Aug;8(4):207-13 (38 ref.)

Antigen analogs as tools to study T-cell activation function and activation. Sette A, et al. **Semin Immunol** 1996 Apr; 8(2):103-8 (29 ref.)

The effect of endogenous altered peptide ligands on peripheral T-cell responses. Vidal K, et al. **Semin Immunol** 1996 Apr;8(2):117-22 (44 ref.)

Genes involved in T-cell receptor-mediated apoptosis of thymocytes and T-cell hybridomas. Winoto A. **Semin Immunol** 1997 Feb;9(1):51-8 (79 ref.)

Identifying the molecular control of T-cell death; on the hunt for killer genes. Wong B, et al. **Semin Immunol** 1997 Feb;9(1):7-16 (53 ref.)

The role of T cells in primary biliary cirrhosis. Van de Water J, et al. **Semin Liver Dis** 1997 May;17(2):105-13 (60 ref.)

The T-body approach: potential for cancer immunotherapy. Eshhar Z, et al. **Springer Semin Immunopathol** 1996; 18(2):199-209 (31 ref.)

A T cell/B cell/epithelial cell internet for mucosal inflammation and immunity. Fujihashi K, et al. **Springer Semin Immunopathol** 1997;18(4):477-94 (113 ref.)

Rethinking immunosuppression in terms of the redundant and nonredundant steps in the immune response. Halloran PF. **Transplant Proc** 1996 Dec;28(6 Suppl 1):11-8 (95 ref.)

Thymic selection and tolerance. Kisielow P, et al. **Transplant Proc** 1996 Dec;28(6):3429-30 (34 ref.)

Immunomodulation by HLA class I-derived peptides. Krensky AM, et al. **Transplant Proc** 1996 Dec;28(6):3026-8 (14 ref.)

Cytomegalovirus hyperimmune gammaglobulin downregulates in vitro T-cell responses. Yadin O, et al. **Transplant Proc** 1996 Dec;28(6 Suppl 2):7-8 (2 ref.)

Pharmacodynamic monitoring of immunosuppressive drugs. Yatscoff RW, et al. **Transplant Proc** 1996 Dec;28(6):3013-5 (16 ref.)

Suppression of T-cell immunity after measles infection: is the puzzle solved? Salmi AA. **Trends Microbiol** 1997 Mar; 5(3):85-6 (12 ref.)

T cells and memory lapses. Sprent J. **Trends Microbiol** 1997 Jul;5(7):259-60; discussion 260-1 (19 ref.)

NK-lysin, structure and function of a novel effector molecule of porcine T and NK cells. Andersson M, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1-4):123-6 (11 ref.)

How viruses escape from cytotoxic T lymphocytes: molecular parameters and players. Oldstone MB. **Virology** 1997 Aug 4;234(2):179-85 (67 ref.)

[Molecular mechanisms of age-related lymphocyte dysfunction] Proust JJ, et al. **Pathol Biol (Paris)** 1996 Oct; 44(8):729-36 (68 ref.) (Eng. Abstr.) **(Fre)**

[Modulation of alloreactivity using genetically modified T lymphocytes] Tiberghien P. **Transfus Clin Biol** 1997; 4(3):275-80 (32 ref.) (Eng. Abstr.) **(Fre)**

[Current therapy of multiple sclerosis. Therapy with monoclonal antibodies to T-cell antigens (CD3, CD4, CD52)] Schmidt S, et al. **Nervenarzt** 1996 Feb;67(2):170-6 (44 ref.) (Eng. Abstr.) **(Ger)**

[Cell biology of bronchial asthma: interesting new methods. Intracellular determination of cytokines in T-cells and basic proteins in eosinophilic granulocytes using flow cytometry] Krug N, et al. **Pneumologie** 1997 Apr;51(4):381-5 (26 ref.) (Eng. Abstr.) **(Ger)**

[Immune response of fishes with respect to phylogenetic aspects] Ahne W. **Tierarztl Prax** 1996 Feb;24(1):88-95 (27 ref.) (Eng. Abstr.) **(Ger)**

[Cortisone-resistant bronchial asthma] Matucci A, et al. **Ann Ital Med Int** 1996 Jul-Sep;11(3):187-95 (47 ref.) (Eng. Abstr.) **(Ita)**

[Commemorative lecture of receiving Imamura Memorial Prize. Analysis of cellular immunity against tuberculosis in man with special reference to tuberculous pleurisy and cytokines] Shimokata K. **Kekkaku** 1996 Oct;71(10):591-6 (7 ref.) (Eng. Abstr.) **(Jpn)**

[TCR CDR3 motif expression in PLP specific T cell from patients with multiple sclerosis] Kondo T, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):666-9 (8 ref.) **(Jpn)**

[HLA and regulation of immune system] Sasagetsu T. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):595-6 (0 ref.) **(Jpn)**

[Analysis of infiltrating T-cell receptor in multiple organ lesions of patients with Sjogren's syndrome] Sumida T, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec; 18(6):653-9 (20 ref.) **(Jpn)**

[Intra-hepatic infiltrating T cell clonality analysis in patients with autoimmune hepatitis and the clinical significance] Takahashi H, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):708-12 (9 ref.) **(Jpn)**

[Transplantation immunology and immunosuppressive drug] Suzuki S. **Nippon Geka Gakkai Zasshi** 1996 Nov; 97(11):964-9 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular immunology of Japanese cedar pollen allergens: analysis of T cell epitopes] Hashiguchi S, et al. **Nippon Rinsho** 1996 Aug;54(8):2233-42 (24 ref.) (Eng. Abstr.) **(Jpn)**

[T cell tolerance and autoimmune disease] Kobayashi S. **Nippon Rinsho** 1997 Jun;55(6):1345-50 (25 ref.) (Eng. Abstr.) **(Jpn)**

[The expression of IL-2 receptor alpha subunit in T cells] Liu CB, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:183-8 (17 ref.) **(Jpn)**

[Detection of antigen specific T cell clonality in autoimmune diseases and epitope analysis of autoantigen-reactive T cells] Miyazaki Y, et al. **Nippon Rinsho** 1997 Jun; 55(6):1403-9 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Role of TCR V alpha 24 J alpha Q+ T cells in autoimmune diseases] Oishi Y, et al. **Nippon Rinsho** 1997 Jun; 55(6):1425-30 (20 ref.) (Eng. Abstr.) **(Jpn)**

[TCR repertoire of autoreactive T cells in autoimmune disorders] Sumida T, et al. **Nippon Rinsho** 1997 Jun; 55(6):1410-8 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Identification of T cell epitopes by reverse immunogenetics] Takiguchi M. **Nippon Rinsho** 1996 Dec;54(12):3379-88 (17 ref.) (Eng. Abstr.) **(Jpn)**

[TCR peptide vaccination for autoimmune diseases: involvement of T-T interaction between autoimmune T cells presenting TCR peptide and CD4-CD8- regulatory T cells] Yamamura T. **Nippon Rinsho** 1997 Jun; 55(6):1519-24 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Glioma and intracerebral immunity] Shimizu K. **No To Shinkei** 1997 Mar;49(3):239-50 (104 ref.) **(Jpn)**

[Immune response and adhesion molecules] Takeuchi T. **Rinsho Byori** 1996 Sep;Suppl 102:173-80 (20 ref.) **(Jpn)**

[Cellular immunity in tuberculosis particularly the role of gamma delta T lymphocytes] Mróz RM, et al. **Pneumonol Alergol Pol** 1996;64(11-12):815-20 (33 ref.) **(Pol)**

METABOLISM

Ca(2+)-signalling in human T-lymphocytes. Potential roles for cyclic ADP-ribose and 2'-phospho-cyclic ADP-ribose. Guse AH, et al. **Adv Exp Med Biol** 1997; 419:431-6 (16 ref.)

Structure and function of interleukin-4 and its receptor. Puri RK. **Cancer Treat Res** 1995;80:143-85 (318 ref.)

Signals for activation of the GM-CSF promoter and enhancer in T cells. Shannon MF, et al. **Crit Rev Immunol** 1997;17(3-4):301-23 (161 ref.)

T cell antigen receptor signal transduction. Qian D, et al. **Curr Opin Cell Biol** 1997 Apr;9(2):205-12 (71 ref.)

In thymic selection, peptide diversity gives and takes away. Bevan MJ. **Immunity** 1997 Aug;7(2):175-8 (16 ref.)

Making the T cell receptor go the distance: a topological view of T cell activation. Shaw AS, et al. **Immunity** 1997 Apr;6(4):361-9 (58 ref.)

Prolactin as an immunoreactive agent. Draca S. **Immunol Cell Biol** 1995 Dec;73(6):481-3 (35 ref.)

Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes. Moretta A, et al. **Immunol Rev** 1997 Feb;155:105-17 (92 ref.)

Alterations in T cells of cancer-bearers: whence specificity? Levey DL, et al. **Immunol Today** 1996 Aug;17(8):365-8 (39 ref.)

Cell adhesion molecules in HTLV-I infection. Uchiyama T, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996; 13 Suppl 1:S114-8 (22 ref.)

Cytokine flow cytometry: understanding cytokine biology at the single-cell level. Prussin C. **J Clin Immunol** 1997 May;17(3):195-204 (28 ref.)

Control of T lymphocyte signal transduction through clonal anergy. Fields P, et al. **J Mol Med** 1996 Nov;74(11):673-83 (141 ref.)

The effect of immunosuppressive drugs on T cell signalling pathways: non-redundant steps in the T cell response. Halloran PF. **Kidney Blood Press Res** 1996;19(3-4):174-6 (19 ref.)

HLA class-I-specific inhibitory receptor in human T lymphocytes: interference with T-cell functions. Mingari MC, et al. **Res Immunol** 1997 Mar-Apr;148(3):150-5 (32 ref.)

Responses of T cells to ligands for the T-cell receptor. Janeway CA Jr, et al. **Semin Immunol** 1996 Apr; 8(2):108-115 (28 ref.)

Variant TCR ligands: new insights into the molecular basis of antigen-dependent signal transduction and T-cell activation. Madrenas J, et al. **Semin Immunol** 1996 Apr; 8(2):83-101 (99 ref.)

Intracellular protein transport to the thyrocyte plasma membrane: potential implications for thyroid physiology. Arvan P, et al. **Thyroid** 1997 Feb;7(1):89-105 (293 ref.)

Postbinding functions of CD4 in HIV infection. Bachelder RE, et al. **Trends Microbiol** 1996 Sep;4(9):359-63 (48 ref.)

PATHOLOGY

T-cell blast crisis in chronic myelogenous leukemia. Immunophenotypic and molecular biologic findings. Dorfman DM, et al. **Am J Clin Pathol** 1997 Feb; 107(2):168-76 (49 ref.)

Apoptosis in peripheral lymphocytes in systemic lupus erythematosus: a review. Rose LM, et al. **Br J Rheumatol** 1997 Feb;36(2):158-63 (49 ref.)

The dynamic interplay of malignant and benign T cells in cutaneous T-cell lymphoma. Herrick C, et al. **Dermatol Clin** 1997 Jan;15(1):149-57 (36 ref.)

Development and function of T lymphocytes and natural killer cells after bone marrow transplantation of severely immunodeficient mice. Wang B, et al. **Immunol Rev** 1997 Jun;157:53-60 (50 ref.)

T-cell-rich B-cell lymphoma--a distinct clinicopathologic entity? Schmidt U, et al. **Leuk Lymphoma** 1996 Sep; 23(1-2):17-24 (39 ref.)

Apoptosis of mature T lymphocytes: putative role in the regulation of cellular immune responses and in the pathogenesis of HIV infection. Kabelitz D, et al. **Prog Mol Subcell Biol** 1996;16:58-71 (80 ref.)

CD2 induced apoptosis of peripheral T cells. Rouleau M, et al. **Transplant Proc** 1997 Aug;29(5):2377-8 (3 ref.)

[The etiopathogenetic and therapeutic correlations in chronic gastritis (comments apropos a case with a unique evolution) (corrected and republished article originally printed in Chirurgia (Bucur) 1996 May-Jun;45(3):139-45)] Mateş IN, et al. **Chirurgia (Bucur)** 1996 Sep-Oct;45(5):245-51 (17 ref.) (Eng. Abstr.) **(Rum)**

PHYSIOLOGY

Genetic regulation of apoptosis in the mouse thymus. Osborne BA, et al. **Adv Exp Med Biol** 1996;406:199-207 (41 ref.)

Hormones and lupus: defective dehydroepiandrosterone activity induces impaired interleukin-2 activity of T lymphocytes in patients with systemic lupus erythematosus. Suzuki N, et al. **Ann Med Interne (Paris)** 1996;147(4):248-52 (37 ref.)

Cellular interactions in thymocyte development. Anderson G, et al. **Annu Rev Immunol** 1996;14:73-99 (155 ref.)

Regulation and mechanisms of apoptosis in T lymphocytes. van den Dobbelsteen DJ, et al. **Arch Toxicol Suppl** 1997; 19:77-85 (30 ref.)

The role of T cells in the immunopathogenesis of rheumatoid arthritis: new perspectives. Fox DA. **Arthritis Rheum** 1997 Apr;40(4):598-609 (131 ref.)

The roles of adhesion molecules and proteinases in lymphocyte transendothelial migration. Madri JA, et al. **Biochem Cell Biol** 1996;74(6):749-57 (60 ref.)

Regulation of lymphocyte migration into lymph nodes by high endothelial venules. Ager A. **Biochem Soc Trans** 1997 May;25(2):421-8 (46 ref.)

T-lymphocyte-fibroblast interactions. Crowston JG, et al. **Biochem Soc Trans** 1997 May;25(2):529-31 (14 ref.)

T cells in the selection of germinal center B cells. Casamayor-Palleja M, et al. **Chem Immunol** 1997;67:27-44 (54 ref.)

Molecular mechanisms involved in T-B interactions. Lane P. **Chem Immunol** 1997;67:1-13 (65 ref.)

T cell receptor biochemistry, repertoire selection and general features of TCR and Ig structure. Davis MM, et al. **Ciba Found Symp** 1997;204:94-100; discussion 100-4 (21 ref.)

Lymphocyte-fibroblast interactions. Murakami S, et al. **Crit Rev Oral Biol Med** 1997;8(1):40-50 (93 ref.)

Signalling in lymphocyte development. Owen MJ, et al. **Curr Opin Immunol** 1996 Apr;8(2):191-8 (64 ref.)

T-cell-dependent pathways in rheumatoid arthritis. Panayi GS. **Curr Opin Rheumatol** 1997 May;9(3):236-40 (36 ref.)

Modulation of the human IgE response. de Vries JE, et al. **Eur Respir J Suppl** 1996 Aug;22:58s-62s (35 ref.)

Molecular mediators of asthma: current insights. Krishna MT, et al. **Hosp Pract (Off Ed)** 1996 Oct 15;31(10):115-9, 124, 126 passim (0 ref.)

Beta 1 integrin-mediated signaling in human T cells. Morimoto C, et al. **Hum Cell** 1996 Sep;9(3):163-8 (34 ref.)

Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. Mackall CL, et al. **Immunol Rev** 1997 Jun; 157:61-72 (68 ref.)

The physiological role of regulatory T cells in the prevention of autoimmunity: the function of the thymus in the generation of the regulatory T cell subset. Saoudi A, et al. **Immunol Rev** 1996 Feb;149:195-216 (94 ref.)

The structure and ligand interactions of CD2: implications for T-cell function. Davis SJ, et al. **Immunol Today** 1996 Apr;17(4):177-87 (115 ref.)

A model of lymphocyte recirculation. Stekel DJ, et al. **Immunol Today** 1997 May;18(5):216-21 (32 ref.)

The role of T cells in the regulation of B cell tolerance. Fazekas de St. Groth B, et al. **Int Rev Immunol** 1997; 15(1-2):73-99 (77 ref.)

B-cell activation versus tolerance--the central role of immunoglobulin receptor engagement and T-cell help. Fulcher DA, et al. **Int Rev Immunol** 1997;15(1-2):33-52 (22 ref.)

Repertoires of antigen receptors in Tdt congenitally deficient mice. Komori T, et al. **Int Rev Immunol** 1996;13(4):317-25 (63 ref.)

Insights into T cell development and signal transduction provided by TCR-zeta chain deficient mice. Shores EW, et al. **Int Rev Immunol** 1996;13(4):301-15 (97 ref.)

Complexity and redundancy in the pathogenesis of asthma: reassessing the roles of mast cells and T cells. Galli SJ. **J Exp Med** 1997 Aug 4;186(3):343-7 (46 ref.)

Epidermal T cells: their functional role and disease relevance for dermatologists. Shiohara T, et al. **J Invest Dermatol** 1997 Sep;109(3):271-5 (45 ref.)

Regulation of signal transduction through the T cell antigen receptor. Zhao H, et al. **J Lab Clin Med** 1997 Aug; 130(2):126-31 (56 ref.)

Mig and IP-10: CXC chemokines that target lymphocytes. Farber JM. **J Leukoc Biol** 1997 Mar;61(3):246-57 (45 ref.)

Lifespans of T lymphocytes. Adibzadeh M, et al. **Mech Ageing Dev** 1996 Oct 25;91(2):145-54 (42 ref.)

Selectins, T-cell rolling and inflammation. Rossiter H, et al. **Mol Med Today** 1997 May;3(5):214-22 (49 ref.)

Cardiopulmonary bypass and the adaptive immune system: perspectives on T cell function. Hornick P. **Perfusion** 1996 May;11(3):281-90 (58 ref.)

Immunopathogenesis of systemic sclerosis. White B. **Rheum Dis Clin North Am** 1996 Nov;22(4):695-708 (81 ref.)

T-cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms. Gold R, et al. **Trends Neurosci** 1997 Sep;20(9):399-404 (64 ref.)

[Granulated CD56 lymphocytes of decidual tissue] Calatayud S, et al. **Pathol Biol (Paris)** 1995 Nov;43(9):788-98 (101 ref.) (Eng. Abstr.) **(Fre)**

[Molecular mechanism of apoptosis operated in the immune system] Tadakuma T. **Nippon Rinsho** 1997 Jun; 55(6):1337-44 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Visual review: signal transduction in T cells] Nakayama T. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1092-9 (5 ref.) **(Jpn)**

[Cross-talk between transcription factors AP-1 and NFAT in the regulation of gene expression] Kamińska B, et al. **Postepy Biochem** 1996;42(2):120-8 (51 ref.) **(Pol)**

TRANSPLANTATION

Human immunodeficiency virus infection of human cells transplanted to severe combined immunodeficient mice. Mosier DE. **Adv Immunol** 1996;63:79-125 (278 ref.)

Therapy with cultured T cells: principles revisited. Cheever MA, et al. **Immunol Rev** 1997 Jun;157:177-94 (56 ref.)

ULTRASTRUCTURE

Thymic nurse cells: their functional ultrastructure. Brelińska R, et al. **Microsc Res Tech** 1997 Aug 1;38(3):250-66 (56 ref.)

VIROLOGY

Human immunodeficiency virus infection of human cells transplanted to severe combined immunodeficient mice. Mosier DE. **Adv Immunol** 1996;63:79-125 (278 ref.)

Epstein-Barr virus infection of T cells: implications for altered T-lymphocyte activation, repertoire development and autoimmunity. Dreyfus DH, et al. **Immunol Rev** 1996 Aug;152:89-110 (67 ref.)

Clonal expansion of infected cells: a way of life for HTLV-I. Wattel E, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S92-9 (28 ref.)

HIV-1 viral protein R (Vpr) regulates viral replication and cellular proliferation in T cells and monocytoid cells in vitro. Ayyavoo V, et al. **J Leukoc Biol** 1997 Jul;62(1):93-9 (42 ref.)

The positive influence of Nef on viral infectivity. Guatelli JC. **Res Virol** 1997 Jan-Feb;148(1):34-7 (34 ref.)

EBV infection of T cells: potential role in malignant transformation. Kelleher CA, et al. **Semin Cancer Biol** 1996 Aug;7(4):197-207 (69 ref.)

How viruses escape from cytotoxic T lymphocytes: molecular parameters and players. Oldstone MB. **Virology** 1997 Aug 4;234(2):179-85 (67 ref.)

[Isolation and characterization of Epstein-Barr virus-infected clones of a human T-lymphoblastoid cell line] Fujiwara S, et al. **Nippon Rinsho** 1997 Feb;55(2):416-23 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Epstein-Barr virus penetration mechanism to T lymphoblastoid cell lines] Uno M. **Nippon Rinsho** 1997 Feb; 55(2):404-8 (19 ref.) (Eng. Abstr.) **(Jpn)**

T-LYMPHOCYTES, CYTOTOXIC

Recognition of tumor-associated antigens by T-lymphocytes: perspectives for peptide-based vaccines. Cerottini JC, et al. **Ann Oncol** 1996 Apr;7(4):339-42 (52 ref.)

Chimeric T-cell receptors: highly specific tools to target cytotoxic T-lymphocytes to tumour cells. Abken H, et al. **Cancer Treat Rev** 1997 Mar;23(2):97-112 (42 ref.)

Killing mechanisms of cytotoxic lymphocytes. Berke G. **Curr Opin Hematol** 1997 Jan;4(1):32-40 (83 ref.)

Danger versus tolerance: paradigms for future studies of tumor-specific cytotoxic T lymphocytes [editorial; comment] Fenton RG, et al. **J Natl Cancer Inst** 1997 Feb 19;89(4):272-5 (28 ref.) Comment on: J Natl Cancer Inst 1997 Feb 19;89(4):293-300.

Protein sorting and secretion during CTL killing. Griffiths GM. **Semin Immunol** 1997 Apr;9(2):109-15 (48 ref.)

[Therapy of patients with head and neck neoplasms using cytotoxic T lymphocytes] IshikawaT, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):621-4 (10 ref.) **(Jpn)**

CHEMISTRY

Inhibitory receptors for HLA class I molecules on cytolytic T lymphocytes. Functional relevance and implications for anti-tumor immune responses. Mingari MC, et al. **Int J Clin Lab Res** 1997;27(2):87-94 (57 ref.)

CLASSIFICATION

Evolution and plasticity of CTL responses against HIV. Autran B, et al. **Curr Opin Immunol** 1996 Aug;8(4):546-53 (71 ref.)

CYTOLOGY

Interactions between endothelial cells and effector cells in allergic inflammation. Tonnel AB, et al. **Ann N Y Acad Sci** 1996 Oct 31;796:9-20 (26 ref.)

DRUG EFFECTS

Will killing the last HIV1 particle cure AIDS patients? II: Second Part. Decrease of viral load and of T-suppressor cells, and increase of the cytotoxic cells, without effect on CD4, after the use of 10 virostatics applied in 3 or 4 drug combinations of different sequences. The time for CD4 immunotherapy? [editorial] Mathé G, et al. **Biomed Pharmacother** 1996;50(10):473-9 (41 ref.)

Cytokine-induced cytotoxic function expressed by lymphocytes of the innate immune system: distinguishing characteristics of NK and LAK based on functional and molecular markers. Frederick M, et al. **J Interferon Cytokine Res** 1997 Aug;17(8):435-47 (124 ref.)

The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease. Schultz KR, et al. **Leuk Lymphoma** 1997 Jan;24(3-4):201-10 (59 ref.)

ENZYMOLOGY

Granzymes: a variety of serine protease specificities encoded by genetically distinct subfamilies. Smyth MJ, et al. **J Leukoc Biol** 1996 Nov;60(5):555-62 (107 ref.)

The role of granzyme B cluster proteases in cell-mediated cytotoxicity. Pham CT, et al. **Semin Immunol** 1997 Apr;

9(2):127-33 (55 ref.)

IMMUNOLOGY

HIV-peplotion vaccine. A novel approach to vaccination against AIDS by transepithelial transport of viral peptides and antigens to Langerhans cells for induction of cytolytic T cells by HLA class I and CD1 molecules for long term protection. Becker Y. **Adv Exp Med Biol** 1996;397:97-104 (22 ref.)

Cytotoxic lymphocyte killing enters the ice age. Martin SJ, et al. **Adv Exp Med Biol** 1996;406:29-37 (67 ref.)

Cellular immune responses to HIV-1 in progressive and non-progressive infections. Bollinger RC, et al. **AIDS** 1996; 10 Suppl A:S85-96 (158 ref.)

HIV-1-specific cytotoxic T-cell responses. Schooley RT. **AIDS** 1995;9 Suppl A:S113-6 (42 ref.)

HIV type 1 vaccine-induced cytotoxic T cell responses: potential role in vaccine efficacy. Ada GL, et al. **AIDS Res Hum Retroviruses** 1997 Feb 10;13(3):205-10 (83 ref.)

HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: detection, characterization, and quantitation. McElrath MJ, et al. **AIDS Res Hum Retroviruses** 1997 Feb 10;13(3):211-6 (34 ref.)

Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Rickinson AB, et al. **Annu Rev Immunol** 1997;15:405-31 (135 ref.)

Making the most of mucin: a novel target for tumor immunotherapy. Barratt-Boyes SM. **Cancer Immunol Immunother** 1996 Nov;43(3):142-51 (65 ref.)

Oncogene products represent potential targets of tumor vaccines. Tuttle TM. **Cancer Immunol Immunother** 1996 Nov;43(3):135-41 (62 ref.)

Immunotherapy II: Antigens, receptors and costimulation. Searle PF, et al. **Cancer Metastasis Rev** 1996 Sep; 15(3):329-49 (103 ref.)

Molecular mechanisms in cell-mediated cytotoxicity. Moretta A. **Cell** 1997 Jul 11;90(1):13-8 (49 ref.)

NK cells and CTL: opposite sides of the same coin. Valiante NM, et al. **Chem Immunol** 1996;64:146-63 (81 ref.)

Mechanisms of lysis by cytotoxic T cells. Atkinson EA, et al. **Crit Rev Immunol** 1995;15(3-4):359-84 (216 ref.)

AIDS: decline and fall of immune surveillance? [see comments] Feinberg MB, et al. **Curr Biol** 1997 Mar 1; 7(3):R136-40 (10 ref.) Comment in: Curr Biol 1997 Jul 1;7(7):R403-5.

Evolution and plasticity of CTL responses against HIV. Autran B, et al. **Curr Opin Immunol** 1996 Aug;8(4):546-53 (71 ref.)

Different roles for cytotoxic T cells in the control of infections with cytopathic versus noncytopathic viruses. Kägi D, et al. **Curr Opin Immunol** 1996 Aug;8(4):472-7 (49 ref.)

Cytotoxic T lymphocyte responses to Epstein-Barr virus. Rickinson AB, et al. **Curr Opin Immunol** 1996 Aug; 8(4):492-7 (44 ref.)

Immunotoxicology of T cell-dependent experimental liver injury. Tiegs G, et al. **Exp Toxicol Pathol** 1996 Jul; 48(5):471-6 (39 ref.)

The Fas-based mechanism of lymphocytotoxicity. Berke G. **Hum Immunol** 1997 Apr 15;54(1):1-7 (61 ref.)

MHC class I-restricted CTL responses to exogenous antigens. Jondal M, et al. **Immunity** 1996 Oct;5(4):295-302 (140 ref.)

Cytotoxic T cells--protection from disease progression--protection from infection. Gotch F, et al. **Immunol Lett** 1996 Jun;51(1-2):125-8 (26 ref.)

Dynamics of HIV variants and specific cytotoxic T-cell recognition in nonprogressors and progressors. Haas G, et al. **Immunol Lett** 1997 Jun 1;57(1-3):63-8 (48 ref.)

Class I HLA-restricted cytotoxic T lymphocyte responses against malaria--elucidation on the basis of HLA peptide binding motifs. Doolan DL, et al. **Immunol Res** 1996; 15(4):280-305 (180 ref.)

Cytotoxic T lymphocyte recognition of non-Hodgkin's B cell lymphomas. Krensky AM. **Immunol Res** 1996; 15(2):91-7 (44 ref.)

Involvement of CD80 in the generation of CD4+ cytotoxic T cells. Mauri D, et al. **Immunol Res** 1996;15(2):126-40 (112 ref.)

Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloid leukemia. Falkenburg JH, et al. **Immunol Rev** 1997 Jun;157:223-30 (71 ref.)

On T cell memory: arguments for antigen dependence. Kündig TM, et al. **Immunol Rev** 1996 Apr;150:63-90 (100 ref.)

Aspects of cytotoxic T cell memory. Müllbacher A, et al. **Immunol Rev** 1996 Apr;150:113-27 (70 ref.)

The HLA likes and dislikes of allospecific and non-MHC-restricted cytotoxic T lymphocytes. Nössner E, et al. **Immunol Rev** 1996 Dec;154:105-35 (131 ref.)

Tumor antigens recognized by T cells. Boon T, et al. **Immunol Today** 1997 Jun;18(6):267-8 (14 ref.)

Opposing functions of activatory T-cell receptors and inhibitory NK-cell receptors on cytotoxic T cells. Ciccone E, et al. **Immunol Today** 1996 Oct;17(10):450-3 (9 ref.)

Antiviral immunity. Zinkernagel RM, et al. **Immunol Today** 1997 Jun;18(6):258-60 (17 ref.)

Identification of tumor-regression antigens in melanoma. Kawakami Y, et al. **Important Adv Oncol** 1996;:3-21 (140 ref.)

Molecular mechanism of target lysis by cytotoxic T cells. Dennert G. **Int Rev Immunol** 1997;14(2-3):133-52 (91 ref.)

Cytotoxic T cells and viral hepatitis. Chisari FV. **J Clin Invest** 1997 Apr 1;99(7):1472-7 (50 ref.)

Human tumor antigens recognized by T lymphocytes: implications for cancer therapy. Wang RF, et al. **J Leukoc Biol** 1996 Sep;60(3):296-309 (120 ref.)

Do cytotoxic T lymphocytes clear some HIV/SIV infections? Ada G. **J Med Primatol** 1996 Jun;25(3):158-62 (33 ref.)

Specific cytotoxic T lymphocytes in gene therapy. Altenschmidt U, et al. **J Mol Med** 1997 Apr;75(4):259-66 (76 ref.)

Inhibition of MHC class I antigen presentation by viral proteins. Früh K, et al. **J Mol Med** 1997 Jan;75(1):18-27 (110 ref.)

Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumor antigens. Melero I, et al. **Life Sci** 1997;60(23):2035-41 (62 ref.)

Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes. De Plaen E, et al. **Methods** 1997 Jun;12(2):125-42 (85 ref.)

Antigen processing by proteasomes: insights into the molecular basis of crypticity. Djaballah H. **Mol Biol Rep** 1997 Mar;24(1-2):63-7 (44 ref.)

Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines? Coulie PG. **Mol Med Today** 1997 Jun;3(6):261-8 (39 ref.)

Adoptive immunotherapy of malignant glioma using tumor-sensitized T lymphocytes. Merchant RE, et al. **Neurol Res** 1997 Apr;19(2):145-52 (11 ref.)

Association of cytotoxic T lymphocyte (CTL) escape mutations with persistent hepatitis C virus (HCV) infection. Weiner AJ, et al. **Princess Takamatsu Symp** 1995;25:227-35 (35 ref.)

CTL effector functions. Henkart PA. **Semin Immunol** 1997 Apr;9(2):85-6 (10 ref.)

Functions of CD8 T-cell subsets secreting different cytokine patterns. Mosmann TR, et al. **Semin Immunol** 1997 Apr; 9(2):87-92 (26 ref.)

Targeting of peripheral blood T lymphocytes. Bolhuis RL, et al. **Springer Semin Immunopathol** 1996;18(2):211-26 (123 ref.)

HIV-1-specific cytotoxic T lymphocytes and the control of HIV-1 replication. Jassoy C, et al. **Springer Semin Immunopathol** 1997;18(3):341-54 (102 ref.)

Characteristics of the intrahepatic cytotoxic T lymphocyte response in chronic hepatitis C virus infection. Koziel MJ, et al. **Springer Semin Immunopathol** 1997;19(1):69-83 (90 ref.)

Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens. Romero P. **Springer Semin Immunopathol** 1996;18(2):185-98 (78 ref.)

Cytotoxic lymphocytes: redirecting the cell-mediated immune response for the therapy of cancer. Kershaw MH, et al. **Ther Immunol** 1995 Jun;2(3):173-81 (80 ref.)

Immune selection and virus evolution: be cautious of paradigms [letter] Daenke S. **Trends Microbiol** 1997 Mar; 5(3):92-3 (6 ref.)

The role of cytotoxic T lymphocytes in the evolution of genetically stable viruses. Khanna R, et al. **Trends Microbiol** 1997 Feb;5(2):64-9 (64 ref.)

How viruses hide from T cells. McMichael A. **Trends Microbiol** 1997 Jun;5(6):211-2; discussion 212-3 (20 ref.)

Identification of potential CTL epitopes of bovine RSV using allele-specific peptide motifs from bovine MHC class I molecules. Gaddum RM, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1-4):211-9 (50 ref.)

T lymphocyte mediated protection against facultative intracellular bacteria. Splitter G, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1-4):309-19 (45 ref.)

[Cytotoxic T-lymphocytes and the recognition of tumor antigens--an approach to "preventive tumor vaccination?"] Peiper M, et al. **Zentralbl Chir** 1997;122(3):141-8 (50 ref.) (Eng. Abstr.) **(Ger)**

[Cancer vaccine therapy using peptides derived from tumor-rejection antigens] Akiyoshi T. **Gan To Kagaku Ryoho** 1997 Mar;24(5):511-9 (38 ref.) (Eng. Abstr.) **(Jpn)**

[Analysis of the mechanism of the development of insulin-dependent diabetes mellitus and an attempt to prevent its onset by the functional T cell molecules] Yokono K, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Dec;19(6):618-21 (4 ref.) **(Jpn)**

[Adoptive immune therapy using EBV-specific CTL] Kuzushima K, et al. **Nippon Rinsho** 1997 Feb;55(2):473-8 (17 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Killer cell inhibitory receptor interactions with HLA class I molecules: implications for alloreactivity and transplantation. Young NT, et al. **Hum Immunol** 1997 Jan; 52(1):1-11 (109 ref.)

Opposing functions of activatory T-cell receptors and inhibitory NK-cell receptors on cytotoxic T cells. Ciccone E, et al. **Immunol Today** 1996 Oct;17(10):450-3 (9 ref.)

PHYSIOLOGY

Granzyme B-induced apoptosis. Greenberg AH. **Adv Exp Med Biol** 1996;406:219-28 (69 ref.)

Role of cellular immunity in protection against HIV infection. Rowland-Jones S, et al. **Adv Immunol** 1997; 65:277-346 (381 ref.)

Mechanisms of lysis by cytotoxic T cells. Atkinson EA, et al. **Crit Rev Immunol** 1995;15(3-4):359-84 (216 ref.)

Immune regulation: a critical link between NK cells and CTLs. Kos FJ, et al. **Immunol Today** 1996 Apr;17(4):174-6 (31 ref.)

A new foreign policy: MHC class I molecules monitor the outside world. Rock KL. **Immunol Today** 1996 Mar; 17(3):131-7 (56 ref.)

Fas and other cell death signaling pathways. Depraetere V, et al. **Semin Immunol** 1997 Apr;9(2):93-107 (186 ref.)

Do CTL kill target cells by inducing apoptosis? Henkart PA, et al. **Semin Immunol** 1997 Apr;9(2):135-44 (57 ref.)

Granulysin, a new human cytolytic granule-associated protein with possible involvement in cell-mediated cytotoxicity. Peña SV, et al. **Semin Immunol** 1997 Apr; 9(2):117-25 (50 ref.)

TRANSPLANTATION

Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Heslop HE, et al. **Immunol Rev** 1997 Jun;157:217-22 (39 ref.)

Adoptive cell therapy with donor lymphocytes for EBV-associated lymphomas developing after allogeneic marrow transplants. O'Reilly RJ, et al. **Important Adv Oncol** 1996;:149-66 (172 ref.)

Adoptive immunotherapy of malignant glioma using tumor-sensitized T lymphocytes. Merchant RE, et al. **Neurol Res** 1997 Apr;19(2):145-52 (11 ref.)

VIROLOGY

Identification of potential CTL epitopes of bovine RSV using allele-specific peptide motifs from bovine MHC class I molecules. Gaddum RM, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1-4):211-9 (50 ref.)

T-LYMPHOCYTES, HELPER see **T-LYMPHOCYTES, HELPER-INDUCER**

T-LYMPHOCYTES, HELPER-INDUCER

see related
INTERLEUKIN-2
LYMPHOCYTE COOPERATION

CYTOLOGY

Th cell development and regulation in experimental cutaneous leishmaniasis. Scott P. **Chem Immunol** 1996; 63:98-114 (72 ref.)

Differentiation of T-helper lymphocytes: selective regulation by members of the STAT family of transcription factors. Schindler U, et al. **Genes Cells** 1996 Jun;1(6):507-15 (64 ref.)

DRUG EFFECTS

The 1996 Moyer Award. Effects of endotoxin on the Th1/Th2 response in humans. Zimmer S, et al. **J Burn Care Rehabil** 1996 Nov-Dec;17(6 Pt 1):491-6 (39 ref.)

IMMUNOLOGY

Regulation of interleukin-12 signalling during T helper phenotype development. Jacobson NG, et al. **Adv Exp Med Biol** 1996;409:61-73 (31 ref.)

Nucleosome-driven autoimmune response in lupus. Pathogenic T helper cell epitopes and costimulatory signals. Datta SK, et al. **Ann N Y Acad Sci** 1997 Apr 5; 815:155-70 (168 ref.)

Stat4- and Stat6-deficient mice as models for manipulating T helper cell responses. Grusby MJ. **Biochem Soc Trans** 1997 May;25(2):359-60 (23 ref.)

Th cell development and regulation in experimental cutaneous leishmaniasis. Scott P. **Chem Immunol** 1996; 63:98-114 (72 ref.)

Tracking antigen-specific helper T cell responses. McHeyzer-Williams MG, et al. **Curr Opin Immunol** 1996 Apr;8(2):278-84 (56 ref.)

Ozone alters T-helper cell mediated bronchial hyperreactivity and resistance to bacterial infection. Steerenberg PA, et al. **Exp Toxicol Pathol** 1996 Nov; 48(6):497-9 (12 ref.)

Enumeration and characterization of memory cells in the TH compartment. McHeyzer-Williams MG, et al. **Immunol Rev** 1996 Apr;150:5-21 (45 ref.)

Do effector and memory T helper cells also need B7 ligand costimulatory signals? Gause WC, et al. **J Immunol** 1997 Aug 1;159(3):1055-8 (49 ref.)

The role of hepatitis C virus specific CD4+ T lymphocytes in acute and chronic hepatitis C. Diepolder HM, et al. **J Mol Med** 1996 Oct;74(10):583-8 (54 ref.)

T helper cells driving pathogenic anti-DNA autoantibody production in lupus: nucleosomal epitopes and CD40 ligand

signals. Datta SK, et al. **Lupus** 1997;6(3):333–6 (4 ref.)
T and B cell recognition of idiotypes of anti-DNA autoantibodies. Gavalchin J, et al. **Lupus** 1997;6(3):337–43 (52 ref.)
Functional diversity of helper T lymphocytes. Abbas AK, et al. **Nature** 1996 Oct 31;383(6603):787–93 (94 ref.)
Regulation of interleukin-12 signal transduction during T helper phenotype development. Jacobson NG, et al. **Res Immunol** 1995 Sep–Oct;146(7–8):446–56 (23 ref.)
T lymphocyte mediated protection against facultative intracellular bacteria. Splitter G, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):309–19 (45 ref.)
T cell cytokines and disease prevention. Wood PR, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):33–44 (83 ref.)
[Action of cytokines IL-12 and IL-4 on T helper cells. Cellular immunity or humoral immunity?] Asselin S, et al. **Presse Med** 1997 Mar 1;26(6):278–83 (30 ref.) (Eng. Abstr.) **(Fre)**
[Immunologic bases of graft vs. host disease: 1997] Uher F. **Orv Hetil** 1997 Aug 31;138(35):2163–8 (33 ref.) (Eng. Abstr.) **(Hun)**
[Functional differentiation of human naive helper T cells] Mayumi M. **Arerugi** 1997 May;46(5):407–9 (1 ref.) **(Jpn)**
[Production of lymphokines by T lymphocytes] Hamano T. **Nippon Rinsho** 1997 Mar;55 Suppl 1:180–2 (6 ref.) **(Jpn)**
[The new vaccines and immunologic response (and II). The antigenic presentation. Adjuvants as inducers of inducer T-lymphocyte cell-mediated response] Villarrubia VG, et al. **Med Clin (Barc)** 1996 Jun 29;107(5):185–96 (162 ref.) **(Spa)**

METABOLISM

Differentiation of T-helper lymphocytes: selective regulation by members of the STAT family of transcription factors. Schindler U, et al. **Genes Cells** 1996 Jun;1(6):507–15 (64 ref.)
Enhanced T-helper 2 lymphocyte responses: immune mechanism of Helicobacter pylori infection. Fan XG, et al. **Ir J Med Sci** 1996 Jan–Mar;165(1):37–9 (30 ref.)
Immunological determinants of disease caused by respiratory syncytial virus [see comments] Graham BS. **Trends Microbiol** 1996 Jul;4(7):290–3 (39 ref.) Comment in: Trends Microbiol 1996 Aug;4(8):299–300.
[Restricted expression of ganglioside GD1C on mouse naive helper T cells] Nakamura K. **Seikagaku** 1996 Dec; 68(12):1812–6 (16 ref.) **(Jpn)**

MICROBIOLOGY

Biological role of Th cell subsets in candidiasis. Romani L, et al. **Chem Immunol** 1996;63:115–37 (124 ref.)

PATHOLOGY

[Allergic diseases and infection with human immunodeficiency virus (HIV)–AIDS in pediatric patients] Linnemann de Martínez DL, et al. **Rev Alerg Mex** 1997 Mar–Apr;44(2):55–9 (21 ref.) (Eng. Abstr.) **(Spa)**

T-LYMPHOCYTES, INDUCER see **T-LYMPHOCYTES, HELPER-INDUCER**

T-LYMPHOCYTES, REGULATORY see **T-LYMPHOCYTES**

T-LYMPHOCYTES, SUPPRESSOR-EFFECTOR

DRUG EFFECTS

Will killing the last HIV1 particle cure AIDS patients? II: Second Part. Decrease of viral load and of T-suppressor cells, and increase of the cytotoxic cells, without effect on CD4, after the use of 10 virostatics applied in 3 or 4 drug combinations of different sequences. The time for CD4 immunotherapy? [editorial] Mathé G, et al. **Biomed Pharmacother** 1996;50(10):473–9 (41 ref.)

IMMUNOLOGY

Controversial issues and possible answers on the antigen-specific regulation of the IgE antibody response. Ishizaka K, et al. **Adv Exp Med Biol** 1996;409:317–25 (23 ref.)
Suppressive cellular and molecular activities in maternofetal immune interactions; suppressor cell activity, prostaglandins, and alpha-fetoproteins. Olding LB, et al. **Curr Top Microbiol Immunol** 1997;222:159–87 (218 ref.)
Cellular and molecular analyses of major histocompatibility complex (MHC) restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy. Schendel DJ, et al. **J Mol Med** 1997 Jun;75(6):400–13 (119 ref.)

T4 LYMPHOCYTES see **CD4-POSITIVE T-LYMPHOCYTES**

T8 LYMPHOCYTES see **CD8-POSITIVE T-LYMPHOCYTES**

LYMPHOCYTES, TUMOR-INFILTRATING

see related
IMMUNOTHERAPY, ADOPTIVE

Follicular mycosis fungoides: a clinicohistopathologic study. Pereyo NG, et al. **J Am Acad Dermatol** 1997 Apr; 36(4):563–8 (28 ref.)

IMMUNOLOGY

Identification of the genes encoding cancer antigens: implications for cancer immunotherapy. Rosenberg SA, et al. **Adv Cancer Res** 1996;70:145–77 (156 ref.)
Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes. Freedman RS, et al. **Cancer Treat Res** 1996;82:115–46 (114 ref.)
Identification of tumor-regression antigens in melanoma. Kawakami Y, et al. **Important Adv Oncol** 1996;:3–21 (140 ref.)

LYMPHOCYTIC CHORIOMENINGITIS

DIAGNOSIS

[Encephalitis due to the lymphocytic choriomeningitis virus] Martos Fernández E, et al. **An Esp Pediatr** 1996 May; 44(5):512–4 (14 ref.) **(Spa)**

EPIDEMIOLOGY

[Epidemiological studies on lymphocytic choriomeningitis virus in Japan] Morita C. **Nippon Rinsho** 1997 Apr; 55(4):886–90 (10 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

The cell-mediated immune response against lymphocytic choriomeningitis virus in beta 2-microglobulin deficient mice. Quinn DG, et al. **Immunol Rev** 1995 Dec;148:151–69 (95 ref.)
Viruses and T cell turnover: evidence for bystander proliferation. Tough DF, et al. **Immunol Rev** 1996 Apr; 150:129–42 (50 ref.)
IL12 in acute viral infectious disease. Biron CA, et al. **Res Immunol** 1995 Sep–Oct;146(7–8):590–600 (37 ref.)

LYMPHOCYTIC CHORIOMENINGITIS VIRUS

Pathogenesis and treatment of virus-induced autoimmune diabetes: novel insights gained from the RIP-LCMV transgenic mouse model. von Herrath MG, et al. **Biochem Soc Trans** 1997 May;25(2):630–5 (55 ref.)

IMMUNOLOGY

The cell-mediated immune respor.se against lymphocytic choriomeningitis virus in beta 2-microglobulin deficient mice. Quinn DG, et al. **Immunol Rev** 1995 Dec;148:151–69 (95 ref.)
Viruses and T cell turnover: evidence for bystander proliferation. Tough DF, et al. **Immunol Rev** 1996 Apr; 150:129–42 (50 ref.)
Using transgenic mouse models to dissect the pathogenesis of virus-induced autoimmune disorders of the islets of Langerhans and the central nervous system. von Herrath MG, et al. **Immunol Rev** 1996 Aug;152:111–43 (190 ref.)
IL12 in acute viral infectious disease. Biron CA, et al. **Res Immunol** 1995 Sep–Oct;146(7–8):590–600 (37 ref.)

PATHOGENICITY

Using transgenic mouse models to dissect the pathogenesis of virus-induced autoimmune disorders of the islets of Langerhans and the central nervous system. von Herrath MG, et al. **Immunol Rev** 1996 Aug;152:111–43 (190 ref.)

LYMPHOCYTIC LEUKEMIA see **LEUKEMIA, LYMPHOCYTIC**

B-LYMPHOCYTIC LEUKEMIA see **LEUKEMIA, B-CELL**

T-LYMPHOCYTIC LEUKEMIA see **LEUKEMIA, T-CELL**

LYMPHOCYTIC LEUKEMIA, ACUTE see **LEUKEMIA, LYMPHOCYTIC, ACUTE**

B-LYMPHOCYTIC LEUKEMIA, ACUTE see **LEUKEMIA, B-CELL, ACUTE**

LYMPHOCYTIC LEUKEMIA, ACUTE, B- AND T-CELL see **LEUKEMIA, MIXED-CELL**

T-LYMPHOCYTIC LEUKEMIA, ACUTE see **LEUKEMIA, T-CELL, ACUTE**

LYMPHOCYTIC LEUKEMIA, B-CELL see **LEUKEMIA, B-CELL**

LYMPHOCYTIC LEUKEMIA, B-CELL, ACUTE see **LEUKEMIA, B-CELL, ACUTE**

LYMPHOCYTIC LEUKEMIA, CHRONIC see **LEUKEMIA, LYMPHOCYTIC, CHRONIC**

B-LYMPHOCYTIC LEUKEMIA, CHRONIC see **LEUKEMIA, B-CELL, CHRONIC**

T-LYMPHOCYTIC LEUKEMIA, CHRONIC see **LEUKEMIA, T-CELL, CHRONIC**

LYMPHOCYTIC LEUKEMIA, CHRONIC, B-CELL see **LEUKEMIA, B-CELL, CHRONIC**

LYMPHOCYTIC LEUKEMIA, L1 see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L1**

LYMPHOCYTIC LEUKEMIA, L2 see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L2**

LYMPHOCYTIC LEUKEMIA, L3 see **LEUKEMIA, B-CELL, ACUTE**

LYMPHOCYTIC LEUKEMIA, T-CELL see **LEUKEMIA, T-CELL**

LYMPHOCYTIC LEUKEMIA, T-CELL, ACUTE see **LEUKEMIA, T-CELL, ACUTE**

LYMPHOCYTIC LEUKEMIA, T-CELL, CHRONIC see **LEUKEMIA, T-CELL, CHRONIC**

LYMPHOCYTIC LYMPHOMA see **LYMPHOMA, SMALL-CELL**

LYMPHOCYTIC LYMPHOMA, DIFFUSE, POORLY-DIFFERENTIATED see **LYMPHOMA, SMALL CLEAVED-CELL, DIFFUSE**

LYMPHOCYTIC LYMPHOMA, DIFFUSE, WELL-DIFFERENTIATED see **LYMPHOMA, SMALL LYMPHOCYTIC**

LYMPHOCYTIC LYMPHOMA, WELL-DIFFERENTIATED see **LYMPHOMA, SMALL LYMPHOCYTIC**

LYMPHOCYTOMA see **PSEUDOLYMPHOMA**

LYMPHOCYTOPENIA see **LYMPHOPENIA**

LYMPHOCYTOSIS

Lymphocytic adenohypophysitis and lymphocytic infundibuloneurohypophysitis. Hashimoto K, et al. **Endocr J** 1997 Feb;44(1):1–10 (107 ref.)

COMPLICATIONS

Polymyositis in a patient with thymoma and T cell lymphocytosis. Cranney A, et al. **J Rheumatol** 1997 Jul; 24(7):1413–6 (19 ref.)

DIAGNOSIS

Acute infectious lymphocytosis caused by coxsackievirus B2. Arnež M, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1127–8 (10 ref.)

ETIOLOGY

Inflammatory cardiomyopathy. The controversy of diagnosis and management. James KB, et al. **Rheum Dis Clin North Am** 1997 May;23(2):333–43 (53 ref.)

LYMPHOCYTOTOXIC ANTIBODIES see **ANTILYMPHOCYTE SERUM**

LYMPHOGRANULOMA, MALIGNANT see **HODGKIN'S DISEASE**

LYMPHOGRAPHY

METHODS

Contrast-enhanced lymphography. CT or MR imaging? Vogl TJ, et al. **Acta Radiol Suppl** 1997;412:47–50 (41 ref.)

LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC see **HISTIOCYTOSIS, NON-LANGERHANS-CELL**

LYMPHOID CELLS see **LYMPHOCYTES**

LYMPHOID HYPERPLASIA, REACTIVE see **PSEUDOLYMPHOMA**

LYMPHOID IRRADIATION see **LYMPHATIC IRRADIATION**

LYMPHOID LEUKEMIA see **LEUKEMIA, LYMPHOCYTIC**

LYMPHOID TISSUE

CYTOLOGY

Dendritic cells in the T-cell areas of lymphoid organs. Steinman RM, et al. **Immunol Rev** 1997 Apr;156:25-37 (132 ref.)

The life and times of an intestinal M cell. Savidge TC. **Trends Microbiol** 1996 Aug;4(8):301-6 (50 ref.)

DRUG EFFECTS

Regulatory effects of vasoactive intestinal peptide on cytokine production in central and peripheral lymphoid organs. Ganea D. **Adv Neuroimmunol** 1996;6(1):61-74 (143 ref.)

GROWTH & DEVELOPMENT

Control of gene expression during lymphoid development: targeted gene disruption provides new clues. Dooijes D, et al. **APMIS** 1997 May;105(5):337-44 (43 ref.)

IMMUNOLOGY

Special features of the intestinal lymphocytic system. Köhne G, et al. **Baillieres Clin Gastroenterol** 1996 Sep;10(3):427-42 (82 ref.)

Peritoneal defences and peritoneum-associated lymphoid tissue. Heel KA, et al. **Br J Surg** 1996 Aug;83(8):1031-6 (59 ref.)

Avian gut-associated lymphoid tissues and intestinal immune responses to Eimeria parasites. Lillehoj HS, et al. **Clin Microbiol Rev** 1996 Jul;9(3):349-60 (118 ref.)

Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system. Wu HY, et al. **Immunol Res** 1997;16(2):187-201 (88 ref.)

Delineation of the human hematolymphoid system: potential applications of defined cell populations in cellular therapy. Chen BP, et al. **Immunol Rev** 1997 Jun;157:41-51 (65 ref.)

Role of the common cytokine receptor gamma chain in cytokine signaling and lymphoid development. Leonard WJ, et al. **Immunol Rev** 1995 Dec;148:97-114 (77 ref.)

Follicular dendritic cells and germinal centers. Liu YJ, et al. **Int Rev Cytol** 1996;166:139-79 (205 ref.)

Generation of diversity in mammalian gut-associated lymphoid tissues: restricted V gene usage does not preclude complex V gene organization. Reynaud CA, et al. **J Immunol** 1997 Oct 1;159(7):3093-5 (18 ref.)

Mucosal immunology and models of mucosal HIV infection. Griffin GE, et al. **Mem Inst Oswaldo Cruz** 1996 May-Jun; 91(3):367-9 (9 ref.)

Effects of mercury on the immune system. Pollard KM, et al. **Met Ions Biol Syst** 1997;34:421-40 (100 ref.)

Microflora-associated defense stimulating factors. Pulverer G, et al. **Scand J Gastroenterol Suppl** 1997;222:107-11 (41 ref.)

Studies on lymphoid tissue from HIV-infected individuals: implications for the design of therapeutic strategies. Cohen OJ, et al. **Springer Semin Immunopathol** 1997;18(3):305-22 (67 ref.)

The immunopathology of M cells. Davis IC, et al. **Springer Semin Immunopathol** 1997;18(4):421-48 (257 ref.)

The life and times of an intestinal M cell. Savidge TC. **Trends Microbiol** 1996 Aug;4(8):301-6 (50 ref.)

METABOLISM

A suppressive protein generated in peripheral lymph tissue induced by restraint stress. Fan SG, et al. **Adv Neuroimmunol** 1996;6(3):279-88 (44 ref.)

Regulatory effects of vasoactive intestinal peptide on cytokine production in central and peripheral lymphoid organs. Ganea D. **Adv Neuroimmunol** 1996;6(1):61-74 (143 ref.)

Lymphotoxin: from chronic inflammation to lymphoid organs. Sacca R, et al. **J Inflamm** 1995-96;47(1-2):81-4 (14 ref.)

MICROBIOLOGY

Microflora-associated defense stimulating factors. Pulverer G, et al. **Scand J Gastroenterol Suppl** 1997;222:107-11 (41 ref.)

PATHOLOGY

Tissue lesions in AIDS patients involve both the lymphoid and the nervous system. Chiodi F. **AIDS** 1995;9 Suppl A:S41-8 (104 ref.)

Lymphoid infiltrates of the salivary glands: pathology, biology and clinical significance. DiGiuseppe JA, et al. **Curr Opin Oncol** 1996 May;8(3):232-7 (36 ref.)

Lymphoid lesions. Burke JS. **Pathology (Phila)** 1996; 3(2):503-12 (32 ref.)

PHYSIOLOGY

Epithelial cell growth and differentiation. III. Promoting diversity in the intestine: conversations between the microflora, epithelium, and diffuse GALT. Gordon JI, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):G565-70 (29 ref.)

Role of omentum-associated lymphoid tissue in the progression of peritoneal carcinomatosis. Shimotsuma M, et al. **Cancer Treat Res** 1996;82:147-54 (21 ref.)

Tumour necrosis factors in immune regulation: everything that's interesting is...new! Pasparakis M, et al. **Cytokine Growth Factor Rev** 1996 Oct;7(3):223-9 (55 ref.)

The somatogenic hormones and insulin-like growth factor-1: stimulators of lymphopoiesis and immune function. Clark R. **Endocr Rev** 1997 Apr;18(2):157-79 (287 ref.)

Lymphotoxins: from cytotoxicity to lymphoid organogenesis. von Boehmer H. **Proc Natl Acad Sci U S A** 1997 Aug 19;94(17):8926-7 (27 ref.)

PHYSIOPATHOLOGY

M cells as portals of infection: clinical and pathophysiological aspects. Fujimura Y, et al. **Infect Agents Dis** 1996 Jun; 5(3):144-56 (108 ref.)

SURGERY

Lymphoid lesions. Burke JS. **Pathology (Phila)** 1996; 3(2):503-12 (32 ref.)

VIROLOGY

Quantification of the reservoir of HIV-1. Blacklaws BA. **Trends Microbiol** 1997 Jun;5(6):215-6 (11 ref.)

LYMPHOKINE-ACTIVATED KILLER CELLS see **KILLER CELLS, LYMPHOKINE-ACTIVATED**

LYMPHOKINES

see related

IMMUNITY, CELLULAR

Histamine-releasing factors. MacDonald SM. **Curr Opin Immunol** 1996 Dec;8(6):778-83 (34 ref.)

The biology of vascular endothelial growth factor. Ferrara N, et al. **Endocr Rev** 1997 Feb;18(1):4-25 (250 ref.)

Fibrosin, a novel fibrogenic protein: discovery, cloning and implications for fibrotic disorders. Wyler DJ. **Int Arch Allergy Immunol** 1996 Dec;111(4):326-9 (22 ref.)

[Ciliary neurotrophic factor and leukemia inhibitory factor] Matsuoka I. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):496-503 (51 ref.) **(Jpn)**

BIOSYNTHESIS

Vascular endothelial growth factor and ocular neovascularization [comment] Miller JW. **Am J Pathol** 1997 Jul;151(1):13-23 (97 ref.) Comment on: Am J Pathol 1997 Jul;151(1):281-91.

Angiogenesis and the expression of vascular endothelial growth factor in endometrium and placenta. Torry DS, et al. **Am J Reprod Immunol** 1997 Jan;37(1):21-9 (87 ref.)

Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants. Neufeld G, et al. **Cancer Metastasis Rev** 1996 Jun;15(2):153-8 (48 ref.)

Eukaryotic expression systems: a comparison. Geisse S, et al. **Protein Expr Purif** 1996 Nov;8(3):271-82 (111 ref.)

[Production of lymphokines by T lymphocytes] Hamano T. **Nippon Rinsho** 1997 Mar;55 Suppl 1:180-2 (6 ref.) **(Jpn)**

CLASSIFICATION

Chemokines: what chemokine is that? Mackay CR. **Curr Biol** 1997 Jun 1;7(6):R384-6 (14 ref.)

GENETICS

Atherosclerosis and angiogenesis. Its pathophysiological significance in humans as well as in an animal model induced by the gene transfer of vascular endothelial growth factor. Sueishi K, et al. **Ann N Y Acad Sci** 1997 Apr 15; 811:311-22; 322-4 (37 ref.)

Angiogenic gene therapy. A leg to stand on? [editorial; comment] Fox JC, et al. **Circulation** 1996 Dec 15; 94(12):3065-6 (11 ref.) Comment on: Circulation 1996 Dec 15;94(12):3281-90.

A little VEGF goes a long way. Therapeutic angiogenesis by direct injection of vascular endothelial growth factor-encoding plasmid DNA [editorial; comment] Majesky MW. **Circulation** 1996 Dec 15;94(12):3062-4 (17 ref.) Comment on: Circulation 1996 Dec 15;94(12):3281-90.

Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene. Levy AP, et al. **Kidney Int** 1997 Feb; 51(2):575-8 (28 ref.)

[Correlation of neovascularization and vascular endothelial growth factor in human renal cell carcinoma] Sato K, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(4):389-94 (17 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Controversial issues and possible answers on the antigen-specific regulation of the IgE antibody response. Ishizaka K, et al. **Adv Exp Med Biol** 1996;409:317-25 (23 ref.)

Soluble, antigen-specific T-cell proteins: T-cell-based humoral immunity? Cone RE, et al. **Immunol Today** 1996 Jul;17(7):318-22 (53 ref.)

METABOLISM

Retinal development: communication helps you see the light. Wechsler-Reya RJ, et al. **Curr Biol** 1997 Jul 1;7(7):R433-6 (16 ref.)

Vascular endothelial growth factor, a specific regulator of angiogenesis. Ferrara N, et al. **Curr Opin Nephrol Hypertens** 1996 Jan;5(1):35-44 (124 ref.)

PHYSIOLOGY

Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system. Carmeliet P, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:191-206 (58 ref.)

Role of vascular permeability factor/vascular endothelial growth factor in eye disease. Schlingemann RO, et al. **Br J Ophthalmol** 1997 Jun;81(6):501-12 (257 ref.)

Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Claffey KP, et al. **Cancer Metastasis Rev** 1996 Jun;15(2):165-76 (108 ref.)

Biological properties of VEGF/VPF receptors. Terman BI, et al. **Cancer Metastasis Rev** 1996 Jun;15(2):159-63 (42 ref.)

Vascular endothelial growth factor and its receptors. Klagsbrun M, et al. **Cytokine Growth Factor Rev** 1996 Oct; 7(3):259-70 (136 ref.)

Cardiotrophin-1: a multifunctional cytokine that signals via LIF receptor-gp 130 dependent pathways. Pennica D, et al. **Cytokine Growth Factor Rev** 1996 Jun;7(1):81-91 (63 ref.)

Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Miller JW, et al. **Diabetes Metab Rev** 1997 Mar;13(1):37-50 (119 ref.)

Role of leukemia inhibitory factor during mammalian development. Shellard J, et al. **Eur Cytokine Netw** 1996 Dec;7(4):699-712 (69 ref.)

Vascular endothelial growth factor. Ferrara N. **Eur J Cancer** 1996 Dec;32A(14):2413-22 (132 ref.)

Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. Brown LF, et al. **EXS** 1997;79:233-69 (133 ref.)

Vascular endothelial growth factor: basic biology and clinical implications. Ferrara N, et al. **EXS** 1997;79:209-32 (142 ref.)

Vascular endothelial growth factor and the endometrium. Smith SK. **Hum Reprod** 1996 Oct;11 Suppl 2:56-61 (43 ref.)

Regulation of angiogenesis by hypoxic stress: from solid tumours to the ovarian follicle. Neeman M, et al. **Int J Exp Pathol** 1997 Apr;78(2):57-70 (121 ref.)

Vascular endothelial growth factor. 20th-century mechanisms, 21st-century therapies. Aiello LP. **Invest Ophthalmol Vis Sci** 1997 Aug;38(9):1647-52 (19 ref.)

Leukemia inhibitory factor and ciliary neurotrophic factor in sensory neuron development. Horton AR, et al. **Perspect Dev Neurobiol** 1996;4(1):35-8 (30 ref.)

Regulation of oligodendrocyte cell survival and differentiation by ciliary neurotrophic factor, leukemia inhibitory factor, oncostatin M, and interleukin-6. Vos JP, et al. **Perspect Dev Neurobiol** 1996;4(1):39-52 (133 ref.)

Changes in neuropeptide phenotype after axotomy of adult peripheral neurons and the role of leukemia inhibitory factor. Zigmond RE, et al. **Perspect Dev Neurobiol** 1996; 4(1):75-90 (146 ref.)

Endothelial and glial cell interaction in diabetic retinopathy via the function of vascular endothelial growth factor (VEGF). Sueishi K, et al. **Pol J Pharmacol** 1996 May-Jun; 48(3):307-16 (30 ref.)

Possible involvement of VEGF-FLT tyrosine kinase receptor system in normal and tumor angiogenesis. Shibuya M, et al. **Princess Takamatsu Symp** 1994;24:162-70 (23 ref.)

Angiogenesis in embryos and ischemic diseases. Breier G, et al. **Thromb Haemost** 1997 Jul;78(1):678-83 (70 ref.)

Tumor angiogenesis: the pivotal role of vascular endothelial growth factor. Marmé D. **World J Urol** 1996;14(3):166-74 (92 ref.)

THERAPEUTIC USE

A little VEGF goes a long way. Therapeutic angiogenesis by direct injection of vascular endothelial growth factor-encoding plasmid DNA [editorial; comment] Majesky MW. **Circulation** 1996 Dec 15;94(12):3062-4 (17 ref.) Comment on: Circulation 1996 Dec 15;94(12):3281-90.

LYMPHOMA

One and a half decades of the Lugano International Conference on Malignant Lymphoma: variations on a theme or true progress? Ultmann JE, et al. **Ann Oncol** 1997; 8 Suppl 1:1-3 (0 ref.)

Management of cutaneous lymphoma. Russell-Jones R, et al. **Baillieres Clin Haematol** 1996 Dec;9(4):743-67 (125 ref.)

ABC of clinical haematology. Malignant lymphomas and chronic lymphocytic leukaemia. Mead GM. **BMJ** 1997 Apr 12;314(7087):1103-6 (0 ref.)

Current approach to the biology and treatment of chronic lymphoid malignancies other than CLL. Catovsky D. **Hematol Cell Ther** 1996 Dec;38 Suppl 2:S63-6 (27 ref.)

[Malignant histiocytofibroma of the bladder. A case report] Barriol D, et al. **Prog Urol** 1997 Apr;7(2):270-2 (9 ref.) (Eng. Abstr.) **(Fre)**

[Cutaneous lymphoma] Hauschild A, et al. **Dtsch Med Wochenschr** 1996 Oct 25;121(43):1335-40 (32

ref.) (Ger)
[Currently available classifications of lymphoid neoplasia and their clinical applicability] Nakamine H, et al. **Nippon Rinsho** 1996 Nov;54(11):3163–74 (39 ref.) (Eng. Abstr.) (Jpn)
[Primary malignant lymphoma of the heart] Arai Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):257–9 (14 ref.) (Jpn)
[Pericardial lymphoma] Shibata K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):276–8 (8 ref.) (Jpn)
[Malignant lymphoma] Taguchi H. **Ryoikibetsu Shokogun Shirizu** 1996;(15):121–4 (22 ref.) (Jpn)
[Retrotrigonal bladder lymphoma] Rodríguez Martín F, et al. **Actas Urol Esp** 1996 Nov–Dec;20(10):900–3 (10 ref.) (Eng. Abstr.) (Spa)

BLOOD

Apoptosis in normal and neoplastic hematopoiesis. Yoshida Y, et al. **Crit Rev Oncol Hematol** 1996 Nov;24(3):185–211 (273 ref.)
Antithrombin deficiency in special clinical syndromes--Part II: hematologic malignancies and bone marrow transplantation. Haire WD. **Semin Hematol** 1995 Oct;32(4 Suppl 2):56–60 (8 ref.)

CLASSIFICATION

The problem of classifying lymphomas: an orderly prescription for progress. Berard CW, et al. **Ann Oncol** 1997;8 Suppl 2:3–9 (78 ref.)
Lymphoma classification--the gap between biology and clinical management is closing. Hiddemann W, et al. **Blood** 1996 Dec 1;88(11):4085–9 (15 ref.)
EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Willemze R, et al. **Blood** 1997 Jul 1;90(1):354–71 (130 ref.)
Pathogenesis and classification of primary central nervous system lymphoma: an update. Morgello S. **Brain Pathol** 1995 Oct;5(4):383–93 (103 ref.)
Further considerations on the Revised European–American Lymphoma classification. De Wolf-Peeters C, et al. **Curr Opin Oncol** 1996 Sep;8(5):366–70 (36 ref.)
Classification of malignant lymphomas: the updated Kiel classification. Diebold J, et al. **Haematologia (Budap)** 1997; 28(3):155–67 (6 ref.)
The Revised European–American Classification of Lymphoid Neoplasms (REAL): a new perspective for the classification of cutaneous lymphomas. Sander CA, et al. **J Cutan Pathol** 1997 Jul;24(6):329–41 (93 ref.)

COMPLICATIONS

Pyothorax-associated lymphoma. Aozasa K. **Int J Hematol** 1996 Dec;65(1):9–16 (23 ref.)
Case report: primary hepatic lymphoma associated with chronic liver disease. Higuchi T, et al. **J Gastroenterol Hepatol** 1997 Mar;12(3):237–42 (90 ref.)
Rheumatic manifestations of dysproteinemias and lymphoproliferative disorders. Duna GF, et al. **Rheum Dis Clin North Am** 1996 Feb;22(1):39–51 (107 ref.)
[Secondary lymphomatous polyposis of the gastrointestinal tract in patients with nodal lymphomas] Bányai A, et al. **Orv Hetil** 1996 Jul 21;137(29):1591–5 (19 ref.) (Eng. Abstr.) (Hun)

DIAGNOSIS

The status of immunohistochemical studies in lymphoma diagnosis. Taylor CR. **Biotech Histochem** 1997 Mar; 72(2):62–77 (57 ref.)
Clinical utility of molecular probes in lymphoproliferative disorders. Kay NE. **Blood Rev** 1996 Jun;10(2):81–8 (60 ref.)
The lymphomas. Jacobs P, et al. **Cent Afr J Med** 1996 Sep; 42(9):273–80 (117 ref.)
Primary malignant lymphoma of the bladder. A case report and review of the literature. Arda K, et al. **Int Urol Nephrol** 1997;29(3):319–22 (10 ref.)
Lymphoproliferative disease of the orbit. Weber AL, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):93–111 (51 ref.)
Thyroid cancers. II. Medullary, anaplastic, lymphoma, sarcoma, squamous cell. Austin JR, et al. **Otolaryngol Clin North Am** 1996 Aug;29(4):611–27 (86 ref.)
Gastrointestinal lymphomas: an overview with emphasis on new findings and diagnostic problems. Chan JK. **Semin Diagn Pathol** 1996 Nov;13(4):260–96 (154 ref.)
[Primary malignant lymphoma of the brain] Hartmann M, et al. **Radiologe** 1997 Jan;37(1):42–50 (26 ref.) (Eng. Abstr.) (Ger)
[A solitary lymphoma (primary brain lymphoma) in the posterior cranial fossa] Seitz J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Jan;166(1):72–4 (9 ref.) (Ger)
[Clinical use of polymerase chain reaction in diagnosis and monitoring of malignant diseases] Jäger U, et al. **Wien Klin Wochenschr** 1996;108(20):634–9 (35 ref.) (Eng. Abstr.) (Ger)
[Malignant lymphoma--progress in management] Hirano M. **Nippon Naika Gakkai Zasshi** 1996 Sep 10;85(9):1561–8 (18 ref.) (Jpn)

DRUG THERAPY

Bcl-2 family proteins: strategies for overcoming chemoresistance in cancer. Reed JC. **Adv Pharmacol** 1997; 41:501–32 (190 ref.)
Central nervous system relapse of lymphoid malignancies in adults: the role of high-dose chemotherapy. van Besien K, et al. **Ann Oncol** 1997 Jun;8(6):515–24 (122 ref.)
The emerging role of immunotoxins in leukemia and lymphoma. Winkler U, et al. **Ann Oncol** 1997;8 Suppl 1:139–46 (46 ref.)
Chemotherapy: the more, the better in malignant lymphoma? Tobinai K. **Cancer Chemother Pharmacol** 1997;40 Suppl:S110–4 (25 ref.)
Fludarabine phosphate in lymphoma: an important new therapeutic agent. McLaughlin P, et al. **Cancer Treat Res** 1996;85:3–14 (56 ref.)
2-Chlorodeoxyadenosine treatment of lymphoma. Saven A, et al. **Cancer Treat Res** 1996;85:15–26 (52 ref.)
Malignant lymphomas in the elderly. O'Reilly SE, et al. **Clin Geriatr Med** 1997 May;13(2):251–63 (29 ref.)
Role of interleukin-2 in human hematological malignancies. Toren A, et al. **Med Oncol** 1995 Sep;12(3):177–86 (94 ref.)
[Management of hematologic malignancies during pregnancy] Maloisel F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(6):602–7 (49 ref.) (Eng. Abstr.) (Fre)
[High dose chemotherapy with autologous stem cell transplantation] Weissinger F, et al. **Fortschr Med** 1997 Mar 30;115(9):39–43 (20 ref.) (Eng. Abstr.) (Ger)
[Etoposide 21 therapy for malignant lymphoma] Masaoka T. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1936–40 (2 ref.) (Eng. Abstr.) (Jpn)

ETIOLOGY

Infectious agents and environmental factors in lymphoid malignancies. Toren A, et al. **Blood Rev** 1996 Jun; 10(2):89–94 (63 ref.)
Pathogenesis and classification of primary central nervous system lymphoma: an update. Morgello S. **Brain Pathol** 1995 Oct;5(4):383–93 (103 ref.)
The hu-PBL-SCID mouse in human lymphocyte function and lymphomagenesis studies: achievements and caveats. Amadori A, et al. **Semin Immunol** 1996 Aug;8(4):249–54 (50 ref.)
Lymphocyte-specific genomic instability and risk of lymphoid malignancy. Kirsch IR, et al. **Semin Immunol** 1997 Jun;9(3):207–15 (96 ref.)

GENETICS

The MDR phenotype in hematologic malignancies: prognostic relevance and future perspectives. Hegewisch-Becker S, et al. **Ann Hematol** 1996 Mar; 72(3):105–17 (128 ref.)
Genetic alterations in leukemias and lymphomas: impressive progress and continuing complexity. Nowell PC. **Cancer Genet Cytogenet** 1997 Mar;94(1):13–9 (52 ref.)
Molecular diagnosis of lymphomas and associated diseases. McCarthy KP. **Cancer Metastasis Rev** 1997 Jun; 16(1–2):109–25 (98 ref.)
Transrearrangements as biomarkers for risk of lymphoid malignancy. Kirsch IR, et al. **Cancer Surv** 1996;28:311–27 (81 ref.)
Bcl-2 family proteins and the regulation of programmed cell death in leukemia and lymphoma. Reed JC, et al. **Cancer Treat Res** 1996;84:31–72 (231 ref.)
BCL-2 gene rearrangements in lymphoid malignancies. Crisan D. **Clin Lab Med** 1996 Mar;16(1):23–47 (107 ref.)
Implication of cyclin D1 in malignant lymphoma. Callanan M, et al. **Crit Rev Oncog** 1996;7(3–4):191–203 (89 ref.)
Molecular diagnosis of lymphoma. Veronese ML, et al. **Curr Opin Oncol** 1996 Sep;8(5):346–52 (44 ref.)
Alternate hypothesis for the bimodal size distribution of mutant colonies of L5178Y mouse lymphoma cells. Mitchell AD. **Environ Mol Mutagen** 1997;29(4):431–3 (15 ref.)
Telomeres and telomerase in normal and malignant haematopoietic cells. Norrback KF, et al. **Eur J Cancer** 1997 Apr;33(5):774–80 (57 ref.)
Chromosomal abnormalities and oncogenes. Mitani K. **Int J Hematol** 1996 Feb;63(2):81–93 (74 ref.)
Non-pyothorax-associated primary pleural lymphoma with complex karyotypic abnormalities. Keung YK, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):621–4 (16 ref.)
The involvement of the candidate proto-oncogene NFKB2/lyt-10 in lymphoid malignancies. Neri A, et al. **Leuk Lymphoma** 1996 Sep;23(1–2):43–8 (38 ref.)
Role of the cyclin-dependent kinase 4 and 6 inhibitor gene family p15, p16, p18 and p19 in leukemia and lymphoma. Siebert R, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):505–20 (107 ref.)
C-kit receptors in childhood malignant lymphoblastic cells. Sykora KW, et al. **Leuk Lymphoma** 1997 Apr; 25(3–4):201–16 (94 ref.)
Overexpression of the MDM2 oncogene in leukemia and lymphoma. Watanabe T, et al. **Leuk Lymphoma** 1996 May; 21(5–6):391–7, color plates XVI following 5 (49 ref.)
Genetic predisposition to lymphomas in mice. Hiai H. **Pathol Int** 1996 Oct;46(10):707–18 (47 ref.)
Tlag1, a novel murine tumor susceptibility gene that regulates MNU-induced thymic lymphoma development. Richie ER, et al. **Prog Clin Biol Res** 1996;395:23–32 (17 ref.)

IMMUNOLOGY

The role of the immune response in MULV-induced lymphomagenesis. Marshall DJ, et al. **Leukemia** 1996 Dec; 10(12):1860–6 (79 ref.)
Determination of clonality in patients who present with diagnostic dilemmas: a laboratory experience and review of the literature. Rockman SP. **Leukemia** 1997 Jun; 11(6):852–62 (61 ref.)
[The immunocompetent structures of the skin and their role in the development of primary skin lymphomas (editorial)] Vavilov AM, et al. **Arkh Patol** 1996 Nov–Dec;58(6):7–12 (52 ref.) (Eng. Abstr.) (Rus)

METABOLISM

New insights into tumor–host interactions in lymphoma metastasis. Umansky V, et al. **J Mol Med** 1996 Jul; 74(7):353–63 (122 ref.)
CD40/CD40 ligand interactions in normal, reactive and malignant lympho-hematopoietic tissues. Gruss HJ, et al. **Leuk Lymphoma** 1997 Feb;24(5–6):393–422 (236 ref.)
Cyclin D1 overexpression in malignant lymphomas. Nakamura S, et al. **Pathol Int** 1997 Jul;47(7):421–9 (75 ref.)

PATHOLOGY

Molecular diagnosis of lymphomas and associated diseases. McCarthy KP. **Cancer Metastasis Rev** 1997 Jun; 16(1–2):109–25 (98 ref.)
Liver endothelial cells: participation in host response to lymphoma metastasis. Umansky V, et al. **Cancer Metastasis Rev** 1996 Jun;15(2):273–9 (54 ref.)
Lymphoma of the thyroid gland. Isaacson PG. **Curr Top Pathol** 1997;91:1–14 (15 ref.)
Aggressive natural killer (NK) cell lymphoma: report of a pediatric case and review of the literature. Ohnuma K, et al. **Leuk Lymphoma** 1997 Apr;25(3–4):387–92 (7 ref.)
Gastrointestinal lymphomas: an overview with emphasis on new findings and diagnostic problems. Chan JK. **Semin Diagn Pathol** 1996 Nov;13(4):260–96 (154 ref.)
Mucocutaneous neoplasms in patients with human immunodeficiency virus infection. Cockerell CJ. **Semin Diagn Pathol** 1996 Feb;13(1):19–39 (131 ref.)
[Malignant lymphoma. Diagnosis and after-care in adults with special reference to cross-sectional imaging] Brado M, et al. **Radiologe** 1997 Jan;37(1):10–8 (42 ref.) (Eng. Abstr.) (Ger)
[Intraocular and orbital involvement in lymphomas and leukemias] Pe'er J. **Harefuah** 1996 Aug;131(3–4):116–20 (37 ref.) (Heb)
[Staging of lymphoma with imaging techniques] D'Agostino A, et al. **Clin Ter** 1996 Jul–Aug;147(7–8):385–97 (23 ref.) (Eng. Abstr.) (Ita)
[Cyclin D1: from the study of the cell cycle to the histopathologic diagnosis] Barbareschi M, et al. **Pathologica** 1996 Jun;88(3):236–8 (9 ref.) (Ita)

PHYSIOPATHOLOGY

Apoptosis in normal and neoplastic hematopoiesis. Yoshida Y, et al. **Crit Rev Oncol Hematol** 1996 Nov;24(3):185–211 (273 ref.)
Modelling human leukemia and lymphoma in severe combined immunodeficient (SCID) mice: practical applications. Flavell DJ. **Hematol Oncol** 1996 Jun; 14(2):67–82 (100 ref.)

RADIOGRAPHY

[Radiologic diagnosis of primary extranodal lymphoma manifestations] Malms J, et al. **Radiologe** 1997 Jan; 37(1):27–34 (28 ref.) (Eng. Abstr.) (Ger)
[Extranodal lymphomas: computerized tomography features and differential diagnosis] Ferrozzi F, et al. **Radiol Med (Torino)** 1997 Apr;93(4):429–41 (25 ref.) (Ita)

RADIONUCLIDE IMAGING

PET for diagnosis of malignant lymphoma of the scalp: comparison of [11C]methyl-L-methionine and [18F]fluoro-2-deoxyglucose. Tsuyuguchi N, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):590–3 (16 ref.)

SURGERY

Autologous bone marrow and peripheral blood stem cell transplantation in haematological malignancies: current status. Marcoullis G, et al. **Med Oncol** 1995 Dec; 12(4):209–18 (91 ref.)

THERAPY

Autologous stem cell transplants in lymphomas. Vandenberghe EA, et al. **Ann Med** 1996 Apr;28(2):137–43 (74 ref.)
Anti-sense and gene therapy approaches to the treatment of lymphomas. Devereux S, et al. **Baillieres Clin Haematol** 1996 Dec;9(4):819–34 (86 ref.)
Management of histologically aggressive lymphomas with a high risk of CNS disease. Horak ID, et al. **Baillieres Clin Haematol** 1996 Dec;9(4):707–26 (60 ref.)
The role of interferon in the therapy of malignant lymphoma. McLaughlin P. **Biomed Pharmacother** 1996;50(3–4):140–8 (60 ref.)
Autologous bone marrow transplantation for leukemia and

LYMPHOMA

lymphoma. van Besien K, et al. **Cancer Treat Res** 1996; 84:207–59 (228 ref.)

The lymphomas. Jacobs P, et al. **Cent Afr J Med** 1996 Sep; 42(9):273–80 (117 ref.)

Antiblastic chemotherapy for haematologic malignancies and second tumours. Barillari G, et al. **Eur J Cancer Prev** 1996 Oct;5(5):402–4 (14 ref.)

Hematological malignancies. Brenner MK. **FASEB J** 1997 Jul;11(8):640–8 (39 ref.)

Aggressive natural killer (NK) cell lymphoma: report of a pediatric case and review of the literature. Ohnuma K, et al. **Leuk Lymphoma** 1997 Apr;25(3–4):387–92 (7 ref.)

Myelodysplasia and acute myeloid leukemia occurring after autologous bone marrow transplantation for lymphoma. Traweek ST, et al. **Leuk Lymphoma** 1996 Feb; 20(5–6):365–72 (47 ref.)

[Malignant lymphoma--progress in management] Hirano M. **Nippon Naika Gakkai Zasshi** 1996 Sep 10;85(9):1561–8 (18 ref.) **(Jpn)**

[Mobilization and collection of peripheral blood stem cells] Shimazaki C, et al. **Rinsho Ketsueki** 1996 Jul;37(7):574–8 (10 ref.) **(Jpn)**

ULTRASONOGRAPHY

[Ultrasound criteria for staging and follow-up of malignant lymphoma] Mende U, et al. **Radiologe** 1997 Jan;37(1):19–26 (34 ref.) (Eng. Abstr.) **(Ger)**

[Ultrasound manifestations of abdominal lymphomas. An overview] Görg C, et al. **Ultraschall Med** 1996 Aug; 17(4):179–84 (13 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Radiographic abnormalities in canine multicentric lymphoma: a review of 84 cases. Blackwood L, et al. **J Small Anim Pract** 1997 Feb;38(2):62–9 (54 ref.)

Cooperating events in lymphomagenesis mediated by feline leukemia virus. Levy LS, et al. **Leukemia** 1997 Apr;11 Suppl 3:239–41 (16 ref.)

Chemoimmunotherapy of canine lymphoma with adjuvant canine monoclonal antibody 231. Jeglum KA. **Vet Clin North Am Small Anim Pract** 1996 Jan;26(1):73–85 (19 ref.)

The role of radiotherapy in the treatment of lymphoma and thymoma. Meleo KA. **Vet Clin North Am Small Anim Pract** 1997 Jan;27(1):115–29 (36 ref.)

Lymphoma in dogs: chemotherapy. Rosenthal RC. **Vet Clin North Am Small Anim Pract** 1996 Jan;26(1):63–71 (49 ref.)

VIROLOGY

A new human herpesvirus as a factor in the pathogenesis of Kaposi's sarcoma and body-cavity lymphoma [comment] Sarris A. **Cancer J Sci Am** 1997 May–Jun; 3(3):140–1 (29 ref.) Comment on: Cancer J Sci Am 1997 May–Jun;3(3):153–6.

The role of Epstein–Barr virus in lymphoid malignancies. Su IJ, et al. **Crit Rev Oncol Hematol** 1997 May;26(1):25–41 (148 ref.)

The role of the immune response in MULV-induced lymphomagenesis. Marshall DJ, et al. **Leukemia** 1996 Dec; 10(12):1860–6 (79 ref.)

Diagnosis of Epstein–Barr virus-related diseases. Linde A. **Scand J Infect Dis Suppl** 1996;100:83–8 (46 ref.)

[Opportunistic lymphoma] Katano H, et al. **Nippon Rinsho** 1997 Feb;55(2):441–5 (17 ref.) (Eng. Abstr.) **(Jpn)**

[EBV-associated lymphoma] Mori S, et al. **Nippon Rinsho** 1997 Feb;55(2):391–3 (5 ref.) (Eng. Abstr.) **(Jpn)**

LYMPHOMA, AIDS-RELATED

Pulmonary complications of HIV-associated malignancies. White DA. **Clin Chest Med** 1996 Dec;17(4):755–61 (72 ref.)

Malignant tumors in patients with HIV infection. Tirelli U, et al. **Crit Rev Oncol Hematol** 1996 Nov;24(3):165–84 (142 ref.)

AIDS primary central nervous system lymphoma. Flinn IW, et al. **Curr Opin Oncol** 1996 Sep;8(5):373–6 (32 ref.)

AIDS lymphoma. Sandler AS, et al. **Curr Opin Oncol** 1996 Sep;8(5):377–85 (71 ref.)

Primary lymphoma of the liver in AIDS. Report of one new case and review of the literature. Scerpella EG, et al. **J Clin Gastroenterol** 1996 Jan;22(1):51–3 (20 ref.)

Human immunodeficiency virus-associated lymphomas. Straus DJ. **Med Clin North Am** 1997 Mar;81(2):495–510 (73 ref.)

DIAGNOSIS

AIDS-related non-Hodgkin's lymphoma of the pancreas. Jones WF, et al. **Am J Gastroenterol** 1997 Feb;92(2):335–8 (29 ref.)

The coexistence of primary esophageal lymphoma and Candida glabrata esophagitis presenting as dysphagia and odynophagia in a patient with acquired immunodeficiency syndrome. Marnejon T, et al. **Am J Gastroenterol** 1997 Feb; 92(2):354–6 (10 ref.)

Diagnosis and management of systemic non-Hodgkin's lymphoma in HIV disease. Sandler AS, et al. **Hematol Oncol Clin North Am** 1996 Oct;10(5):1111–24 (53 ref.)

Small-cell noncleaved non-Hodgkin's lymphoma of the mandible in previously unrecognized human immunodeficiency virus infection: report of a case. Stolarski CR, et al. **J Oral Maxillofac Surg** 1997 Aug; 55(8):853–6 (18 ref.)

Primary central nervous system lymphoma in patients with AIDS. Ruiz A, et al. **Neuroimaging Clin N Am** 1997 May; 7(2):281–96 (44 ref.)

DRUG THERAPY

Treatment of Burkitt's lymphoma in HIV-positive patients. Straus DJ. **Biomed Pharmacother** 1996;50(9):447–50 (29 ref.)

Malignant lymphomas in patients with HIV infection. Tirelli U, et al. **Leuk Lymphoma** 1996 Jul;22(3–4):245–57 (95 ref.)

EPIDEMIOLOGY

Primary non-Hodgkin's lymphoma of the cranial vault. Bhatia S, et al. **Clin Oncol (R Coll Radiol)** 1997;9(3):195–6 (7 ref.)

ETIOLOGY

Etiology and pathogenesis of AIDS-related non--Hodgkin's lymphoma. Knowles DM. **Hematol Oncol Clin North Am** 1996 Oct;10(5):1081–109 (176 ref.)

[Malignant neoplasms and AIDS. Review of the literature and critical considerations on a case of epidermoid carcinoma of the anus] Romito A, et al. **Recenti Prog Med** 1997 Jul–Aug;88(7–8):348–55 (48 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Cutaneous T-cell lymphoma of the eyelid in a patient with acquired immunodeficiency syndrome. Gibertson EO, et al. **Cutis** 1996 Jun;57(6):437–40 (31 ref.)

T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL). Bunn PA Jr, et al. **J Cell Biochem Suppl** 1996;24:12–23 (125 ref.)

Primary cerebellar T-cell lymphoma with acquired immunodeficiency syndrome. Embil JM, et al. **J Neurovirol** 1997 Jun;3(3):229–32 (14 ref.)

Malignant lymphomas in patients with HIV infection. Tirelli U, et al. **Leuk Lymphoma** 1996 Jul;22(3–4):245–57 (95 ref.)

[AIDS-related primary central nervous system lymphoma] Hojo I. **No To Shinkei** 1997 Jan;49(1):19–24 (23 ref.) **(Jpn)**

[Spontaneous bacterial peritonitis and primary hepatic lymphoma in a female patient with human immunodeficiency virus infection (letter)] Sancho JM, et al. **Med Clin (Barc)** 1997 Feb 15;108(6):238 (7 ref.) **(Spa)**

RADIOGRAPHY

Imaging of pulmonary lymphomas. Lee KS, et al. **AJR Am J Roentgenol** 1997 Feb;168(2):339–45 (44 ref.)

[AIDS-associated illnesses in radiologic diagnosis: overview and differential diagnosis] Rademaker J, et al. **Aktuelle Radiol** 1997 Mar;7(2):69–73 (30 ref.) **(Ger)**

[Sinus involvement in a patient with human immunodeficiency virus infection] Carratalá C, et al. **Rev Clin Esp** 1997 Jun;197(6):447–8 (9 ref.) **(Spa)**

RADIOTHERAPY

A comparison of survival of patients treated for AIDS-related central nervous system lymphoma with and without tissue diagnosis. Kaufmann T, et al. **Int J Radiat Oncol Biol Phys** 1996 Sep 1;36(2):429–32 (16 ref.)

THERAPY

Management of histologically aggressive lymphomas with a high risk of CNS disease. Horak ID, et al. **Baillieres Clin Haematol** 1996 Dec;9(4):707–26 (60 ref.)

Biology and management of AIDS-associated primary CNS lymphomas. Forsyth PA, et al. **Hematol Oncol Clin North Am** 1996 Oct;10(5):1125–34 (49 ref.)

VIROLOGY

Human herpesvirus-8-associated body cavity-based lymphoma in human immunodeficiency virus-infected patients: a unique B-cell neoplasm. Karcher DS, et al. **Hum Pathol** 1997 Jul;28(7):801–8 (47 ref.)

LYMPHOMA, ATYPICAL DIFFUSE SMALL LYMPHOID see **LYMPHOMA, SMALL CLEAVED-CELL, DIFFUSE**

LYMPHOMA, B-CELL

Primary renal lymphoma. Case report and review of the literature. Saito S. **Urol Int** 1996;56(3):192–5 (17 ref.)

[Primary malignant lymphoma of corpus uteri] Wu X, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Feb;31(2):122–4 (8 ref.) **(Chi)**

[Progress and view of the studies on intravascular malignant lymphomatosis] Mannen T. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1476–7 (10 ref.) (Eng. Abstr.) **(Jpn)**

[B-cell lymphoma and low aggressiveness: from the historical paradigm of a clinico-biological entity to the challenge of an effective therapeutic strategy] Sánchez Fayos J, et al. **Sangre (Barc)** 1996 Oct;41(5):367–77 (116 ref.) **(Spa)**

CLASSIFICATION

Mantle-cell lymphoma: classification and therapeutic implications. Fisher RI. **Ann Oncol** 1996;7 Suppl 6:S35–9 (38 ref.)

Primary B-cell lymphomas of the skin. Kerl H, et al. **Ann Oncol** 1997;8 Suppl 2:29–32 (26 ref.)

COMPLICATIONS

Malignant B-cell lymphoma in an infant with severe combined immunodeficiency with short-limbed skeletal dysplasia. van den Berg H, et al. **Acta Paediatr** 1997 Jul; 86(7):778–80 (10 ref.)

Sick sinus syndrome in association with malignant lymphoma [letter] Suzuki T, et al. **Eur Heart J** 1996 Jun;17(6):968 (5 ref.)

Angiotropic B-cell lymphoma presenting with progressive dementia: an autopsy case and review of the literature in Japan. Hayashi T, et al. **Intern Med** 1995 Nov;34(11):1134–9 (29 ref.)

Case report: primary splenic non-Hodgkin's B cell lymphoma in a patient with chronic hepatitis C. Fukutomi T, et al. **J Gastroenterol Hepatol** 1996 Aug;11(8):724–7 (29 ref.)

A case report of Down syndrome and centroblastic lymphoma. Satge D, et al. **Pathol Res Pract** 1996 Dec; 192(12):1266–9 (22 ref.)

[Malignant lymphoma of the chest wall in a patient with chronic empyema] Nishiyama N, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 May; 34(5):579–85 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Pyothorax-associated lymphoma: EBV-positive lymphoma developing in immunocompetent patients] Kanno H, et al. **Nippon Rinsho** 1997 Feb;55(2):436–40 (17 ref.) (Eng. Abstr.) **(Jpn)**

[A case of jejunal malignant lymphoma resulting in perforation 2 years after transcatheter arterial embolization for hepatocellular carcinoma] Yokohama A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Aug;93(8):578–82 (21 ref.) **(Jpn)**

DIAGNOSIS

The medium cell sIg+, proplasmocytic lymphoma/leukemia. Positive and differential diagnosis with other B-lymphoblastoid neoplasias [editorial] Mathé G, et al. **Biomed Pharmacother** 1996;50(9):425–32 (23 ref.)

PCR-based alternative for diagnosis of immunoglobulin heavy chain gene rearrangement: principles, practice, and polemics. Diaz-Cano S. **Diagn Mol Pathol** 1996 Mar; 5(1):3–9 (34 ref.)

Intravascular lymphomatosis diagnosed by transbronchial lung biopsy. Takamura K, et al. **Eur Respir J** 1997 Apr; 10(4):955–7 (13 ref.)

A case of primary urethral lymphoma presenting as a huge mass surrounding the female urethra. Shimizu Y, et al. **Hinyokika Kiyo** 1997 Mar;43(3):229–32 (18 ref.)

Gastrobronchial fistula in untreated lymphoma. Cameron EW, et al. **J Thorac Imaging** 1996 Spring;11(2):150–2 (15 ref.)

Mantle cell lymphoma: diagnostic criteria, clinical aspects and therapeutic problems. Meusers P, et al. **Leukemia** 1997 Apr;11 Suppl 2:S60–4 (50 ref.)

A case report of Down syndrome and centroblastic lymphoma. Satge D, et al. **Pathol Res Pract** 1996 Dec; 192(12):1266–9 (22 ref.)

[Intravascular lymphomatosis of the nervous system--case report and review of the literature] Heesen C, et al. **Fortschr Neurol Psychiatr** 1996 Jun;64(6):234–41 (104 ref.) (Eng. Abstr.) **(Ger)**

[Malignant lymphoma of the penis: report of two cases] Kuwahara Y, et al. **Hinyokika Kiyo** 1997 May;43(5):371–4 (14 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Mantle-cell lymphoma: classification and therapeutic implications. Fisher RI. **Ann Oncol** 1996;7 Suppl 6:S35–9 (38 ref.)

Purine analogs in marginal-zone lymphomas. Horning SJ. **Ann Oncol** 1996;7 Suppl 6:S21–6 (34 ref.)

Immunotoxins for the treatment of B-cell lymphomas. Ghetie MA, et al. **Mol Med** 1997 Jul;3(7):420–7 (43 ref.)

Chemotherapy-induced spontaneous pneumothorax in a patient with bulky mediastinal lymphoma: a rare oncologic emergency. Stein ME, et al. **Oncology** 1997 Jan–Feb; 54(1):15–8 (18 ref.)

[Metastatic malignant melanoma in treated non-Hodgkin's lymphoma] Falk S, et al. **Hautarzt** 1996 Sep;47(9):716–8 (21 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Primary lymphoma of the gallbladder; case report and review of the literature. Chatila R, et al. **Am J Gastroenterol** 1996 Oct;91(10):2242–4 (14 ref.)

ETIOLOGY

Malignant lymphomas stem from different B cell populations. Kluin PM, et al. **Chem Immunol** 1997;67:70–84 (73 ref.)

What do chronic B cell malignancies teach us about B cell subsets? Pritsch O, et al. **Chem Immunol** 1997;67:85–101 (114 ref.)

Immunologic aspects of Helicobacter pylori infection and malignant transformation of B cells. Crabtree JE, et al. **Semin Gastrointest Dis** 1996 Jan;7(1):30–40 (111 ref.)

[Non-Hodgkin's lymphoma associated with polymyositis] Onishi S, et al. **Rinsho Ketsueki** 1997 Jul;38(7):582–6 (16 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

PCR-based alternative for diagnosis of immunoglobulin heavy chain gene rearrangement: principles, practice, and polemics. Diaz-Cano S. **Diagn Mol Pathol** 1996 Mar; 5(1):3–9 (34 ref.)

Minimal residual disease detection in B-cell malignancies by assessing IgH rearrangement. Maloum K, et al. **Hematol Cell Ther** 1997 Jun;39(3):119–24 (52 ref.)

VH gene expression in CD5 positive and CD5 negative B cell chronic lymphoid malignancies. Maloum K, et al. **Leuk Lymphoma** 1997 Feb;24(5–6):437–48 (114 ref.)

PRAD1/Cyclin D1 gene overexpression in mantle cell lymphoma. Oka K, et al. **Leuk Lymphoma** 1996 Mar; 21(1–2):37–42 (50 ref.)

Genetic lesions in mantle cell lymphoma. Ott G, et al. **Recent Results Cancer Res** 1997;143:307–19 (26 ref.)

IMMUNOLOGY

Cytotoxic T lymphocyte recognition of non-Hodgkin's B cell lymphomas. Krensky AM. **Immunol Res** 1996; 15(2):91–7 (44 ref.)

Immunotoxins for the treatment of B-cell lymphomas. Ghetie MA, et al. **Mol Med** 1997 Jul;3(7):420–7 (43 ref.)

Autoimmunity and B-cell malignancies. Dighiero G. **Verh Dtsch Ges Pathol** 1996;80:148–59 (105 ref.)

Autoantigen receptors in extranodal non-Hodgkin B-cell lymphomas. Greiner A, et al. **Verh Dtsch Ges Pathol** 1996; 80:160–8 (42 ref.)

[Clonality analysis of B-cell lymphoproliferative disorders by means of immunoglobulin heavy chain polymerase reaction] László T, et al. **Orv Hetil** 1996 Sep 8; 137(36):1963–7 (25 ref.) (Eng. Abstr.) **(Hun)**

[B cell malignancies and adhesion molecules] Kawano MM. **Rinsho Byori** 1996 Sep;Suppl 102:207–15 (17 ref.) **(Jpn)**

METABOLISM

VH gene expression in CD5 positive and CD5 negative B cell chronic lymphoid malignancies. Maloum K, et al. **Leuk Lymphoma** 1997 Feb;24(5–6):437–48 (114 ref.)

PRAD1/Cyclin D1 gene overexpression in mantle cell lymphoma. Oka K, et al. **Leuk Lymphoma** 1996 Mar; 21(1–2):37–42 (50 ref.)

PATHOLOGY

Purine analogs in marginal-zone lymphomas. Horning SJ. **Ann Oncol** 1996;7 Suppl 6:S21–6 (34 ref.)

Combining fine-needle aspiration and flow cytometric immunophenotyping in evaluation of nodal and extranodal sites for possible lymphoma: a retrospective review. Dunphy CH, et al. **Diagn Cytopathol** 1997 Mar;16(3):200–6 (16 ref.)

Marginal zone B-cell lymphomas: an appraisal. Nathwani BN, et al. **Hum Pathol** 1997 Jan;28(1):42–6 (46 ref.)

Malignant lymphoma in patients with rheumatic diseases other than Sjögren's syndrome: a clinicopathologic study of five cases and a review of the Japanese literature. Kojima M, et al. **Jpn J Clin Oncol** 1997 Apr;27(2):84–90 (43 ref.)

Cellular interactions among marrow stromal and normal/neoplastic pre-B- and B-lymphoblastic cells. Patrick CW Jr, et al. **Leuk Lymphoma** 1996 Jul; 22(3–4):205–19 (117 ref.)

The role of the CD40 antigen on malignant B cells. Planken EV, et al. **Leuk Lymphoma** 1996 Jul;22(3–4):229–35 (63 ref.)

T-cell-rich B-cell lymphoma--a distinct clinicopathologic entity? Schmidt U, et al. **Leuk Lymphoma** 1996 Sep; 23(1–2):17–24 (39 ref.)

Low-grade B-cell lymphomas of lung and lymphomatoid granulomatosis. Koss M, et al. **Pathology (Phila)** 1996; 4(1):125–39 (48 ref.)

Autoantigen receptors in extranodal non-Hodgkin B-cell lymphomas. Greiner A, et al. **Verh Dtsch Ges Pathol** 1996; 80:160–8 (42 ref.)

[Primary pulmonary lymphoma] Cadranel J, et al. **Rev Mal Respir** 1997 Apr;14(2):73–92 (122 ref.) (Eng. Abstr.) **(Fre)**

[Synopsis of primary cutaneous lymphomas] Piérard GE, et al. **Rev Med Liege** 1996 Dec;51(12):754–8 (23 ref.) **(Fre)**

[AIDS-related primary central nervous system lymphoma] Hojo I. **No To Shinkei** 1997 Jan;49(1):19–24 (23 ref.) **(Jpn)**

[Lymphoma of the marginal zone of the spleen. A case study] Navarro JT, et al. **Med Clin (Barc)** 1996 Feb 3;106(4):141–3 (15 ref.) (Eng. Abstr.) **(Spa)**

[Homogeneous clinical behavior of a group of cutaneous B-cell lymphomas] de Misa RF, et al. **Sangre (Barc)** 1995 Dec;40(6):465–70 (21 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Effects of CD40 stimulation in the prevention of human EBV-lymphomagenesis. Funakoshi S, et al. **Leuk Lymphoma** 1997 Jan;24(3–4):187–99 (32 ref.)

RADIOGRAPHY

Imaging of pulmonary lymphomas. Lee KS, et al. **AJR Am J Roentgenol** 1997 Feb;168(2):339–45 (44 ref.)

SURGERY

Primary non-Hodgkin's lymphoma of the sciatic nerve followed by localization in the central nervous system: case report and review of the literature. Roncaroli F, et al. **Neurosurgery** 1997 Mar;40(3):618–21; discussion 621–2 (11 ref.)

[Consensus of the CAO, AIO and ARO in diagnosis and therapy of primary stomach lymphoma] **Zentralbl Chir** 1996;121(7):599–602 (4 ref.) **(Ger)**

THERAPY

Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Anderson DR, et al. **Biochem Soc Trans** 1997 May;25(2):705–8 (18 ref.)

Bone marrow transplantation for low-grade B-cell malignancies [see comments] Gribben JG. **Curr Opin Oncol** 1997 Mar;9(2):117–21 (34 ref.) Comment in: Curr Opin Oncol 1997 Mar;9(2):115–6.

Prolonged corticosteroid-induced remission in primary central nervous system lymphoma: report of a case and review of the literature. Herrlinger U, et al. **Eur Neurol** 1996;36(4):241–3 (11 ref.)

Adoptive cell therapy with donor lymphocytes for EBV-associated lymphomas developing after allogeneic marrow transplants. O'Reilly RJ, et al. **Important Adv Oncol** 1996;:149–66 (172 ref.)

Adoptive immunotherapy for Epstein-Barr virus-related lymphoma. Smith CA, et al. **Leuk Lymphoma** 1996 Oct; 23(3–4):213–20 (31 ref.)

Mantle cell lymphoma: diagnostic criteria, clinical aspects and therapeutic problems. Meusers P, et al. **Leukemia** 1997 Apr;11 Suppl 2:S60–4 (50 ref.)

VIROLOGY

The association of the Epstein-Barr virus with malignant lymphoma. Chang KL, et al. **Biomed Pharmacother** 1996; 50(9):459–67 (113 ref.)

Epstein-Barr virus and its possible role in the pathogenesis of B-cell lymphomas. Oudejans JJ, et al. **Crit Rev Oncol Hematol** 1997 Feb;25(2):127–38 (133 ref.)

Adoptive immunotherapy for Epstein-Barr virus-related lymphoma. Smith CA, et al. **Leuk Lymphoma** 1996 Oct; 23(3–4):213–20 (31 ref.)

[Pyothorax-associated lymphoma: EBV-positive lymphoma developing in immunocompetent patients] Kanno H, et al. **Nippon Rinsho** 1997 Feb;55(2):436–40 (17 ref.) (Eng. Abstr.) **(Jpn)**

LYMPHOMA, BOVINE see **ENZOOTIC BOVINE LEUKOSIS**

LYMPHOMA, BURKITT'S see **BURKITT'S LYMPHOMA**

LYMPHOMA, CENTROCYTIC SMALL-CELL see **LYMPHOMA, SMALL CLEAVED-CELL, DIFFUSE**

LYMPHOMA, CONVOLUTED T-CELL see **LYMPHOMA, LYMPHOBLASTIC**

LYMPHOMA, DIFFUSE

Management of histologically indolent non-Hodgkin's lymphomas. Solal-Celigny P. **Baillieres Clin Haematol** 1996 Dec;9(4):669–87 (106 ref.)

COMPLICATIONS

[Non-Hodgkin's lymphoma associated with cold agglutinin disease] Niitsu N, et al. **Rinsho Ketsueki** 1997 Jul; 38(7):587–92 (12 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

[Non-Hodgkin's lymphoma associated with polymyositis] Onishi S, et al. **Rinsho Ketsueki** 1997 Jul;38(7):582–6 (16 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Clinicopathological studies on coexisting gastric malignant lymphoma and gastric adenocarcinoma: report of four cases and review of the Japanese literature. Ishihama T, et al. **Jpn J Clin Oncol** 1997 Apr;27(2):101–6 (24 ref.)

VETERINARY

Tumours of the haematopoietic system. Barthold SW. **IARC Sci Publ** 1996;(126):365–83 (74 ref.)

Diagnostic exercise: sheep with enlarged lymph nodes. Rand MS. **Lab Anim Sci** 1996 Jun;46(3):335–7 (10 ref.)

LYMPHOMA, DIFFUSE, LARGE FOLLICULAR CENTER-CELL see **LYMPHOMA, LARGE-CELL, DIFFUSE**

LYMPHOMA, FOLLICULAR

Management of histologically indolent non-Hodgkin's lymphomas. Solal-Celigny P. **Baillieres Clin Haematol** 1996 Dec;9(4):669–87 (106 ref.)

DRUG THERAPY

Purine nucleoside therapy of low-grade follicular lymphoma. Piro LD. **Ann Oncol** 1996;7 Suppl 6:S41–7 (50 ref.)

Burkitt's lymphoma-leukemia in patients treated for Hodgkin's disease. Salloum E, et al. **Cancer Invest** 1996; 14(6):527–33 (47 ref.)

ETIOLOGY

Malignant lymphomas stem from different B cell populations. Kluin PM, et al. **Chem Immunol** 1997;67:70–84 (73 ref.)

GENETICS

Transformation of follicular lymphoma with both t(14;18) and t(8;22). Bisiau H, et al. **Nouv Rev Fr Hematol** 1995; 37(4):241–4 (12 ref.)

PATHOLOGY

Histological transformation of indolent (follicular) lymphoma. Ottensmeier C, et al. **Ann Oncol** 1996 Oct; 7(8):849–53 (31 ref.)

Malignant lymphomas with a follicular growth pattern. Isaacson PG. **Histopathology** 1996 Jun;28(6):487–95 (37 ref.)

THERAPY

Follicular lymphoma: grounds for optimism. Lister TA. **Ann Oncol** 1997;8 Suppl 1:89–92 (41 ref.)

Aggressive treatment in follicular non-Hodgkin's lymphoma. Schouten HC. **Br J Hosp Med** 1996 Nov 20–Dec 10; 56(10):525–8 (32 ref.)

Current management of follicular lymphoma. Gupta RK, et al. **Curr Opin Oncol** 1996 Sep;8(5):360–5 (49 ref.)

[Current status of therapy of follicular germ center lymphoma and mantel cell lymphoma] Hiddemann W, et al. **Internist (Berl)** 1997 Feb;38(2):122–34 (67 ref.) **(Ger)**

LYMPHOMA, GIANT FOLLICULAR see **LYMPHOMA, FOLLICULAR**

LYMPHOMA, HIGH-GRADE

DIAGNOSIS

The coexistence of primary esophageal lymphoma and Candida glabrata esophagitis presenting as dysphagia and odynophagia in a patient with acquired immunodeficiency syndrome. Marnejon T, et al. **Am J Gastroenterol** 1997 Feb; 92(2):354–6 (10 ref.)

DRUG THERAPY

Primary cerebral lymphoma--a case report and review of the management. Li Q, et al. **Ann Acad Med Singapore** 1995 Nov;24(6):856–9 (25 ref.)

Cladribine in the treatment of low-grade non-Hodgkin's lymphoma. Piro LD. **Semin Hematol** 1996 Jan;33(1 Suppl 1):34–9 (37 ref.)

PATHOLOGY

Acute liver failure due to hepatic involvement by hematologic malignancy. Shehab TM, et al. **Dig Dis Sci** 1997 Jul;42(7):1400–5 (28 ref.)

[Primary pulmonary lymphoma] Cadranel J, et al. **Rev Mal Respir** 1997 Apr;14(2):73–92 (122 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Effects of CD40 stimulation in the prevention of human EBV-lymphomagenesis. Funakoshi S, et al. **Leuk Lymphoma** 1997 Jan;24(3–4):187–99 (32 ref.)

THERAPY

[Therapy of recurrent high-grade non-Hodgkin's lymphoma] Schmitz N. **Internist (Berl)** 1997 Feb;38(2):143–9 (42 ref.) **(Ger)**

LYMPHOMA, HISTIOCYTIC see **LYMPHOMA, LARGE-CELL**

LYMPHOMA, HISTIOCYTIC, DIFFUSE see **LYMPHOMA, LARGE-CELL, DIFFUSE**

LYMPHOMA, HIV-RELATED see **LYMPHOMA, AIDS-RELATED**

LYMPHOMA, INTERMEDIATE-GRADE

COMPLICATIONS

[Malignant lymphoma of the chest wall in a patient with chronic empyema] Nishiyama N, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 May; 34(5):579–85 (15 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Histological transformation of indolent (follicular) lymphoma. Ottensmeier C, et al. **Ann Oncol** 1996 Oct; 7(8):849–53 (31 ref.)

Factors that influence prognosis of intermediate-grade lymphomas at relapse. Rodriguez MA. **Cancer Treat Res** 1996;85:79–86 (19 ref.)

LYMPHOMA, KI-1 see **LYMPHOMA, LARGE-CELL, KI-1**

LYMPHOMA, LARGE-CELL

Primary lymphoma of the liver in AIDS. Report of one new case and review of the literature. Scerpella EG, et al. **J Clin Gastroenterol** 1996 Jan;22(1):51–3 (20 ref.)

CLASSIFICATION

True histiocytic lymphoma: is it an entity? Elghetany MT. **Leukemia** 1997 May;11(5):762–4 (32 ref.)

COMPLICATIONS

Hypercalcemia may indicate Richter's syndrome: report of four cases and review. Beaudreuil J, et al. **Cancer** 1997 Mar 15;79(6):1211–5 (33 ref.)

DIAGNOSIS

The coexistence of primary esophageal lymphoma and Candida glabrata esophagitis presenting as dysphagia and odynophagia in a patient with acquired immunodeficiency syndrome. Marnejon T, et al. **Am J Gastroenterol** 1997 Feb; 92(2):354–6 (10 ref.)

[Malignant endovascular large-cell lymphoma: disclosing central nervous system involvement confirmed by cerebral biopsy] Viguier A, et al. **Rev Med Interne** 1997;18(6):481–4 (18 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Primary cerebral lymphoma—a case report and review of the management. Li Q, et al. **Ann Acad Med Singapore** 1995 Nov;24(6):856–9 (25 ref.)

Is CHOP the standard of therapy for poor-prognosis large-cell lymphoma? Canellos GP. **Ann Oncol** 1997;8 Suppl 1:61–2 (7 ref.)

EPIDEMIOLOGY

Primary non-Hodgkin's lymphoma of the cranial vault. Bhatia S, et al. **Clin Oncol (R Coll Radiol)** 1997;9(3):195–6 (7 ref.)

ETIOLOGY

Primary intestinal Hodgkin's disease complicating ileal Crohn's disease. Kelly MD, et al. **Aust N Z J Surg** 1997 Jul;67(7):485–9 (38 ref.)

Malignant lymphomas stem from different B cell populations. Kluin PM, et al. **Chem Immunol** 1997;67:70–84 (73 ref.)

IMMUNOLOGY

Case report: primary CD30 (Ki-1)-positive anaplastic large cell lymphoma of the duodenum. Yoshikawa I, et al. **Dig Dis Sci** 1996 Dec;41(12):2343–7 (17 ref.)

MORTALITY

Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Chan JK, et al. **Blood** 1997 Jun 15;89(12):4501–13 (84 ref.)

PATHOLOGY

Interdigitating reticulum-cell sarcoma of the intestine: a case report and review of the literature. Banner B, et al. **Diagn Cytopathol** 1997 Sep;17(3):216–22 (23 ref.)

CD11c integrin gene promoter activity during myeloid differentiation. Córbi AL, et al. **Leuk Lymphoma** 1997 May; 25(5–6):415–25 (67 ref.)

True histiocytic lymphoma: is it an entity? Elghetany MT. **Leukemia** 1997 May;11(5):762–4 (32 ref.)

Intragraft angiotropic large-cell lymphoma of T cell-type in a long-term renal allograft recipient [see comments] Ghorbani RP, et al. **Mod Pathol** 1996 Jun;9(6):671–6 (43 ref.) Comment in: Mod Pathol 1996 Nov;9(11):1089–90.

[Anaplastic large cell lymphoma based on our clinicopathological cases] Iványi JL, et al. **Orv Hetil** 1997 Mar 30;138(13):779–84 (27 ref.) (Eng. Abstr.) **(Hun)**

[Spontaneous bacterial peritonitis and primary hepatic lymphoma in a female patient with human immunodeficiency virus infection (letter)] Sancho JM, et al. **Med Clin (Barc)** 1997 Feb 15;108(6):238 (7 ref.) **(Spa)**

RADIOGRAPHY

Malignant lymphoma. Hillemanns M, et al. **Skeletal Radiol** 1996 Jan;25(1):73–5 (14 ref.)

THERAPY

Treatment of aggressive non-Hodgkin's lymphoma in adults—are we doing any better? Hagberg H, et al. **Med Oncol** 1996 Dec;13(4):185–94 (80 ref.)

LYMPHOMA, LARGE-CELL, DIFFUSE

Mikulicz syndrome. Aleem A, et al. **JPMA J Pak Med Assoc** 1997 Apr;47(4):126–9 (21 ref.)

DIAGNOSIS

Follicular dendritic cell sarcoma mimicking diffuse large cell lymphoma: a case report. Fonseca R, et al. **Am J Hematol** 1997 Jul;55(3):148–55 (45 ref.)

A case of primary urethral lymphoma presenting as a huge mass surrounding the female urethra. Shimizu Y, et al. **Hinyokika Kiyo** 1997 Mar;43(3):229–32 (18 ref.)

[Primary bilateral adrenal lymphoma as viewed by MRI. Apropos of a case] Dhôte R, et al. **J Radiol** 1997 Apr; 78(4):299–302 (20 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Primary hepatic lymphoma associated with chronic hepatitis C. Andres E, et al. **Ann Med Interne (Paris)** 1997; 148(3):280–3 (18 ref.)

GENETICS

BCL-6 in diffuse large-cell lymphomas. Dalla-Favera R, et al. **Important Adv Oncol** 1996;:139–48 (49 ref.)

METABOLISM

Bcl-6 protein expression in normal and neoplastic lymphoid tissues. Falini B, et al. **Ann Oncol** 1997;8 Suppl 2:101–4 (28 ref.)

SURGERY

Primary non-Hodgkin's lymphoma of the sciatic nerve followed by localization in the central nervous system: case report and review of the literature. Roncaroli F, et al. **Neurosurgery** 1997 Mar;40(3):618–21; discussion 621–2 (11 ref.)

LYMPHOMA, LARGE-CELL, DIFFUSE, UNDIFFERENTIATED see **LYMPHOMA, LARGE-CELL, DIFFUSE**

LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC

see related
LYMPHOMA, T-CELL, PERIPHERAL

LYMPHOMA, LARGE-CELL, KI-1

see related
ANTIGENS, CD30

Spectrum of CD30 lymphoproliferative diseases from lymphomatoid papulosis to anaplastic large cell lymphoma. Louvet S, et al. **Int J Dermatol** 1996 Dec;35(12):842–8 (61 ref.)

[(CD30+) anaplastic large-cell lymphoma (Ki-1 anaplastic lymphoma)] Liozon E, et al. **Ann Med Interne (Paris)** 1996; 147(8):553–66 (178 ref.) **(Fre)**

COMPLICATIONS

A case of lymphomatoid papulosis occurred simultaneously with Ki-1-positive anaplastic large cell lymphoma. Lee NS, et al. **Korean J Intern Med** 1997 Jan;12(1):84–8 (19 ref.)

PATHOLOGY

Lymphomatoid papulosis and cutaneous CD30+ lymphoma. LeBoit PE. **Am J Dermatopathol** 1996 Jun;18(3):221–35 (61 ref.)

Anaplastic Ki-1-positive large cell lymphoma of the pancreas: a case report and review of the literature. Maruyama H, et al. **Jpn J Clin Oncol** 1997 Feb;27(1):51–7 (25 ref.)

A case of lymphomatoid papulosis occurred simultaneously with Ki-1-positive anaplastic large cell lymphoma. Lee NS, et al. **Korean J Intern Med** 1997 Jan;12(1):84–8 (19 ref.)

The clinicopathological features of anaplastic large cell lymphomas expressing p80NPM/ALK. Shiota M, et al. **Leuk Lymphoma** 1996 Sep;23(1–2):25–32 (25 ref.)

RADIOTHERAPY

Ki-1 skin lymphoproliferative disorders: management with radiation therapy. Kaufmann TP, et al. **Cancer Invest** 1997; 15(2):91–7 (30 ref.)

LYMPHOMA, LARGE LYMPHOID, DIFFUSE see **LYMPHOMA, LARGE-CELL, DIFFUSE**

LYMPHOMA, LOW-GRADE

Low-grade non-Hodgkin's lymphoma—biology and therapeutic approaches. Bentley M, et al. **Aust N Z J Med** 1997 Apr;27(2):150–5 (44 ref.)

[B-cell lymphoma and low aggressiveness: from the historical paradigm of a clinico-biological entity to the challenge of an effective therapeutic strategy] Sánchez Fayos J, et al. **Sangre (Barc)** 1996 Oct;41(5):367–77 (116 ref.) **(Spa)**

CLASSIFICATION

New classification of low-grade lymphoma. Grogan TM. **Ann Oncol** 1996;7 Suppl 6:S3–12 (37 ref.)

Classification and clinical course of low-grade non-Hodgkin's lymphomas with overview of therapy. Vose JM. **Ann Oncol** 1996;7 Suppl 6:S13–9 (57 ref.)

DIAGNOSIS

MR imaging of primary non-Hodgkin's breast lymphoma. A case report. Mussurakis S, et al. **Acta Radiol** 1997 Jan; 38(1):104–7 (14 ref.)

DRUG THERAPY

Purine nucleoside therapy of low-grade follicular lymphoma. Piro LD. **Ann Oncol** 1996;7 Suppl 6:S41–7 (50 ref.)

PCR monitoring of response in patients treated with high-dose chemotherapy for low-grade lymphoma. Gribben JG. **Cancer Treat Res** 1996;85:141–60 (58 ref.)

Cladribine for the treatment of indolent non-Hodgkin's lymphomas. Hoffman MA. **Semin Hematol** 1996 Jan;33(1 Suppl 1):40–4 (23 ref.)

[Metastatic malignant melanoma in treated non-Hodgkin's lymphoma] Falk S, et al. **Hautarzt** 1996 Sep;47(9):716–8 (21 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Molecular pathology of low grade malignant lymphomas. Ratech H. **Med Oncol** 1995 Sep;12(3):167–76 (101 ref.)

PATHOLOGY

New classification of low-grade lymphoma. Grogan TM. **Ann Oncol** 1996;7 Suppl 6:S3–12 (37 ref.)

Low-grade lymphomas: new entities and treatment concepts. Hagemeister FB. **Med Oncol** 1995 Sep;12(3):131–42 (90 ref.)

Molecular pathology of low grade malignant lymphomas. Ratech H. **Med Oncol** 1995 Sep;12(3):167–76 (101 ref.)

Low-grade B-cell lymphomas of lung and lymphomatoid granulomatosis. Koss M, et al. **Pathology (Phila)** 1996; 4(1):125–39 (48 ref.)

[Primary pulmonary lymphoma] Cadranel J, et al. **Rev Mal Respir** 1997 Apr;14(2):73–92 (122 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Classification and clinical course of low-grade non-Hodgkin's lymphomas with overview of therapy. Vose JM. **Ann Oncol** 1996;7 Suppl 6:S13–9 (57 ref.)

Low-grade lymphomas: new entities and treatment concepts. Hagemeister FB. **Med Oncol** 1995 Sep;12(3):131–42 (90 ref.)

LYMPHOMA, LYMPHOBLASTIC

see related
LEUKEMIA, T-CELL, ACUTE

[Epstein-Barr virus (EBV)-positive NK cell line YT, and ALL/LBL of NK-lineage] Tani A, et al. **Rinsho Byori** 1996 Oct;44(10):936–43 (28 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Case report: magnetic resonance imaging of primary lymphoma of the cauda equina. Ooi GC, et al. **Br J Radiol** 1996 Nov;69(827):1057–60 (13 ref.)

GENETICS

Coexistent T-cell lymphoblastic lymphoma and an atypical myeloproliferative disorder associated with t(8;13)(p21;q14). Somers GR, et al. **Pediatr Pathol Lab Med** 1997 Jan–Feb;17(1):141–58 (58 ref.)

LYMPHOMA, LYMPHOBLASTIC, CONVOLUTED see **LYMPHOMA, LYMPHOBLASTIC**

LYMPHOMA, LYMPHOBLASTIC, DIFFUSE see **LYMPHOMA, LYMPHOBLASTIC**

LYMPHOMA, LYMPHOBLASTIC, LARGE-CELL see **LYMPHOMA, LYMPHOBLASTIC**

LYMPHOMA, LYMPHOBLASTIC, NONCONVOLUTED see **LYMPHOMA, LYMPHOBLASTIC**

LYMPHOMA, LYMPHOCYTIC see **LYMPHOMA, SMALL-CELL**

LYMPHOMA, LYMPHOCYTIC, DIFFUSE, INTERMEDIATE DIFFERENTIATION see **LYMPHOMA, SMALL CLEAVED-CELL, DIFFUSE**

LYMPHOMA, LYMPHOCYTIC, DIFFUSE, POORLY-DIFFERENTIATED see **LYMPHOMA, SMALL CLEAVED-CELL, DIFFUSE**

LYMPHOMA, LYMPHOCYTIC, DIFFUSE, WELL-DIFFERENTIATED see **LYMPHOMA, SMALL LYMPHOCYTIC**

LYMPHOMA, LYMPHOCYTIC, PLASMACYTOID see **LYMPHOMA, SMALL-CELL**

LYMPHOMA, LYMPHOCYTIC, WELL-DIFFERENTIATED see **LYMPHOMA, SMALL LYMPHOCYTIC**

LYMPHOMA, LYMPHOPLASMACYTOID, CLL see **LYMPHOMA, SMALL LYMPHOCYTIC**

LYMPHOMA, MALIGNANT see **LYMPHOMA**

LYMPHOMA, MEDITERRANEAN see **IMMUNOPROLIFERATIVE SMALL INTESTINAL DISEASE**

LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE

[From pseudolymphomas to primary pulmonary lymphomas of MALT type] Cadranel J, et al. **Presse Med** 1996 Sep 28;25(28):1285–91 (30 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

Immunological and molecular classification of mucosa-associated lymphoid tissue lymphoma. Schmitt-Gräff A. **Recent Results Cancer Res** 1996; 142:121–36 (59 ref.)

DRUG THERAPY

Purine analogs in marginal-zone lymphomas. Horning SJ. **Ann Oncol** 1996;7 Suppl 6:S21–6 (34 ref.)

ETIOLOGY

Gastric lymphoma and Helicobacter pylori. Isaacson PG, et al. **Important Adv Oncol** 1996;:111–21 (58 ref.)

IMMUNOLOGY

Autoantigen receptors in extranodal non-Hodgkin B-cell lymphomas. Greiner A, et al. **Verh Dtsch Ges Pathol** 1996; 80:160–8 (42 ref.)

MICROBIOLOGY

Gastric MALT-lymphoma and Helicobacter pylori infection. Bayerdörffer E, et al. **Aliment Pharmacol Ther** 1997 Apr; 11 Suppl 1:89–94 (32 ref.)

Helicobacter pylori, gastric cancer and gastric MALT lymphoma. Williams CN. **Can J Gastroenterol** 1996 Oct; 10(6):359–60 (13 ref.)

[Gastric lymphomas: role of Helicobacter pylori] Ruskoné-Fourmestraux A. **Presse Med** 1997 Feb 15; 26(4):184–9 (26 ref.) **(Fre)**

[Helicobacter pylori and MALT gastric lymphomas] Belaiche J. **Rev Med Liege** 1997 May;52(5):352–4 (12 ref.) **(Fre)**

[Stomach cancer and MALT lymphoma: prevention with Helicobacter pylori eradication] Fischbach W. **Dtsch Med Wochenschr** 1997 Aug 1;122(31–32):983–7 (67 ref.) **(Ger)**

[Recent progress in the management of malignant lymphoma] Ohnishi K. **Gan To Kagaku Ryoho** 1997 Jul;24(9):1074–8 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Gastric MALT lymphoma and Helicobacter pylori infection] Chiba T. **Nippon Shokakibyo Gakkai Zasshi** 1997 Apr;94(4):233–40 (57 ref.) **(Jpn)**

[Is gastric cancer an infectious disease?] Gisbert JP, et al. **Rev Esp Enferm Dig** 1996 Aug;88(8):555–62 (91 ref.) **(Spa)**

PATHOLOGY

Purine analogs in marginal-zone lymphomas. Horning SJ. **Ann Oncol** 1996;7 Suppl 6:S21–6 (34 ref.)

Biology and treatment of MALT lymphoma: the state-of-the-art in 1996. A workshop at the 6th International Conference on Malignant Lymphoma. Mucosa-Associated Lymphoid Tissue. Zucca E, et al. **Ann Oncol** 1996 Oct;7(8):787–92 (37 ref.)

Lymphoid infiltrates of the salivary glands: pathology, biology and clinical significance. DiGiuseppe JA, et al. **Curr Opin Oncol** 1996 May;8(3):232–7 (36 ref.)

Autoantigen receptors in extranodal non-Hodgkin B-cell lymphomas. Greiner A, et al. **Verh Dtsch Ges Pathol** 1996; 80:160–8 (42 ref.)

Gastric MALT lymphoma and Helicobacter pylori. Wotherspoon AC. **Yale J Biol Med** 1996 Jan–Feb; 69(1):61–8 (32 ref.)

[Association of a low-grade MALT lymphoma and a slightly differentiated adenocarcinoma of the stomach] Brocheriou I, et al. **Ann Pathol** 1997 Apr;17(2):109–12 (12 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Biology and treatment of MALT lymphoma: the state-of-the-art in 1996. A workshop at the 6th International Conference on Malignant Lymphoma. Mucosa-Associated Lymphoid Tissue. Zucca E, et al. **Ann Oncol** 1996 Oct;7(8):787–92 (37 ref.)

PREVENTION & CONTROL

[Stomach cancer and MALT lymphoma: prevention with Helicobacter pylori eradication] Fischbach W. **Dtsch Med Wochenschr** 1997 Aug 1;122(31–32):983–7 (67 ref.) **(Ger)**

RADIOGRAPHY

Non-Hodgkin's lymphoma of the gastrointestinal tract: radiographic findings. Levine MS, et al. **AJR Am J Roentgenol** 1997 Jan;168(1):165–72 (46 ref.)

SURGERY

[MALT-lymphoma--surgical therapy] Verreet PR. **Schweiz Rundsch Med Prax** 1996 Nov 5;85(45):1451–4 (53 ref.) (Eng. Abstr.) **(Ger)**

[Consensus of the CAO, AIO and ARO in diagnosis and therapy of primary stomach lymphoma] **Zentralbl Chir** 1996;121(7):599–602 (4 ref.) **(Ger)**

THERAPY

Eradication of Helicobacter pylori and regression of B-cell lymphoma. Vanagunas A. **Biomed Pharmacother** 1997; 51(4):156–60 (32 ref.)

LYMPHOMA, NODULAR see **LYMPHOMA, FOLLICULAR**

LYMPHOMA, NON-HODGKIN'S

Synchronous Hodgkin's disease and non-Hodgkin's lymphoma. Adnan E, et al. **Acta Oncol** 1996;35(6):755–7 (22 ref.)

Primary testicular non-Hodgkin's lymphoma: a clinical study and review of the literature. Sasai K, et al. **Am J Clin Oncol** 1997 Feb;20(1):59–62 (15 ref.)

Management of the histologically aggressive non-Hodgkin's lymphomas in adults. Linch DC. **Baillieres Clin Haematol** 1996 Dec;9(4):689–706 (75 ref.)

Management of paediatric lymphoma. Philip T, et al. **Baillieres Clin Haematol** 1996 Dec;9(4):769–97 (156 ref.)

Gut lymphomas. Zucca E, et al. **Baillieres Clin Haematol** 1996 Dec;9(4):727–41 (83 ref.)

Non-Hodgkin's lymphoma. Smith MR. **Curr Probl Cancer** 1996 Jan–Feb;20(1):6–77 (288 ref.)

Lymphoproliferative disorders in organ transplant recipients. Vanrenterghem Y. **Eur Radiol** 1997;7(5):665–7 (14 ref.)

Occupational exposure and malignant lymphoma. Persson B. **Int J Occup Med Environ Health** 1996;9(4):309–21 (119 ref.)

Primary lymphoma of the esophagus. Gupta NM, et al. **J Clin Gastroenterol** 1996 Oct;23(3):203–6 (21 ref.)

Primary hepatic non-Hodgkin's lymphoma in children: a case report and review of the literature. Ramos G, et al. **Med Pediatr Oncol** 1997 May;28(5):370–2 (12 ref.)

CHEMICALLY INDUCED

Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment [see comments] Georgescu L, et al. **Semin Arthritis Rheum** 1997 Jun;26(6):794–804 (98 ref.) Comment in: Semin Arthritis Rheum 1997 Jun;26(6):785–7.

CHEMISTRY

Bcl-1/cyclin D1 in malignant lymphoma. de Boer CJ, et al. **Ann Oncol** 1997;8 Suppl 2:109–17 (145 ref.)

Adhesion molecules in non-Hodgkin's lymphoma. Neff PT, et al. **Cancer Treat Res** 1996;85:119–39 (77 ref.)

CLASSIFICATION

Classification of non-Hodgkin's lymphomas. Norton AJ. **Baillieres Clin Haematol** 1996 Dec;9(4):641–52 (31 ref.)

The last revised "Euro-American classification" of lymphoid leukemias and non-Hodgkin's lymphomas: the same inaccuracies and inconsistencies in a chaotic complexity [editorial] Mathé G. **Biomed Pharmacother** 1996; 50(3–4):97–117 (44 ref.)

The influence of immunology and genetics on lymphoma classification: a historical perspective. Sreenan JJ, et al. **Cancer Invest** 1996;14(6):572–88 (163 ref.)

[Histopathology and classification of non-Hodgkin's lymphoma] Müller-Hermelink HK, et al. **Internist (Berl)** 1997 Feb;38(2):113–21 (30 ref.) **(Ger)**

[Applicability of the R.E.A.L. classification of non-Hodgkin's lymphoma in clinical practice] Carbone A. **Pathologica** 1995 Oct;87(5):473–84 (48 ref.) (Eng. Abstr.) **(Ita)**

[Classification of non-granulomatous lymphomas] Dwilewicz-Trojaczek J. **Pol Merkuriusz Lek** 1996 Dec; 1(6):424–7 (25 ref.) (Eng. Abstr.) **(Pol)**

[Non-Hodgkin's lymphoma: morphologic, immunologic and cytogenetic classification] Ristić S, et al. **Srp Arh Celok Lek** 1996 Sep–Oct;124(9–10):276–82 (30 ref.) (Eng. Abstr.) **(Scc)**

COMPLICATIONS

Malignant tumors and AIDS. Nasti G, et al. **Biomed Pharmacother** 1997;51(6–7):243–51 (78 ref.)

Minimal residual disease in non-Hodgkin's lymphoma. Schultze JL, et al. **Biomed Pharmacother** 1996;50(9):451–8 (36 ref.)

Non-Hodgkin's lymphoma presenting with biliary tract obstruction. A discussion of seven patients and a review of the literature. Fidias P, et al. **Cancer** 1995 Apr 1; 75(7):1669–77 (29 ref.)

Non-Hodgkin's lymphoma of the heart in patients infected with human immunodeficiency virus. Duong M, et al. **Clin Cardiol** 1997 May;20(5):497–502 (24 ref.)

Spinal cord compression due to concomitant primary lymphoma and Mycobacterium avium-intracellulare infection of the paravertebral muscles in an AIDS patient [letter] Moulignier A, et al. **Eur J Clin Microbiol Infect Dis** 1996 Nov;15(11):891–3 (15 ref.)

High grade non-Hodgkins stage IEB primary malignant lymphoma of the cervix and upper vagina. A case report. Papadopoulos AJ, et al. **Eur J Gynaecol Oncol** 1996; 17(6):484–6 (11 ref.)

Aggressive non-Hodgkin's lymphoma with massive involvement of the right ventricle. Tanaka T, et al. **Intern Med** 1996 Oct;35(10):826–30 (22 ref.)

Melkersson-Rosenthal syndrome with malignant pharyngeal lymphoma [letter] Kanda A, et al. **J Dermatol** 1996 Sep; 23(9):658–9 (6 ref.)

Case report: primary splenic non-Hodgkin's B cell lymphoma in a patient with chronic hepatitis C. Fukutomi T, et al. **J Gastroenterol Hepatol** 1996 Aug;11(8):724–7 (29 ref.)

Glomerulonephritis and non-Hodgkin lymphoma. Harper L, et al. **Nephrol Dial Transplant** 1997 Jul;12(7):1520–5 (40 ref.)

Sjögren's syndrome in patients with newly diagnosed untreated non-Hodgkin's lymphoma. Andonopoulos AP, et al. **Rev Rhum Engl Ed** 1997 May;64(5):287–92 (21 ref.)

Spinal epidural non-Hodgkin's lymphoma: case reports of three patients presenting with spinal cord compression. Lim CC, et al. **Singapore Med J** 1996 Oct;37(5):497–500 (19 ref.)

[Actinomycosis and non-Hodgkin's malignant lymphoma: fortuitous association?] Guerci AP, et al. **Rev Med Interne** 1996;17(7):571–5 (15 ref.) (Eng. Abstr.) **(Fre)**

[Disseminated pneumoperitoneum during the therapy of lymphoma with methotrexate and cytosine arabinoside] Kirchner J, et al. **Dtsch Med Wochenschr** 1996 Oct 18; 121(42):1288–91 (15 ref.) (Eng. Abstr.) **(Ger)**

[Malignant lymphoma of the chest wall in a patient with chronic empyema] Nishiyama N, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 May; 34(5):579–85 (15 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

HIV-associated lymphoma. Kaplan LD. **AIDS Clin Rev** 1997–98;:349–73 (80 ref.)

Practical role of molecular diagnostics in non-Hodgkin's lymphomas. Mauvieux L, et al. **Baillieres Clin Haematol** 1996 Dec;9(4):653–67 (51 ref.)

Diagnosis and management of systemic non-Hodgkin's lymphoma in HIV disease. Sandler AS, et al. **Hematol Oncol Clin North Am** 1996 Oct;10(5):1111–24 (53 ref.)

Primary skeletal lymphoma imaging and pathologic correlation. Cook MA, et al. **J Am Osteopath Assoc** 1996 Oct;96(10):610–2 (17 ref.)

Cardiac localization of non-Hodgkin's lymphoma: two case reports and review of the literature. Delmas-Marsalet B, et al. **Nouv Rev Fr Hematol** 1995;37(4):223–30 (40 ref.)

Non-Hodgkin's lymphoma. Shad A, et al. **Pediatr Clin North Am** 1997 Aug;44(4):863–90 (147 ref.)

Primary cardiac lymphoma: initial symptoms suggestive of gastrointestinal disease. Nakchbandi IA, et al. **South Med J** 1997 May;90(5):539–43 (32 ref.)

[Malignant lymphoma. Pathology, diagnosis, therapy] Goldschmidt H, et al. **Radiologe** 1997 Jan;37(1):1–9 (27 ref.) (Eng. Abstr.) **(Ger)**

[Lymphoma in childhood] Wunsch C, et al. **Radiologe** 1997 Jan;37(1):51–61 (48 ref.) (Eng. Abstr.) **(Ger)**

[Primary gastrointestinal localization of N-H lymphoma: authors' experience] Versaci A, et al. **G Chir** 1997 Jun–Jul; 18(6–7):340–3 (40 ref.) (Eng. Abstr.) **(Ita)**

[Primary adrenal lymphoma: review and report of a case] López Hernández E, et al. **An Med Interna** 1997 Feb; 14(2):76–8 (26 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

HIV-associated lymphoma. Kaplan LD. **AIDS Clin Rev** 1997–98;:349–73 (80 ref.)

New drugs in non-Hodgkin's lymphoma. Arbuck SG, et al. **Ann Oncol** 1997;8 Suppl 1:119–28 (98 ref.)

Ennui or not ennui, that is the question... [editorial; comment] Cheson BD. **Ann Oncol** 1996 Oct;7(8):767–9 (37 ref.) Comment on: Ann Oncol 1996 Oct;7(8):793–9.

The treatment of pediatric lymphomas: paradigms to plagiarize? Magrath IT. **Ann Oncol** 1997;8 Suppl 1:7–14 (36 ref.)

High-dose therapy for aggressive non-Hodgkin's lymphoma. Pettengell R. **Br J Hosp Med** 1996 Nov 20–Dec 10; 56(10):521–4 (15 ref.)

Infusional chemotherapy for non-Hodgkin's lymphoma. Molldrem J, et al. **Cancer Invest** 1997;15(5):465-74 (65 ref.)
High-dose chemotherapy in non-Hodgkin's lymphoma. Blay JY, et al. **Cancer Treat Res** 1996;85:87-103 (85 ref.)
The phenomenon of multidrug resistance in non-Hodgkin's lymphoma. Miller TP, et al. **Cancer Treat Res** 1996; 85:107-17 (49 ref.)
Current guidelines for the management of aggressive non-Hodgkin's lymphoma. Martelli M, et al. **Drugs** 1997 Jun;53(6):957-72 (72 ref.)
Primary ovarian non-Hodgkin's lymphoma: outcome after treatment with combination chemotherapy. Dimopoulos MA, et al. **Gynecol Oncol** 1997 Mar;64(3):446-50 (20 ref.)
High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma. Wang WS, et al. **Jpn J Clin Oncol** 1997 Jun;27(3):154-7 (26 ref.)
The lymphomas: an update for surgeons. Whalen TV, et al. **Semin Pediatr Surg** 1997 Feb;6(1):50-5 (62 ref.)

EPIDEMIOLOGY

Ultraviolet light and non-Hodgkin's lymphoma. Melbye M, et al. **Acta Oncol** 1996;35(6):655-7 (37 ref.)
The epidemiology of non-Hodgkin's lymphoma. Kirsner RS, et al. **Conn Med** 1996 Oct;60(10):579-82 (43 ref.)
Primary intestinal lymphoma: clinical and therapeutic features of 32 patients. Zinzani PL, et al. **Haematologica** 1997 May-Jun;82(3):305-8 (27 ref.)
Occupational exposure and malignant lymphoma. Persson B. **Int J Occup Med Environ Health** 1996;9(4):309-21 (119 ref.)
[Recent data on the epidemiology of non-Hodgkin lymphoma. Groupe d'Etudes des Lymphomes de l'Adulte (GELA) (editorial)] Bosly A, et al. **Pathol Biol (Paris)** 1997 Jun;45(6):449-52 (39 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Ultraviolet light and non-Hodgkin's lymphoma. Melbye M, et al. **Acta Oncol** 1996;35(6):655-7 (37 ref.)
New epidemiologic leads in the etiology of non-Hodgkin lymphoma in the elderly: the role of blood transfusion and diet. Cerhan JR. **Biomed Pharmacother** 1997;51(5):200-7 (38 ref.)
Etiology and pathogenesis of AIDS-related non--Hodgkin's lymphoma. Knowles DM.
Hematol Oncol Clin North Am 1996 Oct;10(5):1081-109 (176 ref.)
Hepatitis C virus and non-Hodgkin's lymphomas. Pozzato G, et al. **Leuk Lymphoma** 1996 Jun;22(1-2):53-60 (88 ref.)
Malignant tumours after renal transplantation. Fahlenkamp D, et al. **Scand J Urol Nephrol** 1996 Oct;30(5):357-62 (34 ref.)
[Recent insights on the pathogenesis of non-Hodgkin's lymphoma] Gaidano G, et al. **Pathologica** 1995 Dec; 87(6):595-602 (86 ref.) (Eng. Abstr.) **(Ita)**
[Malignant neoplasms and AIDS. Review of the literature and critical considerations on a case of epidermoid carcinoma of the anus] Romito A, et al.
Recenti Prog Med 1997 Jul-Aug;88(7-8):348-55 (48 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

Diagnostic and prognostic implications of genetic lesions in non-hodgkin's lymphoma. Gaidano G, et al.
Eur J Cancer 1996 Aug;32A(9):1477-82 (67 ref.)
Molecular genetic biomarkers in hematological malignancies. Bagg A, et al. **J Cell Biochem Suppl** 1996;25:165-71 (33 ref.)
Molecular pathology of acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Knowles DM. **Semin Diagn Pathol** 1997 Feb;14(1):67-82 (141 ref.)

IMMUNOLOGY

Flow cytometric immunophenotyping of non-Hodgkin's lymphomas and related disorders. Tbakhi A, et al.
Cytometry 1996 Oct 1;25(2):113-24 (90 ref.)
Autoimmunity and B-cell malignancies. Dighiero G.
Verh Dtsch Ges Pathol 1996;80:148-59 (105 ref.)
[Immunophenotyping in the diagnosis of non-Hodgkin lymphomas: a literature review] Rauh S, et al.
Bull Soc Sci Med Grand Duche Luxemb 1996;133(2):27-33 (28 ref.) **(Fre)**
[Clonality analysis of B-cell lymphoproliferative disorders by means of immunoglobulin heavy chain polymerase reaction] László T, et al. **Orv Hetil** 1996 Sep 8; 137(36):1963-7 (25 ref.) (Eng. Abstr.) **(Hun)**

MORTALITY

[p53 mutation does not determine prognosis in non-Hodgkin's lymphoma] Osada M, et al.
Gan To Kagaku Ryoho 1997 Feb;24(4):471-5 (25 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Report of a case of primary skeletal muscle lymphoma and review of the literature. Keung YK, et al.
Acta Haematol 1996;96(3):184-6 (27 ref.)
Adhesion molecules in the dissemination of non-Hodgkin's lymphomas. Pals ST, et al. **Acta Haematol** 1997; 97(1-2):73-80 (84 ref.)
The emergence of Hodgkin's disease in a patient with long-standing chronic lymphocytic leukemia--case report and review of the literature. Samuelsson J, et al.
Acta Oncol 1997;36(3):351-3 (24 ref.)
Primary non-Hodgkin's lymphoma of the common bile duct. Maymind M, et al. **Am J Gastroenterol** 1997 Sep; 92(9):1543-6 (20 ref.)
Breast lymphoma--a pathologic study of 14 cases. Tan PH, et al. **Ann Acad Med Singapore** 1996 Nov;25(6):783-90 (22 ref.)
Histological transformation of indolent (follicular) lymphoma. Ottensmeier C, et al. **Ann Oncol** 1996 Oct; 7(8):849-53 (31 ref.)
Can we improve upon the International Index? Shipp MA. **Ann Oncol** 1997;8 Suppl 1:43-7 (62 ref.)
Pathology and "molecular histology" of Hodgkin's disease and the border to non-Hodgkin's lymphomas. Hansmann ML, et al. **Baillieres Clin Haematol** 1996 Sep;9(3):459-77 (63 ref.)
Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Chan JK, et al. **Blood** 1997 Jun 15;89(12):4501-13 (84 ref.)
Can prognostic factors be applied in treatment selection for aggressive lymphoma patients? Coiffier B.
Cancer Treat Res 1996;85:53-77 (152 ref.)
Extranodal non-Hodgkin's lymphomas of the oral cavity. Jordan RC, et al. **Curr Top Pathol** 1996;90:125-46 (89 ref.)
Kaposi's sarcoma-associated herpesvirus: a lymphotropic human herpesvirus associated with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Cesarman E, et al. **Semin Diagn Pathol** 1997 Feb; 14(1):54-66 (153 ref.)
Molecular pathology of acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Knowles DM. **Semin Diagn Pathol** 1997 Feb;14(1):67-82 (141 ref.)
[Reactive angioendotheliomatosis in chronic lymphatic leukemia] Schmidt K, et al. **Hautarzt** 1996 Jul;47(7):550-5 (33 ref.) (Eng. Abstr.) **(Ger)**
[Testicular lymphomas. A clinico-pathological study of 5 cases and a review of the literature] Zamagni MD, et al. **Recenti Prog Med** 1996 Jun;87(6):275-8 (18 ref.) (Eng. Abstr.) **(Ita)**

RADIOGRAPHY

Imaging of pulmonary lymphomas. Lee KS, et al.
AJR Am J Roentgenol 1997 Feb;168(2):339-45 (44 ref.)
Non-Hodgkin's lymphoma of the gastrointestinal tract: radiographic findings. Levine MS, et al.
AJR Am J Roentgenol 1997 Jan;168(1):165-72 (46 ref.)
[Primary gastrointestinal lymphoma] Antes G. **Radiologe** 1997 Jan;37(1):35-41 (38 ref.) (Eng. Abstr.) **(Ger)**
[Sinus involvement in a patient with human immunodeficiency virus infection] Carratalá C, et al.
Rev Clin Esp 1997 Jun;197(6):447-8 (9 ref.) **(Spa)**

RADIONUCLIDE IMAGING

The continuing clinical role of gallium 67 scintigraphy in the age of receptor imaging. Front D, et al.
Semin Nucl Med 1997 Jan;27(1):68-74 (21 ref.)

RADIOTHERAPY

Radioimmunotherapy strategies for non-Hodgkin's lymphomas. Corcoran MC, et al. **Ann Oncol** 1997;8 Suppl 1:133-8 (49 ref.)
Radiation therapy for malignancies in the setting of HIV disease. Swift PS. **Oncology (Huntingt)** 1997 May; 11(5):683-94; discussion 694, 701-2 (82 ref.)
[Is there still a place for radiation therapy in the management of non-Hodgkin's lymphoma?] Hennequin C, et al.
Bull Cancer Radiother 1996;83(4):269-72 (30 ref.) **(Fre)**
[Radiotherapy of Hodgkin's and non-Hodgkin's lymphomas. Indications, techniques and outcome] Engenhart-Cabillic R, et al. **Radiologe** 1997 Jan;37(1):81-8 (34 ref.) (Eng. Abstr.) **(Ger)**
[Value of radiotherapy in disseminated high-grade non-Hodgkin's lymphoma] Kaiser U, et al.
Strahlenther Onkol 1997 Mar;173(3):136-40 (20 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Bone marrow transplantation in chronic lymphocytic leukemia and lymphomas. Pavletic ZS, et al.
Biomed Pharmacother 1996;50(3-4):118-24 (53 ref.)
[Gastric lymphomas in old age] Pannella A, et al.
Minerva Chir 1996 Jul-Aug;51(7-8):527-31 (10 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Bone marrow transplantation for non-Hodgkin's lymphoma: a review. Salzman DE, et al. **Am J Med Sci** 1997 Apr; 313(4):228-35 (32 ref.)
Vaccine strategies in non-Hodgkin's lymphomas. Brissinck J, et al. **Baillieres Clin Haematol** 1996 Dec;9(4):799-817 (89 ref.)
Lymphoblastic leukaemia and non-Hodgkin's lymphoma. Lilleyman JS, et al. **Br Med Bull** 1996 Oct;52(4):742-63 (95 ref.)
Blood stem cell transplantation in non-Hodgkin's lymphoma. Bishop MR, et al. **Cancer Invest** 1997;15(2):138-42 (55 ref.)
Bone marrow transplantation for low-grade B-cell malignancies [see comments] Gribben JG.
Curr Opin Oncol 1997 Mar;9(2):117-21 (34 ref.) Comment in: Curr Opin Oncol 1997 Mar;9(2):115-6.
Immunotherapy for non-Hodgkin's lymphoma. Longo DL. **Curr Opin Oncol** 1996 Sep;8(5):353-9 (46 ref.)
Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Nichols J, et al. **Eur J Cancer** 1997 Jan;33 Suppl 1:S34-6 (27 ref.)
Autologous stem cell transplantation in aggressive non-Hodgkin's lymphoma. Gisselbrecht C.
Hematol Cell Ther 1996 Aug;38(4):297-304 (43 ref.)
Primary cerebral non-Hodgkin's lymphoma (PCNSL): a review of new trends in management. Boiardi A, et al. **Ital J Neurol Sci** 1997 Feb;18(1):1-7 (71 ref.)
Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma: recent results and future prospects. Renner C, et al. **Leukemia** 1997 Apr;11 Suppl 2:S55-9 (41 ref.)
Treatment of lymphoma in the elderly: an update. Tirelli U, et al. **Rays** 1997 Jan-Mar;22(1 Suppl):24-9 (34 ref.)
[Malignant non-Hodgkin's lymphomas. What indications for bone marrow autotransplantation? (editorial)] Sebban C, et al. **Presse Med** 1997 May 24;26(17):810-3 (23 ref.) (Eng. Abstr.) **(Fre)**
[Immunotherapy strategies in lymphoma] Engert A, et al. **Internist (Berl)** 1997 Feb;38(2):150-6 (45 ref.) **(Ger)**
[Treatment of aggressive non-Hodgkin's lymphoma] Kaiser U, et al. **Internist (Berl)** 1997 Feb;38(2):135-42 (56 ref.) **(Ger)**
[Therapy of recurrent high-grade non-Hodgkin's lymphoma] Schmitz N. **Internist (Berl)** 1997 Feb;38(2):143-9 (42 ref.) **(Ger)**
[New developments in diagnosis and therapy of primary non-Hodgkin's lymphoma of the central nervous system] Schabet M, et al. **Nervenarzt** 1997 Apr;68(4):298-308 (91 ref.) (Eng. Abstr.) **(Ger)**
[Recent progress in the management of malignant lymphoma] Ohnishi K. **Gan To Kagaku Ryoho** 1997 Jul;24(9):1074-8 (9 ref.) (Eng. Abstr.) **(Jpn)**
[High-clore chemotherapy followed by autologous peripheral blood stem cell transplantation (PBSCT) for patients with malignant lymphoma--its role in the treatment strategy for non-Hodgkin's lymphoma, and ESHAP + PBSCT therapy] Tanosaki R, et al.
Rinsho Ketsueki 1996 Jul;37(7):591-7 (24 ref.) **(Jpn)**
[Autologous transplantation of peripheral blood stem cells in malignant lymphomas] Sánchez Luceros A, et al.
Medicina (B Aires) 1995;55(4):366-72 (30 ref.) (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

[Transesophageal cardiac echography and paracardiac tumor masses. Apropos of a case] Fakhry A, et al.
Ann Cardiol Angeiol (Paris) 1996 Nov;45(9):527-30 (11 ref.) (Eng. Abstr.) **(Fre)**
[Malignant lymphoma in childhood. Ultrasound diagnosis] Betsch B, et al. **Radiologe** 1997 Jan;37(1):62-73 (60 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

HHV-8-positive body-cavity-based lymphoma: a novel lymphoma entity. Carbone A, et al. **Br J Haematol** 1997 Jun;97(3):515-22 (40 ref.)

LYMPHOMA, PLEOMORPHIC see **LYMPHOMA, UNDIFFERENTIATED**

LYMPHOMA, SMALL-CELL

Management of histologically indolent non-Hodgkin's lymphomas. Solal-Celigny P. **Baillieres Clin Haematol** 1996 Dec;9(4):669-87 (106 ref.)

DIAGNOSIS

[Primary lymphoma of the small intestine. A clinical case report and review of the literature] Bonaccorso R, et al. **Minerva Chir** 1997 May;52(5):643-7 (13 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Adverse and beneficial immunological effects of purine nucleoside analogues. Dighiero G. **Hematol Cell Ther** 1996 Dec;38 Suppl 2:S75-81 (98 ref.)

PATHOLOGY

Amyloidoma of bone, a plasma cell/plasmacytoid neoplasm. Report of three cases and review of the literature. Pambuccian SE, et al. **Am J Surg Pathol** 1997 Feb; 21(2):179-86 (55 ref.)
Demonstration of composite nodal B-cell lymphoma and subsequent Hodgkin's disease by flow cytometry and immunohistochemistry. Case report and review of the literature. Dunphy CH, et al. **Arch Pathol Lab Med** 1997 Jun;121(6):637-40 (14 ref.)

LYMPHOMA, SMALL-CELL, CENTROCYTIC see **LYMPHOMA, SMALL CLEAVED-CELL, DIFFUSE**

LYMPHOMA, SMALL CLEAVED-CELL, DIFFUSE

CLASSIFICATION

Mantle cell lymphomas. Rodriguez MA, et al. **Cancer Treat Res** 1996;85:41-50 (37 ref.)

LYMPHOMA, SMALL LYMPHOCYTIC

see related
LEUKEMIA, LYMPHOCYTIC, CHRONIC

COMPLICATIONS

Malignancy-associated pulmonary veno-occlusive disease: report of a case following autologous bone marrow transplantation and review. Salzman D, et al. **Bone Marrow Transplant** 1996 Oct;18(4):755-60 (40 ref.)

THERAPY

Malignancy-associated pulmonary veno-occlusive disease: report of a case following autologous bone marrow transplantation and review. Salzman D, et al. **Bone Marrow Transplant** 1996 Oct;18(4):755-60 (40 ref.)

LYMPHOMA, SMALL LYMPHOCYTIC, PLASMACYTOID see **LYMPHOMA, SMALL LYMPHOCYTIC**

LYMPHOMA, SMALL NONCLEAVED-CELL

DIAGNOSIS

AIDS-related non-Hodgkin's lymphoma of the pancreas. Jones WF, et al. **Am J Gastroenterol** 1997 Feb;92(2):335-8 (29 ref.)

Small-cell noncleaved non-Hodgkin's lymphoma of the mandible in previously unrecognized human immunodeficiency virus infection: report of a case. Stolarski CR, et al. **J Oral Maxillofac Surg** 1997 Aug; 55(8):853-6 (18 ref.)

DRUG THERAPY

Treatment of small non-cleaved cell lymphoma in the adult. Hagemeister FB. **Biomed Pharmacother** 1996;50(9):433-41 (47 ref.)

LYMPHOMA, T-CELL

[Primary malignant T-cell lymphoma of large intestine] Furubayashi T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Apr;94(4):278-83 (20 ref.) **(Jpn)**

CLASSIFICATION

Classification of T-cell and NK-cell neoplasms based on the REAL classification. Jaffe ES, et al. **Ann Oncol** 1997;8 Suppl 2:17-24 (77 ref.)

Aggressive primary natural killer cell lymphoma of the caecum: a case report and literature review. Lei KI, et al. **Clin Oncol (R Coll Radiol)** 1997;9(3):191-4 (23 ref.)

COMPLICATIONS

Primary sinusoidal lymphoma of the liver revealed by autoimmune hemolytic anemia. Pouderoux P, et al. **Gastroenterol Clin Biol** 1997;21(6-7):514-8 (23 ref.)

Primary adrenal lymphoma associated with adrenal insufficiency: a distinct clinical entity. Pimentel M, et al. **Leuk Lymphoma** 1997 Jan;24(3-4):363-7 (23 ref.)

Rapidly progressive T cell lymphoma presenting as acute renal failure: case report and review of the literature. Neuhauser TS, et al. **Pediatr Pathol Lab Med** 1997 May-Jun;17(3):449-60 (47 ref.)

DIAGNOSIS

Hepatic manifestation of malignant histiocytosis: a case study. Chow WC, et al. **Ann Acad Med Singapore** 1996 Nov; 25(6):804-7 (9 ref.)

Primary central nervous system lymphoma of T-cell origin: description of two cases and review of the literature. Villegas E, et al. **J Neurooncol** 1997 Sep;34(2):157-61 (28 ref.)

Rapidly progressive T cell lymphoma presenting as acute renal failure: case report and review of the literature. Neuhauser TS, et al. **Pediatr Pathol Lab Med** 1997 May-Jun;17(3):449-60 (47 ref.)

[A case of primary gastric T-cell malignant lymphoma] Ozaki M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jul; 93(7):470-4 (10 ref.) **(Jpn)**

ETIOLOGY

[A case of T-cell malignant lymphoma developing in the chest wall of chronic pyothorax after artificial pneumothorax] Kamiya I. **Nippon Kyobu Geka Gakkai Zasshi** 1996 May;44(5):709-13 (11 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Hepatosplenic gamma/delta T-cell lymphoma: a report of two cases in immunocompromised patients, associated with isochromosome 7q. François A, et al. **Am J Surg Pathol** 1997 Jul;21(7):781-90 (43 ref.)

Coexistent T-cell lymphoblastic lymphoma and an atypical myeloproliferative disorder associated with t(8;13)(p21;q14). Somers GR, et al. **Pediatr Pathol Lab Med** 1997 Jan-Feb;17(1):141-58 (58 ref.)

IMMUNOLOGY

A new immunobiological view of radiation-promoted lymphomagenesis. Coggin JH Jr, et al. **Int J Radiat Biol** 1997 Jan;71(1):81-94 (14 ref.)

PATHOLOGY

Pleomorphic medium-sized T-cell lymphoma following Hodgkin's disease (nodular sclerosis type). Gaulier A, et al. **Arch Pathol Lab Med** 1997 Apr;121(4):411-6 (27 ref.)

Angiocentric T-cell lymphoma presenting as lethal midline granuloma. Lee PY, et al. **Int J Dermatol** 1997 Jun; 36(6):419-27 (37 ref.)

Primary cerebellar T-cell lymphoma with acquired immunodeficiency syndrome. Embil JM, et al. **J Neurovirol** 1997 Jun;3(3):229-32 (14 ref.)

Intragraft angiotropic large-cell lymphoma of T cell-type in a long-term renal allograft recipient [see comments] Ghorbani RP, et al. **Mod Pathol** 1996 Jun;9(6):671-6 (43 ref.) Comment in: Mod Pathol 1996 Nov;9(11):1089-90.

Coeliac disease and lymphoma: current status. Mathus-Vliegen EM. **Neth J Med** 1996 Nov;49(5):212-20 (79 ref.)

Apoptosis of T lymphoma cells and its inhibition by monoclonal antibodies against cell surface adhesion molecules. Tsuruo T, et al. **Princess Takamatsu Symp** 1994; 24:91-8 (18 ref.)

[Primary cerebral T-cell lymphoma] Vajtai I, et al. **Orv Hetil** 1996 Mar 24;137(12):637-41 (32 ref.) (Eng. Abstr.) **(Hun)**

SURGERY

Surgically resected primary malignant lymphoma of the liver. Taketomi A, et al. **Hepatogastroenterology** 1996 May-Jun; 43(9):651-7 (24 ref.)

[Consensus of the CAO, AIO and ARO in diagnosis and therapy of primary stomach lymphoma] **Zentralbl Chir** 1996;121(7):599-602 (4 ref.) **(Ger)**

THERAPY

[Nephrotic syndrome related to chronic graft versus host disease after allogeneic bone marrow transplantation in a patient with malignant lymphoma] Haseyama K, et al. **Rinsho Ketsueki** 1996 Dec;37(12):1383-8 (20 ref.) (Eng. Abstr.) **(Jpn)**

VIROLOGY

The association of the Epstein-Barr virus with malignant lymphoma. Chang KL, et al. **Biomed Pharmacother** 1996; 50(9):459-67 (113 ref.)

Viral genetic variation, AIDS, and the multistep nature of carcinogenesis: the feline leukemia virus model. Rohn JL, et al. **Leukemia** 1996 Dec;10(12):1867-9 (31 ref.)

[Immunophenotype of nasal T-cell lymphoma] Eizuru Y, et al. **Nippon Rinsho** 1997 Feb;55(2):400-3 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical, phenotypic and genotypic aspects of nasal T-cell lymphoma and its causal association with Epstein-Barr virus] Harabuchi Y, et al. **Nippon Rinsho** 1997 Feb; 55(2):394-9 (18 ref.) (Eng. Abstr.) **(Jpn)**

LYMPHOMA, T-CELL, CUTANEOUS

DIAGNOSIS

Subcutaneous T-cell lymphoma. von den Driesch P, et al. **J Am Acad Dermatol** 1997 Feb;36(2 Pt 2):285-9 (34 ref.)

[Rare variants of cutaneous T-cell lymphomas] Goerdt S, et al. **Hautarzt** 1996 Feb;47(2):96-105 (68 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis. Rook AH, et al. **Clin Exp Immunol** 1997 Jan;107 Suppl 1:16-20 (35 ref.)

PATHOLOGY

Clinical and pathological heterogeneity in cutaneous gamma-delta T-cell lymphoma: a report of three cases and a review of the literature. Munn SE, et al. **Br J Dermatol** 1996 Dec;135(6):976-81 (17 ref.)

Cutaneous T-cell lymphoma of the eyelid in a patient with acquired immunodeficiency syndrome. Gibertson EO, et al. **Cutis** 1996 Jun;57(6):437-40 (31 ref.)

Subcutaneous T-cell lymphoma: a case report and additional observations. Sajben FP, et al. **Cutis** 1996 Oct;58(4):297-302 (42 ref.)

The dynamic interplay of malignant and benign T cells in cutaneous T-cell lymphoma. Herrick C, et al. **Dermatol Clin** 1997 Jan;15(1):149-57 (36 ref.)

Subcutaneous panniculitic T-cell lymphoma. Wang CY, et al. **Int J Dermatol** 1996 Jan;35(1):1-8 (34 ref.)

Plantar granulomatous cutaneous T-cell lymphoma. Gibson GE, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):326-8 (13 ref.)

[Synopsis of primary cutaneous lymphomas] Piérard GE, et al. **Rev Med Liege** 1996 Dec;51(12):754-8 (23 ref.) **(Fre)**

THERAPY

Proceedings of the International Consensus Conference on Cutaneous T-cell Lymphoma (CTCL) Treatment Recommendations. Boston, Massachusetts, Oct. 1 and 2, 1994. Demierre MF, et al. **J Am Acad Dermatol** 1997 Mar; 36(3 Pt 1):460-6 (44 ref.)

[Current therapy concepts in cutaneous T-cell lymphomas] Nestle FO, et al. **Schweiz Med Wochenschr** 1997 Feb 22; 127(8):311-20 (62 ref.) (Eng. Abstr.) **(Ger)**

LYMPHOMA, T-CELL, PERIPHERAL

Gamma/delta T-cell hepatosplenic lymphoma: review of the literature, diagnosis by flow cytometry and concomitant autoimmune hemolytic anemia. Sallah S, et al. **Ann Hematol** 1997 Mar;74(3):139-42 (15 ref.)

CLASSIFICATION

Classification of peripheral T-cell lymphomas: cytogenetic findings support the updated Kiel classification. Schlegelberger B, et al. **Leuk Lymphoma** 1996 Feb; 20(5-6):411-6 (54 ref.)

MORTALITY

Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Chan JK, et al. **Blood** 1997 Jun 15;89(12):4501-13 (84 ref.)

LYMPHOMA, UNDIFFERENTIATED

PATHOLOGY

Pleomorphic medium-sized T-cell lymphoma following Hodgkin's disease (nodular sclerosis type). Gaulier A, et al. **Arch Pathol Lab Med** 1997 Apr;121(4):411-6 (27 ref.)

LYMPHOMA, UNDIFFERENTIATED, DIFFUSE see **LYMPHOMA, SMALL NONCLEAVED-CELL**

LYMPHOMATOID GRANULOMATOSIS

Lymphomatoid granulomatosis: case report and review of the literature. Ng P, et al. **Australas Radiol** 1997 Feb; 41(1):57-62 (36 ref.)

DIAGNOSIS

[Lymphomatoid granulomatosis of the brain with multiple lesions on MRI] Adachi T, et al. **Rinsho Shinkeigaku** 1996 Jun;36(6):757-63 (30 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Parinaud's oculoglandular conjunctivitis and cat-scratch disease. Huang MC, et al. **Int Ophthalmol Clin** 1996 Summer;36(3):29-36 (30 ref.)

PATHOLOGY

Low-grade B-cell lymphomas of lung and lymphomatoid granulomatosis. Koss M, et al. **Pathology (Phila)** 1996; 4(1):125-39 (48 ref.)

[Primary pulmonary lymphoma] Cadranel J, et al. **Rev Mal Respir** 1997 Apr;14(2):73-92 (122 ref.) (Eng. Abstr.) **(Fre)**

LYMPHOMATOID PAPULOSIS

Spectrum of CD30 lymphoproliferative diseases from lymphomatoid papulosis to anaplastic large cell lymphoma. Louvet S, et al. **Int J Dermatol** 1996 Dec;35(12):842-8 (61 ref.)

COMPLICATIONS

A case of lymphomatoid papulosis occurred simultaneously with Ki-1-positive anaplastic large cell lymphoma. Lee NS, et al. **Korean J Intern Med** 1997 Jan;12(1):84-8 (19 ref.)

PATHOLOGY

Lymphomatoid papulosis and cutaneous CD30+ lymphoma. LeBoit PE. **Am J Dermatopathol** 1996 Jun;18(3):221-35 (61 ref.)

A case of lymphomatoid papulosis occurred simultaneously with Ki-1-positive anaplastic large cell lymphoma. Lee NS, et al. **Korean J Intern Med** 1997 Jan;12(1):84-8 (19 ref.)

LYMPHOMATOSIS VIRUS, AVIAN see **LEUKOSIS VIRUS, AVIAN**

LYMPHOPENIA

COMPLICATIONS

[Metastatic epidermoid carcinoma in idiopathic CD4+ T lymphocytopenia syndrome] Michel JL, et al. **Ann Dermatol Venereol** 1996;123(8):478–82 (24 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

M. Kansasii pulmonary disease in idiopathic CD4+ T-lymphocytopenia. Anzalone G, et al. **Eur Respir J** 1996 Aug;9(8):1754–6 (14 ref.)

IMMUNOLOGY

Organ-specific autoimmunity induced by lymphopenia. Gleeson PA, et al. **Immunol Rev** 1996 Feb;149:97–125 (99 ref.)

LYMPHOPLASMACYTOID LYMPHOMA, CLL see **LYMPHOMA, SMALL LYMPHOCYTIC**

LYMPHOPOIETIN-1 see **INTERLEUKIN-7**

LYMPHOPROLIFERATIVE DISORDERS

Chronic lymphoproliferative disorders. Montserrat E. **Curr Opin Oncol** 1997 Jan;9(1):34–41 (60 ref.)

Lymphoproliferative disorders in organ transplant recipients. Vanrenterghem Y. **Eur Radiol** 1997;7(5):665–7 (14 ref.)

[Clinical characteristics of Epstein-Barr virus-associated natural killer cell lymphoma/leukemia] Kawa K. **Nippon Rinsho** 1997 Feb;55(2):424–8 (8 ref.) (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

Classification of the posttransplant lymphoproliferative disorders: from the past to the present. Swerdlow SH. **Semin Diagn Pathol** 1997 Feb;14(1):2–7 (21 ref.)

COMPLICATIONS

Lymphoproliferative disorders and motor neuron disease: an update. Gordon PH, et al. **Neurology** 1997 Jun;48(6):1671–8 (45 ref.)

Post-transplantation lymphoproliferative disease. Savage P, et al. **QJM** 1997 Aug;90(8):497–503 (57 ref.)

Vasculitis and lymphoproliferative diseases. Wooten MD, et al. **Semin Arthritis Rheum** 1996 Oct;26(2):564–74 (125 ref.)

[Vasculitis and malignant diseases] Gran JT. **Tidsskr Nor Laegeforen** 1997 Apr 30;117(11):1627–9 (47 ref.) (Eng. Abstr.) **(Nor)**

DIAGNOSIS

Tumorous intrahepatic lymphoproliferative disorder in transplanted livers. Strouse PJ, et al. **AJR Am J Roentgenol** 1996 Nov;167(5):1159–62 (11 ref.)

Immunophenotypic characterization of acute leukemias and chronic lymphoproliferative disorders: practical recommendations and classifications. Garand R, et al. **Hematol Cell Ther** 1996 Dec;38(6):471–86 (162 ref.)

Lymphoproliferative disease of the orbit. Weber AL, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):93–111 (51 ref.)

DRUG THERAPY

Purine analogues in the management of lymphoproliferative diseases. Johnson SA. **Clin Oncol (R Coll Radiol)** 1996; 8(5):289–96 (107 ref.)

2-Chlorodeoxyadenosine: a potent antimetabolite with major activity in the treatment of indolent lymphoproliferative disorders. Saven A, et al. **Hematol Cell Ther** 1996 Dec;38 Suppl 2:S93–101 (73 ref.)

[Clinical pharmacology of 2-chlorodeoxyadenosine (Cladribine)] Góra-Tybor J, et al. **Przegl Lek** 1996; 53(8):614–8 (38 ref.) (Eng. Abstr.) **(Pol)**

EPIDEMIOLOGY

Incidence and consequences of post-transplantation lymphoproliferative disorders. Boubenider S, et al. **J Nephrol** 1997 May-Jun;10(3):136–45 (106 ref.)

ETIOLOGY

Epstein-Barr virus. A serial killer or an innocent bystander? [editorial; comment] Sangüeza OP. **Arch Dermatol** 1997 Sep;133(9):1156–7 (17 ref.) Comment on: Arch Dermatol 1997 Sep;133(9):1081–6.

Interactions involving cyclosporine A, interleukin-6, and Epstein-Barr virus lead to the promotion of B-cell lymphoproliferative disease. Tanner JE, et al. **Leuk Lymphoma** 1996 May;21(5–6):379–90 (77 ref.)

Lymphoproliferative disorders associated with congenital immunodeficiencies. Elenitoba-Johnson KS, et al. **Semin Diagn Pathol** 1997 Feb;14(1):35–47 (75 ref.)

Iatrogenic lymphoproliferative disorders in nontransplantation settings. Kamel OW. **Semin Diagn Pathol** 1997 Feb;14(1):27–34 (28 ref.)

Human immunodeficiency virus-related lymphoid proliferations. Said JW. **Semin Diagn Pathol** 1997 Feb; 14(1):48–53 (53 ref.)

GENETICS

Mechanisms that contribute to the development of lymphoid malignancies: roles for genetic alterations and cytokine production. Levy LS, et al. **Crit Rev Immunol** 1996; 16(1):31–57 (214 ref.)

Molecular genetics and lymphoproliferative disorders. Lust JA. **J Clin Lab Anal** 1996;10(6):359–67 (73 ref.)

Two brothers in a Malaysian family with X-linked lymphoproliferative disease--a case report. Hany A, et al. **Singapore Med J** 1996 Jun;37(3):325–7 (8 ref.)

IMMUNOLOGY

B cells and their fate in health and disease. Caligaris-Cappio F, et al. **Immunol Today** 1996 May;17(5):206–8 (17 ref.)

Production of cytokines by human B cells in health and disease. Pistoia V. **Immunol Today** 1997 Jul;18(7):343–50 (81 ref.)

Determination of clonality in patients who present with diagnostic dilemmas: a laboratory experience and review of the literature. Rockman SP. **Leukemia** 1997 Jun; 11(6):852–62 (61 ref.)

[Clonality analysis of B-cell lymphoproliferative disorders by means of immunoglobulin heavy chain polymerase reaction] László T, et al. **Orv Hetil** 1996 Sep 8; 137(36):1963–7 (25 ref.) (Eng. Abstr.) **(Hun)**

[Polyclonal and clonal proliferation of large granular lymphocytes] Kowal M, et al. **Pol Arch Med Wewn** 1995 Oct;94(4):349–57 (31 ref.) **(Pol)**

MICROBIOLOGY

Post-transplant EBV induced lymphoproliferative disorders. Lucas KG, et al. **Leuk Lymphoma** 1997 Mar;25(1–2):1–8 (68 ref.)

PATHOLOGY

B cells and their fate in health and disease. Caligaris-Cappio F, et al. **Immunol Today** 1996 May;17(5):206–8 (17 ref.)

Molecular pathology of posttransplantation lymphoproliferative disorders. Chadburn A, et al. **Semin Diagn Pathol** 1997 Feb;14(1):15–26 (62 ref.)

Iatrogenic lymphoproliferative disorders in nontransplantation settings. Kamel OW. **Semin Diagn Pathol** 1997 Feb;14(1):27–34 (28 ref.)

Human immunodeficiency virus-related lymphoid proliferations. Said JW. **Semin Diagn Pathol** 1997 Feb; 14(1):48–53 (53 ref.)

Classification of the posttransplant lymphoproliferative disorders: from the past to the present. Swerdlow SH. **Semin Diagn Pathol** 1997 Feb;14(1):2–7 (21 ref.)

PHYSIOPATHOLOGY

Interleukin-6: biologic properties and role in lymphoproliferative disorders. Seymour JF, et al. **Cancer Treat Res** 1996;84:167–206 (231 ref.)

PREVENTION & CONTROL

Gene-marking and haemopoietic stem-cell transplantation. Heslop HE, et al. **Blood Rev** 1995 Dec;9(4):220–5 (39 ref.)

THERAPY

Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Heslop HE, et al. **Immunol Rev** 1997 Jun;157:217–22 (39 ref.)

Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. O'Reilly RJ, et al. **Immunol Rev** 1997 Jun;157:195–216 (186 ref.)

[Adoptive immune therapy using EBV-specific CTL] Kuzushima K, et al. **Nippon Rinsho** 1997 Feb;55(2):473–8 (17 ref.) (Eng. Abstr.) **(Jpn)**

VETERINARY

Diagnostic exercise: sheep with enlarged lymph nodes. Rand MS. **Lab Anim Sci** 1996 Jun;46(3):335–7 (10 ref.)

VIROLOGY

Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Heslop HE, et al. **Immunol Rev** 1997 Jun;157:217–22 (39 ref.)

Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. O'Reilly RJ, et al. **Immunol Rev** 1997 Jun;157:195–216 (186 ref.)

The human T-cell lymphotropic viruses types I/II are not involved in T prolymphocytic leukemia and large granular lymphocytic leukemia. Pawson R, et al. **Leukemia** 1997 Aug;11(8):1305–11 (34 ref.)

Control of virus-induced lymphoproliferation: Epstein-Barr virus-induced lymphoproliferation and host immunity. Rooney CM, et al. **Mol Med Today** 1997 Jan;3(1):24–30 (44 ref.)

Molecular pathology of posttransplantation lymphoproliferative disorders. Chadburn A, et al. **Semin Diagn Pathol** 1997 Feb;14(1):15–26 (62 ref.)

[Oncogenic mechanisms of Epstein-Barr virus] Herrero JA. **Enferm Infecc Microbiol Clin** 1996 Nov;14(9):551–60 (132 ref.) **(Spa)**

[Lymphoproliferative syndromes associated to the Epstein Barr virus in organ transplants] Hidalgo M, et al. **Med Clin (Barc)** 1996 Sep 14;107(8):310–6 (116 ref.) **(Spa)**

LYMPHOPROLIFERATIVE VIRUSES see **GAMMAHERPESVIRINAE**

LYMPHOSARCOMA see **LYMPHOMA, DIFFUSE**

LYMPHOSARCOMA, BOVINE see **ENZOOTIC BOVINE LEUKOSIS**

LYMPHOSARCOMA, LYMPHOBLASTIC, DIFFUSE see **LYMPHOMA, LYMPHOBLASTIC**

LYMPHOTOXIN

Transforming growth factor-beta. Cox DA, et al. **Clin Immunol Immunopathol** 1997 Apr;83(1):25–30 (34 ref.)

GENETICS

[Idiopathic interstitial pneumonia and TNF gene restriction fragment length polymorphism] Ohe M, et al. **Nippon Rinsho** 1996 Feb;54(2):544–9 (16 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Tumour necrosis factor and lymphotoxin: molecular aspects and role in tissue-specific autoimmunity. Körner H, et al. **Immunol Cell Biol** 1996 Oct;74(5):465–72 (88 ref.)

Lymphotoxin-alpha-deficient and TNF receptor-I-deficient mice define developmental and functional characteristics of germinal centers. Matsumoto M, et al. **Immunol Rev** 1997 Apr;156:137–44 (40 ref.)

METABOLISM

Lymphotoxin: from chronic inflammation to lymphoid organs. Sacca R, et al. **J Inflamm** 1995–96;47(1–2):81–4 (14 ref.)

PHARMACOLOGY

Tumor necrosis factor and lymphotoxin: protection against oxidative stress through induction of MnSOD. Wong GH, et al. **EXS** 1996;77:321–33 (77 ref.)

THERAPEUTIC USE

Strategies for manipulating apoptosis for cancer therapy with tumor necrosis factor and lymphotoxin. Wong GH, et al. **J Cell Biochem** 1996 Jan;60(1):56–60 (29 ref.)

T-LYMPHOTROPIC VIRUS, TYPE I, SIMIAN see **STLV**

T-LYMPHOTROPIC VIRUS TYPE III ANTIBODIES, HUMAN see **HIV ANTIBODIES**

T-LYMPHOTROPIC VIRUS TYPE III ANTIGENS, HUMAN see **HIV ANTIGENS**

T-LYMPHOTROPIC VIRUS TYPE III INFECTIONS, HUMAN see **HIV INFECTIONS**

T-LYMPHOTROPIC VIRUS, TYPE III, SIMIAN see **SIV**

LYNCH SYNDROME see **COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS**

LYOPHILIZATION see **FREEZE DRYING**

LYSERGIC ACID

CHEMISTRY

Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent. Nichols DE, et al. **Behav Brain Res** 1996;73(1–2):117–9 (9 ref.)

Lysergamides revisited. Pfaff RC, et al. **NIDA Res Monogr** 1994;146:52–73 (13 ref.)

PHARMACOLOGY

Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent. Nichols DE, et al. **Behav Brain Res** 1996;73(1–2):117–9 (9 ref.)

Lysergamides revisited. Pfaff RC, et al. **NIDA Res Monogr** 1994;146:52–73 (13 ref.)

LYSERGIC ACID DIETHYLAMIDE

["Acid parties" and the return of LSD to Israel] Winkler E, et al. **Harefuah** 1996 Sep;131(5–6):176–8 (14 ref.) **(Heb)**

CHEMISTRY

Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent. Nichols DE, et al. **Behav Brain Res** 1996;73(1–2):117–9 (9 ref.)

PHARMACOLOGY

Stereoselective pharmacological effects of lysergic acid

amides possessing chirality in the amide substituent. Nichols DE, et al. **Behav Brain Res** 1996;73(1-2):117-9 (9 ref.)
Molecular modeling of the interaction of LSD and other hallucinogens with 5-HT2 receptors. Westkaemper RB, et al. **NIDA Res Monogr** 1994;146:263-83 (32 ref.)

URINE

Screening for drugs of abuse (II): Cannabinoids, lysergic acid diethylamide, buprenorphine, methadone, barbiturates, benzodiazepines and other drugs. Simpson D, et al. **Ann Clin Biochem** 1997 Sep;34 (Pt 5):460-510 (408 ref.)

LYSERGIDE see **LYSERGIC ACID DIETHYLAMIDE**

LYSINE

The metabolic roles, pharmacology, and toxicology of lysine. Flodin NW. **J Am Coll Nutr** 1997 Feb;16(1):7-21 (118 ref.)

ANALOGS & DERIVATIVES

New quinocofactors in eukaryotes. Klinman JP. **J Biol Chem** 1996 Nov 1;271(44):27189-92 (39 ref.)
Fluorophore-linked assays for high-performance liquid chromatography postcolumn reaction detection of biotin and biocytin. Hentz NG, et al. **Methods Enzymol** 1997; 279:275-86 (11 ref.)
[New perspectives of antioxidant therapy with thiols: nacystelyn] Gillissen A. **Pneumologie** 1996 Dec;50 Suppl 3:834-7 (31 ref.) **(Ger)**

BIOSYNTHESIS

Molecular control mechanisms of lysine and threonine biosynthesis in amino acid-producing corynebacteria: redirecting carbon flow. Malumbres M, et al. **FEMS Microbiol Lett** 1996 Oct 1;143(2-3):103-14 (43 ref.)
The DAP pathway to lysine as a target for antimicrobial agents. Cox RJ. **Nat Prod Rep** 1996 Feb;13(1):29-43 (159 ref.)

DIAGNOSTIC USE

[Lysine-vasopressin test] Horiba N, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:272-4 (5 ref.) **(Jpn)**

PHYSIOLOGY

Feedback inhibition of dihydrodipicolinate synthase enzymes by L-lysine. Blickling S, et al. **Biol Chem** 1997 Mar-Apr; 378(3-4):207-10 (25 ref.)

LYSINE-SPECIFIC TRNA see **RNA, TRANSFER, LYS**

LYSOGENY

PHYSIOLOGY

[Role of prophages in the formation of antibiotic-resistant populations of Staphylococcus in the process of transformation, transduction and conjugation] Zueva VS, et al. **Antibiot Khimioter** 1996;41(10):35-42 (35 ref.) **(Rus)**

LYSOLECITHINS see **LYSOPHOSPHATIDYLCHOLINES**

LYSOPHOSPHATIDIC ACIDS see **LYSOPHOSPHOLIPIDS**

LYSOPHOSPHATIDYLCHOLINES

METABOLISM

Endocytic uptake of lysophosphatidylcholine mediated by macrophage scavenger receptor plays a major role in oxidized low density lipoprotein-induced macrophage growth. Sakai M, et al. **J Atheroscler Thromb** 1996; 2(2):81-6 (19 ref.)

LYSOPHOSPHOLIPIDS

BIOSYNTHESIS

Lysophosphatidic acid as a phospholipid mediator: pathways of synthesis. Gaits F, et al. **FEBS Lett** 1997 Jun 23; 410(1):54-8 (57 ref.)

LYSOSOMAL ELASTASE see **LEUKOCYTE ELASTASE**

LYSOSOMAL ENZYME DISORDERS see **LYSOSOMAL STORAGE DISEASES**

LYSOSOMAL STORAGE DISEASES

[Lysosomal diseases] Owada M. **Ryoikibetsu Shokogun Shirizu** 1996;(15):85-9 (15 ref.) **(Jpn)**

COMPLICATIONS

Hydrops fetalis: manifestation in lysosomal storage diseases including Farber disease. Kattner E, et al. **Eur J Pediatr** 1997 Apr;156(4):292-5 (46 ref.)
[Two siblings of galactosialidosis with marked progression of cardiac involvement during 10 years] Hisahara S, et al. **Rinsho Shinkeigaku** 1996 Apr;36(4):562-5 (17 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Lipidoses in Poland. Czartoryska B, et al. **Neurol Neurochir Pol** 1996;30 Suppl 2:13-6 (8 ref.)

METABOLISM

Lysosomal proteinosis based on decreased degradation of a specific protein, mitochondrial ATP synthase subunit C: Batten disease. Ezaki J, et al. **Adv Exp Med Biol** 1996; 389:121-8 (31 ref.)
The neuronal ceroid lipofuscinoses (Batten disease): a group of lysosomal proteinoses. Palmer DN, et al. **Adv Exp Med Biol** 1996;389:129-36 (55 ref.)

THERAPY

Bone marrow transplantation therapy for metabolic disease: animal models as predictors of success and in utero approaches. Haskins M. **Bone Marrow Transplant** 1996 Dec; 18 Suppl 3:S25-7 (18 ref.)
Therapeutic approaches to lysosomal storage diseases. Kaye EM. **Curr Opin Pediatr** 1995 Dec;7(6):650-4 (47 ref.)
[Gene therapy in lysosomal diseases] Moullier P, et al. **C R Seances Soc Biol Fil** 1996;190(1):45-51 (18 ref.) (Eng. Abstr.) **(Fre)**

LYSOSOMES

CLASSIFICATION

The taxonomy of lysosomes and related structures. Lloyd JB. **Subcell Biochem** 1996;27:1-13 (32 ref.)

DRUG EFFECTS

The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease. Schultz KR, et al. **Leuk Lymphoma** 1997 Jan;24(3-4):201-10 (59 ref.)
A review of drug-induced lysosomal disorders of the liver in man and laboratory animals. Schneider P, et al. **Microsc Res Tech** 1997 Feb 15;36(4):253-75 (145 ref.)
Lysosomes and microtubules as targets for photochemotherapy of cancer. Berg K, et al. **Photochem Photobiol** 1997 Mar;65(3):403-9 (93 ref.)

ENZYMOLOGY

Lysosomal glycosylasparaginase: a member of a family of amidases that employ a processed N-terminal threonine, serine or cysteine as a combined base-nucleophile catalyst. Aronson NN Jr. **Glycobiology** 1996 Oct;6(7):669-75 (60 ref.)
Proteinases 1: lysosomal cysteine proteinases. Kirschke H, et al. **Protein Profile** 1995;2(14):1581-643 (1237 ref.)
Intracellular organelles involved in antigen processing and the binding of peptides to class II MHC molecules. Harding CV. **Semin Immunol** 1995 Dec;7(6):355-60 (77 ref.)
[Intracellular transport of lysosomal enzyme--role of mannose-6-phosphate receptors] Czartoryska B. **Postepy Biochem** 1996;42(4):350-7 (75 ref.) **(Pol)**

METABOLISM

Structural aspects of autophagy. Seglen PO, et al. **Adv Exp Med Biol** 1996;389:103-11 (19 ref.)
The role of lysosomes in the selective concentration of mineral elements. A microanalytical study. Berry JP. **Cell Mol Biol (Noisy-le-grand)** 1996 May;42(3):395-411 (26 ref.)
Autophagic proteolysis: control and specificity. Blommaart EF, et al. **Histochem J** 1997 May;29(5):365-85 (187 ref.)
Regulation of yolk degradation, or how to make sleepy lysosomes. Fagotto F. **J Cell Sci** 1995 Dec;108 (Pt 12):3645-7 (18 ref.)
Trafficking of lysosomal membrane proteins in polarized kidney cells. Hunziker W, et al. **Nephrologie** 1996; 17(7):347-50 (22 ref.)
Origin of lysosomal proteins. Braulke T. **Subcell Biochem** 1996;27:15-49 (193 ref.)
Lysosomal metabolism of lipids. Johnson WJ, et al. **Subcell Biochem** 1996;27:239-93 (250 ref.)
Metabolite efflux and influx across the lysosome membrane. Lloyd JB. **Subcell Biochem** 1996;27:361-86 (65 ref.)
Lysosomal metabolism of proteins. Mason RW. **Subcell Biochem** 1996;27:159-90 (120 ref.)
Lysosomal nucleic acid and phosphate metabolism and related metabolic reactions. Pisoni RL. **Subcell Biochem** 1996;27:295-330 (134 ref.)
Acidification of lysosomes and endosomes. Van Dyke RW. **Subcell Biochem** 1996;27:331-60 (148 ref.)
Lysosome pharmacology and toxicology. Wattiaux R, et al. **Subcell Biochem** 1996;27:387-409 (84 ref.)
Lysosomal metabolism of glycoconjugates. Winchester BG. **Subcell Biochem** 1996;27:191-238 (210 ref.)

MICROBIOLOGY

Interaction of Salmonella with lysosomes of eukaryotic cells. García-del Portillo F. **Microbiologia** 1996 Jun;12(2):259-66 (30 ref.)

PATHOLOGY

Abnormalities of the endosomal-lysosomal system in Alzheimer's disease: relationship to disease pathogenesis. Cataldo AM, et al. **Adv Exp Med Biol** 1996;389:271-80 (44 ref.)

PHYSIOLOGY

Endosome-lysosomes, ubiquitin and neurodegeneration. Mayer RJ, et al. **Adv Exp Med Biol** 1996;389:261-9 (36 ref.)
The biogenesis of lysosomes: is it a kiss and run, continuous fusion and fission process? Storrie B, et al. **Bioessays** 1996 Nov;18(11):895-903 (65 ref.)
SNAREs and NSF in targeted membrane fusion. Hay JC, et al. **Curr Opin Cell Biol** 1997 Aug;9(4):505-12 (70 ref.)

ULTRASTRUCTURE

Node-paranode regions as local degradative centres in alpha-motor axons. Gatzinsky KP. **Microsc Res Tech** 1996 Aug 15;34(6):492-506 (117 ref.)
Lipoproteins, lipid droplets, lysosomes, and adrenocortical steroid hormone synthesis: morphological studies. Tóth IE, et al. **Microsc Res Tech** 1997 Mar 15;36(6):480-92 (107 ref.)

LYSOSTAPHIN

[Bacteriolytic enzymes produced by the staphylococci] Sugai M, et al. **Nippon Saikingaku Zasshi** 1997 Apr;52(2):461-73 (61 ref.) **(Jpn)**

LYSOZYME see **MURAMIDASE**

LYSYL OXIDASE see **PROTEIN-LYSINE 6-OXIDASE**

LYT 1 ANTIGEN see **ANTIGENS, LY**

M-CSF see **MACROPHAGE COLONY-STIMULATING FACTOR**

M PHASE see **MITOSIS**

M PHASE-PROMOTING FACTOR see **MATURATION-PROMOTING FACTOR**

MAC-1 ANTIGEN see **MACROPHAGE-1 ANTIGEN**

MACACA

PHYSIOLOGY

Motor and sensory fusion in monkeys: psychophysical measurements. Harwerth RS, et al. **Eye** 1996;10 (Pt 2):209-16 (59 ref.)

MACACA MULATTA

Effects of acute total and prolonged partial asphyxia on the central nervous system of the foetal neonatal and juvenile rhesus monkey: a review. Brann AW. **Equine Vet J Suppl** 1988 Sep;(5):25-7 (17 ref.)

ANATOMY & HISTOLOGY

Anatomic organization of the basilar pontine projections from prefrontal cortices in rhesus monkey. Schmahmann JD, et al. **J Neurosci** 1997 Jan 1;17(1):438-58 (96 ref.)

EMBRYOLOGY

Specificity of retinal ganglion cell projections in the embryonic rhesus monkey. Chalupa LM, et al. **Perspect Dev Neurobiol** 1996;3(3):223-31 (82 ref.)
Synaptic development in macaque monkey retina and its implications for other developmental sequences. Hendrickson AE. **Perspect Dev Neurobiol** 1996; 3(3):195-201 (58 ref.)
Morphogenesis of retinal ganglion cells: a model of dendritic, mosaic, and foveal development. Kirby MA, et al. **Perspect Dev Neurobiol** 1996;3(3):177-94 (71 ref.)
Spatiotemporal gradients of cell genesis in the primate retina. Rapaport DH, et al. **Perspect Dev Neurobiol** 1996; 3(3):147-59 (116 ref.)

GROWTH & DEVELOPMENT

Neurobiological bases of age-related cognitive decline in the rhesus monkey. Peters A, et al. **J Neuropathol Exp Neurol** 1996 Aug;55(8):861-74 (105 ref.)

PHYSIOLOGY

Coital and estrogen signals: a contrast in the preovulatory neuroendocrine networks of rabbits and rhesus monkeys. Spies HG, et al. **Biol Reprod** 1997 Feb;56(2):310-9 (157 ref.)
Anatomic organization of the basilar pontine projections from prefrontal cortices in rhesus monkey. Schmahmann JD, et al. **J Neurosci** 1997 Jan 1;17(1):438-58 (96 ref.)

PSYCHOLOGY

Psychobiology of early social attachment in rhesus monkeys. Clinical implications. Kraemer GW. **Ann N Y Acad Sci** 1997 Jan 15;807:401-18 (34 ref.)

MACACA MULATTA

Neurobiological bases of age-related cognitive decline in the rhesus monkey. Peters A, et al. **J Neuropathol Exp Neurol** 1996 Aug;55(8):861-74 (105 ref.)

MACAQUE see **MACACA**

MACHADO-JOSEPH DISEASE

GENETICS

[Molecular genetics of Machado-Joseph disease] Kawakami H, et al. **Nippon Rinsho** 1996 Mar;54(3):854-60 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Analyses of dominant mutations and their phenotypes: unraveling of physiological functions of retinoid and identification of the responsible gene for Machado-Joseph disease] Kakizuka A. **Seikagaku** 1997 Feb;69(2):87-103 (51 ref.) **(Jpn)**

METABOLISM

Machado-Joseph disease gene products carrying different carboxyl termini. Goto J, et al. **Neurosci Res** 1997 Aug; 28(4):373-7 (12 ref.)

MACHIAVELLIANISM

Machiavellianism: a synthesis of the evolutionary and psychological literatures. Wilson DS, et al. **Psychol Bull** 1996 Mar;119(2):285-99 (152 ref.)

Machiavellianism and management: a review of single-nation studies exclusive of the USA and cross-national studies. Corzine JB. **Psychol Rep** 1997 Feb;80(1):291-304 (46 ref.)

MACHINE INTELLIGENCE see **ARTIFICIAL INTELLIGENCE**

MACHINE LEARNING see **ARTIFICIAL INTELLIGENCE**

MACROGLOBULINEMIA see **WALDENSTROM'S MACROGLOBULINEMIA**

MACROGLOSSIA

see related
BECKWITH-WIEDEMANN SYNDROME

CONGENITAL

Transient neonatal diabetes mellitus and macroglossia. Battin M, et al. **J Perinatol** 1996 Jul-Aug;16(4):288-91 (19 ref.)

MACROGOLS see **POLYETHYLENE GLYCOLS**

MACROLIDE ANTIBIOTICS see **ANTIBIOTICS, MACROLIDE**

MACROMOLECULAR SYSTEMS

see related
POLYMERS

Organic SIMS of biologic tissue. Todd PJ, et al. **Anal Chem** 1997 Sep 1;69(17):529A-535A (22 ref.)

Use of surface plasmon resonance to probe the equilibrium and dynamic aspects of interactions between biological macromolecules. Schuck P. **Annu Rev Biophys Biomol Struct** 1997;26:541-66 (118 ref.)

Influence of excluded volume upon macromolecular structure and associations in 'crowded' media. Minton AP. **Curr Opin Biotechnol** 1997 Feb;8(1):65-9 (44 ref.)

Crystallization of biological macromolecules for X-ray diffraction studies. Gilliland GL, et al. **Curr Opin Struct Biol** 1996 Oct;6(5):595-603 (60 ref.)

Structure calculation from NMR data. Nilges M. **Curr Opin Struct Biol** 1996 Oct;6(5):617-23 (64 ref.)

Liquid water and biological systems: the most important problem in science that hardly anyone wants to see solved. Cho CH, et al. **Faraday Discuss** 1996;(103):19-27 (43 ref.)

Overview lecture. Hydration processes in biological and macromolecular systems. Finney JL. **Faraday Discuss** 1996; (103):1-18 (64 ref.)

Biomolecular structure and dynamics--experiment and theory. Forsén S, et al. **J Pharm Biomed Anal** 1996 Jan; 14(3):233-6 (33 ref.)

Self-assessing supramolecular biovectors: a new dimension in novel drug delivery systems. Vyas SP, et al. **Pharmazie** 1997 Apr;52(4):259-67 (98 ref.)

Application of the anomalous dispersion of X-rays to macromolecular crystallography. Fourme R, et al. **Prog Biophys Mol Biol** 1995;64(2-3):167-99 (111 ref.)

Macromolecular structure information and databases. The EU BRIDGE Database Project Consortium. Gray PM, et al. **Trends Biochem Sci** 1996 Jul;21(7):251-6 (42 ref.)

MACROPHAGE ACTIVATION

Molecular mechanisms of microglial activation. Zielasek J, et al. **Adv Neuroimmunol** 1996;6(2):191-22 (206 ref.)

Immune therapy with macrophages: present status and critical requirements for implementation. Bartoleyns J, et al. **Immunobiology** 1996 Oct;195(4-5):550-62 (50 ref.)

Lipopolysaccharide dependent cellular activation. Tobias PS, et al. **J Periodontal Res** 1997 Jan;32(1 Pt 2):99-103 (40 ref.)

Regional macrophage activation after injury and the compartmentalization of inflammation in trauma. Hauser CJ. **New Horiz** 1996 May;4(2):235-51 (129 ref.)

[Elimination of minimal residual leukemic cells by biological response modifiers] Yamamoto K. **Rinsho Ketsueki** 1996 Aug;37(8):666-70 (10 ref.) **(Jpn)**

DRUG EFFECTS

Immunobiology of picolinic acid. Melillo G, et al. **Adv Exp Med Biol** 1996;398:135-41 (43 ref.)

Lipopolysaccharide binding protein participation in cellular activation by LPS. Su GL, et al. **Crit Rev Immunol** 1995; 15(3-4):201-14 (97 ref.)

Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases [see comments] Mouy R, et al. **J Pediatr** 1996 Nov; 129(5):750-4 (22 ref.) Comment in: J Pediatr 1996 Nov;129(5):630-2. Comment in: J Pediatr 1997 Jun;130(6):1012.

[Mechanism of action of gold in treatment of rheumatoid arthritis] Burmester GR, et al. **Z Rheumatol** 1996 Sep-Oct; 55(5):299-306 (21 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Function of metal-ion homeostasis in the cell division cycle, mitochondrial protein processing, sensitivity to mycobacterial infection and brain function. Supek F, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):321-30 (73 ref.)

The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Eikelenboom P, et al. **Neurobiol Aging** 1996 Sep-Oct;17(5):673-80 (99 ref.)

Molecular mechanisms of microglial activation. A. Implications for regeneration and neurodegenerative diseases. Gebicke-Haerter PJ, et al. **Neurochem Int** 1996 Jul;29(1):1-12 (145 ref.)

Molecular mechanisms of microglial activation. B. Voltage- and purinoceptor-operated channels in microglia. Illes P, et al. **Neurochem Int** 1996 Jul;29(1):13-24 (63 ref.)

MACROPHAGE COLONY-STIMULATING FACTOR

see related
RECEPTORS, MACROPHAGE COLONY-STIMULATING FACTOR

ADMINISTRATION & DOSAGE

ACOS presentations for publication in the Japanese Journal of Cancer and Chemotherapy. Masaoka T. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:178-81 (1 ref.)

CHEMISTRY

Macrophage colony-stimulating-factor (M-CSF or CSF-1) and its receptor: structure-function relationships. Fixe P, et al. **Eur Cytokine Netw** 1997 Jun;8(2):125-36 (140 ref.)

Structure-function studies on human macrophage colony-stimulating factor (M-CSF). Koths K. **Mol Reprod Dev** 1997 Jan;46(1):31-7; discussion 37-8 (17 ref.)

DEFICIENCY

Macrophage differentiation and granulomatous inflammation in osteopetrotic mice (op/op) defective in the production of CSF-1. Naito M, et al. **Mol Reprod Dev** 1997 Jan; 46(1):85-91 (13 ref.)

Cytokine regulation of the macrophage (M phi) system studied using the colony stimulating factor-1-deficient op/op mouse. Wiktor-Jedrzejczak W, et al. **Physiol Rev** 1996 Oct;76(4):927-47 (158 ref.)

GENETICS

Transcriptional regulation of the mouse CSF-1 gene. Harrington M, et al. **Mol Reprod Dev** 1997 Jan;46(1):39-44; discussion 44-5 (16 ref.)

PHARMACOLOGY

Phosphatidylcholine signaling in response to CSF-1. Jackowski S, et al. **Mol Reprod Dev** 1997 Jan;46(1):24-30 (23 ref.)

Cytokine regulation of the macrophage (M phi) system studied using the colony stimulating factor-1-deficient op/op mouse. Wiktor-Jedrzejczak W, et al. **Physiol Rev** 1996 Oct;76(4):927-47 (158 ref.)

PHYSIOLOGY

Macrophage colony-stimulating-factor (M-CSF or CSF-1) and its receptor: structure-function relationships. Fixe P, et al. **Eur Cytokine Netw** 1997 Jun;8(2):125-36 (140 ref.)

CSF-I signal transduction: what is of functional significance? Hamilton JA. **Immunol Today** 1997 Jul;18(7):313-7 (34 ref.)

CSF-1 signal transduction. Hamilton JA. **J Leukoc Biol** 1997 Aug;62(2):145-55 (121 ref.)

Role of CSF-1 in bone and bone marrow development. Cecchini MG, et al. **Mol Reprod Dev** 1997 Jan;46(1):75-83; discussion 83-4 (32 ref.)

CSF-1 and cell cycle control in macrophages. Hamilton JA. **Mol Reprod Dev** 1997 Jan;46(1):19-23 (13 ref.)

Role of c-Src in cellular events associated with colony-stimulating factor-1-induced spreading in osteoclasts. Insogna K, et al. **Mol Reprod Dev** 1997 Jan; 46(1):104-8 (22 ref.)

CSF-1 and its receptor in breast carcinomas and neoplasms of the female reproductive tract. Kacinski BM. **Mol Reprod Dev** 1997 Jan;46(1):71-4 (17 ref.)

Role of colony-stimulating factor-1 in reproduction and development. Pollard JW. **Mol Reprod Dev** 1997 Jan; 46(1):54-60; discussion 60-1 (31 ref.)

Growth and differentiation signals regulated by the M-CSF receptor. Rohrschneider LR, et al. **Mol Reprod Dev** 1997 Jan;46(1):96-103 (11 ref.)

Regulation of cell cycle entry and G1 progression by CSF-1. Roussel MF. **Mol Reprod Dev** 1997 Jan;46(1):11-8 (39 ref.)

Biology and action of colony--stimulating factor-1. Stanley ER, et al. **Mol Reprod Dev** 1997 Jan;46(1):4-10 (16 ref.)

Relative role of CSF-1, MCP-1/JE, and RANTES in macrophage recruitment during successful pregnancy. Wood GW, et al. **Mol Reprod Dev** 1997 Jan;46(1):62-9; discussion 69-70 (24 ref.)

THERAPEUTIC USE

Use of cytokines in the treatment of acute lymphoblastic leukemia. Nemunaitis J. **Leukemia** 1997 May;11 Suppl 4:S36-7 (19 ref.)

[Clinical application of neutrophil hematopoietic factors] Sakurada K. **Nippon Naika Gakkai Zasshi** 1996 Jun 10; 85(6):844-9 (5 ref.) **(Jpn)**

MACROPHAGE-GRANULOCYTE INDUCER see **COLONY-STIMULATING FACTORS**

MACROPHAGE MIGRATION-INHIBITORY FACTORS

CHEMISTRY

Crystal structure of macrophage migration inhibitory factor (MIF), a glucocorticoid-induced regulator of cytokine production, reveals a unique architecture. Lolis E, et al. **Proc Assoc Am Physicians** 1996 Nov;108(6):415-9 (15 ref.)

IMMUNOLOGY

Macrophage migration inhibitory factor (MIF): a glucocorticoid counter-regulator within the immune system. Calandra T, et al. **Crit Rev Immunol** 1997; 17(1):77-88 (52 ref.)

MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune response. Bucala R. **FASEB J** 1996 Dec;10(14):1607-13 (46 ref.)

[New concepts on the nature of the macrophage migration-inhibitory factor: a hormone with immunocytokine activity] Koval'chuk LV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Nov-Dec; (6):91-4 (34 ref.) **(Rus)**

METABOLISM

Macrophage migration inhibitory factor: a counter-regulator of glucocorticoid action and critical mediator of septic shock. Calandra T, et al. **J Inflamm** 1995-96;47(1-2):39-51 (52 ref.)

PHYSIOLOGY

The emerging role of MIF in septic shock and infection. Bernhagen J, et al. **Biotherapy** 1994;8(2):123-7 (35 ref.)

MIF re-discovered: pituitary hormone and glucocorticoid-induced regulator of cytokine production. Bucala R. **Cytokine Growth Factor Rev** 1996 Jun;7(1):19-24 (31 ref.)

MACROPHAGE MIGRATION TEST see **CELL MIGRATION INHIBITION**

MACROPHAGE-1 ANTIGEN

METABOLISM

Interaction of GPI-anchored cell surface proteins and complement receptor type 3. Stockinger H. **Exp Clin Immunogenet** 1997;14(1):5-10 (23 ref.)

Amplification of the inflammatory response: adhesion molecules associated with platelet/white cell responses. Rinder C, et al. **J Cardiovasc Pharmacol** 1996;27 Suppl 1:S6-12 (41 ref.)

PHYSIOLOGY

Beta 2 (CD11/CD18) integrins can serve as signaling partners for other leukocyte receptors. Todd RF 3rd, et al. **J Lab Clin Med** 1997 May;129(5):492-8 (64 ref.)

MACROPHAGES

see related
PHAGOCYTOSIS

Macrophage membrane molecules: markers of tissue differentiation and heterogeneity. Martinez-Pomares L, et al. **Immunobiology** 1996 Oct;195(4-5):407-16 (64 ref.)

[Study on Mato cells (Mato's FGP cells) under various

conditions] Mato M, et al. **Nippon Rinsho** 1997 Jul; 55(7):1845–52 (10 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Scavenger receptors in innate immunity. Pearson AM. **Curr Opin Immunol** 1996 Feb;8(1):20–8 (92 ref.)

CLASSIFICATION

Development and heterogeneity of macrophages and their related cells through their differentiation pathways. Takahashi K, et al. **Pathol Int** 1996 Jul;46(7):473–85 (133 ref.)

CYTOLOGY

Murine bone marrow–derived macrophages. Stanley ER. **Methods Mol Biol** 1997;75:301–4 (6 ref.)

CSF–1 and cell cycle control in macrophages. Hamilton JA. **Mol Reprod Dev** 1997 Jan;46(1):19–23 (13 ref.)

Development and heterogeneity of macrophages and their related cells through their differentiation pathways. Takahashi K, et al. **Pathol Int** 1996 Jul;46(7):473–85 (133 ref.)

DRUG EFFECTS

Hepatoprotection by agents which modulate macrophage activity may be mediated by their mitogenic properties. Barriault C, et al. **Drug Metab Rev** 1997 Feb–May; 29(1–2):397–411 (60 ref.)

The mechanisms of action of disease-modifying antirheumatic drugs: a review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines. Bondeson J. **Gen Pharmacol** 1997 Aug;29(2):127–50 (287 ref.)

IMMUNOLOGY

Leukocytes, macrophages and secondary brain damage following cerebral ischemia. Tomita M, et al. **Acta Neurochir Suppl (Wien)** 1996;66:32–9 (58 ref.)

Mechanisms for recognition and phagocytosis of apoptotic lymphocytes by macrophages. Schlegel RA, et al. **Adv Exp Med Biol** 1996;406:21–8 (26 ref.)

HIV–1 neuropathogenesis and abused drugs: current reviews, problems, and solutions. Shapshak P, et al. **Adv Exp Med Biol** 1996;402:171–86 (122 ref.)

Viral and cellular determinants of HIV–1 replication in macrophages. Schuitemaker H, et al. **AIDS** 1996;10 Suppl A:S25–32 (115 ref.)

Nitric oxide and macrophage function. MacMicking J, et al. **Annu Rev Immunol** 1997;15:323–50 (190 ref.)

T–cells and macrophages in HIV disease. McGrath MS. **Clin Rev Allergy Immunol** 1996–97 Winter;14(4):359–66 (48 ref.)

Inter–relationship among macrophages, natural killer cells and neutrophils in early stages of Listeria resistance. Unanue ER. **Curr Opin Immunol** 1997 Feb;9(1):35–43 (114 ref.)

Role of macrophage–derived cytokines in the induction and regulation of cell–mediated immunity to Toxoplasma gondii. Gazzinelli RT, et al. **Curr Top Microbiol Immunol** 1996;219:127–39 (46 ref.)

Heterogeneity of mouse brain macrophages in alloantigen presentation to naive CD8+ T cells as revealed by a panel of microglial cell lines. Askew D, et al. **Immunobiology** 1996 Oct;195(4–5):417–30 (56 ref.)

Immune therapy with macrophages: present status and critical requirements for implementation. Bartoleyns J, et al. **Immunobiology** 1996 Oct;195(4–5):550–62 (50 ref.)

Macrophages in islet destruction in autoimmune diabetes mellitus. Burkart V, et al. **Immunobiology** 1996 Oct; 195(4–5):601–13 (49 ref.)

The role of macrophages in septic shock. Evans TJ. **Immunobiology** 1996 Oct;195(4–5):655–9 (16 ref.)

TNF–alpha–induced regulation and signalling in macrophages. Riches DW, et al. **Immunobiology** 1996 Oct; 195(4–5):477–90 (31 ref.)

The role of macrophages in chronic arthritis. van den Berg WB, et al. **Immunobiology** 1996 Oct;195(4–5):614–23 (19 ref.)

Do macrophages kill through apoptosis? Aliprantis AO, et al. **Immunol Today** 1996 Dec;17(12):573–6 (45 ref.)

The B/macrophage cell: an elusive link between CD5+ B lymphocytes and macrophages. Borrello MA, et al. **Immunol Today** 1996 Oct;17(10):471–5 (36 ref.)

A continuing enigma: the role of cells of macrophage lineage in the development of HIV disease. Perno CF, et al. **J Leukoc Biol** 1997 Jul;62(1):1–3 (22 ref.)

Immune stimulation and HIV–1 viral replication. Wahl SM, et al. **J Leukoc Biol** 1997 Jul;62(1):67–71 (60 ref.)

Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis [see comments] Benveniste EN. **J Mol Med** 1997 Mar;75(3):165–73 (107 ref.) Comment in: J Mol Med 1997 Mar;75(3):164.

Uterine macrophages and environmental programming for pregnancy success. Hunt JS, et al. **J Reprod Immunol** 1996 Nov;32(1):1–25 (120 ref.)

Macrophages in resistance to candidiasis. Vázquez–Torres A, et al. **Microbiol Mol Biol Rev** 1997 Jun;61(2):170–92 (278 ref.)

Cytokines, viruses and macrophages: an interactive network. An immune dysregulation involving the members of the tumor necrosis factor (TNF) receptor superfamily could be critical in AIDS pathogenesis. Herbein G. **Pathol Biol (Paris)** 1997 Feb;45(2):115–25 (127 ref.)

Immunobiology of human uteroplacental macrophages––friend and foe? Vince GS, et al. **Placenta** 1996 May;17(4):191–9 (106 ref.)

The role of macrophage– and dendritic cell–derived IL12 in Th1 phenotype development. O'Garra A, et al. **Res Immunol** 1995 Sep–Oct;146(7–8):466–72 (50 ref.)

The origin of immunoglobulins and T–cell receptors is likely to be the cell death sensor of macrophages. Ohno S. **Res Immunol** 1996 May;147(4):247–52 (12 ref.)

Macrophages, NK cells and neutrophils in the cytokine loop of Listeria resistance. Unanue ER. **Res Immunol** 1996 Oct–Dec;147(8–9):499–505 (55 ref.)

Signalling heterogeneity as a contributing factor in macrophage functional diversity. Riches DW. **Semin Cell Biol** 1995 Dec;6(6):377–84 (40 ref.)

Immune dysfunction in murine polymicrobial sepsis: mediators, macrophages, lymphocytes and apoptosis. Ayala A, et al. **Shock** 1996;6 Suppl 1:S27–38 (134 ref.)

[Role of monocytes and macrophages in the defense against malignant tumors] Schuurman B, et al. **Ned Tijdschr Geneeskd** 1996 Oct 5;140(40):1978–81 (34 ref.) **(Dut)**

[Role of macrophages in papillomavirus infections] Bianchi A, et al. **Pathol Biol (Paris)** 1997 Feb;45(2):165–8 (25 ref.) (Eng. Abstr.) **(Fre)**

[Nitric oxide and macrophages] Drapier JC. **Pathol Biol (Paris)** 1997 Feb;45(2):110–4 (73 ref.) (Eng. Abstr.) **(Fre)**

[HIV and macrophage] Russo–Marie F. **Pathol Biol (Paris)** 1997 Feb;45(2):137–45 (44 ref.) (Eng. Abstr.) **(Fre)**

[Antigen presentation and macrophages] Toubert A, et al. **Pathol Biol (Paris)** 1997 Feb;45(2):126–30 (34 ref.) (Eng. Abstr.) **(Fre)**

[Attempts to elucidate reasons why mycobacterial infections are intractable, by using an experimental mouse infection model] Tomioka H. **Nihon Hansenbyo Gakkai Zasshi** 1996 Nov;65(3):155–65 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Scavenger receptor gene––regulation of scavenger receptor gene expression in alveolar macrophages and the pathogenesis of pulmonary alveolar proteinosis] Mori T, et al. **Nippon Rinsho** 1996 Feb;54(2):353–7 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Current issues in immunotherapy of tumors in the context of macrophage reaction to tissue damage fixed through evolution] Okulov VB. **Vopr Onkol** 1997;43(1):102–6 (33 ref.) **(Rus)**

METABOLISM

The importance of fuel metabolism to macrophage function. Newsholme P, et al. **Cell Biochem Funct** 1996 Mar; 14(1):1–10 (28 ref.)

Elevation of macrophage SeGSHPx gene expression prevents from its formation of foam cell and inhibits atherogenesis. Chen Y, et al. **Chin Med J (Engl)** 1996 Jan;109(1):51–4 (17 ref.)

P2 purinoceptors and pyrimidinoceptors of catecholamine–producing cells and immunocytes. Illes P, et al. **Ciba Found Symp** 1996;198:110–25; discussion 125–9 (59 ref.)

Collagenous macrophage scavenger receptors. Kodama T, et al. **Curr Opin Lipidol** 1996 Oct;7(5):287–91 (37 ref.)

Macrophages and atherosclerotic plaque stability. Libby P, et al. **Curr Opin Lipidol** 1996 Oct;7(5):330–5 (45 ref.)

Apolipoprotein E secretion by macrophages: its potential physiological functions. Mazzone T. **Curr Opin Lipidol** 1996 Oct;7(5):303–7 (46 ref.)

Modification of macrophage function and effects on atherosclerosis. Murakami T, et al. **Curr Opin Lipidol** 1996 Oct;7(5):320–3 (24 ref.)

Cholesterol efflux from macrophages and other cells. von Eckardstein A. **Curr Opin Lipidol** 1996 Oct;7(5):308–19 (122 ref.)

Inflammation in AIDS and the role of the macrophage in brain pathology. Achim CL, et al. **Curr Opin Neurol** 1996 Jun;9(3):221–5 (52 ref.)

Interaction of oxidized low density lipoprotein with macrophages in atherosclerosis, and the antiatherogenicity of antioxidants. Aviram M. **Eur J Clin Chem Clin Biochem** 1996 Aug;34(8):599–608 (95 ref.)

Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease [published erratum appears in Gastroenterology 1997 Aug;113(2):732] Rugtveit J, et al. **Gastroenterology** 1997 May;112(5):1493–505 (78 ref.)

TNF–alpha–induced regulation and signalling in macrophages. Riches DW, et al. **Immunobiology** 1996 Oct; 195(4–5):477–90 (31 ref.)

Cellular binding and degradation of lipoprotein (a). Fless GM. **J Atheroscler Thromb** 1995;2 Suppl 1:S1–4 (20 ref.)

Multi–functional aspects of high density lipoprotein as an anti–atherogenic lipoprotein in vivo: evidence from in vitro experiments using macrophages. Miyazaki A, et al. **J Atheroscler Thromb** 1995;2(1):30–6 (34 ref.)

Endocytic uptake of lysophosphatidylcholine mediated by macrophage scavenger receptor plays a major role in oxidized low density lipoprotein–induced macrophage growth. Sakai M, et al. **J Atheroscler Thromb** 1996; 2(2):81–6 (19 ref.)

A T–helper–2 bias in decidua: the prostaglandin contribution of the macrophage and trophoblast. Kelly RW, et al. **J Reprod Immunol** 1997 Jul;33(3):181–7 (48 ref.)

The role of macrophage– and dendritic cell–derived IL12 in Th1 phenotype development. O'Garra A, et al. **Res Immunol** 1995 Sep–Oct;146(7–8):466–72 (50 ref.)

Macrophage production of IL12 is a critical link between the innate and specific immune responses to Listeria. Tripp CS, et al. **Res Immunol** 1995 Sep–Oct;146(7–8):515–20 (32 ref.)

[High density lipoproteins: physiological importance] Kurashvili LV. **Patol Fiziol Eksp Ter** 1997 Jul–Sep;(3):40–3 (52 ref.) **(Rus)**

MICROBIOLOGY

Vesicular transport of microorganisms in macrophages. Alvarez–Dominguez C. **Biocell** 1996 Dec;20(3):355–65 (29 ref.)

The molecular mechanisms of actin–based intracellular motility by Listeria monocytogenes. Chakraborty T. **Microbiologia** 1996 Jun;12(2):237–44 (34 ref.)

How do macrophages distinguish the living from the dead? Cheers C, et al. **Trends Microbiol** 1996 Nov;4(11):453–5 (28 ref.)

Characterization of the Mycobacterium tuberculosis phagosome. Clemens DL. **Trends Microbiol** 1996 Mar; 4(3):113–8 (39 ref.)

[Strategies of Histoplasma capsulatum for evading the cytocidal mechanisms of phagocytes] Taylor ML, et al. **Rev Invest Clin** 1995 Nov–Dec;47(6):499–506 (50 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Cellular components and features of immune response in abdominal aortic aneurysms. Pearce WH, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:175–85 (45 ref.)

Is overamplification of the normal macrophage defensive role critical to lesion development? Raines EW, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:76–85; discussion 85–7 (54 ref.)

Macrophages in islet destruction in autoimmune diabetes mellitus. Burkart V, et al. **Immunobiology** 1996 Oct; 195(4–5):601–13 (49 ref.)

[Histiocytoses as diseases of the macrophage system] Lukina EA. **Ter Arkh** 1996;68(7):82–8 (70 ref.) **(Rus)**

PHYSIOLOGY

Immunobiology of picolinic acid. Melillo G, et al. **Adv Exp Med Biol** 1996;398:135–41 (43 ref.)

Neuroimmunologic implications in coronary artery disease. Fricchione GL, et al. **Adv Neuroimmunol** 1996;6(2):131–42 (60 ref.)

The role of macrophages in Wallerian degeneration. Brück W. **Brain Pathol** 1997 Apr;7(2):741–52 (124 ref.)

The molecular control of granulocytes and macrophages. Metcalf D. **Ciba Found Symp** 1997;204:40–50; discussion 50–6 (33 ref.)

Hypercholesterolemia and progressive kidney disease: the role of macrophages and macrophage–derived products. Ricardo SD, et al. **Contrib Nephrol** 1997;120:197–209 (51 ref.)

Atherosclerosis: cell biology and lipoproteins [editorial] Tabas I. **Curr Opin Lipidol** 1997 Apr;8(2):U25–7 (16 ref.)

How the extracellular matrix and macrophages contribute to angiogenesis–dependent diseases. Polverini PJ. **Eur J Cancer** 1996 Dec;32A(14):2430–7 (70 ref.)

Dendritic cells and macrophages in the pituitary and the gonads. Evidence for their role in the fine regulation of the reproductive endocrine response. Hoek A, et al. **Eur J Endocrinol** 1997 Jan;136(1):8–24 (193 ref.)

Role of the macrophage in angiogenesis–dependent diseases. Polverini PJ. **EXS** 1997;79:11–28 (111 ref.)

The role of macrophages in septic shock. Evans TJ. **Immunobiology** 1996 Oct;195(4–5):655–9 (16 ref.)

Targeting antiviral nucleotide analogues to macrophages. Magnani M, et al. **J Leukoc Biol** 1997 Jul;62(1):133–7 (32 ref.)

Osteoclasts, macrophages, and the molecular mechanisms of bone resorption. Teitelbaum SL, et al. **J Leukoc Biol** 1997 Apr;61(4):381–8 (67 ref.)

The effect of granulocyte–macrophage colony stimulating factor (rGM–CSF) on macrophage function in microbial disease. Jones TC. **Med Oncol** 1996 Sep;13(3):141–7 (54 ref.)

Macrophage differentiation and granulomatous inflammation in osteopetrotic mice (op/op) defective in the production of CSF–1. Naito M, et al. **Mol Reprod Dev** 1997 Jan; 46(1):85–91 (13 ref.)

Relative role of CSF–1, MCP–1/JE, and RANTES in macrophage recruitment during successful pregnancy. Wood GW, et al. **Mol Reprod Dev** 1997 Jan;46(1):62–9; discussion 69–70 (24 ref.)

The biology of macrophages. Bosque F, et al. **Pathol Biol (Paris)** 1997 Feb;45(2):103–9 (52 ref.)

Cytokine regulation of the macrophage (M phi) system studied using the colony stimulating factor–1–deficient op/op mouse. Wiktor–Jedrzejczak W, et al. **Physiol Rev** 1996 Oct;76(4):927–47 (158 ref.)

Nitric oxide, a vital poison inside the immune and inflammatory network. Dugas B, et al. **Res Immunol** 1995

Nov-Dec;146(9):664-70 (45 ref.)
The macrophage and fibrinolysis. Loscalzo J. **Semin Thromb Hemost** 1996;22(6):503-6 (39 ref.)
[Membrane currents in macrophages] Zhang ZS, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan;27(1):76-8 (10 ref.) **(Chi)**
[Role of Kupffer cells in liver diseases] Yamamoto H, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):701-3 (5 ref.) **(Jpn)**

SECRETION

Cytokines acting on or secreted by macrophages during intracellular infection (IL-10, IL-12, IFN-gamma). Trinchieri G. **Curr Opin Immunol** 1997 Feb;9(1):17-23 (69 ref.)

TRANSPLANTATION

Immune therapy with macrophages: present status and critical requirements for implementation. Bartoleyns J, et al. **Immunobiology** 1996 Oct;195(4-5):550-62 (50 ref.)

VIROLOGY

Latent and persistent infections of monocytes and macrophages. Sinclair J, et al. **Intervirology** 1996; 39(5-6):293-301 (71 ref.)
Macrophages, cytokines, and HIV. Bornemann MA, et al. **J Lab Clin Med** 1997 Jan;129(1):10-6 (73 ref.)
Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes. Aquaro S, et al. **J Leukoc Biol** 1997 Jul;62(1):138-43 (39 ref.)
GM-CSF and its effects on replication of HIV-1 in cells of macrophage lineage. Crowe SM, et al. **J Leukoc Biol** 1997 Jul;62(1):41-8 (100 ref.)
Targeting antiviral nucleotide analogues to macrophages. Magnani M, et al. **J Leukoc Biol** 1997 Jul;62(1):133-7 (32 ref.)
Cellular aspects of HIV-1 infection of macrophages leading to neuronal dysfunction in in vitro models for HIV-1 encephalitis. Nottet HS, et al. **J Leukoc Biol** 1997 Jul; 62(1):107-16 (112 ref.)
Interaction of human cytomegalovirus with monocytes/macrophages: a love-hate relationship. Michelson S. **Pathol Biol (Paris)** 1997 Feb;45(2):146-58 (155 ref.)
[Herpes simplex virus and macrophages] Scieux C. **Pathol Biol (Paris)** 1997 Feb;45(2):159-64 (37 ref.) (Eng. Abstr.) **(Fre)**
[Hepatic macrophages and virus] Steffan AM. **Pathol Biol (Paris)** 1997 Feb;45(2):169-83 (59 ref.) (Eng. Abstr.) **(Fre)**

MACROPHAGES, ALVEOLAR

CHEMISTRY

[Lipid-laden alveolar macrophages as markers of gastro-esophageal reflux in pulmonary disease in childhood] Bibi H, et al. **Harefuah** 1997 Jan 1;132(1):40-2 (31 ref.) **(Heb)**

IMMUNOLOGY

The role of alveolar macrophages and dendritic cells in allergic airway sensitization. Jansen HM. **Allergy** 1996 May; 51(5):279-92 (138 ref.)

METABOLISM

Novel pathways for elimination of cholesterol by extrahepatic formation of side-chain oxidized oxysterols. Diczfalusy U, et al. **Scand J Clin Lab Invest Suppl** 1996; 226:9-17 (18 ref.)

PATHOLOGY

Intra-alveolar pulmonary siderophages in sudden infant death: a marker for previous imposed suffocation. Becroft DM, et al. **Pathology** 1997 Feb;29(1):60-3 (19 ref.)

PHYSIOLOGY

Cellular effects of particles--impact of dissolution on toxicity of man-made mineral fibers. Luoto K, et al. **Cent Eur J Public Health** 1996;4 Suppl:29-32 (40 ref.)
[Role of alveolar macrophages in the pathogenesis of interstitial lung diseases-MCP-1-] Suga M. **Nippon Ika Daigaku Zasshi** 1996 Oct;63(5):384-90 (5 ref.) **(Jpn)**
[Role of alveolar macrophages in the pathogenesis of idiopathic interstitial pneumonia] Suga M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:175-80 (5 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

[Cellular and subcellular morphology of the repair process in pulmonary tuberculosis] Erokhin VV. **Probl Tuberk** 1996;(6):10-4 (10 ref.) (Eng. Abstr.) **(Rus)**

VIROLOGY

Macrophages and respiratory viruses. Van Reeth K, et al. **Pathol Biol (Paris)** 1997 Feb;45(2):184-92 (74 ref.)
Pathogenesis and clinical aspects of a respiratory porcine reproductive and respiratory syndrome virus infection. Van Reeth K. **Vet Microbiol** 1997 Apr;55(1-4):223-30 (29 ref.)

MACROPHAGES, PERITONEAL

IMMUNOLOGY

Peritonitis: pathophysiology and local defense mechanisms. Heemken R, et al. **Hepatogastroenterology** 1997 Jul-Aug; 44(16):927-36 (20 ref.)

MACROPHAGES, PULMONARY see **MACROPHAGES, ALVEOLAR**

MACROSOMIA, FETAL see **FETAL MACROSOMIA**

MACULA LUTEA

Resuturing the scleral flap leads to resolution of hypotony maculopathy. Schwartz GF, et al. **J Glaucoma** 1996 Aug; 5(4):246-51 (50 ref.)
[Chloroquine maculopathy and prevention of malaria] Balo KP, et al. **J Fr Ophtalmol** 1996;19(12):770-6 (15 ref.) (Eng. Abstr.) **(Fre)**
[Vitrectomy-laser-gas for treating optic disk pits complicated by serous macular detachment] Taiel-Sartral M, et al. **J Fr Ophtalmol** 1996;19(10):603-9 (31 ref.) (Eng. Abstr.) **(Fre)**

BLOOD SUPPLY

Macular hemorrhage after excimer laser photorefractive keratectomy. Loewenstein A, et al. **J Cataract Refract Surg** 1997 Jun;23(5):808-10 (8 ref.)

INJURIES

Traumatic retinopathy resembling acute macular neuroretinopathy. Gillies M, et al. **Aust N Z J Ophthalmol** 1997 Aug;25(3):207-10 (11 ref.)
Traumatic maculopathy. Klopfer J. **Optom Clin** 1996; 5(1):131-46 (68 ref.)

PATHOLOGY

Atrophic armd--a nutrition responsive chronic disease [editorial; comment] Richer S. **J Am Optom Assoc** 1996 Jan;67(1):6-10 (24 ref.) Comment on: J Am Optom Assoc 1996 Jan;67(1):50-7.
Torpedo maculopathy. Teitelbaum BA, et al. **J Am Optom Assoc** 1997 Jun;68(6):373-6 (12 ref.)

SURGERY

Laser treatment of macular disease. Bass SJ, et al. **Optom Clin** 1996;5(1):161-73 (20 ref.)

MACULAR DEGENERATION

Age-related macular degeneration: a leading cause of blindness [see comments] O'Shea JG. **Med J Aust** 1996 Nov 18;165(10):561-4 (32 ref.) Comment in: Med J Aust 1997 Mar 17;166(6):331.
Age-related macular degeneration. Oshinskie LJ. **Optom Clin** 1996;5(1):25-53 (102 ref.)

COMPLICATIONS

The peril of the pilot study [editorial; comment] Ferris FL 3rd, et al. **Arch Ophthalmol** 1996 Dec;114(12):1506-7 (10 ref.) Comment on: Arch Ophthalmol 1996 Dec;114(12):1456-64.
We are very spoiled [editorial; comment] Fine SL, et al. **Arch Ophthalmol** 1997 Jul;115(7):915-6 (11 ref.) Comment on: Arch Ophthalmol 1997 Jul;115(7):865-72.
Angiogenesis inhibition in age-related macular degeneration [editorial] D'Amato RJ, et al. **Ophthalmology** 1995 Sep; 102(9):1261-2 (9 ref.)

DIAGNOSIS

Age-related ocular diseases. Li W. **Chin Med J (Engl)** 1996 Jan;109(1):65-7 (15 ref.)
[Progressive dystrophy of the cones] Cernea P, et al. **Oftalmologia** 1996 Oct-Dec;40(4):383-5 (9 ref.) (Eng. Abstr.) **(Rum)**
[Aicardi's syndrome: agenesis of the corpus callosum, infantile flexor spasms and macular dystrophy] Badalian LO, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996; 96(5):87-90 (13 ref.) **(Rus)**

EPIDEMIOLOGY

Age-related macular degeneration. An epidemiological study of 1000 elderly individuals. With reference to prevalence, funduscopic findings, visual impairment and risk factors. Vinding T. **Acta Ophthalmol Scand Suppl** 1995;(217):1-32 (126 ref.)
Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Mitchell P, et al. **Ophthalmology** 1995 Oct;102(10):1450-60 (26 ref.)

ETIOLOGY

Lipofuscin fluorophore inhibits lysosomal protein degradation and may cause early stages of macular degeneration. Eldred GE. **Gerontology** 1995;41 Suppl 2:15-28 (72 ref.)

GENETICS

The genetics of complex ophthalmic disorders. Evans K, et al. **Br J Ophthalmol** 1996 Aug;80(8):763-8 (104 ref.)
Age-related macular degeneration: genetics and implications for detection and treatment. Silvestri G. **Mol Med Today** 1997 Feb;3(2):84-91 (39 ref.)
[Genetics of macular degeneration] Weber BH. **Klin Monatsbl Augenheilkd** 1997 Jan;210(1):aA9-17 (19 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Atrophic armd--a nutrition responsive chronic disease [editorial; comment] Richer S. **J Am Optom Assoc** 1996 Jan;67(1):6-10 (24 ref.) Comment on: J Am Optom Assoc 1996 Jan;67(1):50-7.
Preventative ophthalmology. Age-related macular degeneration. Bressler NM, et al. **Ophthalmology** 1995 Aug; 102(8):1206-11 (46 ref.)

RADIOTHERAPY

Teletherapy in the management of patients with age-related macular degeneration complicated by subfoveal neovascularisation: an overview. Hart PM, et al. **Front Radiat Ther Oncol** 1997;30:229-37 (26 ref.)
[Radiotherapy and age-related macular degeneration: a review of the literature] Schwartz LH, et al. **Cancer Radiother** 1997;1(3):208-12 (38 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Macular surgery [published erratum appears in Br J Hosp Med 1996 Apr 17-30;55(8):526] Aylward GW. **Br J Hosp Med** 1996 Feb 7-20;55(3):85-8 (14 ref.)
[Is it possible to treat age-related macular degeneration? (editorial)] Immonen I. **Duodecim** 1995;111(12):1083-5 (14 ref.) **(Fin)**

THERAPY

The medical and surgical management of age-related macular degeneration. Joffe L. **Int Ophthalmol Clin** 1996 Spring; 36(2):99-116 (47 ref.)
Age-related macular degeneration: genetics and implications for detection and treatment. Silvestri G. **Mol Med Today** 1997 Feb;3(2):84-91 (39 ref.)
Retinal cell transplantation in the macula: new techniques. Gouras P, et al. **Vision Res** 1996 Dec;36(24):4121-5 (31 ref.)
[Age-related macular degeneration. 2. Therapeutic approaches] Holz FG, et al. **Ophthalmologe** 1996 Aug; 93(4):483-506 (36 ref.) **(Ger)**
[Interferon treatment for age-related macular degeneration] Loewenstein A, et al. **Harefuah** 1997 Feb 16;132(4):275-9 (44 ref.) **(Heb)**

MACULAR DYSTROPHY, CORNEAL see **CORNEAL DYSTROPHIES, HEREDITARY**

MACULAR EDEMA, CYSTOID

Cystoid macular edema. Quinn CJ. **Optom Clin** 1996; 5(1):111-30 (107 ref.)

PHYSIOPATHOLOGY

Pathophysiology and treatment of cystoid macular edema. Rocha G, et al. **Can J Ophthalmol** 1996 Oct;31(6):282-8 (50 ref.)

THERAPY

Pathophysiology and treatment of cystoid macular edema. Rocha G, et al. **Can J Ophthalmol** 1996 Oct;31(6):282-8 (50 ref.)

MACULAR HOLES see **RETINAL PERFORATIONS**

MACULOPATHY, AGE-RELATED see **MACULAR DEGENERATION**

MAD COW DISEASE see **ENCEPHALOPATHY, BOVINE SPONGIFORM**

MADELUNG'S NECK see **LIPOMATOSIS, MULTIPLE SYMMETRICAL**

MADURA FOOT see **MADUROMYCOSIS**

MADURELLA see **HYPHOMYCETES**

MADUROMYCOSIS

Mycetoma. McGinnis MR. **Dermatol Clin** 1996 Jan; 14(1):97-104 (65 ref.)
Actinomycosis, nocardiosis, and actinomycetoma. Warren NG. **Dermatol Clin** 1996 Jan;14(1):85-95 (30 ref.)
[Mycetoma: report of 3 cases in Falcón State, Venezuela] Pérez-Blanco M, et al. **Invest Clin** 1996 Mar;37(1):61-73 (23 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

First report of mycetoma caused by Arthrographis kalrae: successful treatment with itraconazole. Degavre B, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):318–20 (15 ref.)

ETIOLOGY

First report of mycetoma caused by Arthrographis kalrae: successful treatment with itraconazole. Degavre B, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):318–20 (15 ref.)

PATHOLOGY

Criteria for the diagnosis of sinus mycetoma. deShazo RD, et al. **J Allergy Clin Immunol** 1997 Apr;99(4):475–85 (29 ref.)

MAEDI see **PNEUMONIA, PROGRESSIVE INTERSTITIAL, OF SHEEP**

MAEDI VIRUS see **VISNA-MAEDI VIRUS**

MAEDI-VISNA VIRUS see **VISNA-MAEDI VIRUS**

MAFFUCCI SYNDROME see **ENCHONDROMATOSIS**

MAG PROTEIN see **MYELIN-ASSOCIATED GLYCOPROTEIN**

MAGGOT INFESTATIONS see **MYIASIS**

MAGIC

The magic of science and the science of magic: an essay on the process of healing. Coe RM. **J Health Soc Behav** 1997 Mar;38(1):1–8 (47 ref.)

Hauntings and poltergeist-like episodes as a confluence of conventional phenomena: a general hypothesis. Houran J, et al. **Percept Mot Skills** 1996 Dec;83(3 Pt 2):1307–16 (80 ref.)

MAGNESIUM

[Role of magnesium in the management of cardiopathy] Ramos RA, et al. **Arq Bras Cardiol** 1995 Nov;65(5):431–5 (30 ref.) **(Por)**

[Magnesium: metabolism and requirements] López Martínez J, et al. **Nutr Hosp** 1997 Jan–Feb;12(1):4–14 (58 ref.) (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

[Medicamentous anti-arrhythmia therapy. Is oral adjuvant therapy with electrolytes of value?] Haberl R. **Herz** 1997 Jun;22 Suppl 1:77–80 (20 ref.) (Eng. Abstr.) **(Ger)**

[Value of K+ and Mg2+ in treatment of acute myocardial infarct] Kunert M, et al. **Herz** 1997 Jun;22 Suppl 1:63–72 (24 ref.) (Eng. Abstr.) **(Ger)**

[Magnesium deficiency and magnesium substitution. Effect on ventricular cardiac arrhythmias of various etiology] Zehender M, et al. **Herz** 1997 Jun;22 Suppl 1:56–62 (54 ref.) (Eng. Abstr.) **(Ger)**

[Significance of supraphysiologic administration of magnesium after myocardial infarct] Benzer W. **Wien Klin Wochenschr Suppl** 1997;2:38–41 (26 ref.) (Eng. Abstr.) **(Ger)**

[Value of magnesium in acute myocardial infarct] Beuckelmann DJ. **Z Kardiol** 1996;85 Suppl 6:129–34 (15 ref.) (Eng. Abstr.) **(Ger)**

[Magnesium: current studies--critical evaluation--consequences] Meinertz T. **Z Kardiol** 1996;85 Suppl 6:147–51 (13 ref.) (Eng. Abstr.) **(Ger)**

[Clinical use of magnesium] Martyka Z, et al. **Przegl Lek** 1996;53(3):155–8 (18 ref.) (Eng. Abstr.) **(Pol)**

ANALYSIS

Role of magnesium in patho-physiological processes and the clinical utility of magnesium ion selective electrodes. Altura BM, et al. **Scand J Clin Lab Invest Suppl** 1996;224:211–34 (127 ref.)

More on the measurement of ionized magnesium in whole blood. Ritter C, et al. **Scand J Clin Lab Invest Suppl** 1996; 224:275–80 (5 ref.)

BLOOD

Hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and severe hypocalciuria: a new syndrome? Mehrotra R, et al. **Am J Kidney Dis** 1997 Jan; 29(1):106–14 (27 ref.)

An incidental finding of Gitelman's syndrome. Leonard MB, et al. **Br J Clin Pract** 1997 Mar;51(2):121–4 (17 ref.)

More on the measurement of ionized magnesium in whole blood. Ritter C, et al. **Scand J Clin Lab Invest Suppl** 1996; 224:275–80 (5 ref.)

[Comments on the kinetics and extracellular effects of potassium and magnesium] Vierling W. **Herz** 1997 Jun;22 Suppl 1:3–10 (8 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Interactions between magnesium and vitamin D: possible implications in the immune system. McCoy H, et al. **Magnes Res** 1996 Oct;9(3):185–203 (196 ref.)

METABOLISM

Clinical disorders of magnesium metabolism. Whang R. **Compr Ther** 1997 Mar;23(3):168–73 (46 ref.)

Ca2+ and Mg2+ sensor in the thick ascending limb of the loop of Henle. Di Stefano A, et al. **Kidney Blood Press Res** 1997;20(3):190–3 (23 ref.)

Extracellular calcium-sensing receptor: implications for calcium and magnesium handling in the kidney. Hebert SC. **Kidney Int** 1996 Dec;50(6):2129–39 (97 ref.)

Commentary on recent clinical advances: magnesium depletion, magnesium deficiency and asthma. Durlach J. **Magnes Res** 1995 Dec;8(4):403–5 (10 ref.)

Interactions between magnesium and vitamin D: possible implications in the immune system. McCoy H, et al. **Magnes Res** 1996 Oct;9(3):185–203 (196 ref.)

Potassium and magnesium retaining triamterene derivatives. Priewer H, et al. **Pharmazie** 1997 Mar;52(3):179–81 (56 ref.)

Pathophysiology of calcium, phosphorus, and magnesium metabolism in animals. Rosol TJ, et al. **Vet Clin North Am Small Anim Pract** 1996 Sep; 26(5):1155–84 (127 ref.)

[Mg(2+) transport in the heart. An overview] Ebel H. **Herz** 1997 Jun;22 Suppl 1:10–7 (30 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOKINETICS

Bioavailability of calcium and magnesium. Schaafsma G. **Eur J Clin Nutr** 1997 Jan;51 Suppl 1:S13–6 (26 ref.)

Effects of milk and milk components on calcium, magnesium, and trace element absorption during infancy. Lönnerdal B. **Physiol Rev** 1997 Jul;77(3):643–69 (243 ref.)

PHARMACOLOGY

Effects of antiarrhythmic agents and Mg2+ on aconitine-induced arrhythmias. Sawanobori T, et al. **Jpn Heart J** 1996 Sep;37(5):709–18 (26 ref.)

Antioxidant dietary status and genetic cardiovascular risk, or how an adequate intake of a-tocopherol, selenium, taurine, magnesium and various other natural antioxidants may overcome the deleterious metabolic consequences related to the E4-4 type of apolipoprotein E [editorial] Durlach J, et al. **Magnes Res** 1996 Jun;9(2):139–41 (24 ref.)

Neuromodulation by Mg2+ and polyamines of excitatory amino acid currents in rodent neurones in culture. Kumamoto E. **Magnes Res** 1996 Dec;9(4):317–27 (50 ref.)

[The effect of magnesium on blood coagulation--state of the art literature review from 1959 to 1995] Sacha T, et al. **Przegl Lek** 1997;54(2):122–5 (20 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Hypertension, diabetes mellitus, and insulin resistance: the role of intracellular magnesium [see comments] Paolisso G, et al. **Am J Hypertens** 1997 Mar;10(3):346–55 (74 ref.) Comment in: Am J Hypertens 1997 Mar;10(3):368–70.

Magnesium and cardiovascular biology: an important link between cardiovascular risk factors and atherogenesis. Altura BM, et al. **Cell Mol Biol Res** 1995;41(5):347–59 (95 ref.)

Magnesium: its role in cellular functions--a review. Bronzetti G, et al. **J Environ Pathol Toxicol Oncol** 1995; 14(3–4):197–204 (86 ref.)

Function of metal-ion homeostasis in the cell division cycle, mitochondrial protein processing, sensitivity to mycobacterial infection and brain function. Supek F, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):321–30 (73 ref.)

Role of magnesium in patho-physiological processes and the clinical utility of magnesium ion selective electrodes. Altura BM, et al. **Scand J Clin Lab Invest Suppl** 1996;224:211–34 (127 ref.)

[Magnesium, its role and metabolism] Kutílek S, et al. **Cas Lek Cesk** 1996 Sep 18;135(18):597–600 (28 ref.) (Eng. Abstr.) **(Cze)**

[Homeostasis of magnesium ions in animal cells] Bogucka K. **Postepy Biochem** 1996;42(2):178–85 (54 ref.) **(Pol)**

[Magnesium and its balance] Andrianova MIu, et al. **Anesteziol Reanimatol** 1995 Nov–Dec;(6):73–6 (88 ref.) **(Rus)**

[Magnesium salts in physiology and pathology: the potentials for their use in medicine] Spasov AA, et al. **Usp Fiziol Nauk** 1997 Apr–Jun;28(2):79–93 (110 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Pharmacologic control of heart rate in atrial fibrillation. Falk RH. **Cardiol Clin** 1996 Nov;14(4):521–36 (71 ref.)

Magnesium in acute myocardial infarction: scientific, statistical, and economic rationale for its use [editorial] Antman EM, et al. **Cardiovasc Drugs Ther** 1996 Jul; 10(3):297–301 (55 ref.)

The role of magnesium therapy in acute myocardial infarction. Rabbani LE, et al. **Clin Cardiol** 1996 Nov; 19(11):841–4 (35 ref.)

How magnesium therapy may influence clinical outcome in acute myocardial infarction: review of potential mechanisms. Herzog WR, et al. **Coron Artery Dis** 1996 May;7(5):364–70 (50 ref.)

Magnesium and arrhythmias in acute myocardial infarction. Horner SM. **Coron Artery Dis** 1996 May;7(5):359–63 (66 ref.)

Review of clinical evidence--is there a role for supplemental magnesium in acute myocardial infarction in high-risk populations (patients ineligible for thrombolysis and the elderly)? Shechter M, et al. **Coron Artery Dis** 1996 May; 7(5):352–8 (80 ref.)

Results of randomized clinical trials of magnesium--can a consensus be reached? Teo KK, et al. **Coron Artery Dis** 1996 May;7(5):341–7 (42 ref.)

Magnesium in acute myocardial infarction. Thel MC, et al. **Coron Artery Dis** 1995 Oct;6(10):831–7 (50 ref.)

Review of research methodology used in clinical trials of magnesium and myocardial infarction--why does controversy persist despite ISIS-4? Woods KL. **Coron Artery Dis** 1996 May;7(5):348–51 (24 ref.)

Antiarrhythmic action of pharmacological administration of magnesium in heart failure: a critical review of new data. Sueta CA, et al. **Magnes Res** 1995 Dec;8(4):389–401 (78 ref.)

Preterm birth, cerebral palsy and magnesium [news] Goldenberg RL, et al. **Nat Med** 1997 Feb;3(2):146–7 (10 ref.)

[Antithrombocytic effectiveness of magnesium] Gawaz M. **Fortschr Med** 1996 Sep 20;114(26):329–32 (16 ref.) (Eng. Abstr.) **(Ger)**

[Clinico-electrophysiologic effects of magnesium, especially in supraventricular tachycardia] Vester EG. **Herz** 1997 Jun; 22 Suppl 1:40–50 (33 ref.) (Eng. Abstr.) **(Ger)**

[Magnesium as an anti-arrhythmic therapy principle in supraventricular and ventricular cardiac arrhythmias] Zehender M. **Z Kardiol** 1996;85 Suppl 6:135–45 (120 ref.) (Eng. Abstr.) **(Ger)**

[Magnesium salts in physiology and pathology: the potentials for their use in medicine] Spasov AA, et al. **Usp Fiziol Nauk** 1997 Apr–Jun;28(2):79–93 (110 ref.) (Eng. Abstr.) **(Rus)**

[Forced fibrinolysis causes damage to the myocardium. Magnesium therapy is considerate in myocardial infarction (see comments)] Nilsson CG, et al. **Lakartidningen** 1997 Jan 15;94(3):148–50 (31 ref.) Comment in: Lakartidningen 1997 Jan 22;94(4):251–2. **(Swe)**

URINE

Hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and severe hypocalciuria: a new syndrome? Mehrotra R, et al. **Am J Kidney Dis** 1997 Jan; 29(1):106–14 (27 ref.)

MAGNESIUM ADENOSINETRIPHOSPHATASE see **CA(2+) MG(2+)-ATPASE**

MAGNESIUM ADP see **ADENOSINE DIPHOSPHATE**

MAGNESIUM ATP see **ADENOSINE TRIPHOSPHATE**

MAGNESIUM ATPASE see **CA(2+) MG(2+)-ATPASE**

MAGNESIUM CHLORIDE

PHARMACOLOGY

A hint on pharmacological and toxicological differences between magnesium chloride and magnesium sulphate, or of scallops and men. Durlach J, et al. **Magnes Res** 1996 Oct;9(3):217–9 (15 ref.)

TOXICITY

A hint on pharmacological and toxicological differences between magnesium chloride and magnesium sulphate, or of scallops and men. Durlach J, et al. **Magnes Res** 1996 Oct;9(3):217–9 (15 ref.)

MAGNESIUM COMPOUNDS

Treatment options in struvite stones. Wang LP, et al. **Urol Clin North Am** 1997 Feb;24(1):149–62 (149 ref.)

MAGNESIUM DEFICIENCY

Clinical disorders of magnesium metabolism. Whang R. **Compr Ther** 1997 Mar;23(3):168–73 (46 ref.)

A review of evidence for a role of magnesium and possibly copper deficiency in necrotizing enterocolitis. Caddell JL. **Magnes Res** 1996 Mar;9(1):55–66 (106 ref.)

BLOOD

Commentary on magnesium deficiency and nitric oxide. Rayssiguier Y, et al. **Magnes Res** 1996 Dec;9(4):329–30 (5 ref.)

COMPLICATIONS

Magnesium and cardiovascular biology: an important link between cardiovascular risk factors and atherogenesis. Altura BM, et al. **Cell Mol Biol Res** 1995;41(5):347–59 (95 ref.)

Environmental magnesium deficiency as a cardiovascular risk factor. Rylander R. **J Cardiovasc Risk** 1996 Feb;3(1):4–10 (48 ref.)

Evidence for magnesium deficiency in the pathogenesis of bronchopulmonary dysplasia (BPD). Caddell JL. **Magnes Res** 1996 Oct;9(3):205–16 (116 ref.)

Commentary on recent clinical advances: magnesium depletion, magnesium deficiency and asthma. Durlach J.

MAGNESIUM DEFICIENCY

Magnes Res 1995 Dec;8(4):403–5 (10 ref.)

DRUG THERAPY

[Magnesium deficiency and magnesium substitution. Effect on ventricular cardiac arrhythmias of various etiology] Zehender M, et al. **Herz** 1997 Jun;22 Suppl 1:56–62 (54 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Magnesium deficiency and cardiogenic shock after cardiopulmonary bypass. Storm W, et al.
Ann Thorac Surg 1997 Aug;64(2):572–7 (60 ref.)

[Magnesium: metabolism and requirements] López Martínez J, et al. **Nutr Hosp** 1997 Jan–Feb;12(1):4–14 (58 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Role of free radicals and substance P in magnesium deficiency [see comments] Weglicki WB, et al. **Cardiovasc Res** 1996 May;31(5):677–82 (51 ref.) Comment in: Cardiovasc Res 1996 May;31(5):675.

Commentary on magnesium deficiency,'substance P receptor up-regulation and NO overproduction. Weglicki WB, et al. **Magnes Res** 1996 Dec;9(4):331–2 (10 ref.)

PHYSIOPATHOLOGY

[Comments on the kinetics and extracellular effects of potassium and magnesium] Vierling W. **Herz** 1997 Jun;22 Suppl 1:3–10 (8 ref.) (Eng. Abstr.) **(Ger)**

MAGNESIUM SULFATE

PHARMACOLOGY

Role of magnesium sulfate in seizure prevention in patients with eclampsia and pre-eclampsia. Anthony J, et al.
Drug Saf 1996 Sep;15(3):188–99 (115 ref.)

A hint on pharmacological and toxicological differences between magnesium chloride and magnesium sulphate, or of scallops and men. Durlach J, et al. **Magnes Res** 1996 Oct;9(3):217–9 (15 ref.)

The osmotic and intrinsic mechanisms of the pharmacological laxative action of oral high doses of magnesium sulphate. Importance of the release of digestive polypeptides and nitric oxide. Izzo AA, et al. **Magnes Res** 1996 Jun; 9(2):133–8 (35 ref.)

THERAPEUTIC USE

An ion for the lungs [editorial; comment] Skobeloff EM. **Acad Emerg Med** 1996 Dec;3(12):1082–4 (15 ref.) Comment on: Acad Emerg Med 1996 Dec;3(12):1093–7.

Magnesium sulfate therapy in certain emergency conditions. Frakes MA, et al. **Am J Emerg Med** 1997 Mar;15(2):182–7 (81 ref.)

Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy. Management with intravenous magnesium sulfate. Winters SL, et al. **Chest** 1997 May; 111(5):1454–7 (6 ref.)

Phenytoin as an alternative treatment for preeclampsia. Lucas LS, et al. **J Obstet Gynecol Neonatal Nurs** 1997 May–Jun; 26(3):263–9 (9 ref.)

Experimental and clinical effects of magnesium infusion in the treatment of neonatal pulmonary hypertension. Patole SK, et al. **Magnes Res** 1995 Dec;8(4):373–88 (160 ref.)

[Magnesium sulfate in obstetrics: finally recognized! (editorial)] Treisser A.
J Gynecol Obstet Biol Reprod (Paris) 1997;26(2):120–2 (8 ref.) **(Fre)**

TOXICITY

A hint on pharmacological and toxicological differences between magnesium chloride and magnesium sulphate, or of scallops and men. Durlach J, et al. **Magnes Res** 1996 Oct;9(3):217–9 (15 ref.)

MAGNETIC RESONANCE see **NUCLEAR MAGNETIC RESONANCE**

MAGNETIC RESONANCE ANGIOGRAPHY

The application of magnetic resonance techniques to the evaluation of the patient with sickle-cell disease. Terk MR, et al. **Biomed Instrum Technol** 1996 Jul–Aug;30(4):349–53 (12 ref.)

Absence of flow in ovarian vein by time-of-flight magnetic resonance angiography without evidence of thrombosis. Rizk B, et al. **Clin Imaging** 1997 May–Jun;21(3):203–6 (11 ref.)

MRA of vascular malformations. Angtuaco EE, et al.
Clin Neurosci 1997;4(3):130–6 (14 ref.)

Spine MR angiography. Bowen BC, et al. **Clin Neurosci** 1997; 4(3):165–73 (45 ref.)

Magnetic resonance angiography in children. Glasier CM, et al. **Clin Neurosci** 1997;4(3):153–7 (6 ref.)

MRA in cerebrovascular disease. Hoeffner EG.
Clin Neurosci 1997;4(3):117–22 (32 ref.)

Magnetic resonance angiography in trauma. James CA.
Clin Neurosci 1997;4(3):137–45 (19 ref.)

MRA image production and display. Stringer WA.
Clin Neurosci 1997;4(3):110–6 (14 ref.)

MRA of cranial tumors and vascular compressive lesions. Van Hemert RL. **Clin Neurosci** 1997;4(3):146–52 (20 ref.)

MRA of venous sinus thrombosis. Wang AM.
Clin Neurosci 1997;4(3):158–64 (15 ref.)

MRA of intracranial aneurysms. Zamani A. **Clin Neurosci** 1997;4(3):123–9 (20 ref.)

Pictorial review: magnetic resonance angiography of arterial variants at the Circle of Willis. Barboriak DP, et al.
Clin Radiol 1997 Jun;52(6):429–36 (9 ref.)

Magnetic resonance coronary angiography in heart transplant recipients. Mohiaddin RH, et al. **Coron Artery Dis** 1996 Aug;7(8):591–7 (28 ref.)

Recent advances in cardiac magnetic resonance imaging [see comments] Taylor AM, et al. **Curr Opin Cardiol** 1996 Nov; 11(6):635–42 (37 ref.) Comment in: Curr Opin Cardiol 1996 Nov;11(6):611–23.

Three-dimensional contrast-enhanced magnetic resonance angiography of the thoracic vasculature. Leung DA, et al. **Eur Radiol** 1997;7(7):981–9 (28 ref.)

Assessment of coronary artery anatomy and function by MRI. Taylor AM, et al. **G Ital Cardiol** 1996 Dec; 26(12):1451–65 (61 ref.)

Cerebral infarction as multifocal clonic seizures in a term neonate. Balcom TA, et al. **J Am Board Fam Pract** 1997 Jan–Feb;10(1):43–9 (42 ref.)

Evaluation of the quality of clinical research studies of magnetic resonance angiography: 1991–1994. Sostman HD, et al. **J Magn Reson Imaging** 1996 Jan–Feb;6(1):33–8 (60 ref.)

Renal MR angiography. Borrello JA.
Magn Reson Imaging Clin N Am 1997 Feb;5(1):83–93 (49 ref.)

Vascular diseases and MR angiography of the liver. Spritzer CE. **Magn Reson Imaging Clin N Am** 1997 May;5(2):377–96 (66 ref.)

Determination of ventricular ejection fraction: a comparison of available imaging methods. The Cardiovascular Imaging Working Group. Rumberger JA, et al. **Mayo Clin Proc** 1997 Sep;72(9):860–70 (54 ref.)

Magnetic resonance angiography of the neck. Technical issues. Keller PJ. **Neuroimaging Clin N Am** 1996 Nov; 6(4):853–61 (20 ref.)

The role of magnetic resonance angiography in the assessment of intracranial vascular disease. Knopp EA.
Neuroimaging Clin N Am 1996 Aug;6(3):769–80 (33 ref.)

Magnetic resonance carotid angiography of the neck. Clinical implications. Rosovsky MA, et al.
Neuroimaging Clin N Am 1996 Nov;6(4):863–74 (36 ref.)

Cine gradient-echo MR imaging and MR velocity mapping in the evaluation of congenital heart disease. Rebergen SA, et al. **Radiographics** 1996 May;16(3):467–81 (28 ref.)

MR imaging of cystic adventitial disease of the popliteal artery: 2 cases. Decleir P, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1997 Feb;166(2):167–9 (8 ref.)

MR angiography of abdominal ischemia. Li KC.
Semin Ultrasound CT MR 1996 Aug;17(4):352–9 (35 ref.)

MR angiography of the peripheral vasculature. Schmiedl UP, et al. **Semin Ultrasound CT MR** 1996 Aug;17(4):404–11 (36 ref.)

MR imaging techniques for evaluation of the pancreas. Outwater EK, et al. **Top Magn Reson Imaging** 1996 Oct; 8(5):248–64 (98 ref.)

[MR angiography of the pelvic-leg blood vessels: current status and perspectives] Vosshenrich R, et al.
Aktuelle Radiol 1997 Jan;7(1):14–8 (24 ref.) (Eng. Abstr.) **(Ger)**

[MR angiography: abdominal veins] Arlart IP. **Radiologe** 1997 Jul;37(7):554–65 (48 ref.) (Eng. Abstr.) **(Ger)**

[Magnetic resonance angiography in stenosing-occlusive diseases of the carotid arteries: 3D with time of flight versus 3D with phase contrast] Scarabino T, et al.
Radiol Med (Torino) 1997 Mar;93(3):214–7 (23 ref.) (Eng. Abstr.) **(Ita)**

[Pulmonary MR angiography] Honda N. **Nippon Rinsho** 1997 Apr;55 Suppl 2:48–50 (10 ref.) **(Jpn)**

[Dynamics of cerebral blood flow using MR angiography] Ikushima I, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:337–40 (14 ref.) **(Jpn)**

[Estimation of portal flow by MR angiography] Machida K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:173–6 (9 ref.) **(Jpn)**

[Evaluation of coronary flow using MR angiography] Nitatori T, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:638–40 (10 ref.) **(Jpn)**

[MRA] Takahashi M. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1567–8 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Study of aortic pathology using magnetic resonance] Méndez Fernández R, et al. **Rev Esp Cardiol** 1996;49 Suppl 4:37–51 (41 ref.) (Eng. Abstr.) **(Spa)**

METHODS

Magnetic resonance angiography. Graves MJ.
Br J Radiol 1997 Jan;70:6–28 (138 ref.)

Peripheral magnetic resonance angiography: review of techniques, indications and artifacts. Mclennan A, et al.
Can Assoc Radiol J 1997 Apr;48(2):108–18 (33 ref.)

Quantification of myocardial perfusion with MRI and exogenous contrast agents. Vallée JP, et al. **Cardiology** 1997 Jan–Feb;88(1):90–105 (117 ref.)

New imaging techniques for assessing cardiac function. Johnson LL, et al. **Crit Care Clin** 1996 Oct;12(4):919–37 (24 ref.)

MRI of coronary arteries. Duerinckx AJ.
Int J Card Imaging 1997 Jun;13(3):191–7 (53 ref.)

MR first pass imaging: quantitative assessment of transmural perfusion and collateral flow. Jerosch-Herold M, et al.
Int J Card Imaging 1997 Jun;13(3):205–18 (53 ref.)

A practical approach to MRI of coronary artery bypass graft patency and flow. van Rossum AC, et al.
Int J Card Imaging 1997 Jun;13(3):199–204 (20 ref.)

Phase-derivative analysis in MR angiography: reduced Venc dependency and improved vessel wall detection in laminar and disturbed flow. Hoogeveen RM, et al.
J Magn Reson Imaging 1997 Mar–Apr;7(2):321–30 (32 ref.)

Contrast-enhanced MR angiography. Bosmans H, et al.
Radiologe 1996 Feb;36(2):115–23 (42 ref.)

Pulmonary embolism: the role of computed tomography and magnetic resonance imaging. Bonomo L, et al. **Rays** 1996 Jul–Sep;21(3):378–96 (73 ref.) **(Eng, Ita)**

Pulmonary MR angiography. Gefter WB, et al.
Semin Ultrasound CT MR 1996 Aug;17(4):316–23 (67 ref.)

MR angiography of the renal arteries. King BF Jr.
Semin Ultrasound CT MR 1996 Aug;17(4):398–403 (15 ref.)

Gadolinium-enhanced three-dimensional MR angiography of the thoracoabdominal aorta. Krinsky G, et al.
Semin Ultrasound CT MR 1996 Aug;17(4):280–303 (19 ref.)

Peripheral magnetic resonance imaging. Round ME, et al.
Tex Heart Inst J 1996;23(2):155–61 (18 ref.)

Magnetic resonance imaging in congenital heart disease in children. Schlesinger AE, et al. **Tex Heart Inst J** 1996; 23(2):128–43 (95 ref.)

[Myocardial wall motion analysis with phase shift imaging: cine phase contrast technique] Kawamitsu H, et al.
Nippon Rinsho 1997 Jul;55(7):1794–9 (11 ref.) (Eng. Abstr.) **(Jpn)**

[MR angiography and MR cholangiopancreatography] Morimoto K, et al. **Nippon Rinsho** 1996 Sep;54(9):2591–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

MAGNETIC RESONANCE IMAGING

see related
NUCLEAR MAGNETIC RESONANCE

Magnetic resonance imaging and computed tomography in Alzheimer's disease. Wahlund LO.
Acta Neurol Scand Suppl 1996;168:50–3 (47 ref.)

Gd-DPTA enhanced MRI in Bell's palsy and herpes zoster oticus: an overview and implications for future studies. Jonsson L, et al. **Acta Otolaryngol (Stockh)** 1995 Sep; 115(5):577–84 (56 ref.)

MR imaging of primary non-Hodgkin's breast lymphoma. A case report. Mussurakis S, et al. **Acta Radiol** 1997 Jan; 38(1):104–7 (14 ref.)

MR imaging before arthroscopy in knee joint disorders? [see comments] Rappeport ED, et al. **Acta Radiol** 1996 Sep; 37(5):602–9 (44 ref.) Comment in: Acta Radiol 1996 Sep;37(5):601.

Intracranial chondroma. Brownlee RD, et al.
AJNR Am J Neuroradiol 1997 May;18(5):889–93 (17 ref.)

Progressive multifocal leukoencephalopathy: clinical and MR response to treatment. Garrels K, et al.
AJNR Am J Neuroradiol 1996 Mar;17(3):597–600 (18 ref.)

Functional neuroimaging studies in posttraumatic stress disorder. Rauch SL, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:83–98 (49 ref.)

MRI-MRS of the brain in systemic lupus erythematosus. How do we use it to understand causes of clinical signs? Tanabe J, et al. **Ann N Y Acad Sci** 1997 Aug 14;823:169–84 (53 ref.)

Preliminary evidence for abnormal cortical development in physically and sexually abused children using EEG coherence and MRI. Teicher MH, et al.
Ann N Y Acad Sci 1997 Jun 21;821:160–75 (84 ref.)

Magnetic resonance spectroscopy and spectroscopic imaging for the study of brain metabolism. Van Zijl PC, et al.
Ann N Y Acad Sci 1997 May 30;820:75–96 (51 ref.)

Rapid prototyping techniques for anatomical modelling in medicine. McGurk M, et al. **Ann R Coll Surg Engl** 1997 May;79(3):169–74 (29 ref.)

A prospective study comparing the accuracy of the clinical diagnosis of meniscus tear with magnetic resonance imaging and its effect on clinical outcome [see comments] Miller GK. **Arthroscopy** 1996 Aug;12(4):406–13 (42 ref.) Comment in: Arthroscopy 1997 Apr;13(2):271–5; discussion 276–7, 279–80. Comment in: Arthroscopy 1997 Apr;13(2):275–6; discussion 277–80.

Brain MRI findings in two cases with eclampsia. Unal M, et al. **Australas Radiol** 1996 Aug;40(3):348–50 (13 ref.)

MR imaging. Peterfy CG. **Baillieres Clin Rheumatol** 1996 Nov;10(4):635–78 (53 ref.)

Magnetic resonance imaging applications to cardiac diagnosis. Colletti PM, et al. **Biomed Instrum Technol** 1996 Jul–Aug;30(4):354–8 (14 ref.)

Three-dimensional methods for quantification of cancellous bone architecture. Odgaard A. **Bone** 1997 Apr;20(4):315–28 (189 ref.)

Primary sellar haemorrhagic melanoma: case report and review of the literature. Aubin MJ, et al.
Br J Neurosurg 1997 Feb;11(1):80–3 (12 ref.)

Neural arch tuberculosis: radiological features and their

correlation with surgical findings. Naim-Ur-Rahman, et al. **Br J Neurosurg** 1997 Feb;11(1):32–8 (7 ref.)
Does magnetic resonance imaging make a difference for patients with musculoskeletal sarcoma? Bloem JL, et al. **Br J Radiol** 1997 Apr;70:327–37 (68 ref.)
MRI in assessment of the systemic manifestations of rheumatological disease. Kainberger F, et al. **Br J Rheumatol** 1996 Dec;35 Suppl 3:40–4 (22 ref.)
MRI in the assessment of synovium and cartilage. Peterfy CG. **Br J Rheumatol** 1996 Dec;35 Suppl 3:3–5 (10 ref.)
Biochemistry below 0 degrees C: nature's frozen vertebrates. Storey KB, et al. **Braz J Med Biol Res** 1996 Mar; 29(3):283–307 (92 ref.)
Approach to the incidentally discovered pituitary mass. Molitch ME. **Cancer Treat Res** 1997;89:73–90 (83 ref.)
Magnetic resonance imaging in cardiology: current status and perspectives. Fedele F, et al. **Cardiologia** 1996 Jul; 41(7):595–611 (109 ref.)
MR imaging of the abnormal sternoclavicular joint--a pictorial essay. Klein MA, et al. **Clin Imaging** 1997 Mar-Apr;21(2):138–43 (14 ref.)
MRI of the liver. A pictorial essay. Shapiro RS, et al. **Clin Imaging** 1997 Jul-Aug;21(4):293–302 (34 ref.)
Magnetic resonance imaging in optic neuropathy. Moseley I, et al. **Clin Neurosci** 1997;4(5):302–19 (217 ref.)
Magnetic resonance imaging of the musculoskeletal system: part 7. The ankle. Haygood TM. **Clin Orthop** 1997 Mar; (336):318–36 (41 ref.)
Magnetic resonance imaging of the musculoskeletal system. Part 6. The Shoulder. Oxner KG. **Clin Orthop** 1997 Jan; (334):354–73 (78 ref.)
Magnetic resonance imaging of the musculoskeletal system. Part 5. The wrist. Siegel S, et al. **Clin Orthop** 1996 Nov; (332):281–300 (35 ref.)
Pictorial review: magnetic resonance imaging of acute orthopaedic trauma to the upper extremity. Eustace S, et al. **Clin Radiol** 1997 May;52(5):338–44 (15 ref.)
Pictorial review: magnetic resonance imaging of the paediatric elbow. Gordon AC, et al. **Clin Radiol** 1997 Aug; 52(8):582–8 (25 ref.)
The characterization of liver tumours by MRI. Robinson PJ. **Clin Radiol** 1996 Nov;51(11):749–61 (145 ref.)
Pictorial review: MR imaging of parotid tumours. Soler R, et al. **Clin Radiol** 1997 Apr;52(4):269–75 (13 ref.)
Magnetic resonance imaging of thymic epithelial tumors. Kushihashi T, et al. **Crit Rev Diagn Imaging** 1996 Aug; 37(3):191–259 (76 ref.)
Magnetic resonance imaging (MRI) of the knee: a pattern approach for evaluating bone marrow edema. Yu JS, et al. **Crit Rev Diagn Imaging** 1996 Sep;37(4):261–303 (51 ref.)
Recent advances in cardiac magnetic resonance imaging [see comments] Taylor AM, et al. **Curr Opin Cardiol** 1996 Nov; 11(6):635–42 (37 ref.) Comment in: Curr Opin Cardiol 1996 Nov;11(6):611-23.
What fMRI has taught us about human vision. Courtney SM, et al. **Curr Opin Neurobiol** 1997 Aug;7(4):554–61 (90 ref.)
Functional anatomy of object recognition in humans: evidence from positron emission tomography and functional magnetic resonance imaging. Bly BM, et al. **Curr Opin Neurol** 1997 Feb;10(1):5–9 (27 ref.)
The anatomical localization of saccades using functional imaging studies and transcranial magnetic stimulation. Carter N, et al. **Curr Opin Neurol** 1997 Feb;10(1):10–7 (47 ref.)
Metabolic imaging in the diagnosis of brain tumors. Slosman DO, et al. **Curr Opin Neurol** 1996 Dec;9(6):429–35 (46 ref.)
MRI in breast cancer diagnosis and treatment. Harms SE. **Curr Probl Diagn Radiol** 1996 Nov-Dec;25(6):193–215 (111 ref.)
Seeing visual hallucinations with functional magnetic resonance imaging. Howard R, et al. **Dement Geriatr Cogn Disord** 1997 Mar-Apr;8(2):73–7 (36 ref.)
Magnetoencephalography/magnetic source imaging in the assessment of patients with epilepsy. Ebersole JS. **Epilepsia** 1997;38 Suppl 4:S1–5 (21 ref.)
Stroke: the role of functional imaging. Bakker D, et al. **Eur J Nucl Med** 1997 Jan;24(1):2–5 (42 ref.)
Lung cancer staging: the role of computed tomography and magnetic resonance imaging. Bonomo L, et al. **Eur J Radiol** 1996 Aug;23(1):35–45 (48 ref.)
Contrast agents in magnetic resonance imaging. Dawson P. **Eur J Radiol** 1996 Nov;23(3):201–4 (14 ref.)
Contrast-enhanced MRI of the breast: accuracy, value, controversies, solutions. Heywang-Köbrunner SH, et al. **Eur J Radiol** 1997 Feb;24(2):94–108 (73 ref.)
Survey of CT and MR imaging of the orbit. Weber AL, et al. **Eur J Radiol** 1996 Mar;22(1):42–52 (28 ref.)
Functional magnetic resonance imaging in clinical neurology. Humberstone MR, et al. **Eur Neurol** 1996;36(3):117–24 (45 ref.)
Slowly progressive limb-kinetic apraxia. Otsuki M, et al. **Eur Neurol** 1997;37(2):100–3 (17 ref.)
MRI of pancreatic tumors. Kelekis NL, et al. **Eur Radiol** 1997;7(6):875–86 (60 ref.)
Contrast agents for MR imaging of the liver: a clinical overview. Mahfouz AE, et al. **Eur Radiol** 1997;7(4):507–13 (27 ref.)
Magnetic resonance imaging assessment of labyrinthine pathology. Marsot-Dupuch K, et al. **Eur Radiol** 1996; 6(5):621–30 (28 ref.)
MR imaging characteristics of hepatic tumors. Martí-Bonmatí L. **Eur Radiol** 1997;7(2):249–58 (48 ref.)
State-of-the-art CT and MRI of the adrenal gland. Peppercorn PD, et al. **Eur Radiol** 1997;7(6):822–36 (117 ref.)
High-resolution MR imaging of the eye and orbit. Hosten N, et al. **Front Radiat Ther Oncol** 1997;30:8–19 (37 ref.)
Recent developments in biliary tract imaging. Gillams AR, et al. **Gastrointest Endosc Clin N Am** 1996 Jan;6(1):1–15 (37 ref.)
Magnetic resonance cholangiopancreatography. Mehta SN, et al. **Gastrointest Endosc Clin N Am** 1997 Apr;7(2):247–70 (66 ref.)
Cerebral activity during visual stimulation: a positron emission tomography and functional magnetic resonance imaging study. Schiefer U, et al. **Ger J Ophthalmol** 1996 Mar;5(2):109–17 (63 ref.)
Magnetic resonance cholangiopancreatography. Bearcroft PW, et al. **Gut** 1997 Aug;41(2):135–7 (27 ref.)
Diagnostic strategies in pediatric imaging. Adamsbaum C, et al. **Horm Res** 1996;46(4–5):165–9 (30 ref.)
A novel volumetric feature extraction technique with applications to MR images. Ashton EA, et al. **IEEE Trans Med Imaging** 1997 Aug;16(4):365–71 (23 ref.)
Magnetic resonance imaging of the postoperative spine. Genant HK. **Instr Course Lect** 1994;43:471–3 (12 ref.)
Magnetic resonance imaging studies of the shoulder: diagnosis of lesions of the rotator cuff. Recht MP, et al. **Instr Course Lect** 1994;43:483–92 (50 ref.)
Magnetic resonance in monitoring the natural history of multiple sclerosis and the effects of treatment [see comments] Filippi M, et al. **Ital J Neurol Sci** 1996 Dec; 17(6):385–91 (72 ref.) Comment in: Ital J Neurol Sci 1996 Dec;17(6):383–4.
Primary skeletal lymphoma imaging and pathologic correlation. Cook MA, et al. **J Am Osteopath Assoc** 1996 Oct;96(10):610–2 (17 ref.)
Osteoarthropathy versus osteomyelitis: does magnetic resonance imaging help? Naftulin KA, et al. **J Am Podiatr Med Assoc** 1996 Apr;86(4):164–9 (28 ref.)
Magnetic resonance angiography. Shetty PG, et al. **J Assoc Physicians India** 1996 Nov;44(11):793–8, 803–7 (23 ref.)
Adolescent schizophrenia: a methodologic review of the current neuroimaging and neuropsychologic literature. Findling RL, et al. **J Autism Dev Disord** 1995 Dec; 25(6):627–39 (39 ref.)
Magnetic resonance imaging of cardiac and pericardial disease. Croisille P, et al. **J Belge Radiol** 1997 Jun; 80(3):133–6 (15 ref.)
Magnetic resonance imaging of thoracic vascular disease (congenital diseases excluded). Croisille P, et al. **J Belge Radiol** 1997 Jun;80(3):136–8 (8 ref.)
Imaging findings in patients with failed back surgery syndrome. Van Goethem JW, et al. **J Belge Radiol** 1997 Apr;80(2):81–4 (19 ref.)
Neuroimaging of focal malformations of cortical development. Barkovich AJ, et al. **J Clin Neurophysiol** 1996 Nov;13(6):481–94 (103 ref.)
Clinical image. MRI of scrotal hemangioma. Aizenstein RI, et al. **J Comput Assist Tomogr** 1996 Nov-Dec;20(6):888–9 (8 ref.)
Case report. MRI findings of severe Epstein-Barr virus encephalomyelitis. Donovan WD, et al. **J Comput Assist Tomogr** 1996 Nov-Dec;20(6):1027–9 (8 ref.)
Clinical image. MR demonstration of submucosal fat in a patient with Crohn's disease. Funt SA, et al. **J Comput Assist Tomogr** 1996 Nov-Dec;20(6):940–1 (5 ref.)
Clinical image. Lipoblastoma of the thigh: MR appearance. Katz DS, et al. **J Comput Assist Tomogr** 1996 Nov-Dec; 20(6):1002–3 (8 ref.)
Clinical image. Tophaceous gout of the lumbar spine: MR findings. Miller LJ, et al. **J Comput Assist Tomogr** 1996 Nov-Dec;20(6):1004–5 (7 ref.)
Tuberculosis of the prostate: MR appearance. Wang JH, et al. **J Comput Assist Tomogr** 1997 Jul-Aug;21(4):639–40 (6 ref.)
High-resolution magnetic resonance imaging to characterize the geometry of fatigued porcine bioprosthetic heart valves. Smith DB, et al. **J Heart Valve Dis** 1997 Jul;6(4):424–32 (32 ref.)
Magnetic resonance imaging in lactic acidosis. van der Knaap MS, et al. **J Inherit Metab Dis** 1996;19(4):535–47 (51 ref.)
Acute non-tuberculous retropharyngeal abscess in an adult. A case report and review of the literature. Karkanevatos A, et al. **J Laryngol Otol** 1997 Feb;111(2):169–71 (9 ref.)
CT and MRI of stroke. Bahn MM, et al. **J Magn Reson Imaging** 1996 Sep-Oct;6(5):833–45 (88 ref.)
MRI efficacy and effectiveness research: who needs it and who pays for it? Harms SE, et al. **J Magn Reson Imaging** 1996 Jan-Feb;6(1):4–6 (5 ref.)
MR imaging contrast agents--what's in a name? Mitchell DG. **J Magn Reson Imaging** 1997 Jan-Feb;7(1):1–4 (29 ref.)
Cardiovascular applications of magnetic resonance flow and velocity measurements. Szolar DH, et al. **J Magn Reson Imaging** 1996 Jan-Feb;6(1):78–89 (95 ref.)
Magnetic resonance imaging and clinical follow-up: study of 27 patients receiving chiropractic care for cervical and lumbar disc herniations. BenEliyahu DJ. **J Manipulative Physiol Ther** 1996 Nov-Dec;19(9):597–606 (58 ref.)
Epidemiological, genetic, pharmacological, kinesiological, nuclear medical (IBZM-SPECT), standard and functional MRI studies on Parkinson's disease and related disorders and economic evaluation of Parkinson's disease therapy--clinical projects in the BMFT-research program Munich: "Parkinson's disease and other basal ganglia disorders". Oertel WH, et al. **J Neural Transm Suppl** 1995; 46:325–37 (40 ref.)
MRI as a method to reveal in-vivo pathology in MS. Paty DW. **J Neural Transm Suppl** 1997;49:211–7 (37 ref.)
Primary diffuse leptomeningeal gliomatosis with signs of increased intracranial pressure and progressive meningeal enhancement on MRI. Park JS, et al. **J Neuroimaging** 1996 Oct;6(4):250–4 (16 ref.)
Successful surgical removal of an asymptomatic optic nerve hemangioblastoma in von Hippel-Lindau disease. Raila FA, et al. **J Neuroimaging** 1997 Jan;7(1):48–50 (23 ref.)
Giant spinal cord ependymoma in a child. Case report. Gangemi M, et al. **J Neurosurg Sci** 1996 Mar;40(1):71–5 (23 ref.)
Assessment of myocardial viability with two-dimensional echocardiography and magnetic resonance imaging. Lindner JR, et al. **J Nucl Cardiol** 1996 Mar-Apr; 3(2):167–82 (93 ref.)
Rounded atelectasis. Batra P, et al. **J Thorac Imaging** 1996 Summer;11(3):187–97 (34 ref.)
Magnetic resonance imaging of pulmonary apical tumors. Freundlich IM, et al. **J Thorac Imaging** 1996 Summer; 11(3):210–22 (11 ref.)
Imaging evaluation of obstructive atelectasis. Molina PL, et al. **J Thorac Imaging** 1996 Summer;11(3):176–86 (49 ref.)
Interventional MR imaging. Hagspiel KD, et al. **J Vasc Interv Radiol** 1997 Sep-Oct;8(5):745–58 (107 ref.)
Normal MR anatomy and techniques for imaging of the male pelvis. Banson ML. **Magn Reson Imaging Clin N Am** 1996 Aug;4(3):481–96 (27 ref.)
MR imaging of renal function. Bennett HF, et al. **Magn Reson Imaging Clin N Am** 1997 Feb;5(1):107–26 (58 ref.)
MR imaging of renal and adrenal masses in children. Bilal MM, et al. **Magn Reson Imaging Clin N Am** 1997 Feb; 5(1):179–97 (74 ref.)
MR imaging of soft-tissue masses in children. Bissett GS 3rd. **Magn Reson Imaging Clin N Am** 1996 Nov; 4(4):697–719 (39 ref.)
MR imaging of the pediatric pelvis. Boechat MI. **Magn Reson Imaging Clin N Am** 1996 Nov;4(4):679–96 (72 ref.)
Imaging of pediatric liver tumors. Buetow PC, et al. **Magn Reson Imaging Clin N Am** 1997 May;5(2):397–413 (50 ref.)
MR imaging of the liver. Primary malignant neoplasms in the adult. Buetow PC, et al. **Magn Reson Imaging Clin N Am** 1997 May;5(2):289–318 (55 ref.)
MR imaging of the pediatric spine. Byrd SE, et al. **Magn Reson Imaging Clin N Am** 1996 Nov;4(4):797–833 (31 ref.)
Detection and staging of renal cancer. Choyke PL. **Magn Reson Imaging Clin N Am** 1997 Feb;5(1):29–47 (50 ref.)
The role of MR imaging in the selection of therapy for prostate cancer. D'Amico AV. **Magn Reson Imaging Clin N Am** 1996 Aug;4(3):471–9 (26 ref.)
MR imaging of the prostate and seminal vesicles. David V. **Magn Reson Imaging Clin N Am** 1996 Aug;4(3):497–518 (67 ref.)
MR imaging of ligamentous abnormalities of the elbow. Desharnais L, et al. **Magn Reson Imaging Clin N Am** 1997 Aug;5(3):515–28 (34 ref.)
Retroperitoneal MR imaging. Engelken JD, et al. **Magn Reson Imaging Clin N Am** 1997 Feb;5(1):165–78 (51 ref.)
Pediatric musculoskeletal lesions simulating neoplasms. Fletcher BD, et al. **Magn Reson Imaging Clin N Am** 1996 Nov;4(4):721–47 (71 ref.)
Incidentally discovered adrenal masses. Francis IR, et al. **Magn Reson Imaging Clin N Am** 1997 Feb;5(1):147–64 (82 ref.)
MR imaging of osteochondral and articular lesions. Fritz RC. **Magn Reson Imaging Clin N Am** 1997 Aug;5(3):579–602 (94 ref.)
Cardiovascular MR imaging of children. Hernandez RJ. **Magn Reson Imaging Clin N Am** 1996 Nov;4(4):615–36 (49 ref.)
MR imaging of tendon injuries in the elbow. Ho CP. **Magn Reson Imaging Clin N Am** 1997 Aug;5(3):529–43 (24 ref.)
MR urography. Hussain S, et al. **Magn Reson Imaging Clin N Am** 1997 Feb;5(1):95–106 (22 ref.)
Pediatric musculoskeletal neoplasms. Evaluation with MR imaging. Jaramillo D, et al. **Magn Reson Imaging Clin N Am** 1996 Nov;4(4):749–70 (45 ref.)
The adrenal gland: radiologic-pathologic correlation. Krebs TL, et al. **Magn Reson Imaging Clin N Am** 1997 Feb; 5(1):127–46 (54 ref.)
Normal MR imaging anatomy of the elbow. Mallisee TA, et al. **Magn Reson Imaging Clin N Am** 1997 Aug;5(3):451–79 (23 ref.)
Benign liver tumors. Mathieu D, et al.

Magn Reson Imaging Clin N Am 1997 May;5(2):255–88 (71 ref.)

MR imaging of inflammatory disease of the liver. Mergo PJ, et al. **Magn Reson Imaging Clin N Am** 1997 May; 5(2):367–76 (41 ref.)

Retroperitoneal MR imaging in children. Meyer JS. **Magn Reson Imaging Clin N Am** 1996 Nov;4(4):657–78 (70 ref.)

Renal cysts and cystic neoplasms. Miller MA, et al. **Magn Reson Imaging Clin N Am** 1997 Feb;5(1):49–66 (29 ref.)

MR imaging of the liver. Cirrhosis and premalignant nodules. Ohtomo K. **Magn Reson Imaging Clin N Am** 1997 May; 5(2):331–46 (38 ref.)

Renal masses: urologic management. Ornstein DK, et al. **Magn Reson Imaging Clin N Am** 1997 Feb;5(1):1–12 (85 ref.)

MR imaging of the liver--a practical approach. Paley MR, et al. **Magn Reson Imaging Clin N Am** 1997 May; 5(2):415–29 (34 ref.)

MR imaging in the evaluation of small (< or =3.0 cm) renal masses. Rofsky NM, et al. **Magn Reson Imaging Clin N Am** 1997 Feb;5(1):67–81 (54 ref.)

MR imaging of normal variants and interpretation pitfalls of the elbow. Rosenberg ZS, et al. **Magn Reson Imaging Clin N Am** 1997 Aug;5(3):481–99 (50 ref.)

MR features of nerve disorders at the elbow. Rosenberg ZS, et al. **Magn Reson Imaging Clin N Am** 1997 Aug;5(3):545–65 (66 ref.)

Arthropathies and inflammatory conditions of the elbow. Schweitzer M, et al. **Magn Reson Imaging Clin N Am** 1997 Aug;5(3):603–17 (48 ref.)

Hepatic hemangiomas. Semelka RC, et al. **Magn Reson Imaging Clin N Am** 1997 May;5(2):241–53 (27 ref.)

MR imaging of scrotal, testicular, and penile diseases. Sica GT, et al. **Magn Reson Imaging Clin N Am** 1996 Aug; 4(3):545–63 (27 ref.)

MR imaging of the liver in children. Siegel MJ, et al. **Magn Reson Imaging Clin N Am** 1996 Nov;4(4):637–56 (50 ref.)

Pediatric chest MR imaging. Noncardiac clinical uses. Siegel MJ, et al. **Magn Reson Imaging Clin N Am** 1996 Nov; 4(4):599–613 (27 ref.)

Bone marrow imaging in children. Siegel MJ, et al. **Magn Reson Imaging Clin N Am** 1996 Nov;4(4):771–96 (70 ref.)

MR imaging of diffuse liver disease. Hepatic fat and iron. Siegelman ES. **Magn Reson Imaging Clin N Am** 1997 May; 5(2):347–65 (104 ref.)

MR imaging of musculoskeletal tumors in the elbow region. Steinbach LS, et al. **Magn Reson Imaging Clin N Am** 1997 Aug;5(3):619–53 (194 ref.)

MR imaging of bladder diseases. Teeger S, et al. **Magn Reson Imaging Clin N Am** 1996 Aug;4(3):565–81 (60 ref.)

MR staging of prostate cancer. How we can improve our accuracy with decisions aids and optimal techniques. Tempany CM. **Magn Reson Imaging Clin N Am** 1996 Aug; 4(3):519–32 (20 ref.)

The kidney: radiologic–pathologic correlation. Wagner BJ. **Magn Reson Imaging Clin N Am** 1997 Feb;5(1):13–28 (42 ref.)

Pediatric orbital and visual pathway lesions. Barnes PD, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):179–98 (86 ref.)

Vascular lesions in the orbit. Forbes G. **Neuroimaging Clin N Am** 1996 Feb;6(1):113–22 (22 ref.)

Normal computed tomography and magnetic resonance imaging anatomy of the globe, orbit, and visual pathways. Hesselink JR, et al. **Neuroimaging Clin N Am** 1996 Feb; 6(1):15–27 (16 ref.)

Hippocampus. Normal magnetic resonance imaging anatomy with volumetric studies. Hui F, et al. **Neuroimaging Clin N Am** 1997 Feb;7(1):11–30 (104 ref.)

Clinical signs and symptoms requiring computed tomography and magnetic resonance imaging evaluation. Levin LA. **Neuroimaging Clin N Am** 1996 Feb;6(1):1–14 (38 ref.)

Radiologic assessment of trauma and foreign bodies of the eye and orbit. Lustrin ES, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):219–37 (40 ref.)

Surgical methods and approaches in the treatment of orbital disease. Rubin PA, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):239–55 (68 ref.)

Benign and malignant tumors of the orbital cavity including the lacrimal gland. Warner MA, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):123–42 (109 ref.)

Graves' disease of the orbit. Weber AL, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):61–72 (34 ref.)

Pseudotumor of the orbit. Weber AL, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):73–92 (71 ref.)

Imaging evaluation of the optic nerve and visual pathway including cranial nerves affecting the visual pathway. Weber AL, et al. **Neuroimaging Clin N Am** 1996 Feb; 6(1):143–77 (162 ref.)

Normal anatomy and lesions of the lacrimal sac and duct: evaluated by dacryocystography, computed tomography, and MR imaging. Weber AL, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):199–217 (122 ref.)

Lymphoproliferative disease of the orbit. Weber AL, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):93–111 (51 ref.)

MR imaging and CT of pituitary abscess: case report and review. Kabuto M, et al. **Neurol Res** 1996 Dec;18(6):495–8 (22 ref.)

MRI of optic nerve enlargement in optic neuritis. Cornblath WT, et al. **Neurology** 1997 Apr;48(4):821–5 (15 ref.)

Localized proton magnetic resonance spectroscopy of cerebral metabolites. Frahm J, et al. **Neuropediatrics** 1996 Apr;27(2):64–9 (30 ref.)

Tumefactive demyelinating lesions. Dagher AP, et al. **Neuroradiology** 1996 Aug;38(6):560–5 (27 ref.)

"Dural tail" adjacent to a giant posterior cerebral artery aneurysm: case report and review of the literature. Good CD, et al. **Neuroradiology** 1997 Aug;39(8):577–80 (25 ref.)

Superficial siderosis of the central nervous system: MRI findings and clinical significance. Offenbacher H, et al. **Neuroradiology** 1996 May;38 Suppl 1:S51–6 (20 ref.)

MRI of mesenchymal chondrosarcoma of the orbit: case report and review of the literature. Shinaver CN, et al. **Neuroradiology** 1997 Apr;39(4):296–301 (22 ref.)

MRI of pituitary abscess: two cases and review of the literature. Wolansky LJ, et al. **Neuroradiology** 1997 Jul; 39(7):499–503 (35 ref.)

Magnetic resonance imaging of human brain function. Principles, practicalities, and possibilities. Bandettini PA, et al. **Neurosurg Clin N Am** 1997 Jul;8(3):345–71 (197 ref.)

Functional magnetic resonance imaging of the somatosensory cortex. Mueller WM, et al. **Neurosurg Clin N Am** 1997 Jul;8(3):373–81 (49 ref.)

Osteoblastoma of the calvaria: report of two cases diagnosed with MRI and clinical review. Cervoni L, et al. **Neurosurg Rev** 1997;20(1):51–4 (16 ref.)

Brain stem involvement in children with neurofibromatosis type 1: role of magnetic resonance imaging and spectroscopy in the distinction from diffuse pontine glioma. Broniscer A, et al. **Neurosurgery** 1997 Feb;40(2):331–7; discussion 337–8 (29 ref.)

Cavernous sinus thrombophlebitis: case report. Kriss TC, et al. **Neurosurgery** 1996 Aug;39(2):385–9 (31 ref.)

New aspects of brain physiology. Ross BD, et al. **NMR Biomed** 1996 Oct;9(7):279–96 (108 ref.)

MRI evidence of labyrinthine and eighth-nerve bundle involvement in mumps virus sudden deafness and vertigo. Comacchio F, et al. **ORL J Otorhinolaryngol Relat Spec** 1996 Nov–Dec; 58(6):295–7 (18 ref.)

Cystic chondroblastoma. Mermelstein LE, et al. **Orthopedics** 1997 Jan;20(1):69–71 (9 ref.)

Image guidance with laser applications. Fried MP, et al. **Otolaryngol Clin North Am** 1996 Dec;29(6):1063–78 (45 ref.)

Imaging of laryngeal cancer. Williams DW 3rd. **Otolaryngol Clin North Am** 1997 Feb;30(1):35–58 (51 ref.)

Imaging of paranasal sinus disease. Bangert BA. **Pediatr Clin North Am** 1997 Jun;44(3):681–99 (55 ref.)

Magnetic resonance imaging of the cardiovascular system and airway. Berlin SC. **Pediatr Clin North Am** 1997 Jun; 44(3):659–79 (71 ref.)

Imaging of developmental dysplasia of the hip. Donaldson JS, et al. **Pediatr Clin North Am** 1997 Jun;44(3):591–614 (35 ref.)

Imaging the child with a limp. Myers MT, et al. **Pediatr Clin North Am** 1997 Jun;44(3):637–58 (30 ref.)

Imaging of child abuse. Nimkin K, et al. **Pediatr Clin North Am** 1997 Jun;44(3):615–35 (47 ref.)

Diagnostic imaging in neuro-oncology. Vezina LG. **Pediatr Clin North Am** 1997 Jun;44(3):701–19 (33 ref.)

A serial CT scan and MRI verification of diffuse cerebrospinal gliomatosis: a case report with stereotactic diagnosis and radiological confirmation. Onal C, et al. **Pediatr Neurosurg** 1996 Aug;25(2):94–9 (50 ref.)

Neuroimaging of pediatric brain stem diseases other than brain stem glioma. Zimmerman RA. **Pediatr Neurosurg** 1996 Aug;25(2):83–92 (11 ref.)

Hypomelanosis of Ito and brain abnormalities: MRI findings and literature review. Steiner J, et al. **Pediatr Radiol** 1996 Nov;26(11):763–8 (36 ref.)

Magnetic resonance imaging and spectroscopy of the brain in propionic acidemia: clinical and biochemical considerations. Bergman AJ, et al. **Pediatr Res** 1996 Sep; 40(3):404–9 (30 ref.)

Easier access to MRI scanning? Moore N. **Practitioner** 1996 Sep;240(1566):522–31 (6 ref.)

Can receptors be imaged with MRI agents? Nunn AD, et al. **Q J Nucl Med** 1997 Jun;41(2):155–62 (33 ref.)

Germinoma arising in the basal ganglia in early stage: CT and MR findings. Yamana D, et al. **Radiat Med** 1995 Nov–Dec;13(6):305–8 (30 ref.)

MR imaging of bone marrow disorders. Deely DM, et al. **Radiol Clin North Am** 1997 Jan;35(1):193–212 (42 ref.)

MR imaging of the ankle and foot. Erickson SJ, et al. **Radiol Clin North Am** 1997 Jan;35(1):163–92 (78 ref.)

MR imaging of acute orthopedic trauma to the extremities. Eustace S. **Radiol Clin North Am** 1997 May;35(3):615–29 (68 ref.)

MR imaging of the elbow. An update. Fritz RC, et al. **Radiol Clin North Am** 1997 Jan;35(1):117–44 (123 ref.)

MR imaging of injuries to the small joints. Horton MG, et al. **Radiol Clin North Am** 1997 May;35(3):671–700 (111 ref.)

MR imaging of the knee ligaments and the postoperative knee. Irizarry JM, et al. **Radiol Clin North Am** 1997 Jan; 35(1):45–76 (80 ref.)

MR imaging of the female pelvis. Lipson SA, et al. **Radiol Clin North Am** 1996 Nov;34(6):1157–82 (67 ref.)

Role of MR imaging in acute injuries to the appendicular skeleton. Ohashi K, et al. **Radiol Clin North Am** 1997 May; 35(3):591–613 (166 ref.)

MR imaging of the wrist. Pretorius ES, et al. **Radiol Clin North Am** 1997 Jan;35(1):145–61 (54 ref.)

MR imaging of the knee menisci. Rubin DA. **Radiol Clin North Am** 1997 Jan;35(1):21–44 (79 ref.)

MR arthrography of the glenohumeral joint. Stoller DW. **Radiol Clin North Am** 1997 Jan;35(1):97–116 (47 ref.)

MR imaging of shoulder impingement and rotator cuff disease. Uri DS. **Radiol Clin North Am** 1997 Jan;35(1):77–96 (60 ref.)

Primary tumors of the musculoskeletal system. Vanel D, et al. **Radiol Clin North Am** 1997 Jan;35(1):213–37 (48 ref.)

Imaging of skeletal and soft tissue injuries in and around the knee. Walker CW, et al. **Radiol Clin North Am** 1997 May; 35(3):631–53 (61 ref.)

MR imaging of the meninges. Part II. Neoplastic disease. Fukui MB, et al. **Radiology** 1996 Dec;201(3):605–12 (82 ref.)

MR imaging of the meninges. Part I. Normal anatomic features and nonneoplastic disease. Meltzer CC, et al. **Radiology** 1996 Nov;201(2):297–308 (90 ref.)

Magnetic resonance imaging (MRI): considerations and applications in radiotherapy treatment planning. Khoo VS, et al. **Radiother Oncol** 1997 Jan;42(1):1–15 (100 ref.)

Magnetic resonance imaging of the spine in plasma cell dyscrasias. A review. Pertuiset E, et al. **Rev Rhum Engl Ed** 1996 Dec;63(11):837–45 (39 ref.)

VBR in schizophrenia: relationship to family history of psychosis and season of birth [published erratum appears in Schizophr Res 1997 May 24;25(2):167] DeQuardo JR, et al. **Schizophr Res** 1996 Jul 5;20(3):275–85 (60 ref.)

Noninvasive neuroinvestigation in liver disease. Morgan MY. **Semin Liver Dis** 1996 Aug;16(3):293–314 (112 ref.)

Magnetic resonance imaging of the bile ducts. Soto JA, et al. **Semin Roentgenol** 1997 Jul;32(3):188–201 (72 ref.)

The use of gadolinium in the MR evaluation of soft tissue tumors. Kransdorf MJ, et al. **Semin Ultrasound CT MR** 1997 Aug;18(4):251–68 (25 ref.)

High-resolution MR imaging of the breast. Orel SG. **Semin Ultrasound CT MR** 1996 Oct;17(5):476–93 (46 ref.)

MR arthrography of the rotator cuff and labral–ligamentous complex. Palmer WE. **Semin Ultrasound CT MR** 1997 Aug; 18(4):278–90 (19 ref.)

Current concepts of MR arthrography of the hip. Petersilge CA. **Semin Ultrasound CT MR** 1997 Aug;18(4):291–301 (37 ref.)

The use of intravenous contrast in MRI of extremity infection. Towers JD. **Semin Ultrasound CT MR** 1997 Aug; 18(4):269–75 (14 ref.)

Current status of imaging of articular cartilage. Hodler J, et al. **Skeletal Radiol** 1996 Nov;25(8):703–9 (41 ref.)

MRI in chronic recurrent multifocal osteomyelitis. Jurik AG, et al. **Skeletal Radiol** 1997 Apr;26(4):230–8 (38 ref.)

Intraosseous lipoma of the distal femur: MRI appearance. Levin MF, et al. **Skeletal Radiol** 1996 Jan;25(1):82–4 (5 ref.)

Traumatic spinal subarachnoid hematoma: report of a case with MRI. Gupta SK, et al. **Surg Neurol** 1997 Aug; 48(2):189–92 (36 ref.)

A review of MRI pulse sequences and techniques in neuroimaging. Jackson EF, et al. **Surg Neurol** 1997 Feb; 47(2):185–99 (62 ref.)

The eighth cranial nerve. Enterline DS. **Top Magn Reson Imaging** 1996 Jun;8(3):164–79 (83 ref.)

MR imaging of the gallbladder. Kelekis NL, et al. **Top Magn Reson Imaging** 1996 Oct;8(5):312–20 (35 ref.)

Cranial nerves III, IV, and VI. Laine FJ. **Top Magn Reson Imaging** 1996 Apr;8(2):111–30 (61 ref.)

Controversies in magnetic resonance imaging of the hip. MacDougall L, et al. **Top Magn Reson Imaging** 1996 Feb; 8(1):44–50 (27 ref.)

Magnetization transfer magnetic resonance imaging: a clinical review. Mehta RC, et al. **Top Magn Reson Imaging** 1996 Aug;8(4):214–30 (66 ref.)

The trigeminal nerve. Nemzek WR. **Top Magn Reson Imaging** 1996 Jun;8(3):132–54 (60 ref.)

MR imaging of pancreatic disorders. Outwater EK, et al. **Top Magn Reson Imaging** 1996 Oct;8(5):265–89 (115 ref.)

MR arthrography: is it worthwhile? Palmer WE. **Top Magn Reson Imaging** 1996 Feb;8(1):24–43 (50 ref.)

Magnetic resonance imaging of cranial nerve VII. Perry JR, et al. **Top Magn Reson Imaging** 1996 Jun;8(3):155–63 (30 ref.)

MR of the postoperative knee. Tuite MJ, et al. **Top Magn Reson Imaging** 1996 Feb;8(1):2–14 (51 ref.)

Orbit and optic nerve. Villablanca P, et al. **Top Magn Reson Imaging** 1996 Apr;8(2):87–110 (75 ref.)

Magnetic resonance imaging in musculoskeletal assessment: a surgeon's perspective. Zuelzer WA. **Top Magn Reson Imaging** 1996 Feb;8(1):68–77 (79 ref.)

What is new in bladder cancer imaging. Barentsz JO, et al. **Urol Clin North Am** 1997 Aug;24(3):583–602 (31 ref.)

Imaging approach to staging of renal cell carcinoma. Bechtold RE, et al. **Urol Clin North Am** 1997 Aug; 24(3):507–22 (60 ref.)

[Imaging methods, particularly magnetic resonance, in multiple sclerosis] Seidl Z, et al. **Cas Lek Cesk** 1996 Dec 4;135(23):747–52 (53 ref.) (Eng. Abstr.) **(Cze)**

[The most rapid detection of ischemic strokes] Kalvach P.

Vnitr Lek 1997 Jan;43(1):29–33 (18 ref.) **(Cze)**

[MRI of the joints] Haltiala T, et al. **Duodecim** 1995; 111(16):1553–64 (21 ref.) **(Fin)**

[MRI of degenerative extrapyramidal syndromes. Parkinson disease, progressive supranuclear palsy and multiple system atrophy] Elkeslassy A, et al. **J Neuroradiol** 1996 Dec; 23(3):157–63 (14 ref.) (Eng. Abstr.) **(Fre)**

[Rhabdoid tumor of the central nervous system. Ultrasonographic, computed tomographic and MRI aspects apropos of a case in an infant] Guessoum M, et al. **J Neuroradiol** 1997 Jun;24(1):60–4 (16 ref.) (Eng. Abstr.) **(Fre)**

[Hepatic hamartoma in adults. Apropos of a case documented by MRI] Beal D, et al. **J Radiol** 1996 Dec;77(12):1229–32 (19 ref.) (Eng. Abstr.) **(Fre)**

[MRI of the pulmonary parenchyma. Clinical value and research prospects] Berthezène Y, et al. **J Radiol** 1997 May; 78(5):347–51 (25 ref.) (Eng. Abstr.) **(Fre)**

[Primary bilateral adrenal lymphoma as viewed by MRI. Apropos of a case] Dhôte R, et al. **J Radiol** 1997 Apr; 78(4):299–302 (20 ref.) (Eng. Abstr.) **(Fre)**

[Intra-parotid neurogenic tumors of the facial nerve. Value of MRI] Fisch-Ponsot C, et al. **J Radiol** 1997 Feb; 78(2):141–4 (14 ref.) (Eng. Abstr.) **(Fre)**

[Imaging of osteoarticular diseases of the anterior chest wall] Grignon B, et al. **J Radiol** 1997 Feb;78(2):103–10 (31 ref.) (Eng. Abstr.) **(Fre)**

[Digestive tract imaging: what's new in 1996?] Legmann P. **J Radiol** 1996 Sep;77(9):679–82 (30 ref.) **(Fre)**

[Magnetic resonance imaging of temporal lobe epilepsy] Lehéricy S, et al. **J Radiol** 1996 Nov;77(11):1095–104 (59 ref.) (Eng. Abstr.) **(Fre)**

[Serial anatomy and MRI of the basal ganglia and the thalamus] Francke JP, et al. **Neurochirurgie** 1997;43 Suppl 1:20–32 (0 ref.) **(Fre)**

[Functional imaging] Rascol O, et al. **Neurochirurgie** 1997; 43 Suppl 1:41–51 (0 ref.) **(Fre)**

[Morphological and functional neuro-imaging of surgical partial epilepsies in adults] Mauguière F, et al. **Rev Neurol (Paris)** 1996 Aug-Sep;152(8–9):501–16 (121 ref.) (Eng. Abstr.) **(Fre)**

[MR mammography: current status and indications] Umschaden HW, et al. **Acta Med Austriaca** 1997; 24(2):39–45 (32 ref.) (Eng. Abstr.) **(Ger)**

[Radiologic diagnosis of hypophyseal adenomas] Brechtelsbauer D, et al. **Aktuelle Radiol** 1996 Nov; 6(6):301–7 (38 ref.) (Eng. Abstr.) **(Ger)**

[Injuries of the spine: current concepts in radiologic diagnosis] du Mesnil de Rochemont R, et al. **Aktuelle Radiol** 1997 Jan;7(1):1–13 (51 ref.) (Eng. Abstr.) **(Ger)**

[Imaging methods in traumatology of the shoulder- and elbow joint] Heyer D. **Aktuelle Radiol** 1996 Sep;6(5):225–31 (50 ref.) (Eng. Abstr.) **(Ger)**

[Neuroradiologic activation studies of cerebral organization of language capacities. A review of the literature] Ackermann H, et al. **Fortschr Neurol Psychiatr** 1997 Apr; 65(4):182–94 (125 ref.) (Eng. Abstr.) **(Ger)**

[Intravascular lymphomatosis of the nervous system--case report and review of the literature] Heesen C, et al. **Fortschr Neurol Psychiatr** 1996 Jun;64(6):234–41 (104 ref.) (Eng. Abstr.) **(Ger)**

[Structural magnetic resonance tomography in diagnosis and research of Alzheimer type dementia] Hampel H, et al. **Nervenarzt** 1997 May;68(5):365–78 (108 ref.) (Eng. Abstr.) **(Ger)**

[Imaging of the labyrinth and vestibular nerve. Clinical significance for differential diagnosis of vestibular diseases] Jäger L, et al. **Nervenarzt** 1997 Jun;68(6):443–58 (42 ref.) (Eng. Abstr.) **(Ger)**

[Value of computerized tomography and magnetic resonance tomography in psychiatric diagnosis] Schlegel S, et al. **Nervenarzt** 1997 Jan;68(1):1–10 (95 ref.) (Eng. Abstr.) **(Ger)**

[Examination of psychological functions by functional imaging with positron emission tomography and magnetic resonance imaging] Schneider F, et al. **Nervenarzt** 1996 Sep;67(9):721–9 (60 ref.) (Eng. Abstr.) **(Ger)**

[Tracheobronchomegaly--Mounier-Kuhn syndrome--case report and review of the literature] Wiesner B, et al. **Pneumologie** 1997 Mar;51(3):291–5 (31 ref.) (Eng. Abstr.) **(Ger)**

[Malignant lymphoma. Diagnosis and after-care in adults with special reference to cross-sectional imaging] Brado M, et al. **Radiologe** 1997 Jan;37(1):10–8 (42 ref.) (Eng. Abstr.) **(Ger)**

[Primary malignant lymphoma of the brain] Hartmann M, et al. **Radiologe** 1997 Jan;37(1):42–50 (26 ref.) (Eng. Abstr.) **(Ger)**

[Pericardium--radiologic diagnosis] Kopsa W, et al. **Radiologe** 1997 May;37(5):378–87 (28 ref.) (Eng. Abstr.) **(Ger)**

[Rare intracranial plasmacytoma manifestations. Case reports and review of the literature in diffuse plasmocytoma, in primary solitary extramedullary plasmacytoma in in primary solitary osseous plasmacytoma] Kujat C, et al. **Radiologe** 1996 Nov;36(11):914–20 (42 ref.) (Eng. Abstr.) **(Ger)**

[Inflammatory facial paralysis in MRI. An overview] Sartoretti-Schefer S, et al. **Radiologe** 1996 Nov; 36(11):890–6 (52 ref.) (Eng. Abstr.) **(Ger)**

[Inflammatory diseases of the spinal cord and spinal nerve roots in the MRI] Sartoretti-Schefer S, et al. **Radiologe** 1996 Nov;36(11):897–913 (159 ref.) (Eng. Abstr.) **(Ger)**

[Lymphoma in childhood] Wunsch C, et al. **Radiologe** 1997 Jan;37(1):51–61 (48 ref.) (Eng. Abstr.) **(Ger)**

[Traumatic paresis of the n. facialis and n. cochlearis: its comparative imaging in MRT and CT] Mack MG, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Feb;166(2):170–2 (7 ref.) **(Ger)**

[MRT in tuberculous gonarthritis in childhood] Staatz G, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Aug;167(2):210–2 (10 ref.) **(Ger)**

[Magnetic resonance tomography in myocardial ischemia: state of the art] Szolar DH, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Sep;165(3):216–26 (53 ref.) (Eng. Abstr.) **(Ger)**

[Odontogenic keratocysts--their imaging via MRT] Wildberger JE, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Aug;167(2):207–9 (8 ref.) **(Ger)**

[Periarticular fractures--what should be observed?] Hald HJ. **Rontgenpraxis** 1997 Jun;50(6):158–67 (41 ref.) **(Ger)**

[Possibilities of abdominal tumor volumetry] Helmberger H, et al. **Rontgenpraxis** 1997 Jan;50(1):11–7 (55 ref.) **(Ger)**

[MRI in urology] Kutschker C, et al. **Rontgenpraxis** 1997 May;50(5):110–4 (18 ref.) **(Ger)**

[Modern imaging methods in diagnosis of tumors of the oropharynx and mouth cavity] Lenz M. **Rontgenpraxis** 1996 Nov;49(11):286–96 (28 ref.) **(Ger)**

[Avascular bone necrosis] Tomczak R, et al. **Rontgenpraxis** 1997 Jun;50(6):155–7 (18 ref.) **(Ger)**

[Magnetic resonance tomography in early diagnosis of rheumatoid arthritis] Uhl M, et al. **Rontgenpraxis** 1997 Jun; 50(6):130–4 (22 ref.) **(Ger)**

[Magnetic resonance tomography (MRI) of ligament injuries of the upper ankle joint] Zanetti M, et al. **Sportverletz Sportschaden** 1996 Sep;10(3):58–62 (23 ref.) (Eng. Abstr.) **(Ger)**

[Diagnostic imaging and radiation protection in trauma surgery. 2] Wolf K, et al. **Unfallchirurg** 1996 Dec; 99(12):975–85 (23 ref.) **(Ger)**

[Value and importance of magnetic resonance tomography] Schmidt F. **Z Arztl Fortbild Qualitatssich** 1997 Jul; 91(4):309–17 (44 ref.) (Eng. Abstr.) **(Ger)**

[Radiology and geriatrics: limits between normal values and pathology exemplified by conventional thoracic roentgen image, cerebral CT and MRI and pelvic-leg angiography] Osterheider MA. **Z Gerontol Geriatr** 1997 May-Jun; 30(3):226–34 (17 ref.) (Eng. Abstr.) **(Ger)**

[Imaging of hip joint cartilage and its significance for the intertrochanteric transposition osteotomies in coxarthrosis] Bernd L, et al. **Z Orthop Ihre Grenzgeb** 1996 Jul-Aug; 134(4):366–70 (41 ref.) (Eng. Abstr.) **(Ger)**

[Image diagnosis and functional tests--vertigo due to cerebellar and brain stem disorders] Kitamura T. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Jul;99(7):1036–9 (9 ref.) **(Jpn)**

[Progress in instrument used for diagnosis of obstructive jaundice. 4. MRCP] Akahane M. **Nippon Naika Gakkai Zasshi** 1997 Apr 10;86(4):602–7 (5 ref.) **(Jpn)**

[Lung cancer: Progress in diagnosis and treatment. II. Diagnostic imaging: 3. Thoracic CT and MRI] Kusumoto M, et al. **Nippon Naika Gakkai Zasshi** 1997 Jan 10; 86(1):51–7 (7 ref.) **(Jpn)**

[Obstructive jaundice: progress in instrument used for diagnosis. 5) CT and MRI] Moriyama N, et al. **Nippon Naika Gakkai Zasshi** 1997 Apr 10;86(4):608–14 (4 ref.) **(Jpn)**

[The use of magnetic resonance imaging (MRI) and single photon emission computing tomography (SPECT) for the differential diagnosis of Parkinson's disease and other neurodegenerative disorders presenting as parkinsonism] Kohira I. **Nippon Rinsho** 1997 Jan;55(1):39–42 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Evaluation of intracranial deep cerebral veins using MRI] Ohkawa M, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:345–7 (8 ref.) **(Jpn)**

[Measurement of gastric emptying by MRI] Takazakura R, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:150–2 (9 ref.) **(Jpn)**

[Interpretation of bone and cartilage magnetic resonance images and their future prospect] Kusaka Y. **Nippon Seikeigeka Gakkai Zasshi** 1996 Dec;70(12):807–16 (26 ref.) **(Jpn)**

[Diagnostic imaging of the orthopaedic diseases with special emphasis on magnetic resonance technology] Miyasaka K. **Nippon Seikeigeka Gakkai Zasshi** 1997 Jan;71(1):1–10 (5 ref.) **(Jpn)**

[A case of hepatic hemangiosarcoma in which heterogeneous MRI findings were useful for diagnosis] Oba S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Jan;94(1):49–55 (13 ref.) **(Jpn)**

[Clinical application of functional mapping; the present state of the art and its future prospects: (series 2) Identification of motor, sensory, visual and speech cortex by functional MRI] Ito T, et al. **No Shinkei Geka** 1996 Feb;24(2):109–18 (23 ref.) **(Jpn)**

[Functional mapping of the brain in a patient before neurological surgery by superposition of activation SPECT and MR images] Otsuki H, et al. **No Shinkei Geka** 1996 Jul;24(7):598–603 (26 ref.) **(Jpn)**

[Principle and clinical application of MRI] Harada J. **Rinsho Byori** 1997 Mar;45(3):237–41 (3 ref.) (Eng. Abstr.) **(Jpn)**

[Functional MRI of the brain] Naruse S. **Rinsho Shinkeigaku** 1995 Dec;35(12):1345–50 (10 ref.) (Eng. Abstr.) **(Jpn)**

[CT and MRI: what you see and don't see] Okuda S. **Rinsho Shinkeigaku** 1995 Dec;35(12):1564–6 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Immunotherapy of multiple sclerosis: the use of magnetic resonance imaging in the evaluation of clinical trials] Ozawa K, et al. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1501–3 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Two siblings with familial schizencephaly--report of a family and review in relation to clinical features and neuroradiological findings] Ueda M, et al. **Rinsho Shinkeigaku** 1996 Jun;36(6):774–9 (22 ref.) (Eng. Abstr.) **(Jpn)**

[MR imaging of the brain of amyotrophic lateral sclerosis] Yagishita A. **Rinsho Shinkeigaku** 1995 Dec;35(12):1554–6 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Neuroimaging and fundamental symptoms in schizophrenia] Lopez-Ibor MI, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 Jan-Feb;24(1):25–8 (30 ref.) (Eng. Abstr.) **(Spa)**

[Gram-negative meningitis secondary to congenital dermal sinus demonstrated by magnetic resonance] Verdú Pérez A, et al. **An Esp Pediatr** 1996 May;44(5):491–2 (9 ref.) **(Spa)**

[Cor triatriatum with interventricular communication: Doppler color ultrasonography and magnetic resonance diagnosis. Repair in the first months] Cabrera A, et al. **Rev Esp Cardiol** 1997 Apr;50(4):290–2 (8 ref.) (Eng. Abstr.) **(Spa)**

[Diagnosis by imaging of the brain affected by AIDS] Mercader-Sobrequés JM, et al. **Rev Neurol** 1996 Dec; 24(136):1577–89 (43 ref.) (Eng. Abstr.) **(Spa)**

[Investigation of epilepsy. Magnetic tomography more and more important as a diagnostic technique] Holtås S, et al. **Lakartidningen** 1997 Jun 4;94(23):2194–200 (20 ref.) (Eng. Abstr.) **(Swe)**

ECONOMICS

Economics of MRI technology. Bell RA. **J Magn Reson Imaging** 1996 Jan-Feb;6(1):10–25 (50 ref.)

Future cost-effective MRI will be at high field. Bradley WG. **J Magn Reson Imaging** 1996 Jan-Feb;6(1):63–6 (5 ref.)

Benefits and costs of MR imaging of prostate cancer. Langlotz CP. **Magn Reson Imaging Clin N Am** 1996 Aug; 4(3):533–44 (32 ref.)

INSTRUMENTATION

Intracerebral depth electrode monitoring in partial epilepsy: the morbidity and efficacy of placement using magnetic resonance image-guided stereotactic surgery. Ross DA, et al. **Neurosurgery** 1996 Aug;39(2):327–33; discussion 333–4 (39 ref.)

Technology and principles of tomographic image-guided interventions and surgery. Melzer A, et al. **Surg Endosc** 1997 Sep;11(9):946–56 (25 ref.)

[Computer-assisted orthopedic surgery. From pedicle screw insertion to further applications] Berlemann U, et al. **Orthopade** 1997 May;26(5):463–9 (34 ref.) (Eng. Abstr.) **(Ger)**

[Determining heart muscle perfusion by magnetic resonance tomography progressing to clinical application] Fischer SE, et al. **Radiologe** 1997 May;37(5):366–71 (30 ref.) (Eng. Abstr.) **(Ger)**

[MRI and ultrasound in rheumatology] Kainberger F, et al. **Radiologe** 1996 Aug;36(8):609–16 (38 ref.) (Eng. Abstr.) **(Ger)**

[High-field (3.0T) MR system: advantages in functional analysis] Nakada T. **Nippon Rinsho** 1997 Jul;55(7):1628–32 (9 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Overview of MnDPDP as a pancreas-specific contrast agent for MR imaging [see comments] Ahlström H, et al. **Acta Radiol** 1997 Jul;38(4 Pt 2):660–4 (18 ref.) Comment in: Acta Radiol 1997 Jul;38(4 Pt 2):623–5.

Myocardial perfusion by contrast-enhanced echocardiography and dynamic contrast-enhanced MR imaging. Lombardi M, et al. **Acta Radiol Suppl** 1997; 412:79–84 (26 ref.)

Image postprocessing and contrast agents in clinical MR imaging--an introductory overview. Rinck PA, et al. **Acta Radiol Suppl** 1997;412:7–19 (57 ref.)

Contrast-enhanced lymphography. CT or MR imaging? Vogl TJ, et al. **Acta Radiol Suppl** 1997;412:47–50 (41 ref.)

Signal sources in bold contrast fMRI. Turner R. **Adv Exp Med Biol** 1997;413:19–25 (31 ref.)

MR arthrography: a review of current technique and applications. Helgason JW, et al. **AJR Am J Roentgenol** 1997 Jun;168(6):1473–80 (50 ref.)

Rhinopharyngoscopy, computed tomography and magnetic resonance imaging. Bonifazi F, et al. **Allergy** 1997;52(33 Suppl):28–31 (32 ref.)

Detection of cerebral ischemia in systemic lupus erythematosus by magnetic resonance techniques. Welch KM, et al. **Ann N Y Acad Sci** 1997 Aug 14;823:120–31 (27 ref.)

Value of fat suppression magnetic resonance imaging in the diagnosis of lipomas of the internal auditory canal. Hara A, et al. **Ann Otol Rhinol Laryngol** 1997 Apr;106(4):343–7 (27 ref.)

Assessment of systolic and diastolic LV function by MR myocardial tagging. Matter C, et al. **Basic Res Cardiol** 1996; 91 Suppl 2:23–8 (26 ref.)

Magnetic resonance imaging of the bone marrow in hematologic malignancies. Moulopoulos LA, et al. **Blood** 1997 Sep 15;90(6):2127–47 (92 ref.)

Magnetic resonance imaging. Panting JR, et al. **Br J Hosp Med** 1997 Jan 15–Feb 5;57(1–2):27–30 (16 ref.)

Neuroimaging techniques for the ophthalmologist. Gans M. **Can J Ophthalmol** 1997 Jun;32(4):277–81 (11 ref.)

Towards absolute quantitation of myocardial blood flow in patients. Bianco JA, et al. **Cardiology** 1997 Jan–Feb; 88(1):52–3 (25 ref.)

NMR perfusion and metabolic imaging and some examples on brain tumours. Bovée WM, et al. **Cell Mol Biol (Noisy-le-grand)** 1997 Jul;43(5):675–89 (41 ref.)

A 'BOLD' new approach to renal oxygen economy [editorial; comment] Kone BC. **Circulation** 1996 Dec 15;94(12):3067–8 (17 ref.) Comment on: Circulation 1996 Dec 15;94(12):3271–5.

Imaging of articular pathology: MRI, CT, arthrography. Berquist TH. **Clin Anat** 1997;10(1):1–13 (35 ref.)

Imaging techniques for coronary artery disease: current status and future directions. Merz CN, et al. **Clin Cardiol** 1997 Jun;20(6):526–32 (41 ref.)

Innovations in minimalism: intraoperative MRI. Alexander E 3rd, et al. **Clin Neurosurg** 1996;43:338–52 (34 ref.)

MR imaging of soft tissues adjacent to orthopaedic hardware: techniques to minimize susceptibility artefact. Eustace S, et al. **Clin Radiol** 1997 Aug;52(8):589–94 (9 ref.)

Optimization of sequences for MRI of the abdomen and pelvis. Lomas DJ. **Clin Radiol** 1997 Jun;52(6):412–28 (78 ref.)

The use of MR imaging in the assessment and clinical management of stress reactions of bone in high-performance athletes. Arendt EA, et al. **Clin Sports Med** 1997 Apr;16(2):291–306 (15 ref.)

Imaging of stress injuries to bone. Radiography, scintigraphy, and MR imaging. Deutsch AL, et al. **Clin Sports Med** 1997 Apr;16(2):275–90 (29 ref.)

Contemporary imaging of athletic injuries. Tung GA, et al. **Clin Sports Med** 1997 Jul;16(3):393–417 (46 ref.)

Liver MRI with contrast enhancement. Runge VM. **Crit Rev Diagn Imaging** 1997 Jun;38(3):207–30 (29 ref.)

Magnetic resonance and functional magnetic resonance imaging: tools for the study of human epilepsy. Kuzniecky R. **Curr Opin Neurol** 1997 Apr;10(2):88–91 (24 ref.)

Do magnetic resonance techniques contribute to the management of clinical problems? van der Wall EE. **Eur Heart J** 1996 May;17(5):666–73 (25 ref.)

Optimizing joint imaging: MR imaging techniques. Adam G, et al. **Eur Radiol** 1996;6(6):882–9 (55 ref.)

Imaging and medical staging of lung cancer. Shaffer K. **Hematol Oncol Clin North Am** 1997 Apr;11(2):197–213 (47 ref.)

Assessment of myocardial perfusion by magnetic resonance imaging. Crnac J, et al. **Herz** 1997 Feb;22(1):16–28 (59 ref.)

Multishot rosette trajectories for spectrally selective MR imaging. Noll DC. **IEEE Trans Med Imaging** 1997 Aug; 16(4):372–7 (18 ref.)

Learning-based ventricle detection from cardiac MR and CT images. Weng J, et al. **IEEE Trans Med Imaging** 1997 Aug; 16(4):378–91 (36 ref.)

Magnetic resonance imaging in valvular heart disease. Schmidt M, et al. **Int J Card Imaging** 1997 Jun;13(3):219–31 (96 ref.)

Ischemic heart disease: value of MR techniques. van der Wall EE, et al. **Int J Card Imaging** 1997 Jun;13(3):179–89 (21 ref.)

Dynamic breath-hold 3D gadolinium-enhanced MRI of intraarterial masses: findings in two patients. Krinsky G, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):631–4 (9 ref.)

Venous aneurysms: MR diagnosis with the "layered gadolinium" sign. Krinsky G, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):623–7 (12 ref.)

Iron oxide-enhanced MR lymphography: the evaluation of cervical lymph node metastases in head and neck cancer. Anzai Y, et al. **J Magn Reson Imaging** 1997 Jan–Feb; 7(1):75–81 (41 ref.)

Report from efficacy subgroup MR methodology workshop. Black WC, et al. **J Magn Reson Imaging** 1996 Jan–Feb; 6(1):1–3 (13 ref.)

Use of gadolinium chelates in MR imaging of the spine. Bradley WG. **J Magn Reson Imaging** 1997 Jan–Feb; 7(1):38–46 (24 ref.)

Assessing tumor angiogenesis using macromolecular MR imaging contrast media. Brasch R, et al. **J Magn Reson Imaging** 1997 Jan–Feb;7(1):68–74 (40 ref.)

Water diffusion and exchange as they influence contrast enhancement. Donahue KM, et al. **J Magn Reson Imaging** 1997 Jan–Feb;7(1):102–10 (47 ref.)

Assessment of tumor microcirculation: a new role of dynamic contrast MR imaging. Griebel J, et al. **J Magn Reson Imaging** 1997 Jan–Feb;7(1):111–9 (73 ref.)

Contrast agents for MR imaging of the liver. Low RN. **J Magn Reson Imaging** 1997 Jan–Feb;7(1):56–67 (76 ref.)

Application of contrast agents in the evaluation of stroke: conventional MR and echo-planar MR imaging. Maeda M, et al. **J Magn Reson Imaging** 1997 Jan–Feb;7(1):23–8 (24 ref.)

Effects of contrast dose, delayed imaging, and magnetization transfer saturation on gadolinium-enhanced MR imaging of brain lesions. Mathews VP, et al. **J Magn Reson Imaging** 1997 Jan–Feb;7(1):14–22 (38 ref.)

Fast MR imaging techniques: impact in the abdomen. Mitchell DG. **J Magn Reson Imaging** 1996 Sep–Oct; 6(5):812–21 (87 ref.)

Recent technical advances in MR imaging of the abdomen. Riederer SJ. **J Magn Reson Imaging** 1996 Sep–Oct; 6(5):822–32 (59 ref.)

Physiologic measurements by contrast-enhanced MR imaging: expectations and limitations. Roberts TP. **J Magn Reson Imaging** 1997 Jan–Feb;7(1):82–90 (60 ref.)

Principles of contrast enhancement in the evaluation of brain diseases: an overview. Runge VM, et al. **J Magn Reson Imaging** 1997 Jan–Feb;7(1):5–13 (24 ref.)

The impact of field strength on image quality in MRI. Rutt BK, et al. **J Magn Reson Imaging** 1996 Jan–Feb;6(1):57–62 (12 ref.)

Contrast-enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple sclerosis. Simon JH. **J Magn Reson Imaging** 1997 Jan–Feb; 7(1):29–37 (74 ref.)

Contrast agents in functional MR imaging. Sorensen AG, et al. **J Magn Reson Imaging** 1997 Jan–Feb;7(1):47–55 (24 ref.)

Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. Tofts PS. **J Magn Reson Imaging** 1997 Jan–Feb; 7(1):91–101 (56 ref.)

Dynamic contrast-enhanced MR imaging of musculoskeletal tumors: basic principles and clinical applications. Verstraete KL, et al. **J Magn Reson Imaging** 1996 Mar–Apr; 6(2):311–21 (68 ref.)

Magnetic resonance: a multimodal approach to the brain? Laubenberger J. **J Neural Transm Suppl** 1997;50:3–8 (29 ref.)

Functional magnetic resonance imaging of the human brain. Kim SG, et al. **J Neurosci Methods** 1997 Jun 27; 74(2):229–43 (132 ref.)

Hepatic metastases. Lewis KH, et al. **Magn Reson Imaging Clin N Am** 1997 May;5(2):319–30 (54 ref.)

MR imaging of the liver. Contrast agents. Mahfouz AE, et al. **Magn Reson Imaging Clin N Am** 1997 May;5(2):223–40 (28 ref.)

MR imaging of the liver. Technique. Soyer P, et al. **Magn Reson Imaging Clin N Am** 1997 May;5(2):205–21 (78 ref.)

The role of magnetic susceptibility in magnetic resonance imaging: MRI magnetic compatibility of the first and second kinds. Schenck JF. **Med Phys** 1996 Jun;23(6):815–50 (376 ref.)

Looking into the black box: new directions in neuroimaging. Engel SA. **Neuron** 1996 Sep;17(3):375–8 (25 ref.)

Use of functional magnetic resonance imaging. Lee CC, et al. **Neurosurg Clin N Am** 1996 Oct;7(4):665–83 (58 ref.)

Evidence of optic pathway gliomas after previously negative neuroimaging. Massry GG, et al. **Ophthalmology** 1997 Jun; 104(6):930–5 (35 ref.)

Echo-planar FLAIR imaging in evaluation of intracranial lesions. Simonson TM, et al. **Radiographics** 1996 May; 16(3):575–84 (14 ref.)

Dedicated extremity MR imaging. An emerging technology. Peterfy CG, et al. **Radiol Clin North Am** 1997 Jan; 35(1):1–20 (32 ref.)

Contrast-enhanced MR imaging of the liver. Van Beers BE, et al. **Radiology** 1997 May;203(2):297–306 (105 ref.)

An update on osteonecrosis of the femoral head. Mazieres B. **Rev Rhum Engl Ed** 1996 Nov;63(10):648–58 (64 ref.)

Oncologic imaging: interactions of nuclear medicine with CT and MRI using the bone scan as a model. Tryciecky EW, et al. **Semin Nucl Med** 1997 Apr;27(2):142–51 (39 ref.)

MRI and CT in blunt renal trauma: an update. Leppäniemi A, et al. **Semin Ultrasound CT MR** 1997 Apr;18(2):129–35 (25 ref.)

Indirect MR arthrography: techniques and applications. Vahlensieck M, et al. **Semin Ultrasound CT MR** 1997 Aug; 18(4):302–6 (9 ref.)

Variable agreement between visual rating scales for white matter hyperintensities on MRI. Comparison of 13 rating scales in a poststroke cohort. Mäntylä R, et al. **Stroke** 1997 Aug;28(8):1614–23 (61 ref.)

Magnetic resonance imaging of acquired cardiac disease. Carrol CL, et al. **Tex Heart Inst J** 1996;23(2):144–54 (87 ref.)

MR imaging of cartilage: evaluation and comparison of MR imaging techniques. Balkissoon A. **Top Magn Reson Imaging** 1996 Feb;8(1):57–67 (34 ref.)

Magnetic resonance cholangiopancreatography of the biliary ducts: techniques, clinical applications, and limitations. Barish MA, et al. **Top Magn Reson Imaging** 1996 Oct; 8(5):302–11 (49 ref.)

MRI of avascular necrosis of bone. Bluemke DA, et al. **Top Magn Reson Imaging** 1996 Aug;8(4):231–46 (91 ref.)

MR of the brain in children. Grattan-Smith JD, et al. **Top Magn Reson Imaging** 1996 Aug;8(4):193–213 (99 ref.)

The use of gadolinium in the MR evaluation of musculoskeletal tumors. Kransdorf MJ. **Top Magn Reson Imaging** 1996 Feb;8(1):15–23 (25 ref.)

MR imaging techniques for evaluation of the pancreas. Outwater EK, et al. **Top Magn Reson Imaging** 1996 Oct; 8(5):248–64 (98 ref.)

MR pancreatography: technique and applications. Takehara Y. **Top Magn Reson Imaging** 1996 Oct;8(5):290–301 (54 ref.)

Magnetic resonance microscopy--a new tool for the toxicologic pathologist. Delnomdedieu M, et al. **Toxicol Pathol** 1996 Jan–Feb;24(1):36–44 (10 ref.)

[MRI and cognition] Le Bihan D. **Encephale** 1997 Jun;23 Spec No 3:5–8 (36 ref.) (Eng. Abstr.) **(Fre)**

[Magnetic resonance imaging of the thorax] Berthezène Y, et al. **Rev Mal Respir** 1997 Jan;14(1):64–6 (14 ref.) **(Fre)**

[What's new in spiral tomodensitometry?] Rémy J, et al. **Rev Mal Respir** 1996;13(4):445–9 (11 ref.) **(Fre)**

[High dosage administration of paramagnetic contrast media in diagnosis of focal brain lesions] Forsting M, et al. **Radiologe** 1996 Feb;36(2):101–6 (29 ref.) (Eng. Abstr.) **(Ger)**

[Anesthesia for magnetic resonance tomography in neonates, infants and young children] Funk W, et al. **Radiologe** 1997 Feb;37(2):159–64 (10 ref.) (Eng. Abstr.) **(Ger)**

[Development and experimental use of receptor-specific MR contrast media] Reimer P, et al. **Radiologe** 1996 Feb; 36(2):153–63 (77 ref.) (Eng. Abstr.) **(Ger)**

[Contrast media for magnetic resonance tomographic lymph node diagnosis (MR lymphography)] Taupitz M, et al. **Radiologe** 1996 Feb;36(2):134–40 (28 ref.) (Eng. Abstr.) **(Ger)**

[Value of magnetic resonance tomography in diagnosis of drug-resistant epilepsy] Zeitler H, et al. **Rontgenpraxis** 1997 Apr;50(4):83–7 (18 ref.) **(Ger)**

[Evaluation of brain perfusion using dynamic functional MRI] Anno I, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:348–53 (7 ref.) **(Jpn)**

[Evaluation of the biliary system and pancreatic duct using MR cholangiopancreatography] Hanaoka H, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:187–9 (8 ref.) **(Jpn)**

[Historical developments and present status of rapid NMR imaging] Kose K. **Nippon Rinsho** 1997 Jul;55(7):1633–7 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Brain structures of reading Japanese words with functional MRI] Makabe T, et al. **Nippon Rinsho** 1997 Jul; 55(7):1699–705 (29 ref.) (Eng. Abstr.) **(Jpn)**

[Advances in high speed MR imaging for the functional assessment of cardiovascular system] Matsuda T. **Nippon Rinsho** 1997 Jul;55(7):1789–93 (17 ref.) (Eng. Abstr.) **(Jpn)**

[MR angiography and MR cholangiopancreatography] Morimoto K, et al. **Nippon Rinsho** 1996 Sep;54(9):2591–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

[The evaluation of left ventricular wall motion with MRI tagging method] Saito I, et al. **Nippon Rinsho** 1997 Mar; 55 Suppl 1:634–7 (6 ref.) **(Jpn)**

[Technical aspects of fast, ultra-fast MR imaging] Tsukamoto T. **Nippon Rinsho** 1997 Jul;55(7):1638–42 (6 ref.) (Eng. Abstr.) **(Jpn)**

[MR imaging and dynamic MR imaging] Yoshikawa K, et al. **Nippon Rinsho** 1996 May;54(5):1255–62 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Bone marrow MRI in hematological disorders] Heshiki A. **Rinsho Ketsueki** 1997 May;38(5):345–8 (11 ref.) **(Jpn)**

[Diffusion MRI for evaluating cerebrovascular disease] Minematsu K, et al. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1575–7 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Consensus SOCESP-SBC on magnetic resonance imaging in cardiology] Pinto IM, et al. **Arq Bras Cardiol** 1995 Nov; 65(5):451–7 (38 ref.) **(Por)**

[Artificial contrasting during magnetic resonance tomography] Sergeev PV, et al. **Vestn Rentgenol Radiol** 1997 Jan–Feb;(1):45–52 (41 ref.) **(Rus)**

[Demyelinating diseases in childhood: diagnostic contribution of magnetic resonance] Menor F. **Rev Neurol** 1997 Jun; 25(142):966–9 (22 ref.) (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

[Anxiety-induced reactions in connection with magnetic resonance tomography (MRI) examinations] Goyen M, et al. **Rontgenpraxis** 1997 Mar;50(3):63–6 (32 ref.) **(Ger)**

[The anxious patient during magnetic resonance tomography (MRI) examination. Health care economic aspects of patient education] Goyen M, et al. **Z Arztl Fortbild Qualitatssich** 1997 Jul;91(4):319–22 (21 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Imaging of adrenal gland disorders. Tidwell AS, et al. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):237–54 (47 ref.)

Brain imaging. Tucker RL, et al. **Vet Clin North Am Small Anim Pract** 1996 Jul;26(4):735–58 (69 ref.)

Magnetic resonance imaging and computed tomography characteristics of intracranial intra-arachnoid cysts in 6 dogs. Vernau KM, et al. **Vet Radiol Ultrasound** 1997 May–Jun;38(3):171–6 (37 ref.)

MAGNETIC RESONANCE IMAGING, CINE

Comparison between abnormalities in segmental endocardial

motion and abnormalities in segmental wall thickening after anterior myocardial infarction. A cine-magnetic resonance study. Germain P, et al. **Eur Heart J** 1996 Sep; 17(9):1350–61 (30 ref.)

Scimitar syndrome: MR assessment of hemodynamic significance. Henk CB, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):628–30 (9 ref.)

Cine gradient-echo MR imaging and MR velocity mapping in the evaluation of congenital heart disease. Rebergen SA, et al. **Radiographics** 1996 May;16(3):467–81 (28 ref.)

[Cardiac functional analysis with cine MR imaging] Tachiki S, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:630–3 (10 ref.) **(Jpn)**

INSTRUMENTATION

[Methodological approaches to quantitative evaluation of microcirculation in tissues with dynamic magnetic resonance tomography] Brix G, et al. **Radiologe** 1997 Jun; 37(6):470–80 (47 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Quantitative analysis of cardiovascular MR images. van der Geest RJ, et al. **Int J Card Imaging** 1997 Jun;13(3):247–58 (39 ref.)

[The measurement of the coronary flow by the phase contrast method (cine PC, Fastcard PC)] Harada M, et al. **Nippon Rinsho** 1997 Jul;55(7):1828–32 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Evaluation of left ventricular systolic function using cine MRI--application to hypertrophic cardiomyopathy] Ishino Y, et al. **Nippon Rinsho** 1997 Jul;55(7):1805–10 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Myocardial wall motion analysis with phase shift imaging: cine phase contrast technique] Kawamitsu H, et al. **Nippon Rinsho** 1997 Jul;55(7):1794–9 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Technical progress of three dimensional cinematic MR imaging and functional images] Kinosada Y. **Nippon Rinsho** 1997 Jul;55(7):1648–54 (3 ref.) **(Jpn)**

[Estimation of left ventricular wall motion and viability by SPAMM tagging cine MRI] Miura T, et al. **Nippon Rinsho** 1997 Jul;55(7):1811–5 (4 ref.) (Eng. Abstr.) **(Jpn)**

[Assessment of ventricular wall motion and volume by fast cine MRI using Fastcard sequence] Nakanishi T, et al. **Nippon Rinsho** 1997 Jul;55(7):1800–4 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Assessment of coronary flow reserve using fast phase contrast cine MR imaging] Sakuma H, et al. **Nippon Rinsho** 1997 Jul;55(7):1833–8 (17 ref.) (Eng. Abstr.) **(Jpn)**

MAGNETIC RESONANCE IMAGING, ECHO-PLANAR see **ECHO-PLANAR IMAGING**

MAGNETIC RESONANCE IMAGING, FUNCTIONAL see **MAGNETIC RESONANCE IMAGING**

MAGNETIC RESONANCE SPECTROSCOPY see **NUCLEAR MAGNETIC RESONANCE**

MAGNETICS

Microbeads, magnets, and magic: the enchanting science of immunochemistry. Bertholf RL, et al. **Ann Clin Lab Sci** 1996 Sep–Oct;26(5):377–88 (8 ref.)

Clinical application of magnets in orthodontics and biological implications: a review. Darendeliler MA, et al. **Eur J Orthod** 1997 Aug;19(4):431–42 (89 ref.)

Long term beneficial effects of weak electromagnetic fields in multiple sclerosis. Sandyk R. **Int J Neurosci** 1995 Nov; 83(1–2):45–57 (100 ref.)

Reversal of alexia in multiple sclerosis by weak electromagnetic fields. Sandyk R. **Int J Neurosci** 1995 Nov; 83(1–2):69–79 (93 ref.)

Review of magnetic neurosurgery research. Howard MA 3rd, et al. **J Image Guid Surg** 1995;1(6):295–9 (11 ref.)

Techniques and mechanisms of action of transcranial stimulation of the human motor cortex. Rothwell JC. **J Neurosci Methods** 1997 Jun 27;74(2):113–22 (45 ref.)

The role of magnetic susceptibility in magnetic resonance imaging: MRI magnetic compatibility of the first and second kinds. Schenck JF. **Med Phys** 1996 Jun;23(6):815–50 (376 ref.)

Nuclear application of antisense oligonucleotides by microinjection and ballistomagnetic transfer to identify G protein heterotrimers activating phospholipase C. Kalkbrenner F, et al. **Methods Mol Biol** 1997;83:203–16 (16 ref.)

Magnetic source imaging as a tool for presurgical functional brain mapping. Roberts TP, et al. **Neurosurg Clin N Am** 1997 Jul;8(3):421–38 (68 ref.)

[Magnetocardiogram] Nomura M, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:569–74 (20 ref.) **(Jpn)**

[Magnetic brain stimulation in treatment of depression: the search for effective parameters of stimulation] Zyss T, et al. **Psychiatr Pol** 1996 Jul–Aug;30(4):611–28 (28 ref.) (Eng. Abstr.) **(Pol)**

DIAGNOSTIC USE

Applications of magnetic targeting in diagnosis and therapy--possibilities and limitations: a mini-review. Schütt W, et al. **Hybridoma** 1997 Feb;16(1):109–17 (101 ref.)

[Central motor conduction time using magnetic and vibratory stimulation in Parkinson's disease, especially in patients with rigidity] Mochio S, et al. **Nippon Rinsho** 1997 Jan; 55(1):173–8 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Central motor conduction time] Uozumi T. **Nippon Rinsho** 1997 Mar;55 Suppl 1:327–9 (7 ref.) **(Jpn)**

[Magnetically controlled immobilized systems in the microbiological monitoring of natural foci and environmental objects for the presence of the causative agents of dangerous infectious diseases] Efremenko VI. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Mar–Apr; (2):102–6 (50 ref.) **(Rus)**

THERAPEUTIC USE

Bridging the skull: electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation (rTMS) in psychiatry. Kirkcaldie M, et al. **Convuls Ther** 1997 Jun; 13(2):83–91 (55 ref.)

Applications of magnetic targeting in diagnosis and therapy--possibilities and limitations: a mini-review. Schütt W, et al. **Hybridoma** 1997 Feb;16(1):109–17 (101 ref.)

Transcranial magnetic stimulation: a neuropsychiatric tool for the 21st century. George MS, et al. **J Neuropsychiatry Clin Neurosci** 1996 Fall;8(4):373–82 (109 ref.)

MAGNETIZATION TRANSFER CONTRAST IMAGING see **MAGNETIC RESONANCE IMAGING**

MAGNETOENCEPHALOGRAPHY

Evoked magnetic fields. Del Gratta C, et al. **Electroencephalogr Clin Neurophysiol Suppl** 1996;46:107–18 (44 ref.)

Biophysical issues at the frontiers of the interpretation of EEG/MEG signals. Lopes da Silva FH. **Electroencephalogr Clin Neurophysiol Suppl** 1996;45:1–7 (28 ref.)

Magnetoencephalography/magnetic source imaging in the assessment of patients with epilepsy. Ebersole JS. **Epilepsia** 1997;38 Suppl 4:S1–5 (21 ref.)

Magnetoencephalographic cortical rhythms. Hari R, et al. **Int J Psychophysiol** 1997 Jun;26(1–3):51–62 (30 ref.)

Human cortical oscillations: a neuromagnetic view through the skull. Hari R, et al. **Trends Neurosci** 1997 Jan;20(1):44–9 (59 ref.)

[Evaluation of brain function using somatosensory evoked magnetic fields] Kanno A, et al. **Nippon Rinsho** 1997 Mar; 55 Suppl 1:386–8 (9 ref.) **(Jpn)**

[Magnetoencephalograph] Takanashi Y, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:389–92 (8 ref.) **(Jpn)**

[Clinical application of functional mapping: the present state of the art and its future prospects: (series 7) magneto-encephalographic study of higher brain function] Mikuni N, et al. **No Shinkei Geka** 1996 Aug;24(8):691–700 (47 ref.) **(Jpn)**

[Clinical application of functional mapping: the present state of the art and its future prospects: (series 3) functional brain mapping using evoked magnetic fields] Nakasato N, et al. **No Shinkei Geka** 1996 Apr;24(4):305–10 (46 ref.) **(Jpn)**

[Clinical application of magnetoencephalography (MEG): a review of recent progress] Nakasato N, et al. **No To Shinkei** 1996 Feb;49(2):113–20 (75 ref.) **(Jpn)**

[Clinical application of magnetoencephalography for brain infarction] Toyoda K, et al. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1588–90 (6 ref.) (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

Information processing in the human brain: magnetoencephalographic approach. Lounasmaa OV, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20;93(17):8809–15 (41 ref.)

MAGNETOMETRY see **MAGNETICS**

MAIC see **MYCOBACTERIUM AVIUM COMPLEX**

MAIDS see **MURINE ACQUIRED IMMUNODEFICIENCY SYNDROME**

MAILLARD REACTION

Role of the Maillard reaction in diabetes mellitus and diseases of aging. Thorpe SR, et al. **Drugs Aging** 1996 Aug; 9(2):69–77 (47 ref.)

The role of the Maillard reaction in other pathologies: Alzheimer's disease. Colaco CA, et al. **Nephrol Dial Transplant** 1996;11 Suppl 5:7–12 (51 ref.)

The Maillard reaction--from food chemistry to uraemia research [editorial] Henle T, et al. **Nephrol Dial Transplant** 1996 Sep;11(9):1718–22 (22 ref.)

Structure of advanced Maillard reaction products and their pathological role. Monnier VM, et al. **Nephrol Dial Transplant** 1996;11 Suppl 5:20–6 (30 ref.)

New biomarkers of Maillard reaction damage to proteins. Wells-Knecht KJ, et al. **Nephrol Dial Transplant** 1996;11 Suppl 5:41–7 (53 ref.)

[The effect of Maillard reaction products on enzyme reactions] Schumacher D, et al. **Z Ernahrungswiss** 1996 Sep;35(3):213–25 (108 ref.) (Eng. Abstr.) **(Ger)**

MAINSTREAMING (EDUCATION)

Full inclusion and students with autism. Mesibov GB, et al. **J Autism Dev Disord** 1996 Jun;26(3):337–46 (14 ref.)

MAIZE see **CORN**

MAJEWSKI SYNDROME see **SHORT RIB–POLYDACTYLY SYNDROME**

MAJOR CORE PROTEIN see **VIRAL CORE PROTEINS**

MAJOR CORE PROTEINS, VIRAL see **VIRAL CORE PROTEINS**

MAJOR HISTOCOMPATIBILITY COMPLEX

see related
GENES, MHC CLASS I

Molecular mimicry with MHC-derived peptides: does this underlie MHC association with autoimmune disease? Baum H. **Biochem Soc Trans** 1997 May;25(2):636–42 (27 ref.)

Molecular evolution of the vertebrate immune system. Hughes AL, et al. **Bioessays** 1997 Sep;19(9):777–86 (71 ref.)

The roles of the human major histocompatibility complex and human papillomavirus infection in cervical intraepithelial neoplasia and cervical cancer. Odunsi KO, et al. **Clin Oncol (R Coll Radiol)** 1997;9(1):4–13 (115 ref.)

T-cell receptors: is the repertoire inherently MHC-specific? Janeway CA, et al. **Curr Biol** 1997 May 1;7(5):R299–300 (11 ref.)

Infectious diseases and immunity: special reference to major histocompatibility complex. Singh N, et al. **Emerg Infect Dis** 1997 Jan–Mar;3(1):41–9 (61 ref.)

MHC studies in domestic animals. Ellis SA. **Eur J Immunogenet** 1994 Jun;21(3):209–15 (46 ref.)

Primate Mhc-E and -G alleles. Arnaiz-Villena A, et al. **Immunogenetics** 1997;46(4):251–66 (24 ref.)

Genetics of multiple sclerosis--how could disease-associated HLA-types contribute to pathogenesis? Martin R. **J Neural Transm Suppl** 1997;49:177–94 (89 ref.)

Major histocompatibility complex as an antigen pump: self-declaration in somatic cell society. Chigira M. **Med Hypotheses** 1997 Jul;49(1):41–5 (63 ref.)

Immunogenetic studies in autism and related disorders. Warren RP, et al. **Mol Chem Neuropathol** 1996 May–Aug; 28(1–3):77–81 (9 ref.)

The MIC gene family. Bahram S, et al. **Res Immunol** 1996 Jun;147(5):328–33 (40 ref.)

Current status of the genetic and physical maps of the major histocompatibility complex in the rat. Gill TJ 3rd, et al. **Transplant Proc** 1997 May;29(3):1657–9 (67 ref.)

The HLA system: an update and relevance to patient–donor matching strategies in clinical transplantation. Howell WM, et al. **Vox Sang** 1996;71(1):6–12 (44 ref.)

GENETICS

Ulcerative colitis: a genetic disease? Cavanaugh JA, et al. **Baillieres Clin Gastroenterol** 1997 Mar;11(1):1–15 (64 ref.)

Immunogenetics in liver disease. Donaldson PT. **Baillieres Clin Gastroenterol** 1996 Sep;10(3):533–49 (68 ref.)

The nature of selection on the major histocompatibility complex. Apanius V, et al. **Crit Rev Immunol** 1997; 17(2):179–224 (388 ref.)

Chicken MHC molecules, disease resistance and the evolutionary origin of birds. Kaufman J, et al. **Curr Top Microbiol Immunol** 1996;212:129–41 (50 ref.)

Non-classical-MHC genetics of immunological disease in man and mouse. The key role of pro-inflammatory cytokine genes. Daser A, et al. **Cytokine** 1996 Aug; 8(8):593–7 (43 ref.)

Current status of the molecular genetic analysis of the rat major histocompatibility complex. Günther E. **Folia Biol (Praha)** 1996;42(4):129–45 (135 ref.)

Molecular mechanisms of class I major histocompatibility complex antigen processing and presentation. Yang Y, et al. **Immunol Res** 1996;15(3):208–33 (204 ref.)

HLA-DP--part of the concert. Meyer CG, et al. **Immunol Today** 1997 Feb;18(2):58–61 (29 ref.)

The discovery of MHC restriction. Zinkernagel RM, et al. **Immunol Today** 1997 Jan;18(1):14–7 (46 ref.)

Studies of transplantation immunology with major histocompatibility complex knockout mice. Chitilian HV, et al. **J Heart Lung Transplant** 1997 Feb;16(2):153–9 (27 ref.)

Interstitial lung disease: basic mechanisms and genetic predisposition. Lympany PA, et al. **Monaldi Arch Chest Dis** 1997 Feb;52(1):33–6 (34 ref.)

Chromosomal duplication and the emergence of the adaptive immune system. Kasahara M, et al. **Trends Genet** 1997 Mar; 13(3):90–2 (22 ref.)

[The HLA system: a clinical help?] Fajardy I, et al. **Ann Biol Clin (Paris)** 1997 Mar–Apr;55(2):93–101 (34 ref.) (Eng. Abstr.) **(Fre)**

[Ancient chromosomal duplication involving the major

histocompatibility complex] Kasahara M. **Seikagaku** 1996 Nov;68(11):1717–21 (15 ref.) **(Jpn)**

IMMUNOLOGY

Antigen-specific T-cell receptors and their reactions with complexes formed by peptides with major histocompatibility complex proteins. Eisen HN, et al. **Adv Protein Chem** 1996;49:1–56 (227 ref.)

Cellular immune recognition and the biological role of major transplantation antigens. Zinkernagel RM. **Biosci Rep** 1997 Apr;17(2):91–111 (116 ref.)

The nature of selection on the major histocompatibility complex. Apanius V, et al. **Crit Rev Immunol** 1997; 17(2):179–224 (388 ref.)

Interactions of TCRs with MHC-peptide complexes: a quantitative basis for mechanistic models. Margulies DH. **Curr Opin Immunol** 1997 Jun;9(3):390–5 (56 ref.)

Chicken MHC molecules, disease resistance and the evolutionary origin of birds. Kaufman J, et al. **Curr Top Microbiol Immunol** 1996;212:129–41 (50 ref.)

Peptide-MHC complexes assembled following multiple pathways: an opportunity for the design of vaccines and therapeutic molecules. Corradin G, et al. **Hum Immunol** 1997 May;54(2):137–47 (106 ref.)

Molecular mechanisms of class I major histocompatibility complex antigen processing and presentation. Yang Y, et al. **Immunol Res** 1996;15(3):208–33 (204 ref.)

HLA-DP--part of the concert. Meyer CG, et al. **Immunol Today** 1997 Feb;18(2):58–61 (29 ref.)

TAP off--tumors on. Seliger B, et al. **Immunol Today** 1997 Jun;18(6):292–9 (96 ref.)

Major histocompatibility complex regulation of cytokine production. Caruso C, et al. **J Interferon Cytokine Res** 1996 Dec;16(12):983–8 (66 ref.)

Cellular and molecular analyses of major histocompatibility complex (MHC) restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy. Schendel DJ, et al. **J Mol Med** 1997 Jun;75(6):400–13 (119 ref.)

Host genetic factors influencing the outcome of hepatitis. Thursz MR. **J Viral Hepat** 1997 Jul;4(4):215–20 (34 ref.)

Novel immunotherapeutic strategies using MHC derived peptides. Sayegh MH, et al. **Kidney Int Suppl** 1996 Jan; 53:S13–20 (53 ref.)

The nature of the peptide/MHC ligand involved in positive selection. Hogquist KA, et al. **Semin Immunol** 1996 Apr; 8(2):63–8 (31 ref.)

PHYSIOLOGY

Role of the major histocompatibility complex region in reproduction, cancer, and autoimmunity. Gill TJ 3rd. **Am J Reprod Immunol** 1996 Mar;35(3):211–5 (14 ref.)

Cellular immune recognition and the biological role of major transplantation antigens. Zinkernagel RM. **Biosci Rep** 1997 Apr;17(2):91–111 (116 ref.)

Three-part inventions: intracellular signaling and induced proximity. Crabtree GR, et al. **Trends Biochem Sci** 1996 Nov;21(11):418–22 (46 ref.)

MALABSORPTION SYNDROMES

Malabsorption syndrome in India. Ramakrishna BS. **Indian J Gastroenterol** 1996 Oct;15(4):135–41 (109 ref.)

Disaccharide digestion and maldigestion. Gudmand-Høyer E, et al. **Scand J Gastroenterol Suppl** 1996;216:111–21 (63 ref.)

[Secondary malabsorption syndrome] Asakura H, et al. **Nippon Naika Gakkai Zasshi** 1996 Jul 10;85(7):1066–71 (71 ref.) **(Jpn)**

[Concept of malabsorption syndrome and nutrition assessment] Takahashi T, et al. **Nippon Naika Gakkai Zasshi** 1996 Jul 10;85(7):1022–8 (6 ref.) **(Jpn)**

DIAGNOSIS

A rapidly progressive ischemic enteropathy with malabsorption syndrome. Case report. Cicchinelli M, et al. **Minerva Gastroenterol Dietol** 1996 Jun;42(2):103–5 (11 ref.)

[Strategies for investigating non-assimilation. A critical status] Rumessen JJ. **Ugeskr Laeger** 1997 Apr 14; 159(16):2356–63 (40 ref.) (Eng. Abstr.) **(Dan)**

[Absorption and leakage test for diagnosis of malabsorption syndrome or protein-losing enteropathy] Masamune O. **Nippon Naika Gakkai Zasshi** 1996 Jul 10;85(7):1048–53 (5 ref.) **(Jpn)**

[Image diagnosis of malabsorption syndrome or protein-losing enteropathy] Yao T. **Nippon Naika Gakkai Zasshi** 1996 Jul 10;85(7):1054–60 (5 ref.) **(Jpn)**

ETIOLOGY

Dairy sensitivity, lactose malabsorption, and elimination diets in inflammatory bowel disease. Mishkin S. **Am J Clin Nutr** 1997 Feb;65(2):564–7 (54 ref.)

Point mutations in the ileal bile salt transporter cause leaks in the enterohepatic circulation leading to severe chronic diarrhea and malabsorption [editorial] Small DM. **J Clin Invest** 1997 Apr 15;99(8):1807–8 (14 ref.)

[Malabsorption syndrome due to membrane transporter abnormality in absorptive epithelial cells] Bamba T, et al. **Nippon Rinsho** 1996 Mar;54(3):782–7 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Systemic sclerosis with various gastrointestinal problems including pneumoperitoneum, pneumatosis cystoides intestinalis and malabsorption syndrome] Satoh A, et al. **Ryumachi** 1995 Dec;35(6):927–33 (29 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

The metabolic importance of unabsorbed dietary lipids in the colon. Vonk RJ, et al. **Scand J Gastroenterol Suppl** 1997;222:65–7 (42 ref.)

PATHOLOGY

Pancreatic steatorrhea, malabsorption, and nutrition biochemistry: a comparison of Japanese, European, and American patients with chronic pancreatitis. Nakamura T, et al. **Pancreas** 1997 May;14(4):323–33 (127 ref.)

PREVENTION & CONTROL

[Choice of the method of restoration of intestinal continuity after removal of the ileocecal region] Poĭda AI, et al. **Klin Khir** 1996;(10):45–7 (29 ref.) **(Rus)**

THERAPY

Pancreatic steatorrhea, malabsorption, and nutrition biochemistry: a comparison of Japanese, European, and American patients with chronic pancreatitis. Nakamura T, et al. **Pancreas** 1997 May;14(4):323–33 (127 ref.)

[Enteral nutrition therapy of malabsorption syndrome or protein-losing enteropathy] Matsueda K. **Nippon Naika Gakkai Zasshi** 1996 Jul 10;85(7):1085–97 (7 ref.) **(Jpn)**

MALACOPLAKIA

[Genitourinary malacoplakia] Cambronero Santos J, et al. **Actas Urol Esp** 1997 Feb;21(2):140–9 (42 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Malakoplakia and colorectal adenocarcinoma. Bates AW, et al. **Postgrad Med J** 1997 Mar;73(857):171–3 (10 ref.)

[Vesical malacoplakia accompanied with bilateral hydronephrosis: a case report] Nukui M, et al. **Hinyokika Kiyo** 1997 Jan;43(1):49–52 (14 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Malakoplakia of the appendix. Borghesi MR, et al. **Minerva Chir** 1997 Apr;52(4):465–7 (9 ref.)

Malakoplakia of the prostate gland--report of two cases and review of the literature. Sarma HN, et al. **Scand J Urol Nephrol** 1996 Apr;30(2):155–7 (20 ref.)

ETIOLOGY

[A case of ureteral malacoplakia in a hemodialysis patient] Suzuki N, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Aug; 87(8):1056–9 (6 ref.) (Eng. Abstr.) **(Jpn)**

MALAR BONE see **ZYGOMA**

MALARIA

see related

ANTIMALARIALS

Global overview of malaria. Kondrachine AV, et al. **Indian J Med Res** 1997 Aug;106:39–52 (59 ref.)

Malaria--need for a more integrated approach. Satyavati GV, et al. **Indian J Med Res** 1997 Aug;106:iii–iv (8 ref.)

BLOOD

From malaria to chemokine receptor: the emerging physiologic role of the Duffy blood group antigen. Hadley TJ, et al. **Blood** 1997 May 1;89(9):3077–91 (129 ref.)

Antimalarial drugs and glucose metabolism. Davis TM. **Br J Clin Pharmacol** 1997 Jul;44(1):1–7 (45 ref.)

The redox status of malaria-infected erythrocytes: an overview with an emphasis on unresolved problems. Ginsburg H, et al. **Parasite** 1994 Mar;1(1):5–13 (65 ref.)

Oxidative stress in malaria; implications for prevention and therapy. Postma NS, et al. **Pharm World Sci** 1996 Aug; 18(4):121–9 (124 ref.)

COMPLICATIONS

Hyperreactive malarial syndrome. Ackerman L. **J Am Board Fam Pract** 1996 Sep–Oct;9(5):356–9 (12 ref.)

Interactions between AIDS viruses and malaria parasites: a role for macrophages? Marussig M, et al. **Res Virol** 1996 Mar–Jun;147(2–3):139–45 (55 ref.)

DRUG THERAPY

Molecular approaches to the spreading problem of drug resistant malaria. Plowe CV, et al. **Adv Exp Med Biol** 1995; 390:197–209 (48 ref.)

Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. White NJ. **Antimicrob Agents Chemother** 1997 Jul;41(7):1413–22 (74 ref.)

The safety of antimalarial drugs in pregnancy. Phillips-Howard PA, et al. **Drug Saf** 1996 Mar;14(3):131–45 (101 ref.)

Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. de Vries PJ, et al. **Drugs** 1996 Dec;52(6):818–36 (116 ref.)

Malarial infection during pregnancy. Silver HM. **Infect Dis Clin North Am** 1997 Mar;11(1):99–107 (35 ref.)

Oxidative stress in malaria; implications for prevention and therapy. Postma NS, et al. **Pharm World Sci** 1996 Aug; 18(4):121–9 (124 ref.)

Treatment seeking for malaria: a review of recent research. McCombie SC. **Soc Sci Med** 1996 Sep;43(6):933–45 (90 ref.)

Plants as a source of antimalarial drugs. Kirby GC. **Trop Doct** 1997;27 Suppl 1:7–11 (34 ref.)

ECONOMICS

Malaria: cost to India and future trends. Sharma VP. **Southeast Asian J Trop Med Public Health** 1996 Mar; 27(1):4–14 (37 ref.)

EPIDEMIOLOGY

Profile of Morong, Bataan, an area of low malaria endemicity in the Philippines. Bustos MD, et al. **Acta Trop** 1997 Mar; 63(4):195–207 (16 ref.)

Malaria in children. Steele RW. **Adv Pediatr Infect Dis** 1996; 12:325–49 (68 ref.)

Malaria in the 1990s: plus ça change, plus ça même chose [editorial] Walker J. **Aust N Z J Public Health** 1997 Jun; 21(3):244–6 (11 ref.)

Malaria as a reemerging disease. Krogstad DJ. **Epidemiol Rev** 1996;18(1):77–89 (143 ref.)

Urban malaria vector biology. Hati AK. **Indian J Med Res** 1997 Aug;106:149–63 (111 ref.)

Role of geographic information system in malaria control. Sharma VP, et al. **Indian J Med Res** 1997 Aug;106:198–204 (5 ref.)

Re-emergence of malaria in India. Sharma VP. **Indian J Med Res** 1996 Jan;103:26–45 (99 ref.)

Mixed-species Plasmodium infections of humans. McKenzie FE, et al. **J Parasitol** 1997 Aug;83(4):593–600 (85 ref.)

[In Africa, urban malaria is the malaria of tomorrow] Baudon D, et al. **Med Trop (Mars)** 1996;56(4):323–5 (11 ref.) **(Fre)**

[Malaria in South Africa: past, present and perspectives] Sharp BL, et al. **Med Trop (Mars)** 1996;56(2):189–96 (27 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

A recent case of congenital malaria in Singapore. Lee WW, et al. **Singapore Med J** 1996 Oct;37(5):541–3 (18 ref.)

GENETICS

The genetics of common diseases: the implications of population variability. Weatherall DJ. **Ciba Found Symp** 1996;197:300–8; discussion 308–11 (30 ref.)

IMMUNOLOGY

Hybrid hepatitis B virus core antigen as a vaccine carrier moiety. II. Expression in avirulent Salmonella spp. for mucosal immunization. Schödel F, et al. **Adv Exp Med Biol** 1996;397:15–21 (18 ref.)

Class I HLA-restricted cytotoxic T lymphocyte responses against malaria--elucidation on the basis of HLA peptide binding motifs. Doolan DL, et al. **Immunol Res** 1996; 15(4):280–305 (180 ref.)

T cell immunity in malaria. Kabilan L. **Indian J Med Res** 1997 Aug;106:130–48 (96 ref.)

Gamma delta T cells: their immunobiology and role in malaria infections. Rzepczyk CM, et al. **Int J Parasitol** 1997 Feb;27(2):191–200 (74 ref.)

Interleukin-12 and malaria. Crutcher JM, et al. **Res Immunol** 1995 Sep–Oct;146(7–8):552–9 (42 ref.)

[Immunopathology of malaria: emergence of a new T-lymphocyte reactivity] Behr C. **C R Seances Soc Biol Fil** 1996;190(4):357–68 (67 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Biochemical changes induced by malarial parasites. Ganguly NK, et al. **Indian J Med Res** 1997 Aug;106:70–8 (32 ref.)

PARASITOLOGY

Biological control of malaria vectors. Das PK, et al. **Indian J Med Res** 1997 Aug;106:174–97 (225 ref.)

Current trends in research on tissue stage of malaria. Kamboj KK. **Indian J Med Res** 1997 Aug;106:120–9 (99 ref.)

The malaria sporozoite's journey into the liver. Sinnis P. **Infect Agents Dis** 1996 Jun;5(3):182–9 (54 ref.)

The biology of malarial parasite in the mosquito--a review. Simonetti AB. **Mem Inst Oswaldo Cruz** 1996 Sep–Oct; 91(5):519–41 (277 ref.)

Latency of Plasmodium merozoites and drug-resistance. A review. Landau I, et al. **Parasite** 1994 Jun;1(2):105–14 (18 ref.)

PREVENTION & CONTROL

Clinical trials of malaria vaccines: progress and prospects.

Facer CA, et al. **Adv Parasitol** 1997;39:1–68 (180 ref.)
Antimalarial activity of artemisinin (qinghaosu) and related trioxanes: mechanism(s) of action. Cumming JN, et al. **Adv Pharmacol** 1997;37:253–97 (257 ref.)
Malaria in the 1990s: plus ça change, plus ça même chose [editorial] Walker J. **Aust N Z J Public Health** 1997 Jun; 21(3):244–6 (11 ref.)
Science, medicine, and the future. Malaria. Krishna S. **BMJ** 1997 Sep 20;315(7110):730–2 (7 ref.)
Malaria. Stanley J. **Emerg Med Clin North Am** 1997 Feb; 15(1):113–55 (139 ref.)
Malaria as a reemerging disease. Krogstad DJ. **Epidemiol Rev** 1996;18(1):77–89 (143 ref.)
Anopheline species complexes & malaria control. Subbarao SK, et al. **Indian J Med Res** 1997 Aug;106:164–73 (41 ref.)
DNA vaccines against malaria: immunogenicity and protection in a rodent model. Gardner MJ, et al. **J Pharm Sci** 1996 Dec;85(12):1294–300 (56 ref.)
[Progresses in tropical diseases and parasitosis in China, 1996] Zheng J. **Chung Hua I Hsueh Tsa Chih** 1996 Dec; 76(12):898–9 (0 ref.) **(Chi)**
[Malaria prophylaxis. Effects and side-effects of drugs used for prevention of malaria (see comments)] Petersen E. **Ugeskr Laeger** 1997 Apr 28;159(18):2723–30 (39 ref.) Comment in: Ugeskr Laeger 1997 Aug 4;159(32):4866–8. **(Dan)**
[Chloroquine maculopathy and prevention of malaria] Balo KP, et al. **J Fr Ophtalmol** 1996;19(12):770–6 (15 ref.) (Eng. Abstr.) **(Fre)**
[Malaria in South Africa: past, present and perspectives] Sharp BL, et al. **Med Trop (Mars)** 1996;56(2):189–96 (27 ref.) (Eng. Abstr.) **(Fre)**
[The prevention and therapy of malaria] Weinke T, et al. **Dtsch Med Wochenschr** 1997 Feb 28;122(9):265–7 (15 ref.) **(Ger)**
[Current state and problems of the development of malaria vaccine] Tanabe K. **Nippon Rinsho** 1996 Aug;54(8):2252–60 (18 ref.) (Eng. Abstr.) **(Jpn)**

TRANSMISSION

Climate change and malaria transmission. Lindsay SW, et al. **Ann Trop Med Parasitol** 1996 Dec;90(6):573–88 (82 ref.)
The ecology of malaria--as seen from Earth-observation satellites. Thomson MC, et al. **Ann Trop Med Parasitol** 1996 Jun;90(3):243–64 (110 ref.)
Imported malaria in children in the UK. Brabin BJ, et al. **Arch Dis Child** 1997 Jul;77(1):76–81 (23 ref.)
Changing patterns of autochthonous malaria transmission in the United States: a review of recent outbreaks. Zucker JR. **Emerg Infect Dis** 1996 Jan–Mar;2(1):37–43 (37 ref.)
Transmission-blocking vaccines: uses and current status of development. Kaslow DC. **Int J Parasitol** 1997 Feb; 27(2):183–9 (45 ref.)
[In Africa, urban malaria is the malaria of tomorrow] Baudon D, et al. **Med Trop (Mars)** 1996;56(4):323–5 (11 ref.) **(Fre)**

VETERINARY

Malarial parasites of lizards: diversity and ecology. Schall JJ. **Adv Parasitol** 1996;37:255–333 (125 ref.)

MALARIA, CEREBRAL

Cerebral malaria [editorial] Sanchetee PC, et al. **J Assoc Physicians India** 1996 Oct;44(10):675–6 (12 ref.)

PATHOLOGY

Cerebral malaria. Turner G. **Brain Pathol** 1997 Jan; 7(1):569–82 (108 ref.)
TNF receptors in the microvascular pathology of acute respiratory distress syndrome and cerebral malaria. Lucas R, et al. **J Leukoc Biol** 1997 May;61(5):551–8 (65 ref.)

PHYSIOPATHOLOGY

[From the murine model to human cerebral malaria] Diakite D, et al. **C R Seances Soc Biol Fil** 1996;190(4):369–83 (90 ref.) (Eng. Abstr.) **(Fre)**

MALARIA, FALCIPARUM

Knob proteins in falciparum malaria. Sharma YD. **Indian J Med Res** 1997 Aug;106:53–62 (55 ref.)
Falciparum malaria. Murphy GS, et al. **Infect Dis Clin North Am** 1996 Dec;10(4):747–75 (123 ref.)

BLOOD

Erythrocyte membrane alterations in Plasmodium falciparum malaria sequestration. Oh SS, et al. **Curr Opin Hematol** 1997 Mar;4(2):148–54 (67 ref.)

COMPLICATIONS

Mixed-species Plasmodium infections of humans. McKenzie FE, et al. **J Parasitol** 1997 Aug;83(4):593–600 (85 ref.)
Renal disease. II. Malaria and acute renal failure. Day NP, et al. **J R Coll Physicians Lond** 1997 Mar–Apr;31(2):146–8 (16 ref.)

DRUG THERAPY

Molecular approaches to the spreading problem of drug resistant malaria. Plowe CV, et al. **Adv Exp Med Biol** 1995; 390:197–209 (48 ref.)
Systematic review of amodiaquine treatment in uncomplicated malaria [see comments] Olliaro P, et al. **Lancet** 1996 Nov 2;348(9036):1196–201 (15 ref.) Comment in: Lancet 1996 Nov 2;348(9036):1184–5. Comment in: Lancet 1996 Dec 14;348(9042):1659–60.

EPIDEMIOLOGY

Plasmodium falciparum malaria: some epidemiological implications of parasite and host diversity. Molineaux L. **Ann Trop Med Parasitol** 1996 Aug;90(4):379–93 (62 ref.)

ETIOLOGY

The molecular basis of pathogenesis of cerebral malaria. Fujioka H, et al. **Microb Pathog** 1996 Feb;20(2):63–72 (50 ref.)

GENETICS

[Genetic susceptibility to malaria in man: contribution of genetic epidemiology (editorial)] Abel L. **Pathol Biol (Paris)** 1995 Nov;43(9):745–8 (19 ref.) **(Fre)**
[Sickle cell anemia and malaria--interferences] Născuţiu AM. **Bacteriol Virusol Parazitol Epidemiol** 1997 Jan–Jun; 42(1–2):11–4 (31 ref.) (Eng. Abstr.) **(Rum)**

IMMUNOLOGY

Antigenic variation and immune evasion in Plasmodium falciparum malaria. Reeder JC, et al. **Immunol Cell Biol** 1996 Dec;74(6):546–54 (103 ref.)
Novel putative protective antigens of Plasmodium falciparum. Sharma S, et al. **Indian J Med Res** 1997 Aug; 106:63–9 (42 ref.)
Gamma delta T cells: their immunobiology and role in malaria infections. Rzepczyk CM, et al. **Int J Parasitol** 1997 Feb;27(2):191–200 (74 ref.)
Reverse immunogenetics: from HLA-disease associations to vaccine candidates. Davenport MP, et al. **Mol Med Today** 1996 Jan;2(1):38–45 (25 ref.)
Clinical and parasitological studies on immunity to Plasmodium falciparum malaria in children. Høgh B. **Scand J Infect Dis Suppl** 1996;102:1–53 (203 ref.)
Host resistance to malaria runs into swampy water. Wilkinson RJ, et al. **Trends Microbiol** 1997 Jun;5(6):213–5 (13 ref.)

METABOLISM

Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Krishna S, et al. **Clin Pharmacokinet** 1996 Apr;30(4):263–99 (267 ref.)
Metabolic enzymes as potential drug targets in Plasmodium falciparum. Subbayya IN, et al. **Indian J Med Res** 1997 Aug;106:79–94 (127 ref.)

PARASITOLOGY

Antigenic variation and immune evasion in Plasmodium falciparum malaria. Reeder JC, et al. **Immunol Cell Biol** 1996 Dec;74(6):546–54 (103 ref.)

PHYSIOPATHOLOGY

The pathogenesis of severe malaria in African children. Marsh K, et al. **Ann Trop Med Parasitol** 1996 Aug; 90(4):395–402 (26 ref.)

PREVENTION & CONTROL

Malaria vaccine trials: the missing qualitative data. Ferreira M. **Immunol Cell Biol** 1996 Aug;74(4):301–5 (20 ref.)
DNA vaccines for malaria: the past, the present, & the future. Doolan DL, et al. **Indian J Med Res** 1997 Aug;106:109–19 (77 ref.)
Field trials of malaria vaccines. Kitua AY. **Indian J Med Res** 1997 Aug;106:95–108 (51 ref.)

THERAPY

[Severe falciparum malaria among travellers to Thailand. Blood exchange and artemisinine treatment are therapeutic alternatives] Ekvall H, et al. **Lakartidningen** 1997 Apr 30; 94(18):1713–5 (15 ref.) **(Swe)**

MALARIA VACCINES

Clinical trials of malaria vaccines: progress and prospects. Facer CA, et al. **Adv Parasitol** 1997;39:1–68 (180 ref.)
Science, medicine, and the future. Malaria. Krishna S. **BMJ** 1997 Sep 20;315(7110):730–2 (7 ref.)
DNA vaccines for malaria: the past, the present, & the future. Doolan DL, et al. **Indian J Med Res** 1997 Aug;106:109–19 (77 ref.)
Field trials of malaria vaccines. Kitua AY. **Indian J Med Res** 1997 Aug;106:95–108 (51 ref.)
Transmission-blocking vaccines: uses and current status of development. Kaslow DC. **Int J Parasitol** 1997 Feb; 27(2):183–9 (45 ref.)
Malaria vaccines. Amador R, et al. **J Clin Immunol** 1996 Jul;16(4):183–9 (51 ref.)
[Current state and problems of the development of malaria vaccine] Tanabe K. **Nippon Rinsho** 1996 Aug;54(8):2252–60 (18 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Malaria vaccine trials: the missing qualitative data. Ferreira M. **Immunol Cell Biol** 1996 Aug;74(4):301–5 (20 ref.)
DNA vaccines against malaria: immunogenicity and protection in a rodent model. Gardner MJ, et al. **J Pharm Sci** 1996 Dec;85(12):1294–300 (56 ref.)

MALARIA, VIVAX

COMPLICATIONS

Mixed-species Plasmodium infections of humans. McKenzie FE, et al. **J Parasitol** 1997 Aug;83(4):593–600 (85 ref.)

DRUG THERAPY

Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Baird JK, et al. **Am J Trop Med Hyg** 1997 Jun;56(6):621–6 (34 ref.)

MALASSEZIA

Malassezia pachydermatis with special reference to canine skin disease. Akerstedt J, et al. **Br Vet J** 1995 May; 152(3):269–81 (94 ref.)
Malassezia dermatitis. Charach M. **Can Vet J** 1997 May; 38(5):311–4 (13 ref.)
[Cutaneous lesions related to Malassezia furfur] Aspiroz Sancho MC, et al. **Rev Clin Esp** 1997 Jun;197(6):420–8 (178 ref.) **(Spa)**

ISOLATION & PURIFICATION

The superficial mycoses. Assaf RR, et al. **Dermatol Clin** 1996 Jan;14(1):57–67 (67 ref.)
Yeast infections. Hay RJ. **Dermatol Clin** 1996 Jan; 14(1):113–24 (33 ref.)

MALATE DEHYDROGENASE

GENETICS

Nutritional and hormonal regulation of expression of the gene for malic enzyme. Goodridge AG, et al. **Prog Nucleic Acid Res Mol Biol** 1996;52:89–122 (72 ref.)

METABOLISM

Role of NAD(+)-dependent 'malic' enzyme and pyruvate dehydrogenase complex in leaf metabolism. Hill S, et al. **Biochem Soc Trans** 1996 Aug;24(3):743–6 (15 ref.)

MALATES

METABOLISM

A specific porin is involved in the malate shuttle of leaf peroxisomes. Reumann S, et al. **Biochem Soc Trans** 1996 Aug;24(3):754–7 (17 ref.)

MALD-MS see **SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION**

MALE BREAST NEOPLASMS see **BREAST NEOPLASMS, MALE**

MALE PATTERN BALDNESS see **ALOPECIA**

MALIGNANT CARCINOID SYNDROME

[Advances in the study of anesthesia in patients with carcinoid syndrome] Huang YG, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Jul;76(7):536–8 (15 ref.) (Eng. Abstr.) **(Chi)**

EPIDEMIOLOGY

An 18-year follow-up of primary hepatic carcinoid with carcinoid syndrome. Mehta DC, et al. **J Clin Gastroenterol** 1996 Jul;23(1):60–2 (22 ref.)

MALIGNANT HYPERPYREXIA see **MALIGNANT HYPERTHERMIA**

MALIGNANT HYPERTHERMIA

[Malignant hyperthermia (MH)] Hata T. **Ryoikibetsu Shokogun Shirizu** 1996;(15):387–90 (10 ref.) **(Jpn)**

DIAGNOSIS

[Neurological aspects of malignant hyperthermia. Clinics, physiopathology, genetics] Serratrice G, et al. **Rev Neurol (Paris)** 1997 Jun;153(5):304–13 (59 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Malignant hyperthermia in a 3-month-old infant: a case report. Pennington GP, et al. **J Med Assoc Ga** 1996 Sep; 85(3):162–3 (10 ref.)

MALIGNANT HYPERTHERMIA

Myoglobinuria, malignant hyperthermia, neuroleptic malignant syndrome and serotonin syndrome. Bertorini TE. **Neurol Clin** 1997 Aug;15(3):649–71 (193 ref.)

GENETICS

To fire the train: a second malignant–hyperthermia gene [editorial; comment] Hogan K. **Am J Hum Genet** 1997 Jun; 60(6):1303–8 (30 ref.) Comment on: Am J Hum Genet 1997 Jun;60(6):1316–25.

The role of the calcium release channel of skeletal muscle sarcoplasmic reticulum in malignant hyperthermia. MacLennan DH, et al. **Ann N Y Acad Sci** 1993 Dec 20; 707:294–304 (46 ref.)

[Malignant hyperthermia as a complication of anesthesia: predisposition is hereditary] Snoeck MM, et al. **Ned Tijdschr Geneeskd** 1997 Mar 29;141(13):616–9 (19 ref.) (Eng. Abstr.) **(Dut)**

[Diagnosis of disposition for malignant hyperthermia––an updated review based on 1,001 studies] Olthoff D, et al. **Anaesthesiol Reanim** 1997;22(2):32–40 (60 ref.) (Eng. Abstr.) **(Ger)**

[What significance to genotype changes have in diagnosis of malignant hyperthermia? (see comments)] Steinfath M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Aug;31(6):334–43 (96 ref.) (Eng. Abstr.) Comment in: Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Aug;31(6):331–3. **(Ger)**

NURSING

Malignant hyperthermia. Dunn D. **AORN J** 1997 Apr; 65(4):728, 731, passim; quiz 755–8, 760–2 (40 ref.)

PHYSIOPATHOLOGY

Disorders of temperature regulation. Lee–Chiong TL Jr, et al. **Compr Ther** 1995 Dec;21(12):697–704 (25 ref.)

PREVENTION & CONTROL

Malignant hyperthermia susceptibility: anaesthetic implications and risk stratification. Ben Abraham R, et al. **QJM** 1997 Jan;90(1):13–8 (67 ref.)

THERAPY

Malignant hyperthermia. Miranda AD, et al. **Am J Crit Care** 1997 Sep;6(5):368–74; quiz 375–6 (49 ref.)

VETERINARY

[Physiology and physiopathology of ryanodine receptors in swine. Significance of sensitivity to stress, stress myopathies, malignant hyperthermia and meat quality] Martens H. **Tierarztl Prax** 1997 Jan;25(1):41–51 (62 ref.) (Eng. Abstr.) **(Ger)**

MALIGNANT MELANOMA see **MELANOMA**

MALINGERING

DIAGNOSIS

Mental defenses and posttraumatic stress disorder: assessment of criminal intent. Sparr LF. **J Trauma Stress** 1996 Jul; 9(3):405–25 (100 ref.)

Practical guidelines in the use of symptom validity and other psychological tests to measure malingering and symptom exaggeration in traumatic brain injury cases. Etcoff LM, et al. **Neuropsychol Rev** 1996 Dec;6(4):171–201 (91 ref.)

[Simulated illness] Bock KD. **Med Klin** 1997 Jan 15; 92(1):41–5 (14 ref.) **(Ger)**

MALNUTRITION see **NUTRITION DISORDERS**

MALOCCLUSION

see related
ORTHODONTICS, CORRECTIVE
PROGNATHISM

DIAGNOSIS

The importance of determination of jaw position in orthodontic diagnosis and treatment planning for adult patients. Chang FH, et al. **Dent Clin North Am** 1997 Jan; 41(1):49–66 (24 ref.)

ETIOLOGY

Open bite: a review of etiology and management. Ngan P, et al. **Pediatr Dent** 1997 Mar–Apr;19(2):91–8 (76 ref.)

SURGERY

Surgically–assisted maxillary expansion. Woods M, et al. **Aust Dent J** 1997 Feb;42(1):38–42 (25 ref.)

[Principles of surgical treatment of obstructive sleep apnea by interventions on the facial bones] Reinert S, et al. **Wien Med Wochenschr** 1996;146(13–14):368–72 (20 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Surgical–orthodontic correction of adult facial deformities. Blanchaert R, et al. **Dent Clin North Am** 1996 Oct; 40(4):945–59 (26 ref.)

Retention and stability considerations for adult patients. Kahl–Nieke B. **Dent Clin North Am** 1996 Oct;40(4):961–94 (75 ref.)

Correction of deep overbite in adults. Nanda R. **Dent Clin North Am** 1997 Jan;41(1):67–87 (14 ref.)

Correction of posterior crossbite. Dolce C. **N Y State Dent J** 1996 Aug–Sep;62(7):50–2 (5 ref.)

Open bite: a review of etiology and management. Ngan P, et al. **Pediatr Dent** 1997 Mar–Apr;19(2):91–8 (76 ref.)

MALOCCLUSION, ANGLE CLASS II

THERAPY

Orthopedics in orthodontics: Part I, Fiction or reality––a review of the literature [see comments] Aelbers CM, et al. **Am J Orthod Dentofacial Orthop** 1996 Nov;110(5):513–9 (101 ref.) Comment in: Am J Orthod Dentofacial Orthop 1997 Jun;111(6):16A.

Predicting functional appliance treatment outcome in Class II malocclusions––a review. Barton S, et al. **Am J Orthod Dentofacial Orthop** 1997 Sep;112(3):282–6 (31 ref.)

MALOCCLUSION, ANGLE CLASS III

see related
PROGNATHISM

THERAPY

Orthopedics in orthodontics: Fiction or reality. A review of the literature––Part II [see comments] Dermaut LR, et al. **Am J Orthod Dentofacial Orthop** 1996 Dec; 110(6):667–71 (77 ref.) Comment in: Am J Orthod Dentofacial Orthop 1997 Jun;111(6):16A.

Maxillary development revisited: relevance to the orthopaedic treatment of Class III malocclusions. Delaire J. **Eur J Orthod** 1997 Jun;19(3):289–311 (49 ref.)

MALPRACTICE

see related
INSURANCE, LIABILITY

Malpractice in the new millennium: better than today? Managed care, telemedicine, genetic tests create new liabilities. **Alaska Med** 1996 Jul–Sep;38(3):106–8 (0 ref.)

From delivery suite to laboratory: optimizing returns from placental examination in medico–legal defence. Khong TY. **Aust N Z J Obstet Gynaecol** 1997 Feb;37(1):1–5 (46 ref.)

Persistence is not always a virtue: tort reform, civil liability for health care, and the lack of empirical evidence. Daniels S, et al. **Behav Sci Law** 1997 Winter;15(1):3–19 (104 ref.)

Malpractice protection: communication of diagnostic uncertainty. Skoumal SM, et al. **Diagn Cytopathol** 1996 Jun; 14(4):385–9 (51 ref.)

Torture and medical profession––an overview. Umesh MS. **J Indian Med Assoc** 1996 Jul;94(7):257–8, 261 (17 ref.)

Licensing, practice, and malpractice in occupational medicine. Rischitelli DG. **Occup Med** 1996 Jan–Mar; 11(1):121–35 (51 ref.)

The legal ramifications of the NCCN practice guidelines. Miller FH. **Oncology (Huntingt)** 1996 Nov;10(11 Suppl):35–9 (20 ref.)

Can regional anesthesia worsen outcome? Medicolegal risk. Wedel DJ. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):71–4 (13 ref.)

HISTORY

Personal liability implications of the duty to warn are hard pills to swallow: from Tarasoff to Hutchinson v. Patel and beyond. Almason AL. **J Contemp Health Law Policy** 1997 Spring;13(2):471–96 (174 ref.)

LEGISLATION & JURISPRUDENCE

Medical–legal considerations related to symptom duration and patient outcome after bacterial meningitis. Bonadio WA. **Am J Emerg Med** 1997 Jul;15(4):420–3 (37 ref.)

Groping for the reins: ERISA, HMO malpractice, and enterprise liability. Kilcullen JK. **Am J Law Med** 1996; 22(1):7–50 (414 ref.)

An overview of professional liability in occupational therapy. Ranke BA, et al. **Am J Occup Ther** 1997 Sep;51(8):671–80 (17 ref.)

Guidelines for experts reviewing Papanicolaou smear litigation cases. Frable WJ. **Arch Pathol Lab Med** 1997 Mar; 121(3):331–4 (12 ref.)

Liability issues with the Papanicolaou smear: general legal background. Kline TJ. **Arch Pathol Lab Med** 1997 Mar; 121(3):250–2 (14 ref.)

Liability issues with the Papanicolaou smear: the view of a hospital administrator at Newport Hospital, Newport, Rhode Island. Sampson AJ. **Arch Pathol Lab Med** 1997 Mar;121(3):241–5 (2 ref.)

Liability issues with the Papanicolaou smear: an insurance industry perspective. Scott MD. **Arch Pathol Lab Med** 1997 Mar;121(3):239–40 (0 ref.)

The elements of medical malpractice: an overview. Gittler GJ, et al. **Clin Infect Dis** 1996 Nov;23(5):1152–5 (13 ref.)

Expert testimony, legal reasoning, and justice. The case for adopting a data–based standard of care in allegations of medical negligence in the NICU. Meadow W, et al. **Clin Perinatol** 1996 Sep;23(3):583–95 (32 ref.)

Ethical and legal implications of managed care. Hall RC. **Gen Hosp Psychiatry** 1997 May;19(3):200–8 (88 ref.)

Survivors of sexual abuse allege therapist negligence. Regehr C, et al. **J Am Acad Psychiatry Law** 1997;25(1):49–58 (70 ref.)

Glaucoma––a clinicolegal review. Classé JG. **J Am Optom Assoc** 1997 Jun;68(6):389–94 (21 ref.)

Criminal or merely human?: the prosecution of negligent doctors. Smith AM. **J Contemp Health Law Policy** 1995 Fall;12(1):131–46 (46 ref.)

Clinical guidelines and the law: advice, guidance or regulation? Hurwitz B. **J Eval Clin Pract** 1995 Sep; 1(1):49–60 (80 ref.)

Most common causes of chiropractic malpractice lawsuits. Jagbandhansingh MP. **J Manipulative Physiol Ther** 1997 Jan;20(1):60–4 (26 ref.)

The search for the elusive electronic medical record system––medical liability, the missing factor. Grams RR, et al. **J Med Syst** 1997 Feb;21(1):1–10 (5 ref.)

Complications and medicolegal aspects of endoscopic sinus surgery. Lund VJ, et al. **J R Soc Med** 1997 Aug;90(8):422–8 (41 ref.)

Liability risks in gynaecology and obstetrics under German and Austrian law. Bernat E. **Med Law** 1995;14(5–6):413–23 (63 ref.)

Determining the standard of care in medical negligence litigation in Australia. Collins A, et al. **Med Law** 1997; 16(2):201–7 (0 ref.)

Errors in cervical smears: minimizing the risk of medicolegal consequences. Greening SE. **Monogr Pathol** 1997; (39):16–39 (52 ref.)

Legal and practical impact of clinical practice guidelines on nursing and medical practice. Murphy RN. **Nurse Pract** 1997 Mar;22(3):138, 147–8 (3 ref.)

Do you have nursing professional liability insurance?––Part I. Byrd CM. **Prog Cardiovasc Nurs** 1997 Spring;12(2):37–9 (7 ref.)

Refusing to pay for health care––Part II (of III): Emerging trends in third–party payer liability. Ross EJ. **Prog Cardiovasc Nurs** 1996 Spring;11(2):40–5 (57 ref.)

Refusing to pay for health care––Part III (of III): Avoiding third–party payer liability. Ross EJ. **Prog Cardiovasc Nurs** 1996 Summer;11(3):41–5 (35 ref.)

Medical malpractice arbitration: a primer for Texas physicians. Fraser JJ Jr. **Tex Med** 1997 Jan;93(1):76–80 (44 ref.)

[Consent and patient education in anesthesia. Legal principles and forensic consequences] Biermann E. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jul; 32(7):427–52 (108 ref.) **(Ger)**

[Medico–legal aspects of anesthesia and intensive care medicine. 1: The treatment error] Biermann E. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Mar; 32(3):175–93 (62 ref.) **(Ger)**

[Medical expert assessment in civil and criminal law from the medical viewpoint] Carstensen G. **Z Arztl Fortbild (Jena)** 1996 Nov;90(7):581–6 (8 ref.) (Eng. Abstr.) **(Ger)**

[Conflicting expert opinions from the legal viewpoint] Pelz FJ. **Z Arztl Fortbild (Jena)** 1996 Nov;90(7):636–9 (27 ref.) (Eng. Abstr.) **(Ger)**

[Medical expert assessment in civil and criminal law––legal evaluation of medical expert opinion] Schlund GH. **Z Arztl Fortbild (Jena)** 1996 Nov;90(7):596–602 (37 ref.) (Eng. Abstr.) **(Ger)**

[Medical expert assessment in criminal processes from the legal viewpoint] Ulsenheimer K. **Z Arztl Fortbild (Jena)** 1996 Nov;90(7):574–81 (24 ref.) (Eng. Abstr.) **(Ger)**

[Legal implications, patient education responsibilities for referring and treating physicians] Ulsenheimer K. **Z Kardiol** 1996 Aug;85(8):529–36 (29 ref.) **(Ger)**

STATISTICS & NUMERICAL DATA

Most common causes of chiropractic malpractice lawsuits. Jagbandhansingh MP. **J Manipulative Physiol Ther** 1997 Jan;20(1):60–4 (26 ref.)

TRENDS

Malpractice in the lower Rio Grande Valley. Oshel RE, et al. **Tex Med** 1997 Jan;93(1):66–75 (22 ref.)

MALT see **CEREALS**

MALT LYMPHOMA see **LYMPHOMA, MUCOSA–ASSOCIATED LYMPHOID TISSUE**

MALTA FEVER see **BRUCELLOSIS**

MALTASES see **ALPHA–GLUCOSIDASES**

MALTHUSIANISM see **POPULATION DYNAMICS**

MALTOSE

SECRETION

Bioregeneration with maltose excreting Chlorella: system concept, technological development, and experiments. Wolf L. **Adv Space Biol Med** 1997;6:255–74 (16 ref.)

MAMBA see ELAPIDAE

MAMILLARY BODIES

PHYSIOLOGY

The tuberomammillary nucleus projections in the control of learning, memory and reinforcement processes: evidence for an inhibitory role. Huston JP, et al. **Behav Brain Res** 1997 Feb;83(1-2):97-105 (58 ref.)

MAMMAE

ANATOMY & HISTOLOGY

Tumours of the mammary gland. Fernandez PL, et al. **IARC Sci Publ** 1996;(126):45-58 (29 ref.)

BLOOD SUPPLY

Regulation of blood flow in the mammary microvasculature. Prosser CG, et al. **J Dairy Sci** 1996 Jul;79(7):1184-97 (116 ref.)

CYTOLOGY

Cellular defense mechanisms in the udder and lactation of goats. Paape MJ, et al. **J Anim Sci** 1997 Feb;75(2):556-65 (81 ref.)

The insulin-like growth factor and epidermal growth factor families in mammary cell growth in ruminants: action and interaction with hormones. Forsyth IA. **J Dairy Sci** 1996 Jun;79(6):1085-96 (84 ref.)

Plasminogen activator system: implications for mammary cell growth and involution. Politis I. **J Dairy Sci** 1996 Jun; 79(6):1097-107 (55 ref.)

Does an IGF-binding protein (IGFBP) present in involuting rat mammary gland regulate apoptosis? Tonner E, et al. **Prog Growth Factor Res** 1995;6(2-4):409-14 (21 ref.)

IMMUNOLOGY

Immunobiology of the mammary gland. Sordillo LM, et al. **J Dairy Sci** 1997 Aug;80(8):1851-65 (117 ref.)

METABOLISM

Lipid metabolism in the lactating mammary gland. Barber MC, et al. **Biochim Biophys Acta** 1997 Aug 16; 1347(2-3):101-26 (257 ref.)

Connexin expression and gap junctions in the mammary gland. Monaghan P, et al. **Cell Biol Int** 1996 Feb; 20(2):121-5 (29 ref.)

Prolactin signaling in mammary gland development. Hennighausen L, et al. **J Biol Chem** 1997 Mar 21; 272(12):7567-9 (40 ref.)

Molecular mechanisms of hormone controlled gene expression in the breast. Hennighausen L. **Mol Biol Rep** 1997 Aug;24(3):169-74 (43 ref.)

Amino acid supply and metabolism by the ruminant mammary gland. Bequette BJ, et al. **Proc Nutr Soc** 1997 Jul;56(2):593-605 (45 ref.)

Mammary-tissue amino acid transport systems. Shennan DB, et al. **Proc Nutr Soc** 1997 Mar;56(1A):177-91 (64 ref.)

Nutritional control of amino acid supply to the mammary gland during lactation in the pig. Trottier NL. **Proc Nutr Soc** 1997 Jul;56(2):581-91 (39 ref.)

PATHOLOGY

Programmed cell death and mammary neoplasia. Schedin PJ, et al. **Cancer Treat Res** 1996;83:3-22 (73 ref.)

PHYSIOLOGY

Breastfeeding: physiological, endocrine and behavioural adaptations caused by oxytocin and local neurogenic activity in the nipple and mammary gland. Uvnäs-Moberg K, et al. **Acta Paediatr** 1996 May;85(5):525-30 (43 ref.)

Cellular defense mechanisms in the udder and lactation of goats. Paape MJ, et al. **J Anim Sci** 1997 Feb;75(2):556-65 (81 ref.)

SECRETION

Cellular components of mammary secretions and neonatal immunity: a review. Le Jan C. **Vet Res** 1996;27(4-5):403-17 (82 ref.)

MAMMALS

Antigens with application toward immune control of blood-feeding parasitic nematodes. Jasmer DP, et al. **Br Vet J** 1995 May;152(3):251-68 (89 ref.)

Polytene chromosomes in mammalian cells. Zybina EV, et al. **Int Rev Cytol** 1996;165:53-119 (267 ref.)

Australian and New Zealand mammal species considered to be pests or problems. Cowan PE, et al. **Reprod Fertil Dev** 1997;9(1):27-36 (61 ref.)

Fertility control of mammal pests and the conservation of endangered marsupials. Sinclair AR. **Reprod Fertil Dev** 1997;9(1):1-16 (59 ref.)

Quarantine protocols and preventive medicine procedures for reptiles, birds and mammals in zoos. Miller RE. **Rev Sci Tech** 1996 Mar;15(1):183-9 (1 ref.)

ANATOMY & HISTOLOGY

Osteocyte density and histomorphometric parameters in cancellous bone of the proximal femur in five mammalian species. Mullender MG, et al. **J Orthop Res** 1996 Nov; 14(6):972-9 (35 ref.)

Cellular and molecular correlates to plasticity during recovery from injury in the developing mammalian brain. Ide CF, et al. **Prog Brain Res** 1996;108:365-77 (21 ref.)

Transverse and longitudinal patterns in the mammalian cerebellum. Voogd J, et al. **Prog Brain Res** 1997;114:21-37 (78 ref.)

A comparison of oocyte organelles in Monodelphis domestica with those of other marsupials and eutherians. Kress A. **Reprod Fertil Dev** 1996;8(4):521-33 (90 ref.)

A comparison of eutherian and marsupial optic chiasms: a brief review. Guillery RW. **Rev Bras Biol** 1995 Dec;55 Suppl 1:1-10 (31 ref.)

[Intramural vascular system of the large intestine of mammals. A study of the literature] Wille KH, et al. **Anat Histol Embryol** 1997 Jun;26(2):85-91 (49 ref.) (Eng. Abstr.) **(Ger)**

[Modern concepts of the structure and function of muscle spindles in mammals] Arutiunian RS. **Usp Fiziol Nauk** 1996 Oct-Dec;27(4):73-95 (142 ref.) (Eng. Abstr.) **(Rus)**

EMBRYOLOGY

Regionalization in the mammalian telencephalon. Fishell G. **Curr Opin Neurobiol** 1997 Feb;7(1):62-9 (72 ref.)

A comparative review of the sites of histoenzymatic dephosphorylating activities and of gene expression in developing limb buds of mammalian and avian species. Milaire J. **Eur J Morphol** 1997 Jul;35(3):143-69 (193 ref.)

The primordial germ cells of mammals: some current perspectives. Buehr M. **Exp Cell Res** 1997 May 1; 232(2):194-207 (129 ref.)

Can developmentally significant spatial patterning of the egg be discounted in mammals? Gardner RL. **Hum Reprod Update** 1996 Jan-Feb;2(1):3-27 (226 ref.)

Surgical manipulation of mammalian embryos in vitro. Naruse I, et al. **Int J Dev Biol** 1997 Apr;41(2):195-8 (52 ref.)

Mammalian craniofacial embryology in vitro. Osumi-Yamashita N, et al. **Int J Dev Biol** 1997 Apr; 41(2):187-94 (73 ref.)

Primordial germ cell development: is the urodele pattern closer to mammals than to anurans? Wakahara M. **Int J Dev Biol** 1996 Aug;40(4):653-9 (55 ref.)

Developmental functions of mammalian Hox genes. Favier B, et al. **Mol Hum Reprod** 1997 Feb;3(2):115-31 (128 ref.)

The chronotopic reordering of optic axons. Reese BE. **Perspect Dev Neurobiol** 1996;3(3):233-42 (70 ref.)

Avian models in developmental biology. Dieterlen-Lièvre F. **Poult Sci** 1997 Jan;76(1):78-82 (44 ref.)

[The creation of genetic cryobanks and the use of the methods of developmental biology as a means for preserving rare animal species. II. The obtaining and cryopreservation of the embryos of wild mammals] Rott NN. **Ontogenez** 1996 Jul-Aug;27(4):245-55 (84 ref.) (Eng. Abstr.) **(Rus)**

[From regional specification to cell differentiation in preimplantation mammalian development] Izquierdo L. **Arch Biol Med Exp (Santiago)** 1986;19(3-4):279-300 (181 ref.) **(Spa)**

GENETICS

Novel members of mammalian kexin family proteases, pace 4C, pace 4D, PC 7A and PC 7B. Matsuda Y, et al. **Adv Exp Med Biol** 1996;389:63-71 (15 ref.)

Semper fidelis: what man's best friend can teach us about human biology and disease. Ostrander EA, et al. **Am J Hum Genet** 1997 Sep;61(3):475-80 (32 ref.)

Translational termination efficiency in both bacteria and mammals is regulated by the base following the stop codon. Tate WP, et al. **Biochem Cell Biol** 1995 Nov-Dec; 73(11-12):1095-103 (42 ref.)

A comparison of mammalian and yeast pre-mRNA 3'-end processing. Keller W, et al. **Curr Opin Cell Biol** 1997 Jun; 9(3):329-36 (52 ref.)

Comparative maps: adding pieces to the mammalian jigsaw puzzle. Eppig JT. **Curr Opin Genet Dev** 1996 Dec; 6(6):723-30 (52 ref.)

SRY and mammalian sex determination. Greenfield A, et al. **Curr Top Dev Biol** 1996;34:1-23 (76 ref.)

Stage-specific and cell type-specific aspects of genomic imprinting effects in mammals. Latham KE. **Differentiation** 1995 Dec;59(5):269-82 (147 ref.)

The biology of replicative senescence. Campisi J. **Eur J Cancer** 1997 Apr;33(5):703-9 (79 ref.)

Genetic influences on aging. Johnson TE. **Exp Gerontol** 1997 Jan-Apr;32(1-2):11-22 (83 ref.)

Sequence and context effects on origin function in mammalian cells. Dijkwel PA, et al. **J Cell Biochem** 1996 Aug;62(2):210-22 (85 ref.)

The effects of habitat fragmentation on the genetic structure of small mammal populations. Gaines MS, et al. **J Hered** 1997 Jul-Aug;88(4):294-304 (48 ref.)

Molecular basis governing primary sex in mammals. Nagai K. **Jpn J Hum Genet** 1996 Dec;41(4):363-79 (57 ref.)

Developmental functions of mammalian Hox genes. Favier B, et al. **Mol Hum Reprod** 1997 Feb;3(2):115-31 (128 ref.)

Formation of methylation patterns in the mammalian genome [see comments] Turker MS, et al. **Mutat Res** 1997 Apr; 386(2):119-30 (86 ref.) Comment in: Mutat Res 1997 Apr;386(2):x103-5.

Genetic dissection of the function of mammalian P-glycoproteins. Borst P, et al. **Trends Genet** 1997 Jun; 13(6):217-22 (46 ref.)

Mammalian artificial chromosomes and chromosome transgenics. Huxley C. **Trends Genet** 1997 Sep;13(9):345-7 (24 ref.)

[X-chromosome inactivation in mammalian ontogeny] Evdokimova VN, et al. **Ontogenez** 1997 Jul-Aug; 28(4):245-61 (116 ref.) (Eng. Abstr.) **(Rus)**

[MtDNA-like sequences and the coordination of the functioning of mammalian nuclear and mitochondrial genomes] Maliarchuk BA. **Tsitol Genet** 1997 Mar-Apr; 31(2):53-61 (51 ref.) (Eng. Abstr.) **(Rus)**

GROWTH & DEVELOPMENT

DNA methylation and imprinting: why bother? [see comments] Jaenisch R. **Trends Genet** 1997 Aug;13(8):323-9 (68 ref.) Comment in: Trends Genet 1997 Aug;13(8):293-5.

METABOLISM

Variable peroxisomal and mitochondrial targeting of alanine: glyoxylate aminotransferase in mammalian evolution and disease. Danpure CJ. **Bioessays** 1997 Apr;19(4):317-26 (69 ref.)

The mutual sparing effects of selenium and vitamin E in animal nutrition may be further explained by the discovery that mammalian thioredoxin reductase is a selenoenzyme. Tamura T, et al. **Biofactors** 1995-96;5(2):99-102 (42 ref.)

Actions of insulin on the mammalian heart: metabolism, pathology and biochemical mechanisms. Brownsey RW, et al. **Cardiovasc Res** 1997 Apr;34(1):3-24 (263 ref.)

Concentrations of chlorinated hydrocarbons and trace elements in marine mammal tissues archived in the U.S. National Biomonitoring Specimen Bank. Becker PR, et al. **Chemosphere** 1997 May;34(9-10):2067-98 (38 ref.)

Mammalian plasma and tissue-bound semicarbazide-sensitive amine oxidases: biochemical, pharmacological and toxicological aspects. Lyles GA. **Int J Biochem Cell Biol** 1996 Mar;28(3):259-74 (113 ref.)

Acyltransferases and transacylases involved in fatty acid remodeling of phospholipids and metabolism of bioactive lipids in mammalian cells. Yamashita A, et al. **J Biochem (Tokyo)** 1997 Jul;122(1):1-16 (149 ref.)

Molecular characteristics of mammalian and insect amino acid transporters: implications for amino acid homeostasis. Castagna M, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):269-86 (200 ref.)

Evolution of processes and regulators of lipoprotein synthesis: from birds to mammals. Davis RA. **J Nutr** 1997 May;127(5 Suppl):795S-800S (44 ref.)

Cellular energy utilization and molecular origin of standard metabolic rate in mammals. Rolfe DF, et al. **Physiol Rev** 1997 Jul;77(3):731-58 (221 ref.)

Cellular fatty acid-binding proteins: their function and physiological significance. Glatz JF, et al. **Prog Lipid Res** 1996 Sep;35(3):243-82 (450 ref.)

Biosynthesis, metabolization and biological importance of the primary 15-lipoxygenase metabolites 15-hydro(pero)XY-5Z,8Z,11Z,13E-eicosatetraenoic acid and 13-hydro(pero)XY-9Z,11E-octadecadienoic acid. Kühn H. **Prog Lipid Res** 1996 Sep;35(3):203-26 (251 ref.)

Biosynthesis of triacylglycerols. Lehner R, et al. **Prog Lipid Res** 1996;35(2):169-201 (208 ref.)

[The harderian gland in mammals: The biochemical and physiological aspects] Bodiak ND. **Izv Akad Nauk Ser Biol** 1996 Nov-Dec;(6):725-35 (92 ref.) (Eng. Abstr.) **(Rus)**

[Structure ond regulation of gene expression of tyrosine aminotransferase and proopiomelanocortin in mammals] Mertvetsov NP. **Vestn Ross Akad Med Nauk** 1997;(8):10-5 (50 ref.) **(Rus)**

[The biological design of the oxygen transport system in mammals and the law of symmorphism] Ivanov KP. **Zh Obshch Biol** 1996 Nov-Dec;57(6):699-717 (75 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Biophysical aspects of blood flow in the microvasculature. Pries AR, et al. **Cardiovasc Res** 1996 Oct;32(4):654-67 (105 ref.)

Components and connections of the circadian timing system in mammals. Reuss S. **Cell Tissue Res** 1996 Sep; 285(3):353-78 (280 ref.)

Anoxia tolerant animals from a neurobiological perspective. Lutz PL, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Jan; 113(1):3-13 (100 ref.)

Maintenance of cardiac function during anoxia in turtles: from cell to organism. Wasser JS. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Jan; 113(1):15-22 (39 ref.)

Newborn intensive care--success, failure and opportunities. Stahlman MT. **Equine Vet J Suppl** 1988 Sep;(5):1-4; discussion 5 (39 ref.)

Comparative aging and life histories in mammals. Austad SN. **Exp Gerontol** 1997 Jan-Apr;32(1-2):23-38 (115 ref.)

Why do albinos and other hypopigmented mutants lack normal binocular vision, and what else is abnormal in their

MAMMALS

central visual pathways? Guillery RW. **Eye** 1996;10 (Pt 2):217–21 (46 ref.)
Insulin exposure and aging theory. Parr T. **Gerontology** 1997; 43(3):182–200 (165 ref.)
Direct regulation of mammalian reproductive organs by serotonin and melatonin. Sirotkin AV, et al. **J Endocrinol** 1997 Jul;154(1):1–5 (60 ref.)
The response to calorie restriction in mammals shows features also common to hibernation: a cross–adaptation hypothesis. Walford RL, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jul;52(4):B179–83 (58 ref.)
Information processing in mammalian olfactory system. Sullivan SL, et al. **J Neurobiol** 1996 May;30(1):20–36 (171 ref.)
Does Hebbian synaptic plasticity explain learning–induced sensory plasticity in adult mammals? Edeline JM. **J Physiol Paris** 1996;90(3–4):271–6 (52 ref.)
Mechanisms regulating the reproduction and fertility of some mammalian species in their natural environments. Hearn JP. **Lab Anim Sci** 1996 Apr;46(2):152–8 (31 ref.)
Insulin exposure controls the rate of mammalian aging. Parr T. **Mech Ageing Dev** 1996 Jul 5;88(1–2):75–82 (45 ref.)
Innervation of the adrenal cortex, its physiological relevance, with primary focus on the noradrenergic transmission. Tóth IE, et al. **Microsc Res Tech** 1997 Mar 15;36(6):534–45 (93 ref.)
The early intracellular signaling pathway for the insulin/insulin–like growth factor receptor family in the mammalian central nervous system. Folli F, et al. **Mol Neurobiol** 1996 Oct;13(2):155–83 (162 ref.)
Physiology of diving of birds and mammals. Butler PJ, et al. **Physiol Rev** 1997 Jul;77(3):837–99 (424 ref.)
What marsupial gametes disclose about gamete function in eutherian mammals. Bedford JM. **Reprod Fertil Dev** 1996; 8(4):569–80 (65 ref.)
Capacitation mechanisms, and the role of capacitation as seen in eutherian mammals. Harrison RA. **Reprod Fertil Dev** 1996;8(4):581–94 (106 ref.)
Regulation of the motility and metabolism of spermatozoa for storage in the epididymis of eutherian and marsupial mammals. Jones RC, et al. **Reprod Fertil Dev** 1996; 8(4):553–68 (169 ref.)
New insights into the mammalian circadian clock. Miller JD, et al. **Sleep** 1996 Oct;19(8):641–67 (230 ref.)
Four beta–adrenoceptor subtypes in the mammalian heart. Kaumann AJ. **Trends Pharmacol Sci** 1997 Mar;18(3):70–6 (61 ref.)
Influence of granulosa cells and of different somatic cell types on mammalian oocyte development in vitro. Cecconi S, et al. **Zygote** 1996 Nov;4(4):305–7 (34 ref.)
[Fertilization in mammals] Thibault C. **Contracept Fertil Sex** 1996 Jul–Aug;24(7–8):519–25 (39 ref.) (Eng. Abstr.) **(Fre)**
[Importance of ultradian rhythms in endocrinology] Goubillon ML, et al. **Pathol Biol (Paris)** 1996 Sep; 44(7):585–91 (58 ref.) (Eng. Abstr.) **(Fre)**
[Anesthesia in domestic animals (small mammals, psittacines and reptiles)] Kuntze A. **Tierarztl Prax** 1996 Dec; 24(6):600–3 (24 ref.) (Eng. Abstr.) **(Ger)**
[The regulation of spermatogenesis in mammals] Stefanini M, et al. **Ital J Anat Embryol** 1995 Oct–Dec;100(4):73–112 (0 ref.) **(Ita)**

PSYCHOLOGY

Cooperative care of young in mammals. König B. **Naturwissenschaften** 1997 Mar;84(3):95–104 (95 ref.)

MAMMAPLASTY

Skin–sparing mastectomy with immediate breast reconstruction. Singletary SE, et al. **Adv Surg** 1996; 30:39–52 (45 ref.)
Breast size, breast reduction, and cancer risk [editorial; comment] Franceschi S. **Cancer Causes Control** 1997 Mar; 8(2):125–6 (18 ref.) Comment on: Cancer Causes Control 1997 Mar;8(2):253–8.

METHODS

Immediate breast reconstruction. A review. Kroll SS. **Ann Chir Gynaecol** 1997;86(1):5–12 (18 ref.)
Reconstruction of the breast. Bostwick J 3rd, et al. **Surg Oncol Clin N Am** 1997 Jan;6(1):71–89 (57 ref.)

PSYCHOLOGY

[Beautifying the breast] Le Gouès G. **Contracept Fertil Sex** 1997 Jun;25(6):475–81 (31 ref.) (Eng. Abstr.) **(Fre)**

REHABILITATION

Physical therapy implications following the TRAM procedure. Monteiro M. **Phys Ther** 1997 Jul;77(7):765–70 (20 ref.)

MAMMARY ARTERIES

TRANSPLANTATION

Total arterial myocardial revascularization [editorial] Calafiore AM. **Thorac Cardiovasc Surg** 1997 Jun; 45(3):105–8 (17 ref.)

MAMMARY CANCER VIRUS see **MAMMARY TUMOR VIRUSES, MOUSE**

MAMMARY DYSPLASIA see **FIBROCYSTIC DISEASE OF BREAST**

MAMMARY GLANDS see **BREAST**

MAMMARY GLANDS, ANIMAL see **MAMMAE**

MAMMARY NEOPLASMS

DRUG THERAPY

[Dose intensification of adjuvant chemotherapy in high–risk non–metastatic breast cancer: a critical review] Ganem G. **Bull Cancer** 1997 Jan;84(1):97–105 (84 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Breast size, breast reduction, and cancer risk [editorial; comment] Franceschi S. **Cancer Causes Control** 1997 Mar; 8(2):125–6 (18 ref.) Comment on: Cancer Causes Control 1997 Mar;8(2):253–8.
Dual role of oestrogens as hormones and pro–carcinogens: tumour initiation by metabolic activation of oestrogens. Liehr JG. **Eur J Cancer Prev** 1997 Feb;6(1):3–10 (75 ref.)

IMMUNOLOGY

[Immunoregulation of murine mammary tumor growth] Klein S. **Medicina (B Aires)** 1996;56 Suppl 1:32–44 (85 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Tumours of the mammary gland. Fernandez PL, et al. **IARC Sci Publ** 1996;(126):45–58 (29 ref.)
[Immunoregulation of murine mammary tumor growth] Klein S. **Medicina (B Aires)** 1996;56 Suppl 1:32–44 (85 ref.) (Eng. Abstr.) **(Spa)**

MAMMARY NEOPLASMS, EXPERIMENTAL

Perspectives on integrating experimental and epidemiologic research on diet, anthropometry and breast cancer. Ballard–Barbash R, et al. **J Nutr** 1997 May;127(5 Suppl):936S–939S (22 ref.)
Diet and breast cancer: studies in laboratory animals. Rogers AE. **J Nutr** 1997 May;127(5 Suppl):933S–935S (28 ref.)

CHEMICALLY INDUCED

Mammary gland neoplasia [comment] Neumann DA, et al. **Environ Health Perspect** 1996 Sep;104(9):912–4 (13 ref.) Comment on: Environ Health Perspect 1996 Sep;104(9):938–67.

DRUG THERAPY

Antimetastatic action of the prostacyclin analogue cicaprost in experimental mammary tumors. Schneider MR, et al. **Breast Cancer Res Treat** 1996;38(1):133–41 (21 ref.)

ENZYMOLOGY

The role of stromelysin–1 in stromal–epithelial interactions and cancer. Wiesen JF, et al. **Enzyme Protein** 1996; 49(1–3):174–81 (53 ref.)

ETIOLOGY

Transgenic models of breast cancer metastasis. Dankort DL, et al. **Cancer Treat Res** 1996;83:71–88 (116 ref.)
Tissue reconstitution, or transgenic mammary gland, technique for modeling breast cancer development. Edwards PA. **Cancer Treat Res** 1996;83:23–36 (41 ref.)
Preneoplasia in mammary tumorigenesis. Medina D. **Cancer Treat Res** 1996;83:37–69 (145 ref.)
Programmed cell death and mammary neoplasia. Schedin PJ, et al. **Cancer Treat Res** 1996;83:3–22 (73 ref.)
Mammary gland neoplasia in long–term rodent studies [see comments] Russo IH, et al. **Environ Health Perspect** 1996 Sep;104(9):938–67 (266 ref.) Comment in: Environ Health Perspect 1996 Sep;104(9):912–4.
Toward a unified concept of mammary carcinogenesis. Russo J, et al. **Prog Clin Biol Res** 1997;396:1–16 (69 ref.)

GENETICS

Inherited susceptibility and acquired allelic imbalance in rat mammary carcinogenesis. Gould MN, et al. **J Cell Biochem Suppl** 1996;25:37–40 (11 ref.)
Intrinsic multidrug class 1 and 2 gene expression and localization in rat and human mammary tumors. Zhang F, et al. **Lab Invest** 1996 Sep;75(3):413–26 (133 ref.)
The role of p53 loss in genomic instability and tumor progression in a murine mammary cancer model. Donehower LA, et al. **Prog Clin Biol Res** 1996;395:1–11 (19 ref.)

PATHOLOGY

Models of progression spanning preneoplasia and metastasis: the human MCF10AneoT.TGn series and a panel of mouse mammary tumor subpopulations. Miller FR. **Cancer Treat Res** 1996;83:243–63 (42 ref.)

PHYSIOPATHOLOGY

Estrogens, phytoestrogens, and breast cancer. Clarke R, et al. **Adv Exp Med Biol** 1996;401:63–85 (141 ref.)
Ethanol and experimental breast cancer: a review. Singletary K. **Alcohol Clin Exp Res** 1997 Apr;21(2):334–9 (61 ref.)

VIROLOGY

Mouse mammary tumor virus and mammary tumorigenesis in wild mice. Imai S. **Pathol Int** 1996 Dec;46(12):919–32 (136 ref.)

MAMMARY TUMOR VIRUSES, MOUSE

Mouse mammary tumor virus and mammary tumorigenesis in wild mice. Imai S. **Pathol Int** 1996 Dec;46(12):919–32 (136 ref.)

GENETICS

Chromatin structure of the MMTV promoter and its changes during hormonal induction. Truss M, et al. **Cell Mol Neurobiol** 1996 Apr;16(2):85–101 (110 ref.)
Chromatin structure and the regulation of gene expression: remodeling at the MMTV promoter. Beato M. **J Mol Med** 1996 Dec;74(12):711–24 (154 ref.)
Transcriptional regulation by steroid hormones. Beato M, et al. **Steroids** 1996 Apr;61(4):240–51 (176 ref.)

IMMUNOLOGY

Mouse mammary tumor virus: immunological interplays between virus and host. Luther SA, et al. **Adv Immunol** 1997;65:139–243 (584 ref.)
Mouse mammary tumor virus and the immune system. Ross SR. **Adv Pharmacol** 1997;39:21–46 (95 ref.)
Immune response to mouse mammary tumour virus. Luther SA, et al. **Curr Opin Immunol** 1996 Aug;8(4):498–502 (24 ref.)
Superantigens of mouse mammary tumour virus: implications for diabetes? Acha–Orbea H. **Diabetes Metab Rev** 1996 Jul; 12(2):111–9 (59 ref.)

MAMMILLARY BODIES see **MAMILLARY BODIES**

MAMMOGRAPHY

NCI and NIH consensus panel issue recommendations on mammography for women ages 40 to 49. **Am Fam Physician** 1997 May 15;55(7):2536–9 (0 ref.)
Controversies in women's health maintenance [see comments] Morrison EH. **Am Fam Physician** 1997 Mar;55(4):1283–90 (50 ref.) Comment in: Am Fam Physician 1997 Mar;55(4):1039, 1042, 1047–8.
Image–guided breast biopsy. Burns RP. **Am J Surg** 1997 Jan; 173(1):9–11; discussion 12–3 (16 ref.)
Traditional and future management of nonpalpable breast cancer. Cady B. **Am Surg** 1997 Jan;63(1):55–8 (24 ref.)
US panel fails to recommend mammography screening for women under the age of 50 [news] **Ann Oncol** 1997 Mar; 8(3):210–1 (0 ref.)
An update on core needle biopsy for radiologically detected breast lesions. Nguyen M, et al. **Cancer** 1996 Dec 1; 78(11):2340–5 (17 ref.)
Update in digital mammography. Hogge JP, et al. **Crit Rev Diagn Imaging** 1997;38(1):89–113 (51 ref.)
Controversies regarding screening mammography. Ciatto S. **Crit Rev Oncol Hematol** 1997 May;26(1):55–9 (31 ref.)
Mammographic screening in older women. Is it worthwhile? van Dijck JA, et al. **Drugs Aging** 1997 Feb;10(2):69–79 (62 ref.)
The debate over mass mammography: is it beneficial for women? Dilhuydy MH, et al. **Eur J Radiol** 1997 Feb; 24(2):86–93 (36 ref.)
Lesion detection in breast carcinoma. Mortier M, et al. **J Belge Radiol** 1997 Apr;80(2):85–8 (13 ref.)
Breast imaging and the diagnosis of breast disease. Monticciolo DL. **J Med Assoc Ga** 1997 Sep;86(3):207–9 (18 ref.)
National Institutes of Health Consensus Development Conference Statement: Breast Cancer Screening for Women Ages 40–49, January 21–23, 1997. National Institutes of Health Consensus Development Panel. **J Natl Cancer Inst** 1997 Jul 16;89(14):1015–26 (94 ref.)
Should we recommend screening mammography for women aged 40 to 49? Esserman L, et al. **Oncology (Huntingt)** 1996 Mar;10(3):357–64; discussion: 370–6 (46 ref.)
Lessons from mammographic–histopathologic correlation of large–core needle breast biopsy. Berg WA, et al. **Radiographics** 1996 Sep;16(5):1111–30 (31 ref.)
Mammographic evaluation of the postsurgical and irradiated breast. Briggs J. **Radiol Technol** 1997 Mar–Apr; 68(4):287–304; quiz 305–8 (22 ref.)
Breast cancer in older women: screening and selection of locoregional therapy. Sener SF. **Semin Surg Oncol** 1996 Sep–Oct;12(5):328–31 (24 ref.)
Current status of digital mammography. Feig SA, et al. **Semin Ultrasound CT MR** 1996 Oct;17(5):424–43 (28 ref.)
The role of stereotactic biopsy in abnormal mammograms.

Fajardo LL, et al. **Surg Oncol Clin N Am** 1997 Apr; 6(2):285–99 (24 ref.)
Current use and how to increase mammography screening in women. Rimer BK. **Surg Oncol Clin N Am** 1997 Apr; 6(2):203–11 (52 ref.)
[Mammography] Schmidt F. **Acta Med Austriaca** 1997; 24(2):29–32 (18 ref.) (Eng. Abstr.) **(Ger)**
[Computer-assisted diagnosis in screening mammography] Bick U. **Radiologe** 1996 Jan;36(1):72–80 (53 ref.) (Eng. Abstr.) **(Ger)**
[The role of imaging techniques in benign breast lesions] Facchini M. **Ann Ital Chir** 1997 Mar–Apr;68(2):173–8 (12 ref.) (Eng. Abstr.) **(Ita)**
[Calcifications visible in mammographic examination as a diagnostic problem] Urbanowicz Z, et al. **Ginekol Pol** 1996 Jul;67(7):366–9 (17 ref.) (Eng. Abstr.) **(Pol)**

METHODS

Magnetic resonance mammography [see comments] Drew PJ, et al. **Br J Surg** 1996 Oct;83(10):1316–8 (9 ref.) Comment in: Br J Surg 1997 Mar;84(3):426.
Direct digital mammography image acquisition. Cowen AR, et al. **Eur Radiol** 1997;7(6):918–30 (59 ref.)
Computer-assisted reading of mammograms. Karssemeijer N, et al. **Eur Radiol** 1997;7(5):743–8 (33 ref.)
Role of stereotactic biopsy in diagnosing breast cancer [published erratum appears in Radiol Technol 1997 Mar–Apr;68(4):285] Newman J. **Radiol Technol** 1996 Nov–Dec;68(2):131–48; quiz 149–52 (42 ref.)
The role of mammography in clinical practice--a review. Du Toit RS, et al. **S Afr J Surg** 1996 Nov;34(4):165–8 (50 ref.)
Age and interval for screening mammography: whom do you believe? Venta LA, et al. **Semin Surg Oncol** 1996 Sep–Oct; 12(5):281–9 (39 ref.)

STANDARDS

The mammography consensus jury speaks out [news] Nelson NJ. **J Natl Cancer Inst** 1997 Mar 5;89(5):344–7 (00 ref.)
Determinants of quality in mammography. Bassett LW. **Surg Oncol Clin N Am** 1997 Apr;6(2):213–32 (41 ref.)
[European recommendations for quality assurance in the setting of mammographic screening for breast cancer. Report of pathologists of the working group "Breast Cancer Screening" of the European Union] **Ann Pathol** 1996 Nov; 16(5):315–33 (25 ref.) **(Fre)**

STATISTICS & NUMERICAL DATA

[Significance of roentgen mammography for breast carcinoma screening] Schulz-Wendtland R, et al. **Rontgenpraxis** 1997 May;50(5):103–9 (65 ref.) **(Ger)**

TRENDS

Future prospects of population-based mammographic screening. Holmberg L. **Semin Surg Oncol** 1996 Jan–Feb; 12(1):26–31 (36 ref.)

UTILIZATION

Breast-cancer screening with mammography in women aged 40–49 years. Swedish Cancer Society and the Swedish National Board of Health and Welfare. **Int J Cancer** 1996 Dec 11;68(6):693–9 (26 ref.)
NIH Consensus Statement. Breast cancer screening for women ages 40–49. **NIH Consens Statement** 1997 Jan 21–23;15(1):1–35 (94 ref.)

MAMMOGRAPHY, ULTRASONIC see **ULTRASONOGRAPHY, MAMMARY**

MAMMOTROPIC HORMONE, PITUITARY see **PROLACTIN**

MAMMOTROPIC HORMONE, PLACENTAL see **PLACENTAL LACTOGEN**

MAMMOTROPIN see **PROLACTIN**

MAN-MACHINE SYSTEMS

The AcCell series 2000 as a support system for training and evaluation in educational and clinical settings. Greening SE, et al. **Acta Cytol** 1997 Jan–Feb;41(1):153–9 (10 ref.)
Utility of the TracCell system in mapping Papanicolaou-stained cytologic material. Grohs DH, et al. **Acta Cytol** 1997 Jan–Feb;41(1):144–52 (20 ref.)
Clinical validation of interactive cytologic screening. Automating the search, not the interpretation. Mango LJ. **Acta Cytol** 1997 Jan–Feb;41(1):93–7 (15 ref.)

MANAGED CARE PROGRAMS

Malpractice in the new millennium: better than today? Managed care, telemedicine, genetic tests create new liabilities. **Alaska Med** 1996 Jul–Sep;38(3):106–8 (0 ref.)
Disease management programs [published erratum appears in Am J Health Syst Pharm 1996 Feb 1;53(3):325] Armstrong EP, et al. **Am J Health Syst Pharm** 1996 Jan 1;53(1):53–8 (15 ref.)
Responding to the ethical challenges posed by the business tools of managed care in the practice of obstetrics and gynecology. Chervenak FA, et al. **Am J Obstet Gynecol** 1996 Sep;175(3 Pt 1):523–7 (10 ref.)
Physician payment policies: impacts and implications. Kice T. **Annu Rev Public Health** 1997;18:549–65 (32 ref.)
Peering into the 'black box'. Measuring outcomes of managed care. Pincus HA, et al. **Arch Gen Psychiatry** 1996 Oct; 53(10):870–7 (55 ref.)
Managed care, managing uncertainty. Mirvis DM, et al. **Arch Intern Med** 1997 Feb 24;157(4):385–8 (38 ref.)
Do we understand the effects of 'managed care' in ophthalmology? A review and analysis. Asch S, et al. **Arch Ophthalmol** 1997 Apr;115(4):531–6 (48 ref.)
Managed care. Origins, principles, and evolution. Fairfield G, et al. **BMJ** 1997 Jun 21;314(7097):1823–6 (16 ref.)
Academic cardiology division in the era of managed care. A paradigm for survival [see comments] Feldman AM, et al. **Circulation** 1997 Feb 4;95(3):740–4 (25 ref.) Comment in: Circulation 1997 Feb 4;95(3):545. Comment in: Circulation 1997 Feb 4;95(3):546–7.
Managed care and the infectious diseases specialist. Tice AD, et al. **Clin Infect Dis** 1996 Aug;23(2):341–68 (99 ref.)
More on managed care. Bloomgarden ZT. **Diabetes Care** 1997 Feb;20(2):227–31 (4 ref.)
The market comes to Medicare: adding choice and protections. Lewin ME, et al. **Health Aff (Millwood)** 1996 Winter;15(4):57–61 (12 ref.)
Technology and health system reform. Lang AC. **Int Anesthesiol Clin** 1995 Fall;33(4):119–32 (19 ref.)
Voiceless and vulnerable: dementia patients without surrogates in an era of capitation [editorial; comment] Meier DE. **J Am Geriatr Soc** 1997 Mar;45(3):375–7 (22 ref.) Comment on: J Am Geriatr Soc 1997 Mar;45(3):369–74.
Osteopathic medical education: the introduction of managed care principles into our undergraduate curriculum. Musser AE, et al. **J Am Osteopath Assoc** 1996 Oct;96(10):627–30 (46 ref.)
Public health in a managed care environment. Walker B Jr. **J Health Care Poor Underserved** 1997 Aug;8(3):345–50; discussion 350–1 (9 ref.)
The Medicaid managed care policy consensus for welfare recipients: a reflection of traditional welfare concerns [see comments] Grogan CM. **J Health Polit Policy Law** 1997 Jun;22(3):815–38 (17 ref.) Comment in: J Health Polit Policy Law 1997 Jun;22(3):879–96. Comment in: J Health Polit Policy Law 1997 Jun;22(3):897–906.
The synergistic relationship between ethics and quality improvement: thriving in managed care. Mitchell K, et al. **J Nurs Care Qual** 1996 Oct;11(1):9–21 (27 ref.)
Managed care of substance abuse disorders. Implications for generalist physicians. Larson MJ, et al. **Med Clin North Am** 1997 Jul;81(4):1053–69 (58 ref.)
Meaningful linkage practices: challenges and opportunities. Boyer CA. **New Dir Ment Health Serv** 1997 Spring; (73):87–101 (54 ref.)
The challenges of managed care. Mechanic D. **New Dir Ment Health Serv** 1997 Spring;(73):5–10 (3 ref.)
Toward an integrated approach to the study of inpatient treatment of schizophrenia. Olfson M, et al. **New Dir Ment Health Serv** 1997 Spring;(73):25–38 (43 ref.)
Family involvement in general hospital inpatient care. Walkup J. **New Dir Ment Health Serv** 1997 Spring; (73):51–64 (43 ref.)
The effect of managed care on breast cancer detection, treatment, and research. Haas BK. **Nurs Outlook** 1997 Jul–Aug;45(4):167–72 (36 ref.)
The last physician? "The parable of the last physician". Geppert CM. **Pharos** 1997 Spring;60(2):15–20 (15 ref.)
Medicine's mission. Ortolon K. **Tex Med** 1997 Jan; 93(1):44–51 (0 ref.)
The effects of managed care on transfusion medicine. Popovsky MA, et al. **Transfus Med Rev** 1997 Jul; 11(3):195–9 (15 ref.)

ECONOMICS

Management of otitis media in the era of managed care. Klein JO, et al. **Adv Pediatr Infect Dis** 1996;12:351–86 (98 ref.)
The evolution of physician credentialing into managed care selective contracting. Blum JD. **Am J Law Med** 1996; 22(2–3):173–203 (0 ref.)
Insurance regulation of providers that bear risk. Overbay A, et al. **Am J Law Med** 1996;22(2–3):361–87 (0 ref.)
Occupational therapy practice: focusing on occupational performance. Baum CM, et al. **Am J Occup Ther** 1997 Apr; 51(4):277–88 (39 ref.)
Managed care and managed golf: lessons for neurosurgery in 1995. Dacey RG Jr. **Clin Neurosurg** 1996;43:1–11 (11 ref.)
The impact of managed care on genetic testing laboratories in the United States. Mark HF, et al. **Cytobios** 1996; 88(352):43–52 (8 ref.)
Health care and America's rolling depression. Hodge MH. **Health Care Manage Rev** 1996 Summer;21(3):7–12 (17 ref.)
Activity-based costing for integrated delivery systems. Baker JJ. **J Health Care Finance** 1995 Winter;22(2):57–61 (3 ref.)
Markets and public programs: insights from Oregon and Tennessee. Gold M. **J Health Polit Policy Law** 1997 Apr; 22(2):633–66 (26 ref.)
Managed care and Medicare reform. Oberlander JB. **J Health Polit Policy Law** 1997 Apr;22(2):595–631 (100 ref.)
Charity and community: the role of nonprofit ownership in a managed health care system. Schlesinger M, et al. **J Health Polit Policy Law** 1996 Winter;21(4):697–751 (114 ref.)
Psychiatric rehabilitation: a breath of fresh air in a turbulent health-care environment. Palmer-Erbs V. **J Psychosoc Nurs Ment Health Serv** 1996 Sep;34(9):16–21 (38 ref.)
Functional outcomes in spinal cord injury (SCI): quality care versus cost containment. Ditunno JF Jr. **J Spinal Cord Med** 1997 Jan;20(1):1–7 (36 ref.)
Treatment of embolic stroke as a medical emergency. Implications in a managed care environment. Lanzieri CF. **Neurosurg Clin N Am** 1997 Apr;8(2):253–62 (11 ref.)
Clinicoeconomics in geropsychiatry. Burke MJ. **Psychiatr Clin North Am** 1997 Mar;20(1):219–40 (65 ref.)
Quality of care and cost-containment in managed mental health: policy, education, research, advocacy. Dana RH, et al. **Psychol Rep** 1996 Dec;79(3 Pt 2):1395–422 (125 ref.)
The impact of health care changes on home health. Seeber S, et al. **Semin Oncol Nurs** 1996 Aug;12(3):179–87 (26 ref.)
Payment hassles [see comments] BeSaw L. **Tex Med** 1997 Jan;93(1):36–9 (0 ref.) Comment in: Tex Med 1997 Mar;93(3):7–8.
[Economic impact of bipolar mood disorders] Martin P. **Encephale** 1997 Jan;23 Spec No 1:49–54 (9 ref.) (Eng. Abstr.) **(Fre)**

LEGISLATION & JURISPRUDENCE

The fraud and abuse statute in an evolving health care marketplace: life in the health care speakeasy. Blumstein JF. **Am J Law Med** 1996;22(2–3):205–31 (0 ref.)
The legal and ethical implications of gag clauses in physician contracts. Martin JA, et al. **Am J Law Med** 1996; 22(4):433–76 (351 ref.)
Ethical and legal implications of managed care. Hall RC. **Gen Hosp Psychiatry** 1997 May;19(3):200–8 (88 ref.)
Civil rights in a changing health care system. Rosenbaum S, et al. **Health Aff (Millwood)** 1997 Jan–Feb;16(1):90–105 (24 ref.)
Emergency! Says who?: analysis of the legal issues concerning managed care and emergency medical services. Young CJ. **J Contemp Health Law Policy** 1997 Spring; 13(2):553–79 (206 ref.)
Capitation, disease management, and physician liability. Frenkel M. **J Health Care Finance** 1997 Spring;23(3):87–90 (0 ref.)
Chiropractic liability within managed health care--implications for managed-care organizations. Sigler DC. **J Manipulative Physiol Ther** 1996 Jun;19(5):350–6 (32 ref.)
Managed care and the next generation of mental health law. Appelbaum PS. **New Dir Ment Health Serv** 1996 Winter; (72):65–9 (8 ref.)
Risk management issues in the new managed care environment. Bettman JW, et al. **Surv Ophthalmol** 1996 Nov–Dec;41(3):268–70 (6 ref.)

MANPOWER

The clinician-teacher in managed care settings. Shorey JM, et al. **J Gen Intern Med** 1997 Apr;12 Suppl 2:S98–103 (14 ref.)

ORGANIZATION & ADMINISTRATION

Managed care, ethics, and academic health centers: maximizing potential, minimizing drawbacks. Morreim EH. **Acad Med** 1997 May;72(5):332–40 (141 ref.)
The future role of managed care and capitation in worker's compensation. Hashimoto DM. **Am J Law Med** 1996; 22(2–3):233–61 (0 ref.)
Procedural protections for patients in capitated health plans. Kinney ED. **Am J Law Med** 1996;22(2–3):301–30 (0 ref.)
Capitation, advances in medical technology, and the advent of a new era in medical ethics. Malinowski MJ. **Am J Law Med** 1996;22(2–3):331–60 (0 ref.)
Managed care merged with the German model [see comments] Weil TP. **Am J Med Qual** 1997 Spring; 12(1):19–24 (22 ref.) Comment in: Am J Med Qual 1997 Spring;12(1):25–7.
Managed care and nuclear medicine in the USA. Sy WM. **Ann Nucl Med** 1997 Feb;11(1):1–6 (14 ref.)
Managed health care's approach to infertility. Cohen A. **Clin Obstet Gynecol** 1997 Jun;40(2):420–6 (5 ref.)
The spectrum of managed care model types. Fabius R. **Clin Obstet Gynecol** 1997 Jun;40(2):391–4 (0 ref.)
Preparing obstetricians and gynecologists for capitation. Huey JR Jr, et al. **Clin Obstet Gynecol** 1997 Jun; 40(2):427–36 (12 ref.)
Obstetrics/gynecology network development. Krieg KA. **Clin Obstet Gynecol** 1997 Jun;40(2):446–52 (5 ref.)
Obstetrician/gynecologist as primary care physician in managed health care. Pritzker J. **Clin Obstet Gynecol** 1997 Jun;40(2):402–13 (21 ref.)
Looking down the prospectoscope: obstetrics/gynecology in the year 2000 and beyond. Sanfilippo J. **Clin Obstet Gynecol** 1997 Jun;40(2):395–401 (0 ref.)
Negotiating managed care contracts. Beckman PA, et al. **Compr Ther** 1997 Aug;23(8):554–9 (8 ref.)
Infertility services in a managed care environment. Bates GW, et al. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):300–4 (16 ref.)
Outcomes-oriented research and managed care. Chelmow

MANAGED CARE PROGRAMS

D. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):293–5 (15 ref.)
Managed care in gynecologic oncology. Cohen CJ, et al. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):325–8 (13 ref.)
Managed care in obstetrics. Devoe LD. **Curr Opin Obstet Gynecol** 1997 Aug;9(4):258–61 (17 ref.)
The managed care of early pregnancy problems. Draycott T, et al. **Curr Opin Obstet Gynecol** 1997 Aug;9(4):262–6 (32 ref.)
Managed care in benign gynecology. Gambone JC, et al. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):314–8 (11 ref.)
Managed care of infertility. Hull MG. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):305–13 (68 ref.)
Managed care in benign gynecology. Montz FJ. **Curr Opin Obstet Gynecol** 1997 Aug;9(4):267–9 (15 ref.)
Managed care in obstetrics. Richman RS. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):329–32 (33 ref.)
Managed care in reconstructive pelvic surgery and urogynecology. Strohbehn K. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):319–24 (27 ref.)
Managed care of hormone replacement therapy in the menopause. Wardle PG. **Curr Opin Obstet Gynecol** 1997 Aug;9(4):270–7 (64 ref.)
A social contract for 21st century health care: three–tier health care with bounty hunting [editorial] Reinhardt UE. **Health Econ** 1996 Nov–Dec;5(6):479–99 (45 ref.)
Documentation of client dangerousness in a managed care environment. Callahan J. **Health Soc Work** 1996 Aug; 21(3):202–7 (34 ref.)
Confidentiality and managed care: ethical and legal concerns. Davidson JR, et al. **Health Soc Work** 1996 Aug; 21(3):208–15 (23 ref.)
What role for social work in the new health care practice paradigm? Keigher SM. **Health Soc Work** 1997 May; 22(2):149–55 (17 ref.)
Medicaid managed care and urban poor people: implications for social work. Perloff JD. **Health Soc Work** 1996 Aug; 21(3):189–95 (33 ref.)
Keeping managed care in balance [editorial] Poole DL. **Health Soc Work** 1996 Aug;21(3):163–6 (29 ref.)
Managed care and people with severe mental illness: challenges and opportunities for social work. Shera W. **Health Soc Work** 1996 Aug;21(3):196–201 (56 ref.)
Administrative and health policy training for residents. Bischof RO, et al. **Hosp Pract (Off Ed)** 1996 Aug 15; 31(8):93–4, 99–100 (17 ref.)
The operating rooms: cost center management in a managed care environment. DeRiso B, et al. **Int Anesthesiol Clin** 1995 Fall;33(4):133–50 (11 ref.)
Medicaid, managed care and optometry: a review. Soroka M. **J Am Optom Assoc** 1996 Jun;67(6):335–42 (16 ref.)
Preparing for the coming consumer revolution in health care. Bartlett DF. **J Health Care Finance** 1997 Summer; 23(4):33–9 (2 ref.)
Data mining: sophisticated forms of managed care modeling through artificial intelligence. Borok LS. **J Health Care Finance** 1997 Spring;23(3):20–36 (0 ref.)
When will managed care come to anesthesia? Klein JD. **J Health Care Finance** 1997 Spring;23(3):62–86 (61 ref.)
Managed behavioral health care: a key component of integrated regional delivery systems. Nauert RC. **J Health Care Finance** 1997 Spring;23(3):49–61 (2 ref.)
The technocratic wish: making sense and finding power in the "managed" medical marketplace. Belkin GS. **J Health Polit Policy Law** 1997 Apr;22(2):509–32 (63 ref.)
The dynamics of market–level change. Ginsburg PB. **J Health Polit Policy Law** 1997 Apr;22(2):363–82 (16 ref.)
Introduction. Health care into the next century. Peterson MA. **J Health Polit Policy Law** 1997 Apr;22(2):291–313 (55 ref.)
The doctor as businessman: the changing politics of a cultural icon. Stone DA. **J Health Polit Policy Law** 1997 Apr; 22(2):533–56 (43 ref.)
The health system in transition: care, cost, and coverage. Thorpe KE. **J Health Polit Policy Law** 1997 Apr; 22(2):339–61 (24 ref.)
The need for more primary care physicians to contain costs and improve access: myths versus realities. Stimmel B. **Mt Sinai J Med** 1996 Jan;63(1):49–59 (44 ref.)
Public managed care: the role of the consultant. Cohen MD. **New Dir Ment Health Serv** 1996 Winter;(72):35–44 (5 ref.)
Managing the whole system of care. Hogan MF. **New Dir Ment Health Serv** 1996 Winter;(72):13–24 (14 ref.)
Creating incentives for the delivery of services. Hyde PS. **New Dir Ment Health Serv** 1996 Winter;(72):25–34 (19 ref.)
An overview of managed behavioral health care. Shore MF. **New Dir Ment Health Serv** 1996 Winter;(72):3–12 (11 ref.)
Advocacy and managed behavioral health care. Shore MF. **New Dir Ment Health Serv** 1996 Winter;(72):59–64 (2 ref.)
The public sector–private sector interface: current issues, future trends. Surles RC, et al. **New Dir Ment Health Serv** 1996 Winter;(72):71–9 (8 ref.)
Onsite clinical services in the era of managed health care. Larkin GN. **Occup Med** 1997 Jan–Mar;12(1):145–54 (11 ref.)
Managed care and the public health challenge of TB. Halverson PK, et al. **Public Health Rep** 1997 Jan–Feb; 112(1):22–8 (14 ref.)
The next medical revolution should be quality. Friedenberg RM. **Radiology** 1997 Jul;204(1):31A–34A (14 ref.)
Women's access to appropriate providers within managed care: implications for the quality of primary care. Bartman BA. **Womens Health Issues** 1996 Jan–Feb;6(1):45–50 (21 ref.)
Planning for women's health care services. Warner CK. **Womens Health Issues** 1996 Jan–Feb;6(1):60–3 (4 ref.)

STANDARDS

Costs, outcomes, and patient satisfaction by provider type for patients with rheumatic and musculoskeletal conditions: a critical review of the literature and proposed methodologic standards [see comments] Solomon DH, et al. **Ann Intern Med** 1997 Jul 1;127(1):52–60 (35 ref.) Comment in: Ann Intern Med 1997 Jul 1;127(1):72–4.
Who is holding whom accountable for quality? [see comments] Gosfield AG. **Health Aff (Millwood)** 1997 May–Jun;16(3):26–40 (21 ref.) Comment in: Health Aff (Millwood) 1997 May–Jun;16(3):41–3.
Defining value in health care: outcomes. Macario A. **Int Anesthesiol Clin** 1995 Fall;33(4):15–31 (76 ref.)
Relationships between primary care physicians and consultants in managed care. Brett AS. **J Clin Ethics** 1997 Spring;8(1):60–5 (13 ref.)
Consumer satisfaction: a key to financial success in the managed care environment. Jones KC. **J Health Care Finance** 1997 Summer;23(4):21–32 (10 ref.)
Informing consumer decisions in health care: implications from decision–making research. Hibbard JH, et al. **Milbank Q** 1997;75(3):395–414 (31 ref.)
How will mental health outcomes data be used in private systems. Feldman J. **New Dir Ment Health Serv** 1996 Fall; (71):103–9 (10 ref.)
The ethics of providing intensive care in managed care organizations. Danis M, et al. **New Horiz** 1997 Feb; 5(1):85–93 (39 ref.)

TRENDS

The future of Medicare and managed care: implications for optometry. Soroka M. **J Am Optom Assoc** 1997 Mar; 68(3):147–54 (12 ref.)
Prevention in managed care: obstacles and opportunities. Bailey JE, et al. **J Tenn Med Assoc** 1996 Apr;89(4):122–5 (29 ref.)
Consultation–liaison psychiatry in the managed care arena. Gonzales JJ, et al. **Psychiatr Clin North Am** 1996 Sep; 19(3):449–66 (53 ref.)
Psychiatry in medical practice. Implications for the education of primary care physicians in the era of managed care: Part 2. Stoudemire A. **Psychosomatics** 1997 Jan–Feb; 38(1):1–9 (74 ref.)
Is patient care suffering? Cordell RE. **W V Med J** 1997 Jul–Aug;93(4):170 (0 ref.)

UTILIZATION

"My patients are sicker": adjusting outcomes by severity of illness. Hopkins DS. **Int Anesthesiol Clin** 1995 Fall; 33(4):33–47 (15 ref.)

MANAGED COMPETITION

ORGANIZATION & ADMINISTRATION

From managed competition to managed cooperation: theory and lessons from the British experience. Light DW. **Milbank Q** 1997;75(3):297–341 (131 ref.)
Countervailing agency: a strategy of principaled regulation under managed competition. Schlesinger M. **Milbank Q** 1997;75(1):35–87 (138 ref.)

TRENDS

The technocratic wish: making sense and finding power in the "managed" medical marketplace. Belkin GS. **J Health Polit Policy Law** 1997 Apr;22(2):509–32 (63 ref.)
Markets, Medicare, and making do: business strategies after national health care reform. Martin CJ. **J Health Polit Policy Law** 1997 Apr;22(2):557–93 (90 ref.)

MANAGED HEALTH CARE INSURANCE PLANS see **MANAGED CARE PROGRAMS**

MANAGEMENT AUDIT

ORGANIZATION & ADMINISTRATION

Toward effective regional trauma networks: management auditing initiatives in Ontario. Caro DH. **Health Care Manage Rev** 1997 Spring;22(2):21–32 (46 ref.)

MANAGEMENT INFORMATION SYSTEMS

Technology assessment. A framework for generating questions useful in evaluating nursing information systems. Manning J, et al. **Comput Nurs** 1997 May–Jun;15(3):141–6 (12 ref.)
Health services organizations computer innovation. Ready or not? Snyder–Halpern R. **Comput Nurs** 1997 May–Jun; 15(3):147–52; quiz 153–4 (22 ref.)

MANAGEMENT SERVICE ORGANIZATIONS see **HOSPITAL–PHYSICIAN JOINT VENTURES**

MANDATORY REPORTING

see related
DISEASE NOTIFICATION

Shaken baby syndrome: inflicted cerebral trauma. Committee on Child Abuse and Neglect, 1993–1994. **Del Med J** 1997 Jul;69(7):365–70 (25 ref.)
Physical abuse of children: an update. Sirotnak AP, et al. **Del Med J** 1997 Jul;69(7):335–43 (20 ref.)
The differential diagnosis of ritual abuse allegations. Bernet W, et al. **J Forensic Sci** 1997 Jan;42(1):32–8 (69 ref.)
[Physical child abuse––characteristics, diagnosis and reporting] Goldstick O, et al. **Harefuah** 1996 Jun 16; 130(12):836–42 (42 ref.) **(Heb)**

MANDATORY SCREENING see **MANDATORY TESTING**

MANDATORY TESTING

see related
SUBSTANCE ABUSE DETECTION

The future of prenatal HIV testing. Minkoff H, et al. **Acta Paediatr Suppl** 1997 Jun;421:72–7 (36 ref.)

MANDELIC ACIDS

THERAPEUTIC USE

[Drug therapy of enuresis] von Gontard A, et al. **Z Kinder Jugenpsychiatr** 1996 Mar;24(1):18–33 (65 ref.) **(Ger)**

MANDIBLE

see related
TEMPOROMANDIBULAR JOINT

ABNORMALITIES

Cerebro–costo–mandibular syndrome [published erratum appears in Am J Med Genet 1996 Aug 23;64(3):527] Plötz FB, et al. **Am J Med Genet** 1996 Mar 29;62(3):286–92 (20 ref.)
Tessier 30 median mandibular cleft: case report and literature review. Armstrong AP, et al. **Br J Plast Surg** 1996 Dec; 49(8):536–8 (11 ref.)
Congenital bony syngnathia: a proposed classification. Dawson KH, et al. **Cleft Palate Craniofac J** 1997 Mar; 34(2):141–6 (26 ref.)
[Robin sequence] Dudkiewicz Z, et al. **Pediatr Pol** 1996 Sep; 71(9):811–5 (18 ref.) **(Pol)**

ANATOMY & HISTOLOGY

A pilot study of the mandibular angle in black Zimbabweans. Mbajiorgu FE, et al. **Cent Afr J Med** 1996 Oct;42(10):285–7 (17 ref.)
Mandibular form and function in North American and European Adapidae and Omomyidae. Ravosa MJ. **J Morphol** 1996 Aug;229(2):171–90 (91 ref.)

BLOOD SUPPLY

High–flow vascular malformations: literature review and case report. Kula K, et al. **Pediatr Dent** 1996 Jul–Aug; 18(4):322–7 (30 ref.)
[Arteriovenous malformation of the mandible. Apropos of a case in a 6–year–old child] Mosnier I, et al. **Ann Otolaryngol Chir Cervicofac** 1996;113(7–8):434–9 (31 ref.) (Eng. Abstr.) **(Fre)**

GROWTH & DEVELOPMENT

Orthopedics in orthodontics: Part I, Fiction or reality––a review of the literature [see comments] Aelbers CM, et al. **Am J Orthod Dentofacial Orthop** 1996 Nov;110(5):513–9 (101 ref.) Comment in: Am J Orthod Dentofacial Orthop 1997 Jun;111(6):16A.

PATHOLOGY

The importance of determination of jaw position in orthodontic diagnosis and treatment planning for adult patients. Chang FH, et al. **Dent Clin North Am** 1997 Jan; 41(1):49–66 (24 ref.)

PHYSIOLOGY

Mandibular form and function in North American and European Adapidae and Omomyidae. Ravosa MJ. **J Morphol** 1996 Aug;229(2):171–90 (91 ref.)

RADIATION EFFECTS

Placement of dental implants in the irradiated mandible: a protocol without adjunctive hyperbaric oxygen. Keller EE. **J Oral Maxillofac Surg** 1997 Sep;55(9):972–80 (43 ref.)
Placement of dental implants in the irradiated mandible: a protocol involving adjunctive hyperbaric oxygen. Larsen PE. **J Oral Maxillofac Surg** 1997 Sep;55(9):967–71 (45 ref.)

SURGERY

Mandibular reconstruction by vascularized free tissue transfer. Genden E, et al. **Am J Otolaryngol** 1996 Jul–Aug; 17(4):219–27 (50 ref.)
"Mandibular and facial reconstruction" rehabilitation of the

head and neck cancer patient. Marx RE, et al. **Bone** 1996 Jul;19(1 Suppl):59S–82S (17 ref.)

Stability of orthognathic surgery: a review of rigid fixation. Van Sickels JE, et al. **Br J Oral Maxillofac Surg** 1996 Aug; 34(4):279–85 (62 ref.)

Sagittal ramus split osteotomy: literature review and suggested modification of technique. Wyatt WM. **Br J Oral Maxillofac Surg** 1997 Apr;35(2):137–41 (23 ref.)

Adverse outcomes in orthognathic surgery and management of residual problems. Schendel SA, et al. **Clin Plast Surg** 1997 Jul;24(3):489–505 (63 ref.)

Peripheral facial palsy after sagittal split ramus osteotomy for setback of the mandible. A case report. Sakashita H, et al. **Int J Oral Maxillofac Surg** 1996 Jun;25(3):182–3 (11 ref.)

Current concepts in oromandibular reconstruction. Burkey BB, et al. **Otolaryngol Clin North Am** 1997 Aug; 30(4):607–30 (47 ref.)

[The value of ultrasonographic monitoring in mandibular lengthening using the Ilizarov principle. Preliminary results] Lucas R, et al. **Rev Stomatol Chir Maxillofac** 1996 Oct;97(5):313–20 (22 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

[The value of ultrasonographic monitoring in mandibular lengthening using the Ilizarov principle. Preliminary results] Lucas R, et al. **Rev Stomatol Chir Maxillofac** 1996 Oct;97(5):313–20 (22 ref.) (Eng. Abstr.) **(Fre)**

MANDIBULAR CONDYLE

see related

TEMPOROMANDIBULAR JOINT

Eosinophilic granuloma of the mandibular condyle: report of three cases and review of the literature. Wong GB, et al. **J Oral Maxillofac Surg** 1997 Aug;55(8):870–8 (29 ref.)

PATHOLOGY

Hepatocellular carcinoma metastatic to the mandibular ramus and condyle: report of a case and review of the literature. Yoshimura Y, et al. **J Oral Maxillofac Surg** 1997 Mar; 55(3):297–306 (38 ref.)

[Giant cell tumor of the mandibular condyle. Apropos of a case] Paume P, et al. **Rev Stomatol Chir Maxillofac** 1997 Aug;98(2):100–3 (24 ref.) (Eng. Abstr.) **(Fre)**

MANDIBULAR DISEASES

DIAGNOSIS

Chronic diffuse sclerosing osteomyelitis of the mandible or mandibular location of S.A.P.H.O. syndrome. García-Marín F, et al. **Acta Stomatol Belg** 1996 Jun; 93(2):65–71 (31 ref.)

The diagnosis and treatment of central giant cell granuloma. Roberson JB, et al. **J Am Dent Assoc** 1997 Jan;128(1):81–4 (13 ref.)

Eosinophilic granuloma of the mandibular condyle: report of three cases and review of the literature. Wong GB, et al. **J Oral Maxillofac Surg** 1997 Aug;55(8):870–8 (29 ref.)

[Histiocytosis X with mandibular involvement. Apropos of a case] Benjelloun A, et al. **Rev Stomatol Chir Maxillofac** 1997 Jan;98(1):31–6 (12 ref.) (Eng. Abstr.) **(Fre)**

[Odontogenic keratocysts--their imaging via MRT] Wildberger JE, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Aug;167(2):207–9 (8 ref.) **(Ger)**

ETIOLOGY

Dental observations in Gaucher's disease: review of the literature and two case reports with 13- and 60-year follow-ups. Bender IB, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Dec;82(6):650–9 (38 ref.)

Oral complications associated with sickle cell anemia: a review and case report. Kelleher M, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Aug;82(2):225–8 (13 ref.)

PATHOLOGY

Odontogenic keratocysts: review of the literature and report of a case. Blanchard SB. **J Periodontol** 1997 Mar; 68(3):306–11 (29 ref.)

The buccal bifurcation cyst: a prospective study of treatment outcomes in 44 sites. Pompura JR, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Feb;83(2):215–21 (23 ref.)

Glandular odontogenic cyst: report of a case and review of the literature. Ramer M, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jul;84(1):54–7 (21 ref.)

[The keratocyst or epidermoid cyst: the current state of understanding apropos of a case with intracranial involvement] Franc C, et al. **Rev Stomatol Chir Maxillofac** 1996 Oct;97(5):270–82 (134 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Secondary deformities following mandibular reconstruction. Miller MJ, et al. **Clin Plast Surg** 1997 Jul;24(3):551–63 (14 ref.)

The diagnosis and treatment of central giant cell granuloma. Roberson JB, et al. **J Am Dent Assoc** 1997 Jan;128(1):81–4 (13 ref.)

MANDIBULAR NEOPLASMS

COMPLICATIONS

Mandibular metastatic hepatocellular carcinoma: a case involving severe postbiopsy hemorrhage. Ashar A, et al. **J Oral Maxillofac Surg** 1997 Jun;55(6):547–52 (36 ref.)

DIAGNOSIS

Brown tumor of the mandible. Keyser JS, et al. **Am J Otolaryngol** 1996 Nov-Dec;17(6):407–10 (14 ref.)

Primary leiomyosarcoma of the mandible. Laccourreye O, et al. **Am J Otolaryngol** 1996 Nov-Dec;17(6):415–9 (22 ref.)

Small-cell noncleaved non-Hodgkin's lymphoma of the mandible in previously unrecognized human immunodeficiency virus infection: report of a case. Stolarski CR, et al. **J Oral Maxillofac Surg** 1997 Aug; 55(8):853–6 (18 ref.)

Malignant fibrous histiocytoma of the mandible. Narvaez JA, et al. **Skeletal Radiol** 1996 Jan;25(1):96–9 (20 ref.)

ETIOLOGY

Squamous cell carcinoma associated with a mandibular staple implant. Moxley JE, et al. **J Oral Maxillofac Surg** 1997 Sep;55(9):1020–2 (6 ref.)

PATHOLOGY

Atypical ameloblastoma: report of 3 cases and a review of the literature. Ameerally P, et al. **Br J Oral Maxillofac Surg** 1996 Jun;34(3):235–9 (35 ref.)

Osteogenic sarcoma of the jaws: factors influencing prognosis. August M, et al. **Int J Oral Maxillofac Surg** 1997 Jun;26(3):198–204 (24 ref.)

Metastasis of a malignant melanoma to the region of an impacted mandibular third molar: a case report. Santamaría J, et al. **J Oral Maxillofac Surg** 1997 Sep;55(9):1003–6 (15 ref.)

Central mucoepidermoid carcinoma of the mandible: report of a case treated 13 years after first radiographic demonstration. Sidoni A, et al. **J Oral Maxillofac Surg** 1996 Oct;54(10):1242–5 (27 ref.)

An asymptomatic enlargement of the mandible causing marked root resorption [clinical conference] Stoll C, et al. **J Oral Maxillofac Surg** 1997 Jul;55(7):740–6 (43 ref.)

Clear cell odontogenic carcinoma in the mandible: histochemical and immunohistochemical observations with a review of the literature. Muramatsu T, et al. **J Oral Pathol Med** 1996 Oct;25(9):516–21 (20 ref.)

Neuroendocrine (carcinoid) tumor of the mandible: a case report and review of the literature. Coleman H, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Jan;81(1):74–8 (14 ref.)

Primary Hodgkin's disease of the mandible: a case report and review of the literature. Jamshed A, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jun;83(6):680–4 (16 ref.)

Leiomyoma of the mandible: a rapid growing case with immunohistochemical and electron microscopic observations. Katou F, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jul;84(1):45–50 (23 ref.)

[Giant cell tumor of the mandibular condyle. Apropos of a case] Paume P, et al. **Rev Stomatol Chir Maxillofac** 1997 Aug;98(2):100–3 (24 ref.) (Eng. Abstr.) **(Fre)**

[Intra-mandibular location of a adenoid cystic carcinoma. Review of the literature] Tarayre F, et al. **Rev Stomatol Chir Maxillofac** 1996;97(4):221–4 (13 ref.) (Eng. Abstr.) **(Fre)**

[Primary Ewing's sarcoma of the mandible. A clinico-pathological and immunohistochemical case study] Zavaglia V, et al. **Minerva Stomatol** 1997 Apr;46(4):207–12 (8 ref.) (Eng. Abstr.) **(Ita)**

SECONDARY

Mandibular metastatic hepatocellular carcinoma: a case involving severe postbiopsy hemorrhage. Ashar A, et al. **J Oral Maxillofac Surg** 1997 Jun;55(6):547–52 (36 ref.)

Esophageal carcinoma metastatic centrally to the mandible: a case report with implication of cell proliferating marker Ki-67. Koyama T, et al. **J Oral Maxillofac Surg** 1997 Jun; 55(6):640–5 (16 ref.)

Metastasis of a malignant melanoma to the region of an impacted mandibular third molar: a case report. Santamaría J, et al. **J Oral Maxillofac Surg** 1997 Sep;55(9):1003–6 (15 ref.)

Hepatocellular carcinoma metastatic to the mandibular ramus and condyle: report of a case and review of the literature. Yoshimura Y, et al. **J Oral Maxillofac Surg** 1997 Mar; 55(3):297–306 (38 ref.)

[The mental foramen syndrome] Altay A, et al. **Fogorv Sz** 1997 May;90(5):145–50 (23 ref.) (Eng. Abstr.) **(Hun)**

[Metastatic tumors of the mandible. Review of the literature] Colella G, et al. **Minerva Stomatol** 1995 Nov;44(11):521–30 (66 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Anterior ischemic optic neuropathy following neck dissection. Strome SE, et al. **Head Neck** 1997 Mar; 19(2):148–52 (12 ref.)

[Mandibular reconstruction using a microvascular method in the transplantation of a fibular flap] Kiss G, et al. **Orv Hetil** 1997 Jul 20;138(29):1855–8 (3 ref.) (Eng. Abstr.) **(Hun)**

VETERINARY

Ameloblastic fibromas and related tumors in cattle. Gardner DG. **J Oral Pathol Med** 1996 Mar;25(3):119–24 (29 ref.)

Case of calcifying epithelial odontogenic tumour in a dog. Ishikawa T, et al. **J Small Anim Pract** 1996 Dec; 37(12):597–9 (13 ref.)

MANDIBULAR NERVE

The "ART" mandibular nerve block: a new approach to accomplishing regional anesthesia. Gaum LI, et al. **J Can Dent Assoc** 1997 Jun;63(6):454–9 (18 ref.)

INJURIES

Trigeminal nerve injury and repair. Ruggiero SL. **N Y State Dent J** 1996 Oct;62(8):36–40 (6 ref.)

MANDIBULAR PROSTHESIS

Oral appliance therapy for the treatment of obstructive sleep apnea. Fleetham JA, et al. **Sleep** 1996 Dec;19(10 Suppl):S288–90 (5 ref.)

MANDIBULAR REST POSITION see **VERTICAL DIMENSION**

MANDIBULOFACIAL DYSOSTOSIS

[Treacher Collins syndrome] Imaizumi K. **Ryoikibetsu Shokogun Shirizu** 1996;(15):307–8 (8 ref.) **(Jpn)**

DIAGNOSIS

Special imaging casebook. Treacher Collins syndrome. Herman TE, et al. **J Perinatol** 1996 Sep-Oct;16(5):413–5 (10 ref.)

GENETICS

Treacher Collins syndrome. Dixon MJ. **Hum Mol Genet** 1996; 5 Spec No:1391–6 (57 ref.)

MANDRAGORA see **PLANTS, TOXIC**

MANDRAKE, AMERICAN see **PODOPHYLLUM**

MANDRAKE, EUROPEAN see **PLANTS, TOXIC**

MANDRAKE ROOT see **PODOPHYLLUM**

MANDRILL see **PAPIO**

MANDUCA

PHYSIOLOGY

Neural mechanisms of behavioral plasticity: metamorphosis and learning in Manduca sexta. Weeks JC, et al. **Brain Behav Evol** 1997;50 Suppl 1:69–80 (60 ref.)

MANDUCA SEXTA see **MANDUCA**

MANGANESE

ADVERSE EFFECTS

[Neuropsychologic effects of occupational exposure to manganese] Bazylewicz-Walczak B. **Med Pr** 1996; 47(6):677–83 (15 ref.) (Eng. Abstr.) **(Pol)**

DIAGNOSTIC USE

Overview of MnDPDP as a pancreas-specific contrast agent for MR imaging [see comments] Ahlström H, et al. **Acta Radiol** 1997 Jul;38(4 Pt 2):660–4 (18 ref.) Comment in: Acta Radiol 1997 Jul;38(4 Pt 2):623–5.

Clinical implications of studies with MnDPDP in animal models of hepatic abnormalities [see comments] Ni Y, et al. **Acta Radiol** 1997 Jul;38(4 Pt 2):724–31 (42 ref.) Comment in: Acta Radiol 1997 Jul;38(4 Pt 2):623–5.

METABOLISM

Salen-manganese complexes: combined superoxide dismutase/catalase mimics with broad pharmacological efficacy. Doctrow SR, et al. **Adv Pharmacol** 1997;38:247–69 (86 ref.)

PHARMACOLOGY

[Analysis of manganese-induced platelet aggregation] Yabusaki K. **Rinsho Byori** 1997 Feb;Suppl 104:89–98 (21

MANGANESE

ref.) **(Jpn)**

POISONING

Early manifestations of manganese neurotoxicity in humans: an update. Mergler D, et al. **Environ Res** 1997; 73(1-2):92-100 (52 ref.)

[Changes in the nervous system during occupational exposure to manganese in light of the literature] Sinczuk-Walczak H. **Med Pr** 1996;47(6):657-61 (13 ref.) (Eng. Abstr.) **(Pol)**

TOXICITY

Cardiovascular safety of MnDPDP and MnCl2. Jynge P, et al. **Acta Radiol** 1997 Jul;38(4 Pt 2):740-9 (49 ref.)

General toxicology of MnDPDP. Larsen LE, et al. **Acta Radiol** 1997 Jul;38(4 Pt 2):770-9 (70 ref.)

MANGANESE COMPOUNDS

TOXICITY

Cardiovascular safety of MnDPDP and MnCl2. Jynge P, et al. **Acta Radiol** 1997 Jul;38(4 Pt 2):740-9 (49 ref.)

MANGE see **MITE INFESTATIONS**

MANGE, SARCOPTIC see **SCABIES**

MANIA see **MANIC DISORDER**

MANIC-DEPRESSIVE PSYCHOSIS see **BIPOLAR DISORDER**

MANIC DISORDER

Mania [see comments] Daly I. **Lancet** 1997 Apr 19; 349(9059):1157-60 (34 ref.) Comment in: Lancet 1997 Jul 26;350(9073):292.

CHEMICALLY INDUCED

Systemic toxicity from ocular homatropine. Reilly KM, et al. **Acad Emerg Med** 1996 Sep;3(9):868-71 (15 ref.)

Hormone replacement therapy and late-life mania [see comments] Young RC, et al. **Am J Geriatr Psychiatry** 1997 Spring;5(2):179-81 (26 ref.) Comment in: Am J Geriatr Psychiatry 1997 Spring;5(2):177-8.

COMPLICATIONS

The role of mania in the genesis of dangerous delusional misidentification. Silva JA, et al. **J Forensic Sci** 1997 Jul; 42(4):670-4 (39 ref.)

DIAGNOSIS

The diagnosis and treatment of mania in the elderly. McDonald WM, et al. **Bull Menninger Clin** 1996 Spring; 60(2):174-96 (136 ref.)

DRUG THERAPY

Alopecia and mood stabilizer therapy. McKinney PA, et al. **Ann Clin Psychiatry** 1996 Sep;8(3):183-5 (12 ref.)

The diagnosis and treatment of mania in the elderly. McDonald WM, et al. **Bull Menninger Clin** 1996 Spring; 60(2):174-96 (136 ref.)

Dosing strategies and time course of response to antimanic drugs. Bowden CL. **J Clin Psychiatry** 1996;57 Suppl 13:4-9; discussion 10-2 (44 ref.)

Health-economic implications of the onset of action of antimanic agents. Keck PE Jr, et al. **J Clin Psychiatry** 1996; 57 Suppl 13:13-8; discussion 19-22 (53 ref.)

ETIOLOGY

Mania following left hemisphere injury. Lim LC. **Singapore Med J** 1996 Aug;37(4):448-50 (18 ref.)

GENETICS

Genetics of manic depressive illness. MacKinnon DF, et al. **Annu Rev Neurosci** 1997;20:355-73 (65 ref.)

PSYCHOLOGY

Neurologic comorbidity and mania in old age. Shulman KI. **Clin Neurosci** 1997;4(1):37-40 (48 ref.)

THERAPY

[Indications for electroconvulsive therapy] Boiteux J, et al. **Encephale** 1997 Jun;23 Spec No 3:21-6 (27 ref.) (Eng. Abstr.) **(Fre)**

MANIC STATE see **MANIC DISORDER**

MANIPULATION, CHIROPRACTIC see **CHIROPRACTIC**

MANIPULATION, ORTHOPEDIC

see related
CHIROPRACTIC

Spinal manipulation: when, how, and who? Haldeman SD. **Bull Hosp Jt Dis** 1996;55(3):135-7 (19 ref.)

Spinal manipulation as a valid treatment for low back pain. Vernon LF. **Del Med J** 1996 Mar;68(3):175-8 (33 ref.)

Osteopathic medical considerations of reflex sympathetic dystrophy. Nelson KE. **J Am Osteopath Assoc** 1997 May; 97(5):286-9 (30 ref.)

The physics of spinal manipulation: a critical review of four articles by Haas. Solinger AB. **J Manipulative Physiol Ther** 1996 Feb;19(2):141-5 (21 ref.)

Cervical spine manipulation: summary report of a systematic review of the literature and a multidisciplinary expert panel. Shekelle PG, et al. **J Spinal Disord** 1997 Jun;10(3):223-8 (21 ref.)

Spinal manipulation for low back pain. An updated systematic review of randomized clinical trials. Koes BW, et al. **Spine** 1996 Dec 15;21(24):2860-71; discussion 2872-3 (72 ref.)

ADVERSE EFFECTS

The safety of manipulative treatment: review of the literature from 1925 to 1993. Vick DA, et al. **J Am Osteopath Assoc** 1996 Feb;96(2):113-5 (7 ref.)

METHODS

The McKenzie method: a general practice interpretation: the lumbar spine. Taylor MD. **Aust Fam Physician** 1996 Feb; 25(2):189-93, 196-7, 200-1 (5 ref.)

Common errors in the treatment of congenital clubfoot. Ponseti IV. **Int Orthop** 1997;21(2):137-41 (12 ref.)

Repositioning maneuver for benign paroxysmal positional vertigo (BPPV). Brooks JG, et al. **J Am Osteopath Assoc** 1997 May;97(5):277-9 (10 ref.)

Update on osteopathic medical concepts and the lymphatic system. Degenhardt BF, et al. **J Am Osteopath Assoc** 1996 Feb;96(2):97-100 (31 ref.)

Anterior shoulder dislocation reduction technique--revisited. Zahiri CA, et al. **Orthopedics** 1997 Jun;20(6):515-21 (25 ref.)

Separation or synthesis: a holistic approach to therapeutics [see comments] Kemper KJ. **Pediatr Rev** 1996 Aug; 17(8):279-83 (25 ref.) Comment in: Pediatr Rev 1996 Aug;17(8):263.

Manipulation and mobilization of the cervical spine. A systematic review of the literature. Hurwitz EL, et al. **Spine** 1996 Aug 1;21(15):1746-59; discussion 1759-60 (134 ref.)

MANIPULATION, PSYCHOLOGICAL see **MACHIAVELLIANISM**

MANIPULATION THERAPY see **MANIPULATION, ORTHOPEDIC**

MANN-WHITNEY U TEST see **STATISTICS, NONPARAMETRIC**

MANNANS

BLOOD

[Immunodiagnosis and blood biochemical diagnosis of visceral candidiasis and the cutoff limits of positive] Kume H, et al. **Rinsho Byori** 1996 Jun;44(6):505-11 (21 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

The lectin pathway of the complement system. Matsushita M. **Microbiol Immunol** 1996;40(12):887-93 (67 ref.)

MANNITOL

DIAGNOSTIC USE

Clinical implications of the sugar absorption test: intestinal permeability test to assess mucosal barrier function. Uil JJ, et al. **Scand J Gastroenterol Suppl** 1997;223:70-8 (75 ref.)

PHARMACOKINETICS

Osmotherapy. Basic concepts and controversies. Paczynski RP. **Crit Care Clin** 1997 Jan;13(1):105-29 (89 ref.)

THERAPEUTIC USE

Osmotherapy. Basic concepts and controversies. Paczynski RP. **Crit Care Clin** 1997 Jan;13(1):105-29 (89 ref.)

The use of mannitol in severe head injury. Brain Trauma Foundation. **J Neurotrauma** 1996 Nov;13(11):705-9 (43 ref.)

MANNOSE

IMMUNOLOGY

Mannose-binding lectin: the pluripotent molecule of the innate immune system. Turner MW. **Immunol Today** 1996 Nov;17(11):532-40 (76 ref.)

METABOLISM

Mannose-binding lectin: the pluripotent molecule of the innate immune system. Turner MW. **Immunol Today** 1996 Nov;17(11):532-40 (76 ref.)

MANNOSE-6-PHOSPHATE RECEPTORS see **RECEPTORS, INSULIN-LIKE-GROWTH-FACTOR II**

MANNOSIDOSIS

DIAGNOSIS

[Beta mannosidosis: a new case] Gourrier E, et al. **Arch Pediatr** 1997 Feb;4(2):147-51 (17 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

The mannosidoses and ceroid-lipofuscinoses: experimental studies on two types of storage disease. Jolly RD. **Pathology** 1997 Feb;29(1):51-6 (59 ref.)

MANNOSYLTRANSFERASES

METABOLISM

The role of the lipid matrix in the biosynthesis of dolichyl-linked oligosaccharides. Schutzbach JS. **Glycoconj J** 1997 Feb;14(2):175-82 (77 ref.)

MANOMETRY

Antroduodenal manometry: an evaluation of an emerging methodology. Byrne KG, et al. **Dig Dis** 1997;15 Suppl 1:53-63 (39 ref.)

Recent developments in the manometric assessment of upper esophageal sphincter function and dysfunction. Castell JA, et al. **Dig Dis** 1997;15 Suppl 1:28-39 (42 ref.)

The relevance of abnormal motility patterns in intra-mural oesophageal leiomyomata. Amer KM, et al. **Eur J Cardiothorac Surg** 1996;10(8):634-40 (12 ref.)

Manometric evaluation of defecation disorders: Part II. Fecal incontinence. Rao SS. **Gastroenterologist** 1997 Jun; 5(2):99-111 (57 ref.)

Sphincter of Oddi manometry. Hogan WJ, et al. **Gastrointest Endosc** 1997 Mar;45(3):342-8 (74 ref.)

A medical position statement of the North American Society for Pediatric Gastroenterology and Nutrition. Indications for pediatric esophageal manometry. Gilger MA, et al. **J Pediatr Gastroenterol Nutr** 1997 May;24(5):616-8 (23 ref.)

[Vital preoperative function diagnosis in deep anterior rectum resection] Stern J, et al. **Chirurg** 1996 Feb;67(2):129-32 (20 ref.) (Eng. Abstr.) **(Ger)**

[Normal values for 24-hour manometry of the esophagus] Prassler R, et al. **Dtsch Med Wochenschr** 1997 Sep 5; 122(36):1065-9 (22 ref.) (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

Manometric evaluation of constipation--Part I. Rao SS. **Gastroenterologist** 1996 Sep;4(3):145-54 (53 ref.)

METHODS

Tonometry. A review of clinical studies. Taylor DE, et al. **Crit Care Clin** 1996 Oct;12(4):1007-18 (46 ref.)

[Manometric examination in diagnosis of esophageal motility disorders] Paradowski L. **Pol Tyg Lek** 1996 Apr; 51(14-18):242-5 (23 ref.) (Eng. Abstr.) **(Pol)**

STANDARDS

Does gastric tonometry work? No. Benjamin E, et al. **Crit Care Clin** 1996 Jul;12(3):587-601 (77 ref.)

Does gastric tonometry work? Yes. Brown SD, et al. **Crit Care Clin** 1996 Jul;12(3):569-85 (72 ref.)

MANTIDS see **ORTHOPTERA**

MANUALS

Manual-based treatments: the clinical application of research findings. Wilson GT. **Behav Res Ther** 1996 Apr; 34(4):295-314 (120 ref.)

The validity of atypical depression in DSM-IV. Lam RW, et al. **Compr Psychiatry** 1996 Nov-Dec;37(6):375-83 (66 ref.)

Rationales, values, and DSM-IV: the case of "medication-induced movement disorders". Sadler JZ. **Compr Psychiatry** 1996 Nov-Dec;37(6):441-51 (59 ref.)

The DSM-IV-PC: a manual for diagnosing mental disorders in the primary care setting. deGruy FV 3rd, et al. **J Am Board Fam Pract** 1996 Jul-Aug;9(4):274-81 (14 ref.)

Preparation and applications of the International Aquatic Animal Health Code and Diagnostic Manual for Aquatic Animal Diseases of the Office International des Epizooties. Håstein T. **Rev Sci Tech** 1996 Jun;15(2):723-31 (4 ref.)

STANDARDS

Comorbidity in ADHD: implications for research, practice, and DSM-V. Jensen PS, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Aug; 36(8):1065-79 (69 ref.)

MANURE

Swine manure cleanup criteria calculation for odor causing volatile organic compounds based on manure-to-ventilation air exposure pathway. Liao CM, et al. **J Environ Sci Health B** 1997 Jul;32(4):449-68 (33 ref.)

ANALYSIS

Ruminant nutrition from an environmental perspective: factors affecting whole-farm nutrient balance. Van Horn HH, et al. **J Anim Sci** 1996 Dec;74(12):3082-102 (81 ref.)

MICROBIOLOGY

[Effects of residues of anti-infective agents in animal excretions on slurry treatment and the soil] Böhm R. **DTW Dtsch Tierarztl Wochenschr** 1996 Jul;103(7):264-8 (12 ref.) (Eng. Abstr.) **(Ger)**

MANUSCRIPTS, MEDICAL

How to "peer review" a medical journal manuscript [editorial] Salasche SJ. **Dermatol Surg** 1997 Jun;23(6):423-8 (17 ref.)

MAO INHIBITORS see **MONOAMINE OXIDASE INHIBITORS**

MAP KINASES see **CALMODULIN-DEPENDENT PROTEIN KINASES**

MAPLE SYRUP URINE DISEASE

DIAGNOSIS

Metabolism of branched-chain amino acids in maple syrup urine disease. Schadewaldt P, et al. **Eur J Pediatr** 1997 Aug;156 Suppl 1:S62-6 (17 ref.)

MAPPINE see **BUFOTENIN**

MAPS

The use of mapping in public health and planning health services. Gordon A, et al. **J Public Health Med** 1997 Jun; 19(2):139-47 (8 ref.)

MARASMUS see **PROTEIN-ENERGY MALNUTRITION**

MARBLE BONE DISEASE see **OSTEOPETROSIS**

MARBURG VIRUS

Marburg and Ebola viruses. Feldmann H, et al. **Adv Virus Res** 1996;47:1-52 (169 ref.)

MARBURG VIRUS DISEASE

VIROLOGY

Marburg and Ebola viruses. Feldmann H, et al. **Adv Virus Res** 1996;47:1-52 (169 ref.)

MARCHIAFAVA-MICHELI SYNDROME see **HEMOGLOBINURIA, PAROXYSMAL**

MARFAN SYNDROME

Interstitial deletion 2(p11.2p13): a rare chromosomal abnormality. Wenger SL, et al. **Clin Genet** 1997 Jul; 52(1):61-2 (3 ref.)

Overgrowth. Section V. Syndromes and other disorders associated with overgrowth. Sotos JF. **Clin Pediatr (Phila)** 1997 Feb;36(2):89-103 (54 ref.)

Aortic root replacement for annuloaortic ectasia in Shprintzen-Goldberg syndrome: a case report. Fukunaga S, et al. **J Heart Valve Dis** 1997 Mar;6(2):181-3 (11 ref.)

[Marfan syndrome] Sanada J. **Ryoikibetsu Shokogun Shirizu** 1996;(15):103-5 (19 ref.) **(Jpn)**

[Anesthesia in 3 cases of Marfan's syndrome] Puebla G, et al. **Rev Esp Anestesiol Reanim** 1996 Jan;43(1):30-4 (15 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Marfan's syndrome and surgical repair of ascending aortic aneurysms. Wieczorek P, et al. **AORN J** 1996 Dec; 64(6):895-913; quiz 916-8, 921-2 (46 ref.)

Aortic root dilatation in Marfan's syndrome: a contribution from obstructive sleep apnea? Cistulli PA, et al. **Chest** 1997 Jun;111(6):1763-6 (16 ref.)

Bentall operation for a child with Marfan syndrome: a case report. Miura M, et al. **J Card Surg** 1997 Mar-Apr; 12(2):116-9 (14 ref.)

Ascending aortic aneurysm with or without features of Marfan syndrome and other fibrillinopathies: new insights. Furthmayr H, et al. **Semin Thorac Cardiovasc Surg** 1997 Jul;9(3):191-205 (45 ref.)

Surgical implication of aortic dissection on long-term outcome in Marfan patients. Hayashi J, et al. **Surg Today** 1996;26(12):980-4 (19 ref.)

[A case of bilateral pneumothorax in the patient with Marfan syndrome] Nishida M, et al. **Kyobu Geka** 1996 Jul; 49(7):591-4 (18 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[A hyperventilation syndrome in a patient with hereditary mesenchymal dysplasia] Kakhnovskiĭ IM, et al. **Ter Arkh** 1997;69(3):45-7 (8 ref.) **(Rus)**

GENETICS

Fibrillin mutations in Marfan syndrome and related phenotypes. Ramirez F. **Curr Opin Genet Dev** 1996 Jun; 6(3):309-15 (55 ref.)

The phenotype/genotype relation and the current status of genetic screening in hypertrophic cardiomyopathy, Marfan syndrome, and the long QT syndrome. Burn J, et al. **Heart** 1997 Aug;78(2):110-6 (40 ref.)

Marfan syndrome--current medical and genetic knowledge: how to treat and when. Child AH. **J Card Surg** 1997 Mar-Apr;12(2 Suppl):131-5; discussion 135-6 (30 ref.)

NURSING

Marfan's syndrome and surgical repair of ascending aortic aneurysms. Wieczorek P, et al. **AORN J** 1996 Dec; 64(6):895-913; quiz 916-8, 921-2 (46 ref.)

PATHOLOGY

Protrusio acetabuli: its occurrence in the completely expressed Marfan syndrome and its musculoskeletal component and a procedure to arrest the course of protrusion in the growing pelvis [see comments] Steel HH. **J Pediatr Orthop** 1996 Nov-Dec;16(6):704-18 (100 ref.) Comment in: J Pediatr Orthop 1996 Nov-Dec;16(6):701-3.

SURGERY

Aortic root surgery in Marfan syndrome: current practice and evolving techniques. LeMaire SA, et al. **J Card Surg** 1997 Mar-Apr;12(2 Suppl):137-41 (38 ref.)

[Cardiovascular surgery in Marfan syndrome. A review with case examples] Carrel T. **Schweiz Med Wochenschr** 1997 Jun 7;127(23):992-1006 (51 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Marfan syndrome--current medical and genetic knowledge: how to treat and when. Child AH. **J Card Surg** 1997 Mar-Apr;12(2 Suppl):131-5; discussion 135-6 (30 ref.)

MARGARINE

Butter, margarine and serum lipoproteins. Zock PL, et al. **Atherosclerosis** 1997 May;131(1):7-16 (72 ref.)

MARGINAL ULCER see **PEPTIC ULCER**

MARIE-BAMBERGER DISEASE see **OSTEOARTHROPATHY, SECONDARY HYPERTROPHIC**

MARIE-STRUEMPELL DISEASE see **SPONDYLITIS, ANKYLOSING**

MARIJUANA see **CANNABIS**

MARIJUANA ABUSE

DIAGNOSIS

Cannabis and the brain [see comments] Castle DJ, et al. **Aust N Z J Psychiatry** 1996 Apr;30(2):179-83 (28 ref.) Comment in: Aust N Z J Psychiatry 1997 Apr;31(2):304-5.

PSYCHOLOGY

Do patients use marijuana as an antidepressant? Gruber AJ, et al. **Depression** 1996;4(2):77-80 (34 ref.)

MARIJUANA SMOKING

ADVERSE EFFECTS

Cannabis and the brain [see comments] Castle DJ, et al. **Aust N Z J Psychiatry** 1996 Apr;30(2):179-83 (28 ref.) Comment in: Aust N Z J Psychiatry 1997 Apr;31(2):304-5.

PREVENTION & CONTROL

Reducing the harm of adolescent substance use [editorial; comment] Erickson PG. **Can Med Assoc J** 1997 May 15; 156(10):1397-9 (15 ref.) Comment on: Can Med Assoc J 1997 May 15;156(10):1387-93.

MARINE BIOLOGY

Environmental bioadhesion: themes and applications. Burzio LO, et al. **Curr Opin Biotechnol** 1997 Jun;8(3):309-12 (32 ref.)

Aquatic ecotoxicology: from the ecosystem to the cellular and molecular levels. Boudou A, et al. **Environ Health Perspect** 1997 Feb;105 Suppl 1:21-35 (95 ref.)

Humoral factors in marine invertebrates. Leclerc M. **Prog Mol Subcell Biol** 1996;15:1-9 (70 ref.)

MARINE TOXINS

Marine natural products. Diversity in molecular structure and bioactivity. Scheuer PJ. **Adv Exp Med Biol** 1996; 391:1-8 (28 ref.)

Trophic controls on stage transformations of a toxic ambush-predator dinoflagellate. Burkholder JM, et al. **J Eukaryot Microbiol** 1997 May-Jun;44(3):200-5 (29 ref.)

CHEMISTRY

Steroid and triterpenoid oligoglycosides of marine origin. Minale L, et al. **Adv Exp Med Biol** 1996;404:335-56 (63 ref.)

PHARMACOLOGY

Antimalarial activity: the search for marine-derived natural products with selective antimalarial activity. Wright AD, et al. **J Nat Prod** 1996 Jul;59(7):710-6 (24 ref.)

POISONING

Health effects associated with algal toxins from seafood. Aune T. **Arch Toxicol Suppl** 1997;19:389-97 (25 ref.)

Cyanobacterial toxins: occurrence, modes of action, health effects and exposure routes. Codd GA, et al. **Arch Toxicol Suppl** 1997;19:399-410 (35 ref.)

MARINESCO-SJOGREN SYNDROME see **SPINOCEREBELLAR DEGENERATION**

MARITAL RELATIONSHIP see **MARRIAGE**

MARITAL STATUS

STATISTICS & NUMERICAL DATA

The private insurance industry's tactics against suspected homosexuals: redlining based on occupation, residence and marital status. Li KC. **Am J Law Med** 1996;22(4):477-502 (202 ref.)

MARITAL THERAPY

see related
COUPLES THERAPY

MANPOWER

Marriage and family therapists and the clergy: a need for clinical collaboration, training, and research. Weaver AJ, et al. **J Marital Fam Ther** 1997 Jan;23(1):13-25 (86 ref.)

METHODS

A critical review of marital therapy outcome research [see comments] Wesley S, et al. **Can J Psychiatry** 1996 Sep; 41(7):421-8 (22 ref.) Comment in: Can J Psychiatry 1996 Sep;41(7):419-20. Comment in: Can J Psychiatry 1997 Apr;42(3):323-4.

ORGANIZATION & ADMINISTRATION

Exploring a fourth dimension: spirituality as a resource for the couple therapist. Anderson DA, et al. **J Marital Fam Ther** 1997 Jan;23(1):3-12 (32 ref.)

MARKER ANTIGENS see **ANTIGENS, DIFFERENTIATION**

MARKERS, BIOCHEMICAL see **BIOLOGICAL MARKERS**

MARKERS, BIOLOGICAL see **BIOLOGICAL MARKERS**

MARKERS, CLINICAL see **BIOLOGICAL MARKERS**

MARKERS, DNA see **GENETIC MARKERS**

MARKERS, GENETIC see **GENETIC MARKERS**

MARKERS, IMMUNOLOGIC see **BIOLOGICAL MARKERS**

MARKERS, LABORATORY see **BIOLOGICAL MARKERS**

MARKERS, SERUM see **BIOLOGICAL MARKERS**

MARKERS, SURROGATE see **BIOLOGICAL MARKERS**

MARKERS, TUMOR see **TUMOR MARKERS, BIOLOGICAL**

MARKERS, VIRAL see **BIOLOGICAL MARKERS**

MARKETING OF HEALTH SERVICES

Consumer health plan choice: current knowledge and future directions. Scanlon DP, et al. **Annu Rev Public Health** 1997; 18:507-28 (62 ref.)

The valuation of health care intangible assets. Reilly RF, et al. **Health Care Manage Rev** 1997 Spring;22(2):55-64 (0 ref.)

Making new markets in the British NHS. Meyer GS. **Nutrition** 1997 Feb;13(2):171-2 (8 ref.)

ECONOMICS

Health economics in rheumatology. McCabe CJ, et al. **Baillieres Clin Rheumatol** 1997 Feb;11(1):145-56 (23 ref.)

MARKETING OF HEALTH SERVICES

METHODS

Preparing for the coming consumer revolution in health care. Bartlett DF. **J Health Care Finance** 1997 Summer; 23(4):33–9 (2 ref.)

Working with education reporters to advocate for comprehensive school health education. Sofalvi AJ, et al. **J Sch Health** 1997 May;67(5):185–6 (19 ref.)

ORGANIZATION & ADMINISTRATION

UK general practice fundholding [editorial] Peckham S. **Can Fam Physician** 1997 Sep;43:1485–7, 1492–5 (19 ref.) **(Eng, Fre)**

Marketing: applications in a military health care setting. Roark GA, et al. **Mil Med** 1997 Aug;162(8):543–7 (18 ref.)

TRENDS

From health services to medical markets: the commodity transformation of medical production and the nonprofit sector. Imershein AW, et al. **Int J Health Serv** 1996; 26(2):221–38 (44 ref.)

MARKOV CHAINS

Hidden Markov models. Eddy SR. **Curr Opin Struct Biol** 1996 Jun;6(3):361–5 (33 ref.)

MARKOV PROCESS see **MARKOV CHAINS**

MARMOSET, COMMON see **CALLITHRIX**

MARMOSET, COTTON-TOP see **SAGUINUS**

MARMOSET, LONG-TUSKED see **SAGUINUS**

MARMOSET, SHORT-TUSKED see **CALLITHRIX**

MARMOSET VIRUS see **SIMPLEXVIRUS**

MARMOSETS see **CALLITHRIX**

MARRIAGE

see related

SPOUSES

Coincident cold urticaria in a married couple: case report and a literature review. Leong KP, et al. **Ann Acad Med Singapore** 1997 Mar;26(2):221–4 (27 ref.)

Mating assortment and the liability to substance abuse. Vanyukov MM, et al. **Drug Alcohol Depend** 1996 Sep; 42(1):1–10 (100 ref.)

Social relationships in later life: a review of the research literature [editorial] Phillipson C. **Int J Geriatr Psychiatry** 1997 May;12(5):505–12 (61 ref.)

An additional facet of the incest taboo: a protection of the mating-strategy template. Immerman RS, et al. **J Genet Psychol** 1997 Jun;158(2):151–64 (100 ref.)

TRENDS

Does marriage matter? Waite LJ. **Demography** 1995 Nov; 32(4):483–507 (62 ref.)

MARRIAGE THERAPY see **MARITAL THERAPY**

MARRIED PERSONS see **SPOUSES**

MARROW see **BONE MARROW**

MARS

Life on Mars: a clue to life on Earth? Brack A. **Chem Biol** 1997 Jan;4(1):9–12 (27 ref.)

Water on early Mars. Carr MH. **Ciba Found Symp** 1996; 202:249–65; discussion 265–7 (36 ref.)

The transfer of viable microorganisms between planets. Davies PC. **Ciba Found Symp** 1996;202:304–14; discussion 314–7 (32 ref.)

Hydrothermal systems on Mars: an assessment of present evidence. Farmer JD. **Ciba Found Symp** 1996;202:273–95; discussion 295–9 (51 ref.)

Hydrothermal systems as environments for the emergence of life. Shock EL. **Ciba Found Symp** 1996;202:40–52; discussion 52–60 (42 ref.)

Extraterrestrial life: life on Mars—then and now [published erratum appears in Curr Biol 1996 Dec 1;6(12):1698] Arrhenius G, et al. **Curr Biol** 1996 Oct 1;6(10):1213–6 (12 ref.)

Origins of life: a comparison of theories and application to Mars. Davis WL, et al. **Orig Life Evol Biosph** 1996 Feb; 26(1):61–73 (105 ref.)

The search for life on Mars. McKay CP. **Orig Life Evol Biosph** 1997 Jun;27(1–3):263–89 (123 ref.)

[Medico-biological aspects of a Mars expedition] Grigor'ev AI, et al. **Fiziol Cheloveka** 1997 Jan–Feb;23(1):88–92 (30 ref.) **(Rus)**

MARSUPIALIA

Likely targets for immunocontraception in marsupials. Rodger JC. **Reprod Fertil Dev** 1997;9(1):131–6 (47 ref.)

Fertility control of mammal pests and the conservation of endangered marsupials. Sinclair AR. **Reprod Fertil Dev** 1997;9(1):1–16 (59 ref.)

ANATOMY & HISTOLOGY

A comparison of oocyte organelles in Monodelphis domestica with those of other marsupials and eutherians. Kress A. **Reprod Fertil Dev** 1996;8(4):521–33 (90 ref.)

Mammalian oocyte organelles with special reference to pleomorphic mitochondria and vacuole formation in marsupials. Ullmann SL, et al. **Reprod Fertil Dev** 1996; 8(4):491–508 (117 ref.)

EMBRYOLOGY

The blastocyst epithelium is not a protoderm in dasyurid marsupials: a review of the evidence. Selwood L. **Reprod Fertil Dev** 1996;8(4):711–23 (62 ref.)

GENETICS

Mammals that break the rules: genetics of marsupials and monotremes. Graves JA. **Annu Rev Genet** 1996;30:233–60 (111 ref.)

METABOLISM

Metabolism of Eucalyptus terpenes by herbivorous marsupials. McLean S, et al. **Drug Metab Rev** 1997 Feb–May;29(1–2):213–8 (27 ref.)

PHYSIOLOGY

What marsupial gametes disclose about gamete function in eutherian mammals. Bedford JM. **Reprod Fertil Dev** 1996; 8(4):569–80 (65 ref.)

Egg maturation and fertilization in marsupials. Breed WG. **Reprod Fertil Dev** 1996;8(4):617–43 (46 ref.)

Hormones of oestrus and ovulation and their manipulation in marsupials. Hinds LA, et al. **Reprod Fertil Dev** 1996; 8(4):661–72 (56 ref.)

Regulation of the motility and metabolism of spermatozoa for storage in the epididymis of eutherian and marsupial mammals. Jones RC, et al. **Reprod Fertil Dev** 1996; 8(4):553–68 (169 ref.)

Cytoplasmic maturation of the marsupial oocyte during the periovulatory period. Mate KE. **Reprod Fertil Dev** 1996; 8(4):509–19 (63 ref.)

Capacitation and the acrosome reaction in marsupial spermatozoa. Mate KE, et al. **Reprod Fertil Dev** 1996; 8(4):595–603 (46 ref.)

MARTIAL ARTS

INJURIES

Complications of type I coronoid fractures in competitive athletes: report of two cases and review of the literature. Liu SH, et al. **J Shoulder Elbow Surg** 1996 May–Jun; 5(3):223–7 (18 ref.)

MARYLAND BRIDGE see **DENTURE, PARTIAL, FIXED, RESIN-BONDED**

MASKING, PERCEPTUAL see **PERCEPTUAL MASKING**

MASKS

[Non-invasive ventilation in acute respiratory insufficiency] Karg O, et al. **Pneumologie** 1996 Nov;50(11):759–63 (31 ref.) (Eng. Abstr.) **(Ger)**

MASS FRAGMENTOGRAPHY

Stimulants, narcotics and beta-blockers: 25 years of development in analytical techniques for doping control. Hemmersbach P, et al. **J Chromatogr B Biomed Appl** 1996 Dec 6;687(1):221–38 (107 ref.)

Bioanalysis of beta 2-agonists by hyphenated chromatographic and mass spectrometric techniques. Polettini A. **J Chromatogr B Biomed Appl** 1996 Dec 6; 687(1):27–42 (58 ref.)

Structure analysis of fatty acids by gas chromatography—low resolution electron impact mass spectrometry of their 4,4-dimethyloxazoline derivatives—a review. Spitzer V. **Prog Lipid Res** 1996 Dec;35(4):387–408 (48 ref.)

METHODS

Screening and analysis of polar pesticides in environmental monitoring programmes by coupled-column liquid chromatography and gas chromatography-mass spectrometry. Hogendoorn EA, et al. **J Chromatogr A** 1996 Nov 22;754(1–2):49–60 (37 ref.)

Analysis of organic volatile impurities as a forensic tool for the examination of bulk pharmaceuticals. Mulligan KJ, et al. **J Chromatogr B Biomed Appl** 1996 Nov 8;686(1):85–95 (46 ref.)

Measuring DNA adducts by gas chromatography-electron capture-mass spectrometry: trace organic analysis. Giese RW, et al. **Methods Enzymol** 1996;271:504–22 (21 ref.)

Use of gas chromatography-ion trap tandem mass spectrometry for the detection and characterization of microorganisms in complex samples. Larsson L, et al. **Mol Biotechnol** 1997 Jun;7(3):279–87 (33 ref.)

MASS MEDIA

Media violence, gun control, and public policy. Zuckerman DM. **Am J Orthopsychiatry** 1996 Jul;66(3):378–89 (32 ref.)

Medical scientists and health news reporting: a case of miscommunication. Shuchman M, et al. **Ann Intern Med** 1997 Jun 15;126(12):976–82 (67 ref.)

Disasters, the media and social structures: a typology of credibility hierarchy persistence based on a newspaper coverage of the Love Canal and six other disasters. Ploughman P. **Disasters** 1997 Jun;21(2):118–37 (79 ref.)

Media advocacy: lessons from community experiences. Jernigan DH, et al. **J Public Health Policy** 1996; 17(3):306–30 (23 ref.)

Evolving coverage in reporting refractive surgery in the popular press. Shah S, et al. **J Refract Surg** 1996 Jul–Aug; 12(5):638–41 (19 ref.)

Working with education reporters to advocate for comprehensive school health education. Sofalvi AJ, et al. **J Sch Health** 1997 May;67(5):185–6 (19 ref.)

Alcohol and the media. Montonen M. **WHO Reg Publ Eur Ser** 1996;62:1–165 (289 ref.)

[Reflections on the cause and consequences of exposure to violent presentations in children] Rauchfleisch U. **Prax Kinderpsychol Kinderpsychiatr** 1997 Jul–Aug; 46(6):435–44 (27 ref.) (Eng. Abstr.) **(Ger)**

MASS SCREENING

see related

SENSITIVITY AND SPECIFICITY

Sjögren's syndrome with membranous glomerulonephritis detected by urine screening of schoolchildren. Yoshida K, et al. **Acta Paediatr Jpn** 1996 Oct;38(5):533–6 (13 ref.)

The acceptability of voluntary HIV antibody testing in the United States: a decade of lessons learned. Irwin KL, et al. **AIDS** 1996 Dec;10(14):1707–17 (103 ref.)

Screening for disease. Black WC, et al. **AJR Am J Roentgenol** 1997 Jan;168(1):3–11 (80 ref.)

Cholesterol screening should be targeted. Garber AM. **Am J Med** 1997 Feb 17;102(2A):26–30 (18 ref.)

Traditional and future management of nonpalpable breast cancer. Cady B. **Am Surg** 1997 Jan;63(1):55–8 (24 ref.)

Screening for and treatment of hypercholesterolaemia—a review. Hughes K. **Ann Acad Med Singapore** 1997 Mar; 26(2):215–20 (31 ref.)

Screening for prostate cancer. American College of Physicians [see comments] **Ann Intern Med** 1997 Mar 15; 126(6):480–4 (52 ref.) Comment in: Ann Intern Med 1997 Mar 15;126(6):465–7.

The Oxford Screening Program for aortic aneurysm and screening first-order male siblings of probands with abdominal aortic aneurysm. Collin J. **Ann N Y Acad Sci** 1996 Nov 18;800:36–43 (29 ref.)

Ethical considerations in the provision of controversial screening tests. Doukas DJ, et al. **Arch Fam Med** 1997 Sep–Oct;6(5):486–90 (18 ref.)

Prostate cancer screening: what general practitioners and patients need to know. Boyden A. **Aust Fam Physician** 1996 Sep;25(9 Suppl 2):S86–90 (28 ref.)

Hypothyroidism: screening and subclinical disease. Weetman AP. **BMJ** 1997 Apr 19;314(7088):1175–8 (30 ref.)

Doppler ultrasound in obstetric practice: 2. Beattie RB. **Br J Hosp Med** 1994 Jan 19–Feb 1;51(1–2):34–9 (27 ref.)

What is the value of screening? [editorial] Munro J. **Br J Hosp Med** 1996 Oct 16–Nov 5;56(8):382, 384 (6 ref.)

Risk profiles and cardiovascular preparticipation screening of competitive athletes. Maron BJ. **Cardiol Clin** 1997 Aug; 15(3):473–83 (75 ref.)

Cancer screening in the older patient. Robinson B, et al. **Clin Geriatr Med** 1997 Feb;13(1):97–118 (76 ref.)

Overseas screening for tuberculosis in immigrants and refugees to the United States: current status. Binkin NJ, et al. **Clin Infect Dis** 1996 Dec;23(6):1226–32 (21 ref.)

Cancer screening in the postmenopausal woman. Seltzer V. **Clin Obstet Gynecol** 1996 Dec;39(4):889–92 (5 ref.)

Screening and treatment recommendations for adults with hypercholesterolemia. Ennis ED, et al. **Compr Ther** 1996 Aug;22(8):492–500 (21 ref.)

Controversies regarding screening mammography. Ciatto S. **Crit Rev Oncol Hematol** 1997 May;26(1):55–9 (31 ref.)

Role of surveillance endoscopy, biopsy and biomarkers in early detection of Barrett's adenocarcinoma. Ellis FH Jr, et al. **Dis Esophagus** 1997 Jul;10(3):165–71 (85 ref.)

Mammographic screening in older women. Is it worthwhile? van Dijck JA, et al. **Drugs Aging** 1997 Feb;10(2):69–79 (62 ref.)

The infectious diseases impact statement: a mechanism for addressing emerging diseases. McSweegan E. **Emerg Infect Dis** 1996 Apr–Jun;2(2):103–8 (21 ref.)

The epidemiology of thyroid disease and implications for screening. Wang C, et al. **Endocrinol Metab Clin North Am** 1997 Mar;26(1):189–218 (142 ref.)

Screening for neuroblastoma: 20 years and still no answer. Craft AW, et al. **Eur J Cancer** 1996 Aug;32A(9):1540–3 (40 ref.)

Early cancer detection programmes for women at high risk for breast and ovarian cancer: a proposal of practical guidelines. Beckmann MW, et al. **Eur J Cancer Prev** 1996 Dec;5(6):468–75 (87 ref.)

The debate over mass mammography: is it beneficial for

women? Dilhuydy MH, et al. **Eur J Radiol** 1997 Feb; 24(2):86–93 (36 ref.)

Prostate cancer: to screen or not to screen? Bouffioux C. **Eur Urol** 1997;31 Suppl 1:2–4 (17 ref.)

Fecal occult blood testing for colorectal cancer. Can we afford to do this? Ahlquist DA. **Gastroenterol Clin North Am** 1997 Mar;26(1):41–55 (73 ref.)

Fecal occult blood testing for colorectal cancer. Can we afford not to do this? Bond JH. **Gastroenterol Clin North Am** 1997 Mar;26(1):57–70 (51 ref.)

Screening for colorectal cancer: confuting the refuters [editorial] Bond JH. **Gastrointest Endosc** 1997 Jan; 45(1):105–9 (30 ref.)

Screening and surveillance of ulcerative colitis. Axon ATR. **Gastrointest Endosc Clin N Am** 1997 Jan;7(1):129–45 (66 ref.)

Screening of patients with a positive family history of colorectal cancer. Burt RW. **Gastrointest Endosc Clin N Am** 1997 Jan;7(1):65–79 (71 ref.)

Contributions of the molecular biologist in gastrointestinal cancer and precancer screening: current possibilities and future prospects. Craanen ME, et al. **Gastrointest Endosc Clin N Am** 1997 Jan;7(1):147–64 (142 ref.)

Colon cancer screening. Sigmoidoscopy or colonoscopy. Khullar SK, et al. **Gastrointest Endosc Clin N Am** 1997 Jul;7(3):365–86 (113 ref.)

Significance of Helicobacter pylori infection and gastric cancer: implications for screening. Moayyedi P, et al. **Gastrointest Endosc Clin N Am** 1997 Jan;7(1):47–64 (141 ref.)

Population-based care of depression: effective disease management strategies to decrease prevalence. Katon W, et al. **Gen Hosp Psychiatry** 1997 May;19(3):169–78 (39 ref.)

Clinical decision-making with the woman after menopause. Bidikov I, et al. **Geriatrics** 1997 Mar;52(3):28–35; quiz 36 (22 ref.)

Neonatal screening for congenital hypothyroidism: results and perspectives. Delange F. **Horm Res** 1997;48(2):51–61 (116 ref.)

Breast-cancer screening with mammography in women aged 40–49 years. Swedish Cancer Society and the Swedish National Board of Health and Welfare. **Int J Cancer** 1996 Dec 11;68(6):693–9 (26 ref.)

Preventive medicine and screening in older adults. Goldberg TH, et al. **J Am Geriatr Soc** 1997 Mar;45(3):344–54 (150 ref.)

Epidemiology as an essential tool for establishing prevention programs and evaluating their impact and outcome. Antoniadis A, et al. **J Commun Disord** 1997 Jul–Aug; 30(4):269–83; quiz 283–4 (23 ref.)

A review of behavioral screening practices in pediatric settings: do they pass the test? Stancin T, et al. **J Dev Behav Pediatr** 1997 Jun;18(3):183–94 (64 ref.)

Screening for toxoplasmosis in pregnancy: what is the evidence of reducing a health problem? Eskild A, et al. **J Med Screen** 1996;3(4):188–94 (76 ref.)

Decision making in colorectal cancer screening [editorial] Trowers E Jr, et al. **J Natl Med Assoc** 1997 Jan;89(1):9–12 (32 ref.)

Discussion of the controversies associated with prostate cancer screening. Wolfe ES, et al. **J R Soc Health** 1997 Jun;117(3):151–5 (20 ref.)

Controversies in prostate cancer screening. Analogies to the early lung cancer screening debate [see comments] Collins MM, et al. **JAMA** 1996 Dec 25;276(24):1976–9 (73 ref.) Comment in: JAMA 1997 Apr 9;277(14):1120; discussion 1121–2. Comment in: JAMA 1997 Apr 9;277(14):1120–1; discussion 1121–2. Comment in: JAMA 1997 Apr 9;277(14):1121; discussion 1121–2.

Lead poisoning: the implications of current biomedical knowledge for public policy. Silbergeld EK. **Md Med J** 1996 Mar;45(3):209–17 (38 ref.)

Screening of children with Down syndrome for atlantoaxial (C1–2) instability: another contentious health question. Taylor TK, et al. **Med J Aust** 1996 Oct 21;165(8):448–50 (20 ref.)

Screening for Wilms' tumor in children with high-risk congenital syndromes: considerations for an intervention trial. DeBaun MR, et al. **Med Pediatr Oncol** 1996 Nov; 27(5):415–21 (38 ref.)

Do healthy adults need to know their cholesterol level?[see comments] Weaver KD, et al. **N C Med J** 1996 Sep–Oct; 57(5):275–8 (16 ref.) Comment in: N C Med J 1996 Sep–Oct;57(5):278–9.

Screening for colorectal cancer. Timins JK. **N J Med** 1997 Aug;94(8):37–41 (17 ref.)

NIH Consensus Statement. Breast cancer screening for women ages 40–49. **NIH Consens Statement** 1997 Jan 21–23;15(1):1–35 (94 ref.)

Clinical role of HPV testing. Cox JT. **Obstet Gynecol Clin North Am** 1996 Dec;23(4):811–51 (153 ref.)

Prostate cancer: to screen or not to screen? **Oncology (Huntingt)** 1997 Apr;11(4):447–8, 451–2 (9 ref.)

Prostate cancer: to screen or not to screen? **Oncology (Huntingt)** 1997 Mar;11(3):325–6, 329–30 (11 ref.)

Should we recommend screening mammography for women aged 40 to 49? Esserman L, et al. **Oncology (Huntingt)** 1996 Mar;10(3):357–64; discussion: 370–6 (46 ref.)

Colon cancer screening and the evaluation and follow-up of colonic polyps. Lefton HB, et al. **Prim Care** 1996 Sep; 23(3):515–23 (15 ref.)

Screening for thyroid abnormalities among immigrants to Israel from the former USSR. Slater PE, et al. **Public Health Rev** 1997;25(1):43–7 (19 ref.)

Recent progress in the prevention of osteoporosis. To screen or not to screen? Sørensen OH, et al. **Scand J Rheumatol Suppl** 1996;103:25–9 (38 ref.)

Screening, diagnosis, and management of neurogenic dysphagia. Logemann JA. **Semin Neurol** 1996 Dec; 16(4):319–27 (94 ref.)

Breast cancer in older women: screening and selection of locoregional therapy. Sener SF. **Semin Surg Oncol** 1996 Sep–Oct;12(5):328–31 (24 ref.)

Approaches to screening and antibiotic use for syphilis prevention [editorial; comment] Farley TA. **Sex Transm Dis** 1997 Apr;24(4):227–8 (13 ref.) Comment on: Sex Transm Dis 1997 Apr;24(4):218–26.

Cardiovascular evaluation of the athlete. Issues regarding performance, screening and sudden cardiac death. Franklin BA, et al. **Sports Med** 1997 Aug;24(2):97–119 (139 ref.)

Screening programs in the population at large and in high-risk groups. Lush DT. **Surg Oncol Clin N Am** 1996 Jul;5(3):545–52 (35 ref.)

Newly diagnosed malignancy in patients with venous thromboembolism. Search or wait and see? Prins MH, et al. **Thromb Haemost** 1997 Jul;78(1):121–5 (21 ref.)

Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program. Rietbergen JB, et al. **Urology** 1997 Jun; 49(6):875–80 (26 ref.)

[Mass screening of colorectal cancer: where are we up to?] Tazi MA, et al. **Bull Cancer** 1996 Sep;83(9):746–9 (21 ref.) (Eng. Abstr.) **(Fre)**

[Should hepatitis C be screened? Hepatitis C: screening tools] Lunel F. **Gastroenterol Clin Biol** 1997;21(1 Pt 2):S11–24 (86 ref.) **(Fre)**

[Efficacy and psychosocial impact of hepatitis C screening] Perez P. **Gastroenterol Clin Biol** 1997;21(1 Pt 2):S140–7 (40 ref.) **(Fre)**

[Hepatitis C: screening tools] Pham BN, et al. **Gastroenterol Clin Biol** 1997;21(1 Pt 2):S130–9 (70 ref.) **(Fre)**

[Should hepatitis C be screened? Value of hepatitis C screening] Trépo C. **Gastroenterol Clin Biol** 1997;21(1 Pt 2):S1–3 (14 ref.) **(Fre)**

[Is an ultrasound screening program in pregnancy justified?] Holzgreve W. **Arch Gynecol Obstet** 1996;259 Suppl 1:S118–27 (30 ref.) **(Ger)**

[Computer-assisted diagnosis in screening mammography] Bick U. **Radiologe** 1996 Jan;36(1):72–80 (53 ref.) (Eng. Abstr.) **(Ger)**

[Relationship between prenatal and postnatal echographic diagnosis of uropathy: is mass screening useful?] Cacciari A, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):13–7 (27 ref.) (Eng. Abstr.) **(Ita)**

[Screening for carcinoma of the cervix today (editorial)] Calzolari E, et al. **Minerva Ginecol** 1996 Nov;48(11):453–61 (106 ref.) (Eng. Abstr.) **(Ita)**

[Mass screening of urinary tract infection for elementary and junior high school children] Murakami M. **Nippon Ika Daigaku Zasshi** 1996 Dec;63(6):441–5 (9 ref.) **(Jpn)**

[Mass screening for prostate cancer in Japan] Akimoto S, et al. **Nippon Rinsho** 1996 May;54(5):1447–51 (17 ref.) (Eng. Abstr.) **(Jpn)**

[The role of screening for carcinoma of the pancreas] Amikura K, et al. **Nippon Rinsho** 1996 May;54(5):1431–4 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Early detection of hepatobiliary cancer in mass health screening] Kiyosawa K, et al. **Nippon Rinsho** 1996 May; 54(5):1425–30 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Early detection in the mass screening for breast cancer] Kuroishi T, et al. **Nippon Rinsho** 1996 May;54(5):1435–40 (12 ref.) (Eng. Abstr.) **(Jpn)**

[The efficacy of mass screening for uterine cancer] Kuzuya K, et al. **Nippon Rinsho** 1996 May;54(5):1441–6 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Detection of early esophageal and gastric cancers by mass screening] Mitsunaga N, et al. **Nippon Rinsho** 1996 May; 54(5):1415–20 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Sensitivity of immunochemical occult blood testing in detecting early colorectal cancer] Saito H. **Nippon Rinsho** 1996 May;54(5):1421–4 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Detection of early cancer by lung cancer screening] Saito Y, et al. **Nippon Rinsho** 1996 May;54(5):1410–4 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Calcifications visible in mammographic examination as a diagnostic problem] Urbanowicz Z, et al. **Ginekol Pol** 1996 Jul;67(7):366–9 (17 ref.) (Eng. Abstr.) **(Pol)**

[Screening for early diagnosis of colon cancer. Current medical conditions] Lundstedt C, et al. **Lakartidningen** 1996 Oct 2;93(40):3451–3 (44 ref.) **(Swe)**

ECONOMICS

Is mass screening for breast cancer cost-effective? de Koning HJ, et al. **Eur J Cancer** 1996 Oct;32A(11):1835–44 (51 ref.)

Economic aspects of endoscopic screening for intestinal precancerous conditions. Sonnenberg A, et al. **Gastrointest Endosc Clin N Am** 1997 Jan;7(1):165–84 (19 ref.)

Is Europe ready for STD screening? Mårdh PA. **Genitourin Med** 1997 Apr;73(2):96–8 (17 ref.)

Is screening for Chlamydia trachomatis infection cost effective? Paavonen J. **Genitourin Med** 1997 Apr; 73(2):103–4 (23 ref.)

Health screening, development, and equity. Braveman P, et al. **J Public Health Policy** 1996;17(1):14–27 (49 ref.)

Cost benefit of early diagnosis of colorectal cancer. Bolin TD. **Scand J Gastroenterol Suppl** 1996;220:142–6 (33 ref.)

Screening for prostate cancer is neither appropriate nor cost-effective. Albertsen PC. **Urol Clin North Am** 1996 Nov;23(4):521–30 (58 ref.)

INSTRUMENTATION

Utility of the TracCell system in mapping Papanicolaou-stained cytologic material. Grohs DH, et al. **Acta Cytol** 1997 Jan–Feb;41(1):144–52 (20 ref.)

[Portable home monitoring system in screening for sleep-disordered breathing] Hida W, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Dec;33 Suppl:46–9 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Prospects of using computer expert system in the diagnosis of diseases of the respiratory system] Akhlakov MK, et al. **Klin Med (Mosk)** 1996;74(8):48–9 (4 ref.) (Eng. Abstr.) **(Rus)**

LEGISLATION & JURISPRUDENCE

Unresolved issues in controlling the tuberculosis epidemic among the foreign-born in the United States. Weber GS. **Am J Law Med** 1996;22(4):503–36 (353 ref.)

Huntington's disease predictive testing: the case for an assessment approach to requests from adolescents. Binedell J, et al. **J Med Genet** 1996 Nov;33(11):912–8 (49 ref.)

Legal and ethical aspects of medical screening. Rothstein MA. **Occup Med** 1996 Jan–Mar;11(1):31–9 (27 ref.)

METHODS

Automated rescreening in cervical cytology. Mathematical models for evaluating overall process sensitivity, specificity and cost. Kaminsky FC, et al. **Acta Cytol** 1997 Jan–Feb; 41(1):209–23 (35 ref.)

The use and abuse of upper digestive endoscopy. Axon AT. **Acta Gastroenterol Belg** 1997 Apr–Jun;60(2):172–5 (17 ref.)

Screening for colorectal cancer with the fecal occult blood test: a background paper. American College of Physicians. Ransohoff DF, et al. **Ann Intern Med** 1997 May 15; 126(10):811–22 (82 ref.)

US panel fails to recommend mammography screening for women under the age of 50 [news] **Ann Oncol** 1997 Mar; 8(3):210–1 (0 ref.)

MRCOG. Screening for fetal abnormalities. Smith NC. **Br J Hosp Med** 1996 Jun 5–18;55(11):679–82 (15 ref.)

Customised fetal growth assessment. Leeson S, et al. **Br J Obstet Gynaecol** 1997 Jun;104(6):648–51 (38 ref.)

High touch meets high tech. Distance mental health screening for rural youth using Teleform. Puskar KR, et al. **Comput Nurs** 1996 Nov–Dec;14(6):323–9; quiz 330–2 (31 ref.)

Neural tube defects/alpha-fetoprotein/Down's syndrome screening. Aitken DA, et al. **Curr Opin Obstet Gynecol** 1997 Apr;9(2):113–20 (62 ref.)

Epidemiology of antepartum fetal testing. Ananth CV, et al. **Curr Opin Obstet Gynecol** 1997 Apr;9(2):101–6 (12 ref.)

Antenatal genetic counselling: implications for population screening. Stock A, et al. **Curr Opin Obstet Gynecol** 1997 Apr;9(2):109–12 (13 ref.)

Population screening for cystic fibrosis. Brock DJ. **Curr Opin Pediatr** 1996 Dec;8(6):635–8 (22 ref.)

Chlamydia trachomatis screening in the adolescent population. Holder DW, et al. **Curr Opin Pediatr** 1997 Aug; 9(4):317–24 (62 ref.)

The infant neurodevelopmental assessment: a clinical interpretive manual for CAT-CLAMS in the first two years of life, part 1. Capute AJ, et al. **Curr Probl Pediatr** 1996 Aug;26(7):238–57 (11 ref.)

Is screening for prostate cancer the current gold standard?—"no". Kramer BS, et al. **Eur J Cancer** 1997 Mar; 33(3):348–53 (50 ref.)

Is screening for prostate cancer the current gold standard?—"yes". Lange PH. **Eur J Cancer** 1997 Mar; 33(3):354–6 (23 ref.)

An easy test for coeliac disease using human umbilical vein endothelial cells. Usselmann B, et al. **Eur J Gastroenterol Hepatol** 1996 Oct;8(10):947–50 (23 ref.)

Endoscopic screening for colorectal cancer. Lieberman D. **Gastroenterol Clin North Am** 1997 Mar;26(1):71–83 (37 ref.)

Initial management and follow-up surveillance of patients with colorectal adenomas. Zauber AG, et al. **Gastroenterol Clin North Am** 1997 Mar;26(1):85–101 (51 ref.)

Screening modalities in familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer. Spigelman AD. **Gastrointest Endosc Clin N Am** 1997 Jan;7(1):81–6 (27 ref.)

Chlamydia screening: which sample for which technique? Stary A. **Genitourin Med** 1997 Apr;73(2):99–102 (26 ref.)

Can screening for early-stage prostate cancer be rationalized? Jacobson JO. **Hematol Oncol Clin North Am** 1996 Jun; 10(3):549–64 (72 ref.)

Screening and surveillance for colorectal carcinoma. Markowitz AJ, et al. **Hematol Oncol Clin North Am** 1997 Aug;11(4):579–608 (128 ref.)

Cervical cytology: perspectives from both sides of the Atlantic [editorial; comment] Bonfiglio TA. **Hum Pathol** 1997 Feb;28(2):117–9 (4 ref.) Comment on: Hum Pathol 1997 Feb;28(2):120–6.

Is cervical screening working? A cytopathologist's view from the United Kingdom [see comments] Herbert A. **Hum Pathol** 1997 Feb;28(2):120–6 (64 ref.) Comment in: Hum Pathol 1997 Feb;28(2):117–9.

ACOG educational bulletin. Maternal serum screening. Number 228, September 1996 (replaces no. 154, April 1991). Committee on Educational Bulletins of the American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1996 Dec;55(3):299–308 (34 ref.)

The detection of alcohol misuse in accident and emergency departments--grasping the opportunity [comment] Paton A. **J Accid Emerg Med** 1996 Sep;13(5):306–8 (22 ref.) Comment on: J Accid Emerg Med 1996 Sep;13(5):308–12.

Urine-based diagnosis of sexually transmitted infections using amplified DNA techniques: a shift in paradigms? Orr DP. **J Adolesc Health** 1997 Jan;20(1):3–5 (7 ref.)

A review of screening and early detection of endometrial cancer and use of risk assessment. Brooks SE. **J Assoc Acad Minor Phys** 1997;8(2):34–7 (32 ref.)

Underestimation of ovarian pathology: a review. Guida M, et al. **J Chemother** 1997 Apr;9(2):135–7 (10 ref.)

Bone density measurement—a systematic review. A report from SBU, the Swedish Council on Technology Assessment in Health Care. **J Intern Med Suppl** 1997; 739:1–60 (148 ref.)

Screening for fragile X syndrome: information needs for health planners. Murray J, et al. **J Med Screen** 1997; 4(2):60–94 (301 ref.)

Group B streptococcus and pregnancy: update and recommendations. Mitchell A, et al. **MCN Am J Matern Child Nurs** 1997 Sep–Oct;22(5):242–8 (16 ref.)

Screening for prostate cancer: the role of prostate-specific antigen. Ferrer RL. **Md Med J** 1996 Nov;45(11):938–40 (7 ref.)

Screening for alcohol and drug abuse. Schorling JB, et al. **Med Clin North Am** 1997 Jul;81(4):845–65 (97 ref.)

Domestic violence: the new standard of care. Holtz HA. **N J Med** 1996 Aug;93(8):33–6 (10 ref.)

Electromyography in myopathy. Liguori R, et al. **Neurophysiol Clin** 1997 Jun;27(3):200–3 (19 ref.)

The importance of screening for domestic violence in all women. Poirier L. **Nurse Pract** 1997 May;22(5):105–8, 111–2, 115 passim (24 ref.)

Screening for ovarian cancer. Guidozzi F. **Obstet Gynecol Surv** 1996 Nov;51(11):696–701 (42 ref.)

Preschool development. Part 2: Psychosocial/behavioral development. Sturner RA, et al. **Pediatr Rev** 1997 Oct; 18(10):327–36 (13 ref.)

Colorectal cancer. Screening strategies. Gelfand DW. **Radiol Clin North Am** 1997 Mar;35(2):431–8 (18 ref.)

Recommendations on follow-up of breast cancer patients following primary therapy. Khandekar JD. **Semin Surg Oncol** 1996 Sep–Oct;12(5):346–51 (37 ref.)

Age and interval for screening mammography: whom do you believe? Venta LA, et al. **Semin Surg Oncol** 1996 Sep–Oct; 12(5):281–9 (39 ref.)

Prediction of postoperative deep-vein thrombosis. Lowe GD. **Thromb Haemost** 1997 Jul;78(1):47–52 (41 ref.)

Screening for colorectal cancer. Campbell WJ, et al. **Ulster Med J** 1997 May;66(1):1–8 (71 ref.)

Screening for prostate cancer. Kirkels WJ, et al. **Urol Res** 1997;25 Suppl 2:S53–6 (17 ref.)

Delivering breast and cervical cancer screening services to underserved women: Part I. Literature review and telephone survey. Vellozzi CJ, et al. **Womens Health Issues** 1996 Mar–Apr;6(2):65–73 (34 ref.)

[European recommendations for quality assurance in the setting of mammographic screening for breast cancer. Report of pathologists of the working group "Breast Cancer Screening" of the European Union] **Ann Pathol** 1996 Nov; 16(5):315–33 (25 ref.) **(Fre)**

[Cervical smears. Contribution of automated screening] Ziol M, et al. **Ann Pathol** 1996 Nov;16(5):351–5 (26 ref.) **(Fre)**

[Breast cancer screening, European Union and France] Tubiana M. **Bull Cancer** 1996 Sep;83(9):726–31 (40 ref.) **(Fre)**

[Can microcolpohysteroscopy be used to screen cervical lesions?] Hamou J, et al. **Contracept Fertil Sex** 1997 May; 25(5):358–62 (17 ref.) **(Fre)**

[Breast cancer screening between forty and fifty years old] Raulic P, et al. **Contracept Fertil Sex** 1997 Jan; 25(1):XI–XVII (29 ref.) **(Fre)**

[Early ultrasonographic detection of endometrial cancer] Rudigoz RC, et al. **Contracept Fertil Sex** 1997 Jan; 25(1):21–6 (49 ref.) **(Fre)**

[Mass screening for colorectal cancer] Faivre J, et al. **Rev Epidemiol Sante Publique** 1996;44 Suppl 1:S7–14 (24 ref.) (Eng. Abstr.) **(Fre)**

[Value of tumor markers for screening and diagnosis (except prognostic and surveillance values) in primary bronchial cancers] Grivaux M. **Rev Mal Respir** 1997 Apr;14 Suppl 3:S15–9 (41 ref.) **(Fre)**

[How I investigate... a patient newly diagnosed with/or at risk of diabetes type 1] Philips JC, et al. **Rev Med Liege** 1997 May;52(5):363–6 (9 ref.) **(Fre)**

[Cervical cancer screening] Delaloye JF, et al. **Rev Med Suisse Romande** 1997 Aug;117(8):589–91 (20 ref.) **(Fre)**

[Proposals for a strategy for evaluation and utilization of screening tests for hepatitis C] Lunel F, et al. **Transfus Clin Biol** 1996;3(5):279–88 (23 ref.) (Eng. Abstr.) **(Fre)**

[Biomarkers of hepatotoxic effects: their usefulness in occupational medicine] Indulski JA, et al. **Med Pr** 1997; 48(2):177–87 (34 ref.) (Eng. Abstr.) **(Pol)**

[The significance of diagnosing microalbuminuria and microglobulinuria in diabetes mellitus and arterial hypertension] Kasprowicz B, et al. **Przegl Lek** 1997; 54(3):180–4 (70 ref.) (Eng. Abstr.) **(Pol)**

[Significance of expedition studies in epidemiology of tuberculosis in Iakutia (to 70 anniversary of the first expedition)] Anisimov IV. **Probl Tuberk** 1997;(2):8–9 (5 ref.) (Eng. Abstr.) **(Rus)**

[Programmed complex for automated prophylactic check-ups of chronic outpatients. Communication 1. Tasks and fundamentals] Lapochkin VI, et al. **Vestn Oftalmol** 1997 Mar–Apr;113(2):32–4 (0 ref.) (Eng. Abstr.) **(Rus)**

ORGANIZATION & ADMINISTRATION

The case against a national screening programme for aortic aneurysms [see comments] Cheatle TR. **Ann R Coll Surg Engl** 1997 Mar;79(2):90–5 (65 ref.) Comment in: Ann R Coll Surg Engl 1997 Jul;79(4):310.

[Trends in tuberculosis epidemiology in the Ivanovo Region and its stabilizing measures] Punga VV, et al. **Probl Tuberk** 1997;(1):8–10 (0 ref.) (Eng. Abstr.) **(Rus)**

[The first results of the international project "Tuberculosis in the Tomsk region"] Strelis AK, et al. **Probl Tuberk** 1997; (1):10–2 (0 ref.) **(Rus)**

PSYCHOLOGY

Attitudes to Papanicolaou smears. Conway K. **J Psychosom Obstet Gynaecol** 1996 Dec;17(4):189–94 (45 ref.)

STANDARDS

Cervicography. Does it improve cervical cancer screening? Baldauf JJ, et al. **Acta Cytol** 1997 Mar–Apr;41(2):295–301 (27 ref.)

Screening for coeliac disease--has the time come for mass screening? Logan RF. **Acta Paediatr Suppl** 1996 May; 412:15–9 (15 ref.)

Reducing cervical cancer by two-thirds: a public health target within our reach [editorial; comment] Ward J. **Aust N Z J Public Health** 1997 Jun;21(3):248–9 (14 ref.) Comment on: Aust N Z J Public Health 1997 Jun;21(3):265–7.

How to read a paper. Papers that report diagnostic or screening tests. Greenhalgh T. **BMJ** 1997 Aug 30; 315(7107):540–3 (15 ref.)

There is no longer a place for underage cytology in genitourinary medicine clinics. O'Mahony C. **Genitourin Med** 1996 Dec;72(6):433–4 (14 ref.)

National Institutes of Health Consensus Development Conference Statement: Breast Cancer Screening for Women Ages 40–49, January 21–23, 1997. National Institutes of Health Consensus Development Panel. **J Natl Cancer Inst** 1997 Jul 16;89(14):1015–26 (94 ref.)

National Institutes of Health Consensus Development Conference Statement: cervical cancer, April 1–3, 1996. National Institutes of Health Consensus Development Panel. **J Natl Cancer Inst Monogr** 1996;(21):vii–xix (78 ref.)

Screening for Chlamydia in general practice: a literature review and summary of the evidence. Stokes T. **J Public Health Med** 1997 Jun;19(2):222–32 (70 ref.)

Cancer incidence and mortality: the priority of screening frequency and population coverage. Colditz GA, et al. **Milbank Q** 1997;75(2):147–73 (50 ref.)

Is screening for chronic obstructive pulmonary disease justified? Badgett RG, et al. **Prev Med** 1997 Jul–Aug; 26(4):466–72 (86 ref.)

[Cervical cancer screening. False negative smears] Vassilakos P, et al. **Rev Med Suisse Romande** 1997 Aug;117(8):597–601 (7 ref.) **(Fre)**

STATISTICS & NUMERICAL DATA

[Significance of roentgen mammography for breast carcinoma screening] Schulz-Wendtland R, et al. **Rontgenpraxis** 1997 May;50(5):103–9 (65 ref.) **(Ger)**

TRENDS

Future prospects of population-based mammographic screening. Holmberg L. **Semin Surg Oncol** 1996 Jan–Feb; 12(1):26–31 (36 ref.)

[Follow-up and treatment of cervical intraepithelial neoplasia (current trends)] Sopena B. **Ann Pathol** 1996 Nov; 16(5):356–63 (44 ref.) **(Fre)**

[Prediction of lung cancer deaths and the role of lung cancer screening in Japan] Sobue T. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Dec;33 Suppl:8–12 (29 ref.) (Eng. Abstr.) **(Jpn)**

UTILIZATION

Barriers to cancer prevention in the older person. Fox SA, et al. **Clin Geriatr Med** 1997 Feb;13(1):79–95 (129 ref.)

MASS SPECTROMETRY see **SPECTRUM ANALYSIS, MASS**

MASS SPECTROMETRY, MATRIX-ASSISTED LASER DESORPTION-IONIZATION see **SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION**

MASS SPECTROSCOPY see **SPECTRUM ANALYSIS, MASS**

MASS SPECTROSCOPY, MATRIX-ASSISTED LASER DESORPTION-IONIZATION see **SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION**

MASSAGE

Modification of ventricular tachycardia by carotid sinus massage. Kappos KG, et al. **J Electrocardiol** 1996 Oct; 29(4):327–32 (32 ref.)

Manual massage and recovery of muscle function following exercise: a literature review. Tiidus PM. **J Orthop Sports Phys Ther** 1997 Feb;25(2):107–12 (40 ref.)

The Pre and Post Massage Test (PPMT): a simple screen for prostatitis. Nickel JC. **Tech Urol** 1997 Spring;3(1):38–43 (23 ref.)

ADVERSE EFFECTS

Popliteal artery pseudoaneurysm caused by an osteochondroma--a traditional medicine massage sequelae. Kalinga MJ, et al. **Singapore Med J** 1996 Aug;37(4):443–5 (8 ref.)

MASSETER MUSCLE

Submasseteric abscess caused by a dentigerous cyst mimicking a parotitis: report of two cases. Mandel L. **J Oral Maxillofac Surg** 1997 Sep;55(9):996–9 (17 ref.)

MAST-CELL COLONY-STIMULATING FACTOR see **INTERLEUKIN-3**

MAST-CELL DISEASE see **MASTOCYTOSIS**

MAST CELL GROWTH FACTOR see **STEM CELL FACTOR**

MAST CELL GROWTH FACTOR-2 see **INTERLEUKIN-4**

MAST-CELL SARCOMA see **SARCOMA, MAST-CELL**

MAST CELLS

Does the mast cell still have a key role in asthma? Rossi GL, et al. **Chest** 1997 Aug;112(2):523–9 (75 ref.)

CHEMISTRY

Mast cell-lineage versus basophil lineage involvement in myeloproliferative and myelodysplastic syndromes: diagnostic role of cell-immunophenotyping. Agis H, et al. **Leuk Lymphoma** 1996 Jul;22(3-4):187–204 (104 ref.)

CYTOLOGY

Mast cell apoptosis: from the DNA to the bedside. Mekori AY. **Allerg Immunol (Paris)** 1997 Jan;29(1):4–6 (13 ref.)

Molecular genetics and development of mast cells: implications for molecular medicine. Födinger M, et al. **Mol Med Today** 1997 Mar;3(3):131–7 (31 ref.)

Mast cells as potent inflammatory cells. Dumitrașcu D. **Rom J Intern Med** 1996 Jul–Dec;34(3-4):159–72 (30 ref.)

DRUG EFFECTS

Dual effects of allergen-mPEG conjugates. Induction of immunological suppression and inactivation of sensitized mast cells. Sehon AH, et al. **Adv Exp Med Biol** 1996; 409:177–84 (17 ref.)

ENZYMOLOGY

[Tryptase--an sign of mastocyte activation] Wrzyszcz M, et al. **Pneumonol Alergol Pol** 1996;64(5-6):366–70 (30 ref.) **(Pol)**

[Tryptase: a diagnostic marker in allergic diseases] Martínez Infante E, et al. **Rev Alerg Mex** 1996 May–Jun;43(3):73–6 (58 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Cytokine and drug modulation of TNF alpha in mast cells. Lin TJ, et al. **Adv Exp Med Biol** 1996;409:279–85 (45 ref.)

The role of basophils and mast cells in acute and late reactions in the skin. Charlesworth EN. **Allergy** 1997;52(34 Suppl):31–43 (73 ref.)

The differentiation and maturation of inflammatory cells involved in the allergic response: mast cells and basophils. Enerbäck L. **Allergy** 1997 Jan;52(1):4–10 (71 ref.)

Functions of IL-4 and control of its expression. Brown MA, et al. **Crit Rev Immunol** 1997;17(1):1–32 (257 ref.)

Mast cells in the front line. Innate immunity. Erb KJ, et al. **Curr Biol** 1996 Aug 1;6(8):941–2 (9 ref.)

Role of C3a and C5a in the activation of mast cells. Erdei

A, et al. **Exp Clin Immunogenet** 1997;14(1):16–8 (11 ref.)
IgE, allergies and helminth parasites: a new perspective on an old conundrum. Bell RG. **Immunol Cell Biol** 1996 Aug; 74(4):337–45 (81 ref.)
Products from mast cells influence T lymphocyte proliferation and cytokine production--relevant to allergic asthma? de Pater-Huijsen FL, et al. **Immunol Lett** 1997 Jun 1;57(1–3):47–51 (33 ref.)
Unravelling the mast cell dilemma: culprit or victim of its generosity? Mécheri S, et al. **Immunol Today** 1997 May; 18(5):212–5 (32 ref.)
Mucosal T cells and mast cells share common adhesion receptors. Smith TJ, et al. **Immunol Today** 1996 Feb; 17(2):60–3 (53 ref.)
Mast cells in infection and immunity. Abraham SN, et al. **Infect Immun** 1997 Sep;65(9):3501–8 (80 ref.)
The human mast cell. Church MK, et al. **J Allergy Clin Immunol** 1997 Feb;99(2):155–60 (7 ref.)
A newly recognized pathway for the negative regulation of mast cell–dependent hypersensitivity and inflammation mediated by an endogenous cell surface receptor of the gp49 family. Katz HR, et al. **J Immunol** 1997 Jun 1; 158(11):5065–70 (32 ref.)
Hypothesis: a possible role for mast cells and their inflammatory mediators in the pathogenesis of autoimmune encephalomyelitis. Bebo BF Jr, et al. **J Neurosci Res** 1996 Aug 15;45(4):340–8 (55 ref.)
Mucosal mast cells and the allergic response against nematode parasites. Miller HR. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):331–6 (28 ref.)

METABOLISM

The mast cell as a source of cytokines in asthma. Bradding P, et al. **Ann N Y Acad Sci** 1996 Oct 31;796:272–81 (56 ref.)
Downstream signals initiated in mast cells by Fc epsilon RI and other receptors. Beaven MA, et al. **Curr Opin Immunol** 1996 Dec;8(6):766–72 (66 ref.)
Mast cells in human fatty streaks and atheromas: implications for intimal lipid accumulation. Kovanen PT. **Curr Opin Lipidol** 1996 Oct;7(5):281–6 (35 ref.)
The human mast cell. Church MK, et al. **J Allergy Clin Immunol** 1997 Feb;99(2):155–60 (7 ref.)
Critical protective role of mast cell–derived tumour necrosis factor in bacterial infection. Männel DN, et al. **Res Immunol** 1996 Oct–Dec;147(8–9):491–3 (14 ref.)
Nerve growth factor: from neurotrophin to neurokine. Levi-Montalcini R, et al. **Trends Neurosci** 1996 Nov; 19(11):514–20 (91 ref.)
[Arachidonate metabolism in mast cells] Murakami M. **Seikagaku** 1997 Feb;69(2):108–13 (23 ref.) **(Jpn)**

PATHOLOGY

The differentiation and maturation of inflammatory cells involved in the allergic response: mast cells and basophils. Enerbäck L. **Allergy** 1997 Jan;52(1):4–10 (71 ref.)
Mast cell–tumor cell interactions: for or against tumour growth and metastasis? Dimitriadou V, et al. **Anticancer Res** 1997 May–Jun;17(3A):1541–9 (141 ref.)
Mast cells, eosinophils and fibrosis. Levi-Schaffer F, et al. **Clin Exp Allergy** 1997 May;27 Suppl 1:64–70 (64 ref.)

PHYSIOLOGY

Contemporary issues in mast cell biology. Nilsson G, et al. **Allergy Asthma Proc** 1996 Mar–Apr;17(2):59–63 (55 ref.)
Ion channels and calcium signaling in mast cells. Hoth M, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:198–209 (49 ref.)
Mucosal allergy: role of mast cells and eosinophil granulocytes in the gut. Bischoff SC. **Baillieres Clin Gastroenterol** 1996 Sep;10(3):443–59 (79 ref.)
Leukocyte-endothelial cell interactions evoked by mast cells. Kubes P, et al. **Cardiovasc Res** 1996 Oct;32(4):699–708 (85 ref.)
Regulation of mast cell growth and proliferation. Nechushtan H, et al. **Crit Rev Oncol Hematol** 1996 Jun;23(2):131–50 (132 ref.)
Negative regulation of mast cell activation by receptors for IgG. Daëron M. **Int Arch Allergy Immunol** 1997 May–Jul; 113(1–3):138–41 (29 ref.)
New aspects of mast cell biology. Dvorak AM. **Int Arch Allergy Immunol** 1997 Sep;114(1):1–9 (48 ref.)
The Paul Kallos Memorial Lecture. The mast cell: a versatile effector cell for a challenging world. Galli SJ. **Int Arch Allergy Immunol** 1997 May–Jul;113(1–3):14–22 (74 ref.)
The role of mast cells in atherosclerosis. Metzler B, et al. **Int Arch Allergy Immunol** 1997 Sep;114(1):10–4 (34 ref.)
The mast cell: a neuroimmunoendocrine master player. Theoharides TC. **Int J Tissue React** 1996;18(1):1–21 (266 ref.)
Mast cell effector mechanisms. Lane SJ, et al. **J Allergy Clin Immunol** 1996 Nov;98(5 Pt 2):S67–71; discussion S71–2 (40 ref.)
Complexity and redundancy in the pathogenesis of asthma: reassessing the roles of mast cells and T cells. Galli SJ. **J Exp Med** 1997 Aug 4;186(3):343–7 (46 ref.)
Development, significance, and heterogeneity of mast cells with particular regard to the mast cell–specific proteases chymase and tryptase. Welle M. **J Leukoc Biol** 1997 Mar; 61(3):233–45 (177 ref.)
Mast cell interactions with the nervous system: relationship to mechanisms of disease. Dines KC, et al. **J Neuropathol Exp Neurol** 1997 Jun;56(6):627–40 (95 ref.)
Melatonin in mast cells and tumor radiosensitivity. Kvetnoy IM, et al. **J Pineal Res** 1997 Apr;22(3):169–70 (16 ref.)
The role of gastric mast cells, enterochromaffin-like cells and parietal cells in the regulation of acid secretion. Kurbel S, et al. **Med Hypotheses** 1995 Dec;45(6):539–42 (22 ref.)
Role of c-kit receptor tyrosine kinase in the development, survival and neoplastic transformation of mast cells. Tsujimura T. **Pathol Int** 1996 Dec;46(12):933–8 (35 ref.)
Regulation of store-operated calcium currents in mast cells. Parekh AB, et al. **Soc Gen Physiol Ser** 1996;51:231–9 (18 ref.)

SECRETION

[Exocytotic hormone release] Kawasaki Y. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1233–7 (15 ref.) **(Jpn)**

ULTRASTRUCTURE

Ultrastructural localization of histamine in human basophils and mast cells; changes associated with anaphylactic degranulation and recovery demonstrated with a diamine oxidase–gold probe. Dvorak AM. **Allergy** 1997;52(34 Suppl):14–24 (30 ref.)

MASTECTOMY

Breast cancer: current issues in diagnosis and treatment [see comments] Furnival CM. **Aust N Z J Surg** 1997 Jan; 67(1):47–58 (55 ref.) Comment in: Aust N Z J Surg 1997 Jul;67(7):476.
Histopathological reporting of breast biopsies and mastectomies for carcinoma of the breast. Looi LM. **Malays J Pathol** 1994 Dec;16(2):173 (0 ref.)
Postmastectomy radiation: then and now. Fowble B. **Oncology (Huntingt)** 1997 Feb;11(2):213–34, 239; discussion 239–40, 243 (169 ref.)
Definitive breast cancer surgery as an outpatient: a rational basis for the transition. Hoehn JL. **Semin Surg Oncol** 1996 Jan–Feb;12(1):53–8 (14 ref.)
Chest wall reconstruction. Arnold PG, et al. **Surg Oncol Clin N Am** 1997 Jan;6(1):91–114 (14 ref.)
Reconstruction of the breast. Bostwick J 3rd, et al. **Surg Oncol Clin N Am** 1997 Jan;6(1):71–89 (57 ref.)
[Primary angiosarcoma of the breast. Apropos of 2 cases] Melhouf MM, et al. **Bull Cancer** 1997 Feb;84(2):218–22 (55 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Postmastectomy pain syndromes. Kwekkeboom K. **Cancer Nurs** 1996 Feb;19(1):37–43 (24 ref.)
Perioperative stimulation of residual cancer cells promotes local and distant recurrence of breast cancer. Reid SE, et al. **J Am Coll Surg** 1997 Sep;185(3):290–306 (143 ref.)
Chronic arm edema following breast cancer treatment. Stanton AW, et al. **Kidney Int Suppl** 1997 Jun;59:S76–81 (34 ref.)
[Frequency of lymphedema of the upper limb after treatment of breast cancer. Risk factors. Apropos of 683 cases] Ferrandez JC, et al. **Bull Cancer** 1996 Dec;83(12):989–95 (21 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Skin-sparing mastectomy with immediate breast reconstruction. Singletary SE, et al. **Adv Surg** 1996; 30:39–52 (45 ref.)
Treatment of breast cancer. Townsend CM Jr. **Clin Symp** 1997;49(1):1–32 (10 ref.)
Surgery for early and minimally invasive breast cancer. Graves TA, et al. **Curr Opin Oncol** 1996 Nov;8(6):468–77 (43 ref.)
Treatment options in surgical management of breast cancer. Edney JA. **Nebr Med J** 1996 Mar;81(3):51–7 (22 ref.)
[Respective role of conservative and radical treatment of breast cancers] Body G, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(4):350–6 (36 ref.) **(Fre)**
[Current surgical therapy of breast carcinoma and subsequent requirements for histopathologic diagnosis] Schönfelder M. **Zentralbl Chir** 1997;122(2):74–8 (17 ref.) (Eng. Abstr.) **(Ger)**
[Recent changes in breast cancer surgery] Kisida E. **Orv Hetil** 1996 May 26;137(21):1123–6 (26 ref.) (Eng. Abstr.) **(Hun)**

TRENDS

Future prospects in limited surgery for early breast cancer. Gazet JC. **Semin Surg Oncol** 1996 Jan–Feb;12(1):39–45 (22 ref.)

MASTECTOMY, MODIFIED RADICAL

Central nervous system infection due to Clostridium septicum: a case report and review of the literature. Cheng YT, et al. **Infection** 1997 May–Jun;25(3):171–4 (14 ref.)

MASTECTOMY, RADICAL

Second ipsilateral breast cancer after modified radical mastectomy: a case report and review of the literature. Miller LA, et al. **Surgery** 1997 Jan;121(1):109–11 (5 ref.)
[Pulmonary metastasis from breast cancer: a case report with 19-year disease-free interval] Kamiyoshihara M, et al. **Kyobu Geka** 1997 Mar;50(3):194–6 (12 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Acquired lymphangiectasis following mastectomy and radiation therapy--report of a case and review of the literature. Giannelli V, et al. **Cutis** 1996 Oct;58(4):276–8 (11 ref.)

MASTECTOMY, SEGMENTAL

Local resection and brachytherapy confined to the lumpectomy site for early breast cancer: a pilot study. Perera F, et al. **J Surg Oncol** 1997 Aug;65(4):263–7; discussion 267–8 (7 ref.)
Lumpectomy with and without radiation for early-stage breast cancer and DCIS. Marks LB, et al. **Oncology (Huntingt)** 1997 Sep;11(9):1361–8, 1371; discussion 1372, 1374 (68 ref.)
Breast conservation: predictors and treatment of local recurrence. Bethke KP. **Semin Surg Oncol** 1996 Sep–Oct; 12(5):332–8 (36 ref.)
Local recurrences after breast-conserving treatment: an open problem. Salvadori B. **Semin Surg Oncol** 1996 Jan–Feb; 12(1):46–52 (45 ref.)
The role of radiation therapy after local excision of invasive and noninvasive breast cancer. Marks LB, et al. **Surg Oncol Clin N Am** 1997 Apr;6(2):359–79 (86 ref.)
[Role of radiotherapy in the management of adenocarcinoma of the breast accessible to conservative surgery] Romestaing P, et al. **Cancer Radiother** 1997;1(1):14–28 (134 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Clinical and histologic determinations of adequate breast resection in breast-conserving surgery. A review. Noguchi M, et al. **Int Surg** 1996 Jul–Sep;81(3):309–15 (80 ref.)

MASTECTOMY, SUBCUTANEOUS

METHODS

[Subcutaneous mastectomy] Olbrisch RR. **Zentralbl Chir** 1997;122(2):86–90; discussion 90–1 (5 ref.) (Eng. Abstr.) **(Ger)**

MASTICATION

Chewing-induced visual impairment from a dumbbell dermoid cyst. Emerick GT, et al. **Ophthal Plast Reconstr Surg** 1997 Mar;13(1):57–61 (11 ref.)
[Myoarthropathies of the chewing system--more than a problem of dental medicine] Türp JC. **Dtsch Med Wochenschr** 1997 Apr 11;122(15):483–7 (40 ref.) **(Ger)**
[Rehabilitation of chewing function and after care in geriatrics] Müller N. **Fortschr Med** 1996 Aug 20; 114(22–23):270–2 (0 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Development of a mechanistic model of intake and chewing activities of sheep. Sauvant D, et al. **J Anim Sci** 1996 Nov; 74(11):2785–802 (90 ref.)

MASTIGOPHORA

CLASSIFICATION

Progress in understanding the phylogeny of flagellates. Sleigh MA. **Tsitologiia** 1995;37(11):985–1009 (82 ref.)

CYTOLOGY

[The cell biology of amebas and ameba-flagellates--parasites of man and animals] Sopina VA. **Tsitologiia** 1997; 39(4–5):361–86 (126 ref.) (Eng. Abstr.) **(Rus)**

MASTITIS

PATHOLOGY

Lymphocytic mastitis and fibrosis of the breast in long-standing insulin-dependent diabetics. A histopathologic study on diabetic mastopathy and report of ten cases. Hunfeld KP, et al. **Gen Diagn Pathol** 1997 Jul;143(1):49–58 (39 ref.)
[Mastitis. Classification, histopathology and clinical aspects] Bässler R. **Pathologe** 1997 Jan;18(1):27–36 (67 ref.) (Eng. Abstr.) **(Ger)**

MASTITIS, BOVINE

DRUG THERAPY

[Contribution to the treatment of acute bovine mastitis with

MASTITIS, BOVINE

cefquinome] Shpigel NY, et al. **Tierarztl Prax** 1997 May; 25(3):200–6 (9 ref.) (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

Streptococcus agalactiae mastitis: a review. Keefe GP. **Can Vet J** 1997 Jul;38(7):429–37 (94 ref.)

PREVENTION & CONTROL

Streptococcus agalactiae mastitis: a review. Keefe GP. **Can Vet J** 1997 Jul;38(7):429–37 (94 ref.)

Dietary vitamin E and selenium affect mastitis and milk quality. Smith KL, et al. **J Anim Sci** 1997 Jun;75(6):1659–65 (54 ref.)

MASTITIS, CYSTIC see **FIBROCYSTIC DISEASE OF BREAST**

MASTOCYTOMA, BENIGN see **MASTOCYTOSIS**

MASTOCYTOMA, MALIGNANT see **SARCOMA, MAST-CELL**

MASTOCYTOSIS

Mastocytosis: new understandings in cutaneous pathophysiology. Lazarus GS. **J Dermatol** 1996 Nov; 23(11):769–72 (15 ref.)

Mastocytosis. Golkar L, et al. **Lancet** 1997 May 10; 349(9062):1379–85 (80 ref.)

[Mastocytosis in children. Report of 3 cases] Gazca Aguilar A, et al. **Rev Alerg Mex** 1996 Jul–Aug;43(4):84–9 (33 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Intrahepatic cholestasis due to systemic mastocytosis: a case report and review of literature. Safyan EL, et al. **Am J Gastroenterol** 1997 Jul;92(7):1197–200 (14 ref.)

DIAGNOSIS

Intrahepatic cholestasis due to systemic mastocytosis: a case report and review of literature. Safyan EL, et al. **Am J Gastroenterol** 1997 Jul;92(7):1197–200 (14 ref.)

Mast cell disease. Schneider I, et al. **Cutis** 1997 Feb;59(2):63–6 (49 ref.)

GENETICS

C-kit mutations and mast cell disorders. A model of activating mutations of growth factor receptors. Pignon JM. **Hematol Cell Ther** 1997 Apr;39(2):114–6 (14 ref.)

Molecular genetics and development of mast cells: implications for molecular medicine. Födinger M, et al. **Mol Med Today** 1997 Mar;3(3):131–7 (31 ref.)

RADIOGRAPHY

[The computed tomographic findings on the lumbar spine in systemic mastocytosis] Lugmayr H, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Feb;166(2):162–3 (7 ref.) **(Ger)**

THERAPY

Mast cell disease. Schneider I, et al. **Cutis** 1997 Feb;59(2):63–6 (49 ref.)

MASTOCYTOSIS, BULLOUS see **URTICARIA PIGMENTOSA**

MASTOCYTOSIS, DIFFUSE CUTANEOUS see **URTICARIA PIGMENTOSA**

MASTOID

Cemento-ossifying fibroma of the petromastoid region: case report and review of the literature. Brademann G, et al. **J Laryngol Otol** 1997 Feb;111(2):152–5 (28 ref.)

[Osteoma of the mastoid: apropos of 2 cases] Guérin N, et al. **Rev Laryngol Otol Rhinol (Bord)** 1996;117(2):127–32 (30 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Hearing preservation in the removal of intracanalicular acoustic neuromas via the retrosigmoid approach. Rowed DW, et al. **J Neurosurg** 1997 Mar;86(3):456–61 (38 ref.)

MASTOIDITIS

COMPLICATIONS

Spontaneous drainage of an infratentorial extradural empyema: case report. Nathoo N, et al. **Br J Neurosurg** 1997 Feb;11(1):75–7 (6 ref.)

[Two pediatric cases of facial palsy caused by masked mastoiditis] Takamatsu I, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Jul;99(7):985–90 (20 ref.) (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

Otitis media and mastoiditis due to Mycobacterium fortuitum: case report, review of four cases, and a cautionary note. Plemmons RM, et al. **Clin Infect Dis** 1996 Jun;22(6):1105–6 (10 ref.)

[Mycobacterium avium otomastoiditis] de Juan Martín F, et al. **An Esp Pediatr** 1996 Dec;45(6):649–50 (11 ref.) **(Spa)**

MASTOMYS see **MURIDAE**

MASTURBATION

Orgasm without organisms: science or propaganda? Genuis SJ, et al. **Clin Pediatr (Phila)** 1996 Jan;35(1):10–7 (105 ref.)

PSYCHOLOGY

Masturbation in prepubescent children: a case report and review of the literature. Finkelstein E, et al. **Child Care Health Dev** 1996 Sep;22(5):323–6 (8 ref.)

MATCHED CASE-CONTROL STUDIES see **CASE-CONTROL STUDIES**

MATERIA MEDICA

see related
MEDICINE, TRADITIONAL

MATERIALS MANAGEMENT, HOSPITAL

ORGANIZATION & ADMINISTRATION

Estimating the capacity of warehouses. Cosgrave J. **Disasters** 1997 Jun;21(2):155–65 (31 ref.)

MATERIALS TESTING

The utility of superelasticity in medicine. Duerig TW, et al. **Biomed Mater Eng** 1996;6(4):255–66 (4 ref.)

Bioresorbable implants: applications in orthopaedic surgery. Blasier RD, et al. **Instr Course Lect** 1997;46:531–46 (64 ref.)

Embolic materials for endovascular treatment of cerebral lesions. Matsumaru Y, et al. **J Biomater Sci Polym Ed** 1997; 8(7):555–69 (81 ref.)

Intraocular lens implants: a biocompatibility review. Beasley AM, et al. **J Invest Surg** 1996 Nov–Dec;9(6):399–413 (88 ref.)

Evaluation of Ca–P coatings in animal experiments: importance of study design. Jansen JA, et al. **J Invest Surg** 1996 Nov–Dec;9(6):463–79 (26 ref.)

Bipolar leads for use with permanently implantable cardiac pacing systems: a review of limitations of traditional and coaxial configurations and the development and testing of new conductor, insulation, and electrode designs. Tyers GF, et al. **J Invest Surg** 1997 Jan–Apr;10(1–2):1–15 (80 ref.)

METHODS

Acoustic emission and nondestructive evaluation of biomaterials and tissues. Kohn DH. **Crit Rev Biomed Eng** 1995;23(3–4):221–306 (338 ref.)

Implantable hearing device performance measured by laser Doppler interferometry. Gan RZ, et al. **Ear Nose Throat J** 1997 May;76(5):297–9, 302, 305–9 (27 ref.)

Mechanical validation of whole bone composite femur models [see comments] Cristofolini L, et al. **J Biomech** 1996 Apr;29(4):525–35 (44 ref.) Comment in: J Biomech 1996 Sep;29(9):1241.

Wear assessment in bileaflet heart valves. Arru P, et al. **J Heart Valve Dis** 1996 Jun;5 Suppl 1:S133–43; discussion 144–8 (26 ref.)

Mechanical performance of pyrolytic carbon in prosthetic heart valve applications. Cao H. **J Heart Valve Dis** 1996 Jun;5 Suppl 1:S32–49 (58 ref.)

Fatigue and fracture of pyrolytic carbon: a damage- tolerant approach to structural integrity and life prediction in "ceramic" heart valve prostheses. Ritchie RO. **J Heart Valve Dis** 1996 Jun;5 Suppl 1:S9–31 (60 ref.)

Structural integrity assessment of heart valve prostheses: a damage tolerance analysis of the CarboMedics Prosthetic Heart Valve. Ryder JK, et al. **J Heart Valve Dis** 1996 Jun; 5 Suppl 1:S86–96 (32 ref.)

Methods of clinical evaluation of dental restorative materials. Knibbs PJ. **J Oral Rehabil** 1997 Feb;24(2):109–23 (174 ref.)

MATERNAL AGE

Pregnancy wastage and reproductive aging: the oocyte donation model. Sauer MV. **Curr Opin Obstet Gynecol** 1996 Jun;8(3):226–9 (42 ref.)

Estimating the risk of breast cancer in relation to the interval since last term pregnancy [see comments] Cummings P, et al. **Epidemiology** 1997 Sep;8(5):488–94 (18 ref.) Comment in: Epidemiology 1997 Sep;8(5):471–3.

Age at and time since: modeling temporal aspects of exposure [editorial; comment] Thompson WD. **Epidemiology** 1997 Sep;8(5):471–3 (11 ref.) Comment on: Epidemiology 1997 Sep;8(5):488–94.

Infertility risks associated with postponing pregnancy. Hasty LA, et al. **J Med Assoc Ga** 1997 Sep;86(3):228–9 (5 ref.)

[Prognostic role of age and base hormonal levels in infertility treatment] Rongières-Bertrand C, et al. **Contracept Fertil Sex** 1997 Mar;25(3):202–5 (23 ref.) **(Fre)**

MATERNAL AGE 35 AND OVER

see related
PREGNANCY, HIGH-RISK

Preimplantation diagnosis in older patients--but of course! [see comments] Munné S, et al. **Hum Reprod** 1997 Mar; 12(3):413–4 (11 ref.) Comment in: Hum Reprod 1997 Apr;12(4):870–1. Comment in: Hum Reprod 1997 Apr;12(4):871.

Preimplantation diagnosis in older patients, To biopsy or not to biopsy? Reubinoff B, et al. **Hum Reprod** 1996 Oct; 11(10):2071–5 (52 ref.)

In-vitro fertilization and embryo transfer in women aged 40 years and over. Marcus SF, et al. **Hum Reprod Update** 1996 Nov–Dec;2(6):459–68 (106 ref.)

[Pregnancy in women over forty years old] Dufour P, et al. **Contracept Fertil Sex** 1997 Jun;25(6):415–22 (49 ref.) **(Fre)**

MATERNAL BEHAVIOR

Integrative functions of lactational hormones in social behavior and stress management. Carter CS, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:164–74 (78 ref.)

Brain sexual dimorphism and sex differences in parental and other social behaviors. De Vries GJ, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:273–86 (89 ref.)

Oxytocin control of maternal behavior. Regulation by sex steroids and offspring stimuli. Pedersen CA. **Ann N Y Acad Sci** 1997 Jan 15;807:126–45 (65 ref.)

Offspring-induced nurturance: animal-human parallels. Stern JM. **Dev Psychobiol** 1997 Jul;31(1):19–37 (114 ref.)

[Expression of brain prolactin receptor mRNA and induction of maternal behavior] Sakaguchi K, et al. **Seikagaku** 1997 Apr;69(4):247–50 (15 ref.) **(Jpn)**

DRUG EFFECTS

On mouse pups and their lactating dams: behavioral consequences of early exposure to oxazepam and interacting factors. Laviola G. **Pharmacol Biochem Behav** 1996 Dec;55(4):459–74 (130 ref.)

PHYSIOLOGY

Neuroanatomical circuitry for mammalian maternal behavior. Numan M, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:101–25 (71 ref.)

Gene targeting approaches to neuroendocrinology: oxytocin, maternal behavior, and affiliation. Young LJ, et al. **Horm Behav** 1997 Jun;31(3):221–31 (34 ref.)

MATERNAL-CHILD HEALTH CENTERS

Sources of information on women's and infants' health. Lee MA. **J Nurse Midwifery** 1996 Sep–Oct;41(5):393–400 (63 ref.)

MATERNAL-CHILD NURSING

Ethical dilemmas in maternal–fetal research. Sams L. **MCN Am J Matern Child Nurs** 1997 Mar–Apr;22(2):67–71 (6 ref.)

METHODS

How NIC describes MCH nursing. Eganhouse DJ, et al. **MCN Am J Matern Child Nurs** 1996 Sep–Oct;21(5):247–52 (22 ref.)

Caring for the pregnant woman with sickle cell disease. Montgomery KS. **MCN Am J Matern Child Nurs** 1996 Sep–Oct;21(5):224–8 (10 ref.)

ORGANIZATION & ADMINISTRATION

Case management and clinical paths: strategies to support the perinatal experience. Bower KA. **J Obstet Gynecol Neonatal Nurs** 1997 May–Jun; 26(3):329–33 (6 ref.)

Patient-focused models of care. Pence M. **J Obstet Gynecol Neonatal Nurs** 1997 May–Jun;26(3):320–6 (18 ref.)

The high-touch paradigm: a 21st century model for maternal-child nursing. With a brief glimpse into nursing on the starship Nightingale. Kowalski K, et al. **MCN Am J Matern Child Nurs** 1996 Jan–Feb;21(1):43–50 (10 ref.)

STANDARDS

A typology of the potential outcomes of maternal-child home visits: a literature analysis. Byrd ME. **Public Health Nurs** 1997 Feb;14(1):3–11 (34 ref.)

MATERNAL DEPRIVATION

Brain–corticosteroid hormone dialogue: slow and persistent. de Kloet ER, et al. **Cell Mol Neurobiol** 1996 Jun; 16(3):345–56 (52 ref.)

On the nature and consequences of early loss. Hofer MA. **Psychosom Med** 1996 Nov–Dec;58(6):570–81 (50 ref.)

MATERNAL EXPOSURE

see related
MATERNAL-FETAL EXCHANGE
PATERNAL EXPOSURE

Neurodevelopmental test selection, administration, and performance in the main Seychelles child development study. Davidson PW, et al. **Neurotoxicology** 1995 Winter; 16(4):665–76 (22 ref.)

ADVERSE EFFECTS

Adverse consequences of prenatal illicit drug exposure. Woods JR Jr. **Curr Opin Obstet Gynecol** 1996 Dec; 8(6):403–11 (71 ref.)

MATERNAL-FETAL EXCHANGE

see related
ABNORMALITIES, DRUG-INDUCED

Prenatal cocaine exposure and mother-infant interaction: implications for occupational therapy intervention. Miller H. **Am J Occup Ther** 1997 Feb;51(2):119–31 (100 ref.)

Detection of intrauterine illicit drug exposure by newborn drug testing.National Academy of Clinical Biochemistry. Kwong TC, et al. **Clin Chem** 1997 Jan;43(1):235–42 (85 ref.)

Sexual and perinatal transmission of hepatitis C. Dienstag JL. **Hepatology** 1997 Sep;26(3 Suppl 1):66S–70S (41 ref.)

Viewing AIDS from a glycobiological perspective: potential linkages to the human fetoembryonic defence system hypothesis. Clark GF, et al. **Mol Hum Reprod** 1997 Jan; 3(1):5–13 (75 ref.)

Culture of syncytiotrophoblast for the study of human placental transfer. Part I: Isolation and purification of cytotrophoblast. Bloxam DL, et al. **Placenta** 1997 Mar–Apr;18(2–3):93–8 (61 ref.)

Culture of syncytiotrophoblast for the study of human placental transfer. Part II: Production, culture and use of syncytiotrophoblast. Bloxam DL, et al. **Placenta** 1997 Mar–Apr;18(2–3):99–108 (103 ref.)

Growth factors, proteases and protease inhibitors in the maternal–fetal dialogue. Lala PK, et al. **Placenta** 1996 Nov; 17(8):545–55 (135 ref.)

Cardiovascular effects of cocaine during pregnancy. Chao CR. **Semin Perinatol** 1996 Apr;20(2):107–14 (48 ref.)

The maternal and fetal physiologic effects of nicotine. Lambers DS, et al. **Semin Perinatol** 1996 Apr;20(2):115–26 (47 ref.)

Glucocorticoids, feto-placental 11 beta-hydroxysteroid dehydrogenase type 2, and the early life origins of adult disease. Seckl JR. **Steroids** 1997 Jan;62(1):89–94 (88 ref.)

DRUG EFFECTS

Pediatric HIV infection. Wiznia AA, et al.
Med Clin North Am 1996 Nov;80(6):1309–36 (206 ref.)

Maternal–fetal mercury transport and fetal methylmercury poisoning. Hamada R, et al. **Met Ions Biol Syst** 1997; 34:405–20 (37 ref.)

Placental transfer of selected substances of abuse. Little BB, et al. **Semin Perinatol** 1996 Apr;20(2):147–53 (52 ref.)

GENETICS

Altercation of generations: genetic conflicts of pregnancy. Haig D. **Am J Reprod Immunol** 1996 Mar;35(3):226–32 (31 ref.)

IMMUNOLOGY

Maternofetal interaction and allergy. Warner JA, et al.
Allergy 1996 Jul;51(7):447–51 (35 ref.)

Evolution of the fetal–maternal immunological relationship. Loke YW, et al. **Am J Reprod Immunol** 1996 Mar; 35(3):256–7 (1 ref.)

Immunodystrophism, T cells, cytokines, and pregnancy failure. Raghupathy R, et al. **Am J Reprod Immunol** 1996 Apr;35(4):291–6 (58 ref.)

Human placental Fc gamma-binding proteins in the maternofetal transfer of IgG. Kristoffersen EK.
APMIS Suppl 1996;64:5–36 (375 ref.)

The structural basis of maternal–fetal immune interactions in the human placenta. Redline RW.
Curr Top Microbiol Immunol 1997;222:25–44 (122 ref.)

Regulation of fetal allograft survival by a hormone-controlled Th1- and Th2-type cytokines. Piccinni MP, et al. **Immunol Res** 1996;15(2):141–50 (54 ref.)

Immunological interaction between the mother and her infant in relation to the development of food allergy. Björkstén B. **Monogr Allergy** 1996;32:16–24 (40 ref.)

The maturation of the immune system. Hanson LA, et al. **Monogr Allergy** 1996;32:10–5 (23 ref.)

Prenatal sensitisation. Warner JA, et al.
Pediatr Allergy Immunol 1996;7(9 Suppl):98–101 (39 ref.)

The mother–child union: the case of missing-self and protection of the fetus [comment] Yokoyama WM.
Proc Natl Acad Sci U S A 1997 Jun 10;94(12):5998–6000 (52 ref.) Comment on: Proc Natl Acad Sci U S A 1997 May 13;94(10):5249–54.

PHYSIOLOGY

The role of the placenta in fetal nutrition and growth [see comments] Garnica AD, et al. **J Am Coll Nutr** 1996 Jun; 15(3):206–22 (203 ref.) Comment in: J Am Coll Nutr 1996 Jun;15(3):197–8.

Screening for Down's syndrome. Chard T, et al.
J Perinat Med 1995;23(6):421–36 (170 ref.)

Placental transfer of inorganic ions and water. Stulc J.
Physiol Rev 1997 Jul;77(3):805–36 (297 ref.)

Infectious causes of hydrops fetalis. Barron SD, et al.
Semin Perinatol 1995 Dec;19(6):493–501 (94 ref.)

Growth factors and cytokines in endometrium, embryonic development, and maternal: embryonic interactions. Tazuke SI, et al. **Semin Reprod Endocrinol** 1996 Aug; 14(3):231–45 (162 ref.)

[Animal experiment and clinical studies of the significance of carnitine for energy metabolism in pregnant patients and the fetus during the pre- and perinatal period] Lohninger A, et al. **Wien Klin Wochenschr** 1996;108(2):33–9 (64 ref.) (Eng. Abstr.) **(Ger)**

MATERNAL HEALTH see **MATERNAL WELFARE**

MATERNAL HEALTH SERVICES

Methodological issues of randomized controlled trials for the evaluation of reproductive health interventions. Villar J, et al. **Prev Med** 1996 May–Jun;25(3):365–75 (53 ref.)

ECONOMICS

Medicaid and private insurance: evidence and implications [see comments] Cutler DM, et al.
Health Aff (Millwood) 1997 Jan–Feb;16(1):194–200 (13 ref.) Comment in: Health Aff (Millwood) 1997 Jan–Feb;16(1):201–3. Comment in: Health Aff (Millwood) 1997 Jan–Feb;16(1):204–6.

LEGISLATION & JURISPRUDENCE

State actions on reproductive health issues in 1996. Sollom T. **Fam Plann Perspect** 1997 Jan–Feb;29(1):35–40 (4 ref.)

ORGANIZATION & ADMINISTRATION

Choosing the choices in the USA: examples in the maternity area. Mander R. **J Adv Nurs** 1997 Jun;25(6):1192–7 (24 ref.)

Maternal and child health services in India with special focus on perinatal services. Singh M, et al. **J Perinatol** 1997 Jan–Feb;17(1):65–9 (28 ref.)

The implementation of integrated mother and child health and family planning services. Walley J. **Trop Doct** 1997 Apr;27(2):69–72 (6 ref.)

STANDARDS

Safe motherhood and district health systems. Tarimo E.
Eur J Obstet Gynecol Reprod Biol 1996 Oct;69(1):5–10 (18 ref.)

Primary reproductive health care in Tanzania [see comments] Walraven GE. **Eur J Obstet Gynecol Reprod Biol** 1996 Oct; 69(1):41–5 (19 ref.) Comment in: Eur J Obstet Gynecol Reprod Biol 1996 Oct;69(1):3–4.

MATERNAL MORTALITY

Maternal mortality in different Pakistani sites: ratios, clinical causes and determinants. Fikree FF, et al.
Acta Obstet Gynecol Scand 1997 Aug;76(7):637–45 (19 ref.)

Pregnancy-associated deaths in Finland 1987–1994--definition problems and benefits of record linkage. Gissler M, et al. **Acta Obstet Gynecol Scand** 1997 Aug;76(7):651–7 (32 ref.)

Underreporting and misclassification of maternal mortality in Taiwan. Kao S, et al. **Acta Obstet Gynecol Scand** 1997 Aug;76(7):629–36 (33 ref.)

Reduction of maternal and perinatal mortality in rural and peri-urban settings: what works? Kwast BE.
Eur J Obstet Gynecol Reprod Biol 1996 Oct;69(1):47–53 (22 ref.)

Safe motherhood and district health systems. Tarimo E.
Eur J Obstet Gynecol Reprod Biol 1996 Oct;69(1):5–10 (18 ref.)

The postpartum period: the key to maternal mortality. Li XF, et al. **Int J Gynaecol Obstet** 1996 Jul;54(1):1–10 (20 ref.)

Reproduction: a global nutritional challenge. Goldberg GR.
Proc Nutr Soc 1997 Mar;56(1B):319–33 (58 ref.)

[New perspectives for an old problem: premature labor] Barrón Vallejo J, et al. **Ginecol Obstet Mex** 1997 Aug; 65:326–31 (34 ref.) (Eng. Abstr.) **(Spa)**

MATERNAL PATTERNS OF CARE see **MATERNAL BEHAVIOR**

MATERNAL WELFARE

see related
MATERNAL HEALTH SERVICES

Breastfeeding and health in the Western world [see comments] Campbell C. **Br J Gen Pract** 1996 Oct; 46(411):613–7 (66 ref.) Comment in: Br J Gen Pract 1997 Jan;47(414):54. Comment in: Br J Gen Pract 1997 Apr;47(417):254–5.

MATERNALLY-ACQUIRED IMMUNITY see **IMMUNITY, MATERNALLY-ACQUIRED**

MATERNITY NURSING see **MATERNAL-CHILD NURSING**

MATHEMATICAL COMPUTING

Population genetics of tumours. Bodmer WF, et al.
Ciba Found Symp 1996;197:181–9; discussion 189–93 (21 ref.)

Methods for analysis of DNA fragment distributions on pulsed field gel electrophoretic gels. Cedervall B, et al.
Electrophoresis 1996 Jun;17(6):1080–6 (63 ref.)

Mathematical analysis of DNA fragment distribution models used with pulsed-field gel electrophoresis for DNA double-strand break calculations. Radivoyevitch T, et al.
Electrophoresis 1996 Jun;17(6):1087–93 (12 ref.)

Time series analysis and its relationship with longitudinal analysis. Molenaar PC. **Int J Sports Med** 1997 Jul;18 Suppl 3:S232–7 (25 ref.)

Psychological subtypes of erectile dysfunction: results of statistically analyses and clinical practice. Hartmann U.
World J Urol 1997;15(1):56–64 (12 ref.)

[NIHS information and computing infrastructure (NICI)] Nakata K, et al. **Eisei Shikenjo Hokoku** 1996;(114):53–61 (8 ref.) (Eng. Abstr.) **(Jpn)**

MATHEMATICS

Quantitative and conceptual contributions of mathematical modeling to current views on vitamin A metabolism, biochemistry, and nutrition. Green MH, et al.
Adv Food Nutr Res 1996;40:3–24 (29 ref.)

Mathematical modeling in nutrition: constructing a physiologic compartmental model of the dynamics of beta-carotene metabolism. Novotny JA, et al.
Adv Food Nutr Res 1996;40:25–54 (39 ref.)

Graph theoretical methods for physiologically based modeling. Zhang H, et al. **Adv Food Nutr Res** 1996; 40:339–52 (8 ref.)

Mathematical calculations in transfusion medicine. Walker RH. **Clin Lab Med** 1996 Dec;16(4):895–906 (10 ref.)

Nuclear medicine and mathematics [see comments] Pedroso de Lima JJ. **Eur J Nucl Med** 1996 Jun;23(6):705–19 (36 ref.) Comment in: Eur J Nucl Med 1997 Feb;24(2):234.

Mathematical modelling of avascular-tumour growth. Ward JP, et al. **IMA J Math Appl Med Biol** 1997 Mar;14(1):39–69 (50 ref.)

Two centuries of conflict–collaboration between medicine and mathematics. Feinstein AR. **J Clin Epidemiol** 1996 Dec; 49(12):1339–43 (8 ref.)

The spirit of D'arcy Thompson dwells in empirical morphospace. Stone JR. **Math Biosci** 1997 May; 142(1):13–30 (55 ref.)

Creating phyllotaxis: the stack-and-drag model. Van Der Linden FM. **Math Biosci** 1996 Apr 1;133(1):21–50 (63 ref.)

Meridional profiles of variance–covariance of symmetric dioptric power: classes of variation that are uniform across the meridians of the eye. Harris WF. **Optom Vis Sci** 1997 Jun;74(6):397–413 (44 ref.)

Invariance of ophthalmic properties under spherocylindrical transposition. Harris WF. **Optom Vis Sci** 1997 Jun; 74(6):459–62 (9 ref.)

Clinical refraction in three-dimensional dioptric space revisited [see comments] Raasch T. **Optom Vis Sci** 1997 Jun;74(6):376–80 (28 ref.) Comment in: Optom Vis Sci 1997 Jun;74(6):339–41.

Mathematical modelling of nitrogen flow in growing pigs and lactating sows. Pettigrew JE. **Proc Nutr Soc** 1997 Jul; 56(2):645–56 (27 ref.)

MATING BEHAVIOR, ANIMAL see **SEX BEHAVIOR, ANIMAL**

MATING-TYPE GENES see **GENES, FUNGAL**

MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY see **SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION**

MATRIX, EXTRACELLULAR see **EXTRACELLULAR MATRIX**

MATRIX METALLOPROTEINASE 3 see **STROMELYSIN 1**

MATTRESSES see **BEDS**

MATURATION-PROMOTING FACTOR

see related
CYCLINS

PHARMACOLOGY

Nuclear transplantation in mammals: remodelling of transplanted nuclei under the influence of maturation promoting factor. Fulka J Jr, et al. **Bioessays** 1996 Oct; 18(10):835–40 (49 ref.)

MATURITY-ONSET DIABETES MELLITUS see **DIABETES MELLITUS, NON-INSULIN-DEPENDENT**

MAXILLA

see related
MAXILLOFACIAL DEVELOPMENT

The impacted maxillary canine. Further observations on aetiology, radiographic localization, prevention/interception of impaction, and when to suspect impaction. Jacobs SG. **Aust Dent J** 1996 Oct;41(5):310–6 (15 ref.)

ABNORMALITIES

Congenital bony syngnathia: a proposed classification. Dawson KH, et al. **Cleft Palate Craniofac J** 1997 Mar; 34(2):141–6 (26 ref.)

Secondary management of congenital and acquired craniomaxillofacial deformities. Individualized treatment planning. Cohen SR, et al. **Clin Plast Surg** 1997 Jul; 24(3):475–88 (13 ref.)

GROWTH & DEVELOPMENT

Maxillary development revisited: relevance to the orthopaedic treatment of Class III malocclusions. Delaire J. **Eur J Orthod** 1997 Jun;19(3):289–311 (49 ref.)

SURGERY

Surgically-assisted maxillary expansion. Woods M, et al. **Aust Dent J** 1997 Feb;42(1):38–42 (25 ref.)

Stability of orthognathic surgery: a review of rigid fixation. Van Sickels JE, et al. **Br J Oral Maxillofac Surg** 1996 Aug; 34(4):279–85 (62 ref.)

Secondary management of congenital and acquired craniomaxillofacial deformities. Individualized treatment planning. Cohen SR, et al. **Clin Plast Surg** 1997 Jul; 24(3):475–88 (13 ref.)

Adverse outcomes in orthognathic surgery and management of residual problems. Schendel SA, et al. **Clin Plast Surg** 1997 Jul;24(3):489–505 (63 ref.)

Maxillectomy. McGuirt WF. **Otolaryngol Clin North Am** 1995 Dec;28(6):1175–89 (31 ref.)

MAXILLARY ANTRUM see **MAXILLARY SINUS**

MAXILLARY ARTERY

ABNORMALITIES

High-flow vascular malformations: literature review and case report. Kula K, et al. **Pediatr Dent** 1996 Jul–Aug; 18(4):322–7 (30 ref.)

MAXILLARY DISEASES

PATHOLOGY

[Mucoepidermoid carcinoma and mucoepidermoid cyst of the jaw bones in the same patient. A clinical case and discussion of their histogenesis] Tanda F, et al. **Minerva Stomatol** 1996 Dec;45(12):599–603 (9 ref.) (Eng. Abstr.) **(Ita)**

MAXILLARY NEOPLASMS

DIAGNOSIS

[Mixoma of maxilla in a child, report of case and review of the literature] Uvo SA, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1996 May–Jun; 51(3):99–102 (22 ref.) (Eng. Abstr.) **(Por)**

ETIOLOGY

Malignant fibrous histiocytoma after radiation for ameloblastoma of the maxilla. Li KK, et al. **J Oral Maxillofac Surg** 1997 Jan;55(1):85–8 (19 ref.)

PATHOLOGY

Central epithelial odontogenic ghost cell tumour. A case report. Junquera LM, et al. **Ann Otolaryngol Chir Cervicofac** 1997;114(3):76–9 (24 ref.)

Atypical ameloblastoma: report of 3 cases and a review of the literature. Ameerally P, et al. **Br J Oral Maxillofac Surg** 1996 Jun;34(3):235–9 (35 ref.)

Osteogenic sarcoma of the jaws: factors influencing prognosis. August M, et al. **Int J Oral Maxillofac Surg** 1997 Jun;26(3):198–204 (24 ref.)

Clear cell ameloblastoma or odontogenic carcinoma. A case report. Marí A, et al. **J Craniomaxillofac Surg** 1995 Dec; 23(6):387–90 (18 ref.)

Maxillary chondroblastic sarcoma: presentation of two cases and a literature review. Altuwairgi O, et al. **J Oral Maxillofac Surg** 1996 Nov;54(11):1357–64 (65 ref.)

[Mucoepidermoid carcinoma and mucoepidermoid cyst of the jaw bones in the same patient. A clinical case and discussion of their histogenesis] Tanda F, et al. **Minerva Stomatol** 1996 Dec;45(12):599–603 (9 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Oncocytomas of the upper jaw. Corbridge RJ, et al. **Head Neck** 1996 Jul–Aug;18(4):374–80 (46 ref.)

Surgical treatment of central epithelial ghost cell tumor. Limongelli WA, et al. **N Y State Dent J** 1997 Aug–Sep; 63(7):42–6 (9 ref.)

Maxillectomy. McGuirt WF. **Otolaryngol Clin North Am** 1995 Dec;28(6):1175–89 (31 ref.)

MAXILLARY SINUS

Full intrusion of a tooth after facial trauma. Tung TC, et al. **J Trauma** 1997 Aug;43(2):357–9 (7 ref.)

ABNORMALITIES

Bilateral sinonasal papillomas in aplastic maxillary sinuses. Tsue TT, et al. **Am J Otolaryngol** 1997 Jul–Aug;18(4):263–8 (36 ref.)

MICROBIOLOGY

Effects of viral and bacterial infection on nasal and sinus mucosa. van Cauwenberge P, et al. **Acta Otolaryngol (Stockh)** 1996 Mar;116(2):316–21 (25 ref.)

SURGERY

Pneumosinus dilatans of the maxillary sinus: a report of two cases. Breidahl AF, et al. **Br J Plast Surg** 1997 Jan; 50(1):33–9 (22 ref.)

Maxillectomy. McGuirt WF. **Otolaryngol Clin North Am** 1995 Dec;28(6):1175–89 (31 ref.)

Endonasal surgery for nasal wall tumors. Rice DH. **Otolaryngol Clin North Am** 1995 Dec;28(6):1117–25 (26 ref.)

Lateral rhinotomy and medial maxillectomy. Weisman R. **Otolaryngol Clin North Am** 1995 Dec;28(6):1145–56 (23 ref.)

VIROLOGY

Effects of viral and bacterial infection on nasal and sinus mucosa. van Cauwenberge P, et al. **Acta Otolaryngol (Stockh)** 1996 Mar;116(2):316–21 (25 ref.)

MAXILLARY SINUS NEOPLASMS

PATHOLOGY

Haemangioma of the maxillary sinus. Raboso E, et al. **J Laryngol Otol** 1997 Jul;111(7):638–40 (11 ref.)

RADIOTHERAPY

Is prophylactic neck irradiation indicated in patients with squamous cell carcinoma of the maxillary sinus? Paulino AC, et al. **Int J Radiat Oncol Biol Phys** 1997 Sep 1; 39(2):283–9 (25 ref.)

SURGERY

Maxillectomy. McGuirt WF. **Otolaryngol Clin North Am** 1995 Dec;28(6):1175–89 (31 ref.)

Endonasal surgery for nasal wall tumors. Rice DH. **Otolaryngol Clin North Am** 1995 Dec;28(6):1117–25 (26 ref.)

Lateral rhinotomy and medial maxillectomy. Weisman R. **Otolaryngol Clin North Am** 1995 Dec;28(6):1145–56 (23 ref.)

MAXILLARY SINUSITIS

COMPLICATIONS

Asymptomatic posterior orbital cellulitis resulting from ethmoid/maxillary sinusitis. Filips RF, et al. **J Am Optom Assoc** 1997 Jan;68(1):55–60 (18 ref.)

Orbital complications of sinusitis. Jabor MA, et al. **J La State Med Soc** 1997 Apr;149(4):105–8 (13 ref.)

[Mucormycosis-actinomycosis and caseous dental sinusitis associated with sinusal foreign body] Braun JJ, et al. **Ann Otolaryngol Chir Cervicofac** 1996;113(5):289–93 (22 ref.) (Eng. Abstr.) **(Fre)**

MAXILLOFACIAL DEVELOPMENT

see related
CEPHALOMETRY
VERTICAL DIMENSION

Orthopedics in orthodontics: Part I, Fiction or reality--a review of the literature [see comments] Aelbers CM, et al. **Am J Orthod Dentofacial Orthop** 1996 Nov;110(5):513–9 (101 ref.) Comment in: Am J Orthod Dentofacial Orthop 1997 Jun;111(6):16A.

Development, maturation, and aging of the alveolar bone. New insights. Zernik JH, et al. **Dent Clin North Am** 1997 Jan;41(1):1–15 (41 ref.)

Facial growth and the need for orthognathic surgery after cleft palate repair: literature review and report of 28 cases. DeLuke DM, et al. **J Oral Maxillofac Surg** 1997 Jul; 55(7):694–7; discussion 697–8 (20 ref.)

PHYSIOLOGY

Some methods of assessing postnatal craniofaciodental growth: a retrospective of personal research. Sarnat BG. **Cleft Palate Craniofac J** 1997 Mar;34(2):159–72 (57 ref.)

Craniofacial development: knockout mice take one on the chin. Richman J, et al. **Curr Biol** 1996 Apr 1;6(4):364–7 (23 ref.)

MAXILLOFACIAL INJURIES

DIAGNOSIS

Imaging of maxillo-facial trauma. Hermans R, et al. **J Belge Radiol** 1997 Feb;80(1):25–9 (8 ref.)

EPIDEMIOLOGY

Maxillofacial injuries in a group of South Africans under 18 years of age. Bamjee Y, et al. **Br J Oral Maxillofac Surg** 1996 Aug;34(4):298–302 (43 ref.)

PREVENTION & CONTROL

Athletic mouth guards prevent orofacial injuries. Woodmansey KF. **J Am Coll Health** 1997 Jan;45(4):179–82 (26 ref.)

RADIOGRAPHY

Imaging of facial trauma. Daffner RH. **Curr Probl Diagn Radiol** 1997 Jul–Aug;26(4):153–84 (21 ref.)

THERAPY

Airway managements of patients with maxillofacial trauma [published erratum appears in Acta Anaesthesiol Sin 1997 Mar;35(1):59] King HK. **Acta Anaesthesiol Sin** 1996 Dec; 34(4):213–20 (51 ref.)

MAXIMAL EXPIRATORY FLOW-VOLUME CURVES

[Flow-volume curve] Huang J, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:15–8 (10 ref.) **(Jpn)**

MAXIMUM ALLOWABLE CONCENTRATION see **MAXIMUM PERMISSIBLE EXPOSURE LEVEL**

MAXIMUM LIKELIHOOD ESTIMATES see **LIKELIHOOD FUNCTIONS**

MAXIMUM PERMISSIBLE EXPOSURE LEVEL

Interpretation and use of occupational exposure limits for chronic disease agents. Hewett P. **Occup Med** 1996 Jul–Sep; 11(3):561–90 (125 ref.)

MAY APPLE see **PODOPHYLLUM**

MAZE LEARNING

IL1 beta impairs relational but not procedural rodent learning in a water maze task. Gibertini M. **Adv Exp Med Biol** 1996; 402:207–17 (53 ref.)

DRUG EFFECTS

Effects of trophic factors on the CNS cholinergic phenotype. Cuello AC. **Prog Brain Res** 1996;109:347–58 (59 ref.)

PHYSIOLOGY

Maze procedures: the radial-arm and water maze compared. Hodges H. **Brain Res Cogn Brain Res** 1996 Jun; 3(3–4):167–81 (62 ref.)

5-HT systems and anxiety: multiple mechanisms in the elevated X-maze. McCreary AC, et al. **Pol J Pharmacol** 1996 Jan–Feb;48(1):1–12 (87 ref.)

The neuroscience of spatial navigation: focus on behavior yields advances. Cain DP, et al. **Rev Neurosci** 1996 Jul–Sep; 7(3):215–31 (140 ref.)

MCARDLE'S DISEASE see **GLYCOGEN STORAGE DISEASE TYPE V**

MCCUNE-ALBRIGHT SYNDROME see **FIBROUS DYSPLASIA, POLYOSTOTIC**

MCGILL PAIN QUESTIONNAIRE see **PAIN MEASUREMENT**

MCLS see **MUCOCUTANEOUS LYMPH NODE SYNDROME**

MCNAUGHTON RULE see **INSANITY DEFENSE**

MCP-1 see **MONOCYTE CHEMOATTRACTANT PROTEIN-1**

MDA see **3,4-METHYLENEDIOXYAMPHETAMINE**

MDMA see **N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE**

MDR GENES see **GENES, MDR**

MDR1 GENE see **GENES, MDR**

MDR1 PROTEIN see **P-GLYCOPROTEIN**

MEALS ON WHEELS see **FOOD SERVICES**

MEASLES

Clinical problems in measles case management. Hussey GD, et al. **Ann Trop Paediatr** 1996 Dec;16(4):307–17 (69 ref.)

COMPLICATIONS

Perinatal exposure to measles virus and the risk of inflammatory bowel disease. Lione A, et al. **Reprod Toxicol** 1997 Sep–Oct;11(5):647–52 (55 ref.)

[Optic neuritis and measles infection] Inokuchi N, et al. **Nippon Rinsho** 1997 Apr;55(4):861–4 (6 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

New aspects of exanthematous diseases of childhood. Resnick SD. **Dermatol Clin** 1997 Apr;15(2):257–66 (95 ref.)

EPIDEMIOLOGY

The impact of immunization control activities on measles outbreaks in middle and low income countries. Aylward RB, et al. **Int J Epidemiol** 1997 Jun;26(3):662–9 (68 ref.)

Measles vaccine efficacy in India: a review. Singh J, et al. **J Commun Dis** 1997 Mar;29(1):47–56 (45 ref.)

Appropriate season for measles immunisation campaign in India. Singh J, et al. **J Commun Dis** 1995 Sep;27(3):164–9 (44 ref.)

Epidemiological considerations of the age distribution of measles in India: a review. Singh J, et al. **J Trop Pediatr** 1997 Apr;43(2):111–5 (52 ref.)

IMMUNOLOGY

Vaccination in pulses: a strategy for global eradication of measles and polio? Nokes DJ, et al. **Trends Microbiol** 1997 Jan;5(1):14–9 (37 ref.)

Suppression of T-cell immunity after measles infection: is the puzzle solved? Salmi AA. **Trends Microbiol** 1997 Mar; 5(3):85–6 (12 ref.)

[Measles virus infection and immunosuppression] Yanagi Y. **Uirusu** 1995 Dec;45(2):117–23 (29 ref.) **(Jpn)**

[Do infections reduce the development of allergy? Do measles reduce the risk of allergic disease?] Løvik M. **Tidsskr Nor Laegeforen** 1997 Feb 20;117(5):688–90 (37 ref.) (Eng. Abstr.) **(Nor)**

PREVENTION & CONTROL

The impact of immunization control activities on measles outbreaks in middle and low income countries. Aylward RB, et al. **Int J Epidemiol** 1997 Jun;26(3):662–9 (68 ref.)

Measles vaccine efficacy in India: a review. Singh J, et al. **J Commun Dis** 1997 Mar;29(1):47–56 (45 ref.)

Appropriate season for measles immunisation campaign in India. Singh J, et al. **J Commun Dis** 1995 Sep;27(3):164–9 (44 ref.)

Vaccination in pulses: a strategy for global eradication of measles and polio? Nokes DJ, et al. **Trends Microbiol** 1997 Jan;5(1):14–9 (37 ref.)

TRANSMISSION

Dynamical complexity in age-structured models of the transmission of the measles virus: epidemiological implications at high levels of vaccine uptake. Ferguson NM, et al. **Math Biosci** 1996 Dec;138(2):101–30 (52 ref.)

MEASLES, GERMAN see **RUBELLA**

MEASLES VACCINE

CHEMISTRY

Thermostability of poliovirus and measles vaccines. Melnick JL. **Dev Biol Stand** 1996;87:155–60 (20 ref.)

IMMUNOLOGY

Measles vaccine efficacy in India: a review. Singh J, et al. **J Commun Dis** 1997 Mar;29(1):47–56 (45 ref.)

STANDARDS

Measles vaccine efficacy in India: a review. Singh J, et al. **J Commun Dis** 1997 Mar;29(1):47–56 (45 ref.)

MEASLES VIRUS

Perinatal exposure to measles virus and the risk of inflammatory bowel disease. Lione A, et al. **Reprod Toxicol** 1997 Sep–Oct;11(5):647–52 (55 ref.)

[Measles virus infection and immunosuppression] Yanagi Y. **Uirusu** 1995 Dec;45(2):117–23 (29 ref.) **(Jpn)**

DRUG EFFECTS

Thermostability of poliovirus and measles vaccines. Melnick JL. **Dev Biol Stand** 1996;87:155–60 (20 ref.)

IMMUNOLOGY

Interactions of viruses with dendritic cells: a double-edged sword. Bhardwaj N. **J Exp Med** 1997 Sep 15;186(6):795–9 (36 ref.)

[Measles virus receptor CD46] Yanagi Y. **Uirusu** 1995 Dec; 45(2):159–64 (21 ref.) **(Jpn)**

METABOLISM

CD46, a complement regulatory protein/measles virus receptor, and its relation to hematological disorders. Seya T. **Int J Hematol** 1996 Aug;64(2):101–9 (38 ref.)

Is CD46 the cellular receptor for measles virus? Buckland R, et al. **Virus Res** 1997 Apr;48(1):1–9 (44 ref.)

PATHOGENICITY

Interactions of viruses with dendritic cells: a double-edged sword. Bhardwaj N. **J Exp Med** 1997 Sep 15;186(6):795–9 (36 ref.)

PHYSIOLOGY

Molecular and cellular aspects of measles virus persistence in the CNS. ter Meulen V. **J Neurovirol** 1997 May;3 Suppl 1:S3–5 (25 ref.)

Virus–lymphoid cell interactions [comment] Oldstone MB. **Proc Natl Acad Sci U S A** 1996 Nov 12;93(23):12756–8 (48 ref.) Comment on: Proc Natl Acad Sci U S A 1996 Nov 12;93(23):13125–30. Comment on: Proc Natl Acad Sci U S A 1996 Nov 12;93(23):13194–9.

MEAT

Bovine spongiform encephalopathy--the beginning of the end? [see comments] Taylor DM. **Br Vet J** 1996 Sep; 152(5):501–18 (75 ref.) Comment in: Br Vet J 1996 Sep;152(5):491–2.

Enzymatic studies of the activation of heterocyclic food mutagens in man. Boobis AR, et al. **Princess Takamatsu Symp** 1995;23:134–44 (38 ref.)

Factors affecting the formation and yield of heterocyclic amines. Skog K, et al. **Princess Takamatsu Symp** 1995; 23:9–19 (23 ref.)

Metabolism of heterocyclic aromatic amines and strategies of human biomonitoring. Turesky RJ, et al. **Princess Takamatsu Symp** 1995;23:59–68 (30 ref.)

ADVERSE EFFECTS

Interplay between heterocyclic amines in cooked meat and metabolic phenotype in the etiology of colon cancer. Vineis P, et al. **Cancer Causes Control** 1996 Jul;7(4):479–86 (53 ref.)

ANALYSIS

Heterocyclic amines: evaluation of their role in diet associated human cancer. Gooderham NJ, et al. **Br J Clin Pharmacol** 1996 Jul;42(1):91–8 (56 ref.)

Fate of ochratoxin A on processing of meat products. Gareis M. **Food Addit Contam** 1996;13 Suppl:35–7 (6 ref.)

Quantitative determination of heterocyclic amines in food products. Gross GA, et al. **Princess Takamatsu Symp** 1995; 23:20–9 (23 ref.)

Identification of new mutagenic heterocyclic amines and quantification of known heterocyclic amines. Wakabayashi K, et al. **Princess Takamatsu Symp** 1995;23:39–49 (31 ref.)

Public health impact on drug residues in animal tissues. Paige JC, et al. **Vet Hum Toxicol** 1997 Jun;39(3):162–9 (22 ref.)

MICROBIOLOGY

Hazard identification in swine slaughter with respect to foodborne bacteria. Borch E, et al. **Int J Food Microbiol** 1996 Jun;30(1–2):9–25 (56 ref.)

Bacterial spoilage of meat and cured meat products. Borch E, et al. **Int J Food Microbiol** 1996 Nov;33(1):103–20 (64 ref.)

Effectiveness of microbiologic criteria for the safety of foods of animal origin. Dreesen DW. **J Am Vet Med Assoc** 1996 Dec 15;209(12):2052–4 (3 ref.)

Current trends in human diseases associated with foods of animal origin. Morris JG Jr. **J Am Vet Med Assoc** 1996 Dec 15;209(12):2045–7 (2 ref.)

PARASITOLOGY

Strategies to reduce transmission of Toxoplasma gondii to animals and humans. Dubey JP. **Vet Parasitol** 1996 Aug; 64(1–2):65–70 (39 ref.)

Marine parasitology with special reference to Japanese fisheries and mariculture. Ogawa K. **Vet Parasitol** 1996 Aug;64(1–2):95–105 (36 ref.)

STANDARDS

Safe poultry meat production in the next century. Mulder RW. **Acta Vet Hung** 1997;45(3):307–15 (9 ref.)

Beef carcase characteristics that may be of value in selecting for genetic merit. Johnson ER. **Aust Vet J** 1996 Jun; 73(6):233–40 (65 ref.)

Natural sex steroids and their xenobiotic analogs in animal production: growth, carcass quality, pharmacokinetics, metabolism, mode of action, residues, methods, and epidemiology. Lone KP. **Crit Rev Food Sci Nutr** 1997 Mar; 37(2):93–209 (1177 ref.)

Bovine spongiform encephalopathy: "mad cow disease". **Nutr Rev** 1996 Jul;54(7):208–10 (10 ref.)

Meat inspection: an overview of present practices and future trends. Edwards DS, et al. **Vet J** 1997 Sep;154(2):135–47 (78 ref.)

[Physiology and physiopathology of ryanodine receptors in swine. Significance of sensitivity to stress, stress myopathies, malignant hyperthermia and meat quality] Martens H. **Tierarztl Prax** 1997 Jan;25(1):41–51 (62 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

Bovine spongiform encephalopathy (BSE): causes and consequences of a common source epidemic. Nathanson N, et al. **Am J Epidemiol** 1997 Jun 1;145(11):959–69 (63 ref.)

MEAT PRODUCTS

MICROBIOLOGY

Bacterial spoilage of meat and cured meat products. Borch E, et al. **Int J Food Microbiol** 1996 Nov;33(1):103–20 (64 ref.)

MEBENDAZOLE

THERAPEUTIC USE

[Advances of medical treatment of human hydatidosis] De Rosa F, et al. **Recenti Prog Med** 1996 Jul–Aug; 87(7–8):346–52 (48 ref.) (Eng. Abstr.) **(Ita)**

MECHANICAL VENTILATOR WEANING see **VENTILATOR WEANING**

MECHANICS

see related
BIOMECHANICS

MECHANORECEPTORS

see related
PROPRIOCEPTION

ANATOMY & HISTOLOGY

The evolution of insect wings and their sensory apparatus. Dickinson MH, et al. **Brain Behav Evol** 1997 Jul;50(1):13–24 (70 ref.)

CHEMISTRY

A supramolecular complex underlying touch sensitivity. Hamill OP, et al. **Trends Neurosci** 1996 Jul;19(7):258–61 (39 ref.)

METABOLISM

The molecules of mechanosensation. Garcia-Anoveros J, et al. **Annu Rev Neurosci** 1997;20:567–94 (162 ref.)

Immunohistochemistry of human cutaneous Meissner and pacinian corpuscles. Vega JA, et al. **Microsc Res Tech** 1996 Jul 1;34(4):351–61 (110 ref.)

The pharmacology of mechanogated membrane ion channels. Hamill OP, et al. **Pharmacol Rev** 1996 Jun;48(2):231–52 (257 ref.)

PHYSIOLOGY

Cardiovascular reflexes from ventricular and coronary receptors. Hainsworth R. **Adv Exp Med Biol** 1995; 381:157–74 (62 ref.)

The functional matrix hypothesis revisited. 1. The role of mechanotransduction. Moss ML. **Am J Orthod Dentofacial Orthop** 1997 Jul;112(1):8–11 (0 ref.)

The molecules of mechanosensation. Garcia-Anoveros J, et al. **Annu Rev Neurosci** 1997;20:567–94 (162 ref.)

Induced membrane hypo/hyper-mechanosensitivity: a limitation of patch-clamp recording. Hamill OP, et al. **Annu Rev Physiol** 1997;59:621–31 (51 ref.)

Tensegrity: the architectural basis of cellular mechanotransduction. Ingber DE. **Annu Rev Physiol** 1997; 59:575–99 (80 ref.)

Mechanosensitive channels of Escherichia coli: the MscL gene, protein, and activities. Sukharev SI, et al. **Annu Rev Physiol** 1997;59:633–57 (94 ref.)

Molecular modeling of mechanotransduction in the nematode Caenorhabditis elegans. Tavernarakis N, et al. **Annu Rev Physiol** 1997;59:659–89 (93 ref.)

Traction fibre: toward a "tensegral" model of the spindle. Pickett-Heaps JD, et al. **Cell Motil Cytoskeleton** 1997; 37(1):1–6 (32 ref.)

Pattern formation in the urodele mechanoreceptive lateral line: what features can be exploited for the study of development and evolution? Smith SC. **Int J Dev Biol** 1996 Aug;40(4):727–33 (41 ref.)

Mammalian cutaneous mechanoreceptors. Hamann W. **Prog Biophys Mol Biol** 1995;64(1):81–104 (140 ref.)

Visceral polymodal receptors. Gebhart GF. **Prog Brain Res** 1996;113:101–12 (31 ref.)

Cutaneous polymodal receptors: characteristics and plasticity. Perl ER. **Prog Brain Res** 1996;113:21–37 (49 ref.)

PHYSIOPATHOLOGY

Neurally mediated syncope: a review of cardiac and arterial

MECHANORECEPTORS

receptors. Grimm DR. **J Clin Neurophysiol** 1997 May; 14(3):170–82 (142 ref.)

MECHLORETHAMINE

PHARMACOKINETICS

Glutathione conjugation of alkylating cytostatic drugs with a nitrogen mustard group and the role of glutathione S-transferases. Dirven HA, et al. **Chem Res Toxicol** 1996 Mar;9(2):350–60 (92 ref.)

MECHLORETHAMINE OXIDE see **MECHLORETHAMINE**

MECKEL'S DIVERTICULUM

COMPLICATIONS

Intussusception in an adult secondary to an inverted Meckel's diverticulum. Steinwald PM, et al. **Am Surg** 1996 Nov; 62(11):889–94 (20 ref.)

Bay leaf perforation of Meckel's diverticulum [letter] Bell CD, et al. **Can J Surg** 1997 Apr;40(2):146–7 (9 ref.)

Case report: vitello-intestinal remnant complicating laparoscopic cholecystectomy. Durkan GC, et al. **Ir J Med Sci** 1996 Jul–Sep;165(3):164 (5 ref.)

Leiomyosarcoma originating in Meckel's diverticulum: report of a case and a review of 59 cases in the English literature. Shimizu N, et al. **Surg Today** 1997;27(6):546–9 (35 ref.)

Malignant stromal tumor consistent with fibrosarcoma arising from Meckel's diverticulum. Clinicopathological study of an incidentally discovered tumor and review of the literature. Calderale SM, et al. **Tumori** 1997 May–Jun; 83(3):703–8 (66 ref.)

[Carcinoid tumor in Meckel's diverticulum: case presentation and review of the literature] Sutter PM, et al. **Schweiz Med Wochenschr Suppl** 1997;89:20S–24S (37 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Gastric pathology in Meckel's diverticulum. Review of cases resected between 1965 and 1995. Cserni G. **Am J Clin Pathol** 1996 Dec;106(6):782–5 (28 ref.)

SURGERY

Meckel's diverticulum: should it be excised prophylactically in service personnel? Farrar MJ. **J R Army Med Corps** 1994 Feb;140(1):42–4 (09 ref.)

MECLASTINE see **CLEMASTINE**

MECLOPRODIN see **CLEMASTINE**

MECONIUM

[Intestinal emergencies in newborn infants] Brzezinska R. **Radiologe** 1997 Jun;37(6):432–8 (25 ref.) (Eng. Abstr.) **(Ger)**

MECONIUM ASPIRATION

THERAPY

Clinical role of amnio-infusion. Ouzounian JG, et al. **Baillieres Clin Obstet Gynaecol** 1996 Jun;10(2):259–72 (56 ref.)

[Meconium aspiration syndrome] Groneck P, et al. **Z Geburtshilfe Neonatol** 1996 Jul–Aug;200(4):132–7 (41 ref.) (Eng. Abstr.) **(Ger)**

MEDEX see **PHYSICIAN ASSISTANTS**

MEDIAL COLLATERAL LIGAMENT, KNEE

INJURIES

Biomechanics of knee ligament healing, repair and reconstruction. Woo SL, et al. **J Biomech** 1997 May; 30(5):431–9 (68 ref.)

Medial collateral ligament injuries in athletes. Reider B. **Sports Med** 1996 Feb;21(2):147–56 (56 ref.)

SURGERY

Biomechanics of knee ligament healing, repair and reconstruction. Woo SL, et al. **J Biomech** 1997 May; 30(5):431–9 (68 ref.)

MEDIAL GENICULATE BODY see **GENICULATE BODIES**

MEDIAL LIGAMENT OF KNEE see **MEDIAL COLLATERAL LIGAMENT, KNEE**

MEDIAL MENISCI see **MENISCI, TIBIAL**

MEDIAN NERVE

see related
CARPAL TUNNEL SYNDROME

High median nerve entrapments. An obscure cause of upper-extremity pain. Tetro AM, et al. **Hand Clin** 1996 Nov;12(4):691–703 (80 ref.)

Brachial neuritis presenting as anterior interosseous nerve compression--implications for diagnosis and treatment: a case report. Wong L, et al. **J Hand Surg [Am]** 1997 May; 22(3):536–9 (29 ref.)

ANATOMY & HISTOLOGY

Patterns of median nerve sensory innervation to the thumb and index finger: an anatomic study. Jolley BJ, et al. **J Hand Surg [Am]** 1997 Mar;22(2):228–31 (30 ref.)

PHYSIOLOGY

Mechanisms of reorganization in sensory systems of primates after peripheral nerve injury. Kaas JH, et al. **Adv Neurol** 1997;73:147–58 (122 ref.)

Long-segment nerve allograft regeneration in the sheep model: experimental study and review of the literature. Strasberg SR, et al. **J Reconstr Microsurg** 1996 Nov; 12(8):529–37 (89 ref.)

PHYSIOPATHOLOGY

Somatosensory evoked potentials to median nerve stimulation in meningomyelocele: what is occurring in the hindbrain and its connections during growth? Nishimura T, et al. **Childs Nerv Syst** 1996 Jan;12(1):13–26 (35 ref.)

MEDIASTINAL CYST

[Pericardial diverticulum] Morishita Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):559–60 (11 ref.) **(Jpn)**

[Pericardial cyst] Morita H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):579–81 (17 ref.) **(Jpn)**

[Pericardial cyst] Shimada T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):272–5 (17 ref.) **(Jpn)**

COMPLICATIONS

Mediastinal parathyroid cysts. Landau O, et al. **Ann Thorac Surg** 1997 Apr;63(4):951–3 (10 ref.)

Giant mediastinal parathyroid cyst: an unusual cause of hypercalcemic crisis--case report and review of the literature. Gurbuz AT, et al. **Surgery** 1996 Nov; 120(5):795–800 (43 ref.)

DIAGNOSIS

Non-nodal neck masses. Woodruff WW, et al. **Semin Ultrasound CT MR** 1997 Jun;18(3):182–204 (40 ref.)

[Two patients with mediastinal parathyroid cysts] Hirano H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 Jan; 35(1):82–8 (20 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

Pleuropericardial cysts: treatment by videothoracoscopy. Mouroux J, et al. **Surg Laparosc Endosc** 1996 Oct;6(5):403–4 (5 ref.)

[Mediastinal thoracic duct cyst--a case report] Nishizaki K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Oct; 44(10):1871–6 (29 ref.) (Eng. Abstr.) **(Jpn)**

MEDIASTINAL DISEASES

Spontaneous mediastinal hemorrhage: a case report with a review of the literature [published erratum appears in Md Med J 1997 Apr;46(4):171] Gomelsky A, et al. **Md Med J** 1997 Feb;46(2):83–7 (34 ref.)

Pediatric thoracoscopy: a new vista [see comments] Bullard KM, et al. **Pediatr Pulmonol** 1996 Aug;22(2):129–35 (34 ref.) Comment in: Pediatr Pulmonol 1996 Aug;22(2):79.

DIAGNOSIS

[Magnetic resonance imaging of the thorax] Berthezène Y, et al. **Rev Mal Respir** 1997 Jan;14(1):64–6 (14 ref.) **(Fre)**

[Parathyroid cyst presenting as a mediastinal tumor] Shishido M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Aug; 34(8):894–7 (11 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Profuse mediastinal haemorrhage due to mediastinitis after sternotomy. Report of three cases and review of the literature. Partanen J, et al. **Scand J Thorac Cardiovasc Surg** 1996;30(3–4):167–73 (31 ref.)

PATHOLOGY

Calcifying fibrous pseudotumor of mediastinum--a case report. Jeong HS, et al. **J Korean Med Sci** 1997 Feb; 12(1):58–62 (14 ref.)

[Flow cytometry for extensive thoracic diagnosis] Bernhardt K. **Acta Med Austriaca** 1997;24(1):5–7 (24 ref.) (Eng. Abstr.) **(Ger)**

MEDIASTINAL EMPHYSEMA

CHEMICALLY INDUCED

Spontaneous pneumothoraces, pneumomediastinum, and pneumoperitoneum: consequences of smoking crack cocaine. Uva JL. **Pediatr Emerg Care** 1997 Feb;13(1):24–6 (29 ref.)

ETIOLOGY

Closed rhinolalia as a symptom of pneumomediastinum after tonsillectomy: a case report and literature review. Braverman I, et al. **Otolaryngol Head Neck Surg** 1997 Apr; 116(4):551–3 (14 ref.)

Pneumomediastinum following penetrating oral trauma. McHugh TP. **Pediatr Emerg Care** 1997 Jun;13(3):211–3 (20 ref.)

[Spontaneous pneumomediastinum and cavitary pulmonary tuberculosis (letter)] Molina M, et al. **Enferm Infecc Microbiol Clin** 1997 Apr;15(4):230–1 (7 ref.) **(Spa)**

RADIOGRAPHY

Neonatal radiology casebook. Retropharyngeal abscess in the neonate. Gaglani MJ, et al. **J Perinatol** 1996 May–Jun;16(3 Pt 1):231–3 (12 ref.)

MEDIASTINAL NEOPLASMS

Primary mediastinal tumors. Part 1: tumors of the anterior mediastinum. Strollo DC, et al. **Chest** 1997 Aug; 112(2):511–22 (73 ref.)

Intrathoracic neoplasms other than bronchogenic carcinoma. Yoneda KY, et al. **Curr Opin Pulm Med** 1997 Jul; 3(4):257–64 (76 ref.)

Malignant cartilaginous tumors of the mediastinum: clinicopathological study of six cases presenting as extraskeletal soft tissue masses. Suster S, et al. **Hum Pathol** 1997 May;28(5):588–94 (19 ref.)

[Primary mediastinal non-seminomatous germ-cell tumors: from clinics to biology] Fizazi K, et al. **Bull Cancer** 1997 Mar;84(3):313–27 (142 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Mediastinal epithelioid hemangioendothelioma in a patient with type IV Ehlers-Danlos syndrome: a case report and review of the literature. Begbie SD, et al. **Am J Clin Oncol** 1997 Aug;20(4):412–5 (21 ref.)

Mediastinal teratoma presenting as massive hemoptysis in an adult. Gunes S, et al. **J Emerg Med** 1997 May–Jun; 15(3):313–6 (14 ref.)

Hypertrophic osteoarthropathy and intrathoracic Hodgkin disease of childhood. Kebudi R, et al. **Med Pediatr Oncol** 1997 Dec;29(6):578–81 (15 ref.)

[A case of mediastinal chordoma with Horner's syndrome] Sasaki H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Oct;44(10):1867–70 (17 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Cellular hemangioma of the posterior mediastinum: unusual presentation of a rare vascular neoplasm. Parker JR, et al. **J Okla State Med Assoc** 1997 Jan;90(1):7–9 (8 ref.)

A review of open biopsy for mediastinal masses. Massie RJ, et al. **J Paediatr Child Health** 1997 Jun;33(3):230–3 (20 ref.)

Interval to cancer diagnosis following "negative" transthoracic fine needle aspiration biopsy. Woodard WL 3rd, et al. **N C Med J** 1997 Jan–Feb;58(1):56–9 (20 ref.)

Foolers: things that look like pneumonia in children. Oermann CM, et al. **Semin Respir Infect** 1996 Sep; 11(3):204–13 (31 ref.)

[A case of asymptomatic posterior mediastinal pheochromocytoma diagnosed during the procedure of video-assisted thoracic surgery (VATS)] Yajima H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Feb;45(2):155–60 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Thoracoscopic surgery for diagnosis and treatment of pleural and mediastinal disease] Ando A. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:155–8 (6 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Burkitt's lymphoma-leukemia in patients treated for Hodgkin's disease. Salloum E, et al. **Cancer Invest** 1996; 14(6):527–33 (47 ref.)

Chemotherapy-induced spontaneous pneumothorax in a patient with bulky mediastinal lymphoma: a rare oncologic emergency. Stein ME, et al. **Oncology** 1997 Jan–Feb; 54(1):15–8 (18 ref.)

GENETICS

[A case of ectopic familial pheochromocytoma] Nakada J, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Aug; 87(8):1060–3 (11 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Primary mediastinal germ cell tumor with intratubular germ cell neoplasia of the testis--further support for germ cell origin of these tumors: a case report. Hailemariam S, et al. **Cancer** 1997 Mar 1;79(5):1031–6 (43 ref.)

Nonfunctioning malignant paraganglioma of the posterior mediastinum with spinal cord compression. A case report. Noorda RJ, et al. **Spine** 1996 Jul 15;21(14):1703–9 (61 ref.)
Giant mediastinal lymphangioma in a neonate: report of a case. Takamatsu H, et al. **Surg Today** 1996;26(7):527–31 (24 ref.)
[Flow cytometry for extensive thoracic diagnosis] Bernhardt K. **Acta Med Austriaca** 1997;24(1):5–7 (24 ref.) (Eng. Abstr.) **(Ger)**
[A case report of cervicomediastinal lipoma] Kitami A, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):624–7 (21 ref.) (Eng. Abstr.) **(Jpn)**
[Venous hemangioma of the mediastinum: apropos of a case] Vázquez Oliva R, et al. **An Med Interna** 1995 Aug; 12(8):388–90 (20 ref.) (Eng. Abstr.) **(Spa)**

RADIONUCLIDE IMAGING

[Diagnosis of early cancer with positron emission tomography] Kubota K. **Nippon Rinsho** 1996 May; 54(5):1263–7 (12 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

The current management of patients with mediastinal tumors. Luketich JD, et al. **Adv Surg** 1996;30:311–32 (86 ref.)
[A case of primary anterior mediastinal liposarcoma with a heterotopic mass in the pericardium of the same histology] Kiyama H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Dec;44(12):2191–5 (14 ref.) (Eng. Abstr.) **(Jpn)**
[A case of leiomyoma of the posterior mediastinum] Nakamura M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Nov;44(11):2082–6 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Current status of surgery for mediastinal tumors] Nakahara K. **Rinsho Kyobu Geka** 1989 Oct;9(5):429–33 (36 ref.) (Eng. Abstr.) **(Jpn)**
[A case of mediastinal lymphangioma] Takahashi Y, et al. **Rinsho Kyobu Geka** 1988 Apr;8(2):195–9 (17 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Primary malignant germ cell tumours of the mediastinum--results of multimodality treatment. Jyothirmayi R, et al. **Acta Oncol** 1997;36(3):317–21 (32 ref.)
Lung and mediastinum [editorial; comment] Ruckdeschel JC. **Curr Opin Oncol** 1997 Mar;9(2):147–8 (20 ref.) Comment on: Curr Opin Oncol 1997 Mar;9(2):149–55. Comment on: Curr Opin Oncol 1997 Mar;9(2):156–60. Comment on: Curr Opin Oncol 1997 Mar;9(2):161–9. Comment on: Curr Opin Oncol 1997 Mar;9(2):170–4.
Mediastinal yolk sac tumor in a young girl: case report and review of the literature. Uchiyama M, et al. **J Pediatr Surg** 1996 Sep;31(9):1318–21 (25 ref.)

ULTRASONOGRAPHY

[Transesophageal cardiac echography and paracardiac tumor masses. Apropos of a case] Fakhry A, et al. **Ann Cardiol Angeiol (Paris)** 1996 Nov;45(9):527–30 (11 ref.) (Eng. Abstr.) **(Fre)**

MEDIASTINITIS

CHEMICALLY INDUCED

Mediastinitis related to probable central vinblastine extravasation in a woman undergoing adjuvant chemotherapy for early breast cancer. Anderson CM, et al. **Am J Clin Oncol** 1996 Dec;19(6):566–8 (6 ref.)

COMPLICATIONS

Profuse mediastinal haemorrhage due to mediastinitis after sternotomy. Report of three cases and review of the literature. Partanen J, et al. **Scand J Thorac Cardiovasc Surg** 1996;30(3–4):167–73 (31 ref.)
Mediastinal compression syndromes due to idiopathic fibrosing mediastinitis--report of three cases and review of the literature. Kalweit G, et al. **Thorac Cardiovasc Surg** 1996 Apr;44(2):105–9 (34 ref.)

ETIOLOGY

Cervical cellulitis with mediastinitis from an odontogenic infection complicated by diabetes mellitus: report of a case. Sugata T, et al. **J Oral Maxillofac Surg** 1997 Aug; 55(8):864–9 (14 ref.)
Profuse mediastinal haemorrhage due to mediastinitis after sternotomy. Report of three cases and review of the literature. Partanen J, et al. **Scand J Thorac Cardiovasc Surg** 1996;30(3–4):167–73 (31 ref.)
[Mediastinitis following sternotomy: a potential complication of heart transplantation] Bouza E, et al. **Rev Clin Esp** 1995 Oct;195 Spec No:30–6 (73 ref.) **(Spa)**

MICROBIOLOGY

Fatal Streptococcus viridans descending mediastinitis: case report and review of the literature. Berlot G, et al. **Eur J Emerg Med** 1997 Jun;4(2):111–4 (10 ref.)
Tubercular sternal osteomyelitis and mediastinitis after open heart surgery. Aggarwal B, et al. **Indian Heart J** 1997 May–Jun;49(3):313–4 (4 ref.)

RADIOGRAPHY

The radiology of melioidosis. Chong VF, et al. **Australas Radiol** 1996 Aug;40(3):244–9 (14 ref.)

SURGERY

Approaches to sternal wound infections. Gottlieb LJ, et al. **Adv Card Surg** 1996;7:147–62 (44 ref.)

THERAPY

[A case of successful treatment of mediastinitis and prosthetic graft infection after aortic arch and thoracoabdominal aortic reconstruction] Kawashima T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Feb;45(2):220–4 (12 ref.) (Eng. Abstr.) **(Jpn)**

MEDIASTINOSCOPY

[Video-assisted esophagectomy for carcinoma of the esophagus, using thoracoscopy or mediastinoscopy] Mafune K, et al. **Gan To Kagaku Ryoho** 1997 Mar; 24(5):525–31 (9 ref.) (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

Endoscopic ligation of perforating veins using a mediastinoscope. Pierik RG, et al. **Surg Laparosc Endosc** 1997 Feb;7(1):25–8 (28 ref.)

MEDIASTINUM

see related
MEDIASTINOSCOPY

PATHOLOGY

Differential diagnostic considerations and potential pitfalls in fine-needle aspiration biopsies of the mediastinum. Geisinger KR. **Diagn Cytopathol** 1995 Dec;13(5):436–42 (46 ref.)
The mediastinum. Marchevsky A. **Pathology (Phila)** 1996; 3(2):339–48 (19 ref.)
Nonfunctioning malignant paraganglioma of the posterior mediastinum with spinal cord compression. A case report. Noorda RJ, et al. **Spine** 1996 Jul 15;21(14):1703–9 (61 ref.)

SURGERY

Anterior mediastinal tracheostomy. Orringer MB. **Chest Surg Clin N Am** 1996 Nov;6(4):701–24 (45 ref.)
The mediastinum. Marchevsky A. **Pathology (Phila)** 1996; 3(2):339–48 (19 ref.)

MEDIATING see **NEGOTIATING**

MEDIATORS OF INFLAMMATION see **INFLAMMATION MEDIATORS**

MEDICAGO see **ALFALFA**

MEDICAID

Health care coverage for children who are on and off welfare. Moffitt RA, et al. **Future Child** 1997 Spring; 7(1):87–98 (20 ref.)

ECONOMICS

Mid-1990s review of Medicaid and Medicaid dentistry. Waldman HB. **ASDC J Dent Child** 1997 Mar–Apr; 64(2):141–8 (21 ref.)
The evolution of support for safety-net hospitals. Fishman LE, et al. **Health Aff (Millwood)** 1997 Jul–Aug;16(4):30–47 (30 ref.)

LEGISLATION & JURISPRUDENCE

Medicaid reform. Villarruel AM, et al. **J Soc Pediatr Nurs** 1996 Apr–Jun;1(1):43–5 (7 ref.)

ORGANIZATION & ADMINISTRATION

An evaluation of Oregon's Medicaid rationing algorithms [editorial] Tengs TO. **Health Econ** 1996 May–Jun; 5(3):171–81 (16 ref.)
Medicaid managed care and urban poor people: implications for social work. Perloff JD. **Health Soc Work** 1996 Aug; 21(3):189–95 (33 ref.)
Medicaid, managed care and optometry: a review. Soroka M. **J Am Optom Assoc** 1996 Jun;67(6):335–42 (16 ref.)
Markets and public programs: insights from Oregon and Tennessee. Gold M. **J Health Polit Policy Law** 1997 Apr; 22(2):633–66 (26 ref.)
The Medicaid managed care policy consensus for welfare recipients: a reflection of traditional welfare concerns [see comments] Grogan CM. **J Health Polit Policy Law** 1997 Jun;22(3):815–38 (17 ref.) Comment in: J Health Polit Policy Law 1997 Jun;22(3):879–96. Comment in: J Health Polit Policy Law 1997 Jun;22(3):897–906.
Medicaid and the politics of groups: recipients, providers, and policy making [see comments] Kronebusch K. **J Health Polit Policy Law** 1997 Jun;22(3):839–78 (54 ref.) Comment in: J Health Polit Policy Law 1997 Jun;22(3):879–96. Comment in: J Health Polit Policy Law 1997 Jun;22(3):897–906.
Medicaid and primary care. Rushton FE. **J S C Med Assoc** 1997 Feb;93(2):63–7 (12 ref.)
Advocacy and managed behavioral health care. Shore MF. **New Dir Ment Health Serv** 1996 Winter;(72):59–64 (2 ref.)
An overview of managed behavioral health care. Shore MF. **New Dir Ment Health Serv** 1996 Winter;(72):3–12 (11 ref.)
The public sector-private sector interface: current issues, future trends. Surles RC, et al. **New Dir Ment Health Serv** 1996 Winter;(72):71–9 (8 ref.)
The ethical dilemmas of the Oregon health plan. Burton L. **Nurse Pract** 1996 Feb;21(2):62, 65–6, 71–2 (20 ref.)

STATISTICS & NUMERICAL DATA

Medicaid and private insurance: evidence and implications [see comments] Cutler DM, et al. **Health Aff (Millwood)** 1997 Jan–Feb;16(1):194–200 (13 ref.) Comment in: Health Aff (Millwood) 1997 Jan–Feb;16(1):201–3. Comment in: Health Aff (Millwood) 1997 Jan–Feb;16(1):204–6.

MEDICAL ASSISTANCE, TITLE 19 see **MEDICAID**

MEDICAL AUDIT

What is clinical audit? Williams O. **Ann R Coll Surg Engl** 1996 Sep;78(5):406–11 (7 ref.)
Recommendations for qualification of centres implanting and following defibrillators. Study Group on Qualification of ICD Implanting Centers of the Working Groups on Arrhythmias and Cardiac Pacing of the European Society of Cardiology. Lévy S, et al. **Eur Heart J** 1996 Dec; 17(12):1796–9 (13 ref.)
The involvement of pharmacists in professional and clinical audit in the UK: a review and assessment of their potential role. Panton R, et al. **J Eval Clin Pract** 1996 Aug;2(3):193–8 (53 ref.)
Audit and education in transfusion medicine. Toy PT. **Vox Sang** 1996;70(1):1–5 (34 ref.)
[Quality assurance in surgery--more than documentation of postoperative complications] Grundmann RT. **Zentralbl Chir** 1996;121(3):157–66 (65 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

The role of health economics in clinical evaluation. Drummond M. **J Eval Clin Pract** 1995 Sep;1(1):71–5 (15 ref.)

METHODS

Involving clients in clinical audits of mental health services. Balogh R, et al. **Int J Qual Health Care** 1995 Dec; 7(4):343–53 (74 ref.)
Case mix adjustment in comparative audit. Hayes C, et al. **J Eval Clin Pract** 1995 Nov;1(2):105–11 (37 ref.)
User involvement in clinical audit: a review of developments and issues of good practice. Kelson M. **J Eval Clin Pract** 1996 May;2(2):97–109 (109 ref.)
The Total Health Care Audit System: a systematic methodology for clinical practice evaluation and development in NHS provider organizations. Miles A, et al. **J Eval Clin Pract** 1996 Feb;2(1):37–64 (53 ref.)
Acquisition and use of clinical data for audit and research. Wyatt J. **J Eval Clin Pract** 1995 Sep;1(1):15–27 (76 ref.)
Outcome measures in palliative care for advanced cancer patients: a review. Hearn J, et al. **J Public Health Med** 1997 Jun;19(2):193–9 (22 ref.)

ORGANIZATION & ADMINISTRATION

Audit in obstetrics. Maresh MM, et al. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):296–9 (19 ref.)
Evaluation in clinical practice: problems, precedents and principles. McIntyre N. **J Eval Clin Pract** 1995 Sep; 1(1):5–13 (24 ref.)
Clinical audit in the National Health Service: fact or fiction? Miles A, et al. **J Eval Clin Pract** 1996 Feb;2(1):29–35 (53 ref.)
Central dimensions of clinical practice evaluation: efficiency, appropriateness and effectiveness--I. O'Neill D, et al. **J Eval Clin Pract** 1996 Feb;2(1):13–27 (77 ref.)
Clinical audit: time for a reappraisal? [see comments] Hopkins A. **J R Coll Physicians Lond** 1996 Sep–Oct;30(5):415–25 (92 ref.) Comment in: J R Coll Physicians Lond 1996 Nov–Dec;30(6):586. Comment in: J R Coll Physicians Lond 1997 Jan–Feb;31(1):113. Comment in: J R Coll Physicians Lond 1997 Mar–Apr;31(2):221.

STANDARDS

Evaluating healthcare policies: the case of clinical audit. Lord J, et al. **BMJ** 1997 Sep 13;315(7109):668–71 (30 ref.)

MEDICAL CARE COSTS see **HEALTH CARE COSTS**

MEDICAL CARE RESEARCH see **HEALTH SERVICES RESEARCH**

MEDICAL CARE TEAM see **PATIENT CARE TEAM**

MEDICAL CENTERS, ACADEMIC see **ACADEMIC MEDICAL CENTERS**

MEDICAL CENTERS, UNIVERSITY

MEDICAL CENTERS, UNIVERSITY see **ACADEMIC MEDICAL CENTERS**

MEDICAL COMPUTER SCIENCE see **MEDICAL INFORMATICS**

MEDICAL DECISION MAKING, COMPUTER-ASSISTED see **DECISION MAKING, COMPUTER-ASSISTED**

MEDICAL DEVICE DESIGN see **EQUIPMENT DESIGN**

MEDICAL DEVICE SAFETY see **EQUIPMENT SAFETY**

MEDICAL DEVICES see **EQUIPMENT AND SUPPLIES**

MEDICAL DIRECTORS see **PHYSICIAN EXECUTIVES**

MEDICAL ECONOMICS see **ECONOMICS, MEDICAL**

MEDICAL EDUCATION see **EDUCATION, MEDICAL**

MEDICAL EDUCATION, CONTINUING see **EDUCATION, MEDICAL, CONTINUING**

MEDICAL EDUCATION, GRADUATE see **EDUCATION, MEDICAL, GRADUATE**

MEDICAL EDUCATION, UNDERGRADUATE see **EDUCATION, MEDICAL, UNDERGRADUATE**

MEDICAL ERRORS

see related
IATROGENIC DISEASE
MALPRACTICE

Error detection and reduction in blood banking. Motschman TL, et al. **Clin Lab Med** 1996 Dec;16(4):961–73 (23 ref.)

MEDICAL FUTILITY

see related
RESUSCITATION ORDERS

A preventive ethics approach to counseling patients about clinical futility in the primary care setting. Doukas DJ, et al. **Arch Fam Med** 1996 Nov–Dec;5(10):589–92 (35 ref.)

Medical futility. Youngner SJ. **Crit Care Clin** 1996 Jan; 12(1):165–78 (31 ref.)

Consensus statement of the Society of Critical Care Medicine's Ethics Committee regarding futile and other possibly inadvisable treatments. **Crit Care Med** 1997 May; 25(5):887–91 (32 ref.)

Utility and the principle of medical futility: safeguarding autonomy and the prohibition against cruel and unusual punishment [published erratum appears in J Contemp Health Law Policy 1996 Spring;12(2):following table of contents] Smith GP 2nd. **J Contemp Health Law Policy** 1995 Fall;12(1):1–39 (178 ref.)

Discussing futility with patients and families. Dunn PM, et al. **J Gen Intern Med** 1996 Nov;11(11):689–93 (33 ref.)

Health care management of children with cognitive and physical disabilities: to treat or not to treat. Mims J, et al. **J Neurosci Nurs** 1996 Aug;28(4):238–44, 250–1 (27 ref.)

Futile care: confronting the high costs of dying [see comments] Coppa S. **J Nurs Adm** 1996 Dec;26(12):18–23 (30 ref.) Comment in: J Nurs Adm 1997 Jun;27(6):55.

The uncertain 'best interests' of neonates: decision making in the neonatal intensive care unit. Shewchuk TR. **Med Law** 1995;14(5–6):331–58 (128 ref.)

Preventing harm in resuscitation medicine. Ardagh M. **N Z Med J** 1997 Apr 11;110(1041):113–5 (28 ref.)

As fiduciaries physicians hold in trust: life, death, and money—and least of those is money. Kjellstrand CM. **Ren Fail** 1996 May;18(3):417–23 (32 ref.)

Medical futility and appropriate medical care in patients whose death is thought to be imminent. Escalante CP, et al. **Support Care Cancer** 1997 Jul;5(4):274–80 (36 ref.)

MEDICAL GEOGRAPHY see **GEOGRAPHY**

MEDICAL HISTORY TAKING

see related
DATA COLLECTION

Patient history in the diagnosis of urinary incontinence and determining the quality of life. Kujansuu E. **Acta Obstet Gynecol Scand Suppl** 1997;166:15–8 (14 ref.)

Diagnosing syncope. Part 1: Value of history, physical examination, and electrocardiography. Clinical Efficacy Assessment Project of the American College of Physicians. Linzer M, et al. **Ann Intern Med** 1997 Jun 15;126(12):989–96 (34 ref.)

Risk assessment in psychiatry. Maden A. **Br J Hosp Med** 1996 Jul 10–Aug 20;56(2–3):78–82 (16 ref.)

Dental erosion clinical diagnosis and case history taking. Lussi A. **Eur J Oral Sci** 1996 Apr;104(2 (Pt 2)):191–8 (43 ref.)

The detection of alcohol misuse in accident and emergency departments—grasping the opportunity [comment] Paton A. **J Accid Emerg Med** 1996 Sep;13(5):306–8 (22 ref.) Comment on: J Accid Emerg Med 1996 Sep;13(5):308–12.

Sexuality, sexual abuse. Omissions in admissions? Sharkey VB. **J Adv Nurs** 1997 May;25(5):1025–32 (56 ref.)

Communication and the medical interview. Strategies for learning and teaching. Kaplan CB, et al. **J Gen Intern Med** 1997 Apr;12 Suppl 2:S49–55 (24 ref.)

Hearing the patient's 'voice': toward a social poetics in diagnostic interviews. Katz AM, et al. **Soc Sci Med** 1996 Sep;43(6):919–31 (32 ref.)

History and physical examination in patients with herniated lumbar discs. Andersson GB, et al. **Spine** 1996 Dec 15;21(24 Suppl):10S–18S (25 ref.)

About signs and symptoms: can semiotics expand the view of clinical medicine? Nessa J. **Theor Med** 1996 Dec; 17(4):363–77 (54 ref.)

[Specificity of the anesthetic consultation for ambulatory surgery] Forster A, et al. **Rev Med Suisse Romande** 1997 May;117(5):371–3 (1 ref.) **(Fre)**

METHODS

The genetics of gynaecological malignancy. Eccles DM. **Br J Hosp Med** 1996 Oct 16–Nov 5;56(8):416–9 (6 ref.)

Assisting sexually abused adults. Practical guide to interviewing patients. Leach MM, et al. **Can Fam Physician** 1996 Jan;42:82–6 (22 ref.)

Pressure ulcer assessment. Maklebust J. **Clin Geriatr Med** 1997 Aug;13(3):455–81 (62 ref.)

Spinal stenosis: history and physical examination. Mirkovic S, et al. **Instr Course Lect** 1994;43:435–40 (41 ref.)

Ambulatory surgery. Preoperative assessment and health history interview. Williams GD. **Nurs Clin North Am** 1997 Jun;32(2):395–416 (22 ref.)

Collection of occupational epidemiologic data: the use of surrogate respondents to provide occupational histories. Henneberger PK. **Occup Med** 1996 Jul–Sep;11(3):393–401 (28 ref.)

Case history: cornerstone in the neuro-ophthalmic examination. Carr L. **Optom Clin** 1996;5(3–4):17–32 (26 ref.)

STANDARDS

Evidence-based diagnosis. Fowler PB. **J Eval Clin Pract** 1997 Apr;3(2):153–9 (3 ref.)

MEDICAL ILLUSTRATION

Silverpoint drawing for scientific illustration. Hodge GP. **J Biocommun** 1996;23(3):18–21 (5 ref.)

The use of color in scientific and medical illustration. Hofkin BD. **J Biocommun** 1996;23(3):8–13 (7 ref.)

The transition to digital media in biocommunications. Lynch PJ. **J Biocommun** 1996;23(3):2–7 (22 ref.)

MEDICAL IMAGING see **DIAGNOSTIC IMAGING**

MEDICAL INDIGENCY

see related
MEDICALLY UNINSURED
UNCOMPENSATED CARE

ECONOMICS

The evolution of support for safety-net hospitals. Fishman LE, et al. **Health Aff (Millwood)** 1997 Jul–Aug;16(4):30–47 (30 ref.)

Market commodities and poor relief: the world bank proposal for health. Laurell AC, et al. **Int J Health Serv** 1996; 26(1):1–18 (42 ref.)

TRENDS

The safety-net role of international medical graduates. Mick SS, et al. **Health Aff (Millwood)** 1997 Jul–Aug;16(4):141–50 (26 ref.)

MEDICAL INFORMATICS

Information technology and media in allergy. The Computing Group of the Audiovisual Subcommittee of the European Academy of Allergology and Clinical Immunology. **Allergy** 1996 Sep;51(9):603–7 (23 ref.)

Obtaining useful information from expert based sources. Slawson DC, et al. **BMJ** 1997 Mar 29;314(7085):947–9 (25 ref.)

Medical software and information technology transfer methods. Schertzer RM. **Can J Ophthalmol** 1996 Feb; 31(1):45–50 (11 ref.)

Funding nursing informatics activities. Internet access to announcements of government funding. McCormick KA, et al. **Comput Nurs** 1996 Nov–Dec;14(6):315–22 (10 ref.)

Facing future challenges in general practice: a clinical method with computer support. Purves IN. **Fam Pract** 1996 Dec;13(6):536–43 (62 ref.)

Genitourinary medicine and The Internet No. 4. Lau RK. **Genitourin Med** 1997 Feb;73(1):73–4 (0 ref.)

Genitourinary medicine and the Internet No 5. Lau RK. **Genitourin Med** 1997 Apr;73(2):144–5 (0 ref.)

Toward a model for nursing informatics. Turley JP. **Image J Nurs Sch** 1996 Winter;28(4):309–13 (26 ref.)

Humans, information and science. Jones P. **J Adv Nurs** 1996 Sep;24(3):591–8 (23 ref.)

Computational tools for the modern andrologist. Niederberger C. **J Androl** 1996 Sep–Oct;17(5):462–6 (16 ref.)

Medical informatics, art or science? van Bemmel JH. **Methods Inf Med** 1996 Sep;35(3):157–72; discussion 173–201 (54 ref.)

[Medicine and the Internet] Feingold M, et al. **Harefuah** 1997 Jan 1;132(1):31–4 (28 ref.) **(Heb)**

ORGANIZATION & ADMINISTRATION

Antecedents of the people and organizational aspects of medical informatics: review of the literature. Lorenzi NM, et al. **J Am Med Inform Assoc** 1997 Mar–Apr;4(2):79–93 (156 ref.)

TRENDS

Information technology, medical education, and anatomy for the twenty-first century. Marks SC Jr. **Clin Anat** 1996; 9(5):343–8 (47 ref.)

Critical dimensions in medical informatics. Degoulet P, et al. **Int J Med Inf** 1997 Mar;44(1):21–6 (19 ref.)

Challenges for medical informatics in the 21st century. Hasman A. **Int J Med Inf** 1997 Mar;44(1):1–7 (10 ref.)

Aims and tasks of medical informatics [see comments] Haux R. **Int J Med Inf** 1997 Mar;44(1):9–20; discussion 39–44, 45–52, 61–6 (19 ref.) Comment in: Int J Med Inf 1997 Mar;44(1):53–5. Comment in: Int J Med Inf 1997 Mar;44(1):67–74. Comment in: Int J Med Inf 1997 Mar;44(1):75–81. Comment in: Int J Med Inf 1997 Mar;44(1):83–7.

Beyond the superhighway: exploiting the Internet with medical informatics. Cimino JJ. **J Am Med Inform Assoc** 1997 Jul–Aug;4(4):279–84 (43 ref.)

MEDICAL INFORMATICS APPLICATIONS

Using the technology of the World Wide Web to manage clinical information. Fraser HS, et al. **BMJ** 1997 May 31; 314(7094):1600–3 (21 ref.)

Critical dimensions in medical informatics. Degoulet P, et al. **Int J Med Inf** 1997 Mar;44(1):21–6 (19 ref.)

Evidence-based approach to the medical literature. Fletcher RH, et al. **J Gen Intern Med** 1997 Apr;12 Suppl 2:S5–14 (22 ref.)

Informatics: a physician's view. Welsh F. **J Health Care Finance** 1997 Spring;23(3):37–43 (17 ref.)

Electronic communication with patients. Evaluation of distance medicine technology. Balas EA, et al. **JAMA** 1997 Jul 9;278(2):152–9 (93 ref.)

MEDICAL INFORMATICS COMPUTING

Evidence-based approach to the medical literature. Fletcher RH, et al. **J Gen Intern Med** 1997 Apr;12 Suppl 2:S5–14 (22 ref.)

The questions of medical informatics. Dimitrov I. **Methods Inf Med** 1996 Mar;35(1):8–11 (10 ref.)

MEDICAL INFORMATION SCIENCE see **MEDICAL INFORMATICS**

MEDICAL JOURNALISM see **JOURNALISM**

MEDICAL JURISPRUDENCE see **JURISPRUDENCE**

MEDICAL LABORATORY TECHNOLOGY see **TECHNOLOGY, MEDICAL LABORATORY**

MEDICAL MISSIONS, OFFICIAL

ORGANIZATION & ADMINISTRATION

[Practical gynecology in the African bush: from humanitarianism to humanism] Géraud R, et al. **Contracept Fertil Sex** 1997 Jun;25(6):482–91 (28 ref.) **(Fre)**

MEDICAL MISTAKES see **MEDICAL ERRORS**

MEDICAL ONCOLOGY

see related
NEOPLASMS

Cancer in children. Introduction. Malpas JS. **Br Med Bull** 1996 Oct;52(4):671–81 (33 ref.)

Palliative medicine and the medical oncologist. Defining the purview of care. Cherny NI, et al. **Hematol Oncol Clin North Am** 1996 Feb;10(1):1–20 (137 ref.)

The Eugene M. Landis Award Lecture 1996. Delivery of molecular and cellular medicine to solid tumors. Jain RK. **Microcirculation** 1997 Mar;4(1):1–23 (150 ref.)

Supportive care of the patient with pancreatic cancer: role of the psycho-oncologist. Passik SD. **Oncology (Huntingt)** 1996 Sep;10(9 Suppl):33–4 (11 ref.)

Pediatric oncology in Argentina: a historical overview. Diez B, et al. **Pediatr Hematol Oncol** 1997 Jul–Aug;14(4):299–305 (11 ref.)

Overview by an oncologist: what are the imaging needs of the oncologist and oncological surgeon? Gucalp R, et al. **Semin Nucl Med** 1997 Jan;27(1):3–9 (46 ref.)

Veterinary cancer epidemiology. Misdorp W. **Vet Q** 1996 Mar;18(1):32–6 (53 ref.)

[Predictive oncology and familial breast cancer] Pescia G, et al. **Rev Med Suisse Romande** 1997 Aug;117(8):603–6 (10 ref.) **(Fre)**

ECONOMICS

Cost–effectiveness of PET imaging in clinical oncology. Valk PE, et al. **Nucl Med Biol** 1996 Aug;23(6):737–43 (23 ref.)

METHODS

Geriatric assessment in oncology. Reuben DB. **Cancer** 1997 Oct 1;80(7):1311–6 (15 ref.)

Cell line banks and their role in cancer research. Hay RJ, et al. **J Cell Biochem Suppl** 1996;24:107–30 (29 ref.)

Practising oncology via telemedicine. Doolittle GC, et al. **J Telemed Telecare** 1997;3(2):63–70 (14 ref.)

Oncologic imaging: interactions of nuclear medicine with CT and MRI using the bone scan as a model. Tryciecky EW, et al. **Semin Nucl Med** 1997 Apr;27(2):142–51 (39 ref.)

Clinical trials in veterinary oncology: a clinician's viewpoint. Crow SE. **Vet Clin North Am Small Anim Pract** 1996 Jan; 26(1):29–37 (18 ref.)

Surgical oncology. Harvey J.
Vet Clin North Am Small Anim Pract 1996 Jan;26(1):9–16 (11 ref.)

New approaches in the treatment of metastatic transitional–cell cancer of the bladder. Corral DA, et al. **World J Urol** 1997;15(2):139–43 (28 ref.)

Applications of telomerase in urologic oncology. Landman J, et al. **World J Urol** 1997;15(2):120–4 (39 ref.)

[Application of three–dimensional computer graphics in oncology] Joyeux H, et al. **Bull Acad Natl Med** 1996 Jun–Jul;180(6):1455–65; discussion 1465–6 (25 ref.) (Eng. Abstr.) **(Fre)**

ORGANIZATION & ADMINISTRATION

Managed care in gynecologic oncology. Cohen CJ, et al. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):325–8 (13 ref.)

STANDARDS

Current status of practice guidelines in oncology. Winn RJ. **Oncology (Huntingt)** 1995 Jul;9(7):601–5, 609 DISC 609–10, 615 (34 ref.)

Critical appraisal meets clinical reality: evaluating evidence in the literature using canine hemangiosarcoma as an example. Bonnett B, et al.
Vet Clin North Am Small Anim Pract 1996 Jan;26(1):39–61 (53 ref.)

[Diagnostic, therapeutic and socioeconomic problems in geriatric oncology] Jerusalem G, et al. **Rev Med Liege** 1997 Apr;52(4):255–7 (9 ref.) **(Fre)**

TRENDS

Nuclear oncology and the Imagene concept. Urbain JL, et al. **Acta Radiol Suppl** 1997;412:21–8 (71 ref.)

Advances in molecular genetics. Lairmore TC, et al.
Am J Surg 1997 Jan;173(1):37–41; discussion 42–3 (15 ref.)

Secondary prevention of cancer. Caplan LS, et al.
Curr Opin Oncol 1996 Sep;8(5):441–6 (62 ref.)

The role of supportive care in quality of life. Warr D, et al. **Curr Opin Oncol** 1996 Jul;8(4):279–83 (24 ref.)

Does fluorine–18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology? [see comments] Brock CS, et al. **Eur J Nucl Med** 1997 Jun;24(6):691–705 (136 ref.) Comment in: Eur J Nucl Med 1997 Jun;24(6):587–9.

Oncology. Are Voltaire and Rousseau now wrong? Raghavan D. **Lancet** 1996 Dec 21–28;348 Suppl 2:sII17 (5 ref.)

Recent advances in lung cancer surgery in Europe. Motta G. **Lung Cancer** 1996 Dec;16(1):1–11 (27 ref.)

Recent advances in medical oncology—1995–1996. Sikov WM. **Med Health R I** 1996 Mar;79(3):92–9 (39 ref.)

Pediatric hematology and oncology in Cameroon, Africa: past and future perspectives. Abena Obama MT.
Pediatr Hematol Oncol 1996 Jul–Aug;13(4):315–7 (5 ref.)

Current controversies in the application of meta–analysis (with special reference to oncological treatments). A commentary [comment] Kleijnen J. **Pharm World Sci** 1997 Jun;19(3):117–8 (2 ref.) Comment on: Pharm World Sci 1997 Jun;19(3):152–8.

Current controversies in the application of meta–analysis (with special reference to oncological treatments) [see comments] Messori A. **Pharm World Sci** 1997 Jun; 19(3):152–8 (50 ref.) Comment in: Pharm World Sci 1997 Jun;19(3):117–8.

Current status of enhancing the detection of prostate cancer [editorial] Babaian RJ. **Prostate** 1997 May 15;31(3):204–5 (10 ref.)

Prostate cancer treatment strategies based on tumor–specific biological principles: future directions. Carducci MA, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 14):56–62 (41 ref.)

Current concepts in the role of intravesical instillations in the therapy and prophylaxis of superficial transitional–cell cancer of the bladder. The Finnbladder Research Group. Alfthan O, et al. **World J Urol** 1997;15(2):89–95 (64 ref.)

Current and future strategies to block tumor angiogenesis, invasion, and metastasis. Effert PJ, et al. **World J Urol** 1996; 14(3):131–40 (81 ref.)

MEDICAL RECORD LINKAGE

Pregnancy–associated deaths in Finland 1987–1994—definition problems and benefits of record linkage. Gissler M, et al. **Acta Obstet Gynecol Scand** 1997 Aug;76(7):651–7 (32 ref.)

METHODS

[Linking of individual data. Methods of linkage] Rumeau–Rouquette C. **Rev Epidemiol Sante Publique** 1997 Jun;45(3):248–56 (29 ref.) (Eng. Abstr.) **(Fre)**

MEDICAL RECORDS

see related
FORMS AND RECORDS CONTROL
MEDICAL HISTORY TAKING

Documentation of client dangerousness in a managed care environment. Callahan J. **Health Soc Work** 1996 Aug; 21(3):202–7 (34 ref.)

The social worker's record of the hospitalized patient: a physician's perspective. Benbassat J.
Isr J Psychiatry Relat Sci 1996;33(4):246–52 (27 ref.)

How severity measures rate hospitalized patients. Hughes JS, et al. **J Gen Intern Med** 1996 May;11(5):303–11 (24 ref.)

Medical records and other stories: a narratological framework [see comments] Kay S, et al.
Methods Inf Med 1996 Jun;35(2):72–87 (119 ref.) Comment in: Methods Inf Med 1996 Jun;35(2):88–92. Comment in: Methods Inf Med 1996 Jun;35(2):93–7. Comment in: Methods Inf Med 1996 Jun;35(2):98–100. Comment in: Methods Inf Med 1996 Jun;35(2):101–3.

The clinical reasoning case study: a powerful teaching tool. Ryan–Wenger NA, et al. **Nurse Pract** 1997 May;22(5):66–7, 70, 76–9 passim (36 ref.)

LEGISLATION & JURISPRUDENCE

Implications of mandating amended reports following retrospective review of Papanicolaou smears. Freedman LF. **Arch Pathol Lab Med** 1997 Mar;121(3):299–300 (0 ref.)

Medical records and access thereto. McQuoid–Mason D.
Med Law 1996;15(3):499–517 (111 ref.)

STANDARDS

Standardized forms to use in the management of HIV infection [see comments] Parra EO. **Am Fam Physician** 1997 May 1;55(6):2166–72, 2182–4 (24 ref.) Comment in: Am Fam Physician 1997 May 1;55(6):2063–4.

Use of veterinary clinic records for evaluating possible risk factors for disease. Morton JM. **Aust Vet J** 1996 Nov; 74(5):365–6 (9 ref.)

Clinical audit: time for a reappraisal? [see comments] Hopkins A. **J R Coll Physicians Lond** 1996 Sep–Oct;30(5):415–25 (92 ref.) Comment in: J R Coll Physicians Lond 1996 Nov–Dec;30(6):586. Comment in: J R Coll Physicians Lond 1997 Jan–Feb;31(1):113. Comment in: J R Coll Physicians Lond 1997 Mar–Apr;31(2):221.

MEDICAL RECORDS, PROBLEM–ORIENTED

[Documentation and therapeutic standards in anesthesia and intensive care medicine—means for quality assurance and cost control] Bach A, et al. **Zentralbl Chir** 1996; 121(7):521–8 (35 ref.) (Eng. Abstr.) **(Ger)**

MEDICAL RECORDS SYSTEMS, COMPUTERIZED

Information technology for doctors. Kalra D.
Br J Hosp Med 1996 Feb 7–20;55(3):144–6 (12 ref.)

The International Classification of Primary Care (ICPC): new applications in research and computer–based patient records in family practice. Hofmans–Okkes IM, et al.
Fam Pract 1996 Jun;13(3):294–302 (36 ref.)

Practical implementation of the computer–based medical record in orthopaedic surgery. Branson PJ, et al.
Instr Course Lect 1994;43:613–23 (5 ref.)

Serious technology assessment for health care information technology. Cushman R. **J Am Med Inform Assoc** 1997 Jul–Aug;4(4):259–65 (31 ref.)

Nursing classification systems: necessary but not sufficient for representing "what nurses do" for inclusion in computer–based patient record systems [see comments] Henry SB, et al. **J Am Med Inform Assoc** 1997 May–Jun; 4(3):222–32 (48 ref.) Comment in: J Am Med Inform Assoc 1997 May–Jun;4(3):254–5.

Generic data modeling for clinical repositories. Johnson SB.
J Am Med Inform Assoc 1996 Sep–Oct;3(5):328–39 (34 ref.)

How NIC describes MCH nursing. Eganhouse DJ, et al.
MCN Am J Matern Child Nurs 1996 Sep–Oct;21(5):247–52 (22 ref.)

Outcome analysis: considerations for an electronic health record. Dolin RH. **MD Comput** 1997 Jan–Feb;14(1):50–6 (64 ref.)

Review paper: coding systems in health care. Cimino JJ.
Methods Inf Med 1996 Dec;35(4–5):273–84 (73 ref.)

The questions of medical informatics. Dimitrov I.
Methods Inf Med 1996 Mar;35(1):8–11 (10 ref.)

Toward an evaluation of an integrated clinical imaging system: identifying clinical benefits. Kaplan B, et al.
Methods Inf Med 1996 Sep;35(3):221–9 (71 ref.)

Medical records and other stories: a narratological framework [see comments] Kay S, et al.
Methods Inf Med 1996 Jun;35(2):72–87 (119 ref.) Comment in: Methods Inf Med 1996 Jun;35(2):88–92. Comment in: Methods Inf Med 1996 Jun;35(2):93–7. Comment in: Methods Inf Med 1996 Jun;35(2):98–100. Comment in: Methods Inf Med 1996 Jun;35(2):101–3.

Natural language processing in medicine: an overview. Spyns P. **Methods Inf Med** 1996 Dec;35(4–5):285–301 (194 ref.)

Safeguarding patient records. King AB. **Nutrition** 1996 Oct; 12(10):726–7 (3 ref.)

The ED on line: computerization of the pediatric emergency department. Endom EE, et al. **Pediatr Emerg Care** 1996 Aug;12(4):301–4 (4 ref.)

[Automated anesthesia record systems] Heinrichs W, et al. **Anaesthesist** 1997 Jul;46(7):574–82 (37 ref.) (Eng. Abstr.) **(Ger)**

[Programmed complex for automated prophylactic check–ups of chronic outpatients. Communication I. Tasks and fundamentals] Lapochkin VI, et al. **Vestn Oftalmol** 1997 Mar–Apr;113(2):32–4 (0 ref.) (Eng. Abstr.) **(Rus)**

LEGISLATION & JURISPRUDENCE

The search for the elusive electronic medical record system—medical liability, the missing factor. Grams RR, et al. **J Med Syst** 1997 Feb;21(1):1–10 (5 ref.)

ORGANIZATION & ADMINISTRATION

The barriers to electronic medical record systems and how to overcome them. McDonald CJ.
J Am Med Inform Assoc 1997 May–Jun;4(3):213–21 (32 ref.)

STANDARDS

Critical care computing: outcomes, confidentiality, and appropriate use. Goodman KW. **Crit Care Clin** 1996 Jan; 12(1):109–22 (36 ref.)

Accuracy of data in computer–based patient records. Hogan WR, et al. **J Am Med Inform Assoc** 1997 Sep–Oct; 4(5):342–55 (36 ref.)

MEDICAL RESEARCH see **RESEARCH**

MEDICAL SCHOOLS see **SCHOOLS, MEDICAL**

MEDICAL SOCIOLOGY see **SOCIOLOGY, MEDICAL**

MEDICAL STAFF

EDUCATION

Office spirometry: equipment selection and training of staff in the private practice setting. Wanger J, et al.
J Asthma 1997;34(2):93–104 (24 ref.)

PSYCHOLOGY

Ethnocultural factors in the development of an Asian American psychiatrist. Chung H, et al.
Cult Divers Ment Health 1996;2(2):99–106 (12 ref.)

MEDICAL STAFF, HOSPITAL

The surgical team as a source of postoperative wound infections caused by Streptococcus pyogenes. Kolmos HJ, et al. **J Hosp Infect** 1997 Mar;35(3):207–14 (19 ref.)

EDUCATION

How to be an effective educational supervisor. Lloyd B.
Br J Hosp Med 1996 Dec 11–1997 Jan 14;56(11):585–7 (4 ref.)

Surgery and training in surgery in remote rural hospitals. Steiner AK. **East Afr Med J** 1996 Dec;73(12):830–1 (10 ref.)

The clinical learning environment. Rotem A, et al.
Isr J Med Sci 1996 Sep;32(9):705–10 (31 ref.)

Procedural skills in medicine: linking theory to practice. Kovacs G. **J Emerg Med** 1997 May–Jun;15(3):387–91 (22 ref.)

ORGANIZATION & ADMINISTRATION

Does a full–time, 24–hour intensivist improve care and efficiency? Carlson RW, et al. **Crit Care Clin** 1996 Jul; 12(3):525–51 (63 ref.)

PSYCHOLOGY

Burnout and its correlates in emergency physicians: four years' experience with a wellness booth. Goldberg R, et al. **Acad Emerg Med** 1996 Dec;3(12):1156–64 (37 ref.)

MEDICAL STAFF PRIVILEGES

STANDARDS

The evolution of physician credentialing into managed care selective contracting. Blum JD. **Am J Law Med** 1996; 22(2–3):173–203 (0 ref.)

Introduction to economic credentialing. Cruz ML.

MEDICAL STAFF PRIVILEGES

Bol Asoc Med P R 1997 Jan-Mar;89(1-3):35-8 (12 ref.)

MEDICAL STAFF PRIVILEGES, NONPHYSICIAN see **MEDICAL STAFF PRIVILEGES**

MEDICAL TECHNOLOGY see **TECHNOLOGY, MEDICAL**

MEDICAL TOPOGRAPHY see **TOPOGRAPHY, MEDICAL**

MEDICAL TRANSCRIPTION see **MEDICAL RECORDS**

MEDICAL WASTE

see related
BLOOD-BORNE PATHOGENS

Research and the problems of litter and medical wastes on the UK coastline. Philipp R, et al. **Br J Clin Pract** 1997 Apr-May;51(3):164-8 (54 ref.)

MEDICAL WASTE DISPOSAL

Disposal of dialysate in HIV-positive patients: an update. Scheel PJ Jr, et al. **Adv Ren Replace Ther** 1996 Oct; 3(4):298-301 (25 ref.)

Control of biologic hazards. Stave GM. **Occup Med** 1996 Jan-Mar;11(1):79-85 (9 ref.)

METHODS

Laboratory waste disposal. Thergaonkar A, et al. **Indian J Pathol Microbiol** 1997 Apr;40(2):171-9 (10 ref.)

Protecting the patient and the environment--new aspects and challenges in hospital infection control. Daschner FD, et al. **J Hosp Infect** 1997 May;36(1):7-15 (30 ref.)

MEDICALLY ASSISTED SUICIDE see **SUICIDE, ASSISTED**

MEDICALLY UNDERINSURED see **MEDICALLY UNINSURED**

MEDICALLY UNDERSERVED AREA

see related
HEALTH SERVICES ACCESSIBILITY

Breast cancer control among the underserved--an overview. Breen N, et al. **Breast Cancer Res Treat** 1996;40(1):105-15 (77 ref.)

Breast cancer prevention and control among the medically underserved. Kerner JF. **Breast Cancer Res Treat** 1996; 40(1):1-9 (32 ref.)

Health care reform and rural mental health: severe mental illness. Kane CF, et al. **Community Ment Health J** 1996 Oct;32(5):445-62 (80 ref.)

Surgery and training in surgery in remote rural hospitals. Steiner AK. **East Afr Med J** 1996 Dec;73(12):830-1 (10 ref.)

The safety-net role of international medical graduates. Mick SS, et al. **Health Aff (Millwood)** 1997 Jul-Aug;16(4):141-50 (26 ref.)

Pharmaceutical care for rural patients: ominous trends. Gangeness DE. **J Am Pharm Assoc (Wash)** 1997 Jan-Feb; NS37(1):62-5, 84 (21 ref.)

Screening patterns for cervical cancer: how best to reach the unscreened population. Brown CL. **J Natl Cancer Inst Monogr** 1996;(21):7-11 (55 ref.)

Delivering breast and cervical cancer screening services to underserved women: Part I. Literature review and telephone survey. Vellozzi CJ, et al. **Womens Health Issues** 1996 Mar-Apr;6(2):65-73 (34 ref.)

[Practical gynecology in the African bush: from humanitarianism to humanism] Géraud R, et al. **Contracept Fertil Sex** 1997 Jun;25(6):482-91 (28 ref.) **(Fre)**

MEDICALLY UNINSURED

see related
UNCOMPENSATED CARE

Health care coverage for children who are on and off welfare. Moffitt RA, et al. **Future Child** 1997 Spring; 7(1):87-98 (20 ref.)

Health insurance and child support. Meyer DR. **Health Aff (Millwood)** 1997 Mar-Apr;16(2):207-17 (18 ref.)

Medicaid managed care and urban poor people: implications for social work. Perloff JD. **Health Soc Work** 1996 Aug; 21(3):189-95 (33 ref.)

MEDICARE

Outcomes of enhanced prenatal services for Medicaid-eligible women in public and private settings. Simpson L, et al. **Public Health Rep** 1997 Mar-Apr; 112(2):122-32; discussion 133-4 (42 ref.)

ECONOMICS

The evolution of support for safety-net hospitals. Fishman LE, et al. **Health Aff (Millwood)** 1997 Jul-Aug;16(4):30-47 (30 ref.)

LEGISLATION & JURISPRUDENCE

Provider sponsored organizations and provider service networks--rationale and regulation. Hirshfeld EB. **Am J Law Med** 1996;22(2-3):263-300 (0 ref.)

ORGANIZATION & ADMINISTRATION

The market comes to Medicare: adding choice and protections. Lewin ME, et al. **Health Aff (Millwood)** 1996 Winter;15(4):57-61 (12 ref.)

Markets, Medicare, and making do: business strategies after national health care reform. Martin CJ. **J Health Polit Policy Law** 1997 Apr;22(2):557-93 (90 ref.)

Managed care and Medicare reform. Oberlander JB. **J Health Polit Policy Law** 1997 Apr;22(2):595-631 (100 ref.)

STANDARDS

HCFA's health care quality improvement program: the medical informatics challenge. Grant JB, et al. **J Am Med Inform Assoc** 1996 Jan-Feb;3(1):15-26 (47 ref.)

TRENDS

The home health visit: an appropriate unit for Medicare payment? [see comments] Bishop CE, et al. **Health Aff (Millwood)** 1996 Winter;15(4):145-55 (19 ref.) Comment in: Health Aff (Millwood) 1997 Mar-Apr;16(2):261-3.

The future of Medicare and managed care: implications for optometry. Soroka M. **J Am Optom Assoc** 1997 Mar; 68(3):147-54 (12 ref.)

MEDICATION ERRORS

Intrathecal methotrexate overdose. Lee AC, et al. **Acta Paediatr** 1997 Apr;86(4):434-7 (15 ref.)

Medication errors. How common are they and what can be done to prevent them? Bates DW. **Drug Saf** 1996 Nov; 15(5):303-10 (66 ref.)

[Human error in the anesthesiological field. Up to what point is it possible to speak of prevention?] De Amici D, et al. **Epidemiol Prev** 1997 Jan-Mar;21(1):19-29 (51 ref.) (Eng. Abstr.) **(Ita)**

MEDICATION SYSTEM, HOSPITAL see **MEDICATION SYSTEMS, HOSPITAL**

MEDICATION SYSTEMS

STANDARDS

A medication capture and analysis system for use in epidemiology. Thomson WM. **Drugs Aging** 1997 Apr; 10(4):290-8 (16 ref.)

MEDICATION SYSTEMS, HOSPITAL

The challenge of in-hospital medication use: an opportunity for clinical pharmacology. Atkinson AJ Jr, et al. **Clin Pharmacol Ther** 1996 Oct;60(4):363-7 (18 ref.)

STANDARDS

Prophylactic, empiric and therapeutic use of antibiotics. Do we need a guide: a universal edition or a local one? Peetermans WE. **Eur J Emerg Med** 1997 Mar;4(1):15-8 (12 ref.)

MEDICINAL HERBS see **PLANTS, MEDICINAL**

MEDICINE

see related
ECONOMICS, MEDICAL
EDUCATION, MEDICAL
HEALTH CARE
LEGISLATION, MEDICAL

Mental representations of medical diagnostic knowledge: a review [see comments] Custers EJ, et al. **Acad Med** 1996 Oct;71(10 Suppl):S55-61 (95 ref.) Comment in: Acad Med 1997 May;72(5):315-8.

Medical scientists and health news reporting: a case of miscommunication. Shuchman M, et al. **Ann Intern Med** 1997 Jun 15;126(12):976-82 (67 ref.)

Fuzzy set theory in medicine [editorial] Steimann F. **Artif Intell Med** 1997 Sep;11(1):1-7 (15 ref.)

Two centuries of conflict-collaboration between medicine and mathematics. Feinstein AR. **J Clin Epidemiol** 1996 Dec; 49(12):1339-43 (8 ref.)

Medicine and evolution: time for a new paradigm? Herman J. **Med Hypotheses** 1997 May;48(5):403-6 (18 ref.)

Consultation-liaison psychiatry and the practice of medicine. The Thomas P. Hackett Award lecture given at the 42nd annual meeting of the Academy of Psychosomatic Medicine, 1995. Kornfeld DS. **Psychosomatics** 1996 May-Jun;37(3):236-48 (66 ref.)

The meaning of professionalism in medicine. Benatar SR. **S Afr Med J** 1997 Apr;87(4):427-31 (45 ref.)

[Axioms of systematic progress in medicine] Bauer AW. **Internist (Berl)** 1997 Apr;38(4):299-306 (42 ref.) **(Ger)**

[Recombinant probiotics: problems and prospects of their use for medicine and veterinary practice] Sorokulova IB, et al. **Vestn Ross Akad Med Nauk** 1997;(3):46-9 (15 ref.) (Eng. Abstr.) **(Rus)**

[Dysbacteriosis: topical medical problem] Vorobév AA, et al. **Vestn Ross Akad Med Nauk** 1997;(3):4-7 (3 ref.) **(Rus)**

[Techniques, strategies, and uses of molecular biology in medicine (see comments)] Cerezo Román J, et al. **Rev Invest Clin** 1995 Nov-Dec;47(6):487-98 (62 ref.) (Eng. Abstr.) Comment in: Rev Invest Clin 1996 Mar-apr;48(2):167. **(Spa)**

MEDICINE, AFRICAN TRADITIONAL

[How to manage HIV seropositive or AIDS patients in rural Burkina Faso?] Taverne B. **Sante** 1997 May-Jun; 7(3):177-86 (16 ref.) (Eng. Abstr.) **(Fre)**

MEDICINE, ALTERNATIVE see **ALTERNATIVE MEDICINE**

MEDICINE, AYURVEDIC

Indigenous drugs and liver disease. Bhatt AD, et al. **Indian J Gastroenterol** 1996 Apr;15(2):63-7 (30 ref.)

Dava, Daktar, and Dua: anthropology of practiced medicine in India. Khare RS. **Soc Sci Med** 1996 Sep;43(5):837-48 (73 ref.)

MEDICINE, CHINESE TRADITIONAL

see related
DRUGS, CHINESE HERBAL

Chinese herbal medicine in the treatment of asthma and allergies. But P, et al. **Clin Rev Allergy Immunol** 1996 Fall; 14(3):253-69 (40 ref.)

The eastern perspective on functional foods based on traditional Chinese medicine. Weng W, et al. **Nutr Rev** 1996 Nov;54(11 Pt 2):S11-6 (11 ref.)

Perspective and overview of Chinese traditional medicine and contemporary pharmacology. Way EL, et al. **Prog Drug Res** 1996;47:131-64 (84 ref.)

Sleep disorders in Chinese culture: experiences from a study of insomnia in Taiwan. Lee YJ. **Psychiatry Clin Neurosci** 1995 May;49(2):103-6 (9 ref.)

[Research on plasma TXA2, PGI2 levels, blood stasis syndrome and promoting blood circulation] Li H. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Nov; 15(11):701-4 (30 ref.) **(Chi)**

[Progress in the studies on traditional Chinese medicine syndrome differentiation of chronic glomerulonephritis with laboratory findings] Liu HW, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Feb; 16(2):126-8 (21 ref.) **(Chi)**

[Modern research on the types of hypertension in traditional Chinese medicine] Xia YS, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Apr; 16(4):252-4 (29 ref.) **(Chi)**

[Review and prospect of making blood-stasis animal model] Zhang WH, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Mar; 16(3):184-6 (26 ref.) **(Chi)**

MEDICINE, COMPLEMENTARY see **ALTERNATIVE MEDICINE**

MEDICINE, EMPORIATRIC see **TRAVEL**

MEDICINE, EVIDENCE-BASED see **EVIDENCE-BASED MEDICINE**

MEDICINE, FOLK see **MEDICINE, TRADITIONAL**

MEDICINE, HERBAL

see related
DRUGS, CHINESE HERBAL
PLANTS, MEDICINAL

Phytotherapy for the prostate. Buck AC. **Br J Urol** 1996 Sep;78(3):325-36 (59 ref.)

Hepatotoxicity of herbal remedies: insights into the intricacies of plant-animal warfare and cell death [editorial; comment] Kaplowitz N. **Gastroenterology** 1997 Oct;113(4):1408-12 (19 ref.) Comment on: Gastroenterology 1997 Oct;113(4):1334-46.

What pharmacists should know about herbal remedies. Tyler VE. **J Am Pharm Assoc (Wash)** 1996 Jan;NS36(1):29-37 (25 ref.)

Hepatotoxicity of herbal remedies. Larrey D. **J Hepatol** 1997; 26 Suppl 1:47-51 (56 ref.)

Safety issues in herbal medicine: implications for the health professions [see comments] Drew AK, et al. **Med J Aust** 1997 May 19;166(10):538-41 (38 ref.) Comment in: Med J Aust 1997 May 19;166(10):516-7.

A review and critique of common herbal alternative therapies. Youngkin EQ, et al. **Nurse Pract** 1996 Oct; 21(10):39, 43-6, 49-52 passim (25 ref.)

Herbal remedies. Menke J. **S D J Med** 1997 Jun;50(6):207-8 (6 ref.)

[Pharmacovigilance off the beaten track: herbal surveillance or pharmacovigilance of medicinal plants] Castot A, et al. **Therapie** 1997 Mar-Apr;52(2):97-103 (41 ref.) (Eng. Abstr.) **(Fre)**

[Planning, realization and evaluation of post-marketing surveillance studies. Recommendations of the Society for Phytotherapy] Kraft K, et al. **Arzneimittelforschung** 1997 Aug;47(8):990–4 (16 ref.) (Eng. Abstr.) **(Ger)**

MEDICINE, HINDU see **MEDICINE, AYURVEDIC**

MEDICINE IN LITERATURE

The portrayal of the doctor in non-medical literature: the impaired doctor. Posen S. **Med J Aust** 1997 Jan 6; 166(1):48–51 (34 ref.)

Arthur Miller's drama from the standpoint of self psychology. Schneiderman L. **Psychoanal Rev** 1997 Jun;84(3):417–35 (29 ref.)

Beauty and the beast: a myth of sadness, madness, and hope in anaclitic depression. Wu J. **Psychoanal Rev** 1997 Jun; 84(3):365–80 (16 ref.)

Cordelia, Goneril and the febrile response. Mackowiak PA. **Trans Am Clin Climatol Assoc** 1996;108:136–47; discussion 147–8 (58 ref.)

[Literature and psychiatry] Borgna E. **Recenti Prog Med** 1996 Dec;87(12):628–34 (26 ref.) (Eng. Abstr.) **(Ita)**

[Two literary characters in the language of neurology: Pickwick (1)] Navarro FA. **Rev Neurol** 1997 Aug; 25(144):1297–302 (92 ref.) **(Spa)**

MEDICINE, INDIGENOUS see **MEDICINE, TRADITIONAL**

MEDICINE, ORIENTAL TRADITIONAL

Skin scraping, cupping, and moxibustion that may mimic physical abuse. Look KM, et al. **J Forensic Sci** 1997 Jan; 42(1):103–5 (9 ref.)

MEDICINE, PRIMITIVE see **MEDICINE, TRADITIONAL**

MEDICINE, TRADITIONAL

A Malay crosscultural worldview and forensic review of amok. Hatta SM. **Aust N Z J Psychiatry** 1996 Aug; 30(4):505–10 (30 ref.)

Modern role of pharmacology in health sciences: assessing and accessing traditional medicines. Smith CM. **Braz J Med Biol Res** 1996 May;29(5):563–8 (19 ref.)

From plant to patient: an ethnomedical approach to the identification of new drugs for the treatment of NIDDM. Oubré AY, et al. **Diabetologia** 1997 May;40(5):614–7 (23 ref.)

Screening of medicinal plants used by the Garífuna of eastern Nicaragua for bioactive compounds. Coe FG, et al. **J Ethnopharmacol** 1996 Jul 26;53(1):29–50 (71 ref.)

Ritual and medicinal plants of the Ese'ejas of the Amazonian rainforest (Madre de Dios, Perú). Desmarchelier C, et al. **J Ethnopharmacol** 1996 May;52(1):45–51 (20 ref.)

Biological diversity, indigenous knowledge, drug discovery and intellectual property rights: creating reciprocity and maintaining relationships. King SR, et al. **J Ethnopharmacol** 1996 Apr;51(1–3):45–57 (25 ref.)

An analysis of the food plants and drug plants of native North America. Moerman DE. **J Ethnopharmacol** 1996 May; 52(1):1–22 (69 ref.)

Pharmacological activities of Chelidonium majus L. (Papaveraceae). Colombo ML, et al. **Pharmacol Res** 1996 Feb;33(2):127–34 (63 ref.)

Popliteal artery pseudoaneurysm caused by an osteochondroma--a traditional medicine massage sequelae. Kalinga MJ, et al. **Singapore Med J** 1996 Aug;37(4):443–5 (8 ref.)

Triaga Brasilica: renewed interest in a seventeenth-century panacea. Pereira NA, et al. **Toxicon** 1996 May;34(5):511–6 (10 ref.)

MEDICINE, VETERINARY see **VETERINARY MEDICINE**

MEDITATION

see related
YOGA

MEDITERRANEAN FEVER, FAMILIAL see **PERIODIC DISEASE**

MEDITERRANEAN FRUIT FLY see **DIPTERA**

MEDITERRANEAN SPOTTED FEVER see **BOUTONNEUSE FEVER**

MEDLINE

Searching for the evidence. Palmer J, et al. **Genitourin Med** 1997 Feb;73(1):70–2 (8 ref.)

STANDARDS

How to read a paper. The Medline database. Greenhalgh T. **BMJ** 1997 Jul 19;315(7101):180–3 (4 ref.)

MEDPHALAN see **MELPHALAN**

MEDROXYPROGESTERONE

ADMINISTRATION & DOSAGE

In utero medroxyprogesterone exposure after contraceptive failure [see comments] Brady JE, et al. **J Am Board Fam Pract** 1996 Jul-Aug;9(4):285–8 (38 ref.) Comment in: J Am Board Fam Pract 1996 Nov-Dec;9(6):467.

DIAGNOSTIC USE

The progestogen challenge test in postmenopausal women: clinical and morphologic aspects. Bortoletto C de C, et al. **Rev Paul Med** 1996 May-Jun;114(3):1166–72 (28 ref.)

MEDROXYPROGESTERONE 17-ACETATE

ADVERSE EFFECTS

Depot medroxyprogesterone acetate and breast cancer. A review of current knowledge. Chilvers CE. **Drug Saf** 1996 Sep;15(3):212–8 (20 ref.)

THERAPEUTIC USE

Medroxyprogesterone acetate in the treatment of obstructive sleep apnea. Terra SG, et al. **Ann Pharmacother** 1997 Jun; 31(6):776–8 (15 ref.)

MEDULLA OBLONGATA

Intramedullary subependymoma of the spinal cord [see comments] Jallo GI, et al. **Neurosurgery** 1996 Feb; 38(2):251–7 (27 ref.) Comment in: Neurosurgery 1996 Oct;39(4):879.

[A case of cystic hemangioblastoma of the medulla oblongata] Masuda A, et al. **No Shinkei Geka** 1996 Oct;24(10):949–53 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Primary intramedullary melanocytoma of medulla oblongata: a case report] Takenaka N, et al. **No Shinkei Geka** 1996 Mar;24(3):247–52 (28 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD SUPPLY

Spontaneous medullary haemorrhage due to occult vascular malformations. Chaudhuri A, et al. **J Assoc Physicians India** 1996 Jun;44(6):424–6 (15 ref.)

[Laterobulbar infarction (letter; comment)] De Smet Y, et al. **Rev Neurol (Paris)** 1996 Nov;152(11):718–9 (11 ref.) Comment on: Rev Neurol (Paris) 1995 Dec;151(12):714–21. **(Fre)**

DRUG EFFECTS

Functions of angiotensin peptides in the rostral ventrolateral medulla. Dampney RA, et al. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S105–11 (65 ref.)

METABOLISM

Angiotensin receptor heterogeneity in the dorsal medulla oblongata as defined by angiotensin-(1–7). Diz DI, et al. **Adv Exp Med Biol** 1996;396:225–35 (65 ref.)

PHYSIOLOGY

The activation of bulbo-spinal controls by peripheral nociceptive inputs: diffuse noxious inhibitory controls. Villanueva L, et al. **Biol Res** 1995;28(1):113–25 (96 ref.)

Long-term sympatho-excitatory effect of angiotensin II: a mechanism of spontaneous and renovascular hypertension. Fink GD. **Clin Exp Pharmacol Physiol** 1997 Jan;24(1):91–5 (35 ref.)

The neuronal mechanisms of respiratory rhythm generation. Ramirez JM, et al. **Curr Opin Neurobiol** 1996 Dec; 6(6):817–25 (85 ref.)

The medullary raphe nuclei: a system for integration and gain control in autonomic and somatomotor responsiveness? Lovick TA. **Exp Physiol** 1997 Jan; 82(1):31–41 (32 ref.)

Medullary regions for neurogenesis of gasping: noeud vital or noeuds vitals? St John WM. **J Appl Physiol** 1996 Nov; 81(5):1865–77 (92 ref.)

Neurons and receptors in the rostroventrolateral medulla mediating the antihypertensive actions of drugs acting at imidazoline receptors. Reis DJ. **J Cardiovasc Pharmacol** 1996;27 Suppl 3:S11–18 (65 ref.)

The medullary subnucleus reticularis dorsalis (SRD) as a key link in both the transmission and modulation of pain signals. Villanueva L, et al. **Pain** 1996 Oct;67(2–3):231–40 (109 ref.)

Midbrain and medullary regulation of respiration and vocalization. Davis PJ, et al. **Prog Brain Res** 1996; 107:315–25 (61 ref.)

Role of medulla oblongata in generation of sympathetic and vagal outflows. Guyenet PG, et al. **Prog Brain Res** 1996; 107:127–44 (142 ref.)

The ventro-medial medullary projections to spinal motoneurons: ultrastructure, transmitters and functional aspects. Holstege JC. **Prog Brain Res** 1996;107:159–81 (167 ref.)

Midbrain and medullary regulation of defensive cardiovascular functions. Lovick TA. **Prog Brain Res** 1996; 107:301–13 (42 ref.)

Physiological functions of pontomedullary raphe and medial reticular neurons. Mason P, et al. **Prog Brain Res** 1996; 107:269–82 (130 ref.)

PHYSIOPATHOLOGY

Novel estrogen feedback sites associated with stress-induced suppression of luteinizing hormone secretion in female rats. Maeda K, et al. **Cell Mol Neurobiol** 1996 Jun;16(3):311–24 (32 ref.)

SURGERY

Surgical removal of cavernous angioma in the medulla oblongata. A case report. Abe M, et al. **Neurosurg Rev** 1997;20(2):128–31 (10 ref.)

Microsurgical excision of a pontomedullary epidermoid cyst with prepontine extension: case report. Malcolm GP, et al. **Neurosurgery** 1996 Mar;38(3):579–83; discussion 582–3 (21 ref.)

MEDULLOBLASTOMA

COMPLICATIONS

Intracranial aneurysm following radiation therapy for medulloblastoma. A case report and review of the literature. Jensen FK, et al. **Acta Radiol** 1997 Jan; 38(1):37–42 (29 ref.)

DRUG THERAPY

Chemotherapy for medulloblastomas and primitive neuroectodermal tumors. Cohen BH, et al. **J Neurooncol** 1996 Jul;29(1):55–68 (58 ref.)

High dose chemotherapy with autologous stem cell rescue for patients with medulloblastoma. Dunkel IJ, et al. **J Neurooncol** 1996 Jul;29(1):69–74 (20 ref.)

[High-dose chemotherapy in relapse of medulloblastoma in young children] Dupuis-Girod S, et al. **Bull Cancer** 1997 Mar;84(3):264–72 (45 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Tumor suppressor genes and medulloblastoma. Cogen PH, et al. **J Neurooncol** 1996 Jul;29(1):103–12 (40 ref.)

HISTORY

Medulloblastoma: a historical perspective and overview. Rutka JT, et al. **J Neurooncol** 1996 Jul;29(1):1–7 (14 ref.)

MORTALITY

Importance of patient evaluation for long-term survival in medulloblastoma recurrence. La Marca F, et al. **Childs Nerv Syst** 1997 Jan;13(1):30–4 (30 ref.)

PATHOLOGY

Growth factor receptors and medulloblastoma. Goumnerova LC. **J Neurooncol** 1996 Jul;29(1):85–9 (17 ref.)

Cellular and molecular 'pathology of medulloblastoma. Provias JP, et al. **J Neurooncol** 1996 Jul;29(1):35–43 (48 ref.)

PHYSIOPATHOLOGY

Neurotrophin signal transduction in medulloblastoma. Chou TT, et al. **J Neurosci Res** 1997 Sep 1;49(5):522–7 (51 ref.)

RADIOGRAPHY

Neuroradiology of pediatric posterior fossa medulloblastoma. Blaser SI, et al. **J Neurooncol** 1996 Jul;29(1):23–34 (31 ref.)

RADIOTHERAPY

Impact of radiation technique upon the outcome of treatment for medulloblastoma. Halperin EC. **Int J Radiat Oncol Biol Phys** 1996 Aug 1;36(1):233–9 (44 ref.)

The radiation treatment of medulloblastoma. Jenkin D. **J Neurooncol** 1996 Jul;29(1):45–54 (46 ref.)

Radiotherapeutic management of medulloblastoma. Paulino AC. **Oncology (Huntingt)** 1997 Jun;11(6):813–23; discussion 823, 827–8, 831 (83 ref.)

SURGERY

Cerebellar mutism following posterior fossa tumour surgery. Jones S, et al. **Br J Neurosurg** 1996 Apr;10(2):221–4 (18 ref.)

Cure of recurrent medulloblastoma: the contribution of surgical resection at relapse. Balter-Seri J, et al. **Cancer** 1997 Mar 15;79(6):1241–7 (65 ref.)

Surgical management of medulloblastoma. Sutton LN, et al. **J Neurooncol** 1996 Jul;29(1):9–21 (68 ref.)

Cerebellar mutism after posterior cranial fossa surgery. Salvati M, et al. **J Neurosurg Sci** 1996 Mar;40(1):59–63 (21 ref.)

Brain tumors of childhood. Duncan JA 3rd. **Med Health R I** 1996 Jun;79(6):229–31 (11 ref.)

THERAPY

Medulloblastoma: a historical perspective and overview. Rutka JT, et al. **J Neurooncol** 1996 Jul;29(1):1–7 (14 ref.)

MEDULLOBLASTOMA

[Medulloblastoma in adults. Val-de-Grace hospital experience (1975-1994) and literature review] Noël G, et al. **Cancer Radiother** 1997;1(1):60-7 (47 ref.) (Eng. Abstr.) **(Fre)**

MEDULLOMYOBLASTOMA see **MEDULLOBLASTOMA**

MEFLOQUINE

ADVERSE EFFECTS

Mefloquine--a brief review. Ruff T. **Aust Fam Physician** 1996 May;25(5):793 (0 ref.)

MEGACOLON

Primary and secondary disorders to gut muscle and nerve. Kamm MA. **Scand J Gastroenterol Suppl** 1996;220:91-3 (17 ref.)

MEGACOLON, CONGENITAL see **HIRSCHSPRUNG DISEASE**

MEGACOLON, TOXIC

[Toxic megacolon] Real Martínez Y, et al. **Rev Esp Enferm Dig** 1997 Mar;89(3):206-11 (75 ref.) **(Spa)**

DIAGNOSIS

[Toxic megacolon. Apropos 3 cases] Cortesi N, et al. **Minerva Chir** 1997 May;52(5):649-54 (30 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Fulminant primary manifestation of Crohn's colitis "Hot Crohn's disease". Heise W, et al. **Z Gastroenterol** 1997 Jun; 35(6):481-90 (54 ref.)

MEGAESOPHAGUS see **ESOPHAGEAL ACHALASIA**

MEGAKARYOBLASTIC LEUKEMIA, ACUTE see **LEUKEMIA, MEGAKARYOCYTIC, ACUTE**

MEGAKARYOCYTES

CYTOLOGY

Interleukin-6 and megakaryocytopoiesis: an update. Baatout S. **Ann Hematol** 1996 Oct;73(4):157-62 (90 ref.)

The evolution of megakaryocytes to platelets. Nurden P, et al. **Baillieres Clin Haematol** 1997 Feb;10(1):1-27 (101 ref.)

Megakaryocytic cell lines. Saito H. **Baillieres Clin Haematol** 1997 Feb;10(1):47-63 (79 ref.)

The importance of cytoskeleton proteins in megakaryocyte spreading and platelet formation. Baatout S. **Blood Rev** 1996 Mar;10(1):17-9 (25 ref.)

Control of thrombocytopoiesis: current state of the art. Hoffman R, et al. **Cancer Treat Res** 1995;80:25-49 (144 ref.)

Mechanism of action and clinical trials of Mpl ligand. Sheridan WP, et al. **Curr Opin Hematol** 1997 Sep;4(5):312-6 (35 ref.)

Cell cycle: what is wrong in megakaryocyte polyploidization? Baatout S, et al. **Hematol Cell Ther** 1996 Aug;38(4):361-2 (7 ref.)

[Advance in the regulation of megakaryopoiesis] Cao H, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan;27(1):73-5 (10 ref.) **(Chi)**

[Effects of heparin on megakaryocytopoiesis. From fundamental data to clinical applications] Bellucci S, et al. **Ann Med Interne (Paris)** 1997;148(2):150-3 (29 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Anti-platelet drugs: do they affect megakaryocytes? Cazenave JP, et al. **Baillieres Clin Haematol** 1997 Feb; 10(1):163-80 (93 ref.)

IMMUNOLOGY

Megakaryocytes and platelets in immune thrombocytopenic purpura. Wang ZY, et al. **Baillieres Clin Haematol** 1997 Feb;10(1):89-107 (80 ref.)

METABOLISM

[Positive and negative regulation of megakaryocytopoiesis] Bellucci S, et al. **C R Seances Soc Biol Fil** 1996; 190(5-6):515-32 (85 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Megakaryocytes and inherited thrombocytopenias. Bellucci S. **Baillieres Clin Haematol** 1997 Feb;10(1):149-62 (90 ref.)

Megakaryocytes and platelets in myeloproliferative disorders. Briere J, et al. **Baillieres Clin Haematol** 1997 Feb; 10(1):65-88 (103 ref.)

Megakaryocytes and platelets in alpha-granule disorders. Smith MP, et al. **Baillieres Clin Haematol** 1997 Feb; 10(1):125-48 (108 ref.)

Megakaryocytes and platelets in vascular disease. van der Loo B, et al. **Baillieres Clin Haematol** 1997 Feb; 10(1):109-23 (102 ref.)

Clonality assays and megakaryocyte culture techniques in essential thrombocythemia. Yan L, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:31-40 (61 ref.)

[Dysmegakaryocytopoiesis and thrombopoiesis in autoimmune thrombocytopenias] Bellucci S. **C R Seances Soc Biol Fil** 1996;190(5-6):541-8 (25 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Positive and negative regulation of megakaryocytopoiesis. Wendling F, et al. **Baillieres Clin Haematol** 1997 Feb; 10(1):29-45 (85 ref.)

Human megakaryocyte biology and pathophysiology. Zauli G, et al. **Crit Rev Oncol Hematol** 1995 Nov;21(1-3):135-57 (304 ref.)

Thrombopoietin: the primary regulator of megakaryocytopoiesis and thrombopoiesis. Eaton DL, et al. **Exp Hematol** 1997 Jan;25(1):1-7 (74 ref.)

[Positive and negative regulation of megakaryocytopoiesis] Bellucci S, et al. **C R Seances Soc Biol Fil** 1996; 190(5-6):515-32 (85 ref.) (Eng. Abstr.) **(Fre)**

[Regulation of megakaryocyte and platelet production] Nagasawa T, et al. **Rinsho Ketsueki** 1997 Apr;38(4):241-4 (17 ref.) **(Jpn)**

[The megakaryocyte-thrombocyte system] Ermolaeva TA, et al. **Vestn Ross Akad Med Nauk** 1996;(12):34-43 (56 ref.) (Eng. Abstr.) **(Rus)**

MEGAKARYOCYTIC LEUKEMIA see **LEUKEMIA, MEGAKARYOCYTIC, ACUTE**

MEGAKARYOCYTIC LEUKEMIA, ACUTE see **LEUKEMIA, MEGAKARYOCYTIC, ACUTE**

MEGAVOLT RADIOTHERAPY see **RADIOTHERAPY, HIGH-ENERGY**

MEGESTROL

ADVERSE EFFECTS

Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature. Mann M, et al. **Arch Intern Med** 1997 Aug 11-25; 157(15):1651-6 (23 ref.)

MEGESTROL ACETATE

THERAPEUTIC USE

The effect of megestrol acetate on anorexia, weight loss and cachexia in cancer and AIDS patients (review). Strang P. **Anticancer Res** 1997 Jan-Feb;17(1B):657-62 (36 ref.)

Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Kim YB, et al. **Cancer** 1997 Jan 15;79(2):320-7 (38 ref.)

Endocrinology of melanoma. Neifeld JP. **Semin Surg Oncol** 1996 Nov-Dec;12(6):402-6 (37 ref.)

MEGLUMINE

DIAGNOSTIC USE

Venous aneurysms: MR diagnosis with the "layered gadolinium" sign. Krinsky G, et al. **J Comput Assist Tomogr** 1997 Jul-Aug;21(4):623-7 (12 ref.)

MEGLUMINE DIATRIZOATE see **DIATRIZOATE MEGLUMINE**

MEIGE SYNDROME

DRUG THERAPY

[Oromandibular dystonia and botulinum toxins] Van Durme B, et al. **Acta Stomatol Belg** 1996 Mar;93(1):37-41 (38 ref.) (Eng. Abstr.) **(Fre)**

MEIOSIS

see related
MATURATION-PROMOTING FACTOR

The license to pair: identification of meiotic pairing sites in Drosophila. McKee BD. **Chromosoma** 1996 Sep; 105(3):135-41 (34 ref.)

Parental age-related aneuploidy in human germ cells and offspring: a story of past and present. Eichenlaub-Ritter U. **Environ Mol Mutagen** 1996;28(3):211-36 (200 ref.)

Meiotic recombination and germ cell aneuploidy. Ferguson LR, et al. **Environ Mol Mutagen** 1996;28(3):192-210 (178 ref.)

Chromosomal differences in susceptibility to meiotic aneuploidy. Warburton D, et al. **Environ Mol Mutagen** 1996;28(3):237-47 (52 ref.)

Meiotic analysis. Spencer JF, et al. **Methods Mol Biol** 1996; 53:51-8 (9 ref.)

How cells get the right chromosomes. Nicklas RB. **Science** 1997 Jan 31;275(5300):632-7 (45 ref.)

[The roles of the Mos-MAPK pathway in oocyte meiosis and cellular transformation] Sagata N. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1847-55 (62 ref.) **(Jpn)**

[How different is the meiotic cell cycle control from the mitotic one?] Shimoda C. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1856-62 (49 ref.) **(Jpn)**

[Functions of recombination proteins in meiosis] Terasawa M, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep; 41(11):1535-42 (39 ref.) **(Jpn)**

GENETICS

Human female meiosis: new insights into an error-prone process [editorial] Warburton D. **Am J Hum Genet** 1997 Jul;61(1):1-4 (20 ref.)

Meiotic recombination hotspots. Lichten M, et al. **Annu Rev Genet** 1995;29:423-44 (157 ref.)

A super new twist on the initiation of meiotic recombination. Haber JE. **Cell** 1997 Apr 18;89(2):163-6 (21 ref.)

Meiotic recombination in yeast: coronation of the double-strand-break repair model. Stahl F. **Cell** 1996 Dec 13;87(6):965-8 (10 ref.)

DNA mismatch repair in mammals: role in disease and meiosis. Arnheim N, et al. **Curr Opin Genet Dev** 1997 Jun; 7(3):364-70 (92 ref.)

Affected sibpair linkage tests for multiple linked susceptibility genes. Farrall M. **Genet Epidemiol** 1997;14(2):103-15 (18 ref.)

Interactions between and along chromosomes during meiosis. Kleckner N. **Harvey Lect** 1995-96;91:21-45 (66 ref.)

[Cytogenetic patterns in synapsis of meiotic chromosomes in animals and plants] Bogdanov IuF, et al. **Genetika** 1996 Nov;32(11):1474-93 (95 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Synthesis and function of Mos: the control switch of vertebrate oocyte meiosis. Gebauer F, et al. **Bioessays** 1997 Jan;19(1):23-8 (61 ref.)

Regulation of meiosis in fission yeast. Yamamoto M. **Cell Struct Funct** 1996 Oct;21(5):431-6 (43 ref.)

Stopping and starting the meiotic cell cycle. Page AW, et al. **Curr Opin Genet Dev** 1997 Feb;7(1):23-31 (64 ref.)

Strange bedfellows in even stranger places: the role of ATM in meiotic cells, lymphocytes, tumors, and its functional links to p53 [comment] Hawley RS, et al. **Genes Dev** 1996 Oct 1;10(19):2383-8 (49 ref.) Comment on: Genes Dev 1996 Oct 1;10(19):2423-37. Comment on: Genes Dev 1996 Oct 1;10(19):2401-10. Comment on: Genes Dev 1996 Oct 1;10(19):2411-22.

The transcriptional basis of chromosome pairing. Cook PR. **J Cell Sci** 1997 May;110 (Pt 9):1033-40 (75 ref.)

MEISSNER'S CORPUSCLE see **MECHANORECEPTORS**

MEISSNER'S PLEXUS see **SUBMUCOUS PLEXUS**

MELANCHOLIA see **DEPRESSIVE DISORDER**

MELANINS

Melanotropic peptides in the mammalian brain: the melanin-concentrating hormone. Knigge KM, et al. **Peptides** 1996;17(6):1063-73 (147 ref.)

ANALYSIS

Melanotic cerebral astrocytoma: case report and literature review. Kanzawa T, et al. **Acta Neuropathol (Berl)** 1997 Feb;93(2):200-4 (21 ref.)

BIOSYNTHESIS

Aspects of exposure to UVA tanning sources. Carcinogenic effect in mice and melanogenic effect in man and mice. Bech-Thomsen N. **Dan Med Bull** 1997 Jun;44(3):242-56 (116 ref.)

Melanosomal proteins as melanoma-specific immune targets. Sakai C, et al. **Melanoma Res** 1997 Apr;7(2):83-95 (130 ref.)

The role of peroxidase in mammalian melanogenesis: a review. Okun MR. **Physiol Chem Phys Med NMR** 1996; 28(2):91-100; discussion 100-1 (58 ref.)

Vitiligo, psoralen, and melanogenesis: some observations and understanding. Chakraborty DP, et al. **Pigment Cell Res** 1996 Jun;9(3):107-16 (90 ref.)

The interaction of agouti signal protein and melanocyte stimulating hormone to regulate melanin formation in mammals. Furumura M, et al. **Pigment Cell Res** 1996 Aug; 9(4):191-203 (135 ref.)

Markers of melanogenesis in malignant melanoma. Matous B, et al. **Sb Lek** 1994;95(4):333-38 (20 ref.)

METABOLISM

Actin-dependent pigment granule transport in retinal pigment epithelial cells. Burnside B, et al. **Biol Bull** 1997 Feb;192(1):181-2 (7 ref.)

Hair melanin and hair color. Castanet J, et al. **EXS** 1997; 78:209-25 (56 ref.)

The color of the human eye: a review of morphologic correlates and of some conditions that affect iridial pigmentation. Imesch PD, et al. **Surv Ophthalmol** 1997 Feb; 41 Suppl 2:S117-23 (46 ref.)

[New possible pathways for melanogenesis: opiomelanins] Rosei MA, et al. **Recenti Prog Med** 1997 Mar;88(3):134-9 (13 ref.) (Eng. Abstr.) **(Ita)**

MELANISM see MELANOSIS

MELANOAMELOBLASTOMA see NEUROECTODERMAL TUMOR, MELANOTIC

MELANOCYTE-STIMULATING HORMONES see MSH

MELANOCYTES

CYTOLOGY

Regulation of melanocyte differentiation and growth. Goding CR, et al. **Cell Growth Differ** 1997 Sep;8(9):935–40 (18 ref.)

Evidence to suggest that expression of MITF induces melanocyte differentiation and haploinsufficiency of MITF causes Waardenburg syndrome type 2A. Tachibana M. **Pigment Cell Res** 1997 Feb–Apr;10(1–2):25–33 (33 ref.)

ENZYMOLOGY

Activation of human pp60c-src. Bjorge JD, et al. **Biochem Cell Biol** 1996;74(4):477–84 (88 ref.)

METABOLISM

Melanosomal proteins as melanoma-specific immune targets. Sakai C, et al. **Melanoma Res** 1997 Apr;7(2):83–95 (130 ref.)

Biological role of tyrosinase related protein and its biosynthesis and transport from TGN to stage I melanosome, late endosome, through gene transfection study. Jimbow K, et al. **Pigment Cell Res** 1997 Aug; 10(4):206–13 (34 ref.)

PATHOLOGY

Pigmented squamous cell carcinoma with dendritic melanocytes. Kossard S, et al. **Australas J Dermatol** 1997 Aug;38(3):145–7 (16 ref.)

Dermal melanocytosis: a clinical spectrum. Stanford DG, et al. **Australas J Dermatol** 1996 Feb;37(1):19–25 (35 ref.)

Primary melanocytomas of the spinal cord: a report of seven cases. Glick R, et al. **Clin Neuropathol** 1997 May–Jun; 16(3):127–32 (11 ref.)

Acquired dermal melanocytosis on the wrist. Kuniyuki S. **J Dermatol** 1997 Feb;24(2):120–4 (18 ref.)

Stromal melanocytosis of an adenoid cystic carcinoma arising from the palatal minor salivary gland. Takeda Y. **Pathol Int** 1996 Jun;46(6):467–70 (19 ref.)

Piebaldism, Waardenburg syndrome, and related disorders of melanocyte development. Spritz RA. **Semin Cutan Med Surg** 1997 Mar;16(1):15–23 (59 ref.)

[Activation of epidermal melanocytes is independent of epithelial proliferation and vascularization. Immunohistologic study using HMB-45 antibody with review of the literature] Lommel K, et al. **Hautarzt** 1996 Aug;47(8):616–23 (65 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

The control of gene expression in melanocytes and melanomas. Eisen TG. **Melanoma Res** 1996 Aug; 6(4):277–84 (36 ref.)

RADIATION EFFECTS

Relevance of in vitro melanocytic cell studies to the understanding of melanoma. Linge C. **Cancer Surv** 1996; 26:71–87 (49 ref.)

ULTRASTRUCTURE

The intracellular origin of the melanosome in pigment cells: a review of ultrastructural data. Schraermeyer U. **Histol Histopathol** 1996 Apr;11(2):445–62 (125 ref.)

MELANOMA

Cutaneous malignant melanoma. Ringborg U. **Acta Otolaryngol (Stockh)** 1996 Sep;116(5):641–6 (25 ref.)

Melanoma: epidemiology, pathogenesis, and new modes of treatment. Dreiling L, et al. **Adv Intern Med** 1996; 41:553–604 (152 ref.)

Malignant melanoma in children. A review [published erratum appears in Arch Dermatol 1997 Jul;133(7):833] Ruiz-Maldonado R, et al. **Arch Dermatol** 1997 Mar; 133(3):363–71 (133 ref.)

Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Tsao H, et al. **Cancer** 1997 Jun 15; 79(12):2361–70 (29 ref.)

Animal models of melanoma. Kusewitt DF, et al. **Cancer Surv** 1996;26:35–70 (199 ref.)

Malignant melanoma: Mayo Clinic experience. Sim FH, et al. **Mayo Clin Proc** 1997 Jun;72(6):565–9 (35 ref.)

Melanomas of the vulva and vagina. Trimble EL. **Oncology (Huntingt)** 1996 Jul;10(7):1017–23; discussion 1024 (37 ref.)

Primary malignant melanoma of the ovary. Boscaino A, et al. **Pathologica** 1995 Dec;87(6):685–8 (11 ref.)

The multidisciplinary melanoma center. Sagebiel RW. **Surg Clin North Am** 1996 Dec;76(6):1433–9 (6 ref.)

[Malignant melanoma of the esophagus and anorectum] Stremmel C, et al. **Dtsch Med Wochenschr** 1996 Dec 13; 121(50):1573–5 (16 ref.) **(Ger)**

BLOOD SUPPLY

The importance of L-arginine metabolism in melanoma: an hypothesis for the role of nitric oxide and polyamines in tumor angiogenesis. Joshi M. **Free Radic Biol Med** 1997; 22(3):573–8 (63 ref.)

CHEMICALLY INDUCED

Malignant melanoma and levodopa: is there a relationship? Two new cases and a review of the literature. Pfützner W, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):332–6 (68 ref.)

[Metastatic malignant melanoma in treated non-Hodgkin's lymphoma] Falk S, et al. **Hautarzt** 1996 Sep;47(9):716–8 (21 ref.) (Eng. Abstr.) **(Ger)**

CLASSIFICATION

The classification of melanoma: time for a further revision? Cochran AJ, et al. **Melanoma Res** 1997 Feb;7(1):4–9 (12 ref.)

Prognostic value of morphometric features and the callender classification in uveal melanomas. Coleman K, et al. **Ophthalmology** 1996 Oct;103(10):1634–41 (23 ref.)

Cutaneous malignant melanoma: classification and clinical diagnosis. Porras BH, et al. **Semin Cutan Med Surg** 1997 Jun;16(2):88–96 (34 ref.)

Variants of melanoma. Reed RJ, et al. **Semin Cutan Med Surg** 1997 Jun;16(2):137–58 (12 ref.)

COMPLICATIONS

Dermatomyositis and malignant melanoma. Shorr AF, et al. **Am J Med Sci** 1997 Apr;313(4):249–51 (11 ref.)

Colosplenic fistula in a patient treated with interleukin-2 for malignant melanoma. Chun ES, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):674–6 (8 ref.)

DIAGNOSIS

Posterior uveal melanoma. The Swedish perspective [see comments] Seregard S. **Acta Ophthalmol Scand** 1996 Aug; 74(4):315–29 (158 ref.) Comment in: Acta Ophthalmol Scand 1996 Aug;74(4):313.

Ring melanoma of the anterior uvea presenting as unilateral neovascular glaucoma. Allaire GS, et al. **Can J Ophthalmol** 1997 Aug;32(5):338–41 (14 ref.)

Screening for melanoma. Elwood JM. **Cancer Treat Res** 1996; 86:129–47 (76 ref.)

Malignant primary skin tumors in children. Sasson M, et al. **Curr Opin Pediatr** 1996 Aug;8(4):372–7 (34 ref.)

Superficial spreading melanoma resembling Spitz nevus on the plantar surface [letter] Kato T, et al. **Dermatology** 1996; 193(4):353–4 (17 ref.)

Meningeal melanocytoma: case report and review of the literature. Ibáñez J, et al. **Histopathology** 1997 Jun; 30(6):576–81 (49 ref.)

Dynamic breath-hold 3D gadolinium-enhanced MRI of intraarterial masses: findings in two patients. Krinsky G, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):631–4 (9 ref.)

Pigmented lesions of the conjunctiva. Farber M, et al. **J Dermatol** 1996 Nov;23(11):746–50 (8 ref.)

Multiple nodular lesions seen in a patient with neurocutaneous melanosis. Sasaki Y, et al. **J Dermatol** 1996 Nov;23(11):828–31 (11 ref.)

Malignant melanoma: differential diagnosis of pigmented lesions. Le AD, et al. **J Fla Med Assoc** 1997 Mar; 84(3):166–74 (45 ref.)

Malignant melanoma: prognostic indicators. Ahmed I. **Mayo Clin Proc** 1997 Apr;72(4):356–61 (40 ref.)

Diagnosis of right atrial metastatic melanoma by transesophageal echocardiographic-guided transvenous biopsy. Malouf JF, et al. **Mayo Clin Proc** 1996 Dec; 71(12):1167–70 (14 ref.)

Mucosal, genital, and unusual clinical variants of melanoma. Rogers RS 3rd, et al. **Mayo Clin Proc** 1997 Apr;72(4):362–6 (15 ref.)

Systematic review of the diagnostic accuracy of dermatoscopy in detecting malignant melanoma. Mayer J. **Med J Aust** 1997 Aug 18;167(4):206–10 (25 ref.)

Cutaneous malignant melanoma: classification and clinical diagnosis. Porras BH, et al. **Semin Cutan Med Surg** 1997 Jun;16(2):88–96 (34 ref.)

Diagnosis and treatment of uveal melanoma. Shields JA, et al. **Semin Oncol** 1996 Dec;23(6):763–7 (23 ref.)

Malignant melanoma from the dermatologic perspective. Swetter SM. **Surg Clin North Am** 1996 Dec;76(6):1287–98 (64 ref.)

[Malignant anorectal melanoma: description of a clinical case and review of the literature] Malaguarnera M, et al. **Bull Cancer** 1997 Apr;84(4):423–6 (35 ref.) (Eng. Abstr.) **(Fre)**

[Activation of epidermal melanocytes is independent of epithelial proliferation and vascularization. Immunohistologic study using HMB-45 antibody with review of the literature] Lommel K, et al. **Hautarzt** 1996 Aug;47(8):616–23 (65 ref.) (Eng. Abstr.) **(Ger)**

[Clinical diagnosis of primary melanoma of the skin] Barchuk AS, et al. **Vopr Onkol** 1996;42(5):96–100 (18 ref.) (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Compartment syndrome after isolated perfusion of the leg: a case report. Chan PS, et al. **Am J Orthop** 1997 May; 26(5):369–70 (7 ref.)

Cytokine therapy of malignant melanoma. Villikka K, et al. **Ann Med** 1996 Jun;28(3):227–33 (63 ref.)

Mortality, major amputation rates, and leukopenia after isolated limb perfusion with phenylalanine mustard for the treatment of melanoma. Taber SW, et al. **Ann Surg Oncol** 1997 Jul–Aug;4(5):440–5 (30 ref.)

Frequency and duration of remission after isolated limb perfusion for melanoma. Thompson JF, et al. **Arch Surg** 1997 Aug;132(8):903–7 (23 ref.)

Thirty-five years of isolated limb perfusion for melanoma: indications and results. Vrouenraets BC, et al. **Br J Surg** 1996 Oct;83(10):1319–28 (131 ref.)

Retinoids in the management of non-melanoma skin cancer and melanoma. Craven NM, et al. **Cancer Surv** 1996; 26:267–88 (145 ref.)

Interaction of chemotherapy and biological response modifiers in the treatment of melanoma. Anderson CM, et al. **Cancer Treat Res** 1996;87:357–80 (126 ref.)

The treatment of disseminated malignant melanoma with special reference to the role of interferons, vinca alkaloids and tamoxifen. Bezwoda WR. **Cancer Treat Rev** 1997 Jan; 23(1):17–34 (144 ref.)

Interferons in melanoma. Agarwala SS, et al. **Curr Opin Oncol** 1996 Mar;8(2):167–74 (57 ref.)

Chemotherapy for metastatic melanoma during pregnancy. Dipaola RS, et al. **Gynecol Oncol** 1997 Sep;66(3):526–30 (21 ref.)

The role of interferon alfa in the treatment of metastatic melanoma. Legha SS. **Semin Oncol** 1997 Feb;24(1 Suppl 4):S24–31 (35 ref.)

Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. Legha SS. **Semin Oncol** 1997 Feb;24(1 Suppl 4):S39–43 (25 ref.)

Systemic chemotherapy for the treatment of metastatic melanoma. Mc Clay EF, et al. **Semin Oncol** 1996 Dec; 23(6):744–53 (91 ref.)

Treatment of malignant melanoma with interleukin-2. Philip PA, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 4):S32–8 (64 ref.)

Isolated limb perfusion for malignant melanoma. Alexander HR Jr, et al. **Semin Surg Oncol** 1996 Nov–Dec;12(6):416–28 (85 ref.)

Endocrinology of melanoma. Neifeld JP. **Semin Surg Oncol** 1996 Nov–Dec;12(6):402–6 (37 ref.)

Medical treatment of metastatic melanoma. Houghton AN, et al. **Surg Clin North Am** 1996 Dec;76(6):1343–54 (113 ref.)

[Melanoma: a new interferon is coming ... handle with care!] Négrier S. **Bull Cancer** 1997 Apr;84(4):435–7 (22 ref.) **(Fre)**

[L-MTP-PE--a potential antineoplastic agent] Dzierzbicka K, et al. **Postepy Hig Med Dosw** 1997;51(2):227–36 (37 ref.) (Eng. Abstr.) **(Pol)**

ENZYMOLOGY

Activation of human pp60c-src. Bjorge JD, et al. **Biochem Cell Biol** 1996;74(4):477–84 (88 ref.)

The plasminogen activation system in melanoma cell lines and in melanocytic lesions. de Vries TJ, et al. **Melanoma Res** 1996 Apr;6(2):79–88 (93 ref.)

EPIDEMIOLOGY

Differences in malignant melanoma between children and adolescents. A 35-year epidemiological study. Berg P, et al. **Arch Dermatol** 1997 Mar;133(3):295–7 (20 ref.)

Melanoma epidemiology [see comments] Berwick M, et al. **Curr Opin Oncol** 1997 Mar;9(2):178–82 (55 ref.) Comment in: Curr Opin Oncol 1997 Mar;9(2):175–7.

Malignant melanoma: incidence issues and their effect on diagnosis and treatment in the 1990s. Rigel DS. **Mayo Clin Proc** 1997 Apr;72(4):367–71 (35 ref.)

Melanoma and sun exposure. Elwood JM. **Semin Oncol** 1996 Dec;23(6):650–66 (69 ref.)

Dysplastic nevi and other risk markers for melanoma. Seykora J, et al. **Semin Oncol** 1996 Dec;23(6):682–7 (52 ref.)

The genetics of melanoma. Fraser MC, et al. **Semin Oncol Nurs** 1997 May;13(2):108–14 (72 ref.)

Epidemiology of malignant melanoma. Liu T, et al. **Surg Clin North Am** 1996 Dec;76(6):1205–22 (66 ref.)

[Melanoma of the oral cavity. Review of the literature] Garzino Demo P, et al. **Minerva Stomatol** 1997 Jun; 46(6):329–35 (70 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Relevance of in vitro melanocytic cell studies to the understanding of melanoma. Linge C. **Cancer Surv** 1996; 26:71–87 (49 ref.)

Sunburn, sunscreen, and melanoma. Donawho C, et al. **Curr Opin Oncol** 1996 Mar;8(2):159–66 (57 ref.)

Neovaginal malignant melanoma following surgery and radiation for vulvar squamous cell carcinoma. Lara PN Jr, et al. **Gynecol Oncol** 1997 Jun;65(3):520–2 (18 ref.)

The skin cancer cascade: from ozone depletion to melanoma--some definitions and some new interpretation,

1996. Fitzpatrick TB. **J Dermatol** 1996 Nov;23(11):816–20 (11 ref.)
Relevance of in vivo models in melanoma skin cancer. Setlow RB. **Photochem Photobiol** 1996 Apr;63(4):410–2 (18 ref.)
Controversies in the role of sunlight in the pathogenesis of cutaneous melanoma. Weinstock MA. **Photochem Photobiol** 1996 Apr;63(4):406–10 (33 ref.)
Melanoma and sun exposure. Elwood JM. **Semin Oncol** 1996 Dec;23(6):650–66 (69 ref.)
[Etiology of malignant melanoma--what do we know?] Helsing P. **Tidsskr Nor Laegeforen** 1997 Mar 10; 117(7):969–71 (33 ref.) (Eng. Abstr.) **(Nor)**

GENETICS

Molecular pathology of melanoma. Newton Bishop JA. **Cancer Metastasis Rev** 1997 Jun;16(1–2):141–54 (114 ref.)
DNA damage and repair in melanoma and non-melanoma skin cancer. Camplejohn RS. **Cancer Surv** 1996;26:193–206 (46 ref.)
CDKN2 mutations in melanoma. Dracopoli NC, et al. **Cancer Surv** 1996;26:115–32 (72 ref.)
The role of atypical mole syndrome and cutaneous naevi in the development of melanoma. Easton D. **Cancer Surv** 1996;26:237–49 (43 ref.)
Detection of melanoma cells in peripheral blood using reverse transcription polymerase chain reaction assay for tyrosinase mRNA. Jung FA, et al. **Cancer Surv** 1996;26:251–65 (38 ref.)
Molecular genetic approaches to non-melanoma and melanoma skin cancer. Rees JL, et al. **Clin Exp Dermatol** 1996 Jul;21(4):253–62 (141 ref.)
The current situation with regard to human melanoma and genetic inferences. Hayward NK. **Curr Opin Oncol** 1996 Mar;8(2):136–42 (69 ref.)
Screening for CDKN2A mutations in hereditary melanoma [editorial; comment] Goldstein AM, et al. **J Natl Cancer Inst** 1997 May 21;89(10):676–8 (33 ref.) Comment on: J Natl Cancer Inst 1997 May 21;89(10):697–702.
Genetics of cutaneous melanoma and nevi. Greene MH. **Mayo Clin Proc** 1997 May;72(5):467–74 (75 ref.)
The control of gene expression in melanocytes and melanomas. Eisen TG. **Melanoma Res** 1996 Aug; 6(4):277–84 (36 ref.)
Involvement of the p16INK4 (CDKN2) gene in familial melanoma. Naylor MF, et al. **Melanoma Res** 1996 Apr; 6(2):139–45 (93 ref.)
Oncogenes and tumor suppressor genes in cutaneous malignant melanoma. Albino AP, et al. **Photochem Photobiol** 1996 Apr;63(4):412–8 (79 ref.)
Molecular aspects of malignant melanoma. Role of protooncogenes and oncosuppressor genes. Křemen J, et al. **Sb Lek** 1994;95(4):321–31 (62 ref.)
A review of inherited predisposition to melanoma. Cannon-Albright LA, et al. **Semin Oncol** 1996 Dec; 23(6):667–72 (66 ref.)
Genetic aspects of uveal melanoma: a brief review. Singh AD, et al. **Semin Oncol** 1996 Dec;23(6):768–72 (45 ref.)
The genetics of melanoma. Fraser MC, et al. **Semin Oncol Nurs** 1997 May;13(2):108–14 (72 ref.)
Clinical implications of cytogenetic abnormalities in melanoma. Nelson MA, et al. **Surg Clin North Am** 1996 Dec;76(6):1257–71 (65 ref.)
[Molecular biology of melanoma--1997] Zlotogorski A, et al. **Harefuah** 1997 Jun 15;132(12):855–8 (33 ref.) **(Heb)**

IMMUNOLOGY

Cytokine-based gene therapy of human tumors. An overview. Parmiani G, et al. **Folia Biol (Praha)** 1996; 42(6):305–9 (21 ref.)
Identification of tumor-regression antigens in melanoma. Kawakami Y, et al. **Important Adv Oncol** 1996;:3–21 (140 ref.)
T-cell recognition of melanoma antigens and its therapeutic applications. Castelli C, et al. **Int J Clin Lab Res** 1997; 27(2):103–10 (46 ref.)
Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. Kawakami Y, et al. **Int Rev Immunol** 1997;14(2–3):173–92 (103 ref.)
Melanosomal proteins as melanoma-specific immune targets. Sakai C, et al. **Melanoma Res** 1997 Apr;7(2):83–95 (130 ref.)
Immunology of malignant melanoma. Armstrong CA, et al. **Photochem Photobiol** 1996 Apr;63(4):418–20 (32 ref.)
Melanoma-associated tumor antigens and their clinical relevance to immunotherapy. Gattoni-Celli S, et al. **Semin Oncol** 1996 Dec;23(6):754–8 (39 ref.)
Tumor antigens and tumor vaccines: peptides as immunogens. Slingluff CL Jr. **Semin Surg Oncol** 1996 Nov-Dec; 12(6):446–53 (89 ref.)
Immunological gene therapy approaches for malignant melanoma. 1. Tumor-immunological background. Bonnekoh B, et al. **Skin Pharmacol** 1997;10(2):49–62 (86 ref.)
Immunological gene therapy approaches for malignant melanoma. 2. Preclinical studies and clinical strategies. Bonnekoh B, et al. **Skin Pharmacol** 1997;10(3):105–25 (93 ref.)

METABOLISM

Xenograft model systems for human melanoma. Rofstad EK, et al. **Mol Med Today** 1996 Sep;2(9):394–403 (40 ref.)
Signal transduction by the oncogenic receptor tyrosine kinase Xmrk in melanoma formation of Xiphophorus. Wellbrock C, et al. **Pigment Cell Res** 1997 Feb–Apr;10(1–2):34–40 (60 ref.)
Markers of melanogenesis in malignant melanoma. Matous B, et al. **Sb Lek** 1994;95(4):333–38 (20 ref.)

MORTALITY

Gender and cutaneous melanoma. Miller JG, et al. **Br J Dermatol** 1997 May;136(5):657–65 (58 ref.)

PATHOLOGY

Myxoid metastases of melanoma: report of three cases and review of the literature. Collina G, et al. **Am J Dermatopathol** 1997 Feb;19(1):52–7 (23 ref.)
Sentinel lymph node evaluation in melanoma. Brady MS, et al. **Arch Dermatol** 1997 Aug;133(8):1014–20 (32 ref.)
Primary choroidal melanoma in a patient with previous cutaneous melanoma. Scull JJ, et al. **Arch Ophthalmol** 1997 Jun;115(6):796–8 (16 ref.)
Maternal melanoma metastatic to the placenta: a case report and review of the literature. Baergen RN, et al. **Arch Pathol Lab Med** 1997 May;121(5):508–11 (26 ref.)
Primary sellar haemorrhagic melanoma: case report and review of the literature. Aubin MJ, et al. **Br J Neurosurg** 1997 Feb;11(1):80–3 (12 ref.)
Role of intermediate filaments in migration, invasion and metastasis. Hendrix MJ, et al. **Cancer Metastasis Rev** 1996 Dec;15(4):507–25 (105 ref.)
Molecular pathology of melanoma. Newton Bishop JA. **Cancer Metastasis Rev** 1997 Jun;16(1–2):141–54 (114 ref.)
Primary melanocytomas of the spinal cord: a report of seven cases. Glick R, et al. **Clin Neuropathol** 1997 May-Jun; 16(3):127–32 (11 ref.)
Pathology of malignant melanoma, including new markers and techniques in diagnosis and prognosis. De Wit PE, et al. **Curr Opin Oncol** 1996 Mar;8(2):143–51 (69 ref.)
A pigmented scalp nodule: malignant blue nevus. English JC 3rd, et al. **Cutis** 1996 Jul;58(1):40–2 (6 ref.)
Juvenile melanoma (Spitz nevus). Helm KF, et al. **Cutis** 1996 Jul;58(1):35–9 (63 ref.)
Desmoplastic malignant melanoma of the gingiva: case report and review of the literature. Ueta E, et al. **Eur J Cancer B Oral Oncol** 1996 Nov;32B(6):423–7 (13 ref.)
Malignant melanoma arising in mature ovarian cystic teratoma (dermoid cyst). Report of two cases and literature analysis. Davis GL. **Int J Gynecol Pathol** 1996 Oct; 15(4):356–62 (50 ref.)
A study of large congenital melanocytic nevi and associated malignant melanomas: review of cases in the New York University Registry and the world literature. DeDavid M, et al. **J Am Acad Dermatol** 1997 Mar;36(3 Pt 1):409–16 (106 ref.)
Familial atypical mole syndrome manifesting as polypoid melanoma: a case report and review of the Japanese literature. Misago N, et al. **J Dermatol** 1996 Oct; 23(10):689–96 (38 ref.)
Metastasis of a malignant melanoma to the region of an impacted mandibular third molar: a case report. Santamaría J, et al. **J Oral Maxillofac Surg** 1997 Sep;55(9):1003–6 (15 ref.)
Dermatopathologic variants of malignant melanoma. Perniciaro C. **Mayo Clin Proc** 1997 Mar;72(3):273–9 (38 ref.)
Malignant melanoma: basic approach to clinicopathologic correlation. Su WP. **Mayo Clin Proc** 1997 Mar;72(3):267–72 (5 ref.)
Prognostic value of morphometric features and the callender classification in uveal melanomas. Coleman K, et al. **Ophthalmology** 1996 Oct;103(10):1634–41 (23 ref.)
Desmoplastic melanoma of the vulva. Mulvany NJ, et al. **Pathology** 1997 May;29(2):241–5 (33 ref.)
Staging and prognosis of melanoma. Brown M. **Semin Cutan Med Surg** 1997 Jun;16(2):113–21 (51 ref.)
Biopsy technique for pigmented lesions. Cockerell CJ. **Semin Cutan Med Surg** 1997 Jun;16(2):108–12 (15 ref.)
Neoplastic progression and prognosis in melanoma. Elder DE, et al. **Semin Cutan Med Surg** 1996 Dec;15(4):336–48 (87 ref.)
Melanoma and melanoma in situ: build a better diagnosis through architecture. McCalmont TH. **Semin Cutan Med Surg** 1997 Jun;16(2):97–107 (7 ref.)
Melanoma and stroma: an interaction of biological and prognostic importance. Smolle J, et al. **Semin Cutan Med Surg** 1996 Dec;15(4):326–35 (108 ref.)
Desmoplastic neurotropic melanoma. Tsao H, et al. **Semin Cutan Med Surg** 1997 Jun;16(2):131–6 (24 ref.)
Prognosis and staging in melanoma. Garrison M, et al. **Semin Oncol** 1996 Dec;23(6):725–33 (77 ref.)
Pregnancy and the prognosis of malignant melanoma. Grin CM, et al. **Semin Oncol** 1996 Dec;23(6):734–6 (20 ref.)
The clinical and histological differential diagnosis of malignant melanoma. Keller JM, et al. **Semin Oncol** 1996 Dec;23(6):693–702 (25 ref.)
Melanoma: criteria for histological diagnosis and its reporting. Metcalf JS. **Semin Oncol** 1996 Dec;23(6):688–92 (11 ref.)
Detection of occult melanoma cells in sentinel lymph nodes and blood. Reintgen DS, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 4):S11–5 (23 ref.)
Pathology of malignant melanoma. Heasley DD, et al. **Surg Clin North Am** 1996 Dec;76(6):1223–55 (34 ref.)
Staging evaluation and surveillance for melanoma patients in a fiscally restrictive medical environment. A commentary. Ross MI. **Surg Clin North Am** 1996 Dec; 76(6):1423–32 (43 ref.)
Prognostic factors in malignant melanoma. Kashani-Sabet M, et al. **Surg Oncol Clin N Am** 1997 Jul;6(3):599–623 (143 ref.)
Melanoma nodal metastases: biologic significance and therapeutic considerations. Reintgen D. **Surg Oncol Clin N Am** 1996 Jan;5(1):105–20 (24 ref.)
Prognostic parameters in uveal melanoma: a review. Mooy CM, et al. **Surv Ophthalmol** 1996 Nov-Dec;41(3):215–28 (137 ref.)
Recommendations for the reporting of tissues removed as part of the surgical treatment of cutaneous melanoma. Association of Directors of Anatomic and Surgical Pathology. **Virchows Arch** 1997 Aug;431(2):79–81 (7 ref.)
[Vulvar dermatoses and intra-epithelial neoplasia. Classification, criticism and suggestions] Leibowitch M, et al. **Ann Pathol** 1996 Nov;16(5):334–42 (18 ref.) **(Fre)**
[Sentinal node sampling in patients with malignant melanoma] Yaniv D, et al. **Harefuah** 1997 May 15;132(10):711–3 (18 ref.) **(Heb)**
[Primary melanoma of the esophagus. 2 new cases] Cosme A, et al. **Rev Esp Enferm Dig** 1996 Oct;88(10):705–8 (21 ref.) (Eng. Abstr.) **(Spa)**
[Melanocytic tumors. Liberal nevus surgery and histopathological scrutiny reduce mortality] Larsson O, et al. **Lakartidningen** 1997 Jul 9;94(28–29):2545–7 (10 ref.) **(Swe)**

PHYSIOPATHOLOGY

Growth factors and melanomas. Halaban R. **Semin Oncol** 1996 Dec;23(6):673–81 (145 ref.)
Endocrinology of melanoma. Neifeld JP. **Semin Surg Oncol** 1996 Nov-Dec;12(6):402–6 (37 ref.)

PREVENTION & CONTROL

The case for sunscreens. A review of their use in preventing actinic damage and neoplasia. Naylor MF, et al. **Arch Dermatol** 1997 Sep;133(9):1146–54 (50 ref.)
Atypical mole syndrome: a brief overview for the primary care physician. Henneberry JM, et al. **Md Med J** 1997 May-Jun;46(5):243–6 (15 ref.)
Diagnosis of pigmented skin lesions aided by epiluminescence microscopy. Peck GL. **Md Med J** 1997 May-Jun; 46(5):247–50 (5 ref.)
Skin self-examination for melanoma--another golden rule. Howell JB. **Semin Cutan Med Surg** 1997 Jun;16(2):174–8 (19 ref.)

PSYCHOLOGY

The psychological challenges facing melanoma patients. Kneier AW. **Surg Clin North Am** 1996 Dec;76(6):1413–21 (23 ref.)

RADIONUCLIDE IMAGING

The clinical role of immunoscintigraphy for the detection of ocular melanoma. Schaling DF, et al. **Q J Nucl Med** 1996 Dec;40(4):335–40 (50 ref.)
Lymphoscintigraphy, the sentinel node concept, and the intraoperative gamma probe in melanoma, breast cancer, and other potential cancers. Alazraki NP, et al. **Semin Nucl Med** 1997 Jan;27(1):55–67 (51 ref.)
The role of lymphoscintigraphy and sentinel node mapping in assessing patient risk in melanoma. Essner R. **Semin Oncol** 1997 Feb;24(1 Suppl 4):S8–10 (15 ref.)

RADIOTHERAPY

New approaches to treating advanced melanoma: adjuvant treatment of high-risk primary melanoma and boron neutron capture therapy. Rogers GS, et al. **Semin Cutan Med Surg** 1997 Jun;16(2):165–73 (40 ref.)
Malignant melanoma: the role of radiation therapy revisited. Jenrette JM. **Semin Oncol** 1996 Dec;23(6):759–62 (33 ref.)
Brachytherapy in primary ocular tumors. Freire JE, et al. **Semin Surg Oncol** 1997 May-Jun;13(3):167–76 (47 ref.)
Role of radiotherapy and hyperthermia in the management of malignant melanoma. Schmidt-Ullrich RK, et al. **Semin Surg Oncol** 1996 Nov-Dec;12(6):407–15 (66 ref.)
Radiation therapy for malignant melanoma. Geara FB, et al. **Surg Clin North Am** 1996 Dec;76(6):1383–98 (84 ref.)

SECONDARY

Cutaneous metastasis of ocular malignant melanoma. An unusual presentation simulating blue nevi. Wieselthier JS, et al. **Am J Dermatopathol** 1996 Jun;18(3):289–95 (17 ref.)
Sentinel lymph node evaluation in melanoma. Brady MS, et al. **Arch Dermatol** 1997 Aug;133(8):1014–20 (32 ref.)
Maternal melanoma metastatic to the placenta: a case report and review of the literature. Baergen RN, et al. **Arch Pathol Lab Med** 1997 May;121(5):508–11 (26 ref.)
Frequency and duration of remission after isolated limb perfusion for melanoma. Thompson JF, et al. **Arch Surg** 1997 Aug;132(8):903–7 (23 ref.)
Malignant melanoma presenting as bilateral breast masses.

Jayalakshmi S, et al. **Australas Radiol** 1997 Feb;41(1):38–40 (11 ref.)

Acute cholecystitis from metastatic melanoma to the gall-bladder in a patient with a low-risk melanoma. Langley RG, et al. **Br J Dermatol** 1997 Feb;136(2):279–82 (25 ref.)

Sentinel node dissection in the treatment of melanoma. Report of three cases and review of the literature. Cottingham T, et al. **Dermatol Surg** 1997 Feb;23(2):113–8; discussion 118–9 (33 ref.)

Chemotherapy for metastatic melanoma during pregnancy. Dipaola RS, et al. **Gynecol Oncol** 1997 Sep;66(3):526–30 (21 ref.)

Metastasis of a malignant melanoma to the region of an impacted mandibular third molar: a case report. Santamaria J, et al. **J Oral Maxillofac Surg** 1997 Sep;55(9):1003–6 (15 ref.)

Lymphoscintigraphy, the sentinel node concept, and the intraoperative gamma probe in melanoma, breast cancer, and other potential cancers. Alazraki NP, et al. **Semin Nucl Med** 1997 Jan;27(1):55–67 (51 ref.)

Systemic chemotherapy for the treatment of metastatic melanoma. Mc Clay EF, et al. **Semin Oncol** 1996 Dec; 23(6):744–53 (91 ref.)

Treatment of melanoma metastases in the brain. Ewend MG, et al. **Semin Surg Oncol** 1996 Nov-Dec;12(6):429–35 (48 ref.)

[Orbital metastases of melanoma of the choroid. Value of imaging] Menif E, et al. **J Radiol** 1997 May;78(5):385–7 (10 ref.) (Eng. Abstr.) **(Fre)**

[Sentinal node sampling in patients with malignant melanoma] Yaniv D, et al. **Harefuah** 1997 May 15;132(10):711–3 (18 ref.) **(Heb)**

[Two cases of melanoma metastasis. Description and review of the literature] Zanon C, et al. **Minerva Chir** 1996 Nov; 51(11):979–82 (8 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Recent advances in the care of the patient with malignant melanoma [see comments] Reintgen D, et al. **Ann Surg** 1997 Jan;225(1):1–14 (51 ref.) Comment in: Ann Surg 1997 Jan;225(1):15–6.

Theoretical and empirical arguments in relation to elective lymph node dissection for melanoma. Piepkorn M, et al. **Arch Dermatol** 1997 Aug;133(8):995–1002 (110 ref.)

Surgical issues in the management of melanoma [see comments] Fraker DL. **Curr Opin Oncol** 1997 Mar; 9(2):183–8 (40 ref.) Comment in: Curr Opin Oncol 1997 Mar;9(2):175–7.

More rational and conservative surgical strategies for malignant melanoma using lymphatic mapping and sentinel node biopsy techniques. Reintgen D. **Curr Opin Oncol** 1996 Mar;8(2):152–8 (23 ref.)

Advances in dermatologic surgery. Perez M. **Dermatol Clin** 1997 Jan;15(1):9–18 (61 ref.)

Sentinel node dissection in the treatment of melanoma. Report of three cases and review of the literature. Cottingham T, et al. **Dermatol Surg** 1997 Feb;23(2):113–8; discussion 118–9 (33 ref.)

The surgical management of invasive primary melanoma: an update. Lange JR. **Md Med J** 1997 May-Jun;46(5):251–4 (21 ref.)

Role of sentinel node biopsy in the management of malignant melanoma. North JH Jr, et al. **Oncology (Huntingt)** 1996 Aug;10(8):1237–42; discussion 1242–6 (20 ref.)

Surgical treatment of malignant melanoma. Huth JF. **Semin Cutan Med Surg** 1997 Jun;16(2):159–64 (19 ref.)

The surgical management of melanoma: from diagnosis to local treatment. Baron PL. **Semin Oncol** 1996 Dec; 23(6):714–8 (34 ref.)

Surgical management of patients with intermediate thickness melanoma: current role of elective lymph node dissection. Cole DJ, et al. **Semin Oncol** 1996 Dec;23(6):719–24 (41 ref.)

Surgical therapy of primary cutaneous melanoma. Geraghty PJ, et al. **Semin Surg Oncol** 1996 Nov-Dec;12(6):386–93 (33 ref.)

Surgical management of stage I and II melanoma patients: approach to the regional lymph node basin. Ross MI. **Semin Surg Oncol** 1996 Nov-Dec;12(6):394–401 (43 ref.)

Malignant melanoma of the oesophagus--a case report. Chan HS, et al. **Singapore Med J** 1995 Oct;36(5):566–7 (9 ref.)

The role of plastic surgery in the treatment of malignant melanoma. Eshima I. **Surg Clin North Am** 1996 Dec; 76(6):1331–42 (37 ref.)

Surgical treatment of malignant melanoma. Karakousis CP. **Surg Clin North Am** 1996 Dec;76(6):1299–312 (58 ref.)

Reconstructive surgery in melanoma patients. Ariyan S. **Surg Oncol Clin N Am** 1996 Oct;5(4):785–807 (09 ref.)

Melanoma nodal metastases: biologic significance and therapeutic considerations. Reintgen D. **Surg Oncol Clin N Am** 1996 Jan;5(1):105–20 (24 ref.)

[Surgery of primary malignant melanomas of the mucosa of the nasal fossa and facial sinuses] Laccourreye O, et al. **Ann Otolaryngol Chir Cervicofac** 1996;113(3):163–9 (30 ref.) (Eng. Abstr.) **(Fre)**

[Lymph node dissections in malignant melanoma] Hohenberger W, et al. **Chirurg** 1996 Aug;67(8):779–87 (24 ref.) (Eng. Abstr.) **(Ger)**

[Basic principles of melanoma surgery] Walz MK. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:111–4 (18 ref.) (Eng. Abstr.) **(Ger)**

[Primary intramedullary melanocytoma of medulla oblongata: a case report] Takenaka N, et al. **No Shinkei Geka** 1996 Mar;24(3):247–52 (28 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Posterior uveal melanoma. The Swedish perspective [see comments] Seregard S. **Acta Ophthalmol Scand** 1996 Aug; 74(4):315–29 (158 ref.) Comment in: Acta Ophthalmol Scand 1996 Aug;74(4):313.

Somatic gene therapy and its implications in melanoma treatment. Möller P, et al. **Arch Dermatol Res** 1997 Jan; 289(2):71–7 (67 ref.)

High-dose chemotherapy and autologous stem cell support for patients with malignant melanoma. Meisenberg B. **Bone Marrow Transplant** 1996 Jun;17(6):903–6 (25 ref.)

The development of therapeutic vaccines of the management of malignant melanoma. Dalgleish AG, et al. **Cancer Surv** 1996;26:289–319 (158 ref.)

Treatment of melanoma in-transit metastases confined to the limb. Eggermont AM. **Cancer Surv** 1996;26:335–49 (65 ref.)

Current immunotherapy for melanoma. Newton Bishop JA. **Cancer Surv** 1996;26:321–33 (54 ref.)

Use of vaccines in treatment of malignant melanoma. Bystryn JC, et al. **Clin Dermatol** 1996 Jul-Aug;14(4):337–41 (13 ref.)

The treatment of metastatic melanoma with chemotherapy and biologics [see comments] Atkins MB. **Curr Opin Oncol** 1997 Mar;9(2):205–13 (71 ref.) Comment in: Curr Opin Oncol 1997 Mar;9(2):175–7.

Melanoma and other skin neoplasms [editorial; comment] Schuchter LM. **Curr Opin Oncol** 1997 Mar;9(2):175–7 (7 ref.) Comment on: Curr Opin Oncol 1997 Mar;9(2):178–82. Comment on: Curr Opin Oncol 1997 Mar;9(2):183–8. Comment on: Curr Opin Oncol 1997 Mar;9(2):189–204. Comment on: Curr Opin Oncol 1997 Mar;9(2):205–13.

Adjuvant therapy for melanoma [see comments] Sondak VK, et al. **Curr Opin Oncol** 1997 Mar;9(2):189–204 (119 ref.) Comment in: Curr Opin Oncol 1997 Mar;9(2):175–7.

Current status of melanoma vaccines. Kuhn CA, et al. **Dermatol Surg** 1997 Aug;23(8):649–54; discussion 654–5 (33 ref.)

Interleukin-7. Biology and implications for dermatology. Möller P, et al. **Exp Dermatol** 1996 Jun;5(3):129–37 (91 ref.)

Cytokine-based gene therapy of human tumors. An overview. Parmiani G, et al. **Folia Biol (Praha)** 1996; 42(6):305–9 (21 ref.)

The success of TNF alpha in isolated limb perfusion for irresectable extremity soft tissue sarcomas, melanoma and carcinomas: observations in patients and preclinical perfusion models. Eggermont AM. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1357–70 (74 ref.)

T-cell recognition of melanoma antigens and its therapeutic applications. Castelli C, et al. **Int J Clin Lab Res** 1997; 27(2):103–10 (46 ref.)

Uveal melanoma: updated considerations on current management modalities. Manschot WA, et al. **Int Ophthalmol** 1995-96;19(4):203–9 (46 ref.)

Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. Kawakami Y, et al. **Int Rev Immunol** 1997;14(2-3):173–92 (103 ref.)

Adjuvant therapy for cutaneous malignant melanoma. Demierre MF, et al. **J Am Acad Dermatol** 1997 May;36(5 Pt 1):747–64 (153 ref.)

Update on active specific immunotherapy with melanoma vaccines. Conforti AM, et al. **J Surg Oncol** 1997 Sep; 66(1):55–64 (93 ref.)

Melanosomal proteins as melanoma-specific immune targets. Sakai C, et al. **Melanoma Res** 1997 Apr;7(2):83–95 (130 ref.)

The role of adoptive immunotherapy in solid cancers. Kruit WH, et al. **Neth J Med** 1997 Feb;50(2):47–68 (270 ref.)

Melanoma-associated tumor antigens and their clinical relevance to immunotherapy. Gattoni-Celli S, et al. **Semin Oncol** 1996 Dec;23(6):754–8 (39 ref.)

Adjuvant application of interferons. el Kassas H, et al. **Semin Oncol** 1996 Dec;23(6):737–43 (35 ref.)

Active specific immunization in the treatment of patients with melanoma. Mastrangelo MJ, et al. **Semin Oncol** 1996 Dec; 23(6):773–81 (57 ref.)

Diagnosis and treatment of uveal melanoma. Shields JA, et al. **Semin Oncol** 1996 Dec;23(6):763–7 (23 ref.)

Biologic therapy of melanoma with cytokines and lymphocytes. Bear HD, et al. **Semin Surg Oncol** 1996 Nov-Dec;12(6):436–45 (63 ref.)

Treatment of melanoma metastases in the brain. Ewend MG, et al. **Semin Surg Oncol** 1996 Nov-Dec;12(6):429–35 (48 ref.)

Role of radiotherapy and hyperthermia in the management of malignant melanoma. Schmidt-Ullrich RK, et al. **Semin Surg Oncol** 1996 Nov-Dec;12(6):407–15 (66 ref.)

Tumor antigens and tumor vaccines: peptides as immunogens. Slingluff CL Jr. **Semin Surg Oncol** 1996 Nov-Dec; 12(6):446–53 (89 ref.)

Immunological gene therapy approaches for malignant melanoma. 1. Tumor-immunological background. Bonnekoh B, et al. **Skin Pharmacol** 1997;10(2):49–62 (86 ref.)

Immunological gene therapy approaches for malignant melanoma. 2. Preclinical studies and clinical strategies. Bonnekoh B, et al. **Skin Pharmacol** 1997;10(3):105–25 (93 ref.)

Immunotherapy of malignant melanoma. Leong SP. **Surg Clin North Am** 1996 Dec;76(6):1355–81 (165 ref.)

Computer database for melanoma registry. A clinical management and research tool to monitor outcomes and ensure continuous quality improvement. Reintgen D, et al. **Surg Clin North Am** 1996 Dec;76(6):1273–85 (20 ref.)

[Malignant anorectal melanoma: description of a clinical case and review of the literature] Malaguarnera M, et al. **Bull Cancer** 1997 Apr;84(4):423–6 (35 ref.) (Eng. Abstr.) **(Fre)**

[Chemotherapy and immunotherapy of metastatic malignant melanomas] Benhammouda A; et al. **Presse Med** 1996 Nov 16;25(35):1690–7 (80 ref.) (Eng. Abstr.) **(Fre)**

[Modern tumor therapy as seen in melanoma] Dummer R, et al. **Schweiz Rundsch Med Prax** 1996 Dec 10; 85(50):1609–14 (32 ref.) (Eng. Abstr.) **(Ger)**

[Malignant melanoma in childhood and adolescence] Karplus G, et al. **Harefuah** 1996 Jun 16;130(12):843–50 (43 ref.) **(Heb)**

[Treatment of malignant melanoma: recent advances and perspectives] Saida T. **Gan To Kagaku Ryoho** 1997 Jan; 24(1):10–5 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Modern treatment of malignant intraocular melanomas] Zygulska-Mach H. **Klin Oczna** 1996 Jan;98(1):61–6 (87 ref.) **(Pol)**

ULTRASONOGRAPHY

[Non-invasive high resolution ultrasound of malignant melanoma of the skin. Possibilities, limits, alternatives] Freitag M, et al. **Fortschr Med** 1996 Jul 20;114(20-21):251–6 (0 ref.) (Eng. Abstr.) **(Ger)**

[Ultrasound morphology of peripheral lymph nodes] Abolmaali N, et al. **Z Arztl Fortbild Qualitatssich** 1997 Jul; 91(4):355–60 (11 ref.) (Eng. Abstr.) **(Ger)**

[High resolution 20 MHz ultrasound diagnosis in dermatology for noninvasive imaging of malignant melanomas] Happe M, et al. **Z Arztl Fortbild Qualitatssich** 1997 Jul;91(4):347–53 (0 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Intraocular melanomata in the horse. Barnett KC, et al. **Equine Vet J Suppl** 1990 Sep;(10):76–82 (27 ref.)

Tumours of the skin. Ghadially FN, et al. **IARC Sci Publ** 1996;(126):1–43 (111 ref.)

Analysis of genetic factors and molecular mechanisms in the development of hereditary and carcinogen-induced tumors of Xiphophorus. Schartl A, et al. **Recent Results Cancer Res** 1997;143:225–35 (24 ref.)

MELANOMA, AMELANOTIC

DIAGNOSIS

Amelanotic malignant melanoma of the vulva. Case report and review of the literature. Ulmer A, et al. **Arch Gynecol Obstet** 1996;259(1):45–50 (30 ref.)

PATHOLOGY

Amelanotic malignant melanoma. Adler MJ, et al. **Semin Cutan Med Surg** 1997 Jun;16(2):122–30 (52 ref.)

VETERINARY

Intraocular melanomata in the horse. Barnett KC, et al. **Equine Vet J Suppl** 1990 Sep;(10):76–82 (27 ref.)

MELANOMA, B16 see **MELANOMA, EXPERIMENTAL**

MELANOMA, CLOUDMAN S91 see **MELANOMA, EXPERIMENTAL**

MELANOMA, EXPERIMENTAL

PATHOLOGY

Analysis of genetic factors and molecular mechanisms in the development of hereditary and carcinogen-induced tumors of Xiphophorus. Schartl A, et al. **Recent Results Cancer Res** 1997;143:225–35 (24 ref.)

MELANOMA, HARDING-PASSEY see **MELANOMA, EXPERIMENTAL**

MELANOMA, MALIGNANT, OF SOFT PARTS see **SARCOMA, CLEAR CELL**

MELANOSIS

CHEMICALLY INDUCED

Initial description of gastric melanosis in a laxative-abusing patient. Mitty RD, et al. **Am J Gastroenterol** 1997 Apr; 92(4):707–8 (4 ref.)

Prostaglandins: a new approach to glaucoma management with a new, intriguing side effect. Bito LZ. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S1–14 (74 ref.)

COMPLICATIONS

Neurocutaneous melanosis: clinical features of large congenital melanocytic nevi in patients with manifest

MELANOSIS

central nervous system melanosis. DeDavid M, et al. **J Am Acad Dermatol** 1996 Oct;35(4):529–38 (104 ref.)

Glaucoma in phakomatosis pigmentovascularis. Teekhasaenee C, et al. **Ophthalmology** 1997 Jan; 104(1):150–7 (66 ref.)

DIAGNOSIS

Melasma of the forearms. O'Brien TJ, et al. **Australas J Dermatol** 1997 Feb;38(1):35–7 (6 ref.)

Melanosis jejuni. Banai J, et al. **Gastrointest Endosc** 1997 May;45(5):432–4 (23 ref.)

[Neurocutaneous melanosis] Martínez-Granero MA, et al. **Rev Neurol** 1997 Sep;25 Suppl 3:S265–8 (35 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Becker's melanosis. Chima KN, et al. **Cutis** 1996 May; 57(5):311–4 (43 ref.)

PATHOLOGY

Pigmented squamous cell carcinoma with dendritic melanocytes. Kossard S, et al. **Australas J Dermatol** 1997 Aug;38(3):145–7 (16 ref.)

Linear and whorled nevoid hypermelanosis versus incontinentia pigmenti: is pigmentary incontinence really a distinctive feature? Delaporte E, et al. **Dermatology** 1996; 192(1):70–2 (17 ref.)

Linear and whorled nevoid hypermelanosis in a boy with mental retardation and congenital defects. Schepis C, et al. **Int J Dermatol** 1996 Sep;35(9):654–5 (10 ref.)

Pseudomelanosis duodeni in an adolescent male: case report and review of the literature. Pueblitz S, et al. **Pediatr Pathol Lab Med** 1997 Jan–Feb;17(1):115–23 (23 ref.)

The clinical and histological differential diagnosis of malignant melanoma. Keller JM, et al. **Semin Oncol** 1996 Dec;23(6):693–702 (25 ref.)

MELANOSOMES see **MELANOCYTES**

MELANOTROPIN see **MSH**

MELAS SYNDROME

GENETICS

[Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) with chronic renal failure: report of mother-child cases] Ihara M, et al. **Rinsho Shinkeigaku** 1996 Sep;36(9):1069–73 (13 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Mitochondrial encephalomyopathy with elderly onset of stroke-like episodes [see comments] Minamoto H, et al. **Intern Med** 1996 Dec;35(12):991–5 (13 ref.) Comment in: Intern Med 1996 Dec;35(12):924.

MELASMA see **MELANOSIS**

MELATONIN

ADMINISTRATION & DOSAGE

[Melatonin: from hormone to drug?] Claustrat B, et al. **Pathol Biol (Paris)** 1996 Sep;44(7):645–53 (60 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Melatonin and the immune–hematopoietic system therapeutic and adverse pharmacological correlates. Maestroni GJ, et al. **Neuroimmunomodulation** 1996 Nov–Dec;3(6):325–32 (66 ref.)

ANALYSIS

Melatonin measurements in tissues. Different recovery of endogenously contained and exogenously added melatonin. George A, et al. **Adv Exp Med Biol** 1996;398:691–6 (15 ref.)

BIOSYNTHESIS

Neural control of the pineal gland. Moore RY. **Behav Brain Res** 1996;73(1–2):125–30 (36 ref.)

BLOOD

The melatonin rhythm-generating enzyme: molecular regulation of serotonin N-acetyltransferase in the pineal gland. Klein DC, et al. **Recent Prog Horm Res** 1997; 52:307–57; discussion 357–8 (72 ref.)

IMMUNOLOGY

Melatonin and the immune system. Liebmann PM, et al. **Int Arch Allergy Immunol** 1997 Mar;112(3):203–11 (110 ref.)

METABOLISM

The indoleamine melatonin as a free radical scavenger, electron donor, and antioxidant. In vitro and in vivo studies. Reiter RJ. **Adv Exp Med Biol** 1996;398:307–13 (43 ref.)

Antioxidant actions of melatonin. Reiter RJ. **Adv Pharmacol** 1997;38:103–17 (49 ref.)

Oxygen radical detoxification processes during aging: the functional importance of melatonin. Reiter RJ. **Aging (Milano)** 1995 Oct;7(5):340–51 (98 ref.)

[Melatonin and biological rhythms: various aspects in human physiopathology] Touitou Y, et al. **Ann Pharm Fr** 1996; 54(6):241–50 (53 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Effects of melatonin infused into the III ventricle on prolactin, beta-endorphin and luteotropin secretion in ewes during the different stages of the reproductive cycle. Misztal T, et al. **Acta Neurobiol Exp (Warsz)** 1996; 56(3):769–78 (32 ref.)

Neuroprotective effects of melatonin. Lipartiti M, et al. **Adv Exp Med Biol** 1996;398:315–21 (28 ref.)

Pharmacological actions of melatonin in oxygen radical pathophysiology. Reiter R, et al. **Life Sci** 1997; 60(25):2255–71 (103 ref.)

Melatonin effects on behavior: possible mediation by the central GABAergic system. Golombek DA, et al. **Neurosci Biobehav Rev** 1996 Autumn;20(3):403–12 (175 ref.)

PHYSIOLOGY

Melatonin as a chemical indicator of environmental light–dark cycle. Zawilska JB. **Acta Neurobiol Exp (Warsz)** 1996;56(3):757–67 (65 ref.)

Cell physiology of the pineal body. Marchiafava PL, et al. **Arch Ital Biol** 1997 Mar;135(2):183–94 (73 ref.)

Circadian actions of melatonin at the suprachiasmatic nucleus. Gillette MU, et al. **Behav Brain Res** 1996; 73(1–2):135–9 (41 ref.)

Phase shifting the human circadian clock using melatonin. Lewy AJ, et al. **Behav Brain Res** 1996;73(1–2):131–4 (24 ref.)

Influences of melatonin on human circadian rhythms. Cagnacci A. **Chronobiol Int** 1997 Mar;14(2):205–20 (138 ref.)

Melatonin as an antiaging drug: between facts and fantasy. Huether G. **Gerontology** 1996;42(2):87–96 (67 ref.)

The pineal gland and reproduction. Aleandri V, et al. **Hum Reprod Update** 1996 May–Jun;2(3):225–35 (115 ref.)

Melatonin: a master hormone and a candidate for universal panacea. Kumar V. **Indian J Exp Biol** 1996 May; 34(5):391–402 (135 ref.)

Melatonin as a hormone and an antioxidant: implications for organisms at high latitudes. Reiter RJ, et al. **Int J Circumpolar Health** 1997 Apr;56(1–2):4–11 (43 ref.)

Melatonin and the skin: from frog to human. Cohn BA. **Int J Dermatol** 1996 Oct;35(10):695–7 (34 ref.)

Physiology of the circadian system in animals and humans. Murphy PJ, et al. **J Clin Neurophysiol** 1996 Jan;13(1):2–16 (110 ref.)

Direct regulation of mammalian reproductive organs by serotonin and melatonin. Sirotkin AV, et al. **J Endocrinol** 1997 Jul;154(1):1–5 (60 ref.)

Influence of melatonin and photoperiod on animal and human reproduction. Cagnacci A, et al. **J Endocrinol Invest** 1996 Jun;19(6):382–411 (419 ref.)

The diffuse neuroendocrine system and extrapineal melatonin. Kvetnoy I, et al. **J Mol Endocrinol** 1997 Feb; 18(1):1–3 (27 ref.)

Melatonin in relation to physiology in adult humans. Cagnacci A. **J Pineal Res** 1996 Nov;21(4):200–13 (197 ref.)

Comparative aspects of the pineal/melatonin system of poikilothermic vertebrates. Filadelfi AM, et al. **J Pineal Res** 1996 May;20(4):175–86 (161 ref.)

Melatonin in mast cells and tumor radiosensitivity. Kvetnoy IM, et al. **J Pineal Res** 1997 Apr;22(3):169–70 (16 ref.)

Melatonin, sleep, aging, and the health protection branch [editorial] Young SN. **J Psychiatry Neurosci** 1996 May; 21(3):161–4 (34 ref.)

Melatonin in humans. Brzezinski A. **N Engl J Med** 1997 Jan 16;336(3):186–95 (88 ref.)

Melatonin: media hype or therapeutic breakthrough? Kendler BS. **Nurse Pract** 1997 Feb;22(2):66–7, 71–2, 77 (75 ref.)

The role of melatonin and light in the human circadian system. Lewy AJ, et al. **Prog Brain Res** 1996;111:205–16 (71 ref.)

[The effect of melatonin as anti-convulsant and neuron protector] Sánchez-Forte M, et al. **Rev Neurol** 1997 Aug; 25(144):1229–34 (89 ref.) (Eng. Abstr.) **(Spa)**

SECRETION

Gonadal steroid modulation of neuroendocrine transduction: a transynaptic view. Alonso-Solís R, et al. **Cell Mol Neurobiol** 1996 Jun;16(3):357–82 (94 ref.)

[Melatonin in humans: a biochemical marker of the circadian clock and an endogenous synchronizer] Claustrat B, et al. **Neurophysiol Clin** 1995;25(6):351–9 (43 ref.) (Eng. Abstr.) **(Fre)**

[Melatonin: from hormone to drug?] Claustrat B, et al. **Pathol Biol (Paris)** 1996 Sep;44(7):645–53 (60 ref.) (Eng. Abstr.) **(Fre)**

[The effect of melatonin as anti-convulsant and neuron protector] Sánchez-Forte M, et al. **Rev Neurol** 1997 Aug; 25(144):1229–34 (89 ref.) (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

Treatment of circadian rhythm disorders--melatonin. Arendt J, et al. **Chronobiol Int** 1997 Mar;14(2):185–204 (74 ref.)

Melatonin supplements for aging. Sandyk R. **Int J Neurosci** 1996 Nov;87(3–4):219–24 (45 ref.)

Use of melatonin in the treatment of paediatric sleep disorders. Jan JE, et al. **J Pineal Res** 1996 Nov;21(4):193–9 (61 ref.)

The validity of melatonin as an oncostatic agent. Panzer A, et al. **J Pineal Res** 1997 May;22(4):184–202 (165 ref.)

The use of anti-aging hormones. Melatonin, growth hormone, testosterone, and dehydroepiandrosterone: consumer enthusiasm for unproven therapies. Shomali ME. **Md Med J** 1997 Apr;46(4):181–6 (45 ref.)

Melatonin in osteosarcoma: an effective drug? Panzer A. **Med Hypotheses** 1997 Jun;48(6):523–5 (36 ref.)

Melatonin and jet lag. Croughs RJ, et al. **Neth J Med** 1996 Oct;49(4):164–6 (12 ref.)

Melatonin and the immune–hematopoietic system therapeutic and adverse pharmacological correlates. Maestroni GJ, et al. **Neuroimmunomodulation** 1996 Nov–Dec;3(6):325–32 (66 ref.)

Melatonin: media hype or therapeutic breakthrough? Kendler BS. **Nurse Pract** 1997 Feb;22(2):66–7, 71–2, 77 (75 ref.)

Chronobiotics--drugs that shift rhythms. Dawson D, et al. **Pharmacol Ther** 1996;69(1):15–36 (204 ref.)

[Melatonin. Hormone or wonder drug?] Stoll S, et al. **Med Monatsschr Pharm** 1996 Mar;19(3):69–75 (64 ref.) **(Ger)**

MELEDA DISEASE see **KERATODERMA, PALMOPLANTAR**

MELENA

COMPLICATIONS

Colonic variceal bleeding in a patient with mesenteric venous obstruction due to an ileal carcinoid tumour. Miao YM, et al. **Eur J Gastroenterol Hepatol** 1996 Nov;8(11):1133–5 (13 ref.)

THERAPY

Management of haematemesis and melaena. Roberts SK, et al. **Med J Aust** 1997 May 19;166(10):549–53 (41 ref.)

MELIOIDOSIS

DIAGNOSIS

The laboratory diagnosis of melioidosis. Walsh AL, et al. **Br J Biomed Sci** 1996 Dec;53(4):249–53 (32 ref.)

Case report and review of Chromobacterium sepsis--a gram-negative sepsis mimicking melioidosis. Chong CY, et al. **Singapore Med J** 1997 Jun;38(6):263–5 (19 ref.)

Melioidosis presenting with orbital cellulitis. Wong PK, et al. **Singapore Med J** 1996 Apr;37(2):220–1 (7 ref.)

[An acute septic course of melioidosis after a stay in Thailand] Koch FW, et al. **Dtsch Med Wochenschr** 1997 Jan 31; 122(5):122–6 (21 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

[Melioidosis: a tropical time bomb that is spreading] Perret JL. **Med Trop (Mars)** 1997;57(2):195–201 (64 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

[Melioidosis: a tropical time bomb that is spreading] Perret JL. **Med Trop (Mars)** 1997;57(2):195–201 (64 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

The radiology of melioidosis. Chong VF, et al. **Australas Radiol** 1996 Aug;40(3):244–9 (14 ref.)

MELITTEN

CHEMISTRY

Structure and functions of channel-forming peptides: magainins, cecropins, melittin and alamethicin. Bechinger B. **J Membr Biol** 1997 Apr 1;156(3):197–211 (262 ref.)

MELITTIN see **MELITTEN**

MELKERSSON-ROSENTHAL SYNDROME

Melkersson-Rosenthal syndrome--a challenge for dermatologists to participate in the field of oral medicine. Hornstein OP. **J Dermatol** 1997 May;24(5):281–96 (54 ref.)

[Melkersson-Rosenthal syndrome. Presentation of a clinical case and review of the literature] Nifosì G, et al. **Minerva Med** 1997 Apr;88(4):163–6 (36 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

Association of Melkersson-Rosenthal syndrome with rosacea. Bose SK. **J Dermatol** 1996 Dec;23(12):902–4 (8 ref.)

Melkersson-Rosenthal syndrome with malignant pharyngeal lymphoma [letter] Kanda A, et al. **J Dermatol** 1996 Sep; 23(9):658-9 (6 ref.)

MELLITIN see **MELITTEN**

MELNICK-NEEDLES SYNDROME see **OSTEOCHONDRODYSPLASIAS**

MELOIDOGYNE see **TYLENCHOIDEA**

MELORHEOSTOSIS

Melorheostosis. Rozencwaig R, et al. **Am J Orthop** 1997 Feb; 26(2):83-9 (65 ref.)

COMPLICATIONS

Arthroscopic excision of intra-articular ossifications. A case report and review of the literature. Rooney RC, et al. **Am J Orthop** 1996 Jun;25(6):437-40 (7 ref.)

Linear scleroderma and melorheostosis: case presentation and literature review. Moreno Alvarez MJ, et al. **Clin Rheumatol** 1996 Jul;15(4):389-93 (24 ref.)

DIAGNOSIS

Mixed sclerosing bone dystrophy. Report of a case and review of the literature. Belzunegui J, et al. **Clin Rheumatol** 1996 Jul;15(4):378-81 (16 ref.)

MELPHALAN

ADMINISTRATION & DOSAGE

Evolution of multiple myeloma treatment from melphalan monotherapy to bone marrow transplantation. Hájek R, et al. **Acta Med Austriaca** 1996;23(3):85-91 (76 ref.)

Mortality, major amputation rates, and leukopenia after isolated limb perfusion with phenylalanine mustard for the treatment of melanoma. Taber SW, et al. **Ann Surg Oncol** 1997 Jul-Aug;4(5):440-5 (30 ref.)

Isolated limb perfusion for malignant melanoma. Alexander HR Jr, et al. **Semin Surg Oncol** 1996 Nov-Dec;12(6):416-28 (85 ref.)

THERAPEUTIC USE

The role of high-dose chemotherapy with hematopoietic stem cell support in the treatment of patients with epithelial ovarian carcinoma. Hussein AM. **Cancer Invest** 1997; 15(3):288-95 (50 ref.)

MEMANTINE

PHARMACOLOGY

Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents--preclinical studies. Danysz W, et al. **Neurosci Biobehav Rev** 1997 Jul;21(4):455-68 (151 ref.)

MEMBRANE ALANYL AMINOPEPTIDASE see **ANTIGENS, CD13**

MEMBRANE ATTACK COMPLEX see **COMPLEMENT MEMBRANE ATTACK COMPLEX**

MEMBRANE-BOUND IMMUNOGLOBULINS see **IMMUNOGLOBULINS, SURFACE**

MEMBRANE CHANNELS see **ION CHANNELS**

MEMBRANE FLUIDITY

PHYSIOLOGY

Single-particle tracking: applications to membrane dynamics. Saxton MJ, et al. **Annu Rev Biophys Biomol Struct** 1997; 26:373-99 (105 ref.)

Effect of some environmental factors on the content and composition of microbial membrane lipids. Sajbidor J. **Crit Rev Biotechnol** 1997;17(2):87-103 (112 ref.)

MEMBRANE FUSION

Virus-cell and cell-cell fusion. Hernandez LD, et al. **Ann Rev Cell Dev Biol** 1996;12:627-61 (176 ref.)

Nuclear fusion in the yeast Saccharomyces cerevisiae. Rose MD. **Ann Rev Cell Dev Biol** 1996;12:663-95 (131 ref.)

Non-bilayer lipids and biological fusion intermediates. Chernomordik L. **Chem Phys Lipids** 1996 Jul 15; 81(2):203-13 (87 ref.)

Cofactors provide the entry keys. HIV-1. Wilkinson D. **Curr Biol** 1996 Sep 1;6(9):1051-3 (24 ref.)

SNAREs and NSF in targeted membrane fusion. Hay JC, et al. **Curr Opin Cell Biol** 1997 Aug;9(4):505-12 (70 ref.)

Chemokine receptors as fusion cofactors for human immunodeficiency virus type 1 (HIV-1). Doranz BJ, et al. **Immunol Res** 1997 Feb;16(1):15-28 (79 ref.)

DRUG EFFECTS

Botulinum and tetanus neurotoxins: emerging tools for the study of membrane fusion. Jahn R, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:329-35 (66 ref.)

Membrane fusion by the influenza hemagglutinin: the fusion pore. White JM, et al. **Soc Gen Physiol Ser** 1996;51:223-9 (39 ref.)

PHYSIOLOGY

Rab5 regulates the dynamics of early endosome fusion. Barbieri MA, et al. **Biocell** 1996 Dec;20(3):331-8 (47 ref.)

The roles of NSF, SNAPs and SNAREs during membrane fusion. Woodman PG. **Biochim Biophys Acta** 1997 Jun 27; 1357(2):155-72 (173 ref.)

Botulinum and tetanus neurotoxins: emerging tools for the study of membrane fusion. Jahn R, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:329-35 (66 ref.)

Membrane fusion by influenza hemagglutinin. Skehel JJ, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:573-80 (55 ref.)

Insight into the molecular mechanisms of synaptic vesicle docking and fusion. Ting AE, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:361-9 (75 ref.)

Membrane fusion: the influenza paradigm. White JM. **Cold Spring Harb Symp Quant Biol** 1995;60:581-8 (55 ref.)

Bacterial protein toxins and cell vesicle trafficking. Montecucco C, et al. **Experientia** 1996 Dec 15; 52(12):1026-32 (91 ref.)

Molecular machinery mediating vesicle budding, docking and fusion. Söllner TH, et al. **Experientia** 1996 Dec 15; 52(12):1021-5 (9 ref.)

Regulation of membrane stability and the acrosome reaction in mammalian sperm. Nolan JP, et al. **FASEB J** 1997 Jul; 11(8):670-82 (103 ref.)

Low-pH induced conformational changes in viral fusion proteins: implications for the fusion mechanism. Gaudin Y, et al. **J Gen Virol** 1995 Jul;76 (Pt 7):1541-56 (128 ref.)

[The vacuolar apparatus and membrane fusion in the cell] Bulychev AG, et al. **Tsitologiia** 1996;38(10):1001-35 (280 ref.) (Eng. Abstr.) **(Rus)**

MEMBRANE GLYCOPROTEINS

Protein tyrosine phosphatase-like proteins: link with IDDM. Pietropaolo M, et al. **Diabetes Care** 1997 Feb;20(2):208-14 (42 ref.)

Macrophage membrane molecules: markers of tissue differentiation and heterogeneity. Martinez-Pomares L, et al. **Immunobiology** 1996 Oct;195(4-5):407-16 (64 ref.)

The CD40 ligand. At the center of the immune universe? Grewal IS, et al. **Immunol Res** 1997 Feb;16(1):59-70 (71 ref.)

[Urea transporters] Ripoche P, et al. **Nephrologie** 1996; 17(7):383-8 (41 ref.) (Eng. Abstr.) **(Fre)**

[Expression of Fas/Fas ligand and proto-oncogenes in rheumatoid synovial tissues] Asahara H, et al. **Nippon Rinsho** 1996 Jul;54(7):1960-4 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Fas antigen is expressed in human diseased muscles, but does not link to apoptosis] Inukai A, et al. **Nippon Rinsho** 1996 Jul;54(7):1992-6 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Expression of Fas and Fas-ligand in epithelium of ulcerative colitis] Iwamoto M, et al. **Nippon Rinsho** 1996 Jul; 54(7):1970-4 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Metalloproteinase-mediated release of human fas ligand] Kayagaki N, et al. **Nippon Rinsho** 1996 Jul;54(7):1747-52 (25 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular biology of Fas antigen-Fas ligand system] Mita E, et al. **Nippon Rinsho** 1996 Jul;54(7):1736-40 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Involvement of Fas and Fas ligand in case of human fulminant hepatitis] Ryo K, et al. **Nippon Rinsho** 1996 Jul; 54(7):1965-9 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Fas antigen (CD95) expressions and apoptosis of neoplastic cells from various lymphoid malignancies including adult T-cell leukemia/lymphoma] Sasao T, et al. **Nippon Rinsho** 1996 Jul;54(7):1986-91 (23 ref.) (Eng. Abstr.) **(Jpn)**

[ADAM family proteins and cell fusion] Endo T. **Seikagaku** 1996 Aug;68(8):1453-8 (17 ref.) **(Jpn)**

[Telencephalin, a dendrite-associated cell adhesion molecule with brain segment-specific expression] Mori K, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):555-60 (13 ref.) **(Jpn)**

[Aminetransporters] Shimada S. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):244-52 (41 ref.) **(Jpn)**

[Measles virus receptor CD46] Yanagi Y. **Uirusu** 1995 Dec; 45(2):159-64 (21 ref.) **(Jpn)**

ANALYSIS

Accumulation of synaptic vesicle proteins and cytoskeletal specializations at the peripheral node of Ranvier. Zimmermann H. **Microsc Res Tech** 1996 Aug 1; 34(5):462-73 (70 ref.)

BIOSYNTHESIS

Regulation of CD95 ligand expression: a key element in immune regulation? Brunner T, et al. **Behring Inst Mitt** 1996 Oct;(97):161-74 (81 ref.)

Constitutive Fas ligand expression in several non-lymphoid mouse tissues: implications for immune-protection and cell turnover. French LE, et al. **Behring Inst Mitt** 1996 Oct; (97):156-60 (31 ref.)

Nutrient regulation of intestinal sugar-transporter expression. Shirazi-Beechey SP, et al. **Biochem Soc Trans** 1996 May; 24(2):389-92 (18 ref.)

FasL expression on epithelial cells: the Bottazzo-Feldman hypothesis revisited. Dayan CM, et al. **Immunol Today** 1997 May;18(5):203 (15 ref.)

Overexpression of growth-associated proteins in the neurons of adult transgenic mice. Caroni P. **J Neurosci Methods** 1997 Jan;71(1):3-9 (19 ref.)

Post-transcriptional control of PARP gene expression. Clayton C, et al. **Mol Biochem Parasitol** 1996 Apr;77(1):1-6 (40 ref.)

Structural and functional analysis of bovine herpesvirus 1 minor glycoproteins. Baranowski E, et al. **Vet Microbiol** 1996 Nov;53(1-2):91-101 (73 ref.)

CHEMISTRY

Urea transporters in kidney and erythrocytes. Sands JM, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):F321-39 (163 ref.)

Structure and function of the pre-T cell receptor. von Boehmer H, et al. **Annu Rev Immunol** 1997;15:433-52 (53 ref.)

Fimbrial adhesins: similarities and variations in structure and biogenesis. Smyth CJ, et al. **FEMS Immunol Med Microbiol** 1996 Dec 1;16(2):127-39 (65 ref.)

Biochemistry of S-layers. Messner P, et al. **FEMS Microbiol Rev** 1997 Jun;20(1-2):25-46 (92 ref.)

Structure and function of the CD94 C-type lectin receptor complex involved in recognition of HLA class I molecules. López-Botet M, et al. **Immunol Rev** 1997 Feb;155:165-74 (74 ref.)

Membrane topology motifs in the SGLT cotransporter family. Turk E, et al. **J Membr Biol** 1997 Sep 1;159(1):1-20 (75 ref.)

S-layers of Bacillus species. Sidhu MS, et al. **Microbiology** 1997 Apr;143 (Pt 4):1039-52 (150 ref.)

Synaptotagmins: C2-domain proteins that regulate membrane traffic. Südhof TC, et al. **Neuron** 1996 Sep;17(3):379-88 (70 ref.)

N-syndecan: structure and function of a transmembrane heparan sulfate proteoglycan. Carey DJ. **Perspect Dev Neurobiol** 1996;3(4):331-46 (77 ref.)

Why mammalian cell surface proteins are glycoproteins [published erratum appears in Trends Biochem Sci 1996 Dec;21(12):491] Gahmberg CG, et al. **Trends Biochem Sci** 1996 Aug;21(8):308-11 (36 ref.)

[7TM receptors--from the olfactory system and new hormones against HIV infection] Schwartz TW. **Ugeskr Laeger** 1997 Feb 24;159(9):1239-45 (34 ref.) (Eng. Abstr.) **(Dan)**

[Structure and biological functions of the spike protein of mouse hepatitis virus] Taguchi F. **Uirusu** 1996 Dec; 46(2):109-17 (52 ref.) **(Jpn)**

DEFICIENCY

From adhalinopathies to alpha-sarcoglycanopathies: an overview. Jeanpierre M, et al. **Neuromuscul Disord** 1996 Dec;6(6):463-5 (26 ref.)

DRUG EFFECTS

Drug targets in the embryo. Studies on the cocaine- and antidepressant-sensitive serotonin transporter. Schroeter S, et al. **Ann N Y Acad Sci** 1996 Oct 31;801:239-55 (83 ref.)

GENETICS

Molecular studies of visna virus gene expression: analysis of envelope gene expression in transgenic sheep. Clements JE, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):421-3 (65 ref.)

Understanding the heterogeneity of the limb-girdle muscular dystrophies. Bushby K. **Biochem Soc Trans** 1996 May; 24(2):489-96 (55 ref.)

Bone dysplasias in man: molecular insights. Francomano CA, et al. **Curr Opin Genet Dev** 1996 Jun;6(3):301-8 (57 ref.)

Muscular dystrophies and the dystrophin-glycoprotein complex. Straub V, et al. **Curr Opin Neurol** 1997 Apr; 10(2):168-75 (63 ref.)

Molecular genetic analysis of type-4 pilus biogenesis and twitching motility using Pseudomonas aeruginosa as a model system--a review. Darzins A, et al. **Gene** 1997 Jun 11;192(1):109-15 (56 ref.)

Development of contraceptive vaccines for humans using antigens derived from gametes (spermatozoa and zona pellucida) and hormones (human chorionic gonadotrophin): current status. Naz RK, et al. **Hum Reprod Update** 1995 Jan;1(1):1-18 (133 ref.)

The Ly-49 family: genes, proteins and recognition of class I MHC. Takei F, et al. **Immunol Rev** 1997 Feb;155:67-77 (55 ref.)

Phylogenetic characterization of the MIP family of transmembrane channel proteins. Park JH, et al. **J Membr Biol** 1996 Oct;153(3):171-80 (31 ref.)

Recent advances in the biochemical and molecular biological basis of cystinuria. Gitomer WL, et al. **J Urol** 1996 Dec; 156(6):1907-12 (33 ref.)

In situ PCR amplification of intracellular mRNA. Chen RH, et al. **Methods Mol Biol** 1997;71:123-32 (20 ref.)

The molecular genetics of the zona pellucida: mouse mutations and infertility. Rankin T, et al. **Mol Hum Reprod** 1996 Nov;2(11):889-94 (56 ref.)

MEMBRANE GLYCOPROTEINS

Association between the serotonin transporter gene and affective disorder: the evidence so far. Ogilvie AD, et al. **Mol Med** 1997 Feb;3(2):90–3 (25 ref.)

Structure, function and immunogenicity of streptococcal antigen I/II polypeptides. Jenkinson HF, et al. **Mol Microbiol** 1997 Jan;23(2):183–90 (33 ref.)

From adhalinopathies to alpha-sarcoglycanopathies: an overview. Jeanpierre M, et al. **Neuromuscul Disord** 1996 Dec;6(6):463–5 (26 ref.)

Synaptotagmins: C2-domain proteins that regulate membrane traffic. Südhof TC, et al. **Neuron** 1996 Sep;17(3):379–88 (70 ref.)

[Regulation of osmolyte transporter gene expression by tonicity] Takenaka M, et al. **Nippon Rinsho** 1996 Oct; 54(10):2821–8 (25 ref.) (Eng. Abstr.) **(Jpn)**

[Gene analysis in patients with muscular dystrophy: alpha-sarcoglycan (adhalin) gene mutations in patients with malignant limb-girdle muscular dystrophy] Akaike M, et al. **Rinsho Byori** 1997 Feb;45(2):136–40 (21 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

The T cell marker RT6 in a rat model of autoimmune diabetes. Greiner DL, et al. **Adv Exp Med Biol** 1997; 419:209–16 (42 ref.)

The role of FasL and TNF in the homeostatic regulation of immune responses. Lynch DH. **Adv Exp Med Biol** 1996; 406:135–8 (23 ref.)

Fas-mediated apoptosis. Nagata S. **Adv Exp Med Biol** 1996; 406:119–24 (36 ref.)

Fas splicing variants and their effect on apoptosis. Ruberti G, et al. **Adv Exp Med Biol** 1996;406:125–34 (67 ref.)

CD40 and its ligand. Clark LB, et al. **Adv Immunol** 1996; 63:43–78 (152 ref.)

Surrogate light chain in B cell development. Karasuyama H, et al. **Adv Immunol** 1996;63:1–41 (178 ref.)

CD40–CD40 ligand: a multifunctional receptor–ligand pair. Van Kooten C, et al. **Adv Immunol** 1996;61:1–77 (371 ref.)

Zona pellucida antigens: targets for contraceptive vaccines. Skinner SM, et al. **Am J Reprod Immunol** 1996 Mar; 35(3):163–74 (112 ref.)

CD40 and its ligand in autoimmunity. Noelle RJ, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:384–91 (32 ref.)

Immune regulation by CD40 and its ligand GP39. Foy TM, et al. **Annu Rev Immunol** 1996;14:591–617 (111 ref.)

Gp130 and the interleukin-6 family of cytokines. Taga T, et al. **Annu Rev Immunol** 1997;15:797–819 (130 ref.)

The role of Fas/FasL interactions in the regulation of B cell function. Jacobson BA, et al. **Behring Inst Mitt** 1996 Oct; (97):185–99 (44 ref.)

B7-mediated costimulation and the immune response. Schultze J, et al. **Blood Rev** 1996 Jun;10(2):111–27 (107 ref.)

Recognition and signaling by mouse Ly-49 receptors. Seaman WE, et al. **Chem Immunol** 1996;64:19–27 (31 ref.)

T-cell costimulation: T cells themselves call the shots. Owens T. **Curr Biol** 1996 Jan 1;6(1):32–7 (21 ref.)

Sevenspan transmembrane molecules: novel receptors involved in leukocyte adhesion. van Lier RA, et al. **Immunol Lett** 1996 Dec;54(2–3):185–7 (13 ref.)

Skin-homing T cells in human cutaneous allergic inflammation. Santamaria Babi LF, et al. **Immunol Res** 1995;14(4):317–24 (43 ref.)

Targeted disruption of the IL-6 related genes: gp130 and NF-IL-6. Akira S, et al. **Immunol Rev** 1995 Dec; 148:221–53 (135 ref.)

A vision of cell death: insights into immune privilege. Ferguson TA, et al. **Immunol Rev** 1997 Apr;156:167–84 (86 ref.)

Specificity, tolerance and developmental regulation of natural killer cells defined by expression of class I-specific Ly49 receptors. Raulet DH, et al. **Immunol Rev** 1997 Feb; 155:41–52 (46 ref.)

The role of FasL-induced apoptosis in immune privilege [published erratum appears in Imunol Today 1997 Jul;18(7):361] Griffith TS, et al. **Immunol Today** 1997 May; 18(5):240–4 (46 ref.)

Immunoregulatory effects of Fas-mediated signalling. Lynch DH, et al. **J Cell Biochem** 1996 Jan;60(1):39–46 (34 ref.)

Cell death and the immune response: a lesson from the privileged. Ferguson TA, et al. **J Clin Immunol** 1997 Jan; 17(1):1–10 (51 ref.)

Upregulation of Fas ligand by simian immunodeficiency virus – a nef-arious mechanism of immune evasion? Johnson RP. **J Exp Med** 1997 Jul 7;186(1):1–5 (50 ref.)

A newly recognized pathway for the negative regulation of mast cell-dependent hypersensitivity and inflammation mediated by an endogenous cell surface receptor of the gp49 family. Katz HR, et al. **J Immunol** 1997 Jun 1; 158(11):5065–70 (32 ref.)

IL-6 cytokine family and signal transduction: a model of the cytokine system. Hibi M, et al. **J Mol Med** 1996 Jan; 74(1):1–12 (168 ref.)

Molecular genetics of the zona pellucida: implications for immunocontraceptive strategies. Castle PE, et al. **J Reprod Fertil Suppl** 1996;50:1–8 (39 ref.)

Comparative structural and antigenic properties of zona pellucida glycoproteins. Hedrick JL. **J Reprod Fertil Suppl** 1996;50:9–17 (32 ref.)

T helper cells driving pathogenic anti-DNA autoantibody production in lupus: nucleosomal epitopes and CD40 ligand signals. Datta SK, et al. **Lupus** 1997;6(3):333–6 (4 ref.)

Structure, function and immunogenicity of streptococcal antigen I/II polypeptides. Jenkinson HF, et al. **Mol Microbiol** 1997 Jan;23(2):183–90 (33 ref.)

Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. Reiser H, et al. **N Engl J Med** 1996 Oct 31;335(18):1369–77 (69 ref.)

A possible role for the alpha 1-->3 galactosyl epitope and the natural anti-gal antibody in oncogenesis. Gollogly L, et al. **Neoplasma** 1996;43(5):285–9 (27 ref.)

Fas-ligand: privilege and peril [see comments] Green DR, et al. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):5986–90 (37 ref.) Comment in: Proc Natl Acad Sci U S A 1997 Apr 15;94(8):3914–9. Comment in: Proc Natl Acad Sci U S A 1997 Apr 15;94(8):3943–7.

Role for NK-cell-associated Fas ligand in cell-mediated cytotoxicity and apoptosis. Eischen CM, et al. **Res Immunol** 1997 Mar-Apr;148(3):164–9 (43 ref.)

Antibodies against Candida: potential therapeutics? Matthews R, et al. **Trends Microbiol** 1996 Sep;4(9):354–8 (41 ref.)

Large-scale production in Pichia pastoris of the recombinant vaccine Gavac against cattle tick. Canales M, et al. **Vaccine** 1997 Mar;15(4):414–22 (27 ref.)

[Molecular analysis of experimental membranous glomerulonephritis (Heymann nephritis)] Kerjaschki D. **Verh Dtsch Ges Pathol** 1996;80:139–47 (45 ref.) (Eng. Abstr.) **(Ger)**

[CD95 (APO-1/Fas) and CD95-ligand (CD95L). Implications of these apoptosis mediating receptor/ligand systems in the pathogenesis of autoimmune diseases] Möller P, et al. **Verh Dtsch Ges Pathol** 1996;80:12–20 (38 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Expression of an L-selectin ligand on hematopoietic progenitor cells. Sackstein R. **Acta Haematol** 1997; 97(1–2):22–8 (51 ref.)

The Fas pathway in apoptosis. Eischen CM, et al. **Adv Pharmacol** 1997;41:107–32 (163 ref.)

MUC1 as a cell surface and secretory component of endometrial epithelium: reduced levels in recurrent miscarriage. Aplin JD, et al. **Am J Reprod Immunol** 1996 Mar;35(3):261–6 (47 ref.)

The signal transducer gp130 is shared by interleukin-6 family of haematopoietic and neurotrophic cytokines. Taga T. **Ann Med** 1997 Feb;29(1):63–72 (88 ref.)

Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86. Lane P. **Ann N Y Acad Sci** 1997 Apr 5;815:392–400 (40 ref.)

Analysis of CD40-CD40 ligand interactions in the regulation of human B cell function. Lipsky PE, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:372–83 (34 ref.)

Structure and function of the pre-T cell receptor. von Boehmer H, et al. **Annu Rev Immunol** 1997;15:433–52 (53 ref.)

Molecular and biochemical basis of the interaction between tomato and its fungal pathogen Cladosporium fulvum. de Wit PJ, et al. **Antonie Van Leeuwenhoek** 1997 Feb; 71(1–2):137–41 (27 ref.)

Costameric distribution of beta-dystroglycan (43 kDa dystrophin-associated glycoprotein) in normal and dystrophin-deficient human skeletal muscle. Herrmann R, et al. **Biochem Soc Trans** 1996 May;24(2):501–6 (43 ref.)

Role of the b(o,+)-like amino acid-transport system in the renal reabsorption of cystine and dibasic amino acids. Palacín M, et al. **Biochem Soc Trans** 1996 Aug;24(3):856–63 (53 ref.)

TGN38 and its orthologues: roles in post-TGN vesicle formation and maintenance of TGN morphology. Banting G, et al. **Biochim Biophys Acta** 1997 Mar 1;1355(3):209–17 (48 ref.)

Supramolecular assembly of basement membranes. Timpl R, et al. **Bioessays** 1996 Feb;18(2):123–32 (80 ref.)

Water channels and urea transporters. Wintour EM. **Clin Exp Pharmacol Physiol** 1997 Jan;24(1):1–9 (78 ref.)

Pattern formation: The link between ovary and embryo. Stein D. **Curr Biol** 1995 Dec 1;5(12):1360–3 (16 ref.)

Dystroglycan: an extracellular matrix receptor linked to the cytoskeleton. Henry MD, et al. **Curr Opin Cell Biol** 1996 Oct;8(5):625–31 (69 ref.)

ADAMs and cell fusion. Huovila APJ, et al. **Curr Opin Cell Biol** 1996 Oct;8(5):692–9 (44 ref.)

Transducing signals of life and death. Yuan J. **Curr Opin Cell Biol** 1997 Apr;9(2):247–51 (31 ref.)

Mammalian urea transporters. Shayakul C, et al. **Curr Opin Nephrol Hypertens** 1996 Sep;5(5):401–5 (21 ref.)

Ca2+ and the regulation of neurotransmitter secretion. Bennett MK. **Curr Opin Neurobiol** 1997 Jun;7(3):316–22 (69 ref.)

Towards an understanding of the dystrophin-glycoprotein complex: linkage between the extracellular matrix and the membrane cytoskeleton in muscle fibers. Ohlendieck K. **Eur J Cell Biol** 1996 Jan;69(1):1–10 (107 ref.)

Pharmacology and regulation of the neuronal dopamine transporter. Reith ME, et al. **Eur J Pharmacol** 1997 Apr 11;324(1):1–10 (92 ref.)

Dystroglycan and laminins: glycoconjugates involved in branching epithelial morphogenesis. Durbeej M, et al. **Exp Lung Res** 1997 Mar-Apr;23(2):109–18 (43 ref.)

Transformation competence and type-4 pilus biogenesis in Neisseria gonorrhoeae--a review. Fussenegger M, et al. **Gene** 1997 Jun 11;192(1):125–34 (93 ref.)

Remodeling of cell surface glycoproteins by N-acetylglucosaminyltransferase III gene transfection: modulation of metastatic potentials and down regulation of hepatitis B virus replication. Taniguchi N, et al. **Glycobiology** 1996 Oct;6(7):691–4 (25 ref.)

The Sialoadhesins--a family of sialic acid-dependent cellular recognition molecules within the immunoglobulin superfamily. Kelm S, et al. **Glycoconj J** 1996 Dec; 13(6):913–26 (114 ref.)

Killer cell inhibitory receptor interactions with HLA class I molecules: implications for alloreactivity and transplantation. Young NT, et al. **Hum Immunol** 1997 Jan; 52(1):1–11 (109 ref.)

The CD94/NKG2 C-type lectin receptor complex: involvement in NK cell-mediated recognition of HLA class I molecules. López-Botet M, et al. **Immunol Res** 1997; 16(2):175–85 (50 ref.)

The role of CD40 ligand in costimulation and T-cell activation. Grewal IS, et al. **Immunol Rev** 1996 Oct; 153:85–106 (100 ref.)

CD40–CD40L interactions in atherosclerosis. Laman JD, et al. **Immunol Today** 1997 Jun;18(6):272–7 (31 ref.)

Molecular mechanisms of the interaction between sperm and the zona pellucida in mammals: studies on the pig. Töpfer-Petersen E, et al. **Int J Androl** 1995 Dec;18 Suppl 2:20–6 (56 ref.)

Regulation of Na+/glucose cotransporters. Wright EM, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):287–93 (23 ref.)

The roles of the thiol:protein disulfide oxidoreductases in membrane and secretory protein synthesis within the lumen of the endoplasmic reticulum. Holtzman JL. **J Investig Med** 1997 Feb;45(2):28–34 (52 ref.)

Structure and function of the N-linked carbohydrate chains of pig zona pellucida glycoproteins. Nakano M, et al. **J Reprod Fertil Suppl** 1996;50:25–34 (40 ref.)

CD40/CD40 ligand interactions in normal, reactive and malignant lympho-hematopoietic tissues. Gruss HJ, et al. **Leuk Lymphoma** 1997 Feb;24(5–6):393–422 (236 ref.)

The role of carbohydrate in sperm-ZP3 adhesion. Chapman NR, et al. **Mol Hum Reprod** 1996 Oct;2(10):767–74 (74 ref.)

SV2proteoglycan: a potential synaptic vesicle transporter and nerve terminal extracellular matrix receptor. Carlson SS. **Perspect Dev Neurobiol** 1996;3(4):373–86 (79 ref.)

Intestinal sodium-dependent D-glucose co-transporter: dietary regulation. Shirazi-Beechey SP. **Proc Nutr Soc** 1996 Mar;55(1B):167–78 (44 ref.)

Apoptosis mediated by the Fas system. Nagata S. **Prog Mol Subcell Biol** 1996;16:87–103 (70 ref.)

The CD94/NKG2C-type lectin receptor complex in recognition of HLA class I molecules. López-Botet M, et al. **Res Immunol** 1997 Mar-Apr;148(3):155–9 (30 ref.)

The CD95 system and the death of a lymphocyte. Matiba B, et al. **Semin Immunol** 1997 Feb;9(1):59–68 (108 ref.)

Why mammalian cell surface proteins are glycoproteins [published erratum appears in Trends Biochem Sci 1996 Dec;21(12):491] Gahmberg CG, et al. **Trends Biochem Sci** 1996 Aug;21(8):308–11 (36 ref.)

Is CD46 the cellular receptor for measles virus? Buckland R, et al. **Virus Res** 1997 Apr;48(1):1–9 (44 ref.)

[Coupling of seven transmembrane domains receptors cytosolic PLA2: role of G proteins and protein kinases] Masliah J, et al. **C R Seances Soc Biol Fil** 1996; 190(4):417–23 (28 ref.) (Eng. Abstr.) **(Fre)**

[The role of syndecan and tenascine during tooth development. Review o the literature] Bucci P, et al. **Minerva Stomatol** 1996 Jun;45(6):259–66 (15 ref.) (Eng. Abstr.) **(Ita)**

[Abnormal Fas and Fas ligand expression of lymphocytes in patients with SLE] Suzuki N, et al. **Nippon Rinsho** 1996 Jul;54(7):1955–9 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Regulation of apoptosis through altered expression of Fas-ligand and Fas genes] Nakanishi Y. **Tanpakushitsu Kakusan Koso** 1996 Dec;41(16):2552–8 (26 ref.) **(Jpn)**

PHYSIOLOGY

Presynaptic phosphoprotein B-50/GAP-43 in neuronal and synaptic plasticity. Biewenga JE, et al. **Acta Biochim Pol** 1996;43(2):327–38 (121 ref.)

The role of adhesion and costimulation molecules in graft-versus-host disease. Schlegel PG. **Acta Haematol** 1997;97(1–2):105–17 (191 ref.)

Restriction of plastic fiber growth after lesions by central nervous system myelin-associated neurite growth inhibitors. Kapfhammer JP. **Adv Neurol** 1997;73:7–27 (180 ref.)

Urea transporters in kidney and erythrocytes. Sands JM, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):F321–39 (163 ref.)

The role of syndecan-1 in malignancies. Inki P, et al. **Ann Med** 1996 Feb;28(1):63–7 (32 ref.)

The signal transducer gp130 is shared by interleukin-6 family of haematopoietic and neurotrophic cytokines. Taga T. **Ann Med** 1997 Feb;29(1):63–72 (88 ref.)

Unique site of autoantibody production in Fas-deficient mice. Jacobson BA, et al. **Ann N Y Acad Sci** 1997 Apr 5; 815:218–29 (43 ref.)

New knowledge about T-cell cytotoxicity. Cerottini JC, et al. **Ann Oncol** 1997;8 Suppl 2:75–8 (20 ref.)

Immune regulation by CD40 and its ligand GP39. Foy TM, et al. **Annu Rev Immunol** 1996;14:591–617 (111 ref.)

FasL/Fas and TNF/TNFR interactions in the regulation of immune responses and disease. Lynch DH, et al.

Behring Inst Mitt 1996 Oct;(97):175–84 (36 ref.)
CD95 (APO–1/Fas) and its ligand in the mouse immune system. Mariani SM, et al. **Behring Inst Mitt** 1996 Oct; (97):12–23 (77 ref.)
Autoimmune disease results from multiple interactive defects in apoptosis induction molecules and signaling pathways. Mountz JD, et al. **Behring Inst Mitt** 1996 Oct;(97):200–19 (116 ref.)
A death factor––the other side of the coin. Nagata S. **Behring Inst Mitt** 1996 Oct;(97):1–11 (48 ref.)
Heterogeneity of interactions mediated by membrane glycoproteins of lymphocytes. Barclay AN, et al. **Biochem Soc Trans** 1997 Feb;25(1):224–8 (15 ref.)
Regulation of apoptosis through CD95 (APO–I/Fas) receptor–ligand interaction. Debatin KM, et al. **Biochem Soc Trans** 1997 May;25(2):405–10 (48 ref.)
Why did the sperm cross the cumulus? To get to the oocyte. Functions of the sperm surface proteins PH–20 and fertilin in arriving at, and fusing with, the egg. Myles DG, et al. **Biol Reprod** 1997 Feb;56(2):320–7 (58 ref.)
Members of the Tc–85 protein family from Trypanosoma cruzi are adhesion proteins. Alves MJ. **Braz J Med Biol Res** 1996 Jul;29(7):831–3 (32 ref.)
Apoptosis by death factor. Nagata S. **Cell** 1997 Feb 7; 88(3):355–65 (85 ref.)
Functional resemblance between the Ig–related NK cell receptors specific for HLA class I molecules and the CD94 C–type lectin. López–Botet M, et al. **Chem Immunol** 1996; 64:116–34 (60 ref.)
Functions of CD40 and its ligand, gp39 (CD40L). Laman JD, et al. **Crit Rev Immunol** 1996;16(1):59–108 (220 ref.)
Mammalian urea transporters. Shayakul C, et al. **Curr Opin Nephrol Hypertens** 1996 Sep;5(5):401–5 (21 ref.)
Cardiotrophin–1: a multifunctional cytokine that signals via LIF receptor–gp 130 dependent pathways. Pennica D, et al. **Cytokine Growth Factor Rev** 1996 Jun;7(1):81–91 (63 ref.)
Thrombospondin as a regulator of angiogenesis. DiPietro LA. **EXS** 1997;79:295–314 (74 ref.)
Fas–induced apoptosis, and diseases caused by its abnormality. Nagata S. **Genes Cells** 1996 Oct;1(10):873–9 (51 ref.)
The role of dystroglycan, a novel receptor of laminin and agrin, in cell differentiation. Matsumura K, et al. **Histol Histopathol** 1997 Jan;12(1):195–203 (59 ref.)
The Fas–based mechanism of lymphocytotoxicity. Berke G. **Hum Immunol** 1997 Apr 15;54(1):1–7 (61 ref.)
Arousal and inhibition of human NK cells. Lanier LL, et al. **Immunol Rev** 1997 Feb;155:145–54 (98 ref.)
Structure and function of the CD94 C–type lectin receptor complex involved in recognition of HLA class I molecules. López–Botet M, et al. **Immunol Rev** 1997 Feb;155:165–74 (74 ref.)
FasL expression on epithelial cells: the Bottazzo–Feldman hypothesis revisited. Dayan CM, et al. **Immunol Today** 1997 May;18(5):203 (15 ref.)
A central role of CD40 ligand in the regulation of CD4+ T–cell responses. Grewal IS, et al. **Immunol Today** 1996 Sep;17(9):410–4 (41 ref.)
Functional role of CD40 and its ligand. van Kooten C, et al. **Int Arch Allergy Immunol** 1997 Aug;113(4):393–9 (47 ref.)
CD46, a complement regulatory protein/measles virus receptor, and its relation to hematological disorders. Seya T. **Int J Hematol** 1996 Aug;64(2):101–9 (38 ref.)
The surrogate light chain in mouse B–cell development. Rolink A, et al. **Int Rev Immunol** 1996;13(4):341–56 (41 ref.)
Roles of gp130 signaling pathways in cardiac myocytes: recent advances and implications for cardiovascular disease. Yamauchi–Takihara K, et al. **J Card Fail** 1996 Dec; 2(4 Suppl):S63–8 (44 ref.)
Syndecans, signaling, and cell adhesion. Couchman JR, et al. **J Cell Biochem** 1996 Jun 15;61(4):578–84 (34 ref.)
Deciphering the function of neurexins at cellular junctions. Littleton JT, et al. **J Cell Biol** 1997 May 19;137(4):793–6 (26 ref.)
Perspectives series: cell adhesion in vascular biology. Role of PSGL–1 binding to selectins in leukocyte recruitment. McEver RP, et al. **J Clin Invest** 1997 Aug 1;100(3):485–91 (70 ref.)
Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. Walker PR, et al. **J Immunol** 1997 May 15;158(10):4521–4 (51 ref.)
Molecular bases of adhesion of Candida albicans. Fukazawa Y, et al. **J Med Vet Mycol** 1997 Mar–Apr;35(2):87–99 (106 ref.)
Cardiotrophin–1 and the role of gp130–dependent signaling pathways in cardiac growth and development. Wollert KC, et al. **J Mol Med** 1997 Jul;75(7):492–501 (98 ref.)
Neural cell adhesion molecule L1: signaling pathways and growth cone motility. Kamiguchi H, et al. **J Neurosci Res** 1997 Jul 1;49(1):1–8 (81 ref.)
Molecular and cellular aspects of measles virus persistence in the CNS. ter Meulen V. **J Neurovirol** 1997 May;3 Suppl 1:S3–5 (25 ref.)
CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells. Gruss H–J, et al. **Leuk Lymphoma** 1996 Feb;20(5–6):397–409 (79 ref.)
Fas receptor (CD95)–mediated apoptosis in leukemic cells. Komada Y, et al. **Leuk Lymphoma** 1997 Mar;25(1–2):9–21 (65 ref.)
The L1 family of neural cell adhesion molecules: old proteins performing new tricks. Hortsch M. **Neuron** 1996 Oct; 17(4):587–93 (44 ref.)
N–syndecan: structure and function of a transmembrane heparan sulfate proteoglycan. Carey DJ. **Perspect Dev Neurobiol** 1996;3(4):331–46 (77 ref.)
GAP–43: putting constraints on neuronal plasticity. Fishman MC. **Perspect Dev Neurobiol** 1996;4(2–3):193–8 (46 ref.)
GAP–43: an intrinsic determinant of neuronal development and plasticity. Benowitz LI, et al. **Trends Neurosci** 1997 Feb;20(2):84–91 (140 ref.)
[Kidney and complement regulatory factors] Matsuo S. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):643–6 (14 ref.) **(Jpn)**
[Complement regulatory membrane factors in experimental animal models] Okada N. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):631–3 (6 ref.) **(Jpn)**
[Structure and biological functions of the spike protein of mouse hepatitis virus] Taguchi F. **Uirusu** 1996 Dec; 46(2):109–17 (52 ref.) **(Jpn)**
[The role of bacteriophage lambda coded proteins in destruction of the bacterial cell wall and the control of lysis timing] Kędzierska S, et al. **Postepy Biochem** 1996; 42(4):331–9 (49 ref.) **(Pol)**

ULTRASTRUCTURE

Advances in S–layer nanotechnology and biomimetics. Sleytr UB, et al. **Adv Biophys** 1997;34:71–9 (38 ref.)

MEMBRANE LIPIDS

Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Horrobin DF. **Prostaglandins Leukot Essent Fatty Acids** 1996 Aug; 55(1–2):3–7 (46 ref.)

ANALYSIS

Macroamphiphilic cell envelope components of Rhodococcus equi and closely related bacteria. Sutcliffe IC. **Vet Microbiol** 1997 Jun 16;56(3–4):287–99 (43 ref.)

BLOOD

Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Zwaal RF, et al. **Blood** 1997 Feb 15;89(4):1121–32 (196 ref.)

CHEMISTRY

Molecular and physicochemical aspects of local anesthetic–membrane interaction. de–Paula E, et al. **Braz J Med Biol Res** 1996 Jul;29(7):877–94 (199 ref.)
Effect of some environmental factors on the content and composition of microbial membrane lipids. Sajbidor J. **Crit Rev Biotechnol** 1997;17(2):87–103 (112 ref.)
Lipid microdomains in cell surface membranes. Edidin M. **Curr Opin Struct Biol** 1997 Aug;7(4):528–32 (44 ref.)
Small–scale lipid–membrane structure: simulation versus experiment. Mouritsen OG, et al. **Curr Opin Struct Biol** 1997 Aug;7(4):518–27 (110 ref.)
Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. Peet M, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Aug; 55(1–2):71–5 (33 ref.)

IMMUNOLOGY

Cross–linking of cell surface ganglioside GM1 induces the selective apoptosis of mature CD8+ T lymphocytes. Nahar TO, et al. **Int Immunol** 1996 May;8(5):731–6 (24 ref.)

METABOLISM

Psoralen photosensitization: damages to nucleic acid and membrane lipid components. Caffieri S, et al. **Acta Biochim Pol** 1996;43(1):241–6 (31 ref.)
Cut–off effects in biological activities of surfactants. Balgavý P, et al. **Adv Colloid Interface Sci** 1996 Aug 12;66:23–63 (101 ref.)
Single–particle tracking: applications to membrane dynamics. Saxton MJ, et al. **Annu Rev Biophys Biomol Struct** 1997; 26:373–99 (105 ref.)
Cross–linking of cell surface ganglioside GM1 induces the selective apoptosis of mature CD8+ T lymphocytes. Nahar TO, et al. **Int Immunol** 1996 May;8(5):731–6 (24 ref.)
Signalling through the lipid products of phosphoinositide–3–OH kinase. Toker A, et al. **Nature** 1997 Jun 12;387(6634):673–6 (47 ref.)
Membrane phospholipid alterations in Alzheimer's disease: deficiency of ethanolamine plasmalogens. Farooqui AA, et al. **Neurochem Res** 1997 Apr;22(4):523–7 (48 ref.)
Recent advances in membrane cholesterol domain dynamics and intracellular cholesterol trafficking. Schroeder F, et al. **Proc Soc Exp Biol Med** 1996 Nov;213(2):150–77 (178 ref.)
The lipid membrane hypothesis of schizophrenia: implications for possible clinical breath tests. Dodd GH. **Prostaglandins Leukot Essent Fatty Acids** 1996 Aug; 55(1–2):95–9 (24 ref.)
Abnormal membrane concentrations of 20 and 22–carbon essential fatty acids: a common link between risk factors and coronary and peripheral vascular disease? Horrobin DF. **Prostaglandins Leukot Essent Fatty Acids** 1995 Dec; 53(6):385–96 (157 ref.)
Oxidative injury and potential use of antioxidants in schizophrenia. Mahadik SP, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Aug; 55(1–2):45–54 (117 ref.)
31P magnetic resonance spectroscopy studies in schizophrenia. Williamson PC, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Aug; 55(1–2):115–8 (19 ref.)
[The value of oil baths for adjuvant basic therapy of inflammatory dermatoses with dry, barrier–disrupted skin] Melnik B, et al. **Hautarzt** 1996 Sep;47(9):665–72 (62 ref.) (Eng. Abstr.) **(Ger)**
[Tirilazad mesylate (Freedox)––an effective inhibitor of lipid membrane peroxidation] Sániová B. **Bratisl Lek Listy** 1997 Jun;98(6):339–42 (20 ref.) (Eng. Abstr.) **(Slo)**

PHYSIOLOGY

Molecular basis for membrane phospholipid diversity: why are there so many lipids? Dowhan W. **Annu Rev Biochem** 1997;66:199–232 (195 ref.)
Membrane assembly studied by spin–label electron spin resonance. Marsh D. **Braz J Med Biol Res** 1996 Jul; 29(7):863–71 (47 ref.)
Caveolae, DIGs, and the dynamics of sphingolipid–cholesterol microdomains. Harder T, et al. **Curr Opin Cell Biol** 1997 Aug;9(4):534–42 (75 ref.)
The role of lipid signaling in constitutive membrane traffic. Roth MG, et al. **Curr Opin Cell Biol** 1997 Aug;9(4):519–26 (64 ref.)
Nuclear magnetic resonance spectroscopy: new insights into the pathophysiology of mood disorders. Soares JC, et al. **Depression** 1996;4(1):14–30 (165 ref.)
Regulatory mechanisms in maintenance and modulation of transmembrane lipid asymmetry: pathophysiological implications. Bevers EM, et al. **Lupus** 1996 Oct;5(5):480–7 (101 ref.)
Phosphatidylcholine signaling in response to CSF–1. Jackowski S, et al. **Mol Reprod Dev** 1997 Jan;46(1):24–30 (23 ref.)
Functional rafts in cell membranes. Simons K, et al. **Nature** 1997 Jun 5;387(6633):569–72 (67 ref.)
[Role of plasmalemma in the process of aging, elimination and reproduction of erythrocytes: plasmalemmal microvesicles as stimulators of erythropoiesis] Sorokovoi VI, et al. **Vestn Ross Akad Med Nauk** 1996;(9):35–40 (71 ref.) (Eng. Abstr.) **(Rus)**
[Gangliosides as neurobiochemical markers] De Luka SR, et al. **Med Pregl** 1996;49(9–10):377–83 (23 ref.) (Eng. Abstr.) **(Scr)**

MEMBRANE METALLO–ENDOPEPTIDASE see **NEPRILYSIN**

MEMBRANE POTENTIALS

Membrane polarity in epithelial cells: protein sorting and establishment of polarized domains. Caplan MJ. **Am J Physiol** 1997 Apr;272(4 Pt 2):F425–9 (62 ref.)
[Anesthesia mechanisms: nerve excitation and temperature] Suzuki A, et al. **Masui** 1996 Jun;45(6):670–5 (31 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Cellular mechanisms underlying reinforcement–related processing in the nucleus accumbens: electrophysiological studies in behaving animals. Carelli RM, et al. **Pharmacol Biochem Behav** 1997 Jul;57(3):495–504 (55 ref.)
Excitatory and inhibitory amino acids and synaptic transmission in the suprachiasmatic nucleus. van den Pol AN, et al. **Prog Brain Res** 1996;111:41–56 (76 ref.)
[Possible applications of the "patch–clamp" method in anesthesiologic research; comment] Bräu ME, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Nov; 31(9):537–42 (21 ref.) (Eng. Abstr.) Comment on: Anasthesiol Intensivmed Notfallmed Schmer 1996 Nov;31(9):535–6. **(Ger)**

PHYSIOLOGY

Electroporation of cell membranes: a review. Ho SY, et al. **Crit Rev Biotechnol** 1996;16(4):349–62 (70 ref.)
Mechanisms of paresthesiae, dysesthesiae, and hyperesthesiae: role of Na+ channel heterogeneity. Rizzo MA, et al. **Eur Neurol** 1996;36(1):3–12 (44 ref.)
Role of mitochondria–rich cells in epithelial chloride uptake. Larsen EH, et al. **Exp Physiol** 1996 May;81(3):525–34 (25 ref.)
The NEURON simulation environment. Hines ML, et al. **Neural Comput** 1997 Aug 15;9(6):1179–209 (38 ref.)

MEMBRANE PROTEINS

Focal adhesions, contractility, and signaling. Burridge K, et al. **Ann Rev Cell Dev Biol** 1996;12:463–518 (385 ref.)
Protein tyrosine phosphatase–like proteins: link with IDDM. Pietropaolo M, et al. **Diabetes Care** 1997 Feb;20(2):208–14 (42 ref.)
[Aquaporin water channels] Ishibashi K. **Nippon Rinsho** 1996 Mar;54(3):685–91 (6 ref.) (Eng. Abstr.) **(Jpn)**

MEMBRANE PROTEINS

[Artificial models of transport proteins in membrane] Kobuke Y. **Nippon Rinsho** 1996 Mar;54(3):737–43 (13 ref.) (Eng. Abstr.) **(Jpn)**

[RP105 and B cell apoptosis] Miura Y, et al. **Nippon Rinsho** 1996 Jul;54(7):1784–9 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Cell membrane transport proteins: cross point of pharmacology and molecular biology] Shigekawa S, et al. **Nippon Yakurigaku Zasshi** 1996 Sep;108(3):160–2 (6 ref.) **(Jpn)**

[Group A Streptococcus and autoimmune] Ohkuni H. **Ryumachi** 1996 Dec;36(6):874–83 (36 ref.) **(Jpn)**

[Amino acid neurotransmitter transporters] Saito N, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):253–60 (46 ref.) **(Jpn)**

[NADH–quinone oxidoreductase: the hugest and most complicated membrane–bound enzyme complex] Yano T. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(2):154–63 (46 ref.) **(Jpn)**

ANALYSIS

The neurochemistry of Alzheimer's disease. Blennow K, et al. **Acta Neurol Scand Suppl** 1996;168:77–86 (129 ref.)

Nonerythroid membrane skeletal proteins in normal and diseased human skin. Shimizu T, et al. **Histol Histopathol** 1996 Apr;11(2):495–501 (72 ref.)

Measurement of intracellular cytokines. Schauer U, et al. **Immunol Today** 1996 Jul;17(7):305–6 (9 ref.)

Cell–surface markers for assessing gene transfer into human hematopoietic cells [see comments] Phillips K, et al. **Nat Med** 1996 Oct;2(10):1154–6 (25 ref.) Comment in: Nat Med 1996 Dec;2(12):1280–1.

Why is CTX all the RAGE? Du Pasquier L, et al. **Res Immunol** 1996 May;147(4):261–6 (15 ref.)

[Analysis of abnormal erythrocyte proteins and the etiological relation to hemolytic anemia] Fujioka S. **Nippon Rinsho** 1996 Sep;54(9):2423–9 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Hereditary elliptocytosis] Iyori H, et al. **Nippon Rinsho** 1996 Sep;54(9):2484–91 (16 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Development of connectin/titin and nebulin in striated muscles of chicken. Shimada Y, et al. **Adv Biophys** 1996; 33:223–33 (37 ref.)

Uncoupling protein in brown adipose tissue: molecular differentiation of the adipose tissues. Trayhurn P. **Biochem Soc Trans** 1996 May;24(2):402–6 (36 ref.)

Impact of the discovery of membrane inhibitors of complement. Atkinson JP. **Res Immunol** 1996 Feb; 147(2):95–100 (58 ref.)

CHEMISTRY

Structural perspectives of phospholamban, a helical transmembrane pentamer. Arkin IT, et al. **Annu Rev Biophys Biomol Struct** 1997;26:157–79 (76 ref.)

Antibodies as tools to study the structure of membrane proteins: the case of the nicotinic acetylcholine receptor. Conti–Fine BM, et al. **Annu Rev Biophys Biomol Struct** 1996;25:197–229 (112 ref.)

Membrane protein secretases. Hooper NM, et al. **Biochem J** 1997 Jan 15;321 (Pt 2):265–79 (164 ref.)

Protein structure: proton–pumping oxidases. Gennis RB, et al. **Curr Biol** 1996 Jan 1;6(1):36–8 (10 ref.)

Receptor signaling: dimerization and beyond. Stock J. **Curr Biol** 1996 Jul 1;6(7):825–7 (18 ref.)

Modeling transmembrane helical oligomers. Dieckmann GR, et al. **Curr Opin Struct Biol** 1997 Aug;7(4):486–94 (82 ref.)

Helix packing in polytopic membrane proteins: the lactose permease of Escherichia coli. Kaback HR, et al. **Curr Opin Struct Biol** 1997 Aug;7(4):537–42 (57 ref.)

Recognition at the cell surface: recent structural insights. Stuart DI, et al. **Curr Opin Struct Biol** 1995 Dec;5(6):735–43 (50 ref.)

ISGF3 gamma p48, a specificity switch for interferon activated transcription factors. Bluyssen AR, et al. **Cytokine Growth Factor Rev** 1996 Jun;7(1):11–7 (54 ref.)

ADAMs in fertilization and development. Wolfsberg TG, et al. **Dev Biol** 1996 Dec 15;180(2):389–401 (63 ref.)

Membrane proteins which exhibit multiple topological orientations. Levy D. **Essays Biochem** 1996;31:49–60 (21 ref.)

Phylogenetic analysis of membrane trafficking proteins: a family reunion and secondary structure predictions. Terrian DM, et al. **Eur J Cell Biol** 1997 Jul;73(3):198–204 (13 ref.)

The tetraspanin superfamily: molecular facilitators. Maecker HT, et al. **FASEB J** 1997 May;11(6):428–42 (140 ref.)

A new model for the membrane topology of glucose–6–phosphatase: the enzyme involved in von Gierke disease. Hemrika W, et al. **FEBS Lett** 1997 Jun 16; 409(3):317–9 (20 ref.)

EGF–TM7: a novel subfamily of seven–transmembrane–region leukocyte cell–surface molecules. McKnight AJ, et al. **Immunol Today** 1996 Jun; 17(6):283–7 (32 ref.)

What causes ion channel proteins to fluctuate open and closed? Liebovitch LS, et al. **Int J Neural Syst** 1996 Sep; 7(4):321–31 (16 ref.)

Intramembrane signaling mediated by hydrogen–bonding of water and carboxyl groups in bacteriorhodopsin and rhodopsin. Maeda A, et al. **J Biochem (Tokyo)** 1997 Mar; 121(3):399–406 (62 ref.)

Transmembrane auxiliary subunits of voltage–dependent ion channels. Gurnett CA, et al. **J Biol Chem** 1996 Nov 8; 271(45):27975–8 (52 ref.)

Ectodomain interactions of leukocyte integrins and pro–inflammatory GPI–linked membrane proteins. Petty HR, et al. **J Pharm Biomed Anal** 1997 Jun;15(9–10):1405–16 (94 ref.)

In vitro translation analysis of integral membrane proteins. Bayle D, et al. **J Recept Signal Transduct Res** 1997 Jan–May;17(1–3):29–56 (70 ref.)

Membrane proteins. Josic D, et al. **Methods Enzymol** 1996; 271:113–34 (29 ref.)

NMR studies of peptides and proteins associated with membranes. Klassen RB, et al. **Methods Mol Biol** 1997; 60:271–97 (68 ref.)

Regulation of targeting signals in membrane proteins. [review] Stanley KK. **Mol Membr Biol** 1996 Jan–Mar; 13(1):19–27 (108 ref.)

Experimentally determined hydrophobicity scale for proteins at membrane interfaces. Wimley WC, et al. **Nat Struct Biol** 1996 Oct;3(10):842–8 (46 ref.)

Membrane composition of adrenergic large and small dense cored vesicles and of synaptic vesicles: consequences for their biogenesis. Winkler H. **Neurochem Res** 1997 Aug; 22(8):921–32 (143 ref.)

Crystalline bacterial cell surface layers (S–layers): from cell structure to biomimetics. Sára M, et al. **Prog Biophys Mol Biol** 1996;65(1–2):83–111 (200 ref.)

Principles of membrane protein assembly and structure. von Heijne G. **Prog Biophys Mol Biol** 1996;66(2):113–39 (199 ref.)

Magic angle spinning NMR spectroscopy of membrane proteins. Smith SO, et al. **Q Rev Biophys** 1996 Dec; 29(4):395–449 (213 ref.)

Snake venom metalloproteinases: structure, function and relationship to the ADAMs family of proteins. Jia LG, et al. **Toxicon** 1996 Nov–Dec;34(11–12):1269–76 (22 ref.)

Peptides in membranes: tipping the balance of membrane stability. Brasseur R, et al. **Trends Biochem Sci** 1997 May; 22(5):167–71 (41 ref.)

[Neurofibromatosis type 2 (NF2)] Araki N, et al. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1427–31 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular defects of erythrocyte membrane proteins] Storozhok SA, et al. **Vopr Med Khim** 1996 Apr–Jun; 42(2):103–10 (73 ref.) **(Rus)**

CLASSIFICATION

Let's think about coat proteins. Berón W. **Biocell** 1996 Dec; 20(3):307–12 (5 ref.)

Chemokines: what chemokine is that? Mackay CR. **Curr Biol** 1997 Jun 1;7(6):R384–6 (14 ref.)

DEFICIENCY

Paroxysmal nocturnal hemoglobinuria: new insights from murine Pig–a–deficient hematopoiesis. Devetten MP, et al. **Proc Assoc Am Physicians** 1997 Mar;109(2):99–110 (68 ref.)

[The complete band4.2 deficiency in human red cells] Kanzaki A, et al. **Nippon Rinsho** 1996 Sep;54(9):2492–501 (20 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Clostridium difficile toxins attack Rho. Wilkins TD, et al. **Trends Microbiol** 1996 Feb;4(2):49–51 (17 ref.)

GENETICS

Molecular genetics of hereditary elliptocytosis and hereditary spherocytosis. Delaunay J, et al. **Ann Genet** 1996; 39(4):209–21 (93 ref.)

X–linked adrenoleukodystrophy. Aubourg P, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:461–76 (75 ref.)

A point mutation associated with a severe phenotype of neurofibromatosis 2. MacCollin M, et al. **Ann Neurol** 1996 Sep;40(3):440–5 (29 ref.)

Membrane protein assembly: genetic, evolutionary and medical perspectives. Manoil C, et al. **Annu Rev Genet** 1995; 29:131–50 (86 ref.)

Transcriptional regulation of the betaine/gamma–aminobutyric acid transporter by hypertonicity. Kwon HM. **Biochem Soc Trans** 1996 Aug; 24(3):853–6 (27 ref.)

Regulation of cationic amino acid transporter (CAT) gene expression. MacLeod CL. **Biochem Soc Trans** 1996 Aug; 24(3):846–52 (46 ref.)

PDZ domains: targeting signalling molecules to sub–membranous sites. Ponting CP, et al. **Bioessays** 1997 Jun;19(6):469–79 (88 ref.)

Origin of metazoan adhesion molecules and adhesion receptors as deduced from cDNA analyses in the marine sponge Geodia cydonium: a review. M–uller WE. **Cell Tissue Res** 1997 Sep;289(3):383–95 (85 ref.)

Molecular biology of phospholipid transfer protein. Albers JJ, et al. **Curr Opin Lipidol** 1996 Apr;7(2):88–93 (26 ref.)

Interaction of ion channels and receptors with PDZ domain proteins. Kornau HC, et al. **Curr Opin Neurobiol** 1997 Jun; 7(3):368–73 (35 ref.)

Presenile because of presenilin: the presenilin genes and early onset Alzheimer's disease. Haass C. **Curr Opin Neurol** 1996 Aug;9(4):254–9 (39 ref.)

Phylogenetic analysis of membrane trafficking proteins: a family reunion and secondary structure predictions. Terrian DM, et al. **Eur J Cell Biol** 1997 Jul;73(3):198–204 (13 ref.)

Regulation of the uncoupling protein gene expression. Silva JE, et al. **Eur J Endocrinol** 1997 Mar;136(3):251–64 (102 ref.)

The tetraspanin superfamily: molecular facilitators. Maecker HT, et al. **FASEB J** 1997 May;11(6):428–42 (140 ref.)

Molecular genetics of Alzheimer's disease. Goate AM. **Geriatrics** 1997 Sep;52 Suppl 2:S9–12 (11 ref.)

Somatic mutation in paroxysmal nocturnal hemoglobinuria. Luzzatto L. **Hosp Pract (Off Ed)** 1997 Sep 15;32(9):125–31, 135–6, 139–40 (7 ref.)

The presenilin genes: a new gene family involved in Alzheimer disease pathology. Cruts M, et al. **Hum Mol Genet** 1996;5 Spec No:1449–55 (55 ref.)

The presenilins and Alzheimer's disease. Hutton M, et al. **Hum Mol Genet** 1997;6(10):1639–46 (70 ref.)

Exploring the etiology of Alzheimer disease using molecular genetics. Lendon CL, et al. **JAMA** 1997 Mar 12; 277(10):825–31 (130 ref.)

Heterologous expression of receptors and signaling proteins in adult mammalian sympathetic neurons by microinjection. Ikeda SR. **Methods Mol Biol** 1997;83:191–202 (15 ref.)

Unraveling the molecular pathway of Alzheimer's disease: research about presenilins gathers momentum. Sandbrink R, et al. **Mol Psychiatry** 1996 Dec;1(6):438–44 (54 ref.)

Presenilins: genes for life and death. Haass C. **Neuron** 1997 May;18(5):687–90 (26 ref.)

Presenilins and early–onset familial Alzheimer's disease. Rohan de Silva HA, et al. **Neuroreport** 1997 May 27; 8(8):i–xii (145 ref.)

Comparative aspects of Notch signaling in lower and higher eukaryotes. Blaumueller CM, et al. **Perspect Dev Neurobiol** 1997;4(4):325–43 (123 ref.)

Paroxysmal nocturnal hemoglobinuria: new insights from murine Pig–a–deficient hematopoiesis. Devetten MP, et al. **Proc Assoc Am Physicians** 1997 Mar;109(2):99–110 (68 ref.)

The Alzheimer family of diseases: many etiologies, one pathogenesis? [comment] Hardy J. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2095–7 (21 ref.) Comment on: Proc Natl Acad Sci U S A 1997 Mar 4;94(5):2025–30.

The mitochondrial uncoupling protein: structural and genetic studies. Ricquier D, et al. **Prog Nucleic Acid Res Mol Biol** 1997;56:83–108 (81 ref.)

CTX, a new lymphocyte receptor in Xenopus, and the early evolution of Ig domains. DuPasquier L, et al. **Res Immunol** 1996 May;147(4):218–26 (28 ref.)

Significance of the antimicrobial resistance gene, Nramp1, in resistance to virulent Mycobacterium tuberculosis infection. North RJ, et al. **Res Immunol** 1996 Oct–Dec; 147(8–9):493–9 (13 ref.)

Pathogenesis of Alzheimer's disease: current status on apolipoprotein E4 gene research. Das HK, et al. **Rev Neurosci** 1996 Oct–Dec;7(4):277–83 (25 ref.)

Alzheimer's disease: genotypes, phenotypes, and treatments. Selkoe DJ. **Science** 1997 Jan 31;275(5300):630–1 (17 ref.)

Functional cloning of genes involved in T–cell receptor–induced programmed cell death. D'Adamio L, et al. **Semin Immunol** 1997 Feb;9(1):17–23 (61 ref.)

Molecular basis of paroxysmal nocturnal hemoglobinuria. Parker CJ. **Stem Cells** 1996 Jul;14(4):396–411 (56 ref.)

Topogenesis of inner membrane proteins of mitochondria. Stuart RA, et al. **Trends Biochem Sci** 1996 Jul;21(7):261–7 (40 ref.)

Resistance to intracellular infections: comparative genomic analysis of Nramp. Cellier M, et al. **Trends Genet** 1996 Jun; 12(6):201–4 (20 ref.)

Presenilin mutations in Alzheimer's disease: molecular models suggest a potential functional locus [published erratum appears in Trends Pharmacol Sci 1996 Dec;17(12):465] Murgolo NJ, et al. **Trends Pharmacol Sci** 1996 Nov; 17(11):389–93 (22 ref.)

[Signalling by Notch family receptors] Schweisguth F, et al. **C R Seances Soc Biol Fil** 1997;191(1):55–75 (71 ref.) (Eng. Abstr.) **(Fre)**

[Presenilin–1 (S182) causative gene of early–onset familial Alzheimer's disease] Ikeda M. **Tanpakushitsu Kakusan Koso** 1996 Aug;41(10):1441–7 (28 ref.) **(Jpn)**

[A mammalian telomerase component gene TLP1] Ishikawa F, et al. **Tanpakushitsu Kakusan Koso** 1997 Jul; 42(9):1407–19 (21 ref.) **(Jpn)**

[STM–2, a candidate gene for the familiar Alzheimer's disease on chromosome 1] Oshima J, et al. **Tanpakushitsu Kakusan Koso** 1996 Aug;41(10):1448–52 (28 ref.) **(Jpn)**

IMMUNOLOGY

T–call development: is notch a key player in lineage decisions? von Boehmer H. **Curr Biol** 1997 May 1; 7(5):R308–10 (13 ref.)

TCR zeta chain in T cell development and selection. Shores EW, et al. **Curr Opin Immunol** 1997 Jun;9(3):380–9 (96 ref.)

Update on the thyroid sodium iodide symporter: a novel thyroid antigen emerging on the horizon. Spitzweg C, et al. **Eur J Endocrinol** 1997 Jul;137(1):22–3 (7 ref.)

Nuclear envelope protein autoantibodies in primary biliary cirrhosis. Courvalin JC, et al. **Semin Liver Dis** 1997 Feb; 17(1):79–90 (88 ref.)

METABOLISM

Cell surface dynamics of GPI-anchored proteins. Maxfield FR, et al. **Adv Exp Med Biol** 1997;419:355-64 (58 ref.)

Signal transduction via GPI-anchored membrane proteins. Robinson PJ. **Adv Exp Med Biol** 1997;419:365-70 (22 ref.)

Signal-mediated sorting of membrane proteins between the endoplasmic reticulum and the golgi apparatus. Teasdale RD, et al. **Ann Rev Cell Dev Biol** 1996;12:27-54 (115 ref.)

Single-particle tracking: applications to membrane dynamics. Saxton MJ, et al. **Annu Rev Biophys Biomol Struct** 1997; 26:373-99 (105 ref.)

Membrane protein assembly: genetic, evolutionary and medical perspectives. Manoil C, et al. **Annu Rev Genet** 1995; 29:131-50 (86 ref.)

The F0F1-type ATP synthases of bacteria: structure and function of the F0 complex. Deckers-Hebestreit G, et al. **Annu Rev Microbiol** 1996;50:791-824 (174 ref.)

Vesicular transport: implications for cell polarity. Burdick D, et al. **Biocell** 1996 Dec;20(3):343-53 (79 ref.)

Localization signals in proteins internalized from the cell surface. Banting G. **Biochem Soc Trans** 1996 May; 24(2):531-4 (29 ref.)

Transcriptional regulation of the betaine/gamma-aminobutyric acid transporter by hypertonicity. Kwon HM. **Biochem Soc Trans** 1996 Aug; 24(3):853-6 (27 ref.)

Transmembrane Ca2+ gradient and function of membrane proteins. Yang FY, et al. **Biosci Rep** 1995 Oct;15(5):351-64 (44 ref.)

The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Brown MS, et al. **Cell** 1997 May 2;89(3):331-40 (63 ref.)

Does COPI go both ways? Schekman R, et al. **Cell** 1997 Jul 25;90(2):197-200 (20 ref.)

Recognition of a transmembrane domain: another role for the ribosome? [comment] Siegel V. **Cell** 1997 Jul 11; 90(1):5-8 (19 ref.) Comment on: Cell 1997 Jul 11;90(1):31-41.

Cell surface expression of heat shock proteins and the immune response. Multhoff G, et al. **Cell Stress Chaperones** 1996 Sep;1(3):167-76 (90 ref.)

Engineered cell surfaces: fertile ground for molecular landscaping. Mahal LK, et al. **Chem Biol** 1997 Jun; 4(6):415-22 (59 ref.)

The effects of non-lamellar forming lipids on membrane protein-lipid interactions. Stubbs CD, et al. **Chem Phys Lipids** 1996 Jul 15;81(2):185-95 (71 ref.)

Obesity research continues to spring leaks. Harper ME. **Clin Invest Med** 1997 Aug;20(4):239-44 (32 ref.)

Targeting to the endoplasmic reticulum by dilysine motifs: role of coat proteins. Cosson P, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:113-7 (27 ref.)

Dissecting the molecular mechanisms of polarized membrane traffic: reconstitution of three transport steps in epithelial cells using streptolysin-O permeabilization. Lafont F, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:753-62 (44 ref.)

Protein insertion into the membrane of the endoplasmic reticulum: the architecture of the translocation site. Martoglio B, et al. **Cold Spring Harb Symp Quant Biol** 1995; 60:41-5 (35 ref.)

Molecular sorting of membrane proteins in polarized and nonpolarized cells. Mellman I. **Cold Spring Harb Symp Quant Biol** 1995;60:745-52 (53 ref.)

Coat proteins and selective protein packaging into transport vesicles. Schekman R, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:11-21 (59 ref.)

Cell signalling: MAGUK magic. Anderson JM. **Curr Biol** 1996 Apr 1;6(4):382-4 (13 ref.)

Go outside and see the proteasome. Protein degradation. Lord JM. **Curr Biol** 1996 Sep 1;6(9):1067-9 (13 ref.)

The Tom and Tim machine. Pfanner N, et al. **Curr Biol** 1997 Feb 1;7(2):R100-3 (23 ref.)

Receptor signaling: dimerization and beyond. Stock J. **Curr Biol** 1996 Jul 1;6(7):825-7 (18 ref.)

Focalized proteolysis: spatial and temporal regulation of extracellular matrix degradation at the cell surface. Basbaum CB, et al. **Curr Opin Cell Biol** 1996 Oct;8(5):731-8 (63 ref.)

Molecular biology of iron and zinc uptake in eukaryotes. Eide D. **Curr Opin Cell Biol** 1997 Aug;9(4):573-7 (28 ref.)

Neurofibromatosis 2: loss of merlin's protective spell. Gusella JF, et al. **Curr Opin Genet Dev** 1996 Feb;6(1):87-92 (65 ref.)

Notch in vertebrates. Robey E. **Curr Opin Genet Dev** 1997 Aug;7(4):551-7 (71 ref.)

Notch signalling in development: on equivalence groups and asymmetric developmental potential. Simpson P. **Curr Opin Genet Dev** 1997 Aug;7(4):537-42 (47 ref.)

Collagenous macrophage scavenger receptors. Kodama T, et al. **Curr Opin Lipidol** 1996 Oct;7(5):287-91 (37 ref.)

Neurotransmitter release - four years of SNARE complexes. Hanson PI, et al. **Curr Opin Neurobiol** 1997 Jun;7(3):310-5 (56 ref.)

The major surface proteins of Toxoplasma gondii: structures and functions. Tomavo S. **Curr Top Microbiol Immunol** 1996;219:45-54 (38 ref.)

Interaction of GPI-anchored cell surface proteins and complement receptor type 3. Stockinger H. **Exp Clin Immunogenet** 1997;14(1):5-10 (23 ref.)

Bile acid transport across the hepatocyte canalicular membrane. Suchy FJ, et al. **FASEB J** 1997 Mar; 11(4):199-205 (41 ref.)

The E. coli SRP: preferences of a targeting factor. De Gier JW, et al. **FEBS Lett** 1997 May 12;408(1):1-4 (33 ref.)

Rho effectors and reorganization of actin cytoskeleton. Narumiya S, et al. **FEBS Lett** 1997 Jun 23;410(1):68-72 (41 ref.)

Biogenesis of COPI-coated transport vesicles. Nickel W, et al. **FEBS Lett** 1997 Aug 25;413(3):395-400 (77 ref.)

Adenosine transporters. Thorn JA, et al. **Gen Pharmacol** 1996 Jun;27(4):613-20 (75 ref.)

The major pathways of protein translocation across membranes. Ito K. **Genes Cells** 1996 Apr;1(4):337-46 (64 ref.)

Transporters of nucleotide sugars, nucleotide sulfate and ATP in the Golgi apparatus membrane: where next? Hirschberg CB. **Glycobiology** 1997 Mar;7(2):169-71 (40 ref.)

Epididymal sperm maturation proteins. Hegde UC. **Indian J Biochem Biophys** 1996 Apr;33(2):103-10 (93 ref.)

Multidrug efflux pumps of gram-negative bacteria. Nikaido H. **J Bacteriol** 1996 Oct;178(20):5853-9 (57 ref.)

Membrane-type matrix metalloproteinases (MT-MMPs) in tumor metastasis. Sato H, et al. **J Biochem (Tokyo)** 1996 Feb;119(2):209-15 (36 ref.)

Coupling chemical energy by the hsp70/tim44 complex to drive protein translocation into mitochondria. Cyr DM. **J Bioenerg Biomembr** 1997 Feb;29(1):29-34 (32 ref.)

Mitochondrial channels revisited. Mannella CA. **J Bioenerg Biomembr** 1996 Apr;28(2):89-91 (42 ref.)

Is there VDAC in cell compartments other than the mitochondria? Yu WH, et al. **J Bioenerg Biomembr** 1996 Apr;28(2):93-100 (49 ref.)

Protein translocation at the envelope and thylakoid membranes of chloroplasts. Kouranov A, et al. **J Biol Chem** 1996 Dec 6;271(49):31009-12 (53 ref.)

Membrane-protein traffic in pathogen-infected cells. Joiner KA. **J Clin Invest** 1997 Apr 15;99(8):1814-7 (5 ref.)

Epidermal structural proteins in skin disorders. Manabe M, et al. **J Dermatol Sci** 1997 Sep;15(3):143-65 (167 ref.)

Bidirectional feedback regulation on 17 kD tumor necrosis factor (TNF) production by 26 kD membrane-bound TNF precursor. Soma IG, et al. **J Inflamm** 1995-96;47(1-2):52-60 (9 ref.)

Protein translocation across the membrane of the endoplasmic reticulum. Wilkinson BM, et al. **J Membr Biol** 1997 Feb 1;155(3):189-97 (109 ref.)

Membrane protein damage and methylation reactions in chronic renal failure [editorial] Perna AF, et al. **Kidney Int** 1996 Aug;50(2):358-66 (94 ref.)

Notch signaling in vertebrate development and disease. Gridley T. **Mol Cell Neurosci** 1997;9(2):103-8 (43 ref.)

Cell-to-cell transfer of glycosylphosphatidylinositol-anchored membrane proteins during sperm maturation. Kirchhoff C, et al. **Mol Hum Reprod** 1996 Mar;2(3):177-84 (77 ref.)

Regulation of targeting signals in membrane proteins. [review] Stanley KK. **Mol Membr Biol** 1996 Jan-Mar; 13(1):19-27 (108 ref.)

Control of bacterial chemotaxis. Eisenbach M. **Mol Microbiol** 1996 Jun;20(5):903-10 (56 ref.)

Getting greasy: how transmembrane polypeptide segments integrate into the lipid bilayer. von Heijne G. **Mol Microbiol** 1997 Apr;24(2):249-53 (30 ref.)

Display of heterologous proteins on the surface of microorganisms: from the screening of combinatorial libraries to live recombinant vaccines. Georgiou G, et al. **Nat Biotechnol** 1997 Jan;15(1):29-34 (90 ref.)

Obesity research springs a proton leak [news; comment] Flier JS, et al. **Nat Genet** 1997 Mar;15(3):223-4 (17 ref.) Comment on: Nat Genet 1997 Mar;15(3):269-72.

Trafficking of lysosomal membrane proteins in polarized kidney cells. Hunziker W, et al. **Nephrologie** 1996; 17(7):347-50 (22 ref.)

Presenilins and early-onset familial Alzheimer's disease. Rohan de Silva HA, et al. **Neuroreport** 1997 May 27; 8(8):i-xii (145 ref.)

The structure and biogenesis of plant oil bodies: the role of the ER membrane and the oleosin class of proteins. Napier JA, et al. **Plant Mol Biol** 1996 Aug;31(5):945-56 (68 ref.)

Oleosins and oil bodies in seeds and other organs. Huang AH. **Plant Physiol** 1996 Apr;110(4):1055-61 (27 ref.)

Patch-clamping and other molecular approaches for the study of plasma membrane transporters demystified. Ward JM. **Plant Physiol** 1997 Aug;114(4):1151-9 (43 ref.)

Cell surface adenosine deaminase: much more than an ectoenzyme. Franco R, et al. **Prog Neurobiol** 1997 Jul; 52(4):283-94 (104 ref.)

The mitochondrial uncoupling protein: structural and genetic studies. Ricquier D, et al. **Prog Nucleic Acid Res Mol Biol** 1997;56:83-108 (81 ref.)

The chemistry and enzymology of the type I signal peptidases. Dalbey RE, et al. **Protein Sci** 1997 Jun; 6(6):1129-38 (100 ref.)

Analysis of the interactions between Nef and cellular proteins. Coates K, et al. **Res Virol** 1997 Jan-Feb; 148(1):68-70 (14 ref.)

Coreceptors: implications for HIV pathogenesis and therapy. Moore JP. **Science** 1997 Apr 4;276(5309):51-2 (19 ref.)

Signaling across membranes: a one and a two and a... [comment] Stock J. **Science** 1996 Oct 18;274(5286):370-1 (10 ref.) Comment on: Science 1996 Oct 18;274(5286):423-5. Comment on: Science 1996 Oct 18;274(5286):425-6.

A membrane skeleton that clusters nicotinic acetylcholine receptors in muscle. Bloch RJ, et al. **Soc Gen Physiol Ser** 1997;52:177-95 (68 ref.)

Syntrophins: modular adapter proteins at the neuromuscular junction and the sarcolemma. Froehner SC, et al. **Soc Gen Physiol Ser** 1997;52:197-207 (49 ref.)

Molecular architecture of tight junctions: occludin and ZO-1. Tsukita S, et al. **Soc Gen Physiol Ser** 1997;52:69-76 (27 ref.)

Origin of lysosomal proteins. Braulke T. **Subcell Biochem** 1996;27:15-49 (193 ref.)

Amyloid, the presenilins and Alzheimer's disease. Hardy J. **Trends Neurosci** 1997 Apr;20(4):154-9 (53 ref.)

[Analysis of membrane protein movement by single particle tracking and laser-beam gradient force optical trap] Tomishige M, et al. **Nippon Seirigaku Zasshi** 1997; 59(1):11-21 (25 ref.) **(Jpn)**

[Characterization of topogenic sequences which regulate the integration and membrane topology of proteins in the endoplasmic reticulum membrane] Sakaguchi M. **Seikagaku** 1997 Jan;69(1):1-15 (90 ref.) **(Jpn)**

[Dynamic structure change of protein secretion machinery] Nishiyama K, et al. **Tanpakushitsu Kakusan Koso** 1997 Jan; 42(1):1-11 (80 ref.) **(Jpn)**

[ERM (ezrin/radixin/moesin) as crosslinkers between actin filaments and plasma membranes] Tsukita S. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1899-905 (44 ref.) **(Jpn)**

[Membrane proteins as regulators of the complement system] Galebskaia LV. **Ukr Biokhim Zh** 1996 May-Jun;68(3):26-35 (62 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Policing the membrane: cell surface proteins which regulate complement. Davies A. **Res Immunol** 1996 Feb;147(2):82-7 (66 ref.)

PHYSIOLOGY

The spectrin-based membrane skeleton as a membrane protein-sorting machine. Beck KA, et al. **Am J Physiol** 1996 May;270(5 Pt 1):C1263-70 (67 ref.)

Transport vesicle docking: SNAREs and associates. Pfeffer SR. **Ann Rev Cell Dev Biol** 1996;12:441-61 (87 ref.)

The adaptor complexes: a bridge between the transmembrane proteins and clathrin lattices. Sosa MA. **Biocell** 1996 Dec; 20(3):301-5 (15 ref.)

SNAPs and SNAREs in exocytosis in chromaffin cells. Burgoyne RD, et al. **Biochem Soc Trans** 1996 Aug; 24(3):653-7 (47 ref.)

SNAP-25, enSNAREd in neurotransmission and regulation of behaviour. Wilson MC, et al. **Biochem Soc Trans** 1996 Aug;24(3):670-76 (49 ref.)

Formation of secretory vesicles in the biosynthetic pathway. Urbé S, et al. **Biochim Biophys Acta** 1997 Aug 21; 1358(1):6-22 (143 ref.)

The roles of NSF, SNAPs and SNAREs during membrane fusion. Woodman PG. **Biochim Biophys Acta** 1997 Jun 27; 1357(2):155-72 (173 ref.)

Obesity genes and the regulation of body fat content. Weigle DS, et al. **Bioessays** 1996 Nov;18(11):867-74 (79 ref.)

Membrane assembly studied by spin-label electron spin resonance. Marsh D. **Braz J Med Biol Res** 1996 Jul; 29(7):863-71 (47 ref.)

Metalloprotease-disintegrins: links to cell adhesion and cleavage of TNF alpha and Notch. Blobel CP. **Cell** 1997 Aug 22;90(4):589-92 (17 ref.)

Molecular dissection of tight junctions. Tsukita S, et al. **Cell Struct Funct** 1996 Oct;21(5):381-5 (35 ref.)

Cell migration: don't tread on me. Doren MV, et al. **Curr Biol** 1997 Mar 1;7(3):R148-50 (13 ref.)

Cholesterol homeostasis: clipping out a slippery regulator [published erratum appears in Curr Biol 1997 Apr 1;7(4):285] Osborne TF. **Curr Biol** 1997 Mar 1;7(3):R172-4 (11 ref.)

Coatomer (COPI)-coated vesicles: role in intracellular transport and protein sorting. Cosson P, et al. **Curr Opin Cell Biol** 1997 Aug;9(4):484-7 (29 ref.)

SNAREs and NSF in targeted membrane fusion. Hay JC, et al. **Curr Opin Cell Biol** 1997 Aug;9(4):505-12 (70 ref.)

The role of lipid signaling in constitutive membrane traffic. Roth MG, et al. **Curr Opin Cell Biol** 1997 Aug;9(4):519-26 (64 ref.)

ERM (ezrin/radixin/moesin) family: from cytoskeleton to signal transduction. Tsukita S, et al. **Curr Opin Cell Biol** 1997 Feb;9(1):70-5 (42 ref.)

Rho GTPases and leukocyte cytoskeletal regulation. Dharmawardhane S, et al. **Curr Opin Hematol** 1997 Jan; 4(1):12-8 (83 ref.)

The Eph family in retinal axon guidance. Drescher U, et al. **Curr Opin Neurobiol** 1997 Feb;7(1):75-80 (54 ref.)

The Notch pathway: democracy and aristocracy in the selection of cell fate. Kopan R, et al. **Curr Opin Neurobiol** 1996 Oct;6(5):594-601 (61 ref.)

ADAMs in fertilization and development. Wolfsberg TG, et al. **Dev Biol** 1996 Dec 15;180(2):389-401 (63 ref.)

The steroidogenic acute regulatory (StAR) protein two years later. An update. Stocco DM. **Endocrine** 1997 Apr; 6(2):99-109 (146 ref.)

Membrane proteins which exhibit multiple topological orientations. Levy D. **Essays Biochem** 1996;31:49-60 (21

ref.)
Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. Turner AJ, et al. **FASEB J** 1997 Apr; 11(5):355–64 (56 ref.)
Insights into T cell development and signal transduction provided by TCR-zeta chain deficient mice. Shores EW, et al. **Int Rev Immunol** 1996;13(4):301–15 (97 ref.)
VDAC, a channel in the outer mitochondrial membrane. Colombini M, et al. **Ion Channels** 1996;4:169–202 (75 ref.)
Volume-sensitive transport systems and volume homeostasis in vertebrate red blood cells. Cossins AR, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):343–52 (97 ref.)
EmrE, the smallest ion-coupled transporter, provides a unique paradigm for structure-function studies. Schuldiner S, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):335–41 (36 ref.)
Function of metal-ion homeostasis in the cell division cycle, mitochondrial protein processing, sensitivity to mycobacterial infection and brain function. Supek F, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):321–30 (73 ref.)
The molecular mechanisms of actin-based intracellular motility by Listeria monocytogenes. Chakraborty T. **Microbiologia** 1996 Jun;12(2):237–44 (34 ref.)
The role of Notch in lateral inhibition and cell fate specification [corrected and republished with original paging, article originally printed in Mol Cell Neurosci 1995 Aug;6(4):311–21] Chitnis AB. **Mol Cell Neurosci** 1995 Dec; 6(6):311–21 (73 ref.)
The ins and outs of notch signaling. Weinmaster G. **Mol Cell Neurosci** 1997;9(2):91–102 (118 ref.)
GABA transporter heterogeneity: pharmacology and cellular localization. Borden LA. **Neurochem Int** 1996 Oct; 29(4):335–56 (110 ref.)
Sorting of GABA transporter proteins in polarized cells. Caplan MJ. **Neurochem Int** 1996 Oct;29(4):357–60 (19 ref.)
Numb diverts notch pathway off the tramtrack. Campos-Ortega JA. **Neuron** 1996 Jul;17(1):1–4 (18 ref.)
Control of daughter cell fates during asymmetric division: interaction of Numb and Notch. Guo M, et al. **Neuron** 1996 Jul;17(1):27–41 (84 ref.)
Role of suppressor of hairless in the delta-activated Notch signaling pathway. Lecourtois M, et al. **Perspect Dev Neurobiol** 1997;4(4):305–11 (50 ref.)
Notch signaling in development. Simpson P. **Perspect Dev Neurobiol** 1997;4(4):297–304 (67 ref.)
Diverse roles for the Notch receptor in the development of D. melanogaster. Young MW, et al. **Perspect Dev Neurobiol** 1997;4(4):345–55 (77 ref.)
Rho small G protein and cytoskeletal control. Takai Y, et al. **Princess Takamatsu Symp** 1994;24:338–50 (64 ref.)
Possible involvement of adherens junction plaque proteins in tumorigenesis and metastasis. Tsukita S, et al. **Princess Takamatsu Symp** 1994;24:38–50 (69 ref.)
Tumor suppressor genes and signal transduction in Drosophila. Woods DF, et al. **Princess Takamatsu Symp** 1994;24:1–13 (69 ref.)
Eubacterial signal transduction by ligands of the mammalian peripheral benzodiazepine receptor complex [see comments] Donohue TJ. **Proc Natl Acad Sci U S A** 1997 May 13;94(10):4821–2 (18 ref.) Comment in: Proc Natl Acad Sci U S A 1997 May 13;94(10):5101–6.
SNAREs and regulated vesicle exocytosis [comment] Goda Y. **Proc Natl Acad Sci U S A** 1997 Feb 4;94(3):769–72 (23 ref.) Comment on: Proc Natl Acad Sci U S A 1997 Feb 4;94(3):997–1001.
Molecular properties and cellular distribution of cholinergic synaptic proteins. Zimmermann H, et al. **Prog Brain Res** 1996;109:31–40 (53 ref.)
Protection of host from its own complement by membrane-bound complement inhibitors: C3 convertase inhibitors vs membrane attack complex inhibitors. Kinoshita T. **Res Immunol** 1996 Feb;147(2):100–3 (32 ref.)
Functional studies of the membrane skeleton in Drosophila: identification of a positional cue that targets polarized membrane skeleton assembly. Dubreuil RR, et al. **Soc Gen Physiol Ser** 1997;52:91–106 (62 ref.)
Functional studies of the protein 4.1 family of junctional proteins in Drosophila. Fehon RG, et al. **Soc Gen Physiol Ser** 1997;52:149–59 (38 ref.)
Structure and function of the yeast outer mitochondrial membrane channel, VDAC. Forte M, et al. **Soc Gen Physiol Ser** 1996;51:145–54 (19 ref.)
Roles of the membrane cytoskeleton in protein sorting. Nelson WJ, et al. **Soc Gen Physiol Ser** 1997;52:47–54 (53 ref.)
Regulatory roles of the ligand for Flk2/Flt3 tyrosine kinase receptor on human hematopoiesis. Namikawa R, et al. **Stem Cells** 1996 Jul;14(4):388–95 (69 ref.)
How the Listeria monocytogenes ActA protein converts actin polymerization into a motile force. Smith GA, et al. **Trends Microbiol** 1997 Jul;5(7):272–6 (42 ref.)
[Role of the Notch receptors in intercellular communication] Seugnet L, et al. **Pathol Biol (Paris)** 1996 Apr;44(4):282–6 (43 ref.) (Eng. Abstr.) **(Fre)**
[Neurofibromatosis type 2 (NF2)] Araki N, et al. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1427–31 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Integral proteins of red cell membranes: their genetic and phenotypic expressions] Yawata Y. **Nippon Rinsho** 1996 Sep;54(9):2348–63 (72 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

Electron and atomic force microscopy of membrane proteins. Heymann JB, et al. **Curr Opin Struct Biol** 1997 Aug; 7(4):543–9 (66 ref.)
SDS-digested freeze-fracture replica labeling electron microscopy to study the two-dimensional distribution of integral membrane proteins and phospholipids in biomembranes: practical procedure, interpretation and application. Fujimoto K. **Histochem Cell Biol** 1997 Feb; 107(2):87–96 (30 ref.)
Structural changes in native membrane proteins monitored at subnanometer resolution with the atomic force microscope: a review. Müller DJ, et al. **J Struct Biol** 1997 Jul;119(2):149–57 (56 ref.)

MEMBRANE PROTEINS, VIRAL see **VIRAL MATRIX PROTEINS**

MEMBRANES

see related
CELL MEMBRANE
CELL WALL
INTRACELLULAR MEMBRANES
MEMBRANE LIPIDS
MEMBRANE PROTEINS
NUCLEAR MEMBRANE
SYNOVIAL MEMBRANE

Lateral pressure in membranes. Marsh D. **Biochim Biophys Acta** 1996 Oct 29;1286(3):183–223 (139 ref.)

METABOLISM

Network thermodynamics: analysis and synthesis of membrane transport system. Imai Y. **Jpn J Physiol** 1996 Jun;46(3):187–99 (19 ref.)

MEMBRANES, ARTIFICIAL

Lateral forces acting between particles in liquid films or lipid membranes. Kralchevsky PA. **Adv Biophys** 1997;34:25–39 (74 ref.)
The role of platelet-activating factor in the biocompatibility of hemodialysis membranes. Tetta C, et al. **Adv Exp Med Biol** 1996;416:243–8 (40 ref.)
Acute renal failure: role of dialysis membrane biocompatibility. Pascual M, et al. **Annu Rev Med** 1997; 48:467–76 (39 ref.)
Dilemma of membrane biocompatibility and reuse. Klinkmann H, et al. **Artif Organs** 1996 May;20(5):426–32 (57 ref.)
Characterization of molecular transport in artificial kidneys. Leypoldt JK, et al. **Artif Organs** 1996 May;20(5):381–9 (37 ref.)
Low-density lipoprotein removal methods by membranes and future perspectives. Matsuda Y, et al. **Artif Organs** 1996 Apr;20(4):346–54 (37 ref.)
Inconsequence of membrane choice in acute renal failure? Mujais SK, et al. **Artif Organs** 1996 May;20(5):454–5 (10 ref.)
Membranes in artificial organs. Schmidt B. **Artif Organs** 1996 May;20(5):375–80 (16 ref.)
Dialyzers and dialysis membranes. Research directions [editorial] Leypoldt JK. **ASAIO J** 1996 May-Jun; 42(3):133–5 (24 ref.)
Barrier membrane techniques in endodontic microsurgery. Pecora G, et al. **Dent Clin North Am** 1997 Jul;41(3):585–602 (32 ref.)
Preclinical evaluation of Seprafilm bioresorbable membrane. Burns JW, et al. **Eur J Surg Suppl** 1997;(577):40–8 (21 ref.)
A review of material properties of biodegradable and bioresorbable polymers and devices for GTR and GBR applications. Hutmacher D, et al. **Int J Oral Maxillofac Implants** 1996 Sep-Oct;11(5):667–78 (73 ref.)
Relationship between immobilised artificial membrane chromatographic retention and the brain penetration of structurally diverse drugs. Salminen T, et al. **J Pharm Biomed Anal** 1997 Jan;15(4):469–77 (64 ref.)
Is adsorption an important characteristic of dialysis membranes? Pascual M, et al. **Kidney Int** 1996 Feb; 49(2):309–13 (60 ref.)
Dialysis membranes in the year 2000: performance and biocompatibility. Akizawa T, et al. **Nephrol Dial Transplant** 1996;11 Suppl 8:16–9 (20 ref.)
Dialysis fluid and water: their roles in biocompatibility. Berland Y, et al. **Nephrol Dial Transplant** 1995;10 Suppl 10:45–7 (32 ref.)
Clinical impact of biocompatible dialysis membranes on patient morbidity and mortality: an appraisal of the evidence. Churchill DN. **Nephrol Dial Transplant** 1995;10 Suppl 10:52–6 (22 ref.)
Protein catabolism in maintenance haemodialysis: the influence of the dialysis membrane. Gutierrez A. **Nephrol Dial Transplant** 1996;11 Suppl 2:108–11 (40 ref.)
Recent advances in the biocompatibility of haemodialysis membranes. Hakim RM. **Nephrol Dial Transplant** 1995;10 Suppl 10:7–11 (50 ref.)
The 'first-use syndrome' revisited: a dialysis centre's perspective. Ing TS, et al. **Nephrol Dial Transplant** 1995; 10 Suppl 10:39–44 (66 ref.)
Membrane biocompatibility in the treatment of acute renal failure: what is the evidence in 1996? Jacobs C. **Nephrol Dial Transplant** 1997 Jan;12(1):38–42 (32 ref.)
Influence of membranes on morbidity. Locatelli F. **Nephrol Dial Transplant** 1996;11 Suppl 2:116–20 (16 ref.)
Acute haemodialysis membrane-associated reactions. Tielemans C, et al. **Nephrol Dial Transplant** 1996;11 Suppl 2:112–5 (32 ref.)
Effects of haemodialysis on coagulation and platelets: are we measuring membrane biocompatibility? Ward RA. **Nephrol Dial Transplant** 1995;10 Suppl 10:12–17 (46 ref.)
Different types of dialyzer membranes: does the bio(in)compatibility matter in the treatment of ARF? Vanholder R, et al. **Ren Fail** 1996 May;18(3):471–9 (42 ref.)
Computer simulation studies of biological membranes: progress, promise and pitfalls. Jakobsson E. **Trends Biochem Sci** 1997 Sep;22(9):339–44 (40 ref.)
[Artificial models of transport proteins in membrane] Kobuke Y. **Nippon Rinsho** 1996 Mar;54(3):737–43 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Protein immobilization in lipid bilayer membrane films on electrodes and their electron transfer reactions] Tominaga M, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep; 41(11):1600–6 (8 ref.) **(Jpn)**

MEMBRANES, INTRACELLULAR see **INTRACELLULAR MEMBRANES**

MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS see **GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE**

MEMBRANOUS GLOMERULOPATHY see **GLOMERULONEPHRITIS, MEMBRANOUS**

MEMORY

Issues in cognitive psychology: implications for professional education. Regehr G, et al. **Acad Med** 1996 Sep; 71(9):988–1001 (72 ref.)
Fetal memory: does it exit? What does it do? Hepper PG. **Acta Paediatr Suppl** 1996 Oct;416:16–20 (59 ref.)
The social construction of the remembered self: family recounting. Hirst W, et al. **Ann N Y Acad Sci** 1997 Jun 18;818:163–88 (43 ref.)
Implicit and explicit memory for trauma-related information in PTSD. McNally RJ. **Ann N Y Acad Sci** 1997 Jun 21; 821:219–24 (23 ref.)
Trauma, dissociation, and memory. Spiegel D. **Ann N Y Acad Sci** 1997 Jun 21;821:225–37 (86 ref.)
The psychobiology of traumatic memory. Clinical implications of neuroimaging studies. Van Der Kolk BA, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:99–113 (58 ref.)
Performance of PTSD patients on standard tests of memory. Implications for trauma. Wolfe J, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:208–18 (52 ref.)
Beyond "true" and "false" memories: remembering and recovery in the survival of childhood sexual abuse. Hall JM, et al. **ANS Adv Nurs Sci** 1997 Jun;19(4):37–54 (109 ref.)
Memory in the cortex of the primate. Fuster JM. **Biol Res** 1995;28(1):59–72 (15 ref.)
Information processing and symmetry-breaking in memory evolutive systems. Ehresmann AC, et al. **Biosystems** 1997; 43(1):25–40 (19 ref.)
The bailiwick of visuo-spatial working memory: evidence from unilateral spatial neglect. Ellis AX, et al. **Brain Res Cogn Brain Res** 1996 Mar;3(2):71–8 (39 ref.)
Memory distortion and false memory creation. Loftus EF. **Bull Am Acad Psychiatry Law** 1996;24(3):281–95 (45 ref.)
Can cognitive neuroscience illuminate the nature of traumatic childhood memories? Schacter DL, et al. **Curr Opin Neurobiol** 1996 Apr;6(2):207–14 (111 ref.)
Functional screening and complex traits: human 21q22.2 sequences affecting learning in mice. Smith DJ, et al. **Hum Mol Genet** 1997;6(10):1729–33 (38 ref.)
On the characteristics of the quadratic order associative memory that uses synchronous update and direct convergence. Wang JH. **Int J Neural Syst** 1996 Mar; 7(1):69–81 (20 ref.)
Cognitive and neurobiologic markers of early Alzheimer disease. Albert MS. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13547–51 (62 ref.)
The fractionation of working memory. Baddeley A. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13468–72 (50 ref.)
Illusory memories: a cognitive neuroscience analysis. Schacter DL. **Proc Natl Acad Sci U S A** 1996 Nov 26; 93(24):13527–33 (85 ref.)
[Gene expression controlled by neural activity] Tsuda M, et al. **Tanpakushitsu Kakusan Koso** 1997 Mar;42(4):632–42 (68 ref.) **(Jpn)**
[An extensive system of explicit memory] Reinoso Suárez F. **An R Acad Nac Med (Madr)** 1996;113(3):565–77 (61 ref.) **(Spa)**
[Complex memory function for mental trauma. Memory and forgetting ae necessary for the emotional adaptation process] Christianson SA, et al. **Lakartidningen** 1997 Apr 30;94(18):1721–4 (20 ref.) **(Swe)**

DRUG EFFECTS

Drugs for amnesia in the ICU. Wagner BK, et al. **Am J Crit Care** 1997 May;6(3):192–201; quiz 202–3 (145 ref.)

Patients' memories of events during general anaesthesia. Bailey AR, et al. **Anaesthesia** 1997 May;52(5):460–76 (102 ref.)
Glucocorticoid medication, memory and steroid psychosis in medical illness. Wolkowitz OM, et al. **Ann N Y Acad Sci** 1997 Aug 14;823:81–96 (99 ref.)
Neuropeptides in learning and memory processes. de Wied D. **Behav Brain Res** 1997 Feb;83(1–2):83–90 (76 ref.)
Interaction of neuromodulatory systems in modulating memory storage. McGaugh JL, et al. **Behav Brain Res** 1997 Feb;83(1–2):31–8 (79 ref.)
Studies on traditional Chinese drugs. Zhang J. **Chin Med J (Engl)** 1996 Jan;109(1):54–8 (0 ref.)
Investigations of hypesthesia: using anesthetics to explore relationships between consciousness, learning, and memory. Andrade J. **Conscious Cogn** 1996 Dec;5(4):562–80 (42 ref.)
Nootropics: preclinical results in the light of clinical effects; comparison with tacrine. Mondadori C. **Crit Rev Neurobiol** 1996;10(3–4):357–70 (85 ref.)
Behavioural evaluation of cholinergic drugs. Iversen SD. **Life Sci** 1997;60(13–14):1145–52 (17 ref.)
The role of the hypothalamic–pituitary–adrenocortical axis in memory-related effects of anxiolytics. Korneyev AY. **Neurobiol Learn Mem** 1997 Jan;67(1):1–13 (162 ref.)
Increased regional cerebral glucose metabolism and semantic memory performance in Alzheimer's disease: a pilot double blind transdermal nicotine positron emission tomography study. Parks RW, et al. **Neuropsychol Rev** 1996 Jun; 6(2):61–79 (79 ref.)
The need for cellular, biochemical, and mechanistic studies. Hanneman WH, et al. **Neurotoxicol Teratol** 1996 May–Jun; 18(3):247–50; discussion 271–6 (34 ref.)
Modulation of memory storage processes by peripherally acting pharmacological agents. Jensen RA. **Proc West Pharmacol Soc** 1996;39:85–9 (19 ref.)

PHYSIOLOGY

Mapping human memory--a brief review. Frackowiak RS, et al. **Acta Neurol Belg** 1996 Sep;96(3):189–92 (24 ref.)
Functional uncertainty, aging and memory processes during sleep. Salzarulo P, et al. **Acta Neurol Belg** 1997 Jun; 97(2):118–22 (31 ref.)
Utilizing compensatory task conditions for episodic memory in Alzheimer's disease. Bäckman L. **Acta Neurol Scand Suppl** 1996;165:109–13 (40 ref.)
Metabotropic glutamate receptors in hippocampal long-term potentiation and learning and memory. Riedel G, et al. **Acta Physiol Scand** 1996 May;157(1):1–19 (125 ref.)
Some functions of primary auditory cortex in learning and memory formation. Scheich H, et al. **Adv Neurol** 1997; 73:179–93 (33 ref.)
Memory, abuse, and science. Questioning claims about the false memory syndrome epidemic. Pope KS. **Am Psychol** 1996 Sep;51(9):957–74 (140 ref.)
Learning and memory during general anesthesia: an update. Ghoneim MM, et al. **Anesthesiology** 1997 Aug; 87(2):387–410 (152 ref.)
The neurobiology of emotionally influenced memory. Implications for understanding traumatic memory. Cahill L. **Ann N Y Acad Sci** 1997 Jun 21;821:238–46 (41 ref.)
Stress-activated hormonal systems and the regulation of memory storage. Roozendaal B, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:247–58 (81 ref.)
Molecular genetic analysis of synaptic plasticity, activity-dependent neural development, learning, and memory in the mammalian brain. Chen C, et al. **Annu Rev Neurosci** 1997;20:157–84 (149 ref.)
Learning and memory in honeybees: from behavior to neural substrates. Menzel R, et al. **Annu Rev Neurosci** 1996; 19:379–404 (204 ref.)
Declarative memory: insights from cognitive neurobiology. Eichenbaum H. **Annu Rev Psychol** 1997;48:547–72 (120 ref.)
Psychobiological models of hippocampal function in learning and memory. Gluck MA, et al. **Annu Rev Psychol** 1997; 48:481–514 (110 ref.)
Neurobiological principles of learning and memory. Brunelli M, et al. **Arch Ital Biol** 1997 Jan;135(1):15–36 (69 ref.)
Psychopharmacology of memory modulation: evidence for multiple interaction among neurotransmitters and hormones. Castellano C, et al. **Behav Brain Res** 1996 May; 77(1–2):1–21 (175 ref.)
Neuropeptides in learning and memory processes. de Wied D. **Behav Brain Res** 1997 Feb;83(1–2):83–90 (76 ref.)
Selecting a model system for neurobiological studies of learning and memory. Eisenstein EM. **Behav Brain Res** 1997 Jan;82(2):121–32 (56 ref.)
The tuberomammillary nucleus projections in the control of learning, memory and reinforcement processes: evidence for an inhibitory role. Huston JP, et al. **Behav Brain Res** 1997 Feb;83(1–2):97–105 (58 ref.)
Sleep states, memory processes and synaptic plasticity. Smith C. **Behav Brain Res** 1996 Jun;78(1):49–56 (71 ref.)
Information processing and intracellular 'neural' (protein) networks: considerations regarding the diffusion-based hypothesis of Bray. Agutter PS, et al. **Biol Cell** 1997 Mar; 89(1):13–8 (25 ref.)
The case for a relationship between human memory, hippocampus and corpus callosum. Zaidel DW. **Biol Res** 1995;28(1):51–7 (35 ref.)
The neuronal role of angiotensin II in thirst, sodium appetite, cognition and memory. Mosimann R, et al. **Biol Rev Camb Philos Soc** 1996 Nov;71(4):545–59 (117 ref.)
Paradoxical functional facilitation in brain-behaviour research. A critical review [see comments] Kapur N. **Brain** 1996 Oct;119 (Pt 5):1775–90 (156 ref.) Comment in: Brain 1997 Jul;120 (Pt 7):1261–4.
Acetylcholine: a neurotransmitter for learning and memory? Blokland A. **Brain Res Brain Res Rev** 1995 Nov; 21(3):285–300 (135 ref.)
Possible confounding influence of strain, age and gender on cognitive performance in rats. Andrews JS. **Brain Res Cogn Brain Res** 1996 Jun;3(3–4):251–67 (193 ref.)
Impulsivity as a confounding factor in certain animal tests of cognitive function. Bizot JC, et al. **Brain Res Cogn Brain Res** 1996 Jun;3(3–4):243–50 (124 ref.)
Maze procedures: the radial-arm and water maze compared. Hodges H. **Brain Res Cogn Brain Res** 1996 Jun; 3(3–4):167–81 (62 ref.)
Functional imagining of human visual recognition. Kanwisher N, et al. **Brain Res Cogn Brain Res** 1996 Dec; 5(1–2):55–67 (39 ref.)
The acquisition of perceptual and motor skills: a memory system in the adult human cortex. Karni A. **Brain Res Cogn Brain Res** 1996 Dec;5(1–2):39–48 (50 ref.)
Neuropharmacology of timing and time perception. Meck WH. **Brain Res Cogn Brain Res** 1996 Jun;3(3–4):227–42 (130 ref.)
Further developments in the measurement of working memory in rodents. Pontecorvo MJ, et al. **Brain Res Cogn Brain Res** 1996 Jun;3(3–4):205–13 (69 ref.)
Comparison of cognitive function in human and non-human primates. Roberts AC. **Brain Res Cogn Brain Res** 1996 Jun; 3(3–4):319–27 (45 ref.)
Measurement of cognitive function: relating rodent performance with human minds. Steckler T, et al. **Brain Res Cogn Brain Res** 1996 Jun;3(3–4):299–308 (90 ref.)
Memory procedures, performance and processes in pigeons. White KG, et al. **Brain Res Cogn Brain Res** 1996 Jun; 3(3–4):309–17 (45 ref.)
Spatial learning and memory: the beginning of a dream [comment] Stevens CF. **Cell** 1996 Dec 27;87(7):1147–8 (10 ref.) Comment on: Cell 1996 Dec 27;87(7):1317–26. Comment on: Cell 1996 Dec 27;87(7):1327–38. Comment on: Cell 1996 Dec 27;87(7):1339–49. Comment on: Cell 1996 Dec 27;87(7):1351–61.
Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Fink G, et al. **Cell Mol Neurobiol** 1996 Jun;16(3):325–44 (87 ref.)
The hippocampus, long-term potentiation and memory. Redman S. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov; 23(10–11):961–4 (29 ref.)
Neurobiology of memory for emotional events: converging evidence from infra-human and human studies. Cahill L. **Cold Spring Harb Symp Quant Biol** 1996;61:259–64 (37 ref.)
Neural mechanisms of declarative memory. Eichenbaum H, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:197–206 (45 ref.)
Emotional memory: a search for sites of plasticity. Quirk GJ, et al. **Cold Spring Harb Symp Quant Biol** 1996; 61:247–57 (78 ref.)
Memory, memory impairment, and the medial temporal lobe. Squire LR, et al. **Cold Spring Harb Symp Quant Biol** 1996; 61:185–95 (104 ref.)
A return to genetic dissection of memory in Drosophila. Tully T, et al. **Cold Spring Harb Symp Quant Biol** 1996; 61:207–18 (99 ref.)
Constraints on awareness, attention, processing, and memory: some recent investigations with ignored speech. Cowan N, et al. **Conscious Cogn** 1997 Jun–Sep;6(2–3):182–203 (34 ref.)
Synaptic plasticity: the basis of particular types of learning. Goda Y, et al. **Curr Biol** 1996 Apr 1;6(4):375–8 (12 ref.)
Human memory: the hippocampus is the key. Parkin AJ. **Curr Biol** 1996 Dec 1;6(12):1583–5 (7 ref.)
Emotional memory: what does the amygdala do? Phelps EA, et al. **Curr Biol** 1997 May 1;7(5):R311–4 (25 ref.)
Working memory: trouble in mind. Tovée MJ, et al. **Curr Biol** 1996 Jan 1;6(1):13–5 (23 ref.)
Modulation of memory storage. Cahill L, et al. **Curr Opin Neurobiol** 1996 Apr;6(2):237–42 (67 ref.)
Memory consolidation, retrograde amnesia and the hippocampal complex. Nadel L, et al. **Curr Opin Neurobiol** 1997 Apr;7(2):217–27 (88 ref.)
Memory beyond the hippocampus. Tulving E, et al. **Curr Opin Neurobiol** 1997 Apr;7(2):209–16 (103 ref.)
Mnemonic functions of the basal ganglia. White NM. **Curr Opin Neurobiol** 1997 Apr;7(2):164–9 (66 ref.)
CREB and the formation of long-term memory. Yin JC, et al. **Curr Opin Neurobiol** 1996 Apr;6(2):264–8 (42 ref.)
Neuropsychology and advances in memory function. Gordon B. **Curr Opin Neurol** 1997 Aug;10(4):306–12 (70 ref.)
Memory in utero? [see comments] Hepper PG. **Dev Med Child Neurol** 1997 May;39(5):343–6 (60 ref.) Comment in: Dev Med Child Neurol 1997 May;39(5):285.
The functional organization of working memory processes within human lateral frontal cortex: the contribution of functional neuroimaging. Owen AM. **Eur J Neurosci** 1997 Jul;9(7):1329–39 (73 ref.)
Control of remembered reaching sequences in monkey. II. Storage and preparation before movement in motor and premotor cortex. Kettner RE, et al. **Exp Brain Res** 1996 Dec;112(3):347–58 (51 ref.)
Cerebral ischemia: are the memory deficits associated with hippocampal cell loss? Bachevalier J, et al. **Hippocampus** 1996;6(5):553–60 (84 ref.)
Computational models of hippocampal function in memory. Gluck MA. **Hippocampus** 1996;6(6):565–6 (4 ref.)
LTP and spatial learning--where to next? Jeffery KJ. **Hippocampus** 1997;7(1):95–110 (105 ref.)
Ischemic brain damage and memory impairment: a commentary. Squire LR, et al. **Hippocampus** 1996; 6(5):546–52 (50 ref.)
Thought disorder, working memory and attention: interrelationships and the effects of neuroleptic medications. Goldberg TE, et al. **Int Clin Psychopharmacol** 1995 Sep;10 Suppl 3:99–104 (46 ref.)
The receptor mosaic hypothesis of the engram: possible relevance of Boolean network modeling. Zoli M, et al. **Int J Neural Syst** 1996 Sep;7(4):363–8 (40 ref.)
EEG-alpha rhythms and memory processes. Klimesch W. **Int J Psychophysiol** 1997 Jun;26(1–3):319–40 (35 ref.)
Memory processes, brain oscillations and EEG synchronization. Klimesch W. **Int J Psychophysiol** 1996 Nov;24(1–2):61–100 (138 ref.)
Endogenous opioid regulation of hippocampal function. Simmons ML, et al. **Int Rev Neurobiol** 1996;39:145–96 (241 ref.)
The neurobiology of recovery memory. Zola SM. **J Neuropsychiatry Clin Neurosci** 1997 Summer;9(3):449–59 (45 ref.)
The nucleus accumbens and learning and memory. Setlow B. **J Neurosci Res** 1997 Sep 1;49(5):515–21 (56 ref.)
Olfactory recognition memory. Keverne EB, et al. **J Physiol Paris** 1996;90(5–6):399–401 (13 ref.)
Behavioral, neural and cellular components underlying olfactory learning in the honeybee. Menzel R, et al. **J Physiol Paris** 1996;90(5–6):395–8 (36 ref.)
Cell adhesion molecules and the transition from short- to long-term memory. Rose SP. **J Physiol Paris** 1996; 90(5–6):387–91 (37 ref.)
The role of neuropeptides in learning and memory: possible mechanisms. Shen Y, et al. **Med Hypotheses** 1995 Dec; 45(6):529–38 (80 ref.)
A brain model with the circuit to convert short-term memory into long-term memory. Wong CW. **Med Hypotheses** 1997 Mar;48(3):221–6 (34 ref.)
Bioactive lipids in excitatory neurotransmission and neuronal plasticity. Bazan NG, et al. **Neurochem Int** 1997 Feb; 30(2):225–31 (59 ref.)
Cholinergic neurotransmission and synaptic plasticity concerning memory processing. Jerusalinsky D, et al. **Neurochem Res** 1997 Apr;22(4):507–15 (91 ref.)
Neurochemical modulation of the hippocampus in learning, remembering and forgetting in primates. Ridley RM, et al. **Neurodegeneration** 1996 Dec;5(4):467–71 (27 ref.)
Time to remember. Dudai Y. **Neuron** 1997 Feb;18(2):179–82 (23 ref.)
Consolidation: fragility on the road to the engram. Dudai Y. **Neuron** 1996 Sep;17(3):367–70 (20 ref.)
A kinase to remember: dual roles for MAP kinase in long-term memory [comment] Kornhauser JM, et al. **Neuron** 1997 Jun;18(6):839–42 (23 ref.) Comment on: Neuron 1997 Jun;18(6):913–24.
Synapse specificity and long-term information storage. Schuman EM. **Neuron** 1997 Mar;18(3):339–42 (22 ref.)
Systems of memory in the human brain. Willingham DB. **Neuron** 1997 Jan;18(1):5–8 (19 ref.)
Genetic approaches to the study of memory in insects. Lopatina NG, et al. **Neurosci Behav Physiol** 1997 May–Jun; 27(3):250–3 (12 ref.)
Behavioral consequences of intracerebral vasopressin and oxytocin: focus on learning and memory. Engelmann M, et al. **Neurosci Biobehav Rev** 1996 Autumn;20(3):341–58 (219 ref.)
The delayed-conditional-discrimination task improves measurement of working memory in rats. Herremans AH, et al. **Neurosci Biobehav Rev** 1997 May;21(3):371–9 (41 ref.)
Memory, sleep, and dynamic stabilization of neural circuitry: evolutionary perspectives. Kavanau JL. **Neurosci Biobehav Rev** 1996 Summer;20(2):289–311 (236 ref.)
Complex roles of glutamate in the Gibbs–Ng model of one-trial aversive learning in the new-born chick. Ng KT, et al. **Neurosci Biobehav Rev** 1997 Jan;21(1):45–54 (76 ref.)
Messengers from the synapses to the nucleus (MSNs) that establish late phase of long-term potentiation (LTP) and long-term memory. Suzuki T. **Neurosci Res** 1996 May; 25(1):1–6 (75 ref.)
Memory, sleep and the evolution of mechanisms of synaptic efficacy maintenance. Kavanau JL. **Neuroscience** 1997 Jul; 79(1):7–44 (347 ref.)
Global and serial neurons form A hierarchically arranged interface proposed to underlie memory and cognition. Woolf NJ. **Neuroscience** 1996 Oct;74(3):625–51 (288 ref.)
Imaging studies of memory and attention. Ojemann JG, et al. **Neurosurg Clin N Am** 1997 Jul;8(3):307–19 (74 ref.)
Working memory and executive control. Baddeley A, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Oct 29; 351(1346):1397–403; discussion 1403–4 (34 ref.)
The prefrontal landscape: implications of functional architecture for understanding human mentation and the central executive. Goldman-Rakic PS. **Philos Trans R Soc Lond B Biol Sci** 1996 Oct 29; 351(1346):1445–53 (72 ref.)
Specialized systems for the processing of mnemonic

information within the primate frontal cortex. Petrides M. **Philos Trans R Soc Lond B Biol Sci** 1996 Oct 29; 351(1346):1455–61; discussion 1461–2 (30 ref.)
Dissociating executive functions of the prefrontal cortex. Robbins TW. **Philos Trans R Soc Lond B Biol Sci** 1996 Oct 29;351(1346):1463–70; discussion 1470–1 (37 ref.)
Toward a molecular definition of long-term memory storage. Bailey CH, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13445–52 (69 ref.)
A synaptic basis for memory storage in the cerebral cortex. Bear MF. **Proc Natl Acad Sci U S A** 1996 Nov 26; 93(24):13453–9 (59 ref.)
Neural mechanisms for visual memory and their role in attention. Desimone R. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13494–9 (66 ref.)
Functional organization of the hippocampal memory system. Eichenbaum H, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13500–7 (51 ref.)
Memory systems analyses of mnemonic disorders in aging and age-related diseases. Gabrieli JD. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13534–40 (57 ref.)
Memory: recording experience in cells and circuits: diversity in memory research. Goldman-Rakic PS. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13435–7 (24 ref.)
Regional and cellular fractionation of working memory. Goldman-Rakic PS. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13473–80 (94 ref.)
Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease. Levey AI. **Proc Natl Acad Sci U S A** 1996 Nov 26; 93(24):13541–6 (64 ref.)
Involvement of the amygdala in memory storage: interaction with other brain systems. McGaugh JL, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13508–14 (110 ref.)
Memory from the dynamics of intrinsic membrane currents. Marder E, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26; 93(24):13481–6 (42 ref.)
Structure and function of declarative and nondeclarative memory systems. Squire LR, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13515–22 (66 ref.)
Memory systems in the brain and localization of a memory. Thompson RF, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13438–44 (104 ref.)
Discovery of genes involved with learning and memory: an experimental synthesis of Hirschian and Benzerian perspectives. Tully T. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13460–7 (77 ref.)
The neurobiology of memory for emotional events: adrenergic activation and the amygdala. Cahill L, et al. **Proc West Pharmacol Soc** 1996;39:81–4 (24 ref.)
Long-term potentiation: a good model for learning and memory? Hölscher C. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Jan; 21(1):47–68 (69 ref.)
Protein kinase C, learning and memory: a circular determinism between physiology and behaviour [see comments] Noguès X. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Apr; 21(3):507–29 (68 ref.) Comment in: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):373–8.
Protein kinase C: a memory kinase? [comment] Riedel G. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Apr; 21(3):373–8 (21 ref.) Comment on: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):379–406. Comment on: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):407–25. Comment on: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):427–54. Comment on: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):455–86. Comment on: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):487–505. Comment on: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):507–29. Comment on: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):531–72.
Comparing the role of metabotropic glutamate receptors in long-term potentiation and in learning and memory. Riedel G, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Jul;20(5):761–89 (118 ref.)
Historical review of research on protein kinase C in learning and memory [see comments] Van der Zee EA, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Apr; 21(3):379–406 (117 ref.) Comment in: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):373–8.
Affect, attachment, memory: contributions toward psychobiologic integration. Amini F, et al. **Psychiatry** 1996 Fall;59(3):213–39 (113 ref.)
An application of prefrontal cortex function theory to cognitive aging. West RL. **Psychol Bull** 1996 Sep; 120(2):272–92 (130 ref.)
Neuropeptide modulation of learning and memory processes. Feany MB. **Rev Neurosci** 1996 Apr-Jun;7(2):151–64 (123 ref.)
Nitric oxide in learning and memory. Jachimowicz A, et al. **Rocz Akad Med Bialymst** 1996;41(2):161–75 (81 ref.)
The neural basis of aware and unaware forms of memory. Verfaellie M, et al. **Semin Neurol** 1997 Jun;17(2):153–61 (90 ref.)
The functional neuroanatomy of episodic memory. Fletcher PC, et al. **Trends Neurosci** 1997 May;20(5):213–8 (52 ref.)
[An olfactory memory formed in the vomeronasal system] Kaba H. **Tanpakushitsu Kakusan Koso** 1996 Nov; 41(14):2077–83 (29 ref.) **(Jpn)**
[The molecular scenarios of the consolidation of long-term memory] Anokhin KV. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 Mar-Apr; 47(2):261–79 (97 ref.) (Eng. Abstr.) **(Rus)**

MEMORY DISORDERS

Confabulation and the control of recollection. Burgess PW, et al. **Memory** 1996 Jul;4(4):359–411 (115 ref.)
[Implicit memory in Alzheimer's disease] Cacho Gutiérrez J. **Neurologia** 1996 Nov;11(9):341–3 (30 ref.) **(Spa)**

COMPLICATIONS

Advances in pharmacotherapy for decline of memory and cognition in patients with Alzheimer's disease. Kumar V, et al. **Psychiatr Serv** 1996 Mar;47(3):249–53 (28 ref.)
[Memory and epilepsy] Mataró-Serrat M, et al. **Rev Neurol** 1997 Aug;25(144):1241–5 (56 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Memory, abuse, and science. Questioning claims about the false memory syndrome epidemic. Pope KS. **Am Psychol** 1996 Sep;51(9):957–74 (140 ref.)
The heterogeneity of memory dysfunction in schizophrenia. Stip E, et al. **Can J Psychiatry** 1996 Sep;41(7 Suppl 1):S14–20 (33 ref.)
Disorders of semantic memory [editorial] Garrard P, et al. **J Neurol Neurosurg Psychiatry** 1997 May;62(5):431–5 (52 ref.)
[Nondeclarative memory--neuropsychological findings and neuroanatomic principles] Daum I, et al. **Fortschr Neurol Psychiatr** 1997 Mar;65(3):122–32 (115 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Advances in pharmacotherapy for decline of memory and cognition in patients with Alzheimer's disease. Kumar V, et al. **Psychiatr Serv** 1996 Mar;47(3):249–53 (28 ref.)
[A critical review of available tools for evaluating memory enhancers in Alzheimer's disease] Poitrenaud J, et al. **Rev Med Interne** 1997;18(1):59–71 (59 ref.) (Eng. Abstr.) **(Fre)**
[Neuropharmacological effects of sigma receptor ligands: anxiolytic, anti-amnesic and neuroprotective effects] Amano M, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Jun; 16(3):73–84 (103 ref.) (Eng. Abstr.) **(Jpn)**
[Memory disorders due to extreme impacts and their pharmacological correction] Iasnetsov VV. **Aviakosm Ekolog Med** 1996;30(4):4–14 (161 ref.) (Eng. Abstr.) **(Rus)**
[Memory disorders due to extreme exposures and their pharmacological correction] Iasnetsov VV, et al. **Usp Fiziol Nauk** 1997 Jan-Mar;28(1):97–116 (188 ref.) (Eng. Abstr.) **(Rus)**

ETIOLOGY

A critical review of recovered memories in psychotherapy: Part I--Trauma and memory. Paris J. **Can J Psychiatry** 1996 May;41(4):201–5 (52 ref.)
A critical review of recovered memories in psychotherapy: Part II--Trauma and therapy. Paris J. **Can J Psychiatry** 1996 May;41(4):206–10 (35 ref.)
Decline of frontal lobe functions in subjects with age-associated memory impairment. Hänninen T, et al. **Neurology** 1997 Jan;48(1):148–53 (71 ref.)
[Memory disorders] Heuser I. **Internist (Berl)** 1996 Nov; 37(11):1189–202 (0 ref.) **(Ger)**
[Memory disorders due to extreme impacts and their pharmacological correction] Iasnetsov VV. **Aviakosm Ekolog Med** 1996;30(4):4–14 (161 ref.) (Eng. Abstr.) **(Rus)**
[Memory disorders due to extreme exposures and their pharmacological correction] Iasnetsov VV, et al. **Usp Fiziol Nauk** 1997 Jan-Mar;28(1):97–116 (188 ref.) (Eng. Abstr.) **(Rus)**

PATHOLOGY

Neuropathological studies on strains of senescence-accelerated mice (SAM) with age-related deficits in learning and memory. Kawamata T, et al. **Exp Gerontol** 1997 Jan-Apr;32(1-2):161–9 (45 ref.)
Possible role of the cholinergic system and disease models. Weinstock M. **J Neural Transm Suppl** 1997;49:93–102 (46 ref.)

PHYSIOPATHOLOGY

Memory, memory impairment, and the medial temporal lobe. Squire LR, et al. **Cold Spring Harb Symp Quant Biol** 1996; 61:185–95 (104 ref.)
Cerebral ischemia: are the memory deficits associated with hippocampal cell loss? Bachevalier J, et al. **Hippocampus** 1996;6(5):553–60 (84 ref.)
Ischemic brain damage and memory impairment: a commentary. Squire LR, et al. **Hippocampus** 1996; 6(5):546–52 (50 ref.)
Possible role of the cholinergic system and disease models. Weinstock M. **J Neural Transm Suppl** 1997;49:93–102 (46 ref.)
The neurobiology of recovery memory. Zola SM. **J Neuropsychiatry Clin Neurosci** 1997 Summer;9(3):449–59 (45 ref.)
Decline of frontal lobe functions in subjects with age-associated memory impairment. Hänninen T, et al. **Neurology** 1997 Jan;48(1):148–53 (71 ref.)
[An extensive system of explicit memory] Reinoso Suárez F. **An R Acad Nac Med (Madr)** 1996;113(3):565–77 (61 ref.) **(Spa)**

PSYCHOLOGY

Memory systems analyses of mnemonic disorders in aging and age-related diseases. Gabrieli JD. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13534–40 (57 ref.)
[Memory disturbances in schizophrenia] Brand A, et al. **Fortschr Neurol Psychiatr** 1996 Feb;64(2):49–65 (132 ref.) (Eng. Abstr.) **(Ger)**
[Memory disturbances in Parkinson's disease] Ringendahl H. **Fortschr Neurol Psychiatr** 1996 Feb;64(2):43–8 (91 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Memory enhancement program for community-based older adults: development and evaluation. Caprio-Prevette MD, et al. **Exp Aging Res** 1996 Jul-Sep;22(3):281–303 (41 ref.)

MEMORY FOR DESIGNS TEST see **NEUROPSYCHOLOGICAL TESTS**

MEMORY, IMMEDIATE see **MEMORY, SHORT-TERM**

MEMORY, SHORT-TERM

PHYSIOLOGY

Retrograde messengers, long-term potentiation and memory. Medina JH, et al. **Brain Res Brain Res Rev** 1995 Sep; 21(2):185–94 (113 ref.)
Functional modular organization of the primate prefrontal cortex for representing working memory process. Sawaguchi T. **Brain Res Cogn Brain Res** 1996 Dec; 5(1-2):157–63 (31 ref.)
The clinical utility of event-related potentials to a short-term memory task. Blumhardt LD. **Electroencephalogr Clin Neurophysiol Suppl** 1996;46:73–84 (23 ref.)
Cell adhesion molecules and the transition from short- to long-term memory. Rose SP. **J Physiol Paris** 1996; 90(5-6):387–91 (37 ref.)
A brain model with the circuit to convert short-term memory into long-term memory. Wong CW. **Med Hypotheses** 1997 Mar;48(3):221–6 (34 ref.)

MEN

PSYCHOLOGY

See no evil, hear no evil, speak no evil: why do relatively few male victims of childhood sexual abuse receive help for abuse-related issues in adulthood? Holmes GR, et al. **Clin Psychol Rev** 1997;17(1):69–88 (80 ref.)

MEN 1 see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 1**

MEN 2 see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A**

MEN 2A see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A**

MEN 2B see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B**

MEN 3 see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B**

MENADIONE see **VITAMIN K**

MENADIONE REDUCTASE see **NAD(P)H DEHYDROGENASE (QUINONE)**

MENAQUINONE see **VITAMIN K**

MENARCHE

[Body composition at menarche. Estimation of total body weight, total body water, lean and fat body weight] Zurlo de Mirotti SM, et al. **Rev Fac Cien Med Univ Nac Cordoba** 1995;53 Suppl:23–30 (46 ref.) (Eng. Abstr.) **(Spa)**
[Age of menarche. Secondary sex characteristics.

Interrelation. Secular trend] Zurlo de Mirotti SM, et al. **Rev Fac Cien Med Univ Nac Cordoba** 1995;53 Suppl:7-15 (40 ref.) (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Variation in menarcheal age of Assamese girls. Sengupta S, et al. **J Indian Med Assoc** 1996 Mar;94(3):88-90 (10 ref.)

PHYSIOLOGY

Variation in menarcheal age of Assamese girls. Sengupta S, et al. **J Indian Med Assoc** 1996 Mar;94(3):88-90 (10 ref.)
Menarche and beyond--do eating and exercise make a difference? Emans SJ. **Pediatr Ann** 1997 Feb;26(2 Suppl):S137-41 (46 ref.)

MENETRIER DISEASE see **GASTRITIS, HYPERTROPHIC**

MENIERE'S DISEASE

see related
ENDOLYMPHATIC HYDROPS

DIAGNOSIS

Definition, classification and reporting of Menière's disease and its symptoms. Van de Heyning PH, et al. **Acta Otolaryngol Suppl (Stockh)** 1997;526:5-9 (9 ref.)
Menière's disease: differential diagnosis and treatment. Knox GW, et al. **Am Fam Physician** 1997 Mar;55(4):1185-90, 1193-4 (17 ref.)

DRUG THERAPY

Medical treatment of Menière's disease: a review of literature. Claes J, et al. **Acta Otolaryngol Suppl (Stockh)** 1997; 526:37-42 (44 ref.)
Dexamethasone perfusion of the labyrinth plus intravenous dexamethasone for Ménière's disease. Shea JJ Jr, et al. **Otolaryngol Clin North Am** 1996 Apr;29(2):353-8 (24 ref.)

ETIOLOGY

Deafness and vertigo. Gresty M, et al. **Curr Opin Neurol** 1997 Feb;10(1):36-42 (70 ref.)
Medicolegal aspects of neurotology. Hart CW, et al. **Otolaryngol Clin North Am** 1996 Jun;29(3):503-20 (29 ref.)
[Acute vestibular deficit with initial deafness as the first manifestation of late onset multiple sclerosis] Schweri T, et al. **HNO** 1996 Jul;44(7):397-9 (20 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Impediment of basilar membrane motion reduces overload protection but not threshold sensitivity: evidence from clinical and experimental hydrops. Braun M. **Hear Res** 1996 Aug;97(1-2):1-10 (46 ref.)

PSYCHOLOGY

Illness behaviour, personality traits, anxiety, and depression in patients with Menière's disease. Savastano M, et al. **J Otolaryngol** 1996 Oct;25(5):329-33 (12 ref.)

SURGERY

Selective vestibular neurectomy in Menière's disease: a review. Van de Heyning PH, et al. **Acta Otolaryngol Suppl (Stockh)** 1997;526:58-66 (47 ref.)
Surgical treatment of Ménière's disease. LaRouere MJ. **Otolaryngol Clin North Am** 1996 Apr;29(2):311-22 (45 ref.)

THERAPY

Menière's disease: differential diagnosis and treatment. Knox GW, et al. **Am Fam Physician** 1997 Mar;55(4):1185-90, 1193-4 (17 ref.)

MENIERE'S SYNDROME see **MENIERE'S DISEASE**

MENINGEAL ARTERIES

SURGERY

[An arteriosinusal anastomosis between the middle meningeal artery and the cavernous sinus. Its surgical treatment using the balloon catheter] Iakovlev SB. **Zh Vopr Neirokhir Im N N Burdenko** 1997 Apr-Jun; (2):31-3 (19 ref.) **(Rus)**

MENINGEAL NEOPLASMS

Intrasellar meningioma: case report and review of the literature. Nozaki K, et al. **Surg Neurol** 1997 May; 47(5):447-52; discussion 452-4 (14 ref.)

COMPLICATIONS

Intracranial meningioma with intratumoral hemorrhage. Cheng MH, et al. **J Formos Med Assoc** 1997 Feb; 96(2):116-20 (17 ref.)

DIAGNOSIS

Meningeal carcinomatosis as the presenting manifestation of gastric adenocarcinoma. Deeb LS, et al. **Am J Gastroenterol** 1997 Feb;92(2):329-31 (22 ref.)
High-dose radiation-induced meningiomas following acute lymphoblastic leukemia in children. Salvati M, et al. **Childs Nerv Syst** 1996 May;12(5):266-9 (35 ref.)
Spinal meningiomas in pregnancy: report of two cases and review of the literature. Cioffi F, et al. **Eur J Gynaecol Oncol** 1996;17(5):384-8 (40 ref.)
Meningeal melanocytoma: case report and review of the literature. Ibáñez J, et al. **Histopathology** 1997 Jun; 30(6):576-81 (49 ref.)
Primary diffuse leptomeningeal gliomatosis with signs of increased intracranial pressure and progressive meningeal enhancement on MRI. Park JS, et al. **J Neuroimaging** 1996 Oct;6(4):250-4 (16 ref.)
Solitary fibrous tumor of the meninges. Case report and review of the literature. Prayson RA, et al. **J Neurosurg** 1997 Jun;86(6):1049-52 (21 ref.)
MR imaging of the meninges. Part II. Neoplastic disease. Fukui MB, et al. **Radiology** 1996 Dec;201(3):605-12 (82 ref.)
Cystic meningiomas resembling glial tumors. Carvalho GA, et al. **Surg Neurol** 1997 Mar;47(3):284-9; discussion 289-90 (31 ref.)
Association of breast carcinoma and meningioma: report of nine new cases and review of the literature. Salvati M, et al. **Tumori** 1996 Sep-Oct;82(5):491-3 (25 ref.)
[Meningiomas of the sellar diaphragm. Apropos of 4 cases] Civit T, et al. **Neurochirurgie** 1997;43(1):21-6; discussion 26-7 (18 ref.) (Eng. Abstr.) **(Fre)**
[Primary extradural meningioma of the orbits: a report of a patient and review of the literature] Spraul CW, et al. **Klin Monatsbl Augenheilkd** 1996 Nov;209(5):322-7 (41 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Pharmacologic strategies for the treatment of meningeal malignancy. Blaney SM, et al. **Invest New Drugs** 1996; 14(1):69-85 (85 ref.)
Chemotherapy for meningiomas. Kyritsis AP. **J Neurooncol** 1996 Sep;29(3):269-72 (19 ref.)

EPIDEMIOLOGY

Epidemiology and etiology of intracranial meningiomas: a review. Bondy M, et al. **J Neurooncol** 1996 Sep; 29(3):197-205 (82 ref.)

ETIOLOGY

Suprasellar meningioma subsequent to treatment for a pituitary adenoma: case report. Rao MB, et al. **Surg Neurol** 1997 May;47(5):443-6 (11 ref.)
[Post-radiotherapy multifocal meningioma] Bazin A, et al. **Rev Neurol (Paris)** 1997 Jun;153(5):344-6 (11 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Intracytoplasmic chromophobe inclusion bodies in an anaplastic meningioma. Saito A, et al. **Acta Neuropathol (Berl)** 1997 Apr;93(4):421-5 (9 ref.)
Meningeal localization in a patient with Hodgkin's disease. Description of a case and review of the literature. Anselmo AP, et al. **Ann Oncol** 1996 Dec;7(10):1071-5 (40 ref.)
Cystic meningioma in children: a case report. Lui TN, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Oct; 58(4):303-7 (25 ref.)
Primary diffuse leptomeningeal glioblastoma multiforme of brainstem and spinal cord clinically mimicking meningitis: case report and review of literature. Shuangshoti S, et al. **J Med Assoc Thai** 1996 Jun;79(6):403-8 (24 ref.)
Pathology of meningiomas. Langford LA. **J Neurooncol** 1996 Sep;29(3):217-21 (22 ref.)
The biology of meningiomas. McCutcheon IE. **J Neurooncol** 1996 Sep;29(3):207-16 (60 ref.)
Subdural sarcoma associated with chronic subdural hematoma. Report of two cases and review of the literature. Cinalli G, et al. **J Neurosurg** 1997 Mar;86(3):553-7 (12 ref.)
Lymphoplasmacyte-rich meningioma with clinical resemblance to inflammatory pseudotumor. Report of two cases. Yamaki T, et al. **J Neurosurg** 1997 May;86(5):898-904 (22 ref.)

RADIOTHERAPY

Radiotherapy in recurrent malignant meningiomas with multiple spinal manifestations. Schiebe ME, et al. **Acta Oncol** 1997;36(1):88-90 (18 ref.)
Fractionated stereotactic radiotherapy. Shrieve DC, et al. **Important Adv Oncol** 1996;:205-24 (67 ref.)

SECONDARY

Carcinomatous meningitis in solid tumours. Jayson GC, et al. **Ann Oncol** 1996 Oct;7(8):773-86 (112 ref.)
Association of breast carcinoma and meningioma: report of nine new cases and review of the literature. Salvati M, et al. **Tumori** 1996 Sep-Oct;82(5):491-3 (25 ref.)
[Carcinomatous meningitis: rare complication of bladder cancer] Hasbini A, et al. **Rev Med Interne** 1997;18(5):402-6 (36 ref.) (Eng. Abstr.) **(Fre)**
[Breast carcinoma metastatic to meningioma: review of the literature and description of 2 new cases] Fornelli A, et al. **Pathologica** 1995 Oct;87(5):506-12 (37 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Management of petroclival meningiomas: a critical analysis of surgical treatment. Tatagiba M, et al. **Acta Neurochir Suppl (Wien)** 1996;65:92-4 (8 ref.)
Pineal region meningioma without dural attachment. Madawi AA, et al. **Br J Neurosurg** 1996 Jun;10(3):305-7 (13 ref.)
Spinal meningeal melanocytoma: a case report and review of the literature. Sankhla SK, et al. **Br J Neurosurg** 1996 Apr;10(2):205-9 (28 ref.)
Surgical treatment of anterior basal meningiomas. DeMonte F. **J Neurooncol** 1996 Sep;29(3):239-48 (31 ref.)
Petroclival and foramen magnum meningiomas: surgical approaches and pitfalls. Sekhar LN, et al. **J Neurooncol** 1996 Sep;29(3):249-59 (22 ref.)
Primary intraosseous meningioma of the temporal bone in an infant. A case report. Kuzeyli K, et al. **Neurosurg Rev** 1996;19(3):197-9 (15 ref.)
Multiple meningiomas of the central nervous system without the stigmata of neurofibromatosis. Clinical and therapeutic study. Turgut M, et al. **Neurosurg Rev** 1997;20(2):117-23 (37 ref.)
The surgical resectability of meningiomas of the cavernous sinus. O'Sullivan MG, et al. **Neurosurgery** 1997 Feb; 40(2):238-44; discussion 245-7 (45 ref.)
Contralateral cerebellar hemorrhagic infarction after pterional craniotomy: report of five cases and review of the literature. Papanastassiou V, et al. **Neurosurgery** 1996 Oct;39(4):841-51; discussion 851-2 (38 ref.)

THERAPY

Hormonal dependency of cerebral meningiomas. Schrell UM, et al. **Acta Neurochir Suppl (Wien)** 1996;65:54-7 (32 ref.)
Current treatment of meningiomas. McDermott MW. **Curr Opin Neurol** 1996 Dec;9(6):409-13 (40 ref.)
Management of benign and aggressive intracranial meningiomas. Akeyson EW, et al. **Oncology (Huntingt)** 1996 May;10(5):747-56; discussion 756-9 (85 ref.)

MENINGES

Spinal meningeal cyst in a dog: a case report and literature review. Hardie RJ, et al. **J Am Anim Hosp Assoc** 1996 Nov-Dec;32(6):477-80 (14 ref.)
Cutaneous neural heterotopias and related tumors relevant for the dermatopathologist. Argenyi ZB. **Semin Diagn Pathol** 1996 Feb;13(1):60-71 (62 ref.)

ANATOMY & HISTOLOGY

MR imaging of the meninges. Part I. Normal anatomic features and nonneoplastic disease. Meltzer CC, et al. **Radiology** 1996 Nov;201(2):297-308 (90 ref.)
[Anatomy of cerebrospinal fluid system and blood-brain barrier] Amano T. **Nippon Naika Gakkai Zasshi** 1996 May 10;85(5):659-62 (6 ref.) **(Jpn)**

DRUG EFFECTS

[Neurotoxicity of intrathecally administrated agents] Malinovsky JM, et al. **Ann Fr Anesth Reanim** 1996; 15(5):647-58 (128 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Unusual pattern of enhancement in cryptococcal meningitis: in vivo findings with postmortem correlation. Arnder L, et al. **J Comput Assist Tomogr** 1996 Nov-Dec;20(6):1023-6 (8 ref.)
Primary diffuse leptomeningeal gliomatosis with signs of increased intracranial pressure and progressive meningeal enhancement on MRI. Park JS, et al. **J Neuroimaging** 1996 Oct;6(4):250-4 (16 ref.)

RADIOGRAPHY

Unusual pattern of enhancement in cryptococcal meningitis: in vivo findings with postmortem correlation. Arnder L, et al. **J Comput Assist Tomogr** 1996 Nov-Dec;20(6):1023-6 (8 ref.)

MENINGIOMA

Intrasellar meningioma: case report and review of the literature. Nozaki K, et al. **Surg Neurol** 1997 May; 47(5):447-52; discussion 452-4 (14 ref.)

COMPLICATIONS

Intracranial meningioma with intratumoral hemorrhage. Cheng MH, et al. **J Formos Med Assoc** 1997 Feb; 96(2):116-20 (17 ref.)
Meningioangiomatosis is associated with neurofibromatosis 2 but not with somatic alterations of the NF2 gene. Stemmer-Rachamimov AO, et al. **J Neuropathol Exp Neurol** 1997 May;56(5):485-9 (43 ref.)

DIAGNOSIS

January 1997--7 year old girl with seizures. al-Hindi H, et al. **Brain Pathol** 1997 Jul;7(3):1023-4 (6 ref.)
High-dose radiation-induced meningiomas following acute lymphoblastic leukemia in children. Salvati M, et al. **Childs Nerv Syst** 1996 May;12(5):266-9 (35 ref.)

MENINGIOMA

Spinal meningiomas in pregnancy: report of two cases and review of the literature. Cioffi F, et al. **Eur J Gynaecol Oncol** 1996;17(5):384–8 (40 ref.)

Cystic meningiomas resembling glial tumors. Carvalho GA, et al. **Surg Neurol** 1997 Mar;47(3):284–9; discussion 289–90 (31 ref.)

Association of breast carcinoma and meningioma: report of nine new cases and review of the literature. Salvati M, et al. **Tumori** 1996 Sep–Oct;82(5):491–3 (25 ref.)

[Meningiomas of the sellar diaphragm. Apropos of 4 cases] Civit T, et al. **Neurochirurgie** 1997;43(1):21–6; discussion 26–7 (18 ref.) (Eng. Abstr.) **(Fre)**

[Primary extradural meningioma of the orbits: a report of a patient and review of the literature] Spraul CW, et al. **Klin Monatsbl Augenheilkd** 1996 Nov;209(5):322–7 (41 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Chemotherapy for meningiomas. Kyritsis AP. **J Neurooncol** 1996 Sep;29(3):269–72 (19 ref.)

EPIDEMIOLOGY

Epidemiology and etiology of intracranial meningiomas: a review. Bondy M, et al. **J Neurooncol** 1996 Sep; 29(3):197–205 (82 ref.)

ETIOLOGY

Suprasellar meningioma subsequent to treatment for a pituitary adenoma: case report. Rao MB, et al. **Surg Neurol** 1997 May;47(5):443–6 (11 ref.)

[Post-radiotherapy multifocal meningioma] Bazin A, et al. **Rev Neurol (Paris)** 1997 Jun;153(5):344–6 (11 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Meningioangiomatosis is associated with neurofibromatosis 2 but not with somatic alterations of the NF2 gene. Stemmer-Rachamimov AO, et al. **J Neuropathol Exp Neurol** 1997 May;56(5):485–9 (43 ref.)

PATHOLOGY

Intracytoplasmic chromophobe inclusion bodies in an anaplastic meningioma. Saito A, et al. **Acta Neuropathol (Berl)** 1997 Apr;93(4):421–5 (9 ref.)

Primary pulmonary meningioma: report of a case and review of the literature. Lockett L, et al. **Am J Surg Pathol** 1997 Apr;21(4):453–60 (24 ref.)

Primary pulmonary meningioma. Report of a case and review of the literature. Kaleem Z, et al. **Arch Pathol Lab Med** 1997 Jun;121(6):631–6 (40 ref.)

Cystic meningioma in children: a case report. Lui TN, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Oct; 58(4):303–7 (25 ref.)

Pathology of meningiomas. Langford LA. **J Neurooncol** 1996 Sep;29(3):217–21 (22 ref.)

The biology of meningiomas. McCutcheon IE. **J Neurooncol** 1996 Sep;29(3):207–16 (60 ref.)

Lymphoplasmacyte-rich meningioma with clinical resemblance to inflammatory pseudotumor. Report of two cases. Yamaki T, et al. **J Neurosurg** 1997 May;86(5):898–904 (22 ref.)

Intraparenchymal meningioma in an infant--case report. Kohama I, et al. **Neurol Med Chir (Tokyo)** 1996 Aug; 36(8):598–601 (11 ref.)

Craniofacial approaches to sinus malignancy. Osguthorpe JD, et al. **Otolaryngol Clin North Am** 1995 Dec;28(6):1239–57 (36 ref.)

Third ventricular meningiomas of infancy. A case report. Pau A, et al. **Pathologica** 1996 Jun;88(3):204–6 (10 ref.)

[Breast carcinoma metastatic to meningioma: review of the literature and description of 2 new cases] Fornelli A, et al. **Pathologica** 1995 Oct;87(5):506–12 (37 ref.) (Eng. Abstr.) **(Ita)**

RADIOTHERAPY

Radiotherapy in recurrent malignant meningiomas with multiple spinal manifestations. Schiebe ME, et al. **Acta Oncol** 1997;36(1):88–90 (18 ref.)

SECONDARY

Association of breast carcinoma and meningioma: report of nine new cases and review of the literature. Salvati M, et al. **Tumori** 1996 Sep–Oct;82(5):491–3 (25 ref.)

SURGERY

Management of petroclival meningiomas: a critical analysis of surgical treatment. Tatagiba M, et al. **Acta Neurochir Suppl (Wien)** 1996;65:92–4 (8 ref.)

Pineal region meningioma without dural attachment. Madawi AA, et al. **Br J Neurosurg** 1996 Jun;10(3):305–7 (13 ref.)

Creutzfeldt-Jakob disease transmitted by dura mater graft. Clavel M, et al. **Eur Neurol** 1996;36(4):239–40 (10 ref.)

Surgical treatment of anterior basal meningiomas. DeMonte F. **J Neurooncol** 1996 Sep;29(3):239–48 (31 ref.)

Petroclival and foramen magnum meningiomas: surgical approaches and pitfalls. Sekhar LN, et al. **J Neurooncol** 1996 Sep;29(3):249–59 (22 ref.)

Primary intraosseous meningioma of the temporal bone in an infant. A case report. Kuzeyli K, et al. **Neurosurg Rev** 1996;19(3):197–9 (15 ref.)

Multiple meningiomas of the central nervous system without the stigmata of neurofibromatosis. Clinical and therapeutic study. Turgut M, et al. **Neurosurg Rev** 1997;20(2):117–23 (37 ref.)

The surgical resectability of meningiomas of the cavernous sinus. O'Sullivan MG, et al. **Neurosurgery** 1997 Feb; 40(2):238–44; discussion 245–7 (45 ref.)

Contralateral cerebellar hemorrhagic infarction after pterional craniotomy: report of five cases and review of the literature. Papanastassiou V, et al. **Neurosurgery** 1996 Oct;39(4):841–51; discussion 851–2 (38 ref.)

Craniofacial approaches to sinus malignancy. Osguthorpe JD, et al. **Otolaryngol Clin North Am** 1995 Dec;28(6):1239–57 (36 ref.)

Intraspinal meningiomas: review of 54 cases with discussion of poor prognosis factors and modern therapeutic management. Roux FX, et al. **Surg Neurol** 1996 Nov; 46(5):458–63; discussion 463–4 (28 ref.)

THERAPY

Hormonal dependency of cerebral meningiomas. Schrell UM, et al. **Acta Neurochir Suppl (Wien)** 1996;65:54–7 (32 ref.)

Current treatment of meningiomas. McDermott MW. **Curr Opin Neurol** 1996 Dec;9(6):409–13 (40 ref.)

Management of benign and aggressive intracranial meningiomas. Akeyson EW, et al. **Oncology (Huntingt)** 1996 May;10(5):747–56; discussion 756–9 (85 ref.)

MENINGIOMAS, MULTIPLE see **MENINGIOMA**

MENINGIOMATOSIS see **MENINGIOMA**

MENINGISM

DIAGNOSIS

[Meningeal syndrome in differential diagnosis of infectious diseases] Bogomolov BP. **Klin Med (Mosk)** 1997; 75(3):47–53 (0 ref.) **(Rus)**

MENINGISMUS see **MENINGISM**

MENINGITIS

Lyme neuroborreliosis in children. Christen HJ. **Ann Med** 1996 Jun;28(3):235–40 (48 ref.)

[Clinical symptoms and physiopathology of meningitis] Nagashima K. **Nippon Naika Gakkai Zasshi** 1996 May 10; 85(5):663–6 (5 ref.) **(Jpn)**

COMPLICATIONS

Group B streptococcal sepsis and meningitis complicated with severe sensorineural hearing loss in a fourteen-year-old boy. Likitnukul S, et al. **Pediatr Infect Dis J** 1996 May;15(5):468–70 (15 ref.)

[Idiopathic hypertrophic cranial pachymeningitis associated with Horner's syndrome. A case report] Shindo K, et al. **Rinsho Shinkeigaku** 1997 Apr;37(4):300–3 (22 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Clinical implications of nucleic acid amplification methods for the diagnosis of viral infections of the nervous system. Weber T, et al. **J Neurovirol** 1996 Jun;2(3):175–90 (170 ref.)

[Importance of EEG and diagnostic image for diagnosis of nervous system infections] Higuchi J, et al. **Nippon Naika Gakkai Zasshi** 1996 May 10;85(5):677–81 (4 ref.) **(Jpn)**

[Clinical significance of cerebrospinal fluid findings] Takeoka T. **Nippon Naika Gakkai Zasshi** 1996 May 10;85(5):672–6 (5 ref.) **(Jpn)**

[Persistent neutrophilic meningitis in a patient with the acquired immunodeficiency syndrome] Marinho SF, et al. **Rev Soc Bras Med Trop** 1997 May–Jun;30(3):241–5 (22 ref.) (Eng. Abstr.) **(Por)**

EPIDEMIOLOGY

[Epidemiology of patients with nervous system infections] Kaji M, et al. **Nippon Naika Gakkai Zasshi** 1996 May 10; 85(5):693–8 (7 ref.) **(Jpn)**

ETIOLOGY

Carcinomatous meningitis in solid tumours. Jayson GC, et al. **Ann Oncol** 1996 Oct;7(8):773–86 (112 ref.)

Chronic meningitis with cranial neuropathies in Wegener's granulomatosis. Case report and review of the literature. Jinnah HA, et al. **Arthritis Rheum** 1997 Mar;40(3):573–7 (17 ref.)

Risks of regional anesthesia--infectious, septic. Wedel DJ, et al. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):57–61 (30 ref.)

[Infectious complications after peridural obstetric anesthesia] Marsaudon E, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(2):159–62 (20 ref.) (Eng. Abstr.) **(Fre)**

[Suppurative meningitis as a complication of suppurative-necrotic ethmoiditis with fusion of the ethmoid bone] Bondariev LS, et al. **Lik Sprava** 1996 Jul–Sep; (7–9):166–8 (7 ref.) (Eng. Abstr.) **(Ukr)**

MICROBIOLOGY

Group B streptococcal sepsis and meningitis complicated with severe sensorineural hearing loss in a fourteen-year-old boy. Likitnukul S, et al. **Pediatr Infect Dis J** 1996 May;15(5):468–70 (15 ref.)

PATHOLOGY

Primary diffuse leptomeningeal glioblastoma multiforme of brainstem and spinal cord clinically mimicking meningitis: case report and review of literature. Shuangshoti S, et al. **J Med Assoc Thai** 1996 Jun;79(6):403–8 (24 ref.)

Hypertrophic spinal pachymeningitis. A case report. Kanamori M, et al. **Spine** 1997 Aug 1;22(15):1787–90 (22 ref.)

RADIONUCLIDE IMAGING

[Positron emission tomographic evaluation for frontal hypertrophic cranial pachymeningitis using 11C-methyl-L-methionine] Takahashi M, et al. **No Shinkei Geka** 1996 Mar;24(3):287–93 (27 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Infections. Bolton CF. **Baillieres Clin Neurol** 1996 Oct; 5(3):599–626 (57 ref.)

VETERINARY

Encephalitis and meningitis. Muñana KR. **Vet Clin North Am Small Anim Pract** 1996 Jul;26(4):857–74 (65 ref.)

MENINGITIS, ASEPTIC

PATHOLOGY

Leukemic meningitis complicating early stage chronic lymphocytic leukemia. Miller K, et al. **Arch Pathol Lab Med** 1997 May;121(5):524–7 (30 ref.)

MENINGITIS, BACTERIAL

Bacterial meningitis. Richardson M. **Br J Hosp Med** 1996 Jun 5–18;55(11):685–8 (20 ref.)

Corynebacterium striatum meningitis: case report and review of an increasingly important Corynebacterium species. Weiss K, et al. **Clin Infect Dis** 1996 Dec;23(6):1246–8 (20 ref.)

Acute bacterial meningitis. Segreti J, et al. **Infect Dis Clin North Am** 1996 Dec;10(4):797–809 (44 ref.)

COMPLICATIONS

Medical-legal considerations related to symptom duration and patient outcome after bacterial meningitis. Bonadio WA. **Am J Emerg Med** 1997 Jul;15(4):420–3 (37 ref.)

Capnocytophaga meningitis in a cancer patient. Kim JO, et al. **Pediatr Infect Dis J** 1996 Jul;15(7):636–7 (11 ref.)

DIAGNOSIS

Meningitis in older patients: how to diagnose and treat a deadly infection. Miller LG, et al. **Geriatrics** 1997 Aug; 52(8):43–4, 47–50, 55 (21 ref.)

Bacillus species pseudomeningitis. Cunha BA, et al. **Heart Lung** 1997 May–Jun;26(3):249–51 (19 ref.)

Selected pediatric emergencies in community practice. Mangione RA. **J Am Pharm Assoc (Wash)** 1997 Jan–Feb; NS37(1):22–9 (36 ref.)

Congenital malformation of the inner ear and recurrent meningitis. A case report. Hultcrantz M, et al. **ORL J Otorhinolaryngol Relat Spec** 1996 Nov–Dec; 58(6):333–7 (8 ref.)

Spontaneous group B streptococcal meningitis in a patient with cirrhosis. Tung BY, et al. **West J Med** 1996 Oct; 165(4):229–30 (13 ref.)

[Progress on diagnosis and therapy of bacterial meningitis] Hirose Y, et al. **Nippon Naika Gakkai Zasshi** 1996 May 10;85(5):699–704 (5 ref.) **(Jpn)**

[Gram-negative meningitis secondary to congenital dermal sinus demonstrated by magnetic resonance] Verdú Pérez A, et al. **An Esp Pediatr** 1996 May;44(5):491–2 (9 ref.) **(Spa)**

DRUG THERAPY

The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: current antibiotic therapy in the 1990s. Bradley JS, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S213–21 (58 ref.)

Meningitis in older patients: how to diagnose and treat a deadly infection. Miller LG, et al. **Geriatrics** 1997 Aug; 52(8):43–4, 47–50, 55 (21 ref.)

The use of corticosteroids in the management of bacterial meningitis in adults [see comments] Townsend GC, et al. **J Antimicrob Chemother** 1996 Jun;37(6):1051–61 (31 ref.) Comment in: J Antimicrob Chemother 1997 Apr;39(4):557–8.

Treatment of bacterial meningitis. Quagliarello VJ, et al. **N Engl J Med** 1997 Mar 6;336(10):708–16 (96 ref.)

[Role of corticoids in purulent meningitis in children: analysis of literature studies] Jacqz-Aigrain E, et al. **Arch Pediatr** 1997 Jan;4(1):52–60 (46 ref.) (Eng. Abstr.)

(Fre)

[Classical and current aspects of purulent meningitis] Ring A, et al. **Nervenarzt** 1996 Aug;67(8):630–8 (30 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Gram negative bacillary meningitis in infants and children in developing countries. Akpede GO, et al. **East Afr Med J** 1996 Sep;73(9):586–91 (21 ref.)

ETIOLOGY

Enterobacter sakazakii: a review. Nazarowec-White M, et al. **Int J Food Microbiol** 1997 Feb;34(2):103–13 (40 ref.)

IMMUNOLOGY

The Gal alpha 1–4 Gal-binding adhesin of Streptococcus suis, a gram-positive meningitis-associated bacterium. Haataja S, et al. **Adv Exp Med Biol** 1996;408:25–34 (21 ref.)

MICROBIOLOGY

Neonatal meningitis due to Moraxella catarrhalis and review of the literature. Daoud A, et al. **Ann Trop Paediatr** 1996 Sep;16(3):199–201 (14 ref.)

Nontuberculous mycobacterial meningitis: report of two cases and review. Flor A, et al. **Clin Infect Dis** 1996 Dec; 23(6):1266–73 (43 ref.)

Alpha-hemolytic streptococci: a major pathogen of iatrogenic meningitis following lumbar puncture. Case reports and a review of the literature. Schneeberger PM, et al. **Infection** 1996 Jan–Feb;24(1):29–33 (38 ref.)

Streptococcus B meningitis in post-partum. Guerin JM, et al. **J Infect** 1997 Mar;34(2):151–3 (14 ref.)

Stenotrophomonas maltophilia meningitis. Report of two cases and review of the literature. Papadakis KA, et al. **J Neurosurg** 1997 Jul;87(1):106–8 (14 ref.)

PHYSIOPATHOLOGY

Brain injury in bacterial meningitis: therapeutic implications. Pfister HW, et al. **Curr Opin Neurol** 1997 Jun;10(3):254–9 (44 ref.)

Roles of proinflammatory and anti-inflammatory cytokines in pathophysiology of bacterial meningitis and effect of adjunctive therapy. van Furth AM, et al. **Infect Immun** 1996 Dec;64(12):4883–90 (165 ref.)

THERAPY

Brain injury in bacterial meningitis: therapeutic implications. Pfister HW, et al. **Curr Opin Neurol** 1997 Jun;10(3):254–9 (44 ref.)

ULTRASONOGRAPHY

Cranial sonography in bacterial meningitis. Mahajan R, et al. **Indian Pediatr** 1995 Sep;32(9):989–93 (10 ref.)

MENINGITIS, CRYPTOCOCCAL

DIAGNOSIS

Unusual pattern of enhancement in cryptococcal meningitis: in vivo findings with postmortem correlation. Arnder L, et al. **J Comput Assist Tomogr** 1996 Nov–Dec;20(6):1023–6 (8 ref.)

ETIOLOGY

[Neuromeningeal cryptococcosis and alcoholic cirrhosis] Artru P, et al. **Gastroenterol Clin Biol** 1997;21(1):78–81 (29 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. Zeind CS, et al. **Pharmacotherapy** 1996 Jul–Aug;16(4):547–61 (127 ref.)

MENINGITIS, FUNGAL

[Progress on diagnosis and therapy of fungal and tuberculous meningitis] Kuroiwa Y, et al. **Nippon Naika Gakkai Zasshi** 1996 May 10;85(5):705–10 (6 ref.) **(Jpn)**

MENINGITIS, LISTERIA

COMPLICATIONS

Fatal Listeria meningitis, endocarditis and pericarditis in a patient with haemochromatosis. Manso C, et al. **Scand J Infect Dis** 1997;29(3):308–9 (14 ref.)

MENINGITIS, MENINGOCOCCAL

CEREBROSPINAL FLUID

Meningococcal meningitis revisited: normocellular CSF. Sivakmaran M. **Clin Pediatr (Phila)** 1997 Jun;36(6):351; discussion 351–5 (11 ref.)

COMPLICATIONS

Hemorrhagic stroke as a complication of bacterial meningitis in adults: report of three cases and review. Gironell A, et al. **Clin Infect Dis** 1995 Dec;21(6):1488–91 (12 ref.)

DIAGNOSIS

Neonatal meningococcal meningitis: case reports and review of literature [see comments] Arango CA, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1134–6 (32 ref.) Comment in: Pediatr Infect Dis J 1997 Jun;16(6):634.

IMMUNOLOGY

Bacterial outer membrane protein vaccines. The meningococcal example. Poolman JT. **Adv Exp Med Biol** 1996;397:73–7 (39 ref.)

The immune response to the capsular polysaccharide of Neisseria meningitidis group B. Romero JD, et al. **Zentralbl Bakteriol** 1997 Feb;285(3):331–40 (62 ref.)

PREVENTION & CONTROL

"Love's labours lost": failure to implement mass vaccination against group A meningococcal meningitis in sub-Saharan Africa. Robbins JB, et al. **Lancet** 1997 Sep 20; 350(9081):880–2 (41 ref.)

The immune response to the capsular polysaccharide of Neisseria meningitidis group B. Romero JD, et al. **Zentralbl Bakteriol** 1997 Feb;285(3):331–40 (62 ref.)

SURGERY

Treatment of thromboembolic complications of fulminant meningococcal septic shock. Mele JA 3rd, et al. **Ann Plast Surg** 1997 Mar;38(3):283–90 (29 ref.)

MENINGITIS, PNEUMOCOCCAL

COMPLICATIONS

Hemorrhagic stroke as a complication of bacterial meningitis in adults: report of three cases and review. Gironell A, et al. **Clin Infect Dis** 1995 Dec;21(6):1488–91 (12 ref.)

[Adult pneumococcal meningitis complicated by cerebral infarction: a case report] Mukai K, et al. **Rinsho Shinkeigaku** 1996 Sep;36(9):1110–3 (10 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[Fulminant meningitis due to Streptococcus pneumoniae] Pérez Navero JL, et al. **An Esp Pediatr** 1996 May; 44(5):499–500 (10 ref.) **(Spa)**

DRUG THERAPY

Failure of cefotaxime treatment in an adult with Streptococcus pneumoniae meningitis. Pacheco TR, et al. **Am J Med** 1997 Mar;102(3):303–5 (14 ref.)

[Purulent meningitis in an adult patient caused by multi-drug resistant Streptococcus pneumoniae 19A] Vukmirovits G, et al. **Orv Hetil** 1996 Jul 21;137(29):1587–90 (28 ref.) (Eng. Abstr.) **(Hun)**

[Increasing antibiotic resistance of pneumococcus. Management of respiratory tract infections and meningitis (see comments)] Kalin M, et al. **Lakartidningen** 1997 Mar 19;94(12):1061–4, 1067–8 (41 ref.) Comment in: Lakartidningen 1997 May 14;94(20):1867–8. **(Swe)**

IMMUNOLOGY

New vaccines for the prevention of pneumococcal infections. Käyhty H, et al. **Emerg Infect Dis** 1996 Oct–Dec; 2(4):289–98 (74 ref.)

MICROBIOLOGY

Molecular and cellular mechanisms of pneumococcal meningitis. Tuomanen EI. **Ann N Y Acad Sci** 1996 Oct 25;797:42–52 (66 ref.)

[Purulent meningitis in an adult patient caused by multi-drug resistant Streptococcus pneumoniae 19A] Vukmirovits G, et al. **Orv Hetil** 1996 Jul 21;137(29):1587–90 (28 ref.) (Eng. Abstr.) **(Hun)**

PREVENTION & CONTROL

New vaccines for the prevention of pneumococcal infections. Käyhty H, et al. **Emerg Infect Dis** 1996 Oct–Dec; 2(4):289–98 (74 ref.)

MENINGITIS, TUBERCULOUS see **TUBERCULOSIS, MENINGEAL**

MENINGITIS, VIRAL

[Adenovirus CNS infections] Kaji M, et al. **Nippon Rinsho** 1997 Apr;55(4):876–9 (11 ref.) (Eng. Abstr.) **(Jpn)**

CEREBROSPINAL FLUID

[Cerebrospinal fluid examination in the infectious meningitis and encephalitis] Takeoka T. **Nippon Rinsho** 1997 Apr; 55(4):809–14 (20 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Reovirus type 1 associated with meningitis. Johansson PJ, et al. **Scand J Infect Dis** 1996;28(2):117–20 (11 ref.)

[Diagnosis of nervous system infections using polymerase chain reaction] Nakamura S, et al. **Nippon Naika Gakkai Zasshi** 1996 May 10;85(5):687–92 (5 ref.) **(Jpn)**

EPIDEMIOLOGY

[Epidemiology of virus-related nervous infections in Japan] Ishii K, et al. **Nippon Rinsho** 1997 Apr;55(4):839–48 (22 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

[Neurologic signs and symptoms in viral infections—disease involving meninges, central nervous system or peripheral nerve system] Araga S, et al. **Nippon Rinsho** 1997 Apr; 55(4):805–8 (24 ref.) (Eng. Abstr.) **(Jpn)**

MENINGOCELE

Uncommon craniospinal dysraphism. Sharma V, et al. **Ann Acad Med Singapore** 1996 Jul;25(4):602–8 (30 ref.)

[Cephalocele] Yokota A, et al. **No Shinkei Geka** 1996 Dec; 24(12):1067–77 (74 ref.) **(Jpn)**

DIAGNOSIS

Surgically verified case of optic sheath nerve meningocele: case report with review of the literature. Lunardi P, et al. **Neurosurg Rev** 1997;20(3):201–5 (21 ref.)

EMBRYOLOGY

Cervical meningoceles and myelocystoceles: a unifying hypothesis. Steinbok P, et al. **Pediatr Neurosurg** 1995; 23(6):317–22 (9 ref.)

PATHOLOGY

Lateral meningocele syndrome: three new patients and review of the literature. Gripp KW, et al. **Am J Med Genet** 1997 Jun 13;70(3):229–39 (11 ref.)

[A case of meningoencephalocele with a rare location] Petrova N, et al. **Akush Ginekol (Sofiia)** 1996;35(3):39–42 (27 ref.) (Eng. Abstr.) **(Bul)**

MENINGOCOCCAL INFECTIONS

Meningococcemia. Salzman MB, et al. **Infect Dis Clin North Am** 1996 Dec;10(4):709–25 (87 ref.)

Neisseria meningitidis: clinical aspects. Cartwright KA, et al. **J Infect** 1997 Jan;34(1):15–9 (32 ref.)

Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience [see comments] Kirsch EA, et al. **Pediatr Infect Dis J** 1996 Nov;15(11):967–78; quiz 979 (133 ref.) Comment in: Pediatr Infect Dis J 1997 May;16(5):540–2.

CLASSIFICATION

A new classification for pericarditis associated with meningococcal infection. Finkelstein Y, et al. **Eur J Pediatr** 1997 Aug;156(8):585–8 (53 ref.)

COMPLICATIONS

Osteonecrosis following meningococcemia and disseminated intravascular coagulation in an adult: case report and review. Campbell WN, et al. **Clin Infect Dis** 1997 Mar; 24(3):452–5 (12 ref.)

DIAGNOSIS

Chronic meningococcemia in childhood: case report and review of the literature. Ploysangam T, et al. **Pediatr Dermatol** 1996 Nov–Dec;13(6):483–7 (29 ref.)

DRUG THERAPY

Acute meningococcaemia: recent advances in management (with particular reference to children). Kennedy NJ, et al. **Anaesth Intensive Care** 1996 Apr;24(2):197–216 (184 ref.)

Antibiotic resistance in Neisseria meningitidis. Oppenheim BA. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S98–101 (44 ref.)

ETIOLOGY

Meningococcal conjunctivitis. Irani F, et al. **Aust N Z J Ophthalmol** 1997 May;25(2):167–8 (7 ref.)

IMMUNOLOGY

Bacterial outer membrane protein vaccines. The meningococcal example. Poolman JT. **Adv Exp Med Biol** 1996;397:73–7 (39 ref.)

MICROBIOLOGY

Microevolution and epidemic spread of serogroup A Neisseria meningitidis—a review. Achtman M. **Gene** 1997 Jun 11;192(1):135–40 (23 ref.)

PREVENTION & CONTROL

[Meningococcal infection: should we vaccinate?] Casado Flores J. **An Esp Pediatr** 1997 Mar;46(3):221–3 (27 ref.)

MENINGOCOCCAL INFECTIONS

(Spa)

TRANSMISSION

[Bronchopneumonia caused by Neisseria meningitidis--probable transmission by a family member who had been in Hong Kong] Ohtaki M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 Apr;35(4):461–5 (10 ref.) (Eng. Abstr.) **(Jpn)**

MENINGOCOCCUS see **NEISSERIA MENINGITIDIS**

MENINGOENCEPHALITIS

CHEMICALLY INDUCED

[Manifestation of neuro–Behçet disease in cyclosporin A therapy] Meusser S, et al. **Z Rheumatol** 1997 Jan–Feb; 56(1):31–9 (37 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

[Neuropathology of Rasmussen syndrome] Vajtai I, et al. **Orv Hetil** 1996 Sep 15;137(37):2035–9 (29 ref.) (Eng. Abstr.) **(Hun)**

[Recurrent polychondritis and meningoencephalitis (letter)] Taborcias D, et al. **Med Clin (Barc)** 1996 Nov 2; 107(15):597–8 (10 ref.) **(Spa)**

ETIOLOGY

[Sjögren's syndrome with presenting as aseptic meningoencephaloradiculopathy in an elderly woman] Miyachi T, et al. **Nippon Ronen Igakkai Zasshi** 1997 May; 34(5):415–20 (12 ref.) (Eng. Abstr.) **(Jpn)**

PARASITOLOGY

Primary amoebic meningoencephalitis with Naegleria fowleri: clinical review. Barnett ND, et al. **Pediatr Neurol** 1996 Oct;15(3):230–4 (22 ref.)

PATHOLOGY

Neuro–Behçet's disease. Hadfield MG, et al. **Clin Neuropathol** 1997 Mar–Apr;16(2):55–60 (42 ref.)

VIROLOGY

[Borna disease virus. An etiological agent in neuropsychiatric diseases?] Christensen LS. **Ugeskr Laeger** 1997 Jun 16; 159(25):3930–3 (30 ref.) (Eng. Abstr.) **(Dan)**

MENINGOMYELOCELE

COMPLICATIONS

[Latex allergy in children with myelomeningocele. Incidence and associated factors] Estornell Moragues F, et al. **Actas Urol Esp** 1997 Mar;21(3):227–35 (46 ref.) (Eng. Abstr.) **(Spa)**

EMBRYOLOGY

Cervical meningoceles and myelocystoceles: a unifying hypothesis. Steinbok P, et al. **Pediatr Neurosurg** 1995; 23(6):317–22 (9 ref.)

PHYSIOPATHOLOGY

Somatosensory evoked potentials to median nerve stimulation in meningomyelocele: what is occurring in the hindbrain and its connections during growth? Nishimura T, et al. **Childs Nerv Syst** 1996 Jan;12(1):13–26 (35 ref.)

ULTRASONOGRAPHY

Sonographic detection of lipomyelomeningocele: a retrospective documentation. Chreston J, et al. **J Clin Ultrasound** 1997 Jan;25(1):50–1 (5 ref.)

MENISCI, LATERAL see **MENISCI, TIBIAL**

MENISCI, MEDIAL see **MENISCI, TIBIAL**

MENISCI, TIBIAL

Destruction of a cyropreserved meniscal allograft: a case for acute rejection. Hamlet W, et al. **Arthroscopy** 1997 Aug; 13(4):517–21 (34 ref.)

INJURIES

Patterns of meniscal injury in the anterior cruciate–deficient knee: a review of the literature. Bellabarba C, et al. **Am J Orthop** 1997 Jan;26(1):18–23 (90 ref.)

A prospective study comparing the accuracy of the clinical diagnosis of meniscus tear with magnetic resonance imaging and its effect on clinical outcome [see comments] Miller GK. **Arthroscopy** 1996 Aug;12(4):406–13 (42 ref.) Comment in: Arthroscopy 1997 Apr;13(2):271–5; discussion 276–7, 279–80. Comment in: Arthroscopy 1997 Apr;13(2):275–6; discussion 277–80.

Complications of arthroscopic meniscal repair. Austin KS. **Clin Sports Med** 1996 Jul;15(3):613–9 (45 ref.)

Meniscal repair. Where do we go from here? Kollias SL, et al. **Clin Sports Med** 1996 Jul;15(3):621–30 (48 ref.)

Allograft meniscus transplantation. Kuhn JE, et al. **Clin Sports Med** 1996 Jul;15(3):537–6 (109 ref.)

Arthroscopic all–inside meniscus repair. Reigel CA, et al. **Clin Sports Med** 1996 Jul;15(3):483–98 (22 ref.)

Meniscal repair using the outside–to–inside technique. Rodeo SA, et al. **Clin Sports Med** 1996 Jul;15(3):469–81 (44 ref.)

The management of meniscal tears in the ACL–deficient knee. Schmitz MA, et al. **Clin Sports Med** 1996 Jul; 15(3):573–93 (142 ref.)

Rehabilitation after meniscal repair. Shelbourne KD, et al. **Clin Sports Med** 1996 Jul;15(3):595–612 (36 ref.)

Meniscus replacement. Stone KR. **Clin Sports Med** 1996 Jul; 15(3):557–71 (63 ref.)

Use of lasers for meniscal repair. Vangsness CT Jr. **Clin Sports Med** 1996 Jul;15(3):531–5 (43 ref.)

Meniscal repair: arthroscopic repair techniques. Cannon WD Jr, et al. **Instr Course Lect** 1994;43:77–96 (19 ref.)

Meniscus repair: basic science, indications for repair, and open repair. DeHaven KE, et al. **Instr Course Lect** 1994; 43:65–76 (56 ref.)

Different patterns of meniscal tears in acute anterior cruciate ligament (ACL) ruptures and in chronic ACL–deficient knees. Classification, staging and timing of treatment. Cipolla M, et al. **Knee Surg Sports Traumatol Arthrosc** 1995; 3(3):130–4 (15 ref.)

Rehabilitation programmes following arthroscopic meniscectomy in athletes. Wheatley WB, et al. **Sports Med** 1996 Jun;21(6):447–56 (22 ref.)

[Meniscus lesions] Wirth CJ, et al. **Orthopade** 1997 Feb; 26(2):191–208 (74 ref.) **(Ger)**

[Arthroscopy: possibilities and limitations in the diagnosis and therapy of meniscus lesions] Hackenbruch W. **Ther Umsch** 1996 Oct;53(10):767–74 (36 ref.) (Eng. Abstr.) **(Ger)**

[Development of replacement meniscus of autogenous tissue] Metak G, et al. **Unfallchirurg** 1996 Jul;99(7):477–86 (36 ref.) (Eng. Abstr.) **(Ger)**

[Meniscus lesion] Wirth CJ, et al. **Unfallchirurg** 1997 May; 100(5):386–401 (74 ref.) **(Ger)**

[Meniscal repair] Kimura M. **Nippon Seikeigeka Gakkai Zasshi** 1996 May;70(5):274–84 (26 ref.) **(Jpn)**

SURGERY

Complications of arthroscopic meniscal repair. Austin KS. **Clin Sports Med** 1996 Jul;15(3):613–9 (45 ref.)

Arthroscopic medial meniscal repair in the athlete. DeHaven KE, et al. **Clin Sports Med** 1997 Jan;16(1):69–86 (49 ref.)

Meniscal repair. Where do we go from here? Kollias SL, et al. **Clin Sports Med** 1996 Jul;15(3):621–30 (48 ref.)

Arthroscopic all–inside meniscus repair. Reigel CA, et al. **Clin Sports Med** 1996 Jul;15(3):483–98 (22 ref.)

Meniscal repair using the outside–to–inside technique. Rodeo SA, et al. **Clin Sports Med** 1996 Jul;15(3):469–81 (44 ref.)

The management of meniscal tears in the ACL–deficient knee. Schmitz MA, et al. **Clin Sports Med** 1996 Jul; 15(3):573–93 (142 ref.)

Rehabilitation after meniscal repair. Shelbourne KD, et al. **Clin Sports Med** 1996 Jul;15(3):595–612 (36 ref.)

Meniscus replacement. Stone KR. **Clin Sports Med** 1996 Jul; 15(3):557–71 (63 ref.)

Use of lasers for meniscal repair. Vangsness CT Jr. **Clin Sports Med** 1996 Jul;15(3):531–5 (43 ref.)

Meniscal repair: arthroscopic repair techniques. Cannon WD Jr, et al. **Instr Course Lect** 1994;43:77–96 (19 ref.)

Meniscus repair: basic science, indications for repair, and open repair. DeHaven KE, et al. **Instr Course Lect** 1994; 43:65–76 (56 ref.)

Rehabilitation following allograft meniscal transplantation: a review of the literature and case study. Fritz JM, et al. **J Orthop Sports Phys Ther** 1996 Aug;24(2):98–106 (91 ref.)

Different patterns of meniscal tears in acute anterior cruciate ligament (ACL) ruptures and in chronic ACL–deficient knees. Classification, staging and timing of treatment. Cipolla M, et al. **Knee Surg Sports Traumatol Arthrosc** 1995; 3(3):130–4 (15 ref.)

Partial meniscectomy and osteoarthritis. Implications for treatment of athletes. Rangger C, et al. **Sports Med** 1997 Jan;23(1):61–8 (95 ref.)

[Meniscal repair] Kimura M. **Nippon Seikeigeka Gakkai Zasshi** 1996 May;70(5):274–84 (26 ref.) **(Jpn)**

TRANSPLANTATION

Allograft meniscus transplantation. Kuhn JE, et al. **Clin Sports Med** 1996 Jul;15(3):537–6 (109 ref.)

Rehabilitation following allograft meniscal transplantation: a review of the literature and case study. Fritz JM, et al. **J Orthop Sports Phys Ther** 1996 Aug;24(2):98–106 (91 ref.)

MENKES SYNDROME see **KINKY HAIR SYNDROME**

MENOPAUSE

see related
ESTROGEN REPLACEMENT THERAPY
OSTEOPOROSIS, POSTMENOPAUSAL
POSTMENOPAUSE
PREMENOPAUSE

Management of menopause. Hammond CB. **Am Fam Physician** 1997 Apr;55(5):1667–74, 1679–80 (38 ref.)

Obstetric and gynaecological factors in susceptibility to peripheral joint osteoarthritis. Silman AJ, et al. **Ann Rheum Dis** 1996 Sep;55(9):671–3 (19 ref.)

The menopause and the cardiovascular system. Beale CM, et al. **Baillieres Clin Obstet Gynaecol** 1996 Sep; 10(3):483–513 (149 ref.)

Urogenital effects of the menopause. Schaffer J, et al. **Baillieres Clin Obstet Gynaecol** 1996 Sep;10(3):401–17 (69 ref.)

Treatments for menopausal and post–menopausal problems: present and future. Whitehead M. **Baillieres Clin Obstet Gynaecol** 1996 Sep;10(3):515–30 (74 ref.)

The breast and the menopause. Wren BG. **Baillieres Clin Obstet Gynaecol** 1996 Sep;10(3):433–47 (37 ref.)

Estrogens, menopause, and coronary artery disease. Sullivan JM, et al. **Cardiol Clin** 1996 Feb;14(1):105–16 (57 ref.)

Current issues in menopausal hormone replacement therapy. Thacker HL. **Cleve Clin J Med** 1996 Oct;63(6):344–53 (9 ref.)

Alternatives to conventional hormone replacement therapy. Taylor M. **Compr Ther** 1997 Aug;23(8):514–32 (88 ref.)

Hormone replacement and the menopause: a European position paper. Writing Group on Women's Health of the Fondazione Giovanni Lorenzini Medical Science Foundation. Crosignani PG, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Jul;74(1):67–72 (81 ref.)

Progestogen intolerance and compliance with hormone replacement therapy in menopausal women. Panay N, et al. **Hum Reprod Update** 1997 Mar–Apr;3(2):159–71 (73 ref.)

Hormone replacement therapy in the menopause. Sarrel PM. **Int J Fertil Womens Med** 1997 Mar–Apr;42(2):78–84 (23 ref.)

Perimenopausal and postmenopausal hormone replacement therapy. Part 1. An update of the literature on benefits and risks [see comments] Lichtman R. **J Nurse Midwifery** 1996 Jan–Feb;41(1):3–28 (269 ref.) Comment in: J Nurse Midwifery 1996 May–Jun;41(3):228–9.

Theories of menopause. Brief comparative synopsis [see comments] Barile LA. **J Psychosoc Nurs Ment Health Serv** 1997 Feb;35(2):36–9 (19 ref.) Comment in: J Psychosoc Nurs Ment Health Serv 1997 May;35(5):10–1.

Menopause and osteoporosis: theoretical aspects. Effects of pluriform practices for present day health care and for women. Klinge I. **J Psychosom Obstet Gynaecol** 1997 Jun; 18(2):105–12 (26 ref.)

The social construction of menopause as risk. Palmlund I. **J Psychosom Obstet Gynaecol** 1997 Jun;18(2):87–94 (61 ref.)

Estrogen effects on cognition in menopausal women. Sherwin BB. **Neurology** 1997 May;48(5 Suppl 7):S21–6 (36 ref.)

Menopause and risk of cardiovascular disease. Gensini GF, et al. **Thromb Res** 1996 Oct 1;84(1):1–19 (121 ref.)

[Menopause and sexuality] Mimoun S. **Contracept Fertil Sex** 1996 Jan;24(1):62–6 (12 ref.) (Eng. Abstr.) **(Fre)**

[Hormone therapy of breast cancer in the metastatic phase in menopausal women] Namer M. **Presse Med** 1996 Nov 16;25(35):1745–53 (63 ref.) (Eng. Abstr.) **(Fre)**

[Menopause and postmenopause. Prognostic criteria in insurance medicine] Schiefeling M. **Versicherungsmedizin** 1996 Aug 1;48(4):116–25 (62 ref.) (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Managed care of hormone replacement therapy in the menopause. Wardle PG. **Curr Opin Obstet Gynecol** 1997 Aug;9(4):270–7 (64 ref.)

Nonestrogen management of menopausal symptoms. Hendrix SL. **Endocrinol Metab Clin North Am** 1997 Jun; 26(2):379–90 (53 ref.)

The role of androgens in menopausal hormonal replacement. Kaunitz AM. **Endocrinol Metab Clin North Am** 1997 Jun; 26(2):391–7 (19 ref.)

The effects of hormone replacement therapy on coronary heart disease. Sotelo MM, et al. **Endocrinol Metab Clin North Am** 1997 Jun;26(2):313–28 (70 ref.)

Management of the menopause and HRT by ultrasound. Jakab A Jr. **Eur J Obstet Gynecol Reprod Biol** 1997 Feb; 71(2):155–62 (45 ref.)

Hormone replacement therapy and cardiovascular disease. Gupta S, et al. **Int J Gynaecol Obstet** 1996 Feb;52(2):119–25 (50 ref.)

Female menopause, hormone replacement therapy, and cognitive processes. Erkkola R. **Maturitas** 1996 May;23 Suppl:S27–30 (24 ref.)

Hormone replacement therapy. Scharbo–Dehaan M. **Nurse Pract** 1996 Dec;21(12 Pt 2):1–13; quiz 14–5 (54 ref.)

[Do progestins have drawbacks?] Sitruk–Ware R. **Contracept Fertil Sex** 1997 May;25(5):352–7 (44 ref.) **(Fre)**

[Evaluation of the risk–benefit ratio of hormonal replacement therapy for menopause and susceptible elements in maximizing compliance] Lopes P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(7):694–8 (21 ref.) (Eng. Abstr.) **(Fre)**

[Prevention and treatment during the postmenopausal period] Klimek R. **Przegl Lek** 1997;54(4):279–83 (8 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Metabolic effects of the menopause and oestrogen replacement. Stevenson JC.
Baillieres Clin Obstet Gynaecol 1996 Sep;10(3):449–67 (80 ref.)
The menopause and lipid metabolism: strategies for cardiovascular disease prevention. Soma MR, et al.
Curr Opin Lipidol 1997 Aug;8(4):229–35 (52 ref.)
Androgen replacement therapy in women: myths and realities. Casson PR, et al.
Int J Fertil Menopausal Stud 1996 Jul–Aug;41(4):412–22 (79 ref.)

PHYSIOLOGY

The menopausal transition. Burger HG.
Baillieres Clin Obstet Gynaecol 1996 Sep;10(3):347–59 (26 ref.)
The menopause and the skeleton: key issues. Kanis JA.
Baillieres Clin Obstet Gynaecol 1996 Sep;10(3):469–81 (23 ref.)
The uterus and the menopause. Rees MC.
Baillieres Clin Obstet Gynaecol 1996 Sep;10(3):419–32 (69 ref.)
Dermatologic problems of the menopause. Graham-Brown R. **Clin Dermatol** 1997 Jan–Feb;15(1):143–5 (19 ref.)
Menopause. Agarwal SK, et al.
Curr Ther Endocrinol Metab 1997;6:624–31 (4 ref.)
Sexual function in menopause and postmenopause. Nachtigall LE. **Curr Ther Endocrinol Metab** 1997;6:632–6 (15 ref.)
Perimenopause. Stuenkel CA.
Curr Ther Endocrinol Metab 1997;6:270–4 (10 ref.)
The menopause transition. Greendale GA, et al.
Endocrinol Metab Clin North Am 1997 Jun;26(2):261–77 (121 ref.)
The controversial endocrinology of the menopausal transition [letter; comment] Prior JC, et al.
J Clin Endocrinol Metab 1996 Aug;81(8):3127–9 (21 ref.) Comment on: J Clin Endocrinol Metab 1995 Dec;80(12):3537–45.
Secular trends in menopause age. Flint MP.
J Psychosom Obstet Gynaecol 1997 Jun;18(2):65–72 (34 ref.)
Medicalization of women's third age. Kaufert PA, et al.
J Psychosom Obstet Gynaecol 1997 Jun;18(2):81–6 (7 ref.)
Menopause in different cultures. Richters JM.
J Psychosom Obstet Gynaecol 1997 Jun;18(2):73–80 (34 ref.)
Medicalization of menopause and public health. Rueda Martinez de Santos JR. **J Psychosom Obstet Gynaecol** 1997 Jun;18(2):175–80 (20 ref.)
Menopause and cardiovascular disease. van der Graaf Y, et al. **J Psychosom Obstet Gynaecol** 1997 Jun;18(2):113–20 (49 ref.)
Menopause and the brain. van Duijn CM.
J Psychosom Obstet Gynaecol 1997 Jun;18(2):121–5 (31 ref.)
The female brain hypoestrogenic continuum from the premenstrual syndrome to menopause. A hypothesis and review of supporting data. Arpels JC. **J Reprod Med** 1996 Sep;41(9):633–9 (87 ref.)
Menopause. Thacker HL. **Prim Care** 1997 Mar;24(1):205–21 (46 ref.)

PSYCHOLOGY

Psychological and sexual aspects of the menopause and HRT. Pearce MJ, et al. **Baillieres Clin Obstet Gynaecol** 1996 Sep;10(3):385–99 (66 ref.)
Causality, menopause, and depression: a critical review of the literature [see comments] Nicol-Smith L. **BMJ** 1996 Nov 16;313(7067):1229–32 (134 ref.) Comment in: BMJ 1996 Nov 16;313(7067):1217–8. Comment in: BMJ 1997 Feb 22;314(7080):608.
Mood disorders and menopause. Pearlstein T, et al.
Endocrinol Metab Clin North Am 1997 Jun;26(2):279–94 (137 ref.)
Menopause in different cultures. Richters JM.
J Psychosom Obstet Gynaecol 1997 Jun;18(2):73–80 (34 ref.)
Blood and nerves revisited: menopause and the privatization of the body in a Newfoundland postindustrial fishery. Davis DL. **Med Anthropol Q** 1997 Mar;11(1):3–20; discussion 21–5 (44 ref.)
[Evaluation of the risk–benefit ratio of hormonal replacement therapy for menopause and susceptible elements in maximizing compliance] Lopes P, et al.
J Gynecol Obstet Biol Reprod (Paris) 1996;25(7):694–8 (21 ref.) (Eng. Abstr.) **(Fre)**

MENOPAUSE, PREMATURE

Premature ovarian failure. Barlow DH.
Baillieres Clin Obstet Gynaecol 1996 Sep;10(3):361–84 (142 ref.)
[Early menopause] Aubard Y, et al.
J Gynecol Obstet Biol Reprod (Paris) 1997;26(3):231–7 (46 ref.) (Eng. Abstr.) **(Fre)**

MENORRHAGIA

Menorrhagia: a clinical update. Wood CE. **Med J Aust** 1996 Nov 4;165(9):510–4 (46 ref.)

DIAGNOSIS

A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Janssen CA. **Eur J Obstet Gynecol Reprod Biol** 1996 Dec;70(1):21–2 (8 ref.)

ETIOLOGY

[Uterine adenomyosis. Renaissance of a disease] Mergui JL, et al. **Contracept Fertil Sex** 1997 Feb;25(2):105–11 (69 ref.) **(Fre)**

SURGERY

Endometrial resection. Ledingham MA, et al.
Br J Hosp Med 1997 May 21–Jun 3;57(10):505–8 (17 ref.)
[Endometrial resection for refractory menorrhagia. An alternative to hysterectomy] Martinez C, et al.
Presse Med 1997 Mar 1;26(6):284–9 (24 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Hypermenorrhea and anovulatory cycles in the adolescent. Flamigni C, et al. **Curr Ther Endocrinol Metab** 1997;6:243–5 (6 ref.)

MENOTROPIN RECEPTORS see **RECEPTORS, GONADOTROPIN**

MENOTROPINS

see related
RECEPTORS, GONADOTROPIN

MENSTRUAL CYCLE

The probability of conception on different days of the cycle with respect to ovulation: an overview. Ferreira-Poblete A. **Adv Contracept** 1997 Jun–Sep;13(2–3):83–95 (14 ref.)
Women's issues in epilepsy. Menses, childbearing, and more. Liporace JD. **Postgrad Med** 1997 Jul;102(1):123–4, 127–9, 133–5 passim (32 ref.)
[Premenstrual asthma: relation to hormones] Hernández Colin D, et al. **Rev Alerg Mex** 1997 Mar–Apr;44(2):35–8 (33 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Contraception with anti-progesterone. Swahn ML, et al.
Baillieres Clin Obstet Gynaecol 1996 Apr;10(1):43–53 (51 ref.)

PHYSIOLOGY

Prediction and detection of the fertile phase of the menstrual cycle: an overview. Martinez AR. **Adv Contracept** 1997 Jun–Sep;13(2–3):131–8 (8 ref.)
Women, alcohol and the menstrual cycle. Gill J.
Alcohol Alcohol 1997 Jul–Aug;32(4):435–41 (23 ref.)
Stress-related disturbances of the menstrual cycle. Xiao E, et al. **Ann Med** 1997 Jun;29(3):215–9 (38 ref.)
Neuroendocrinology of the menstrual cycle. Genazzani AR, et al. **Ann N Y Acad Sci** 1997 Jun 17;816:143–50 (41 ref.)
Anovulation and monophasic cycles. Spence JE.
Ann N Y Acad Sci 1997 Jun 17;816:173–6 (07 ref.)
Perimenstrual eruptions. Stephens CJ. **Clin Dermatol** 1997 Jan–Feb;15(1):31–4 (33 ref.)
An overview on the effectiveness of natural family planning. Guida M, et al. **Gynecol Endocrinol** 1997 Jun;11(3):203–19 (81 ref.)
Menstrual cycle and appetite control: implications for weight regulation. Dye L, et al. **Hum Reprod** 1997 Jun;12(6):1142–51 (104 ref.)
Sleep in women [editorial] Driver HS. **J Psychosom Res** 1996 Mar;40(3):227–30 (21 ref.)
Hormonal regulation of the normal breast. von Schoultz B, et al. **Maturitas** 1996 May;23 Suppl:S23–5 (13 ref.)
Menstrual variability and the measurement of menstrual synchrony. Weller L, et al. **Psychoneuroendocrinology** 1997 Feb;22(2):115–28 (35 ref.)

PSYCHOLOGY

Stress-related disturbances of the menstrual cycle. Xiao E, et al. **Ann Med** 1997 Jun;29(3):215–9 (38 ref.)

MENSTRUAL CYCLE, FOLLICULAR PHASE see **FOLLICULAR PHASE**

MENSTRUAL CYCLE, LUTEAL PHASE see **LUTEAL PHASE**

MENSTRUAL PROLIFERATIVE PHASE see **MENSTRUAL CYCLE**

MENSTRUAL SECRETORY PHASE see **MENSTRUAL CYCLE**

MENSTRUATION

see related
MENSTRUATION-INDUCING AGENTS
PREMENSTRUAL SYNDROME

Menstrual migraines: etiology, treatment, and relationship to premenstrual syndrome. Kornstein SG, et al.
Curr Opin Obstet Gynecol 1997 Jun;9(3):154–9 (67 ref.)
Menstrual migraine. Methods of prevention and control. Fettes I. **Postgrad Med** 1997 May;101(5):67–70, 73–7 (32 ref.)

PHYSIOLOGY

Endometriosis--a disease because it is characterized by bleeding. Brosens IA. **Am J Obstet Gynecol** 1997 Feb;176(2):263–7 (25 ref.)
Contraception for the older woman. Glasier A, et al.
Baillieres Clin Obstet Gynaecol 1996 Apr;10(1):121–38 (64 ref.)
Prostaglandins and menstruation. Baird DT, et al.
Eur J Obstet Gynecol Reprod Biol 1996 Dec;70(1):15–7 (25 ref.)
Why do women menstruate? Historical and evolutionary review. Finn CA. **Eur J Obstet Gynecol Reprod Biol** 1996 Dec;70(1):3–8 (37 ref.)
A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Janssen CA. **Eur J Obstet Gynecol Reprod Biol** 1996 Dec;70(1):21–2 (8 ref.)
Endothelin and menstruation. Marsh MM, et al.
Hum Reprod 1996 Oct;11 Suppl 2:83–9 (28 ref.)
Matrix metalloproteinases in normal menstruation. Salamonsen LA, et al. **Hum Reprod** 1996 Oct;11 Suppl 2:124–33 (45 ref.)
The signals and molecular pathways involved in human menstruation, a unique process of tissue destruction and remodelling. Tabibzadeh S. **Mol Hum Reprod** 1996 Feb;2(2):77–92 (173 ref.)
Nuclear factor-kappa-B/steroid hormone receptor interactions as a functional basis of anti-inflammatory action of steroids in reproductive organs. van der Burg B, et al. **Mol Hum Reprod** 1996 Jun;2(6):433–8 (57 ref.)
Menstruation, sex hormones, and migraine. MacGregor EA. **Neurol Clin** 1997 Feb;15(1):125–41 (75 ref.)

MENSTRUATION DISORDERS

Menstrual disorders. Braverman PK, et al. **Pediatr Rev** 1997 Jan;18(1):17–25; quiz 26 (3 ref.)

ETIOLOGY

Disturbances of menstruation in thyroid disease. Koutras DA. **Ann N Y Acad Sci** 1997 Jun 17;816:280–4 (35 ref.)
Polycystic ovary syndrome: clinical aspects. Conway GS. **Baillieres Clin Endocrinol Metab** 1996 Apr;10(2):263–79 (55 ref.)
The female athlete. Thein LA, et al.
J Orthop Sports Phys Ther 1996 Feb;23(2):134–48 (93 ref.)
[Endocrino-gynecologic problems of the female adolescent] Sirpresi S, et al. **Pediatr Med Chir** 1996 Sep–Oct;18(5 Suppl):1–7 (6 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

"Menstrual" migraine: towards a definition. MacGregor EA. **Cephalalgia** 1996 Feb;16(1):11–21 (57 ref.)

PREVENTION & CONTROL

Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Sulak PJ, et al. **Obstet Gynecol** 1997 Feb;89(2):179–83 (7 ref.)

SURGERY

Endometrial ablation. Hart R, et al.
Curr Opin Obstet Gynecol 1997 Aug;9(4):226–32 (31 ref.)
Hysteroscopic management of menstrual disorders: a review of 395 patients. Cravello L, et al.
Eur J Obstet Gynecol Reprod Biol 1996 Aug;67(2):163–7 (24 ref.)

THERAPY

The levonorgestrel-releasing intrauterine device: a wider role than contraception. Coleman M, et al.
Aust N Z J Obstet Gynaecol 1997 May;37(2):195–201 (68 ref.)

MENSTRUATION, FOLLICULAR PHASE see **FOLLICULAR PHASE**

MENSTRUATION-INDUCING AGENTS

THERAPEUTIC USE

RU486 (mifepristone): mechanisms of action and clinical uses. Cadepond F, et al. **Annu Rev Med** 1997;48:129–56 (179 ref.)

MENSTRUATION, LUTEAL PHASE see **LUTEAL PHASE**

MENSTRUATION, RETROGRADE see **MENSTRUATION DISORDERS**

MENTAL COMPETENCY

Research with cognitively impaired subjects. Unfinished business in the regulation of human research [see comments] Bonnie RJ. **Arch Gen Psychiatry** 1997 Feb;54(2):105–11 (30 ref.) Comment in: Arch Gen Psychiatry 1997 Feb;54(2):117–20. Comment in: Arch Gen Psychiatry

MENTAL COMPETENCY

1997 Feb;54(2):121-3.
Caring about risks. Are severely depressed patients competent to consent to research? [see comments] Elliott C. **Arch Gen Psychiatry** 1997 Feb;54(2):113-6 (29 ref.) Comment in: Arch Gen Psychiatry 1997 Feb;54(2):117-20. Comment in: Arch Gen Psychiatry 1997 Feb;54(2):121-3.
Bioethics for clinicians: 3. Capacity. Etchells E, et al. **Can Med Assoc J** 1996 Sep 15;155(6):657-61 (29 ref.)
Procreation after death or mental incompetence: medical advance or technology gone awry? Ohl DA, et al. **Fertil Steril** 1996 Dec;66(6):889-95 (24 ref.)
Informed consent: putting risks into perspective. Singh AD, et al. **Surv Ophthalmol** 1997 Jul-Aug;42(1):83-6 (10 ref.)

LEGISLATION & JURISPRUDENCE

Informed consent by children and adolescents to psychiatric treatment. Batten DA. **Aust N Z J Psychiatry** 1996 Oct; 30(5):623-9; discussion 630-2 (24 ref.)
Capacity to decide about medical treatment. Feenan D. **Br J Hosp Med** 1996 Sep 18-Oct 1;56(6):295-7 (20 ref.)
Ethical research with the developmentally disabled. Weisstub DN, et al. **Can J Psychiatry** 1997 Jun;42(5):492-6 (31 ref.)
Treatment decisions for patients without surrogates: rethinking policies for a vulnerable population [see comments] Miller TE, et al. **J Am Geriatr Soc** 1997 Mar; 45(3):369-74 (35 ref.) Comment in: J Am Geriatr Soc 1997 Mar;45(3):375-7.
Asking the impossible: the negligence liability of the mentally ill. Goldstein EJ. **J Contemp Health Law Policy** 1995 Fall; 12(1):67-92 (184 ref.)
Sleepwalking disorder and mens rea: a review and case report. Maricopa County Superior Court. Thomas TN. **J Forensic Sci** 1997 Jan;42(1):17-24 (51 ref.)
Making decisions about medical treatment for mentally incapable adults in the UK. Luttrell S. **Lancet** 1997 Sep 27;350(9082):950-3 (27 ref.)
Assessment of understanding by people manifesting mental retardation: a preliminary report. Coles EM, et al. **Percept Mot Skills** 1996 Aug;83(1):187-92 (18 ref.)
[Mental competence of dementia patients to execute a will] Wetterling T, et al. **Psychiatr Prax** 1996 Sep;23(5):213-8 (61 ref.) (Eng. Abstr.) **(Ger)**

MENTAL DEFICIENCY see **MENTAL RETARDATION**

MENTAL DISORDERS

Developing a strategy for managing behavioral health care within the context of primary care. Fisher L, et al. **Arch Fam Med** 1997 Jul-Aug;6(4):324-33 (97 ref.)
Rethinking the conduct of psychiatric research [comment] [see comments] Appelbaum PS. **Arch Gen Psychiatry** 1997 Feb;54(2):117-20 (29 ref.) Comment on: Arch Gen Psychiatry 1997 Feb;54(2):105-11. Comment on: Arch Gen Psychiatry 1997 Feb;54(2):113-6. Comment on: Arch Gen Psychiatry 1997 Feb;54(2):121-3. Comment in: Arch Gen Psychiatry 1997 Feb;54(2):121-3.
Research with cognitively impaired subjects. Unfinished business in the regulation of human research [see comments] Bonnie RJ. **Arch Gen Psychiatry** 1997 Feb; 54(2):105-11 (30 ref.) Comment in: Arch Gen Psychiatry 1997 Feb;54(2):117-20. Comment in: Arch Gen Psychiatry 1997 Feb;54(2):121-3.
ABC of mental health. Mental health emergencies. Atakan Z, et al. **BMJ** 1997 Jun 14;314(7096):1740-2 (0 ref.)
ABC of mental health. Common mental health problems in primary care. Craig TK, et al. **BMJ** 1997 May 31; 314(7094):1609-12 (8 ref.)
ABC of mental health. Common mental health problems in hospital. Ramirez A, et al. **BMJ** 1997 Jun 7; 314(7095):1679-81 (0 ref.)
Physician-assisted suicide and the Dutch courts. Gevers JK. **Camb Q Healthc Ethics** 1996 Winter;5(1):93-9 (4 ref.)
Adolescent psychiatric conditions. Hodgman CH. **Compr Ther** 1996 Dec;22(12):796-801 (18 ref.)
The rights of psychiatric patients in the light of the principles announced by the United Nations: a recognition of the right to consent to treatment? Gendreau C. **Int J Law Psychiatry** 1997 Spring;20(2):259-78 (77 ref.)
A sense of proportion: the place of psychiatry in medicine. Lloyd GG. **J R Soc Med** 1996 Oct;89(10):563-7 (37 ref.)
Dual diagnosis in primary care. Detecting and treating both the addiction and mental illness. Ziedonis D, et al. **Med Clin North Am** 1997 Jul;81(4):1017-36 (53 ref.)
Psychiatric illness in female physicians. Are high rates of depression an occupational hazard? North CS, et al. **Postgrad Med** 1997 May;101(5):233-6, 239-40, 242 (20 ref.)
[The holy cows of pregnancy and puerperium mental syndrome] Schoenfeld H. **Harefuah** 1996 Nov 1; 131(9):344-7 (32 ref.) **(Heb)**
[Syndrome of dropout and premature termination at psychiatric clinics--reasons and characteristics] Shamir D, et al. **Harefuah** 1996 Jul;131(1-2):39-42 (25 ref.) **(Heb)**

BLOOD

Cholesterol and mental disorder. Boston PF, et al. **Br J Psychiatry** 1996 Dec;169(6):682-9 (31 ref.)

CHEMICALLY INDUCED

The serotonin syndrome. LoCurto MJ. **Emerg Med Clin North Am** 1997 Aug;15(3):665-75 (36 ref.)
Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. Lane R, et al. **J Clin Psychopharmacol** 1997 Jun;17(3):208-21 (149 ref.)
[The influence of lead on fetal development] Nowak-Węgrzyn A, et al. **Przegl Lek** 1996;53(10):744-9 (29 ref.) (Eng. Abstr.) **(Pol)**
[Psychiatric complications of L-dopa: physiopathology and treatment] Castro-García A. **Rev Neurol** 1997 Aug;25 Suppl 2:S157-62 (70 ref.) (Eng. Abstr.) **(Spa)**

CLASSIFICATION

[Classification of voluntary homicides and psychiatry] Bénézech M. **Ann Med Psychol (Paris)** 1996 Jun; 154(3):161-73 (45 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Psychoneuroimmunology and cancer: historical perspectives and current research. Fife A, et al. **Adv Neuroimmunol** 1996; 6(2):179-90 (73 ref.)
The clinical management of co-morbidity. Pols RG. **Alcohol Alcohol Suppl** 1994;2:485-90 (35 ref.)
Behavioral and psychiatric aspects of HIV infection. Searight HR, et al. **Am Fam Physician** 1997 Mar;55(4):1227-37, 1241-2 (57 ref.)
Psychiatric and neurocognitive concomitants of systemic lupus erythematosus. Keenan PA, et al. **Ann N Y Acad Sci** 1997 Aug 14;823:69-80 (18 ref.)
Psychiatric illness and syncope. Oh JH, et al. **Cardiol Clin** 1997 May;15(2):269-75 (31 ref.)
Rationales, values, and DSM-IV: the case of "medication-induced movement disorders". Sadler JZ. **Compr Psychiatry** 1996 Nov-Dec;37(6):441-51 (59 ref.)
Psychiatric disorders in children and adolescents with mental retardation and developmental disabilities. Des Noyers Hurley A. **Curr Opin Pediatr** 1996 Aug;8(4):361-5 (35 ref.)
Rheumatic manifestations of neurologic and psychiatric diseases. Aviña-Zubieta JA, et al. **Curr Opin Rheumatol** 1997 Jan;9(1):51-5 (30 ref.)
Interventions for homeless men and women with mental illness: reducing sexual risk behaviours for HIV. Susser E, et al. **Int J STD AIDS** 1996;7 Suppl 2:66-70 (28 ref.)
The little imitator--porphyria: a neuropsychiatric disorder. Crimlisk HL. **J Neurol Neurosurg Psychiatry** 1997 Apr; 62(4):319-28 (87 ref.)
The effects of dual diagnosis on pregnancy and parenting. Mallouh C. **J Psychoactive Drugs** 1996 Oct-Dec; 28(4):367-80 (98 ref.)
Psychiatric problems among alcohol and other drug dependent women. Zweben JE. **J Psychoactive Drugs** 1996 Oct-Dec;28(4):345-66 (69 ref.)
Antidepressant drugs and the cardiovascular system: a comparison of tricylics and selective serotonin reuptake inhibitors and their relevance for the treatment of psychiatric patients with cardiovascular problems. Coupland N, et al. **J Psychopharmacol (Oxf)** 1997; 11(1):83-92 (117 ref.)
Psychiatric implications of surgical treatment of epilepsy. Krahn LE, et al. **Mayo Clin Proc** 1996 Dec;71(12):1201-4 (23 ref.)
Behavioral and emotional aspects of Tourette syndrome. Coffey BJ, et al. **Neurol Clin** 1997 May;15(2):277-89 (84 ref.)
Comorbidity of migraine and psychiatric disorders. Merikangas KR, et al. **Neurol Clin** 1997 Feb;15(1):115-23 (33 ref.)
Comorbidity and outcome in eating disorders. Herzog DB, et al. **Psychiatr Clin North Am** 1996 Dec;19(4):843-59 (90 ref.)
New rights for deaf patients; new responsibilities for mental hospitals. Raifman LJ, et al. **Psychiatr Q** 1996 Fall; 67(3):209-20 (18 ref.)
Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. Halbreich U, et al. **Schizophr Bull** 1996;22(3):447-54 (61 ref.)
Dual diagnosis: developmental disability complicated by mental illness. Bongiorno FP. **South Med J** 1996 Dec; 89(12):1142-6 (12 ref.)
[Serotonin syndrome: critical review of the literature] Baubet T, et al. **Rev Med Interne** 1997;18(5):380-7 (60 ref.) (Eng. Abstr.) **(Fre)**
[Recent research trends in diagnosis, treatment, and prevention of drug-induced extrapyramidal symptoms seen in psychiatric patients] Inada T. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Oct; 16(5):181-5 (30 ref.) (Eng. Abstr.) **(Jpn)**
[Alcohol dependence and psychiatric comorbidity. II. Clinical and therapeutic implications] Cuadrado Callejo P. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1997 Jan-Feb;25(1):34-44 (150 ref.) (Eng. Abstr.) **(Spa)**
[Alcohol dependence and psychiatric comorbidity. I. Epidemiology and etiopathogenic involvement] Cuadrado Callejo P. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 Sep-Oct;24(5):231-44 (162 ref.) (Eng. Abstr.) **(Spa)**
[Legal aspects of epilepsy and coexisting psychiatric disorders] Diez-Cuervo A. **Rev Neurol** 1997 Mar; 25(139):435-47 (26 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Child psychiatric disorder. Measures, causal mechanisms, and interventions [comment] Rutter M. **Arch Gen Psychiatry** 1997 Sep;54(9):785-9 (66 ref.) Comment on: Arch Gen Psychiatry 1997 Sep;54(9):793-9. Comment on: Arch Gen Psychiatry 1997 Sep;54(9):801-8. Comment on: Arch Gen Psychiatry 1997 Sep;54(9):809-16. Comment on: Arch Gen Psychiatry 1997 Sep;54(9):817-22. Comment on: Arch Gen Psychiatry 1997 Sep;54(9):824-30. Comment on: Arch Gen Psychiatry 1997 Sep;54(9):831-8. Comment on: Arch Gen Psychiatry 1997 Sep;54(9):839-46. Comment on: Arch Gen Psychiatry 1997 Sep;54(9):847-56. Comment on: Arch Gen Psychiatry 1997 Sep;54(9):871-6.
Identification and treatment of children's mental health problems by primary care providers: a critical review of research. Richardson LA, et al. **Arch Psychiatr Nurs** 1996 Oct;10(5):293-303 (30 ref.)
ABC of mental health. Mental health assessment. Davies T. **BMJ** 1997 May 24;314(7093):1536-9 (6 ref.)
Risk assessment in psychiatry. Maden A. **Br J Hosp Med** 1996 Jul 10-Aug 20;56(2-3):78-82 (16 ref.)
Psychopathology among Asian Americans: a model minority? Sue S, et al. **Cult Divers Ment Health** 1995;1(1):39-51 (41 ref.)
Psychiatric disorders in children and adolescents with mental retardation and developmental disabilities. Des Noyers Hurley A. **Curr Opin Pediatr** 1996 Aug;8(4):361-5 (35 ref.)
The book of names: DSM-IV in context. Jensen PS, et al. **Dev Psychopathol** 1997 Spring;9(2):231-49 (100 ref.)
Conceptualizing psychopathology: the importance of developmental profiles. Kagan J. **Dev Psychopathol** 1997 Spring;9(2):321-34 (27 ref.)
Proposal for a structured assessment of parenting based on attachment theory: theoretical background, description and initial clinical experience. Green JM. **Eur Child Adolesc Psychiatry** 1996 Sep;5(3):133-8 (46 ref.)
The DSM-IV-PC: a manual for diagnosing mental disorders in the primary care setting. deGruy FV 3rd, et al. **J Am Board Fam Pract** 1996 Jul-Aug;9(4):274-81 (14 ref.)
Experimental avoidance and behavioral disorders: a functional dimensional approach to diagnosis and treatment. Hayes SC, et al. **J Consult Clin Psychol** 1996 Dec;64(6):1152-68 (168 ref.)
Psychiatric illnesses in the elderly: a review. Jenike MA. **J Geriatr Psychiatry Neurol** 1996 Apr;9(2):57-82 (125 ref.)
Elucidating mental disorder in liaison psychiatry: the Johns Hopkins "perspectives" [editorial] Lobo A. **J Psychosom Res** 1996 Jul;41(1):7-11 (29 ref.)
Popular press diagnoses and psychiatric diagnoses. Elks ML. **Med Hypotheses** 1996 Apr;46(4):331-6 (37 ref.)
The contribution of astrocytes to the 18F-2-deoxyglucose signal in PET activation studies. Magistretti PJ, et al. **Mol Psychiatry** 1996 Dec;1(6):445-52 (92 ref.)
Emotional disturbances and their interaction with neuropsychological deficits. Reitan RM, et al. **Neuropsychol Rev** 1997 Mar;7(1):3-19 (67 ref.)
Late-life psychiatric diagnosis in DSM-IV. Martin RL. **Psychiatr Clin North Am** 1997 Mar;20(1):1-14 (18 ref.)
Measurement of aggression in psychiatric patients. Gothelf D, et al. **Psychiatry Res** 1997 Jul 4;71(2):83-95 (90 ref.)
Evaluation of screens for mental disorders in primary care: methodological issues. Leon AC, et al. **Psychopharmacol Bull** 1996;32(3):353-61 (21 ref.)
Computer-administered clinical rating scales. A rev ew. Kobak KA, et al. **Psychopharmacology (Berl)** 1996 Oct; 127(4):291-301 (70 ref.)
Dual diagnosis: developmental disability complicated by mental illness. Bongiorno FP. **South Med J** 1996 Dec; 89(12):1142-6 (12 ref.)
[Psychological autopsies in the study of suicide] Bourgeois ML. **Encephale** 1996 Dec;22 Spec No 4:46-51 (38 ref.) (Eng. Abstr.) **(Fre)**
[Testimony of the psychiatric expert from the viewpoint of the criminal judge] Schmitt B. **Arch Kriminol** 1996 Jul-Aug;198(1-2):38-54 (68 ref.) **(Ger)**
[Quantitative and topographical analysis of EEG: its application in some psychiatric disorders] Dróżdż W, et al. **Psychiatr Pol** 1995 Nov-Dec;29(6):827-38 (28 ref.) (Eng. Abstr.) **(Pol)**
[PTSD--diagnostic criteria, clinical and certification application] Heitzman J. **Psychiatr Pol** 1995 Nov-Dec; 29(6):751-66 (31 ref.) (Eng. Abstr.) **(Pol)**

DIET THERAPY

Behavioral effects of dietary neurotransmitter precursors: basic and clinical aspects. Young SN. **Neurosci Biobehav Rev** 1996 Summer;20(2):313-23 (142 ref.)

DRUG THERAPY

Clinical applications of neurotransmitter-receptor studies in geriatric neuropharmacology. Gómez-Vargas M, et al. **Acta Med Okayama** 1996 Aug;50(4):173-90 (148 ref.)
Pharmacotherapy of aggressive behavior. Pabis DJ, et al. **Ann Pharmacother** 1996 Mar;30(3):278-87 (106 ref.)
Medication development and testing in children and adolescents. Current problems, future directions [see comments] Vitiello B, et al. **Arch Gen Psychiatry** 1997 Sep; 54(9):871-6 (45 ref.) Comment in: Arch Gen Psychiatry 1997 Sep;54(9):785-9.
ABC of mental health. Psychotropic drug treatment. Pathare SR, et al. **BMJ** 1997 Sep 13;315(7109):661-4 (0 ref.)
Are psychotropic drugs at therapeutic levels a concern for

cardiologists? Burggraf GW. **Can J Cardiol** 1997 Jan; 13(1):75–80 (55 ref.)

Pharmacological treatment of psychiatric disorders in children and adolescents: focus on guidelines for the primary care practitioner. Carrey NJ, et al. **Drugs** 1996 May;51(5):750–9 (69 ref.)

Clinical relevance of response and improvement in psychopharmacology: European College of Neuropsychopharmacology. **Eur Neuropsychopharmacol** 1995 Dec;5(4):531–3 (0 ref.)

Traditional and alternative research designs and methods in clinical pediatric psychopharmacology. Fava M. **J Am Acad Child Adolesc Psychiatry** 1996 Oct; 35(10):1292–303 (20 ref.)

Regulatory issues in pediatric psychopharmacology. Laughren TP. **J Am Acad Child Adolesc Psychiatry** 1996 Oct;35(10):1276–82 (19 ref.)

The application of neuroimaging techniques to drug development. Tamminga CA, et al. **J Clin Psychiatry** 1997; 58 Suppl 10:3–6 (19 ref.)

The clinical potential of Deprenyl in neurologic and psychiatric disorders. Kuhn W, et al. **J Neural Transm Suppl** 1996;48:85–93 (51 ref.)

Psychopharmacologic management of women with common mental health problems. Clarke C, et al. **J Nurse Midwifery** 1997 May–Jun;42(3):254–74 (97 ref.)

Pregnancy outcome and neurodevelopment of children exposed in utero to psychoactive drugs: the Motherisk experience. Loebstein R, et al. **J Psychiatry Neurosci** 1997 May;22(3):192–6 (21 ref.)

Psychotropic drug use by women: could violence account for the gender difference? Mazza D, et al. **J Psychosom Obstet Gynaecol** 1996 Dec;17(4):229–34 (43 ref.)

The art and science of the psychopharmacotherapy of African Americans. Lawson WB. **Mt Sinai J Med** 1996 Oct–Nov;63(5–6):301–5 (52 ref.)

Medication noncompliance. Olfson M, et al. **New Dir Ment Health Serv** 1997 Spring;(73):39–49 (36 ref.)

The impact of clinical pharmacists on psychiatric patients. Jenkins MH, et al. **Pharmacotherapy** 1996 Jul–Aug; 16(4):708–14 (40 ref.)

Calcium channel blockers in psychiatry. Hollister LE, et al. **Prog Drug Res** 1996;47:279–92 (59 ref.)

Pharmacodynamic and pharmacokinetic considerations in geriatric psychopharmacology. Catterson ML, et al. **Psychiatr Clin North Am** 1997 Mar;20(1):205–18 (73 ref.)

Toward clinically relevant clinical trials. Arnold LE, et al. **Psychopharmacol Bull** 1997;33(1):135–42 (15 ref.)

The importance of considering non–monetary costs and benefits in selecting pharmacologic interventions in mental health. Pleil AM. **Psychopharmacol Bull** 1995;31(4):727–34 (30 ref.)

Pharmaceutical decisionmaking: pharmacoepidemiology or pharmacoeconomics--who's in the driver's seat? Zito JM, et al. **Psychopharmacol Bull** 1995;31(4):735–44 (40 ref.)

[Special characteristics of psychopharmacotherapy of elderly patients] Bauer J. **Fortschr Med** 1996 Sep 10; 114(25):297–302 (0 ref.) (Eng. Abstr.) **(Ger)**

[Therapy with selective serotonin reuptake inhibitors (SSRI). Indications, uses and risks] Ebert D. **Fortschr Med** 1996 Jul 1;114(18–19):243–7 (4 ref.) (Eng. Abstr.) **(Ger)**

[Compulsory psychiatric drug therapy in Switzerland--legislation and reality exemplified by a few clinical cases] Caduff F. **Schweiz Med Wochenschr** 1997 Apr 5;127(14):585–96 (44 ref.) (Eng. Abstr.) **(Ger)**

[Selective serotonin reuptake inhibitors (SSRI) in childhood and adolescence] Stilke D. **Z Kinder Jugenpsychiatr** 1997 May;25(2):106–16 (60 ref.) **(Ger)**

[Clinical significance of the pharmacogenetics in psychiatric and neurological syndromes] Milejski P, et al. **Neurol Neurochir Pol** 1996 Nov–Dec;30(6):997–1007 (28 ref.) (Eng. Abstr.) **(Pol)**

ECONOMICS

Veterans affairs disability compensation: a case study in countertherapeutic jurisprudence. Mossman D. **Bull Am Acad Psychiatry Law** 1996;24(1):27–44 (100 ref.)

Economic evaluations and interventions for children and adolescents with mental health problems. Knapp M. **J Child Psychol Psychiatry** 1997 Jan;38(1):3–25 (210 ref.)

Psychiatric rehabilitation: a breath of fresh air in a turbulent health-care environment. Palmer–Erbs V. **J Psychosoc Nurs Ment Health Serv** 1996 Sep;34(9):16–21 (38 ref.)

The importance of considering non–monetary costs and benefits in selecting pharmacologic interventions in mental health. Pleil AM. **Psychopharmacol Bull** 1995;31(4):727–34 (30 ref.)

Pharmaceutical decisionmaking: pharmacoepidemiology or pharmacoeconomics--who's in the driver's seat? Zito JM, et al. **Psychopharmacol Bull** 1995;31(4):735–44 (40 ref.)

Mental health care costs: paucity of measurement. McCrone P, et al. **Soc Psychiatry Psychiatr Epidemiol** 1996 Mar; 31(2):70–7 (62 ref.)

EPIDEMIOLOGY

Cognitive change, medical illness, and crash risk among older drivers: an epidemiological consideration. Wallace RB. **Alzheimer Dis Assoc Disord** 1997 Jun;11 Suppl 1:31–7 (18 ref.)

Comorbid psychiatric disorders in PTSD. Implications for research. Keane TM, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:24–34 (30 ref.)

HIV in the mentally ill. Checkley GE, et al. **Aust N Z J Psychiatry** 1996 Apr;30(2):184–94 (48 ref.)

The present state of psychiatric epidemiology. Henderson AS. **Aust N Z J Psychiatry** 1996 Feb;30(1):9–19 (66 ref.)

A reassessment of the link between mental disorder and violent behaviour, and its implications for clinical practice. Mullen PE. **Aust N Z J Psychiatry** 1997 Feb;31(1):3–11 (54 ref.)

Comorbidity (psycho) analysed. van Praag HM. **Br J Psychiatry Suppl** 1996 Jun;(30):129–34 (27 ref.)

Critical issues in the evaluation of comorbidity of psychiatric disorders. Wittchen HU. **Br J Psychiatry Suppl** 1996 Jun; (30):9–16 (40 ref.)

Genetic epidemiology. Sham P. **Br Med Bull** 1996 Jul; 52(3):408–33 (205 ref.)

Contributions of risk–factor research to developmental psychopathology. Kazdin AE, et al. **Clin Psychol Rev** 1997; 17(4):375–406 (84 ref.)

Posttraumatic stress disorder and comorbidity: recognizing the many faces of PTSD. Brady KT. **J Clin Psychiatry** 1997;58 Suppl 9:12–5 (23 ref.)

The overlap of attention deficit hyperactivity disorder with other common mental disorders. Hazell P. **J Paediatr Child Health** 1997 Apr;33(2):131–7 (60 ref.)

Substance use and HIV risk among people with severe mental illness. Cournos F, et al. **NIDA Res Monogr** 1997; 172:110–29 (47 ref.)

The course and treatment of substance use disorder in persons with severe mental illness. Mueser KT, et al. **NIDA Res Monogr** 1997;172:86–109 (76 ref.)

Contribution of genetic epidemiologic research to psychiatry. Merikangas KR. **Psychopathology** 1995;28 Suppl 1:41–50 (42 ref.)

The genetic epidemiology of psychiatric disorders: a current perspective. Kendler KS. **Soc Psychiatry Psychiatr Epidemiol** 1997 Jan;32(1):5–11 (61 ref.)

Psychiatric assessment instruments developed by the World Health Organization. Sartorius N, et al. **Soc Psychiatry Psychiatr Epidemiol** 1996 Mar;31(2):55–69 (59 ref.)

SCAN and the PSE tradition. Wing J. **Soc Psychiatry Psychiatr Epidemiol** 1996 Mar;31(2):50–4 (42 ref.)

[Contributions of epidemiology to therapeutic decisions in psychiatry] Hardy P. **Encephale** 1996 Jul–Aug;22(4):264–9 (39 ref.) (Eng. Abstr.) **(Fre)**

[Physicians as patients--on the problem of the mentally ill physician] Loevenich A, et al. **Fortschr Neurol Psychiatr** 1996 Sep;64(9):344–52 (47 ref.) (Eng. Abstr.) **(Ger)**

[Psychiatric disorders in homeless persons—Anglo–American studies of epidemiology and management (see comments)] Driessen M, et al. **Psychiatr Prax** 1997 Jul;24(4):162–6 (54 ref.) (Eng. Abstr.) Comment in: Psychiatr Prax 1997 Jul;24(4):161. **(Ger)**

[Seasonality and psychiatric emergencies] Díaz RJ, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 Sep–Oct;24(5):253–9 (43 ref.) (Eng. Abstr.) **(Spa)**

ETHNOLOGY

ABC of mental health. Mental health in a multiethnic society. Dein S. **BMJ** 1997 Aug 23;315(7106):473–6 (0 ref.)

Cultures in psychiatric nosology: the CCMD–2–R and international classification of mental disorders. Lee S. **Cult Med Psychiatry** 1996 Dec;20(4):421–72 (115 ref.)

Racism and the mental health of African Americans: the role of self and system blame. Neighbors HW, et al. **Ethn Dis** 1996 Winter–Spring;6(1–2):167–75 (53 ref.)

Issues and recommendations for the recruitment and retention of older ethnic minority adults into clinical research. Areán PA, et al. **J Consult Clin Psychol** 1996 Oct;64(5):875–80 (38 ref.)

Ethnic minority populations and mental health outcomes. Snowden LR. **New Dir Ment Health Serv** 1996 Fall; (71):79–87 (41 ref.)

Framing research on culture in psychiatric diagnosis: the case of the DSM–IV. Rogler LH. **Psychiatry** 1996 Summer; 59(2):145–55 (35 ref.)

ETIOLOGY

Mental deterioration in childhood epilepsy. Oka E, et al. **Acta Med Okayama** 1997 Aug;51(4):173–8 (14 ref.)

Research in psychopathology in patients with HIV/AIDS and psychiatric services in Spain. Ayuso Mateos JL, et al. **AIDS Care** 1996 Apr;8(2):233–9 (22 ref.)

Psychiatric implications of displacement: contributions from the psychology of place [see comments] Fullilove MT. **Am J Psychiatry** 1996 Dec;153(12):1516–23 (84 ref.) Comment in: Am J Psychiatry 1997 Sep;154(9):1328–9.

Neuropsychiatric lupus and hormones. Robinson T, et al. **Ann Med Interne (Paris)** 1996;147(4):276–80 (23 ref.)

Anti–P antibodies and neuropsychiatric lupus erythematosus. Georgescu L, et al. **Ann N Y Acad Sci** 1997 Aug 14; 823:263–9 (28 ref.)

Neuropsychiatric systemic lupus erythematosus. Stress, stroke, and seizures. Moore PM. **Ann N Y Acad Sci** 1997 Aug 14;823:1–17 (114 ref.)

Delayed neuronal degeneration results from endogenous glutamate excess. Possible role in NP–SLE. Volpe BT. **Ann N Y Acad Sci** 1997 Aug 14;823:185–7 (23 ref.)

Psychological factors in postoperative adjustment to stoma surgery. White CA, et al. **Ann R Coll Surg Engl** 1997 Jan; 79(1):3–7 (57 ref.)

Hysterectomy: social and psychosexual aspects. Ryan MM. **Baillieres Clin Obstet Gynaecol** 1997 Mar;11(1):23–36 (56 ref.)

Fortnighly review. Stress, the brain, and mental illness. Herbert J. **BMJ** 1997 Aug 30;315(7107):530–5 (47 ref.)

ABC of mental health. Mental health on the margins. Timms P, et al. **BMJ** 1997 Aug 30;315(7107):536–9 (0 ref.)

Behavioural and psychiatric aspects of silent cerebral infarction. Nagaratnam N, et al. **Br J Clin Pract** 1997 Apr–May;51(3):160–3 (24 ref.)

The grieving adult and the general practitioner: a literature review in two parts (Part 2). Woof WR, et al. **Br J Gen Pract** 1997 Aug;47(421):509–14 (108 ref.)

Childhood adversities and psychosocial disorders. Maughan B, et al. **Br Med Bull** 1997 Jan;53(1):156–69 (50 ref.)

Neuropsychiatric disorders in cancer patients. Baile WF. **Curr Opin Oncol** 1996 May;8(3):182–7 (31 ref.)

Twin and adoption studies in child and adolescent psychiatric disorders. Folstein S. **Curr Opin Pediatr** 1996 Aug; 8(4):339–47 (52 ref.)

Psychiatric symptoms, bone density and non–specific symptoms in patients with mild hypercalcemia due to primary hyperparathyroidism: a systematic overview of the literature. Okamoto T, et al. **Endocr J** 1997 Jun; 44(3):367–74 (43 ref.)

Multiple sclerosis and psychiatric disturbances: clinical aspects and a review of the literature. Giberti L, et al. **Ital J Neurol Sci** 1996 Jun;17(3):189–91 (24 ref.)

Infant development and developmental risk: a review of the past 10 years. Zeanah CH, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Feb;36(2):165–78 (119 ref.)

Neuropsychiatric lupus: getting beyond the barrier of the brain [editorial] Mevorach D, et al. **Lupus** 1996 Jun; 5(3):173–4 (32 ref.)

Behavioural problems in dementia and biochemistry: clinical aspects. Hope T, et al. **Neurodegeneration** 1996 Dec; 5(4):399–402 (6 ref.)

Emotional disturbances and their interaction with neuropsychological deficits. Reitan RM, et al. **Neuropsychol Rev** 1997 Mar;7(1):3–19 (67 ref.)

Psychological and psychosexual implications of herpes simplex virus infections. Mindel A. **Scand J Infect Dis Suppl** 1996;100:27–32 (53 ref.)

Psychosocial issues and lung cancer: a behavioral approach. Ryan LS. **Semin Oncol Nurs** 1996 Nov;12(4):318–23 (80 ref.)

Fragile X syndrome. Molecular and clinical insights and treatment issues [see comments] Hagerman RJ. **West J Med** 1997 Feb;166(2):129–37 (122 ref.) Comment in: West J Med 1997 Feb;166(2):150–1.

[Relapsing polychondritis with mental disorders: a case report] Watanabe T, et al. **Rinsho Shinkeigaku** 1997 Mar; 37(3):243–8 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Various problems in mental health care of immigrants living in Japan] Ehata K. **Seishin Shinkeigaku Zasshi** 1996; 98(9):650–6 (33 ref.) **(Jpn)**

[The induction of psychopathology by somatic disorders, medications, toxins and drugs after systemic disorders] García Toro M, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1997 Jan–Feb;25(1):50–60 (93 ref.) (Eng. Abstr.) **(Spa)**

[Systemic lupus erythematosus and the central nervous system] Rojas E, et al. **Rev Alerg** 1993 Mar–Apr;40(2):46–9 (49 ref.) (Eng. Abstr.) **(Spa)**

[Mental disorders in HIV–1 infection] Lozano Suárez M, et al. **Rev Clin Esp** 1996 Nov;196(11):774–84 (120 ref.) **(Spa)**

GENETICS

Psychiatric genetics. Craddock N. **Br J Psychiatry** 1996 Sep; 169(3):386–92 (75 ref.)

Genetic epidemiology. Sham P. **Br Med Bull** 1996 Jul; 52(3):408–33 (205 ref.)

Implications of genetic research for child psychiatry [see comments] Rutter M. **Can J Psychiatry** 1997 Aug; 42(6):569–76 (115 ref.) Comment in: Can J Psychiatry 1997 Aug;42(6):561–2.

Genetic factors in the etiology of child psychiatric disorders. Skuse DH. **Curr Opin Pediatr** 1997 Aug;9(4):354–60 (76 ref.)

Epigenetic approaches to developmental psychopathology. Goldsmith HH, et al. **Dev Psychopathol** 1997 Spring; 9(2):365–87 (105 ref.)

A paradigmatic shift in the approach to neuropsychiatric gene linkage may require an anthropogenetic perspective. Gericke GS. **Med Hypotheses** 1995 Dec;45(6):517–22 (65 ref.)

Modern molecular genetic approaches to complex traits: implications for psychiatric disorders [see comments] Owen MJ, et al. **Mol Psychiatry** 1996 Mar;1(1):21–6 (58 ref.) Comment in: Mol Psychiatry 1996 Mar;1(1):15.

Association studies in psychiatric genetics [editorial] Owen MJ, et al. **Mol Psychiatry** 1997 Jul;2(4):270–3 (21 ref.)

Contribution of genetic epidemiologic research to psychiatry. Merikangas KR. **Psychopathology** 1995;28 Suppl 1:41–50

(42 ref.)

The genetic epidemiology of psychiatric disorders: a current perspective. Kendler KS.
Soc Psychiatry Psychiatr Epidemiol 1997 Jan;32(1):5–11 (61 ref.)

The TiPS/TINS lecture. Catecholamines: from gene regulation to neuropsychiatric disorders. Mallet J.
Trends Pharmacol Sci 1996 Apr;17(4):129–35 (69 ref.)

[Genetic information and counseling in psychiatry?] Kringlen E. **Tidsskr Nor Laegeforen** 1997 Jun 20;117(16):2347–50 (23 ref.) **(Nor)**

IMMUNOLOGY

Neuroimmune mechanisms in health and disease: 2. Disease. Anisman H, et al. **Can Med Assoc J** 1996 Oct 15; 155(8):1075–82 (63 ref.)

[Role of the cytokine network in the CNS and psychiatric disorders] Müller N. **Nervenarzt** 1997 Jan;68(1):11–20 (117 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Magnetic resonance spectroscopy in psychiatry: basic principles and applications. Frangou S, et al.
Br Med Bull 1996 Jul;52(3):474–85 (43 ref.)

Hedonic valence, dopamine and motivation. Koob GF.
Mol Psychiatry 1996 Jul;1(3):186–9 (27 ref.)

Possible mechanisms for atrophy of the human hippocampus. McEwen BS. **Mol Psychiatry** 1997 May;2(3):255–62 (71 ref.)

Behavioural problems in dementia and biochemistry: clinical aspects. Hope T, et al. **Neurodegeneration** 1996 Dec; 5(4):399–402 (6 ref.)

MORTALITY

Mortality and medical comorbidity among psychiatric patients: a review. Felker B, et al. **Psychiatr Serv** 1996 Dec; 47(12):1356–63 (67 ref.)

NURSING

The psychiatric advanced practice nurse with prescriptive authority: role development, practice issues, and outcomes measurement. Cornwell C, et al. **Arch Psychiatr Nurs** 1997 Apr;11(2):57–65 (36 ref.)

Towards a rhetoric of spirituality in mental health care. Nolan P, et al. **J Adv Nurs** 1997 Aug;26(2):289–94 (27 ref.)

Sexuality, sexual abuse. Omissions in admissions? Sharkey VB. **J Adv Nurs** 1997 May;25(5):1025–32 (56 ref.)

Catastrophic consequences secondary to psychotropic drugs, Part 1. Keltner NL.
J Psychosoc Nurs Ment Health Serv 1997 Apr;35(4):41–5 (35 ref.)

PATHOLOGY

Structural brain imaging in biological psychiatry. Lewis S. **Br Med Bull** 1996 Jul;52(3):465–73 (33 ref.)

The accumbens: beyond the core-shell dichotomy. Heimer L, et al. **J Neuropsychiatry Clin Neurosci** 1997 Summer; 9(3):354–81 (154 ref.)

Transgenic modeling of neuropsychiatric disorders. Campbell IL, et al. **Mol Psychiatry** 1996 May;1(2):105–20 (148 ref.)

PHYSIOPATHOLOGY

Modifiable neuronal connections: an overview for psychiatrists. Jeffery KJ, et al. **Am J Psychiatry** 1997 Feb; 154(2):156–64 (35 ref.)

Neuropsychiatric manifestations of right hemisphere lesions. Cummings JL. **Brain Lang** 1997 Mar;57(1):22–37 (85 ref.)

The relationship of endogenous cortisol to psychiatric disorder: a review. Kiraly SJ, et al. **Can J Psychiatry** 1997 May;42(4):415–20 (85 ref.)

Event-related potentials in brain-injured patients with neuropsychological disorders: a review. Viggiano MP.
J Clin Exp Neuropsychol 1996 Oct;18(5):631–47 (109 ref.)

rCBF SPECT in Parkinson's disease patients with mental dysfunction. Bissessur S, et al. **J Neural Transm Suppl** 1997; 50:25–30 (38 ref.)

Auras and experiential responses arising in the temporal lobe. Fried I. **J Neuropsychiatry Clin Neurosci** 1997 Summer; 9(3):420–8 (45 ref.)

The limbic system: an anatomic, phylogenetic, and clinical perspective. Mega MS, et al.
J Neuropsychiatry Clin Neurosci 1997 Summer;9(3):315–30 (101 ref.)

Paroxysmal limbic disorders in neuropsychiatry. Salloway S, et al. **J Neuropsychiatry Clin Neurosci** 1997 Summer; 9(3):403–19 (37 ref.)

The thalamus and neuropsychiatric illness. Scheibel AB.
J Neuropsychiatry Clin Neurosci 1997 Summer;9(3):342–53 (94 ref.)

Computer modeling: a new approach to the investigation of disease [editorial] Reggia JA, et al. **MD Comput** 1997 May–Jun;14(3):160, 162, 164 passim (27 ref.)

The placebo effect on mood and behavior: the role of the endogenous opioid system. Sher L. **Med Hypotheses** 1997 Apr;48(4):347–9 (32 ref.)

Sleep in psychiatric disorders. Benca RM. **Neurol Clin** 1996 Nov;14(4):739–64 (140 ref.)

Substantia innominata: a notion which impedes clinical-anatomical correlations in neuropsychiatric disorders. Heimer L, et al. **Neuroscience** 1997 Feb; 76(4):957–1006 (562 ref.)

Review of experimental male-mediated behavioral and neurochemical disorders. Nelson BK, et al.
Neurotoxicol Teratol 1996 Nov–Dec;18(6):611–6 (69 ref.)

Serotonin, sex, and psychiatric illness [see comments] Heninger GR. **Proc Natl Acad Sci U S A** 1997 May 13; 94(10):4823–4 (26 ref.) Comment in: Proc Natl Acad Sci U S A 1997 May 13;94(10):5308–13.

Psychosocial factors and their role in symptomatic gastroesophageal reflux disease and functional dyspepsia. Wiklund I, et al. **Scand J Gastroenterol Suppl** 1996; 220:94–100 (68 ref.)

Linking mind and brain in the study of mental illnesses: a project for a scientific psychopathology. Andreasen NC. **Science** 1997 Mar 14;275(5306):1586–93 (55 ref.)

The TiPS/TINS lecture. Catecholamines: from gene regulation to neuropsychiatric disorders. Mallet J.
Trends Pharmacol Sci 1996 Apr;17(4):129–35 (69 ref.)

[Psychopathology and cognitive neurosciences: theoretical conflicts and experimental paradigms] Jouvent R, et al.
Encephale 1997 Jun;23 Spec No 3:9–14 (30 ref.) (Eng. Abstr.) **(Fre)**

[Event related brain potentials as indicators of neurochemical dysfunctions in psychiatric patients] Hegerl U, et al.
Nervenarzt 1996 May;67(5):360–8 (67 ref.) (Eng. Abstr.) **(Ger)**

[Neuronal networks and psychopathology] Spitzer M.
Nervenarzt 1997 Jan;68(1):21–37 (74 ref.) (Eng. Abstr.) **(Ger)**

[Aging and mental disorders] Nishimura T.
Nippon Ronen Igakkai Zasshi 1996 Jan;33(1):1–3 (2 ref.) **(Jpn)**

[Psychiatric complications of L-dopa: physiopathology and treatment] Castro-García A. **Rev Neurol** 1997 Aug;25 Suppl 2:S157–62 (70 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

National research agenda for prevention research. The National Institute of Mental Health Report [see comments] Reiss D, et al. **Am Psychol** 1996 Nov;51(11):1109–15 (10 ref.) Comment in: Am Psychol 1996 Nov;51(11):1130–3.

Psychiatry and the Health of the Nation: the view from the Department of Health. Jenkins R. **Br J Hosp Med** 1996 Aug 21–Sep 3;56(4):155–8 (26 ref.)

Psychiatric interventions for prevention of mental disorders. A psychosocial perspective. Dalgard OS, et al.
Int J Technol Assess Health Care 1996 Fall;12(4):604–17 (24 ref.)

Meeting the challenge of adolescent mental health [editorial] Patton GC. **Med J Aust** 1997 Apr 21;166(8):399–400 (18 ref.)

PSYCHOLOGY

Co-factors for smoking and evolutionary psychobiology. Pomerleau CS. **Addiction** 1997 Apr;92(4):397–408 (115 ref.)

Disordered views of aggressive children. A late twentieth century perspective. Richters JE. **Ann N Y Acad Sci** 1996 Sep 20;794:208–23 (65 ref.)

Families of psychiatric patients: a critical review and future research directions. Rose LE. **Arch Psychiatr Nurs** 1996 Apr;10(2):67–76 (57 ref.)

Psychiatric symptom-provoking studies: an ethical appraisal. Miller FG, et al. **Biol Psychiatry** 1997 Sep 1;42(5):403–9 (32 ref.)

A process view of the self. DeWaele M.
Br J Med Psychol 1996 Dec;69 (Pt 4):299–311 (66 ref.)

Neuropsychiatric manifestations of right hemisphere lesions. Cummings JL. **Brain Lang** 1997 Mar;57(1):22–37 (85 ref.)

Poverty and mental illness. Saraceno B, et al.
Can J Psychiatry 1997 Apr;42(3):285–90 (42 ref.)

Psychopathology among Asian Americans: a model minority? Sue S, et al. **Cult Divers Ment Health** 1995;1(1):39–51 (41 ref.)

A person-oriented approach in research on developmental psychopathology. Bergman LR, et al. **Dev Psychopathol** 1997 Spring;9(2):291–319 (120 ref.)

The Hubble hypothesis and the developmentalist's dilemma. Richters JE. **Dev Psychopathol** 1997 Spring;9(2):193–9 (120 ref.)

Integrating nature and nurture: implications of person-environment correlations and interactions for developmental psychopathology. Rutter M, et al.
Dev Psychopathol 1997 Spring;9(2):335–64 (270 ref.)

Psychopathology as an outcome of development. Sroufe LA.
Dev Psychopathol 1997 Spring;9(2):251–68 (95 ref.)

When is development disordered? Developmental psychopathology and the harmful dysfunction analysis of mental disorder. Wakefield JC. **Dev Psychopathol** 1997 Spring;9(2):269–90 (52 ref.)

Recent undesirable life events: their influence on subsequent psychopathology. Goodyer IM.
Eur Child Adolesc Psychiatry 1996;5 Suppl 1:33–7 (29 ref.)

Psychosocial assessment of organ transplant candidates and the Americans with Disabilities Act. Orentlicher D.
Gen Hosp Psychiatry 1996 Nov;18(6 Suppl):5S–12S (24 ref.)

Psychopathology in infancy. Zeanah CH, et al.
J Child Psychol Psychiatry 1997 Jan;38(1):81–99 (200 ref.)

Event-related potentials in brain-injured patients with neuropsychological disorders: a review. Viggiano MP.
J Clin Exp Neuropsychol 1996 Oct;18(5):631–47 (109 ref.)

Epilogue: bridging the gap between research on attachment and psychopathology. del Carmen R, et al.
J Consult Clin Psychol 1996 Apr;64(2):291–4 (33 ref.)

Introduction to the special section on attachment and psychopathology: 2. Overview of the field of attachment. Main M. **J Consult Clin Psychol** 1996 Apr;64(2):237–43 (50 ref.)

Adolescent attachment and psychopathology. Rosenstein DS, et al. **J Consult Clin Psychol** 1996 Apr;64(2):244–53 (45 ref.)

The social context of mental illness and violence. Hiday VA.
J Health Soc Behav 1995 Jun;36(2):122–37 (143 ref.)

Auras and experiential responses arising in the temporal lobe. Fried I. **J Neuropsychiatry Clin Neurosci** 1997 Summer; 9(3):420–8 (45 ref.)

Walking a mile in their shoes... Symbolic interactionism for families living with severe mental illness. Saunders J.
J Psychosoc Nurs Ment Health Serv 1997 Jun;35(6):8–13 (24 ref.)

Psychotropic drug use by women: could violence account for the gender difference? Mazza D, et al.
J Psychosom Obstet Gynaecol 1996 Dec;17(4):229–34 (43 ref.)

Creativity: is there a worm in the apple? [see comments] Frosch WA. **J R Soc Med** 1996 Sep;89(9):506–8 (19 ref.) Comment in: J R Soc Med 1996 Dec;89(12):728.

Considerations for research on consumer empowerment and psychosocial interventions. Corrigan PW, et al.
Psychiatr Serv 1997 Mar;48(3):347–52 (59 ref.)

Risk appraisal and management of violent behavior. Harris GT, et al. **Psychiatr Serv** 1997 Sep;48(9):1168–76 (132 ref.)

Suicide and mental disorders. Asukai N.
Psychiatry Clin Neurosci 1995 May;49 Suppl 1:S91–7 (42 ref.)

Mental disorders and suicide prevention. Lönnqvist JK, et al. **Psychiatry Clin Neurosci** 1995 May;49 Suppl 1:S111–6 (37 ref.)

Research on homeless men and women: existential-humanistic and clinical thinking. Sumerlin JR, et al. **Psychol Rep** 1997 Jun;80(3 Pt 2):1303–14 (55 ref.)

Measures of quality of life among persons with severe and persistent mental disorders. Lehman AF.
Soc Psychiatry Psychiatr Epidemiol 1996 Mar;31(2):78–88 (26 ref.)

Measuring the quality of life of severely mentally ill people using the Lancashire Quality of Life Profile. Oliver JP, et al. **Soc Psychiatry Psychiatr Epidemiol** 1997 Feb; 32(2):76–83 (24 ref.)

Chronic cocaine use as a neuropsychiatric syndrome: a model for debate. Cadet JL, et al. **Synapse** 1996 Jan;22(1):28–34 (77 ref.)

[Classification of voluntary homicides and psychiatry] Bénézech M. **Ann Med Psychol (Paris)** 1996 Jun; 154(3):161–73 (45 ref.) (Eng. Abstr.) **(Fre)**

[Philosophical principles of psychopathology] Wienbruch U.
Fortschr Neurol Psychiatr 1996 Oct;64(10):375–81 (42 ref.) (Eng. Abstr.) **(Ger)**

[Life change event--life history--life plant: psychopathologic and forensic aspects] Janzarik W.
Nervenarzt 1996 Jul;67(7):545–51 (15 ref.) (Eng. Abstr.) **(Ger)**

[Open self-injury behavior with special reference to child and adolescent psychiatry. A review of the literature and first study findings] Wewetzer G, et al.
Z Kinder Jugenpsychiatr 1997 May;25(2):95–105 (57 ref.) (Eng. Abstr.) **(Ger)**

[Various problems in mental health care of immigrants living in Japan] Ehata K. **Seishin Shinkeigaku Zasshi** 1996; 98(9):650–6 (33 ref.) **(Jpn)**

[Research on siblings of mentally ill and retarded persons. Review of literature] Namysłowska I. **Psychiatr Pol** 1996 Nov–Dec;30(6):907–18 (29 ref.) (Eng. Abstr.) **(Pol)**

[The practical problems in the orthodontic treatment of middle-aged and elderly patients with mental diseases] Shvartszaid EE. **Stomatologiia (Mosk)** 1996;75(4):48–53 (58 ref.) (Eng. Abstr.) **(Rus)**

RADIONUCLIDE IMAGING

rCBF SPECT in Parkinson's disease patients with mental dysfunction. Bissessur S, et al. **J Neural Transm Suppl** 1997; 50:25–30 (38 ref.)

REHABILITATION

Behavior therapy empowers persons with severe mental illness. Corrigan PW. **Behav Modif** 1997 Jan;21(1):45–61 (70 ref.)

Psychosocial rehabilitation and psychiatry: what are the boundaries? Bachrach LL. **Can J Psychiatry** 1996 Feb; 41(1):28–35 (55 ref.)

Treatment of the mentally ill physician. Myers MF.
Can J Psychiatry 1997 Aug;42(6):12 p. (43 ref.) **(Eng, Fre)**

Consultation to residential psychosocial rehabilitation agencies. Kupers TA. **Community Ment Health J** 1996 Aug; 32(4):403–13; discussion 415–8 (32 ref.)

New directions for treatment research on sequelae of sexual abuse in persons with severe mental illness. Rosenberg SD, et al. **Community Ment Health J** 1996 Aug;32(4):387–400 (75 ref.)

Process over person?: occupational therapy students' fieldwork experiences of people in psychiatric settings.

Lyons M. **Disabil Rehabil** 1996 Apr;18(4):197–204 (51 ref.)
Forensic conditional release programs and outcomes in three states. Wiederanders MR, et al. **Int J Law Psychiatry** 1997 Spring;20(2):249–57 (19 ref.)
Assessing psychiatric care settings. Hospitalization versus outpatient care. Durham ML, et al. **Int J Technol Assess Health Care** 1996 Fall;12(4):618–33 (98 ref.)
Mental illness and the Americans with Disabilities Act. Understanding the fundamentals. Wasserbauer LI. **J Psychosoc Nurs Ment Health Serv** 1997 Jan;35(1):22–6 (13 ref.)
Can psychiatric and chemical dependency treatment units be smoke free? Patten CA, et al. **J Subst Abuse Treat** 1996 Mar–Apr;13(2):107–18 (77 ref.)
Outcomes of psychiatric rehabilitation service delivery. Cook JA, et al. **New Dir Ment Health Serv** 1996 Fall;(71):33–47 (74 ref.)
Patients' quality of life: a continuing concern in the literature. Bachrach LI. **Psychiatr Serv** 1996 Dec;47(12):1305–6, 1330 (15 ref.)
An update on supported employment for people with severe mental illness. Bond GR, et al. **Psychiatr Serv** 1997 Mar; 48(3):335–46 (101 ref.)
Assessing clinical outcomes: the community functioning of persons with serious mental illness. Dickerson FB. **Psychiatr Serv** 1997 Jul;48(7):897–902 (51 ref.)
Predictors of receipt of aftercare and recidivism among persons with severe mental illness: a review. Klinkenberg WD, et al. **Psychiatr Serv** 1996 May;47(5):487–96 (117 ref.)
Factors associated with the outcome of adults treated in psychiatric hospitals: a synthesis of findings. Pfeiffer SI, et al. **Psychiatr Serv** 1996 Mar;47(3):263–9 (69 ref.)
Principles for assessment of patient outcomes in mental health care. Smith GR Jr, et al. **Psychiatr Serv** 1997 Aug; 48(8):1033–6 (14 ref.)
A behavioral diagnostic paradigm for integrating behavior-analytic and psychopharmacological interventions for people with a dual diagnosis. Pyles DA, et al. **Res Dev Disabil** 1997 May–Jun;18(3):185–214 (60 ref.)
Quality of mental health service care: the forgotten pathway from process to outcome. Brugha TS, et al. **Soc Psychiatry Psychiatr Epidemiol** 1996 Mar;31(2):89–98 (72 ref.)
The strengths perspective in social work practice: extensions and cautions. Saleebey D. **Soc Work** 1996 May; 41(3):296–305 (55 ref.)
[Horseback riding as a means of treatment and rehabilitation in neurology and psychiatry] Gurvich PT. **Zh Nevrol Psikhiatr Im S S Korsakova** 1997;97(8):65–7 (0 ref.) **(Rus)**

SURGERY

The frontal lobes and neurosurgery for psychiatric disorders. Malizia AL. **J Psychopharmacol (Oxf)** 1997;11(2):179–87 (100 ref.)

THERAPY

The clinical management of co-morbidity. Pols RG. **Alcohol Alcohol Suppl** 1994;2:485–90 (35 ref.)
The economic impact of psychotherapy: a review. Gabbard GO, et al. **Am J Psychiatry** 1997 Feb;154(2):147–55 (47 ref.)
Half a century of ECT use in young people. Rey JM, et al. **Am J Psychiatry** 1997 May;154(5):595–602 (96 ref.)
Clinical experience with electroconvulsive therapy at the Instituto Mexicano de Psiquiatría. Sánchez de Carmona Luna Y Parra M, et al. **Arch Med Res** 1996 Autumn; 27(3):339–43 (44 ref.)
Informed consent by children and adolescents to psychiatric treatment. Batten DA. **Aust N Z J Psychiatry** 1996 Oct; 30(5):623–9; discussion 630–2 (24 ref.)
Gender, race and poverty: bringing the sociopolitical into psychotherapy. Krawitz R, et al. **Aust N Z J Psychiatry** 1997 Aug;31(4):474–9 (30 ref.)
Swimming against the tide? A review of the therapeutic community. Schimmel P. **Aust N Z J Psychiatry** 1997 Feb; 31(1):120–7 (31 ref.)
Cognitive behaviour therapy—clinical applications. Enright SJ. **BMJ** 1997 Jun 21;314(7097):1811–6 (84 ref.)
ABC of mental health. Mental health in old age. Macdonald AJ. **BMJ** 1997 Aug 16;315(7105):413–7 (0 ref.)
ABC of mental health. Psychological treatments. Richardson P. **BMJ** 1997 Sep 20;315(7110):733–5 (0 ref.)
ABC of mental health. Community mental health services. White K, et al. **BMJ** 1997 Jun 21;314(7097):1817–20 (0 ref.)
The evolution of social attractiveness and its role in shame, humiliation, guilt and therapy. Gilbert P. **Br J Med Psychol** 1997 Jun;70 (Pt 2):113–47 (140 ref.)
Psychotherapy integration: its implications for psychiatry. Albeniz A, et al. **Br J Psychiatry** 1996 Nov;169(5):563–70 (20 ref.)
Evaluating the effectiveness of interventions in child psychiatry. Fonagy P. **Can J Psychiatry** 1997 Aug; 42(6):584–94 (165 ref.)
Psychotherapy outcome research in child psychiatric disorders. Pearsall DF. **Can J Psychiatry** 1997 Aug; 42(6):595–601 (62 ref.)
Health care reform and rural mental health: severe mental illness. Kane CF, et al. **Community Ment Health J** 1996 Oct;32(5):445–62 (80 ref.)
The history and future of cross-cultural psychiatric services. Moffic HS, et al. **Community Ment Health J** 1996 Dec; 32(6):581–92 (32 ref.)
Bridging the skull: electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation (rTMS) in psychiatry. Kirkcaldie M, et al. **Convuls Ther** 1997 Jun; 13(2):83–91 (55 ref.)
Deinstitutionalization and criminalization: tinkering in the interstices. Aderibigbe YA. **Forensic Sci Int** 1997 Feb 28; 85(2):127–34 (47 ref.)
Psychiatric emergencies in terminally ill cancer patients. Roth AJ, et al. **Hematol Oncol Clin North Am** 1996 Feb; 10(1):235–59 (71 ref.)
Psychiatry of the elderly: a consensus statement [editorial] Wertheimer J. **Int J Geriatr Psychiatry** 1997 Apr; 12(4):432–5 (0 ref.)
Mental health reform and inclusion of the mentally ill: dilemmas of U.S. policy-making. Rochefort DA. **Int J Law Psychiatry** 1996 Summer–Fall;19(3–4):223–37 (40 ref.)
Involuntary commitment as a psychiatric technology. Hiday VA. **Int J Technol Assess Health Care** 1996 Fall; 12(4):585–603 (121 ref.)
Assessing outcome in psychoanalysis and long-term dynamic psychotherapy. Marshall RD, et al. **J Am Acad Psychoanal** 1996 Winter;24(4):575–604 (150 ref.)
More theory-driven and less diagnosis-based behavior therapy. Eifert GH. **J Behav Ther Exp Psychiatry** 1996 Jun;27(2):75–86 (50 ref.)
How can behavior therapy treat the same disorder with different techniques and different disorders with the same technique? [see comments] Gavino A, et al. **J Behav Ther Exp Psychiatry** 1996 Jun;27(2):107–17 (50 ref.) Comment in: J Behav Ther Exp Psychiatry 1996 Sep;27(3):311–2.
A model for developing effective treatments: progression and interplay of theory, research, and practice. Kazdin AE. **J Clin Child Psychol** 1997 Jun;26(2):114–29 (66 ref.)
Experimental avoidance and behavioral disorders: a functional dimensional approach to diagnosis and treatment. Hayes SC, et al. **J Consult Clin Psychol** 1996 Dec;64(6):1152–68 (168 ref.)
The appropriate role for the state hospital. Belcher JR, et al. **J Ment Health Adm** 1997 Winter;24(1):64–71 (63 ref.)
Services for perinatal women with substance abuse and mental health disorders: the unmet need. Grella CE. **J Psychoactive Drugs** 1997 Jan–Mar;29(1):67–78 (53 ref.)
Background and overview of mental health and substance abuse treatment systems: meeting the needs of women who are pregnant or parenting. Grella CE. **J Psychoactive Drugs** 1996 Oct–Dec;28(4):319–43 (236 ref.)
The placebogenic phenomenon: art in psychiatric nursing. Blair DT. **J Psychosoc Nurs Ment Health Serv** 1996 Aug; 34(8):11–5 (24 ref.)
Psychiatric implications of surgical treatment of epilepsy. Krahn LE, et al. **Mayo Clin Proc** 1996 Dec;71(12):1201–4 (23 ref.)
Halachic perspective on involuntary psychiatric care of the mentally ill. Cohen DA, et al. **Med Law** 1995;14(5–6):463–9 (32 ref.)
Meaningful linkage practices: challenges and opportunities. Boyer CA. **New Dir Ment Health Serv** 1997 Spring; (73):87–101 (54 ref.)
What drives outcomes for emotional and behavioral disorders in children and adolescents? Burns BJ. **New Dir Ment Health Serv** 1996 Fall;(71):89–102 (44 ref.)
The challenges of managed care. Mechanic D. **New Dir Ment Health Serv** 1997 Spring;(73):5–10 (3 ref.)
The psychiatric unit comes to the general hospital: a history of the movement. Walkup J. **New Dir Ment Health Serv** 1997 Spring;(73):11–23 (62 ref.)
Immunotherapy for brain diseases and mental illnesses. Singh VK. **Prog Drug Res** 1997;48:129–46 (100 ref.)
Is psychotherapy ever medically necessary? Bennett MJ. **Psychiatr Serv** 1996 Sep;47(9):966–70 (23 ref.)
Does managed care permit appropriate use of psychotherapy? Borenstein DB. **Psychiatr Serv** 1996 Sep;47(9):971–4 (41 ref.)
Issues in the treatment of lesbian women and gay men with chronic mental illness. Hellman RE. **Psychiatr Serv** 1996 Oct;47(10):1093–8 (54 ref.)
Continuity of care for the severely mentally ill: concepts and measures. Johnson S, et al. **Soc Psychiatry Psychiatr Epidemiol** 1997 Apr;32(3):137–42 (25 ref.)
Measuring the quality of life of severely mentally ill people using the Lancashire Quality of Life Profile. Oliver JP, et al. **Soc Psychiatry Psychiatr Epidemiol** 1997 Feb; 32(2):76–83 (24 ref.)
Olfactory remediation: current evidence and possible applications. Martin GN. **Soc Sci Med** 1996 Jul;43(1):63–70 (75 ref.)
[Filters in mental health care for the elderly. A literature study of the prevalence of psychiatric problems and the utilization of care by the elderly] Depla MF. **Tijdschr Gerontol Geriatr** 1996 Oct;27(5):206–14 (29 ref.) (Eng. Abstr.) **(Dut)**
[The imagery of geometrical figures in psychiatry] Marchais P. **Ann Med Psychol (Paris)** 1996 Jun;154(4):266–70; discussion 270–1 (10 ref.) (Eng. Abstr.) **(Fre)**
[The importance of hypnosis in psychiatry] Schäfer ML. **Fortschr Neurol Psychiatr** 1997 Jul;65(7):304–12 (69 ref.) (Eng. Abstr.) **(Ger)**
[Family therapy and work with relatives in various psychiatric diseases] Wiedemann G, et al. **Nervenarzt** 1996 Jul;67(7):524–44 (182 ref.) (Eng. Abstr.) **(Ger)**
[What is supportive psychotherapy?] Wöller W, et al. **Nervenarzt** 1996 Mar;67(3):249–52 (17 ref.) (Eng. Abstr.) **(Ger)**
[Results of research on therapeutic factors and treatment effectiveness of group therapy with adolescent patients] Tschuschke V. **Prax Kinderpsychol Kinderpsychiatr** 1996 Feb;45(2):38–47 (85 ref.) (Eng. Abstr.) **(Ger)**
[Mother-child treatment in psychiatry. I: Overview of experiences up to now] Hartmann HP. **Psychiatr Prax** 1997 Mar;24(2):56–60 (56 ref.) (Eng. Abstr.) **(Ger)**
[Behavioral disorders in psittacines. 2: Therapeutic measures] Hollmann P. **Tierarztl Prax** 1997 Jul;25(4):356–62 (46 ref.) (Eng. Abstr.) **(Ger)**
[History of mental disease therapy—concept of the diseases and method of the therapy] Yagi K, et al. **Seishin Shinkeigaku Zasshi** 1996;98(9):603–11 (0 ref.) **(Jpn)**
[Phototherapy in neurology and psychiatry] Levin IaI, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996; 96(3):107–12 (100 ref.) **(Rus)**

MENTAL DISORDERS, ORGANIC see **ORGANIC MENTAL DISORDERS**

MENTAL DISORDERS, ORGANIC, PSYCHOTIC see **ORGANIC MENTAL DISORDERS, PSYCHOTIC**

MENTAL DISORDERS, ORGANIC, SUBSTANCE-INDUCED see **ORGANIC MENTAL DISORDERS, SUBSTANCE-INDUCED**

MENTAL HEALING

The healing power of pets: a look at animal-assisted therapy. Dossey L. **Altern Ther Health Med** 1997 Jul;3(4):8–16 (31 ref.)
The magic of science and the science of magic: an essay on the process of healing. Coe RM. **J Health Soc Behav** 1997 Mar;38(1):1–8 (47 ref.)

MENTAL HEALTH

Psychiatric implications of displacement: contributions from the psychology of place [see comments] Fullilove MT. **Am J Psychiatry** 1996 Dec;153(12):1516–23 (84 ref.) Comment in: Am J Psychiatry 1997 Sep;154(9):1328–9.
Approaches to measuring quality of life and their relevance to mental health. Stedman T. **Aust N Z J Psychiatry** 1996 Dec;30(6):731–40 (65 ref.)
ABC of mental health. Mental health and the law. Barker A. **BMJ** 1997 Sep 6;315(7108):590–2 (0 ref.)
ABC of mental health. Mental health assessment. Davies T. **BMJ** 1997 May 24;314(7093):1536–9 (6 ref.)
Politics and South African mental health: hope, truth, and reconciliation. Comas-Díaz L, et al. **Cult Divers Ment Health** 1996;2(2):133–8 (14 ref.)
Fundamental analysis in research on well-being: distress and the sense of control. Mirowsky J, et al. **Gerontologist** 1996 Oct;36(5):584–94 (26 ref.)
Towards a rhetoric of spirituality in mental health care. Nolan P, et al. **J Adv Nurs** 1997 Aug;26(2):289–94 (27 ref.)
Integration of therapeutic approaches: a new direction for mental health nurses? Wilshaw G. **J Adv Nurs** 1997 Jul; 26(1):15–9 (17 ref.)
Trajectories of poverty and children's mental health. Mcleod JD, et al. **J Health Soc Behav** 1996 Sep;37(3):207–20 (46 ref.)
Public mental health. II: The psychological dimension. Curle A. **Med Confl Surviv** 1997 Jan–Mar;13(1):26–36 (3 ref.)
Public mental health. III: Hatred and reconciliation. Curle A. **Med Confl Surviv** 1997 Jan–Mar;13(1):37–47 (2 ref.)
Psychosocial disorders in young people: on the agenda but not on the mend. Eckersley R. **Med J Aust** 1997 Apr 21; 166(8):423–4 (23 ref.)
Meeting the challenge of adolescent mental health [editorial] Patton GC. **Med J Aust** 1997 Apr 21;166(8):399–400 (18 ref.)
Mental and physical health effects of intimate partner violence on women and children. Campbell JC, et al. **Psychiatr Clin North Am** 1997 Jun;20(2):353–74 (149 ref.)
QALYs and mental health care. Chisholm D, et al. **Soc Psychiatry Psychiatr Epidemiol** 1997 Feb;32(2):68–75 (44 ref.)
[The factors affecting the mental health status and dynamics of the population] Zharikov NM, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(3):79–87 (113 ref.) (Eng. Abstr.) **(Rus)**

MENTAL HEALTH SERVICES

Mental health services in England: the 1990s. Hollingsworth EJ. **Int J Law Psychiatry** 1996 Summer–Fall;19(3–4):309–25 (73 ref.)
The Chinese equation in mental health policy and practice: order plus control equal stability. Pearson V. **Int J Law Psychiatry** 1996 Summer–Fall;19(3–4):437–58 (58 ref.)
Burnout among mental health workers: a review and a

research agenda. Leiter MP, et al. **Int J Soc Psychiatry** 1996 Summer;42(2):90–101 (46 ref.)
Stress in mental health professionals: a theoretical overview. Moore KA, et al. **Int J Soc Psychiatry** 1996 Summer; 42(2):82–9 (28 ref.)
Stress experiences of occupational therapists in mental health practice arenas: a review of the literature. Sweeney G, et al. **Int J Soc Psychiatry** 1996 Summer;42(2):132–40 (35 ref.)
Mental health service delivery in rural areas: organizational and clinical issues. Wagenfeld MO, et al. **NIDA Res Monogr** 1997;168:418–37 (59 ref.)
Quality of life as an outcome measure in evaluating mental health services: a review of the empirical evidence. Barry MM, et al. **Soc Psychiatry Psychiatr Epidemiol** 1997 Jan; 32(1):38–47 (32 ref.)
Quality of mental health service care: the forgotten pathway from process to outcome. Brugha TS, et al. **Soc Psychiatry Psychiatr Epidemiol** 1996 Mar;31(2):89–98 (72 ref.)
[Various problems in mental health care of immigrants living in Japan] Ehata K. **Seishin Shinkeigaku Zasshi** 1996; 98(9):650–6 (33 ref.) **(Jpn)**

ECONOMICS

Economic evaluation of mental health care interventions. A review. Evers SM, et al. **Health Econ** 1997 Mar–Apr; 6(2):161–77 (161 ref.)
Economic evaluations and interventions for children and adolescents with mental health problems. Knapp M. **J Child Psychol Psychiatry** 1997 Jan;38(1):3–25 (210 ref.)
Depression, use of medical services and cost–offset effects. Simon GE, et al. **J Psychosom Res** 1997 Apr;42(4):333–44 (55 ref.)
An overview of managed behavioral health care. Shore MF. **New Dir Ment Health Serv** 1996 Winter;(72):3–12 (11 ref.)
Quality of care and cost–containment in managed mental health: policy, education, research, advocacy. Dana RH, et al. **Psychol Rep** 1996 Dec;79(3 Pt 2):1395–422 (125 ref.)
Mental health care costs: paucity of measurement. McCrone P, et al. **Soc Psychiatry Psychiatr Epidemiol** 1996 Mar; 31(2):70–7 (62 ref.)

HISTORY

The Japanese mental health system and law: social and structural impediments to reform. Mandiberg JM. **Int J Law Psychiatry** 1996 Summer–Fall;19(3–4):413–35 (61 ref.)

LEGISLATION & JURISPRUDENCE

ABC of mental health. Mental health and the law. Barker A. **BMJ** 1997 Sep 6;315(7108):590–2 (0 ref.)
Mental health services in Israel at a crossroads: promises and pitfalls of mental health services in the context of the new national health insurance. Aviram U. **Int J Law Psychiatry** 1996 Summer–Fall;19(3–4):327–72 (142 ref.)
Psychiatric reform in Italy: developments since 1978. Burti L, et al. **Int J Law Psychiatry** 1996 Summer–Fall; 19(3–4):373–90 (62 ref.)
The Japanese mental health system and law: social and structural impediments to reform. Mandiberg JM. **Int J Law Psychiatry** 1996 Summer–Fall;19(3–4):413–35 (61 ref.)
Mental health reform and inclusion of the mentally ill: dilemmas of U.S. policy–making. Rochefort DA. **Int J Law Psychiatry** 1996 Summer–Fall;19(3–4):223–37 (40 ref.)
Managed care and the next generation of mental health law. Appelbaum PS. **New Dir Ment Health Serv** 1996 Winter; (72):65–9 (8 ref.)

ORGANIZATION & ADMINISTRATION

Consumer empowerment in mental health organizations: concept, benefits, and impediments. Salzer MS. **Adm Policy Ment Health** 1997 May;24(5):425–34 (28 ref.)
Research in psychopathology in patients with HIV/AIDS and psychiatric services in Spain. Ayuso Mateos JL, et al. **AIDS Care** 1996 Apr;8(2):233–9 (22 ref.)
Interpreting nullity. The Fort Bragg experiment––a comparative success or failure? Hoagwood K. **Am Psychol** 1997 May;52(5):546–50 (32 ref.)
Interpreting the Fort Bragg Children's Mental Health Demonstration Project. The cup is half full. Saxe L, et al. **Am Psychol** 1997 May;52(5):553–6 (25 ref.)
More of what? Issues raised by the Fort Bragg study. Weisz JR, et al. **Am Psychol** 1997 May;52(5):541–5 (37 ref.)
Psychiatry and the Health of the Nation: the view from the Department of Health. Jenkins R. **Br J Hosp Med** 1996 Aug 21–Sep 3;56(4):155–8 (26 ref.)
Mental health services for rural elderly: innovative service strategies. Chalifoux Z, et al. **Community Ment Health J** 1996 Oct;32(5):463–80 (70 ref.)
High touch meets high tech. Distance mental health screening for rural youth using Teleform. Puskar KR, et al. **Comput Nurs** 1996 Nov–Dec;14(6):323–9; quiz 330–2 (31 ref.)
Intercountry adoption of Latin American children: the importance of early bilingual/bicultural services. de Verthelyi RF. **Cult Divers Ment Health** 1996;2(1):53–63 (33 ref.)
Psychiatry of the elderly: a consensus statement [editorial] Wertheimer J. **Int J Geriatr Psychiatry** 1997 Apr; 12(4):432–5 (0 ref.)
Technologies for the delivery of mental health care. Mechanic D. **Int J Technol Assess Health Care** 1996 Fall; 12(4):673–87 (49 ref.)
Consumerism for neurobiological disorders. An assessment. Peschel RE, et al. **Int J Technol Assess Health Care** 1996 Fall;12(4):644–56 (40 ref.)
Foster care: an update. Rosenfeld AA, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Apr;36(4):448–57 (57 ref.)
Managed behavioral health care: a key component of integrated regional delivery systems. Nauert RC. **J Health Care Finance** 1997 Spring;23(3):49–61 (2 ref.)
Background and overview of mental health and substance abuse treatment systems: meeting the needs of women who are pregnant or parenting. Grella CE. **J Psychoactive Drugs** 1996 Oct–Dec;28(4):319–43 (236 ref.)
A sense of proportion: the place of psychiatry in medicine. Lloyd GG. **J R Soc Med** 1996 Oct;89(10):563–7 (37 ref.)
Public managed care: the role of the consultant. Cohen MD. **New Dir Ment Health Serv** 1996 Winter;(72):35–44 (5 ref.)
Managing the whole system of care. Hogan MF. **New Dir Ment Health Serv** 1996 Winter;(72):13–24 (14 ref.)
Creating incentives for the delivery of services. Hyde PS. **New Dir Ment Health Serv** 1996 Winter;(72):25–34 (19 ref.)
Advocacy and managed behavioral health care. Shore MF. **New Dir Ment Health Serv** 1996 Winter;(72):59–64 (2 ref.)
The public sector–private sector interface: current issues, future trends. Surles RC, et al. **New Dir Ment Health Serv** 1996 Winter;(72):71–9 (8 ref.)
EPPIC: an evolving system of early detection and optimal management. McGorry PD, et al. **Schizophr Bull** 1996; 22(2):305–26 (75 ref.)
Monitoring and care of young people at incipient risk of psychosis. Yung AR, et al. **Schizophr Bull** 1996; 22(2):283–303 (83 ref.)
Services for adults who have experienced child sexual assault: improving agency response. Gibbons J. **Soc Sci Med** 1996 Dec;43(12):1755–63 (48 ref.)

STANDARDS

Involving clients in clinical audits of mental health services. Balogh R, et al. **Int J Qual Health Care** 1995 Dec; 7(4):343–53 (74 ref.)
Systematic literature review: outcome measures for child and adolescent mental health services. Hunter J, et al. **J Public Health Med** 1996 Jun;18(2):197–206 (90 ref.)
The National Depressive and Manic–Depressive Association consensus statement on the undertreatment of depression [see comments] Hirschfeld RM, et al. **JAMA** 1997 Jan 22–29;277(4):333–40 (38 ref.) Comment in: JAMA 1997 May 14;277(18):1433.
What drives outcomes for emotional and behavioral disorders in children and adolescents? Burns BJ. **New Dir Ment Health Serv** 1996 Fall;(71):89–102 (44 ref.)
Toward collaborative mental health outcomes systems. Campbell J. **New Dir Ment Health Serv** 1996 Fall; (71):69–78 (45 ref.)
Outcomes of psychiatric rehabilitation service delivery. Cook JA, et al. **New Dir Ment Health Serv** 1996 Fall;(71):33–47 (74 ref.)
How will mental health outcomes data be used in private systems. Feldman J. **New Dir Ment Health Serv** 1996 Fall; (71):103–9 (10 ref.)
Ethnic minority populations and mental health outcomes. Snowden LR. **New Dir Ment Health Serv** 1996 Fall; (71):79–87 (41 ref.)
Principles for assessment of patient outcomes in mental health care. Smith GR Jr, et al. **Psychiatr Serv** 1997 Aug; 48(8):1033–6 (14 ref.)
QALYs and mental health care. Chisholm D, et al. **Soc Psychiatry Psychiatr Epidemiol** 1997 Feb;32(2):68–75 (44 ref.)
Continuity of care for the severely mentally ill: concepts and measures. Johnson S, et al. **Soc Psychiatry Psychiatr Epidemiol** 1997 Apr;32(3):137–42 (25 ref.)
Measuring the quality of life of severely mentally ill people using the Lancashire Quality of Life Profile. Oliver JP, et al. **Soc Psychiatry Psychiatr Epidemiol** 1997 Feb; 32(2):76–83 (24 ref.)

SUPPLY & DISTRIBUTION

Trauma and its sequelae in male prisoners: effects of confinement, overcrowding, and diminished services. Kupers TA. **Am J Orthopsychiatry** 1996 Apr;66(2):189–96 (65 ref.)
Health care reform and rural mental health: severe mental illness. Kane CF, et al. **Community Ment Health J** 1996 Oct;32(5):445–62 (80 ref.)

TRENDS

School–based mental health services in the United States: history, current models and needs. Flaherty LT, et al. **Community Ment Health J** 1996 Aug;32(4):341–52 (27 ref.)
Deinstitutionalization and criminalization: tinkering in the interstices. Aderibigbe YA. **Forensic Sci Int** 1997 Feb 28; 85(2):127–34 (47 ref.)
Changing patterns of mental health care in Germany. Rössler W, et al. **Int J Law Psychiatry** 1996 Summer–Fall; 19(3–4):391–411 (58 ref.)
The impact of managed mental health care on women. Newell AR, et al. **J Am Med Womens Assoc** 1997 Spring; 52(2):69–74 (58 ref.)
Patients' quality of life: a continuing concern in the literature. Bachrach LI. **Psychiatr Serv** 1996 Dec;47(12):1305–6, 1330 (15 ref.)

UTILIZATION

Research on mental health services for Hispanics: targets of convergence. Rogler LH. **Cult Divers Ment Health** 1996; 2(3):145–56 (60 ref.)
Depression, use of medical services and cost–offset effects. Simon GE, et al. **J Psychosom Res** 1997 Apr;42(4):333–44 (55 ref.)
Help–seeking among Asian and Pacific Americans: a multiperspective analysis. Yamashiro G, et al. **Soc Work** 1997 Mar;42(2):176–86 (41 ref.)
[Filters in mental health care for the elderly. A literature study of the prevalence of psychiatric problems and the utilization of care by the elderly] Depla MF. **Tijdschr Gerontol Geriatr** 1996 Oct;27(5):206–14 (29 ref.) (Eng. Abstr.) **(Dut)**

MENTAL HEALTH SERVICES, COMMUNITY see **COMMUNITY MENTAL HEALTH SERVICES**

MENTAL HOSPITALS see **HOSPITALS, PSYCHIATRIC**

MENTAL HYGIENE see **MENTAL HEALTH**

MENTAL HYGIENE SERVICES see **MENTAL HEALTH SERVICES**

MENTAL PROCESSES

A critique of social bonding and control theory of delinquency using the principles of Psychology of Mind. Kelley TM. **Adolescence** 1996 Summer;31(122):321–37 (31 ref.)
Initial management of the patient with altered mental status. Ferrera PC, et al. **Am Fam Physician** 1997 Apr; 55(5):1773–80 (20 ref.)
Event–related–potential (ERP) reflections of mental resources: a review and synthesis. Kok A. **Biol Psychol** 1997 Mar 21;45(1–3):19–56 (104 ref.)
A summary of resource theories from a behavioral perspective. Sanders AF. **Biol Psychol** 1997 Mar 21; 45(1–3):5–18 (50 ref.)
Emergent models of supple dynamics in life and mind. Bedau MA. **Brain Cogn** 1997 Jun;34(1):5–27 (48 ref.)
Computing machinery and mentality. McMullin B. **Brain Cogn** 1997 Jun;34(1):28–47 (24 ref.)
Autism and Asperger's syndrome. Towbin KE. **Curr Opin Pediatr** 1997 Aug;9(4):361–6 (51 ref.)
Radical constructivism and narrative. Gomez EA. **J Am Acad Psychoanal** 1996 Spring;24(1):1–14 (21 ref.)
Reductionism and intelligence: the case of inspection time. Deary IJ. **J Biosoc Sci** 1996 Oct;28(4):405–23 (80 ref.)
Hypnosis and phenomenological–perceptual psychology [published erratum appears in J Clin Psychol 1996 May;52(3):373] Woodard FJ. **J Clin Psychol** 1996 Mar; 52(2):209–18 (28 ref.)
Variables that influence the generation of random sequences: an update. Brugger P. **Percept Mot Skills** 1997 Apr; 84(2):627–61 (295 ref.)
The emerging conceptualization of groups as information processors. Hinsz VB, et al. **Psychol Bull** 1997 Jan; 121(1):43–64 (285 ref.)
A computational theory of executive cognitive processes and multiple–task performance: Part 1. Basic mechanisms. Meyer DE, et al. **Psychol Rev** 1997 Jan;104(1):3–65 (280 ref.)
Linking mind and brain in the study of mental illnesses: a project for a scientific psychopathology. Andreasen NC. **Science** 1997 Mar 14;275(5306):1586–93 (55 ref.)
[Metabolic, cerebral and neuropsychological characterization of Parkinson syndromes] Salmon E, et al. **Rev Med Liege** 1996 Sep;51(9):566–70 (20 ref.) **(Fre)**

PHYSIOLOGY

Keeping in mind the mind: mental functions, networks and neurosurgery. Steiger HJ, et al. **Acta Neurochir (Wien)** 1996;138(8):898–906 (48 ref.)
Mental resources, processing speed, and inhibitory control: a developmental perspective. Ridderinkhof KR, et al. **Biol Psychol** 1997 Mar 21;45(1–3):241–61 (67 ref.)
Brain, language and the origin of human mental functions. Maturana H, et al. **Biol Res** 1995;28(1):15–26 (13 ref.)
Attention control: explorations of the work of an executive controller. Gopher D. **Brain Res Cogn Brain Res** 1996 Dec; 5(1–2):23–38 (51 ref.)
Mental transformations in the motor cortex. Pellizzer G. **Brain Res Cogn Brain Res** 1996 Dec;5(1–2):123–30 (23 ref.)
Combining time and intensity effects in assessing operator information–processing load. Hendy KC, et al. **Hum Factors** 1997 Mar;39(1):30–47 (56 ref.)
Impact of information compression on intellectual activities in the brain. Eriksson JT. **Int J Neural Syst** 1996 Sep; 7(4):543–50 (14 ref.)

A descriptive framework for information processing: an integrative approach. Karakas S. **Int J Psychophysiol** 1997 Jun;26(1-3):353-68 (50 ref.)
Intention as a component of the alpha-rhythm response to mental activity. Shaw JC. **Int J Psychophysiol** 1996 Nov; 24(1-2):7-23 (140 ref.)
Intelligence is not just mental speed. Rabbitt P. **J Biosoc Sci** 1996 Oct;28(4):425-49 (72 ref.)
Olfactory information processing in the brain: encoding chemical and temporal features of odors. Christensen TA, et al. **J Neurobiol** 1996 May;30(1):82-91 (68 ref.)
Information processing in mammalian olfactory system. Sullivan SL, et al. **J Neurobiol** 1996 May;30(1):20-36 (171 ref.)
Information synthesis in key parts of the cerebral cortex as the basis of subjective experience. Ivanitskii AM. **Neurosci Behav Physiol** 1997 Jul-Aug;27(4):414-26 (64 ref.)
Some reflections on (or by?) grandmother cells [editorial] Rose D. **Perception** 1996;25(8):881-6 (26 ref.)
Information processing in the human brain: magnetoencephalographic approach. Lounasmaa OV, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20;93(17):8809-15 (41 ref.)
[Non-invasive analysis of visual information processing] Tobimatsu S. **Fukuoka Igaku Zasshi** 1997 Jun;88(6):241-6 (5 ref.) **(Jpn)**
[The cerebral basis of subjective experiences: the hypothesis of information synthesis] Ivanitskii AM. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Mar-Apr; 46(2):241-52 (41 ref.) (Eng. Abstr.) **(Rus)**
[Information synthesis in key sections of the cortex as the basis of subjective experiences] Ivanitskii AM. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 Mar-Apr; 47(2):209-25 (64 ref.) (Eng. Abstr.) **(Rus)**

MENTAL RETARDATION

see related
CRETINISM
EDUCATION OF MENTALLY RETARDED

Heterogeneity in adducted thumbs sequence. Moldavsky M, et al. **Am J Med Genet** 1997 May 16;70(2):114-7 (13 ref.)
Acute lymphoblastic leukemia in a child with the CHIME neuroectodermal dysplasia syndrome. Schnur RE, et al. **Am J Med Genet** 1997 Oct 3;72(1):24-9 (13 ref.)
Life-threatening cardiac involvement throughout life in a case of Costello syndrome. Fukao T, et al. **Clin Genet** 1996 Oct;50(4):244-7 (17 ref.)
Preference, choice, and persons with disabilities: a synopsis of assessments, interventions, and future directions. Kearney CA, et al. **Clin Psychol Rev** 1997;17(2):217-38 (176 ref.)
Classification, prevalence, prevention and rehabilitation of intellectual disability: an overview of research in the People's Republic of China. Sonnander K, et al. **J Intellect Disabil Res** 1997 Apr;41 (Pt 2):180-92 (36 ref.)
[A case of Dyke-Davidoff-Masson syndrome with total hemiatrophy] Hozumi A, et al. **Rinsho Shinkeigaku** 1996 Oct;36(10):1143-9 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Research on siblings of mentally ill and retarded persons. Review of literature] Namysłowska I. **Psychiatr Pol** 1996 Nov-Dec;30(6):907-18 (29 ref.) (Eng. Abstr.) **(Pol)**

COMPLICATIONS

Interstitial deletion of 11(p11.2p12): a newly described contiguous gene deletion syndrome involving the gene for hereditary multiple exostoses (EXT2). Potocki L, et al. **Am J Med Genet** 1996 Mar 29;62(3):319-25 (24 ref.)
Depression in adults with intellectual disability. Part 1: A review. Davis JP, et al. **Aust N Z J Psychiatry** 1997 Apr; 31(2):232-42 (85 ref.)
Psychiatric disorders in children and adolescents with mental retardation and developmental disabilities. Des Noyers Hurley A. **Curr Opin Pediatr** 1996 Aug;8(4):361-5 (35 ref.)
Comprehensive management of epilepsy in persons with mental retardation. Coulter DL. **Epilepsia** 1997;38 Suppl 4:S24-31 (45 ref.)
The role of the old and the new antiepileptic drugs in special populations: mental and multiple handicaps. Mattson RH. **Epilepsia** 1996;37 Suppl 6:S45-53 (82 ref.)
Linear and whorled nevoid hypermelanosis in a boy with mental retardation and congenital defects. Schepis C, et al. **Int J Dermatol** 1996 Sep;35(9):654-5 (10 ref.)
The health needs of adults with learning disabilities and the Health of the Nation strategy. Turner S, et al. **J Intellect Disabil Res** 1996 Oct;40 (Pt 5):438-50 (112 ref.)
[Urination disorders and neurological disease except for o obvious medullary pathology: perinatal brain lesions with mental handicap] Gautheron V. **Arch Pediatr** 1997;4 Suppl 1:37s-40s (13 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Bardet-Biedl syndrome: delayed diagnosis in a child with Hirschsprung disease [letter] Işlek I, et al. **Clin Dysmorphol** 1996 Jul;5(3):271-3 (7 ref.)
Assessment of understanding by people manifesting mental retardation: a preliminary report. Coles EM, et al. **Percept Mot Skills** 1996 Aug;83(1):187-92 (18 ref.)
[Aicardi syndrome and choroid plexus papilloma: a rare association. Case report] Aguiar MD, et al. **Arq Neuropsiquiatr** 1996 Jun;54(2):313-7 (16 ref.) (Eng. Abstr.) **(Por)**
[Neurometabolic diagnosis of mental retardation] Garcia L. **Rev Neurol** 1997 May;25(141):765-8 (13 ref.) (Eng. Abstr.) **(Spa)**

EMBRYOLOGY

Behavioral consequences of abnormal cortical development: insights into developmental disabilities. Berger-Sweeney J, et al. **Behav Brain Res** 1997 Jul;86(2):121-42 (244 ref.)

EPIDEMIOLOGY

The prevalence of mental retardation: a critical review of recent literature. Roeleveld N, et al. **Dev Med Child Neurol** 1997 Feb;39(2):125-32 (71 ref.)

ETIOLOGY

MAOA deficiency and abnormal behaviour: perspectives on an association. Brunner HG. **Ciba Found Symp** 1996; 194:155-64; discussion 164-7 (39 ref.)
[Risk factors in recurrent seizures and in mental retardation] Aicardi J. **Rev Neurol** 1997 May;25(141):754-6 (40 ref.) **(Spa)**

GENETICS

How many X-linked genes for non-specific mental retardation (MRX) are there? [letter] Gedeon AK, et al. **Am J Med Genet** 1996 Jul 12;64(1):158-62 (40 ref.)
Study of X-linked mental retardation (XLMR): summary of 61 families in the Miami/Greenwood Study. Lubs HA, et al. **Am J Med Genet** 1996 Jul 12;64(1):169-75 (34 ref.)
XLMR genes: update 1996. Lubs HA, et al. **Am J Med Genet** 1996 Jul 12;64(1):147-57 (105 ref.)
Severe mental retardation and macroorchidism without mutation in the FMR1 gene. Reyniers E, et al. **Am J Med Genet** 1996 Aug 9;64(2):408-12 (26 ref.)
Mapping of the loci for mental retardation syndromes in the distal Xq [letter] Schmidt M. **Am J Med Genet** 1996 Jul 12;64(1):163-5 (41 ref.)
X chromosome inactivation and X-linked mental retardation. Willard HF. **Am J Med Genet** 1996 Jul 12;64(1):21-6 (53 ref.)
Further delineation of 7p trisomy. Case report and review of literature. Pallotta R, et al. **Ann Genet** 1996;39(3):152-8 (26 ref.)
The genetics of mental retardation. Flint J, et al. **Br Med Bull** 1996 Jul;52(3):453-64 (71 ref.)
New autosomal recessive multiple congenital abnormalities/mental retardation syndrome with craniofacial dysmorphism absent corpus callosum, iris colobomas and connective tissue dysplasia. Temtamy SA, et al. **Clin Dysmorphol** 1996 Jul;5(3):231-40 (31 ref.)
Two brothers with multiple congenital anomalies and mental retardation due to disomy (X)(q12-->q13.3) inherited from the mother. Apacik C, et al. **Clin Genet** 1996 Aug; 50(2):63-73 (23 ref.)
Terminal deletion of the long arm of chromosome 4 in a mother and two sons. Descartes M, et al. **Clin Genet** 1996 Dec;50(6):538-40 (2 ref.)
Nonsyndromic X-linked mental retardation: review and mapping of MRX29 to Xp21. Häne B, et al. **Clin Genet** 1996 Oct;50(4):176-83 (49 ref.)
Partial trisomy 15q: report of a patient and literature review. Chandler K, et al. **Genet Couns** 1997;8(2):91-7 (25 ref.)
Del(4)(pter-->q33:) case report and review of the literature. Grammatico P, et al. **Genet Couns** 1997;8(1):39-42 (8 ref.)
Kabuki syndrome in son and low grade mosaic 45,X/46,XX in mother. Van Hagen JM, et al. **Genet Couns** 1996; 7(3):201-6 (16 ref.)
L1-associated diseases: clinical geneticists divide, molecular geneticists unite. Fransen E, et al. **Hum Mol Genet** 1997; 6(10):1625-32 (103 ref.)
Genetic influences on mild mental retardation: concepts, findings and research implications. Rutter M, et al. **J Biosoc Sci** 1996 Oct;28(4):509-26 (100 ref.)
Similarities in genetic mental retardation and neuroteratogenic syndromes. Adams J. **Pharmacol Biochem Behav** 1996 Dec;55(4):683-90 (75 ref.)
Fragile X syndrome and fragile XE mental retardation. Sutherland GR, et al. **Prenat Diagn** 1996 Dec; 16(13):1199-211 (63 ref.)
[Kohlschütter syndrome--an example of a rare progressive neuroectodermal disease. Case report and review of the literature] Wygold T, et al. **Klin Padiatr** 1996 Sep-Oct; 208(5):271-5 (4 ref.) (Eng. Abstr.) **(Ger)**
[The genetic diagnosis of children with mental retardation] Dunoyer-Mejía C. **Rev Neurol** 1997 May;25(141):759-64 (34 ref.) (Eng. Abstr.) **(Spa)**

NURSING

Health care management of children with cognitive and physical disabilities: to treat or not to treat. Mims J, et al. **J Neurosci Nurs** 1996 Aug;28(4):238-44, 250-1 (27 ref.)

PREVENTION & CONTROL

Neonatal screening for congenital hypothyroidism: results and perspectives. Delange F. **Horm Res** 1997;48(2):51-61 (116 ref.)
The problem of low birthweight, the cost and possibilities of prevention. Wynn M, et al. **Nutr Health** 1997; 11(3):159-84 (70 ref.)

PSYCHOLOGY

Sexual abuse prevention for persons with mental retardation. Lumley VA, et al. **Am J Ment Retard** 1997 Mar; 101(5):459-72 (51 ref.)
Ethical research with the developmentally disabled. Weisstub DN, et al. **Can J Psychiatry** 1997 Jun;42(5):492-6 (31 ref.)
The elderly with a learning disability (mental retardation): an overview. McCarthy JM, et al. **Int Psychogeriatr** 1996 Fall;8(3):489-501 (60 ref.)
A review of choice research with people with severe and profound developmental disabilities. Lancioni GE, et al. **Res Dev Disabil** 1996 Sep-Oct;17(5):391-411 (88 ref.)
Mental retardation and domestic violence: an ecological approach to intervention. Carlson BE. **Soc Work** 1997 Jan; 42(1):79-89 (30 ref.)

REHABILITATION

Intellectual handicap in contemporary psychiatry. Einfeld SL. **Aust N Z J Psychiatry** 1997 Aug;31(4):452-6 (14 ref.)
The potentials of virtual environments in the education and training of people with learning disabilities. Cromby JJ, et al. **J Intellect Disabil Res** 1996 Dec;40 (Pt 6):489-501 (80 ref.)
Awareness, action, and collaboration: how the self-advocacy movement is empowering for persons with developmental disabilities. Miller AB, et al. **Ment Retard** 1996 Oct; 34(5):312-9 (45 ref.)
Changing jobs: an essential part of career development. Pumpian I, et al. **Ment Retard** 1997 Feb;35(1):39-48 (50 ref.)
A behavioral diagnostic paradigm for integrating behavior-analytic and psychopharmacological interventions for people with a dual diagnosis. Pyles DA, et al. **Res Dev Disabil** 1997 May-Jun;18(3):185-214 (60 ref.)
[Combined verbal and sign language for promoting communication development in non-verbal or pre-verbal children and adolescents with mental retardation] Wilken E. **Rehabilitation (Stuttg)** 1996 Nov; 35(4):228-32 (11 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Primary care of adults with mental retardation living in the community. Martin BA. **Am Fam Physician** 1997 Aug; 56(2):485-94 (32 ref.)
Developing a technology for the use of operant extinction in clinical settings: an examination of basic and applied research. Lerman DC, et al. **J Appl Behav Anal** 1996 Fall; 29(3):345-82; discussion 383-5 (260 ref.)
Some current themes in functional analysis research. Vollmer TR, et al. **Res Dev Disabil** 1996 May-Jun;17(3):229-49 (75 ref.)

MENTAL TESTS see **INTELLIGENCE TESTS**

MENTALLY HANDICAPPED see **MENTAL RETARDATION**

MENTHOL

ADVERSE EFFECTS

African-American smokers and cancers of the lung and of the upper respiratory and digestive tracts. Is menthol part of the puzzle? Richardson TL. **West J Med** 1997 Mar; 166(3):189-94 (44 ref.)

MENTORS

The role of mentors for women in animal science: perspectives from government. Glenn BP. **J Anim Sci** 1996 Nov;74(11):2855-9 (15 ref.)
An evolutionary concept analysis of mentoring in nursing. Stewart BM, et al. **J Prof Nurs** 1996 Sep-Oct;12(5):311-21 (83 ref.)
On mentoring. Barondess JA. **J R Soc Med** 1997 Jun; 90(6):347-9 (18 ref.)

EDUCATION

Mentoring in biomedicine. Barondess JA. **J Lab Clin Med** 1997 May;129(5):487-91 (16 ref.)

MENTORSHIPS see **MENTORS**

MEPACRINE see **QUINACRINE**

MEPHENYTOIN

METABOLISM

Genetic polymorphism of S-mephenytoin 4'-hydroxylation. Daniel HI, et al. **Psychopharmacol Bull** 1996;32(2):219-30 (115 ref.)

MERCAPTAMINE see **CYSTEAMINE**

MERCAPTO COMPOUNDS see **SULFHYDRYL COMPOUNDS**

2-MERCAPTOETHANESULFONATE see **MESNA**

MERCAPTOVALINE see **PENICILLAMINE**

MERCAPTURIC ACID see **ACETYLCYSTEINE**

MERCURY

Will mercury manometers soon be obsolete? [editorial] O'Brien E. **J Hum Hypertens** 1995 Dec;9(12):933–4 (18 ref.)

Case report of metallic mercury injury. Smith SR, et al. **Pediatr Emerg Care** 1997 Apr;13(2):114–6 (14 ref.)

ADVERSE EFFECTS

The future of dental amalgam: a review of the literature. Part 6: Possible harmful effects of mercury from dental amalgam. Eley BM. **Br Dent J** 1997 Jun 28;182(12):455–9 (42 ref.)

The future of dental amalgam: a review of the literature. Part 4: Mercury exposure hazards and risk assessment. Eley BM. **Br Dent J** 1997 May 24;182(10):373–81 (36 ref.)

Can tremor be used to measure the effect of chronic mercury exposure in human subjects? Beuter A, et al. **Neurotoxicology** 1996 Spring;17(1):213–27 (46 ref.)

Neurotoxicity of mercury--indicators and effects of low-level exposure: overview. Cranmer M, et al. **Neurotoxicology** 1996 Spring;17(1):9–14 (14 ref.)

[Mercury as an allergic factor] Kieć-Swierczyńska M. **Med Pr** 1996;47(1):77–81 (33 ref.) (Eng. Abstr.) **(Pol)**

ANALYSIS

The future of dental amalgam: a review of the literature. Part 5: Mercury in the urine, blood and body organs from amalgam fillings. Eley BM. **Br Dent J** 1997 Jun 14; 182(11):413–7 (32 ref.)

The future of dental amalgam: a review of the literature. Part 2: Mercury exposure in dental practice. Eley BM. **Br Dent J** 1997 Apr 26;182(8):293–7 (38 ref.)

The future of dental amalgam: a review of the literature. Part 3: Mercury exposure from amalgam restorations in dental patients. Eley BM. **Br Dent J** 1997 May 10; 182(9):333–8 (20 ref.)

Calculation of soil-water and benthic sediment partition coefficients for mercury. Lyon BF, et al. **Chemosphere** 1997 Aug;35(4):791–808 (30 ref.)

The Swedish Environmental Specimen Bank--application in trend monitoring of mercury and some organohalogenated compounds. Odsjö T, et al. **Chemosphere** 1997 May; 34(9–10):2059–66 (28 ref.)

BLOOD

Do historic studies of fish consumers support the widely accepted LOEL for methylmercury in adults. Kosatsky T, et al. **Neurotoxicology** 1996 Spring;17(1):177–86 (30 ref.)

CHEMISTRY

The toxicology of mercury. Clarkson TW. **Crit Rev Clin Lab Sci** 1997 Aug;34(4):369–403 (80 ref.)

Mercury-responsive gene regulation and mercury-199 as a probe of protein structure. Huffman DL, et al. **Met Ions Biol Syst** 1997;34:503–26 (61 ref.)

Interaction of mercury with nucleic acids and their components. Sletten E, et al. **Met Ions Biol Syst** 1997; 34:479–501 (50 ref.)

A problem associated with the use of a calomel reference electrode in an ISE analytical system. Vitiello JD, et al. **Scand J Clin Lab Invest Suppl** 1996;224:165–71 (4 ref.)

METABOLISM

Bioaccumulation of mercury in the aquatic food chain in newly flooded areas. Bodaly RA, et al. **Met Ions Biol Syst** 1997;34:259–87 (93 ref.)

Mercury in the food web: accumulation and transfer mechanisms. Boudou A, et al. **Met Ions Biol Syst** 1997; 34:289–319 (95 ref.)

Maternal-fetal mercury transport and fetal methylmercury poisoning. Hamada R, et al. **Met Ions Biol Syst** 1997; 34:405–20 (37 ref.)

bacterial mercury-resistance genes. Hobman JL, et al. **Met Ions Biol Syst** 1997;34:527–68 (185 ref.)

Interaction of mercury with nucleic acids and their components. Sletten E, et al. **Met Ions Biol Syst** 1997; 34:479–501 (50 ref.)

PHARMACOLOGY

Distribution, diversity and evolution of the bacterial mercury resistance (mer) operon. Osborn AM, et al. **FEMS Microbiol Rev** 1997 Apr;19(4):239–62 (173 ref.)

bacterial mercury-resistance genes. Hobman JL, et al. **Met Ions Biol Syst** 1997;34:527–68 (185 ref.)

Mercury-responsive gene regulation and mercury-199 as a probe of protein structure. Huffman DL, et al. **Met Ions Biol Syst** 1997;34:503–26 (61 ref.)

The impact of mercury released from dental "silver" fillings on antibiotic resistances in the primate oral and intestinal bacterial flora. Liebert CA, et al. **Met Ions Biol Syst** 1997; 34:441–60 (69 ref.)

PHYSIOLOGY

Microbial transformation of mercury species and their importance in the biogeochemical cycle of mercury. Baldi F. **Met Ions Biol Syst** 1997;34:213–57 (187 ref.)

Physiology and toxicology of mercury. Magos L. **Met Ions Biol Syst** 1997;34:321–70 (257 ref.)

TOXICITY

The toxicology of mercury. Clarkson TW. **Crit Rev Clin Lab Sci** 1997 Aug;34(4):369–403 (80 ref.)

Microbial transformation of mercury species and their importance in the biogeochemical cycle of mercury. Baldi F. **Met Ions Biol Syst** 1997;34:213–57 (187 ref.)

Bioaccumulation of mercury in the aquatic food chain in newly flooded areas. Bodaly RA, et al. **Met Ions Biol Syst** 1997;34:259–87 (93 ref.)

Mercury in the food web: accumulation and transfer mechanisms. Boudou A, et al. **Met Ions Biol Syst** 1997; 34:289–319 (95 ref.)

Physiology and toxicology of mercury. Magos L. **Met Ions Biol Syst** 1997;34:321–70 (257 ref.)

Inhibition of brain tubulin–guanosine 5'-triphosphate interactions by mercury: similarity to observations in Alzheimer's diseased brain. Pendergrass JC, et al. **Met Ions Biol Syst** 1997;34:461–78 (35 ref.)

Effects of mercury on the immune system. Pollard KM, et al. **Met Ions Biol Syst** 1997;34:421–40 (100 ref.)

Astrocytes as modulators of mercury-induced neurotoxicity. Aschner M. **Neurotoxicology** 1996 Fall-Winter; 17(3–4):663–9 (59 ref.)

Neurodevelopmental test selection, administration, and performance in the main Seychelles child development study. Davidson PW, et al. **Neurotoxicology** 1995 Winter; 16(4):665–76 (22 ref.)

Evidence for delayed neurotoxicity produced by methylmercury. Rice DC. **Neurotoxicology** 1996 Fall-Winter;17(3–4):583–96 (31 ref.)

[Acute toxic actions of mercury on the cardiovascular system] Vassallo DV, et al. **Arq Bras Cardiol** 1996 Jul; 67(1):39–45 (40 ref.) **(Por)**

MERCURY COMPOUNDS

POISONING

Human exposure to mercury: a critical assessment of the evidence of adverse health effects. Ratcliffe HE, et al. **J Toxicol Environ Health** 1996 Oct 25;49(3):221–70 (264 ref.)

TOXICITY

Mercurial-induced alterations in neuronal divalent cation homeostasis. Denny MF, et al. **Neurotoxicology** 1996 Spring;17(1):47–61 (90 ref.)

Effects of mercurials on ligand- and voltage-gated ion channels: a review. Sirois JE, et al. **Neurotoxicology** 1996 Spring;17(1):63–84 (140 ref.)

MERCURY ISOTOPES

Mercury-responsive gene regulation and mercury-199 as a probe of protein structure. Huffman DL, et al. **Met Ions Biol Syst** 1997;34:503–26 (61 ref.)

MERCURY POISONING

Landscapes of longevity: the calcium–selenium–mercury connection in cancer and heart disease. Foster HD. **Med Hypotheses** 1997 Apr;48(4):355–60 (76 ref.)

Physiology and toxicology of mercury. Magos L. **Met Ions Biol Syst** 1997;34:321–70 (257 ref.)

DIAGNOSIS

[Voluntary mercury poisoning: biological consequences and psychiatric significance (published erratum appears in Schweiz Rundsch Med Prax 1997 Jul 2;86(27–28):1123)] Jornod P, et al. **Schweiz Rundsch Med Prax** 1997 May 28; 86(22):946–51 (51 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Maternal-fetal mercury transport and fetal methylmercury poisoning. Hamada R, et al. **Met Ions Biol Syst** 1997; 34:405–20 (37 ref.)

MORTALITY

Occupational exposure to mercury in dentistry and dentist mortality. McComb D. **J Can Dent Assoc** 1997 May; 63(5):372–6 (30 ref.)

PHYSIOPATHOLOGY

[Neurophysiological studies of minamata disease with HTLV-I associated myelopathy--a case report] Nakanishi R, et al. **Rinsho Shinkeigaku** 1996 Sep;36(9):1060–4 (12 ref.) (Eng. Abstr.) **(Jpn)**

MERCY KILLING see **EUTHANASIA**

MERGER, HEALTH FACILITY see **HEALTH FACILITY MERGER**

MERISTEM

GENETICS

Genetic control of shoot and flower meristem behavior. Liljegren SJ, et al. **Curr Opin Cell Biol** 1996 Dec;8(6):865–9 (35 ref.)

GROWTH & DEVELOPMENT

Plant meristems: cell signalling keeps the balance. Hudson A, et al. **Curr Biol** 1997 Jul 1;7(7):R427–9 (10 ref.)

Last exit: senescence, abscission, and meristem arrest in Arabidopsis. Bleecker AB, et al. **Plant Cell** 1997 Jul; 9(7):1169–79 (50 ref.)

MERKEL CELL TUMOR see **CARCINOMA, MERKEL CELL**

MERKEL CELLS

see related
CARCINOMA, MERKEL CELL

PHYSIOLOGY

[Merkel cell and neuro-cutaneous system] Misery L, et al. **Pathol Biol (Paris)** 1996 Dec;44(10):849–55 (81 ref.) (Eng. Abstr.) **(Fre)**

MERKEL'S RECEPTOR see **MERKEL CELLS**

MEROMYOSIN SUBFRAGMENTS see **MYOSIN SUBFRAGMENTS**

MEROSIN see **LAMININ**

MERPHALAN see **MELPHALAN**

MESANGIOCAPILLARY GLOMERULONEPHRITIS see **GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE**

MESANGIUM, GLOMERULAR see **GLOMERULAR MESANGIUM**

MESENCEPHALIC CENTRAL GRAY see **PERIAQUEDUCTAL GRAY**

MESENCEPHALON

BLOOD SUPPLY

Circadian fluctuations in onset of subarachnoid hemorrhage. New data on aneurysmal and perimesencephalic hemorrhage and a systematic review. Vermeer SE, et al. **Stroke** 1997 Apr;28(4):805–8 (29 ref.)

DRUG EFFECTS

Endogenous opioid systems and alcohol addiction. Herz A. **Psychopharmacology (Berl)** 1997 Jan;129(2):99–111 (150 ref.)

EMBRYOLOGY

Engrailed, Wnt and Pax genes regulate midbrain--hindbrain development. Joyner AL. **Trends Genet** 1996 Jan; 12(1):15–20 (50 ref.)

GROWTH & DEVELOPMENT

Epigenetic factors and midbrain dopaminergic neurone development. Perrone-Capano C, et al. **Bioessays** 1996 Oct; 18(10):817–24 (60 ref.)

METABOLISM

Development of mesencephalic dopaminergic neurons and the transforming growth factor-beta superfamily. Krieglstein K, et al. **J Neural Transm Suppl** 1995;46:209–16 (32 ref.)

The dopaminergic mesencephalic projections to the hippocampal formation in the rat. Gasbarri A, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Jan; 21(1):1–22 (95 ref.)

PHYSIOLOGY

Synaptic regulation of mesocorticolimbic dopamine neurons. White FJ. **Annu Rev Neurosci** 1996;19:405–36 (191 ref.)

Epigenetic factors and midbrain dopaminergic neurone development. Perrone-Capano C, et al. **Bioessays** 1996 Oct; 18(10):817–24 (60 ref.)

A framework for mesencephalic dopamine systems based on predictive Hebbian learning. Montague PR, et al. **J Neurosci** 1996 Mar 1;16(5):1936–47 (52 ref.)

Stress, glucocorticoids, and mesencephalic dopaminergic neurons: a pathophysiological chain determining vulnerability to psychostimulant abuse. Piazza PV, et al. **NIDA Res Monogr** 1996;163:277–99 (91 ref.)

Midbrain and medullary regulation of respiration and vocalization. Davis PJ, et al. **Prog Brain Res** 1996; 107:315–25 (61 ref.)

Midbrain and medullary regulation of defensive cardiovascular functions. Lovick TA. **Prog Brain Res** 1996;

107:301–13 (42 ref.)
Olfaction and brainstem circuits of reproductive behavior in the rat. Shipley MT, et al. **Prog Brain Res** 1996; 107:355–77 (188 ref.)
A neural substrate of prediction and reward. Schultz W, et al. **Science** 1997 Mar 14;275(5306):1593–9 (37 ref.)

PHYSIOPATHOLOGY

Alcohol dependence: a commentary on mechanisms. Hoffman PL, et al. **Alcohol Alcohol** 1996 Jul;31(4):333–40 (60 ref.)
Clinical neurophysiology of tremor. Deuschl G, et al. **J Clin Neurophysiol** 1996 Mar;13(2):110–21 (79 ref.)
[Skeletal myoclonus and midbrain tremor] Nagaoka M. **No To Shinkei** 1996 Mar;48(3):209–16 (12 ref.) **(Jpn)**

SURGERY

Perimesencephalic nonaneurysmal subarachnoid hemorrhage: review of the literature [see comments] Schwartz TH, et al. **Neurosurgery** 1996 Sep;39(3):433–40; discussion 440 (58 ref.) Comment in: Neurosurgery 1997 Apr;40(4):885.

TRANSPLANTATION

Treatment of Parkinson's disease. Symptomatic cell therapies: cells as biological minipumps. Zurn AD, et al. **Eur Neurol** 1996;36(6):405–8 (40 ref.)
CNS immunological modulation of neural graft rejection and survival. Borlongan CV, et al. **Neurol Res** 1996 Aug; 18(4):297–304 (70 ref.)

MESENCHYME see **MESODERM**

MESENCHYMOMA

DIAGNOSIS

Clinical image. Malignant mesenchymoma of the buttock. Johnson GL, et al. **J Comput Assist Tomogr** 1996 Nov–Dec; 20(6):999–1001 (13 ref.)

ETIOLOGY

A shorter lag period of mesenchymal malignancy on Marjolin's ulcer. Celiköz B, et al. **Burns** 1997 Feb; 23(1):72–4 (10 ref.)

PATHOLOGY

Malignant mesenchymoma of the spermatic cord with a brief review of the literature. Inagaki T, et al. **Int J Urol** 1997 Mar;4(2):225–8 (13 ref.)
Dedifferentiated cystic nephroma with malignant mesenchymoma as the dedifferentiated component. Faria PA, et al. **Pediatr Pathol Lab Med** 1996 Nov–Dec; 16(6):1003–11 (21 ref.)

RADIOGRAPHY

Malignant mesenchymoma of the spermatic cord with a brief review of the literature. Inagaki T, et al. **Int J Urol** 1997 Mar;4(2):225–8 (13 ref.)

MESENTERIC ARTERIES

Nonocclusive mesenteric infarction in continuous ambulatory peritoneal dialysis. Korzets Z, et al. **Nephron** 1996; 74(2):415–8 (15 ref.)
Unusual causes of mesenteric ischemia. Krupski WC, et al. **Surg Clin North Am** 1997 Apr;77(2):471–502 (80 ref.)
Acute mesenteric ischemia. McKinsey JF, et al. **Surg Clin North Am** 1997 Apr;77(2):307–18 (29 ref.)
Chronic mesenteric ischemia. Clinical presentation and diagnosis. Moawad J, et al. **Surg Clin North Am** 1997 Apr; 77(2):357–69 (35 ref.)

ANATOMY & HISTOLOGY

The mesenteric circulation. Anatomy and physiology. Rosenblum JD, et al. **Surg Clin North Am** 1997 Apr; 77(2):289–306 (23 ref.)

PATHOLOGY

Mesenteric ischemia secondary to cocaine abuse: case reports and literature review. Sudhakar CB, et al. **Am J Gastroenterol** 1997 Jun;92(6):1053–4 (12 ref.)

RADIOGRAPHY

Clinics in diagnostic imaging (16). Lower gastrointestinal bleeding caused by ileal tumour. Au VW, et al. **Singapore Med J** 1996 Aug;37(4):434–7 (10 ref.)

SURGERY

Mesenteric revascularization during aneurysmectomy. Donaldson MC, et al. **Surg Clin North Am** 1997 Apr; 77(2):443–59 (51 ref.)

MESENTERIC ARTERY, INFERIOR

SURGERY

Ruptured inferior mesenteric artery aneurysm due to segmental mediolytic arteritis. Kato T, et al. **Cardiovasc Surg** 1996 Oct;4(5):644–6 (10 ref.)
Aneurysm of the inferior mesenteric artery: case report and review of the literature. Sallou C, et al. **Eur J Vasc Endovasc Surg** 1997 Jul;14(1):71–4 (26 ref.)

MESENTERIC ARTERY, SUPERIOR

see related
SUPERIOR MESENTERIC ARTERY SYNDROME

Visceral artery aneurysms. Messina LM, et al. **Surg Clin North Am** 1997 Apr;77(2):425–42 (40 ref.)

ABNORMALITIES

Congenital mesenteric aneurysm and mesenteric arterioportal fistula. Paşaoğlu E, et al. **Abdom Imaging** 1996 Sep–Oct; 21(5):451–2 (10 ref.)

DRUG EFFECTS

Acute mesenteric ischaemia associated with 5-FU, cisplatin and vincristine chemotherapy. Allerton R. **Clin Oncol (R Coll Radiol)** 1996;8(2):116–7 (15 ref.)
Pharmacological manipulation of human gastrointestinal blood flow. Mathias CJ. **Fundam Clin Pharmacol** 1997; 11(1):29–34 (47 ref.)

MESENTERIC CIRCULATION see **SPLANCHNIC CIRCULATION**

MESENTERIC CYST

COMPLICATIONS

Case report: vitello-intestinal remnant complicating laparoscopic cholecystectomy. Durkan GC, et al. **Ir J Med Sci** 1996 Jul–Sep;165(3):164 (5 ref.)

DIAGNOSIS

Mesenteric cysts. Srivatsa KM, et al. **Arch Dis Child** 1996 Oct;75(4):272 (10 ref.)

MESENTERIC DUODENAL COMPRESSION SYNDROME see **SUPERIOR MESENTERIC ARTERY SYNDROME**

MESENTERIC PANNICULITIS see **PANNICULITIS, PERITONEAL**

MESENTERIC VASCULAR OCCLUSION

Mesenteric venous thrombosis. Rhee RY, et al. **Surg Clin North Am** 1997 Apr;77(2):327–38 (30 ref.)

COMPLICATIONS

Colonic variceal bleeding in a patient with mesenteric venous obstruction due to an ileal carcinoid tumour. Miao YM, et al. **Eur J Gastroenterol Hepatol** 1996 Nov;8(11):1133–5 (13 ref.)
[Portal vein thrombosis associated with essential thrombocytosis. Clinical cases and review of the literature] Carvajal S, et al. **Rev Med Chil** 1996 Mar;124(3):353–8 (26 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

The splanchnic syndrome. Diagnosis and indications for treatment. Geelkerken RH, et al. **Acta Chir Belg** 1997 Apr; 97(2):69–75 (57 ref.)
[Mesenteric venous thrombosis (MVT): a problem in diagnosis and management] Ghisletta N, et al. **Swiss Surg** 1996;2(5):223–9 (37 ref.) (Eng. Abstr.) **(Ger)**
[The current state of the diagnosis and treatment of acute mesenteric ischemia] Loba MM, et al. **Klin Khir** 1996; (7):40–3 (49 ref.) **(Ukr)**

ETIOLOGY

Neonatal antiphospholipid syndrome [letter] Navarro F, et al. **J Rheumatol** 1997 Jun;24(6):1240–1 (17 ref.)

SURGERY

The splanchnic syndrome. Diagnosis and indications for treatment. Geelkerken RH, et al. **Acta Chir Belg** 1997 Apr; 97(2):69–75 (57 ref.)

MESENTERIC VEINS

Mesenteric vein thrombosis. Four cases and review of the literature. Chen MC, et al. **Dig Dis** 1996 Nov–Dec; 14(6):382–9 (44 ref.)
Appendicitis in an eleven-year-old boy complicated by thrombosis of the portal and superior mesenteric veins. van Spronsen FJ, et al. **Pediatr Infect Dis J** 1996 Oct; 15(10):910–2 (10 ref.)

MESENTERY

Mesenteric pleomorphic liposarcoma in an adolescent. Pawel BR, et al. **Arch Pathol Lab Med** 1997 Feb;121(2):173–6 (15 ref.)
Diffuse mesenteric amyloidosis. Mohan V, et al. **Dig Dis Sci** 1997 May;42(5):1079–82 (17 ref.)
[Complicated intestinal tuberculosis of the mesenteric root] Wagner JB, et al. **Dtsch Med Wochenschr** 1997 May 16; 122(20):643–7 (25 ref.) (Eng. Abstr.) **(Ger)**

BLOOD SUPPLY

Protein tyrosine phosphorylation modulates microvessel permeability in frog mesentery. Adamson RH. **Microcirculation** 1996 Jun;3(2):245–7 (13 ref.)
MR angiography of abdominal ischemia. Li KC. **Semin Ultrasound CT MR** 1996 Aug;17(4):352–9 (35 ref.)
History of mesenteric ischemia. The evolution of a diagnosis and management. Boley SJ, et al. **Surg Clin North Am** 1997 Apr;77(2):275–88 (90 ref.)

PATHOLOGY

Mesenteric neurofibroma in von Recklinghausen's disease. Kataria R, et al. **J Pediatr Surg** 1997 Jan;32(1):128–9 (9 ref.)
Retractile mesenteritis of the large bowel: report of a case and review of the literature. Ikoma A, et al. **Surg Today** 1996;26(6):435–8 (21 ref.)

SURGERY

[Late results of Childs–Phillips mesenteric plication for therapy and prevention of small intestine ileus] Sclabas G, et al. **Chirurg** 1997 Jul;68(7):693–9 (32 ref.) (Eng. Abstr.) **(Ger)**

MESMERISM see **HYPNOSIS**

MESNA

PHARMACOLOGY

[Chemoprotectors. Mechanisms of action and clinical applications] Raymond E. **Rev Med Interne** 1996; 17(11):936–44 (59 ref.) (Eng. Abstr.) **(Fre)**

MESOCRICETUS

EMBRYOLOGY

The low pH Syrian hamster embryo (SHE) cell transformation assay: a revitalized role in carcinogen prediction. Aardema MJ, et al. **Mutat Res** 1996 Sep 21; 356(1):5–9 (16 ref.)
Comparison of the standard and reduced pH Syrian hamster embryo (SHE) cell in vitro transformation assays in predicting the carcinogenic potential of chemicals. Isfort RJ, et al. **Mutat Res** 1996 Sep 21;356(1):11–63 (262 ref.)
The pH 6.7 Syrian hamster embryo cell transformation assay for assessing the carcinogenic potential of chemicals. LeBoeuf RA, et al. **Mutat Res** 1996 Sep 21;356(1):85–127 (105 ref.)

GENETICS

Limited diversity in the major histocompatibility complex class II loci of Syrian hamster DNA. Hixon ML, et al. **Lab Anim Sci** 1996 Dec;46(6):679–81 (15 ref.)

MESODERM

[Vg1, a possible natural mesoderm inducer derived from the study of the localized maternal mRNA in the Xenopus egg cytoplasm] Shiokawa K, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(11):1594–9 (18 ref.) **(Jpn)**
[Subdivision of the mesoderm along the dorso-ventral axis] Takahashi Y, et al. **Tanpakushitsu Kakusan Koso** 1996 Dec; 41(16):2532–41 (29 ref.) **(Jpn)**

ENZYMOLOGY

Roles of kringle domain-containing serine proteases in epithelial–mesenchymal transitions during embryonic development. Théry C, et al. **Acta Anat (Basel)** 1996; 156(3):162–72 (101 ref.)

METABOLISM

The organizer formation: two molecules are better than one. Lombardo A. **Bioessays** 1996 Apr;18(4):267–70 (47 ref.)

PATHOLOGY

Mesenchymal hamartoma of the chest wall in infancy—a case report of this rare entity with cytologic findings [see comments] Szadowska A, et al. **Cytopathology** 1996 Jun; 7(3):211–7 (28 ref.) Comment in: Cytopathology 1997 Jun;8(3):215–7.
Experimental induction of epithelial–mesenchymal interconversions. Guarino M, et al. **Exp Toxicol Pathol** 1995 Nov;47(5):325–34 (76 ref.)

PHYSIOLOGY

Epithelial–mesenchymal transitions in cancer progression. Birchmeier C, et al. **Acta Anat (Basel)** 1996;156(3):217–26 (102 ref.)
Model systems of epithelium–mesenchyme transitions. Boyer B, et al. **Acta Anat (Basel)** 1996;156(3):227–39 (89 ref.)
Mesenchyme to epithelium transition during development of

MESODERM

the mammalian kidney tubule. Davies JA. **Acta Anat (Basel)** 1996;156(3):187–201 (121 ref.)

Epithelial–mesenchymal transformations in early avian heart development. Markwald R, et al. **Acta Anat (Basel)** 1996; 156(3):173–86 (60 ref.)

Epithelial–mesenchymal transition during trophoblast differentiation. Vićovac L, et al. **Acta Anat (Basel)** 1996; 156(3):202–16 (157 ref.)

Morphogenesis: FGF branches out. Skaer H. **Curr Biol** 1997 Apr 1;7(4):R238–41 (14 ref.)

Development of the hematopoietic system. Orkin SH. **Curr Opin Genet Dev** 1996 Oct;6(5):597–602 (44 ref.)

The role of positive and negative signals in somite patterning. Lassar AB, et al. **Curr Opin Neurobiol** 1996 Feb;6(1):57–63 (64 ref.)

Induction and differentiation of extra-embryonic mesoderm in the mouse. Boucher DM, et al. **Reprod Fertil Dev** 1996; 8(4):765–77 (121 ref.)

Amphibian limb regeneration: rebuilding a complex structure. Brockes JP. **Science** 1997 Apr 4;276(5309):81–7 (55 ref.)

Mesenchymal–epithelial interactions in the bladder. Baskin LS, et al. **World J Urol** 1996;14(5):301–9 (45 ref.)

MESONEPHROMA

DIAGNOSIS

[Mesonephric tumor, mesonephric carcinoma] Asano T, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):512–5 (10 ref.) **(Jpn)**

PATHOLOGY

[Mesonephric adenocarcinoma arising in the female urethral diverticulum] Okubo Y, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Sep;87(9):1138–41 (11 ref.) (Eng. Abstr.) **(Jpn)**

MESONEPHROS

ABNORMALITIES

[Bilateral persistence of the common mesonephric duct in children. Apropos of a case. Review of the literature] Merrot T, et al. **Prog Urol** 1996 Aug–Sep;6(4):582–6 (12 ref.) (Eng. Abstr.) **(Fre)**

MESOPORPHYRINS

PHARMACOLOGY

Control of bilirubin production by synthetic heme analogs: pharmacologic and toxicologic considerations. Drummond GS, et al. **J Perinatol** 1996 May–Jun;16(3 Pt 2):S72–9 (36 ref.)

TOXICITY

Control of bilirubin production by synthetic heme analogs: pharmacologic and toxicologic considerations. Drummond GS, et al. **J Perinatol** 1996 May–Jun;16(3 Pt 2):S72–9 (36 ref.)

MESOTHELIOMA

[Solitary fibrous mesothelioma of the peritoneum. Considerations of a clinical case in our observation] Cebrelli C, et al. **Minerva Chir** 1996 Nov;51(11):993–5 (17 ref.) (Eng. Abstr.) **(Ita)**

[Solitary fibrous tumor of the pleura. Clinical case] Trombetta F, et al. **Minerva Chir** 1996 Jun;51(6):485–8 (13 ref.) (Eng. Abstr.) **(Ita)**

[Cardiac mesothelioma] Natsume T. **Ryoikibetsu Shokogun Shirizu** 1996;(14):263–4 (5 ref.) **(Jpn)**

[Pericardial mesothelioma (benign, malignant)] Natsume T. **Ryoikibetsu Shokogun Shirizu** 1996;(14):270–1 (5 ref.) **(Jpn)**

CHEMICALLY INDUCED

Malignant peritoneal mesothelioma following asbestos exposure. Manavoğlu O, et al. **J Environ Pathol Toxicol Oncol** 1996;15(2–4):191–4 (27 ref.)

CHEMISTRY

Primary malignant mesothelioma of the tunica vaginalis of the testis. Immunohistochemistry and electron microscopy. Berti E, et al. **Pathology** 1997 Feb;29(1):96–9 (20 ref.)

COMPLICATIONS

Endobronchial inflammatory pseudotumour in a patient with B-cell chronic lymphocytic leukemia and malignant pleural mesothelioma. Stappaerts I, et al. **Acta Clin Belg** 1996; 51(4):261–4 (8 ref.)

Peritoneal mesothelioma in recurrent familial peritonitis. Gentiloni N, et al. **J Clin Gastroenterol** 1997 Jun; 24(4):276–9 (20 ref.)

[Two cases of recurrent hydropneumothorax caused by malignant pleural mesothelioma] Tanaka H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Oct; 44(10):1877–81 (16 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Malignant mesothelioma of the tunica vaginalis testis diagnosed by aspiration cytology--a case report with review of literature. Ahmed M, et al. **Int Urol Nephrol** 1996;28(6):793–6 (19 ref.)

[Problems in diagnosis and therapy of malignant pleural mesothelioma] Türler A, et al. **Med Klin** 1997 Feb 15; 92(2):101–5 (40 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

[A case of peritoneum malignant mesothelioma responding to arterial infusion chemotherapy] Tohda G, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Jun;94(6):445–9 (10 ref.) **(Jpn)**

EPIDEMIOLOGY

The epidemiology of mesothelioma in historical context. McDonald JC, et al. **Eur Respir J** 1996 Sep;9(9):1932–42 (85 ref.)

Occupational and geographical factors in the epidemiology of malignant mesothelioma. Ross D, et al. **Monaldi Arch Chest Dis** 1995 Dec;50(6):459–63 (47 ref.)

ETIOLOGY

Chrysotile asbestos is the main cause of pleural mesothelioma. Smith AH, et al. **Am J Ind Med** 1996 Sep;30(3):252–66 (113 ref.)

Pathology of malignant mesothelioma. Attanoos RL, et al. **Histopathology** 1997 May;30(5):403–18 (120 ref.)

Pleural mesothelioma and household asbestos exposure. Schneider J, et al. **Rev Environ Health** 1996 Jan–Jun; 11(1–2):65–70 (68 ref.)

[Malignant mesothelioma of the pleura following radiotherapy of Hodgkin disease] Falchero L, et al. **Bull Cancer** 1996 Nov;83(11):964–8 (32 ref.) (Eng. Abstr.) **(Fre)**

[The biological effect of fireproof ceramic fibers—literature review] Krajnow A. **Med Pr** 1996;47(6):663–75 (26 ref.) (Eng. Abstr.) **(Pol)**

PATHOLOGY

Pathology of peritoneal mesothelioma. Kass ME. **Cancer Treat Res** 1996;81:213–25 (28 ref.)

Malignant pleural mesothelioma. Hoogsteden HC, et al. **Crit Rev Oncol Hematol** 1997 Feb;25(2):97–126 (342 ref.)

Pathology of malignant mesothelioma. Attanoos RL, et al. **Histopathology** 1997 May;30(5):403–18 (120 ref.)

Brain metastasis in malignant pleural mesothelioma. Kawai A, et al. **Intern Med** 1997 Aug;36(8):591–4 (20 ref.)

In vitro and in vivo studies of mesothelioma. Pass HI, et al. **J Cell Biochem Suppl** 1996;24:142–51 (73 ref.)

Small cell carcinoma of lung simulating pleural mesothelioma. Report of 4 cases with autopsy confirmation. Falconieri G, et al. **Pathol Res Pract** 1995 Nov; 191(11):1147–52 (17 ref.)

Immunopathology of malignant mesothelioma. Sheibani K, et al. **Pathology (Phila)** 1996;4(1):191–212 (89 ref.)

From the archives of the AFIP. Malignant pleural mesothelioma: radiologic-pathologic correlation. Miller BH, et al. **Radiographics** 1996 May;16(3):613–44 (72 ref.)

[Solitary fibrous tumor of the nasopharynx. Apropos of a case] Ferrario F, et al. **Ann Otolaryngol Chir Cervicofac** 1997;114(3):71–5 (35 ref.) (Eng. Abstr.) **(Fre)**

[Bilateral malignant mesothelioma of the tunica vaginalis testis. Apropos of a case] Menut P, et al. **Prog Urol** 1996 Aug–Sep;6(4):587–9 (9 ref.) (Eng. Abstr.) **(Fre)**

[Mesothelioma. Pathology/pathogenesis/mesothelioma register] Müller KM. **Pneumologie** 1997 Apr;51(4):335–44 (18 ref.) **(Ger)**

[Malignant mesothelioma of the tunica vaginalis: a case report] Machida T, et al. **Hinyokika Kiyo** 1997 Feb; 43(2):161–4 (9 ref.) (Eng. Abstr.) **(Jpn)**

[A case of malignant mesothelioma associated intrascrotal mass] Wakasugi E, et al. **Nippon Hinyokika Gakkai Zasshi** 1997 Mar;88(3):443–6 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Localized fibrous tumor in the parenchyma. Report of 2 cases, one of them multiple and bilateral] Vázquez-Pelillo JC, et al. **Arch Bronconeumol** 1996 Jan;32(1):43–6 (41 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Diffuse malignant pleural mesotheslioma at CAMC: a retrospective study of 50 patients. Jubelirer SJ, et al. **W V Med J** 1997 May–Jun;93(3):120–5 (10 ref.)

RADIOGRAPHY

From the archives of the AFIP. Malignant pleural mesothelioma: radiologic-pathologic correlation. Miller BH, et al. **Radiographics** 1996 May;16(3):613–44 (72 ref.)

SECONDARY

Brain metastasis in malignant pleural mesothelioma. Kawai A, et al. **Intern Med** 1997 Aug;36(8):591–4 (20 ref.)

SURGERY

[Fibrous tumors localized in the pleura] Biancari F, et al. **G Chir** 1996 Aug–Sep;17(8–9):437–43 (57 ref.) (Eng. Abstr.) **(Ita)**

[Complete Pleuropneumonectomy] Morita T, et al. **Kyobu Geka** 1996 Jul;49(8 Suppl):697–705 (90 ref.) **(Jpn)**

THERAPY

Peritoneal mesothelioma: treatment approach based on natural history. Averbach AM, et al. **Cancer Treat Res** 1996;81:193–211 (80 ref.)

Gene therapy for lung cancer and mesothelioma. Albelda SM. **Chest** 1997 Jun;111(6 Suppl):144S–149S (48 ref.)

ULTRASONOGRAPHY

[Imaging of peritoneal mesotheliomas] Lewin M, et al. **J Radiol** 1996 Sep;77(9):649–56 (39 ref.) (Eng. Abstr.) **(Fre)**

ULTRASTRUCTURE

Malignant mesothelioma: current conundrums over risk estimates and whither electron microscopy for diagnosis? [editorial] Comin CE, et al. **Ultrastruct Pathol** 1997 Jul–Aug;21(4):315–20 (89 ref.)

VIROLOGY

Evidence for and implications of SV40-like sequences in human mesotheliomas. Pass HI, et al. **Important Adv Oncol** 1996;:89–108 (129 ref.)

MESOTHELIOMA, CYSTIC

DIAGNOSIS

Cystic mesothelioma of the peritoneum. Moriwaki Y, et al. **J Gastroenterol** 1996 Dec;31(6):868–74 (24 ref.)

MESOTHELIUM see **EPITHELIUM**

MESOZOA see **INVERTEBRATES**

MESSENGER RNA see **RNA, MESSENGER**

MESSENGER RNA, POLYADENYLATED see **RNA, MESSENGER**

MESULAM SYNDROME see **APHASIA, PRIMARY PROGRESSIVE**

MESYLATES

TOXICITY

Mammalian germ cell mutagenicity of ENU, IPMS and MMS, chemicals selected for a transgenic mouse collaborative study. Shelby MD, et al. **Mutat Res** 1997 Feb 14;388(2–3):99–109 (65 ref.)

META-ANALYSIS

see related
PUBLICATION BIAS
REVIEW LITERATURE

Randomized controlled trials and systematic reviews: a foundation for evidence-based perinatal medicine. Ohlsson A. **Acta Paediatr** 1996 Jun;85(6):647–55 (100 ref.)

Review article: critical review of meta-analyses of randomized clinical trials in hepatogastroenterology. Auperin A, et al. **Aliment Pharmacol Ther** 1997 Apr; 11(2):215–25 (97 ref.)

Formulating questions and locating primary studies for inclusion in systematic reviews. Counsell C. **Ann Intern Med** 1997 Sep 1;127(5):380–7 (57 ref.)

Papers that summarise other papers (systematic reviews and meta-analyses). Greenhalgh T. **BMJ** 1997 Sep 13; 315(7109):672–5 (21 ref.)

The relation between treatment benefit and underlying risk in meta-analysis [see comments] Sharp SJ, et al. **BMJ** 1996 Sep 21;313(7059):735–8 (29 ref.) Comment in: BMJ 1996 Dec 14;313(7071):1550–1.

The need for large-scale randomized evidence. Baigent C. **Br J Clin Pharmacol** 1997 Apr;43(4):349–53 (24 ref.)

Alternatives to mega-trials in cardiovascular disease. Hampton JR. **Cardiovasc Drugs Ther** 1997 Jan;10(6):759–65 (34 ref.)

What meta-analyses have and have not taught us about psychotherapy effects: a review and future directions. Matt GE, et al. **Clin Psychol Rev** 1997;17(1):1–32 (114 ref.)

Meta-analysis and endocrinology. Petitti DB. **Endocrinol Metab Clin North Am** 1997 Mar;26(1):31–44 (58 ref.)

Meta-analyses/meta-projects: a small but relevant contribution by Sight and Life to the prevention of vitamin A deficiency. Frigg M. **Eur J Clin Nutr** 1996 Jul;50 Suppl 3:S68–9 (7 ref.)

The uses and abuses of meta-analysis [see comments] Charlton BG. **Fam Pract** 1996 Aug;13(4):397–401 (26 ref.) Comment in: Fam Pract 1997 Feb;14(1):90. Comment in: Fam Pract 1997 Feb;14(1):90–1.

Meta-analysis of clinical trials: a consumer's guide. Geller NL, et al. **J Biopharm Stat** 1996 Nov;6(4):377–94 (31 ref.)

Random versus nonrandom assignment in controlled experiments: do you get the same answer? Shadish WR, et al. **J Consult Clin Psychol** 1996 Dec;64(6):1290–305 (169

ref.)
Systematic reviews of randomized controlled trials: the need for complete data. Clarke MJ, et al. **J Eval Clin Pract** 1995 Nov;1(2):119–26 (23 ref.)
Meta-analysis of best-evidence synthesis? Eysenck HJ. **J Eval Clin Pract** 1995 Sep;1(1):29–36 (36 ref.)
The case for failed meta-analyses. Naylor CD. **J Eval Clin Pract** 1995 Nov;1(2):127–30 (21 ref.)
Post hoc analysis: use and dangers in perspective. Elliott HL. **J Hypertens Suppl** 1996 Sep;14(2):S21–4; discussion S24–5 (25 ref.)
Advantages and disadvantages of the meta-analysis approach. Fagard RH, et al. **J Hypertens Suppl** 1996 Sep; 14(2):S9–12; discussion S13 (29 ref.)
Integration of trial, meta-analysis and cohort results with treatment guidelines. Ménard J, et al. **J Hypertens Suppl** 1996 Sep;14(2):S129–33; discussion S133–4 (33 ref.)
Interpretation of data from multiple trials: a critical review. Conn HO. **J Intern Med** 1997 Mar;241(3):177–83 (48 ref.)
Assembling comparison groups to assess the effects of health care. Chalmers I. **J R Soc Med** 1997 Jul;90(7):379–86 (69 ref.)
Large trials vs meta-analysis of smaller trials: how do their results compare? [see comments] Cappelleri JC, et al. **JAMA** 1996 Oct 23–30;276(16):1332–8 (62 ref.) Comment in: JAMA 1997 Feb 5;277(5):376–7; discussion 377–8. Comment in: JAMA 1997 Feb 5;277(5):377; discussion 377–8.
Meta-analytical issues for prevention intervention research. Tobler N. **NIDA Res Monogr** 1994;142:342–403 (63 ref.)
Meta-analysis and public policy: opportunity for nursing impact. Conn VS, et al. **Nurs Outlook** 1996 Nov–Dec; 44(6):267–71 (29 ref.)
Application of meta-analysis in reviewing occupational cohort studies. Wong O, et al. **Occup Environ Med** 1996 Dec;53(12):793–800 (29 ref.)
Current controversies in the application of meta-analysis (with special reference to oncological treatments). A commentary [comment] Kleijnen J. **Pharm World Sci** 1997 Jun;19(3):117–8 (2 ref.) Comment on: Pharm World Sci 1997 Jun;19(3):152–8.
Current controversies in the application of meta-analysis (with special reference to oncological treatments) [see comments] Messori A. **Pharm World Sci** 1997 Jun; 19(3):152–8 (50 ref.) Comment in: Pharm World Sci 1997 Jun;19(3):117–8.
Focus on qualitative methods. Qualitative metasynthesis: issues and techniques. Sandelowski M, et al. **Res Nurs Health** 1997 Aug;20(4):365–71 (47 ref.)
The role of meta-analysis in monitoring clinical trials. Begg CB. **Stat Med** 1996 Jun 30;15(12):1299–306; discussion 1307–11 (25 ref.)
Meta-analysis and meta-analytic monitoring of clinical trials. Feinstein AR. **Stat Med** 1996 Jun 30;15(12):1273–80; discussion 1281–3 (12 ref.)
Meta-analysis: current issues in research synthesis. Olkin I. **Stat Med** 1996 Jun 30;15(12):1253–7; discussion 1259–62 (14 ref.)
The role of external evidence in data monitoring of a clinical trial. Pocock SJ. **Stat Med** 1996 Jun 30;15(12):1285–93; discussion 1295–7 (18 ref.)
Meta-analysis in transfusion medicine. Vamvakas EC. **Transfusion** 1997 Mar;37(3):329–45 (184 ref.)
[Meta-analysis] Döpfmer S, et al. **Dtsch Med Wochenschr** 1997 May 2;122(18):589–93 (28 ref.) **(Ger)**
[Systematic reviews in cardiology: approaches to evidence-based medicine and the Cochrane Collaboration] Hense HW, et al. **Z Kardiol** 1997 May;86(5):313–9 (30 ref.) (Eng. Abstr.) **(Ger)**
[Methods of investigation in clinical cardiology. VIII. Meta-analysis and systematic reviews in cardiology] Guallar E, et al. **Rev Esp Cardiol** 1997 May;50(5):345–54 (43 ref.) (Eng. Abstr.) **(Spa)**

META-DIHYDROXYBENZENES see **RESORCINOLS**

METABOLIC ACTIVATION see **BIOTRANSFORMATION**

METABOLIC CLEARANCE RATE

PHYSIOLOGY

Noncompartmental models of whole-body clearance of tracers: a review. Norwich KH. **Ann Biomed Eng** 1997 May–Jun;25(3):421–39 (72 ref.)

METABOLIC DETOXICATION, DRUG

PHYSIOLOGY

Plant glutathione S-transferases and herbicide detoxification. Neuefeind T, et al. **Biol Chem** 1997 Mar–Apr; 378(3–4):199–205 (55 ref.)

METABOLIC DISEASES

Clinical disorders of magnesium metabolism. Whang R. **Compr Ther** 1997 Mar;23(3):168–73 (46 ref.)
Endocrine/metabolic syndromes of cancer. Odell WD. **Semin Oncol** 1997 Jun;24(3):299–317 (186 ref.)
[Syndrome X--insulin resistance and common metabolic disorders] Geffel D, et al. **Harefuah** 1996 Oct; 131(7–8):275–9 (34 ref.) **(Heb)**

COMPLICATIONS

Metabolic-associated skin disorders. Giacalone VF, et al. **Clin Podiatr Med Surg** 1996 Jan;13(1):119–38 (90 ref.)
Photosensitivity in the pediatric patient. Garzon MC, et al. **Curr Opin Pediatr** 1997 Aug;9(4):377–87 (101 ref.)
Fulminant hepatic failure: pediatric aspects. Bhaduri BR, et al. **Semin Liver Dis** 1996 Nov;16(4):349–55 (50 ref.)

DIAGNOSIS

Miscellaneous metabolic diseases [see comments] Van Linthoudt D, et al. **Curr Opin Rheumatol** 1996 May; 8(3):262–5 (29 ref.) Comment in: Curr Opin Rheumatol 1996 May;8(3):235–7.
[Neurometabolic diagnosis of mental retardation] García L. **Rev Neurol** 1997 May;25(141):765–8 (13 ref.) (Eng. Abstr.) **(Spa)**

DIET THERAPY

Nutrition in children affected by inherited metabolic diseases. Giovannini M, et al. **Ann Ist Super Sanita** 1995; 31(4):489–502 (26 ref.)

DRUG THERAPY

Growth hormone and IGF-I therapy in the hypercatabolic patient. Wolf SE, et al. **Baillieres Clin Endocrinol Metab** 1996 Jul;10(3):447–63 (75 ref.)
[Current therapeutics 1990–1995 in the field of endocrinology-metabolism] Scheen AJ. **Rev Med Liege** 1996 Aug;51(8):503–9 (24 ref.) **(Fre)**

ENZYMOLOGY

[Transitory hyperphosphatasemia in childhood. Nine cases and revision of Spanish contributions] Diego Núñez MA, et al. **An Esp Pediatr** 1997 May;46(5):503–7 (57 ref.) **(Spa)**

ETIOLOGY

Metabolic complications of urinary diversions: an overview. Cruz DN, et al. **Am J Med** 1997 May;102(5):477–84 (73 ref.)
[Mitochondrial cytopathies (editorial)] Rötig A. **Pathol Biol (Paris)** 1996 Apr;44(4):229–31 (11 ref.) **(Fre)**
[Abnormalities in urate metabolism: concept and classification] Akaoka I, et al. **Nippon Rinsho** 1996 Dec; 54(12):3243–7 (12 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Nutrition in children affected by inherited metabolic diseases. Giovannini M, et al. **Ann Ist Super Sanita** 1995; 31(4):489–502 (26 ref.)
Genetics and cholesterol metabolism. Kesäniemi YA. **Curr Opin Lipidol** 1996 Jun;7(3):124–31 (80 ref.)
Apolipoprotein function in health and disease: insights from natural mutations. Franceschini G. **Eur J Clin Invest** 1996 Sep;26(9):733–46 (109 ref.)
The regulation of 17,20 lyase activity. Miller WL, et al. **Steroids** 1997 Jan;62(1):133–42 (77 ref.)

METABOLISM

Distinctive aspects of metabolism and nutrition in infancy. Wharton BA, et al. **Clin Biochem** 1996 Oct;29(5):419–28 (22 ref.)
Assessment of energy expenditure in metabolic disorders. Bodamer OA, et al. **Eur J Pediatr** 1997 Aug;156 Suppl 1:S24–8 (11 ref.)
[Free radicals: concepts, associated diseases, defense system and oxidative stress] Ferreira AL, et al. **Rev Assoc Med Bras** 1997 Jan–Mar;43(1):61–8 (54 ref.) **(Por)**

PHYSIOPATHOLOGY

Insulin-like growth factor bioactivity and its modification in growth hormone resistant states. Donaghy AJ, et al. **Baillieres Clin Endocrinol Metab** 1996 Jul;10(3):421–46 (101 ref.)
Miscellaneous metabolic diseases [see comments] Van Linthoudt D, et al. **Curr Opin Rheumatol** 1996 May; 8(3):262–5 (29 ref.) Comment in: Curr Opin Rheumatol 1996 May;8(3):235–7.
Wernicke-Korsakoff syndrome. Zubaran C, et al. **Postgrad Med J** 1997 Jan;73(855):27–31 (55 ref.)

PREVENTION & CONTROL

Exercise in the prevention of atherosclerotic, metabolic and hypertensive diseases: a review. Hardman AE. **J Sports Sci** 1996 Jun;14(3):201–18 (145 ref.)

THERAPY

Syndrome X. Recognition and management of this metabolic disorder in primary care. Minchoff LE, et al. **Nurse Pract** 1996 Jun;21(6):74–5, 79–80, 83–6 (30 ref.)

VETERINARY

Nutritional metabolic diseases of poultry and disorders of the biological antioxidant defence system. Mézes M, et al. **Acta Vet Hung** 1997;45(3):349–60 (55 ref.)

METABOLIC PUMP see **BIOLOGICAL TRANSPORT, ACTIVE**

METABOLISM

Estimation and use of kinetic parameter distributions in metabolism and nutrition. Beltz WF. **Adv Food Nutr Res** 1996;40:265–79 (19 ref.)
Nutrient-response: a "top down" approach to metabolic control. Schulz AR. **Adv Food Nutr Res** 1996;40:227–41 (23 ref.)
Regulation of metabolism by retinoic acid and its nuclear receptors. Pfahl M, et al. **Annu Rev Nutr** 1996;16:257–83 (157 ref.)
Use of continuous-flow combustion MS in studies of human metabolism. Rennie MJ, et al. **Biochem Soc Trans** 1996 Aug; 24(3):927–32 (19 ref.)
Isotopic methods for probing organization of cellular metabolism. Sherry AD, et al. **Cell Biochem Funct** 1996 Dec;14(4):259–68 (34 ref.)
Decision analysis in endocrinology and metabolism. Powe NR, et al. **Endocrinol Metab Clin North Am** 1997 Mar; 26(1):89–111 (35 ref.)
Using models to explore whole-body metabolism and accessing models through a model library. Wastney ME, et al. **Metabolism** 1997 Mar;46(3):330–2 (18 ref.)
Secondary metabolites play primary roles in human affairs. Bentley R. **Perspect Biol Med** 1997 Winter;40(2):197–221 (69 ref.)
Prospects for advancing the understanding of complex biochemical systems. Liu J, et al. **Plant Mol Biol** 1997 Mar; 33(4):573–81 (65 ref.)
[Tissue microdialysis: practical and theoretical aspects] Cimmino M, et al. **Diabetes Metab** 1997 Apr;23(2):164–70 (29 ref.) (Eng. Abstr.) **(Fre)**
[The other side of metabolism] Golubev AG. **Biokhimiia** 1996 Nov;61(11):2018–39 (176 ref.) (Eng. Abstr.) **(Rus)**
[Organization of biochemical systems] Poglazov BF. **Biokhimiia** 1996 Nov;61(11):1941–7 (41 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Effects of calcium antagonists on insulin sensitivity and other metabolic parameters. Sowers JR. **Am J Cardiol** 1997 May 22;79(10A):24–8; discussion 47–8 (57 ref.)
Adverse metabolic effects of antihypertensive drugs. Implications for treatment. Preuss HG, et al. **Drug Saf** 1996 Jun;14(6):355–64 (93 ref.)
Metabolic effects of recombinant human insulin-like growth factor-I in humans: comparison with recombinant human growth hormone. Mauras N, et al. **Pediatr Nephrol** 1996 Jun;10(3):318–23 (70 ref.)

GENETICS

Analysis of metabolic control in vivo using molecular genetics. Brindle KM. **Cell Biochem Funct** 1996 Dec; 14(4):269–76 (41 ref.)

PHYSIOLOGY

Control of fertility by metabolic cues [see comments] Wade GN, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):E1–19 (175 ref.) Comment in: Am J Physiol 1997 Jul;273(1 Pt 1):E231–2.
Metabolic consequences of enzyme interactions. Ovádi J, et al. **Cell Biochem Funct** 1996 Dec;14(4):249–58 (47 ref.)
Distribution control of metabolic flux. Veech RL, et al. **Cell Biochem Funct** 1996 Dec;14(4):229–36 (27 ref.)
Interactions among metabolic rate, hypoxia, and control of breathing. Gautier H. **J Appl Physiol** 1996 Aug;81(2):521–7 (67 ref.)
Use of stable isotopically labeled tracers for studies of metabolic kinetics: an overview. Patterson BW. **Metabolism** 1997 Mar;46(3):322–9 (35 ref.)
[Metabolism and health: yesterday--today-tomorrow] Klumpp S, et al. **Pharm Unserer Zeit** 1997 May;26(3):123–6 (8 ref.) **(Ger)**

METABOLISM AND ENDOCRINOLOGY (SPECIALTY) see **ENDOCRINOLOGY**

METABOLISM, BASAL see **BASAL METABOLISM**

METABOLISM, INBORN ERRORS

see related
ANEMIA, HEMOLYTIC, CONGENITAL
MENTAL RETARDATION

Phytosterolaemia: diagnosis, characterization and therapeutical approaches [editorial] Lütjohann D, et al. **Ann Med** 1997 Jun;29(3):181–4 (59 ref.)
Benign familial hyperphosphatasemia: a report of two families and review of the literature. Crespo-Peña M, et al. **Clin Exp Rheumatol** 1997 Jul–Aug;15(4):425–31 (36 ref.)
Disorders of the electron transport chain. Adams PL, et al. **J Inherit Metab Dis** 1996;19(4):463–9 (26 ref.)

METABOLISM, INBORN ERRORS

Neuropathology and pathogenesis of mitochondrial diseases. Brown GK, et al. **J Inherit Metab Dis** 1996;19(4):553–72 (76 ref.)

Tetrahydrobiopterin and inherited hyperphenylalaninemias. Blau N, et al. **Turk J Pediatr** 1996 Jan–Mar;38(1):19–35 (102 ref.)

BLOOD

Hyperhomocysteinaemia and associated disease. Bakker RC, et al. **Pharm World Sci** 1997 Jun;19(3):126–32 (83 ref.)

COMPLICATIONS

Early recognition of metabolic decompensation. Morris AA, et al. **Arch Dis Child** 1997 Jun;76(6):555–6 (3 ref.)

Mild hyperhomocysteinemia and arterial occlusive disease [editorial] Selhub J. **Haematologica** 1997 Mar–Apr; 82(2):129–32 (36 ref.)

Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy. Morrison GB, et al. **Oncol Nurs Forum** 1997 Jan–Feb;24(1):83–8 (22 ref.)

Reproductive effects of maternal metabolic disorders: implications for pediatrics and obstetrics. Levy HL. **Turk J Pediatr** 1996 Jul–Sep;38(3):335–44 (36 ref.)

DIAGNOSIS

Mild liver enzyme abnormalities: eliminating hemochromatosis as cause. Witte DL. **Clin Chem** 1997 Aug; 43(8 Pt 2):1535–8 (26 ref.)

Breath tests: concepts, applications and limitations. Rating D, et al. **Eur J Pediatr** 1997 Aug;156 Suppl 1:S18–23 (9 ref.)

Clinical presentation of mitochondrial disorders in childhood. Munnich A, et al. **J Inherit Metab Dis** 1996;19(4):521–7 (16 ref.)

Magnetic resonance imaging in lactic acidosis. van der Knaap MS, et al. **J Inherit Metab Dis** 1996;19(4):535–47 (51 ref.)

DRUG THERAPY

Management of primary idiopathic hyperphosphatasemia with calcitonin: a case report. Roth AJ, et al. **Int Orthop** 1996;20(1):58–60 (14 ref.)

ENZYMOLOGY

Clinical heterogeneity and molecular mechanisms in inborn muscle AMP deaminase deficiency. Gross M. **J Inherit Metab Dis** 1997 Jun;20(2):186–92 (30 ref.)

Impaired folding and subunit assembly as disease mechanism: the example of medium-chain acyl-CoA dehydrogenase deficiency. Bross P, et al. **Prog Nucleic Acid Res Mol Biol** 1998;58:301–37 (143 ref.)

GENETICS

Inherited surfactant protein-B deficiency. Hamvas A. **Adv Pediatr** 1997;44:369–88 (65 ref.)

Realities and virtual realities of inborn errors of metabolism: biochemical genetics in the molecular genetic era. Scriver CR. **Am J Med Genet** 1997 Mar 3;69(1):1–6 (25 ref.)

Inborn errors of the Krebs cycle: a group of unusual mitochondrial diseases in human. Rustin P, et al. **Biochim Biophys Acta** 1997 Aug 22;1361(2):185–97 (35 ref.)

The sulfatase gene family. Parenti G, et al. **Curr Opin Genet Dev** 1997 Jun;7(3):386–91 (35 ref.)

Protein processing: a role in the pathophysiology of genetic disease. Brooks DA. **FEBS Lett** 1997 Jun 9;409(2):115–20 (50 ref.)

Mutations in mut methylmalonic acidemia: clinical and enzymatic correlations. Ledley FD, et al. **Hum Mutat** 1997; 9(1):1–6 (39 ref.)

Inherited metabolic diseases affecting the carrier. Endres W. **J Inherit Metab Dis** 1997 Mar;20(1):9–20 (79 ref.)

Inborn errors of signal transduction: mutations in G proteins and G protein-coupled receptors as a cause of disease. Spiegel AM. **J Inherit Metab Dis** 1997 Jun;20(2):113–21 (20 ref.)

Neurological presentations of mitochondrial diseases. Zeviani M, et al. **J Inherit Metab Dis** 1996;19(4):504–20 (41 ref.)

[Genetic diagnosis of inborn error of metabolism by microsatellite marker analysis] Kure S. **Rinsho Byori** 1996 Feb;44(2):116–9 (2 ref.) (Eng. Abstr.) **(Jpn)**

[Abnormal gene expression related with symptoms in inherited metabolic disease] Horiuchi M, et al. **Seikagaku** 1996 Oct;68(10):1654–7 (16 ref.) **(Jpn)**

METABOLISM

Abnormal cholesterol metabolism in Smith-Lemli-Opitz syndrome. Elias ER, et al. **Curr Opin Pediatr** 1995 Dec; 7(6):710–4 (27 ref.)

Iron, copper, and zinc absorption and turnover; the use of stable isotopes. Aggett PJ. **Eur J Pediatr** 1997 Aug;156 Suppl 1:S29–34 (27 ref.)

New insights into lipid and fatty acid metabolism via stable isotopes. Demmelmair H, et al. **Eur J Pediatr** 1997 Aug; 156 Suppl 1:S70–4 (20 ref.)

Measurement of glucose turnover--implications for the study of inborn errors of metabolism. Halliday D, et al. **Eur J Pediatr** 1997 Aug;156 Suppl 1:S35–8 (24 ref.)

The role of magnetic resonance spectroscopy in the investigation of lactic acidosis and inborn errors of energy metabolism. Gadian DG, et al. **J Inherit Metab Dis** 1996; 19(4):548–52 (21 ref.)

Urea cycle disorders: clinical paradigm of hyperammonemic encephalopathy. Brusilow SW. **Prog Liver Dis** 1995; 13:293–309 (52 ref.)

PATHOLOGY

[Diagnosis of neurometabolic and neurodegenerative diseases by cutaneous biopsy] Idoate Gastearena MA, et al. **Rev Neurol** 1997 Sep;25 Suppl 3:S269–80 (64 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

A Ca(2+)-sensing receptor: from physiology to inherited disorders of calcium homeostasis. Hebert SC, et al. **Adv Nephrol Necker Hosp** 1996;25:245–55 (55 ref.)

Protein processing: a role in the pathophysiology of genetic disease. Brooks DA. **FEBS Lett** 1997 Jun 9;409(2):115–20 (50 ref.)

THERAPY

The treatment of congenital lactic acidoses. Morris AA, et al. **J Inherit Metab Dis** 1996;19(4):573–80 (44 ref.)

VETERINARY

Congenital erythrocyte enzyme deficiencies. Harvey JW. **Vet Clin North Am Small Anim Pract** 1996 Sep; 26(5):1003–11 (45 ref.)

METABOLITE MARKERS, NEOPLASM see **TUMOR MARKERS, BIOLOGICAL**

METABOTROPIC GLUTAMATE RECEPTORS see **RECEPTORS, METABOTROPIC GLUTAMATE**

METACARPOPHALANGEAL JOINT

Metacarpophalangeal joints in rheumatoid arthritis of the hand. Stirrat CR. **Hand Clin** 1996 Aug;12(3):515–29 (34 ref.)

PATHOLOGY

[Diabetic cheiroarthropathy] Bruscas C, et al. **An Med Interna** 1996 Jun;13(6):295–8 (38 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Current status of metacarpophalangeal arthroplasty and basilar joint arthroplasty of the thumb. Murray PM. **Clin Plast Surg** 1996 Jul;23(3):395–406 (73 ref.)

Simultaneous open dislocations of the interphalangeal and metacarpo-phalangeal joints in a thumb--a case report. Lee JC, et al. **Singapore Med J** 1996 Jun;37(3):318–9 (7 ref.)

METACARPUS

INJURIES

Coronal fracture of the hamate body. Chase JM, et al. **Am J Orthop** 1997 Aug;26(8):568–71 (14 ref.)

PATHOLOGY

[Metastasis of an adenocarcinoma of the colon to the 1st metacarpal bone] Méndez López JM, et al. **Ann Chir Main Memb Super** 1997;16(2):134–7 (8 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Aneurysmal bone cyst of metacarpal. Apaydin A, et al. **Skeletal Radiol** 1996 Jan;25(1):76–8 (11 ref.)

METAETHICS see **ETHICS**

METAGONIMIASIS see **TREMATODE INFECTIONS**

METAL ANTAGONISTS see **CHELATING AGENTS**

METAL CERAMIC ALLOYS

[The restoration of metal-ceramic dentures in the patient's mouth] Kopeĭkin VN, et al. **Stomatologiia (Mosk)** 1996; 75(6):74–8 (61 ref.) **(Rus)**

METAL CERAMIC RESTORATIONS see **METAL CERAMIC ALLOYS**

METALLO-CERAMIC ALLOYS see **METAL CERAMIC ALLOYS**

METALLO-ORGANIC COMPOUNDS see **ORGANOMETALLIC COMPOUNDS**

METALLOPORPHYRINS

PHARMACOLOGY

Pitfalls using metalloporphyrins in carbon monoxide research. Grundemar L, et al. **Trends Pharmacol Sci** 1997 Jun;18(6):193–5 (35 ref.)

METALLOPROTEASES see **METALLOPROTEINASES**

METALLOPROTEINASES

Matrix metalloproteinases. Parsons SL, et al. **Br J Surg** 1997 Feb;84(2):160–6 (99 ref.)

Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. Chandler S, et al. **J Neuroimmunol** 1997 Feb;72(2):155–61 (95 ref.)

[Metalloproteinase-mediated release of human fas ligand] Kayagaki N, et al. **Nippon Rinsho** 1996 Jul;54(7):1747–52 (25 ref.) (Eng. Abstr.) **(Jpn)**

[ADAM family proteins and cell fusion] Endo T. **Seikagaku** 1996 Aug;68(8):1453–8 (17 ref.) **(Jpn)**

[Matrix metalloproteinases: their structures and functions, with special reference to their roles in tumor invasion and metastasis] Miyazaki K, et al. **Seikagaku** 1996 Dec; 68(12):1791–807 (97 ref.) **(Jpn)**

AGONISTS

Involvement of tissue inhibitors of metalloproteinases (TIMPS) during matrix metalloproteinase activation. Nagase H, et al. **Adv Exp Med Biol** 1996;389:23–31 (37 ref.)

ANTAGONISTS & INHIBITORS

Neutral proteinases and their inhibitors in the loosening of total hip prostheses. Takagi M. **Acta Orthop Scand Suppl** 1996 Oct;271:3–29 (198 ref.)

The role of metalloproteinases and their inhibitors in hematological disorders. Guedez L, et al. **Crit Rev Oncog** 1996;7(3–4):205–25 (177 ref.)

Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Talbot DC, et al. **Eur J Cancer** 1996 Dec;32A(14):2528–33 (42 ref.)

Matrix metalloproteinase inhibitors. Wojtowicz-Praga SM, et al. **Invest New Drugs** 1997;15(1):61–75 (94 ref.)

Matrix metalloproteinase inhibitors in the treatment of cancer. Brown PD. **Med Oncol** 1997 Mar;14(1):1–10 (74 ref.)

Metalloproteinase inhibitors and the prevention of connective tissue breakdown. Cawston TE. **Pharmacol Ther** 1996; 70(3):163–82 (278 ref.)

The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Moses MA. **Stem Cells** 1997;15(3):180–9 (88 ref.)

[CDK and MMP inhibitors] Okuyama A, et al. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1547–62 (62 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

MMP-2: expression, activation and inhibition. Corcoran ML, et al. **Enzyme Protein** 1996;49(1–3):7–19 (79 ref.)

Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Basset P, et al. **Matrix Biol** 1997 Mar;15(8–9):535–41 (51 ref.)

The AP-1 site and MMP gene regulation: what is all the fuss about? Benbow U, et al. **Matrix Biol** 1997 Mar; 15(8–9):519–26 (60 ref.)

Regulation of matrix metalloproteinase expressions in astrocytes, microglia and neurons. Gottschall PE, et al. **Neuroimmunomodulation** 1996 Mar–Jun;3(2–3):69–75 (57 ref.)

CHEMISTRY

Structure and biosynthesis of meprins. Marchand P, et al. **Adv Exp Med Biol** 1996;389:13–22 (41 ref.)

Involvement of tissue inhibitors of metalloproteinases (TIMPS) during matrix metalloproteinase activation. Nagase H, et al. **Adv Exp Med Biol** 1996;389:23–31 (37 ref.)

Structural features and biochemical properties of TNF-alpha converting enzyme (TACE). Moss ML, et al. **J Neuroimmunol** 1997 Feb;72(2):127–9 (18 ref.)

Relating matrix metalloproteinase structure to function: why the "hemopexin" domain? Murphy G, et al. **Matrix Biol** 1997 Mar;15(8–9):511–8 (56 ref.)

Structure and function of tetanus and botulinum neurotoxins. Montecucco C, et al. **Q Rev Biophys** 1995 Nov;28(4):423–72 (335 ref.)

Snake venom metalloproteinases: structure, function and relationship to the ADAMs family of proteins. Jia LG, et al. **Toxicon** 1996 Nov-Dec;34(11–12):1269–76 (22 ref.)

Biochemical characterization of atroxase and nucleotide sequence encoding the fibrinolytic enzyme. TU AT, et al. **Toxicon** 1996 Nov-Dec;34(11–12):1295–300 (7 ref.)

[Metalloproteinases in the extracellular matrix: structure and activity] Cuvelier A, et al. **Rev Mal Respir** 1997 Jan; 14(1):1–10 (42 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

The metzincin-superfamily of zinc-peptidases. Bode W, et al. **Adv Exp Med Biol** 1996;389:1–11 (49 ref.)

Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases. Borden P, et al. **Crit Rev Eukaryot Gene Expr** 1997;7(1–2):159–78 (150 ref.)

Mechanisms controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells.

Crawford HC, et al. **Enzyme Protein** 1996;49(1-3):20-37 (105 ref.)
Nuclear hormone receptors inhibit matrix metalloproteinase (MMP) gene expression through diverse mechanisms. Schroen DJ, et al. **Gene Expr** 1996;6(4):197-207 (95 ref.)
Biochemical characterization of atroxase and nucleotide sequence encoding the fibrinolytic enzyme. TU AT, et al. **Toxicon** 1996 Nov-Dec;34(11-12):1295-300 (7 ref.)

IMMUNOLOGY

Cross-reactivities of polyclonal antibodies against lebetase, fibrinolytic enzyme of Levantine viper (Vipera lebetina) venom. Siigur J, et al. **Toxicon** 1996 May;34(5):608-13 (17 ref.)

METABOLISM

Involvement of tissue inhibitors of metalloproteinases (TIMPS) during matrix metalloproteinase activation. Nagase H, et al. **Adv Exp Med Biol** 1996;389:23-31 (37 ref.)
Tetanus and botulism neurotoxins: a novel group of zinc-endopeptidases. Tonello F, et al. **Adv Exp Med Biol** 1996;389:251-60 (47 ref.)
Regulation of matrilysin in the rat uterus. Woessner JF Jr. **Biochem Cell Biol** 1996;74(6):777-84 (62 ref.)
Activation mechanisms of matrix metalloproteinases. Nagase H. **Biol Chem** 1997 Mar-Apr;378(3-4):151-60 (73 ref.)
Upregulation of enzymatic activity by interleukin-1 in osteoarthritis. Chevalier X. **Biomed Pharmacother** 1997; 51(2):58-62 (34 ref.)
Human matrix metalloproteinase specificity studies using collagen sequence-based synthetic peptides. Nagase H, et al. **Biopolymers** 1996;40(4):399-416 (101 ref.)
Mechanisms of glioma invasion: role of matrix-metalloproteinases. Uhm JH, et al. **Can J Neurol Sci** 1997 Feb;24(1):3-15 (143 ref.)
The role of matrix metalloproteinases in heart disease [see comments] Cleutjens JP. **Cardiovasc Res** 1996 Nov; 32(5):816-21 (35 ref.) Comment in: Cardiovasc Res 1996 Nov;32(5):814-5.
Matrix metalloproteinases and the development of cancer. Coussens LM, et al. **Chem Biol** 1996 Nov;3(11):895-904 (56 ref.)
Morphogenesis: collagen it takes and bone it makes. Olsen BR. **Curr Biol** 1996 Jun 1;6(6):645-7 (11 ref.)
ADAMs and cell fusion. Huovila APJ, et al. **Curr Opin Cell Biol** 1996 Oct;8(5):692-9 (44 ref.)
What structure and function of avian plasminogen activator and matrix metalloproteinase-2 reveal about their counterpart mammalian enzymes, their regulation and their role in tumor invasion. Alexander DS, et al. **Enzyme Protein** 1996;49(1-3):38-58 (98 ref.)
Cooperation between matrix metalloproteinases and the plasminogen activator-plasmin system in tumor progression. DeClerck YA, et al. **Enzyme Protein** 1996; 49(1-3):72-84 (95 ref.)
Stromal cell expression of components of matrix-degrading protease systems in human cancer. Hewitt R, et al. **Enzyme Protein** 1996;49(1-3):163-73 (89 ref.)
The mitochondrial processing peptidase: function and specificity. Luciano P, et al. **Experientia** 1996 Dec 15; 52(12):1077-82 (70 ref.)
Membrane-type matrix metalloproteinases (MT-MMPs) in tumor metastasis. Sato H, et al. **J Biochem (Tokyo)** 1996 Feb;119(2):209-15 (36 ref.)
Changing views of the role of matrix metalloproteinases in metastasis. Chambers AF, et al. **J Natl Cancer Inst** 1997 Sep 3;89(17):1260-70 (127 ref.)
Matrix metalloproteinases (MMPs) in renal fibrosis. Norman JT, et al. **Kidney Int Suppl** 1996 May;54:S61-3 (9 ref.)
Relating matrix metalloproteinase structure to function: why the "hemopexin" domain? Murphy G, et al. **Matrix Biol** 1997 Mar;15(8-9):511-8 (56 ref.)
Mighty mice: transgenic technology "knocks out" questions of matrix metalloproteinase function. Shapiro SD. **Matrix Biol** 1997 Mar;15(8-9):527-33 (32 ref.)
Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases. Fowlkes JL, et al. **Prog Growth Factor Res** 1995;6(2-4):255-63 (26 ref.)
Extracellular matrix-remodeling metalloproteinases and infection of the central nervous system with retrovirus human T-lymphotropic virus type I (HTLV-I). Giraudon P, et al. **Prog Neurobiol** 1996 Jun;49(2):169-84 (60 ref.)
The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Moses MA. **Stem Cells** 1997;15(3):180-9 (88 ref.)
Membrane-type matrix metalloproteinases (MT-MMPs) in cell invasion. Sato H, et al. **Thromb Haemost** 1997 Jul; 78(1):497-500 (37 ref.)
[Autocrine-generated matrix metalloproteinases of tumor cells and the cascade network of protease activation mediated by membrane associated urokinase-type plasminogen activator: involvement in the degradation of extracellular matrices] Takahashi K. **Rinsho Byori** 1997 Feb;Suppl 104:159-69 (28 ref.) **(Jpn)**
[Structural study of staphylokinase related with the expression of activity] Ueshima S, et al. **Rinsho Byori** 1997 Feb;Suppl 104:171-8 (23 ref.) **(Jpn)**

PHYSIOLOGY

Neutral proteinases and their inhibitors in the loosening of total hip prostheses. Takagi M. **Acta Orthop Scand Suppl** 1996 Oct;271:3-29 (198 ref.)
Role of matrix metalloproteinases in abdominal aortic aneurysms. Thompson RW, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:157-74 (93 ref.)
Inflammation and cytokine signaling in aneurysms. McMillan WD, et al. **Ann Vasc Surg** 1997 Sep;11(5):540-5 (36 ref.)
The roles of adhesion molecules and proteinases in lymphocyte transendothelial migration. Madri JA, et al. **Biochem Cell Biol** 1996;74(6):749-57 (60 ref.)
Molecular regulation of cellular invasion--role of gelatinase A and TIMP-2. Yu AE, et al. **Biochem Cell Biol** 1996; 74(6):823-31 (74 ref.)
Why did the sperm cross the cumulus? To get to the oocyte. Functions of the sperm surface proteins PH-20 and fertilin in arriving at, and fusing with, the egg. Myles DG, et al. **Biol Reprod** 1997 Feb;56(2):320-7 (58 ref.)
Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. MacDougall JR, et al. **Cancer Metastasis Rev** 1995 Dec;14(4):351-62 (84 ref.)
Metalloprotease-disintegrins: links to cell adhesion and cleavage of TNF alpha and Notch. Blobel CP. **Cell** 1997 Aug 22;90(4):589-92 (17 ref.)
The role of metalloproteinases and their inhibitors in hematological disorders. Guedez L, et al. **Crit Rev Oncog** 1996;7(3-4):205-25 (177 ref.)
Stromelysin-3: a paradigm for stroma-derived factors implicated in carcinoma progression. Basset P, et al. **Crit Rev Oncol Hematol** 1997 May;26(1):43-53 (99 ref.)
Plasminogen activators and matrix metalloproteinases in angiogenesis. Mignatti P, et al. **Enzyme Protein** 1996; 49(1-3):117-37 (216 ref.)
Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. Turner AJ, et al. **FASEB J** 1997 Apr; 11(5):355-64 (56 ref.)
Matrix metalloproteinases in normal menstruation. Salamonsen LA, et al. **Hum Reprod** 1996 Oct;11 Suppl 2:124-33 (45 ref.)
The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application. Bramhall SR. **Int J Pancreatol** 1997 Feb; 21(1):1-12 (100 ref.)
The functional balance of metalloproteinases and inhibitors in tissue degradation: relevance to oral pathologies. Reynolds JJ, et al. **J R Coll Surg Edinb** 1997 Jun; 42(3):154-60 (76 ref.)
Gelatinase A is a glomerular mesangial cell growth and differentiation factor. Turck J, et al. **Kidney Int** 1997 May; 51(5):1397-400 (9 ref.)
Matrix metalloproteinases as mediators of reproductive function. Hulboy DL, et al. **Mol Hum Reprod** 1997 Jan; 3(1):27-45 (211 ref.)
Matrix-degrading metalloproteinases in tumor progression. Matrisian LM, et al. **Princess Takamatsu Symp** 1994; 24:152-61 (27 ref.)
Steroid and growth factor regulation of matrix metalloproteinase expression and endometriosis. Osteen KG, et al. **Semin Reprod Endocrinol** 1996 Aug;14(3):247-55 (75 ref.)
[Metalloproteinases in the extracellular matrix: structure and activity] Cuvelier A, et al. **Rev Mal Respir** 1997 Jan; 14(1):1-10 (42 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Fibrin-selective thrombolytic therapy with recombinant staphylokinase. Collen D, et al. **Haemostasis** 1996 Oct;26 Suppl 4:294-300 (25 ref.)

TOXICITY

Structure and function of tetanus and botulinum neurotoxins. Montecucco C, et al. **Q Rev Biophys** 1995 Nov;28(4):423-72 (335 ref.)
Insights into the mechanism of haemorrhage caused by snake venom metalloproteinases. Kamiguti AS, et al. **Toxicon** 1996 Jun;34(6):627-42 (96 ref.)

METALLOPROTEINS

[Xanthine oxidase deficiency (hereditary xanthinuria), molybdenum cofactor deficiency] Sumi S, et al. **Nippon Rinsho** 1996 Dec;54(12):3333-6 (11 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

[Protein immobilization in lipid bilayer membrane films on electrodes and their electron transfer reactions] Tominaga M, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep; 41(11):1600-6 (8 ref.) **(Jpn)**

CHEMISTRY

Molybdenum-cofactor-containing enzymes: structure and mechanism. Kisker C, et al. **Annu Rev Biochem** 1997; 66:233-67 (74 ref.)
Reactions of nitric oxide with metalloproteins. Radi R. **Chem Res Toxicol** 1996 Jul-Aug;9(5):828-35 (84 ref.)
Novel metal sites in protein structures. Volbeda A, et al. **Curr Opin Struct Biol** 1996 Dec;6(6):804-12 (54 ref.)
Metal NMR for the study of metalloproteins. Drakenberg T, et al. **Methods Mol Biol** 1997;60:299-323 (67 ref.)
The solution structure of paramagnetic metalloproteins. Bertini I, et al. **Prog Biophys Mol Biol** 1996;66(1):43-80 (148 ref.)
[Biological activity of a carrier molecule-iron complex: probable mechanisms of intestinal absorption] Curri SB. **Boll Chim Farm** 1996 Apr;135(4):248-58 (21 ref.) (Eng. Abstr.) **(Ita)**

METABOLISM

Molybdenum-cofactor-containing enzymes: structure and mechanism. Kisker C, et al. **Annu Rev Biochem** 1997; 66:233-67 (74 ref.)
Structure and function of rotavirus NSP1. Taniguchi K, et al. **Arch Virol Suppl** 1996;12:53-8 (22 ref.)
Modulation by nitric oxide of metalloprotein regulatory activities. Drapier JC, et al. **Bioessays** 1996 Jul;18(7):549-56 (89 ref.)
Heavy metal detoxification in higher plants--a review. Zenk MH. **Gene** 1996 Nov 7;179(1):21-30 (40 ref.)
Aconitases: a class of metalloproteins highly sensitive to nitric oxide synthesis. Drapier JC, et al. **Methods Enzymol** 1996; 269:26-36 (53 ref.)

PHYSIOLOGY

Calcium- and zinc-binding proteins in intracellular transport. Aballay A, et al. **Biocell** 1996 Dec;20(3):339-42 (28 ref.)

METALLOTHIONEIN

[Metallothionein] Naganuma A. **Nippon Rinsho** 1997 May; 55(5):1091-5 (21 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

[Metallothionein expression as a marker of therapeutic sensitivity in the early stages of testicular cancer] Eid H, et al. **Orv Hetil** 1997 Jan 19;138(3):135-9 (28 ref.) (Eng. Abstr.) **(Hun)**

GENETICS

Yeast metallothionein gene expression in response to metals and oxidative stress. Liu XD, et al. **Methods** 1997 Mar; 11(3):289-99 (56 ref.)

IMMUNOLOGY

Stress proteins as agents of immunological change: some lessons from metallothionein. Borghesi LA, et al. **Cell Stress Chaperones** 1996 Jun;1(2):99-108 (114 ref.)

METABOLISM

Role of metallothionein in cadmium-induced hepatotoxicity and nephrotoxicity. Klaassen CD, et al. **Drug Metab Rev** 1997 Feb-May;29(1-2):79-102 (66 ref.)
Small-intestinal absorption of cadmium and the significance of mucosal metallothionein. Elsenhans B, et al. **Hum Exp Toxicol** 1997 Aug;16(8):429-34 (28 ref.)
Further observations on the etiology of pre-eclampsia: mobilization of toxic cadmium-metallothionein into the serum during pregnancy. Chisolm JC, et al. **Med Hypotheses** 1996 Aug;47(2):123-8 (93 ref.)

PHYSIOLOGY

Metallothionein in physiological and physiopathological processes. Moffatt P, et al. **Drug Metab Rev** 1997 Feb-May; 29(1-2):261-307 (243 ref.)
Metallothioneins in brain--the role in physiology and pathology. Aschner M, et al. **Toxicol Appl Pharmacol** 1997 Feb;142(2):229-42 (120 ref.)
[Metallothionein '96] Abe T. **Sangyo Ika Daigaku Zasshi** 1997 Mar 1;19(1):57-61 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Function of metallothionein in the body] Floriańczyk B. **Postepy Hig Med Dosw** 1996;50(4):375-82 (39 ref.) (Eng. Abstr.) **(Pol)**

METALLURGY

Prevention by exposure assessment. Flyvholm MA. **Curr Probl Dermatol** 1996;25:97-105 (29 ref.)
Metal workers and repairmen at risk for prostate cancer: a review. van der Gulden JW. **Prostate** 1997 Feb 1; 30(2):107-16 (93 ref.)

METALS

see related
ORGANOMETALLIC COMPOUNDS

Microrough surface of metallic biomaterials: a literature review. Wen X, et al. **Biomed Mater Eng** 1996;6(3):173-89 (97 ref.)
Clinical perspective of inorganic dusts, metals, and fumes exposures. Skarote SJ, et al. **Curr Opin Pulm Med** 1997 May;3(3):209-14 (53 ref.)
[Biliary endoprosthesis using metallic stents in management of malignant biliary strictures] Ogawa K, et al. **Nippon Rinsho** 1996 Nov;54(11):3143-56 (28 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Experimental research into the pathogenesis of cobalt/hard metal lung disease. Lison D, et al. **Eur Respir J** 1996 May;

9(5):1024–8 (21 ref.)
Metal implants and surface reactions. Steinemann SG. **Injury** 1996;27 Suppl 3:SC16–22 (22 ref.)
Metallosis mimicking infection in a cemented total knee replacement. Huo MH, et al. **Orthopedics** 1997 May; 20(5):466–70 (18 ref.)
Epidemiology and the identification of metals as human carcinogens. Duffus JH. **Sci Prog** 1996;79 (Pt 4):311–26 (36 ref.)
[Nephropathy induced by non-drug chemical agents] Miyazaki K, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):577–9 (15 ref.) **(Jpn)**

ANALYSIS

Analysis of inorganic pollutants by capillary electrophoresis. Timerbaev AR. **Electrophoresis** 1997 Feb;18(2):185–95 (104 ref.)
Chromatographic and hyphenated methods for elemental speciation analysis in environmental media. Ellis LA, et al. **J Chromatogr A** 1997 Jul 11;774(1–2):3–19 (110 ref.)

BLOOD

Blood radicals: reactive nitrogen species, reactive oxygen species, transition metal ions, and the vascular system. Darley-Usmar V, et al. **Pharm Res** 1996 May;13(5):649–62 (192 ref.)

CHEMISTRY

Nitric oxide and metal–catalyzed reactions. Kanner J. **Methods Enzymol** 1996;269:218–29 (42 ref.)
Improved immuno double labelling for cell and structural biology. Koeck PJ, et al. **Micron** 1996 Apr;27(2):157–65 (124 ref.)

CLASSIFICATION

Metal–microbe interactions: contemporary approaches. Beveridge TJ, et al. **Adv Microb Physiol** 1997;38:177–243 (220 ref.)

ISOLATION & PURIFICATION

The role of lysosomes in the selective concentration of mineral elements. A microanalytical study. Berry JP. **Cell Mol Biol (Noisy-le-grand)** 1996 May;42(3):395–411 (26 ref.)
Phytoremediation of soil metals. Chaney RL, et al. **Curr Opin Biotechnol** 1997 Jun;8(3):279–84 (63 ref.)
Bioremediation of metal contamination. Lovley DR, et al. **Curr Opin Biotechnol** 1997 Jun;8(3):285–9 (68 ref.)

METABOLISM

Metal–microbe interactions: contemporary approaches. Beveridge TJ, et al. **Adv Microb Physiol** 1997;38:177–243 (220 ref.)
Metal–ion sites as structural and functional probes of helix–helix interactions in 7TM receptors. Elling CE, et al. **Ann N Y Acad Sci** 1997 Apr 24;814:142–51 (57 ref.)
The role of lysosomes in the selective concentration of mineral elements. A microanalytical study. Berry JP. **Cell Mol Biol (Noisy-le-grand)** 1996 May;42(3):395–411 (26 ref.)
Engineering metal–binding sites in proteins. Lu Y, et al. **Curr Opin Struct Biol** 1997 Aug;7(4):495–500 (61 ref.)
Microbial solubilization and immobilization of toxic metals: key biogeochemical processes for treatment of contamination. White C, et al. **FEMS Microbiol Rev** 1997 Jul;20(3–4):503–16 (98 ref.)

PHARMACOKINETICS

Phytoremediation of soil metals. Chaney RL, et al. **Curr Opin Biotechnol** 1997 Jun;8(3):279–84 (63 ref.)
Bioremediation of metal contamination. Lovley DR, et al. **Curr Opin Biotechnol** 1997 Jun;8(3):285–9 (68 ref.)
A conceptual framework for implementation of bioavailability of metals for environmental management purposes. Peijnenburg WJ, et al. **Ecotoxicol Environ Saf** 1997 Jul;37(2):163–72 (48 ref.)

PHARMACOLOGY

Toxic and essential metal interactions. Goyer RA. **Annu Rev Nutr** 1997;17:37–50 (74 ref.)
Yeast metallothionein gene expression in response to metals and oxidative stress. Liu XD, et al. **Methods** 1997 Mar; 11(3):289–99 (56 ref.)
[Metal resistance systems in Pseudomonas] Cervantes C, et al. **Rev Latinoam Microbiol** 1996 Jan–Mar;38(1):45–64 (138 ref.) (Eng. Abstr.) **(Spa)**

POISONING

Toxic and essential metal interactions. Goyer RA. **Annu Rev Nutr** 1997;17:37–50 (74 ref.)

TOXICITY

Intranuclear dense bodies after metal intoxication: a review of ultrastructural and microanalytical findings. Boulahdour H, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 May; 42(3):421–9 (43 ref.)
Factors influencing susceptibility to metals. Gochfeld M. **Environ Health Perspect** 1997 Jun;105 Suppl 4:817–22 (66 ref.)
Toxic metal–responsive gene transcription. Zhu Z, et al. **EXS** 1996;77:307–20 (59 ref.)
Microbial solubilization and immobilization of toxic metals: key biogeochemical processes for treatment of contamination. White C, et al. **FEMS Microbiol Rev** 1997 Jul;20(3–4):503–16 (98 ref.)
Bacterial resistances to toxic metal ions—a review. Silver S. **Gene** 1996 Nov 7;179(1):9–19 (70 ref.)

METALS, HEAVY

ADVERSE EFFECTS

Occupational and environmental renal disease. Wedeen RP. **Semin Nephrol** 1997 Jan;17(1):46–53 (35 ref.)
[The effect of heavy metals on neutrophils] Hrycek A, et al. **Wiad Lek** 1996;49(7–12):107–11 (23 ref.) (Eng. Abstr.) **(Pol)**

ANALYSIS

Environmental health implications of heavy metal pollution from car tires. Horner JM. **Rev Environ Health** 1996 Oct–Dec;11(4):175–8 (12 ref.)
[The heavy metal problem in food products and the approaches to using raw foodstuffs with a high content of heavy metals (a review)] Karpliuk IA, et al. **Vopr Pitan** 1996;(1):22–6 (25 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

A novel family of ubiquitous heavy metal ion transport proteins. Paulsen IT, et al. **J Membr Biol** 1997 Mar 15; 156(2):99–103 (26 ref.)
Public health benefits of using algae for simultaneous multiple metal extraction from waters. Pascucci PR, et al. **Rev Environ Health** 1996 Oct–Dec;11(4):205–11 (16 ref.)

PHARMACOKINETICS

Heavy metal detoxification in higher plants—a review. Zenk MH. **Gene** 1996 Nov 7;179(1):21–30 (40 ref.)

PHARMACOLOGY

Bacterial heavy metal resistance: new surprises. Silver S, et al. **Annu Rev Microbiol** 1996;50:753–89 (132 ref.)

TOXICITY

Threats by heavy metals: human and environmental contamination in Brazil. Moreira JC. **Sci Total Environ** 1996 Sep;188 Suppl 1:S61–71 (22 ref.)
[Heavy metals in the soil–plant–man system (review)] Mudryĭ IV. **Gig Sanit** 1997 Jan–Feb;(1):14–7 (23 ref.) **(Rus)**

METALS, RARE EARTH

Liquid chromatographic determination using lanthanides as time-resolved luminescence probes for drugs and xenobiotics: advantages and limitations. Rieutord A, et al. **Analyst** 1997 May;122(5):59R–66R (44 ref.)

CHEMISTRY

Modern bioassays using metal chelates as luminescent probes. Sammes PG, et al. **Nat Prod Rep** 1996 Feb;13(1):1–28 (125 ref.)

METAMORPHOSIS, BIOLOGICAL

Dueling orphans—interacting nuclear receptors coordinate Drosophila metamorphosis. Thummel CS. **Bioessays** 1997 Aug;19(8):669–72 (26 ref.)
The analysis of complex developmental programmes: amphibian metamorphosis. Kanamori A, et al. **Genes Cells** 1996 May;1(5):429–35 (59 ref.)
What mechanisms control neoteny and regulate induced metamorphosis in urodeles? Rosenkilde P, et al. **Int J Dev Biol** 1996 Aug;40(4):665–73 (55 ref.)
[Proteases participating in metamorphosis of flesh fly (Sarcophaga peregrina)] Homma K. **Seikagaku** 1997 Apr; 69(4):259–64 (14 ref.) **(Jpn)**

GENETICS

Files on steroids—Drosophila metamorphosis and the mechanisms of steroid hormone action. Thummel CS. **Trends Genet** 1996 Aug;12(8):306–10 (48 ref.)

PHYSIOLOGY

Ecdysone signaling cascade and regulation of Drosophila metamorphosis. Baehrecke EH. **Arch Insect Biochem Physiol** 1996;33(3–4):231–44 (69 ref.)
Metamorphosis: an exquisite model for hormonal regulation of post–embryonic development. Tata JR. **Biochem Soc Symp** 1996;62:123–36 (62 ref.)
Evolution of gnathostome lateral line ontogenies. Northcutt RG. **Brain Behav Evol** 1997 Jul;50(1):25–37 (70 ref.)
Neural mechanisms of behavioral plasticity: metamorphosis and learning in Manduca sexta. Weeks JC, et al. **Brain Behav Evol** 1997;50 Suppl 1:69–80 (60 ref.)
Steroid receptors and nervous system metamorphosis in insects. Truman JW. **Dev Neurosci** 1996;18(1–2):87–101 (41 ref.)

METAPHASE

[The latest achievements of radiation cytogenetics in connection with the discovery of the method for the fluorescence hybridization in situ of the metaphase chromosomes of man and experimental animals using DNA probes (FISH)] Pilinskaia MA. **Tsitol Genet** 1996 Jul–Aug; 30(4):70–85 (74 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

The metaphase chromosome as a reporter of nuclear activity. Bickmore W. **Exp Cell Res** 1996 Dec 15;229(2):198–200 (18 ref.)

PHYSIOLOGY

The metaphase chromosome as a reporter of nuclear activity. Bickmore W. **Exp Cell Res** 1996 Dec 15;229(2):198–200 (18 ref.)

METAPHOR

Containers, mental space and psychodynamics. Rosenbaum B, et al. **Br J Med Psychol** 1996 Dec;69 (Pt 4):281–97 (44 ref.)
Understanding diverse effects of visual attention with the VAP-filters metaphor. Cheal M. **Conscious Cogn** 1997 Jun–Sep;6(2–3):348–62 (76 ref.)

METAPLASIA

see related
MYELOID METAPLASIA

METASTASIS see **NEOPLASM METASTASIS**

METATARSAL BONES

INJURIES

Metatarsal stress fractures. Weinfeld SB, et al. **Clin Sports Med** 1997 Apr;16(2):319–38 (30 ref.)
Acute hematogenous osteomyelitis in intravenous drug users. Fox IM, et al. **J Foot Ankle Surg** 1997 Jul–Aug;36(4):301–5 (13 ref.)

SURGERY

Laterally closing metatarsal head osteotomy in the correction of a medially overlapping digit. Berens TA. **Clin Podiatr Med Surg** 1996 Apr;13(2):293–307 (7 ref.)
Current concepts of absorbable fixation in first ray surgery. Cicchinelli LD, et al. **Clin Podiatr Med Surg** 1996 Jul; 13(3):533–47 (45 ref.)
Clawfoot deformity: an analysis of the causes and surgical treatment using a modification of the Jones suspension procedure. Grumbine NA, et al. **Clin Podiatr Med Surg** 1996 Apr;13(2):221–38 (19 ref.)
Complications of distal first metatarsal osteotomies. Hanft J. **Clin Podiatr Med Surg** 1996 Jul;13(3):355–65 (21 ref.)
Research perspectives in first metatarsal osteotomy and fixation stability. Landsman AS, et al. **Clin Podiatr Med Surg** 1996 Jul;13(3):575–87 (34 ref.)

METATARSAL DEFORMITY see **FOOT DEFORMITIES**

METATARSALS see **METATARSAL BONES**

METATARSOPHALANGEAL JOINT

Hallux limitus and hallux rigidus. Clinical examination, radiographic findings, and natural history. Camasta CA. **Clin Podiatr Med Surg** 1996 Jul;13(3):423–48 (64 ref.)
Sesamoid complex disorders. Oloff LM, et al. **Clin Podiatr Med Surg** 1996 Jul;13(3):497–513 (36 ref.)
The hallucal interphalangeal sesamoid [see comments] Roukis TS, et al. **J Foot Ankle Surg** 1996 Jul–Aug;35(4):303–8; discussion 372 (17 ref.) Comment in: J Foot Ankle Surg 1997 Jan–Feb;36(1):76–7.

PATHOLOGY

Pathological anatomy and dynamic effect of the displaced plantar plate and the importance of the integrity of the plantar plate–deep transverse metatarsal ligament tie–bar. Stainsby GD. **Ann R Coll Surg Engl** 1997 Jan;79(1):58–68 (17 ref.)

PHYSIOPATHOLOGY

Hallux limitus in the athlete. Lichniak JE. **Clin Podiatr Med Surg** 1997 Jul;14(3):407–26 (24 ref.)

SURGERY

Laterally closing metatarsal head osteotomy in the correction of a medially overlapping digit. Berens TA. **Clin Podiatr Med Surg** 1996 Apr;13(2):293–307 (7 ref.)
Arthrodesis of the first metatarsophalangeal joint in active people. Bouché RT, et al. **Clin Podiatr Med Surg** 1996 Jul; 13(3):461–84 (21 ref.)
Stepwise approach to hallux limitus. A surgical perspective. Chang TJ. **Clin Podiatr Med Surg** 1996 Jul;13(3):449–59 (14 ref.)
Displacement osteotomy for the treatment of digital

transverse plane deformities. Goforth WP, et al. **Clin Podiatr Med Surg** 1996 Apr;13(2):279–92 (16 ref.)
Arthrodesis of the first metatarsophalangeal joint to salvage failed silicone implant arthroplasty. Hecht PJ, et al. **Foot Ankle Int** 1997 Jul;18(7):383–90 (63 ref.)
The misuse of the Lapidus procedure: re-evaluation of the preoperative criteria [see comments] Frankel JP, et al. **J Foot Ankle Surg** 1996 Jul–Aug;35(4):355–61; discussion 371–2 (29 ref.) Comment in: J Foot Ankle Surg 1997 Jan–Feb;36(1):71–2. Comment in: J Foot Ankle Surg 1997 Jan–Feb;36(1);72–3. Comment in: J Foot Ankle Surg 1997 Jan–Feb;36(1);73–4. Comment in: J Foot Ankle Surg 1997 Jan–Feb;36(1):74–6.

METATARSUS

see related
METATARSAL BONES

ABNORMALITIES

Rotational deformities in the lower extremities. Karol LA. **Curr Opin Pediatr** 1997 Feb;9(1):77–80 (6 ref.)

PATHOLOGY

Spontaneous fusion of the midfoot following reflex sympathetic dystrophy. A case report and review of the literature. Stratton NJ, et al. **Am J Orthop** 1996 Jul; 25(7):497–9 (16 ref.)

METAVANADATE see **VANADATES**

METENCEPHALON see **PONS**

METEORITES see **METEOROIDS**

METEOROIDS

Comet Hale–Bopp. Stardust memories [comment] Cruikshank DP. **Science** 1997 Mar 28;275(5308):1895–6 (16 ref.) Comment on: Science 1997 Mar 28;275(5308):1900–4. Comment on: Science 1997 Mar 28;275(5308):1904–7. Comment on: Science 1997 Mar 28;275(5308):1907–9. Comment on: Science 1997 Mar 28;275(5308):1909–12. Comment on: Science 1997 Mar 28;275(5308):1913–5. Comment on: Science 1997 Mar 28;275(5308):1915–8. Comment on: Science 1997 Mar 28;275(5308):1918–20.

METEOROLOGICAL FACTORS

Remotely sensed surrogates of meteorological data for the study of the distribution and abundance of arthropod vectors of disease. Hay SI, et al. **Ann Trop Med Parasitol** 1996 Feb;90(1):1–19 (93 ref.)
Biometeorological studies on urban climate. Fukuoka Y. **Int J Biometeorol** 1997 Feb;40(1):54–7 (15 ref.)
The last Ms for 40th anniversary issue. Aspects of urban human biometeorology. Jauregui E. **Int J Biometeorol** 1997 Feb;40(1):58–61 (32 ref.)
Overview of meteorological measurements for aerial spray modeling. Rafferty JE, et al. **J Am Mosq Control Assoc** 1996 Jun;12(2 Pt 2):364–7 (7 ref.)

METEORS see **METEOROIDS**

METFORMIN

PHARMACOLOGY

Metformin hydrochloride: an antihyperglycemic agent [published erratum appears in Am J Health Syst Pharm 1997 Jun 1;54(11):1335] Klepser TB, et al. **Am J Health Syst Pharm** 1997 Apr 15;54(8):893–903 (58 ref.)
Metformin: a new oral biguanide. Campbell RK, et al. **Clin Ther** 1996 May–Jun;18(3):360–71; discussion 359 (37 ref.)

THERAPEUTIC USE

An overview of metformin in the treatment of type 2 diabetes mellitus. Davidson MB, et al. **Am J Med** 1997 Jan; 102(1):99–110 (87 ref.)
Metformin and insulin: is there a role for combination therapy? Daniel JR, et al. **Ann Pharmacother** 1997 Apr; 31(4):474–80 (19 ref.)
Metformin: an antihyperglycemic agent for treatment of type II diabetes. Melchior WR, et al. **Ann Pharmacother** 1996 Feb;30(2):158–64 (48 ref.)
Treatment of non-insulin-dependent diabetes mellitus with metformin. Guthrie R. **J Am Board Fam Pract** 1997 May–Jun;10(3):213–21 (57 ref.)
Metformin: a safe and effective treatment in the management of NIDDM. Kilo C. **Mo Med** 1997 Mar;94(3):114–23 (70 ref.)
Metformin, a promising oral antihyperglycemic for the treatment of noninsulin-dependent diabetes mellitus. Wildasin EM, et al. **Pharmacotherapy** 1997 Jan–Feb; 17(1):62–73 (51 ref.)
[Insulin sparing and metabolic control with metformin–insulin combination] Isnard F. **Journ Annu Diabetol Hotel Dieu** 1997;:305–25 (90 ref.) **(Fre)**
[Value of biguanide in therapy of diabetes mellitus] Haupt E, et al. **Med Klin** 1997 Aug 15;92(8):472–9, 505 (63 ref.) (Eng. Abstr.) **(Ger)**

METHACRYLATES

THERAPEUTIC USE

[Thromboxane A2 synthetase inhibitor in asthma therapy] Machida K, et al. **Nippon Rinsho** 1996 Nov;54(11):3034–9 (17 ref.) (Eng. Abstr.) **(Jpn)**

METHADONE

Prenatal diagnosis of amniotic band syndrome in a methadone user: review of the literature and a case report. Daly CA, et al. **Ultrasound Obstet Gynecol** 1996 Aug;8(2):123–5 (12 ref.)

ADVERSE EFFECTS

Should people taking opioids for medical reasons be allowed to work and drive? [editorial] Zacny JP. **Addiction** 1996 Nov;91(11):1581–4 (16 ref.)

ECONOMICS

Treatment as harm reduction, defunding as harm maximization: the case of methadone maintenance. Rosenbaum M, et al. **J Psychoactive Drugs** 1996 Jul–Sep; 28(3):241–9 (21 ref.)

THERAPEUTIC USE

Treatment of depressive syndromes in detoxified drug addicts: use of methadone. Laqueille X, et al. **Biomed Pharmacother** 1996;50(6–7):279–82 (20 ref.)
Opiate-dependent patients receiving methadone. How physicians should manage therapy. Kahan M, et al. **Can Fam Physician** 1996 Sep;42:1769–78 (47 ref.)
Mainstreaming methadone maintenance treatment: the role of the family physician [editorial] Latowsky M, et al. **CMAJ** 1997 Aug 15;157(4):395–8 (31 ref.)
Improving detoxification outcomes from methadone maintenance treatment: the interrelationship of affective states and protracted withdrawal. Latowsky M. **J Psychoactive Drugs** 1996 Jul–Sep;28(3):251–7 (58 ref.)
Motivational factors in cocaine pharmacotherapy trials with methadone-maintained patients: problems and paradoxes. Margolin A, et al. **J Psychoactive Drugs** 1997 Apr–Jun; 29(2):205–12 (50 ref.)
Treatment as harm reduction, defunding as harm maximization: the case of methadone maintenance. Rosenbaum M, et al. **J Psychoactive Drugs** 1996 Jul–Sep; 28(3):241–9 (21 ref.)
An update on the clinical use of methadone for cancer pain. Ripamonti C, et al. **Pain** 1997 Apr;70(2–3):109–15 (70 ref.)
Managing drug misusers—a guide. Kemp K, et al. **Practitioner** 1996 May;240(1562):326–8, 330, 333–4 (8 ref.)
[Possibilities and limits of drug substitution treatment in ambulatory practice] Siegel I. **Z Arztl Fortbild (Jena)** 1996 Jun;90(4):307–13 (11 ref.) (Eng. Abstr.) **(Ger)**

METHAMINODIAZEPOXIDE see **CHLORDIAZEPOXIDE**

METHAMPHETAMINE

[Context-dependent sensitization: reconsideration and a hypothesis] Ohmori T, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1997 Apr; 17(2):61–8 (66 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research. Yasar S, et al. **J Neural Transm Suppl** 1996;48:61–73 (50 ref.)

PHARMACOKINETICS

[Alterations in brain distribution of methamphetamine in methamphetamine-sensitized animals.] Mizugaki M. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Oct; 16(5):187–91 (13 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

The role of glutamate in behavioral and neurotoxic effects of methamphetamine. Ohmori T, et al. **Neurochem Int** 1996 Sep;29(3):301–7 (41 ref.)

TOXICITY

Test methods for predicting tardive toxicity of therapeutic drugs using laboratory animals. Ando K. **J Toxicol Sci** 1996 Feb;21(1):105–7 (5 ref.)
Methamphetamine and methylenedioxymethamphetamine neurotoxicity: possible mechanisms of cell destruction. Seiden LS, et al. **NIDA Res Monogr** 1996;163:251–76 (103 ref.)
Potential new insights into the molecular mechanisms of methamphetamine-induced neurodegeneration. Wrona MZ, et al. **NIDA Res Monogr** 1997;173:146–74 (85 ref.)

METHANE

METABOLISM

Biodiversity and unity in biochemistry. Thauer R. **Antonie Van Leeuwenhoek** 1997 Feb;71(1–2):21–32 (112 ref.)
Enzymology of the fermentation of acetate to methane by Methanosarcina thermophila. Ferry JG. **Biofactors** 1997; 6(1):25–35 (43 ref.)
Development of genetic approaches for the methane-producing archaebacterium Methanococcus maripaludis. Whitman WB, et al. **Biofactors** 1997;6(1):37–46 (34 ref.)
Methanogenesis: genes, genomes, and who's on first? Reeve JN, et al. **J Bacteriol** 1997 Oct;179(19):5975–86 (134 ref.)
Energetics of syntrophic cooperation in methanogenic degradation. Schink B. **Microbiol Mol Biol Rev** 1997 Jun; 61(2):262–80 (149 ref.)
Soil microorganisms as controllers of atmospheric trace gases (H2, CO, CH4, OCS, N2O, and NO). Conrad R. **Microbiol Rev** 1996 Dec;60(4):609–40 (602 ref.)

METHANESULFONATES see **MESYLATES**

METHANOBACTERIA see **METHANOGENS**

METHANOCOCCUS

GENETICS

Development of genetic approaches for the methane-producing archaebacterium Methanococcus maripaludis. Whitman WB, et al. **Biofactors** 1997;6(1):37–46 (34 ref.)
Genomes: Methanococcus jannaschii and the golden fleece. Garrett RA. **Curr Biol** 1996 Nov 1;6(11):1377–80 (9 ref.)
Lessons from an Archaeal genome: what are we learning from Methanococcus jannaschii? Olsen GJ, et al. **Trends Genet** 1996 Oct;12(10):377–9 (14 ref.)
[What we can learn from the whole genome sequence of an archaeon Methanococcus jannaschii] Yamagishi A, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(2):174–7 (14 ref.) **(Jpn)**

METABOLISM

Development of genetic approaches for the methane-producing archaebacterium Methanococcus maripaludis. Whitman WB, et al. **Biofactors** 1997;6(1):37–46 (34 ref.)

METHANOGENS

GENETICS

Methanogenesis: genes, genomes, and who's on first? Reeve JN, et al. **J Bacteriol** 1997 Oct;179(19):5975–86 (134 ref.)

METABOLISM

Biodiversity and unity in biochemistry. Thauer R. **Antonie Van Leeuwenhoek** 1997 Feb;71(1–2):21–32 (112 ref.)
Methanogenesis: genes, genomes, and who's on first? Reeve JN, et al. **J Bacteriol** 1997 Oct;179(19):5975–86 (134 ref.)
Energetics of syntrophic cooperation in methanogenic degradation. Schink B. **Microbiol Mol Biol Rev** 1997 Jun; 61(2):262–80 (149 ref.)

PHYSIOLOGY

Endosymbiotic interactions in anaerobic protozoa. Hackstein JH, et al. **Antonie Van Leeuwenhoek** 1997 Feb;71(1–2):151–8 (52 ref.)

METHANOL see **ALCOHOL, METHYL**

METHANOSARCINA

ENZYMOLOGY

Enzymology of the fermentation of acetate to methane by Methanosarcina thermophila. Ferry JG. **Biofactors** 1997; 6(1):25–35 (43 ref.)

METHBIPYRANONE see **METYRAPONE**

METHEMOGLOBIN

ANALYSIS

Methemoglobinemia caused by benzocaine topical spray. Cooper HA. **South Med J** 1997 Sep;90(9):946–8 (15 ref.)

METHEMOGLOBINEMIA

Methaemoglobinaemia. Griffin JP. **Adverse Drug React Toxicol Rev** 1997 Mar;16(1):45–63 (65 ref.)

CHEMICALLY INDUCED

Drug-induced methaemoglobinaemia. Treatment issues. Coleman MD, et al. **Drug Saf** 1996 Jun;14(6):394–405 (84

METHEMOGLOBINEMIA

ref.)
Protracted methemoglobinemia after phenazopyridine overdose in an infant. Christensen CM, et al. **J Clin Pharmacol** 1996 Feb;36(2):112–6 (11 ref.)
Flutamide induced methemoglobinemia. Khan AM, et al. **J Urol** 1997 Apr;157(4):1363 (3 ref.)
Food-borne nitrates and nitrites as a cause of methemoglobinemia. Chan TY. **Southeast Asian J Trop Med Public Health** 1996 Mar; 27(1):189–92 (24 ref.)

THERAPY

Drug-induced methaemoglobinaemia. Treatment issues. Coleman MD, et al. **Drug Saf** 1996 Jun;14(6):394–405 (84 ref.)

METHICILLIN

see related
METHICILLIN RESISTANCE

METHICILLIN RESISTANCE

Managing methicillin-resistant Staphylococcus aureus in hospital: the balance of risk. Stone SP. **Age Ageing** 1997 May;26(3):165–8 (45 ref.)
Mechanisms of methicillin resistance in staphylococci. Brakstad OG, et al. **APMIS** 1997 Apr;105(4):264–76 (112 ref.)
The progressive intercontinental spread of methicillin-resistant Staphylococcus aureus. Ayliffe GA. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S74–9 (60 ref.)
Epidemiology, control and treatment of methicillin-resistant Staphylococcus aureus. Peters G, et al. **Drugs** 1996;52 Suppl 2:50–4 (11 ref.)
Methicillin-resistant Staphylococcus aureus in nursing homes. Epidemiology, prevention and management. Bradley SF. **Drugs Aging** 1997 Mar;10(3):185–98 (90 ref.)
Review of methicillin resistant Staphylococcus aureus with special reference to handling of surgical patients. Gakuu LN. **East Afr Med J** 1997 Mar;74(3):198–202 (22 ref.)
Mupirocin resistance and methicillin-resistant Staphylococcus aureus (MRSA). Eltringham I. **J Hosp Infect** 1997 Jan;35(1):1–8 (44 ref.)
Methicillin-resistant Staphylococcus aureus (MRSA)--a re-appraisal of control measures in the light of changing circumstances. Humphreys H, et al. **J Hosp Infect** 1997 Jul;36(3):167–70 (20 ref.)
Methicillin resistant Staphylococcus aureus (MRSA): disease spectrum, biological characteristics, resistant mechanisms, and typing methods. Abdo RA, et al. **J Med Liban** 1996; 44(1):21–30 (90 ref.)
Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities. Michel M, et al. **Lancet** 1997 Jun 28; 349(9069):1901–6 (63 ref.)
Is control of methicillin-resistant Staphylococcus aureus justified? Bowler IC. **QJM** 1997 Apr;90(4):243–6 (26 ref.)
[Clinically isolated bacterii seen in complicated infections] Iwai S. **Nippon Geka Gakkai Zasshi** 1996 Dec;97(12):1091–6 (12 ref.) (Eng. Abstr.) **(Jpn)**
[A case of toxic shock syndrome (TSS) induced by methicillin-resistant staphylococcus aureus (MRSA) presenting as acute renal failure with disseminated intravascular coagulation] Fukuuchi F, et al. **Nippon Jinzo Gakkai Shi** 1996 Jan;38(1):27–32 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Molecular design of anti-MRSA drugs] Hanaki H. **Nippon Rinsho** 1997 May;55(5):1281–6 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Mini review: a factor enhanced the antibacterial effect of beta-lactams on methicillin-resistant Staphylococcus aureus] Tajima Y. **Rinsho Byori** 1996 Nov;44(11):1093–9 (6 ref.) (Eng. Abstr.) **(Jpn)**
[MRSA-related glomerulonephritis] Muro K, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):99–101 (8 ref.) **(Jpn)**

GENETICS

Borderline susceptibility to methicillin in Staphylococcus aureus: a new mechanism of resistance? Montanari MP, et al. **Microb Drug Resist** 1996 Summer;2(2):257–60 (27 ref.)
[Genetics of multiresistant MRSA] Ito T, et al. **Nippon Rinsho** 1997 May;55(5):1200–5 (7 ref.) (Eng. Abstr.) **(Jpn)**
[Genetic basis for molecular epidemiology of MRSA] Kondo N, et al. **Nippon Saikingaku Zasshi** 1997 Apr;52(2):417–34 (57 ref.) **(Jpn)**

PHYSIOLOGY

Borderline susceptibility to metlhicillin in Staphylococcus aureus: a new mechanism of resistance? Montanari MP, et al. **Microb Drug Resist** 1996 Summer;2(2):257–60 (27 ref.)

METHIMAZOLE

ADMINISTRATION & DOSAGE

Evans' syndrome associated with Graves' disease. Yashiro M, et al. **Intern Med** 1996 Dec;35(12):987–90 (13 ref.)

METHIONINE

ANALOGS & DERIVATIVES

PET for diagnosis of malignant lymphoma of the scalp: comparison of [11C]methyl-L-methionine and [18F]fluoro-2-deoxyglucose. Tsuyuguchi N, et al. **J Comput Assist Tomogr** 1997 Jul-Aug;21(4):590–3 (16 ref.)
[11C-methionine: an effective radio-tracer for PET scan in the detection of tumors of low proliferating capacity] Trón L, et al. **Orv Hetil** 1997 Aug 24;138(34):2107–12 (44 ref.) (Eng. Abstr.) **(Hun)**
[Positron emission tomographic evaluation for frontal hypertrophic cranial pachymeningitis using 11C-methyl-L-methionine] Takahashi M, et al. **No Shinkei Geka** 1996 Mar;24(3):287–93 (27 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Methionine production by microorganisms. Mondal S, et al. **Folia Microbiol (Praha)** 1996;41(6):465–72 (73 ref.)

DEFICIENCY

The role of folate, choline, and methionine in carcinogenesis induced by methyl-deficient diets. Henning SM, et al. **Adv Exp Med Biol** 1996;399:143–55 (78 ref.)

METABOLISM

Methioninase: a therapeutic for diseases related to altered methionine metabolism and transmethylation: cancer, heart disease, obesity, aging, and Parkinson's disease. Hoffman RM. **Hum Cell** 1997 Mar;10(1):69–80 (117 ref.)
Metabolism of methionine in liver disease. Mato JM, et al. **Methods Find Exp Clin Pharmacol** 1996;18 Suppl B:35–46 (87 ref.)

PHYSIOLOGY

Disturbances of one-carbon metabolism in neuropsychiatric disorders: a review. Smythies JR, et al. **Biol Psychiatry** 1997 Jan 15;41(2):230–3 (35 ref.)

METHIONINE ADENOSYLTRANSFERASE

GENETICS

S-adenosylmethionine synthesis: molecular mechanisms and clinical implications. Mato JM, et al. **Pharmacol Ther** 1997; 73(3):265–80 (174 ref.)

METHIONINE ENKEPHALIN see **ENKEPHALIN, METHIONINE**

METHIONINE-SPECIFIC TRNA see **RNA, TRANSFER, MET**

METHIONINE-SPECIFIC TRNAM see **RNA, TRANSFER, MET**

METHIONINE SYNTHETASE see **TETRAHYDROPTEROYLGLUTAMATE METHYLTRANSFERASE**

METHIONYL T RNA SYNTHETASE

METABOLISM

Yeast tRNA(Met) recognition by methionyl-tRNA synthetase requires determinants from the primary, secondary and tertiary structure: a review. Senger B, et al. **Biochimie** 1996;78(7):597–604 (58 ref.)

METHODOLOGIES, COMPUTING see **COMPUTING METHODOLOGIES**

METHODOLOGY RESEARCH, NURSING see **NURSING METHODOLOGY RESEARCH**

METHOIN see **MEPHENYTOIN**

METHOPYRAPONE see **METYRAPONE**

D-METHORPHAN see **DEXTROMETHORPHAN**

METHOTREXATE

Medical abortion in early pregnancy: a review of the evidence. Grimes DA. **Obstet Gynecol** 1997 May;89(5 Pt 1):790–6 (55 ref.)

ADMINISTRATION & DOSAGE

Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Bannwarth B, et al. **Clin Pharmacokinet** 1996 Mar;30(3):194–210 (105 ref.)
Aggressive giant keratoacanthoma of the face treated with intramuscular methotrexate and triamcinolone acetonide. Santoso-Pham JC, et al. **Cutis** 1997 Jun;59(6):329–32 (26 ref.)
[Low dose methotrexate therapy in chronic polyarthritis--an update] Leeb BF, et al. **Acta Med Austriaca** 1996; 23(4):114–9 (63 ref.) (Eng. Abstr.) **(Ger)**
[Methotrexate in gynecologic oncology] Isonishi S, et al. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1896–900 (17 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Intrathecal methotrexate overdose. Lee AC, et al. **Acta Paediatr** 1997 Apr;86(4):434–7 (15 ref.)
Review article: methotrexate in gastroenterology--dangerous villain or simply misunderstood? Tang H, et al. **Aliment Pharmacol Ther** 1996 Dec;10(6):851–8 (64 ref.)
Liver toxicity does not have to follow methotrexate therapy of patients with rheumatoid arthritis [editorial] [see comments] Kremer JM. **Am J Gastroenterol** 1997 Feb; 92(2):194–6 (29 ref.) Comment in: Am J Gastroenterol 1997 Aug;92(8):1402–3.
Study of eight cases of cancer in 426 rheumatoid arthritis patients treated with methotrexate. Bologna C, et al. **Ann Rheum Dis** 1997 Feb;56(2):97–102 (33 ref.)
Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis: comment on the article by Gutierrez-Ureña et al [letter; comment] Berthelot JM, et al. **Arthritis Rheum** 1997 Jan;40(1):193–4; discussion 195–6 (27 ref.) Comment on: Arthritis Rheum 1996 Feb;39(2):272–6.
Methotrexate-associated appearance and rapid progression of rheumatoid nodules in systemic-onset juvenile rheumatoid arthritis. Falcini F, et al. **Arthritis Rheum** 1997 Jan;40(1):175–8 (22 ref.)
Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature. Salaffi F, et al. **Clin Rheumatol** 1997 May;16(3):296–304 (53 ref.)
Methotrexate related cutaneous vasculitis [letter] Torner O, et al. **Clin Rheumatol** 1997 Jan;16(1):108–9 (7 ref.)
Erosion of psoriatic plaques: an early sign of methotrexate toxicity. Pearce HP, et al. **J Am Acad Dermatol** 1996 Nov; 35(5 Pt 2):835–8 (44 ref.)
A biochemical perspective of methotrexate neurotoxicity with insight on nonfolate rescue modalities. Quinn CT, et al. **J Investig Med** 1996 Dec;44(9):522–30 (106 ref.)
Listeria monocytogenes joint infection in a patient with psoriatic arthritis [letter] Marangos MN, et al. **J Rheumatol** 1996 Nov;23(11):2005–6 (3 ref.)
Methotrexate and oral mucositis [editorial; comment] Moe PJ. **Pediatr Hematol Oncol** 1996 Jul-Aug;13(4):313–4 (6 ref.) Comment on: Pediatr Hematol Oncol 1996 Jul-Aug;13(4):359–73.
Pneumocystis carinii pneumonia in rheumatoid arthritis patients treated with methotrexate. A report of two cases. Roux N, et al. **Rev Rhum Engl Ed** 1996 Jun;63(6):453–6 (30 ref.)
Methotrexate update [editorial] Kremer JM. **Scand J Rheumatol** 1996;25(6):341–4 (31 ref.)
Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment [see comments] Georgescu L, et al. **Semin Arthritis Rheum** 1997 Jun;26(6):794–804 (98 ref.) Comment in: Semin Arthritis Rheum 1997 Jun;26(6):785–7.
[Treatment with low dose methotrexate in rheumatoid arthritis: risk factors for severe complications] Berthelot JM, et al. **Therapie** 1997 Mar-Apr;52(2):111–6 (40 ref.) (Eng. Abstr.) **(Fre)**
[Pancytopenia and Pneumocystis carinii pneumonia associated with low dose methotrexate pulse therapy for rheumatoid arthritis--case report and review of literature] Kitsuwa S, et al. **Ryumachi** 1996 Jun;36(3):551–8 (43 ref.) (Eng. Abstr.) **(Jpn)**
[Pneumocystis pneumonia in patients with steroid-dependent asthma] Dziedziczko A, et al. **Pneumonol Alergol Pol** 1997; 65(5–6):399–405 (24 ref.) **(Pol)**

METABOLISM

Resistance mechanisms to methotrexate in tumors. Bertino JR, et al. **Stem Cells** 1996 Jan;14(1):5–9 (27 ref.)
Methotrexate: an effective agent for treating cancer and building careers. The polyglutamate era. Schilsky RL. **Stem Cells** 1996 Jan;14(1):29–32 (10 ref.)

PHARMACOKINETICS

Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Bannwarth B, et al. **Clin Pharmacokinet** 1996 Mar;30(3):194–210 (105 ref.)
Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia. Matherly LH, et al. **Leuk Lymphoma** 1996 May;21(5–6):359–68 (70 ref.)
Does pharmacokinetic variability influence the efficacy of high-dose methotrexate for the treatment of children with acute lymphoblastic leukemia: what can we learn from small studies? [comment] Evans WE, et al. **Leuk Res** 1997 May;21(5):435–7 (13 ref.) Comment on: Leuk Res 1997 May;21(5):429–34.
[Pharmacokinetics of methotrexate in rheumatoid arthritis: therapeutic implications] Bannwarth B, et al. **Therapie** 1997 Mar-Apr;52(2):129–32 (19 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Drug-resistant dihydrofolate reductases: generation, expression and therapeutic application. McIvor RS. **Bone Marrow Transplant** 1996 Dec;18 Suppl 3:S50–4 (19

ref.)
Resistance mechanisms to methotrexate in tumors. Bertino JR, et al. **Stem Cells** 1996 Jan;14(1):5–9 (27 ref.)

POISONING

[Acute methotrexate poisoning: apropos of 16 cases reported to the Paris Poison Control Center and review of the literature] Maignen F, et al. **Therapie** 1996 Sep–Oct; 51(5):527–31 (35 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Review article: methotrexate in gastroenterology--dangerous villain or simply misunderstood? Tang H, et al. **Aliment Pharmacol Ther** 1996 Dec;10(6):851–8 (64 ref.)
Current management of asthma patients with corticosteroid resistance. Busse WW, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 2):S70–2; discussion S72–3 (16 ref.)
Molecular therapeutics. Methotrexate and its mechanism of action [see comments] Cronstein BN. **Arthritis Rheum** 1996 Dec;39(12):1951–60 (109 ref.) Comment in: Arthritis Rheum 1997 Aug;40(8):1545–6.
Methotrexate for psoriasis. Boffa MJ, et al. **Clin Exp Dermatol** 1996 Nov;21(6):399–408 (113 ref.)
Alternative treatments in the patient with intractable asthma. Spector SL. **Curr Opin Pulm Med** 1997 Jan;3(1):23–9 (64 ref.)
A risk–benefit assessment of methotrexate in corticosteroid–dependent asthma. Shulimzon TR, et al. **Drug Saf** 1996 Oct;15(4):283–90 (51 ref.)
Subsequent reproduction and obstetric outcome after methotrexate treatment of cervical pregnancy: a review of original literature and international collaborative follow–up. Kung FT, et al. **Hum Reprod** 1997 Mar; 12(3):591–5 (27 ref.)
Controversies and problems in the current management of tubal pregnancy. Maymon R, et al. **Hum Reprod Update** 1996 Nov–Dec;2(6):541–51 (82 ref.)
Folate, antifolates, and folate analogs in pediatric oncology. Hum MC, et al. **Invest New Drugs** 1996;14(1):101–11 (59 ref.)
Medical management of ectopic pregnancy--the role of methotrexate. Ander DS, et al. **J Emerg Med** 1997 Mar–Apr;15(2):177–82 (33 ref.)
Initial experience combining methotrexate with biologic agents for treating rheumatoid arthritis. Moreland LW. **J Rheumatol Suppl** 1996 Mar;44:78–83 (74 ref.)
Combination sulfasalazine and methotrexate in the management of rheumatoid arthritis. Shiroky JB. **J Rheumatol Suppl** 1996 Mar;44:69–71 (31 ref.)
Refractory IBD: medical management. Tremaine WJ. **Neth J Med** 1997 Feb;50(2):S12–4 (12 ref.)
Juvenile generalized pustular psoriasis. Kalla G, et al. **Pediatr Dermatol** 1996 Jan–Feb;13(1):45–6 (5 ref.)
The use of methotrexate, colchicine, and other immunomodulatory drugs in the treatment of primary biliary cirrhosis. Kaplan MM. **Semin Liver Dis** 1997 May; 17(2):129–36 (57 ref.)
[Non–cancer uses of methotrexate] Brion N, et al. **Presse Med** 1996 Dec 14;25(39):1929–34 (37 ref.) (Eng. Abstr.) **(Fre)**
[Pharmacokinetics of methotrexate in rheumatoid arthritis: therapeutic implications] Bannwarth B, et al. **Therapie** 1997 Mar–Apr;52(2):129–32 (19 ref.) (Eng. Abstr.) **(Fre)**
[Methotrexate and non–steroidal anti–inflammatory agent combination in rheumatoid arthritis] Bertin P, et al. **Therapie** 1997 Mar–Apr;52(2):133–7 (20 ref.) (Eng. Abstr.) **(Fre)**
[Treating polymyositis: methotrexate or azathioprine?] Mader R. **Harefuah** 1997 Jan 1;132(1):56–8 (20 ref.) **(Heb)**
[Methotrexate–leucovorin rescue therapy: pharmacological characteristics and clinical effective use] Fujimoto T. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1901–6 (6 ref.) (Eng. Abstr.) **(Jpn)**
[The use of methotrexate in rheumatology: results and prospects] Nasonov EL. **Klin Med (Mosk)** 1996;74(5):10–5 (74 ref.) **(Rus)**
[Methotrexate in the treatment of inflammatory intestinal diseases] Díaz Blasco J, et al. **Rev Esp Enferm Dig** 1997 May;89(5):385–90 (67 ref.) **(Spa)**

METHOXSALEN

ADMINISTRATION & DOSAGE

Therapy with orally administered methoxsalen and ultraviolet A radiation during childhood increases the risk of basal cell carcinoma. The PUVA Follow–up Study. Stern RS, et al. **J Pediatr** 1996 Dec;129(6):915–7 (8 ref.)

METHOXYCHLOR

TOXICITY

Methoxychlor as a model for environmental estrogens. Cummings AM. **Crit Rev Toxicol** 1997 Jul;27(4):367–79 (75 ref.)

12-METHOXYIBOGAMINE see **IBOGAINE**

8-METHOXYPSORALEN see **METHOXSALEN**

METHOXYVERAPAMIL see **GALLOPAMIL**

N-METHYL-D-ASPARTATE RECEPTORS see **RECEPTORS, N-METHYL-D-ASPARTATE**

METHYL ETHERS

ADVERSE EFFECTS

Dangerous and cancer–causing properties of products and chemicals in the oil–refining and petrochemical industry--Part XXII: Health hazards from exposure to gasoline containing methyl tertiary butyl ether: study of New Jersey residents. Mehlman MA. **Toxicol Ind Health** 1996 Sep–Oct;12(5):613–27 (56 ref.)

METHYL MERCURY COMPOUNDS see **METHYLMERCURY COMPOUNDS**

METHYL METHANESULFONATE

PHARMACOLOGY

Mechanisms of action of methyl methanesulfonate on Escherichia coli: mutagenesis, DNA damage and repair. Janion C. **Postepy Biochem** 1995;41(5 Suppl):308–13 (72 ref.)

TOXICITY

Mammalian germ cell mutagenicity of ENU, IPMS and MMS, chemicals selected for a transgenic mouse collaborative study. Shelby MD, et al. **Mutat Res** 1997 Feb 14;388(2–3):99–109 (65 ref.)

METHYL PHENETOIN see **MEPHENYTOIN**

METHYL VIOLET see **GENTIAN VIOLET**

METHYL VIOLOGEN see **PARAQUAT**

METHYLADENINE RECEPTORS see **RECEPTORS, PURINERGIC**

OMEGA-N-METHYLARGININE

ADVERSE EFFECTS

Just say no to NO., yes? [editorial] Fink MP. **Crit Care Med** 1996 Nov;24(11):1772–4 (30 ref.)

PHARMACOLOGY

Cell death, survival and proliferation in Tetrahymena thermophila. Effects of insulin, sodium nitroprusside, 8–Bromo cyclic GMP, NG–methyl–L–arginine and methylene blue. Christensen ST, et al. **Cell Biol Int** 1996 Oct;20(10):653–66 (78 ref.)
Nitric oxide: biological and clinical perspectives [editorial] Saklayen MG, et al. **Int J Artif Organs** 1996 Nov; 19(11):630–2 (17 ref.)

THERAPEUTIC USE

[Inhibition of nitric oxide synthase in septic shock. Therapeutic limits and perspectives] Endres S, et al. **Internist (Berl)** 1997 May;38(5):466–9 (17 ref.) **(Ger)**

N-METHYLASPARTATE

see related
RECEPTORS, N-METHYL-D-ASPARTATE

ANTAGONISTS & INHIBITORS

Development of the NMDA ion–channel blocker, aptiganel hydrochloride, as a neuroprotective agent for acute CNS injury. McBurney RN. **Int Rev Neurobiol** 1997;40:173–95 (28 ref.)
NMDA antagonists: their role in neuroprotection. Small DL, et al. **Int Rev Neurobiol** 1997;40:137–71 (229 ref.)

PHARMACOLOGY

Metabotropic glutamate receptors and neuronal degeneration in culture. Bruno V, et al. **Adv Neurol** 1996;71:47–51, discussion 51–2 (23 ref.)

PHYSIOLOGY

LTP, NMDA, genes and learning. Cain DP. **Curr Opin Neurobiol** 1997 Apr;7(2):235–42 (75 ref.)

N-METHYL-D-ASPARTATE see **N-METHYLASPARTATE**

METHYLAZOXYMETHANOL ACETATE

ANALOGS & DERIVATIVES

Developmental models of brain dysfunctions induced by targeted cellular ablations with methylazoxymethanol. Cattabeni F, et al. **Physiol Rev** 1997 Jan;77(1):199–215 (145 ref.)

PHARMACOLOGY

Cell death in the normal developing brain, and following ionizing radiation, methyl–azoxymethanol acetate, and hypoxia–ischaemia in the rat. Ferrer I. **Neuropathol Appl Neurobiol** 1996 Dec;22(6):489–94 (40 ref.)

METHYLCELLULOSE

ANALOGS & DERIVATIVES

[Viscoelastic substances in cataract surgery. Principles and current overview] Hessemer V, et al. **Klin Monatsbl Augenheilkd** 1996 Aug–Sep;209(2–3):55–61 (77 ref.) (Eng. Abstr.) **(Ger)**

METHYLCHOLANTHRENE

ADMINISTRATION & DOSAGE

Tumours of the mammary gland. Fernandez PL, et al. **IARC Sci Publ** 1996;(126):45–58 (29 ref.)

METHYLDOPA

THERAPEUTIC USE

Commentary: calcium antagonist controversy, does the accusing finger also point to beta–blockers and methyldopa? Opie LH. **J Hum Hypertens** 1997 Apr; 11(4):201–4 (21 ref.)

METHYLDOPATE see **METHYLDOPA**

METHYLENE BICHLORIDE see **METHYLENE CHLORIDE**

METHYLENE BLUE

PHARMACOLOGY

Cell death, survival and proliferation in Tetrahymena thermophila. Effects of insulin, sodium nitroprusside, 8–Bromo cyclic GMP, NG–methyl–L–arginine and methylene blue. Christensen ST, et al. **Cell Biol Int** 1996 Oct;20(10):653–66 (78 ref.)

THERAPEUTIC USE

Methylene blue: NO panacea [editorial; comment] Schreiber MD. **J Pediatr** 1996 Dec;129(6):790–3 (45 ref.) Comment on: J Pediatr 1996 Dec;129(6):904–8.
[Methyl thionine (methylene blue) in the treatment of sepsis] Bindels AJ, et al. **Ned Tijdschr Geneeskd** 1996 Dec 7; 140(49):2447–50 (20 ref.) **(Dut)**

METHYLENE CHLORIDE

TOXICITY

Methylene chloride induced mouse liver and lung tumours: an overview of the role of mechanistic studies in human safety assessment. Green T. **Hum Exp Toxicol** 1997 Jan; 16(1):3–13 (60 ref.)

METHYLENE DICHLORIDE see **METHYLENE CHLORIDE**

3,4-METHYLENEDIOXYAMPHETAMINE

ANALOGS & DERIVATIVES

MDEA related death in Crete: a case report and literature review. Tsatsakis AM, et al. **Vet Hum Toxicol** 1997 Aug; 39(4):241–4 (23 ref.)
[Entactogenic drugs "ecstasy" (MDMA), "eve" (MDE) and other ring–substituted methamphetamine derivatives. A new class of substances among illegal designer drugs?] Gouzoulis–Mayfrank E, et al. **Nervenarzt** 1996 May; 67(5):369–80 (98 ref.) (Eng. Abstr.) **(Ger)**

METHYLENEDIOXYMETHAMPHETAMINE see **N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE**

METHYLENESULFONATES see **MESYLATES**

METHYLERGOBASIN see **METHYLERGONOVINE**

METHYLERGOMETRIN see **METHYLERGONOVINE**

METHYLERGONOVINE

STANDARDS

Instability of (methyl)ergometrine in tropical climates: an overview. Hogerzeil HV, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Oct;69(1):25–9 (19 ref.)

METHYLERGONOVINE

THERAPEUTIC USE

The role of oral (methyl)ergometrine in the prevention of postpartum haemorrhage [see comments] de Groot AN. **Eur J Obstet Gynecol Reprod Biol** 1996 Oct;69(1):31–6 (19 ref.) Comment in: Eur J Obstet Gynecol Reprod Biol 1996 Oct;69(1):3–4.

Methylergonovine maleate as a cluster headache prophylactic: a study and review. Mueller L, et al. **Headache** 1997 Jul–Aug;37(7):437–42 (63 ref.)

METHYLGLUCAMINE see **MEGLUMINE**

METHYLGLUCAMINE DIATRIZOATE see **DIATRIZOATE MEGLUMINE**

METHYLGLYOXAL see **PYRUVALDEHYDE**

METHYLHYDROXYPROGESTERONE see **MEDROXYPROGESTERONE**

METHYLMALONIC ACID

BLOOD

[Blood and urinary level of methylmalonic acid: an important index in evaluating cobalamin deficiency] Sela BA, et al. **Harefuah** 1997 Jun 15;132(12):866–71 (30 ref.) **(Heb)**

METABOLISM

Stable isotope studies in propionic and methylmalonic acidaemia. Leonard JV. **Eur J Pediatr** 1997 Aug;156 Suppl 1:S67–9 (19 ref.)

URINE

[A molecular study of methylmalonic aciduria: structure–function correlations] Rosenblatt DS, et al. **Bull Acad Natl Med** 1996 Oct;180(7):1553–63; discussion 1563–4 (33 ref.) (Eng. Abstr.) **(Fre)**

METHYLMALONYL–COA ISOMERASE see **METHYLMALONYL–COA MUTASE**

METHYLMALONYL–COA MUTASE

CHEMISTRY

Structure–based perspectives on B12–dependent enzymes. Ludwig ML, et al. **Annu Rev Biochem** 1997;66:269–313 (155 ref.)

GENETICS

Mutations in mut methylmalonic acidemia: clinical and enzymatic correlations. Ledley FD, et al. **Hum Mutat** 1997; 9(1):1–6 (39 ref.)

METHYLMERCURY COMPOUNDS

ADVERSE EFFECTS

Do historic studies of fish consumers support the widely accepted LOEL for methylmercury in adults. Kosatsky T, et al. **Neurotoxicology** 1996 Spring;17(1):177–86 (30 ref.)

ANALYSIS

Calculation of soil–water and benthic sediment partition coefficients for mercury. Lyon BF, et al. **Chemosphere** 1997 Aug;35(4):791–808 (30 ref.)

METABOLISM

Metabolism of methylmercury in the brain and its toxicological significance. Mottet NK, et al. **Met Ions Biol Syst** 1997;34:371–403 (202 ref.)

POISONING

Neurobehavioral epidemiology: application in risk assessment. Grandjean P, et al. **Environ Health Perspect** 1996 Apr;104 Suppl 2:397–400 (30 ref.)

Evolution of our understanding of methylmercury as a health threat. Watanabe C, et al. **Environ Health Perspect** 1996 Apr;104 Suppl 2:367–79 (69 ref.)

TOXICITY

Maternal–fetal mercury transport and fetal methylmercury poisoning. Hamada R, et al. **Met Ions Biol Syst** 1997; 34:405–20 (37 ref.)

Metabolism of methylmercury in the brain and its toxicological significance. Mottet NK, et al. **Met Ions Biol Syst** 1997;34:371–403 (202 ref.)

Methylmercury in astrocytes—what possible significance? Aschner M. **Neurotoxicology** 1996 Spring;17(1):93–106 (75 ref.)

Mercurial–induced alterations in neuronal divalent cation homeostasis. Denny MF, et al. **Neurotoxicology** 1996 Spring;17(1):47–61 (90 ref.)

Sensory and cognitive effects of developmental methylmercury exposure in monkeys, and a comparison to effects in rodents. Rice DC. **Neurotoxicology** 1996 Spring;17(1):139–54 (58 ref.)

Cellular resistance to methylmercury. Sarafian TA, et al. **Neurotoxicology** 1996 Spring;17(1):27–36 (90 ref.)

Effects of mercurials on ligand– and voltage–gated ion channels: a review. Sirois JE, et al. **Neurotoxicology** 1996 Spring;17(1):63–84 (140 ref.)

Regulatory volume decrease in primary astrocyte cultures: relevance to methylmercury neurotoxicity. Vitarella D, et al. **Neurotoxicology** 1996 Spring;17(1):117–23 (50 ref.)

METHYLMETHACRYLATES

Intrastromal corneal ring technology. Krueger RR, et al. **Int Ophthalmol Clin** 1996 Fall;36(4):89–106 (20 ref.)

[The intrastromal corneal ring (KeraVision Ring, ICR, ICRS). A modern method for correcting minor myopia] Grabner G, et al. **Wien Med Wochenschr** 1997; 147(12–13):309–21 (45 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Osteolysis caused by polymethylmethacrylate (PMMA). Eftekhar NS. **Instr Course Lect** 1994;43:263–75 (53 ref.)

METHYLMETHANE SULFONATE see **METHYL METHANESULFONATE**

N–METHYL–3,4–METHYLENEDIOXYAMPHETAMINE

New dimensions in toxicology: hyperthermic syndrome following amphetamine derivatives [editorial; comment] Bodenham AR, et al. **Intensive Care Med** 1996 Jul; 22(7):622–4 (15 ref.) Comment on: Intensive Care Med 1996 Jul;22(7):670–1.

MDMA (Ecstacy): useful information for health professionals involved in drug education programs. Elk C. **J Drug Educ** 1996;26(4):349–56 (14 ref.)

MDMA (ecstasy) and the rave: a review. Schwartz RH, et al. **Pediatrics** 1997 Oct;100(4):705–8 (5 ref.)

[Ecstasy: psychostimulant, hallucinogen and toxic substance] Burnat P, et al. **Presse Med** 1996 Sep 14;25(26):1208–12 (25 ref.) (Eng. Abstr.) **(Fre)**

[Ecstasy—the status in French–speaking Switzerland. Composition of seized drugs, analysis of biological specimens and short review of its pharmacological action and toxicity] Giroud C, et al. **Schweiz Rundsch Med Prax** 1997 Mar 25;86(13):510–23 (42 ref.) (Eng. Abstr.) **(Fre)**

[Entactogenic drugs "ecstasy" (MDMA), "eve" (MDE) and other ring–substituted methamphetamine derivatives. A new class of substances among illegal designer drugs?] Gouzoulis–Mayfrank E, et al. **Nervenarzt** 1996 May; 67(5):369–80 (98 ref.) (Eng. Abstr.) **(Ger)**

[Ecstasy, a new designer drug in the techno–scene] Kuhlmann T. **Psychiatr Prax** 1996 Nov;23(6):266–9 (10 ref.) (Eng. Abstr.) **(Ger)**

[MDMA or ecstasy: pharmacologic, toxicologic and clinical aspects] Prada C, et al. **Med Clin (Barc)** 1996 Oct 26; 107(14):549–55 (69 ref.) **(Spa)**

ADVERSE EFFECTS

Adverse reactions with 3,4–methylenedioxymethamphetamine (MDMA; 'ecstasy'). McCann UD, et al. **Drug Saf** 1996 Aug;15(2):107–15 (88 ref.)

Liver transplantation for the treatment of fulminant hepatic failure induced by the ingestion of ecstasy. Brauer RB, et al. **Transpl Int** 1997;10(3):229–33 (11 ref.)

[MDMA ("Ecstasy") use—an overview of psychiatric and medical sequelae] Thomasius R, et al. **Fortschr Neurol Psychiatr** 1997 Feb;65(2):49–61 (125 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOKINETICS

Distribution of 3,4–methylenedioxymethamphetamine (MDMA) and 3,4–methylenedioxyamphetamine (MDA) stereoisomers in a fatal poisoning. Moore KA, et al. **Forensic Sci Int** 1996 Dec 2;83(2):111–9 (28 ref.)

PHARMACOLOGY

Effects of MDMA on complex brain function in laboratory animals. Frederick DL, et al. **Neurosci Biobehav Rev** 1997 Jan;21(1):67–78 (70 ref.)

The effects of methylenedioxymethamphetamine (MDMA, "Ecstasy") on monoaminergic neurotransmission in the central nervous system. White SR, et al. **Prog Neurobiol** 1996 Aug;49(5):455–79 (136 ref.)

POISONING

Distribution of 3,4–methylenedioxymethamphetamine (MDMA) and 3,4–methylenedioxyamphetamine (MDA) stereoisomers in a fatal poisoning. Moore KA, et al. **Forensic Sci Int** 1996 Dec 2;83(2):111–9 (28 ref.)

MDMA induced hyperthermia: report of a fatality and review of current therapy. Dar KJ, et al. **Intensive Care Med** 1996 Sep;22(9):995–6 (13 ref.)

TOXICITY

Neurotoxicity of amphetamines and their metabolites. Gibb JW, et al. **NIDA Res Monogr** 1997;173:128–45 (27 ref.)

Methamphetamine and methylenedioxymethamphetamine neurotoxicity: possible mechanisms of cell destruction. Seiden LS, et al. **NIDA Res Monogr** 1996;163:251–76 (103 ref.)

METHYLNITRONITROSOGUANIDINE

ADMINISTRATION & DOSAGE

Tumours of the glandular stomach. Takahashi M, et al. **IARC Sci Publ** 1996;(126):127–35 (29 ref.)

METHYLNITROSONITROGUANIDINE see **METHYLNITRONITROSOGUANIDINE**

METHYLNITROSOUREA

Tlag1, a novel murine tumor susceptibility gene that regulates MNU–induced thymic lymphoma development. Richie ER, et al. **Prog Clin Biol Res** 1996;395:23–32 (17 ref.)

METHYLOXAZEPAM see **TEMAZEPAM**

METHYLPHENIDATE

ADMINISTRATION & DOSAGE

Optimizing ADHD therapy with sustained–release methylphenidate. Lawrence JD, et al. **Am Fam Physician** 1997 Apr;55(5):1705–9, 1711–2 (21 ref.)

THERAPEUTIC USE

Depression in the medically ill elderly: a focus on methylphenidate. Emptage RE, et al. **Ann Pharmacother** 1996 Feb;30(2):151–7 (43 ref.)

Methylphenidate treatment of negative symptoms in patients with dementia. Galynker I, et al. **J Neuropsychiatry Clin Neurosci** 1997 Spring;9(2):231–9 (76 ref.)

Adults with attention deficit hyperactivity disorder: assessment and treatment considerations. Murphy K. **Semin Speech Lang** 1996 Aug;17(3):245–53; quiz 254 (35 ref.)

[Methylphenidate (Ritalin) treatment in attention deficit hyperactivity disorder] Shalev R, et al. **Harefuah** 1997 May 1;132(9):672–5 (33 ref.) **(Heb)**

METHYLPHENYL ETHERS see **ANISOLES**

1–METHYL–4–PHENYL–1,2,3,6–TETRAHYDROPYRIDINE

ADVERSE EFFECTS

The etiology of Parkinson's disease with emphasis on the MPTP story. Langston JW. **Neurology** 1996 Dec;47(6 Suppl 3):S153–60 (66 ref.)

[Drug–related motor disorders in aged people] Martí–Massó JF. **Rev Neurol** 1997 Jul;25 Suppl 1:S37–43 (35 ref.) **(Spa)**

PHARMACOKINETICS

Metabolic bioactivation reactions potentially related to drug toxicities. Castagnoli N Jr, et al. **NIDA Res Monogr** 1997; 173:85–105 (81 ref.)

TOXICITY

Astrocytes as the site for bioactivation of neurotoxins. Di Monte DA, et al. **Neurotoxicology** 1996 Fall–Winter; 17(3–4):697–703 (32 ref.)

METHYLPREDNISOLONE

ADMINISTRATION & DOSAGE

Progressive visual loss from giant cell arteritis despite high–dose intravenous methylprednisolone. Cornblath WT, et al. **Ophthalmology** 1997 May;104(5):854–8 (28 ref.)

[Methylprednisolone pulse therapy in the early phases of lupus nephritis] Mitić I, et al. **Srp Arh Celok Lek** 1996;124 Suppl 1:67–9 (42 ref.) (Eng. Abstr.) **(Scc)**

ADVERSE EFFECTS

Hypersensitivity to glucocorticoids: does it exist? Pizzuti P, et al. **Rev Rhum Engl Ed** 1996 Mar;63(3):223–6 (27 ref.)

ANALOGS & DERIVATIVES

Anaphylactic shock induced by intraarticular injection of methylprednisolone acetate. Mace S, et al. **J Rheumatol** 1997 Jun;24(6):1191–4 (37 ref.)

PHARMACOLOGY

Effect of a single huge dose of methylprednisolone on blood flow, evoked potentials, and histology after acute spinal cord injury in the rat. Koyanagi I, et al. **Neurol Res** 1997 Jun;19(3):289–99 (49 ref.)

THERAPEUTIC USE

Chemotherapy for malignant gliomas. Forsyth PA, et al. **Baillieres Clin Neurol** 1996 Jun;5(2):371–93 (112 ref.)
Intra-articular corticosteroids. Guide to selection and indications for use. Caldwell JR. **Drugs** 1996 Oct; 52(4):507–14 (29 ref.)

METHYLROSANILINE CHLORIDE see **GENTIAN VIOLET**

METHYLSTANAZOL see **STANOZOLOL**

METHYLTETRAHYDROFOLATE HOMOCYSTEINE METHYLTRANSFERASE see **TETRAHYDROPTEROYLGLUTAMATE METHYLTRANSFERASE**

METHYLTHIONINE CHLORIDE see **METHYLENE BLUE**

METHYLTRANSFERASES

[Glycine methyltransferase: structure, function and a variety of ligand- bindings] Ogawa H. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(7):908–14 (40 ref.) **(Jpn)**

GENETICS

Chemoprotection of normal tissues by transfer of drug resistance genes. Rafferty JA, et al. **Cancer Metastasis Rev** 1996 Sep;15(3):365–83 (110 ref.)
Improved retroviral vectors for hematopoietic stem cell protection and in vivo selection. Baum C, et al. **J Hematother** 1996 Aug;5(4):323–9 (40 ref.)
Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Krynetski EY, et al. **Pharmacogenetics** 1996 Aug;6(4):279–90 (60 ref.)

METABOLISM

DNA repair in eukaryotes. Wood RD. **Annu Rev Biochem** 1996;65:135–67 (272 ref.)
Genomic instability and tolerance to alkylating agents. Karran P, et al. **Cancer Surv** 1996;28:69–85 (38 ref.)
Thiopurine methyltransferase: a review and a clinical pilot study. Keuzenkamp-Jansen CW, et al. **J Chromatogr B Biomed Appl** 1996 Mar 29;678(1):15–22 (53 ref.)
Formation of methylation patterns in the mammalian genome [see comments] Turker MS, et al. **Mutat Res** 1997 Apr; 386(2):119–30 (86 ref.) Comment in: Mutat Res 1997 Apr;386(2):x103–5.
Viral and cellular enzymes involved in synthesis of mRNA cap structure. Bisaillon M, et al. **Virology** 1997 Sep 15; 236(1):1–7 (65 ref.)

PHYSIOLOGY

Role of DNA repair in resistance to drugs that alkylate O6 of guanine. Koç ON, et al. **Cancer Treat Res** 1996;87:123–46 (138 ref.)

METHYMAZOL see **METHIMAZOLE**

METOCLOPRAMIDE

ADVERSE EFFECTS

Metoclopramide in a patient with renal failure may be an increased risk of neuroleptic malignant syndrome [letter] Fujita Y, et al. **Intensive Care Med** 1996 Jul;22(7):717 (5 ref.)

DIAGNOSTIC USE

[Metoclopramide, sulpiride, and chlorpromazine loading test] Azuma K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:249–51 (9 ref.) **(Jpn)**
[Metoclopramide test] Shimizu K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:360–2 (12 ref.) **(Jpn)**

PHARMACOLOGY

Regulation of plasma aldosterone levels by metoclopramide: a reappraisal of its mechanism from dopaminergic antagonism to serotonergic agonism. Rizzi CA, et al. **Neuropharmacology** 1997 Jun;36(6):763–8 (65 ref.)

THERAPEUTIC USE

[Pharmacologic and clinical differentiation of prokinetic drugs] May B, et al. **Leber Magen Darm** 1996 Jul; 26(4):193–8 (52 ref.) (Eng. Abstr.) **(Ger)**

METRONIDAZOLE

THERAPEUTIC USE

Review article: the management of pouchitis. Keighley MR. **Aliment Pharmacol Ther** 1996 Aug;10(4):449–57 (67 ref.)
Bacterial vaginosis. Priestley CJ, et al. **Br J Clin Pract** 1996 Sep;50(6):331–4 (26 ref.)

METRORRHAGIA

ETIOLOGY

[Uterine adenomyosis. Renaissance of a disease] Mergui JL, et al. **Contracept Fertil Sex** 1997 Feb;25(2):105–11 (69 ref.) **(Fre)**
[Early ultrasonographic detection of endometrial cancer] Rudigoz RC, et al. **Contracept Fertil Sex** 1997 Jan; 25(1):21–6 (49 ref.) **(Fre)**

SURGERY

[Hormone substitution following transcervical endometrial ablation] Römer T. **Zentralbl Gynakol** 1997;119(5):229–31 (26 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[General practitioners' choice of treatment for young women with metrorrhagia as evaluated by vignettes] Rohr G, et al. **Ugeskr Laeger** 1997 Feb 3;159(6):761–4 (5 ref.) (Eng. Abstr.) **(Dan)**

METYRAPONE

DIAGNOSTIC USE

[Metopiron test] Horiba N, et al. **Nippon Rinsho** 1997 Apr; 55 Suppl 2:268–71 (3 ref.) **(Jpn)**
[Metyrapone test] Tanaka K, et al. **Nippon Rinsho** 1997 Apr; 55 Suppl 2:349–52 (20 ref.) **(Jpn)**

MEVALONIC ACID

METABOLISM

Regulation of mesangial cell proliferation by the mevalonate pathway. Massy ZA, et al. **Contrib Nephrol** 1997;120:191–6 (21 ref.)

MEVINOLIN see **LOVASTATIN**

MEXICAN AMERICANS

Family dynamics and family therapy with Mexican Americans. Grothaus KL. **J Psychosoc Nurs Ment Health Serv** 1996 Feb;34(2):31–7 (9 ref.)

MGADP see **ADENOSINE DIPHOSPHATE**

MGATP see **ADENOSINE TRIPHOSPHATE**

MGI-1 see **COLONY-STIMULATING FACTORS**

MGI-2 see **INTERLEUKIN-6**

MGN see **GLOMERULONEPHRITIS, MEMBRANOUS**

MHC CLASS I GENES see **GENES, MHC CLASS I**

MHC CLASS II GENES see **GENES, MHC CLASS II**

MIANSERIN

ANALOGS & DERIVATIVES

The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission [published erratum appears in Int Clin Psychopharmacol 1996 Jun;11(2):153] de Boer T. **Int Clin Psychopharmacol** 1995 Dec;10 Suppl 4:19–23 (33 ref.)
Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine [published erratum appears in Int Clin Psychopharmacol 1996 Jun;11(2):153] Haddjeri N, et al. **Int Clin Psychopharmacol** 1995 Dec;10 Suppl 4:11–7 (30 ref.)
Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data [published erratum appears in Int Clin Psychopharmacol 1996 Jun;11(2):153] Kasper S. **Int Clin Psychopharmacol** 1995 Dec;10 Suppl 4:25–35 (45 ref.)
Safety of mirtazapine: a review [published erratum appears in Int Clin Psychopharmacol 1996 Jun;11(2):153] Montgomery SA. **Int Clin Psychopharmacol** 1995 Dec;10 Suppl 4:37–45 (28 ref.)
Selection of an antidepressant: mirtazapine. Preskorn SH. **J Clin Psychiatry** 1997;58 Suppl 6:3–8 (17 ref.)
Mirtazapine: clinical advantages in the treatment of depression. Burrows GD, et al. **J Clin Psychopharmacol** 1997 Apr;17(2):34S–39S (36 ref.)
The clinical relevance of preclinical data: mirtazapine, a model compound. Delbressine LP, et al. **J Clin Psychopharmacol** 1997 Apr;17(2):29S–33S (16 ref.)
Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine. Kasper S. **J Clin Psychopharmacol** 1997 Apr;17(2):19S–28S (52 ref.)
Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Stimmel GL, et al. **Pharmacotherapy** 1997 Jan-Feb;17(1):10–21 (60 ref.)

MIBELLI POROKERATOSIS see **POROKERATOSIS**

MICE

What could mice tell us about goiter or other benign thyroid diseases? Denef JF, et al. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 3:48–51 (35 ref.)
The emergence of mouse models of atherosclerosis and their relevance to clinical research. Smith JD, et al. **J Intern Med** 1997 Aug;242(2):99–109 (99 ref.)
Rodent models of experimental allergic encephalomyelitis applied to the study of multiple sclerosis. Goverman J, et al. **Lab Anim Sci** 1996 Oct;46(5):482–92 (167 ref.)

EMBRYOLOGY

Tyrosine phosphorylation and axon guidance: of mice and flies. Desai CJ, et al. **Curr Opin Neurobiol** 1997 Feb; 7(1):70–4 (33 ref.)
Computer-aided 3-D reconstruction of serially sectioned mouse embryos: its use in integrating anatomical organization. Kaufman MH, et al. **Int J Dev Biol** 1997 Apr; 41(2):223–33 (15 ref.)

GENETICS

The role of the laboratory mouse in the human genome project. Meisler MH. **Am J Hum Genet** 1996 Oct; 59(4):764–71 (56 ref.)
Physiological assessment of complex cardiac phenotypes in genetically engineered mice. Christensen G, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):H2513–24 (106 ref.)
Telomere structure and telomerase expression during mouse development and tumorigenesis. Kipling D. **Eur J Cancer** 1997 Apr;33(5):792–800 (44 ref.)
Possible mechanism for resistance to Alzheimer's disease (AD) in mice suggests a new approach to generate a mouse model for sporadic AD and may explain familial resistance to AD in man. Volloch V. **Exp Neurol** 1997 Mar; 144(1):214–8 (39 ref.)
Impact of migration and fitness on the stability of lethal t-haplotype polymorphism in Mus musculus: a computer study. Durand D, et al. **Genetics** 1997 Apr;145(4):1093–108 (38 ref.)
Transport of wild mice genetic material by in vitro fertilization, cryopreservation, and embryo transfer. Suzuki H, et al. **Lab Anim Sci** 1996 Dec;46(6):687–8 (16 ref.)
Fre2, a proviral integration site of Friend murine leukemia virus that is closely linked to Fv2. Friedrich RW, et al. **Leukemia** 1997 May;11(5):619–23 (31 ref.)
Hybrid sterility in the mouse [published erratum appears in Trends Genet 1997 Jan;13(1):42] Forejt J. **Trends Genet** 1996 Oct;12(10):412–7 (51 ref.)

GROWTH & DEVELOPMENT

Renin angiotensin system in development of mice and men [comment] Fogo A, et al. **Am J Pathol** 1996 Dec; 149(6):1797–801 (32 ref.) Comment on: Am J Pathol 1996 Dec;149(6):2067–79.

IMMUNOLOGY

B cell development in mice. Kearney JF, et al. **Int Rev Immunol** 1997;15(3–4):207–41 (168 ref.)

MICROBIOLOGY

Transport of wild mice genetic material by in vitro fertilization, cryopreservation, and embryo transfer. Suzuki H, et al. **Lab Anim Sci** 1996 Dec;46(6):687–8 (16 ref.)

PARASITOLOGY

Cryptosporidiosis in mice in Argentina. Fernández PE, et al. **Lab Anim Sci** 1996 Dec;46(6):685–6 (22 ref.)

PHYSIOLOGY

Renin angiotensin system in development of mice and men [comment] Fogo A, et al. **Am J Pathol** 1996 Dec; 149(6):1797–801 (32 ref.) Comment on: Am J Pathol 1996 Dec;149(6):2067–79.
Murine models of brain aging and age-related neurodegenerative diseases. Jucker M, et al. **Behav Brain Res** 1997 Apr;85(1):1–26 (261 ref.)

MICE, ATHYMIC see **MICE, NUDE**

MICE, HAIRLESS see **MICE, INBRED HRS**

MICE, HOUSE see **MICE**

MICE, INBRED AKR

GENETICS

Tlag1, a novel murine tumor susceptibility gene that regulates MNU-induced thymic lymphoma development. Richie ER, et al. **Prog Clin Biol Res** 1996;395:23–32 (17 ref.)

MICE, INBRED BALB C

Sustained estrogenization is insufficient to support long-term experimentally induced genital Trichomonas vaginalis infection in BALB/c mice. Van Andel RA, et al. **Lab Anim Sci** 1996 Dec;46(6):689–90 (11 ref.)

MICE, INBRED HRS

The hairless mouse model for photoaging. Kligman LH. **Clin Dermatol** 1996 Mar-Apr;14(2):183-95 (101 ref.)

MICE, INBRED MRL LPR

PSYCHOLOGY

Behaviour of MRL mice: an animal model of disturbed behaviour in systemic autoimmune disease. Szechtman H, et al. **Lupus** 1997;6(3):223-9 (40 ref.)

MICE, INBRED NOD

The non-obese diabetic (NOD) mouse: an animal model for autoimmune thyroiditis. Many MC, et al. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 3:17-20 (39 ref.)

Iodine-induced thyroiditis in the non-obese diabetic (NOD) mouse--more questions than answers. Scherbaum WA. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 3:20-3 (7 ref.)

IMMUNOLOGY

Autoreactive T-cell clones from the nonobese diabetic mouse. Bergman B, et al. **Proc Soc Exp Biol Med** 1997 Jan;214(1):41-8 (53 ref.)

MICE, INBRED NZB

New methods of treatment in an experimental murine model of systemic lupus erythematosus induced by idiotypic manipulation. Shoenfeld Y, et al. **Ann Rheum Dis** 1997 Jan; 56(1):5-11 (71 ref.)

MICE, INBRED STRAINS

Immune responses to filarial infection in laboratory mice. Hörauf A, et al. **Med Microbiol Immunol (Berl)** 1997 Mar; 185(4):207-15 (81 ref.)

GENETICS

Mouse models of human genetic disease: which mouse is more like a man? Erickson RP. **Bioessays** 1996 Dec; 18(12):993-8 (58 ref.)

The genetics of obesity. Naggert J, et al. **Curr Opin Genet Dev** 1997 Jun;7(3):398-404 (58 ref.)

Mouse and rat genotype choices. Sprott RL. **Exp Gerontol** 1997 Jan-Apr;32(1-2):79-86 (15 ref.)

Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Crawley JN, et al. **Psychopharmacology (Berl)** 1997 Jul;132(2):107-24 (175 ref.)

PARASITOLOGY

Parasite-host relationships: in-situ study of Leishmania spp. in resistant and susceptible mice. Bosque F, et al. **Ann Trop Med Parasitol** 1995 Dec;89 Suppl 1:19-22 (16 ref.)

PHYSIOLOGY

Lessons from angiotensin-converting enzyme-deficient mice. Esther CR Jr, et al. **Curr Opin Nephrol Hypertens** 1996 Nov;5(6):463-7 (48 ref.)

MICE, KNOCKOUT

Transgenic and knock-out models for studying DNA repair. Allemand I, et al. **Biochimie** 1995;77(10):826-32 (62 ref.)

Transgenic and gene knock-out mouse models of sickle cell anemia and the thalassemias. Pászty C. **Curr Opin Hematol** 1997 Mar;4(2):88-93 (49 ref.)

Transgenic and knockout analyses of the role of TNF in immune regulation and disease pathogenesis. Douni E, et al. **J Inflamm** 1995-96;47(1-2):27-38 (64 ref.)

Transgenic and null mutant animals for psychosomatic research. Crnic LS. **Psychosom Med** 1996 Nov-Dec; 58(6):622-32 (57 ref.)

Physiological roles for parathyroid hormone-related protein: lessons from gene knockout mice. Karaplis AC, et al. **Vitam Horm** 1996;52:177-93 (24 ref.)

[The use of biotechnological recombinant-mice in biological safety research] Inoue T. **Eisei Shikenjo Hokoku** 1996; (114):1-12 (97 ref.) (Eng. Abstr.) **(Jpn)**

[Mice deficient for the IL-3/GM-CSF/IL-5 beta receptors] Nishinakamura R. **Rinsho Ketsueki** 1997 Mar;38(3):181-5 (8 ref.) **(Jpn)**

GENETICS

Impact of knockout mice in toxicology. Ryffel B. **Crit Rev Toxicol** 1997 Mar;27(2):135-54 (120 ref.)

A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Crawley JN, et al. **Horm Behav** 1997 Jun;31(3):197-211 (200 ref.)

The use of genetic "knockout" mice in behavioral endocrinology research. Nelson RJ. **Horm Behav** 1997 Jun; 31(3):188-96 (55 ref.)

Estrogen receptor function as revealed by knockout studies: neuroendocrine and behavioral aspects. Rissman EF, et al. **Horm Behav** 1997 Jun;31(3):232-43 (90 ref.)

Using genetically modified mice to study apolipoprotein B. Young SG. **J Atheroscler Thromb** 1996;3(2):62-74 (45 ref.)

Searching for genes involved in the pathogenesis of primary immunodeficiency diseases: lessons from mouse knockouts. Kokron CM, et al. **J Clin Immunol** 1997 Mar;17(2):109-26 (236 ref.)

Xeroderma pigmentosum knockout mice: an immunologic tale [editorial] Kraemer KH. **J Invest Dermatol** 1996 Sep; 107(3):291-2 (18 ref.)

Xpa knockout mice. de Vries A, et al. **Semin Cancer Biol** 1996 Oct;7(5):229-40 (59 ref.)

Genes in the RB pathway and their knockout in mice. Lin SC, et al. **Semin Cancer Biol** 1996 Oct;7(5):279-89 (73 ref.)

[Knockout and knockin mice] Goldberg M, et al. **Harefuah** 1997 Feb 16;132(4):269-74 (35 ref.) **(Heb)**

IMMUNOLOGY

Gene knockout mice as investigative tools in pathophysiology. Ryffel B. **Int J Exp Pathol** 1996 Aug; 77(4):125-41 (98 ref.)

The use of CD4 and CD8 knockout mice to study the role of T-cell subsets in allotransplant rejection. Krieger NR, et al. **J Heart Lung Transplant** 1997 Mar;16(3):263-7 (40 ref.)

PHYSIOLOGY

Physiological role of brain endothelin in the central autonomic control: from neuron to knockout mouse. Kuwaki T, et al. **Prog Neurobiol** 1997 Apr;51(5):545-79 (365 ref.)

MICE, LABORATORY see **MICE**

MICE, MUTANT STRAINS

Shaker mice and a peek into the House of Usher. Saw D Jr, et al. **Exp Anim** 1997 Jan;46(1):1-9 (50 ref.)

Human-mouse xenografts in stem cell research. Wermann K, et al. **J Hematother** 1996 Aug;5(4):379-90 (69 ref.)

Transgenic and null mutant animals for psychosomatic research. Crnic LS. **Psychosom Med** 1996 Nov-Dec; 58(6):622-32 (57 ref.)

The Min mouse: a genetic model for intestinal carcinogenesis. Thompson MB. **Toxicol Pathol** 1997 May-Jun;25(3):329-32 (31 ref.)

Combining mutagenesis and genomics in the mouse--closing the phenotype gap. Brown SD, et al. **Trends Genet** 1996 Nov;12(11):433-5 (22 ref.)

EMBRYOLOGY

Early mouse development: lessons from gene targeting. St-Jacques B, et al. **Curr Opin Genet Dev** 1996 Aug; 6(4):439-44 (67 ref.)

GENETICS

Early mouse development: lessons from gene targeting. St-Jacques B, et al. **Curr Opin Genet Dev** 1996 Aug; 6(4):439-44 (67 ref.)

Naturally occurring mutations in mice affecting lipid transport and metabolism. Reue K, et al. **J Lipid Res** 1996 Jul;37(7):1387-405 (120 ref.)

Manipulation of the mouse germline in the study of Min-induced neoplasia. Bilger A, et al. **Semin Cancer Biol** 1996 Oct;7(5):249-60 (118 ref.)

The p53-deficient mouse: a model for basic and applied cancer studies. Donehower LA. **Semin Cancer Biol** 1996 Oct;7(5):269-78 (73 ref.)

[Knockout and knockin mice] Goldberg M, et al. **Harefuah** 1997 Feb 16;132(4):269-74 (35 ref.) **(Heb)**

PHYSIOLOGY

Intestinal physiology and pathology in gene-targeted mouse models of cystic fibrosis. Grubb BR, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):G258-66 (76 ref.)

Peripheral nerve involvement in merosin-deficient congenital muscular dystrophy and dy mouse. Matsumura K, et al. **Neuromuscul Disord** 1997 Jan;7(1):7-12 (50 ref.)

Cytokine regulation of the macrophage (M phi) system studied using the colony stimulating factor-1-deficient op/op mouse. Wiktor-Jedrzejczak W, et al. **Physiol Rev** 1996 Oct;76(4):927-47 (158 ref.)

MICE, NEUROLOGIC MUTANTS

GENETICS

A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Crawley JN, et al. **Horm Behav** 1997 Jun;31(3):197-211 (200 ref.)

MICE, NUDE

Model of the athymic nude mouse for the study of benign goiter disease. Gerber H, et al. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 3:56-9 (32 ref.)

In vivo models in thyroid research. The limitations of the athymic nude mice model for studies on goiter benign disease. Hoang-Vu C, et al. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 3:59-60 (7 ref.)

Xenotransplantation of human thyroid carcinomas in athymic nude mice. Wenisch HJ. **Exp Clin Endocrinol Diabetes** 1996; 104 Suppl 3:61-3 (23 ref.)

MICE, OBESE

GENETICS

The genetics of obesity. Naggert J, et al. **Curr Opin Genet Dev** 1997 Jun;7(3):398-404 (58 ref.)

Genetics of obesity: advances from rodent studies. Chagnon YC, et al. **Trends Genet** 1996 Nov;12(11):441-4 (25 ref.)

MICE, SCID

The use of SCID mice in biotechnology and as a model for human disease. Sandhu JS, et al. **Crit Rev Biotechnol** 1996; 16(1):95-118 (86 ref.)

Graves' disease/model of SCID mouse. Volpé R. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 3:37-40 (16 ref.)

The SCID mouse model: a discussion. Weetman AP. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 3:40-2 (7 ref.)

Modelling human leukemia and lymphoma in severe combined immunodeficient (SCID) mice: practical applications. Flavell DJ. **Hematol Oncol** 1996 Jun; 14(2):67-82 (100 ref.)

Modeling AIDS in a mouse. Mosier DE. **Hosp Pract (Off Ed)** 1996 Sep 15;31(9):41-8, 53-5, 59-60 (10 ref.)

Animal models of cutaneous lupus erythematosus and lupus erythematosus photosensitivity. Furukawa F. **Lupus** 1997; 6(2):193-202 (88 ref.)

The hu-PBL-SCID mouse in human lymphocyte function and lymphomagenesis studies: achievements and caveats. Amadori A, et al. **Semin Immunol** 1996 Aug;8(4):249-54 (50 ref.)

Normal and leukemic human stem cells assayed in SCID mice. Dick JE. **Semin Immunol** 1996 Aug;8(4):197-206 (69 ref.)

SCID-hu mice: a model for studying disseminated HIV infection. Goldstein H, et al. **Semin Immunol** 1996 Aug; 8(4):223-31 (42 ref.)

SCID-hu-PBL: a model for making human antibodies? Ifversen P, et al. **Semin Immunol** 1996 Aug;8(4):243-8 (51 ref.)

The SCID-hu mouse: an in-vivo model for HIV-1 pathogenesis and stem cell gene therapy for AIDS. Jamieson BD, et al. **Semin Immunol** 1996 Aug;8(4):215-21 (43 ref.)

Defining antibody protection against HIV-1 transmission in Hu-PBL-SCID mice. Koup RA, et al. **Semin Immunol** 1996 Aug;8(4):263-8 (52 ref.)

Development and applications of the SCID-hu mouse model. McCune JM. **Semin Immunol** 1996 Aug;8(4):187-96 (66 ref.)

Viral pathogenesis in hu-PBL-SCID mice [published erratum appears in Semin Immunol 1996 Oct;8(5):311] Mosier DE. **Semin Immunol** 1996 Aug;8(4):255-62 (87 ref.)

The huPBL-SCID mouse as a means to examine human immune function in vivo. Murphy WJ, et al. **Semin Immunol** 1996 Aug;8(4):233-41 (69 ref.)

Human T-and B-cell functions in SCID-hu mice. Roncarolo MG, et al. **Semin Immunol** 1996 Aug;8(4):207-13 (38 ref.)

GENETICS

Identification of the catalytic subunit of DNA dependent protein kinase as the product of the mouse scid gene. Jeggo PA, et al. **Curr Top Microbiol Immunol** 1996;217:79-89 (60 ref.)

IMMUNOLOGY

Immune deficiency in SCID mice. Nonoyama S, et al. **Int Rev Immunol** 1996;13(4):289-300 (59 ref.)

PARASITOLOGY

SCID mice and the study of parasitic disease. Seydel KB, et al. **Clin Microbiol Rev** 1996 Apr;9(2):126-34 (98 ref.)

MICE, TRANSGENIC

The use of transgenic mouse models to investigate the immune mechanisms of allergic contact dermatitis: an area of emerging opportunities. Burns RP Jr, et al. **Am J Contact Dermat** 1996 Jun;7(2):120-30 (91 ref.)

Transgenic and knock-out models for studying DNA repair. Allemand I, et al. **Biochimie** 1995;77(10):826-32 (62 ref.)

Transgenic and gene knock-out mouse models of sickle cell anemia and the thalassemias. Pászty C. **Curr Opin Hematol** 1997 Mar;4(2):88-93 (49 ref.)

Phototransduction in transgenic mice. Lem J, et al. **Curr Opin Neurobiol** 1996 Aug;6(4):453-8 (45 ref.)

Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Hanahan D, et al. **Eur J Cancer** 1996 Dec;32A(14):2386-93 (44 ref.)

Transgenic models for proliferative and hyperfunctional thyroid diseases. Ledent C, et al. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 3:43-6 (20 ref.)

Transgenic mice models in autoimmunity--discussion. Rink L, et al. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 3:46-8 (5 ref.)
Gene expression in kidney using transgenic approaches. Kopp JB. **Exp Nephrol** 1997 Mar-Apr;5(2):157-67 (50 ref.)
Targeted oncogenesis in the thyroid of transgenic mice. Feunteun J, et al. **Horm Res** 1997;47(4-6):137-9 (30 ref.)
Using transgenic mouse models to dissect the pathogenesis of virus-induced autoimmune disorders of the islets of Langerhans and the central nervous system. von Herrath MG, et al. **Immunol Rev** 1996 Aug;152:111-43 (190 ref.)
Transgenic mice to study viral pathogenesis and autoimmunity. Hengartner H. **Int J Exp Pathol** 1996 Dec; 77(6):279-82 (25 ref.)
Transgenic technology: principles. Märki U, et al. **Int J Exp Pathol** 1996 Dec;77(6):247-50 (8 ref.)
The use of transgenic mice in the investigation of transmissible spongiform encephalopathies. Weissmann C, et al. **Int J Exp Pathol** 1996 Dec;77(6):283-93 (73 ref.)
Transgenic mouse models for HTLV-I infection. Grossman WJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S162-9 (99 ref.)
HTLV-I transgenic models: an overview. Ozden S, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S154-61 (49 ref.)
Transgenic and knockout analyses of the role of TNF in immune regulation and disease pathogenesis. Douni E, et al. **J Inflamm** 1995-96;47(1-2):27-38 (64 ref.)
Gene targeting in embryonic stem cells: the new physiology and metabolism. Moreadith RW, et al. **J Mol Med** 1997 Mar;75(3):208-16 (81 ref.)
Development of a neurovirulent testing system for oral poliovirus vaccine with transgenic mice. Levenbook I, et al. **Lab Anim Sci** 1997 Apr;47(2):118-20 (28 ref.)
Oxidative stress, mutant SOD1, and neurofilament pathology in transgenic mouse models of human motor neuron disease. Tu PH, et al. **Lab Invest** 1997 Apr;76(4):441-56 (144 ref.)
Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. Tennant RW, et al. **Mutat Res** 1996 Sep;365(1-3):119-27 (36 ref.)
Of mice and (mad) cows--transgenic mice help to understand prions. Gabizon R, et al. **Trends Genet** 1997 Jul;13(7):264-9 (54 ref.)
[The use of biotechnological recombinant-mice in biological safety research] Inoue T. **Eisei Shikenjo Hokoku** 1996; (114):1-12 (97 ref.) (Eng. Abstr.) **(Jpn)**
[Contribution of transgenic mice to the study of diabetes mellitus] Miyazaki J. **Nippon Naika Gakkai Zasshi** 1996 Aug 10;85(8):1319-24 (10 ref.) **(Jpn)**

GENETICS

Development of genetically engineered mice with hypertension and hypotension. Sugiyama F. **Exp Anim** 1997 Jul;46(3):171-82 (44 ref.)
Conditionally immortalized cell lines with differentiated functions established from temperature-sensitive T-antigen transgenic mice. Obinata M. **Genes Cells** 1997 Apr; 2(4):235-44 (47 ref.)
A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Crawley JN, et al. **Horm Behav** 1997 Jun;31(3):197-211 (200 ref.)
Conditional mutagenesis in mice: the Cre/loxP recombination system. Plück A. **Int J Exp Pathol** 1996 Dec;77(6):269-78 (15 ref.)
Transgenic model applications to drug discovery. Polites HG. **Int J Exp Pathol** 1996 Dec;77(6):257-62 (10 ref.)
Using genetically modified mice to study apolipoprotein B. Young SG. **J Atheroscler Thromb** 1996;3(2):62-74 (45 ref.)
Validation issues for the use of transgenic mouse mutation assays in risk assessment. Gorelick NJ. **Prog Clin Biol Res** 1996;395:81-108 (85 ref.)
Variegated gene expression in mice. Dobie K, et al. **Trends Genet** 1997 Apr;13(4):127-30 (43 ref.)
Production of transgenic mice with yeast artificial chromosomes. Peterson KR, et al. **Trends Genet** 1997 Feb; 13(2):61-6 (42 ref.)
Alzheimer transgenic mouse models come of age. Duff K. **Trends Neurosci** 1997 Jul;20(7):279-80 (11 ref.)

IMMUNOLOGY

Strategies for expressing human antibody repertoires in transgenic mice. Brüggemann M, et al. **Immunol Today** 1996 Aug;17(8):391-7 (47 ref.)

METABOLISM

Animal models for studying the genetic basis of metabolic regulation. Nizielski SE, et al. **J Nutr** 1996 Nov; 126(11):2697-708 (65 ref.)

PHYSIOLOGY

Transgenic mice to study the role of dopamine receptors in cardiovascular function. Jose PA, et al. **Clin Exp Hypertens** 1997 Jan-Feb;19(1-2):15-25 (61 ref.)
Islet regeneration in IFNgamma transgenic mice. Jones EM, et al. **Horm Metab Res** 1997 Jun;29(6):308-10 (32 ref.)
Use of transgenic mice for understanding the physiology of insulin-like growth factors. D'Ercole AJ, et al. **Horm Res** 1996;45 Suppl 1:5-7 (11 ref.)
Transgenic modeling of neuropsychiatric disorders. Campbell IL, et al. **Mol Psychiatry** 1996 May;1(2):105-20 (148 ref.)

MICELLES

Chiral micelle polymers for chiral separations in capillary electrophoresis. Williams CC, et al. **Adv Chromatogr** 1997; 37:363-423 (94 ref.)
Protein and peptide analysis by capillary zone electrophoresis and micellar electrokinetic chromatography. Szökö E. **Electrophoresis** 1997 Jan;18(1):74-81 (99 ref.)
Pharmacokinetic considerations in the development of labeled liposomes and micelles for diagnostic imaging. Torchilin VP. **Q J Nucl Med** 1997 Jun;41(2):141-53 (64 ref.)

MICROABRASION, DENTAL see **ENAMEL MICROABRASION**

MICROABRASION, ENAMEL see **ENAMEL MICROABRASION**

MICROANGIOPATHY, DIABETIC see **DIABETIC ANGIOPATHIES**

MICROBIAL ANTAGONISM see **ANTIBIOSIS**

MICROBIAL SENSITIVITY TESTS

see related
DRUG RESISTANCE, MICROBIAL

Emerging trends in antimicrobial resistance: a laboratory perspective. Sahm DF. **Adv Exp Med Biol** 1995;390:141-54 (46 ref.)
Susceptibility testing of Mycobacterium avium complex isolates. Heifets L. **Antimicrob Agents Chemother** 1996 Aug; 40(8):1759-67 (117 ref.)
The antibiotic selective process: concentration-specific amplification of low-level resistant populations. Baquero F, et al. **Ciba Found Symp** 1997;207:93-105; discussion 105-11 (27 ref.)
Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards [see comments] Rex JH, et al. **Clin Infect Dis** 1997 Feb; 24(2):235-47 (123 ref.) Comment in: Clin Infect Dis 1997 Feb;24(2):248-9.
Clinical mycobacteriology. Drug susceptibility testing. Heifets LB. **Clin Lab Med** 1996 Sep;16(3):641-56 (58 ref.)
Interactions among antibiotics, bacteria and the human immune system: the clinical relevance of in vitro testing. Bergogne-Berezin E. **J Chemother** 1997 May;9 Suppl 1:109-15 (26 ref.)
Problems arising in antimicrobial therapy due to false susceptibility testing. Cunha BA. **J Chemother** 1997 May; 9 Suppl 1:25-35 (15 ref.)
In-vitro antimicrobial susceptibility testing: does it really matter? [editorial] Finch RG. **J Chemother** 1997 May;9 Suppl 1:3-6 (5 ref.)
What's the use of susceptibility testing? Greenwood D. **J Chemother** 1997 May;9 Suppl 1:7-12 (25 ref.)
In vitro antibiotics testing and its relationship to clinical activity. Mouton Y, et al. **J Chemother** 1997 May;9 Suppl 1:93-9 (24 ref.)
The importance of in-vitro susceptibility testing in the management of compromised hosts. Venditti M, et al. **J Chemother** 1997 May;9 Suppl 1:116-22 (23 ref.)
Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. Ghannoum MA, et al. **J Clin Microbiol** 1996 Mar;34(3):489-95 (96 ref.)
In vitro testing of antibiotics. Ackerman BH, et al. **Pharmacotherapy** 1996 Mar-Apr;16(2):201-17 (161 ref.)

INSTRUMENTATION

WHONET: removing obstacles to the full use of information about antimicrobial resistance. O'Brien TF, et al. **Diagn Microbiol Infect Dis** 1996 Aug;25(4):162-8 (21 ref.)

METHODS

Antifungal susceptibility testing: technical advances and potential clinical applications[see comments] Pfaller MA, et al. **Clin Infect Dis** 1997 May;24(5):776-84 (75 ref.) Comment in: Clin Infect Dis 1997 May;24(5):775.
Antimicrobial agents and gonorrhoea: therapeutic choice, resistance and susceptibility testing [see comments] Ison CA. **Genitourin Med** 1996 Aug;72(4):253-7 (46 ref.) Comment in: Genitourin Med 1997 Apr;73(2):149.
Breakpoints in antibiotic sensitivity testing and their clinical relevance. Hamilton-Miler JM. **J Chemother** 1997 May;9 Suppl 1:47-54 (50 ref.)
In vitro models for prediction of antimicrobial activity: a pharmacokinetic and pharmacodynamic perspective. Li RC, et al. **J Chemother** 1997 May;9 Suppl 1:55-63 (81 ref.)
The chemotherapeutic formula revisited. Periti P. **J Chemother** 1997 May;9 Suppl 1:123-33 (19 ref.)
Standardization of susceptibility testing methods. Phillips I, et al. **J Chemother** 1997 May;9 Suppl 1:13-8 (20 ref.)
In vitro antibiotic sensitivity testing breakpoints and therapeutic activity in induced infections in animal models. Soriano F, et al. **J Chemother** 1997 May;9 Suppl 1:36-46 (60 ref.)
[The quantitative expression of susceptibility and its clinical significance] Kanno H. **Nippon Rinsho** 1997 May; 55(5):1191-9 (8 ref.) (Eng. Abstr.) **(Jpn)**

STANDARDS

Standardization of antifungal susceptibility testing. Cormican MG, et al. **J Antimicrob Chemother** 1996 Oct;38(4):561-78 (78 ref.)
Standardization of susceptibility testing methods. Phillips I, et al. **J Chemother** 1997 May;9 Suppl 1:13-8 (20 ref.)

MICROBIOLOGICAL TECHNIQUES

Investigation of the carbon- and sulfur-oxidizing capabilities of microorganisms by active-site modeling. Holland HL. **Adv Appl Microbiol** 1997;44:125-65 (90 ref.)
The role of nucleic acid amplification and detection in the clinical microbiology laboratory. Whelen AC, et al. **Annu Rev Microbiol** 1996;50:349-73 (210 ref.)
Current blood culture methods and systems: clinical concepts, technology, and interpretation of results. Weinstein MP. **Clin Infect Dis** 1996 Jul;23(1):40-6 (71 ref.)
Strategies for whole microbial genome sequencing and analysis. Fraser CM, et al. **Electrophoresis** 1997 Aug; 18(8):1207-16 (55 ref.)
Microorganisms as tracers in groundwater injection and recovery experiments: a review. Harvey RW. **FEMS Microbiol Rev** 1997 Jul;20(3-4):461-72 (46 ref.)
Recent examples of novel secondary metabolites. Brown AG. **Folia Microbiol (Praha)** 1995;40(1):31-42 (37 ref.)
Laboratory diagnosis of hepatitis C. Nolte FS. **Immunol Invest** 1997 Jan-Feb;26(1-2):199-207 (43 ref.)
The microbiology of colonization, including techniques for assessing and measuring colonization. Greene JN. **Infect Control Hosp Epidemiol** 1996 Feb;17(2):114-8 (34 ref.)
Impedance microbiology--a rapid change for microbiologists. Silley P, et al. **J Appl Bacteriol** 1996 Mar; 80(3):233-43 (89 ref.)
RAPD typing in microbiology--a technical review. Power EG. **J Hosp Infect** 1996 Dec;34(4):247-65 (55 ref.)
New rapid microbiological diagnostic techniques. Burgner D, et al. **J Paediatr Child Health** 1996 Apr;32(2):83-5 (15 ref.)
[On the revision of microbial tests in the Pharmacopoeia of Japan] Mise K. **Eisei Shikenjo Hokoku** 1994;(112):206-8 (2 ref.) (Eng. Abstr.) **(Jpn)**
[Detection systems of microorganisms] Kawasaki Y. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1173-6 (5 ref.) **(Jpn)**
[New microbiological Techniques in diagnosis of tuberculosis] Golyshevskaia VI, et al. **Probl Tuberk** 1996; (6):22-5 (17 ref.) (Eng. Abstr.) **(Rus)**

ECONOMICS

Clinically relevant, cost-effective clinical microbiology. Strategies to decrease unnecessary testing. Wilson ML. **Am J Clin Pathol** 1997 Feb;107(2):154-67 (68 ref.)

INSTRUMENTATION

In situ microcosms in aquifer bioremediation studies. Mandelbaum RT, et al. **FEMS Microbiol Rev** 1997 Jul; 20(3-4):489-502 (40 ref.)

STANDARDS

The role of the microbiology laboratory in the investigation of child sexual abuse. Dyson C, et al. **J Med Microbiol** 1996 Nov;45(5):313-8 (51 ref.)
The possibilities and limitations of nucleic acid amplification technology in diagnostic microbiology. Vaneechoutte M, et al. **J Med Microbiol** 1997 Mar;46(3):188-94 (63 ref.)
[Improvement of microbiological diagnosis of dysbacteriosis] Raevskii KK, et al. **Vestn Ross Akad Med Nauk** 1997; (3):13-6 (11 ref.) (Eng. Abstr.) **(Rus)**

UTILIZATION

Clinically relevant, cost-effective clinical microbiology. Strategies to decrease unnecessary testing. Wilson ML. **Am J Clin Pathol** 1997 Feb;107(2):154-67 (68 ref.)

MICROBIOLOGY

see related
BACTERIA
FUNGI
PROTOZOA
VIRUSES

The role of molecular diagnostics in the clinical microbiology laboratory. Baselski VS. **Clin Lab Med** 1996 Mar; 16(1):49-60 (37 ref.)
Biodiversity: are microbial species threatened? Staley JT. **Curr Opin Biotechnol** 1997 Jun;8(3):340-5 (24 ref.)
The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance. Jones RN. **Diagn Microbiol Infect Dis** 1996 Aug;25(4):153-61 (57 ref.)

MICROBIOLOGY

Opening the door onto the natural microbial world: molecular microbial ecology. Pace NR. **Harvey Lect** 1995-96;91:59-78 (39 ref.)

Special considerations for the clinical microbiology laboratory in the diagnosis of infections in the cancer patient. Sandin RL, et al. **Infect Dis Clin North Am** 1996 Jun;10(2):413-30 (41 ref.)

Role of the microbiology laboratory in monitoring and identifying resistance: use of molecular biology. Pfaller MA, et al. **New Horiz** 1996 Aug;4(3):361-9 (31 ref.)

EDUCATION

Toward an integrated program for patient care in pediatric infections. Schaad UB. **Pediatr Infect Dis J** 1997 Mar;16(3 Suppl):S34-8 (17 ref.)

STANDARDS

Clinical mycobacteriology. Work flow and optional protocols for laboratories in industrialized countries. Della-Latta P. **Clin Lab Med** 1996 Sep;16(3):677-95 (76 ref.)

Microbiology testing and the pediatrician's office. Rogers WO, et al. **Pediatr Infect Dis J** 1997 Apr;16(4):339-45 (13 ref.)

MICROBODIES

A unified nomenclature for peroxisome biogenesis factors. Distel B, et al. **J Cell Biol** 1996 Oct;135(1):1-3 (48 ref.)

Peroxisome isolation. Distel B, et al. **Methods Mol Biol** 1996; 53:133-8 (7 ref.)

CHEMISTRY

Biochemistry of peroxisomes in health and disease. Singh I. **Mol Cell Biochem** 1997 Feb;167(1-2):1-29 (308 ref.)

DRUG EFFECTS

The peroxisome proliferator-activated receptors: ligands and activators. Forman BM, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:266-75 (42 ref.)

Hepatocarcinogenesis of peroxisome proliferators. Rao MS, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:573-87 (142 ref.)

Peroxisome proliferator-induced pleiotropic responses: pursuit of a phenomenon. Reddy JK, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:176-201 (99 ref.)

Mechanism-based risk assessment of peroxisome proliferating rodent hepatocarcinogens. Williams GM, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:554-72 (69 ref.)

Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators of lipid metabolism. Latruffe N, et al. **Biochimie** 1997 Feb-Mar; 79(2-3):81-94 (162 ref.)

Perfluorodecanoic acid as a useful pharmacologic tool for the study of peroxisome proliferation. Vahden Heuvel JP. **Gen Pharmacol** 1996 Oct;27(7):1123-9 (60 ref.)

[Pleiotrophic peroxisome induction by hypolipidemic agents in primates and rodents] Stangl H, et al. **Wien Klin Wochenschr** 1996;108(2):40-4 (56 ref.) (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

The peroxisome in retrospect. de Duve C. **Ann N Y Acad Sci** 1996 Dec 27;804:1-10 (64 ref.)

Peroxisomal beta-oxidation: enzymology and molecular biology. Hashimoto T. **Ann N Y Acad Sci** 1996 Dec 27; 804:86-98 (56 ref.)

Functions and organization of peroxisomal beta-oxidation. Mannaerts GP, et al. **Ann N Y Acad Sci** 1996 Dec 27; 804:99-115 (68 ref.)

Peroxisomal disorders: overview. Moser HW, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:427-41 (100 ref.)

Variable peroxisomal and mitochondrial targeting of alanine: glyoxylate aminotransferase in mammalian evolution and disease. Danpure CJ. **Bioessays** 1997 Apr;19(4):317-26 (69 ref.)

In situ heterogeneity of peroxisomal oxidase activities: an update. Van den Munckhof RJ. **Histochem J** 1996 Jun; 28(6):401-29 (348 ref.)

METABOLISM

The role of peroxisomes in ether lipid synthesis. Back to the roots of PAF. van den Bosch H, et al. **Adv Exp Med Biol** 1996;416:33-40 (27 ref.)

Lipid biosynthesis in peroxisomes. Hajra AK, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:129-41 (51 ref.)

Peroxisomal beta-oxidation and polyunsaturated fatty acids. Hiltunen JK, et al. **Ann N Y Acad Sci** 1996 Dec 27; 804:116-28 (85 ref.)

Cell compartmentalization of cholesterol biosynthesis. Krisans SK. **Ann N Y Acad Sci** 1996 Dec 27;804:142-64 (53 ref.)

Protein import into peroxisomes: new developments. Rehling P, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:34-46 (81 ref.)

Mammalian peroxisomes: metabolism of oxygen and reactive oxygen species. Singh I. **Ann N Y Acad Sci** 1996 Dec 27; 804:612-27 (50 ref.)

Signals, receptors, and cytosolic factors involved in peroxisomal protein import. Terlecky SR, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:11-20 (71 ref.)

Peroxisomal purine metabolism. Yeldandi AV, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:165-75 (25 ref.)

Peroxisomes as a source of superoxide and hydrogen peroxide in stressed plants. del Río LA, et al. **Biochem Soc Trans** 1996 May;24(2):434-8 (43 ref.)

Peroxisome biogenesis. Waterham HR, et al. **Bioessays** 1997 Jan;19(1):57-66 (74 ref.)

Cellular signalling: the role of the peroxisome. Masters CJ. **Cell Signal** 1996 Mar;8(3):197-208 (42 ref.)

Protein import into peroxisomes: an exception to the rule? Huhse B, et al. **Cold Spring Harb Symp Quant Biol** 1995; 60:657-62 (62 ref.)

Transport of proteins and metabolites across the impermeable membrane of peroxisomes. Tabak HF, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:649-55 (37 ref.)

Production of lactones and peroxisomal beta-oxidation in yeasts. Endrizzi A, et al. **Crit Rev Biotechnol** 1996; 16(4):301-29 (195 ref.)

Peroxisome proliferator-activated receptor gamma and the control of adipogenesis. Brun RP, et al. **Curr Opin Lipidol** 1997 Aug;8(4):212-8 (55 ref.)

In vitro systems in the study of peroxisomal protein import. Baker A. **Experientia** 1996 Dec 15;52(12):1055-62 (45 ref.)

The cytosolic and membrane components required for peroxisomal protein import. Terlecky SR, et al. **Experientia** 1996 Dec 15;52(12):1050-4 (51 ref.)

Protein translocation into peroxisomes. Subramani S. **J Biol Chem** 1996 Dec 20;271(51):32483-6 (50 ref.)

Secondary alterations of human hepatocellular peroxisomes. De Craemer D. **J Inherit Metab Dis** 1995;18 Suppl 1:181-213 (124 ref.)

Omega-3 fatty acids and the peroxisome. Masters C. **Mol Cell Biochem** 1996 Dec 20;165(2):83-93 (48 ref.)

Gluconeogenesis and the peroxisome. Masters C. **Mol Cell Biochem** 1997 Jan;166(1-2):159-68 (30 ref.)

Polyunsaturated fatty acids regulate lipogenic and peroxisomal gene expression by independent mechanisms. Clarke SD, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Jul; 57(1):65-9 (22 ref.)

PHYSIOLOGY

Saccharomyces cerevisiae as a model organism for studying function and biogenesis of peroxisomes. Skoneczny M, et al. **Acta Microbiol Pol** 1995;44(3-4):209-18 (26 ref.)

Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Lemberger T, et al. **Ann Rev Cell Dev Biol** 1996;12:335-63 (116 ref.)

Proteins involved in peroxisome biogenesis and functioning. Elgersma Y, et al. **Biochim Biophys Acta** 1996 Oct 29; 1286(3):269-83 (129 ref.)

Functional transformation of microbodies in higher plant cells. Nishimura M, et al. **Cell Struct Funct** 1996 Oct; 21(5):387-93 (42 ref.)

Mitogenic actions of peroxidase proliferators: involvement of protein kinase C and tumor necrosis factor alpha. Bojes HK, et al. **Drug Metab Rev** 1997 Feb-May;29(1-2):235-60 (71 ref.)

Regulating adipogenesis. Mandrup S, et al. **J Biol Chem** 1997 Feb 28;272(9):5367-70 (56 ref.)

Role of metabolism in the activation of dehydroepiandrosterone as a peroxisome proliferator. Waxman DJ. **J Endocrinol** 1996 Sep;150 Suppl:S129-47 (140 ref.)

Peroxisomes in adrenal steroidogenesis. Magalhães MM, et al. **Microsc Res Tech** 1997 Mar 15;36(6):493-502 (98 ref.)

Biochemistry of peroxisomes in health and disease. Singh I. **Mol Cell Biochem** 1997 Feb;167(1-2):1-29 (308 ref.)

[Proliferation of peroxisomes and the hepatocarcinogenic process] Palut D. **Rocz Panstw Zakl Hig** 1997;48(1):1-11 (65 ref.) (Eng. Abstr.) **(Pol)**

ULTRASTRUCTURE

Approaches to studies on peroxisome biogenesis and human peroxisome-deficient disorders. Fujiki Y. **Ann N Y Acad Sci** 1996 Dec 27;804:491-501 (43 ref.)

Contributions of the immunogold technique to investigation of the biology of peroxisomes. Fahimi HD, et al. **Histochem Cell Biol** 1996 Jul;106(1):105-14 (54 ref.)

Secondary alterations of human hepatocellular peroxisomes. De Craemer D. **J Inherit Metab Dis** 1995;18 Suppl 1:181-213 (124 ref.)

Practical guide for morphometry of human peroxisomes on electron micrographs. Kerckaert I, et al. **J Inherit Metab Dis** 1995;18 Suppl 1:172-80 (39 ref.)

MICROCAPSULES see **CAPSULES**

MICROCEPHALY

Heterogeneity in adducted thumbs sequence. Moldavsky M, et al. **Am J Med Genet** 1997 May 16;70(2):114-7 (13 ref.)

Microcephaly. Rios A. **Pediatr Rev** 1996 Nov;17(11):386-7 (3 ref.)

[Microcephaly with chromosomal instability and immunodeficiency--Nijmegen syndrome] Chrzanowska KH. **Pediatr Pol** 1996 Mar;71(3):223-34 (44 ref.) (Eng. Abstr.) **(Pol)**

[Partial agenesis of the sacrum and microcephaly: an uncommon association] Ruiz Moreno JA, et al. **An Esp Pediatr** 1997 Jun;46(6):607-10 (18 ref.) **(Spa)**

COMPLICATIONS

Coffin-Siris syndrome: a case of an extremely low birthweight infant with severe kyphoscoliosis. Suzumura H, et al. **Acta Paediatr Jpn** 1996 Oct;38(5):537-40 (5 ref.)

GENETICS

Mammalian X ray sensitive mutants: a tool for the elucidation of the cellular response to ionizing radiation. Zdzienicka MZ. **Cancer Surv** 1996;28:281-93 (62 ref.)

Nijmegen breakage syndrome. van der Burgt I, et al. **J Med Genet** 1996 Feb;33(2):153-6 (25 ref.)

MICROCHEMISTRY

METHODS

Calorimetry of whole yeast cells. Ashby LJ, et al. **Methods Mol Biol** 1996;53:367-82 (14 ref.)

MICROCIRCULATION

Microcirculation: its significance in clinical and molecular medicine. Fagrell B, et al. **J Intern Med** 1997 May; 241(5):349-62 (118 ref.)

Systemic sclerosis. A vascular perspective. LeRoy EC. **Rheum Dis Clin North Am** 1996 Nov;22(4):675-94 (52 ref.)

Remodeling of hepatic microvascular responsiveness after ischemia/reperfusion. Clemens MG, et al. **Shock** 1997 Aug; 8(2):80-5 (66 ref.)

[Microvascular function and regulation of coronary blood flow in ischemic cardiomyopathy] Sambuceti G, et al. **G Ital Cardiol** 1996 Dec;26(12):1495-505 (60 ref.) **(Ita)**

ANATOMY & HISTOLOGY

[Basic trends in the study of the general biological and functional-morphological bases of the microcirculatory system] Kozlov VI, et al. **Arkh Anat Gistol Embriol** 1981 Dec;81(12):7-23 (150 ref.) **(Rus)**

CYTOLOGY

Pericytes in the microvasculature. Hirschi KK, et al. **Cardiovasc Res** 1996 Oct;32(4):687-98 (144 ref.)

DRUG EFFECTS

Angiotensin II-receptor (AT1) blockade in the human forearm. Ritter JM, et al. **Blood Press Suppl** 1996;2:67-70 (31 ref.)

IMMUNOLOGY

Mechanisms and consequences of cell activation in the microcirculation. Mazzoni MC, et al. **Cardiovasc Res** 1996 Oct;32(4):709-19 (95 ref.)

The microcirculation in venous hypertension. Smith PD. **Cardiovasc Res** 1996 Oct;32(4):789-95 (59 ref.)

METABOLISM

Microvascular and tissue oxygen distribution. Intaglietta M, et al. **Cardiovasc Res** 1996 Oct;32(4):632-43 (78 ref.)

Transport of macromolecules through microvascular walls. Michel CC. **Cardiovasc Res** 1996 Oct;32(4):644-53 (64 ref.)

PATHOLOGY

Brain parenchymal and microvascular amyloid in Alzheimer's disease. Vinters HV, et al. **Brain Pathol** 1996 Apr;6(2):179-95 (169 ref.)

The microcirculation in experimental hypertension and aging. Hutchins PM, et al. **Cardiovasc Res** 1996 Oct;32(4):772-80 (53 ref.)

The microcirculation in atherogenesis. Lehr HA, et al. **Cardiovasc Res** 1996 Oct;32(4):781-8 (61 ref.)

Assessment of tumor microcirculation: a new role of dynamic contrast MR imaging. Griebel J, et al. **J Magn Reson Imaging** 1997 Jan-Feb;7(1):111-9 (73 ref.)

PHYSIOLOGY

The microphysiology of lung liquid clearance. Bhattacharya J. **Adv Exp Med Biol** 1995;381:95-108 (32 ref.)

Microcirculation, vitamin E and omega 3 fatty acids: an overview. Bruckner G. **Adv Exp Med Biol** 1997; 415:195-208 (104 ref.)

Vascular regulation at sub millimeter range. Sources of intrinsic signals for high resolution optical imaging. Malonek D, et al. **Adv Exp Med Biol** 1997;413:215-20 (18 ref.)

The role of microvasculature in normal and perturbed bone healing as revealed by intravital microscopy. Winet H. **Bone** 1996 Jul;19(1 Suppl):39S-57S (73 ref.)

Consequences of alteration in capillary permeability. Plante GE, et al. **Can J Physiol Pharmacol** 1996 Jul;74(7):824-33 (65 ref.)

Physiological and pathophysiological roles of eicosanoids in the microcirculation. Gerritsen ME. **Cardiovasc Res** 1996 Oct;32(4):720-32 (133 ref.)

The role of nitric oxide and cell adhesion molecules on the microcirculation in ischaemia-reperfusion. Lefer AM, et al. **Cardiovasc Res** 1996 Oct;32(4):743-51 (70 ref.)

Molecular mechanisms of leukocyte recruitment in the inflammatory process. Ley K. **Cardiovasc Res** 1996 Oct;

32(4):733–42 (129 ref.)
Biophysical aspects of blood flow in the microvasculature. Pries AR, et al. **Cardiovasc Res** 1996 Oct;32(4):654–67 (105 ref.)
Role of nitric oxide in the control of glomerular microcirculation. Ito S, et al. **Clin Exp Pharmacol Physiol** 1997 Aug;24(8):578–81 (18 ref.)
Control of angiogenesis by the pericyte: molecular mechanisms and significance. Hirschi KK, et al. **EXS** 1997; 79:419–28 (46 ref.)
Role of fibrin and plasminogen activators in repair-associated angiogenesis: in vitro studies with human endothelial cells. van Hinsbergh VW, et al. **EXS** 1997;79:391–411 (119 ref.)
Erythrocyte rheology in microcirculation. Maeda N. **Jpn J Physiol** 1996 Feb;46(1):1–14 (118 ref.)
[Observation and RBC velocity measurement of microcirculation] Oshio C, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1106–12 (8 ref.) **(Jpn)**
[Laser Doppler flowmetry--a new promising technique for assessment of the microcirculation] Szulkowska E, et al. **Pol Tyg Lek** 1996 Mar;51(10–13):179–81 (32 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

The microcirculation during endotoxemia. McCuskey RS, et al. **Cardiovasc Res** 1996 Oct;32(4):752–63 (158 ref.)
Microvasculature in diabetes. Tooke JE. **Cardiovasc Res** 1996 Oct;32(4):764–71 (56 ref.)
Microvascular functional abnormalities in diabetes: the role of the endothelium. Tooke JE, et al. **Diabetes Res Clin Pract** 1996 Jul;31 Suppl:S127–32 (33 ref.)
[Disturbances of the normal structuring of the blood flow in the microvessels as the cause of hemorheological disorders] Mchedlishvili GI. **Fiziol Zh Im I M Sechenova** 1996 Dec;82(12):41–7 (27 ref.) **(Rus)**

SURGERY

Surgical treatment of spasmodic torticollis: is there a role for microvascular decompression? With an illustrative case report. Brunori A, et al. **J Neurosurg Sci** 1996 Mar; 40(1):43–51 (41 ref.)

ULTRASTRUCTURE

[Observation and RBC velocity measurement of microcirculation] Oshio C, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1106–12 (8 ref.) **(Jpn)**

MICROCLIMATE

Evaluation of indoor air quality using the decibel concept. Part I--proposal of new units. Jokl MV. **Cent Eur J Public Health** 1997 Mar;5(1):3–8 (22 ref.)
[The microclimate conditions of the environment for treating patients in hospital clinics and wards (a review)] Toshkov S. **Probl Khig** 1996;21:20–6 (20 ref.) (Eng. Abstr.) **(Bul)**

MICROCOCCUS DENITRIFICANS see **PARACOCCUS DENITRIFICANS**

MICROCOMPUTERS

Computers in biology: the future is today. Prilusky J. **Arch Biol Med Exp (Santiago)** 1986;19(3–4):323–8 (7 ref.)
Microcomputers and biologists. Smith IC. **Arch Biol Med Exp (Santiago)** 1986;19(3–4):313–21 (18 ref.)
Computer aids to treatment in psychiatry. Kirkby KC, et al. **Aust N Z J Psychiatry** 1996 Feb;30(1):142–5 (20 ref.)
Microcomputers in hospital epidemiology. Reagan DR. **Infect Control Hosp Epidemiol** 1997 Jun;18(6):440–8 (37 ref.)
New PC versions of the kinetic-simulation and fitting programs, KINSIM and FITSIM. Dang Q, et al. **Trends Biochem Sci** 1997 Aug;22(8):317 (6 ref.)
[Computer applications in ophthalmology] Kuchenbecker J, et al. **Ophthalmologe** 1997 Mar;94(3):248–60 (42 ref.) **(Ger)**
[Desk-top simulation of crisis management in anesthesiology] Ozaki M. **Masui** 1996 Dec;45 Suppl:S161–3 (0 ref.) **(Jpn)**
[Phthisiologist's qualification certification by using tests and personal computers] Kopylova IF, et al. **Probl Tuberk** 1997; (2):59–62 (4 ref.) **(Rus)**

MICROCYTOTOXICITY TESTS see **CYTOTOXICITY TESTS, IMMUNOLOGIC**

MICRODIALYSIS

Clinical microdialysis: the role of on-line measurement and quantitative microdialysis. Boutelle MG, et al. **Acta Neurochir Suppl (Wien)** 1996;67:13–20 (41 ref.)
Microdialysis and ultrafiltration. Janle EM, et al. **Adv Food Nutr Res** 1996;40:183–96 (16 ref.)
In vivo monitoring of brain neurotransmitter release for the assessment of neuroendocrine interactions. Mas M, et al. **Cell Mol Neurobiol** 1996 Jun;16(3):383–96 (51 ref.)
Cerebral microdialysis as a diagnostic tool in acute brain injury. Landolt H, et al. **Eur J Anaesthesiol** 1996 May; 13(3):269–78 (38 ref.)
Microdialysis: a way to study in vivo release of neurotrophic bioactivity: a critical summary. Humpel C, et al. **J Mol Med** 1996 Sep;74(9):523–6 (25 ref.)
Microdialysis in the human brain: review of its applications. Hamani C, et al. **Neurol Res** 1997 Jun;19(3):281–8 (28 ref.)
Application of microdialysis in pharmacokinetic studies. Elmquist WF, et al. **Pharm Res** 1997 Mar;14(3):267–88 (182 ref.)
The use of microdialysis in pharmacokinetics and pharmacodynamics. Johansen MJ, et al. **Pharmacotherapy** 1997 May–Jun;17(3):464–81 (98 ref.)
Application of in situ microdialysis to measure metabolic and vascular responses in adipose tissue. Lafontan M, et al. **Trends Pharmacol Sci** 1996 Sep;17(9):309–13 (25 ref.)

METHODS

Cutaneous microdialysis. Methodology and validation. Groth L. **Acta Derm Venereol Suppl (Stockh)** 1996;197:1–61 (200 ref.)
Measurement and analysis of unbound drug concentrations. Wright JD, et al. **Clin Pharmacokinet** 1996 Jun;30(6):445–62 (142 ref.)
Microdialysis-coupled place cell detection in the hippocampus: a new strategy for the search for cognition enhancer drugs. Ludvig N. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Feb; 21(2):249–71 (91 ref.)
Topics in xenobiochemistry--application of microdialysis techniques in pharmacokinetic studies. Fettweis G, et al. **Xenobiotica** 1996 May;26(5):473–85 (34 ref.)
[Tissue microdialysis: practical and theoretical aspects] Cimmino M, et al. **Diabetes Metab** 1997 Apr;23(2):164–70 (29 ref.) (Eng. Abstr.) **(Fre)**
[Microdialysis for the determination of free drugs in tissues] Kovar A, et al. **Pharm Unserer Zeit** 1997 Jan;26(1):17–23 (29 ref.) **(Ger)**

MICROELECTRODES

Unit identification, sampling bias and technical issues in microneurographic recordings from muscle spindle afferents. Burke D. **J Neurosci Methods** 1997 Jun 27; 74(2):137–44 (39 ref.)
The methodology and scope of human microneurography. Gandevia SC, et al. **J Neurosci Methods** 1997 Jun 27; 74(2):123–36 (87 ref.)
[Micro fabricated enzyme battery] Sasaki S, et al. **Nippon Rinsho** 1996 Oct;54(10):2813–20 (0 ref.) (Eng. Abstr.) **(Jpn)**
[Measurement of plant bio-cell: towards the elucidation of systemic response mechanism in plant] Matsuoka H, et al. **Tanpakushitsu Kakusan Koso** 1997 Apr;42(5):784–9 (10 ref.) **(Jpn)**

MICROENCAPSULATION see **DRUG COMPOUNDING**

MICROFILAMENT PROTEINS

GENETICS

Fibrillin mutations in Marfan syndrome and related phenotypes. Ramirez F. **Curr Opin Genet Dev** 1996 Jun; 6(3):309–15 (55 ref.)
Ascending aortic aneurysm with or without features of Marfan syndrome and other fibrillinopathies: new insights. Furthmayr H, et al. **Semin Thorac Cardiovasc Surg** 1997 Jul;9(3):191–205 (45 ref.)

METABOLISM

A role of cofilin/destrin in reorganization of actin cytoskeleton in response to stresses and cell stimuli. Yahara I, et al. **Cell Struct Funct** 1996 Oct;21(5):421–4 (34 ref.)
Accelerating on a treadmill: ADF/cofilin promotes rapid actin filament turnover in the dynamic cytoskeleton [comment] Theriot JA. **J Cell Biol** 1997 Mar 24; 136(6):1165–8 (28 ref.) Comment on: J Cell Biol 1997 Mar 24;136(6):1307–22. Comment on: J Cell Biol 1997 Mar 24;136(6):1323–32.
[Activation induces dephosphorylation of cofilin (an actin/PIP2-binding protein) and its translocation to plasma membranes in leukocytes] Suzuki K. **Seikagaku** 1997 Apr; 69(4):254–9 (16 ref.) **(Jpn)**
[ERM (ezrin/radixin/moesin) as crosslinkers between actin filaments and plasma membranes] Tsukita S. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1899–905 (44 ref.) **(Jpn)**

PHYSIOLOGY

Accelerating on a treadmill: ADF/cofilin promotes rapid actin filament turnover in the dynamic cytoskeleton [comment] Theriot JA. **J Cell Biol** 1997 Mar 24; 136(6):1165–8 (28 ref.) Comment on: J Cell Biol 1997 Mar 24;136(6):1307–22. Comment on: J Cell Biol 1997 Mar 24;136(6):1323–32.
[F-actin cappers] Maruta H. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1442–7 (29 ref.) (Eng. Abstr.) **(Jpn)**

MICROFILAMENTS

The structure, function, and assembly of actin filament bundles. Furukawa R, et al. **Int Rev Cytol** 1997;175:29–90 (272 ref.)
Microtubule-microfilament synergy in the cytoskeleton. Gavin RH. **Int Rev Cytol** 1997;173:207–42 (151 ref.)
Shape and length of myosin heads and radial compressive forces in muscle. Morel JE, et al. **J Theor Biol** 1997 Jan 21;184(2):133–8 (37 ref.)
Review: an overview of the Saccharomyces cerevisiae microtubule and microfilament cytoskeleton. Winsor B, et al. **Yeast** 1997 Apr;13(5):399–434 (240 ref.)

METABOLISM

Structural interactions responsible for the assembly of the troponin complex on the muscle thin filament. Reinach FC, et al. **Cell Struct Funct** 1997 Feb;22(1):219–23 (30 ref.)
mRNA and cytoskeletal filaments. Bassell G, et al. **Curr Opin Cell Biol** 1997 Feb;9(1):109–15 (58 ref.)
Accelerating on a treadmill: ADF/cofilin promotes rapid actin filament turnover in the dynamic cytoskeleton [comment] Theriot JA. **J Cell Biol** 1997 Mar 24; 136(6):1165–8 (28 ref.) Comment on: J Cell Biol 1997 Mar 24;136(6):1307–22. Comment on: J Cell Biol 1997 Mar 24;136(6):1323–32.

PHYSIOLOGY

Molecular mechanisms regulating the myofilament response to Ca2+: implications of mutations causal for familial hypertrophic cardiomyopathy. Palmiter KA, et al. **Basic Res Cardiol** 1997;92 Suppl 1:63–74 (96 ref.)
The molecular mechanisms of actin-based intracellular motility by Listeria monocytogenes. Chakraborty T. **Microbiologia** 1996 Jun;12(2):237–44 (34 ref.)
Roles of microfilaments and intermediate filaments in adrenal steroidogenesis. Hall PF, et al. **Microsc Res Tech** 1997 Mar 15;36(6):463–79 (108 ref.)
Microfibrillar elements of the dermal matrix. Kielty CM, et al. **Microsc Res Tech** 1997 Aug 15;38(4):413–27 (150 ref.)
[Polarity of epithelial cells. Role of the actin microfilament system] Louvard D. **Nephrologie** 1996;17(7):351–7 (17 ref.) (Eng. Abstr.) **(Fre)**

ULTRASTRUCTURE

Models of thin filament assembly in cardiac and skeletal muscle. Gregorio CC. **Cell Struct Funct** 1997 Feb; 22(1):191–5 (37 ref.)
Microfibrillar elements of the dermal matrix. Kielty CM, et al. **Microsc Res Tech** 1997 Aug 15;38(4):413–27 (150 ref.)

MICROFLUOROMETRY, FLOW see **FLOW CYTOMETRY**

MICROGLIA

CYTOLOGY

Microglia: a pictorial. Streit WJ, et al. **Prog Histochem Cytochem** 1996;31(1):1–89 (70 ref.)

ENZYMOLOGY

Functional implication of secretory proteases derived from microglia in the central nervous system. Kohsaka S, et al. **Keio J Med** 1996 Sep;45(3):263–9 (51 ref.)
Regulation of matrix metalloproteinase expressions in astrocytes, microglia and neurons. Gottschall PE, et al. **Neuroimmunomodulation** 1996 Mar–Jun;3(2–3):69–75 (57 ref.)

IMMUNOLOGY

Molecular mechanisms of microglial activation. Zielasek J, et al. **Adv Neuroimmunol** 1996;6(2):191–22 (206 ref.)
The immune response in the Alzheimer's disease brain. Banati RB. **Biochem Soc Trans** 1997 May;25(2):683–5 (13 ref.)
Microglia in health and disease. Cuzner ML. **Biochem Soc Trans** 1997 May;25(2):671–3 (24 ref.)
Microglial in neurodegenerative disorders: emphasis on Alzheimer's disease. McRae A, et al. **Gerontology** 1997; 43(1–2):95–108 (100 ref.)
Heterogeneity of mouse brain macrophages in alloantigen presentation to naive CD8+ T cells as revealed by a panel of microglial cell lines. Askew D, et al. **Immunobiology** 1996 Oct;195(4–5):417–30 (56 ref.)
Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis [see comments] Benveniste EN. **J Mol Med** 1997 Mar;75(3):165–73 (107 ref.) Comment in: J Mol Med 1997 Mar;75(3):164.
Inflammation in EAE: role of chemokine/cytokine expression by resident and infiltrating cells. Eng LF, et al. **Neurochem Res** 1996 Apr;21(4):511–25 (133 ref.)
Indictment of the microglia as the villain in multiple sclerosis. Sriram S, et al. **Neurology** 1997 Feb;48(2):464–70 (69 ref.)
Microglia: a sensor to threats in the nervous system? Gehrmann J. **Res Virol** 1996 Mar–Jun;147(2–3):79–88 (76 ref.)
The brain's immune system. Streit WJ, et al. **Sci Am** 1995 Nov;273(5):54–5, 58–61 (3 ref.)

METABOLISM

Opiates, glia, and neurotoxicity. Chao CC, et al. **Adv Exp Med Biol** 1996;402:29–33 (20 ref.)
Induction of nitric oxide in cultured microglia: evidence for

MICROGLIA

a cytoprotective role. Colton CA. **Adv Neuroimmunol** 1995; 5(4):491–503 (57 ref.)
Detection of endothelial cell–derived nitric oxide: current trends and future directions. Magazine HI. **Adv Neuroimmunol** 1995;5(4):479–90 (49 ref.)
Species differences in the generation of reactive oxygen species by microglia. Colton C, et al. **Mol Chem Neuropathol** 1996 May–Aug;28(1–3):15–20 (18 ref.)
[Glial cells–derived neurotrophic factors] Nakajima K, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):489–95 (20 ref.) **(Jpn)**

PHYSIOLOGY

Microglia and prion disease: a review. Brown DR, et al. **Histol Histopathol** 1997 Jul;12(3):883–92 (74 ref.)
Modulation of glial cell signaling by adenosine and pharmacological reinforcement. A neuroprotective strategy? Schubert P, et al. **Mol Chem Neuropathol** 1996 May–Aug;28(1–3):185–90 (19 ref.)
The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Eikelenboom P, et al. **Neurobiol Aging** 1996 Sep–Oct;17(5):673–80 (99 ref.)
Molecular mechanisms of microglial activation. A. Implications for regeneration and neurodegenerative diseases. Gebicke–Haerter PJ, et al. **Neurochem Int** 1996 Jul;29(1):1–12 (145 ref.)
Molecular mechanisms of microglial activation. B. Voltage– and purinoceptor–operated channels in microglia. Illes P, et al. **Neurochem Int** 1996 Jul;29(1):13–24 (63 ref.)
The role of microglia in brain injury. Streit WJ. **Neurotoxicology** 1996 Fall–Winter;17(3–4):671–8 (52 ref.)
Microglia in human retina: a heterogeneous population with distinct ontogenies. Provis JM, et al. **Perspect Dev Neurobiol** 1996;3(3):213–22 (40 ref.)
The concept of microglia in relation to central nervous system disease and regeneration. Moore S, et al. **Prog Neurobiol** 1996 Mar–Apr;48(4–5):441–60 (149 ref.)
Microglia: a sensor for pathological events in the CNS. Kreutzberg GW. **Trends Neurosci** 1996 Aug;19(8):312–8 (75 ref.)

VIROLOGY

Mouse Moloney leukemia virus infects microglia but not neurons even though it induces motor neuron disease. Zachary JF, et al. **Mol Psychiatry** 1997 Mar;2(2):104–6 (19 ref.)

MICROGNATHISM

COMPLICATIONS

Cerebro–costo–mandibular syndrome [published erratum appears in Am J Med Genet 1996 Aug 23;64(3):527] Plötz FB, et al. **Am J Med Genet** 1996 Mar 29;62(3):286–92 (20 ref.)

MICROGRAPHIC SURGERY, MOHS see **MOHS SURGERY**

MICROGRAVITY see **WEIGHTLESSNESS**

MICROINJECTIONS

Approaching the next millennium: how should we manage andrology diagnosis in the intracytoplasmic sperm injection era? [editorial] Oehninger S, et al. **Fertil Steril** 1997 Mar; 67(3):434–6 (15 ref.)
Are there genetic risks associated with microassisted reproduction? Engel W, et al. **Hum Reprod** 1996 Nov; 11(11):2359–70 (85 ref.)
Heterologous expression of receptors and signaling proteins in adult mammalian sympathetic neurons by microinjection. Ikeda SR. **Methods Mol Biol** 1997;83:191–202 (15 ref.)
Nuclear application of antisense oligonucleotides by microinjection and ballistomagnetic transfer to identify G protein heterotrimers activating phospholipase C. Kalkbrenner F, et al. **Methods Mol Biol** 1997;83:203–16 (16 ref.)

ADVERSE EFFECTS

[Genetic risks associated with intracytoplasmic sperm injection] Plachot M. **Contracept Fertil Sex** 1996 Jul–Aug; 24(7–8):577–80 (14 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Azoospermia and intracytoplasmic sperm injection. Ubaldi F, et al. **Acta Eur Fertil** 1995 Jan–Feb;26(1):21–4 (16 ref.)
New approaches to male infertility: IVF and microinjection. Diedrich K, et al. **Int J Androl** 1995 Dec;18 Suppl 2:78–80 (11 ref.)
[Physiology of human gamete interaction] Wolf JP, et al. **Contracept Fertil Sex** 1997 Jan;25(1):69–78 (20 ref.) (Eng. Abstr.) **(Fre)**

MICROINTERFEROMETRY see **MICROSCOPY, INTERFERENCE**

MICROMANIPULATION

METHODS

Update on micromanipulation techniques for assisted conception. Ng SC, et al. **Curr Opin Obstet Gynecol** 1996 Jun;8(3):171–7 (73 ref.)
Ascus dissection. Saunders–Singer C. **Methods Mol Biol** 1996; 53:59–67 (3 ref.)
Meiotic analysis. Spencer JF, et al. **Methods Mol Biol** 1996; 53:51–8 (9 ref.)

MICRONUCLEI

GENETICS

Age–related increase of baseline frequencies of sister chromatid exchanges, chromosome aberrations, and micronuclei in human lymphocytes. Bolognesi C, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Apr;6(4):249–56 (112 ref.)

RADIATION EFFECTS

Micronuclei: a biological indicator of radiation damage. Müller WU, et al. **Mutat Res** 1996 Nov;366(2):163–9 (29 ref.)

ULTRASTRUCTURE

Mechanisms leading to the expression of recessive alleles: the use of polymorphic microsatellites and whole–chromosome painting probes to analyze mouse tumors, mutants, and micronuclei. Caspary WJ, et al. **Recent Results Cancer Res** 1997;143:161–82 (82 ref.)

MICRONUCLEUS ASSAYS see **MICRONUCLEUS TESTS**

MICRONUCLEUS TESTS

Evaluation of the rodent micronucleus assay in the screening of IARC carcinogens (groups 1, 2A and 2B) the summary report of the 6th collaborative study by CSGMT/JEMS MMS. Collaborative Study of the Micronucleus Group Test. Mammalian Mutagenicity Study Group [published erratum appears in Mutat Res 1997 Jul 14;391(3):259–67] Morita T, et al. **Mutat Res** 1997 Feb 28;389(1):3–122 (153 ref.)
Chromosome aberrations, micronuclei, aneuploidy, sister chromatid exchanges, and cancer risk assessment. Tucker JD, et al. **Mutat Res** 1996 Sep;365(1–3):147–59 (47 ref.)
[The micronucleus test in human exfoliative cells as a method for studying the action of mutagens/carcinogens] Nersesian AK. **Tsitol Genet** 1996 Sep–Oct;30(5):91–6 (46 ref.) (Eng. Abstr.) **(Rus)**

INSTRUMENTATION

[The use of an automated micronucleus test for the biological dosimetry of radiation lesions] Romanova EP, et al. **Tsitol Genet** 1997 Mar–Apr;31(2):61–9 (67 ref.) (Eng. Abstr.) **(Rus)**

METHODS

The advantages and disadvantages of the cytokinesis–block micronucleus method. Fenech M. **Mutat Res** 1997 Aug 1;392(1–2):11–8 (38 ref.)
The in vitro micronucleus test: a multi–endpoint assay to detect simultaneously mitotic delay, apoptosis, chromosome breakage, chromosome loss and non–disjunction. Kirsch–Volders M, et al. **Mutat Res** 1997 Aug 1;392(1–2):19–30 (79 ref.)
Application of the in vitro rat hepatocyte micronucleus assay in genetic toxicology testing. Müller–Tegethoff K, et al. **Mutat Res** 1997 Aug 1;392(1–2):125–38 (82 ref.)

MICRONUTRIENTS

see related
TRACE ELEMENTS
Micronutrients and exercise: anti–oxidants and minerals. Clarkson PM. **J Sports Sci** 1995 Summer;13 Spec No:S11–24 (161 ref.)
Developing industrial–governmental–academic partnerships to address micronutrient malnutrition. Darnton–Hill I. **Nutr Rev** 1997 Mar;55(3):76–81 (24 ref.)
[Trace elements, human nutrition and health] Malbohan IM, et al. **Cas Lek Cesk** 1997 May 29;136(11):356–9 (35 ref.) (Eng. Abstr.) **(Cze)**

ANALYSIS

Effects of cooking and storage methods on the micronutrient content of foods. Severi S, et al. **Eur J Cancer Prev** 1997 Mar;6 Suppl 1:S21–4 (15 ref.)
Micronutrient and cytokine interaction in congenital pediatric HIV infection. Cunningham–Rundles S, et al. **J Nutr** 1996 Oct;126(10 Suppl):2674S–2679S (42 ref.)

METABOLISM

Impact of disease on markers of micronutrient status. Thurnham DI. **Proc Nutr Soc** 1997 Mar;56(1B):421–31 (66 ref.)

PHARMACOLOGY

Micronutrients (vitamins and minerals) as cancer–preventive agents. Omenn GS. **IARC Sci Publ** 1996;(139):33–45 (55 ref.)
Micronutrients as chemopreventive agents. Reddy BS. **IARC Sci Publ** 1996;(139):221–35 (92 ref.)
Identifiability of food components for cancer chemoprevention. Riboli E, et al. **IARC Sci Publ** 1996; (139):23–31 (24 ref.)

MICROPHTHALMOS

[Presentation of a case of sclerocornea with bilateral microphthalmos and auricular malformations] Guffanti A. **Minerva Oftalmol** 1967 Jul–Aug;9(4):149–52 (15 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

Molecular genetics and neurobiology of neurodegenerative and neurodevelopmental disorders. Zoghbi HY. **Pediatr Res** 1997 May;41(5):722–6 (33 ref.)

PHYSIOPATHOLOGY

Molecular genetics and neurobiology of neurodegenerative and neurodevelopmental disorders. Zoghbi HY. **Pediatr Res** 1997 May;41(5):722–6 (33 ref.)

MICROPROCESSORS see **MICROCOMPUTERS**

MICROPUNCTURES see **PUNCTURES**

MICRORADIOGRAPHY

METHODS

Quantitative radiography in osteoarthritis: microfocal radiography. Buckland–Wright JC. **Baillieres Clin Rheumatol** 1996 Aug;10(3):415–20 (18 ref.)

MICROSATELLITE MARKERS see **MICROSATELLITE REPEATS**

MICROSATELLITE REPEATS

Genetic instability and methylation tolerance in colon cancer. Aquilina G, et al. **Ann Ist Super Sanita** 1996;32(1):123–31 (63 ref.)
Cancer of the microsatellite mutator phenotype. Perucho M. **Biol Chem** 1996 Nov;377(11):675–84 (90 ref.)
Microsatellites: evolution and mutational processes. Freimer NB, et al. **Ciba Found Symp** 1996;197:51–67; discussion 67–72 (56 ref.)
Mini– and microsatellites. Ramel C. **Environ Health Perspect** 1997 Jun;105 Suppl 4:781–9 (69 ref.)
Microsatellite marker development, mapping and applications in rice genetics and breeding. McCouch SR, et al. **Plant Mol Biol** 1997 Sep;35(1–2):89–99 (76 ref.)
Mechanisms leading to the expression of recessive alleles: the use of polymorphic microsatellites and whole–chromosome painting probes to analyze mouse tumors, mutants, and micronuclei. Caspary WJ, et al. **Recent Results Cancer Res** 1997;143:161–82 (82 ref.)
Microsatellites in the HLA region: on overview. Foissac A, et al. **Tissue Antigens** 1997 Mar;49(3 Pt 1):197–214 (101 ref.)
[A detection for replication error (RER) and LOH by microsatellite analysis in human lung cancer] Hadama T, et al. **Nippon Rinsho** 1996 Feb;54(2):487–91 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Allelic chromosomal deletion using microsatellite polymorphism—the clue to the positional cloning of the tumor suppressor genes responsible for gastric carcinoma] Sato J, et al. **Nippon Rinsho** 1996 Apr;54(4):992–5 (7 ref.) (Eng. Abstr.) **(Jpn)**
[Microsatellite analysis] Tamura G, et al. **Nippon Rinsho** 1996 Apr;54(4):928–32 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Analysis system of microsatellite polymorphism using automated laser fluorescent DNA sequencer] Tanaka H, et al. **Nippon Rinsho** 1996 Feb;54(2):322–8 (4 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Molecular tumor clocks and dynamic phenotype. Shibata D. **Am J Pathol** 1997 Sep;151(3):643–6 (29 ref.)
Infrequent microsatellite instability in oesophageal cancers. Muzeau F, et al. **Br J Cancer** 1997;75(9):1336–9 (40 ref.)
Genomic instability and tolerance to alkylating agents. Karran P, et al. **Cancer Surv** 1996;28:69–85 (38 ref.)
Microsatellite instability in hematologic malignancies. Gartenhaus RB. **Leuk Lymphoma** 1997 May;25(5–6):455–61 (38 ref.)
Microsatellite instability in human solid tumors. Lothe RA. **Mol Med Today** 1997 Feb;3(2):61–8 (51 ref.)
Genetic control of microsatellite stability. Sia EA, et al. **Mutat Res** 1997 Jan 31;383(1):61–70 (50 ref.)
Selection for genome instability by DNA damage in human cells: unstable microsatellites and their consequences for tumourigenesis. Hampson R. **Radiat Oncol Investig** 1997; 5(3):111–4 (16 ref.)
[Microsatellite instability--a new aspects in genetics and

molecular biology of hereditary nonpolyposis and sporadic colorectal tumors] Kullmann F, et al. **Z Gastroenterol** 1996 Dec;34(12):813–22 (107 ref.) (Eng. Abstr.) **(Ger)**

[Genetic diagnosis of inborn error of metabolism by microsatellite marker analysis] Kure S. **Rinsho Byori** 1996 Feb;44(2):116–9 (2 ref.) (Eng. Abstr.) **(Jpn)**

MICROSCOPY

Specialized imaging techniques. Van de Water L. **Clin Lab Med** 1997 Jun;17(2):299–314 (31 ref.)

Photon upmanship: why multiphoton imaging is more than a gimmick. Denk W, et al. **Neuron** 1997 Mar;18(3):351–7 (39 ref.)

[Optical microscopy] Hamaguchi Y. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1026–32 (10 ref.) **(Jpn)**

[Near-field optical microscopy using Evanescent-photons] Inouye Y, et al. **Tanpakushitsu Kakusan Koso** 1997 May; 42(7 Suppl):1167–9 (15 ref.) **(Jpn)**

INSTRUMENTATION

Slide-based laser scanning cytometry. Kamentsky LA, et al. **Acta Cytol** 1997 Jan–Feb;41(1):123–43 (34 ref.)

Image-guided stereotactic neurosurgery with the multicoordinate manipulator microscope. Pillay PK. **Surg Neurol** 1997 Feb;47(2):171–6; discussion 176–7 (10 ref.)

[Imaging for realtime analysis system] Suzuki M, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1158–62 (5 ref.) **(Jpn)**

METHODS

Magnetic resonance microscopy in basic studies of brain structure and function. Johnson GA, et al. **Ann N Y Acad Sci** 1997 May 30;820:139–47; discussion 147–8 (18 ref.)

Automated light microscopy for the study of the brain: cellular and molecular dynamics, development, and tumorigenesis. Taylor DL, et al. **Ann N Y Acad Sci** 1997 May 30;820:208–28 (57 ref.)

Bedside testing: the diagnostic cornerstone of dermatology. Brodell RT, et al. **Compr Ther** 1997 Mar;23(3):211–7 (25 ref.)

High resolution imaging of native biological sample surfaces using scanning probe microscopy. Engel A, et al. **Curr Opin Struct Biol** 1997 Apr;7(2):279–84 (35 ref.)

Dermoscopy (epiluminescence microscopy) of pigmented skin lesions. Current status and evolving trends. Argenyi ZB. **Dermatol Clin** 1997 Jan;15(1):79–95 (43 ref.)

Ultrasound biomicroscopy of the anterior segment. Liebmann JM, et al. **J Am Optom Assoc** 1996 Aug;67(8):469–79 (42 ref.)

Biotin and digoxigenin as labels for light and electron microscopy in situ hybridization probes: where do we stand? Chevalier J, et al. **J Histochem Cytochem** 1997 Apr; 45(4):481–91 (72 ref.)

Light microscopy methods. Streiblová E, et al. **Methods Mol Biol** 1996;53:383–90 (5 ref.)

Advances in the microscopy of osteoarthritis. Gardner DL, et al. **Microsc Res Tech** 1997 May 15;37(4):245–70 (250 ref.)

Magnetic resonance microscopy--a new tool for the toxicologic pathologist. Delnomdedieu M, et al. **Toxicol Pathol** 1996 Jan–Feb;24(1):36–44 (10 ref.)

[Visualized dynamics of microtubules and liposomes] Kaneko T, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1215–20 (13 ref.) **(Jpn)**

[Optical tweezers: their principle and applications] Miyata H. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1170–2 (15 ref.) **(Jpn)**

[Panoramic nailfold capillary microscopy and its application in rheumatic diseases] da Silva LS, et al. **Rev Assoc Med Bras** 1997 Jan–Mar;43(1):69–73 (27 ref.) **(Por)**

[New methods for cancer classification. Current light microscopy can and should be added (see comments)] Andrén-Sandberg A, et al. **Lakartidningen** 1997 Feb 12; 94(7):501–4 (43 ref.) Comment in: Lakartidningen 1997 Apr 2;94(14):1262. **(Swe)**

MICROSCOPY, ATOMIC FORCE

see related
MICROSCOPY, SCANNING TUNNELING

Visualizing protein-nucleic acid interactions on a large scale with the scanning force microscope. Bustamante C, et al. **Annu Rev Biophys Biomol Struct** 1996;25:395–429 (93 ref.)

The role of scanning probe microscopy in drug delivery research. Shakesheff KM, et al. **Crit Rev Ther Drug Carrier Syst** 1996;13(3–4):225–56 (87 ref.)

Atomic (scanning) force microscopy in cardiovascular research. Arnsdorf MF, et al. **J Cardiovasc Electrophysiol** 1996 Jul;7(7):639–52 (82 ref.)

Molecules under the microscope. Tendler SJ, et al. **J Pharm Pharmacol** 1996 Jan;48(1):2–8 (27 ref.)

Properties of biomolecules measured from atomic force microscope images: a review. Hansma HG, et al. **J Struct Biol** 1997 Jul;119(2):99–108 (59 ref.)

Structural changes in native membrane proteins monitored at subnanometer resolution with the atomic force microscope: a review. Müller DJ, et al. **J Struct Biol** 1997 Jul;119(2):149–57 (56 ref.)

Viewing the renal epithelium with the atomic force microscope. Oberleithner H, et al. **Kidney Blood Press Res** 1996;19(3–4):142–7 (38 ref.)

Scanning force microscopy of biological samples. Lekka M, et al. **Pol J Pathol** 1996;47(2):51–5 (17 ref.)

A review of nuclear microscopy and applications in medicine. Thong PS, et al. **Singapore Med J** 1996 Oct;37(5):527–31 (23 ref.)

[Scanning probe microscope] Amako K, et al. **Nippon Saikingaku Zasshi** 1996 Aug;51(3):689–96 (26 ref.) **(Jpn)**

[An application of the atomic force microscopy technique to observe microorganisms] Fukushima S, et al. **Nippon Saikingaku Zasshi** 1996 Feb;51(2):621–6 (7 ref.) **(Jpn)**

[Scanning probe microscopy] Masai J. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1142–5 (9 ref.) **(Jpn)**

[Imaging of intermolecular interactions: focused on actin–myosin interactions] Tokunaga M. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1209–14 (14 ref.) **(Jpn)**

INSTRUMENTATION

Atomic force microscopy in histology and cytology. Ushiki T, et al. **Arch Histol Cytol** 1996 Dec;59(5):421–31 (47 ref.)

Life on biomembranes viewed with the atomic force microscope. Oberleithner H, et al. **Wien Klin Wochenschr** 1997 Jun 27;109(12–13):419–23 (19 ref.)

METHODS

Electron and atomic force microscopy of membrane proteins. Heymann JB, et al. **Curr Opin Struct Biol** 1997 Aug; 7(4):543–9 (66 ref.)

Biological cryo atomic force microscopy: a brief review. Shao Z, et al. **Ultramicroscopy** 1996 Dec;66(3–4):141–52 (69 ref.)

[Atomic force microscopy for biochemist] Tokumasu F, et al. **Seikagaku** 1997 Jun;69(6):429–33 (19 ref.) **(Jpn)**

MICROSCOPY, CONFOCAL

Laser scanning microscopy and calcium imaging. Schild D. **Cell Calcium** 1996 Apr;19(4):281–96 (80 ref.)

Applications of confocal and fluorescence microscopy. Pedley KC. **Digestion** 1997;58 Suppl 2:62–8 (31 ref.)

Immunology and the confocal microscope. Ojcius DM, et al. **Res Immunol** 1996 Mar–Apr;147(3):175–88 (40 ref.)

[Confocal laser scanning microscopy for the study of membrane transporter proteins] Tanaka H, et al. **Nippon Rinsho** 1996 Mar;54(3):711–7 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Application of laser technology to basic cell biology and its future] Tasaka K. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Aug; 48(8):678–82 (0 ref.) **(Jpn)**

[Analysis of membrane protein movement by single particle tracking and laser-beam gradient force optical trap] Tomishige M, et al. **Nippon Seirigaku Zasshi** 1997; 59(1):11–21 (25 ref.) **(Jpn)**

[Observation of intracellular calcium kinetics with confocal laser scanning microscope] Yokoyama K, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1221–6 (14 ref.) **(Jpn)**

INSTRUMENTATION

[Improvement of instruments] Ishikawa H. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1177–8 (5 ref.) **(Jpn)**

METHODS

Near-field scanning optical microscopy and near-field confocal optical spectroscopy: emerging techniques in biology. Marchese-Ragona SP, et al. **Ann N Y Acad Sci** 1997 May 30;820:196–206; discussion 206–7 (6 ref.)

Tandem scanning confocal microscopic imaging of the living kidney. Andrews P. **Int Rev Exp Pathol** 1996;36:131–43 (19 ref.)

In vivo confocal imaging. Petroll WM, et al. **Int Rev Exp Pathol** 1996;36:93–129 (122 ref.)

Three-dimensional confocal light and electron microscopy of central nervous system tissue and neurons and glia in culture. Turner JN, et al. **Int Rev Exp Pathol** 1996;36:53–72 (88 ref.)

The contribution of quantitative confocal laser scanning microscopy in cartilage research: chondrocyte insulin-like growth factor-1 receptors in health and pathology. Verschure PJ, et al. **Microsc Res Tech** 1997 May 15; 37(4):285–98 (65 ref.)

Further developments of the laser scanning confocal microscope in biomedical research. Paddock SW. **Proc Soc Exp Biol Med** 1996 Oct;213(1):24–31 (54 ref.)

MICROSCOPY, CONFOCAL, LASER SCANNING see **MICROSCOPY, CONFOCAL**

MICROSCOPY, ELECTRON

Ribosomes: protein synthesis in slow motion. Moore PB. **Curr Biol** 1997 Mar 1;7(3):R179–81 (10 ref.)

Electron microscopy in AIDS-related infectious diseases. I. Acanthamoebiasis. Hashimoto K, et al. **J Dermatol** 1996 Nov;23(11):773–7 (11 ref.)

Transmission and scanning electron microscope preparation of whole cultured cells. Neumüller J. **Methods Mol Biol** 1997;75:377–97 (25 ref.)

Malignant mesothelioma: current conundrums over risk estimates and whither electron microscopy for diagnosis? [editorial] Comin CE, et al. **Ultrastruct Pathol** 1997 Jul–Aug;21(4):315–20 (89 ref.)

As you like it. Ghadially FN. **Ultrastruct Pathol** 1997 May–Jun;21(3):211–26 (38 ref.)

The role of electron microscopy in the diagnosis of nonneoplastic muscle diseases. Kyriacou K, et al. **Ultrastruct Pathol** 1997 May–Jun;21(3):243–52 (25 ref.)

[Morphology of micro-organism--development of my electron microscopical study] Hosaka Y. **Nippon Saikingaku Zasshi** 1996 Oct;51(4):1003–13 (15 ref.) **(Jpn)**

[Electron microscope] Ishikawa H. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1033–8 (10 ref.) **(Jpn)**

INSTRUMENTATION

[Improvement of instruments] Ishikawa H. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1177–8 (5 ref.) **(Jpn)**

METHODS

Osmium ammine: review of current applications to visualize DNA in electron microscopy. Biggiogera M, et al. **Biol Cell** 1996;87(3):121–32 (38 ref.)

Practical aspects of electron energy loss spectroscopy (EELS) in biology. Jeanguillaume C, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 May;42(3):439–50 (20 ref.)

Low resolution meets high: towards a resolution continuum from cells to atoms. Baker TS, et al. **Curr Opin Struct Biol** 1996 Oct;6(5):585–94 (95 ref.)

Visualizing nucleic acids and their complexes using electron microscopy. Griffith JD, et al. **Curr Opin Struct Biol** 1997 Jun;7(3):362–6 (42 ref.)

Electron and atomic force microscopy of membrane proteins. Heymann JB, et al. **Curr Opin Struct Biol** 1997 Aug; 7(4):543–9 (66 ref.)

The making and breaking of symmetry in virus capsid assembly: glimpses of capsid biology from cryoelectron microscopy. Steven AC, et al. **FASEB J** 1997 Aug; 11(10):733–42 (75 ref.)

What can electron microscopy tell us about chaperoned protein folding? Saibil HR. **Fold Des** 1996;1(3):R45–9 (24 ref.)

SDS-digested freeze-fracture replica labeling electron microscopy to study the two-dimensional distribution of integral membrane proteins and phospholipids in biomembranes: practical procedure, interpretation and application. Fujimoto K. **Histochem Cell Biol** 1997 Feb; 107(2):87–96 (30 ref.)

Three-dimensional confocal light and electron microscopy of central nervous system tissue and neurons and glia in culture. Turner JN, et al. **Int Rev Exp Pathol** 1996;36:53–72 (88 ref.)

Recent developments in electron holography for phase microscopy. Tonomura A. **J Electron Microsc (Tokyo)** 1995 Dec;44(6):425–35 (31 ref.)

Biotin and digoxigenin as labels for light and electron microscopy in situ hybridization probes: where do we stand? Chevalier J, et al. **J Histochem Cytochem** 1997 Apr; 45(4):481–91 (72 ref.)

The physical chemical basis for preserving cell structure for electron microscopy at the molecular level and available preparatory methods. Sjöstrand FS. **J Submicrosc Cytol Pathol** 1997 Apr;29(2):157–72 (27 ref.)

Cross-sectional sample preparation by focused ion beam: a review of ion-sample interaction. Ishitani T, et al. **Microsc Res Tech** 1996 Nov 1;35(4):320–33 (57 ref.)

Engery-filtering transmission electron microscopy of biological specimens. de Bruijn WC, et al. **Scanning Microsc** 1993 Jun;7(2):693–708; discussion 709 (107 ref.)

High-resolution icosahedral reconstruction: fulfilling the promise of cryo-electron microscopy. Mancini EJ, et al. **Structure** 1997 Jun 15;5(6):741–50 (81 ref.)

[Applications of electron microscopy in dermatology] Sterniczky B, et al. **Hautarzt** 1996 Feb;47(2):148–65 quiz 162–3 (41 ref.) **(Ger)**

[Visualization of virus particles] Yazaki K, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1065–8 (10 ref.) **(Jpn)**

MICROSCOPY, ELECTRON, SCANNING

see related
CORROSION CASTING

[Scanning probe microscopy] Masai J. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1142–5

(9 ref.) **(Jpn)**

INSTRUMENTATION

The development of field-emission scanning electron microscopy for imaging biological surfaces. Pawley J. **Scanning** 1997 Aug;19(5):324–36 (143 ref.)

METHODS

Immunogold labeling in scanning electron microscopy. Hermann R, et al. **Histochem Cell Biol** 1996 Jul;106(1):31–9 (62 ref.)

Morphometric analysis of vascular smooth muscle cells by scanning electron microscopy. Evan AP, et al. **Int Rev Exp Pathol** 1996;36:31–52 (44 ref.)

Scanning electron microscopy of "fibrillated" and "malacic" human articular cartilage: technical considerations. Clark JM, et al. **Microsc Res Tech** 1997 May 15;37(4):299–313 (55 ref.)

Cross-sectional sample preparation by focused ion beam: a review of ion-sample interaction. Ishitani T, et al. **Microsc Res Tech** 1996 Nov 1;35(4):320–33 (57 ref.)

The development of field-emission scanning electron microscopy for imaging biological surfaces. Pawley J. **Scanning** 1997 Aug;19(5):324–36 (143 ref.)

Double-layer coating for field-emission cryo-scanning electron microscopy--present state and applications. Walther P, et al. **Scanning** 1997 Aug;19(5):343–8 (12 ref.)

[Physicochemical dissociation methods in the preparation of biological objects for scanning electron microscopy] Mironov AA, et al. **Morfologiia** 1996;109(3):78–88 (72 ref.) **(Rus)**

MICROSCOPY, ELECTRON, SCANNING TRANSMISSION

A review of nuclear microscopy and applications in medicine. Thong PS, et al. **Singapore Med J** 1996 Oct;37(5):527–31 (23 ref.)

[Electron microscope] Ishikawa H. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1033–8 (10 ref.) **(Jpn)**

MICROSCOPY, ELECTRON, TRANSMISSION see **MICROSCOPY, ELECTRON**

MICROSCOPY, ELECTRON, X-RAY MICROANALYSIS see **ELECTRON PROBE MICROANALYSIS**

MICROSCOPY, FLUORESCENCE

Fluorescence imaging of mammalian living cells. Hiraoka Y, et al. **Chromosome Res** 1996 Apr;4(3):173–6 (8 ref.)

Applications of confocal and fluorescence microscopy. Pedley KC. **Digestion** 1997;58 Suppl 2:62–8 (31 ref.)

Diagnosis of pigmented skin lesions aided by epiluminescence microscopy. Peck GL. **Md Med J** 1997 May-Jun; 46(5):247–50 (5 ref.)

[Analysis of axonal transport using video microscopy] Hori H, et al. **Nippon Seirigaku Zasshi** 1996;58(7–8):283–99 (18 ref.) **(Jpn)**

[Visualization of protein molecules using fluorescence-labeled bioactive compounds] Hiratsuka T. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1069–74 (15 ref.) **(Jpn)**

[Detection systems of microorganisms] Kawasaki Y. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1173–6 (5 ref.) **(Jpn)**

[Two-photon excitation fluorescence microscopy] Kusumi A, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1151–3 (6 ref.) **(Jpn)**

METHODS

Imaging techniques: picture the world with kaleidoscope dyes. Paddock SW. **Curr Biol** 1997 Mar 1;7(3):R182–5 (30 ref.)

Total internal reflection fluorescence: applications in cellular biophysics. Thompson NL, et al. **Curr Opin Biotechnol** 1997 Feb;8(1):58–64 (64 ref.)

Optical studies of intracellular pH in kidney cells in vitro. Hamm LL, et al. **Int Rev Exp Pathol** 1996;36:161–73 (52 ref.)

Fluorescence microscopy methods. Hašek J, et al. **Methods Mol Biol** 1996;53:391–405 (14 ref.)

Immunohistochemistry for light microscopy in safety evaluation of therapeutic agents: an overview. Burnett R, et al. **Toxicology** 1997 Apr 11;119(1):83–93 (38 ref.)

[Three-dimensional analysis of chromosomes by a computerized fluorescence microscope system] Haraguchi T, et al. **Nippon Rinsho** 1996 Sep;54(9):2574–82 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Analysis of chromosome organization and dynamics by three-dimensional fluorescence microscopy] Hiraoka Y, et al. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(15 Suppl):2165–73 (13 ref.) **(Jpn)**

[Gaseous monoxides as an endogenous modulator of organ function--application of multifunctional digital microfluorography] Suematsu M, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1075–9 (10 ref.) **(Jpn)**

MICROSCOPY, IMMUNOELECTRON

Adhesion molecules on isolated and cultured microvascular endothelial cells demonstrated by immunofluorescence and immune electron microscopy. Neumüller J, et al. **Methods Mol Biol** 1997;75:399–425 (108 ref.)

Light and electron microscopic immunohistochemistry of the localization of adrenal steroidogenic enzymes. Ishimura K, et al. **Microsc Res Tech** 1997 Mar 15;36(6):445–53 (76 ref.)

METHODS

Immunoelectron microscopy. van Tuinen EJ. **Methods Mol Biol** 1996;53:407–22 (24 ref.)

Improved immuno double labelling for cell and structural biology. Koeck PJ, et al. **Micron** 1996 Apr;27(2):157–65 (124 ref.)

The use of monoclonal antibodies with colloidal gold-labeled probes in postembedding immunoelectron microscopy. Suarez CE, et al. **Mol Biotechnol** 1997 Apr;7(2):145–51 (29 ref.)

MICROSCOPY, IMMUNOFLUORESCENCE see **MICROSCOPY, FLUORESCENCE**

MICROSCOPY, INTERFERENCE

[Observation of brain slice using infra-red differential interference contrast (IR-DIC) video microscopy] Miyakawa H, et al. **Nippon Seirigaku Zasshi** 1996; 58(7–8):301–6 (13 ref.) **(Jpn)**

MICROSCOPY, SCANNING TUNNELING

see related
MICROSCOPY, ATOMIC FORCE

The role of scanning probe microscopy in drug delivery research. Shakesheff KM, et al. **Crit Rev Ther Drug Carrier Syst** 1996;13(3–4):225–56 (87 ref.)

Molecules under the microscope. Tendler SJ, et al. **J Pharm Pharmacol** 1996 Jan;48(1):2–8 (27 ref.)

[Scanning probe microscope] Amako K, et al. **Nippon Saikingaku Zasshi** 1996 Aug;51(3):689–96 (26 ref.) **(Jpn)**

[Tunneling microscopy] Hibino M, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1146–8 (5 ref.) **(Jpn)**

METHODS

Scanning force microscopy for imaging biostructures at high-resolution. Diaspro A, et al. **Eur J Histochem** 1997; 41(1):7–16 (24 ref.)

MICROSCOPY, VIDEO

[Dynamic analysis of neuronal responses by video microscopy: direct visualization of release and acceptance of neuronal signals] Terakawa S. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Apr; 16(2):59–64 (11 ref.) **(Jpn)**

[Analysis of axonal transport using video microscopy] Hori H, et al. **Nippon Seirigaku Zasshi** 1996;58(7–8):283–99 (18 ref.) **(Jpn)**

[Observation of brain slice using infra-red differential interference contrast (IR-DIC) video microscopy] Miyakawa H, et al. **Nippon Seirigaku Zasshi** 1996; 58(7–8):301–6 (13 ref.) **(Jpn)**

[Basic study of videomicroscopy] Terakawa S. **Nippon Seirigaku Zasshi** 1996;58(5):199–210 (23 ref.) **(Jpn)**

[Analysis of membrane protein movement by single particle tracking and laser-beam gradient force optical trap] Tomishige M, et al. **Nippon Seirigaku Zasshi** 1997; 59(1):11–21 (25 ref.) **(Jpn)**

[Low light level imaging] Kamiya K. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1154–7 (4 ref.) **(Jpn)**

[Video microscopy] Terakawa S. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1039–46 (11 ref.) **(Jpn)**

INSTRUMENTATION

[Standardization of nailfold capillary microscopy in routine diagnosis] Schmidt JA, et al. **Vasa** 1997;26(1):5–10 (12 ref.) (Eng. Abstr.) **(Ger)**

[Development of instrumental and technical measurement aspects for clinical capillary microscopy] Gasser P, et al. **Z Rheumatol** 1996 Jul-Aug;55(4):260–6 (30 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Single-particle tracking: applications to membrane dynamics. Saxton MJ, et al. **Annu Rev Biophys Biomol Struct** 1997; 26:373–99 (105 ref.)

Steps in tumor metastasis: new concepts from intravital videomicroscopy. Chambers AF, et al. **Cancer Metastasis Rev** 1995 Dec;14(4):279–301 (45 ref.)

Blood flow in the cerebral capillary network: a review emphasizing observations with intravital microscopy. Hudetz AG. **Microcirculation** 1997 Jun;4(2):233–52 (137 ref.)

MICROSOMES

ENZYMOLOGY

Investigating the role of the microsomal epoxide hydrolase membrane topology and its implication for drug metabolism pathways. Friedberg T, et al. **Adv Exp Med Biol** 1996; 387:17–24 (21 ref.)

Wheat microsomal cytochrome P450 monooxygenases: characterization and importance in the metabolic detoxification and selectivity of wheat herbicides. Frear DS. **Drug Metabol Drug Interact** 1995;12(3–4):329–57 (77 ref.)

Commentary--measurement of microsomal epoxide hydrolase activity in humans: problems and perspectives. Paolini M, et al. **J Environ Pathol Toxicol Oncol** 1997; 16(2–3):73–6 (27 ref.)

METABOLISM

Recent advances in elucidating the role of the microsomal triglyceride transfer protein in apolipoprotein B lipoprotein assembly. Gordon DA. **Curr Opin Lipidol** 1997 Jun; 8(3):131–7 (41 ref.)

MICROSOMES, LIVER

CHEMISTRY

Microsomal triglyceride transfer protein. Wetterau JR, et al. **Biochim Biophys Acta** 1997 Apr 1;1345(2):136–50 (74 ref.)

Chromatographic separation and behavior of microsomal cytochrome P450 and cytochrome b5. Roos PH. **J Chromatogr B Biomed Appl** 1996 Sep 20;684(1–2):107–31 (154 ref.)

DRUG EFFECTS

An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Parkinson A. **Toxicol Pathol** 1996 Jan-Feb;24(1):48–57 (37 ref.)

ENZYMOLOGY

Enzymatic studies of the activation of heterocyclic food mutagens in man. Boobis AR, et al. **Princess Takamatsu Symp** 1995;23:134–44 (38 ref.)

An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Parkinson A. **Toxicol Pathol** 1996 Jan-Feb;24(1):48–57 (37 ref.)

[The microsomal enzyme system and liver pathology] Posokhova EA. **Eksp Klin Farmakol** 1996 Jul-Aug; 59(4):73–9 (120 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Clinical implications of antidepressant pharmacokinetics and pharmacogenetics. Cohen LJ, et al. **Ann Pharmacother** 1996 Dec;30(12):1471–80 (90 ref.)

Biotransformation of taxoids by human cytochromes P450: structure-activity relationship. Monsarrat B, et al. **Bull Cancer** 1997 Feb;84(2):125–33 (59 ref.)

On the metabolizing systems for short-term genotoxicity assays: a review. Paolini M, et al. **Mutat Res** 1997 Aug; 387(1):17–34 (96 ref.)

MICROSPHERES

see related
ENZYMES, IMMOBILIZED

Microbeads, magnets, and magic: the enchanting science of immunochemistry. Bertholf RL, et al. **Ann Clin Lab Sci** 1996 Sep-Oct;26(5):377–88 (8 ref.)

Pharmacokinetic rationale for chemotherapeutic drugs combined with intra-arterial degradable starch microspheres (Spherex). Johansson CJ. **Clin Pharmacokinet** 1996 Sep;31(3):231–40 (44 ref.)

The intestinal uptake of particles and the implications for drug and antigen delivery. O'Hagan DT. **J Anat** 1996 Dec; 189 (Pt 3):477–82 (38 ref.)

MICROSPORA INFECTIONS

[Microsporidiosis: current state of a new parasitosis] Ruíz-Sánchez D, et al. **Rev Latinoam Microbiol** 1996 Apr-Jun;38(2):151–66 (145 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Enterocytozoon bieneusi infection and diarrheal disease in patients who were not infected with human immunodeficiency virus: case report and review. Wanke CA, et al. **Clin Infect Dis** 1996 Oct;23(4):816–8 (13 ref.)

Microsporidium-associated sinusitis. Moss RB, et al. **Ear Nose Throat J** 1997 Feb;76(2):95–101 (19 ref.)

Application of molecular techniques to the diagnosis of microsporidial infection. Fedorko DP, et al. **Emerg Infect Dis** 1996 Jul-Sep;2(3):183–91 (44 ref.)

Intestinal microsporidiosis. Croft SL, et al. **Semin Gastrointest Dis** 1997 Jan;8(1):45–55 (70 ref.)

MICROSPORIDA

[Intestinal and systemic infections caused by Microsporidia] Weber R, et al. **Internist (Berl)** 1996 Sep;37(9):912–8 (22 ref.) **(Ger)**

[Myositis caused by Pleistophora in a patient with AIDS] Grau A, et al. **Med Clin (Barc)** 1996 Dec 7;107(20):779–81 (23 ref.) (Eng. Abstr.) **(Spa)**

[Microsporidiosis: current state of a new parasitosis] Ruíz-Sánchez D, et al. **Rev Latinoam Microbiol** 1996 Apr-Jun;38(2):151–66 (145 ref.) (Eng. Abstr.) **(Spa)**

ISOLATION & PURIFICATION

Microsporidium-associated sinusitis. Moss RB, et al. **Ear Nose Throat J** 1997 Feb;76(2):95–101 (19 ref.)

Intestinal microsporidiosis. Croft SL, et al. **Semin Gastrointest Dis** 1997 Jan;8(1):45–55 (70 ref.)

PATHOGENICITY

Application of molecular techniques to the diagnosis of microsporidial infection. Fedorko DP, et al. **Emerg Infect Dis** 1996 Jul-Sep;2(3):183–91 (44 ref.)

MICROSPORUM

Hair loss in a 5-year-old boy. Tinea capitis caused by Microsporum gypseum. Burke EM, et al. **Arch Dermatol** 1997 Sep;133(9):1161–2, 1164–5 (9 ref.)

MICROSURGERY

New therapeutic possibilities handling residual azoospermia. Schoysman R, et al. **Acta Eur Fertil** 1995 Jul-Aug; 26(4):131–6 (21 ref.)

The best treatment for vestibular schwannoma (acoustic neuroma): microsurgery or radiosurgery? Sekhar LN, et al. **Am J Otol** 1996 Jul;17(4):676–82; discussion 683–9 (34 ref.)

Pseudoaneurysms of the radial artery. Importance of microsurgery. Apropos of a case. Moufarrège R, et al. **Ann Chir Main** 1982;1(1):40–4 (13 ref.) **(Eng, Fre)**

Current principles in microsurgical nerve repair. Hausamen JE, et al. **Br J Oral Maxillofac Surg** 1996 Apr;34(2):143–57 (51 ref.)

Recent advances in microsurgical anatomy. Zhong S. **Chin Med J (Engl)** 1996 Jan;109(1):64–5 (0 ref.)

Cushing's disease: pituitary microsurgery. Hardy J. **Curr Ther Endocrinol Metab** 1997;6:63–5 (14 ref.)

Soft tissue management in endodontic surgery. Peters LB, et al. **Dent Clin North Am** 1997 Jul;41(3):513–28 (24 ref.)

Microsurgical aspects of the treatment of azoospermia. The BMFT Study Group for Microsurgery. Weidner W, et al. **Int J Androl** 1995 Dec;18 Suppl 2:63–6 (32 ref.)

Microsurgical excision of a pontomedullary epidermoid cyst with prepontine extension: case report. Malcolm GP, et al. **Neurosurgery** 1996 Mar;38(3):579–83; discussion 582–3 (21 ref.)

Management of 1000 vestibular schwannomas (acoustic neuromas): hearing function in 1000 tumor resections. Samii M, et al. **Neurosurgery** 1997 Feb;40(2):248–60; discussion 260–2 (99 ref.)

Acoustic neuroma update. Kartush JM, et al. **Otolaryngol Clin North Am** 1996 Jun;29(3):377–92 (19 ref.)

[Progresses in microsurgery in China, 1996] Zhu S. **Chung Hua I Hsueh Tsa Chih** 1996 Dec;76(12):909–11 (0 ref.) **(Chi)**

[Andrologic/gynecologic microsurgery and fertilization in vitro: complementary approaches?] Schoysman R, et al. **Contracept Fertil Sex** 1997 Apr;25(4):306–12 (30 ref.) (Eng. Abstr.) **(Fre)**

[Differential therapy of cerebral arteriovenous malformations. An analysis with reference to personal microsurgery experiences] Schaller C, et al. **Nervenarzt** 1996 Oct;67(10):860–9 (72 ref.) (Eng. Abstr.) **(Ger)**

[Differential therapy of cerebral angiomas] Grzyska U, et al. **Wien Med Wochenschr** 1997;147(7–8):186–93 (50 ref.) (Eng. Abstr.) **(Ger)**

[Micro- and modern minilaparotomy in biliary tract surgery. (Remembering János Balassa)] Rozsos I. **Orv Hetil** 1996 Oct 13;137(41):2243–8 (38 ref.) (Eng. Abstr.) **(Hun)**

[Surgical therapy of obstructive azoospermia: microsurgery] Fenice O, et al. **Arch Ital Urol Androl** 1996 Dec; 68(5):379–88 (29 ref.) (Eng. Abstr.) **(Ita)**

INSTRUMENTATION

[Technique and indications for sphincter-saving transanal resection in rectal carcinoma] Buess G, et al. **Chirurg** 1996 Feb;67(2):121–8 (22 ref.) (Eng. Abstr.) **(Ger)**

[The operating microscope in root tip resection. I. The resection] Velvart P. **Schweiz Monatsschr Zahnmed** 1997; 107(6):506–21 (26 ref.) **(Ger, Fre)**

[Micro-endoscopy, minimal access endoscopy--an overview of current status and future possibilities] Wallwiener D, et al. **Zentralbl Gynakol** 1996;118(2):83–6 (11 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Microsurgery--its role in soft tissue and bone tumour reconstruction. Rostek M, et al. **Acta Orthop Scand Suppl** 1997 Feb;273:95–100 (50 ref.)

Anatomy, physiology, and functional restoration of the thumb. Emerson ET, et al. **Ann Plast Surg** 1996 Feb; 36(2):180–91 (58 ref.)

Macular surgery [published erratum appears in Br J Hosp Med 1996 Apr 17-30;55(8):526] Aylward GW. **Br J Hosp Med** 1996 Feb 7-20;55(3):85–8 (14 ref.)

New reconstructive procedure for brachial plexus injury. Doi K. **Clin Plast Surg** 1997 Jan;24(1):75–85 (17 ref.)

Microvascular reconstruction of the distal digits by partial toe transfer. el-Gammal TA, et al. **Clin Plast Surg** 1997 Jan;24(1):49–55 (36 ref.)

Secondary craniofacial management following skeletal correction in facial asymmetry. Application of microsurgical techniques. Siebert JW, et al. **Clin Plast Surg** 1997 Jul;24(3):447–58 (26 ref.)

Barrier membrane techniques in endodontic microsurgery. Pecora G, et al. **Dent Clin North Am** 1997 Jul;41(3):585–602 (32 ref.)

Approaches to postoperative blood flow monitoring after free tissue transfer. Which is the best? Berger A, et al. **Int Angiol** 1995 Sep;14(3):288–96 (92 ref.)

Vascularized nerve grafts. A review. Terzis JK, et al. **Int Angiol** 1995 Sep;14(3):264–77 (53 ref.)

Free tissue transplantation in the 90's. Yim KK, et al. **Int Angiol** 1995 Sep;14(3):327–31 (36 ref.)

Microsurgical epididymal sperm aspiration: review of techniques, preoperative considerations, and results. Girardi SK, et al. **J Androl** 1996 Jan-Feb;17(1):5–9 (13 ref.)

Laser(-assisted) nerve repair. A review. Menovsky T, et al. **Neurosurg Rev** 1995;18(4):225–35 (67 ref.)

Focus issue on lumbar disc herniation: macro- and microdiscectomy. McCulloch JA. **Spine** 1996 Dec 15;21(24 Suppl):45S–56S (105 ref.)

Transanal endoscopic microsurgery. Saclarides TJ. **Surg Clin North Am** 1997 Feb;77(1):229–39 (10 ref.)

Successful treatment of a rectal anastomotic stenosis by transanal endoscopic microsurgery (TEM) using the contact Nd:YAG laser. Kato K, et al. **Surg Endosc** 1997 May;11(5):485–7 (11 ref.)

[Diagnosis and surgical indications of traumatic brachial plexus lesions from the neurosurgery viewpoint] Carvalho GA, et al. **Orthopade** 1997 Jul;26(7):599–605 (30 ref.) (Eng. Abstr.) **(Ger)**

[Nerve transfer (neurotization) for functional reconstruction of arm functions in cervical root avulsions] Nikkhah G, et al. **Orthopade** 1997 Jul;26(7):606–11 (21 ref.) (Eng. Abstr.) **(Ger)**

[Nerve transplantation and neurolysis of the brachial plexus after post-traumatic lesions] Nikkhah G, et al. **Orthopade** 1997 Jul;26(7):612–20 (24 ref.) (Eng. Abstr.) **(Ger)**

[Microanatomy and microsurgery for tumors involving the cavernous sinus] Tamaki N, et al. **No Shinkei Geka** 1997 May;25(5):399–409 (19 ref.) **(Jpn)**

MICROSURGERY, LASER see **LASER SURGERY**

MICROSURGICAL REVASCULARIZATION, CEREBRAL see **CEREBRAL REVASCULARIZATION**

MICROTOMY

Alopecia: histologic diagnosis by transverse sections. Templeton SF, et al. **Semin Diagn Pathol** 1996 Feb; 13(1):2–18 (33 ref.)

HISTORY

Past, present, and future applications of precision-cut liver slices for in vitro xenobiotic metabolism. Ekins S. **Drug Metab Rev** 1996 Nov;28(4):591–623 (151 ref.)

METHODS

Past, present, and future applications of precision-cut liver slices for in vitro xenobiotic metabolism. Ekins S. **Drug Metab Rev** 1996 Nov;28(4):591–623 (151 ref.)

Use of precision-cut liver slices as an in vitro tool for evaluating liver function. Gandolfi AJ, et al. **Toxicol Pathol** 1996 Jan-Feb;24(1):58–61 (37 ref.)

MICROTRABECULAR LATTICE see **CYTOSKELETON**

MICROTUBULE-ASSOCIATED PROTEIN KINASES see **CALMODULIN-DEPENDENT PROTEIN KINASES**

MICROTUBULE-ASSOCIATED PROTEINS

CHEMISTRY

Cyclin-dependent kinase inhibitors: the age of crystals. Pines J. **Biochim Biophys Acta** 1997 Feb 22;1332(1):M39–42 (40 ref.)

GENETICS

[Microtubules: functional polymorphisms of tubulin and associated proteins (structural and motor MAP's)] Regnard C, et al. **C R Seances Soc Biol Fil** 1996;190(2-3):255–68 (61 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Use of the two-hybrid system to identify cellular partners of the HIV1 Nef protein. Benichou S, et al. **Res Virol** 1997 Jan-Feb;148(1):71–3 (30 ref.)

PHYSIOLOGY

Microtubule-associated proteins, phosphorylation gradients, and the establishment of neuronal polarity. Mandell JW, et al. **Perspect Dev Neurobiol** 1996;4(2-3):125–35 (100 ref.)

MICROTUBULE-ORGANIZING CENTER see **CENTROSOME**

MICROTUBULE PROTEINS

CHEMISTRY

Structure and dynamics of molecular motors. Amos LA, et al. **Curr Opin Struct Biol** 1997 Apr;7(2):239–46 (58 ref.)

Kinesin and NCD, two structural cousins of myosin. Sellers JR. **J Muscle Res Cell Motil** 1996 Apr;17(2):173–5 (23 ref.)

METABOLISM

Motor proteins: a dynamic duo. Allan V. **Curr Biol** 1996 Jun 1;6(6):630–3 (21 ref.)

MICROTUBULES

Electrodynamics of microtubular motors: the building blocks of a new model. Insinna EM, et al. **Biosystems** 1996; 39(3):187–226 (215 ref.)

Making a connection: the "other" microtubule end. Koonce MP. **Cell Motil Cytoskeleton** 1996;35(2):85–93 (73 ref.)

Microtubule-microfilament synergy in the cytoskeleton. Gavin RH. **Int Rev Cytol** 1997;173:207–42 (151 ref.)

Review: an overview of the Saccharomyces cerevisiae microtubule and microfilament cytoskeleton. Winsor B, et al. **Yeast** 1997 Apr;13(5):399–434 (240 ref.)

CHEMISTRY

Evolution of the multi-tubulin hypothesis. Wilson PG, et al. **Bioessays** 1997 Jun;19(6):451–4 (37 ref.)

The structure of microtubule-motor complexes. Amos LA, et al. **Curr Opin Cell Biol** 1997 Feb;9(1):4–11 (52 ref.)

Microtubule structure and dynamics. Wade RH, et al. **Curr Opin Cell Biol** 1997 Feb;9(1):12–7 (44 ref.)

DRUG EFFECTS

The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Rowinsky EK. **Annu Rev Med** 1997;48:353–74 (117 ref.)

New microtubular agents in pediatric oncology. Seibel NL, et al. **Invest New Drugs** 1996;14(1):49–54 (45 ref.)

Lysosomes and microtubules as targets for photochemotherapy of cancer. Berg K, et al. **Photochem Photobiol** 1997 Mar;65(3):403–9 (93 ref.)

GENETICS

[Microtubules: functional polymorphisms of tubulin and associated proteins (structural and motor MAP's)] Regnard C, et al. **C R Seances Soc Biol Fil** 1996;190(2-3):255–68 (61 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Billingsley ML, et al. **Biochem J** 1997 May 1;323 (Pt 3):577–91 (216 ref.)

The molecular mechanism of organelle transport along microtubules: the identification and characterization of KIFs (kinesin superfamily proteins). Hirokawa N. **Cell Struct Funct** 1996 Oct;21(5):357–67 (36 ref.)

Microtubule motor complexes moving membranous organelles. Sheetz MP. **Cell Struct Funct** 1996 Oct; 21(5):369–73 (31 ref.)

Cytoskeleton: a catastrophic kinesin. Waters JC, et al. **Curr Biol** 1996 Apr 1;6(4):361–3 (13 ref.)

Modulation of microtubule dynamics during the cell cycle. McNally FJ. **Curr Opin Cell Biol** 1996 Feb;8(1):23–9 (62 ref.)

Microtubule structure and dynamics. Wade RH, et al. **Curr Opin Cell Biol** 1997 Feb;9(1):12–7 (44 ref.)

Centrosome-microtubule nucleation. Pereira G, et al. **J Cell Sci** 1997 Feb;110 (Pt 3):295–300 (69 ref.)

Retroactive motors. Schnapp BJ. **Neuron** 1997 Apr; 18(4):523–6 (24 ref.)

How cells get the right chromosomes. Nicklas RB. **Science** 1997 Jan 31;275(5300):632–7 (45 ref.)

[Visualized dynamics of microtubules and liposomes] Kaneko T, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1215–20 (13 ref.) **(Jpn)**

PHYSIOLOGY

Factors regulating organelles transport along microtubules. Lopez LA. **Biocell** 1996 Dec;20(3):313–6 (27 ref.)

Ordering microtubules. Haimo LT. **Bioessays** 1997 Jul; 19(7):547–50 (16 ref.)

The enigma of microtubules and their self-organizing behavior in the cytoskeleton. Tuszyński JA, et al. **Biosystems** 1997;42(2-3):153–75 (43 ref.)

Microtubule function in morphological differentiation:

growth zones and growth cones. Vega LR, et al. **Cell** 1997 Jun 13;89(6):825–8 (14 ref.)
The role of dynein in microtubule-based motility. Gibbons IR. **Cell Struct Funct** 1996 Oct;21(5):331–42 (59 ref.)
Mitotic organization and force generation by assembly/disassembly of microtubules. Inoué S. **Cell Struct Funct** 1996 Oct;21(5):375–9 (20 ref.)
Cytoskeleton: microtubule nucleation takes shape. Murphy SM, et al. **Curr Biol** 1996 Jun 1;6(6):642–4 (16 ref.)
Microtubule dynamics: treadmilling comes around again. Waterman-Storer CM, et al. **Curr Biol** 1997 Jun 1; 7(6):R369–72 (19 ref.)
Microtubules and axonal growth. Baas PW. **Curr Opin Cell Biol** 1997 Feb;9(1):29–36 (32 ref.)
Nuclear components with microtubule-organizing properties in multicellular eukaryotes: functional and evolutionary considerations. Baluška F, et al. **Int Rev Cytol** 1997; 175:91–135 (295 ref.)
Normal and pathological Tau proteins as factors for microtubule assembly. Delacourte A, et al. **Int Rev Cytol** 1997;171:167–224 (269 ref.)
Pathways of spindle pole formation: different mechanisms; conserved components. Merdes A, et al. **J Cell Biol** 1997 Sep 8;138(5):953–6 (32 ref.)
The role of microtubule assembly dynamics in mitotic force generation and functional organization of living cells. Inoué S. **J Struct Biol** 1997 Mar;118(2):87–93 (40 ref.)
How tubulin subunits are lost from the shortening ends of microtubules. Tran PT, et al. **J Struct Biol** 1997 Mar; 118(2):107–18 (65 ref.)
Selected physical issues in the structure and function of microtubules. Tuszyński JA, et al. **J Struct Biol** 1997 Mar; 118(2):94–106 (54 ref.)
A composite model for establishing the microtubule arrays of the neuron. Baas PW, et al. **Mol Neurobiol** 1996 Apr; 12(2):145–61 (75 ref.)
[Antimitotic agents] Fukuoka K, et al. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1519–25 (22 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

The neuronal centrosome as a generator of microtubules for the axon. Baas PW. **Curr Top Dev Biol** 1996;33:281–98 (55 ref.)
Protofilaments and rings, two conformations of the tubulin family conserved from bacterial FtsZ to alpha/beta and gamma tubulin. Erickson HP, et al. **J Cell Biol** 1996 Oct; 135(1):5–8 (25 ref.)
Microtubules: a brief historical perspective. Brinkley W. **J Struct Biol** 1997 Mar;118(2):84–6 (35 ref.)
A composite model for establishing the microtubule arrays of the neuron. Baas PW, et al. **Mol Neurobiol** 1996 Apr; 12(2):145–61 (75 ref.)

MICROVASCULAR PERMEABILITY see **CAPILLARY PERMEABILITY**

MICROVILLI

METABOLISM

Function and molecular structure of brush border membrane peptide/H+ symporters. Daniel H. **J Membr Biol** 1996 Dec;154(3):197–203 (68 ref.)
Renal brush border membrane Na/Pi-cotransport: molecular aspects in PTH-dependent and dietary regulation. Murer H, et al. **Kidney Int** 1996 Jun;49(6):1769–73 (44 ref.)
Isolated renal brush border and basolateral membrane vesicles and cultured renal cells. Gutierrez MM, et al. **Pharm Biotechnol** 1996;8:193–210 (31 ref.)

PHYSIOLOGY

Microvesiculation of the microvilli provides a membranous medium within the lumen during digestion. Ozgünes N. **Med Hypotheses** 1996 Apr;46(4):319–22 (38 ref.)

ULTRASTRUCTURE

Microvesiculation of the microvilli provides a membranous medium within the lumen during digestion. Ozgünes N. **Med Hypotheses** 1996 Apr;46(4):319–22 (38 ref.)

MICROWAVES

see related
DIATHERMY

[A comparative analysis of the biological action of microwaves and laser radiation] Zubkova SM. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Nov-Dec; (6):31–4 (16 ref.) (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Radiation hazard assessment of pulsed microwave radars. Puranen L, et al. **J Microw Power Electromagn Energy** 1996;31(3):165–77 (32 ref.)

DIAGNOSTIC USE

Microwaves in diagnostic immunohistochemistry. Leong AS. **Eur J Morphol** 1996 Dec;34(5):381–3 (8 ref.)

THERAPEUTIC USE

Current status of thermotherapy of the prostate. de la Rosette JJ, et al. **J Urol** 1997 Feb;157(2):430–8 (75 ref.)
[Percutaneous microwave coagulation therapy and endoscopic microwave coagulo-necrotic therapy for small hepatocellular carcinoma] Otsuka S. **Nippon Rinsho** 1996 May;54(5):1343–6 (8 ref.) (Eng. Abstr.) **(Jpn)**

MICRURUS see **ELAPIDAE**

MIDAZOLAM

PHARMACOKINETICS

Pharmacokinetics and pharmacodynamics of midazolam given via continuous intravenous infusion in intensive care units. Fragen RJ. **Clin Ther** 1997 May-Jun;19(3):405–19; discussion 367–8 (38 ref.)

PHARMACOLOGY

Pharmacokinetics and pharmacodynamics of midazolam given via continuous intravenous infusion in intensive care units. Fragen RJ. **Clin Ther** 1997 May-Jun;19(3):405–19; discussion 367–8 (38 ref.)

THERAPEUTIC USE

Midazolam: a review of therapeutic uses and toxicity. Nordt SP, et al. **J Emerg Med** 1997 May-Jun;15(3):357–65 (83 ref.)
Long-term subcutaneous infusion of midazolam for refractory delirium in terminal breast cancer. Ramani S, et al. **South Med J** 1996 Nov;89(11):1101–3 (12 ref.)

MIDBRAIN see **MESENCEPHALON**

MIDBRAIN CENTRAL GRAY see **PERIAQUEDUCTAL GRAY**

MIDDLE AGE

PHYSIOLOGY

The middle years: women, sexuality, and the self. Wilmoth MC. **J Obstet Gynecol Neonatal Nurs** 1996 Sep; 25(7):615–21 (34 ref.)
Male menopause. How to define it, how to treat it. Schow DA, et al. **Postgrad Med** 1997 Mar;101(3):62–4, 67–8, 71–4 passim (47 ref.)

PSYCHOLOGY

The middle years: women, sexuality, and the self. Wilmoth MC. **J Obstet Gynecol Neonatal Nurs** 1996 Sep; 25(7):615–21 (34 ref.)

MIDDLE EAR CHOLESTEATOMA see **CHOLESTEATOMA, MIDDLE EAR**

MIDDLE EAR IMPLANT see **OSSICULAR REPLACEMENT PROSTHESIS**

MIDDLE EAR VENTILATION

Care of the child with tympanostomy tubes. Isaacson G, et al. **Pediatr Clin North Am** 1996 Dec;43(6):1183–93 (64 ref.)

MIDDLE PROMOTERS see **PROMOTER REGIONS (GENETICS)**

MIDGES, NONBITING see **CHIRONOMIDAE**

MIDTRIMESTER see **PREGNANCY TRIMESTER, SECOND**

MIDWIFERY

see related
NURSE MIDWIVES

ORGANIZATION & ADMINISTRATION

National action plans for nursing and midwifery. Leenders F, et al. **WHO Reg Publ Eur Ser** 1997;74:145–66 (16 ref.)
Nursing and midwifery in Europe. Salvage J, et al. **WHO Reg Publ Eur Ser** 1997;74:21–123 (32 ref.)

STANDARDS

Is there a place for traditional midwives in the provision of community-health services? Piper CJ. **Ann Trop Med Parasitol** 1997 Apr;91(3):237–45 (21 ref.)

MIFEPRISTONE

Pregnancy interruption using mifepristone (RU-486). A new choice for women in the USA. Mackenzie SJ, et al. **J Nurse Midwifery** 1997 Mar-Apr;42(2):86–90 (32 ref.)
Medical abortion in early pregnancy: a review of the evidence. Grimes DA. **Obstet Gynecol** 1997 May;89(5 Pt 1):790–6 (55 ref.)

PHARMACOLOGY

Contraception with anti-progesterone. Swahn ML, et al. **Baillieres Clin Obstet Gynaecol** 1996 Apr;10(1):43–53 (51 ref.)
The corpus luteum revisited: are the paradoxical effects of RU486 a clue to how progesterone stimulates its own secretion? Rothchild I. **Biol Reprod** 1996 Jul;55(1):1–4 (34 ref.)
Medical abortion. Bardin CW, et al. **Curr Ther Endocrinol Metab** 1997;6:305–11 (6 ref.)
Hormonal requirement for blastocyst implantation and a new approach for anti-implantation strategy. Ghosh D, et al. **Indian J Physiol Pharmacol** 1997 Apr;41(2):101–8 (54 ref.)
The antiglucocorticoid action of mifepristone. Agarwai MK. **Pharmacol Ther** 1996;70(3):183–213 (552 ref.)

THERAPEUTIC USE

RU486 (mifepristone): mechanisms of action and clinical uses. Cadepond F, et al. **Annu Rev Med** 1997;48:129–56 (179 ref.)

MIGRAINE

Menstrual migraines: etiology, treatment, and relationship to premenstrual syndrome. Kornstein SG, et al. **Curr Opin Obstet Gynecol** 1997 Jun;9(3):154–9 (67 ref.)
Pediatric migraine. Welborn CA. **Emerg Med Clin North Am** 1997 Aug;15(3):625–36 (41 ref.)
[Migraine: genetic, physiopathological, and therapeutic innovations] Schoenen J. **Rev Med Liege** 1997 Feb; 52(2):83–8 (17 ref.) **(Fre)**

BLOOD

Blood platelet fibrinogen receptors in migraine and related headaches. Kozubski W, et al. **Neurol Neurochir Pol** 1996; 30 Suppl 2:25–33 (40 ref.)

CHEMICALLY INDUCED

Sumatriptan relieves migrainelike headaches associated with carbon monoxide exposure. Lipton RB, et al. **Headache** 1997 Jun;37(6):392–5 (39 ref.)

COMPLICATIONS

Migraine and oral contraceptives. Becker WJ. **Can J Neurol Sci** 1997 Feb;24(1):16–21 (41 ref.)
Coexistence of migraine and cluster headache: report of 10 cases and possible pathogenetic implications. D'Amico D, et al. **Headache** 1997 Jan;37(1):21–5 (47 ref.)
Posterior ischemic optic neuropathy associated with migraine. Lee AG, et al. **Headache** 1996 Sep;36(8):506–10 (12 ref.)
Migraine stroke: a possible complication of both migraine with and without aura [see comments] Narbone MC, et al. **Headache** 1996 Sep;36(8):481–3 (10 ref.) Comment in: Headache 1997 Jul-Aug;37(7):463–4.
Migraine-related visual-field loss with prolonged recovery. Sullivan-Mee M, et al. **J Am Optom Assoc** 1997 Jun; 68(6):377–88 (29 ref.)
Comorbidity of migraine and psychiatric disorders. Merikangas KR, et al. **Neurol Clin** 1997 Feb;15(1):115–23 (33 ref.)
Migraine and epilepsy. Welch KM, et al. **Neurol Clin** 1997 Feb;15(1):107–14 (26 ref.)
Complicated migraine syndromes and migraine variants. Parker C. **Pediatr Ann** 1997 Jul;26(7):417–21 (13 ref.)

DIAGNOSIS

Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society. Pryse-Phillips WE, et al. **Can Med Assoc J** 1997 May 1; 156(9):1273–87 (160 ref.)
A 30-year-old woman with headache. Longworth DL, et al. **Cleve Clin J Med** 1997 Jun;64(6):293–7 (4 ref.)
Diagnosis and epidemiology of pediatric migraine. Lipton RB. **Curr Opin Neurol** 1997 Jun;10(3):231–6 (33 ref.)
Diagnosis and symptomatic treatment of migraine. Saper JR. **Headache** 1997;37 Suppl 1:S1–14 (56 ref.)
An overview of the diagnosis and pharmacologic treatment of migraine. Capobianco DJ, et al. **Mayo Clin Proc** 1996 Nov;71(11):1055–66 (77 ref.)
Migraine and pregnancy. Silberstein SD. **Neurol Clin** 1997 Feb;15(1):209–31 (59 ref.)
Headaches in children. When is a complete diagnostic workup indicated? Winner PK. **Postgrad Med** 1997 May; 101(5):81–5, 89–90 (22 ref.)

DRUG THERAPY

Current developments in neurology, Part I: Advances in the pharmacotherapy of headache, epilepsy, and multiple sclerosis. Gidal BE, et al. **Ann Pharmacother** 1996 Nov; 30(11):1272–6 (37 ref.)
Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society. Pryse-Phillips WE, et al. **Can Med Assoc J** 1997 May 1; 156(9):1273–87 (160 ref.)
Possible mechanisms of valproate in migraine prophylaxis. Cutrer FM, et al. **Cephalalgia** 1997 Apr;17(2):93–100 (84 ref.)
How do the currently used prophylactic agents work in migraine? Goadsby PJ. **Cephalalgia** 1997 Apr;17(2):85–92 (91 ref.)
Side effects of ergotamine. Meyler WJ. **Cephalalgia** 1996 Feb;

16(1):5–10 (34 ref.)
Clinical studies of valproate for migraine prophylaxis. Rothrock JF. **Cephalalgia** 1997 Apr;17(2):81–3 (14 ref.)
A 30–year–old woman with headache. Longworth DL, et al. **Cleve Clin J Med** 1997 Jun;64(6):293–7 (4 ref.)
Clinical presentation and treatment of migraine. Skaer TL. **Clin Ther** 1996 Mar–Apr;18(2):229–45; discussion 228 (71 ref.)
Acute migraine therapy: the newer drugs. Schoenen J. **Curr Opin Neurol** 1997 Jun;10(3):237–43 (38 ref.)
Drug treatment of migraine: acute treatment and migraine prophylaxis. Tfelt–Hansen P. **Curr Opin Neurol** 1996 Jun; 9(3):211–3 (14 ref.)
Inhibition of the trigemino–vascular system with 5–HT1D agonist drugs: selectively targeting additional sites of action. Martin GR. **Eur Neurol** 1996;36 Suppl 2:13–8 (22 ref.)
Ergotamine tartrate and dihydroergotamine mesylate: safety profiles. Lipton RB. **Headache** 1997;37 Suppl 1:S33–41 (33 ref.)
Sumatriptan relieves migrainelike headaches associated with carbon monoxide exposure. Lipton RB, et al. **Headache** 1997 Jun;37(6):392–5 (39 ref.)
Dosing and administration of ergotamine tartrate and dihydroergotamine. Mathew NT. **Headache** 1997;37 Suppl 1:S26–32 (48 ref.)
Diagnosis and symptomatic treatment of migraine. Saper JR. **Headache** 1997;37 Suppl 1:S1–14 (56 ref.)
The pharmacology of ergotamine and dihydroergotamine. Silberstein SD. **Headache** 1997;37 Suppl 1:S15–25 (57 ref.)
Divalproex sodium in headache: literature review and clinical guidelines. Silberstein SD. **Headache** 1996 Oct;36(9):547–55 (66 ref.)
An overview of the diagnosis and pharmacologic treatment of migraine. Capobianco DJ, et al. **Mayo Clin Proc** 1996 Nov;71(11):1055–66 (77 ref.)
Current concepts of the pathophysiology of migraine. Goadsby PJ. **Neurol Clin** 1997 Feb;15(1):27–42 (42 ref.)
Serotonin 1D (5–HT1D) agonists and other agents in acute migraine. Mathew NT. **Neurol Clin** 1997 Feb;15(1):61–83 (127 ref.)
Migraine and pregnancy. Silberstein SD. **Neurol Clin** 1997 Feb;15(1):209–31 (59 ref.)
Prophylactic pharmacotherapy of migraine. Some practical guidelines. Tfelt–Hansen P. **Neurol Clin** 1997 Feb; 15(1):153–65 (27 ref.)
311C90: increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists. Ferrari MD. **Neurology** 1997 Mar;48(3 Suppl 3):S21–4 (15 ref.)
Increasing the options for effective migraine management. Goadsby PJ, et al. **Neurology** 1997 Mar;48(3 Suppl 3):S1–3 (16 ref.)
Emergency treatment of migraine. Insights into current options. Diamond S, et al. **Postgrad Med** 1997 Jan; 101(1):169–72, 175–6, 179 (12 ref.)
Headaches in children. When is a complete diagnostic workup indicated? Winner PK. **Postgrad Med** 1997 May; 101(5):81–5, 89–90 (22 ref.)
[Migraine and serotonin: mechanisms and treatments] Jacquy J. **J Pharm Belg** 1996 Jan–Feb;51(1):43–6 (0 ref.) **(Fre)**

EPIDEMIOLOGY

Diagnosis and epidemiology of pediatric migraine. Lipton RB. **Curr Opin Neurol** 1997 Jun;10(3):231–6 (33 ref.)
Prevalence and impact of migraine. Lipton RB, et al. **Neurol Clin** 1997 Feb;15(1):1–13 (66 ref.)
Burden of migraine: societal costs and therapeutic opportunities. Lipton RB, et al. **Neurology** 1997 Mar;48(3 Suppl 3):S4–9 (37 ref.)

ETIOLOGY

Menstrual migraine. Methods of prevention and control. Fettes I. **Postgrad Med** 1997 May;101(5):67–70, 73–7 (32 ref.)
[Headache as the chief symptom. I] Paulus W. **HNO** 1996 Jan;44(1):33–47 (0 ref.) **(Ger)**
[Migraine and cerebral stroke] Smirnov VE. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996; 96(5):97–101 (60 ref.) **(Rus)**

GENETICS

Migraines in mice? Hess EJ. **Cell** 1996 Dec 27;87(7):1149–51 (16 ref.)
From genetics to prophylaxis. Ferrari M. **Cephalalgia** 1997 Jun;17 Suppl 17:2–4; discussion 4–5 (15 ref.)
Genetics of migraine and other headache. Merikangas KR. **Curr Opin Neurol** 1996 Jun;9(3):202–5 (23 ref.)
The quest for migraine genes. Terwindt GM, et al. **Curr Opin Neurol** 1997 Jun;10(3):221–5 (56 ref.)
Genetics of migraine. Haan J, et al. **Neurol Clin** 1997 Feb; 15(1):43–60 (149 ref.)
[Genetics of migraine] Evers S, et al. **Nervenarzt** 1996 Oct; 67(10):837–45 (88 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Pathogenesis of posttraumatic headache and migraine: a common headache pathway? Packard RC, et al. **Headache** 1997 Mar;37(3):142–52 (114 ref.)

PHYSIOPATHOLOGY

Visual system dysfunction in migraine: a review of clinical and psychophysical findings. Chronicle EP, et al. **Cephalalgia** 1996 Dec;16(8):525–35; discussion 523 (136 ref.)
"Menstrual" migraine: towards a definition. MacGregor EA. **Cephalalgia** 1996 Feb;16(1):11–21 (57 ref.)
New aspects of migraine pathophysiology: lessons learned from positron emission tomography [editorial] Diener HC, et al. **Curr Opin Neurol** 1996 Jun;9(3):199–201 (12 ref.)
Migraine––better understanding, better treatment? Edmeads JG. **Eur Neurol** 1996;36 Suppl 2:1–3 (10 ref.)
Animal models for the study of migraine: update and future perspective. Tassorelli C, et al. **Funct. Neurol** 1996 Nov–Dec;11(6):327–31 (23 ref.)
Central effects of nitroglycerin in the rat: new perspectives in migraine research. Tassorelli C, et al. **Funct Neurol** 1996 Sep–Oct;11(5):219–23, 227–35 (66 ref.)
Current concepts of the pathophysiology of migraine. Goadsby PJ. **Neurol Clin** 1997 Feb;15(1):27–42 (42 ref.)
Menstruation, sex hormones, and migraine. MacGregor EA. **Neurol Clin** 1997 Feb;15(1):125–41 (75 ref.)
Dopamine and migraine. Peroutka SJ. **Neurology** 1997 Sep; 49(3):650–6 (68 ref.)
Evolution of the measurement of quality of life in migraine. Solomon GD. **Neurology** 1997 Mar;48(3 Suppl 3):S10–5 (33 ref.)
Cerebral circulatory changes during migraine headache with aura. Meyer JS, et al. **Rev Neurosci** 1993 Jul–Sep; 4(3):305–19 (68 ref.)
The menagerie of migraine. Buchholz DW, et al. **Semin Neurol** 1996 Mar;16(1):83–93 (226 ref.)
[Migraine and serotonin: mechanisms and treatments] Jacquy J. **J Pharm Belg** 1996 Jan–Feb;51(1):43–6 (0 ref.) **(Fre)**
[Exteroceptive suppression of activity of the temporal muscle. Principles and applications] Göbel H, et al. **Nervenarzt** 1996 Oct;67(10):846–59 (102 ref.) (Eng. Abstr.) **(Ger)**
[Autonomic nervous activity in migraine] Araki N. **Rinsho Shinkeigaku** 1995 Dec;35(12):1336–8 (10 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Valproic acid: a migraine prophylaxis alternative. Shelton CE, et al. **Ann Pharmacother** 1996 Jul–Aug;30(7–8):865–6 (9 ref.)
Preventive treatment of migraine: an overview. Silberstein SD. **Cephalalgia** 1997 Apr;17(2):67–72 (30 ref.)
Drug treatment of migraine: acute treatment and migraine prophylaxis. Tfelt–Hansen P. **Curr Opin Neurol** 1996 Jun; 9(3):211–3 (14 ref.)
Divalproex sodium in headache: literature review and clinical guidelines. Silberstein SD. **Headache** 1996 Oct;36(9):547–55 (66 ref.)
Magnesium taurate and fish oil for prevention of migraine. McCarty MF. **Med Hypotheses** 1996 Dec;47(6):461–6 (94 ref.)
Prophylactic pharmacotherapy of migraine. Some practical guidelines. Tfelt–Hansen P. **Neurol Clin** 1997 Feb; 15(1):153–65 (27 ref.)
Menstrual migraine. Methods of prevention and control. Fettes I. **Postgrad Med** 1997 May;101(5):67–70, 73–7 (32 ref.)

PSYCHOLOGY

Evolution of the measurement of quality of life in migraine. Solomon GD. **Neurology** 1997 Mar;48(3 Suppl 3):S10–5 (33 ref.)

RADIONUCLIDE IMAGING

New aspects of migraine pathophysiology: lessons learned from positron emission tomography [editorial] Diener HC, et al. **Curr Opin Neurol** 1996 Jun;9(3):199–201 (12 ref.)
Imaging the brain of migraine sufferers. Flippen C, et al. **Curr Opin Neurol** 1997 Jun;10(3):226–30 (32 ref.)

THERAPY

Preventive treatment of migraine: an overview. Silberstein SD. **Cephalalgia** 1997 Apr;17(2):67–72 (30 ref.)
A review of the treatment of primary headaches. Part I: Migraine. Leone M, et al. **Ital J Neurol Sci** 1995 Dec; 16(9):577–86 (55 ref.)
Burden of migraine: societal costs and therapeutic opportunities. Lipton RB, et al. **Neurology** 1997 Mar;48(3 Suppl 3):S4–9 (37 ref.)

MIGRANTS see **TRANSIENTS AND MIGRANTS**

MIGRATING MOTOR COMPLEX see **MYOELECTRIC COMPLEX, MIGRATING**

MIGRATION, CELL see **CELL MOVEMENT**

MIGRATION INHIBITION FACTORS, MACROPHAGE see **MACROPHAGE MIGRATION–INHIBITORY FACTORS**

MIGRATION INHIBITORY TESTS, LEUKOCYTE see **CELL MIGRATION INHIBITION**

MIKAMYCIN see **VIRGINIAMYCIN**

MIKULICZ' DISEASE

Mikulicz syndrome. Aleem A, et al. **JPMA J Pak Med Assoc** 1997 Apr;47(4):126–9 (21 ref.)

MILIARIA

PATHOLOGY

Miliaria profunda. Kirk JF, et al. **J Am Acad Dermatol** 1996 Nov;35(5 Pt 2):854–6 (11 ref.)

MILIARIA RUBRA see **MILIARIA**

MILIEU THERAPY

[Nonpharmacologic and rehabilitation aspects in inpatient settings] Gatterer G, et al. **Wien Med Wochenschr** 1996; 146(21–22):559–65 (46 ref.) (Eng. Abstr.) **(Ger)**

MILITARY MEDICINE

Incorporating occupational medicine methodology into military fitness for duty and readiness issues. Popper SE. **Aviat Space Environ Med** 1997 Aug;68(8):740–5 (28 ref.)
Acute dissecting aortic aneurysm in an operational environment. Henning KS. **Mil Med** 1997 Aug;162(8):573–4 (5 ref.)
Deterrence of biological and chemical warfare: a review of policy options. Lebeda FJ. **Mil Med** 1997 Mar; 162(3):156–61 (61 ref.)
Applications of predictive environmental strain models. Reardon MJ, et al. **Mil Med** 1997 Feb;162(2):136–40 (35 ref.)

EDUCATION

A proposal for the training of regional medical experts. Johnson DE. **Mil Med** 1997 Aug;162(8):533–6 (11 ref.)

METHODS

Biosensors for chemical and biological agents of defence interest. Paddle BM. **Biosens Bioelectron** 1996; 11(11):1079–113 (156 ref.)
Trauma management on the battlefield: a modern approach. Hawley A. **J R Army Med Corps** 1996 Oct;142(3):120–5 (33 ref.)

ORGANIZATION & ADMINISTRATION

A research note about military–civilian humanitarianism: more questions than answers. Weiss TG. **Disasters** 1997 Jun;21(2):95–117 (116 ref.)
Ethical issues in military medicine. Dolev E. **Isr J Med Sci** 1996 Sep;32(9):785–8 (20 ref.)
A proposal for the training of regional medical experts. Johnson DE. **Mil Med** 1997 Aug;162(8):533–6 (11 ref.)
Marketing: applications in a military health care setting. Roark GA, et al. **Mil Med** 1997 Aug;162(8):543–7 (18 ref.)
TRICARE: implications for military executive management education––a review of current data [see comments] Texidor MS, et al. **Mil Med** 1996 Apr;161(4):217–20 (11 ref.) Comment in: Mil Med 1997 Jan;162(1):vii.

STANDARDS

Preventing heat injury: military versus civilian perspective. Cooper JK. **Mil Med** 1997 Jan;162(1):55–8 (34 ref.)

TRENDS

Military medical sciences being faced with the 21st century. Wu Z. **Chin Med J (Engl)** 1996 Jul;109(7):501–3 (0 ref.)

MILITARY NURSING

HISTORY

Nursing at war: catalyst for change. Brunk Q. **Annu Rev Nurs Res** 1997;15:217–36 (53 ref.)

MILITARY PERSONNEL

see related
VETERANS

Anterior knee pain in the military population. Chang PC, et al. **Ann Acad Med Singapore** 1997 Jan;26(1):60–3 (12 ref.)
Effects of sleep deprivation with reference to military operations. Giam GC. **Ann Acad Med Singapore** 1997 Jan; 26(1):88–93 (20 ref.)
Colostomy in conflict: military colonic surgery. Edwards DP, et al. **Ann R Coll Surg Engl** 1997 Jul;79(4):243–4 (13 ref.)
Development and biomedical testing of military operational rations. Friedl KE, et al. **Annu Rev Nutr** 1997;17:51–75 (110 ref.)
Lipid lowering therapy and military aviators. Khan MA, et al. **Aviat Space Environ Med** 1996 Sep;67(9):867–71 (28 ref.)
Percutaneous transluminal coronary angioplasty (PTCA): long–term outcome and aeromedical implications. Moorman DL, et al. **Aviat Space Environ Med** 1996 Oct; 67(10):990–6 (45 ref.)
The Fort Bragg continuum of care Demonstration Project: the population served was unique and the outcomes are questionable. Mordock JB. **Child Psychiatry Hum Dev** 1997 Summer;27(4):241–54 (63 ref.)

MILITARY PERSONNEL

Effects of food restriction in military training on T-lymphocyte responses. Kramer TR, et al. **Int J Sports Med** 1997 Mar;18 Suppl 1:S84–90 (18 ref.)

Penetrating cranio-cerebral injuries. Buxton N. **J R Army Med Corps** 1997 Jun;143(2):112–4 (34 ref.)

Recurrent sacro-iliac joint abscess. Eskander MB, et al. **J R Army Med Corps** 1994 Jun;140(2):95–6 (7 ref.)

Meckel's diverticulum: should it be excised prophylactically in service personnel? Farrar MJ. **J R Army Med Corps** 1994 Feb;140(1):42–4 (09 ref.)

A review of Gulf War illness. Coker WJ. **J R Navy Med Serv** 1996 Summer;82(2):141–6 (11 ref.)

The anti-personnel land mine epidemic: a case report and review of the literature [see comments] Gondring WH. **Mil Med** 1996 Dec;161(12):760–2 (6 ref.) Comment in: Mil Med 1997 Apr;162(4):i.

Acute dissecting aortic aneurysm in an operational environment. Henning KS. **Mil Med** 1997 Aug;162(8):573–4 (5 ref.)

Is caffeine involved in the pathogenesis of combat-stress reaction? Iancu I, et al. **Mil Med** 1996 Apr;161(4):230–32 (14 ref.)

Al Eskan disease: Persian Gulf syndrome [see comments] Korényi-Both AL, et al. **Mil Med** 1997 Jan;162(1):1–13 (75 ref.) Comment in: Mil Med 1997 Mar;162(3):ii.

Sudden exertional death in a soldier with sickle cell trait. Murray MJ, et al. **Mil Med** 1996 May;161(5):303–5 (18 ref.)

Treatment of comminuted subtrochanteric femoral fractures in a young population with a reconstruction nail. Taylor DC, et al. **Mil Med** 1996 Dec;161(12):735–8 (30 ref.)

Ring avulsion injuries in a field environment. Varela CD. **Mil Med** 1996 May;161(5):308–10 (9 ref.)

Possibilities for unexplained chronic illnesses among reserve units deployed in Operation Desert Shield/Desert Storm. Malone JD, et al. **South Med J** 1996 Dec;89(12):1147–55 (38 ref.)

Vaginitis/cervicitis: diagnosis and treatment options in a limited resource environment. Landers DV. **Womens Health Issues** 1996 Nov-Dec;6(6):342–8 (32 ref.)

[Gulf War syndrome—more than meets the eye] Vidan A, et al. **Harefuah** 1996 Jul;131(1–2):27–30 (22 ref.) **(Heb)**

[Examination methods for the prevention of traumatic and nontraumatic osteoarthropathies related to flying activity] Rotondo G. **Riv Med Aeronaut Spaz** 1975 Oct-Dec; 38(4):375–91 (25 ref.) (Eng. Abstr.) **(Ita)**

[The toxicological problems of disaster medicine in the Navy Fleet] Sharaevskiĭ GIu, et al. **Voen Med Zh** 1996 Aug; 317(8):66–70, 80 (21 ref.) (Eng. Abstr.) **(Rus)**

[The graft-vs-host reaction in military transfusion treatment] Shevchenko IuL, et al. **Voen Med Zh** 1997 Feb;318(2):32–5 (17 ref.) **(Rus)**

HISTORY

Don't ask, don't tell: the same old policy in a new uniform? Yount AN. **J Contemp Health Law Policy** 1995 Fall; 12(1):215–238 (211 ref.)

LEGISLATION & JURISPRUDENCE

Don't ask, don't tell: the same old policy in a new uniform? Yount AN. **J Contemp Health Law Policy** 1995 Fall; 12(1):215–238 (211 ref.)

"Don't ask, don't tell, don't pursue": military policy and the construction of heterosexual masculinity. Britton DM, et al. **J Homosex** 1995;30(1):1–21 (54 ref.)

PSYCHOLOGY

Psychological disorders in Singaporean national servicemen. Ang YG. **Ann Acad Med Singapore** 1997 Jan;26(1):70–5 (3 ref.)

Psychosocial aspects of coronary artery disease related to military patients. Grenier JL, et al. **Can J Psychiatry** 1997 Mar;42(2):176–84 (88 ref.)

Militarism: a psychosocial disease. Coulter NA. **Med War** 1992 Jan-Mar;8(1):7–17 (15 ref.)

Preventing post-traumatic stress disorders in military medical personnel. Baker MS, et al. **Mil Med** 1996 May;161(5):262–4 (16 ref.)

MILITARY PSYCHIATRY

Military psychiatry: a cross-cultural perspective. Kutz DL. **Mil Med** 1996 Feb;161(2):78–83 (19 ref.)

MILK

see related
LACTATION

Role of human milk constituents in blocking the adherence of enteric pathogens. Ashkenazi S. **Adv Exp Med Biol** 1996; 408:187–92 (18 ref.)

Lactose intolerance. Diagnosis and dietary treatment with milk substitutes. Talhouk RS, et al. **J Med Liban** 1996; 44(1):36–40 (51 ref.)

[Milk in our diet: pro and con. Alternative prophylactic measures] Loranskaia TI, et al. **Klin Med (Mosk)** 1997; 75(2):13–6 (39 ref.) **(Rus)**

[Poor digestion of lactose. Its definition, prevalence in Mexico, and its implications in milk consumption] López P, et al. **Rev Invest Clin** 1996 Nov;48 Suppl:15–22 (47 ref.) (Eng. Abstr.) **(Spa)**

[Lactose intolerance. Its definition, its prevalence in Mexico, and its implications in milk consumption] Palma M, et al. **Rev Invest Clin** 1996 Nov;48 Suppl:25–31 (22 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Cow's milk, bovine serum albumin, and IDDM: can we settle the controversies? Hammond-McKibben D, et al. **Diabetes Care** 1997 May;20(5):897–901 (59 ref.)

Gastrointestinal disorders due to cow's milk consumption. Barnard J. **Pediatr Ann** 1997 Apr;26(4):244–50 (19 ref.)

CHEMISTRY

Artificial feeding: progresses and problems. Piacentini GL, et al. **Ann Ist Super Sanita** 1995;31(4):411–8 (10 ref.)

Regulation of milk lipid secretion and composition. Neville MC, et al. **Annu Rev Nutr** 1997;17:159–83 (140 ref.)

Biologically active factors in bovine milk and dairy byproducts: influence on cell culture. Guimont C, et al. **Crit Rev Food Sci Nutr** 1997 Jun;37(4):393–410 (176 ref.)

Structures and functionalities of milk proteins [published erratum appears in Crit Rev Food Sci Nutr 1997 Feb;37(1):92] Wong DW, et al. **Crit Rev Food Sci Nutr** 1996 Dec;36(8):807–44 (270 ref.)

Unlabeled milk from cows treated with biosynthetic growth hormones: a case of regulatory abdication. Epstein SS. **Int J Health Serv** 1996;26(1):173–85 (66 ref.)

Intestinal effects of milkborne growth factors in neonates of agricultural importance. Odle J, et al. **J Anim Sci** 1996 Oct;74(10):2509–22 (120 ref.)

PP3 component of bovine milk: a phosphorylated whey glycoprotein. Girardet JM, et al. **J Dairy Res** 1996 May; 63(2):333–50 (79 ref.)

Quality milk and tests for antibiotic residues. Sischo WM. **J Dairy Sci** 1996 Jun;79(6):1065–73 (20 ref.)

Cows' milk fat components as potential anticarcinogenic agents. Parodi PW. **J Nutr** 1997 Jun;127(6):1055–60 (71 ref.)

Protein and nonprotein nitrogen components in human milk, bovine milk, and infant formula: quantitative and qualitative aspects in infant nutrition. Rudloff S, et al. **J Pediatr Gastroenterol Nutr** 1997 Mar;24(3):328–44 (191 ref.)

Analytical considerations for trace determinations of drugs in breast milk. Rossi DT, et al. **J Pharm Biomed Anal** 1997 Jan;15(4):495–504 (62 ref.)

Detection of inhibitors in milk by microbial tests. A review. Suhren G, et al. **Nahrung** 1996 Feb;40(1):1–7 (42 ref.)

IMMUNOLOGY

Cow's milk, bovine serum albumin, and IDDM: can we settle the controversies? Hammond-McKibben D, et al. **Diabetes Care** 1997 May;20(5):897–901 (59 ref.)

Infants diets and insulin-dependent diabetes: evaluating the "cows' milk hypothesis" and a role for anti-bovine serum albumin immunity. Atkinson MA, et al. **J Am Coll Nutr** 1997 Aug;16(4):334–40 (56 ref.)

Oral desensitization with cow's milk in IgE-mediated cow's milk allergy. Contra! Bahna SL. **Monogr Allergy** 1996; 32:233–5 (17 ref.)

Oral desensitization with cow's milk in cow's milk allergy. Pro! Wüthrich B. **Monogr Allergy** 1996;32:236–40 (10 ref.)

METABOLISM

Mechanisms of the intestinal effects of dietary fats and milk products on colon carcinogenesis. Van der Meer R, et al. **Cancer Lett** 1997 Mar 19;114(1–2):75–83 (34 ref.)

The interplay of feeding and genetics on heifer rearing and first lactation milk yield: a review. Lee AJ. **J Anim Sci** 1997 Mar;75(3):846–51 (23 ref.)

Influence of prepubertal feeding level on milk yield potential of dairy heifers: a review. Sejrsen K, et al. **J Anim Sci** 1997 Mar;75(3):828–35 (63 ref.)

Effects of milk and milk components on calcium, magnesium, and trace element absorption during infancy. Lönnerdal B. **Physiol Rev** 1997 Jul;77(3):643–69 (243 ref.)

Current progress in the production of recombinant human fibrinogen in the milk of transgenic animals. Butler SP, et al. **Thromb Haemost** 1997 Jul;78(1):537–42 (25 ref.)

MICROBIOLOGY

Antifungal attributes of lactic acid bacteria--a review. Batish VK, et al. **Crit Rev Biotechnol** 1997;17(3):209–25 (61 ref.)

Detection of inhibitors in milk by microbial tests. A review. Suhren G, et al. **Nahrung** 1996 Feb;40(1):1–7 (42 ref.)

POISONING

Food poisoning, listeriosis, and febrile gastroenteritis. **Nutr Rev** 1997 Feb;55(2):57–60 (6 ref.)

STANDARDS

Dietary vitamin E and selenium affect mastitis and milk quality. Smith KL, et al. **J Anim Sci** 1997 Jun;75(6):1659–65 (54 ref.)

A new procedure to fortify fluid milk and dairy products with high-bioavailable ferrous sulfate. Boccio JR, et al. **Nutr Rev** 1997 Jun;55(6):240–6 (21 ref.)

VIROLOGY

Minimization of viral contamination in human pharmaceuticals produced in the milk of transgenic goats. Ziomek CA. **Dev Biol Stand** 1996;88:265–8 (5 ref.)

MILK-ALKALI SYNDROME see **HYPERCALCEMIA**

MILK FACTOR see **MAMMARY TUMOR VIRUSES, MOUSE**

MILK FEVER, ANIMAL see **PARTURIENT PARESIS**

MILK, HUMAN

see related
BREAST FEEDING
LACTATION

Special properties of human milk. Wagner CL, et al. **Clin Pediatr (Phila)** 1996 Jun;35(6):283–93 (126 ref.)

Which milk for the preterm infant? Tudehope DI, et al. **J Paediatr Child Health** 1996 Aug;32(4):275–7 (12 ref.)

Importance of milk and diet on the ontogeny and adaptation of the intestine. Perin NM, et al. **J Pediatr Gastroenterol Nutr** 1997 Apr;24(4):419–25 (76 ref.)

CHEMISTRY

Composition of human milk: nutritional aspects. Hambraeus L. **Bibl Nutr Dieta** 1996;(53):37–44 (16 ref.)

Rationale for the introduction of long chain polyunsaturated fatty acids and for concomitant increase in the level of vitamin E in infant formulas. Bendich A, et al. **Int J Vitam Nutr Res** 1997;67(4):213–31 (98 ref.)

Is milk-borne insulin-like growth factor-I essential for neonatal development? Burrin DG. **J Nutr** 1997 May;127(5 Suppl):975S–979S (47 ref.)

Do milk-borne cytokines and hormones influence neonatal immune cell function? Ellis LA, et al. **J Nutr** 1997 May; 127(5 Suppl):985S–988S (30 ref.)

Should infant formulas be supplemented with bioactive components and conditionally essential nutrients present in human milk? Hamosh M. **J Nutr** 1997 May;127(5 Suppl):971S–974S (38 ref.)

Do the binding properties of oligosaccharides in milk protect human infants from gastrointestinal bacteria? Newburg DS. **J Nutr** 1997 May;127(5 Suppl):980S–984S (18 ref.)

Protein and nonprotein nitrogen components in human milk, bovine milk, and infant formula: quantitative and qualitative aspects in infant nutrition. Rudloff S, et al. **J Pediatr Gastroenterol Nutr** 1997 Mar;24(3):328–44 (191 ref.)

Analytical considerations for trace determinations of drugs in breast milk. Rossi DT, et al. **J Pharm Biomed Anal** 1997 Jan;15(4):495–504 (62 ref.)

The lipids in human milk. Jensen RG. **Prog Lipid Res** 1996 Mar;35(1):53–92 (102 ref.)

Environmental contaminants in breast milk from the central Asian republics. Lederman SA. **Reprod Toxicol** 1996 Mar-Apr;10(2):93–104 (42 ref.)

Significance of lipid consumption during lactation. Ortiz-Olaya N, et al. **Rev Invest Clin** 1996 Nov-Dec; 48(6):473–8 (40 ref.)

DRUG EFFECTS

Drug therapy in the nursing mother. Dillon AE, et al. **Obstet Gynecol Clin North Am** 1997 Sep;24(3):675–96 (47 ref.)

IMMUNOLOGY

Transfer of maternal leukocytes to the infant by human milk. Goldman AS, et al. **Curr Top Microbiol Immunol** 1997; 222:205–13 (60 ref.)

Immunological interaction between the mother and her infant in relation to the development of food allergy. Björkstén B. **Monogr Allergy** 1996;32:16–24 (40 ref.)

METABOLISM

Effects of milk and milk components on calcium, magnesium, and trace element absorption during infancy. Lönnerdal B. **Physiol Rev** 1997 Jul;77(3):643–69 (243 ref.)

VIROLOGY

Human cytomegalovirus infection of breast milk. Numazaki K. **FEMS Immunol Med Microbiol** 1997 Jun;18(2):91–8 (44 ref.)

MILK HYPERSENSITIVITY

see related
LACTOSE INTOLERANCE

Cow milk allergy in infancy and early childhood [editorial; comment] Hill DJ, et al. **Clin Exp Allergy** 1996 Mar; 26(3):243–6 (35 ref.) Comment on: Clin Exp Allergy 1996 Mar;26(3):254–61.

Cow's milk protein allergy and hypoallergenic formulas [editorial] Wyllie R. **Clin Pediatr (Phila)** 1996 Oct; 35(10):497–500 (40 ref.)

COMPLICATIONS

Gastrointestinal disorders due to cow's milk consumption. Barnard J. **Pediatr Ann** 1997 Apr;26(4):244–50 (19 ref.)

DIAGNOSIS

Cow's milk allergy. Høst A. **J R Soc Med** 1997;90 Suppl 30:34–9 (52 ref.)

IMMUNOLOGY

Oral desensitization with cow's milk in IgE–mediated cow's milk allergy. Contra! Bahna SL. **Monogr Allergy** 1996; 32:233–5 (17 ref.)

[Favorable effect of breast feeding and late introduction of cow's milk on the prevention of suspected allergic symptoms in infancy] Arató A, et al. **Orv Hetil** 1996 Sep 8;137(36):1979–82 (32 ref.) (Eng. Abstr.) **(Hun)**

PREVENTION & CONTROL

Prophylaxis of cow's milk allergy. Businco L, et al. **Monogr Allergy** 1996;32:30–5 (26 ref.)

THERAPY

Oral desensitization with cow's milk in IgE–mediated cow's milk allergy. Contra! Bahna SL. **Monogr Allergy** 1996; 32:233–5 (17 ref.)

Prophylaxis of cow's milk allergy. Businco L, et al. **Monogr Allergy** 1996;32:30–5 (26 ref.)

Oral desensitization with cow's milk in cow's milk allergy. Pro! Wüthrich B. **Monogr Allergy** 1996;32:236–40 (10 ref.)

MILK PROTEINS

New opportunities from the isolation and utilization of whey proteins. Smithers GW, et al. **J Dairy Sci** 1996 Aug; 79(8):1454–9 (13 ref.)

ADMINISTRATION & DOSAGE

[Favorable effect of breast feeding and late introduction of cow's milk on the prevention of suspected allergic symptoms in infancy] Arató A, et al. **Orv Hetil** 1996 Sep 8;137(36):1979–82 (32 ref.) (Eng. Abstr.) **(Hun)**

ANALYSIS

PP3 component of bovine milk: a phosphorylated whey glycoprotein. Girardet JM, et al. **J Dairy Res** 1996 May; 63(2):333–50 (79 ref.)

Protein and nonprotein nitrogen components in human milk, bovine milk, and infant formula: quantitative and qualitative aspects in infant nutrition. Rudloff S, et al. **J Pediatr Gastroenterol Nutr** 1997 Mar;24(3):328–44 (191 ref.)

[Nutritional physiology of whey and why components] Barth CA, et al. **Nahrung** 1997 Feb;41(1):2–12 (90 ref.) (Eng. Abstr.) **(Ger)**

CHEMISTRY

A review of the interactions between milk proteins and dairy flavor compounds. Hansen AP. **Adv Exp Med Biol** 1997; 415:67–76 (35 ref.)

Disulfide–mediated polymerization of whey proteins in whey protein isolate–stabilized emulsions. Monahan FJ, et al. **Adv Exp Med Biol** 1997;415:127–36 (24 ref.)

Production of whey–protein–enriched products. Mulvihill DM, et al. **Adv Exp Med Biol** 1997;415:77–93 (59 ref.)

Biochemical properties of regulatory peptides derived from milk proteins. Meisel H. **Biopolymers** 1997;43(2):119–28 (79 ref.)

Structures and functionalities of milk proteins [published erratum appears in Crit Rev Food Sci Nutr 1997 Feb;37(1):92] Wong DW, et al. **Crit Rev Food Sci Nutr** 1996 Dec;36(8):807–44 (270 ref.)

GENETICS

[Problems in the study of structure and expression of milk protein genes] Popov LS. **Mol Biol (Mosk)** 1996 Nov–Dec; 30(6):1242–60 (139 ref.) **(Rus)**

IMMUNOLOGY

Cow's milk protein allergy and hypoallergenic formulas [editorial] Wyllie R. **Clin Pediatr (Phila)** 1996 Oct; 35(10):497–500 (40 ref.)

T–cell response to milk proteins in atopic and nonatopic donors. Parronchi P, et al. **Monogr Allergy** 1996;32:121–9 (30 ref.)

[Favorable effect of breast feeding and late introduction of cow's milk on the prevention of suspected allergic symptoms in infancy] Arató A, et al. **Orv Hetil** 1996 Sep 8;137(36):1979–82 (32 ref.) (Eng. Abstr.) **(Hun)**

ISOLATION & PURIFICATION

Blood proteins from transgenic animal bioreactors. Lubon H, et al. **Transfus Med Rev** 1996 Apr;10(2):131–43 (86 ref.)

METABOLISM

Milk protein–derived opioid receptor ligands. Teschemacher H, et al. **Biopolymers** 1997;43(2):99–117 (171 ref.)

MILKER'S NODES see **POXVIRIDAE INFECTIONS**

MILROY'S DISEASE see **LYMPHEDEMA**

MIMA see **ACINETOBACTER**

MIMAE INFECTIONS see **ACINETOBACTER INFECTIONS**

MIMETIC MUSCLES see **FACIAL MUSCLES**

MIMICRY, MOLECULAR see **MOLECULAR MIMICRY**

MINAMATA DISEASE see **MERCURY POISONING**

MIND–BODY RELATIONS (METAPHYSICS)

see related

PSYCHOPHYSIOLOGY

Mind–body fitness: encouraging prospects for primary and secondary prevention. La Forge R. **J Cardiovasc Nurs** 1997 Apr;11(3):53–65 (55 ref.)

A therapy to live by: public health, the self and nationalism in the practice of a north Indian yoga society. Alter JS. **Med Anthropol** 1997 Jun;17(4):309–35 (83 ref.)

MIND–BODY RELATIONS (NON–PHYSIOLOGY) see **MIND–BODY RELATIONS (METAPHYSICS)**

MIND–BODY RELATIONS (PHYSIOLOGY) see **PSYCHOPHYSIOLOGY**

MINERAL FIBERS

see related

PNEUMOCONIOSIS

Cellular effects of particles—impact of dissolution on toxicity of man–made mineral fibers. Luoto K, et al. **Cent Eur J Public Health** 1996;4 Suppl:29–32 (40 ref.)

ADVERSE EFFECTS

[The biological effect of fireproof ceramic fibers—literature review] Krajnow A. **Med Pr** 1996;47(6):663–75 (26 ref.) (Eng. Abstr.) **(Pol)**

TOXICITY

Consensus report. International Agency for Research on Cancer. Mechanisms of fibre carcinogenesis. **IARC Sci Publ** 1996;(140):1–9 (2 ref.)

MINERAL OIL

ANALYSIS

[Mineral oil hydrocarbons as ground water contaminants] Schewe C, et al. **Schriftenr Ver Wasser Boden Lufthyg** 1996; 98:III–XVI, 1–92 (72 ref.) **(Ger)**

MINERAL WATERS

Mineral water and spas in Italy. Andreassi L, et al. **Clin Dermatol** 1996 Nov–Dec;14(6):627–32 (16 ref.)

The influence of mineral water solutions in phototherapy. Boer J. **Clin Dermatol** 1996 Nov–Dec;14(6):665–73 (48 ref.)

Mineral water and spas in France. Karam P. **Clin Dermatol** 1996 Nov–Dec;14(6):607–10 (21 ref.)

Climatotherapy at the Dead Sea in Jordan. Oumeish OY. **Clin Dermatol** 1996 Nov–Dec;14(6):659–64 (12 ref.)

Mineral water and spas in Bulgaria. Vassileva S. **Clin Dermatol** 1996 Nov–Dec;14(6):601–5 (16 ref.)

ADMINISTRATION & DOSAGE

Mineral waters: instead of soap or better than soap? Lotti TM, et al. **Clin Dermatol** 1996 Jan–Feb;14(1):101–4 (28 ref.)

HISTORY

Mineral water and spas in the United States. Benedetto AV, et al. **Clin Dermatol** 1996 Nov–Dec;14(6):583–600 (76 ref.)

Balneology, mineral water, and spas in historical perspective. Routh HB, et al. **Clin Dermatol** 1996 Nov–Dec;14(6):551–4 (35 ref.)

THERAPEUTIC USE

Mineral water and spas in Italy. Andreassi L, et al. **Clin Dermatol** 1996 Nov–Dec;14(6):627–32 (16 ref.)

Dermatologic aspects of mineral water. Bernstein JE. **Clin Dermatol** 1996 Nov–Dec;14(6):567–9 (12 ref.)

Rheumatologic aspects of mineral water. Fabiani D, et al. **Clin Dermatol** 1996 Nov–Dec;14(6):571–5 (21 ref.)

The spa and sexually transmitted diseases. Freedman D, et al. **Clin Dermatol** 1996 Nov–Dec;14(6):577–82 (34 ref.)

Immunologic aspects: immunology of mineral water spas. Ghersetich I, et al. **Clin Dermatol** 1996 Nov–Dec; 14(6):563–6 (36 ref.)

Mineral water and spas in Greece. Katsambas A, et al. **Clin Dermatol** 1996 Nov–Dec;14(6):615–8 (12 ref.)

Mineral water and spas in Spain. Ledo E. **Clin Dermatol** 1996 Nov–Dec;14(6):641–6 (19 ref.)

Mineral water and spas in Germany. Titzmann T, et al. **Clin Dermatol** 1996 Nov–Dec;14(6):611–3 (7 ref.)

MINERALOCORTICOID RECEPTORS see **RECEPTORS, MINERALOCORTICOID**

MINERALOCORTICOIDS

ADVERSE EFFECTS

Hypertension and hypokalemia: unusual syndromes. Cruz DN, et al. **Conn Med** 1997 Feb;61(2):67–75 (42 ref.)

[Mineralocorticoid–induced hypertension] Hensen J, et al. **Med Klin** 1997 May 15;92(5):273–8 (27 ref.) (Eng. Abstr.) **(Ger)**

BIOSYNTHESIS

17 Alpha–hydroxylase deficiency. Biglieri EG. **J Endocrinol Invest** 1995 Jul–Aug;18(7):540–4 (13 ref.)

GENETICS

Molecular biology of mineralocorticoid metabolism. Fardella CE, et al. **Annu Rev Nutr** 1996;16:443–70 (128 ref.)

Inherited forms of mineralocorticoid hypertension. White PC. **Hypertension** 1996 Dec;28(6):927–36 (84 ref.)

[Apparent mineralocorticoid syndrome] Shimosawa T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):110–3 (8 ref.) **(Jpn)**

METABOLISM

Molecular biology of mineralocorticoid metabolism. Fardella CE, et al. **Annu Rev Nutr** 1996;16:443–70 (128 ref.)

Analysis of glucocorticoid and mineralocorticoid signalling by gene targeting. Berger S, et al. **Endocr Res** 1996 Nov; 22(4):641–52 (19 ref.)

11 beta–Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. White PC, et al. **Endocr Rev** 1997 Feb;18(1):135–56 (209 ref.)

11 beta–Hydroxysteroid dehydrogenases: tissue–specific dictators of glucocorticoid action. Benediktsson R, et al. **Essays Biochem** 1996;31:23–36 (20 ref.)

Apparent mineralocorticoid excess syndromes. Shimojo M, et al. **J Endocrinol Invest** 1995 Jul–Aug;18(7):518–32 (107 ref.)

11 beta–Hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess. White PC, et al. **Pediatr Res** 1997 Jan;41(1):25–9 (37 ref.)

Apparent mineralocorticoid excess: type I and type II. Mantero F, et al. **Steroids** 1996 Apr;61(4):193–6 (34 ref.)

Molecular analysis of 11 beta–hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess. White PC, et al. **Steroids** 1997 Jan;62(1):83–8 (43 ref.)

PHARMACOLOGY

Mineralocorticoids, salt and high blood pressure. Gómez–Sánchez EP, et al. **Steroids** 1996 Apr;61(4):184–8 (51 ref.)

Mineralocorticoids, salt, hypertension: effects on the heart. Young MJ, et al. **Steroids** 1996 Apr;61(4):233–5 (16 ref.)

Mineralocorticoid resistance. Zennaro MC. **Steroids** 1996 Apr;61(4):189–92 (26 ref.)

PHYSIOLOGY

Glucocorticoid and mineralocorticoid resistance. Komesaroff PA, et al. **J Endocrinol Invest** 1995 Jul–Aug;18(7):550–64 (121 ref.)

Vascular remodeling and mineralocorticoids. Weber KT, et al. **J Endocrinol Invest** 1995 Jul–Aug;18(7):533–9 (62 ref.)

MINERALS

The uptake of mineral particles by pulmonary epithelial cells. Churg A. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 1):1124–40 (185 ref.)

The role of remote sensing in finding hydrothermal mineral deposits on earth. Huntington JF. **Ciba Found Symp** 1996; 202:214–31; discussion 231–5 (19 ref.)

Functional changes appropriate for determining mineral element requirements. Lukaski HC, et al. **J Nutr** 1996 Sep; 126(9 Suppl):2354S–2364S (26 ref.)

How should dietary guidance be given for mineral elements with beneficial actions or suspected of being essential? Nielsen FH. **J Nutr** 1996 Sep;126(9 Suppl):2377S–2385S (25 ref.)

ADMINISTRATION & DOSAGE

Vitamin and mineral supplement prior to and during pregnancy. Menard MK. **Obstet Gynecol Clin North Am** 1997 Sep;24(3):479–98 (21 ref.)

ADVERSE EFFECTS

Mixed fibrous and non–fibrous dust exposures and interactions between agents in fibre carcinogenesis. Davis JM. **IARC Sci Publ** 1996;(140):127–35 (62 ref.)

Short–term animal studies for detecting inflammation, fibrosis and pre–neoplastic changes induced by fibres. Donaldson K. **IARC Sci Publ** 1996;(140):97–106 (54 ref.)

Effects of fibres on cell proliferation, cell activation and gene expression. Driscoll KE. **IARC Sci Publ** 1996;(140):73–96 (110 ref.)

Use of physico–chemical and cell–free assays to evaluate the potential carcinogenicity of fibres. Fubini B. **IARC Sci Publ** 1996;(140):35–54 (90 ref.)

MINERALS

Use of in-vitro genotoxicity and cell transformation assays to evaluate the potential carcinogenicity of fibres. Jaurand MC. **IARC Sci Publ** 1996;(140):55-72 (107 ref.)
Mechanisms of mineral fibre carcinogenesis. Kane AB. **IARC Sci Publ** 1996;(140):11-34 (138 ref.)
Evaluation and use of animal models to assess mechanisms of fibre carcinogenicity. Oberdörster G. **IARC Sci Publ** 1996;(140):107-25 (80 ref.)

ANALYSIS

Bone mineralization as studied by small-angle x-ray scattering. Fratzl P, et al. **Connect Tissue Res** 1996; 34(4):247-54 (21 ref.)

CHEMISTRY

Did minerals perform prebiotic combinatorial chemistry? Schwartz AW. **Chem Biol** 1996 Jul;3(7):515-8 (18 ref.)
Mineral characterization in calcifying tissues: atomic, molecular and macromolecular perspectives. Landis WJ. **Connect Tissue Res** 1996;34(4):239-46 (44 ref.)

METABOLISM

Mineral metabolism: new aspects and perspectives [editorial] Drüeke TB. **Curr Opin Nephrol Hypertens** 1996 Jul; 5(4):297-9 (16 ref.)
Mineral metabolism [editorial] Drüeke TB, et al. **Curr Opin Nephrol Hypertens** 1997 Jul;6(4):305-7 (28 ref.)
Stable isotope methods for studying nutrient mineral metabolism in humans. Mellon FA, et al. **Endeavour** 1997; 21(1):12-8 (22 ref.)
Essential microminerals and their response to burn injury. Gamliel Z, et al. **J Burn Care Rehabil** 1996 May-Jun; 17(3):264-72 (108 ref.)
Micronutrients and exercise: anti-oxidants and minerals. Clarkson PM. **J Sports Sci** 1995 Summer;13 Spec No:S11-24 (161 ref.)
Extracellular bacterial mineralization within the context of geomicrobiology. Ben Omar N, et al. **Microbiologia** 1997 Jun;13(2):161-72 (40 ref.)
Lipids and biomineralizations. Goldberg M, et al. **Prog Histochem Cytochem** 1996;31(2):1-187 (500 ref.)

PHARMACOKINETICS

Bioavailability of oral vitamins, minerals, and trace elements in perspective. Schümann K, et al. **Arzneimittelforschung** 1997 Apr;47(4):369-80 (73 ref.)
Bioavailability of dietary minerals. Fairweather-Tait SJ. **Biochem Soc Trans** 1996 Aug;24(3):775-80 (26 ref.)

THERAPEUTIC USE

Vitamins and minerals: efficacy and safety. Hathcock JN. **Am J Clin Nutr** 1997 Aug;66(2):427-37 (152 ref.)
Micronutrients (vitamins and minerals) as cancer-preventive agents. Omenn GS. **IARC Sci Publ** 1996;(139):33-45 (55 ref.)

MINIATURE SWINE see **SWINE, MINIATURE**

MINIMAL ACCESS SURGERY see **SURGERY, MINIMALLY INVASIVE**

MINIMAL BRAIN DYSFUNCTION see **ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY**

MINIMAL RESIDUAL DISEASE see **NEOPLASM, RESIDUAL**

MINIMALLY INVASIVE SURGERY see **SURGERY, MINIMALLY INVASIVE**

MINING

Interactive effects of polycyclic aromatic hydrocarbons and iron oxides particles. Epidemiological and fundamental aspects. Haguenoer JM, et al. **Cent Eur J Public Health** 1996;4 Suppl:41-5 (42 ref.)
Pneumoconiosis in carbon black workers [published erratum appears in Sangyo Ika Daigaku Zasshi 1996 Dec 1;18(4):307] Szozda R. **Sangyo Ika Daigaku Zasshi** 1996 Sep 1;18(3):223-8 (29 ref.)
Policy development for compensating workers exposed to crystalline silica in Ontario, Canada. Elinson L, et al. **Scand J Work Environ Health** 1995;21 Suppl 2:111-4 (14 ref.)
The longevity of minewater pollution: a basis for decision-making. Younger PL. **Sci Total Environ** 1997 Feb 24;194-195:457-66 (26 ref.)

HISTORY

The industrial panopticon: mining and the medical construction of migrant African labour in South Africa, 1900-1950. Butchart A. **Soc Sci Med** 1996 Jan;42(2):185-97 (63 ref.)

MINIPIGS see **SWINE, MINIATURE**

MINISATELLITE REPEATS

see related
DNA FINGERPRINTING

Molecular genetics of triplet repeats: unstable expansion of triplet repeats as a new mechanism for neurodegenerative diseases. Tsuji S. **Intern Med** 1997 Jan;36(1):3-8 (36 ref.)
Etiology of (CAG)n triplet repeat neurodegenerative diseases such as Huntington's disease is connected to stimulation of glutamate receptors. Fischer KM. **Med Hypotheses** 1997 May;48(5):393-8 (66 ref.)

MINK ENCEPHALOPATHY VIRUS see **PRIONS**

MINNESOTA MULTIPHASIC PERSONALITY INVENTORY see **MMPI**

MINOCYCLINE

ADVERSE EFFECTS

Anaphylactoid symptoms due to oral minocycline [letter] Okano M, et al. **Acta Derm Venereol** 1996 Mar;76(2):164 (6 ref.)
Minocycline-induced intraoral pharmacogenic pigmentation: case reports and review of the literature. Westbury LW, et al. **J Periodontol** 1997 Jan;68(1):84-91 (78 ref.)
Minocycline related lupus. Masson C, et al. **J Rheumatol** 1996 Dec;23(12):2160-1 (7 ref.)
Minocycline-induced scleral pigmentation. Fraunfelder FT, et al. **Ophthalmology** 1997 Jun;104(6):936-8 (11 ref.)
[Acute hepatitis associated with treatment with minocycline (letter)] Bruguera M, et al. **Med Clin (Barc)** 1997 Apr 19; 108(15):596 (10 ref.) **(Spa)**

THERAPEUTIC USE

Should minocycline be used to treat rheumatoid arthritis? [see comments] Panush RS, et al. **Bull Rheum Dis** 1996 Apr;45(2):2-5 (33 ref.) Comment in: Bull Rheum Dis 1996 Dec;45(8):6-7.
TNP-470/minocycline/cytotoxic therapy: a systems approach to cancer therapy. Teicher BA, et al. **Eur J Cancer** 1996 Dec;32A(14):2461-6 (52 ref.)
[Study on the sclerosing agent for the treatment of simple renal cysts] Akiyama H, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Dec;87(12):1277-80 (18 ref.) (Eng. Abstr.) **(Jpn)**

MINOR HISTOCOMPATIBILITY ANTIGENS

Human minor histocompatibility antigens. Goulmy E. **Curr Opin Immunol** 1996 Feb;8(1):75-81 (77 ref.)

IMMUNOLOGY

Minor histocompatibility antigens: from T cell recognition to peptide identification [editorial] Goulmy E. **Hum Immunol** 1997 Apr 15;54(1):8-14 (63 ref.)
Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Goulmy E. **Immunol Rev** 1997 Jun;157:125-40 (165 ref.)

MINOR HISTOCOMPATIBILITY PEPTIDES see **MINOR HISTOCOMPATIBILITY ANTIGENS**

MINORITY GROUPS

Assessments of food-frequency questionnaires in minority populations. Coates RJ, et al. **Am J Clin Nutr** 1997 Apr; 65(4 Suppl):1108S-1115S (46 ref.)
Ageing in black and ethnic minorities: a challenge to service provision. Askham J. **Br J Hosp Med** 1996 Dec 11-1997 Jan 14;56(11):602-4 (14 ref.)
Geriatric gynecologic care of minorities. Haynes MO. **Clin Obstet Gynecol** 1996 Dec;39(4):946-58 (31 ref.)
Civil rights in a changing health care system. Rosenbaum S, et al. **Health Aff (Millwood)** 1997 Jan-Feb;16(1):90-105 (24 ref.)
Common health problems among minority elders. Bernard MA, et al. **J Am Diet Assoc** 1997 Jul;97(7):771-6 (39 ref.)
Faculty commitment: retaining minority nursing students in majority institutions. Campbell AR, et al. **J Nurs Educ** 1996 Oct;35(7):298-303 (28 ref.)
Issues in recruitment and retention of minority nursing students. Dowell MA. **J Nurs Educ** 1996 Oct;35(7):293-7 (43 ref.)
Cultural differences in beliefs and practices about pregnancy and childbearing. Garcia Coll C, et al. **Med Health R I** 1996 Jul;79(7):257-60 (36 ref.)
Inclusion of ethnic minorities in sarcopenia research: challenges and strategies. Hazuda HP. **Muscle Nerve Suppl** 1997;5:S27-31 (13 ref.)
Ethnic minority populations and mental health outcomes. Snowden LR. **New Dir Ment Health Serv** 1996 Fall; (71):79-87 (41 ref.)

PSYCHOLOGY

An integrative model for the study of developmental competencies in minority children. Garcia Coll C, et al. **Child Dev** 1996 Oct;67(5):1891-914 (165 ref.)
Issues and recommendations for the recruitment and retention of older ethnic minority adults into clinical research. Areán PA, et al. **J Consult Clin Psychol** 1996 Oct;64(5):875-80 (38 ref.)

STATISTICS & NUMERICAL DATA

The dilemma of factitious demographic distinctions in psychological research. Beutler LE, et al. **J Consult Clin Psychol** 1996 Oct;64(5):892-902 (50 ref.)

MIOSIS

ETIOLOGY

Pseudomyopia in a patient with blocked ventriculo-peritoneal shunt--a case report. Voon LW, et al. **Ann Acad Med Singapore** 1997 Mar;26(2):229-31 (15 ref.)

MIOTICS

see related
ADRENERGIC ANTAGONISTS
CHOLINESTERASE INHIBITORS
MUSCARINIC AGONISTS
PARASYMPATHOMIMETICS
SYMPATHOLYTICS

POISONING

Eye drops--the hidden poison. Jones AL, et al. **Scott Med J** 1996 Aug;41(4):110-2 (32 ref.)

THERAPEUTIC USE

The pilocarpine paradox [editorial; comment] Ritch R. **J Glaucoma** 1996 Aug;5(4):225-7 (33 ref.) Comment on: J Glaucoma 1996 Aug;5(4):228-32.

MIRROR WRITING see **DOMINANCE, CEREBRAL**

MISCARRIAGE see **ABORTION**

MISOPROSTOL

PHARMACOLOGY

NSAID-induced gastrointestinal damage. Epidemiology, risk and prevention, with an evaluation of the role of misoprostol. An Asia-Pacific perspective and consensus. Champion GD, et al. **Drugs** 1997 Jan;53(1):6-19 (112 ref.)

THERAPEUTIC USE

[Prevention and therapy of NSAID-induced ulcers: fact versus myth] Fried M, et al. **Schweiz Med Wochenschr** 1996 Sep 14;126(37):1569-72 (15 ref.) (Eng. Abstr.) **(Ger)**
[Is misoprostol effective in NSAID-induced gastrointestinal complications?] Stucki G, et al. **Schweiz Med Wochenschr** 1996 Sep 14;126(37):1573-8 (26 ref.) (Eng. Abstr.) **(Ger)**

MISSIONS, OFFICIAL MEDICAL see **MEDICAL MISSIONS, OFFICIAL**

MISTLETOE see **VISCUM**

MISUSE OF HEALTH SERVICES see **HEALTH SERVICES MISUSE**

MITE CONTROL see **TICK CONTROL**

MITE INFESTATIONS

DIAGNOSIS

[Animal mite-induced epizoonoses and their significance in dermatology] Beck W. **Hautarzt** 1996 Oct;47(10):744-8 (32 ref.) (Eng. Abstr.) **(Ger)**

MITES

Mite species of allergologic importance in Europe. Fernández-Caldas E. **Allergy** 1997 Apr;52(4):383-7 (56 ref.)
Domestic mites from an acarologic perspective. Spieksma FT. **Allergy** 1997 Apr;52(4):360-8 (71 ref.)
Prevention and nonpharmacologic treatment of mite allergy. Wickman M. **Allergy** 1997 Apr;52(4):369-73 (43 ref.)
Can house dust mite-triggered atopic dermatitis be alleviated using acaricides? Cameron MM. **Br J Dermatol** 1997 Jul; 137(1):1-8 (93 ref.)
Allergen avoidance. Custovic A, et al. **Br J Hosp Med** 1996 Oct 16-Nov 5;56(8):409-12 (26 ref.)
House dust mite allergy in Southern Africa--historical perspective and current status. Potter PC, et al. **Clin Exp Allergy** 1996 Feb;26(2):132-7 (26 ref.)
A new triad: sensitivity to aspirin, allergic rhinitis, and severe allergic reaction to ingested aeroallergens. Sánchez-Borges M, et al. **Cutis** 1997 Jun;59(6):311-4 (11 ref.)

ENZYMOLOGY

On the potential significance of the enzymatic activity of mite allergens to immunogenicity. Clues to structure and function revealed by molecular characterization. Robinson C, et al. **Clin Exp Allergy** 1997 Jan;27(1):10-21 (58 ref.)

IMMUNOLOGY

Expression of the house dust mite allergen Der p2 and

mutants in the baker's yeast Saccharomyces cerevisiae. Hakkaart GA, et al. **Adv Exp Med Biol** 1996;409:395–8 (5 ref.)

Recombinant mite allergens. New technologies for the management of patients with asthma. Chapman MD, et al. **Allergy** 1997 Apr;52(4):374–9 (34 ref.)

Measurement of mite allergen in the environment. Kuehr J. **Allergy** 1997 Apr;52(4):380–2 (22 ref.)

Allergic and nonallergic interactions between house dust mite allergens and airway mucosa. Roche N, et al. **Eur Respir J** 1997 Mar;10(3):719–26 (83 ref.)

Immunologic responses following respiratory sensitization to house dust mite allergens in mice. O'Brien R, et al. **Immunol Cell Biol** 1996 Apr;74(2):174–9 (23 ref.)

Critical evaluation of food and mite allergy in the management of atopic dermatitis. Hanifin JM. **J Dermatol** 1997 Aug;24(8):495–503 (46 ref.)

Patch test response to house dust mites is positive in children with atopic dermatitis and in their parents. Meglio P, et al. **J Investig Allergol Clin Immunol** 1996 May–Jun; 6(3):190–5 (33 ref.)

[Molecular biological analysis of house dust mite allergens] Okudaira H, et al. **Nippon Rinsho** 1996 Feb;54(2):466–71 (10 ref.) (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

[Symbiotic relationship between Orientia tsutsugamushi and vector mites] Urakami H, et al. **Nippon Saikingaku Zasshi** 1996 Feb;51(2):497–511 (78 ref.) **(Jpn)**

MITOCHONDRIA

Origin and evolution of mitochondria: what have we learnt from red algae? Leblanc C, et al. **Curr Genet** 1997 Mar; 31(3):193–207 (100 ref.)

Mitochondrial dysfunction in neurodegeneration. Cooper JM, et al. **J Bioenerg Biomembr** 1997 Apr;29(2):175–83 (113 ref.)

Treatment of mitochondrial disease. Taylor RW, et al. **J Bioenerg Biomembr** 1997 Apr;29(2):195–205 (88 ref.)

Mitochondrial implication in accidental and programmed cell death: apoptosis and necrosis. Zamzami N, et al. **J Bioenerg Biomembr** 1997 Apr;29(2):185–93 (75 ref.)

[Precursor targeting to mitochondria] Mihara K. **Seikagaku** 1996 Oct;68(10):1605–14 (22 ref.) **(Jpn)**

CHEMISTRY

Mitochondrial metabolite carrier family, topology, structure and functional properties: an overview. Sluse FE. **Acta Biochim Pol** 1996;43(2):349–60 (63 ref.)

Topogenesis of inner membrane proteins of mitochondria. Stuart RA, et al. **Trends Biochem Sci** 1996 Jul;21(7):261–7 (40 ref.)

DRUG EFFECTS

Mitochondrial injury. Lessons from the fialuridine trial. Honkoop P, et al. **Drug Saf** 1997 Jul;17(1):1–7 (37 ref.)

TaClo as a neurotoxic lead: improved synthesis, stereochemical analysis, and inhibition of the mitochondrial respiratory chain. Bringmann G, et al. **J Neural Transm Suppl** 1995;46:245–54 (19 ref.)

[Value of protecting mitochondrial functions during treatment with cyclosporin A] Simon N, et al. **Therapie** 1997 Mar–Apr;52(2):151–4 (30 ref.) (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

Variable peroxisomal and mitochondrial targeting of alanine: glyoxylate aminotransferase in mammalian evolution and disease. Danpure CJ. **Bioessays** 1997 Apr;19(4):317–26 (69 ref.)

The role of protein degradation in mitochondrial function and biogenesis. Rep M, et al. **Curr Genet** 1996 Nov; 30(5):367–80 (170 ref.)

The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. McGarry JD, et al. **Eur J Biochem** 1997 Feb 15;244(1):1–14 (113 ref.)

Plant mitochondrial RNase P. Marchfelder A. **Mol Biol Rep** 1995–96;22(2–3):151–6 (29 ref.)

GENETICS

Genomic evolution drives the evolution of the translation system. Andersson SG, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):775–87 (102 ref.)

Relocation of the unusual VAR1 gene from the mitochondrion to the nucleus. Sanchirico M, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):987–95 (46 ref.)

Transmission of mitochondrial DNA--playing favorites? Boore JL. **Bioessays** 1997 Sep;19(9):751–3 (30 ref.)

Response to "Germ-line therapy to cure mitochondrial disease: protocol and ethics of in vitro ovum nuclear transplantation" by Donald S. Rubenstein, David C. Thomasma, Eric A. Schon, and Michael J. Zinaman (CQ Vol 4, No 3). Bacchetta MD, et al. **Camb Q Healthc Ethics** 1996 Summer;5(3):450–7 (10 ref.)

Mitochondrial fusion promoting plasmid. Takano H, et al. **Cell Struct Funct** 1997 Jun;22(3):299–308 (43 ref.)

Mitochondrial distribution and inheritance. Berger KH, et al. **Experientia** 1996 Dec 15;52(12):1111–6 (57 ref.)

RNA editing in metazoan mitochondria: staying fit without sex. Börner GV, et al. **FEBS Lett** 1997 Jun 16;409(3):320–4 (34 ref.)

Age-associated alterations of the mitochondrial genome. Lee CM, et al. **Free Radic Biol Med** 1997;22(7):1259–69 (118 ref.)

Mitochondrial control of apoptosis. Kroemer G, et al. **Immunol Today** 1997 Jan;18(1):44–51 (71 ref.)

Nuclear control of respiratory chain expression in mammalian cells. Scarpulla RC. **J Bioenerg Biomembr** 1997 Apr; 29(2):109–19 (82 ref.)

Disorders of nuclear–mitochondrial intergenomic signalling. Zeviani M, et al. **J Bioenerg Biomembr** 1997 Apr; 29(2):121–30 (68 ref.)

Genetic and functional changes in mitochondria associated with aging. Ozawa T. **Physiol Rev** 1997 Apr;77(2):425–64 (440 ref.)

[Mitochondrial cytopathies (editorial)] Rötig A. **Pathol Biol (Paris)** 1996 Apr;44(4):229–31 (11 ref.) **(Fre)**

[The role of nuclear genome in regulation of mitochondrial function in Saccharomyces cerevisiae] Boguta M. **Postepy Biochem** 1996;42(3):259–68 (84 ref.) **(Pol)**

[MtDNA-like sequences and the coordination of the functioning of mammalian nuclear and mitochondrial genomes] Maliarchuk BA. **Tsitol Genet** 1997 Mar–Apr; 31(2):53–61 (51 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

The ATP-regulated K+ channel in mitochondria: five years after its discovery. Szewczyk A. **Acta Biochim Pol** 1996; 43(4):713–9 (38 ref.)

Lysosomal proteinosis based on decreased degradation of a specific protein, mitochondrial ATP synthase subunit C: Batten disease. Ezaki J, et al. **Adv Exp Med Biol** 1996; 389:121–8 (31 ref.)

GSH transport in mitochondria: defense against TNF-induced oxidative stress and alcohol-induced defect. Fernández-Checa JC, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):G7–17 (85 ref.)

Protein import into mitochondria. Neupert W. **Annu Rev Biochem** 1997;66:863–917 (501 ref.)

Mammalian mitochondrial beta-oxidation. Eaton S, et al. **Biochem J** 1996 Dec 1;320 (Pt 2):345–57 (232 ref.)

Batten disease and mitochondrial pathways of proteolysis. Tanner AJ, et al. **Biochem Mol Med** 1996 Feb;57(1):1–9 (63 ref.)

Targeting proteins to mitochondria: is there a role for mRNA localization? Lightowlers RN, et al. **Biochem Soc Trans** 1996 May;24(2):527–31 (41 ref.)

Developmental regulation of respiratory activity and protein import in plant mitochondria. Wood CK, et al. **Biochem Soc Trans** 1996 Aug;24(3):746–9 (23 ref.)

What is the driving force for protein import into mitochondria? Horst M, et al. **Biochim Biophys Acta** 1997 Jan 16;1318(1–2):71–8 (72 ref.)

Control of gene expression by base deamination: the case of RNA editing in wheat mitochondria. Blanc V, et al. **Biochimie** 1996;78(6):511–7 (50 ref.)

Mechanisms of tRNA import into yeast mitochondria: an overview. Tarassov IA, et al. **Biochimie** 1996;78(6):502–10 (55 ref.)

Mitochondrial genetics and human disease. Grossman LI, et al. **Bioessays** 1996 Dec;18(12):983–91 (77 ref.)

Role of the mitochondrial permeability transition pore in apoptosis. Hirsch T, et al. **Biosci Rep** 1997 Feb;17(1):67–76 (60 ref.)

Hyperthyroidism and mitochondrial uncoupling. Luvisetto S. **Biosci Rep** 1997 Feb;17(1):17–21 (39 ref.)

The physiological significance of mitochondrial proton leak in animal cells and tissues. Rolfe DF, et al. **Biosci Rep** 1997 Feb;17(1):9–16 (36 ref.)

Superoxide production by the mitochondrial respiratory chain. Turrens JF. **Biosci Rep** 1997 Feb;17(1):3–8 (38 ref.)

The role of reactive oxygen species in mitochondrial permeability transition. Vercesi AE, et al. **Biosci Rep** 1997 Feb;17(1):43–52 (74 ref.)

Mechanisms of protein import into mitochondria. Stuart RA, et al. **Cell Struct Funct** 1996 Oct;21(5):403–6 (37 ref.)

Dissection of protein translocation across the mitochondrial outer and inner membranes. Brunner M, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:619–27 (46 ref.)

Import and folding of proteins by mitochondria. Lithgow T, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:609–17 (75 ref.)

The role of protein degradation in mitochondrial function and biogenesis. Rep M, et al. **Curr Genet** 1996 Nov; 30(5):367–80 (170 ref.)

Mitochondria, free radicals, and neurodegeneration. Beal MF. **Curr Opin Neurobiol** 1996 Oct;6(5):661–6 (45 ref.)

The GABA network and the pathogenesis of IDDM [see comments] Degli Esposti M, et al. **Diabetologia** 1997 Mar; 40(3):352–6 (51 ref.) Comment in: Diabetologia 1997 Mar;40(3):357–61.

Contact sites and transport in mitochondria. Moynagh PN. **Essays Biochem** 1995;30:1–14 (35 ref.)

Thyroid hormone and gene expression in the regulation of mitochondrial respiratory function. Pillar TM, et al. **Eur J Endocrinol** 1997 Mar;136(3):231–9 (75 ref.)

Mitochondrial distribution and inheritance. Berger KH, et al. **Experientia** 1996 Dec 15;52(12):1111–6 (57 ref.)

Translational control of endogenous and recoded nuclear genes in yeast mitochondria: regulation and membrane targeting. Fox TD. **Experientia** 1996 Dec 15;52(12):1130–5 (63 ref.)

Regulated protein degradation in mitochondria. Langer T, et al. **Experientia** 1996 Dec 15;52(12):1069–76 (62 ref.)

The mitochondrial processing peptidase: function and specificity. Luciano P, et al. **Experientia** 1996 Dec 15; 52(12):1077–82 (70 ref.)

Molecular genetics of the peptidyl transferase center and the unusual Var1 protein in yeast mitochondrial ribosomes. Mason TL, et al. **Experientia** 1996 Dec 15;52(12):1148–57 (66 ref.)

Cytosolic factors in mitochondrial protein import. Mihara K, et al. **Experientia** 1996 Dec 15;52(12):1063–8 (30 ref.)

Mitochondrial fatty acid synthesis: a relic of endosymbiontic origin and a specialized means for respiration. Schneider R, et al. **FEBS Lett** 1997 May 5;407(3):249–52 (40 ref.)

Cytochromes in the respiratory chain of helminth mitochondria. Kita K, et al. **Int J Parasitol** 1997 Jun; 27(6):617–30 (87 ref.)

The role of molecular chaperones in mitochondrial protein import and folding. Ryan MT, et al. **Int Rev Cytol** 1997; 174:127–93 (382 ref.)

Escape and migration of nucleic acids between chloroplasts, mitochondria, and the nucleus. Thorsness PE, et al. **Int Rev Cytol** 1996;165:207–34 (112 ref.)

Anion channels of the inner membrane of mammalian and yeast mitochondria. Ballarin C, et al. **J Bioenerg Biomembr** 1996 Apr;28(2):125–30 (30 ref.)

The permeability transition pore as a mitochondrial calcium release channel: a critical appraisal. Bernardi P, et al. **J Bioenerg Biomembr** 1996 Apr;28(2):131–8 (67 ref.)

Coupling chemical energy by the hsp70/tim44 complex to drive protein translocation into mitochondria. Cyr DM. **J Bioenerg Biomembr** 1997 Feb;29(1):29–34 (32 ref.)

Control of mitochondrial and cellular respiration by oxygen. Gnaiger E, et al. **J Bioenerg Biomembr** 1995 Dec; 27(6):583–96 (62 ref.)

The first steps of protein import into mitochondria. Haucke V, et al. **J Bioenerg Biomembr** 1997 Feb;29(1):11–7 (56 ref.)

Characterization and function of the mitochondrial outer membrane peptide-sensitive channel. Henry JP, et al. **J Bioenerg Biomembr** 1996 Apr;28(2):101–8 (31 ref.)

Importance of mitochondrial transmembrane processes in human mitochondriopathies. Huizing M, et al. **J Bioenerg Biomembr** 1996 Apr;28(2):109–14 (62 ref.)

The mitochondrial protein import pathway: are precursors imported through membrane channels? Jensen RE, et al. **J Bioenerg Biomembr** 1997 Feb;29(1):3–10 (77 ref.)

Perspectives on the mitochondrial multiple conductance channel. Kinnally KW, et al. **J Bioenerg Biomembr** 1996 Apr;28(2):115–23 (72 ref.)

Mitochondrial channels revisited. Mannella CA. **J Bioenerg Biomembr** 1996 Apr;28(2):89–91 (42 ref.)

Permeability transition pore of the inner mitochondrial membrane can operate in two open states with different selectivities. Novgorodov SA, et al. **J Bioenerg Biomembr** 1996 Apr;28(2):139–46 (56 ref.)

Recognition and binding of mitochondrial presequences during the import of proteins into mitochondria. Roise D. **J Bioenerg Biomembr** 1997 Feb;29(1):19–27 (98 ref.)

ATP-regulated K+ channel in mitochondria: pharmacology and function. Szewczyk A, et al. **J Bioenerg Biomembr** 1996 Apr;28(2):147–52 (41 ref.)

Homologous and heterologous interactions between hexokinase and mitochondrial porin: evolutionary implications. Wilson JE. **J Bioenerg Biomembr** 1997 Feb; 29(1):97–102 (38 ref.)

Is there VDAC in cell compartments other than the mitochondria? Yu WH, et al. **J Bioenerg Biomembr** 1996 Apr;28(2):93–100 (49 ref.)

The protein import system of mitochondria. Schatz G. **J Biol Chem** 1996 Dec 13;271(50):31763–6 (42 ref.)

Function of metal–ion homeostasis in the cell division cycle, mitochondrial protein processing, sensitivity to mycobacterial infection and brain function. Supek F, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):321–30 (73 ref.)

Neuropathology and pathogenesis of mitochondrial diseases. Brown GK, et al. **J Inherit Metab Dis** 1996;19(4):553–72 (76 ref.)

Nitric oxide-mediated mitochondrial damage in the brain: mechanisms and implications for neurodegenerative diseases. Bolaños JP, et al. **J Neurochem** 1997 Jun; 68(6):2227–40 (173 ref.)

Sideroblastic anemia: a mitochondrial disorder. Bridges KR. **J Pediatr Hematol Oncol** 1997 Jul–Aug;19(4):274–8 (51 ref.)

The kidney in mitochondrial cytopathies [editorial] Niaudet P, et al. **Kidney Int** 1997 Apr;51(4):1000–7 (100 ref.)

Mitochondrial diseases and aging. Papa S, et al. **Mol Aspects Med** 1996 Dec;17(6):513–63 (254 ref.)

tRNA processing in human mitochondrial disorders. Masucci JP, et al. **Mol Biol Rep** 1995–96;22(2–3):187–93 (78 ref.)

Obesity research springs a proton leak [news; comment] Flier JS, et al. **Nat Genet** 1997 Mar;15(3):223–4 (17 ref.) Comment on: Nat Genet 1997 Mar;15(3):269–72.

Renal failure from mitochondrial cytopathies. Buemi M, et al. **Nephron** 1997;76(3):249–53 (23 ref.)

Measurement of cytochrome oxidase and mitochondrial energetics by near-infrared spectroscopy. Cooper CE, et al. **Philos Trans R Soc Lond B Biol Sci** 1997 Jun 29; 352(1354):669–76 (62 ref.)

Function of coenzyme Q in the cell: some biochemical and physiological properties. Rauchová H, et al. **Physiol Res** 1995;44(4):209–16 (63 ref.)

MITOCHONDRIA

Regulation of gene expression in plant mitochondria. Binder S, et al. **Plant Mol Biol** 1996 Oct;32(1-2):303-14 (78 ref.)
RNA editing in plant mitochondria and chloroplasts. Maier RM, et al. **Plant Mol Biol** 1996 Oct;32(1-2):343-65 (113 ref.)
Protein import into plant mitochondria. Whelan J, et al. **Plant Mol Biol** 1997 Mar;33(5):771-89 (195 ref.)
Eubacterial signal transduction by ligands of the mammalian peripheral benzodiazepine receptor complex [see comments] Donohue TJ. **Proc Natl Acad Sci U S A** 1997 May 13;94(10):4821-2 (18 ref.) Comment in: Proc Natl Acad Sci U S A 1997 May 13;94(10):5101-6.
The mitochondrial uncoupling protein: structural and genetic studies. Ricquier D, et al. **Prog Nucleic Acid Res Mol Biol** 1997;56:83-108 (81 ref.)
Role of uncoupled and non-coupled oxidations in maintenance of safely low levels of oxygen and its one-electron reductants. Skulachev VP. **Q Rev Biophys** 1996 May;29(2):169-202 (166 ref.)
Mitochondrial inner membrane channels in yeast and mammals. Ballarin C, et al. **Soc Gen Physiol Ser** 1996; 51:155-71 (51 ref.)
The ADP/ATP transport system: a paradigm of metabolite transport in mitochondria. Brandolin G, et al. **Soc Gen Physiol Ser** 1996;51:173-85 (48 ref.)
Regulation of mitochondrial cholesterol metabolism. Martínez F, et al. **Subcell Biochem** 1997;28:205-34 (152 ref.)
Compartmentation of glutathione: implications for the study of toxicity and disease. Smith CV, et al. **Toxicol Appl Pharmacol** 1996 Sep;140(1):1-12 (82 ref.)
Highways for protein delivery to the mitochondria [see comments] Lithgow T, et al. **Trends Biochem Sci** 1997 Apr; 22(4):110-3 (30 ref.) Comment in: Trends Biochem Sci 1997 Aug;22(8):290.
RNA turnover and the control of mitochondrial gene expression. Margossian SP, et al. **Trends Biochem Sci** 1996 Oct;21(10):392-6 (36 ref.)
[Value of protecting mitochondrial functions during treatment with cyclosporin A] Simon N, et al. **Therapie** 1997 Mar-Apr;52(2):151-4 (30 ref.) (Eng. Abstr.) **(Fre)**
[Disorders of organic acid metabolism] Tsuda M. **Ryoikibetsu Shokogun Shirizu** 1996;(15):81-4 (11 ref.) **(Jpn)**
[Cytoplasmic chaperones in precursor targeting to mitochondria] Mihara K. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(7):868-74 (16 ref.) **(Jpn)**
[Mitochondrial transport of nucleic acids. Participation of the benzodiazepine receptor] Zorov DB. **Biokhimiia** 1996 Jul;61(7):1320-32 (88 ref.) (Eng. Abstr.) **(Rus)**
[RNA import into mitochondria] Kazakova EA, et al. **Mol Biol (Mosk)** 1996 Jul-Aug;30(4):748-58 (48 ref.) **(Rus)**

PATHOLOGY

Mitochondrial disorders in neuro-ophthalmology. Riordan-Eva P, et al. **Curr Opin Neurol** 1996 Feb;9(1):1-4 (20 ref.)

PHYSIOLOGY

Mitochondrial oxidative phosphorylation changes in the life span. Molecular aspects and physiopathological implications. Papa S. **Biochim Biophys Acta** 1996 Sep 12; 1276(2):87-105 (243 ref.)
A proposed refinement of the mitochondrial free radical theory of aging. de Grey AD. **Bioessays** 1997 Feb; 19(2):161-6 (32 ref.)
Reactive oxygen and nitrogen species regulate mitochondrial Ca2+ homeostasis and respiration. Richter C. **Biosci Rep** 1997 Feb;17(1):53-66 (106 ref.)
The Tom and Tim machine. Pfanner N, et al. **Curr Biol** 1997 Feb 1;7(2):R100-3 (23 ref.)
Oxidative stress and mitochondrial dysfunction in neurodegeneration. Schapira AH. **Curr Opin Neurol** 1996 Aug;9(4):260-4 (49 ref.)
Thyroid hormone and gene expression in the regulation of mitochondrial respiratory function. Pillar TM, et al. **Eur J Endocrinol** 1997 Mar;136(3):231-9 (75 ref.)
Role of mitochondria-rich cells in epithelial chloride uptake. Larsen EH, et al. **Exp Physiol** 1996 May;81(3):525-34 (25 ref.)
RNA editing in metazoan mitochondria: staying fit without sex. Börner GV, et al. **FEBS Lett** 1997 Jun 16;409(3):320-4 (34 ref.)
Mitochondria and programmed cell death: back to the future. Petit PX, et al. **FEBS Lett** 1996 Oct 28;396(1):7-13 (85 ref.)
Mitochondrial control of apoptosis. Kroemer G, et al. **Immunol Today** 1997 Jan;18(1):44-51 (71 ref.)
VDAC, a channel in the outer mitochondrial membrane. Colombini M, et al. **Ion Channels** 1996;4:169-202 (75 ref.)
Lactic acidosis and other mitochondrial disorders. Stacpoole PW. **Metabolism** 1997 Mar;46(3):306-21 (220 ref.)
The role of mitochondria in aging [editorial] Kalous M, et al. **Physiol Res** 1996;45(5):351-9 (77 ref.)
Genetic and functional changes in mitochondria associated with aging. Ozawa T. **Physiol Rev** 1997 Apr;77(2):425-64 (440 ref.)
Clinical spectrum of mitochondrial diseases. Fadic R, et al. **Semin Neurol** 1996 Mar;16(1):11-20 (40 ref.)
Structure and function of the yeast outer mitochondrial membrane channel, VDAC. Forte M, et al. **Soc Gen Physiol Ser** 1996;51:145-54 (19 ref.)

ULTRASTRUCTURE

The Tom and Tim machine. Pfanner N, et al. **Curr Biol** 1997 Feb 1;7(2):R100-3 (23 ref.)
Mitochondria-rich, proton-secreting epithelial cells. Brown D, et al. **J Exp Biol** 1996 Nov;199 (Pt 11):2345-58 (156 ref.)
The physical chemical basis for preserving cell structure for electron microscopy at the molecular level and available preparatory methods. Sjöstrand FS. **J Submicrosc Cytol Pathol** 1997 Apr;29(2):157-72 (27 ref.)
Mammalian oocyte organelles with special reference to pleomorphic mitochondria and vacuole formation in marsupials. Ullmann SL, et al. **Reprod Fertil Dev** 1996; 8(4):491-508 (117 ref.)

MITOCHONDRIA, HEART

Mitochondrial cardiomyopathy: molecular and biochemical analysis. Marin-Garcia J, et al. **Pediatr Cardiol** 1997 Jul-Aug;18(4):251-60 (84 ref.)

ENZYMOLOGY

Why are ATP depletion rates in situ in ischemic myocardium so much lower than one might predict from the activity of the mitochondrial ATPase in sonicated heart mitochondria? [editorial] Rouslin W, et al. **J Mol Cell Cardiol** 1997 Jun;29(6):1505-10 (13 ref.)

GENETICS

[Mitochondrial cardiomyopathies: a new entity in cardiology research and diagnosis] Bernucci P, et al. **G Ital Cardiol** 1996 Sep;26(9):1031-7 (31 ref.) **(Ita)**

PHYSIOLOGY

The role of mitochondria in ischemic heart disease. Ferrari R. **J Cardiovasc Pharmacol** 1996;28 Suppl 1:S1-10 (80 ref.)

MITOCHONDRIA, LIVER

DRUG EFFECTS

Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines. Fromenty B, et al. **J Hepatol** 1997;26 Suppl 2:43-53 (35 ref.)

IMMUNOLOGY

Antimitochondrial antibodies in primary biliary cirrhosis. Leung PS, et al. **Semin Liver Dis** 1997 Feb;17(1):61-9 (72 ref.)

METABOLISM

Regulation of energy metabolism in liver. Soboll S. **J Bioenerg Biomembr** 1995 Dec;27(6):571-82 (92 ref.)
Mitochondrial ammonia metabolism and the proton-neutral theory of hepatic ammonia detoxication. Campbell JW. **J Exp Zool** 1997 Aug 1;278(5):308-21 (121 ref.)
Microvesicular steatosis and steatohepatitis: role of mitochondrial dysfunction and lipid peroxidation. Fromenty B, et al. **J Hepatol** 1997;26 Suppl 1:13-22 (54 ref.)

MITOCHONDRIA, MUSCLE

see related
MITOCHONDRIAL ENCEPHALOMYOPATHIES
MITOCHONDRIAL MYOPATHIES

ENZYMOLOGY

31P-NMR-measured creatine kinase reaction flux in muscle: a caveat! Wallimann T. **J Muscle Res Cell Motil** 1996 Apr; 17(2):177-81 (30 ref.)

METABOLISM

Is the mitochondrial benzodiazepine receptor involved in the control of airway smooth muscle tone? Pelaia G, et al. **Gen Pharmacol** 1997 Apr;28(4):495-8 (18 ref.)

PHYSIOLOGY

Mitochondrial biogenesis in skeletal muscle in response to endurance exercises. Freyssenet D, et al. **Arch Physiol Biochem** 1996;104(2):129-41 (114 ref.)

MITOCHONDRIAL CONTRACTION see **MITOCHONDRIA**

MITOCHONDRIAL DNA see **DNA, MITOCHONDRIAL**

MITOCHONDRIAL ENCEPHALOMYOPATHIES

Mitochondrial encephalomyopathy with elderly onset of stroke-like episodes [see comments] Minamoto H, et al. **Intern Med** 1996 Dec;35(12):991-5 (13 ref.) Comment in: Intern Med 1996 Dec;35(12):924.
[Mitochondrial disorders] Suzuki M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):78-80 (6 ref.) **(Jpn)**

CLASSIFICATION

Respiratory chain encephalomyopathies: a diagnostic classification. Walker UA, et al. **Eur Neurol** 1996; 36(5):260-7 (74 ref.)

DIAGNOSIS

Mitochondrial disorders. Schapira AH. **Curr Opin Neurol** 1997 Feb;10(1):43-7 (31 ref.)
Respiratory chain encephalomyopathies: a diagnostic classification. Walker UA, et al. **Eur Neurol** 1996; 36(5):260-7 (74 ref.)
Mitochondrial encephalopathies. Maertens P. **Semin Pediatr Neurol** 1996 Dec;3(4):279-97 (132 ref.)
[Diagnosis and therapy of mitochondriopathies] Sperl W. **Wien Klin Wochenschr** 1997 Feb 14;109(3):93-9 (68 ref.) (Eng. Abstr.) **(Ger)**
[Mitochondrial encephalopathies: clinical considerations] DiMauro S. **Rev Neurol** 1997 Jan;25(137):126-30 (11 ref.) **(Spa)**

GENETICS

Cellular models for pathogenesis in mitochondrial diseases [editorial] Di Donato S. **Curr Opin Neurol** 1996 Dec; 9(6):469-72 (27 ref.)
Fatty acid mitochondrial beta-oxidation and hypoglycaemia in children. Taroni F, et al. **Curr Opin Neurol** 1996 Dec; 9(6):477-85 (88 ref.)
Disorders of mitochondria and related metabolism. Zeviani M, et al. **Curr Opin Neurol** 1997 Apr;10(2):160-7 (99 ref.)
Mitochondrial encephalomyopathies: what next? DiMauro S. **J Inherit Metab Dis** 1996;19(4):489-503 (81 ref.)
[Mitochondrial encephalomyopathies: 3243 mutation as a central matter] Goto Y, et al. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1425-6 (4 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Mitochondria, free radicals, and neurodegeneration. Beal MF. **Curr Opin Neurobiol** 1996 Oct;6(5):661-6 (45 ref.)
Mitochondrial disorders in neuro-ophthalmology. Riordan-Eva P, et al. **Curr Opin Neurol** 1996 Feb;9(1):1-4 (20 ref.)

PHYSIOPATHOLOGY

Movement disorders and mitochondrial dysfunction. Hanna MG, et al. **Curr Opin Neurol** 1997 Aug;10(4):351-6 (56 ref.)
Clinical spectrum of mitochondrial diseases. Fadic R, et al. **Semin Neurol** 1996 Mar;16(1):11-20 (40 ref.)

MITOCHONDRIAL MYOPATHIES

Mitochondrial cardiomyopathy: molecular and biochemical analysis. Marin-Garcia J, et al. **Pediatr Cardiol** 1997 Jul-Aug;18(4):251-60 (84 ref.)

DIAGNOSIS

Mitochondrial disorders. Schapira AH. **Curr Opin Neurol** 1997 Feb;10(1):43-7 (31 ref.)
[Diagnosis and therapy of mitochondriopathies] Sperl W. **Wien Klin Wochenschr** 1997 Feb 14;109(3):93-9 (68 ref.) (Eng. Abstr.) **(Ger)**
[Mitochondrial cardiomyopathies: a new entity in cardiology research and diagnosis] Bernucci P, et al. **G Ital Cardiol** 1996 Sep;26(9):1031-7 (31 ref.) **(Ita)**

ETIOLOGY

Mitochondrial disorders. Zeviani M, et al. **Mol Hum Reprod** 1997 Feb;3(2):133-48 (170 ref.)

GENETICS

Mitochondrial genetics and human disease. Grossman LI, et al. **Bioessays** 1996 Dec;18(12):983-91 (77 ref.)
New genetics of mitochondrial DNA diseases. Poulton J. **Br J Hosp Med** 1996 Jun 5-18;55(11):712-6 (24 ref.)
Mitochondrial DNA defects: a widening clinical spectrum of disorders [editorial] Sherratt EJ, et al. **Clin Sci (Colch)** 1997 Mar;92(3):225-35 (93 ref.)
Mitochondrial disorders [see comments] Moraes CT. **Curr Opin Neurol** 1996 Oct;9(5):369-74 (49 ref.) Comment in: Curr Opin Neurol 1996 Oct;9(5):367-8.
Disorders of mitochondria and related metabolism. Zeviani M, et al. **Curr Opin Neurol** 1997 Apr;10(2):160-7 (99 ref.)
Protean manifestations of mitochondrial diseases: a minireview. Kerr DS. **J Pediatr Hematol Oncol** 1997 Jul-Aug;19(4):279-86 (31 ref.)
Mitochondrial diseases and aging. Papa S, et al. **Mol Aspects Med** 1996 Dec;17(6):513-63 (254 ref.)
tRNA processing in human mitochondrial disorders. Masucci JP, et al. **Mol Biol Rep** 1995-96;22(2-3):187-93 (78 ref.)
The other human genome: mitochondrial DNA and disease [see comments] Johns DR. **Nat Med** 1996 Oct;2(10):1065-8 (20 ref.) Comment in: Nat Med 1997 Feb;3(2):124-5.
Metabolic myopathies. Tein I. **Semin Pediatr Neurol** 1996 Jun;3(2):59-98 (357 ref.)
[Mitochondrial cytopathies: identification of responsible nuclear genes] Paquis V. **Arch Pediatr** 1996 Sep;3(9):915-6 (6 ref.) **(Fre)**

[Mitochondrial anomalies in oculopharyngeal muscular dystrophy] de Seze J, et al. **Rev Neurol (Paris)** 1997 Jun; 153(5):335–8 (19 ref.) (Eng. Abstr.) **(Fre)**
[Mitochondrial cardiomyopathies: a new entity in cardiology research and diagnosis] Bernucci P, et al. **G Ital Cardiol** 1996 Sep;26(9):1031–7 (31 ref.) **(Ita)**
[Oxidative damage of mitochondrial DNA associated with degenerative diseases and aging] Jurgowiak M, et al. **Postepy Biochem** 1997;43(1):30–40 (97 ref.) **(Pol)**
[Molecular genetics of mitochondrial cytopathologies] Arenas J, et al. **Neurologia** 1995 Dec;10 Suppl 1:44–9 (19 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Mitochondrial disorders in neuro–ophthalmology. Riordan–Eva P, et al. **Curr Opin Neurol** 1996 Feb;9(1):1–4 (20 ref.)
Importance of mitochondrial transmembrane processes in human mitochondriopathies. Huizing M, et al. **J Bioenerg Biomembr** 1996 Apr;28(2):109–14 (62 ref.)
Oxidative metabolism in muscle. Ferrari M, et al. **Philos Trans R Soc Lond B Biol Sci** 1997 Jun 29; 352(1354):677–83 (72 ref.)

PHYSIOPATHOLOGY

Renal involvement in mitochondrial cytopathies [see comments] Niaudet P, et al. **Pediatr Nephrol** 1996 Jun; 10(3):368–73 (81 ref.) Comment in: Pediatr Nephrol 1997 Jun;11(3):386.

THERAPY

Gene therapy of mitochondrial diseases using human cytoplasts. Kagawa Y, et al. **Gene Ther** 1997 Jan;4(1):6–10 (28 ref.)

MITOCHONDRIAL SWELLING

PHYSIOLOGY

Swelling–activated organic osmolyte channels. Kirk K. **J Membr Biol** 1997 Jul 1;158(1):1–16 (132 ref.)

MITOGEN RECEPTORS see **RECEPTORS, MITOGEN**

MITOGENIC FACTORS, LYMPHOCYTE see **INTERLEUKIN–2**

MITOGENS

see related
RECEPTORS, MITOGEN

CHEMISTRY

Structurally related receptors and antagonists compete for secreted Wnt ligands. Moon RT, et al. **Cell** 1997 Mar 21; 88(6):725–8 (16 ref.)
Biochemical and mitogenic properties of the heparin–binding growth factor HARP. Laaroubi K, et al. **Prog Growth Factor Res** 1995;6(1):25–34 (49 ref.)

GENETICS

Connective tissue growth factor. Friend or foe? Oemar BS, et al. **Arterioscler Thromb Vasc Biol** 1997 Aug;17(8):1483–9 (40 ref.)

METABOLISM

[MAP kinases and their role in regulation of protein level, subunit composition and degree of phosphorylation of transcription factor AP–1] Biedermann IW. **Postepy Biochem** 1996;42(3):244–52 (57 ref.) **(Pol)**

PHARMACOLOGY

MAP kinases in mitogenesis and development. Ferrell JE Jr. **Curr Top Dev Biol** 1996;33:1–60 (350 ref.)
Hepatoprotection by agents which modulate macrophage activity may be mediated by their mitogenic properties. Barriault C, et al. **Drug Metab Rev** 1997 Feb–May; 29(1–2):397–411 (60 ref.)

PHYSIOLOGY

A new role for an old molecule: serotonin as a mitogen. Fanburg BL, et al. **Am J Physiol** 1997 May;272(5 Pt 1):L795–806 (156 ref.)
Logical analysis of timing–dependent receptor signalling specificity: application to the insulin receptor metabolic and mitogenic signalling pathways. Shymko RM, et al. **Biochem J** 1997 Sep 1;326 (Pt 2):463–9 (51 ref.)

TOXICITY

Mitogenic actions of peroxidase proliferators: involvement of protein kinase C and tumor necrosis factor alpha. Bojes HK, et al. **Drug Metab Rev** 1997 Feb–May;29(1–2):235–60 (71 ref.)

MITOGENS, ENDOGENOUS see **GROWTH SUBSTANCES**

MITOMYCIN C

ADMINISTRATION & DOSAGE

[Filtering glaucoma operations. Can growth factor blockers replace antimetabolites?] Mietz H. **Ophthalmologe** 1997 Mar;94(3):242–7 (64 ref.) **(Ger)**

ADVERSE EFFECTS

Mitomycin–C induced hemolytic uremic syndrome: a case report and literature review. Wu DC, et al. **Jpn J Clin Oncol** 1997 Apr;27(2):115–8 (27 ref.)

PHARMACOLOGY

[DT–diaphorase] Mikami K, et al. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1606–10 (22 ref.) (Eng. Abstr.) **(Jpn)**
[gamma–Glutamylcysteine synthetase and chemosensitivity] Nishio K, et al. **Gan To Kagaku Ryoho** 1997 Feb; 24(4):418–23 (10 ref.) (Eng. Abstr.) **(Jpn)**

MITOSIS

see related
MATURATION–PROMOTING FACTOR
MITOGENS

A hypothesis to explain why translation inhibitors stabilize mRNAs in mammalian cells: mRNA stability and mitosis. Ross J. **Bioessays** 1997 Jun;19(6):527–9 (18 ref.)
Untangling the role of DNA topoisomerase II in mitotic chromosome structure and function. Warburton PE, et al. **Bioessays** 1997 Feb;19(2):97–9 (44 ref.)
Calcium, BOBs, QEDs, microdomains and a cellular decision: control of mitotic cell division in sand dollar blastomeres. Silver RB. **Cell Calcium** 1996 Aug;20(2):161–79 (99 ref.)
Oncoprotein signalling and mitosis. Laird AD, et al. **Cell Signal** 1997 May–Jun;9(3–4):249–55 (126 ref.)
Mitosis in the human embryo: the vital role of the sperm centrosome (centriole). Sathananthan AH. **Histol Histopathol** 1997 Jul;12(3):827–56 (86 ref.)
Intermediate filament aggregates in mitoses of primary cutaneous neuroendocrine (Merkel cell) carcinoma. Alvarez–Gago T, et al. **Histopathology** 1996 Apr; 28(4):349–55 (30 ref.)
Mini review: mitosis and the spindle pole body in Saccharomyces cerevisiae. Sobel SG. **J Exp Zool** 1997 Feb 1;277(2):120–38 (168 ref.)
Unresolvable endings: defective telomeres and failed separation [comment] Hawley RS. **Science** 1997 Mar 7; 275(5305):1441–3 (9 ref.) Comment on: Science 1997 Mar 7;275(5305):1478–81.
How cells get the right chromosomes. Nicklas RB. **Science** 1997 Jan 31;275(5300):632–7 (45 ref.)
Mitotic repression of the transcriptional machinery. Gottesfeld JM, et al. **Trends Biochem Sci** 1997 Jun; 22(6):197–202 (51 ref.)
A quantitative model for the cdc2 control of S phase and mitosis in fission yeast. Stern B, et al. **Trends Genet** 1996 Sep;12(9):345–50 (36 ref.)
Illuminating the force: bacterial mitosis? Harry EJ. **Trends Microbiol** 1997 Aug;5(8):295–7 (18 ref.)
[Execution of M–phase by Cdc2 kinase] Kishimoto T. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1839–46 (32 ref.) **(Jpn)**
[Functions of centromere protein B (CENP–B) and control of metaphase progression] Masumoto H, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1876–82 (43 ref.) **(Jpn)**
[DNA checkpoint control in Saccharomyces cerevisae] Sugimoto K, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep; 41(12 Suppl):1807–12 (20 ref.) **(Jpn)**

DRUG EFFECTS

Metabolic and mitotic changes associated with the fetal alcohol syndrome. Shibley IA Jr, et al. **Alcohol Alcohol** 1997 Jul–Aug;32(4):423–34 (146 ref.)
Perturbation of the mitosis/apoptosis balance: a fundamental mechanism in toxicology. Roberts RA, et al. **Fundam Appl Toxicol** 1997 Aug;38(2):107–15 (44 ref.)

GENETICS

Two different pregnancy outcomes of trisomic zygote rescue through postzygotic mitotic error. Kalousek DK. **Birth Defects Orig Artic Ser** 1996;30(1):295–9 (12 ref.)

PHYSIOLOGY

Cell cycle checkpoints: arresting progress in mitosis. Gorbsky GJ. **Bioessays** 1997 Mar;19(3):193–7 (42 ref.)
Histone acetylation: a possible mechanism for the inheritance of cell memory at mitosis. Jeppesen P. **Bioessays** 1997 Jan; 19(1):67–74 (50 ref.)
Bacterial chromosome segregation: is there a mitotic apparatus? Wheeler RT, et al. **Cell** 1997 Mar 7;88(5):577–9 (20 ref.)
Mitotic organization and force generation by assembly/disassembly of microtubules. Inoué S. **Cell Struct Funct** 1996 Oct;21(5):375–9 (20 ref.)
Signalling pathways involved in the mitogenic effects of cAMP. Withers DJ. **Clin Sci (Colch)** 1997 May;92(5):445–51 (21 ref.)
Mitotic disassembly and reassembly of the Golgi apparatus. Levine TP, et al. **Cold Spring Harb Symp Quant Biol** 1995; 60:549–57 (43 ref.)
Mitosis: don't get mad, get even. Glotzer M. **Curr Biol** 1996 Dec 1;6(12):1592–4 (16 ref.)
Dynamic changes in nuclear architecture during mitosis: on the role of protein phosphorylation in spindle assembly and chromosome segregation. Nigg EA, et al. **Exp Cell Res** 1996 Dec 15;229(2):174–80 (80 ref.)
Polo kinase: the choreographer of the mitotic stage? Glover DM, et al. **J Cell Biol** 1996 Dec;135(6 Pt 2):1681–4 (28 ref.)
Reversible phosphorylation and mitotic control. Piwnica–Worms H. **J Lab Clin Med** 1996 Oct;128(4):350–4 (34 ref.)
The role of microtubule assembly dynamics in mitotic force generation and functional organization of living cells. Inoué S. **J Struct Biol** 1997 Mar;118(2):87–93 (40 ref.)
The molecular mechanism of aflatoxin B1–induced liver cancer: is mitotic recombination involved? Sengstag C. **Mol Carcinog** 1997 Jul;19(3):147–52 (22 ref.)
Hepatocyte growth factor as mitogen, motogen and morphogen, and its roles in organ regeneration. Nakamura T. **Princess Takamatsu Symp** 1994;24:195–213 (76 ref.)
Replicative senescence and cell immortality: the role of telomeres and telomerase. Chiu CP, et al. **Proc Soc Exp Biol Med** 1997 Feb;214(2):99–106 (81 ref.)
An unequal split. Altman J. **Trends Neurosci** 1996 Feb; 19(2):45 (7 ref.)

MITOSIS–PROMOTING FACTOR see **MATURATION–PROMOTING FACTOR**

MITOTANE

THERAPEUTIC USE

Medical treatment of pituitary–dependent hyperadrenocorticism. Mitotane. Peterson ME, et al. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):255–72 (37 ref.)

MITOTIC INDEX

The value of markers for cell proliferation and cell loss in gynaecological cancer. Cheung AN. **Curr Opin Obstet Gynecol** 1997 Feb;9(1):32–6 (35 ref.)
Estimating mitotic activity in tumours [comment] [see comments] Cross SS, et al. **Histopathology** 1996 Nov; 29(5):485–8 (58 ref.) Comment on: Histopathology 1996 Nov;29(5):421–8. Comment in: Histopathology 1997 Jun;30(6):605–6.

GENETICS

Importance of proliferation markers in oral pathology. Warnakulasuriya KA, et al. **Curr Top Pathol** 1996;90:147–77 (105 ref.)

MITOTIC SPINDLE APPARATUS

see related
CENTROMERE
CENTROSOME
KINETOCHORES
MICROTUBULES

Mini review: mitosis and the spindle pole body in Saccharomyces cerevisiae. Sobel SG. **J Exp Zool** 1997 Feb 1;277(2):120–38 (168 ref.)

CHEMISTRY

The spindle assembly checkpoint. Rudner AD, et al. **Curr Opin Cell Biol** 1996 Dec;8(6):773–80 (74 ref.)
Pathways of spindle assembly. Waters JC, et al. **Curr Opin Cell Biol** 1997 Feb;9(1):37–43 (60 ref.)
Dynamic continuity of nuclear and mitotic matrix proteins in the cell cycle. Mancini MA, et al. **J Cell Biochem** 1996 Aug;62(2):158–64 (55 ref.)

ENZYMOLOGY

The spindle assembly checkpoint. Rudner AD, et al. **Curr Opin Cell Biol** 1996 Dec;8(6):773–80 (74 ref.)

GENETICS

Genetic analysis of the mitotic spindle. Hoyt MA, et al. **Annu Rev Genet** 1996;30:7–33 (163 ref.)

METABOLISM

Pathways of spindle assembly. Waters JC, et al. **Curr Opin Cell Biol** 1997 Feb;9(1):37–43 (60 ref.)
How cells get the right chromosomes. Nicklas RB. **Science** 1997 Jan 31;275(5300):632–7 (45 ref.)

PHYSIOLOGY

Bacterial chromosome segregation: is there a mitotic apparatus? Wheeler RT, et al. **Cell** 1997 Mar 7;88(5):577–9 (20 ref.)
Motors involved in spindle assembly and chromosome segregation. Vernos I, et al. **Curr Opin Cell Biol** 1996 Feb; 8(1):4–9 (45 ref.)
Nuclear components with microtubule–organizing properties in multicellular eukaryotes: functional and evolutionary

MITOTIC SPINDLE APPARATUS

considerations. Baluška F, et al. **Int Rev Cytol** 1997; 175:91–135 (295 ref.)

Pathways of spindle pole formation: different mechanisms; conserved components. Merdes A, et al. **J Cell Biol** 1997 Sep 8;138(5):953–6 (32 ref.)

Motoring to the finish: kinesin and dynein work together to orient the yeast mitotic spindle [comment] Stearns T. **J Cell Biol** 1997 Sep 8;138(5):957–60 (23 ref.) Comment on: J Cell Biol 1997 Sep 8;138(5):1023–40. Comment on: J Cell Biol 1997 Sep 8;138(5):1041–53.

Rappaport rules: cleavage furrow induction in animal cells [comment] Oegema K, et al. **Proc Natl Acad Sci U S A** 1997 May 13;94(10):4817–20 (35 ref.) Comment on: Proc Natl Acad Sci U S A 1997 May 13;94(10):5107–12.

ULTRASTRUCTURE

Traction fibre: toward a "tensegral" model of the spindle. Pickett-Heaps JD, et al. **Cell Motil Cytoskeleton** 1997; 37(1):1–6 (32 ref.)

Rappaport rules: cleavage furrow induction in animal cells [comment] Oegema K, et al. **Proc Natl Acad Sci U S A** 1997 May 13;94(10):4817–20 (35 ref.) Comment on: Proc Natl Acad Sci U S A 1997 May 13;94(10):5107–12.

MITOXANTRONE

ADMINISTRATION & DOSAGE

Other chemotherapy regimens including mitoxantrone and suramin. Siu LL, et al. **Semin Urol Oncol** 1997 Feb; 15(1):20–7 (38 ref.)

ANALOGS & DERIVATIVES

Aza and diaza bioisosteric anthracene-9,10-diones as antitumor agents. Krapcho AP, et al. **Acta Biochim Pol** 1995;42(4):427–32 (8 ref.)

PHARMACOLOGY

Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia. Dunn CJ, et al. **Drugs Aging** 1996 Aug;9(2):122–47 (132 ref.)

THERAPEUTIC USE

Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia. Dunn CJ, et al. **Drugs Aging** 1996 Aug;9(2):122–47 (132 ref.)

Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. Wiseman LR, et al. **Drugs Aging** 1997 Jun; 10(6):473–85 (52 ref.)

[Lipiodol with and without Gelfoam in primary liver tumors. Plasma levels of Mitoxantrone and clinical results] Civalleri D, et al. **G Chir** 1997 Jun-Jul;18(6-7):362–7 (36 ref.) (Eng. Abstr.) **(Ita)**

MITOZANTRONE see **MITOXANTRONE**

MITRAL CLICK-MURMUR SYNDROME see **MITRAL VALVE PROLAPSE**

MITRAL INCOMPETENCE see **MITRAL VALVE INSUFFICIENCY**

MITRAL REGURGITATION see **MITRAL VALVE INSUFFICIENCY**

MITRAL VALVE

[A case report of mitral valve papillary fibroelastoma leading to embolic stroke] Shirota K, et al. **Kyobu Geka** 1996 Jul; 49(7):571–4 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Left ventricular rupture following mitral valve replacement] Fujita T, et al. **Rinsho Kyobu Geka** 1989 Jun;9(3):241–5 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Mitral ring abscess] Kato I, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):399–402 (20 ref.) **(Jpn)**

[Mitral annular calcification] Mori H. **Ryoikibetsu Shokogun Shirizu** 1996;(13):407–10 (19 ref.) **(Jpn)**

[Mitral valve disease, mitral valve prolapse syndrome, ruptured chordae tendineae of the mitral valve] Murakami E, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):403–6 (10 ref.) **(Jpn)**

[Combined valvular heart disease] Ohashi H. **Ryoikibetsu Shokogun Shirizu** 1996;(13):448–50 (8 ref.) **(Jpn)**

ABNORMALITIES

Repair of parachute mitral valve with multiple ventricular septal defects: a case report and literature review. Suri RK, et al. **J Heart Valve Dis** 1997 Jan;6(1):63–6 (9 ref.)

Humero-spinal dysostosis: report of the fourth case with emphasis on generalized skeletal involvement, abnormal craniofacial features, and mitral valve thickening. Hall BD. **J Pediatr Orthop B** 1997 Jan;6(1):11–4 (3 ref.)

[Double-orifice mitral valve] Hadama T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):129–32 (17 ref.) **(Jpn)**

[Mitral atresia with ventricular septal defect] Hoshino S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):152–4 (3 ref.) **(Jpn)**

[Shone's syndrome] Muraki N, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):311–3 (10 ref.) **(Jpn)**

[Mitral stenosis, mitral atresia and mitral insufficiency] Ohkubo M, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (13):217–20 (18 ref.) **(Jpn)**

[Supravalvular mitral ridge] Okada M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):221–3 (12 ref.) **(Jpn)**

[Accessory mitral valve in the aged] Yoshio H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):359–62 (22 ref.) **(Jpn)**

INJURIES

Mitral valve disruption following blunt trauma: case report and review of the literature. Pathi V, et al. **Eur J Cardiothorac Surg** 1996;10(9):806–8 (20 ref.)

[Valvular lesions in the course of nonpenetrating thoracic trauma: their diagnosis by transesophageal echocardiography] Ussia GP, et al. **Cardiologia** 1996 Nov; 41(11):1107–11 (39 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

[Perforation of the mitral valve] Goh K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):396–8 (18 ref.) **(Jpn)**

[Myxomatous degeneration of heart valves] Obayashi T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):389–92 (14 ref.) **(Jpn)**

SURGERY

Clinical presentation and treatment options for mitral valve myxoma. Chakfé N, et al. **Ann Thorac Surg** 1997 Sep; 64(3):872–7 (37 ref.)

Mitral, tricuspid, and aortic valve repair or reconstruction. Hammond GL, et al. **Curr Opin Cardiol** 1997 Mar; 12(2):100–7 (47 ref.)

Allograft valves for aortic and mitral valve replacement. Reardon MJ, et al. **Curr Opin Cardiol** 1997 Mar; 12(2):114–22 (30 ref.)

Importance of the right ventricle in valvular heart disease. Nagel E, et al. **Eur Heart J** 1996 Jun;17(6):829–36 (75 ref.)

Percutaneous mitral valvuloplasty: a decade of experience. Stefanadis C, et al. **Eur Heart J** 1995 Nov;16(11):1463–8 (28 ref.)

Mitral annuloplasty: a ring-side view. Ghosh PK. **J Heart Valve Dis** 1996 May;5(3):286–93 (103 ref.)

Repair of parachute mitral valve with multiple ventricular septal defects: a case report and literature review. Suri RK, et al. **J Heart Valve Dis** 1997 Jan;6(1):63–6 (9 ref.)

[Adherence to valve repair surgery: from the mitral to the aortic valve] Kawazoe K. **J Cardiol** 1997;29 Suppl 2:3–9 (9 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

The vital role of papillary muscles in mitral and ventricular function: echocardiographic insights [see comments] Madu EC, et al. **Clin Cardiol** 1997 Feb;20(2):93–8 (30 ref.) Comment in: Clin Cardiol 1997 May;20(5):506.

Echocardiographic evaluation of papillary fibroelastoma: a case report and review of the literature. Hicks KA, et al. **J Am Soc Echocardiogr** 1996 May-Jun;9(3):353–60 (64 ref.)

Echocardiography in mitral valve repair for mitral regurgitation: the surgeon's needs. Lee EM, et al. **J Heart Valve Dis** 1997 May;6(3):228–33 (22 ref.)

MITRAL VALVE INCOMPETENCE see **MITRAL VALVE INSUFFICIENCY**

MITRAL VALVE INSUFFICIENCY

[Rheumatic valvular heart disease] Kitamura F. **Ryoikibetsu Shokogun Shirizu** 1996;(13):444–7 (4 ref.) **(Jpn)**

[Syndrome of papillary muscle dysfunction] Koshiji T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):431–4 (16 ref.) **(Jpn)**

COMPLICATIONS

[Surgical treatment of left ventricular aneurysm with acute myocardial infarction associated to mitral valve stenosis: a case report] Sunazawa T, et al. **Kyobu Geka** 1997 May; 50(5):400–3 (22 ref.) (Eng. Abstr.) **(Jpn)**

CONGENITAL

[Mitral stenosis, mitral atresia and mitral insufficiency] Ohkubo M, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (13):217–20 (18 ref.) **(Jpn)**

DIAGNOSIS

[Can Doppler echocardiography help to avoid cardiac catheterization in the surgical decision-making in isolated left heart valve diseases?] Tribouilloy C, et al. **Arch Mal Coeur Vaiss** 1996 Dec;89(12):1607–16 (28 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Vasoactive drugs in chronic regurgitant lesions of the mitral and aortic valves. Levine HJ, et al. **J Am Coll Cardiol** 1996 Nov 1;28(5):1083–91 (53 ref.)

ETIOLOGY

Severe mitral valve dysfunction due to unsuspected granulomatous myocarditis: successful cardiac transplantation following attempted mitral valve repair. el-Gamel A, et al. **Eur J Cardiothorac Surg** 1996; 10(8):702–4 (8 ref.)

Cardiac valve disease in Wegener's granulomatosis [letter] Greidinger EL, et al. **J Rheumatol** 1996 Aug;23(8):1485–7 (11 ref.)

Mitral insufficiency caused by systemic lupus erythematosus requiring valve replacement: three case reports and a review of the literature. Morin AM, et al. **Thorac Cardiovasc Surg** 1996 Dec;44(6):313–6 (25 ref.)

[Mitral regurgitation due to papillary muscle rupture after myocardial infarction] Okada M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):381–4 (11 ref.) **(Jpn)**

SURGERY

Nonreplacement operations for mitral valve regurgitation. Hahn C, et al. **Annu Rev Med** 1997;48:295–306 (22 ref.)

Echocardiography to assist mitral valve repair in patients with coronary artery disease. Muehrcke DD, et al. **Coron Artery Dis** 1996 Mar;7(3):211–6 (36 ref.)

Severe mitral valve dysfunction due to unsuspected granulomatous myocarditis: successful cardiac transplantation following attempted mitral valve repair. el-Gamel A, et al. **Eur J Cardiothorac Surg** 1996; 10(8):702–4 (8 ref.)

Mitral valve disease: a cardiologic-surgical interaction. Barlow JB. **Isr J Med Sci** 1996 Oct;32(10):831–42; 843–4 (56 ref.)

Mitral annuloplasty: different surgical techniques. Salati M, et al. **Isr J Med Sci** 1996 Oct;32(10):848–51 (30 ref.)

Mitral annuloplasty: a ring-side view. Ghosh PK. **J Heart Valve Dis** 1996 May;5(3):286–93 (103 ref.)

Mitral valve reconstruction for mitral insufficiency. Reul RM, et al. **Prog Cardiovasc Dis** 1997 May-Jun;39(6):567–99 (263 ref.)

Mitral insufficiency caused by systemic lupus erythematosus requiring valve replacement: three case reports and a review of the literature. Morin AM, et al. **Thorac Cardiovasc Surg** 1996 Dec;44(6):313–6 (25 ref.)

[Initial results of mitral valvuloplasty using the Physio-Carpentier-Edwards ring] Sousa Uva M, et al. **Arch Mal Coeur Vaiss** 1997 Jun;90(6):789–95 (29 ref.) (Eng. Abstr.) **(Fre)**

[The timing of surgical correction of mitral insufficiency] Scognamiglio R, et al. **Cardiologia** 1997 Jun;42(6):591–6 (36 ref.) **(Ita)**

[Adherence to valve repair surgery: from the mitral to the aortic valve] Kawazoe K. **J Cardiol** 1997;29 Suppl 2:3–9 (9 ref.) (Eng. Abstr.) **(Jpn)**

[A case of scheduled mitral valve replacement for mitral regurgitation caused by papillary muscle rupture after acute myocardial infarction] Minakata K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):639–44 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Mitral valve replacement and coronary artery bypass grafting for postinfarction mitral papillary muscle rupture] Sasaki Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 May;44(5):697–701 (15 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

The management of mitral valve disease. Gaasch WH, et al. **Curr Opin Cardiol** 1996 Mar;11(2):114–9 (26 ref.)

ULTRASONOGRAPHY

Echocardiographic evaluation of the mechanisms of ischemic mitral regurgitation. Dent JM, et al. **Coron Artery Dis** 1996 Mar;7(3):188–95 (30 ref.)

Multiplane transesophageal imaging in mitral regurgitation due to coronary artery disease. Flachskampf FA, et al. **Coron Artery Dis** 1996 Mar;7(3):202–5 (20 ref.)

The use of echocardiography in the coronary care unit for assessment of mitral regurgitation. Harris KM, et al. **Coron Artery Dis** 1996 Mar;7(3):196–201 (34 ref.)

Three-dimensional echocardiography in mitral regurgitation. Laskari CV, et al. **Coron Artery Dis** 1996 Mar;7(3):206–10 (19 ref.)

Echocardiography in mitral valve repair for mitral regurgitation: the surgeon's needs. Lee EM, et al. **J Heart Valve Dis** 1997 May;6(3):228–33 (22 ref.)

[Quantification of mitral insufficiency in color Doppler by studying the convergence zone] Tribouilloy C. **Ann Cardiol Angeiol (Paris)** 1997 Mar;46(3):163–70 (34 ref.) (Eng. Abstr.) **(Fre)**

[Calculation of the regurgitation fraction in mitral insufficiency by Doppler echocardiography using a study of the zone of flow convergence] Gallet B, et al. **Arch Mal Coeur Vaiss** 1997 Jan;90(1):17–25 (30 ref.) (Eng. Abstr.) **(Fre)**

[Combined calcified valvular disease] Ishimitsu T. **Ryoikibetsu Shokogun Shirizu** 1996;(13):385–8 (8 ref.) **(Jpn)**

MITRAL VALVE PROLAPSE

[Mitral valve disease, mitral valve prolapse syndrome, ruptured chordae tendineae of the mitral valve] Murakami E, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):403–6 (10 ref.) **(Jpn)**

ETIOLOGY

[Small heart syndrome] Yasukochi S.
Ryoikibetsu Shokogun Shirizu 1996;(13):142–5 (12 ref.) **(Jpn)**

PATHOLOGY

[Myxomatous degeneration of heart valves] Obayashi T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):389–92 (14 ref.) **(Jpn)**

PHYSIOPATHOLOGY

[Mid-systolic click-late systolic murmur syndrome (MSC-LSMS)] Ohara M. **Ryoikibetsu Shokogun Shirizu** 1996;(13):378–80 (12 ref.) **(Jpn)**

RADIONUCLIDE IMAGING

[A study of 36 cases of mitral valve prolapse by isotopic ventricular tomography] Delhomme C, et al.
Arch Mal Coeur Vaiss 1996 Sep;89(9):1127–35 (30 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Haemophilus parainfluenzae infective endocarditis. Lee P, et al. **Ann Acad Med Singapore** 1996 Sep;25(5):761–2 (12 ref.)

MITRAL VALVE STENOSIS

[Rheumatic valvular heart disease] Kitamura F.
Ryoikibetsu Shokogun Shirizu 1996;(13):444–7 (4 ref.) **(Jpn)**

BLOOD

Biochemical markers of coagulation activation in mitral stenosis, atrial fibrillation, and cardiomyopathy. Ikeda U, et al. **Clin Cardiol** 1997 Jan;20(1):7–10 (36 ref.)

COMPLICATIONS

[Surgical treatment of left ventricular aneurysm with acute myocardial infarction associated to mitral valve stenosis: a case report] Sunazawa T, et al. **Kyobu Geka** 1997 May; 50(5):400–3 (22 ref.) (Eng. Abstr.) **(Jpn)**

CONGENITAL

[Mitral stenosis, mitral atresia and mitral insufficiency] Ohkubo M, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (13):217–20 (18 ref.) **(Jpn)**

DIAGNOSIS

Changing concepts in the determination of valvular stenosis. Dangas G, et al. **Prog Cardiovasc Dis** 1997 Jul–Aug; 40(1):55–64 (29 ref.)

[Can Doppler echocardiography help to avoid cardiac catheterization in the surgical decision-making in isolated left heart valve diseases?] Tribouilloy C, et al.
Arch Mal Coeur Vaiss 1996 Dec;89(12):1607–16 (28 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

[Shone's syndrome] Muraki N, et al.
Ryoikibetsu Shokogun Shirizu 1996;(14):311–3 (10 ref.) **(Jpn)**

SURGERY

Management of mitral valve stenosis in pregnancy: case presentation and review of the literature. Yaryura RA, et al. **J Heart Valve Dis** 1996 Jan;5(1):16–9 (32 ref.)

[5 years results of percutaneous mitral commissurotomy. Apropos of a series of 606 patients; late results after mitral dilatation] Iung B, et al. **Arch Mal Coeur Vaiss** 1996 Dec; 89(12):1591–8 (30 ref.) (Eng. Abstr.) **(Fre)**

[Is tricuspid valve necessary in patients with mitral stenosis undergoing mitral valve repair or replacement?] Sagie A, et al. **Harefuah** 1996 Oct;131(7–8):260–3 (22 ref.) **(Heb)**

THERAPY

Pitfalls and tips in inoue balloon mitral commissurotomy [see comments] Hung JS, et al. **Cathet Cardiovasc Diagn** 1996 Feb;37(2):188–99 (41 ref.) Comment in: Cathet Cardiovasc Diagn 1996 Feb;37(2):200.

Percutaneous transvenous mitral commissurotomy versus surgical commissurotomy in the treatment of mitral stenosis. Lau KW, et al. **Clin Cardiol** 1997 Feb;20(2):99–106 (62 ref.)

The management of mitral valve disease. Gaasch WH, et al. **Curr Opin Cardiol** 1996 Mar;11(2):114–9 (26 ref.)

Percutaneous mitral commissurotomy. Vahanian A.
Eur Heart J 1996 Oct;17(10):1465–9 (22 ref.)

How to do a mitral valvuloplasty. Vahanian A.
Int J Cardiol 1996 Jul 5;55(1):1–7 (10 ref.)

Percutaneous balloon mitral valvuloplasty. Glazier JJ, et al. **Prog Cardiovasc Dis** 1997 Jul–Aug;40(1):5–26 (134 ref.)

MIXED CONNECTIVE TISSUE DISEASE

[Mixed connective tissue disease: progress in diagnosis and treatment. I. Background for the start of its concept and history] Kasukawa R. **Nippon Naika Gakkai Zasshi** 1996 Aug 10;85(8):1191–5 (6 ref.) **(Jpn)**

CLASSIFICATION

[Mixed connective tissue disease: progress in diagnosis and treatment. II. Physiopathology and diagnosis. 6. Overlap syndrome and MCTD] Akizuki M.
Nippon Naika Gakkai Zasshi 1996 Aug 10;85(8):1223–7 (6 ref.) **(Jpn)**

COMPLICATIONS

Mixed connective tissue disease and radiation toxicity. A case report. Mayr NA, et al. **Cancer** 1997 Feb 1;79(3):612–8 (12 ref.)

[Mixed connective tissue disease: progress in diagnosis and treatment. III. Treatment. 3. Clinical aspects of specific conditions and treatment. 3) Interstitial pulmonary lesions and serositis] Hirakata M, et al.
Nippon Naika Gakkai Zasshi 1996 Aug 10;85(8):1248–53 (6 ref.) **(Jpn)**

[Mixed connective tissue disease: progress in diagnosis and treatment. III. Treatment. 3. Clinical aspects and treatment of specific conditions. 1) Pulmonary hypertension] Kunieda T. **Nippon Naika Gakkai Zasshi** 1996 Aug 10;85(8):1237–43 (10 ref.) **(Jpn)**

[Mixed connective tissue disease: progress in diagnosis and treatment. III. Treatment. 3. Clinical aspects and treatment of specific conditions. 2) Disorders of the trigeminal nerve] Okada J. **Nippon Naika Gakkai Zasshi** 1996 Aug 10; 85(8):1244–7 (5 ref.) **(Jpn)**

[Mixed connective tissue disease: progress in diagnosis and treatment. III. Treatment. 3. Clinical aspects and treatment of specific conditions. 3) Renal lesions] Takasaki Y.
Nippon Naika Gakkai Zasshi 1996 Aug 10;85(8):1254–8 (6 ref.) **(Jpn)**

[Mixed connective tissue disease: progress in diagnosis and treatment. III. Treatment. 3. Clinical aspects and treatment of specific conditions. 5) Peripheral circulatory dysfunction] Yoshida S, et al.
Nippon Naika Gakkai Zasshi 1996 Aug 10;85(8):1259–64 (5 ref.) **(Jpn)**

[A case of esophageal intramural pseudodiverticulosis complicated with primary biliary cirrhosis and mixed connective tissue disease] Iguchi Y, et al.
Nippon Shokakibyo Gakkai Zasshi 1997 Mar;94(3):180–5 (11 ref.) **(Jpn)**

[Mixed connective tissue disease] Kitamoto K.
Ryoikibetsu Shokogun Shirizu 1996;(15):173–5 (11 ref.) **(Jpn)**

[Cardiovascular complications of overlap syndrome] Suzuki T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):161–4 (18 ref.) **(Jpn)**

DIAGNOSIS

[Mixed connective tissue disease: progress in diagnosis and treatment. II. Physiopathology and diagnosis. 4. Diagnosis and the sequence of diagnostic tests conducted for observation] Hara M. **Nippon Naika Gakkai Zasshi** 1996 Aug 10;85(8):1213–6 (4 ref.) **(Jpn)**

[Mixed connective tissue disease: progress in diagnosis and treatment. II. Physiopathology and diagnosis. 3. Clinical symptoms of MCTD] Shimizu M.
Nippon Naika Gakkai Zasshi 1996 Aug 10;85(8):1208–12 (5 ref.) **(Jpn)**

DRUG THERAPY

[Mixed connective tissue disease: progress in diagnosis and treatment. III. Treatment. 2. Timing for the start of the therapy with adrenocorticosteroids and immunosuppressive agents and methods of their administration] Tanaka H.
Nippon Naika Gakkai Zasshi 1996 Aug 10;85(8):1233–6 (5 ref.) **(Jpn)**

ETIOLOGY

Connective tissue and joint disease in diabetes mellitus. Rosenbloom AL, et al.
Endocrinol Metab Clin North Am 1996 Jun;25(2):473–83 (47 ref.)

IMMUNOLOGY

Clinical and immunological aspects of autoantibodies to RA33/hnRNP-A/B proteins--a link between RA, SLE and MCTD. Steiner G, et al. **Mol Biol Rep** 1996; 23(3–4):167–71 (29 ref.)

[Mixed connective tissue disease: progress in diagnosis and treatment. II. Physiopathology and diagnosis. 1. Etiology and pathogenesis] Mimori T.
Nippon Naika Gakkai Zasshi 1996 Aug 10;85(8):1196–202 (9 ref.) **(Jpn)**

MORTALITY

[Mixed connective tissue disease: Progress in diagnosis and treatment. IV. Its clinical course and prognosis] Kashiwagi H. **Nippon Naika Gakkai Zasshi** 1996 Aug 10;85(8):1265–8 (19 ref.) **(Jpn)**

PATHOLOGY

[Mixed connective tissue disease:progress in diagnosis and treatment. II. Physiopathology and diagnosis. 2. Pathology] Sawai T, et al. **Nippon Naika Gakkai Zasshi** 1996 Aug 10; 85(8):1203–7 (8 ref.) **(Jpn)**

PHYSIOPATHOLOGY

[Mixed connective tissue disease: Progress in diagnosis and treatment. IV. Its clinical course and prognosis] Kashiwagi H. **Nippon Naika Gakkai Zasshi** 1996 Aug 10;85(8):1265–8 (19 ref.) **(Jpn)**

THERAPY

[Mixed connective tissue disease: progress in diagnosis and treatment. III. Treatment. 1. Designing treatment and methods for follow-up] Nagasawa K.
Nippon Naika Gakkai Zasshi 1996 Aug 10;85(8):1228–32 (4 ref.) **(Jpn)**

MIXED FUNCTION OXIDASES

BIOSYNTHESIS

A review of the hepatic tumors related to mixed-function oxidase induction in the mouse [see comments] Butler WH. **Toxicol Pathol** 1996 Jul–Aug;24(4):484–92 (54 ref.) Comment in: Toxicol Pathol 1996 Jul–Aug;24(4):507–8.

METABOLISM

The assessment of flavin-containing monooxygenase activity in intact animals. Damani LA, et al.
Drug Metabol Drug Interact 1996;13(1):1–28 (110 ref.)

MIXED FUNCTION OXYGENASES see **MIXED FUNCTION OXIDASES**

MIXED SALIVARY GLAND TUMOR see **ADENOMA, PLEOMORPHIC**

MIXED TUMOR, MALIGNANT

VETERINARY

Ceruminous gland tumors in dogs and cats: a review of 124 cases. Moisan PG, et al. **J Am Anim Hosp Assoc** 1996 Sep–Oct;32(5):448–52 (9 ref.)

MIXED TUMOR, MESODERMAL

PATHOLOGY

[Mesodermal mixed tumors of the endometrium with a report of 7 cases] Veselinova T, et al. **Akush Ginekol (Sofiia)** 1997; 36(1):29–31 (7 ref.) (Eng. Abstr.) **(Bul)**

MIXED TUMOR, MULLERIAN

[Müllerian mixed tumors. Experience of the Rennes Regional University Hospital] Leveque J, et al. **Chirurgie** 1996; 121(3):198–202 (20 ref.) (Eng. Abstr.) **(Fre)**

CHEMICALLY INDUCED

Mullerian adenosarcoma of the uterine corpus associated with tamoxifen therapy: a report of six cases and a review of tamoxifen-associated endometrial lesions. Clement PB, et al. **Int J Gynecol Pathol** 1996 Jul;15(3):222–9 (59 ref.)

PATHOLOGY

Malignant müllerian mixed tumor of the uterus with a prominent alpha-fetoprotein-producing component of yolk sac tumor. Shokeir MO, et al. **Mod Pathol** 1996 Jun; 9(6):647–51 (22 ref.)

MMP-3 see **STROMELYSIN 1**

MMPI

STANDARDS

Future directions for the MMPI-A: research and clinical issues. Archer RP. **J Pers Assess** 1997 Feb;68(1):95–109 (38 ref.)

MN SIALOGLYCOPROTEIN see **GLYCOPHORIN**

MNSS BLOOD-GROUP SYSTEM

GENETICS

Molecular genetics of glycophorin MNS variants. Blumenfeld OO, et al. **Transfus Clin Biol** 1997 Jul; 4(4):357–65 (33 ref.)

MO1 ANTIGEN see **MACROPHAGE-1 ANTIGEN**

MOBILE GENETIC ELEMENTS

MOBILE GENETIC ELEMENTS see **DNA INSERTION ELEMENTS**

MOBILE HEALTH UNITS

ORGANIZATION & ADMINISTRATION

Mobile environmental labs. Frazer L. **Environ Health Perspect** 1997 May;105(5):492–5 (0 ref.)

MOBIUS SYNDROME see **FACIAL PARALYSIS**

MODELS, ANATOMIC

Rapid prototyping techniques for anatomical modelling in medicine. McGurk M, et al. **Ann R Coll Surg Engl** 1997 May;79(3):169–74 (29 ref.)

Finite element methods in spine biomechanics research. Gilbertson LG, et al. **Crit Rev Biomed Eng** 1995; 23(5–6):411–73 (123 ref.)

The spirit of D'arcy Thompson dwells in empirical morphospace. Stone JR. **Math Biosci** 1997 May; 142(1):13–30 (55 ref.)

Creating phyllotaxis: the stack-and-drag model. Van Der Linden FM. **Math Biosci** 1996 Apr 1;133(1):21–50 (63 ref.)

Finite-element models of the human head. Voo K, et al. **Med Biol Eng Comput** 1996 Sep;34(5):375–81 (25 ref.)

Finite element applications in human cervical spine modeling. Yoganandan N, et al. **Spine** 1996 Aug 1;21(15):1824–34 (59 ref.)

MODELS, BIOLOGICAL

see related
DISEASE MODELS, ANIMAL

The information processing organisms. Arianova L. **Acta Biotheor** 1996 Jun;44(2):143–51 (3 ref.)

Elements of a unifying theory of biology. Norris V, et al. **Acta Biotheor** 1996 Nov;44(3–4):209–18 (60 ref.)

Modeling vitamin B6 metabolism. Coburn SP. **Adv Food Nutr Res** 1996;40:107–32 (87 ref.)

Quantitative and conceptual contributions of mathematical modeling to current views on vitamin A metabolism, biochemistry, and nutrition. Green MH, et al. **Adv Food Nutr Res** 1996;40:3–24 (29 ref.)

Modeling of folate metabolism. Gregory JF 3rd, et al. **Adv Food Nutr Res** 1996;40:81–93 (32 ref.)

Modeling membrane transport. King RB. **Adv Food Nutr Res** 1996;40:243–62 (15 ref.)

Molecular biology in nutrition research: modeling of folate metabolism. Lin BF, et al. **Adv Food Nutr Res** 1996; 40:95–106 (9 ref.)

Mathematical modeling in nutrition: constructing a physiologic compartmental model of the dynamics of beta-carotene metabolism. Novotny JA, et al. **Adv Food Nutr Res** 1996;40:25–54 (39 ref.)

Dynamic systems and neural networks: modeling in physiology and medicine. Sayegh SI. **Adv Food Nutr Res** 1996;40:323–38 (14 ref.)

Nutrient-response: a "top down" approach to metabolic control. Schulz AR. **Adv Food Nutr Res** 1996;40:227–41 (23 ref.)

Experimental approaches to the study of beta-carotene metabolism: potential of a 13C tracer approach to modeling beta-carotene kinetics in humans. Swanson JE, et al. **Adv Food Nutr Res** 1996;40:55–79 (66 ref.)

Graph theoretical methods for physiologically based modeling. Zhang H, et al. **Adv Food Nutr Res** 1996; 40:339–52 (8 ref.)

Murine and simian retrovirus models: the threshold hypothesis. Ruprecht RM, et al. **AIDS** 1996;10 Suppl A:S33–40 (107 ref.)

Theoretical considerations of what regulates low-density-lipoprotein and high-density-lipoprotein cholesterol. Dietschy JM. **Am J Clin Nutr** 1997 May;65(5 Suppl):1581S–1589S (62 ref.)

Unilateral vs. bilateral carpal tunnel: challenges and approaches. Stanek EJ 3rd, et al. **Am J Ind Med** 1996 Jun; 29(6):669–78 (14 ref.)

Mechanism of nonlinear responses of taste cells to mixed tastes. Kashimori Y, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):C405–22 (40 ref.)

Contributions of modeling to understanding stimulus-secretion coupling in pancreatic beta-cells. Sherman A. **Am J Physiol** 1996 Aug;271(2 Pt 1):E362–72 (70 ref.)

Cell cycle kinetics in the alveolar epithelium. Uhal BD. **Am J Physiol** 1997 Jun;272(6 Pt 1):L1031–45 (120 ref.)

Modeling the transmission of schistosomiasis: an introductory view. Barbour AD. **Am J Trop Med Hyg** 1996 Nov;55(5 Suppl):135–43 (10 ref.)

The microsimulation approach to epidemiologic modeling of helminthic infections, with special reference to schistosomiasis. Habbema JD, et al. **Am J Trop Med Hyg** 1996 Nov;55(5 Suppl):165–9 (13 ref.)

Dynamic modeling of epidemiologic patterns of schistosomiasis morbidity. Medley GF, et al. **Am J Trop Med Hyg** 1996 Nov;55(5 Suppl):149–58 (27 ref.)

SCHISTOSIM: a microsimulation model for the epidemiology and control of schistosomiasis. Vlas SJ, et al. **Am J Trop Med Hyg** 1996 Nov;55(5 Suppl):170–5 (16 ref.)

Mathematical models of transmission dynamics and control of schistosomiasis. Woolhouse ME. **Am J Trop Med Hyg** 1996 Nov;55(5 Suppl):144–8 (19 ref.)

Do recent operational studies indicate that a single state model is no longer applicable to G protein-coupled receptors? Bond RA. **Ann N Y Acad Sci** 1997 May 30; 812:92–7 (24 ref.)

What size should a bacterium be? A question of scale. Koch AL. **Annu Rev Microbiol** 1996;50:317–48 (111 ref.)

Human body composition: advances in models and methods. Heymsfield SB, et al. **Annu Rev Nutr** 1997;17:527–58 (78 ref.)

Determination of the chemical mechanism of neurotransmitter receptor-mediated reactions by rapid chemical kinetic methods. Hess GP. **Arch Physiol Biochem** 1996 Oct;104(6):752–61 (31 ref.)

Prediction of responses to cold. Holmér I. **Arctic Med Res** 1995;54 Suppl 2:48–54 (34 ref.)

Hypothesis: is soluble P-selectin a new marker of platelet activation? Blann AD, et al. **Atherosclerosis** 1997 Feb 10; 128(2):135–8 (33 ref.)

Neuroendocrine immune responses to inflammation: the concept of the neuroendocrine immune loop. Chikanza IC, et al. **Baillieres Clin Rheumatol** 1996 May;10(2):199–225 (135 ref.)

The importance of the microenvironment in breast cancer progression: recapitulation of mammary tumorigenesis using a unique human mammary epithelial cell model and a three-dimensional culture assay. Weaver VM, et al. **Biochem Cell Biol** 1996;74(6):833–51 (163 ref.)

The role of the sodium cycle of energy coupling in the emergence and persistence of natural foci of modern cholera. Brown II, et al. **Biochemistry (Mosc)** 1997 Feb; 62(2):225–30 (52 ref.)

The epithelial cell default-phenotype hypothesis and its implications for cancer. Frisch SM. **Bioessays** 1997 Aug; 19(8):705–9 (37 ref.)

Human physiology in space. Vernikos J. **Bioessays** 1996 Dec; 18(12):1029–37 (50 ref.)

Origin of life and the underlying physics of the universe. Conrad M. **Biosystems** 1997;42(2–3):177–90 (24 ref.)

Electrodynamics of microtubular motors: the building blocks of a new model. Insinna EM, et al. **Biosystems** 1996; 39(3):187–226 (215 ref.)

A criterion of relative degree of chaos or order for open systems. Klimontovich YuL. **Biosystems** 1997; 42(2–3):85–102 (31 ref.)

Biodynamics for the emergence of energy consumers. Matsuno K. **Biosystems** 1997;42(2–3):119–27 (26 ref.)

Molecular semantics and the origin of life. Matsuno K. **Biosystems** 1997;42(2–3):129–39 (43 ref.)

The emergence of the non-cellular phase of life on the fine-grained clayish particles of the early Earth's regolith. Nussinov MD, et al. **Biosystems** 1997;42(2–3):111–8 (40 ref.)

Emerging concepts of self-organization and the living state. Introduction. Santoli S. **Biosystems** 1997;42(2–3):77–84 (14 ref.)

Concentration and second gas effects: can the accepted explanation be improved? Korman B, et al. **Br J Anaesth** 1997 May;78(5):618–25 (37 ref.)

Endothelial cells in culture: an experimental model for the study of vascular dysfunctions. Chappey O, et al. **Cell Biol Toxicol** 1996 Dec;12(4–6):199–205 (17 ref.)

Advantages and limitations of the use of isolated kidney tubules in pharmacotoxicology. Chauvin MF, et al. **Cell Biol Toxicol** 1996 Dec;12(4–6):283–7 (27 ref.)

Bilirubin, REM sleep, and phototransduction of environmental time cues. A hypothesis. Oren DA. **Chronobiol Int** 1997 May;14(3):319–29 (75 ref.)

The within-host population dynamics of antibacterial chemotherapy: conditions for the evolution of resistance. Lipsitch M, et al. **Ciba Found Symp** 1997;207:112–27; discussion 127–30 (27 ref.)

Ischemic optic neuropathy: models for mechanism of disease. Potarazu SV. **Clin Neurosci** 1997;4(5):264–9 (22 ref.)

Toward a pathophysiology of attention-deficit/hyperactivity disorder. Castellanos FX. **Clin Pediatr (Phila)** 1997 Jul; 36(7):381–93 (154 ref.)

The N-end rule. Varshavsky A. **Cold Spring Harb Symp Quant Biol** 1995;60:461–78 (90 ref.)

Finite element methods in spine biomechanics research. Gilbertson LG, et al. **Crit Rev Biomed Eng** 1995; 23(5–6):411–73 (123 ref.)

Modeling the mechanical behavior of the jaws and their related structures by finite element (FE) analysis. Korioth TW, et al. **Crit Rev Oral Biol Med** 1997;8(1):90–104 (158 ref.)

Structural identifiability of PBPK models: practical consequences for modeling strategies and study designs. Slob W, et al. **Crit Rev Toxicol** 1997 May;27(3):261–72 (22 ref.)

Ageing: levelling of the grim reaper. Charlesworth B, et al. **Curr Biol** 1997 Jul 1;7(7):R440–2 (19 ref.)

Protein transports: the nonclassical ins and outs. Cleves AE. **Curr Biol** 1997 May 1;7(5):R318–20 (10 ref.)

The swinging lever-arm hypothesis of muscle contraction. Holmes KC. **Curr Biol** 1997 Feb 1;7(2):R112–8 (27 ref.)

Ecology: engineered food webs. Manne L, et al. **Curr Biol** 1996 Jan 1;6(1):29–31 (5 ref.)

Tropical rainforests: diversity begets diversity. Mayer AL, et al. **Curr Biol** 1997 Jul 1;7(7):R430–2 (10 ref.)

Interactions of TCRs with MHC-peptide complexes: a quantitative basis for mechanistic models. Margulies DH. **Curr Opin Immunol** 1997 Jun;9(3):390–5 (56 ref.)

Searching for regulatory elements in human noncoding sequences. Duret L, et al. **Curr Opin Struct Biol** 1997 Jun; 7(3):399–406 (48 ref.)

Role of glucose effectiveness in the determination of glucose tolerance. Best JD, et al. **Diabetes Care** 1996 Sep; 19(9):1018–30 (102 ref.)

The pancreatic beta-cell as a fuel sensor: an electrophysiologist's viewpoint. Rorsman P. **Diabetologia** 1997 May;40(5):487–95 (56 ref.)

Biologically based cancer modeling. Luebeck EG, et al. **Drug Chem Toxicol** 1996 Aug;19(3):221–43 (55 ref.)

Using a mathematical model to evaluate the efficacy of TB control measures. Gammaitoni L, et al. **Emerg Infect Dis** 1997 Jul–Sep;3(3):335–42 (37 ref.)

Human drug discrimination and multiple chemical sensitivity: caffeine exposure as an experimental model. Eissenberg T, et al. **Environ Health Perspect** 1997 Mar;105 Suppl 2:509–13 (21 ref.)

The process of leukemogenesis. Irons RD, et al. **Environ Health Perspect** 1996 Dec;104 Suppl 6:1239–46 (122 ref.)

Mechanistic considerations in benzene physiological model development. Medinsky MA, et al. **Environ Health Perspect** 1996 Dec;104 Suppl 6:1399–404 (39 ref.)

Emerging foodborne pathogens: Escherichia coli O157:H7 as a model of entry of a new pathogen into the food supply of the developed world. Armstrong GL, et al. **Epidemiol Rev** 1996;18(1):29–51 (179 ref.)

Cancer: a challenge for control theory and computer modelling. Düchting W, et al. **Eur J Cancer** 1996 Jul; 32A(8):1283–92 (48 ref.)

Absorption of beta-carotene and other carotenoids in humans and animal models. van Vliet T. **Eur J Clin Nutr** 1996 Jul;50 Suppl 3:S32–7 (59 ref.)

Foulds' dangerous idea revisited: the multistep development of tumors 40 years later. Klein G. **Folia Biol (Praha)** 1996; 42(6):273–81 (0 ref.)

Skin sensitization thresholds: determination in predictive models. Basketter DA, et al. **Food Chem Toxicol** 1997 Mar–Apr;35(3–4):417–25 (65 ref.)

The importance of L-arginine metabolism in melanoma: an hypothesis for the role of nitric oxide and polyamines in tumor angiogenesis. Joshi M. **Free Radic Biol Med** 1997; 22(3):573–8 (63 ref.)

Protein quality control: triage by chaperones and proteases. Gottesman S, et al. **Genes Dev** 1997 Apr 1;11(7):815–23 (70 ref.)

Ultraviolet light may contribute to geographic and racial blood pressure differences. Rostand SG. **Hypertension** 1997 Aug;30(2 Pt 1):150–6 (110 ref.)

A nonlinear mathematical model of electrically stimulated skeletal muscle. Dorgan SJ, et al. **IEEE Trans Rehabil Eng** 1997 Jun;5(2):179–94 (55 ref.)

Mathematical modelling of the spread of HIV/AIDS amongst injecting drug users. Greenhalgh D, et al. **IMA J Math Appl Med Biol** 1997 Mar;14(1):11–38 (42 ref.)

Mathematical modelling of avascular-tumour growth. Ward JP, et al. **IMA J Math Appl Med Biol** 1997 Mar;14(1):39–69 (50 ref.)

Computational analysis of blood volume dynamics during hemodialysis. Lopot F, et al. **Int J Artif Organs** 1997 Feb; 20(2):91–5 (4 ref.)

Building intelligent alarm systems by combining mathematical models and inductive machine learning techniques. Müller B, et al. **Int J Biomed Comput** 1996 Apr; 41(2):107–24 (18 ref.)

How did urodele embryos come into prominence as a model system? Beetschen JC. **Int J Dev Biol** 1996 Aug; 40(4):629–36 (97 ref.)

Models of biological pattern formation: common mechanism in plant and animal development. Meinhardt H. **Int J Dev Biol** 1996 Feb;40(1):123–34 (82 ref.)

What are the key advantages and disadvantages of urodele species compared to anurans as a model system for experimental analysis of early development? Nieuwkoop PD. **Int J Dev Biol** 1996 Aug;40(4):617–9 (16 ref.)

The chick embryo chorioallantoic membrane as a model for in vivo research on angiogenesis. Ribatti D, et al. **Int J Dev Biol** 1996 Dec;40(6):1189–97 (76 ref.)

The human/sheep xenograft model: a large animal model of human hematopoiesis. Zanjani ED, et al. **Int J Hematol** 1996 Apr;63(3):179–92 (88 ref.)

An adaptive Boolean automation to model circadian cycles. Perazzo RP, et al. **Int J Neural Syst** 1996 Mar;7(1):83–99 (10 ref.)

Cultural discourse and the myth of stress in nursing and medicine. Mulhall A. **Int J Nurs Stud** 1996 Oct; 33(5):455–68 (75 ref.)

Muscle cell and oxidative damage in aging: a century of hypothesis and personal contribution. Montanari G, et al. **Int J Tissue React** 1996;18(1):33–41 (55 ref.)

Cell model systems in plant cytoskeleton studies. Sonobe S. **Int Rev Cytol** 1997;175:1–27 (141 ref.)

Mathematical models of prevascular spheroid development and catastrophe-theoretic description of rapid metastatic growth/tumor remission. Adam JA. **Invasion Metastasis** 1996;16(4–5):247–67 (36 ref.)

Mathematical modelling, simulation and prediction of tumour-induced angiogenesis. Chaplain MA, et al.

Invasion Metastasis 1996;16(4–5):222–34 (62 ref.)
Tumor heterogeneity and progression: conceptual foundations for modeling. Greller LD, et al.
Invasion Metastasis 1996;16(4–5):177–208 (196 ref.)
Host response in tumor growth and progression. Michelson S, et al. **Invasion Metastasis** 1996;16(4–5):235–46 (31 ref.)
Biological inferences from a mathematical model for malignant invasion. Perumpanani AJ, et al.
Invasion Metastasis 1996;16(4–5):209–21 (46 ref.)
An operational perspective on measuring aerosol cloud dynamics. Burkett DA, et al.
J Am Mosq Control Assoc 1996 Jun;12(2 Pt 2):380–3 (4 ref.)
Overview of meteorological measurements for aerial spray modeling. Rafferty JE, et al. **J Am Mosq Control Assoc** 1996 Jun;12(2 Pt 2):364–7 (7 ref.)
Host response profiles: a new theory to help us understand why and how attractants attract. Roitberg BD, et al.
J Am Mosq Control Assoc 1994 Jun;10(2 Pt 2):333–8 (18 ref.)
An introduction to aerial spray modeling with FSCBG. Forest Service Cramer-Barry-Grim. Teske ME.
J Am Mosq Control Assoc 1996 Jun;12(2 Pt 2):353–8 (47 ref.)
Angiotensin in progressive renal diseases: theory and practice [editorial] Matsusaka T, et al. **J Am Soc Nephrol** 1996 Oct; 7(10):2025–43 (245 ref.)
Mathematical modeling of digestion and nutrient absorption in pigs. Bastianelli D, et al. **J Anim Sci** 1996 Aug; 74(8):1873–87 (86 ref.)
Modeling ruminant feed intake with protein, chemostatic, and distention feedbacks. Fisher DS. **J Anim Sci** 1996 Dec; 74(12):3076–81 (13 ref.)
Development of a mechanistic model of intake and chewing activities of sheep. Sauvant D, et al. **J Anim Sci** 1996 Nov; 74(11):2785–802 (90 ref.)
Characterization of growth parameters needed as inputs for pig growth models. Schinckel AP, et al. **J Anim Sci** 1996 Aug;74(8):2021–36 (132 ref.)
Predicting body cell mass with bioimpedance by using theoretical methods: a technological review. De Lorenzo A, et al. **J Appl Physiol** 1997 May;82(5):1542–58 (50 ref.)
Skeletal muscle: a paradigm for testing principles of bioenergetics. Kushmerick MJ. **J Bioenerg Biomembr** 1995 Dec;27(6):555–69 (65 ref.)
Regulation of energy metabolism in liver. Soboll S.
J Bioenerg Biomembr 1995 Dec;27(6):571–82 (92 ref.)
Mechanical validation of whole bone composite femur models [see comments] Cristofolini L, et al. **J Biomech** 1996 Apr;29(4):525–35 (44 ref.) Comment in: J Biomech 1996 Sep;29(9):1241.
Vibration effects on setting pregnant women--subjects of various masses. Qassem W, et al. **J Biomech** 1996 Apr; 29(4):493–501 (28 ref.)
Discussion of individual bioequivalence by M.-L. Chen. Gould AL. **J Biopharm Stat** 1997 Mar;7(1):23–9 (22 ref.)
Gastrointestinal illness and the biopsychosocial model [editorial] Drossman DA. **J Clin Gastroenterol** 1996 Jun; 22(4):252–4 (11 ref.)
Cell adhesion in vascular biology. New insights into integrin-ligand interaction. Loftus JC, et al.
J Clin Invest 1997 May 15;99(10):2302–6 (34 ref.)
Optimization of methods and models in clinical pharmacology. Gerloff J. **J Clin Pharmacol** 1997 Jan;37(1 Suppl):4S–7S (10 ref.)
Pharmacodynamic models to evaluate antithrombotics in clinical pharmacology. Müller TH. **J Clin Pharmacol** 1997 Jan;37(1 Suppl):49S–58S (77 ref.)
A novel approach to the understanding of human skin barrier function. Forslind B, et al. **J Dermatol Sci** 1997 Feb; 14(2):115–25 (28 ref.)
The influence of surface atmospheric conditions on the range and area reached by animal vocalizations. Larom D, et al. **J Exp Biol** 1997 Feb;200 (Pt 3):421–31 (31 ref.)
The response to calorie restriction in mammals shows features also common to hibernation: a cross-adaptation hypothesis. Walford RL, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jul;52(4):B179–83 (58 ref.)
Impact of intraocular pressure on venous outflow from the globe: a hypothesis regarding IOP-dependent vascular damage in normal-tension and hypertensive glaucoma. Bito LZ. **J Glaucoma** 1996 Apr;5(2):127–34 (40 ref.)
Early nutritional origins of hypertension: a hypothesis still lacking support. Paneth N, et al. **J Hypertens Suppl** 1996 Dec;14(5):S121–9 (45 ref.)
Myxoma T2 protein as a model for poxvirus TNF receptor homologs. McFadden G, et al. **J Neuroimmunol** 1997 Feb; 72(2):119–26 (47 ref.)
Functional changes appropriate for determining mineral element requirements. Lukaski HC, et al. **J Nutr** 1996 Sep; 126(9 Suppl):2354S–2364S (26 ref.)
Animal models for studying the genetic basis of metabolic regulation. Nizielski SE, et al. **J Nutr** 1996 Nov; 126(11):2697–708 (65 ref.)
Bayesian color constancy. Brainard DH, et al.
J Opt Soc Am A 1997 Jul;14(7):1393–411 (104 ref.)
Theories of menopause. Brief comparative synopsis [see comments] Barile LA.
J Psychosoc Nurs Ment Health Serv 1997 Feb;35(2):36–9 (19 ref.) Comment in: J Psychosoc Nurs Ment Health Serv 1997 May;35(5):10–1.
Multiple receptor populations: binding isotherms and their numerical analysis. Pliska V.
J Recept Signal Transduct Res 1995 Jan-Mar; 15(1–4):651–75 (36 ref.)
Relevance of multidrug resistance to rheumatoid arthritis: development of a new therapeutic hypothesis. Salmon SE, et al. **J Rheumatol Suppl** 1996 Mar;44:97–101 (30 ref.)
The role of microtubule assembly dynamics in mitotic force generation and functional organization of living cells. Inoué S. **J Struct Biol** 1997 Mar;118(2):87–93 (40 ref.)
Mechanism of fluid secretion common to aglomerular and glomerular kidneys. Beyenbach KW, et al. **Kidney Int** 1996 Jun;49(6):1543–8 (9 ref.)
A new biological framework for cancer research. Schipper H, et al. **Lancet** 1996 Oct 26;348(9035):1149–51 (33 ref.)
The myelodysplastic syndromes in 1996: complex stem cell disorders confounded by dual actions of cytokines [editorial; comment] Raza A, et al. **Leuk Res** 1996 Nov-Dec;20(11-12):881–90 (77 ref.) Comment on: Leuk Res 1996 Nov-Dec;20(11-12):891–900.
Acute leukemia and chemotherapy: a modeling viewpoint. Afenya E. **Math Biosci** 1996 Dec;138(2):79–100 (30 ref.)
Dynamical complexity in age-structured models of the transmission of the measles virus: epidemiological implications at high levels of vaccine uptake. Ferguson NM, et al. **Math Biosci** 1996 Dec;138(2):101–30 (52 ref.)
A patient-specific in vivo tumor model. Wasserman R, et al. **Math Biosci** 1996 Sep;136(2):111–40 (47 ref.)
A diversity of responses displayed by a stochastic model of radiation carcinogenesis allowing for cell death. Yakovlev A, et al. **Math Biosci** 1996 Feb;132(1):1–33 (80 ref.)
Modelling nanoscale fluid dynamics and transport in physiological flows. Ciofalo M, et al. **Med Eng Phys** 1996 Sep;18(6):437–51 (88 ref.)
Discussion on the design of a hip joint simulator. Viceconti M, et al. **Med Eng Phys** 1996 Apr;18(3):234–40 (20 ref.)
Three-component model of oestrogen formation and regulation of intratumoural oestrogen pool in breast neoplasms. Berstein LM, et al. **Med Hypotheses** 1995 Dec; 45(6):588–90 (23 ref.)
What is the role of the gamma-hydroxybutyrate receptor? Cash CD. **Med Hypotheses** 1996 Dec;47(6):455–9 (41 ref.)
De virginibus puerisque: the function of the human foreskin considered from an evolutionary perspective. Cox G.
Med Hypotheses 1995 Dec;45(6):617–21 (18 ref.)
The role of radial reflux in the genesis of varicose veins. Crotty TP. **Med Hypotheses** 1996 Dec;47(6):449–54 (32 ref.)
Sudden infant death syndrome: a hypothesis. David CM.
Med Hypotheses 1997 Jul;49(1):61–7 (73 ref.)
Figuring out why we breathe. Farnsworth WE.
Med Hypotheses 1997 Mar;48(3):229–36 (54 ref.)
Landscapes of longevity: the calcium-selenium-mercury connection in cancer and heart disease. Foster HD.
Med Hypotheses 1997 Apr;48(4):355–60 (76 ref.)
"Aging bull'. Geelhoed GW. **Med Hypotheses** 1996 Dec; 47(6):471–9 (9 ref.)
The 'cancell' theory of carcinogenesis: re-evolution of an ancient, holistic neoplastic unicellular concept of cancer. Grossgebauer K. **Med Hypotheses** 1995 Dec;45(6):545–55 (92 ref.)
Reverse learning and the physiological basis of eye movement desensitization. Hassard A. **Med Hypotheses** 1996 Oct; 47(4):277–82 (45 ref.)
Interleukin-1 beta: a common cause of Alzheimer's disease and diabetes mellitus. Holden RJ, et al.
Med Hypotheses 1995 Dec;45(6):559–71 (108 ref.)
Immunological influences in attention-deficit disorder and schizophrenia; is there a link between these two conditions? Holden RJ, et al. **Med Hypotheses** 1995 Dec;45(6):575–87 (121 ref.)
Possible relevance of phospholipid abnormalities and genetic interactions in psychiatric disorders: the relationship between dyslexia and schizophrenia. Horrobin DF, et al. **Med Hypotheses** 1995 Dec;45(6):605–13 (70 ref.)
Tissue regeneration as the basic oncogenic factor. Korystov YN. **Med Hypotheses** 1996 Sep;47(3):183–90 (51 ref.)
The role of gastric mast cells, enterochromaffin-like cells and parietal cells in the regulation of acid secretion. Kurbel S, et al. **Med Hypotheses** 1995 Dec;45(6):539–42 (22 ref.)
Complexity and complicity in eclampsia: barriers or bridges? López-Llera M. **Med Hypotheses** 1995 Dec;45(6):591–601 (152 ref.)
Mutations in the c-erbA beta 1 gene: do they underlie euthyroid fibromyalgia? Lowe JC, et al.
Med Hypotheses 1997 Feb;48(2):125–35 (152 ref.)
natural antimutagenic agents may prolong efficacy of human immunodeficiency virus drug therapy. McCarty MF.
Med Hypotheses 1997 Mar;48(3):215–20 (77 ref.)
Magnesium taurate and fish oil for prevention of migraine. McCarty MF. **Med Hypotheses** 1996 Dec;47(6):461–6 (94 ref.)
The post-activation refractory phase: a mechanism to measure antigenic complexity and ensure self-tolerance among mature peripheral T lymphocytes. Mannie MD.
Med Hypotheses 1996 Dec;47(6):467–70 (37 ref.)
An electromagnetic coupling hypothesis to explain the proton translocation mechanism in mitochondria, bacteria and chloroplasts. Menèndez RG. **Med Hypotheses** 1996 Sep; 47(3):179–82 (12 ref.)
Evolutionary sexology: the hypothesis of song and sex. Money J. **Med Hypotheses** 1997 May;48(5):399–402 (14 ref.)
Deleterious effects of prostaglandin E2 in oesophageal carcinogenesis. Morgan G. **Med Hypotheses** 1997 Feb; 48(2):177–81 (10 ref.)
Homeostatic disruption and depression. Naisberg Y.
Med Hypotheses 1996 Dec;47(6):415–22 (60 ref.)
Dairy products and breast cancer: the IGF-I, estrogen, and bGH hypothesis. Outwater JL, et al. **Med Hypotheses** 1997 Jun;48(6):453–61 (131 ref.)
High plasma interleukin-2: a potential cause of insulin resistance. Penttinen J. **Med Hypotheses** 1995 Dec; 45(6):614–6 (30 ref.)
Is sleep apnea a predisposing factor for tobacco use? Schrand JR. **Med Hypotheses** 1996 Dec;47(6):443–8 (37 ref.)
Cancer as a complex adaptive system. Schwab ED, et al.
Med Hypotheses 1996 Sep;47(3):235–41 (15 ref.)
Modeling signal transduction in normal and cancer cells using complex adaptive systems. Schwab ED, et al.
Med Hypotheses 1997 Feb;48(2):111–23 (55 ref.)
Effects of natural and man-made electric/electromagnetic fields on human health: a possible mechanism. Sher L.
Med Hypotheses 1997 Jul;49(1):31–4 (29 ref.)
Eating disorders and reflex sympathetic dystrophy syndrome: is there a common pathway? Silber TJ.
Med Hypotheses 1997 Mar;48(3):197–200 (21 ref.)
Zinc-controlled Th1/Th2 switch significantly determines development of diseases. Sprietsma JE. **Med Hypotheses** 1997 Jul;49(1):1–14 (82 ref.)
Unifying concepts in mechanism of amblyopia. Tong LM.
Med Hypotheses 1997 Feb;48(2):97–102 (31 ref.)
CYP 2D6 PM phenotype hypothesis of antidepressant extrapyramidal side-effects. Vandel P, et al.
Med Hypotheses 1996 Dec;47(6):439–42 (35 ref.)
The possible role of peroxynitrite in Alzheimer's disease: a simple hypothesis that could be tested more thoroughly. Van Dyke K. **Med Hypotheses** 1997 May;48(5):375–80 (49 ref.)
Can risk factors for over-heating explain epidemiological features of sudden infant death syndrome? Wells JC.
Med Hypotheses 1997 Feb;48(2):103–6 (42 ref.)
Gaining more insight into the pathomechanisms of thiol-induced acanthолysis. Wolf R, et al.
Med Hypotheses 1997 Feb;48(2):107–10 (23 ref.)
Deleterious network hypothesis of aging. Ying W.
Med Hypotheses 1997 Feb;48(2):143–8 (71 ref.)
Using models to explore whole-body metabolism and accessing models through a model library. Wastney ME, et al. **Metabolism** 1997 Mar;46(3):330–2 (18 ref.)
Mechanism of leakage of contents of membrane vesicles determined by fluorescence requenching. Ladokhin AS, et al. **Methods Enzymol** 1997;278:474–86 (17 ref.)
Distribution analysis of depth-dependent fluorescence quenching in membranes: a practical guide. Ladokhin AS.
Methods Enzymol 1997;278:462–73 (27 ref.)
Are bacterial biofilms constrained to Darwin's concept of evolution through natural selection? Caldwell DE, et al.
Microbiologia 1996 Sep;12(3):347–58 (61 ref.)
Control of cardiac performance by Ca-turnover. Simurda J, et al. **Mol Cell Biochem** 1996 Jul-Aug;160–161:5–12 (20 ref.)
Model organisms illuminate human genetics and disease. van Heyningen V. **Mol Med** 1997 Apr;3(4):231–7 (48 ref.)
Coating the surface: a model for expression of capsular polysialic acid in Escherichia coli K1. Bliss JM, et al.
Mol Microbiol 1996 Jul;21(2):221–31 (68 ref.)
Quelling the red menace: haem capture by bacteria [see comments] Lee BC. **Mol Microbiol** 1995 Nov;18(3):383–90 (82 ref.) Comment in: Mol Microbiol 1996 Apr;20(1):238.
Complexity measures in molecular psychiatry. Rapp PE, et al. **Mol Psychiatry** 1996 Nov;1(5):408–16 (83 ref.)
Studies on the regulation of food intake using rat total parenteral nutrition as a model. Opara EI, et al.
Neurosci Biobehav Rev 1996 Autumn;20(3):413–43 (206 ref.)
A model of the transmission of antibiotic-resistant bacteria in the intensive care unit. Barza M. **New Horiz** 1996 Aug; 4(3):333–7 (29 ref.)
Origins of life: a comparison of theories and application to Mars. Davis WL, et al. **Orig Life Evol Biosph** 1996 Feb; 26(1):61–73 (105 ref.)
The peritoneal dialysis system: importance of each component. Flessner MF. **Perit Dial Int** 1997;17 Suppl 2:S91–7 (39 ref.)
Beta innervation and recurrent inhibition: a hypothesis for manipulatory and postural control. Illert M, et al.
Pflugers Arch 1996;432(3 Suppl):R61–7 (62 ref.)
The theory of and experimentation into respiratory gas exchange--Carl Ludwig and his school. Schubert E.
Pflugers Arch 1996;432(3 Suppl):R111–9 (34 ref.)
Controversies on glomerular filtration from Ludwig to the present. Steinhausen M, et al. **Pflugers Arch** 1996;432(3 Suppl):R73–81 (79 ref.)
Review of theoretical passive drug absorption models: historical background, recent developments and limitations. Camenisch G, et al. **Pharm Acta Helv** 1996 Nov; 71(5):309–27 (114 ref.)
General principles in the characterization and use of model systems for biopharmaceutical studies. Borchardt RT, et al. **Pharm Biotechnol** 1996;8:1–11 (51 ref.)
Working memory and executive control. Baddeley A, et al.
Philos Trans R Soc Lond B Biol Sci 1996 Oct 29; 351(1346):1397–403; discussion 1403–4 (34 ref.)
A computational approach to prefrontal cortex, cognitive control and schizophrenia: recent developments and current challenges. Cohen JD, et al.
Philos Trans R Soc Lond B Biol Sci 1996 Oct 29;

351(1346):1515–27 (80 ref.)
The somatic marker hypothesis and the possible functions of the prefrontal cortex. Damasio AR. **Philos Trans R Soc Lond B Biol Sci** 1996 Oct 29; 351(1346):1413–20 (43 ref.)
Avian models in developmental biology. Dieterlen-Lièvre F. **Poult Sci** 1997 Jan;76(1):78–82 (44 ref.)
Modeling incubation temperature: the effects of incubator design, embryonic development, and egg size. French NA. **Poult Sci** 1997 Jan;76(1):124–33 (52 ref.)
Coordinating DNA replication with cell division: current status of the licensing concept [comment] Botchan M. **Proc Natl Acad Sci U S A** 1996 Sep 17;93(19):9997–10000 (42 ref.) Comment on: Proc Natl Acad Sci U S A 1996 Sep 17;93(19):10189–94.
Directionality principles in thermodynamics and evolution. Demetrius L. **Proc Natl Acad Sci U S A** 1997 Apr 15; 94(8):3491–8 (40 ref.)
Rappaport rules: cleavage furrow induction in animal cells [comment] Oegema K, et al. **Proc Natl Acad Sci U S A** 1997 May 13;94(10):4817–20 (35 ref.) Comment on: Proc Natl Acad Sci U S A 1997 May 13;94(10):5107–12.
The N-end rule: functions, mysteries, uses. Varshavsky A. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12142–9 (79 ref.)
Modelling post-absorptive protein and amino acid metabolism in the ruminant. Hanigan MD, et al. **Proc Nutr Soc** 1997 Jul;56(2):631–43 (49 ref.)
Mathematical modelling of nitrogen flow in growing pigs and lactating sows. Pettigrew JE. **Proc Nutr Soc** 1997 Jul; 56(2):645–56 (27 ref.)
Biologically based artificial navigation systems: review and prospects. Trullier O, et al. **Prog Neurobiol** 1997 Apr; 51(5):483–544 (153 ref.)
Nonesterified fatty acids in the pathogenesis of hypertension: theory and evidence. Goodfriend TL, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Jul; 57(1):57–63 (43 ref.)
Models of parasite virulence. Frank SA. **Q Rev Biol** 1996 Mar;71(1):37–78 (105 ref.)
Modelling immunocontraception in disseminating systems. Barlow ND. **Reprod Fertil Dev** 1997;9(1):51–60 (14 ref.)
On the asymmetry of bifurcations in the bronchial tree. Phillips CG, et al. **Respir Physiol** 1997 Jan;107(1):85–98 (22 ref.)
Regulation of energy balance and adiposity: a model with new approaches. Martínez JA, et al. **Rev Esp Fisiol** 1996 Dec;52(4):255–8 (21 ref.)
Development and applications of the SCID-hu mouse model. McCune JM. **Semin Immunol** 1996 Aug;8(4):187–96 (66 ref.)
Preclinical models of prostate cancer. Royai R, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 14):35–40 (18 ref.)
The use of animal models in exercise and pregnancy research. Mottola MF. **Semin Perinatol** 1996 Aug;20(4):222–31 (59 ref.)
An integrated computational model of three-dimensional vision. Uttal WR, et al. **Spat Vis** 1996;9(4):393–422 (46 ref.)
Is the nucleus pulposus a solid or a fluid? Mechanical behaviors of the nucleus pulposus of the human intervertebral disc. Iatridis JC, et al. **Spine** 1996 May 15; 21(10):1174–84 (68 ref.)
Modeling of risk factors for ischemic stroke. The Willis Lecture. Whisnant JP. **Stroke** 1997 Sep;28(9):1840–4 (8 ref.)
Using structural information to create physiologically based pharmacokinetic models for all polychlorinated biphenyls. Parham FM, et al. **Toxicol Appl Pharmacol** 1997 Jun; 144(2):340–7 (27 ref.)
Fractional effective dose model for post-crash aircraft survivability. Speitel LC. **Toxicology** 1996 Dec 31; 115(1–3):167–77 (30 ref.)
Biological response to blast overpressure: a summary of modeling. Stuhmiller JH. **Toxicology** 1997 Jul 25; 121(1):91–103 (45 ref.)
Tripping the switch fantastic: how a protein kinase cascade can convert graded inputs into switch-like outputs [see comments] Ferrell JE Jr. **Trends Biochem Sci** 1996 Dec; 21(12):460–6 (32 ref.) Comment in: Trends Biochem Sci 1997 Aug;22(8):288.
Chemical kinetic theory: understanding cell-cycle regulation. Tyson JJ, et al. **Trends Biochem Sci** 1996 Mar;21(3):89–96 (47 ref.)
Evolutionary origins and maintenance of redundant gene expression during metazoan development. Cooke J, et al. **Trends Genet** 1997 Sep;13(9):360–4 (44 ref.)
Multiple mechanisms underlying the orientation selectivity of visual cortical neurones. Vidyasagar TR, et al. **Trends Neurosci** 1996 Jul;19(7):272–7 (61 ref.)
The design of veterinary vaccination programmes [see comments] Woolhouse ME, et al. **Vet J** 1997 Jan; 153(1):41–7 (18 ref.) Comment in: Vet J 1997 Jan;153(1):7–8.
[Mini-review: oocyte activation mechanisms. Different models, comparison: marine invertebrate and mammal] Ciapa B, et al. **Contracept Fertil Sex** 1996 Jul–Aug; 24(7–8):564–70 (47 ref.) (Eng. Abstr.) **(Fre)**
[Assessment of insulin resistance by minimal model analysis] Takahashi Y, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:252–5 (9 ref.) **(Jpn)**

MODELS, CARDIOVASCULAR

Theoretical predictions of end-capillary PO2 in muscles of athletic and nonathletic animals at VO2max. Roy TK, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):H721–37 (72 ref.)
Stratified multiphase model for blood flow in a venular bifurcation. Das B, et al. **Ann Biomed Eng** 1997 Jan–Feb; 25(1):135–53 (32 ref.)
Role of wavefront curvature in propagation of cardiac impulse. Fast VG, et al. **Cardiovasc Res** 1997 Feb; 33(2):258–71 (86 ref.)
Lipid hypothesis of cardiovascular calcification [editorial; comment] Demer LL. **Circulation** 1997 Jan 21;95(2):297–8 (18 ref.) Comment on: Circulation 1997 Jan 21;95(2):479–88.
Abnormalities of the S–T segment--Part I. Hurst JW. **Clin Cardiol** 1997 Jun;20(6):511–20 (10 ref.)
Oxygen delivery in critical illness. Baigorri F, et al. **Crit Care Clin** 1996 Oct;12(4):971–94 (91 ref.)
Pulmonary capillary pressure. Clinical implications. Levy MM. **Crit Care Clin** 1996 Oct;12(4):819–39 (47 ref.)
Determination of oxygen delivery and consumption versus cardiac index and oxygen extraction ratio. Vincent JL. **Crit Care Clin** 1996 Oct;12(4):995–1006 (29 ref.)
Modeling of cardiac electrophysiological mechanisms: from action potential genesis to its propagation in myocardium. Bardou AL, et al. **Crit Rev Biomed Eng** 1996; 24(2–3):141–221 (113 ref.)
Experimental models of accelerated atherosclerosis syndromes. Mehta D, et al. **Int J Cardiol** 1996 Oct 25; 56(3):235–57 (182 ref.)
Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. Becker BN, et al. **J Am Soc Nephrol** 1997 Mar;8(3):475–86 (136 ref.)
The autonomic nervous system: a Sherringtonian revision of its integrated properties in the control of circulation. Malliani A. **J Auton Nerv Syst** 1997 Jun 6;64(2–3):158–61 (26 ref.)
Stretch-activated ion channels in the heart. Hu H, et al. **J Mol Cell Cardiol** 1997 Jun;29(6):1511–23 (145 ref.)
Glucosamine may retard atherogenesis by promoting endothelial production of heparan sulfate proteoglycans. McCarty MF. **Med Hypotheses** 1997 Mar;48(3):245–51 (94 ref.)
Cardiomyopathies and oxidative stress. Romero-Alvira D, et al. **Med Hypotheses** 1996 Aug;47(2):137–44 (89 ref.)
A unifying theory of atherogenesis. Sloop GD. **Med Hypotheses** 1996 Oct;47(4):321–5 (35 ref.)
The elusive local factor in atherosclerosis. Stehbens WE. **Med Hypotheses** 1997 Jun;48(6):503–9 (55 ref.)
Clinical models of cardiovascular regulation after weightlessness. Robertson D, et al. **Med Sci Sports Exerc** 1996 Oct;28(10 Suppl):S80–4 (28 ref.)
Relevance and reliability of Ludwig's scientific conceptions of the physiology of the microcirculation. Schröer H. **Pflugers Arch** 1996;432(3 Suppl):R23–32 (59 ref.)
Fibrin degradation in the synovial fluid of rheumatoid arthritis patients: a model for extravascular fibrinolysis. Carmassi F, et al. **Semin Thromb Hemost** 1996;22(6):489–96 (90 ref.)
The heart as a self-regulating system: integration of homeodynamic mechanisms. Kresh JY, et al. **Technol Health Care** 1997 Apr;5(1–2):159–69 (30 ref.)
The heart muscle's putative "secondary structure'. Functional implications of a band-like anisotropy. Lunkenheimer PP, et al. **Technol Health Care** 1997 Apr;5(1–2):53–64 (53 ref.)

MODELS, CHEMICAL

Chemical morphogenesis: turing patterns in an experimental chemical system. Dulos E, et al. **Acta Biotheor** 1996 Nov; 44(3–4):249–61 (38 ref.)
Criticality found in a model for orientational ordering of protein arrays. Hogyoku M. **Adv Biophys** 1997;34:55–68 (25 ref.)
Historical evolution of circuit models for the electrode-electrolyte interface. Geddes LA. **Ann Biomed Eng** 1997 Jan–Feb;25(1):1–14 (52 ref.)
Advanced EPR spectroscopy on electron transfer processes in photosynthesis and biomimetic model systems. Levanon H, et al. **Annu Rev Biophys Biomol Struct** 1997;26:495–540 (223 ref.)
Catalysis by entropic guidance from enzymes. Young L, et al. **Biochemistry** 1996 Dec 3;35(48):15129–33 (23 ref.)
Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The "wooden shoe' paradigm. Breimer DD, et al. **Clin Pharmacokinet** 1997 Apr;32(4):259–67 (35 ref.)
Purpose and guidelines for toxicokinetic studies within the National Toxicology Program. Buchanan JR, et al. **Environ Health Perspect** 1997 May;105(5):468–71 (4 ref.)
Folding studies on ribonuclease A, a model protein. Neira JL, et al. **Fold Des** 1997;2(1):R1–11 (70 ref.)
Modeling protein folding: the beauty and power of simplicity. Shakhnovich EI. **Fold Des** 1996;1(3):R50–4 (41 ref.)
Hydrogen bonding and stacking of DNA bases: a review of quantum-chemical ab initio studies. Sponer J, et al. **J Biomol Struct Dyn** 1996 Aug;14(1):117–35 (122 ref.)
Theory of phase formation in aqueous two-phase systems. Cabezas H Jr. **J Chromatogr B Biomed Appl** 1996 May 17;680(1–2):3–30 (98 ref.)
Current limitations to protein threading approaches. Smith TF, et al. **J Comput Biol** 1997 Fall;4(3):217–25 (23 ref.)
Molecular docking towards drug discovery. Gschwend DA, et al. **J Mol Recognit** 1996 Mar–Apr;9(2):175–86 (112 ref.)
Experimental results from host-guest complexes for the design of effectors in biological systems and of enzyme analogous catalysts. Schneider HJ, et al. **J Mol Recognit** 1996 Mar–Apr;9(2):123–32 (48 ref.)
Thermodynamic parameters of ligand-receptor interactions: computation and error margins [published erratum appears in J Recept Signal Transduct Res 1997 Jul;17(4):667] Pliška V. **J Recept Signal Transduct Res** 1997 Jan–May; 17(1–3):495–510 (22 ref.)
1La and 1Lb transitions of tryptophan: applications of theory and experimental observations to fluorescence of proteins. Callis PR. **Methods Enzymol** 1997;278:113–50 (86 ref.)
Mirror symmetry breaking at the molecular level. Avetisov V, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15; 93(21):11435–42 (59 ref.)
The N-end rule: functions, mysteries, uses. Varshavsky A. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12142–9 (79 ref.)
Orientational order determination by internal reflection infrared spectroscopy. Axelsen PH, et al. **Prog Biophys Mol Biol** 1996;66(3):227–53 (107 ref.)
Membrane bioelectrogenesis and ionic channel activity simulation under drug action. Pennec JP, et al. **Rom J Physiol** 1995 Jan–Dec;32(1–4):3–10 (20 ref.)
Checking your imagination: applications of the free R value. Kleywegt GJ, et al. **Structure** 1996 Aug 15;4(8):897–904 (39 ref.)
[Accounting for conformational flexibility of molecules in structure-property studies] Mekenian OG, et al. **Vopr Med Khim** 1997 May–Jun;43(3):127–38 (19 ref.) (Eng. Abstr.) **(Rus)**

MODELS, COMPUTER see **COMPUTER SIMULATION**

MODELS, DECISION SUPPORT see **DECISION SUPPORT TECHNIQUES**

MODELS, ECONOMETRIC

Assigning values to intermediate health states for cost-utility analysis: theory and practice. Cohen BJ. **Med Decis Making** 1996 Oct–Dec;16(4):376–85 (56 ref.)

MODELS, ECONOMIC

Different approaches to modeling the cost-effectiveness of schistosomiasis control. Guyatt HL, et al. **Am J Trop Med Hyg** 1996 Nov;55(5 Suppl):159–64 (27 ref.)
Physician payment policies: impacts and implications. Rice T. **Annu Rev Public Health** 1997;18:549–65 (32 ref.)
Pharmacoeconomics: state of the art in 1997. Schulman KA, et al. **Annu Rev Public Health** 1997;18:529–48 (50 ref.)
Income dynamics and health. Duncan GJ. **Int J Health Serv** 1996;26(3):419–44 (57 ref.)
Discounting the future: influence of the economic model [see comments] West RR. **J Epidemiol Community Health** 1996 Jun;50(3):239–44 (27 ref.) Comment in: J Epidemiol Community Health 1997 Jun;51(3):339–40.
What does economics have to say about health policy anyway? A comment and correction on Evans and Rice [comment] Gaynor M, et al. **J Health Polit Policy Law** 1997 Apr;22(2):475–96; discussion 497–508 (8 ref.) Comment on: J Health Polit Policy Law 1997 Apr;22(2):383–426. Comment on: J Health Polit Policy Law 1997 Apr;22(2):427–65.
Can markets give us the health system we want? [see comments] Rice T. **J Health Polit Policy Law** 1997 Apr; 22(2):383–426 (76 ref.) Comment in: J Health Polit Policy Law 1997 Apr;22(2):467–73. Comment in: J Health Polit Policy Law 1997 Apr;22(2):475–96.
Productivity growth in health-care delivery. Färe R, et al. **Med Care** 1997 Apr;35(4):354–66 (31 ref.)

MODELS, EDUCATIONAL

The reproductive health awareness (RHA) model: a qualitative perspective. Wilson A. **Adv Contracept** 1997 Jun–Sep;13(2–3):339–42 (3 ref.)
Early intervention for young children with developmental delay: the Portage approach. Cameron RJ. **Child Care Health Dev** 1997 Jan;23(1):11–27 (51 ref.)
Analysis of Akinsanya's model of bionursing. Casey G. **J Adv Nurs** 1996 Jun;23(6):1065–70 (29 ref.)
Constructing meaning in the learning experience: the role of alternative theoretical frameworks. Lauder W. **J Adv Nurs** 1996 Jul;24(1):91–7 (50 ref.)
Supportive learning in distance education. Lawton S. **J Adv Nurs** 1997 May;25(5):1076–83 (34 ref.)
[Educational training simulator systems in anesthesiology] Morita K. **Masui** 1996 Dec;45 Suppl:S164–7 (9 ref.) **(Jpn)**
[Crisis management training using anesthesia simulator] Tominaga M, et al. **Masui** 1996 Dec;45 Suppl:S156–60 (1 ref.) **(Jpn)**

MODELS, GENETIC

Lessons from genetic models of inflammatory bowel disease.

Podolsky DK. **Acta Gastroenterol Belg** 1997 Apr-Jun; 60(2):163-5 (20 ref.)
Is genomic imprinting involved in the pathogenesis of hyperdiploid and haploid acute lymphoblastic leukemia of childhood? Haas OA. **Acta Genet Med Gemellol (Roma)** 1996;45(1-2):239-42 (18 ref.)
Semper fidelis: what man's best friend can teach us about human biology and disease. Ostrander EA, et al. **Am J Hum Genet** 1997 Sep;61(3):475-80 (32 ref.)
Baboons as an animal model for genetic studies of common human disease. Rogers J, et al. **Am J Hum Genet** 1997 Sep;61(3):489-93 (41 ref.)
Coalescents and genealogical structure under neutrality. Donnelly P, et al. **Annu Rev Genet** 1995;29:401-21 (52 ref.)
Towards a unified evolutionary genetics of microorganisms. Tibayrenc M. **Annu Rev Microbiol** 1996;50:401-29 (75 ref.)
A model of the translational apparatus based on a three-dimensional reconstruction of the Escherichia coli ribosome. Frank J, et al. **Biochem Cell Biol** 1995 Nov-Dec; 73(11-12):757-65 (38 ref.)
Regulation of promoters by two transcription activators: evidence for a 'simultaneous touching' model. Savery N, et al. **Biochem Soc Trans** 1996 May;24(2):351-3 (9 ref.)
Transgenic and knock-out models for studying DNA repair. Allemand I, et al. **Biochimie** 1995;77(10):826-32 (62 ref.)
Mouse models of human genetic disease: which mouse is more like a man? Erickson RP. **Bioessays** 1996 Dec; 18(12):993-8 (58 ref.)
Another nail in the coffin of the multiple-origins theory? Wills C. **Bioessays** 1996 Dec;18(12):1017-20 (15 ref.)
A molecular genetic model of astrocytoma histopathology. Louis DN. **Brain Pathol** 1997 Apr;7(2):755-64 (81 ref.)
Population genetics of tumours. Bodmer WF, et al. **Ciba Found Symp** 1996;197:181-9; discussion 189-93 (21 ref.)
Microsatellites: evolution and mutational processes. Freimer NB, et al. **Ciba Found Symp** 1996;197:51-67; discussion 67-72 (56 ref.)
Genetic architecture of common multifactorial diseases. Sing CF, et al. **Ciba Found Symp** 1996;197:211-29; discussion 229-32 (70 ref.)
Interaction of ion channels and receptors with PDZ domain proteins. Kornau HC, et al. **Curr Opin Neurobiol** 1997 Jun; 7(3):368-73 (35 ref.)
The Thrifty Phenotype hypothesis: how does it look after 5 years? Hales CN, et al. **Diabet Med** 1997 Mar;14(3):189-95 (53 ref.)
The topology of transcription by immobilized polymerases. Iborra FJ, et al. **Exp Cell Res** 1996 Dec 15;229(2):167-73 (27 ref.)
Retroviruses and retroelements in diseases and in gene therapy. Svoboda J. **Folia Biol (Praha)** 1996;42(6):283-94 (46 ref.)
Once and only once upon a time: specifying and regulating origins of DNA replication in eukaryotic cells. Diffley JF. **Genes Dev** 1996 Nov 15;10(22):2819-30 (80 ref.)
Impact of migration and fitness on the stability of lethal t-haplotype polymorphism in Mus musculus: a computer study. Durand D, et al. **Genetics** 1997 Apr;145(4):1093-108 (38 ref.)
Chiasma interference is blind to centromeres. Colombo PC, et al. **Heredity** 1997 Aug;79 (Pt 2):214-27 (46 ref.)
Genetic models in the study of anesthetic drug action. Simpson VJ, et al. **Int Rev Neurobiol** 1996;39:223-41 (59 ref.)
Technical note: optimization of breed composition to maximize net merit of synthetic populations. Lin CY. **J Anim Sci** 1996 Jul;74(7):1477-80 (12 ref.)
Functional interrelationships between nuclear structure and transcriptional control: contributions to regulation of cell cycle- and tissue-specific gene expression. Stein GS, et al. **J Cell Biochem** 1996 Aug;62(2):198-209 (102 ref.)
Hypothesis for a serine proteinase-like domain at the COOH terminus of Slowpoke calcium-activated potassium channels. Moss GW, et al. **J Gen Physiol** 1996 Dec; 108(6):473-84 (82 ref.)
A paradigmatic shift in the approach to neuropsychiatric gene linkage may require an anthropogenetic perspective. Gericke GS. **Med Hypotheses** 1995 Dec;45(6):517-22 (65 ref.)
Splicing glue: a role for SR proteins in trans splicing? Bruzik JP. **Microb Pathog** 1996 Sep;21(3):149-55 (65 ref.)
Stable DNA replication: interplay between DNA replication, homologous recombination, and transcription. Kogoma T. **Microbiol Mol Biol Rev** 1997 Jun;61(2):212-38 (266 ref.)
Transgenic modeling of neuropsychiatric disorders. Campbell IL, et al. **Mol Psychiatry** 1996 May;1(2):105-20 (148 ref.)
Natural antisense RNA/target RNA interactions: possible models for antisense oligonucleotide drug design. Delihas N, et al. **Nat Biotechnol** 1997 Aug;15(8):751-3 (55 ref.)
The minimal cell genome: "on being the right size" [comment] Maniloff J. **Proc Natl Acad Sci U S A** 1996 Sep 17; 93(19):10004-6 (25 ref.) Comment on: Proc Natl Acad Sci U S A 1996 Sep 17;93(19):10268-73.
The objects of selection. Mayr E. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2091-4 (19 ref.)
Genetic conflicts. Hurst LD, et al. **Q Rev Biol** 1996 Sep; 71(3):317-64 (279 ref.)
What can genetic models tell us about behavioral plasticity? Sadile AG. **Rev Neurosci** 1993 Jul-Sep;4(3):287-303 (142 ref.)
The Min mouse: a genetic model for intestinal carcinogenesis. Thompson MB. **Toxicol Pathol** 1997 May-Jun;25(3):329-32 (31 ref.)
Molecular determinants of mammmalian sex. Werner MH, et al. **Trends Biochem Sci** 1996 Aug;21(8):302-8 (49 ref.)
Directing alternative splicing: cast and scenarios. Chabot B. **Trends Genet** 1996 Nov;12(11):472-8 (63 ref.)
Complications and implications of linear bacterial chromosomes. Chen CW. **Trends Genet** 1996 May; 12(5):192-6 (25 ref.)
Hybrid sterility in the mouse [published erratum appears in Trends Genet 1997 Jan;13(1):42] Forejt J. **Trends Genet** 1996 Oct;12(10):412-7 (51 ref.)
Puzzling out the genetics of mammalian sex determination. Jiménez R, et al. **Trends Genet** 1996 May;12(5):164-6 (34 ref.)

MODELS, IMMUNOLOGICAL

Food allergy in atopic dogs. Frick OL. **Adv Exp Med Biol** 1996;409:1-7 (9 ref.)
Murine animal models to study the central role of T cells in immediate-type hypersensitivity responses. Herz U, et al. **Adv Exp Med Biol** 1996;409:25-32 (20 ref.)
Mechanisms of allergic bronchoconstriction in the rat. Martin JG. **Adv Exp Med Biol** 1996;409:9-15 (21 ref.)
The microcirculation in venous hypertension. Smith PD. **Cardiovasc Res** 1996 Oct;32(4):789-95 (59 ref.)
T-cell repertoire: political correctness in the immune system. Lucas B, et al. **Curr Biol** 1996 Jul 1;6(7):783-7 (12 ref.)
Lymphocyte migration into tissue: the paradigm derived from CD4 subsets. Bradley LM, et al. **Curr Opin Immunol** 1996 Jun;8(3):312-20 (64 ref.)
The immunopathogenesis of multiple sclerosis and Guillain-Barré syndrome. Giovannoni G, et al. **Curr Opin Neurol** 1996 Jun;9(3):165-77 (134 ref.)
QSAR predictive of contact allergy: scope and limitations. Hostýnek JJ, et al. **Curr Probl Dermatol** 1996;25:18-27 (34 ref.)
The avian model in the study of tolerance to self. Corbel C. **Curr Top Microbiol Immunol** 1996;212:95-106 (44 ref.)
Making the T cell receptor go the distance: a topological view of T cell activation. Shaw AS, et al. **Immunity** 1997 Apr;6(4):361-9 (58 ref.)
A model for developmentally acquired thymus-dependent tolerance to central and peripheral antigens. Modigliani Y, et al. **Immunol Rev** 1996 Feb;149:155-20 (58 ref.)
Immune deviation--the third dimension of nondeletional T cell tolerance. Röcken M, et al. **Immunol Rev** 1996 Feb; 149:175-94 (104 ref.)
CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model. Van Gool SW, et al. **Immunol Rev** 1996 Oct;153:47-83 (150 ref.)
CTLA-4, a negative regulator of T-lymphocyte activation. Waterhouse P, et al. **Immunol Rev** 1996 Oct;153:183-207 (130 ref.)
Terra firma: a retreat from "danger". Langman RE, et al. **J Immunol** 1996 Nov 15;157(10):4273-6 (15 ref.)
A model for induction of T cell-independent humoral immunity in response to polysaccharide antigens. Snapper CM, et al. **J Immunol** 1996 Sep 15;157(6):2229-33 (72 ref.)
Mechanism and computer simulation of immune complex formation, opsonization, and clearance. Head M, et al. **J Lab Clin Med** 1996 Jul;128(1):61-74 (42 ref.)
Acquired immune deficiency syndrome caused by hyperimmunity. Chigira M. **Med Hypotheses** 1996 Jun; 46(6):489-98 (139 ref.)
Does human toxoplasmosis involve an imbalance in T1/T2 cytokines? Gómez Marín JE, et al. **Med Hypotheses** 1997 Feb;48(2):161-9 (72 ref.)
Do holes in the T-cell repertoire have a center-surround regulatory structure? A rationale for the bifurcation of the Th1 and Th2 pathways of differentiation. Mannie MD. **Med Hypotheses** 1997 Mar;48(3):261-5 (56 ref.)
A short history of time and space in immune discrimination [see comments] Langman RE, et al. **Scand J Immunol** 1996 Dec;44(6):544-8 (10 ref.) Comment in: Scand J Immunol 1996 Dec;44(6):549-50.
Portrait of an executioner: the molecular mechanism of FAS/APO-1-induced apoptosis. Chinnaiyan AM, et al. **Semin Immunol** 1997 Feb;9(1):69-76 (84 ref.)
Antigen unfolding and disulfide reduction in antigen presenting cells. Jensen PE. **Semin Immunol** 1995 Dec; 7(6):347-53 (45 ref.)

MODELS, LINEAR see **LINEAR MODELS**

MODELS, LOGISTIC see **LOGISTIC MODELS**

MODELS, MOLECULAR

Computational studies of protein folding. Friesner RA, et al. **Annu Rev Biophys Biomol Struct** 1996;25:315-42 (73 ref.)
Bridging the protein sequence-structure gap by structure predictions. Rost B, et al. **Annu Rev Biophys Biomol Struct** 1996;25:113-36 (99 ref.)
Biomolecular dynamics at long timesteps: bridging the timescale gap between simulation and experimentation. Schlick T, et al. **Annu Rev Biophys Biomol Struct** 1997; 26:181-222 (122 ref.)
Molecular modeling of mechanotransduction in the nematode Caenorhabditis elegans. Tavernarakis N, et al. **Annu Rev Physiol** 1997;59:659-89 (93 ref.)
Molecular mechanisms underlying the activation and regulation of the alpha 1B-adrenergic receptor. Cotecchia S, et al. **Biochem Soc Trans** 1996 Nov;24(4):959-63 (21 ref.)
Can a two-state MWC allosteric model explain hemoglobin kinetics? Henry ER, et al. **Biochemistry** 1997 May 27; 36(21):6511-28 (74 ref.)
Rational approach to improving reductive catalysis by cytochrome P450cam. Manchester JI, et al. **Biochimie** 1996; 78(8-9):714-22 (58 ref.)
A hypothesis to explain why translation inhibitors stabilize mRNAs in mammalian cells: mRNA stability and mitosis. Ross J. **Bioessays** 1997 Jun;19(6):527-9 (18 ref.)
Form and function in protein dephosphorylation [comment] Denu JM, et al. **Cell** 1996 Nov 1;87(3):361-4 (20 ref.) Comment on: Cell 1996 Nov 1;87(3):365-8.
A new class of models for computing receptor-ligand binding affinities. Gilson MK, et al. **Chem Biol** 1997 Feb;4(2):87-92 (78 ref.)
Motor proteins: a dynamic duo. Allan V. **Curr Biol** 1996 Jun 1;6(6):630-3 (21 ref.)
RNA turnover: the helicase story unwinds. Anderson JS, et al. **Curr Biol** 1996 Jul 1;6(7):780-2 (16 ref.)
Motile systems: Tubulin-based motility races ahead. Egelman EH. **Curr Biol** 1995 Dec 1;5(12):1354-6 (19 ref.)
Protein kinase C: ports of anchor in the cell. Newton AC. **Curr Biol** 1996 Jul 1;6(7):806-9 (20 ref.)
Axon guidance: motor-way madness. Stoker AW. **Curr Biol** 1996 Jul 1;6(7):794-7 (17 ref.)
Novel methods of sampling phase space in the simulation of biological systems. Berne BJ, et al. **Curr Opin Struct Biol** 1997 Apr;7(2):181-9 (76 ref.)
Modeling transmembrane helical oligomers. Dieckmann GR, et al. **Curr Opin Struct Biol** 1997 Aug;7(4):486-94 (82 ref.)
Three-dimensional domain duplication, swapping and stealing. Heringa J, et al. **Curr Opin Struct Biol** 1997 Jun; 7(3):416-21 (55 ref.)
Progress in protein structure prediction. Jones DT. **Curr Opin Struct Biol** 1997 Jun;7(3):377-87 (89 ref.)
Computational methods for biomolecular docking. Lengauer T, et al. **Curr Opin Struct Biol** 1996 Jun;6(3):402-6 (46 ref.)
Predicting coiled-coil regions in proteins. Lupas A. **Curr Opin Struct Biol** 1997 Jun;7(3):388-93 (53 ref.)
Molecular dynamics simulations of lipid bilayers. Merz KM Jr. **Curr Opin Struct Biol** 1997 Aug;7(4):511-7 (54 ref.)
Comparison of database potentials and molecular mechanics force fields. Moult J. **Curr Opin Struct Biol** 1997 Apr; 7(2):194-9 (44 ref.)
Advances in comparative protein-structure modelling. Sánchez R, et al. **Curr Opin Struct Biol** 1997 Apr; 7(2):206-14 (105 ref.)
Modern developments in molecular replacement. Turkenburg JP, et al. **Curr Opin Struct Biol** 1996 Oct;6(5):604-10 (53 ref.)
Mathematical analysis of DNA fragment distribution models used with pulsed-field gel electrophoresis for DNA double-strand break calculations. Radivoyevitch T, et al. **Electrophoresis** 1996 Jun;17(6):1087-93 (12 ref.)
Viscous effects in capillary electrophoresis: theory and experiment. Schure MR, et al. **Electrophoresis** 1995 Nov; 16(11):2074-85 (26 ref.)
Capillary electrophoresis with polymeric separation media: considerations for theory. Smisek DL. **Electrophoresis** 1995 Nov;16(11):2094-9 (89 ref.)
Electrophoresis between sieving and reptation: an investigation of the role of shape fluctuations in electrophoresis. Völkel AR, et al. **Electrophoresis** 1995 Nov;16(11):2086-93 (24 ref.)
A new model for the membrane topology of glucose-6-phosphatase: the enzyme involved in von Gierke disease. Hemrika W, et al. **FEBS Lett** 1997 Jun 16; 409(3):317-9 (20 ref.)
C-reactive protein: structural biology, gene expression, and host defense function. Szalai AJ, et al. **Immunol Res** 1997; 16(2):127-36 (34 ref.)
Developing three-dimensional models of ion channel proteins. Guy HR, et al. **Ion Channels** 1996;4:1-40 (135 ref.)
The megaprior heuristic for discovering protein sequence patterns. Bailey TL, et al. **Ismb** 1996;4:15-24 (12 ref.)
Discovering patterns and subfamilies in biosequences. Brazma A, et al. **Ismb** 1996;4:34-43 (26 ref.)
A sequence similarity search algorithm based on a probabilistic interpretation of an alignment scoring system. Bucher P, et al. **Ismb** 1996;4:44-51 (25 ref.)
Hydrogen bonding and stacking of DNA bases: a review of quantum-chemical ab initio studies. Sponer J, et al. **J Biomol Struct Dyn** 1996 Aug;14(1):117-35 (122 ref.)
Molecular interaction analysis in ligand design using mass transport, kinetic and thermodynamic methods. Doyle ML, et al. **J Mol Recognit** 1996 Mar-Apr;9(2):65-74 (33 ref.)
Experimental results from host-guest complexes for the design of effectors in biological systems and of enzyme analogous catalysts. Schneider HJ, et al. **J Mol Recognit** 1996 Mar-Apr;9(2):123-32 (48 ref.)
A systems approach to molecular structure, intermolecular recognition, and emergence-dissolvence in medicinal research. Testa B, et al. **Med Res Rev** 1997 Jul;17(4):303-26 (25 ref.)
Predicting physical properties of peroxynitrite by quantum mechanics. Hamilton TP, et al. **Methods Enzymol** 1996;

MODELS, MOLECULAR

269:329–46 (33 ref.)
A perspective on biological catalysis. Cannon WR, et al. **Nat Struct Biol** 1996 Oct;3(10):821–33 (68 ref.)
The Drosophila genes timeless and period collaborate to promote cycles of gene expression composing a circadian pacemaker. Young MW. **Prog Brain Res** 1996;111:29–39 (51 ref.)
Automated modelling of the transmembrane region of G–protein coupled receptor by Swiss–model. Peitsch MC, et al. **Receptors Channels** 1996;4(3):161–4 (12 ref.)
The estradiol pharmacophore: ligand structure–estrogen receptor binding affinity relationships and a model for the receptor binding site. Anstead GM, et al. **Steroids** 1997 Mar;62(3):268–303 (248 ref.)
A structural explanation for the twilight zone of protein sequence homology. Chung SY, et al. **Structure** 1996 Oct 15;4(10):1123–7 (26 ref.)
Now we're cooking: new successes for shake–and–bake. Ealick SE. **Structure** 1997 Apr 15;5(4):469–72 (30 ref.)
Knowledge–based potentials for protein folding: what can we learn from known protein structures? Godzik A. **Structure** 1996 Apr 15;4(4):363–6 (14 ref.)
Angströms and calories. Janin J. **Structure** 1997 Apr 15; 5(4):473–9 (41 ref.)
Serendipity meets precision: the integration of structure–based drug design and combinatorial chemistry for efficient drug discovery. Salemme FR, et al. **Structure** 1997 Mar 15;5(3):319–24 (28 ref.)
Stopping death cold. Werner MH. **Structure** 1996 Aug 15; 4(8):879–83 (23 ref.)
Presenilin mutations in Alzheimer's disease: molecular models suggest a potential functional locus [published erratum appears in Trends Pharmacol Sci 1996 Dec;17(12):465] Murgolo NJ, et al. **Trends Pharmacol Sci** 1996 Nov; 17(11):389–93 (22 ref.)
[Computer simulations using molecular dynamics methods] Hirono S, et al. **Tanpakushitsu Kakusan Koso** 1997 May; 42(7 Suppl):1015–22 (15 ref.) **(Jpn)**

MODELS, NEURAL NETWORK see **NEURAL NETWORKS (COMPUTER)**

MODELS, NEUROLOGICAL

see related
KINDLING (NEUROLOGY)
Construction of a model demonstrating neural pathways and reflex arcs. Chan V, et al. **Am J Physiol** 1996 Dec;271(6 Pt 3):S14–42 (4 ref.)
Mechanism of nonlinear responses of taste cells to mixed tastes. Kashimori Y, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):C405–22 (40 ref.)
The drosophila neuromuscular junction: a model system for studying synaptic development and function. Keshishian H, et al. **Annu Rev Neurosci** 1996;19:545–75 (133 ref.)
The neuroethology of cognitive maps: contributions from research on the hippocampus and homing pigeon navigation. Casini G, et al. **Arch Ital Biol** 1997 Jan; 135(1):73–92 (69 ref.)
Changes in gene expression during the sleep–waking cycle: a new view of activating systems. Tononi G, et al. **Arch Ital Biol** 1995 Dec;134(1):21–37 (121 ref.)
Selecting a model system for neurobiological studies of learning and memory. Eisenstein EM. **Behav Brain Res** 1997 Jan;82(2):121–32 (56 ref.)
Information processing and intracellular 'neural' (protein) networks: considerations regarding the diffusion–based hypothesis of Bray. Agutter PS, et al. **Biol Cell** 1997 Mar; 89(1):13–8 (25 ref.)
Neural assemblies and laminar interactions in the cerebral cortex. Miller R. **Biol Cybern** 1996 Sep;75(3):253–61 (49 ref.)
Cortico–thalamic interplay and the security of operation of neural assemblies and temporal chains in the cerebral cortex. Miller R. **Biol Cybern** 1996 Sep;75(3):263–75 (78 ref.)
The role of inhibition in the hierarchical gating of executed and imagined movements. Berthoz A. **Brain Res Cogn Brain Res** 1996 Mar;3(2):101–13 (112 ref.)
Vertebrate embryonic cells will become nerve cells unless told otherwise. Hemmati–Brivanlou A, et al. **Cell** 1997 Jan 10;88(1):13–7 (25 ref.)
A model of color vision based on cortical reentry. Wray J, et al. **Cereb Cortex** 1996 Sep–Oct;6(5):701–16 (81 ref.)
Experimental basis for realistic large–scale computer simulation of the enteric nervous system. Furness JB, et al. **Clin Exp Pharmacol Physiol** 1996 Sep;23(9):786–92 (27 ref.)
A functional neuroanatomy of anxiety and fear: implications for the pathophysiology and treatment of anxiety disorders. Charney DS, et al. **Crit Rev Neurobiol** 1996;10(3–4):419–46 (237 ref.)
Neuronal firing: does function follow form? Connors BW, et al. **Curr Biol** 1996 Dec 1;6(12):1560–2 (16 ref.)
Insect physiology: the emerging story of ecdysis. Hesterlee S, et al. **Curr Biol** 1996 Jun 1;6(6):648–50 (9 ref.)
Signal selection by cortical feedback. King AJ. **Curr Biol** 1997 Feb 1;7(2):R85–8 (21 ref.)
Visual cortex: looking into a Klein bottle. Swindale NV. **Curr Biol** 1996 Jul 1;6(7):776–9 (11 ref.)
Cortical dynamic tuning: the role of intrinsic connections, as revealed by modeling. Lukashin AV. **Curr Opin Neurobiol** 1996 Dec;6(6):765–72 (43 ref.)
Neural induction in Xenopus laevis: evidence for the default model. Weinstein DC, et al. **Curr Opin Neurobiol** 1997 Feb; 7(1):7–12 (51 ref.)
Neuronal pathfinding and recognition: roles of cell adhesion molecules. Chiba A, et al. **Dev Biol** 1996 Dec 15; 180(2):424–32 (86 ref.)
Statistical mechanics of neocortical interactions: multiple scales of EEG. Ingber L. **Electroencephalogr Clin Neurophysiol Suppl** 1996;45:79–112 (75 ref.)
Source localization and bioelectric imaging as it relates to continuous waveform analysis. Sidman RD, et al. **Electroencephalogr Clin Neurophysiol Suppl** 1996;45:9–21 (41 ref.)
Computational models of hippocampal function in memory. Gluck MA. **Hippocampus** 1996;6(6):565–6 (4 ref.)
Encoding and retrieval of episodic memories: role of cholinergic and GABAergic modulation in the hippocampus. Hasselmo ME, et al. **Hippocampus** 1996; 6(6):693–708 (107 ref.)
Cognitive maps beyond the hippocampus. Redish AD, et al. **Hippocampus** 1997;7(1):15–35 (182 ref.)
Some aspects of alpha activity in relation to a new generalized model for the EEG. Barlow JS. **Int J Psychophysiol** 1997 Jun;26(1–3):341–52 (8 ref.)
The autonomic nervous system: a Sherringtonian revision of its integrated properties in the control of circulation. Malliani A. **J Auton Nerv Syst** 1997 Jun 6;64(2–3):158–61 (26 ref.)
Why do cats need a dorsal cochlear nucleus? Nelken I, et al. **J Basic Clin Physiol Pharmacol** 1996;7(3):199–220 (74 ref.)
A model for the coupling between cerebral blood flow and oxygen metabolism during neural stimulation. Buxton RB, et al. **J Cereb Blood Flow Metab** 1997 Jan;17(1):64–72 (53 ref.)
Connectionism and developmental psychology. Plunkett K, et al. **J Child Psychol Psychiatry** 1997 Jan;38(1):53–80 (60 ref.)
Synthesis of models for excitable membranes, synaptic transmission and neuromodulation using a common kinetic formalism. Destexhe A, et al. **J Comput Neurosci** 1994 Aug; 1(3):195–230 (119 ref.)
A model of selective processing of auditory–nerve inputs by stellate cells of the antero–ventral cochlear nucleus. Lai YC, et al. **J Comput Neurosci** 1994 Aug;1(3):167–94 (43 ref.)
Cognitive graphs, resistive grids, and the hippocampal representation of space. Burgess N, et al. **J Gen Physiol** 1996 Jun;107(6):659–62 (32 ref.)
The hippocampus as a cognitive graph. Muller RU, et al. **J Gen Physiol** 1996 Jun;107(6):663–94 (108 ref.)
Neuromuscular transmission at an active zone: the secretosome hypothesis. Bennett MR. **J Neurocytol** 1996 Dec;25(12):869–91 (116 ref.)
The role of synapses in cortical computation. Douglas RJ, et al. **J Neurocytol** 1996 Dec;25(12):893–911 (104 ref.)
A framework for mesencephalic dopamine systems based on predictive Hebbian learning. Montague PR, et al. **J Neurosci** 1996 Mar 1;16(5):1936–47 (52 ref.)
Computer modeling: a new approach to the investigation of disease [editorial] Reggia JA, et al. **MD Comput** 1997 May–Jun;14(3):160, 162, 164 passim (27 ref.)
Ascorbate availability and neurodegeneration in amyotrophic lateral sclerosis. Kok AB. **Med Hypotheses** 1997 Apr; 48(4):281–96 (171 ref.)
The role of neuropeptides in learning and memory: possible mechanisms. Shen Y, et al. **Med Hypotheses** 1995 Dec; 45(6):529–38 (80 ref.)
The placebo effect on mood and behavior: the role of the endogenous opioid system. Sher L. **Med Hypotheses** 1997 Apr;48(4):347–9 (32 ref.)
A brain model with the circuit to convert short–term memory into long–term memory. Wong CW. **Med Hypotheses** 1997 Mar;48(3):221–6 (34 ref.)
CAM–FGF receptor interactions: a model for axonal growth. Doherty P, et al. **Mol Cell Neurosci** 1996;8(2–3):99–111 (77 ref.)
A composite model for establishing the microtubule arrays of the neuron. Baas PW, et al. **Mol Neurobiol** 1996 Apr; 12(2):145–61 (75 ref.)
The neuropsychology of anxiety: reprise. Gray JA, et al. **Nebr Symp Motiv** 1996;43:61–134 (175 ref.)
The activation and regulation of fear and anxiety. Izard CE, et al. **Nebr Symp Motiv** 1996;43:1–59 (105 ref.)
Similarity, connectionism, and the problem of representation in vision. Edelman S, et al. **Neural Comput** 1997 May 15; 9(4):701–20 (48 ref.)
Models of orientation and ocular dominance columns in the visual cortex: a critical comparison. Erwin E, et al. **Neural Comput** 1995 May;7(3):425–68 (83 ref.)
The NEURON simulation environment. Hines ML, et al. **Neural Comput** 1997 Aug 15;9(6):1179–209 (38 ref.)
On the mathematical modelling of pain. Britton NF, et al. **Neurochem Res** 1996 Sep;21(9):1133–40 (53 ref.)
Neurobiological basis of motor learning in mammals. Asanuma H, et al. **Neuroreport** 1997 Mar 3;8(4):i–vi (59 ref.)
The neural coding of stereoscopic depth. Ohzawa I, et al. **Neuroreport** 1997 Feb 10;8(3):iii–xii (36 ref.)
Outlining a brain model of mental imaging abilities. Faw B. **Neurosci Biobehav Rev** 1997 May;21(3):283–8 (63 ref.)
Behavioral, structural and neurochemical asymmetries in the avian brain: a model system for studying visual development and processing. Rogers L. **Neurosci Biobehav Rev** 1996 Autumn;20(3):487–503 (149 ref.)
Neostriatal cell subtypes and their functional roles. Kawaguchi Y. **Neurosci Res** 1997 Jan;27(1):1–8 (77 ref.)
Population coding by cell assemblies—what it really is in the brain. Sakurai Y. **Neurosci Res** 1996 Sep;26(1):1–16 (80 ref.)
Post–sympathectomy neuralgia: hypotheses on peripheral and central neuronal mechanisms [see comments] Kramis RC, et al. **Pain** 1996 Jan;64(1):1–9 (66 ref.) Comment in: Pain 1996 Sep;67(1):218–20. Comment in: Pain 1997 Apr;70(2–3):290–1.
Some reflections on (or by?) grandmother cells [editorial] Rose D. **Perception** 1996;25(8):881–6 (26 ref.)
Developmental models of brain dysfunctions induced by targeted cellular ablations with methylazoxymethanol. Cattabeni F, et al. **Physiol Rev** 1997 Jan;77(1):199–215 (145 ref.)
Toward a molecular definition of long–term memory storage. Bailey CH, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13445–52 (69 ref.)
A synaptic basis for memory storage in the cerebral cortex. Bear MF. **Proc Natl Acad Sci U S A** 1996 Nov 26; 93(24):13453–9 (59 ref.)
Regional and cellular fractionation of working memory. Goldman–Rakic PS. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13473–80 (94 ref.)
From conductances to neural network properties: analysis of simple circuits using the hybrid network method. Le Masson G, et al. **Prog Biophys Mol Biol** 1995; 64(2–3):201–20 (51 ref.)
Highest level automatisms in the nervous system: a theory of functional principles underlying the highest forms of brain function. Baev KV. **Prog Neurobiol** 1997 Feb; 51(2):129–66 (74 ref.)
The microscopic anatomy and physiology of the mammalian saccadic system. Moschovakis AK, et al. **Prog Neurobiol** 1996 Oct;50(2–3):133–254 (699 ref.)
The spinal cord and its brain: representations and models. To what extent do forebrain mechanisms appear at brainstem spinal cord levels? Windhorst U. **Prog Neurobiol** 1996 Aug;49(5):381–414 (251 ref.)
On the role of recurrent inhibitory feedback in motor control. Windhorst U. **Prog Neurobiol** 1996 Aug;49(6):517–87 (367 ref.)
Does the genotype for schizophrenia often remain unexpressed because of canalization and stochastic events during development? Woolf CM. **Psychol Med** 1997 May; 27(3):659–68 (73 ref.)
Brainstem respiratory networks and cough. Shannon R, et al. **Pulm Pharmacol** 1996 Oct–Dec;9(5–6):343–7 (20 ref.)
A neural substrate of prediction and reward. Schultz W, et al. **Science** 1997 Mar 14;275(5306):1593–9 (37 ref.)
p75NTR and apoptosis: Trk–dependent and Trk–independent effects. Bredesen DE, et al. **Trends Neurosci** 1997 Jul; 20(7):287–90 (36 ref.)
Variation and selection in neural function [letter; comment] Changeux JP. **Trends Neurosci** 1997 Jul;20(7):291–3 (20 ref.) Comment on: Trends Neurosci 1996 Nov;19(11):460–4.
Neural correlates of key stimulus and releasing mechanism: a case study and two concepts. Ewert JP. **Trends Neurosci** 1997 Aug;20(8):332–9 (71 ref.)
Dopamine–cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Grace AA, et al. **Trends Neurosci** 1997 Jan;20(1):31–7 (71 ref.)
Variation and selection in neural function [letter; comment] Sporns O. **Trends Neurosci** 1997 Jul;20(7):291; discussion 293 (20 ref.) Comment on: Trends Neurosci 1996 Nov;19(11):460–4.
Mach bands: how many models are possible? Recent experimental findings and modeling attempts. Pessoa L. **Vision Res** 1996 Oct;36(19):3205–27 (115 ref.)

MODELS, NONLINEAR see **NONLINEAR DYNAMICS**

MODELS, NURSING

Toward a middle–range theory of resilience. Polk LV. **ANS Adv Nurs Sci** 1997 Mar;19(3):1–13 (42 ref.)
Analysis of the concept of mutuality. Henson RH. **Image J Nurs Sch** 1997 Spring;29(1):77–81 (50 ref.)
Perspectives unifying symptom interpretation. Teel CS, et al. **Image J Nurs Sch** 1997;29(2):175–81 (47 ref.)
Toward a model for nursing informatics. Turley JP. **Image J Nurs Sch** 1996 Winter;28(4):309–13 (26 ref.)
A concept analysis of consent. Brennan M. **J Adv Nurs** 1997 Mar;25(3):477–84 (37 ref.)
Themes relating to sexuality that emerged from a discourse analysis of the Nursing Times during 1980–1990. Carr G. **J Adv Nurs** 1996 Jul;24(1):196–212 (129 ref.)
Analysis of Akinsanya's model of bionursing. Casey G. **J Adv Nurs** 1996 Jun;23(6):1065–70 (29 ref.)
Community development: theoretical and practical issues for community health nursing in Canada. Chalmers KI, et al. **J Adv Nurs** 1996 Oct;24(4):719–26 (61 ref.)
Towards further clarification of the concept 'dignity'. Haddock J. **J Adv Nurs** 1996 Nov;24(5):924–31 (49 ref.)
Is non–judgemental care possible in the context of nurses'

attitudes to patients' sexuality? Hayter M. **J Adv Nurs** 1996 Oct;24(4):662–6 (39 ref.)
Models of differentiated practice and specialization in community nursing: a review of the literature. Jansen PG, et al. **J Adv Nurs** 1996 Nov;24(5):968–80 (89 ref.)
Constructing meaning in the learning experience: the role of alternative theoretical frameworks. Lauder W. **J Adv Nurs** 1996 Jul;24(1):91–7 (50 ref.)
Exploring the nursing role in pain management from a post–structuralist perspective. Price K, et al. **J Adv Nurs** 1996 Nov;24(5):899–904 (35 ref.)
Addressing barriers: disabled rights and the implications for nursing of the social construct of disability. Richardson M. **J Adv Nurs** 1997 Jun;25(6):1269–75 (47 ref.)
Science, abduction and the fuzzy nurse: an exploration of expertise. Rolfe G. **J Adv Nurs** 1997 May;25(5):1070–5 (10 ref.)
Reinstating the person in the professional: reflections on empathy and aesthetic experience. Smyth T. **J Adv Nurs** 1996 Nov;24(5):932–7 (28 ref.)
Nursing ideology: identification and legitimation. Taylor JS. **J Adv Nurs** 1997 Mar;25(3):442–6 (37 ref.)
Looking at discourse in a literature review of nursing texts. Traynor M. **J Adv Nurs** 1996 Jun;23(6):1155–61 (46 ref.)
Understanding healing: a conceptual analysis. Wendler MC. **J Adv Nurs** 1996 Oct;24(4):836–42 (39 ref.)
Patient education for behavior change: help from the Transtheoretical and Harm Reduction models. Bradley–Springer L. **J Assoc Nurses AIDS Care** 1996;7 Suppl 1:23–33; discussion 34–40 (18 ref.)
Prenatal care for low–income women and the health belief model: a new beginning. Stout AE. **J Community Health Nurs** 1997;14(3):169–80 (21 ref.)
The practice role in the academic nursing community. Broussard AB, et al. **J Nurs Educ** 1996 Feb;35(2):82–7 (54 ref.)
Cultural competence in the care of abused women. Campbell JC, et al. **J Nurse Midwifery** 1996 Nov–Dec;41(6):457–62 (22 ref.)
Patient–focused models of care. Pence M. **J Obstet Gynecol Neonatal Nurs** 1997 May–Jun;26(3):320–6 (18 ref.)
An analysis of the concept of hope in the adolescent with cancer. Hendricks–Ferguson VL. **J Pediatr Oncol Nurs** 1997 Apr;14(2):73–80; discussion 81–2 (47 ref.)
Elements of a nursing professional practice model. Hoffart N, et al. **J Prof Nurs** 1996 Nov–Dec;12(6):354–64 (62 ref.)
Walking a mile in their shoes... Symbolic interactionism for families living with severe mental illness. Saunders J. **J Psychosoc Nurs Ment Health Serv** 1997 Jun;35(6):8–13 (24 ref.)
Parental coping with childhood hospitalization: a theoretical framework to guide research and clinical interventions. Melnyk BM. **Matern Child Nurs J** 1995 Oct–Dec; 23(4):123–31 (51 ref.)
The high–touch paradigm: a 21st century model for maternal–child nursing. With a brief glimpse into nursing on the starship Nightingale. Kowalski K, et al. **MCN Am J Matern Child Nurs** 1996 Jan–Feb;21(1):43–50 (10 ref.)
Looking beyond primary care to primary health care: an approach to community–based action. Shoultz J, et al. **Nurs Outlook** 1997 Jan–Feb;45(1):23–6 (27 ref.)
Community–based nursing versus community health nursing: what does it all mean? Zotti ME, et al. **Nurs Outlook** 1996 Sep–Oct;44(5):211–7 (25 ref.)
Nursing presence: an existential exploration of the concept. Doona ME, et al. **Sch Inq Nurs Pract** 1997 Spring; 11(1):3–16; discussion 17–20 (51 ref.)
Development of a conceptual model of quality of life. Ferrans CE. **Sch Inq Nurs Pract** 1996 Fall;10(3):293–304 (71 ref.)

MODELS, ORGANIZATIONAL

Integration or evolution: women's health as a model for interdisciplinary change in medical education. Nelson M, et al. **Acad Med** 1997 Sep;72(9):737–40 (14 ref.)
Managed care merged with the German model [see comments] Weil TP. **Am J Med Qual** 1997 Spring; 12(1):19–24 (22 ref.) Comment in: Am J Med Qual 1997 Spring;12(1):25–7.
Should we trade person–centered service for a consumer–based model? Peloquin SM. **Am J Occup Ther** 1997 Jul–Aug;51(7):612–5 (26 ref.)
Modeling case mix adjustment of stroke rehabilitation outcomes. Segal ME, et al. **Am J Phys Med Rehabil** 1997 Mar–Apr;76(2):154–61 (74 ref.)
Living systems theory as a paradigm for organizational behavior: understanding humans, organizations, and social processes. Vancouver JB. **Behav Sci** 1996 Jul;41(3):165–204 (200 ref.)
The spectrum of managed care model types. Fabius R. **Clin Obstet Gynecol** 1997 Jun;40(2):391–4 (0 ref.)
Health services organizations computer innovation. Ready or not? Snyder–Halpern R. **Comput Nurs** 1997 May–Jun; 15(3):147–52; quiz 153–4 (22 ref.)
Action research—a strategy for evaluation of medical interventions. Malterud K. **Fam Pract** 1995 Dec; 12(4):476–81 (25 ref.)
Health care system reforms in western European countries: the relevance of health care organization. Elola J. **Int J Health Serv** 1996;26(2):239–51 (56 ref.)
A model to create "organizational readiness" for the successful implementation of quality management systems. Penland T. **Int J Qual Health Care** 1997 Feb;9(1):69–72 (10 ref.)
A framework for the management of intellectual capital in the health care industry. Grantham CE, et al. **J Health Care Finance** 1997 Spring;23(3):1–19 (52 ref.)
Organizational effectiveness: toward an integrated model for schools of nursing. Baker CM, et al. **J Prof Nurs** 1997 Jul–Aug;13(4):246–55 (49 ref.)
Conducting a comprehensive school health program. Resnicow K, et al. **J Sch Health** 1996 Feb;66(2):59–63 (19 ref.)
Organizing care for patients with chronic illness. Wagner EH, et al. **Milbank Q** 1996;74(4):511–44 (121 ref.)
Health system reforms—toward a framework for international comparisons [published erratum appears in Soc Sci Med 1996 Nov;43(10):III–IV] Twaddle AC. **Soc Sci Med** 1996 Sep;43(5):637–54 (101 ref.)
Market–oriented health care reforms: trends and future options. van de Ven WP. **Soc Sci Med** 1996 Sep; 43(5):655–66 (40 ref.)
Afrocentricity: an emerging paradigm in social work practice. Schiele JH. **Soc Work** 1996 May;41(3):284–94 (63 ref.)

MODELS, PROPORTIONAL HAZARDS see **PROPORTIONAL HAZARDS MODELS**

MODELS, PSYCHOLOGICAL

see related
PROBABILITY LEARNING

Mental representations of medical diagnostic knowledge: a review [see comments] Custers EJ, et al. **Acad Med** 1996 Oct;71(10 Suppl):S55–61 (95 ref.) Comment in: Acad Med 1997 May;72(5):315–8.
Dentist–patient communication: a review of relevant models. Sondell K, et al. **Acta Odontol Scand** 1997 Apr;55(2):116–26 (119 ref.)
Sex, drugs and escape: a psychological model of HIV–risk sexual behaviours. McKirnan DJ, et al. **AIDS Care** 1996 Dec;8(6):655–69 (93 ref.)
Predictors of functional outcome among adolescents and young adults with psychotic disorders. Henry AD, et al. **Am J Occup Ther** 1996 Mar;50(3):171–81 (97 ref.)
Stressor–induced oscillation. A possible model of the bidirectional symptoms in PTSD. Antelman SM, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:296–304 (21 ref.)
Performance of PTSD patients on standard tests of memory. Implications for trauma. Wolfe J, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:208–18 (52 ref.)
A conceptual model for studying parenting behaviors in immigrant populations. Foss GF. **ANS Adv Nurs Sci** 1996 Dec;19(2):74–87 (66 ref.)
Oklahoma City bombing: exacerbation of symptoms in veterans with PTSD. Moyers F. **Arch Psychiatr Nurs** 1996 Feb;10(1):55–9 (19 ref.)
Modelling cognition in emotional disorder: the S–REF model. Wells A, et al. **Behav Res Ther** 1996 Nov–Dec; 34(11–12):881–8 (25 ref.)
The topology of perceptive functions as a corollary of the theorem of existence in closed spaces. Bounias M, et al. **Biosystems** 1997;42(2–3):191–205 (56 ref.)
The grieving adult and the general practitioner: a literature review in two parts (Part 1). Woof WR, et al. **Br J Gen Pract** 1997 Jul;47(420):443–8 (69 ref.)
Containers, mental space and psychodynamics. Rosenbaum B, et al. **Br J Med Psychol** 1996 Dec;69 (Pt 4):281–97 (44 ref.)
On knowing how to do things: a theory of motor imagery. Annett J. **Brain Res Cogn Brain Res** 1996 Mar;3(2):65–9 (17 ref.)
The role of inhibition in the hierarchical gating of executed and imagined movements. Berthoz A. **Brain Res Cogn Brain Res** 1996 Mar;3(2):101–13 (112 ref.)
An information–processing perspective on childhood anxiety. Daleiden EL, et al. **Clin Psychol Rev** 1997;17(4):407–29 (81 ref.)
The role of patient participation in the doctor visit. Implications for adherence to diabetes care. Golin CE, et al. **Diabetes Care** 1996 Oct;19(10):1153–64 (134 ref.)
Hidden Markov models for speech and signal recognition. Rose RC, et al. **Electroencephalogr Clin Neurophysiol Suppl** 1996;45:137–52 (43 ref.)
Shifting attention from objective risk factors to patients' self–assessed health resources: a clinical model for general practice. Hollnagel H, et al. **Fam Pract** 1995 Dec; 12(4):423–9 (50 ref.)
Toward a definition of family resilience: integrating life–span and family perspectives. Hawley DR, et al. **Fam Process** 1996 Sep;35(3):283–98 (66 ref.)
Family bereavement and cultural diversity: a social developmental perspective. Shapiro ER. **Fam Process** 1996 Sep;35(3):313–32 (76 ref.)
Aging and heterogeneity: genetics, social structure, and personality [see commer ts] Light JM, et al. **Gerontologist** 1996 Apr;36(2):165–73 (52 ref.) Comment in: Gerontologist 1996 Apr;36(2):145–6. Comment in: Gerontologist 1996 Apr;36(2):174–7.
Cognitive maps beyond the hippocampus. Redish AD, et al. **Hippocampus** 1997;7(1):15–35 (182 ref.)
Cognitive developmental approach to dementia. Matteson MA, et al. **Image J Nurs Sch** 1996 Fall;28(3):233–40 (98 ref.)
Mothers' help seeking as care initiated in a social context. Pridham KF. **Image J Nurs Sch** 1997 Spring;29(1):65–70 (39 ref.)
Dreams in group therapy: a review of models. Derr DB, et al. **Int J Group Psychother** 1996 Oct;46(4):501–15 (28 ref.)
Searching for resilience among African–American youth exposed to community violence: theoretical issues. Howard DE. **J Adolesc Health** 1996 Apr;18(4):254–62 (66 ref.)
Attitudes towards people with HIV/AIDS: entropy and health care ethics. Hodgson I. **J Adv Nurs** 1997 Aug; 26(2):283–8 (42 ref.)
Gastrointestinal illness and the biopsychosocial model [editorial] Drossman DA. **J Clin Gastroenterol** 1996 Jun; 22(4):252–4 (11 ref.)
Curricula, competition and conventional bonds: the educational role in drug control. Norland S, et al. **J Drug Educ** 1996;26(3):231–42 (28 ref.)
The social context of mental illness and violence. Hiday VA. **J Health Soc Behav** 1995 Jun;36(2):122–37 (143 ref.)
An analysis of the concept of hope in the adolescent with cancer. Hendricks–Ferguson VL. **J Pediatr Oncol Nurs** 1997 Apr;14(2):73–80; discussion 81–2 (47 ref.)
The semantics of addiction: moving beyond expert models to lay understandings. Quintero G, et al. **J Psychoactive Drugs** 1996 Jul–Sep;28(3):219–28 (66 ref.)
Theories of menopause. Brief comparative synopsis [see comments] Barile LA. **J Psychosoc Nurs Ment Health Serv** 1997 Feb;35(2):36–9 (19 ref.) Comment in: J Psychosoc Nurs Ment Health Serv 1997 May;35(5):10–1.
Theoretical and practical considerations in investigating motivation and discomfort during prolonged exercise. Tenenbaum G. **J Sports Med Phys Fitness** 1996 Sep; 36(3):145–54 (78 ref.)
An existential model for promoting life change. Confronting the disease concept. Ford GG. **J Subst Abuse Treat** 1996 Mar–Apr;13(2):151–8 (35 ref.)
Parental coping with childhood hospitalization: a theoretical framework to guide research and clinical interventions. Melnyk BM. **Matern Child Nurs J** 1995 Oct–Dec; 23(4):123–31 (51 ref.)
G explained. Anderson B. **Med Hypotheses** 1995 Dec; 45(6):602–4 (27 ref.)
Reverse learning and the physiological basis of eye movement desensitization. Hassard A. **Med Hypotheses** 1996 Oct; 47(4):277–82 (45 ref.)
Homeostatic disruption and sexual disorders. Naisberg Y. **Med Hypotheses** 1996 Sep;47(3):243–7 (26 ref.)
Dissociation as complex adaptation. Sel R. **Med Hypotheses** 1997 Mar;48(3):205–8 (31 ref.)
A brain model with the circuit to convert short–term memory into long–term memory. Wong CW. **Med Hypotheses** 1997 Mar;48(3):221–6 (34 ref.)
The recall of physical activity: using a cognitive model of the question–answering process. Durante R, et al. **Med Sci Sports Exerc** 1996 Oct;28(10):1282–91 (61 ref.)
What do theories of the functional deficit(s) underlying amnesia have to explain? Mayes AR, et al. **Memory** 1997 Jan–Mar;5(1–2):3–36 (87 ref.)
Fear, panic, anxiety, and disorders of emotion. Barlow DH, et al. **Nebr Symp Motiv** 1996;43:251–328 (100 ref.)
The neuropsychology of anxiety: reprise. Gray JA, et al. **Nebr Symp Motiv** 1996;43:61–134 (175 ref.)
The activation and regulation of fear and anxiety. Izard CE, et al. **Nebr Symp Motiv** 1996;43:1–59 (105 ref.)
Conditioning and ethological models of anxiety disorders: stress–in–dynamic–context anxiety models. Mineka S, et al. **Nebr Symp Motiv** 1996;43:135–210 (235 ref.)
Reinforcement processes in opiate addiction: a homeostatic model. Schulteis G, et al. **Neurochem Res** 1996 Nov; 21(11):1437–54 (133 ref.)
Do theoretical bridges exist between perceptual experience and neurophysiology? Uttal WA. **Perspect Biol Med** 1997 Winter;40(2):280–302 (41 ref.)
Opponent process model and psychostimulant addiction. Koob GF, et al. **Pharmacol Biochem Behav** 1997 Jul; 57(3):513–21 (67 ref.)
Successful coping, adaptation and resilience in the elderly: an interpretation of epidemiologic data. Foster JR. **Psychiatr Q** 1997 Fall;68(3):189–219 (96 ref.)
Fear of cancer recurrence—a literature review and proposed cognitive formulation to explain exacerbation of recurrence fears. Lee–Jones C, et al. **Psychooncology** 1997 Jun; 6(2):95–105 (41 ref.)
Development of a conceptual model of quality of life. Ferrans CE. **Sch Inq Nurs Pract** 1996 Fall;10(3):293–304 (71 ref.)
The social construction of anticipatory grief. Fulton G, et al. **Soc Sci Med** 1996 Nov;43(9):1349–58 (69 ref.)
Some conceptual considerations on the sense of coherence. Geyer S. **Soc Sci Med** 1997 Jun;44(12):1771–9 (59 ref.)
The (dis)embodied self in anorexia nervosa. Lester RJ. **Soc Sci Med** 1997 Feb;44(4):479–89 (56 ref.)
Conventions of measurement in psychophysics: von Kries on the so–called psychophysical law. Niall KK. **Spat Vis** 1995;9(3):275–305 (38 ref.)
Women's HIV risk reduction efforts and traditional models of health behavior: a review and critique. Gillespie CC.

MODELS, PSYCHOLOGICAL

Womens Health 1997 Spring;3(1):1–30 (123 ref.)

MODELS, SPACE see **SPACE SIMULATION**

MODELS, STATISTICAL

see related
META-ANALYSIS

Survival analysis in public health research. Lee ET, et al. **Annu Rev Public Health** 1997;18:105–34 (62 ref.)

Categorical data analysis in public health. Preisser JS, et al. **Annu Rev Public Health** 1997;18:51–82 (94 ref.)

Predicting survival in the intensive care unit. Hunt JP, et al. **Curr Probl Surg** 1997 Jul;34(7):527–99 (188 ref.)

What demographers can learn from fruit fly actuarial models and biology. Carey JR. **Demography** 1997 Feb;34(1):17–30 (151 ref.)

A mathematical model of coagulation factor VIII kinetics. Noe DA. **Haemostasis** 1996 Nov–Dec;26(6):289–303 (31 ref.)

Mathematical models in decision analysis. Tom E, et al. **Infect Control Hosp Epidemiol** 1997 Jan;18(1):65–73 (28 ref.)

On the characteristics of the quadratic order associative memory that uses synchronous update and direct convergence. Wang JH. **Int J Neural Syst** 1996 Mar; 7(1):69–81 (20 ref.)

Assessing individual risk for breast cancer: risky business. McTiernan A, et al. **J Clin Epidemiol** 1997 May; 50(5):547–56 (60 ref.)

Case mix adjustment in comparative audit. Hayes C, et al. **J Eval Clin Pract** 1995 Nov;1(2):105–11 (37 ref.)

Causal analysis: theory and application. Peyrot M. **J Pediatr Psychol** 1996 Feb;21(1):3–24 (36 ref.)

Structural equation modeling: basic concepts and applications in personality assessment research. Crowley SL, et al. **J Pers Assess** 1997 Jun;68(3):508–31 (44 ref.)

How to express an effect mean as percentage of a control mean? Feuerstein TJ, et al. **J Pharmacol Toxicol Methods** 1997 Jun;37(4):187–90 (7 ref.)

When do the "dollars" make sense? Toward a conceptual framework for contingent valuation studies in health care. O'Brien B, et al. **Med Decis Making** 1996 Jul–Sep; 16(3):288–99 (49 ref.)

Estimating the risks of cardiac surgery [editorial; comment] Dobb GJ. **Med J Aust** 1997 Apr 21;166(8):397–8 (18 ref.) Comment on: Med J Aust 1997 Apr 21;166(8):408–11.

Dynamic systems-modeling as a means to estimate community-based prevention effects. Kibel BM, et al. **NIDA Res Monogr** 1994;142:404–46 (91 ref.)

Adaptive sampling in behavioral surveys. Thompson SK. **NIDA Res Monogr** 1997;167:296–319 (76 ref.)

Menstrual variability and the measurement of menstrual synchrony. Weller L, et al. **Psychoneuroendocrinology** 1997 Feb;22(2):115–28 (35 ref.)

Model trains of thought [editorial; comment] Rothenberg R. **Sex Transm Dis** 1997 Apr;24(4):201–3 (20 ref.) Comment on: Sex Transm Dis 1997 Apr;24(4):185–200.

Meta-analysis: current issues in research synthesis. Olkin I. **Stat Med** 1996 Jun 30;15(12):1253–7; discussion 1259–62 (14 ref.)

An introduction to finite mixture distributions [comment] Everitt BS. **Stat Methods Med Res** 1996 Jun;5(2):107–27 (68 ref.) Comment on: Stat Methods Med Res 1996 Jun;5(2):129–53. Comment on: Stat Methods Med Res 1996 Jun;5(2):179–211.

Latent class analysis in medical research [see comments] Formann AK, et al. **Stat Methods Med Res** 1996 Jun; 5(2):179–211 (170 ref.) Comment in: Stat Methods Med Res 1996 Jun;5(2):107–27.

Modelling the sampling design in the analysis of health surveys. Graubard BI, et al. **Stat Methods Med Res** 1996 Sep;5(3):263–81 (53 ref.)

Mixture models in haematology: a series of case studies [see comments] McLaren CE. **Stat Methods Med Res** 1996 Jun; 5(2):129–53 (83 ref.) Comment in: Stat Methods Med Res 1996 Jun;5(2):107–27.

Mixture distributions in human genetics research. Schork NJ, et al. **Stat Methods Med Res** 1996 Jun;5(2):155–78 (138 ref.)

The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. Kleinman S, et al. **Transfus Med Rev** 1997 Jul;11(3):155–72 (69 ref.)

[Development of a model for explaining health inequality] Elkeles T, et al. **Gesundheitswesen** 1997 Mar;59(3):137–43 (68 ref.) (Eng. Abstr.) **(Ger)**

MODELS, STRUCTURAL

Modeling the structure of the ribosome. Easterwood TR, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):751–6 (35 ref.)

A milestone in ribosomal crystallography: the construction of preliminary electron density maps at intermediate resolution. Schlünzen F, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):739–49 (53 ref.)

MODELS, THEORETICAL

Automated rescreening in cervical cytology. Mathematical models for evaluating overall process sensitivity, specificity and cost. Kaminsky FC, et al. **Acta Cytol** 1997 Jan–Feb; 41(1):209–23 (35 ref.)

Why the profession of occupational therapy will flourish in the 21st century. The 1996 Eleanor Clarke Slagle Lecture. Nelson DL. **Am J Occup Ther** 1997 Jan;51(1):11–24 (51 ref.)

Culture as a stressor: a revised model of biocultural interaction. Schell LM. **Am J Phys Anthropol** 1997 Jan; 102(1):67–77 (49 ref.)

Perspectives: a proposed general model of the "mechanostat" (suggestions from a new skeletal-biologic paradigm). Frost HM. **Anat Rec** 1996 Feb;244(2):139–47 (177 ref.)

Noncompartmental models of whole-body clearance of tracers: a review. Norwich KH. **Ann Biomed Eng** 1997 May–Jun;25(3):421–39 (72 ref.)

New histological and physiological stains derived from diffusion-tensor MR images. Basser PJ. **Ann N Y Acad Sci** 1997 May 30;820:123–38 (45 ref.)

Prions and molecular chaperones. Liautard JP. **Arch Virol Suppl** 1993;7:227–43 (45 ref.)

Modelling clinical accelerator beams: a review. Ebert MA, et al. **Australas Phys Eng Sci Med** 1996 Sep;19(3):131–50 (148 ref.)

Conversion of PDD for photon beams from one SSD to another and calculation of TAR, TMR and TPR. Burns JE. **Br J Radiol** 1996;Suppl 25:153–7 (12 ref.)

The within-host population dynamics of antibacterial chemotherapy: conditions for the evolution of resistance. Lipsitch M, et al. **Ciba Found Symp** 1997;207:112–27; discussion 127–30 (27 ref.)

Computational and numerical methods for bioelectric field problems. Johnson CR. **Crit Rev Biomed Eng** 1997; 25(1):1–81 (251 ref.)

Neutral theory of molecular evolution. Takahata N. **Curr Opin Genet Dev** 1996 Dec;6(6):767–72 (60 ref.)

Disablement observed, addressed, and experienced: integrating subjective experience into disablement models. Peters DJ. **Disabil Rehabil** 1996 Dec;18(12):593–603 (44 ref.)

A simple but flexible growth function. France J, et al. **Growth Dev Aging** 1996 Summer;60(2):71–83 (34 ref.)

Emerging model of quality. Larrabee JH. **Image J Nurs Sch** 1996 Winter;28(4):353–8 (44 ref.)

A model of lymphocyte recirculation. Stekel DJ, et al. **Immunol Today** 1997 May;18(5):216–21 (32 ref.)

Quality in health care: traditions, influences and future directions. Harvey G. **Int J Qual Health Care** 1996 Aug; 8(4):341–50 (85 ref.)

Developments in microbiological risk assessment models for drinking water—a short review. Gale P. **J Appl Bacteriol** 1996 Oct;81(4):403–10 (27 ref.)

A model for developing effective treatments: progression and interplay of theory, research, and practice. Kazdin AE. **J Clin Child Psychol** 1997 Jun;26(2):114–29 (66 ref.)

Adherence in AIDS clinical trials: a framework for clinical research and clinical care. Ickovics JR, et al. **J Clin Epidemiol** 1997 Apr;50(4):385–91 (58 ref.)

Swine manure cleanup criteria calculation for odor causing volatile organic compounds based on manure-to-ventilation air exposure pathway. Liao CM, et al. **J Environ Sci Health B** 1997 Jul;32(4):449–68 (33 ref.)

Theory, explanation, and a third generation of theoretical development in social gerontology. Bengtson VL, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 Mar;52(2):S72–88 (154 ref.)

Sexually transmitted diseases and sexual behavior: insights from mathematical models. Garnett GP, et al. **J Infect Dis** 1996 Oct;174 Suppl 2:S150–61 (43 ref.)

Personal risk taking and the spread of disease: beyond core groups. Rothenberg RB, et al. **J Infect Dis** 1996 Oct;174 Suppl 2:S144–9 (36 ref.)

The development and use of the concept of a sexually transmitted disease core. Thomas JC, et al. **J Infect Dis** 1996 Oct;174 Suppl 2:S134–43 (103 ref.)

Quasi-equivalent viruses: a paradigm for protein assemblies. Johnson JE, et al. **J Mol Biol** 1997 Jun 27;269(5):665–75 (35 ref.)

An effective model for reorganization of perinatal services in a metropolitan area: a descriptive analysis and historical perspective. Pollack LD. **J Perinatol** 1996 Jan–Feb; 16(1):3–8 (30 ref.)

Mechanism of leakage of contents of membrane vesicles determined by fluorescence requenching. Ladokhin AS, et al. **Methods Enzymol** 1997;278:474–86 (17 ref.)

On the mathematical modelling of pain. Britton NF, et al. **Neurochem Res** 1996 Sep;21(9):1133–40 (53 ref.)

Analogs of the early solar system. Koerner DW. **Orig Life Evol Biosph** 1997 Jun;27(1–3):157–84 (178 ref.)

Physics and chemistry of the solar nebula. Lunine JI. **Orig Life Evol Biosph** 1997 Jun;27(1–3):205–24 (46 ref.)

Is extraterrestrial organic matter relevant to the origin of life on Earth? Whittet DC. **Orig Life Evol Biosph** 1997 Jun;27(1–3):249–62 (50 ref.)

Is there a research paradigm for palliative care? Corner J. **Palliat Med** 1996 Jul;10(3):201–8 (26 ref.)

Computational methods in radionuclide dosimetry. Bardiès M, et al. **Phys Med Biol** 1996 Oct;41(10):1941–55 (130 ref.)

Prospects for advancing the understanding of complex biochemical systems. Liu J, et al. **Plant Mol Biol** 1997 Mar; 33(4):573–81 (65 ref.)

Directionality principles in thermodynamics and evolution. Demetrius L. **Proc Natl Acad Sci U S A** 1997 Apr 15; 94(8):3491–8 (40 ref.)

A conceptual framework for the study of early readmission as an indicator of quality of care. Ashton CM, et al. **Soc Sci Med** 1996 Dec;43(11):1533–41 (39 ref.)

Measuring the magnitude of socio-economic inequalities in health: an overview of available measures illustrated with two examples from Europe. Mackenbach JP, et al. **Soc Sci Med** 1997 Mar;44(6):757–71 (35 ref.)

[Institutionalization of community programs: review of theoretical models and proposal of a model- Renaud L, et al. **Can J Public Health** 1997 Mar–Apr;88(2):109–13 (28 ref.) (Eng. Abstr.) **(Fre)**

MODELS, WEIGHTLESSNESS see **WEIGHTLESSNESS SIMULATION**

MODIFICATION METHYLASES see **DNA MODIFICATION METHYLASES**

MODY see **DIABETES MELLITUS, NON-INSULIN-DEPENDENT**

MOERSCH-WOLTMANN SYNDROME see **STIFF-MAN SYNDROME**

MOHAMMEDANISM see **ISLAM**

MOHS SURGERY

Mohs micrographic surgery for nonmelanoma skin cancer. Telfer NR. **Clin Dermatol** 1995 Nov–Dec;13(6):593–600 (54 ref.)

Recurrent lentigo maligna invading a skin graft successfully treated with Mohs' micrographic surgery. Cohen LM, et al. **Cutis** 1996 Mar;57(3):175–8 (26 ref.)

Peritumoral B cell infiltrate associated with chronic lymphocytic leukemia obscuring margin evaluation during Mohs micrographic surgery [letter] Humphreys TR, et al. **Dermatol Surg** 1996 Oct;22(10):894–6 (21 ref.)

[Verrucous carcinoma of the penis: local excision with the Mohs micrographic technique] Muro Vidaurre I, et al. **Arch Esp Urol** 1996 Nov;49(9):959–64 (39 ref.) (Eng. Abstr.) **(Spa)**

METHODS

Dermatofibrosarcoma protuberans (DFSP): growth characteristics based on tumor modeling and a review of cases treated with Mohs micrographic surgery. Haycox CL, et al. **Ann Plast Surg** 1997 Mar;38(3):246–51 (32 ref.)

Surgery and laser therapy. Lawrence CM. **J R Coll Physicians Lond** 1997 Jul–Aug;31(4):369–73 (25 ref.)

Mohs micrographic surgery for the treatment of difficult skin cancers. Skouge JW. **Md Med J** 1997 May–Jun;46(5):231–7 (42 ref.)

MOIRE TOPOGRAPHY

[EEG topography] Yamadera H. **Nippon Rinsho** 1997 Mar; 55 Suppl 1:361–4 (6 ref.) **(Jpn)**

MOLAR

Ectopic eruption of maxillary first permanent molars in children with cleft lip. da Silva Filho OG, et al. **Angle Orthod** 1996;66(5):373–80 (22 ref.)

The buccal bifurcation cyst: a prospective study of treatment outcomes in 44 sites. Pompura JR, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Feb;83(2):215–21 (23 ref.)

ABNORMALITIES

Monilethrix: a review and case report. Carreras D. **Pediatr Dent** 1996 Jul–Aug;18(4):331–3 (10 ref.)

[Supernumerary molars. Apropos of 10 cases] Ntima-Nsiemi K, et al. **Rev Stomatol Chir Maxillofac** 1997 Aug;98(2):72–5 (20 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

A review of root resective therapy as a treatment option for maxillary molars. Hempton T, et al. **J Am Dent Assoc** 1997 Apr;128(4):449–55 (30 ref.)

MOLAR, FOURTH see **TOOTH, SUPERNUMERARY**

MOLAR, THIRD

Metastasis of a malignant melanoma to the region of an impacted mandibular third molar: a case report. Santamaría J, et al. **J Oral Maxillofac Surg** 1997 Sep;55(9):1003–6 (15 ref.)

SURGERY

Prophylactic removal of impacted third molars: an assessment of published reviews. Song F, et al. **Br Dent J** 1997 May 10;182(9):339–46 (45 ref.)

Intentional partial odontectomy: review of cases. Freedman GL. **J Oral Maxillofac Surg** 1997 May;55(5):524–6 (2 ref.)

[Benefits and risk of the extraction of wisdom teeth] Torres JH. **Rev Stomatol Chir Maxillofac** 1997 Sep;98(3):173–8 (33 ref.) **(Fre)**

MOLECULAR BIOLOGY

Molecular biology of growth-hormone-secreting human pituitary tumours: biochemical consequences and potential clinical significance. Adams EF, et al. **Acta Neurochir Suppl (Wien)** 1996;65:7-10 (18 ref.)

Molecular biological research in pituitary adenomas from the pathologists' view. Kovacs K. **Acta Neurochir Suppl (Wien)** 1996;65:4-6 (8 ref.)

Role of molecular biology in risk assessment. Puga A, et al. **Adv Exp Med Biol** 1996;387:395-404 (46 ref.)

Molecular biology and medicine. A primer for the clinician. Bello EA, et al. **Anesthesiology** 1996 Dec;85(6):1462-78 (55 ref.)

Molecular biological investigations into the role of the NMDA receptor in the pathophysiology of schizophrenia. Catts SV, et al. **Aust N Z J Psychiatry** 1997 Feb;31(1):17-26 (110 ref.)

Utilising molecular biological and histopathological techniques to study the dopaminergic system in patients with melancholia. Hickie I, et al. **Aust N Z J Psychiatry** 1997 Feb;31(1):27-35 (36 ref.)

Molecular biology and the major psychoses. Lloyd A, et al. **Aust N Z J Psychiatry** 1997 Feb;31(1):12-6 (13 ref.)

Role of molecular cell biology in understanding disease. Savill J. **BMJ** 1997 Jan 18;314(7075):203-6 (0 ref.)

Molecular biology and molecular genetics of nitric oxide synthase genes. Nadaud S, et al. **Clin Exp Hypertens** 1996 Feb;18(2):113-43 (88 ref.)

The molecular biology of olfactory perception. Mombaerts P, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:135-45 (41 ref.)

Dying by default, the biology of apoptosis: a review [see comments] Olasode BJ. **East Afr Med J** 1997 Feb; 74(2):108-11 (21 ref.) Comment in: East Afr Med J 1997 Feb;74(2):61.

Reasons underlying discrepancies in results between immunohistochemistry and molecular biology. Kopolovic J, et al. **Eur J Histochem** 1996;40(3):177-80 (32 ref.)

Molecular biology of pituitary development and disease. Bedford FK, et al. **Horm Res** 1996;45 Suppl 1:19-21 (9 ref.)

Use of isolated immature-stage B cells to understand negative selection and tolerance induction at the molecular level. Norvell A, et al. **Immunol Res** 1996;15(3):191-207 (71 ref.)

Molecular mechanisms of class I major histocompatibility complex antigen processing and presentation. Yang Y, et al. **Immunol Res** 1996;15(3):208-33 (204 ref.)

Anti-inflammatory therapies: application of molecular biology techniques in intensive care medicine. Liu M, et al. **Intensive Care Med** 1997 Jul;23(7):718-31 (127 ref.)

Applied molecular biology of sepsis. Remick DG. **J Crit Care** 1995 Dec;10(4):198-212 (85 ref.)

Microcirculation: its significance in clinical and molecular medicine. Fagrell B, et al. **J Intern Med** 1997 May; 241(5):349-62 (118 ref.)

Biomolecular structure and dynamics--experiment and theory. Forsén S, et al. **J Pharm Biomed Anal** 1996 Jan; 14(3):233-6 (33 ref.)

Cancer genes and molecular oncology in the clinic. Caldas C, et al. **Lancet** 1997 May;349 Suppl 2:SII16-8 (32 ref.)

Impact of molecular biology on the detection of foodborne pathogens. Feng P. **Mol Biotechnol** 1997 Jun;7(3):267-78 (49 ref.)

Complexity measures in molecular psychiatry. Rapp PE, et al. **Mol Psychiatry** 1996 Nov;1(5):408-16 (83 ref.)

Molecular biology of autoantigens in rheumatic diseases. Galperin C, et al. **Rheum Dis Clin North Am** 1996 Feb; 22(1):175-210 (243 ref.)

Concepts and techniques in molecular biology--an overview. Sheffield WP. **Transfus Med Rev** 1997 Jul;11(3):209-23 (64 ref.)

Corticotrophin-releasing factor receptors: from molecular biology to drug design. Chalmers DT, et al. **Trends Pharmacol Sci** 1996 Apr;17(4):166-72 (46 ref.)

[Molecular biology and cardiology. Molecular mechanisms in heart failure] Sheikh SP, et al. **Ugeskr Laeger** 1997 Apr 21;159(17):2523-8 (20 ref.) **(Dan)**

[Molecular biological aspects of animal production] Wrenzycki C, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Aug-Sep;103(8-9):316-20 (23 ref.) (Eng. Abstr.) **(Ger)**

[Contribution of molecular biology to surgical therapy of neoplasms] Mitsudomo T, et al. **Kyobu Geka** 1997 Jan; 50(1):4-8 (15 ref.) **(Jpn)**

[Contribution of molecular biology to cardiovascular surgery] Sawa Y, et al. **Kyobu Geka** 1997 Jan;50(1):9-12 (11 ref.) **(Jpn)**

[Recent progress of molecular oncology and its contribution to clinical gastroenterology] Imai K, et al. **Nippon Rinsho** 1996 Apr;54(4):906-10 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular approach for analyses of gut function: an overview] Kamada T, et al. **Nippon Rinsho** 1996 Apr; 54(4):897-905 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Introduction of molecular biology in respiratory medicine and its perspective] Kira S, et al. **Nippon Rinsho** 1996 Feb; 54(2):287-91 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Libraries as tools to explore the specificities of molecular interactions] Udaka K. **Seikagaku** 1997 May;69(5):339-43 (15 ref.) **(Jpn)**

[Impact of molecular genetics to clinical neurology] Tsuji S. **Seishin Shinkeigaku Zasshi** 1996;98(9):622-8 (36 ref.) **(Jpn)**

[Drug design based on genome project and structural biology] Yasuoka N. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):956-60 (15 ref.) **(Jpn)**

[The introduction to molecular biology and its application go pediatrics (4): study of mutations in DNA amplified by PCR] Castaño L, et al. **An Esp Pediatr** 1997 Mar; 46(3):305-10 (7 ref.) **(Spa)**

[Introduction to molecular biology and application to pediatrics (1): basic concepts] Castaño L, et al. **An Esp Pediatr** 1996 Sep;45(3):315-20 (5 ref.) **(Spa)**

[Techniques, strategies, and uses of molecular biology in medicine (see comments)] Cerezo Román J, et al. **Rev Invest Clin** 1995 Nov-Dec;47(6):487-98 (62 ref.) (Eng. Abstr.) Comment in: Rev Invest Clin 1996 Mar-apr;48(2):167. **(Spa)**

EDUCATION

Chronic allograft arteriosclerosis: contributing factors and molecular mechanisms in the light of experimental studies. Räisänen-Sokolowski A, et al. **Transpl Immunol** 1996 Jun; 4(2):91-8 (87 ref.)

[Essays on modern molecular genetics from a lecture course for students of the biology department of Moscow State University. Essay 5. Transgenosis and new molecular genetics] Sverdlov ED. **Mol Gen Mikrobiol Virusol** 1996 Oct-Dec;(4):3-32 (65 ref.) **(Rus)**

METHODS

Clinical molecular biology: concepts and applications. Aziz KJ. **Adv Clin Chem** 1996;32:39-72 (32 ref.)

Concepts, principles, and applications of selected molecular biology techniques in clinical biochemistry. Narayanan S. **Adv Clin Chem** 1996;32:1-38 (79 ref.)

Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin. Knepper MA. **Am J Physiol** 1997 Jan;272(1 Pt 2):F3-12 (59 ref.)

The molecular biology of ependymomas. Hamilton RL, et al. **Brain Pathol** 1997 Apr;7(2):807-22 (177 ref.)

A molecular genetic model of astrocytoma histopathology. Louis DN. **Brain Pathol** 1997 Apr;7(2):755-64 (81 ref.)

Molecular biological methods in diagnosis and treatment of liver diseases. Worman HJ. **Clin Chem** 1997 Aug;43(8 Pt 2):1476-86 (103 ref.)

Molecular biology techniques in endocrinology. Davis JR. **Clin Endocrinol (Oxf)** 1996 Aug;45(2):125-33 (15 ref.)

Molecular basis of genetic disease and molecular methods. McPherson RA. **Clin Lab Med** 1995 Dec;15(4):779-94 (54 ref.)

Clinical use of quantitative molecular methods in studying human immunodeficiency virus type 1 infection. Clementi M, et al. **Clin Microbiol Rev** 1996 Apr;9(2):135-47 (176 ref.)

Relevance of nucleic acid amplification techniques for diagnosis of respiratory tract infections in the clinical laboratory. Ieven M, et al. **Clin Microbiol Rev** 1997 Apr; 10(2):242-56 (220 ref.)

Cellular and molecular biology in urogynaecology. Blakeman P, et al. **Curr Opin Obstet Gynecol** 1996 Oct;8(5):357-60 (37 ref.)

Molecular approaches to the identification of unculturable infectious agents [see comments] Gao SJ, et al. **Emerg Infect Dis** 1996 Jul-Sep;2(3):159-67 (92 ref.) Comment in: Emerg Infect Dis 1997 Jan-Mar;3(1):77-8.

Diagnostic molecular microbiology in posterior uveitis: principles and applications. Adra CN, et al. **Int Ophthalmol Clin** 1995 Summer;35(3):75-92 (40 ref.)

Molecular biology of somatostatin receptor subtypes. Patel YC, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):31-8 (31 ref.)

Molecular approaches to the diagnosis of male infertility. Jeremias J, et al. **Mol Hum Reprod** 1996 Mar;2(3):195-202 (60 ref.)

Serological and molecular biology screening techniques for HVC infection. De Lamballerie X. **Nephrol Dial Transplant** 1996;11 Suppl 4:9-11 (17 ref.)

Molecular insights into neurofibromatosis 2. Gutmann DH. **Neurobiol Dis** 1997;3(4):247-61 (83 ref.)

Molecular biology of axon guidance. Nieto MA. **Neuron** 1996 Dec;17(6):1039-48 (49 ref.)

Role of the microbiology laboratory in monitoring and identifying resistance: use of molecular biology. Pfaller MA, et al. **New Horiz** 1996 Aug;4(3):361-9 (31 ref.)

Molecular genetics of small round cell tumors. López-Terrada D. **Semin Diagn Pathol** 1996 Aug; 13(3):242-9 (93 ref.)

An overview of the development, validation, and application of neurobehavioral and neuromolecular toxicity assessment batteries: potential applications to combustion toxicology. Rossi J 3rd, et al. **Toxicology** 1996 Dec 31;115(1-3):107-17 (18 ref.)

In search of virulence factors of human bacterial disease. Quinn FD, et al. **Trends Microbiol** 1997 Jan;5(1):20-6 (56 ref.)

Application of molecular biology in veterinary parasitology. Prichard R. **Vet Parasitol** 1997 Jul 31;71(2-3):155-75 (102 ref.)

[Molecular biology at the service of the daily medical virology. 1. Methodological principles] Wattré P. **Ann Biol Clin (Paris)** 1997 Jan-Feb;55(1):25-31 (8 ref.) (Eng. Abstr.) **(Fre)**

[Application of molecular biological methods for diagnosis and epidemiology of human fungal infections] Schönian G, et al. **Mycoses** 1996;39 Suppl 1:73-80 (48 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

Vascular remodelling and molecular biology: new concepts and therapeutic possibilities. Agrotis A, et al. **Clin Exp Pharmacol Physiol** 1996 May;23(5):363-8 (57 ref.)

Modern molecular genetic approaches to complex traits: implications for psychiatric disorders [see comments] Owen MJ, et al. **Mol Psychiatry** 1996 Mar;1(1):21-6 (58 ref.) Comment in: Mol Psychiatry 1996 Mar;1(1):15.

MOLECULAR BIOLOGY, COMPUTATIONAL see **COMPUTATIONAL BIOLOGY**

MOLECULAR CHAPERONES

see related

HEAT-SHOCK PROTEINS

Propeptide-mediated folding in subtilisin: the intramolecular chaperone concept. Shinde U, et al. **Adv Exp Med Biol** 1996;379:147-54 (35 ref.)

Prions and molecular chaperones. Liautard JP. **Arch Virol Suppl** 1993;7:227-43 (45 ref.)

The effect of molecular chaperones on in vivo and in vitro folding processes. Schwarz E, et al. **Biol Chem** 1996 Jul-Aug;377(7-8):411-6 (77 ref.)

Discovery of molecular chaperones. Ellis RJ. **Cell Stress Chaperones** 1996 Sep;1(3):155-60 (26 ref.)

Heat shock proteins, molecular chaperones and the prion encephalopathies. Kenward N, et al. **Cell Stress Chaperones** 1996 Apr;1(1):18-22 (34 ref.)

[Biological significance of the higher order structure of chromosomal DNA: function of DNA chaperones] Imamoto F. **Tanpakushitsu Kakusan Koso** 1996 Oct; 41(13):2009-23 (68 ref.) **(Jpn)**

[Functions of Hsp90, a major stress protein, as a molecular chaperone] Kimura Y, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(7):883-7 (31 ref.) **(Jpn)**

[Collagen-specific molecular chaperone, HSP47] Nagata K. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(7):888-95 (32 ref.) **(Jpn)**

[Chaperonin: structure and function] Taguchi H, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(7):849-59 (53 ref.) **(Jpn)**

CHEMISTRY

Protein folding in vivo: unraveling complex pathways. Johnson JL, et al. **Cell** 1997 Jul 25;90(2):201-4 (19 ref.)

Molecular chaperones and the heat shock response at Cold Spring Harbor. Hightower LE, et al. **Cell Stress Chaperones** 1997 Mar;2(1):1-11 (21 ref.)

Molecular chaperones: physical and mechanistic properties. Burston SG, et al. **Essays Biochem** 1995;29:125-36 (26 ref.)

GENETICS

Chaperone-assisted protein expression. Cole PA. **Structure** 1996 Mar 15;4(3):239-42 (29 ref.)

METABOLISM

The final stage of gene expression: chaperones and the regulation of protein fate. Ashkenas J, et al. **Am J Hum Genet** 1997 Aug;61(2):267-72 (39 ref.)

Regulation and function of collagen-specific molecular chaperone, HSP47. Nagata K, et al. **Cell Struct Funct** 1996 Oct;21(5):425-30 (30 ref.)

Role of lipid synthesis, chaperone proteins and proteasomes in the assembly and secretion of apoprotein B-containing lipoproteins from cultured liver cells. Ginsberg HN. **Clin Exp Pharmacol Physiol** 1997 May;24(5):A29-32 (61 ref.)

Mechanisms and pathways of chaperone-mediated protein folding. Hartle FU. **Cold Spring Harb Symp Quant Biol** 1995;60:429-34 (56 ref.)

Molecular chaperones: clasping the prize. Gething MJ. **Curr Biol** 1996 Dec 1;6(12):1573-6 (19 ref.)

Chaperones get Hip. Protein folding. Ziegelhoffer T, et al. **Curr Biol** 1996 Mar 1;6(3):272-5 (20 ref.)

Steroid receptor interactions with heat shock protein and immunophilin chaperones. Pratt WB, et al. **Endocr Rev** 1997 Jun;18(3):306-60 (698 ref.)

Molecular chaperones: physical and mechanistic properties. Burston SG, et al. **Essays Biochem** 1995;29:125-36 (26 ref.)

Molecular chaperoning of steroid hormone receptors. Pratt WB, et al. **EXS** 1996;77:79-95 (103 ref.)

Involvement of molecular chaperones in intracellular protein breakdown. Sherman MY, et al. **EXS** 1996;77:57-78 (100 ref.)

Protein quality control: triage by chaperones and proteases. Gottesman S, et al. **Genes Dev** 1997 Apr 1;11(7):815-23 (70 ref.)

The role of molecular chaperones in mitochondrial protein import and folding. Ryan MT, et al. **Int Rev Cytol** 1997; 174:127-93 (382 ref.)

Molecular chaperones and the cytoskeleton. Liang P, et al. **J Cell Sci** 1997 Jul;110 (Pt 13):1431-40 (135 ref.)

Customized secretion chaperones in pathogenic bacteria.

MOLECULAR CHAPERONES

Wattiau P, et al. **Mol Microbiol** 1996 Apr;20(2):255–62 (59 ref.)

The Clp ATPases define a novel class of molecular chaperones. Wawrzynow A, et al. **Mol Microbiol** 1996 Sep; 21(5):895–9 (26 ref.)

Molecular chaperones and protein folding in plants. Boston RS, et al. **Plant Mol Biol** 1996 Oct;32(1–2):191–222 (344 ref.)

Chaperones get in touch: the Hip–Hop connection. Frydman J, et al. **Trends Biochem Sci** 1997 Mar;22(3):87–92 (50 ref.)

PHYSIOLOGY

The role of the hsp90-based chaperone system in signal transduction by nuclear receptors and receptors signaling via MAP kinase. Pratt WB.
Annu Rev Pharmacol Toxicol 1997;37:297–326 (183 ref.)

Molecular chaperones, folding catalysts, and the recovery of active recombinant proteins from E. coli. To fold or to refold. Thomas JG, et al. **Appl Biochem Biotechnol** 1997 Jun;66(3):197–238 (214 ref.)

Molecular chaperones and the heat shock response at Cold Spring Harbor. Hightower LE, et al.
Cell Stress Chaperones 1997 Mar;2(1):1–11 (21 ref.)

Fit for life? Evolution of chaperones and folding catalysts parallels the development of complex organisms. Pahl A, et al. **Cell Stress Chaperones** 1997 Jun;2(2):78–86 (41 ref.)

Influence of molecular and chemical chaperones on protein folding [published erratum appears in Cell Stress Chaperones 1996 Sep;1(3):207] Welch WJ, et al.
Cell Stress Chaperones 1996 Jun;1(2):109–15 (34 ref.)

The roles of molecular chaperones in vivo. Lund PA.
Essays Biochem 1995;29:113–23 (19 ref.)

Assisted protein folding. Ruddon RW, et al. **J Biol Chem** 1997 Feb 7;272(6):3125–8 (60 ref.)

The roles of the thiol:protein disulfide oxidoreductases in membrane and secretory protein synthesis within the lumen of the endoplasmic reticulum. Holtzman JL.
J Investig Med 1997 Feb;45(2):28–34 (52 ref.)

[Cytoplasmic chaperones in precursor targeting to mitochondria] Mihara K. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(7):868–74 (16 ref.) **(Jpn)**

MOLECULAR CLONING see **CLONING, MOLECULAR**

MOLECULAR CONFIGURATION see **MOLECULAR CONFORMATION**

MOLECULAR CONFORMATION

Crystal structures of some acyclonucleosides with antiviral activity and related compounds. Birnbaum KB.
Acta Biochim Pol 1996;43(1):65–76 (33 ref.)

Lateral forces acting between particles in liquid films or lipid membranes. Kralchevsky PA. **Adv Biophys** 1997;34:25–39 (74 ref.)

Automated docking of flexible ligands: applications of AutoDock. Goodsell DS, et al. **J Mol Recognit** 1996 Jan–Feb;9(1):1–5 (23 ref.)

New applications of simulated annealing in X-ray crystallography and solution NMR. Brünger AT, et al.
Structure 1997 Mar 15;5(3):325–36 (82 ref.)

MOLECULAR EPIDEMIOLOGY see **EPIDEMIOLOGY, MOLECULAR**

MOLECULAR EVOLUTION see **EVOLUTION, MOLECULAR**

MOLECULAR EVOLUTION, DIRECTED see **DIRECTED MOLECULAR EVOLUTION**

MOLECULAR GENETICS see **GENETICS, BIOCHEMICAL**

MOLECULAR MIMICRY

Imprinting through molecular mimicry. Protein synthesis. Liljas A. **Curr Biol** 1996 Mar 1;6(3):247–9 (12 ref.)

Mimicry meets the mitochondrion. Evolution. Mallet J, et al. **Curr Biol** 1996 Aug 1;6(8):937–40 (15 ref.)

Molecular mimicry of host structures by bacterial lipopolysaccharides and its contribution to disease. Moran AP, et al. **FEMS Immunol Med Microbiol** 1996 Dec 1; 16(2):105–15 (94 ref.)

Insulin-dependent diabetes mellitus: the hypothesis of molecular mimicry between islet cell antigens and microorganisms. Maclaren NK, et al. **Mol Med Today** 1997 Feb;3(2):76–83 (37 ref.)

Immunologic mechanisms in Lyme neuroborreliosis: the potential role of autoimmunity and molecular mimicry. Sigal LH. **Semin Neurol** 1997 Mar;17(1):63–8 (63 ref.)

Molecular mimicry between Helicobacter pylori and the host. Appelmelk BJ, et al. **Trends Microbiol** 1997 Feb;5(2):70–3 (31 ref.)

[Pathogenesis of Guillain-Barré syndrome and Fisher's syndrome: molecular mimicry between antecedent infectious agents and components of nerve tissues] Yuki N. **Rinsho Shinkeigaku** 1995 Dec;35(12):1373–5 (10 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Molecular mimicry: the geographical distribution of immune responses to Klebsiella in ankylosing spondylitis and its relevance to therapy. Ebringer A, et al. **Clin Rheumatol** 1996 Jan;15 Suppl 1:57–61 (24 ref.)

Molecular mimicry: can epitope mimicry induce autoimmune disease? Davies JM. **Immunol Cell Biol** 1997 Apr; 75(2):113–26 (143 ref.)

PHYSIOLOGY

[Molecular mimicry and mechanisms of autoantibody production] Miyazawa M. **Nippon Rinsho** 1997 Jun; 55(6):1370–6 (18 ref.) (Eng. Abstr.) **(Jpn)**

MOLECULAR MODELS see **MODELS, MOLECULAR**

MOLECULAR NEUROBIOLOGY see **NEUROBIOLOGY**

MOLECULAR PROBE TECHNIQUES

[Molecular markers in plant genetics and plant breeding] Marczewski W. **Postepy Biochem** 1995;41(4):237–43 (8 ref.) **(Pol)**

MOLECULAR PROBES

Genetic and biochemical probes for protein–protein interactions. McNabb DS, et al. **Curr Opin Biotechnol** 1996 Oct;7(5):554–9 (51 ref.)

[Monoclonal antibodies] Arai T.
Tanpakushitsu Kakusan Koso 1997 May;42(7 Suppl):1128–33 (20 ref.) **(Jpn)**

[Tracer molecules and caged compounds] Furuno T.
Tanpakushitsu Kakusan Koso 1997 May;42(7 Suppl):1122–7 (21 ref.) **(Jpn)**

[Functional biosensor] Teshima R, et al.
Tanpakushitsu Kakusan Koso 1997 May;42(7 Suppl):1134–40 (36 ref.) **(Jpn)**

DIAGNOSTIC USE

Clinical utility of molecular probes in lymphoproliferative disorders. Kay NE. **Blood Rev** 1996 Jun;10(2):81–8 (60 ref.)

The role of molecular diagnostics in the clinical microbiology laboratory. Baselski VS. **Clin Lab Med** 1996 Mar; 16(1):49–60 (37 ref.)

[Peroperative detection probes. Evaluation and perspectives in endocrinology] Tenenbaum F, et al.
Ann Endocrinol (Paris) 1997;58(1):39–46 (32 ref.) (Eng. Abstr.) **(Fre)**

MOLECULAR SEQUENCE DATA

see related
SEQUENCE ALIGNMENT

Submission of nucleotide sequence data to EMBL/GenBank/DDBJ. Tuli MA, et al.
Mol Biotechnol 1996 Aug;6(1):47–51 (3 ref.)

MOLECULAR STEREOCHEMISTRY see **MOLECULAR CONFORMATION**

MOLECULAR STRUCTURE

see related
MODELS, MOLECULAR

Structure calculation from NMR data. Nilges M.
Curr Opin Struct Biol 1996 Oct;6(5):617–23 (64 ref.)

A systems approach to molecular structure, intermolecular recognition, and emergence–dissolvence in medicinal research. Testa B, et al. **Med Res Rev** 1997 Jul;17(4):303–26 (25 ref.)

Force: a new structural control parameter? Bensimon D.
Structure 1996 Aug 15;4(8):885–9 (36 ref.)

MOLECULAR VACCINES see **VACCINES, SYNTHETIC**

MOLESTATION, SEXUAL, CHILD see **CHILD ABUSE, SEXUAL**

MOLLUSCA

see related
SHELLFISH

International trade in live molluscs: perspective from the Americas. Elston RA. **Rev Sci Tech** 1996 Jun;15(2):483–90 (6 ref.)

Preparation and applications of the International Aquatic Animal Health Code and Diagnostic Manual for Aquatic Animal Diseases of the Office International des Epizooties. Håstein T. **Rev Sci Tech** 1996 Jun;15(2):723–31 (4 ref.)

CHEMISTRY

[Antineoplastic glycoproteins in marine invertebrates] Yamazaki M, et al. **Gan To Kagaku Ryoho** 1997 Sep; 24(11):1477–85 (19 ref.) (Eng. Abstr.) **(Jpn)**

CYTOLOGY

A cellular approach to the study of complex natural behavior patterns in the ragged sea hare (Bursatella leachii), a marine invertebrate indigenous to Puerto Rico. Miller MW.
P R Health Sci J 1997 Mar;16(1):23–36 (105 ref.)

DRUG EFFECTS

A hint on pharmacological and toxicological differences between magnesium chloride and magnesium sulphate, or of scallops and men. Durlach J, et al. **Magnes Res** 1996 Oct;9(3):217–9 (15 ref.)

GENETICS

Gene flow and genetic diversity in naturally fragmented metapopulations of deep-sea hydrothermal vent animals. Vrijenhoek RC. **J Hered** 1997 Jul–Aug;88(4):285–93 (67 ref.)

IMMUNOLOGY

Host–parasite interactions in molluscs. Fryer SE, et al.
Prog Mol Subcell Biol 1996;15:131–53 (131 ref.)

PARASITOLOGY

Host–parasite interactions in molluscs. Fryer SE, et al.
Prog Mol Subcell Biol 1996;15:131–53 (131 ref.)

Southern hemisphere mollusc diseases and an overview of associated risk assessment problems. Hine PM.
Rev Sci Tech 1996 Jun;15(2):563–77 (77 ref.)

Appearance and spread of diseases among bivalve molluscs in the northern hemisphere in relation to international trade. Renault T. **Rev Sci Tech** 1996 Jun;15(2):551–61 (40 ref.)

PHYSIOLOGY

From Polyplacophora to Cephalopoda: comparative analysis of nitric oxide signalling in mollusca. Moroz LL, et al.
Acta Biol Hung 1995;46(2–4):169–82 (55 ref.)

Single-channel studies in molluscan neurons. Fejtl M, et al.
Ion Channels 1996;4:333–76 (130 ref.)

Oscillations and gaseous oxides in invertebrate olfaction. Gelperin A, et al. **J Neurobiol** 1996 May;30(1):110–22 (119 ref.)

VIROLOGY

Southern hemisphere mollusc diseases and an overview of associated risk assessment problems. Hine PM.
Rev Sci Tech 1996 Jun;15(2):563–77 (77 ref.)

Appearance and spread of diseases among bivalve molluscs in the northern hemisphere in relation to international trade. Renault T. **Rev Sci Tech** 1996 Jun;15(2):551–61 (40 ref.)

MOLLUSCACIDES

ISOLATION & PURIFICATION

Search for molluscicidal and antifungal saponins from tropical plants. Hostettmann K, et al.
Adv Exp Med Biol 1996;404:117–28 (18 ref.)

Investigations of molluscicidal saponins from the Endod plant Phytolacca dodecandra. Thiilborg ST, et al.
Adv Exp Med Biol 1996;404:151–64 (52 ref.)

Novel anthelmintic compounds and molluscicides from medicinal plants. Whitfield PJ.
Trans R Soc Trop Med Hyg 1996 Nov–Dec;90(6):596–600 (46 ref.)

TOXICITY

Investigations of molluscicidal saponins from the Endod plant Phytolacca dodecandra. Thiilborg ST, et al.
Adv Exp Med Biol 1996;404:151–64 (52 ref.)

MOLLUSCUM CONTAGIOSUM

Molluscum contagiosum virus. Birthistle K, et al. **J Infect** 1997 Jan;34(1):21–8 (176 ref.)

DIAGNOSIS

An update on molluscum contagiosum. Lewis EJ, et al.
Cutis 1997 Jul;60(1):29–34 (32 ref.)

DRUG THERAPY

Successful treatment of molluscum contagiosum in the immunosuppressed adult with topical injection of streptococcal preparation OK-432. Inui S, et al.
J Dermatol 1996 Sep;23(9):628–30 (19 ref.)

THERAPY

An update on molluscum contagiosum. Lewis EJ, et al.
Cutis 1997 Jul;60(1):29–34 (32 ref.)

Warts and molluscum contagiosum: beware of treatments worse than the disease. Ordoukhanian E, et al.
Postgrad Med 1997 Feb;101(2):223–6, 229–32, 235 (31 ref.)

MOLLUSCUM CONTAGIOSUM VIRUS

Molluscum contagiosum virus. Birthistle K, et al. **J Infect** 1997 Jan;34(1):21–8 (176 ref.)

MOLLUSK VENOMS

Metamorphoses of a conotoxin. Zlotkin E, et al.
Adv Exp Med Biol 1996;391:387–401 (45 ref.)

CHEMISTRY

Primary structural motifs of Conus peptides. Cruz LJ. **Adv Exp Med Biol** 1996;391:155–67 (62 ref.)

MOLLY see **POECILIA**

MOLONEY LEUKEMIA VIRUS

IMMUNOLOGY

Moloney leukemia virus–induced cell surface antigen mimicry by monoclonal antibodies. Baskin JG, et al. **Immunol Res** 1995;14(4):292–316 (96 ref.)

PATHOGENICITY

Leukemogenesis by Moloney murine leukemia virus: a multistep process. Fan H. **Trends Microbiol** 1997 Feb; 5(2):74–82 (48 ref.)

PHYSIOLOGY

Mouse Moloney leukemia virus infects microglia but not neurons even though it induces motor neuron disease. Zachary JF, et al. **Mol Psychiatry** 1997 Mar;2(2):104–6 (19 ref.)

MOLSIDOMINE

ANALOGS & DERIVATIVES

Nitric oxide donor, linsidomine chlorhydrate (SIN–1), in the diagnosis and treatment of erectile dysfunction: critical appraisal and review of the literature. Wegner HE, et al. **Int Urol Nephrol** 1995;27(5):621–8 (29 ref.)

THERAPEUTIC USE

[Nitric oxide donors in therapy of chronic heart failure] Blasini R, et al. **Internist (Berl)** 1997 May;38(5):448–52 (48 ref.) **(Ger)**

[Nitric oxide in therapy of angina pectoris: nitrates or molsidomine?] Schächinger V, et al. **Internist (Berl)** 1997 May;38(5):438–47 (49 ref.) **(Ger)**

MOLTING

see related
ECDYSONE
ECDYSTERONE

PHYSIOLOGY

Insect physiology: the emerging story of ecdysis. Hesterlee S, et al. **Curr Biol** 1996 Jun 1;6(6):648–50 (9 ref.)

The molting gland of the cockroach Periplaneta americana: secretory activity and its regulation. Richter K, et al. **Gen Pharmacol** 1997 Jul;29(1):17–21 (32 ref.)

MOLTING HORMONE see **ECDYSONE**

MOLYBDENUM

METABOLISM

Molybdenum–cofactor–containing enzymes: structure and mechanism. Kisker C, et al. **Annu Rev Biochem** 1997; 66:233–67 (74 ref.)

Distribution and pathophysiologic role of molybdenum–containing enzymes. Moriwaki Y, et al. **Histol Histopathol** 1997 Apr;12(2):513–24 (114 ref.)

MONGOLISM see **DOWN SYNDROME**

MONGOLOID RACE

An epidemiologic review of dietary intake studies among American Indians and Alaska Natives: implications for heart disease and cancer risk [see comments] Bell RA, et al. **Ann Epidemiol** 1997 May;7(4):229–40 (84 ref.) Comment in: Ann Epidemiol 1997 May;7(4):227–8.

Asian blepharoplasty. Kikkawa DO, et al. **Int Ophthalmol Clin** 1997 Summer;37(3):193–204 (27 ref.)

Alzheimer–type of pathological changes in Chinese. Ng H, et al. **J Neurol Sci** 1997 Jan;145(1):97–103 (45 ref.)

Cystic fibrosis in Malay children––a report of three cases. Norzila MZ, et al. **Singapore Med J** 1996 Jun;37(3):273–4 (3 ref.)

GENETICS

beta–thalassemia mutations in Japanese and Koreans [published erratum appears in Hemoglobin 1997 Jul;21(4):389] Ohba Y, et al. **Hemoglobin** 1997 Mar; 21(2):191–200 (19 ref.)

[Genetic analysis of bronchial asthma in Japanese population––Fc epsilon RI beta gene and beta 2 adrenergic receptor gene] Hizawa N, et al. **Nippon Rinsho** 1996 Feb; 54(2):539–43 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Alpha 1–antitrypsin deficiency in Japan] Seyama K, et al. **Nippon Rinsho** 1996 Feb;54(2):533–8 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Genotypes of cystic fibrosis (CF) reported in the world and polymorphisms of cystic fibrosis transmembrane conductance regulator (CFTR) gene in Japanese] Wang W, et al. **Nippon Rinsho** 1996 Feb;54(2):525–32 (26 ref.) (Eng. Abstr.) **(Jpn)**

MONILIA see **CANDIDA**

MONILIALES see **HYPHOMYCETES**

MONILIASIS see **CANDIDIASIS**

MONILIASIS, ORAL see **CANDIDIASIS, ORAL**

MONILIASIS, VULVOVAGINAL see **CANDIDIASIS, VULVOVAGINAL**

MONITORING, AMBULATORY

Ambulatory bladder monitoring: is it an advance? Heslington K. **Br J Urol** 1997 Jul;80 Suppl 1:49–53 (18 ref.)

METHODS

[Software for automated follow–up of chronic outpatients] Lapochkin VI, et al. **Vestn Oftalmol** 1997 May–Jun; 113(3):30–2 (0 ref.) (Eng. Abstr.) **(Rus)**

MONITORING, AMBULATORY BLOOD PRESSURE see **BLOOD PRESSURE MONITORING, AMBULATORY**

MONITORING, AMBULATORY ELECTROCARDIOGRAPHIC see **ELECTROCARDIOGRAPHY, AMBULATORY**

MONITORING, DRUG see **DRUG MONITORING**

MONITORING, ENVIRONMENTAL see **ENVIRONMENTAL MONITORING**

MONITORING, FETAL see **FETAL MONITORING**

MONITORING, HOLTER see **ELECTROCARDIOGRAPHY, AMBULATORY**

MONITORING, HOME BLOOD GLUCOSE see **BLOOD GLUCOSE SELF–MONITORING**

MONITORING, IMMUNE see **MONITORING, IMMUNOLOGIC**

MONITORING, IMMUNOLOGIC

METHODS

Monitoring of cancer patients undergoing active or passive immunotherapy. Salgaller ML. **J Immunother** 1997 Jan; 20(1):1–14 (113 ref.)

MONITORING, INTRAOPERATIVE see **INTRAOPERATIVE MONITORING**

MONITORING, PHYSIOLOGIC

see related
SIGNAL PROCESSING, COMPUTER–ASSISTED

Monitoring during mechanical ventilation. Jubran A, et al. **Clin Chest Med** 1996 Sep;17(3):453–73 (117 ref.)

Provocation tests versus 24–h pH and pressure measurements. Ghillebert G, et al. **Eur J Gastroenterol Hepatol** 1995 Dec; 7(12):1141–6 (27 ref.)

Analysis of 24–h oesophageal pH and pressure recordings. Weusten BL, et al. **Eur J Gastroenterol Hepatol** 1995 Dec; 7(12):1147–51 (23 ref.)

Recent developments in cerebral monitoring––near–infrared light spectroscopy. An overview. Williams IM, et al. **Eur J Vasc Endovasc Surg** 1996 Oct;12(3):263–71 (53 ref.)

Renal function monitoring. Garwood S, et al. **Int Anesthesiol Clin** 1996 Summer;34(3):175–94 (87 ref.)

The current status of point–of–care monitoring. Gilbert HC, et al. **Int Anesthesiol Clin** 1996 Summer;34(3):243–61 (33 ref.)

Assessment of sedation, analgesia, and neuromuscular blockade in the perioperative period. Habibi S, et al. **Int Anesthesiol Clin** 1996 Summer;34(3):215–41 (68 ref.)

Methods for monitoring hemostasis during and following cardiac surgery. Huffman SM, et al. **Int Anesthesiol Clin** 1996 Spring;34(2):123–39 (34 ref.)

Monitoring respiratory function. Jacobsohn E, et al. **Int Anesthesiol Clin** 1996 Summer;34(3):1–36 (50 ref.)

The monitoring of mechanically ventilated patients. Kirby RR. **Int Anesthesiol Clin** 1997 Winter;35(1):65–86 (61 ref.)

Monitoring and analysis of outcome studies. Lagasse RS. **Int Anesthesiol Clin** 1996 Summer;34(3):263–77 (37 ref.)

Cardiac output technologies. Mantin R, et al. **Int Anesthesiol Clin** 1996 Summer;34(3):79–107 (48 ref.)

Evoked potential monitoring. Sloan TB. **Int Anesthesiol Clin** 1996 Summer;34(3):109–36 (124 ref.)

Monitoring hemostasis. Whalen J, et al. **Int Anesthesiol Clin** 1996 Summer;34(3):195–213 (63 ref.)

Approaches to postoperative blood flow monitoring after free tissue transfer. Which is the best? Berger A, et al. **Int Angiol** 1995 Sep;14(3):288–96 (92 ref.)

Basic principles of optical radiation and some common applications in anesthesia. Gravenstein D, et al. **J Clin Monit** 1996 Nov;12(6):445–54 (75 ref.)

Guidelines for cerebral perfusion pressure. Brain Trauma Foundation. **J Neurotrauma** 1996 Nov;13(11):693–7 (35 ref.)

Indications for intracranial pressure monitoring. Brain Trauma Foundation. **J Neurotrauma** 1996 Nov; 13(11):667–79 (52 ref.)

Monitoring of blood volume during haemodialysis treatment of acute renal and multiple organ failures. Katzarski KS. **Nephrol Dial Transplant** 1996;11 Suppl 8:20–3 (46 ref.)

Invasive and noninvasive oxygen consumption and hemodynamic monitoring in elderly surgical patients. Yu M. **New Horiz** 1996 Nov;4(4):443–52 (111 ref.)

[How should hepatitis C be monitored? Monitoring of treated hepatitis C] Larrey D. **Gastroenterol Clin Biol** 1997;21(1 Pt 2):S99–110 (124 ref.) **(Fre)**

[Monitoring of treated or non–treated chronic viral hepatitis C. 2: Criteria of efficacy and monitoring of treatment with interferon–alpha] Payen JL. **Gastroenterol Clin Biol** 1997; 21(1 Pt 2):S175–89 (276 ref.) **(Fre)**

[How should hepatitis C be monitored? Monitoring of non–treated hepatitis C] Poupon R. **Gastroenterol Clin Biol** 1997;21(1 Pt 2):S96–8 (32 ref.) **(Fre)**

[Control of training intensity in rehabilitation of chronic obstructive respiratory tract diseases] Müller C, et al. **Pneumologie** 1997 May;51(5):519–22 (51 ref.) **(Ger)**

[Value of electroneurophysiological monitoring on the intensive care unit] Engelhardt W. **Zentralbl Neurochir** 1997;58(1):36–42 (23 ref.) **(Ger)**

[Monitoring cerebral perfusion pressure] Jantzen JP. **Zentralbl Neurochir** 1997;58(1):32–5 (31 ref.) **(Ger)**

[Monitoring cerebral oxygenation in increased intracranial pressure] Unterberg A. **Zentralbl Neurochir** 1997;58(1):47–9 (24 ref.) **(Ger)**

[Measurement of stress response during surgery and anesthesia] Ninomiya S, et al. **Masui** 1996 Dec;45 Suppl:S38–43 (4 ref.) **(Jpn)**

[Current systems of ventilation of the lungs and methods of their monitoring] Al'es VF, et al. **Anesteziol Reanimatol** 1996 Nov–Dec;(6):67–71 (80 ref.) **(Rus)**

[24–hour pH–metry in the diagnosis of acid–related diseases. Indications and usefulness] Azpiroz Vidaur F. **Gastroenterol Hepatol** 1996 Mar;19(3):178–82 (31 ref.) **(Spa)**

INSTRUMENTATION

Coronary vein flow velocity changes during transluminal balloon angioplasty: a study using the Doppler guide wire. Manginas A, et al. **Cathet Cardiovasc Diagn** 1997 Jan; 40(1):85–91 (23 ref.)

Intracerebral depth electrode monitoring in partial epilepsy: the morbidity and efficacy of placement using magnetic resonance image–guided stereotactic surgery. Ross DA, et al. **Neurosurgery** 1996 Aug;39(2):327–33; discussion 333–4 (39 ref.)

[Effectiveness of pulmonary artery catheterization in the critically ill patient––attempt at evaluating current status (see comments)] Sakka SG, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 May; 32(5):271–82 (90 ref.) (Eng. Abstr.) Comment in: Anasthesiol Intensivmed Notfallmed Schmer 1997 May;32(5):269–10. **(Ger)**

[Portable home monitoring system in screening for sleep–disordered breathing] Hida W, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Dec;33 Suppl:46–9 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Nocturnal penile tumescence] Takanami M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:393–6 (6 ref.) **(Jpn)**

METHODS

Medical monitoring in long–term space missions. Grigoriev AI, et al. **Adv Space Biol Med** 1997;6:167–91 (36 ref.)

Advances in critical care monitoring. Barie PS. **Arch Surg** 1997 Jul;132(7):734–9 (43 ref.)

In vivo monitoring of brain neurotransmitter release for the assessment of neuroendocrine interactions. Mas M, et al. **Cell Mol Neurobiol** 1996 Jun;16(3):383–96 (51 ref.)

Clinical chemistry and post–liver–transplant monitoring. Hickman PE, et al. **Clin Chem** 1997 Aug;43(8 Pt 2):1546–54 (67 ref.)

Oxygen transport and oxygen metabolism in shock and critical illness. Invasive and noninvasive monitoring of circulatory dysfunction and shock. Shoemaker WC. **Crit Care Clin** 1996 Oct;12(4):939–69 (55 ref.)

Determination of oxygen delivery and consumption versus cardiac index and oxygen extraction ratio. Vincent JL. **Crit Care Clin** 1996 Oct;12(4):995–1006 (29 ref.)

Bioelectrical impedance techniques in medicine. Part II: Monitoring of physiological events by impedance. Valentinuzzi ME, et al. **Crit Rev Biomed Eng** 1996; 24(4–6):353–466 (408 ref.)

Delivery and monitoring of inhaled nitric oxide. Young JD, et al. **Intensive Care Med** 1996 Jan;22(1):77–86 (61 ref.)

What can EEG–video monitoring do for you and your patients? Benbadis SR. **J Fla Med Assoc** 1997 Jun–Jul; 84(5):320–2 (21 ref.)

Microdialysis in the human brain: review of its applications. Hamani C, et al. **Neurol Res** 1997 Jun;19(3):281–8 (28 ref.)

Thromboelastography for the assessment of hypercoagulability during general surgery. Arcelus JI, et al. **Semin Thromb Hemost** 1995;21 Suppl 4:21–6 (62 ref.)

Thromboelastography and liver transplantation. Gillies BS.

Semin Thromb Hemost 1995;21 Suppl 4:45–9 (15 ref.)
Thromboelastography and cardiopulmonary bypass. Spiess BD. **Semin Thromb Hemost** 1995;21 Suppl 4:27–33 (31 ref.)
Thromboelastographic modifications induced by intravenous and subcutaneous heparin administration. Traverso CI, et al. **Semin Thromb Hemost** 1995;21 Suppl 4:53–8 (47 ref.)
Role of thromboelastography in evaluating other anticoagulant agents: warfarin and heparin–dihydroergotamine. Traverso CI, et al. **Semin Thromb Hemost** 1995;21 Suppl 4:59–62 (12 ref.)
New approaches to monitoring sleep–related breathing disorders. Stradling JR, et al. **Sleep** 1996 Nov;19(9 Suppl):S77–84 (49 ref.)
[Management in subsequent children in families where crib death occurred: management or home monitoring?] Hoir MP, et al. **Ned Tijdschr Geneeskd** 1996 Sep 21; 140(38):1888–90 (20 ref.) **(Dut)**
[Fulminant liver insufficiency and the possible role of intracranial pressure monitoring, also in children] Plötz FB, et al. **Ned Tijdschr Geneeskd** 1996 Nov 16;140(46):2274–6 (28 ref.) **(Dut)**
[Value of monitoring muscle relaxation] Jöhr M, et al. **Schweiz Med Wochenschr** 1996 Sep 28;126(39):1649–53 (31 ref.) (Eng. Abstr.) **(Ger)**
[Clinical evaluation of neuromuscular block] Saitoh Y. **Masui** 1996 Oct;45(10):1198–208 (45 ref.) (Eng. Abstr.) **(Jpn)**
[Evaluation of the severity of cardiogenic shock by monitoring of their hemodynamics] Matsuzaki M, et al. **Nippon Naika Gakkai Zasshi** 1996 Jan 10;85(1):27–32 (5 ref.) **(Jpn)**
[Continuous intragastric pH monitoring] Asaki S, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:95–8 (3 ref.) **(Jpn)**
[Objective measurement of motor activity in Parkinson's disease by actigraphy. Clinical assessment of akinesia] Fujikane M, et al. **Nippon Rinsho** 1997 Jan;55(1):153–7 (7 ref.) (Eng. Abstr.) **(Jpn)**
[Esophageal pH monitoring] Sekiguchi T. **Nippon Rinsho** 1997 Apr;55 Suppl 2:99–102 (7 ref.) **(Jpn)**
[The simplest methods for controlling patient status in resuscitation and intensive therapy units] Zolotokrylina ES, et al. **Anesteziol Reanimatol** 1996 Sep–Oct;(5):81–6 (30 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

Recommendations for intracranial pressure monitoring technology. Brain Trauma Foundation. **J Neurotrauma** 1996 Nov;13(11):685–92 (35 ref.)

TRENDS

The future. Monitoring cellular energetics. Beilman GJ, et al. **Crit Care Clin** 1996 Oct;12(4):1031–42 (53 ref.)

VETERINARY

Monitoring techniques and equipment for small animal anaesthesia. Nicholson A. **Aust Vet J** 1996 Aug; 74(2):114–23 (32 ref.)
Arterial blood pressure monitoring in anesthetized animals. Wagner AE, et al. **J Am Vet Med Assoc** 1997 May 1; 210(9):1279–85 (74 ref.)
[Monitoring of emergency and intensive care patients: simple diagnostic aids] Spreng DE, et al. **Schweiz Arch Tierheilkd** 1996;138(11):537–45 (18 ref.) (Eng. Abstr.) **(Ger)**

MONITORING, RADIOIMMUNOLOGIC see **MONITORING, IMMUNOLOGIC**

MONITORING, SLEEP see **POLYSOMNOGRAPHY**

MONITORS, BLOOD PRESSURE see **BLOOD PRESSURE MONITORS**

MONKEY DISEASES

PARASITOLOGY

Diagnostic exercise: abdominal parasites in a spider monkey. Baker DG, et al. **Lab Anim Sci** 1996 Jun;46(3):338–40 (11 ref.)

PHYSIOPATHOLOGY

What happens to binocularity in primate strabismus? Boothe RG, et al. **Eye** 1996;10 (Pt 2):199–208 (47 ref.)

RADIOGRAPHY

Rickets in a 6–month–old monkey. Liu SK. **Skeletal Radiol** 1996 Jan;25(1):70–2 (13 ref.)

VIROLOGY

The GB hepatitis viruses. Karayiannis P, et al. **J Viral Hepat** 1995;2(5):221–6 (17 ref.)

MONKEY, JAPANESE see **MACACA**

MONKEY, RHESUS see **MACACA MULATTA**

MONKEY, SPIDER see **CEBIDAE**

MONKEY, WOOLLY see **CEBIDAE**

MONKEYS see **HAPLORHINI**

MONKEYS, NEW WORLD see **CEBIDAE**

MONOACYLGLYCEROLS see **GLYCERIDES**

MONO–ADP–RIBOSYLTRANSFERASE see **NAD(P)(+)–ARGININE ADP–RIBOSYLTRANSFERASE**

MONOAMINE OXIDASE

BLOOD

The 1996 James B. Isaacson Award Lecture. Platelet MAO activity in type 1/type 2 alcoholics. von Knorring L. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):224A–230A (82 ref.)

DEFICIENCY

MAOA deficiency and abnormal behaviour: perspectives on an association. Brunner HG. **Ciba Found Symp** 1996; 194:155–64; discussion 164–7 (39 ref.)

GENETICS

MAOA deficiency and abnormal behaviour: perspectives on an association. Brunner HG. **Ciba Found Symp** 1996; 194:155–64; discussion 164–7 (39 ref.)

METABOLISM

Modulation of gene expression rather than monoamine oxidase inhibition: (–)–deprenyl–related compounds in controlling neurodegeneration. Tatton WG, et al. **Neurology** 1996 Dec;47(6 Suppl 3):S171–83 (205 ref.)
The influence of estrogen on monoamine oxidase activity. Chakravorty SG, et al. **Psychopharmacol Bull** 1997; 33(2):229–33 (58 ref.)

MONOAMINE OXIDASE INHIBITORS

see related
ANTIDEPRESSIVE AGENTS

Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide. Goldberg RJ. **Drugs Aging** 1997 Aug;11(2):119–31 (86 ref.)

ADMINISTRATION & DOSAGE

Continuation and maintenance treatments in major depression: the neglected role of monoamine oxidase inhibitors. Kennedy SH. **J Psychiatry Neurosci** 1997 Mar; 22(2):127–31 (34 ref.)

ADVERSE EFFECTS

Retrospective study of selegiline–antidepressant drug interactions and a review of the literature. Ritter JL, et al. **Ann Clin Psychiatry** 1997 Mar;9(1):7–13 (37 ref.)
Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment. Young BK, et al. **Drugs Aging** 1997 May;10(5):367–83 (153 ref.)
Serotonin syndrome and drug combinations: focus on MAOI and RIMA. Hilton SE, et al. **Eur Arch Psychiatry Clin Neurosci** 1997;247(3):113–9 (49 ref.)

METABOLISM

One fatal and one nonfatal intoxication with tranylcypromine. Absence of amphetamines as metabolites. Iwersen S, et al. **J Anal Toxicol** 1996 Sep;20(5):301–4 (21 ref.)
[Tribulin—a novel endogenous monoaminoxidase inhibitor (dedicated to the memory of Merton Sandler)] Medvedev AR. **Vopr Med Khim** 1996 Apr–Jun;42(2):95–103 (90 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Mahmood I. **Clin Pharmacokinet** 1997 Aug;33(2):91–102 (44 ref.)

PHARMACOLOGY

Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Mahmood I. **Clin Pharmacokinet** 1997 Aug;33(2):91–102 (44 ref.)
Moclobemide. An update of its pharmacological properties and therapeutic use [published erratum appears in Drugs 1996 Dec;52(6):869] Fulton B, et al. **Drugs** 1996 Sep; 52(3):450–74 (115 ref.)
Brofaromine—a review of its pharmacological properties and therapeutic use. Volz HP, et al. **J Neural Transm** 1996; 103(1–2):217–45 (99 ref.)
The pharmacology of B–type selective monoamine oxidase inhibitors; milestones in (–)–deprenyl research. Magyar K, et al. **J Neural Transm Suppl** 1996;48:29–43 (65 ref.)
Sexual side effects of antidepressants: a review. Margolese HC, et al. **J Sex Marital Ther** 1996 Fall;22(3):209–17 (68 ref.)

THERAPEUTIC USE

Selegiline in treatment of behavioral and cognitive symptoms of Alzheimer disease. Tolbert SR, et al. **Ann Pharmacother** 1996 Oct;30(10):1122–9 (90 ref.)
The pharmacotherapy of panic disorder. Rosenbaum JF, et al. **Bull Menninger Clin** 1996 Spring;60(2 Suppl A):A54–75 (119 ref.)
Moclobemide. An update of its pharmacological properties and therapeutic use [published erratum appears in Drugs 1996 Dec;52(6):869] Fulton B, et al. **Drugs** 1996 Sep; 52(3):450–74 (115 ref.)
Moclobemide: a paradigm of research in clinical psychopharmacology. Angst J, et al. **Int Clin Psychopharmacol** 1996 Jun;11 Suppl 3:3–7 (32 ref.)
Moclobemide in the treatment of social phobia. Nutt D, et al. **Int Clin Psychopharmacol** 1996 Jun;11 Suppl 3:77–82 (22 ref.)
The pharmacotherapy of social phobia. Pollack MH, et al. **Int Clin Psychopharmacol** 1996 Jun;11 Suppl 3:71–5 (40 ref.)
The failure of 'adult' interventions with adolescent depression: what does it mean for theory, research and practice? Mueller C, et al. **J Affect Disord** 1997 Jul; 44(2–3):203–15 (88 ref.)
Recent developments in the psychopharmacology of anxiety disorders. Lydiard RB, et al. **J Consult Clin Psychol** 1996 Aug;64(4):660–8 (85 ref.)
Brofaromine—a review of its pharmacological properties and therapeutic use. Volz HP, et al. **J Neural Transm** 1996; 103(1–2):217–45 (99 ref.)
New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline. Gerlach M, et al. **J Neural Transm Suppl** 1996;48:7–21 (63 ref.)
Pharmacological aspects of human and canine narcolepsy. Nishino S, et al. **Prog Neurobiol** 1997 May;52(1):27–78 (380 ref.)
Management of canine pituitary–dependent hyperadrenocorticism with l–deprenyl (Anipryl). Bruyette DS, et al. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):273–86 (34 ref.)
Parkinson's disease. Diagnosis and treatment. Ng DC. **West J Med** 1996 Oct;165(4):234–40 (26 ref.)
[Monoamine oxidase inhibitors in psychiatry. Status of current knowledge] Volz HP, et al. **Nervenarzt** 1996 May; 67(5):339–47 (62 ref.) (Eng. Abstr.) **(Ger)**
[The treatment of the resistant obsessive–compulsive disorder: an update] Crespo Facorro B, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1997 Jan–Feb;25(1):61–9 (106 ref.) (Eng. Abstr.) **(Spa)**
[Neuroprotective and neurorestorative therapy in Parkinson's disease] Jiménez–Jiménez FJ, et al. **Rev Neurol** 1997 Aug; 25 Suppl 2:S185–93 (207 ref.) (Eng. Abstr.) **(Spa)**

MONOAMINES, BIOGENIC see **BIOGENIC MONOAMINES**

MONOBLASTIC LEUKEMIA, ACUTE see **LEUKEMIA, MONOCYTIC, ACUTE**

MONOCLONAL ANTIBODIES see **ANTIBODIES, MONOCLONAL**

MONOCLONAL ANTIBODY OKT3 see **MUROMONAB–CD3**

MONOCLONAL GAMMOPATHIES see **PARAPROTEINEMIAS**

MONOCLONAL GAMMOPATHIES, BENIGN

COMPLICATIONS

Monoclonal gammopathy and neuropathy. Notermans NC. **Curr Opin Neurol** 1996 Oct;9(5):334–7 (20 ref.)
Neuropathy associated with "benign" anti–myelin–associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases. Ellie E, et al. **J Neurol** 1996 Jan; 243(1):34–43 (43 ref.)
Temporal artery involvement revealing AL amyloidosis and IgD monoclonal gammopathy. Rodon P, et al. **J Rheumatol** 1996 Jan;23(1):189–90 (17 ref.)
[A "not–so–benign" monoclonal gammopathy! Corneal deposits of immunoglobulins (letter)] Duarte F, et al. **Ann Med Interne (Paris)** 1996;147(6):453–5 (12 ref.) **(Fre)**

PHYSIOPATHOLOGY

Neuropathy associated with "benign" anti–myelin–associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases. Ellie E, et al. **J Neurol** 1996 Jan; 243(1):34–43 (43 ref.)

MONOCULAR VISION see **VISION, MONOCULAR**

MONOCYTE CHEMOATTRACTANT PROTEIN-1

BIOSYNTHESIS

MCP-1 and CCR2 in HIV infection: regulation of agonist and receptor expression. Sozzani S, et al. **J Leukoc Biol** 1997 Jul;62(1):30-3 (23 ref.)

GENETICS

Transcriptional regulation of chemokine gene expression in astrocytes. Majumder S, et al. **J Neurosci Res** 1996 Sep 15;45(6):758-69 (79 ref.)

PHYSIOLOGY

Relative role of CSF-1, MCP-1/JE, and RANTES in macrophage recruitment during successful pregnancy. Wood GW, et al. **Mol Reprod Dev** 1997 Jan;46(1):62-9; discussion 69-70 (24 ref.)

Chemokines as targets for pharmacological intervention. Sozzani S, et al. **Prog Drug Res** 1996;47:53-80 (161 ref.)

[Role of alveolar macrophages in the pathogenesis of interstitial lung diseases-MCP-1-] Suga M. **Nippon Ika Daigaku Zasshi** 1996 Oct;63(5):384-90 (5 ref.) **(Jpn)**

[Role of alveolar macrophages in the pathogenesis of idiopathic interstitial pneumonia] Suga M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:175-80 (5 ref.) (Eng. Abstr.) **(Jpn)**

MONOCYTE CHEMOATTRACTANT PROTEINS

[Expression of monocyte chemotactic activity by cross-linked dimerization of a ribosomal protein] Yamamoto T. **Seikagaku** 1997 May;69(5):324-8 (15 ref.) **(Jpn)**

PHYSIOLOGY

Chemokines as targets for pharmacological intervention. Sozzani S, et al. **Prog Drug Res** 1996;47:53-80 (161 ref.)

MONOCYTE CHEMOTACTIC PROTEIN-1 see **MONOCYTE CHEMOATTRACTANT PROTEIN-1**

MONOCYTE CHEMOTACTIC PROTEINS see **MONOCYTE CHEMOATTRACTANT PROTEINS**

MONOCYTES

A global view on the role of monocytes and platelets in atherogenesis. Osterud B. **Thromb Res** 1997 Jan 1; 85(1):1-22 (116 ref.)

CHEMISTRY

Scavenger receptors in innate immunity. Pearson AM. **Curr Opin Immunol** 1996 Feb;8(1):20-8 (92 ref.)

DRUG EFFECTS

Regulation of tissue factor gene expression in human monocytic and endothelial cells. Mackman N. **Haemostasis** 1996;26 Suppl 1:17-9 (20 ref.)

Monocyte-platelet function and protection against cardiovascular disease. Oian P, et al. **Maturitas** 1996 May; 23 Suppl:S57-60 (14 ref.)

IMMUNOLOGY

Monocyte deactivation--rationale for a new therapeutic strategy in sepsis. Volk HD, et al. **Intensive Care Med** 1996 Oct;22 Suppl 4:S474-81 (24 ref.)

Immune deficiency in glycogen storage disease type 1B. Garty BZ, et al. **Isr J Med Sci** 1996 Dec;32(12):1276-81 (40 ref.)

MCP-1 and CCR2 in HIV infection: regulation of agonist and receptor expression. Sozzani S, et al. **J Leukoc Biol** 1997 Jul;62(1):30-3 (23 ref.)

[Role of monocytes and macrophages in the defense against malignant tumors] Schuurman B, et al. **Ned Tijdschr Geneeskd** 1996 Oct 5;140(40):1978-81 (34 ref.) **(Dut)**

METABOLISM

Role of CD23 in NO production by human monocytic cells. Kolb JP, et al. **Res Immunol** 1995 Nov-Dec;146(9):684-9 (52 ref.)

Role of CD69 in NO production by human monocytes. Testi R, et al. **Res Immunol** 1995 Nov-Dec;146(9):682-3 (19 ref.)

MICROBIOLOGY

Human monocytic and granulocytic ehrlichioses. Discovery and diagnosis of emerging tick-borne infections and the critical role of the pathologist. Walker DH, et al. **Arch Pathol Lab Med** 1997 Aug;121(8):785-91 (50 ref.)

Legionella pneumophila invasion of mononuclear phagocytes. Shuman HA, et al. **Curr Top Microbiol Immunol** 1996;209:99-112 (64 ref.)

PATHOLOGY

Involvement of selectins in atherogenesis: a primary or secondary event? Miyasaka M, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:25-34; discussion 34-5 (19 ref.)

Regulation of leucocyte-endothelial interactions of special relevance to atherogenesis. Vadas MA, et al. **Clin Exp Pharmacol Physiol** 1997 May;24(5):A33-5 (20 ref.)

[May-Heggelin anomaly and pregnancy. A case report, review of the literature] Tordjeman N, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(8):836-40 (16 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

New molecular aspects of chronic uraemia and dialysis-related immunocompetent cell activation. Descamps-Latscha B, et al. **Nephrol Dial Transplant** 1996; 11 Suppl 2:121-4 (23 ref.)

Nitric oxide, a vital poison inside the immune and inflammatory network. Dugas B, et al. **Res Immunol** 1995 Nov-Dec;146(9):664-70 (45 ref.)

[The interaction between beta 1 integrin (VLA-5) and extracellular matrix protein (fibronectin)--activation of cultured monocytes by fibronectin] Nishinarita S, et al. **Rinsho Byori** 1996 Sep;Suppl 102:140-6 (19 ref.) **(Jpn)**

[Interaction of monocytes and blood platelets in vascular wall diseases] Giedrojć J. **Postepy Hig Med Dosw** 1996; 50(3):265-76 (69 ref.) (Eng. Abstr.) **(Pol)**

VIROLOGY

Latent and persistent infections of monocytes and macrophages. Sinclair J, et al. **Intervirology** 1996; 39(5-6):293-301 (71 ref.)

Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes. Aquaro S, et al. **J Leukoc Biol** 1997 Jul;62(1):138-43 (39 ref.)

HIV-1 viral protein R (Vpr) regulates viral replication and cellular proliferation in T cells and monocytoid cells in vitro. Ayyavoo V, et al. **J Leukoc Biol** 1997 Jul;62(1):93-9 (42 ref.)

Neuropathogenesis of simian immunodeficiency virus infection in macaque monkeys. Sasseville VG, et al. **J Neurovirol** 1997 Feb;3(1):1-9 (104 ref.)

Interaction of human cytomegalovirus with monocytes/macrophages: a love-hate relationship. Michelson S. **Pathol Biol (Paris)** 1997 Feb;45(2):146-58 (155 ref.)

MONOCYTES, ACTIVATED KILLER

see related
IMMUNOTHERAPY, ADOPTIVE

MONOCYTIC LEUKEMIA, ACUTE see **LEUKEMIA, MONOCYTIC, ACUTE**

MONOCYTIC LEUKEMIA, CHRONIC see **LEUKEMIA, MONOCYTIC, CHRONIC**

MONODELPHIS see **OPOSSUMS**

L-MONOMETHYLARGININE see **OMEGA-N-METHYLARGININE**

MONONUCLEAR LEUKOCYTES see **LEUKOCYTES, MONONUCLEAR**

MONOPHENOL MONOOXYGENASE

see related
ALBINISM

GENETICS

Detection of melanoma cells in peripheral blood using reverse transcription polymerase chain reaction assay for tyrosinase mRNA. Jung FA, et al. **Cancer Surv** 1996;26:251-65 (38 ref.)

METABOLISM

Lag kinetics of tyrosinase: its physiological implications. Ramaiah A. **Indian J Biochem Biophys** 1996 Oct; 33(5):349-56 (56 ref.)

MONOPHOSPHATIDYLGLYCEROLS see **PHOSPHATIDYLGLYCEROLS**

MONOSACCHARIDE TRANSPORT PROTEINS

[Glucose transporter] Oka Y. **Nippon Rinsho** 1996 Mar; 54(3):632-7 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Membrane carrier proteins and NIDDM] Tamori Y, et al. **Nippon Rinsho** 1996 Mar;54(3):765-9 (16 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

Mechanism of glucose transport across the human and rat placental barrier: a review. Takata K, et al. **Microsc Res Tech** 1997 Jul 1-15;38(1-2):145-52 (70 ref.)

BIOSYNTHESIS

Nutrient regulation of intestinal sugar-transporter expression. Shirazi-Beechey SP, et al. **Biochem Soc Trans** 1996 May; 24(2):389-92 (18 ref.)

CHEMISTRY

Structure, function, and regulation of the mammalian facilitative glucose transporter gene family. Olson AL, et al. **Annu Rev Nutr** 1996;16:235-56 (143 ref.)

Membrane topology motifs in the SGLT cotransporter family. Turk E, et al. **J Membr Biol** 1997 Sep 1;159(1):1-20 (75 ref.)

CLASSIFICATION

The hexose transporter family of Saccharomyces cerevisiae. Kruckeberg AL. **Arch Microbiol** 1996 Nov;166(5):283-9? (70 ref.)

GENETICS

The hexose transporter family of Saccharomyces cerevisiae. Kruckeberg AL. **Arch Microbiol** 1996 Nov;166(5):283-92 (70 ref.)

The metabolic consequences of altered glucose transporter expression in transgenic mice. Katz EB, et al. **J Mol Med** 1996 Nov;74(11):639-52 (75 ref.)

METABOLISM

Regulation of glucose transport, and glucose transporters expression and trafficking in the heart: studies in cardiac myocytes. Zorzano A, et al. **Am J Cardiol** 1997 Aug 4; 80(3A):65A-76A (118 ref.)

Kinetoplastid glucose transporters. Tetaud E, et al. **Biochem J** 1997 Aug 1;325 (Pt 3):569-80 (103 ref.)

Trafficking, targeting and translocation of the insulin-responsive glucose transporter, GLUT4, in adipocytes. Rice JE, et al. **Biochem Soc Trans** 1996 May; 24(2):540-6 (47 ref.)

Control of glucose transport by GLUT1: regulated secretion in an unexpected environment. Widnell CC. **Biosci Rep** 1995 Dec;15(6):427-43 (42 ref.)

Biotechnological aspects of membrane function. Sigler K, et al. **Crit Rev Biotechnol** 1997;17(2):69-86 (77 ref.)

Lilly lecture 1995. Glucose transport: pivotal step in insulin action. Kahn BB. **Diabetes** 1996 Nov;45(11):1644-54 (63 ref.)

Glucose transporter proteins in brain: delivery of glucose to neurons and glia. Vannucci SJ, et al. **Glia** 1997 Sep; 21(1):2-21 (140 ref.)

Glucose transporters in the transepithelial transport of glucose. Takata K. **J Electron Microsc (Tokyo)** 1996 Aug; 45(4):275-84 (86 ref.)

Regulation of Na+/glucose cotransporters. Wright EM, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):287-93 (23 ref.)

The metabolic consequences of altered glucose transporter expression in transgenic mice. Katz EB, et al. **J Mol Med** 1996 Nov;74(11):639-52 (75 ref.)

Differential regulation of the fructose transporters GLUT2 and GLUT5 in the intestinal cell line Caco-2. Brot-Laroche E. **Proc Nutr Soc** 1996 Mar;55(1B):201-8 (28 ref.)

Over-expression of GLUT4 selectively in adipose tissue in transgenic mice: implications for nutrient partitioning. Gnudi L, et al. **Proc Nutr Soc** 1996 Mar;55(1B):191-9 (30 ref.)

Glucose transporters in obesity. Guerre-Millo M. **Proc Nutr Soc** 1996 Mar;55(1B):237-44 (21 ref.)

Facilitative glucose transporters in ruminants. Hocquette JF, et al. **Proc Nutr Soc** 1996 Mar;55(1B):221-36 (70 ref.)

Hormonal regulation of the insulin-responsive glucose transporter, GLUT4: some recent advances. Livingstone C, et al. **Proc Nutr Soc** 1996 Mar;55(1B):179-90 (54 ref.)

Glucose transporters in the brain. Rayner DV. **Proc Nutr Soc** 1996 Mar;55(1B):209-19 (75 ref.)

Intestinal sodium-dependent D-glucose co-transporter: dietary regulation. Shirazi-Beechey SP. **Proc Nutr Soc** 1996 Mar;55(1B):167-78 (44 ref.)

PHYSIOLOGY

Glucose transporters in the regulation of intestinal, renal, and liver glucose fluxes. Thorens B. **Am J Physiol** 1996 Apr; 270(4 Pt 1):G541-53 (130 ref.)

Structure, function, and regulation of the mammalian facilitative glucose transporter gene family. Olson AL, et al. **Annu Rev Nutr** 1996;16:235-56 (143 ref.)

Is GLUT2 required for glucose sensing? Schuit FC. **Diabetologia** 1997 Jan;40(1):104-11 (67 ref.)

Are there kinetic advantages of GLUT2 in pancreatic glucose sensing? Sweet IR, et al. **Diabetologia** 1997 Jan;40(1):112-9 (16 ref.)

The molecular genetics of hexose transport in yeasts. Boles E, et al. **FEMS Microbiol Rev** 1997 Aug;21(1):85-111 (177 ref.)

MONOSACCHARIDES

METABOLISM

Aldose reductase: monosaccharide autoxidation and NADPH

MONOSACCHARIDES

binding. Crabbe MJ. **Biochem Soc Trans** 1996 Aug; 24(3):888–91 (40 ref.)

MONOSIALOSYL TETRAGLYCOSYL CERAMIDE see **G(M1) GANGLIOSIDE**

MONOSOMY

Partial trisomy 17q22–qter and partial monosomy Xq27–qter in a girl with a de novo unbalanced translocation due to a postzygotic error: case report and review of the literature on partial trisomy 17qter. Sarri C, et al. **Am J Med Genet** 1997 May 2;70(1):87–94 (46 ref.)

Monosomy 7 and 7q–-associated with myeloid malignancy. Johnson E, et al. **Blood Rev** 1997 Mar;11(1):46–55 (127 ref.)

Prenatal diagnosis of a de novo trisomy 6q22.2–->6qter and monosomy 1pter–->1p36.3. Case report with a 2-year follow-up and a brief review of other prenatal cases of partial trisomy 6q. Kulharya AS, et al. **Clin Genet** 1997 Feb;51(2):115–7 (2 ref.)

DIAGNOSIS

Diabetes insipidus, acute myelogenous leukemia, and monosomy 7. Mozersky RP, et al. **J Am Osteopath Assoc** 1996 Feb;96(2):116–8 (8 ref.)

GENETICS

A case of presumptive monosomy 21 re-diagnosed as unbalanced t(5p;21q) by FISH and review of literature. Iqbal MA, et al. **Am J Med Genet** 1997 May 16;70(2):174–8 (21 ref.)

Monosomy X as a recurring sole cytogenetic abnormality associated with myelodysplastic diseases. Abruzzese E, et al. **Cancer Genet Cytogenet** 1997 Feb;93(2):140–6 (41 ref.)

Partial trisomy and partial monosomy of the distal long arm of chromosome 4: patient report and literature review. Frints SG, et al. **Genet Couns** 1996;7(2):135–42 (55 ref.)

MONOSOMY, PARTIAL see **CHROMOSOME DELETION**

MONOTREMATA

GENETICS

Mammals that break the rules: genetics of marsupials and monotremes. Graves JA. **Annu Rev Genet** 1996;30:233–60 (111 ref.)

MOOD see **AFFECT**

MOOD DISORDERS, NON-PSYCHOTIC see **AFFECTIVE DISORDERS**

MOOD DISORDERS, PSYCHOTIC see **AFFECTIVE DISORDERS, PSYCHOTIC**

MOPEDS see **MOTORCYCLES**

MORALE

Politics and South African mental health: hope, truth, and reconciliation. Comas-Díaz L, et al. **Cult Divers Ment Health** 1996;2(2):133–8 (14 ref.)

An analysis of the concept of hope in the adolescent with cancer. Hendricks-Ferguson VL. **J Pediatr Oncol Nurs** 1997 Apr;14(2):73–80; discussion 81–2 (47 ref.)

Strategies for assessing and fostering hope: the hope assessment guide. Penrod J, et al. **Oncol Nurs Forum** 1997 Jul;24(6):1055–63 (12 ref.)

MORALS

see related
CONFLICT OF INTEREST

Family processes as predictors of adolescents' preferences for ascribed sources of moral authority: a proposed model. White FA. **Adolescence** 1996 Spring;31(121):133–44 (22 ref.)

Prospective autonomy and critical interests: a narrative defense of the moral authority of advance directives. Rich BA. **Camb Q Healthc Ethics** 1997 Spring;6(2):138–47 (24 ref.)

The origin and formulation of Chinese character: an introduction to confucianism and its influence on Chinese behavior patterns. Huang DD, et al. **Cult Divers Ment Health** 1996;2(1):35–42 (24 ref.)

Why does removing machines count as "passive" euthanasia? Hopkins PD. **Hastings Cent Rep** 1997 May–Jun;27(3):29–37 (20 ref.)

Geographies of responsibility. Walker M. **Hastings Cent Rep** 1997 Jan–Feb;27(1):38–44 (15 ref.)

The patient as moral agent in psychotherapy. Chazan R. **Isr J Psychiatry Relat Sci** 1997;34(1):26–36 (27 ref.)

Embryo experimentation and the murder prohibition: a casuistic examination of the utilitarian and pro-life positions on the moral status of the embryo. Sullivan L. **Med Law** 1995;14(5–6):369–86 (15 ref.)

[Sexuality and religions] Chaix-Durand G, et al. **Contracept Fertil Sex** 1997 Mar;25(3):I–XIII (26 ref.) **(Fre)**

MORAXELLA

ENZYMOLOGY

Microbial dehalogenation of halogenated alkanoic acids, alcohols and alkanes. Slater JH, et al. **Adv Microb Physiol** 1997;38:133–76 (170 ref.)

METABOLISM

Novel microbial transformations of steroids. Madyastha KM. **Adv Exp Med Biol** 1996;405:259–70 (43 ref.)

Microbial dehalogenation of halogenated alkanoic acids, alcohols and alkanes. Slater JH, et al. **Adv Microb Physiol** 1997;38:133–76 (170 ref.)

MORAXELLA (BRANHAMELLA) CATARRHALIS

Neonatal meningitis due to Moraxella catarrhalis and review of the literature. Daoud A, et al. **Ann Trop Paediatr** 1996 Sep;16(3):199–201 (14 ref.)

Moraxella (Branhamella) catarrhalis--clinical and molecular aspects of a rediscovered pathogen. Enright MC, et al. **J Med Microbiol** 1997 May;46(5):360–71 (129 ref.)

DRUG EFFECTS

Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media. Block SL. **Pediatr Infect Dis J** 1997 Apr;16(4):449–56 (39 ref.)

ISOLATION & PURIFICATION

Microbiology and management of sinusitis. Brook I. **J Otolaryngol** 1996 Aug;25(4):249–56 (44 ref.)

PATHOGENICITY

Acute otitis media. Maxson S, et al. **Pediatr Rev** 1996 Jun; 17(6):191–5; quiz 196 (18 ref.)

[Moraxella catarrhalis: virulence and resistance mechanisms] Cullmann W. **Med Klin** 1997 Mar 15;92(3):162–6 (52 ref.) (Eng. Abstr.) **(Ger)**

MORAXELLA CATARRHALIS see **MORAXELLA (BRANHAMELLA) CATARRHALIS**

MORAXELLA KINGAE see **KINGELLA KINGAE**

MORBID OBESITY see **OBESITY, MORBID**

MORBIDITY

The human health effects of DDT (dichlorodiphenyltrichloroethane) and PCBS (polychlorinated biphenyls) and an overview of organochlorines in public health. Longnecker MP, et al. **Annu Rev Public Health** 1997;18:211–44 (127 ref.)

Child health statistical review, 1996. Platt MJ, et al. **Arch Dis Child** 1996 Dec;75(6):527–33 (18 ref.)

What should obstetricians be doing about the Barker hypothesis? Fraser R Sr, et al. **Br J Obstet Gynaecol** 1997 Jun;104(6):645–7 (16 ref.)

Aboriginal health [see comments] MacMillan HL, et al. **Can Med Assoc J** 1996 Dec 1;155(11):1569–78 (85 ref.) Comment in: Can Med Assoc J 1996 Dec 1;155(11):1581–3.

Review: pathways to morbidity in carers of dementia sufferers. Wijeratne C. **Int Psychogeriatr** 1997 Mar; 9(1):69–79 (74 ref.)

Health problems of refugees. Ackerman LK. **J Am Board Fam Pract** 1997 Sep–Oct;10(5):337–48 (72 ref.)

Profiles of non-cancer diseases in atomic bomb survivors. Kodama K, et al. **World Health Stat Q** 1996;49(1):7–16 (79 ref.)

[Significance of intentional weight loss on health] Heitmann BL, et al. **Ugeskr Laeger** 1997 Jun 23;159(26):4099–104 (38 ref.) (Eng. Abstr.) **(Dan)**

[Practical gynecology in the African bush: from humanitarianism to humanism] Géraud R, et al. **Contracept Fertil Sex** 1997 Jun;25(6):482–91 (28 ref.) **(Fre)**

TRENDS

Population growth, poverty and health. Kibirige JS. **Soc Sci Med** 1997 Jul;45(2):247–59 (70 ref.)

[Development of a model for explaining health inequality] Elkeles T, et al. **Gesundheitswesen** 1997 Mar;59(3):137–43 (68 ref.) (Eng. Abstr.) **(Ger)**

MORBILLIVIRUS

CLASSIFICATION

Rinderpest and other animal morbillivirus infections: comparative aspects and recent developments. Haas L, et al. **Zentralbl Veterinarmed [B]** 1996 Sep;43(7):411–20 (55 ref.)

GENETICS

Two morbilliviruses implicated in bottlenose dolphin epizootics. Taubenberger JK, et al. **Emerg Infect Dis** 1996 Jul–Sep;2(3):213–6 (21 ref.)

ISOLATION & PURIFICATION

Two morbilliviruses implicated in bottlenose dolphin epizootics. Taubenberger JK, et al. **Emerg Infect Dis** 1996 Jul–Sep;2(3):213–6 (21 ref.)

MORBILLIVIRUS INFECTIONS

VETERINARY

Two morbilliviruses implicated in bottlenose dolphin epizootics. Taubenberger JK, et al. **Emerg Infect Dis** 1996 Jul–Sep;2(3):213–6 (21 ref.)

Rinderpest and other animal morbillivirus infections: comparative aspects and recent developments. Haas L, et al. **Zentralbl Veterinarmed [B]** 1996 Sep;43(7):411–20 (55 ref.)

MORMONS see **CHRISTIANITY**

MORMYRID see **ELECTRIC FISH**

MORNING-AFTER PILL see **CONTRACEPTIVES, POSTCOITAL**

MORPHEA see **SCLERODERMA, CIRCUMSCRIBED**

MORPHINANS

PHARMACOLOGY

The nonnarcotic antitussive drug dimemorfan: a review. Ida H. **Clin Ther** 1997 Mar–Apr;19(2):215–31 (26 ref.)

THERAPEUTIC USE

The nonnarcotic antitussive drug dimemorfan: a review. Ida H. **Clin Ther** 1997 Mar–Apr;19(2):215–31 (26 ref.)

MORPHINE

see related
RECEPTORS, OPIOID

ADMINISTRATION & DOSAGE

Pain relief from intra-articular morphine after knee surgery: a qualitative systematic review. Kalso E, et al. **Pain** 1997 Jun;71(2):127–34 (47 ref.)

Intrathecal granuloma after implantation of a morphine pump: case report and review of the literature. Bejjani GK, et al. **Surg Neurol** 1997 Sep;48(3):288–91 (23 ref.)

METABOLISM

[Morphine metabolism--pharmacokinetics and pharmacodynamics] Andersen G, et al. **Ugeskr Laeger** 1997 May 26;159(22):3383–6 (38 ref.) (Eng. Abstr.) **(Dan)**

PHARMACOKINETICS

The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Milne RW, et al. **Drug Metab Rev** 1996 Aug;28(3):345–472 (489 ref.)

Recommended use of morphine in neonates, infants and children based on a literature review: Part 1--Pharmacokinetics. Kart T, et al. **Paediatr Anaesth** 1997; 7(1):5–11 (38 ref.)

PHARMACOLOGY

Morphine affects the brain-immune axis by modulating an interleukin-1 beta dependent pathway. Chang SL, et al. **Adv Exp Med Biol** 1996;402:35–42 (34 ref.)

Molecular mechanisms of drug addiction: adaptations in signal transduction pathways. Nestler EJ, et al. **Mol Psychiatry** 1996 Jul;1(3):190–9 (65 ref.)

Modulatory effects of Gs-coupled excitatory opioid receptor functions on opioid analgesia, tolerance, and dependence. Crain SM, et al. **Neurochem Res** 1996 Nov;21(11):1347–51 (59 ref.)

Insights into opioid action in the intestinal tract. De Luca A, et al. **Pharmacol Ther** 1996;69(2):103–15 (164 ref.)

THERAPEUTIC USE

Recommended use of morphine in neonates, infants and children based on a literature review: Part 2--Clinical use. Kart T, et al. **Paediatr Anaesth** 1997;7(2):93–101 (82 ref.)

Pain relief from intra-articular morphine after knee surgery: a qualitative systematic review. Kalso E, et al. **Pain** 1997 Jun;71(2):127–34 (47 ref.)

TOXICITY

The neurochemistry of morphine addiction in the neocortex [see comments] Simonato M. **Trends Pharmacol Sci** 1996 Nov;17(11):410–5 (64 ref.) Comment in: Trends Pharmacol Sci 1997 Mar;18(3):77–8.

MORPHINE DEPENDENCE

METABOLISM

The neurochemistry of morphine addiction in the neocortex

[see comments] Simonato M. **Trends Pharmacol Sci** 1996 Nov;17(11):410–5 (64 ref.) Comment in: Trends Pharmacol Sci 1997 Mar;18(3):77–8.

MORPHINE DERIVATIVES

Morphine metabolites. Christrup LL.
Acta Anaesthesiol Scand 1997 Jan;41(1 Pt 2):116–22 (80 ref.)

PHARMACOKINETICS

The disposition of morphine and its 3– and 6–glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Milne RW, et al. **Drug Metab Rev** 1996 Aug;28(3):345–472 (489 ref.)

MORPHINE RECEPTORS see **RECEPTORS, OPIOID, MU**

MORPHINE SULFATE see **MORPHINE**

MORPHOGENESIS

Left–right asymmetry in vertebrate embryogenesis. Levin M. **Bioessays** 1997 Apr;19(4):287–96 (94 ref.)
Morphogenesis on the move: cell–to–cell trafficking of plant regulatory proteins. Jackson D, et al.
Curr Opin Genet Dev 1997 Aug;7(4):495–500 (40 ref.)
Neural tube morphogenesis. Spörle R, et al.
Curr Opin Genet Dev 1997 Aug;7(4):507–12 (57 ref.)
Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Pepper MS, et al. **Enzyme Protein** 1996;49(1–3):138–62 (94 ref.)
Twisted liquid crystalline supramolecular arrangements in morphogenesis. Giraud–Guille MM. **Int Rev Cytol** 1996; 166:59–101 (120 ref.)
[Cellular interactions which control differentiation and morphogenesis in dictyostelium] Yamada Y, et al.
Tanpakushitsu Kakusan Koso 1996 Sep;41(11):1560–8 (44 ref.) **(Jpn)**

GENETICS

Asymmetry––where evolutionary and developmental genetics meet. Batterham P, et al. **Bioessays** 1996 Oct; 18(10):841–5 (53 ref.)
[Molecular mechanism of morphogenesis: a theory of locational DNA] Olovnikov AM. **Biokhimiia** 1996 Nov; 61(11):1948–70 (69 ref.) (Eng. Abstr.) **(Rus)**
[The role of homeobox cluster genes in animal morphogenesis] Dondua AK. **Ontogenez** 1997 Jan–Feb; 28(1):3–17 (120 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Chemical morphogenesis: turing patterns in an experimental chemical system. Dulos E, et al. **Acta Biotheor** 1996 Nov; 44(3–4):249–61 (38 ref.)
Fish are like flies are like frogs: conservation of dorsal–ventral patterning mechanisms. Holley SA, et al. **Bioessays** 1997 Apr;19(4):281–4 (30 ref.)
Programmed cell death in animal development. Jacobson MD, et al. **Cell** 1997 Feb 7;88(3):347–54 (71 ref.)
Where am I? How a cell recognizes its positional information during morphogenesis. Hata RI. **Cell Biol Int** 1996 Jan; 20(1):59–65 (38 ref.)
Tissue engineering, morphogenesis, and regeneration of the periodontal tissues by bone morphogenetic proteins. Ripamonti U, et al. **Crit Rev Oral Biol Med** 1997; 8(2):154–63 (86 ref.)
Signalling pathways: a common theme in plants and animals? Wilson I, et al. **Curr Biol** 1997 Mar 1;7(3):R175–8 (10 ref.)
Hepatocyte growth factor as mitogen, motogen and morphogen, and its roles in organ regeneration. Nakamura T. **Princess Takamatsu Symp** 1994;24:195–213 (76 ref.)

MORPHOLINES

Morpholino antisense oligomers: design, preparation, and properties. Summerton J, et al.
Antisense Nucleic Acid Drug Dev 1997 Jun;7(3):187–95 (41 ref.)

PHARMACOKINETICS

Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Dostert P, et al. **Eur Neuropsychopharmacol** 1997 Apr;7 Suppl 1:S23–35; discussion S71–3 (80 ref.)

THERAPEUTIC USE

The effects of antidepressants on psychomotor function with particular reference to reboxetine. Hindmarch I.
Eur Neuropsychopharmacol 1997 Apr;7 Suppl 1:S17–21; discussion S71–3 (31 ref.)
Noradrenaline in basic models of depression. Leonard BE. **Eur Neuropsychopharmacol** 1997 Apr;7 Suppl 1:S11–6; discussion S71–3 (17 ref.)
Is there a role for a pure noradrenergic drug in the treatment of depression? Montgomery SA.
Eur Neuropsychopharmacol 1997 Apr;7 Suppl 1:S3–9; discussion S71–3 (40 ref.)

MORQUIO'S DISEASE see **MUCOPOLYSACCHARIDOSIS IV**

MORSYDOMINE see **MOLSIDOMINE**

MORTALITY

Social ties and health: the benefits of social integration. Seeman TE. **Ann Epidemiol** 1996 Sep;6(5):442–51 (69 ref.)
Rethinking disease: where do we go from here? Syme SL. **Ann Epidemiol** 1996 Sep;6(5):463–8 (28 ref.)
Child health statistical review, 1996. Platt MJ, et al.
Arch Dis Child 1996 Dec;75(6):527–33 (18 ref.)
What should obstetricians be doing about the Barker hypothesis? Fraser R Sr, et al. **Br J Obstet Gynaecol** 1997 Jun;104(6):645–7 (16 ref.)
Ageing: levelling of the grim reaper. Charlesworth B, et al. **Curr Biol** 1997 Jul 1;7(7):R440–2 (19 ref.)
What demographers can learn from fruit fly actuarial models and biology. Carey JR. **Demography** 1997 Feb;34(1):17–30 (151 ref.)
Segregation, discrimination and mortality in U.S. blacks. Polednak AP. **Ethn Dis** 1996 Winter–Spring;6(1–2):99–108 (67 ref.)
Intersections of mortality–rate and survival functions: model–independent considerations. Hirsch HR.
Exp Gerontol 1997 May–Jun;32(3):287–96 (24 ref.)
Co–morbidity analysis: a strategy for understanding mortality, disability and use of health care facilities of older people. Cornoni–Huntley JC, et al. **Int J Epidemiol** 1991; 20 Suppl 1:S8–17 (19 ref.)
Occupational exposure to mercury in dentistry and dentist mortality. McComb D. **J Can Dent Assoc** 1997 May; 63(5):372–6 (30 ref.)
Association of serum albumin and mortality risk. Goldwasser P, et al. **J Clin Epidemiol** 1997 Jun;50(6):693–703 (92 ref.)
Fatal air transport accidents involving athletic teams from the United States. Murphy GK. **J Forensic Sci** 1997 Jan; 42(1):74–8 (14 ref.)
Self–rated health and mortality: a review of twenty–seven community studies. Idler EL, et al. **J Health Soc Behav** 1997 Mar;38(1):21–37 (95 ref.)
Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. Hebert PR, et al. **JAMA** 1997 Jul 23–30;278(4):313–21 (53 ref.)
Demographic yearbook 1992: the disease picture of the developed and developing worlds compared [see comments] Brockington CF. **Public Health** 1997 May; 111(3):129–33 (6 ref.) Comment in: Public Health 1997 May;111(3):123.
Particulate air pollution. Bates DV. **Thorax** 1996 Aug;51 Suppl 2:S3–8 (42 ref.)
Refugees: do not forget the basics. Malé S.
World Health Stat Q 1996;49(3–4):221–5 (19 ref.)
[Significance of intentional weight loss on health] Heitmann BL, et al. **Ugeskr Laeger** 1997 Jun 23;159(26):4099–104 (38 ref.) (Eng. Abstr.) **(Dan)**

TRENDS

Trends in US asthma mortality: good news and bad news [editorial; comment] Lang DM.
Ann Allergy Asthma Immunol 1997 Apr;78(4):333–7 (58 ref.) Comment on: Ann Allergy Asthma Immunol 1997 Apr;78(4):347–54.
Stabilization of asthma mortality [see comments] Sly RM, et al. **Ann Allergy Asthma Immunol** 1997 Apr;78(4):347–54 (66 ref.) Comment in: Ann Allergy Asthma Immunol 1997 Apr;78(4):333–7.
A theory of technophysio evolution, with some implications for forecasting population, health care costs, and pension costs [published erratum appears in Demography 1997 May;34(2):170] Fogel RW, et al. **Demography** 1997 Feb; 34(1):49–66 (119 ref.)
Changes in the age dependence of mortality and disability: cohort and other determinants. Manton KG, et al.
Demography 1997 Feb;34(1):135–57 (77 ref.)
A critical review of the evidence on particulate air pollution and mortality. Moolgavkar SH, et al. **Epidemiology** 1996 Jul;7(4):420–8 (44 ref.)
Refocusing the lens: epidemiologic transition theory, mortality differentials, and the AIDS pandemic. Gaylin DS, et al. **Soc Sci Med** 1997 Mar;44(5):609–21 (48 ref.)
Population growth, poverty and health. Kibirige JS.
Soc Sci Med 1997 Jul;45(2):247–59 (70 ref.)
[Development of a model for explaining health inequality] Elkeles T, et al. **Gesundheitswesen** 1997 Mar;59(3):137–43 (68 ref.) (Eng. Abstr.) **(Ger)**

MORTALITY, HOSPITAL see **HOSPITAL MORTALITY**

MORULA

Establishment of the axis in chordates: facts and speculations. Eyal–Giladi H. **Development** 1997 Jun;124(12):2285–96 (95 ref.)

MOS PROTO–ONCOGENE PROTEINS see **PROTO–ONCOGENE PROTEINS C–MOS**

MOSAICISM

see related
FREEMARTINISM
MICE, TRANSGENIC
RADIATION CHIMERA

Aneuploid correction and confined placental mosaicism. Simoni G, et al. **Acta Genet Med Gemellol (Roma)** 1996; 45(1–2):153–61 (24 ref.)
Mosaic trisomy 22: a case presentation and literature review of trisomy 22 phenotypes. Crowe CA, et al.
Am J Med Genet 1997 Sep 5;71(4):406–13 (35 ref.)
Tetrasomy 5p mosaicism due to an extra i(5p) in a severely affected girl. Lorda–Sánchez I, et al. **Am J Med Genet** 1997 Feb 11;68(4):481–4 (5 ref.)
Sibs with cleidocranial dysplasia born to normal parents: germ line mosaicism? Zackai EH, et al.
Am J Med Genet 1997 Apr 14;69(4):348–51 (30 ref.)
Partial trisomy 10 mosaicism with cutaneous manifestations: report of a case and review of the literature. Boon C, et al. **Clin Genet** 1996 Nov;50(5):417–21 (16 ref.)
Three cases of trisomy 13 mosaicism and a review of the literature. Delatycki M, et al. **Clin Genet** 1997 Jun; 51(6):403–7 (29 ref.)
Detection of SRY in 45,X/47,XYY mosaicism leading to phenotypic female. Imai A, et al. **Clin Genet** 1997 Feb; 51(2):124–6 (15 ref.)
A history of miscarriages and mild prognathism as possible mode of presentation of mosaic trisomy 18 in women. Satge D, et al. **Clin Genet** 1996 Dec;50(6):470–3 (22 ref.)
Mosaicism: implications for postnatal outcome. Johnson A, et al. **Curr Opin Obstet Gynecol** 1997 Apr;9(2):126–35 (119 ref.)
Confined placental mosaicism for trisomies 2, 3, 7, 8, 9, 16, and 22: their incidence, likely origins, and mechanisms for cell lineage compartmentalization. Wolstenholme J.
Prenat Diagn 1996 Jun;16(6):511–24 (51 ref.)
Moisaicism in the human preimplantation embryo. Handyside AH. **Reprod Nutr Dev** 1996;36(6):643–9 (29 ref.)

GENETICS

Familial ring (19) chromosome mosaicism: case report and review. Flejter WL, et al. **Am J Med Genet** 1996 Dec 18; 66(3):276–80 (11 ref.)
Mutator genes and mosaicism in colorectal cancer. Dunlop MG. **Curr Opin Genet Dev** 1996 Feb;6(1):76–81 (55 ref.)
Kabuki syndrome in son and low grade mosaic 45,X/46,XX in mother. Van Hagen JM, et al. **Genet Couns** 1996; 7(3):201–6 (16 ref.)
Confined placental mosaicism. Kalousek DK, et al.
J Med Genet 1996 Jul;33(7):529–33 (45 ref.)
[The main etiopathogenic mechanisms of neurocutaneous diseases] Vicente FJ, et al. **Rev Neurol** 1997 Sep;25 Suppl 3:S214–21 (63 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Linear hypopigmentation and hyperpigmentation, including mosaicism. Loomis CA. **Semin Cutan Med Surg** 1997 Mar; 16(1):44–53 (80 ref.)

MOSCHKOWITZ DISEASE see **PURPURA, THROMBOTIC THROMBOCYTOPENIC**

MOSQUITO CONTROL

see related
INSECTICIDE RESISTANCE
PEST CONTROL, BIOLOGICAL

Biological control of malaria vectors. Das PK, et al.
Indian J Med Res 1997 Aug;106:174–97 (225 ref.)
Anopheline species complexes & malaria control. Subbarao SK, et al. **Indian J Med Res** 1997 Aug;106:164–73 (41 ref.)
Olfactory attractants for mosquito surveillance and control: 1–octen–3–ol. Kline DL. **J Am Mosq Control Assoc** 1994 Jun;10(2 Pt 2):280–7 (25 ref.)
The tsetse (Diptera: Glossinidae) story: implications for mosquitoes. Torr SJ. **J Am Mosq Control Assoc** 1994 Jun; 10(2 Pt 2):258–65 (63 ref.)
Effects of open marsh water management on selected tidal marsh resources: a review. Wolfe RJ.
J Am Mosq Control Assoc 1996 Dec;12(4):701–12 (83 ref.)
[Control of mosquitos in Martinique. A collective public health action and improvement of the quality of life] Yebakima A. **Bull Soc Pathol Exot** 1996;89(2):145–7 (4 ref.) (Eng. Abstr.) **(Fre)**

METHODS

An operational perspective on measuring aerosol cloud dynamics. Burkett DA, et al.
J Am Mosq Control Assoc 1996 Jun;12(2 Pt 2):380–3 (4 ref.)
A review of ultralow–volume aerial sprays of insecticide for mosquito control. Mount GA, et al.
J Am Mosq Control Assoc 1996 Dec;12(4):601–18 (78 ref.)
Adverse assessments of Gambusia affinis: an alternate view for mosquito control practitioners [published erratum appears in J Am Mosq Control Assoc 1996 Dec;12(4):752] [see comments] Rupp HR. **J Am Mosq Control Assoc** 1996 Jun;12(2 Pt 1):155–9; discussion 160–6 (25 ref.) Comment in: J Am Mosq Control Assoc 1997 Mar;13(1):101.
Application of deltamethrin–impregnated bednets for

MOSQUITO CONTROL

mosquito and malaria control in Yunnan, China. Zhang Z, et al. **Southeast Asian J Trop Med Public Health** 1996 Jun;27(2):367–71 (14 ref.)

Review: mosquito nets and insecticides for net treatment: a discussion of existing and potential distribution systems in Africa. Lines J. **Trop Med Int Health** 1996 Oct; 1(5):616–32 (54 ref.)

MOSQUITO FISH see **CYPRINODONTIFORMES**

MOSQUITOES see **CULICIDAE**

MOSSES

Allergic contact dermatitis to liverworts, lichens, and mosses. Schmidt RJ. **Semin Dermatol** 1996 Jun;15(2):95–102 (86 ref.)

MOTH FLIES see **PSYCHODIDAE**

MOTHER CELLS see **STEM CELLS**

MOTHER-CHILD RELATIONS

Prenatal cocaine exposure and mother–infant interaction: implications for occupational therapy intervention. Miller H. **Am J Occup Ther** 1997 Feb;51(2):119–31 (100 ref.)

Dyssynchrony, conflict, and resolution: positive contributions to infant development. Biringen Z, et al. **Am J Orthopsychiatry** 1997 Jan;67(1):4–19 (69 ref.)

Postpartum psychiatric disorder: who should be admitted and to which hospital? Barnett B, et al. **Aust N Z J Psychiatry** 1996 Dec;30(6):709–14 (29 ref.)

Offspring–induced nurturance: animal–human parallels. Stern JM. **Dev Psychobiol** 1997 Jul;31(1):19–37 (114 ref.)

Dead babies and the birth of desire: maternal erotic transferences and countertransferences. Wrye HK. **J Am Acad Psychoanal** 1996 Spring;24(1):75–94 (14 ref.)

Lesbian motherhood: the impact on child development and family functioning. Brewaeys A, et al. **J Psychosom Obstet Gynaecol** 1997 Mar;18(1):1–16 (82 ref.)

Winnicott goes to the movies: the false self in Ordinary People. Newman KM. **Psychoanal Q** 1996 Oct; 65(4):787–807 (9 ref.)

Postpartum depression and child development [editorial] Murray L, et al. **Psychol Med** 1997 Mar;27(2):253–60 (36 ref.)

[Mother–child treatment in psychiatry. I: Overview of experiences up to now] Hartmann HP. **Psychiatr Prax** 1997 Mar;24(2):56–60 (56 ref.) (Eng. Abstr.) **(Ger)**

MOTHERS

see related

MATERNAL BEHAVIOR

Scientific basis for the content of routine antenatal care. I. Philosophy, recent studies, and power to eliminate or alleviate adverse maternal outcomes. Villar J, et al. **Acta Obstet Gynecol Scand** 1997 Jan;76(1):1–14 (130 ref.)

A mother and daughter with agenesis of the corpus callosum. Fuchigami T, et al. **Acta Paediatr Jpn** 1996 Feb;38(1):52–6 (21 ref.)

"Fearing our mothers": an overview of the psychoanalytic theories concerning the vagina dentata motif F547.1.1. Otero S. **Am J Psychoanal** 1996 Sep;56(3):269–88 (81 ref.)

Parenting the prematurely born child. Holditch-Davis D, et al. **Annu Rev Nurs Res** 1997;15:3–34 (92 ref.)

Welfare recipients' job skills and employment prospects. Burtless GT. **Future Child** 1997 Spring;7(1):39–51 (20 ref.)

Arranging child care. Kisker EE, et al. **Future Child** 1997 Spring;7(1):99–109 (39 ref.)

Effects of low–wage employment on family well–being [comment] Parcel TL, et al. **Future Child** 1997 Spring; 7(1):116–21 (16 ref.) Comment on: Future Child 1997 Spring;7(1):110–5.

When low–income mothers go to work: implications for children [see comments] Zaslow MJ, et al. **Future Child** 1997 Spring;7(1):110–5 (30 ref.) Comment in: Future Child 1997 Spring;7(1):116–21. Comment in: Future Child 1997 Spring;7(1):122–7.

Sex determination and the maternal dominance hypothesis. Grant VJ. **Hum Reprod** 1996 Nov;11(11):2371–5 (59 ref.)

EDUCATION

Turning job finders into job keepers. Hershey AM, et al. **Future Child** 1997 Spring;7(1):74–86 (39 ref.)

Alternative strategies for increasing employment. Nightingale DS, et al. **Future Child** 1997 Spring;7(1):52–64 (30 ref.)

PSYCHOLOGY

Treatment of maternal addiction to prevent child abuse and neglect. Peterson L, et al. **Addict Behav** 1996 Nov–Dec; 21(6):789–801 (62 ref.)

No more mother blaming: a feminist nursing perspective on the mother's role in father–daughter incest. Ehrmin JT. **Arch Psychiatr Nurs** 1996 Aug;10(4):252–60 (53 ref.)

Postpartum psychiatric disorder: who should be admitted and to which hospital? Barnett B, et al. **Aust N Z J Psychiatry** 1996 Dec;30(6):709–14 (29 ref.)

Single motherhood and mental health: implications for primary prevention [editorial; comment] Avison WR. **Can Med Assoc J** 1997 Mar 1;156(5):661–3 (9 ref.) Comment on: Can Med Assoc J 1997 Mar 1;156(5):639–45.

Mothers' help seeking as care initiated in a social context. Pridham KF. **Image J Nurs Sch** 1997 Spring;29(1):65–70 (39 ref.)

The relationship of partner support to outcomes for teenage mothers and their children: a review. Roye CF, et al. **J Adolesc Health** 1996 Aug;19(2):86–93 (45 ref.)

Privileged knowledge and mothers' "perceptions": the case of breast–feeding and insufficient milk in Bangladesh. Zeitlyn S, et al. **Med Anthropol Q** 1997 Mar;11(1):56–68 (17 ref.)

[Mother–child treatment in psychiatry. I: Overview of experiences up to now] Hartmann HP. **Psychiatr Prax** 1997 Mar;24(2):56–60 (56 ref.) (Eng. Abstr.) **(Ger)**

MOTHS

PARASITOLOGY

Toxins produced by arthropod parasites: salivary gland proteins of human body lice and venom proteins of chelonine wasps. Jones D, et al. **Toxicon** 1996 Nov–Dec; 34(11–12):1421–9 (32 ref.)

PHYSIOLOGY

Peripheral mechanisms of pheromone reception in moths. Kaissling KE. **Chem Senses** 1996 Apr;21(2):257–68 (66 ref.)

Central olfactory pathways in mosquitoes and other insects. Anton S. **Ciba Found Symp** 1996;200:184–92; discussion 192–6, 226–32 (20 ref.)

The multiple role of the pheromone–binding protein in olfactory transduction. Ziegelberger G. **Ciba Found Symp** 1996;200:267–75; discussion 275–80 (41 ref.)

MOTILIN

see related

GASTROINTESTINAL AGENTS

[Motilin and motilin receptor] Satoh M, et al. **Nippon Rinsho** 1996 Apr;54(4):1092–6 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Motilin and its clinical application] Itoh Z. **Nippon Shokakibyo Gakkai Zasshi** 1996 Aug;93(8):517–29 (87 ref.) **(Jpn)**

THERAPEUTIC USE

Motilin and clinical application. Itoh Z. **Peptides** 1997; 18(4):593–608 (242 ref.)

MOTILITY, CELL see **CELL MOVEMENT**

MOTION

see related

MOVEMENT

The King Solomon Lectures in Neuroethology. Deciding about motion: linking perception to action. Newsome WT. **J Comp Physiol [A]** 1997 Jul;181(1):5–12 (47 ref.)

Interaction of motion and color in the visual pathways. Gegenfurtner KR, et al. **Trends Neurosci** 1996 Sep; 19(9):394–401 (67 ref.)

[Visualization of DNA–protein interaction and sliding motion of protein molecules along DNA] Kabata H, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1181–6 (14 ref.) **(Jpn)**

MOTION PERCEPTION

Early diagnosis of functional damage in patients with glaucoma [editorial; comment] Caprioli J. **Arch Ophthalmol** 1997 Jan;115(1):113–4 (31 ref.) Comment on: Arch Ophthalmol 1997 Jan;115(1):26–33.

PHYSIOLOGY

Spatial representations for action in parietal cortex. Colby CL, et al. **Brain Res Cogn Brain Res** 1996 Dec; 5(1–2):105–15 (34 ref.)

Neural mechanisms for heading and structure–from–motion perception. Andersen RA, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:15–25 (61 ref.)

Where is the naso–temporal asymmetry? Motion processing. Braddick O. **Curr Biol** 1996 Mar 1;6(3):250–3 (17 ref.)

Interactions between motor commands and somatic perception in sensorimotor cortex. Nelson RJ. **Curr Opin Neurobiol** 1996 Dec;6(6):801–10 (79 ref.)

Abnormal motion processing and binocularity: infantile esotropia as a model system for effects of early interruptions of binocularity. Norcia AM. **Eye** 1996;10 (Pt 2):259–65 (49 ref.)

Neural mechanisms of visual motion perception in primates. Andersen RA. **Neuron** 1997 Jun;18(6):865–72 (41 ref.)

Afferent and developmentally inherent mechanisms of form and motion processing in cat extrastriate cortex. Spear PD. **Prog Brain Res** 1996;112:223–30 (41 ref.)

Displacement field estimation and image segmentation using block matching enhanced by a neural network. Chen YS, et al. **Spat Vis** 1996;10(1):31–50 (19 ref.)

Pulfrich revisited. Diaper CJ. **Surv Ophthalmol** 1997 May–Jun;41(6):493–9 (64 ref.)

MOTION PICTURES

Winnicott goes to the movies: the false self in Ordinary People. Newman KM. **Psychoanal Q** 1996 Oct; 65(4):787–807 (9 ref.)

MOTION SICKNESS

PATHOLOGY

[The structural variability of the otolithic apparatus and the problem of motion sickness] Lychakov DV. **Zh Evol Biokhim Fiziol** 1996 Sep–Oct;32(5):629–42 (66 ref.) **(Rus)**

MOTION THERAPY, CONTINUOUS PASSIVE

The 1995 John M. Kinney International Award for Nutrition and Metabolism. Effect of passive stretching on the wasting of muscle in the critically ill: background. Griffiths RD. **Nutrition** 1997 Jan;13(1):70–4 (24 ref.)

MOTIVATION

see related

LIBIDO

Motivational interviewing: research, practice, and puzzles. Miller WR. **Addict Behav** 1996 Nov–Dec;21(6):835–42 (35 ref.)

Relapse revisited: a critique of current concepts and clinical practice in the management of alcohol problems. Saunders B, et al. **Addict Behav** 1996 Nov–Dec;21(6):843–55 (45 ref.)

Alcohol reinforcement and neuropharmacological therapeutics. Lewis MJ. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:17–25 (36 ref.)

Detrimental effects of reward. Reality or myth? Eisenberger R, et al. **Am Psychol** 1996 Nov;51(11):1153–66 (110 ref.)

The self in relation to others: cognitive and motivational underpinnings. Andersen SM, et al. **Ann N Y Acad Sci** 1997 Jun 18;818:233–75 (220 ref.)

Neurobiological constraints on behavioral models of motivation. Nader K, et al. **Annu Rev Psychol** 1997; 48:85–114 (165 ref.)

Organ donors and nondonors. An American dilemma. Peters TG, et al. **Arch Intern Med** 1996 Nov 25;156(21):2419–24 (25 ref.)

Psychobiology of novelty seeking and drug seeking behavior. Bardo MT, et al. **Behav Brain Res** 1996 May;77(1–2):23–43 (205 ref.)

Do patients use marijuana as an antidepressant? Gruber AJ, et al. **Depression** 1996;4(2):77–80 (34 ref.)

In defense of weight phobia as the central organizing motive in anorexia nervosa: historical and cultural arguments for a culture–sensitive psychological conception. Habermas T. **Int J Eat Disord** 1996 May;19(4):317–34 (73 ref.)

Hope facilitating strategies for the family of the head injury patient. Johnson LH, et al. **J Neurosci Nurs** 1996 Aug; 28(4):259–66 (35 ref.)

Construing benefits from adversity: adaptational significance and dispositional underpinnings. Affleck G, et al. **J Pers** 1996 Dec;64(4):899–922 (85 ref.)

Frontal–subcortical circuits: the anatomic basis of executive, social and motivated behaviors. Masterman DL, et al. **J Psychopharmacol (Oxf)** 1997;11(2):107–14 (60 ref.)

Theoretical and practical considerations in investigating motivation and discomfort during prolonged exercise. Tenenbaum G. **J Sports Med Phys Fitness** 1996 Sep; 36(3):145–54 (78 ref.)

Mental defenses and posttraumatic stress disorder: assessment of criminal intent. Sparr LF. **J Trauma Stress** 1996 Jul; 9(3):405–25 (100 ref.)

Hedonic valence, dopamine and motivation. Koob GF. **Mol Psychiatry** 1996 Jul;1(3):186–9 (27 ref.)

Motivation and reinforcement in the systemic mechanisms of behavior: dynamic reinforcement engrams. Sudakov KV. **Neurosci Behav Physiol** 1996 Sep–Dec;26(5):445–53 (40 ref.)

An integrative framework for explaining reactions to decisions: interactive effects of outcomes and procedures. Brockner J, et al. **Psychol Bull** 1996 Sep;120(2):189–208 (73 ref.)

Complaints and complaining: functions, antecedents, and consequences. Kowalski RM. **Psychol Bull** 1996 Mar; 119(2):179–96 (169 ref.)

Counterfactual thinking. Roese NJ. **Psychol Bull** 1997 Jan; 121(1):133–48 (165 ref.)

Shaping perceptions to motivate healthy behavior: the role of message framing. Rothman AJ, et al. **Psychol Bull** 1997 Jan;121(1):3–19 (125 ref.)

A neuroendocrine role in cocaine reinforcement. Goeders NE. **Psychoneuroendocrinology** 1997 May;22(4):237–59 (180 ref.)

A review of choice research with people with severe and profound developmental disabilities. Lancioni GE, et al. **Res Dev Disabil** 1996 Sep–Oct;17(5):391–411 (88 ref.)

Donor insemination: the gifting and selling of semen. Daniels KR, et al. **Soc Sci Med** 1996 Jun;42(11):1521–36 (96 ref.)

Heroin addicts in the community and in treatment compared for severity of problems and need for help.

Eland-Goossensen A, et al. **Subst Use Misuse** 1997 Aug; 32(10):1313–30 (24 ref.)

[Somatic gain, somatic transfer and somatic neurosis] Chemouni J. **Ann Med Psychol (Paris)** 1996 Jun; 154(3):174–83 (18 ref.) (Eng. Abstr.) **(Fre)**

[Perfectionism: conceptual and clinical aspects] Todorov C, et al. **Can J Psychiatry** 1996 Jun;41(5):291–8 (29 ref.) (Eng. Abstr.) **(Fre)**

[Reflections on the cause and consequences of exposure to violent presentations in children] Rauchfleisch U. **Prax Kinderpsychol Kinderpsychiatr** 1997 Jul–Aug; 46(6):435–44 (27 ref.) (Eng. Abstr.) **(Ger)**

MOTOR ACTIVITY

see related

HYPERKINESIS

On knowing how to do things: a theory of motor imagery. Annett J. **Brain Res Cogn Brain Res** 1996 Mar;3(2):65–9 (17 ref.)

Obesity and physical activity. Ferro-Luzzi A, et al. **Ciba Found Symp** 1996;201:207–21; discussion 221–7 (59 ref.)

Primary motor cortex influences on the descending and ascending systems. Canedo A. **Prog Neurobiol** 1997 Feb; 51(3):287–335 (531 ref.)

The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Schwarting RK, et al. **Prog Neurobiol** 1996 Oct;50(2–3):275–331 (395 ref.)

On the role of recurrent inhibitory feedback in motor control. Windhorst U. **Prog Neurobiol** 1996 Aug;49(6):517–87 (367 ref.)

[Objective measurement of motor activity in Parkinson's disease by actigraphy. Clinical assessment of akinesia] Fujikane M, et al. **Nippon Rinsho** 1997 Jan;55(1):153–7 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Clinicophysiological study of tremor in Parkinson's disease: quantitative tremor-based assessment of motor count using actigraphy] Mochio S, et al. **Nippon Rinsho** 1997 Jan; 55(1):158–62 (11 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Stimulation of basal and L-DOPA-induced motor activity by glutamate antagonists in animal models of Parkinson's disease. Starr MS, et al. **Neurosci Biobehav Rev** 1997 Jul; 21(4):437–46 (69 ref.)

[Age-related changes in the effect of catecholamines on spontaneous periodic motor activity in rat pups] Bursian AV. **Zh Evol Biokhim Fiziol** 1996 May–Jun;32(3):292–301 (38 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Late recovery of motor functions. Mauritz KH, et al. **Adv Neurol** 1997;73:395–408 (47 ref.)

Extrapyramidal motor signs in clinically diagnosed Alzheimer disease. Ellis RJ, et al. **Alzheimer Dis Assoc Disord** 1996 Summer;10(2):103–14 (76 ref.)

Serotonergic functions in arousal and motor activity. Geyer MA. **Behav Brain Res** 1996;73(1–2):31–5 (45 ref.)

Do imagined and executed actions share the same neural substrate? Decety J. **Brain Res Cogn Brain Res** 1996 Mar; 3(2):87–93 (57 ref.)

Insights into motor performance and muscle fatigue based on transcranial stimulation of the human motor cortex. Gandevia SC. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov; 23(10–11):957–60 (48 ref.)

Motor control research in rehabilitation medicine. Latash ML, et al. **Disabil Rehabil** 1996 Jun;18(6):293–9 (40 ref.)

Invertebrate presynaptic inhibition and motor control. Clarac F, et al. **Exp Brain Res** 1996 Nov;112(2):163–80 (112 ref.)

Toward an agreement on terminology of nuclear and subnuclear divisions of the motor thalamus. Macchi G, et al. **J Neurosurg** 1997 Apr;86(4):670–85 (93 ref.)

Modulation and dynamic specification of motor rythm-generating circuits in crustacea. Simmers J, et al. **J Physiol Paris** 1995;89(4–6):195–208 (40 ref.)

Neurons, networks, and motor behavior. Katz PS. **Neuron** 1996 Feb;16(2):245–53 (9 ref.)

Neurobiological basis of motor learning in mammals. Asanuma H, et al. **Neuroreport** 1997 Mar 3;8(4):i–vi (59 ref.)

Modulation of insulin secretion by feeding behavior and physical activity: possible beneficial effects on obese and aged rats. Carpinelli AR, et al. **Neurosci Biobehav Rev** 1996 Summer;20(2):183–8 (64 ref.)

Behavioral characterization of mice packing the 5-HT1B receptor. Ramboz S, et al. **NIDA Res Monogr** 1996; 161:39–57 (32 ref.)

Aspects of cerebellar function in relation to locomotor movements. Armstrong DM, et al. **Prog Brain Res** 1997; 114:401–21 (84 ref.)

Cerebellar contributions to the acquisition and execution of learned reflex and volitional movements. Bloedel JR, et al. **Prog Brain Res** 1997;114:499–509 (38 ref.)

Is the cerebellum sensory for motor's sake, or motor for sensory's sake: the view from the whiskers of a rat? Bower JM. **Prog Brain Res** 1997;114:463–96 (193 ref.)

Signal processing in the C2 module of the flocculus and its role in head movement control. De Zeeuw CI, et al. **Prog Brain Res** 1997;114:299–320 (86 ref.)

What features of visually guided arm movements are encoded in the simple spike discharge of cerebellar Purkinje cells? Ebner TJ, et al. **Prog Brain Res** 1997;114:431–47 (80 ref.)

The control of forelimb movements by intermediate cerebellum. Ekerot CF, et al. **Prog Brain Res** 1997; 114:423–9 (21 ref.)

Arousal and locomotion: from schizophrenia to narcolepsy. Garcia-Rill E, et al. **Prog Brain Res** 1996;107:417–34 (73 ref.)

Emotional networks and motor control: a fearful view. LeDoux J. **Prog Brain Res** 1996;107:437–46 (82 ref.)

Light entrainment of the mammalian biological clock. Meijer JH, et al. **Prog Brain Res** 1996;111:175–90 (82 ref.)

Dentate output channels: motor and cognitive components. Middleton FA, et al. **Prog Brain Res** 1997;114:553–66 (56 ref.)

Regulation and integration in the mammalian circadian system. Ralph MR, et al. **Prog Brain Res** 1996;111:191–203 (44 ref.)

Behavioural complications of limbic epilepsy: implications for an understanding of the emotional motor system in man. Trimble M. **Prog Brain Res** 1996;107:605–16 (42 ref.)

Some organizing principles for the control of movement based on olivocerebellar physiology. Welsh JP, et al. **Prog Brain Res** 1997;114:449–61 (57 ref.)

Neural representations for action. Decety J. **Rev Neurosci** 1996 Oct–Dec;7(4):285–97 (76 ref.)

Primordial respiratory-like rhythm generation in the vertebrate embryo. Champagnat J, et al. **Trends Neurosci** 1997 Mar;20(3):119–24 (40 ref.)

[Dynamic joint control training as neuromuscular coordination] Ihara H. **Nippon Seikeigeka Gakkai Zasshi** 1996 Sep;70(9):583–93 (30 ref.) **(Jpn)**

[The cholinergic system of the striatum: its participation in the motor and sensory components of motor behavior] Shapovalova KB. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 Mar–Apr;47(2):393–411 (50 ref.) (Eng. Abstr.) **(Rus)**

MOTOR CORTEX

ANATOMY & HISTOLOGY

The anatomy of manual dexterity. The new connectivity of the primate sensorimotor thalamus and cerebral cortex. Darian-Smith I, et al. **Adv Anat Embryol Cell Biol** 1996; 133:1–140 (400 ref.)

Premotor and parietal cortex: corticocortical connectivity and combinatorial computations. Wise SP, et al. **Annu Rev Neurosci** 1997;20:25–42 (72 ref.)

Functions and structures of the motor cortices in humans. Roland PE, et al. **Curr Opin Neurobiol** 1996 Dec; 6(6):773–81 (105 ref.)

Toward an agreement on terminology of nuclear and subnuclear divisions of the motor thalamus. Macchi G, et al. **J Neurosurg** 1997 Apr;86(4):670–85 (93 ref.)

PHYSIOLOGY

Neurophysiological aspects of voluntary movements. Godaux E. **Acta Neurol Belg** 1996 Sep;96(3):193–202 (21 ref.)

Static and dynamic organization of motor cortex. Sanes JN, et al. **Adv Neurol** 1997;73:277–96 (88 ref.)

Plasticity of the human motor cortex. Seitz RJ, et al. **Adv Neurol** 1997;73:321–33 (107 ref.)

Premotor and parietal cortex: corticocortical connectivity and combinatorial computations. Wise SP, et al. **Annu Rev Neurosci** 1997;20:25–42 (72 ref.)

Force and the motor cortex. Ashe J. **Behav Brain Res** 1997 Jun;86(1):1–15 (75 ref.)

Stimulation over the human supplementary motor area interferes with the organization of future elements in complex motor sequences. Gerloff C, et al. **Brain** 1997 Sep; 120 (Pt 9):1587–602 (84 ref.)

On the translation of directional motor cortical commands to activation of muscles via spinal interneuronal systems. Georgopoulos AP. **Brain Res Cogn Brain Res** 1996 Mar; 3(2):151–5 (23 ref.)

Mental transformations in the motor cortex. Pellizzer G. **Brain Res Cogn Brain Res** 1996 Dec;5(1–2):123–30 (23 ref.)

Multiple cortical motor areas and temporal sequencing of movements. Tanji J, et al. **Brain Res Cogn Brain Res** 1996 Dec;5(1–2):117–22 (66 ref.)

Comparison of neuronal activity in the supplementary motor area and primary motor cortex. Tanji J, et al. **Brain Res Cogn Brain Res** 1996 Mar;3(2):143–50 (80 ref.)

Role of the cerebellum and motor cortex in the regulation of visually controlled locomotion. Armstrong DM, et al. **Can J Physiol Pharmacol** 1996 Apr;74(4):443–55 (55 ref.)

Role of the motor cortex in the control of visually triggered gait modifications. Drew T, et al. **Can J Physiol Pharmacol** 1996 Apr;74(4):426–42 (85 ref.)

Modulation of corticospinal influence over hand muscles during gripping tasks in man and monkey. Lemon RN, et al. **Can J Physiol Pharmacol** 1996 Apr;74(4):547–58 (67 ref.)

Cooperative structures for visually guided reach. MacKay WA. **Can J Physiol Pharmacol** 1996 Apr;74(4):463–8 (46 ref.)

The premotor cortex and nonstandard sensorimotor mapping. Wise SP, et al. **Can J Physiol Pharmacol** 1996 Apr; 74(4):469–82 (92 ref.)

Limits of reorganization in cortical circuits [comment] Donoghue JP. **Cereb Cortex** 1997 Mar;7(2):97–9 (18 ref.) Comment on: Cereb Cortex 1997 Mar;7(2):143–56.

Insights into motor performance and muscle fatigue based on transcranial stimulation of the human motor cortex. Gandevia SC. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov; 23(10–11):957–60 (48 ref.)

'Monkey see, monkey do' cells. Neurophysiology. Carey DP. **Curr Biol** 1996 Sep 1;6(9):1087–8 (13 ref.)

Visuomotor functions of the lateral pre-motor cortex. Jackson SR, et al. **Curr Opin Neurobiol** 1996 Dec; 6(6):788–95 (70 ref.)

Interactions between motor commands and somatic perception in sensorimotor cortex. Nelson RJ. **Curr Opin Neurobiol** 1996 Dec;6(6):801–10 (79 ref.)

Functions and structures of the motor cortices in humans. Roland PE, et al. **Curr Opin Neurobiol** 1996 Dec; 6(6):773–81 (105 ref.)

New concepts of the supplementary motor area. Tanji J. **Curr Opin Neurobiol** 1996 Dec;6(6):782–7 (69 ref.)

Supplementary motor cortex in organization of movement. Tanji J, et al. **Eur Neurol** 1996;36 Suppl 1:13–9 (103 ref.)

Control of remembered reaching sequences in monkey. I. Activity during movement in motor and premotor cortex. Kettner RE, et al. **Exp Brain Res** 1996 Dec;112(3):335–46 (38 ref.)

Control of remembered reaching sequences in monkey. II. Storage and preparation before movement in motor and premotor cortex. Kettner RE, et al. **Exp Brain Res** 1996 Dec;112(3):347–58 (51 ref.)

The medullary raphe nuclei: a system for integration and gain control in autonomic and somatomotor responsiveness? Lovick TA. **Exp Physiol** 1997 Jan; 82(1):31–41 (32 ref.)

Foot and hand area mu rhythms. Pfurtscheller G, et al. **Int J Psychophysiol** 1997 Jun;26(1–3):121–35 (43 ref.)

Event-related synchronization (ERS) in the alpha band--an electrophysiological correlate of cortical idling: a review. Pfurtscheller G, et al. **Int J Psychophysiol** 1996 Nov; 24(1–2):39–46 (47 ref.)

Spike train analysis. Awiszus F. **J Neurosci Methods** 1997 Jun 27;74(2):155–66 (32 ref.)

Neurophysiological methods for studies of the motor system in freely moving human subjects. Capaday C. **J Neurosci Methods** 1997 Jun 27;74(2):201–18 (119 ref.)

Techniques and mechanisms of action of transcranial stimulation of the human motor cortex. Rothwell JC. **J Neurosci Methods** 1997 Jun 27;74(2):113–22 (45 ref.)

Primary motor cortex influences on the descending and ascending systems. Canedo A. **Prog Neurobiol** 1997 Feb; 51(3):287–335 (531 ref.)

Transmission of the cortical command for human voluntary movement through cervical propriospinal premotoneurons. Pierrot-Deseilligny E. **Prog Neurobiol** 1996 Mar–Apr; 48(4–5):489–517 (60 ref.)

[Clinical application of functional mapping; the present state of the art and its future prospects: (series 2) Identification of motor, sensory, visual and speech cortex by functional MRI] Ito T, et al. **No Shinkei Geka** 1996 Feb;24(2):109–18 (23 ref.) **(Jpn)**

[Noninvasive study of cortical neuronal mechanism in voluntary movements: role of basal ganglia and cerebellum] Ikeda A, et al. **Rinsho Shinkeigaku** 1995 Dec;35(12):1522–4 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Motor reorganization in the motor cortex] Mano Y, et al. **Rinsho Shinkeigaku** 1995 Dec;35(12):1515–7 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Analysis of cortical excitation and inhibition using transcranial magnetic stimulation] Uozumi T. **Rinsho Shinkeigaku** 1995 Dec;35(12):1512–4 (6 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Attention-deficit hyperactivity disorder (ADHD) and frontal-motor cortex disconnection. Niedermeyer E, et al. **Clin Electroencephalogr** 1997 Jul;28(3):130–6 (53 ref.)

MOTOR ENDPLATE

METABOLISM

Acetylcholine release at motor endplates and autonomic neuroeffector junctions: a comparison. Wessler I. **Pharmacol Res** 1996 Feb;33(2):81–94 (156 ref.)

MOTOR EVOKED POTENTIALS see **EVOKED POTENTIALS, MOTOR**

MOTOR NEURON DISEASE

CHEMICALLY INDUCED

Toxic models of upper motor neuron disease. Ludolph AC, et al. **J Neurol Sci** 1996 Aug;139 Suppl:53–9 (60 ref.)

CLASSIFICATION

Overview of motor neuron disease: classification and nomenclature. Bradley WG. **Clin Neurosci** 1995–96; 3(6):323–6 (12 ref.)

MOTOR NEURON DISEASE

COMPLICATIONS

Lymphoproliferative disorders and motor neuron disease: an update. Gordon PH, et al. **Neurology** 1997 Jun;48(6):1671–8 (45 ref.)

[Multifocal motor neuropathies with persistent conduction blocks: a form of inflammatory demyelinating neuropathy] Pouget J, et al. **Rev Neurol (Paris)** 1996 May;152(5):370–4 (30 ref.) (Eng. Abstr.) **(Fre)**

[A case of severe involvement of the motor neuron system accompanied with cerebellar ataxia] Horiuchi I, et al. **Rinsho Shinkeigaku** 1997 Feb;37(2):123–6 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Frontal dementia–motor neuron disease: a case report and literature review] Tamayo JA, et al. **Rev Neurol** 1996 Mar; 24(127):287–9 (13 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Madras pattern of motor neuron disease: case report from Thailand. Phanthumchinda K, et al. **J Med Assoc Thai** 1996 Jun;79(6):399–402 (11 ref.)

Multifocal motor neuropathy. Biessels GJ, et al. **J Neurol** 1997 Mar;244(3):143–52 (94 ref.)

The contribution to spasticity qualification in neurological rehabilitation of patients with upper motor neuron syndrome. Kinalski R. **Neurol Neurochir Pol** 1996;30 Suppl 3:111–20 (14 ref.)

[How reliably does electromyography differentiate myopathies and neurogenic diseases?] Pfeiffer G. **Nervenarzt** 1996 Feb;67(2):123–32 (60 ref.) (Eng. Abstr.) **(Ger)**

[Frontal lobe-type dementia associated with motor neuron disease] Santana I, et al. **Acta Med Port** 1995 Nov; 8(11):629–34 (50 ref.) (Eng. Abstr.) **(Por)**

DRUG THERAPY

Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. Bryson HM, et al. **Drugs** 1996 Oct;52(4):549–63 (60 ref.)

Riluzole [see comments] Wokke J. **Lancet** 1996 Sep 21; 348(9030):795–9 (38 ref.) Comment in: Lancet 1996 Dec 14;348(9042):1660; discussion 1660–1. Comment in: Lancet 1996 Dec 14;348(9042):1661.

Neurotrophic factors for experimental treatment of motoneuron disease. Sendtner M. **Prog Brain Res** 1996; 109:365–71 (25 ref.)

EPIDEMIOLOGY

British motor neuron disease twin study. Graham AJ, et al. **J Neurol Neurosurg Psychiatry** 1997 Jun;62(6):562–9 (60 ref.)

ETIOLOGY

Postradiation lower motor neuron syndrome--a case report and brief literature review. Tallaksen CM, et al. **Acta Oncol** 1997;36(3):345–7 (40 ref.)

Acquired motor neuron disorders. Ross MA. **Neurol Clin** 1997 Aug;15(3):481–500 (78 ref.)

[Reappraisal of amyotrophic lateral sclerosis with dementia] Murakami N, et al. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1560–2 (10 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

[X chromosomal bulbospinal neuropathy (X-BSN, Kennedy syndrome): an illness with repetitive triplet sequences. Case report, differential diagnosis and molecular genetics aspects] Abel A, et al. **Nervenarzt** 1996 Dec;67(12):1011–9 (44 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Antibodies to GM1 and Gal(beta 1–3)GalNAc at the nodes of Ranvier in human and experimental autoimmune neuropathy. Thomas FP. **Microsc Res Tech** 1996 Aug 15; 34(6):536–43 (124 ref.)

METABOLISM

Mechanisms of selective motor neuron death in transgenic mouse models of motor neuron disease. Cleveland DW, et al. **Neurology** 1996 Oct;47(4 Suppl 2):S54–61; discussion S61–2 (37 ref.)

PATHOLOGY

Neurofilaments, radial growth of axons, and mechanisms of motor neuron disease. Williamson TL, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:709–23 (73 ref.)

Frontal lobe dementia and motor neuron disease. Talbot PR. **J Neural Transm Suppl** 1996;47:125–32 (23 ref.)

Mechanisms of selective motor neuron death in ALS: insights from transgenic mouse models of motor neuron disease. Bruijn LI, et al. **Neuropathol Appl Neurobiol** 1996 Oct; 22(5):373–87 (87 ref.)

PHYSIOPATHOLOGY

Transgenic models of neurodegenerative diseases. Lee MK, et al. **Curr Opin Neurobiol** 1996 Oct;6(5):651–60 (115 ref.)

Reflex hyperexcitability and muscle contracture in relation to spastic hypertonia. O'Dwyer NJ, et al. **Curr Opin Neurol** 1996 Dec;9(6):451–5 (38 ref.)

Toxic models of upper motor neuron disease. Ludolph AC, et al. **J Neurol Sci** 1996 Aug;139 Suppl:53–9 (60 ref.)

Motor neurone disease and animal models. Price DL, et al. **Neurobiol Dis** 1994 Nov;1(1–2):3–11 (131 ref.)

Animal models for motor neuron diseases: research directions. Ludolph AC. **Neurology** 1996 Dec;47(6 Suppl 4):S228–32 (34 ref.)

[Potassium channel dysfunction at the lesion site in multifocal motor neuropathy as revealed by threshold electrotonus] Kaji R, et al. **Rinsho Shinkeigaku** 1995 Dec;35(12):1368–9 (0 ref.) (Eng. Abstr.) **(Jpn)**

[Motor neuron diseases: a type of programmed cell death?] Ferrer I. **Neurologia** 1996 Dec;11 Suppl 5:7–13 (68 ref.) (Eng. Abstr.) **(Spa)**

[Motor neuron diseases. Present] Pou A. **Neurologia** 1996 Dec;11 Suppl 5:1–6 (44 ref.) (Eng. Abstr.) **(Spa)**

REHABILITATION

EEG-based communication: prospects and problems. Vaughan TM, et al. **IEEE Trans Rehabil Eng** 1996 Dec; 4(4):425–30 (35 ref.)

THERAPY

Motor neuron disease and model systems: aetiologies, mechanisms and therapies. Price DL, et al. **Ciba Found Symp** 1996;196:3–13; discussion 13–7 (54 ref.)

Chronic inflammatory polyneuritis and neuropathies. Toyka KV, et al. **Curr Opin Neurol** 1996 Jun;9(3):240–50 (126 ref.)

Intravenous immunoglobulin treatment in multifocal motor neuropathy and other chronic immune-mediated neuropathies. Comi G, et al. **Mult Scler** 1997 Apr;3(2):93–7 (53 ref.)

[Treatment of multifocal motor neuropathies] Azulay JP, et al. **Rev Neurol (Paris)** 1996 May;152(5):380–2 (19 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Lead toxicosis in 2 horses: similarity to equine degenerative lower motor neuron disease. Sojka JE, et al. **J Vet Intern Med** 1996 Nov–Dec;10(6):420–3 (22 ref.)

Equine motor neuron disease. Divers TJ, et al. **Vet Clin North Am Equine Pract** 1997 Apr;13(1):97–105 (28 ref.)

Progressive neuronopathy in two Cairn terrier litter mates. Zaal MD, et al. **Vet Q** 1997 Mar;19(1):34–6 (15 ref.)

VIROLOGY

Mouse Moloney leukemia virus infects microglia but not neurons even though it induces motor neuron disease. Zachary JF, et al. **Mol Psychiatry** 1997 Mar;2(2):104–6 (19 ref.)

MOTOR NEURONS

see related

NEUROMUSCULAR JUNCTION

The primate motor thalamus. Percheron G, et al. **Brain Res Brain Res Rev** 1996 Aug;22(2):93–181 (388 ref.)

[Electrophysiologic assessment in motor neuron diseases] Espadaler-Gamissans JM. **Neurologia** 1996 Dec;11 Suppl 5:20–8 (34 ref.) (Eng. Abstr.) **(Spa)**

CYTOLOGY

Neurotrophic factors and the development of drugs to promote motoneuron survival. Hughes RA, et al. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov;23(10–11):965–9 (43 ref.)

Ciliary neurotrophic factor as a motor neuron trophic factor. Kuzis K, et al. **Perspect Dev Neurobiol** 1996;4(1):65–74 (89 ref.)

[The motor innervation of the axial skeletal musculature in vertebrates] Balezina OP. **Usp Fiziol Nauk** 1997 Apr–Jun; 28(2):57–78 (99 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Therapeutic potential of the neurotrophins and neurotrophin–CNTF combinations in peripheral neuropathies and motor neuron diseases. Lindsay RM. **Ciba Found Symp** 1996;196:39–48; discussion 48–53 (41 ref.)

Neurotrophic factors and the development of drugs to promote motoneuron survival. Hughes RA, et al. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov;23(10–11):965–9 (43 ref.)

Motor neuron growth factors. Elliott JL, et al. **Neurology** 1996 Oct;47(4 Suppl 2):S47–53 (70 ref.)

Pharmacology of reticulospinal vasomotor neurons in cardiovascular regulation. Sun MK. **Pharmacol Rev** 1996 Dec;48(4):465–94 (408 ref.)

Serotonin, norepinephrine and associated neuropeptides: effects on somatic motoneuron excitability. White SR, et al. **Prog Brain Res** 1996;107:183–99 (111 ref.)

Presynaptic inhibition by serotonin: a possible mechanism for switching motor output of the hypoglossal nucleus. Singer JH, et al. **Sleep** 1996 Dec;19(10 Suppl):S146–9 (28 ref.)

METABOLISM

Axon guidance: motor-way madness. Stoker AW. **Curr Biol** 1996 Jul 1;6(7):794–7 (17 ref.)

PATHOLOGY

Principles of neuronal regeneration. Kreutzberg GW. **Acta Neurochir Suppl (Wien)** 1996;66:103–6 (10 ref.)

Neuropathology of amyotrophic lateral sclerosis: new perspectives on an old disease. Chou SM. **J Formos Med Assoc** 1997 Jul;96(7):488–98 (74 ref.)

PHYSIOLOGY

Postnatal development of hypoglossal motoneuron intrinsic properties. Berger AJ, et al. **Adv Exp Med Biol** 1995; 381:63–71 (20 ref.)

Long-term changes in spinal motor neurons after injury. Bowe CM, et al. **Adv Neurol** 1997;72:201–17 (86 ref.)

The drosophila neuromuscular junction: a model system for studying synaptic development and function. Keshishian H, et al. **Annu Rev Neurosci** 1996;19:545–75 (133 ref.)

Molecular characterization of the protein products of the fragile X syndrome gene and the survival of motor neurons gene. Liu Q, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:689–97 (57 ref.)

Sensorimotor processing: charting the frontier. Carpenter RH. **Curr Biol** 1997 Jun 1;7(6):R348–51 (10 ref.)

Origins of spinal cord oligodendrocytes: possible developmental and evolutionary relationships with motor neurons. Richardson WD, et al. **Dev Neurosci** 1997; 19(1):58–68 (44 ref.)

Pigeon basal ganglia: insights into the neuroanatomy underlying telencephalic sensorimotor processes in birds. Veenman CL. **Eur J Morphol** 1997 Oct;35(4):220–33 (138 ref.)

Nerve fibre regeneration across the peripheral–central transitional zone. Carlstedt T. **J Anat** 1997 Jan;190 (Pt 1):51–6 (40 ref.)

Development of hypoglossal motoneurons. Berger AJ, et al. **J Appl Physiol** 1996 Sep;81(3):1039–48 (45 ref.)

Noninvasive approach to motor unit characterization: muscle structure, membrane dynamics and neuronal control. Rau G, et al. **J Biomech** 1997 May;30(5):441–6 (28 ref.)

Physiology and interpretation of the electromyogram. Kamen G, et al. **J Clin Neurophysiol** 1996 Sep;13(5):366–84 (200 ref.)

Analysis of the electromyographic interference pattern. Sanders DB, et al. **J Clin Neurophysiol** 1996 Sep; 13(5):385–400 (36 ref.)

Quantitative motor unit potential analysis. Stålberg E, et al. **J Clin Neurophysiol** 1996 Sep;13(5):401–22 (105 ref.)

A review of recent applications of cross-correlation methodologies to human motor unit recording. Farmer SF, et al. **J Neurosci Methods** 1997 Jun 27;74(2):175–87 (61 ref.)

Estimating post-synaptic potentials in tonically discharging human motoneurons. Miles TS. **J Neurosci Methods** 1997 Jun 27;74(2):167–74 (32 ref.)

Age-related changes in motor unit function. Roos MR, et al. **Muscle Nerve** 1997 Jun;20(6):679–90 (128 ref.)

Quantitative methods for estimating the number of motor units in human muscles. Brown WF, et al. **Muscle Nerve Suppl** 1997;5:S70–3 (16 ref.)

Neural strategies in the control of muscle force. Enoka RM. **Muscle Nerve Suppl** 1997;5:S66–9 (21 ref.)

The response of motoneurons to neurotrophins. Sendtner M, et al. **Neurochem Res** 1996 Jul;21(7):831–41 (125 ref.)

Mechanisms of selective motor neuron death in ALS: insights from transgenic mouse models of motor neuron disease. Bruijn LI, et al. **Neuropathol Appl Neurobiol** 1996 Oct; 22(5):373–87 (87 ref.)

The motornervous system of Ascaris: electrophysiology and anatomy of the neurons and their control by neuromodulators. Davis RE, et al. **Parasitology** 1996;113 Suppl:S97–117 (114 ref.)

Ciliary neurotrophic factor as a motor neuron trophic factor. Kuzis K, et al. **Perspect Dev Neurobiol** 1996;4(1):65–74 (89 ref.)

Pharmacology of reticulospinal vasomotor neurons in cardiovascular regulation. Sun MK. **Pharmacol Rev** 1996 Dec;48(4):465–94 (408 ref.)

A framework for the analysis of mixed time series/point process data--theory and application to the study of physiological tremor, single motor unit discharges and electromyograms. Halliday DM, et al. **Prog Biophys Mol Biol** 1995;64(2–3):237–78 (41 ref.)

Theories of basal forebrain organization and the "emotional motor system". Alheid GF, et al. **Prog Brain Res** 1996; 107:461–84 (250 ref.)

The neuronal control of micturition and its relation to the emotional motor system. Blok BF, et al. **Prog Brain Res** 1996;107:113–26 (82 ref.)

The nucleus accumbens: gateway for limbic structures to reach the motor system? Groenewegen HJ, et al. **Prog Brain Res** 1996;107:485–511 (157 ref.)

Rostral brain regions contributing to respiratory control. Harper RM, et al. **Prog Brain Res** 1996;107:145–56 (76 ref.)

The somatic motor system. Holstege G. **Prog Brain Res** 1996; 107:9–26 (81 ref.)

The ventro-medial medullary projections to spinal motoneurons: ultrastructure, transmitters and functional aspects. Holstege JC. **Prog Brain Res** 1996;107:159–81 (167 ref.)

The greater limbic system, the emotional motor system and the brain. Nieuwenhuys R. **Prog Brain Res** 1996;107:551–80 (115 ref.)

Role of the cerebral cortex and striatum in emotional motor response. Saper CB. **Prog Brain Res** 1996;107:537–50 (91 ref.)
The paraventricular nucleus of the hypothalamus and the functional neuroanatomy of visceromotor responses to stress. Sawchenko PE, et al. **Prog Brain Res** 1996; 107:201–22 (104 ref.)
Clinical observations on the emotional motor system. Waxman SG. **Prog Brain Res** 1996;107:595–604 (37 ref.)
Ganglionic axons in motor roots and pia mater. Hildebrand C, et al. **Prog Neurobiol** 1997 Feb;51(2):89–128 (276 ref.)
The basal ganglia: focused selection and inhibition of competing motor programs. Mink JW. **Prog Neurobiol** 1996 Nov;50(4):381–425 (250 ref.)
Transmission of the cortical command for human voluntary movement through cervical propriospinal premotoneurons. Pierrot-Deseilligny E. **Prog Neurobiol** 1996 Mar–Apr; 48(4–5):489–517 (60 ref.)
On the role of recurrent inhibitory feedback in motor control. Windhorst U. **Prog Neurobiol** 1996 Aug;49(6):517–87 (367 ref.)
Influence of the postsynaptic target on the functional properties of neurons in the adult mammalian central nervous system. de la Cruz RR, et al. **Rev Neurosci** 1996 Apr–Jun;7(2):115–49 (183 ref.)
Effects of aging on neuromotor processes of swallowing. Caruso AJ, et al. **Semin Speech Lang** 1997 May;18(2):181–92 (68 ref.)
[F wave conduction study] Kohara N. **Nippon Rinsho** 1997 Mar;55 Suppl 1:426–9 (4 ref.) **(Jpn)**
[Central motor conduction time using magnetic and vibratory stimulation in Parkinson's disease, especially in patients with rigidity] Mochio S, et al. **Nippon Rinsho** 1997 Jan; 55(1):173–8 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Motor nerve conduction study] Ozaki I, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:413–6 (6 ref.) **(Jpn)**
[Central motor conduction time] Uozumi T. **Nippon Rinsho** 1997 Mar;55 Suppl 1:327–9 (7 ref.) **(Jpn)**
[Spinal neural mechanisms in voluntary movements] Shindo M. **Rinsho Shinkeigaku** 1995 Dec;35(12):1509–11 (7 ref.) (Eng. Abstr.) **(Jpn)**
[Motor neurons regenerate axons after CNS-injury. Surgery in cases of rotavulsion restore motor functions] Cullheim S, et al. **Lakartidningen** 1996 Dec 4;93(49):4537–41 (20 ref.) **(Swe)**

ULTRASTRUCTURE

Cell adhesion/recognition molecule-mediated steps during the guidance of commissural and motor axons. Landmesser L. **Prog Brain Res** 1996;108:109–16 (37 ref.)

MOTOR NEURONS, GAMMA

see related
MUSCLE SPINDLES

MOTOR SKILLS

The anatomy of manual dexterity. The new connectivity of the primate sensorimotor thalamus and cerebral cortex. Darian-Smith I, et al. **Adv Anat Embryol Cell Biol** 1996; 133:1–140 (400 ref.)
Music performance. Palmer C. **Annu Rev Psychol** 1997; 48:115–38 (125 ref.)
Manual dexterity: how does the cerebral cortex contribute? Darian-Smith I, et al. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov;23(10–11):948–56 (33 ref.)
A question of foot dominance. Gabbard C, et al. **J Gen Psychol** 1996 Oct;123(4):289–96 (33 ref.)
Effect of divergent self-monitoring strategies on motor performance and emotion as a function of alternating task complexity. Anshel MH, et al. **J Sports Sci** 1996 Jun; 14(3):233–42 (47 ref.)

PHYSIOLOGY

Nature and nurture in the development of postural control in human infants. Hadders-Algra M, et al. **Acta Paediatr Suppl** 1997 Jul;422:48–53 (38 ref.)
The neurophysiological basis of motor imagery. Decety J. **Behav Brain Res** 1996 May;77(1–2):45–52 (60 ref.)
The acquisition of perceptual and motor skills: a memory system in the adult human cortex. Karni A. **Brain Res Cogn Brain Res** 1996 Dec;5(1–2):39–48 (50 ref.)
Motor control, excitement, and overarm throwing. Hore J. **Can J Physiol Pharmacol** 1996 Apr;74(4):385–9 (25 ref.)
Cortical plasticity underlying perceptual, motor, and cognitive skill development: implications for neurorehabilitation. Merzenich M, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:1–8 (59 ref.)
Motor function in microgravity: movement in weightlessness. Lackner JR, et al. **Curr Opin Neurobiol** 1996 Dec; 6(6):744–50 (48 ref.)
Motor control research in rehabilitation medicine. Latash ML, et al. **Disabil Rehabil** 1996 Jun;18(6):293–9 (40 ref.)
New control strategies for neuroprosthetic systems. Crago PE, et al. **J Rehabil Res Dev** 1996 Apr;33(2):158–72 (40 ref.)
Challenges to clinical deployment of upper limb neuroprostheses. Triolo R, et al. **J Rehabil Res Dev** 1996 Apr;33(2):111–22 (19 ref.)
Attention to action. Passingham RE. **Philos Trans R Soc Lond B Biol Sci** 1996 Oct 29; 351(1346):1473–9 (28 ref.)

MOTOR VEHICLES

see related
ACCIDENTS, TRAFFIC

MOTORCYCLES

Injury of the cervical spine associated with carotid and vertebral artery occlusion: case report and literature review. Schippinger G, et al. **Injury** 1997 May;28(4):315–8 (24 ref.)

MOTTLED ENAMEL see **FLUOROSIS, DENTAL**

MOULAGES see **MODELS, ANATOMIC**

MOUNIER-KUHN SYNDROME see **TRACHEOBRONCHOMEGALY**

MOUNTAINEERING

see related
ALTITUDE
High altitude medicine and physiology in the former Soviet Union. Gippenreiter E, et al. **Aviat Space Environ Med** 1996 Jun;67(6):576–84 (103 ref.)

INJURIES

Elbow, forearm, wrist, and hand injuries among sport rock climbers. Holtzhausen LM, et al. **Clin J Sport Med** 1996 Jul;6(3):196–203 (25 ref.)
Rock climbing injuries. Rooks MD. **Sports Med** 1997 Apr; 23(4):261–70 (15 ref.)

MOURNING see **GRIEF**

MOUSE CYTOMEGALOVIRUS see **MUROMEGALOVIRUS**

MOUSE HEPATITIS VIRUS see **GASTROENTERITIS VIRUS, MURINE**

MOUSE LEUKEMIA VIRUSES see **LEUKEMIA VIRUSES, MURINE**

MOUSE MAMMARY TUMOR VIRUS see **MAMMARY TUMOR VIRUSES, MOUSE**

MOUSE POLIOVIRUSES see **THEILER'S MURINE ENCEPHALOMYELITIS VIRUS**

MOUSE THYMIC VIRUS see **HERPESVIRIDAE**

MOUSE TUMOR VIRUSES see **TUMOR VIRUSES, MURINE**

MOUTH

see related
SURGERY, ORAL

GROWTH & DEVELOPMENT

Effects of preterm birth on oral growth and development. Seow WK. **Aust Dent J** 1997 Apr;42(2):85–91 (33 ref.)

INJURIES

Dental injuries during general anaesthesia [see comments] Chadwick RG, et al. **Br Dent J** 1996 Apr 6;180(7):255–8 (21 ref.) Comment in: Br Dent J 1996 Jul 6;181(1):11.
Pneumomediastinum following penetrating oral trauma. McHugh TP. **Pediatr Emerg Care** 1997 Jun;13(3):211–3 (20 ref.)

MICROBIOLOGY

Mechanisms of adhesion by oral bacteria. Whittaker CJ, et al. **Annu Rev Microbiol** 1996;50:513–52 (224 ref.)
Human oral microbial ecology and dental caries and periodontal diseases. Liljemark WF, et al. **Crit Rev Oral Biol Med** 1996;7(2):180–98 (196 ref.)
Modifications of the microflora of the oral cavity arising during immunosuppressive chemotherapy. Sixou JL, et al. **Eur J Cancer B Oral Oncol** 1996 Sep;32B(5):306–10 (35 ref.)
Antimicrobial treatment of periodontal diseases disturbs the human ecology: a review. Edlund C, et al. **J Chemother** 1996 Oct;8(5):331–41 (65 ref.)
The impact of mercury released from dental "silver" fillings on antibiotic resistances in the primate oral and intestinal bacterial flora. Liebert CA, et al. **Met Ions Biol Syst** 1997; 34:441–60 (69 ref.)
The indigenous gastrointestinal microflora. Berg RD. **Trends Microbiol** 1996 Nov;4(11):430–5 (35 ref.)
[Candida in the ecological system of the orointestinal tract] Bernhardt H. **Mycoses** 1996;39 Suppl 1:44–7 (12 ref.) (Eng. Abstr.) **(Ger)**
[The significance of the microflora of the oral cavity in the etiology and pathogenesis of lichen ruber planus] Rabinovich IM, et al. **Stomatologiia (Mosk)** 1997;76(2):72–5 (60 ref.) **(Rus)**

PATHOLOGY

[Liposarcoma of the oral cavity: description of a case and review of the literature] Gialdini F, et al. **Acta Otorhinolaryngol Ital** 1995 Apr;15(2):112–6 (37 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

Control pathways from the basal ganglia to the orofacial motor system in the lower brainstem. Yasui Y, et al. **Kaibogaku Zasshi** 1996 Jun;71(3):177–82 (22 ref.)

RADIATION EFFECTS

[Dental changes induced by radiotherapy: a study of subjects with retinoblastoma. I] Mascagni EE, et al. **Minerva Stomatol** 1997 Apr;46(4):191–200 (66 ref.) (Eng. Abstr.) **(Ita)**
[The evaluation of radiotherapy in the treatment of epidermoid carcinoma of the oral cavity] Kowalik S, et al. **Otolaryngol Pol** 1996;50(1):46–51 (27 ref.) (Eng. Abstr.) **(Pol)**

SURGERY

Current concepts in oromandibular reconstruction. Burkey BB, et al. **Otolaryngol Clin North Am** 1997 Aug; 30(4):607–30 (47 ref.)
[The evaluation of radiotherapy in the treatment of epidermoid carcinoma of the oral cavity] Kowalik S, et al. **Otolaryngol Pol** 1996;50(1):46–51 (27 ref.) (Eng. Abstr.) **(Pol)**

MOUTH ABNORMALITIES

[Mohr-Claussen syndrome] Nakano M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):281–3 (10 ref.) **(Jpn)**

DIAGNOSIS

Examine your orofacial cleft patients for Gorlin-Goltz syndrome. Lambrecht JT, et al. **Cleft Palate Craniofac J** 1997 Jul;34(4):342–50 (72 ref.)

GENETICS

[Autosomal chromosomes and anomalies of the oromaxillofacial area] Giacchetti D, et al. **Minerva Stomatol** 1996 Apr;45(4):157–67 (52 ref.) (Eng. Abstr.) **(Ita)**

MOUTH DISEASES

see related
HALITOSIS
ORAL HEALTH
Oral lesions in pediatric patients. Hebert AA, et al. **Adv Dermatol** 1997;12:169–93; discussion 194 (46 ref.)
HPV-associated diseases of oral mucosa. Praetorius F. **Clin Dermatol** 1997 May–Jun;15(3):399–413 (100 ref.)
Crohn's disease of the upper gastrointestinal tract. Wagtmans MJ, et al. **Neth J Med** 1997 Feb;50(2):S2–7 (58 ref.)

CHEMICALLY INDUCED

Oral complications from cancer therapy: Part 1--Pathophysiology and secondary complications. Madeya ML. **Oncol Nurs Forum** 1996 Jun;23(5):801–7 (28 ref.)
Oral complications from cancer therapy: Part 2--Nursing implications for assessment and treatment. Madeya ML. **Oncol Nurs Forum** 1996 Jun;23(5):808–19 (63 ref.)
Methotrexate and oral mucositis [editorial; comment] Moe PJ. **Pediatr Hematol Oncol** 1996 Jul–Aug;13(4):313–4 (6 ref.) Comment on: Pediatr Hematol Oncol 1996 Jul–Aug;13(4):359–73.

COMPLICATIONS

[Clinico-diagnostic and odonto-stomatologic therapeutic problems in patients with HIV infection and AIDS] Spadari F, et al. **Minerva Stomatol** 1997 Jun;46(6):307–28 (100 ref.) (Eng. Abstr.) **(Ita)**

CONGENITAL

[Venous angiodysplasias of the cheek. The problems of therapy] Di Giovanni A, et al. **Minerva Stomatol** 1996 Apr; 45(4):169–77 (12 ref.) (Eng. Abstr.) **(Ita)**
[Venous angiodysplasias with endoral manifestation. The problems of therapy] Di Giovanni A, et al. **Minerva Stomatol** 1996 Mar;45(3):113–9 (12 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Oral pigmentation representing Laugier-Hunziker syndrome. Mowad CM, et al. **Cutis** 1997 Jul;60(1):37–9 (9 ref.)
Clinical diagnosis and management of hormonally responsive oral pregnancy tumor (pyogenic granuloma). Sills ES, et al. **J Reprod Med** 1996 Jul;41(7):467–70 (30 ref.)
[Pemphigus and pemphigoid. A review and case reports] von Arx T, et al. **Schweiz Monatsschr Zahnmed** 1996; 106(9):796–811 (39 ref.) **(Ger, Fre)**

MOUTH DISEASES

[Oral mucosal changes in children. The clinical picture and therapy of selected pediatric diseases] Zedler C, et al. **Schweiz Monatsschr Zahnmed** 1996;106(1):14–30 (7 ref.) **(Ger, Fre)**

[Pemphigoid of the mucous membranes. The clinical, histopathological and immunological aspects and current therapeutic concepts] Carrozzo M, et al. **Minerva Stomatol** 1996 Oct;45(10):455–63 (73 ref.) (Eng. Abstr.) **(Ita)**

[Venous angiodysplasias of the cheek. The problems of therapy] Di Giovanni A, et al. **Minerva Stomatol** 1996 Apr; 45(4):169–77 (12 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Pharmacology of the gastrointestinal tract. Terezhalmy GT, et al. **Dent Clin North Am** 1996 Jul;40(3):493–520 (150 ref.)

EPIDEMIOLOGY

Women as dental patients: are there any gender differences? Zakrzewska JM. **Int Dent J** 1996 Dec;46(6):548–57 (82 ref.)

ETIOLOGY

Human immunodeficiency virus infection: a review of the mode of infection, pathogenesis, disease course, and the general and clinical manifestations. McCullough MJ, et al. **Aust Dent J** 1997 Feb;42(1):30–7 (46 ref.)

Oral and maxillofacial manifestations of hereditary sensory neuropathy. Narayanan V. **Br J Oral Maxillofac Surg** 1996 Oct;34(5):446–9 (16 ref.)

Graft-vs.-host disease. Woo SB, et al. **Crit Rev Oral Biol Med** 1997;8(2):201–16 (138 ref.)

Oral and esophageal disorders. Noyer CM, et al. **Gastroenterol Clin North Am** 1997 Jun;26(2):241–57 (99 ref.)

Traumatic herniation of the buccal fat pad: a report of two cases and a review of the literature. Zipfel TE, et al. **Int J Pediatr Otorhinolaryngol** 1996 Dec 20;38(2):175–9 (15 ref.)

An atlas of HIV-associated oral lesions: a new classification and diagnostic criteria. Wiebe CB, et al. **J Can Dent Assoc** 1997 Apr;63(4):288–9, 292–4 (8 ref.)

Three decades of pain research and its control. Dubner R. **J Dent Res** 1997 Mar;76(3):730–3 (30 ref.)

Oral lesions in organ transplant patients. Seymour RA, et al. **J Oral Pathol Med** 1997 Aug;26(7):297–304 (99 ref.)

Orthodontic appliances in relation to nickel hypersensitivity. A review. Lindsten R, et al. **J Orofac Orthop** 1997; 58(2):100–8 (23 ref.) **(Eng, Ger)**

The functional balance of metalloproteinases and inhibitors in tissue degradation: relevance to oral pathologies. Reynolds JJ, et al. **J R Coll Surg Edinb** 1997 Jun; 42(3):154–60 (76 ref.)

Immune surveillance of the oral cavity and lymphocyte migration: relevance for alcohol abusers. Chiappelli F, et al. **Lymphology** 1995 Dec;28(4):196–207 (52 ref.)

[Alcohol and smoking. The risk factors for the oral cavity] Weinstein RL, et al. **Minerva Stomatol** 1996 Sep; 45(9):405–13 (100 ref.) (Eng. Abstr.) **(Ita)**

MICROBIOLOGY

Histological and ultrastructural study of one case of oral bacillary angiomatosis in HIV disease and review of the literature. Monteil RA, et al. **Eur J Cancer B Oral Oncol** 1994 Jan;30B(1):65–71 (64 ref.)

Oral botryomycosis: a case report. Devaiah AK, et al. **J Laryngol Otol** 1997 Jan;111(1):77–9 (15 ref.)

PATHOLOGY

Oral pathology of acquired immunodeficiency syndrome and oro-facial Kaposi's sarcoma. Reichart PA. **Curr Top Pathol** 1996;90:97–123 (43 ref.)

Mucocutaneous conditions affecting the mouth. Williams DM. **Curr Top Pathol** 1996;90:1–28 (92 ref.)

An atlas of HIV-associated oral lesions: a new classification and diagnostic criteria. Wiebe CB, et al. **J Can Dent Assoc** 1997 Apr;63(4):288–9, 292–4 (8 ref.)

A hamartoma-like mass on the palate? A possible discussion regarding the components of a pigmented naevus and hyperplastic salivary gland. Harada H, et al. **J Laryngol Otol** 1997 Mar;111(3):296–9 (17 ref.)

Oral manifestations of sarcoidosis. Blinder D, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Apr;83(4):458–61 (53 ref.)

Lichen sclerosus et atrophicus of the oral cavity: report of two cases. Brown AR, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Aug;84(2):165–70 (37 ref.)

PSYCHOLOGY

[Psychiatric and psychologic aspects of stomatologic diseases, or stomatologic aspects of psychiatric diseases. Review of the literature] Hajnal A. **Fogorv Sz** 1997 Jun;90(6):163–76 (45 ref.) (Eng. Abstr.) **(Hun)**

SURGERY

Clinical diagnosis and management of hormonally responsive oral pregnancy tumor (pyogenic granuloma). Sills ES, et al. **J Reprod Med** 1996 Jul;41(7):467–70 (30 ref.)

THERAPY

Oral health care for the cancer patient. Scully C, et al. **Eur J Cancer B Oral Oncol** 1996 Sep;32B(5):281–92 (282 ref.)

VIROLOGY

New aspects of oral viral diseases. Scully C. **Curr Top Pathol** 1996;90:29–96 (648 ref.)

Viral lesions of the mouth in HIV-infected patients. Itin PH, et al. **Dermatology** 1997;194(1):1–7 (85 ref.)

Oro-facial lesions occurring in HIV-infected individuals in Dar es Salaam. Matee MI, et al. **East Afr Med J** 1996 Dec; 73(12):813–5 (7 ref.)

Oral manifestations of human immunodeficiency virus infection. Phelan JA. **Med Clin North Am** 1997 Mar; 81(2):511–31 (81 ref.)

Infections of the oral cavity. Peter JR, et al. **Pediatr Ann** 1996 Oct;25(10):572–6 (11 ref.)

MOUTH DRYNESS see **XEROSTOMIA**

MOUTH, EDENTULOUS

see related
DENTURE, COMPLETE

COMPLICATIONS

Prosthetic rehabilitation in patients with temporomandibular disorders. Türp JC, et al. **J Prosthet Dent** 1996 Oct; 76(4):418–23 (53 ref.)

REHABILITATION

Prosthetic rehabilitation in patients with temporomandibular disorders. Türp JC, et al. **J Prosthet Dent** 1996 Oct; 76(4):418–23 (53 ref.)

MOUTH MUCOSA

[Dental materials--problem substances in allergologic diagnosis? II: Patch test diagnosis and relevance evaluation of selected dental material groups] Richter G. **Hautarzt** 1996 Nov;47(11):844–9 (50 ref.) (Eng. Abstr.) **(Ger)**

ANATOMY & HISTOLOGY

[The tissue and cell defense mechanisms of the oral mucosa] Bykov VL. **Morfologiia** 1996;110(6):14–24 (105 ref.) (Eng. Abstr.) **(Rus)**

CYTOLOGY

Buccal tissues and cell culture. Quadros E, et al. **Pharm Biotechnol** 1996;8:103–13 (13 ref.)

Growth and transformation of human oral epithelium in vitro. Grafström RC, et al. **Recent Results Cancer Res** 1997; 143:275–306 (159 ref.)

IMMUNOLOGY

Salivary mucins in oral mucosal defense. Slomiany BL, et al. **Gen Pharmacol** 1996 Jul;27(5):761–71 (60 ref.)

Immaturity, ageing and oral tolerance. Vaz N, et al. **Scand J Immunol** 1997 Sep;46(3):225–9 (75 ref.)

[The mechanisms of oral tolerance] Yamamoto M, et al. **Nippon Rinsho** 1997 Jun;55(6):1444–9 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Dendritic antigen-presenting cells of the oral mucosa in health and in pathological conditions] Bykov VL. **Arkh Patol** 1997 Mar-Apr;59(2):71–5 (70 ref.) (Eng. Abstr.) **(Rus)**

INJURIES

Traumatic herniation of the buccal fat pad: a report of two cases and a review of the literature. Zipfel TE, et al. **Int J Pediatr Otorhinolaryngol** 1996 Dec 20;38(2):175–9 (15 ref.)

METABOLISM

Review of the transmucosal drug delivery. Manganaro AM. **Mil Med** 1997 Jan;162(1):27–30 (36 ref.)

Buccal tissues and cell culture. Quadros E, et al. **Pharm Biotechnol** 1996;8:103–13 (13 ref.)

PATHOLOGY

Mucocutaneous conditions affecting the mouth. Williams DM. **Curr Top Pathol** 1996;90:1–28 (92 ref.)

Histological and ultrastructural study of one case of oral bacillary angiomatosis in HIV disease and review of the literature. Monteil RA, et al. **Eur J Cancer B Oral Oncol** 1994 Jan;30B(1):65–71 (64 ref.)

Oral exfoliative cytology: review of methods of assessment. Ogden GR, et al. **J Oral Pathol Med** 1997 May;26(5):201–5 (63 ref.)

Birt-Hogg-Dubé syndrome: a review and presentation of the first case with oral lesions. Nadershahi NA, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Apr;83(4):496–500 (19 ref.)

Oral mucositis with features of psoriasis: report of a case and review of the literature. Younai FS, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jul;84(1):61–7 (58 ref.)

Methotrexate and oral mucositis [editorial; comment] Moe PJ. **Pediatr Hematol Oncol** 1996 Jul-Aug;13(4):313–4 (6 ref.) Comment on: Pediatr Hematol Oncol 1996 Jul-Aug;13(4):359–73.

Mucosal calcified nodule of the hard palate in an infant: case report and review of the literature. Afzal MN, et al. **Pediatr Pathol Lab Med** 1997 Jul-Aug;17(4):611–5 (10 ref.)

Growth and transformation of human oral epithelium in vitro. Grafström RC, et al. **Recent Results Cancer Res** 1997; 143:275–306 (159 ref.)

[The mouth as a mirror of the body] Syrjänen S. **Duodecim** 1995;111(14):1360–9 (18 ref.) **(Fin)**

PHYSIOLOGY

[Importance of the masticatory mucosa in the maintenance of healthy peri-implant soft tissues. Review of the literature] Francetti L, et al. **Minerva Stomatol** 1997 Jul-Aug;46(7–8):399–405 (38 ref.) (Eng. Abstr.) **(Ita)**

[The functional morphology of the epithelial barrier of the oral mucosa] Bykov VL. **Stomatologiia (Mosk)** 1997; 76(3):12–7 (86 ref.) (Eng. Abstr.) **(Rus)**

TRANSPLANTATION

Lower eyelid reconstruction using pedicled skin flap and palatal mucoperiosteum. Perry MJ, et al. **Dermatol Surg** 1997 May;23(5):395–7; discussion 397–8 (10 ref.)

VIROLOGY

Human papillomavirus expression in oral mucosa, premalignant conditions, and squamous cell carcinoma: a retrospective review of the literature [see comments] Miller CS, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Jul;82(1):57–68 (99 ref.) Comment in: Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Feb;83(2):187–8.

MOUTH NEOPLASMS

Human papillomavirus and cancers of the upper aerodigestive tract: a review of epidemiological and experimental evidence. Franceschi S, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Jul;5(7):567–75 (104 ref.)

Dermatofibrosarcoma protuberans of the upper lip: an overview and a case report. Vandeweyer E, et al. **Eur J Surg Oncol** 1997 Jun;23(3):275–7 (22 ref.)

CHEMICALLY INDUCED

Carcinogenic and genotoxic effects of the tobacco substitute pan masala: present status and likely future impact on the Indian population. Trivedi AH, et al. **Cancer Treat Rev** 1996 Sep;22(5):345–54 (70 ref.)

Adenocarcinoma of the mouth in a patient with psoriasis under short-term cyclosporine therapy [letter] Yamamoto T, et al. **Dermatology** 1996;193(1):72–3 (9 ref.)

[Selenium and oral cancer. Review of the literature] Carinci F, et al. **Minerva Stomatol** 1996 Jul-Aug;45(7–8):345–8 (12 ref.) (Eng. Abstr.) **(Ita)**

CHEMISTRY

Suppressor protein p53 and its occurrence in oral tumours. Slootweg PJ. **Curr Top Pathol** 1996;90:179–200 (119 ref.)

COMPLICATIONS

Fanconi's anaemia and recurrent squamous cell carcinoma of the oral cavity: a case report. Koo WH, et al. **Ann Acad Med Singapore** 1996 Mar;25(2):289–92 (26 ref.)

[Oral candidiasis following radiotherapy for neoplasms of the oromaxillofacial area] Tartaro GP, et al. **Minerva Stomatol** 1996 Oct;45(10):451–4 (9 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Detection and treatment of early cancers of the oral cavity. Scully C, et al. **Crit Rev Oncol Hematol** 1995 Nov; 21(1–3):63–75 (111 ref.)

Oncogenes and growth factor receptors as diagnostic and prognostic markers in precancers and cancers of the oral mucosa. Burkhardt A. **Curr Top Pathol** 1996;90:223–39 (136 ref.)

Health care auxiliaries in the detection and prevention of oral cancer. Sankaranarayanan R. **Oral Oncol** 1997 May; 33(3):149–54 (29 ref.)

[Modern imaging methods in diagnosis of tumors of the oropharynx and mouth cavity] Lenz M. **Rontgenpraxis** 1996 Nov;49(11):286–96 (28 ref.) **(Ger)**

[Dermoid cysts of the oral cavity] Szporek B, et al. **Wiad Lek** 1996;49(1–6):36–42 (34 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Photodynamic therapy of oral cancer. A review of basic mechanisms and clinical applications. Nauta JM, et al. **Eur J Oral Sci** 1996 Apr;104(2 (Pt 1)):69–81 (138 ref.)

EPIDEMIOLOGY

Nutrition and oral cancer. Marshall JR, et al. **Cancer Causes Control** 1996 Jan;7(1):101–11 (48 ref.)

Cancers of the oral cavity and pharynx in the United States: an epidemiologic overview. Swango PA. **J Public Health Dent** 1996 Fall;56(6):309–18 (33 ref.)

[Melanoma of the oral cavity. Review of the literature] Garzino Demo P, et al. **Minerva Stomatol** 1997 Jun; 46(6):329–35 (70 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Pathogenesis of oral Kaposi's Sarcoma in HIV–infection: relevance of endogenous glucocorticoid excess in blood and saliva. Enwonwu CO. **Eur J Cancer B Oral Oncol** 1996 Jul;32B(4):271–4 (49 ref.)

Oral squamous cell carcinoma: new insights. Jordan RC, et al. **J Can Dent Assoc** 1997 Jul–Aug;63(7):517–8, 521–5 (47 ref.)

GENETICS

Molecular biology of human oral cancer. Wong DT, et al. **Crit Rev Oral Biol Med** 1996;7(4):319–28 (117 ref.)

The molecular biology of oral carcinogenesis: toward a tumor progression model. Todd R, et al. **J Oral Maxillofac Surg** 1997 Jun;55(6):613–23; discussion 623–5 (96 ref.)

Early genetic and functional events in the pathogenesis of oral cancer. Prime SS, et al. **Radiat Oncol Investig** 1997; 5(3):93–6 (19 ref.)

PATHOLOGY

Oral infiltrating lipomas. Bataineh AB, et al. **Br J Oral Maxillofac Surg** 1996 Dec;34(6):520–3 (20 ref.)

Extranodal non–Hodgkin's lymphomas of the oral cavity. Jordan RC, et al. **Curr Top Pathol** 1996;90:125–46 (89 ref.)

Oral pathology of acquired immunodeficiency syndrome and oro–facial Kaposi's sarcoma. Reichart PA. **Curr Top Pathol** 1996;90:97–123 (43 ref.)

Leiomyoma of the oral cavity: a light microscopic and immunohistochemical study with review of the literature from 1884 to 1992. Baden E, et al. **Eur J Cancer B Oral Oncol** 1994 Jan;30B(1):1–7 (101 ref.)

Tumours of the oral cavity, buccal pouch, oesophagus, forestomach and salivary glands. Takahashi M, et al. **IARC Sci Publ** 1996;(126):59–77 (60 ref.)

Cancer of the gingiva, buccal mucosa, and palate. McGaw WT, et al. **J Can Dent Assoc** 1996 Feb;62(2):146–50 (29 ref.)

Quintuple cancers: report of a case with triple cancers in the head and neck. Martin–Granizo R, et al. **J Craniomaxillofac Surg** 1997 Jun;25(3):153–7 (34 ref.)

Oral exfoliative cytology: review of methods of assessment. Ogden GR, et al. **J Oral Pathol Med** 1997 May;26(5):201–5 (63 ref.)

The future role for oral exfoliative cytology––bleak or bright? Ogden GR. **Oral Oncol** 1997 Jan;33(1):2–4 (50 ref.)

Nerve sheath myxoma of the oral cavity: case report and review. Tiffee JC, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Oct;82(4):423–5 (13 ref.)

Growth and transformation of human oral epithelium in vitro. Grafström RC, et al. **Recent Results Cancer Res** 1997; 143:275–306 (159 ref.)

[Liposarcoma of the oral cavity: description of a case and review of the literature] Gialdini F, et al. **Acta Otorhinolaryngol Ital** 1995 Apr;15(2):112–6 (37 ref.) (Eng. Abstr.) **(Ita)**

[A case of Kaposi's sarcoma with involvement of the facial skin and the mucosa of the right cheek] Popov NV, et al. **Stomatologiia (Mosk)** 1996;75(3):30–2 (16 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Growth and transformation of human oral epithelium in vitro. Grafström RC, et al. **Recent Results Cancer Res** 1997; 143:275–306 (159 ref.)

PREVENTION & CONTROL

Chemoprevention of cancers of the oral cavity and the head and neck. Sankaranarayanan R, et al. **IARC Sci Publ** 1996; (136):13–25 (72 ref.)

Retinoid actions and implications for prevention and therapy of oral cancer. Girod SC, et al. **Int J Oral Maxillofac Surg** 1996 Feb;25(1):69–73 (79 ref.)

Current status of retinoids in chemoprevention of oral squamous cell carcinoma: an overview. Conley BA, et al. **J Craniomaxillofac Surg** 1996 Dec;24(6):339–45 (56 ref.)

The need for health promotion in oral cancer prevention and early detection. Horowitz AM, et al. **J Public Health Dent** 1996 Fall;56(6):319–30 (124 ref.)

Detecting, diagnosing, and preventing oral cancer. Shugars DC, et al. **Nurse Pract** 1997 Jun;22(6):105, 109–10, 113–5 passim (20 ref.)

RADIOTHERAPY

Radiation treatment of oral epidemic Kaposi's sarcoma lesions: potential adverse effects. Fogel SC, et al. **J Assoc Nurses AIDS Care** 1996 Jul–Aug;7(4):25–30 (23 ref.)

Applications of brachytherapy in head and neck cancer. Harrison LB. **Semin Surg Oncol** 1997 May–Jun; 13(3):177–84 (25 ref.)

[The evaluation of radiotherapy in the treatment of epidermoid carcinoma of the oral cavity] Kowalik S, et al. **Otolaryngol Pol** 1996;50(1):46–51 (27 ref.) (Eng. Abstr.) **(Pol)**

REHABILITATION

Oral rehabilitation with endosteal implants and free flaps. Hayter JP, et al. **Int J Oral Maxillofac Surg** 1996 Feb; 25(1):3–12 (59 ref.)

SURGERY

Microendoscopic transoral CO2–laser resection of an extensive nasopharyngeal and oral teratoma. Gunkel AR, et al. **Am J Otolaryngol** 1997 Mar–Apr;18(2):140–4 (14 ref.)

Use of the laser in the oral cavity. Burkey MD BB, et al. **Otolaryngol Clin North Am** 1996 Dec;29(6):949–61 (37 ref.)

[The evaluation of radiotherapy in the treatment of epidermoid carcinoma of the oral cavity] Kowalik S, et al. **Otolaryngol Pol** 1996;50(1):46–51 (27 ref.) (Eng. Abstr.) **(Pol)**

THERAPY

Detection and treatment of early cancers of the oral cavity. Scully C, et al. **Crit Rev Oncol Hematol** 1995 Nov; 21(1–3):63–75 (111 ref.)

VETERINARY

Radiation therapy in the treatment of oral neoplasia. Burk RL. **Vet Clin North Am Small Anim Pract** 1996 Jan; 26(1):155–63 (56 ref.)

Oral tumors: the surgeon and the medical oncologist. Jeglum KA, et al. **Vet Clin North Am Small Anim Pract** 1996 Jan; 26(1):145–53 (12 ref.)

VIROLOGY

HPV–11– and HPV–16–associated oral verrucous carcinoma. Lübbe J, et al. **Dermatology** 1996;192(3):217–21 (35 ref.)

Human papillomavirus expression in oral mucosa, premalignant conditions, and squamous cell carcinoma: a retrospective review of the literature [see comments] Miller CS, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Jul;82(1):57–68 (99 ref.) Comment in: Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Feb;83(2):187–8.

[High–risk HPV types in oral and laryngeal papilloma and leukoplakia] Arndt O, et al. **Laryngorhinootologie** 1997 Mar; 76(3):142–9 (58 ref.) (Eng. Abstr.) **(Ger)**

MOUTH PROTECTORS

Athletic mouth guards prevent orofacial injuries. Woodmansey KF. **J Am Coll Health** 1997 Jan;45(4):179–82 (26 ref.)

MOUTH–TO–MOUTH RESUSCITATION see **CARDIOPULMONARY RESUSCITATION**

MOUTH ULCER see **ORAL ULCER**

MOUTHPIECES see **MOUTH PROTECTORS**

MOUTHWASHES

Cyclosporin A mouthwash in the treatment of oral lichen planus. Jungell P, et al. **Int J Oral Maxillofac Surg** 1996 Feb;25(1):60–2 (20 ref.)

ADVERSE EFFECTS

Alcohol–containing mouthwashes and oropharyngeal cancer: a spurious association due to underascertainment of confounders? Shapiro S, et al. **Am J Epidemiol** 1996 Dec 15;144(12):1091–5 (19 ref.)

MOVEMENT

see related
IMMOBILIZATION
MOTION

The assessment of general movements is a valuable technique for the detection of brain dysfunction in young infants. A review. Hadders–Algra M. **Acta Paediatr Suppl** 1996 Oct;416:39–43 (60 ref.)

Difficulties in mobility among elderly people and their association with socioeconomic factors, dwelling environment and use of services. Sakari–Rantala R, et al. **Aging (Milano)** 1995 Dec;7(6):433–40 (58 ref.)

Activation without selection: parallel right hemisphere roles in language and intentional movement? Richards L, et al. **Brain Lang** 1997 Mar;57(1):151–78 (140 ref.)

Planning, preparation, execution, and imagery of volitional action. Deecke L. **Brain Res Cogn Brain Res** 1996 Mar; 3(2):59–64 (51 ref.)

Posteroanterior spinal mobilization: state of the art review and discussion. Björnsdóttir SV, et al. **Disabil Rehabil** 1997 Feb;19(2):39–46 (40 ref.)

Control pathways from the basal ganglia to the orofacial motor system in the lower brainstem. Yasui Y, et al. **Kaibogaku Zasshi** 1996 Jun;71(3):177–82 (22 ref.)

Protein dynamics and conformational transitions in allosteric proteins. Jardetzky O. **Prog Biophys Mol Biol** 1996; 65(3):171–219 (220 ref.)

The role of the basal ganglia in movement control. Kaneoke Y, et al. **Rinsho Shinkeigaku** 1995 Dec;35(12):1518–21 (10 ref.)

Paroxysmal kinesigenic choreoathetosis. Choi IS, et al. **Yonsei Med J** 1996 Feb;37(1):68–71 (22 ref.)

[Examination of eye–head coordination] Arai Y. **Nippon Rinsho** 1997 Mar;55 Suppl 1:432–4 (8 ref.) **(Jpn)**

[Impaired associated movement in Parkinson's disease] Kawakami O, et al. **Nippon Rinsho** 1997 Jan;55(1):179–84 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Noninvasive study of cortical neuronal mechanism in voluntary movements: role of basal ganglia and cerebellum] Ikeda A, et al. **Rinsho Shinkeigaku** 1995 Dec;35(12):1522–4 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Pathophysiology of involuntary movements––dystonia and myoclonus. Symptomatological view] Kachi T. **Rinsho Shinkeigaku** 1995 Dec;35(12):1381–3 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Spinal neural mechanisms in voluntary movements] Shindo M. **Rinsho Shinkeigaku** 1995 Dec;35(12):1509–11 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Movement–related cortical potentials (MRCPs) and voluntary movement––clinical usefulness of MRCPs] Washimi Y, et al. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1525–7 (10 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Modulation of levodopa–induced motor response complications by NMDA antagonists in Parkinson's disease. Blanchet PJ, et al. **Neurosci Biobehav Rev** 1997 Jul;21(4):447–53 (80 ref.)

PHYSIOLOGY

Neurophysiological aspects of voluntary movements. Godaux E. **Acta Neurol Belg** 1996 Sep;96(3):193–202 (21 ref.)

Motor control physiology below spinal cord injury: residual volitional control of motor units in paretic and paralyzed muscles. Dimitrijevic MR, et al. **Adv Neurol** 1997;72:335–45 (32 ref.)

Muscle function in movement and sports. Herzog W. **Am J Sports Med** 1996;24(6 Suppl):S14–9 (17 ref.)

Multimodal representation of space in the posterior parietal cortex and its use in planning movements. Andersen RA, et al. **Annu Rev Neurosci** 1997;20:303–30 (72 ref.)

Posture and movement: coordination and control. Lacquaniti F, et al. **Arch Ital Biol** 1997 Sep;135(4):353–67 (80 ref.)

Stimulation over the human supplementary motor area interferes with the organization of future elements in complex motor sequences. Gerloff C, et al. **Brain** 1997 Sep; 120 (Pt 9):1587–602 (84 ref.)

The role of inhibition in the hierarchical gating of executed and imagined movements. Berthoz A. **Brain Res Cogn Brain Res** 1996 Mar;3(2):101–13 (112 ref.)

Ideomotor apraxia and cerebral dominance for motor control. Goldenberg G, et al. **Brain Res Cogn Brain Res** 1996 Mar; 3(2):95–100 (24 ref.)

Multiple cortical motor areas and temporal sequencing of movements. Tanji J, et al. **Brain Res Cogn Brain Res** 1996 Dec;5(1–2):117–22 (66 ref.)

The decision to make a movement: neurophysiological insights. Aminoff MJ, et al. **Can J Neurol Sci** 1997 Aug; 24(3):181–90 (29 ref.)

Cortical myoclonus: an insight into the organization of normal movement in man. Brown P. **Clin Neurosci** 1995–96; 3(4):193–7 (44 ref.)

Hemispheric asymmetry of movement. Haaland KY, et al. **Curr Opin Neurobiol** 1996 Dec;6(6):796–800 (34 ref.)

The representation of temporal information in perception and motor control. Ivry RB. **Curr Opin Neurobiol** 1996 Dec; 6(6):851–7 (51 ref.)

Motor function in microgravity: movement in weightlessness. Lackner JR, et al. **Curr Opin Neurobiol** 1996 Dec; 6(6):744–50 (48 ref.)

Interactions between motor commands and somatic perception in sensorimotor cortex. Nelson RJ. **Curr Opin Neurobiol** 1996 Dec;6(6):801–10 (79 ref.)

Parietal cortex: from sight to action. Rizzolatti G, et al. **Curr Opin Neurobiol** 1997 Aug;7(4):562–7 (51 ref.)

Hippocampal lesions and path integration. Whishaw IQ, et al. **Curr Opin Neurobiol** 1997 Apr;7(2):228–34 (64 ref.)

Sensory representation in the cerebellum and control circuits of motion. Arends JJ. **Eur J Morphol** 1997 Oct;35(4):234–45 (94 ref.)

Supplementary motor cortex in organization of movement. Tanji J, et al. **Eur Neurol** 1996;36 Suppl 1:13–9 (103 ref.)

Control of remembered reaching sequences in monkey. I. Activity during movement in motor and premotor cortex. Kettner RE, et al. **Exp Brain Res** 1996 Dec;112(3):335–46 (38 ref.)

Arm movements in monkeys: behavior and neurophysiology. Georgopoulos AP. **J Comp Physiol [A]** 1996 Nov; 179(5):603–12 (46 ref.)

Restless legs and periodic leg movements in sleep syndromes. Wetter TC, et al. **J Neurol** 1997 Apr;244(4 Suppl 1):S37–45 (104 ref.)

Neurophysiological methods for studies of the motor system in freely moving human subjects. Capaday C. **J Neurosci Methods** 1997 Jun 27;74(2):201–18 (119 ref.)

Assessing changes in presynaptic inhibition of Ia afferents during movement in humans. Pierrot–Deseilligny E.

MOVEMENT

J Neurosci Methods 1997 Jun 27;74(2):189–99 (46 ref.)
Biomechanical investigation of the glenohumeral joint. Itoi E, et al. **J Shoulder Elbow Surg** 1996 Sep–Oct;5(5):407–24 (122 ref.)
The control of head movements during human balance corrections. Allum JH, et al. **J Vestib Res** 1997 Mar–Jun; 7(2–3):189–218 (91 ref.)
Roles of cerebellar cortex and nuclei in motor learning: contradictions or clues? Mauk MD. **Neuron** 1997 Mar; 18(3):343–6 (21 ref.)
Clinical observations on the emotional motor system. Waxman SG. **Prog Brain Res** 1996;107:595–604 (37 ref.)
Some organizing principles for the control of movement based on olivocerebellar physiology. Welsh JP, et al. **Prog Brain Res** 1997;114:449–61 (57 ref.)
Sensori–sensory afferent conditioning with leg movement: gain control in spinal reflex and ascending paths. Brooke JD, et al. **Prog Neurobiol** 1997 Mar;51(4):393–421 (180 ref.)
The basal ganglia: focused selection and inhibition of competing motor programs. Mink JW. **Prog Neurobiol** 1996 Nov;50(4):381–425 (250 ref.)
Transmission of the cortical command for human voluntary movement through cervical propriospinal premotoneurons. Pierrot–Deseilligny E. **Prog Neurobiol** 1996 Mar–Apr; 48(4–5):489–517 (60 ref.)
Encoding of tooth loads by human periodontal afferents and their role in jaw motor control. Trulsson M, et al. **Prog Neurobiol** 1996 Jun;49(3):267–84 (89 ref.)
[Neural mechanisms of apraxia] Yamadori A. **No To Shinkei** 1996 Nov;48(11):991–8 (73 ref.) **(Jpn)**
[Current concepts of the neuromorphology and neurochemistry of the striatal cholinergic system and its role in regulating movement] Shapovalova KB. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jul–Aug; 46(4):656–73 (145 ref.) (Eng. Abstr.) **(Rus)**

MOVEMENT, CELL see **CELL MOVEMENT**

MOVEMENT DISORDER AGENTS see **ANTI-DYSKINESIA AGENTS**

MOVEMENT DISORDERS

see related
PSYCHOMOTOR DISORDERS
Paroxysmal movement disorders. Vedanarayanan VV. **Pediatr Ann** 1997 Jul;26(7):402–8 (24 ref.)
Movement disorders in childhood [published erratum appears in Pediatr Rev 1997 Feb;18(2):71] Pranzatelli MR. **Pediatr Rev** 1996 Nov;17(11):388–94 (17 ref.)

CLASSIFICATION
Rationales, values, and DSM–IV: the case of "medication–induced movement disorders". Sadler JZ. **Compr Psychiatry** 1996 Nov–Dec;37(6):441–51 (59 ref.)

COMPLICATIONS
What is developmental dyspraxia? Dewey D. **Brain Cogn** 1995 Dec;29(3):254–74 (80 ref.)
Movement disorders and substance abuse. Lopez W, et al. **Psychiatr Serv** 1997 May;48(5):634–6 (23 ref.)
[Respiratory disorders in movement disorders] Jiménez Jiménez FJ, et al. **Med Clin (Barc)** 1996 Sep 21;107(9):342–6 (69 ref.) **(Spa)**

DIAGNOSIS
Moving on: autism and movement disturbance. Leary MR, et al. **Ment Retard** 1996 Feb;34(1):39–53 (145 ref.)
Imaging the child with a limp. Myers MT, et al. **Pediatr Clin North Am** 1997 Jun;44(3):637–58 (30 ref.)
[Functional imaging] Rascol O, et al. **Neurochirurgie** 1997; 43 Suppl 1:41–51 (0 ref.) **(Fre)**
[Gait disorders in the elderly] Vela L. **Neurologia** 1996 Nov; 11(9):313–5 (10 ref.) **(Spa)**

DIET THERAPY
Dyskinesias and their treatment with essential fatty acids: a review. Vaddadi K. **Prostaglandins Leukot Essent Fatty Acids** 1996 Aug; 55(1–2):89–94 (44 ref.)

DRUG THERAPY
Management of motor fluctuations in Parkinson's disease. Koller WC. **Eur Neurol** 1996;36 Suppl 1:43–8 (48 ref.)
Glial cell line–derived neurotrophic factor: a novel therapeutic approach to treat motor dysfunction in Parkinson's disease. Lapchak PA, et al. **Exp Neurol** 1997 Mar;144(1):29–34 (20 ref.)
Intrathecal baclofen in cerebral palsy movement disorders. Albright AL. **J Child Neurol** 1996 Nov;11 Suppl 1:S29–35 (34 ref.)
Oral pharmacotherapy for the movement disorders of cerebral palsy. Pranzatelli MR. **J Child Neurol** 1996 Nov; 11 Suppl 1:S13–22 (102 ref.)
Antidyskinetic drug therapy for pediatric movement disorders [see comments] Pranzatelli MR. **J Child Neurol** 1996 Sep;11(5):355–69 (178 ref.) Comment in: J Child Neurol 1996 Sep;11(5):353–4.
The emerging role of clozapine in the treatment of movement disorders. Factor SA, et al. **Mov Disord** 1997 Jul; 12(4):483–96 (147 ref.)

ETIOLOGY
Rationales, values, and DSM–IV: the case of "medication–induced movement disorders". Sadler JZ. **Compr Psychiatry** 1996 Nov–Dec;37(6):441–51 (59 ref.)
The serotonin syndrome. LoCurto MJ. **Emerg Med Clin North Am** 1997 Aug;15(3):665–75 (36 ref.)
Cognitive–motor dysfunction in Parkinson's disease. Brown RG, et al. **Eur Neurol** 1996;36 Suppl 1:24–31 (38 ref.)
Clinicophysiological features of akinesia. Imai H. **Eur Neurol** 1996;36 Suppl 1:9–12 (103 ref.)
Motor fluctuations in levodopa treatment: clinical pharmacology. Stocchi F, et al. **Eur Neurol** 1996;36 Suppl 1:38–42 (38 ref.)
Glial cell line–derived neurotrophic factor: a novel therapeutic approach to treat motor dysfunction in Parkinson's disease. Lapchak PA, et al. **Exp Neurol** 1997 Mar;144(1):29–34 (20 ref.)
The reflex sympathetic dystrophy syndrome: a review with special reference to chronic pain and motor impairments. Ribbers G, et al. **Int J Rehabil Res** 1995 Dec;18(4):277–95 (78 ref.)
Episodic undulating hyperkinesias of the tongue associated with brainstem ischemia. Postert T, et al. **Mov Disord** 1997 Jul;12(4):619–21 (13 ref.)
[Late form with psychiatric presentation of Wilson's disease, with pseudo–compulsive stereotyped movements. Neuro–radiological correlations] Garnier H, et al. **Rev Neurol (Paris)** 1997 Mar;153(2):124–8 (30 ref.) (Eng. Abstr.) **(Fre)**

GENETICS
Genetics of movement disorders. Dürr A, et al. **Curr Opin Neurol** 1996 Aug;9(4):290–7 (113 ref.)
Movement disorders and mitochondrial dysfunction. Hanna MG, et al. **Curr Opin Neurol** 1997 Aug;10(4):351–6 (56 ref.)
Familial dystonia and choreoathetosis in three generations associated with bilateral striatal necrosis. Craver RD, et al. **J Child Neurol** 1996 May;11(3):185–8 (23 ref.)
Advances in the genetics of movement disorders: implications for molecular diagnosis. Gasser T. **J Neurol** 1997 Jun; 244(6):341–8 (72 ref.)
Dentatorubral and pallidoluysian atrophy (DRPLA). Clinical and neuropathological findings in genetically confirmed North American and European pedigrees. Becher MW, et al. **Mov Disord** 1997 Jul;12(4):519–30 (76 ref.)

PATHOLOGY
Familial dystonia and choreoathetosis in three generations associated with bilateral striatal necrosis. Craver RD, et al. **J Child Neurol** 1996 May;11(3):185–8 (23 ref.)

PHYSIOPATHOLOGY
What is developmental dyspraxia? Dewey D. **Brain Cogn** 1995 Dec;29(3):254–74 (80 ref.)
Serotonin, dopamine, and motor effects in Parkinson's disease. Miyawaki E, et al. **Clin Neuropharmacol** 1997 Aug; 20(4):300–10 (103 ref.)
Neurophysiology of gait disorders: present and future applications. Dietz V. **Electroencephalogr Clin Neurophysiol** 1997 Sep; 103(3):333–55 (234 ref.)
Pathophysiology of cerebellar dysmetria: the imbalance between the agonist and the antagonist electromyographic activities. Manto M. **Eur Neurol** 1996;36(6):333–7 (51 ref.)
Neuropathophysiology of movement disorders in cerebral palsy. Filloux FM. **J Child Neurol** 1996 Nov;11 Suppl 1:S5–12 (66 ref.)
Pathophysiology of movement disorders studied using PET. Leenders KL. **J Neural Transm Suppl** 1997;50:39–46 (12 ref.)
Cerebellar hypermetria: reduction in the early component of the antagonist electromyogram. Wild B, et al. **Mov Disord** 1997 Jul;12(4):604–7 (10 ref.)
Extrapyramidal symptoms during long–term treatment with antipsychotics: special focus on clozapine and D1 and D2 dopamine antagonists. Gerlach J, et al. **Neuropsychopharmacology** 1996 Mar;14(3 Suppl):35S–39S (24 ref.)
Basal ganglia and movement disorders: an update [see comments] Chesselet MF, et al. **Trends Neurosci** 1996 Oct; 19(10):417–22 (50 ref.) Comment in: Trends Neurosci 1997 Apr;20(4):152–3.
[The clinical characteristics of involuntary movements in childhood] Nomura Y. **No To Hattatsu** 1997 May; 29(3):199–205 (20 ref.) (Eng. Abstr.) **(Jpn)**
[The alien hand sign] Tanaka Y. **No To Shinkei** 1996 Mar; 48(3):229–38 (38 ref.) **(Jpn)**
[Action myoclonus, intention tremor and terminal oscillation] Ugawa Y. **No To Shinkei** 1996 Mar;48(3):203–8 (12 ref.) **(Jpn)**
[Hemichorea–hemiballism associated to basal ganglia hemorrhage in uncontrolled diabetes mellitus: report of two cases] Cava PA, et al. **Arq Neuropsiquiatr** 1996 Sep; 54(3):461–5 (14 ref.) (Eng. Abstr.) **(Por)**

PREVENTION & CONTROL
Maintaining and restoring mobility in middle and old age: the importance of the soft tissues. Buckwalter JA. **Instr Course Lect** 1997;46:459–69 (80 ref.)

RADIONUCLIDE IMAGING
Pathophysiology of movement disorders studied using PET. Leenders KL. **J Neural Transm Suppl** 1997;50:39–46 (12 ref.)

SURGERY
Surgical control of akinesia in Parkinson's disease. Shima F, et al. **Eur Neurol** 1996;36 Suppl 1:55–61 (24 ref.)
[Stereotactic treatment of movement disorders] Ostertag CB, et al. **Nervenarzt** 1997 Jun;68(6):477–84 (70 ref.) (Eng. Abstr.) **(Ger)**

THERAPY
Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. Stocchi F, et al. **Clin Neuropharmacol** 1997 Apr;20(2):95–115 (146 ref.)
[Functional neurosurgery with an implantable and programmable pulse–generator: control of involuntary movement disorders] Katayama Y. **No Shinkei Geka** 1997 Feb;25(2):101–8 (56 ref.) **(Jpn)**

MOXIBUSTION

ADVERSE EFFECTS
Skin scraping, cupping, and moxibustion that may mimic physical abuse. Look KM, et al. **J Forensic Sci** 1997 Jan; 42(1):103–5 (9 ref.)

MOYAMOYA DISEASE

Current state of study on moyamoya disease in Japan. Fukui M. **Surg Neurol** 1997 Feb;47(2):138–43 (23 ref.)

COMPLICATIONS
Characteristics of intracranial aneurysms associated with moyamoya disease. A review of 111 cases. Kawaguchi S, et al. **Acta Neurochir (Wien)** 1996;138(11):1287–94 (46 ref.)

DIAGNOSIS
[Moyamoya disease. Its clinical picture, diagnosis and new therapies] Gomes AL, et al. **Acta Med Port** 1997 May; 10(5):401–8 (26 ref.) (Eng. Abstr.) **(Por)**

EPIDEMIOLOGY
Moyamoya disease in Brazil. Minelli C, et al. **Acta Neurol Scand** 1997 Feb;95(2):125–8 (20 ref.)

NURSING
Pial synangiosis for treatment of Moyamoya syndrome in children. Hannon KE. **AORN J** 1996 Oct;64(4):540–54; quiz 557–60 (40 ref.)

PATHOLOGY
Autopsy findings in Down's syndrome with cerebrovascular disorder. Nagasaka T, et al. **Clin Neuropathol** 1996 May–Jun;15(3):145–9 (21 ref.)

PHYSIOPATHOLOGY
[A case of adult moyamoya disease showing fulminant clinical course associated with progression from unilateral to bilateral involvement] Fujiwara F, et al. **No Shinkei Geka** 1997 Jan;25(1):79–84 (15 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY
Pial synangiosis for treatment of Moyamoya syndrome in children. Hannon KE. **AORN J** 1996 Oct;64(4):540–54; quiz 557–60 (40 ref.)
Arteriovenous malformation associated with moyamoya disease. Fuse T, et al. **Childs Nerv Syst** 1996 Jul;12(7):404–8 (7 ref.)

MPGN see **GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE**

MPTP see **1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE**

MR SPECTROSCOPY see **NUCLEAR MAGNETIC RESONANCE**

MR TOMOGRAPHY see **MAGNETIC RESONANCE IMAGING**

MR TOMOGRAPHY, ECHO-PLANAR see **ECHO-PLANAR IMAGING**

MRI ANGIOGRAPHY see **MAGNETIC RESONANCE ANGIOGRAPHY**

MRI, FUNCTIONAL see **MAGNETIC RESONANCE IMAGING**

MRI SCANS see **MAGNETIC RESONANCE IMAGING**

MRNA see **RNA, MESSENGER**

MRNA, NON-POLYADENYLATED see **RNA, MESSENGER**

MRNA, POLYADENYLATED see **RNA, MESSENGER**

MSH

Melanocortin receptors: identification and characterization by melanotropic peptide agonists and antagonists. Hadley ME, et al. **Pigment Cell Res** 1996 Oct;9(5):213–34 (117 ref.)

METABOLISM

The interaction of agouti signal protein and melanocyte stimulating hormone to regulate melanin formation in mammals. Furumura M, et al. **Pigment Cell Res** 1996 Aug; 9(4):191–203 (135 ref.)

PHYSIOLOGY

Obesity, diabetes and functions for proopiomelanocortin-derived peptides. Mountjoy KG, et al. **Mol Cell Endocrinol** 1997 Apr 4;128(1–2):171–7 (51 ref.)

MSH, ALPHA see **ALPHA-MSH**

MTDNA see **DNA, MITOCHONDRIAL**

MU PHAGE see **BACTERIOPHAGE MU**

MU RECEPTORS see **RECEPTORS, OPIOID, MU**

MUC1 MUCIN see **CA-15-3 ANTIGEN**

MUCHA-HABERMANN DISEASE see **PITYRIASIS LICHENOIDES**

MUCINOSES

COMPLICATIONS

Papular mucinosis associated with human-immunodeficiency-virus infection. Azaña JM, et al. **Int J Dermatol** 1996 Sep;35(9):652–4 (15 ref.)

DIAGNOSIS

Uncommon cutaneous manifestations of lupus erythematosus. Mascaro JM, et al. **Lupus** 1997;6(2):122–31 (84 ref.)

PATHOLOGY

Nodular cutaneous lupus mucinosis: report of a case and review of previously reported cases. Kano Y, et al. **Cutis** 1996 Jun;57(6):441–4 (22 ref.)

Papular mucinosis associated with human-immunodeficiency-virus infection. Azaña JM, et al. **Int J Dermatol** 1996 Sep;35(9):652–4 (15 ref.)

PHYSIOPATHOLOGY

Self-healing cutaneous mucinosis. de las Heras ME, et al. **Dermatology** 1996;192(3):268–70 (18 ref.)

MUCINS

Breast cancer associated mucin: a review. Segal-Eiras A, et al. **Allergol Immunopathol (Madr)** 1997 Jul-Aug; 25(4):176–81 (34 ref.)

Structure, function and gene expression of epithelial mucins. Seregni E, et al. **Tumori** 1997 May-Jun;83(3):625–32 (74 ref.)

CHEMISTRY

Glycoconjugates facing the outside world. Carlstedt I, et al. **Biochem Soc Trans** 1997 Feb;25(1):214–9 (30 ref.)

Mucin glycoproteins in neoplasia. Kim YS, et al. **Glycoconj J** 1996 Oct;13(5):693–707 (196 ref.)

GENETICS

Recognition of mucin by the adhesin-flagellar system of Pseudomonas aeruginosa. Ramphal R, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 2):S170–4 (32 ref.)

Airway mucosa: secretory cells, mucus and mucin genes [see comments] Jeffery PK, et al. **Eur Respir J** 1997 Jul; 10(7):1655–62 (63 ref.) Comment in: Eur Respir J 1997 Jul;10(7):1438.

[Mucin antigen gene and host reaction] Imai H. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):594 (0 ref.) **(Jpn)**

[Mucin gene--regulation of the expression of MUC2 and MUC3 mucin gene in the airway] Ohmori H, et al. **Nippon Rinsho** 1996 Feb;54(2):411–7 (24 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Making the most of mucin: a novel target for tumor immunotherapy. Barratt-Boyes SM. **Cancer Immunol Immunother** 1996 Nov;43(3):142–51 (65 ref.)

Salivary mucins in oral mucosal defense. Slomiany BL, et al. **Gen Pharmacol** 1996 Jul;27(5):761–71 (60 ref.)

[Mucin antigen gene and host reaction] Imai H. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):594 (0 ref.) **(Jpn)**

METABOLISM

MUC1 as a cell surface and secretory component of endometrial epithelium: reduced levels in recurrent miscarriage. Aplin JD, et al. **Am J Reprod Immunol** 1996 Mar;35(3):261–6 (47 ref.)

Expression of sialosyl-T and disialosyl-T antigens in erythroid cells. Muroi K, et al. **Leuk Lymphoma** 1997 May; 25(5–6):403–14 (31 ref.)

PHYSIOLOGY

Glycoconjugates facing the outside world. Carlstedt I, et al. **Biochem Soc Trans** 1997 Feb;25(1):214–9 (30 ref.)

Mucus glycoproteins and their role in colorectal disease. Corfield AP, et al. **J Pathol** 1996 Sep;180(1):8–17 (110 ref.)

Sialomucin ligands for selectins: a new family of cell adhesion molecules. Lasky LA. **Princess Takamatsu Symp** 1994; 24:81–90 (39 ref.)

SECRETION

MUC1 as a cell surface and secretory component of endometrial epithelium: reduced levels in recurrent miscarriage. Aplin JD, et al. **Am J Reprod Immunol** 1996 Mar;35(3):261–6 (47 ref.)

THERAPEUTIC USE

Breast cancer immunotherapy: current status and future prospects. Apostolopoulos V, et al. **Immunol Cell Biol** 1996 Oct;74(5):457–64 (41 ref.)

MUCOCELE

COMPLICATIONS

Pediatric ethmoid mucoceles in cystic fibrosis: long-term follow-up of reported cases. Alvarez RJ, et al. **Ear Nose Throat J** 1997 Aug;76(8):538–9, 543–6 (17 ref.)

[Mucocele of the appendix with pseudomyxoma peritonei--a rare cause of a paraneoplastic syndrome] Pollack T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Mar;166(3):266–8 (13 ref.) **(Ger)**

ETIOLOGY

[Sinus mucoceles. Apropos of 5 cases] Kpemissi E, et al. **Ann Otolaryngol Chir Cervicofac** 1996;113(3):179–82 (18 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Dacryocystocele in an adult: endoscopic management. Bhaya M, et al. **Am J Otolaryngol** 1997 Mar-Apr;18(2):131–4 (24 ref.)

Pediatric ethmoid mucoceles in cystic fibrosis: long-term follow-up of reported cases. Alvarez RJ, et al. **Ear Nose Throat J** 1997 Aug;76(8):538–9, 543–6 (17 ref.)

MUCOCILIARY CLEARANCE

Treatment of mucociliary dysfunction [see comments] Salathe M, et al. **Chest** 1996 Oct;110(4):1048–57 (154 ref.) Comment in: Chest 1996 Oct;110(4):876.

[Tracheo bronchial mucociliary clearance] Kitada O. **Nippon Rinsho** 1997 Apr;55 Suppl 2:84–6 (9 ref.) **(Jpn)**

DRUG EFFECTS

Mucolytic and mucokinetic therapy. Wills PJ, et al. **Pulm Pharmacol** 1996 Aug;9(4):197–204 (93 ref.)

[Mucociliary clearance function and medicamentous modification] Konrad F. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Sep; 31(7):404–8 (38 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

[The significance of muco-ciliary clearance as a defense mechanism in the respiratory tract] Pietrzyk A, et al. **Pneumonol Alergol Pol** 1996;64(11–12):821–8 (25 ref.) **(Pol)**

PHYSIOLOGY

Nasal physiology: neurochemical receptors, nasal cycle, and ciliary action. Lund VJ. **Allergy Asthma Proc** 1996 Jul-Aug;17(4):179–84 (29 ref.)

Mucociliary clearance in the airways. Wanner A, et al. **Am J Respir Crit Care Med** 1996 Dec;154(6 Pt 1):1868–902 (678 ref.)

Methods for studying respiratory mucus and mucus clearance. Macchione M, et al. **Braz J Med Biol Res** 1995 Nov-Dec;28(11–12):1347–55 (30 ref.)

MUCOCILIARY TRANSPORT see **MUCOCILIARY CLEARANCE**

MUCOCUTANEOUS LYMPH NODE SYNDROME

Kawasaki disease [published erratum appears in Compr Ther 1997 Mar;23(3):223] Shulman ST, et al. **Compr Ther** 1997 Jan;23(1):13–8 (23 ref.)

Vasculitis, Kawasaki disease, and pseudovasculitis. Cuttica RJ. **Curr Opin Rheumatol** 1997 Sep;9(5):448–57 (52 ref.)

Kawasaki disease. Jacobs JC. **Curr Opin Rheumatol** 1996 Jan; 8(1):41–3 (33 ref.)

Kawasaki disease. Narayanan SN, et al. **Indian Pediatr** 1997 Feb;34(2):139–43 (11 ref.)

Kawasaki disease: update on diagnosis, treatment, and a still controversial etiology. Fischer P, et al. **Pediatr Hematol Oncol** 1996 Nov-Dec;13(6):487–501 (98 ref.)

Kawasaki syndrome. Melish ME. **Pediatr Rev** 1996 May; 17(5):153–62 (18 ref.)

[Kawasaki disease (editorial)] Pedroni E. **G Ital Cardiol** 1996 May;26(5):579–603 (215 ref.) **(Ita)**

COMPLICATIONS

An ulcerated lesion at the BCG vaccination site during the course of Kawasaki disease. Kuniyuki S, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):303–4 (15 ref.)

Peritonsillar abscess--an unusual presentation of Kawasaki disease. Ravi KV, et al. **J Laryngol Otol** 1997 Jan; 111(1):73–4 (8 ref.)

Simultaneous presentation of Kawasaki disease and toxic shock syndrome in an adolescent male [see comments] Davies HD, et al. **Pediatr Infect Dis J** 1996 Dec; 15(12):1136–8 (14 ref.) Comment in: Pediatr Infect Dis J 1997 Jun;16(6):633–4.

[Myocardial infarction in childhood] Isaka N, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):679–83 (17 ref.) **(Jpn)**

[Sequelae of Kawasaki disease] Takase B, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):406–10 (14 ref.) **(Jpn)**

DIAGNOSIS

New aspects of exanthematous diseases of childhood. Resnick SD. **Dermatol Clin** 1997 Apr;15(2):257–66 (95 ref.)

Kawasaki disease: cardiac sequelae and management. Pahl E. **Pediatr Ann** 1997 Feb;26(2):112–5 (21 ref.)

A case of relapsing Kawasaki disease and review of the literature. Dimakakos P, et al. **Vasa** 1996;25(4):317–26 (71 ref.)

[Kawasaki disease] Sekarski N, et al. **Rev Med Suisse Romande** 1996 Oct;116(10):793–9 (10 ref.) **(Fre)**

DRUG THERAPY

Kawasaki disease: cardiac sequelae and management. Pahl E. **Pediatr Ann** 1997 Feb;26(2):112–5 (21 ref.)

ETIOLOGY

The role of T cells in Kawasaki disease. de Inocencio J, et al. **Crit Rev Immunol** 1995;15(3–4):349–57 (54 ref.)

Superantigens related to Kawasaki syndrome. Leung DY. **Springer Semin Immunopathol** 1996;17(4):385–96 (47 ref.)

[Inflammatory myopathies] Espinosa E. **Rev Neurol** 1996 Nov;24(135):1376–81 (33 ref.) **(Spa)**

IMMUNOLOGY

The role of T cells in Kawasaki disease. de Inocencio J, et al. **Crit Rev Immunol** 1995;15(3–4):349–57 (54 ref.)

Superantigens related to Kawasaki syndrome. Leung DY. **Springer Semin Immunopathol** 1996;17(4):385–96 (47 ref.)

MUCOEPIDERMOID TUMOR

PATHOLOGY

Childhood bronchial mucoepidermoid tumors. Tsuchiya H, et al. **J Pediatr Surg** 1997 Jan;32(1):106–9 (30 ref.)

MUCOLIPIDOSIS

RADIOGRAPHY

Neonatal mucolipidosis II (I-cell disease) with dysharmonic epiphyseal ossification and butterfly vertebral body. Herman TE, et al. **J Perinatol** 1996 Sep-Oct;16(5):400–2 (16 ref.)

MUCOLYTIC AGENTS see **EXPECTORANTS**

MUCOPEPTIDE AMIDOHYDROLASE see **N-ACETYLMURAMOYL-L-ALANINE AMIDASE**

MUCOPOLYSACCHARIDES see **GLYCOSAMINOGLYCANS**

MUCOPOLYSACCHARIDOSES

GENETICS

Molecular basis of Zellweger syndrome, beta-ketothiolase deficiency and mucopolysaccharidoses. Orii T.

MUCOPOLYSACCHARIDOSES

Jpn J Hum Genet 1997 Mar;42(1):1–11 (63 ref.)

MUCOPOLYSACCHARIDOSIS IV

A review of Morquio syndrome. Mikles M, et al. **Am J Orthop** 1997 Aug;26(8):533–40 (31 ref.)

COMPLICATIONS

Mucopolysaccharidosis type IVA (Morquio syndrome): a clinical review. Northover H, et al. **J Inherit Metab Dis** 1996;19(3):357–65 (13 ref.)

MUCOPOLYSACCHARIDOSIS VII

VETERINARY

Gene therapy for murine mucopolysaccharidosis type VII. Sands MS, et al. **Neuromuscul Disord** 1997 Jul;7(5):352–60 (69 ref.)

MUCOR

METABOLISM

Novel microbial transformations of steroids. Madyastha KM. **Adv Exp Med Biol** 1996;405:259–70 (43 ref.)

PATHOGENICITY

Virulence factors of medically important fungi. Hogan LH, et al. **Clin Microbiol Rev** 1996 Oct;9(4):469–88 (326 ref.)

MUCORALES

[A case of pulmonary zygomycosis caused by Cunninghamella bertholletiae] Hashiguchi K, et al. **Kansenshogaku Zasshi** 1997 Mar;71(3):264–8 (14 ref.) (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

Primary cutaneous zygomycosis due to Saksenaea vasiformis and Apophysomyces elegans. Chakrabarti A, et al. **Clin Infect Dis** 1997 Apr;24(4):580–3 (29 ref.)

Zygomycosis. Elgart ML. **Dermatol Clin** 1996 Jan; 14(1):141–146 (24 ref.)

[Zygomycosis: review of 16 cases] González A, et al. **Enferm Infecc Microbiol Clin** 1996 Apr;14(4):233–9 (39 ref.) (Eng. Abstr.) **(Spa)**

MUCORMYCOSIS

Zygomycosis. Elgart ML. **Dermatol Clin** 1996 Jan; 14(1):141–146 (24 ref.)

[A case of pulmonary zygomycosis caused by Cunninghamella bertholletiae] Hashiguchi K, et al. **Kansenshogaku Zasshi** 1997 Mar;71(3):264–8 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Pulmonary mucormycosis: a case report and review of the literature] Escobar Sacristán JA, et al. **Arch Bronconeumol** 1996 Jan;32(1):47–9 (42 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Recovery from rhinocerebral mucormycosis with carotid artery occlusion: a pediatric case and review of the literature. Shah PD, et al. **Pediatr Infect Dis J** 1997 Jan; 16(1):68–71 (27 ref.)

DIAGNOSIS

Disseminated mucormycosis presenting with lower extremity weakness. von Pohle WR. **Eur Respir J** 1996 Aug; 9(8):1751–3 (10 ref.)

Chronic rhinocerebral mucormycosis. Harril WC, et al. **Laryngoscope** 1996 Oct;106(10):1292–7 (23 ref.)

Pulmonary mucormycosis diagnosed by bronchoalveolar lavage: a case report and review of the literature. al-Abbadi MA, et al. **Pediatr Pulmonol** 1997 Mar;23(3):222–5 (14 ref.)

Pulmonary mucormycosis. Murphy RA, et al. **Semin Roentgenol** 1996 Jan;31(1):83–7 (28 ref.)

DRUG THERAPY

Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. Gonzalez CE, et al. **Clin Infect Dis** 1997 Feb;24(2):192–6 (37 ref.)

Nonfatal gastric mucormycosis in a renal transplant recipient. Martinez EJ, et al. **South Med J** 1997 Mar;90(3):341–4 (39 ref.)

EPIDEMIOLOGY

[Zygomycosis: review of 16 cases] González A, et al. **Enferm Infecc Microbiol Clin** 1996 Apr;14(4):233–9 (39 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Pulmonary mucormycosis in diabetic renal allograft recipients. Latif S, et al. **Am J Kidney Dis** 1997 Mar; 29(3):461–4 (26 ref.)

Cutaneous mucormycosis with subsequent visceral dissemination in a child with neutropenia: a case report and review of the pediatric literature. Wirth F, et al. **J Am Acad Dermatol** 1997 Feb;36(2 Pt 2):336–41 (58 ref.)

[Mucormycosis–actinomycosis and caseous dental sinusitis associated with sinusal foreign body] Braun JJ, et al. **Ann Otolaryngol Chir Cervicofac** 1996;113(5):289–93 (22 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Primary cutaneous zygomycosis due to Saksenaea vasiformis and Apophysomyces elegans. Chakrabarti A, et al. **Clin Infect Dis** 1997 Apr;24(4):580–3 (29 ref.)

MUCOSAL DISEASE VIRUS see **DIARRHEA VIRUS, BOVINE VIRAL**

MUCOSAL IMMUNITY see **IMMUNITY, MUCOSAL**

MUCOUS MEMBRANE

DRUG EFFECTS

Mucosal protectants and their application for head and neck chemoirradiation. Marks JE. **Curr Opin Oncol** 1997 May; 9(3):267–73 (35 ref.)

IMMUNOLOGY

[Mucosal immune system and mucosal vaccine] Yanagita M, et al. **Nippon Rinsho** 1997 Feb;55(2):492–501 (38 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

M cells as portals of infection: clinical and pathophysiological aspects. Fujimura Y, et al. **Infect Agents Dis** 1996 Jun; 5(3):144–56 (108 ref.)

MUCOVISCIDOSIS see **CYSTIC FIBROSIS**

MUCUS

Airway mucosa: secretory cells, mucus and mucin genes [see comments] Jeffery PK, et al. **Eur Respir J** 1997 Jul; 10(7):1655–62 (63 ref.) Comment in: Eur Respir J 1997 Jul;10(7):1438.

[Gastrointestinal mucus] Paerregaard A. **Ugeskr Laeger** 1996 Sep 23;158(39):5423–7 (40 ref.) (Eng. Abstr.) **(Dan)**

CHEMISTRY

Role of CFTR gene in the regulation of airway mucus composition. Luisetti M. **Monaldi Arch Chest Dis** 1996 Aug; 51(4):329–30 (7 ref.)

PHYSIOLOGY

Methods for studying respiratory mucus and mucus clearance. Macchione M, et al. **Braz J Med Biol Res** 1995 Nov–Dec;28(11–12):1347–55 (30 ref.)

[Mucus and bicarbonate secretion in the gastric mucosal barrier] Arroyo Villarino MT, et al. **Gastroenterol Hepatol** 1997 May;20 Suppl 2:4–11 (51 ref.) **(Spa)**

SECRETION

Lung mucus: a clinician's view. Kim WD. **Eur Respir J** 1997 Aug;10(8):1914–7 (25 ref.)

Recent aspects of the regulation of intestinal mucus secretion. Laboisse C, et al. **Proc Nutr Soc** 1996 Mar;55(1B):259–64 (18 ref.)

[Pharmacology of airway inflammation—special reference to hypersecretion of the mucous] Miyata K, et al. **Nippon Yakurigaku Zasshi** 1996 Sep;108(3):144–6 (0 ref.) **(Jpn)**

MUD BATHS see **MUD THERAPY**

MUD THERAPY

METHODS

[The current aspects of the pelotherapy of patients with rheumatoid arthritis] Sidorov VD, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1997 May–Jun; (3):42–5 (45 ref.) **(Rus)**

MUERTO CANYON VIRUS see **HANTAVIRUS**

MULLERIAN DUCTS

Immunoreactive inhibin, müllerian inhibitory substance, and activin as biochemical markers for juvenile granulosa cell tumors. Silverman LA, et al. **J Pediatr** 1996 Dec; 129(6):918–21 (20 ref.)

ABNORMALITIES

Clinical aspects and molecular genetics of the persistent müllerian duct syndrome. Josso N, et al. **Clin Endocrinol (Oxf)** 1997 Aug;47(2):137–44 (44 ref.)

Müllerian agenesis: an update. Lindenman E, et al. **Obstet Gynecol** 1997 Aug;90(2):307–12 (21 ref.)

Surgical management of persistent müllerian duct syndrome. Vandersteen DR, et al. **Urology** 1997 Jun;49(6):941–5 (26 ref.)

[The persistent müllerian duct syndrome with transverse testicular ectopia. A hypothesis on the role of müllerian inhibiting factor in the process of testicular migration] Asero L, et al. **Pediatr Med Chir** 1997 May–Jun;19(3):223–5 (14 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Surgical management of persistent müllerian duct syndrome. Vandersteen DR, et al. **Urology** 1997 Jun;49(6):941–5 (26 ref.)

MULTICENTER STUDIES

see related
CLINICAL TRIALS, PHASE III

On the value of large multicenter drug intervention trials. Dernol P, et al. **Arzneimittelforschung** 1997 Aug; 47(8):985–9 (34 ref.)

The role of multi-centre cohort studies in studying the relation between diet and cancer. Kaaks R, et al. **Cancer Lett** 1997 Mar 19;114(1–2):263–70 (30 ref.)

Clinical trials with implications regarding heart failure therapy. Young JB. **Curr Opin Cardiol** 1997 Jul; 12(4):407–17 (20 ref.)

The multicentre trial philosophy in stress echocardiography: lessons learned from the EPIC study. EPIC-EDIC Study Project.Echo Persantine International Cooperative Study. Echo-Dobutamine International Cooperative Study. Picano E, et al. **Eur Heart J** 1995 Oct;16 Suppl J:2–4 (21 ref.)

The role of the clinical research coordinator in multicenter clinical trials. Pelke S, et al. **J Obstet Gynecol Neonatal Nurs** 1997 May–Jun; 26(3):279–85 (14 ref.)

MULTICENTER TRIALS see **MULTICENTER STUDIES**

MULTICULTURALISM see **CULTURAL DIVERSITY**

MULTIDISCIPLINARY PAIN CENTERS see **PAIN CLINICS**

MULTIDRUG RESISTANCE see **DRUG RESISTANCE, MULTIPLE**

MULTIDRUG RESISTANCE GENE see **GENES, MDR**

MULTIDRUG TRANSPORTER see **P-GLYCOPROTEIN**

MULTIENZYME COMPLEXES

[World smallest motor, ATP synthase] Yoshida M, et al. **Tanpakushitsu Kakusan Koso** 1997 Jul;42(9):1396–406 (21 ref.) **(Jpn)**

CHEMISTRY

Protein and gene structures of 20S and 26S proteasomes. Tanaka K, et al. **Adv Exp Med Biol** 1996;389:187–95 (32 ref.)

Structure and function of the 20S proteasome and of its regulatory complexes. Lupas A, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:515–24 (68 ref.)

Catalytic mechanism of the 20S proteasome of Thermoplasma acidophilum revealed by X-ray crystallography. Stock D, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:525–32 (54 ref.)

Lipoylation of acyltransferase components of 2-oxo acid dehydrogenase complexes. Quinn J. **Methods Enzymol** 1997;279:193–202 (25 ref.)

Biochemical properties of insect and crustacean proteasomes. Mykles DL. **Mol Biol Rep** 1997 Mar;24(1–2):133–8 (34 ref.)

Structure and structure formation of the 20S proteasome. Schmidt M, et al. **Mol Biol Rep** 1997 Mar;24(1–2):103–12 (47 ref.)

[Organization of biochemical systems] Poglazov BF. **Biokhimiia** 1996 Nov;61(11):1941–7 (41 ref.) (Eng. Abstr.) **(Rus)**

DEFICIENCY

Peroxisomal bifunctional enzyme deficiency: serial neurophysiological examinations of a case. Akaboshi S, et al. **Brain Dev** 1997 Jun;19(4):295–9 (24 ref.)

GENETICS

The genetics of proteasomes and antigen processing. Monaco JJ, et al. **Annu Rev Genet** 1995;29:729–54 (143 ref.)

Metabolic engineering of polyketide biosynthesis. Hershberger CL. **Curr Opin Biotechnol** 1996 Oct;7(5):560–2 (17 ref.)

Fatty acid mitochondrial beta-oxidation and hypoglycaemia in children. Taroni F, et al. **Curr Opin Neurol** 1996 Dec; 9(6):477–85 (88 ref.)

Evolution of the proteasome components. Hughes AL. **Immunogenetics** 1997;46(2):82–92 (48 ref.)

The ovine model of neuronal ceroid lipofuscinosis (NCL): its contribution to understanding the pathogenesis of Batten disease. Jolly RD. **Neuropediatrics** 1997 Feb;28(1):60–2 (30 ref.)

[Origin and evolution of the proteasome subunit genes, LMP2 and LMP7] Nonaka M, et al. **Seikagaku** 1996 Sep;

68(9):1559–63 (13 ref.) **(Jpn)**
[Controlled biosynthesis of polyketide antibiotics] Kuczek K, et al. **Postepy Biochem** 1996;42(3):276–83 (61 ref.) **(Pol)**

IMMUNOLOGY

Proteasomes and antigen processing. Tanaka K, et al. **Adv Immunol** 1997;64:1–38 (123 ref.)
Functions of the proteasome in antigen presentation. Goldberg AL, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:479–90 (74 ref.)
Antigen processing by proteasomes: insights into the molecular basis of crypticity. Djaballah H. **Mol Biol Rep** 1997 Mar;24(1–2):63–7 (44 ref.)
Biochemistry and autoimmune response to the 2-oxoacid dehydrogenase complexes in primary biliary cirrhosis. Bassendine MF, et al. **Semin Liver Dis** 1997 Feb;17(1):49–60 (99 ref.)

ISOLATION & PURIFICATION

Quantitative two-dimensional gel electrophoresis: from proteins to proteomes. Dunn MJ. **Biochem Soc Trans** 1997 Feb;25(1):248–54 (41 ref.)

METABOLISM

The proteasome and protein degradation in yeast. Hilt W, et al. **Adv Exp Med Biol** 1996;389:197–202 (28 ref.)
Proposed role of a gamma-interferon inducible proteasome-regulator in antigen presentation. Realini CA, et al. **Adv Exp Med Biol** 1996;389:51–61 (40 ref.)
The ubiquitin-proteasome pathway: review of a novel intracellular mechanism of muscle protein breakdown during sepsis and other catabolic conditions. Hasselgren PO, et al. **Ann Surg** 1997 Mar;225(3):307–16 (59 ref.)
Structure and functions of the 20S and 26S proteasomes. Coux O, et al. **Annu Rev Biochem** 1996;65:801–47 (287 ref.)
The proteasome: a macromolecular assembly designed to confine proteolysis to a nanocompartment. Baumeister W, et al. **Biol Chem** 1997 Mar–Apr;378(3–4):121–30 (92 ref.)
New insights into the mechanisms and importance of the proteasome in intracellular protein degradation. Goldberg AL, et al. **Biol Chem** 1997 Mar–Apr;378(3–4):131–40 (51 ref.)
Role of the ubiquitin/proteasome system in regulated protein degradation in Saccharomyces cerevisiae. Smith SE, et al. **Biol Chem** 1996 Jul–Aug;377(7–8):437–46 (107 ref.)
Proteasome inhibitors and antigen presentation. Bogyo M, et al. **Biopolymers** 1997;43(4):269–80 (73 ref.)
Role of lipid synthesis, chaperone proteins and proteasomes in the assembly and secretion of apoprotein B-containing lipoproteins from cultured liver cells. Ginsberg HN. **Clin Exp Pharmacol Physiol** 1997 May;24(5):A29–32 (61 ref.)
Catalytic mechanism of the 20S proteasome of Thermoplasma acidophilum revealed by X-ray crystallography. Stock D, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:525–32 (54 ref.)
The cellulosome: an exocellular, multiprotein complex specialized in cellulose degradation. Béguin P, et al. **Crit Rev Biochem Mol Biol** 1996 Jun;31(3):201–36 (177 ref.)
Go outside and see the proteasome. Protein degradation. Lord JM. **Curr Biol** 1996 Sep 1;6(9):1067–9 (13 ref.)
Metabolic engineering of polyketide biosynthesis. Hershberger CL. **Curr Opin Biotechnol** 1996 Oct;7(5):560–2 (17 ref.)
The AMP-activated protein kinase--fuel gauge of the mammalian cell? Hardie DG, et al. **Eur J Biochem** 1997 Jun 1;246(2):259–73 (138 ref.)
Peptide antigen production by the proteasome: complexity provides efficiency. Groettrup M, et al. **Immunol Today** 1996 Sep;17(9):429–35 (75 ref.)
Lipoate addition to acyltransferases of alpha-keto acid dehydrogenase complexes and H-protein of glycine cleavage system. Fujiwara K, et al. **Methods Enzymol** 1997; 279:184–93 (23 ref.)
Prosomes (proteasomes) changes during differentiation are related to the type of inducer. Bureau JP, et al. **Mol Biol Rep** 1997 Mar;24(1–2):57–62 (65 ref.)
Structural and functional properties of proteasome activator PA28. Kuehn L, et al. **Mol Biol Rep** 1997 Mar; 24(1–2):89–93 (39 ref.)
Proteasome (prosome) associated endonuclease activity. Petit F, et al. **Mol Biol Rep** 1997 Mar;24(1–2):113–7 (39 ref.)
Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. Mitch WE, et al. **N Engl J Med** 1996 Dec 19;335(25):1897–905 (70 ref.)
Protein degradation by proteasomes: molecular mechanisms of muscle catabolism [editorial] Mitch WE, et al. **Nephrol Dial Transplant** 1997 Jan;12(1):13–5 (15 ref.)

PHYSIOLOGY

Physiological functions of proteasomes in ascidian fertilization and embryonic cell cycle. Sawada H, et al. **Adv Exp Med Biol** 1996;389:229–32 (12 ref.)
Succinate: quinone oxidoreductases. Variations on a conserved theme. Hägerhäll C. **Biochim Biophys Acta** 1997 Jun 13;1320(2):107–41 (188 ref.)
Structure and function of the 20S proteasome and of its regulatory complexes. Lupas A, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:515–24 (68 ref.)
Proteasome and myogenesis. Gardrat F, et al. **Mol Biol Rep** 1997 Mar;24(1–2):77–81 (28 ref.)
Regulation of lipid biosynthesis by the AMP-activated protein kinase and its role in the hepatocellular response to stress. Corton JM, et al. **Prog Liver Dis** 1996;14:69–99 (133 ref.)
Proteasomes: destruction as a programme. Hilt W, et al. **Trends Biochem Sci** 1996 Mar;21(3):96–102 (48 ref.)
[Degradation mechanism of cell cycle factors by the proteasome] Tsurumi C, et al. **Nippon Rinsho** 1996 Mar; 54(3):861–9 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Proteolysis and cell cycle regulation] Tsurumi C, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1813–9 (19 ref.) **(Jpn)**

ULTRASTRUCTURE

The proteasome. Baumeister W, et al. **Curr Opin Struct Biol** 1997 Apr;7(2):273–8 (52 ref.)

MULTIFACTORIAL CAUSALITY see **CAUSALITY**

MULTIFUNCTIONAL ENZYMES see **MULTIENZYME COMPLEXES**

MULTIGENE FAMILY

see related
REPETITIVE SEQUENCES, NUCLEIC ACID

Transforming growth factor-beta system and its regulation by members of the steroid-thyroid hormone superfamily. Koli K, et al. **Adv Cancer Res** 1996;70:63–94 (133 ref.)
The metzincin-superfamily of zinc-peptidases. Bode W, et al. **Adv Exp Med Biol** 1996;389:1–11 (49 ref.)
Novel members of mammalian kexin family proteases, pace 4C, pace 4D, PC 7A and PC 7B. Matsuda Y, et al. **Adv Exp Med Biol** 1996;389:63–71 (15 ref.)
Regulation of programmed cell death by interleukin-1 beta-converting enzyme family of proteases. Miura M, et al. **Adv Exp Med Biol** 1996;389:165–72 (57 ref.)
Protein and gene structures of 20S and 26S proteasomes. Tanaka K, et al. **Adv Exp Med Biol** 1996;389:187–95 (32 ref.)
De novo interstitial tandem duplication of chromosome 4(q21–q28). Navarro EG, et al. **Am J Med Genet** 1996 Mar 29;62(3):297–9 (12 ref.)
Interstitial duplication 8q22–q24: report of a case proven by FISH with mapped cosmid probes. Wakui K, et al. **Am J Med Genet** 1996 Oct 2;65(1):36–9 (20 ref.)
De novo direct duplication 7p (p11.2-->pter) in an Arab child with MCA/MR syndrome: trisomy 7p a delineated syndrome? Redha MA, et al. **Ann Genet** 1996;39(1):5–9 (18 ref.)
Comparison of lantibiotic gene clusters and encoded proteins. Siezen RJ, et al. **Antonie Van Leeuwenhoek** 1996 Feb; 69(2):171–84 (73 ref.)
Structure-function relationships of the PEA3 group of Ets-related transcription factors. de Launoit Y, et al. **Biochem Mol Med** 1997 Aug;61(2):127–35 (47 ref.)
Why are Hox genes clustered? Mann RS. **Bioessays** 1997 Aug;19(8):661–4 (36 ref.)
Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Rebbeck TR. **Cancer Epidemiol Biomarkers Prev** 1997 Sep;6(9):733–43 (121 ref.)
Multigenic control of skin tumour development in mice. Nagase H, et al. **Ciba Found Symp** 1996;197:156–68; discussion 168–80 (85 ref.)
Complex multigene family of functionally distinct Hsp70s of yeast. Craig E, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:441–9 (59 ref.)
Gen(om)e duplications in the evolution of early vertebrates. Sidow A. **Curr Opin Genet Dev** 1996 Dec;6(6):715–22 (39 ref.)
The EGFR gene family in embryonic cell activities. Adamson ED, et al. **Curr Top Dev Biol** 1997;35:71–120 (321 ref.)
Transcription factors of the bHLH and LIM families: synergistic mediators of T cell acute leukemia? Baer R, et al. **Curr Top Microbiol Immunol** 1997;220:55–65 (58 ref.)
The tetraspanin superfamily: molecular facilitators. Maecker HT, et al. **FASEB J** 1997 May;11(6):428–42 (140 ref.)
Regulation of catalases in Arabidopsis. McClung CR. **Free Radic Biol Med** 1997;23(3):489–96 (66 ref.)
Evolution of a fungal regulatory gene family: the Zn(II)2Cys6 binuclear cluster DNA binding motif. Todd RB, et al. **Fungal Genet Biol** 1997 Jun;21(3):388–405 (159 ref.)
Emergence of the immunoglobulin family: conservation in protein sequence and plasticity in gene organization. Marchalonis JJ, et al. **Glycobiology** 1996 Oct;6(7):657–63 (60 ref.)
Immunoglobulin evolution, 30 years on. Steiner LA. **Glycobiology** 1996 Oct;6(7):649–56 (90 ref.)
The retinoblastoma gene family and its role in proliferation, differentiation and development. De Luca A, et al. **Histol Histopathol** 1996 Oct;11(4):1029–34 (65 ref.)
Regulation of hematopoietic cell proliferation and differentiation by the myb oncogene family of transcription factors. Golay J, et al. **Int J Clin Lab Res** 1996;26(1):24–32 (95 ref.)
Chemokines: a superfamily of chemotactic cytokines. Sozzani S, et al. **Int J Clin Lab Res** 1996;26(2):69–82 (166 ref.)
A myosin family reunion. Sellers JR, et al. **J Muscle Res Cell Motil** 1996 Feb;17(1):7–22 (112 ref.)
The Sec1 family: a novel family of proteins involved in synaptic transmission and general secretion. Halachmi N, et al. **J Neurochem** 1996 Mar;66(3):889–97 (51 ref.)
Transcriptional regulation of chemokine gene expression in astrocytes. Majumder S, et al. **J Neurosci Res** 1996 Sep 15;45(6):758–69 (79 ref.)
Functional relationships among ETS gene family members. Papas TS, et al. **Leukemia** 1997 Apr;11 Suppl 3:557–66 (49 ref.)
neurogenins, a novel family of atonal-related bHLH transcription factors, are putative mammalian neuronal determination genes that reveal progenitor cell heterogeneity in the developing CNS and PNS. Sommer L, et al. **Mol Cell Neurosci** 1996;8(4):221–41 (51 ref.)
The Escherichia coli phage-shock-protein (psp) operon. Model P, et al. **Mol Microbiol** 1997 Apr;24(2):255–61 (50 ref.)
Expression of the calcitonin gene family in medullary thyroid carcinoma. Schifter S. **Peptides** 1997;18(2):307–17 (151 ref.)
The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Mackenzie PI, et al. **Pharmacogenetics** 1997 Aug;7(4):255–69 (58 ref.)
Microdeletion and microduplication syndromes. Malcolm S. **Prenat Diagn** 1996 Dec;16(13):1213–9 (57 ref.)
Glutathione-independent prostaglandin D synthase as a lead molecule for designing new functional proteins. Toh H, et al. **Protein Eng** 1996 Dec;9(12):1067–82 (51 ref.)
The growing phospholipase A2 superfamily of signal transduction enzymes. Dennis EA. **Trends Biochem Sci** 1997 Jan;22(1):1–2 (26 ref.)
The aconitase family: three structural variations on a common theme. Gruer MJ, et al. **Trends Biochem Sci** 1997 Jan; 22(1):3–6 (20 ref.)
The protein kinases of budding yeast: six score and more. Hunter T, et al. **Trends Biochem Sci** 1997 Jan;22(1):18–22 (39 ref.)
The coevolution of gene family trees. Fryxell KJ. **Trends Genet** 1996 Sep;12(9):364–9 (56 ref.)
Chromosomal duplication and the emergence of the adaptive immune system. Kasahara M, et al. **Trends Genet** 1997 Mar; 13(3):90–2 (22 ref.)
Extra specificity from extradenticle: the partnership between HOX and PBX/EXD homeodomain proteins [published erratum appears in Trends Genet 1996 Aug;12(8):328] Mann RS, et al. **Trends Genet** 1996 Jul;12(7):258–62 (52 ref.)
[ADAM family proteins and cell fusion] Endo T. **Seikagaku** 1996 Aug;68(8):1453–8 (17 ref.) **(Jpn)**
[Ancient chromosomal duplication involving the major histocompatibility complex] Kasahara M. **Seikagaku** 1996 Nov;68(11):1717–21 (15 ref.) **(Jpn)**
[Rearrangement of the mitochondrial DNA in Kearns-Sayre syndrome: is it necessary to differentiate deletions from duplications or polymerization?] Barrientos A, et al. **Neurologia** 1996 Aug–Sep;11(7):257–60 (10 ref.) **(Spa)**

GENETICS

Metabolic pathway gene clusters in filamentous fungi. Keller NP, et al. **Fungal Genet Biol** 1996 Feb;21(1):17–29 (93 ref.)

IMMUNOLOGY

The natural killer gene complex: a genetic basis for understanding natural killer cell function and innate immunity. Brown MG, et al. **Immunol Rev** 1997 Feb; 155:53–65 (135 ref.)
Specificity and function of immunoglobulin superfamily NK cell inhibitory and stimulatory receptors. Colonna M. **Immunol Rev** 1997 Feb;155:127–33 (55 ref.)
The Ly-49 family: genes, proteins and recognition of class I MHC. Takei F, et al. **Immunol Rev** 1997 Feb;155:67–77 (55 ref.)
Generation of diversity in mammalian gut-associated lymphoid tissues: restricted V gene usage does not preclude complex V gene organization. Reynaud CA, et al. **J Immunol** 1997 Oct 1;159(7):3093–5 (18 ref.)
The VH and CH immunoglobulin genes of swine: implications for repertoire development. Butler JE, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):7–17 (20 ref.)

MULTI-HOSPITAL INFORMATION SYSTEMS see **HOSPITAL INFORMATION SYSTEMS**

MULTI-INFARCT DEMENTIA see **DEMENTIA, MULTI-INFARCT**

MULTILINGUALISM

The cognitive assessment of limited-English-proficient children: current problems and practical recommendations. Lopez MC, et al. **Cult Divers Ment Health** 1997;3(2):117–30 (65 ref.)

MULTIMEDIA

Filmless multimedia display following cardiac catheterization. Mathewson JW. **Cathet Cardiovasc Diagn** 1997 Aug;41(4):456–66 (18 ref.)

MULTIMODAL TREATMENT

MULTIMODAL TREATMENT see **COMBINED MODALITY THERAPY**

MULTINUCLEATED GIANT CELLS see **GIANT CELLS**

MULTIPARITY see **PARITY**

MULTIPLE CAUSATION see **CAUSALITY**

MULTIPLE CHEMICAL SENSITIVITY

see related
PERSIAN GULF SYNDROME

Multiple chemical sensitivities syndrome: a review [see comments] Brod BA. **Am J Contact Dermat** 1996 Dec; 7(4):202–11 (66 ref.) Comment in: Am J Contact Dermat 1996 Dec;7(4):199–201.

COMPLICATIONS

Multiple chemical sensitivity syndrome and porphyria. A note of caution and concern. Hahn M, et al.
Arch Intern Med 1997 Feb 10;157(3):281–5 (35 ref.)

DIAGNOSIS

Multiple chemical sensitivity. A view from under the grassroots. von Mühlendahl KE. **Eur J Pediatr** 1997 Jun; 156(6):499–500 (6 ref.)

ETIOLOGY

Effects of combined exposure to noise and toxic substances—critical review of the literature. Cary R, et al. **Ann Occup Hyg** 1997 Aug;41(4):455–65 (19 ref.)

Neurogenic inflammation: with additional discussion of central and perceptual integration of nonneurogenic inflammation. Bascom R, et al. **Environ Health Perspect** 1997 Mar;105 Suppl 2:531–7 (43 ref.)

Testing the neural sensitization and kindling hypothesis for illness from low levels of environmental chemicals. Bell IR, et al. **Environ Health Perspect** 1997 Mar;105 Suppl 2:539–47 (103 ref.)

Individual differences in neural sensitization and the role of context in illness from low-level environmental chemical exposures. Bell IR, et al. **Environ Health Perspect** 1997 Mar; 105 Suppl 2:457–66 (109 ref.)

Human drug discrimination and multiple chemical sensitivity: caffeine exposure as an experimental model. Eissenberg T, et al. **Environ Health Perspect** 1997 Mar;105 Suppl 2:509–13 (21 ref.)

Chemical sensitivity: the scientific literature. Fiedler N, et al. **Environ Health Perspect** 1997 Mar;105 Suppl 2:409–15 (39 ref.)

Psychophysiological hypotheses regarding multiple chemical sensitivity syndrome. Lehrer PM.
Environ Health Perspect 1997 Mar;105 Suppl 2:479–83 (55 ref.)

Hypothesis for induction and propagation of chemical sensitivity based on biopsy studies. Meggs WJ.
Environ Health Perspect 1997 Mar;105 Suppl 2:473–8 (21 ref.)

Toxicant-induced loss of tolerance—an emerging theory of disease? Miller CS. **Environ Health Perspect** 1997 Mar;105 Suppl 2:445–53 (34 ref.)

Pavlovian conditioning and multiple chemical sensitivity. Siegel S, et al. **Environ Health Perspect** 1997 Mar;105 Suppl 2:521–6 (52 ref.)

Potential role of stress and sensitization in the development and expression of multiple chemical sensitivity. Sorg BA, et al. **Environ Health Perspect** 1997 Mar;105 Suppl 2:467–71 (46 ref.)

Experimental strategies for research on multiple chemical sensitivity. Weiss B. **Environ Health Perspect** 1997 Mar;105 Suppl 2:487–94 (23 ref.)

Low-level chemical sensitivity: current perspectives. Ashford NA, et al. **Int Arch Occup Environ Health** 1996; 68(6):367–76 (28 ref.)

A case of drug eruption due to simultaneous sensitization with three different kinds of drugs. Nagayama H, et al. **J Dermatol** 1996 Dec;23(12):899–901 (9 ref.)

Multiple chemical sensitivity: state of the art symposium. The role of chemical allergens. Bernstein DI.
Regul Toxicol Pharmacol 1996 Aug;24(1 Pt 2):S28–31 (18 ref.)

[Multiple chemical sensitivity (MCS)—the so-called chemical multiple hypersensitivity] Wolf C.
Versicherungsmedizin 1996 Oct 1;48(5):175–8 (25 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

A behavior-genetic approach to multiple chemical sensitivity. Newlin DB. **Environ Health Perspect** 1997 Mar; 105 Suppl 2:505–8 (26 ref.)

PATHOLOGY

Hypothesis for induction and propagation of chemical sensitivity based on biopsy studies. Meggs WJ.
Environ Health Perspect 1997 Mar;105 Suppl 2:473–8 (21 ref.)

PHYSIOPATHOLOGY

Testing the neural sensitization and kindling hypothesis for illness from low levels of environmental chemicals. Bell IR, et al. **Environ Health Perspect** 1997 Mar;105 Suppl 2:539–47 (103 ref.)

Neural sensitization and physiological markers in multiple chemical sensitivity. Bell IR, et al.
Regul Toxicol Pharmacol 1996 Aug;24(1 Pt 2):S39–47 (74 ref.)

PSYCHOLOGY

Human drug discrimination and multiple chemical sensitivity: caffeine exposure as an experimental model. Eissenberg T, et al. **Environ Health Perspect** 1997 Mar;105 Suppl 2:509–13 (21 ref.)

Psychophysiological hypotheses regarding multiple chemical sensitivity syndrome. Lehrer PM.
Environ Health Perspect 1997 Mar;105 Suppl 2:479–83 (55 ref.)

A behavior-genetic approach to multiple chemical sensitivity. Newlin DB. **Environ Health Perspect** 1997 Mar; 105 Suppl 2:505–8 (26 ref.)

Pavlovian conditioning and multiple chemical sensitivity. Siegel S, et al. **Environ Health Perspect** 1997 Mar;105 Suppl 2:521–6 (52 ref.)

Cognitive and psychomotor performance tests and experiment design in multiple chemical sensitivity. Wetherell A. **Environ Health Perspect** 1997 Mar;105 Suppl 2:495–503 (45 ref.)

Multiple chemical sensitivities or idiopathic environmental intolerances: psychophysiologic foundation of knowledge for a psychogenic explanation [editorial; comment] Staudenmayer H. **J Allergy Clin Immunol** 1997 Apr; 99(4):434–7 (23 ref.) Comment on: J Allergy Clin Immunol 1997 Apr;99(4):438–42. Comment on: J Allergy Clin Immunol 1997 Apr;99(4):570–4.

MULTIPLE ENDOCRINE NEOPLASIA

Recent advances in multiple endocrine neoplasia syndromes. Gardner DG. **Adv Intern Med** 1997;42:597–627 (127 ref.)

Endocrinopathy and ectopic hormones in malignancy. Keffer JH. **Hematol Oncol Clin North Am** 1996 Aug;10(4):811–23 (52 ref.)

Parathyroid glands and the multiple endocrine neoplasia syndromes and familial hypocalciuric hypercalcemia. Herfarth KK, et al. **Semin Surg Oncol** 1997 Mar–Apr; 13(2):114–24 (57 ref.)

DIAGNOSIS

Clinical and molecular aspects of multiple endocrine neoplasia. Wick MJ. **Clin Lab Med** 1997 Mar;17(1):39–57 (59 ref.)

Genetic testing in presymptomatic diagnosis of multiple endocrine neoplasia. Calender A, et al. **Horm Res** 1997; 47(4–6):199–210 (74 ref.)

GENETICS

Clinical and molecular aspects of multiple endocrine neoplasia. Wick MJ. **Clin Lab Med** 1997 Mar;17(1):39–57 (59 ref.)

Familial neuroendocrine tumors as a model of hereditary cancer. Anderson RJ, et al. **Curr Opin Oncol** 1997 Jan; 9(1):45–54 (85 ref.)

Genetic testing in presymptomatic diagnosis of multiple endocrine neoplasia. Calender A, et al. **Horm Res** 1997; 47(4–6):199–210 (74 ref.)

MULTIPLE ENDOCRINE NEOPLASIA TYPE 1

Management of patients and subjects at risk for multiple endocrine neoplasia type 1: MEN 1. GENEM 1. Groupe d'Etude des Néoplasies Endocriniennes Multiples de type 1. Chanson P, et al. **Horm Res** 1997;47(4–6):211–20 (63 ref.)

[New etiopathogenic, clinical and therapeutic findings in multiple endocrine neoplasia type 1] Tomassetti P, et al. **Minerva Gastroenterol Dietol** 1996 Sep;42(3):133–43 (53 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

Multiple endocrine neoplasia type 1 associated with spinal ependymoma. Kato H, et al. **Intern Med** 1996 Apr; 35(4):285–9 (18 ref.)

DIAGNOSIS

Gastrointestinal endocrine tumours. Gastrinoma. Jensen RT. **Baillieres Clin Gastroenterol** 1996 Dec;10(4):603–43 (220 ref.)

DRUG THERAPY

Surgical versus medical management of multiple endocrine neoplasia (MEN) type I. Veldhuis JD, et al.
J Clin Endocrinol Metab 1997 Feb;82(2):357–64 (49 ref.)

GENETICS

Tracking the MEN1 gene. Ebrahimi SA, et al.
Am J Surg 1997 Sep;174(3):266–70 (23 ref.)

Multiple endocrine neoplasia type I. Clinical genetics and diagnosis. Skogseid B. **Cancer Treat Res** 1997;89:383–406 (64 ref.)

Molecular genetics of hyperparathyroid disease. Tominaga Y, et al. **Curr Opin Nephrol Hypertens** 1996 Jul;5(4):336–41 (55 ref.)

Multiple endocrine neoplasia type 1 and the search for the genetic trigger. Farnebo F, et al. **Horm Res** 1997; 47(4–6):179–84 (23 ref.)

[Characteristic pathological associations in multiple endocrine neoplasia type 1] Chigot JP, et al.
Presse Med 1996 Sep 21;25(27):1229–33 (13 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

[Pathologic study with immunohistochemistry of 61 pancreatic endocrine tumors in 16 patients suffering from multiple endocrine neoplasia type I (MEN I). Review of the literature] Heymann MF, et al. **Ann Pathol** 1996; 16(3):167–73 (45 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

[Multiple endocrine neoplasia] Matsuzaki K.
Ryoikibetsu Shokogun Shirizu 1996;(15):22–5 (7 ref.) **(Jpn)**

SURGERY

Multiple endocrine neoplasia type I. Surgical therapy. Thompson NW. **Cancer Treat Res** 1997;89:407–19 (46 ref.)

Surgical versus medical management of multiple endocrine neoplasia (MEN) type I. Veldhuis JD, et al.
J Clin Endocrinol Metab 1997 Feb;82(2):357–64 (49 ref.)

MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A

Phaeochromocytoma in Northern Ireland: a 21 year review. Beatty OL, et al. **Eur J Surg** 1996 Sep;162(9):695–702 (41 ref.)

Multiple endocrine neoplasia type 2: management of patients and subjects at risk. French Study Group on Calcitonin-Secreting Tumors (GETC). Conte-Devolx B, et al. **Horm Res** 1997;47(4–6):221–6 (38 ref.)

[Sipple syndrome (review of foreign literature)] Vetshev PS, et al. **Khirurgiia (Mosk)** 1996;(2):122–7 (82 ref.) **(Rus)**

GENETICS

The MEN II syndromes and the role of the ret proto-oncogene. Ponder BA, et al. **Adv Cancer Res** 1996; 70:179–222 (194 ref.)

Genetic testing and early thyroidectomy for inherited medullary thyroid carcinoma. Lairmore TC, et al.
Ann Med 1996 Oct;28(5):401–6 (39 ref.)

Genetic screening for RET mutations in families with multiple endocrine neoplasia 2 syndromes. Alevizaki M, et al. **Ann N Y Acad Sci** 1997 Jun 17;816:383–8 (23 ref.)

The molecular genetics of multiple endocrine neoplasia type 2A and related syndromes. Moley JF. **Annu Rev Med** 1997; 48:409–20 (27 ref.)

Multiple endocrine neoplasia type II and familial medullary thyroid carcinoma. Impact of genetic screening on management. Gagel RF. **Cancer Treat Res** 1997;89:421–41 (74 ref.)

RET oncogene. Mak YF, et al. **Curr Opin Genet Dev** 1996 Feb;6(1):82–6 (45 ref.)

Molecular genetics of hyperparathyroid disease. Tominaga Y, et al. **Curr Opin Nephrol Hypertens** 1996 Jul;5(4):336–41 (55 ref.)

RET mutations in multiple endocrine neoplasia type 2 and Hirschsprung disease. Reynolds LF, et al.
Curr Opin Pediatr 1995 Dec;7(6):702–9 (63 ref.)

Application of genetic screening information to the management of medullary thyroid carcinoma and multiple endocrine neoplasia type 2. Wohllk N, et al.
Endocrinol Metab Clin North Am 1996 Mar;25(1):1–25 (101 ref.)

Unresolved issues in the genesis and management of multiple endocrine neoplasia type 2. Gagel RF.
Horm Metab Res 1997 Mar;29(3):135–7 (31 ref.)

RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. Marsh DJ, et al. **Horm Res** 1997;47(4–6):168–78 (105 ref.)

Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease. Eng C, et al.
Hum Mutat 1997;9(2):97–109 (105 ref.)

Medullary carcinoma of the thyroid gland and the MEN 2 syndromes. Skinner MA, et al. **Semin Pediatr Surg** 1997 Aug;6(3):134–40 (35 ref.)

[Neural crest and multiple endocrinopathies] Pasini A, et al. **C R Seances Soc Biol Fil** 1996;190(5–6):557–67 (22 ref.) (Eng. Abstr.) **(Fre)**

NURSING

Medullary thyroid carcinoma: one component of the inherited disorder multiple endocrine neoplasia type 2A. Giarelli E. **Oncol Nurs Forum** 1997 Jul;24(6):1007–20; quiz 1021–2 (48 ref.)

PHYSIOPATHOLOGY

[Multiple endocrine neoplasia] Matsuzaki K. **Ryoikibetsu Shokogun Shirizu** 1996;(15):22–5 (7 ref.) **(Jpn)**

SURGERY

[Primary hyperthyroidism 1996] Schweizer I, et al. **Schweiz Med Wochenschr** 1997 Feb 15;127(7):243–53 (58 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Unresolved issues in the genesis and management of multiple endocrine neoplasia type 2. Gagel RF. **Horm Metab Res** 1997 Mar;29(3):135–7 (31 ref.)

MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B

COMPLICATIONS

Malignant pheochromocytoma in multiple endocrine neoplasia type 2B syndrome. Case report and review of the literature. Scopsi L, et al. **Tumori** 1996 Sep–Oct; 82(5):480–4 (36 ref.)

GENETICS

The MEN II syndromes and the role of the ret proto–oncogene. Ponder BA, et al. **Adv Cancer Res** 1996; 70:179–222 (194 ref.)

Genetic testing and early thyroidectomy for inherited medullary thyroid carcinoma. Lairmore TC, et al. **Ann Med** 1996 Oct;28(5):401–6 (39 ref.)

Multiple endocrine neoplasia type II and familial medullary thyroid carcinoma. Impact of genetic screening on management. Gagel RF. **Cancer Treat Res** 1997;89:421–41 (74 ref.)

RET protooncogene mutational analysis in multiple endocrine neoplasia syndrome type 2B: case report and review of the literature. Kahn MA, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Sep;82(3):288–94 (21 ref.)

[Neural crest and multiple endocrinopathies] Pasini A, et al. **C R Seances Soc Biol Fil** 1996;190(5–6):557–67 (22 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Multiple idiopathic mucosal neuromas: a minor form of multiple endocrine neoplasia type 2B or a new entity? Pujol RM, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):349–52 (22 ref.)

Multiple endocrine neoplasia type 2B (mucosal neuroma syndrome, Wagenmann–Froboese syndrome). Morrison PJ, et al. **J Med Genet** 1996 Sep;33(9):779–82 (31 ref.)

PHYSIOPATHOLOGY

[Multiple endocrine neoplasia] Matsuzaki K. **Ryoikibetsu Shokogun Shirizu** 1996;(15):22–5 (7 ref.) **(Jpn)**

MULTIPLE EPIPHYSEAL DYSPLASIA see **OSTEOCHONDRODYSPLASIAS**

MULTIPLE HAMARTOMA SYNDROME see **HAMARTOMA SYNDROME, MULTIPLE**

MULTIPLE MYELOMA

ABC of clinical haematology. Multiple myeloma and related conditions [see comments] Singer CR. **BMJ** 1997 Mar 29; 314(7085):960–3 (0 ref.) Comment in: BMJ 1997 Jul 19;315(7101):186.

The biological features of multiple myeloma. Michaeli J, et al. **Cancer Invest** 1997;15(1):76–84 (75 ref.)

Pathogenesis and management of bone lesions in multiple myeloma. Bataille R, et al. **Hematol Oncol Clin North Am** 1997 Apr;11(2):349–61 (80 ref.)

Experimental plasmacytomagenesis in mice. Potter M. **Hematol Oncol Clin North Am** 1997 Apr;11(2):323–47 (136 ref.)

Myeloma stem cells in autografting in multiple myeloma. To LB, et al. **J Hematother** 1996 Oct;5(5):557–9 (14 ref.)

Multiple myeloma. Bataille R, et al. **N Engl J Med** 1997 Jun 5;336(23):1657–64 (100 ref.)

Myeloma: new aspects of biology, prognosis and treatment. Joshua DE. **Pathology** 1996 Jan;28(1):2–7 (43 ref.)

[Advances in the pathogenesis, biology, and management of multiple myeloma] Kosaka M. **Rinsho Byori** 1996 Aug; 44(8):743–9 (31 ref.) (Eng. Abstr.) **(Jpn)**

CHEMICALLY INDUCED

Multiple myeloma: clusters, clues, and dioxins. Schwartz GG. **Cancer Epidemiol Biomarkers Prev** 1997 Jan;6(1):49–56 (84 ref.)

Does benzene cause multiple myeloma? An analysis of the published case–control literature. Bezabeh S, et al. **Environ Health Perspect** 1996 Dec;104 Suppl 6:1393–8 (28 ref.)

COMPLICATIONS

Multiple myeloma and AIDS [letter] Nogués X, et al. **Am J Hematol** 1996 Nov;53(3):210–1 (5 ref.)

Profound hypophosphatemia and isolated hyperphosphaturia in two cases of multiple myeloma. Dash T, et al. **Am J Kidney Dis** 1997 Mar;29(3):445–8 (19 ref.)

Osteosclerotic myeloma and 'POEMS' syndrome. Schey S. **Blood Rev** 1996 Jun;10(2):75–80 (50 ref.)

A case of primary hyperparathyroidism accompanying multiple myeloma. Otsuka F, et al. **Endocr J** 1997 Feb; 44(1):105–9 (16 ref.)

Common bile duct obstruction caused by multiple myeloma of the pancreas. Abu–Hammour AM, et al. **Gastrointest Endosc** 1996 Nov;44(5):606–8 (18 ref.)

Subungual nodule as manifestation of multiple myeloma. Borrego L, et al. **Int J Dermatol** 1996 Sep;35(9):661–2 (8 ref.)

Secretion of parathyroid hormone–related peptide in patients with multiple myeloma. Beaudreuil J, et al. **Rev Rhum Engl Ed** 1996 Jul–Sep;63(7–8):502–3 (11 ref.)

Rheumatic manifestations of dysproteinemias and lymphoproliferative disorders. Duna GF, et al. **Rheum Dis Clin North Am** 1996 Feb;22(1):39–51 (107 ref.)

Systemic lupus erythematosus and multiple myeloma: a rare association. Afeltra A, et al. **Semin Arthritis Rheum** 1997 Jun;26(6):845–9 (30 ref.)

[Tubulo–interstitial nephritis associated with abnormal immune system] Kawaguchi K. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):281–3 (9 ref.) **(Jpn)**

[Kidneys involvement in multiple myeloma. Therapeutic issues] Gordeev AV, et al. **Klin Med (Mosk)** 1997; 75(8):60–2 (3 ref.) **(Rus)**

[A case of a combination of sarcoidosis and myeloma] Kamaeva OI, et al. **Ter Arkh** 1995;67(12):57–9 (19 ref.) **(Rus)**

DIAGNOSIS

Bilateral pleural masses and shortness of breath associated with multiple myeloma. Cabrera A, et al. **Chest** 1997 Jun; 111(6):1750–3 (11 ref.)

Diagnosis, prognosis, and standard treatment of multiple myeloma. Boccadoro M, et al. **Hematol Oncol Clin North Am** 1997 Feb;11(1):111–31 (162 ref.)

[Imaging of multiple myeloma] Ravaud P, et al. **Ann Med Interne (Paris)** 1996;147(8):370–5 (34 ref.) (Eng. Abstr.) **(Fre)**

[Rare intracranial plasmacytoma manifestations. Case reports and review of the literature in diffuse plasmocytoma, in primary solitary extramedullary plasmacytoma in in primary solitary osseous plasmacytoma] Kujat C, et al. **Radiologe** 1996 Nov;36(11):914–20 (42 ref.) (Eng. Abstr.) **(Ger)**

[Rheumatoid arthritis and multiple myeloma—the risk of a combination of the 2 diseases] Lila AM, et al. **Ter Arkh** 1997;69(2):50–2 (21 ref.) **(Rus)**

DRUG THERAPY

Evolution of multiple myeloma treatment from melphalan monotherapy to bone marrow transplantation. Hájek R, et al. **Acta Med Austriaca** 1996;23(3):85–91 (76 ref.)

Bisphosphonate therapy in multiple myeloma. Laakso M, et al. **Acta Oncol** 1996;35 Suppl 5:55–6 (7 ref.)

Detection of multidrug resistance gene expression in multiple myeloma. Dalton WS. **Leukemia** 1997 Jul;11(7):1166–9 (13 ref.)

[Clodronate and myeloma (editorial)] Jantunen E, et al. **Duodecim** 1995;111(12):1085–7 (14 ref.) **(Fin)**

[Role of glucocorticoids in the treatment of multiple myeloma] Juge–Morineau N, et al. **Ann Med Interne (Paris)** 1996;147(8):576–9 (27 ref.) (Eng. Abstr.) **(Fre)**

[High dose chemotherapy with autologous stem cell transplantation] Weissinger F, et al. **Fortschr Med** 1997 Mar 30;115(9):39–43 (20 ref.) (Eng. Abstr.) **(Ger)**

[Skeletal bone lesion and the effectiveness of Bonephos (clodronate) in the comprehensive therapy of multiple myeloma] Bessmel'tsev SS, et al. **Vopr Onkol** 1996; 42(4):12–8 (51 ref.) **(Rus)**

EPIDEMIOLOGY

Multiple myeloma: clusters, clues, and dioxins. Schwartz GG. **Cancer Epidemiol Biomarkers Prev** 1997 Jan;6(1):49–56 (84 ref.)

ETIOLOGY

B cell populations: the multiple myeloma model. Caligaris–Cappio F, et al. **Chem Immunol** 1997;67:102–13 (75 ref.)

GENETICS

The MDR phenotype in hematologic malignancies: prognostic relevance and future perspectives. Hegewisch–Becker S, et al. **Ann Hematol** 1996 Mar; 72(3):105–17 (128 ref.)

Cytogenetics and molecular genetics in multiple myeloma. Feinman R, et al. **Hematol Oncol Clin North Am** 1997 Feb; 11(1):1–25 (108 ref.)

The retinoblastoma susceptibility gene RB–1 in multiple myeloma. Juge–Morineau N, et al. **Leuk Lymphoma** 1997 Jan;24(3–4):229–37 (71 ref.)

DNA cell content studies in multiple myeloma. San Miguel JF, et al. **Leuk Lymphoma** 1996 Sep;23(1–2):33–41 (45 ref.)

Non–random chromosomal rearrangements and their implications in clinical features and outcome of multiple myeloma and plasma cell leukemia. Taniwaki M, et al. **Leuk Lymphoma** 1996 Mar;21(1–2):25–30 (39 ref.)

Detection of minimal residual disease in multiple myeloma and acute leukaemia. Bakkus MH, et al. **Med Oncol** 1996 Jun;13(2):121–31 (88 ref.)

IMMUNOLOGY

Immunoglobulin J chain. An early differentiation marker of human B cells. Mestecky J, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:111–3 (9 ref.)

Fas/Apo–1 (CD95)–mediated and CD95–independent apoptosis of malignant plasma cells. Hata H, et al. **Leuk Lymphoma** 1996 Dec;24(1–2):35–42 (21 ref.)

Circulating clonotypic B cells in the biology of multiple myeloma: speculations on the origin of myeloma. Pilarski LM, et al. **Leuk Lymphoma** 1996 Aug;22(5–6):375–83 (56 ref.)

Idiotype–specific T cells in multiple myeloma: targets for an immunotherapeutic intervention? Yi Q, et al. **Med Oncol** 1996 Mar;13(1):1–7 (70 ref.)

METABOLISM

Expression of adhesion molecules in malignant plasma cells in multiple myeloma: comparison with normal plasma cells and functional significance. Helfrich MH, et al. **Blood Rev** 1997 Mar;11(1):28–38 (89 ref.)

Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Teoh G, et al. **Hematol Oncol Clin North Am** 1997 Feb;11(1):27–42 (67 ref.)

The neural cell adhesion molecule NCAM in multiple myeloma. Kaiser U, et al. **Leuk Lymphoma** 1996 Feb; 20(5–6):389–95 (57 ref.)

Fas antigen/APO–1 (CD95) expression on myeloma cells. Shima Y, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):521–31 (92 ref.)

CD40 and the effect of anti–CD40–binding on human multiple myeloma clonogenicity. Tong AW, et al. **Leuk Lymphoma** 1996 Mar;21(1–2):1–8 (83 ref.)

PATHOLOGY

The role of adhesion molecules in multiple myeloma. Cook G, et al. **Acta Haematol** 1997;97(1–2):81–9 (65 ref.)

Myeloma stem cell phenotype. Implications for treatment. Epstein J. **Hematol Oncol Clin North Am** 1997 Feb; 11(1):43–9 (38 ref.)

The role of the CD40 antigen on malignant B cells. Planken EV, et al. **Leuk Lymphoma** 1996 Jul;22(3–4):229–35 (63 ref.)

Tumor necrosis factor–alpha and interleukin 4 in myeloma cell precursor differentiation. Sawamura M, et al. **Leuk Lymphoma** 1996 Mar;21(1–2):31–6 (45 ref.)

Fas antigen/APO–1 (CD95) expression on myeloma cells. Shima Y, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):521–31 (92 ref.)

CD40 and the effect of anti–CD40–binding on human multiple myeloma clonogenicity. Tong AW, et al. **Leuk Lymphoma** 1996 Mar;21(1–2):1–8 (83 ref.)

New insights in the clinical biology of multiple myeloma. Bataille R. **Semin Hematol** 1997 Jan;34(1 Suppl 1):23–8 (48 ref.)

Key differentiation steps in normal B cells and in myeloma cells. Zubler RH. **Semin Hematol** 1997 Jan;34(1 Suppl 1):13–22 (52 ref.)

[gp–130 related cytokines in mechanisms of myeloma cell growth] Fukutoku M, et al. **Rinsho Ketsueki** 1997 Apr; 38(4):262–5 (13 ref.) **(Jpn)**

[Mechanisms of growth and apoptosis in myeloma cells] Hata H, et al. **Rinsho Ketsueki** 1997 Apr;38(4):266–70 (6 ref.) **(Jpn)**

[Role of adhesion molecules on pathogenesis of multiple myeloma] Uchiyama H. **Rinsho Ketsueki** 1997 Apr; 38(4):271–4 (6 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Pathophysiology and management of bone disease in multiple myeloma. Niesvizky R, et al. **Cancer Invest** 1997; 15(1):85–90 (69 ref.)

Monoclonal gammopathy of undetermined significance and solitary plasmacytoma. Implications for progression to overt multiple myeloma. Kyle RA. **Hematol Oncol Clin North Am** 1997 Feb;11(1):71–87 (54 ref.)

Myeloma biology and therapy. Present status and future developments. Nishimoto N, et al. **Hematol Oncol Clin North Am** 1997 Feb;11(1):159–72 (85 ref.)

Biology and therapy of multiple myeloma in 1996. Barlogie B, et al. **Semin Hematol** 1997 Jan;34(1 Suppl 1):67–72 (42 ref.)

[Activin A induces apoptotic cell death of myeloma cells] Yamato K, et al. **Rinsho Ketsueki** 1996 Jul;37(7):564–73 (18 ref.) **(Jpn)**

MULTIPLE MYELOMA

[Multiple myeloma and Takatsuki syndrome] Matsuzaki H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):143–6 (15 ref.) **(Jpn)**

[Multiple myeloma and the kidneys] Kamaeva OI. **Ter Arkh** 1997;69(6):73–5 (26 ref.) **(Rus)**

SURGERY

Autologous bone marrow and peripheral blood stem cell transplantation in haematological malignancies: current status. Marcoullis G, et al. **Med Oncol** 1995 Dec; 12(4):209–18 (91 ref.)

Renal transplantation in multiple myeloma. Case report and review of the literature [published erratum appears in Transplantation 1997 Mar 27;63(6):916] Dagher F, et al. **Transplantation** 1996 Dec 15;62(11):1577–80 (24 ref.)

THERAPY

New approaches to management of multiple myeloma. Hájek R, et al. **Acta Med Austriaca** 1996;23(3):91–8 (131 ref.)

Bone marrow and peripheral blood stem cell transplantation in multiple myeloma [editorial; comment] Gahrton G. **Ann Oncol** 1997 Mar;8(3):219–21 (27 ref.) Comment on: Ann Oncol 1997 Mar;8(3):243–6.

Cytokine therapy in multiple myeloma. Peest D, et al. **Br J Haematol** 1996 Sep;94(3):425–32 (80 ref.)

Multiple myeloma: prognosis and standard treatment. Oken MM. **Cancer Invest** 1997;15(1):57–64 (60 ref.)

Bone marrow transplantation in multiple myeloma. Schlossman RL, et al. **Cancer Invest** 1997;15(1):65–75 (69 ref.)

Advances in the treatment of multiple myeloma. Singhal S, et al. **Curr Opin Hematol** 1997 Jul;4(4):291–7 (56 ref.)

Biology and treatment of myeloma [see comments] Greipp PR, et al. **Curr Opin Oncol** 1996 Jan;8(1):20–7 (46 ref.) Comment in: Curr Opin Oncol 1996 Jan;8(1):1–2.

Treatment of multiple myeloma in elderly patients. New developments. Ossenkoppele GJ. **Drugs Aging** 1997 Aug; 11(2):152–64 (112 ref.)

Peripheral blood stem cell transplantation for the treatment of multiple myeloma: biological and clinical implications. Cappio FC, et al. **Haematologica** 1996 Jul–Aug; 81(4):356–75 (177 ref.)

Current therapeutic options for multiple myeloma [editorial] Pileri A, et al. **Haematologica** 1996 Jul–Aug;81(4):291–4 (33 ref.)

Allogeneic stem cell transplantation for multiple myeloma. Bensinger WI, et al. **Hematol Oncol Clin North Am** 1997 Feb;11(1):147–57 (37 ref.)

Diagnosis, prognosis, and standard treatment of multiple myeloma. Boccadoro M, et al. **Hematol Oncol Clin North Am** 1997 Feb;11(1):111–31 (162 ref.)

Autotransplants in multiple myeloma: pushing the envelope. Jagannath S, et al. **Hematol Oncol Clin North Am** 1997 Apr;11(2):363–81 (58 ref.)

Advances in the treatment of plasma cell diseases. Comenzo RL. **Hosp Pract (Off Ed)** 1996 Aug 15;31(8):67–70, 73–4, 79–84 passim (11 ref.)

Autologous transplantation with tumor-free graft: a model for multiple myeloma patients. Gazitt Y, et al. **Leuk Lymphoma** 1996 Oct;23(3–4):203–12 (65 ref.)

Hematopoietic stem cell transplants for multiple myeloma. Tricot G, et al. **Leuk Lymphoma** 1996 Jun;22(1–2):25–36 (79 ref.)

Multiple myeloma, high-dose treatment and autologous stem cell transplantation--current status. Björkstrand B. **Med Oncol** 1996 Mar;13(1):23–30 (90 ref.)

Biology and therapy of multiple myeloma in 1996. Barlogie B, et al. **Semin Hematol** 1997 Jan;34(1 Suppl 1):67–72 (42 ref.)

The role of autologous hematopoietic stem cell transplantation in multiple myeloma. Harousseau JL, et al. **Semin Hematol** 1997 Jan;34(1 Suppl 1):61–6 (45 ref.)

Intensive treatment strategies in multiple myeloma. Kovacsovics TJ, et al. **Semin Hematol** 1997 Jan;34(1 Suppl 1):49–60 (74 ref.)

[Multiple myeloma and bone manifestations. Role of clodronate] Bauduer F, et al. **Bull Cancer** 1996 Jul; 83(7):542–7 (42 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of myeloma: role of intensive treatments] Fermand JP, et al. **Presse Med** 1997 Apr 5;26(11):521–4 (22 ref.) (Eng. Abstr.) **(Fre)**

[Therapy of multiple myeloma] La Verde G, et al. **Recenti Prog Med** 1997 Apr;88(4):186–93 (41 ref.) (Eng. Abstr.) **(Ita)**

[Progress in the treatment of multiple myeloma] Wada M, et al. **Gan To Kagaku Ryoho** 1997 Jul;24(9):1079–88 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical application of interleukin-6 receptor antibody] Nishimoto N, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1997 Apr;20(2):87–94 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Alpha-interferon in present-day treatment of myeloma] Demina EA, et al. **Gematol Transfuziol** 1996 Mar–Apr; 41(2):32–6 (70 ref.) **(Rus)**

[The intensive treatment of multiple myeloma with support from hematopoietic progenitors] Paz-Ares L, et al. **Med Clin (Barc)** 1997 Feb 15;108(6):226–9 (37 ref.) **(Spa)**

MULTIPLE ORGAN FAILURE

Chronic heart failure: a multisystem syndrome [editorial; comment] Piepoli M, et al. **Eur Heart J** 1996 Dec; 17(12):1777–8 (8 ref.) Comment on: Eur Heart J 1996 Dec;17(12):1860–6.

[Systemic inflammatory response syndrome] Huang Y. **Chung Hua I Hsueh Tsa Chih** 1996 Aug;76(8):629–31 (16 ref.) **(Chi)**

[Multiple organ failure or dysfunction] Casado Flores J, et al. **An Esp Pediatr** 1996 Dec;45(6):563–9 (28 ref.) **(Spa)**

COMPLICATIONS

Infected pancreatic necrosis complicated by multiple organ failure. Dominioni L, et al. **Hepatogastroenterology** 1997 Jul–Aug;44(16):968–74 (22 ref.)

Acute renal failure in multiple-organ dysfunction syndrome. Kierdorf HP, et al. **Kidney Blood Press Res** 1997; 20(3):164–6 (21 ref.)

DIAGNOSIS

Multiple chemical sensitivity multiorgan dysesthesia, multiple symptom complex, and multiple confusion: problems in diagnosing the patient presenting with unexplained multisystemic symptoms. Salvaggio JE, et al. **Crit Rev Toxicol** 1996 Nov;26(6):617–31 (77 ref.)

How should multiple organ dysfunction syndrome be assessed? A review of the variations in current scoring systems. Bertleff MJ, et al. **Eur J Surg** 1997 Jun; 163(6):405–9; discussion 410 (36 ref.)

EPIDEMIOLOGY

MOF/MODS, SIRS: an update. Baue AE. **Shock** 1996;6 Suppl 1:S1–5 (45 ref.)

ETIOLOGY

Sepsis: a new hypothesis for pathogenesis of the disease process. Bone RC, et al. **Chest** 1997 Jul;112(1):235–43 (57 ref.)

[Cytokine storm in the pathogenesis of multiple organ dysfunction syndrome associated with surgical insults] Aikawa N. **Nippon Geka Gakkai Zasshi** 1996 Sep; 97(9):771–7 (31 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

[The role of the polymorphonuclear neutrophil in the failure of multiple organs and systems] Fontes B, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1996 Jan–Feb;51(1):21–5 (47 ref.) (Eng. Abstr.) **(Por)**

MICROBIOLOGY

The relationship between gut-derived bacteria and the development of the multiple organ dysfunction syndrome. Nieuwenhuijzen GA, et al. **J Anat** 1996 Dec;189 (Pt 3):537–48 (165 ref.)

MORTALITY

Prognosis and mortality in patients with multiple organ system failure. French Study Group on Acute Renal Failure. Kleinknecht D, et al. **Ren Fail** 1996 May; 18(3):347–53 (25 ref.)

PHYSIOPATHOLOGY

Posttraumatic multiple-organ dysfunction syndrome: role of mediators in systemic inflammation and subsequent organ failure. Pastores SM, et al. **Acad Emerg Med** 1996 Jun; 3(6):611–22 (150 ref.)

Multiple organ failure, multiple organ dysfunction syndrome, and systemic inflammatory response syndrome. Why no magic bullets? Baue AE. **Arch Surg** 1997 Jul;132(7):703–7 (42 ref.)

Oxygen delivery in critical illness. Baigorri F, et al. **Crit Care Clin** 1996 Oct;12(4):971–94 (91 ref.)

Systemic inflammatory response syndrome: interactions between immune cells and the endothelium. Ahmed N, et al. **Shock** 1996;6 Suppl 1:S39–42 (16 ref.)

[The multiple organ failure syndrome--its pathophysiology and treatment] Karadimov D, et al. **Khirurgiia (Sofiia)** 1996; 49(6):46–52 (32 ref.) (Eng. Abstr.) **(Bul)**

[The heart in infection and MODS (multiple organ dysfunction syndrome)] Müller-Werdan U, et al. **Wien Klin Wochenschr Suppl** 1997;1:3–24 (200 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

[Prevention and treatment of postoperative septic MOF and DIC and efficacy of blood purification] Hirasawa H, et al. **Nippon Geka Gakkai Zasshi** 1996 Dec;97(12):1079–84 (20 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Organ transplantation in Taiwan. Lee CJ. **Artif Organs** 1996 Dec;20(12):1270–3 (10 ref.)

Anti-inflammatory therapies: application of molecular biology techniques in intensive care medicine. Liu M, et al. **Intensive Care Med** 1997 Jul;23(7):718–31 (127 ref.)

Monitoring of blood volume during haemodialysis treatment of acute renal and multiple organ failures. Katzarski KS. **Nephrol Dial Transplant** 1996;11 Suppl 8:20–3 (46 ref.)

Hemofiltration in multiorgan failure syndrome secondary to sepsis: a critical analysis of heterogeneity [editorial] Gotloib L. **Nephron** 1996;73(2):125–30 (86 ref.)

Can body composition in multiple organ failure be favorably influenced by feeding? Campbell IT. **Nutrition** 1997 Sep; 13(9 Suppl):79S–83S (56 ref.)

The treatment of patients with ARF and MOSF: a framework for a discussion on ethical issues. Abel F. **Ren Fail** 1996 May;18(3):409–16 (11 ref.)

Acute renal failure in patients with kidney transplant: continuous versus intermittent renal replacement therapy. Ronco C, et al. **Ren Fail** 1996 May;18(3):461–70 (36 ref.)

[The multiple organ failure syndrome--its pathophysiology and treatment] Karadimov D, et al. **Khirurgiia (Sofiia)** 1996; 49(6):46–52 (32 ref.) (Eng. Abstr.) **(Bul)**

MULTIPLE-PERSONALITY DISORDER

PHYSIOPATHOLOGY

Visual function in multiple personality disorder. Birnbaum MH, et al. **J Am Optom Assoc** 1996 Jun;67(6):327–34 (35 ref.)

MULTIPLE SCLEROSIS

Multiple sclerosis: immune mechanism and update on current therapies. Bansil S, et al. **Ann Neurol** 1995 May;37 Suppl 1:S87–101 (147 ref.)

Creation of a model for multiple sclerosis in Callithrix jacchus marmosets [see comments] Genain CP, et al. **J Mol Med** 1997 Mar;75(3):187–97 (75 ref.) Comment in: J Mol Med 1997 Mar;75(3):164.

Nonlinear dynamics and multiple sclerosis. Bharanidharan P. **J Neurol Sci** 1997 Aug;149(2):139–40 (10 ref.)

Rodent models of experimental allergic encephalomyelitis applied to the study of multiple sclerosis. Goverman J, et al. **Lab Anim Sci** 1996 Oct;46(5):482–92 (167 ref.)

Cluster studies in multiple sclerosis. Riise T. **Neurology** 1997 Aug;49(2 Suppl 2):S27–32 (39 ref.)

Multiple sclerosis. Primary health care implications. Swain SE. **Nurse Pract** 1996 Jul;21(7):40, 43, 47–50 passim (23 ref.)

[Disseminated sclerosis. New knowledge about etiology, physiopathology and treatment] Sørensen PS. **Ugeskr Laeger** 1997 Mar 3;159(10):1409–12 (11 ref.) **(Dan)**

[Physiopathology and treatment of multiple sclerosis] Itoyama Y. **Nippon Naika Gakkai Zasshi** 1997 Mar 10; 86(3):416–9 (5 ref.) **(Jpn)**

[Multiple sclerosis viewed from the point of HTLV-I associated myelopathy] Osame M, et al. **Rinsho Shinkeigaku** 1995 Dec;35(12):1498–500 (8 ref.) (Eng. Abstr.) **(Jpn)**

CHEMICALLY INDUCED

Exposure to organic solvents and multiple sclerosis. Landtblom AM. **Neurology** 1997 Aug;49(2 Suppl 2):S70–4 (26 ref.)

COMPLICATIONS

Multiple sclerosis presenting solely with bladder disturbance [letter] Betts CD. **Br J Urol** 1997 Sep;80(3):513–4 (7 ref.)

White matter disease and dementia. Rao SM. **Brain Cogn** 1996 Jul;31(2):250–68 (161 ref.)

Bullous pemphigoid and multiple sclerosis: a report of three cases and review of the literature. Kirtschig G, et al. **Clin Exp Dermatol** 1995 Nov;20(6):449–53 (41 ref.)

Medical causes of faecal incontinence. Jameson JS, et al. **Eur J Gastroenterol Hepatol** 1997 May;9(5):428–30 (17 ref.)

Reversal of alexia in multiple sclerosis by weak electromagnetic fields. Sandyk R. **Int J Neurosci** 1995 Nov; 83(1–2):69–79 (93 ref.)

Multiple sclerosis leading to blepharospasm and dystonia in a sibling pair [letter] Moore CE, et al. **J Neurol** 1996 Sep; 243(9):667–70 (28 ref.)

[Image diagnosis and functional tests--vertigo due to cerebellar and brain stem disorders] Kitamura T. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Jul;99(7):1036–9 (9 ref.) **(Jpn)**

[Left hand clumsiness due to disturbance of kinesthesia after damage to the dorsal column of the high cervical cord] Hashimoto R, et al. **Rinsho Shinkeigaku** 1997 Apr; 37(4):319–25 (22 ref.) (Eng. Abstr.) **(Jpn)**

[2 cases of anterior uveitis in multiple sclerosis patients] Karlova IZ, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1997;97(5):57–8 (6 ref.) **(Rus)**

DIAGNOSIS

Central nervous system white matter diseases other than multiple sclerosis. O'Riordan JI. **Curr Opin Neurol** 1997 Jun;10(3):211–4 (41 ref.)

Clinical utility of somatosensory evoked potentials (SEPs): present debates and future trends. Mauguière F. **Electroencephalogr Clin Neurophysiol Suppl** 1996;46:27–33 (58 ref.)

Contrast-enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple

sclerosis. Simon JH. **J Magn Reson Imaging** 1997 Jan–Feb; 7(1):29–37 (74 ref.)

Clinical scales for multiple sclerosis. Sharrack B, et al. **J Neurol Sci** 1996 Jan;135(1):1–9 (79 ref.)

What is your diagnosis? Multiple sclerosis. Mathews DE. **Optom Clin** 1996;5(3–4):193–203 (28 ref.)

[Imaging methods, particularly magnetic resonance, in multiple sclerosis] Seidl Z, et al. **Cas Lek Cesk** 1996 Dec 4;135(23):747–52 (53 ref.) (Eng. Abstr.) **(Cze)**

[Acute vestibular deficit with initial deafness as the first manifestation of late onset multiple sclerosis] Schweri T, et al. **HNO** 1996 Jul;44(7):397–9 (20 ref.) (Eng. Abstr.) **(Ger)**

[Prognosis in multiple sclerosis] Kesselring J. **Schweiz Med Wochenschr** 1997 Mar 22;127(12):500–5 (35 ref.) (Eng. Abstr.) **(Ger)**

[Diagnosis and differential diagnosis in multiple sclerosis] Huber S, et al. **Schweiz Rundsch Med Prax** 1997 Jan 14; 86(3):46–54 (82 ref.) (Eng. Abstr.) **(Ger)**

[Clinical aspects and diagnosis of multiple sclerosis] Berger T, et al. **Wien Med Wochenschr** 1996;146(19–20):504–13 (69 ref.) (Eng. Abstr.) **(Ger)**

[Brain MRI in multiple sclerosis] Avitzur Y, et al. **Harefuah** 1996 Nov 15;131(10):421–7 (39 ref.) **(Heb)**

[Image diagnosis and functional tests--vertigo due to cerebellar and brain stem disorders] Kitamura T. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Jul;99(7):1036–9 (9 ref.) **(Jpn)**

[Multiple Sclerosis--diagnosis and its problems] Itoyama Y. **Rinsho Shinkeigaku** 1995 Dec;35(12):1496–7 (4 ref.) (Eng. Abstr.) **(Jpn)**

[Immunotherapy of multiple sclerosis: the use of magnetic resonance imaging in the evaluation of clinical trials] Ozawa K, et al. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1501–3 (10 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Current developments in neurology, Part I: Advances in the pharmacotherapy of headache, epilepsy, and multiple sclerosis. Gidal BE, et al. **Ann Pharmacother** 1996 Nov; 30(11):1272–6 (37 ref.)

The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections. Arnon R. **Immunol Lett** 1996 Apr;50(1–2):1–15 (67 ref.)

Italian Neurological Society Consensus Conference. New therapies in multiple sclerosis: beta-interferon. **Ital J Neurol Sci** 1996 Apr;17(2):175–8 (0 ref.)

Does a placebo-effect exist in clinical trials on multiple sclerosis? Review of the literature. La Mantia L, et al. **Ital J Neurol Sci** 1996 Apr;17(2):135–9 (28 ref.)

Therapeutic advances: beta-interferon for multiple sclerosis. Clark W. **J Clin Pharm Ther** 1996 Aug;21(4):195–9 (27 ref.)

Cop 1 as a candidate drug for multiple sclerosis. Teitelbaum D, et al. **J Neural Transm Suppl** 1997;49:85–91 (29 ref.)

New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis. Arnon R, et al. **J Neurol** 1996 Apr;243(4 Suppl 1):S8–13 (28 ref.)

A review of the clinical efficacy profile of copolymer 1: new U.S. phase III trial data. Johnson KP. **J Neurol** 1996 Apr; 243(4 Suppl 1):S3–7 (15 ref.)

Current and investigational therapies used to alter the course of disease in multiple sclerosis. Miller A. **South Med J** 1997 Apr;90(4):367–75 (56 ref.)

Mechanisms of action of interferon-beta in multiple sclerosis. Arnason BG, et al. **Springer Semin Immunopathol** 1996; 18(1):125–48 (163 ref.)

Current pharmacologic treatment of multiple sclerosis symptoms [see comments] Andersson PB, et al. **West J Med** 1996 Nov;165(5):313–7 (43 ref.) Comment in: West J Med 1996 Nov;165(5):320–1.

[Immune modulation in multiple sclerosis: linomide (published erratum appears in Nervenarzt 1996 Oct;67(10):885)] Weilbach EX, et al. **Nervenarzt** 1996 Aug; 67(8):701–5 (48 ref.) **(Ger)**

[Interferons in multiple sclerosis] Tintoré M. **Rev Neurol** 1997 Feb;25(138):267–9 (7 ref.) **(Spa)**

ENZYMOLOGY

Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. Chandler S, et al. **J Neuroimmunol** 1997 Feb;72(2):155–61 (95 ref.)

EPIDEMIOLOGY

The epidemiology of multiple sclerosis. Martyn CN, et al. **Acta Neurol Scand Suppl** 1997;169:3–7 (28 ref.)

Genetic epidemiology of multiple sclerosis. Ebers GC. **Curr Opin Neurol** 1996 Jun;9(3):155–8 (42 ref.)

Genetic epidemiology of multiple sclerosis. Compston A. **J Neurol Neurosurg Psychiatry** 1997 Jun;62(6):553–61 (79 ref.)

The epidemiology of multiple sclerosis. Hogancamp WE, et al. **Mayo Clin Proc** 1997 Sep;72(9):871–8 (69 ref.)

Ecologic studies of multiple sclerosis. Lauer K. **Neurology** 1997 Aug;49(2 Suppl 2):S18–26 (92 ref.)

Migrant studies in multiple sclerosis. Gale CR, et al. **Prog Neurobiol** 1995 Nov–Dec;47(4–5):425–48 (79 ref.)

The genetic analysis of multiple sclerosis. Sawcer S, et al. **Trends Genet** 1997 Jun;13(6):234–9 (65 ref.)

ETHNOLOGY

[Multiple sclerosis and migration] Materljan E, et al. **Lijec Vjesn** 1996 May–Jun;118(5–6):129–32 (35 ref.) (Eng. Abstr.) **(Scr)**

ETIOLOGY

Multiple sclerosis: early management. Zajicek J. **Br J Hosp Med** 1997 Feb 19–Mar 4;57(4):137–40 (12 ref.)

The role of nitric oxide in multiple sclerosis [see comments] Parkinson JF, et al. **J Mol Med** 1997 Mar;75(3):174–86 (151 ref.) Comment in: J Mol Med 1997 Mar;75(3):164.

Multiple sclerosis: an altered immune response or an altered stress response? van Noort JM. **J Mol Med** 1996 Jun; 74(6):285–96 (49 ref.)

A multicenter study methodologic experience from a multicenter case-control study in Italy. The Italian Multiple Sclerosis Study Group. Granieri E, et al. **Neurology** 1997 Aug;49(2 Suppl 2):S33–41 (51 ref.)

Selected reviews common childhood and adolescent infections and multiple sclerosis. Granieri E, et al. **Neurology** 1997 Aug;49(2 Suppl 2):S42–54 (73 ref.)

Diet and multiple sclerosis. Lauer K. **Neurology** 1997 Aug; 49(2 Suppl 2):S55–61 (66 ref.)

Historical cohort studies in multiple sclerosis. Riise T. **Neurology** 1997 Aug;49(2 Suppl 2):S15–7 (13 ref.)

Case-control studies in multiple sclerosis. Wolfson C, et al. **Neurology** 1997 Aug;49(2 Suppl 2):S5–14 (28 ref.)

Folate, vitamin B12, and neuropsychiatric disorders. Bottiglieri T. **Nutr Rev** 1996 Dec;54(12):382–90 (59 ref.)

Vitamin D and multiple sclerosis. Hayes CE, et al. **Proc Soc Exp Biol Med** 1997 Oct;216(1):21–7 (65 ref.)

[Systemic manifestations of hemorrhagic rectocolitis: apropos of a case of hemorrhagic rectocolitis associated with multiple sclerosis] Alric L, et al. **Rev Med Interne** 1997; 18(2):132–7 (20 ref.) (Eng. Abstr.) **(Fre)**

[A view for understanding the pathogenesis of multiple sclerosis] Tabira T. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1493–5 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Cytokines in the immunopathogenesis of multiple sclerosis] Demina TL, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1997;97(5):68–73 (121 ref.) **(Rus)**

GENETICS

Genetic epidemiology of multiple sclerosis. Ebers GC. **Curr Opin Neurol** 1996 Jun;9(3):155–8 (42 ref.)

New insights into the immunogenetics of multiple sclerosis. Oksenberg JR, et al. **Curr Opin Neurol** 1997 Jun;10(3):181–5 (33 ref.)

Genetics of multiple sclerosis. Dyment DA, et al. **Hum Mol Genet** 1997;6(10):1693–8 (100 ref.)

Genetics of multiple sclerosis--how could disease-associated HLA-types contribute to pathogenesis? Martin R. **J Neural Transm Suppl** 1997;49:177–94 (89 ref.)

Update on management and genetics of multiple sclerosis. Sadovnick AD. **J Neural Transm Suppl** 1997;50:167–72 (36 ref.)

Analysis of a sequenced cDNA library from multiple sclerosis lesions. Becker KG, et al. **J Neuroimmunol** 1997 Jul; 77(1):27–38 (101 ref.)

Genetic epidemiology of multiple sclerosis. Compston A. **J Neurol Neurosurg Psychiatry** 1997 Jun;62(6):553–61 (79 ref.)

The genetic analysis of multiple sclerosis. Sawcer S, et al. **Trends Genet** 1997 Jun;13(6):234–9 (65 ref.)

[Genetic aspects in multiple sclerosis: I. Twin studies] de Rezende PA, et al. **Arq Neuropsiquiatr** 1996 Sep; 54(3):433–8 (16 ref.) (Eng. Abstr.) **(Por)**

[Genetic aspects in multiple sclerosis. II: HLA system] De Rezende PA, et al. **Arq Neuropsiquiatr** 1996 Sep; 54(3):439–50 (42 ref.) (Eng. Abstr.) **(Por)**

IMMUNOLOGY

The neuroimmunology of multiple sclerosis. Coyle PK. **Adv Neuroimmunol** 1996;6(2):143–54 (83 ref.)

Microglia in health and disease. Cuzner ML. **Biochem Soc Trans** 1997 May;25(2):671–3 (24 ref.)

Mechanisms of immune injury in multiple sclerosis. Brosnan CF, et al. **Brain Pathol** 1996 Jul;6(3):243–57 (100 ref.)

Role of Th1 and Th2 cells in neurologic disorders. Windhagen A, et al. **Chem Immunol** 1996;63:171–86 (75 ref.)

Autoimmune pathogenesis of multiple sclerosis: role of autoreactive T lymphocytes and new immunotherapeutic strategies. Stinissen P, et al. **Crit Rev Immunol** 1997; 17(1):33–75 (357 ref.)

The immunopathogenesis of multiple sclerosis and Guillain-Barré syndrome. Giovannoni G, et al. **Curr Opin Neurol** 1996 Jun;9(3):165–77 (134 ref.)

New insights into the immunogenetics of multiple sclerosis. Oksenberg JR, et al. **Curr Opin Neurol** 1997 Jun;10(3):181–5 (33 ref.)

Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis [see comments] Benveniste EN. **J Mol Med** 1997 Mar;75(3):165–73 (107 ref.) Comment in: J Mol Med 1997 Mar;75(3):164.

Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis. Bernard CC, et al. **J Mol Med** 1997 Feb;75(2):77–88 (64 ref.)

Role of interferons in demyelinating diseases. Arnason BG, et al. **J Neural Transm Suppl** 1997;49:117–23 (23 ref.)

Induction of experimental autoimmune encephalomyelitis by CD4+ T cells specific for an astrocyte protein, S100 beta. Kojima K, et al. **J Neural Transm Suppl** 1997;49:43–51 (45 ref.)

Genetics of multiple sclerosis--how could disease-associated HLA-types contribute to pathogenesis? Martin R. **J Neural Transm Suppl** 1997;49:177–94 (89 ref.)

Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis and their application for new therapeutic strategies. Martin R. **J Neural Transm Suppl** 1997;49:53–67 (96 ref.)

Analysis of a sequenced cDNA library from multiple sclerosis lesions. Becker KG, et al. **J Neuroimmunol** 1997 Jul; 77(1):27–38 (101 ref.)

Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. Chandler S, et al. **J Neuroimmunol** 1997 Feb;72(2):155–61 (95 ref.)

Review: cytokines and the pathogenesis of multiple sclerosis. Navikas V, et al. **J Neurosci Res** 1996 Aug 15;45(4):322–33 (115 ref.)

Vaccination with autoreactive T cell clones in multiple sclerosis: overview of immunological and clinical data. Stinissen P, et al. **J Neurosci Res** 1996 Aug 15;45(4):500–11 (75 ref.)

The controversy surrounding the pathogenesis of the multiple sclerosis lesion. Lucchinetti CF, et al. **Mayo Clin Proc** 1997 Jul;72(7):665–78 (137 ref.)

The role of adhesion molecules in multiple sclerosis: biology, pathogenesis and therapeutic implications. Archelos JJ, et al. **Mol Med Today** 1997 Jul;3(7):310–21 (54 ref.)

IgG subclasses in neurological disorders. Losy J, et al. **Neurol Neurochir Pol** 1996;30 Suppl 2:17–24 (16 ref.)

Indictment of the microglia as the villain in multiple sclerosis. Sriram S, et al. **Neurology** 1997 Feb;48(2):464–70 (69 ref.)

[Multiple sclerosis] Offenhäusser M, et al. **Med Monatsschr Pharm** 1997 Jun;20(6):149–57 (23 ref.) **(Ger)**

[Pathogenesis of multiple sclerosis and other neural autoimmune diseases] Lassmann H. **Verh Dtsch Ges Pathol** 1996;80:109–15 (37 ref.) (Eng. Abstr.) **(Ger)**

[Pathogenesis of multiple sclerosis: status of research] Hartung HP. **Wien Med Wochenschr** 1996;146(19–20):520–7 (114 ref.) (Eng. Abstr.) **(Ger)**

[Perspectives in multiple sclerosis research] Lassmann H. **Wien Med Wochenschr** 1996;146(19–20):528–32 (38 ref.) (Eng. Abstr.) **(Ger)**

[TCR CDR3 motif expression in PLP specific T cell from patients with multiple sclerosis] Kondo T, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):666–9 (8 ref.) **(Jpn)**

[Genetic aspects in multiple sclerosis. II: HLA system] De Rezende PA, et al. **Arq Neuropsiquiatr** 1996 Sep; 54(3):439–50 (42 ref.) (Eng. Abstr.) **(Por)**

METABOLISM

Multiple sclerosis and amyloid deposits in the white matter of the brain. Nennesmo I, et al. **Acta Neuropathol (Berl)** 1997 Feb;93(2):205–9 (36 ref.)

Tryptophan availability and the susceptibility to stress in multiple sclerosis: a hypothesis. Sandyk R. **Int J Neurosci** 1996 Jul;86(1–2):47–53 (85 ref.)

PATHOLOGY

Multiple sclerosis and amyloid deposits in the white matter of the brain. Nennesmo I, et al. **Acta Neuropathol (Berl)** 1997 Feb;93(2):205–9 (36 ref.)

Mechanisms of immune injury in multiple sclerosis. Brosnan CF, et al. **Brain Pathol** 1996 Jul;6(3):243–57 (100 ref.)

Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Lucchinetti CF, et al. **Brain Pathol** 1996 Jul;6(3):259–74 (94 ref.)

Magnetic resonance imaging in the differential diagnosis and monitoring of the treatment of multiple sclerosis. Filippi M, et al. **Curr Opin Neurol** 1996 Jun;9(3):178–86 (94 ref.)

Magnetic resonance in monitoring the natural history of multiple sclerosis and the effects of treatment [see comments] Filippi M, et al. **Ital J Neurol Sci** 1996 Dec; 17(6):385–91 (72 ref.) Comment in: Ital J Neurol Sci 1996 Dec;17(6):383–4.

MRI as a method to reveal in-vivo pathology in MS. Paty DW. **J Neural Transm Suppl** 1997;49:211–7 (37 ref.)

The Norton Lecture: a review of the oligodendrocyte in the multiple sclerosis lesion. Raine CS. **J Neuroimmunol** 1997 Aug;77(2):135–52 (123 ref.)

Multiple sclerosis: from a myelin point of view. Boccaccio GL, et al. **J Neurosci Res** 1996 Sep 15;45(6):647–54 (87 ref.)

Imaging of remyelination. Barkhof F. **Mult Scler** 1997 Apr; 3(2):129–32 (24 ref.)

[Pathogenesis of multiple sclerosis and other neural autoimmune diseases] Lassmann H. **Verh Dtsch Ges Pathol** 1996;80:109–15 (37 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Molecular remodeling of neurons in multiple sclerosis: what we know, and what we must ask about brain plasticity in demyelinating diseases. Waxman SG. **Adv Neurol** 1997; 73:109–20 (72 ref.)

MULTIPLE SCLEROSIS

Primary progressive multiple sclerosis. Thompson AJ, et al. **Brain** 1997 Jun;120 (Pt 6):1085–96 (88 ref.)
White matter disease and dementia. Rao SM. **Brain Cogn** 1996 Jul;31(2):250–68 (161 ref.)
Influence of the pineal gland on the expression of experimental allergic encephalomyelitis: possible relationship to the aquisition of multiple sclerosis. Sandyk R. **Int J Neurosci** 1997 Jun;90(1–2):129–33 (32 ref.)
The pineal gland, cataplexy, and multiple sclerosis. Sandyk R. **Int J Neurosci** 1995 Dec;83(3–4):153–63 (139 ref.)
Premenstrual exacerbation of symptoms in multiple sclerosis is attenuated by treatment with weak electromagnetic fields. Sandyk R. **Int J Neurosci** 1995 Dec;83(3–4):187–98 (139 ref.)
Clinical scales for multiple sclerosis. Sharrack B, et al. **J Neurol Sci** 1996 Jan;135(1):1–9 (79 ref.)
Review: cytokines and the pathogenesis of multiple sclerosis. Navikas V, et al. **J Neurosci Res** 1996 Aug 15;45(4):322–33 (115 ref.)
Rational clinical immunotherapy for multiple sclerosis. Hunter SF, et al. **Mayo Clin Proc** 1997 Aug;72(8):765–80 (120 ref.)
Both soluble and membrane-associated TNF activate brain microvascular endothelium: relevance to multiple sclerosis. Burger D, et al. **Mol Psychiatry** 1997 Mar;2(2):113–6 (31 ref.)
Remyelination in multiple sclerosis: a challenge for therapy. The 1996 European Charcot Foundation Lecture. Compston A. **Mult Scler** 1997 Apr;3(2):51–70 (87 ref.)
To what extent is oligodendrocyte progenitor migration a limiting factor in the remyelination of multiple sclerosis lesions? Franklin RJ, et al. **Mult Scler** 1997 Apr;3(2):84–7 (29 ref.)
Remyelination in multiple sclerosis. Lassmann H, et al. **Mult Scler** 1997 Apr;3(2):133–6 (30 ref.)
Promotion of endogenous remyelination in multiple sclerosis. Lucchinetti CF, et al. **Mult Scler** 1997 Apr;3(2):71–5 (56 ref.)
Growth factors and myelin regeneration in multiple sclerosis. Webster HD. **Mult Scler** 1997 Apr;3(2):113–20 (128 ref.)
Gastrointestinal dysfunction in multiple sclerosis. Fowler CJ, et al. **Semin Neurol** 1996 Sep;16(3):277–9 (13 ref.)
[Multiple sclerosis and quality of life] Hernández MA. **Rev Neurol** 1996 Oct;24(134):1221–3 (11 ref.) **(Spa)**

PREVENTION & CONTROL

Vaccination with autoreactive T cell clones in multiple sclerosis: overview of immunological and clinical data. Stinissen P, et al. **J Neurosci Res** 1996 Aug 15;45(4):500–11 (75 ref.)
Current and investigational therapies used to alter the course of disease in multiple sclerosis. Miller A. **South Med J** 1997 Apr;90(4):367–75 (56 ref.)

PSYCHOLOGY

Psychiatric manifestations of multiple sclerosis: a review [see comments] Rodgers J, et al. **Can J Psychiatry** 1996 Sep; 41(7):441–5 (41 ref.) Comment in: Can J Psychiatry 1997 Apr;42(3):324–5.
Multiple sclerosis and psychiatric disturbances: clinical aspects and a review of the literature. Giberti L, et al. **Ital J Neurol Sci** 1996 Jun;17(3):189–91 (24 ref.)

REHABILITATION

Effect of long-term implanted nerve cuff electrodes on the electrophysiological properties of human sensory nerves. Slot PJ, et al. **Artif Organs** 1997 Mar;21(3):207–9 (7 ref.)
Rehabilitation of progressive neurological disorders: a worthwhile challenge [editorial] Thompson AJ. **Curr Opin Neurol** 1996 Dec;9(6):437–40 (36 ref.)
Providing a neuropsychology service for people with multiple sclerosis in an interdisciplinary rehabilitation unit. Thompson SB. **Disabil Rehabil** 1996 Jul;18(7):348–53 (60 ref.)

THERAPY

Clinical outcomes assessment in multiple sclerosis. Rudick R, et al. **Ann Neurol** 1996 Sep;40(3):469–79 (47 ref.)
Interferon beta: the current position. Boothman BR. **Br J Hosp Med** 1997 Mar 19–Apr 1;57(6):277–80 (10 ref.)
Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Hohlfeld R. **Brain** 1997 May;120 (Pt 5):865–916 (372 ref.)
Interferon beta in multiple sclerosis. Arnason BG. **Clin Immunol Immunopathol** 1996 Oct;81(1):1–11 (101 ref.)
Understanding the molecular basis of cell migration; implications for clinical therapy in multiple sclerosis. Milner R. **Clin Sci (Colch)** 1997 Feb;92(2):113–22 (57 ref.)
Autoimmune pathogenesis of multiple sclerosis: role of autoreactive T lymphocytes and new immunotherapeutic strategies. Stinissen P, et al. **Crit Rev Immunol** 1997; 17(1):33–75 (357 ref.)
Measurement of treatment efficacy and new trial results in multiple sclerosis. Noseworthy JH, et al. **Curr Opin Neurol** 1997 Jun;10(3):201–10 (58 ref.)
New treatments for multiple sclerosis: a clinical perspective. Thompson AJ, et al. **Curr Opin Neurol** 1996 Jun; 9(3):187–98 (82 ref.)
Newer versus older treatments for relapsing-remitting multiple sclerosis. Weinstock-Guttman B, et al. **Drug Saf** 1996 Feb;14(2):121–30 (22 ref.)
Interferon beta-1B--hope or hype? **Drug Ther Bull** 1996 Feb; 34(2):9–11 (17 ref.)
Long term beneficial effects of weak electromagnetic fields in multiple sclerosis. Sandyk R. **Int J Neurosci** 1995 Nov; 83(1–2):45–57 (100 ref.)
Premenstrual exacerbation of symptoms in multiple sclerosis is attenuated by treatment with weak electromagnetic fields. Sandyk R. **Int J Neurosci** 1995 Dec;83(3–4):187–98 (139 ref.)
Role of interferons in demyelinating diseases. Arnason BG, et al. **J Neural Transm Suppl** 1997;49:117–23 (23 ref.)
Role of interferons in demyelinating disease. Johnson KP. **J Neural Transm Suppl** 1997;49:111–5 (13 ref.)
Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis and their application for new therapeutic strategies. Martin R. **J Neural Transm Suppl** 1997;49:53–67 (96 ref.)
Update on management and genetics of multiple sclerosis. Sadovnick AD. **J Neural Transm Suppl** 1997;50:167–72 (36 ref.)
Multiple sclerosis: symptomatic treatment. Thompson AJ. **J Neurol** 1996 Aug;243(8):559–65 (62 ref.)
Rational clinical immunotherapy for multiple sclerosis. Hunter SF, et al. **Mayo Clin Proc** 1997 Aug;72(8):765–80 (120 ref.)
The role of adhesion molecules in multiple sclerosis: biology, pathogenesis and therapeutic implications. Archelos JJ, et al. **Mol Med Today** 1997 Jul;3(7):310–21 (54 ref.)
Intravenous immunoglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis--the Israeli experience. MS Study Group. Achiron A, et al. **Mult Scler** 1997 Apr;3(2):142–4 (21 ref.)
Imaging of remyelination. Barkhof F. **Mult Scler** 1997 Apr; 3(2):129–32 (24 ref.)
Remyelination in multiple sclerosis: a challenge for therapy. The 1996 European Charcot Foundation Lecture. Compston A. **Mult Scler** 1997 Apr;3(2):51–70 (87 ref.)
Remyelination in multiple sclerosis. Lassmann H, et al. **Mult Scler** 1997 Apr;3(2):133–6 (30 ref.)
Experimental immunotherapies for multiple sclerosis. Martin R, et al. **Springer Semin Immunopathol** 1996;18(1):1–24 (163 ref.)
Beta-interferon and multiple sclerosis. Hall GL, et al. **Trends Neurosci** 1997 Feb;20(2):63–7 (66 ref.)
[Interferon-beta-1b treatment of disseminated sclerosis] Sørensen S. **Ugeskr Laeger** 1997 Feb 3;159(6):779–84 (30 ref.) **(Dan)**
[Clinical testing of the treatment effect of interferon-beta Ia and Ib in multiple sclerosis] de Haan RJ, et al. **Ned Tijdschr Geneeskd** 1996 Nov 2;140(44):2168–71 (24 ref.) **(Dut)**
[Causal therapy of multiple sclerosis] Pöhlau D, et al. **Dtsch Med Wochenschr** 1996 Nov 8;121(45):1407–14 (44 ref.) **(Ger)**
[Interferon-beta 1a in therapy of relapsing-remitting multiple sclerosis] Hartung HP, et al. **Nervenarzt** 1997 Jun; 68(6):525–7 (13 ref.) **(Ger)**
[Current therapy of multiple sclerosis. Therapy with monoclonal antibodies to T-cell antigens (CD3, CD4, CD52)] Schmidt S, et al. **Nervenarzt** 1996 Feb;67(2):170–6 (44 ref.) (Eng. Abstr.) **(Ger)**
[Multiple sclerosis. New therapeutic strategies in the experimental stage] Zipp F, et al. **Nervenarzt** 1997 Feb; 68(2):94–101 (66 ref.) (Eng. Abstr.) **(Ger)**
[Current therapy of multiple sclerosis] Vass K, et al. **Wien Med Wochenschr** 1996;146(19–20):514–9 (54 ref.) (Eng. Abstr.) **(Ger)**
[Immunotherapy of multiple sclerosis: the use of magnetic resonance imaging in the evaluation of clinical trials] Ozawa K, et al. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1501–3 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Multiple sclerosis: update on current therapies] Sato T. **Rinsho Shinkeigaku** 1995 Dec;35(12):1505–7 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Pathogenesis and therapy of multiple sclerosis] Nouza K, et al. **Bratisl Lek Listy** 1997 Apr;98(4):199–203 (35 ref.) (Eng. Abstr.) **(Slo)**
[Treatment of multiple sclerosis with interferons] Nogales-Gaete J, et al. **Rev Med Chil** 1996 May; 124(5):597–604 (38 ref.) (Eng. Abstr.) **(Spa)**

VIROLOGY

Viruses and multiple sclerosis. Dalgleish AG. **Acta Neurol Scand Suppl** 1997;169:8–15 (98 ref.)
Pathogenesis of chronic progressive myelopathy associated with human T-cell lymphotropic virus type I. Höllsberg P. **Acta Neurol Scand Suppl** 1997;169:86–93 (62 ref.)
The implications of Epstein-Barr virus in multiple sclerosis--a review. Munch M, et al. **Acta Neurol Scand Suppl** 1997;169:59–64 (56 ref.)
Possible involvement of endogenous retroviruses in the development of autoimmune disorders, especially multiple sclerosis. Rasmussen HB, et al. **Acta Neurol Scand Suppl** 1997;169:32–7 (28 ref.)
Canine distemper virus and multiple sclerosis. Hodge MJ, et al. **Neurology** 1997 Aug;49(2 Suppl 2):S62–9 (43 ref.)

MULTIPLE TRAUMA

Thyrotoxicosis in a patient with multiple trauma: value of "AMPLE" history taking [see comments] Fitz-Henry J, et al. **BMJ** 1996 Oct 19;313(7063):997–8 (6 ref.) Comment in: BMJ 1997 Mar 8;314(7082):752; discussion 753. Comment in: BMJ 1997 Mar 8;314(7082):752–3.

CLASSIFICATION

[Value of clinical scoring systems for evaluation of injury severity and as an instrument for quality management of severely injured patients] Bouillon B, et al. **Zentralbl Chir** 1996;121(11):914–23 (45 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Traumatic asphyxia: an indicator of potentially severe injury in trauma. Dunne JR, et al. **Injury** 1996 Dec;27(10):746–9 (29 ref.)
[Bacillus cereus pneumonia after thoracic trauma. Case report and review of the literature] Bastian L, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Feb; 32(2):124–9 (28 ref.) (Eng. Abstr.) **(Ger)**
[Ventricular septal rupture after blunt chest trauma] Roithinger FX, et al. **Dtsch Med Wochenschr** 1996 Nov 15;121(46):1424–7 (23 ref.) (Eng. Abstr.) **(Ger)**
[Hemolysis and multiple trauma. A clinical case report] Buzio M, et al. **Minerva Chir** 1997 Apr;52(4):485–7 (10 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Late displacement of a fracture dislocation at the lumbosacral junction. A case study. Steinitz DK, et al. **Spine** 1997 May 1;22(9):1024–7 (9 ref.)
[Severe trauma in children] Paut O, et al. **Arch Pediatr** 1997 May;4(5):443–59 (93 ref.) (Eng. Abstr.) **(Fre)**
[Renal injury in childhood] Rengo M, et al. **G Chir** 1997 Jun–Jul;18(6–7):359–61 (22 ref.) (Eng. Abstr.) **(Ita)**
[Delayed rupture of the spleen in a multiply injured patient] Lică I, et al. **Chirurgia (Bucur)** 1997 May–Jun;92(3):205–10 (12 ref.) (Eng. Abstr.) **(Rum)**

ETIOLOGY

Obstructed labor injury complex: obstetric fistula formation and the multifaceted morbidity of maternal birth trauma in the developing world. Arrowsmith S, et al. **Obstet Gynecol Surv** 1996 Sep;51(9):568–74 (15 ref.)
[Coronary vascular damage in thoracic trauma] Schwaiblmair M, et al. **Dtsch Med Wochenschr** 1997 Aug 22; 122(34–35):1043–6 (34 ref.) **(Ger)**

IMMUNOLOGY

[Mediators and antagonists in therapy of multiple trauma. Reliable outcome or wishful thinking?] Gebhard F. **Unfallchirurg** 1997 Apr;100(4):324–8 (43 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

[Fat embolism--a too infrequently determined pathoanatomic diagnosis] Behn C, et al. **Versicherungsmedizin** 1997 Jun 1;49(3):89–93 (30 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Posttraumatic multiple-organ dysfunction syndrome: role of mediators in systemic inflammation and subsequent organ failure. Pastores SM, et al. **Acad Emerg Med** 1996 Jun; 3(6):611–22 (150 ref.)
[Pathophysiology of polytrauma] Rose S, et al. **Zentralbl Chir** 1996;121(11):896–913 (66 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

New concepts in trauma. Burch JM. **Am J Surg** 1997 Jan; 173(1):44–6; discussion 47–8 (11 ref.)
Massive pelvis injuries treated with amputations: case reports and literature review. Lawless MW, et al. **J Trauma** 1997 Jun;42(6):1169–75 (19 ref.)
Management of pelvic fractures with concomitant urologic injuries. Taffet R. **Orthop Clin North Am** 1997 Jul; 28(3):389–96 (47 ref.)
Damage control for devastating pelvic and extremity injuries. Henry SM, et al. **Surg Clin North Am** 1997 Aug; 77(4):879–95 (47 ref.)
Reoperation. Planned and unplanned. Hirshberg A, et al. **Surg Clin North Am** 1997 Aug;77(4):897–907 (14 ref.)
[Impalement injury of the colon, iliac vein and sacrum--a rare combination in penetrating abdominal trauma. A case report] Funke M, et al. **Chirurg** 1996 Nov;67(11):1184–7 (27 ref.) (Eng. Abstr.) **(Ger)**
[Injuries of the pelvic ring] Culemann U, et al. **Unfallchirurg** 1997 Jun;100(6):487–96 (14 ref.) **(Ger)**
[Intramedullary nailing in polytrauma. Pro and contra early management] Nast-Kolb D. **Unfallchirurg** 1997 Jan; 100(1):80–4 (34 ref.) (Eng. Abstr.) **(Ger)**
[Complex injury of the elbow joint] Regel G, et al. **Unfallchirurg** 1996 Feb;99(2):92–99 (18 ref.) (Eng. Abstr.) **(Ger)**
[Fracture management in polytrauma. Timing and tactics] Regel G, et al. **Unfallchirurg** 1997 Mar;100(3):234–48 (21 ref.) **(Ger)**
[Strategy of surgical management of polytrauma] Marzi I, et al. **Zentralbl Chir** 1996;121(11):950–62 (47 ref.) (Eng. Abstr.) **(Ger)**

[Emergency pancreaticoduodenal resection in closed abdominal trauma] Dolgushin NE, et al. **Vestn Khir Im I I Grek** 1996;155(2):58–9 (17 ref.) **(Rus)**

THERAPY

Blunt abdominal trauma and severe pelvic rupture. What to do? Hötker U, et al. **Acta Chir Belg** 1997 Apr;97(2):65–8 (16 ref.)

Setting standards and implementing quality improvement in trauma care. Dick WF. **Eur J Emerg Med** 1996 Dec; 3(4):270–3 (7 ref.)

The Kobe earthquake: the system response. A disaster report from Japan. Tanaka K. **Eur J Emerg Med** 1996 Dec; 3(4):263–9 (7 ref.)

Orthopaedic challenges in the aging population: trauma treatment and related clinical issues. Koval KJ, et al. **Instr Course Lect** 1997;46:423–30 (39 ref.)

The management of fractures with soft-tissue disruptions. Sanders R, et al. **Instr Course Lect** 1994;43:559–70 (87 ref.)

Care of the polytraumatised patient [see comments] Tscherne H, et al. **J Bone Joint Surg Br** 1996 Sep;78(5):840–52 (32 ref.) Comment in: J Bone Joint Surg Br 1997 May;79(3):510. Comment in: J Bone Joint Surg Br 1997 Jul;79(4):696–7.

Felvic and bladder trauma: a case report and subject review. Wright DG, et al. **J Orthop Trauma** 1996;10(5):351–4 (28 ref.)

[Planning for evacuation of the severely traumatised patient in Africa] Thiery JF, et al. **Med Trop (Mars)** 1996; 56(4):341–4 (6 ref.) **(Fre)**

[Avalanche emergency. New aspects of the pathophysiology and therapy of buried avalanche victims] Brugger H, et al. **Wien Klin Wochenschr** 1997 Mar 14;109(5):145–59 (114 ref.) (Eng. Abstr.) **(Ger)**

[Perspectives of polytrauma management] Mutschler W, et al. **Zentralbl Chir** 1996;121(11):979–84 (39 ref.) (Eng. Abstr.) **(Ger)**

[Intensive care medicine aspects of polytrauma] Ziegenfuss T, et al. **Zentralbl Chir** 1996;121(11):963–78 (122 ref.) (Eng. Abstr.) **(Ger)**

[Emergency management of polytrauma patients] Ziegenfuss T. **Zentralbl Chir** 1996;121(11):924–42 (91 ref.) (Eng. Abstr.) **(Ger)**

[Airway management of the multiple trauma patient] Ben-Abraham R, et al. **Harefuah** 1997 Jun 15; 132(12):897–902 (35 ref.) **(Heb)**

ULTRASONOGRAPHY

[Valvular lesions in the course of nonpenetrating thoracic trauma: their diagnosis by transesophageal echocardiography] Ussia GP, et al. **Cardiologia** 1996 Nov; 41(11):1107–11 (39 ref.) (Eng. Abstr.) **(Ita)**

MULTIPLICATION-STIMULATING ACTIVITY see **INSULIN-LIKE GROWTH FACTOR II**

MULTIPOTENTIAL COLONY-STIMULATING FACTOR see **INTERLEUKIN-3**

MULTIVARIATE ANALYSIS

Multivariate statistical analysis for anatomic pathology. Part II: failure time analysis. Vollmer RT. **Am J Clin Pathol** 1996 Oct;106(4):522–34 (16 ref.)

An overview of techniques for dealing with large numbers of independent variables in epidemiologic studies. Dohoo IR, et al. **Prev Vet Med** 1997 Jan;29(3):221–39 (24 ref.)

Regression analysis and multivariate analysis. Duleba AJ, et al. **Semin Reprod Endocrinol** 1996 May;14(2):139–53 (10 ref.)

Classical versus artificial neural network analysis [comment] Newey VR. **Ultrasound Obstet Gynecol** 1997 Jul;10(1):5–8 (45 ref.) Comment on: Ultrasound Obstet Gynecol 1997 Jul;10(1):41–7. Comment on: Ultrasound Obstet Gynecol 1997 Jul;10(1):48–53.

Quantitative analysis of multivariate data using artificial neural networks: a tutorial review and applications to the deconvolution of pyrolysis mass spectra. Goodacre R, et al. **Zentralbl Bakteriol** 1996 Aug;284(4):516–39 (114 ref.)

[Examples of pitfalls in statistical analysis—5: Analysis of a multiple factor model] Nagata O. **Masui** 1997 Jan; 46(1):42–8 (7 ref.) (Eng. Abstr.) **(Jpn)**

MUMMIES

PATHOLOGY

[Pre-Columbian paleopathology] Allison MJ. **Arch Biol Med Exp (Santiago)** 1987;20(1):21–30 (8 ref.) **(Spa)**

MUMPS

COMPLICATIONS

Guillain-Barré syndrome and ethylene diamine tetraacetic acid-dependent pseudothrombocytopenia associated with mumps. Sawazaki A, et al. **Intern Med** 1996 Dec; 35(12):996–9 (34 ref.)

Mumps labyrinthitis, endolymphatic hydrops and sudden deafness in succession in the same ear. Hydén D. **ORL J Otorhinolaryngol Relat Spec** 1996 Nov-Dec; 58(6):338–42 (9 ref.)

[Central nervous system infection caused by mumps virus] Saijo M, et al. **Nippon Rinsho** 1997 Apr;55(4):870–5 (32 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Mumps virus infection: case report of an unusual head and neck manifestation. Linder TE, et al. **Am J Otolaryngol** 1996 Nov-Dec;17(6):420–3 (15 ref.)

MRI evidence of labyrinthine and eighth-nerve bundle involvement in mumps virus sudden deafness and vertigo. Comacchio F, et al. **ORL J Otorhinolaryngol Relat Spec** 1996 Nov-Dec; 58(6):295–7 (18 ref.)

MUMPS VACCINE

Laboratory tests for mumps vaccines. Minor PD. **Biologicals** 1997 Mar;25(1):35–40 (17 ref.)

MUNCHAUSEN SYNDROME

Factitious sickle cell acute painful episodes: a secondary type of Munchausen syndrome. Ballas SK. **Am J Hematol** 1996 Dec;53(4):254–8 (7 ref.)

DIAGNOSIS

Munchausen syndrome/Munchausen syndrome by proxy. Murray JB. **J Psychol** 1997 May;131(3):343–52 (69 ref.)

Factitious quadriplegia. A rare new case and literature review. Feldman MD, et al. **Psychosomatics** 1997 Jan-Feb; 38(1):76–80 (18 ref.)

[Simulated illness] Bock KD. **Med Klin** 1997 Jan 15; 92(1):41–5 (14 ref.) **(Ger)**

[Artificially-induced disorders and dissociation] Freyberger HJ, et al. **Med Klin** 1997 Jan 15;92(1):46–8 (11 ref.) **(Ger)**

PSYCHOLOGY

Munchausen's syndrome: a medico-legal dilemma. Mydlo JH, et al. **Med Sci Law** 1997 Jul;37(3):198–201 (15 ref.)

[Self-injury behavior] Hönigl D, et al. **Acta Med Austriaca** 1997;24(1):19–22 (16 ref.) (Eng. Abstr.) **(Ger)**

MUNCHAUSEN SYNDROME BY PROXY

DIAGNOSIS

Munchausen syndrome by proxy. Anderson J, et al. **Br J Hosp Med** 1996 Jun 19-Jul 9;56(1):43–5 (18 ref.)

Factitious illness by proxy. Munchausen syndrome by proxy. Bools C. **Br J Psychiatry** 1996 Sep;169(3):268–75 (50 ref.)

Persistent cerebrospinal fluid otorrhea: a case of Munchausen's syndrome by proxy. Mra Z, et al. **Int J Pediatr Otorhinolaryngol** 1997 Jul 18;41(1):59–63 (14 ref.)

Munchausen syndrome/Munchausen syndrome by proxy. Murray JB. **J Psychol** 1997 May;131(3):343–52 (69 ref.)

Case records of the LeBonheur Children's Medical Center: a 17-month-old girl with abdominal distension and portal vein gas [clinical conference] Herman MI, et al. **Pediatr Emerg Care** 1997 Jun;13(3):237–42 (45 ref.)

[Simulated illness] Bock KD. **Med Klin** 1997 Jan 15; 92(1):41–5 (14 ref.) **(Ger)**

ETIOLOGY

Munchausen syndrome by proxy. Anderson J, et al. **Br J Hosp Med** 1996 Jun 19-Jul 9;56(1):43–5 (18 ref.)

PREVENTION & CONTROL

Illness induction syndrome: paper I—a series of 41 children from 37 families identified at The Great Ormond Street Hospital for Children NHS Trust. Gray J, et al. **Child Abuse Negl** 1996 Aug;20(8):655–73 (41 ref.)

MUNG BEAN NUCLEASE see **ASPERGILLUS NUCLEASE S1**

MUPIROCIN

THERAPEUTIC USE

Mupirocin resistance and methicillin-resistant Staphylococcus aureus (MRSA). Eltringham I. **J Hosp Infect** 1997 Jan;35(1):1–8 (44 ref.)

MUR-NAC-L-ALA-D-ISOGLN see **ACETYLMURAMYL-ALANYL-ISOGLUTAMINE**

MURAMIDASE

BIOSYNTHESIS

Cytosine methylation changes during normal hematopoiesis and in acute myeloid leukemia. Lübbert M, et al. **Leukemia** 1997 Mar;11 Suppl 1:S12–8 (46 ref.)

GENETICS

Regulation of the chicken lysozyme locus in transgenic mice. Bonifer C, et al. **Crit Rev Eukaryot Gene Expr** 1996; 6(2–3):285–97 (58 ref.)

Cytosine methylation changes during normal hematopoiesis and in acute myeloid leukemia. Lübbert M, et al. **Leukemia** 1997 Mar;11 Suppl 1:S12–8 (46 ref.)

IMMUNOLOGY

Appreciating the complexity of MHC class II peptide binding: lysozyme peptide and I-Ak. Nelson CA, et al. **Immunol Rev** 1996 Jun;151:81–105 (57 ref.)

METABOLISM

Appreciating the complexity of MHC class II peptide binding: lysozyme peptide and I-Ak. Nelson CA, et al. **Immunol Rev** 1996 Jun;151:81–105 (57 ref.)

MURAMOYLPENTAPEPTIDE CARBOXYPEPTIDASE

GENETICS

Genetics and molecular biology of beta-lactam-resistant pneumococci. Coffey TJ, et al. **Microb Drug Resist** 1995 Spring;1(1):29–34 (39 ref.)

METABOLISM

[Penicillin—binding protein: the target for beta-lactam antibiotics, beta-lactamases and their inhibitors] Lessel J. **Pharm Unserer Zeit** 1996 Jan;25(1):17–27 (24 ref.) **(Ger)**

MURAMYL DIPEPTIDE see **ACETYLMURAMYL-ALANYL-ISOGLUTAMINE**

MURDER see **HOMICIDE**

MUREIN see **PEPTIDOGLYCAN**

MURIDAE

GENETICS

Chromosomal and molecular divergence in the Indian pygmy field mice Mus booduga-terricolor lineage of the subgenus Mus. Sharma T. **Genetica** 1996 May;97(3):331–8 (34 ref.)

Hybrid sterility in the mouse [published erratum appears in Trends Genet 1997 Jan;13(1):42] Forejt J. **Trends Genet** 1996 Oct;12(10):412–7 (51 ref.)

MURIDS see **MURIDAE**

MURINE ACQUIRED IMMUNODEFICIENCY SYNDROME

COMPLICATIONS

Interactions between AIDS viruses and malaria parasites: a role for macrophages? Marussig M, et al. **Res Virol** 1996 Mar-Jun;147(2-3):139–45 (55 ref.)

IMMUNOLOGY

Alcohol consumption alters cytokine release during murine AIDS. Wang JY, et al. **Alcohol** 1997 Mar-Apr;14(2):155–9 (38 ref.)

Role of IL12 in MAIDS. Giese NA, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):600–5 (25 ref.)

Murine AIDS, a key to understanding retrovirus-induced immunodeficiency. Liang B, et al. **Viral Immunol** 1996; 9(4):225–39 (122 ref.)

MURINE AIDS see **MURINE ACQUIRED IMMUNODEFICIENCY SYNDROME**

MURINE GASTROENTERITIS VIRUS see **GASTROENTERITIS VIRUS, MURINE**

MURINE HERPESVIRUS 1 see **MUROMEGALOVIRUS**

MURINE LEUKEMIA VIRUSES see **LEUKEMIA VIRUSES, MURINE**

MURINE TUMOR VIRUSES see **TUMOR VIRUSES, MURINE**

MUROMEGALOVIRUS

IMMUNOLOGY

Novel therapeutic strategies against cytomegalovirus infection. Ranger-Zisman B, et al. **Nat Immun** 1995 Sep; 14(5-6):250–61 (26 ref.)

IL12 in acute viral infectious disease. Biron CA, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):590–600 (37 ref.)

MUROMONAB-CD3

PHARMACOLOGY

Muromonab CD3: a reappraisal of its pharmacology and use

MUROMONAB-CD3

as prophylaxis of solid organ transplant rejection. Wilde MI, et al. **Drugs** 1996 May;51(5):865–94 (214 ref.)

THERAPEUTIC USE

Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Wilde MI, et al. **Drugs** 1996 May;51(5):865–94 (214 ref.)

Biological immunosuppressants: the way to clinical transplantation tolerance. Chatenoud L. **Transplant Proc** 1997 Feb–Mar;29(1–2):51–5 (44 ref.)

MUS see **MURIDAE**

MUS MUSCULUS see **MICE**

MUSCA AUTUMNALIS see **MUSCIDAE**

MUSCARINE

METABOLISM

[Regulation of muscarinic potassium channels] Thiebot H, et al. **C R Seances Soc Biol Fil** 1996;190(2–3):237–41 (13 ref.) (Eng. Abstr.) **(Fre)**

MUSCARINIC ACETYLCHOLINE RECEPTORS see **RECEPTORS, MUSCARINIC**

MUSCARINIC AGENTS see **CHOLINERGIC AGENTS**

MUSCARINIC AGONISTS

Selective muscarinic receptor agonists and antagonists. Eglen RM, et al. **Pharmacol Toxicol** 1996 Feb;78(2):59–68 (101 ref.)

PHARMACOLOGY

Behavioural evaluation of cholinergic drugs. Iversen SD. **Life Sci** 1997;60(13–14):1145–52 (17 ref.)

Muscarinic regulation of the L-type calcium current in isolated cardiac myocytes. Méry PF, et al. **Life Sci** 1997; 60(13–14):1113–20 (111 ref.)

In vivo pharmacology of butylthio[2.2.2] (LY297802 / NNC11-1053), an orally acting antinociceptive muscarinic agonist. Shannon HE, et al. **Life Sci** 1997;60(13–14):969–76 (24 ref.)

THERAPEUTIC USE

From molecular structure to Alzheimer therapy. Giacobini E. **Jpn J Pharmacol** 1997 Jul;74(3):225–41 (87 ref.)

MUSCARINIC ANTAGONISTS

see related
PARASYMPATHOLYTICS

Selective muscarinic receptor agonists and antagonists. Eglen RM, et al. **Pharmacol Toxicol** 1996 Feb;78(2):59–68 (101 ref.)

PHARMACOLOGY

Studies of the pharmacology, localization, and structure of muscarinic acetylcholine receptors. Brann MR, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:225–36 (59 ref.)

Drug receptor mechanisms in smooth muscle: beta-chloroethylamine-sensitive and -resistant receptor mechanisms. Takayanagi I, et al. **Jpn J Pharmacol** 1997 Jan;73(1):1–22 (89 ref.)

Tolterodine--a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Nilvebrant L, et al. **Life Sci** 1997;60(13–14):1129–36 (26 ref.)

Side effects of nondepolarizing muscle relaxants: relationship to their antinicotinic and antimuscarinic actions. Vizi ES, et al. **Pharmacol Ther** 1997;73(2):75–89 (105 ref.)

POISONING

Hyoscyamus falezlez C: a poisonous plant of north Africa. el Bahri L, et al. **Vet Hum Toxicol** 1996 Oct;38(5):378–9 (19 ref.)

THERAPEUTIC USE

Syncope: pathophysiology, diagnosis, and pharmacotherapy. Lazarus JC, et al. **Ann Pharmacother** 1996 Sep; 30(9):994–1005 (51 ref.)

Discovery & development of selective M3 antagonists for clinical use. Alabaster VA. **Life Sci** 1997;60(13–14):1053–60 (24 ref.)

[Gastrocepin in the treatment of gastroenterological diseases] Sheptulin AA. **Klin Med (Mosk)** 1996;74(9):13–5 (36 ref.) **(Rus)**

MUSCARINIC RECEPTORS see **RECEPTORS, MUSCARINIC**

MUSCI see **MOSSES**

MUSCIDAE

Bionomics of the face fly, Musca autumnalis. Krafsur ES, et al. **Annu Rev Entomol** 1997;42:503–23 (135 ref.)

PHYSIOLOGY

Daily rhythms in cells of the fly's optic lobe: taking time out from the circadian clock. Meinertzhagen IA, et al. **Trends Neurosci** 1996 Jul;19(7):285–91 (62 ref.)

MUSCIMOL

see related
RECEPTORS, GABA-A

MUSCLE CONTRACTION

see related
MUSCLE FATIGUE
MUSCLE RELAXATION

Viscoelasticity and function of connectin/titin filaments in skinned muscle fibers. Higuchi H. **Adv Biophys** 1996; 33:159–71 (26 ref.)

Titin/connectin and nebulin: giant protein rulers of muscle structure and function. Wang K. **Adv Biophys** 1996; 33:123–34 (84 ref.)

Exercise pressor reflex: studies on the effect of skeletal muscle fiber type and spinal cord transmission. Wilson LB, et al. **Adv Exp Med Biol** 1995;381:187–97 (34 ref.)

Protein kinase C mediation of Ca(2+)-independent contractions of vascular smooth muscle. Walsh MP, et al. **Biochem Cell Biol** 1996;74(4):485–502 (214 ref.)

Fifty ways to love your lever: myosin motors. Block SM. **Cell** 1996 Oct 18;87(2):151–7 (51 ref.)

The swinging lever-arm hypothesis of muscle contraction. Holmes KC. **Curr Biol** 1997 Feb 1;7(2):R112–8 (27 ref.)

Three-dimensional scapular orientation and muscle activity at selected positions of humeral elevation. Ludewig PM, et al. **J Orthop Sports Phys Ther** 1996 Aug;24(2):57–65 (58 ref.)

Shape and length of myosin heads and radial compressive forces in muscle. Morel JE, et al. **J Theor Biol** 1997 Jan 21;184(2):133–8 (37 ref.)

Contractility of the ventilatory pump muscles. Farkas GA, et al. **Med Sci Sports Exerc** 1996 Sep;28(9):1106–14 (101 ref.)

Muscle contraction and fatigue. The role of adenosine 5'-diphosphate and inorganic phosphate. McLester JR Jr. **Sports Med** 1997 May;23(5):287–305 (124 ref.)

[Analysis of intracellular calcium concentration in tissues--special reference to synchronous analysis of the calcium and smooth muscle contraction] Karaki H. **Nippon Seirigaku Zasshi** 1995;57(12):469–76 (10 ref.) **(Jpn)**

DRUG EFFECTS

Therapeutic uses of botulinum toxin. Wheeler AH. **Am Fam Physician** 1997 Feb 1;55(2):541–5, 548 (13 ref.)

Pharmacology of the internal anal sphincter and abnormalities in faecal incontinence. Speakman CT. **Eur J Gastroenterol Hepatol** 1997 May;9(5):442–6 (56 ref.)

Modulation of the calcium sensitivity of the smooth muscle contractile apparatus: molecular mechanisms, pharmacological and pathophysiological implications. Savineau JP, et al. **Fundam Clin Pharmacol** 1997; 11(4):289–99 (103 ref.)

[Effect of vitamin E on the endothelial function of the regenerated aorta in rats following direct arterial injury] Cartier R, et al. **Ann Chir** 1996;50(8):673–81 (36 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Calcium in close quarters: microdomain feedback in excitation-contraction coupling and other cell biological phenomena. Ríos E, et al. **Annu Rev Biophys Biomol Struct** 1997;26:47–82 (105 ref.)

Dihydropyridine receptor-ryanodine receptor interactions in skeletal muscle excitation-contraction coupling. Meissner G, et al. **Biosci Rep** 1995 Oct;15(5):399–408 (53 ref.)

Contractile properties of afferent and efferent arterioles. Ito S, et al. **Clin Exp Pharmacol Physiol** 1997 Jul;24(7):532–5 (30 ref.)

Functional consequences of acute and chronic hypoxia on respiratory and skeletal muscles in mammals. Jammes Y, et al. **Comp Biochem Physiol A Physiol** 1997 Sep; 118(1):15–22 (54 ref.)

Crustacean muscle plasticity: molecular mechanisms determining mass and contractile properties. Mykles DL. **Comp Biochem Physiol B Biochem Mol Biol** 1997 Jul; 117(3):367–78 (105 ref.)

F-waves in clinical neurophysiology: a review, methodological issues and overall value in peripheral neuropathies. Panayiotopoulos CP, et al. **Electroencephalogr Clin Neurophysiol** 1996 Oct; 101(5):365–74 (75 ref.)

A nonlinear mathematical model of electrically stimulated skeletal muscle. Dorgan SJ, et al. **IEEE Trans Rehabil Eng** 1997 Jun;5(2):179–94 (55 ref.)

Current research on muscle activity about the shoulder. Kelly BT, et al. **Instr Course Lect** 1997;46:53–66 (98 ref.)

The physiological and metabolic consequences of muscle denervation. Frostick SP. **Int Angiol** 1995 Sep;14(3):278–87 (92 ref.)

Eccentric contractions require unique activation strategies by the nervous system. Enoka RM. **J Appl Physiol** 1996 Dec;81(6):2339–46 (51 ref.)

Sliding and ATPase. Oosawa F. **J Biochem (Tokyo)** 1995 Nov;118(5):863–70 (37 ref.)

Analysis of the electromyographic interference pattern. Sanders DB, et al. **J Clin Neurophysiol** 1996 Sep; 13(5):385–400 (36 ref.)

Cellular metabolic homeostasis during large-scale change in ATP turnover rates in muscles. Hochachka PW, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):381–6 (46 ref.)

Measurement of human muscle fatigue. Vøllestad NK. **J Neurosci Methods** 1997 Jun 27;74(2):219–27 (54 ref.)

Regulation of vascular smooth muscle contraction. The roles of Ca2+, protein kinase C and myosin light chain phosphatase. Takuwa Y. **Jpn Heart J** 1996 Nov; 37(6):793–813 (116 ref.)

Maturational aspects of human airway smooth muscle function. Panitch HB. **Monaldi Arch Chest Dis** 1996 Oct; 51(5):413–8 (41 ref.)

Excitation-Ca2+ release-contraction coupling in single aged human skeletal muscle fiber. Delbono O, et al. **Muscle Nerve Suppl** 1997;5:S88–92 (19 ref.)

Neural strategies in the control of muscle force. Enoka RM. **Muscle Nerve Suppl** 1997;5:S66–9 (21 ref.)

Noninvasive measures of central and peripheral activation in human muscle fatigue. Kent-Braun JA. **Muscle Nerve Suppl** 1997;5:S98–101 (12 ref.)

Contractile protein changes in urinary bladder smooth muscle during obstruction-induced hypertrophy. Chacko S, et al. **Scand J Urol Nephrol Suppl** 1997;184:67–76 (82 ref.)

Initiation of contraction in detrusor smooth muscle. Fry CH, et al. **Scand J Urol Nephrol Suppl** 1997;184:7–14 (26 ref.)

Changed metabolism of detrusor muscle cells from obstructed rat urinary bladder. Uvelius B, et al. **Scand J Urol Nephrol Suppl** 1997;184:59–65 (27 ref.)

The role of ryanodine receptor isoforms in the structure and function of the vertebrate triad. Block BA, et al. **Soc Gen Physiol Ser** 1996;51:47–65 (56 ref.)

Functional significance of membrane architecture in skeletal and cardiac muscle. Franzini-Armstrong C. **Soc Gen Physiol Ser** 1996;51:3–18 (72 ref.)

Triadin, a linker for calsequestrin and the ryanodine receptor. Guo W, et al. **Soc Gen Physiol Ser** 1996;51:19–28 (28 ref.)

Regulatory interactions between calcium ATPases and phospholamban. MacLennan DH, et al. **Soc Gen Physiol Ser** 1996;51:89–103 (72 ref.)

[Exteroceptive suppression of activity of the temporal muscle. Principles and applications] Göbel H, et al. **Nervenarzt** 1996 Oct;67(10):846–59 (102 ref.) (Eng. Abstr.) **(Ger)**

[Molecular mechanisms for Ca2+ dependent regulation of various muscle types] Dąbrowska R. **Postepy Biochem** 1996;42(2):195–203 (69 ref.) **(Pol)**

MUSCLE CRAMP

Leg cramps in children. Leung AK, et al. **Clin Pediatr (Phila)** 1997 Feb;36(2):69–73 (32 ref.)

ETIOLOGY

Aetiology of skeletal muscle 'cramps' during exercise: a novel hypothesis. Schwellnus MP, et al. **J Sports Sci** 1997 Jun; 15(3):277–85 (45 ref.)

Exercise-induced muscle cramp. Proposed mechanisms and management. Bentley S. **Sports Med** 1996 Jun;21(6):409–20 (28 ref.)

MUSCLE DYSTONIA see **DYSTONIA**

MUSCLE FATIGUE

Evaluation of skeletal muscle fatigue in patients with heart failure. Wilson JR. **J Mol Cell Cardiol** 1996 Nov; 28(11):2287–92 (22 ref.)

DRUG EFFECTS

The effects of sodium bicarbonate ingestion on exercise performance. Linderman JK, et al. **Sports Med** 1994 Aug; 18(2):75–80 (34 ref.)

PHYSIOLOGY

Insights into motor performance and muscle fatigue based on transcranial stimulation of the human motor cortex. Gandevia SC. **Clin Exp Pharmacol Physiol** 1996 Oct-Nov; 23(10–11):957–60 (48 ref.)

Fatigue of the respiratory muscles. Roussos C, et al. **Intensive Care Med** 1996 Feb;22(2):134–55 (87 ref.)

Measurement of human muscle fatigue. Vøllestad NK. **J Neurosci Methods** 1997 Jun 27;74(2):219–27 (54 ref.)

Mechanisms of muscle fatigue in intense exercise. Green HJ. **J Sports Sci** 1997 Jun;15(3):247–56 (68 ref.)

Aetiology of skeletal muscle 'cramps' during exercise: a novel hypothesis. Schwellnus MP, et al. **J Sports Sci** 1997 Jun; 15(3):277–85 (45 ref.)

Respiratory muscle fatigue during exercise: implications for performance. Johnson BD, et al. **Med Sci Sports Exerc** 1996 Sep;28(9):1129–37 (48 ref.)

Noninvasive measures of central and peripheral activation in human muscle fatigue. Kent-Braun JA. **Muscle Nerve Suppl** 1997;5:S98–101 (12 ref.)

Muscle contraction and fatigue. The role of adenosine 5'-diphosphate and inorganic phosphate. McLester JR Jr. **Sports Med** 1997 May;23(5):287–305 (124 ref.)

[Skeletal musculature modifications and mechanisms of fatigue in chronic heart failure] Serafini F, et al. **G Ital Cardiol** 1997 Jun;27(6):603–11 (62 ref.) (Eng. Abstr.) **(Ita)**

MUSCLE FIBERS

Human skeletal muscle fiber types: delineation, development, and distribution. Staron RS. **Can J Appl Physiol** 1997 Aug; 22(4):307–27 (142 ref.)

CHEMISTRY

Towards an understanding of the dystrophin–glycoprotein complex: linkage between the extracellular matrix and the membrane cytoskeleton in muscle fibers. Ohlendieck K. **Eur J Cell Biol** 1996 Jan;69(1):1–10 (107 ref.)

CYTOLOGY

Mechanisms of formation of muscle fiber types. Stockdale FE. **Cell Struct Funct** 1997 Feb;22(1):37–43 (54 ref.)

Mammalian skeletal muscle fiber type transitions. Pette D, et al. **Int Rev Cytol** 1997;170:143–223 (750 ref.)

DRUG EFFECTS

Sarcoplasmic reticulum calcium release in frog cut muscle fibers in the presence of a large concentration of EGTA. Jong DS, et al. **Soc Gen Physiol Ser** 1996;51:255–68 (28 ref.)

METABOLISM

Enhancement of glucose uptake and utilization in cultured human muscle fibres overexpressing muscle glycogen phosphorylase. Gómez-Foix AM, et al. **Biochem Soc Trans** 1997 Feb;25(1):7–10 (30 ref.)

The immunopathogenic role of complement in human muscle disease. Mendell JR, et al. **Curr Opin Neurol** 1996 Jun; 9(3):226–34 (48 ref.)

Towards an understanding of the dystrophin–glycoprotein complex: linkage between the extracellular matrix and the membrane cytoskeleton in muscle fibers. Ohlendieck K. **Eur J Cell Biol** 1996 Jan;69(1):1–10 (107 ref.)

Sliding and ATPase. Oosawa F. **J Biochem (Tokyo)** 1995 Nov;118(5):863–70 (37 ref.)

PATHOLOGY

[Cytoplasmic inclusion bodies: a study in several diseases and a review of the literature] Scola RH, et al. **Arq Neuropsiquiatr** 1996 Jun;54(2):245–59 (62 ref.) (Eng. Abstr.) **(Por)**

PHYSIOLOGY

Viscoelasticity and function of connectin/titin filaments in skinned muscle fibers. Higuchi H. **Adv Biophys** 1996; 33:159–71 (26 ref.)

Exercise pressor reflex: studies on the effect of skeletal muscle fiber type and spinal cord transmission. Wilson LB, et al. **Adv Exp Med Biol** 1995;381:187–97 (34 ref.)

A new measurement of tissue capillarity: the capillary–to–fibre perimeter exchange index. Hepple RT. **Can J Appl Physiol** 1997 Feb;22(1):11–22 (40 ref.)

Morphological adaptations of neuromuscular junctions depend on fiber type. Sieck GC, et al. **Can J Appl Physiol** 1997 Jun;22(3):197–230 (156 ref.)

Mammalian skeletal muscle fiber type transitions. Pette D, et al. **Int Rev Cytol** 1997;170:143–223 (750 ref.)

To quark or to spark, that is the question. Lipp P, et al. **J Physiol (Lond)** 1997 Jul 1;502 (Pt 1):1 (8 ref.)

Age-related changes in motor unit function. Roos MR, et al. **Muscle Nerve** 1997 Jun;20(6):679–90 (128 ref.)

AAEM minimonograph #25: single–fiber electromyography. Sanders DB, et al. **Muscle Nerve** 1996 Sep;19(9):1069–83 (34 ref.)

Excitation–Ca2+ release–contraction coupling in single aged human skeletal muscle fiber. Delbono O, et al. **Muscle Nerve Suppl** 1997;5:S88–92 (19 ref.)

MUSCLE FIBERS, INTERMEDIATE see **MUSCLE FIBERS, SLOW-TWITCH**

MUSCLE FIBERS, SLOW-TWITCH

PATHOLOGY

Early–onset myopathy with tubular aggregates. Tulinius MH, et al. **Pediatr Neurol** 1996 Jul;15(1):68–71 (15 ref.)

MUSCLE FIBERS, TYPE I see **MUSCLE FIBERS, SLOW-TWITCH**

MUSCLE FLACCIDITY see **MUSCLE HYPOTONIA**

MUSCLE HYPERTONIA

CONGENITAL

Hyperekplexia: abnormal startle response due to glycine receptor mutations. Andrew M, et al. **Br J Psychiatry** 1997 Feb;170:106–8 (30 ref.)

GENETICS

[Familial hyperekplexia: startle disease. Clinical, electrophysiological and genetic study of a family] Bernasconi A, et al. **Rev Neurol (Paris)** 1996 Jun–Jul; 152(6–7):447–50 (31 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Reflex hyperexcitability and muscle contracture in relation to spastic hypertonia. O'Dwyer NJ, et al. **Curr Opin Neurol** 1996 Dec;9(6):451–5 (38 ref.)

MUSCLE HYPOTONIA

CLASSIFICATION

[Periodic palsies and myotonias are ion channel diseases (editorial)] Fontaine B, et al. **Rev Neurol (Paris)** 1996 Oct; 152(10):579–86 (39 ref.) **(Fre)**

DIAGNOSIS

[Evaluation of muscle weakness] Wada F, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:409–12 (8 ref.) **(Jpn)**

MUSCLE, INVOLUNTARY see **MUSCLE, SMOOTH**

MUSCLE NEOPLASMS

DIAGNOSIS

Does magnetic resonance imaging make a difference for patients with musculoskeletal sarcoma? Bloem JL, et al. **Br J Radiol** 1997 Apr;70:327–37 (68 ref.)

Dynamic contrast–enhanced MR imaging of musculoskeletal tumors: basic principles and clinical applications. Verstraete KL, et al. **J Magn Reson Imaging** 1996 Mar–Apr; 6(2):311–21 (68 ref.)

Pediatric musculoskeletal neoplasms. Evaluation with MR imaging. Jaramillo D, et al. **Magn Reson Imaging Clin N Am** 1996 Nov;4(4):749–70 (45 ref.)

Intramuscular malignant granular cell tumor. Tsuchida T, et al. **Skeletal Radiol** 1997 Feb;26(2):116–21 (39 ref.)

GENETICS

New advances in the molecular biology of musculoskeletal neoplasms. Morcuende JA, et al. **Iowa Orthop J** 1997; 17:115–20 (58 ref.)

PATHOLOGY

Report of a case of primary skeletal muscle lymphoma and review of the literature. Keung YK, et al. **Acta Haematol** 1996;96(3):184–6 (27 ref.)

Malignant endovascular papillary angioendothelioma (Dabska tumor) arising within a deep intramuscular hemangioma. Argani P, et al. **Arch Pathol Lab Med** 1997 Sep;121(9):992–5 (13 ref.)

Extra–articular localized nodular synovitis (giant cell tumor of tendon sheath origin) attached to the subtalar joint. Villani C, et al. **Foot Ankle Int** 1996 Jul;17(7):413–6 (30 ref.)

Case report of intramuscular myxoma with review of literature. Calton N, et al. **Indian J Pathol Microbiol** 1996 Oct;39(4):299–301 (9 ref.)

Staging systems for musculoskeletal neoplasia. Springfield DS. **Instr Course Lect** 1994;43:537–42 (11 ref.)

An unique tumour of the geniohyoid muscle: an intramuscular haemangioma. Harar RP, et al. **J Laryngol Otol** 1997 Aug;111(8):769–71 (14 ref.)

Malignant rhabdoid tumor in adults—heterogenous tumors with a unique morphological phenotype. Leong FJ, et al. **Pathol Res Pract** 1996 Aug;192(8):796–807 (34 ref.)

PREVENTION & CONTROL

Port site metastasis after laparoscopic–assisted vaginal hysterectomy for endometrial cancer: possible mechanisms and prevention. Wang PH, et al. **Gynecol Oncol** 1997 Jul; 66(1):151–5 (26 ref.)

SECONDARY

Port site metastasis after laparoscopic–assisted vaginal hysterectomy for endometrial cancer: possible mechanisms and prevention. Wang PH, et al. **Gynecol Oncol** 1997 Jul; 66(1):151–5 (26 ref.)

[Muscle metastasis in a patient with epidermoid carcinoma of the lung] Romano L, et al. **Radiol Med (Torino)** 1997 Mar;93(3):294–5 (11 ref.) **(Ita)**

[A metastatic muscle mass as the first manifestation of renal–cell cancer. A case report and review of the literature] de Portugal Fernández del Rivero T, et al. **An Med Interna** 1997 Apr;14(4):184–6 (20 ref.) (Eng. Abstr.) **(Spa)**

MUSCLE PROTEINS

The giant protein titin. Emerging roles in physiology and pathophysiology [see comments] Labeit S, et al. **Circ Res** 1997 Feb;80(2):290–4 (40 ref.) Comment in: Circ Res 1997 Feb;80(2):295–6.

ANALYSIS

Ubiquitin C–terminal hydrolases in chick skeletal muscle. Chung CH, et al. **Adv Exp Med Biol** 1996;389:203–8 (19 ref.)

BIOSYNTHESIS

Development of connectin/titin and nebulin in striated muscles of chicken. Shimada Y, et al. **Adv Biophys** 1996; 33:223–33 (37 ref.)

CHEMISTRY

The super–repeats of titin/connectin and their interactions: glimpses at sarcomeric assembly. Gautel M. **Adv Biophys** 1996;33:27–37 (61 ref.)

cDNA sequence of rabbit cardiac titin/connectin. Greaser ML, et al. **Adv Biophys** 1996;33:13–25 (27 ref.)

Nebulin and nebulin–related proteins in striated muscle. Horowits R, et al. **Adv Biophys** 1996;33:143–50 (32 ref.)

Proteolytic cleavage of connectin/titin. Suzuki A, et al. **Adv Biophys** 1996;33:53–64 (48 ref.)

Myomesin, M–protein and the structure of the sarcomeric M–band. Van Der Ven PF, et al. **Adv Biophys** 1996;33:91–9 (37 ref.)

Structure and distribution of mini–titins. Vibert P, et al. **Adv Biophys** 1996;33:199–209 (37 ref.)

Application of NMR spectroscopy to muscle calcium–binding proteins. Sykes BD. **Braz J Med Biol Res** 1996 Jul;29(7):825–9 (27 ref.)

Muscle proteins—their actions and interactions. Holmes KC. **Curr Opin Struct Biol** 1996 Dec;6(6):781–9 (45 ref.)

Ryanodine receptor Ca2+ release channels: does diversity in form equal diversity in function? Sutko JL, et al. **Physiol Rev** 1996 Oct;76(4):1027–71 (396 ref.)

DRUG EFFECTS

The pharmacology of ryanodine and related compounds. Sutko JL, et al. **Pharmacol Rev** 1997 Mar;49(1):53–98 (196 ref.)

GENETICS

cDNA sequence of rabbit cardiac titin/connectin. Greaser ML, et al. **Adv Biophys** 1996;33:13–25 (27 ref.)

The role of the calcium release channel of skeletal muscle sarcoplasmic reticulum in malignant hyperthermia. MacLennan DH, et al. **Ann N Y Acad Sci** 1993 Dec 20; 707:294–304 (46 ref.)

The bimC family of kinesins: essential bipolar mitotic motors driving centrosome separation. Kashina AS, et al. **Biochim Biophys Acta** 1997 Jul 24;1357(3):257–71 (49 ref.)

H19 in normal development and neoplasia. Looijenga LH, et al. **Mol Reprod Dev** 1997 Mar;46(3):419–39 (244 ref.)

The genetic basis of neuromuscular disorders. Nawrotzki R, et al. **Trends Genet** 1996 Aug;12(8):294–8 (48 ref.)

[Molecular genetics of cardiovascular calcium channels] Lory P, et al. **Arch Mal Coeur Vaiss** 1997 Jun;90 Spec No 3:17–24 (37 ref.) (Eng. Abstr.) **(Fre)**

[Muscle specific gene expression during embryonal development] Krempler A, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Oct;103(10):408–13 (65 ref.) (Eng. Abstr.) **(Ger)**

[Physiology and physiopathology of ryanodine receptors in swine. Significance of sensitivity to stress, stress myopathies, malignant hyperthermia and meat quality] Martens H. **Tierarztl Prax** 1997 Jan;25(1):41–51 (62 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

The super–repeats of titin/connectin and their interactions: glimpses at sarcomeric assembly. Gautel M. **Adv Biophys** 1996;33:27–37 (61 ref.)

Proteolytic cleavage of connectin/titin. Suzuki A, et al. **Adv Biophys** 1996;33:53–64 (48 ref.)

Protein metabolism and therapy in burn injury. Le Boucher J, et al. **Ann Nutr Metab** 1997;41(2):69–82 (117 ref.)

The ubiquitin–proteasome pathway: review of a novel intracellular mechanism of muscle protein breakdown during sepsis and other catabolic conditions. Hasselgren PO, et al. **Ann Surg** 1997 Mar;225(3):307–16 (59 ref.)

Hormonal regulation of human muscle protein metabolism. Rooyackers OE, et al. **Annu Rev Nutr** 1997;17:457–85 (172 ref.)

Cellular mechanisms of catabolism activated by metabolic acidosis. Mitch WE. **Blood Purif** 1995 Nov–Dec; 13(6):368–74 (29 ref.)

Dystrophin–associated proteins and the muscular dystrophies: a glossary. Brown RH Jr. **Brain Pathol** 1996 Jan;6(1):19–24 (40 ref.)

Sequential roles of agrin, MuSK and rapsyn during neuromuscular junction formation. Glass DJ, et al. **Curr Opin Neurobiol** 1997 Jun;7(3):379–84 (45 ref.)

Muscle proteins—their actions and interactions. Holmes KC. **Curr Opin Struct Biol** 1996 Dec;6(6):781–9 (45 ref.)

Nuclear magnetic resonance spectroscopy of skeletal muscle and muscle proteins. Yamada T, et al. **Jpn J Physiol** 1996 Jun;46(3):201–13 (87 ref.)

Mechanisms of muscle wasting. The role of the ubiquitin–proteasome pathway. Mitch WE, et al. **N Engl J Med** 1996 Dec 19;335(25):1897–905 (70 ref.)

The sarcoplasmic reticulum Ca2+ channel/ryanodine

receptor: modulation by endogenous effectors, drugs and disease states. Zucchi R, et al. **Pharmacol Rev** 1997 Mar; 49(1):1–51 (759 ref.)

Measurement of muscle proteolysis and the impact on muscle wasting. Nissen S. **Proc Nutr Soc** 1997 Jul;56(2):793–9 (26 ref.)

Nutrient–hormone signals regulating muscle protein turnover in pigs. Sève B, et al. **Proc Nutr Soc** 1997 Jul;56(2):565–80 (62 ref.)

Regulation of skeletal muscle protein turnover during sepsis: mechanisms and mediators. Cooney RN, et al. **Shock** 1997 Jan;7(1):1–16 (170 ref.)

Syntrophins: modular adapter proteins at the neuromuscular junction and the sarcolemma. Froehner SC, et al. **Soc Gen Physiol Ser** 1997;52:197–207 (49 ref.)

The search for the uremic toxin: the case for metabolic acidosis [see comments] Bailey JL, et al. **Wien Klin Wochenschr** 1997 Jan 17;109(1):7–12 (50 ref.) Comment in: Wien Klin Wochenschr 1997 Jan 17;109(1):1–2.

PHYSIOLOGY

Twitchin and related giant Ig superfamily members of C. elegans and other invertebrates. Benian GM, et al. **Adv Biophys** 1996;33:183–98 (58 ref.)

Modular proteins of insect muscle. Bullard B, et al. **Adv Biophys** 1996;33:211–21 (46 ref.)

Viscoelasticity and function of connectin/titin filaments in skinned muscle fibers. Higuchi H. **Adv Biophys** 1996; 33:159–71 (26 ref.)

Nebulin and nebulin-related proteins in striated muscle. Horowits R, et al. **Adv Biophys** 1996;33:143–50 (32 ref.)

Comparative aspects of muscle elastic proteins. Kawamura Y, et al. **Adv Biophys** 1996;33:175–81 (29 ref.)

Structure and physiological functions of ubiquitous and tissue-specific calpain species. Muscle-specific calpain, p94, interacts with connectin/titin. Sorimachi H, et al. **Adv Biophys** 1996;33:101–22 (89 ref.)

Physiological significance of viscoelastic structures in myoplasm. Takemori S, et al. **Adv Biophys** 1996;33:151–7 (16 ref.)

Titin/connectin and nebulin: giant protein rulers of muscle structure and function. Wang K. **Adv Biophys** 1996; 33:123–34 (84 ref.)

Conformation state of the ryanodine receptor and functional effects of ryanodine on skeletal muscle. Bianchi CP. **Biochem Pharmacol** 1997 Apr 4;53(7):909–12 (30 ref.)

Dihydropyridine receptor–ryanodine receptor interactions in skeletal muscle excitation–contraction coupling. Meissner G, et al. **Biosci Rep** 1995 Oct;15(5):399–408 (53 ref.)

Titin as a scaffold and spring. Cytoskeleton. Trinick J. **Curr Biol** 1996 Mar 1;6(3):258–60 (15 ref.)

Sequential roles of agrin, MuSK and rapsyn during neuromuscular junction formation. Glass DJ, et al. **Curr Opin Neurobiol** 1997 Jun;7(3):379–84 (45 ref.)

The functions of two species of calcium channel in cardiac muscle excitation–contraction coupling. Williams AJ. **Eur Heart J** 1997 Jan;18 Suppl A:A27–35 (50 ref.)

Connectin/titin, giant elastic protein of muscle. Maruyama K. **FASEB J** 1997 Apr;11(5):341–5 (43 ref.)

Kinase-related protein: a smooth muscle myosin-binding protein. Vorotnikov AV. **Int J Biochem Cell Biol** 1997 May;29(5):727–30 (7 ref.)

Ryanodine receptors of striated muscles: a complex channel capable of multiple interactions. Franzini-Armstrong C, et al. **Physiol Rev** 1997 Jul;77(3):699–729 (356 ref.)

Ryanodine receptor Ca2+ release channels: does diversity in form equal diversity in function? Sutko JL, et al. **Physiol Rev** 1996 Oct;76(4):1027–71 (396 ref.)

The role of ryanodine receptor isoforms in the structure and function of the vertebrate triad. Block BA, et al. **Soc Gen Physiol Ser** 1996;51:47–65 (56 ref.)

Triadin, a linker for calsequestrin and the ryanodine receptor. Guo W, et al. **Soc Gen Physiol Ser** 1996;51:19–28 (28 ref.)

Functional properties of inositol 1,4,5-trisphosphate receptor and Ca2+ signaling. Iino M. **Soc Gen Physiol Ser** 1996; 51:67–73 (29 ref.)

[Role of the M protein of Streptococcus pyogenes and its regulation] Okada N. **Nippon Saikingaku Zasshi** 1996 Feb; 51(2):571–81 (44 ref.) **(Jpn)**

[Ryanodine receptor] Takeshima H. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):230–4 (15 ref.) **(Jpn)**

ULTRASTRUCTURE

Modular proteins of insect muscle. Bullard B, et al. **Adv Biophys** 1996;33:211–21 (46 ref.)

Microscopic analysis of the elastic properties of connectin/titin and nebulin in myofibrils. Ishiwata S, et al. **Adv Biophys** 1996;33:135–42 (23 ref.)

Myomesin, M-protein and the structure of the sarcomeric M-band. Van Der Ven PF, et al. **Adv Biophys** 1996;33:91–9 (37 ref.)

Architecture and function in the muscle sarcomere. Squire JM. **Curr Opin Struct Biol** 1997 Apr;7(2):247–57 (87 ref.)

Ryanodine receptors: structure and macromolecular interactions. Wagenknecht T, et al. **Curr Opin Struct Biol** 1997 Apr;7(2):258–65 (63 ref.)

MUSCLE RELAXANTS, CENTRAL

[New muscle relaxants. Update on mivacurium, rocuronium and cis-atracurium] Fuchs-Buder T. **Anaesthesist** 1997 Apr;46(4):350–9 (17 ref.) **(Ger)**

ADVERSE EFFECTS

Quinine-induced hemolytic uremic syndrome. McDonald SP, et al. **Clin Nephrol** 1997 Jun;47(6):397–400 (21 ref.)

PHARMACOLOGY

The use of muscle relaxants in the intensive care unit. Booij LH. **Acta Anaesthesiol Belg** 1997;48(1):35–44 (98 ref.)

Neuromuscular transmission and its pharmacological blockade. Part 1: Neuromuscular transmission and general aspects of its blockade. Booij LH. **Pharm World Sci** 1997 Feb;19(1):1–12 (159 ref.)

Neuromuscular transmission and its pharmacological blockade. Part 4: Use of relaxants in paediatric and elderly patients, in obstetrics, and in the intensive care unit. Booij LH. **Pharm World Sci** 1997 Feb;19(1):45–52 (11 ref.)

[Muscle relaxants. New substances and neuromuscular monitoring] Diefenbach C, et al. **Anaesthesist** 1997 Jan; 46(1):3–13 (79 ref.) (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Intrathecal baclofen in cerebral palsy movement disorders. Albright AL. **J Child Neurol** 1996 Nov;11 Suppl 1:S29–35 (34 ref.)

Anti-inflammatory drugs and myorelaxants. Pharmacology and clinical use in musculoskeletal disease. Balano KB. **Prim Care** 1996 Jun;23(2):329–34 (11 ref.)

[Cerebral palsy therapy] Papazian O, et al. **Rev Neurol** 1997 May;25(141):728–39 (69 ref.) (Eng. Abstr.) **(Spa)**

MUSCLE RELAXANTS, DEPOLARIZING see **NEUROMUSCULAR DEPOLARIZING AGENTS**

MUSCLE RELAXANTS, NON-DEPOLARIZING see **NEUROMUSCULAR NONDEPOLARIZING AGENTS**

MUSCLE RELAXATION

Long-lasting reductions of spasticity induced by skin electrical stimulation. Dewald JP, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):231–42 (57 ref.)

DRUG EFFECTS

Neuromuscular transmission and its pharmacological blockade. Part 3: Continuous infusion of relaxants and reversal and monitoring of relaxation. Booij LH. **Pharm World Sci** 1997 Feb;19(1):35–44 (152 ref.)

PHYSIOLOGY

Use of isolated ocular arteries in vitro to define the pathology of vascular changes in glaucoma. Buckley CH, et al. **Br J Ophthalmol** 1997 Jul;81(7):599–607 (112 ref.)

[Value of monitoring muscle relaxation] Jöhr M, et al. **Schweiz Med Wochenschr** 1996 Sep 28;126(39):1649–53 (31 ref.) (Eng. Abstr.) **(Ger)**

MUSCLE RIGIDITY

CHEMICALLY INDUCED

Muscle rigidity due to fentanyl infusion in the pediatric patient. Glick C, et al. **South Med J** 1996 Nov; 89(11):1119–20 (11 ref.)

ETIOLOGY

Non-Parkinson akinetic-rigid syndromes. Riley DE, et al. **Curr Opin Neurol** 1996 Aug;9(4):321–6 (86 ref.)

PHYSIOPATHOLOGY

[Central motor conduction time using magnetic and vibratory stimulation in Parkinson's disease, especially in patients with rigidity] Mochio S, et al. **Nippon Rinsho** 1997 Jan; 55(1):173–8 (17 ref.) (Eng. Abstr.) **(Jpn)**

MUSCLE, SKELETAL

Necrotizing soft tissue infections of the chest wall. Urschel JD, et al. **Ann Thorac Surg** 1997 Jul;64(1):276–9 (28 ref.)

Significance of sarcopenia in the elderly. Dutta C. **J Nutr** 1997 May;127(5 Suppl):992S–993S (23 ref.)

Sarcopenia: origins and clinical relevance. Rosenberg IH. **J Nutr** 1997 May;127(5 Suppl):990S–991S (2 ref.)

Compression of the lateral antebrachial cutaneous nerve by the biceps tendon. Gillingham BL, et al. **J Shoulder Elbow Surg** 1996 Jul-Aug;5(4):330–2 (10 ref.)

[Development of adenoviral vectors in gene therapy: application to gene transfer in muscles] Ragot T, et al. **C R Seances Soc Biol Fil** 1996;190(1):13–31 (37 ref.) (Eng. Abstr.) **(Fre)**

[Malignant fibrous histiocytoma. Two case reports and review of the literature] Martinazzoli A, et al. **Minerva Chir** 1997 Jan-Feb;52(1-2):123–8 (43 ref.) (Eng. Abstr.) **(Ita)**

ABNORMALITIES

Accessory soleus muscle. A report of 4 cases and review of literature. Brodie JT, et al. **Clin Orthop** 1997 Apr; (337):180–6 (29 ref.)

Accessory soleus muscle: a review of the literature and case report. Downey MS, et al. **J Foot Ankle Surg** 1996 Nov-Dec;35(6):537–43 (35 ref.)

Accessory soleus muscle. Two case-reports, with a review of the literature. Boisgard S, et al. **Rev Rhum Engl Ed** 1996 Dec;63(11):862–5 (15 ref.)

ANATOMY & HISTOLOGY

A variation in the organization of abductor pollicis longus. Fabrizio PA, et al. **Clin Anat** 1996;9(6):371–5 (20 ref.)

Flexor digitorum accessorius longus muscle. VanCourt RB, et al. **J Am Podiatr Med Assoc** 1996 Nov;86(11):559–60 (5 ref.)

Sarcopenia: assessment of muscle mass. Lukaski H. **J Nutr** 1997 May;127(5 Suppl):994S–997S (23 ref.)

Review of the functional anatomy of the cartilages and muscles of the nose. Bruintjes TD, et al. **Rhinology** 1996 Jun;34(2):66–74 (54 ref.)

BLOOD SUPPLY

Graded restriction of blood flow in exercising leg muscles: a human model. Bjurstedt H, et al. **Adv Exp Med Biol** 1995; 381:147–56 (32 ref.)

Anomaly of the femoral artery passage through the substance of sartorius muscle. Clinical consequences. Banjo AO. **Afr J Med Med Sci** 1995 Dec;24(4):343–6 (12 ref.)

Crohn's disease and gastrocnemius vasculitis: two new cases. Disdier P, et al. **Am J Gastroenterol** 1997 May;92(5):880–2 (10 ref.)

Diabetic muscle infarction [see comments] Umpierrez GE, et al. **Am J Med** 1996 Sep;101(3):245–50 (15 ref.) Comment in: Am J Med 1997 Aug;103(2):171–2.

Role of blood flow in the regulation of muscle glucose uptake. Baron AD, et al. **Annu Rev Nutr** 1997;17:487–99 (34 ref.)

A review of effects of hypothyroidism on vascular transport in skeletal muscle during exercise. McAllister RM, et al. **Can J Appl Physiol** 1997 Feb;22(1):1–10 (18 ref.)

Angiogenic gene therapy. A leg to stand on? [editorial; comment] Fox JC, et al. **Circulation** 1996 Dec 15; 94(12):3065–6 (11 ref.) Comment on: Circulation 1996 Dec 15;94(12):3281–90.

A little VEGF goes a long way. Therapeutic angiogenesis by direct injection of vascular endothelial growth factor-encoding plasmid DNA [editorial; comment] Majesky MW. **Circulation** 1996 Dec 15;94(12):3062–4 (17 ref.) Comment on: Circulation 1996 Dec 15;94(12):3281–90.

Neural control of muscle blood flow: importance during dynamic exercise. Rowell LB. **Clin Exp Pharmacol Physiol** 1997 Feb;24(2):117–25 (71 ref.)

Mechanisms of postischemic injury in skeletal muscle: intervention strategies. Rubin BB, et al. **J Appl Physiol** 1996 Feb;80(2):369–87 (220 ref.)

Direct and indirect assessment of skeletal muscle blood flow in patients with congestive heart failure. LeJemtel TH, et al. **J Mol Cell Cardiol** 1996 Nov;28(11):2249–54 (50 ref.)

Vasovagal syncope and skeletal muscle vasodilatation: the continuing conundrum. Dietz NM, et al. **Pacing Clin Electrophysiol** 1997 Mar;20(3 Pt 2):775–80 (45 ref.)

Oxidative metabolism in muscle. Ferrari M, et al. **Philos Trans R Soc Lond B Biol Sci** 1997 Jun 29; 352(1354):677–83 (72 ref.)

Capillary dysfunction in striated muscle ischemia/reperfusion: on the mechanisms of capillary "no-reflow". Menger MD, et al. **Shock** 1997 Jul;8(1):2–7 (47 ref.)

Control of skeletal muscle blood flow during dynamic exercise: contribution of endothelium-derived nitric oxide. Green DJ, et al. **Sports Med** 1996 Feb;21(2):119–46 (265 ref.)

CHEMISTRY

Distribution of GLP-1 and PACAP receptors in human tissues. Wei Y, et al. **Acta Physiol Scand** 1996 Jul; 157(3):355–7 (7 ref.)

Skeletal muscle determination and differentiation: story of a core regulatory network and its context. Yun K, et al. **Curr Opin Cell Biol** 1996 Dec;8(6):877–89 (68 ref.)

Actomyosin interaction in striated muscle. Cooke R. **Physiol Rev** 1997 Jul;77(3):671–97 (157 ref.)

Capping actin filament growth: tropomodulin in muscle and nonmuscle cells. Fowler VM. **Soc Gen Physiol Ser** 1997; 52:79–89 (46 ref.)

CYTOLOGY

Skeletal muscle development and the role of the myogenic regulatory factors. Buckingham M. **Biochem Soc Trans** 1996 May;24(2):506–9 (27 ref.)

Human skeletal muscle fiber types: delineation, development, and distribution. Staron RS. **Can J Appl Physiol** 1997 Aug; 22(4):307–27 (142 ref.)

Meeting of the Cell Transplantation Society in Miami [letter] Partridge T, et al. **Cell Transplant** 1997 Mar-Apr;6(2):195–8 (18 ref.)

Skeletal muscle determination and differentiation: story of a core regulatory network and its context. Yun K, et al. **Curr Opin Cell Biol** 1996 Dec;8(6):877–89 (68 ref.)
Mammalian skeletal muscle fiber type transitions. Pette D, et al. **Int Rev Cytol** 1997;170:143–223 (750 ref.)
Tissue culture of skeletal muscle. Partridge TA. **Methods Mol Biol** 1997;75:131–44 (17 ref.)
Proliferation of murine myoblasts as measured by bromodeoxyuridine incorporation. Shah B, et al. **Methods Mol Biol** 1997;75:349–55 (3 ref.)

DRUG EFFECTS

Compartmentalization of protein traffic in insulin-sensitive cells. Kandror KV, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):E1–14 (134 ref.)
Conformation state of the ryanodine receptor and functional effects of ryanodine on skeletal muscle. Bianchi CP. **Biochem Pharmacol** 1997 Apr 4;53(7):909–12 (30 ref.)
Effect of gallopamil on excitation–contraction coupling. Zucchi R. **Gen Pharmacol** 1996 Jul;27(5):749–53 (55 ref.)

EMBRYOLOGY

Molecular embryology of skeletal myogenesis. Venuti JM, et al. **Curr Top Dev Biol** 1996;34:169–206 (177 ref.)
Molecular control of muscle diversity and plasticity. Buonanno A, et al. **Dev Genet** 1996;19(2):95–107 (139 ref.)
Targeted inactivation of myogenic factor genes reveals their role during mouse myogenesis: a review. Arnold HH, et al. **Int J Dev Biol** 1996 Feb;40(1):345–53 (42 ref.)
Proteasome and myogenesis. Gardrat F, et al. **Mol Biol Rep** 1997 Mar;24(1–2):77–81 (28 ref.)
Regulatory factors in the control of muscle development. Dauncey MJ, et al. **Proc Nutr Soc** 1996 Mar;55(1B):543–59 (86 ref.)
[Muscle specific gene expression during embryonal development] Krempler A, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Oct;103(10):408–13 (65 ref.) (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

Ubiquitin C-terminal hydrolases in chick skeletal muscle. Chung CH, et al. **Adv Exp Med Biol** 1996;389:203–8 (19 ref.)
Glycogen synthase: activation by insulin and effect of transgenic overexpression in skeletal muscle. Lawrence JC Jr, et al. **Biochem Soc Trans** 1997 Feb;25(1):14–9 (42 ref.)
31P-NMR-measured creatine kinase reaction flux in muscle: a caveat! Wallimann T. **J Muscle Res Cell Motil** 1996 Apr; 17(2):177–81 (30 ref.)
Expression of subunits of the 19S complex and of the PA28 activator in rat skeletal muscle. Attaix D, et al. **Mol Biol Rep** 1997 Mar;24(1–2):95–8 (30 ref.)
[Structure, regulation, and denaturation of muscle glycogen phosphorylase b] Livanova NB, et al. **Biokhimiia** 1996 Nov; 61(11):2005–17 (81 ref.) (Eng. Abstr.) **(Rus)**

GROWTH & DEVELOPMENT

Mechanisms of formation of muscle fiber types. Stockdale FE. **Cell Struct Funct** 1997 Feb;22(1):37–43 (54 ref.)

IMMUNOLOGY

How is myogenesis initiated in the embryo? Cossu G, et al. **Trends Genet** 1996 Jun;12(6):218–23 (58 ref.)

INJURIES

Muscle strain injuries. Garrett WE Jr. **Am J Sports Med** 1996; 24(6 Suppl):S2–8 (28 ref.)
Soft-tissue injuries and muscle tears. Best TM. **Clin Sports Med** 1997 Jul;16(3):419–34 (44 ref.)
Mechanisms of postischemic injury in skeletal muscle: intervention strategies. Rubin BB, et al. **J Appl Physiol** 1996 Feb;80(2):369–87 (220 ref.)
Imaging of muscle injuries. El-Khoury GY, et al. **Skeletal Radiol** 1996 Jan;25(1):3–11 (26 ref.)
Hamstring injuries. Current trends in treatment and prevention. Kujala UM, et al. **Sports Med** 1997 Jun; 23(6):397–404 (41 ref.)
Non-invasive and quantitative evaluation of post-injection muscle damage by pharmacokinetic analysis of creatine kinase release. Lefebvre HP, et al. **Vet Res** 1996; 27(4–5):343–61 (44 ref.)

INNERVATION

Accessory nerve palsy and serratus palsy. Vastamäki M. **Ann Chir Gynaecol** 1996;85(2):167–71 (14 ref.)
Studies on anterograde trophic interactions based on general muscle properties. Cangiano A, et al. **Arch Ital Biol** 1997 Sep;135(4):331–41 (29 ref.)
Modulation of corticospinal influence over hand muscles during gripping tasks in man and monkey. Lemon RN, et al. **Can J Physiol Pharmacol** 1996 Apr;74(4):547–58 (67 ref.)
Neural control of muscle blood flow: importance during dynamic exercise. Rowell LB. **Clin Exp Pharmacol Physiol** 1997 Feb;24(2):117–25 (71 ref.)
New control strategies for neuroprosthetic systems. Crago PE, et al. **J Rehabil Res Dev** 1996 Apr;33(2):158–72 (40 ref.)
A comparative anatomical study of muscles of the pelvic outlet and the piriformis with special reference to their innervation. Akita K. **Kaibogaku Zasshi** 1997 Feb; 72(1):9–12 (21 ref.)
Electrical stimulation of denervated muscle: is it worthwhile? Eberstein A, et al. **Med Sci Sports Exerc** 1996 Dec; 28(12):1463–9 (83 ref.)
Influence of gravity on cardiovascular reflexes from skeletal muscle receptors. Essfeld D, et al. **Med Sci Sports Exerc** 1996 Oct;28(10 Suppl):S23–8 (26 ref.)
Neural control of the cardiovascular system: insights from muscle sympathetic nerve recordings in humans. Mitchell JH, et al. **Med Sci Sports Exerc** 1996 Oct;28(10 Suppl):S60–9 (48 ref.)
Heart rate control during exercise by baroreceptors and skeletal muscle afferents. O'Leary DS. **Med Sci Sports Exerc** 1996 Feb;28(2):210–7 (55 ref.)
Persistent serratus anterior paralysis after fracture of an anterior cervical bone graft. Smith MD, et al. **Orthopedics** 1996 Jul;19(7):611–3 (16 ref.)
Beta innervation and recurrent inhibition: a hypothesis for manipulatory and postural control. Illert M, et al. **Pflugers Arch** 1996;432(3 Suppl):R61–7 (62 ref.)
Group III and IV receptors in skeletal muscle: are they specific or polymodal? Mense S. **Prog Brain Res** 1996; 113:83–100 (75 ref.)
On the role of recurrent inhibitory feedback in motor control. Windhorst U. **Prog Neurobiol** 1996 Aug;49(6):517–87 (367 ref.)
[The motor innervation of the axial skeletal musculature in vertebrates] Balezina OP. **Usp Fiziol Nauk** 1997 Apr–Jun; 28(2):57–78 (99 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Compartmentalization of protein traffic in insulin-sensitive cells. Kandror KV, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):E1–14 (134 ref.)
Role of blood flow in the regulation of muscle glucose uptake. Baron AD, et al. **Annu Rev Nutr** 1997;17:487–99 (34 ref.)
Gene transfer to muscle. Dickson G. **Biochem Soc Trans** 1996 May;24(2):514–9 (48 ref.)
Enhancement of glucose uptake and utilization in cultured human muscle fibres overexpressing muscle glycogen phosphorylase. Gómez-Foix AM, et al. **Biochem Soc Trans** 1997 Feb;25(1):7–10 (30 ref.)
Costameric distribution of beta-dystroglycan (43 kDa dystrophin-associated glycoprotein) in normal and dystrophin-deficient human skeletal muscle. Herrmann R, et al. **Biochem Soc Trans** 1996 May;24(2):501–6 (43 ref.)
Endocrine and nutritional modulation of glucose disposal and storage in muscle. Holness MJ, et al. **Biochem Soc Trans** 1997 Feb;25(1):1–7 (23 ref.)
Replenishment of muscle glycogen after high-intensity exercise: a role for intramuscular lactate glyconeogenesis? Palmer TN, et al. **Biochem Soc Trans** 1997 Feb;25(1):25–30 (43 ref.)
Amino acid transport in heart and skeletal muscle and the functional consequences. Rennie MJ, et al. **Biochem Soc Trans** 1996 Aug;24(3):869–73 (35 ref.)
Lipid structure and Ca(2+)-ATPase function. Lee AG, et al. **Biosci Rep** 1995 Oct;15(5):289–98 (50 ref.)
Derangements of protein metabolism in chronic renal failure. Kaysen GA, et al. **Blood Purif** 1996;14(5):373–81 (68 ref.)
Oxygen deficit: introduction to the assumptions and the skepticism [comment] Graham TE. **Can J Appl Physiol** 1996 Oct;21(5):347–9 (3 ref.) Comment on: Can J Appl Physiol 1996 Oct;21(5):350–63; discussion 364–9. Comment on: Can J Appl Physiol 1996 Oct;21(5):370–83; discussion 384–8.
Structural interactions responsible for the assembly of the troponin complex on the muscle thin filament. Reinach FC, et al. **Cell Struct Funct** 1997 Feb;22(1):219–23 (30 ref.)
The giant protein titin. Emerging roles in physiology and pathophysiology [see comments] Labeit S, et al. **Circ Res** 1997 Feb;80(2):290–4 (40 ref.) Comment in: Circ Res 1997 Feb;80(2):295–6.
Functional significance of alterations in cardiac contractile protein isoforms. Kitsis RN, et al. **Clin Cardiol** 1996 Jan; 19(1):9–18 (115 ref.)
Regulation of actin filament length in erythrocytes and striated muscle. Fowler VM. **Curr Opin Cell Biol** 1996 Feb; 8(1):86–96 (73 ref.)
New insights into the role and mechanism of glycogen synthase activation by insulin. Lawrence JC Jr, et al. **Diabetes** 1997 Apr;46(4):541–7 (63 ref.)
Exercise, free radical generation and vitamins. Giuliani A, et al. **Eur J Cancer Prev** 1997 Mar;6 Suppl 1:S55–67 (163 ref.)
Interactions between muscle glycogen and blood glucose during exercise. Hargreaves M. **Exerc Sport Sci Rev** 1997; 25:21–39 (112 ref.)
The cellular stress response to exercise: role of stress proteins. Locke M. **Exerc Sport Sci Rev** 1997;25:105–36 (192 ref.)
Aging and the acute phase response to exercise: implications for the role of systemic factors on skeletal muscle protein turnover. Fielding RA, et al. **Int J Sports Med** 1997 Mar; 18 Suppl 1:S22–7 (59 ref.)
Skeletal muscle: a paradigm for testing principles of bioenergetics. Kushmerick MJ. **J Bioenerg Biomembr** 1995 Dec;27(6):555–69 (65 ref.)
Brain and skeletal muscle bioenergetic failure in familial hypobetalipoproteinaemia. Lodi R, et al. **J Neurol Neurosurg Psychiatry** 1997 Jun;62(6):574–80 (61 ref.)
Acute-phase protein synthesis in rats is influenced by alterations in plasma and muscle free amino acid pools related to lower plasma volume following trauma. Sevaljević LM, et al. **J Nutr** 1996 Dec;126(12):3136–42 (39 ref.)
Identification of binding sites for calcium channel antagonists. Nakayama H, et al. **Jpn Heart J** 1996 Sep;37(5):643–50 (22 ref.)
Nuclear magnetic resonance spectroscopy of skeletal muscle and muscle proteins. Yamada T, et al. **Jpn J Physiol** 1996 Jun;46(3):201–13 (87 ref.)
Effect of endurance training on ammonia and amino acid metabolism in humans. Graham TE, et al. **Med Sci Sports Exerc** 1997 May;29(5):646–53 (57 ref.)
Oxidative metabolism in muscle. Ferrari M, et al. **Philos Trans R Soc Lond B Biol Sci** 1997 Jun 29; 352(1354):677–83 (72 ref.)
Lactate-proton cotransport in skeletal muscle. Juel C. **Physiol Rev** 1997 Apr;77(2):321–58 (344 ref.)
Mechanisms causing loss of muscle in acute uremia. Mitch WE. **Ren Fail** 1996 May;18(3):389–94 (36 ref.)
Regulation of glucose transport into skeletal muscle. Holloszy JO, et al. **Rev Physiol Biochem Pharmacol** 1996;128:99–193 (300 ref.)
Regulation of skeletal muscle protein turnover during sepsis: mechanisms and mediators. Cooney RN, et al. **Shock** 1997 Jan;7(1):1–16 (170 ref.)
A membrane skeleton that clusters nicotinic acetylcholine receptors in muscle. Bloch RJ, et al. **Soc Gen Physiol Ser** 1997;52:177–95 (68 ref.)
Carbohydrate-loading and exercise performance. An update. Hawley JA, et al. **Sports Med** 1997 Aug;24(2):73–81 (43 ref.)
Muscle glycogen resynthesis after short term, high intensity exercise and resistance exercise. Pascoe DD, et al. **Sports Med** 1996 Feb;21(2):98–118 (152 ref.)
[Effect of physical load deficiency on the system of calcium transport in the sarcoplasmic reticulum of skeletal muscles amd myocardium] Stepanova VV, et al. **Aviakosm Ekolog Med** 1996;30(5):33–5 (24 ref.) (Eng. Abstr.) **(Rus)**
[Is hypoxia a stimulus for structural and metabolic changes in skeletal muscles?] Nemirovskaia TL, et al. **Fiziol Cheloveka** 1997 Jan–Feb;23(1):123–30 (65 ref.) **(Rus)**
[Insulin resistance, calcium cell metabolism, and essential arterial hypertension. Role of skeletal muscle] Sánchez M, et al. **Med Clin (Barc)** 1996 Jun 15;107(3):102–6 (62 ref.) **(Spa)**

PARASITOLOGY

Trichinella infection and clinical disease. Clausen MR, et al. **QJM** 1996 Aug;89(8):631–6 (58 ref.)

PATHOLOGY

Protection against muscle damage exerted by oestrogen: hormonal or antioxidant action? Bär PR, et al. **Biochem Soc Trans** 1997 Feb;25(1):50–4 (39 ref.)
The regulation of gene expression in hypertrophying skeletal muscle. Carson JA. **Exerc Sport Sci Rev** 1997;25:301–20 (57 ref.)
Morphology and neuropathology of the pelvic floor in patients with stress incontinence. Morley R, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1996;7(1):3–12 (63 ref.)
Morphological studies of skeletal muscle in lactic acidosis. Romero NB, et al. **J Inherit Metab Dis** 1996;19(4):528–34 (12 ref.)
Calf enlargement in neuromuscular diseases: a quantitative ultrasound study in 350 patients and review of the literature. Reimers CD, et al. **J Neurol Sci** 1996 Nov; 143(1–2):46–56 (75 ref.)
Muscle mass and strength: relation to function in population studies. Harris T. **J Nutr** 1997 May;127(5 Suppl):1004S–1006S (17 ref.)
Manual massage and recovery of muscle function following exercise: a literature review. Tiidus PM. **J Orthop Sports Phys Ther** 1997 Feb;25(2):107–12 (40 ref.)
Protection against ischemic-reperfusion injury of skeletal muscle: role of ischemic preconditioning and adenosine pretreatment. Lee HT, et al. **J Reconstr Microsurg** 1996 Aug;12(6):383–8 (39 ref.)
Muscle mass, survival, and the elderly ICU patient. Griffiths RD. **Nutrition** 1996 Jun;12(6):456–8 (28 ref.)
Imaging of muscle injuries. El-Khoury GY, et al. **Skeletal Radiol** 1996 Jan;25(1):3–11 (26 ref.)
The role of antioxidant vitamins and enzymes in the prevention of exercise-induced muscle damage. Dekkers JC, et al. **Sports Med** 1996 Mar;21(3):213–38 (62 ref.)
Non-invasive and quantitative evaluation of post-injection muscle damage by pharmacokinetic analysis of creatine kinase release. Lefebvre HP, et al. **Vet Res** 1996; 27(4–5):343–61 (44 ref.)

PHYSIOLOGY

Neural and musculoskeletal contributions to the development of stance balance control in typical children and in children with cerebral palsy. Woollacott MH, et al. **Acta Paediatr Suppl** 1996 Oct;416:58–62 (11 ref.)

MUSCLE, SKELETAL

Modular proteins of insect muscle. Bullard B, et al. **Adv Biophys** 1996;33:211–21 (46 ref.)

Viscoelasticity and function of connectin/titin filaments in skinned muscle fibers. Higuchi H. **Adv Biophys** 1996; 33:159–71 (26 ref.)

Nebulin and nebulin-related proteins in striated muscle. Horowits R, et al. **Adv Biophys** 1996;33:143–50 (32 ref.)

Microscopic analysis of the elastic properties of connectin/titin and nebulin in myofibrils. Ishiwata S, et al. **Adv Biophys** 1996;33:135–42 (23 ref.)

Comparative aspects of muscle elastic proteins. Kawamura Y, et al. **Adv Biophys** 1996;33:175–81 (29 ref.)

Development of connectin/titin and nebulin in striated muscles of chicken. Shimada Y, et al. **Adv Biophys** 1996; 33:223–33 (37 ref.)

Structure and physiological functions of ubiquitous and tissue-specific calpain species. Muscle-specific calpain, p94, interacts with connectin/titin. Sorimachi H, et al. **Adv Biophys** 1996;33:101–22 (89 ref.)

Proteolytic cleavage of connectin/titin. Suzuki A, et al. **Adv Biophys** 1996;33:53–64 (48 ref.)

Physiological significance of viscoelastic structures in myoplasm. Takemori S, et al. **Adv Biophys** 1996;33:151–7 (16 ref.)

Structure and distribution of mini-titins. Vibert P, et al. **Adv Biophys** 1996;33:199–209 (37 ref.)

Titin/connectin and nebulin: giant protein rulers of muscle structure and function. Wang K. **Adv Biophys** 1996; 33:123–34 (84 ref.)

Exercise pressor reflex: studies on the effect of skeletal muscle fiber type and spinal cord transmission. Wilson LB, et al. **Adv Exp Med Biol** 1995;381:187–97 (34 ref.)

Apoptosis of skeletal and cardiac muscles and physical exercise. Carraro U, et al. **Aging (Milano)** 1997 Feb–Apr; 9(1–2):19–34 (118 ref.)

Exercise, free radical generation, and aging. Fielding RA, et al. **Aging (Milano)** 1997 Feb–Apr;9(1–2):12–8 (64 ref.)

Muscle function in movement and sports. Herzog W. **Am J Sports Med** 1996;24(6 Suppl):S14–9 (17 ref.)

Structure and function of voltage-dependent calcium channels from muscle. Tanabe T, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:81–6 (40 ref.)

Calcium in close quarters: microdomain feedback in excitation–contraction coupling and other cell biological phenomena. Ríos E, et al. **Annu Rev Biophys Biomol Struct** 1997;26:47–82 (105 ref.)

Introduction to the neurophysiological study of sleep: central regulation of skeletal and ocular activities. Gottesmann C. **Arch Ital Biol** 1997 Jun;135(3):279–314 (274 ref.)

Experimental skeletal muscle grafts as a model of regeneration. Lawson-Smith MJ, et al. **Aust N Z J Surg** 1997 Jan;67(1):35–9 (53 ref.)

Protection against muscle damage exerted by oestrogen: hormonal or antioxidant action? Bär PR, et al. **Biochem Soc Trans** 1997 Feb;25(1):50–4 (39 ref.)

Skeletal muscle development and the role of the myogenic regulatory factors. Buckingham M. **Biochem Soc Trans** 1996 May;24(2):506–9 (27 ref.)

Smooth and skeletal muscle single-molecule mechanical experiments [comment] Molloy JE, et al. **Biophys J** 1997 Mar;72(3):984–6 (8 ref.) Comment on: Biophys J 1997 Mar;72(3):1006–21.

Dihydropyridine receptor–ryanodine receptor interactions in skeletal muscle excitation–contraction coupling. Meissner G, et al. **Biosci Rep** 1995 Oct;15(5):399–408 (53 ref.)

Exercise for the older woman: choosing the right prescription. Taunton JE, et al. **Br J Sports Med** 1997 Mar; 31(1):5–10 (75 ref.)

The pressor reflex evoked by static contraction: neurochemistry at the site of the first synapse. Wilson LB, et al. **Brain Res Brain Res Rev** 1997 Apr;23(3):196–209 (120 ref.)

Molecular basis of skeletal muscle regeneration. Chambers RL, et al. **Can J Appl Physiol** 1996 Jun;21(3):155–84 (133 ref.)

The potential role of insulin-like growth factors in skeletal muscle regeneration. MacGregor J, et al. **Can J Appl Physiol** 1996 Aug;21(4):236–50 (35 ref.)

Physiologic consequences of training. Charlton GA, et al. **Cardiol Clin** 1997 Aug;15(3):345–54 (59 ref.)

Sarcomeric calcium sparks activated by fiber depolarization and by cytosolic Ca2+ in skeletal muscle [published erratum appears in Cell Calcium 1997 Feb;21(2):173] Schneider MF, et al. **Cell Calcium** 1996 Aug;20(2):123–8 (27 ref.)

Molecular cogs in machina carnis. Stephenson DG. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov; 23(10–11):898–907 (91 ref.)

Functional consequences of acute and chronic hypoxia on respiratory and skeletal muscles in mammals. Jammes Y, et al. **Comp Biochem Physiol A Physiol** 1997 Sep; 118(1):15–22 (54 ref.)

Crustacean muscle plasticity: molecular mechanisms determining mass and contractile properties. Mykles DL. **Comp Biochem Physiol B Biochem Mol Biol** 1997 Jul; 117(3):367–78 (105 ref.)

The swinging lever-arm hypothesis of muscle contraction. Holmes KC. **Curr Biol** 1997 Feb 1;7(2):R112–8 (27 ref.)

Growth factors in skeletal muscle regeneration. Husmann I, et al. **Cytokine Growth Factor Rev** 1996 Oct;7(3):249–58 (108 ref.)

Growth hormone and the insulin-like growth factor system in myogenesis. Florini JR, et al. **Endocr Rev** 1996 Oct; 17(5):481–517 (465 ref.)

The regulation of gene expression in hypertrophying skeletal muscle. Carson JA. **Exerc Sport Sci Rev** 1997;25:301–20 (57 ref.)

Functional adaptations in patients with ACL-deficient knees. Hurwitz DE, et al. **Exerc Sport Sci Rev** 1997;25:1–20 (43 ref.)

Force transmission in skeletal muscle: from actomyosin to external tendons. Patel TJ, et al. **Exerc Sport Sci Rev** 1997; 25:321–63 (121 ref.)

A nonlinear mathematical model of electrically stimulated skeletal muscle. Dorgan SJ, et al. **IEEE Trans Rehabil Eng** 1997 Jun;5(2):179–94 (55 ref.)

Current research on muscle activity about the shoulder. Kelly BT, et al. **Instr Course Lect** 1997;46:53–66 (98 ref.)

Physiology of exercising muscle. Kibler WB. **Instr Course Lect** 1994;43:3–4 (13 ref.)

Development and regeneration of muscle spindles in mammals and birds. Maier A. **Int J Dev Biol** 1997 Feb; 41(1):1–17 (175 ref.)

Influence of varying muscle forces on lumbar intradiscal pressure: an in vitro study. Wilke HJ, et al. **J Biomech** 1996 Apr;29(4):549–55 (39 ref.)

Effect of training and nutrition on the development of skeletal muscle. Henriksson J. **J Sports Sci** 1995 Summer;13 Spec No:S25–30 (55 ref.)

Diet composition and the performance of high-intensity exercise. Maughan RJ, et al. **J Sports Sci** 1997 Jun; 15(3):265–75 (67 ref.)

Aetiology of skeletal muscle 'cramps' during exercise: a novel hypothesis. Schwellnus MP, et al. **J Sports Sci** 1997 Jun; 15(3):277–85 (45 ref.)

A review of adaptive change in musculoskeletal impedance during space flight and associated implications for postflight head movement control. McDonald PV, et al. **J Vestib Res** 1997 Mar–Jun;7(2–3):239–50 (63 ref.)

Effect of spaceflight on the functional, biochemical, and metabolic properties of skeletal muscle. Baldwin KM. **Med Sci Sports Exerc** 1996 Aug;28(8):983–7 (25 ref.)

1996 J.B. Wolffe Memorial Lecture. Challenging beliefs: ex Africa semper aliquid novi. Noakes TD. **Med Sci Sports Exerc** 1997 May;29(5):571–90 (118 ref.)

Excitation–Ca2+ release–contraction coupling in single aged human skeletal muscle fiber. Delbono O, et al. **Muscle Nerve Suppl** 1997;5:S88–92 (19 ref.)

Blood flow and substrate exchange in skeletal muscle of man: techniques relevant for use in the study of the ageing process of muscle. Saltin B. **Muscle Nerve Suppl** 1997; 5:S107–9 (12 ref.)

Functional differences of myosin heavy-chain isoforms in skeletal muscle. Hilber K, et al. **Naturwissenschaften** 1997 May;84(5):201–4 (20 ref.)

Actomyosin interaction in striated muscle. Cooke R. **Physiol Rev** 1997 Jul;77(3):671–97 (157 ref.)

Ryanodine receptors of striated muscles: a complex channel capable of multiple interactions. Franzini-Armstrong C, et al. **Physiol Rev** 1997 Jul;77(3):699–729 (356 ref.)

Muscle growth and muscle function: a molecular biological perspective. Goldspink G. **Res Vet Sci** 1996 May; 60(3):193–204 (100 ref.)

The role of ryanodine receptor isoforms in the structure and function of the vertebrate triad. Block BA, et al. **Soc Gen Physiol Ser** 1996;51:47–65 (56 ref.)

Functional significance of membrane architecture in skeletal and cardiac muscle. Franzini-Armstrong C. **Soc Gen Physiol Ser** 1996;51:3–18 (72 ref.)

Physiological factors associated with efficiency in high intensity exercise. Bangsbo J. **Sports Med** 1996 Nov; 22(5):299–305 (18 ref.)

The use of electromyography for the noninvasive prediction of muscle forces. Current issues. Dowling JJ. **Sports Med** 1997 Aug;24(2):82–96 (74 ref.)

Muscle contraction and fatigue. The role of adenosine 5'-diphosphate and inorganic phosphate. McLester JR Jr. **Sports Med** 1997 May;23(5):287–305 (124 ref.)

Anthropometric and physiological characteristics of rugby union football players. Nicholas CW. **Sports Med** 1997 Jun; 23(6):375–96 (75 ref.)

The use of isometric tests of muscular function in athletic assessment. Wilson GJ, et al. **Sports Med** 1996 Jul; 22(1):19–37 (89 ref.)

Muscular causes of exercise intolerance in horses. Valberg SJ. **Vet Clin North Am Equine Pract** 1996 Dec; 12(3):495–515 (52 ref.)

[Physiology and physiopathology of ryanodine receptors in swine. Significance of sensitivity to stress, stress myopathies, malignant hyperthermia and meat quality] Martens H. **Tierarztl Prax** 1997 Jan;25(1):41–51 (62 ref.) (Eng. Abstr.) **(Ger)**

[Asymmetry of posture and truncal musculature following unilateral arm amputation--a clinical, electromyographic, posture analytical and photogrammetric study] Greitemann B, et al. **Z Orthop Ihre Grenzgeb** 1996 Nov–Dec; 134(6):498–510 (39 ref.) (Eng. Abstr.) **(Ger)**

[Molecular mechanisms for Ca2+ dependent regulation of various muscle types] Dąbrowska R. **Postepy Biochem** 1996;42(2):195–203 (69 ref.) **(Pol)**

[Dystrophin-glycoprotein complex of skeletal muscle sarcolemma] Jakubiec-Puka A, et al. **Postepy Biochem** 1996;42(2):204–13 (90 ref.) **(Pol)**

PHYSIOPATHOLOGY

Motor control physiology below spinal cord injury: residual volitional control of motor units in paretic and paralyzed muscles. Dimitrijevic MR, et al. **Adv Neurol** 1997;72:335–45 (32 ref.)

The role of the calcium release channel of skeletal muscle sarcoplasmic reticulum in malignant hyperthermia. MacLennan DH, et al. **Ann N Y Acad Sci** 1993 Dec 20; 707:294–304 (46 ref.)

The electrically stimulated gracilis neo-anal sphincter. Mander BJ, et al. **Eur J Gastroenterol Hepatol** 1997 May; 9(5):435–41 (41 ref.)

Peripheral and respiratory muscles in chronic heart failure. Stassijns G, et al. **Eur Respir J** 1996 Oct;9(10):2161–7 (55 ref.)

FES standing: control by handle reactions of leg muscle stimulation (CHRELMS). Donaldson N de N, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):280–4 (12 ref.)

Basic science and conservative care of patellofemoral dysfunction: a review of the literature. Banovetz JM, et al. **Iowa Orthop J** 1996;16:88–96 (63 ref.)

The "muscle hypothesis" of chronic heart failure. Coats AJ. **J Mol Cell Cardiol** 1996 Nov;28(11):2255–62 (49 ref.)

Role of skeletal muscle in the syndrome of chronic heart failure. Poole-Wilson PA, et al. **J Mol Cell Cardiol** 1996 Nov;28(11):2275–85 (120 ref.)

Evaluation of skeletal muscle fatigue in patients with heart failure. Wilson JR. **J Mol Cell Cardiol** 1996 Nov; 28(11):2287–92 (22 ref.)

Brain and skeletal muscle bioenergetic failure in familial hypobetalipoproteinaemia. Lodi R, et al. **J Neurol Neurosurg Psychiatry** 1997 Jun;62(6):574–80 (61 ref.)

Functional and metabolic consequences of sarcopenia. Evans W. **J Nutr** 1997 May;127(5 Suppl):998S–1003S (56 ref.)

Muscle mass and strength: relation to function in population studies. Harris T. **J Nutr** 1997 May;127(5 Suppl):1004S–1006S (17 ref.)

The pelvic floor muscles: muscle thickness in healthy and urinary-incontinent women measured by perineal ultrasonography with reference to the effect of pelvic floor training. Estrogen receptor studies. Bernstein IT. **Neurourol Urodyn** 1997;16(4):237–75 (145 ref.)

The 1995 John M. Kinney International Award for Nutrition and Metabolism. Effect of passive stretching on the wasting of muscle in the critically ill: background. Griffiths RD. **Nutrition** 1997 Jan;13(1):70–4 (24 ref.)

The possible role of substance P in eliciting and modulating deep somatic pain. Mense S, et al. **Prog Brain Res** 1996; 110:125–35 (55 ref.)

Exercise-induced muscle cramp. Proposed mechanisms and management. Bentley S. **Sports Med** 1996 Jun;21(6):409–20 (28 ref.)

[The significance of nutrition for muscular function after surgery] Jensen MB. **Ugeskr Laeger** 1997 Feb 10; 159(7):923–6 (40 ref.) (Eng. Abstr.) **(Dan)**

[Evaluation of muscle weakness] Wada F, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:409–12 (8 ref.) **(Jpn)**

[Skeletal myoclonus and midbrain tremor] Nagaoka M. **No To Shinkei** 1996 Mar;48(3):209–16 (12 ref.) **(Jpn)**

RADIOGRAPHY

Pediatric musculoskeletal computed radiography. Kottamasu SR, et al. **Pediatr Radiol** 1997 Jul;27(7):563–75 (25 ref.)

Imaging of muscle injuries. El-Khoury GY, et al. **Skeletal Radiol** 1996 Jan;25(1):3–11 (26 ref.)

SURGERY

Intrathoracic muscle transposition. Surgical anatomy and techniques of harvest. Harris SU, et al. **Chest Surg Clin N Am** 1996 Aug;6(3):501–18 (11 ref.)

Laplace's law and the risks and prevention of bladder rupture after enterocystoplasty and bladder autoaugmentation. Chancellor MB, et al. **Neurourol Urodyn** 1996;15(3):223–33 (19 ref.)

TRANSPLANTATION

Experimental skeletal muscle grafts as a model of regeneration. Lawson-Smith MJ, et al. **Aust N Z J Surg** 1997 Jan;67(1):35–9 (53 ref.)

Functioning free-muscle transplantation for the upper extremity. Chuang DC. **Hand Clin** 1997 May;13(2):279–89 (22 ref.)

Gracilis muscle transposition in the treatment of faecal incontinence. Sieleneff I, et al. **Int J Colorectal Dis** 1996; 11(1):15–8 (36 ref.)

Axonal regeneration through acellular muscle grafts. Hall S. **J Anat** 1997 Jan;190 (Pt 1):57–71 (110 ref.)

Skeletal muscle ventricles: another alternative for heart failure. Niinami H, et al. **J Card Surg** 1996 Jul–Aug; 11(4):280–7 (40 ref.)

Dynamic myoplasty: surgical transfer and stimulation of skeletal muscle for functional substitution or enhancement. Grandjean P, et al. **J Rehabil Res Dev** 1996 Apr; 33(2):133–44 (30 ref.)

[Use of skeletal muscle in cardiac assist] Pęczalski K, et al. **Pol Tyg Lek** 1996 Mar;51(10–13):166–9 (23 ref.) **(Pol)**

ULTRASONOGRAPHY

Calf enlargement in neuromuscular diseases: a quantitative ultrasound study in 350 patients and review of the literature. Reimers CD, et al. **J Neurol Sci** 1996 Nov; 143(1–2):46–56 (75 ref.)

[Sonography of the knee extensor system] Gruber G. **Ultraschall Med** 1996 Oct;17(5):206–11 (16 ref.) (Eng. Abstr.) **(Ger)**

ULTRASTRUCTURE

Myomesin, M–protein and the structure of the sarcomeric M–band. Van Der Ven PF, et al. **Adv Biophys** 1996;33:91–9 (37 ref.)

Mitochondrial biogenesis in skeletal muscle in response to endurance exercises. Freyssenet D, et al. **Arch Physiol Biochem** 1996;104(2):129–41 (114 ref.)

Models of thin filament assembly in cardiac and skeletal muscle. Gregorio CC. **Cell Struct Funct** 1997 Feb; 22(1):191–5 (37 ref.)

MUSCLE, SMOOTH

ABNORMALITIES

[A congenital hamartoma of smooth muscle: an atypical presentation] Sánchez Miralles E, et al. **An Esp Pediatr** 1996 May;44(5):488–90 (15 ref.) **(Spa)**

ANATOMY & HISTOLOGY

Cells and cell junctions in the muscle coat of the bladder. Gabella G. **Scand J Urol Nephrol Suppl** 1997;184:3–6 (11 ref.)

CHEMISTRY

Myosin isoform heterogeneity in single smooth muscle cells. Eddinger TJ, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 May; 117(1):29–38 (80 ref.)

Characterization of isoform diversity among smooth muscle and nonmuscle myosin heavy chains. Kelley CA. **Comp Biochem Physiol B Biochem Mol Biol** 1997 May; 117(1):39–49 (39 ref.)

Myosin heavy chain isoforms in smooth muscle. Loukianov E, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 May;117(1):13–8 (51 ref.)

Myosin isoforms and functional diversity in vertebrate smooth muscle. Murphy RA, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 May; 117(1):51–60 (102 ref.)

Kinase–related protein: a smooth muscle myosin–binding protein. Vorotnikov AV. **Int J Biochem Cell Biol** 1997 May;29(5):727–30 (7 ref.)

CYTOLOGY

Airway smooth muscle cell culture: application to studies of airway wall remodelling and phenotype plasticity in asthma. Hirst SJ. **Eur Respir J** 1996 Apr;9(4):808–20 (107 ref.)

Therapeutic manipulation of cell cycle in smooth muscle cells: implications for restenosis. Simons M. **J Lab Clin Med** 1996 Oct;128(4):361–6 (27 ref.)

The cellular derivation and the life span of the myofibroblast. Gabbiani G. **Pathol Res Pract** 1996 Jul;192(7):708–11 (61 ref.)

Role of stromal myofibroblasts infiltrating colon cancer in tumor invasion. Martin M, et al. **Pathol Res Pract** 1996 Jul;192(7):712–7 (47 ref.)

DRUG EFFECTS

Modulation of the calcium sensitivity of the smooth muscle contractile apparatus: molecular mechanisms, pharmacological and pathophysiological implications. Savineau JP, et al. **Fundam Clin Pharmacol** 1997; 11(4):289–99 (103 ref.)

Drug receptor mechanisms in smooth muscle: beta–chloroethylamine–sensitive and –resistant receptor mechanisms. Takayanagi I, et al. **Jpn J Pharmacol** 1997 Jan;73(1):1–22 (89 ref.)

Calcium movements, distribution, and functions in smooth muscle. Karaki H, et al. **Pharmacol Rev** 1997 Jun; 49(2):157–230 (868 ref.)

Actions of neurotransmitters and other messengers on Ca2+ channels and K+ channels in smooth muscle cells. Beech DJ. **Pharmacol Ther** 1997;73(2):91–119 (353 ref.)

[Treatment of spasms of visceral smooth muscles] Milovanović DR, et al. **Med Pregl** 1997 May–Jun; 50(5–6):194–200 (50 ref.) (Eng. Abstr.) **(Scr)**

GROWTH & DEVELOPMENT

Molecular analysis of gastrointestinal smooth muscle development. McHugh KM. **J Pediatr Gastroenterol Nutr** 1996 Nov;23(4):379–94 (97 ref.)

IMMUNOLOGY

Endomysium: autoantigen in coeliac disease [comment] Feighery C, et al. **Eur J Gastroenterol Hepatol** 1997 Jul; 9(7):655–6 (14 ref.) Comment on: Eur J Gastroenterol Hepatol 1997 Jul;9(7):657–60.

INNERVATION

Interplay of VIP and nitric oxide in the regulation of neuromuscular function in the gut. Murthy KS, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:355–62; discussion 362–3 (27 ref.)

NANC neural control of airway smooth muscle tone. Lindén A. **Gen Pharmacol** 1996 Oct;27(7):1109–21 (140 ref.)

Autonomic neuromuscular transmission at a varicosity. Bennett MR. **Prog Neurobiol** 1996 Dec;50(5–6):505–32 (123 ref.)

Non–adrenergic non–cholinergic (NANC) transmission to smooth muscle: 35 years on. Bennett MR. **Prog Neurobiol** 1997 Jun;52(3):159–95 (261 ref.)

[Inhibitory neuronal control of smooth muscle activity of the gastrointestinal tract] Hata F, et al. **Nippon Yakurigaku Zasshi** 1997 Feb;109(2):61–73 (51 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Regulation of ion channels in smooth muscles by calcium. Carl A, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):C9–34 (266 ref.)

Signal transduction in gastrointestinal smooth muscle. Makhlouf GM, et al. **Cell Signal** 1997 May–Jun; 9(3–4):269–76 (92 ref.)

Superoxide anions, free–radical scavengers, and nitrergic neurotransmission. Gibson A, et al. **Gen Pharmacol** 1997 Apr;28(4):489–93 (37 ref.)

Is the mitochondrial benzodiazepine receptor involved in the control of airway smooth muscle tone? Pelaia G, et al. **Gen Pharmacol** 1997 Apr;28(4):495–8 (18 ref.)

Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: implications for uveoscleral outflow. Lindsey JD, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S53–9 (53 ref.)

Synthetic functions of airway smooth muscle in asthma. Johnson SR, et al. **Trends Pharmacol Sci** 1997 Aug; 18(8):288–92 (60 ref.)

Mesenchymal–epithelial interactions in the bladder. Baskin LS, et al. **World J Urol** 1996;14(5):301–9 (45 ref.)

PATHOLOGY

Smooth muscle–epithelial interactions in normal and neoplastic prostatic development. Cunha GR, et al. **Acta Anat (Basel)** 1996;155(1):63–72 (57 ref.)

Deficiency of c–kit+ cells in patients with a myopathic form of chronic idiopathic intestinal pseudo–obstruction. Isozaki K, et al. **Am J Gastroenterol** 1997 Feb;92(2):332–4 (18 ref.)

Congenital pulmonary myofibroblastic tumor: a case report with cytogenetic analysis and review of the literature. Alobeid B, et al. **Am J Surg Pathol** 1997 May;21(5):610–4 (16 ref.)

Airway smooth muscle cell culture: application to studies of airway wall remodelling and phenotype plasticity in asthma. Hirst SJ. **Eur Respir J** 1996 Apr;9(4):808–20 (107 ref.)

Role of stromal myofibroblasts infiltrating colon cancer in tumor invasion. Martin M, et al. **Pathol Res Pract** 1996 Jul;192(7):712–7 (47 ref.)

PHYSIOLOGY

Characteristics and physiological role of the Ca(2+)–activated Cl– conductance in smooth muscle. Large WA, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):C435–54 (170 ref.)

Role of PACAP in the regulation of gastrointestinal motility. Katsoulis S, et al. **Ann N Y Acad Sci** 1996 Dec 26; 805:364–78 (35 ref.)

Ca2+ transient, cell volume, and microviscosity of the plasma membrane in smooth muscle. Ochsner M. **Biochem Pharmacol** 1997 Jun 15;53(12):1765–77 (123 ref.)

Smooth and skeletal muscle single–molecule mechanical experiments [comment] Molloy JE, et al. **Biophys J** 1997 Mar;72(3):984–6 (8 ref.) Comment on: Biophys J 1997 Mar;72(3):1006–21.

Spontaneous transient outward currents in smooth muscle cells. Bolton TB, et al. **Cell Calcium** 1996 Aug;20(2):141–52 (109 ref.)

C–terminal isoforms of the myosin heavy chain and smooth muscle function. Martin AF, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 May; 117(1):3–11 (52 ref.)

NANC neural control of airway smooth muscle tone. Lindén A. **Gen Pharmacol** 1996 Oct;27(7):1109–21 (140 ref.)

Therapeutic manipulation of cell cycle in smooth muscle cells: implications for restenosis. Simons M. **J Lab Clin Med** 1996 Oct;128(4):361–6 (27 ref.)

Ocular outflow facility with emphasis on neuronal regulation of intraocular smooth muscles. Suzuki R. **J Smooth Muscle Res** 1996 Dec;32(6):229–47 (82 ref.)

Maturational aspects of human airway smooth muscle function. Panitch HB. **Monaldi Arch Chest Dis** 1996 Oct; 51(5):413–8 (41 ref.)

The cellular derivation and the life span of the myofibroblast. Gabbiani G. **Pathol Res Pract** 1996 Jul;192(7):708–11 (61 ref.)

Muscarinic receptor subtypes and smooth muscle function. Eglen RM, et al. **Pharmacol Rev** 1996 Dec;48(4):531–65 (482 ref.)

Mechanisms of smooth muscle contraction. Horowitz A, et al. **Physiol Rev** 1996 Oct;76(4):967–1003 (461 ref.)

Muscarinic M2 and M3 receptor function in smooth muscle. Eglen RM. **Proc West Pharmacol Soc** 1996;39:57–60 (48 ref.)

Smooth muscle as a direct or indirect target accounting for bronchopulmonary hyperresponsiveness. Wills–Karp M. **Res Immunol** 1997 Jan;148(1):59–72 (125 ref.)

Initiation of contraction in detrusor smooth muscle. Fry CH, et al. **Scand J Urol Nephrol Suppl** 1997;184:7–14 (26 ref.)

Change in length of the detrusor muscle cells. Tammela T. **Scand J Urol Nephrol Suppl** 1997;184:19–24 (22 ref.)

Multiple types of ion channels in cavernous smooth muscle. Noack T, et al. **World J Urol** 1997;15(1):45–9 (12 ref.)

Signal transduction in cavernous smooth muscle. Stief CG, et al. **World J Urol** 1997;15(1):27–31 (29 ref.)

[Interaction between tumor necrosis factor–alpha and the smooth muscle cells of the airway: implication in the physiopathology of asthma] Amrani Y, et al. **Rev Mal Respir** 1996 Dec;13(6):539–46 (49 ref.) (Eng. Abstr.) **(Fre)**

[Intraocular smooth muscle physiology relating to pathogenesis and therapy of glaucoma] Suzuki R. **J Smooth Muscle Res** 1996 Oct;32(5):175–94 (68 ref.) **(Jpn)**

[Analysis of intracellular calcium concentration in tissues—special reference to synchronous analysis of the calcium and smooth muscle contraction] Karaki H. **Nippon Seirigaku Zasshi** 1995;57(12):469–76 (10 ref.) **(Jpn)**

[Molecular mechanisms for Ca2+ dependent regulation of various muscle types] Dąbrowska R. **Postepy Biochem** 1996;42(2):195–203 (69 ref.) **(Pol)**

[The intracellular signal systems of the smooth muscles in the gastrointestinal tract] Medvedev MA, et al. **Vestn Ross Akad Med Nauk** 1996;(1):21–9 (33 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Alterations in the physiological properties of urinary bladder smooth muscle caused by bladder emptying against an obstruction. Brading AF. **Scand J Urol Nephrol Suppl** 1997; 184:51–8 (46 ref.)

Contractile protein changes in urinary bladder smooth muscle during obstruction–induced hypertrophy. Chacko S, et al. **Scand J Urol Nephrol Suppl** 1997;184:67–76 (82 ref.)

TRANSPLANTATION

Autotransplanted jejunum in head and neck cancer. Kornfehl J. **Eur J Cancer B Oral Oncol** 1994 Jan;30B(1):16–22 (96 ref.)

ULTRASTRUCTURE

Adenosarcoma of the uterus with extensive smooth muscle differentiation: ultrastructural study and review of the literature. Fehmian C, et al. **Ultrastruct Pathol** 1997 Jan–Feb;21(1):73–9 (15 ref.)

MUSCLE, SMOOTH, VASCULAR

Role of thromboxane A2 in mitogenesis of vascular smooth muscle cells. Dorn GW 2nd. **Agents Actions Suppl** 1997; 48:42–62 (61 ref.)

Regulation of differentiation/maturation in vascular smooth muscle cells by hormones and growth factors. Owens GK, et al. **Agents Actions Suppl** 1997;48:3–24 (90 ref.)

Vascular myofibroblasts. Lessons from coronary repair and remodeling. Zalewski A, et al. **Arterioscler Thromb Vasc Biol** 1997 Mar;17(3):417–22 (46 ref.)

Aortic function. Boudoulas H, et al. **J Heart Valve Dis** 1996 Nov;5 Suppl 3:S258–63 (26 ref.)

CHEMISTRY

What are the molecular mechanisms for the antiproliferative effects of nitric oxide and cGMP in vascular smooth muscle? [editorial; comment] Murad F. **Circulation** 1997 Mar 4;95(5):1101–3 (16 ref.) Comment on: Circulation 1997 Mar 4;95(5):1269–77.

Potassium channels in vascular smooth muscle. Brayden JE. **Clin Exp Pharmacol Physiol** 1996 Dec;23(12):1069–76 (74 ref.)

Endothelium–derived hyperpolarizing factor. Félétou M, et al. **Clin Exp Pharmacol Physiol** 1996 Dec;23(12):1082–90 (110 ref.)

CYTOLOGY

Smooth muscle cell heterogeneity in pulmonary and systemic vessels. Importance in vascular disease. Frid MG, et al. **Arterioscler Thromb Vasc Biol** 1997 Jul;17(7):1203–9 (40 ref.)

Myosin gene expression and cell phenotypes in vascular smooth muscle during development, in experimental models, and in vascular disease. Sartore S, et al. **Arterioscler Thromb Vasc Biol** 1997 Jul;17(7):1210–5 (42 ref.)

Biointeractive polymers and tissue engineered blood vessels. Greisler HP, et al. **Biomaterials** 1996 Feb;17(3):329–36 (15 ref.)

Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases. Berk BC, et al. **Circ Res** 1997 May;

80(5):607–16 (19 ref.)
Role of mechanical strain in regulation of differentiation of vascular smooth muscle cells [editorial] Owens GK. **Circ Res** 1996 Nov;79(5):1054–5 (20 ref.)
Interactions between endothelial cells and smooth muscle cells after their activation by hypoxia. A possible etiology for venous disease. Michiels C, et al. **Int Angiol** 1996 Jun; 15(2):124–30 (31 ref.)
Differentiated properties and proliferation of arterial smooth muscle cells in culture. Thyberg J. **Int Rev Cytol** 1996; 169:183–265 (520 ref.)
Morphometric analysis of vascular smooth muscle cells by scanning electron microscopy. Evan AP, et al. **Int Rev Exp Pathol** 1996;36:31–52 (44 ref.)
Vascular gene therapy in the 21st century. Clowes AW. **Thromb Haemost** 1997 Jul;78(1):605–10 (70 ref.)
[Advances in the study on the inhibition of vascular smooth muscle proliferation by gene rearrangement and gene transfer techniques] Liang H, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1996 Apr;25(2):114–7 (15 ref.) (Eng. Abstr.) **(Chi)**
[Vascular smooth muscle cell and extrinsic coagulation pathway] Nakahara Y, et al. **Rinsho Byori** 1997 Feb;Suppl 104:205–15 (39 ref.) **(Jpn)**
[A novel growth-regulating factor for vascular smooth muscle cells and its receptors, Gas6 and Axl/Sky] Nakano T. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(11):1543–9 (44 ref.) **(Jpn)**

DRUG EFFECTS

Antimitotic actions of vasodilatory prostaglandins—clinical aspects. Sinzinger H, et al. **Agents Actions Suppl** 1997; 48:92–106 (33 ref.)
Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease? Ruschitzka FT, et al. **Am Heart J** 1997 Aug;134(2 Pt 2):S31–47 (117 ref.)
The regulation of pulmonary vascular tone. Wilkins MR, et al. **Br J Clin Pharmacol** 1996 Jul;42(1):127–31 (39 ref.)
Pharmacological aspects of calcium channel blockers. Scholz H. **Cardiovasc Drugs Ther** 1997 Jan;10 Suppl 3:869–72 (25 ref.)
Angiotensin II–induced tyrosine phosphorylation in mesangial and vascular smooth muscle cells. Marrero MB, et al. **Clin Exp Pharmacol Physiol** 1996 Jan;23(1):83–8 (46 ref.)
A proposed mechanism for the cardioprotective effect of oestrogen in women: enhanced endothelial nitric oxide release decreases coronary artery reactivity. Wellman GC, et al. **Clin Exp Pharmacol Physiol** 1996 Mar;23(3):260–6 (70 ref.)
Vascular effects of selected antihypertensive drugs derived from traditional medicinal herbs. Kwan CY. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S297–9 (12 ref.)
Antihypertensive therapy and arterial function in experimental hypertension. Kähönen M, et al. **Gen Pharmacol** 1996 Mar;27(2):221–38 (263 ref.)
Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology [clinical conference] Sowers JR. **Hypertension** 1997 Mar;29(3):691–9 (157 ref.)
Vascular actions of diadenosine phosphates. Schlüter H, et al. **J Auton Pharmacol** 1996 Dec;16(6):357–62 (26 ref.)
Vascular aldosterone. Biosynthesis and a link to angiotension II–induced hypertrophy of vascular smooth muscle cells. Gómez-Sánchez EP. **J Endocrinol Invest** 1995 Jul–Aug; 18(7):580–5 (22 ref.)
Vascular remodeling and mineralocorticoids. Weber KT, et al. **J Endocrinol Invest** 1995 Jul–Aug;18(7):533–9 (62 ref.)
Inhibition of endothelial cell function: should this be a main goal of immunosuppressive strategies? [editorial; comment] Bach FH. **J Heart Lung Transplant** 1997 May;16(5):493–5 (16 ref.) Comment on: J Heart Lung Transplant 1997 May;16(5):484–92.
The role of isoprenoids in vascular smooth muscle: potential benefits of statins unrelated to cholesterol lowering. Hughes AD. **J Hum Hypertens** 1996 Jun;10(6):387–90 (37 ref.)
Calcium antagonism in vascular smooth muscle cells. Fleckenstein-Grün G. **Pflugers Arch** 1996;432(3 Suppl):R53–60 (54 ref.)
Potential uses of a new class of low-molecular-weight heparins in cardiovascular indications. Cohen M, et al. **Semin Thromb Hemost** 1996;22 Suppl 2:25–7 (22 ref.)
[Action of natural estrogens on the vessel wall: molecular mechanisms and clinical implications] Lüscher TF, et al. **Schweiz Med Wochenschr** 1996 Oct 12;126(41):1748–55 (31 ref.) (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

Potential involvement of type II phospholipase A2 in atherosclerosis. Hurt-Camejo E, et al. **Atherosclerosis** 1997 Jul 11;132(1):1–8 (91 ref.)
Plasma membrane and sarcoplasmic reticulum Ca-ATPase and smooth muscle. Gonzalez JM, et al. **Miner Electrolyte Metab** 1996;22(5–6):345–8 (27 ref.)
Nitric oxide and the pulmonary artery smooth muscle cell. Degnim AC, et al. **Semin Pediatr Surg** 1996 Aug;5(3):160–4 (42 ref.)

GROWTH & DEVELOPMENT

Factors controlling growth and matrix production in vascular smooth muscle and glomerular mesangial cells. Dubey RK, et al. **Curr Opin Nephrol Hypertens** 1997 Jan;6(1):88–105 (170 ref.)

INJURIES

Investigation in the use of topical solutions for management or prevention of thrombosis in traumatized vessels. Cooley BC, et al. **Int Angiol** 1995 Sep;14(3):297–302 (87 ref.)

METABOLISM

Functional aspects of angiotensin type 2 receptor. Horiuchi M. **Adv Exp Med Biol** 1996;396:217–24 (39 ref.)
Regulation of 4-aminopyridine-sensitive, delayed rectifier K+ channels in vascular smooth muscle by phosphorylation. Cole WC, et al. **Biochem Cell Biol** 1996; 74(4):439–47 (52 ref.)
Endothelium-dependent hyperpolarization of vascular smooth muscle: role for a non-nitric oxide synthase product. Waldron GJ, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Jan;17(1):3–7 (49 ref.)
Light microscope autoradiography of peripheral dopamine receptor subtypes. Amenta F. **Clin Exp Hypertens** 1997 Jan–Feb;19(1–2):27–41 (30 ref.)
Arterial muscle myosin heavy chains and light chains in spontaneous hypertension. Packer CS. **Comp Biochem Physiol B Biochem Mol Biol** 1997 May; 117(1):19–28 (43 ref.)
Control of the renal microcirculation: cellular and integrative perspectives. Casellas D, et al. **Curr Opin Nephrol Hypertens** 1996 Jan;5(1):57–63 (52 ref.)
The role of inflammation in atherosclerosis. Blum A, et al. **Isr J Med Sci** 1996 Nov;32(11):1059–65 (79 ref.)
Modulation of elastin expression and cell proliferation in vascular smooth muscle cells in vitro. Tajima S. **Keio J Med** 1996 Mar;45(1):58–62 (33 ref.)
Diversity of response in vascular smooth muscle cells to changes in oxygen tension. Weir EK, et al. **Kidney Int** 1997 Feb;51(2):462–6 (41 ref.)
Regulation of cytosolic calcium levels in vascular smooth muscle. Orallo F. **Pharmacol Ther** 1996;69(3):153–71 (267 ref.)
Protein tyrosine phosphorylation in smooth muscle: a potential coupling mechanism between receptor activation and intracellular calcium. Di Salvo J, et al. **Proc Soc Exp Biol Med** 1997 Apr;214(4):285–301 (97 ref.)
[Carbon monoxide: an essential modulator of blood vessel tone] Netzer D, et al. **Harefuah** 1997 Apr 1;132(7):494–9 (20 ref.) **(Heb)**
[Abnormalities of vascular wall metabolism and arteriosclerosis] Saito Y. **Nippon Naika Gakkai Zasshi** 1997 Mar 10;86(3):365–8 (6 ref.) **(Jpn)**

PATHOLOGY

Potential involvement of growth factors in the proliferation of arteriolar smooth muscle cells during chronic graft rejection. Vuillemin T, et al. **Adv Nephrol Necker Hosp** 1996;25:39–49 (26 ref.)
Roles of vasodilatory prostaglandins in mitogenesis of vascular smooth muscle cells. Schrör K, et al. **Agents Actions Suppl** 1997;48:63–91 (123 ref.)
Inhibition of neointimal formation by natural heparan sulfate proteoglycans of the arterial wall. Bingley JA, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:238–42; 242–4 (19 ref.)
Vascular gene transfer using smooth muscle cells. Clowes AW. **Ann N Y Acad Sci** 1997 Apr 15;811:293–7; discussion 297–8 (18 ref.)
Molecular determinants of atherosclerotic plaque vulnerability. Libby P, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:134–42; discussion 142–5 (33 ref.)
C-type natriuretic protein inhibits intimal thickening after vascular injury. Matsuo H, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:45–7 (10 ref.)
Contribution of adventitial myofibroblasts to vascular remodeling and lesion formation after experimental angioplasty in pig coronary arteries. Wilcox JN, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:437–47 (67 ref.)
The intima: development and monoclonal responses to injury. Schwartz SM, et al. **Atherosclerosis** 1995 Dec;118 Suppl:S125–40 (125 ref.)
Regulation of vascular smooth-muscle cell growth by angiotensin II. Pratt RE. **Blood Press Suppl** 1996;2:6–9 (31 ref.)
New insights into vascular reactivity: from altered structure to neural control. Angus JA. **Clin Exp Pharmacol Physiol** 1997 May;24(5):297–304 (27 ref.)
Proliferation, migration, matrix turnover, and death of smooth muscle cells in native coronary and vein graft atherosclerosis. Newby AC, et al. **Curr Opin Cardiol** 1996 Nov;11(6):574–82 (77 ref.)
Cellular and molecular biology of vascular remodeling. Cowan DB, et al. **Curr Opin Lipidol** 1996 Apr;7(2):94–100 (54 ref.)
Potential role of the adventitia in arteritis and atherosclerosis. Wilcox JN, et al. **Int J Cardiol** 1997 Aug;54 Suppl:S21–35 (102 ref.)
The renin-angiotensin system and vascular hypertrophy. Rosendorff C. **J Am Coll Cardiol** 1996 Oct;28(4):803–12 (131 ref.)
Smooth muscle phenotypes in developing and atherosclerotic human arteries demonstrated by myosin expression. Aikawa M, et al. **J Atheroscler Thromb** 1995;2(1):14–23 (12 ref.)
Perspectives series: cell adhesion in vascular biology. Smooth muscle migration in atherosclerosis and restenosis. Schwartz SM. **J Clin Invest** 1997 Jun 15;99(12):2814–6 (22 ref.)
Vascular remodeling and mineralocorticoids. Weber KT, et al. **J Endocrinol Invest** 1995 Jul–Aug;18(7):533–9 (62 ref.)
How to assess vascular remodelling in small and medium-sized muscular arteries in humans. Schiffrin EL, et al. **J Hypertens** 1997 Jun;15(6):571–84 (112 ref.)
Molecular regulation of smooth muscle cell differentiation. Owens GK, et al. **J Hypertens Suppl** 1996 Dec;14(5):S55–64 (97 ref.)
Thrombin and vascular smooth muscle cell proliferation: implications for atherosclerosis and restenosis. McNamara CA, et al. **Semin Thromb Hemost** 1996;22(2):139–44 (55 ref.)
[New concept of cardiovasology: vascular remodeling] Dai SM, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan; 27(1):57–60 (10 ref.) **(Chi)**

PHYSIOLOGY

Modulation of voltage-gated Ca2+ channels by O2 tension. Significance for arterial oxygen chemoreception. Franco-Obregón A, et al. **Adv Exp Med Biol** 1996; 410:97–103 (283 ref.)
O2-sensing mechanisms in excitable cells: role of plasma membrane K+ channels. Haddad GG, et al. **Annu Rev Physiol** 1997;59:23–42 (73 ref.)
Protein kinase C mediation of Ca(2+)-independent contractions of vascular smooth muscle. Walsh MP, et al. **Biochem Cell Biol** 1996;74(4):485–502 (214 ref.)
Actions of oestrogen on vascular endothelial and smooth-muscle cells. Ruehlmann DO, et al. **Biochem Soc Trans** 1997 Feb;25(1):40–5 (79 ref.)
The influence of oxidized lipoproteins, oxidation products and antioxidants on the release of nitric oxide from the endothelium and the response of platelets to nitric oxide. Bruckdorfer KR, et al. **Biofactors** 1997;6(2):191–9 (49 ref.)
Ca2+ sparks and Ca2+ waves activate different Ca(2+)-dependent ion channels in single myocytes from rat portal vein. Mironneau J, et al. **Cell Calcium** 1996 Aug; 20(2):153–60 (25 ref.)
Gap junctions in vascular tissues. Evaluating the role of intercellular communication in the modulation of vasomotor tone. Christ GJ, et al. **Circ Res** 1996 Oct; 79(4):631–46 (154 ref.)
What are the molecular mechanisms for the antiproliferative effects of nitric oxide and cGMP in vascular smooth muscle? [editorial; comment] Murad F. **Circulation** 1997 Mar 4;95(5):1101–3 (16 ref.) Comment on: Circulation 1997 Mar 4;95(5):1269–77.
Contractile properties of afferent and efferent arterioles. Ito S, et al. **Clin Exp Pharmacol Physiol** 1997 Jul;24(7):532–5 (30 ref.)
Mechanisms for regulation of arterial tone by Ca2+-dependent K+ channels in hypertension. Rusch NJ, et al. **Clin Exp Pharmacol Physiol** 1996 Dec;23(12):1077–81 (30 ref.)
Role of endothelin in the regulation of vascular tone and blood pressure. Webb DJ, et al. **Contrib Nephrol** 1996; 119:1–7 (10 ref.)
Modulation of vascular tone by low density lipoproteins: effects on L-arginine transport and nitric oxide synthesis. Jay MT, et al. **Exp Physiol** 1997 Mar;82(2):349–60 (60 ref.)
Regulation of capillary formation by laminin and other components of the extracellular matrix. Grant DS, et al. **EXS** 1997;79:317–33 (64 ref.)
Regulation of angiogenesis by scatter factor. Rosen EM, et al. **EXS** 1997;79:193–208 (93 ref.)
Platelet-derived growth factor (PDGF): actions and mechanisms in vascular smooth muscle. Hughes AD, et al. **Gen Pharmacol** 1996 Oct;27(7):1079–89 (190 ref.)
Endothelin regulation of vascular tonus. Kanaide H. **Gen Pharmacol** 1996 Jun;27(4):559–63 (31 ref.)
The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Rockey D. **Hepatology** 1997 Jan;25(1):2–5 (43 ref.)
Growth factors and vascular wall. Chabrier PE. **Int Angiol** 1996 Jun;15(2):100–3 (10 ref.)
Influence of endothelial mediators on the vascular smooth muscle and circulating platelets and blood cells. Warner TD. **Int Angiol** 1996 Jun;15(2):93–9 (69 ref.)
Vascular control mechanisms in penile erection: phylogeny and the inevitability of multiple and overlapping systems. Adams MA, et al. **Int J Impot Res** 1997 Jun;9(2):85–91 (30 ref.)
Integrative erectile biology: the role of signal transduction and cell-to-cell communication in coordinating corporal smooth muscle tone and penile erection. Christ GJ, et al. **Int J Impot Res** 1997 Jun;9(2):69–84 (65 ref.)
Extracellular matrix components and integrins in the control of arterial smooth muscle cell structure and function. Hedin U. **J Atheroscler Thromb** 1994;1 Suppl 1:S39–46 (13 ref.)
Signal transduction in vascular smooth muscle. Alexander RW, et al. **J Hypertens Suppl** 1996 Dec;14(5):S51–4 (35 ref.)
Effects of pH on vascular tension: which are the important mechanisms? Aalkjaer C, et al. **J Vasc Res** 1996 Sep–Oct; 33(5):347–59 (109 ref.)
Regulation of vascular smooth muscle contraction. The roles of Ca2+, protein kinase C and myosin light chain

phosphatase. Takuwa Y. **Jpn Heart J** 1996 Nov; 37(6):793–813 (116 ref.)
Angiotensin II signal transduction in vascular smooth muscle cells: role of tyrosine kinases. Ishida M, et al. **Keio J Med** 1997 Jun;46(2):61–8 (86 ref.)
Calcium antagonism in vascular smooth muscle cells. Fleckenstein-Grün G. **Pflugers Arch** 1996;432(3 Suppl):R53–60 (54 ref.)
Interaction of nitric oxide with myogenic and adrenergic vasoconstrictor processes in the control of microcirculatory blood flow. Pohl U, et al. **Pflugers Arch** 1996;432(3 Suppl):R107–10 (46 ref.)
Bradykinin receptors and receptor ligands (with special emphasis on vascular receptors). Regoli D, et al. **Regul Pept** 1996 Aug 27;65(1):83–9 (51 ref.)
[Cell membrane receptors and intracellular signalling. Characterization in cultivated, contractile and endothelial cells] Briner V. **Fortschr Med** 1996 Oct 20;114(29):384–6 (18 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Signal transduction for PDGF-induced chemotaxis of vascular smooth muscle cells. Shimokado K, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:130–3 (14 ref.)
Apoptosis and vascular wall remodeling in hypertension. Hamet P, et al. **Can J Physiol Pharmacol** 1996 Jul; 74(7):850–61 (90 ref.)
New insights into vascular reactivity: from altered structure to neural control. Angus JA. **Clin Exp Pharmacol Physiol** 1997 May;24(5):297–304 (27 ref.)
Activation of latent TGF-beta at the vascular wall--roles of endothelial cells and mural pericytes or smooth muscle cells. Sato Y. **J Atheroscler Thromb** 1995;2(1):24–9 (38 ref.)
How to assess vascular remodelling in small and medium-sized muscular arteries in humans. Schiffrin EL, et al. **J Hypertens** 1997 Jun;15(6):571–84 (112 ref.)
Pathogenesis of atherosclerosis. Ylä-Herttuala S, et al. **Maturitas** 1996 May;23 Suppl:S47–9 (13 ref.)

RADIATION EFFECTS

Management of peripheral vascular disease: innovative approaches using radiation therapy. Nori D, et al. **Int J Radiat Oncol Biol Phys** 1996 Nov 1;36(4):847–56 (71 ref.)

ULTRASTRUCTURE

Ultrastructure of sympathetic axons and their structural relationship with vascular smooth muscle. Luff SE. **Anat Embryol (Berl)** 1996 Jun;193(6):515–31 (150 ref.)
Morphometric analysis of vascular smooth muscle cells by scanning electron microscopy. Evan AP, et al. **Int Rev Exp Pathol** 1996;36:31–52 (44 ref.)

MUSCLE SPASTICITY

see related
SPASM

DIAGNOSIS

The contribution to spasticity qualification in neurological rehabilitation of patients with upper motor neuron syndrome. Kinalski R. **Neurol Neurochir Pol** 1996;30 Suppl 3:111–20 (14 ref.)

DRUG THERAPY

Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Wagstaff AJ, et al. **Drugs** 1997 Mar;53(3):435–52 (112 ref.)

EPIDEMIOLOGY

Spasticity after stroke. Epidemiology and optimal treatment. O'Brien CF, et al. **Drugs Aging** 1996 Nov;9(5):332–40 (43 ref.)

PHYSIOPATHOLOGY

Functional outcome measures to assess interventions for spasticity. Hinderer SR, et al. **Arch Phys Med Rehabil** 1996 Oct;77(10):1083–9 (54 ref.)
Reflex hyperexcitability and muscle contracture in relation to spastic hypertonia. O'Dwyer NJ, et al. **Curr Opin Neurol** 1996 Dec;9(6):451–5 (38 ref.)
[Spasticity] Zavalishin IA, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1997;97(3):68–70 (31 ref.) **(Rus)**

REHABILITATION

The contribution to spasticity qualification in neurological rehabilitation of patients with upper motor neuron syndrome. Kinalski R. **Neurol Neurochir Pol** 1996;30 Suppl 3:111–20 (14 ref.)

SURGERY

Sensory rhizotomy for the treatment of childhood spasticity. Abbott R. **J Child Neurol** 1996 Nov;11 Suppl 1:S36–42 (60 ref.)
[Role of neurosurgical techniques in the treatment of spasticity] Privat JM. **J Belge Med Phys Rehabil** 1980; 3(2):127–52 (34 ref.) **(Fre)**

THERAPY

Functional outcome measures to assess interventions for spasticity. Hinderer SR, et al. **Arch Phys Med Rehabil** 1996 Oct;77(10):1083–9 (54 ref.)
Spasticity after stroke. Epidemiology and optimal treatment. O'Brien CF, et al. **Drugs Aging** 1996 Nov;9(5):332–40 (43 ref.)
Long-lasting reductions of spasticity induced by skin electrical stimulation. Dewald JP, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):231–42 (57 ref.)
[Spasticity--treatment in children] Truscelli D. **J Belge Med Phys Rehabil** 1980;3(2):158–68 (0 ref.) **(Fre)**

MUSCLE SPINDLES

see related
REFLEX, STRETCH

ANATOMY & HISTOLOGY

[Modern concepts of the structure and function of muscle spindles in mammals] Arutiunian RS. **Usp Fiziol Nauk** 1996 Oct-Dec;27(4):73–95 (142 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Unit identification, sampling bias and technical issues in microneurographic recordings from muscle spindle afferents. Burke D. **J Neurosci Methods** 1997 Jun 27; 74(2):137–44 (39 ref.)
[Modern concepts of the structure and function of muscle spindles in mammals] Arutiunian RS. **Usp Fiziol Nauk** 1996 Oct-Dec;27(4):73–95 (142 ref.) (Eng. Abstr.) **(Rus)**

MUSCLE STRETCH RECEPTORS see **MUSCLE SPINDLES**

MUSCLE, STRIATED see **MUSCLE, SKELETAL**

MUSCLE TONUS

see related
DYSTONIA
MUSCLE HYPERTONIA
MUSCLE HYPOTONIA

DRUG EFFECTS

The regulation of pulmonary vascular tone. Wilkins MR, et al. **Br J Clin Pharmacol** 1996 Jul;42(1):127–31 (39 ref.)

PHYSIOLOGY

Role of coronary vasomotor tone in patients with stable angina pectoris. Kaufmann P, et al. **Cardiologia** 1996 Oct; 41(10):945–51 (63 ref.)
Modulation of vascular tone by low density lipoproteins: effects on L-arginine transport and nitric oxide synthesis. Jay MT, et al. **Exp Physiol** 1997 Mar;82(2):349–60 (60 ref.)
Endothelin regulation of vascular tonus. Kanaide H. **Gen Pharmacol** 1996 Jun;27(4):559–63 (31 ref.)
NANC neural control of airway smooth muscle tone. Lindén A. **Gen Pharmacol** 1996 Oct;27(7):1109–21 (140 ref.)

MUSCLE, VOLUNTARY see **MUSCLE, SKELETAL**

MUSCLE WEAKNESS

Muscle weakness in osteoarthritis. O'Reilly S, et al. **Curr Opin Rheumatol** 1997 May;9(3):259–62 (28 ref.)

CHEMICALLY INDUCED

Respiratory muscle pharmacology. Decramer M. **Monaldi Arch Chest Dis** 1996 Dec;51(6):499–503 (47 ref.)

DIAGNOSIS

Approach to generalized weakness and peripheral neuromuscular disease. LoVecchio F, et al. **Emerg Med Clin North Am** 1997 Aug;15(3):605–23 (35 ref.)

ETIOLOGY

Approach to generalized weakness and peripheral neuromuscular disease. LoVecchio F, et al. **Emerg Med Clin North Am** 1997 Aug;15(3):605–23 (35 ref.)
Respiratory muscles: clinical relevance. Gibson GJ. **Monaldi Arch Chest Dis** 1996 Dec;51(6):504–6 (12 ref.)

PATHOLOGY

Early-onset myopathy with tubular aggregates. Tulinius MH, et al. **Pediatr Neurol** 1996 Jul;15(1):68–71 (15 ref.)

PHYSIOPATHOLOGY

Mechanisms of muscle fatigue in intense exercise. Green HJ. **J Sports Sci** 1997 Jun;15(3):247–56 (68 ref.)
Pure motor hand weakness. Lewis RA. **Semin Neurol** 1996 Mar;16(1):75–81 (48 ref.)
[Prolonged muscle weakness in intensive care patients with special attention to the so-called intensive care polyneuromyopathy] Hinder F, et al. **Anaesthesist** 1997 Mar;46(3):211–9 (49 ref.) (Eng. Abstr.) **(Ger)**

MUSCLES

see related
SARCOLEMMA
SARCOPLASMIC RETICULUM

ANATOMY & HISTOLOGY

Muscle architecture and function in humans. Fukunaga T, et al. **J Biomech** 1997 May;30(5):457–63 (34 ref.)
Noninvasive approach to motor unit characterization: muscle structure, membrane dynamics and neuronal control. Rau G, et al. **J Biomech** 1997 May;30(5):441–6 (28 ref.)

BLOOD SUPPLY

Theoretical predictions of end-capillary PO2 in muscles of athletic and nonathletic animals at VO2max. Roy TK, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):H721–37 (72 ref.)
Intravascular fasciitis: a case report and review of the literature. Samaratunga H, et al. **Pathology** 1996 Jan; 28(1):8–11 (12 ref.)
[Myonephropathic metabolic syndrome (MNMS)] Shimai S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):469–71 (11 ref.) **(Jpn)**

CHEMISTRY

Measuring cytosolic Ca2+ in cells with fluorescent probes: an aid to understanding cell pathophysiology. Hayes A, et al. **Int Rev Exp Pathol** 1996;36:197–212 (65 ref.)

CYTOLOGY

Interdependence between muscle differentiation and cell-cycle control. Maione R, et al. **Biochim Biophys Acta** 1997 Feb 22;1332(1):M19–30 (131 ref.)
The transition from proliferation to differentiation in nerve cells: what can we learn from muscle? Piette J. **Exp Cell Res** 1997 Aug 1;234(2):193–204 (117 ref.)
Strategies to accomplish targeted gene delivery to muscle cells employing tropism-modified adenoviral vectors. Douglas JT, et al. **Neuromuscul Disord** 1997 Jul;7(5):284–98 (98 ref.)
Trans-differentiation of myoblasts to adipoblasts: triggering effects of fatty acids and thiazolidinediones. Grimaldi PA, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Jul; 57(1):71–5 (22 ref.)
[Cell transplantation for neuronal and muscular disorders] Kondoh T, et al. **No To Shinkei** 1997 Jun;49(6):507–15 (50 ref.) **(Jpn)**
[Gene network regulating muscle development] Nabeshima Y. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1008–17 (53 ref.) **(Jpn)**

DRUG EFFECTS

Action of cholinesters on sensory nerve endings in skin and muscle. Carr RW, et al. **Clin Exp Pharmacol Physiol** 1996 May;23(5):355–62 (81 ref.)

EMBRYOLOGY

Desmin in muscle formation and maintenance: knockouts and consequences. Capetanaki Y, et al. **Cell Struct Funct** 1997 Feb;22(1):103–16 (125 ref.)
A myogenic switch. Muscle development. Taylor MV. **Curr Biol** 1996 Aug 1;6(8):924–6 (16 ref.)
Defining the regulatory networks for muscle development. Molkentin JD, et al. **Curr Opin Genet Dev** 1996 Aug; 6(4):445–53 (58 ref.)
Embryonic stem cells and in vitro muscle development. Baker RK, et al. **Curr Top Dev Biol** 1996;33:263–79 (68 ref.)
Unorthodox myogenesis: possible developmental significance and implications for tissue histogenesis and regeneration. Cossu G. **Histol Histopathol** 1997 Jul;12(3):755–60 (30 ref.)
Muscle development and attachment to the epidermis is accompanied by expression of beta 3 and beta 1 tubulin isotypes, respectively. Buttgereit D, et al. **Int J Dev Biol** 1996 Feb;40(1):189–96 (49 ref.)
[Gene network regulating muscle development] Nabeshima Y. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1008–17 (53 ref.) **(Jpn)**

ENZYMOLOGY

[Exercise intolerance caused by muscular phosphorylase kinase deficiency. Contribution of in vivo metabolic studies] Laforêt P, et al. **Rev Neurol (Paris)** 1996 Jun-Jul; 152(6-7):458–64 (27 ref.) (Eng. Abstr.) **(Fre)**

GROWTH & DEVELOPMENT

Alternative strategies in muscle genotype and phenotype studies. A model of intrafusal muscle fibre type differentiation. Soukup T, et al. **Gen Physiol Biophys** 1996 Oct;15(5):345–56 (37 ref.)

INNERVATION

Action of cholinesters on sensory nerve endings in skin and muscle. Carr RW, et al. **Clin Exp Pharmacol Physiol** 1996

May;23(5):355–62 (81 ref.)
Propriospinal myoclonus. Chokroverty S. **Clin Neurosci** 1995–96;3(4):219–22 (19 ref.)
Sources of afferent fibers from the tongue muscles. Woźniak W, et al. **Folia Morphol (Warsz)** 1996;55(3):129–32 (23 ref.)
The physiological and metabolic consequences of muscle denervation. Frostick SP. **Int Angiol** 1995 Sep;14(3):278–87 (92 ref.)
Physiology and interpretation of the electromyogram. Kamen G, et al. **J Clin Neurophysiol** 1996 Sep;13(5):366–84 (200 ref.)
Quantitative motor unit potential analysis. Stålberg E, et al. **J Clin Neurophysiol** 1996 Sep;13(5):401–22 (105 ref.)

METABOLISM

In vitro insulinomimetic [corrected] effects of GLP-1 in liver, muscle and fat [published erratum appears in Acta Physiol Scand 1996 Nov;158(3):297] Valverde I, et al. **Acta Physiol Scand** 1996 Jul;157(3):359–60 (11 ref.)
Muscle development and attachment to the epidermis is accompanied by expression of beta 3 and beta 1 tubulin isotypes, respectively. Buttgereit D, et al. **Int J Dev Biol** 1996 Feb;40(1):189–96 (49 ref.)
Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. Mitch WE, et al. **N Engl J Med** 1996 Dec 19;335(25):1897–905 (70 ref.)
Protein degradation by proteasomes: molecular mechanisms of muscle catabolism [editorial] Mitch WE, et al. **Nephrol Dial Transplant** 1997 Jan;12(1):13–5 (15 ref.)
Naked DNA transport and expression in mammalian cells. Wolff JA. **Neuromuscul Disord** 1997 Jul;7(5):314–8 (32 ref.)
Measurements of scattering and absorption changes in muscle and brain. Gratton E, et al. **Philos Trans R Soc Lond B Biol Sci** 1997 Jun 29; 352(1354):727–35 (50 ref.)
Relationships between enzymatic flux capacities and metabolic flux rates: nonequilibrium reactions in muscle glycolysis. Suarez RK, et al. **Proc Natl Acad Sci U S A** 1997 Jun 24;94(13):7065–9 (79 ref.)
Exercise, muscle metabolism and the antioxidant defense. Karlsson J. **World Rev Nutr Diet** 1997;82:81–100 (47 ref.)
[Myogenic hyperuricemia] Yamasaki T, et al. **Nippon Rinsho** 1996 Dec;54(12):3343–8 (29 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Mechanisms of loss of lean body mass in patients on chronic dialysis. Dinarello CA, et al. **Blood Purif** 1996;14(5):388–94 (27 ref.)
Measuring cytosolic Ca2+ in cells with fluorescent probes: an aid to understanding cell pathophysiology. Hayes A, et al. **Int Rev Exp Pathol** 1996;36:197–212 (65 ref.)
AAEM minimonograph #46: neurogenic muscle hypertrophy [see comments] Gutmann L. **Muscle Nerve** 1996 Jul;19(7):811–8 (57 ref.) Comment in: Muscle Nerve 1997 Mar;20(3):390–1.
Some considerations about the "Fibrolipocalcareous myopathy" (Mattioli-Foggia and Raso disease). Menditto V, et al. **Pathologica** 1996 Oct;88(5):452–6 (60 ref.)
The ovine callipyge locus: a paradigm illustrating the importance of non-Mendelian genetics in livestock. Georges M, et al. **Reprod Nutr Dev** 1996;36(6):651–7 (21 ref.)
Is there muscle pathology in fibromyalgia syndrome? Simms RW. **Rheum Dis Clin North Am** 1996 May;22(2):245–66 (72 ref.)

PHYSIOLOGY

On the translation of directional motor cortical commands to activation of muscles via spinal interneuronal systems. Georgopoulos AP. **Brain Res Cogn Brain Res** 1996 Mar; 3(2):151–5 (23 ref.)
Muscle architecture and function in humans. Fukunaga T, et al. **J Biomech** 1997 May;30(5):457–63 (34 ref.)
Noninvasive approach to motor unit characterization: muscle structure, membrane dynamics and neuronal control. Rau G, et al. **J Biomech** 1997 May;30(5):441–6 (28 ref.)
Muscle strength and rising from a chair in older adults. Alexander NB, et al. **Muscle Nerve Suppl** 1997;5:S56–9 (19 ref.)
Measurement of muscle strength and power. Bassey EJ. **Muscle Nerve Suppl** 1997;5:S44–6 (14 ref.)
Quantitative methods for estimating the number of motor units in human muscles. Brown WF, et al. **Muscle Nerve Suppl** 1997;5:S70–3 (16 ref.)
Choosing the best strength measure in frail older persons: importance of task specificity. Chandler J, et al. **Muscle Nerve Suppl** 1997;5:S47–51 (34 ref.)
Neural strategies in the control of muscle force. Enoka RM. **Muscle Nerve Suppl** 1997;5:S66–9 (21 ref.)
Gene transfer to muscle using herpes simplex virus-based vectors. Huard J, et al. **Neuromuscul Disord** 1997 Jul; 7(5):299–313 (101 ref.)
Electrophysiology of Ascaris muscle and anti-nematodal drug action. Martin RJ, et al. **Parasitology** 1996;113 Suppl:S137–56 (76 ref.)
Neuromuscular physiology and pharmacology of parasitic flatworms. Pax RA, et al. **Parasitology** 1996;113 Suppl:S83–96 (111 ref.)
Modular regulation of muscle gene transcription: a mechanism for muscle cell diversity. Firulli AB, et al. **Trends Genet** 1997 Sep;13(9):364–9 (51 ref.)

PHYSIOPATHOLOGY

Anatomy, biomechanics, and pathomechanics of lesser digital deformities. Green DR, et al. **Clin Podiatr Med Surg** 1996 Apr;13(2):179–200 (14 ref.)
Repetitive CMAPs: mechanisms of neural and synaptic genesis. van Dijk JG, et al. **Muscle Nerve** 1996 Sep; 19(9):1127–33 (51 ref.)

SURGERY

Pitfalls and complications of cricopharyngeal myotomy. Brouillette D, et al. **Chest Surg Clin N Am** 1997 Aug; 7(3):457–75; discussion 476 (28 ref.)
Failure after esophagomyotomy for esophageal motor disorders. Causes, prevention, and management. Ellis FH Jr. **Chest Surg Clin N Am** 1997 Aug;7(3):477–87; discussion 488 (29 ref.)

ULTRASTRUCTURE

Connectin/titin, giant elastic protein of muscle. Maruyama K. **FASEB J** 1997 Apr;11(5):341–5 (43 ref.)
Muscle cell and oxidative damage in aging: a century of hypothesis and personal contribution. Montanari G, et al. **Int J Tissue React** 1996;18(1):33–41 (55 ref.)
Muscle capillarization: morphological and morphometrical analyses of biopsy samples. Lexell J. **Muscle Nerve Suppl** 1997;5:S110–2 (21 ref.)

MUSCULAR ATROPHY

Significance of sarcopenia in the elderly. Dutta C. **J Nutr** 1997 May;127(5 Suppl):992S–993S (23 ref.)
Sarcopenia: origins and clinical relevance. Rosenberg IH. **J Nutr** 1997 May;127(5 Suppl):990S–991S (2 ref.)

CHEMICALLY INDUCED

Glucocorticoid-induced muscle atrophy. The role of exercise in treatment and prevention. LaPier TK. **J Cardiopulm Rehabil** 1997 Mar–Apr;17(2):76–84 (60 ref.)

EPIDEMIOLOGY

Confounding variables and comorbidity in sarcopenia research. Miller JP. **Muscle Nerve Suppl** 1997;5:S35–8 (4 ref.)

METABOLISM

Measurement of muscle proteolysis and the impact on muscle wasting. Nissen S. **Proc Nutr Soc** 1997 Jul;56(2):793–9 (26 ref.)

PATHOLOGY

A neuropsychiatric disorder associated with dense calcification of the external ears and distal muscle wasting: 'Primrose syndrome'. Lindor NM, et al. **Clin Dysmorphol** 1996 Jan;5(1):27–34 (17 ref.)
Muscle mass and strength: relation to function in population studies. Harris T. **J Nutr** 1997 May;127(5 Suppl):1004S–1006S (17 ref.)
Early-onset myopathy with tubular aggregates. Tulinius MH, et al. **Pediatr Neurol** 1996 Jul;15(1):68–71 (15 ref.)

PHYSIOPATHOLOGY

Functional and metabolic consequences of sarcopenia. Evans W. **J Nutr** 1997 May;127(5 Suppl):998S–1003S (56 ref.)
Muscle mass and strength: relation to function in population studies. Harris T. **J Nutr** 1997 May;127(5 Suppl):1004S–1006S (17 ref.)
Changes in musculoskeletal structure and function with prolonged bed rest. Bloomfield SA. **Med Sci Sports Exerc** 1997 Feb;29(2):197–206 (65 ref.)
Sarcopenia and physical performance in old age: overview. Dutta C, et al. **Muscle Nerve Suppl** 1997;5:S5–9 (15 ref.)
Inclusion of ethnic minorities in sarcopenia research: challenges and strategies. Hazuda HP. **Muscle Nerve Suppl** 1997;5:S27–31 (13 ref.)
Functional and behavioral consequences of sarcopenia. Jette AM, et al. **Muscle Nerve Suppl** 1997;5:S39–41 (11 ref.)
Magnetic resonance as a tool to study sarcopenia. McCully K. **Muscle Nerve Suppl** 1997;5:S102–6 (29 ref.)
Sarcopenia and physical performance in old age: introduction. Schwartz RS. **Muscle Nerve Suppl** 1997; 5:S10–2 (3 ref.)
The search for the uremic toxin: the case for metabolic acidosis [see comments] Bailey JL, et al. **Wien Klin Wochenschr** 1997 Jan 17;109(1):7–12 (50 ref.) Comment in: Wien Klin Wochenschr 1997 Jan 17;109(1):1–2.

PREVENTION & CONTROL

Functional and metabolic consequences of sarcopenia. Evans W. **J Nutr** 1997 May;127(5 Suppl):998S–1003S (56 ref.)

THERAPY

Glucocorticoid-induced muscle atrophy. The role of exercise in treatment and prevention. LaPier TK. **J Cardiopulm Rehabil** 1997 Mar–Apr;17(2):76–84 (60 ref.)

MUSCULAR ATROPHY, POSTPOLIOMYELITIS see **POSTPOLIOMYELITIS SYNDROME**

MUSCULAR ATROPHY, SPINAL

Kennedy disease. Fischbeck KH. **J Inherit Metab Dis** 1997 Jun;20(2):152–8 (21 ref.)
Labor analgesia and anesthesia in a patient with spinal muscular atrophy and vocal cord paralysis. A rare and unusual case report. Weston LA, et al. **Reg Anesth** 1996 Jul–Aug;21(4):350–4 (11 ref.)

CLASSIFICATION

Spinal muscular atrophy--clinical and genetic correlations. Zerres K, et al. **Neuromuscul Disord** 1997 May;7(3):202–7 (35 ref.)

COMPLICATIONS

[Characteristics in the treatment of scoliosis in muscular diseases] Forst R, et al. **Z Orthop Ihre Grenzgeb** 1997 Mar–Apr;135(2):95–105 (84 ref.) (Eng. Abstr.) **(Ger)**
[A case of X-linked bulbospinal muscular atrophy with bilateral abductor vocal cord paralysis] Tomiyasu K, et al. **Rinsho Shinkeigaku** 1996 May;36(5):683–6 (20 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Spinal muscular atrophies: recent insights and impact on molecular diagnosis. Brahe C, et al. **J Mol Med** 1996 Oct; 74(10):555–62 (71 ref.)
[Electrophysiologic assessment in motor neuron diseases] Espadaler-Gamissans JM. **Neurologia** 1996 Dec;11 Suppl 5:20–8 (34 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

When is a deletion not a deletion? When it is converted [editorial] Burghes AH. **Am J Hum Genet** 1997 Jul; 61(1):9–15 (49 ref.)
Trinucleotide repeat disorders in humans: discussions of mechanisms and medical issues. Timchenko LT, et al. **FASEB J** 1996 Dec;10(14):1589–97 (70 ref.)
Molecular analysis of the androgen receptor gene in Kennedy's disease. Report of two families and review of the literature. Lumbroso S, et al. **Horm Res** 1997;47(1):23–9 (44 ref.)
Spinal muscular atrophies: recent insights and impact on molecular diagnosis. Brahe C, et al. **J Mol Med** 1996 Oct; 74(10):555–62 (71 ref.)
Molecular genetics of autosomal recessive spinal muscular atrophy. Rodrigues NR, et al. **Mol Med** 1996 Jul;2(4):400–4 (38 ref.)
Advances in SMA research: review of gene deletions. Morrison KE. **Neuromuscul Disord** 1996 Dec;6(6):397–408 (89 ref.)
Spinal muscular atrophy--clinical and genetic correlations. Zerres K, et al. **Neuromuscul Disord** 1997 May;7(3):202–7 (35 ref.)
Molecular basis of androgen insensitivity. Brinkmann A, et al. **Steroids** 1996 Apr;61(4):172–5 (30 ref.)
[The contribution of molecular genetics to the study of spinal muscular atrophy] Bussaglia E, et al. **Neurologia** 1996 Dec; 11 Suppl 5:14–9 (24 ref.) (Eng. Abstr.) **(Spa)**
[Juvenile and adult forms of spinal muscular atrophies] Pou A. **Neurologia** 1996 Dec;11 Suppl 5:43–57 (73 ref.) (Eng. Abstr.) **(Spa)**
[Proximal spinal muscular atrophy in the adult] Serratrice G. **Neurologia** 1996 Dec;11 Suppl 5:66–71 (20 ref.) (Eng. Abstr.) **(Spa)**
[Distal spinal muscular atrophy] Sevilla T. **Neurologia** 1996 Dec;11 Suppl 5:58–65 (61 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

[Electrophysiologic assessment in motor neuron diseases] Espadaler-Gamissans JM. **Neurologia** 1996 Dec;11 Suppl 5:20–8 (34 ref.) (Eng. Abstr.) **(Spa)**
[Motor neuron diseases. Present] Pou A. **Neurologia** 1996 Dec;11 Suppl 5:1–6 (44 ref.) (Eng. Abstr.) **(Spa)**

MUSCULAR ATROPHY, SPINAL, INFANTILE see **WERDNIG-HOFFMANN DISEASE**

MUSCULAR DISEASES

Necrotizing soft tissue infections of the chest wall. Urschel JD, et al. **Ann Thorac Surg** 1997 Jul;64(1):276–9 (28 ref.)
Sarcoid arthropathy. Totemchokchyakarn K, et al. **Bull Rheum Dis** 1997 May;46(3):3–5 (5 ref.)
Posterior tibial tendon dysfunction in the athlete. Ross JA. **Clin Podiatr Med Surg** 1997 Jul;14(3):479–88 (21 ref.)
Hematoma of the rectus abdominis muscle: case report and review of the literature. Dubinsky IL. **J Emerg Med** 1997 Mar–Apr;15(2):165–7 (07 ref.)

CHEMICALLY INDUCED

Acute myopathy associated with combined use of corticosteroids and neuromuscular blocking agents. Fischer JR, et al. **Ann Pharmacother** 1996 Dec;30(12):1437–45 (52 ref.)
Toxic myopathies. George KK, et al. **Neurol Clin** 1997 Aug; 15(3):711–30 (103 ref.)

COMPLICATIONS

The spectrum of osteoarticular and soft tissue changes in patients with human immunodeficiency virus (HIV) infection. Tehranzadeh J, et al. **Crit Rev Diagn Imaging** 1996 Sep;37(4):305–47 (43 ref.)

Scapular instability associated with brachial plexus irritation: a proposed causative relationship with treatment implications. Langley P. **J Hand Ther** 1997 Jan–Mar; 10(1):35–40 (15 ref.)

Muscular involvement in Behçet's disease: case report and review of the literature. Worthmann F, et al. **Neuromuscul Disord** 1996 Aug;6(4):247–53 (24 ref.)

[Cardiac failure with muscle diseases] Igarashi K. **Ryoikibetsu Shokogun Shirizu** 1996;(12):30–2 (5 ref.) **(Jpn)**

DIAGNOSIS

Electromyography in myopathy. Liguori R, et al. **Neurophysiol Clin** 1997 Jun;27(3):200–3 (19 ref.)

Sciatic pain and piriformis syndrome. Douglas S. **Nurse Pract** 1997 May;22(5):166–8, 170, 172 passim (18 ref.)

Rotator cuff evaluation: imaging and diagnosis. Miniaci A, et al. **Orthop Clin North Am** 1997 Jan;28(1):43–58 (61 ref.)

Musculoskeletal manifestations of AIDS. Major NM, et al. **Radiol Clin North Am** 1997 Sep;35(5):1167–89 (88 ref.)

Accessory soleus muscle. Two case-reports, with a review of the literature. Boisgard S, et al. **Rev Rhum Engl Ed** 1996 Dec;63(11):862–5 (15 ref.)

The role of electron microscopy in the diagnosis of nonneoplastic muscle diseases. Kyriacou K, et al. **Ultrastruct Pathol** 1997 May–Jun;21(3):243–52 (25 ref.)

[Dropped head syndrome: diagnostic discussion apropos of 3 cases] Petiot P, et al. **Rev Neurol (Paris)** 1997 May; 153(4):251–5 (15 ref.) (Eng. Abstr.) **(Fre)**

[How reliably does electromyography differentiate myopathies and neurogenic diseases?] Pfeiffer G. **Nervenarzt** 1996 Feb;67(2):123–32 (60 ref.) (Eng. Abstr.) **(Ger)**

[The "pedrada" ("coup-de-fouet") syndrome. A possibility to be considered in acute leg pain] Toscano F, et al. **Minerva Chir** 1997 Apr;52(4):489–91 (12 ref.) (Eng. Abstr.) **(Ita)**

[Early-onset hyperthyroidism with muscle involvement: a report on a patient] Greco F, et al. **Pediatr Med Chir** 1996 Nov–Dec;18(6):611–3 (11 ref.) (Eng. Abstr.) **(Ita)**

[Myopathies manifested in neonatal period] Campos-Castelló J. **Rev Neurol** 1996 Nov;24(135):1367–75 (20 ref.) **(Spa)**

DRUG THERAPY

[A case of the "shrinking lung syndrome" in SLE--improvement with corticosteroid therapy] Kitamura Y, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Jun; 19(3):217–22 (11 ref.) (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

Clinical heterogeneity and molecular mechanisms in inborn muscle AMP deaminase deficiency. Gross M. **J Inherit Metab Dis** 1997 Jun;20(2):186–92 (30 ref.)

EPIDEMIOLOGY

Toxicologists versus toxicological disasters: toxic oil syndrome, clinical aspects. Gómez de la Cámara A, et al. **Arch Toxicol Suppl** 1997;19:31–40 (40 ref.)

Epidemiology of the toxic oil syndrome. Philen RM, et al. **Arch Toxicol Suppl** 1997;19:41–52 (25 ref.)

ETIOLOGY

Alcoholic myopathies. Fernández-Solà J, et al. **Curr Opin Neurol** 1996 Oct;9(5):400–5 (28 ref.)

Acute complications of cocaine intoxication. Zafar H, et al. **Hosp Pract (Off Ed)** 1997 Feb 15;32(2):167–70, 175–7, 181 (12 ref.)

Sjögren's syndrome associated with hypokalemic myopathy due to Bartter's syndrome [letter] Higashi K, et al. **J Rheumatol** 1997 Aug;24(8):1663–4 (17 ref.)

Muscle pain, fatigue, and fasiculations. Kincaid JC. **Neurol Clin** 1997 Aug;15(3):697–709 (23 ref.)

[Uremic myopathy] Arimura Y, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):72–5 (15 ref.) **(Jpn)**

[Uremic myopathy] Wanic-Kossowska M. **Pol Arch Med Wewn** 1996 Jun;95(6):578–84 (39 ref.) **(Pol)**

GENETICS

Phenotype variation and newcomers in ion channel disorders. Bulman DE. **Hum Mol Genet** 1997;6(10):1679–85 (84 ref.)

Familial desmin-related myopathies and cardiomyopathies—from myopathology to molecular and clinical genetics. 36th European Neuromuscular Center (ENMC)-Sponsored International Workshop 20–22 October, 1995, Naarden, The Netherlands. Goebel HH, et al. **Neuromuscul Disord** 1996 Oct;6(5):383–8 (36 ref.)

X-linked myotubular myopathy: refinement of the critical gene region. Smolenicka Z, et al. **Neuromuscul Disord** 1996 Aug;6(4):275–81 (33 ref.)

Metabolic myopathies. Tein I. **Semin Pediatr Neurol** 1996 Jun;3(2):59–98 (357 ref.)

[Molecular pathogenesis of muscular diseases] Ohlendieck K. **Naturwissenschaften** 1996 Dec;83(12):555–65 (98 ref.) (Eng. Abstr.) **(Ger)**

[Cousins with X-linked recessive myotubular myopathy] Mori Y, et al. **No To Hattatsu** 1997 Jul;29(4):310–4 (14 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Immunological aspects of the toxic oil syndrome. Lahoz C, et al. **Arch Toxicol Suppl** 1997;19:65–73 (35 ref.)

METABOLISM

Cellular sodium pumps in hypokalaemic periodic muscle paralysis. Taylor EA, et al. **Clin Sci (Colch)** 1996 Sep; 91(3):261–4 (28 ref.)

The immunopathogenic role of complement in human muscle disease. Mendell JR, et al. **Curr Opin Neurol** 1996 Jun; 9(3):226–34 (48 ref.)

Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. Mitch WE, et al. **N Engl J Med** 1996 Dec 19;335(25):1897–905 (70 ref.)

[Fas antigen is expressed in human diseased muscles, but does not link to apoptosis] Inukai A, et al. **Nippon Rinsho** 1996 Jul;54(7):1992–6 (10 ref.) (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

Cutaneous and muscular abscesses secondary to Actinomyces meyeri pneumonia. Liaudet L, et al. **Clin Infect Dis** 1996 Jan;22(1):185–6 (9 ref.)

PARASITOLOGY

Musculoskeletal involvement in cystic echinococcosis: report of eight cases and review of the literature. Merkle EM, et al. **AJR Am J Roentgenol** 1997 Jun;168(6):1531–4 (12 ref.)

Hydatid cysts of the kidney, seminal vesicle and gluteus muscle. Pasaoglu E, et al. **Australas Radiol** 1997 Aug; 41(3):297–9 (12 ref.)

Disseminated cysticercosis. Kumar A, et al. **Indian Pediatr** 1996 Apr;33(4):337–9 (5 ref.)

PATHOLOGY

Pathology of failure of the rotator cuff tendon. Uhthoff HK, et al. **Orthop Clin North Am** 1997 Jan;28(1):31–41 (21 ref.)

Some considerations about the "Fibrolipocalcareous myopathy" (Mattioli-Foggia and Raso disease). Menditto V, et al. **Pathologica** 1996 Oct;88(5):452–6 (60 ref.)

[Apoptosis and myopathies] Inukai A, et al. **Rinsho Byori** 1997 Jul;45(7):621–7 (31 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Muscle abnormalities in scleroderma. Olsen NJ, et al. **Rheum Dis Clin North Am** 1996 Nov;22(4):783–96 (45 ref.)

THERAPY

Progress, problems, and prospects for gene therapy in muscle. Brown RH, et al. **Curr Opin Rheumatol** 1996 Nov; 8(6):539–43 (29 ref.)

Electrical stimulation of denervated muscle: is it worthwhile? Eberstein A, et al. **Med Sci Sports Exerc** 1996 Dec; 28(12):1463–9 (83 ref.)

Nonoperative management of full-thickness tears of the rotator cuff. Wirth MA, et al. **Orthop Clin North Am** 1997 Jan;28(1):59–67 (34 ref.)

VETERINARY

[Physiology and physiopathology of ryanodine receptors in swine. Significance of sensitivity to stress, stress myopathies, malignant hyperthermia and meat quality] Martens H. **Tierarztl Prax** 1997 Jan;25(1):41–51 (62 ref.) (Eng. Abstr.) **(Ger)**

MUSCULAR DYSTROPHY

Duchenne muscular dystrophy and the neuromuscular junction: the utrophin link. Gramolini AO, et al. **Bioessays** 1997 Sep;19(9):747–50 (42 ref.)

Beyond dystrophin: current progress in the muscular dystrophies [published erratum appears in Curr Opin Pediatr 1997 Apr;9(2):196] Bönnemann CG, et al. **Curr Opin Pediatr** 1996 Dec;8(6):569–82 (125 ref.)

HyperCKemic, proximal muscular dystrophies and the dystrophin membrane cytoskeleton, including dystrophinopathies, sarcoglycanopathies, and merosinopathies. Hoffman EP, et al. **Curr Opin Rheumatol** 1996 Nov;8(6):528–38 (42 ref.)

[Anesthesia and postoperative management management of patients with Duchenne's dystrophy] Ben Abraham R, et al. **Harefuah** 1996 Nov 15;131(10):435–7 (20 ref.) **(Heb)**

CLASSIFICATION

Understanding the heterogeneity of the limb-girdle muscular dystrophies. Bushby K. **Biochem Soc Trans** 1996 May; 24(2):489–96 (55 ref.)

COMPLICATIONS

Ventricular tachycardia in Duchenne's muscular dystrophy. Muñoz J, et al. **Int J Cardiol** 1996 Jun;54(3):259–62 (7 ref.)

[Characteristics in the treatment of scoliosis in muscular diseases] Forst R, et al. **Z Orthop Ihre Grenzgeb** 1997 Mar–Apr;135(2):95–105 (84 ref.) (Eng. Abstr.) **(Ger)**

[Muscular dystrophies] Ishihara T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):93–5 (20 ref.) **(Jpn)**

CONGENITAL

[Congenital muscular dystrophy (CMD)] Hayashi YK, et al. **No To Shinkei** 1997 Apr;49(4):311–8 (30 ref.) **(Jpn)**

[Recent progress, genetic diagnosis and its problem on congenital muscular dystrophies (Fukuyama and non-Fukuyama types)] Toda T. **Rinsho Shinkeigaku** 1995 Dec;35(12):1419–21 (11 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Duchenne/Becker muscular dystrophy: from molecular diagnosis to gene therapy. Matsuo M. **Brain Dev** 1996 May–Jun;18(3):167–72 (38 ref.)

Perspectives and molecular diagnosis of Duchenne and Becker muscular dystrophies. Prior TW. **Clin Lab Med** 1995 Dec;15(4):927–41 (63 ref.)

Congenital muscular dystrophy: a review of the literature. Leyten QH, et al. **Clin Neurol Neurosurg** 1996 Nov; 98(4):267–80 (108 ref.)

The differential diagnosis of the human dystrophinopathies and related disorders [see comments] Kakulas BA. **Curr Opin Neurol** 1996 Oct;9(5):380–8 (73 ref.) Comment in: Curr Opin Neurol 1996 Oct;9(5):367–8.

Cystic fibrosis, Duchenne muscular dystrophy and preimplantation genetic diagnosis. Liu J, et al. **Hum Reprod Update** 1996 Nov–Dec;2(6):531–9 (95 ref.)

Distal muscular dystrophy of Miyoshi type. Report of two cases and review of the literature. Flachenecker P, et al. **J Neurol** 1997 Jan;244(1):23–9 (28 ref.)

Recent advances in diagnosis of the childhood muscular dystrophies. Jones KJ, et al. **J Paediatr Child Health** 1997 Jun;33(3):195–201 (18 ref.)

Prenatal diagnosis of Duchenne and Becker muscular dystrophy. Abbs S. **Prenat Diagn** 1996 Dec;16(13):1187–98 (44 ref.)

[Genetic analysis of facioscapulohumeral muscular dystrophy (FSHD)] Goto K, et al. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1416–8 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Problems found in genetic diagnosis of DMD/BMD] Matsuo M. **Rinsho Shinkeigaku** 1995 Dec;35(12):1413–5 (4 ref.) (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

Elevated aminotransferase activity as an indication of muscular dystrophy: case reports and review of the literature. Zamora S, et al. **Can J Gastroenterol** 1996 Oct; 10(6):389–93 (30 ref.)

ETIOLOGY

[Severe childhood autosomal recessive muscular dystrophy] Matsumura K, et al. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1422–4 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Acute muscular weakness during childhood in cases of severe asthma due to the use of corticoids and neuromuscular blockers] Campistol Plana J, et al. **An Esp Pediatr** 1996 Aug;45(2):196–8 (5 ref.) **(Spa)**

GENETICS

Dystrophin-associated proteins and the muscular dystrophies. Brown RH Jr. **Annu Rev Med** 1997;48:457–66 (42 ref.)

Understanding the heterogeneity of the limb-girdle muscular dystrophies. Bushby K. **Biochem Soc Trans** 1996 May; 24(2):489–96 (55 ref.)

Dystrophies and heart disease. Cox GF, et al. **Curr Opin Cardiol** 1997 May;12(3):329–43 (112 ref.)

Advances in the molecular genetics of the limb-girdle type of autosomal recessive progressive muscular dystrophy [see comments] Beckmann JS, et al. **Curr Opin Neurol** 1996 Oct;9(5):389–93 (35 ref.) Comment in: Curr Opin Neurol 1996 Oct;9(5):367–8.

The molecular genetics of human facioscapulohumeral muscular dystrophy and the myodystrophy mouse model. Mathews KD, et al. **Curr Opin Neurol** 1996 Oct;9(5):394–9 (35 ref.)

Muscular dystrophies and the dystrophin-glycoprotein complex. Straub V, et al. **Curr Opin Neurol** 1997 Apr; 10(2):168–75 (63 ref.)

Plectin and human genetic disorders of the skin and muscle. The paradigm of epidermolysis bullosa with muscular dystrophy. Uitto J, et al. **Exp Dermatol** 1996 Oct; 5(5):237–46 (71 ref.)

Cystic fibrosis, Duchenne muscular dystrophy and preimplantation genetic diagnosis. Liu J, et al. **Hum Reprod Update** 1996 Nov–Dec;2(6):531–9 (95 ref.)

Molecular genetics of facioscapulohumeral muscular dystrophy (FSHD). Fisher J, et al. **Neuromuscul Disord** 1997 Jan;7(1):55–62 (69 ref.)

Merosin/laminin-2 and muscular dystrophy. Wewer UM, et al. **Neuromuscul Disord** 1996 Dec;6(6):409–18 (69 ref.)

Nondystrophinopathic muscular dystrophies including myotonic dystrophy. Nonaka I, et al. **Semin Pediatr Neurol** 1996 Jun;3(2):110–21 (45 ref.)

Dystrophinopathies. Reitter B, et al. **Semin Pediatr Neurol** 1996 Jun;3(2):99–109 (90 ref.)

MUSCULAR DYSTROPHY

[Mitochondrial anomalies in oculopharyngeal muscular dystrophy] de Seze J, et al. **Rev Neurol (Paris)** 1997 Jun; 153(5):335–8 (19 ref.) (Eng. Abstr.) **(Fre)**

[A family of autosomal dominant facio–limb–girdle muscular dystrophy] Takao S, et al. **Fukuoka Igaku Zasshi** 1996 Dec; 87(12):278–82 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Gene analysis in patients with muscular dystrophy: alpha–sarcoglycan (adhalin) gene mutations in patients with malignant limb–girdle muscular dystrophy] Akaike M, et al. **Rinsho Byori** 1997 Feb;45(2):136–40 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Genetic analysis of facioscapulohumeral muscular dystrophy (FSHD)] Goto K, et al. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1416–8 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Problems found in genetic diagnosis of DMD/BMD] Matsuo M. **Rinsho Shinkeigaku** 1995 Dec;35(12):1413–5 (4 ref.) (Eng. Abstr.) **(Jpn)**

[Recent progress, genetic diagnosis and its problem on congenital muscular dystrophies (Fukuyama and non–Fukuyama types)] Toda T. **Rinsho Shinkeigaku** 1995 Dec;35(12):1419–21 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Dystrophinopathies] Gallano P, et al. **Neurologia** 1995 Dec; 10 Suppl 1:8–11 (22 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Towards an understanding of the dystrophin–glycoprotein complex: linkage between the extracellular matrix and the membrane cytoskeleton in muscle fibers. Ohlendieck K. **Eur J Cell Biol** 1996 Jan;69(1):1–10 (107 ref.)

From adhalinopathies to alpha–sarcoglycanopathies: an overview. Jeanpierre M, et al. **Neuromuscul Disord** 1996 Dec;6(6):463–5 (26 ref.)

Peripheral nerve involvement in merosin–deficient congenital muscular dystrophy and dy mouse. Matsumura K, et al. **Neuromuscul Disord** 1997 Jan;7(1):7–12 (50 ref.)

[Muscular dystrophy and dystrophin and its associated proteins] Ozawa E. **No To Hattatsu** 1996 Mar;28(2):102–8 (5 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Clinical and histopathological features of abnormalities of the dystrophin–based membrane cytoskeleton. Hoffman EP. **Brain Pathol** 1996 Jan;6(1):49–61 (44 ref.)

PHYSIOPATHOLOGY

Clinical and histopathological features of abnormalities of the dystrophin–based membrane cytoskeleton. Hoffman EP. **Brain Pathol** 1996 Jan;6(1):49–61 (44 ref.)

Cardiac involvement in progressive muscular dystrophy of the Duchenne type. Ishikawa K. **Jpn Heart J** 1997 Mar; 38(2):163–80 (97 ref.)

Peripheral nerve involvement in merosin–deficient congenital muscular dystrophy and dy mouse. Matsumura K, et al. **Neuromuscul Disord** 1997 Jan;7(1):7–12 (50 ref.)

THERAPY

Gene therapy in Duchenne muscular dystrophy. Inui K, et al. **Brain Dev** 1996 Sep–Oct;18(5):357–61 (47 ref.)

Duchenne/Becker muscular dystrophy: from molecular diagnosis to gene therapy. Matsuo M. **Brain Dev** 1996 May–Jun;18(3):167–72 (38 ref.)

[Development of adenoviral vectors in gene therapy: application to gene transfer in muscles] Ragot T, et al. **C R Seances Soc Biol Fil** 1996;190(1):13–31 (37 ref.) (Eng. Abstr.) **(Fre)**

[Cell transplantation for neuronal and muscular disorders] Kondoh T, et al. **No To Shinkei** 1997 Jun;49(6):507–15 (50 ref.) **(Jpn)**

MUSCULAR DYSTROPHY, ANIMAL

GENETICS

The molecular genetics of human facioscapulohumeral muscular dystrophy and the myodystrophy mouse model. Mathews KD, et al. **Curr Opin Neurol** 1996 Oct;9(5):394–9 (35 ref.)

METABOLISM

Dystrophin–associated proteins and the muscular dystrophies: a glossary. Brown RH Jr. **Brain Pathol** 1996 Jan;6(1):19–24 (40 ref.)

PHYSIOPATHOLOGY

Measuring cytosolic Ca2+ in cells with fluorescent probes: an aid to understanding cell pathophysiology. Hayes A, et al. **Int Rev Exp Pathol** 1996;36:197–212 (65 ref.)

Peripheral nerve involvement in merosin–deficient congenital muscular dystrophy and dy mouse. Matsumura K, et al. **Neuromuscul Disord** 1997 Jan;7(1):7–12 (50 ref.)

MUSCULOCUTANEOUS NERVE

INJURIES

Compression of the lateral antebrachial cutaneous nerve by the biceps tendon. Gillingham BL, et al. **J Shoulder Elbow Surg** 1996 Jul–Aug;5(4):330–2 (10 ref.)

MUSCULOSKELETAL DISEASES

Legal rights of children with musculoskeletal disabilities. Cassidy JT, et al. **Bull Rheum Dis** 1996 Nov;45(7):1–5 (24 ref.)

Juvenile rheumatoid arthritis. Pertusi RM, et al. **J Am Osteopath Assoc** 1996 May;96(5):298–302 (7 ref.)

Pain mechanisms involved in musculoskeletal disorders. Sluka KA. **J Orthop Sports Phys Ther** 1996 Oct; 24(4):240–54 (105 ref.)

Rheumatic and musculoskeletal diseases and impaired quality of life: a challenge for rheumatologists [editorial] [see comments] Morales–Torres J, et al. **J Rheumatol** 1996 Jan; 23(1):1–3 (30 ref.) Comment in: J Rheumatol 1997 Feb;24(2):411.

Shoulder pain in the work place. Curtis AS, et al. **Orthop Clin North Am** 1996 Oct;27(4):763–81 (42 ref.)

Low back and cervical spine disorders. Rainville J, et al. **Orthop Clin North Am** 1996 Oct;27(4):729–46 (80 ref.)

Occupational disorders of the foot and ankle. Trepman E, et al. **Orthop Clin North Am** 1996 Oct;27(4):815–29 (37 ref.)

COMPLICATIONS

Endocrine disorders and musculoskeletal diseases. Ramos–Remus C, et al. **Curr Opin Rheumatol** 1996 Jan; 8(1):77–84 (81 ref.)

Spinal cord compression due to concomitant primary lymphoma and Mycobacterium avium–intracellulare infection of the paravertebral muscles in an AIDS patient [letter] Moulignier A, et al. **Eur J Clin Microbiol Infect Dis** 1996 Nov;15(11):891–3 (15 ref.)

The role of physical agents in modulating pain. Fedorczyk J. **J Hand Ther** 1997 Apr–Jun;10(2):110–21 (90 ref.)

Head and neck pain review: traditional and new perspectives. Friedman MH, et al. **J Orthop Sports Phys Ther** 1996 Oct; 24(4):268–78 (79 ref.)

Non–nociceptive aspects of persistent musculoskeletal pain. Kramis RC, et al. **J Orthop Sports Phys Ther** 1996 Oct; 24(4):255–67 (66 ref.)

DIAGNOSIS

Non–inflammatory musculoskeletal disorders in childhood. Sills JA. **Arch Dis Child** 1997 Jul;77(1):71–5 (27 ref.)

Pediatric musculoskeletal lesions simulating neoplasms. Fletcher BD, et al. **Magn Reson Imaging Clin N Am** 1996 Nov;4(4):721–47 (71 ref.)

Diagnostic imaging in pediatric AIDS. Haller JO, et al. **Pediatr Clin North Am** 1997 Jun;44(3):721–40 (64 ref.)

Easier access to MRI scanning? Moore N. **Practitioner** 1996 Sep;240(1566):522–31 (6 ref.)

Dedicated extremity MR imaging. An emerging technology. Peterfy CG, et al. **Radiol Clin North Am** 1997 Jan; 35(1):1–20 (32 ref.)

If you have to prove you are ill, you can't get well. The object lesson of fibromyalgia. Hadler NM. **Spine** 1996 Oct 15;21(20):2397–400 (32 ref.)

The use of gadolinium in the MR evaluation of musculoskeletal tumors. Kransdorf MJ. **Top Magn Reson Imaging** 1996 Feb;8(1):15–23 (25 ref.)

[Relative significance of clinical examinations, imaging techniques and EMG] Ganel A. **Harefuah** 1997 Feb 2; 132(3):225–9 (29 ref.) **(Heb)**

DRUG THERAPY

Pharmacologic management of common musculoskeletal disorders in women. Kriebs JM, et al. **J Nurse Midwifery** 1997 May–Jun;42(3):207–27 (145 ref.)

Anti–inflammatory drugs and myorelaxants. Pharmacology and clinical use in musculoskeletal disease. Balano KB. **Prim Care** 1996 Jun;23(2):329–34 (11 ref.)

EPIDEMIOLOGY

Methodological limitations in the study of video display terminal use and upper extremity musculoskeletal disorders. Gerr F, et al. **Am J Ind Med** 1996 Jun;29(6):649–56 (38 ref.)

Epidemiology of work–related musculoskeletal disorders. Hales TR, et al. **Orthop Clin North Am** 1996 Oct; 27(4):679–709 (243 ref.)

ETIOLOGY

Is self–reported pain an appropriate outcome measure in ergonomic–epidemiologic studies of work–related musculoskeletal disorders? Schierhout GH, et al. **Am J Ind Med** 1996 Jul;30(1):93–8 (45 ref.)

Upper extremity musculoskeletal manifestations of dialysis–associated amyloidosis. Fitzpatrick DC, et al. **Iowa Orthop J** 1996;16:135–8 (28 ref.)

Effects of pediatric cancer therapy on the musculoskeletal system. Fletcher BD. **Pediatr Radiol** 1997 Aug;27(8):623–36 (102 ref.)

Musculoskeletal manifestations of osteomalacia. Reginato AJ. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):107S–113S (71 ref.)

[Musculoskeletal infections in HIV–positive patients] Melamed EA, et al. **Harefuah** 1996 Sep;131(5–6):181–4 (32 ref.) **(Heb)**

PATHOLOGY

Biopsy of bone and soft–tissue lesions. Simon MA, et al. **Instr Course Lect** 1994;43:521–6 (21 ref.)

PHYSIOPATHOLOGY

Musculoskeletal pain in children. Sherry DD. **Curr Opin Rheumatol** 1997 Sep;9(5):465–70 (59 ref.)

PREVENTION & CONTROL

Review of applicability of existing functional status measures to the study of workers with musculoskeletal disorders of the neck and upper limb. Stock SR, et al. **Am J Ind Med** 1996 Jun;29(6):679–88 (102 ref.)

Exercise in the prevention and treatment of chronic disorders. Deuster PA. **Womens Health Issues** 1996 Nov–Dec; 6(6):320–31 (73 ref.)

PSYCHOLOGY

The assessment of disability and handicap in musculoskeletal disease. McFarlane AC, et al. **J Rheumatol** 1997 May; 24(5):985–9 (16 ref.)

Psychosocial measures in musculoskeletal trials. Newman SP. **J Rheumatol** 1997 May;24(5):979–84 (60 ref.)

Psychological medicine, pain, and musculoskeletal disorders. Merskey H. **Rheum Dis Clin North Am** 1996 Aug; 22(3):623–37 (48 ref.)

RADIONUCLIDE IMAGING

Three–phase bone scan in osteomyelitis and other musculoskeletal disorders. Sutter CW, et al. **Am Fam Physician** 1996 Oct;54(5):1639–47 (26 ref.)

REHABILITATION

Prognosis of nonspecific work–related musculoskeletal disorders of the neck and upper extremity. Cole DC, et al. **Am J Ind Med** 1996 Jun;29(6):657–68 (46 ref.)

Rehabilitation advances in the treatment of arthritis and musculoskeletal disease. Hudgins TH, et al. **Curr Opin Rheumatol** 1997 Mar;9(2):112–7 (30 ref.)

Pain in arthritis and musculoskeletal disorders: the role of coping skills training and exercise interventions. Keefe FJ, et al. **J Orthop Sports Phys Ther** 1996 Oct;24(4):279–90 (43 ref.)

A team approach to reduce disability in work–related disorders. Millender LH, et al. **Orthop Clin North Am** 1996 Oct;27(4):669–77 (68 ref.)

[Musculoskeletal pain disorders] Klockars M. **Duodecim** 1995; 111(17):1671–4 (10 ref.) **(Fin)**

SURGERY

Orthopaedic surgery on the HIV–positive patient: complications and outcome. Luck JV Jr. **Instr Course Lect** 1994;43:543–9 (36 ref.)

THERAPY

New concepts in pain management and in the application of low–power laser for relief of cervicothoracic pain syndromes [editorial] Lee G, et al. **Am Heart J** 1996 Dec; 132(6):1329–34 (27 ref.)

Costs, outcomes, and patient satisfaction by provider type for patients with rheumatic and musculoskeletal conditions: a critical review of the literature and proposed methodologic standards [see comments] Solomon DH, et al. **Ann Intern Med** 1997 Jul 1;127(1):52–60 (35 ref.) Comment in: Ann Intern Med 1997 Jul 1;127(1):72–4.

Orthopaedic challenges in an aging population. Goldberg VM, et al. **Instr Course Lect** 1997;46:417–22 (24 ref.)

Growth factors as therapeutic agents. Trippel SB. **Instr Course Lect** 1997;46:473–6 (27 ref.)

Transcutaneous electrical nerve stimulation for the control of pain in musculoskeletal disorders. Robinson AJ. **J Orthop Sports Phys Ther** 1996 Oct;24(4):208–26 (83 ref.)

Primary care management of chronic musculoskeletal pain [see comments] Davis AE. **Nurse Pract** 1996 Aug;21(8):72, 75, 79–82, passim (44 ref.) Comment in: Nurse Pract 1996 Dec;21(12 Pt 1):8, 13.

An assessment of the efficacy of physical therapy and physical modalities for the control of chronic musculoskeletal pain. Feine JS, et al. **Pain** 1997 May; 71(1):5–23 (91 ref.)

Physical therapy for musculoskeletal syndromes. Guccione AA. **Rheum Dis Clin North Am** 1996 Aug;22(3):551–62 (53 ref.)

Psychological medicine, pain, and musculoskeletal disorders. Merskey H. **Rheum Dis Clin North Am** 1996 Aug; 22(3):623–37 (48 ref.)

VETERINARY

Hyperkalemic periodic paralysis. Naylor JM. **Vet Clin North Am Equine Pract** 1997 Apr;13(1):129–44 (31 ref.)

Acquired conditions that lead to osteoarthritis in the dog. Martinez SA, et al. **Vet Clin North Am Small Anim Pract** 1997 Jul;27(4):759–75 (41 ref.)

MUSCULOSKELETAL SYSTEM

[Transplantation in orthopedic surgery and traumatology] Cara JA, et al. **Rev Med Univ Navarra** 1994 Oct-Dec; 38(4):207-11 (15 ref.) (Eng. Abstr.) **(Spa)**

ABNORMALITIES

Secondary deformities following mandibular reconstruction. Miller MJ, et al. **Clin Plast Surg** 1997 Jul;24(3):551-63 (14 ref.)

Sporadic hypomelanosis of Ito with focal hypertrichosis in a 16-month-old girl. Ballmer-Weber BK, et al. **Dermatology** 1996;193(1):63-4 (14 ref.)

INJURIES

Injury of an extremity as a risk factor for the development of osteoporosis. Järvinen M, et al. **J Bone Joint Surg Am** 1997 Feb;79(2):263-76 (88 ref.)

The imaging of sports injuries. Nelson MC. **Md Med J** 1996 Aug;45(8):659-69 (80 ref.)

Occupational ergonomics and injury prevention. Stobbe TJ. **Occup Med** 1996 Jul-Sep;11(3):531-43 (37 ref.)

PATHOLOGY

Magnetic resonance imaging in musculoskeletal assessment: a surgeon's perspective. Zuelzer WA. **Top Magn Reson Imaging** 1996 Feb;8(1):68-77 (79 ref.)

PHYSIOLOGY

Exercise and physical health: musculoskeletal health and functional capabilities. Vuori I. **Res Q Exerc Sport** 1995 Dec;66(4):276-85 (75 ref.)

PHYSIOPATHOLOGY

Maintaining and restoring mobility in middle and old age: the importance of the soft tissues. Buckwalter JA. **Instr Course Lect** 1997;46:459-69 (80 ref.)

Changes in musculoskeletal structure and function with prolonged bed rest. Bloomfield SA. **Med Sci Sports Exerc** 1997 Feb;29(2):197-206 (65 ref.)

SURGERY

Secondary deformities following mandibular reconstruction. Miller MJ, et al. **Clin Plast Surg** 1997 Jul;24(3):551-63 (14 ref.)

ULTRASONOGRAPHY

Musculoskeletal ultrasound. Gibbon WW. **Baillieres Clin Rheumatol** 1996 Nov;10(4):561-88 (38 ref.)

MUSHROOM POISONING

see related
MYCOTOXINS

Mushroom poisoning. McPartland JM, et al. **Am Fam Physician** 1997 Apr;55(5):1797-800, 1805-9, 1811-2 (27 ref.)

COMPLICATIONS

End-stage renal failure from mushroom poisoning with Cortinarius orellanus: report of four cases and review of the literature. Horn S, et al. **Am J Kidney Dis** 1997 Aug; 30(2):282-6 (16 ref.)

[Renal failure caused by the ingestion of poisonous mushrooms] Koyama K. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):580-3 (10 ref.) **(Jpn)**

DIAGNOSIS

[Clinical course and treatment of acute poisoning caused by some mushrooms] Kołaciński Z, et al. **Pol Merkuriusz Lek** 1996 Jul;1(1):66-9 (29 ref.) (Eng. Abstr.) **(Pol)**

[Poisoning with spotted and red mushrooms--pathogenesis, symptoms, treatment] Tupalska-Wilczyńska K, et al. **Wiad Lek** 1996;49(1-6):66-71 (18 ref.) (Eng. Abstr.) **(Pol)**

THERAPY

[Clinical course and treatment of acute poisoning caused by some mushrooms] Kołaciński Z, et al. **Pol Merkuriusz Lek** 1996 Jul;1(1):66-9 (29 ref.) (Eng. Abstr.) **(Pol)**

[Treatment of poisoning with Amanita phalloides--facts and controversies] Kołaciński Z. **Pol Tyg Lek** 1996 Jun; 51(23-26):350-4, 356 (40 ref.) **(Pol)**

MUSIC

Music performance. Palmer C. **Annu Rev Psychol** 1997; 48:115-38 (125 ref.)

Musicogenic epilepsy: review of the literature and case report with ictal single photon emission computed tomography. Wieser HG, et al. **Epilepsia** 1997 Feb;38(2):200-7 (32 ref.)

Idiopathic musical hallucinations in the elderly. Pasquini F, et al. **J Geriatr Psychiatry Neurol** 1997 Jan;10(1):11-4 (32 ref.)

American Academy of Pediatrics. Impact of music lyrics and music videos on children and youth (RE9144). Committee on Communications. **Pediatrics** 1996 Dec;98(6 Pt 1):1219-21 (38 ref.)

MUSIC THERAPY

Models of music therapy intervention in stroke rehabilitation. Purdie H, et al. **Int J Rehabil Res** 1995 Dec;18(4):341-50 (26 ref.)

STANDARDS

Effects of relaxation and music on postoperative pain: a review. Good M. **J Adv Nurs** 1996 Nov;24(5):905-14 (51 ref.)

MUSLIMS see **ISLAM**

MUSSELS

Health effects associated with algal toxins from seafood. Aune T. **Arch Toxicol Suppl** 1997;19:389-97 (25 ref.)

Cyanobacterial toxins: occurrence, modes of action, health effects and exposure routes. Codd GA, et al. **Arch Toxicol Suppl** 1997;19:399-410 (35 ref.)

MUSTARD COMPOUNDS

ADVERSE EFFECTS

Chronic hyperpigmentation from a heated mustard compress burn: a case report. Linder SA, et al. **J Burn Care Rehabil** 1996 Jul-Aug;17(4):351-2 (3 ref.)

MUSTARD GAS

Ocular injury by mustard gas. Solberg Y, et al. **Surv Ophthalmol** 1997 May-Jun;41(6):461-6 (59 ref.)

ADVERSE EFFECTS

Toxicology and pharmacology of the chemical warfare agent sulfur mustard. Dacre JC, et al. **Pharmacol Rev** 1996 Jun; 48(2):289-326 (347 ref.)

MUSTINE see **MECHLORETHAMINE**

MUTAGEN SCREENING see **MUTAGENICITY TESTS**

MUTAGENESIS

see related
ANTIMUTAGENIC AGENTS
MUTAGENS

Neoplastic transformation: the contrasting stability of human and mouse cells. Holliday R. **Cancer Surv** 1996;28:103-15 (63 ref.)

Carcinogenic and genotoxic effects of the tobacco substitute pan masala: present status and likely future impact on the Indian population. Trivedi AH, et al. **Cancer Treat Rev** 1996 Sep;22(5):345-54 (70 ref.)

Mutational spectra: from model systems to cancer-related genes. Dogliotti E. **Carcinogenesis** 1996 Oct;17(10):2113-8 (48 ref.)

Microsatellites: evolution and mutational processes. Freimer NB, et al. **Ciba Found Symp** 1996;197:51-67; discussion 67-72 (56 ref.)

Somatic hypermutability. Wabl M, et al. **Curr Top Microbiol Immunol** 1996;217:203-19 (90 ref.)

Targeted mutations in cell adhesion genes: what have we learned from them? Hynes RO. **Dev Biol** 1996 Dec 15; 180(2):402-12 (89 ref.)

Principles of genetic toxicology. Choy WN. **Drug Chem Toxicol** 1996 Aug;19(3):149-60 (92 ref.)

Finding new mutator strains of Escherichia coli--a review. Miller JH, et al. **Gene** 1996 Nov 7;179(1):129-32 (11 ref.)

MutT-related error avoidance mechanism for DNA synthesis. Sekiguchi M. **Genes Cells** 1996 Feb;1(2):139-45 (37 ref.)

Spontaneous mutations in bacteria: chance or necessity? MacPhee DG, et al. **Genetica** 1996 Jan;97(1):87-101 (56 ref.)

Recombination hot spots and human disease. Purandare SM, et al. **Genome Res** 1997 Aug;7(8):773-86 (102 ref.)

Random sequence mutagenesis for the generation of active enzymes. Black ME, et al. **Methods Mol Biol** 1996; 57:335-49 (13 ref.)

Use of random-saturation mutagenesis to study receptor-G protein coupling. Burstein ES, et al. **Methods Mol Biol** 1997;83:143-57 (18 ref.)

Saturation mutagenesis by mutagenic oligonucleotide-directed PCR amplification (Mod-PCR). Chiang LW. **Methods Mol Biol** 1996;57:311-21 (7 ref.)

Oligonucleotide-directed random mutagenesis using the phosphorothioate method. Dale SJ, et al. **Methods Mol Biol** 1996;57:369-74 (5 ref.)

An efficient random mutagenesis technique using an E. coli mutator strain. Greener A, et al. **Methods Mol Biol** 1996; 57:375-85 (10 ref.)

Construction of linker-scanning mutations using PCR. Harlow PP, et al. **Methods Mol Biol** 1996;57:287-95 (19 ref.)

Construction of linker-scanning mutations by oligonucleotide ligation. Hobson GM, et al. **Methods Mol Biol** 1996; 57:279-85 (7 ref.)

Use of codon cassette mutagenesis for saturation mutagenesis. Kegler-Ebo DM, et al. **Methods Mol Biol** 1996;57:297-310 (14 ref.)

Random mutagenesis of short target DNA sequences via PCR with degenerate oligonucleotides. Kirchhoff F, et al. **Methods Mol Biol** 1996;57:323-33 (11 ref.)

Random mutagenesis by using mixtures of dNTP and dITP in PCR. Kuipers OP. **Methods Mol Biol** 1996;57:351-6 (9 ref.)

PCR-mediated chemical mutagenesis. Roufa DJ. **Methods Mol Biol** 1996;57:357-67 (16 ref.)

Mutagenesis in yeast. Spencer JF, et al. **Methods Mol Biol** 1996;53:17-38 (22 ref.)

Human follitropin heterodimerization and receptor binding structural motifs: identification and analysis by a combination of synthetic peptide and mutagenesis approaches. Dias JA. **Mol Cell Endocrinol** 1996 Dec 20; 125(1-2):45-54 (74 ref.)

Induction of frameshift mutations at hotspot sequences by carcinogen adducts. Burnouf D, et al. **Recent Results Cancer Res** 1997;143:1-20 (42 ref.)

Chemical mechanisms of formation of DNA-carcinogen adducts, elucidation of potential of adducts for mutagenicity, and mechanisms of polymerase fidelity and mutation in the presence of adducts. Guengerich FP, et al. **Recent Results Cancer Res** 1997;143:49-63 (52 ref.)

Ultraviolet-induced photolesions: repair and mutagenesis. Mullenders LH, et al. **Recent Results Cancer Res** 1997; 143:89-99 (33 ref.)

Combining mutagenesis and genomics in the mouse--closing the phenotype gap. Brown SD, et al. **Trends Genet** 1996 Nov;12(11):433-5 (22 ref.)

DRUG EFFECTS

Genetic toxicology and risk assessment of complex environmental mixtures. Houk VS, et al. **Drug Chem Toxicol** 1996 Aug;19(3):187-219 (104 ref.)

Antimutagenesis and anticancer effects. Bronzetti G, et al. **J Environ Pathol Toxicol Oncol** 1996;15(2-4):59-64 (28 ref.)

Genetic changes induced by heterocyclic amines. Nagao M, et al. **Mutat Res** 1997 May 12;376(1-2):161-7 (43 ref.)

Particles, inflammation and respiratory tract carcinogenesis. Borm PJ, et al. **Toxicol Lett** 1996 Nov;88(1-3):109-13 (16 ref.)

[Receptor regulatory mechanisms of antimutagenic action] Semenov VV. **Vestn Ross Akad Med Nauk** 1997;(7):28-33 (53 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Mutation in resting cells: the role of endogenous DNA damage. Bridges BA. **Cancer Surv** 1996;28:155-67 (47 ref.)

DNA polymerase zeta and the control of DNA damage induced mutagenesis in eukaryotes. Lawrence CW, et al. **Cancer Surv** 1996;28:21-31 (38 ref.)

Patterns of mutation in cancer cells. Meuth M. **Cancer Surv** 1996;28:33-46 (50 ref.)

DNA synthesis errors, mutators and cancer. Minnick DT, et al. **Cancer Surv** 1996;28:3-20 (95 ref.)

Damage inducible mutagenesis: recent insights into the activities of the Umu family of mutagenesis proteins. Woodgate R, et al. **Cancer Surv** 1996;28:117-40 (98 ref.)

Environmental chemical mutagens and genetic risks: lessons from radiation genetics. Sankaranarayanan K. **Environ Mol Mutagen** 1996;28(2):65-70 (24 ref.)

Evidence for a role for genomic instability in radiation-induced mutagenesis. Caron RM, et al. **Radiat Oncol Investig** 1997;5(3):119-23 (15 ref.)

[Molecular mechanisms of spontaneous mutagenesis] Maki H. **Seikagaku** 1997 Mar;69(3):159-71 (31 ref.) **(Jpn)**

PHYSIOLOGY

Role of the IGF-I receptor in mutagenesis and tumor promotion. Blakesley VA, et al. **J Endocrinol** 1997 Mar; 152(3):339-44 (51 ref.)

Structure and mechanism of action of the vitamin K-dependent gamma-glutamyl carboxylase: recent advances from mutagenesis studies. Furie BC, et al. **Thromb Haemost** 1997 Jul;78(1):595-8 (25 ref.)

RADIATION EFFECTS

Environmental chemical mutagens and genetic risks: lessons from radiation genetics. Sankaranarayanan K. **Environ Mol Mutagen** 1996;28(2):65-70 (24 ref.)

MUTAGENESIS, CASSETTE see **MUTAGENESIS, INSERTIONAL**

MUTAGENESIS, INSERTIONAL

Applications of transposition mutagenesis in antibiotic producing streptomycetes. Baltz RH, et al. **Antonie Van Leeuwenhoek** 1997 Feb;71(1-2):179-87 (39 ref.)

Insertional mutagenesis by Ty elements in Saccharomyces cerevisiae. Garfinkel DJ. **Methods Mol Biol** 1996;53:227-37 (23 ref.)

PCR-assisted mutagenesis for site-directed insertion/deletion of large DNA segments. Tessier DC, et al. **Methods Mol Biol** 1996;57:229-37 (17 ref.)

MUTAGENESIS, OLIGONUCLEOTIDE-DIRECTED

MUTAGENESIS, OLIGONUCLEOTIDE-DIRECTED see **MUTAGENESIS, SITE-DIRECTED**

MUTAGENESIS, SITE-DIRECTED

Antibiotic resistance mechanisms of mutant EF-Tu species in Escherichia coli. Kraal B, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11-12):1167-77 (36 ref.)

Bioengineering: alpha 1-proteinase inhibitor site-specific mutagenesis. The prospect for improving the inhibitor. Luisetti M, et al. **Chest** 1996 Dec;110(6 Suppl):278S-283S (41 ref.)

Conditional mutagenesis in mice: the Cre/loxP recombination system. Plück A. **Int J Exp Pathol** 1996 Dec;77(6):269-78 (15 ref.)

Site-directed mutagenesis using overlap extension PCR. Aiyar A, et al. **Methods Mol Biol** 1996;57:177-91 (12 ref.)

Site-directed mutagenesis in vitro by megaprimer PCR. Barik S. **Methods Mol Biol** 1996;57:203-15 (14 ref.)

Multiple site-directed mutagenesis. Bhat KS. **Methods Mol Biol** 1996;57:269-77 (6 ref.)

Site-directed mutagenesis using double-stranded plasmid DNA templates. Braman J, et al. **Methods Mol Biol** 1996; 57:31-44 (9 ref.)

Ordered deletions using exonuclease III. Clark D, et al. **Methods Mol Biol** 1996;57:139-47 (7 ref.)

Site-directed mutagenesis using a rapid PCR-based method. Costa GL, et al. **Methods Mol Biol** 1996;57:239-48 (15 ref.)

Oligonucleotide-directed mutagenesis using an improved phosphorothioate approach. Dale SJ, et al. **Methods Mol Biol** 1996;57:55-64 (8 ref.)

Solid-phase in vitro mutagenesis using a plasmid DNA template. Edward R. **Methods Mol Biol** 1996;57:97-107 (12 ref.)

Targeted mutagenesis mediated by the triple helix formation. Glazer PM, et al. **Methods Mol Biol** 1996;57:109-18 (17 ref.)

Site-directed mutagenesis using a uracil-containing phagemid template. Hagemeier C. **Methods Mol Biol** 1996; 57:45-54 (3 ref.)

A simple method for site-directed mutagenesis with double-stranded plasmid DNA. Lai D, et al. **Methods Mol Biol** 1996;57:75-85 (20 ref.)

Analysis of point mutations by use of amber stop codon suppression. Lesley SA. **Methods Mol Biol** 1996;57:65-73 (6 ref.)

Modification of the overlap extension method for extensive mutagenesis on the same template. Mikaelian I, et al. **Methods Mol Biol** 1996;57:193-202 (9 ref.)

Site-directed mutagenesis and chimeric receptors in the study of receptor-ligand binding. Olah ME, et al. **Methods Mol Biol** 1997;83:25-43 (29 ref.)

Chromosome engineering in yeast with a site-specific recombination system from a heterologous yeast plasmid. Oshima Y, et al. **Methods Mol Biol** 1996;53:217-25 (10 ref.)

In vitro recombination and mutagenesis by overlap extension PCR. Pogulis RJ, et al. **Methods Mol Biol** 1996;57:167-76 (19 ref.)

Ligase chain reaction for site-directed in vitro mutagenesis. Rouwendal GJ, et al. **Methods Mol Biol** 1996;57:149-56 (14 ref.)

PCR-based site-directed mutagenesis. Shimada A. **Methods Mol Biol** 1996;57:157-65 (5 ref.)

PCR-assisted mutagenesis for site-directed insertion/deletion of large DNA segments. Tessier DC, et al. **Methods Mol Biol** 1996;57:229-37 (17 ref.)

A simple method to introduce internal deletions or mutations into any position of a target DNA sequence. Tomic-Canic M, et al. **Methods Mol Biol** 1996;57:249-57 (7 ref.)

A simple method for site-specific mutagenesis that leaves the rest of the template unaltered. Tomic-Canic M, et al. **Methods Mol Biol** 1996;57:259-67 (6 ref.)

Double-stranded DNA site-directed mutagenesis. Viville S. **Methods Mol Biol** 1996;57:87-95 (8 ref.)

Using PCR for rapid site-specific mutagenesis in large plasmids. Watkins BA, et al. **Methods Mol Biol** 1996; 57:217-27 (16 ref.)

A universal nested deletion method using an arbitrary primer and elimination of a unique restriction site. Zhu L, et al. **Methods Mol Biol** 1996;57:119-37 (14 ref.)

In vitro site-directed mutagenesis using the unique restriction site elimination (USE) method. Zhu L. **Methods Mol Biol** 1996;57:13-29 (22 ref.)

Binding of native kappa-neurotoxins and site-directed mutants to nicotinic acetylcholine receptors. Chiappinelli VA, et al. **Toxicon** 1996 Nov-Dec;34(11-12):1243-56 (41 ref.)

GENETICS

Transcriptional control of lymphoid development: lessons from gene targeting. Clevers HC, et al. **Immunol Today** 1996 Jul;17(7):336-43 (59 ref.)

Recent advances in gene mutagenesis by site-directed recombination. Marth JD. **J Clin Invest** 1996;98(11 Suppl):S47-50 (29 ref.)

MUTAGENESIS, SITE-SPECIFIC see **MUTAGENESIS, SITE-DIRECTED**

MUTAGENICITY TESTS

see related
CARCINOGENICITY TESTS

Current cytogenetic methods for detecting exposure and effects of mutagens and carcinogens. Natarajan AT, et al. **Environ Health Perspect** 1996 May;104 Suppl 3:445-8 (24 ref.)

Mutagen sensitivity: enhanced risk assessment of squamous cell carcinoma. Cloos J, et al. **Eur J Cancer B Oral Oncol** 1996 Nov;32B(6):367-72 (78 ref.)

Genotoxicity testing in Schizosaccharomyces pombe. McAthey P. **Methods Mol Biol** 1996;53:343-53 (3 ref.)

Mutation assays in male germ cells from transgenic mice: overview of study and conclusions. Ashby J, et al. **Mutat Res** 1997 Feb 14;388(2-3):111-22 (10 ref.)

Future approaches to genetic toxicology risk assessment. Elespuru RK. **Mutat Res** 1996 Sep;365(1-3):191-204 (100 ref.)

Recent advances in the construction of bacterial genotoxicity assays. Josephy PD, et al. **Mutat Res** 1997 Mar;386(1):1-23 (172 ref.)

Mammalian germ cell mutagenicity of ENU, IPMS and MMS, chemicals selected for a transgenic mouse collaborative study. Shelby MD, et al. **Mutat Res** 1997 Feb 14;388(2-3):99-109 (65 ref.)

Challenge to the simple paradigm that 'carcinogens' are 'mutagens' and to the in vitro and in vivo assays used to test the paradigm. Trosko JE. **Mutat Res** 1997 Feb 3; 373(2):245-9 (44 ref.)

METHODS

Principles of genetic toxicology. Choy WN. **Drug Chem Toxicol** 1996 Aug;19(3):149-60 (92 ref.)

Genetic toxicology and risk assessment of complex environmental mixtures. Houk VS, et al. **Drug Chem Toxicol** 1996 Aug;19(3):187-219 (104 ref.)

A strategy for the application of transgenic rodent mutagenesis assays. Gorelick NJ, et al. **Environ Mol Mutagen** 1996;28(4):434-42 (83 ref.)

Alternate hypothesis for the bimodal size distribution of mutant colonies of L5178Y mouse lymphoma cells. Mitchell AD. **Environ Mol Mutagen** 1997;29(4):431-3 (15 ref.)

A case study: evaluation of results and selection of additional studies. Furihata C. **J Toxicol Sci** 1996 Dec;21(5):465-7 (15 ref.)

Risk estimation from somatic mutation assays. Heddle JA, et al. **Mutat Res** 1996 Sep;365(1-3):107-17 (69 ref.)

Evaluation of the rodent micronucleus assay in the screening of IARC carcinogens (groups 1, 2A and 2B) the summary report of the 6th collaborative study by CSGMT/JEMS MMS. Collaborative Study of the Micronucleus Group Test. Mammalian Mutagenicity Study Group [published erratum appears in Mutat Res 1997 Jul 14;391(3):259-67] Morita T, et al. **Mutat Res** 1997 Feb 28;389(1):3-122 (153 ref.)

On the metabolizing systems for short-term genotoxicity assays: a review. Paolini M, et al. **Mutat Res** 1997 Aug; 387(1):17-34 (96 ref.)

Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. Tennant RW, et al. **Mutat Res** 1996 Sep;365(1-3):119-27 (36 ref.)

STANDARDS

Validation issues for the use of transgenic mouse mutation assays in risk assessment. Gorelick NJ. **Prog Clin Biol Res** 1996;395:81-108 (85 ref.)

STATISTICS & NUMERICAL DATA

Statistical analysis of the lacI transgenic mouse mutagenicity assay. Fung KY, et al. **Mutat Res** 1997 Mar 4;374(1):21-40 (32 ref.)

MUTAGENS

see related
ALKYLATING AGENTS
DNA ADDUCTS
MUTAGENESIS

Mutagenesis in the P53 gene. Pfeifer GP, et al. **Biochim Biophys Acta** 1997 Aug 8;1333(1):M1-8 (55 ref.)

Macromolecule adducts as biomarkers of exposure to environmental mutagens in human populations. Ehrenberg L, et al. **Environ Health Perspect** 1996 May;104 Suppl 3:423-8 (38 ref.)

DNA adducts and chronic degenerative disease. Pathogenetic relevance and implications in preventive medicine. De Flora S, et al. **Mutat Res** 1996 Dec; 366(3):197-238 (221 ref.)

Review of the genotoxic properties of chlorpromazine and related phenothiazines. Gocke E. **Mutat Res** 1996 Oct; 366(1):9-21 (78 ref.)

Recent advances in the construction of bacterial genotoxicity assays. Josephy PD, et al. **Mutat Res** 1997 Mar;386(1):1-23 (172 ref.)

Mutagenicity, carcinogenicity and teratogenicity of antimony compounds. Léonard A, et al. **Mutat Res** 1996 Oct; 366(1):1-8 (61 ref.)

Carbon tetrachloride: genetic effects and other modes of action. McGregor D, et al. **Mutat Res** 1996 Dec; 366(3):181-95 (113 ref.)

Overview of carcinogenic heterocyclic amines. Sugimura T. **Mutat Res** 1997 May 12;376(1-2):211-9 (62 ref.)

Factors affecting the formation and yield of heterocyclic amines. Skog K, et al. **Princess Takamatsu Symp** 1995; 23:9-19 (23 ref.)

History, present and future, of heterocyclic amines, cooked food mutagens. Sugimura T. **Princess Takamatsu Symp** 1995;23:214-31 (88 ref.)

Genotoxicity and carcinogenicity of ozone. Victorin K. **Scand J Work Environ Health** 1996;22 Suppl 3:42-51 (81 ref.)

Comparative metabolism of tamoxifen and DNA adduct formation and in vitro studies on genotoxicity. Tannenbaum SR. **Semin Oncol** 1997 Feb;24(1 Suppl 1):S1-81-S1-6 (38 ref.)

[Genotoxicity of urban air particulate matter] Clonfero E. **Med Lav** 1997 Jan-Feb;88(1):13-23 (81 ref.) (Eng. Abstr.) **(Ita)**

[Problems in the study of mutagenic effects of environmental factors (review)] Mozhaeva TE. **Gig Sanit** 1996 Sep-Oct; (5):38-40 (21 ref.) **(Rus)**

ADVERSE EFFECTS

Food and cancer prevention. Sugimura T. **Cancer Lett** 1997 Mar 19;114(1-2):3-5 (15 ref.)

Carcinogenicity of food mutagens. Sugimura T, et al. **Environ Health Perspect** 1996 May;104 Suppl 3:429-33 (48 ref.)

Genotoxic effects of pesticides. de Bertoldi M. **Eur J Cancer Prev** 1996 Oct;5(5):397-9 (24 ref.)

Use of in-vitro genotoxicity and cell transformation assays to evaluate the potential carcinogenicity of fibres. Jaurand MC. **IARC Sci Publ** 1996;(140):55-72 (107 ref.)

Genotoxicity of environmental agents in human mammary epithelial cells: a trigger for human breast cancer. Eldridge SR, et al. **Prog Clin Biol Res** 1997;396:125-31 (35 ref.)

[Cytogenetic indicators of genotoxicity in subjects occupationally exposed to antineoplastic drugs] Forni A, et al. **Med Lav** 1996 May-Jun;87(3):222-9 (34 ref.) (Eng. Abstr.) **(Ita)**

ANALYSIS

Methods for the determination of mutagenic heterocyclic amines and their applications in environmental analysis. Kataoka H. **J Chromatogr A** 1997 Jul 11;774(1-2):121-42 (159 ref.)

Quantitative determination of heterocyclic amines in food products. Gross GA, et al. **Princess Takamatsu Symp** 1995; 23:20-9 (23 ref.)

Mutagenic activity and heterocyclic amine content of the human diet. Knize MG, et al. **Princess Takamatsu Symp** 1995;23:30-8 (37 ref.)

Identification of new mutagenic heterocyclic amines and quantification of known heterocyclic amines. Wakabayashi K, et al. **Princess Takamatsu Symp** 1995;23:39-49 (31 ref.)

Methods for routine biological monitoring of carcinogenic PAH-mixtures. Jongeneelen FJ. **Sci Total Environ** 1997 Jun 20;199(1-2):141-9 (57 ref.)

[Mutagens and antimutagens in food products] Durnev AD. **Genetika** 1997 Feb;33(2):165-76 (123 ref.) (Eng. Abstr.) **(Rus)**

CHEMISTRY

Review of mutagenicity of monocyclic aromatic amines: quantitative structure-activity relationships. Chung KT, et al. **Mutat Res** 1997 Aug;387(1):1-16 (75 ref.)

Complex formation of heterocyclic amines with porphyrins: its use in detection and prevention. Hayatsu H. **Princess Takamatsu Symp** 1995;23:172-80 (14 ref.)

METABOLISM

Activation of toxic chemicals by cytochrome P450 enzymes: regio- and stereoselective oxidation of aflatoxin B1. Guengerich FP, et al. **Adv Exp Med Biol** 1996;387:7-15 (38 ref.)

Benzene-induced bone marrow cell depression caused by inhibition of the conversion of pre-interleukins-1alpha and -1beta to active cytokines by hydroquinone, a biological reactive metabolite of benzene. Niculescu R, et al. **Adv Exp Med Biol** 1996;387:329-37 (30 ref.)

Quantitative structure-activity relationships in substrates, inducers, and inhibitors of cytochrome P4501 (CYP1). Lewis DF. **Drug Metab Rev** 1997 Aug;29(3):589-650 (64 ref.)

Sulfation and sulfotransferases 4: bioactivation of mutagens via sulfation. Glatt H. **FASEB J** 1997 Apr;11(5):314-21 (41 ref.)

Enzymatic studies of the activation of heterocyclic food mutagens in man. Boobis AR, et al. **Princess Takamatsu Symp** 1995;23:134-44 (38 ref.)

Systemic exposure to dietary heterocyclic amines in man. Davies DS, et al. **Princess Takamatsu Symp** 1995;23:190-6 (30 ref.)

Mechanisms of cytochrome P450 1A2-mediated formation of N-hydroxy arylamines and heterocyclic amines and their reaction with guanyl residues. Guengerich FP, et al. **Princess Takamatsu Symp** 1995;23:78-84 (32 ref.)

Superoxide radical generation from heterocyclic amines.

Maeda H, et al. **Princess Takamatsu Symp** 1995;23:103–12 (27 ref.)
Activation and effects of the food-derived heterocyclic amines in extrahepatic tissues. Overvik E, et al. **Princess Takamatsu Symp** 1995;23:123–33 (50 ref.)
Metabolism of heterocyclic aromatic amines and strategies of human biomonitoring. Turesky RJ, et al. **Princess Takamatsu Symp** 1995;23:59–68 (30 ref.)
Assessment of the DNA adduction and pharmacokinetics of PhIP and MeIOx in rodents at doses approximating human exposure using the technique of accelerator mass spectrometry (AMS) and 32P-postlabeling. Turteltaub KW, et al. **Princess Takamatsu Symp** 1995;23:93–102 (30 ref.)

PHARMACOKINETICS

Exposure to and activation of dietary heterocyclic amines in humans. Lynch AM, et al. **Crit Rev Oncol Hematol** 1995 Nov;21(1–3):19–31 (124 ref.)
Reductive activation of nitroheterocyclic compounds. Tocher JH. **Gen Pharmacol** 1997 Apr;28(4):485–7 (27 ref.)

PHARMACOLOGY

DNA modifying agents as tools for studying chromatin structure. Millard JT. **Biochimie** 1996;78(10):803–16 (174 ref.)
Assessment of the genotoxic risk from laxative senna products. Brusick D, et al. **Environ Mol Mutagen** 1997; 29(1):1–9 (33 ref.)
Signaling events controlling the molecular response to genotoxic stress. Holbrook NJ, et al. **EXS** 1996;77:273–88 (72 ref.)
Review of mutagenicity of monocyclic aromatic amines: quantitative structure-activity relationships. Chung KT, et al. **Mutat Res** 1997 Aug;387(1):1–16 (75 ref.)
Mechanisms of action of methyl methanesulfonate on Escherichia coli: mutagenesis, DNA damage and repair. Janion C. **Postepy Biochem** 1995;41(5 Suppl):308–13 (72 ref.)
Induction of cytochrome P4501A isozymes by heterocyclic amines and other food-derived compounds. Kleman MI, et al. **Princess Takamatsu Symp** 1995;23:163–71 (37 ref.)
Oxidative DNA damage induced by dioxetanes, photosensitizing ketones, and photo-fenton reagents. Adam W, et al. **Recent Results Cancer Res** 1997;143:21–34 (40 ref.)
[The micronucleus test in human exfoliative cells as a method for studying the action of mutagens/carcinogens] Nersesian AK. **Tsitol Genet** 1996 Sep–Oct;30(5):91–6 (46 ref.) (Eng. Abstr.) **(Rus)**
[The selectivity of the mutagenic action of DNA and other polynucleotides] Gershenzon SM. **Zh Obshch Biol** 1996 Nov–Dec;57(6):661–83 (80 ref.) (Eng. Abstr.) **(Rus)**

TOXICITY

Toxicology and epidemiology of 1,3-butadiene. Himmelstein MW, et al. **Crit Rev Toxicol** 1997 Jan;27(1):1–108 (239 ref.)
Human exposure to carcinogenic heterocyclic amines and their mutational fingerprints in experimental animals. Nagao M, et al. **Environ Health Perspect** 1996 May;104 Suppl 3:497–501 (31 ref.)
Anomalous nonidentity between Salmonella genotoxicants and rodent carcinogens: nongenotoxic carcinogens and genotoxic noncarcinogens. Yoshikawa K. **Environ Health Perspect** 1996 Jan;104(1):40–6 (80 ref.)
Predicting rodent carcinogenicity from mutagenic potency measured in the Ames Salmonella assay. Fetterman BA, et al. **Environ Mol Mutagen** 1997;29(3):312–22 (23 ref.)
Environmental chemical mutagens and genetic risks: lessons from radiation genetics. Sankaranarayanan K. **Environ Mol Mutagen** 1996;28(2):65–70 (24 ref.)
Some current approaches for studying combination toxicology in chemical mixtures. Yang RS. **Food Chem Toxicol** 1996 Nov–Dec;34(11–12):1037–44 (56 ref.)
The use of toxicologic data in mechanistic risk assessment: 1,3-butadiene as a case study. Bond JA, et al. **Int Arch Occup Environ Health** 1996;68(6):415–20 (34 ref.)
Health risks of heterocyclic amines. Felton JS, et al. **Mutat Res** 1997 May 12;376(1–2):37–41 (25 ref.)
Genetic toxicology of epichlorohydrin: a review. Giri AK. **Mutat Res** 1997 Mar;386(1):25–38 (133 ref.)
Mutagenicity, carcinogenicity and teratogenicity of thallium compounds. Léonard A, et al. **Mutat Res** 1997 Aug; 387(1):47–53 (56 ref.)
Evaluation of the rodent micronucleus assay in the screening of IARC carcinogens (groups 1, 2A and 2B) the summary report of the 6th collaborative study by CSGMT/JEMS MMS. Collaborative Study of the Micronucleus Group Test. Mammalian Mutagenicity Study Group [published erratum appears in Mutat Res 1997 Jul 14;391(3):259–67] Morita T, et al. **Mutat Res** 1997 Feb 28;389(1):3–122 (153 ref.)
Mammalian germ cell mutagenicity of ENU, IPMS and MMS, chemicals selected for a transgenic mouse collaborative study. Shelby MD, et al. **Mutat Res** 1997 Feb 14;388(2–3):99–109 (65 ref.)
Interrelationship of photocarcinogenicity, photomutagenicity and phototoxicity. Loveday KS. **Photochem Photobiol** 1996 Apr;63(4):369–72 (26 ref.)
Heterocyclic amine mutagenicity/carcinogenicity: influence of repair, metabolism, and structure. Felton JS, et al. **Princess Takamatsu Symp** 1995;23:50–8 (25 ref.)
Psoralen photobiology: the relationship between DNA damage, chromatin structure, transcription, and immunogenic effects. Gasparro FP, et al. **Recent Results Cancer Res** 1997;143:101–27 (77 ref.)
A discussion of mechanisms of NO genotoxicity: implication of inhibition of DNA repair proteins. Laval F, et al. **Rev Physiol Biochem Pharmacol** 1997;131:175–91 (64 ref.)
Genetic effects of contaminant exposure--towards an assessment of impacts on animal populations. Hebert PD, et al. **Sci Total Environ** 1996 Nov 18;191(1–2):23–58 (276 ref.)
Review of risk assessments on 1,3-butadiene (1985–1991). Cagen SZ, et al. **Toxicology** 1996 Oct 28;113(1–3):215–20 (17 ref.)
Review of reproductive and developmental toxicity of 1,3-butadiene. Christian MS. **Toxicology** 1996 Oct 28; 113(1–3):137–43 (26 ref.)
Future research needs for non-cancer and cancer effects among populations exposed to 1,3-butadiene. Koppikar AM. **Toxicology** 1996 Oct 28;113(1–3):203–9 (43 ref.)
Inhalation toxicity and carcinogenicity of isoprene in rats and mice: comparisons with 1,3-butadiene. Melnick RL, et al. **Toxicology** 1996 Oct 28;113(1–3):247–52 (22 ref.)

MUTATION

see related
ANTIMUTAGENIC AGENTS
MUTAGENESIS
MUTAGENS
SUPPRESSION, GENETIC

Familial amyotrophic lateral sclerosis with a mutation in exon 4 of the Cu/Zn superoxide dismutase gene: pathological and immunocytochemical changes. Ince PG, et al. **Acta Neuropathol (Berl)** 1996 Oct;92(4):395–403 (28 ref.)
The testis: the witness of the mating system, the site of mutation and the engine of desire. Short RV. **Acta Paediatr Suppl** 1997 Jul;422:3–7 (26 ref.)
The natural somatic mutation frequency and human carcinogenesis. Simpson AJ. **Adv Cancer Res** 1997; 71:209–40 (139 ref.)
The ornithine transcarbamylase (OTC) gene: mutations in 50 Japanese families with OTC deficiency. Matsuda I, et al. **Am J Med Genet** 1997 Sep 5;71(4):378–83 (37 ref.)
Dominance and homozygosity. Zlotogora J. **Am J Med Genet** 1997 Feb 11;68(4):412–6 (28 ref.)
Role of BRCA1 mutation screening in the management of familial ovarian cancer. Berchuck A, et al. **Am J Obstet Gynecol** 1996 Sep;175(3 Pt 1):738–46 (61 ref.)
Tumors associated with p53 germline mutations: a synopsis of 91 families. Kleihues P, et al. **Am J Pathol** 1997 Jan; 150(1):1–13 (92 ref.)
Molecular tumor clocks and dynamic phenotype. Shibata D. **Am J Pathol** 1997 Sep;151(3):643–6 (29 ref.)
Genetic screening for RET mutations in families with multiple endocrine neoplasia 2 syndromes. Alevizaki M, et al. **Ann N Y Acad Sci** 1997 Jun 17;816:383–8 (23 ref.)
Tumor suppressor gene mutations in mice. Jacks T. **Annu Rev Genet** 1996;30:603–36 (171 ref.)
Somatic hypermutation of immunoglobulin genes. Wagner SD, et al. **Annu Rev Immunol** 1996;14:441–57 (114 ref.)
Molecular mechanisms regulating the myofilament response to Ca2+: implications of mutations causal for familial hypertrophic cardiomyopathy. Palmiter KA, et al. **Basic Res Cardiol** 1997;92 Suppl 1:63–74 (96 ref.)
Somatic mutations and aging: cause or effect? Barnett YA. **Biochem Soc Trans** 1997 Feb;25(1):332–5 (36 ref.)
Adaptive mutation: a general phenomenon or special case? Benson S. **Bioessays** 1997 Jan;19(1):9–11 (32 ref.)
DNA turnover and mutation in resting cells. Bridges BA. **Bioessays** 1997 Apr;19(4):347–52 (40 ref.)
Mouse models of human genetic disease: which mouse is more like a man? Erickson RP. **Bioessays** 1996 Dec; 18(12):993–8 (58 ref.)
Myelin mutants: model systems for the study of normal and abnormal myelination. Griffiths IR. **Bioessays** 1996 Oct; 18(10):789–97 (71 ref.)
Atypical presentation of Denys-Drash syndrome in a female with a novel Wt1 gene mutation. Machin GA. **Birth Defects Orig Artic Ser** 1996;30(1):269–86 (29 ref.)
Activating mutations in cytokine receptors: implications for receptor function and role in disease. Gonda TJ, et al. **Blood** 1997 Jan 15;89(2):355–69 (138 ref.)
Hematologically important mutations: Gaucher disease. Beutler E, et al. **Blood Cells Mol Dis** 1997;23(1):2–7 (49 ref.)
Factor V Leiden: should we screen oral contraceptive users and pregnant women? [see comments] Vandenbroucke JP, et al. **BMJ** 1996 Nov 2;313(7065):1127–30 (34 ref.) Comment in: BMJ 1997 Jul 5;315(7099):60.
Hyperekplexia: abnormal startle response due to glycine receptor mutations. Andrew M, et al. **Br J Psychiatry** 1997 Feb;170:106–8 (30 ref.)
Can mutated genes cause common osteoarthritis? [editorial] Prockop DJ, et al. **Br J Rheumatol** 1997 Aug;36(8):827–9 (21 ref.)
Tumour-suppressor genes in prostatic oncogenesis: a positional approach. Bookstein R, et al. **Br J Urol** 1997 Mar;79 Suppl 1:28–36 (73 ref.)
The relevance of p53 mutation in urological malignancies: possible clinical implications for bladder cancer. Nouri AM, et al. **Br J Urol** 1996 Sep;78(3):337–44 (53 ref.)
Genetics of childhood cancer. Pritchard-Jones K. **Br Med Bull** 1996 Oct;52(4):704–23 (68 ref.)
Molecular analysis of CYP21 and C4 genes in Brazilian families with the classical form of steroid 21-hydroxylase deficiency. de-Araujo M, et al. **Braz J Med Biol Res** 1996 Jan;29(1):1–13 (37 ref.)
Molecular biomarkers for aflatoxins: from adducts to gene mutations to human liver cancer. Groopman JD, et al. **Can J Physiol Pharmacol** 1996 Feb;74(2):203–9 (40 ref.)
Molecular and cellular biology of prostate cancer. Lalani el-N, et al. **Cancer Metastasis Rev** 1997 Jun;16(1–2):29–66 (403 ref.)
Androgen receptor mutations in prostate cancer. Gelmann EP. **Cancer Treat Res** 1996;87:285–302 (84 ref.)
Mutator specificity and disease: looking over the FENce [comment] Kunkel TA, et al. **Cell** 1997 Jan 24;88(2):155–8 (20 ref.) Comment on: Cell 1997 Jan 24;88(2):253–63.
Dystrophinopathy, the expanding phenotype. Dystrophin abnormalities in X-linked dilated cardiomyopathy [editorial; comment] Beggs AH. **Circulation** 1997 May 20; 95(10):2344–7 (24 ref.) Comment on: Circulation 1997 May 20;95(10):2434–40.
Dynamic mutations pose unique challenges for the molecular diagnostics laboratory [comment] McGlennen RC. **Clin Chem** 1996 Oct;42(10):1582–8 (16 ref.) Comment on: Clin Chem 1996 Oct;42(10):1601–3.
DNA helicases in inherited human disorders. Ellis NA. **Curr Opin Genet Dev** 1997 Jun;7(3):354–63 (79 ref.)
Practical methods of mutation detection. Mashal RD, et al. **Curr Opin Genet Dev** 1996 Jun;6(3):275–80 (39 ref.)
Limb mutants: what can they tell us about normal limb development? Niswander L. **Curr Opin Genet Dev** 1997 Aug;7(4):530–6 (60 ref.)
High density lipoprotein and coronary heart disease: insights from mutations leading to low high density lipoprotein. Calabresi L, et al. **Curr Opin Lipidol** 1997 Aug;8(4):219–24 (46 ref.)
Chinese hamster ovary cell mutants affecting cholesterol metabolism. Chang TY, et al. **Curr Opin Lipidol** 1997 Apr; 8(2):65–71 (79 ref.)
Unravelling high density lipoprotein-apolipoprotein metabolism in human mutants and animal models. Rader DJ, et al. **Curr Opin Lipidol** 1996 Jun;7(3):117–23 (74 ref.)
Molecular and cellular defects in nephrogenic diabetes insipidus. Knoers NV, et al. **Curr Opin Nephrol Hypertens** 1996 Jul;5(4):353–8 (43 ref.)
RET mutations in multiple endocrine neoplasia type 2 and Hirschsprung disease. Reynolds LF, et al. **Curr Opin Pediatr** 1995 Dec;7(6):702–9 (63 ref.)
Abnormal activation of cytokine gene expression by intracisternal type A particle transposition: effects of mutations that result in autocrine growth stimulation and malignant transformation. Wang XY, et al. **Cytokines Cell Mol Ther** 1997 Mar;3(1):3–19 (153 ref.)
Androgen receptor gene mutations in prostate cancer. Implications for disease progression and therapy. Culig Z, et al. **Drugs Aging** 1997 Jan;10(1):50–8 (69 ref.)
DNA adducts and mutations in occupational and environmental biomonitoring. Hemminki K. **Environ Health Perspect** 1997 Jun;105 Suppl 4:823–7 (38 ref.)
DNA mismatch repair gene mutations in human cancer. Peltomäki P. **Environ Health Perspect** 1997 Jun;105 Suppl 4:775–80 (81 ref.)
Alternate hypothesis for the bimodal size distribution of mutant colonies of L5178Y mouse lymphoma cells. Mitchell AD. **Environ Mol Mutagen** 1997;29(4):431–3 (15 ref.)
Oestrogen receptor mutants and variants in breast cancer. Dowsett M, et al. **Eur J Cancer** 1997 Jul;33(8):1177–83 (67 ref.)
Apolipoprotein function in health and disease: insights from natural mutations. Franceschini G. **Eur J Clin Invest** 1996 Sep;26(9):733–46 (109 ref.)
The significance of p53 mutations in human cancers. Pellegata NS, et al. **Eur J Histochem** 1996;40(4):273–82 (50 ref.)
Constitutively activating TSH receptor mutations as the cause of toxic thyroid adenoma, multinodular toxic goiter and autosomal dominant non autoimmune hyperthyroidism. Paschke R. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 4:129–32 (18 ref.)
Does selective gene activation direct evolution? Wright BE. **FEBS Lett** 1997 Jan 27;402(1):4–8 (42 ref.)
Alterations of p53 gene in soft tissue and bone tumors. Roessner A, et al. **Gen Diagn Pathol** 1997 Jul;143(1):1–13 (61 ref.)
Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Pollock PM, et al. **Genes Chromosomes Cancer** 1996 Feb;15(2):77–88 (69 ref.)
Genomic instability in 1p and human malignancies. Schwab M, et al. **Genes Chromosomes Cancer** 1996 Aug; 16(4):211–29 (210 ref.)
Mismatch repair as a source of mutations in non-dividing cells. MacPhee DG. **Genetica** 1996 Mar;97(2):183–95 (38 ref.)
Comparing mutational variabilities. Houle D, et al. **Genetics** 1996 Jul;143(3):1467–83 (130 ref.)
C-kit mutations and mast cell disorders. A model of

activating mutations of growth factor receptors. Pignon JM. **Hematol Cell Ther** 1997 Apr;39(2):114–6 (14 ref.)
Clinical consequences of activating germline mutations of TSH receptor, the concept of toxic hyperplasia. Leclère J, et al. **Horm Res** 1997;47(4–6):158–62 (15 ref.)
RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. Marsh DJ, et al. **Horm Res** 1997;47(4–6):168–78 (105 ref.)
The molecular basis of disorders caused by defects in G proteins. Spiegel AM. **Horm Res** 1997;47(3):89–96 (28 ref.)
Identical mutations and phenotypic variation. Wolf U. **Hum Genet** 1997 Sep;100(3–4):305–21 (99 ref.)
Transgenic models of Huntington's disease. Bates GP, et al. **Hum Mol Genet** 1997;6(10):1633–7 (40 ref.)
L1 associated diseases: clinical geneticists divide, molecular geneticists unite. Fransen E, et al. **Hum Mol Genet** 1997; 6(10):1625–32 (103 ref.)
The presenilins and Alzheimer's disease. Hutton M, et al. **Hum Mol Genet** 1997;6(10):1639–46 (70 ref.)
Homologous pigmentation mutations in human, mouse and other model organisms. Jackson IJ. **Hum Mol Genet** 1997; 6(10):1613–24 (122 ref.)
Craniosynostosis: genes and mechanisms. Wilkie AO. **Hum Mol Genet** 1997;6(10):1647–56 (103 ref.)
Diversity of ATM gene mutations detected in patients with ataxia–telangiectasia. Concannon P, et al. **Hum Mutat** 1997; 10(2):100–7 (40 ref.)
Mutations in the adrenoleukodystrophy gene. Dodd A, et al. **Hum Mutat** 1997;9(6):500–11 (57 ref.)
Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease. Eng C, et al. **Hum Mutat** 1997;9(2):97–109 (105 ref.)
Oligonucleotide micro-arrays for identification of unknown mutations: how far from reality? Ginot F. **Hum Mutat** 1997; 10(1):1–10 (50 ref.)
Mutations in mut methylmalonic acidemia: clinical and enzymatic correlations. Ledley FD, et al. **Hum Mutat** 1997; 9(1):1–6 (39 ref.)
The clinical spectrum of type IV collagen mutations. Lemmink HH, et al. **Hum Mutat** 1997;9(6):477–99 (129 ref.)
A clinical overview of WT1 gene mutations. Little M, et al. **Hum Mutat** 1997;9(3):209–25 (118 ref.)
Tay–Sachs disease–causing mutations and neutral polymorphisms in the Hex A gene. Myerowitz R. **Hum Mutat** 1997;9(3):195–208 (66 ref.)
Molecular basis of HNPCC: mutations of MMR genes. Papadopoulos N, et al. **Hum Mutat** 1997;10(2):89–99 (62 ref.)
Mutations in the GTP cyclohydrolase I and 6-pyruvoyl-tetrahydropterin synthase genes. Thöny B, et al. **Hum Mutat** 1997;10(1):11–20 (54 ref.)
Molecular basis of choroideremia (CHM): mutations involving the Rab escort protein-1 (REP-1) gene. van den Hurk JA, et al. **Hum Mutat** 1997;9(2):110–7 (54 ref.)
Genetic determinants of teratogen-induced abnormal development in mouse and rat embryos in vitro. Kapron CM, et al. **Int J Dev Biol** 1997 Apr;41(2):337–44 (54 ref.)
Mutations of the thyroxine–binding globulin gene in Japanese [editorial] Seo H. **Intern Med** 1996 Apr;35(4):237 (13 ref.)
Leber hereditary optic neuropathy: how do mitochondrial DNA mutations cause degeneration of the optic nerve? Howell N. **J Bioenerg Biomembr** 1997 Apr;29(2):165–73 (57 ref.)
Mitochondrial DNA mutations and pathogenesis. Schon EA, et al. **J Bioenerg Biomembr** 1997 Apr;29(2):131–49 (188 ref.)
TSH receptor and Gs-alpha gene mutations in the pathogenesis of toxic thyroid adenomas--a note of caution [editorial] Derwahl M. **J Clin Endocrinol Metab** 1996 Aug; 81(8):2783–5 (27 ref.)
Mutation of cytochrome P-45017 alpha gene (CYP17) in a Japanese patient previously reported as having glucocorticoid-responsive hyperaldosteronism: with a review of Japanese patients with mutations of CYP17. Miura K, et al. **J Clin Endocrinol Metab** 1996 Oct; 81(10):3797–801 (36 ref.)
Activating mutations of the thyrotropin receptor--unanswered questions [editorial; comment] Morris JC. **J Clin Endocrinol Metab** 1996 Jun;81(6):2021–2 (17 ref.) Comment on: J Clin Endocrinol Metab 1996 Jun;81(6):2023–6.
Gonadotropin receptor mutations. Themmen AP, et al. **J Endocrinol** 1997 May;153(2):179–83 (33 ref.)
Molecular insights into TSH receptor abnormality and thyroid disease. Russo D, et al. **J Endocrinol Invest** 1997 Jan;20(1):36–47 (74 ref.)
Review: molecular pathogenesis of hepatic acute porphyrias. Grandchamp B, et al. **J Gastroenterol Hepatol** 1996 Nov; 11(11):1046–52 (41 ref.)
Mitochondrial encephalomyopathies: what next? DiMauro S. **J Inherit Metab Dis** 1996;19(4):489–503 (81 ref.)
Clinical presentation of mitochondrial disorders in childhood. Munnich A, et al. **J Inherit Metab Dis** 1996;19(4):521–7 (16 ref.)
Disorders of pyruvate carboxylase and the pyruvate dehydrogenase complex. Robinson BH, et al. **J Inherit Metab Dis** 1996;19(4):452–62 (35 ref.)
Genetic counselling and prenatal diagnosis in disorders of the mitochondrial energy metabolism. Ruitenbeek W, et al. **J Inherit Metab Dis** 1996;19(4):581–7 (33 ref.)
Neurological presentations of mitochondrial diseases. Zeviani M, et al. **J Inherit Metab Dis** 1996;19(4):504–20 (41 ref.)
The molecular genetics of non-insulin-dependent diabetes mellitus [editorial] Groop LC. **J Intern Med** 1997 Feb; 241(2):95–101 (33 ref.)
Naturally occurring mutations in mice affecting lipid transport and metabolism. Reue K, et al. **J Lipid Res** 1996 Jul;37(7):1387–405 (120 ref.)
Neutral and nonneutral mutations: the creative mix--evolution of complexity in gene interaction systems [published erratum appears in J Mol Evol 1997 Apr;44(4):470] Zuckerkandl E. **J Mol Evol** 1997;44 Suppl 1:S2–8 (20 ref.)
Time for integration of predictive factors for selection of breast cancer patients who need postoperative radiation therapy? [editorial; comment] Bergh J. **J Natl Cancer Inst** 1997 May 7;89(9):605–7 (31 ref.) Comment on: J Natl Cancer Inst 1997 May 7;89(9):639–45.
Developmental genes and cancer: role of patched in basal cell carcinoma of the skin. Gailani MR, et al. **J Natl Cancer Inst** 1997 Aug 6;89(15):1103–9 (98 ref.)
Retinoic acid receptor expression abnormalities in lung cancer: important clues or major obstacles? [editorial; comment] Minna JD, et al. **J Natl Cancer Inst** 1997 May 7;89(9):602–4 (42 ref.) Comment on: J Natl Cancer Inst 1997 May 7;89(9):624–9.
Familial amyotrophic lateral sclerosis. Siddique T, et al. **J Neural Transm Suppl** 1997;49:219–33 (66 ref.)
Mutations and diseases of G protein coupled receptors. Birnbaumer M. **J Recept Signal Transduct Res** 1995 Jan–Mar;15(1–4):131–60 (74 ref.)
Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium [see comments] Burke W, et al. **JAMA** 1997 Mar 26;277(12):997–1003 (120 ref.) Comment in: JAMA 1997 Jul 23–30;278(4):289–90; discussion 290. Comment in: JAMA 1997 Jul 23–30;278(4):290.
Exploring the etiology of Alzheimer disease using molecular genetics. Lendon CL, et al. **JAMA** 1997 Mar 12; 277(10):825–31 (130 ref.)
TP53 mutations in myelodysplastic syndrome. Misawa S, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):417–22 (51 ref.)
Mutation watch. Meisler M. **Mamm Genome** 1997 May; 8(5):305–6 (9 ref.)
Murine models of human genetic skeletal disorders. Li Y, et al. **Matrix Biol** 1997 May;16(2):49–52 (22 ref.)
Mutations in the c-erbA beta 1 gene: do they underlie euthyroid fibromyalgia? Lowe JC, et al. **Med Hypotheses** 1997 Feb;48(2):125–35 (152 ref.)
GS protein mutations and pituitary tumors: functional correlates and possible therapeutic implications. Faglia G, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):117–9 (18 ref.)
Gs protein mutations and the pathogenesis and function of pituitary tumors. Harris PE. **Metabolism** 1996 Aug;45(8 Suppl 1):120–2 (23 ref.)
Use of single-cycle analysis to study rates and mechanisms of retroviral mutation. Yu H, et al. **Methods** 1997 Aug; 12(4):325–36 (62 ref.)
Capillary affinity gel electrophoresis. New tool for detection of the mutation on DNA. Baba Y. **Mol Biotechnol** 1996 Oct;6(2):143–53 (20 ref.)
Functional and clinical consequences of mutations in the FSH receptor. Gromoll J, et al. **Mol Cell Endocrinol** 1996 Dec 20;125(1–2):177–82 (21 ref.)
Inherited disorders of the gonadotropin hormones. Jameson JL. **Mol Cell Endocrinol** 1996 Dec 20;125(1–2):143–9 (32 ref.)
Mutations in the cystic fibrosis gene in men with congenital bilateral absence of the vas deferens. De Braekeleer M, et al. **Mol Hum Reprod** 1996 Sep;2(9):669–77 (124 ref.)
The molecular genetics of the zona pellucida: mouse mutations and infertility. Rankin T, et al. **Mol Hum Reprod** 1996 Nov;2(11):889–94 (56 ref.)
The CDKN2A (p16) gene and human cancer. Foulkes WD, et al. **Mol Med** 1997 Jan;3(1):5–20 (93 ref.)
The Werner mutation: does it lead to a "public" or "private" mechanism of aging? Martin GM. **Mol Med** 1997 Jun; 3(6):356–8 (20 ref.)
Androgen receptor mutations in prostate cancer. Barrack ER. **Mt Sinai J Med** 1996 Oct–Nov;63(5–6):403–12 (61 ref.)
Impairment of central and peripheral myelin in mitochondrial diseases. Kalman B, et al. **Mult Scler** 1997 Jan;2(6):267–78 (112 ref.)
Mutagenic and epigenetic effects of DNA methylation [see comments] Gonzalgo ML, et al. **Mutat Res** 1997 Apr; 386(2):107–18 (78 ref.) Comment in: Mutat Res 1997 Apr;386(2):103–5.
Risk estimation from somatic mutation assays. Heddle JA, et al. **Mutat Res** 1996 Sep;365(1–3):107–17 (69 ref.)
DNA methylation and gene expression: introduction and overview [comment] Klein CB, et al. **Mutat Res** 1997 Apr; 386(2):103–5 (5 ref.) Comment on: Mutat Res 1997 Apr;386(2):107–18. Comment on: Mutat Res 1997 Apr;386(2):119–30. Comment on: Mutat Res 1997 Apr;386(2):131–40. Comment on: Mutat Res 1997 Apr;386(2):141–53. Comment on: Mutat Res 1997 Apr;386(2):153–61.
DNA methylation and the association between genetic and epigenetic changes: relation to carcinogenesis. Wachsman JT. **Mutat Res** 1997 Apr 14;375(1):1–8 (54 ref.)
Numb diverts notch pathway off the tramtrack. Campos-Ortega JA. **Neuron** 1996 Jul;17(1):1–4 (18 ref.)
Mutations of the X region of hepatitis B virus and their clinical implications. Uchida T, et al. **Pathol Int** 1997 Apr; 47(4):183–93 (150 ref.)
Genotypes and phenotypes of beta-thalassemia in Mediterranean populations [editorial] Kattamis C, et al. **Pediatr Hematol Oncol** 1997 May–Jun;14(3):vii–ix (11 ref.)
The RET proto-oncogene: a challenge to our understanding of disease pathogenesis. Kusafuka T, et al. **Pediatr Surg Int** 1997;12(1):11–8 (99 ref.)
Mutations of the endothelin-B receptor and endothelin-3 genes in Hirschsprung's disease. Kusafuka T, et al. **Pediatr Surg Int** 1997;12(1):19–23 (38 ref.)
Hirschsprung's disease as a neurochristopathy. Martucciello G. **Pediatr Surg Int** 1997;12(1):2–10 (74 ref.)
Somatic mutation detection in human biomonitoring. Olsen LS, et al. **Pharmacol Toxicol** 1996 Jun;78(6):364–73 (76 ref.)
Tumor suppressor gene mutations and photocarcinogenesis. Ziegler A, et al. **Photochem Photobiol** 1996 Apr;63(4):432–5 (38 ref.)
Prospects for DNA-based prenatal diagnosis of mitochondrial disorders. Poulton J, et al. **Prenat Diagn** 1996 Dec;16(13):1247–56 (41 ref.)
Association of cytotoxic T lymphocyte (CTL) escape mutations with persistent hepatitis C virus (HCV) infection. Weiner AJ, et al. **Princess Takamatsu Symp** 1995;25:227–35 (35 ref.)
The high spontaneous mutation rate: is it a health risk? Crow JF. **Proc Natl Acad Sci U S A** 1997 Aug 5;94(16):8380–6 (48 ref.)
Mutations contributing to human blood pressure variation. Karet FE, et al. **Recent Prog Horm Res** 1997;52:263–76; discussion 276–7 (59 ref.)
Mechanisms leading to the expression of recessive alleles: the use of polymorphic microsatellites and whole-chromosome painting probes to analyze mouse tumors, mutants, and micronuclei. Caspary WJ, et al. **Recent Results Cancer Res** 1997;143:161–82 (82 ref.)
P53 gene alterations in human tumors: perspectives for cancer control. Hollstein M, et al. **Recent Results Cancer Res** 1997; 143:369–89 (140 ref.)
The ovine callipyge locus: a paradigm illustrating the importance of non-Mendelian genetics in livestock. Georges M, et al. **Reprod Nutr Dev** 1996;36(6):651–7 (21 ref.)
Induced mouse chromosomal rearrangements as tools for identifying critical developmental genes and pathways. Culiat CT, et al. **Reprod Toxicol** 1997 Mar–Jun; 11(2–3):345–51 (58 ref.)
Erythropoietin receptor mutations and human disease. Gregg XT, et al. **Semin Hematol** 1997 Jan;34(1):70–6 (46 ref.)
A mild variant of cystic fibrosis. Alton EW. **Thorax** 1996 Aug;51 Suppl 2:S51–4 (18 ref.)
Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Lane DA, et al. **Thromb Haemost** 1997 Jan;77(1):197–211 (131 ref.)
RNA editing and hypermutation by adenosine deamination [published erratum appears in Trends Biochem Sci 1997 Jul;22(7):278] Bass BL. **Trends Biochem Sci** 1997 May; 22(5):157–62 (54 ref.)
Slowly but surely towards better scanning for mutations [published erratum appears in Trends Genet 1997 May;13(5):208] Cotton RG. **Trends Genet** 1997 Feb; 13(2):43–6 (23 ref.)
The molecular epidemiology of p53 gene mutations in human breast cancer. Hartmann A, et al. **Trends Genet** 1997 Jan; 13(1):27–33 (79 ref.)
Paramutation and related allelic interactions [see comments] Hollick JB, et al. **Trends Genet** 1997 Aug;13(8):302–8 (53 ref.) Comment in: Trends Genet 1997 Aug;13(8):293–5.
The genetic basis of neuromuscular disorders. Nawrotzki R, et al. **Trends Genet** 1996 Aug;12(8):294–8 (48 ref.)
T-box family reunion. Papaioannou VE. **Trends Genet** 1997 Jun;13(6):212–3 (20 ref.)
RET mutations in human disease. Pasini B, et al. **Trends Genet** 1996 Apr;12(4):138–44 (60 ref.)
Zebrafish genomics: from mutants to genes. Postlethwait JH, et al. **Trends Genet** 1997 May;13(5):183–90 (63 ref.)
Genome organization, natural genetic engineering and adaptive mutation. Shapiro JA. **Trends Genet** 1997 Mar; 13(3):98–104 (68 ref.)
Presenilin mutations in Alzheimer's disease: molecular models suggest a potential functional locus [published erratum appears in Trends Pharmacol Sci 1996 Dec;17(12):465] Murgolo NJ, et al. **Trends Pharmacol Sci** 1996 Nov; 17(11):389–93 (22 ref.)
Gene–nutrient interactions in single-gene defects and polygenic diseases: methodologic considerations. Velázquez A. **World Rev Nutr Diet** 1997;80:145–64 (65 ref.)
[The p53 tumor suppressor gene and ovarian cancer] Li G, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Nov; 30(11):698–701 (18 ref.) **(Chi)**
[Mismatch repair gene defects in large intestinal cancers] Huang J, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Sep; 76(9):717–8 (12 ref.) **(Chi)**
[Association of achondroplasia to a mutation in the transmembrane domain of fibroblastic growth factor receptor 3 (FGFR3)] Rousseau F, et al. **Ann Endocrinol (Paris)** 1996;57(3):151–2 (6 ref.) **(Fre)**
[Mutations of the androgen receptor gene a possible role in

prostate cancer] Mowszowicz I, et al. **Bull Cancer** 1997 Feb;84(2):183–8 (37 ref.) (Eng. Abstr.) **(Fre)**

[Detection and prevalence of mitochondrial genome mutations in diabetes] Paquis–Flucklinger V, et al. **Journ Annu Diabetol Hotel Dieu** 1997;:25–31 (28 ref.) **(Fre)**

[Mitochondrial diabetes] Rötig A, et al. **Journ Annu Diabetol Hotel Dieu** 1997;:33–42 (36 ref.) **(Fre)**

[Clinical manifestation of diabetes from mitochondrial cytopathy] Vialettes B, et al. **Journ Annu Diabetol Hotel Dieu** 1997;:17–23 (31 ref.) **(Fre)**

[Familial ovarian cancer—detection of the responsible genes] Menczer J. **Harefuah** 1997 Jan 15;132(2):100–3 (41 ref.) **(Heb)**

[Mitochondrial cardiomyopathies: a new entity in cardiology research and diagnosis] Bernucci P, et al. **G Ital Cardiol** 1996 Sep;26(9):1031–7 (31 ref.) **(Ita)**

[Azoospermia and genetic mutations: implications for the methods of in vitro fertilization] Rocchietti March M, et al. **Minerva Endocrinol** 1996 Dec;21(4):123–31 (19 ref.) (Eng. Abstr.) **(Ita)**

[Topographic genomapping of p53 mutations in non–small cell lung cancer using in situ PCR] Ebina M, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(4):406–11 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Functional screening of p53 status in tumor cells using Saccharomyces cerevisiae] Jia LQ, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(4):466–70 (13 ref.) (Eng. Abstr.) **(Jpn)**

[p53 mutation does not determine prognosis in non–Hodgkin's lymphoma] Osada M, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(4):471–5 (25 ref.) (Eng. Abstr.) **(Jpn)**

[Mutation of hepatitis viruses and the pathophysiology] Komata M, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):583–93 (7 ref.) **(Jpn)**

[Mechanisms of endogenous drug resistance acquisition by spontaneous chromosomal gene mutation] Fukuda H, et al. **Nippon Rinsho** 1997 May;55(5):1185–90 (21 ref.) (Eng. Abstr.) **(Jpn)**

[The mutation and the selection of inactivating enzymes against antibiotic resistances] Inoue M, et al. **Nippon Rinsho** 1997 May;55(5):1161–6 (7 ref.) (Eng. Abstr.) **(Jpn)**

[p53 gene mutations in the human lung carcinoma] Saito M, et al. **Nippon Rinsho** 1996 Feb;54(2):497–502 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Mutation frequency of the p16/CDKN2 gene and amplification of the cyclin E gene in human primary gastric carcinomas] Sasaki H, et al. **Nippon Rinsho** 1996 Apr; 54(4):1049–53 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Genetic events during development of esophageal squamous cell carcinoma] Sasaki H, et al. **Nippon Rinsho** 1996 Apr; 54(4):1060–5 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Genetic alterations of gliomas] Tabuchi K, et al. **No To Shinkei** 1997 Mar;49(3):205–13 (36 ref.) **(Jpn)**

[Gene mutation and pathology in human prion disease] Tashiro H, et al. **No To Shinkei** 1997 Aug;49(8):681–7 (30 ref.) **(Jpn)**

[Gene analysis in patients with muscular dystrophy: alpha–sarcoglycan (adhalin) gene mutations in patients with malignant limb–girdle muscular dystrophy] Akaike M, et al. **Rinsho Byori** 1997 Feb;45(2):136–40 (21 ref.) (Eng. Abstr.) **(Jpn)**

[alpha–Galactosidase gene mutation and its expression product in Fabry disease (alpha–galactosidase deficiency)] Okumiya T, et al. **Rinsho Byori** 1997 Feb;45(2):127–35 (27 ref.) (Eng. Abstr.) **(Jpn)**

[Computer softwares for DNA diagnosis: GeneViewPLUS and Mutation View] Shimizu N, et al. **Rinsho Byori** 1997 Mar;45(3):209–12 (4 ref.) (Eng. Abstr.) **(Jpn)**

[Mutations of c–kit receptor tyrosine kinase in hematologic disease] Ikeda H, et al. **Rinsho Ketsueki** 1997 Mar; 38(3):177–80 (10 ref.) **(Jpn)**

[Mitochondrial encephalomyopathies: 3243 mutation as a central matter] Goto Y, et al. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1425–6 (4 ref.) (Eng. Abstr.) **(Jpn)**

[Mutation of the myelin Po gene in hereditary motor and sensory neuropathy] Hayasaka K. **Rinsho Shinkeigaku** 1995 Dec;35(12):1444–6 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Familial amyotrophic lateral sclerosis and mutations in the Cu/Zn superoxide dismutase gene] Nakano R. **Rinsho Shinkeigaku** 1995 Dec;35(12):1546–8 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical, pathologic and molecular genetic studies of patients with hereditary motor and sensory neuropathy (HMSN)] Ohnishi A. **Rinsho Shinkeigaku** 1995 Dec;35(12):1438–40 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular pathology of Charcot–Marie–Tooth disease type 1A: abnormal expression of PMP–22] Yoshikawa H, et al. **Rinsho Shinkeigaku** 1995 Dec;35(12):1441–3 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular basis of hypertrophic cardiomyopathy] Rokicka A, et al. **Pol Merkuriusz Lek** 1996 Aug;1(2):78–81 (45 ref.) **(Pol)**

[Molecular genetics of human tumors] Imianitov EN, et al. **Vopr Onkol** 1997;43(1):95–101 (46 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Protective effects of ascorbic acid against radiation–induced clastogenesis. Kesavan PC, et al. **Subcell Biochem** 1996; 25:407–21 (79 ref.)

GENETICS

Conservation genetics. Frankham R. **Annu Rev Genet** 1995; 29:305–27 (170 ref.)

delta F508 in cystic fibrosis: willing but not able. Southern KW. **Arch Dis Child** 1997 Mar;76(3):278–82 (49 ref.)

Genetic alterations in leukemias and lymphomas: impressive progress and continuing complexity. Nowell PC. **Cancer Genet Cytogenet** 1997 Mar;94(1):13–9 (52 ref.)

The genetic basis of cancer. Dimond E, et al. **Cancer Nurs** 1997 Jun;20(3):213–22; quiz 223–6 (23 ref.)

Many mutations in cancers. Loeb LA. **Cancer Surv** 1996; 28:329–42 (74 ref.)

The relevance of bacterial mutators to understanding human cancer. Miller JH. **Cancer Surv** 1996;28:141–53 (89 ref.)

TP53 tumour suppressor gene: clues to molecular carcinogenesis and cancer therapy. Wang XW, et al. **Cancer Surv** 1996;28:169–96 (231 ref.)

Somatic mutations in paroxysmal nocturnal hemoglobinuria: a blessing in disguise? Luzzatto L, et al. **Cell** 1997 Jan 10; 88(1):1–4 (22 ref.)

Basic science of small cell lung cancer. Williams CL. **Chest Surg Clin N Am** 1997 Feb;7(1):1–19 (140 ref.)

Somatic hypermutation: Another piece in the hypermutation puzzle. Winter DB, et al. **Curr Biol** 1995 Dec 1;5(12):1345–6 (14 ref.)

Skeletal disorders associated with fibroblast growth factor receptor mutations. De Moerlooze L, et al. **Curr Opin Genet Dev** 1997 Jun;7(3):378–85 (68 ref.)

Fibroblast growth factor receptor 3 and the human chondrodysplasias. Horton WA. **Curr Opin Pediatr** 1997 Aug;9(4):437–42 (49 ref.)

Endocrine and metabolism [editorial; comment] Root AW. **Curr Opin Pediatr** 1997 Aug;9(4):407–12 (19 ref.) Comment on: Curr Opin Pediatr 1997 Aug;9(4):413–80. Comment on: Curr Opin Pediatr 1997 Aug;9(4):419–23. Comment on: Curr Opin Pediatr 1997 Aug;9(4):424–30.

Hepatocellular carcinoma p53 G > T transversions at codon 249: the fingerprint of aflatoxin exposure? Lasky T, et al. **Environ Health Perspect** 1997 Apr;105(4):392–7 (48 ref.)

RET receptor tyrosine kinase gene mutations: molecular biological, physiological and clinical aspects. Höppener JW, et al. **Eur J Clin Invest** 1996 Aug;26(8):613–24 (88 ref.)

Taking the message to the nucleus: MAD protein as a mediator of bone morphogenetic protein signaling. Hofbauer LC, et al. **Eur J Endocrinol** 1996 Dec; 135(6):654–5 (13 ref.)

The influence of mutations of enzyme activity and phenylalanine tolerance in phenylalanine hydroxylase deficiency. Güttler F, et al. **Eur J Pediatr** 1996 Jul;155 Suppl 1:S6–10 (27 ref.)

Somatic mutation in paroxysmal nocturnal hemoglobinuria. Luzzatto L. **Hosp Pract (Off Ed)** 1997 Sep 15;32(9):125–31, 135–6, 139–40 (7 ref.)

Mutations in fibrillar collagens (types I, II, III, and XI), fibril–associated collagen (type IX), and network–forming collagen (type X) cause a spectrum of diseases of bone, cartilage, and blood vessels. Kuivaniemi H, et al. **Hum Mutat** 1997;9(4):300–15 (78 ref.)

Mutations in the fumarylacetoacetate hydrolase gene causing hereditary tyrosinemia type I: overview. St–Louis M, et al. **Hum Mutat** 1997;9(4):291–9 (44 ref.)

Mutational and susceptibility genetics are different clinical paradigms [editorial] Roses AD. **Int Psychogeriatr** 1997 Mar;9(1):7–10 (11 ref.)

The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. Kuivenhoven JA, et al. **J Lipid Res** 1997 Feb;38(2):191–205 (102 ref.)

Cu/Zn superoxide dismutase gene mutations in amyotrophic lateral sclerosis: correlation between genotype and clinical features. Radunovic A, et al. **J Neurol Neurosurg Psychiatry** 1996 Dec;61(6):565–72 (82 ref.)

Disorders of puberty: inactivating and activating molecular mutations. DiMeglio LA, et al. **J Pediatr** 1997 Jul;131(1 Pt 2):S8–12 (22 ref.)

Mutations of the BRCA1 and BRCA2 genes and the possibilities for predictive testing. Gayther SA, et al. **Mol Med Today** 1997 Apr;3(4):168–74 (36 ref.)

Somatic mutation theory, DNA repair rates, and the molecular epidemiology of p53 mutations. Holmquist GP, et al. **Mutat Res** 1997 Mar;386(1):69–101 (160 ref.)

New developments in congenital lipoid adrenal hyperplasia and steroidogenic acute regulatory protein [published erratum appears in Pediatr Clin North Am 1997 Jun;44(3):viii] Saenger P. **Pediatr Clin North Am** 1997 Apr; 44(2):397–421 (95 ref.)

Deleterious mutations, variable epistatic interactions, and the evolution of recombination. Otto SP, et al. **Theor Popul Biol** 1997 Apr;51(2):134–47 (37 ref.)

Mechanisms of retroviral mutation. Preston BD, et al. **Trends Microbiol** 1996 Jan;4(1):16–21 (88 ref.)

Androgen–receptor gene structure and function in prostate cancer. Hakimi JM, et al. **World J Urol** 1996;14(5):329–37 (46 ref.)

[Hepatitis B virus mutants—clinical significance] Blum HE, et al. **Z Gastroenterol** 1997 May;35(5):347–55 (79 ref.) (Eng. Abstr.) **(Ger)**

[Analyses of dominant mutations and their phenotypes: unraveling of physiological functions of retinoid and identification of the responsible gene for Machado–Joseph disease] Kakizuka A. **Seikagaku** 1997 Feb;69(2):87–103 (51 ref.) **(Jpn)**

IMMUNOLOGY

The use of dominant–negative mutations to elucidate signal transduction pathways in lymphocytes. Perlmutter RM, et al. **Curr Opin Immunol** 1996 Apr;8(2):285–90 (48 ref.)

The molecular basis of somatic hypermutation of immunoglobulin genes. Storb U. **Curr Opin Immunol** 1996 Apr;8(2):206–14 (88 ref.)

Mechanism of antigen–driven somatic hypermutation of rearranged immunoglobulin V(D)J genes in the mouse. Steele EJ, et al. **Immunol Cell Biol** 1997 Feb;75(1):82–95 (92 ref.)

Unique tumor antigens redefined as mutant tumor–specific antigens. Mumberg D, et al. **Semin Immunol** 1996 Oct; 8(5):289–93 (31 ref.)

PHYSIOLOGY

Pathogenesis of neurodegenerative disorders: the role of dynamic mutations. Martin JB. **Neuroreport** 1996 Dec 20; 8(1):i–vii (82 ref.)

RADIATION EFFECTS

Radioadaptation for gene mutation and the possible molecular mechanisms of the adaptive response. Rigaud O, et al. **Mutat Res** 1996 Nov 4;358(2):127–34 (46 ref.)

MUTATION, FRAMESHIFT see **FRAMESHIFT MUTATION**

MUTATION, GERM–LINE see **GERM–LINE MUTATION**

MUTATION, POINT see **POINT MUTATION**

MUTATIONAL ANALYSIS, DNA see **DNA MUTATIONAL ANALYSIS**

MUTISM

DIAGNOSIS

Cerebellar mutism: report of two unusual cases and review of the literature. Erşahin Y, et al. **Clin Neurol Neurosurg** 1997 May;99(2):130–4 (27 ref.)

ETIOLOGY

Cerebellar mutism following posterior fossa tumour surgery. Jones S, et al. **Br J Neurosurg** 1996 Apr;10(2):221–4 (18 ref.)

Cerebellar mutism after posterior cranial fossa surgery. Salvati M, et al. **J Neurosurg Sci** 1996 Mar;40(1):59–63 (21 ref.)

MYASTHENIA GRAVIS

Myasthenia gravis. Pourmand R. **Dis Mon** 1997 Feb; 43(2):65–109 (179 ref.)

[Myasthenic cardiomyopathy] Namakanov BA, et al. **Klin Med (Mosk)** 1997;75(8):16–8 (43 ref.) **(Rus)**

CHEMICALLY INDUCED

Drugs and myasthenia gravis. An update. Wittbrodt ET. **Arch Intern Med** 1997 Feb 24;157(4):399–408 (101 ref.)

COMPLICATIONS

Bilateral pseudo–internuclear ophthalmoplegia in myasthenia gravis. Ito K, et al. **ORL J Otorhinolaryngol Relat Spec** 1997 Mar–Apr; 59(2):122–6 (18 ref.)

CONGENITAL

Genes at the junction—candidates for congenital myasthenic syndromes. Vincent A, et al. **Trends Neurosci** 1997 Jan; 20(1):15–22 (32 ref.)

DIAGNOSIS

Myasthenia gravis and the Miller–Fisher variant of Guillain–Barré syndrome. Newsom–Davis J. **Curr Opin Neurol** 1997 Feb;10(1):18–21 (23 ref.)

A practical guide to the recognition and management of myasthenia gravis. Evoli A, et al. **Drugs** 1996 Nov; 52(5):662–70 (39 ref.)

[Late onset myasthenia: 34 cases in patients over 65 years of age] Billé–Turc F, et al. **Rev Neurol (Paris)** 1997 Mar; 153(2):129–34 (24 ref.) (Eng. Abstr.) **(Fre)**

[Myasthenia gravis in childhood and adolescence] Arroyo HA. **Rev Neurol** 1996 Nov;24(135):1385–9 (27 ref.) **(Spa)**

DRUG THERAPY

[Therapy of myasthenia gravis with cholinesterase

inhibitors--principles and pharmacologic monitoring] **Henze T. Fortschr Neurol Psychiatr** 1996 Mar;64(3):110–21 (92 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Stiff-persons' syndrome associated with thymoma and subsequent myasthenia gravis. Nicholas AP, et al. **Muscle Nerve** 1997 Apr;20(4):493–8 (49 ref.)

Acquired myasthenia gravis. Massey JM. **Neurol Clin** 1997 Aug;15(3):577–95 (65 ref.)

Pathogenesis of myasthenia gravis. Marx A, et al. **Virchows Arch** 1997 May;430(5):355–64 (127 ref.)

[A case of myasthenia gravis which developed myasthenic crisis after alpha-interferon therapy for chronic hepatitis C] Konishi T. **Rinsho Shinkeigaku** 1996 Aug;36(8):980–5 (14 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Genes at the junction--candidates for congenital myasthenic syndromes. Vincent A, et al. **Trends Neurosci** 1997 Jan; 20(1):15–22 (32 ref.)

IMMUNOLOGY

Myasthenia gravis and primary biliary cirrhosis. Common immunological features and rare coincidence. Kiechl S, et al. **Acta Neurol Scand** 1996 Apr;93(4):263–5 (21 ref.)

Antigenic structure of the muscle nicotinic acetylcholine receptor. Tzartos SJ, et al. **Ann Med Interne (Paris)** 1996; 147(6):442–6 (28 ref.)

Myasthenia gravis: immunological mechanisms and immunotherapy. Lewis RA, et al. **Ann Neurol** 1995 May; 37 Suppl 1:S51–62 (109 ref.)

Heterogeneity and immunotherapy of specific T-cells in myasthenia gravis. Bond A, et al. **Biochem Soc Trans** 1997 May;25(2):665–70 (44 ref.)

T-lymphocyte activation and regulation in the central nervous system. Sedgwick JD. **Biochem Soc Trans** 1997 May;25(2):673–9 (36 ref.)

Autoimmune T cells in myasthenia gravis: heterogeneity and potential for specific immunotargeting. Hawke S, et al. **Immunol Today** 1996 Jul;17(7):307–11 (32 ref.)

Myasthenia gravis. Marx A, et al. **Verh Dtsch Ges Pathol** 1996;80:116–26 (63 ref.)

PATHOLOGY

Myasthenia gravis. Marx A, et al. **Verh Dtsch Ges Pathol** 1996;80:116–26 (63 ref.)

PHYSIOPATHOLOGY

Myasthenia gravis. Somnier FE. **Dan Med Bull** 1996 Feb; 43(1):1–10 (126 ref.)

[Autoimmune myasthenia: recent physiopathological data] Eymard B, et al. **Presse Med** 1997 May 31;26(18):872–9 (42 ref.) (Eng. Abstr.) **(Fre)**

[Nicotine and worsening myasthenia] Moreau T, et al. **Rev Neurol (Paris)** 1997 Mar;153(2):141–3 (10 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

[Indications and value of thymectomy in myasthenia gravis] Nix WA. **Nervenarzt** 1997 Feb;68(2):85–93 (73 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Heterogeneity and immunotherapy of specific T-cells in myasthenia gravis. Bond A, et al. **Biochem Soc Trans** 1997 May;25(2):665–70 (44 ref.)

Therapy of myasthenic crisis [see comments] Berrouschot J, et al. **Crit Care Med** 1997 Jul;25(7):1228–35 (51 ref.) Comment in: Crit Care Med 1997 Jul;25(7):1111–2.

Myasthenia gravis. Somnier FE. **Dan Med Bull** 1996 Feb; 43(1):1–10 (126 ref.)

Current and future therapies for myasthenia gravis. Yi Q, et al. **Drugs Aging** 1997 Aug;11(2):132–9 (61 ref.)

Autoimmune T cells in myasthenia gravis: heterogeneity and potential for specific immunotargeting. Hawke S, et al. **Immunol Today** 1996 Jul;17(7):307–11 (32 ref.)

[Respective indications of plasma exchange and high-dose immunoglobulins in polyradiculoneuritis and myasthenia gravis] Raphaël JC, et al. **Presse Med** 1996 Oct 19; 25(31):1516–22 (31 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of myasthenia] Gajdos P, et al. **Rev Neurol (Paris)** 1997 Mar;153(2):91–105 (123 ref.) **(Fre)**

[Therapeutic guideline for myasthenia gravis] Yoshikawa H, et al. **Nippon Naika Gakkai Zasshi** 1997 May 10; 86(5):849–55 (12 ref.) **(Jpn)**

MYATONIA CONGENITA see **NEUROMUSCULAR DISEASES**

MYB GENES see **ONCOGENES**

MYC GENES see **GENES, MYC**

MYC PROTO-ONCOGENE PROTEINS see **PROTO-ONCOGENE PROTEINS C-MYC**

MYCETOMA see **MADUROMYCOSIS**

MYCOBACTERIACEAE

CHEMISTRY

Macroamphiphilic cell envelope components of Rhodococcus equi and closely related bacteria. Sutcliffe IC. **Vet Microbiol** 1997 Jun 16;56(3–4):287–99 (43 ref.)

PATHOGENICITY

The molecular basis of mycobacterial infection. Colston MJ. **Mol Aspects Med** 1996 Aug;17(4):383–454 (296 ref.)

MYCOBACTERIUM

Mycobacteriology laboratory. Heifets L. **Clin Chest Med** 1997 Mar;18(1):35–53 (68 ref.)

Clinical mycobacteriology. Work flow and optional protocols for laboratories in industrialized countries. Della-Latta P. **Clin Lab Med** 1996 Sep;16(3):677–95 (76 ref.)

The mycobacteriology laboratory. Past, present, and future. Heifets LB. **Clin Lab Med** 1996 Sep;16(3):513–25 (32 ref.)

Clinical mycobacteriology. Activities and recommendations by the association of state and territorial public health laboratory directors. Warren NG, et al. **Clin Lab Med** 1996 Sep;16(3):731–43 (24 ref.)

Quality assurance in the mycobacteriology laboratory. Quality control, quality improvement, and proficiency testing. Woods GL, et al. **Clin Lab Med** 1996 Sep; 16(3):657–75 (45 ref.)

Epidemiology of infection by nontuberculous mycobacteria. Falkinham JO 3rd. **Clin Microbiol Rev** 1996 Apr; 9(2):177–215 (571 ref.)

CHEMISTRY

[The lipid and carbohydrate components of mycobacteria and the methods for their determination] Gizatulina NM. **Probl Tuberk** 1996;(4):59–62 (42 ref.) **(Rus)**

CLASSIFICATION

Microbiology of nontuberculosis mycobacteria. Gangadharam PR. **Semin Respir Infect** 1996 Dec; 11(4):231–43 (71 ref.)

The biology of the genus Mycobacterium. Grange JM. **Soc Appl Bacteriol Symp Ser** 1996;25:1S–9S (43 ref.)

DRUG EFFECTS

The value of in vitro drug activity and pharmacokinetics in predicting the effectiveness of antimycobacterial therapy: a critical review. Burman WJ. **Am J Med Sci** 1997 Jun; 313(6):355–63 (100 ref.)

Clinical mycobacteriology. Drug susceptibility testing. Heifets LB. **Clin Lab Med** 1996 Sep;16(3):641–56 (58 ref.)

In-vitro sensitivities and treatment of less common mycobacteria. Watt B. **J Antimicrob Chemother** 1997 May; 39(5):567–74 (56 ref.)

Activity of biocides against mycobacteria. Russell AD. **Soc Appl Bacteriol Symp Ser** 1996;25:87S–101S (135 ref.)

GENETICS

Polymerase chain reaction and other amplification techniques in mycobacteriology. Sandin RL. **Clin Lab Med** 1996 Sep; 16(3):617–39 (40 ref.)

DNA insertion sequences and the molecular epidemiology of Salmonella and Mycobacterium. Stanley J, et al. **J Med Microbiol** 1996 Oct;45(4):236–51 (116 ref.)

Biochemistry and molecular genetics of cell-wall lipid biosynthesis in mycobacteria. Kolattukudy PE, et al. **Mol Microbiol** 1997 Apr;24(2):263–70 (30 ref.)

Recombination in mycobacteria. McFadden J. **Mol Microbiol** 1996 Jul;21(2):205–11 (36 ref.)

GROWTH & DEVELOPMENT

Identification of mycobacteria by conventional methods. Witebsky FG, et al. **Clin Lab Med** 1996 Sep;16(3):569–601 (62 ref.)

IMMUNOLOGY

In vitro cellular and cytokine responses to mycobacterial antigens: application to diagnosis of tuberculosis infection and assessment of response to mycobacterial vaccines. Lein AD, et al. **Am J Med Sci** 1997 Jun;313(6):364–71 (66 ref.)

The CD1-restricted T-cell response to mycobacteria. Moody DB, et al. **Res Immunol** 1996 Oct-Dec;147(8–9):550–9 (31 ref.)

Immunotherapy with Mycobacterium vaccae and the treatment of tuberculosis. Stanford JL, et al. **Soc Appl Bacteriol Symp Ser** 1996;25:81S–86S (30 ref.)

ISOLATION & PURIFICATION

Mycobacterium szulgai infection of the lung: case report and review of an unusual pathogen. Benator DA, et al. **Am J Med Sci** 1997 Jun;313(6):346–51 (25 ref.)

Nontuberculous mycobacterial meningitis: report of two cases and review. Flor A, et al. **Clin Infect Dis** 1996 Dec; 23(6):1266–73 (43 ref.)

Methods for the rapid identification of mycobacterial species. Roberts GD, et al. **Clin Lab Med** 1996 Sep;16(3):603–15 (40 ref.)

Identification of mycobacteria by conventional methods. Witebsky FG, et al. **Clin Lab Med** 1996 Sep;16(3):569–601 (62 ref.)

Mycobacterial cervical lymphadenitis: a review. Fitzpatrick EL, et al. **J La State Med Soc** 1996 Nov;148(11):451–4 (12 ref.)

Two case reports and review of vascular catheter-associated bacteremia caused by nontuberculous Mycobacterium species. Rodgers GL, et al. **Pediatr Infect Dis J** 1996 Mar; 15(3):260–4 (50 ref.)

Microbiology of nontuberculosis mycobacteria. Gangadharam PR. **Semin Respir Infect** 1996 Dec; 11(4):231–43 (71 ref.)

Epidemiology of disease caused by nontuberculous mycobacteria. Horsburgh CR Jr. **Semin Respir Infect** 1996 Dec;11(4):244–51 (111 ref.)

METABOLISM

Biochemistry and molecular genetics of cell-wall lipid biosynthesis in mycobacteria. Kolattukudy PE, et al. **Mol Microbiol** 1997 Apr;24(2):263–70 (30 ref.)

PATHOGENICITY

Nontuberculous mycobacterial infections. Guay DR. **Ann Pharmacother** 1996 Jul-Aug;30(7–8):819–30 (199 ref.)

PHYSIOLOGY

Drug sensitivity and environmental adaptation of mycobacterial cell wall components. Barry CE 3rd, et al. **Trends Microbiol** 1996 Jul;4(7):275–81 (58 ref.)

MYCOBACTERIUM, ATYPICAL

Otitis media and mastoiditis due to Mycobacterium fortuitum: case report, review of four cases, and a cautionary note. Plemmons RM, et al. **Clin Infect Dis** 1996 Jun;22(6):1105–6 (10 ref.)

GENETICS

[Molecular biology methods in detection of mycobacteria. Improved and newly developed test systems for the diagnosis of mycobacteria] Reischl U, et al. **Fortschr Med** 1996 Jul 1;114(18–19):237–41 (15 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Immune response to atypical mycobacteria. Appelberg R. **Res Immunol** 1996 Oct-Dec;147(8–9):560–4 (38 ref.)

ISOLATION & PURIFICATION

Mycobacterium xenopi--an unusual presentation as tenosynovitis of the wrist in an immunocompetent patient. Coombes GM, et al. **Br J Rheumatol** 1996 Oct; 35(10):1008–10 (25 ref.)

[Disseminated infection by Mycobacterium scrofulaceum: apropos of 3 cases (see comments)] Campos-Herrero MI, et al. **Enferm Infecc Microbiol Clin** 1996 Apr;14(4):258–60 (13 ref.) (Eng. Abstr.) Comment in: Enferm Infecc Microbiol Clin 1996 Dec;14(10):628. **(Spa)**

[Cutaneous infections by Mycobacterium marinum. Description of 3 cases and review of the literature] Dorronsoro I, et al. **Enferm Infecc Microbiol Clin** 1997 Feb;15(2):82–4 (22 ref.) (Eng. Abstr.) **(Spa)**

[Disseminated Mycobacterium genavense infection in patients with HIV infection. Description of 5 cases and review of the literature] Rodríguez P, et al. **Enferm Infecc Microbiol Clin** 1996 Apr;14(4):220–6 (35 ref.) (Eng. Abstr.) **(Spa)**

MYCOBACTERIUM AVIUM

Skin infection caused by Mycobacterium avium. Ichiki Y, et al. **Br J Dermatol** 1997 Feb;136(2):260–3 (19 ref.)

ISOLATION & PURIFICATION

Tuberculin conversion and abnormal chest radiograph in an infant. Magdorf K, et al. **Eur Respir J** 1996 Aug;9(8):1763–5 (12 ref.)

PATHOGENICITY

Co-infection of Toxoplasma gondii with other pathogens: pathogenicity and chemotherapy in animal models. Lacroix C, et al. **Curr Top Microbiol Immunol** 1996;219:223–33 (33 ref.)

Mycobacterial virulence factors. Gordon S, et al. **Soc Appl Bacteriol Symp Ser** 1996;25:10S–22S (120 ref.)

MYCOBACTERIUM AVIUM COMPLEX

[Mycobacterium avium complex infections: the point on the treatments] Brandissou S, et al. **Therapie** 1997 Jan-Feb; 52(1):65–71 (47 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

New trends in the drug therapy of localized and disseminated Mycobacterium avium complex infection [see comments] Sesin GP, et al. **Am J Health Syst Pharm** 1996 Nov 1; 53(21):2585–90 (29 ref.) Comment in: Am J Health Syst

Pharm 1997 May 15;54(10):1208–9.
Susceptibility testing of Mycobacterium avium complex isolates. Heifets L. **Antimicrob Agents Chemother** 1996 Aug; 40(8):1759–67 (117 ref.)

ISOLATION & PURIFICATION

Case report: a rare case of chylous ascites from Mycobacterium avium intracellulare in a patient with AIDS: review of the literature. Rollhauser C, et al. **Dig Dis Sci** 1996 Dec;41(12):2499–501 (21 ref.)
Mycobacterium avium complex (MAC) isolated from AIDS patients and the criteria required for its implication in disease. Hadad DJ, et al. **Rev Inst Med Trop Sao Paulo** 1995 Sep–Oct;37(5):375–83 (39 ref.)
Nontuberculous mycobacteria in patients with human immunodeficiency virus infection. Benator DA, et al. **Semin Respir Infect** 1996 Dec;11(4):285–300 (86 ref.)

PATHOGENICITY

[Attempts to elucidate reasons why mycobacterial infections are intractable, by using an experimental mouse infection model] Tomioka H. **Nihon Hansenbyo Gakkai Zasshi** 1996 Nov;65(3):155–65 (20 ref.) (Eng. Abstr.) **(Jpn)**

MYCOBACTERIUM AVIUM–INTRACELLULARE see **MYCOBACTERIUM AVIUM COMPLEX**

MYCOBACTERIUM AVIUM–INTRACELLULARE COMPLEX see **MYCOBACTERIUM AVIUM COMPLEX**

MYCOBACTERIUM AVIUM–INTRACELLULARE INFECTION

[Atypical mycobacteria. Disseminated infection in patients with hematologic diseases] Vejlgaard TB, et al. **Ugeskr Laeger** 1997 Sep 1;159(36):5362–7 (40 ref.) (Eng. Abstr.) **(Dan)**
[Mycobacterium avium otomastoiditis] de Juan Martín F, et al. **An Esp Pediatr** 1996 Dec;45(6):649–50 (11 ref.) **(Spa)**

COMPLICATIONS

Recent advances. HIV infection–II. Beiser C. **BMJ** 1997 Feb 22;314(7080):579–83 (56 ref.)
Intrathoracic Mycobacterium avium complex infection in immunocompetent children: case report and review. Fergie JE, et al. **Clin Infect Dis** 1997 Feb;24(2):250–3 (22 ref.)
Spinal cord compression due to concomitant primary lymphoma and Mycobacterium avium–intracellulare infection of the paravertebral muscles in an AIDS patient [letter] Moulignier A, et al. **Eur J Clin Microbiol Infect Dis** 1996 Nov;15(11):891–3 (15 ref.)
Nontuberculous mycobacteria in patients with human immunodeficiency virus infection. Benator DA, et al. **Semin Respir Infect** 1996 Dec;11(4):285–300 (86 ref.)
Mycobacterium avium complex in AIDS: who, when, where, why and how? Pozniak AL, et al. **Soc Appl Bacteriol Symp Ser** 1996;25:40S–46S (45 ref.)

DIAGNOSIS

Mycobacterium avium complex (MAC) isolated from AIDS patients and the criteria required for its implication in disease. Hadad DJ, et al. **Rev Inst Med Trop Sao Paulo** 1995 Sep–Oct;37(5):375–83 (39 ref.)
The application of molecular techniques to the diagnosis and epidemiology of mycobacterial diseases. Butcher PD, et al. **Soc Appl Bacteriol Symp Ser** 1996;25:53S–71S (140 ref.)
[Ubiquitous mycobacteria: clinical and microbiological aspects] Schütt-Gerowitt H. **Med Klin** 1996 Oct 15; 91(10):654–9 (32 ref.) **(Ger)**

DRUG THERAPY

Disseminated Mycobacterium avium complex infection: implications of recent clinical trials on prophylaxis and treatment. Benson CA. **AIDS Clin Rev** 1997–98;:271–87 (37 ref.)
New trends in the drug therapy of localized and disseminated Mycobacterium avium complex infection [see comments] Sesin GP, et al. **Am J Health Syst Pharm** 1996 Nov 1; 53(21):2585–90 (29 ref.) Comment in: Am J Health Syst Pharm 1997 May 15;54(10):1208–9.
Susceptibility testing of Mycobacterium avium complex isolates. Heifets L. **Antimicrob Agents Chemother** 1996 Aug; 40(8):1759–67 (117 ref.)
Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease. Brown BA, et al. **Clin Infect Dis** 1997 May;24(5):958–64 (25 ref.)
Mycobacterium avium complex infection. Pharmacokinetic and pharmacodynamic considerations that may improve clinical outcomes. Peloquin CA. **Clin Pharmacokinet** 1997 Feb;32(2):132–44 (60 ref.)
The use of rifabutin in Europe for the treatment of mycobacterial infection in AIDS patients. Dautzenberg B. **Infection** 1997 Jan–Feb;25(1):63–6 (16 ref.)
Uveitis associated with rifabutin therapy: a clinical alert. Petrowski JT 3rd. **J Am Optom Assoc** 1996 Nov; 67(11):693–6 (17 ref.)
Future indications for macrolides. Tarlow MJ, et al. **Pediatr Infect Dis J** 1997 Apr;16(4):457–62 (27 ref.)
New developments in the treatment of nontuberculous mycobacterial (NTM) disease. Griffith DE, et al. **Semin Respir Infect** 1996 Dec;11(4):301–10 (54 ref.)
[Mycobacterium avium complex infections: the point on the treatments] Brandissou S, et al. **Therapie** 1997 Jan–Feb; 52(1):65–71 (47 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

The application of molecular techniques to the diagnosis and epidemiology of mycobacterial diseases. Butcher PD, et al. **Soc Appl Bacteriol Symp Ser** 1996;25:53S–71S (140 ref.)
Mycobacterium avium complex in AIDS: who, when, where, why and how? Pozniak AL, et al. **Soc Appl Bacteriol Symp Ser** 1996;25:40S–46S (45 ref.)
[Mycobacterium avium infection in HIV-infected patients: epidemiology, diagnosis, prevention and treatment (see comments)] Schneider MM, et al. **Ned Tijdschr Geneeskd** 1997 Jan 11;141(2):80–3 (46 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1997 Mar 22;141(12):602–3. **(Dut)**

ETIOLOGY

Case report: a rare case of chylous ascites from Mycobacterium avium intracellulare in a patient with AIDS: review of the literature. Rollhauser C, et al. **Dig Dis Sci** 1996 Dec;41(12):2499–501 (21 ref.)

IMMUNOLOGY

Nontuberculous mycobacteria in patients with human immunodeficiency virus infection. Benator DA, et al. **Semin Respir Infect** 1996 Dec;11(4):285–300 (86 ref.)
[Attempts to elucidate reasons why mycobacterial infections are intractable, by using an experimental mouse infection model] Tomioka H. **Nihon Hansenbyo Gakkai Zasshi** 1996 Nov;65(3):155–65 (20 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Disseminated Mycobacterium avium complex infection: implications of recent clinical trials on prophylaxis and treatment. Benson CA. **AIDS Clin Rev** 1997–98;:271–87 (37 ref.)
The role of advanced generation macrolides in the prophylaxis and treatment of Mycobacterium avium complex (MAC) infections. Amsden GW, et al. **Drugs** 1997 Jul;54(1):69–80 (63 ref.)
Against the proposition: all patients with advanced HIV disease should be offered rifabutin prophylaxis. Pozniak A, et al. **Genitourin Med** 1996 Aug;72(4):269–71 (14 ref.)
Is rifabutin prophylaxis against Mycobacterium avium complex infection in HIV infection worthwhile? The net impact on patients suggests not. Stephenson JM, et al. **Genitourin Med** 1996 Aug;72(4):272–6 (10 ref.)
Prophylaxis against Mycobacterium avium–intracellulare complex infections in human immunodeficiency virus–infected patients. Nightingale SD. **Infection** 1997 Jan–Feb;25(1):67–70 (9 ref.)
Therapeutic options for the management and prevention of Mycobacterium avium complex infection in patients with the acquired immunodeficiency syndrome. Tartaglione TA. **Pharmacotherapy** 1996 Mar–Apr;16(2):171–82 (89 ref.)
[Current status in the prevention of Mycobacterium avium complex infections in patients with HIV infection] Doco-Lecompte T, et al. **Ann Med Interne (Paris)** 1997; 148(2):167–71 (21 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Bronchial artery aneurysms in association with Mycobacterium avium intracellulare complex. Siegler CM, et al. **J Thorac Imaging** 1996 Spring;11(2):155–7 (15 ref.)

THERAPY

Therapeutic options for the management and prevention of Mycobacterium avium complex infection in patients with the acquired immunodeficiency syndrome. Tartaglione TA. **Pharmacotherapy** 1996 Mar–Apr;16(2):171–82 (89 ref.)

MYCOBACTERIUM BOVIS

Correlation of granuloma structure with clinical outcome defines two types of idiopathic disseminated BCG infection. Emile JF, et al. **J Pathol** 1997 Jan;181(1):25–30 (35 ref.)
[The Calmette-Guérin bacillus (BCG). An agent to consider in pediatric infection] Marcelino F, et al. **Acta Med Port** 1996 Oct–Dec;9(10–12):397–400 (12 ref.) (Eng. Abstr.) **(Por)**

IMMUNOLOGY

The role of immunotherapy in urologic malignancies. Abubakr YA, et al. **Cancer Treat Res** 1996;88:235–48 (86 ref.)
Vaccination against leprosy--the view from 1996 [editorial] Fine PE, et al. **Lepr Rev** 1996 Dec;67(4):249–52 (18 ref.)
Vaccination of the badger (Meles meles) against Mycobacterium bovis. Hughes MS, et al. **Vet Microbiol** 1996 Aug;51(3–4):363–79 (115 ref.)

PATHOGENICITY

The bovine tuberculosis cycle--an African perspective. Daborn CJ, et al. **Soc Appl Bacteriol Symp Ser** 1996; 25:27S–32S (23 ref.)
Mycobacterial virulence factors. Gordon S, et al. **Soc Appl Bacteriol Symp Ser** 1996;25:10S–22S (120 ref.)

MYCOBACTERIUM HAEMOPHILUM

PATHOGENICITY

Mycobacterium haemophilum: microbiology and expanding clinical and geographic spectra of disease in humans. Saubolle MA, et al. **Clin Microbiol Rev** 1996 Oct; 9(4):435–47 (56 ref.)

MYCOBACTERIUM INFECTIONS

Mycobacterial complications of HIV infection. Chin DP, et al. **Clin Chest Med** 1996 Dec;17(4):697–711 (155 ref.)
Mycobacterial infections: new threats from old disease. Preheim LC, et al. **Compr Ther** 1997 May;23(5):310–8 (19 ref.)
Nontuberculous mycobacterial disease in children. Correa AG, et al. **Semin Respir Infect** 1996 Dec;11(4):262–71 (53 ref.)

COMPLICATIONS

Infections in solid-organ transplant recipients. Patel R, et al. **Clin Microbiol Rev** 1997 Jan;10(1):86–124 (800 ref.)
Mycobacteriosis and HIV infection: the new public health challenge. Porter JD. **J Antimicrob Chemother** 1996 May; 37 Suppl B:113–20 (35 ref.)
Nontuberculous mycobacterial pulmonary disease in cystic fibrosis. Olivier KN, et al. **Semin Respir Infect** 1996 Dec; 11(4):272–84 (48 ref.)

DIAGNOSIS

Gene amplification in the diagnosis of mycobacterial infections. Soini H, et al. **APMIS** 1997 May;105(5):345–53 (57 ref.)
Mycobacteriology laboratory. Heifets L. **Clin Chest Med** 1997 Mar;18(1):35–53 (68 ref.)
Disseminated Mycobacterium simiae infection in a patient with AIDS: clinical features and treatment. Koeck JL, et al. **Clin Infect Dis** 1996 Oct;23(4):832–3 (7 ref.)
Otitis media and mastoiditis due to Mycobacterium fortuitum: case report, review of four cases, and a cautionary note. Plemmons RM, et al. **Clin Infect Dis** 1996 Jun;22(6):1105–6 (10 ref.)
Diagnosis of tuberculosis and other diseases caused by mycobacteria. Salfinger M. **Infection** 1997 Jan–Feb; 25(1):60–2 (5 ref.)
Nontuberculous mycobacterial disease in the immunocompetent adult. Rosenzweig DY. **Semin Respir Infect** 1996 Dec;11(4):252–61 (75 ref.)
The application of molecular techniques to the diagnosis and epidemiology of mycobacterial diseases. Butcher PD, et al. **Soc Appl Bacteriol Symp Ser** 1996;25:53S–71S (140 ref.)
On the development of mycobacterial infections II. Changing mycobacterial infection spectrum in the Cologne area 1983–1993. Schütt-Gerowitt H. **Zentralbl Bakteriol** 1995 Dec;283(2):225–38 (71 ref.)

DRUG THERAPY

The value of in vitro drug activity and pharmacokinetics in predicting the effectiveness of antimycobacterial therapy: a critical review. Burman WJ. **Am J Med Sci** 1997 Jun; 313(6):355–63 (100 ref.)
Nontuberculous mycobacterial infections. Guay DR. **Ann Pharmacother** 1996 Jul–Aug;30(7–8):819–30 (199 ref.)
Epidemiology of infection by nontuberculous mycobacteria. Falkinham JO 3rd. **Clin Microbiol Rev** 1996 Apr; 9(2):177–215 (571 ref.)
The pharmacology, metabolism, and chemistry of clofazimine. O'Connor R, et al. **Drug Metab Rev** 1995; 27(4):591–614 (152 ref.)
In-vitro sensitivities and treatment of less common mycobacteria. Watt B. **J Antimicrob Chemother** 1997 May; 39(5):567–74 (56 ref.)
Clinical experience with rifabutin in the treatment of mycobacterial infections. De Cian W, et al. **Scand J Infect Dis Suppl** 1995;98:22–6 (28 ref.)
[Value of ciprofloxacin in the therapy of tuberculosis and other mycobacterioses] Padeiskaia EN. **Antibiot Khimioter** 1997;42(6):15–25 (69 ref.) **(Rus)**

EPIDEMIOLOGY

Epidemiology of infection by nontuberculous mycobacteria. Falkinham JO 3rd. **Clin Microbiol Rev** 1996 Apr; 9(2):177–215 (571 ref.)
Epidemiological and clinical aspects of mycobacterial infections. Opravil M. **Infection** 1997 Jan–Feb;25(1):56–9 (33 ref.)
DNA insertion sequences and the molecular epidemiology of Salmonella and Mycobacterium. Stanley J, et al. **J Med Microbiol** 1996 Oct;45(4):236–51 (116 ref.)
Epidemiology of disease caused by nontuberculous mycobacteria. Horsburgh CR Jr. **Semin Respir Infect** 1996 Dec;11(4):244–51 (111 ref.)

MYCOBACTERIUM INFECTIONS

Nontuberculous mycobacterial pulmonary disease in cystic fibrosis. Olivier KN, et al. **Semin Respir Infect** 1996 Dec; 11(4):272–84 (48 ref.)

The application of molecular techniques to the diagnosis and epidemiology of mycobacterial diseases. Butcher PD, et al. **Soc Appl Bacteriol Symp Ser** 1996;25:53S–71S (140 ref.)

ETIOLOGY

Mycobacteria as possible causes of sarcoidosis and Crohn's disease. McFadden JJ, et al.
Soc Appl Bacteriol Symp Ser 1996;25:47S–52S (45 ref.)

GENETICS

Unravelling the genetic basis of susceptibility to mycobacterial infection. Levin M, et al. **J Pathol** 1997 Jan; 181(1):5–7 (22 ref.)

IMMUNOLOGY

In vitro cellular and cytokine responses to mycobacterial antigens: application to diagnosis of tuberculosis infection and assessment of response to mycobacterial vaccines. Lein AD, et al. **Am J Med Sci** 1997 Jun;313(6):364–71 (66 ref.)

Modulation of protective and pathological immunity in mycobacterial infections. Ottenhoff TH, et al.
Int Arch Allergy Immunol 1997 Aug;113(4):400–8 (70 ref.)

Function of metal–ion homeostasis in the cell division cycle, mitochondrial protein processing, sensitivity to mycobacterial infection and brain function. Supek F, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):321–30 (73 ref.)

Cytokine networks with infection: mycobacterial infections, leishmaniasis, human immunodeficiency virus infection, and sepsis. DiPiro JT. **Pharmacotherapy** 1997 Mar–Apr; 17(2):205–23 (175 ref.)

Host defense against nontuberculous mycobacterial infections. Holland SM. **Semin Respir Infect** 1996 Dec; 11(4):217–30 (104 ref.)

Nontuberculous mycobacterial disease in the immunocompetent adult. Rosenzweig DY.
Semin Respir Infect 1996 Dec;11(4):252–61 (75 ref.)

[Host defense against mycobacterial infections—new strategies for combatting multidrug–resistant mycobacterial diseases] Kobayashi K. **Nippon Saikingaku Zasshi** 1997 Apr; 52(2):485–91 (15 ref.) **(Jpn)**

MICROBIOLOGY

Nontuberculous mycobacterial infections. Guay DR.
Ann Pharmacother 1996 Jul–Aug;30(7–8):819–30 (199 ref.)

Mycobacteriology laboratory. Heifets L. **Clin Chest Med** 1997 Mar;18(1):35–53 (68 ref.)

Nontuberculous mycobacterial meningitis: report of two cases and review. Flor A, et al. **Clin Infect Dis** 1996 Dec; 23(6):1266–73 (43 ref.)

Mycobacterium haemophilum: microbiology and expanding clinical and geographic spectra of disease in humans. Saubolle MA, et al. **Clin Microbiol Rev** 1996 Oct; 9(4):435–47 (56 ref.)

Two case reports and review of vascular catheter–associated bacteremia caused by nontuberculous Mycobacterium species. Rodgers GL, et al. **Pediatr Infect Dis J** 1996 Mar; 15(3):260–4 (50 ref.)

Microbiology of nontuberculosis mycobacteria.
Gangadharam PR. **Semin Respir Infect** 1996 Dec; 11(4):231–43 (71 ref.)

Mycobacterial virulence factors. Gordon S, et al.
Soc Appl Bacteriol Symp Ser 1996;25:10S–22S (120 ref.)

The biology of the genus Mycobacterium. Grange JM.
Soc Appl Bacteriol Symp Ser 1996;25:1S–9S (43 ref.)

Activity of biocides against mycobacteria. Russell AD.
Soc Appl Bacteriol Symp Ser 1996;25:87S–101S (135 ref.)

[Recent advances in diagnostic microbiology for mycobacterial infections] Ichiyama S. **Rinsho Byori** 1996 Sep;44(9):813–7 (16 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Modulation of protective and pathological immunity in mycobacterial infections. Ottenhoff TH, et al.
Int Arch Allergy Immunol 1997 Aug;113(4):400–8 (70 ref.)

PREVENTION & CONTROL

Biosafety in the clinical mycobacteriology laboratory. Richmond JY, et al. **Clin Lab Med** 1996 Sep;16(3):527–50 (38 ref.)

RADIOGRAPHY

Mycobacterium szulgai infection of the lung: case report and review of an unusual pathogen. Benator DA, et al.
Am J Med Sci 1997 Jun;313(6):346–51 (25 ref.)

THERAPY

Therapy of mycobacterial infections. Holland SM.
Res Immunol 1996 Oct–Dec;147(8–9):572–81 (79 ref.)

[Host defense against mycobacterial infections—new strategies for combatting multidrug–resistant mycobacterial diseases] Kobayashi K. **Nippon Saikingaku Zasshi** 1997 Apr; 52(2):485–91 (15 ref.) **(Jpn)**

TRANSMISSION

Activity of biocides against mycobacteria. Russell AD.
Soc Appl Bacteriol Symp Ser 1996;25:87S–101S (135 ref.)

VETERINARY

Naturally acquired leprosy in two wild–born chimpanzees. Alford PL, et al. **Lab Anim Sci** 1996 Jun;46(3):341–6 (29 ref.)

MYCOBACTERIUM INFECTIONS, ATYPICAL

Mycobacterium fortuitum infection of the sternum. Review of the literature and case illustration. Samuels LE, et al. **Arch Surg** 1996 Dec;131(12):1344–6 (7 ref.)

Mycobacterial complications of HIV infection. Chin DP, et al. **Clin Chest Med** 1996 Dec;17(4):697–711 (155 ref.)

Nontuberculous mycobacterial cervical adenitis. Suskind DL, et al. **Clin Pediatr (Phila)** 1997 Jul;36(7):403–9 (28 ref.)

Nontuberculous mycobacteria. Griffith DE.
Curr Opin Pulm Med 1997 Mar;3(2):139–45 (37 ref.)

Nontuberculous mycobacterial infections. French AL, et al. **Med Clin North Am** 1997 Mar;81(2):361–79 (84 ref.)

[Disseminated Mycobacterium genavense infection in patients with HIV infection. Description of 5 cases and review of the literature] Rodríguez P, et al.
Enferm Infecc Microbiol Clin 1996 Apr;14(4):220–6 (35 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. **Am J Respir Crit Care Med** 1997 Aug;156(2 Pt 2):S1–25 (218 ref.)

Mycobacterium smegmatis infection in a healthy woman following a facelift: case report and review of the literature. Pennekamp A, et al. **Ann Plast Surg** 1997 Jul;39(1):80–3 (12 ref.)

Mycobacterium xenopi—an unusual presentation as tenosynovitis of the wrist in an immunocompetent patient. Coombes GM, et al. **Br J Rheumatol** 1996 Oct; 35(10):1008–10 (25 ref.)

M. Kansasii pulmonary disease in idiopathic CD4+ T–lymphocytopenia. Anzalone G, et al. **Eur Respir J** 1996 Aug;9(8):1754–6 (14 ref.)

Atypical mycobacteriosis as a complication of talc pneumoconiosis. De Coster C, et al. **Eur Respir J** 1996 Aug;9(8):1757–9 (12 ref.)

Facial sporotrichoid infection with Mycobacterium marinum. Brady RC, et al. **J Pediatr** 1997 Feb;130(2):324–6 (13 ref.)

[A case of arthritis of the wrist caused by Mycobacterium marinum. Review of the literature] Flisch CW, et al.
Ann Chir Main Memb Super 1996;15(4):238–43 (15 ref.) (Eng. Abstr.) **(Fre)**

[Atypical mycobacterial skin infections] Gbery IP, et al.
Sante 1996 Sep–Oct;6(5):317–22 (31 ref.) (Eng. Abstr.) **(Fre)**

[Cervical lymphadenitis in an immunocompetent patient: Mycobacterium gordonae as the cause?] Fleisch F, et al. **Dtsch Med Wochenschr** 1997 Jan 17;122(3):51–3 (11 ref.) (Eng. Abstr.) **(Ger)**

[Molecular biology methods in detection of mycobacteria. Improved and newly developed test systems for the diagnosis of mycobacteria] Reischl U, et al.
Fortschr Med 1996 Jul 1;114(18–19):237–41 (15 ref.) (Eng. Abstr.) **(Ger)**

[Illnesses caused by ubiquitous mycobacteria. Clinical, therapeutic and microbiological aspects] Schütt–Gerowitt H. **Fortschr Med** 1996 Jul 1;114(18–19):233–6 (10 ref.) (Eng. Abstr.) **(Ger)**

[Skin infections caused by Mycobacterium gordonae. Case report and review of the literature] Weyers W, et al.
Hautarzt 1996 Oct;47(10):771–5 (48 ref.) (Eng. Abstr.) **(Ger)**

[Ubiquitous mycobacteria: clinical and microbiological aspects] Schütt–Gerowitt H. **Med Klin** 1996 Oct 15; 91(10):654–9 (32 ref.) **(Ger)**

[Cutaneous infections by Mycobacterium marinum. Description of 3 cases and review of the literature] Dorronsoro I, et al. **Enferm Infecc Microbiol Clin** 1997 Feb;15(2):82–4 (22 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

New antimycobacterial agents. Yew WW, et al.
Monaldi Arch Chest Dis 1996 Oct;51(5):394–404 (143 ref.)

IMMUNOLOGY

Immune response to atypical mycobacteria. Appelberg R. **Res Immunol** 1996 Oct–Dec;147(8–9):560–4 (38 ref.)

MICROBIOLOGY

[Disseminated infection by Mycobacterium scrofulaceum: apropos of 3 cases (see comments)] Campos–Herrero MI, et al. **Enferm Infecc Microbiol Clin** 1996 Apr;14(4):258–60 (13 ref.) (Eng. Abstr.) Comment in: Enferm Infecc Microbiol Clin 1996 Dec;14(10):628. **(Spa)**

PREVENTION & CONTROL

[Prevention of atypical mycobacterium infections in immunocompromised patients] Meynard JL.
Ann Med Interne (Paris) 1997;148(3):230–4 (38 ref.) (Eng. Abstr.) **(Fre)**

MYCOBACTERIUM INTRACELLULARE see **MYCOBACTERIUM AVIUM COMPLEX**

MYCOBACTERIUM INTRACELLULARE INFECTION see **MYCOBACTERIUM AVIUM–INTRACELLULARE INFECTION**

MYCOBACTERIUM LEPRAE

see related
LEPROSTATIC AGENTS

The epidemiology of Mycobacterium leprae: recent insight. van Beers SM, et al. **FEMS Microbiol Lett** 1996 Mar 1; 136(3):221–30 (49 ref.)

DRUG EFFECTS

Vaccination against leprosy—the view from 1996 [editorial] Fine PE, et al. **Lepr Rev** 1996 Dec;67(4):249–52 (18 ref.)

IMMUNOLOGY

Immunoprophylaxis against leprosy; the case for improved vaccines against leprosy. Britton WJ.
Int J Lepr Other Mycobact Dis 1996 Dec;64(4 Suppl):S77–9 (12 ref.)

The contribution of serological tests to leprosy control. Klatser PR, et al. **Int J Lepr Other Mycobact Dis** 1996 Dec;64(4 Suppl):S63–6; discussion S66–7 (21 ref.)

Immunological and functional characterization of Mycobacterium leprae protein antigens: an overview. Thole JE, et al. **Mol Microbiol** 1995 Dec;18(5):791–800 (53 ref.)

IL12 and the human immune response to mycobacteria. Modlin RL, et al. **Res Immunol** 1995 Sep–Oct; 146(7–8):526–31 (43 ref.)

Humoral immunity in Hansen's disease. Cossermelli–Messina W, et al. **Rev Paul Med** 1995 Jul–Aug;113(4):929–34 (86 ref.)

METABOLISM

Mycobacterium leprae: biochemical studies of clinical relevance. Prabhakaran K. **Indian J Lepr** 1997 Apr–Jun; 69(2):173–8 (25 ref.)

MYCOBACTERIUM LEPRAEMURIUM

ISOLATION & PURIFICATION

Naturally acquired leprosy in two wild–born chimpanzees. Alford PL, et al. **Lab Anim Sci** 1996 Jun;46(3):341–6 (29 ref.)

MYCOBACTERIUM PARATUBERCULOSIS

GENETICS

Paratuberculosis and molecular biology [editorial; comment] Clarke CJ. **Vet J** 1997 May;153(3):245–7 (12 ref.) Comment on: Vet J 1997 May;153(3):260–86.

ISOLATION & PURIFICATION

Relationship between soil type and Mycobacterium paratuberculosis. Johnson–Ifearulundu YJ, et al.
J Am Vet Med Assoc 1997 Jun 15;210(12):1735–40 (44 ref.)

Mycobacterium paratuberculosis and Crohn's disease. Engstrand L. **Scand J Infect Dis Suppl** 1995;98:27–9 (21 ref.)

Mycobacteria as possible causes of sarcoidosis and Crohn's disease. McFadden JJ, et al.
Soc Appl Bacteriol Symp Ser 1996;25:47S–52S (45 ref.)

PATHOGENICITY

Paratuberculosis: a potential zoonosis? Chiodini RJ, et al. **Vet Clin North Am Food Anim Pract** 1996 Jul;12(2):457–67 (25 ref.)

[Mycobacterium paratuberculosis—an etiological agent in Crohn disease?] Andersen J, et al. **Ugeskr Laeger** 1997 Jan 6;159(2):159–63 (40 ref.) **(Dan)**

MYCOBACTERIUM TUBERCULOSIS

see related
ANTITUBERCULAR AGENTS

The origin and erratic global spread of tuberculosis. How the past explains the present and is the key to the future. Stead WW. **Clin Chest Med** 1997 Mar;18(1):65–77 (60 ref.)

How contagious is tuberculosis? Sepkowitz KA.
Clin Infect Dis 1996 Nov;23(5):954–62 (96 ref.)

The mycobacteriology laboratory. Past, present, and future. Heifets LB. **Clin Lab Med** 1996 Sep;16(3):513–25 (32 ref.)

Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Aguado JM, et al. **Transplantation** 1997 May 15; 63(9):1278–86 (22 ref.)

CYTOLOGY

The viability of Mycobacterium tuberculosis in formalin-fixed pulmonary autopsy tissue: review of the literature and brief report. Kappel TJ, et al. **Hum Pathol** 1996 Dec;27(12):1361-4 (34 ref.)

DRUG EFFECTS

Molecular mechanisms of drug resistance in Mycobacterium tuberculosis. Blanchard JS. **Annu Rev Biochem** 1996; 65:215-39 (127 ref.)

Future directions in the development of new antitubercular drugs. Where do we go from here? Yew WW, et al. **Drugs Aging** 1997 Jun;10(6):405-10 (66 ref.)

Modern methods for assessing the drugs used in the chemotherapy of mycobacterial disease. Mitchison DA. **Soc Appl Bacteriol Symp Ser** 1996;25:72S-80S (50 ref.)

Life without KatG. Zhang Y. **Trends Microbiol** 1996 Nov; 4(11):415-6 (15 ref.)

[Multiple-drug-resistant tubercle bacilli] Kuze F. **Nippon Naika Gakkai Zasshi** 1997 Feb 10;86(2):319-23 (10 ref.) **(Jpn)**

GENETICS

Differentially expressed genes of Mycobacterium tuberculosis. Marston BJ, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:32-41 (51 ref.)

Molecular diagnosis, detection of drug resistance and epidemiology of tuberculosis. Drobniewski FA, et al. **Br J Hosp Med** 1996 Sep 4-17;56(5):204-8 (22 ref.)

Genetics of drug resistance in tuberculosis. Telenti A. **Clin Chest Med** 1997 Mar;18(1):55-64 (52 ref.)

Detection of Mycobacterium tuberculosis by molecular methods. Jonas V, et al. **Clin Lab Med** 1997 Mar; 17(1):119-28 (44 ref.)

Critical assessment of gene amplification approaches on the diagnosis of tuberculosis. Forbes BA. **Immunol Invest** 1997 Jan-Feb;26(1-2):105-16 (44 ref.)

Loss of oxyR in Mycobacterium tuberculosis. Deretic V, et al. **Trends Microbiol** 1997 Sep;5(9):367-72 (49 ref.)

Why sequence the genome of Mycobacterium tuberculosis? Cole ST. **Tuber Lung Dis** 1996 Dec;77(6):486-90 (46 ref.)

The contribution of molecular biology to Mycobacterium avium subspecies Paratuberculosis research [see comments] Stevenson K, et al. **Vet J** 1997 May;153(3):269-86 (165 ref.) Comment in: Vet J 1997 May;153(3):245-7.

[Molecular biology methods in detection of mycobacteria. Improved and newly developed test systems for the diagnosis of mycobacteria] Reischl U, et al. **Fortschr Med** 1996 Jul 1;114(18-19):237-41 (15 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

In vitro cellular and cytokine responses to mycobacterial antigens: application to diagnosis of tuberculosis infection and assessment of response to mycobacterial vaccines. Lein AD, et al. **Am J Med Sci** 1997 Jun;313(6):364-71 (66 ref.)

The role of cytokines in the immune response to tuberculosis. Kaplan G, et al. **Res Immunol** 1996 Oct-Dec; 147(8-9):565-72 (62 ref.)

IL12 and the human immune response to mycobacteria. Modlin RL, et al. **Res Immunol** 1995 Sep-Oct; 146(7-8):526-31 (43 ref.)

Host responses and antigens involved in protective immunity to Mycobacterium tuberculosis. Andersen P. **Scand J Immunol** 1997 Feb;45(2):115-31 (222 ref.)

ISOLATION & PURIFICATION

Tuberculous infection of the hand and wrist. Visuthikosol V, et al. **Ann Plast Surg** 1996 Jul;37(1):55-9 (23 ref.)

Simultaneous occurrence of papulonecrotic tuberculide and erythema induratum and the identification of Mycobacterium tuberculosis DNA by polymerase chain reaction. Chuang YH, et al. **Br J Dermatol** 1997 Aug; 137(2):276-81 (33 ref.)

Bacterial L-forms research in China. Huang G, et al. **Chin Med J (Engl)** 1996 Jan;109(1):18-20 (0 ref.)

Primary processing of specimens and isolation and cultivation of mycobacteria. Hall GS. **Clin Lab Med** 1996 Sep; 16(3):551-67 (47 ref.)

Detection of Mycobacterium tuberculosis by molecular methods. Jonas V, et al. **Clin Lab Med** 1997 Mar; 17(1):119-28 (44 ref.)

Methods for the rapid identification of mycobacterial species. Roberts GD, et al. **Clin Lab Med** 1996 Sep;16(3):603-15 (40 ref.)

[New microbiological Techniques in diagnosis of tuberculosis] Golyshevskaia VI, et al. **Probl Tuberk** 1996; (6):22-5 (17 ref.) (Eng. Abstr.) **(Rus)**

PATHOGENICITY

Current issues in the pathogenesis and management of HIV-related tuberculosis. Daley CL. **AIDS Clin Rev** 1997-98;:289-321 (96 ref.)

Differentially expressed genes of Mycobacterium tuberculosis. Marston BJ, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:32-41 (51 ref.)

Significance of the antimicrobial resistance gene, Nramp1, in resistance to virulent Mycobacterium tuberculosis infection. North RJ, et al. **Res Immunol** 1996 Oct-Dec; 147(8-9):493-9 (13 ref.)

Mycobacterial virulence factors. Gordon S, et al. **Soc Appl Bacteriol Symp Ser** 1996;25:10S-22S (120 ref.)

Characterization of the Mycobacterium tuberculosis phagosome. Clemens DL. **Trends Microbiol** 1996 Mar; 4(3):113-8 (39 ref.)

In search of tuberculosis virulence genes. Collins DM. **Trends Microbiol** 1996 Nov;4(11):426-30 (33 ref.)

[BCG vaccination] Hutás I. **Orv Hetil** 1996 Mar 24; 137(12):619-22 (31 ref.) (Eng. Abstr.) **(Hun)**

[Attempts to elucidate reasons why mycobacterial infections are intractable, by using an experimental mouse infection model] Tomioka H. **Nihon Hansenbyo Gakkai Zasshi** 1996 Nov;65(3):155-65 (20 ref.) (Eng. Abstr.) **(Jpn)**

MYCOLOGICAL TYPING TECHNIQUES

Strain-relatedness among different populations of the pathogenic yeast Candida albicans analyzed by DNA-based typing methods. Tanaka K. **Nagoya J Med Sci** 1997 Mar;60(1-2):1-14 (55 ref.)

MYCOLOGY

[Mycology of usefulness to clinicians] Torres-Rodríguez JM. **Rev Clin Esp** 1997 Apr;197 Suppl 1:3-11 (40 ref.) **(Spa)**

METHODS

Antifungal susceptibility testing: technical advances and potential clinical applications[see comments] Pfaller MA, et al. **Clin Infect Dis** 1997 May;24(5):776-84 (75 ref.) Comment in: Clin Infect Dis 1997 May;24(5):775.

Update on detection of bacteremia and fungemia. Reimer LG, et al. **Clin Microbiol Rev** 1997 Jul;10(3):444-65 (218 ref.)

Calorimetry of whole yeast cells. Ashby LJ, et al. **Methods Mol Biol** 1996;53:367-82 (14 ref.)

Chromosomal localization of genes through pulsed-field gel electrophoresis techniques. Bignell GR, et al. **Methods Mol Biol** 1996;53:79-88 (11 ref.)

Genomic yeast DNA clone banks. Construction and gene isolation. Bignell GR, et al. **Methods Mol Biol** 1996; 53:155-87 (21 ref.)

Isolation of mitochondrial DNA. Bignell GR, et al. **Methods Mol Biol** 1996;53:109-16 (11 ref.)

Preparation of total RNA. Brown AJ. **Methods Mol Biol** 1996;53:269-76 (9 ref.)

mRNA abundance and half-life measurements. Brown AJ, et al. **Methods Mol Biol** 1996;53:277-95 (10 ref.)

Protoplast fusion in Saccharomyces cerevisiae. Curran BP, et al. **Methods Mol Biol** 1996;53:45-9 (6 ref.)

Peroxisome isolation. Distel B, et al. **Methods Mol Biol** 1996; 53:133-8 (7 ref.)

Insertional mutagenesis by Ty elements in Saccharomyces cerevisiae. Garfinkel DJ. **Methods Mol Biol** 1996;53:227-37 (23 ref.)

Electrophoretic analysis of yeast proteins. Grant CM, et al. **Methods Mol Biol** 1996;53:259-67 (8 ref.)

Determination of chromosome ploidy in yeast. Hadfield C, et al. **Methods Mol Biol** 1996;53:205-16 (10 ref.)

Preparation and use of yeast cell-free translation lysate. Hartley AD, et al. **Methods Mol Biol** 1996;53:249-57 (9 ref.)

Fluorescence microscopy methods. Hašek J, et al. **Methods Mol Biol** 1996;53:391-405 (14 ref.)

Karyotyping of yeast strains by pulsed-field gel electrophoresis. Johnston JR. **Methods Mol Biol** 1996; 53:69-78 (30 ref.)

Determination of plasmid copy number in yeast. Jordan BE, et al. **Methods Mol Biol** 1996;53:193-203 (5 ref.)

Yeast colony hybridization. Kleinman MJ. **Methods Mol Biol** 1996;53:189-92 (1 ref.)

Genotoxicity testing in Schizosaccharomyces pombe. McAthey P. **Methods Mol Biol** 1996;53:343-53 (3 ref.)

Reporter gene systems for assaying gene expression in yeast. Mount RC, et al. **Methods Mol Biol** 1996;53:239-48 (8 ref.)

Transformation of lithium-treated yeast cells and the selection of auxotrophic and dominant markers. Mount RC, et al. **Methods Mol Biol** 1996;53:139-45 (19 ref.)

Chromosome engineering in yeast with a site-specific recombination system from a heterologous yeast plasmid. Oshima Y, et al. **Methods Mol Biol** 1996;53:217-25 (10 ref.)

Nystatin-rhodamine B assay for estimating activity of killer toxin from Kluyveromyces lactis. Palková Z, et al. **Methods Mol Biol** 1996;53:325-9 (5 ref.)

Killer plaque technique for selecting hybrids and cybrids obtained by induced protoplast fusion. Palková Z, et al. **Methods Mol Biol** 1996;53:339-42 (2 ref.)

Isolation of yeast plasma membranes. Panaretou B, et al. **Methods Mol Biol** 1996;53:117-21 (9 ref.)

Isolation of yeast DNA. Piper P. **Methods Mol Biol** 1996; 53:103-7 (6 ref.)

Induction of heat shock proteins and thermotolerance. Piper P. **Methods Mol Biol** 1996;53:313-7 (15 ref.)

The extraction and analysis of sterols from yeast. Quail MA, et al. **Methods Mol Biol** 1996;53:123-31 (7 ref.)

Polysome analysis. Sagliocco FA, et al. **Methods Mol Biol** 1996;53:297-311 (13 ref.)

Ascus dissection. Saunders-Singer C. **Methods Mol Biol** 1996; 53:59-67 (3 ref.)

Meiotic analysis. Spencer JF, et al. **Methods Mol Biol** 1996; 53:51-8 (9 ref.)

Maintenance and culture of yeasts. Spencer JF, et al. **Methods Mol Biol** 1996;53:5-15 (6 ref.)

Rare-mating and cytoduction in Saccharomyces cerevisiae. Spencer JF, et al. **Methods Mol Biol** 1996;53:39-44 (5 ref.)

Isolation and identification of yeasts from natural habitats. Spencer JF, et al. **Methods Mol Biol** 1996;53:1-4 (8 ref.)

Mutagenesis in yeast. Spencer JF, et al. **Methods Mol Biol** 1996;53:17-38 (22 ref.)

Purification and quantification of Saccharomyces cerevisiae cytochrome P450. Stansfield I, et al. **Methods Mol Biol** 1996;53:355-66 (4 ref.)

Light microscopy methods. Streiblová E, et al. **Methods Mol Biol** 1996;53:383-90 (5 ref.)

Immunoelectron microscopy. van Tuinen EJ. **Methods Mol Biol** 1996;53:407-22 (24 ref.)

Isolation, purification, and analysis of nuclear DNA in yeast taxonomy. Vaughan-Martini A, et al. **Methods Mol Biol** 1996;53:89-102 (14 ref.)

Rhodamine B assay for estimating activity of killer toxins permeabilizing cytoplasmic membranes. Vondrejs V, et al. **Methods Mol Biol** 1996;53:319-24 (4 ref.)

Application of killer toxins in stepwise selection of hybrids and cybrids obtained by induced protoplast fusion. Vondrejs V, et al. **Methods Mol Biol** 1996;53:331-8 (15 ref.)

MYCOPHENOLIC ACID

ADMINISTRATION & DOSAGE

[Mycophenolate mofetil--a new immunosuppressive agent] Bergan S, et al. **Tidsskr Nor Laegeforen** 1996 Aug 30; 116(20):2439-41 (10 ref.) (Eng. Abstr.) **(Nor)**

ANALOGS & DERIVATIVES

Mycophenolate mofetil: a unique immunosuppressive agent. Hood KA, et al. **Am J Health Syst Pharm** 1997 Feb 1; 54(3):285-94 (43 ref.)

A review of clinical experience with the novel immunosuppressive drug mycophenolate mofetil in renal transplantation. Behrend M. **Clin Nephrol** 1996 May; 45(5):336-41 (13 ref.)

The use of tacrolimus and mycophenolate mofetil after cardiac transplantation. Taylor DO. **Curr Opin Cardiol** 1997 Mar;12(2):161-5 (33 ref.)

Mycophenolate mofetil in kidney transplantation. Lui SL, et al. **Curr Opin Nephrol Hypertens** 1996 Nov;5(6):508-13 (54 ref.)

Clinically significant drug interactions with new immunosuppressive agents. Mignat C. **Drug Saf** 1997 Apr; 16(4):267-78 (62 ref.)

Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Simmons WD, et al. **Drug Saf** 1997 Aug;17(2):75-92 (68 ref.)

Mycophenolate mofetil for the transplanted kidney? **Drug Ther Bull** 1997 May;35(5):38-40 (9 ref.)

Mycophenolate mofetil. Lipsky JJ. **Lancet** 1996 Nov 16; 348(9038):1357-9 (28 ref.)

The use of Mycophenolate Mofetil (Cellcept) in renal transplantation [clinical conference] Vanrenterghem Y. **Nephron** 1997;76(4):392-9 (31 ref.)

Update on preclinical and clinical experience with mycophenolate mofetil. Sollinger HW. **Transplant Proc** 1996 Dec;28(6 Suppl 1):24-9 (66 ref.)

Rescue therapy with mycophenolate mofetil. Mycophenolate Mofetil Renal Refractory Rejection Study Group. Tomlanovich SJ. **Transplant Proc** 1996 Dec;28(6 Suppl 1):34-6 (33 ref.)

Pharmacodynamic monitoring of immunosuppressive drugs. Yatscoff RW, et al. **Transplant Proc** 1996 Dec;28(6):3013-5 (16 ref.)

The role of mycophenolate mofetil in clinical renal transplantation. Hodge EE. **World J Urol** 1996;14(4):249-55 (26 ref.)

[Mycophenolate mofetil. A new immunosuppressive agent in transplantation therapy] Pedersen EB. **Ugeskr Laeger** 1997 Jul 21;159(30):4664-8 (24 ref.) **(Dan)**

[Mycophenolate mofetil--a new immunosuppressive agent] Bergan S, et al. **Tidsskr Nor Laegeforen** 1996 Aug 30; 116(20):2439-41 (10 ref.) (Eng. Abstr.) **(Nor)**

THERAPEUTIC USE

Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. Kitchin JE, et al. **J Am Acad Dermatol** 1997 Sep;37(3 Pt 1):445-9 (25 ref.)

MYCOPLASMA

Enzootic pneumonia in pigs. Maes D, et al. **Vet Q** 1996 Sep; 18(3):104-9 (52 ref.)

ENZYMOLOGY

RNase P RNA of Mycoplasma capricolum. Ushida C, et al. **Mol Biol Rep** 1995-96;22(2-3):125-9 (28 ref.)

GENETICS

DNA amplification methods for diagnosis and epidemiological investigations of avian mycoplasmosis. Kempf I. **Acta Vet Hung** 1997;45(3):373-86 (65 ref.)

MYCOPLASMA

Molecular biology of mycoplasmas. Dybvig K, et al. **Annu Rev Microbiol** 1996;50:25–57 (207 ref.)
Complete genome sequences of cellular life forms: glimpses of theoretical evolutionary genomics. Koonin EV, et al. **Curr Opin Genet Dev** 1996 Dec;6(6):757–62 (39 ref.)
RNase P RNA of Mycoplasma capricolum. Ushida C, et al. **Mol Biol Rep** 1995–96;22(2–3):125–9 (28 ref.)
The minimal cell genome: "on being the right size" [comment] Maniloff J. **Proc Natl Acad Sci U S A** 1996 Sep 17; 93(19):10004–6 (25 ref.) Comment on: Proc Natl Acad Sci U S A 1996 Sep 17;93(19):10268–73.
Molecular biology of Mycoplasma. Christiansen G, et al. **Wien Klin Wochenschr** 1997 Aug 8;109(14–15):557–61 (23 ref.)
Mycoplasma genetic variation and its implication for pathogenesis. Citti C, et al. **Wien Klin Wochenschr** 1997 Aug 8;109(14–15):562–8 (29 ref.)
Comparative genomics of mycoplasmas. Razin S. **Wien Klin Wochenschr** 1997 Aug 8;109(14–15):551–6 (21 ref.)
[The 16S–23s rRNA intergenic spacer regions of mycoplasmas] Harasawa R. **Nippon Saikingaku Zasshi** 1996 Feb;51(2):583–8 (15 ref.) **(Jpn)**
[Molecular genetic approaches to the study of the persistence of pathogenic Mycoplasma] Zigangirova NA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 May–Jun; (3):39–42 (14 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Alternative inhibitors of mycoplasma adherence. Kahane I, et al. **Adv Exp Med Biol** 1996;408:107–11 (14 ref.)

ISOLATION & PURIFICATION

Changing expectations in the control of Mycoplasma gallisepticum. Kleven SH. **Acta Vet Hung** 1997; 45(3):299–305 (38 ref.)
Routine testing of cell cultures and their products for mycoplasma contamination. Stacey A, et al. **Methods Mol Biol** 1997;75:305–11 (6 ref.)
[The persistence of mycoplasmas in the infected organism: observations, causes and mechanisms, diagnosis] Prozorovskii SV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Jul–Aug; (4):47–51 (21 ref.) **(Rus)**

PATHOGENICITY

Infections due to species of Mycoplasma and Ureaplasma: an update. Taylor–Robinson D. **Clin Infect Dis** 1996 Oct; 23(4):671–82; quiz 683–4 (85 ref.)
Mycoplasmas: sophisticated, reemerging, and burdened by their notoriety. Baseman JB, et al. **Emerg Infect Dis** 1997 Jan–Mar;3(1):21–32 (79 ref.)
Non-cultivable phytopathogenic mycoplasmas: characterization, detection and perspectives for control. Garnier M. **Wien Klin Wochenschr** 1997 Aug 8; 109(14–15):613–7 (46 ref.)
[Molecular genetic approaches to the study of the persistence of pathogenic Mycoplasma] Zigangirova NA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 May–Jun; (3):39–42 (14 ref.) (Eng. Abstr.) **(Rus)**

MYCOPLASMA FERMENTANS

PATHOGENICITY

Infections due to species of Mycoplasma and Ureaplasma: an update. Taylor–Robinson D. **Clin Infect Dis** 1996 Oct; 23(4):671–82; quiz 683–4 (85 ref.)

MYCOPLASMA HOMINIS

Sternotomy infection with Mycoplasma hominis: a cause of "culture negative" wound infection. Mossad SB, et al. **J Cardiovasc Surg (Torino)** 1996 Oct;37(5):505–9 (29 ref.)
[Mycoplasma hominis. A rare causative agent of acute pyelonephritis] Küchle C, et al. **Dtsch Med Wochenschr** 1997 Apr 25;122(17):542–4 (15 ref.) (Eng. Abstr.) **(Ger)**
[The spread of Mycoplasma infections] Fovi G, et al. **Ann Ig** 1996 May–Jun;8(3):329–39 (61 ref.) **(Ita)**

PATHOGENICITY

Infections due to species of Mycoplasma and Ureaplasma: an update. Taylor–Robinson D. **Clin Infect Dis** 1996 Oct; 23(4):671–82; quiz 683–4 (85 ref.)

MYCOPLASMA INCOGNITUS see **MYCOPLASMA FERMENTANS**

MYCOPLASMA INFECTIONS

Sternotomy infection with Mycoplasma hominis: a cause of "culture negative" wound infection. Mossad SB, et al. **J Cardiovasc Surg (Torino)** 1996 Oct;37(5):505–9 (29 ref.)
Mycoplasma-associated pericarditis. Farraj RS, et al. **Mayo Clin Proc** 1997 Jan;72(1):33–6 (19 ref.)
Mycoplasmas and arthritides. Schaeverbeke T, et al. **Rev Rhum Engl Ed** 1997 Feb;64(2):120–8 (92 ref.)
[Mycoplasma pericarditis] Baba K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):600–1 (5 ref.) **(Jpn)**
[Myocarditis caused by Mycoplasma] Morimoto S. **Ryoikibetsu Shokogun Shirizu** 1996;(14):211–4 (24 ref.) **(Jpn)**

CLASSIFICATION

Infections due to species of Mycoplasma and Ureaplasma: an update. Taylor–Robinson D. **Clin Infect Dis** 1996 Oct; 23(4):671–82; quiz 683–4 (85 ref.)

COMPLICATIONS

[Mycoplasma infection and hemolytic anemia] Nasu K. **Nippon Rinsho** 1996 Sep;54(9):2545–9 (20 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Severe encephalitis in a three-year-old girl. Lum G, et al. **Pediatr Infect Dis J** 1996 Feb;15(2):181, 4–6 (12 ref.)
New developments in diagnostic and treatment of mycoplasma infections in humans. Bébéar C, et al. **Wien Klin Wochenschr** 1997 Aug 8;109(14–15):594–9 (29 ref.)
[Mycoplasma hominis. A rare causative agent of acute pyelonephritis] Küchle C, et al. **Dtsch Med Wochenschr** 1997 Apr 25;122(17):542–4 (15 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

[The spread of Mycoplasma infections] Fovi G, et al. **Ann Ig** 1996 May–Jun;8(3):329–39 (61 ref.) **(Ita)**

IMMUNOLOGY

Mycoplasmas and HIV infection, a possible interaction through immune activation. Blanchard A. **Wien Klin Wochenschr** 1997 Aug 8;109(14–15):590–3 (31 ref.)

MICROBIOLOGY

Models of mycoplasma respiratory and genital tract infections. Brunner H. **Wien Klin Wochenschr** 1997 Aug 8;109(14–15):569–73 (30 ref.)
Molecular biology of Mycoplasma. Christiansen G, et al. **Wien Klin Wochenschr** 1997 Aug 8;109(14–15):557–61 (23 ref.)
Mycoplasma genetic variation and its implication for pathogenesis. Citti C, et al. **Wien Klin Wochenschr** 1997 Aug 8;109(14–15):562–8 (29 ref.)
Comparative genomics of mycoplasmas. Razin S. **Wien Klin Wochenschr** 1997 Aug 8;109(14–15):551–6 (21 ref.)
Genital mycoplasma infections. Taylor–Robinson D, et al. **Wien Klin Wochenschr** 1997 Aug 8;109(14–15):578–83 (44 ref.)
[The persistence of mycoplasmas in the infected organism: observations, causes and mechanisms, diagnosis] Prozorovskii SV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Jul–Aug; (4):47–51 (21 ref.) **(Rus)**

TRANSMISSION

[Seal fingers and other infections transmitted from seals] Krag ML, et al. **Ugeskr Laeger** 1996 Sep 2;158(36):5015–7 (31 ref.) (Eng. Abstr.) **(Dan)**

VETERINARY

DNA amplification methods for diagnosis and epidemiological investigations of avian mycoplasmosis. Kempf I. **Acta Vet Hung** 1997;45(3):373–86 (65 ref.)
Changing expectations in the control of Mycoplasma gallisepticum. Kleven SH. **Acta Vet Hung** 1997; 45(3):299–305 (38 ref.)

MYCOPLASMA PNEUMONIA see **PNEUMONIA, MYCOPLASMA**

MYCOPLASMA PNEUMONIAE

Mycoplasma-associated pericarditis. Farraj RS, et al. **Mayo Clin Proc** 1997 Jan;72(1):33–6 (19 ref.)

GENETICS

Interplay between mycoplasma surface proteins, airway cells, and the protean manifestations of mycoplasma-mediated human infections. Baseman JB, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 2):S137–44 (45 ref.)

IMMUNOLOGY

Carbohydrate recognition by Mycoplasma pneumoniae and pathologic consequences. Feizi T, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 2):S133–6 (34 ref.)
Restricted B-cell responses to microbial challenge of the respiratory tract. Walker J, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):197–204 (28 ref.)

ISOLATION & PURIFICATION

Severe pleuropneumonia without a cough and myocarditis with mixed mycoplasma infection [letter] Chang AB, et al. **J Paediatr Child Health** 1996 Dec;32(6):546–7 (5 ref.)
Acute bilateral striatal necrosis associated with Mycoplasma pneumoniae infection. Larsen PD, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1124–6 (16 ref.)
Severe encephalitis in a three-year-old girl. Lum G, et al. **Pediatr Infect Dis J** 1996 Feb;15(2):181, 4–6 (12 ref.)

METABOLISM

Mycoplasma pneumoniae cytadherence: unravelling the tie that binds. Krause DC. **Mol Microbiol** 1996 Apr; 20(2):247–53 (35 ref.)

PATHOGENICITY

Infections due to species of Mycoplasma and Ureaplasma: an update. Taylor–Robinson D. **Clin Infect Dis** 1996 Oct; 23(4):671–82; quiz 683–4 (85 ref.)

MYCOPLASMATALES INFECTIONS

MICROBIOLOGY

Spiroplasmas: infectious agents of plants, arthropods and vertebrates. Bové JM. **Wien Klin Wochenschr** 1997 Aug 8;109(14–15):604–12 (70 ref.)

MYCOSES

see related
ANTIFUNGAL AGENTS
Allergic fungal sinusitis/polyposis. Bent JP 3rd, et al. **Allergy Asthma Proc** 1996 Sep–Oct;17(5):259–68 (30 ref.)
Recent advances in the management of opportunistic fungal infections. Sanchez JL, et al. **Compr Ther** 1996 Nov; 22(11):703–12 (85 ref.)
Diagnosis and treatment of infectious diseases in HIV-infected hosts. Castano-Molina C, et al. **Dermatol Clin** 1997 Apr;15(2):267–83 (197 ref.)
Phaeohyphomycosis. Rinaldi MG. **Dermatol Clin** 1996 Jan; 14(1):147–53 (13 ref.)
Emerging disease issues and fungal pathogens associated with HIV infection. Ampel NM. **Emerg Infect Dis** 1996 Apr–Jun;2(2):109–16 (50 ref.)
Allergic fungal sinusitis: a clinicopathologic study of 16 cases. Torres C, et al. **Hum Pathol** 1996 Aug;27(8):793–9 (50 ref.)
Epidemiology, diagnosis, and therapy of fungal infections in surgery. Giamarellou H, et al. **Infect Control Hosp Epidemiol** 1996 Aug;17(8):558–64 (64 ref.)
Fungal infections in patients with acquired immunodeficiency syndrome. Minamoto GY, et al. **Med Clin North Am** 1997 Mar;81(2):381–409 (194 ref.)
Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium Prolificans Spanish Study Group. Berenguer J, et al. **Medicine (Baltimore)** 1997 Jul;76(4):256–65 (47 ref.)
Community-acquired fungal pneumonia in children. Maxson S, et al. **Semin Respir Infect** 1996 Sep;11(3):196–203 (18 ref.)
[Successful surgical treatment for fungal endocarditis involving the aortic valve: report of a case] Fukui T, et al. **Kyobu Geka** 1996 Sep;49(10):855–8 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Microbes that invade nervous system] Shimada K. **Nippon Naika Gakkai Zasshi** 1996 May 10;85(5):655–8 (12 ref.) **(Jpn)**

BLOOD

["Sergeantella"--a morphological index of erythrodieresis or a result of degradation by fungi of the genus Paecilomyces] Grigor'ev GI. **Ter Arkh** 1995;67(12):53–5 (27 ref.) (Eng. Abstr.) **(Rus)**

COMPLICATIONS

Infections in solid-organ transplant recipients. Patel R, et al. **Clin Microbiol Rev** 1997 Jan;10(1):86–124 (800 ref.)
Are we making progress in antifungal therapy? Martino P, et al. **Curr Opin Oncol** 1997 Jul;9(4):314–20 (56 ref.)
Rheumatic manifestations of tropical diseases. Adebajo AO. **Curr Opin Rheumatol** 1996 Jan;8(1):85–9 (30 ref.)
Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo–radiotherapy. A single-center experience and review of the literature. Martino R, et al. **Haematologica** 1997 May–Jun;82(3):297–304 (38 ref.)
Septic shock: pathogenesis and treatment [see comments] Bansal T, et al. **J Assoc Physicians India** 1996 Jun; 44(6):407–14 (51 ref.) Comment in: J Assoc Physicians India 1996 Jun;44(6):371–4.
Hepatosplenic abscess caused by Curvularia boedijn in a patient with acute monocytic leukemia. Shigemori M, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1128–9 (11 ref.)
Lethal disseminated Fusarium infection with sinus involvement in the immunocompromised host: case report and review of the literature. Rombaux P, et al. **Rhinology** 1996 Dec;34(4):237–41 (27 ref.)

DIAGNOSIS

Molecular diagnosis of microbial infections. Blum HE. **Biologicals** 1996 Sep;24(3):193–5 (10 ref.)
Basidiobolomycosis: an unusual fungal infection mimicking

inflammatory bowel disease. Pasha TM, et al. **Gastroenterology** 1997 Jan;112(1):250–4 (20 ref.)

Fungal infections of the cardiovascular system—a review. Kuttin ES. **Mycoses** 1997 Jan–Feb;40(1–2):3–24 (324 ref.)

Fungal sinusitis. deShazo RD, et al. **N Engl J Med** 1997 Jul 24;337(4):254–9 (50 ref.)

Neuroimaging of AIDS. I. Fungal infections of the central nervous system. Harris DE, et al. **Neuroimaging Clin N Am** 1997 May;7(2):187–98 (60 ref.)

Orbitofascial conidiobolomycosis in a child. al-Hajjar S, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1130–2 (15 ref.)

[White genital piedra] Schwinn A, et al. **Hautarzt** 1996 Aug; 47(8):638–41 (32 ref.) (Eng. Abstr.) **(Ger)**

[Diagnosis and therapy of fungal keratitis—a review] Behrens-Baumann W. **Klin Monatsbl Augenheilkd** 1997 May;210(5):aA10–3 (51 ref.) (Eng. Abstr.) **(Ger)**

[Application of molecular biological methods for diagnosis and epidemiology of human fungal infections] Schönian G, et al. **Mycoses** 1996;39 Suppl 1:73–80 (48 ref.) (Eng. Abstr.) **(Ger)**

[Diagnosis and treatment of mycoses] Saito A. **Nippon Naika Gakkai Zasshi** 1996 Sep 10;85(9):1528–33 (0 ref.) **(Jpn)**

[Diagnosis and treatment of deep-seated mycosis] Watanabe K. **Nippon Naika Gakkai Zasshi** 1997 Mar 10;86(3):496–500 (500 ref.) **(Jpn)**

[Recent progress in molecular diagnostic technology in clinical mycology] Yamaguchi H. **Nippon Rinsho** 1996 Sep; 54(9):2600–13 (35 ref.) (Eng. Abstr.) **(Jpn)**

[Plasma (1—>3)-beta-D-glucan determination for screening deep mycosis] Obayashi T. **Rinsho Byori** 1996 Jun; 44(6):528–32 (8 ref.) (Eng. Abstr.) **(Jpn)**

[PCR—a new era in clinical microbiologic diagnosis and epidemiologic studies? (Part II)] Kur J, et al. **Przegl Epidemiol** 1996;50(3):227–37 (124 ref.) (Eng. Abstr.) **(Pol)**

[Coccidioidomycosis and other regional mycoses] Bouza Santiago E. **Rev Clin Esp** 1997 Apr;197 Suppl 1:75–85 (131 ref.) **(Spa)**

[The importance of fungal infections in pediatrics] Hernández-Sampelayo T, et al. **Rev Clin Esp** 1997 Apr;197 Suppl 1:60–6 (70 ref.) **(Spa)**

DRUG THERAPY

Antifungal drugs and resistance. Graybill JR. **Adv Exp Med Biol** 1995;390:217–34 (98 ref.)

Use of azoles for systemic antifungal therapy. Kauffman CA, et al. **Adv Pharmacol** 1997;39:143–89 (340 ref.)

Antifungal agents: chemotherapeutic targets and immunologic strategies. Georgopapadakou NH, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):279–91 (300 ref.)

Evolving concepts of prevention and treatment of invasive fungal infections in pediatric bone marrow transplant recipients. Chanock SJ, et al. **Bone Marrow Transplant** 1996 Dec;18 Suppl 3:S15–20 (53 ref.)

Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: a retrospective analysis. Peters BG, et al. **Bone Marrow Transplant** 1996 Jul;18(1):93–102 (60 ref.)

Antifungal susceptibility testing: technical advances and potential clinical applications[see comments] Pfaller MA, et al. **Clin Infect Dis** 1997 May;24(5):776–84 (75 ref.) Comment in: Clin Infect Dis 1997 May;24(5):775.

Are we making progress in antifungal therapy? Martino P, et al. **Curr Opin Oncol** 1997 Jul;9(4):314–20 (56 ref.)

Antibiotic treatment of febrile episodes in neutropenic cancer patients. Clinical and economic considerations. de Lalla F. **Drugs** 1997 May;53(5):789–804 (103 ref.)

Hematopoietic growth factors in cancer patients with invasive fungal infections. Offner F. **Eur J Clin Microbiol Infect Dis** 1997 Jan;16(1):56–63 (55 ref.)

Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Walsh TJ, et al. **Infect Dis Clin North Am** 1996 Jun;10(2):365–400 (179 ref.)

Treatment of fungal infection in AIDS. Hood S, et al. **J Antimicrob Chemother** 1996 May;37 Suppl B:71–85 (62 ref.)

Susceptibility testing of fungi and correlation with clinical outcome. Ghannoum MA. **J Chemother** 1997 May;9 Suppl 1:19–24 (49 ref.)

Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. Ghannoum MA, et al. **J Clin Microbiol** 1996 Mar;34(3):489–95 (96 ref.)

Lipid complexes of amphotericin B: the competitive picture [editorial] Richardson MD. **J Med Microbiol** 1997 Mar; 46(3):185–7 (10 ref.)

Treatment of fungal and other opportunistic infections in immunocompromised patients. Wade JC. **Leukemia** 1997 May;11 Suppl 4:S38–9 (7 ref.)

Topical antimycotics in ophthalmology. Behrens-Baumann W. **Ophthalmologica** 1997;211 Suppl 1:33–8 (79 ref.)

Update on antifungal resistance. Klepser ME, et al. **Trends Microbiol** 1997 Sep;5(9):372–5 (51 ref.)

[Prevention, diagnosis and therapy of infections in patients with malignant diseases] Hiddemann W, et al. **Internist (Berl)** 1996 Dec;37(12):1212–24 (56 ref.) **(Ger)**

[Therapy of infections in patients with acute leukemia] Hiddemann W, et al. **Med Klin** 1997 Jul 15;92(7):406–9 (18 ref.) (Eng. Abstr.) **(Ger)**

[Plasma and tissue concentrations of fluconazole: discussion of the breakpoint problem] Pittrow L, et al. **Mycoses** 1996; 39 Suppl 2:58–65 (44 ref.) (Eng. Abstr.) **(Ger)**

[Fluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility of yeasts] Wildfeuer A, et al. **Mycoses** 1996;39 Suppl 2:51–7 (42 ref.) (Eng. Abstr.) **(Ger)**

[Diagnosis and treatment of mycoses] Saito A. **Nippon Naika Gakkai Zasshi** 1996 Sep 10;85(9):1528–33 (0 ref.) **(Jpn)**

[Diagnosis and treatment of deep-seated mycosis] Watanabe K. **Nippon Naika Gakkai Zasshi** 1997 Mar 10;86(3):496–500 (500 ref.) **(Jpn)**

[Fungal myocarditis] Kubo N, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):138–40 (14 ref.) **(Jpn)**

[Antifungal resistance in opportunistic pathogenic fungi (I). Polyenes and fluorocytosine] Martínez-Suárez JV, et al. **Enferm Infecc Microbiol Clin** 1996 Jun-Jul;14(6):384–9 (43 ref.) **(Spa)**

EPIDEMIOLOGY

Risk assessment of fungi reported from humans and animals. de Hoog GS. **Mycoses** 1996 Nov-Dec;39(11–12):407–17 (28 ref.)

[Epidemiology of invasive mycoses. Experience of a university hospital center in Paris] Hennequin C. **Rev Med Interne** 1996;17(9):754–60 (40 ref.) (Eng. Abstr.) **(Fre)**

[Application of molecular biological methods for diagnosis and epidemiology of human fungal infections] Schönian G, et al. **Mycoses** 1996;39 Suppl 1:73–80 (48 ref.) (Eng. Abstr.) **(Ger)**

[The epidemiology of nosocomial fungal infection] Cisterna Cancer R, et al. **Rev Clin Esp** 1997 Apr;197 Suppl 1:12–6 (24 ref.) **(Spa)**

[Fungal infection in patients admitted to the intensive care unit] León Gil C, et al. **Rev Clin Esp** 1997 Apr;197 Suppl 1:17–28 (86 ref.) **(Spa)**

ETIOLOGY

Clinical approach to infective endocarditis. Saccente M, et al. **Cardiol Clin** 1996 Aug;14(3):351–62 (73 ref.)

Infection due to Penicillium marneffei, an emerging pathogen: review of 155 reported cases [see comments] Duong TA. **Clin Infect Dis** 1996 Jul;23(1):125–30 (42 ref.) Comment in: Clin Infect Dis 1997 May;24(5):1026.

Noncandidal fungal peritonitis in patients with AIDS: report of three cases and review. Spindel SJ, et al. **Clin Infect Dis** 1997 Feb;24(2):279–80 (10 ref.)

New fungal pathogens. Bodey GP. **Curr Clin Top Infect Dis** 1997;17:205–35 (134 ref.)

Pancreatic infections. Stephan RN, et al. **Gastroenterologist** 1996 Sep;4(3):163–8 (39 ref.)

Brain abscess caused by Schizophyllum commune: an emerging basidiomycete pathogen. Rihs JD, et al. **J Clin Microbiol** 1996 Jul;34(7):1628–32 (13 ref.)

Complicated soft tissue infection with prepatellar bursitis caused by Paecilomyces lilacinus in an immunocompetent host: case report and review. Westenfeld F, et al. **J Clin Microbiol** 1996 Jun;34(6):1559–62 (29 ref.)

Emerging fungal infections in cancer patients. Krcmery V Jr. **J Hosp Infect** 1996 Jun;33(2):109–17 (50 ref.)

Infections in neutropenic patients I: aetiology. Engervall P, et al. **Med Oncol** 1995 Dec;12(4):251–6 (65 ref.)

Fungal infections in lung and heart-lung transplant recipients. Report of 9 cases and review of the literature. Kanj SS, et al. **Medicine (Baltimore)** 1996 May;75(3):142–56 (127 ref.)

Bacterial and fungal infection in acute liver failure. Rolando N, et al. **Semin Liver Dis** 1996 Nov;16(4):389–402 (89 ref.)

[Peritoneal dialysis: peritonitis and catheter infections] Bergeron E, et al. **Ann Chir** 1996;50(8):606–12 (37 ref.) (Eng. Abstr.) **(Fre)**

[Fungal infections in patients undergoing solid organ transplantation] Muñoz P, et al. **Enferm Infecc Microbiol Clin** 1997 May;15 Suppl 2:34–50 (241 ref.) **(Spa)**

[Characteristics of non-bacterial infections in solid organ transplantation] Cisterna Cancer R, et al. **Rev Clin Esp** 1995 Oct;195 Spec No:37–43 (57 ref.) **(Spa)**

[Fungal infections in patients with solid tumors and other immunodepressed patients] Muñoz García-Paredes P, et al. **Rev Clin Esp** 1997 Apr;197 Suppl 1:35–43 (81 ref.) **(Spa)**

GENETICS

DNA analysis in the study of fungal infections in the immunocompromised host. Zervos MJ, et al. **Clin Lab Med** 1996 Mar;16(1):73–88 (62 ref.)

IMMUNOLOGY

Fungal infections in immunocompromised individuals. Conant MA. **Dermatol Clin** 1996 Jan;14(1):155–62 (30 ref.)

Penicillium marneffei infection in a non-HIV infected child. Kwan EY, et al. **J Paediatr Child Health** 1997 Jun; 33(3):267–71 (34 ref.)

Shared themes of antigenic variation and virulence in bacterial, protozoal, and fungal infections. Deitsch KW, et al. **Microbiol Mol Biol Rev** 1997 Sep;61(3):281–93 (192 ref.)

METABOLISM

Role of oxidants in microbial pathophysiology. Miller RA, et al. **Clin Microbiol Rev** 1997 Jan;10(1):1–18 (334 ref.)

MICROBIOLOGY

Pathogenic mechanisms induced by microbial proteases in microbial infections. Maeda H, et al. **Biol Chem Hoppe Seyler** 1996 Apr;377(4):217–26 (90 ref.)

Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Boutati EI, et al. **Blood** 1997 Aug 1;90(3):999–1008 (111 ref.)

Paecilomyces sinusitis in an immunocompromised adult patient: case report and review. Gucalp R, et al. **Clin Infect Dis** 1996 Aug;23(2):391–3 (10 ref.)

Infections due to dematiaceous fungi in organ transplant recipients: case report and review. Singh N, et al. **Clin Infect Dis** 1997 Mar;24(3):369–74 (35 ref.)

Virulence factors of medically important fungi. Hogan LH, et al. **Clin Microbiol Rev** 1996 Oct;9(4):469–88 (326 ref.)

Treatment of fungal infection in AIDS. Hood S, et al. **J Antimicrob Chemother** 1996 May;37 Suppl B:71–85 (62 ref.)

Penicillium marneffei infection in a non-HIV infected child. Kwan EY, et al. **J Paediatr Child Health** 1997 Jun; 33(3):267–71 (34 ref.)

Infectious complications of patients undergoing therapy for acute leukemia: current status and future prospects. Chanock SJ, et al. **Semin Oncol** 1997 Feb;24(1):132–40 (65 ref.)

[Importance of mycoses in intra-abdominal infections] Blinzler L, et al. **Langenbecks Arch Chir** 1997;382(4 Suppl 1):S5–8 (16 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Pathology of Penicillium marneffei. An emerging acquired immunodeficiency syndrome-related pathogen. Cooper CR Jr, et al. **Arch Pathol Lab Med** 1997 Aug;121(8):798–804 (44 ref.)

Fungal infections. Chimelli L, et al. **Brain Pathol** 1997 Jan; 7(1):613–27 (90 ref.)

PREVENTION & CONTROL

Antifungal prophylaxis during neutropenia and immunodeficiency. Lortholary O, et al. **Clin Microbiol Rev** 1997 Jul;10(3):477–504 (390 ref.)

Practical modalities for prevention of fungal infections in cancer patients. De Pauw BE. **Eur J Clin Microbiol Infect Dis** 1997 Jan;16(1):32–41 (46 ref.)

Prevention of fungal infections in hematology patients. Philpott-Howard J. **Infect Control Hosp Epidemiol** 1996 Aug;17(8):545–51 (68 ref.)

Host immunologic augmentation for the control of infection. Wingard JR, et al. **Infect Dis Clin North Am** 1996 Jun; 10(2):345–64 (111 ref.)

Treatment of fungal and other opportunistic infections in immunocompromised patients. Wade JC. **Leukemia** 1997 May;11 Suppl 4:S38–9 (7 ref.)

Antifungal prophylaxis with itraconazole in neutropenic patients: pharmacological, microbiological and clinical aspects. Glasmacher A, et al. **Mycoses** 1996 Jul-Aug; 39(7–8):249–58 (117 ref.)

[Azole antifungal agents in the prevention of fungal infections in neutropenic patients and bone marrow graft recipients] Lortholary O, et al. **Ann Med Interne (Paris)** 1997; 148(3):258–67 (106 ref.) (Eng. Abstr.) **(Fre)**

[Prevention of opportunistic infections in HIV seropositive patients. Prevention of viral infections and mycoses] Casassus P, et al. **Presse Med** 1997 Mar 8;26(7):344–7 (25 ref.) (Eng. Abstr.) **(Fre)**

[Preventive antimycotic therapy of neutropenic and immunosuppressed patients] Ruhnke M, et al. **Med Klin** 1997 Jan 15;92(1):28–36 (76 ref.) (Eng. Abstr.) **(Ger)**

[Antifungal prophylaxis in neutropenic cancer patients and in allogeneic bone marrow transplantation] Blau IW, et al. **Mycoses** 1996;39 Suppl 1:81–6 (52 ref.) (Eng. Abstr.) **(Ger)**

[The prevention and treatment of fungal infections in the neutropenic patient] Vázquez López ML. **Rev Clin Esp** 1997 Apr;197 Suppl 1:29–34 (26 ref.) **(Spa)**

THERAPY

Corneal chromoblastomycosis. Barton K, et al. **Cornea** 1997 Mar;16(2):235–9 (18 ref.)

Trends in immunotherapy of fungal infections. Kullberg BJ. **Eur J Clin Microbiol Infect Dis** 1997 Jan;16(1):51–5 (31 ref.)

Fungal endocarditis—a report on seven cases and a brief review. Hogevik H, et al. **Infection** 1996 Jan-Feb; 24(1):17–21 (40 ref.)

Combination therapy with BRMs in cancer and infectious diseases. Garaci E, et al. **Mech Ageing Dev** 1997 Jun; 96(1-3):103–16 (57 ref.)

Fungal infections of the cardiovascular system—a review. Kuttin ES. **Mycoses** 1997 Jan-Feb;40(1–2):3–24 (324 ref.)

Orbitofascial conidiobolomycosis in a child. al-Hajjar S, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1130–2 (15 ref.)

MYCOSES

TRANSMISSION

Virulence and transmissibility of pathogens: what is the relationship? Lipsitch M, et al. **Trends Microbiol** 1997 Jan; 5(1):31–7 (69 ref.)

[Fungi in the home and hospital environment] Staib F. **Mycoses** 1996;39 Suppl 1:26–9 (28 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Utility of transesophageal echocardiography in infective endocarditis. A review. Jessurun C, et al. **Tex Heart Inst J** 1996;23(2):98–107 (87 ref.)

VETERINARY

Risk assessment of fungi reported from humans and animals. de Hoog GS. **Mycoses** 1996 Nov–Dec;39(11–12):407–17 (28 ref.)

Special challenges of maintaining wild animals in captivity in Australia and New Zealand: prevention of infectious and parasitic diseases. Schultz DJ, et al. **Rev Sci Tech** 1996 Mar;15(1):289–308 (53 ref.)

Review of the literature and investigations on the prevalence and consequences of yeasts in reptiles. Kostka VM, et al. **Vet Rec** 1997 Mar 15;140(11):282–7 (36 ref.)

MYCOSIS FUNGOIDES

Mycosis fungoides and Sezary syndrome [see comments] Diamandidou E, et al. **Blood** 1996 Oct 1;88(7):2385–409 (296 ref.) Comment in: Blood 1997 Apr 15;89(8):3062–4.

[Primary cutaneous lymphoma––mycosis fungoides] Nagatani T, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(1):23–9 (20 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Indurated plaques of mycosis fungoides in a woman with fulminant hepatic failure. Vannucci SA, et al. **Cutis** 1996 Mar;57(3):159–62 (11 ref.)

DRUG THERAPY

Photochemotherapy for mycosis fungoides: current status. Watson A. **Australas J Dermatol** 1997 Feb;38(1):9–11 (20 ref.)

PATHOLOGY

Follicular mycosis fungoides: a clinicohistopathologic study. Pereyo NG, et al. **J Am Acad Dermatol** 1997 Apr; 36(4):563–8 (28 ref.)

T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia–lymphomas (ATLL). Bunn PA Jr, et al. **J Cell Biochem Suppl** 1996;24:12–23 (125 ref.)

RADIOTHERAPY

Mycosis fungoides and total skin electron beam radiation [letter; comment] Jones GW, et al. **Blood** 1997 Apr 15; 89(8):3062–4 (12 ref.) Comment on: Blood 1996 Oct 1;88(7):2385–409.

MYCOSIS, OCULAR see **EYE INFECTIONS, FUNGAL**

MYCOTIC ANEURYSM see **ANEURYSM, INFECTED**

MYCOTIC INFECTIONS, OCULAR see **EYE INFECTIONS, FUNGAL**

MYCOTOXINS

see related
ERGOTISM

The chemistry and biological activities of the natural products AAL-toxin and the fumonisins. Abbas HK, et al. **Adv Exp Med Biol** 1996;391:293–308 (82 ref.)

Fumonisins: history, world-wide occurrence and impact. Marasas WF. **Adv Exp Med Biol** 1996;392:1–17 (118 ref.)

Regulatory aspects of fumonisins in the United States. Troxell TC. **Adv Exp Med Biol** 1996;392:355–61 (4 ref.)

Yeast killer systems. Magliani W, et al. **Clin Microbiol Rev** 1997 Jul;10(3):369–400 (461 ref.)

The effects of processing on the occurrence of ochratoxin A in cereals. Alldrick AJ. **Food Addit Contam** 1996;13 Suppl:27–8 (8 ref.)

Aspartame as a preventive agent of chronic toxic effects of ochratoxin A in experimental animals. Creppy EE, et al. **Food Addit Contam** 1996;13 Suppl:51–2 (6 ref.)

Mechanistic approaches to ochratoxin toxicity. Dirheimer G. **Food Addit Contam** 1996;13 Suppl:45–8 (28 ref.)

Fate of ochratoxin A on processing of meat products. Gareis M. **Food Addit Contam** 1996;13 Suppl:35–7 (6 ref.)

Sampling and analysis for ochratoxin A in foods. Gilbert J. **Food Addit Contam** 1996;13 Suppl:17–8 (3 ref.)

Risk assessment of ochratoxin A: an update. Kuiper-Goodman T. **Food Addit Contam** 1996;13 Suppl:53–7 (13 ref.)

Mode of formation of ochratoxin A. Moss MO. **Food Addit Contam** 1996;13 Suppl:5–9 (27 ref.)

Nephrotoxicity of ochratoxin A. Pleština R. **Food Addit Contam** 1996;13 Suppl:49–50 (9 ref.)

Carcinogenicity and kinetic aspects of ochratoxin A. Schlatter C, et al. **Food Addit Contam** 1996;13 Suppl:43–4 (6 ref.)

Effects of processing and detoxification treatments on ochratoxin A: introduction. Scott PM. **Food Addit Contam** 1996;13 Suppl:19–21 (18 ref.)

Ochratoxin A in animal feed––effects of processing. Scudamore KA. **Food Addit Contam** 1996;13 Suppl:39–42 (14 ref.)

Fate of ochratoxin A during breadmaking. Subirade I. **Food Addit Contam** 1996;13 Suppl:25–6 (3 ref.)

Analytical methodology and regulations for ochratoxin A. Van Egmond HP. **Food Addit Contam** 1996;13 Suppl:11–3 (8 ref.)

Fate of ochratoxin A (OTA) during processing of coffee. Cooperative work by PEC (Physiological Effects of Coffee committee). Viani R. **Food Addit Contam** 1996;13 Suppl:29–33 (15 ref.)

Recent acute and subacute mycotoxicoses recognized in France. Le Bars J, et al. **Vet Res** 1996;27(4–5):383–94 (36 ref.)

ANALYSIS

Occurrence of Fusarium and fumonisins on food grains and in foods. Bullerman LB. **Adv Exp Med Biol** 1996;392:27–38 (31 ref.)

Immunochemical methods for fumonisins. Chu FS. **Adv Exp Med Biol** 1996;392:122–33 (68 ref.)

Approaches to the risk assessment of fumonisins in corn-based foods in Canada. Kuiper-Goodman T, et al. **Adv Exp Med Biol** 1996;392:369–93 (80 ref.)

Regulatory aspects of fumonisins with respect to animal feed. Animal derived residues in foods. Miller MA, et al. **Adv Exp Med Biol** 1996;392:363–8 (4 ref.)

Effect of processing on fumonisin content of corn. Murphy PA, et al. **Adv Exp Med Biol** 1996;392:323–34 (21 ref.)

Occurrence of fumonisins in the U.S. food supply. Pohland AE. **Adv Exp Med Biol** 1996;392:19–26 (34 ref.)

The reliability and significance of analytical data on the natural occurrence of fumonisins in food. Thiel PG, et al. **Adv Exp Med Biol** 1996;392:145–51 (43 ref.)

Mycotoxins transmitted into beer from contaminated grains during brewing. Scott PM. **J AOAC Int** 1996 Jul–Aug; 79(4):875–82 (85 ref.)

BIOSYNTHESIS

Liquid culture methods for the production of fumonisin. Keller SE, et al. **Adv Exp Med Biol** 1996;392:205–12 (23 ref.)

CHEMISTRY

NMR structural studies of fumonisin B1 and related compounds from Fusarium moniliforme. Blackwell BA, et al. **Adv Exp Med Biol** 1996;392:75–91 (35 ref.)

Effect of thermal processing on the stability of fumonisins. Jackson LS, et al. **Adv Exp Med Biol** 1996;392:345–53 (38 ref.)

Chemistry and biological activity of AAL toxins. Winter CK, et al. **Adv Exp Med Biol** 1996;392:307–16 (42 ref.)

GENETICS

Genetic and biochemical aspects of fumonisin production. Desjardins AE, et al. **Adv Exp Med Biol** 1996;392:165–73 (18 ref.)

Yeast killer toxin K1 and its exploitation in genetic manipulations. Vondrejs V, et al. **Folia Microbiol (Praha)** 1996;41(5):379–93 (88 ref.)

ISOLATION & PURIFICATION

[Mycotoxin-producing fungi in foods] Fernández Pinto VE, et al. **Rev Argent Microbiol** 1996 Jul–Sep;28(3):147–62 (73 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Chemistry and biological activity of AAL toxins. Winter CK, et al. **Adv Exp Med Biol** 1996;392:307–16 (42 ref.)

Nystatin-rhodamine B assay for estimating activity of killer toxin from Kluyveromyces lactis. Palková Z, et al. **Methods Mol Biol** 1996;53:325–9 (5 ref.)

Killer plaque technique for selecting hybrids and cybrids obtained by induced protoplast fusion. Palková Z, et al. **Methods Mol Biol** 1996;53:339–42 (2 ref.)

Application of killer toxins in stepwise selection of hybrids and cybrids obtained by induced protoplast fusion. Vondrejs V, et al. **Methods Mol Biol** 1996;53:331–8 (15 ref.)

Rhodamine B assay for estimating activity of killer toxins permeabilizing cytoplasmic membranes. Vondrejs V, et al. **Methods Mol Biol** 1996;53:319–24 (4 ref.)

TOXICITY

Hepatotoxicity and –carcinogenicity of the fumonisins in rats. A review regarding mechanistic implications for establishing risk in humans. Gelderblom WC, et al. **Adv Exp Med Biol** 1996;392:279–96 (62 ref.)

Fumonisin B1–immunological effects. The influence of FB1 on the early stage of immune response. Martinova EA. **Adv Exp Med Biol** 1996;391:331–42 (70 ref.)

Fumonisin toxicity and sphingolipid biosynthesis. Merrill AH Jr, et al. **Adv Exp Med Biol** 1996;392:297–306 (39 ref.)

Fumonisin toxicity and metabolism studies at the USDA. Fumonisin toxicity and metabolism. Norred WP, et al. **Adv Exp Med Biol** 1996;392:225–36 (73 ref.)

Is ochratoxin a nephrotoxic in human beings? Godin M, et al. **Adv Nephrol Necker Hosp** 1997;26:181–206 (123 ref.)

Fungal ribotoxins: a family of naturally engineered targeted toxins? Kao R, et al. **Biochem Cell Biol** 1995 Nov–Dec; 73(11–12):1151–9 (70 ref.)

Renal toxicodynamics of ochratoxin A: a pathophysiological approach. Gekle M, et al. **Kidney Blood Press Res** 1996; 19(5):225–35 (74 ref.)

Fumonisins, mycotoxins of increasing importance: their nature and their effects. Dutton MF. **Pharmacol Ther** 1996; 70(2):137–61 (400 ref.)

Host-selective toxins: agents of compatibility. Walton JD. **Plant Cell** 1996 Oct;8(10):1723–33 (60 ref.)

[Natural toxin series: (2) A sphingosine-like mycotoxin, fumonisin] Ueno Y, et al. **J Toxicol Sci** 1996 Feb;21(1 Appendix):27–39 (78 ref.) **(Jpn)**

MYDRIASIS

ETIOLOGY

A guide to the isolated dilated pupil. Lee AG, et al. **Arch Fam Med** 1997 Jul–Aug;6(4):385–8 (19 ref.)

MYELENCEPHALON see **MEDULLA OBLONGATA**

MYELIN-ASSOCIATED GLYCOPROTEIN

GENETICS

Myelination and axonal regeneration in the central nervous system of mice deficient in the myelin-associated glycoprotein. Bartsch U. **J Neurocytol** 1996 May; 25(5):303–13 (70 ref.)

IMMUNOLOGY

Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis. Bernard CC, et al. **J Mol Med** 1997 Feb;75(2):77–88 (64 ref.)

Neuropathy associated with "benign" anti-myelin-associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases. Ellie E, et al. **J Neurol** 1996 Jan; 243(1):34–43 (43 ref.)

[Treatment of peripheral neuropathies associated with IgM anti-myelin monoclonal gammopathy] Mariette X, et al. **Rev Neurol (Paris)** 1996 May;152(5):413–6 (23 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Restriction of plastic fiber growth after lesions by central nervous system myelin-associated neurite growth inhibitors. Kapfhammer JP. **Adv Neurol** 1997;73:7–27 (180 ref.)

The muddle with MAG. Filbin MT. **Mol Cell Neurosci** 1996; 8(2–3):84–92 (56 ref.)

MYELIN BASIC PROTEINS

IMMUNOLOGY

Fine specificity of myelin basic protein reactive T-cells: implications for T-cell receptor antagonism. Anderton SM, et al. **Biochem Soc Trans** 1997 May;25(2):659–61 (14 ref.)

Using transgenic mouse models to dissect the pathogenesis of virus-induced autoimmune disorders of the islets of Langerhans and the central nervous system. von Herrath MG, et al. **Immunol Rev** 1996 Aug;152:111–43 (190 ref.)

The dominant and the cryptic T cell repertoire to myelin basic protein in the Lewis rat. Mor F, et al. **J Neurosci Res** 1996 Sep 15;45(6):670–9 (60 ref.)

METABOLISM

Biological methylation of myelin basic protein: enzymology and biological significance. Kim S, et al. **Int J Biochem Cell Biol** 1997 May;29(5):743–51 (69 ref.)

MYELIN P0 PROTEIN

CHEMISTRY

Packing of myelin protein zero. Choe S. **Neuron** 1996 Sep; 17(3):363–5 (17 ref.)

Membrane adhesion in peripheral myelin: good and bad wraps with protein P0. Kirschner DA, et al. **Structure** 1996 Nov 15;4(11):1239–44 (32 ref.)

GENETICS

De novo mutation (Arg98––>Cys) of the myelin P0 gene and uncompaction of the major dense line of the myelin sheath in a severe variant of Charcot-Marie-Tooth disease type 1B. Komiyama A, et al. **J Neurol Sci** 1997 Jul; 149(1):103–9 (31 ref.)

[Mutation of the myelin Po gene in hereditary motor and

sensory neuropathy] Hayasaka K. **Rinsho Shinkeigaku** 1995 Dec;35(12):1444–6 (10 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

[L1 and P0 proteins] Takeda Y, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):542–51 (36 ref.) **(Jpn)**

MYELIN P2 PROTEIN

GENETICS

Intracellular lipid-binding proteins and their genes. Bernlohr DA, et al. **Annu Rev Nutr** 1997;17:277–303 (133 ref.)

PHYSIOLOGY

Heart-type fatty acid binding protein – involvement in growth inhibition and differentiation. Börchers T, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Jul; 57(1):77–84 (40 ref.)

MYELIN PROTEINS

BIOSYNTHESIS

Molecular bases of myelin formation as revealed by investigations on mice deficient in glial cell surface molecules. Martini R, et al. **Glia** 1997 Apr;19(4):298–310 (88 ref.)

CHEMISTRY

Phosphorylation of myelin protein: recent advances. Eichberg J, et al. **Neurochem Res** 1996 Apr;21(4):527–35 (84 ref.)

Molecular pathogenesis of peripheral neuropathy. Trapp BD, et al. **Rev Neurol (Paris)** 1996 May;152(5):314–9 (48 ref.)

GENETICS

Deletion of the PMP22 gene and hereditary neuropathy with liability to pressure palsies. Pareyson D, et al. **Curr Opin Neurol** 1996 Oct;9(5):348–54 (58 ref.)

Molecular genetics of demyelination: new wrinkles on an old membrane. Scherer SS. **Neuron** 1997 Jan;18(1):13–6 (22 ref.)

[Molecular pathology of Charcot-Marie-Tooth disease type 1A: abnormal expression of PMP-22] Yoshikawa H, et al. **Rinsho Shinkeigaku** 1995 Dec;35(12):1441–3 (10 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

[Perspectives in multiple sclerosis research] Lassmann H. **Wien Med Wochenschr** 1996;146(19–20):528–32 (38 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Relationship of iron to oligodendrocytes and myelination. Connor JR, et al. **Glia** 1996 Jun;17(2):83–93 (92 ref.)

MYELIN PROTEOLIPID PROTEIN

PHYSIOLOGY

Proteolipid protein: is it more than just a structural component of myelin? Knapp PE. **Dev Neurosci** 1996; 18(4):297–308 (128 ref.)

MYELIN SHEATH

see related
DEMYELINATING DISEASES
MYELIN PROTEINS

[Neurinomas-neurofibromas] Goujon JM, et al. **Neurochirurgie** 1997;43(1):35–8 (9 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Glycoproteins of myelin sheaths. Quarles RH. **J Mol Neurosci** 1997 Feb;8(1):1–12 (90 ref.)

GENETICS

Myelin mutants: model systems for the study of normal and abnormal myelination. Griffiths IR. **Bioessays** 1996 Oct; 18(10):789–97 (71 ref.)

METABOLISM

Myelination and axonal regeneration in the central nervous system of mice deficient in the myelin-associated glycoprotein. Bartsch U. **J Neurocytol** 1996 May; 25(5):303–13 (70 ref.)

TNF-alpha receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyelination in Lewis rats: an overview. Klinkert WE, et al. **J Neuroimmunol** 1997 Feb;72(2):163–8 (44 ref.)

Origin of cholesterol in myelin. Morell P, et al. **Neurochem Res** 1996 Apr;21(4):463–70 (31 ref.)

Cholesterol and myelin. Snipes GJ, et al. **Subcell Biochem** 1997;28:173–204 (170 ref.)

PATHOLOGY

TNF-alpha receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyelination in Lewis rats: an overview. Klinkert WE, et al. **J Neuroimmunol** 1997 Feb;72(2):163–8 (44 ref.)

Imaging of remyelination. Barkhof F. **Mult Scler** 1997 Apr; 3(2):129–32 (24 ref.)

Remyelination in multiple sclerosis: a challenge for therapy. The 1996 European Charcot Foundation Lecture. Compston A. **Mult Scler** 1997 Apr;3(2):51–70 (87 ref.)

Impairment of central and peripheral myelin in mitochondrial diseases. Kalman B, et al. **Mult Scler** 1997 Jan;2(6):267–78 (112 ref.)

PHYSIOLOGY

Myelin mutants: model systems for the study of normal and abnormal myelination. Griffiths IR. **Bioessays** 1996 Oct; 18(10):789–97 (71 ref.)

Biochemistry of demyelination. Cuzner ML, et al. **Brain Pathol** 1996 Jul;6(3):231–42 (110 ref.)

Regulation of oligodendrocyte development and CNS myelination by growth factors: prospects for therapy of demyelinating disease. McMorris FA, et al. **Brain Pathol** 1996 Jul;6(3):313–29 (170 ref.)

Central nervous system remyelination clinical application of basic neuroscience principles. Miller DJ, et al. **Brain Pathol** 1996 Jul;6(3):331–44 (101 ref.)

Schwann cell development, differentiation and myelination. Mirsky R, et al. **Curr Opin Neurobiol** 1996 Feb;6(1):89–96 (70 ref.)

Strategies for repair and remyelination in demyelinating diseases. Scolding N. **Curr Opin Neurol** 1997 Jun; 10(3):193–200 (91 ref.)

Proteolipid protein: is it more than just a structural component of myelin? Knapp PE. **Dev Neurosci** 1996; 18(4):297–308 (128 ref.)

Periventricular leukomalacia, glial development and myelination. Takashima S, et al. **Early Hum Dev** 1995 Oct 2;43(2):177–84 (40 ref.)

Molecular bases of myelin formation as revealed by investigations on mice deficient in glial cell surface molecules. Martini R, et al. **Glia** 1997 Apr;19(4):298–310 (88 ref.)

Growth factors and remyelination in the CNS. Woodruff RH, et al. **Histol Histopathol** 1997 Apr;12(2):459–66 (109 ref.)

Schwann cell invasion of the central nervous system of the myelin mutants. Duncan ID, et al. **J Anat** 1997 Jan;190 (Pt 1):35–49 (58 ref.)

Transplanting oligodendrocyte progenitors into the adult CNS. Franklin RJ, et al. **J Anat** 1997 Jan;190 (Pt 1):23–33 (52 ref.)

Exogenous lipids in myelination and myelination. Di Biase A, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1997 Jan;13(1):19–29 (85 ref.)

Immunocytochemical investigations of sodium channels along nodal and internodal portions of demyelinated axons. England JD, et al. **Microsc Res Tech** 1996 Aug 1; 34(5):445–51 (51 ref.)

Schwann cell transplantation and myelin repair of the CNS. Baron-Van Evercooren A, et al. **Mult Scler** 1997 Apr; 3(2):157–61 (50 ref.)

Neurosteroids, with special reference to the effect of progesterone on myelination in peripheral nerves. Baulieu EE, et al. **Mult Scler** 1997 Apr;3(2):105–12 (51 ref.)

Remyelination in multiple sclerosis: a challenge for therapy. The 1996 European Charcot Foundation Lecture. Compston A. **Mult Scler** 1997 Apr;3(2):51–70 (87 ref.)

To what extent is oligodendrocyte progenitor migration a limiting factor in the remyelination of multiple sclerosis lesions? Franklin RJ, et al. **Mult Scler** 1997 Apr;3(2):84–7 (29 ref.)

Regulation of myelin development. Kamholz JA. **Mult Scler** 1996 Dec;2(5):236–40 (23 ref.)

Remyelination in multiple sclerosis. Lassmann H, et al. **Mult Scler** 1997 Apr;3(2):133–6 (30 ref.)

Promotion of endogenous remyelination in multiple sclerosis. Lucchinetti CF, et al. **Mult Scler** 1997 Apr;3(2):71–5 (56 ref.)

Enhancement of central nervous system remyelination in immune and non-immune experimental models of demyelination. van Engelen BG, et al. **Mult Scler** 1997 Apr;3(2):76–9 (39 ref.)

Immunomodulation and remyelination: two aspects of human polyclonal immunoglobulin treatment in immune mediated neuropathies? van Schaik IN, et al. **Mult Scler** 1997 Apr; 3(2):98–104 (91 ref.)

Growth factors and myelin regeneration in multiple sclerosis. Webster HD. **Mult Scler** 1997 Apr;3(2):113–20 (128 ref.)

Molecular genetics of demyelination: new wrinkles on an old membrane. Scherer SS. **Neuron** 1997 Jan;18(1):13–6 (22 ref.)

Myelin-associated neurite growth inhibitors: regulators of plastic changes of neural connections in the central nervous system. Kapfhammer JP. **Prog Brain Res** 1996;108:183–202 (61 ref.)

Alterations in the functional properties of dorsal root ganglion cells with unmyelinated axons after a chronic nerve constriction in the rat. LaMotte RH, et al. **Prog Brain Res** 1996;110:105–11 (32 ref.)

ULTRASTRUCTURE

Multiple sclerosis: from a myelin point of view. Boccaccio GL, et al. **J Neurosci Res** 1996 Sep 15;45(6):647–54 (87 ref.)

Membrane adhesion in peripheral myelin: good and bad wraps with protein P0. Kirschner DA, et al. **Structure** 1996 Nov 15;4(11):1239–44 (32 ref.)

MYELINOCLASIS, CENTRAL PONTINE see **MYELINOLYSIS, CENTRAL PONTINE**

MYELINOLYSIS, CENTRAL PONTINE

ETIOLOGY

Myelinolysis after correction of hyponatremia [see comments] Laureno R, et al. **Ann Intern Med** 1997 Jan 1;126(1):57–62 (49 ref.) Comment in: Ann Intern Med 1997 Jul 15;127(2):163.

PHYSIOPATHOLOGY

[Clinical case of the month, apropos of a case of central pontine myelinolysis in a patient with chronic alcoholism] Lebrun F, et al. **Rev Med Liege** 1997;52(1):7–11 (18 ref.) **(Fre)**

MYELITIS

DIAGNOSIS

[Inflammatory diseases of the spinal cord and spinal nerve roots in the MRI] Sartoretti-Schefer S, et al. **Radiologe** 1996 Nov;36(11):897–913 (159 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Toxoplasmosis of the spinal cord in a patient with AIDS: case report and review. Vyas R, et al. **Clin Infect Dis** 1996 Nov;23(5):1061–5 (29 ref.)

MYELITIS, TRANSVERSE

DIAGNOSIS

Acute transverse myelitis. Thomas M, et al. **J La State Med Soc** 1997 Feb;149(2):75–7 (9 ref.)

ETIOLOGY

Transverse myelopathy in SLE: clinical features and functional outcomes. Chan KF, et al. **Lupus** 1996 Aug; 5(4):294–9 (13 ref.)

MYELOBLASTIC LEUKEMIA, ACUTE see **LEUKEMIA, MYELOCYTIC, ACUTE**

MYELOBLASTOSIS VIRUS, AVIAN

PATHOGENICITY

[Genetic alterations associated with pathologic differentiation of Wilms' tumors] Chevalier G, et al. **Bull Cancer** 1997 Mar;84(3):289–303 (127 ref.) (Eng. Abstr.) **(Fre)**

MYELOCELE see **MENINGOMYELOCELE**

MYELOCYTIC LEUKEMIA see **LEUKEMIA, MYELOID**

MYELOCYTIC LEUKEMIA, ACUTE see **LEUKEMIA, MYELOCYTIC, ACUTE**

MYELOCYTIC LEUKEMIA, CHRONIC see **LEUKEMIA, MYELOID, CHRONIC**

MYELODYSPLASIA see **NEURAL TUBE DEFECTS**

MYELODYSPLASTIC SYNDROMES

ABC of clinical haematology. The myelodysplastic syndromes. Oscier DG. **BMJ** 1997 Mar 22;314(7084):883–6 (0 ref.)

Myelodysplastic syndromes. San Miguel JF, et al. **Crit Rev Oncol Hematol** 1996 May;23(1):57–93 (447 ref.)

Myelodysplasia and myeloproliferative disorders. Anderson JE, et al. **Curr Opin Hematol** 1997 Jul;4(4):261–7 (53 ref.)

Myelodysplastic syndromes. Fenaux P. **Hematol Cell Ther** 1996 Oct;38(5):363–80 (112 ref.)

Myelodysplasia in childhood may be a polyclonal disease. Tchernia G, et al. **Hematol Cell Ther** 1996 Aug; 38(4):325–30 (35 ref.)

Myelodysplastic syndromes. Lowenthal RM, et al. **Int J Hematol** 1997 Jun;65(4):319–38 (217 ref.)

Myelodysplastic syndromes: clinical features. Hofmann WK, et al. **Semin Hematol** 1996 Jul;33(3):177–85 (95 ref.)

Myelodysplastic syndromes. Koeffler HP. **Semin Hematol** 1996 Apr;33(2):87–94 (0 ref.)

[Bone marrow failure—current progress in pathophysiology] Hotta T. **Rinsho Ketsueki** 1996 Jun;37(6):472–7 (43 ref.) **(Jpn)**

[Abnormalities in blood cell production] Kanamaru A. **Rinsho Ketsueki** 1996 Jun;37(6):478–82 (12 ref.) **(Jpn)**

[9th Antonio Raichs memorial lecture. Myelodysplastic syndromes] Giralt M. **Sangre (Barc)** 1997 Feb;42(1):63–71

MYELODYSPLASTIC SYNDROMES

(29 ref.) **(Spa)**

BLOOD

Granulocyte dysplasia and dysfunction, and CD11/CD18 defects in myelodysplastic syndromes. Mazzone A, et al. **Leuk Lymphoma** 1996 Oct;23(3–4):267–75 (71 ref.)

[The role of bone marrow stromal cells in apoptosis in myelodysplastic syndrome] Yaguchi M, et al. **Rinsho Ketsueki** 1996 Jul;37(7):542–6 (10 ref.) **(Jpn)**

CHEMICALLY INDUCED

Therapy-related myelodysplastic syndromes. Park DJ, et al. **Semin Hematol** 1996 Jul;33(3):256–73 (160 ref.)

CLASSIFICATION

The myelodysplastic syndromes. Masey JA. **Br J Biomed Sci** 1997 Mar;54(1):65–70 (17 ref.)

Morphology and classification of the myelodysplastic syndromes and their pathologic variants. Kouides PA, et al. **Semin Hematol** 1996 Apr;33(2):95–110 (133 ref.)

[Myelodysplastic syndromes in children, Groupe d'étude des myélodysplasies de l'enfant de la Société d'hématologie et d'immunologie pédiatrique (SHIP)] Bader-Meunier B, et al. **Arch Pediatr** 1997 Jun;4(6):561–7 (38 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Systemic vasculitis and myelodysplastic syndromes. A report of two cases. Philippe B, et al. **Arthritis Rheum** 1997 Jan; 40(1):179–82 (16 ref.)

Behcet's disease complicated with myelodysplastic syndrome: a report of two cases and review of the literature. Yano K, et al. **Clin Rheumatol** 1996 Jan;15(1):91–3 (13 ref.)

Crohn's disease and the myelodysplastic syndrome. Castellote J, et al. **J Clin Gastroenterol** 1997 Jun;24(4):286–7 (11 ref.)

Simultaneous development of Crohn's disease and myelodysplastic syndrome progressing to acute myelocytic leukemia in a patient with a normal karyotype. Tani T, et al. **J Gastroenterol** 1996 Aug;31(4):599–602 (18 ref.)

Extramedullary myeloid cell tumors in myelodysplastic-syndromes: not a true indication of impending acute myeloid leukemia. Byrd JC, et al. **Leuk Lymphoma** 1996 Mar;21(1–2):153–9 (50 ref.)

Joint manifestations in myelodysplastic syndromes. A report of three cases presenting as polymyalgia rheumatica. Berthelot JM, et al. **Rev Rhum Engl Ed** 1997 Feb; 64(2):95–100 (35 ref.)

[A case of malignant rheumatoid arthritis associated with myelodysplastic syndrome] Hisakawa N, et al. **Ryumachi** 1997 Feb;37(1):30–5 (29 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Mast cell-lineage versus basophil lineage involvement in myeloproliferative and myelodysplastic syndromes: diagnostic role of cell-immunophenotyping. Agis H, et al. **Leuk Lymphoma** 1996 Jul;22(3–4):187–204 (104 ref.)

The role of magnetic resonance imaging in the diagnosis and monitoring of myelodysplastic syndromes or leukemia. Takagi S, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):443–50 (33 ref.)

Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count. Chan GC, et al. **Leukemia** 1997 Feb;11(2):206–11 (32 ref.)

Recurring diagnostic problems in the pathology of the myelodysplastic syndromes. Rosati S, et al. **Semin Hematol** 1996 Apr;33(2):111–26 (104 ref.)

[Myelodysplastic syndromes: their pathogenesis, diagnosis and differential diagnosis] Klimenko VI, et al. **Lik Sprava** 1996 Jan–Feb;(1–2):35–41 (36 ref.) **(Rus)**

DRUG THERAPY

Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes. Gassmann W, et al. **Semin Hematol** 1996 Jul;33(3):196–205 (65 ref.)

Differentiation therapy in myelodysplastic syndromes. Morosetti R, et al. **Semin Hematol** 1996 Jul;33(3):236–45 (120 ref.)

Treatment of the myelodysplastic syndromes: an updated Japanese experience. Yoshida Y. **Semin Hematol** 1996 Jul; 33(3):246–55 (43 ref.)

ETIOLOGY

Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment. van Leeuwen FE. **Baillieres Clin Haematol** 1996 Mar;9(1):57–85 (115 ref.)

Could aplastic anaemia be considered a pre-pre-leukaemic disorder? Socié G. **Eur J Haematol Suppl** 1996;60:60–3 (39 ref.)

[Myelodysplastic syndrome with multiple chromosome aberrations in a patient with Werner's syndrome] Mita M, et al. **Rinsho Ketsueki** 1996 Aug;37(8):725–30 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Myelodysplastic syndromes: their pathogenesis, diagnosis and differential diagnosis] Klimenko VI, et al. **Lik Sprava** 1996 Jan–Feb;(1–2):35–41 (36 ref.) **(Rus)**

[The myelodysplastic syndrome: the problems of its pathogenesis and treatment] Savchenko VG, et al. **Ter Arkh** 1996;68(7):31–7 (33 ref.) **(Rus)**

GENETICS

Molecular and cytogenetic abnormalities in acute myeloid leukaemia and myelodysplastic syndromes. de Greef GE, et al. **Baillieres Clin Haematol** 1996 Mar;9(1):1–18 (86 ref.)

The myelodysplastic syndromes. Masey JA. **Br J Biomed Sci** 1997 Mar;54(1):65–70 (17 ref.)

p190bcr/abl rearrangement in myelodysplastic syndromes: two reports and review of the literature. Lesesve JF, et al. **Br J Haematol** 1996 Nov;95(2):372–5 (34 ref.)

Monosomy X as a recurring sole cytogenetic abnormality associated with myelodysplastic diseases. Abruzzese E, et al. **Cancer Genet Cytogenet** 1997 Feb;93(2):140–6 (41 ref.)

Double minute chromosomes and myelodysplastic syndrome: a case report and literature review. Keung YK, et al. **Cancer Genet Cytogenet** 1997 Sep;97(2):94–6 (26 ref.)

XYY male and hematologic malignancy. Oguma N, et al. **Cancer Genet Cytogenet** 1996 Sep;90(2):179–81 (22 ref.)

5q–, twenty-five years later: a synopsis. Van den Berghe H, et al. **Cancer Genet Cytogenet** 1997 Mar;94(1):1–7 (37 ref.)

The molecular basis of myelodysplastic syndromes. Gallagher A, et al. **Haematologica** 1997 Mar–Apr;82(2):191–204 (202 ref.)

Diagnostic and prognostic significance of cytogenetics in adult primary myelodysplastic syndromes. Jotterand M, et al. **Leuk Lymphoma** 1996 Oct;23(3–4):253–66 (189 ref.)

TP53 mutations in myelodysplastic syndrome. Misawa S, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):417–22 (51 ref.)

Clinical aspects, cytogenetics and disease evolution in myelodysplastic syndromes. Ohyashiki K, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):409–15 (75 ref.)

Pattern of expression and their clinical implications of the GATA family, stem cell leukemia gene, and EVI1 in leukemia and myelodysplastic syndromes. Ohyashiki K, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):431–6 (47 ref.)

The non-random distribution of point mutations in leukaemia and myelodysplasia--a possible pointer to their aetiology. Parry TE. **Leuk Res** 1997 Jun;21(6):559–74 (81 ref.)

Molecular genetic aspects of myelodysplastic syndromes. Bartram CR. **Semin Hematol** 1996 Apr;33(2):139–49 (118 ref.)

Cytogenetics of myelodysplastic syndromes. Fenaux P, et al. **Semin Hematol** 1996 Apr;33(2):127–38 (90 ref.)

Ras and myelodysplasia: lessons from the last decade. Parker J, et al. **Semin Hematol** 1996 Jul;33(3):206–24 (205 ref.)

[Apropos of the case "Erythroblastopenia associated with myelodysplastic syndrome" (letter; comment) (see comments)] Aventín A. **Sangre (Barc)** 1996 Dec;41(6):483 (7 ref.) Comment on: Sangre (Barc) 1996 Jun;41(3):260. Comment in: Sangre (Barc) 1997 Feb;42(1):85. **(Spa)**

IMMUNOLOGY

Immunophenotyping of AML and MDS and detection of residual disease. Sanz MA, et al. **Baillieres Clin Haematol** 1996 Mar;9(1):35–55 (146 ref.)

Autoimmune phenomena in patients with myelodysplastic syndromes. Enright H, et al. **Leuk Lymphoma** 1997 Feb; 24(5–6):483–9 (33 ref.)

Immunological abnormalities in myelodysplastic syndromes. Hamblin TJ. **Semin Hematol** 1996 Apr;33(2):150–62 (127 ref.)

METABOLISM

Pattern of expression and their clinical implications of the GATA family, stem cell leukemia gene, and EVI1 in leukemia and myelodysplastic syndromes. Ohyashiki K, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):431–6 (47 ref.)

MORTALITY

Prognostic implications in myelodysplastic syndromes: A review of 62 cases. Higuchi T, et al. **Leuk Lymphoma** 1996 May;21(5–6):479–84 (30 ref.)

PATHOLOGY

Special cytological subtypes of acute myeloid leukaemias and myelodysplastic syndromes. Castoldi G, et al. **Baillieres Clin Haematol** 1996 Mar;9(1):19–33 (55 ref.)

Granulocyte dysplasia and dysfunction, and CD11/CD18 defects in myelodysplastic syndromes. Mazzone A, et al. **Leuk Lymphoma** 1996 Oct;23(3–4):267–75 (71 ref.)

Clinical aspects, cytogenetics and disease evolution in myelodysplastic syndromes. Ohyashiki K, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):409–15 (75 ref.)

Proliferation and differentiation of myelodysplastic CD34+ cells. Sawada K. **Leuk Lymphoma** 1996 Jun;22(1–2):43–51 (127 ref.)

Apoptosis as a parameter of cytokine treatment in myelodysplasia [comment] Yoshida Y. **Leuk Res** 1997 May; 21(5):427–8 (11 ref.) Comment on: Leuk Res 1997 May;21(5):415–25.

Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes. Greenberg PL. **Semin Hematol** 1996 Apr;33(2):163–75 (165 ref.)

PHYSIOPATHOLOGY

Myelodysplasia and the leukemias. Jacobs P. **Dis Mon** 1997 Aug;43(8):505–97 (183 ref.)

The myelodysplastic syndromes in 1996: complex stem cell disorders confounded by dual actions of cytokines [editorial; comment] Raza A, et al. **Leuk Res** 1996 Nov-Dec;20(11–12):881–90 (77 ref.) Comment on: Leuk Res 1996 Nov-Dec;20(11–12):891–900.

[Myelodysplastic syndrome] Segawa I. **Ryoikibetsu Shokogun Shirizu** 1996;(15):133–4 (6 ref.) **(Jpn)**

THERAPY

Treatment and prognostic factors in myelodysplastic syndromes. Boogaerts MA, et al. **Baillieres Clin Haematol** 1996 Mar;9(1):161–83 (123 ref.)

Role of allogeneic bone marrow transplantation for the treatment of myelodysplastic syndromes in childhood. The European Working Group on Childhood Myelodysplastic Syndrome (EWOG-MDS) and the Austria-Germany-Italy (AGI) Bone Marrow Transplantation Registry. Locatelli F, et al. **Bone Marrow Transplant** 1996 Nov;18 Suppl 2:63–8 (21 ref.)

Paediatric myelodysplasia. Passmore SJ, et al. **Br Med Bull** 1996 Oct;52(4):778–86 (29 ref.)

Adoptive immunotherapy with donor lymphocyte transfusions. Kolb HJ, et al. **Curr Opin Oncol** 1997 Mar; 9(2):139–45 (53 ref.)

Myelodysplasia and the leukemias. Jacobs P. **Dis Mon** 1997 Aug;43(8):505–97 (183 ref.)

Clinical use of hematopoietic growth factors in patients with myelodysplastic syndromes. Geissler RG, et al. **Int J Hematol** 1997 Jun;65(4):339–54 (161 ref.)

Apoptosis as a parameter of cytokine treatment in myelodysplasia [comment] Yoshida Y. **Leuk Res** 1997 May; 21(5):427–8 (11 ref.) Comment on: Leuk Res 1997 May;21(5):415–25.

Clinical use of hematopoietic growth factors in the myelodysplastic syndromes. Ganser A, et al. **Semin Hematol** 1996 Jul;33(3):186–95 (95 ref.)

Pathogenesis, biology, and management of myelodysplastic syndromes in children. Haas OA, et al. **Semin Hematol** 1996 Jul;33(3):225–35 (91 ref.)

[Therapy for high-risk MDS] Okamoto T. **Rinsho Ketsueki** 1996 Aug;37(8):661–5 (9 ref.) **(Jpn)**

[Current treatment methods in myelodysplastic syndromes] Klimenko VI, et al. **Lik Sprava** 1996 Oct-Dec;(10–12):20–6 (25 ref.) (Eng. Abstr.) **(Rus)**

MYELOFIBROSIS

ABC of clinical haematology. Polycythaemia, primary (essential) thrombocythaemia and myelofibrosis. Messinezy M, et al. **BMJ** 1997 Feb 22;314(7080):587–90 (0 ref.)

EPIDEMIOLOGY

Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias". Najean Y, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:111–9 (42 ref.)

PATHOLOGY

Clinicopathological impact of the interaction between megakaryocytes and myeloid stroma in chronic myeloproliferative disorders: a concise update. Thiele J, et al. **Leuk Lymphoma** 1997 Feb;24(5–6):463–81 (151 ref.)

MYELOGENOUS LEUKEMIA see **LEUKEMIA, MYELOID**

MYELOGENOUS LEUKEMIA, ACUTE see **LEUKEMIA, MYELOCYTIC, ACUTE**

MYELOGENOUS LEUKEMIA, CHRONIC see **LEUKEMIA, MYELOID, CHRONIC**

MYELOGENOUS LEUKEMIA, CHRONIC, AGGRESSIVE-PHASE see **LEUKEMIA, MYELOID, AGGRESSIVE-PHASE**

MYELOGENOUS LEUKEMIA, CHRONIC, CHRONIC-PHASE see **LEUKEMIA, MYELOID, CHRONIC-PHASE**

MYELOGENOUS LEUKEMIA, PH1-NEGATIVE see **LEUKEMIA, MYELOID, PHILADELPHIA-NEGATIVE**

MYELOGENOUS LEUKEMIA, PH1-POSITIVE see **LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE**

MYELOGRAPHY

ADVERSE EFFECTS

Symptomatic spinal intradural arachnoid cyst development after lumbar myelography. Case report and review of the literature. Kriss TC, et al. **Spine** 1997 Mar 1;22(5):568–72 (50 ref.)

Inadvertent intraoperative myelography with Hypaque: case report and discussion. Killeffer JA, et al. **Surg Neurol** 1997 Jul;48(1):70–3 (23 ref.)

MYELOID DIFFERENTIATION-INDUCING PROTEIN see **INTERLEUKIN-6**

MYELOID LEUKEMIA see **LEUKEMIA, MYELOID**

MYELOID LEUKEMIA, ACUTE, M1 see **LEUKEMIA, MYELOCYTIC, ACUTE**

MYELOID LEUKEMIA, ACUTE, M2 see **LEUKEMIA, MYELOCYTIC, ACUTE**

MYELOID LEUKEMIA, ACUTE, M3 see **LEUKEMIA, PROMYELOCYTIC, ACUTE**

MYELOID LEUKEMIA, ACUTE, M4 see **LEUKEMIA, MYELOMONOCYTIC, ACUTE**

MYELOID LEUKEMIA, ACUTE, M5 see **LEUKEMIA, MONOCYTIC, ACUTE**

MYELOID LEUKEMIA, ACUTE, M6 see **LEUKEMIA, ERYTHROBLASTIC, ACUTE**

MYELOID LEUKEMIA, ACUTE, M7 see **LEUKEMIA, MEGAKARYOCYTIC, ACUTE**

MYELOID LEUKEMIA, CHRONIC see **LEUKEMIA, MYELOID, CHRONIC**

MYELOID LEUKEMIA, CHRONIC, ACCELERATED-PHASE see **LEUKEMIA, MYELOID, AGGRESSIVE-PHASE**

MYELOID LEUKEMIA, CHRONIC, AGGRESSIVE-PHASE see **LEUKEMIA, MYELOID, AGGRESSIVE-PHASE**

MYELOID LEUKEMIA, CHRONIC, CHRONIC-PHASE see **LEUKEMIA, MYELOID, CHRONIC-PHASE**

MYELOID LEUKEMIA, CHRONIC, STABLE-PHASE see **LEUKEMIA, MYELOID, CHRONIC-PHASE**

MYELOID LEUKEMIA, NAEGELI-TYPE see **LEUKEMIA, MYELOMONOCYTIC, ACUTE**

MYELOID LEUKEMIA, PH1-NEGATIVE see **LEUKEMIA, MYELOID, PHILADELPHIA-NEGATIVE**

MYELOID LEUKEMIA, PH1-POSITIVE see **LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE**

MYELOID LEUKEMIA, PHILADELPHIA-NEGATIVE see **LEUKEMIA, MYELOID, PHILADELPHIA-NEGATIVE**

MYELOID LEUKEMIA, PHILADELPHIA-POSITIVE see **LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE**

MYELOID LEUKEMIA, SCHILLING-TYPE see **LEUKEMIA, MONOCYTIC, ACUTE**

MYELOID METAPLASIA

Current perspective in agnogenic myeloid metaplasia. Tefferi A, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:169–71 (30 ref.)

PATHOLOGY

Agnogenic myeloid metaplasia. Tefferi A, et al. **Cancer Invest** 1997;15(2):177–9 (32 ref.)

Diagnostic criteria of the myeloproliferative disorders (MPD): essential thrombocythaemia, polycythaemia vera and chronic megakaryocytic granulocytic metaplasia. Michiels JJ. **Neth J Med** 1997 Aug;51(2):57–64 (45 ref.)

THERAPY

Agnogenic myeloid metaplasia. Tefferi A, et al. **Cancer Invest** 1997;15(2):177–9 (32 ref.)

MYELOLIPOMA

Clinical, radiological and histological features of adrenal myelolipoma: review and experience with a further eight cases. El-Mekresh MM, et al. **Br J Urol** 1996 Sep; 78(3):345–50 (46 ref.)

COMPLICATIONS

Retroperitoneal hemorrhage due to a ruptured adrenal myelolipoma. A case report. Catalano O. **Acta Radiol** 1996 Sep;37(5):688–90 (30 ref.)

Adrenal myelolipoma with abdominal pain. Kobayashi T, et al. **Urol Int** 1997;58(4):254–6 (9 ref.)

DIAGNOSIS

Adrenal myelolipoma: case report with a review of the literature. Bayram F, et al. **Australas Radiol** 1996 Feb; 40(1):68–71 (34 ref.)

PATHOLOGY

Giant intra-adrenal myelolipoma associated with recurrent urinary tract infection. Houshiar AM, et al. **Int Urol Nephrol** 1997;29(2):130–6 (15 ref.)

Bilateral symptomatic adrenal myelolipoma. Bishoff JT, et al. **J Urol** 1997 Oct;158(4):1517–8 (5 ref.)

MYELOMA, PLASMA CELL see **MULTIPLE MYELOMA**

MYELOMENINGOCELE see **MENINGOMYELOCELE**

MYELOMONOCYTIC DIFFERENTIATION ANTIGENS see **ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC**

MYELOMONOCYTIC LEUKEMIA, ACUTE see **LEUKEMIA, MYELOMONOCYTIC, ACUTE**

MYELOMONOCYTIC LEUKEMIA, CHRONIC see **LEUKEMIA, MYELOMONOCYTIC, CHRONIC**

MYELOPATHIC MUSCULAR ATROPHY see **MUSCULAR ATROPHY, SPINAL**

MYELOPEROXIDASE see **PEROXIDASE**

MYELOPROLIFERATIVE DISORDERS

see related
LEUKEMIA

Myelodysplasia and myeloproliferative disorders. Anderson JE, et al. **Curr Opin Hematol** 1997 Jul;4(4):261–7 (53 ref.)

The myeloproliferative disorders. An historical appraisal and personal experiences. Michiels JJ. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:1–14 (155 ref.)

[Myeloproliferative diseases] Adam Z, et al. **Vnitr Lek** 1996 Oct;42(10):710–6 (30 ref.) (Eng. Abstr.) **(Cze)**

BLOOD

Bleeding time and platelet function in essential thrombocythemia and other myeloproliferative syndromes. Finazzi G, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:71–8 (88 ref.)

COMPLICATIONS

Atypical transient ischemic attacks in thrombocythemia of various myeloproliferative disorders. Michiels JJ, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:65–70 (32 ref.)

Acquired von Willebrand disease in myeloproliferative disorders. van Genderen PJ, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:79–82 (24 ref.)

[Vasculitis and malignant diseases] Gran JT. **Tidsskr Nor Laegeforen** 1997 Apr 30;117(11):1627–9 (47 ref.) (Eng. Abstr.) **(Nor)**

DIAGNOSIS

Mast cell-lineage versus basophil lineage involvement in myeloproliferative and myelodysplastic syndromes: diagnostic role of cell-immunophenotyping. Agis H, et al. **Leuk Lymphoma** 1996 Jul;22(3-4):187–204 (104 ref.)

GENETICS

Additional chromosome abnormalities in transient abnormal myelopoiesis in Down's syndrome patients. Kounami S, et al. **Acta Haematol** 1997;98(2):109–12 (17 ref.)

Deletions of chromosome 20q and the pathogenesis of myeloproliferative disorders. Asimakopoulos FA, et al. **Br J Haematol** 1996 Nov;95(2):219–26 (69 ref.)

5q-, twenty-five years later: a synopsis. Van den Berghe H, et al. **Cancer Genet Cytogenet** 1997 Mar;94(1):1–7 (37 ref.)

c-kit Point mutation in patients with myeloproliferative disorders. Kimura A, et al. **Leuk Lymphoma** 1997 Apr; 25(3-4):281–7 (32 ref.)

Coexistent T-cell lymphoblastic lymphoma and an atypical myeloproliferative disorder associated with t(8;13)(p21;q14). Somers GR, et al. **Pediatr Pathol Lab Med** 1997 Jan-Feb;17(1):141–58 (58 ref.)

FISHing among myeloproliferative disorders. Najfeld V. **Semin Hematol** 1997 Jan;34(1):55–63 (80 ref.)

PATHOLOGY

Megakaryocytes and platelets in myeloproliferative disorders. Briere J, et al. **Baillieres Clin Haematol** 1997 Feb; 10(1):65–88 (103 ref.)

Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. Georgii A, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:15–29 (79 ref.)

Clinicopathological impact of the interaction between megakaryocytes and myeloid stroma in chronic myeloproliferative disorders: a concise update. Thiele J, et al. **Leuk Lymphoma** 1997 Feb;24(5-6):463–81 (151 ref.)

In vitro erythropoiesis in polycythemia vera and other myeloproliferative disorders. Weinberg RS. **Semin Hematol** 1997 Jan;34(1):64–9 (55 ref.)

PHYSIOPATHOLOGY

Mechanisms of bleeding and thrombosis in myeloproliferative disorders. Landolfi R, et al. **Thromb Haemost** 1997 Jul; 78(1):617–21 (25 ref.)

THERAPY

Influence of interferon-alpha on cytokine expression by the bone marrow microenvironment--impact on treatment of myeloproliferative disorders. Peschel C, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:129–34 (77 ref.)

Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD). Murphy S. **Thromb Haemost** 1997 Jul;78(1):622–6 (46 ref.)

VETERINARY

Myelopoiesis and myeloproliferative disorders. Raskin RE. **Vet Clin North Am Small Anim Pract** 1996 Sep; 26(5):1023–42 (56 ref.)

MYELOSCLEROSIS see **MYELOFIBROSIS**

MYELOSIS, NONLEUKEMIC see **MYELOID METAPLASIA**

MYENTERIC PLEXUS

PHYSIOLOGY

Interplay of VIP and nitric oxide in the regulation of neuromuscular function in the gut. Murthy KS, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:355–62; discussion 362–3 (27 ref.)

MYERS-BRIGGS TYPE INDICATOR see **PERSONALITY INVENTORY**

MYIASIS

DIAGNOSIS

Cutaneous myiasis due to Dermatobia hominis in Japan. Taniguchi Y, et al. **J Dermatol** 1996 Feb;23(2):125–8 (18 ref.)

ETIOLOGY

Ophthalmomyiasis interna posterior and pigmentary retinopathy of Guam. Hira NK, et al. **J Am Optom Assoc** 1997 Jul;68(7):452–8 (23 ref.)

PARASITOLOGY

External ophthalmomyiasis, a disease established in Hawaii. Yoshimoto CM, et al. **Hawaii Med J** 1997 Jan;56(1):10–2 (21 ref.)

PATHOLOGY

Furuncular cutaneous myiasis caused by Dermatobia hominis larvae following travel to Brazil. Tsuda S, et al. **Int J Dermatol** 1996 Feb;35(2):121–3 (21 ref.)

PHYSIOPATHOLOGY

[Comparative physiopathology of Oestrus ovis (Linne 1761) myiasis in man and animals] Dorchies P. **Bull Acad Natl Med** 1997 Apr;181(4):673–83; discussion 683–4 (28 ref.) (Eng. Abstr.) **(Fre)**

TRANSMISSION

Cutaneous myiasis in a traveller returning from Africa. Ng SO, et al. **Australas J Dermatol** 1997 Feb;38(1):38–9 (16 ref.)

VETERINARY

Control of blowfly strike in sheep: current strategies and future prospects. Tellam RL, et al. **Int J Parasitol** 1997 Mar;27(3):261–73 (99 ref.)

MYO-INOSITOL 1,4,5-TRISPHOSPHATE see **INOSITOL 1,4,5-TRISPHOSPHATE**

MYOBLASTOMA see **NEOPLASMS, MUSCLE TISSUE**

MYOBLASTOMA, GRANULAR CELL see **GRANULAR CELL TUMOR**

MYOCARDIAL CONTRACTION

see related
CARDIOTONIC AGENTS
MYOCARDIAL STUNNING

Ca transport during contraction and relaxation in mammalian ventricular muscle. Bers DM. **Basic Res Cardiol** 1997;92 Suppl 1:1–10 (42 ref.)

The force-frequency relation in normal and failing heart. Faggiano P, et al. **Cardiologia** 1996 Dec;41(12):1155–64 (97 ref.)

Excitation-contraction coupling in heart: new insights from Ca2+ sparks. Cheng H, et al. **Cell Calcium** 1996 Aug; 20(2):129–40 (45 ref.)

Relaxation-systolic pressure relation. A load-independent assessment of left ventricular contractility. Gillebert TC, et al. **Circulation** 1997 Feb 4;95(3):745–52 (43 ref.)

Cytokines and cardiac contractile function [editorial] Kelly RA, et al. **Circulation** 1997 Feb 18;95(4):778–81 (50 ref.)

Regulation of the slow Ca++ channels of myocardial cells.

Sperelakis N, et al. **Mol Cell Biochem** 1996 Oct-Nov; 163-164:85-98 (49 ref.)

Excitation-contraction coupling of the developing rat heart. Vornanen M. **Mol Cell Biochem** 1996 Oct-Nov; 163-164:5-11 (51 ref.)

[Value of echocardiography-dobutamine in the study of reserve myocardial contractility in aortic stenosis with alteration of left ventricular function. Apropos of a case] Deluche L, et al. **Ann Cardiol Angeiol (Paris)** 1996 Nov; 45(9):523-6 (10 ref.) (Eng. Abstr.) **(Fre)**

[Calcium signal and contraction] Sauvadet A, et al. **C R Seances Soc Biol Fil** 1996;190(2-3):243-53 (24 ref.) (Eng. Abstr.) **(Fre)**

[Cardiac contractile dysfunction in response to surgical stress including trauma, hemorrhage, and infection] Suzuki K, et al. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):745-51 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Systole and diastole failure of the heart] Handa S, et al. **Nippon Naika Gakkai Zasshi** 1994 Jan 10;83(1):16-21 (5 ref.) **(Jpn)**

[Molecular mechanism of myocardial contraction and heart failure] Nagai R. **Nippon Naika Gakkai Zasshi** 1994 Jan 10;83(1):3-8 (5 ref.) **(Jpn)**

[Myocardial wall motion analysis with phase shift imaging: cine phase contrast technique] Kawamitsu H, et al. **Nippon Rinsho** 1997 Jul;55(7):1794-9 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Estimation of left ventricular wall motion and viability by SPAMM tagging cine MRI] Miura T, et al. **Nippon Rinsho** 1997 Jul;55(7):1811-5 (4 ref.) (Eng. Abstr.) **(Jpn)**

[Assessment of ventricular wall motion and volume by fast cine MRI using Fastcard sequence] Nakanishi T, et al. **Nippon Rinsho** 1997 Jul;55(7):1800-4 (13 ref.) (Eng. Abstr.) **(Jpn)**

[The evaluation of left ventricular wall motion with MRI tagging method] Saito I, et al. **Nippon Rinsho** 1997 Mar; 55 Suppl 1:634-7 (6 ref.) **(Jpn)**

[II. Role of Doppler echocardiography in the management of chronic ischemic cardiopathy] Alonso Gómez AM, et al. **Rev Esp Cardiol** 1997 Jan;50(1):15-25 (77 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Inotropic agents in older patients with chronic heart failure--current perspectives. Carbonin PU, et al. **Aging (Milano)** 1996 Apr;8(2):90-8 (74 ref.)

Alcohol and the heart: biochemical alterations. Preedy VR, et al. **Cardiovasc Res** 1996 Jan;31(1):139-47 (83 ref.)

Classification of positive inotropic actions based on electrophysiologic characteristics: where should calcium sensitizers be placed? Varro A, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 1:S32-44 (97 ref.)

Positive inotropic effect of angiotensin II. Increases in intracellular Ca2+ or changes in myofilament Ca2+ responsiveness? Mattiazzi A. **J Pharmacol Toxicol Methods** 1997 Jun;37(4):205-14 (80 ref.)

In search of ideal inotropic steroids: recent progress. Repke KR, et al. **Prog Drug Res** 1996;47:9-52 (172 ref.)

[Effect of neurotoxins on the electrical activity and contraction of the heart muscle] Sauviat MP. **C R Seances Soc Biol Fil** 1997;191(3):451-71 (122 ref.) (Eng. Abstr.) **(Fre)**

[Relationship among the heart, vasculature and blood volume at perioperative period: the influence of volatile anesthetics] Hoka S. **Masui** 1996 Jun;45(6):707-16 (33 ref.) (Eng. Abstr.) **(Jpn)**

[Acute toxic actions of mercury on the cardiovascular system] Vassallo DV, et al. **Arq Bras Cardiol** 1996 Jul; 67(1):39-45 (40 ref.) **(Por)**

PHYSIOLOGY

The hemodynamic manifestation of normal myocardial relaxation. A framework for experimental and clinical evaluation. Gillebert TC, et al. **Acta Cardiol** 1997; 52(3):223-46 (50 ref.)

Endothelial cell regulation of contractility of the heart. Winegrad S. **Annu Rev Physiol** 1997;59:505-25 (55 ref.)

Calcium cycling proteins and force-frequency relationship in heart failure. Hasenfuss G, et al. **Basic Res Cardiol** 1996; 91 Suppl 2:17-22 (31 ref.)

Ca(2+)-dependent and Ca(2+)-independent regulation of contractility in isolated human myocardium. Pieske B, et al. **Basic Res Cardiol** 1997;92 Suppl 1:75-86 (52 ref.)

Electrocardiographic characterization of myocardial function in normoxic and hypoxic teleosts. Rantin FT, et al. **Braz J Med Biol Res** 1995 Nov-Dec;28(11-12):1277-89 (47 ref.)

Heart failure and Starling's Law of the heart. ter Keurs HE. **Can J Cardiol** 1996 Oct;12(10):1047-57 (77 ref.)

Phospholamban: a prominent regulator of myocardial contractility. Koss KL, et al. **Circ Res** 1996 Dec; 79(6):1059-63 (42 ref.)

Comparison between abnormalities in segmental endocardial motion and abnormalities in segmental wall thickening after anterior myocardial infarction. A cine-magnetic resonance study. Germain P, et al. **Eur Heart J** 1996 Sep; 17(9):1350-61 (30 ref.)

The functions of two species of calcium channel in cardiac muscle excitation-contraction coupling. Williams AJ. **Eur Heart J** 1997 Jan;18 Suppl A:A27-35 (50 ref.)

Bioenergetics, ischemic contracture and reperfusion injury. Das DK, et al. **EXS** 1996;76:155-73 (50 ref.)

Cardiac contractility: modulation of myofibrillar calcium sensitivity by beta-adrenergic stimulation. Kögler H, et al. **Isr J Med Sci** 1997 Jan;33(1):1-7 (32 ref.)

The role of the NO pathway in the control of cardiac function. Smith TW, et al. **J Card Fail** 1996 Dec;2(4 Suppl):S141-7 (35 ref.)

Regulation of myocardial contractility. Opie LH. **J Cardiovasc Pharmacol** 1995;26 Suppl 1:S1-9 (30 ref.)

Classification of positive inotropic actions based on electrophysiologic characteristics: where should calcium sensitizers be placed? Varro A, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 1:S32-44 (97 ref.)

Optical methods to evaluate the contractile function of unloaded isolated cardiac myocytes. Delbridge LM, et al. **J Mol Cell Cardiol** 1997 Jan;29(1):11-25 (68 ref.)

Myocardial alpha1-adrenoceptor: inotropic effect and physiologic and pathologic implications. Li K, et al. **Life Sci** 1997;60(16):1305-18 (127 ref.)

Cardiac alpha(1)-adrenoceptors that regulate contractile function: subtypes and subcellular signal transduction mechanisms. Endoh M. **Neurochem Res** 1996 Feb; 21(2):217-29 (100 ref.)

Molecular aspects of regulation of cardiac contraction. Pelouch V. **Physiol Res** 1995;44(1):53-60 (63 ref.)

Calcium homeostasis and control of contractility in the developing heart. Mahony L. **Semin Perinatol** 1996 Dec; 20(6):510-9 (112 ref.)

[Contractile force and myocardial ischemia--electrical and ionic mechanisms] Köppel H, et al. **Acta Med Austriaca** 1997;24(3):114-21 (98 ref.) (Eng. Abstr.) **(Ger)**

[Cardiovascular effects of thyroid hormones] Mohr-Kahaly S, et al. **Z Kardiol** 1996;85 Suppl 6:219-31 (126 ref.) (Eng. Abstr.) **(Ger)**

[Frank-Starling mechanism and the 1st temporal derivative of ventricular pressure] Okoshi K, et al. **Arq Bras Cardiol** 1996 Apr;66(4):233-7 (41 ref.) **(Por)**

MYOCARDIAL DEPRESSANTS see **ANTI-ARRHYTHMIA AGENTS**

MYOCARDIAL DISEASES

Inflammatory myocardial diseases and cardiomyopathies. Pisani B, et al. **Am J Med** 1997 May;102(5):459-69 (81 ref.)

Molecular and immune mechanisms in the pathogenesis of cardiomyopathy--role of viruses, cytokines, and nitric oxide. Matsumori A. **Jpn Circ J** 1997 Apr;61(4):275-91 (104 ref.)

Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): progress in supportive care. Hellmann K. **Support Care Cancer** 1996 Jul;4(4):305-7 (5 ref.)

[Postpartum cardiomyopathy] Bertrand E. **Med Trop (Mars)** 1996;56(3 Suppl):45-6 (0 ref.) **(Fre)**

[Cardiomyopathy and enlarged hearts of athletes] Sugishita Y. **Nippon Naika Gakkai Zasshi** 1997 Mar 10;86(3):473-6 (4 ref.) **(Jpn)**

[Cardiac arrhythmias in cardiomyopathies] Yamaoki K, et al. **Nippon Rinsho** 1996 Aug;54(8):2197-201 (6 ref.) **(Jpn)**

[Peripartum cardiomyopathy of multiple pregnancy] Ikeda S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):170-3 (17 ref.) **(Jpn)**

[Electric disturbance type of cardiomyopathy (ECM)] Inoue S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):203-5 (12 ref.) **(Jpn)**

[Amyloidosis] Morishita T. **Ryoikibetsu Shokogun Shirizu** 1996;(15):391-4 (17 ref.) **(Jpn)**

[Cardiomyopathy in childhood] Nagashima M. **Ryoikibetsu Shokogun Shirizu** 1996;(14):115-8 (5 ref.) **(Jpn)**

[Cardiac Fabry's disease] Nakao S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):119-24 (3 ref.) **(Jpn)**

[Endocardial disease] Okada R. **Ryoikibetsu Shokogun Shirizu** 1996;(13):467-71 (20 ref.) **(Jpn)**

[Cardiac sarcoidosis] Sekiguchi M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):451-6 (22 ref.) **(Jpn)**

[Specific heart muscle disease] Suzuki K. **Ryoikibetsu Shokogun Shirizu** 1996;(14):182-5 (12 ref.) **(Jpn)**

[Latent cardiomyopathy] Takarada A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):161-5 (19 ref.) **(Jpn)**

[Peripartum cardiomyopathy] Tateda K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):104-7 (20 ref.) **(Jpn)**

[Cardiomyopathy (idiopathic cardiomyopathy)] Teraoka K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):133-7 (20 ref.) **(Jpn)**

[Cardiac amyloidosis: review of the literature] Gouveia D, et al. **Rev Port Cardiol** 1996 Sep;15(9):657-64, 613 (45 ref.) (Eng. Abstr.) **(Por)**

BLOOD

Biochemical markers of coagulation activation in mitral stenosis, atrial fibrillation, and cardiomyopathy. Ikeda U, et al. **Clin Cardiol** 1997 Jan;20(1):7-10 (36 ref.)

Role of elevated lipids in diabetic cardiomyopathy. McNeill JH. **Diabetes Res Clin Pract** 1996 Jul;31 Suppl:S67-71 (26 ref.)

CHEMICALLY INDUCED

Alcohol and the heart: biochemical alterations. Preedy VR, et al. **Cardiovasc Res** 1996 Jan;31(1):139-47 (83 ref.)

Review of tests for monitoring doxorubicin-induced cardiomyopathy. Ganz WI, et al. **Oncology** 1996 Nov-Dec; 53(6):461-70 (62 ref.)

[Catecholamine-induced cardiomyopathy] Aoyama N. **Ryoikibetsu Shokogun Shirizu** 1996;(14):57-60 (24 ref.) **(Jpn)**

[Acute reversible catecholamine cardiomyopathy] Dote K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):166-9 (12 ref.) **(Jpn)**

[The cardiotoxicity of anticancer agents] Wakasugi S. **Ryoikibetsu Shokogun Shirizu** 1996;(14):83-7 (14 ref.) **(Jpn)**

CLASSIFICATION

[Cardiomyopathies. Definition and classification] Sacrez A. **Med Trop (Mars)** 1996;56(3 Suppl):31-2 (2 ref.) **(Fre)**

[Lights and shadows in the new classification of cardiomyopathy] Sangiorgi M. **G Ital Cardiol** 1997 Jun; 27(6):613-20 (67 ref.) **(Ita)**

COMPLICATIONS

Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy. Management with intravenous magnesium sulfate. Winters SL, et al. **Chest** 1997 May; 111(5):1454-7 (6 ref.)

Cardiovascular manifestations of HIV infection. Epstein JE, et al. **Compr Ther** 1996 Aug;22(8):485-91 (45 ref.)

Idiopathic ventricular fibrillation of the Brugada type: an atypical form of arrhythmogenic right ventricular cardiomyopathy? [editorial; comment] Ohe T. **Intern Med** 1996 Aug;35(8):595 (5 ref.) Comment on: Intern Med 1996 Aug;35(8):637-40.

Therapy of ventricular tachycardia in patients with nonischemic cardiomyopathies. Blanck Z, et al. **J Cardiovasc Electrophysiol** 1996 Jul;7(7):671-83 (66 ref.)

[Left ventricular systolic dysfunction in cardiomyopathies] Bouhour JB, et al. **Arch Mal Coeur Vaiss** 1996 Jul;89 Spec No 2:33-7 (27 ref.) (Eng. Abstr.) **(Fre)**

[Cardiac arrhythmias of primary and secondary origin in cardiomyopathy] Klein RM, et al. **Internist (Berl)** 1996 Jan; 37(1):18-33 (99 ref.) **(Ger)**

[Congenital cardiomyopathies and sudden death] Basso C, et al. **G Ital Cardiol** 1996 Sep;26(9):1039-48 (42 ref.) **(Ita)**

[Muscular dystrophies] Ishihara T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):93-5 (20 ref.) **(Jpn)**

[Cataract and cardiomyopathy] Ohya N. **Ryoikibetsu Shokogun Shirizu** 1996;(15):331-3 (22 ref.) **(Jpn)**

[Arrhythmogenic right ventricular dysplasia (ARVD)] Shimizu W. **Ryoikibetsu Shokogun Shirizu** 1996;(12):479-82 (10 ref.) **(Jpn)**

[A clinical case of restrictive myocarditis due to senile-type amyloidosis] Martins M, et al. **Rev Port Cardiol** 1997 Apr; 16(4):383-9, 352 (12 ref.) (Eng. Abstr.) **(Por)**

[Anaphylaxis due to the rupture of a hydatid cyst in the right ventricle (letter)] Valdovinos Mahave MC, et al. **Med Clin (Barc)** 1997 Feb 15;108(6):238-9 (7 ref.) **(Spa)**

DIAGNOSIS

Cardiac sarcoidosis: diagnostic, prognostic, and therapeutic considerations. Sekiguchi M, et al. **Cardiovasc Drugs Ther** 1996 Nov;10(5):495-510 (288 ref.)

Clinical approach to genetic cardiomyopathy in children. Schwartz ML, et al. **Circulation** 1996 Oct 15;94(8):2021-38 (214 ref.)

Cardiac aspergillosis presenting as myocardial infarction. Cishek MB, et al. **Clin Cardiol** 1996 Oct;19(10):824-7 (11 ref.)

Cardiac troponin I and troponin T: are enzymes still relevant as cardiac markers? Mair J. **Clin Chim Acta** 1997 Jan 3; 257(1):99-115 (63 ref.)

Diagnostic evaluation of myocardial abscesses. A new look at an old problem. Chakrabarti J. **Int J Cardiol** 1995 Dec; 52(3):189-96 (45 ref.)

Arrhythmogenic right ventricular dysplasia. Chauhan A, et al. **Int J Cardiol** 1996 Oct 11;56(2):107-12 (48 ref.)

Absent septal q wave on electrocardiogram: a forgotten marker of myocardial disease. Xiao HB, et al. **Int J Cardiol** 1996 Jan;53(1):1-4 (27 ref.)

[Mitochondrial cardiomyopathies: a new entity in cardiology research and diagnosis] Bernucci P, et al. **G Ital Cardiol** 1996 Sep;26(9):1031-7 (31 ref.) **(Ita)**

[Incessant atrial tachycardia and peripartum cardiomyopathy--a therapeutic challenge] Brito D, et al. **Rev Port Cardiol** 1997 Feb;16(2):157-63, 124 (19 ref.) (Eng. Abstr.) **(Por)**

[Essential aspects of differential diagnosis of coronarogenic and non-coronarogenic myocardial lesions] Gurevich MA, et al. **Klin Med (Mosk)** 1997;75(4):28-32 (0 ref.) **(Rus)**

DRUG THERAPY

Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Eichhorn EJ, et al. **Circulation** 1996 Nov 1;94(9):2285–96 (156 ref.)

Long-term growth hormone deficiency as a cause of cardiomyopathy and its reversibility with specific replacement therapy. Fazio S, et al. **J Clin Endocrinol Metab** 1996 Mar;81(3):887–90 (19 ref.)

ETIOLOGY

Iatrogenic coronary septal artery–to–right ventricular fistula complicating percutaneous transluminal coronary angioplasty with spontaneous resolution. Youssef M, et al. **Am Heart J** 1997 Feb;133(2):260–2 (9 ref.)

Interacting nutritional and infectious etiologies of Keshan disease. Insights from coxsackie virus B–induced myocarditis in mice deficient in selenium or vitamin E. Levander OA, et al. **Biol Trace Elem Res** 1997 Jan; 56(1):5–21 (75 ref.)

Myocardial aspects of HIV infection [editorial] De Castro S, et al. **Cardiologia** 1997 Apr;42(4):337–41 (34 ref.)

Controversies on the sensitivity of the diabetic heart to ischemic injury: the sensitivity of the diabetic heart to ischemic injury is decreased. Feuvray D, et al. **Cardiovasc Res** 1997 Apr;34(1):113–20 (84 ref.)

Aldosterone, salt and cardiac fibrosis. Funder JW. **Clin Exp Hypertens** 1997 Jul–Aug;19(5–6):885–99 (25 ref.)

Diabetic cardiomyopathy: an overview. LeWinter MM. **Coron Artery Dis** 1996 Feb;7(2):95–8 (44 ref.)

Cardiomyopathy and other symptomatic heart diseases associated with HIV infection. Herskowitz A. **Curr Opin Cardiol** 1996 May;11(3):325–31 (34 ref.)

Reversible cardiomyopathy in a child with Addison's disease. Derish M, et al. **Intensive Care Med** 1996 May;22(5):460–3 (15 ref.)

Long-term growth hormone deficiency as a cause of cardiomyopathy and its reversibility with specific replacement therapy. Fazio S, et al. **J Clin Endocrinol Metab** 1996 Mar;81(3):887–90 (19 ref.)

[New concepts in the therapy of diabetic cardiopathies] Pogátsa G. **Orv Hetil** 1997 Jun 8;138(23):1491–4 (50 ref.) (Eng. Abstr.) **(Hun)**

[Cardiopathy in systemic sclerosis] Valentini G, et al. **Recenti Prog Med** 1996 Nov;87(11):557–63 (40 ref.) (Eng. Abstr.) **(Ita)**

[Coping with pathological changes in heart of patients with collagen disease] Matsumoto Y. **Nippon Naika Gakkai Zasshi** 1996 Nov 10;85(11):1833–9 (5 ref.) **(Jpn)**

[Radiation induced cardiomyopathy] Inoue K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):206–10 (20 ref.) **(Jpn)**

[Nutritional disorders and myocardial disease] Masani F, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):36–8 (12 ref.) **(Jpn)**

[Tachycardia–induced cardiomyopathy] Takaoka H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):199–202 (14 ref.) **(Jpn)**

[Uremic cardiomyopathy] Tsuzuki K. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):56–9 (6 ref.) **(Jpn)**

GENETICS

Clinical approach to genetic cardiomyopathy in children. Schwartz ML, et al. **Circulation** 1996 Oct 15;94(8):2021–38 (214 ref.)

Dystrophies and heart disease. Cox GF, et al. **Curr Opin Cardiol** 1997 May;12(3):329–43 (112 ref.)

Mitochondrial DNA mutations in diabetic heart. Takeda N. **Diabetes Res Clin Pract** 1996 Jul;31 Suppl:S123–6 (13 ref.)

Familial desmin–related myopathies and cardiomyopathies—from myopathology to molecular and clinical genetics. 36th European Neuromuscular Center (ENMC)–Sponsored International Workshop 20–22 October, 1995, Naarden, The Netherlands. Goebel HH, et al. **Neuromuscul Disord** 1996 Oct;6(5):383–8 (36 ref.)

Molecular genetics and its application to cardiac muscle disease. Roberts R. **Sports Med** 1997 Jan;23(1):1–10 (37 ref.)

[Cardiomyopathies] Schwartz K. **Pathol Biol (Paris)** 1997 Mar;45(3):213–7 (34 ref.) (Eng. Abstr.) **(Fre)**

[Mitochondrial cardiomyopathies: a new entity in cardiology research and diagnosis] Bernucci P, et al. **G Ital Cardiol** 1996 Sep;26(9):1031–7 (31 ref.) **(Ita)**

[Mitochondria cardiomyopathy] Kira Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):215–8 (17 ref.) **(Jpn)**

[Hereditary heart muscle diseases] Nishikawa T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):22–8 (19 ref.) **(Jpn)**

IMMUNOLOGY

[Cytokines and heart diseases. Attempt at an update] Werdan K. **Med Klin** 1997 Jul 15;92(7):432–8 (29 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Cytosolic Ca2+ concentration decreases in diabetic rat myocytes. Hayashi H, et al. **Cardiovasc Res** 1997 Apr; 34(1):99–103 (53 ref.)

Regulation of energy substrate metabolism in the diabetic heart. Stanley WC, et al. **Cardiovasc Res** 1997 Apr; 34(1):25–33 (110 ref.)

Intracellular calcium levels are unchanged in the diabetic heart. Yu JZ, et al. **Cardiovasc Res** 1997 Apr;34(1):91–8 (74 ref.)

Cardiac troponin I and troponin T: are enzymes still relevant as cardiac markers? Mair J. **Clin Chim Acta** 1997 Jan 3; 257(1):99–115 (63 ref.)

Alterations in myocardial contractile proteins in diabetes mellitus. Akella AB, et al. **Coron Artery Dis** 1996 Feb; 7(2):124–32 (104 ref.)

Newer findings on a unified perspective of copper restriction and cardiomyopathy. Medeiros DM, et al. **Proc Soc Exp Biol Med** 1997 Sep;215(4):299–313 (156 ref.)

[Fatty heart, myocardial fatty infiltration] Nishimiya T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):108–10 (17 ref.) **(Jpn)**

PARASITOLOGY

[Hydatid cyst of the heart] Bréchignac X, et al. **Presse Med** 1997 Apr 26;26(14):663–5 (17 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

The myocardial and vascular pathology of diabetic cardiomyopathy. Hardin NJ. **Coron Artery Dis** 1996 Feb; 7(2):99–108 (61 ref.)

[Myocarditis and cardiomyopathy] Kandolf R. **Verh Dtsch Ges Pathol** 1996;80:127–38 (51 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Peripartum cardiomyopathy: four case histories and a commentary on anaesthetic management. George LM, et al. **Anaesth Intensive Care** 1997 Jun;25(3):292–6 (17 ref.)

Maintenance of cardiac function during anoxia in turtles: from cell to organism. Wasser JS. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Jan; 113(1):15–22 (39 ref.)

Cardiovascular disease in the elderly. Cefalu CA, et al. **Compr Ther** 1996 Aug;22(8):509–14 (23 ref.)

Abnormal microvascular function in diabetes: relationship to diabetic cardiomyopathy. Rossen JD. **Coron Artery Dis** 1996 Feb;7(2):133–8 (43 ref.)

Myocardial alterations in diabetes and hypertension. Factor SM, et al. **Diabetes Res Clin Pract** 1996 Jul;31 Suppl:S133–42 (58 ref.)

Cardiomyopathies and oxidative stress. Romero–Alvira D, et al. **Med Hypotheses** 1996 Aug;47(2):137–44 (89 ref.)

Elucidating molecular mechanisms of septic cardiomyopathy—the cardiomyocyte model. Werdan K, et al. **Mol Cell Biochem** 1996 Oct–Nov;163–164:291–303 (73 ref.)

[The heart in infection and MODS (multiple organ dysfunction syndrome)] Müller–Werdan U, et al. **Wien Klin Wochenschr Suppl** 1997;1:3–24 (200 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Quantitative evaluation of regional myocardial perfusion using fast X–ray computed tomography. Schmermund A, et al. **Herz** 1997 Feb;22(1):29–39 (30 ref.)

Magnetic resonance imaging of acquired cardiac disease. Carrol CL, et al. **Tex Heart Inst J** 1996;23(2):144–54 (87 ref.)

RADIONUCLIDE IMAGING

[Diabetic cardiomyopathy] Aizaki T. **Ryoikibetsu Shokogun Shirizu** 1996;(14):174–7 (20 ref.) **(Jpn)**

THERAPY

Cardiac sarcoidosis: diagnostic, prognostic, and therapeutic considerations. Sekiguchi M, et al. **Cardiovasc Drugs Ther** 1996 Nov;10(5):495–510 (288 ref.)

Removal of autoantibodies in dilated cardiomyopathy by immunoadsorption. Wallukat G, et al. **Int J Cardiol** 1996 May;54(2):191–5 (24 ref.)

Dual–chamber pacing for cardiomyopathies: a 1996 clinical perspective. Nishimura RA, et al. **Mayo Clin Proc** 1996 Nov;71(11):1077–87 (47 ref.)

[Guided anti–arrhythmia therapy by programmed ventricular stimulation. A case of arrhythmogenic dysplasia of the right ventricle] Oliveira M, et al. **Rev Port Cardiol** 1997 Jan; 16(1):33–8, 8 (27 ref.) (Eng. Abstr.) **(Por)**

ULTRASONOGRAPHY

The vital role of papillary muscles in mitral and ventricular function: echocardiographic insights [see comments] Madu EC, et al. **Clin Cardiol** 1997 Feb;20(2):93–8 (30 ref.) Comment in: Clin Cardiol 1997 May;20(5):506.

Left ventricular hydatid cyst: an unusual location of Echinococcus granulosus with multiple organ involvement. Atilgan D, et al. **J Am Soc Echocardiogr** 1996 Mar–Apr; 9(2):212–5 (7 ref.)

MYOCARDIAL DISEASES, PRIMARY see **MYOCARDIAL DISEASES**

MYOCARDIAL DISEASES, SECONDARY see **MYOCARDIAL DISEASES**

MYOCARDIAL HIBERNATION see **MYOCARDIAL STUNNING**

MYOCARDIAL INFARCTION

see related
HEART RUPTURE, POST–INFARCTION

Acute myocardial infarction in a previously healthy adolescent. Frederick H. **Am J Emerg Med** 1996 Oct; 14(6):570–1 (17 ref.)

Acute myocardial infarction associated with pregnancy. Roth A, et al. **Ann Intern Med** 1996 Nov 1;125(9):751–62 (194 ref.)

Social support, social networks and coronary artery disease rehabilitation: a review. Anderson D, et al. **Can J Cardiol** 1996 Aug;12(8):739–44 (52 ref.)

An update on acute myocardial infarction from recent clinical trials. Greenbaum AB, et al. **Curr Opin Cardiol** 1997 Jul; 12(4):418–26 (41 ref.)

Can qualitative echocardiography be used to select patients for angiotensin–converting enzyme inhibitors following acute myocardial infarction? Darbar D, et al. **Eur Heart J** 1996 Dec;17(12):1783–6 (29 ref.)

The role of insulin–like and basic fibroblast growth factors on ischemic and infarcted myocardium: a mini review. Scheinowitz M, et al. **Int J Cardiol** 1997 Mar;59(1):1–5 (43 ref.)

Emergency department management of acute myocardial infarction. Mintz E. **Mt Sinai J Med** 1997 Sep–Oct; 64(4–5):258–74 (143 ref.)

Tracing patients with myocardial infarction for a 10–year follow–up study. Froelicher ES. **Nurs Res** 1996 Nov–Dec; 45(6):341–4 (16 ref.)

The non–Q wave myocardial infarction revisited: 10 years later. Liebson PR, et al. **Prog Cardiovasc Dis** 1997 Mar–Apr;39(5):399–444 (296 ref.)

[Infarction and pregnancy. Review of the literature. A case report] Dufour P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(7):746–51 (24 ref.) (Eng. Abstr.) **(Fre)**

[Non–Q wave myocardial infarction: treatment and risk stratification] Metzker E, et al. **Harefuah** 1997 Apr 1; 132(7):485–90 (44 ref.) **(Heb)**

[Epidemiology of avoidable delay in the treatment of acute myocardial infarct: study conducted by "GISSI" (Italian Group for the Study of Survival after Myocardial Infarct)] **G Ital Cardiol** 1996 Jul;26(7):807–20 (31 ref.) (Eng. Abstr.) **(Ita)**

[Right ventricular infarction] Goto Y. **Ryoikibetsu Shokogun Shirizu** 1996;(12):566–9 (20 ref.) **(Jpn)**

[Hemorrhagic myocardial infarction] Imakita M. **Ryoikibetsu Shokogun Shirizu** 1996;(12):672–5 (16 ref.) **(Jpn)**

[Old myocardial infarction] Miyakawa T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):741–5 (20 ref.) **(Jpn)**

[Coronary spastic myocardial infarction] Ogawa H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):625–8 (6 ref.) **(Jpn)**

[Myocardial infarction with normal coronary arteries] Ohgitani N. **Ryoikibetsu Shokogun Shirizu** 1996;(12):722–5 (14 ref.) **(Jpn)**

[Unrecognized myocardial infarction] Ozono K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):780–4 (12 ref.) **(Jpn)**

[Myocardial infarction during pregnancy] Sakamoto S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):746–8 (15 ref.) **(Jpn)**

BLOOD

To T or not to T, that is the question [editorial; comment] Collinson PO. **Clin Chem** 1997 Mar;43(3):421–3 (37 ref.) Comment on: Clin Chem 1997 Mar;43(3):458–66. Comment on: Clin Chem 1997 Mar;43(3):476–84.

Biochemical markers of myocardial damage for early diagnosis and prognosis in patients with acute coronary syndromes. Minireview based on a doctorial thesis. Lindahl B. **Ups J Med Sci** 1996;101(3):193–232 (210 ref.)

[Alcohol, lipid metabolism and coronary heart disease] Schneider J, et al. **Herz** 1996 Aug;21(4):217–26 (66 ref.) (Eng. Abstr.) **(Ger)**

[Lipid, apoprotein and fibrinogen levels in the blood of male patients following myocardial infarct and the effect of diet on these parameters in ischemic heart disease] Márk L, et al. **Orv Hetil** 1996 Nov 3;137(44):2447–50 (40 ref.) (Eng. Abstr.) **(Hun)**

[The reduction of cardiovascular events after a myocardial infarct in patients with normal cholesterol levels] Hartley H. **Rev Clin Esp** 1996 Dec;196(4 Monografico):43–6 (27 ref.) **(Spa)**

CHEMICALLY INDUCED

1995: the year of the calcium antagonist controversy. Cohen JD. **Curr Opin Nephrol Hypertens** 1996 May;5(3):214–8 (34 ref.)

Chemotherapy–induced myocardial infarction [letter] Law H. **Eur Heart J** 1996 Jun;17(6):966–7 (7 ref.)

The estrogen component of OCs: cardiovascular benefits and risks. Burkman RT. **Int J Fertil Womens Med** 1997;Suppl 1:145–57 (52 ref.)

Myocardial infarction after toluene inhalation. Carder JR, et al. **Pediatr Emerg Care** 1997 Apr;13(2):117–9 (7 ref.)

Oral contraceptives and myocardial infarction: new evidence leaves unanswered questions. Thorogood M. **Thromb Haemost** 1997 Jul;78(1):334–8 (14 ref.)

COMPLICATIONS

American College of Cardiology/American Heart Association guidelines for pacemaker implantation after acute myocardial infarction. What is persistent advanced block at the atrioventricular node? [editorial] Barold SS. **Am J Cardiol** 1997 Sep 15;80(6):770–4 (41 ref.)

Current role and future perspectives for radiofrequency catheter ablation of postmyocardial infarction ventricular tachycardia. Farré J, et al. **Am J Cardiol** 1996 Sep 12; 78(5A):76–88 (42 ref.)

Amiodarone: a late comer. Futterman LG, et al. **Am J Crit Care** 1997 May;6(3):233–9 (23 ref.)

Evolving concepts in autologous blood procurement and transfusion: case reports of perisurgical anemia complicated by myocardial infarction. Goodnough LT, et al. **Am J Med** 1996 Aug 26;101(2A):33S–37S (30 ref.)

Complications of MI: beyond the acute stage. O'Donnel L. **Am J Nurs** 1996 Sep;96(9):25–30; quiz 30–1 (15 ref.)

Survival following cardiogenic shock caused by acute left main coronary artery total occlusion. A case report and review of the literature. Itoh T, et al. **Angiology** 1997 Feb; 48(2):163–71 (33 ref.)

Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Aronson D, et al. **Ann Intern Med** 1997 Feb 15; 126(4):296–306 (173 ref.)

Remodeling after myocardial infarction: an opportunity for early intervention. Amos DJ, et al. **Basic Res Cardiol** 1997 Apr;92(2):69–71 (10 ref.)

Regional dysfunction and ventricular remodeling in the infarcted patient. Marino P, et al. **Basic Res Cardiol** 1997 Apr;92(2):72–4 (10 ref.)

Management of postinfarction ventricular septal defect. Caputo M, et al. **Br J Hosp Med** 1995 Dec 13–1996 Jan 16;54(11):562–6 (17 ref.)

Impact of therapy on left ventricular remodeling after myocardial infarction: an echocardiographic perspective. Popović AD. **Cardiologia** 1997 Jul;42(7):681–6 (29 ref.)

Hepatic bleeding and hemorrhagic shock following thrombolytic therapy in patients with acute myocardial infarction [letter] Gárcia-Jiménez A, et al. **Chest** 1997 Jun; 111(6):1787 (5 ref.)

Detecting and preventing ventricular remodeling after MI. Popovic AD, et al. **Cleve Clin J Med** 1997 Jun;64(6):319–25 (26 ref.)

Pericardial involvement in acute myocardial infarction in the post-thrombolytic era: clinical meaning and value. Correale E, et al. **Clin Cardiol** 1997 Apr;20(4):327–31 (37 ref.)

Left ventricular mural thrombus after acute myocardial infarction. Keeley EC, et al. **Clin Cardiol** 1996 Feb; 19(2):83–6 (26 ref.)

Evaluation and treatment strategies in patients at high risk of sudden death post myocardial infarction. Underwood RD, et al. **Clin Cardiol** 1997 Sep;20(9):753–8 (60 ref.)

Quantitative echocardiography in left ventricular remodeling after myocardial infarction. Sutton MS. **Curr Opin Cardiol** 1996 Jul;11(4):378–85 (48 ref.)

Gastrointestinal endoscopy in high-risk patients. Cappell MS. **Dig Dis** 1996 Jul–Aug;14(4):228–44 (115 ref.)

Depression and myocardial infarction. Implications for medical prognosis and options for treatment. Cleophas TJ. **Drugs Aging** 1997 Aug;11(2):111–8 (64 ref.)

Angina pectoris in patients with a history of myocardial infarction. Sellier P. **Eur Heart J** 1996 Dec;17 Suppl G:25–9 (30 ref.)

Left ventricular thrombus in acute myocardial infarction. van Dantzig JM, et al. **Eur Heart J** 1996 Nov;17(11):1640–5 (81 ref.)

Mechanisms of subcellular remodelling in post-infarct heart failure. Dhalla NS, et al. **EXS** 1996;76:463–77 (75 ref.)

Digital rectal examination during early acute MI [editorial] Lee JR, et al. **Hosp Pract (Off Ed)** 1997 Sep 15;32(9):15–6 (11 ref.)

Amiodarone in high-risk post-infarction patients, Lessons from EMIAT and CAMIAT. European Myocardial Infarct Amiodarone Trial and Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. Gambhir DS. **Indian Heart J** 1996 Jul–Aug;48(4):339–41 (14 ref.)

Acquired left ventricular to right atrial intracardiac shunt after myocardial infarction: a case report and review of the literature. Newman JN Jr, et al. **J Am Soc Echocardiogr** 1996 Sep–Oct;9(5):716–20 (21 ref.)

Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? [see comments] Vallance P, et al. **Lancet** 1997 May 10;349(9062):1391–2 (30 ref.) Comment in: Lancet 1997 Jul 26;350(9073):293. Comment in: Lancet 1997 Jul 26;350(9073):293–4.

Coronary artery disease in insulin-dependent diabetes mellitus of pregnancy (class H): a review of the literature. Gordon MC, et al. **Obstet Gynecol Surv** 1996 Jul; 51(7):437–44 (36 ref.)

Aortic intimal sarcoma with acute myocardial infarction. Nanjo H, et al. **Pathol Int** 1996 Sep;46(9):673–81 (40 ref.)

[Clinical, echocardiographic and Doppler outcome in ischemic right ventricular dysfunction associated with inferior wall infarction] Logeart D, et al. **Arch Mal Coeur Vaiss** 1997 Mar;90(3):363–9 (22 ref.) (Eng. Abstr.) **(Fre)**

[Can myocardial damage following heart infarct be reversible? (editorial)] Atar D, et al. **Schweiz Rundsch Med Prax** 1997 Mar 11;86(11):421–4 (21 ref.) **(Ger)**

[Prospectives in catheter ablation: treatment of atrial fibrillation and recurrent post-infarct ventricular tachycardia] Della Bella P, et al. **Cardiologia** 1996 Aug; 41(8):747–50 (28 ref.) **(Ita)**

[Disorders of intraventricular conduction in the course of acute myocardial infarct: frequency of occurrence, clinical significance, indications and role of electrical therapy] Berisso MZ, et al. **G Ital Cardiol** 1997 Aug;27(8):840–7 (40 ref.) **(Ita)**

[The role of nitrates in left ventricular insufficiency in patients with acute myocardial infarction] Maggioni AP. **G Ital Cardiol** 1996 Sep;26(9):1095–8 (04 ref.) **(Ita)**

[Role of spectral turbulence analysis of ECG in predicting risk of arrhythmia after myocardial infarction] Vado A, et al. **G Ital Cardiol** 1997 Jul;27(7):674–81 (25 ref.) (Eng. Abstr.) **(Ita)**

[Surgical treatment of left ventricular aneurysm with acute myocardial infarction associated to mitral valve stenosis: a case report] Sunazawa T, et al. **Kyobu Geka** 1997 May; 50(5):400–3 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Underlaying disease and etiology of heart failure] Nakano T, et al. **Nippon Naika Gakkai Zasshi** 1994 Jan 10; 83(1):27–30 (3 ref.) **(Jpn)**

[Therapy of cardiogenic shock due to myocardial infarction] Nonogi H. **Nippon Naika Gakkai Zasshi** 1996 Jan 10; 85(1):54–9 (5 ref.) **(Jpn)**

[Post infarction (congestive) heart failure] Degawa T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):46–50 (25 ref.) **(Jpn)**

[Complications associated with myocardial infarction] Horimoto M. **Ryoikibetsu Shokogun Shirizu** 1996;(12):704–8 (15 ref.) **(Jpn)**

[Myocardial infarction complicated by ventricular aneurysm] Horimoto M. **Ryoikibetsu Shokogun Shirizu** 1996; (12):709–12 (20 ref.) **(Jpn)**

[Mitral isthmus ventricular tachycardia] Miyazaki T. **Ryoikibetsu Shokogun Shirizu** 1996;(12):199–202 (5 ref.) **(Jpn)**

[Postmyocardial infarction syndrome] Shimizu M. **Ryoikibetsu Shokogun Shirizu** 1996;(12):692–5 (14 ref.) **(Jpn)**

[Intracardiac thrombosis in myocardial infarction] Sudo K. **Ryoikibetsu Shokogun Shirizu** 1996;(12):696–9 (11 ref.) **(Jpn)**

[Preinfarction angina and postinfarction angina] Suzuki T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):700–3 (13 ref.) **(Jpn)**

[The current concept of early postinfarct stenocardia and the procedure for patient management] Shumakov VA, et al. **Lik Sprava** 1997 Mar–Apr;(2):15–9 (39 ref.) **(Rus)**

[Pulmonary hemorrhage after thrombolysis in acute myocardial infarct (letter) (corrected and republished letter originally printed in An Med Interna 1996 Oct;13(10):514–5)] Rodríguez Blanco VM, et al. **An Med Interna** 1997 Apr;14(4):209 (7 ref.) **(Spa)**

[Radiofrequency catheter ablation of ventricular tachycardias in patients with postinfarction scars] Merino Lloréns JL, et al. **Rev Esp Cardiol** 1997 Mar;50(3):157–65 (20 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

SGOT, LDH, HBD, CPK, CK-MB, MB1MB2, cTnT, cTnC, cTnI. Futterman LG, et al. **Am J Crit Care** 1997 Jul;6(4):333–8 (6 ref.)

The diagnosis and management of acute myocardial infarction--a role for biochemical markers? [see comments] Tormey WP. **Ann Clin Biochem** 1996 Nov;33 (Pt 6):477–81 (36 ref.) Comment in: Ann Clin Biochem 1997 May;34 (Pt 3):326–8.

Risk stratification after myocardial infarction. Peterson ED, et al. **Ann Intern Med** 1997 Apr 1;126(7):561–82 (280 ref.)

Biochemical markers of myocardial injury during cardiac operations. Birdi I, et al. **Ann Thorac Surg** 1997 Mar; 63(3):879–84 (59 ref.)

Acute myocardial infarction during pregnancy. Fujito T, et al. **Cardiology** 1996 Jul–Aug;87(4):361–4 (20 ref.)

Sinus of Valsalva aneurysm presenting as myocardial infarction during dobutamine stress test. Ferreira AC, et al. **Cathet Cardiovasc Diagn** 1996 Dec;39(4):400–2 (7 ref.)

Cardiac aspergillosis presenting as myocardial infarction. Cishek MB, et al. **Clin Cardiol** 1996 Oct;19(10):824–7 (11 ref.)

Abnormalities of the S-T segment--Part II. Hurst JW. **Clin Cardiol** 1997 Jul;20(7):595–600 (10 ref.)

Usefulness of the 12-lead electrocardiogram in detection of myocardial infarction: electrocardiographic-anatomic correlations--Part II. Parker AB 3d, et al. **Clin Cardiol** 1996 Feb;19(2):141–8 (36 ref.)

Determinants of infarct size in acute myocardial infarction in patients treated with reperfusion therapy. Wagdy HM, et al. **Curr Opin Cardiol** 1996 Jul;11(4):369–77 (60 ref.)

Evaluation of chest pain in the emergency department. Jesse RL, et al. **Curr Probl Cardiol** 1997 Apr;22(4):149–236 (289 ref.)

Detection of myocardial viability using stress echocardiography. Krahwinkel W, et al. **Eur Heart J** 1997 Jun;18 Suppl D:D111–6 (34 ref.)

Role of stress echocardiography in risk stratification early after an acute myocardial infarction. EPIC (Echo Persantin International Cooperative) and EDIC (Echo Dobutamine International Cooperative) Study Groups. Picano E, et al. **Eur Heart J** 1997 Jun;18 Suppl D:D78–85 (32 ref.)

Troponin T: a diagnostic marker for myocardial infarction and minor cardiac cell damage. Rottbauer W, et al. **Eur Heart J** 1996 Dec;17 Suppl F:3–8 (40 ref.)

Recurrent myocardial infarction with patent coronary arteries. Haywood LJ, et al. **J Natl Med Assoc** 1997 Jun; 89(6):415–20 (20 ref.)

Diagnosis and management of acute myocardial infarction. Verani MS. **J Nucl Cardiol** 1997 Mar–Apr;4(2 Pt 2):S158–63 (16 ref.)

Cardiology casebook. Coysackie virus B myocarditis presenting as a myocardial infarction in a newborn infant. Lehoullier PF, et al. **J Perinatol** 1996 Sep–Oct;16(5):403–5 (7 ref.)

Eosinophilic myocarditis manifesting as myocardial infarction: early diagnosis and successful treatment. Galiuto L, et al. **Mayo Clin Proc** 1997 Jul;72(7):603–10 (32 ref.)

Recent advances in the electrocardiographic diagnosis of myocardial infarction: left bundle branch block and pacing. Sgarbossa EB. **Pacing Clin Electrophysiol** 1996 Sep; 19(9):1370–9 (37 ref.)

Improving the early diagnosis of acute myocardial infarction. Banerjee A. **Postgrad Med J** 1996 Dec;72(854):705–8 (52 ref.)

Biochemical markers of myocardial damage for early diagnosis and prognosis in patients with acute coronary syndromes. Minireview based on a doctorial thesis. Lindahl B. **Ups J Med Sci** 1996;101(3):193–232 (210 ref.)

[Troponins--new markers for the detection of myocardial cell damage] Hamm CW. **Fortschr Med** 1996 Nov 20; 114(32):433–6 (20 ref.) (Eng. Abstr.) **(Ger)**

[Determining heart muscle perfusion by magnetic resonance tomography progressing to clinical application] Fischer SE, et al. **Radiologe** 1997 May;37(5):366–71 (30 ref.) (Eng. Abstr.) **(Ger)**

[Creatine kinase MM and MB isoforms and their potential in the diagnosis of acute myocardial infarction] Denkamp Y, et al. **Harefuah** 1996 Nov 1;131(9):331–4 (36 ref.) **(Heb)**

[Directions in the diagnosis and management of acute myocardial infarction: update] Paz Y, et al. **Harefuah** 1997 Feb 2;132(3):212–8 (42 ref.) **(Heb)**

[Coronary risk stratification and aspects of decision making after infarction] Agabiti-Rosei E, et al. **Ann Ital Med Int** 1996 Oct;11 Suppl 2:121S–126S (82 ref.) (Eng. Abstr.) **(Ita)**

[Comparison of electrocardiographic and echocardiographic findings in acute myocardial infarct] Penco M, et al. **Cardiologia** 1996 Aug;41(8):751–8 (44 ref.) (Eng. Abstr.) **(Ita)**

[Patient assessment after an uncomplicated acute myocardial infarct: from instrumental studies to clinical decisions (editorial)] Zardini P, et al. **Cardiologia** 1996 Dec; 41(12):1137–46 (123 ref.) **(Ita)**

[Subendocardial infarction] Miura M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):713–6 (18 ref.) **(Jpn)**

[Non-Q wave myocardial infarction] Miura M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):749–52 (21 ref.) **(Jpn)**

[Biochemical markers of myocardial damage in myocardial infarction] Miłek-Kurzątkowska D, et al. **Pol Arch Med Wewn** 1997 Jan;97(1):69–73 (25 ref.) **(Pol)**

[Pathogenesis and diagnosis of macrofocal myocardial lesions in dilated cardiomyopathy] Gurevich MA, et al. **Klin Med (Mosk)** 1996;74(7):9–11 (26 ref.) **(Rus)**

[A case of a favorable outcome in a large-focus myocardial infarct with the adult respiratory distress syndrome] Shvyrkova NM, et al. **Ter Arkh** 1996;68(5):80–1 (7 ref.) **(Rus)**

[The electrocardiogram in acute myocardial infarct in the "thrombolytic era"] Kuchárová L, et al. **Bratisl Lek Listy** 1996 Jul;97(7):388–96 (65 ref.) (Eng. Abstr.) **(Slo)**

[Biochemical markers in acute myocardial infarct] Pecháň I. **Bratisl Lek Listy** 1996 Jul;97(7):397–405 (72 ref.) (Eng. Abstr.) **(Slo)**

DRUG THERAPY

Treatment of acute myocardial infarction today. Maggioni AP, et al. **Am Heart J** 1997 Aug;134(2 Pt 2):S9–14 (29 ref.)

Safety of heart rate-lowering calcium antagonists: lessons from controlled trials. Messerli FH, et al. **Am Heart J** 1997 Aug;134(2 Pt 2):S21–4 (14 ref.)

Professor Peter Sleight's reflections on the use of beta-blocking agents after myocardial infarction. Sleight P. **Am Heart J** 1997 Aug;134(2 Pt 2):S15–20 (25 ref.)

The place of angiotensin-converting enzyme inhibition after acute myocardial infarction. Torp-Pedersen C, et al. **Am Heart J** 1997 Aug;134(2 Pt 2):S25–30 (24 ref.)

Adenosine for myocardial protection in acute myocardial infarction. Granger CB. **Am J Cardiol** 1997 Jun 19;

79(12A):44–8 (55 ref.)

Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb–IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. Harrington RA. **Am J Cardiol** 1997 Aug 18; 80(4A):34B–38B (27 ref.)

Magnesium sulfate therapy in certain emergency conditions. Frakes MA, et al. **Am J Emerg Med** 1997 Mar;15(2):182–7 (81 ref.)

Calcium channel antagonists: friend or foe in postinfarction patients? Gibson RS, et al. **Am J Hypertens** 1996 Dec;9(12 Pt 2):172S–176S (36 ref.)

Pharmacologic therapies after myocardial infarction. Rapaport E, et al. **Am J Med** 1996 Oct 8; 101(4A):4A61S–69S; discussion 4A69S–70S (61 ref.)

Use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Parmar R, et al. **Am J Med Sci** 1997 Jul; 314(1):31–6 (22 ref.)

Thrombolytic agents--an overview. Gulba DC, et al. **Ann Hematol** 1996;73 Suppl 1:S9–27 (227 ref.)

Thrombolytic therapy in acute myocardial infarction--update 1996. Huber K, et al. **Ann Hematol** 1996; 73 Suppl 1:S29–38 (99 ref.)

Pharmacologic myocardial preconditioning with monophosphoryl lipid A (MLA) reduces infarct size and stunning in dogs and rabbits. Elliott GT. **Ann N Y Acad Sci** 1996 Sep 30;793:386–99 (63 ref.)

What is the role of angiotensin-converting enzyme inhibitors in congestive heart failure and after myocardial infarction? Nelson KM, et al. **Ann Pharmacother** 1996 Sep;30(9):986–93 (44 ref.)

Tissue repair and angiotensin II generated at sites of healing. Weber KT, et al. **Basic Res Cardiol** 1997 Apr;92(2):75–8 (10 ref.)

Heparin as an adjuvant to thrombolytic therapy in acute myocardial infarction. Metz BK, et al. **Biomed Pharmacother** 1996;50(6–7):243–53 (33 ref.)

Anticoagulation trials. Grahame-Clarke C, et al. **Br J Hosp Med** 1996 Jun 19–Jul 9;56(1):25–8 (25 ref.)

Angiotensin-converting enzyme inhibition in myocardial infarction--Part 1: Clinical data. Huckell VF, et al. **Can J Cardiol** 1997 Feb;13(2):161–9 (7 ref.)

Angiotensin-converting enzyme inhibition in myocardial infarction--Part 2: Clinical issues and controversies. Huckell VF, et al. **Can J Cardiol** 1997 Feb;13(2):173–82 (25 ref.)

A pragmatic approach to the use of angiotensin-converting enzyme inhibitors in acute myocardial infarction. Vantrimpont P, et al. **Can J Cardiol** 1996 Oct;12(10):924–9 (37 ref.)

Calcium channel blockers: an evidence-based review. Waters D. **Can J Cardiol** 1997 Aug;13(8):757–66 (70 ref.)

Lipid-lowering therapy after myocardial infarction: is it worth it? [editorial; comment] Warnica JW. **Can Med Assoc J** 1997 Apr 1;156(7):1005–7 (13 ref.) Comment on: Can Med Assoc J 1997 Apr 1;156(7):991–7.

Magnesium in acute myocardial infarction: scientific, statistical, and economic rationale for its use [editorial] Antman EM, et al. **Cardiovasc Drugs Ther** 1996 Jul; 10(3):297–301 (55 ref.)

Clinical aspects of ACE inhibition in patients with acute myocardial infarction. Borghi C, et al. **Cardiovasc Drugs Ther** 1996 Nov;10(5):519–25 (44 ref.)

Heparin after acute myocardial infarction [see comments] Commerford PJ. **Cardiovasc Drugs Ther** 1997 Apr; 11(2):101–9 (43 ref.) Comment in: Cardiovasc Drugs Ther 1997 Apr;11(2):97–100.

Thrombolytic therapy in acute myocardial infarction. Hampton JR. **Cardiovasc Drugs Ther** 1997 May;11 Suppl 1:241–6 (25 ref.)

Heart rate and heart rate variability, a pharmacological target. Swynghedauw B, et al. **Cardiovasc Drugs Ther** 1997 Jan;10(6):677–85 (47 ref.)

Is heparin of value in the management of acute myocardial infarction? [see comments] White HD. **Cardiovasc Drugs Ther** 1997 Apr;11(2):111–9 (73 ref.) Comment in: Cardiovasc Drugs Ther 1997 Apr;11(2):97–100.

Site-specific intravascular administration of drugs: history of a method applicable in humans. Camenzind E, et al. **Cathet Cardiovasc Diagn** 1997 Jul;41(3):342–7 (39 ref.)

Confusion in reperfusion. Problems in the clinical development of antithrombotic drugs [editorial; comment] Catella-Lawson F, et al. **Circulation** 1997 Feb 18; 95(4):793–5 (23 ref.) Comment on: Circulation 1997 Feb 18;95(4):846–54.

The role of magnesium therapy in acute myocardial infarction. Rabbani LE, et al. **Clin Cardiol** 1996 Nov; 19(11):841–4 (35 ref.)

Amiodarone: the expanding antiarrhythmic role and how to follow a patient on chronic therapy. Singh BN. **Clin Cardiol** 1997 Jul;20(7):608–18 (33 ref.)

Post-myocardial infarction trials: beta blockers, antiarrhythmics, thrombolytics. Anderson JL. **Control Clin Trials** 1996 Jun;17(3 Suppl):17S–27S (35 ref.)

Angiographic studies demonstrating the need for conjunctive anticoagulation. Bleich SD. **Coron Artery Dis** 1996 Jul; 7(7):516–21 (29 ref.)

How magnesium therapy may influence clinical outcome in acute myocardial infarction: review of potential mechanisms. Herzog WR, et al. **Coron Artery Dis** 1996 May;7(5):364–70 (50 ref.)

Magnesium and arrhythmias in acute myocardial infarction. Horner SM. **Coron Artery Dis** 1996 May;7(5):359–63 (66 ref.)

Clinical trials of conjunctive anticoagulant strategies in thrombolysis. Kleiman NS. **Coron Artery Dis** 1996 Jul; 7(7):508–15 (100 ref.)

The open infarct-related artery: theoretical and practical considerations. Nash JA. **Coron Artery Dis** 1995 Sep; 6(9):739–49 (63 ref.)

Review of clinical evidence--is there a role for supplemental magnesium in acute myocardial infarction in high-risk populations (patients ineligible for thrombolysis and the elderly)? Shechter M, et al. **Coron Artery Dis** 1996 May; 7(5):352–8 (80 ref.)

Results of randomized clinical trials of magnesium--can a consensus be reached? Teo KK, et al. **Coron Artery Dis** 1996 May;7(5):341–7 (42 ref.)

Magnesium in acute myocardial infarction. Thel MC, et al. **Coron Artery Dis** 1995 Oct;6(10):831–7 (50 ref.)

Intracoronary recombinant tissue-type plasminogen activator (rt-PA). Tiefenbrunn AJ. **Coron Artery Dis** 1996 Sep; 7(9):637–40 (27 ref.)

Review of research methodology used in clinical trials of magnesium and myocardial infarction--why does controversy persist despite ISIS-4? Woods KL. **Coron Artery Dis** 1996 May;7(5):348–51 (24 ref.)

The value of nifedipine in the treatment of hypertension, coronary heart disease and myocardial infarction (post-infarction therapy). Schulz J, et al. **Curr Med Res Opin** 1996;13(7):397–408 (25 ref.)

Calcium-channel blockers in ischemic heart disease. Silvestry FE, et al. **Curr Opin Cardiol** 1996 Jul;11(4):434–9 (45 ref.)

A risk-benefit assessment of ACE inhibitor therapy post-myocardial infarction. Borghi C, et al. **Drug Saf** 1996 May;14(5):277–87 (42 ref.)

Anti-ischaemic therapy during the follow-up phase of acute coronary syndromes. Is there a role for calcium channel blockers? Boden WE. **Drugs** 1996;52 Suppl 4:20–30 (19 ref.)

Lisinopril. A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction. Goa KL, et al. **Drugs** 1996 Oct;52(4):564–88 (154 ref.)

Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction. Noble S, et al. **Drugs** 1996 Oct;52(4):589–605 (55 ref.)

Thrombolytic therapy in the elderly. Pharmacoeconomic considerations. Ramanathan K, et al. **Drugs Aging** 1996 Apr;8(4):237–44 (52 ref.)

Treating the diabetic patient with coronary disease [editorial; comment] Kjekshus J. **Eur Heart J** 1996 Sep;17(9):1298–301 (22 ref.) Comment on: Eur Heart J 1996 Sep;17(9):1337–44.

How European cardiologists perceive the role of calcium antagonists in follow-up after myocardial infarction. Opie LH, et al. **Eur Heart J** 1997 Jan;18 Suppl A:A134–8 (4 ref.)

Should patients with suspected acute myocardial infarction without ST elevation be given thrombolytic treatment? Rawles J. **Eur Heart J** 1997 Jun;18(6):899–906 (39 ref.)

What is the likely benefit of earlier thrombolysis? Rawles J. **Eur Heart J** 1996 Jul;17(7):991–5 (30 ref.)

The value of angiotensin converting enzyme inhibitors for the treatment of patients with left ventricular dysfunction, heart failure or after acute myocardial infarction. Swedberg K, et al. **Eur Heart J** 1996 Sep;17(9):1306–11 (31 ref.)

Secondary preventive potential of nitrates in ischaemic heart disease. Thadani U. **Eur Heart J** 1996 Dec;17 Suppl F:30–6 (72 ref.)

Low molecular weight heparins: a valuable tool in the treatment of acute coronary syndromes. Wallentin L. **Eur Heart J** 1996 Oct;17(10):1470–6 (90 ref.)

The role of thrombolytic drugs in the management of myocardial infarction. Comparative clinical trials. Weaver WD. **Eur Heart J** 1996 Dec;17 Suppl F:9–15 (36 ref.)

Treatment for acute myocardial infarction. Overview of randomized clinical trials. Yusuf S, et al. **Eur Heart J** 1996 Dec;17 Suppl F:16–29 (77 ref.)

Pharmacological intervention in post-infarction wound healing. Jugdutt BI. **EXS** 1996;76:501–12 (60 ref.)

Inhibition of the renin-angiotensin system after acute myocardial infarction--treat first, select later? Hall AS, et al. **Heart** 1996 Nov;76(3 Suppl 3):73–8 (31 ref.)

Changing paradigms in thrombolysis in acute myocardial infarction. Gotsman MS, et al. **Int J Cardiol** 1997 May 23;59(3):227–42 (101 ref.)

Cost-benefit analysis--a prerequisite of a rational pharmacotherapy in cardiovascular diseases. Timely thrombolysis in the acute myocardial infarction. Barthel W, et al. **Int J Clin Pharmacol Ther** 1996 Jul;34(7):277–81 (19 ref.)

Thrombolytic therapy. From myocardial to cerebral infarction. The MAST-I Group. Multicentre Acute Stroke Trial. Candelise L, et al. **Ital J Neurol Sci** 1996 Feb; 17(1):5–21 (134 ref.)

Thrombolysis after acute myocardial infarction. Nee PA. **J Accid Emerg Med** 1997 Jan;14(1):2–9 (49 ref.)

Revisiting reperfusion therapy in inferior myocardial infarction. Bates ER. **J Am Coll Cardiol** 1997 Aug; 30(2):334–42 (102 ref.)

Thrombolysis and intervention in acute myocardial infarction: an overview. Babb JD. **J Atheroscler Thromb** 1995;2(1):1–13 (45 ref.)

The use of ACE inhibitors after myocardial infarction. Swedberg K, et al. **J Card Fail** 1996 Dec;2(4 Suppl):S231–7 (29 ref.)

Antithrombotic and thrombolytic therapies for acute myocardial infarction. Godfried SL, et al. **J Cardiovasc Risk** 1996 Oct;3(5):453–7 (29 ref.)

Impact of pharmacological treatment on mortality after myocardial infarction in diabetic patients. Zuanetti G, et al. **J Diabetes Complications** 1997 Mar–Apr;11(2):131–6 (32 ref.)

Importance of trough : peak ratios in treatment of blood pressure in post-myocardial infarction and heart failure settings. Meredith PA. **J Hum Hypertens** 1997 Jan; 11(1):39–43 (14 ref.)

Treatment with verapamil and trandolapril in patients with congestive heart failure and myocardial infarction. The Danish Verapamil Infarction Trial (DAVIT Study Group). Hansen JF, et al. **J Hypertens Suppl** 1997 Mar; 15(2):S119–22 (32 ref.)

Clinical benefit of angiotensin converting enzyme inhibition after acute myocardial infarction: myocardial reperfusion revisited. Renkin J. **J Hypertens Suppl** 1996 Dec; 14(6):S15–9 (40 ref.)

Helping heart attack victims to save their own lives [editorial; comment] Langton PE, et al. **Med J Aust** 1997 Mar 3; 166(5):228–9 (9 ref.) Comment on: Med J Aust 1997 Mar 3;166(5):233–6.

Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. Collins R, et al. **N Engl J Med** 1997 Mar 20;336(12):847–60 (97 ref.)

Adjunctive drug therapy of acute myocardial infarction--evidence from clinical trials [see comments] Hennekens CH, et al. **N Engl J Med** 1996 Nov 28; 335(22):1660–7 (71 ref.) Comment in: N Engl J Med 1997 May 15;336(20):1455; discussion 1455–6.

Controlled trials comparing reteplase with alteplase and streptokinase in patients with acute myocardial infarction. Amsterdam EA. **Pharmacotherapy** 1996 Sep–Oct;16(5 Pt 2):137S–140S (9 ref.)

Biochemical and pharmacologic comparison of thrombolytic agents. Stringer KA. **Pharmacotherapy** 1996 Sep–Oct;16(5 Pt 2):119S–126S (36 ref.)

Acute myocardial infarction. Recommendations for medical management and primary angioplasty. Whisenant BK, et al. **Postgrad Med** 1997 Sep;102(3):159–60, 163–8, 170–2 passim (29 ref.)

Amiodarone therapy in chronic heart failure and myocardial infarction: a review of the mortality trials with special attention to STAT-CHF and the GESICA trials. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina. Pinto JV Jr, et al. **Prog Cardiovasc Dis** 1997 Jul–Aug;40(1):85–93 (34 ref.)

How have trials of thrombolytics influenced clinical management of patients with acute myocardial infarction. Marder VJ. **Thromb Haemost** 1997 Jul;78(1):548–52 (48 ref.)

Conjunctive use of platelet glycoprotein IIb/IIIa antagonists and thrombolytic therapy for acute myocardial infarction. Moliterno DJ, et al. **Thromb Haemost** 1997 Jul;78(1):214–9 (41 ref.)

Applying the results of large clinical trials in the management of acute myocardial infarction. Sweeney JP, et al. **West J Med** 1996 Mar;164(3):238–48 (60 ref.)

[Calcium inhibitors and post-infarction] Vacheron A. **Ann Cardiol Angeiol (Paris)** 1996 Oct;45(8):465–7 (14 ref.) (Eng. Abstr.) **(Fre)**

[Conversion enzyme inhibitors in myocardial infarct: who, when, how?] Pierard L. **Rev Med Liege** 1996 May; 51(5):336–40 (25 ref.) **(Fre)**

[Nifedipine and coronary insufficiency reasons for controversy] Lièvre M, et al. **Therapie** 1997 Jan–Feb; 52(1):37–45 (49 ref.) (Eng. Abstr.) **(Fre)**

[Value of K+ and Mg2+ in treatment of acute myocardial infarct] Kunert M, et al. **Herz** 1997 Jun;22 Suppl 1:63–72 (24 ref.) (Eng. Abstr.) **(Ger)**

[Direct thrombin inhibitors] Bornkessel B. **Med Monatsschr Pharm** 1997 Apr;20(4):86–9 (3 ref.) **(Ger)**

[Multi-drug management after myocardial infarct] Kritz H, et al. **Wien Klin Wochenschr Suppl** 1997;2:17–24 (73 ref.) (Eng. Abstr.) **(Ger)**

[Acetylsalicylic acid after myocardial infarct] Sinzinger H, et al. **Wien Klin Wochenschr Suppl** 1997;2:25–8 (34 ref.) (Eng. Abstr.) **(Ger)**

[Current aspects of ACE inhibitor therapy from the cardiologic viewpoint] Klein W, et al. **Wien Med Wochenschr** 1996;146(11):221–4 (24 ref.) (Eng. Abstr.) **(Ger)**

[Inhibition of the renin-angiotensin system: ACE inhibitors and angiotensin II receptor blockers] Pichler M, et al. **Wien Med Wochenschr** 1996;146(11):228–31 (35 ref.) (Eng. Abstr.) **(Ger)**

[Value of magnesium in acute myocardial infarct] Beuckelmann DJ. **Z Kardiol** 1996;85 Suppl 6:129–34 (15 ref.) (Eng. Abstr.) **(Ger)**

[Anti-arrhythmia therapy after myocardial infarct: preliminary results of EMIAT and CAMIAT studies] Kuck KH. **Z Kardiol** 1996;85 Suppl 6:107–13 (11 ref.) (Eng. Abstr.) **(Ger)**

[Renaissance of beta blocker therapy in myocardial infarct] Seidl K, et al. **Z Kardiol** 1996 Oct;85(10):737–44 (38 ref.) (Eng. Abstr.) **(Ger)**

[Thrombolytic therapy in acute myocardial

infarction--update] Jaffe R, et al. **Harefuah** 1996 Jun 2; 130(11):751-7 (46 ref.) **(Heb)**

[Directions in the diagnosis and management of acute myocardial infarction: update] Paz Y, et al. **Harefuah** 1997 Feb 2;132(3):212-8 (42 ref.) **(Heb)**

[New agents and challenges in the antithrombotic management of arterial diseases] Udvardy M, et al. **Orv Hetil** 1997 Jan 12;138(2):59-65 (44 ref.) (Eng. Abstr.) **(Hun)**

[Integration of therapeutic options and the candidates for treatment: the ABC of the post-infarction period] Ambrosioni E, et al. **Ann Ital Med Int** 1996 Oct;11 Suppl 2:132S-138S (40 ref.) (Eng. Abstr.) **(Ita)**

[Side effects of thrombolytic therapy in patients with myocardial infarction] Agostoni A, et al. **Cardiologia** 1995 Dec;40(12):899-908 (103 ref.) **(Ita)**

[The role of nitrates in left ventricular insufficiency in patients with acute myocardial infarction] Maggioni AP. **G Ital Cardiol** 1996 Sep;26(9):1095-8 (04 ref.) **(Ita)**

[Current status and problems of coronary thrombolysis] Kambara H. **Rinsho Byori** 1997 Feb;Suppl 104:179-85 (15 ref.) **(Jpn)**

[Imidazoline receptors and use of drug blocking receptors 11] Lada W. **Pol Merkuriusz Lek** 1996 Aug;1(2):124-5 (10 ref.) (Eng. Abstr.) **(Pol)**

[Thrombolysis in acute myocardial infarction] Gabriel HM, et al. **Rev Port Cardiol** 1996 Jun;15(6):507-21 (98 ref.) **(Por)**

[Adhesive molecules as drugs and objects of pharmacological effect in myocardial ischemia and reperfusion] Uteshev DB, et al. **Eksp Klin Farmakol** 1997 May-Jun;60(3):83-8 (57 ref.) (Eng. Abstr.) **(Rus)**

[Adjuvant therapy in patients with acute myocardial infarct] Jurkovičová O, et al. **Bratisl Lek Listy** 1996 Jul; 97(7):413-28 (133 ref.) (Eng. Abstr.) **(Slo)**

[Post-infarction evaluation and treatment in the era of fibrinolytics] Sarmiento X, et al. **Med Clin (Barc)** 1997 Feb 8;108(5):186-96 (128 ref.) **(Spa)**

[The anti-ischemic effects of ACE inhibitors after an acute myocardial infarct] Rutherford JD. **Rev Clin Esp** 1996 Dec; 196(4 Monografico):41-2 (23 ref.) **(Spa)**

[The treatment of acute myocardial infarct in the elderly patient] Simarro E, et al. **Rev Clin Esp** 1997 Jun; 197(6):429-33 (51 ref.) **(Spa)**

[Cardiovascular pharmacology (XIII). The efficacy of different thrombolytic drugs in the treatment of acute myocardial infarct] López-Sendón J, et al. **Rev Esp Cardiol** 1995 Jun;48(6):407-39 (184 ref.) (Eng. Abstr.) **(Spa)**

[Clinical characteristics and hospital mortality of acute myocardial infarction in elderly patients treated with thrombolytic agents] Pabón Osuna P, et al. **Rev Esp Cardiol** 1996 Jul;49(7):501-8 (28 ref.) (Eng. Abstr.) **(Spa)**

[Forced fibrinolysis causes damage to the myocardium. Magnesium therapy is considerate in myocardial infarction (see comments)] Nilsson CG, et al. **Lakartidningen** 1997 Jan 15;94(3):148-50 (31 ref.) Comment in: Lakartidningen 1997 Jan 22;94(4):251-2. **(Swe)**

ECONOMICS

Evidence-based, cost-effective risk stratification and management after myocardial infarction. California Cardiology Working Group on Post-MI Management. Deedwania PC, et al. **Arch Intern Med** 1997 Feb 10; 157(3):273-80 (47 ref.)

Thrombolytic therapy in the elderly. Pharmacoeconomic considerations. Ramanathan K, et al. **Drugs Aging** 1996 Apr;8(4):237-44 (52 ref.)

Cost-benefit analysis--a prerequisite of a rational pharmacotherapy in cardiovascular diseases. Timely thrombolysis in the acute myocardial infarction. Barthel W, et al. **Int J Clin Pharmacol Ther** 1996 Jul;34(7):277-81 (19 ref.)

Need cardiac rehabilitation be cost-effective? Perk J. **J Cardiovasc Risk** 1996 Apr;3(2):167-71 (38 ref.)

ENZYMOLOGY

Using serum markers in the early diagnosis of myocardial infarction [see comments] Chesebro MJ. **Am Fam Physician** 1997 Jun;55(8):2667-74 (25 ref.) Comment in: Am Fam Physician 1997 Jun;55(8):2591, 2594-5.

EPIDEMIOLOGY

Risk stratification after myocardial infarction in the thrombolytic era. Rutherford JD. **Curr Opin Cardiol** 1996 Jul;11(4):428-33 (23 ref.)

Nutrition and cardiovascular disease. Klör HU, et al. **Eur J Med Res** 1997 Jun 16;2(6):243-57 (192 ref.)

Therapeutic implications of the epidemiology and timing of myocardial infarction and other cardiovascular diseases. Flack JM, et al. **J Hum Hypertens** 1997 Jan;11(1):23-8 (34 ref.)

Coronary heart disease and genetics in epidemiologist's view. Cambien F, et al. **Mol Med Today** 1997 May;3(5):197-203 (44 ref.)

Premature myocardial infarction in Singapore. Ng A. **Singapore Med J** 1996 Feb;37(1):18-9 (10 ref.)

[Hanshin-Awaji earthquake and acute myocardial infarction] Sakamoto S, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (12):735-7 (15 ref.) **(Jpn)**

ETHNOLOGY

Typical and atypical clinical signs and symptoms of myocardial infarction and delayed seeking of professional care among blacks. Lee HO. **Am J Crit Care** 1997 Jan; 6(1):7-13; quiz 14-5 (56 ref.)

ETIOLOGY

The causes of acute myocardial infarction revisited. Maseri A. **Acta Cardiol** 1996;51(6):491-500 (36 ref.)

Sleep, dreams, and sudden death: the case for sleep as an autonomic stress test for the heart. Verrier RL, et al. **Cardiovasc Res** 1996 Feb;31(2):181-211 (268 ref.)

Amniotic fluid embolism causing severe left ventricular dysfunction and death: case report and review of the literature. Dib N, et al. **Cathet Cardiovasc Diagn** 1996 Oct; 39(2):177-80 (9 ref.)

Myocardial infarction associated with myocardial bridging: case history and review of the literature. Tauth J, et al. **Cathet Cardiovasc Diagn** 1997 Apr;40(4):364-7 (24 ref.)

Myocardial infarction in an infant due to anomalous origin of the left coronary artery. de Silva MV, et al. **Ceylon Med J** 1996 Sep;41(3):115-7 (10 ref.)

The myth of the myocardial 'infarctlet' during percutaneous coronary revascularization procedures. Abdelmeguid AE, et al. **Circulation** 1996 Dec 15;94(12):3369-75 (43 ref.)

Nonatherosclerotic causes of coronary artery narrowing--Part III. Waller BF, et al. **Clin Cardiol** 1996 Aug;19(8):656-61 (79 ref.)

Outcomes of diabetic patients following acute myocardial infarction: a review of the major thrombolytic trials. Jelesoff NE, et al. **Coron Artery Dis** 1996 Oct;7(10):732-43 (89 ref.)

Blood pressure J-curve: is it cause or effect? Alderman MH. **Curr Opin Nephrol Hypertens** 1996 May;5(3):209-13 (13 ref.)

Neuroleptic malignant syndrome and acute myocardial infarction: case report and review. Freedman MD. **Md Med J** 1997 Aug;46(7):357-9 (18 ref.)

Nature's high-voltage injuries: sometimes a deadly consequence. Shaw PK, et al. **Neth J Med** 1996 Oct; 49(4):153-9 (20 ref.)

[Myocardial infarction caused by thrombosis of the left coronary artery in a patient with thrombocythemia] Joseph T, et al. **Ann Cardiol Angeiol (Paris)** 1996 Dec;45(10):581-4 (16 ref.) (Eng. Abstr.) **(Fre)**

[Myocardial infarction following a bee sting. Apropos of a case and review of the literature] Massing JL, et al. **Ann Cardiol Angeiol (Paris)** 1997 May-Jun;46(5-6):311-5 (11 ref.) (Eng. Abstr.) **(Fre)**

[Myocardial infarction caused by exertion] Bernard F, et al. **Ann Med Interne (Paris)** 1997;148(1):19-24 (27 ref.) (Eng. Abstr.) **(Fre)**

[Myocardial infarct and rhabdomyolysis after a high-voltage accident with successful resuscitation] Franzius C, et al. **Dtsch Med Wochenschr** 1997 Mar 27;122(13):400-6 (22 ref.) (Eng. Abstr.) **(Ger)**

[Myocardial infarct and diabetes mellitus: incidence, management and prognosis] Jánosi A, et al. **Orv Hetil** 1997 May 18;138(20):1243-7 (41 ref.) (Eng. Abstr.) **(Hun)**

[Spontaneous coronary dissection as a cause of acute myocardial infarct: description of a case and review of the literature] Mafrici A, et al. **G Ital Cardiol** 1997 Aug; 27(8):821-6 (37 ref.) (Eng. Abstr.) **(Ita)**

[Exertion-induced myocardial ischemia has little influence on ventricular remodeling in post-infarction patients with preserved systolic function] Temporelli PL, et al. **G Ital Cardiol** 1996 Jul;26(7):729-37 (37 ref.) (Eng. Abstr.) **(Ita)**

[Non-atherosclerotic acute myocardial infarction] Goto Y. **Ryoikibetsu Shokogun Shirizu** 1996;(12):753-7 (16 ref.) **(Jpn)**

[Acute myocardial infarction and thromboembolic complications in the nephrotic syndrome] Harada A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):436-9 (24 ref.) **(Jpn)**

[Myocardial infarction in young patients] Ichikawa T. **Ryoikibetsu Shokogun Shirizu** 1996;(12):664-6 (7 ref.) **(Jpn)**

[Myocardial infarction in childhood] Isaka N, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):679-83 (17 ref.) **(Jpn)**

[Acute myocardial infarction due to left main coronary artery occlusion] Nishikawa H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):660-3 (8 ref.) **(Jpn)**

[Impending myocardial infarction] Shibata M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):730-4 (23 ref.) **(Jpn)**

[Acute myocardial infarction due to trauma] Takino T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):573-6 (20 ref.) **(Jpn)**

[Acute myocardial infarct in a young cocaine user] Caires G, et al. **Rev Port Cardiol** 1996 Dec;15(12):885-91, 864 (32 ref.) (Eng. Abstr.) **(Por)**

[Pathogenesis and diagnosis of macrofocal myocardial lesions in dilated cardiomyopathy] Gurevich MA, et al. **Klin Med (Mosk)** 1996;74(7):9-11 (26 ref.) **(Rus)**

[A case of myocardial infarct in latent porphyria cutanea tarda] Krivosheev AB. **Ter Arkh** 1997;69(4):80-1 (10 ref.) **(Rus)**

[Acute myocardial infarction in a 5-year-old boy] Romero Ibarra C, et al. **Rev Esp Cardiol** 1996 Nov;49(11):855-7 (13 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Thrombosis in the young: effect of atherosclerotic risk factors on the risk of myocardial infarction associated with prothrombotic factors. Siscovick DS, et al. **Thromb Haemost** 1997 Jul;78(1):7-12 (46 ref.)

METABOLISM

The cicatrix: a case of woven intrigue. Weber KT. **Cardiovasc Res** 1996 Jan;31(1):19-27 (37 ref.)

Wound healing following myocardial infarction. Weber KT, et al. **Clin Cardiol** 1996 Jun;19(6):447-55 (68 ref.)

Tissue angiotensin II and myocardial infarction. Sun Y, et al. **EXS** 1996;76:479-88 (54 ref.)

Myocardial infarction and nitric oxide. Bing RJ, et al. **Mol Cell Biochem** 1996 Jul-Aug;160-161:303-6 (30 ref.)

MORTALITY

Complex causes of fatal myocardial infarction. James TN. **Circulation** 1997 Sep 2;96(5):1696-700 (38 ref.)

The "open artery hypothesis" in survivors of myocardial infarction. Pitts WR, et al. **Clin Cardiol** 1997 Jun; 20(6):522-4 (12 ref.)

Role of stress echocardiography in risk stratification early after an acute myocardial infarction. EPIC (Echo Persantin International Cooperative) and EDIC (Echo Dobutamine International Cooperative) Study Groups. Picano E, et al. **Eur Heart J** 1997 Jun;18 Suppl D:D78-85 (32 ref.)

What have the ACE-inhibitor trials in postmyocardial patients with left ventricular dysfunction taught us? Reynolds G, et al. **Eur J Clin Pharmacol** 1996;49 Suppl 1:S35-9 (19 ref.)

Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? [see comments] Vallance P, et al. **Lancet** 1997 May 10;349(9062):1391-2 (30 ref.) Comment in: Lancet 1997 Jul 26;350(9073):293. Comment in: Lancet 1997 Jul 26;350(9073):293-4.

[Implantable cardioverter-defibrillators and mortality after myocardial infarct (editorial)] Bonhorst D. **Rev Port Cardiol** 1997 Apr;16(4):355-7 (14 ref.) **(Por)**

[Clinical characteristics and hospital mortality of acute myocardial infarction in elderly patients treated with thrombolytic agents] Pabón Osuna P, et al. **Rev Esp Cardiol** 1996 Jul;49(7):501-8 (28 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Clinical nuclear cardiology: flow tracers and free fatty acid analogs to detect viable myocardium after infarction. Franken PR, et al. **Acta Cardiol** 1996;51(6):501-14 (20 ref.)

Effects of angiotensin-converting enzyme inhibition and angiotensin II AT1 receptor antagonism on cardiac parameters in left ventricular hypertrophy. Zhu YC, et al. **Am J Cardiol** 1997 Aug 4;80(3A):110A-117A (65 ref.)

Cellular mechanisms of cardiac failure in the infarcted heart. Anversa P, et al. **Cardiologia** 1995 Dec;40(12):909-20 (89 ref.)

Usefulness of the 12-lead electrocardiogram in detection of myocardial infarction: electrocardiographic-anatomic correlations--part I. Parker AB 3rd, et al. **Clin Cardiol** 1996 Jan;19(1):55-61 (42 ref.)

Comparison between abnormalities in segmental endocardial motion and abnormalities in segmental wall thickening after anterior myocardial infarction. A cine-magnetic resonance study. Germain P, et al. **Eur Heart J** 1996 Sep; 17(9):1350-61 (30 ref.)

Structural remodeling of the infarcted rat heart. Weber KT, et al. **EXS** 1996;76:489-99 (42 ref.)

The renin-angiotensin system and cardiac remodelling after acute myocardial infarction. Ikram H. **Heart** 1996 Nov;76(3 Suppl 3):68-72 (33 ref.)

Myocardial infarction as a problem of growth control: cell cycle therapy for cardiac myocytes? Schneider MD. **J Card Fail** 1996 Sep;2(3):259-63 (32 ref.)

[Atrial infarction] Chida K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):717-21 (21 ref.) **(Jpn)**

[Clinical features of patients with incompletely obstructed infarct related artery during evolving acute myocardial infarction] Tateishi H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):726-9 (8 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Cyclic phenomena in early myocardial infarction. Gasser R, et al. **Acta Med Austriaca** 1995;22(4):69-72 (22 ref.)

Beneficial effects of bradykinin on myocardial energy metabolism and infarct size. Linz W, et al. **Am J Cardiol** 1997 Aug 4;80(3A):118A-123A (111 ref.)

The kallikrein-kinin system in post-myocardial infarction cardiac remodeling. Wollert KC, et al. **Am J Cardiol** 1997 Aug 4;80(3A):158A-161A (45 ref.)

Remodeling of the brain post myocardial infarction: focus on central ANF. Ertl G, et al. **Basic Res Cardiol** 1997 Apr; 92(2):82-4 (11 ref.)

Regional dysfunction and ventricular remodeling in the

infarcted patient. Marino P, et al. **Basic Res Cardiol** 1997 Apr;92(2):72–4 (10 ref.)

Left ventricular remodeling: clinical significance and therapy. Rosado A, et al. **Basic Res Cardiol** 1997 Apr;92(2):66–8 (18 ref.)

The decreasing incidence of left ventricular remodeling following myocardial infarction. Solomon SD, et al. **Basic Res Cardiol** 1997 Apr;92(2):61–5 (10 ref.)

Tissue repair and angiotensin II generated at sites of healing. Weber KT, et al. **Basic Res Cardiol** 1997 Apr;92(2):75–8 (10 ref.)

Collagen and ventricular remodeling after acute myocardial infarction: concepts and hypotheses. Whittaker P. **Basic Res Cardiol** 1997 Apr;92(2):79–81 (10 ref.)

Cellular mechanisms of cardiac failure in the infarcted heart. Anversa P, et al. **Cardiologia** 1995 Dec;40(12):909–20 (89 ref.)

Infarct-related artery patency and long-term effects on left ventricular remodelling. Visser CA. **Cardiology** 1997;88 Suppl 1:26–35; discussion 36 (86 ref.)

The open infarct-related artery: theoretical and practical considerations. Nash JA. **Coron Artery Dis** 1995 Sep; 6(9):739–49 (63 ref.)

Pathophysiology and initial management of the acute coronary syndromes. Giri S, et al. **Curr Opin Cardiol** 1996 Jul;11(4):351–60 (85 ref.)

Role of angiotensin converting enzyme inhibitors in preventing left ventricular remodelling following myocardial infarction. Konstam MA. **Eur Heart J** 1995 Nov;16 Suppl K:42–8 (57 ref.)

Should patients with suspected acute myocardial infarction without ST elevation be given thrombolytic treatment? Rawles J. **Eur Heart J** 1997 Jun;18(6):899–906 (39 ref.)

Heart rate and blood pressure variability in cardiac diseases: pharmacological implications. Cloarec-Blanchard L. **Fundam Clin Pharmacol** 1997;11(1):19–28 (98 ref.)

Neuroendocrine activation after myocardial infarction: causes and consequences. Cleland JG, et al. **Heart** 1996 Nov;76(3 Suppl 3):53–9 (68 ref.)

ACC/AHA Guidelines for Exercise Testing. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). Gibbons RJ, et al. **J Am Coll Cardiol** 1997 Jul;30(1):260–311 (343 ref.)

Risk assessment after myocardial infarction: have the rules changed with thrombolytic therapy?. Verani MS. **J Nucl Cardiol** 1996 Nov-Dec;3(6 Pt 2):S50–9 (20 ref.)

Methods for studying experimental myocardial ischemic and reperfusion injury. Black SC, et al. **J Pharmacol Toxicol Methods** 1996 Aug;35(4):179–90 (70 ref.)

Behavioral-neuroendocrine-immunologic interactions in myocardial infarction. Goodkin K, et al. **Med Hypotheses** 1997 Mar;48(3):209–14 (45 ref.)

[Stratification of patients at risk for sudden cardiac death with special reference to the autonomic nervous system] Hohnloser SH, et al. **Z Kardiol** 1996;85 Suppl 6:35–43 (53 ref.) (Eng. Abstr.) **(Ger)**

[Age as a factor in the clinical and prognostic picture and the incidence of myocardial infarct] Astorri E. **Minerva Cardioangiol** 1997 Mar;45(3):107–14 (62 ref.) (Eng. Abstr.) **(Ita)**

[Heart rate variability. Parameters for risk stratification after myocardial infarction] Anfinsen OG, et al. **Tidsskr Nor Laegeforen** 1997 Jan 30;117(3):376–80 (26 ref.) (Eng. Abstr.) **(Nor)**

[Opinions on the effect of time of day on onset of myocardial infarction and safety of physical exertion] Markiewicz A, et al. **Pol Arch Med Wewn** 1996 Sep;96(3):284–9 (46 ref.) **(Pol)**

[Structure and function of the left ventricle as a prognostic factor in patients after myocardial infarction] Witkowska M. **Pol Arch Med Wewn** 1996 Sep;96(3):268–74 (42 ref.) **(Pol)**

[The role of polymorphonuclear granulocytes in biomorphology of thrombus in myocardial infarction] Wysocka J. **Przegl Lek** 1995;52(12):606–9 (21 ref.) **(Pol)**

[The function of pressor humoral substances in myocardial infarct patients (a review of the literature)] Bobrov VA, et al. **Lik Sprava** 1995 Mar-Apr;(3-4):37–42 (59 ref.) **(Rus)**

[Occurrence of abnormal late ventricular potentials in myocardial ischemia and the determination of risk of sudden cardiac death in patients after myocardial infarct] Filipová S, et al. **Bratisl Lek Listy** 1996 Aug;97(8):463–72 (41 ref.) (Eng. Abstr.) **(Slo)**

[Variability of the heart rate: its physiopathological basis and its use as prognostic index after acute myocardial infarction] Vukasovic JL, et al. **Rev Med Chil** 1995 Nov; 123(11):1412–7 (26 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Enhanced preservation of acutely ischemic myocardium and improved clinical outcomes using glucose-insulin-potassium (GIK) solutions. Lazar HL. **Am J Cardiol** 1997 Aug 4;80(3A):90A–93A (26 ref.)

The case of low-dose aspirin for the prevention of myocardial infarction: but how low is low? Förster W, et al. **Cardiovasc Drugs Ther** 1997 Jan;10(6):727–34 (51 ref.)

Therapy and clinical trials [editorial] Game F. **Curr Opin Lipidol** 1996 Jun;7(3):U105–7 (4 ref.)

The role of ACE inhibitors in preventing myocardial infarction: potential mechanisms and clinical implications. Francis GS. **Eur Heart J** 1995 Nov;16 Suppl K:1–3 (16 ref.)

Angina in patients with an active lifestyle. Mittleman MA. **Eur Heart J** 1996 Dec;17 Suppl G:30–5 (33 ref.)

Role of the fibrinolytic system in preventing myocardial infarction. Vaughan DE, et al. **Eur Heart J** 1995 Nov;16 Suppl K:31–6 (31 ref.)

Ischemic preconditioning against infarction: its mechanism and clinical implications. Miura T, et al. **EXS** 1996; 76:365–82 (63 ref.)

Delayed protection of the ischemic heart--from pathophysiology to therapeutic applications. Richard V, et al. **Fundam Clin Pharmacol** 1996;10(5):409–15 (84 ref.)

[Angiotensin-converting enzyme inhibitors following a myocardial infarct: clinical abd echographic indications] de Waard DE, et al. **Ned Tijdschr Geneeskd** 1997 Jan 11; 141(2):84–8 (36 ref.) (Eng. Abstr.) **(Dut)**

[How I treat and manage cholesterol after myocardial infarction] Capron L. **Journ Annu Diabetol Hotel Dieu** 1996;:199–209 (28 ref.) **(Fre)**

[Comparative study of verapamil and bisoprolol in the secondary prevention of myocardial infarction] Sárosi I, et al. **Orv Hetil** 1997 Aug 3;138(31):1939–45 (40 ref.) (Eng. Abstr.) **(Hun)**

[Progress in hypocholesterolemic therapy in the prevention of recurrent infarction] Manzato E, et al. **Ann Ital Med Int** 1996 Oct;11 Suppl 2:127S–131S (14 ref.) (Eng. Abstr.) **(Ita)**

[Clinical studies of the effectiveness of aspirin in the prevention of major cardio-cerebrovascular occurrences] Mariani M, et al. **Cardiologia** 1995 Dec;40(12 Suppl 1):423–8 (43 ref.) **(Ita)**

[Anticoagulant or antiaggregant therapy in the secondary prevention of myocardial infarct?] De Caterina R, et al. **G Ital Cardiol** 1996 Nov;26(11):1309–21 (42 ref.) (Eng. Abstr.) **(Ita)**

[Acute myocardial infarct and left ventricular dysfunction. Morphologic bases, clinical aspects and pharmacologic prevention] Perdigão C. **Acta Med Port** 1996 Feb-Mar; 9(2-3):113–9 (46 ref.) (Eng. Abstr.) **(Por)**

PSYCHOLOGY

Behavioral-neuroendocrine-immunologic interactions in myocardial infarction. Goodkin K, et al. **Med Hypotheses** 1997 Mar;48(3):209–14 (45 ref.)

[Depressive disorders and myocardial infarction] Sacchetti E. **Ann Ital Med Int** 1996 Oct;11 Suppl 2:70S–71S (21 ref.) **(Ita)**

RADIOGRAPHY

Coronary angiography and angioplasty after acute myocardial infarction. Bates DW, et al. **Ann Intern Med** 1997 Apr 1;126(7):539–50 (121 ref.)

Angiographic studies demonstrating the need for conjunctive anticoagulation. Bleich SD. **Coron Artery Dis** 1996 Jul; 7(7):516–21 (29 ref.)

[The importance of coronary angiography in patients with an acute myocardial infarct] Gazarian GA, et al. **Ter Arkh** 1997;69(3):80–3 (36 ref.) **(Rus)**

RADIONUCLIDE IMAGING

Clinical nuclear cardiology: flow tracers and free fatty acid analogs to detect viable myocardium after infarction. Franken PR, et al. **Acta Cardiol** 1996;51(6):501–14 (20 ref.)

FDG SPECT in the assessment of myocardial viability. Comparison with dobutamine echo. Bax JJ, et al. **Eur Heart J** 1997 Jun;18 Suppl D:D124–9 (39 ref.)

Comparison between abnormalities in segmental endocardial motion and abnormalities in segmental wall thickening after anterior myocardial infarction. A cine-magnetic resonance study. Germain P, et al. **Eur Heart J** 1996 Sep; 17(9):1350–61 (30 ref.)

Myocardial viability. Stress echocardiography vs nuclear medicine. Piérard LA, et al. **Eur Heart J** 1997 Jun;18 Suppl D:D117–23 (43 ref.)

Choosing a nuclear medicine study for cardiovascular applications. Moore WH. **Tex Heart Inst J** 1996; 23(2):117–21 (17 ref.)

REHABILITATION

Need cardiac rehabilitation be cost-effective? Perk J. **J Cardiovasc Risk** 1996 Apr;3(2):167–71 (38 ref.)

Cardiac rehabilitation and risk factor management after myocardial infarction. Clinical and economic evaluation. Oldridge NB. **Wien Klin Wochenschr Suppl** 1997;2:6–16 (94 ref.)

[Significance of supraphysiologic administration of magnesium after myocardial infarct] Benzer W. **Wien Klin Wochenschr Suppl** 1997;2:38–41 (26 ref.) (Eng. Abstr.) **(Ger)**

[Current status of drug therapy in rehabilitation after myocardial infarct] Benzer W. **Wien Klin Wochenschr Suppl** 1997;2:3–5 (17 ref.) **(Ger)**

[Reducing cholesterol in cardiovascular rehabilitation--exercise versus drug therapy] Halle M, et al. **Wien Klin Wochenschr Suppl** 1997;2:29–32 (30 ref.) (Eng. Abstr.) **(Ger)**

[Hormone replacement in postmenopausal women with coronary heart disease. Results and clinical consequences from recent studies] Schurz RA, et al. **Wien Klin Wochenschr Suppl** 1997;2:42–5 (32 ref.) (Eng. Abstr.) **(Ger)**

[Value of antioxidants and vitamins in cardiovascular prevention and therapy] Wascher TC. **Wien Klin Wochenschr Suppl** 1997;2:33–7 (26 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Coronary angiography and angioplasty after acute myocardial infarction. Bates DW, et al. **Ann Intern Med** 1997 Apr 1;126(7):539–50 (121 ref.)

Pregnancy after myocardial infarction and a coronary artery bypass graft. Dufour P, et al. **Arch Gynecol Obstet** 1997; 259(4):209–13 (31 ref.)

Transluminal extraction catheter for acute myocardial infarction. Topaz O, et al. **Cathet Cardiovasc Diagn** 1997 Mar;40(3):291–6 (31 ref.)

THERAPY

Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Kleiman NS. **Am J Cardiol** 1997 Aug 18; 80(4A):29B–33B (17 ref.)

Typical and atypical clinical signs and symptoms of myocardial infarction and delayed seeking of professional care among blacks. Lee HO. **Am J Crit Care** 1997 Jan; 6(1):7–13; quiz 14–5 (56 ref.)

Early management of acute myocardial infarction: thrombolysis, angioplasty, and adjunctive therapies. Selig MB. **Am J Emerg Med** 1996 Mar;14(2):209–17 (103 ref.)

The physician's role in minimizing prehospital delay in patients at high risk for acute myocardial infarction: recommendations from the National Heart Attack Alert Program. Working Group on Educational Strategies To Prevent Prehospital Delay in Patients at High Risk for Acute Myocardial Infarction. Dracup K, et al. **Ann Intern Med** 1997 Apr 15;126(8):645–51 (61 ref.)

Risk stratification after myocardial infarction. Peterson ED, et al. **Ann Intern Med** 1997 Apr 1;126(7):561–82 (280 ref.)

Evidence-based, cost-effective risk stratification and management after myocardial infarction. California Cardiology Working Group on Post-MI Management. Deedwania PC, et al. **Arch Intern Med** 1997 Feb 10; 157(3):273–80 (47 ref.)

Remodeling after myocardial infarction: an opportunity for early intervention. Amos DJ, et al. **Basic Res Cardiol** 1997 Apr;92(2):69–71 (10 ref.)

Evolution of the CCU from rhythm, function and protection to reperfusion and beyond: a personal journey and perspective. Armstrong PW. **Can J Cardiol** 1996 Oct; 12(10):909–13 (45 ref.)

Radial access for primary PTCA in patients with acute myocardial infarction and contraindication or impossible femoral access. Steg G, et al. **Cathet Cardiovasc Diagn** 1996 Dec;39(4):424–6 (9 ref.)

Ischemic preconditioning: clinical relevance and investigative studies. Schlaifer JD, et al. **Clin Cardiol** 1997 Jul; 20(7):602–6 (24 ref.)

Management of the older person after MI. Aronow WS. **Compr Ther** 1997 Apr;23(4):259–68 (68 ref.)

Acute myocardial infarction: role of medical therapy versus primary PTCA. Keeley EC, et al. **Coron Artery Dis** 1995 Oct;6(10):759–64 (30 ref.)

Therapeutic options for coronary syndromes. Overview. Rutherford JD. **Coron Artery Dis** 1995 Oct;6(10):757–8 (9 ref.)

Pathophysiology and initial management of the acute coronary syndromes. Giri S, et al. **Curr Opin Cardiol** 1996 Jul;11(4):351–60 (85 ref.)

Determinants of infarct size in acute myocardial infarction in patients treated with reperfusion therapy. Wagdy HM, et al. **Curr Opin Cardiol** 1996 Jul;11(4):369–77 (60 ref.)

Modern management of acute myocardial infarction. Reeder GS, et al. **Curr Probl Cardiol** 1996 Sep;21(9):585–667 (136 ref.)

Electrocardiographic evaluation of reperfusion therapy in patients with acute myocardial infarction. Clemmensen P. **Dan Med Bull** 1996 Feb;43(1):68–85 (193 ref.)

Cardiopulmonary resuscitation: a promise as yet largely unfulfilled. Weil MH, et al. **Dis Mon** 1997 Jul;43(7):429–501 (162 ref.)

Management of acute myocardial infarction in the elderly. Forman DE, et al. **Drugs Aging** 1996 May;8(5):358–77 (149 ref.)

Thrombolytic therapy for evolving myocardial infarction needs an approach that integrates benefit and risk. Arnold AE, et al. **Eur Heart J** 1995 Nov;16(11):1502–9 (37 ref.)

Predictors of outcome of reperfusion therapy. Califf RM, et al. **Eur Heart J** 1997 May;18(5):728–35 (75 ref.)

Management of myocardial infarction: the proper priorities. Simoons ML, et al. **Eur Heart J** 1997 Jun;18(6):896–9 (31 ref.)

Trials for treatment of myocardial infarction ending in tribulation. Puliyel MM. **Indian Heart J** 1995 Sep-Oct; 47(5):527–8 (6 ref.)

Therapeutic implications of the epidemiology and timing of myocardial infarction and other cardiovascular diseases. Flack JM, et al. **J Hum Hypertens** 1997 Jan;11(1):23–8 (34 ref.)

Diagnosis and management of acute myocardial infarction.

Verani MS. **J Nucl Cardiol** 1997 Mar-Apr;4(2 Pt 2):S158-63 (16 ref.)

Strategies in the management of acute myocardial infarction. Talbert RL. **Pharmacotherapy** 1996 Sep-Oct;16(5 Pt 2):127S-136S (52 ref.)

Primary coronary angioplasty in acute myocardial infarction. Grech ED, et al. **Postgrad Med J** 1996 May;72(847):269-73 (38 ref.)

[Orientated management towards reperfusion in the acute phase of myocardial infarction. Results in a cohort of 700 consecutive patients] Juliard JM, et al. **Arch Mal Coeur Vaiss** 1997 Mar;90(3):337-43 (30 ref.) (Eng. Abstr.) **(Fre)**

[Angioplasty of the proximal left anterior descending artery outside the acute phase of myocardial infarction. Apropos of a series of 100 consecutive patients] Maillard JM, et al. **Arch Mal Coeur Vaiss** 1996 Jul;89(7):825-33 (30 ref.) (Eng. Abstr.) **(Fre)**

[Primary angioplasty in acute myocardial infarction. A one-year experience in a small urban community] Moquet B, et al. **Arch Mal Coeur Vaiss** 1997 Jan;90(1):11-5 (30 ref.) (Eng. Abstr.) **(Fre)**

[Late reperfusion in acute myocardial infarct. The importance of the open infarct vessel] Michel CJ, et al. **Dtsch Med Wochenschr** 1997 Mar 27;122(13):415-21 (64 ref.) **(Ger)**

[Reperfusion therapy in acute myocardial infarct, Thrombolysis or balloon dilatation?] Zeymer U, et al. **Dtsch Med Wochenschr** 1997 Sep 5;122(36):1081-5 (30 ref.) **(Ger)**

[Interventional therapy in acute myocardial infarct] Heintzen MP, et al. **Internist (Berl)** 1997 Jan;38(1):44-52 (63 ref.) **(Ger)**

[Current status of stent implantation] Kaufmann U, et al. **Internist (Berl)** 1997 Jan;38(1):20-6 (29 ref.) **(Ger)**

[Treatment of recurrent stenosis by conventional re-PTCA] Schräder R. **Z Kardiol** 1996;85 Suppl 1:99-101 (7 ref.) (Eng. Abstr.) **(Ger)**

[Myocardial infarct: "wanted"] Prati PL, et al. **Cardiologia** 1997 Jan;42(1):31-8 (80 ref.) **(Ita)**

[Acute myocardial infarction and coronary thrombolysis] Kanmatsuse K. **Rinsho Ketsueki** 1996 Sep;37(9):813-6 (7 ref.) **(Jpn)**

[Treatment of patients after myocardial infarction] Halawa B. **Pol Merkuriusz Lek** 1996 Aug;1(2):131-4 (32 ref.) (Eng. Abstr.) **(Pol)**

[Thrombolysis versus angioplasty in acute myocardial infarction] Ferreira Leite P, et al. **Arq Bras Cardiol** 1995 Oct;65(4):349-52 (35 ref.) **(Por)**

[Direct angioplasty and thrombolysis in acute myocardial infarct] Gottschall CA. **Rev Port Cardiol** 1997 Feb; 16(2):165-74 (60 ref.) **(Por)**

[The treatment of postinfarct pulmonary edema: the reserves and potentials] Sirenko IuN, et al. **Lik Sprava** 1996 Jan-Feb; (1-2):26-32 (55 ref.) **(Rus)**

[Prevention of sudden death after myocardial infarction: should the "MADIT" strategy be generally applied? Arguments against] Arenal Maiz A. **Rev Esp Cardiol** 1997 Jul;50(7):464-6 (10 ref.) (Eng. Abstr.) **(Spa)**

[Prevention of sudden death after myocardial infarction: should the "MADIT" strategy be generally applied? Arguments in favor] Brugada P. **Rev Esp Cardiol** 1997 Jul; 50(7):459-63 (10 ref.) (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Echocardiographic assessment of myocardial rupture to direct a successful repair. López-Sendón J, et al. **Coron Artery Dis** 1996 Mar;7(3):217-23 (30 ref.)

Prognostic value of stress echocardiography in stable angina or after myocardial infarction [see comments] Nagueh SF, et al. **Curr Opin Cardiol** 1996 Nov;11(6):627-34 (28 ref.) Comment in: Curr Opin Cardiol 1996 Nov;11(6):611-2.

FDG SPECT in the assessment of myocardial viability. Comparison with dobutamine echo. Bax JJ, et al. **Eur Heart J** 1997 Jun;18 Suppl D:D124-9 (39 ref.)

Myocardial viability. Stress echocardiography vs nuclear medicine. Piérard LA, et al. **Eur Heart J** 1997 Jun;18 Suppl D:D117-23 (43 ref.)

[Significance of early echocardiography in acute myocardial infarct] Tóth C, et al. **Orv Hetil** 1997 Mar 30;138(13):787-91 (39 ref.) (Eng. Abstr.) **(Hun)**

[Myocardial echocontrastography in the study of myocardial infarct] Iliceto S. **Cardiologia** 1996 Sep;41(9):811-21 (90 ref.) **(Ita)**

[Specialized echocardiographic modalities in the early phases of acute myocardial infarct] Dúbrava J, et al. **Bratisl Lek Listy** 1996 Jul;97(7):406-12 (53 ref.) (Eng. Abstr.) **(Slo)**

[Doppler echocardiography. A good examination method after myocardial infarction] Eriksson SV. **Lakartidningen** 1997 Feb 12;94(7):506-8 (18 ref.) **(Swe)**

MYOCARDIAL ISCHEMIA

see related
ISCHEMIC PRECONDITIONING, MYOCARDIAL
MYOCARDIAL INFARCTION
MYOCARDIAL REPERFUSION
MYOCARDIAL REVASCULARIZATION
MYOCARDIAL STUNNING

Thoracic epidural anesthesia and the patient with heart disease: benefits, risks, and controversies. Meissner A, et al. **Anesth Analg** 1997 Sep;85(3):517-28 (137 ref.)

The concept of total ischaemic burden: clinical significance. Lichtlen PR. **Eur Heart J** 1996 Dec;17 Suppl G:38-47 (86 ref.)

Circadian variations in total ischaemic burden and ischaemic threshold. Tzivoni D. **Eur Heart J** 1996 Dec;17 Suppl G:59-63 (35 ref.)

[Perioperative care of patients with heart dysfunction--influence of epidural anesthesia] Shibata K, et al. **Masui** 1996 Dec;45 Suppl:S122-7 (18 ref.) **(Jpn)**

[Arrhythmias in ischemic heart disease] Ogawa S, et al. **Nippon Rinsho** 1996 Aug;54(8):2191-6 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Silent myocardial ischemia] Koyanagi S. **Ryoikibetsu Shokogun Shirizu** 1996;(12):775-9 (15 ref.) **(Jpn)**

[Acute myocardial ischemia] Kusama Y. **Ryoikibetsu Shokogun Shirizu** 1996;(12):641-4 (6 ref.) **(Jpn)**

[Silent myocardial ischemia in children] Ono Y. **Ryoikibetsu Shokogun Shirizu** 1996;(12):684-7 (15 ref.) **(Jpn)**

[Acute coronary syndrome] Tomita Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):636-40 (17 ref.) **(Jpn)**

[Silent ischemia] Castro I, et al. **Rev Port Cardiol** 1997 Jun; 16(6):511-9, 507 (33 ref.) (Eng. Abstr.) **(Por)**

BLOOD

Serum cholesterol and ischaemic heart disease. Wald NJ, et al. **Atherosclerosis** 1995 Dec;118 Suppl:S1-5 (6 ref.)

Hemostatic variables and ischemic cardiovascular disease: do we need a concerted effort for more profitable future clinical investigations? Di Minno G, et al. **Cardiovasc Drugs Ther** 1997 Jan;10(6):743-9 (60 ref.)

Platelet activation during myocardial ischaemia: a contributory arrhythmogenic mechanism. Flores NA. **Pharmacol Ther** 1996;72(2):83-108 (237 ref.)

[Lipid, apoprotein and fibrinogen levels in the blood of male patients following myocardial infarct and the effect of diet on these parameters in ischemic heart disease] Márk L, et al. **Orv Hetil** 1996 Nov 3;137(44):2447-50 (40 ref.) (Eng. Abstr.) **(Hun)**

[Biochemical markers of coronary reperfusion] Miłek-Kurzątkowska D, et al. **Pol Arch Med Wewn** 1997 Jan;97(1):74-7 (23 ref.) **(Pol)**

[Blood platelets and fibrinolysis in ischemic heart disease] Jastrzębska M. **Pol Merkuriusz Lek** 1996 Aug;1(2):135-8 (44 ref.) (Eng. Abstr.) **(Pol)**

[Apo E: blood lipids, ischemic cardiopathy and Alzheimer's disease] Lahoz C, et al. **Med Clin (Barc)** 1997 May 31; 109(1):31-6 (82 ref.) **(Spa)**

CHEMICALLY INDUCED

Cocaine-induced myocardial ischemia and infarction: pathophysiology, recognition, and management. Pitts WR, et al. **Prog Cardiovasc Dis** 1997 Jul-Aug;40(1):65-76 (88 ref.)

COMPLICATIONS

Ischemic heart disease in patients with end-stage renal disease. Fellner SK, et al. **Adv Ren Replace Ther** 1996 Jul; 3(3):240-9 (38 ref.)

Unstable angina--report from a Canadian expert roundtable. Cairns J, et al. **Can J Cardiol** 1996 Dec;12(12):1279-92 (116 ref.)

Myocardial stunning: a post-ischemic syndrome with delayed recovery. Allen JW, et al. **EXS** 1996;76:443-52 (27 ref.)

Cellular mechanisms of cardiac arrhythmias in the ischemic and reperfused heart. Bril A. **EXS** 1996;76:135-53 (78 ref.)

Response to ischemia and reperfusion by the diabetic heart. Feuvray D. **EXS** 1996;76:409-21 (38 ref.)

Electrophysiological mechanisms for ventricular arrhythmias in patients with myocardial ischemia: anesthesiologic considerations, Pt II. Gallagher JD. **J Cardiothorac Vasc Anesth** 1997 Aug;11(5):641-56 (139 ref.)

Electrophysiological mechanisms for ventricular arrhythmias in patients with myocardial ischemia: anesthesiologic considerations, Part I. Gallagher JD. **J Cardiothorac Vasc Anesth** 1997 Jun;11(4):495-505 (80 ref.)

Cardiac cephalgia: a treatable form of exertional headache. Lipton RB, et al. **Neurology** 1997 Sep;49(3):813-6 (30 ref.)

Cellular and pathophysiological mechanisms of ventricular arrhythmias in acute ischemia and infarction. Ehlert FA, et al. **Pacing Clin Electrophysiol** 1997 Apr;20(4 Pt 1):966-75 (77 ref.)

Intracardiac thrombus formation in cardiac impairment: the role of anticoagulant therapy. Lip GY. **Postgrad Med J** 1996 Dec;72(854):731-8 (64 ref.)

Targeting ischaemia--cell swelling and drug efficacy. Wright AR, et al. **Trends Pharmacol Sci** 1997 Jul;18(7):224-8 (45 ref.)

[Myocardial viability in patients with chronic ischemic heart disease and left ventricular dysfunction. Diagnostic methods and clinical significance] Perrone Filardi P, et al. **Cardiologia** 1996 Aug;41(8):707-26 (111 ref.) **(Ita)**

[Combined operation for patients with ischemic heart disease and thoracic aortic aneurysm] Kitamura S, et al. **Rinsho Kyobu Geka** 1989 Aug;9(4):329-32 (16 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

The cardiac profile and proposed practice guideline for acute ischemic heart disease [see comments] Keffer JH. **Am J Clin Pathol** 1997 Apr;107(4):398-409 (60 ref.) Comment in: Am J Clin Pathol 1997 Apr;107(4):383-4.

Stress echocardiography. Mishra MB, et al. **Br J Clin Pract** 1997 Jan-Feb;51(1):41-6 (45 ref.)

What can we learn from exercise testing beyond the detection of myocardial ischemia? Weber KT. **Clin Cardiol** 1997 Aug; 20(8):684-96 (37 ref.)

Diagnostic procedures for myocardial ischaemia. Gottlieb SO. **Eur Heart J** 1996 Dec;17 Suppl G:53-8 (17 ref.)

Detection of intraoperative myocardial ischemia. Perrino AC Jr, et al. **Int Anesthesiol Clin** 1996 Summer;34(3):37-56 (67 ref.)

MR first pass imaging: quantitative assessment of transmural perfusion and collateral flow. Jerosch-Herold M, et al. **Int J Card Imaging** 1997 Jun;13(3):205-18 (53 ref.)

Ischemic heart disease: value of MR techniques. van der Wall EE, et al. **Int J Card Imaging** 1997 Jun;13(3):179-89 (21 ref.)

Nuclear and echocardiographic imaging for prediction of reversible left ventricular ischemic dysfunction after coronary revascularization: current status and future directions. Vanoverschelde JL, et al. **J Cardiovasc Pharmacol** 1996;28 Suppl 1:S27-36 (56 ref.)

Are cardiac troponins reliable serodiagnositic markers of cardiac ischaemia in end-stage renal disease? [editorial] Haller C, et al. **Nephrol Dial Transplant** 1996 Jun; 11(6):941-4 (16 ref.)

[Alteration of myocardial viability and systemic ventricular dysfunction after Senning procedure] Labbé L, et al. **Arch Mal Coeur Vaiss** 1997 May;90(5):631-7 (30 ref.) (Eng. Abstr.) **(Fre)**

[Diagnostic approach in coronary disease in developing countries] Broustet JP, et al. **Med Trop (Mars)** 1996; 56(3):219-22 (0 ref.) **(Fre)**

[Magnetic resonance tomography in myocardial ischemia: state of the art] Szolar DH, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Sep;165(3):216-26 (53 ref.) (Eng. Abstr.) **(Ger)**

[Significance of coronary thrombosis for chronic myocardial ischemia] Schoebel FC, et al. **Z Kardiol** 1997;86 Suppl 1:71-83 (115 ref.) (Eng. Abstr.) **(Ger)**

[Thoracic pain and myocardial ischemia. Applications of the Bayes theorem for the rational use of stress-test including echocardiography-dobutamine] Brandimarte C, et al. **Recenti Prog Med** 1996 Nov;87(11):564-70 (26 ref.) (Eng. Abstr.) **(Ita)**

[Angina pectoris. Silent ischemia] Tuna JL. **Acta Med Port** 1997 Apr;10(4):267-75 (50 ref.) (Eng. Abstr.) **(Por)**

[Ergometric test after surgical revascularization and mechanical recanalization of the myocardium] Chalela WA, et al. **Arq Bras Cardiol** 1996 Jul;67(1):59-62 (27 ref.) **(Por)**

[Functional stress tests in the diagnosis of ischemic heart disease in women] Lupanov VP. **Ter Arkh** 1997;69(4):82-8 (93 ref.) **(Rus)**

[I. Usefulness of the exertion test and other methods based on the electrocardiogram in chronic ischemic disease] Alegría Ezquerra E, et al. **Rev Esp Cardiol** 1997 Jan; 50(1):6-14 (24 ref.) (Eng. Abstr.) **(Spa)**

[Decision making in cardiology: methodology] Gabriel Sánchez R, et al. **Rev Esp Cardiol** 1997 Aug;50(8):573-85 (35 ref.) (Eng. Abstr.) **(Spa)**

DIET THERAPY

Prevention of cardiac arrhythmia by dietary (n-3) polyunsaturated fatty acids and their mechanism of action. Nair SS, et al. **J Nutr** 1997 Mar;127(3):383-93 (93 ref.)

[Significance of food for patients with ischemic heart disease] Stender S, et al. **Ugeskr Laeger** 1996 Nov 25; 158(48):6885-91 (18 ref.) (Eng. Abstr.) **(Dan)**

DRUG THERAPY

Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease? Ruschitzka FT, et al. **Am Heart J** 1997 Aug;134(2 Pt 2):S31-47 (117 ref.)

Use of calcium antagonists in patients with ischemic heart disease and systemic hypertension. Frishman WH, et al. **Am J Cardiol** 1997 May 22;79(10A):33-8; discussion 47-8 (36 ref.)

Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. Harrington RA. **Am J Cardiol** 1997 Aug 18; 80(4A):34B-38B (27 ref.)

Enhanced preservation of acutely ischemic myocardium and improved clinical outcomes using glucose-insulin-potassium (GIK) solutions. Lazar HL. **Am J Cardiol** 1997 Aug 4;80(3A):90A-93A (26 ref.)

Unmet therapeutic needs in the management of acute ischemia. White HD. **Am J Cardiol** 1997 Aug 18; 80(4A):2B-10B (62 ref.)

The role of diltiazem in treating hypertension and coronary artery disease: new approaches to preventing first events. Fodor JG, et al. **Can J Cardiol** 1997 May;13(5):495-503 (85 ref.)

Dihydropyridine calcium antagonists: beneficial or adverse effects in the setting of myocardial ischaemia/reperfusion? Ehring T, et al. **Cardiology** 1997;88 Suppl 1:3–14; discussion 15–6 (117 ref.)

Nisoldipine CC: clinical experience in ischaemic heart disease. Melcher A, et al. **Cardiology** 1997;88 Suppl 1:17–23; discussion 24–5 (30 ref.)

Nisoldipine CC: efficacy and tolerability in hypertension and ischemic heart disease. Fodor JG. **Cardiovasc Drugs Ther** 1997 Jan;10 Suppl 3:873–9 (48 ref.)

Confusion in reperfusion. Problems in the clinical development of antithrombotic drugs [editorial; comment] Catella-Lawson F, et al. **Circulation** 1997 Feb 18; 95(4):793–5 (23 ref.) Comment on: Circulation 1997 Feb 18;95(4):846–54.

Hyperlipoproteinemic states and ischemic heart disease. Prusinski L, et al. **Dent Clin North Am** 1996 Jul; 40(3):563–84 (49 ref.)

Nisoldipine coat-core. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of ischaemic heart disease. Langtry HD, et al. **Drugs** 1997 May;53(5):867–84 (48 ref.)

Pharmacological treatment of ischaemic heart disease. Monotherapy vs combination therapy. Cohn PF. **Eur Heart J** 1997 May;18 Suppl B:B27–34 (43 ref.)

Treatment effects on the total ischaemic burden and prognostic implications. Deanfield J. **Eur Heart J** 1996 Dec;17 Suppl G:64–8 (30 ref.)

Novel uses and potential for calcium antagonists in revascularization. Nikol S, et al. **Eur Heart J** 1997 Jan;18 Suppl A:A105–9 (49 ref.)

Bleeding complications with new antithrombotics used in ischaemic heart disease. Adgey AA. **Haemostasis** 1996 Sep-Oct;26(5):237–46 (35 ref.)

Angiotensin converting enzyme inhibitor–calcium antagonist combination: an alliance for cardioprotection? Ferrari R. **J Hypertens Suppl** 1997 Mar;15(2):S109–17 (87 ref.)

Fifty years of experience with antithrombotic therapy in cardiac disease. A 1996 approach based on pathogenesis and risk. Freudenrerger RS, et al. **Mt Sinai J Med** 1996 Oct–Nov;63(5–6):342–58 (69 ref.)

Clinical trials of direct thrombin inhibitors in acute ischaemic syndromes. White HD. **Thromb Haemost** 1997 Jul; 78(1):364–6 (17 ref.)

[Use of captopril in therapeutic combinations] Alföldi S. **Acta Pharm Hung** 1997 Jul;67(4):149–53 (18 ref.) (Eng. Abstr.) **(Hun)**

[Calcium antagonists and ischemic heart disease] Simon K, et al. **Orv Hetil** 1996 Sep 29;137(39):2131–6 (66 ref.) (Eng. Abstr.) **(Hun)**

[Angina pectoris: progress in diagnosis and treatment. III. Progress in treatment. 4. Practice of drug therapy of ischemic heart disease] Kishida H, et al. **Nippon Naika Gakkai Zasshi** 1997 Feb 10;86(2):259–64 (8 ref.) **(Jpn)**

[Adhesive molecules as drugs and objects of pharmacological effect in myocardial ischemia and reperfusion] Uteshev DB, et al. **Eksp Klin Farmakol** 1997 May–Jun;60(3):83–8 (57 ref.) (Eng. Abstr.) **(Rus)**

[Trimetazidine (Preductal). A new approach in controlling myocardial ischemia] Eliseev OM. **Ter Arkh** 1996; 68(8):57–63 (78 ref.) **(Rus)**

[The use of acetylsalicylic acid in IHD] Lenkovsky F, et al. **Ter Arkh** 1996;68(8):79–83 (66 ref.) **(Rus)**

[Nifedipine in ischemic heart disease: a ban on its use or a differential approach to therapy? (see comments)] Martsevich SIu. **Ter Arkh** 1996;68(9):31–5 (20 ref.) (Eng. Abstr.) Comment in: Ter Arkh 1996;68(9):5–7. **(Rus)**

[The anti-ischemic effects of ACE inhibitors after an acute myocardial infarct] Rutherford JD. **Rev Clin Esp** 1996 Dec; 196(4 Monografico):41–2 (23 ref.) **(Spa)**

ENZYMOLOGY

The role of protein kinase C in ischemic preconditioning. Goto M, et al. **Ann N Y Acad Sci** 1996 Sep 30;793:177–90 (59 ref.)

[Polymorphism and clinical significance of human paraoxonase enzyme] Renczes G, et al. **Orv Hetil** 1997 Aug 17;138(33):2057–9 (25 ref.) (Eng. Abstr.) **(Hun)**

EPIDEMIOLOGY

Cardiovascular disease and environmental pollutants: the Arctic aspect. Bjerregaard P. **Arctic Med Res** 1996;55 Suppl 1:25–31 (7 ref.)

Cold research: Nordic perspectives. Leppäluoto J. **Arctic Med Res** 1995;54 Suppl 2:5–8 (8 ref.)

[Ischemic heart diseases and coronary vasospasm in Japanese population] Shimokawa H. **Fukuoka Igaku Zasshi** 1996 Oct; 87(10):207–14 (22 ref.) **(Jpn)**

ETIOLOGY

Endothelin-1: a scientist's curiosity, or a real player in ischemic heart disease? Cesari M, et al. **Am Heart J** 1996 Dec;132(6):1236–43 (76 ref.)

Lipids, risk factors and ischaemic heart disease. Castelli WP. **Atherosclerosis** 1996 Jul,124 Suppl:S1–9 (48 ref.)

Ischemic heart disease in chronic uremia. Parfrey PS, et al. **Blood Purif** 1996;14(4):321–6 (32 ref.)

Circadian rhythms and ischaemic heart disease. Marchant B. **Br J Hosp Med** 1996 Feb 7–20;55(3):139–43 (35 ref.)

The acute coronary ischemic syndromes--the central role of thrombosis. Cairns JA. **Can J Cardiol** 1996 Oct; 12(10):901–7 (71 ref.)

Silent myocardial ischemia in patients with diabetes mellitus [editorial; comment] Chiariello M, et al. **Circulation** 1996 Jun 15;93(12):2089–91 (36 ref.) Comment on: Circulation 1996 Jun 15;93(12):2097–105.

Ischemia and reperfusion injury in the hypertrophied heart. Allard MF, et al. **EXS** 1996;76:423–41 (78 ref.)

Sodium-hydrogen exchange in myocardial ischemia and reperfusion: a critical determinant of injury? Avkiran M. **EXS** 1996;76:299–311 (60 ref.)

Role of eicosanoids in the ischemic and reperfused myocardium. Bend JR, et al. **EXS** 1996;76:243–62 (93 ref.)

The role of the neutrophil in myocardial ischemia and reperfusion. Frangogiannis NG, et al. **EXS** 1996;76:263–84 (86 ref.)

The role of ATP-sensitive potassium channels in myocardial ischemia: pharmacology and implications for the future. Grover GJ. **EXS** 1996;76:313–24 (31 ref.)

Role of the sympathetic nervous system in the ischemic and reperfused heart. Hara A, et al. **EXS** 1996;76:285–97 (60 ref.)

The molecular basis of adaptation to ischemia in the heart: the role of stress proteins and anti-oxidants in the ischemic and reperfused heart. Heads RJ, et al. **EXS** 1996;76:383–407 (70 ref.)

Role of kinins in myocardial ischemia. Linz W, et al. **EXS** 1996;76:231–41 (60 ref.)

Significance of hypertriglyceridemia in the occurrence of ischemic heart disease. Matsuzawa Y. **J Atheroscler Thromb** 1995;2 Suppl 1:S26–8 (0 ref.)

Ischemia--a coagulation problem? Spiess BD. **J Cardiovasc Pharmacol** 1996;27 Suppl 1:S38–41 (19 ref.)

Acute, reversible myocardial ischemia in a patient with an asthmatic attack. Myrianthefs MM, et al. **J Electrocardiol** 1996 Oct;29(4):337–9 (10 ref.)

Nonatherosclerotic causes of myocardial ischemia. Iskandrian AE, et al. **J Nucl Cardiol** 1996 Sep–Oct;3(5):428–35 (32 ref.)

Are cardiac troponins reliable serodiagnositic markers of cardiac ischaemia in end-stage renal disease? [editorial] Haller C, et al. **Nephrol Dial Transplant** 1996 Jun; 11(6):941–4 (16 ref.)

Occupational exposure to dust: inflammation and ischaemic heart disease. Sjögren B. **Occup Environ Med** 1997 Jul; 54(7):466–9 (49 ref.)

[Endothelin-1 in ischemic cardiopathy] Cesari M, et al. **Cardiologia** 1996 Sep;41(9):823–9 (61 ref.) **(Ita)**

[Exertion-induced myocardial ischemia has little influence on ventricular remodeling in post-infarction patients with preserved systolic function] Temporelli PL, et al. **G Ital Cardiol** 1996 Jul;26(7):729–37 (37 ref.) (Eng. Abstr.) **(Ita)**

[Angina pectoris: progress in diagnosis and therapy. I. Physiopathology. 1. Asymptomatic myocardial ischemia--etiological mechanism and clinical significance] Ito H, et al. **Nippon Naika Gakkai Zasshi** 1997 Feb 10; 86(2):191–5 (5 ref.) **(Jpn)**

[A new approach to the understanding of the mechanism of ischemia/reperfusion damage in the heart and the effects of anti-ischemic drugs] Abiko Y, et al. **Nippon Yakurigaku Zasshi** 1996 Oct;108(4):195–202 (40 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Gene-environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis. Humphries SE, et al. **Thromb Haemost** 1997 Jul;78(1):457–61 (35 ref.)

[The polymorphism of the angiotensin I-converting enzyme gene and its association with ischemic cardiopathy] Calviño Santos R, et al. **Rev Esp Cardiol** 1996 Dec;49(12):863–8 (36 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Lactate transport in heart in relation to myocardial ischemia. Halestrap AP, et al. **Am J Cardiol** 1997 Aug 4; 80(3A):17A–25A (56 ref.)

Alterations in fatty acid oxidation during reperfusion of the heart after myocardial ischemia. Lopaschuk GD. **Am J Cardiol** 1997 Aug 4;80(3A):11A–16A (58 ref.)

Bradykinin and endothelial-cardiac myocyte interactions in ischemic preconditioning. Parratt JR, et al. **Am J Cardiol** 1997 Aug 4;80(3A):124A–131A (49 ref.)

Substrate metabolism as a determinant for postischemic functional recovery of the heart. Taegtmeyer H, et al. **Am J Cardiol** 1997 Aug 4;80(3A):3A–10A (62 ref.)

Exploration of the possible roles of phospholipase D and protein kinase C in the mechanism of ischemic preconditioning in the myocardium. Eskildsen-Helmond YE, et al. **Ann N Y Acad Sci** 1996 Sep 30;793:210–25 (79 ref.)

Anoxia and ischemia tolerance in turtle hearts. Wasser JS. **Braz J Med Biol Res** 1995 Nov–Dec;28(11–12):1233–40 (23 ref.)

Pharmacology of ATP-sensitive potassium channel (KATP) openers in models of myocardial ischemia and reperfusion. Grover GJ. **Can J Physiol Pharmacol** 1997 Apr; 75(4):309–15 (49 ref.)

Metabolic approach to myocardial ischemia: a novel therapeutic strategy for patients with coronary artery disease? Rizzon P, et al. **Cardiologia** 1995 Oct;40(10):717–20 (28 ref.)

Differential electrophysiology of repolarisation from clone to clinic. Coronel R, et al. **Cardiovasc Res** 1997 Mar; 33(3):503–17 (30 ref.)

Endothelin in myocardial ischaemia and reperfusion. Pernow J, et al. **Cardiovasc Res** 1997 Mar;33(3):518–26 (71 ref.)

Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients. Schotborgh CE, et al. **Cardiovasc Res** 1997 Apr;34(1):73–80 (88 ref.)

Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Stanley WC, et al. **Cardiovasc Res** 1997 Feb;33(2):243–57 (184 ref.)

Heat shock-induced myocardial protection against ischemic injury: a role for Hsp70? Plumier JC, et al. **Cell Stress Chaperones** 1996 Apr;1(1):13–7 (51 ref.)

Glucose metabolism in the ischemic heart [editorial; comment] Lopaschuk GD, et al. **Circulation** 1997 Jan 21; 95(2):313–5 (22 ref.) Comment on: Circulation 1997 Jan 21;95(2):415–22.

Ischemia and reperfusion injury in the hypertrophied heart. Allard MF, et al. **EXS** 1996;76:423–41 (78 ref.)

Intracellular calcium regulatory systems during ischemia and reperfusion. Altschuld RA. **EXS** 1996;76:87–97 (58 ref.)

Sodium–hydrogen exchange in myocardial ischemia and reperfusion: a critical determinant of injury? Avkiran M. **EXS** 1996;76:299–311 (60 ref.)

Bioenergetics, ischemic contracture and reperfusion injury. Das DK, et al. **EXS** 1996;76:155–73 (50 ref.)

The role of ATP-sensitive potassium channels in myocardial ischemia: pharmacology and implications for the future. Grover GJ. **EXS** 1996;76:313–24 (31 ref.)

The molecular basis of adaptation to ischemia in the heart: the role of stress proteins and anti-oxidants in the ischemic and reperfused heart. Heads RJ, et al. **EXS** 1996;76:383–407 (70 ref.)

Lipid metabolism in the ischemic and reperfused heart. van der Vusse GJ, et al. **EXS** 1996;76:175–90 (53 ref.)

Signal transduction mechanisms in the ischemic and reperfused myocardium. Ward CA, et al. **EXS** 1996; 76:191–207 (71 ref.)

Why are ATP depletion rates in situ in ischemic myocardium so much lower than one might predict from the activity of the mitochondrial ATPase in sonicated heart mitochondria? [editorial] Rouslin W, et al. **J Mol Cell Cardiol** 1997 Jun;29(6):1505–10 (13 ref.)

Free fatty acid metabolism during myocardial ischemia and reperfusion. Hendrickson SC, et al. **Mol Cell Biochem** 1997 Jan;166(1–2):85–94 (97 ref.)

Accumulation of arachidonic acid in ischemic/reperfused cardiac tissue: possible causes and consequences. Van der Vusse GJ, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Jul; 57(1):85–93 (50 ref.)

[Metabolic prerequisites for sudden death from ischemic heart disease] Kalinkin MN. **Patol Fiziol Eksp Ter** 1997 Jul–Sep; (3):43–6 (46 ref.) **(Rus)**

[Post-clinical period of disease: metabolic aspects] Endakova EA, et al. **Vestn Ross Akad Med Nauk** 1997;(8):15–9 (21 ref.) (Eng. Abstr.) **(Rus)**

PATHOLOGY

Apoptosis in the heart. Umansky SR, et al. **Adv Pharmacol** 1997;41:383–407 (85 ref.)

The cardiac profile and proposed practice guideline for acute ischemic heart disease [see comments] Keffer JH. **Am J Clin Pathol** 1997 Apr;107(4):398–409 (60 ref.) Comment in: Am J Clin Pathol 1997 Apr;107(4):383–4.

Angiogenesis in ischemic heart disease. Ware JA, et al. **Nat Med** 1997 Feb;3(2):158–64 (64 ref.)

Targeting ischaemia--cell swelling and drug efficacy. Wright AR, et al. **Trends Pharmacol Sci** 1997 Jul;18(7):224–8 (45 ref.)

[Ischemic heart disease and apoptosis] Takemura G, et al. **Rinsho Byori** 1997 Jul;45(7):606–13 (22 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Endogenous protective mechanisms in myocardial ischemia: hibernation and ischemic preconditioning. Heusch G, et al. **Am J Cardiol** 1997 Aug 4;80(3A):26A–33A (115 ref.)

Pharmacologic myocardial preconditioning with monophosphoryl lipid A (MLA) reduces infarct size and stunning in dogs and rabbits. Elliott GT. **Ann N Y Acad Sci** 1996 Sep 30;793:386–99 (63 ref.)

Myocardial protection in the elderly. Biology of the senescent heart. McCully JD, et al. **Ann N Y Acad Sci** 1996 Sep 30;793:305–18 (51 ref.)

Myocardial adaptation, stress proteins, and the second window of protection. Marber MS, et al. **Ann N Y Acad Sci** 1996 Sep 30;793:123–41 (98 ref.)

Protection by preconditioning and cardiac pacing against ventricular arrhythmias resulting from ischemia and reperfusion. Parratt JR, et al. **Ann N Y Acad Sci** 1996 Sep 30;793:98–107 (42 ref.)

The slowing of ischemic energy demand in preconditioned myocardium. Reimer KA. **Ann N Y Acad Sci** 1996 Sep 30;793:13–26 (81 ref.)

Windows for HSP 70. Snoeckx LH, et al. **Ann N Y Acad Sci** 1996 Sep 30;793:167–76 (44 ref.)

The role of Na+/H+ exchange in ischemia-reperfusion. Piper HM, et al. **Basic Res Cardiol** 1996 May-Jun; 91(3):191-202 (91 ref.)

Circadian rhythms and ischaemic heart disease. Marchant B. **Br J Hosp Med** 1996 Feb 7-20;55(3):139-43 (35 ref.)

The myocardium. Foëx P, et al. **Can J Anaesth** 1997 May; 44(5 Pt 2):R67-76 (53 ref.) **(Eng, Fre)**

Preconditioning the human myocardium: recent advances and aspirations for the development of a new means of cardioprotection in clinical practice. Jenkins DP, et al. **Cardiovasc Drugs Ther** 1995 Dec;9(6):739-47 (49 ref.)

Reflexes mediated by cardiac sympathetic afferents during myocardial ischaemia: role of adenosine. Thames MD, et al. **Clin Exp Pharmacol Physiol** 1996 Aug;23(8):709-14 (33 ref.)

Myocyte cell death and ventricular remodeling [see comments] Anversa P, et al. **Curr Opin Nephrol Hypertens** 1997 Mar;6(2):169-76 (68 ref.) Comment in: Curr Opin Nephrol Hypertens 1997 Mar;6(2):167-8.

The pathophysiology of myocardial ischaemia. Detry JM. **Eur Heart J** 1996 Dec;17 Suppl G:48-52 (24 ref.)

Characterization of hibernating and stunned myocardium. Heusch G, et al. **Eur Heart J** 1997 Jun;18 Suppl D:D102-10 (91 ref.)

Myocardial hibernation: adaptation to ischaemia. Heusch G, et al. **Eur Heart J** 1996 Jun;17(6):824-8 (17 ref.)

Electrophysiological responses to ischemia and reperfusion. Ruiz Petrich E, et al. **EXS** 1996;76:115-33 (60 ref.)

Is there a link between the circulating renin-angiotensin system and coronary disease? A buoyant view. Alderman MH. **Heart** 1996 Nov;76(3 Suppl 3):18-22 (20 ref.)

The renin-angiotensin-aldosterone system and cardiac ischaemia. Ikram H. **Heart** 1996 Nov;76(3 Suppl 3):60-7 (99 ref.)

Is there a link between the circulating renin-angiotensin system and coronary disease? A sceptical view. Swales JD. **Heart** 1996 Nov;76(3 Suppl 3):23-7 (40 ref.)

Pathophysiology of ischemic heart disease with special reference to the degree of organic stenosis of the coronary artery. Nakamura M. **J Atheroscler Thromb** 1994;1(1):1-7 (39 ref.)

Interactions of adenosine with sympathetic neurotransmission: protective effect in myocardial ischemia. Richardt G, et al. **J Auton Pharmacol** 1996 Dec; 16(6):333-5 (18 ref.)

Left ventricular dysfunction due to the new ischemic outcomes: stunning and hibernation. Ferrari R, et al. **J Cardiovasc Pharmacol** 1996;28 Suppl 1:S18-26 (50 ref.)

The role of mitochondria in ischemic heart disease. Ferrari R. **J Cardiovasc Pharmacol** 1996;28 Suppl 1:S1-10 (80 ref.)

Vasculogenesis and angiogenesis: extracellular matrix remodeling in coronary collateral arteries and the ischemic heart. Tyagi SC. **J Cell Biochem** 1997 Jun 1;65(3):388-94 (51 ref.)

Coronary endothelial dysfunction in the hypertensive patient: from myocardial ischemia to heart failure. Burnett JC Jr. **J Hum Hypertens** 1997 Jan;11(1):45-9 (28 ref.)

The multifarious spectrum of ischemic left ventricular dysfunction: relevance of new ischemic syndromes. Opie LH. **J Mol Cell Cardiol** 1996 Dec;28(12):2403-14 (89 ref.)

Pathophysiological functions of ATP-sensitive K+ channels in myocardial ischemia. Hiraoka M. **Jpn Heart J** 1997 May; 38(3):297-315 (116 ref.)

The guanine nucleotide-binding regulatory proteins (G proteins) in myocardium with ischemia. Ohyanagi M, et al. **Mol Cell Biochem** 1996 Jul-Aug;160-161:153-8 (58 ref.)

Activation of the factor VII-tissue factor pathway. Bauer KA. **Thromb Haemost** 1997 Jul;78(1):108-11 (19 ref.)

Current status of activation markers in ischemic heart disease: markers of coagulation activation. Merlini PA, et al. **Thromb Haemost** 1997 Jul;78(1):276-9 (40 ref.)

Myocardial viability [see comments] Birnbaum Y, et al. **West J Med** 1996 Dec;165(6):364-71 (62 ref.) Comment in: West J Med 1996 Dec;165(6):393-6.

Neurophysiological aspects of angina pectoris. Sylvén C. **Z Kardiol** 1997;86 Suppl 1:95-105 (80 ref.)

[The hibernating myocardium--its use in clinical practice] Knap J, et al. **Cas Lek Cesk** 1997 Mar 12;136(5):138-41 (31 ref.) (Eng. Abstr.) **(Cze)**

[Contractile force and myocardial ischemia--electrical and ionic mechanisms] Köppel H, et al. **Acta Med Austriaca** 1997;24(3):114-21 (98 ref.) (Eng. Abstr.) **(Ger)**

[Pathophysiology of ischemic myocardial dysfunction] Heusch G. **Schweiz Med Wochenschr** 1996 Sep 28; 126(39):1654-60 (26 ref.) (Eng. Abstr.) **(Ger)**

[The heart and ischemia: stunned-hibernating myocardium] Wutte M, et al. **Wien Klin Wochenschr Suppl** 1997;1:25-33 (106 ref.) **(Ger)**

[Exogenous adenosine in cardioplegia] Haverich A, et al. **Z Kardiol** 1996;85 Suppl 6:201-4 (35 ref.) (Eng. Abstr.) **(Ger)**

[Cellular sequelae of myocardial ischemia] Richardt G, et al. **Z Kardiol** 1997;86 Suppl 1:23-32 (79 ref.) (Eng. Abstr.) **(Ger)**

[Interactions of adenosine with sympathetic neurotransmission in the heart] Ungerer M, et al. **Z Kardiol** 1996;85 Suppl 6:171-5 (33 ref.) (Eng. Abstr.) **(Ger)**

[Mechanisms of ischemic preconditioning: relation with ischemia-reperfusion injury] Gattullo D, et al. **G Ital Cardiol** 1997 Mar;27(3):288-96 (66 ref.) (Eng. Abstr.) **(Ita)**

[Microvascular function and regulation of coronary blood flow in ischemic cardiomyopathy] Sambuceti G, et al. **G Ital Cardiol** 1996 Dec;26(12):1495-505 (60 ref.) **(Ita)**

[Angina pectoris: progress in diagnosis and treatment. I. Physiopathology. 3. Cardiac function of the ischemic myocardium] Hori M. **Nippon Naika Gakkai Zasshi** 1997 Feb 10;86(2):201-7 (8 ref.) **(Jpn)**

[Current status of asymptomatic myocardial ischemia] Miura M. **Nippon Naika Gakkai Zasshi** 1996 Sep 10;85(9):1546-53 (25 ref.) **(Jpn)**

PREVENTION & CONTROL

Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Tcheng JE. **Am J Cardiol** 1997 Aug 18;80(4A):21B-28B (15 ref.)

Alcohol, ischemic heart disease, and the French paradox. Constant J. **Clin Cardiol** 1997 May;20(5):420-4 (51 ref.)

Role of calcium channel blockers in reducing acute ischaemia and preventing restenosis in PTCA. Vahanian A, et al. **Drugs** 1996;52 Suppl 4:9-15; discussion 15-6 (35 ref.)

Pulse oximetry and supplemental oxygen during gastrointestinal endoscopy: a critical review [see comments] Holm C, et al. **Endoscopy** 1996 Oct;28(8):703-11 (85 ref.) Comment in: Endoscopy 1996 Oct;28(8):718-21.

Myocardial preconditioning. What have we learned? Sumeray MS, et al. **Eur Heart J** 1997 Jan;18 Suppl A:A8-14 (83 ref.)

Protection of the myocardium by ischaemic preconditioning: mechanisms and therapeutic implications. Millar CG, et al. **Pharmacol Ther** 1996;69(2):143-51 (89 ref.)

[Treatment of hypercholesterolemia--the other side of the coin] Przybyś W. **Pol Merkuriusz Lek** 1996 Sep;1(3):210-2 (14 ref.) (Eng. Abstr.) **(Pol)**

PSYCHOLOGY

[Depression and cardiomyopathies] Muiesan ML, et al. **Ann Ital Med Int** 1996 Oct;11 Suppl 2:67S-69S (17 ref.) **(Ita)**

RADIONUCLIDE IMAGING

The use of positron emission tomography imaging in the management of patients with ischemic cardiomyopathy. Maddahi J, et al. **Adv Card Surg** 1996;7:163-88 (72 ref.)

Recent advances in myocardial perfusion scintigraphy. Gunning MG, et al. **Clin Radiol** 1996 Oct;51(10):677-83 (78 ref.)

[Echocardiography and nuclear medicine: complementary or alternative methods in the study of the ischemic myocardium? (editorial)] La Canna G, et al. **Cardiologia** 1997 Feb;42(2):123-37 (103 ref.) **(Ita)**

[Metabolic, adrenergic, and systolic function assessed by cardiac SPECT] Hattori N, et al. **Nippon Rinsho** 1997 Mar; 55 Suppl 1:656-61 (8 ref.) **(Jpn)**

[Evaluation of myocardial perfusion and injured myocardium by scintigraphy] Nakajima K, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:651-5 (7 ref.) **(Jpn)**

REHABILITATION

Exercise training and the coronary collateral circulation: is its value underestimated in man? Firoozan S, et al. **Eur Heart J** 1996 Dec;17(12):1791-5 (43 ref.)

[Angina pectoris: progress in diagnosis and treatment. III. Progress in treatment. 7. Rehabilitation of patients with ischemic heart disease] Goto Y. **Nippon Naika Gakkai Zasshi** 1997 Feb 10;86(2):276-82 (5 ref.) **(Jpn)**

SURGERY

The use of positron emission tomography imaging in the management of patients with ischemic cardiomyopathy. Maddahi J, et al. **Adv Card Surg** 1996;7:163-88 (72 ref.)

The role of coronary revascularization in the management of heart failure: identification of candidates and review of results. Blitz A, et al. **Curr Opin Cardiol** 1996 May; 11(3):276-90 (74 ref.)

Transmyocardial laser revascularization. Frazier OH, et al. **Curr Opin Cardiol** 1996 Nov;11(6):564-7 (15 ref.)

[Combined operation for patients with ischemic heart disease and thoracic aortic aneurysm] Kitamura S, et al. **Rinsho Kyobu Geka** 1989 Aug;9(4):329-32 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Radiofrequency ablation of the sustained ventricular tachycardia in patients with structural heart disease] de Paola AA, et al. **Arq Bras Cardiol** 1996 Mar;66 Suppl 1:51-8 (52 ref.) **(Por)**

THERAPY

Cost-effectiveness of cardiac positron emission tomography in the treatment of ischemic cardiomyopathy. Schelbert HR. **Am J Card Imaging** 1996 Jul;10(3):191-7 (28 ref.)

The future of the management of ischaemic heart disease. Crossman D. **BMJ** 1997 Feb 1;314(7077):356-9 (18 ref.)

The role of percutaneous revascularization in the treatment of ischemic heart disease: insights from published reports and randomized clinical trials. Levine GN, et al. **Chest** 1997 Sep;112(3):805-21 (95 ref.)

Gene therapy for ischemic heart disease. Malosky S, et al. **Curr Opin Cardiol** 1996 Jul;11(4):361-8 (63 ref.)

Treatment of ischaemic heart disease. Role of drugs, surgery and angioplasty in unstable angina patients. Conti CR. **Eur Heart J** 1997 May;18 Suppl B:B11-5 (25 ref.)

New trends in the interventional treatment of ischaemic heart disease. Konstam MA. **Eur Heart J** 1997 May;18 Suppl B:B16-20 (40 ref.)

Silent ischaemia: to treat or not to treat? Deedwania PC. **Indian Heart J** 1996 Jul-Aug;48(4):415-9 (27 ref.)

Selecting patients with ischemic cardiomyopathy for medical treatment, revascularization, or heart transplantation. Beller GA. **J Nucl Cardiol** 1997 Mar-Apr;4(2 Pt 2):S152-7 (27 ref.)

Current views on neurostimulation in the treatment of cardiac ischemic syndromes. Jessurun GA, et al. **Pain** 1996 Aug; 66(2-3):109-16 (45 ref.)

Arterial gene therapy: a molecular biological perspective for the treatment of arterial ischemia. Asahara T, et al. **Z Kardiol** 1997;86 Suppl 1:65-9 (26 ref.)

[Use of registries for specific evaluation studies: example of ischemic cardiopathies] Amouyel P. **Rev Epidemiol Sante Publique** 1996;44 Suppl 1:S62-9 (9 ref.) (Eng. Abstr.) **(Fre)**

[Methodological aspects and clinicophysiological substantiation of applying the hypoxic therapy] Novikov VS, et al. **Aviakosm Ekolog Med** 1996;30(6):42-6 (34 ref.) (Eng. Abstr.) **(Rus)**

ULTRASONOGRAPHY

Feasibility and cost-effectiveness of stress echocardiography in assessing myocardial ischemia and viability. Talano JV. **Am J Card Imaging** 1996 Jul;10(3):187-90 (7 ref.)

Adenosine stress echocardiography. Chaudhry FA. **Am J Cardiol** 1997 Jun 19;79(12A):25-9 (43 ref.)

Stress echocardiography. Nihoyannopoulos P. **Br J Hosp Med** 1997 Jan 15-Feb 5;57(1-2):31-5 (32 ref.)

Echocardiographic evaluation of the mechanisms of ischemic mitral regurgitation. Dent JM, et al. **Coron Artery Dis** 1996 Mar;7(3):188-95 (30 ref.)

Assessment of myocardial viability by dobutamine stress echocardiography [see comments] Cornel JH, et al. **Curr Opin Cardiol** 1996 Nov;11(6):621-6 (29 ref.) Comment in: Curr Opin Cardiol 1996 Nov;11(6):611-2.

The multicentre trial philosophy in stress echocardiography: lessons learned from the EPIC study. EPIC-EDIC Study Project.Echo Persantine International Cooperative Study. Echo-Dobutamine International Cooperative Study. Picano E, et al. **Eur Heart J** 1995 Oct;16 Suppl J:2-4 (21 ref.)

Stress echocardiography for assessing myocardial ischaemia and viable myocardium. Senior R, et al. **Heart** 1997 Aug; 78 Suppl 1:12-8 (56 ref.)

[Echocardiography and nuclear medicine: complementary or alternative methods in the study of the ischemic myocardium? (editorial)] La Canna G, et al. **Cardiologia** 1997 Feb;42(2):123-37 (103 ref.) **(Ita)**

[Angina pectoris: progress in diagnosis and treatment. II. Progress in imaging diagnosis. 3. Usefulness of echocardiography] Murata K, et al. **Nippon Naika Gakkai Zasshi** 1997 Feb 10;86(2):220-5 (5 ref.) **(Jpn)**

[Angina pectoris: progress in diagnosis and treatment. II. Progress in imaging diagnosis. 4. Current status of intravascular ultrasonography] Saito S, et al. **Nippon Naika Gakkai Zasshi** 1997 Feb 10;86(2):226-36 (12 ref.) **(Jpn)**

[II. Role of Doppler echocardiography in the management of chronic ischemic cardiopathy] Alonso Gómez AM, et al. **Rev Esp Cardiol** 1997 Jan;50(1):15-25 (77 ref.) (Eng. Abstr.) **(Spa)**

MYOCARDIAL MITOCHONDRIA see **MITOCHONDRIA, HEART**

MYOCARDIAL PRECONDITIONING see **ISCHEMIC PRECONDITIONING, MYOCARDIAL**

MYOCARDIAL PREINFARCTION SYNDROME see **ANGINA, UNSTABLE**

MYOCARDIAL REPERFUSION

see related
ISCHEMIC PRECONDITIONING, MYOCARDIAL
MYOCARDIAL STUNNING

Alterations in fatty acid oxidation during reperfusion of the heart after myocardial ischemia. Lopaschuk GD. **Am J Cardiol** 1997 Aug 4;80(3A):11A-16A (58 ref.)

Pharmacology of ATP-sensitive potassium channel (KATP) openers in models of myocardial ischemia and reperfusion. Grover GJ. **Can J Physiol Pharmacol** 1997 Apr; 75(4):309-15 (49 ref.)

Determinants of infarct size in acute myocardial infarction in patients treated with reperfusion therapy. Wagdy HM, et al. **Curr Opin Cardiol** 1996 Jul;11(4):369-77 (60 ref.)

Electrocardiographic evaluation of reperfusion therapy in patients with acute myocardial infarction. Clemmensen P. **Dan Med Bull** 1996 Feb;43(1):68-85 (193 ref.)

Electrophysiological responses to ischemia and reperfusion. Ruiz Petrich E, et al. **EXS** 1996;76:115-33 (60 ref.)

Lipid metabolism in the ischemic and reperfused heart. van

der Vusse GJ, et al. **EXS** 1996;76:175–90 (53 ref.)
Clinical benefit of angiotensin converting enzyme inhibition after acute myocardial infarction: myocardial reperfusion revisited. Renkin J. **J Hypertens Suppl** 1996 Dec; 14(6):S15–9 (40 ref.)
Accumulation of arachidonic acid in ischemic/reperfused cardiac tissue: possible causes and consequences. Van der Vusse GJ, et al.
Prostaglandins Leukot Essent Fatty Acids 1997 Jul; 57(1):85–93 (50 ref.)
[Late reperfusion in acute myocardial infarct. The importance of the open infarct vessel] Michel CJ, et al.
Dtsch Med Wochenschr 1997 Mar 27;122(13):415–21 (64 ref.) **(Ger)**
[Reperfusion therapy in acute myocardial infarct, Thrombolysis or balloon dilatation?] Zeymer U, et al.
Dtsch Med Wochenschr 1997 Sep 5;122(36):1081–5 (30 ref.) **(Ger)**

ADVERSE EFFECTS

Cellular mechanisms of cardiac arrhythmias in the ischemic and reperfused heart. Bril A. **EXS** 1996;76:135–53 (78 ref.)

METHODS

Left ventricular dysfunction due to the new ischemic outcomes: stunning and hibernation. Ferrari R, et al.
J Cardiovasc Pharmacol 1996;28 Suppl 1:S18–26 (50 ref.)
[Orientated management towards reperfusion in the acute phase of myocardial infarction. Results in a cohort of 700 consecutive patients] Juliard JM, et al.
Arch Mal Coeur Vaiss 1997 Mar;90(3):337–43 (30 ref.) (Eng. Abstr.) **(Fre)**

MYOCARDIAL REPERFUSION INJURY

see related
MYOCARDIAL STUNNING
Coronary reperfusion injury. Khanna NN, et al.
J Assoc Physicians India 1996 Apr;44(4):267–8 (20 ref.)

CHEMICALLY INDUCED

[Forced fibrinolysis causes damage to the myocardium. Magnesium therapy is considerate in myocardial infarction (see comments)] Nilsson CG, et al. **Lakartidningen** 1997 Jan 15;94(3):148–50 (31 ref.) Comment in: Lakartidningen 1997 Jan 22;94(4):251–2. **(Swe)**

COMPLICATIONS

Response to ischemia and reperfusion by the diabetic heart. Feuvray D. **EXS** 1996;76:409–21 (38 ref.)
Myocardial stunning, hibernation, and ischemic preconditioning. Vroom MB, et al.
J Cardiothorac Vasc Anesth 1996 Oct;10(6):789–99 (131 ref.)

DIAGNOSIS

Biochemical markers of myocardial injury during cardiac operations. Birdi I, et al. **Ann Thorac Surg** 1997 Mar; 63(3):879–84 (59 ref.)
MR first pass imaging: quantitative assessment of transmural perfusion and collateral flow. Jerosch-Herold M, et al.
Int J Card Imaging 1997 Jun;13(3):205–18 (53 ref.)

DRUG THERAPY

Pharmacologic approaches to reperfusion injury. Willerson JT. **Adv Pharmacol** 1997;39:291–312 (120 ref.)
The sodium–hydrogen exchange system in the heart: its role in ischemic and reperfusion injury and therapeutic implications. Karmazyn M. **Can J Cardiol** 1996 Oct; 12(10):1074–82 (73 ref.)
Dihydropyridine calcium antagonists: beneficial or adverse effects in the setting of myocardial ischaemia/reperfusion? Ehring T, et al. **Cardiology** 1997;88 Suppl 1:3–14; discussion 15–6 (117 ref.)
Angiotensin converting enzyme inhibitor–calcium antagonist combination: an alliance for cardioprotection? Ferrari R. **J Hypertens Suppl** 1997 Mar;15(2):S109–17 (87 ref.)
[Adhesive molecules as drugs and objects of pharmacological effect in myocardial ischemia and reperfusion] Uteshev DB, et al. **Eksp Klin Farmakol** 1997 May–Jun;60(3):83–8 (57 ref.) (Eng. Abstr.) **(Rus)**

ETIOLOGY

The diabetic heart is more sensitive to ischemic injury. Paulson DJ. **Cardiovasc Res** 1997 Apr;34(1):104–12 (116 ref.)
Ischemia and reperfusion injury in the hypertrophied heart. Allard MF, et al. **EXS** 1996;76:423–41 (78 ref.)
Sodium–hydrogen exchange in myocardial ischemia and reperfusion: a critical determinant of injury? Avkiran M. **EXS** 1996;76:299–311 (60 ref.)
Role of eicosanoids in the ischemic and reperfused myocardium. Bend JR, et al. **EXS** 1996;76:243–62 (93 ref.)
Nitric oxide in coronary artery disease: roles in atherosclerosis, myocardial reperfusion and heart failure. Dusting GJ. **EXS** 1996;76:33–55 (108 ref.)
The role of the neutrophil in myocardial ischemia and reperfusion. Frangogiannis NG, et al. **EXS** 1996;76:263–84 (86 ref.)
Role of the sympathetic nervous system in the ischemic and reperfused heart. Hara A, et al. **EXS** 1996;76:285–97 (60 ref.)
The molecular basis of adaptation to ischemia in the heart: the role of stress proteins and anti-oxidants in the ischemic and reperfused heart. Heads RJ, et al. **EXS** 1996;76:383–407 (70 ref.)
[A new approach to the understanding of the mechanism of ischemia/reperfusion damage in the heart and the effects of anti-ischemic drugs] Abiko Y, et al.
Nippon Yakurigaku Zasshi 1996 Oct;108(4):195–202 (40 ref.) (Eng. Abstr.) **(Jpn)**
[Reperfusion arrhythmia] Nagao K, et al.
Ryoikibetsu Shokogun Shirizu 1996;(12):277–81 (19 ref.) **(Jpn)**

METABOLISM

The sodium–hydrogen exchange system in the heart: its role in ischemic and reperfusion injury and therapeutic implications. Karmazyn M. **Can J Cardiol** 1996 Oct; 12(10):1074–82 (73 ref.)
Ischemia and reperfusion injury in the hypertrophied heart. Allard MF, et al. **EXS** 1996;76:423–41 (78 ref.)
Intracellular calcium regulatory systems during ischemia and reperfusion. Altschuld RA. **EXS** 1996;76:87–97 (58 ref.)
Sodium–hydrogen exchange in myocardial ischemia and reperfusion: a critical determinant of injury? Avkiran M. **EXS** 1996;76:299–311 (60 ref.)
Bioenergetics, ischemic contracture and reperfusion injury. Das DK, et al. **EXS** 1996;76:155–73 (50 ref.)
The molecular basis of adaptation to ischemia in the heart: the role of stress proteins and anti-oxidants in the ischemic and reperfused heart. Heads RJ, et al. **EXS** 1996;76:383–407 (70 ref.)
The pH paradox in ischemia–reperfusion injury to cardiac myocytes. Lemasters JJ, et al. **EXS** 1996;76:99–114 (43 ref.)
Signal transduction mechanisms in the ischemic and reperfused myocardium. Ward CA, et al. **EXS** 1996; 76:191–207 (71 ref.)
Free fatty acid metabolism during myocardial ischemia and reperfusion. Hendrickson SC, et al. **Mol Cell Biochem** 1997 Jan;166(1–2):85–94 (97 ref.)

MORTALITY

Predictors of outcome of reperfusion therapy. Califf RM, et al. **Eur Heart J** 1997 May;18(5):728–35 (75 ref.)

PHYSIOPATHOLOGY

Vasoactive intestinal peptide and nitric oxide: divergent roles in relation to tissue injury. Said SI. **Ann N Y Acad Sci** 1996 Dec 26;805:379–87; discussion 387–8 (60 ref.)
Endothelial cell injury in cardiovascular surgery: ischemia–reperfusion. Boyle EM Jr, et al.
Ann Thorac Surg 1996 Dec;62(6):1868–75 (56 ref.)
The role of Na+/H+ exchange in ischemia–reperfusion. Piper HM, et al. **Basic Res Cardiol** 1996 May–Jun; 91(3):191–202 (91 ref.)
Interrelationship between cellular calcium homeostasis and free radical generation in myocardial reperfusion injury. Bagchi D, et al. **Chem Biol Interact** 1997 May 2; 104(2–3):65–85 (99 ref.)
Reactive oxygen species and platelet activation in reperfusion injury [editorial; comment] Forde RC, et al. **Circulation** 1997 Feb 18;95(4):787–9 (26 ref.) Comment on: Circulation 1997 Feb 18;95(4):885–91.
Endothelial function in myocardial protection. Amrani M, et al. **Curr Opin Cardiol** 1996 Nov;11(6):559–63 (39 ref.)
Reperfusion injury: a review of the pathophysiology, clinical manifestations and therapeutic options. Maxwell SR, et al. **Int J Cardiol** 1997 Jan 31;58(2):95–117 (237 ref.)
Methods for studying experimental myocardial ischemic and reperfusion injury. Black SC, et al.
J Pharmacol Toxicol Methods 1996 Aug;35(4):179–90 (70 ref.)
The role of nitric oxide in cardiac ischemia–reperfusion injury. Nonami Y. **Jpn Circ J** 1997 Feb;61(2):119–32 (69 ref.)
Regulation and failure of coronary circulation. Miura M.
Jpn Heart J 1996 Sep;37(5):585–602 (25 ref.)
Neutrophils and myocardial reperfusion injury. Williams FM.
Pharmacol Ther 1996;72(1):1–12 (123 ref.)
[Myocardial reperfusion injury: implications in clinical practice] Ambrosio G, et al. **Cardiologia** 1997 May; 42(5):463–8 (41 ref.) **(Ita)**
[Mechanisms of ischemic preconditioning: relation with ischemia–reperfusion injury] Gattullo D, et al.
G Ital Cardiol 1997 Mar;27(3):288–96 (66 ref.) (Eng. Abstr.) **(Ita)**
[Cell–adhesion molecules involved in cardiac disease] Seko Y, et al. **Rinsho Byori** 1996 Sep;Suppl 102:198–206 (16 ref.) **(Jpn)**
[Ischemia–reperfusion lesion. Physiopathologic aspects and the importance of the endothelial function] Evora PR, et al. **Arq Bras Cardiol** 1996 Apr;66(4):239–45 (40 ref.) **(Por)**

PREVENTION & CONTROL

Adenosine for myocardial protection in acute myocardial infarction. Granger CB. **Am J Cardiol** 1997 Jun 19; 79(12A):44–8 (55 ref.)
Preconditioning the human myocardium: recent advances and aspirations for the development of a new means of cardioprotection in clinical practice. Jenkins DP, et al.
Cardiovasc Drugs Ther 1995 Dec;9(6):739–47 (49 ref.)
Strategies of myocardial protection during cardiac surgery. Hsi CC, et al. **Chin Med J (Engl)** 1996 Dec;109(12):903–8 (28 ref.)
Cardiovascular protection by ginsenosides and their nitric oxide releasing action. Chen X.
Clin Exp Pharmacol Physiol 1996 Aug;23(8):728–32 (19 ref.)
Intracellular pH control mechanisms in the diabetic myocardium. Feuvray D. **Diabetes Res Clin Pract** 1996 Jul;31 Suppl:S87–92 (19 ref.)
Myocardial protection for cardiac surgery. Myers ML, et al. **EXS** 1996;76:345–64 (76 ref.)
Reperfusion injury: a review of the pathophysiology, clinical manifestations and therapeutic options. Maxwell SR, et al. **Int J Cardiol** 1997 Jan 31;58(2):95–117 (237 ref.)
Advances in myocardial protection? Khuri SF.
J Med Liban 1995;43(3):126–30 (12 ref.)

ULTRASONOGRAPHY

Dobutamine echocardiography for determining myocardial viability after reperfusion: experimental and clinical observations. Kaul S. **Eur Heart J** 1995 Nov;16 Suppl M:17–23 (42 ref.)

MYOCARDIAL REVASCULARIZATION

The "open artery hypothesis" in survivors of myocardial infarction. Pitts WR, et al. **Clin Cardiol** 1997 Jun; 20(6):522–4 (12 ref.)
Unstable angina: the role of surgical revascularization. Burtt DM, et al. **Coron Artery Dis** 1995 Oct;6(10):780–7 (28 ref.)
Role of medical versus revascularization therapy in unstable angina. Rodak DJ, et al. **Coron Artery Dis** 1995 Oct; 6(10):765–73 (55 ref.)
The role of coronary revascularization in the management of heart failure: identification of candidates and review of results. Blitz A, et al. **Curr Opin Cardiol** 1996 May; 11(3):276–90 (74 ref.)
Myocardial viability in patients with coronary artery disease and left ventricular dysfunction: transplantation or revascularization? DeNofrio D, et al. **Curr Opin Cardiol** 1996 Jul;11(4):394–402 (54 ref.)
Selecting patients with ischemic cardiomyopathy for medical treatment, revascularization, or heart transplantation. Beller GA. **J Nucl Cardiol** 1997 Mar–Apr;4(2 Pt 2):S152–7 (27 ref.)
[Myocardial revascularization: surgery or angioplasty?] Goy JJ. **Ann Cardiol Angeiol (Paris)** 1996 Oct;45(8):427–9 (17 ref.) (Eng. Abstr.) **(Fre)**
[Ergometric test after surgical revascularization and mechanical recanalization of the myocardium] Chalela WA, et al. **Arq Bras Cardiol** 1996 Jul;67(1):59–62 (27 ref.) **(Por)**

ADVERSE EFFECTS

Nuclear and echocardiographic imaging for prediction of reversible left ventricular ischemic dysfunction after coronary revascularization: current status and future directions. Vanoverschelde JL, et al.
J Cardiovasc Pharmacol 1996;28 Suppl 1:S27–36 (56 ref.)

INSTRUMENTATION

Endovascular stents: a 'break through technology', future challenges. Violaris AG, et al. **Int J Card Imaging** 1997 Feb;13(1):3–13 (59 ref.)

METHODS

Ultrasound-guided stent placement. Russo RJ.
Cardiol Clin 1997 Feb;15(1):49–61 (64 ref.)
Coronary artery and saphenous vein graft remodeling: a review of histologic findings after various interventional procedures—Part II. Waller BF, et al. **Clin Cardiol** 1996 Oct;19(10):817–23 (26 ref.)
Transmyocardial laser revascularization. Frazier OH, et al. **Curr Opin Cardiol** 1996 Nov;11(6):564–7 (15 ref.)
Silent ischaemia: to treat or not to treat? Deedwania PC. **Indian Heart J** 1996 Jul–Aug;48(4):415–9 (27 ref.)
The "hybrid" approach to coronary intervention. Gaxiola E, et al. **Indian Heart J** 1997 Jan–Feb;49(1):93–5 (24 ref.)
Transmyocardial laser revascularization: an anesthetic perspective. Grocott HP, et al.
J Cardiothorac Vasc Anesth 1997 Apr;11(2):206–10 (28 ref.)
New surgical techniques: implications for the cardiac anesthesiologist: mini-thoracotomy for coronary revascularization without cardiopulmonary bypass. Schaff HV. **J Cardiothorac Vasc Anesth** 1997 Apr;11(2 Suppl 1):6–9; discussion 24–5 (17 ref.)
Advances in coronary angioplasty [published erratum appears in N Engl J Med 1997 Feb 27;336(9):670] Bittl JA.
N Engl J Med 1996 Oct 24;335(17):1290–302 (97 ref.)
Total arterial myocardial revascularization [editorial] Calafiore AM. **Thorac Cardiovasc Surg** 1997 Jun; 45(3):105–8 (17 ref.)
[Cardiomyopexy—current status of an indirect revascularization method] Beyer M. **Z Kardiol** 1997;86 Suppl 1:125–32 (20 ref.) (Eng. Abstr.) **(Ger)**

MYOCARDIAL REVASCULARIZATION

[Indications and limits of conventional revascularization methods in coronary heart disease] Heintzen MP, et al. **Z Kardiol** 1997;86 Suppl 1:9–21 (73 ref.) (Eng. Abstr.) **(Ger)**

[Transmyocardial laser revascularization--morphologic, pathophysiologic and historical principles of indirect revascularization of the heart muscle] Moosdorf R, et al. **Z Kardiol** 1997 Mar;86(3):149–64 (130 ref.) (Eng. Abstr.) **(Ger)**

[Angina pectoris: the possibilities for surgical treatment. Recent progress] Queiroz e Melo J. **Acta Med Port** 1997 Apr;10(4):299–302 (8 ref.) (Eng. Abstr.) **(Por)**

MORTALITY

Coronary revascularization in patients on dialysis. What treatment option should we choose? Cruz DN, et al. **ASAIO J** 1996 May–Jun;42(3):139–41 (91 ref.)

TRENDS

Trends and strategies for myocardial revascularization. Schmid C, et al. **Thorac Cardiovasc Surg** 1996 Jun; 44(3):113–7 (49 ref.)

MYOCARDIAL STIMULANTS see **CARDIOTONIC AGENTS**

MYOCARDIAL STUNNING

Hibernating myocardium--mechanisms and clinical implications. Knap J, et al. **Acta Medica (Hradec Kralove)** 1996;39(3):95–9 (37 ref.)

Chronic myocardial hibernation in humans. From bedside to bench. Vanoverschelde JL, et al. **Circulation** 1997 Apr 1;95(7):1961–71 (106 ref.)

Myocardial hibernation: adaptation to ischaemia. Heusch G, et al. **Eur Heart J** 1996 Jun;17(6):824–8 (17 ref.)

Myocardial stunning and hibernation. Rinaldi CA, et al. **Indian Heart J** 1996 Nov–Dec;48(6):721–5 (42 ref.)

Hibernating myocardium: a review. Heusch G, et al. **J Mol Cell Cardiol** 1996 Dec;28(12):2359–72 (81 ref.)

[The hibernating myocardium--its use in clinical practice] Knap J, et al. **Cas Lek Cesk** 1997 Mar 12;136(5):138–41 (31 ref.) (Eng. Abstr.) **(Cze)**

[Stunned myocardium] Kondo T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):69–72 (20 ref.) **(Jpn)**

DIAGNOSIS

Myocardial viability in patients with coronary artery disease and left ventricular dysfunction: transplantation or revascularization? DeNofrio D, et al. **Curr Opin Cardiol** 1996 Jul;11(4):394–402 (54 ref.)

Detection of myocardial viability using stress echocardiography. Krahwinkel W, et al. **Eur Heart J** 1997 Jun;18 Suppl D:D111–6 (34 ref.)

[Hibernating myocardium] Nakamura N. **Ryoikibetsu Shokogun Shirizu** 1996;(14):178–81 (19 ref.) **(Jpn)**

DRUG THERAPY

Pharmacologic myocardial preconditioning with monophosphoryl lipid A (MLA) reduces infarct size and stunning in dogs and rabbits. Elliott GT. **Ann N Y Acad Sci** 1996 Sep 30;793:386–99 (63 ref.)

ETIOLOGY

Myocardial stunning: a post-ischemic syndrome with delayed recovery. Allen JW, et al. **EXS** 1996;76:443–52 (27 ref.)

The hibernating myocardium. Leor J, et al. **EXS** 1996; 76:453–62 (40 ref.)

Myocardial stunning, hibernation, and ischemic preconditioning. Vroom MB, et al. **J Cardiothorac Vasc Anesth** 1996 Oct;10(6):789–99 (131 ref.)

PHYSIOPATHOLOGY

Hibernating myocardium has reduced blood flow at rest that increases with low-dose dobutamine [editorial; comment] Rahimtoola SH. **Circulation** 1996 Dec 15;94(12):3055–61 (76 ref.) Comment on: Circulation 1996 Dec 15;94(12):3146–54.

Myocardial hibernation. A form of endogenous protection? Hearse DJ. **Eur Heart J** 1997 Jan;18 Suppl A:A2–7 (28 ref.)

Characterization of hibernating and stunned myocardium. Heusch G, et al. **Eur Heart J** 1997 Jun;18 Suppl D:D102–10 (91 ref.)

Characterization of hibernating and stunned myocardium. Schulz R, et al. **Eur Heart J** 1995 Oct;16 Suppl J:19–25 (107 ref.)

Left ventricular dysfunction due to the new ischemic outcomes: stunning and hibernation. Ferrari R, et al. **J Cardiovasc Pharmacol** 1996;28 Suppl 1:S18–26 (50 ref.)

Clinical aspects of hibernating myocardium. Rahimtoola SH. **J Mol Cell Cardiol** 1996 Dec;28(12):2397–401 (28 ref.)

[Pathophysiology of ischemic myocardial dysfunction] Heusch G. **Schweiz Med Wochenschr** 1996 Sep 28; 126(39):1654–60 (26 ref.) (Eng. Abstr.) **(Ger)**

[The heart and ischemia: stunned-hibernating myocardium] Wutte M, et al. **Wien Klin Wochenschr Suppl** 1997;1:25–33 (106 ref.) **(Ger)**

[Hibernating myocardium: no involvement of endogenous adenosine] Schulz R, et al. **Z Kardiol** 1996;85 Suppl 6:177–84 (38 ref.) (Eng. Abstr.) **(Ger)**

[Hibernation and stunning of myocardium in light of clinical observations and function studies] Nowak S, et al. **Pol Arch Med Wewn** 1997 Feb;97(2):177–81 (19 ref.) **(Pol)**

RADIONUCLIDE IMAGING

Detection of hibernated myocardium using intracoronary technetium-99m-sestamibi. Giordano A, et al. **Q J Nucl Med** 1997 Mar;41(1):46–50 (30 ref.)

THERAPY

Selecting patients with ischemic cardiomyopathy for medical treatment, revascularization, or heart transplantation. Beller GA. **J Nucl Cardiol** 1997 Mar–Apr;4(2 Pt 2):S152–7 (27 ref.)

ULTRASONOGRAPHY

The use of dobutamine stress echocardiography for the determination of myocardial viability. Hansen TH, et al. **Clin Cardiol** 1996 Aug;19(8):607–12 (22 ref.)

Evaluation of myocardial viability using stress echocardiography. Armstrong WF, et al. **Prog Cardiovasc Dis** 1997 May–Jun;39(6):555–66 (43 ref.)

MYOCARDIOPATHIES see **MYOCARDIAL DISEASES**

MYOCARDITIS

Severe mitral valve dysfunction due to unsuspected granulomatous myocarditis: successful cardiac transplantation following attempted mitral valve repair. el-Gamel A, et al. **Eur J Cardiothorac Surg** 1996; 10(8):702–4 (8 ref.)

Autoimmune myocarditis. Rose NR, et al. **Int J Cardiol** 1996 May;54(2):171–5 (19 ref.)

The role of sensitized T-cells in myocarditis and dilated cardiomyopathy. Schwimmbeck PL, et al. **Int J Cardiol** 1996 May;54(2):117–25 (27 ref.)

Endocarditis, pericarditis, and myocarditis. Zales VR, et al. **Pediatr Ann** 1997 Feb;26(2):116–21 (14 ref.)

[Fulminant myocarditis] Iwasaki K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):76–8 (17 ref.) **(Jpn)**

[Isolated myocarditis, (granulomatous type)] Kanaya T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):7–10 (18 ref.) **(Jpn)**

[Rheumatic carditis] Kunitomi T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):219–21 (11 ref.) **(Jpn)**

[Myopericarditis] Shibata T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):531–4 (14 ref.) **(Jpn)**

COMPLICATIONS

Interaction between infection and exercise with special reference to myocarditis and the increased frequency of sudden deaths among young Swedish orienteers 1979–92. Friman G, et al. **Scand J Infect Dis Suppl** 1997;104:41–9 (50 ref.)

[Acute myocarditis with erythema nodosum] Nishida T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):425–7 (6 ref.) **(Jpn)**

DIAGNOSIS

Successful diagnosis and management of cytomegalovirus carditis. Ng TT, et al. **J Infect** 1997 May;34(3):243–7 (17 ref.)

Severe pleuropneumonia without a cough and myocarditis with mixed mycoplasma infection [letter] Chang AB, et al. **J Paediatr Child Health** 1996 Dec;32(6):546–7 (5 ref.)

Cardiology casebook. Coysackie virus B myocarditis presenting as a myocardial infarction in a newborn infant. Lehoullier PF, et al. **J Perinatol** 1996 Sep–Oct;16(5):403–5 (7 ref.)

Eosinophilic myocarditis manifesting as myocardial infarction: early diagnosis and successful treatment. Galiuto L, et al. **Mayo Clin Proc** 1997 Jul;72(7):603–10 (32 ref.)

Inflammatory cardiomyopathy. The controversy of diagnosis and management. James KB, et al. **Rheum Dis Clin North Am** 1997 May;23(2):333–43 (53 ref.)

DRUG THERAPY

Implications of the Myocarditis Treatment Trial for clinical practice. Brown CA, et al. **Curr Opin Cardiol** 1996 May; 11(3):332–6 (14 ref.)

[Etiopathogenetic differentiation of inflammatory cardiomyopathy. Immunosuppression and immunomodulation] Kühl U, et al. **Internist (Berl)** 1997 Jun;38(6):590–601 (105 ref.) **(Ger)**

[Fungal myocarditis] Kubo N, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):138–40 (14 ref.) **(Jpn)**

[Peculiarities of cardiac failure treatment in diffuse myocarditis and dilated cardiomyopathy] Gurevich MA, et al. **Klin Med (Mosk)** 1997;75(1):48–50 (0 ref.) **(Rus)**

ETIOLOGY

Viral myocarditis: balance between viral infection and immune response. Liu P, et al. **Can J Cardiol** 1996 Oct; 12(10):935–43 (85 ref.)

Successful treatment of severe dysrhythmias in infants with respiratory syncytial virus infections: two cases and a literature review. Thomas JA, et al. **Crit Care Med** 1997 May;25(5):880–6 (44 ref.)

Cytokines in myocarditis and cardiomyopathies. Matsumori A. **Curr Opin Cardiol** 1996 May;11(3):302–9 (72 ref.)

Recognition and optimum management of myocarditis. Caforio AL, et al. **Drugs** 1996 Oct;52(4):515–25 (98 ref.)

Newer aspects of pathogenesis of heart failure: hepatitis C virus infection in myocarditis and cardiomyopathy. Matsumori A, et al. **J Card Fail** 1996 Dec;2(4 Suppl):S187–94 (37 ref.)

[Idiopathic eosinophilic myocarditis] Aoki T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):186–8 (17 ref.) **(Jpn)**

[Inflammatory bowel disease] Iizuka B, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):398–405 (55 ref.) **(Jpn)**

[Polymyositis-dermatomyositis] Kitamoto K. **Ryoikibetsu Shokogun Shirizu** 1996;(15):189–91 (5 ref.) **(Jpn)**

IMMUNOLOGY

Experimental autoimmune myocarditis: a suitable model to study neuroimmune crosstalk. Leiros CP, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995;45(4):201–12 (83 ref.)

Cellular and molecular mechanisms of murine autoimmune myocarditis. Penninger JM, et al. **APMIS** 1997 Jan; 105(1):1–13 (81 ref.)

Viral myocarditis: balance between viral infection and immune response. Liu P, et al. **Can J Cardiol** 1996 Oct; 12(10):935–43 (85 ref.)

Review and hypothesis: the eosinophil and peripartum heart disease (myocarditis and coronary artery dissection)--coincidence or pathogenetic significance? Borczuk AC, et al. **Cardiovasc Res** 1997 Mar;33(3):527–32 (54 ref.)

Autoimmunity in myocarditis: relevance of animal models. Huber SA. **Clin Immunol Immunopathol** 1997 May; 83(2):93–102 (89 ref.)

Evidence for autoimmunity to myosin and other heart-specific autoantigens in patients with dilated cardiomyopathy and their relatives. Caforio AL, et al. **Int J Cardiol** 1996 May;54(2):157–63 (51 ref.)

MICROBIOLOGY

Aspergillus endocarditis, myocarditis and pericarditis complicating necrotizing fasciitis. Case report and subject review. Sergi C, et al. **Virchows Arch** 1996 Oct; 429(2–3):177–80 (44 ref.)

[Bacterial myocarditis] Hiramitsu S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):102–3 (9 ref.) **(Jpn)**

[Infective myocarditis] Hiramitsu S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):61–4 (20 ref.) **(Jpn)**

[Fungal myocarditis] Kubo N, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):138–40 (14 ref.) **(Jpn)**

[Myocarditis caused by Mycoplasma] Morimoto S. **Ryoikibetsu Shokogun Shirizu** 1996;(14):211–4 (24 ref.) **(Jpn)**

[Spirochaeta! myocarditis] Shimizu K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):158–60 (16 ref.) **(Jpn)**

[Rickettsial myocarditis] Uemura A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):222–4 (10 ref.) **(Jpn)**

PARASITOLOGY

[Parasitic myocarditis] Kimura K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):65–8 (14 ref.) **(Jpn)**

[Protozoal myocarditis] Kimura K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):79–82 (21 ref.) **(Jpn)**

[Cardiopulmonary involvement in schistosomiasis] Barbosa MM, et al. **Arq Bras Cardiol** 1995 Oct;65(4):343–8 (59 ref.) **(Por)**

PATHOLOGY

[Myocarditis and cardiomyopathy] Kandolf R. **Verh Dtsch Ges Pathol** 1996;80:127–38 (51 ref.) (Eng. Abstr.) **(Ger)**

[Myocarditis (acute, chronic)--implication of clinical pathology] Hiramitsu S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):125–9 (25 ref.) **(Jpn)**

[Giant cell myocarditis] Iwasaki K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):73–5 (14 ref.) **(Jpn)**

[Eosinophilic myocarditis] Kakuta Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):94–7 (18 ref.) **(Jpn)**

[Necrotizing eosinophilic myocarditis] Takeuchi M, et al.

Ryoikibetsu Shokogun Shirizu 1996;(14):39–40 (14 ref.) **(Jpn)**

PHYSIOPATHOLOGY

[Alcohol and myocarditis] Wilke A, et al. **Herz** 1996 Aug; 21(4):248–57 (70 ref.) (Eng. Abstr.) **(Ger)**

[Cell–adhesion molecules involved in cardiac disease] Seko Y, et al. **Rinsho Byori** 1996 Sep;Suppl 102:198–206 (16 ref.) **(Jpn)**

RADIONUCLIDE IMAGING

Antimyosin antibody imaging in clinical myocarditis and cardiomyopathy: principle and application. Matsumori A, et al. **Int J Cardiol** 1996 May;54(2):183–90 (33 ref.)

THERAPY

Viral myocarditis: diagnosis and management. Drucker NA, et al. **Adv Pediatr** 1997;44:141–71 (78 ref.)

Immunosuppressive and immunomodulatory treatment for myocarditis. Maisch B, et al. **Curr Opin Cardiol** 1996 May; 11(3):310–24 (126 ref.)

Inflammatory cardiomyopathy. The controversy of diagnosis and management. James KB, et al.
Rheum Dis Clin North Am 1997 May;23(2):333–43 (53 ref.)

[Acute–phase therapy of cardiogenic shock and severe myocarditis using percutaneous cardiopulmonary support] Izumi T, et al. **Nippon Naika Gakkai Zasshi** 1996 Jan 10; 85(1):66–72 (4 ref.) **(Jpn)**

VIROLOGY

Viral myocarditis: diagnosis and management. Drucker NA, et al. **Adv Pediatr** 1997;44:141–71 (78 ref.)

[Viral myocarditis and autoimmunity] Kakio T, et al.
Nippon Rinsho 1997 Jun;55(6):1498–504 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Apoptosis in the process from viral myocarditis to dilated cardiomyopathy] Satoh M, et al. **Nippon Rinsho** 1996 Jul; 54(7):1982–5 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Infective myocarditis] Hiramitsu S, et al.
Ryoikibetsu Shokogun Shirizu 1996;(14):61–4 (20 ref.) **(Jpn)**

[Viral myocarditis] Inoue K, et al.
Ryoikibetsu Shokogun Shirizu 1996;(14):29–35 (20 ref.) **(Jpn)**

MYOCARDIUM

CHEMISTRY

Distribution of GLP–1 and PACAP receptors in human tissues. Wei Y, et al. **Acta Physiol Scand** 1996 Jul; 157(3):355–7 (7 ref.)

Cardiac troponin I and troponin T: are enzymes still relevant as cardiac markers? Mair J. **Clin Chim Acta** 1997 Jan 3; 257(1):99–115 (63 ref.)

Measuring cytosolic Ca2+ in cells with fluorescent probes: an aid to understanding cell pathophysiology. Hayes A, et al. **Int Rev Exp Pathol** 1996;36:197–212 (65 ref.)

Heart–type fatty acid binding protein – involvement in growth inhibition and differentiation. Börchers T, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Jul; 57(1):77–84 (40 ref.)

Capping actin filament growth: tropomodulin in muscle and nonmuscle cells. Fowler VM. **Soc Gen Physiol Ser** 1997; 52:79–89 (46 ref.)

CYTOLOGY

Anatomical architecture and electrical activity of the heart. Taccardi B, et al. **Acta Cardiol** 1997;52(2):91–105 (40 ref.)

Molecular basis of cardiocyte cell specification. Goswami SK, et al. **Ann N Y Acad Sci** 1996 Sep 30;793:259–66 (33 ref.)

Myocyte cell death and ventricular remodeling [see comments] Anversa P, et al.
Curr Opin Nephrol Hypertens 1997 Mar;6(2):169–76 (68 ref.) Comment in: Curr Opin Nephrol Hypertens 1997 Mar;6(2):167–8.

Length–dependent mechanisms in single cardiac cells. White E. **Exp Physiol** 1996 Nov;81(6):885–97 (46 ref.)

Magnetic resonance techniques for assessment of myocardial viability. van der Wall EE, et al.
J Cardiovasc Pharmacol 1996;28 Suppl 1:S37–44 (50 ref.)

Comparative aspects of cellular–volume regulation in cardiomyocytes. Deaton LE. **Physiol Zool** 1997 Jul–Aug; 70(4):379–90 (106 ref.)

[Morphology of myocardial adaptive responses to extreme environmental factors] Nepomniashchkh LM.
Vestn Ross Akad Med Nauk 1997;(3):49–54 (42 ref.) (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

SGOT, LDH, HBD, CPK, CK–MB, MB1MB2, cTnT, cTnC, cTnI. Futterman LG, et al. **Am J Crit Care** 1997 Jul;6(4):333–8 (6 ref.)

Bovine–heart NADH:ubiquinone oxidoreductase is a monomer with 8 Fe–S clusters and 2 FMN groups. Albracht SP, et al. **Biochim Biophys Acta** 1997 Jan 16; 1318(1–2):92–106 (83 ref.)

Carbonic anhydrase and the heart. Swenson ER.
Cardiologia 1997 May;42(5):453–62 (97 ref.)

Magentization transfer study of creatine kinase in myocardium. Potential clinical interest of in vivo enzymology. Joubert F, et al.
Cell Mol Biol (Noisy–le–grand) 1997 Jul;43(5):763–72 (68 ref.)

Stimulation of the stress–activated mitogen–activated protein kinase subfamilies in perfused heart. p38/RK mitogen–activated protein kinases and c–Jun N–terminal kinases are activated by ischemia/reperfusion. Bogoyevitch MA, et al. **Circ Res** 1996 Aug;79(2):162–73 (108 ref.)

Cardiac troponin I and troponin T: are enzymes still relevant as cardiac markers? Mair J. **Clin Chim Acta** 1997 Jan 3; 257(1):99–115 (63 ref.)

Beef heart cytochrome c oxidase. Yoshikawa S.
Curr Opin Struct Biol 1997 Aug;7(4):574–9 (32 ref.)

SR Ca(2+)–ATPase/phospholamban in cardiomyocyte function. Tada M, et al. **J Card Fail** 1996 Dec;2(4 Suppl):S77–85 (39 ref.)

Human myocardial Na,K–ATPase concentration in heart failure. Bundgaard H, et al. **Mol Cell Biochem** 1996 Oct–Nov;163–164:277–83 (26 ref.)

[Structures of metal centers of bovine heart cytochrome c oxidase] Tsukihara T, et al.
Tanpakushitsu Kakusan Koso 1996 Jul;41(9):1353–62 (11 ref.) **(Jpn)**

[Crystal structure of fully oxidized cytochrome c–oxidase from the bovine heart at 2.8 A resolution] Yoshikawa S, et al. **Biokhimiia** 1996 Nov;61(11):1931–40 (47 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Anti–M2 muscarinic receptor autoantibodies and idiopathic dilated cardiomyopathy. Fu ML. **Int J Cardiol** 1996 May; 54(2):127–35 (57 ref.)

METABOLISM

cDNA sequence of rabbit cardiac titin/connectin. Greaser ML, et al. **Adv Biophys** 1996;33:13–25 (27 ref.)

What determines cardiac oxygen consumption and how is it regulated? van Beek JH, et al. **Adv Exp Med Biol** 1996; 388:265–74 (27 ref.)

Lactate transport in heart in relation to myocardial ischemia. Halestrap AP, et al. **Am J Cardiol** 1997 Aug 4; 80(3A):17A–25A (56 ref.)

Beneficial effects of bradykinin on myocardial energy metabolism and infarct size. Linz W, et al.
Am J Cardiol 1997 Aug 4;80(3A):118A–123A (111 ref.)

Myocardial blood flow and glucose metabolism in diabetes mellitus. Meyer C, et al. **Am J Cardiol** 1997 Aug 4; 80(3A):94A–101A (72 ref.)

Bradykinin and endothelial–cardiac myocyte interactions in ischemic preconditioning. Parratt JR, et al.
Am J Cardiol 1997 Aug 4;80(3A):124A–131A (49 ref.)

Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Shryock JC, et al. **Am J Cardiol** 1997 Jun 19;79(12A):2–10 (123 ref.)

Substrate metabolism as a determinant for postischemic functional recovery of the heart. Taegtmeyer H, et al.
Am J Cardiol 1997 Aug 4;80(3A):3A–10A (62 ref.)

Effects of angiotensin–converting enzyme inhibition and angiotensin II AT1 receptor antagonism on cardiac parameters in left ventricular hypertrophy. Zhu YC, et al.
Am J Cardiol 1997 Aug 4;80(3A):110A–117A (65 ref.)

Regulation of glucose transport, and glucose transporters expression and trafficking in the heart: studies in cardiac myocytes. Zorzano A, et al. **Am J Cardiol** 1997 Aug 4; 80(3A):65A–76A (118 ref.)

Structure and function of cardiac sodium and potassium channels. Roden DM, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):H511–25 (166 ref.)

Free radicals and heat shock protein in the heart. Kukreja RC, et al. **Ann N Y Acad Sci** 1996 Sep 30;793:108–22 (64 ref.)

The cellular and molecular response of cardiac myocytes to mechanical stress. Sadoshima J, et al.
Annu Rev Physiol 1997;59:551–71 (71 ref.)

Ca transport during contraction and relaxation in mammalian ventricular muscle. Bers DM. **Basic Res Cardiol** 1997;92 Suppl 1:1–10 (42 ref.)

Beta–adrenergic receptors in failing human myocardium. Brodde OE. **Basic Res Cardiol** 1996;91 Suppl 2:35–40 (39 ref.)

Calcium cycling proteins and force–frequency relationship in heart failure. Hasenfuss G, et al. **Basic Res Cardiol** 1996; 91 Suppl 2:17–22 (31 ref.)

Calcium handling proteins in the failing human heart. Hasenfuss G, et al. **Basic Res Cardiol** 1997;92 Suppl 1:87–93 (50 ref.)

Regulation of myocardial calcium channels by cyclic AMP metabolism. Hove–Madsen L, et al. **Basic Res Cardiol** 1996; 91 Suppl 2:1–8 (90 ref.)

Sites of regulatory interaction between calcium ATPases and phospholamban. MacLennan DH, et al.
Basic Res Cardiol 1997;92 Suppl 1:11–5 (32 ref.)

Expression and function of the cardiac Na+/Ca2+ exchanger in postnatal development of the rat, in experimental–induced cardiac hypertrophy and in the failing human heart. Studer R, et al. **Basic Res Cardiol** 1997; 92 Suppl 1:53–8 (34 ref.)

Amino acid transport in heart and skeletal muscle and the functional consequences. Rennie MJ, et al.
Biochem Soc Trans 1996 Aug;24(3):869–73 (35 ref.)

Use of thapsigargin to study Ca2+ homeostasis in cardiac cells. Rogers TB, et al. **Biosci Rep** 1995 Oct;15(5):341–9 (18 ref.)

Anoxia and ischemia tolerance in turtle hearts. Wasser JS. **Braz J Med Biol Res** 1995 Nov–Dec;28(11–12):1233–40 (23 ref.)

Mechanisms of alterations in cardiac membrane Ca2+ transport due to excess catecholamines. Dhalla KS, et al.
Cardiovasc Drugs Ther 1996 Jun;10 Suppl 1:231–8 (24 ref.)

The effect of membrane cholesterol content on ion transport processes in plasma membranes. Bastiaanse EM, et al.
Cardiovasc Res 1997 Feb;33(2):272–83 (82 ref.)

Actions of insulin on the mammalian heart: metabolism, pathology and biochemical mechanisms. Brownsey RW, et al. **Cardiovasc Res** 1997 Apr;34(1):3–24 (263 ref.)

Mechanical and neuroendocrine regulation of the endocrine heart. de Bold AJ, et al. **Cardiovasc Res** 1996 Jan;31(1):7–18 (154 ref.)

Controversies on the sensitivity of the diabetic heart to ischemic injury: the sensitivity of the diabetic heart to ischemic injury is decreased. Feuvray D, et al.
Cardiovasc Res 1997 Apr;34(1):113–20 (84 ref.)

The regulation of intracellular pH in the diabetic myocardium. Feuvray D. **Cardiovasc Res** 1997 Apr; 34(1):48–54 (50 ref.)

Cytosolic Ca2+ concentration decreases in diabetic rat myocytes. Hayashi H, et al. **Cardiovasc Res** 1997 Apr; 34(1):99–103 (53 ref.)

Regulation of contractile proteins in diabetic heart. Malhotra A, et al. **Cardiovasc Res** 1997 Apr;34(1):34–40 (72 ref.)

The diabetic heart is more sensitive to ischemic injury. Paulson DJ. **Cardiovasc Res** 1997 Apr;34(1):104–12 (116 ref.)

Endothelin in myocardial ischaemia and reperfusion. Pernow J, et al. **Cardiovasc Res** 1997 Mar;33(3):518–26 (71 ref.)

Regulation of intracellular Ca2+ in the heart during diabetes. Pierce GN, et al. **Cardiovasc Res** 1997 Apr;34(1):41–7 (99 ref.)

Energy metabolism patterns in mammalian myocardium adapted to chronic physiopathological conditions. Rossi A, et al. **Cardiovasc Res** 1996 Jan;31(1):163–71 (90 ref.)

Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients. Schotborgh CE, et al.
Cardiovasc Res 1997 Apr;34(1):73–80 (88 ref.)

Regulation of energy substrate metabolism in the diabetic heart. Stanley WC, et al. **Cardiovasc Res** 1997 Apr; 34(1):25–33 (110 ref.)

Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Stanley WC, et al.
Cardiovasc Res 1997 Feb;33(2):243–57 (184 ref.)

The cicatrix: a case of woven intrigue. Weber KT.
Cardiovasc Res 1996 Jan;31(1):19–27 (37 ref.)

Intracellular calcium levels are unchanged in the diabetic heart. Yu JZ, et al. **Cardiovasc Res** 1997 Apr;34(1):91–8 (74 ref.)

The giant protein titin. Emerging roles in physiology and pathophysiology [see comments] Labeit S, et al.
Circ Res 1997 Feb;80(2):290–4 (40 ref.) Comment in: Circ Res 1997 Feb;80(2):295–6.

Downregulation of angiotensin II receptor type 1 in heart failure. A process of adaptation or deterioration? [editorial; comment] Kurabayashi M, et al. **Circulation** 1997 Mar 4; 95(5):1104–7 (30 ref.) Comment on: Circulation 1997 Mar 4;95(5):1193–200.

Functional significance of alterations in cardiac contractile protein isoforms. Kitsis RN, et al. **Clin Cardiol** 1996 Jan; 19(1):9–18 (115 ref.)

Wound healing following myocardial infarction. Weber KT, et al. **Clin Cardiol** 1996 Jun;19(6):447–55 (68 ref.)

Light microscope autoradiography of peripheral dopamine receptor subtypes. Amenta F. **Clin Exp Hypertens** 1997 Jan–Feb;19(1–2):27–41 (30 ref.)

Permeability of myocardial capillaries to hydrophilic drugs: the paracellular pathway. Morgan DJ.
Clin Exp Pharmacol Physiol 1996 Oct–Nov;23(10–11):975–9 (32 ref.)

Mechanisms of myocardial protection by amino acids: facts and hypotheses. Pisarenko OI.
Clin Exp Pharmacol Physiol 1996 Aug;23(8):627–33 (88 ref.)

Alterations in myocardial contractile proteins in diabetes mellitus. Akella AB, et al. **Coron Artery Dis** 1996 Feb; 7(2):124–32 (104 ref.)

Abnormal mechanical function in diabetes: relationship to altered myocardial carbohydrate/lipid metabolism. Lopaschuk GD. **Coron Artery Dis** 1996 Feb;7(2):116–23 (124 ref.)

Abnormal mechanical function in diabetes: relation to myocardial calcium handling. Schaffer SW, et al.
Coron Artery Dis 1996 Feb;7(2):109–15 (51 ref.)

Progress in myocardial damage detection: new biochemical markers for clinicians. Mair J. **Crit Rev Clin Lab Sci** 1997; 34(1):1–66 (174 ref.)

Update on local cardiac renin–angiotensin system. Ruzicka M, et al. **Curr Opin Cardiol** 1997 Jul;12(4):347–53 (30 ref.)

Vertebrate heart development. Lyons GE.
Curr Opin Genet Dev 1996 Aug;6(4):454–60 (63 ref.)

Phosphorus magnetic resonance spectroscopy of the human heart: current status and clinical implications. Beyerbacht HP, et al. **Eur Heart J** 1996 Aug;17(8):1158–66 (55 ref.)

Myocardial hibernation: adaptation to ischaemia. Heusch G, et al. **Eur Heart J** 1996 Jun;17(6):824–8 (17 ref.)
Molecular basis of the diversity of calcium channels in cardiovascular tissues. Nargeot J, et al. **Eur Heart J** 1997 Jan;18 Suppl A:A15–26 (67 ref.)
The pH paradox in ischemia–reperfusion injury to cardiac myocytes. Lemasters JJ, et al. **EXS** 1996;76:99–114 (43 ref.)
Is there an internal cardiac renin–angiotensin system? Danser AH, et al. **Heart** 1996 Nov;76(3 Suppl 3):28–32 (39 ref.)
K+ channel opening: a new drug principle in cardiovascular medicine [see comments] Nielsen–Kudsk JE, et al. **Heart** 1996 Aug;76(2):109–16 (51 ref.) Comment in: Heart 1997 May;77(5):487.
Transcription factors and the cardiac gene programme. Doevendans PA, et al. **Int J Biochem Cell Biol** 1996 Apr; 28(4):387–403 (140 ref.)
Roles of gp130 signaling pathways in cardiac myocytes: recent advances and implications for cardiovascular disease. Yamauchi–Takihara K, et al. **J Card Fail** 1996 Dec; 2(4 Suppl):S63–8 (44 ref.)
Atrial natriuretic peptide and cardiac electrophysiology: autonomic and direct effects. Clemo HF, et al. **J Cardiovasc Electrophysiol** 1996 Feb;7(2):149–62 (124 ref.)
Fatty acid oxidation in the heart. Grynberg A, et al. **J Cardiovasc Pharmacol** 1996;28 Suppl 1:S11–7 (21 ref.)
The origins of myocardial substrate utilization from an evolutionary perspective: the enduring role of glucose in energy metabolism. Liedtke AJ. **J Mol Cell Cardiol** 1997 Apr;29(4):1073–86 (75 ref.)
Myocardial beta–adrenergic receptor signaling in vivo: insights from transgenic mice. Rockman HA, et al. **J Mol Med** 1996 Sep;74(9):489–95 (32 ref.)
Cardiotrophin–1 and the role of gp130–dependent signaling pathways in cardiac growth and development. Wollert KC, et al. **J Mol Med** 1997 Jul;75(7):492–501 (98 ref.)
Advantages and limitations of experimental techniques used to measure cardiac energy metabolism. Lopaschuk GD. **J Nucl Cardiol** 1997 Jul–Aug;4(4):316–28 (50 ref.)
Positive inotropic effect of angiotensin II. Increases in intracellular Ca2+ or changes in myofilament Ca2+ responsiveness? Mattiazzi A. **J Pharmacol Toxicol Methods** 1997 Jun;37(4):205–14 (80 ref.)
Rapid cardiac growth—mechanical, neural and endocrine dependence. Morgan HE, et al. **Jpn Circ J** 1997 Aug; 61(8):645–9 (20 ref.)
Hormonal regulation of cardiac cystic fibrosis transmembrane conductance regulator chloride channels. Horie M, et al. **Jpn Heart J** 1996 Sep;37(5):661–71 (72 ref.)
Regulation of cardiolipin biosynthesis in the heart. Hatch GM. **Mol Cell Biochem** 1996 Jun 21;159(2):139–48 (84 ref.)
Glycogen phosphorylase isoenzyme BB in diagnosis of myocardial ischaemic injury and infarction. Krause EG, et al. **Mol Cell Biochem** 1996 Jul–Aug;160–161:289–95 (29 ref.)
Proteinases and myocardial extracellular matrix turnover. Tyagi SC. **Mol Cell Biochem** 1997 Mar;168(1–2):1–12 (90 ref.)
Elucidating molecular mechanisms of septic cardiomyopathy—the cardiomyocyte model. Werdan K, et al. **Mol Cell Biochem** 1996 Oct–Nov;163–164:291–303 (73 ref.)
Cardiac hormones: diagnostic and therapeutic potential. Lainchbury JG, et al. **N Z Med J** 1997 Jun 27; 110(1046):219–21 (34 ref.)
Are cardiac troponins reliable serodiagnositic markers of cardiac ischaemia in end–stage renal disease? [editorial] Haller C, et al. **Nephrol Dial Transplant** 1996 Jun; 11(6):941–4 (16 ref.)
Molecular aspects of regulation of cardiac contraction. Pelouch V. **Physiol Res** 1995;44(1):53–60 (63 ref.)
Comparative aspects of cellular–volume regulation in cardiomyocytes. Deaton LE. **Physiol Zool** 1997 Jul–Aug; 70(4):379–90 (106 ref.)
Newer findings on a unified perspective of copper restriction and cardiomyopathy. Medeiros DM, et al. **Proc Soc Exp Biol Med** 1997 Sep;215(4):299–313 (156 ref.)
Long–term effects of fatty acids on cell viability and gene expression of neonatal cardiac myocytes. Van Bilsen M, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Jul; 57(1):39–45 (37 ref.)
Accumulation of arachidonic acid in ischemic/reperfused cardiac tissue: possible causes and consequences. Van der Vusse GJ, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Jul; 57(1):85–93 (50 ref.)
Substrate metabolism in the developing heart. Ascuitto RJ, et al. **Semin Perinatol** 1996 Dec;20(6):542–63 (148 ref.)
Triadin, a linker for calsequestrin and the ryanodine receptor. Guo W, et al. **Soc Gen Physiol Ser** 1996;51:19–28 (28 ref.)
Role of the ISK protein in the IminK channel complex. Busch AE, et al. **Trends Pharmacol Sci** 1997 Jan;18(1):26–9 (48 ref.)
[Regulation of cardiac calcium current by cGMP/NO route] Fischmeister R, et al. **C R Seances Soc Biol Fil** 1996; 190(2–3):181–206 (221 ref.) (Eng. Abstr.) **(Fre)**
[Beta adrenergic signal transduction and heart adenyl cyclase] Mercadier JJ, et al. **C R Seances Soc Biol Fil** 1996; 190(2–3):207–18 (23 ref.) (Eng. Abstr.) **(Fre)**
[Mg(2+) transport in the heart. An overview] Ebel H. **Herz** 1997 Jun;22 Suppl 1:10–7 (30 ref.) (Eng. Abstr.) **(Ger)**
[Indications for clinical applications of positron emission tomography in cardiology. Position report of the PET Cardiology Study Group of the German Society of Nuclear Medicine and the Nuclear Cardiology Study Circle of the German Society of Cardiology] **Z Kardiol** 1996 Jul; 85(7):453–68 (141 ref.) (Eng. Abstr.) **(Ger)**
[Anesthesia and heart function] Suga H. **Masui** 1996 Dec;45 Suppl:S1–5 (18 ref.) **(Jpn)**
[Metabolic, adrenergic, and systolic function assessed by cardiac SPECT] Hattori N, et al. **Nippon Rinsho** 1997 Mar; 55 Suppl 1:656–61 (8 ref.) **(Jpn)**
[Molecular structure and expression of ion channels in the heart] Isomoto S, et al. **Nippon Rinsho** 1996 Aug; 54(8):2056–65 (24 ref.) (Eng. Abstr.) **(Jpn)**
[Signal transduction system in cardiac cells] Kaibara M, et al. **Nippon Rinsho** 1996 Aug;54(8):2041–4 (4 ref.) (Eng. Abstr.) **(Jpn)**
[Assessment of myocardial energy metabolism with PET] Kinoshita S, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:644–7 (13 ref.) **(Jpn)**
[Oscillatory changes in the intracellular Ca2+ concentration in cardiac muscles] Komukai K, et al. **Nippon Rinsho** 1996 Aug;54(8):2045–9 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Evaluation of oxidative metabolism in the myocardium] Kudoh T. **Nippon Rinsho** 1997 Mar;55 Suppl 1:648–50 (9 ref.) **(Jpn)**
[Recent clinical applications of MR medicine as functional medical imaging in the brain and heart] Nishimura T. **Nippon Rinsho** 1997 Jul;55(7):1621–7 (5 ref.) (Eng. Abstr.) **(Jpn)**
[Clinical efficacy of three–dimensional chemical shift imaging (3D–CSI)—a study of 3D–CSI in the human heart and its clinical perspectives for the future] Yabe T, et al. **Nippon Rinsho** 1997 Jul;55(7):1839–43 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Fatty heart, myocardial fatty infiltration] Nishimiya T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):108–10 (17 ref.) **(Jpn)**
[Positron emission tomography for assessment of myocardial perfusion and metabolism] Chiżyński K. **Pol Tyg Lek** 1996 Mar;51(10–13):182–3 (17 ref.) **(Pol)**
[Radioisotopic methods of estimating perfusion and viability (metabolism) of the myocardium] Budlewski T, et al. **Przegl Lek** 1997;54(1):46–51 (31 ref.) (Eng. Abstr.) **(Pol)**
[Effect of physical load deficiency on the system of calcium transport in the sarcoplasmic reticulum of skeletal muscles amd myocardium] Stepanova VV, et al. **Aviakosm Ekolog Med** 1996;30(5):33–5 (24 ref.) (Eng. Abstr.) **(Rus)**

PATHOLOGY

Myocardial bridging as a factor in heart disorders: critical review and hypothesis. Yamaguchi M, et al. **Acta Anat (Basel)** 1996;157(3):248–60 (102 ref.)
Clinical nuclear cardiology: flow tracers and free fatty acid analogs to detect viable myocardium after infarction. Franken PR, et al. **Acta Cardiol** 1996;51(6):501–14 (20 ref.)
The cardiac profile and proposed practice guideline for acute ischemic heart disease [see comments] Keffer JH. **Am J Clin Pathol** 1997 Apr;107(4):398–409 (60 ref.) Comment in: Am J Clin Pathol 1997 Apr;107(4):383–4.
Insulin–like growth factor–1 and myocyte growth: the danger of a dogma part II. Induced myocardial growth: pathologic hypertrophy [see comments] Anversa P, et al. **Cardiovasc Res** 1996 Sep;32(3):484–95 (109 ref.) Comment in: Cardiovasc Res 1996 Sep;32(3):482–3.
Compensated cardiac hypertrophy: arrhythmogenicity and the new myocardial phenotype. I. Fibrosis. Assayag P, et al. **Cardiovasc Res** 1997 Jun;34(3):439–44 (29 ref.)
Stretching the evidence in the case of cardiac growth [see comments] Yamazaki T, et al. **Cardiovasc Res** 1996 Apr; 31(4):493–8 (45 ref.) Comment in: Cardiovasc Res 1996 Apr;31(4):492.
PTCA of complex atherosclerotic lesion at site of LAD myocardial bridging. Cohen HM, et al. **Cathet Cardiovasc Diagn** 1996 Mar;37(3):272–6 (14 ref.)
The myocardial and vascular pathology of diabetic cardiomyopathy. Hardin NJ. **Coron Artery Dis** 1996 Feb; 7(2):99–108 (61 ref.)
Progress in myocardial damage detection: new biochemical markers for clinicians. Mair J. **Crit Rev Clin Lab Sci** 1997; 34(1):1–66 (174 ref.)
Myocyte death in heart failure. Anversa P, et al. **Curr Opin Cardiol** 1996 May;11(3):245–51 (55 ref.)
Recent advances in cardiac magnetic resonance imaging [see comments] Taylor AM, et al. **Curr Opin Cardiol** 1996 Nov; 11(6):635–42 (37 ref.) Comment in: Curr Opin Cardiol 1996 Nov;11(6):611–23.
The cellular pathophysiology of progression to heart failure. Wagoner LE, et al. **Curr Opin Cardiol** 1996 May; 11(3):237–44 (33 ref.)
The challenge of endomyocardial biopsy interpretation in assessing cardiac allograft rejection. Winters GL. **Curr Opin Cardiol** 1997 Mar;12(2):146–52 (59 ref.)
Age–related changes in cardiac physiology. Can they be postponed or treated by drugs? Svanborg A. **Drugs Aging** 1997 Jun;10(6):463–72 (75 ref.)
Comparison between abnormalities in segmental endocardial motion and abnormalities in segmental wall thickening after anterior myocardial infarction. A cine–magnetic resonance study. Germain P, et al. **Eur Heart J** 1996 Sep; 17(9):1350–61 (30 ref.)
Metabolic imaging using F18–fluorodeoxyglucose to assess myocardial viability. Bax JJ, et al. **Int J Card Imaging** 1997 Apr;13(2):145–55; discussion 157–60 (87 ref.)
Ischemic heart disease: value of MR techniques. van der Wall EE, et al. **Int J Card Imaging** 1997 Jun;13(3):179–89 (21 ref.)
Electrical injury to the heart may cause long–term damage to conducting tissue: a hypothesis and review of the literature. Robinson NM, et al. **Int J Cardiol** 1996 Mar; 53(3):273–7 (20 ref.)
Measuring cytosolic Ca2+ in cells with fluorescent probes: an aid to understanding cell pathophysiology. Hayes A, et al. **Int Rev Exp Pathol** 1996;36:197–212 (65 ref.)
How to use information from echocardiography and magnetic resonance for diagnosing myocardial viability. Sechtem U. **Isr J Med Sci** 1996 Oct;32(10):812–4 (12 ref.)
Myocardial infarction as a problem of growth control: cell cycle therapy for cardiac myocytes? Schneider MD. **J Card Fail** 1996 Sep;2(3):259–63 (32 ref.)
Cardiac involvement in progressive muscular dystrophy of the Duchenne type. Ishikawa K. **Jpn Heart J** 1997 Mar; 38(2):163–80 (97 ref.)
Myocardial alpha1–adrenoceptor: inotropic effect and physiologic and pathologic implications. Li K, et al. **Life Sci** 1997;60(16):1305–18 (127 ref.)
Microfibrosis produces electrical load variations due to loss of side–to–side cell connections: a major mechanism of structural heart disease arrhythmias. Spach MS, et al. **Pacing Clin Electrophysiol** 1997 Feb;20(2 Pt 2):397–413 (60 ref.)
Mineralocorticoids, salt, hypertension: effects on the heart. Young MJ, et al. **Steroids** 1996 Apr;61(4):233–5 (16 ref.)
[Advances in high speed MR imaging for the functional assessment of cardiovascular system] Matsuda T. **Nippon Rinsho** 1997 Jul;55(7):1789–93 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Myocardial fibrosis] Hiruta Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):141–4 (19 ref.) **(Jpn)**
[Arrhythmogenic dysplasia of the right heart ventricle] Kalarus Z, et al. **Przegl Lek** 1997;54(1):43–5 (18 ref.) (Eng. Abstr.) **(Pol)**
[Pharmacologic regression of cardiac and vascular structural changes in the hypertensive patient. A question that goes beyond the exclusive medical bias] Antonio Francischetti E, et al. **Arq Bras Cardiol** 1995 Dec;65(6):555–63 (90 ref.) **(Por)**

ULTRASTRUCTURE

Models of thin filament assembly in cardiac and skeletal muscle. Gregorio CC. **Cell Struct Funct** 1997 Feb; 22(1):191–5 (37 ref.)
The heart muscle's putative "secondary structure'. Functional implications of a band–like anisotropy. Lunkenheimer PP, et al. **Technol Health Care** 1997 Apr;5(1–2):53–64 (53 ref.)

MYOCLONIC EPILEPSY, PROGRESSIVE see **EPILEPSY, MYOCLONIC**

MYOCLONIC JERKING see **EPILEPSY, MYOCLONIC**

MYOCLONIC JERKING, MASSIVE see **SPASMS, INFANTILE**

MYOCLONUS

CHEMICALLY INDUCED

Inadvertent intraoperative myelography with Hypaque: case report and discussion. Killeffer JA, et al. **Surg Neurol** 1997 Jul;48(1):70–3 (23 ref.)

CLASSIFICATION

Overview and classification of myoclonus. Shibasaki H. **Clin Neurosci** 1995–96;3(4):189–92 (40 ref.)

COMPLICATIONS

[Serotonin syndrome: critical review of the literature] Baubet T, et al. **Rev Med Interne** 1997;18(5):380–7 (60 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Paraneoplastic ophthalmological syndromes. Constantinescu A. **Oftalmologia** 1996 Jul–Sep;40(3):214–8 (7 ref.)

DRUG THERAPY

Piracetam in the treatment of myoclonus: an overview. Van Vleymen B, et al. **Acta Neurol Belg** 1996 Dec;96(4):270–80 (62 ref.)
Therapy of myoclonus. Obeso JA. **Clin Neurosci** 1995–96; 3(4):253–7 (26 ref.)
The pharmacology of antimyoclonic drugs. Pranzatelli MR. **Clin Neurosci** 1995–96;3(4):246–52 (60 ref.)

GENETICS

Idiopathic, myoclonic and Dopa–responsive dystonia. Gasser T. **Curr Opin Neurol** 1997 Aug;10(4):357–62 (57 ref.)

IMMUNOLOGY

The immunopharmacology of the opsoclonus–myoclonus syndrome. Pranzatelli MR. **Clin Neuropharmacol** 1996 Feb; 19(1):1–47 (285 ref.)

PHYSIOPATHOLOGY

Cortical myoclonus: an insight into the organization of normal movement in man. Brown P. **Clin Neurosci** 1995–96; 3(4):193–7 (44 ref.)

Propriospinal myoclonus. Chokroverty S. **Clin Neurosci** 1995–96;3(4):219–22 (19 ref.)

Brainstem myoclonus. Rothwell JC. **Clin Neurosci** 1995–96; 3(4):214–8 (33 ref.)

Negative myoclonus. Tassinari CA, et al. **Clin Neurosci** 1995–96;3(4):209–13 (19 ref.)

Myoclonus in corticobasal degeneration. Thompson PD. **Clin Neurosci** 1995–96;3(4):203–8 (17 ref.)

Pathophysiology of sensorimotor cortex in cortical myoclonus. Ugawa Y, et al. **Clin Neurosci** 1995–96; 3(4):198–202 (21 ref.)

Myoclonus. Brown P. **Curr Opin Neurol** 1996 Aug;9(4):314–6 (17 ref.)

Hashimoto's myoclonic encephalopathy: an underdiagnosed treatable condition? [see comments] Ghika–Schmid F, et al. **Mov Disord** 1996 Sep;11(5):555–62 (30 ref.) Comment in: Mov Disord 1997 May;12(3):471–2.

Brainstem encephalopathy with stimulus–sensitive myoclonus leading to respiratory arrest, but with recovery: a description of two cases and review of the literature. Kullmann DM, et al. **Mov Disord** 1996 Nov;11(6):715–8 (22 ref.)

[Skeletal myoclonus and midbrain tremor] Nagaoka M. **No To Shinkei** 1996 Mar;48(3):209–16 (12 ref.) **(Jpn)**

[Action myoclonus, intention tremor and terminal oscillation] Ugawa Y. **No To Shinkei** 1996 Mar;48(3):203–8 (12 ref.) **(Jpn)**

[Pathophysiology of involuntary movements—dystonia and myoclonus. Symptomatological view] Kachi T. **Rinsho Shinkeigaku** 1995 Dec;35(12):1381–3 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Pathophysiology of involuntary movements—dystonia and myoclonus from viewpoint of brain activities] Shibasaki H. **Rinsho Shinkeigaku** 1995 Dec;35(12):1384–6 (13 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Inadvertent intraoperative myelography with Hypaque: case report and discussion. Killeffer JA, et al. **Surg Neurol** 1997 Jul;48(1):70–3 (23 ref.)

[Pathophysiologies of dystonia and myoclonus—consideration from the standpoint of treatment] Segawa M. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1390–3 (10 ref.) (Eng. Abstr.) **(Jpn)**

MYOD PROTEIN

GENETICS

MyoD meets its maker. Rawls A, et al. **Cell** 1997 Apr 4; 89(1):5–8 (17 ref.)

[Gene network regulating muscle development] Nabeshima Y. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1008–17 (53 ref.) **(Jpn)**

PHYSIOLOGY

DNA methylation and developmental genes in lymphomagenesis—more questions than answers? Kay PH, et al. **Leuk Lymphoma** 1997 Jan;24(3–4):211–20 (58 ref.)

MYODYSTROPHIA FETALIS DEFORMANS see **ARTHROGRYPOSIS**

MYOELECTRIC COMPLEX, MIGRATING

PHYSIOLOGY

Intestinal migrating motor complexes and blood flow: what is the link? Fioramonti J, et al. **Eur J Gastroenterol Hepatol** 1996 Aug;8(8):765–7 (18 ref.)

MYOEPITHELIAL TUMOR see **MYOEPITHELIOMA**

MYOEPITHELIOMA

PATHOLOGY

Malignant myoepithelioma of the breast. Case report with immunohistochemical study. Van Dorpe J, et al. **Arch Anat Cytol Pathol** 1996;44(4):193–8 (13 ref.)

A cytologic, immunocytochemical and ultrastructural study of a malignant parotid gland myoepithelioma. Sironi M, et al. **Cytopathology** 1997 Feb;8(1):53–62 (16 ref.)

Myoepithelial carcinoma arising in a benign myoepithelioma: immunohistochemical, ultrastructural, and flow–cytometrical study. Bombí JA, et al. **Ultrastruct Pathol** 1996 Mar–Apr;20(2):145–54 (24 ref.)

ULTRASTRUCTURE

A cytologic, immunocytochemical and ultrastructural study of a malignant parotid gland myoepithelioma. Sironi M, et al. **Cytopathology** 1997 Feb;8(1):53–62 (16 ref.)

Myoepithelial carcinoma arising in a benign myoepithelioma: immunohistochemical, ultrastructural, and flow–cytometrical study. Bombí JA, et al. **Ultrastruct Pathol** 1996 Mar–Apr;20(2):145–54 (24 ref.)

MYOFASCIAL PAIN DYSFUNCTION SYNDROME, TEMPOROMANDIBULAR JOINT see **TEMPOROMANDIBULAR JOINT DYSFUNCTION SYNDROME**

MYOFASCIAL PAIN SYNDROMES

Fibromyalgia, chronic fatigue syndrome, and myofascial pain syndrome. Goldenberg DL. **Curr Opin Rheumatol** 1997 Mar;9(2):135–43 (63 ref.)

DIAGNOSIS

Myofascial pain syndromes in the upper extremity. Gerwin RD. **J Hand Ther** 1997 Apr–Jun;10(2):130–6 (36 ref.)

DRUG THERAPY

Trigger points and tender points: one and the same? Does injection treatment help? Borg–Stein J, et al. **Rheum Dis Clin North Am** 1996 May;22(2):305–22 (62 ref.)

PATHOLOGY

Myofascial pain syndrome and trigger–point management. Han SC, et al. **Reg Anesth** 1997 Jan–Feb;22(1):89–101 (101 ref.)

PHYSIOPATHOLOGY

Orofacial pain mechanisms and their clinical application. Merrill RL. **Dent Clin North Am** 1997 Apr;41(2):167–88 (71 ref.)

Pathophysiology of myofascial trigger point. Hong CZ. **J Formos Med Assoc** 1996 Feb;95(2):93–104 (73 ref.)

THERAPY

Myofascial pain syndromes in the upper extremity. Gerwin RD. **J Hand Ther** 1997 Apr–Jun;10(2):130–6 (36 ref.)

Myofascial pain syndrome and trigger–point management. Han SC, et al. **Reg Anesth** 1997 Jan–Feb;22(1):89–101 (101 ref.)

MYOFIBRILS

see related
MUSCLE CONTRACTION

METABOLISM

Cardiac contractility: modulation of myofibrillar calcium sensitivity by beta–adrenergic stimulation. Kögler H, et al. **Isr J Med Sci** 1997 Jan;33(1):1–7 (32 ref.)

PHYSIOLOGY

Microscopic analysis of the elastic properties of connectin/titin and nebulin in myofibrils. Ishiwata S, et al. **Adv Biophys** 1996;33:135–42 (23 ref.)

Titin/connectin and nebulin: giant protein rulers of muscle structure and function. Wang K. **Adv Biophys** 1996; 33:123–34 (84 ref.)

Force transmission in skeletal muscle: from actomyosin to external tendons. Patel TJ, et al. **Exerc Sport Sci Rev** 1997; 25:321–63 (121 ref.)

[Molecular mechanism of force (motion) generation by actomyosin] Strzelecka–Gołaszewska H. **Postepy Biochem** 1996;42(2):185–94 (83 ref.) **(Pol)**

[Pathogenesis of fibromyalgia] Shelkovnikov IA, et al. **Patol Fiziol Eksp Ter** 1997 Jan–Mar;(1):41–2 (24 ref.) **(Rus)**

ULTRASTRUCTURE

Microscopic analysis of the elastic properties of connectin/titin and nebulin in myofibrils. Ishiwata S, et al. **Adv Biophys** 1996;33:135–42 (23 ref.)

The heart muscle's putative "secondary structure': Functional implications of a band–like anisotropy. Lunkenheimer PP, et al. **Technol Health Care** 1997 Apr;5(1–2):53–64 (53 ref.)

MYOFIBROBLASTOMA see **NEOPLASMS, MUSCLE TISSUE**

MYOFIBROMA see **LEIOMYOMA**

MYOFIBROMATOSIS

Infantile myofibromatosis: a case with unusual features and review of the literature. Kotiloğlu E, et al. **Turk J Pediatr** 1996 Oct–Dec;38(4):527–32 (20 ref.)

MYOFILAMENTS see **MICROFILAMENTS**

MYOGENIC REGULATORY FACTORS

GENETICS

Targeted inactivation of myogenic factor genes reveals their role during mouse myogenesis: a review. Arnold HH, et al. **Int J Dev Biol** 1996 Feb;40(1):345–53 (42 ref.)

PHYSIOLOGY

Skeletal muscle development and the role of the myogenic regulatory factors. Buckingham M. **Biochem Soc Trans** 1996 May;24(2):506–9 (27 ref.)

Interdependence between muscle differentiation and cell–cycle control. Maione R, et al. **Biochim Biophys Acta** 1997 Feb 22;1332(1):M19–30 (131 ref.)

Molecular embryology of skeletal myogenesis. Venuti JM, et al. **Curr Top Dev Biol** 1996;34:169–206 (177 ref.)

MYOGLOBIN

ANALOGS & DERIVATIVES

Isolation and oxygenation reactions of nitrosylmyoglobins. Arnold EV, et al. **Methods Enzymol** 1996;269:41–55 (50 ref.)

BLOOD

[Blood myoglobin: diagnostic significance and methods of studies (literature review)] Titov VN, et al. **Klin Lab Diagn** 1993 May–Jun;(3):3–10 (55 ref.) **(Rus)**

CHEMISTRY

Laue crystallography: Lights! Camera! action! Farber GK. **Curr Biol** 1997 Jun 1;7(6):R352–4 (6 ref.)

Intrinsic fluorescence of hemoglobins and myoglobins. Gryczynski Z, et al. **Methods Enzymol** 1997;278:538–69 (63 ref.)

PHYSIOLOGY

[Role of myoglobin in supplying oxygen to tissues] Vasil'eva VO, et al. **Ukr Biokhim Zh** 1996 Jul–Aug;68(4):45–55 (81 ref.) (Eng. Abstr.) **(Ukr)**

MYOGLOBINURIA

Rhabdomyolysis and myohemoglobinuric acute renal failure [editorial] Zager RA. **Kidney Int** 1996 Feb;49(2):314–26 (148 ref.)

ETIOLOGY

Myoglobinuria, malignant hyperthermia, neuroleptic malignant syndrome and serotonin syndrome. Bertorini TE. **Neurol Clin** 1997 Aug;15(3):649–71 (193 ref.)

[Myoglobinuria following anesthesia with enflurane and succinylcholine in an asthmatic child on theophylline] Shono S, et al. **Masui** 1996 Jan;45(1):91–5 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Myonephropathic metabolic syndrome (MNMS)] Shimai S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):469–71 (11 ref.) **(Jpn)**

GENETICS

[Myoglobinuria and familial hematuria with dominant autosomal transmission: mitochondrial disorder or basal lamina disorder?] Martin–Du Pan RC, et al. **Rev Med Suisse Romande** 1996 Sep;116(9):735–41 (40 ref.) **(Fre)**

MYOINOSITOL see **INOSITOL**

MYOKINASE see **ADENYLATE KINASE**

MYOKYMIA see **FASCICULATION**

MYOMETRIUM

DRUG EFFECTS

Nitric oxide and the myometrium. Norman J. **Pharmacol Ther** 1996;70(2):91–100 (70 ref.)

PATHOLOGY

[Assessment of myometrial invasion in endometrial cancer by transvaginal ultrasonography] Szabó I, et al. **Orv Hetil** 1997 May 25;138(21):1323–7 (23 ref.) (Eng. Abstr.) **(Hun)**

PHYSIOLOGY

Some actions of taurine on ionic currents of myocardial cells and myometrial cells. Sperelakis N, et al. **Adv Exp Med Biol** 1996;403:275–84 (18 ref.)

Nitric oxide and the myometrium. Norman J. **Pharmacol Ther** 1996;70(2):91–100 (70 ref.)

MYONEURAL JUNCTION see **NEUROMUSCULAR JUNCTION**

MYOPATHY, NEMALINE see **NEMALINE MYOPATHY**

MYOPIA

EPIDEMIOLOGY

Epidemiology of myopia. Saw SM, et al. **Epidemiol Rev** 1996; 18(2):175–87 (108 ref.)

Prevalence of myopia in adults: implications for refractive surgeons [see comments] McCarty CA, et al. **J Refract Surg** 1997 May–Jun;13(3):229–34 (41 ref.) Comment in: J Refract Surg 1997 May–Jun;13(3):213–5.

ETIOLOGY

Pseudomyopia in a patient with blocked ventriculo–peritoneal shunt––a case report. Voon LW, et al. **Ann Acad Med Singapore** 1997 Mar;26(2):229–31 (15 ref.)

Nearwork–induced transient myopia: a critical review. Ong E, et al. **Doc Ophthalmol** 1995;91(1):57–85 (64 ref.)

Is computer use a risk factor for myopia? Mutti DO, et al. **J Am Optom Assoc** 1996 Sep;67(9):521–30 (48 ref.)

Clinical findings before the onset of myopia in youth: 3. Heterophoria. Goss DA, et al. **Optom Vis Sci** 1996 Apr; 73(4):269–78 (73 ref.)

[Current status of studies on development of myopia] Schaeffel F. **Klin Monatsbl Augenheilkd** 1997 Jul; 211(1):12–6 (36 ref.) **(Ger)**

PATHOLOGY

Animal models of myopia. A review. Edwards MH. **Acta Ophthalmol Scand** 1996 Jun;74(3):213–9 (68 ref.)

PHYSIOPATHOLOGY

Photorefractive keratectomy for myopia of –8.00 to –24.00 diopters. Goes FJ. **J Refract Surg** 1996 Jan–Feb;12(1):91–7 (14 ref.)

Night myopia and driving. Charman WN. **Ophthalmic Physiol Opt** 1996 Nov;16(6):474–85 (101 ref.)

[Methods for clinical studies of sclera in myopia] Khodzhabekian NV. **Vestn Oftalmol** 1997 May–Jun; 113(3):45–7 (44 ref.) **(Rus)**

PREVENTION & CONTROL

[Software for automated follow–up of chronic outpatients] Lapochkin VI, et al. **Vestn Oftalmol** 1997 May–Jun; 113(3):30–2 (0 ref.) (Eng. Abstr.) **(Rus)**

SURGERY

Intrastromal corneal ring technology. Krueger RR, et al. **Int Ophthalmol Clin** 1996 Fall;36(4):89–106 (20 ref.)

Myopic laser–assisted keratomileusis: an overview of published results. Sànchez–Thorin JC, et al. **Int Ophthalmol Clin** 1996 Fall;36(4):53–63 (20 ref.)

Refractive surgery for myopic and hyperopic astigmatism. Thompson V. **Int Ophthalmol Clin** 1997 Winter;37(1):37–49 (16 ref.)

The current status of phakic intraocular lenses. Zaldivar R, et al. **Int Ophthalmol Clin** 1996 Fall;36(4):107–11 (5 ref.)

Problems of refraction after photorefractive keratectomy. Siow KL, et al. **J Am Optom Assoc** 1996 Dec;67(12):755–61 (7 ref.)

Consultation section. What is your current method of treating myopia of of –2.00, –4.00, –8.00, –12.00, –16.00, and –20.00 diopters? [see comments] **J Cataract Refract Surg** 1997 Jan–Feb;23(1):19–26 (3 ref.) Comment in: J Cataract Refract Surg 1997 May;23(4):462.

Keratomileusis update. Gris O, et al. **J Cataract Refract Surg** 1996 Jun;22(5):620–3 (25 ref.)

Macular hemorrhage after excimer laser photorefractive keratectomy. Loewenstein A, et al. **J Cataract Refract Surg** 1997 Jun;23(5):808–10 (8 ref.)

Bilateral photorefractive keratectomy with intentional unilateral undercorrection performed on an aircraft pilot [editorial; comment] Mader TH. **J Cataract Refract Surg** 1997 Mar;23(2):145–7 (22 ref.) Comment on: J Cataract Refract Surg 1997 Mar;23(2):294–6.

Photorefractive keratectomy for myopia of –8.00 to –24.00 diopters. Goes FJ. **J Refract Surg** 1996 Jan–Feb;12(1):91–7 (14 ref.)

Clear lensectomy and implantation of a low–power posterior chamber intraocular lens for correction of high myopia: a four–year follow–up. Colin J, et al. **Ophthalmology** 1997 Jan;104(1):73–7; discussion 77–8 (9 ref.)

Excimer laser photorefractive keratectomy for high myopia: four–year experience with a multiple zone technique. Piovella M, et al. **Ophthalmology** 1997 Oct;104(10):1554–65 (33 ref.)

[Myopia surgery] Waked N. **J Med Liban** 1996;44(2):86–9 (13 ref.) **(Fre)**

[Excimer laser method for correction of vision disorders. A chance for life without eyeglasses?] Huber I. **Med Monatsschr Pharm** 1996 Dec;19(12):365–70 (15 ref.) **(Ger)**

[The intrastromal corneal ring (KeraVision Ring, ICR, ICRS). A modern method for correcting minor myopia] Grabner G, et al. **Wien Med Wochenschr** 1997; 147(12–13):309–21 (45 ref.) (Eng. Abstr.) **(Ger)**

[Refractive laser surgery of the cornea] Kaminski S, et al. **Wien Med Wochenschr** 1997;147(12–13):302–7 (48 ref.) (Eng. Abstr.) **(Ger)**

MYOSARCOMA

DIAGNOSIS

Retrorectal tumors complicating pregnancy. Report of two cases. Sobrado CW, et al. **Dis Colon Rectum** 1996 Oct; 39(10):1176–9 (13 ref.)

MYOSIN

Myosin I. Coluccio LM. **Am J Physiol** 1997 Aug;273(2 Pt 1):C347–59 (155 ref.)

Structure–function analysis of the motor domain of myosin. Ruppel KM, et al. **Ann Rev Cell Dev Biol** 1996;12:543–73 (140 ref.)

Shape and length of myosin heads and radial compressive forces in muscle. Morel JE, et al. **J Theor Biol** 1997 Jan 21;184(2):133–8 (37 ref.)

CHEMISTRY

Structural studies on myosin II: communication between distant protein domains. Gulick AM, et al. **Bioessays** 1997 Jul;19(7):561–9 (62 ref.)

The chemical mechanism of myosin–I: implications for actin–based motility and the evolution of the myosin family of motor proteins. Pollard TD, et al. **Cell Struct Funct** 1996 Oct;21(5):351–6 (30 ref.)

Myosin and kinesin: mother and child reunited. Hackney DD. **Chem Biol** 1996 Jul;3(7):525–8 (20 ref.)

Myosin structure and function. Spudich JA, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:783–91 (44 ref.)

Myosin isoforms and functional diversity in vertebrate smooth muscle. Murphy RA, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 May; 117(1):51–60 (102 ref.)

Myosins in yeast. Brown SS. **Curr Opin Cell Biol** 1997 Feb; 9(1):44–8 (29 ref.)

Structure and dynamics of molecular motors. Amos LA, et al. **Curr Opin Struct Biol** 1997 Apr;7(2):239–46 (58 ref.)

Kinesin and NCD, two structural cousins of myosin. Sellers JR. **J Muscle Res Cell Motil** 1996 Apr;17(2):173–5 (23 ref.)

CLASSIFICATION

Myosin diversity and disease. Wright AF, et al. **Trends Genet** 1996 Jun;12(6):206–9 (23 ref.)

DIAGNOSTIC USE

Antimyosin antibody imaging in clinical myocarditis and cardiomyopathy: principle and application. Matsumori A, et al. **Int J Cardiol** 1996 May;54(2):183–90 (33 ref.)

GENETICS

Evidence for autoimmunity to myosin and other heart–specific autoantigens in patients with dilated cardiomyopathy and their relatives. Caforio AL, et al. **Int J Cardiol** 1996 May;54(2):157–63 (51 ref.)

A myosin family reunion. Sellers JR, et al. **J Muscle Res Cell Motil** 1996 Feb;17(1):7–22 (112 ref.)

IMMUNOLOGY

Antimyosin antibodies in cardiac rejection. Schütz A, et al. **Ann Thorac Surg** 1997 Feb;63(2):578–81 (19 ref.)

Autoimmune myocarditis. Rose NR, et al. **Int J Cardiol** 1996 May;54(2):171–5 (19 ref.)

METABOLISM

Myosin drives retrograde F–actin flow in neuronal growth cones. Lin CH, et al. **Biol Bull** 1997 Feb;192(1):183–5 (29 ref.)

The swinging lever–arm hypothesis of muscle contraction. Holmes KC. **Curr Biol** 1997 Feb 1;7(2):R112–8 (27 ref.)

Molecular motors: single–molecule mechanics. Simmons R. **Curr Biol** 1996 Apr 1;6(4):392–4 (17 ref.)

Motors and membrane traffic. Goodson HV, et al. **Curr Opin Cell Biol** 1997 Feb;9(1):18–28 (97 ref.)

Sliding and ATPase. Oosawa F. **J Biochem (Tokyo)** 1995 Nov;118(5):863–70 (37 ref.)

PHYSIOLOGY

Myosin II function in non–muscle cells. Maciver SK. **Bioessays** 1996 Mar;18(3):179–82 (35 ref.)

Multiple myosin motors and mechanoelectrical transduction by hair cells. Gillespie PG. **Biol Bull** 1997 Feb; 192(1):186–90 (21 ref.)

Smooth and skeletal muscle single–molecule mechanical experiments [comment] Molloy JE, et al. **Biophys J** 1997 Mar;72(3):984–6 (8 ref.) Comment on: Biophys J 1997 Mar;72(3):1006–21.

Fifty ways to love your lever: myosin motors. Block SM. **Cell** 1996 Oct 18;87(2):151–7 (51 ref.)

Myosin structure and function. Spudich JA, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:783–91 (44 ref.)

Myosins on the move to signal transduction. Bähler M. **Curr Opin Cell Biol** 1996 Feb;8(1):18–22 (43 ref.)

A myosin family reunion. Sellers JR, et al. **J Muscle Res Cell Motil** 1996 Feb;17(1):7–22 (112 ref.)

Myosin light chain kinase: an actin–binding protein that regulates an ATP–dependent interaction with myosin. Kohama K, et al. **Trends Pharmacol Sci** 1996 Aug; 17(8):284–7 (33 ref.)

MYOSIN ADENOSINETRIPHOSPHATASE see **MYOSIN ATPASE**

MYOSIN ALKALI LIGHT CHAINS see **MYOSIN LIGHT CHAINS**

MYOSIN ATPASE

CHEMISTRY

Myosin isoform heterogeneity in single smooth muscle cells. Eddinger TJ, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 May; 117(1):29–38 (80 ref.)

Characterization of isoform diversity among smooth muscle and nonmuscle myosin heavy chains. Kelley CA. **Comp Biochem Physiol B Biochem Mol Biol** 1997 May; 117(1):39–49 (39 ref.)

Myosin heavy chain isoforms in smooth muscle. Loukianov E, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 May;117(1):13–8 (51 ref.)

C–terminal isoforms of the myosin heavy chain and smooth muscle function. Martin AF, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 May; 117(1):3–11 (52 ref.)

Myosin isoforms and functional diversity in vertebrate smooth muscle. Murphy RA, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 May; 117(1):51–60 (102 ref.)

METABOLISM

Modeling of the actomyosin ATPase activity. Origin of the initial phosphate burst and implications of the phosphate release kinetics. Stein LA. **Cell Biochem Biophys** 1995–96; 27(2):63–96 (14 ref.)

PHYSIOLOGY

Multiple myosin isozymes and hair–cell function. Gillespie PG, et al. **Cold Spring Harb Symp Quant Biol** 1996; 61:309–18 (79 ref.)

MYOSIN HEAVY CHAINS

BIOSYNTHESIS

Smooth muscle phenotypes in developing and atherosclerotic human arteries demonstrated by myosin expression. Aikawa M, et al. **J Atheroscler Thromb** 1995;2(1):14–23 (12 ref.)

CHEMISTRY

Myosin isoform heterogeneity in single smooth muscle cells. Eddinger TJ, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 May; 117(1):29–38 (80 ref.)

Characterization of isoform diversity among smooth muscle and nonmuscle myosin heavy chains. Kelley CA. **Comp Biochem Physiol B Biochem Mol Biol** 1997 May; 117(1):39–49 (39 ref.)

Myosin heavy chain isoforms in smooth muscle. Loukianov E, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 May;117(1):13–8 (51 ref.)

C–terminal isoforms of the myosin heavy chain and smooth muscle function. Martin AF, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 May; 117(1):3–11 (52 ref.)

GENETICS

The mammalian myosin heavy chain gene family. Weiss A, et al. **Ann Rev Cell Dev Biol** 1996;12:417–39 (89 ref.)

Myosin gene expression and cell phenotypes in vascular smooth muscle during development, in experimental models, and in vascular disease. Sartore S, et al. **Arterioscler Thromb Vasc Biol** 1997 Jul;17(7):1210–5 (42 ref.)

The vertebrate myosin heavy chain: genetics and assembly properties. Vikstrom KL, et al. **Cell Struct Funct** 1997 Feb; 22(1):123–9 (33 ref.)

METABOLISM

Arterial muscle myosin heavy chains and light chains in spontaneous hypertension. Packer CS. **Comp Biochem Physiol B Biochem Mol Biol** 1997 May; 117(1):19–28 (43 ref.)

PHYSIOLOGY

Functional differences of myosin heavy–chain isoforms in skeletal muscle. Hilber K, et al. **Naturwissenschaften** 1997 May;84(5):201–4 (20 ref.)

MYOSIN ISOENZYMES see **MYOSIN ATPASE**

MYOSIN ISOZYMES see **MYOSIN ATPASE**

MYOSIN KINASE see **MYOSIN–LIGHT–CHAIN KINASE**

MYOSIN-LIGHT-CHAIN KINASE

PHYSIOLOGY

Kinase-related protein: a smooth muscle myosin-binding protein. Vorotnikov AV. **Int J Biochem Cell Biol** 1997 May;29(5):727–30 (7 ref.)
Myosin light chain kinases. Gallagher PJ, et al. **J Muscle Res Cell Motil** 1997 Feb;18(1):1–16 (138 ref.)
Myosin light chain kinase: an actin-binding protein that regulates an ATP-dependent interaction with myosin. Kohama K, et al. **Trends Pharmacol Sci** 1996 Aug; 17(8):284–7 (33 ref.)

MYOSIN LIGHT CHAINS

METABOLISM

Arterial muscle myosin heavy chains and light chains in spontaneous hypertension. Packer CS. **Comp Biochem Physiol B Biochem Mol Biol** 1997 May; 117(1):19–28 (43 ref.)

MYOSIN ROD see **MYOSIN SUBFRAGMENTS**

MYOSIN S-1 see **MYOSIN SUBFRAGMENTS**

MYOSIN S-2 see **MYOSIN SUBFRAGMENTS**

MYOSIN SUBFRAGMENTS

see related
MYOSIN ATPASE

PHYSIOLOGY

Functional analysis of the chicken sarcomeric myosin rod: regulation of dimerization, solubility, and fibrillogenesis. Bandman E, et al. **Cell Struct Funct** 1997 Feb;22(1):131–7 (39 ref.)

MYOSITIS

New developments in the myositis syndromes. Kagen LJ. **Bull Rheum Dis** 1996 Oct;45(6):1–4 (11 ref.)
Pyomyositis: report of three patients and review of the literature. Akman I, et al. **Clin Pediatr (Phila)** 1996 Aug; 35(8):397–401 (15 ref.)
Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rider LG, et al. **Rheum Dis Clin North Am** 1997 Aug;23(3):619–55 (330 ref.)

BLOOD

[Granulomatous idiopathic myositis at pediatric onset. Description of a case and a review of literature] Crisetti M, et al. **Minerva Pediatr** 1996 Jun;48(6):271–3 (12 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

Idiopathic eosinophilic myositis associated with vasculitis and symmetrical polyneuropathy. Espino-Montoro A, et al. **Br J Rheumatol** 1997 Feb;36(2):276–9 (18 ref.)
Rheumatologic manifestations of HIV infections. Kaye BR. **Clin Rev Allergy Immunol** 1996–97 Winter;14(4):385–416 (274 ref.)
Nontropical pyomyositis in patients with AIDS. Antony SJ, et al. **J Natl Med Assoc** 1996 Sep;88(9):565–9 (45 ref.)
[Course of interstitial lung diseases associated with inflammatory myopathies. Apropos of 5 cases] Tubéry M, et al. **Ann Med Interne (Paris)** 1997;148(1):2–10 (78 ref.) (Eng. Abstr.) **(Fre)**
[Myositis caused by Pleistophora in a patient with AIDS] Grau A, et al. **Med Clin (Barc)** 1996 Dec 7;107(20):779–81 (23 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Pyomyositis as a nontropical disease. Harbarth SJ, et al. **Curr Clin Top Infect Dis** 1997;17:37–50 (74 ref.)
Recognition and management of myositis. Cherin P. **Drugs** 1997 Jul;54(1):39–49 (49 ref.)
Pyomyositis--a differential diagnosis in the acute abdomen. Mangell P, et al. **Eur J Surg** 1997 Jul;163(7):553–5 (11 ref.)
Pyomyositis: clinical features and predisposing conditions. Patel SR, et al. **J Rheumatol** 1997 Sep;24(9):1734–8 (61 ref.)
Rheumatology. 11. Systemic sclerosis and the inflammatory myopathies. Rasaratnam I, et al. **Med J Aust** 1997 Mar 17;166(6):322–7 (15 ref.)
Tropical pyomyositis: imaging findings and a review of the literature. Pretorius ES, et al. **Skeletal Radiol** 1996 Aug; 25(6):576–9 (15 ref.)
[Relapsing focal myositis (letter)] García Pont J, et al. **Med Clin (Barc)** 1996 Apr 6;106(13):518–9 (10 ref.) **(Spa)**

DRUG THERAPY

Recognition and management of myositis. Cherin P. **Drugs** 1997 Jul;54(1):39–49 (49 ref.)

ETIOLOGY

Inclusion body myositis and transitional cell carcinoma of the bladder: significant resolution of symptoms after tumor excision. Jensen ML, et al. **Arch Phys Med Rehabil** 1997 Mar;78(3):327–9 (17 ref.)
[Inflammatory myopathies] Espinosa E. **Rev Neurol** 1996 Nov;24(135):1376–81 (33 ref.) **(Spa)**

GENETICS

Genetics of the idiopathic inflammatory myopathies. Garlepp MJ. **Curr Opin Rheumatol** 1996 Nov;8(6):514–20 (65 ref.)

IMMUNOLOGY

Immunopathogenesis of inflammatory myopathies. Dalakas MC. **Ann Neurol** 1995 May;37 Suppl 1:S74–86 (81 ref.)
Inflammatory myopathies [see comments] Tews DS, et al. **Curr Opin Neurol** 1996 Oct;9(5):375–9 (29 ref.) Comment in: Curr Opin Neurol 1996 Oct;9(5):367–8.
Structures targeted by the immune system in myositis. Mimori T. **Curr Opin Rheumatol** 1996 Nov;8(6):521–7 (69 ref.)
Inflammatory myopathies and systemic disorders: a review of immunopathogenetic mechanisms and clinical features. Mantegazza R, et al. **J Neurol** 1997 May;244(5):277–87 (67 ref.)

MICROBIOLOGY

Pyomyositis with toxic shock syndrome presenting as back pain and fever: a case report and literature review. Wolfe MW, et al. **Am J Orthop** 1997 Feb;26(2):135–7 (26 ref.)
Pyomyositis as a nontropical disease. Harbarth SJ, et al. **Curr Clin Top Infect Dis** 1997;17:37–50 (74 ref.)
A case of muscle abscess presenting to an accident and emergency department. Howell MA, et al. **J Accid Emerg Med** 1997 May;14(3):180–2 (22 ref.)

PATHOLOGY

Inflammatory myopathies and systemic disorders: a review of immunopathogenetic mechanisms and clinical features. Mantegazza R, et al. **J Neurol** 1997 May;244(5):277–87 (67 ref.)
[Myositis--a rare complication of Crohn disease] Druschky A, et al. **Fortschr Neurol Psychiatr** 1996 Oct;64(10):422–4 (13 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Assessment of disease activity and its sequelae in children and adults with myositis. Rider LG. **Curr Opin Rheumatol** 1996 Nov;8(6):495–506 (97 ref.)

THERAPY

Are intravenous immunoglobulin infusions beneficial in the treatment of inflammatory myopathies? [editorial; comment] Sakane T. **Intern Med** 1996 Aug;35(8):598–9 (9 ref.) Comment on: Intern Med 1996 Aug;35(8):663–7.

VIROLOGY

Infectious agents associated with myopathies. Ytterberg SR. **Curr Opin Rheumatol** 1996 Nov;8(6):507–13 (74 ref.)
Focal myositis: a polymerase chain reaction analysis for a viral etiology. Toti P, et al. **Hum Pathol** 1997 Jan; 28(1):111–3 (31 ref.)

MYOSITIS, INCLUSION BODY

Inclusion body myositis, a review. Carpenter S. **J Neuropathol Exp Neurol** 1996 Nov;55(11):1105–14 (60 ref.)
[Recent topics on inflammatory myositis] Hase A, et al. **Nippon Naika Gakkai Zasshi** 1996 Jan 10;85(1):123–8 (14 ref.) **(Jpn)**

ETIOLOGY

Idiopathic inflammatory myopathies. Amato AA, et al. **Neurol Clin** 1997 Aug;15(3):615–48 (191 ref.)
[Inflammatory myopathies] Espinosa E. **Rev Neurol** 1996 Nov;24(135):1376–81 (33 ref.) **(Spa)**

METABOLISM

The immunopathologic and inflammatory differences between dermatomyositis, polymyositis and sporadic inclusion body myositis. Dalakas MC, et al. **Curr Opin Neurol** 1996 Jun;9(3):235–9 (34 ref.)

THERAPY

Treatment of inflammatory myopathies. Mastaglia FL, et al. **Muscle Nerve** 1997 Jun;20(6):651–64 (106 ref.)

MYOSITIS, MULTIPLE see **POLYMYOSITIS**

MYOSITIS, ORBITAL see **GRANULOMA, PLASMA CELL, ORBITAL**

MYOSITIS OSSIFICANS

Myositis ossificans: report of seven cases in children. Jouve JL, et al. **J Pediatr Orthop B** 1997 Jan;6(1):33–41 (34 ref.)

DIAGNOSIS

Fibro-osseous pseudotumor that may be mistaken for a malignant tumor in the hand: a case Report and review of the literature. Tang JB, et al. **J Hand Surg [Am]** 1996 Jul;21(4):714–6 (5 ref.)
Fibrodysplasia ossificans progressiva: why do some people have two skeletons? Shore EM, et al. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):92S–97S (30 ref.)
[Myositis ossificans of the pterygoid and temporal muscles with metachronous contralateral involvement] Salgarelli A, et al. **Minerva Stomatol** 1997 May;46(5):259–65 (23 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

Fibrodysplasia ossificans progressiva: why do some people have two skeletons? Shore EM, et al. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):92S–97S (30 ref.)

PATHOLOGY

Myositis ossificans: an unusual presentation in the foot. Allard MM, et al. **Foot Ankle Int** 1997 Jan;18(1):39–42 (26 ref.)

MYOTONIA

[Periodic paralysis, myotonia] Kinoshita M, et al. **Nippon Rinsho** 1996 Mar;54(3):834–8 (12 ref.) (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

A newly-described myotonic disorder (proximal myotonic myopathy--PROMM): personal experience and review of the literature. Meola G, et al. **Ital J Neurol Sci** 1996 Oct; 17(5):347–53 (29 ref.)

COMPLICATIONS

Ocular neuromyotonia in Graves dysthyroid orbitopathy. Chung SM, et al. **Arch Ophthalmol** 1997 Mar;115(3):365–70 (31 ref.)

GENETICS

Ion channel mutations in periodic paralysis and related myotonic diseases. Brown RH Jr. **Ann N Y Acad Sci** 1993 Dec 20;707:305–16 (51 ref.)
Channelopathies: ion channel disorders of muscle as a paradigm for paroxysmal disorders of the nervous system. Ptáček LJ. **Neuromuscul Disord** 1997 Jun;7(4):250–5 (56 ref.)
Channelopathies: the nondystrophic myotonias and periodic paralyses. Lehmann-Horn F, et al. **Semin Pediatr Neurol** 1996 Jun;3(2):122–39 (114 ref.)

PHYSIOPATHOLOGY

Sodium channel defects in myotonia and periodic paralysis. Cannon SC. **Annu Rev Neurosci** 1996;19:141–64 (78 ref.)

MYOTONIA ATROPHICA

[Myotonic dystrophy] Tamura T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):90–2 (14 ref.) **(Jpn)**

COMPLICATIONS

Cardiac disease in myotonic dystrophy. Phillips MF, et al. **Cardiovasc Res** 1997 Jan;33(1):13–22 (61 ref.)
[A rare cause of polyhydramnios: Steinert's syndrome. A clinical case report] Palmerio G, et al. **Minerva Ginecol** 1997 Jan-Feb;49(1-2):49–52 (10 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

[Myotonin protein kinase] Ishiura S, et al. **Rinsho Shinkeigaku** 1995 Dec;35(12):1482–3 (3 ref.) (Eng. Abstr.) **(Jpn)**
[Abnormalities of N-linked oligosaccharide moieties of glycoproteins in patients with myotonic dystrophy] Ito K, et al. **Rinsho Shinkeigaku** 1995 Dec;35(12):1484–5 (4 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Is myotonic dystrophy a single-gene disorder? Johnson KJ, et al. **Biochem Soc Trans** 1996 May;24(2):510–3 (28 ref.)
Trinucleotide repeat disorders in pediatrics. O'Donnell DM, et al. **Curr Opin Pediatr** 1995 Dec;7(6):715–25 (54 ref.)
Trinucleotide repeat disorders in humans: discussions of mechanisms and medical issues. Timchenko LT, et al. **FASEB J** 1996 Dec;10(14):1589–97 (70 ref.)
Myotonic dystrophy: will the real gene please step forward! Harris S, et al. **Hum Mol Genet** 1996;5 Spec No:1417–23 (64 ref.)
Myotonic dystrophy: molecular and cellular consequences of expanded DNA repeats are elusive. Strong PN, et al. **J Inherit Metab Dis** 1997 Jun;20(2):159–70 (57 ref.)
Nondystrophinopathic muscular dystrophies including myotonic dystrophy. Nonaka I, et al. **Semin Pediatr Neurol** 1996 Jun;3(2):110–21 (45 ref.)
Myotonic dystrophy, knockouts, warts and all. Hamshere MG, et al. **Trends Genet** 1996 Sep;12(9):332–4 (31 ref.)
[Molecular genetics of myotonic dystrophy] Miki T, et al. **Rinsho Shinkeigaku** 1995 Dec;35(12):1479–81 (10 ref.) (Eng. Abstr.) **(Jpn)**

MYOTONIA ATROPHICA

[Molecular basis of triplet repeat diseases: genetic instability and unusual DNA structure] Shimizu M. **Tanpakushitsu Kakusan Koso** 1997 Mar;42(4):619–31 (35 ref.) **(Jpn)**

[Genetic diagnosis of the hypotonic newborn] Bauer MS. **Rev Neurol** 1997 May;25(141):703–6 (21 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Myotonic dystrophy: discussion of molecular mechanism. Caskey CT, et al. **Cold Spring Harb Symp Quant Biol** 1996; 61:607–14 (47 ref.)

THERAPY

[The electrotherapy of the arrhythmias in 3 cases of myotonic dystrophy (Steinert's disease)] Gardini A, et al. **Cardiologia** 1996 Dec;41(12):1209–14 (24 ref.) (Eng. Abstr.) **(Ita)**

MYOTONIA CONGENITA

GENETICS

Ion channel mutations in periodic paralysis and related myotonic diseases. Brown RH Jr. **Ann N Y Acad Sci** 1993 Dec 20;707:305–16 (51 ref.)

From mutation to myotonia in sodium channel disorders. Cannon SC. **Neuromuscul Disord** 1997 Jun;7(4):241–9 (44 ref.)

MYOTONIA DYSTROPHICA see **MYOTONIA ATROPHICA**

MYOTONIC DYSTROPHY see **MYOTONIA ATROPHICA**

MYOXIDAE see **RODENTIA**

MYRINGOPLASTY

see related
TYMPANOPLASTY

MYRISTIC ACIDS

CHEMISTRY

Electrostatic interaction of myristoylated proteins with membranes: simple physics, complicated biology. Murray D, et al. **Structure** 1997 Aug 15;5(8):985–9 (45 ref.)

METABOLISM

Myristoylation. Boutin JA. **Cell Signal** 1997 Jan;9(1):15–35 (326 ref.)

Glycosyl phosphatidylinositol myristoylation in African trypanosomes. Werbovetz KA, et al. **Mol Biochem Parasitol** 1997 Mar;85(1):1–7 (34 ref.)

MYSTERY SWINE DISEASE see **PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME**

MYTHOLOGY

Is transplantation only 100 years old? Bhandari M, et al. **Br J Urol** 1997 Apr;79(4):495–8 (21 ref.)

Intraocular foreign bodies: myths and truths. Kuhn F, et al. **Eur J Ophthalmol** 1996 Oct–Dec;6(4):464–71 (51 ref.)

Beauty and the beast: a myth of sadness, madness, and hope in anaclitic depression. Wu J. **Psychoanal Rev** 1997 Jun; 84(3):365–80 (16 ref.)

MYTILUS see **MUSSELS**

MYXEDEMA

see related
CRETINISM

[Metabolic pericarditis (uremia, myxedema)] Katoh S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):585–8 (17 ref.) **(Jpn)**

COMPLICATIONS

Myxedema coma. Pittman CS, et al. **Curr Ther Endocrinol Metab** 1997;6:98–101 (6 ref.)

[Torsade de pointes in myxedema. Report of a case and review of the literature] Albrecht Aguilera G, et al. **Arch Inst Cardiol Mex** 1996 Sep–Oct;66(5):429–33 (11 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Myxedema. Hierholzer K, et al. **Kidney Int Suppl** 1997 Jun; 59:S82–9 (50 ref.)

[Coma in myxedema—a rare complication of hypothyroidism. Possible iatrogenic factors should be taken into account] Hehrmann R. **Fortschr Med** 1996 Dec 10; 114(34):474–8 (14 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Preradial myxedema: a case report. Kohar YM, et al. **Ann Acad Med Singapore** 1996 Mar;25(2):281–2 (6 ref.)

MYXOBACTERALES see **MYXOCOCCALES**

MYXOCOCCALES

PHYSIOLOGY

Recent advances in the social and developmental biology of the myxobacteria. Dworkin M. **Microbiol Rev** 1996 Mar; 60(1):70–102 (268 ref.)

MYXOCOCCUS

ENZYMOLOGY

Bacterial signalling involving eukaryotic-type protein kinases. Zhang CC. **Mol Microbiol** 1996 Apr;20(1):9–15 (32 ref.)

MYXOCOCCUS XANTHUS

PHYSIOLOGY

Regulation of directed motility in Myxococcus xanthus. Ward MJ, et al. **Mol Microbiol** 1997 Jun;24(5):885–93 (39 ref.)

MYXOFIBROMA see **FIBROMA**

MYXOID CYST see **SYNOVIAL CYST**

MYXOMA

Familial cardiac myxoma—a comprehensive review of reported cases. Singh SD, et al. **J Ky Med Assoc** 1996 Mar; 94(3):96–104 (43 ref.)

Aggressive angiomyxoma of the scrotum. Sakata K, et al. **Urol Int** 1997;58(4):247–9 (12 ref.)

[Cardiac myxomas and myxosarcomas] Hayashi T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):265–7 (19 ref.) **(Jpn)**

[Mitral valve tumor] Komiyama N. **Ryoikibetsu Shokogun Shirizu** 1996;(14):279–81 (20 ref.) **(Jpn)**

DIAGNOSIS

Primary tumors of the aorta. Das AK, et al. **Ann Thorac Surg** 1996 Nov;62(5):1526–8 (8 ref.)

Fine-needle aspiration cytology findings in a case of aggressive angiomyxoma: a case report and review of the literature. Layfield LJ, et al. **Diagn Cytopathol** 1997 May; 16(5):425–9 (10 ref.)

[Mixoma of maxilla in a child, report of case and review of the literature] Uvo SA, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1996 May–Jun; 51(3):99–102 (22 ref.) (Eng. Abstr.) **(Por)**

[Systemic vasculitis as the initial presentation of a left atrial myxoma] Macedo ME, et al. **Rev Port Cardiol** 1997 May; 16(5):463–6, 441 (14 ref.) (Eng. Abstr.) **(Por)**

PATHOLOGY

Fine-needle aspiration cytology findings in a case of aggressive angiomyxoma: a case report and review of the literature. Layfield LJ, et al. **Diagn Cytopathol** 1997 May; 16(5):425–9 (10 ref.)

Case report of intramuscular myxoma with review of literature. Calton N, et al. **Indian J Pathol Microbiol** 1996 Oct;39(4):299–301 (9 ref.)

A rare case of laryngeal myxoma. Tsunoda K, et al. **J Laryngol Otol** 1997 Mar;111(3):271–3 (6 ref.)

Aggressive angiomyxoma of the perineum in a man. Hong RD, et al. **J Urol** 1997 Mar;157(3):959–60 (3 ref.)

SURGERY

Clinical presentation and treatment options for mitral valve myxoma. Chakfé N, et al. **Ann Thorac Surg** 1997 Sep; 64(3):872–7 (37 ref.)

[Myxoma of the left atrium, Clinical outcome of 100 operated patients] Loire R. **Arch Mal Coeur Vaiss** 1996 Sep; 89(9):1119–25 (26 ref.) (Eng. Abstr.) **(Fre)**

[A case of right ventricular myxoma] Ishikawa T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):645–8 (15 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Angiosarcomas of the interatrial septum mimicking atrial myxomas. Rodrigues AG, et al. **J Am Soc Echocardiogr** 1996 Mar–Apr;9(2):209–12 (10 ref.)

MYXOMA, NERVE SHEATH see **NEUROTHEKEOMA**

MYXOMA VIRUS

GENETICS

Selection of antigens for use in a virus-vectored immunocontraceptive vaccine: PH-20 as a case study. Holland MK, et al. **Reprod Fertil Dev** 1997;9(1):117–24 (22 ref.)

Progress towards using recombinant myxoma virus as a vector for fertility control in rabbits. Robinson AJ, et al. **Reprod Fertil Dev** 1997;9(1):77–83 (43 ref.)

METABOLISM

Myxoma T2 protein as a model for poxvirus TNF receptor homologs. McFadden G, et al. **J Neuroimmunol** 1997 Feb; 72(2):119–26 (47 ref.)

MYXOMATOSIS VIRUS see **MYXOMA VIRUS**

MYXOSARCOMA

[Cardiac myxomas and myxosarcomas] Hayashi T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):265–7 (19 ref.) **(Jpn)**

MYXOVIRUS INFLUENZAE-A HOMINIS see **INFLUENZA A VIRUS, HUMAN**

MYXOVIRUSES see **ORTHOMYXOVIRIDAE**

N-ACETYLNEURAMINIC ACID

CHEMISTRY

[Lipopolysaccharides containing sialic acid] Gamian A. **Postepy Hig Med Dosw** 1996;50(5):459–72 (43 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

The Sialoadhesins—a family of sialic acid-dependent cellular recognition molecules within the immunoglobulin superfamily. Kelm S, et al. **Glycoconj J** 1996 Dec; 13(6):913–26 (114 ref.)

Sialylation of neisserial lipopolysaccharide: a major influence on pathogenicity. Smith H, et al. **Microb Pathog** 1995 Dec; 19(6):365–77 (59 ref.)

PHYSIOLOGY

Sialic acids in molecular and cellular interactions. Kelm S, et al. **Int Rev Cytol** 1997;175:137–240 (660 ref.)

N-CADHERINS see **CADHERINS**

N-MYC GENES see **GENES, MYC**

N-MYC PROTEINS see **PROTO-ONCOGENE PROTEINS C-MYC**

N OMEGA-NITRO-L-ARGININE METHYL ESTER see **NG-NITROARGININE METHYL ESTER**

N-RAS GENES see **GENES, RAS**

NA(+)-H(+)-ANTIPORTER see **SODIUM-HYDROGEN ANTIPORTER**

NA(+)-H(+)-EXCHANGER see **SODIUM-HYDROGEN ANTIPORTER**

NA(+)-K(+)-EXCHANGING ATPASE

Na,K-adenosinetriphosphatase: the paradigm of a membrane transport protein. Kotyk A, et al. **Physiol Res** 1995; 44(5):261–74 (93 ref.)

ANTAGONISTS & INHIBITORS

Endogenous inhibitors of the Na,K pump. Doris PA. **Miner Electrolyte Metab** 1996;22(5–6):303–10 (73 ref.)

BIOSYNTHESIS

Significance of the beta-subunit in the biogenesis of Na+/K(+)-ATPase. Ueno S, et al. **Biosci Rep** 1997 Apr; 17(2):173–88 (73 ref.)

BLOOD

[Determination of Na+, K(+)-ATPase on human red blood cell membranes] Teraoka K, et al. **Nippon Rinsho** 1997 Mar; 55 Suppl 1:88–93 (17 ref.) **(Jpn)**

CHEMISTRY

Modeling of the three-dimensional structure of the digitalis intercalating matrix in Na+/K(+)-ATPase protodimer. Repke KR, et al. **J Enzyme Inhib** 1996;10(3):147–57 (65 ref.)

Structure and function of the Na,K pump: ten years of molecular biology. Pressley TA. **Miner Electrolyte Metab** 1996;22(5–6):264–71 (63 ref.)

[Na, K-ATPase—its structure, function and intracellular transport] Omori K, et al. **Nippon Rinsho** 1996 Mar; 54(3):586–94 (36 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Significance of the beta-subunit in the biogenesis of Na+/K(+)-ATPase. Ueno S, et al. **Biosci Rep** 1997 Apr; 17(2):173–88 (73 ref.)

METABOLISM

Interpretation of extraordinary kinetics of Na(+)-K(+)-ATPase by a phase change. Post RL, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):C1415–23 (60 ref.)

Cellular sodium pumps in hypokalaemic periodic muscle

paralysis. Taylor EA, et al. **Clin Sci (Colch)** 1996 Sep; 91(3):261–4 (28 ref.)
Ion transport in hepatocytes: mechanisms and correlations to cell volume, hormone actions and metabolism. Graf J, et al. **J Hepatol** 1996;24 Suppl 1:53–77 (315 ref.)
The possible role of sodium–potassium adenosine triphosphatase in preterm labour. Du Toit PJ, et al. **Med Hypotheses** 1996 Sep;47(3):197–8 (11 ref.)
Na,K-pump expression and distribution in the nephron. Farman N. **Miner Electrolyte Metab** 1996;22(5–6):272–8 (36 ref.)
Human myocardial Na,K–ATPase concentration in heart failure. Bundgaard H, et al. **Mol Cell Biochem** 1996 Oct–Nov;163–164:277–83 (26 ref.)

PHYSIOLOGY

Relevance of Na,K–ATPase to local extracellular potassium homeostasis and modulation of synaptic transmission. Gloor SM. **FEBS Lett** 1997 Jul 21;412(1):1–4 (46 ref.)
Voltage dependence of the Na/K pump. Rakowski RF, et al. **J Membr Biol** 1997 Jan 15;155(2):105–12 (68 ref.)
Direct regulation of the Na,K pump by signal transduction mechanisms. Middleton JP. **Miner Electrolyte Metab** 1996; 22(5–6):293–302 (84 ref.)
Corticosteroid regulation of renal Na,K–ATPase. Verrey F, et al. **Miner Electrolyte Metab** 1996;22(5–6):279–92 (99 ref.)
Ammonium transport and the role of the Na,K–ATPase. Wall SM. **Miner Electrolyte Metab** 1996;22(5–6):311–7 (43 ref.)
[Molecular and functional diversity of NA,K–ATPase and renal H,K–ATPases] Jaisser F. **Nephrologie** 1996; 17(7):401–8 (43 ref.) (Eng. Abstr.) **(Fre)**
[Na, K–ATPase--its structure, function and intracellular transport] Omori K, et al. **Nippon Rinsho** 1996 Mar; 54(3):586–94 (36 ref.) (Eng. Abstr.) **(Jpn)**

NA(+)-K(+)-TRANSPORTING ATPASE see **NA(+)-K(+)-EXCHANGING ATPASE**

NA-872 see **AMBROXOL**

NAD

ANALOGS & DERIVATIVES

NAD-analogues as potential anticancer agents: conformational restrictions as basis for selectivity. Pankiewicz KW, et al. **Acta Biochim Pol** 1996;43(1):183–93 (72 ref.)

CHEMICAL SYNTHESIS

NAD-analogues as potential anticancer agents: conformational restrictions as basis for selectivity. Pankiewicz KW, et al. **Acta Biochim Pol** 1996;43(1):183–93 (72 ref.)

METABOLISM

Nicotinoprotein alcohol/aldehyde oxidoreductases. Enzymes with bound NAD(P) as cofactor. Piersma SR, et al. **Adv Exp Med Biol** 1997;414:425–34 (29 ref.)
NAD-binding domains of dehydrogenases. Lesk AM. **Curr Opin Struct Biol** 1995 Dec;5(6):775–83 (24 ref.)
The nicotinamide dinucleotide binding motif: a comparison of nucleotide binding proteins. Bellamacina CR. **FASEB J** 1996 Sep;10(11):1257–69 (47 ref.)

NAD+ ADP-RIBOSYLTRANSFERASE

CHEMISTRY

Sequence and structural links between distant ADP-ribosyltransferase families. Bazan JF, et al. **Adv Exp Med Biol** 1997;419:99–107 (38 ref.)
Three conserved consensus sequences identify the NAD-binding site of ADP-ribosylating enzymes, expressed by eukaryotes, bacteria and T-even bacteriophages. Domenighini M, et al. **Mol Microbiol** 1996 Aug;21(4):667–74 (33 ref.)

METABOLISM

Identification of the catalytic site of clostridial ADP-ribosyltransferases. Aktories K. **Adv Exp Med Biol** 1997;419:53–60 (51 ref.)
Activation of toxin ADP-ribosyltransferases by the family of ADP-ribosylation factors. Vaughan M, et al. **Adv Exp Med Biol** 1997;419:315–20 (24 ref.)
ADP-ribosylation and early transcription regulation by bacteriophage T4. Wilkens K, et al. **Adv Exp Med Biol** 1997;419:71–82 (34 ref.)
The recognition of DNA damage. Jackson SP. **Curr Opin Genet Dev** 1996 Feb;6(1):19–25 (66 ref.)
DNA strand breakage and activation of poly-ADP ribosyltransferase: a cytotoxic pathway triggered by peroxynitrite. Szabó C. **Free Radic Biol Med** 1996; 21(6):855–69 (218 ref.)
[Arginine-specific ADP-ribosylation reaction in eukaryotic cells] Tsuchiya M. **Seikagaku** 1996 Sep;68(9):1538–42 (15 ref.) **(Jpn)**

PHYSIOLOGY

Uncovered: the family relationship of a T-cell-membrane protein and bacterial toxins. Koch-Nolte F, et al. **Immunol Today** 1996 Sep;17(9):402–5 (30 ref.)
The role of poly(ADP-ribosyl)ation in the adaptive response. Kleczkowska HE, et al. **Mutat Res** 1996 Nov 4; 358(2):215–21 (40 ref.)

RADIATION EFFECTS

The role of poly(ADP-ribosyl)ation in the adaptive response. Kleczkowska HE, et al. **Mutat Res** 1996 Nov 4; 358(2):215–21 (40 ref.)

NAD-ARGININE ADP-RIBOSYLTRANSFERASE see **NAD(P)(+)-ARGININE ADP-RIBOSYLTRANSFERASE**

NAD DIAPHORASE see **LIPOAMIDE DEHYDROGENASE**

NAD ISOCITRATE DEHYDROGENASE see **ISOCITRATE DEHYDROGENASE**

NAD+ NUCLEOSIDASE

METABOLISM

Metabolism of cyclic ADP-ribose: a new role for NAD+ glycohydrolases. Ziegler M, et al. **Rev Physiol Biochem Pharmacol** 1997;131:89–126 (198 ref.)

NAD(P)H DEHYDROGENASE (QUINONE)

ANTAGONISTS & INHIBITORS

TaClo as a neurotoxic lead: improved synthesis, stereochemical analysis, and inhibition of the mitochondrial respiratory chain. Bringmann G, et al. **J Neural Transm Suppl** 1995;46:245–54 (19 ref.)

CHEMISTRY

Bovine-heart NADH:ubiquinone oxidoreductase is a monomer with 8 Fe-S clusters and 2 FMN groups. Albracht SP, et al. **Biochim Biophys Acta** 1997 Jan 16; 1318(1–2):92–106 (83 ref.)

METABOLISM

Detection and characterization of a complex I-like NADH-specific dehydrogenase from pea thylakoids. Sazanov LA, et al. **Biochem Soc Trans** 1996 Aug; 24(3):739–43 (18 ref.)
Proton-translocation by membrane-bound NADH:ubiquinone-oxidoreductase (complex I) through redox-gated ligand conduction. Brandt U. **Biochim Biophys Acta** 1997 Jan 16;1318(1–2):79–91 (78 ref.)
Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9. Smitskamp-Wilms E, et al. **Gen Pharmacol** 1996 Apr;27(3):421–9 (88 ref.)
[DT-diaphorase] Mikami K, et al. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1606–10 (22 ref.) (Eng. Abstr.) **(Jpn)**

NAD-PROTEIN ADP-RIBOSYLTRANSFERASE see **NAD(P)(+)-ARGININE ADP-RIBOSYLTRANSFERASE**

NADASE see **NAD+ NUCLEOSIDASE**

NADH CYTOCHROME C REDUCTASE see **NADH DEHYDROGENASE**

NADH DEHYDROGENASE

METABOLISM

Superoxide radical generation from heterocyclic amines. Maeda H, et al. **Princess Takamatsu Symp** 1995;23:103–12 (27 ref.)

NADH DIAPHORASE see **LIPOAMIDE DEHYDROGENASE**

NADH, NADPH OXIDOREDUCTASES

Synthetic applications of NAD(P)(H)-dependent enzymes. Carrea G, et al. **Ann N Y Acad Sci** 1996 Oct 12;799:642–9 (18 ref.)

GENETICS

Fre2, a proviral integration site of Friend murine leukemia virus that is closely linked to Fv2. Friedrich RW, et al. **Leukemia** 1997 May;11(5):619–23 (31 ref.)

NADIDE see **NAD**

NADP

ANALOGS & DERIVATIVES

Adenine nucleotide diphosphates: emerging second messengers acting via intracellular Ca2+ release. Dousa TP, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):C1007–24 (136 ref.)
Cyclic ADP-ribose and calcium signaling in eggs. Lee HC. **Biol Signals** 1996 Mar–Apr;5(2):101–10 (58 ref.)
A Ca2+ release mechanism gated by the novel pyridine nucleotide, NAADP. Genazzani AA, et al. **Trends Pharmacol Sci** 1997 Apr;18(4):108–10 (22 ref.)

METABOLISM

Aldose reductase: monosaccharide autoxidation and NADPH binding. Crabbe MJ. **Biochem Soc Trans** 1996 Aug; 24(3):888–91 (40 ref.)
Methods for chromatographic and electrophoretic separation and assay of NADP oxidoreductases. Toribio F, et al. **J Chromatogr B Biomed Appl** 1996 Sep 20;684(1–2):1–23 (214 ref.)

NADP-ARGININE ADP-RIBOSYLTRANSFERASE see **NAD(P)(+)-ARGININE ADP-RIBOSYLTRANSFERASE**

NAD(P)(+)-ARGININE ADP-RIBOSYLTRANSFERASE

CHEMISTRY

Three conserved consensus sequences identify the NAD-binding site of ADP-ribosylating enzymes, expressed by eukaryotes, bacteria and T-even bacteriophages. Domenighini M, et al. **Mol Microbiol** 1996 Aug;21(4):667–74 (33 ref.)
Structure and function of eukaryotic mono-ADP-ribosyltransferases. Okazaki IJ, et al. **Rev Physiol Biochem Pharmacol** 1996;129:51–104 (268 ref.)

GENETICS

Use of the EST database resource to identify and clone novel mono(ADP-ribosyl)transferase gene family members. Braren R, et al. **Adv Exp Med Biol** 1997;419:163–8 (19 ref.)
Mono(ADP-ribosyl)transferase genes and diabetes in NOD mice. Is there a relationship? Cetkovic-Cvrlje M, et al. **Adv Exp Med Biol** 1997;419:217–27 (48 ref.)
Contemplations on the evolution of pro- and eukaryotic mono(ADP-ribosyl) transferases in the context of the immune system. Howard JC. **Adv Exp Med Biol** 1997; 419:453–8 (31 ref.)
Molecular cloning and characterization of the T-cell mono(ADP-ribosyl)transferase RT6. Relationships to other mADPRTs and possible functions. Thiele HG, et al. **Adv Exp Med Biol** 1997;419:109–20 (82 ref.)

IMMUNOLOGY

The T cell marker RT6 in a rat model of autoimmune diabetes. Greiner DL, et al. **Adv Exp Med Biol** 1997; 419:209–16 (42 ref.)

METABOLISM

Arginine-specific mono(ADP-ribosyl)transferase activity in human neutrophil polymorphs. A possible link with the assembly of filamentous actin and chemotaxis. Kefalas P, et al. **Adv Exp Med Biol** 1997;419:241–4 (6 ref.)
Mono(ADP-ribosyl)transferases and related enzymes in animal tissues. Emerging gene families. Koch-Nolte F, et al. **Adv Exp Med Biol** 1997;419:1–13 (63 ref.)
ADP-ribosylarginine hydrolases and ADP-ribosyltransferases. Partners in ADP-ribosylation cycles. Moss J, et al. **Adv Exp Med Biol** 1997;419:25–33 (39 ref.)

PHARMACOLOGY

Mono-ADP-ribosylation: a reversible posttranslational modification of proteins. Okazaki IJ, et al. **Adv Pharmacol** 1996;35:247–80 (149 ref.)

PHYSIOLOGY

Structure and function of eukaryotic mono-ADP-ribosyltransferases. Okazaki IJ, et al. **Rev Physiol Biochem Pharmacol** 1996;129:51–104 (268 ref.)

NADPH OXIDASE

see related **GRANULOMATOUS DISEASE, CHRONIC**

BLOOD

Activation of the phagocyte NADPH oxidase. Takeshige K, et al. **J Toxicol Sci** 1996 Dec;21(5):291–2 (0 ref.)

CHEMISTRY

Assembly of the phagocyte NADPH oxidase: molecular interaction of oxidase proteins. DeLeo FR, et al. **J Leukoc Biol** 1996 Dec;60(6):677–91 (156 ref.)

IMMUNOLOGY

NADPH oxidase and the respiratory burst. Wientjes FB, et al. **Semin Cell Biol** 1995 Dec;6(6):357–65 (82 ref.)

METABOLISM

NADPH oxidase. Shatwell KP, et al.

NADPH OXIDASE

Int J Biochem Cell Biol 1996 Nov;28(11):1191–5 (10 ref.)
Interactions between the components of the human NADPH oxidase: intrigues in the phox family. Leusen JH, et al. **J Lab Clin Med** 1996 Nov;128(5):461–76 (158 ref.)
[Chronic granulomatous disease (CGD): dysfunction of the neutrophil granulocyte NADPH–oxidase enzyme system] Német K, et al. **Orv Hetil** 1997 Feb 16;138(7):397–401 (20 ref.) (Eng. Abstr.) **(Hun)**
[NADPH oxidase––a specialized enzyme complex for the formation of active oxygen metabolites] Kliubin IV, et al. **Tsitologiia** 1997;39(4–5):320–40 (291 ref.) (Eng. Abstr.) **(Rus)**

NADROPARIN

THERAPEUTIC USE

Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. Davis R, et al. **Drugs Aging** 1997 Apr;10(4):299–322 (110 ref.)
[The use of the new anticoagulant Fraxiparin in preventing and treating thromboembolism] Saenko VF, et al. **Klin Khir** 1995;(3):39–41 (31 ref.) **(Rus)**
[Indication and management of anticoagulants in cerebrovascular disease] Biller J. **Rev Neurol** 1997 Jan; 25(137):120–1 (14 ref.) **(Spa)**

NAEGLERIA FOWLERI

ISOLATION & PURIFICATION

Primary amoebic meningoencephalitis with Naegleria fowleri: clinical review. Barnett ND, et al. **Pediatr Neurol** 1996 Oct;15(3):230–4 (22 ref.)

NAFRONYL

PHARMACOLOGY

Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease. Barradell LB, et al. **Drugs Aging** 1996 Apr; 8(4):299–322 (136 ref.)

THERAPEUTIC USE

Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease. Barradell LB, et al. **Drugs Aging** 1996 Apr; 8(4):299–322 (136 ref.)

NAFRONYLOXALATE see **NAFRONYL**

NAFTIDROFURYL see **NAFRONYL**

NAGANA see **TRYPANOSOMIASIS, AFRICAN**

NAIL DISEASES

Nails and nail disorders in children and adults. Noronha PA, et al. **Am Fam Physician** 1997 May 1;55(6):2129–40 (12 ref.)
Subungual exostosis: case report and review of the literature. Davis DA, et al. **Pediatr Dermatol** 1996 May–Jun; 13(3):212–8 (46 ref.)
[Glomus tumor] Uchida M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):481–4 (22 ref.) **(Jpn)**

CHEMICALLY INDUCED

Transverse leukonychia in patients receiving cancer chemotherapy. Chapman S, et al. **South Med J** 1997 Apr; 90(4):395–8 (26 ref.)

COMPLICATIONS

Nailbed injuries with hallucal phalangeal fractures––evaluation and treatment. Tucker DJ, et al. **J Am Podiatr Med Assoc** 1996 Apr;86(4):170–3 (11 ref.)

DIAGNOSIS

Disorders of the nail unit. Albert SF. **Clin Podiatr Med Surg** 1996 Jan;13(1):1–12 (16 ref.)
Yellow nail syndrome. Hershko A, et al. **Postgrad Med J** 1997 Aug;73(862):466–8 (31 ref.)
[Nail polish allergy. An important differential diagnosis in contact dermatitis] Boehncke WH, et al. **Dtsch Med Wochenschr** 1997 Jul 4;122(27):849–52 (12 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Hair & nail problems. Millikan LE. **Compr Ther** 1997 Jul; 23(7):477–81 (7 ref.)
[Brittle nails. Objective assessment and therapy follow–up] Zaun H. **Hautarzt** 1997 Jul;48(7):455–61 (40 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Renal cell carcinoma metastatic to the thumb: a case report and review of subungual metastases from all primary sites. Vine JE, et al. **Clin Exp Dermatol** 1996 Sep;21(5):377–80 (11 ref.)
Subungual nodule as manifestation of multiple myeloma. Borrego L, et al. **Int J Dermatol** 1996 Sep;35(9):661–2 (8 ref.)
Nail lichen striatus: clinical features and long–term follow–up of five patients. Tosti A, et al. **J Am Acad Dermatol** 1997 Jun;36(6 Pt 1):908–13 (14 ref.)
[Melanocytic tumors. Liberal nevus surgery and histopathological scrutiny reduce mortality] Larsson O, et al. **Lakartidningen** 1997 Jul 9;94(28–29):2545–7 (10 ref.) **(Swe)**

THERAPY

Treating common nail problems. Sinclair R. **Aust Fam Physician** 1997 Aug;26(8):948–52 (0 ref.)
Squamous cell carcinoma of the nail bed. Lai CS, et al. **Cutis** 1996 May;57(5):341–5 (25 ref.)

NAIL–PATELLA SYNDROME

DIAGNOSIS

[Kidney involvement in hereditary osteo–onychodysplasia] Kozlovskaia NL, et al. **Ter Arkh** 1997;69(6):37–9 (13 ref.) (Eng. Abstr.) **(Rus)**

NAILING, INTRAMEDULLARY see **FRACTURE FIXATION, INTRAMEDULLARY**

NAILS

Occupational allergic contact dermatitis caused by photobonded sculptured nails and a review of (meth) acrylates in nail cosmetics. Kanerva L, et al. **Am J Contact Dermat** 1996 Jun;7(2):109–15 (45 ref.)
Juvenile xanthogranuloma beneath a fingernail. Chang P, et al. **Cutis** 1996 Aug;58(2):173–4 (14 ref.)
A case of congenital ectopic nails on bilateral little fingers. Iida N, et al. **J Dermatol** 1997 Jan;24(1):38–42 (10 ref.)

ABNORMALITIES

Coffin–Siris syndrome: a case of an extremely low birthweight infant with severe kyphoscoliosis. Suzumura H, et al. **Acta Paediatr Jpn** 1996 Oct;38(5):537–40 (5 ref.)

BLOOD SUPPLY

[Standardization of nailfold capillary microscopy in routine diagnosis] Schmidt JA, et al. **Vasa** 1997;26(1):5–10 (12 ref.) (Eng. Abstr.) **(Ger)**
[Development of instrumental and technical measurement aspects for clinical capillary microscopy] Gasser P, et al. **Z Rheumatol** 1996 Jul–Aug;55(4):260–6 (30 ref.) (Eng. Abstr.) **(Ger)**

INJURIES

Nailbed injuries with hallucal phalangeal fractures––evaluation and treatment. Tucker DJ, et al. **J Am Podiatr Med Assoc** 1996 Apr;86(4):170–3 (11 ref.)

NAILS, MALFORMED

COMPLICATIONS

Hereditary painful callosities with associated features. Cambiaghi S, et al. **Dermatology** 1996;193(1):47–9 (15 ref.)

DIAGNOSIS

[Psoriatic onycho–pachydermo–periostitis (POPP)] Schröder K, et al. **Hautarzt** 1997 Jul;48(7):500–3 (17 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

A case of double fingernail and ectopic fingernail. Muraoka M, et al. **Ann Plast Surg** 1996 Feb;36(2):201–5 (17 ref.)

NAJA NAJA see **COBRA**

NAJA VENOMS see **COBRA VENOMS**

NAKED DNA VACCINES see **VACCINES, DNA**

NALOXONE

PHARMACOLOGY

The effect of naloxone on spontaneous and evoked dopamine release in the central and peripheral nervous systems. Feigenbaum JJ, et al. **Life Sci** 1996;59(24):2009–19 (128 ref.)

THERAPEUTIC USE

The use of antidotes in the management of central nervous system depression. Ferrer A, et al. **Arch Toxicol Suppl** 1997; 19:289–98 (35 ref.)

NALTREXONE

ANALOGS & DERIVATIVES

Dosing issues in the pharmacotherapy of alcoholism. Mason BJ. **Alcohol Clin Exp Res** 1996 Oct;20(7 Suppl):10A–16A (45 ref.)

THERAPEUTIC USE

Naltrexone in the treatment of alcoholism: a clinical review. O'Brien CP, et al. **Alcohol** 1996 Jan–Feb;13(1):35–9 (25 ref.)
Naltrexone for the treatment of alcoholism. Ciraulo AM, et al. **Am Fam Physician** 1997 Sep 1;56(3):803–6 (29 ref.)
Naltrexone in alcohol dependence. Hartmann PM. **Am Fam Physician** 1997 Apr;55(5):1877–9, 1883–4 (31 ref.)
Naltrexone in the treatment of alcoholism. Weinrieb RM, et al. **Annu Rev Med** 1997;48:477–87 (27 ref.)
A risk–benefit assessment of naltrexone in the treatment of alcohol dependence. Berg BJ, et al. **Drug Saf** 1996 Oct; 15(4):274–82 (44 ref.)
Recent developments in the pharmacotherapy of alcohol dependence. Schuckit MA. **J Consult Clin Psychol** 1996 Aug;64(4):669–76 (82 ref.)
Closing the gap between alcoholism research and practice: the case for pharmacotherapy. Meza E, et al. **Psychiatr Serv** 1996 Sep;47(9):917–20 (49 ref.)
Anti–craving compounds for ethanol: new pharmacological tools to study addictive processes. Spanagel R, et al. **Trends Pharmacol Sci** 1997 Feb;18(2):54–9 (76 ref.)
[Naltrexone––prevention of recurrence in narcotic dependence and in alcoholism] Poser W, et al. **Internist (Berl)** 1996 Oct;37(10):1061–7; discussion 1067 (61 ref.) **(Ger)**

L–NAME see **NG–NITROARGININE METHYL ESTER**

NANISM see **DWARFISM**

NANNIZZIA see **MICROSPORUM**

NANNOMONAS see **TRYPANOSOMA**

NAPHTHALENES

ADMINISTRATION & DOSAGE

Oral terbinafine (Lamisil) in the treatment of fungal infections of the skin and nails. Roberts DT. **Dermatology** 1997;194 Suppl 1:37–9 (13 ref.)

ADVERSE EFFECTS

Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: four case reports and a review of drug–induced psoriasis. Gupta AK, et al. **J Am Acad Dermatol** 1997 May;36(5 Pt 2):858–62 (97 ref.)

PHARMACOLOGY

Adapalene. A review of its pharmacological properties and clinical potential in the management of mild to moderate acne. Brogden RN, et al. **Drugs** 1997 Mar;53(3):511–9 (29 ref.)
Pharmacology and chemistry of adapalene. Shroot B, et al. **J Am Acad Dermatol** 1997 Jun;36(6 Pt 2):S96–103 (14 ref.)

THERAPEUTIC USE

Oral terbinafine: a new antifungal agent. Abdel–Rahman SM, et al. **Ann Pharmacother** 1997 Apr;31(4):445–56 (117 ref.)
Tinea pedis: clinical experience and efficacy of short treatment. Evans EG. **Dermatology** 1997;194 Suppl 1:3–6 (13 ref.)
Onychomycosis––treatment, relapse and re–infection. Hull PR. **Dermatology** 1997;194 Suppl 1:7–9 (18 ref.)
Candida: a review of clinical experience with Lamisil. Zaias N. **Dermatology** 1997;194 Suppl 1:10–3 (5 ref.)
Aldose reductase inhibitors: the end of an era or the need for different trial designs? Pfeifer MA, et al. **Diabetes** 1997 Sep;46 Suppl 2:S82–9 (59 ref.)

NAPHTHOLS

PHARMACOLOGY

The role of dopaminergic agonists in congestive heart failure. Semeraro C, et al. **Clin Exp Hypertens** 1997 Jan–Feb; 19(1–2):201–15 (37 ref.)

1–NAPHTHYLAMINE

ANALOGS & DERIVATIVES

The role of sertraline in a patient with recurrent hyponatremia. Catalano G, et al. **Gen Hosp Psychiatry** 1996 Jul;18(4):278–83 (24 ref.)
Depression: making the diagnosis and using SSRIs in the older patient. Reynolds CF 3rd. **Geriatrics** 1996 Oct; 51(10):28–34 (25 ref.)
Sertraline–induced behavioral activation during the treatment of an adolescent with major depression. Guilé JM. **J Child Adolesc Psychopharmacol** 1996 Winter;6(4):281–5 (10 ref.)
Antidepressants in the treatment of premature ejaculation. Balon R. **J Sex Marital Ther** 1996 Summer;22(2):85–96 (51 ref.)
Sertraline–associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature. Bradley ME, et al. **Pharmacotherapy** 1996 Jul–Aug;16(4):680–3 (24 ref.)

1-NAPHTHYLISOTHIOCYANATE

TOXICITY

Neutrophil- and glutathione-mediated hepatotoxicity of alpha-naphthylisothiocyanate. Roth RA, et al. **Drug Metab Rev** 1997 Feb-May;29(1-2):153-65 (44 ref.)

NAPHTHYRIDINES

PHARMACOKINETICS

Trovafloxacin. Haria M, et al. **Drugs** 1997 Sep;54(3):435-45; discussion 446 (48 ref.)

PHARMACOLOGY

The chemistry and biological profile of trovafloxacin. Brighty KE, et al. **J Antimicrob Chemother** 1997 Jun;39 Suppl B:1-14 (67 ref.)

[Recent progress in development of psychotropic drugs (5)--Hypnotics] Ohta T. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Oct; 16(5):161-70 (40 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: current antibiotic therapy in the 1990s. Bradley JS, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S213-21 (58 ref.)

Trovafloxacin. Haria M, et al. **Drugs** 1997 Sep;54(3):435-45; discussion 446 (48 ref.)

NAPHURIDE see **SURAMIN**

NAPROXEN

ADVERSE EFFECTS

Cutaneous reaction to naproxen. Gonzalo Garijo MA, et al. **Allergol Immunopathol (Madr)** 1996 Mar-Apr;24(2):89-92 (14 ref.)

Naproxen sodium. Sutton LB. **J Am Pharm Assoc (Wash)** 1996 Nov;NS36(11):663-7 (15 ref.)

[Leukocytoclastic vasculitis associated with naproxen] Lossos IS, et al. **Harefuah** 1996 May 1;130(9):600-1, 655 (9 ref.) (Eng. Abstr.) **(Heb)**

PHARMACOKINETICS

Clinical pharmacokinetics of naproxen. Davies NM, et al. **Clin Pharmacokinet** 1997 Apr;32(4):268-93 (139 ref.)

NARCISSISM

Long-term psychotherapy in borderline and narcissistic disorders: when is it necessary? Beatson JA. **Aust N Z J Psychiatry** 1995 Dec;29(4):591-7 (37 ref.)

Identifying narcissistic personality disorders in preadolescents. Guilé JM. **Can J Psychiatry** 1996 Aug; 41(6):343-9 (38 ref.)

Antisocial personality disorder, sexual sadism, malignant narcissism, and serial murder. Geberth VJ, et al. **J Forensic Sci** 1997 Jan;42(1):49-60 (54 ref.)

NARCOLEPSY

Narcolepsy. Bassetti C, et al. **Neurol Clin** 1996 Aug; 14(3):545-71 (132 ref.)

DIAGNOSIS

Narcolepsy in children. Kotagal S. **Semin Pediatr Neurol** 1996 Mar;3(1):36-43 (64 ref.)

[Narcolepsy--an unusual cause of abnormal sleepiness in children] Hublin C, et al. **Duodecim** 1995;111(12):1165-70 (24 ref.) **(Fin)**

DRUG THERAPY

Pharmacological aspects of human and canine narcolepsy. Nishino S, et al. **Prog Neurobiol** 1997 May;52(1):27-78 (380 ref.)

ETIOLOGY

Etiologies and sequelae of excessive daytime sleepiness. Roth T, et al. **Clin Ther** 1996 Jul-Aug;18(4):562-76; discussion 561 (83 ref.)

Narcolepsy. Ware JC. **Va Med Q** 1996 Fall;123(4):251-3, 255 (18 ref.)

GENETICS

Genetics of narcolepsy and other sleep disorders. Mignot E. **Am J Hum Genet** 1997 Jun;60(6):1289-302 (199 ref.)

PHYSIOPATHOLOGY

Arousal and locomotion: from schizophrenia to narcolepsy. Garcia-Rill E, et al. **Prog Brain Res** 1996;107:417-34 (73 ref.)

NARCOTIC ANALGESICS see **ANALGESICS, OPIOID**

NARCOTIC ANTAGONISTS

ADMINISTRATION & DOSAGE

Dosing issues in the pharmacotherapy of alcoholism. Mason BJ. **Alcohol Clin Exp Res** 1996 Oct;20(7 Suppl):10A-16A (45 ref.)

PHARMACOLOGY

Peptide and nonpeptide ligands for opioid receptors. Misicka A. **Acta Pol Pharm** 1995 Sep-Oct;52(5):349-63 (128 ref.)

Cyclazocine revisited. Archer S, et al. **Neurochem Res** 1996 Nov;21(11):1369-73 (22 ref.)

[Opioid agonists and antagonists, opioid receptors] Holzgrabe U, et al. **Pharmazie** 1997 Jan;52(1):4-22 (220 ref.) **(Ger)**

THERAPEUTIC USE

Naltrexone in the treatment of alcoholism: a clinical review. O'Brien CP, et al. **Alcohol** 1996 Jan-Feb;13(1):35-9 (25 ref.)

Use of serotonin (5-HT) and opiate-based drugs in the pharmacotherapy of alcohol dependence: an overview of the preclinical data. Lê AD, et al. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:27-32 (55 ref.)

Opioid antagonists in the treatment of alcohol dependence: clinical efficacy and prevention of relapse. O'Malley SS. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:77-81 (20 ref.)

Pharmacotherapies for alcohol problems: a review of research with focus on developments since 1991 [see comments] Litten RZ, et al. **Alcohol Clin Exp Res** 1996 Aug;20(5):859-76 (247 ref.) Comment in: Alcohol Clin Exp Res 1997 Apr;21(2):380.

Naltrexone for the treatment of alcoholism. Ciraulo AM, et al. **Am Fam Physician** 1997 Sep 1;56(3):803-6 (29 ref.)

Naltrexone in alcohol dependence. Hartmann PM. **Am Fam Physician** 1997 Apr;55(5):1877-9, 1883-4 (31 ref.)

Naltrexone in the treatment of alcoholism. Weinrieb RM, et al. **Annu Rev Med** 1997;48:477-87 (27 ref.)

The use of antidotes in the management of central nervous system depression. Ferrer A, et al. **Arch Toxicol Suppl** 1997; 19:289-98 (35 ref.)

A risk-benefit assessment of naltrexone in the treatment of alcohol dependence. Berg BJ, et al. **Drug Saf** 1996 Oct; 15(4):274-82 (44 ref.)

Oral treatments for erectile dysfunction. Riley A. **Int J STD AIDS** 1996;7 Suppl 3:16-8 (12 ref.)

Rapid opioid detoxification using opioid antagonists: history, theory and the state of the art [see comments] Simon DL. **J Addict Dis** 1997;16(1):103-22 (48 ref.) Comment in: J Addict Dis 1997 ;16(1):1-4.

Recent developments in the pharmacotherapy of alcohol dependence. Schuckit MA. **J Consult Clin Psychol** 1996 Aug;64(4):669-76 (82 ref.)

Cyclazocine revisited. Archer S, et al. **Neurochem Res** 1996 Nov;21(11):1369-73 (22 ref.)

Closing the gap between alcoholism research and practice: the case for pharmacotherapy. Meza E, et al. **Psychiatr Serv** 1996 Sep;47(9):917-20 (49 ref.)

Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Spanagel R, et al. **Trends Pharmacol Sci** 1997 Feb;18(2):54-9 (76 ref.)

[Naltrexone--prevention of recurrence in narcotic dependence and in alcoholism] Poser W, et al. **Internist (Berl)** 1996 Oct;37(10):1061-7; discussion 1067 (61 ref.) **(Ger)**

[An approach to the pharmacological treatment of autism] Ruggieri VL. **Rev Neurol** 1996 Nov;24(135):1451-5 (58 ref.) (Eng. Abstr.) **(Spa)**

[Pharmacological treatment of alcohol dependence. Acamprosate and naltrexone offer new approach] Berglund M, et al. **Lakartidningen** 1997 Jul 23;94(30-31):2645-8 (19 ref.) **(Swe)**

NARCOTIC CONTROL see **DRUG AND NARCOTIC CONTROL**

NARCOTIC DEPENDENCE

Opium revisited: a brief review of its nature, composition, non-medical use and relative risks. Kalant H. **Addiction** 1997 Mar;92(3):267-77 (57 ref.)

Prenatal cocaine exposure and mother-infant interaction: implications for occupational therapy intervention. Miller H. **Am J Occup Ther** 1997 Feb;51(2):119-31 (100 ref.)

HIV in illicit drug users. O'Donnell AE. **Clin Chest Med** 1996 Dec;17(4):797-807 (90 ref.)

Maternal cocaine use: impact on child health and development. Frank DA, et al. **Curr Probl Pediatr** 1996 Feb;26(2):57-70 (159 ref.)

The dopamine D4 receptor. Van Tol HH. **NIDA Res Monogr** 1996;161:20-38 (50 ref.)

Opponent process model and psychostimulant addiction. Koob GF, et al. **Pharmacol Biochem Behav** 1997 Jul; 57(3):513-21 (67 ref.)

Opiate and cocaine addictions: challenge for pharmacotherapies. Kreek MJ. **Pharmacol Biochem Behav** 1997 Jul;57(3):551-69 (152 ref.)

[Signal transduction in mechanism of opioid dependence formed in human body and the molecular study] Miki M, et al. **Nippon Yakurigaku Zasshi** 1996 Sep;108(3):111-2 (0 ref.) **(Jpn)**

[Opioid receptor types and dependence] Suzuki T, et al. **Nippon Yakurigaku Zasshi** 1997 Apr;109(4):165-74 (49 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

[Acute myocardial infarct in a young cocaine user] Caires G, et al. **Rev Port Cardiol** 1996 Dec;15(12):885-91, 864 (32 ref.) (Eng. Abstr.) **(Por)**

DIAGNOSIS

Distinguishing passive contamination from active cocaine consumption: assessing the occupational exposure of narcotics officers to cocaine. Mieczkowski T. **Forensic Sci Int** 1997 Jan 17;84(1-3):87-111 (47 ref.)

DRUG THERAPY

Opiate-dependent patients receiving methadone. How physicians should manage therapy. Kahan M, et al. **Can Fam Physician** 1996 Sep;42:1769-78 (47 ref.)

Managing drug misusers--a guide. Kemp K, et al. **Practitioner** 1996 May;240(1562):326-8, 330, 333-4 (8 ref.)

EPIDEMIOLOGY

Alcohol and cocaine interactions and aggressive behaviors. Denison ME, et al. **Recent Dev Alcohol** 1997;13:283-303 (31 ref.)

GENETICS

Knockout mice and dirty drugs. Drug addiction. Uhl GR, et al. **Curr Biol** 1996 Aug 1;6(8):935-6 (15 ref.)

METABOLISM

Understanding drug addiction: implications for treatment [see comments] Leshner AI. **Hosp Pract (Off Ed)** 1996 Oct 15; 31(10):47-54, 57-9 (8 ref.) Comment in: Hosp Pract (Off Ed) 1997 Mar 15;32(3):41.

Neuropsychological abnormalities in cocaine abusers: possible correlates in SPECT neuroimaging. Kosten TR, et al. **NIDA Res Monogr** 1996;163:175-92 (40 ref.)

PET studies of cerebral glucose metabolism: acute effects of cocaine and long-term deficits in brains of drug abusers. London ED, et al. **NIDA Res Monogr** 1996;163:146-58 (52 ref.)

PATHOLOGY

Imaging studies of cocaine in the human brain and studies of the cocaine addict. Volkow ND, et al. **Ann N Y Acad Sci** 1997 May 30;820:41-54; discussion 54-5 (50 ref.)

Cocaine addiction as a neurological disorder: implications for treatment. Majewska MD. **NIDA Res Monogr** 1996; 163:1-26 (124 ref.)

PHYSIOPATHOLOGY

Cocaine, Neuroleptics, and tardive dyskinesia as paleocortical escape. Howard JS 3rd. **Integr Physiol Behav Sci** 1996 Oct-Dec;31(4):306-14 (33 ref.)

Psychomotor and electroencephalographic sequelae of cocaine dependence. Bauer LO. **NIDA Res Monogr** 1996; 163:66-93 (83 ref.)

Cocaine effects on dopamine and opioid peptide neural systems: implications for human cocaine abuse. Hurd YL. **NIDA Res Monogr** 1996;163:94-116 (114 ref.)

Psychopharmacologic violence associated with cocaine abuse: kindling of a limbic dyscontrol syndrome? Davis WM. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Nov;20(8):1273-300 (143 ref.)

PSYCHOLOGY

Psychomotor and electroencephalographic sequelae of cocaine dependence. Bauer LO. **NIDA Res Monogr** 1996; 163:66-93 (83 ref.)

Is craving mood-driven or self-propelled? Sensitization and "street" stimulant addiction. Gawin FH, et al. **NIDA Res Monogr** 1996;163:224-50 (37 ref.)

Cocaine effects on dopamine and opioid peptide neural systems: implications for human cocaine abuse. Hurd YL. **NIDA Res Monogr** 1996;163:94-116 (114 ref.)

Neuropsychological abnormalities in cocaine abusers: possible correlates in SPECT neuroimaging. Kosten TR, et al. **NIDA Res Monogr** 1996;163:175-92 (40 ref.)

Psychopharmacologic violence associated with cocaine abuse: kindling of a limbic dyscontrol syndrome? Davis WM. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Nov;20(8):1273-300 (143 ref.)

REHABILITATION

Some potential contributions of reinforcement and consumer-demand theory to reducing cocaine use. Higgins ST. **Addict Behav** 1996 Nov-Dec;21(6):803-16 (50 ref.)

Prenatal cocaine exposure and mother-infant interaction: implications for occupational therapy intervention. Miller H. **Am J Occup Ther** 1997 Feb;51(2):119-31 (100 ref.)

Helping patients who misuse drugs. **Drug Ther Bull** 1997 Mar; 35(3):18-22 (25 ref.)

Rapid opioid detoxification using opioid antagonists: history, theory and the state of the art [see comments] Simon DL. **J Addict Dis** 1997;16(1):103-22 (48 ref.) Comment in: J Addict Dis 1997 ;16(1):1-4.

NARCOTIC DEPENDENCE

[Naltrexone--prevention of recurrence in narcotic dependence and in alcoholism] Poser W, et al. **Internist (Berl)** 1996 Oct;37(10):1061–7; discussion 1067 (61 ref.) **(Ger)**

THERAPY

Understanding drug addiction: implications for treatment [see comments] Leshner AI. **Hosp Pract (Off Ed)** 1996 Oct 15; 31(10):47–54, 57–9 (8 ref.) Comment in: Hosp Pract (Off Ed) 1997 Mar 15;32(3):41.

NARCOTIC LAWS see **LEGISLATION, DRUG**

NARCOTIC RECEPTORS see **RECEPTORS, OPIOID**

NARCOTICS

see related
ANALGESICS, OPIOID
COCAINE
NARCOTIC DEPENDENCE
RECEPTORS, OPIOID

Opium revisited: a brief review of its nature, composition, non-medical use and relative risks. Kalant H. **Addiction** 1997 Mar;92(3):267–77 (57 ref.)

Drugs in East Germany. Dressler J, et al. **Am J Forensic Med Pathol** 1997 Sep;18(3):303–5 (14 ref.)

Maternal cocaine use: impact on child health and development. Frank DA, et al. **Curr Probl Pediatr** 1996 Feb;26(2):57–70 (159 ref.)

Opioid and benzodiazepine tolerance and dependence: application of theory to critical care practice. Puntillo K, et al. **Heart Lung** 1997 Jul–Aug;26(4):317–24 (32 ref.)

Postoperative pain management. d'Amours RH, et al. **J Orthop Sports Phys Ther** 1996 Oct;24(4):227–36 (65 ref.)

Pharmacotherapy for opioid and cocaine abuse. Warner EA, et al. **Med Clin North Am** 1997 Jul;81(4):909–25 (115 ref.)

Feeding, drug abuse, and the sensitization of reward by metabolic need. Carr KD. **Neurochem Res** 1996 Nov; 21(11):1455–67 (107 ref.)

Opioid receptors: some perspectives from early studies of their role in normal physiology, stress responsivity, and in specific addictive diseases. Kreek MJ. **Neurochem Res** 1996 Nov;21(11):1469–88 (139 ref.)

Association of enkephalin catabolism inhibitors and CCK-B antagonists: a potential use in the management of pain and opioid addiction. Roques BP, et al. **Neurochem Res** 1996 Nov;21(11):1397–410 (116 ref.)

Reinforcement processes in opiate addiction: a homeostatic model. Schulteis G, et al. **Neurochem Res** 1996 Nov; 21(11):1437–54 (133 ref.)

Psychomotor and electroencephalographic sequelae of cocaine dependence. Bauer LO. **NIDA Res Monogr** 1996; 163:66–93 (83 ref.)

Neuropsychological abnormalities in cocaine abusers: possible correlates in SPECT neuroimaging. Kosten TR, et al. **NIDA Res Monogr** 1996;163:175–92 (40 ref.)

Cocaine addiction as a neurological disorder: implications for treatment. Majewska MD. **NIDA Res Monogr** 1996; 163:1–26 (124 ref.)

Chronic cocaine use as a neuropsychiatric syndrome: a model for debate. Cadet JL, et al. **Synapse** 1996 Jan;22(1):28–34 (77 ref.)

ADMINISTRATION & DOSAGE

Effects on mouse thymocyte biology: a mini-overview with some new evidence. Ou DW, et al. **Adv Exp Med Biol** 1996;402:157–63 (22 ref.)

Intrathecal narcotics for labor analgesia. Stephens MB, et al. **Am Fam Physician** 1997 Aug;56(2):463–70 (27 ref.)

Clinicians' attitudes about prolonged use of opioids and the issue of patient heterogeneity. Turk DC. **J Pain Symptom Manage** 1996 Apr;11(4):218–30 (51 ref.)

ADVERSE EFFECTS

Should people taking opioids for medical reasons be allowed to work and drive? [editorial] Zacny JP. **Addiction** 1996 Nov;91(11):1581–4 (16 ref.)

HIV-1 neuropathogenesis and abused drugs: current reviews, problems, and solutions. Shapshak P, et al. **Adv Exp Med Biol** 1996;402:171–86 (122 ref.)

Withdrawal strategies for outpatients. Alcohol, benzodiazepine, barbiturate, and opiate addictions. Mezciems PE. **Can Fam Physician** 1996 Sep;42:1745–52 (27 ref.)

Diagnosis and management of opioid- and benzodiazepine-induced comatose overdose in children. Perry HE, et al. **Curr Opin Pediatr** 1996 Jun;8(3):243–7 (36 ref.)

Distinguishing passive contamination from active cocaine consumption: assessing the occupational exposure of narcotics officers to cocaine. Mieczkowski T. **Forensic Sci Int** 1997 Jan 17;84(1-3):87–111 (47 ref.)

Effect of occupational exposure to opiates on the respiratory system. Górski P, et al. **Int J Occup Med Environ Health** 1996;9(3):245–53 (48 ref.)

Cocaine withdrawal alters regulatory elements of dopamine neurons. Pilotte NS, et al. **NIDA Res Monogr** 1996; 163:193–202 (34 ref.)

Where is the locus in opioid withdrawal? Christie MJ, et al. **Trends Pharmacol Sci** 1997 Apr;18(4):134–40 (73 ref.)

[Nephropathy induced by stimulants and narcotics (heroin, amphetamine, etc)] Hashimoto K, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):526–8 (9 ref.) **(Jpn)**

ANALYSIS

Quality control by the Society of Hair Testing. Sachs H. **Forensic Sci Int** 1997 Jan 17;84(1-3):145–50 (4 ref.)

CHEMISTRY

Analysis of organic volatile impurities as a forensic tool for the examination of bulk pharmaceuticals. Mulligan KJ, et al. **J Chromatogr B Biomed Appl** 1996 Nov 8;686(1):85–95 (46 ref.)

ECONOMICS

Treatment as harm reduction, defunding as harm maximization: the case of methadone maintenance. Rosenbaum M, et al. **J Psychoactive Drugs** 1996 Jul–Sep; 28(3):241–9 (21 ref.)

ISOLATION & PURIFICATION

Supercritical fluid extraction and hair analysis: the situation in 1996. Staub C. **Forensic Sci Int** 1997 Jan 17; 84(1-3):295–304 (10 ref.)

METABOLISM

A novel view of opiate tolerance. Stefano GB, et al. **Adv Neuroimmunol** 1996;6(3):265–77 (46 ref.)

Opioid and opiate immunoregulatory processes. Stefano GB, et al. **Crit Rev Immunol** 1996;16(2):109–44 (258 ref.)

PHARMACOKINETICS

The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Milne RW, et al. **Drug Metab Rev** 1996 Aug;28(3):345–472 (489 ref.)

PHARMACOLOGY

Peptide and nonpeptide ligands for opioid receptors. Misicka A. **Acta Pol Pharm** 1995 Sep–Oct;52(5):349–63 (128 ref.)

Addictive drugs and brain stimulation reward. Wise RA. **Annu Rev Neurosci** 1996;19:319–40 (202 ref.)

Neural mechanisms of tolerance to the effects of cocaine. Hammer RP Jr, et al. **Behav Brain Res** 1997 Mar; 84(1-2):225–39 (155 ref.)

Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. Richardson NR, et al. **J Neurosci Methods** 1996 May; 66(1):1–11 (60 ref.)

Melanocortins and opiate addiction. Alvaro JD, et al. **Life Sci** 1997;61(1):1–9 (73 ref.)

Opiates, opioids and addiction. Kreek MJ. **Mol Psychiatry** 1996 Jul;1(3):232–54 (158 ref.)

Effects of opioids on the immune system. Roy S, et al. **Neurochem Res** 1996 Nov;21(11):1375–86 (71 ref.)

Stimulatory effects of opioids on transmitter release and possible cellular mechanisms: overview and original results. Sarne Y, et al. **Neurochem Res** 1996 Nov;21(11):1353–61 (113 ref.)

Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence. Maldonado R. **Neurosci Biobehav Rev** 1997 Jan; 21(1):91–104 (137 ref.)

Cocaine effects on dopamine and opioid peptide neural systems: implications for human cocaine abuse. Hurd YL. **NIDA Res Monogr** 1996;163:94–116 (114 ref.)

Pharmacotherapy of opioids: present and future developments. Meert TF. **Pharm World Sci** 1996 Jan; 18(1):1–15 (136 ref.)

Opiate and cocaine addictions: challenge for pharmacotherapies. Kreek MJ. **Pharmacol Biochem Behav** 1997 Jul;57(3):551–69 (152 ref.)

Psychostimulant abuse: the case for combined behavioral and pharmacological treatments. Stitzer ML, et al. **Pharmacol Biochem Behav** 1997 Jul;57(3):457–70 (96 ref.)

The relevance of opioids and opioid receptors on immunocompetence and immune homeostasis. Carr DJ, et al. **Proc Soc Exp Biol Med** 1996 Dec;213(3):248–57 (97 ref.)

Studies on the opioid mechanism in Tetrahymena. Renaud FL, et al. **Prog Mol Subcell Biol** 1996;17:29–39 (27 ref.)

Individual and combined effects of ethanol and cocaine on intracellular signals and gene expression. Torres G, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 May; 20(4):561–96 (154 ref.)

Discriminative stimulus and subjective effects of opioids with mu and kappa activity: data from laboratory animals and human subjects. Dykstra LA, et al. **Psychopharmacology (Berl)** 1997 Mar;130(1):14–27 (94 ref.)

The role of cholecystokinin in nociception, neuropathic pain and opiate tolerance. Wiesenfeld-Hallin Z, et al. **Regul Pept** 1996 Aug 27;65(1):23–8 (59 ref.)

The stimulatory effects of opioids and their possible role in the development of tolerance. Smart D, et al. **Trends Pharmacol Sci** 1996 Jul;17(7):264–9 (58 ref.)

[Cellular mechanism of opioid tolerance] Liaw WJ, et al. **Acta Anaesthesiol Sin** 1996 Dec;34(4):221–34 (114 ref.) (Eng. Abstr.) **(Chi)**

[Opioid agonists and antagonists, opioid receptors] Holzgrabe U, et al. **Pharmazie** 1997 Jan;52(1):4–22 (220 ref.) **(Ger)**

THERAPEUTIC USE

Opiate-dependent patients receiving methadone. How physicians should manage therapy. Kahan M, et al. **Can Fam Physician** 1996 Sep;42:1769–78 (47 ref.)

Mainstreaming methadone maintenance treatment: the role of the family physician [editorial] Latowsky M, et al. **CMAJ** 1997 Aug 15;157(4):395–8 (31 ref.)

Opioid therapy for chronic nonmalignant pain: a review of the critical issues. Portenoy RK. **J Pain Symptom Manage** 1996 Apr;11(4):203–17 (169 ref.)

Improving detoxification outcomes from methadone maintenance treatment: the interrelationship of affective states and protracted withdrawal. Latowsky M. **J Psychoactive Drugs** 1996 Jul–Sep;28(3):251–7 (58 ref.)

Motivational factors in cocaine pharmacotherapy trials with methadone-maintained patients: problems and paradoxes. Margolin A, et al. **J Psychoactive Drugs** 1997 Apr–Jun; 29(2):205–12 (50 ref.)

Treatment as harm reduction, defunding as harm maximization: the case of methadone maintenance. Rosenbaum M, et al. **J Psychoactive Drugs** 1996 Jul–Sep; 28(3):241–9 (21 ref.)

Effects of opioids on the immune system. Roy S, et al. **Neurochem Res** 1996 Nov;21(11):1375–86 (71 ref.)

Postoperative pain management. Tobias JD. **Pediatr Ann** 1997 Aug;26(8):490–500 (23 ref.)

[The problem of opioid tolerance and dependence during clinical use thereof] Osipova NA. **Anesteziol Reanimatol** 1996 Jul–Aug;(4):17–21 (26 ref.) (Eng. Abstr.) **(Rus)**

TOXICITY

Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Mello NK, et al. **Neuropsychopharmacology** 1996 Jun;14(6):375–424 (288 ref.)

Neurologic complications of cocaine. Daras M. **NIDA Res Monogr** 1996;163:43–65 (177 ref.)

Comparability of human and animal studies of developmental cocaine exposure. Dow-Edwards D. **NIDA Res Monogr** 1996;164:146–74 (97 ref.)

The neurotoxic effects of continuous cocaine and amphetamine in Habenula: implications for the substrates of psychosis. Ellison G, et al. **NIDA Res Monogr** 1996; 163:117–45 (72 ref.)

Immunotoxicology of opioids, inhalants, and other drugs of abuse. House RV, et al. **NIDA Res Monogr** 1997; 173:175–200 (51 ref.)

Exposure to opiates: behavioral outcomes in preschool and school-age children. Kaltenbach KA. **NIDA Res Monogr** 1996;164:230–41 (30 ref.)

PET studies of cerebral glucose metabolism: acute effects of cocaine and long-term deficits in brains of drug abusers. London ED, et al. **NIDA Res Monogr** 1996;163:146–58 (52 ref.)

Exposure to cocaine: behavioral outcomes in preschool and school-age children. Mayes LC. **NIDA Res Monogr** 1996; 164:211–29 (55 ref.)

The effects of prenatal cocaine exposure on subsequent learning in the rat. Riley EP, et al. **NIDA Res Monogr** 1996;164:53–77 (13 ref.)

Assessment of the effects of developmental toxicants: pharmacological and stress vulnerability of offspring. Spear LP. **NIDA Res Monogr** 1996;164:125–45 (42 ref.)

Long-term effects of developmental exposure to cocaine on learned and unlearned behaviors. Vorhees CV. **NIDA Res Monogr** 1996;164:3–52 (61 ref.)

Monoamine transporters and the neurobehavioral teratology of cocaine. Meyer JS, et al. **Pharmacol Biochem Behav** 1996 Dec;55(4):585–93 (108 ref.)

URINE

Stimulants, narcotics and beta-blockers: 25 years of development in analytical techniques for doping control. Hemmersbach P, et al. **J Chromatogr B Biomed Appl** 1996 Dec 6;687(1):221–38 (107 ref.)

NASAL BONE

see related
RHINOPLASTY

NASAL CAVITY

Otolaryngological manifestation of Gorlin Goltz syndrome. al-Anazy FH, et al. **J Laryngol Otol** 1997 Mar;111(3):286–9 (10 ref.)

Oncocytoma of the nasal cavity: report of a case and review of the literature. Comin CE, et al. **J Laryngol Otol** 1997 Jul;111(7):671–3 (13 ref.)

Cystic lesions of the nasal cavity and the paranasal sinuses: report of two unusual cases. Vele DD, et al. **J Laryngol Otol** 1996 Dec;110(12):1157–60 (7 ref.)

[Imaging of non-osseous malignant tumors of the anterior skull base. Preoperative evaluation] Elkeslassy A, et al. **Neurochirurgie** 1997;43(2):68–75 (47 ref.) (Eng. Abstr.) **(Fre)**

[Two cases of pleomorphic adenoma of the nasal cavity] Wakami S, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1996

Jan;99(1):38–45 (60 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

A brief review of formaldehyde carcinogenesis in relation to rat nasal pathology and human health risk assessment. Morgan KT. **Toxicol Pathol** 1997 May–Jun;25(3):291–307 (142 ref.)

PATHOLOGY

Squamous carcinoma of the nasal vestibule: an analysis of five cases and literature review. Taxy JB. **Am J Clin Pathol** 1997 Jun;107(6):698–703 (10 ref.)

Tumours of the nasal cavity. Schuller HM. **IARC Sci Publ** 1996;(126):175–87 (28 ref.)

Osteoblastoma of the nasal cavity invading the anterior skull base in a young child. Case report. Imai K, et al. **J Neurosurg** 1997 Oct;87(4):625–8 (9 ref.)

A brief review of formaldehyde carcinogenesis in relation to rat nasal pathology and human health risk assessment. Morgan KT. **Toxicol Pathol** 1997 May–Jun;25(3):291–307 (142 ref.)

PHYSIOLOGY

Nasal physiology: neurochemical receptors, nasal cycle, and ciliary action. Lund VJ. **Allergy Asthma Proc** 1996 Jul–Aug;17(4):179–84 (29 ref.)

Pheromone transduction in the vomeronasal organ. Liman ER. **Curr Opin Neurobiol** 1996 Aug;6(4):487–93 (63 ref.)

PHYSIOPATHOLOGY

[Presumed physiopathology of the nasal wall surgery and contemporary techniques of the inferior turbinates surgery] Passàli D, et al. **Acta Otorhinolaryngol Ital** 1996 Jun;16(3):202–10 (61 ref.) (Eng. Abstr.) **(Ita)**

RADIOGRAPHY

Current status and new developments in techniques for imaging the nose and sinuses. Phillips CD. **Otolaryngol Clin North Am** 1997 Jun;30(3):371–87 (66 ref.)

SURGERY

[Presumed physiopathology of the nasal wall surgery and contemporary techniques of the inferior turbinates surgery] Passàli D, et al. **Acta Otorhinolaryngol Ital** 1996 Jun;16(3):202–10 (61 ref.) (Eng. Abstr.) **(Ita)**

NASAL LAVAGE FLUID

CHEMISTRY

Nasal lavage biomarkers in air pollution epidemiology. Steerenberg PA, et al. **Arch Toxicol Suppl** 1997;19:207–16 (35 ref.)

The use of nasal lavage for objective measurement of irritant-induced nasal inflammation. Peden DB. **Regul Toxicol Pharmacol** 1996 Aug;24(1 Pt 2):S76–8 (23 ref.)

NASAL MUCOSA

Nasal physiology: neurochemical receptors, nasal cycle, and ciliary action. Lund VJ. **Allergy Asthma Proc** 1996 Jul–Aug;17(4):179–84 (29 ref.)

[Surgery of primary malignant melanomas of the mucosa of the nasal fossa and facial sinuses] Laccourreye O, et al. **Ann Otolaryngol Chir Cervicofac** 1996;113(3):163–9 (30 ref.) (Eng. Abstr.) **(Fre)**

BLOOD SUPPLY

Extravasation, lamina propria flooding and lumenal entry of bulk plasma exudate in mucosal defence, inflammation and repair. Persson CG, et al. **Pulm Pharmacol** 1996 Jun;9(3):129–39 (69 ref.)

[Significance of vascular endothelium for specific functional behavior of nasal mucosa] Grevers G, et al. **Laryngorhinootologie** 1997 Jul;76(7):398–404 (24 ref.) (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

Steroid UDP glucuronosyltransferases: characterization and regulation. Mackenzie PI, et al. **J Endocrinol** 1996 Sep;150 Suppl:S79–86 (52 ref.)

IMMUNOLOGY

Immune functions and immunopathology of the mucosa of the upper respiratory pathways. Brandtzaeg P, et al. **Acta Otolaryngol (Stockh)** 1996 Mar;116(2):149–59 (72 ref.)

Clinical efficacy and safety of local nasal immunotherapy. Andri L, et al. **Allergy** 1997;52(33 Suppl):36–9 (38 ref.)

Molecular events in allergic inflammation: experimental models and possible modulation. Canonica GW, et al. **Allergy** 1997;52(34 Suppl):25–30 (46 ref.)

Local nasal immunotherapy: experimental evidences and general considerations. Passalacqua G, et al. **Allergy** 1997;52(33 Suppl):10–6 (32 ref.)

Monitoring methods for local nasal immunotherapy. Passali D, et al. **Allergy** 1997;52(33 Suppl):22–5 (13 ref.)

Nasal sensitization. Van Cauwenberge PB. **Allergy** 1997;52(33 Suppl):7–9 (13 ref.)

Nasal tolerance to dominant and subdominant epitopes of collagen type II and protection against collagen-induced arthritis. Staines NA, et al. **Biochem Soc Trans** 1997 May;25(2):661–4 (32 ref.)

Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system. Wu HY, et al. **Immunol Res** 1997;16(2):187–201 (88 ref.)

METABOLISM

Pharmacokinetics of allergens after local administration. Falagiani P, et al. **Allergy** 1997;52(33 Suppl):17–21 (17 ref.)

Nasal delivery of vaccines. Almeida AJ, et al. **J Drug Target** 1996;3(6):455–67 (125 ref.)

In vitro nasal models. Reardon PM. **Pharm Biotechnol** 1996;8:309–23 (36 ref.)

MICROBIOLOGY

Effects of viral and bacterial infection on nasal and sinus mucosa. van Cauwenberge P, et al. **Acta Otolaryngol (Stockh)** 1996 Mar;116(2):316–21 (25 ref.)

Preventing staphylococcal infections by eradicating nasal carriage of Staphylococcus aureus: proceeding with caution [editorial; comment] Boyce JM. **Infect Control Hosp Epidemiol** 1996 Dec;17(12):775–9 (50 ref.) Comment on: Infect Control Hosp Epidemiol 1996 Dec;17(12):780–5. Comment on: Infect Control Hosp Epidemiol 1996 Dec;17(12):786–92. Comment on: Infect Control Hosp Epidemiol 1996 Dec;17(12):813–6.

PATHOLOGY

[Clinical and laboratory features of 100 patients with perennial allergic rhinitis] Segura Méndez NH, et al. **Rev Alerg Mex** 1993 Sep–Oct;40(5):110–3 (20 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Perireceptor events in olfaction. Pelosi P. **J Neurobiol** 1996 May;30(1):3–19 (99 ref.)

SECRETION

A case of gustatory rhinorrhoea. Franceschini SS, et al. **Rhinology** 1997 Mar;35(1):41–3 (15 ref.)

VIROLOGY

Effects of viral and bacterial infection on nasal and sinus mucosa. van Cauwenberge P, et al. **Acta Otolaryngol (Stockh)** 1996 Mar;116(2):316–21 (25 ref.)

NASAL OBSTRUCTION

COMPLICATIONS

Nasal obstruction and obstructive sleep apnea: a review. Kushida CA, et al. **Allergy Asthma Proc** 1997 Mar–Apr;18(2):69–71 (27 ref.)

DIAGNOSIS

Snoring: analysis, measurement, clinical implications and applications. Dalmasso F, et al. **Eur Respir J** 1996 Jan;9(1):146–59 (92 ref.)

[Modern functional diagnosis of the nose and paranasal sinuses] Deitmer T. **Eur Arch Otorhinolaryngol Suppl** 1996;1:1–71 (447 ref.) **(Ger)**

ETIOLOGY

Birth trauma causing nasal vestibular stenosis. Jablon JH, et al. **Arch Otolaryngol Head Neck Surg** 1997 Sep;123(9):1004–6 (10 ref.)

[Clinical aspects of environmental illnesses of the nose and paranasal sinuses--science and clinical practice] Bachert C. **Eur Arch Otorhinolaryngol Suppl** 1996;1:73–153 (651 ref.) **(Ger)**

PHYSIOPATHOLOGY

[Applications of modern image data processing in clinico-rhinologic research] Weber R, et al. **Eur Arch Otorhinolaryngol Suppl** 1996;1:271–96 (332 ref.) **(Ger)**

SURGERY

Neonatal septoplasty: case report and review of the literature. Emami AJ, et al. **Int J Pediatr Otorhinolaryngol** 1996 May;35(3):271–5 (12 ref.)

NASAL POLYPS

DRUG THERAPY

Nasal polyps treatment: medical management. Mygind N, et al. **Allergy Asthma Proc** 1996 Sep–Oct;17(5):275–82 (41 ref.)

Nasal polyps: medical or surgical management? Holmberg K, et al. **Clin Exp Allergy** 1996 May;26 Suppl 3:23–30 (82 ref.)

Intranasal fluticasone propionate. A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis. Wiseman LR, et al. **Drugs** 1997 May;53(5):885–907 (114 ref.)

EPIDEMIOLOGY

Epidemiology of nasal polyps. Settipane GA. **Allergy Asthma Proc** 1996 Sep–Oct;17(5):231–6 (32 ref.)

ETIOLOGY

Eosinophils in the pathophysiology of nasal polyposis. Jankowski R. **Acta Otolaryngol (Stockh)** 1996 Mar;116(2):160–3 (25 ref.)

Allergic fungal sinusitis/polyposis. Bent JP 3rd, et al. **Allergy Asthma Proc** 1996 Sep–Oct;17(5):259–68 (30 ref.)

Nasal polyps: relationship to infection and inflammation. Stierna PL. **Allergy Asthma Proc** 1996 Sep–Oct;17(5):251–7 (24 ref.)

IMMUNOLOGY

Nasal polyps and immunoglobulin E (IgE). Settipane GA. **Allergy Asthma Proc** 1996 Sep–Oct;17(5):269–73 (28 ref.)

PATHOLOGY

Nasal polyps update. Histopathology. Hellquist HB. **Allergy Asthma Proc** 1996 Sep–Oct;17(5):237–42 (16 ref.)

Rhinosporodium: case report. Ashiru JO, et al. **East Afr Med J** 1996 Jun;73(6):414–5 (16 ref.)

PHYSIOPATHOLOGY

[Applications of modern image data processing in clinico-rhinologic research] Weber R, et al. **Eur Arch Otorhinolaryngol Suppl** 1996;1:271–96 (332 ref.) **(Ger)**

RADIOGRAPHY

Choanal polyp of sphenoidal origin. Report of two cases. Eloy P, et al. **Acta Otorhinolaryngol Belg** 1996;50(3):183–9 (22 ref.)

SURGERY

Nasal polyps: medical or surgical management? Holmberg K, et al. **Clin Exp Allergy** 1996 May;26 Suppl 3:23–30 (82 ref.)

NASAL PROVOCATION TESTS

Various methods for testing nasal responses in vivo: a critical review. Andersson M, et al. **Acta Otolaryngol (Stockh)** 1995 Nov;115(6):705–13 (68 ref.)

Monitoring methods for local nasal immunotherapy. Passali D, et al. **Allergy** 1997;52(33 Suppl):22–5 (13 ref.)

STANDARDS

Challenge tests in nose and bronchi: pharmacological modulation of rhinitis and asthma. Mygind N, et al. **Clin Exp Allergy** 1996 May;26 Suppl 3:39–43 (35 ref.)

NASAL SEPTUM

Microcystic adnexal carcinoma. Kirkland PM, et al. **J Laryngol Otol** 1997 Jul;111(7):674–5 (5 ref.)

ANATOMY & HISTOLOGY

Review of the functional anatomy of the cartilages and muscles of the nose. Bruintjes TD, et al. **Rhinology** 1996 Jun;34(2):66–74 (54 ref.)

INJURIES

Neonatal septoplasty: case report and review of the literature. Emami AJ, et al. **Int J Pediatr Otorhinolaryngol** 1996 May;35(3):271–5 (12 ref.)

PHYSIOLOGY

Pheromone transduction in the vomeronasal organ. Liman ER. **Curr Opin Neurobiol** 1996 Aug;6(4):487–93 (63 ref.)

SURGERY

Neonatal septoplasty: case report and review of the literature. Emami AJ, et al. **Int J Pediatr Otorhinolaryngol** 1996 May;35(3):271–5 (12 ref.)

External septoplasty in children. Crysdale WS. **J Otolaryngol** 1996 Aug;25(4):257–60 (4 ref.)

[Modern corrective nasoseptal surgery] Palma P, et al. **Acta Otorhinolaryngol Ital** 1996 Jun;16(3):211–24 (45 ref.) (Eng. Abstr.) **(Ita)**

NASAL SINUSES see **PARANASAL SINUSES**

NASAL WASHINGS see **NASAL LAVAGE FLUID**

NASOLACRIMAL DUCT

Dacryocystocele in an adult: endoscopic management. Bhaya M, et al. **Am J Otolaryngol** 1997 Mar–Apr;18(2):131–4 (24 ref.)

Nasolacrimal drainage system cyst in an adult. Yamasoba T, et al. **ORL J Otorhinolaryngol Relat Spec** 1996 Nov–Dec;58(6):311–4 (8 ref.)

NASOLACRIMAL DUCT

PATHOLOGY

Normal anatomy and lesions of the lacrimal sac and duct: evaluated by dacryocystography, computed tomography, and MR imaging. Weber AL, et al.
Neuroimaging Clin N Am 1996 Feb;6(1):199–217 (122 ref.)

NASOPHARYNGEAL DISEASES

DIAGNOSIS

Paraorbital lesions. Sanchez R, et al. **Eur J Radiol** 1996 Mar; 22(1):53–67 (30 ref.)

PATHOLOGY

Primary nasopharyngeal tuberculosis: case report and review of the literature. al Serhani AM, et al.
Ear Nose Throat J 1997 Jan;76(1):41–2 (8 ref.)

NASOPHARYNGEAL NEOPLASMS

COMPLICATIONS

Undifferentiated carcinoma of the nasopharynx and leukemoid reaction: report of case with literature review. Saussez S, et al. **J Laryngol Otol** 1997 Jan;111(1):66–9 (12 ref.)

[A case of sleep apnea syndrome due to a nasopharyngeal tumor] Shibata N, et al.
Nippon Jibiinkoka Gakkai Kaiho 1996 Jan;99(1):6–12 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Acute bilateral ophthalmoplegia and nasopharyngeal neoplasms] Marcos Martínez L, et al. **An Med Interna** 1996 Sep;13(9):441–2 (7 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

[Craniopharyngiomas. Pathophysiological and diagnostic aspects] Bona G, et al. **Minerva Pediatr** 1996 Nov; 48(11):471–3 (8 ref.) **(Ita)**

IMMUNOLOGY

Human leucocyte antigens and nasopharyngeal carcinoma. Ren EC, et al. **Clin Sci (Colch)** 1996 Sep;91(3):256–8 (36 ref.)

Salivary gland anlage tumor of the nasopharynx: a clinicopathologic and immunohistochemical study of three cases. Boccon-Gibod LA, et al.
Pediatr Pathol Lab Med 1996 Nov–Dec;16(6):973–83 (23 ref.)

PATHOLOGY

Nasopharyngeal osteosarcoma as second malignant neoplasm in a post-treated unilateral retinoblastoma: report of a case and review of literature. Dubey SP, et al.
Int J Pediatr Otorhinolaryngol 1996 Feb;34(3):265–71 (14 ref.)

Salivary gland anlage tumor of the nasopharynx: a clinicopathologic and immunohistochemical study of three cases. Boccon-Gibod LA, et al.
Pediatr Pathol Lab Med 1996 Nov–Dec;16(6):973–83 (23 ref.)

[Solitary fibrous tumor of the nasopharynx. Apropos of a case] Ferrario F, et al. **Ann Otolaryngol Chir Cervicofac** 1997;114(3):71–5 (35 ref.) (Eng. Abstr.) **(Fre)**

RADIOTHERAPY

Postirradiation laryngeal osteosarcoma: case report and literature review. Sheen TS, et al. **Head Neck** 1997 Jan; 19(1):57–62 (36 ref.)

SURGERY

Microendoscopic transoral CO2-laser resection of an extensive nasopharyngeal and oral teratoma. Gunkel AR, et al. **Am J Otolaryngol** 1997 Mar–Apr;18(2):140–4 (14 ref.)

Craniofacial resection for vascular leiomyoma of the nasal cavity. Nicolai P, et al. **Am J Otolaryngol** 1996 Sep–Oct; 17(5):340–4 (25 ref.)

Transcervico-mandibulo-palatal approach for surgical salvage of recurrent nasopharyngeal cancer. Morton RP, et al. **Head Neck** 1996 Jul–Aug;18(4):352–8 (22 ref.)

[Hemangiopericytoma of the infratemporal fossa of nasopharyngeal manifestation. Value of the cervico-transoral approach] Hémar P, et al.
Rev Laryngol Otol Rhinol (Bord) 1996;117(5):381–4 (14 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Epstein-Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma. Ambinder RF, et al. **Semin Cancer Biol** 1996 Aug;7(4):217–26 (69 ref.)

VIROLOGY

Nasopharyngeal carcinoma, with emphasis on its relationship to Epstein-Barr virus. Vasef MA, et al.
Ann Otol Rhinol Laryngol 1997 Apr;106(4):348–56 (109 ref.)

Diagnosis of Epstein-Barr virus-related diseases. Linde A. **Scand J Infect Dis Suppl** 1996;100:83–8 (46 ref.)

Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: viral gene expression, tumour cell phenotype, and the role of the lymphoid stroma. Niedobitek G, et al. **Semin Cancer Biol** 1996 Aug; 7(4):165–74 (92 ref.)

[Nasopharyngeal carcinoma: present and future] Ooka T.
Nippon Rinsho 1997 Feb;55(2):334–45 (32 ref.) (Eng. Abstr.) **(Jpn)**

NASOPHARYNX

RADIATION EFFECTS

Estimates of numbers of civilians treated with nasopharyngeal radium irradiation in the United States. Mellinger-Birdsong AK. **Otolaryngol Head Neck Surg** 1996 Nov;115(5):429–32 (29 ref.)

Nasopharyngeal radium irradiation: fundamental considerations. Royal HD. **Otolaryngol Head Neck Surg** 1996 Nov;115(5):399–402 (26 ref.)

Epidemiologic issues related to nasopharyngeal radium exposures. Shore RE. **Otolaryngol Head Neck Surg** 1996 Nov;115(5):422–8 (13 ref.)

SURGERY

Craniofacial resection for vascular leiomyoma of the nasal cavity. Nicolai P, et al. **Am J Otolaryngol** 1996 Sep–Oct; 17(5):340–4 (25 ref.)

VIROLOGY

Nasopharyngeal carcinoma, with emphasis on its relationship to Epstein-Barr virus. Vasef MA, et al.
Ann Otol Rhinol Laryngol 1997 Apr;106(4):348–56 (109 ref.)

NATIONAL AMBULATORY MEDICAL CARE SURVEY see **HEALTH CARE SURVEYS**

NATIONAL FORMULARY see **PHARMACOPOEIAS**

NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY see **NUTRITION SURVEYS**

NATIONAL HEALTH INSURANCE, NON-U.S. see **NATIONAL HEALTH PROGRAMS**

NATIONAL HEALTH INSURANCE, UNITED STATES

The new politics of U.S. health policy. Hacker JS, et al. **J Health Polit Policy Law** 1997 Apr;22(2):315–38 (43 ref.)

NATIONAL HEALTH PLANNING AND RESOURCES DEVELOPMENT ACT OF 1974 see **HEALTH PLANNING**

NATIONAL HEALTH POLICY see **HEALTH POLICY**

NATIONAL HEALTH PROGRAMS

The 100% condom program in Thailand. Rojanapithayakorn W, et al. **AIDS** 1996 Jan;10(1):1–7 (21 ref.)

The case against a national screening programme for aortic aneurysms [see comments] Cheatle TR.
Ann R Coll Surg Engl 1997 Mar;79(2):90–5 (65 ref.) Comment in: Ann R Coll Surg Engl 1997 Jul;79(4):310.

Mental health services in Israel at a crossroads: promises and pitfalls of mental health services in the context of the new national health insurance. Aviram U.
Int J Law Psychiatry 1996 Summer-Fall;19(3-4):327–72 (142 ref.)

The Canadian health care crisis and how to survive it: can cost effectiveness save Canadian doctors? Innes G.
J Emerg Med 1997 May–Jun;15(3):410–5 (19 ref.)

Leprosy control program in Thailand. Duangajna P.
Nippon Rai Gakkai Zasshi 1996 Jul;65(2):88–93 (6 ref.)

Drug problems among immigrants and refugees in The Netherlands and the Dutch health care and treatment system. van de Wijngaart GF. **Subst Use Misuse** 1997 Jun; 32(7–8):909–38 (60 ref.)

National blood programs in developed countries. McCullough J. **Transfusion** 1996 Nov–Dec; 36(11–12):1019–32 (9 ref.)

ECONOMICS

What are the costs to society and to individuals regarding diagnostic procedures and care of patients with dementia? Winblad B, et al. **Acta Neurol Scand Suppl** 1996;168:101–4 (35 ref.)

National health accounts in developing countries: appropriate methods and recent applications. Berman PA.
Health Econ 1997 Jan–Feb;6(1):11–30 (52 ref.)

Economic evaluation and the shifting balance towards primary care: definitions, evidence and methodological issues. Godber E, et al. **Health Econ** 1997 May–Jun; 6(3):275–94 (45 ref.)

[Depressive disorders and public health: a review of the economic impact] Martin P. **Encephale** 1996 Sep–Oct; 22(5):321–30 (47 ref.) (Eng. Abstr.) **(Fre)**

[Significance of evidence-based decisions for health policy] Pientka L. **Med Klin** 1996 Aug 15;91(8):541–6 (83 ref.) **(Ger)**

[Clinical economics--a guideline for economic management in the clinic and general practice] Porzsolt F. **Med Klin** 1996 Aug 15;91(8):531–5 (27 ref.) **(Ger)**

LEGISLATION & JURISPRUDENCE

[The Parkinson patient in expert social medicine assessment with special reference to the nursing care law] Semsch-Poppe B, et al. **Gesundheitswesen** 1996 Dec; 58(12):635–40 (18 ref.) (Eng. Abstr.) **(Ger)**

[Determining the extent of nursing care need according to the nursing care insurance law in an interdisciplinary comparison] Cappell E. **Z Gerontol Geriatr** 1996 Nov–Dec; 29(6):418–25 (28 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Managed care merged with the German model [see comments] Weil TP. **Am J Med Qual** 1997 Spring; 12(1):19–24 (22 ref.) Comment in: Am J Med Qual 1997 Spring;12(1):25–7.

The German health system. Lessons for reform in the United States [see comments] Jackson JL. **Arch Intern Med** 1997 Jan 27;157(2):155–60 (31 ref.) Comment in: Arch Intern Med 1997 Aug 11–25;157(15):1773–4.

The Health of the Nation 4 years on: what have we done, what must we do? Troop P, et al. **Br J Hosp Med** 1997 Feb 5–18;57(3):81–2, 99–100 (9 ref.)

Health care system reforms in western European countries: the relevance of health care organization. Elola J.
Int J Health Serv 1996;26(2):239–51 (56 ref.)

Health as an irreversible part of the welfare state: Canadian government policy under the Tories. O'Neill MA.
Int J Health Serv 1996;26(3):547–59 (41 ref.)

Quality of care initiatives in the French context. de Pouvourville G. **Int J Qual Health Care** 1997 Jun; 9(3):163–70 (12 ref.)

The impact of the NHS reforms 1991–1995: a review of research evidence. Robinson R. **J Public Health Med** 1996 Sep;18(3):337–42 (91 ref.)

General practice fundholding in the UK National Health Service: evidence to date. Harrison S, et al.
J Public Health Policy 1996;17(3):331–46 (70 ref.)

STANDARDS

Quality improvement issues in Brazil. Malik AM.
Jt Comm J Qual Improv 1997 Jan;23(1):55–9 (19 ref.)

[Development of standards for quality management in interventional cardiology] Brennecke R. **Herz** 1996 Oct; 21(5):304–13 (45 ref.) (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

[Development of a model for explaining health inequality] Elkeles T, et al. **Gesundheitswesen** 1997 Mar;59(3):137–43 (68 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

Medical necessity in Canadian health policy: four meanings and ... a funeral? Charles C, et al. **Milbank Q** 1997; 75(3):365–94 (93 ref.)

Health sector reform: lessons from China. Bloom G, et al. **Soc Sci Med** 1997 Aug;45(3):351–60 (45 ref.)

[Quality assurance in medicine. Current status, future requirements] Künzel U. **Herz** 1996 Dec;21(6):341–6 (41 ref.) (Eng. Abstr.) **(Ger)**

[Status and perspectives of quality assurance in socialized medical services] Ollenschläger G, et al.
Z Arztl Fortbild Qualitatssich 1997 Feb;91(1):59–67 (34 ref.) (Eng. Abstr.) **(Ger)**

NATIONAL HEALTH SERVICE CORPS see **MEDICALLY UNDERSERVED AREA**

NATIONAL HEALTH SERVICE, BRITISH see **STATE MEDICINE**

NATIONAL HOSPITAL DISCHARGE SURVEY see **HEALTH CARE SURVEYS**

NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH

Experience in the use of the NIOSH diffusive sampler evaluation protocol. Harper M, et al.
Am Ind Hyg Assoc J 1996 Dec;57(12):1115–23 (38 ref.)

NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH (U.S.) see **NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH**

NATIONAL INSTITUTE OF MENTAL HEALTH (U.S.)

National research agenda for prevention research. The National Institute of Mental Health Report [see comments] Reiss D, et al. **Am Psychol** 1996 Nov;51(11):1109–15 (10 ref.) Comment in: Am Psychol 1996 Nov;51(11):1130–3.

NATIONAL INSTITUTES OF HEALTH (U.S.)

Bioelectrical impedance analysis in body composition

measurement: National Institutes of Health Technology Assessment Conference Statement. **Am J Clin Nutr** 1996 Sep;64(3 Suppl):524S–532S (0 ref.)
Pediatric drug development: a perspective from the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI). Smith M, et al. **Invest New Drugs** 1996;14(1):11–22 (73 ref.)

NATIONAL LIBRARY OF MEDICINE (U.S.)

Outreach activities of the National Library of Medicine: a five-year review. Wallingford KT, et al. **Bull Med Libr Assoc** 1996 Apr;84(2 Suppl):1–60 (0 ref.)

NATIONALITY see **ETHNIC GROUPS**

NATIVE AMERICANS see **INDIANS, NORTH AMERICAN**

NATRIURESIS

DRUG EFFECTS

Effects of antihypertensive drugs on various aspects of renal function. de Leeuw PW, et al. **Cardiovasc Drugs Ther** 1997 Jan;10(6):803–8 (27 ref.)
[Low dosage dopamine improves kidney function: current status of knowledge and evaluation of a controversial topic] Kindgen-Milles D, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jun; 32(6):333–42 (85 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Renal dopamine receptors: mechanisms of action and developmental aspects. Cheung PY, et al. **Cardiovasc Res** 1996 Jan;31(1):2–6 (54 ref.)
Interactions between arterial pressure and sodium excretion. Navar LG, et al. **Curr Opin Nephrol Hypertens** 1996 Jan; 5(1):64–71 (89 ref.)
Regulation of renal sodium and water excretion in the nephrotic syndrome and cirrhosis of the liver. Jespersen B. **Dan Med Bull** 1997 Apr;44(2):191–207 (230 ref.)
[Regulation of natriuresis in diabetic nephropathy] Późniak J, et al. **Pol Arch Med Wewn** 1996 Jun;95(6):572–7 (28 ref.) **(Pol)**

NATRIURETIC PEPTIDES, ATRIAL see **ATRIAL NATRIURETIC FACTOR**

NATURAL DISASTERS

see related
RELIEF WORK

What happened to elderly people in the great Hanshin earthquake [see comments] Tanida N. **BMJ** 1996 Nov 2; 313(7065):1133–5 (6 ref.) Comment in: BMJ 1997 Feb 15;314(7079):519.
The health effects of earthquakes in the mid-1990s. Alexander D. **Disasters** 1996 Sep;20(3):231–47 (34 ref.)
Institutional arrangements for flood hazard management in Malaysia: an evaluation using the criteria approach. Chan NW. **Disasters** 1997 Sep;21(3):206–22 (41 ref.)
The Kobe earthquake: the system response. A disaster report from Japan. Tanaka K. **Eur J Emerg Med** 1996 Dec; 3(4):263–9 (7 ref.)
Exploring the determinants of support provision: provider characteristics, personal networks, community contexts, and support following life events. Haines VA, et al. **J Health Soc Behav** 1996 Sep;37(3):252–64 (48 ref.)
Bioaccumulation of mercury in the aquatic food chain in newly flooded areas. Bodaly RA, et al. **Met Ions Biol Syst** 1997;34:259–87 (93 ref.)
The effects of volcanoes on health: preparedness in Mexico. Zeballos JL, et al. **World Health Stat Q** 1996;49(3–4):204–8 (10 ref.)
[Avalanche emergency. New aspects of the pathophysiology and therapy of buried avalanche victims] Brugger H, et al. **Wien Klin Wochenschr** 1997 Mar 14;109(5):145–59 (114 ref.) (Eng. Abstr.) **(Ger)**
[Hanshin-Awaji earthquake and acute myocardial infarction] Sakamoto S, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (12):735–7 (15 ref.) **(Jpn)**

NATURAL KILLER CELL STIMULATORY FACTOR see **INTERLEUKIN-12**

NATURAL KILLER CELLS see **KILLER CELLS, NATURAL**

NATURAL LANGUAGE PROCESSING

Natural language processing in medicine: an overview. Spyns P. **Methods Inf Med** 1996 Dec;35(4–5):285–301 (194 ref.)

NATURAL RADIATION see **BACKGROUND RADIATION**

NATURAL RESOURCES see **CONSERVATION OF NATURAL RESOURCES**

NATURAL SELECTION see **SELECTION (GENETICS)**

NATURE

Reconfiguring nature and culture: intersections of medical anthropology and technoscience studies. Casper MJ, et al. **Med Anthropol Q** 1996 Dec;10(4):523–36 (64 ref.)
Diseases in wild animals in relation to nature management. Broekhuizen S. **Vet Q** 1996;18 Suppl 3:S143–5 (8 ref.)
Health and welfare issues related to using (domestic) ungulates for the management of nature parks in The Netherlands. Oosterbaan J, et al. **Vet Q** 1996;18 Suppl 3:S153–5 (15 ref.)

NAUSEA

see related
ANTIEMETICS

[Chemotherapy-induced nausea and vomiting: from experimentation to experience] Marty M. **Bull Cancer** 1996 Dec;83(12):1014–8 (22 ref.) (Eng. Abstr.) **(Fre)**

CHEMICALLY INDUCED

Nausea and vomiting in the postoperative patient–controlled analgesia environment. Woodhouse A, et al. **Anaesthesia** 1997 Aug;52(8):770–5 (46 ref.)
Physiology of chemotherapy-induced emesis and antiemetic therapy. Predictive models for evaluation of new compounds. Veyrat-Follet C, et al. **Drugs** 1997 Feb; 53(2):206–34 (141 ref.)
Proposal for classifying the acute emetogenicity of cancer chemotherapy. Hesketh PJ, et al. **J Clin Oncol** 1997 Jan; 15(1):103–9 (69 ref.)
Risk factors and antiemetic management of chemotherapy–induced nausea and vomiting. Goodman M. **Oncol Nurs Forum** 1997 Aug;24(7 Suppl):20–32 (39 ref.)
[Postoperative nausea and vomiting (see comments)] Jensen LB, et al. **Ugeskr Laeger** 1997 Jan 13;159(3):269–74 (40 ref.) (Eng. Abstr.) Comment in: Ugeskr Laeger 1997 May 19;159(21):3191–2. **(Dan)**
[Mechanisms of cytotoxic drug-induced emesis and its prevention] Matsuki N. **Yakugaku Zasshi** 1996 Sep; 116(9):710–8 (32 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Propofol in chemotherapy-associated nausea and vomiting. Phelps KC, et al. **Ann Pharmacother** 1996 Mar;30(3):290–2 (22 ref.)
Antiemetic therapy. Axelrod RS. **Compr Ther** 1997 Aug; 23(8):539–45 (24 ref.)
Risks and benefits of drugs used in the management of postoperative nausea and vomiting. Sung YF. **Drug Saf** 1996 Mar;14(3):181–97 (140 ref.)
Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. Balfour JA, et al. **Drugs** 1997 Aug;54(2):273–98 (86 ref.)
Postoperative nausea and vomiting—its pathophysiology and management. Dabbous A. **Middle East J Anesthesiol** 1996 Jun;13(5):495–512 (5 ref.)
5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy. Cunningham RS. **Oncol Nurs Forum** 1997 Aug;24(7 Suppl):33–40 (54 ref.)
[Clinical use of antiemetic drugs for prevention and therapy of postoperative nausea and vomiting] Saur P, et al. **Anaesthesiol Reanim** 1996;21(6):153–8 (67 ref.) (Eng. Abstr.) **(Ger)**
[Recent improvements in antiemetic therapy] Roila F, et al. **Tumori** 1997;83(2 Suppl):S3–14 (63 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Nausea and vomiting in patients with cancer. Lichter I. **Hematol Oncol Clin North Am** 1996 Feb;10(1):207–220 (54 ref.)
Managing the multiple causes of nausea and vomiting in the patient with cancer. Fessele KS. **Oncol Nurs Forum** 1996 Oct;23(9):1409–15; quiz 1416–7 (39 ref.)
Postoperative nausea and vomiting in children. Baines D. **Paediatr Anaesth** 1996;6(1):7–14 (52 ref.)
Postoperative nausea and vomiting: review and clinical approaches. Haynes GR, et al. **South Med J** 1996 Oct; 89(10):940–9 (118 ref.)

NURSING

The middle-range theory of unpleasant symptoms: an update. Lenz ER, et al. **ANS Adv Nurs Sci** 1997 Mar;19(3):14–27 (53 ref.)
Criteria for assessment of nausea, vomiting, and retching. Rhodes VA. **Oncol Nurs Forum** 1997 Aug;24(7 Suppl):13–9 (42 ref.)

PHYSIOPATHOLOGY

Physiology of chemotherapy-induced emesis and antiemetic therapy. Predictive models for evaluation of new compounds. Veyrat-Follet C, et al. **Drugs** 1997 Feb; 53(2):206–34 (141 ref.)
Postoperative nausea and vomiting—its pathophysiology and management. Dabbous A. **Middle East J Anesthesiol** 1996 Jun;13(5):495–512 (5 ref.)
Physiologic mechanisms of nausea and vomiting in patients with cancer. Hogan CM, et al. **Oncol Nurs Forum** 1997 Aug;24(7 Suppl):8–12 (19 ref.)
[Nausea and vomiting. Pathophysiology and new therapeutic methods] Schwörer H, et al. **Dtsch Med Wochenschr** 1997 Aug 15;122(33):1014–9 (49 ref.) **(Ger)**

PREVENTION & CONTROL

[Prevention of postoperative nausea and vomiting with single and repeat administration of ondansetron—review of the literature on different administration forms] Saur P, et al. **Anaesthesiol Reanim** 1996;21(5):131–5 (30 ref.) (Eng. Abstr.) **(Ger)**
[Mechanisms of cytotoxic drug-induced emesis and its prevention] Matsuki N. **Yakugaku Zasshi** 1996 Sep; 116(9):710–8 (32 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Nonpharmacologic management of chemotherapy-induced nausea and vomiting. King CR. **Oncol Nurs Forum** 1997 Aug;24(7 Suppl):41–8 (59 ref.)
[Nausea and vomiting. Pathophysiology and new therapeutic methods] Schwörer H, et al. **Dtsch Med Wochenschr** 1997 Aug 15;122(33):1014–9 (49 ref.) **(Ger)**

NAUTICAL MEDICINE see **NAVAL MEDICINE**

NAVAL MEDICINE

see related
DIVING
SHIPS

Maritime medicine. Scott J, et al. **Emerg Med Clin North Am** 1997 Feb;15(1):241–9 (10 ref.)

NAVICULAR BONE OF FOOT see **TARSAL BONES**

NAZISM see **POLITICAL SYSTEMS**

NCAM

[Cell adhesion proteins in the nervous system: immunoglobulin superfamily—structure, function and involvement in neurological diseases] Yazaki T, et al. **No To Hattatsu** 1996 Nov;28(6):475–83 (26 ref.) (Eng. Abstr.) **(Jpn)**
[Telencephalin, a dendrite-associated cell adhesion molecule with brain segment-specific expression] Mori K, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):555–60 (13 ref.) **(Jpn)**
[Netrin and semaphorin] Murakami F. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):571–6 (17 ref.) **(Jpn)**
[The action of reelin in the layering of cortical neurons in cerebrum] Ogawa M, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):577–83 (19 ref.) **(Jpn)**
[L1 and P0 proteins] Takeda Y, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):542–51 (36 ref.) **(Jpn)**
[Neural proteoglycans: neuroglycan C (NGC), neurocan, and phosphacan] Tokita Y, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):567–70 (17 ref.) **(Jpn)**

CHEMISTRY

The cell adhesion molecule L1: species- and cell-type-dependent multiple binding mechanisms. Kadmon G, et al. **Differentiation** 1997 Feb;61(3):143–50 (43 ref.)
The (Greek) key to structures of neural adhesion molecules. Vaughn DE, et al. **Neuron** 1996 Feb;16(2):261–73 (56 ref.)

GENETICS

Gene regulation of cell adhesion molecules in neural morphogenesis. Edelman GM, et al. **Acta Paediatr Suppl** 1997 Jul;422:12–9 (41 ref.)
L1-associated diseases: clinical geneticists divide, molecular geneticists unite. Fransen E, et al. **Hum Mol Genet** 1997; 6(10):1625–32 (103 ref.)
X linked hydrocephalus and MASA syndrome. Kenwrick S, et al. **J Med Genet** 1996 Jan;33(1):59–65 (77 ref.)
Combined immunocytochemistry and PRINS DNA synthesis for simultaneous detection of phenotypic and genomic parameters in cells. Speel EJ, et al. **Methods Mol Biol** 1997; 71:53–9 (15 ref.)
The (Greek) key to structures of neural adhesion molecules. Vaughn DE, et al. **Neuron** 1996 Feb;16(2):261–73 (56 ref.)

METABOLISM

Axon guidance: motor-way madness. Stoker AW. **Curr Biol** 1996 Jul 1;6(7):794–7 (17 ref.)

PHYSIOLOGY

Review: a role for the FGF receptor in the axonal growth response stimulated by cell adhesion molecules? Hall H, et al. **Cell Adhes Commun** 1996 Apr;3(6):441–50 (97 ref.)
Structure/function relationships of axon-associated adhesion receptors of the immunoglobulin superfamily. Brümmendorf T, et al. **Curr Opin Neurobiol** 1996 Oct; 6(5):584–93 (80 ref.)
The cell adhesion molecule L1: species- and

cell-type-dependent multiple binding mechanisms. Kadmon G, et al. **Differentiation** 1997 Feb;61(3):143-50 (43 ref.)
Elucidation of the molecular actions of NCAM and structurally related cell adhesion molecules. Baldwin TJ, et al. **J Cell Biochem** 1996 Jun 15;61(4):502-13 (75 ref.)
Cell adhesion molecules and the transition from short- to long-term memory. Rose SP. **J Physiol Paris** 1996; 90(5-6):387-91 (37 ref.)
The neural cell adhesion molecule NCAM in multiple myeloma. Kaiser U, et al. **Leuk Lymphoma** 1996 Feb; 20(5-6):389-95 (57 ref.)
Functional and clinical aspects of the myelomonocyte protein calprotectin. Johne B, et al. **Mol Pathol** 1997 Jun; 50(3):113-23 (142 ref.)
The L1 family of neural cell adhesion molecules: old proteins performing new tricks. Hortsch M. **Neuron** 1996 Oct; 17(4):587-93 (44 ref.)
Cell adhesion molecules, CREB, and the formation of new synaptic connections [comment] Martin KC, et al. **Neuron** 1996 Oct;17(4):567-70 (17 ref.) Comment on: Neuron 1996 Oct;17(4):641-54. Comment on: Neuron 1996 Oct;17(4):655-67. Comment on: Neuron 1996 Oct;17(4):669-76.
Selective neural cell adhesion molecule signaling by Src family tyrosine kinases and tyrosine phosphatases. Maness PF, et al. **Perspect Dev Neurobiol** 1996;4(2-3):169-81 (169 ref.)
[Roles of neuropilin and plexin in the development of nervous system] Fujisawa H. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):584-8 (12 ref.) **(Jpn)**
[Expression and function of neural cell adhesion molecule (NCAM) and its polysialic acid moiety in the nervous system] Oka S, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):535-41 (50 ref.) **(Jpn)**
[L1 and P0 proteins] Takeda Y, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):542-51 (36 ref.) **(Jpn)**
[Role of cadherin adhesion systems in selective synapse formation] Uchida N, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):525-34 (58 ref.) **(Jpn)**
[Review of neural cell adhesion molecules] Uyemura K. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):519-24 (22 ref.) **(Jpn)**

NEAR-DEATH EXPERIENCE see **DEATH**

NEAR DROWNING

Submersion injuries in children and adults. DeNicola LK, et al. **Crit Care Clin** 1997 Jul;13(3):477-502 (125 ref.)
Near-drowning: epidemiology, pathophysiology, and initial treatment. Weinstein MD, et al. **J Emerg Med** 1996 Jul-Aug;14(4):461-7 (64 ref.)

NEAR EAST EQUINE ENCEPHALOMYELITIS VIRUS see **BORNA DISEASE VIRUS**

NEARSIGHTEDNESS see **MYOPIA**

NEBRAMYCIN FACTOR 6 see **TOBRAMYCIN**

NEBULIZERS AND VAPORIZERS

see related
AEROSOLS
Compatibility of nebulizer solution admixtures. Joseph JC. **Ann Pharmacother** 1997 Apr;31(4):487-9 (17 ref.)
Changing delivery methods for obstructive lung diseases. Dolovich M. **Curr Opin Pulm Med** 1997 May;3(3):177-89 (112 ref.)
Drugs by inhalatory route: an overview and upcoming clinical perspectives. Melillo EM, et al. **Monaldi Arch Chest Dis** 1996 Oct;51(5):405-12 (117 ref.)
Ambulatory inhalation therapy in obstructive lung diseases. Roche N, et al. **Respiration** 1997;64(2):121-30 (55 ref.)
Current best practice for nebuliser treatment. British Thoracic Society Nebulizer Project Group. **Thorax** 1997 Apr;52 Suppl 2:S1-3 (0 ref.)
Nebuliser therapy in childhood. Barry PW, et al. **Thorax** 1997 Apr;52 Suppl 2:S78-88 (127 ref.)
Nebulised bronchodilators, corticosteroids, and rhDNase in adult patients with cystic fibrosis. Conway SP, et al. **Thorax** 1997 Apr;52 Suppl 2:S64-8 (65 ref.)
The science of nebulised drug delivery. O'Callaghan C, et al. **Thorax** 1997 Apr;52 Suppl 2:S31-44 (104 ref.)
Nebuliser therapy in the intensive care unit. O'Doherty MJ, et al. **Thorax** 1997 Apr;52 Suppl 2:S56-9 (46 ref.)
Nebulisers for the elderly. Pounsford JC. **Thorax** 1997 Apr; 52 Suppl 2:S53-5 (24 ref.)
Nebulised bronchodilators, antibiotics and rhDNase for children with cystic fibrosis. Spencer DA. **Thorax** 1997 Apr;52 Suppl 2:S89-91 (27 ref.)
[A new trend of inhaled corticosteroid therapy in Japan] Sano Y. **Nippon Rinsho** 1996 Nov;54(11):3004-10 (16 ref.) (Eng. Abstr.) **(Jpn)**

STANDARDS
Metered-dose inhaler accessory devices in acute asthma: efficacy and comparison with nebulizers: a literature review. Amirav I, et al. **Arch Pediatr Adolesc Med** 1997 Sep;151(9):876-82 (60 ref.)

NECATOR AMERICANUS

Hookworm control as a strategy to prevent iron deficiency. Stoltzfus RJ, et al. **Nutr Rev** 1997 Jun;55(6):223-32 (54 ref.)
Ascariasis and hookworm. Sarinas PS, et al. **Semin Respir Infect** 1997 Jun;12(2):130-7 (45 ref.)

NECATORIASIS

Ascariasis and hookworm. Sarinas PS, et al. **Semin Respir Infect** 1997 Jun;12(2):130-7 (45 ref.)

PREVENTION & CONTROL
Hookworm control as a strategy to prevent iron deficiency. Stoltzfus RJ, et al. **Nutr Rev** 1997 Jun;55(6):223-32 (54 ref.)

NECK

see related
CERVICAL VERTEBRAE
Neck failure in T2N0 squamous cell carcinoma of the true vocal cords: the Fox Chase experience and review of the literature. Fein DA, et al. **Am J Clin Oncol** 1997 Apr; 20(2):154-7 (17 ref.)
Pictorial review: radiology of the carotid space. Chong VF, et al. **Clin Radiol** 1996 Nov;51(11):762-8 (12 ref.)
Aberrant cervical thymus: a case report and review of literature. Baek CH, et al. **Int J Pediatr Otorhinolaryngol** 1997 Aug 20;41(2):215-22 (11 ref.)
Synovial cyst and degeneration of the transverse ligament: an unusual cause of high cervical myelopathy. Case report. Fransen P, et al. **J Neurosurg** 1997 Jun;86(6):1027-30 (17 ref.)
Management of deep neck infection. Nicklaus PJ, et al. **Pediatr Clin North Am** 1996 Dec;43(6):1277-96 (28 ref.)
Bilateral vertebral artery lesion after dislocating cervical spine trauma. A case report. Wirbel R, et al. **Spine** 1996 Jun 1;21(11):1375-9; discussion 1380 (22 ref.)

ANATOMY & HISTOLOGY
Deep neck infections. Marra S, et al. **Am J Otolaryngol** 1996 Sep-Oct;17(5):287-98 (15 ref.)
An imager's guide to normal neck anatomy. Williams DW 3rd. **Semin Ultrasound CT MR** 1997 Jun;18(3):157-81 (39 ref.)

BLOOD SUPPLY
Aberrant external jugular vein phlebectasia with tongue pain. Stofman GM, et al. **Am J Otolaryngol** 1997 Mar-Apr; 18(2):148-50 (8 ref.)
Tumor angiogenesis. Petruzzelli GJ. **Head Neck** 1996 May-Jun;18(3):283-91 (49 ref.)

INJURIES
Prognosis of nonspecific work-related musculoskeletal disorders of the neck and upper extremity. Cole DC, et al. **Am J Ind Med** 1996 Jun;29(6):657-68 (46 ref.)
Review of applicability of existing functional status measures to the study of workers with musculoskeletal disorders of the neck and upper limb. Stock SR, et al. **Am J Ind Med** 1996 Jun;29(6):679-88 (102 ref.)
Magnetic resonance angiography in trauma. James CA. **Clin Neurosci** 1997;4(3):137-45 (19 ref.)
Diagnosis and management of complications of self-injection injuries of the neck. Kay DJ, et al. **Ear Nose Throat J** 1996 Oct;75(10):670-6 (27 ref.)
Management of war-related neck injuries during the war in Croatia, 1991-1992. Prgomet D, et al. **Eur Arch Otorhinolaryngol** 1996;253(4-5):294-6 (28 ref.)
Angiography in the evaluation of head and neck trauma. Gaskill-Shipley MF, et al. **Neuroimaging Clin N Am** 1996 Aug;6(3):607-24 (69 ref.)
Swimming injuries. An overview. McMaster WC. **Sports Med** 1996 Nov;22(5):332-6 (26 ref.)
[Prevention and treatment of suppuration caused by neck trauma] Fominykh TI. **Vestn Otorinolaringol** 1996 Sep-Oct; (5):46-7 (4 ref.) (Eng. Abstr.) **(Rus)**
[Mild craniocervical trauma] Volkov SV. **Zh Vopr Neirokhir Im N N Burdenko** 1996 Oct-Dec; (4):28-33 (139 ref.) **(Rus)**

INNERVATION
Current principles in microsurgical nerve repair. Hausamen JE, et al. **Br J Oral Maxillofac Surg** 1996 Apr;34(2):143-57 (51 ref.)

MICROBIOLOGY
Deep neck infections. Marra S, et al. **Am J Otolaryngol** 1996 Sep-Oct;17(5):287-98 (15 ref.)
Space-occupying and life-threatening infections of the head, neck, and thorax. Gradon JD. **Infect Dis Clin North Am** 1996 Dec;10(4):857-78 (105 ref.)

PATHOLOGY
Fine-needle aspiration of the head and neck. Layfield LJ. **Pathology (Phila)** 1996;4(2):409-38 (77 ref.)
Inflammatory and infectious lesions of the neck. Ginsberg LE. **Semin Ultrasound CT MR** 1997 Jun;18(3):205-19 (47 ref.)
Imaging of cervical lymphadenopathy. Kaji AV, et al. **Semin Ultrasound CT MR** 1997 Jun;18(3):220-49 (56 ref.)

SURGERY
The clinically N(0) neck: investigation and treatment [editorial] Watkinson J. **Clin Otolaryngol** 1993 Dec; 18(6):443-5 (39 ref.)
Concepts in neck reconstruction. Shindo ML. **Otolaryngol Clin North Am** 1997 Aug;30(4):647-53 (14 ref.)

ULTRASONOGRAPHY
[Screening for fetal chromosome aberrations. Ultrasonic measurement of nuchal translucency thickness is most efficient] Valentin L. **Lakartidningen** 1997 Aug 20; 94(34):2810-2, 2815-6 (52 ref.) **(Swe)**

NECK MUSCLES

ABNORMALITIES
Bilateral anomaly of the semispinalis capitis muscle. Celik HH, et al. **Bull Assoc Anat (Nancy)** 1997 Mar;81(252):15 (3 ref.)

PATHOLOGY
An unique tumour of the geniohyoid muscle: an intramuscular haemangioma. Harar RP, et al. **J Laryngol Otol** 1997 Aug;111(8):769-71 (14 ref.)

PHYSIOPATHOLOGY
[Dropped head syndrome: diagnostic discussion apropos of 3 cases] Petiot P, et al. **Rev Neurol (Paris)** 1997 May; 153(4):251-5 (15 ref.) (Eng. Abstr.) **(Fre)**

SURGERY
Hyoid myotomy and suspension for obstructive sleep apnea syndrome [see comments] Schmitz JP, et al. **J Oral Maxillofac Surg** 1996 Nov;54(11):1339-45 (19 ref.) Comment in: J Oral Maxillofac Surg 1997 Jun;55(6):656.

NECK NEOPLASMS see **HEAD AND NECK NEOPLASMS**

NECK PAIN

Cervical and lumbar pain. Cohen ML. **Med J Aust** 1996 Nov 4;165(9):504-8 (22 ref.)
Low back and cervical spine disorders. Rainville J, et al. **Orthop Clin North Am** 1996 Oct;27(4):729-46 (80 ref.)
Chronic neck pain. Swezey RL. **Rheum Dis Clin North Am** 1996 Aug;22(3):411-37 (72 ref.)

COMPLICATIONS
Head and neck pain review: traditional and new perspectives. Friedman MH, et al. **J Orthop Sports Phys Ther** 1996 Oct; 24(4):268-78 (79 ref.)

ETIOLOGY
Injuries from hovercraft racing. Cattermole HR. **Injury** 1997 Jan;28(1):25-7 (0 ref.)

REHABILITATION
Rehabilitation of neck/shoulder patients in primary health care clinics. Jordan A, et al. **J Manipulative Physiol Ther** 1996 Jan;19(1):32-5 (43 ref.)
Rehabilitation of acute and subacute low back and neck pain in the work-injured patient. Hartigan C, et al. **Orthop Clin North Am** 1996 Oct;27(4):841-60 (61 ref.)

THERAPY
Manual therapy in the treatment of neck pain. Gross AR, et al. **Rheum Dis Clin North Am** 1996 Aug;22(3):579-98 (60 ref.)
Manipulation and mobilization of the cervical spine. A systematic review of the literature. Hurwitz EL, et al. **Spine** 1996 Aug 1;21(15):1746-59; discussion 1759-60 (134 ref.)

NECKACHE see **NECK PAIN**

NECROBACILLOSIS see **FUSOBACTERIUM INFECTIONS**

NECROBIOSIS LIPOIDICA

DRUG THERAPY
Necrobiosis lipoidica treated with topical tretinoin. Heymann WR. **Cutis** 1996 Jul;58(1):53-4 (8 ref.)

ETIOLOGY
Necrobiosis lipoidica and diabetic control revisited. Cohen O, et al. **Med Hypotheses** 1996 Apr;46(4):348-50 (15 ref.)

PATHOLOGY

Perforating elastosis in necrobiosis lipoidica diabeticorum. McDonald L, et al. **Cutis** 1996 May;57(5):336–8 (10 ref.)
An unusual case of giant dermatofibroma in a patient with diabetes mellitus and necrobiosis lipoidica. Omulecki A, et al. **Cutis** 1996 Oct;58(4):282–5 (20 ref.)

NECROSIS

see related
TUMOR NECROSIS FACTOR

Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Darzynkiewicz Z, et al. **Cytometry** 1997 Jan 1;27(1):1–20 (108 ref.)
Mitochondrial implication in accidental and programmed cell death: apoptosis and necrosis. Zamzami N, et al. **J Bioenerg Biomembr** 1997 Apr;29(2):185–93 (75 ref.)
TNF-induced intracellular signaling leading to gene induction or to cytotoxicity by necrosis or by apoptosis. Fiers W, et al. **J Inflamm** 1995–96;47(1–2):67–75 (27 ref.)
Morphological and biochemical characterization and analysis of apoptosis. Allen RT, et al. **J Pharmacol Toxicol Methods** 1997 Jun;37(4):215–28 (68 ref.)

NECROSIS, ASEPTIC, OF BONE see **OSTEONECROSIS**

NECROSIS, AVASCULAR, OF BONE see **OSTEONECROSIS**

NECROSIS, DENTAL PULP see **DENTAL PULP NECROSIS**

NECROTIZING ARTERITIS see **POLYARTERITIS NODOSA**

NECROTIZING PANCREATITIS, ACUTE see **PANCREATITIS, ACUTE NECROTIZING**

NECROTIZING PYELONEPHRITIS see **KIDNEY PAPILLARY NECROSIS**

NECROTIZING SCLERITIS see **SCLERITIS**

NECROTIZING SIALOMETAPLASIA see **SIALOMETAPLASIA, NECROTIZING**

NEDOCROMIL

PHARMACOLOGY

Chloride transport and the action of sodium cromoglycate and nedocromil sodium in asthma. Norris AA, et al. **Clin Exp Allergy** 1996 Mar;26(3):250–3 (35 ref.)
Chloride transport and the actions of nedocromil sodium and cromolyn sodium in asthma. Alton EW, et al. **J Allergy Clin Immunol** 1996 Nov;98(5 Pt 2):S102–5; discussion S105–6 (36 ref.)
Effects of nedocromil sodium on airway neurogenic mechanisms. Chung KF. **J Allergy Clin Immunol** 1996 Nov; 98(5 Pt 2):S112–6; discussion S116–7 (53 ref.)
Effect of nedocromil sodium on neurogenic mechanisms in vitro. Myers AC, et al. **J Allergy Clin Immunol** 1996 Nov; 98(5 Pt 2):S107–11; discussion S116–7 (12 ref.)
The effects of nedocromil sodium and sodium cromoglycate on airway nerves and neurogenic responses in asthma. Norris AA. **Pulm Pharmacol** 1995 Aug–Oct;8(4–5):227–30 (31 ref.)
Sodium cromoglycate and nedocromil sodium in the therapy of asthma, a critical comparison. Parnham MJ. **Pulm Pharmacol** 1996 Apr;9(2):95–105 (81 ref.)

THERAPEUTIC USE

Clinical effects of nedocromil sodium on allergen-related mechanisms. Bleecker ER, et al. **J Allergy Clin Immunol** 1996 Nov;98(5 Pt 2):S118–23; discussion S140–2 (34 ref.)
Effects of nedocromil sodium on inflammation and symptoms in therapeutic studies. Creticos PS. **J Allergy Clin Immunol** 1996 Nov;98(5 Pt 2):S143–9; discussion S149–50 (27 ref.)
Nedocromil sodium and airway inflammation in vivo and in vitro. Devalia JL, et al. **J Allergy Clin Immunol** 1996 Nov;98(5 Pt 2):S51–7; discussion S64–6 (24 ref.)
Clinical effects of nedocromil sodium on challenges invoking neuronal mechanisms and on virally induced symptoms. König P. **J Allergy Clin Immunol** 1996 Nov;98(5 Pt 2):S135–40; discussion S140–2 (33 ref.)
The current place of nedocromil sodium in the treatment of asthma. Pauwels R. **J Allergy Clin Immunol** 1996 Nov; 98(5 Pt 2):S151–5; discussion S155–6 (10 ref.)
Sodium cromoglycate and nedocromil sodium in the therapy of asthma, a critical comparison. Parnham MJ. **Pulm Pharmacol** 1996 Apr;9(2):95–105 (81 ref.)

NEEDLE SHARING

HIV epidemiology and interventions among injecting drug users. Des Jarlais DC, et al. **Int J STD AIDS** 1996;7 Suppl 2:57–61 (35 ref.)
Interventions with drug injectors in the UK: trends in risk behaviour and HIV prevalence. Stimson GV, et al. **Int J STD AIDS** 1996;7 Suppl 2:52–6 (46 ref.)

PSYCHOLOGY

Psychosocial risk factors for HIV transmission in female drug abusers. Brook DW, et al. **Am J Addict** 1997 Spring; 6(2):124–34 (35 ref.)

NEEDLESTICK INJURIES

Research and the problems of litter and medical wastes on the UK coastline. Philipp R, et al. **Br J Clin Pract** 1997 Apr–May;51(3):164–8 (54 ref.)

DIAGNOSIS

Diagnosis and management of complications of self-injection injuries of the neck. Kay DJ, et al. **Ear Nose Throat J** 1996 Oct;75(10):670–6 (27 ref.)

PREVENTION & CONTROL

A critical review of the literature on sharps injuries: epidemiology, management of exposures and prevention. Hanrahan A, et al. **J Adv Nurs** 1997 Jan;25(1):144–54 (130 ref.)

THERAPY

Diagnosis and management of complications of self-injection injuries of the neck. Kay DJ, et al. **Ear Nose Throat J** 1996 Oct;75(10):670–6 (27 ref.)

NEF GENE PRODUCTS see **GENE PRODUCTS, NEF**

NEF GENES see **GENES, NEF**

NEF PROTEIN see **GENE PRODUCTS, NEF**

NEFA see **FATTY ACIDS, NONESTERIFIED**

NEGATIVE-PRESSURE VENTILATORS see **VENTILATORS, NEGATIVE-PRESSURE**

NEGATIVE REGULATORY ELEMENT, HIV see **HIV LONG TERMINAL REPEAT**

NEGATIVE REINFORCEMENT see **REINFORCEMENT (PSYCHOLOGY)**

NEGATRONS see **ELECTRONS**

NEGLIGENCE, PROFESSIONAL see **MALPRACTICE**

NEGOTIATING

Public mental health. III: Hatred and reconciliation. Curle A. **Med Confl Surviv** 1997 Jan–Mar;13(1):37–47 (2 ref.)
Medical malpractice arbitration: a primer for Texas physicians. Fraser JJ Jr. **Tex Med** 1997 Jan;93(1):76–80 (44 ref.)

NEGROES see **BLACKS**

NEGROID RACE

see related
BLACKS

Binge eating in ethnic minority groups. Smith DE. **Addict Behav** 1995 Nov–Dec;20(6):695–703 (45 ref.)
Anomaly of the femoral artery passage through the substance of sartorius muscle. Clinical consequences. Banjo AO. **Afr J Med Med Sci** 1995 Dec;24(4):343–6 (12 ref.)
Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Rybicki BA, et al. **Am J Epidemiol** 1997 Feb 1;145(3):234–41 (30 ref.)
Precursors of cardiovascular risk in young adults from a biracial (black-white) population: the Bogalusa Heart Study. Berenson GS, et al. **Ann N Y Acad Sci** 1997 May 28;817:189–98 (35 ref.)
Trabeculectomy with intraoperative sponge 5-fluorouracil in Afro-Caribbeans. Lachkar Y, et al. **Br J Ophthalmol** 1997 Jul;81(7):555–8 (28 ref.)
Breast cancer. Is ethnicity an independent prognostic factor for survival? Perkins P, et al. **Cancer** 1996 Sep 15; 78(6):1241–7 (19 ref.)
Considerations for racial differences in the athlete's heart and related cardiovascular disease. Lewis JF. **Cardiol Clin** 1997 Aug;15(3):485–91 (64 ref.)
A pilot study of the mandibular angle in black Zimbabweans. Mbajiorgu FE, et al. **Cent Afr J Med** 1996 Oct;42(10):285–7 (17 ref.)
The management of prostate cancer in blacks: the physician's dilemma intensified. Haynes MA. **Compr Ther** 1996 Jul; 22(7):449–53 (11 ref.)
Skin disorders in black children. Laude TA. **Curr Opin Pediatr** 1996 Aug;8(4):381–5 (28 ref.)
Comparison of prognostic determinants in childhood acute lymphoblastic leukaemia in negroid and Caucasian populations. Macharia WM. **East Afr Med J** 1996 Oct; 73(10):638–42 (17 ref.)
Pathophysiology and treatment implications of hypertension in the African-American population. Rahman M, et al. **Endocrinol Metab Clin North Am** 1997 Mar;26(1):125–44 (177 ref.)
Toward a conceptualization of race in epidemiologic research. Herman AA. **Ethn Dis** 1996 Winter–Spring; 6(1–2):7–20 (64 ref.)
Essential hypertension: racial/ethnic differences in pathophysiology. Douglas JG, et al. **J Assoc Acad Minor Phys** 1996;7(1):16–21 (88 ref.)
Group differences: is the good society impossible? Flynn JR. **J Biosoc Sci** 1996 Oct;28(4):573–85 (24 ref.)
Use of beta-adrenergic receptor blockers in blacks. Prisant LM, et al. **J Clin Pharmacol** 1996 Oct;36(10):867–73 (34 ref.)
Dupuytren's contracture in the black population: a case report and review of the literature. Sladicka MS, et al. **J Hand Surg [Am]** 1996 Sep;21(5):898–9 (18 ref.)
Is the pathogenesis of hypertension different in black patients? Seedat YK. **J Hum Hypertens** 1996 Sep;10 Suppl 3:S35–7 (11 ref.)
Stress, stress reduction, and hypertension in African Americans: an updated review. Barnes V, et al. **J Natl Med Assoc** 1997 Jul;89(7):464–76 (139 ref.)
Glaucoma blindness in African Americans: have 55 years of therapies, technologies, and talent altered blindness rates? Merritt JC. **J Natl Med Assoc** 1996 Dec; 88(12):809–19 (56 ref.)
[Biological and therapeutic particularities of non-complicated hypertension in sub-Saharan Africa] Muna WF, et al. **Med Trop (Mars)** 1996;56(3 Suppl):11–3 (7 ref.) **(Fre)**
[Epidemiological aspects of hypertension in the black patient] Van de Walle JP, et al. **Med Trop (Mars)** 1996;56(3 Suppl):8–10 (25 ref.) **(Fre)**

GENETICS

The pharmacologic treatment of anxiety and depression in African Americans. Considerations for the general practitioner. Strickland TL, et al. **Arch Fam Med** 1997 Jul–Aug;6(4):371–5 (43 ref.)
Hypertension, thermotolerance, and the "African gene": an hypothesis. Moskowitz DW. **Clin Exp Hypertens** 1996 Jan; 18(1):1–19 (97 ref.)
Genetic effects on bone mass and turnover-relevance to black/white differences. Parfitt AM. **J Am Coll Nutr** 1997 Aug;16(4):325–33 (86 ref.)
Autosomal dominant cornea plana: clinical findings in a Cuban family and a review of the literature. Sigler-Villanueva A, et al. **Ophthalmic Genet** 1997 Jun; 18(2):55–62 (23 ref.)

NEIGHBORHOOD HEALTH CENTERS see **COMMUNITY HEALTH CENTERS**

NEISSERIA

PATHOGENICITY

The pilus colonization factor of pathogenic neisserial species: organelle biogenesis and structure/function relationships--a review. Tønjum T, et al. **Gene** 1997 Jun 11;192(1):155–63 (90 ref.)
Neisseria sialytransferases and their role in pathogenesis. Rest RF, et al. **Microb Pathog** 1995 Dec;19(6):379–90 (66 ref.)
Adhesion and invasion by the pathogenic neisseria. Jerse AE, et al. **Trends Microbiol** 1997 Jun;5(6):217–21 (9 ref.)

NEISSERIA GONORRHOEAE

CHEMISTRY

Type-4 pilus-structure: outside to inside and top to bottom--a minireview. Forest KT, et al. **Gene** 1997 Jun 11;192(1):165–9 (13 ref.)

DRUG EFFECTS

Antimicrobial resistance in Neisseria gonorrhoeae. Lind I. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S93–7 (70 ref.)
Fluoroquinolone resistance in Neisseria gonorrhoeae. Knapp JS, et al. **Emerg Infect Dis** 1997 Jan–Mar;3(1):33–9 (44 ref.)

GENETICS

Transformation competence and type-4 pilus biogenesis in Neisseria gonorrhoeae--a review. Fussenegger M, et al. **Gene** 1997 Jun 11;192(1):125–34 (93 ref.)

IMMUNOLOGY

Questions about gonococcal pilus phase- and antigenic variation. Seifert HS. **Mol Microbiol** 1996 Aug;21(3):433–40 (54 ref.)

ISOLATION & PURIFICATION

Gonococcal endocarditis in a patient with systemic lupus erythematosus. Tikly M, et al. **Br J Rheumatol** 1997 Feb; 36(2):270–2 (14 ref.)

METABOLISM

Transformation competence and type-4 pilus biogenesis in Neisseria gonorrhoeae--a review. Fussenegger M, et al. **Gene** 1997 Jun 11;192(1):125–34 (93 ref.)

NEISSERIA GONORRHOEAE

PATHOGENICITY

Sialylation of neisserial lipopolysaccharide: a major influence on pathogenicity. Smith H, et al. **Microb Pathog** 1995 Dec; 19(6):365–77 (59 ref.)

NEISSERIA MENINGITIDIS

Acute meningococcaemia: recent advances in management (with particular reference to children). Kennedy NJ, et al. **Anaesth Intensive Care** 1996 Apr;24(2):197–216 (184 ref.)

Neisseria meningitidis: clinical aspects. Cartwright KA, et al. **J Infect** 1997 Jan;34(1):15–9 (32 ref.)

[Meningococcal infection: should we vaccinate?] Casado Flores J. **An Esp Pediatr** 1997 Mar;46(3):221–3 (27 ref.) **(Spa)**

DRUG EFFECTS

Antibiotic resistance in Neisseria meningitidis. Oppenheim BA. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S98–101 (44 ref.)

GENETICS

Microevolution and epidemic spread of serogroup A Neisseria meningitidis--a review. Achtman M. **Gene** 1997 Jun 11;192(1):135–40 (23 ref.)

IMMUNOLOGY

Bacterial outer membrane protein vaccines. The meningococcal example. Poolman JT. **Adv Exp Med Biol** 1996;397:73–7 (39 ref.)

Studies on the molecular mechanisms of meningococcal interactions with human cells. Towards anti-adhesion measures for the control of meningococcal disease. Virji M. **Adv Exp Med Biol** 1996;408:113–22 (40 ref.)

Neisseria meningitidis: vaccines and vaccine candidates. Al'Aldeen AA, et al. **J Infect** 1996 Nov;33(3):153–7 (23 ref.)

The immune response to the capsular polysaccharide of Neisseria meningitidis group B. Romero JD, et al. **Zentralbl Bakteriol** 1997 Feb;285(3):331–40 (62 ref.)

ISOLATION & PURIFICATION

Meningococcal conjunctivitis. Irani F, et al. **Aust N Z J Ophthalmol** 1997 May;25(2):167–8 (7 ref.)

Meningococcal meningitis revisited: normocellular CSF. Sivakmaran M. **Clin Pediatr (Phila)** 1997 Jun;36(6):351; discussion 351–5 (11 ref.)

[Bronchopneumonia caused by Neisseria meningitidis--probable transmission by a family member who had been in Hong Kong] Ohtaki M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 Apr;35(4):461–5 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Neisseria meningitidis: isolation from low respiratory tract secretions of adult patients] Ferrer Marcellés A, et al. **Rev Clin Esp** 1996 Nov;196(11):741–6 (36 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Response of Neisseria meningitidis to iron limitation. Pettersson A, et al. **Antonie Van Leeuwenhoek** 1997 Feb; 71(1–2):129–36 (34 ref.)

Post-translational modifications of meningococcal pili. Identification of common substituents: glycans and alpha-glycerophosphate--a review. Virji M. **Gene** 1997 Jun 11;192(1):141–7 (42 ref.)

PATHOGENICITY

Type-4 pili and meningococcal adhesiveness. Nassif X, et al. **Gene** 1997 Jun 11;192(1):149–53 (28 ref.)

Sialylation of neisserial lipopolysaccharide: a major influence on pathogenicity. Smith H, et al. **Microb Pathog** 1995 Dec; 19(6):365–77 (59 ref.)

NEISSERIACEAE INFECTIONS

Neonatal meningitis due to Moraxella catarrhalis and review of the literature. Daoud A, et al. **Ann Trop Paediatr** 1996 Sep;16(3):199–201 (14 ref.)

DRUG THERAPY

Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media. Block SL. **Pediatr Infect Dis J** 1997 Apr;16(4):449–56 (39 ref.)

EPIDEMIOLOGY

Kingella kingae: an emerging cause of invasive infections in young children. Yagupsky P, et al. **Clin Infect Dis** 1997 May;24(5):860–6 (80 ref.)

MICROBIOLOGY

Moraxella (Branhamella) catarrhalis--clinical and molecular aspects of a rediscovered pathogen. Enright MC, et al. **J Med Microbiol** 1997 May;46(5):360–71 (129 ref.)

Adhesion and invasion by the pathogenic neisseria. Jerse AE, et al. **Trends Microbiol** 1997 Jun;5(6):217–21 (9 ref.)

[Moraxella catarrhalis: virulence and resistance mechanisms] Cullmann W. **Med Klin** 1997 Mar 15;92(3):162–6 (52 ref.) (Eng. Abstr.) **(Ger)**

NEMALINE MYOPATHY

DIAGNOSIS

40th ENMC Sponsored International Workshop: Nemaline Myopathy. 2–4 February 1996, Naarden, The Netherlands. Wallgren-Pettersson C, et al. **Neuromuscul Disord** 1996 Oct;6(5):389–91 (6 ref.)

[Central core disease (its clinical and laboratory diagnosis)] Temin PA, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1997;97(1):62–5 (25 ref.) **(Rus)**

PATHOLOGY

Infantile intranuclear rod myopathy. Goebel HH, et al. **J Child Neurol** 1997 Jan;12(1):22–30 (14 ref.)

Nemaline myopathy with intranuclear rods--intranuclear rod myopathy. Goebel HH, et al. **Neuromuscul Disord** 1997 Jan;7(1):13–9 (30 ref.)

NEMATOCIDES see **ANTINEMATODAL AGENTS**

NEMATODA

see related
ANTINEMATODAL AGENTS

The prospects for biological control of the free-living stages of nematode parasites of livestock. Waller PJ, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):915–25 (81 ref.)

CHEMISTRY

Nematode FMRFamide-related peptide (FaRP)-systems: occurrence, distribution and physiology. Maule AG, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):927–36 (50 ref.)

CYTOLOGY

[Cell-lineage and cell-differentiation of the nematode Caenorhabditis elegans] Katsura I. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1936–43 (40 ref.) **(Jpn)**

DRUG EFFECTS

Management of anthelmintic resistance: inheritance of resistance and selection with persistent drugs [published erratum appears in Int J Parasitol 1997 Jan;27(1):141] Dobson RJ, et al. **Int J Parasitol** 1996 Aug–Sep; 26(8–9):993–1000 (27 ref.)

ENZYMOLOGY

Why do some nematode parasites of the alimentary tract secrete acetylcholinesterase? Lee DL. **Int J Parasitol** 1996 May;26(5):499–508 (91 ref.)

GENETICS

Role of transposable elements in age-related genomic instability. Nikitin AG, et al. **Genet Res** 1997 Jun; 69(3):183–95 (173 ref.)

Nematode spliced leaders--ubiquity, evolution and utility. Blaxter M, et al. **Int J Parasitol** 1996 Oct;26(10):1025–33 (51 ref.)

Worms as an evolutionary model. Emmons SW. **Trends Genet** 1997 Apr;13(4):131–4 (23 ref.)

GROWTH & DEVELOPMENT

Evolution and development--the nematode vulva as a case study. Sommer RJ. **Bioessays** 1997 Mar;19(3):225–31 (36 ref.)

Bioreactor cultivation of the nematode Caenorhabditis elegans: large scale production of biologically active drug receptors for pharmaceutical research. Gbewonyo K, et al. **Biotechnol Genet Eng Rev** 1997;14:37–49 (35 ref.)

IMMUNOLOGY

Cytokine regulation of host defense against parasitic gastrointestinal nematodes: lessons from studies with rodent models. Finkelman FD, et al. **Annu Rev Immunol** 1997; 15:505–33 (152 ref.)

Rational design of nematode vaccines; natural antigens. Meeusen EN. **Int J Parasitol** 1996 Aug–Sep;26(8–9):813–8 (35 ref.)

ISOLATION & PURIFICATION

Treatment of Oslerus osleri infestation in a dog: case report and literature review. Levitan DM, et al. **J Am Anim Hosp Assoc** 1996 Sep–Oct;32(5):435–8 (24 ref.)

PATHOGENICITY

Why do some nematode parasites of the alimentary tract secrete acetylcholinesterase? Lee DL. **Int J Parasitol** 1996 May;26(5):499–508 (91 ref.)

Nematode pathogenesis and resistance in plants. Williamson VM, et al. **Plant Cell** 1996 Oct;8(10):1735–45 (90 ref.)

PHYSIOLOGY

The role of trehalose in the physiology of nematodes. Behm CA. **Int J Parasitol** 1997 Feb;27(2):215–29 (119 ref.)

Nutrition and parasite interaction. Coop RL, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):951–62 (89 ref.)

Molecular biology and electrophysiology of glutamate-gated chloride channels of invertebrates. Cully DF, et al. **Parasitology** 1996;113 Suppl:S191–200 (64 ref.)

FMRFamide-related peptides (FaRPs) in nematodes: occurrence and neuromuscular physiology. Maule AG, et al. **Parasitology** 1996;113 Suppl:S119–35 (71 ref.)

NEMATODE INFECTIONS

see related
ANTINEMATODAL AGENTS

GENETICS

Nematode pathogenesis and resistance in plants. Williamson VM, et al. **Plant Cell** 1996 Oct;8(10):1735–45 (90 ref.)

IMMUNOLOGY

Enteric helminth infection: immunopathology and resistance during intestinal nematode infection. Grencis RK. **Chem Immunol** 1997;66:41–61 (106 ref.)

Defence against the immune barrage: helminth survival strategies. Riffkin M, et al. **Immunol Cell Biol** 1996 Dec; 74(6):564–74 (118 ref.)

PARASITOLOGY

Defence against the immune barrage: helminth survival strategies. Riffkin M, et al. **Immunol Cell Biol** 1996 Dec; 74(6):564–74 (118 ref.)

Why do some nematode parasites of the alimentary tract secrete acetylcholinesterase? Lee DL. **Int J Parasitol** 1996 May;26(5):499–508 (91 ref.)

PREVENTION & CONTROL

Rational design of nematode vaccines: hidden antigens. Munn EA. **Int J Parasitol** 1997 Apr;27(4):359–66 (30 ref.)

VETERINARY

Antigens with application toward immune control of blood-feeding parasitic nematodes. Jasmer DP, et al. **Br Vet J** 1995 May;152(3):251–68 (89 ref.)

Feasibility and implications of breeding sheep for resilience to nematode challenge. Bisset SA, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):857–68 (38 ref.)

Nutrition and parasite interaction. Coop RL, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):951–62 (89 ref.)

Phenotypic markers for selection of nematode-resistant sheep. Douch PG, et al. **Int J Parasitol** 1996 Aug–Sep; 26(8–9):899–911 (44 ref.)

Nutritional enhancement of parasite control in small ruminant production systems in developing countries of South-East Asia and the Pacific. Knox M, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):963–70 (44 ref.)

Rational design of nematode vaccines; natural antigens. Meeusen EN. **Int J Parasitol** 1996 Aug–Sep;26(8–9):813–8 (35 ref.)

Prospects for the immunological control of ruminant gastrointestinal nematodes: natural immunity, can it be harnessed? Miller HR. **Int J Parasitol** 1996 Aug–Sep; 26(8–9):801–11 (87 ref.)

Implications of nutrition for the ability of ruminants to withstand gastrointestinal nematode infections. van Houtert MF, et al. **Int J Parasitol** 1996 Nov;26(11):1151–67 (167 ref.)

The prospects for biological control of the free-living stages of nematode parasites of livestock. Waller PJ, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):915–25 (81 ref.)

Prospects of breeding small ruminants for resistance to internal parasites. Woolaston RR, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):845–55 (63 ref.)

Treatment of Oslerus osleri infestation in a dog: case report and literature review. Levitan DM, et al. **J Am Anim Hosp Assoc** 1996 Sep–Oct;32(5):435–8 (24 ref.)

Mucosal mast cells and the allergic response against nematode parasites. Miller HR. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):331–6 (28 ref.)

[Genetic aspects of sheep resistance to gastrointestinal nematode infections] Doligalska M. **Wiad Parazytol** 1995; 41(4):405–11 (42 ref.) (Eng. Abstr.) **(Pol)**

NEMATOMORPHA see **HELMINTHS**

NEMATOMORPHA INFECTIONS see **HELMINTHIASIS**

NEODYMIUM

THERAPEUTIC USE

[New therapeutic approach to pancreatic cancer by monoclonal antibodies] Sawada T, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1654–6 (10 ref.) (Eng. Abstr.) **(Jpn)**

NEOLIGNANS see **LIGNANS**

NEOMALTHUSIANISM see **POPULATION DYNAMICS**

NEONATAL ABSTINENCE SYNDROME

DIAGNOSIS

Toxicology testing in neonates. Is it ethical, and what does it mean? Millard DD. **Clin Perinatol** 1996 Sep;23(3):491–507 (84 ref.)

DRUG THERAPY

Current management of the neonatal abstinence syndrome: a critical analysis of the evidence. Theis JG, et al. **Biol Neonate** 1997;71(6):345–56 (57 ref.)

ETIOLOGY

The long-term effects of cocaine use during pregnancy--reasons for hope. Kane DJ, et al. **Wis Med J** 1997 Feb;96(2):37–40 (43 ref.)

NEONATAL CALF DIARRHEA VIRUS see **ROTAVIRUS**

NEONATAL IMMUNITY, MATERNALLY-ACQUIRED see **IMMUNITY, MATERNALLY-ACQUIRED**

NEONATAL INTENSIVE CARE see **INTENSIVE CARE, NEONATAL**

NEONATAL INTENSIVE CARE UNITS see **INTENSIVE CARE UNITS, NEONATAL**

NEONATAL MORTALITY see **INFANT MORTALITY**

NEONATAL NURSING

The laryngeal mask airway: potential applications in neonatal health care. Brimacombe J, et al. **J Obstet Gynecol Neonatal Nurs** 1997 Mar–Apr;26(2):171–8 (67 ref.)

METHODS

Ask the expert. Gastroesophageal reflux. Berube M. **J Soc Pediatr Nurs** 1997 Jan–Mar;2(1):43–6 (15 ref.)

Multidisciplinary research of multimodal stimulation of premature infants: an integrated review of the literature. Mueller CR. **Matern Child Nurs J** 1996 Jan–Mar; 24(1):18–31 (31 ref.)

TRENDS

Advanced neonatal nurse practitioners in the United Kingdom: where are they and what do they do? Dillon A, et al. **J Adv Nurs** 1997 Feb;25(2):257–64 (20 ref.)

NEONATAL SCREENING

Can severe neonatal jaundice be prevented by neonatal screening for glucose-6-phosphate dehydrogenase deficiency?--a review of evidence. Chuu WM, et al. **Acta Paediatr Sin** 1996 Sep–Oct;37(5):333–41 (66 ref.)

Ultrasound of the neonatal brain. Ng VW, et al. **Br J Hosp Med** 1997 Jan 15–Feb 5;57(1–2):19–22 (24 ref.)

Outcomes of neonatal screening for congenital hypothyroidism. Dattani M, et al. **Curr Opin Pediatr** 1996 Aug;8(4):389–95 (62 ref.)

Newborn screening for neuroblastoma. Parker L. **Curr Opin Pediatr** 1997 Feb;9(1):70–3 (27 ref.)

Neonatal hearing screening. Oudesluys-Murphy AM, et al. **Eur J Pediatr** 1996 Jun;155(6):429–35 (51 ref.)

Auditory brainstem response screening for hearing loss in high risk neonates. Watson DR, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jul;36(2):147–83 (131 ref.)

Introduction of newborn screening for galactosemia to Arkansas. West R, et al. **J Ark Med Soc** 1996 Mar; 92(10):501–4 (9 ref.)

[Congenital adrenal hyperplasia--is there a need for a national screening program] Davidovitch N, et al. **Harefuah** 1997 Jun 1;132(11):771–5 (32 ref.) **(Heb)**

METHODS

Screening for congenital hypothyroidism. Dussault JH. **Clin Obstet Gynecol** 1997 Mar;40(1):117–23 (18 ref.)

Current status of neonatal screening for congenital adrenal hyperplasia [see comments] Pang S, et al. **Curr Opin Pediatr** 1997 Aug;9(4):419–23 (19 ref.) Comment in: Curr Opin Pediatr 1997 Aug;9(4):407–12.

NEONATAL WITHDRAWAL SYNDROME see **NEONATAL ABSTINENCE SYNDROME**

NEONATE see **INFANT, NEWBORN**

NEONATOLOGY

see related
INFANT, NEWBORN

Ethical decision-making in newborn infants. Yu VY. **Acta Med Port** 1997 Feb–Mar;10(2–3):197–204 (116 ref.)

The socially complex family. New dilemmas for the neonatal social worker. Carson DP. **Clin Perinatol** 1996 Sep; 23(3):609–20 (5 ref.)

The safe introduction of new technologies into neonatal medicine. Clark RH. **Clin Perinatol** 1996 Sep;23(3):519–27 (28 ref.)

The changing nature of neonatal ethics in practice. Kinlaw K. **Clin Perinatol** 1996 Sep;23(3):417–28 (20 ref.)

Equine clinical neonatology in the USA: past, present and future. Koterba AM, et al. **Equine Vet J Suppl** 1988 Sep; (5):6–10 (22 ref.)

Neonatology in the 'Pearl of the East'. Ng PC, et al. **J Paediatr Child Health** 1996 Oct;32(5):362–7 (47 ref.)

LEGISLATION & JURISPRUDENCE

[Ethical questions in neonatology] Popow C. **Wien Klin Wochenschr** 1996;108(3):53–8 (28 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

The outcomes of very low birth weight infants: are we asking the right questions? McCormick MC. **Pediatrics** 1997 Jun; 99(6):869–76 (89 ref.)

TRENDS

Neonatal neurology, past present and future. A window on the brain. Dubowitz LM, et al. **Brain Dev** 1995;17 Suppl:22–30 (34 ref.)

Neonatal medicine. A safer leap into this dangerous world. Chan A, et al. **Lancet** 1996 Dec 21–28;348 Suppl 2:sII12 (5 ref.)

NEOPLASIA, PROSTATIC INTRAEPITHELIAL see **PROSTATIC INTRAEPITHELIAL NEOPLASIA**

NEOPLASIA, CERVICAL INTRAEPITHELIAL see **CERVICAL INTRAEPITHELIAL NEOPLASIA**

NEOPLASIA, MULTIPLE ENDOCRINE see **MULTIPLE ENDOCRINE NEOPLASIA**

NEOPLASIA, MULTIPLE ENDOCRINE TYPE 1 see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 1**

NEOPLASIA, MULTIPLE ENDOCRINE TYPE 2A see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A**

NEOPLASIA, MULTIPLE ENDOCRINE, TYPE 2B see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B**

NEOPLASM ANTIBODIES see **ANTIBODIES, NEOPLASM**

NEOPLASM ANTIGENS see **ANTIGENS, NEOPLASM**

NEOPLASM ANTIGENS, VIRAL see **ANTIGENS, VIRAL, TUMOR**

NEOPLASM CIRCULATING CELLS

Detection of occult tumour cells in bone marrow and blood in breast cancer patients--methods and clinical significance. Kvalheim G. **Acta Oncol** 1996;35 Suppl 8:13–8 (31 ref.)

Pulmonary tumor embolism. Bassiri AG, et al. **Am J Respir Crit Care Med** 1997 Jun;155(6):2089–95 (61 ref.)

Acute vascular embolus resulting from metastatic endocardial involvement with synovial sarcoma: report of a case and review of the literature. Khoo V, et al. **Australas Radiol** 1997 Feb;41(1):49–52 (71 ref.)

Renal cell carcinoma with cavitoatrial extension: case report and review of the literature. López Candales A, et al. **Bol Asoc Med P R** 1996 Apr–Jun;88(4–6):42–5 (27 ref.)

Metastatic inefficiency: intravascular and intraperitoneal implantation of cancer cells. Weiss L. **Cancer Treat Res** 1996;82:1–11 (34 ref.)

Clinical results of Greenfield filter use in patients with cancer. Greenfield LJ, et al. **Cardiovasc Surg** 1997 Apr;5(2):145–9 (21 ref.)

Portal tumor thrombi due to gastric cancer. Sugawara Y, et al. **Hepatogastroenterology** 1996 Jul–Aug;43(10):1000–5 (25 ref.)

Perioperative stimulation of residual cancer cells promotes local and distant recurrence of breast cancer. Reid SE, et al. **J Am Coll Surg** 1997 Sep;185(3):290–306 (143 ref.)

Purging of tumor cells from leukapheresis products: experimental and clinical aspects. Kvalheim G, et al. **J Hematother** 1996 Aug;5(4):427–36 (31 ref.)

Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. Gomella LG, et al. **J Urol** 1997 Aug;158(2):326–37 (87 ref.)

Incidentally detected renal angiomyolipoma with tumour thrombus into the inferior vena cava. Rubio-Briones J, et al. **Scand J Urol Nephrol** 1997 Apr;31(2):189–91 (14 ref.)

Detection of occult melanoma cells in sentinel lymph nodes and blood. Reintgen DS, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 4):S11–5 (23 ref.)

Survival of patients with renal cell carcinoma invading the inferior vena cava. Mattos RM, et al. **Semin Urol Oncol** 1996 Nov;14(4):223–6 (15 ref.)

Transitional cell carcinoma of the kidney with tumor thrombus into the vena cava. Williams JH, et al. **Urology** 1996 Dec;48(6):932–5 (14 ref.)

[Tumor embolism with fatal cerebral infarct in pneumonectomy. Case report and review of the literature] Zürcher M, et al. **Chirurg** 1996 Sep;67(9):959–62 (37 ref.) (Eng. Abstr.) **(Ger)**

[Inhibition of metastases by antithrombotic agents] Donati MB, et al. **Internist (Berl)** 1997 Jul;38(7):644–9 (31 ref.) **(Ger)**

[Rational diagnosis and surgical therapy of renal cell carcinoma with tumor thrombosis in the vena cava] Piechota HJ, et al. **Urologe A** 1997 Jan;36(1):54–63 (47 ref.) (Eng. Abstr.) **(Ger)**

[Molecular diagnostic detection of circulating tumor cells and their prognostic implications] Nakanishi H, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(3):257–65 (33 ref.) (Eng. Abstr.) **(Jpn)**

[Bilateral renal cell carcinoma with extension into the vena cava associated with von Hippel-Lindau disease: a case report and review of the literature] Minamide M, et al. **Hinyokika Kiyo** 1996 May;42(5):361–4 (8 ref.) (Eng. Abstr.) **(Jpn)**

[A case report of mitral valve papillary fibroelastoma leading to embolic stroke] Shirota K, et al. **Kyobu Geka** 1996 Jul; 49(7):571–4 (18 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Evaluating neoadjuvant therapy effectiveness on systemic disease: use of a prostatic-specific membrane reverse transcription polymerase chain reaction. Su SL, et al. **Urology** 1997 Mar;49(3A Suppl):95–101 (37 ref.)

METABOLISM

Adhesive proteins and the hematogenous spread of cancer. Tuszynski GP, et al. **Acta Haematol** 1997;97(1–2):29–39 (100 ref.)

PATHOLOGY

Cytokine-mediated tumor–endothelial cell interaction in metastasis. Giavazzi R. **Curr Top Microbiol Immunol** 1996; 213 (Pt 2):13–30 (149 ref.)

[The detection of circulating prostatic cells using RT-PCR] Eschwege P. **Prog Urol** 1997 Feb;7(1):92–6 (10 ref.) **(Fre)**

[The superior vena cava occlusion syndrome. A case of neoplastic thrombosis due to hepatocarcinoma and cirrhosis] Zanetti PP, et al. **Minerva Chir** 1997 Apr; 52(4):455–9 (20 ref.) (Eng. Abstr.) **(Ita)**

NEOPLASM DNA see **DNA, NEOPLASM**

NEOPLASM INVASIVENESS

see related
LEUKEMIC INFILTRATION

What structure and function of avian plasminogen activator and matrix metalloproteinase-2 reveal about their counterpart mammalian enzymes, their regulation and their role in tumor invasion. Alexander DS, et al. **Enzyme Protein** 1996;49(1–3):38–58 (98 ref.)

Cooperation between matrix metalloproteinases and the plasminogen activator-plasmin system in tumor progression. DeClerck YA, et al. **Enzyme Protein** 1996; 49(1–3):72–84 (95 ref.)

The regulation of proliferation and invasion in differentiated thyroid cancer by growth factors. Hoelting T, et al. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 4:29–31 (9 ref.)

Tumor angiogenesis: functional similarities with tumor invasion. Stetler-Stevenson WG, et al. **EXS** 1997;79:413–8 (27 ref.)

The role of calcium in the regulation of invasion and angiogenesis. Alessandro R, et al. **In Vivo** 1996 Mar–Apr; 10(2):153–60 (61 ref.)

Mechanisms of tumor invasion and metastasis. Lawrence JA, et al. **World J Urol** 1996;14(3):124–30 (84 ref.)

[Endocrinological contribution for invasion and metastasis in gynecological cancers] Fujimoto J. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Aug; 48(8):633–43 (30 ref.) (Eng. Abstr.) **(Jpn)**

[Matrix metalloproteinases: their structures and functions, with special reference to their roles in tumor invasion and metastasis] Miyazaki K, et al. **Seikagaku** 1996 Dec; 68(12):1791–807 (97 ref.) **(Jpn)**

GENETICS

Downregulation in vivo of the invasion-suppressor molecule E-cadherin in experimental and clinical cancer. Mareel M, et al. **Princess Takamatsu Symp** 1994;24:63–80 (71 ref.)

PATHOLOGY

Role of stromal myofibroblasts infiltrating colon cancer in tumor invasion. Martin M, et al. **Pathol Res Pract** 1996 Jul;192(7):712–7 (47 ref.)

Molecular aspects of the loss of cell adhesion and gain of invasiveness in carcinomas. Birchmeier W. **Princess Takamatsu Symp** 1994;24:214–32 (113 ref.)

Matrix-degrading metalloproteinases in tumor progression. Matrisian LM, et al. **Princess Takamatsu Symp** 1994; 24:152–61 (27 ref.)

Cancer-stromal interaction through growth factor/cytokine networks implicated in growth of stomach cancer. Tahara E. **Princess Takamatsu Symp** 1994;24:187–94 (19 ref.)

NEOPLASM INVASIVENESS

Neoplastic progression and prognosis in melanoma. Elder DE, et al. **Semin Cutan Med Surg** 1996 Dec;15(4):336–48 (87 ref.)
Melanoma and stroma: an interaction of biological and prognostic importance. Smolle J, et al.
Semin Cutan Med Surg 1996 Dec;15(4):326–35 (108 ref.)
[Screening for the inhibitors of tumor invasion into basement membranes] Saiki I. **Gan To Kagaku Ryoho** 1997 Jan; 24(2):187–95 (21 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

The biochemistry of cancer dissemination. Price JT, et al. **Crit Rev Biochem Mol Biol** 1997;32(3):175–253 (643 ref.)
A possible role for enzymes in tumour-cell invasion. van Aswegen CH, et al. **Med Hypotheses** 1997 May;48(5):443–7 (63 ref.)
The plasminogen activation system in tumour invasion and metastasis. de Vries TJ, et al. **Pathol Res Pract** 1996 Jul; 192(7):718–33 (242 ref.)
Invasive carcinomas dismantle surrounding stroma induced to express the nuclear factor c-ets-1. Stehelin D.
Princess Takamatsu Symp 1994;24:171–86 (48 ref.)
The role of cell adhesion molecules and proteases in tumor invasion and metastasis. Bussemakers MJ, et al.
World J Urol 1996;14(3):151–6 (63 ref.)
[News from basic research: mechanisms of metastasis] Kath R, et al. **Pneumologie** 1996 Jul;50(7):487–93 (109 ref.) **(Ger)**

PREVENTION & CONTROL

Anti-invasion drugs. Dickson RB, et al.
Breast Cancer Res Treat 1996;38(1):121–32 (126 ref.)
Cadherin/catenin complex: a target for antiinvasive therapy? Mareel M, et al. **J Cell Biochem** 1996 Jun 15;61(4):524–30 (39 ref.)
Regulation of the invasion suppressor function of the cadherin/catenin complex. Vermeulen S, et al.
Pathol Res Pract 1996 Jul;192(7):694–707 (97 ref.)
Current and future strategies to block tumor angiogenesis, invasion, and metastasis. Effert PJ, et al. **World J Urol** 1996; 14(3):131–40 (81 ref.)

NEOPLASM METASTASIS

The biochemistry of metastasis. Duffy MJ.
Adv Clin Chem 1996;32:135–66 (138 ref.)
Inhibition of experimental metastasis by enzyme inhibitors from microorganisms and plants. Umezawa K.
Adv Enzyme Regul 1996;36:267–81 (22 ref.)
Radioisotopes in the treatment of bone metastases. Ben-Josef E, et al. **Ann Med** 1997 Feb;29(1):31–5 (41 ref.)
Use of immunocytochemistry in the diagnosis of metastatic carcinoma. Matthews P, et al. **Ann Med** 1996 Aug; 28(4):297–300 (48 ref.)
Late relapse of germ cell tumors after cisplatin-based chemotherapy. Gerl A, et al. **Ann Oncol** 1997 Jan;8(1):41–7 (28 ref.)
Metastatic inefficiency: intravascular and intraperitoneal implantation of cancer cells. Weiss L. **Cancer Treat Res** 1996;82:1–11 (34 ref.)
Technical considerations for studying cancer metastasis in vivo. Welch DR. **Clin Exp Metastasis** 1997 May; 15(3):272–306 (352 ref.)
Metastatic breast cancer. Kennedy MJ. **Curr Opin Oncol** 1996 Nov;8(6):485–90 (32 ref.)
Alterations and role of human cathepsin D in cancer metastasis. Rochefort H, et al. **Enzyme Protein** 1996; 49(1–3):106–16 (54 ref.)
Pleural diseases related to metastatic malignancies [see comments] Sahn SA. **Eur Respir J** 1997 Aug;10(8):1907–13 (50 ref.) Comment in: Eur Respir J 1997 Aug;10(8):1701–2.
Estradiol receptors and metastasis in human breast cancer. Görlich M, et al. **Folia Biol (Praha)** 1996;42(1–2):3–10 (65 ref.)
The urokinase-type plasminogen activator system in cancer metastasis: a review. Andreasen PA, et al. **Int J Cancer** 1997 Jul 3;72(1):1–22 (325 ref.)
Membrane-type matrix metalloproteinases (MT-MMPs) in tumor metastasis. Sato H, et al. **J Biochem (Tokyo)** 1996 Feb;119(2):209–15 (36 ref.)
The immune-suppressive nature of pain. Page GG, et al.
Semin Oncol Nurs 1997 Feb;13(1):10–5 (50 ref.)
Biological and clinical significance of cathepsin D in breast cancer metastasis. Garcia M, et al. **Stem Cells** 1996 Nov; 14(6):642–50 (63 ref.)
Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Maxon HR, et al. **Thyroid** 1997 Apr; 7(2):183–7 (26 ref.)
Mechanisms of tumor invasion and metastasis. Lawrence JA, et al. **World J Urol** 1996;14(3):124–30 (84 ref.)
[Role of nuclear medicine in the diagnosis and treatment of macroscopic metastases] Chatal LF.
Ann Endocrinol (Paris) 1997;58(3):248–50 (6 ref.) (Eng. Abstr.) **(Fre)**
[Endocrinological contribution for invasion and metastasis in gynecological cancers] Fujimoto J.
Nippon Sanka Fujinka Gakkai Zasshi 1996 Aug; 48(8):633–43 (30 ref.) (Eng. Abstr.) **(Jpn)**
[Adhesion molecules and carbohydrates in cancer metastasis] Kawaguchi T. **Rinsho Byori** 1996 Dec;44(12):1138–46 (26 ref.) (Eng. Abstr.) **(Jpn)**
[Adhesion molecules and cancer metastasis] Ota I, et al.
Rinsho Byori 1997 Jun;45(6):528–33 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Matrix metalloproteinases: their structures and functions, with special reference to their roles in tumor invasion and metastasis] Miyazaki K, et al. **Seikagaku** 1996 Dec; 68(12):1791–807 (97 ref.) **(Jpn)**

DIAGNOSIS

Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer. Isaacs JT.
Am J Pathol 1997 May;150(5):1511–21 (92 ref.)
CD44 as a marker in human cancers. Sy MS, et al.
Curr Opin Oncol 1997 Jan;9(1):108–12 (57 ref.)
Quality management and influential factors for the detection of single metastatic cancer cells by reverse transcriptase polymerase chain reaction. Jung R, et al.
Eur J Clin Chem Clin Biochem 1997 Jan;35(1):3–10 (53 ref.)
Isolated tumor cells in the bone marrow: value of a new diagnostic method in the TNM-staging of solid tumors. Werner M, et al. **Gen Diagn Pathol** 1996 Jun;142(1):1–6 (53 ref.)
Critical evaluation of prognostic factors. Dhingra K, et al. **Semin Oncol** 1996 Aug;23(4):436–45 (79 ref.)

GENETICS

Modulation of tumor cell gene expression and phenotype by the organ-specific metastatic environment. Radinsky R.
Cancer Metastasis Rev 1995 Dec;14(4):323–38 (142 ref.)
Oncogene-initiated aberrant signaling engenders the metastatic phenotype: synergistic transcription factor interactions are targets for cancer therapy. Denhardt DT.
Crit Rev Oncog 1996;7(3–4):261–91 (238 ref.)
Differential gene expression in tumor metastasis: Nm23. Freije JM, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 2):215–32 (62 ref.)
Metastasis-related mts1 gene. Lukanidin EM, et al.
Curr Top Microbiol Immunol 1996;213 (Pt 2):171–95 (110 ref.)
Regulation of autocrine motility factor receptor expression in tumor cell locomotion and metastasis. Silletti S, et al.
Curr Top Microbiol Immunol 1996;213 (Pt 2):137–69 (153 ref.)
Quality management and influential factors for the detection of single metastatic cancer cells by reverse transcriptase polymerase chain reaction. Jung R, et al.
Eur J Clin Chem Clin Biochem 1997 Jan;35(1):3–10 (53 ref.)
The role of motility proteins and metastasis-suppressor genes in prostate cancer progression. Rinker-Schaeffer CW, et al. **Stem Cells** 1996 Sep;14(5):508–16 (50 ref.)
[Molecular mechanisms of cancer metastasis--ets-related nuclear transcription factor play an important role in cancer metastasis] Kaya M, et al. **Gan To Kagaku Ryoho** 1996 Sep; 23(10):1225–34 (52 ref.) (Eng. Abstr.) **(Jpn)**
[Expression of nm23/NDP kinase and cancer metastasis] Okada K, et al. **Nippon Rinsho** 1996 Mar;54(3):845–53 (23 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Adhesive proteins and the hematogenous spread of cancer. Tuszynski GP, et al. **Acta Haematol** 1997;97(1–2):29–39 (100 ref.)
Detection of occult tumour cells in bone marrow and blood in breast cancer patients--methods and clinical significance. Kvalheim G. **Acta Oncol** 1996;35 Suppl 8:13–8 (31 ref.)
Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer. Isaacs JT.
Am J Pathol 1997 May;150(5):1511–21 (92 ref.)
Steps in tumor metastasis: new concepts from intravital videomicroscopy. Chambers AF, et al.
Cancer Metastasis Rev 1995 Dec;14(4):279–301 (45 ref.)
The metastatic phenotype--prognostic implications. Lindblom A, et al. **Crit Rev Oncol Hematol** 1996 Oct; 24(2):71–96 (321 ref.)
Surgical palliation of colorectal cancer. Sigurdson ER.
Curr Probl Cancer 1995 Nov-Dec;19(6):348–59 (58 ref.)
Epithelial differentiation and the control of metastasis in carcinomas. Birchmeier W, et al.
Curr Top Microbiol Immunol 1996;213 (Pt 2):117–35 (163 ref.)
Proteases associated with invadopodia, and their role in degradation of extracellular matrix. Chen WT.
Enzyme Protein 1996;49(1–3):59–71 (83 ref.)
Isolated tumor cells in the bone marrow: value of a new diagnostic method in the TNM-staging of solid tumors. Werner M, et al. **Gen Diagn Pathol** 1996 Jun;142(1):1–6 (53 ref.)
Matrix-degrading metalloproteinases in tumor progression. Matrisian LM, et al. **Princess Takamatsu Symp** 1994; 24:152–61 (27 ref.)
Analysis of molecular functions of the tumor metastasis promoting surface molecule CD44v4–v7 using transgenic mice. Moll J, et al. **Princess Takamatsu Symp** 1994; 24:142–51 (34 ref.)
Cell adhesion and tumor metastasis. Ruoslahti E.
Princess Takamatsu Symp 1994;24:99–105 (36 ref.)
[Follow-up of testicular tumors in the metastatic diffusion phase. Current orientation] Mirone V, et al.
Minerva Urol Nefrol 1997 Jun;49(2):91–4 (13 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Glycoconjugate cross-talk in metastatic cancer cells, leucocytes, parasites and bacteria. Leroy A, et al.
Biochem Soc Trans 1997 Feb;25(1):228–34 (48 ref.)
The biochemistry of cancer dissemination. Price JT, et al.
Crit Rev Biochem Mol Biol 1997;32(3):175–253 (643 ref.)
Cytokine-mediated tumor-endothelial cell interaction in metastasis. Giavazzi R. **Curr Top Microbiol Immunol** 1996; 213 (Pt 2):13–30 (149 ref.)
Regulation of tumor angiogenesis by organ-specific cytokines. Singh RK, et al.
Curr Top Microbiol Immunol 1996;213 (Pt 2):1–11 (50 ref.)
Adhesion molecules and tumor cell-vasculature interactions: modulation by bioactive lipid molecules. Tang DG, et al.
Curr Top Microbiol Immunol 1996;213 (Pt 2):69–88 (76 ref.)
Angiogenesis and metastasis. Ellis LM, et al.
Eur J Cancer 1996 Dec;32A(14):2451–60 (119 ref.)
The role of the vascular endothelium in inflammatory syndromes, atherogenesis, and the propagation of disease. Hill GE, et al. **J Cardiothorac Vasc Anesth** 1997 May; 11(3):316–21 (76 ref.)
New insights into tumor-host interactions in lymphoma metastasis. Umansky V, et al. **J Mol Med** 1996 Jul; 74(7):353–63 (122 ref.)
Changing views of the role of matrix metalloproteinases in metastasis. Chambers AF, et al. **J Natl Cancer Inst** 1997 Sep 3;89(17):1260–70 (127 ref.)
Inflammation and metastases. Nowacki MP, et al.
Med Hypotheses 1996 Sep;47(3):193–6 (47 ref.)
The plasminogen activation system in tumour invasion and metastasis. de Vries TJ, et al. **Pathol Res Pract** 1996 Jul; 192(7):718–33 (242 ref.)
Possible involvement of adherens junction plaque proteins in tumorigenesis and metastasis. Tsukita S, et al.
Princess Takamatsu Symp 1994;24:38–50 (69 ref.)
The role of cell adhesion molecules and proteases in tumor invasion and metastasis. Bussemakers MJ, et al.
World J Urol 1996;14(3):151–6 (63 ref.)
Cytokines in tumour growth, migration and metastasis. Negus RP, et al. **World J Urol** 1996;14(3):157–65 (134 ref.)
The cellular basis of metastasis. Ruiz P, et al.
World J Urol 1996;14(3):141–50 (89 ref.)
[News from basic research: mechanisms of metastasis] Kath R, et al. **Pneumologie** 1996 Jul;50(7):487–93 (109 ref.) **(Ger)**
[Adhesion molecules involved in cancer metastasis] Mitsui H, et al. **Rinsho Byori** 1996 Sep;Suppl 102:164–72 (21 ref.) **(Jpn)**
[CD44--cell receptor for hyaluronate. Clinical aspects of structure and function] Matysiak W.
Pol Arch Med Wewn 1996 Sep;96(3):297–302 (35 ref.) **(Pol)**

PREVENTION & CONTROL

Antimetastatic action of the prostacyclin analogue cicaprost in experimental mammary tumors. Schneider MR, et al.
Breast Cancer Res Treat 1996;38(1):133–41 (21 ref.)
Prevention of cancer metastasis in mice with fibronectin-related substances. Azuma I, et al.
Princess Takamatsu Symp 1994;24:125–41 (70 ref.)
Current and future strategies to block tumor angiogenesis, invasion, and metastasis. Effert PJ, et al. **World J Urol** 1996; 14(3):131–40 (81 ref.)
[Inhibition of metastases by antithrombotic agents] Donati MB, et al. **Internist (Berl)** 1997 Jul;38(7):644–9 (31 ref.) **(Ger)**

NEOPLASM METASTASIS, UNKNOWN PRIMARY see **NEOPLASMS, UNKNOWN PRIMARY**

NEOPLASM PROTEINS

A new transcription factor family associated with human leukemias. Speck NA, et al.
Crit Rev Eukaryot Gene Expr 1995;5(3–4):337–64 (169 ref.)
Protein tyrosine phosphatase-like proteins: link with IDDM. Pietropaolo M, et al. **Diabetes Care** 1997 Feb;20(2):208–14 (42 ref.)
Endothelial-monocyte-activating polypeptide II. Tas MP, et al. **Int J Biochem Cell Biol** 1996 Aug;28(8):837–41 (13 ref.)
[HS1 and EMS1] He H. **Gan To Kagaku Ryoho** 1997 Sep; 24(11):1448–53 (21 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

Laser scanning cytometry in pathology of solid tumors. A review. Gorczyca W, et al. **Acta Cytol** 1997 Jan-Feb; 41(1):98–108 (74 ref.)
Circulating tumor markers in gynecological tumors. Rustin GJ. **Curr Opin Oncol** 1996 Sep;8(5):426–31 (51 ref.)
Molecular oncology in pancreatic cancer. Gansauge S, et al. **J Mol Med** 1996 Jun;74(6):313–20 (97 ref.)
The clinicopathological features of anaplastic large cell lymphomas expressing p80NPM/ALK. Shiota M, et al.
Leuk Lymphoma 1996 Sep;23(1–2):25–32 (25 ref.)
[Activation of epidermal melanocytes is independent of epithelial proliferation and vascularization.

Immunohistologic study using HMB-45 antibody with review of the literature] Lommel K, et al. **Hautarzt** 1996 Aug;47(8):616–23 (65 ref.) (Eng. Abstr.) **(Ger)**

[Usefulness of prostate-specific antigen in the screening of cancer of the prostate] Buitrago F, et al. **Aten Primaria** 1996 Sep 30;18(5):265–70 (67 ref.) **(Spa)**

ANTAGONISTS & INHIBITORS

Antisense-protein kinase A: a single-gene-based therapeutic approach. Cho-Chung YS, et al.
Antisense Nucleic Acid Drug Dev 1997 Jun;7(3):217–23 (20 ref.)

Oncogene products as therapeutic targets for cancer. Huang PS, et al. **Curr Opin Oncol** 1997 Jan;9(1):94–100 (83 ref.)

Multiple pathways to cellular senescence: role of telomerase repressors. Oshimura M, et al. **Eur J Cancer** 1997 Apr; 33(5):710–5 (50 ref.)

Prevention of cancer metastasis in mice with fibronectin-related substances. Azuma I, et al.
Princess Takamatsu Symp 1994;24:125–41 (70 ref.)

BIOSYNTHESIS

Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion. Barrand MA, et al. **Gen Pharmacol** 1997 May;28(5):639–45 (44 ref.)

Regulation of VIP gene expression in general. Human lung cancer cells in particular. Davidson A, et al.
J Mol Neurosci 1996 Summer;7(2):99–110 (77 ref.)

Bcl-2 expression in acute myeloblastic leukaemia: relationship with autonomous growth and CD34 antigen expression. Bradbury DA, et al. **Leuk Lymphoma** 1997 Jan; 24(3–4):221–8 (48 ref.)

Interactions involving cyclosporine A, interleukin-6, and Epstein-Barr virus lead to the promotion of B-cell lymphoproliferative disease. Tanner JE, et al.
Leuk Lymphoma 1996 May;21(5–6):379–90 (77 ref.)

Downregulation in vivo of the invasion-suppressor molecule E-cadherin in experimental and clinical cancer. Mareel M, et al. **Princess Takamatsu Symp** 1994;24:63–80 (71 ref.)

BLOOD

Parathyroid hormone-related protein in an esophageal squamous cell carcinoma with tumor-induced hypercalcemia. Jaïs P, et al. **Am J Gastroenterol** 1997 Feb; 92(2):343–6 (19 ref.)

Gastrin and colon cancer: a unifying hypothesis. Joshi SN, et al. **Dig Dis** 1996 Nov-Dec;14(6):334–44 (78 ref.)

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. Small EJ, et al. **J Clin Oncol** 1997 Jan;15(1):382–8 (39 ref.)

DEFICIENCY

The biological significance of the multidrug resistance gene MRP in inversion 16 leukemias. Kuss BJ, et al.
Leuk Lymphoma 1996 Feb;20(5–6):357–64 (34 ref.)

GENETICS

The PML nuclear compartment and cancer. Doucas V, et al. **Biochim Biophys Acta** 1996 Dec 9;1288(3):M25–9 (38 ref.)

Multidrug resistance: molecular mechanisms and clinical relevance. Ling V. **Cancer Chemother Pharmacol** 1997;40 Suppl:S3–8 (36 ref.)

Hereditary predisposition to breast cancer. Stratton MR, et al. **Curr Opin Genet Dev** 1996 Feb;6(1):93–7 (29 ref.)

Recent advances in breast cancer biology. Blackwood MA, et al. **Curr Opin Oncol** 1996 Nov;8(6):449–54 (49 ref.)

Characterisation of the PML/RAR alpha rearrangement associated with t(15;17) acute promyelocytic leukaemia. Grimwade D, et al. **Curr Top Microbiol Immunol** 1997; 220:81–112 (153 ref.)

Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Pollock PM, et al.
Genes Chromosomes Cancer 1996 Feb;15(2):77–88 (69 ref.)

Recent advances in understanding of genetic susceptibility to breast cancer. Stratton MR. **Hum Mol Genet** 1996;5 Spec No:1515–9 (50 ref.)

Target of skin tumorigenesis: cyclin D1-cdk4. Inohara S, et al. **Int J Dermatol** 1996 Sep;35(9):609–13 (59 ref.)

Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium [see comments] Burke W, et al. **JAMA** 1997 Mar 26;277(12):997–1003 (120 ref.) Comment in: JAMA 1997 Jul 23–30;278(4):289–90; discussion 290. Comment in: JAMA 1997 Jul 23–30;278(4):290.

The involvement of the candidate proto-oncogene NFKB2/lyt-10 in lymphoid malignancies. Neri A, et al.
Leuk Lymphoma 1996 Sep;23(1–2):43–8 (38 ref.)

p16ink4a gene and hematological malignancies. Quesnel B, et al. **Leuk Lymphoma** 1996 Jun;22(1–2):11–24 (126 ref.)

Overexpression of the MDM2 oncogene in leukemia and lymphoma. Watanabe T, et al. **Leuk Lymphoma** 1996 May; 21(5–6):391–7, color plates XVI following 5 (49 ref.)

Trefoil peptides in the defense of the gastrointestinal tract. Plaut AG. **N Engl J Med** 1997 Feb 13;336(7):506–7 (4 ref.)

Double indemnity: p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in Brca1 and Brca2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair [news] Brugarolas J, et al.
Nat Med 1997 Jul;3(7):721–2 (24 ref.)

Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families [see comments] Tonin P, et al. **Nat Med** 1996 Nov;2(11):1179–83 (25 ref.) Comment in: Nat Med 1996 Nov;2(11):1162.

IMMUNOLOGY

Making the most of mucin: a novel target for tumor immunotherapy. Barratt-Boyes SM.
Cancer Immunol Immunother 1996 Nov;43(3):142–51 (65 ref.)

Carcinoembryonic antigen as a target for cancer vaccines. Hodge JW. **Cancer Immunol Immunother** 1996 Nov; 43(3):127–34 (32 ref.)

Carbohydrate antigens as targets for active specific immunotherapy. Ragupathi G.
Cancer Immunol Immunother 1996 Nov;43(3):152–7 (61 ref.)

Oncogene products represent potential targets of tumor vaccines. Tuttle TM. **Cancer Immunol Immunother** 1996 Nov;43(3):135–41 (62 ref.)

Oncogenic proteins as tumor antigens. Disis ML, et al.
Curr Opin Immunol 1996 Oct;8(5):637–42 (42 ref.)

Development of cancer vaccine by tumor rejection antigens. Itoh K, et al. **Int Rev Immunol** 1997;14(2–3):153–71 (29 ref.)

Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. Kawakami Y, et al. **Int Rev Immunol** 1997;14(2–3):173–92 (103 ref.)

Apoptosis of T lymphoma cells and its inhibition by monoclonal antibodies against cell surface adhesion molecules. Tsuruo T, et al. **Princess Takamatsu Symp** 1994; 24:91–8 (18 ref.)

Melanoma-associated tumor antigens and their clinical relevance to immunotherapy. Gattoni-Celli S, et al.
Semin Oncol 1996 Dec;23(6):754–8 (39 ref.)

METABOLISM

Parathyroid hormone-related protein: from hypercalcemia of malignancy to developmental regulatory molecule. Dunbar ME, et al. **Am J Med Sci** 1996 Dec;312(6):287–94 (42 ref.)

Redox regulation of cellular activation. Nakamura H, et al. **Annu Rev Immunol** 1997;15:351–69 (93 ref.)

Telomere dynamics and telomerase activity in in vitro immortalised human cells. Bryan TM, et al.
Eur J Cancer 1997 Apr;33(5):767–73 (60 ref.)

Multiple pathways for the regulation of telomerase activity. Holt SE, et al. **Eur J Cancer** 1997 Apr;33(5):761–6 (52 ref.)

Telomere structure and telomerase expression during mouse development and tumorigenesis. Kipling D.
Eur J Cancer 1997 Apr;33(5):792–800 (44 ref.)

The implications of telomerase biochemistry for human disease. Morin GB. **Eur J Cancer** 1997 Apr;33(5):750–60 (89 ref.)

Telomeres and telomerase in normal and malignant haematopoietic cells. Norrback KF, et al. **Eur J Cancer** 1997 Apr;33(5):774–80 (57 ref.)

Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Manne U, et al. **Int J Cancer** 1997 Jun 20;74(3):346–58 (75 ref.)

Cyclin D1 in mammary carcinoma. Barnes DM. **J Pathol** 1997 Mar;181(3):267–9 (31 ref.)

PHARMACOLOGY

Thioredoxin/adult T-cell leukemia-derived factor (ADF) and redox regulation. Sasada T, et al. **J Toxicol Sci** 1996 Dec;21(5):285–7 (0 ref.)

PHYSIOLOGY

Beta-1-integrin expression in adult acute lymphoblastic leukemia: possible relationship with the stem cell antigen CD34. Cacciola RR, et al. **Acta Haematol** 1997; 97(1–2):63–6 (41 ref.)

The role of adhesion molecules in multiple myeloma. Cook G, et al. **Acta Haematol** 1997;97(1–2):81–9 (65 ref.)

Regulation and function of adhesion molecules in B-cell chronic lymphocytic leukaemia. Jewell AP, et al.
Acta Haematol 1997;97(1–2):67–72 (25 ref.)

Expression and function of adhesion receptors in acute myelogenous leukemia: parallels with normal erythroid and myeloid progenitors. Liesveld JL. **Acta Haematol** 1997; 97(1–2):53–62 (108 ref.)

Adhesion molecules in the dissemination of non-Hodgkin's lymphomas. Pals ST, et al. **Acta Haematol** 1997; 97(1–2):73–80 (84 ref.)

Adhesive proteins and the hematogenous spread of cancer. Tuszynski GP, et al. **Acta Haematol** 1997;97(1–2):29–39 (100 ref.)

The dual role of mutant p53 protein in chemosensitivity of human cancers. Mueller H, et al. **Anticancer Res** 1996 Nov-Dec;16(6B):3845–8 (25 ref.)

The SCL/TAL1 gene: roles in normal and malignant haematopoiesis. Robb L, et al. **Bioessays** 1997 Jul; 19(7):607–13 (69 ref.)

Parathyroid hormone-related peptide and hypercalcemia of malignancy. Goltzman D, et al. **Cancer Treat Res** 1997; 89:193–215 (96 ref.)

The BRCA1 and BRCA2 breast cancer genes. Casey G.
Curr Opin Oncol 1997 Jan;9(1):88–93 (84 ref.)

Role of oncogenes in resistance and killing by cancer therapeutic agents. el-Deiry WS. **Curr Opin Oncol** 1997 Jan;9(1):79–87 (122 ref.)

Transcription factors of the bHLH and LIM families: synergistic mediators of T cell acute leukemia? Baer R, et al. **Curr Top Microbiol Immunol** 1997;220:55–65 (58 ref.)

Role of Tiam 1 in Rac-mediated signal transduction pathways. Collard JG, et al.
Curr Top Microbiol Immunol 1996;213 (Pt 2):253–65 (73 ref.)

Differential gene expression in tumor metastasis: Nm23. Freije JM, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 2):215–32 (62 ref.)

The TEL gene contributes to the pathogenesis of myeloid and lymphoid leukemias by diverse molecular genetic mechanisms. Golub TR, et al.
Curr Top Microbiol Immunol 1997;220:67–79 (15 ref.)

Metastasis-related mts1 gene. Lukanidin EM, et al.
Curr Top Microbiol Immunol 1996;213 (Pt 2):171–95 (110 ref.)

Alterations in cell cycle control during tumor progression: effects on apoptosis and the response to therapeutic agents. Muschel RJ, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 2):197–213 (110 ref.)

Brain metastasis: role of trophic, autocrine, and paracrine factors in tumor invasion and colonization of the central nervous system. Nicolson GL, et al.
Curr Top Microbiol Immunol 1996;213 (Pt 2):89–115 (138 ref.)

NM23/Nucleoside diphosphate kinase as a transcriptional activator of c-myc. Postel EH.
Curr Top Microbiol Immunol 1996;213 (Pt 2):233–52 (96 ref.)

TLS-CHOP and the role of RNA-binding proteins in oncogenic transformation. Ron D.
Curr Top Microbiol Immunol 1997;220:131–42 (53 ref.)

Influence of c-myc on the progression of human breast cancer. Watson PH, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 2):267–83 (146 ref.)

Clinical implications of telomerase in cancer. Kim NW.
Eur J Cancer 1997 Apr;33(5):781–6 (35 ref.)

A survey of telomerase activity in human cancer. Shay JW, et al. **Eur J Cancer** 1997 Apr;33(5):787–91 (51 ref.)

BCL-6 in diffuse large-cell lymphomas. Dalla-Favera R, et al. **Important Adv Oncol** 1996;:139–48 (49 ref.)

Telomerase and cancer. Harley CB, et al.
Important Adv Oncol 1996;:57–67 (71 ref.)

Tumor angiogenesis and the role of vascular cell integrin alphavbeta3. Varner JA, et al. **Important Adv Oncol** 1996; :69–87 (259 ref.)

Telomeres and telomerase in human hematologic neoplasia. Yamada O. **Int J Hematol** 1996 Aug;64(2):87–99 (72 ref.)

Regulation of nuclear oncogenes expressed in lung cancer cell lines. Sabichi AL, et al. **J Cell Biochem Suppl** 1996; 24:218–27 (31 ref.)

CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells. Gruss H-J, et al. **Leuk Lymphoma** 1996 Feb;20(5–6):397–409 (79 ref.)

The retinoblastoma susceptibility gene RB-1 in multiple myeloma. Juge-Morineau N, et al. **Leuk Lymphoma** 1997 Jan;24(3–4):229–37 (71 ref.)

The neural cell adhesion molecule NCAM in multiple myeloma. Kaiser U, et al. **Leuk Lymphoma** 1996 Feb; 20(5–6):389–95 (57 ref.)

DNA methylation and developmental genes in lymphomagenesis—more questions than answers? Kay PH, et al. **Leuk Lymphoma** 1997 Jan;24(3–4):211–20 (58 ref.)

Multidrug resistance-associated protein (MRP) in haematological malignancies. Nooter K, et al.
Leuk Lymphoma 1996 Feb;20(5–6):381–7 (34 ref.)

CSF-1 and its receptor in breast carcinomas and neoplasms of the female reproductive tract. Kacinski BM.
Mol Reprod Dev 1997 Jan;46(1):71–4 (17 ref.)

Mdm2: keeping p53 under control. Piette J, et al.
Oncogene 1997 Aug 28;15(9):1001–10 (111 ref.)

An update on the discovery, pathophysiological actions, clinical manifestations and possible physiology of parathyroid related peptide. Alcantara A, et al.
P R Health Sci J 1997 Mar;16(1):15–22 (19 ref.)

Molecular aspects of the loss of cell adhesion and gain of invasiveness in carcinomas. Birchmeier W.
Princess Takamatsu Symp 1994;24:214–32 (113 ref.)

Integrin signals and tumor growth control. Juliano RL.
Princess Takamatsu Symp 1994;24:118–24 (33 ref.)

Alterations of the cadherin-catenin cell adhesion system in cancers. Kanai Y, et al. **Princess Takamatsu Symp** 1994; 24:51–62 (50 ref.)

Matrix-degrading metalloproteinases in tumor progression. Matrisian LM, et al. **Princess Takamatsu Symp** 1994; 24:152–61 (27 ref.)

Analysis of molecular functions of the tumor metastasis promoting surface molecule CD44v4-v7 using transgenic mice. Moll J, et al. **Princess Takamatsu Symp** 1994; 24:142–51 (34 ref.)

Cell adhesion and tumor metastasis. Ruoslahti E.
Princess Takamatsu Symp 1994;24:99–105 (36 ref.)

Cancer-stromal interaction through growth factor/cytokine networks implicated in growth of stomach cancer. Tahara E. **Princess Takamatsu Symp** 1994;24:187–94 (19 ref.)

Possible involvement of adherens junction plaque proteins

in tumorigenesis and metastasis. Tsukita S, et al. **Princess Takamatsu Symp** 1994;24:38–50 (69 ref.)

TGF beta in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Barrack ER. **Prostate** 1997 Apr 1;31(1):61–70 (100 ref.)

Role of parathyroid hormone-related peptide in hypercalcemia of malignancy and the development of osteolytic metastases. de Vernejoul MC. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):119S–123S (36 ref.)

[Cytokines and chronic B-cell lymphatic leukemia] Berrocal E, et al. **Sangre (Barc)** 1997 Feb;42(1):39–46 (103 ref.) **(Spa)**

NEOPLASM RECURRENCE, LOCAL

Fanconi's anaemia and recurrent squamous cell carcinoma of the oral cavity: a case report. Koo WH, et al. **Ann Acad Med Singapore** 1996 Mar;25(2):289–92 (26 ref.)

Stage IIIC ovarian leiomyosarcoma in a premenopausal woman with multiple recurrences: prolonged survival with surgical therapy. Rasmussen CC, et al. **Gynecol Oncol** 1997 Sep;66(3):519–25 (21 ref.)

Perioperative stimulation of residual cancer cells promotes local and distant recurrence of breast cancer. Reid SE, et al. **J Am Coll Surg** 1997 Sep;185(3):290–306 (143 ref.)

A case of Bednar tumor recurring after 23 years. Mochizuki Y, et al. **J Dermatol** 1996 Sep;23(9):614–8 (17 ref.)

Clinical trials in relapsed prostate cancer: defining the target. Scher HI, et al. **J Natl Cancer Inst** 1996 Nov 20; 88(22):1623–34 (90 ref.)

Laryngeal chondrosarcomas: the Mayo Clinic experience. Kozelsky TF, et al. **J Surg Oncol** 1997 Aug;65(4):269–73 (31 ref.)

Cancer dormancy: opportunities for new therapeutic approaches. Uhr JW, et al. **Nat Med** 1997 May;3(5):505–9 (59 ref.)

Recurrent brain metastases. Alexander E 3rd, et al. **Neurosurg Clin N Am** 1996 Jul;7(3):517–26 (53 ref.)

Interstitial brachytherapy procedures for brain tumors. Sneed PK, et al. **Semin Surg Oncol** 1997 May–Jun;13(3):157–66 (50 ref.)

Local and regional recurrence of carcinoma of the colon and rectum: I. Tumour-host factors and adjuvant therapy. Lee YT. **Surg Oncol** 1995;4(6):283–93 (42 ref.)

[Pelvic recurrence of cancers of the uterine cervix. A study of a series of 49 cases] Martino M, et al. **Ann Chir** 1997; 51(1):36–45 (45 ref.) (Eng. Abstr.) **(Fre)**

[Iridium 192 brachytherapy of supra-tentorial high grade glioma recurring in irradiated areas: technique and preliminary results of the Pitié-Salpêtrière hospital group] Boisserie G, et al. **Bull Cancer Radiother** 1996;83(3):144–52 (20 ref.) (Eng. Abstr.) **(Fre)**

[Recurrence of a stage I thymoma after resection] Nomori H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jul; 34(7):833–6 (10 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD SUPPLY

Bladder cancer angiogenesis, its role in recurrence, stage progression and as a therapeutic target. Crew JP, et al. **Cancer Metastasis Rev** 1996 Jun;15(2):221–30 (84 ref.)

CHEMICALLY INDUCED

Estrogen replacement therapy for the breast cancer survivor: a reappraisal [editorial] Disaia PJ. **J Surg Oncol** 1997 Mar; 64(3):175–80 (35 ref.)

COMPLICATIONS

Transcatheter arterial embolization for the control of life-threatening pelvic hemorrhage in a patient with locally advanced cervix carcinoma. Lin YC, et al. **Eur J Gynaecol Oncol** 1996;17(6):480–3 (12 ref.)

Relapse of colon cancer followed by polymyositis: report of a case and review of the literature. Nyui S, et al. **Surg Today** 1997;27(6):559–62 (11 ref.)

Local recurrence of renal cell carcinoma causing duodenal-inferior vena caval fistula: case report and review of the literature. Benjamin DS, et al. **Urology** 1996 Oct; 48(4):636–8 (16 ref.)

DIAGNOSIS

Recurrent transitional cell carcinoma arising within an ileal conduit following cystectomy. A case report and review of the literature. Carter A, et al. **Eur Urol** 1996;30(4):519–20 (11 ref.)

The utility of follow-up testing after curative cancer therapy. A critical review and economic analysis. Edelman MJ, et al. **J Gen Intern Med** 1997 May;12(5):318–31 (133 ref.)

Granular cell tumor of the vulva: literature review and case report. Simone J, et al. **J La State Med Soc** 1996 Dec; 148(12):539–41 (18 ref.)

Management of asymptomatic rising PSA after prostatectomy or radiation therapy. Waxman S, et al. **Oncology (Huntingt)** 1997 Apr;11(4):457–60, 465; discussion 465–6, 469 (48 ref.)

Laryngeal radionecrosis versus recurrent cancer. McGuirt WF. **Otolaryngol Clin North Am** 1997 Apr;30(2):243–50 (19 ref.)

[Value of serial tumor markers for the detection of recurrences] Quoix E. **Rev Mal Respir** 1997 Apr;14 Suppl 3:S27–9 (32 ref.) **(Fre)**

[After care of breast carcinoma patients--recommendations from the Berlin consensus conference] Hellriegel KP, et al. **Fortschr Med** 1996 Feb 20;114(5):43–5 (0 ref.) **(Ger)**

[Gastric neoplasms: their characterization, assessment of the degree of parietal infiltration and check on recurrence. The potentials and limits of CT, endoscopic US and MR] Gualdi GF, et al. **Clin Ter** 1996 Nov;147(11):585–94 (20 ref.) (Eng. Abstr.) **(Ita)**

[Clinical significance and subject of second look operation] Yakushiji M, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Aug;48(8):761–8 (19 ref.) **(Jpn)**

DRUG THERAPY

Compartment syndrome after isolated perfusion of the leg: a case report. Chan PS, et al. **Am J Orthop** 1997 May; 26(5):369–70 (7 ref.)

Central nervous system relapse of lymphoid malignancies in adults: the role of high-dose chemotherapy. van Besien K, et al. **Ann Oncol** 1997 Jun;8(6):515–24 (122 ref.)

The role of chemotherapy in recurrent malignant gliomas: an overview. Brandes AA, et al. **Cancer Invest** 1996; 14(6):551–9 (83 ref.)

Remission of recurrent mixed germ cell tumor of the ovary after treatment with vincristine, carboplatin, fluorouracil, and ifosfamide: a case report and review of the literature. Balat O, et al. **Eur J Gynaecol Oncol** 1996;17(5):342–4 (20 ref.)

Remission of recurrent cervical cancer with paclitaxel and carboplatin: a case report and review of literature. Termrungruanglert W, et al. **Eur J Gynaecol Oncol** 1996; 17(6):493–6 (21 ref.)

Platinum based chemotherapy to treat recurrent Sertoli-Leydig cell ovarian carcinoma during pregnancy. Tomlinson MW, et al. **Eur J Gynaecol Oncol** 1997; 18(1):44–6 (18 ref.)

Hexamethylmelamine as a single second-line agent in ovarian cancer: follow-up report and review of the literature. Manetta A, et al. **Gynecol Oncol** 1997 Jul;66(1):20–6 (39 ref.)

Chemotherapy for stage IVB or recurrent cancer of the uterine cervix. Omura GA. **J Natl Cancer Inst Monogr** 1996;(21):123–6 (7 ref.)

Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor? Saltz L, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 5):S5-26–S5-30 (24 ref.)

Intravesical chemotherapy for superficial bladder tumors category Ta/T1: who should be treated and how? Kurth KH. **Semin Urol Oncol** 1996 Feb;14(1 Suppl 1):30–5 (7 ref.)

Late relapse of nonseminomatous germ cell tumor of the testis: successful treatment with salvage chemotherapy alone. Papadimitris C, et al. **Urology** 1997 Mar;49(3):469–70 (7 ref.)

[High-dose chemotherapy in relapse of medulloblastoma in young children] Dupuis-Girod S, et al. **Bull Cancer** 1997 Mar;84(3):264–72 (45 ref.) (Eng. Abstr.) **(Fre)**

[Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities] du Bois A, et al. **Zentralbl Gynakol** 1997;119(7):299–323 (330 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Late relapse of germ cell tumors after cisplatin-based chemotherapy. Gerl A, et al. **Ann Oncol** 1997 Jan;8(1):41–7 (28 ref.)

The anatomical substrate for a difference in surgical approach to rectal cancer in male and female patients. Verschueren RC, et al. **Anticancer Res** 1997 Jan–Feb;17(1B):637–41 (18 ref.)

Frequency and duration of remission after isolated limb perfusion for melanoma. Thompson JF, et al. **Arch Surg** 1997 Aug;132(8):903–7 (23 ref.)

Use of predictors of recurrence to plan therapy for DCIS of the breast. Silverstein MJ, et al. **Oncology (Huntingt)** 1997 Mar;11(3):393–406, 409–10; discussion 413–5 (74 ref.)

What is the appropriate follow-up after treatment? Sharir S, et al. **Semin Urol Oncol** 1996 Feb;14(1):45–53 (31 ref.)

ETIOLOGY

Needle tract recurrences after closed biopsy for sarcoma: three cases and review of the literature. Schwartz HS, et al. **Ann Surg Oncol** 1997 Apr–May;4(3):228–36 (58 ref.)

Video-assisted thoracic surgery (VATS) for cancer. Risk of parietal seeding and of early local recurrence. Collard JM, et al. **Int Surg** 1996 Oct–Dec;81(4):343–6 (70 ref.)

Breast conservation: predictors and treatment of local recurrence. Bethke KP. **Semin Surg Oncol** 1996 Sep–Oct; 12(5):332–8 (36 ref.)

MORTALITY

Importance of patient evaluation for long-term survival in medulloblastoma recurrence. La Marca F, et al. **Childs Nerv Syst** 1997 Jan;13(1):30–4 (30 ref.)

PATHOLOGY

Malignant fibrous histiocytomas of the larynx--report of two cases. Soh KB, et al. **Ann Acad Med Singapore** 1996 Nov; 25(6):878–81 (25 ref.)

Bladder cancer angiogenesis, its role in recurrence, stage progression and as a therapeutic target. Crew JP, et al. **Cancer Metastasis Rev** 1996 Jun;15(2):221–30 (84 ref.)

Agminate Spitz naevi occurring in an adult after the excision of a solitary Spitz naevus--report of a case and review of the literature. Sabroe RA, et al. **Clin Exp Dermatol** 1996 May;21(3):197–200 (16 ref.)

Inverted papilloma of the nose and paranasal sinuses: a study of 56 cases and review of the literature. Raveh E, et al. **Isr J Med Sci** 1996 Dec;32(12):1163–7 (21 ref.)

Effect of partial liver resection on tumour growth. de Jong KP, et al. **J Hepatol** 1996 Jul;25(1):109–21 (173 ref.)

Tumour recurrence or treatment sequelae following radiotherapy for larynx cancer [see comments] O'Brien PC. **J Surg Oncol** 1996 Oct;63(2):130–5 (49 ref.) Comment in: J Surg Oncol 1997 Mar;64(3):248.

Local recurrences after breast-conserving treatment: an open problem. Salvadori B. **Semin Surg Oncol** 1996 Jan–Feb; 12(1):46–52 (45 ref.)

Local and regional recurrence of carcinoma of the colon and rectum: II. Factors relating to operative technique. Lee YT. **Surg Oncol** 1996 Feb;5(1):1–13 (71 ref.)

[Malignant granular cell tumor. Report of a clinico-pathologic case] Rochaix P, et al. **Ann Pathol** 1996 Sep;16(4):292–5 (32 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Total mesorectal excision: evaluating the evidence. McCall JL. **Aust N Z J Surg** 1997 Sep;67(9):599–602 (50 ref.)

Adjuvant therapy for prostate cancer patients at high risk of recurrence following radical prostatectomy. Andriole GL. **Eur Urol** 1997;32 Suppl 3:65–9 (59 ref.)

New strategy of bio-chemoprevention on recurrence of superficial bladder cancer based on a hypothesis of the mechanism of recurrence. Akaza H. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:253–6 (13 ref.)

Local recurrence after operative treatment of rectal carcinoma: a strategy for change. Søreide O, et al. **J Am Coll Surg** 1997 Jan;184(1):84–92 (77 ref.)

Time for integration of predictive factors for selection of breast cancer patients who need postoperative radiation therapy? [editorial; comment] Bergh J. **J Natl Cancer Inst** 1997 May 7;89(9):605–7 (31 ref.) Comment on: J Natl Cancer Inst 1997 May 7;89(9):639–45.

Postmastectomy radiation: then and now. Fowble B. **Oncology (Huntingt)** 1997 Feb;11(2):213–34, 239; discussion 239–40, 243 (169 ref.)

Recommendations on follow-up of breast cancer patients following primary therapy. Khandekar JD. **Semin Surg Oncol** 1996 Sep–Oct;12(5):346–51 (37 ref.)

RADIONUCLIDE IMAGING

Positron emission tomography: new hope for early detection of recurrent brain tumors. Garner CM. **Cancer Nurs** 1997 Aug;20(4):277–84 (20 ref.)

RADIOTHERAPY

The role of radiotherapy in the management of pelvic recurrence of rectal cancer. Wong R, et al. **Can J Oncol** 1996 Feb;6 Suppl 1:39–47 (18 ref.)

Radiotherapy for the treatment of locally recurrent cervical cancer. Lanciano R. **J Natl Cancer Inst Monogr** 1996; (21):113–5 (18 ref.)

Applications of brachytherapy in head and neck cancer. Harrison LB. **Semin Surg Oncol** 1997 May–Jun; 13(3):177–84 (25 ref.)

Brachytherapy and breast cancer. White JR, et al. **Semin Surg Oncol** 1997 May–Jun;13(3):190–5 (38 ref.)

Treatment options for localized recurrence of prostate cancer following radiation therapy. Corral DA, et al. **Urol Clin North Am** 1996 Nov;23(4):677–84 (41 ref.)

[Intraoperative radiotherapy in cancers of the pancreas and in recurrent colorectal cancers] Houry S, et al. **Ann Chir** 1996;50(6):438–44 (31 ref.) (Eng. Abstr.) **(Fre)**

[Hyperfractionated reirradiation after salvage surgery in cervico-facial carcinoma. Result of a pilot study in 14 patients] Benchalal M, et al. **Cancer Radiother** 1997; 1(1):68–73 (53 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Synchronous lingual granular cell tumor and squamous carcinoma. A case report and review of the literature. Said-al-Naief N, et al. **Arch Otolaryngol Head Neck Surg** 1997 May;123(5):543–7 (48 ref.)

The assessment and surgical management of recurrent pelvic cancer of the female genitalia. Monaghan JM. **Br J Urol** 1997 Jul;80 Suppl 1:62–5 (10 ref.)

Cure of recurrent medulloblastoma: the contribution of surgical resection at relapse. Balter-Seri J, et al. **Cancer** 1997 Mar 15;79(6):1241–7 (65 ref.)

Recurrent lentigo maligna invading a skin graft successfully treated with Mohs' micrographic surgery. Cohen LM, et al. **Cutis** 1996 Mar;57(3):175–8 (26 ref.)

Repeat resection of recurrent hepatic metastases--improvement in prognosis? Riesener KP, et al. **Eur J Surg** 1996 Sep;162(9):709–15 (36 ref.)

Self-expandable nitinol coil stent for management of colonic obstruction due to a malignant anastomotic stricture. Bashir

RM, et al. **Gastrointest Endosc** 1996 Oct;44(4):497–501 (44 ref.)
Laser photoablation of ileal reservoir adenomas. Geller A, et al. **Gastrointest Endosc** 1996 Oct;44(4):473–7 (57 ref.)
Transcervico-mandibulo-palatal approach for surgical salvage of recurrent nasopharyngeal cancer. Morton RP, et al. **Head Neck** 1996 Jul–Aug;18(4):352–8 (22 ref.)
Role of surgery in the treatment of recurrent esophageal cancer. Carlini S, et al. **Hepatogastroenterology** 1997 Jan–Feb;44(13):187–91 (31 ref.)
Re-resection for colorectal liver metastasis. Bismuth H, et al. **Surg Oncol Clin N Am** 1996 Apr;5(2):353–64 (52 ref.)
Malignant rhabdoid tumor of the central nervous system. Ruiz ME, et al. **Wis Med J** 1996 Dec;95(12):864–6 (7 ref.)
[Repeat interventions in metastases] Seifert JK, et al. **Chirurg** 1997 Mar;68(3):247–54 (37 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Treatment of melanoma in-transit metastases confined to the limb. Eggermont AM. **Cancer Surv** 1996;26:335–49 (65 ref.)
The treated natural history of high risk superficial bladder cancer: 15-year outcome. Cookson MS, et al. **J Urol** 1997 Jul;158(1):62–7 (27 ref.)
Breast conservation: predictors and treatment of local recurrence. Bethke KP. **Semin Surg Oncol** 1996 Sep–Oct; 12(5):332–8 (36 ref.)
New approaches to adjuvant therapy for patients with adverse histopathologic findings following radical prostatectomy. Nelson WG, et al. **Urol Clin North Am** 1996 Nov;23(4):685–96 (117 ref.)
[Therapy of recurrent high-grade non-Hodgkin's lymphoma] Schmitz N. **Internist (Berl)** 1997 Feb;38(2):143–9 (42 ref.) **(Ger)**
[With reference to later intra-/extrathoracic recurrence manifestations also after so-called radical operation: when are (neo-)adjuvant measures indicated?] Drings P. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:805–9 (20 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

[Echography and follow-up of prostate carcinoma: "follow up echography in the course of drug therapy"] Martino P, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):37–42 (10 ref.) (Eng. Abstr.) **(Ita)**

VIROLOGY

Breast cancer in a man with human immunodeficiency virus infection. Widrick P, et al. **Mayo Clin Proc** 1997 Aug; 72(8):761–4 (21 ref.)

NEOPLASM REGRESSION, SPONTANEOUS

Spontaneous regression of metastatic renal cancer. Case report and literature review. Lokich J. **Am J Clin Oncol** 1997 Aug;20(4):416–8 (34 ref.)
Spontaneous regression of cancer. Papac RJ. **Cancer Treat Rev** 1996 Nov;22(6):395–423 (188 ref.)
Spontaneous remission of congenital leukemia [see comments] Dinulos JG, et al. **J Pediatr** 1997 Aug;131(2):300–3 (17 ref.) Comment in: J Pediatr 1997 Aug;131(2):176–7.
'Spontaneous' regression of advanced leiomyosarcoma of the urinary bladder. Lei KI, et al. **Oncology** 1997 Jan–Feb; 54(1):19–22 (20 ref.)

NEOPLASM REMISSION, SPONTANEOUS see **NEOPLASM REGRESSION, SPONTANEOUS**

NEOPLASM, RESIDUAL

The detection of minimal residual disease: implications for bone marrow transplantation. Gribben JG, et al. **Cancer Treat Res** 1997;77:99–120 (96 ref.)
Advances in the detection of minimal residual disease. Radich J, et al. **Curr Opin Hematol** 1997 Jul;4(4):242–7 (31 ref.)
Minimal residual disease: detection, clinical relevance, and treatment strategies. Dwenger A, et al. **J Hematother** 1996 Oct;5(5):537–48 (102 ref.)
Micrometastases and transplantation. Sharp JG. **J Hematother** 1996 Oct;5(5):519–24 (27 ref.)

COMPLICATIONS

Minimal residual disease in non-Hodgkin's lymphoma. Schultze JL, et al. **Biomed Pharmacother** 1996;50(9):451–8 (36 ref.)

DIAGNOSIS

Minimal residual disease in non-Hodgkin's lymphoma. Schultze JL, et al. **Biomed Pharmacother** 1996;50(9):451–8 (36 ref.)
Minimal residual disease detection in B-cell malignancies by assessing IgH rearrangement. Maloum K, et al. **Hematol Cell Ther** 1997 Jun;39(3):119–24 (52 ref.)
Detection of minimal disease in patients with solid tumors. Pantel K. **J Hematother** 1996 Aug;5(4):359–67 (98 ref.)
Management of asymptomatic rising PSA after prostatectomy or radiation therapy. Waxman S, et al. **Oncology (Huntingt)** 1997 Apr;11(4):457–60, 465; discussion 465–6, 469 (48 ref.)
[Diagnosis of minimal residual disease in autologous bone marrow transplantation] Jørgensen H, et al. **Nord Med** 1996 Dec;111(10):344–7 (15 ref.) (Eng. Abstr.) **(Dan)**
[Effect of molecular diagnostic procedures on surgical therapy of malignant diseases] von Knebel Doeberitz M, et al. **Chirurg** 1996 Oct;67(10):967–79 (73 ref.) (Eng. Abstr.) **(Ger)**
[Minimal residual disease in acute leukemias. Optimal method of detection] Deptala A, et al. **Pol Arch Med Wewn** 1996 Jun;95(6):585–94 (35 ref.) **(Pol)**

IMMUNOLOGY

Immunophenotyping of AML and MDS and detection of residual disease. Sanz MA, et al. **Baillieres Clin Haematol** 1996 Mar;9(1):35–55 (146 ref.)

SURGERY

Metastasectomy for soft tissue sarcomas. Pastorino U. **Cancer Treat Res** 1997;91:65–75 (32 ref.)

THERAPY

Minimal residual disease post-bone marrow transplantation for hemato-oncological diseases. Toren A, et al. **Stem Cells** 1996 May;14(3):300–11 (80 ref.)
[Immunotherapy strategies in lymphoma] Engert A, et al. **Internist (Berl)** 1997 Feb;38(2):150–6 (45 ref.) **(Ger)**

NEOPLASM RNA see **RNA, NEOPLASM**

NEOPLASM SEEDING

Metastatic head and neck cancer to the percutaneous endoscopic gastrostomy exit site: a case report and review of the literature. Schneider AM, et al. **Am Surg** 1997 Jun; 63(6):481–6 (11 ref.)
Laparoscopic port site recurrences in oncologic surgery--a review. Weiss EG, et al. **Ann Acad Med Singapore** 1996 Sep;25(5):694–8 (68 ref.)
Laparoscopic resection for colon cancer: cause for pause. Berman IR. **Important Adv Oncol** 1996;:231–43 (51 ref.)
Video-assisted thoracic surgery (VATS) for cancer. Risk of parietal seeding and of early local recurrence. Collard JM, et al. **Int Surg** 1996 Oct–Dec;81(4):343–6 (70 ref.)
Trocar site seeding of inapparent gallbladder carcinoma during laparoscopic cholecystectomy. Cotlar AM, et al. **J Laparoendosc Surg** 1996 Feb;6(1):35–45 (53 ref.)
Implantation metastasis of ovarian cancer after third-look laparoscopy. Gungor M, et al. **JPMA J Pak Med Assoc** 1996 May;46(5):111–2 (6 ref.)
Does transurethral resection of the prostate compromise the radical treatment of prostate cancer? Mansfield JT, et al. **Semin Urol Oncol** 1996 Aug;14(3):174–7 (26 ref.)
Pleural epidermoid carcinoma from displaced skin following extrapleural pneumothorax in a patient exposed to asbestos. Sapino A, et al. **Virchows Arch** 1996 Oct;429(2–3):173–6 (10 ref.)
[Errors and risks in oncologic laparoscopic surgery] Köckerling F, et al. **Chirurg** 1997 Mar;68(3):215–24 (39 ref.) (Eng. Abstr.) **(Ger)**
[Pathogenesis of puncture-site metastases after laparoscopy] Reymond MA, et al. **Zentralbl Chir** 1997;122(5):387–94 (75 ref.) (Eng. Abstr.) **(Ger)**

NEOPLASM STAGING

Role of thoracoscopic lymph node staging for lung and esophageal cancer. Krasna MJ. **Oncology (Huntingt)** 1996 Jun;10(6):793–802; discussion 804, 813–4 (31 ref.)
Visual presentation of the staging of pediatric solid tumors. Cohen MD, et al. **Radiographics** 1996 May;16(3):523–45 (11 ref.)
Staging evaluation and surveillance for melanoma patients in a fiscally restrictive medical environment. A commentary. Ross MI. **Surg Clin North Am** 1996 Dec; 76(6):1423–32 (43 ref.)
[Early stages of laryngeal cancer (I–II stage) and therapeutic options: case report and review of literature] Margarino G, et al. **Acta Otorhinolaryngol Ital** 1996 Feb;16(1):40–6 (50 ref.) (Eng. Abstr.) **(Ita)**

METHODS

A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example. Brierley JD, et al. **Cancer** 1997 Jun 15;79(12):2414–23 (30 ref.)
Staging of the patient with small cell lung cancer. Darling GE. **Chest Surg Clin N Am** 1997 Feb;7(1):81–94 (54 ref.)
Laparoscopic staging of endometrial cancer. Fowler JM. **Clin Obstet Gynecol** 1996 Sep;39(3):669–85 (54 ref.)
Lung cancer staging: the role of computed tomography and magnetic resonance imaging. Bonomo L, et al. **Eur J Radiol** 1996 Aug;23(1):35–45 (48 ref.)
Isolated tumor cells in the bone marrow: value of a new diagnostic method in the TNM-staging of solid tumors. Werner M, et al. **Gen Diagn Pathol** 1996 Jun;142(1):1–6 (53 ref.)
Staging systems for musculoskeletal neoplasia. Springfield DS. **Instr Course Lect** 1994;43:537–42 (11 ref.)
Pretreatment minimal staging and prognostic factors for non-small cell lung cancer. Feld R, et al. **Lung Cancer** 1997 Jun;17 Suppl 1:S3–10 (34 ref.)
Staging classification committee. Ginsberg R, et al. **Lung Cancer** 1997 Jun;17 Suppl 1:S11–3 (0 ref.)
The current role of invasive staging in lung cancer. Van Schil P, et al. **Monaldi Arch Chest Dis** 1997 Jun;52(3):237–41 (22 ref.)
Primary bone tumors of the spine. Terminology and surgical staging. Boriani S, et al. **Spine** 1997 May 1;22(9):1036–44 (28 ref.)
Surgical pathology of lymph nodes in cancer staging: routine and specialized techniques. Siegel RJ. **Surg Oncol Clin N Am** 1996 Jan;5(1):25–31 (33 ref.)
Imaging approach to staging of renal cell carcinoma. Bechtold RE, et al. **Urol Clin North Am** 1997 Aug; 24(3):507–22 (60 ref.)
[TNM--current status. 1. Clinical significance and current status] Hermanek P, et al. **Pathologe** 1997 Mar;18(2):153–9 (2 ref.) **(Ger)**
[Stage classification for pancreatic cancer: its difference between Japan and UICC] Kobari M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Jan;94(1):1–7 (6 ref.) **(Jpn)**

TRENDS

The National Cancer Data Base report on completeness of American Joint Committee on Cancer staging in United States cancer facilities. The American College of Surgeons Commission on Cancer and the American Cancer Society. Fleming ID, et al. **Cancer** 1996 Oct 1;78(7):1498–504 (10 ref.)
Staging prostate cancer--1997: current methods and limitations. Bostwick DG. **Eur Urol** 1997;32 Suppl 3:2–14 (86 ref.)

NEOPLASM STEM CELL ASSAY see **TUMOR STEM CELL ASSAY**

NEOPLASM STRUCTURAL GENES see **GENES, STRUCTURAL, NEOPLASM**

NEOPLASM TRANSPLANTATION

IMMUNOLOGY

Rejection antigens in chemically induced tumors [see comments] Klein G. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):5991–2 (14 ref.) Comment in: Proc Natl Acad Sci U S A 1997 Jun 10;94(12):6375–9.

METHODS

Modelling human leukemia and lymphoma in severe combined immunodeficient (SCID) mice: practical applications. Flavell DJ. **Hematol Oncol** 1996 Jun; 14(2):67–82 (100 ref.)

NEOPLASM VACCINES see **CANCER VACCINES**

NEOPLASMS

see related
ANTIBODIES, NEOPLASM
ANTICARCINOGENIC AGENTS
ANTIGENS, NEOPLASM
ANTINEOPLASTIC AGENTS
CARCINOGENS
DNA, NEOPLASM
GENES, SUPPRESSOR, TUMOR
ONCOGENIC VIRUSES
PLEURAL EFFUSION, MALIGNANT
PRECANCEROUS CONDITIONS
RNA, NEOPLASM

Novel lipids and cancer. Isoprenoids and other phytochemicals. Elson CE. **Adv Exp Med Biol** 1996; 399:71–86 (131 ref.)
Biochemical markers as additional measurements in dietary validity studies: application of the method of triads with examples from the European Prospective Investigation into Cancer and Nutrition. Ocké MC, et al. **Am J Clin Nutr** 1997 Apr;65(4 Suppl):1240S–1245S (14 ref.)
Programmed cell death and cancer. Hwang PL. **Ann Acad Med Singapore** 1996 Mar;25(2):259–64 (46 ref.)
The nuclear matrix as a target for cancer therapy. Catapano CV, et al. **Ann Oncol** 1996 Sep;7(7):659–66 (90 ref.)
The integrin alpha 6 beta 4 and the biology of carcinoma. Rabinovitz I, et al. **Biochem Cell Biol** 1996;74(6):811–21 (112 ref.)
Diet and cancer: a review of scientific evidence. Hill MJ. **Eur J Cancer Prev** 1995 Dec;4 Suppl 2:3–42 (183 ref.)
Cyclin-dependent kinase inhibitors (CKIs) and hematological malignancies. Baghdassarian N, et al. **Hematol Cell Ther** 1996 Aug;38(4):313–23 (79 ref.)
Cancer and hypertension. An unresolved issue. Hamet P. **Hypertension** 1996 Sep;28(3):321–4 (73 ref.)
The Josef Steiner Lecture: CDKs and cell-cycle control in fission yeast: relevance to other eukaryotes and cancer. Nurse P. **Int J Cancer** 1997 May 29;71(5):707–8 (21 ref.)
Micrometastases and transplantation. Sharp JG. **J Hematother** 1996 Oct;5(5):519–24 (27 ref.)
Cancer risk assessment. Walker B Jr. **J Natl Med Assoc** 1997 Jan;89(1):21–6 (20 ref.)
A new biological framework for cancer research. Schipper H, et al. **Lancet** 1996 Oct 26;348(9035):1149–51 (33 ref.)

U.S. Environmental Protection Agency guidelines for carcinogen risk assessment: past and future. Wiltse J, et al. **Mutat Res** 1996 Sep;365(1–3):3–15 (41 ref.)
Oxygen and cancer. Dunn T. **N C Med J** 1997 Mar–Apr; 58(2):140–3 (13 ref.)
Health benefits and risk analysis with reference to cancer studies. Lee HP. **Nutr Rev** 1996 Nov;54(11 Pt 2):S141–2 (1 ref.)
Nutritional issues in cancer management. Laviano A, et al. **Nutrition** 1996 May;12(5):358–71 (184 ref.)
Cancer, cancer cachexia, and diet: lessons from clinical research. Nixon DW. **Nutrition** 1996 Jan;12(1 Suppl):S52–56 (78 ref.)
Definition of standardized nutritional assessment and interventional pathways in oncology. Ottery FD. **Nutrition** 1996 Jan;12(1 Suppl):S15–9 (21 ref.)
The risk of cancer in firefighters. Golden AL, et al. **Occup Med** 1995 Oct–Dec;10(4):803–20 (73 ref.)
The legal ramifications of the NCCN practice guidelines. Miller FH. **Oncology (Huntingt)** 1996 Nov;10(11 Suppl):35–9 (20 ref.)
Legal and societal issues facing survivors of childhood cancer. Monaco GP, et al. **Pediatr Clin North Am** 1997 Aug;44(4):1043–58 (27 ref.)
The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Bristow RG, et al. **Radiother Oncol** 1996 Sep;40(3):197–223 (297 ref.)
Disclosure practices and cultural narratives: understanding concealment and silence around cancer in Tuscany, Italy. Gordon DR, et al. **Soc Sci Med** 1997 May;44(10):1433–52 (80 ref.)
[Tumoral vascularization: physiopathology and therapeutic prospects] Ortéga N, et al. **Bull Cancer** 1997 Apr; 84(4):391–5 (49 ref.) (Eng. Abstr.) **(Fre)**
[Informed consent for cancer patients and their family] Yamawaki S. **Nippon Seikeigeka Gakkai Zasshi** 1996 Sep; 70(9):553–8 (12 ref.) **(Jpn)**
[Telomerase, aging, cancer] Egorov EE. **Mol Biol (Mosk)** 1997 Jan–Feb;31(1):16–24 (97 ref.) **(Rus)**

BLOOD

Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. Folkers K, et al. **Biochem Biophys Res Commun** 1997 May 19;234(2):296–9 (22 ref.)
Hemostatic defects in cancer patients. Kempin SJ. **Cancer Invest** 1997;15(1):23–36 (213 ref.)
Utilization of nuclear matrix proteins for cancer diagnosis. Keesee SK, et al. **Crit Rev Eukaryot Gene Expr** 1996; 6(2–3):189–214 (197 ref.)
Biomarkers of gene expression: growth factors and oncoproteins. Brandt-Rauf PW. **Environ Health Perspect** 1997 Jun;105 Suppl 4:807–16 (125 ref.)
Blood group antigens: molecules seeking a function? Greenwell P. **Glycoconj J** 1997 Feb;14(2):159–73 (223 ref.)
Low cholesterol and cancer. Kritz H, et al. **J Clin Oncol** 1996 Nov;14(11):3043–8 (66 ref.)
The fibrinolytic system in neoplasia. Bell WR. **Semin Thromb Hemost** 1996;22(6):459–78 (402 ref.)
[Introduction to biological rhythms in the domain of health] Touitou Y. **Pathol Biol (Paris)** 1996 Jun;44(6):479–86 (20 ref.) (Eng. Abstr.) **(Fre)**
[Mobilization of peripheral blood stem cells with conventional chemotherapy] Venturini M, et al. **Tumori** 1996 Mar–Apr;82(2 Suppl):S14–8 (25 ref.) (Eng. Abstr.) **(Ita)**
[Serum selenium contents in cancer patients] Ujiie S, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(4):401–5 (12 ref.) (Eng. Abstr.) **(Jpn)**
[EBV-related malignancies and thioredoxin] Noda N, et al. **Nippon Rinsho** 1997 Feb;55(2):461–6 (24 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD SUPPLY

Inhibitors of angiogenesis in a clinical perspective. Voest EE. **Anticancer Drugs** 1996 Sep;7(7):723–7 (36 ref.)
Tumor progression and angiogenesis: cathepsin B & Co. Keppler D, et al. **Biochem Cell Biol** 1996;74(6):799–810 (117 ref.)
Cell adhesion molecules in angiogenesis. Brooks PC. **Cancer Metastasis Rev** 1996 Jun;15(2):187–94 (54 ref.)
Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Claffey KP, et al. **Cancer Metastasis Rev** 1996 Jun;15(2):165–76 (108 ref.)
Tumor angiogenesis: a physiological process or genetically determined? D'Amore PA, et al. **Cancer Metastasis Rev** 1996 Jun;15(2):205–12 (36 ref.)
Antiangiogenis restricted tumor dormancy. Holmgren L. **Cancer Metastasis Rev** 1996 Jun;15(2):241–5 (39 ref.)
Leukocyte–endothelial adhesion and angiogenesis in tumors. Jain RK, et al. **Cancer Metastasis Rev** 1996 Jun; 15(2):195–204 (63 ref.)
Treating cancer by inhibiting angiogenesis: new hopes and potential pitfalls. Rak J, et al. **Cancer Metastasis Rev** 1996 Jun;15(2):231–6 (39 ref.)
A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction). Teicher BA. **Cancer Metastasis Rev** 1996 Jun;15(2):247–72 (316 ref.)
Hitting cancer where it hurts. Sunassee K, et al. **Curr Biol** 1997 May 1;7(5):R282–5 (10 ref.)
Mechanisms and therapeutic implications of angiogenesis. Bicknell R, et al. **Curr Opin Oncol** 1996 Jan;8(1):60–5 (75 ref.)
Regulation of tumor angiogenesis by organ-specific cytokines. Singh RK, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 2):1–11 (50 ref.)
Adhesion molecules and tumor cell-vasculature interactions: modulation by bioactive lipid molecules. Tang DG, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 2):69–88 (76 ref.)
Role of soluble mediators in angiogenesis. Bussolino F, et al. **Eur J Cancer** 1996 Dec;32A(14):2401–12 (110 ref.)
Angiogenesis and metastasis. Ellis LM, et al. **Eur J Cancer** 1996 Dec;32A(14):2451–60 (119 ref.)
New perspectives in clinical oncology from angiogenesis research. Folkman J. **Eur J Cancer** 1996 Dec; 32A(14):2534–9 (60 ref.)
Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis. Rak J, et al. **Eur J Cancer** 1996 Dec;32A(14):2438–50 (149 ref.)
Clinical significance of the determination of angiogenic factors. Toi M, et al. **Eur J Cancer** 1996 Dec; 32A(14):2513–9 (63 ref.)
Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Vermeulen PB, et al. **Eur J Cancer** 1996 Dec;32A(14):2474–84 (78 ref.)
Metabolic and clonogenic consequences of ischaemia reperfusion insult in solid tumours. Parkins CS, et al. **Exp Physiol** 1997 Mar;82(2):361–8 (22 ref.)
Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. Brown LF, et al. **EXS** 1997;79:233–69 (133 ref.)
Thrombospondin as a regulator of angiogenesis. DiPietro LA. **EXS** 1997;79:295–314 (74 ref.)
Vascular endothelial growth factor: basic biology and clinical implications. Ferrara N, et al. **EXS** 1997;79:209–32 (142 ref.)
Fibroblast growth factors as angiogenesis factors: new insights into their mechanism of action. Klein S, et al. **EXS** 1997;79:159–92 (259 ref.)
Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. O'Reilly MS. **EXS** 1997;79:273–94 (62 ref.)
Role of the macrophage in angiogenesis-dependent diseases. Polverini PJ. **EXS** 1997;79:11–28 (111 ref.)
Hypoxia and angiogenesis in experimental tumor models: therapeutic implications. Rockwell S, et al. **EXS** 1997; 79:335–60 (107 ref.)
Regulation of angiogenesis by scatter factor. Rosen EM, et al. **EXS** 1997;79:193–208 (93 ref.)
Tumor angiogenesis: functional similarities with tumor invasion. Stetler-Stevenson WG, et al. **EXS** 1997;79:413–8 (27 ref.)
The role of vascular cell integrins alpha v beta 3 and alpha v beta 5 in angiogenesis. Varner JA. **EXS** 1997;79:361–90 (243 ref.)
Tumour angiogenesis and prognosis. Fox SB. **Histopathology** 1997 Mar;30(3):294–301 (112 ref.)
Tumor angiogenesis and the role of vascular cell integrin alphavbeta3. Varner JA, et al. **Important Adv Oncol** 1996; :69–87 (259 ref.)
Tumoral vascularity as a prognostic factor in cancer. Weidner N, et al. **Important Adv Oncol** 1996;:167–90 (166 ref.)
The role of calcium in the regulation of invasion and angiogenesis. Alessandro R, et al. **In Vivo** 1996 Mar–Apr; 10(2):153–60 (61 ref.)
Regulation of angiogenesis by hypoxic stress: from solid tumours to the ovarian follicle. Neeman M, et al. **Int J Exp Pathol** 1997 Apr;78(2):57–70 (121 ref.)
The modulation of granulomatous tissue and tumour angiogenesis by diclofenac in combination with hyaluronan (HYAL EX-0001). Freemantle C, et al. **Int J Tissue React** 1995;17(4):157–66 (51 ref.)
Mathematical modelling, simulation and prediction of tumour-induced angiogenesis. Chaplain MA, et al. **Invasion Metastasis** 1996;16(4–5):222–34 (62 ref.)
Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy. Fox SB, et al. **Invest New Drugs** 1997;15(1):15–28 (174 ref.)
Angiogenic factors as tumor markers. Nguyen M. **Invest New Drugs** 1997;15(1):29–37 (44 ref.)
The preclinical evaluation of angiogenesis inhibitors. O'Reilly MS. **Invest New Drugs** 1997;15(1):5–13 (87 ref.)
The importance of blood vessels in cancer spread [editorial; comment] Neeman M. **Isr J Med Sci** 1996 Nov; 32(11):1124–6 (20 ref.) Comment on: Isr J Med Sci 1996 Nov;32(11):1086–8.
Assessment of tumor microcirculation: a new role of dynamic contrast MR imaging. Griebel J, et al. **J Magn Reson Imaging** 1997 Jan–Feb;7(1):111–9 (73 ref.)
Tumorangiogenesis: a network of cytokines. Hotfilder M, et al. **Klin Padiatr** 1997 Jul–Aug;209(4):265–70 (108 ref.)
Clinical perspectives of tumor angiogenesis in pediatric oncology. Schweigerer L. **Klin Padiatr** 1997 Jul–Aug; 209(4):257–64 (92 ref.)
The influence of tumor blood flow and microenvironmental factors on the efficacy of radiation, drugs and localized hyperthermia. Vaupel PW. **Klin Padiatr** 1997 Jul–Aug; 209(4):243–9 (45 ref.)
Antiangiogenesis for cancer therapy. Harris AL. **Lancet** 1997 May;349 Suppl 2:SII13–5 (19 ref.)
Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. Reubi JC, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):39–41 (5 ref.)
The Eugene M. Landis Award Lecture 1996. Delivery of molecular and cellular medicine to solid tumors. Jain RK. **Microcirculation** 1997 Mar;4(1):1–23 (150 ref.)
Angiogenesis as a target for tumor treatment. Gastl G, et al. **Oncology** 1997 May–Jun;54(3):177–84 (69 ref.)
Tumor angiogenesis: tutorial on implications for imaging. Passe TJ, et al. **Radiology** 1997 Jun;203(3):593–600 (82 ref.)
Microvascular corrosion casting in the study of tumor vascularity: a review. Konerding MA, et al. **Scanning Microsc** 1995;9(4):1233–43; discussion 1243–4 (68 ref.)
Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Pluda JM. **Semin Oncol** 1997 Apr;24(2):203–18 (181 ref.)
Current and future strategies to block tumor angiogenesis, invasion, and metastasis. Effert PJ, et al. **World J Urol** 1996; 14(3):131–40 (81 ref.)
Tumor angiogenesis: the pivotal role of vascular endothelial growth factor. Marmé D. **World J Urol** 1996;14(3):166–74 (92 ref.)
[Vascularization and perfusion of tumors as target in cancer therapy] Bernsen HJ, et al. **Ned Tijdschr Geneeskd** 1997 Feb 22;141(8):364–8 (25 ref.) (Eng. Abstr.) **(Dut)**
[Tumor vascularization: contribution of Doppler ultrasonography] Flais S, et al. **J Radiol** 1996 Dec; 77(12):1207–12 (27 ref.) (Eng. Abstr.) **(Fre)**
[Tumor angiogenesis--prognostic and therapeutic implications] Bairey D, et al. **Harefuah** 1997 Jan 15; 132(2):117–20 (36 ref.) **(Heb)**
[Development of anti tumor agents targeting angiogenesis] Ono M, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(2):178–86 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Angiogenesis and its inhibitors] Ono M, et al. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1585–93 (12 ref.) (Eng. Abstr.) **(Jpn)**

CHEMICALLY INDUCED

Study of eight cases of cancer in 426 rheumatoid arthritis patients treated with methotrexate. Bologna C, et al. **Ann Rheum Dis** 1997 Feb;56(2):97–102 (33 ref.)
Heterocyclic amines: evaluation of their role in diet associated human cancer. Gooderham NJ, et al. **Br J Clin Pharmacol** 1996 Jul;42(1):91–8 (56 ref.)
Calcium channel blockers: summary and safety issues. Opie LH. **Cardiovasc Drugs Ther** 1997 Jan;10 Suppl 3:893–5 (18 ref.)
Topics in cancer risk assessment. Olin SS, et al. **Environ Health Perspect** 1997 Feb;105 Suppl 1:117–26 (142 ref.)
Carcinogenicity of food mutagens. Sugimura T, et al. **Environ Health Perspect** 1996 May;104 Suppl 3:429–33 (48 ref.)
Environmental exposure to N-nitroso compounds (NNOC) and precursors: an overview. Bartsch H, et al. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:11–7 (54 ref.)
Epidemiology relating N-nitroso compounds to human cancer. Caygill CP. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:125–30 (37 ref.)
Genotoxic effects of pesticides. de Bertoldi M. **Eur J Cancer Prev** 1996 Oct;5(5):397–9 (24 ref.)
DNA damage studies related to the assessment of the role of N-nitroso compounds in human cancer. Kyrtopoulos SA, et al. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:109–14 (47 ref.)
Nitrosamines and human cancer: introduction and overview. Magee PN. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:7–10 (33 ref.)
Chemical-induced genetic alterations in human cancers: relevance to aetiology and pathogenesis. Montesano R, et al. **Eur J Cancer Prev** 1996 Oct;5(5):392–3 (11 ref.)
Cancer risk in the work place, including asbestos. Nicholson WJ. **Eur J Cancer Prev** 1996 Oct;5(5):393–6 (5 ref.)
N-nitroso compounds, their relevance to human cancer and further prospects for prevention. Reed PI. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:137–47 (75 ref.)
Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organisation and the International Society of Hypertension. **Hypertens Res** 1997 Jun;20(2):61–73 (81 ref.)
Printing processes and printing inks. **IARC Monogr Eval Carcinog Risks Hum** 1996;65:33–147 (272 ref.)
Tumour incidence reductions in carcinogenicity bioassays. McGregor D. **IARC Sci Publ** 1996;(139):277–90 (36 ref.)
Assessment of the health effects of trichloroethylene. Kaneko T, et al. **Ind Health** 1997 Jul;35(3):301–24 (97 ref.)
Molecular epidemiology: low-dose carcinogens and genetic susceptibility. Vineis P. **Int J Cancer** 1997 Mar 28;71(1):1–3 (18 ref.)
Arsenic and the skin. Schwartz RA. **Int J Dermatol** 1997 Apr;36(4):241–50 (144 ref.)
Environmental pollution and carcinogenic risk. Karaer F. **J Environ Pathol Toxicol Oncol** 1996;15(2–4):105–13 (15 ref.)
Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organisation

and the International Society of Hypertension. **J Hum Hypertens** 1997 Jun;11(6):331–42 (81 ref.)

Biochemical and molecular changes at the cellular level in response to exposure to environmental estrogen-like chemicals. Roy D, et al. **J Toxicol Environ Health** 1997 Jan;50(1):1–29 (180 ref.)

Analysis of the risks associated with calcium channel blockade: implications for the obstetrician-gynecologist. Davis WB, et al. **Obstet Gynecol Surv** 1997 Mar; 52(3):198–201 (18 ref.)

Epidemiology of occupational carcinogens and mutagens. Ruder AM. **Occup Med** 1996 Jul-Sep;11(3):487–512 (103 ref.)

Pesticides and cancer. Zahm SH, et al. **Occup Med** 1997 Apr-Jun;12(2):269–89 (195 ref.)

Iron-induced tissue damage and cancer: the role of reactive oxygen species-free radicals. Okada S. **Pathol Int** 1996 May;46(5):311–32 (109 ref.)

The use of mechanistic data in the risk assessments of ten chemicals: an introduction to the chemical-specific reviews. International Expert Panel on Carcinogen Risk Assessment. **Pharmacol Ther** 1996;71(1–2):1–5 (7 ref.)

Formaldehyde mechanistic data and risk assessment: endogenous protection from DNA adduct formation. Conaway CC, et al. **Pharmacol Ther** 1996;71(1–2):29–55 (177 ref.)

N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. Verna L, et al. **Pharmacol Ther** 1996; 71(1–2):57–81 (96 ref.)

2-Acetylaminofluorene mechanistic data and risk assessment: DNA reactivity, enhanced cell proliferation and tumor initiation. Verna L, et al. **Pharmacol Ther** 1996; 71(1–2):83–105 (107 ref.)

Vinyl chloride mechanistic data and risk assessment: DNA reactivity and cross-species quantitative risk extrapolation. Whysner J, et al. **Pharmacol Ther** 1996;71(1–2):7–28 (135 ref.)

Benzidine mechanistic data and risk assessment: species- and organ-specific metabolic activation. Whysner J, et al. **Pharmacol Ther** 1996;71(1–2):107–26 (146 ref.)

Butylated hydroxyanisole mechanistic data and risk assessment: conditional species-specific cytotoxicity, enhanced cell proliferation, and tumor promotion. Whysner J, et al. **Pharmacol Ther** 1996;71(1–2):137–51 (101 ref.)

Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion. Whysner J, et al. **Pharmacol Ther** 1996; 71(1–2):153–91 (214 ref.)

History, present and future, of heterocyclic amines, cooked food mutagens. Sugimura T. **Princess Takamatsu Symp** 1995;23:214–31 (88 ref.)

Cancer risk in relation to radioactivity in tobacco. Kilthau GF. **Radiol Technol** 1996 Jan-Feb;67(3):217–22 (53 ref.)

Drinking water chlorination by-products and cancer. Koivusalo M, et al. **Rev Environ Health** 1997 Apr-Jun; 12(2):81–90 (63 ref.)

Lead and cancer--association or causation? [editorial] Vainio H. **Scand J Work Environ Health** 1997 Feb;23(1):1–3 (24 ref.)

Calcium channel blockers, risk of cancer, and the challenge of assessing medication safety. Pahor M. **Tenn Med** 1997 Sep;90(9):367–9 (27 ref.)

Concepts of cell death and application to carcinogenesis. Schulte-Hermann R, et al. **Toxicol Pathol** 1997 Jan-Feb; 25(1):89–93 (36 ref.)

Butadiene epidemiology: a summary of results and outstanding issues. Acquavella JF. **Toxicology** 1996 Oct 28;113(1-3):148–56 (30 ref.)

Coffee and cancer: a review of human and animal data. Nehlig A, et al. **World Rev Nutr Diet** 1996;79:185–221 (396 ref.)

CHEMISTRY

The use of biomarker expression to characterize neoplastic processes. Grizzle WE, et al. **Biotech Histochem** 1997 Mar; 72(2):96–104 (60 ref.)

CD44 as a marker in human cancers. Sy MS, et al. **Curr Opin Oncol** 1997 Jan;9(1):108–12 (57 ref.)

Mucin glycoproteins in neoplasia. Kim YS, et al. **Glycoconj J** 1996 Oct;13(5):693–707 (196 ref.)

Potassium, sodium, and cancer: a review. Jansson B. **J Environ Pathol Toxicol Oncol** 1996;15(2-4):65–73 (12 ref.)

DNA adducts: biological markers of exposure and potential applications to risk assessment. La DK, et al. **Mutat Res** 1996 Sep;365(1-3):129–46 (123 ref.)

Minimizing cancer risk using molecular techniques: a review. Vojdani A, et al. **Toxicol Ind Health** 1997 Sep-Oct; 13(5):589–626 (106 ref.)

CLASSIFICATION

Hypothesis on a casual link between EMF and an evolutionary class of cancer and spontaneous abortion. Cooper WG. **Cancer Biochem Biophys** 1996 Apr; 15(3):151–70 (57 ref.)

Redefining AIDS: towards a modification of the current AIDS case definition. Albrecht H. **Clin Infect Dis** 1997 Jan;24(1):64–74 (128 ref.)

The international classification of childhood cancer. Kramárová E, et al. **Int J Cancer** 1996 Dec 11;68(6):759–65 (36 ref.)

[New methods for cancer classification. Current light microscopy can and should be added (see comments)] Andrén-Sandberg A, et al. **Lakartidningen** 1997 Feb 12; 94(7):501–4 (43 ref.) Comment in: Lakartidningen 1997 Apr 2;94(14):1262. **(Swe)**

COMPLICATIONS

Cancer pain management. Bruera E, et al. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 2):146–53 (68 ref.)

Palliative use of ionizing radiations. Parker RG. **Acta Oncol** 1996;35(8):981–7 (69 ref.)

Role of cysteine and glutathione in HIV infection and cancer cachexia: therapeutic intervention with N-acetylcysteine. Dröge W, et al. **Adv Pharmacol** 1997;38:581–600 (88 ref.)

Cancer and venous thromboembolism. Piccioli A, et al. **Am Heart J** 1996 Oct;132(4):850–5 (50 ref.)

Fanconi's anemia and malignancies. Alter BP. **Am J Hematol** 1996 Oct;53(2):99–110 (163 ref.)

Hypercalcemia of malignancy. Mundy GR, et al. **Am J Med** 1997 Aug;103(2):134–45 (81 ref.)

Cancer-related hypercalcemia: how to spot it, how to manage it. Clayton K. **Am J Nurs** 1997 May;97(5):42–8; quiz 49 (12 ref.)

Primary malignant tumors (lymphoma excluded) in patients with chronic lymphocytic leukemia. A series of 22 cases from a retrospective study of 248 patients. Lauvin R, et al. **Ann Med Interne (Paris)** 1996;147(6):389–92 (16 ref.)

Towards better pain treatment in cancer. Dellemijn PL, et al. **Anticancer Drugs** 1996 Jan;7(1):3–26 (300 ref.)

The effect of megestrol acetate on anorexia, weight loss and cachexia in cancer and AIDS patients (review). Strang P. **Anticancer Res** 1997 Jan-Feb;17(1B):657–62 (36 ref.)

Medical management of intestinal obstruction in terminal care. Frank C. **Can Fam Physician** 1997 Feb;43:259–65 (29 ref.)

Bone remodeling, normal and abnormal: a biological basis for the understanding of cancer-related bone disease and its treatment. Parfitt AM. **Can J Oncol** 1995 Dec;5 Suppl 1:1–10 (50 ref.)

Symptom distress in adult patients with cancer. McClement SE, et al. **Cancer Nurs** 1997 Aug;20(4):236–43 (44 ref.)

Symptomatic management of the older person with cancer. Sheehan DC, et al. **Clin Geriatr Med** 1997 Feb;13(1):203–19 (66 ref.)

T lymphocytes and their cytokines in human immunodeficiency virus (HIV) infection: implications for associated neoplasias. Jassoy C, et al. **Crit Rev Oncog** 1995; 6(3–6):275–89 (143 ref.)

Venous thromboembolism in the cancer patient. Durica SS. **Curr Opin Hematol** 1997 Sep;4(5):306–11 (62 ref.)

Are we making progress in antifungal therapy? Martino P, et al. **Curr Opin Oncol** 1997 Jul;9(4):314–20 (56 ref.)

Antiemetics revisited. Roila F, et al. **Curr Opin Oncol** 1997 Jul;9(4):321–6 (31 ref.)

Infection prophylaxis and antiretroviral therapy in patients with HIV infection and malignancy. Sparano JA, et al. **Curr Opin Oncol** 1996 Sep;8(5):392–9 (41 ref.)

Non-AIDS-defining malignancies in patients with HIV infection. Volm MD, et al. **Curr Opin Oncol** 1996 Sep; 8(5):386–91 (41 ref.)

Rheumatic manifestations of malignancy. Aviña-Zubieta JA, et al. **Curr Opin Rheumatol** 1996 Jan;8(1):47–51 (45 ref.)

Vasculitides associated with malignancy. Fortin PR. **Curr Opin Rheumatol** 1996 Jan;8(1):30–3 (27 ref.)

Rheumatologic manifestations of malignancy. Mody GM, et al. **Curr Opin Rheumatol** 1997 Jan;9(1):75–9 (28 ref.)

Practical modalities for prevention of fungal infections in cancer patients. De Pauw BE. **Eur J Clin Microbiol Infect Dis** 1997 Jan;16(1):32–41 (46 ref.)

Hematopoietic growth factors in cancer patients with invasive fungal infections. Offner F. **Eur J Clin Microbiol Infect Dis** 1997 Jan;16(1):56–63 (55 ref.)

The management of patients with advanced cancer (II). Heys SD, et al. **Eur J Surg Oncol** 1997 Jun;23(3):257–63 (69 ref.)

Pleural diseases related to metastatic malignancies [see comments] Sahn SA. **Eur Respir J** 1997 Aug;10(8):1907–13 (50 ref.) Comment in: Eur Respir J 1997 Aug;10(8):1701–2.

Thrombosis and hemorrhage in oncology patients. Bick RL, et al. **Hematol Oncol Clin North Am** 1996 Aug; 10(4):875–907 (207 ref.)

Nonopioid and opioid analgesic pharmacotherapy of cancer pain. Cherny NI, et al. **Hematol Oncol Clin North Am** 1996 Feb;10(1):79–102 (125 ref.)

Invasive techniques in the management of cancer pain. Cherny NI, et al. **Hematol Oncol Clin North Am** 1996 Feb; 10(1):121–37 (105 ref.)

Management of dyspnea and cough in patients with cancer. Dudgeon DJ, et al. **Hematol Oncol Clin North Am** 1996 Feb;10(1):157–71 (83 ref.)

Pain and symptom control. Patient rights and physician responsibilities. Emanuel EJ. **Hematol Oncol Clin North Am** 1996 Feb;10(1):41–56 (34 ref.)

Opportunistic infections in oncologic patients. Emmanouilides C, et al. **Hematol Oncol Clin North Am** 1996 Aug;10(4):841–60 (83 ref.)

Integrating medical and surgical treatments in gastrointestinal, genitourinary, and biliary obstruction in patients with cancer. Fainsinger RL. **Hematol Oncol Clin North Am** 1996 Feb;10(1):173–88 (115 ref.)

Anemia of malignancy. Frenkel EP, et al. **Hematol Oncol Clin North Am** 1996 Aug;10(4):861–73 (36 ref.)

Nausea and vomiting in patients with cancer. Lichter I. **Hematol Oncol Clin North Am** 1996 Feb;10(1):207–220 (54 ref.)

Clinical use of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in neutropenia associated with malignancy. Lifton R, et al. **Hematol Oncol Clin North Am** 1996 Aug;10(4):825–39 (49 ref.)

Psychological approaches to the management of pain in patients with advanced cancer. Loscalzo M. **Hematol Oncol Clin North Am** 1996 Feb;10(1):139–55 (59 ref.)

Adjuvant analgesic agents. Portenoy RK. **Hematol Oncol Clin North Am** 1996 Feb;10(1):103–19 (66 ref.)

Nutrition therapy for the cancer patient. Shike M. **Hematol Oncol Clin North Am** 1996 Feb;10(1):221–34 (77 ref.)

Liver disease in extrahepatic malignancy. Su AY, et al. **Hematol Oncol Clin North Am** 1996 Aug;10(4):953–66 (45 ref.)

Anorexia and cachexia, asthenia, and lethargy. Watanabe S, et al. **Hematol Oncol Clin North Am** 1996 Feb;10(1):189–206 (100 ref.)

The role of insulin-like growth factors and their binding proteins in tumor hypoglycemia. Baxter RC. **Horm Res** 1996;46(4–5):195–201 (41 ref.)

Pulmonary infiltrates in the cancer patient. New approaches to an old problem. Bergen GA, et al. **Infect Dis Clin North Am** 1996 Jun;10(2):297–325 (140 ref.)

Infections in HIV-infected patients with malignancy. Brown MA, et al. **Infect Dis Clin North Am** 1996 Jun;10(2):401–12 (46 ref.)

Special considerations for the clinical microbiology laboratory in the diagnosis of infections in the cancer patient. Sandin RL, et al. **Infect Dis Clin North Am** 1996 Jun;10(2):413–30 (41 ref.)

Pyrexia of undetermined origin in patients with human immunodeficiency virus infection and AIDS. Miller RF, et al. **Int J STD AIDS** 1996 May-Jun;7(3):170–5 (32 ref.)

Anemia of cancer: pathogenesis and treatment with recombinant erythropoietin. Mittelman M. **Isr J Med Sci** 1996 Dec;32(12):1201–6 (54 ref.)

Nutritional aspects of cancer-related fatigue. Kalman D, et al. **J Am Diet Assoc** 1997 Jun;97(6):650–4 (57 ref.)

Emerging fungal infections in cancer patients. Krcmery V Jr. **J Hosp Infect** 1996 Jun;33(2):109–17 (50 ref.)

Fungaemia due to Fusarium spp. in cancer patients. Krcmery V Jr, et al. **J Hosp Infect** 1997 Jul;36(3):223–8 (19 ref.)

Broviac catheter-related bacteraemias due to unusual pathogens in children with cancer: case reports with literature review. Castagnola E, et al. **J Infect** 1997 May; 34(3):215–8 (22 ref.)

Development and evaluation of a protocol to manage fecal incontinence in the patient with cancer. Beddar SA, et al. **J Palliat Care** 1997 Summer;13(2):27–38 (106 ref.)

How should we use transdermal fentanyl (TF) for pain management in palliative care patients? Fainsinger RL, et al. **J Palliat Care** 1996 Spring;12(1):48–53 (30 ref.)

The management of cancer pain. Rhodes DJ, et al. **Md Med J** 1997 Mar;46(3):141–6 (13 ref.)

Oral bisphosphonates and malignancy. Green MD. **Med J Aust** 1997 Aug 18;167(4):211–2 (13 ref.)

Clinical and laboratory diagnosis of invasive candida infection in neutropenic patients. Kalin M, et al. **Med Oncol** 1996 Dec;13(4):223–31 (85 ref.)

The metabolic basis of cancer cachexia. Argilés JM, et al. **Med Res Rev** 1997 Sep;17(5):477–98 (215 ref.)

Cancer anorexia: new pathogenic and therapeutic insights. Cangiano C, et al. **Nutrition** 1996 Jan;12(1 Suppl):S48–51 (26 ref.)

Food intake and body composition in cancer cachexia. Giacosa A, et al. **Nutrition** 1996 Jan;12(1 Suppl):S20–3 (36 ref.)

Historical perspective and potential use of n-3 fatty acids in therapy of cancer cachexia. Karmali RA. **Nutrition** 1996 Jan;12(1 Suppl):S2–4 (19 ref.)

Cracking the riddle of cancer anorexia. Laviano A, et al. **Nutrition** 1996 Oct;12(10):706–10 (54 ref.)

Cancer cachexia: metabolic alterations and clinical manifestations. Tisdale MJ. **Nutrition** 1997 Jan;13(1):1–7 (76 ref.)

Managing the multiple causes of nausea and vomiting in the patient with cancer. Fessele KS. **Oncol Nurs Forum** 1996 Oct;23(9):1409–15; quiz 1416–7 (39 ref.)

Physiologic mechanisms of nausea and vomiting in patients with cancer. Hogan CM, et al. **Oncol Nurs Forum** 1997 Aug;24(7 Suppl):8–12 (19 ref.)

Current status of patient-controlled analgesia in cancer patients. Ripamonti C, et al. **Oncology (Huntingt)** 1997 Mar; 11(3):373–80, 383–4; discussion 384–6 (102 ref.)

Anorexia/cachexia in patients with HIV: lessons for the oncologist. Von Roenn JH, et al. **Oncology (Huntingt)** 1996 Jul;10(7):1049–56; discussion 1062–4, 1067–8 (52 ref.)

Neoplastic fever. Johnson M. **Palliat Med** 1996 Jul; 10(3):217–24 (56 ref.)

Ketamine in cancer pain: an update. Mercadante S. **Palliat Med** 1996 Jul;10(3):225–30 (35 ref.)

Oncologic emergencies. Kelly KM, et al.
Pediatr Clin North Am 1997 Aug;44(4):809–30 (87 ref.)
Empirical treatment of fever in neutropenic children: the role of the carbapenems. International Antimicrobial Therapy Cooperative Group of the European Organisation for Research and Treatment of Cancer and the Gimema Infection Program. Cometta A, et al.
Pediatr Infect Dis J 1996 Aug;15(8):744–8 (37 ref.)
Isolation of a novel cancer cachectic factor. Tisdale MJ.
Proc Nutr Soc 1997 Jul;56(2):777–83 (46 ref.)
Role of parathyroid hormone-related peptide in hypercalcemia of malignancy and the development of osteolytic metastases. de Vernejoul MC.
Rev Rhum Engl Ed 1997 Jun 30;64(6 Suppl):119S–123S (36 ref.)
Cancer- and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Gordon LI, et al. **Semin Hematol** 1997 Apr;34(2):140–7 (80 ref.)
Patient selection and predicting response to recombinant human erythropoietin in anemic cancer patients. Henry DH 3d, et al. **Semin Hematol** 1996 Jan;33(1 Suppl 1):2–5 (17 ref.)
Fever. Dinarello CA, et al. **Semin Oncol** 1997 Jun; 24(3):288–98 (71 ref.)
The cancer cachexia syndrome. Puccio M, et al.
Semin Oncol 1997 Jun;24(3):277–87 (60 ref.)
Outpatient antibiotic treatment in low-risk febrile neutropenic cancer patients. Escalante CP, et al.
Support Care Cancer 1996 Sep;4(5):358–63 (18 ref.)
Dyspnea: assessment and treatment [see comments] Farncombe M. **Support Care Cancer** 1997 Mar;5(2):94–9 (18 ref.) Comment in: Support Care Cancer 1997 Mar;5(2):77–9.
Secondary alveolar proteinosis in cancer patients. Ladeb S, et al. **Support Care Cancer** 1996 Nov;4(6):420–6 (47 ref.)
Venous thromboembolism and cancer: a two-way clinical association. Agnelli G. **Thromb Haemost** 1997 Jul; 78(1):117–20 (42 ref.)
Efficacy and safety of oral anticoagulation in patients with cancer. Bona RD, et al. **Thromb Haemost** 1997 Jul; 78(1):137–40 (31 ref.)
Antithrombotic strategies in patients with cancer. Prandoni P. **Thromb Haemost** 1997 Jul;78(1):141–4 (33 ref.)
Role of enteral nutrition in advanced cancer patients: indications and contraindications of the different techniques employed. Ripamonti C, et al. **Tumori** 1996 Jul–Aug; 82(4):302–8 (80 ref.)
[Use of opiates for chronic pain] Larue F.
Bull Acad Natl Med 1996 Nov;180(8):1967–78; discussion 1979–85 (27 ref.) (Eng. Abstr.) **(Fre)**
[Antiemetics in oncology] Longueville J. **J Pharm Belg** 1996 Jul–Aug;51(4):220–5 (13 ref.) **(Fre)**
[Systemic scleroderma and cancers: 21 cases and review of the literature] Bielefeld P, et al. **Rev Med Interne** 1996; 17(10):810–3 (34 ref.) (Eng. Abstr.) **(Fre)**
[Central nervous system infections in patients with malignant diseases] Carpentier AF, et al. **Rev Neurol (Paris)** 1996 Oct; 152(10):587–601 (115 ref.) (Eng. Abstr.) **(Fre)**
[Emergencies in oncology] Schefer H, et al.
Schweiz Rundsch Med Prax 1997 Feb 18;86(8):296–301 (47 ref.) (Eng. Abstr.) **(Ger)**
[Balanced spinal analgesia in the treatment of oncologic pain. Review of the literature] Polati E, et al.
Minerva Anestesiol 1996 Nov;62(11):363–75 (155 ref.) (Eng. Abstr.) **(Ita)**
[Treatment of pain in oncology] De Conno F, et al.
Tumori 1997;83(2 Suppl):S20–4 (49 ref.) (Eng. Abstr.) **(Ita)**
[Oncologic emergencies] Furue H. **Gan To Kagaku Ryoho** 1997 Feb;24(3):266–71 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Urological emergency for cancer patients] Ozono S, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(3):292–6 (5 ref.) (Eng. Abstr.) **(Jpn)**
[Interstitial nephritis associated with neoplasms] Kato N, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):242–7 (22 ref.) **(Jpn)**
[The problem of opioid tolerance and dependence during clinical use thereof] Osipova NA. **Anesteziol Reanimatol** 1996 Jul–Aug;(4):17–21 (26 ref.) (Eng. Abstr.) **(Rus)**
[Malignant hypercalcemia with and without bone metastasis] Millán Núñez-Cortés J, et al. **Rev Clin Esp** 1996 Jun; 196(6):388–91 (14 ref.) **(Spa)**
[Fungal infections in patients with solid tumors and other immunodepressed patients] Muñoz García-Paredes P, et al. **Rev Clin Esp** 1997 Apr;197 Suppl 1:35–43 (81 ref.) **(Spa)**
[New approaches to the therapy of hypercalcemia in cancer] Shparyk IaV. **Lik Sprava** 1997 Mar–Apr;(2):109–13 (17 ref.) (Eng. Abstr.) **(Ukr)**

DIAGNOSIS

Oncological problems in AIDS--a review of the clinical features and management. Geh JI, et al.
Ann Acad Med Singapore 1996 May;25(3):380–91 (74 ref.)
Nuclear DNA in histological and cytological specimens: measurement and prognostic significance. Magennis DP.
Br J Biomed Sci 1997 Jun;54(2):140–8 (83 ref.)
Recent advances in the diagnosis, prognosis and classification of childhood solid tumours. Ramani P, et al.
Br Med Bull 1996 Oct;52(4):724–41 (44 ref.)
Limitations of the randomized trial for the early detection of cancer: a clinical perspective. Smart CR. **Cancer** 1997 May 1;79(9):1740–6 (20 ref.)
Applications of fluorescence in situ hybridization techniques in cytopathology. Wolman SR. **Cancer** 1997 Aug 25; 81(4):193–7 (21 ref.)
The use of monoclonal antibodies (MAbs) and the development of an intraoperative hand-held probe for cancer detection [see comments] Martin EW Jr, et al.
Cancer Invest 1996;14(6):560–71 (21 ref.) Comment in: Cancer Invest 1996;14(6):637–9.
The theoretical basis for cancer screening. Day NE.
Cancer Treat Res 1996;86:9–24 (25 ref.)
Screening for cancer in high-risk families. Foulkes WD, et al. **Cancer Treat Res** 1996;86:165–82 (80 ref.)
Somatostatin analogs and receptors. Diagnostic and therapeutic applications. Hofland LJ, et al.
Cancer Treat Res 1997;89:365–82 (91 ref.)
Principles of economic evaluation in cancer screening. Krahn M, et al. **Cancer Treat Res** 1996;86:25–40 (75 ref.)
Screening in developing countries: problems and opportunities. Miller AB. **Cancer Treat Res** 1996;86:183–9 (21 ref.)
The public health basis of cancer screening: principles and ethical aspects. Miller AB. **Cancer Treat Res** 1996;86:1–7 (19 ref.)
Cancer of the oldest old. What we have learned from autopsy studies. Stanta G, et al. **Clin Geriatr Med** 1997 Feb; 13(1):55–68 (18 ref.)
Cytogenetics. An evolving role in the diagnosis and treatment of cancer. Glassman AB. **Clin Lab Med** 1997 Mar; 17(1):21–37 (42 ref.)
Utilization of nuclear matrix proteins for cancer diagnosis. Keesee SK, et al. **Crit Rev Eukaryot Gene Expr** 1996; 6(2-3):189–214 (197 ref.)
The utilization of nuclear matrix proteins for cancer diagnosis. Replogle-Schwab R, et al.
Crit Rev Eukaryot Gene Expr 1996;6(2-3):103–13 (77 ref.)
The diagnostic information of tests for the detection of cancer: the usefulness of the likelihood ratio concept. Giard RW, et al. **Eur J Cancer** 1996 Nov;32A(12):2042–8 (18 ref.)
Monitoring tumour response. Husband JE. **Eur Radiol** 1996; 6(6):775–85 (56 ref.)
Applications of magnetic targeting in diagnosis and therapy--possibilities and limitations: a mini-review. Schütt W, et al. **Hybridoma** 1997 Feb;16(1):109–17 (101 ref.)
PCR- and RT-PCR-based methods of tumor detection: potential applications and clinical implications. Seiden M, et al. **Important Adv Oncol** 1996;:191–204 (59 ref.)
Pyrexia of undetermined origin in patients with human immunodeficiency virus infection and AIDS. Miller RF, et al. **Int J STD AIDS** 1996 May–Jun;7(3):170–5 (32 ref.)
Telomerase in the early detection of cancer. Shay JW, et al. **J Clin Pathol** 1997 Feb;50(2):106–9 (57 ref.)
Assessing tumor angiogenesis using macromolecular MR imaging contrast media. Brasch R, et al.
J Magn Reson Imaging 1997 Jan–Feb;7(1):68–74 (40 ref.)
Telomerase and early detection of cancer: a National Cancer Institute workshop. Breslow RA, et al.
J Natl Cancer Inst 1997 May 7;89(9):618–23 (22 ref.)
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers [see comments] Hayes DF, et al. **J Natl Cancer Inst** 1996 Oct 16; 88(20):1456–66 (65 ref.) Comment in: J Natl Cancer Inst 1996 Oct 16;88(20):1419–20.
Immunologic advances in monoclonal antibody therapy: implications for oncology nursing. Karius D, et al.
Oncol Nurs Forum 1997 Apr;24(3):483–94; QUIZ 495–6 (74 ref.)
DNA ploidy and cell cycle analysis in cancer diagnosis and prognosis. Ross JS. **Oncology (Huntingt)** 1996 Jun; 10(6):867–82, 887; discussion 887–90 (164 ref.)
Oncologic emergencies. Kelly KM, et al.
Pediatr Clin North Am 1997 Aug;44(4):809–30 (87 ref.)
Overview by an oncologist: what are the imaging needs of the oncologist and oncological surgeon? Gucalp R, et al.
Semin Nucl Med 1997 Jan;27(1):3–9 (46 ref.)
Applications of genetic technologies to cancer screening, prevention, diagnosis, prognosis, and treatment. Peters JA.
Semin Oncol Nurs 1997 May;13(2):74–81 (45 ref.)
Neonatal oncology: diagnostic and therapeutic dilemmas. Weitzman S, et al. **Semin Perinatol** 1997 Feb;21(1):102–11 (52 ref.)
Newly diagnosed malignancy in patients with venous thromboembolism. Search or wait and see? Prins MH, et al. **Thromb Haemost** 1997 Jul;78(1):121–5 (21 ref.)
[Deep venous thromboses and occult cancers] Chraibi S, et al. **Ann Cardiol Angeiol (Paris)** 1997 Mar;46(3):145–9 (19 ref.) (Eng. Abstr.) **(Fre)**
[Diagnostic, therapeutic and socioeconomic problems in geriatric oncology] Jerusalem G, et al. **Rev Med Liege** 1997 Apr;52(4):255–7 (9 ref.) **(Fre)**
[Clinical use of polymerase chain reaction in diagnosis and monitoring of malignant diseases] Jäger U, et al.
Wien Klin Wochenschr 1996;108(20):634–9 (35 ref.) (Eng. Abstr.) **(Ger)**
[First Hungarian experiences with positron emission tomography (PET) studies. Members of the PET working group] Trón L, et al. **Orv Hetil** 1997 Feb 2;138(5):259–69 (50 ref.) (Eng. Abstr.) **(Hun)**
[Molecular diagnostic detection of circulating tumor cells and their prognostic implications] Nakanishi H, et al.
Gan To Kagaku Ryoho 1997 Feb;24(3):257–65 (33 ref.) (Eng. Abstr.) **(Jpn)**
[Current diagnosis and prognostic importance of EBV-associated neoplasms] Kawa K. **Nippon Rinsho** 1997 Feb;55(2):446–51 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Tumor associated biomarker for early diagnosis of cancer] Ohkura H. **Nippon Rinsho** 1996 May;54(5):1281–5 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Diagnostic cytology for detection of early cancer] Shibata H, et al. **Nippon Rinsho** 1996 May;54(5):1276–80 (6 ref.) (Eng. Abstr.) **(Jpn)**
[Basics of DNA diagnosis] Hayashi K.
Tanpakushitsu Kakusan Koso 1996 Nov;41(15 Suppl):2478–83 (11 ref.) **(Jpn)**
[The role of cytokines as tumor markers] Mroczko B, et al. **Pol Arch Med Wewn** 1997 Feb;97(2):170–6 (55 ref.) **(Pol)**
[Tissue spectroscopy. New generation of optical methods for cancer detection] Chwirot B, et al. **Pol Merkuriusz Lek** 1996 Nov;1(5):355–8 (29 ref.) (Eng. Abstr.) **(Pol)**
[Molecular diagnostics: sequence or signal amplification?] Słomski R, et al. **Postepy Biochem** 1995;41(4):220–9 (17 ref.) **(Pol)**

DIET THERAPY

Beyond calories: other benefits of macronutrient substitutes. Effects on chronic disease. Hannah JS.
Ann N Y Acad Sci 1997 May 23;819:221–8 (46 ref.)
Vegetables, fruit and phytoestrogens as preventive agents. Potter JD, et al. **IARC Sci Publ** 1996;(139):61–90 (205 ref.)
Identifiability of food components for cancer chemoprevention. Riboli E, et al. **IARC Sci Publ** 1996; (139):23–31 (24 ref.)

DRUG THERAPY

Recent avenues of chemotherapeutic research. Eckhardt S.
Acta Biochim Pol 1996;43(2):301–4 (0 ref.)
Clinical development of topoisomerase-interactive drugs. Muggia FM, et al. **Adv Pharmacol** 1994;29B:1–31 (95 ref.)
Amifostine for protection from antineoplastic drug toxicity. Foster-Nora JA, et al. **Am J Health Syst Pharm** 1997 Apr 1;54(7):787–800 (101 ref.)
Gemcitabine: a cytidine analogue active against solid tumors. Hui YF, et al. **Am J Health Syst Pharm** 1997 Jan 15; 54(2):162–70; quiz 197–8 (69 ref.)
Incidence and prevention of nonhaematological toxicity of high-dose chemotherapy. Hoekman K, et al. **Ann Med** 1996 Apr;28(2):175–82 (66 ref.)
CPT-11. The European experience. Armand JP, et al.
Ann N Y Acad Sci 1996 Dec 13;803:282–91 (34 ref.)
The current status of irinotecan (CPT-11) in the United States. Rothenberg ML. **Ann N Y Acad Sci** 1996 Dec 13; 803:272–81 (18 ref.)
Clinical trials of irinotecan hydrochloride (CPT, campto injection, topotecin injection) in Japan. Saijo N.
Ann N Y Acad Sci 1996 Dec 13;803:292–305 (39 ref.)
Is there a future for cancer chemotherapy? The Michel Clavel Lecture. Connors TA. **Ann Oncol** 1996 Jul; 7(5):445–52 (25 ref.)
Critical factors for optimizing the 5-fluorouracil-folinic acid association in cancer chemotherapy. Etienne MC, et al.
Ann Oncol 1996 Mar;7(3):283–9 (66 ref.)
Clinical studies with angiogenesis inhibitors: biological rationale and challenges for their evaluation [editorial; comment] Gasparini G, et al. **Ann Oncol** 1996 Jul;7(5):441–4 (45 ref.) Comment on: Ann Oncol 1996 Jul;7(5):491–6.
The role of high dose chemotherapy in adult solid tumours other than breast cancer. Hornedo J, et al. **Ann Oncol** 1996; 7 Suppl 2:23–30 (48 ref.)
The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Rowinsky EK.
Annu Rev Med 1997;48:353–74 (117 ref.)
Antisense oligonucleotide inhibitors of isozymes of protein kinase C: in vitro and in vivo activity, and clinical development as anti-cancer therapeutics. McGraw K, et al. **Anticancer Drug Des** 1997 Jul;12(5):315–26 (42 ref.)
The scientific rationale for developing taxoids. Aapro M.
Anticancer Drugs 1996 Aug;7 Suppl 2:33–6 (18 ref.)
Individualizing chemotherapy for solid tumors--is there any alternative? Cree IA, et al. **Anticancer Drugs** 1997 Jul; 8(6):541–8 (78 ref.)
The development of new chemotherapeutic agents. Hanauske AR. **Anticancer Drugs** 1996 Aug;7 Suppl 2:29–32 (39 ref.)
Application of peptide nucleic acid in cancer therapy. Knudsen H, et al. **Anticancer Drugs** 1997 Feb;8(2):113–8 (57 ref.)
Gemcitabine: once-weekly schedule active and better tolerated than twice-weekly schedule. Martin C, et al.
Anticancer Drugs 1996 May;7(3):351–7 (28 ref.)
Mistletoe therapy for human cancer: the role of the natural killer cells. Schink M. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S47–51 (50 ref.)
Folate-based thymidylate synthase inhibitors in cancer chemotherapy. Takemura Y, et al. **Anticancer Drugs** 1997 Jan;8(1):3–16 (115 ref.)
Inhibitors of angiogenesis in a clinical perspective. Voest EE.
Anticancer Drugs 1996 Sep;7(7):723–7 (36 ref.)
Trofosfamide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the oral treatment of cancer. Wagner A, et al.
Anticancer Drugs 1997 Jun;8(5):419–31 (51 ref.)
The dual role of mutant p53 protein in chemosensitivity of

human cancers. Mueller H, et al. **Anticancer Res** 1996 Nov-Dec;16(6B):3845-8 (25 ref.)

Protein kinase A-directed antisense restrains cancer growth: sequence-specific inhibition of gene expression. Cho-Chung YS. **Antisense Nucleic Acid Drug Dev** 1996 Fall;6(3):237-44 (52 ref.)

Antisense-protein kinase A: a single-gene-based therapeutic approach. Cho-Chung YS, et al. **Antisense Nucleic Acid Drug Dev** 1997 Jun;7(3):217-23 (20 ref.)

Apoptosis and cancer chemotherapy. Chresta CM, et al. **Behring Inst Mitt** 1996 Oct;(97):232-40 (35 ref.)

Farnesyl: proteintransferase inhibitors as agents to inhibit tumor growth. Omer CA, et al. **Biofactors** 1997;6(3):359-66 (37 ref.)

Restoration of aging reduced immunity is possible with immunomodulators and is applicable to cancer treatment and prevention [editorial] Mathé G, et al. **Biomed Pharmacother** 1997;51(5):193-9 (58 ref.)

Apoptosis and the dilemma of cancer chemotherapy. Hannun YA. **Blood** 1997 Mar 15;89(6):1845-53 (95 ref.)

Use of haemopoietic growth factors: commentary on the ASCO/ECOG guidelines. American Society of Clinical Oncology/Eastern Co-operative Oncology Group. Byrne JL, et al. **Blood Rev** 1997 Mar;11(1):16-27 (83 ref.)

2-chloro-2'-deoxyadenosine: clinical applications in hematology. Delannoy A. **Blood Rev** 1996 Sep;10(3):148-66 (160 ref.)

The effects of chemotherapy on the long-term survivors of malignancy. Davies HA, et al. **Br J Hosp Med** 1997 Mar 5-18;57(5):215-8 (36 ref.)

Future directions in the pharmacology of anti-cancer agents in children. Pearson AD. **Br Med Bull** 1996 Oct; 52(4):844-72 (95 ref.)

The efficacy of 9-cis retinoic acid in experimental models of cancer. Gottardis MM, et al. **Breast Cancer Res Treat** 1996;38(1):85-96 (57 ref.)

Immunomodulation following chemotherapy. Obadina M, et al. **Breast Cancer Res Treat** 1996;38(1):41-8 (44 ref.)

The potential use of vitamin D analogs in the treatment of cancer. Ogata E. **Calcif Tissue Int** 1997 Jan;60(1):130-3 (9 ref.)

Cancer chemotherapy in the older patient: what the medical oncologist needs to know. Balducci L, et al. **Cancer** 1997 Oct 1;80(7):1317-22 (51 ref.)

Palliative medicine in the elderly. Cleary JF, et al. **Cancer** 1997 Oct 1;80(7):1335-47 (56 ref.)

Hormones, vitamins, and growth factors in cancer treatment and prevention. A critical appraisal. Lupulescu AP. **Cancer** 1996 Dec 1;78(11):2264-80 (131 ref.)

Regrowth resistance as a likely significant contributor to treatment failure in drug-sensitive neoplastic diseases. Preisler HD, et al. **Cancer Invest** 1997;15(4):358-68 (64 ref.)

The use of chemotherapy resistance in cancer treatment. Deisseroth AB, et al. **Cancer J Sci Am** 1997 Mar-Apr; 3(2):60-9 (50 ref.)

Treating cancer by inhibiting angiogenesis: new hopes and potential pitfalls. Rak J, et al. **Cancer Metastasis Rev** 1996 Jun;15(2):231-6 (39 ref.)

A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction). Teicher BA. **Cancer Metastasis Rev** 1996 Jun;15(2):247-72 (316 ref.)

Methodologic considerations in treatment using intraperitoneal chemotherapy. Averbach AM, et al. **Cancer Treat Res** 1996;82:289-309 (64 ref.)

Apoptosis and cancer chemotherapy. Lutzker SG, et al. **Cancer Treat Res** 1996;87:345-56 (75 ref.)

Intraperitoneal taxol. Markman M. **Cancer Treat Res** 1996; 81:1-5 (20 ref.)

Retinoids in clinical cancer therapy. Muindi JR. **Cancer Treat Res** 1996;87:305-42 (242 ref.)

The clinical pharmacology of etoposide: an update. Joel S. **Cancer Treat Rev** 1996 May;22(3):179-221 (317 ref.)

How to starve a tumor. Taunton J. **Chem Biol** 1997 Jul; 4(7):493-6 (17 ref.)

Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes. Masson E, et al. **Clin Pharmacokinet** 1997 Apr;32(4):324-43 (135 ref.)

Circadian rhythms and cancer chemotherapy. Wood PA, et al. **Crit Rev Eukaryot Gene Expr** 1996;6(4):299-343 (292 ref.)

Antisense regulation of oncogenes in human cancer. Mukhopadhyay T, et al. **Crit Rev Oncog** 1996;7(3-4):151-90 (251 ref.)

Irinotecan (CPT-11): pharmacology and clinical applications. Masuda N, et al. **Crit Rev Oncol Hematol** 1996 Sep; 24(1):3-26 (114 ref.)

The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996. O'Reilly S, et al. **Crit Rev Oncol Hematol** 1996 Sep;24(1):47-70 (206 ref.)

Mechanism of action and clinical trials of Mpl ligand. Sheridan WP, et al. **Curr Opin Hematol** 1997 Sep;4(5):312-6 (35 ref.)

Promising new agents in oncologic treatment. Mani S, et al. **Curr Opin Oncol** 1996 Nov;8(6):525-34 (97 ref.)

Targets for cancer therapy in the cell cycle pathway. Rao RN. **Curr Opin Oncol** 1996 Nov;8(6):516-24 (75 ref.)

Antiemetics revisited. Roila F, et al. **Curr Opin Oncol** 1997 Jul;9(4):321-6 (31 ref.)

Infection prophylaxis and antiretroviral therapy in patients with HIV infection and malignancy. Sparano JA, et al. **Curr Opin Oncol** 1996 Sep;8(5):392-9 (41 ref.)

The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Rusch V, et al. **Cytokine Growth Factor Rev** 1996 Aug;7(2):133-41 (64 ref.)

Cellular heterogeneity in malignant tumors. The importance of clonal interaction on tumor evolution, response to chemotherapy and metastatic ability evaluated in experimental systems. Aabo K. **Dan Med Bull** 1996 Sep; 43(4):336-49 (155 ref.)

Clinical use of somatostatin analogues in paediatric oncology. Albers AR, et al. **Digestion** 1996;57 Suppl 1:38-41 (32 ref.)

A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy. Abraham R, et al. **Drug Saf** 1996 Dec;15(6):406-29 (208 ref.)

Antibiotic treatment of febrile episodes in neutropenic cancer patients. Clinical and economic considerations. de Lalla F. **Drugs** 1997 May;53(5):789-804 (103 ref.)

Emerging drug treatments for solid tumours. Schellens JH, et al. **Drugs** 1996 Jan;51(1):45-72 (321 ref.)

Cancer chemotherapy in older adults. A tolerability perspective. Kimmick GG, et al. **Drugs Aging** 1997 Jan; 10(1):34-49 (100 ref.)

The effects of irradiation and chemotherapy on growth. Moshang T Jr, et al. **Endocrinol Metab Clin North Am** 1996 Sep;25(3):731-41 (49 ref.)

Clinical effects of amifostine (Ethyol) in patients treated with carboplatin. Budd GT, et al. **Eur J Cancer** 1996;32A Suppl 4:S43-5 (8 ref.)

The need for cytoprotection. Bukowski RM. **Eur J Cancer** 1996;32A Suppl 4:S2-4 (27 ref.)

TNP-470 (AGM-1470): mechanisms of action and early clinical development. Castronovo V, et al. **Eur J Cancer** 1996 Dec;32A(14):2520-7 (55 ref.)

A call for change in anticancer drug evaluation. Cvitkovic E. **Eur J Cancer** 1997 Jan;33 Suppl 2:S3-7 (11 ref.)

Transcription factors as drug targets in cancer. Hurst HC. **Eur J Cancer** 1996 Oct;32A(11):1857-63 (41 ref.)

Etoposide for the treatment of paediatric tumours: what is the best way to give it? Lowis SP, et al. **Eur J Cancer** 1996 Dec;32A(13):2291-7 (65 ref.)

A plea for improved use of the tools available for the evaluation of anticancer drugs. MacRae K. **Eur J Cancer** 1997 Jan;33 Suppl 2:S14-6 (10 ref.)

The need for endpoints in anticancer drug trials that will simplify the clinical decision-making process. Redmond K. **Eur J Cancer** 1997 Jan;33 Suppl 2:S11-3 (6 ref.)

Exploration of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethyol). Schuchter LM. **Eur J Cancer** 1996;32A Suppl 4:S40-2 (19 ref.)

Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Talbot DC, et al. **Eur J Cancer** 1996 Dec;32A(14):2528-33 (42 ref.)

Anticancer drug evaluation: continuing progress from existing methodology. ten Bokkel Huinink W. **Eur J Cancer** 1997 Jan;33 Suppl 2:S8-10 (15 ref.)

Endocrine sequelae of cancer therapy. Shalet SM. **Eur J Endocrinol** 1996 Aug;135(2):135-43 (46 ref.)

Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. O'Reilly MS. **EXS** 1997;79:273-94 (62 ref.)

The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Connors TA. **Gene Ther** 1995 Dec; 2(10):702-9 (64 ref.)

The use of cytokines in the treatment of solid tumours. Fridman WH, et al. **Hematol Cell Ther** 1997 Apr; 39(2):105-8 (34 ref.)

Toxicity of chemotherapy. Lowenthal RM, et al. **Hematol Oncol Clin North Am** 1996 Aug;10(4):967-90 (156 ref.)

Colloidal systems for tumor targeting. Storm G, et al. **Hybridoma** 1997 Feb;16(1):119-25 (58 ref.)

Relevance of circadian cell kinetics in the timing of chemotherapy in animal tumors. Focan C. **In Vivo** 1995 Nov-Dec;9(6):573-81 (125 ref.)

Circadian cell kinetics in humans. Aspects related to cancer chemotherapy. Smaaland R, et al. **In Vivo** 1995 Nov-Dec; 9(6):529-37 (91 ref.)

Idarubicin: a brief overview on pharmacology and clinical use. Borchmann P, et al. **Int J Clin Pharmacol Ther** 1997 Feb;35(2):80-3 (30 ref.)

Phase I trials in paediatric oncology--the European perspective. The New Agents Group of the United Kingdom Childrens Cancer Study Group. Estlin EJ, et al. **Invest New Drugs** 1996;14(1):23-32 (31 ref.)

An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action. Gradishar WJ. **Invest New Drugs** 1997;15(1):49-59 (103 ref.)

Folate, antifolates, and folate analogs in pediatric oncology. Hum MC, et al. **Invest New Drugs** 1996;14(1):101-11 (59 ref.)

Multidrug resistance in pediatric oncology. Kuttesch JF Jr. **Invest New Drugs** 1996;14(1):55-67 (88 ref.)

The importance of phase I/II trials in pediatric oncology. MacArthur CA, et al. **Invest New Drugs** 1996;14(1):33-5 (11 ref.)

New microtubular agents in pediatric oncology. Seibel NL, et al. **Invest New Drugs** 1996;14(1):49-54 (45 ref.)

Pediatric drug development: a perspective from the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI). Smith M, et al. **Invest New Drugs** 1996;14(1):11-22 (73 ref.)

Topoisomerase I interactive drugs in children with cancer. Stewart CF, et al. **Invest New Drugs** 1996;14(1):37-47 (45 ref.)

New drug development for pediatric oncology. Weitman S, et al. **Invest New Drugs** 1996;14(1):1-10 (92 ref.)

Matrix metalloproteinase inhibitors. Wojtowicz-Praga SM, et al. **Invest New Drugs** 1997;15(1):61-75 (94 ref.)

Cellular drug efflux and reversal therapy of cancer. Wigler PW. **J Bioenerg Biomembr** 1996 Jun;28(3):279-84 (28 ref.)

The erbB 2 oncogene and chemotherapy: a mini-review. Torre EA, et al. **J Chemother** 1997 Feb;9(1):51-5 (46 ref.)

Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors [see comments] Savarese DM, et al. **J Clin Oncol** 1997 Aug; 15(8):2981-95 (84 ref.) Comment in: J Clin Oncol 1997 Aug;15(8):2765-8.

Treatment of cancer with radiation and drugs. Tannock IF. **J Clin Oncol** 1996 Dec;14(12):3156-74 (156 ref.)

Polyethylene glycol modification: relevance of improved methodology to tumour targeting. Francis GE, et al. **J Drug Target** 1996;3(5):321-40 (84 ref.)

Inhibition of and sensitization to the lethal effects of tumor necrosis factor. Brouckaert P, et al. **J Inflamm** 1995-96; 47(1-2):18-26 (31 ref.)

Regional application of TNF alpha in the treatment of cancer: a preclinical-clinical interactive program. Eggermont AM, et al. **J Inflamm** 1995-96;47(1-2):104-13 (77 ref.)

Infusional chemotherapy with new drugs: taxanes, vinorelbine and topoisomerase I inhibitors. Dieras V, et al. **J Infus Chemother** 1995 Fall;5(4):191-2 (15 ref.)

The suitability of selected new anticancer agents for infusional therapy and the effects of others on infusional therapy practices. Rowinsky EK. **J Infus Chemother** 1995 Fall;5(4):173-8 (60 ref.)

Considerations for the combined use of chemotherapy and radiation therapy. Vokes EE. **J Infus Chemother** 1995 Fall; 5(4):179-81 (47 ref.)

Drug stability and compatibility in oncology care. Williams DA. **J Infus Chemother** 1996 Fall;6(4):195-202 (54 ref.)

Biological perspectives on circadian cancer therapy. Wood PA, et al. **J Infus Chemother** 1995 Fall;5(4):182-90 (122 ref.)

Antibodies to interferon-alpha in treated cancer patients: incidence and significance. McKenna RM, et al. **J Interferon Cytokine Res** 1997 Mar;17(3):141-3 (25 ref.)

Assessment of tumor microcirculation: a new role of dynamic contrast MR imaging. Griebel J, et al. **J Magn Reson Imaging** 1997 Jan-Feb;7(1):111-9 (73 ref.)

Toward therapeutic intervention of cancer by vitamin D compounds [editorial; comment] Campbell MJ, et al. **J Natl Cancer Inst** 1997 Feb 5;89(3):182-5 (50 ref.) Comment on: J Natl Cancer Inst 1997 Feb 5;89(3):212-8.

Cytotoxic drugs, programmed cell death, and the immune system: defining new roles in an old play [editorial] Debatin KM. **J Natl Cancer Inst** 1997 Jun 4;89(11):750-1 (17 ref.)

Promise and problems of Bcl-2 antisense therapy [editorial; comment] Reed JC. **J Natl Cancer Inst** 1997 Jul 16; 89(14):988-90 (36 ref.) Comment on: J Natl Cancer Inst 1997 Jul 16;89(14):1027-36.

Photophysical and photobiological processes in the photodynamic therapy of tumours. Ochsner M. **J Photochem Photobiol B** 1997 May;39(1):1-18 (172 ref.)

The validity of melatonin as an oncostatic agent. Panzer A, et al. **J Pineal Res** 1997 May;22(4):184-202 (165 ref.)

A modern tragedy: needless suffering with cancer pain. de Jong RH. **J S C Med Assoc** 1996 Oct;92(10):432-6 (7 ref.)

IP6: a novel anti-cancer agent. Shamsuddin AM, et al. **Life Sci** 1997;61(4):343-54 (68 ref.)

Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis. McCarty MF. **Med Hypotheses** 1997 Aug; 49(2):123-31 (108 ref.)

Matrix metalloproteinase inhibitors in the treatment of cancer. Brown PD. **Med Oncol** 1997 Mar;14(1):1-10 (74 ref.)

Granulocyte-macrophage colony-stimulating factor as an adjuvant in tumor immunotherapy. Fagerberg J. **Med Oncol** 1996 Sep;13(3):155-60 (52 ref.)

Anti-tumoral effect of GM-CSF with or without cytokines and monoclonal antibodies in solid tumors. Ragnhammar P. **Med Oncol** 1996 Sep;13(3):167-76 (64 ref.)

Recent advances in the discovery and development of topoisomerase inhibitors as antitumor agents. Wang HK, et al. **Med Res Rev** 1997 Jul;17(4):367-425 (232 ref.)

The Eugene M. Landis Award Lecture 1996. Delivery of molecular and cellular medicine to solid tumors. Jain RK. **Microcirculation** 1997 Mar;4(1):1-23 (150 ref.)

Antisense technology and prospects for therapy of viral infections and cancer. Wagner RW, et al. **Mol Med Today** 1997 Jan;3(1):31-8 (36 ref.)

Isoenzymes of protein kinase C: differential involvement in apoptosis and pathogenesis. Deacon EM, et al. **Mol Pathol** 1997 Jun;50(3):124-31 (140 ref.)

Drug-induced DNA hypermethylation: a potential mediator of acquired drug resistance during cancer chemotherapy [see comments] Nyce JW. **Mutat Res** 1997 Apr; 386(2):153-61 (60 ref.) Comment in: Mutat Res 1997 Apr;386(2):103-5.

Protein kinase inhibitors: induction of apoptosis and drug-resistance modulation in neoplastic cell lines. Chorváth B, et al. **Neoplasma** 1996;43(1):3-9 (71 ref.)

Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview. Hájek R, et al. **Neoplasma** 1996; 43(3):141–54 (158 ref.)

Tailor-made chemotherapy for cancer patients. van Warmerdam LJ. **Neth J Med** 1997 Jul;51(1):30–5 (25 ref.)

The use of chemotherapeutic agents during pregnancy. Sorosky JI, et al. **Obstet Gynecol Clin North Am** 1997 Sep; 24(3):591–9 (27 ref.)

Outpatient chemotherapy: telephone triage for symptom management. Anastasia PJ, et al. **Oncol Nurs Forum** 1997 Jan–Feb;24(1 Suppl):13–22 (42 ref.)

Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy. Morrison GB, et al. **Oncol Nurs Forum** 1997 Jan–Feb;24(1):83–8 (22 ref.)

Angiogenesis as a target for tumor treatment. Gastl G, et al. **Oncology** 1997 May–Jun;54(3):177–84 (69 ref.)

Current role of protective agents in cancer treatment. Schuchter LM. **Oncology (Huntingt)** 1997 Apr; 11(4):505–12, 515–6; discussion 517–8 (87 ref.)

Use of transcription factors as agents and targets for drug development. Smith LM, et al. **Oncology (Huntingt)** 1996 Oct;10(10):1532–8; discussion 1541–2 (47 ref.)

Clinical trials referral resource. Clinical trials using gemcitabine. Sorensen JM, et al. **Oncology (Huntingt)** 1996 Jun;10(6):855–6 (0 ref.)

New antifolates in clinical development. Takimoto CH, et al. **Oncology (Huntingt)** 1995 Jul;9(7):649–56, 659 DISC 660, 662, 665 (87 ref.)

The concept of laser phototherapy. Castro DJ, et al. **Otolaryngol Clin North Am** 1996 Dec;29(6):1011–29 (84 ref.)

An update on the clinical use of methadone for cancer pain. Ripamonti C, et al. **Pain** 1997 Apr;70(2–3):109–15 (70 ref.)

Molecular mechanisms of multidrug resistance in cancer chemotherapy. Nooter K, et al. **Pathol Res Pract** 1996 Jul; 192(7):768–80 (141 ref.)

Apoptosis: molecular mechanisms and implications for cancer chemotherapy. Guchelaar HJ, et al. **Pharm World Sci** 1997 Jun;19(3):119–25 (93 ref.)

The DNA methylation machinery as a target for anticancer therapy. Szyf M. **Pharmacol Ther** 1996;70(1):1–37 (321 ref.)

Lysosomes and microtubules as targets for photochemotherapy of cancer. Berg K, et al. **Photochem Photobiol** 1997 Mar;65(3):403–9 (93 ref.)

Principles of receptor-based inhibition of erbB family receptor kinases: prospects for new therapies for human cancers. O'Rourke DM, et al. **Proc Assoc Am Physicians** 1997 May;109(3):209–19 (78 ref.)

Cyclooxygenase and lipoxygenase inhibitors in cancer therapy. Ara G, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Jan; 54(1):3–16 (188 ref.)

Phase I studies with the novel nucleoside analog gemcitabine. Abbruzzese JL. **Semin Oncol** 1996 Oct;23(5 Suppl 10):25–31 (30 ref.)

Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute. Christian MC, et al. **Semin Oncol** 1997 Apr;24(2):219–40 (152 ref.)

Coral reefs, forests, and thermal vents: the worldwide exploration of nature for novel antitumor agents. Cragg GM, et al. **Semin Oncol** 1997 Apr;24(2):156–63 (22 ref.)

Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Gelmann EP. **Semin Oncol** 1997 Feb;24(1 Suppl 1):S1-65–S1-70 (71 ref.)

Paclitaxel via 1-hour infusion: clinical experience. Greco FA, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):91–3 (7 ref.)

Gemcitabine safety overview. Green MR. **Semin Oncol** 1996 Oct;23(5 Suppl 10):32–5 (20 ref.)

Increasing effectiveness of interferon-alpha for malignancies. Lindner DJ, et al. **Semin Oncol** 1997 Jun;24(3 Suppl 9):S9-99–S9-104 (26 ref.)

The importance of drug scheduling in cancer chemotherapy: etoposide as an example. Hande KR. **Stem Cells** 1996 Jan; 14(1):18–24 (40 ref.)

Interleukin 1 trials in cancer patients: a review of the toxicity, antitumor and hematopoietic effects. Veltri S, et al. **Stem Cells** 1996 Mar;14(2):164–76 (58 ref.)

Hyponatremia related to medical anticancer treatment. Berghmans T. **Support Care Cancer** 1996 Sep;4(5):341–50 (81 ref.)

Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): progress in supportive care. Hellmann K. **Support Care Cancer** 1996 Jul;4(4):305–7 (5 ref.)

Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Levine MN. **Thromb Haemost** 1997 Jul;78(1):133–6 (22 ref.)

[Vascularization and perfusion of tumors as target in cancer therapy] Bernsen HJ, et al. **Ned Tijdschr Geneeskd** 1997 Feb 22;141(8):364–8 (25 ref.) (Eng. Abstr.) **(Dut)**

[Value and applications of pharmacogenetics in oncology and hematology] Albin N, et al. **Bull Cancer** 1997 Jun; 84(6):643–51 (79 ref.) (Eng. Abstr.) **(Fre)**

[Amifostine: current and future applications in cytoprotection] Lenoble M. **Bull Cancer** 1996 Sep; 83(9):773–87 (48 ref.) (Eng. Abstr.) **(Fre)**

[Role of amphetamines in cancerology : a review of the literature] Reich MG, et al. **Bull Cancer** 1996 Nov; 83(11):891–900 (66 ref.) (Eng. Abstr.) **(Fre)**

[Resistance to antineoplastic treatments: mechanisms, clinical value] Bonnal C, et al. **C R Seances Soc Biol Fil** 1996; 190(4):455–66 (12 ref.) (Eng. Abstr.) **(Fre)**

[Inhibitors of farnesyl transferase in oncology: from basic research to pharmaceutical research] Lavelle F. **C R Seances Soc Biol Fil** 1997;191(2):211–9 (18 ref.) (Eng. Abstr.) **(Fre)**

[Chronopharmacology and chronotherapy of cancers] Lévi F. **Pathol Biol (Paris)** 1996 Sep;44(7):631–44 (68 ref.) (Eng. Abstr.) **(Fre)**

[Venous thrombosis on central catheters in oncology] Devie-Hubert I, et al. **Rev Med Interne** 1996;17(10):821–5 (52 ref.) (Eng. Abstr.) **(Fre)**

[High dose therapy with transplantation of autologous peripheral hematopoietic stem cells. I. Basic principles and clinical development] Gunsilius E, et al. **Acta Med Austriaca** 1997;24(3):97–101 (53 ref.) (Eng. Abstr.) **(Ger)**

[High dose therapy with transplantation of autologous peripheral hematopoietic stem cells. II. Indications and clinical results] Gunsilius E, et al. **Acta Med Austriaca** 1997; 24(3):102–7 (53 ref.) (Eng. Abstr.) **(Ger)**

[High dose chemotherapy with autologous stem cell transplantation] Weissinger F, et al. **Fortschr Med** 1997 Mar 30;115(9):39–43 (20 ref.) (Eng. Abstr.) **(Ger)**

[Prevention, diagnosis and therapy of infections in patients with malignant diseases] Hiddemann W, et al. **Internist (Berl)** 1996 Dec;37(12):1212–24 (56 ref.) **(Ger)**

[High dose chemotherapy of solid tumors] Höffken K, et al. **Med Klin** 1997 Jul 15;92(7):410–4 (18 ref.) (Eng. Abstr.) **(Ger)**

[Pro and contra early systemic therapy of malignant tumors] Oldenkott B, et al. **Med Klin** 1996 Dec 15;91(12):780–90 (144 ref.) **(Ger)**

[Therapeutic use of monoclonal antibodies] Baron D. **Naturwissenschaften** 1997 May;84(5):189–98 (7 ref.) (Eng. Abstr.) **(Ger)**

[Neytumorin as biomodular onco-therapy--allegations without documentation] Allewelt MC, et al. **Schweiz Rundsch Med Prax** 1997 Apr 30;86(18):750–61 (110 ref.) (Eng. Abstr.) **(Ger)**

[Chronochemotherapy for cancer] Akazawa S. **Gan To Kagaku Ryoho** 1997 Aug;24(10):1191–202 (49 ref.) (Eng. Abstr.) **(Jpn)**

[Theory and actual attempts to establish an effective cancer chemotherapy] Fujimoto S. **Gan To Kagaku Ryoho** 1997 Feb;24(4):501–10 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Methotrexate-leucovorin rescue therapy: pharmacological characteristics and clinical effective use] Fujimoto T. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1901–6 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Cancer chemotherapy and apoptosis] Mashima T, et al. **Nippon Rinsho** 1996 Jul;54(7):1935–42 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Overcoming of multidrug resistance and its clinical application] Tsuruo T. **Nippon Rinsho** 1997 May; 55(5):1111–5 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Chemotherapeutic approaches against drug resistant tumors] Tsuruo T. **Rinsho Ketsueki** 1996 Jun;37(6):492–6 (17 ref.) **(Jpn)**

[Selected achievements in pharmacotherapy of malignant neoplasms] Pawlicki M. **Pol Arch Med Wewn** 1997;97 Spec No:46–55 (24 ref.) **(Pol)**

[The concept of immunocorrection in multifactor immunodeficiency states, infectious and cancerous diseases] Kuznetsov VP, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Sep–Oct; (5):104–10 (60 ref.) **(Rus)**

[Multidrug resistance (MDR) in oncology] Souvirón Rodríguez A, et al. **An Med Interna** 1997 Mar;14(3):145–53 (119 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

The utility of follow-up testing after curative cancer therapy. A critical review and economic analysis. Edelman MJ, et al. **J Gen Intern Med** 1997 May;12(5):318–31 (133 ref.)

Cost-effectiveness of PET imaging in clinical oncology. Valk PE, et al. **Nucl Med Biol** 1996 Aug;23(6):737–43 (23 ref.)

Measuring the cost-effectiveness of cancer care. Schulman KA, et al. **Oncology (Huntingt)** 1995 Jun;9(6):523–30, 533; discussion 533–8 (106 ref.)

ENZYMOLOGY

Cathepsin B expression in human tumors. Berquin IM, et al. **Adv Exp Med Biol** 1996;389:281–94 (56 ref.)

Cdc25 protein phosphatases in cell proliferation. Draetta G, et al. **Biochim Biophys Acta** 1997 Apr 18;1332(2):M53–63 (79 ref.)

Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy. Griffiths L, et al. **Br J Cancer** 1997;76(6):689–93 (55 ref.)

Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. MacDougall JR, et al. **Cancer Metastasis Rev** 1995 Dec;14(4):351–62 (84 ref.)

Matrix metalloproteinases and the development of cancer. Coussens LM, et al. **Chem Biol** 1996 Nov;3(11):895–904 (56 ref.)

Telomerase: anti-cancer target or just a fascinating enzyme? Hamilton SE, et al. **Chem Biol** 1996 Nov;3(11):863–7 (32 ref.)

Failure to unwind causes cancer. Genome stability. Watt PM, et al. **Curr Biol** 1996 Mar 1;6(3):265–7 (10 ref.)

Stromal cell expression of components of matrix-degrading protease systems in human cancer. Hewitt R, et al. **Enzyme Protein** 1996;49(1–3):163–73 (89 ref.)

Clinical implications of telomerase in cancer. Kim NW. **Eur J Cancer** 1997 Apr;33(5):781–6 (35 ref.)

A survey of telomerase activity in human cancer. Shay JW, et al. **Eur J Cancer** 1997 Apr;33(5):787–91 (51 ref.)

Antioxidant enzyme levels in cancer. Oberley TD, et al. **Histol Histopathol** 1997 Apr;12(2):525–35 (82 ref.)

Telomerase and early detection of cancer: a National Cancer Institute workshop. Breslow RA, et al. **J Natl Cancer Inst** 1997 May 7;89(9):618–23 (22 ref.)

Protein kinase inhibitors: induction of apoptosis and drug-resistance modulation in neoplastic cell lines. Chorváth B, et al. **Neoplasma** 1996;43(1):3–9 (71 ref.)

Non-classical actions of cholinesterases: role in cellular differentiation, tumorigenesis and Alzheimer's disease. Greenfield S. **Neurochem Int** 1996 May–Jun;28(5–6):485–90 (38 ref.)

Non-classical actions of cholinesterases: role in cellular differentiation, tumorigenesis and Alzheimer's disease. Layer PG. **Neurochem Int** 1996 May–Jun;28(5–6):491–5 (28 ref.)

Non-classical actions of cholinesterases: role in cellular differentiation, tumorigenesis and Alzheimer's disease. Small DH, et al. **Neurochem Int** 1996 May–Jun; 28(5–6):453–83 (399 ref.)

Adenosine deaminase in childhood malignancy: should there be a second look? [editorial; comment] Blatt J. **Pediatr Hematol Oncol** 1996 Jul–Aug;13(4):301–3 (8 ref.) Comment on: Pediatr Hematol Oncol 1996 Jul–Aug;13(4):339–47.

Matrix-degrading metalloproteinases in tumor progression. Matrisian LM, et al. **Princess Takamatsu Symp** 1994; 24:152–61 (27 ref.)

Membrane-type matrix metalloproteinases (MT-MMPs) in cell invasion. Sato H, et al. **Thromb Haemost** 1997 Jul; 78(1):497–500 (37 ref.)

Is telomerase activity in cancer due to selection of stem cells and differentiation arrest? Greaves M. **Trends Genet** 1996 Apr;12(4):127–8 (34 ref.)

The reactivation of telomerase activity in cancer progression. Shay JW, et al. **Trends Genet** 1996 Apr;12(4):129–31 (27 ref.)

[Acquisition of resistance to anticancer agents by overproduction of target enzymes] Inaba M. **Nippon Rinsho** 1997 May;55(5):1030–7 (34 ref.) (Eng. Abstr.) **(Jpn)**

[Autocrine-generated matrix metalloproteinases of tumor cells and the cascade network of protease activation mediated by membrane associated urokinase-type plasminogen activator: involvement in the degradation of extracellular matrices] Takahashi K. **Rinsho Byori** 1997 Feb;Suppl 104:159–69 (28 ref.) **(Jpn)**

[Human senescence, cancer and telomerase] Ide T, et al. **Tanpakushitsu Kakusan Koso** 1997 Jul;42(9):1351–74 (104 ref.) **(Jpn)**

EPIDEMIOLOGY

The future cancer burden as a study subject. Hakulinen T. **Acta Oncol** 1996;35(6):665–70 (23 ref.)

Antioxidant nutrients and cancer incidence and mortality: an epidemiologic perspective. Mayne ST. **Adv Pharmacol** 1997;38:657–75 (75 ref.)

Nuclear energy facilities and cancers. Wakeford R, et al. **Ann Acad Med Singapore** 1996 May;25(3):468–76 (75 ref.)

Mechanisms of carcinogenesis and molecular epidemiology. Vainio H, et al. **Br J Hosp Med** 1996 Aug 21–Sep 3; 56(4):162–70 (153 ref.)

Cancer and depression. Spiegel D. **Br J Psychiatry Suppl** 1996 Jun;(30):109–16 (76 ref.)

Cancer in adolescence. Lewis IJ. **Br Med Bull** 1996 Oct; 52(4):887–97 (27 ref.)

Geographic and ethnic variations in the incidence of childhood cancer. Stiller CA, et al. **Br Med Bull** 1996 Oct; 52(4):682–703 (57 ref.)

Cancer burden in the aged: an epidemiologic and demographic overview. Yancik R. **Cancer** 1997 Oct 1; 80(7):1273–83 (26 ref.)

Epidemiological studies on brassica vegetables and cancer risk. Verhoeven DT, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Sep;5(9):733–48 (146 ref.)

Cancer prevention: epidemiology and experiment. Potter JD. **Cancer Lett** 1997 Mar 19;114(1–2):7–9 (5 ref.)

Vitamins and cancer. van Poppel G, et al. **Cancer Lett** 1997 Mar 19;114(1–2):195–202 (49 ref.)

Cancer in the elderly. Epidemiologic and clinical implications. Balducci L, et al. **Clin Geriatr Med** 1997 Feb; 13(1):1–14 (48 ref.)

Prevalence of cancer in older persons living at home and in institutions. Caranasos GJ. **Clin Geriatr Med** 1997 Feb; 13(1):15–31 (33 ref.)

Cancer of the oldest old. What we have learned from autopsy studies. Stanta G, et al. **Clin Geriatr Med** 1997 Feb; 13(1):55–68 (18 ref.)

Use of cancer incidence data in identification of cancer causation. Lynge E. **Environ Health Perspect** 1996 May;104 Suppl 3:639–41 (33 ref.)

Molecular epidemiology in environmental carcinogenesis. Perera FP, et al. **Environ Health Perspect** 1996 May;104 Suppl 3:441–3 (14 ref.)

Tea and cancer: a review of the epidemiological evidence. Blot WJ, et al. **Eur J Cancer Prev** 1996 Dec;5(6):425–38 (113 ref.)

Main hypotheses on diet and cancer investigated in the EPIC Study. European Prospective Investigation into Cancer and Nutrition. Bueno-de-Mesquita HB, et al. **Eur J Cancer Prev** 1997 Apr;6(2):107–17 (95 ref.)

Epidemiology relating N-nitroso compounds to human cancer. Caygill CP. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:125–30 (37 ref.)

Causes of cancer: an overview. Montesano R. **Eur J Cancer Prev** 1996 Oct;5(5):367–8 (17 ref.)

Multiphasity of neoplastic induction. Parodi S, et al. **Eur J Cancer Prev** 1996 Oct;5(5):368–70 (6 ref.)

Biomarkers, low-dose carcinogenesis and dietary exposures. Vineis P. **Eur J Cancer Prev** 1997 Apr;6(2):147–51 (28 ref.)

Epidemiological evidence for beta-carotene in prevention of cancer and cardiovascular disease. van Poppel G. **Eur J Clin Nutr** 1996 Jul;50 Suppl 3:S57–61 (33 ref.)

The epidemiology of AIDS—related neoplasms. Biggar RJ, et al. **Hematol Oncol Clin North Am** 1996 Oct; 10(5):997–1010 (78 ref.)

Diet and disease—the Israeli paradox: possible dangers of a high omega-6 polyunsaturated fatty acid diet. Yam D, et al. **Isr J Med Sci** 1996 Nov;32(11):1134–43 (135 ref.)

Dietary fat and chronic diseases: epidemiologic overview. Kuller LH. **J Am Diet Assoc** 1997 Jul;97(7 Suppl):S9–15 (84 ref.)

The challenges of assessing fat intake in cancer research investigations. Wynder EL, et al. **J Am Diet Assoc** 1997 Jul;97(7 Suppl):S5–8 (39 ref.)

Defining and analyzing cohorts using molecular markers of cancer risk. Mark SD. **J Cell Biochem Suppl** 1996;25:69–79 (18 ref.)

Cancer mortality among petroleum refinery and chemical manufacturing workers in Texas. Cooper SP, et al. **J Environ Pathol Toxicol Oncol** 1997;16(1):1–14 (65 ref.)

Environment, cancer, and molecular epidemiology: air pollution. Moran EM. **J Environ Pathol Toxicol Oncol** 1996;15(2–4):97–104 (81 ref.)

The scientific platform and activity of the Ukrainian INEC Section. Rubenchik BL, et al. **J Environ Pathol Toxicol Oncol** 1996;15(2–4):299–301 (4 ref.)

Does chronic essential fatty acid deficiency constitute a pro-tumorigenic condition? Eynard AR. **Med Hypotheses** 1997 Jan;48(1):55–62 (67 ref.)

Landscapes of longevity: the calcium-selenium-mercury connection in cancer and heart disease. Foster HD. **Med Hypotheses** 1997 Apr;48(4):355–60 (76 ref.)

Cancer incidence and mortality: the priority of screening frequency and population coverage. Colditz GA, et al. **Milbank Q** 1997;75(2):147–73 (50 ref.)

Epidemiology of occupational cancer. Bang KM. **Occup Med** 1996 Jul–Sep;11(3):467–85 (110 ref.)

Pesticides and cancer. Zahm SH, et al. **Occup Med** 1997 Apr–Jun;12(2):269–89 (195 ref.)

Pediatric hematology and oncology in Cameroon, Africa: past and future perspectives. Abena Obama MT. **Pediatr Hematol Oncol** 1996 Jul–Aug;13(4):315–7 (5 ref.)

Pediatric oncology in Argentina: a historical overview. Diez B, et al. **Pediatr Hematol Oncol** 1997 Jul–Aug;14(4):299–305 (11 ref.)

Etoposide in Langerhans cell histiocytosis [editorial] Gadner H. **Pediatr Hematol Oncol** 1996 Jul–Aug;13(4):309–11 (15 ref.)

Pediatric cancer: environmental and genetic aspects. Toren A, et al. **Pediatr Hematol Oncol** 1996 Jul–Aug;13(4):319–31 (94 ref.)

Molecular epidemiology. Shields PG. **Prog Clin Biol Res** 1996;395:141–57 (57 ref.)

Nutrition and cancer: epidemiological aspects. Fraser D. **Public Health Rev** 1996;24(2):113–21 (19 ref.)

Radioepidemiology in the aftermath of the nuclear program of the former Soviet Union: unique lessons to be learnt. Burkart W. **Radiat Environ Biophys** 1996 May;35(2):65–73 (19 ref.)

Science, imaginable risks, and public policy: anatomy of a mirage. Gori GB. **Regul Toxicol Pharmacol** 1996 Jun; 23(3):304–11 (41 ref.)

Environmental pollution in central and eastern European countries: a basis for cancer epidemiology. Jedrychowski W, et al. **Rev Environ Health** 1997 Jan–Mar;12(1):1–23 (18 ref.)

Epidemiology and the identification of metals as human carcinogens. Duffus JH. **Sci Prog** 1996;79 (Pt 4):311–26 (36 ref.)

Health effects from hazardous waste incineration facilities: five case studies. Pleus RC, et al. **Toxicol Ind Health** 1996 Mar–Apr;12(2):277–87 (23 ref.)

[E3N, a cohort study on cancer risk factors in MGEN women. Description of protocol, main characteristics and population] Clavel-Chapelon F, et al. **Bull Cancer** 1996 Dec;83(12):1008–13 (26 ref.) (Eng. Abstr.) **(Fre)**

[Electromagnetic residential fields and childhood cancers: state of epidemiological research] Coste D, et al. **Rev Epidemiol Sante Publique** 1996 Jan;44(1):80–92 (115 ref.) (Eng. Abstr.) **(Fre)**

[Calcium blockers and cancer—is there any link between them?] Zimlichman R, et al. **Harefuah** 1997 Jun 15; 132(12):876–8 (4 ref.) **(Heb)**

[Cancer in the elderly. Clinico-epidemiologic considerations] Caruso U, et al. **Minerva Med** 1997 Mar;88(3):81–6 (17 ref.) (Eng. Abstr.) **(Ita)**

[Recent trends of epidemiological studies on cancer in Japan—personal experience and view of an epidemiologist] Tominaga S. **Nippon Eiseigaku Zasshi** 1996 Jul;51(2):551–7 (38 ref.) (Eng. Abstr.) **(Jpn)**

[Incidence of cancer among Japanese patients with rheumatoid arthritis] Miyamoto T, et al. **Ryumachi** 1996 Oct;36(5):741–5 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Risk of neoplastic disease in workers from petroleum refineries and in persons employed in fuel distribution] Pepłońska B. **Med Pr** 1995;46(6):603–17 (37 ref.) (Eng. Abstr.) **(Pol)**

[Malignant neoplasms in the general state of health of the population of the Russian Federation] Diatchenko OT, et al. **Vopr Onkol** 1996;42(4):80–8 (00 ref.) **(Rus)**

ETHNOLOGY

An epidemiologic review of dietary intake studies among American Indians and Alaska Natives: implications for heart disease and cancer risk [see comments] Bell RA, et al. **Ann Epidemiol** 1997 May;7(4):229–40 (84 ref.) Comment in: Ann Epidemiol 1997 May;7(4):227–8.

Evaluation of quality of life for diverse patient populations. Yabroff KR, et al. **Breast Cancer Res Treat** 1996; 40(1):87–104 (196 ref.)

Studies of cancer in migrants: rationale and methodology. Parkin DM, et al. **Eur J Cancer** 1996 May;32A(5):761–71 (70 ref.)

ETIOLOGY

Interrelationships of high fat diets, obesity, hormones, and cancer. Heber D. **Adv Exp Med Biol** 1996;399:13–25 (88 ref.)

The role of folate, choline, and methionine in carcinogenesis induced by methyl-deficient diets. Henning SM, et al. **Adv Exp Med Biol** 1996;399:143–55 (78 ref.)

Psychoneuroimmunology and cancer: historical perspectives and current research. Fife A, et al. **Adv Neuroimmunol** 1996; 6(2):179–90 (73 ref.)

Alcohol and cancer. Watson RR, et al. **Alcohol Alcohol Suppl** 1994;2:453–5 (9 ref.)

Health effects of working in pulp and paper mills: malignant diseases [see comments] Torén K, et al. **Am J Ind Med** 1996 Feb;29(2):123–30 (48 ref.) Comment in: Am J Ind Med 1996 Nov;30(5):641.

Genetic epidemiology: a powerful approach for the comprehension of cancer etiology. Stazi MA, et al. **Ann Ist Super Sanita** 1996;32(1):167–72 (53 ref.)

Towards a unified model of tumor suppression: lessons learned from the human patched gene. Dean M. **Biochim Biophys Acta** 1997 Apr 18;1332(2):M43–52 (79 ref.)

IRF-1: the transcription factor linking the interferon response and oncogenesis. Taniguchi T, et al. **Biochim Biophys Acta** 1997 Aug 8;1333(1):M9–17 (58 ref.)

EMF and current cancer concepts. Kavet R. **Bioelectromagnetics** 1996;17(5):339–57 (197 ref.)

Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. Ad hoc subcommittee of the Liaison Committee of the World Health Organisation and the International Society of Hypertension. **Blood Press** 1997 May;6(3):134–46 (81 ref.)

Is hypertension a risk factor for cancer? [editorial] Hedner T, et al. **Blood Press** 1997 May;6(3):132–3 (27 ref.)

Cancer: science and society and the communication of risk [see comments] Calman KC. **BMJ** 1996 Sep 28; 313(7060):799–802 (12 ref.) Comment in: BMJ 1996 Dec 7;313(7070):1483.

Mechanisms of carcinogenesis and molecular epidemiology. Vainio H, et al. **Br J Hosp Med** 1996 Aug 21–Sep 3; 56(4):162–70 (153 ref.)

Hypothesis on a casual link between EMF and an evolutionary class of cancer and spontaneous abortion. Cooper WG. **Cancer Biochem Biophys** 1996 Apr; 15(3):151–70 (57 ref.)

The role of multi-centre cohort studies in studying the relation between diet and cancer. Kaaks R, et al. **Cancer Lett** 1997 Mar 19;114(1–2):263–70 (30 ref.)

The c-erbB3/HER3 receptor in human cancer. Gullick WJ. **Cancer Surv** 1996;27:339–49 (59 ref.)

Perturbation of cell cycle regulators in human cancer. Palmero I, et al. **Cancer Surv** 1996;27:351–67 (129 ref.)

Oncogenic role of heterotrimeric G proteins. Vallar L. **Cancer Surv** 1996;27:325–38 (74 ref.)

Cancer and fluoridation. Cook-Mozaffari P. **Community Dent Health** 1996 Sep;13 Suppl 2:56–62 (38 ref.)

The role of hormones, growth factors and vitamins in carcinogenesis. Lupulescu A. **Crit Rev Oncol Hematol** 1996 Jun;23(2):95–130 (355 ref.)

Effect of diet on human carcinogenesis. Tanaka T. **Crit Rev Oncol Hematol** 1997 Feb;25(2):73–95 (292 ref.)

Genomic stability and instability: a working paradigm. Cheng KC, et al. **Curr Top Microbiol Immunol** 1997;221:5–18 (60 ref.)

Chromosome instability syndromes: lessons for carcinogenesis. Meyn MS. **Curr Top Microbiol Immunol** 1997;221:71–148 (495 ref.)

Carcinogenesis: basic principles. Couch DB. **Drug Chem Toxicol** 1996 Aug;19(3):133–48 (54 ref.)

Biologically based cancer modeling. Luebeck EG, et al. **Drug Chem Toxicol** 1996 Aug;19(3):221–43 (55 ref.)

Cancer risk assessment: historical perspectives, current issues, and future directions. Velazquez SF, et al. **Drug Chem Toxicol** 1996 Aug;19(3):161–85 (106 ref.)

Unfriendly fumes. Clay R. **Environ Health Perspect** 1996 Nov;104(11):1152–7 (0 ref.)

Interaction between dose and susceptibility to environmental cancer: a short review. Hietanen E, et al. **Environ Health Perspect** 1997 Jun;105 Suppl 4:749–54 (70 ref.)

Genetic polymorphism of cytochrome P450 as a biomarker of susceptibility to environmental toxicity. Hong JY, et al. **Environ Health Perspect** 1997 Jun;105 Suppl 4:759–62 (32 ref.)

DNA adducts as exposure biomarkers and indicators of cancer risk. Poirier MC. **Environ Health Perspect** 1997 Jun; 105 Suppl 4:907–12 (97 ref.)

Cigarette smoke radicals and the role of free radicals in chemical carcinogenicity. Pryor WA. **Environ Health Perspect** 1997 Jun;105 Suppl 4:875–82 (110 ref.)

Mechanisms of spontaneous human cancers. Venitt S. **Environ Health Perspect** 1996 May;104 Suppl 3:633–7 (22 ref.)

Multiple pathways to cellular senescence: role of telomerase repressors. Oshimura M, et al. **Eur J Cancer** 1997 Apr; 33(5):710–5 (50 ref.)

General background on diet and cancer. Hill MJ. **Eur J Cancer Prev** 1996 Oct;5(5):413–4 (5 ref.)

Haemoglobin adducts of N-nitroso compounds. Richter E. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:115–9 (32 ref.)

Tobacco-specific nitrosamines. Spiegelhalder B, et al. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:33–8 (38 ref.)

Smoking and cancer with emphasis on Italy. Talamini R, et al. **Eur J Cancer Prev** 1996 Oct;5(5):396–7 (9 ref.)

Biomarkers, low-dose carcinogenesis and dietary exposures. Vineis P. **Eur J Cancer Prev** 1997 Apr;6(2):147–51 (28 ref.)

Cancers in children with HIV infection. McClain KL, et al. **Hematol Oncol Clin North Am** 1996 Oct;10(5):1189–201 (61 ref.)

Non-AIDS-defining cancers. Remick SC. **Hematol Oncol Clin North Am** 1996 Oct;10(5):1203–13 (110 ref.)

The role of gap junctional intercellular communication (GJIC) disorders in experimental and human carcinogenesis. Krutovskikh V, et al. **Histol Histopathol** 1997 Jul;12(3):761–8 (57 ref.)

Methioninase: a therapeutic for diseases related to altered methionine metabolism and transmethylation: cancer, heart disease, obesity, aging, and Parkinson's disease. Hoffman RM. **Hum Cell** 1997 Mar;10(1):69–80 (117 ref.)

Mixed fibrous and non-fibrous dust exposures and interactions between agents in fibre carcinogenesis. Davis JM. **IARC Sci Publ** 1996;(140):127–35 (62 ref.)

Use of physico-chemical and cell-free assays to evaluate the potential carcinogenicity of fibres. Fubini B. **IARC Sci Publ** 1996;(140):35–54 (90 ref.)

Mechanisms of mineral fibre carcinogenesis. Kane AB. **IARC Sci Publ** 1996;(140):11–34 (138 ref.)

The role of telomeres and telomerase in human cancer. Balasubramanian S, et al. **Indian J Physiol Pharmacol** 1996 Jul;40(3):199–204 (62 ref.)

The challenges of assessing fat intake in cancer research investigations. Wynder EL, et al. **J Am Diet Assoc** 1997 Jul;97(7 Suppl):S5–8 (39 ref.)

Cancer-related issues for women. Rospond RM. **J Am Pharm Assoc (Wash)** 1996 Nov;NS36(11):655–60 (26 ref.)

Management of malignancy in HIV infection. Denton AS, et al. **J Antimicrob Chemother** 1996 May;37 Suppl B:121–33 (53 ref.)

Role of the IGF-I receptor in mutagenesis and tumor promotion. Blakesley VA, et al. **J Endocrinol** 1997 Mar; 152(3):339–44 (51 ref.)

Potassium, sodium, and cancer: a review. Jansson B. **J Environ Pathol Toxicol Oncol** 1996;15(2–4):65–73 (12 ref.)

p53, apoptosis and human cancers. Wang TH, et al. **J Formos Med Assoc** 1996 Jul;95(7):509–22 (151 ref.)

Cyclin D1/PRAD1 as a central target in oncogenesis. Hosokawa Y, et al. **J Lab Clin Med** 1996 Mar;127(3):246–52 (67 ref.)

Cancer risk and oxidative DNA damage in man [published erratum appears in J Mol Med 1997 Jan;75(1):67–8] Loft S, et al. **J Mol Med** 1996 Jun;74(6):297–312 (167 ref.)

Celiac disease and malignancy. Holmes GK. **J Pediatr Gastroenterol Nutr** 1997 May;24(5):S20–3; discussion S23–4 (19 ref.)

Is celiac disease (gluten sensitivity) a premalignant disorder? Marsh MN. **J Pediatr Gastroenterol Nutr** 1997 May; 24(5):S25–7 (15 ref.)

Cancer, cigarette smoking and premature death in Europe: a review including the Recommendations of European Cancer Experts Consensus Meeting, Helsinki, October 1996. Boyle P. **Lung Cancer** 1997 May;17(1):1–60 (285 ref.)

The 'cancell' theory of carcinogenesis: re-evolution of an ancient, holistic neoplastic unicellular concept of cancer. Grossgebauer K. **Med Hypotheses** 1995 Dec;45(6):545–55 (92 ref.)

Tissue regeneration as the basic oncogenic factor. Korystov YN. **Med Hypotheses** 1996 Sep;47(3):183–90 (51 ref.)

Cancer as a complex adaptive system. Schwab ED, et al. **Med Hypotheses** 1996 Sep;47(3):235–41 (15 ref.)

Risk assessment and the use of information on underlying

biologic mechanisms: a perspective. Rhomberg L. **Mutat Res** 1996 Sep;365(1-3):175-89 (49 ref.)
Rel/NF-kappaB/IkappaB proteins and cancer. Gilmore TD, et al. **Oncogene** 1996 Oct 3;13(7):1367-78 (171 ref.)
Dietary fatty acids--the N-6/N-3 balance and chronic elderly diseases. Excess linoleic acid and relative N-3 deficiency syndrome seen in Japan. Okuyama H, et al. **Prog Lipid Res** 1996 Dec;35(4):409-57 (491 ref.)
Tumors derived from antigen presenting cells. Levitsky HI. **Semin Immunol** 1996 Oct;8(5):281-7 (38 ref.)
The association of malignancy with rheumatic and connective tissue diseases. Carsons S. **Semin Oncol** 1997 Jun;24(3):360-72 (102 ref.)
Does hyperbaric oxygen (HBO) have a cancer promoting effect? Almeling M, et al. **Strahlenther Onkol** 1996 Nov; 172 Suppl 2:30-1 (30 ref.)
Stress, hormonal changes, alcohol, food constituents and drugs: factors that advance the incidence of tobacco smoke-related cancer? Maser E. **Trends Pharmacol Sci** 1997 Aug;18(8):270-5 (95 ref.)
[Electromagnetic residential fields and childhood cancers: state of epidemiological research] Coste D, et al. **Rev Epidemiol Sante Publique** 1996 Jan;44(1):80-92 (115 ref.) (Eng. Abstr.) **(Fre)**
[Increased cancer incidence in terminal kidney failure: potential pathogenetic mechanisms] Vamvakas S, et al. **Schweiz Med Wochenschr** 1997 Apr 5;127(14):597-604 (100 ref.) (Eng. Abstr.) **(Ger)**
[Role of free radicals, telomeres, and telomerases in aging and cancerogenesis] La Torre F, et al. **Minerva Med** 1997 May;88(5):205-14 (126 ref.) (Eng. Abstr.) **(Ita)**
[Malignant neoplasms and AIDS. Review of the literature and critical considerations on a case of epidermoid carcinoma of the anus] Romito A, et al. **Recenti Prog Med** 1997 Jul-Aug;88(7-8):348-55 (48 ref.) (Eng. Abstr.) **(Ita)**
[Molecular mechanism of cell cycle control] Akiyama T. **Nippon Rinsho** 1996 Apr;54(4):1031-6 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Molecullar structure and function of the p16/INK4a/CDKN2/MTS1 and the INK4 family, and their association with carcinogenesis] Okamoto A, et al. **Nippon Rinsho** 1996 Apr;54(4):1037-42 (23 ref.) (Eng. Abstr.) **(Jpn)**
[Genetic and phenotypic polymorphisms in carcinogen-metabolizing enzymes and cancer susceptibility] Watanabe M. **Nippon Rinsho** 1996 Aug; 54(8):2261-75 (60 ref.) (Eng. Abstr.) **(Jpn)**
[Documentation problems for occupationally related neoplastic diseases] Szeszenia-Dąbrowska N. **Med Pr** 1997; 48(2):189-95 (2 ref.) (Eng. Abstr.) **(Pol)**
[Alcohol and cancer] Sofia C, et al. **Acta Med Port** 1997 May;10(5):373-9 (12 ref.) (Eng. Abstr.) **(Por)**
[Role of extragonadal estrogens and hormonal carcinogenesis] Bershtein LM. **Vestn Ross Akad Med Nauk** 1997;(8):54-8 (41 ref.) **(Rus)**
[Trends and perspectives in environmental oncology] Khudoleĭ VV, et al. **Vopr Onkol** 1997;43(1):116-9 (14 ref.) (Eng. Abstr.) **(Rus)**
[Super-low frequency electric and magnetic fields and their role in development of neoplasms] Muratov EI. **Vopr Onkol** 1996;42(5):13-21 (60 ref.) **(Rus)**
[Evidence and controversies concerning the association between diet and cancer. EPIC (European Prospective Investigation into Cancer) Group in Spain] **Med Clin (Barc)** 1996 Jul 6;107(6):224-30 (65 ref.) **(Spa)**
[Diet and cancer: a controversial relationship] Feliu J, et al. **Med Clin (Barc)** 1997 May 3;108(17):663-8 (55 ref.) **(Spa)**

GENETICS

Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes. Kok K, et al. **Adv Cancer Res** 1997;71:27-92 (417 ref.)
p53 and ATM: cell cycle, cell death, and cancer. Morgan SE, et al. **Adv Cancer Res** 1997;71:1-25 (190 ref.)
The natural somatic mutation frequency and human carcinogenesis. Simpson AJ. **Adv Cancer Res** 1997; 71:209-40 (139 ref.)
Analysis of genetic linkage and somatic loss of heterozygosity in affected pairs of first-degree relatives. Rohde K, et al. **Am J Hum Genet** 1997 Aug;61(2):418-22 (13 ref.)
Tumors associated with p53 germline mutations: a synopsis of 91 families. Kleihues P, et al. **Am J Pathol** 1997 Jan; 150(1):1-13 (92 ref.)
Molecular tumor clocks and dynamic phenotype. Shibata D. **Am J Pathol** 1997 Sep;151(3):643-6 (29 ref.)
Genetic linkage studies for the identification of cancer-related genes. Brancolini V, et al. **Ann Ist Super Sanita** 1996;32(1):173-80 (45 ref.)
Possibilities of gene therapies for cancer [editorial] Lashford LS. **Ann Med** 1997 Feb;29(1):1-4 (36 ref.)
Molecular tumour clocks [editorial] Shibata D. **Ann Med** 1997 Feb;29(1):5-7 (20 ref.)
Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Modrich P, et al. **Annu Rev Biochem** 1996;65:101-33 (225 ref.)
The role of DNA methylation in cancer genetic and epigenetics. Laird PW, et al. **Annu Rev Genet** 1996; 30:441-64 (198 ref.)
Genetic pharmacomodulation of nucleoside analogues and gene therapy for AIDS and cancer. Guettari N, et al. **Antibiot Chemother** 1996;48:198-204 (21 ref.)
The dual role of mutant p53 protein in chemosensitivity of human cancers. Mueller H, et al. **Anticancer Res** 1996 Nov-Dec;16(6B):3845-8 (25 ref.)
Looking at p53: theoretical implications and methodological aspects. Opalka B, et al. **Arch Toxicol Suppl** 1997;19:17-28 (35 ref.)
The genetic testing of children for cancer susceptibility: ethical, legal, and social issues. Patenaude AF. **Behav Sci Law** 1996 Autumn;14(4):393-410 (70 ref.)
Mechanisms of Bcl-2 family protein function and dysfunction in health and disease. Reed JC. **Behring Inst Mitt** 1996 Oct;(97):72-100 (193 ref.)
Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Cox AD, et al. **Biochim Biophys Acta** 1997 Aug 8;1333(1):F51-71 (139 ref.)
DCC: is there a connection between tumorigenesis and cell guidance molecules? Fearon ER. **Biochim Biophys Acta** 1996 Oct 9;1288(2):M17-23 (52 ref.)
Cancer gets Mad: DPC4 and other TGFbeta pathway genes in human cancer. Moskaluk CA, et al. **Biochim Biophys Acta** 1996 Dec 9;1288(3):M31-3 (21 ref.)
Mutagenesis in the P53 gene. Pfeifer GP, et al. **Biochim Biophys Acta** 1997 Aug 8;1333(1):M1-8 (55 ref.)
Cancer of the microsatellite mutator phenotype. Perucho M. **Biol Chem** 1996 Nov;377(11):675-84 (90 ref.)
Genetics of childhood cancer. Pritchard-Jones K. **Br Med Bull** 1996 Oct;52(4):704-23 (68 ref.)
NotI jumping and linking clones as a tool for genome mapping and analysis of chromosome rearrangements in different tumors. Zabarovsky ER, et al. **Cancer Detect Prev** 1996;20(1):1-10 (19 ref.)
Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Rebbeck TR. **Cancer Epidemiol Biomarkers Prev** 1997 Sep;6(9):733-43 (121 ref.)
Are Robertsonian translocations rare in cancers? [letter] Multani AS, et al. **Cancer Genet Cytogenet** 1997 Feb; 93(2):179-80 (21 ref.)
Molecular cytogenetic characterization of cancer cell alterations. Popescu NC, et al. **Cancer Genet Cytogenet** 1997 Jan;93(1):10-21 (109 ref.)
Recent insights into the functions of the retinoblastoma susceptibility gene product. Kaelin WG Jr. **Cancer Invest** 1997;15(3):243-54 (183 ref.)
Oncogenes as inducers of tumor angiogenesis. Rak J, et al. **Cancer Metastasis Rev** 1995 Dec;14(4):263-77 (85 ref.)
Genetic testing for cancer predisposition. Biesecker BB. **Cancer Nurs** 1997 Aug;20(4):285-96; quiz 297-9 (35 ref.)
The genetic basis of cancer. Dimond E, et al. **Cancer Nurs** 1997 Jun;20(3):213-22; quiz 223-6 (23 ref.)
Telomere maintenance in tumour cells. Bacchetti S. **Cancer Surv** 1996;28:197-216 (120 ref.)
The relationship of DNA methylation to cancer. Bird AP. **Cancer Surv** 1996;28:87-101 (64 ref.)
Mismatch repair and cancer. Jiricny J. **Cancer Surv** 1996; 28:47-68 (122 ref.)
Many mutations in cancers. Loeb LA. **Cancer Surv** 1996; 28:329-42 (74 ref.)
The relevance of bacterial mutators to understanding human cancer. Miller JH. **Cancer Surv** 1996;28:141-53 (89 ref.)
DNA synthesis errors, mutators and cancer. Minnick DT, et al. **Cancer Surv** 1996;28:3-20 (95 ref.)
TP53 tumour suppressor gene: clues to molecular carcinogenesis and cancer therapy. Wang XW, et al. **Cancer Surv** 1996;28:169-96 (231 ref.)
Screening for cancer in high-risk families. Foulkes WD, et al. **Cancer Treat Res** 1996;86:165-82 (80 ref.)
Retinoblastoma gene in malignancy. Pagliaro LC. **Cancer Treat Res** 1996;84:261-77 (92 ref.)
Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Zingg JM, et al. **Carcinogenesis** 1997 May;18(5):869-82 (882 ref.)
Mutator specificity and disease: looking over the FENce [comment] Kunkel TA, et al. **Cell** 1997 Jan 24;88(2):155-8 (20 ref.) Comment on: Cell 1997 Jan 24;88(2):253-63.
Advances in cytogenetic analysis of solid tumours. James L, et al. **Chromosome Res** 1996 Nov;4(7):479-85 (47 ref.)
Molecular interactions of aging and cancer. Lee SW, et al. **Clin Geriatr Med** 1997 Feb;13(1):69-77 (64 ref.)
Cytogenetics. An evolving role in the diagnosis and treatment of cancer. Glassman AB. **Clin Lab Med** 1997 Mar; 17(1):21-37 (42 ref.)
Indirect and direct disruption of transcriptional regulation in cancer: E2F and AML-1. Meyers S, et al. **Crit Rev Eukaryot Gene Expr** 1995;5(3-4):365-83 (161 ref.)
Antisense regulation of oncogenes in human cancer. Mukhopadhyay T, et al. **Crit Rev Oncog** 1996;7(3-4):151-90 (251 ref.)
Expression of ras proto-oncogenes: regulation and implications in the development of human tumors. Zachos G, et al. **Crit Rev Oncol Hematol** 1997 Jul;26(2):65-75 (92 ref.)
Laboratory probing of oncogenes from human liquid and solid specimens as markers of exposure to toxicants. Nelson E. **Crit Rev Toxicol** 1996 Sep;26(5):483-549 (397 ref.)
Genetic polymorphisms in human drug-metabolizing enzymes: potential uses of reverse genetics to identify genes of toxicological relevance. Puga A, et al. **Crit Rev Toxicol** 1997 Mar;27(2):199-222 (243 ref.)
On the role of DNA double-strand breaks in toxicity and carcinogenesis. Vamvakas S, et al. **Crit Rev Toxicol** 1997 Mar;27(2):155-74 (158 ref.)
Tumor suppressors: a developing role for p53? Hall PA, et al. **Curr Biol** 1997 Mar 1;7(3):R144-7 (23 ref.)
Transcriptional elongation and cancer. Tumorigenesis. Li XY, et al. **Curr Biol** 1996 Aug 1;6(8):943-4 (24 ref.)
Two tracks but one race? Cancer genetics. Sidransky D. **Curr Biol** 1996 May 1;6(5):523-5 (22 ref.)
Therapeutic targeting of the p53 tumor suppressor gene. Beaudry GA, et al. **Curr Opin Biotechnol** 1996 Dec; 7(6):592-600 (90 ref.)
DNA mismatch repair in mammals: role in disease and meiosis. Arnheim N, et al. **Curr Opin Genet Dev** 1997 Jun; 7(3):364-70 (92 ref.)
Cytogenetics and experimental models. Bridge JA. **Curr Opin Oncol** 1996 Jul;8(4):284-8 (33 ref.)
Genetic alterations in human tumors. Cho KR, et al. **Curr Top Microbiol Immunol** 1997;221:149-76 (137 ref.)
Common patterns of genetic evolution in human solid tumors. Shackney SE, et al. **Cytometry** 1997 Sep 1;29(1):1-27 (325 ref.)
Future research directions for evaluating human genetic and cancer risk from environmental exposures. Albertini RJ, et al. **Environ Health Perspect** 1996 May;104 Suppl 3:503-10 (85 ref.)
The role of individual susceptibility in cancer burden related to environmental exposure. Bartsch H, et al. **Environ Health Perspect** 1996 May;104 Suppl 3:569-77 (99 ref.)
Role of transcription-coupled DNA repair in susceptibility to environmental carcinogenesis. Hanawalt PC. **Environ Health Perspect** 1996 May;104 Suppl 3:547-51 (40 ref.)
p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and cancer risk assessment. Harris CC. **Environ Health Perspect** 1996 May; 104 Suppl 3:435-9 (43 ref.)
Mechanisms controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells. Crawford HC, et al. **Enzyme Protein** 1996;49(1-3):20-37 (105 ref.)
Telomere dynamics and telomerase activity in in vitro immortalised human cells. Bryan TM, et al. **Eur J Cancer** 1997 Apr;33(5):767-73 (60 ref.)
Multiple pathways for the regulation of telomerase activity. Holt SE, et al. **Eur J Cancer** 1997 Apr;33(5):761-6 (52 ref.)
Transcription factors as drug targets in cancer. Hurst HC. **Eur J Cancer** 1996 Oct;32A(11):1857-63 (41 ref.)
The implications of telomerase biochemistry for human disease. Morin GB. **Eur J Cancer** 1997 Apr;33(5):750-60 (89 ref.)
Proliferative lifespan checkpoints: cell-type specificity and influence on tumour biology. Wynford-Thomas D. **Eur J Cancer** 1997 Apr;33(5):716-26 (87 ref.)
The genetic nature of cancer. Boiocchi M. **Eur J Cancer Prev** 1996 Oct;5(5):370-2 (7 ref.)
Chemical-induced genetic alterations in human cancers: relevance to aetiology and pathogenesis. Montesano R, et al. **Eur J Cancer Prev** 1996 Oct;5(5):392-3 (11 ref.)
Multiphasity of neoplastic induction. Parodi S, et al. **Eur J Cancer Prev** 1996 Oct;5(5):368-70 (6 ref.)
Apoptosis and carcinogenesis. Wyllie AH. **Eur J Cell Biol** 1997 Jul;73(3):189-97 (107 ref.)
The significance of p53 mutations in human cancers. Pellegata NS, et al. **Eur J Histochem** 1996;40(4):273-82 (50 ref.)
Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression. Ambs S, et al. **FASEB J** 1997 May;11(6):443-8 (89 ref.)
Psychological opportunities and hazards in predictive genetic testing for cancer risk. Codori AM. **Gastroenterol Clin North Am** 1997 Mar;26(1):19-39 (118 ref.)
Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Pollock PM, et al. **Genes Chromosomes Cancer** 1996 Feb;15(2):77-88 (69 ref.)
Genomic instability in 1p and human malignancies. Schwab M, et al. **Genes Chromosomes Cancer** 1996 Aug; 16(4):211-29 (210 ref.)
Hyper-recombination and Bloom's syndrome: microbes again provide clues about cancer. Rothstein R, et al. **Genome Res** 1995 Dec;5(5):421-6 (30 ref.)
Apoptosis in cancer. Kuchino Y, et al. **Hum Cell** 1996 Sep; 9(3):223-8 (25 ref.)
Mismatch repair defects in human carcinogenesis. Eshleman JR, et al. **Hum Mol Genet** 1996;5 Spec No:1489-94 (81 ref.)
Molecular genetic alterations as intermediate end points in chemoprevention studies. Conti CJ, et al. **IARC Sci Publ** 1996;(139):249-60 (95 ref.)
Telomerase and cancer. Harley CB, et al. **Important Adv Oncol** 1996;:57-67 (71 ref.)
p53 and response to chemotherapy and radiotherapy. Ruley HE. **Important Adv Oncol** 1996;:37-56 (269 ref.)
Molecular epidemiology: low-dose carcinogens and genetic susceptibility. Vineis P. **Int J Cancer** 1997 Mar 28;71(1):1-3 (18 ref.)
HLA class I antigen expression in human solid tumors. Klein B, et al. **Isr J Med Sci** 1996 Dec;32(12):1238-43 (23 ref.)

Genetic basis of tumour development. Ponz de Leon M. **Ital J Gastroenterol** 1996 May;28(4):232–45 (96 ref.)
Genomic imprinting: significance in development and diseases and the molecular mechanisms. Nakao M, et al. **J Biochem (Tokyo)** 1996 Sep;120(3):467–73 (50 ref.)
Regulation of apoptosis by oncogenes. Green DR, et al. **J Cell Biochem** 1996 Jan;60(1):33–8 (25 ref.)
Mdm-2: "big brother" of p53. Momand J, et al. **J Cell Biochem** 1997 Mar 1;64(3):343–52 (98 ref.)
Retinoblastoma protein family in cell cycle and cancer: a review. Paggi MG, et al. **J Cell Biochem** 1996 Sep 1; 62(3):418–30 (160 ref.)
BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. Reed JC, et al. **J Cell Biochem** 1996 Jan;60(1):23–32 (55 ref.)
Mutational specificity and cancer chemoprevention. Curry J, et al. **J Cell Biochem Suppl** 1996;25:99–107 (54 ref.)
Molecular genetic analysis in the pathologic evaluation of solid tumors: theory and practice. Visscher DW, et al. **J Clin Lab Anal** 1997;11(1):10–6 (40 ref.)
Environment, cancer, and molecular epidemiology: air pollution. Moran EM. **J Environ Pathol Toxicol Oncol** 1996;15(2–4):97–104 (81 ref.)
Gene-based strategies for the immunotherapy of cancer. Tüting T, et al. **J Mol Med** 1997 Jul;75(7):478–91 (142 ref.)
Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. Harris CC. **J Natl Cancer Inst** 1996 Oct 16;88(20):1442–55 (288 ref.)
Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. Rosenberg SA. **J Natl Cancer Inst** 1996 Nov 20; 88(22):1635–44 (61 ref.)
Gene therapy for cancer: what have we done and where are we going? Roth JA, et al. **J Natl Cancer Inst** 1997 Jan 1;89(1):21–39 (152 ref.)
Telomeres and disease. Royle NJ. **J Pathol** 1996 Nov; 180(3):233–5 (26 ref.)
Interphase cytogenetics and pathology: a tool for diagnosis and research. Wolfe KQ, et al. **J Pathol** 1997 Apr; 181(4):359–61 (38 ref.)
Senescence, cancer and 'endogenous parasites': a salutogenic hypothesis. Charlton BG. **J R Coll Physicians Lond** 1996 Jan–Feb;30(1):10–2 (22 ref.)
Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent. Geller G, et al. **JAMA** 1997 May 14;277(18):1467–74 (122 ref.)
p21WAF1 mutations and human malignancies. Shiohara M, et al. **Leuk Lymphoma** 1997 Jun;26(1–2):35–41 (75 ref.)
Genetic control of immune responsiveness, aging and tumor incidence. Doria G, et al. **Mech Ageing Dev** 1997 Jun; 96(1–3):1–13 (50 ref.)
Positional cloning of genes involved in the Beckwith–Wiedemann syndrome, hemihypertrophy, and associated childhood tumors. Mannens M, et al. **Med Pediatr Oncol** 1996 Nov;27(5):490–4 (9 ref.)
The CDKN2A (p16) gene and human cancer. Foulkes WD, et al. **Mol Med** 1997 Jan;3(1):5–20 (93 ref.)
Mutations of the BRCA1 and BRCA2 genes and the possibilities for predictive testing. Gayther SA, et al. **Mol Med Today** 1997 Apr;3(4):168–74 (36 ref.)
Oncogenic mechanisms mediated by DNA methylation. Laird PW. **Mol Med Today** 1997 May;3(5):223–9 (40 ref.)
Microsatellite instability in human solid tumors. Lothe RA. **Mol Med Today** 1997 Feb;3(2):61–8 (51 ref.)
H19 in normal development and neoplasia. Looijenga LH, et al. **Mol Reprod Dev** 1997 Mar;46(3):419–39 (244 ref.)
Role of increased DNA replication in the carcinogenic risk of nonmutagenic chemical carcinogens. Cunningham ML. **Mutat Res** 1996 Sep;365(1–3):59–69 (59 ref.)
Mutagenic and epigenetic effects of DNA methylation [see comments] Gonzalgo ML, et al. **Mutat Res** 1997 Apr; 386(2):107–18 (78 ref.) Comment in: Mutat Res 1997 Apr;386(2):103–5.
Risk estimation from somatic mutation assays. Heddle JA, et al. **Mutat Res** 1996 Sep;365(1–3):107–17 (69 ref.)
Chromosome aberrations, micronuclei, aneuploidy, sister chromatid exchanges, and cancer risk assessment. Tucker JD, et al. **Mutat Res** 1996 Sep;365(1–3):147–59 (47 ref.)
DNA methylation and the association between genetic and epigenetic changes: relation to carcinogenesis. Wachsman JT. **Mutat Res** 1997 Apr 14;375(1):1–8 (54 ref.)
The genotype of the human cancer cell: implications for risk analysis. Williams JR, et al. **Mutat Res** 1996 Sep; 365(1–3):17–42 (127 ref.)
Genetic testing: the problems and the promise. Eng C, et al. **Nat Biotechnol** 1997 May;15(5):422–6 (46 ref.)
Gene testing for cancer susceptibility. Reiser G, et al. **Nebr Med J** 1996 Dec;81(12):416–8 (6 ref.)
Cancer and genes: how will molecular biology reshape our clinical practice? Ponder BA. **Neth J Med** 1997 May; 50(5):211–5 (5 ref.)
Tumour suppressive properties of the adenovirus 5 E1A oncogene. Mymryk JS. **Oncogene** 1996 Oct 17;13(8):1581–9 (153 ref.)
Genetic predisposition testing: clinical implications for oncology nurses. Calzone KA. **Oncol Nurs Forum** 1997 May;24(4):712–8 (44 ref.)
Are we ready to screen for inherited susceptibility to cancer? Holtzman NA. **Oncology (Huntingt)** 1996 Jan;10(1):57–64; discussion 67 (65 ref.)
Role of the genetic counselor in familial cancer. Peters JA, et al. **Oncology (Huntingt)** 1996 Feb;10(2):159–66, 175; discussion 176–6, 178, (33 ref.)
DNA ploidy and cell cycle analysis in cancer diagnosis and prognosis. Ross JS. **Oncology (Huntingt)** 1996 Jun; 10(6):867–82, 887; discussion 887–90 (164 ref.)
Hereditary cancer litigation: a status report. Severin MJ. **Oncology (Huntingt)** 1996 Feb;10(2):211–4; discussion 217 (15 ref.)
The role of ras GTPase activating protein in human tumorigenesis. Friedman E. **Pathobiology** 1995;63(6):348–50 (21 ref.)
Molecular mechanisms of multidrug resistance in cancer chemotherapy. Nooter K, et al. **Pathol Res Pract** 1996 Jul; 192(7):768–80 (141 ref.)
Genetic predisposition to cancer and familial cancer syndromes. Quesnel S, et al. **Pediatr Clin North Am** 1997 Aug;44(4):791–808 (116 ref.)
Pediatric cancer: environmental and genetic aspects. Toren A, et al. **Pediatr Hematol Oncol** 1996 Jul–Aug;13(4):319–31 (94 ref.)
Molecular genetics of childhood cancer: implications for pathogenesis, diagnosis, and treatment. Rubnitz JE, et al. **Pediatrics** 1997 Jul;100(1):101–8 (90 ref.)
Altered DNA methylation and genome instability: a new pathway to cancer? [comment] Jones PA, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2103–5 (25 ref.) Comment on: Proc Natl Acad Sci U S A 1997 Mar 18;94(6):2284–9. Comment on: Proc Natl Acad Sci U S A 1997 Mar 18;94(6):2545–50.
Cytochrome P-450 and acetyltransferase expression as biomarkers of carcinogen–DNA adduct levels and human cancer susceptibility. Badawi AF, et al. **Prog Clin Biol Res** 1996;395:109–40 (123 ref.)
Molecular perspectives on cancer, the cell cycle and the inherited disorder ataxia–telangiectasia. Brown KD, et al. **Prog Clin Biol Res** 1997;396:101–13 (81 ref.)
One decade of comparative molecular carcinogenesis. Goodrow TL. **Prog Clin Biol Res** 1996;395:57–80 (137 ref.)
From host factors to genetic susceptibility. Kleihues P, et al. **Prog Clin Biol Res** 1996;395:201–9 (44 ref.)
Interphase cytogenetic analysis of solid tumors by non-isotopic DNA in situ hybridization. Alers JC, et al. **Prog Histochem Cytochem** 1996;31(3):1–133 (748 ref.)
Selection for genome instability by DNA damage in human cells: unstable microsatellites and their consequences for tumourigenesis. Hampson R. **Radiat Oncol Investig** 1997; 5(3):111–4 (16 ref.)
Chromosome changes in human cancer—are they pointers to mechanisms of initiation? Tawn EJ. **Radiat Oncol Investig** 1997;5(3):97–102 (16 ref.)
Mechanisms leading to the expression of recessive alleles: the use of polymorphic microsatellites and whole-chromosome painting probes to analyze mouse tumors, mutants, and micronuclei. Caspary WJ, et al. **Recent Results Cancer Res** 1997;143:161–82 (82 ref.)
P53 gene alterations in human tumors: perspectives for cancer control. Hollstein M, et al. **Recent Results Cancer Res** 1997; 143:369–89 (140 ref.)
The role of carcinogen-metabolizing enzyme polymorphisms in cancer susceptibility. Gonzalez FJ. **Reprod Toxicol** 1997 Mar–Jun;11(2–3):397–412 (205 ref.)
Ha-ras in normal and tumoral tissues: structure, function and regulation. Solanas M, et al. **Rev Esp Fisiol** 1996 Sep; 52(3):173–92 (128 ref.)
Experimental manipulation of genomic methylation. Jackson-Grusby L, et al. **Semin Cancer Biol** 1996 Oct; 7(5):261–8 (86 ref.)
Psychological issues in cancer genetics. Biesecker BB. **Semin Oncol Nurs** 1997 May;13(2):129–34 (51 ref.)
Educational issues related to cancer genetics. Jenkins J. **Semin Oncol Nurs** 1997 May;13(2):141–4 (22 ref.)
The oncology nurse's role in cancer risk assessment and counseling. MacDonald DJ. **Semin Oncol Nurs** 1997 May; 13(2):123–8 (21 ref.)
Principles of genetics and cancer. Williams JK. **Semin Oncol Nurs** 1997 May;13(2):68–73 (23 ref.)
[Advances in the research on multidrug resistance genes] Gao Z, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1996 Jun; 25(3):185–7 (12 ref.) **(Chi)**
[Current status and trends of nuclear DNA assessment and ploidy analysis of neoplasms] Xia C. **Chung Hua Ping Li Hsueh Tsa Chih** 1996 Jun;25(3):180–4 (13 ref.) **(Chi)**
[Apropos of the studies of Lewis, Nusslein-Volhard and Wieschaus, 1995 Nobel prize winners, on the genetic mechanisms of embryonic development of drosophila. A model for human cancer progression] Cillo C. **Bull Cancer** 1996 Jul;83(7):527–34 (30 ref.) (Eng. Abstr.) **(Fre)**
[Hereditary predispositions to cancer: the genetic diagnosis in practice] Girodet C, et al. **Bull Cancer** 1996 Sep; 83(9):764–8 (33 ref.) (Eng. Abstr.) **(Fre)**
[Are the ends of chromosomes the beginning of tumor genesis? On the role of telomeres in cancer development] von Zglinicki T. **Fortschr Med** 1996 Nov 20;114(32):12–4 (12 ref.) **(Ger)**
[Comparative genomic hybridization. A screening method in genetic tumor diagnosis] Petersen I, et al. **Pathologe** 1996 Sep;17(5):333–41 (19 ref.) (Eng. Abstr.) **(Ger)**
[Genetic predisposition and radiation sensitivity of tumors] Budach W. **Strahlenther Onkol** 1997 Sep;173(9):469–79 (52 ref.) (Eng. Abstr.) **(Ger)**
[Evaluation of cancer risk through genetic analysis?] Luz A. **Strahlenther Onkol** 1997 Sep;173(9):444–56 (178 ref.) (Eng. Abstr.) **(Ger)**
[Molecular biology of tobacco smoke associated neoplasia] Zojer N, et al. **Wien Klin Wochenschr** 1996;108(18):574–81 (79 ref.) (Eng. Abstr.) **(Ger)**
[Association of congenital chromosome abnormalities and malignant diseases] Erzsébet B, et al. **Orv Hetil** 1996 Feb 4;137(5):227–31 (25 ref.) (Eng. Abstr.) **(Hun)**
[Disruption of genomic imprinting in human carcinogenesis] Ogawa O. **Hum Cell** 1996 Mar;9(1):37–42 (18 ref.) (Eng. Abstr.) **(Jpn)**
[Contribution of molecular biology to surgical therapy of neoplasms] Mitsudomo T, et al. **Kyobu Geka** 1997 Jan; 50(1):4–8 (15 ref.) **(Jpn)**
[Representational difference analysis (RDA): finding the genetic lesions in cancer DNA] Aburatani H. **Nippon Rinsho** 1996 Apr;54(4):949–54 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Disruption of mismatch repair system in human cancers] Fukushige S, et al. **Nippon Rinsho** 1996 Apr;54(4):1002–7 (24 ref.) (Eng. Abstr.) **(Jpn)**
[Tumor suppressor gene p53] Tokino T. **Nippon Rinsho** 1996 Apr;54(4):960–4 (19 ref.) (Eng. Abstr.) **(Jpn)**
[Detection of genetic alterations in human cancer] Shimizu K. **Seikagaku** 1997 May;69(5):311–23 (37 ref.) **(Jpn)**
[Cancer and transcriptional regulation] Fujinaga K, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1336–41 (30 ref.) **(Jpn)**
[Hereditary neoplasms--prevention, early diagnosis, treatment] Lubiński J. **Pol Arch Med Wewn** 1997;97 Spec No:34–6 (0 ref.) **(Pol)**
[Genetic significance of determined oxidation of drugs and xenobiotics in the pathogenesis of neoplastic diseases] Niewiński P, et al. **Pol Merkuriusz Lek** 1997 Jan;2(7):71–5 (79 ref.) **(Pol)**
[The role of genetically determined oxidation of drugs and xenobiotics in pathogenesis of neoplastic diseases] Niewiński P, et al. **Postepy Hig Med Dosw** 1996; 50(4):321–32 (55 ref.) (Eng. Abstr.) **(Pol)**
[Molecular genetics of human tumors] Imianitov EN, et al. **Vopr Onkol** 1997;43(1):95–101 (46 ref.) (Eng. Abstr.) **(Rus)**
[Cytogenetic diagnosis of tumors. Clinical significance of chromosome aberrations] Mitelman F, et al. **Lakartidningen** 1997 Jun 11;94(24):2277–81 (18 ref.) **(Swe)**

IMMUNOLOGY

Role of antibody signaling in inducing tumor dormancy. Uhr JW, et al. **Adv Exp Med Biol** 1996;406:69–74 (32 ref.)
Human tumor antigens are ready to fly. Henderson RA, et al. **Adv Immunol** 1996;62:217–56 (169 ref.)
NO-synthase: what can research on invertebrates add to what is already known? Johansson KU, et al. **Adv Neuroimmunol** 1995;5(4):431–42 (77 ref.)
Role of the major histocompatibility complex region in reproduction, cancer, and autoimmunity. Gill TJ 3rd. **Am J Reprod Immunol** 1996 Mar;35(3):211–5 (14 ref.)
Immunodeficiency and its relation to lymphoid and other malignancies. Tossing G. **Ann Hematol** 1996 Oct; 73(4):163–7 (13 ref.)
1975–1995 revised anti-cancer serological response: biological significance and clinical implications. Canevari S, et al. **Ann Oncol** 1996 Mar;7(3):227–32 (62 ref.)
Antigens recognized by T-lymphocytes on human tumours. Coulie PG, et al. **Biochem Soc Trans** 1997 May;25(2):544–8 (40 ref.)
Clinical significance of autologous tumor killing (ATK) activity and its induction therapy in human cancer. Uchida A. **Biotherapy** 1994;8(2):113–22 (53 ref.)
Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: a retrospective analysis. Peters BG, et al. **Bone Marrow Transplant** 1996 Jul;18(1):93–102 (60 ref.)
Novel costimulators in the immune gene therapy of cancer. Galea-Lauri J, et al. **Cancer Gene Ther** 1996 May–Jun; 3(3):202–14 (133 ref.)
Immunogenicity increase of autologous tumor cell vaccines by virus infection and attachment of bispecific antibodies. Haas C, et al. **Cancer Immunol Immunother** 1996 Nov; 43(3):190–4 (41 ref.)
Dendritic cells presenting tumor antigen. Shurin MR. **Cancer Immunol Immunother** 1996 Nov;43(3):158–64 (71 ref.)
The role of cyclic AMP and oxygen intermediates in the inhibition of cellular immunity in cancer. Uotila P. **Cancer Immunol Immunother** 1996 Sep;43(1):1–9 (118 ref.)
Controversies in the antibacterial treatment of patients with neutropenia: a matter of comprehension or apprehension? De Pauw BE, et al. **Cancer Invest** 1997;15(1):37–46 (52 ref.)
Immunotherapy II: Antigens, receptors and costimulation. Searle PF, et al. **Cancer Metastasis Rev** 1996 Sep; 15(3):329–49 (103 ref.)
Suppression of cell-mediated immunity due to immune deviation. Zhang Y. **Chin Med J (Engl)** 1996 Oct; 109(10):739–42 (5 ref.)
Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Lucey DR, et al. **Clin Microbiol Rev** 1996 Oct;9(4):532–62 (432 ref.)
Assessment of immune mediator expression levels in

biological fluids and cells: a critical appraisal. Patarca R, et al. **Crit Rev Oncog** 1995;6(2):117–49 (289 ref.)

Integrins and cancer. Varner JA, et al. **Curr Opin Cell Biol** 1996 Oct;8(5):724–30 (77 ref.)

Genetically modified tumour vaccines carrying inserted genes for immunoregulatory molecules. Bubeník J. **Folia Biol (Praha)** 1996;42(6):295–304 (114 ref.)

T-cell recognition of self peptides as tumor rejection antigens. Kawakami Y, et al. **Immunol Res** 1996; 15(3):179–90 (51 ref.)

The potential role of NK cells in the separation of graft–versus–tumor effects from graft–versus–host disease after allogeneic bone marrow transplantation. Murphy WJ, et al. **Immunol Rev** 1997 Jun;157:167–76 (83 ref.)

Surface expression of CD28 single chain Fv for costimulation by tumor cells. Winberg G, et al. **Immunol Rev** 1996 Oct; 153:209–23 (19 ref.)

Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Garrido F, et al. **Immunol Today** 1997 Feb;18(2):89–95 (67 ref.)

Alterations in T cells of cancer-bearers: whence specificity? Levey DL, et al. **Immunol Today** 1996 Aug;17(8):365–8 (39 ref.)

TAP off—tumors on. Seliger B, et al. **Immunol Today** 1997 Jun;18(6):292–9 (96 ref.)

Tumor recognition by the cellular immune system: new aspects of tumor immunology. Maeurer MJ, et al. **Int Rev Immunol** 1997;14(2–3):97–132 (155 ref.)

Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. Walker PR, et al. **J Immunol** 1997 May 15;158(10):4521–4 (51 ref.)

Reversal of tumor-induced immunosuppression: a new approach to cancer therapy [see comments] Wojtowicz-Praga S. **J Immunother** 1997 May;20(3):165–77 (146 ref.) Comment in: J Immunother 1997 May;20(3):178–9.

Gene-based strategies for the immunotherapy of cancer. Tüting T, et al. **J Mol Med** 1997 Jul;75(7):478–91 (142 ref.)

Danger versus tolerance: paradigms for future studies of tumor-specific cytotoxic T lymphocytes [editorial; comment] Fenton RG, et al. **J Natl Cancer Inst** 1997 Feb 19;89(4):272–5 (28 ref.) Comment on: J Natl Cancer Inst 1997 Feb 19;89(4):293–300.

Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. Rosenberg SA. **J Natl Cancer Inst** 1996 Nov 20; 88(22):1635–44 (61 ref.)

Analysis of cytokine profiles in patients with human papillomavirus–associated neoplasms [editorial; comment] Wu TC, et al. **J Natl Cancer Inst** 1997 Feb 5;89(3):185–7 (33 ref.) Comment on: J Natl Cancer Inst 1997 Feb 5;89(3):245–50.

Clinical promise of tumour immunology. Scott AM, et al. **Lancet** 1997 May;349 Suppl 2:SII19–22 (28 ref.)

Immunostimulation of cancer versus immunosurveillance. Prehn RT, et al. **Medicina (B Aires)** 1996;56 Suppl 1:65–73 (56 ref.)

Study of immune response to tumors in the rat. Frey AB. **Methods** 1997 Jun;12(2):173–88 (43 ref.)

Considerations for the clinical development of cytokine gene–transduced tumor cell vaccines. Jaffee EM, et al. **Methods** 1997 Jun;12(2):143–53 (50 ref.)

Purification of heat shock protein–peptide complexes for use in vaccination against cancers and intracellular pathogens. Srivastava PK. **Methods** 1997 Jun;12(2):165–71 (24 ref.)

The Fas counterattack: a molecular mechanism of tumor immune privilege. O'Connell J, et al. **Mol Med** 1997 May; 3(5):294–300 (75 ref.)

Heat shock protein–based cancer vaccines and related thoughts on immunogenicity of human tumors. Blachere NE, et al. **Semin Cancer Biol** 1995 Dec;6(6):349–55 (56 ref.)

Is cancer dangerous to the immune system? Fuchs EJ, et al. **Semin Immunol** 1996 Oct;8(5):271–80 (46 ref.)

Tumors derived from antigen presenting cells. Levitsky HI. **Semin Immunol** 1996 Oct;8(5):281–7 (38 ref.)

Harnessing self–reactivity in cancer immunotherapy. Schoenberger SP, et al. **Semin Immunol** 1996 Oct;8(5):303–9 (44 ref.)

Do human cancers express shared protective antigens? or the necessity of remembrance of things past. Srivastava PK. **Semin Immunol** 1996 Oct;8(5):295–302 (47 ref.)

Monoclonal antibodies in cancer therapy. Gruber R, et al. **Springer Semin Immunopathol** 1996;18(2):243–51 (57 ref.)

Immunosuppression in human tumor–host interaction: role of cytokines and alterations in signal–transducing molecules. Kiessling R, et al. **Springer Semin Immunopathol** 1996;18(2):227–42 (100 ref.)

Cytolytic T lymphocyte responses of cancer patients to tumor–associated antigens. Romero P. **Springer Semin Immunopathol** 1996;18(2):185–98 (78 ref.)

Viruses as pacemakers in the evolution of defence mechanisms against cancer. Eick D, et al. **Trends Genet** 1996 Jan;12(1):4–6 (22 ref.)

[Role of monocytes and macrophages in the defense against malignant tumors] Schuurman B, et al. **Ned Tijdschr Geneeskd** 1996 Oct 5;140(40):1978–81 (34 ref.) **(Dut)**

[IL-4 and tumor immunity] Nogawa S. **Fukuoka Igaku Zasshi** 1996 Jan;87(1):8–13 (45 ref.) **(Jpn)**

[Perspective in tumor immunology] Syuku H. **Rinsho Ketsueki** 1996 Jul;37(7):519–25 (12 ref.) **(Jpn)**

METABOLISM

Tryptophan and niacin nutrition—is there a problem? Bender DA. **Adv Exp Med Biol** 1996;398:565–9 (25 ref.)

Metabolism of exogenous and endogenous arachidonic acid in cancer. Phinney SD. **Adv Exp Med Biol** 1996;399:87–94 (30 ref.)

Oxygen transport in tumors: characteristics and clinical implications. Vaupel P. **Adv Exp Med Biol** 1996;388:341–51 (39 ref.)

The role of nitric oxide (NO.) in the carcinogenic process. Tamir S, et al. **Biochim Biophys Acta** 1996 Oct 9; 1288(2):F31–6 (87 ref.)

Concepts of tumor lectinology. Gabius HJ. **Cancer Invest** 1997;15(5):454–64 (129 ref.)

The utilization of nuclear matrix proteins for cancer diagnosis. Replogle-Schwab R, et al. **Crit Rev Eukaryot Gene Expr** 1996;6(2–3):103–13 (77 ref.)

Plasma protein (albumin) catabolism by the tumor itself—implications for tumor metabolism and the genesis of cachexia. Stehle G, et al. **Crit Rev Oncol Hematol** 1997 Jul;26(2):77–100 (255 ref.)

Telomerase activity in human cancer. Shay JW, et al. **Curr Opin Oncol** 1996 Jan;8(1):66–71 (49 ref.)

The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Aderka D. **Cytokine Growth Factor Rev** 1996 Oct;7(3):231–40 (106 ref.)

Metabolic and clonogenic consequences of ischaemia reperfusion insult in solid tumours. Parkins CS, et al. **Exp Physiol** 1997 Mar;82(2):361–8 (22 ref.)

Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression. Ambs S, et al. **FASEB J** 1997 May;11(6):443–8 (89 ref.)

Cellular resistance to anthracyclines. Nielsen D, et al. **Gen Pharmacol** 1996 Mar;27(2):251–5 (30 ref.)

The molecular histology of neoplasia: the role of the cadherin/catenin complex. Smith ME, et al. **Histopathology** 1997 Aug;31(2):107–11 (65 ref.)

Conditions of drug delivery within solid tumors, and noninvasive methods for studies in humans. Port RE. **Int J Clin Pharmacol Ther** 1997 Feb;35(2):78–9 (11 ref.)

Cell surface carbohydrates as prognostic markers in human carcinomas. Dabelsteen E. **J Pathol** 1996 Aug; 179(4):358–69 (141 ref.)

Glycobiology and medicine: an introduction. Axford J. **J R Soc Med** 1997 May;90(5):260–4 (53 ref.)

Receptor imaging of human diseases using radiolabeled peptides. Reubi JC, et al. **J Recept Signal Transduct Res** 1995 Jan–Mar; 15(1–4):379–92 (19 ref.)

Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. Reubi JC, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):39–41 (5 ref.)

The role of DNA repair in the prevention of cancer. Hall M, et al. **Mol Aspects Med** 1996 Jun;17(3):235–283 (591 ref.)

The application of receptor theory to receptor–binding and enzyme–binding oncologic radiopharmaceuticals. Eckelman WC. **Nucl Med Biol** 1994 Jul;21(5):759–69 (81 ref.)

The mechanism of 67Ga localization in malignant disease. Weiner RE. **Nucl Med Biol** 1996 Aug;23(6):745–51 (114 ref.)

P-glycoprotein mediated multidrug resistance and its implications for pathology. Trambas CM, et al. **Pathology** 1997 May;29(2):122–30 (117 ref.)

Sir David Cuthbertson Medal Lecture. Energy metabolism in cancer and human immunodeficiency virus infection. Jebb SA. **Proc Nutr Soc** 1997 Jul;56(2):763–75 (47 ref.)

Do human cancers express shared protective antigens? or the necessity of remembrance of things past. Srivastava PK. **Semin Immunol** 1996 Oct;8(5):295–302 (47 ref.)

Cholesterol metabolism and tumor cell proliferation. Coleman PS, et al. **Subcell Biochem** 1997;28:363–435 (359 ref.)

[Bromodeoxyuridine (BrdU). Analysis of cellular proliferation] Bosq J, et al. **Ann Pathol** 1997 Jul;17(3):171–8 (71 ref.) **(Fre)**

[Acquisition of resistance associated with impairment of metabolic activation of anticancer drugs] Tashiro T. **Nippon Rinsho** 1997 May;55(5):1038–43 (15 ref.) (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

Cancer and infection: estimates of the attributable fraction in 1990. Pisani P, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Jun;6(6):387–400 (157 ref.)

Are we making progress in antifungal therapy? Martino P, et al. **Curr Opin Oncol** 1997 Jul;9(4):314–20 (56 ref.)

MORTALITY

Natural course of localized prostate cancer. a personal view with a review of published papers. Hugosson J, et al. **Anticancer Res** 1997 May–Jun;17(3A):1441–8 (44 ref.)

Cancer mortality among petroleum refinery and chemical manufacturing workers in Texas. Cooper SP, et al. **J Environ Pathol Toxicol Oncol** 1997;16(1):1–14 (65 ref.)

Cancer, cigarette smoking and premature death in Europe: a review including the Recommendations of European Cancer Experts Consensus Meeting, Helsinki, October 1996. Boyle P. **Lung Cancer** 1997 May;17(1):1–60 (285 ref.)

Attitude and disposition: do they make a difference in cancer survival? Creagan ET. **Mayo Clin Proc** 1997 Feb; 72(2):160–4 (24 ref.)

Curable and non-curable malignancies: lessons from paediatric cancer. Toren A, et al. **Med Oncol** 1996 Mar; 13(1):15–21 (45 ref.)

Frailty modelling for the excess hazard. Zahl PH. **Stat Med** 1997 Jul 30;16(14):1573–85 (24 ref.)

Interpreting survival differences and trends. Berrino F, et al. **Tumori** 1997 Jan–Feb;83(1):9–16 (34 ref.)

Inequalities in survival from cancer. Tomatis L. **Tumori** 1997 Jan–Feb;83(1):505–7 (21 ref.)

[Obesity. Increased mortality caused by arteriosclerotic sequelae and carcinomas] Wirth A. **Internist (Berl)** 1997 Mar;38(3):214–23 (42 ref.) **(Ger)**

NURSING

Current review of cancer nursing in Hong Kong. Mak JM. **Cancer Nurs** 1997 Jun;20(3):197–200 (22 ref.)

Options for venous access in ambulatory care: issues in selection and management. Herbst SL. **J Infus Chemother** 1996 Fall;6(4):186–94 (36 ref.)

Administrative and technical support of ambulatory infusional cancer chemotherapy (ICC). Moore C, et al. **J Infus Chemother** 1996 Fall;6(4):161–3 (6 ref.)

Surveillance of the patient receiving infusional cancer chemotherapy: nursing role in recognition and management of catheter-related complications. The Cancer Center of Boston. Moore C, et al. **J Infus Chemother** 1996 Fall; 6(4):171–80 (44 ref.)

Application of ambulatory infusion devices in infusional cancer chemotherapy: a model for nursing management. Moore C, et al. **J Infus Chemother** 1996 Fall;6(4):181–5 (9 ref.)

Conscious sedation of pediatric oncology patients for painful procedures: development and implementation of a clinical practice protocol. Macpherson CF, et al. **J Pediatr Oncol Nurs** 1997 Jan;14(1):33–42; quiz 43–4 (16 ref.)

Managing bowel elimination problems in patients with cancer. Bisanz A. **Oncol Nurs Forum** 1997 May; 24(4):679–86; quiz 687–8 (11 ref.)

Nonpharmacologic management of chemotherapy–induced nausea and vomiting. King CR. **Oncol Nurs Forum** 1997 Aug;24(7 Suppl):41–8 (59 ref.)

Strategies for assessing and fostering hope: the hope assessment guide. Penrod J, et al. **Oncol Nurs Forum** 1997 Jul;24(6):1055–63 (12 ref.)

Physical exercise as an oncology nursing intervention to enhance quality of life. Smith SL. **Oncol Nurs Forum** 1996 Jun;23(5):771–8 (51 ref.)

Nursing care of the blood cell transplant recipient. Buchsel PC, et al. **Semin Oncol Nurs** 1997 Aug;13(3):172–83 (39 ref.)

Pediatric blood cell transplantation. Secola R. **Semin Oncol Nurs** 1997 Aug;13(3):184–93 (52 ref.)

PATHOLOGY

Laser scanning cytometry in pathology of solid tumors. A review. Gorczyca W, et al. **Acta Cytol** 1997 Jan–Feb; 41(1):98–108 (74 ref.)

CD44: structure, function, and association with the malignant process. Naot D, et al. **Adv Cancer Res** 1997;71:241–319 (489 ref.)

Fundamentals of cancer cell biology. Stoker M. **Adv Cancer Res** 1996;70:1–19 (77 ref.)

Carcinomatous meningitis in solid tumours. Jayson GC, et al. **Ann Oncol** 1996 Oct;7(8):773–86 (112 ref.)

Mast cell–tumor cell interactions: for or against tumour growth and metastasis? Dimitriadou V, et al. **Anticancer Res** 1997 May–Jun;17(3A):1541–9 (141 ref.)

Tumor interstitial fluid: misconsidered component of the internal milieu of a solid tumor. Freitas I, et al. **Anticancer Res** 1997 Jan–Feb;17(1A):165–72 (58 ref.)

A review of tissue inhibitor of metalloproteinases–3 (TIMP–3) and experimental analysis of its effect on primary tumor growth. Anand–Apte B, et al. **Biochem Cell Biol** 1996;74(6):853–62 (75 ref.)

The role of nitric oxide (NO.) in the carcinogenic process. Tamir S, et al. **Biochim Biophys Acta** 1996 Oct 9; 1288(2):F31–6 (87 ref.)

Interferons and the tumor cell. Strander H, et al. **Biotherapy** 1996;8(3–4):213–8 (54 ref.)

Concepts of tumor lectinology. Gabius HJ. **Cancer Invest** 1997;15(5):454–64 (129 ref.)

Regrowth resistance as a likely significant contributor to treatment failure in drug–sensitive neoplastic diseases. Preisler HD, et al. **Cancer Invest** 1997;15(4):358–68 (64 ref.)

Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Claffey KP, et al. **Cancer Metastasis Rev** 1996 Jun;15(2):165–76 (108 ref.)

The role of fibroblasts in tumor behavior. Grégoire M, et al. **Cancer Metastasis Rev** 1995 Dec;14(4):339–50 (110 ref.)

Intermediate filaments. Hendrix MJ. **Cancer Metastasis Rev** 1996 Dec;15(4):413–6 (33 ref.)

Adhesion or anti–adhesion in cancer: what matters more? Jothy S, et al. **Cancer Metastasis Rev** 1995 Dec; 14(4):363–76 (77 ref.)

Significance of tumor–host interactions in cancer growth and metastases. Kerbel RS. **Cancer Metastasis Rev** 1995 Dec;

14(4):259–62 (13 ref.)
Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Hakomori S. **Cancer Res** 1996 Dec 1;56(23):5309–18 (133 ref.)
The biochemistry of cancer dissemination. Price JT, et al. **Crit Rev Biochem Mol Biol** 1997;32(3):175–253 (643 ref.)
Cell cycle and cancer: critical events at the G1 restriction point. DelSal G, et al. **Crit Rev Oncog** 1996;7(1–2):127–42 (156 ref.)
Alterations in cell cycle control during tumor progression: effects on apoptosis and the response to therapeutic agents. Muschel RJ, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 2):197–213 (110 ref.)
Apoptosis—its role in tumour growth and therapy. Ellis PA, et al. **Cytopathology** 1996 Jun;7(3):201–3 (18 ref.)
Cellular heterogeneity in malignant tumors. The importance of clonal interaction on tumor evolution, response to chemotherapy and metastatic ability evaluated in experimental systems. Aabo K. **Dan Med Bull** 1996 Sep; 43(4):336–49 (155 ref.)
Cancer: a challenge for control theory and computer modelling. Düchting W, et al. **Eur J Cancer** 1996 Jul; 32A(8):1283–92 (48 ref.)
Biomarkers and histology of premalignant and malignant lesions. Beltrami AC, et al. **Eur J Cancer Prev** 1996 Oct; 5(5):375–6 (18 ref.)
Tumor angiogenesis: functional similarities with tumor invasion. Stetler-Stevenson WG, et al. **EXS** 1997;79:413–8 (27 ref.)
Taking chemotherapy from random to rational with the histoculture drug response assay. Hoffman RM. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:206–29 (215 ref.)
Cancer therapy and apoptosis. Inoue S. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:102–14 (59 ref.)
Clinicopathologic correlates of common cancer pain syndromes. Caraceni A. **Hematol Oncol Clin North Am** 1996 Feb;10(1):57–78 (64 ref.)
Adhesion molecules as targets for cancer therapy. Huang YW, et al. **Histol Histopathol** 1997 Apr;12(2):467–77 (119 ref.)
Estimating mitotic activity in tumours [comment] [see comments] Cross SS, et al. **Histopathology** 1996 Nov; 29(5):485–8 (58 ref.) Comment on: Histopathology 1996 Nov;29(5):421–8. Comment in: Histopathology 1997 Jun;30(6):605–6.
The molecular histology of neoplasia: the role of the cadherin/catenin complex. Smith ME, et al. **Histopathology** 1997 Aug;31(2):107–11 (65 ref.)
Effects of fibres on cell proliferation, cell activation and gene expression. Driscoll KE. **IARC Sci Publ** 1996;(140):73–96 (110 ref.)
Cancer--a matter of life and cell death. Evan G. **Int J Cancer** 1997 May 29;71(5):709–11 (23 ref.)
Mathematical models of prevascular spheroid development and catastrophe-theoretic description of rapid metastatic growth/tumor remission. Adam JA. **Invasion Metastasis** 1996;16(4–5):247–67 (36 ref.)
Tumor heterogeneity and progression: conceptual foundations for modeling. Greller LD, et al. **Invasion Metastasis** 1996;16(4–5):177–208 (196 ref.)
Host response in tumor growth and progression. Michelson S, et al. **Invasion Metastasis** 1996;16(4–5):235–46 (31 ref.)
Biological inferences from a mathematical model for malignant invasion. Perumpanani AJ, et al. **Invasion Metastasis** 1996;16(4–5):209–21 (46 ref.)
Molecular genetic analysis in the pathologic evaluation of solid tumors: theory and practice. Visscher DW, et al. **J Clin Lab Anal** 1997;11(1):10–6 (40 ref.)
Biology of tumor micrometastasis. Ahmad A, et al. **J Hematother** 1996 Oct;5(5):525–35 (129 ref.)
Minimal residual disease: detection, clinical relevance, and treatment strategies. Dwenger A, et al. **J Hematother** 1996 Oct;5(5):537–48 (102 ref.)
On the growth rates of human malignant tumors: implications for medical decision making. Friberg S, et al. **J Surg Oncol** 1997 Aug;65(4):284–97 (101 ref.)
Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Basset P, et al. **Matrix Biol** 1997 Mar;15(8–9):535–41 (51 ref.)
Aging and cancer: the role of stromal interactions with epithelial cells. Rinehart CA, et al. **Mol Carcinog** 1997 Apr; 18(4):187–92 (21 ref.)
x82p4and the adhesion of neoplastic cells. Rudzki Z, et al. **Mol Pathol** 1997 Apr;50(2):57–71 (146 ref.)
Terms of attachment: SPARC and tumorigenesis [news] Sage EH. **Nat Med** 1997 Feb;3(2):144–6 (15 ref.)
Senescence, immortalization and cancer. Chiarugi V, et al. **Pharmacol Res** 1997 Feb;35(2):95–8 (37 ref.)
Differentiation, differentiation/gene therapy and cancer. Scott RE. **Pharmacol Ther** 1997;73(1):51–65 (152 ref.)
The desmosome and the syndesmos: cell junctions in normal development and in malignancy. Franke WW, et al. **Princess Takamatsu Symp** 1994;24:14–27 (62 ref.)
Integrin signals and tumor growth control. Juliano RL. **Princess Takamatsu Symp** 1994;24:118–24 (33 ref.)
Alterations of the cadherin–catenin cell adhesion system in cancers. Kanai Y, et al. **Princess Takamatsu Symp** 1994; 24:51–62 (50 ref.)
Cellular stress response: stress proteins--physiology and implications for cancer. Benndorf R, et al. **Recent Results Cancer Res** 1997;143:129–44 (73 ref.)
The role of Raf kinases in development and growth of tumors. Naumann U, et al. **Recent Results Cancer Res** 1997; 143:237–44 (24 ref.)
Apoptosis II: Apoptosis in the pathogenesis and treatment of diseases. Moldoveanu E, et al. **Rom J Morphol Embryol** 1996 Jan–Jun;42(1–2):41–51 (37 ref.)
Cancer cell cycles. Sherr CJ. **Science** 1996 Dec 6; 274(5293):1672–7 (79 ref.)
Clear cell tumors of unknown nature and origin: a systematic approach to diagnosis. Nappi O, et al. **Semin Diagn Pathol** 1997 Aug;14(3):164–74 (62 ref.)
Cholesterol metabolism and tumor cell proliferation. Coleman PS, et al. **Subcell Biochem** 1997;28:363–435 (359 ref.)
Surgical pathology of lymph nodes in cancer staging: routine and specialized techniques. Siegel RJ. **Surg Oncol Clin N Am** 1996 Jan;5(1):25–31 (33 ref.)
A general overview of the process of carcinogenesis. Parodi S, et al. **Tumori** 1996 Jul–Aug;82(4):291–301 (22 ref.)
The multiple roles of tumour stroma. Wernert N. **Virchows Arch** 1997 Jun;430(6):433–43 (161 ref.)
Bcl-2 family proteins and the hormonal control of cell life and death in normalcy and neoplasia. Reed JC. **Vitam Horm** 1997;53:99–138 (161 ref.)
[TNM—current status. 1. Clinical significance and current status] Hermanek P, et al. **Pathologe** 1997 Mar;18(2):153–9 (2 ref.) **(Ger)**
[Significance of adhesion molecules in oncology] Terpe HJ, et al. **Pathologe** 1997 Mar;18(2):117–23 (82 ref.) (Eng. Abstr.) **(Ger)**
[CT-guided puncture] Nöldge G, et al. **Radiologe** 1996 Sep; 36(9):683–91 (34 ref.) (Eng. Abstr.) **(Ger)**
[Inhibitors of DNA topoisomerases] Andoh T. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1526–35 (37 ref.) (Eng. Abstr.) **(Jpn)**
[A brief overview of apoptosis] Hashimoto Y. **Gan To Kagaku Ryoho** 1997 Jan;24(2):205–10 (21 ref.) (Eng. Abstr.) **(Jpn)**
[The retinoblastoma gene: from its basic understanding as a signal mediator for growth and differentiation to its use in the treatment of cancer] Lee WH, et al. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1368–80 (87 ref.) (Eng. Abstr.) **(Jpn)**
[Apoptosis and chemosensitivity] Nishio K, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(2):216–21 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Development of anti tumor agents targeting angiogenesis] Ono M, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(2):178–86 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Development of new antitumor reagents which block the cell cycle progression] Osada H. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1541–6 (31 ref.) (Eng. Abstr.) **(Jpn)**
[Screening for the inhibitors of tumor invasion into basement membranes] Saiki I. **Gan To Kagaku Ryoho** 1997 Jan; 24(2):187–95 (21 ref.) (Eng. Abstr.) **(Jpn)**
[Morphological reversion of tumor cells by histone deacetylase inhibitors and radicicol] Yoshida M, et al. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1512–8 (34 ref.) (Eng. Abstr.) **(Jpn)**
[DNA topoisomerases targeting anticancer agents and mechanism for acquirement of drug resistance] Furukawa M, et al. **Nippon Rinsho** 1997 May;55(5):1096–102 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Problems on morphological perception of carcinomas in initial or early phase and precancerous lesion] Nakamura K. **Nippon Rinsho** 1996 May;54(5):1207–16 (24 ref.) **(Jpn)**
[Adhesion molecules and carbohydrates in cancer metastasis] Kawaguchi T. **Rinsho Byori** 1996 Dec;44(12):1138–46 (26 ref.) (Eng. Abstr.) **(Jpn)**
[Mechanism of the induction of apoptosis in cancer cells] Nakaya K. **Seikagaku** 1996 Dec;68(12):1808–12 (16 ref.) **(Jpn)**
[Primary nontrophoblastic tumors of the placenta] Fiutowski M, et al. **Ginekol Pol** 1996 Oct;67(10):515–9 (30 ref.) (Eng. Abstr.) **(Pol)**
[Development of methods of local hyperthermia to achieve more marked tumor pathomorphism] Kharchenko VP, et al. **Arkh Patol** 1996 Jan–Feb;58(1):70–4 (47 ref.) (Eng. Abstr.) **(Rus)**
[Apoptosis and cancer] Romanenko AM. **Arkh Patol** 1996 May–Jun;58(3):18–23 (85 ref.) (Eng. Abstr.) **(Rus)**
[Role of the reparative process in the origin of pathologic cells involved in malignant growth] Shabalkin IP. **Vopr Onkol** 1996;42(6):86–90 (35 ref.) **(Rus)**
[Cell cycle and cancer] Bonilla F, et al. **Rev Clin Esp** 1996 Nov;196(11):766–73 (116 ref.) **(Spa)**

PHYSIOPATHOLOGY

Epithelial–mesenchymal transitions in cancer progression. Birchmeier C, et al. **Acta Anat (Basel)** 1996;156(3):217–26 (102 ref.)
Hypercalcemia of malignancy. Mundy GR, et al. **Am J Med** 1997 Aug;103(2):134–45 (81 ref.)
Lessons from bcl-2 transgenic mice for immunology, cancer biology and cell death research. Strasser A, et al. **Behring Inst Mitt** 1996 Oct;(97):101–17 (120 ref.)
Telomere crisis, the driving force in cancer cell evolution. Ishikawa F. **Biochem Biophys Res Commun** 1997 Jan 3; 230(1):1–6 (53 ref.)
Glycoconjugate cross-talk in metastatic cancer cells, leucocytes, parasites and bacteria. Leroy A, et al. **Biochem Soc Trans** 1997 Feb;25(1):228–34 (48 ref.)
The epithelial cell default-phenotype hypothesis and its implications for cancer. Frisch SM. **Bioessays** 1997 Aug; 19(8):705–9 (37 ref.)
Multidrug resistance: molecular mechanisms and clinical relevance. Ling V. **Cancer Chemother Pharmacol** 1997;40 Suppl:S3–8 (36 ref.)
Is TNF really involved in cachexia? García-Martínez C, et al. **Cancer Invest** 1997;15(1):47–54 (81 ref.)
Managing spiritual distress in patients with advanced cancer pain. Georgesen J, et al. **Cancer Nurs** 1996 Oct;19(5):376–83 (20 ref.)
Analysis of recent literature concerning relaxation and imagery interventions for cancer pain. Wallace KG. **Cancer Nurs** 1997 Apr;20(2):79–87 (45 ref.)
Parathyroid hormone-related peptide and hypercalcemia of malignancy. Goltzman D, et al. **Cancer Treat Res** 1997; 89:193–215 (96 ref.)
Annexins in cancer and autoimmune diseases. Bastian BC. **Cell Mol Life Sci** 1997 Jun;53(6):554–6 (44 ref.)
Bioelectrical impedance techniques in medicine. Part I: Bioimpedance measurement. Second section: impedance spectrometry. Rigaud B, et al. **Crit Rev Biomed Eng** 1996; 24(4–6):257–351 (234 ref.)
Bombesin-like peptides and cancer. Preston SR, et al. **Crit Rev Oncol Hematol** 1996 Jul;23(3):225–38 (143 ref.)
Cdk inhibitors in development and cancer. Harper JW, et al. **Curr Opin Genet Dev** 1996 Feb;6(1):56–64 (63 ref.)
Oncogenic signaling. Jones CL, et al. **Curr Opin Oncol** 1996 Jan;8(1):54–9 (67 ref.)
Tumor suppressor activity of the TGF-beta pathway in human cancers [see comments] Markowitz SD, et al. **Cytokine Growth Factor Rev** 1996 Jun;7(1):93–102 (123 ref.) Comment in: Cytokine Growth Factor Rev 1996 Dec;7(4):295.
Steroid hormones and cancer: (I) basic biology and endocrinology. Miller WR. **Eur J Surg Oncol** 1996 Dec; 22(6):627–33 (25 ref.)
Foulds' dangerous idea revisited: the multistep development of tumors 40 years later. Klein G. **Folia Biol (Praha)** 1996; 42(6):273–81 (0 ref.)
Symptom assessment. Ingham JM, et al. **Hematol Oncol Clin North Am** 1996 Feb;10(1):21–39 (89 ref.)
Bradykinin and nitric oxide in infectious disease and cancer. Maeda H, et al. **Immunopharmacology** 1996 Jun; 33(1–3):222–30 (34 ref.)
The thyroid gland as an intrinsic biologic response-modifier in advanced neoplasia--a novel paradigm. Hercbergs A. **In Vivo** 1996 Mar–Apr;10(2):245–7 (31 ref.)
Integrins--new frontier in cancer biology. Chatterjee A. **Indian J Exp Biol** 1996 Oct;34(10):923–6 (45 ref.)
Neural blockade in chronic and cancer pain. Lamacraft G, et al. **Int Anesthesiol Clin** 1997 Spring;35(2):131–53 (71 ref.)
Circadian-system alterations during cancer processes: a review. Mormont MC, et al. **Int J Cancer** 1997 Jan 17; 70(2):241–7 (70 ref.)
Apoptosis: its role in the progression of and chemotherapy for carcinoma. Meterissian SH. **J Am Coll Surg** 1997 Jun; 184(6):658–66 (87 ref.)
Aging and cancer: the double-edged sword of replicative senescence. Campisi J. **J Am Geriatr Soc** 1997 Apr; 45(4):482–8 (52 ref.)
Regulation of p53 by protein kinase C during multi-stage carcinogenesis [editorial] Magnelli L, et al. **J Cancer Res Clin Oncol** 1997;123(7):365–9 (48 ref.)
Pain and symptom management in cancer patients. Kori S. **J Fla Med Assoc** 1996 Dec;83(10):679–94 (75 ref.)
Psychiatric aspects of cancer pain. Reynolds PT, et al. **J Fla Med Assoc** 1996 Dec;83(10):705–7 (14 ref.)
Promise and problems of Bcl-2 antisense therapy [editorial; comment] Reed JC. **J Natl Cancer Inst** 1997 Jul 16; 89(14):988–90 (36 ref.) Comment on: J Natl Cancer Inst 1997 Jul 16;89(14):1027–36.
Neuropathic pain in cancer patients: mechanisms, syndromes, and clinical controversies. Martin LA, et al. **J Pain Symptom Manage** 1997 Aug;14(2):99–117 (179 ref.)
Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Basset P, et al. **Matrix Biol** 1997 Mar;15(8–9):535–41 (51 ref.)
Does chronic essential fatty acid deficiency constitute a pro-tumorigenic condition? Eynard AR. **Med Hypotheses** 1997 Jan;48(1):55–62 (67 ref.)
Modeling signal transduction in normal and cancer cells using complex adaptive systems. Schwab ED, et al. **Med Hypotheses** 1997 Feb;48(2):111–23 (55 ref.)
Cell cycle regulatory proteins--an overview with relevance to oral cancer. Goodger NM, et al. **Oral Oncol** 1997 Mar; 33(2):61–73 (246 ref.)
Changes in gene structure and regulation of E-cadherin during epithelial development, differentiation, and disease. Jankowski JA, et al. **Prog Nucleic Acid Res Mol Biol** 1997; 57:187–215 (192 ref.)
Cellular stress response: stress proteins--physiology and implications for cancer. Benndorf R, et al. **Recent Results Cancer Res** 1997;143:129–44 (73 ref.)
The role of Raf kinases in development and growth of tumors. Naumann U, et al. **Recent Results Cancer Res** 1997; 143:237–44 (24 ref.)
Exercise and physical health: cancer and immune function.

Lee IM. **Res Q Exerc Sport** 1995 Dec;66(4):286–91 (29 ref.)
International efforts in cancer pain relief. Coyne PJ. **Semin Oncol Nurs** 1997 Feb;13(1):57–62 (29 ref.)
Cancer pain education for patients. Ferrell BR, et al. **Semin Oncol Nurs** 1997 Feb;13(1):42–8 (37 ref.)
The use of computers in cancer pain management. Frandsen JL. **Semin Oncol Nurs** 1997 Feb;13(1):49–56 (21 ref.)
The physical examination in cancer pain assessment. Portenoy RK. **Semin Oncol Nurs** 1997 Feb;13(1):25–9 (12 ref.)
Measurement issues in the comprehensive assessment of cancer pain. Vallerand AH. **Semin Oncol Nurs** 1997 Feb; 13(1):16–24 (34 ref.)
Are cytokines possible mediators of cancer cachexia? Noguchi Y, et al. **Surg Today** 1996;26(7):467–75 (82 ref.)
Tissue factor in health and disease. Semeraro N, et al. **Thromb Haemost** 1997 Jul;78(1):759–64 (77 ref.)
Telomerase and cancer: revisiting the telomere hypothesis. Autexier C, et al. **Trends Biochem Sci** 1996 Oct; 21(10):387–91 (50 ref.)
A general overview of the process of carcinogenesis. Parodi S, et al. **Tumori** 1996 Jul–Aug;82(4):291–301 (22 ref.)
Tumor angiogenesis: the pivotal role of vascular endothelial growth factor. Marmé D. **World J Urol** 1996;14(3):166–74 (92 ref.)
Cytokines in tumour growth, migration and metastasis. Negus RP, et al. **World J Urol** 1996;14(3):157–65 (134 ref.)
The cellular basis of metastasis. Ruiz P, et al. **World J Urol** 1996;14(3):141–50 (89 ref.)
[Tumor cachexia--a special entity and therapeutic sequelae] Heberer M. **Chirurg** 1997 Jun;68(6):568–73 (51 ref.) (Eng. Abstr.) **(Ger)**
[Antifungal prophylaxis in neutropenic cancer patients and in allogeneic bone marrow transplantation] Blau IW, et al. **Mycoses** 1996;39 Suppl 1:81–6 (52 ref.) (Eng. Abstr.) **(Ger)**
[Cancer and male infertility] Botchan A, et al. **Harefuah** 1996 Jun 2;130(11):761–4 (45 ref.) **(Heb)**
[Role of selenium in human pathophysiology] Andrzejak R, et al. **Postepy Hig Med Dosw** 1996;50(3):293–307 (84 ref.) (Eng. Abstr.) **(Pol)**
[Sialosyl-Le(a) and Sialosyl-Le(x) antigens in adhesion of cancer cells and tumor progression] Ugorski M, et al. **Postepy Hig Med Dosw** 1996;50(3):209–31 (111 ref.) (Eng. Abstr.) **(Pol)**
[Catecholestrogens: synthesis, properties and role in carcinogenesis] Kovalenko IG, et al. **Vopr Onkol** 1997; 43(3):257–62 (35 ref.) **(Rus)**
[Diapause and tumors] Makrushin AV. **Zh Evol Biokhim Fiziol** 1996 Sep–Oct;32(5):650–5 (28 ref.) **(Rus)**

PREVENTION & CONTROL

Cancer chemoprevention by polyphenols in green tea and artichoke. Agarwal R, et al. **Adv Exp Med Biol** 1996; 401:35–50 (107 ref.)
Recent results in the organosulfur and organoselenium chemistry of genus Allium and Brassica plants. Relevance for cancer prevention. Block E. **Adv Exp Med Biol** 1996; 401:155–69 (75 ref.)
Is there a need to change the American diet? Dwyer J. **Adv Exp Med Biol** 1996;401:189–98 (48 ref.)
The National 5 A Day for Better Health Program. Heimendinger J, et al. **Adv Exp Med Biol** 1996;401:199–206 (29 ref.)
The attributes of selenium-enriched garlic in cancer prevention. Ip C, et al. **Adv Exp Med Biol** 1996;401:179–87 (25 ref.)
Organosulfur compounds and cancer. Lea MA. **Adv Exp Med Biol** 1996;401:147–54 (60 ref.)
Plant phenolics as potential cancer prevention agents. Newmark HL. **Adv Exp Med Biol** 1996;401:25–34 (42 ref.)
Allium vegetables and the potential for chemoprevention of cancer. Wargovich MJ, et al. **Adv Exp Med Biol** 1996; 401:171–7 (34 ref.)
Effects of tea on carcinogenesis in animal models and humans. Yang CS, et al. **Adv Exp Med Biol** 1996;401:51–61 (82 ref.)
Phyto-oestrogens and Western diseases. Adlercreutz H, et al. **Ann Med** 1997 Apr;29(2):95–120 (356 ref.)
The genetic testing of children for cancer susceptibility: ethical, legal, and social issues. Patenaude AF. **Behav Sci Law** 1996 Autumn;14(4):393–410 (70 ref.)
Plant-derived anticancer agents. Pezzuto JM. **Biochem Pharmacol** 1997 Jan 24;53(2):121–33 (64 ref.)
Role of dietary flavonoids in protection against cancer and coronary heart disease. Hollman PC, et al. **Biochem Soc Trans** 1996 Aug;24(3):785–9 (29 ref.)
Chemoprotection against cancer by isothiocyanates and glucosinolates. Talalay P, et al. **Biochem Soc Trans** 1996 Aug;24(3):806–10 (35 ref.)
Allium vegetables: their role in the prevention of cancer. Wargovich MJ, et al. **Biochem Soc Trans** 1996 Aug; 24(3):811–4 (30 ref.)
Role of dietary phyto-oestrogens in the protection against cancer and heart disease. Wiseman H. **Biochem Soc Trans** 1996 Aug;24(3):795–800 (47 ref.)
Cell proliferation indexes: a biomarker in solid tumors. Elias JM. **Biotech Histochem** 1997 Mar;72(2):78–85 (59 ref.)
Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Kelloff GJ, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Aug;5(8):657–66 (108 ref.)
Assessment of the role of diet in cancer prevention. Chesson A, et al. **Cancer Lett** 1997 Mar 19;114(1–2):237–45 (49 ref.)
Cancer prevention: epidemiology and experiment. Potter JD. **Cancer Lett** 1997 Mar 19;114(1–2):7–9 (5 ref.)
Food and cancer prevention. Sugimura T. **Cancer Lett** 1997 Mar 19;114(1–2):3–5 (15 ref.)
Vitamins and cancer. van Poppel G, et al. **Cancer Lett** 1997 Mar 19;114(1–2):195–202 (49 ref.)
Genetic testing for cancer predisposition. Biesecker BB. **Cancer Nurs** 1997 Aug;20(4):285–96; quiz 297–9 (35 ref.)
Avoided and avoidable risks of cancer. Tomatis L, et al. **Carcinogenesis** 1997 Jan;18(1):97–105 (91 ref.)
A review of mechanisms underlying anticarcinogenicity by brassica vegetables. Verhoeven DT, et al. **Chem Biol Interact** 1997 Feb 28;103(2):79–129 (220 ref.)
Barriers to cancer prevention in the older person. Fox SA, et al. **Clin Geriatr Med** 1997 Feb;13(1):79–95 (129 ref.)
Cancer screening in the older patient. Robinson B, et al. **Clin Geriatr Med** 1997 Feb;13(1):97–118 (76 ref.)
Cancer screening in the postmenopausal woman. Seltzer V. **Clin Obstet Gynecol** 1996 Dec;39(4):889–92 (5 ref.)
The role of hormones, growth factors and vitamins in carcinogenesis. Lupulescu A. **Crit Rev Oncol Hematol** 1996 Jun;23(2):95–130 (355 ref.)
The causes and prevention of cancer: gaining perspective. Ames BN, et al. **Environ Health Perspect** 1997 Jun;105 Suppl 4:865–73 (138 ref.)
Cancer chemoprevention and therapy by monoterpenes. Gould MN. **Environ Health Perspect** 1997 Jun;105 Suppl 4:977–9 (15 ref.)
Dietary restrictions and cancer. Hart RW, et al. **Environ Health Perspect** 1997 Jun;105 Suppl 4:989–92 (54 ref.)
Native cellular fluorescence and its application to cancer prevention. Schantz SP, et al. **Environ Health Perspect** 1997 Jun;105 Suppl 4:941–4 (30 ref.)
Perspectives in cancer chemoprevention. Stoner GD, et al. **Environ Health Perspect** 1997 Jun;105 Suppl 4:945–54 (164 ref.)
Polyphenols as inhibitors of carcinogenesis. Yang CS, et al. **Environ Health Perspect** 1997 Jun;105 Suppl 4:971–6 (72 ref.)
Tea and cancer: a review of the epidemiological evidence. Blot WJ, et al. **Eur J Cancer Prev** 1996 Dec;5(6):425–38 (113 ref.)
Vitamins and cancer chemoprevention. Giacosa A, et al. **Eur J Cancer Prev** 1997 Mar;6 Suppl 1:S47–54 (68 ref.)
Major human cancers are preventable: physiological stimuli induce a dopamine-thyroid-immune efficient mechanism. Gilbert C. **Eur J Cancer Prev** 1997 Jun;6(3):269–76 (60 ref.)
N-nitroso compounds, their relevance to human cancer and further prospects for prevention. Reed PI. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:137–47 (75 ref.)
Epidemiological evidence for beta-carotene in prevention of cancer and cardiovascular disease. van Poppel G. **Eur J Clin Nutr** 1996 Jul;50 Suppl 3:S57–61 (33 ref.)
The Leon Golberg Memorial Lecture. Antioxidants and disease prevention. Diplock AT. **Food Chem Toxicol** 1996 Oct;34(10):1013–20 (33 ref.)
Prophylactic gene therapy for cancer. Hargest R, et al. **Gene Ther** 1996 Feb;3(2):97–102 (57 ref.)
Evaluation of human trial design. Buiatti E. **IARC Sci Publ** 1996;(139):261–9 (30 ref.)
Molecular genetic alterations as intermediate end points in chemoprevention studies. Conti CJ, et al. **IARC Sci Publ** 1996;(139):249–60 (95 ref.)
Methodological issues in the design of primary prevention trials. Gaziano JM, et al. **IARC Sci Publ** 1996;(136):7–12 (13 ref.)
The role of chemoprevention in cancer control. Greenwald P, et al. **IARC Sci Publ** 1996;(139):13–22 (44 ref.)
Cost-effectiveness considerations in chemoprevention of cancer. Habbema JD, et al. **IARC Sci Publ** 1996;(136):131–8 (11 ref.)
Why chemoprevention? Hakama M. **IARC Sci Publ** 1996; (136):1–5 (24 ref.)
Behavioural intervention versus chemoprevention. Henderson M, et al. **IARC Sci Publ** 1996;(136):123–30 (54 ref.)
Evaluation of human trial findings. Huttunen JK. **IARC Sci Publ** 1996;(139):271–6 (15 ref.)
Mechanistic considerations in the evaluation of chemopreventive data. Kelloff GJ, et al. **IARC Sci Publ** 1996;(139):203–19 (77 ref.)
Tumour incidence reductions in carcinogenicity bioassays. McGregor D. **IARC Sci Publ** 1996;(139):277–90 (36 ref.)
Vegetables, fruit and phytoestrogens as preventive agents. Potter JD, et al. **IARC Sci Publ** 1996;(139):61–90 (205 ref.)
Micronutrients as chemopreventive agents. Reddy BS. **IARC Sci Publ** 1996;(139):221–35 (92 ref.)
Identifiability of food components for cancer chemoprevention. Riboli E, et al. **IARC Sci Publ** 1996; (139):23–31 (24 ref.)
Retinoids as cancer-preventive agents. Sankaranarayanan R, et al. **IARC Sci Publ** 1996;(139):47–59 (94 ref.)
Data evaluation as a contribution to cancer prevention. Stewart BW. **IARC Sci Publ** 1996;(139):303–12 (48 ref.)
Chemoprevention research in Europe. Hakama M. **Int J Cancer** 1997;Suppl 10:30–3 (13 ref.)
Chemoprevention: will it work? Mettlin C. **Int J Cancer** 1997; Suppl 10:18–21 (35 ref.)
Vegetables, fruit, and cancer prevention: a review. Steinmetz KA, et al. **J Am Diet Assoc** 1996 Oct;96(10):1027–39 (262 ref.)
Cancer-related issues for women. Rospond RM. **J Am Pharm Assoc (Wash)** 1996 Nov;NS36(11):655–60 (26 ref.)
Cancer risk factors for selecting cohorts for large-scale chemoprevention trials. Greenwald P. **J Cell Biochem Suppl** 1996;25:29–36 (37 ref.)
Risk biomarkers and current strategies for cancer chemoprevention. Kelloff GJ, et al. **J Cell Biochem Suppl** 1996;25:1–14 (73 ref.)
New agents for cancer chemoprevention. Kelloff GJ, et al. **J Cell Biochem Suppl** 1996;26:1–28 (413 ref.)
Relevance of cyclin D1 and other molecular markers to cancer chemoprevention. Weinstein IB. **J Cell Biochem Suppl** 1996;25:23–8 (19 ref.)
Antimutagenesis and anticancer effects. Bronzetti G, et al. **J Environ Pathol Toxicol Oncol** 1996;15(2–4):59–64 (28 ref.)
Interferons in precancer and cancer prevention: where are we? Tanneberger S, et al. **J Interferon Cytokine Res** 1996 May;16(5):339–46 (113 ref.)
Route of immunization and the therapeutic impact of recombinant anticancer vaccines. Irvine KR, et al. **J Natl Cancer Inst** 1997 Mar 5;89(5):390–2 (9 ref.)
Diet in the prevention of cancer: what are the chances of avoidance? Walker AR. **J R Soc Health** 1996 Dec; 116(6):360–6 (82 ref.)
Cancer prevention. Osborne M, et al. **Lancet** 1997 May;349 Suppl 2:SII27–30 (36 ref.)
IP6: a novel anti-cancer agent. Shamsuddin AM, et al. **Life Sci** 1997;61(4):343–54 (68 ref.)
Recent advances in medical oncology--1995–1996. Sikov WM. **Med Health R I** 1996 Mar;79(3):92–9 (39 ref.)
Up-regulation of IGF binding protein-1 as an anticarcinogenic strategy: relevance to caloric restriction, exercise, and insulin sensitivity. McCarty MF. **Med Hypotheses** 1997 Apr;48(4):297–308 (153 ref.)
Chemoprotection: a review of the potential therapeutic antioxidant properties of green tea (Camellia sinensis) and certain of its constituents. Mitscher LA, et al. **Med Res Rev** 1997 Jul;17(4):327–65 (160 ref.)
Cancer incidence and mortality: the priority of screening frequency and population coverage. Colditz GA, et al. **Milbank Q** 1997;75(2):147–73 (50 ref.)
Equitable access to cancer services in the 21st century. Facione NC, et al. **Nurs Outlook** 1997 May–Jun; 45(3):118–24 (32 ref.)
Whole-grain consumption and chronic disease: protective mechanisms. Slavin J, et al. **Nutr Cancer** 1997;27(1):14–21 (73 ref.)
beta-Carotene and the carotenoids: beyond the intervention trials. Erdman JW Jr, et al. **Nutr Rev** 1996 Jun;54(6):185–8 (31 ref.)
Dietary selenium repletion may reduce cancer incidence in people at high risk who live in areas with low soil selenium. Fleet JC. **Nutr Rev** 1997 Jul;55(7):277–9 (9 ref.)
Japanese green tea as a cancer preventive in humans. Fujiki H, et al. **Nutr Rev** 1996 Nov;54(11 Pt 2):S67–70 (25 ref.)
Indian functional foods: role in prevention of cancer. Krishnaswamy K. **Nutr Rev** 1996 Nov;54(11 Pt 2):S127–31 (42 ref.)
An approach to functional food: cancer preventive potential of vegetables and fruits and their active constituents. Ohigashi H, et al. **Nutr Rev** 1996 Nov;54(11 Pt 2):S24–8 (26 ref.)
Experimental and epidemiological evidence of the cancer-preventive effects of Panax ginseng C.A. Meyer. Yun TK. **Nutr Rev** 1996 Nov;54(11 Pt 2):S71–81 (36 ref.)
Dietary bioflavonoids, chalcones, and related alkenones in prevention and treatment of cancer [editorial] Varma RS. **Nutrition** 1996 Sep;12(9):643–5 (28 ref.)
Strategies to improve cancer education materials. Doak LG, et al. **Oncol Nurs Forum** 1996 Sep;23(8):1305–12 (69 ref.)
Chemoprevention of cancer: review of the literature. Swan DK, et al. **Oncol Nurs Forum** 1997 May;24(4):719–27 (48 ref.)
Are we ready to screen for inherited susceptibility to cancer? Holtzman NA. **Oncology (Huntingt)** 1996 Jan;10(1):57–64; discussion 67 (65 ref.)
Strategies for identification and clinical evaluation of promising chemopreventive agents. Kelloff GJ, et al. **Oncology (Huntingt)** 1996 Oct;10(10):1471–84; discussion 1484–8 (102 ref.)
Update on dietary antioxidants and cancer. Gaziano JM, et al. **Pathol Biol (Paris)** 1996 Jan;44(1):42–5 (15 ref.)
A closer look at vitamin E. Can this antioxidant prevent chronic diseases? Meydani M, et al. **Postgrad Med** 1997 Aug;102(2):199–201, 206–7 (22 ref.)
Cancer prevention and screening in women. Melnikow J, et al. **Prim Care** 1997 Mar;24(1):15–26 (74 ref.)
Physiological effects of phyto-oestrogens in relation to cancer and other human health risks. Cassidy A. **Proc Nutr Soc** 1996 Mar;55(1B):399–417 (105 ref.)
Glucosinolates in Brassica: occurrence and significance as cancer-modulating agents. Jongen WM. **Proc Nutr Soc** 1996 Mar;55(1B):433–46 (56 ref.)
Diet intervention for modifying cancer risk. Birt DF, et al. **Prog Clin Biol Res** 1996;395:223–34 (32 ref.)
Nutrition and cancer: epidemiological aspects. Fraser D. **Public Health Rev** 1996;24(2):113–21 (19 ref.)
P53 gene alterations in human tumors: perspectives for cancer control. Hollstein M, et al. **Recent Results Cancer Res** 1997;

143:369–89 (140 ref.)
Cancer prevention, rodent high–dose cancer tests, and risk assessment [letter] Ames BN, et al. **Risk Anal** 1996 Oct; 16(5):613–7 (56 ref.)
Bandura's theory of self–efficacy: applications to oncology. Lev EL. **Sch Inq Nurs Pract** 1997 Spring;11(1):21–37; discussion 39–43 (62 ref.)
Progress in clinical chemoprevention. Kelloff GJ, et al. **Semin Oncol** 1997 Apr;24(2):241–52 (83 ref.)
Educational issues related to cancer genetics. Jenkins J. **Semin Oncol Nurs** 1997 May;13(2):141–4 (22 ref.)
The oncology nurse's role in cancer risk assessment and counseling. MacDonald DJ. **Semin Oncol Nurs** 1997 May; 13(2):123–8 (21 ref.)
Ascorbic acid and cancer. Shklar G, et al. **Subcell Biochem** 1996;25:233–47 (33 ref.)
Chemoprevention of colorectal cancer. Biasco G. **Tumori** 1997 Jan–Feb;83(1 Suppl):S5–6 (15 ref.)
Immunoprophylactic intervention in chemical toxicity and carcinogenicity. Silbart LK, et al. **Vet Hum Toxicol** 1997 Feb;39(1):37–43 (72 ref.)
Physical activity in the prevention and management of cancer. Gerhardsson de Verdier M. **World Rev Nutr Diet** 1997;82:240–9 (84 ref.)
Tea consumption and cancer. Katiyar SK, et al. **World Rev Nutr Diet** 1996;79:154–84 (141 ref.)
Coffee and cancer: a review of human and animal data. Nehlig A, et al. **World Rev Nutr Diet** 1996;79:185–221 (396 ref.)
[Cancer prevention by general practitioners in the Rhône area: a declarative survey] Garcia–Giannoli H, et al. **Bull Cancer** 1996 Oct;83(10):853–63 (39 ref.) (Eng. Abstr.) **(Fre)**
[Cancer preventive value of natural, non–nutritive food constituents] Fröhlich RH, et al. **Acta Med Austriaca** 1997; 24(3):108–13 (82 ref.) (Eng. Abstr.) **(Ger)**
[Cytotoxic T–lymphocytes and the recognition of tumor antigens––an approach to "preventive tumor vaccination?"] Peiper M, et al. **Zentralbl Chir** 1997;122(3):141–8 (50 ref.) (Eng. Abstr.) **(Ger)**
[Prevention and treatment of solid tumors with retinoids] Moriwaki H. **Gan To Kagaku Ryoho** 1996 Oct; 23(12):1625–8 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Bio–chemoprevention of cancer] Nishino H. **Gan To Kagaku Ryoho** 1997 Jul;24(9):1047–52 (2 ref.) (Eng. Abstr.) **(Jpn)**
[Results and perspectives in the chemoprophylaxis of cancer] Aleksandrov VA. **Vopr Onkol** 1997;43(1):124–9 (13 ref.) **(Rus)**
[Trends and perspectives in environmental oncology] Khudolei VV, et al. **Vopr Onkol** 1997;43(1):116–9 (14 ref.) (Eng. Abstr.) **(Rus)**
[Risk factors and cancer prevention] Borràs JM, et al. **Gastroenterol Hepatol** 1997 May;20(5):222–30 (30 ref.) **(Spa)**

PSYCHOLOGY

Evaluation of quality of life for diverse patient populations. Yabroff KR, et al. **Breast Cancer Res Treat** 1996; 40(1):87–104 (196 ref.)
Posttraumatic stress symptoms and medical procedures in children. Wintgens A, et al. **Can J Psychiatry** 1997 Aug; 42(6):611–6 (44 ref.)
Managing spiritual distress in patients with advanced cancer pain. Georgesen J, et al. **Cancer Nurs** 1996 Oct;19(5):376–83 (20 ref.)
Pharmacokinetics and pharmacodynamics of mood–altering drugs in patients with cancer. Lovejoy NC, et al. **Cancer Nurs** 1996 Dec;19(6):407–18 (75 ref.)
Cognitive–behavioral interventions to manage depression in patients with cancer: research and theoretical initiatives. Lovejoy NC, et al. **Cancer Nurs** 1997 Jun;20(3):155–67 (54 ref.)
Diagnosis and treatment of major depression among people with cancer. Valente SM, et al. **Cancer Nurs** 1997 Jun; 20(3):168–77 (34 ref.)
Neuropsychiatric disorders in cancer patients. Baile WF. **Curr Opin Oncol** 1996 May;8(3):182–7 (31 ref.)
Depression in the medically ill: management considerations. Evans DL, et al. **Depress Anxiety** 1996–97;4(4):199–208 (110 ref.)
Quality of life and cancer IORT treatment. del Regato Distinguished Lecture. Caetano Vaeth PA, et al. **Front Radiat Ther Oncol** 1997;31:8–13 (19 ref.)
Psychological opportunities and hazards in predictive genetic testing for cancer risk. Codori AM. **Gastroenterol Clin North Am** 1997 Mar;26(1):19–39 (118 ref.)
Psychiatric emergencies in terminally ill cancer patients. Roth AJ, et al. **Hematol Oncol Clin North Am** 1996 Feb; 10(1):235–59 (71 ref.)
Is there a role for physician–assisted suicide in cancer? Yes. McKhann CF. **Important Adv Oncol** 1996;:267–79 (20 ref.)
Is there a role for physician–assisted suicide in cancer? No. Siegler M. **Important Adv Oncol** 1996;:281–91 (72 ref.)
Protective care–receiving: the active role of care–recipients. Russell CK, et al. **J Adv Nurs** 1997 Mar;25(3):532–40 (14 ref.)
Communication, accrual to clinical trials, and the physician–patient relationship: implications for training programs. Ruckdeschel JC, et al. **J Cancer Educ** 1996 Summer;11(2):73–9 (51 ref.)
Tobacco use among pediatric cancer patients: recommendations for developing clinical smoking interventions [see comments] Tyc VL, et al. **J Clin Oncol** 1997 Jun;15(6):2194–204 (81 ref.) Comment in: J Clin Oncol 1997 Jun;15(6):2181–2.
An analysis of the concept of hope in the adolescent with cancer. Hendricks–Ferguson VL. **J Pediatr Oncol Nurs** 1997 Apr;14(2):73–80; discussion 81–2 (47 ref.)
Sense of self in children with cancer and in childhood cancer survivors: a critical review. Woodgate R, et al. **J Pediatr Oncol Nurs** 1997 Jul;14(3):137–55 (62 ref.)
Attitude and disposition: do they make a difference in cancer survival? Creagan ET. **Mayo Clin Proc** 1997 Feb; 72(2):160–4 (24 ref.)
Quality of life and the cancer experience: the state–of–the–knowledge. King CR, et al. **Oncol Nurs Forum** 1997 Jan–Feb;24(1):27–41 (138 ref.)
Strategies for assessing and fostering hope: the hope assessment guide. Penrod J, et al. **Oncol Nurs Forum** 1997 Jul;24(6):1055–63 (12 ref.)
Emotional and behavioral responses to genetic testing for susceptibility to cancer. Lerman C, et al. **Oncology (Huntingt)** 1996 Feb;10(2):191–5, 9; discussion 200–2 (61 ref.)
Imagery and hypnosis in the treatment of cancer patients. Spiegel D, et al. **Oncology (Huntingt)** 1997 Aug; 11(8):1179–89; discussion 1189–95 (63 ref.)
Understanding the psychosocial late effects of childhood cancer therapy. Simms S. **Pediatr Hematol Oncol** 1997 May–Jun;14(3):187–9 (7 ref.)
Fear of cancer recurrence––a literature review and proposed cognitive formulation to explain exacerbation of recurrence fears. Lee–Jones C, et al. **Psychooncology** 1997 Jun; 6(2):95–105 (41 ref.)
The interpretation of scores from the EORTC quality of life questionnaire QLQ–C30. King MT. **Qual Life Res** 1996 Dec;5(6):555–67 (35 ref.)
Bandura's theory of self–efficacy: applications to oncology. Lev EL. **Sch Inq Nurs Pract** 1997 Spring;11(1):21–37; discussion 39–43 (62 ref.)
Psychological issues in cancer genetics. Biesecker BB. **Semin Oncol Nurs** 1997 May;13(2):129–34 (51 ref.)
[Family–oriented management of children and adolescents with cancer] Häberle H, et al. **Prax Kinderpsychol Kinderpsychiatr** 1997 Jul–Aug; 46(6):405–19 (50 ref.) (Eng. Abstr.) **(Ger)**
[Do psychological factors modify survival of cancer patients? I: Review of the literature] Faller H. **Psychother Psychosom Med Psychol** 1997 May;47(5):163–9 (65 ref.) (Eng. Abstr.) **(Ger)**
[The role of psycho–oncology in the treatment of cancer patients] Blinov NN, et al. **Vopr Onkol** 1996;42(5):86–9 (16 ref.) (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

Synchrotron in cancer medicine. Cartei F. **Eur J Cancer Prev** 1996 Oct;5(5):419–20 (7 ref.)
Use of positron emission tomography to study tumors in vivo. Hamberg LM, et al. **Mol Med Today** 1996 Dec;2(12):528–34 (32 ref.)
Imaging technologies for radionuclide dosimetry. Ott RJ. **Phys Med Biol** 1996 Oct;41(10):1885–94 (34 ref.)
[The role of angiography for the detection of early carcinomas] Isobe Y. **Nippon Rinsho** 1996 May;54(5):1273–5 (4 ref.) (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE IMAGING

Radiolabelled somatostatin analogue scintigraphy in oncology. O'Byrne KJ, et al. **Anticancer Drugs** 1996 Jan; 7 Suppl 1:33–44 (79 ref.)
Pretargeting strategies for radio–immunoguided tumour localisation and therapy. Stoldt HS, et al. **Eur J Cancer** 1997 Feb;33(2):186–92 (49 ref.)
Does fluorine–18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology? [see comments] Brock CS, et al. **Eur J Nucl Med** 1997 Jun;24(6):691–705 (136 ref.) Comment in: Eur J Nucl Med 1997 Jun;24(6):587–9.
Oncological applications of positron emission tomography with fluorine–18 fluorodeoxyglucose. Rigo P, et al. **Eur J Nucl Med** 1996 Dec;23(12):1641–74 (374 ref.)
Fluorine–18 deoxyglucose and false–positive results: a major problem in the diagnostics of oncological patients. Strauss LG. **Eur J Nucl Med** 1996 Oct;23(10):1409–15 (22 ref.)
Radiolabeled somatostatin analog scintigraphy in oncology and immune diseases: an overview. Kwekkeboom DJ, et al. **Eur Radiol** 1997;7(7):1103–9 (37 ref.)
Cancer imaging with radiolabeled antibodies: new advances with technetium–99m–labeled monoclonal antibody Fab' fragments, especially CEA–Scan and prospects for therapy. Goldenberg DM, et al. **J Nucl Med Technol** 1997 Mar; 25(1):18–23; quiz 34 (46 ref.)
Receptor imaging of human diseases using radiolabeled peptides. Reubi JC, et al. **J Recept Signal Transduct Res** 1995 Jan–Mar; 15(1–4):379–92 (19 ref.)
Advances in positron tomography for oncology. Budinger TF, et al. **Nucl Med Biol** 1996 Aug;23(6):659–67 (25 ref.)
PET and [18F]–FDG in oncology: a clinical update. Conti PS, et al. **Nucl Med Biol** 1996 Aug;23(6):717–35 (220 ref.)
Radiolabeled peptides and other ligands for receptors overexpressed in tumor cells for imaging neoplasms. McAfee JG, et al. **Nucl Med Biol** 1996 Aug;23(6):673–6 (36 ref.)
Clinical applications of fusion imaging in oncology. Scott AM, et al. **Nucl Med Biol** 1994 Jul;21(5):775–84 (46 ref.)
Cost–effectiveness of PET imaging in clinical oncology. Valk PE, et al. **Nucl Med Biol** 1996 Aug;23(6):737–43 (23 ref.)
Status of radiolabeled monoclonal antibodies for diagnosis and therapy of cancer. Divgi CR. **Oncology (Huntingt)** 1996 Jun;10(6):939–53; discussion 954, 957–8 (76 ref.)
Diagnostic use of radiolabeled antibodies for cancer. Harrison KA, et al. **Oncology (Huntingt)** 1995 Jul;9(7):625–31 DISC 634, 636, 641 (45 ref.)
Radiolabelled monoclonal antibodies in clinical and surgical oncology: a review. Biassoni L, et al. **Panminerva Med** 1997 Mar;39(1):46–52 (17 ref.)
Single–chain Fv radioimmunotargeting. Huston JS, et al. **Q J Nucl Med** 1996 Sep;40(3):320–33 (61 ref.)
Radiolabeled nucleoside analogs in cancer diagnosis and therapy. Kassis AI, et al. **Q J Nucl Med** 1996 Sep; 40(3):301–19 (93 ref.)
Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Reubi JC. **Q J Nucl Med** 1997 Jun; 41(2):63–70 (18 ref.)
Receptor imaging: competitive or complementary to antibody imaging? Goldsmith SJ. **Semin Nucl Med** 1997 Apr;27(2):85–93 (20 ref.)
PET in oncology: will it replace the other modalities? Hoh CK, et al. **Semin Nucl Med** 1997 Apr;27(2):94–106 (85 ref.)
Trials and tribulations: oncological antibody imaging comes to the fore. Zuckier LS, et al. **Semin Nucl Med** 1997 Jan; 27(1):10–29 (180 ref.)
[Progresses in nuclear medicine in China, 1996] Lin X. **Chung Hua I Hsueh Tsa Chih** 1996 Dec;76(12):941–2 (0 ref.) **(Chi)**
[Clinical value of positron emission tomography (PET) in oncologic questions: results of an interdisciplinary consensus conference. Schirmerreschaft der Deutschen Gesellschaft for Nuklearmedizin] Reske SN, et al. **Nuklearmedizin** 1996 Apr;35(2):42–52 (98 ref.) (Eng. Abstr.) **(Ger)**
[Somatostatin receptor scintigraphy. Methodology, indications, results] Eising EG, et al. **Radiologe** 1996 Jan; 36(1):81–8 (33 ref.) (Eng. Abstr.) **(Ger)**
[11C–methionine: an effective radio–tracer for PET scan in the detection of tumors of low proliferating capacity] Trón L, et al. **Orv Hetil** 1997 Aug 24;138(34):2107–12 (44 ref.) (Eng. Abstr.) **(Hun)**
[Positron emission tomography (PET): characteristics and potential applications in clinical oncology] Crippa F, et al. **Radiol Med (Torino)** 1996 Oct;92(4):453–60 (59 ref.) **(Ita)**
[Scintigraphy with radiogallium in oncologic and non–oncologic diseases. State of the art and main indications] Gasparini M, et al. **Radiol Med (Torino)** 1996 Dec;92(6):770–7 (47 ref.) (Eng. Abstr.) **(Ita)**
[Diagnosis of cancers by FDG–PET] Ichiya Y. **Fukuoka Igaku Zasshi** 1997 Jan;88(1):7–10 (2 ref.) **(Jpn)**
[Tumor imaging in nuclear medicine] Uno K, et al. **Nippon Rinsho** 1996 May;54(5):1268–72 (14 ref.) (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY

Current status of conformal radiotherapy. Dahl O, et al. **Acta Oncol** 1996;35 Suppl 8:41–57 (235 ref.)
ARCON––current status: summary of a workshop on preclinical and clinical studies. Denekamp J, et al. **Acta Oncol** 1997;36(5):517–25 (0 ref.)
Radiotherapy in Sweden––a study of present use in relation to the literature and an estimate of future trends. Frödin JE, et al. **Acta Oncol** 1996;35(8):967–79 (09 ref.)
The role of radiotherapy in the management of cancer––an overview. Tobias JS. **Ann Acad Med Singapore** 1996 May; 25(3):371–9 (50 ref.)
Radioisotopes in the treatment of bone metastases. Ben–Josef E, et al. **Ann Med** 1997 Feb;29(1):31–5 (41 ref.)
Clinical aspects of local and regional tumor therapy with 188Re–RC–160. Bender H, et al. **Anticancer Res** 1997 May–Jun;17(3B):1705–12 (31 ref.)
Two ways to establish potential At–211 radiopharmaceuticals. Wunderlich G, et al. **Anticancer Res** 1997 May–Jun;17(3B):1809–13 (28 ref.)
Pre–clinical experience with Re–188–RC–160, a radiolabeled somatostatin analog for use in peptide–targeted radiotherapy. Zamora PO, et al. **Anticancer Res** 1997 May–Jun;17(3B):1803–8 (33 ref.)
Vehicles, chelators, and radionuclides: choosing the "building blocks" of an effective therapeutic radioimmunoconjugate. Schubiger PA, et al. **Bioconjug Chem** 1996 Mar–Apr; 7(2):165–79 (98 ref.)
Interventional radiology in palliative medicine. Morgan RA, et al. **Br J Hosp Med** 1997 Feb 5–18;57(3):69–75 (9 ref.)
Cancer in children: radiotherapeutic approaches. Taylor RE. **Br Med Bull** 1996 Oct;52(4):873–86 (28 ref.)
Clinical implementation of electronic portal imaging: correction strategies and set–up errors. De Neve W, et al. **Bull Cancer Radiother** 1996;83(4):401–5 (33 ref.)
[Proton and neutron radiation in cancer treatment: clinical and economic outcomes] Fleurette F, et al. **Bull Cancer Radiother** 1996;83 Suppl:223s–7s (29 ref.)
Progress in the field of compounds for boron neutron capture therapy. Gabel D. **Bull Cancer Radiother** 1996;83 Suppl:186s–90s (33 ref.)

Ten years of fast neutron therapy in Münster. Prott FJ, et al. **Bull Cancer Radiother** 1996;83 Suppl:115s–21s (23 ref.)
Present status, trends and needs in fast neutron therapy. Wambersie A, et al. **Bull Cancer Radiother** 1996;83 Suppl:68s–77s (28 ref.)
Palliative radiation therapy in the United States. Coia LR. **Can J Oncol** 1996 Feb;6 Suppl 1:62–8; discussion 84 (14 ref.)
Perspectives of tumour radiotherapy in the Czech Republic and "Oncology 2000" Foundation. Prokeš K, et al. **Cent Eur J Public Health** 1996 Sep;4(3):208–12 (19 ref.)
Radiotherapy in the aged. Olmi P, et al. **Clin Geriatr Med** 1997 Feb;13(1):143–68 (116 ref.)
A role for molecular radiobiology in radiotherapy? Gordon AT, et al. **Clin Oncol (R Coll Radiol)** 1997;9(2):70–8 (107 ref.)
Radiotherapy for palliation of symptoms in incurable cancer. Hoegler D. **Curr Probl Cancer** 1997 May–Jun;21(3):129–83 (140 ref.)
The effects of irradiation and chemotherapy on growth. Moshang T Jr, et al. **Endocrinol Metab Clin North Am** 1996 Sep;25(3):731–41 (49 ref.)
Pretargeting strategies for radio–immunoguided tumour localisation and therapy. Stoldt HS, et al. **Eur J Cancer** 1997 Feb;33(2):186–92 (49 ref.)
Synchrotron in cancer medicine. Cartei F. **Eur J Cancer Prev** 1996 Oct;5(5):419–20 (7 ref.)
Endocrine sequelae of cancer therapy. Shalet SM. **Eur J Endocrinol** 1996 Aug;135(2):135–43 (46 ref.)
Hypoxia and angiogenesis in experimental tumor models: therapeutic implications. Rockwell S, et al. **EXS** 1997; 79:335–60 (107 ref.)
Present and future of intraoperative radiation therapy (IORT). Keynote address. Abe M. **Front Radiat Ther Oncol** 1997;31:3–7 (16 ref.)
Intraoperative radiation therapy terminology. Dobelbower RR Jr, et al. **Front Radiat Ther Oncol** 1997;31:14–7 (14 ref.)
Approaches to enhance cancer radiotherapy employing gene transfer methods. Buchsbaum DJ, et al. **Gene Ther** 1996 Dec;3(12):1042–68 (308 ref.)
Radioimmunotherapy of solid tumors: a review "of mice and men". Behr TM, et al. **Hybridoma** 1997 Feb;16(1):101–7 (27 ref.)
The molecular regulation of apoptosis and implications for radiation oncology. Blank KR, et al. **Int J Radiat Biol** 1997 May;71(5):455–66 (106 ref.)
Treatment of cancer with radiation and drugs. Tannock IF. **J Clin Oncol** 1996 Dec;14(12):3156–74 (156 ref.)
Considerations for the combined use of chemotherapy and radiation therapy. Vokes EE. **J Infus Chemother** 1995 Fall; 5(4):179–81 (47 ref.)
Chemistry and biology of some low molecular weight boron compounds for boron neutron capture therapy. Sjöberg S, et al. **J Neurooncol** 1997 May;33(1–2):41–52 (75 ref.)
Microdosimetry for boron neutron capture therapy: a review. Zamenhof RG. **J Neurooncol** 1997 May;33(1–2):81–92 (37 ref.)
Dose timing in tumor radiotherapy: considerations of cell number stochasticity. Sachs RK, et al. **Math Biosci** 1996 Dec;138(2):131–46 (39 ref.)
Status of radiolabeled monoclonal antibodies for diagnosis and therapy of cancer. Divgi CR. **Oncology (Huntingt)** 1996 Jun;10(6):939–53; discussion 954, 957–8 (76 ref.)
Recent progress in radioimmunotherapy for cancer. Meredith RF, et al. **Oncology (Huntingt)** 1997 Jul;11(7):979–84, 987; discussion 987–8 (50 ref.)
Current role of protective agents in cancer treatment. Schuchter LM. **Oncology (Huntingt)** 1997 Apr; 11(4):505–12, 515–6; discussion 517–8 (87 ref.)
Effects of pediatric cancer therapy on the musculoskeletal system. Fletcher BD. **Pediatr Radiol** 1997 Aug;27(8):623–36 (102 ref.)
Dose–rate effects in targeted radiotherapy. Dale RG. **Phys Med Biol** 1996 Oct;41(10):1871–84 (46 ref.)
The current status of targeted radiotherapy in clinical practice. Gaze MN. **Phys Med Biol** 1996 Oct; 41(10):1895–903 (49 ref.)
Cancer therapy using bone–seeking isotopes. Lewington VJ. **Phys Med Biol** 1996 Oct;41(10):2027–42 (78 ref.)
Microdosimetry and radiocurability: modelling targeted therapy with beta–emitters. Nahum AE. **Phys Med Biol** 1996 Oct;41(10):1957–72 (34 ref.)
Targeted radiotherapy using Auger electron emitters. O'Donoghue JA, et al. **Phys Med Biol** 1996 Oct; 41(10):1973–92 (81 ref.)
Imaging technologies for radionuclide dosimetry. Ott RJ. **Phys Med Biol** 1996 Oct;41(10):1885–94 (34 ref.)
Targeted therapy using alpha emitters. Vaidyanathan G, et al. **Phys Med Biol** 1996 Oct;41(10):1915–31 (76 ref.)
Radionuclides and carrier molecules for therapy. Zweit J. **Phys Med Biol** 1996 Oct;41(10):1905–14 (40 ref.)
Radiolabeled nucleoside analogs in cancer diagnosis and therapy. Kassis AI, et al. **Q J Nucl Med** 1996 Sep; 40(3):301–19 (93 ref.)
Hyperfractionation: where do we stand? Beck–Bornholdt HP, et al. **Radiother Oncol** 1997 Apr;43(1):1–21 (170 ref.)
Potential clinical impact of normal–tissue intrinsic radiosensitivity testing. Bentzen SM. **Radiother Oncol** 1997 May;43(2):121–31 (43 ref.)
Magnetic resonance imaging (MRI): considerations and applications in radiotherapy treatment planning. Khoo VS, et al. **Radiother Oncol** 1997 Jan;42(1):1–15 (100 ref.)
Radiosensitization of human solid tumor cell lines with gemcitabine. Shewach DS, et al. **Semin Oncol** 1996 Oct; 23(5 Suppl 10):65–71 (42 ref.)
Modulating the radiation response. Coleman CN. **Stem Cells** 1996 Jan;14(1):10–5 (35 ref.)
Cell cycle checkpoints and apoptosis: potential for improving radiation therapy. Muschel RJ, et al. **Vitam Horm** 1997; 53:1–25 (149 ref.)
[Three–dimensional dosimetry: realities and perspectives] Bridier A, et al. **Bull Cancer Radiother** 1996;83(4):345–54 (50 ref.) **(Fre)**
[Apoptosis and radiotherapy] Cosset JM. **Bull Cancer Radiother** 1996;83(4):222–9 (53 ref.) **(Fre)**
[Protontherapy. Clinical features] Habrand JL, et al. **Bull Cancer Radiother** 1996;83(4):247–53 (26 ref.) **(Fre)**
[Protontherapy: physical and technical basis] Mazal A, et al. **Bull Cancer Radiother** 1996;83(4):230–46 (60 ref.) **(Fre)**
[Incidence of malignant soft tissue tumors (sarcomas) after previous radiotherapy] Hernandez–Richter T, et al. **Langenbecks Arch Chir** 1996;381(5):295–8 (19 ref.) (Eng. Abstr.) **(Ger)**
[Possibilities of palliative radiotherapy] Berndt–Skorka R. **Z Arztl Fortbild Qualitatssich** 1997 Mar;91(2):145–8 (10 ref.) (Eng. Abstr.) **(Ger)**
[Overview of the development of clinical and dosimetric methods for radiotherapy planning for cancer patients in Hungary (see comments)] Treer T, et al. **Orv Hetil** 1996 Aug 18;137(33):1805–9 (33 ref.) (Eng. Abstr.) Comment in: Orv Hetil 1997 Jun 15;138(24):1604. **(Hun)**
[Antioncogene p53 and apoptosis response: new hypotheses on the molecular bases of tumor resistance to radiotherapy] Corvò R. **Radiol Med (Torino)** 1996 Sep;92(3):298–302 (21 ref.) (Eng. Abstr.) **(Ita)**
[Clinical evaluation and perspective of charged particle therapy] Tsujii H. **Nippon Rinsho** 1997 Jun;55(6):1588–95 (18 ref.) (Eng. Abstr.) **(Jpn)**
[Technological approaches to total body radiotherapy of cancer patients] Korytova LI, et al. **Vestn Rentgenol Radiol** 1997 Jul–Aug;(4):38–40 (3 ref.) **(Rus)**
[Technological problems in use of fast reactors for radiotherapy of patients with malignant tumors] Mardynskii IS, et al. **Vestn Rentgenol Radiol** 1997 Jul–Aug;(4):26–9 (11 ref.) (Eng. Abstr.) **(Rus)**

REHABILITATION

American Indian families and home care: macro social and cultural considerations. Kramer BJ. **Alaska Med** 1995 Oct–Dec;37(4):139–41 (41 ref.)
The concept of rehabilitation of cancer patients. Body JJ, et al. **Curr Opin Oncol** 1997 Jul;9(4):332–40 (60 ref.)
Quality of life among long–term cancer survivors. Ferrell BR, et al. **Oncology (Huntingt)** 1997 Apr;11(4):565–8, 571; discussion 572, 575–6 (32 ref.)
Rehabilitation of the cancer patient at home. Blesch KS. **Semin Oncol Nurs** 1996 Aug;12(3):219–25 (51 ref.)

SURGERY

Effects of postoperative intraperitoneal chemotherapy on peritoneal wound healing and adhesion formation. Jacquet P, et al. **Cancer Treat Res** 1996;82:327–35 (39 ref.)
Cancer surgery in the elderly. Berger DH, et al. **Clin Geriatr Med** 1997 Feb;13(1):119–41 (84 ref.)
Surgical management of patients with advanced cancer (I). Smith IC, et al. **Eur J Surg Oncol** 1997 Apr;23(2):178–82 (58 ref.)
What's new in surgical oncology. Pollock R. **J Am Coll Surg** 1997 Feb;184(2):157–63 (41 ref.)
Efficacy and toxicity of radiation in preparative regimens for pediatric stem cell transplantation. I: Clinical applications and therapeutic effects. Miale TD, et al. **Med Oncol** 1995 Dec;12(4):231–49 (162 ref.)
Autologous blood donation and epoetin alfa in cancer surgery. Jeekel J. **Semin Hematol** 1996 Apr;33(2 Suppl 2):43–6; discussion 47 (13 ref.)
Autologous blood donation and epoetin alfa in cancer surgery. Jeekel J. **Semin Hematol** 1997 Apr;33(2 Suppl 2):43–6; discussion 47 (13 ref.)
The immune–suppressive nature of pain. Page GG, et al. **Semin Oncol Nurs** 1997 Feb;13(1):10–5 (50 ref.)
The gamma–probe–guided resection of radiolabeled primary lymph nodes. Alex JC, et al. **Surg Oncol Clin N Am** 1996 Jan;5(1):33–41 (18 ref.)
General principles of reconstruction following cancer surgery. Ariyan S. **Surg Oncol Clin N Am** 1996 Oct; 5(4):741–50 (13 ref.)
Reconstruction following resection of malignancies of the upper extremity. Upton J, et al. **Surg Oncol Clin N Am** 1996 Oct;5(4):847–92 (99 ref.)
Prevention of post–operative deep leg vein thrombosis in patients with cancer. Gallus AS. **Thromb Haemost** 1997 Jul;78(1):126–32 (67 ref.)
[Adjuvant and neoadjuvant methods: what is their value––do they change surgical procedure?] Meyer HJ, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:70–5 (25 ref.) (Eng. Abstr.) **(Ger)**
[Principles of radical surgery] Siewert JR. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:56–63 (15 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

On the strategy of using nonviral carriers in cancer gene therapy. Sochanik A, et al. **Acta Biochim Pol** 1996; 43(2):293–300 (47 ref.)
HER–2/neu protein: a target for antigen–specific immunotherapy of human cancer. Disis ML, et al. **Adv Cancer Res** 1997;71:343–71 (105 ref.)
Identification of the genes encoding cancer antigens: implications for cancer immunotherapy. Rosenberg SA, et al. **Adv Cancer Res** 1996;70:145–77 (156 ref.)
Targeted tumor cytotoxicity mediated by intracellular single–chain anti–oncogene antibodies. Curiel DT. **Adv Pharmacol** 1997;40:51–84 (76 ref.)
Anti–oncogene ribozymes for cancer gene therapy. Irie A, et al. **Adv Pharmacol** 1997;40:207–57 (350 ref.)
Immunoliposomes for cancer treatment. Park JW, et al. **Adv Pharmacol** 1997;40:399–435 (135 ref.)
Cytokine gene transduction in the immunotherapy of cancer. Parmiani G, et al. **Adv Pharmacol** 1997;40:259–307 (235 ref.)
Gene therapy approaches to enhance antitumor immunity. Shawler DL, et al. **Adv Pharmacol** 1997;40:309–37 (82 ref.)
The present status of hyperthermia in Japan. Matsuda T. **Ann Acad Med Singapore** 1996 May;25(3):420–4 (15 ref.)
Autologous stem cell transplantation in solid tumours of childhood. Atra A, et al. **Ann Med** 1996 Apr;28(2):159–64 (43 ref.)
Possibilities of gene therapies for cancer [editorial] Lashford LS. **Ann Med** 1997 Feb;29(1):1–4 (36 ref.)
Autologous stem cell transplantation in the treatment of cancer. Niskanen E. **Ann Med** 1996 Feb;28(1):57–62 (62 ref.)
Peripheral blood progenitor cell transplantation: where do we stand? Chairman's Summary of the European School of Oncology Task Force meeting Peripheral Blood progenitor cell's held September 29–30, 1995. Boogaerts MA, et al. **Ann Oncol** 1996;7 Suppl 2:1–4 (20 ref.)
Apoptosis: its role in the development of malignancies and its potential as a novel therapeutic target. Dixon SC, et al. **Ann Pharmacother** 1997 Jan;31(1):76–82 (80 ref.)
Getting to the source: dendritic cells as therapeutic reagents for the treatment of patients with cancer [editorial; comment] Lotze MT. **Ann Surg** 1997 Jul;226(1):1–5 (48 ref.) Comment on: Ann Surg 1997 Jul;226(1):6–16.
Peripheral blood stem cells for autografting. Shpall EJ, et al. **Annu Rev Med** 1997;48:241–51 (57 ref.)
Cancer immunotherapy: hopes and pitfalls: a review. Ben–Efraim S. **Anticancer Res** 1996 Sep–Oct; 16(5B):3235–40 (53 ref.)
Ex vivo manipulation of cell subsets for cell therapies. Nordon RE, et al. **Artif Organs** 1996 May;20(5):396–402 (56 ref.)
Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment. van Leeuwen FE. **Baillieres Clin Haematol** 1996 Mar;9(1):57–85 (115 ref.)
Single–chain Fv antibodies for targeting cancer therapy. Begent RH, et al. **Biochem Soc Trans** 1997 May;25(2):715–7 (16 ref.)
Targeted gene therapy for cancer: herpes simplex virus thymidine kinase gene–mediated cell killing leads to anti–tumour immunity that can be augmented by co–expression of cytokines in the tumour cells. Vile RG, et al. **Biochem Soc Trans** 1997 May;25(2):717–22 (51 ref.)
Dendritic cells in the treatment of cancer [editorial] Engleman EG. **Biol Blood Marrow Transplant** 1996 Oct; 2(3):115–7 (27 ref.)
Potential of microsensor–based feedback bioactuators for biophysical cancer treatment. Wolf B, et al. **Biosens Bioelectron** 1997;12(4):301–9 (58 ref.)
The incidence and clinical significance of antibodies to interferon–a in patients with solid tumors. Oberg K, et al. **Biotherapy** 1997;10(1):1–5 (21 ref.)
Clinical significance of autologous tumor killing (ATK) activity and its induction therapy in human cancer. Uchida A. **Biotherapy** 1994;8(2):113–22 (53 ref.)
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders. Current practice in Europe in 1996 and proposals for an operational classification. Accreditation Sub–Committee of the European Group for Blood and Marrow Transplantation (EBMT). Schmitz N, et al. **Bone Marrow Transplant** 1996 Apr;17(4):471–7 (52 ref.)
Multistage designs for phase II clinical trials: statistical issues in cancer research. Kramar A, et al. **Br J Cancer** 1996 Oct;74(8):1317–20 (5 ref.)
Enhancement of immunotoxin activity using chemical and biological reagents. Wu M. **Br J Cancer** 1997;75(9):1347–55 (51 ref.)
The long–term survivors. Hawkins MM, et al. **Br Med Bull** 1996 Oct;52(4):898–923 (68 ref.)
Inhibition of signaling from Type 1 receptor tyrosine kinases via intracellular expression of single–chain antibodies. Beerli RR, et al. **Breast Cancer Res Treat** 1996;38(1):11–7 (32 ref.)
Preclinical testing of an anti–erbB–2 recombinant toxin. King CR, et al. **Breast Cancer Res Treat** 1996;38(1):19–25 (17 ref.)
Inhibition of fibroblast growth factors. Wellstein A, et al. **Breast Cancer Res Treat** 1996;38(1):109–19 (68 ref.)
Novel costimulators in the immune gene therapy of cancer. Galea–Lauri J, et al. **Cancer Gene Ther** 1996 May–Jun; 3(3):202–14 (133 ref.)

Making the most of mucin: a novel target for tumor immunotherapy. Barratt-Boyes SM. **Cancer Immunol Immunother** 1996 Nov;43(3):142–51 (65 ref.)

Gene-modified tumor cells as cellular vaccine. Baskar S. **Cancer Immunol Immunother** 1996 Nov;43(3):165–73 (96 ref.)

Treatment of malignancy by direct gene transfer of a foreign MHC class I molecule. DeBruyne L. **Cancer Immunol Immunother** 1996 Nov;43(3):180–9 (107 ref.)

Immunogenicity increase of autologous tumor cell vaccines by virus infection and attachment of bispecific antibodies. Haas C, et al. **Cancer Immunol Immunother** 1996 Nov; 43(3):190–4 (41 ref.)

Carcinoembryonic antigen as a target for cancer vaccines. Hodge JW. **Cancer Immunol Immunother** 1996 Nov; 43(3):127–34 (32 ref.)

Carbohydrate antigens as targets for active specific immunotherapy. Ragupathi G. **Cancer Immunol Immunother** 1996 Nov;43(3):152–7 (61 ref.)

Oncogene products represent potential targets of tumor vaccines. Tuttle TM. **Cancer Immunol Immunother** 1996 Nov;43(3):135–41 (62 ref.)

Outpatient antibiotic therapy for febrile episodes in low-risk neutropenic patients with cancer. Escalante CP, et al. **Cancer Invest** 1997;15(3):237–42 (25 ref.)

Recent insights into the functions of the retinoblastoma susceptibility gene product. Kaelin WG Jr. **Cancer Invest** 1997;15(3):243–54 (183 ref.)

Preservation of reproductive function before therapy for cancer: new options involving sperm and ovary cryopreservation [editorial] Opsahl MS, et al. **Cancer J Sci Am** 1997 Jul–Aug;3(4):189–91 (12 ref.)

Direct cell killing by suicide genes. Martin LA, et al. **Cancer Metastasis Rev** 1996 Sep;15(3):301–16 (76 ref.)

Immunotherapy II: Antigens, receptors and costimulation. Searle PF, et al. **Cancer Metastasis Rev** 1996 Sep; 15(3):329–49 (103 ref.)

Immunotherapy III: Combinatorial molecular immunotherapy--a synthesis and suggestions. Vile RG, et al. **Cancer Metastasis Rev** 1996 Sep;15(3):351–64 (101 ref.)

Gene therapy for cancer, the course ahead. Vile RG. **Cancer Metastasis Rev** 1996 Sep;15(3):403–10 (52 ref.)

Vectors for cancer gene therapy. Zhang J, et al. **Cancer Metastasis Rev** 1996 Sep;15(3):385–401 (110 ref.)

Programmed instruction: cancer therapy. Associated late effects (III). Rodriguez CS, et al. **Cancer Nurs** 1996 Oct; 19(5):392–400; quiz 401–2 (26 ref.)

TP53 tumour suppressor gene: clues to molecular carcinogenesis and cancer therapy. Wang XW, et al. **Cancer Surv** 1996;28:169–96 (231 ref.)

Autologous bone marrow transplantation in pediatric solid tumors. Kletzel M, et al. **Cancer Treat Res** 1997;77:333–56 (82 ref.)

Interleukin-2: its rationale and role in the treatment of patients with cancer. Rubin JT. **Cancer Treat Res** 1995; 80:83–105 (188 ref.)

Intraperitoneal immunotherapy of cancer: a review of options for treatment. van Ravenswaay Claasen HH, et al. **Cancer Treat Res** 1996;82:13–40 (194 ref.)

Post-bone marrow transplant use of immunotherapy. Verma UN, et al. **Cancer Treat Res** 1997;77:27–55 (158 ref.)

Chimeric T-cell receptors: highly specific tools to target cytotoxic T-lymphocytes to tumour cells. Abken H, et al. **Cancer Treat Rev** 1997 Mar;23(2):97–112 (42 ref.)

Clinical results of Greenfield filter use in patients with cancer. Greenfield LJ, et al. **Cardiovasc Surg** 1997 Apr;5(2):145–9 (21 ref.)

Ethical issues in clinical trials in oncology. Markman M. **Cleve Clin J Med** 1997 May;64(5):275–7 (4 ref.)

Organ preservation. An effective and safe form of cancer treatment. Balducci L, et al. **Clin Geriatr Med** 1997 Feb; 13(1):185–201 (38 ref.)

Life expectancy, comorbidity, and quality of life. A framework of reference for medical decisions. Bennahum DA, et al. **Clin Geriatr Med** 1997 Feb;13(1):33–53 (94 ref.)

Advances in hospice care. Leland JY, et al. **Clin Geriatr Med** 1997 May;13(2):381–401 (73 ref.)

Home care in the older person. Repetto L, et al. **Clin Geriatr Med** 1997 May;13(2):403–13 (41 ref.)

Gene therapy: a brief review. Hess P. **Clin Lab Med** 1996 Mar;16(1):197–211 (17 ref.)

Gynecologic issues in pediatric oncology. Jones KP. **Clin Obstet Gynecol** 1997 Mar;40(1):200–9 (21 ref.)

The CD34 antigen: potential clinical advantages of CD34 selection. Holyoake TL, et al. **Clin Oncol (R Coll Radiol)** 1996;8(4):214–21 (78 ref.)

Peripheral blood stem cell transplantation in common solid tumours: passing phase or new era? [editorial] Ledermann JA. **Clin Oncol (R Coll Radiol)** 1996;8(4):209–11 (21 ref.)

Biological rationale and clinical experience with hyperthermia. Engin K. **Control Clin Trials** 1996 Aug; 17(4):316–42 (183 ref.)

Current status of adoptive immunotherapy of cancer. Chang AE, et al. **Crit Rev Oncol Hematol** 1996 Apr;22(3):213–28 (115 ref.)

Stem cell manipulation: why and how performing peripheral blood progenitor cell purging. Rizzoli V, et al. **Crit Rev Oncol Hematol** 1997 Jul;26(2):101–15 (156 ref.)

Hitting cancer where it hurts. Sunassee K, et al. **Curr Biol** 1997 May 1;7(5):R282–5 (10 ref.)

Therapeutic targeting of the p53 tumor suppressor gene. Beaudry GA, et al. **Curr Opin Biotechnol** 1996 Dec; 7(6):592–600 (90 ref.)

Pulmonary complications of cancer treatment [see comments] Alberts WM. **Curr Opin Oncol** 1997 Mar;9(2):161–9 (42 ref.) Comment in: Curr Opin Oncol 1997 Mar;9(2):147–8.

Current progress in the gene therapy of cancer. Davis BM, et al. **Curr Opin Oncol** 1996 Nov;8(6):499–508 (86 ref.)

Clinical use of hematopoietic growth factors. Ganser A, et al. **Curr Opin Oncol** 1996 Jul;8(4):265–9 (28 ref.)

Prevention of infection in neutropenic cancer patients. Klastersky J. **Curr Opin Oncol** 1996 Jul;8(4):270–8 (37 ref.)

Antisense therapy. Narayanan R, et al. **Curr Opin Oncol** 1996 Nov;8(6):509–15 (66 ref.)

Gene therapy strategies for novel cancer therapeutics. Rosenfeld ME, et al. **Curr Opin Oncol** 1996 Jan;8(1):72–7 (73 ref.)

Complementary medicine. Schimpff SC. **Curr Opin Oncol** 1997 Jul;9(4):327–31 (18 ref.)

Monoclonal antibody-based therapy. von Mehren M, et al. **Curr Opin Oncol** 1996 Nov;8(6):493–8 (34 ref.)

The role of supportive care in quality of life. Warr D, et al. **Curr Opin Oncol** 1996 Jul;8(4):279–83 (24 ref.)

Autologous stem cell transplantation for solid tumors in children. Ladenstein R, et al. **Curr Opin Pediatr** 1997 Feb; 9(1):55–69 (130 ref.)

Immunostimulatory cytokines in somatic cells and gene therapy of cancer. Mackensen A, et al. **Cytokine Growth Factor Rev** 1997 Jun;8(2):119–28 (84 ref.)

Apoptosis--its role in tumour growth and therapy. Ellis PA, et al. **Cytopathology** 1996 Jun;7(3):201–3 (18 ref.)

Do oncologists have an increasing interest in the quality of life of their patients? A literature review of the last 15 years. Batel-Copel LM, et al. **Eur J Cancer** 1997 Jan;33(1):29–32 (23 ref.)

Cancer: a challenge for control theory and computer modelling. Düchting W, et al. **Eur J Cancer** 1996 Jul; 32A(8):1283–92 (48 ref.)

Thymus therapy for cancer? A criteria-based, systematic review [see comments] Ernst E. **Eur J Cancer** 1997 Apr; 33(4):531–5 (29 ref.) Comment in: Eur J Cancer 1997 Apr;33(4):517–8.

TNP-470/minocycline/cytotoxic therapy: a systems approach to cancer therapy. Teicher BA, et al. **Eur J Cancer** 1996 Dec;32A(14):2461–6 (52 ref.)

Oral health care for the cancer patient. Scully C, et al. **Eur J Cancer B Oral Oncol** 1996 Sep;32B(5):281–92 (282 ref.)

Multimodal strategies as prerequisite for organ-salvaging tumor surgery. Urban CE, et al. **Eur J Pediatr Surg** 1996 Jun;6(3):144–7 (20 ref.)

Monitoring tumour response. Husband JE. **Eur Radiol** 1996; 6(6):775–85 (56 ref.)

Genetically modified tumour vaccines carrying inserted genes for immunoregulatory molecules. Bubenik J. **Folia Biol (Praha)** 1996;42(6):295–304 (114 ref.)

Cytokine-based gene therapy of human tumors. An overview. Parmiani G, et al. **Folia Biol (Praha)** 1996; 42(6):305–9 (21 ref.)

Recent status of the antisense oligonucleotide approaches in oncology. Ma L, et al. **Fundam Clin Pharmacol** 1996; 10(2):97–115 (170 ref.)

Cancer therapy and apoptosis. Inoue S. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:102–14 (59 ref.)

Bleomycin: revival of an old drug. Mir LM, et al. **Gen Pharmacol** 1996 Jul;27(5):745–8 (30 ref.)

Guidelines in the care of the dying cancer patient. Cherny NI, et al. **Hematol Oncol Clin North Am** 1996 Feb; 10(1):261–86 (109 ref.)

Gene therapy: targeting tumor cells for destruction. Rabkin SD, et al. **Hum Cell** 1996 Dec;9(4):265–76 (72 ref.)

Applications of magnetic targeting in diagnosis and therapy--possibilities and limitations: a mini-review. Schütt W, et al. **Hybridoma** 1997 Feb;16(1):109–17 (101 ref.)

The potential role of NK cells in the separation of graft-versus-tumor effects from graft-versus-host disease after allogeneic bone marrow transplantation. Murphy WJ, et al. **Immunol Rev** 1997 Jun;157:167–76 (83 ref.)

Cancer vaccines based on the identification of genes encoding cancer regression antigens. Rosenberg SA. **Immunol Today** 1997 Apr;18(4):175–82 (59 ref.)

Chronotherapy for human solid tumors other than colorectal. Focan C. **In Vivo** 1995 Nov–Dec;9(6):549–54 (97 ref.)

Hyperthermia in cancer research: current status. Bisht KS, et al. **Indian J Exp Biol** 1996 Dec;34(12):1183–9 (120 ref.)

Ribozyme-mediated cancer gene therapy. Irie A, et al. **Int J Urol** 1997 Jul;4(4):329–37 (90 ref.)

Monoclonal antibody-conjugated immunotherapy of cancer. Imai K, et al. **Int Rev Immunol** 1997;14(2–3):213–27 (31 ref.)

Interleukin-12 as an inducer of cytotoxic effectors in anti-tumor immunity. Kumagai K, et al. **Int Rev Immunol** 1997;14(2–3):229–56 (107 ref.)

Tumor immunotherapy by vaccination with cytokine gene transfected cells. Viret C, et al. **Int Rev Immunol** 1997; 14(2–3):193–212 (88 ref.)

Gene therapy in pediatric oncology. Benaim E, et al. **Invest New Drugs** 1996;14(1):87–99 (92 ref.)

How to prepare cancer patients for potentially threatening medical procedures: consensus guidelines. NSW Cancer Council Cancer Education Research Program. Schofield MJ, et al. **J Cancer Educ** 1996 Fall;11(3):153–8 (16 ref.)

Strategies for manipulating apoptosis for cancer therapy with tumor necrosis factor and lymphotoxin. Wong GH, et al. **J Cell Biochem** 1996 Jan;60(1):56–60 (29 ref.)

Critical role of phase I clinical trials in cancer treatment. American Society of Clinical Oncology. **J Clin Oncol** 1997 Feb;15(2):853–9 (25 ref.)

Methodologic issues in effectiveness research on palliative cancer care: a systematic review. Rinck GC, et al. **J Clin Oncol** 1997 Apr;15(4):1697–707 (59 ref.)

Therapeutic hyperthermia in cancer and AIDS: an updated survey. Pontiggia P, et al. **J Environ Pathol Toxicol Oncol** 1996;15(2–4):289–97 (39 ref.)

The utility of follow-up testing after curative cancer therapy. A critical review and economic analysis. Edelman MJ, et al. **J Gen Intern Med** 1997 May;12(5):318–31 (133 ref.)

Monitoring of cancer patients undergoing active or passive immunotherapy. Salgaller ML. **J Immunother** 1997 Jan; 20(1):1–14 (113 ref.)

Reversal of tumor-induced immunosuppression: a new approach to cancer therapy [see comments] Wojtowicz-Praga S. **J Immunother** 1997 May;20(3):165–77 (146 ref.) Comment in: J Immunother 1997 May;20(3):178–9.

Why do so many cancer patients fail to respond to interferon therapy? Einhorn S, et al. **J Interferon Cytokine Res** 1996 Apr;16(4):275–81 (83 ref.)

Human tumor antigens recognized by T lymphocytes: implications for cancer therapy. Wang RF, et al. **J Leukoc Biol** 1996 Sep;60(3):296–309 (120 ref.)

Danger versus tolerance: paradigms for future studies of tumor-specific cytotoxic T lymphocytes [editorial; comment] Fenton RG, et al. **J Natl Cancer Inst** 1997 Feb 19;89(4):272–5 (28 ref.) Comment on: J Natl Cancer Inst 1997 Feb 19;89(4):293–300.

Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. Harris CC. **J Natl Cancer Inst** 1996 Oct 16;88(20):1442–55 (288 ref.)

Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. Rosenberg SA. **J Natl Cancer Inst** 1996 Nov 20; 88(22):1635–44 (61 ref.)

Gene therapy for cancer: what have we done and where are we going? Roth JA, et al. **J Natl Cancer Inst** 1997 Jan 1;89(1):21–39 (152 ref.)

Anti-tumor gene therapy. Ciriello C, et al. **J Neurooncol** 1997 Jan;31(1–2):217–23 (67 ref.)

Triumph over mischance: a role for nuclear medicine in gene therapy [editorial; comment] Larson SM, et al. **J Nucl Med** 1997 Aug;38(8):1230–3 (28 ref.) Comment on: J Nucl Med 1997 Aug;38(8):1221–9.

A multicenter evaluation of cancer pain control by palliative care teams. Higginson IJ, et al. **J Pain Symptom Manage** 1997 Jul;14(1):29–35 (41 ref.)

How often can we justify parenteral nutrition in terminally ill cancer patients? Fainsinger RL, et al. **J Palliat Care** 1997 Spring;13(1):48–51 (21 ref.)

Controlled delivery of antigens and adjuvants in vaccine development. Zhao Z, et al. **J Pharm Sci** 1996 Dec; 85(12):1261–70 (185 ref.)

Role of delivery vehicles for photosensitizers in the photodynamic therapy of tumours. Reddi E. **J Photochem Photobiol B** 1997 Feb;37(3):189–95 (50 ref.)

Photodynamic therapy: a promising new modality for the treatment of cancer. Schuitmaker JJ, et al. **J Photochem Photobiol B** 1996 Jun;34(1):3–12 (99 ref.)

Outcome measures in palliative care for advanced cancer patients: a review. Hearn J, et al. **J Public Health Med** 1997 Jun;19(2):193–9 (22 ref.)

The use of autologous transplantation in the treatment of malignant disorders. Territo M. **J Rheumatol Suppl** 1997 May;48:36–40 (24 ref.)

Lasers: reflections on their evolution. Aronoff BL. **J Surg Oncol** 1997 Jan;64(1):84–92 (24 ref.)

Integrins as signaling molecules and targets for tumor therapy. Ruoslahti E. **Kidney Int** 1997 May;51(5):1413–7 (44 ref.)

The influence of tumor blood flow and microenvironmental factors on the efficacy of radiation, drugs and localized hyperthermia. Vaupel PW. **Klin Padiatr** 1997 Jul–Aug; 209(4):243–9 (45 ref.)

Combined modality therapy of solid tumours. Vokes EE. **Lancet** 1997 May;349 Suppl 2:SII4–6 (27 ref.)

Gene therapy of cancer. Weichselbaum RR, et al. **Lancet** 1997 May;349 Suppl 2:SII10–2 (31 ref.)

Potential use of recombinant human interleukin-6 in clinical oncology. Veldhuis GJ, et al. **Leuk Lymphoma** 1996 Feb; 20(5–6):373–9 (61 ref.)

Progress in the treatment of childhood cancer. Eskenazi AE, et al. **Md Med J** 1997 Aug;46(7):360–2 (12 ref.)

Combination therapy with BRMs in cancer and infectious diseases. Garaci E, et al. **Mech Ageing Dev** 1997 Jun; 96(1–3):103–16 (57 ref.)

Technology and alternative cancer therapies: an analysis of heterodoxy and constructivism. Hess DJ. **Med Anthropol Q** 1996 Dec;10(4):657–74 (62 ref.)

Recent advances in medical oncology--1995–1996. Sikov WM. **Med Health R I** 1996 Mar;79(3):92–9 (39 ref.)

The induction of counter-interactions in tumor cells as a basis for the development of a therapy. Douvlis Z.

Med Hypotheses 1996 Apr;46(4):407–13 (50 ref.)
Urotherapy for patients with cancer. Eldor J. **Med Hypotheses** 1997 Apr;48(4):309–15 (96 ref.)
Gene therapy of cancer. Bank A. **Med Oncol** 1995 Sep; 12(3):143–7 (25 ref.)
Considerations for the clinical development of cytokine gene–transduced tumor cell vaccines. Jaffee EM, et al. **Methods** 1997 Jun;12(2):143–53 (50 ref.)
Targeted vectors for gene therapy of cancer and retroviral infections. Walther W, et al. **Mol Biotechnol** 1996 Dec; 6(3):267–86 (66 ref.)
p53 as a target for anti–cancer immunotherapy. Chen HL, et al. **Mol Med Today** 1997 Apr;3(4):160–7 (48 ref.)
Human tumour antigens recognized by T cells: new perspectives for anti–cancer vaccines? Coulie PG. **Mol Med Today** 1997 Jun;3(6):261–8 (39 ref.)
Replicating viruses as selective cancer therapeutics. Kirn DH, et al. **Mol Med Today** 1996 Dec;2(12):519–27 (28 ref.)
Biological properties of dendritic cells: implications to their use in the treatment of cancer. van Schooten WC, et al. **Mol Med Today** 1997 Jun;3(6):254–60 (44 ref.)
Peripheral blood progenitor cell transplantation in France. Reiffers J, et al. **Nouv Rev Fr Hematol** 1995;37(6):321–5 (16 ref.)
Artificial nutrition in cancer patients: an outlook from Europe. Bozzetti F. **Nutrition** 1997 May;13(5):486–9 (36 ref.)
Dietary bioflavonoids, chalcones, and related alkenones in prevention and treatment of cancer [editorial] Varma RS. **Nutrition** 1996 Sep;12(9):643–5 (28 ref.)
Barriers to cancer treatment: a review of published research. Guidry JJ, et al. **Oncol Nurs Forum** 1996 Oct;23(9):1393–8 (18 ref.)
Physiologic mechanisms of nausea and vomiting in patients with cancer. Hogan CM, et al. **Oncol Nurs Forum** 1997 Aug;24(7 Suppl):8–12 (19 ref.)
Immunologic advances in monoclonal antibody therapy: implications for oncology nursing. Karius D, et al. **Oncol Nurs Forum** 1997 Apr;24(3):483–94; QUIZ 495–6 (74 ref.)
Oral complications from cancer therapy: Part 1—Pathophysiology and secondary complications. Madeya ML. **Oncol Nurs Forum** 1996 Jun;23(5):801–7 (28 ref.)
Oral complications from cancer therapy: Part 2—Nursing implications for assessment and treatment. Madeya ML. **Oncol Nurs Forum** 1996 Jun;23(5):808–19 (63 ref.)
Emerging strategies in the management of cancer. Rieger PT. **Oncol Nurs Forum** 1997 May;24(4):728–37 (89 ref.)
Nursing challenges of caring for patients with HIV–related malignancies. Moran TA. **Oncology (Huntingt)** 1996 Oct; 10(10):1509–16; discussion 1523–4, 1527 (55 ref.)
Imagery and hypnosis in the treatment of cancer patients. Spiegel D, et al. **Oncology (Huntingt)** 1997 Aug; 11(8):1179–89; discussion 1189–95 (63 ref.)
Long–term survivors of childhood cancer. The medical consequences of cure. Marina N. **Pediatr Clin North Am** 1997 Aug;44(4):1021–42 (143 ref.)
Bone marrow transplantation for pediatric malignancies. Sanders JE. **Pediatr Clin North Am** 1997 Aug;44(4):1005–20 (68 ref.)
Growth and neuroendocrine dysfunction following therapy for childhood cancer. Sklar CA. **Pediatr Clin North Am** 1997 Apr;44(2):489–503 (64 ref.)
Pediatric hematology/oncology in Russia. Durnov L, et al. **Pediatr Hematol Oncol** 1997 Mar–Apr;14(2):103–7 (8 ref.)
Pediatric oncology and hematology in Manchester, England. Eden OB, et al. **Pediatr Hematol Oncol** 1997 May–Jun; 14(3):191–7 (19 ref.)
History of pediatric hematology–oncology in the Czech Republic. Kavan P, et al. **Pediatr Hematol Oncol** 1997 Jul–Aug;14(4):307–13 (6 ref.)
Present status of pediatric hematology–oncology in China. Lu S, et al. **Pediatr Hematol Oncol** 1997 Jan–Feb;14(1):11–5 (18 ref.)
Academic pediatrics in the Emma Children's Hospital, Academic Medical Center in Amsterdam (The Netherlands). Stuve W, et al. **Pediatr Hematol Oncol** 1997 May–Jun;14(3):199–203 (3 ref.)
Recombinant human erythropoietin in children with cancer [editorial] Tamary H, et al. **Pediatr Hematol Oncol** 1996 Jul–Aug;13(4):305–8 (24 ref.)
Tumor vascular endothelium: barrier or target in tumor directed drug delivery and immunotherapy. Molema G, et al. **Pharm Res** 1997 Jan;14(1):2–10 (68 ref.)
Cytokine gene–modified vaccines in the therapy of cancer. Bubenik J. **Pharmacol Ther** 1996;69(1):1–14 (208 ref.)
Differentiation, differentiation/gene therapy and cancer. Scott RE. **Pharmacol Ther** 1997;73(1):51–65 (152 ref.)
Scope and limitations of boron neutron capture therapy as the selective tool against cancer. Wójtowicz H, et al. **Postepy Biochem** 1995;41(5 Suppl):321–6 (43 ref.)
Cancer vaccines. Durrant LG, et al. **QJM** 1996 Sep; 89(9):645–51 (40 ref.)
Genetic approaches to cancer immunotherapy. Blankenstein T, et al. **Rev Physiol Biochem Pharmacol** 1996;129:1–49 (168 ref.)
Epitope selection and development of peptide based vaccines to treat cancer. Celis E, et al. **Semin Cancer Biol** 1995 Dec; 6(6):329–36 (52 ref.)
Allogeneic transfusion and infection: economic and clinical implications. Blumberg N. **Semin Hematol** 1997 Jul;34(3 Suppl 2):34–40 (29 ref.)
Harnessing self–reactivity in cancer immunotherapy. Schoenberger SP, et al. **Semin Immunol** 1996 Oct;8(5):303–9 (44 ref.)
Nursing care of the blood cell transplant recipient. Buchsel PC, et al. **Semin Oncol Nurs** 1997 Aug;13(3):172–83 (39 ref.)
Gene therapy: current and future implications for oncology nursing practice. Lea DH. **Semin Oncol Nurs** 1997 May; 13(2):115–22 (47 ref.)
Applications of genetic technologies to cancer screening, prevention, diagnosis, prognosis, and treatment. Peters JA. **Semin Oncol Nurs** 1997 May;13(2):74–81 (45 ref.)
Pediatric blood cell transplantation. Secola R. **Semin Oncol Nurs** 1997 Aug;13(3):184–93 (52 ref.)
Diseases treated with blood cell transplants. Yoder LH. **Semin Oncol Nurs** 1997 Aug;13(3):164–71 (60 ref.)
Neonatal oncology: diagnostic and therapeutic dilemmas. Weitzman S, et al. **Semin Perinatol** 1997 Feb;21(1):102–11 (52 ref.)
New therapeutic approaches based on gene transfer techniques. Chong H, et al. **Springer Semin Immunopathol** 1996;18(2):149–70 (140 ref.)
Monoclonal antibodies in cancer therapy. Gruber R, et al. **Springer Semin Immunopathol** 1996;18(2):243–51 (57 ref.)
Does hyperbaric oxygen (HBO) have a cancer promoting effect? Almeling M, et al. **Strahlenther Onkol** 1996 Nov; 172 Suppl 2:30–1 (30 ref.)
When to treat dehydration in a terminally ill patient? Fainsinger RL, et al. **Support Care Cancer** 1997 May; 5(3):205–11 (54 ref.)
Cytotoxic lymphocytes: redirecting the cell–mediated immune response for the therapy of cancer. Kershaw MH, et al. **Ther Immunol** 1995 Jun;2(3):173–81 (80 ref.)
Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Schmitt M, et al. **Thromb Haemost** 1997 Jul; 78(1):285–96 (128 ref.)
Purging: the separation of normal from malignant cells for autologous transplantation. Champlin R. **Transfusion** 1996 Oct;36(10):910–8 (134 ref.)
Response evaluation as the key–point in results interpretation. Labianca R, et al. **Tumori** 1997 Jan–Feb;83(1 Suppl):S73–6 (17 ref.)
Physical activity in the prevention and management of cancer. Gerhardsson de Verdier M. **World Rev Nutr Diet** 1997;82:240–9 (84 ref.)
[Gene therapy of malignant tumors. Prospects of cytokine gene transfer vaccines] Bubeník J. **Cas Lek Cesk** 1997 Jan 8;136(1):17–21 (49 ref.) (Eng. Abstr.) **(Cze)**
[Principles of gene therapy in tumors] Vonka V. **Cas Lek Cesk** 1997 Jan 8;136(1):5–10 (31 ref.) (Eng. Abstr.) **(Cze)**
[Intensive chemotherapy with hematopoietic stem cell autograft in solid malignant tumors in children: current evaluation and prespectives (editorial)] Sommelet D. **Arch Pediatr** 1996 Jul;3(7):643–8 (17 ref.) **(Fre)**
[Recommendations for a successful cancer pain management in adults and children] Krakowski I, et al. **Bull Cancer** 1996 Nov;83 Suppl 1:9s–79s (340 ref.) **(Fre)**
[Pain in cancer patients. Practical attitude] Pichard–Léandri E. **J Chir (Paris)** 1997 May;134(1):14–21 (29 ref.) (Eng. Abstr.) **(Fre)**
[Immunotherapy in the treatment of cancers] Tartour E, et al. **Presse Med** 1996 Nov 16;25(35):1717–22 (35 ref.) (Eng. Abstr.) **(Fre)**
[Diagnostic, therapeutic and socioeconomic problems in geriatric oncology] Jerusalem G, et al. **Rev Med Liege** 1997 Apr;52(4):255–7 (9 ref.) **(Fre)**
[Palliative and supportive care: at the frontiers of medical omnipotence] Stiefel F, et al. **Rev Med Suisse Romande** 1997 Mar;117(3):191–5 (24 ref.) (Eng. Abstr.) **(Fre)**
[Gene therapy—current status and outlook] Hantzopoulos PA, et al. **Chirurg** 1996 Oct;67(10):980–3 (13 ref.) (Eng. Abstr.) **(Ger)**
[Transplantation of hematopoietic stem cells] Hertenstein B, et al. **Internist (Berl)** 1996 Mar;37(3):295–303 (41 ref.) **(Ger)**
[Cytokines] Kath R, et al. **Internist (Berl)** 1996 Oct; 37(10):1075–81 (30 ref.) **(Ger)**
[Oncology '96] Hartmann F, et al. **Med Klin** 1997 Feb 15; 92(2):83–100 (231 ref.) **(Ger)**
[Transplantation of hematopoietic stem cells. I: Definitions, principle indications, complications] Link H, et al. **Med Klin** 1997 Aug 15;92(8):480–91, 505 (106 ref.) (Eng. Abstr.) **(Ger)**
[Therapeutic ultrasound in tumor therapy. Principles, applications and new developments] Huber P, et al. **Radiologe** 1996 Jan;36(1):64–71 (32 ref.) (Eng. Abstr.) **(Ger)**
[JOMOL—immunostimulation and rejection of tumor cells?] Allewelt MC, et al. **Schweiz Rundsch Med Prax** 1997 May 14;86(20):856–60 (29 ref.) (Eng. Abstr.) **(Ger)**
[Current status of the clinical application of hematopoietic growth factors in oncology] Karthaus M, et al. **Ther Umsch** 1996 Nov;53(11):863–73 (49 ref.) (Eng. Abstr.) **(Ger)**
[Possibilities and prospects in gene therapy in cancer patients] Rochlitz CF, et al. **Ther Umsch** 1996 Nov;53(11):847–53 (14 ref.) (Eng. Abstr.) **(Ger)**
[Management of children with oncologic illnesses. Cooperation between the family physician and the clinic] Schwabe D. **Z Arztl Fortbild Qualitatssich** 1997 Jun; 91(3):267–75 (20 ref.) (Eng. Abstr.) **(Ger)**
[High–dose chemotherapy and peripheral hemtopoietic cells (PBPC) in solid tumors] Rosti G, et al. **Tumori** 1996 Mar–Apr;82(2 Suppl):S19–22 (27 ref.) (Eng. Abstr.) **(Ita)**
[Mobilization of peripheral blood stem cells with conventional chemotherapy] Venturini M, et al. **Tumori** 1996 Mar–Apr;82(2 Suppl):S14–8 (25 ref.) (Eng. Abstr.) **(Ita)**
[IL–4 and tumor immunity] Nogawa S. **Fukuoka Igaku Zasshi** 1996 Jan;87(1):8–13 (45 ref.) **(Jpn)**
[Recombinant virus–mediated transfer of the wild–type p53 gene is a potent therapeutic strategy for human cancer] Fujiwara T, et al. **Hum Cell** 1996 Mar;9(1):25–30 (17 ref.) (Eng. Abstr.) **(Jpn)**
[A new look at the history of tumor immunotherapy—for its fruitful future through overcoming the widespread cynicism] Takeuchi S. **Hum Cell** 1996 Mar;9(1):1–10 (41 ref.) (Eng. Abstr.) **(Jpn)**
[Antineoplastic effects of interleukin–12] Fujiwara H, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):611–5 (10 ref.) **(Jpn)**
[Antibody engineering and gene therapy in cancer] Hinoda Y, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Oct; 19(5):453–9 (17 ref.) **(Jpn)**
[Clinical evaluation of ultrasound hyperthermia system] Ono S, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Mar; 56(4):201–7 (48 ref.) (Eng. Abstr.) **(Jpn)**
[Circumventing multidrug resistance in human cancer by anti–ribozyme] Funato T. **Nippon Rinsho** 1997 May; 55(5):1116–21 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Characteristics of hyperthermia–induced apoptotic cell death] Honma T. **Nippon Rinsho** 1996 Jul;54(7):1949–54 (23 ref.) (Eng. Abstr.) **(Jpn)**
[Overcoming of multidrug resistance by anti–P–glycoprotein monoclonal antibody] Nokihara H, et al. **Nippon Rinsho** 1997 May;55(5):1128–34 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Future research for the treatment of intractable diseases] Mizushima Y. **Ryumachi** 1995 Dec;35(6):877–9 (6 ref.) **(Jpn)**
[Gene therapy—vectors and strategies] Huminiecki L. **Postepy Biochem** 1995;41(4):230–6 (50 ref.) **(Pol)**
[Intestinal obstruction in cancer patients. Palliative treatment] Costa I, et al. **Acta Med Port** 1997 May;10(5):381–5 (30 ref.) (Eng. Abstr.) **(Por)**
[Development of methods of local hyperthermia to achieve more marked tumor pathomorphism] Kharchenko VP, et al. **Arkh Patol** 1996 Jan–Feb;58(1):70–4 (47 ref.) (Eng. Abstr.) **(Rus)**
[The role of psycho–oncology in the treatment of cancer patients] Blinov NN, et al. **Vopr Onkol** 1996;42(5):86–9 (16 ref.) (Eng. Abstr.) **(Rus)**
[Current issues in immunotherapy of tumors in the context of macrophage reaction to tissue damage fixed through evolution] Okulov VB. **Vopr Onkol** 1997;43(1):102–6 (33 ref.) **(Rus)**
[Evaluation of quality of life in oncology] Radosavljević D, et al. **Srp Arh Celok Lek** 1997 Sep–Oct;125(9–10):303–10 (36 ref.) (Eng. Abstr.) **(Scc)**
[A scientist's day–dream or future reality? Specific immunotherapy against cancer] Kiessling R, et al. **Lakartidningen** 1997 Apr 23;94(17):1595–600 (20 ref.) **(Swe)**

ULTRASTRUCTURE

Standardized AgNOR analysis: its usefulness in surgical oncology. Ofner D, et al. **Histochem Cell Biol** 1996 Aug; 106(2):193–6 (32 ref.)
Radiolabeled peptides and other ligands for receptors overexpressed in tumor cells for imaging neoplasms. McAfee JG, et al. **Nucl Med Biol** 1996 Aug;23(6):673–6 (36 ref.)

VETERINARY

Genetic immunotherapy for cancer. Elmslie RE, et al. **Semin Vet Med Surg (Small Anim)** 1997 Aug;12(3):193–205 (93 ref.)
Chronic pain: osteoarthritis and cancer. Kyles AE, et al. **Semin Vet Med Surg (Small Anim)** 1997 May;12(2):122–32 (77 ref.)
The potential role and mechanisms of FeLV vaccine–induced neoplasms. Macy DW. **Semin Vet Med Surg (Small Anim)** 1995 Nov;10(4):234–7 (36 ref.)
Molecular tools for the diagnosis of animal diseases. Alleman AR. **Vet Clin North Am Small Anim Pract** 1996 Sep; 26(5):1223–37 (35 ref.)
Clinical trials in veterinary oncology: a clinician's viewpoint. Crow SE. **Vet Clin North Am Small Anim Pract** 1996 Jan; 26(1):29–37 (18 ref.)
Surgical oncology. Harvey J. **Vet Clin North Am Small Anim Pract** 1996 Jan;26(1):9–16 (11 ref.)
Radiation therapy: a radiation oncologist's point of view. Mauldin GN. **Vet Clin North Am Small Anim Pract** 1996 Jan;26(1):17–27 (22 ref.)
Multimodality therapy: using the best available treatments together rationally. Rosenthal RC. **Vet Clin North Am Small Anim Pract** 1996 Jan;26(1):1–8 (5 ref.)
Interstitial implant brachytherapy in small animals. Walker

MA. **Vet Clin North Am Small Anim Pract** 1997 Jan; 27(1):59–71 (6 ref.)
Veterinary cancer epidemiology. Misdorp W. **Vet Q** 1996 Mar;18(1):32–6 (53 ref.)
[Application possibilities of laser surgery in veterinary medicine. 3: Literature review and some case reports] Weigand K, et al. **Tierarztl Prax** 1997 Jul;25(4):289–302 (73 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

Epstein–Barr virus genes and cancer cells. Farrell PJ, et al. **Biomed Pharmacother** 1997;51(6–7):258–67 (82 ref.)
Oncogenes and antioncogenes in the development of HPV associated tumors. Crawford L, et al. **Clin Dermatol** 1997 Mar–Apr;15(2):207–15 (96 ref.)
Molecular mechanisms of virus–induced carcinogenesis: the interaction of viral factors with cellular tumor suppressor proteins. Hoppe–Seyler F, et al. **J Mol Med** 1995 Nov; 73(11):529–38 (96 ref.)
Analysis of cytokine profiles in patients with human papillomavirus–associated neoplasms [editorial; comment] Wu TC, et al. **J Natl Cancer Inst** 1997 Feb 5;89(3):185–7 (33 ref.) Comment on: J Natl Cancer Inst 1997 Feb 5;89(3):245–50.
[EBV–related malignancies and thioredoxin] Noda N, et al. **Nippon Rinsho** 1997 Feb;55(2):461–6 (24 ref.) (Eng. Abstr.) **(Jpn)**
[Epstein–Barr virus oncogenesis and risk factors] Osato T. **Nippon Rinsho** 1997 Feb;55(2):289–92 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Molecular pathological studies on Epstein–Barr virus (EBV) infected cells and EBV–associated tumor cells] Yamamoto T, et al. **Nippon Rinsho** 1997 Feb;55(2):452–60 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Viruses and malignant diseases] Jovanović J, et al. **Med Pregl** 1997 Jan–Feb;50(1–2):23–6 (23 ref.) (Eng. Abstr.) **(Scr)**

NEOPLASMS, ADIPOSE TISSUE

GENETICS

Combined morphologic and karyotypic study of 59 atypical lipomatous tumors. Evaluation of their relationship and differential diagnosis with other adipose tissue tumors (a report of the CHAMP Study Group). Rosai J, et al. **Am J Surg Pathol** 1996 Oct;20(10):1182–9 (21 ref.)

PATHOLOGY

Combined morphologic and karyotypic study of 59 atypical lipomatous tumors. Evaluation of their relationship and differential diagnosis with other adipose tissue tumors (a report of the CHAMP Study Group). Rosai J, et al. **Am J Surg Pathol** 1996 Oct;20(10):1182–9 (21 ref.)
The contribution of image cytometry and artificial intelligence–related methods of numerical data analysis for adipose tumor histopathologic classification. Goldschmidt D, et al. **Lab Invest** 1996 Sep;75(3):295–306 (62 ref.)

NEOPLASMS, BASAL CELL

DIAGNOSIS

[Adenoid cystic cribriform trichoblastoma] Betti R, et al. **Hautarzt** 1997 Jun;48(6):417–9 (13 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Malignant proliferating trichilemmal tumor [letter] Noto G, et al. **Am J Dermatopathol** 1997 Apr;19(2):202–4 (16 ref.)
Trichoepithelioma with an adjacent basal cell carcinoma, transformation or collision? Wallace ML, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):343–5 (10 ref.)
Birt–Hogg–Dubé syndrome: a review and presentation of the first case with oral lesions. Nadershahi NA, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Apr;83(4):496–500 (19 ref.)

NEOPLASMS, BONE TISSUE

VETERINARY

Tumours of the bone. Pour PM. **IARC Sci Publ** 1996; (126):385–426 (84 ref.)

NEOPLASMS, BREAST, MALE see **BREAST NEOPLASMS, MALE**

NEOPLASMS, CONNECTIVE TISSUE

see related
SOFT TISSUE NEOPLASMS

Malignant cartilaginous tumors of the mediastinum: clinicopathological study of six cases presenting as extraskeletal soft tissue masses. Suster S, et al. **Hum Pathol** 1997 May;28(5):588–94 (19 ref.)

DIAGNOSIS

Subungual giant cell tumor of the tendon sheath. Abimelec P, et al. **Cutis** 1996 Oct;58(4):273–5 (10 ref.)

PATHOLOGY

Malignant giant cell tumor of the tendon sheaths and joints (malignant pigmented villonodular synovitis). Bertoni F, et al. **Am J Surg Pathol** 1997 Feb;21(2):153–63 (14 ref.)
Benign and malignant cartilage tumors of bone and joint: their anatomic and theoretical basis with an emphasis on radiology, pathology and clinical biology. I. The intramedullary cartilage tumors. Brien EW, et al. **Skeletal Radiol** 1997 Jun;26(6):325–53 (41 ref.)

VETERINARY

Tumours of the lower respiratory tract. Mohr U, et al. **IARC Sci Publ** 1996;(126):189–222 (162 ref.)
Tumours of the bone. Pour PM. **IARC Sci Publ** 1996; (126):385–426 (84 ref.)

NEOPLASMS, DENTAL TISSUE see **ODONTOGENIC TUMORS**

NEOPLASMS, EMBRYONAL AND MIXED see **NEOPLASMS, GERM CELL AND EMBRYONAL**

NEOPLASMS, EXPERIMENTAL

see related
NEOPLASM TRANSPLANTATION
TUMOR VIRUS INFECTIONS

BLOOD SUPPLY

Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Hanahan D, et al. **Eur J Cancer** 1996 Dec;32A(14):2386–93 (44 ref.)

CHEMICALLY INDUCED

A review of the chronic toxicity, carcinogenicity, and possible mechanisms of action of inorganic acid mists in animals. Swenberg JA, et al. **Crit Rev Toxicol** 1997 May; 27(3):253–9 (28 ref.)
Alternatives to the 2–species bioassay for the identification of potential human carcinogens. Ashby J. **Hum Exp Toxicol** 1996 Mar;15(3):183–202 (67 ref.)
The role of cell proliferation in chemically induced carcinogenesis. Foster JR. **J Comp Pathol** 1997 Feb; 116(2):113–44 (109 ref.)
New nonpurified diet (NTP–2000) for rodents in the National Toxicology Program's toxicology and carcinogenesis studies. Rao GN. **J Nutr** 1997 May;127(5 Suppl):842S–846S (22 ref.)
Possible carcinogenic potential of dimethylarsinic acid as assessed in rat in vivo models: a review. Yamamoto S, et al. **Mutat Res** 1997 Jun;386(3):353–61 (42 ref.)
2,3,7,8–Tetrachlorodibenzo–p–dioxin mechanistic data and risk assessment: gene regulation, cytotoxicity, enhanced cell proliferation, and tumor promotion. Whysner J, et al. **Pharmacol Ther** 1996;71(1–2):193–223 (167 ref.)
Rejection antigens in chemically induced tumors [see comments] Klein G. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):5991–2 (14 ref.) Comment in: Proc Natl Acad Sci U S A 1997 Jun 10;94(12):6375–9.
Trichloroethylene cancer risk: simplified calculation of PBPK–based MCLs for cytotoxic end points. Bogen KT, et al. **Regul Toxicol Pharmacol** 1997 Feb;25(1):26–42 (121 ref.)
Cancer risk assessment at the crossroads: the need to turn to a biological approach. Clayson DB, et al. **Regul Toxicol Pharmacol** 1996 Aug;24(1 Pt 1):45–59 (112 ref.)
A mechanistic interpretation of the oncogenicity of chlorothalonil in rodents and an assessment of human relevance. Wilkinson CF, et al. **Regul Toxicol Pharmacol** 1996 Aug;24(1 Pt 1):69–84 (94 ref.)
A critical appraisal of the value of the mouse cancer bioassay in safety assessment. Alden CL, et al. **Toxicol Pathol** 1996 Nov–Dec;24(6):722–5 (18 ref.)
Experimental chemical carcinogenesis in fish. Bunton TE. **Toxicol Pathol** 1996 Sep–Oct;24(5):603–18 (217 ref.)
Concepts of cell death and application to carcinogenesis. Schulte–Hermann R, et al. **Toxicol Pathol** 1997 Jan–Feb; 25(1):89–93 (36 ref.)
The pathways of cell death: oncosis, apoptosis, and necrosis. Trump BF, et al. **Toxicol Pathol** 1997 Jan–Feb;25(1):82–8 (35 ref.)

DRUG THERAPY

Protocols for the treatment of human tumor xenografts with camptothecins. Giovanella BC, et al. **Ann N Y Acad Sci** 1996 Dec 13;803:181–7 (15 ref.)
Restoration of aging reduced immunity is possible with immunomodulators and is applicable to cancer treatment and prevention [editorial] Mathé G, et al. **Biomed Pharmacother** 1997;51(5):193–9 (58 ref.)
Cytokines in animal models of cancer. Burke F, et al. **Biotherapy** 1996;8(3–4):229–41 (147 ref.)
The use of chemotherapy resistance in cancer treatment. Deisseroth AB, et al. **Cancer J Sci Am** 1997 Mar–Apr; 3(2):60–9 (50 ref.)
Glycosphingolipid antigens and cancer therapy. Hakomori S, et al. **Chem Biol** 1997 Feb;4(2):97–104 (47 ref.)
Irinotecan (CPT–11): pharmacology and clinical applications. Masuda N, et al. **Crit Rev Oncol Hematol** 1996 Sep; 24(1):3–26 (114 ref.)
The preclinical basis for broad–spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol). Capizzi RL. **Eur J Cancer** 1996;32A Suppl 4:S5–16 (88 ref.)
Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. O'Reilly MS. **EXS** 1997;79:273–94 (62 ref.)
Quinacrine: sclerosing agent of the utero–tubal junction in women, with anticarcinogenic actions in transplanted tumors in mice. Zipper J, et al. **Int J Gynaecol Obstet** 1995 Dec;51 Suppl 1:S47–55 (73 ref.)
Inhibition of and sensitization to the lethal effects of tumor necrosis factor. Brouckaert P, et al. **J Inflamm** 1995–96; 47(1–2):18–26 (31 ref.)
Correlation of subcellular and intratumoral photosensitizer localization with ultrastructural features after photodynamic therapy. Peng Q, et al. **Ultrastruct Pathol** 1996 Mar–Apr;20(2):109–129 (200 ref.)

ETIOLOGY

Overview of fat and calories in tumorigenesis. Kritchevsky D. **Adv Exp Med Biol** 1996;399:1–12 (91 ref.)
Testing electromagnetic fields for potential carcinogenic activity: a critical review of animal models. McCann J, et al. **Environ Health Perspect** 1997 Feb;105 Suppl 1:81–103 (248 ref.)
The linearized multistage model and the future of quantitative risk assessment. Crump KS. **Hum Exp Toxicol** 1996 Oct; 15(10):787–98 (50 ref.)
Short–term animal studies for detecting inflammation, fibrosis and pre–neoplastic changes induced by fibres. Donaldson K. **IARC Sci Publ** 1996;(140):97–106 (54 ref.)
Evaluation and use of animal models to assess mechanisms of fibre carcinogenicity. Oberdörster G. **IARC Sci Publ** 1996;(140):107–25 (80 ref.)
Role of disrupted gap junctional intercellular communication in detection and characterization of carcinogens. Yamasaki H. **Mutat Res** 1996 Sep;365(1–3):91–105 (107 ref.)
Tumors derived from antigen presenting cells. Levitsky HI. **Semin Immunol** 1996 Oct;8(5):281–7 (38 ref.)
[Super–low frequency electric and magnetic fields and their role in development of neoplasms] Muratov EI. **Vopr Onkol** 1996;42(5):13–21 (60 ref.) **(Rus)**

GENETICS

Telomere structure and telomerase expression during mouse development and tumorigenesis. Kipling D. **Eur J Cancer** 1997 Apr;33(5):792–800 (44 ref.)
Animal models and the molecular pathology of cancer. Lovejoy EA, et al. **J Pathol** 1997 Feb;181(2):130–5 (42 ref.)
Studies of oncogene activation and tumor suppressor gene inactivation in normal and neoplastic rodent tissue. Buzard GS. **Mutat Res** 1996 Sep;365(1–3):43–58 (111 ref.)
Estrogens and the genetic control of tumor growth. Gorski J, et al. **Prog Clin Biol Res** 1997;396:233–43 (23 ref.)
Mechanisms leading to the expression of recessive alleles: the use of polymorphic microsatellites and whole–chromosome painting probes to analyze mouse tumors, mutants, and micronuclei. Caspary WJ, et al. **Recent Results Cancer Res** 1997;143:161–82 (82 ref.)
The p53–deficient mouse: a model for basic and applied cancer studies. Donehower LA. **Semin Cancer Biol** 1996 Oct;7(5):269–78 (73 ref.)
DNA mismatch repair deficient mice in cancer research. Prolla TA, et al. **Semin Cancer Biol** 1996 Oct;7(5):241–7 (67 ref.)
[Apropos of the studies of Lewis, Nusslein–Volhard and Wieschaus, 1995 Nobel prize winners, on the genetic mechanisms of embryonic development of drosophila. A model for human cancer progression] Cillo C. **Bull Cancer** 1996 Jul;83(7):527–34 (30 ref.) (Eng. Abstr.) **(Fre)**
[Carcinogenesis and ontogenesis: chief trends and results of investigations] Anisimov VN. **Vopr Onkol** 1997;43(1):88–94 (35 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Role of the major histocompatibility complex region in reproduction, cancer, and autoimmunity. Gill TJ 3rd. **Am J Reprod Immunol** 1996 Mar;35(3):211–5 (14 ref.)
Therapy with cultured T cells: principles revisited. Cheever MA, et al. **Immunol Rev** 1997 Jun;157:177–94 (56 ref.)
Alterations in T cells of cancer–bearers: whence specificity? Levey DL, et al. **Immunol Today** 1996 Aug;17(8):365–8 (39 ref.)
Cytokines, tumour–cell death and immunogenicity: a question of choice. Musiani P, et al. **Immunol Today** 1997 Jan; 18(1):32–6 (38 ref.)
Rejection antigens in chemically induced tumors [see comments] Klein G. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):5991–2 (14 ref.) Comment in: Proc Natl Acad Sci U S A 1997 Jun 10;94(12):6375–9.
A sequence of cellular and molecular events involved in IL12–induced tumour regression. Fujiwara H, et al. **Res Immunol** 1995 Sep–Oct;146(7–8):638–44 (25 ref.)
Is cancer dangerous to the immune system? Fuchs EJ, et al. **Semin Immunol** 1996 Oct;8(5):271–80 (46 ref.)
Tumors derived from antigen presenting cells. Levitsky HI. **Semin Immunol** 1996 Oct;8(5):281–7 (38 ref.)

NEOPLASMS, EXPERIMENTAL

Genetically engineered superantigens in experimental tumor therapy. Antonsson P, et al.
Springer Semin Immunopathol 1996;17(4):397–410 (34 ref.)

METABOLISM

Inhibition of experimental metastasis by enzyme inhibitors from microorganisms and plants. Umezawa K.
Adv Enzyme Regul 1996;36:267–81 (22 ref.)
Steroid hormones and cancer: (II) Lessons from experimental systems. Miller WR, et al. **Eur J Surg Oncol** 1997 Feb; 23(1):72–83 (160 ref.)
Iron deprivation and cancer: a view beginning with studies of monoclonal antibodies against the transferrin receptor. Kemp JD. **Histol Histopathol** 1997 Jan;12(1):291–6 (52 ref.)
Xenograft model systems for human melanoma. Rofstad EK, et al. **Mol Med Today** 1996 Sep;2(9):394–403 (40 ref.)
[Metabolic host–tumor relationships during perinatal phase] Argilés JM, et al. **Med Clin (Barc)** 1997 Jun 28; 109(5):186–94 (52 ref.) **(Spa)**

PATHOLOGY

Fundamentals of cancer cell biology. Stoker M.
Adv Cancer Res 1996;70:1–19 (77 ref.)
Programmed cell death and radioresistance. Meyn RE, et al. **Cancer Metastasis Rev** 1996 Mar;15(1):119–31 (78 ref.)
Cytokines, tumour–cell death and immunogenicity: a question of choice. Musiani P, et al. **Immunol Today** 1997 Jan; 18(1):32–6 (38 ref.)
Stress is good and bad for tumors [news] Yuan F.
Nat Biotechnol 1997 Aug;15(8):722–3 (11 ref.)
Terms of attachment: SPARC and tumorigenesis [news] Sage EH. **Nat Med** 1997 Feb;3(2):144–6 (15 ref.)
The pathways of cell death: oncosis, apoptosis, and necrosis. Trump BF, et al. **Toxicol Pathol** 1997 Jan–Feb;25(1):82–8 (35 ref.)
[Adhesion molecules and cancer metastasis] Ota I, et al.
Rinsho Byori 1997 Jun;45(6):528–33 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Development of methods of local hyperthermia to achieve more marked tumor pathomorphism] Kharchenko VP, et al. **Arkh Patol** 1996 Jan–Feb;58(1):70–4 (47 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

1995 Whitaker Lecture: delivery of molecules, particles, and cells to solid tumors. Jain RK. **Ann Biomed Eng** 1996 Jul–Aug;24(4):457–73 (132 ref.)
Growth factors in mechanisms of malignancy: roles for TGF-beta and FGF. Wright JA, et al.
Histol Histopathol 1996 Apr;11(2):521–36 (145 ref.)
Melatonin in mast cells and tumor radiosensitivity. Kvetnoy IM, et al. **J Pineal Res** 1997 Apr;22(3):169–70 (16 ref.)
Biology of a brain metastasis. Walsh JW.
Neurosurg Clin N Am 1996 Jul;7(3):369–76 (53 ref.)

PREVENTION & CONTROL

Cancer chemoprevention by polyphenols in green tea and artichoke. Agarwal R, et al. **Adv Exp Med Biol** 1996; 401:35–50 (107 ref.)
Organosulfur compounds and cancer. Lea MA.
Adv Exp Med Biol 1996;401:147–54 (60 ref.)
Allium vegetables and the potential for chemoprevention of cancer. Wargovich MJ, et al. **Adv Exp Med Biol** 1996; 401:171–7 (34 ref.)
Effects of tea on carcinogenesis in animal models and humans. Yang CS, et al. **Adv Exp Med Biol** 1996;401:51–61 (82 ref.)
Inhibition of tumorigenesis in animals. Wattenberg LW.
IARC Sci Publ 1996;(139):151–8 (43 ref.)
Interferons in precancer and cancer prevention: where are we? Tanneberger S, et al. **J Interferon Cytokine Res** 1996 May;16(5):339–46 (113 ref.)
Antisense DNA toward type I protein kinase A produces sustained inhibition of tumor growth. Cho-Chung YS.
Proc Assoc Am Physicians 1997 Jan;109(1):23–32 (62 ref.)

RADIONUCLIDE IMAGING

A review of new oncotropic tracers for PET imaging. Lang L, et al. **Nucl Med Biol** 1996 Aug;23(6):669–72 (34 ref.)

RADIOTHERAPY

Programmed cell death and radioresistance. Meyn RE, et al. **Cancer Metastasis Rev** 1996 Mar;15(1):119–31 (78 ref.)
Melatonin in mast cells and tumor radiosensitivity. Kvetnoy IM, et al. **J Pineal Res** 1997 Apr;22(3):169–70 (16 ref.)

SECONDARY

Biology of a brain metastasis. Walsh JW.
Neurosurg Clin N Am 1996 Jul;7(3):369–76 (53 ref.)

THERAPY

Cellular and molecular mechanisms underlying IL–12–induced tumor regression. Fujiwara H, et al.
Ann N Y Acad Sci 1996 Oct 31;795:294–309 (47 ref.)
Potential of microsensor-based feedback bioactuators for biophysical cancer treatment. Wolf B, et al.
Biosens Bioelectron 1997;12(4):301–9 (58 ref.)
Iron deprivation and cancer: a view beginning with studies of monoclonal antibodies against the transferrin receptor. Kemp JD. **Histol Histopathol** 1997 Jan;12(1):291–6 (52 ref.)
Therapy with cultured T cells: principles revisited. Cheever MA, et al. **Immunol Rev** 1997 Jun;157:177–94 (56 ref.)
The contribution of animal models to the development of treatments for hematologic recovery following myeloablative therapy: a review. Schneidkraut MJ, et al. **J Hematother** 1996 Dec;5(6):631–46 (226 ref.)
Specific cytotoxic T lymphocytes in gene therapy. Altenschmidt U, et al. **J Mol Med** 1997 Apr;75(4):259–66 (76 ref.)
p53 as a target for anti–cancer immunotherapy. Chen HL, et al. **Mol Med Today** 1997 Apr;3(4):160–7 (48 ref.)
Developing particle–mediated gene–transfer technology for research into gene therapy of cancer. Yang NS, et al.
Mol Med Today 1996 Nov;2(11):476–81 (30 ref.)
A sequence of cellular and molecular events involved in IL12–induced tumour regression. Fujiwara H, et al.
Res Immunol 1995 Sep–Oct;146(7–8):638–44 (25 ref.)
Genetically engineered superantigens in experimental tumor therapy. Antonsson P, et al.
Springer Semin Immunopathol 1996;17(4):397–410 (34 ref.)
New therapeutic approaches based on gene transfer techniques. Chong H, et al.
Springer Semin Immunopathol 1996;18(2):149–70 (140 ref.)

ULTRASTRUCTURE

Correlation of subcellular and intratumoral photosensitizer localization with ultrastructural features after photodynamic therapy. Peng Q, et al.
Ultrastruct Pathol 1996 Mar–Apr;20(2):109–129 (200 ref.)

NEOPLASMS, FIBROUS TISSUE

VETERINARY

Tumours of soft tissues. Berman LD. **IARC Sci Publ** 1996; (126):321–49 (79 ref.)
Tumours of the female genital system. Ribas JL, et al.
IARC Sci Publ 1996;(126):281–305 (118 ref.)
Tumours of the kidney. Tsuda H, et al. **IARC Sci Publ** 1996; (126):223–42 (119 ref.)

NEOPLASMS, GERM CELL AND EMBRYONAL

DIAGNOSIS

Is it feasible to diagnose germ–cell tumors by fine–needle aspiration biopsy? Akhtar M, et al. **Diagn Cytopathol** 1997 Jan;16(1):72–7 (27 ref.)
Testicular carcinoma. O'Callaghan A, et al.
Postgrad Med J 1997 Aug;73(862):481–6 (23 ref.)

GENETICS

Intracranial malignant germ cell tumor and the Klinefelter syndrome. Case report and review of the literature. Prall JA, et al. **Pediatr Neurosurg** 1995;23(4):219–24 (33 ref.)

PATHOLOGY

The growing teratoma syndrome in a nongerminomatous germ cell tumor of the pineal gland: a case report and review. O'Callaghan AM, et al. **Cancer** 1997 Sep 1; 80(5):942–7 (32 ref.)
Is it feasible to diagnose germ–cell tumors by fine–needle aspiration biopsy? Akhtar M, et al. **Diagn Cytopathol** 1997 Jan;16(1):72–7 (27 ref.)
Intracaval extension of germ cell carcinoma: diagnosis via endovascular biopsy and a review of the literature. Fidias P, et al. **Eur Urol** 1997;31(3):376–9 (32 ref.)
Late recurrence of clear cell sarcoma of the kidney. Kusumakumary P, et al. **Med Pediatr Oncol** 1997 May; 28(5):355–7 (12 ref.)
[Clear cell sarcoma of the kidney] Nakamura H.
Ryoikibetsu Shokogun Shirizu 1997;(16 Pt 1):463–5 (20 ref.) **(Jpn)**

SURGERY

Primary intrasellar mixed germ–cell tumor with precocious puberty and diabetes insipidus. Cho DY, et al.
Childs Nerv Syst 1997 Jan;13(1):42–6 (14 ref.)
Pancreatoblastoma in children. Case report and review of the literature. Willnow U, et al. **Eur J Pediatr Surg** 1996 Dec;6(6):369–72 (47 ref.)

THERAPY

Current diagnosis and treatment of central nervous system germ cell tumours. Sawamura Y. **Curr Opin Neurol** 1996 Dec;9(6):419–23 (47 ref.)
Germ cell tumors. Bajorin DF, et al.
Curr Ther Endocrinol Metab 1997;6:387–92 (12 ref.)
Testicular carcinoma. O'Callaghan A, et al.
Postgrad Med J 1997 Aug;73(862):481–6 (23 ref.)
[Risk of secondary neoplasia after treatment of malignant germ cell tumors of the testis] Bokemeyer C, et al.
Med Klin 1996 Nov 15;91(11):703–10 (51 ref.) **(Ger)**
[Effect of biological prognostic factors on therapy of non–seminomatous stage I testicular tumors--an assessment of the current status] Kuczyk MA, et al. **Urologe A** 1996 Jan;35(1):35–45 (94 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Tumours of the pancreas. Pour PM, et al.
IARC Sci Publ 1996;(126):149–73 (29 ref.)

NEOPLASMS, GLANDULAR AND EPITHELIAL

Primary epithelial hepatic malignancies: etiology, epidemiology, and outcome after subtotal and total hepatic resection. Nagorney DM, et al. **Surg Oncol Clin N Am** 1996 Apr;5(2):283–300 (121 ref.)

DIAGNOSIS

Magnetic resonance imaging of thymic epithelial tumors. Kushihashi T, et al. **Crit Rev Diagn Imaging** 1996 Aug; 37(3):191–259 (76 ref.)
Glandular abnormalities: dilemmas in cytological prediction and clinical management [comment] Waddell CA.
Cytopathology 1997 Feb;8(1):27–30 (20 ref.) Comment on: Cytopathology 1997 Feb;8(1):20–6.

PATHOLOGY

Primary thymic epithelial neoplasms showing combined features of thymoma and thymic carcinoma. A clinicopathologic study of 22 cases. Suster S, et al.
Am J Surg Pathol 1996 Dec;20(12):1469–80 (32 ref.)
Tumours of the oral cavity, buccal pouch, oesophagus, forestomach and salivary glands. Takahashi M, et al.
IARC Sci Publ 1996;(126):59–77 (60 ref.)
Mucocutaneous neoplasms in patients with human immunodeficiency virus infection. Cockerell CJ.
Semin Diagn Pathol 1996 Feb;13(1):19–39 (131 ref.)

THERAPY

Glandular abnormalities: dilemmas in cytological prediction and clinical management [comment] Waddell CA.
Cytopathology 1997 Feb;8(1):27–30 (20 ref.) Comment on: Cytopathology 1997 Feb;8(1):20–6.

VETERINARY

Tumours of the skin. Ghadially FN, et al.
IARC Sci Publ 1996;(126):1–43 (111 ref.)
Tumours of the liver. Moore MA, et al. **IARC Sci Publ** 1996; (126):79–108 (83 ref.)
Tumours of the testis and accessory male sex glands. Ribas JL, et al. **IARC Sci Publ** 1996;(126):261–80 (94 ref.)
Tumours of the glandular stomach. Takahashi M, et al.
IARC Sci Publ 1996;(126):127–35 (29 ref.)
Tumours of the intestine. Takahashi M, et al.
IARC Sci Publ 1996;(126):137–47 (29 ref.)
Tumours of the kidney. Tsuda H, et al. **IARC Sci Publ** 1996; (126):223–42 (119 ref.)

VIROLOGY

Epstein–Barr virus in tumours. Anagnostopoulos I, et al.
Histopathology 1996 Oct;29(4):297–315 (182 ref.)

NEOPLASMS, GONADAL TISSUE

VETERINARY

Tumours of the testis and accessory male sex glands. Ribas JL, et al. **IARC Sci Publ** 1996;(126):261–80 (94 ref.)
Tumours of the female genital system. Ribas JL, et al.
IARC Sci Publ 1996;(126):281–305 (118 ref.)

NEOPLASMS, HORMONE-DEPENDENT

see related
ANTINEOPLASTIC AGENTS, HORMONAL

Southwest Oncology Group studies in hormone–refractory prostate cancer. Hussain MH, et al. **Semin Oncol** 1996 Dec; 23(6 Suppl 14):24–7 (13 ref.)
Preclinical models of prostate cancer. Royai R, et al.
Semin Oncol 1996 Dec;23(6 Suppl 14):35–40 (18 ref.)

BLOOD

Metastatic prostate cancer: assessment of response to systemic therapy. Dreicer R. **Semin Urol Oncol** 1997 Feb;15(1):28–32 (36 ref.)

DRUG THERAPY

Endocrine resistance in advanced breast cancer. Dowsett M.
Acta Oncol 1996;35 Suppl 5:91–5 (30 ref.)
Endocrine treatment of advanced breast cancer. Dowsett M.
Acta Oncol 1996;35 Suppl 5:68–72 (32 ref.)
Novel endocrine therapies in breast cancer. Klijn JG, et al.
Acta Oncol 1996;35 Suppl 5:30–7 (90 ref.)
Aromatase inhibition for breast cancer treatment. Lønning PE. **Acta Oncol** 1996;35 Suppl 5:38–43 (31 ref.)
Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer. Lykkesfeldt AE. **Acta Oncol** 1996; 35 Suppl 5:9–14 (60 ref.)
Proper sequence of endocrine therapies in advanced breast cancer. Rose C. **Acta Oncol** 1996;35 Suppl 5:44–9 (14 ref.)
Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.

Blackledge G, et al. **Anticancer Drugs** 1996 Jan;7(1):27–34 (38 ref.)

Androgen deprivation and antagonism in the treatment of advanced prostatic carcinoma. Gibbs SJ, et al. **Clin Oncol (R Coll Radiol)** 1996;8(6):346–52 (44 ref.)

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. Small EJ, et al. **J Clin Oncol** 1997 Jan;15(1):382–8 (39 ref.)

Overview of Canadian trials in hormonally resistant prostate cancer. Moore MJ, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 14):15–9 (7 ref.)

New therapeutic agents for hormone-refractory prostate cancer. Roth BJ. **Semin Oncol** 1996 Dec;23(6 Suppl 14):49–55 (56 ref.)

Cancer and Leukemia Group B trials for advanced prostate cancer. Small EJ, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 14):28–31 (13 ref.)

Estramustine-based chemotherapy. Hudes G. **Semin Urol Oncol** 1997 Feb;15(1):13–9 (47 ref.)

Other chemotherapy regimens including mitoxantrone and suramin. Siu LL, et al. **Semin Urol Oncol** 1997 Feb; 15(1):20–7 (38 ref.)

Intermittent androgen deprivation in advanced prostate cancer. de Reijke TM. **Urol Res** 1997;25 Suppl 2:S63–6 (35 ref.)

[Tamoxifen: modern drug therapy of estrogen-dependent breast tumors] Jovanović-Mićić D, et al. **Med Pregl** 1996; 49(7–8):287–90 (20 ref.) (Eng. Abstr.) **(Scr)**

ETIOLOGY

Medical hypothesis: bifunctional genetic-hormonal pathways to breast cancer. Davis DL, et al. **Environ Health Perspect** 1997 Apr;105 Suppl 3:571–6 (45 ref.)

Hormone-associated cancer: mechanistic similarities between human breast cancer and estrogen-induced kidney carcinogenesis in hamsters. Liehr JG. **Environ Health Perspect** 1997 Apr;105 Suppl 3:565–9 (54 ref.)

Endogenous estrogens and breast cancer risk: the case for prospective cohort studies. Toniolo PG. **Environ Health Perspect** 1997 Apr;105 Suppl 3:587–92 (72 ref.)

GENETICS

Medical hypothesis: bifunctional genetic-hormonal pathways to breast cancer. Davis DL, et al. **Environ Health Perspect** 1997 Apr;105 Suppl 3:571–6 (45 ref.)

Estrogens and the genetic control of tumor growth. Gorski J, et al. **Prog Clin Biol Res** 1997;396:233–43 (23 ref.)

METABOLISM

Insulin-like growth factors in breast cancer. Helle SI, et al. **Acta Oncol** 1996;35 Suppl 5:19–22 (29 ref.)

Estradiol metabolism: an endocrine biomarker for modulation of human mammary carcinogenesis. Telang NT, et al. **Environ Health Perspect** 1997 Apr;105 Suppl 3:559–64 (45 ref.)

Steroid hormones and cancer: (II) Lessons from experimental systems. Miller WR, et al. **Eur J Surg Oncol** 1997 Feb; 23(1):72–83 (160 ref.)

Three-component model of oestrogen formation and regulation of intratumoural oestrogen pool in breast neoplasms. Berstein LM, et al. **Med Hypotheses** 1995 Dec; 45(6):588–90 (23 ref.)

Estrogen receptor status of breast cancer: a marker of different stages of tumor or different entities of the disease? Zhu K, et al. **Med Hypotheses** 1997 Jul;49(1):69–75 (61 ref.)

Clinical use of posttherapy prostate-specific antigen changes in advanced prostate cancer. Kelly WK, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 14):8–14 (36 ref.)

PATHOLOGY

Aromatase inhibitors in clinical practice: current status and a look to the future. Harvey HA. **Semin Oncol** 1996 Aug; 23(4 Suppl 9):33–8 (13 ref.)

PREVENTION & CONTROL

Medicinal drugs with hormonal activity as chemopreventive agents. Cuzick J. **IARC Sci Publ** 1996;(139):99–114 (116 ref.)

RADIOTHERAPY

Palliative radiotherapy in prostate cancer. Catton CN, et al. **Semin Urol Oncol** 1997 Feb;15(1):65–72 (70 ref.)

THERAPY

Hormonal dependency of cerebral meningiomas. Schrell UM, et al. **Acta Neurochir Suppl (Wien)** 1996;65:54–7 (32 ref.)

Treatment of metastatic carcinoma of the prostate. Goethuys H, et al. **Am J Clin Oncol** 1997 Feb;20(1):40–5 (47 ref.)

Prostate cancer treatment strategies based on tumor-specific biological principles: future directions. Carducci MA, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 14):56–62 (41 ref.)

Quality of life in advanced prostate cancer. Fosså SD. **Semin Oncol** 1996 Dec;23(6 Suppl 14):32–4 (15 ref.)

Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach. Slovin SF, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 14):41–8 (61 ref.)

Supportive care in the patient with hormone refractory prostate cancer. Esper PS, et al. **Semin Urol Oncol** 1997 Feb;15(1):56–64 (35 ref.)

Novel therapies for advanced prostate cancer. Konety BR, et al. **Semin Urol Oncol** 1997 Feb;15(1):33–42 (80 ref.)

Biological principles and clinical development of prostate cancer gene therapy. Sanda MG. **Semin Urol Oncol** 1997 Feb;15(1):43–55 (77 ref.)

Secondary hormonal therapy. Smith DC. **Semin Urol Oncol** 1997 Feb;15(1):3–12 (95 ref.)

Proceedings of the 1st International Conference on Neoadjuvant Hormonal Therapy for Prostate Cancer. Boston, Massachusetts, March 29–30, 1996. **Urology** 1997 Mar;49(3A Suppl):1–118; quiz 121–3 (0 ref.)

VETERINARY

Tumours of the kidney. Tsuda H, et al. **IARC Sci Publ** 1996; (126):223–42 (119 ref.)

NEOPLASMS, METACHRONOUS see **NEOPLASMS, SECOND PRIMARY**

NEOPLASMS, METACHRONOUS SECOND PRIMARY see **NEOPLASMS, SECOND PRIMARY**

NEOPLASMS, MULTIPLE ENDOCRINE see **MULTIPLE ENDOCRINE NEOPLASIA**

NEOPLASMS, MULTIPLE ENDOCRINE TYPE 1 see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 1**

NEOPLASMS, MULTIPLE ENDOCRINE TYPE 2A see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A**

NEOPLASMS, MULTIPLE ENDOCRINE, TYPE 2B see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B**

NEOPLASMS, MULTIPLE PRIMARY

see related
NEOPLASMS, SECOND PRIMARY

Synchronous Hodgkin's disease and non-Hodgkin's lymphoma. Adnan E, et al. **Acta Oncol** 1996;35(6):755–7 (22 ref.)

Synchronous bilateral primary male breast carcinoma with hyperprolactinemia. Karamanakos P, et al. **Acta Oncol** 1996;35(6):757–9 (24 ref.)

Concurrent colonic adenocarcinoma and two ileal carcinoids in a 72-year-old male. Tse V, et al. **Aust N Z J Surg** 1997 Oct;67(10):739–41 (10 ref.)

Two synchronous primary tumors of the ovary and kidney: a case report. Balat O, et al. **Eur J Gynaecol Oncol** 1996; 17(4):257–9 (9 ref.)

Coexistence of renal cell carcinoma and renal angiomyolipoma developing in a kidney: a case report. Tsuboniwa N, et al. **Hinyokika Kiyo** 1997 Feb;43(2):131–5 (30 ref.)

A case of renal cell carcinoma associated with synchronous contralateral renal pelvic cancer and bladder tumor. Ando M, et al. **Int J Urol** 1996 Jul;3(4):310–2 (8 ref.)

A study of large congenital melanocytic nevi and associated malignant melanomas: review of cases in the New York University Registry and the world literature. DeDavid M, et al. **J Am Acad Dermatol** 1997 Mar;36(3 Pt 1):409–16 (106 ref.)

Malignant peripheral nerve sheath tumor arising in a "de novo" ganglioneuroma: a case report and review of the literature. Drago G, et al. **Med Pediatr Oncol** 1997 Mar; 28(3):216–22 (21 ref.)

Synchronous bilateral carcinoma of the ureter in association with unilateral incomplete duplication of the ureter. Tan LB, et al. **Urol Int** 1996;56(3):196–9 (22 ref.)

Primary osteosarcoma of the spermatic cord with synchronous bilateral renal cell carcinoma. Beiswanger JC, et al. **Urology** 1997 Jun;49(6):957–9 (14 ref.)

[Plasma-cell granuloma of the sigmoid colon concomitant with adenocarcinoma of the cecum. Viewpoint for debate, literature review on pseudotumors, idiopathic colitis and cancer] De Monti M, et al. **Ann Ital Chir** 1997 Mar–Apr; 68(2):245–51 (55 ref.) (Eng. Abstr.) **(Ita)**

[Metastatic linitis plastica of the bladder] Signori GB, et al. **Arch Ital Urol Androl** 1997 Feb;69(1):69–72 (18 ref.) (Eng. Abstr.) **(Ita)**

[Renal angiomyolipoma and renal cell carcinoma associated with tuberous sclerosis: a case report] Sugimoto M, et al. **Hinyokika Kiyo** 1997 Jan;43(1):33–5 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Double primary lung cancers producing alpha-fetoprotein] Bessho T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Dec;44(12):2216–20 (11 ref.) (Eng. Abstr.) **(Jpn)**

[A case of primary anterior mediastinal liposarcoma with a heterotopic mass in the pericardium of the same histology] Kiyama H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Dec;44(12):2191–5 (14 ref.) (Eng. Abstr.) **(Jpn)**

[A case of ulcerative colitis with minute gastric cancer and intraductal papillary adenoma of the pancreas] Yamamoto T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Aug; 94(8):532–7 (12 ref.) **(Jpn)**

[Lymphangioleiomyoma with retroperitoneal and thoracic involvement] Barron Medrano M, et al. **An Med Interna** 1996 Feb;13(2):75–8 (38 ref.) (Eng. Abstr.) **(Spa)**

[Synchronous multiple renal carcinoma. Review of the literature and report of a new case] Borrego Hernando J, et al. **Arch Esp Urol** 1996 Sep;49(7):760–3 (20 ref.) (Eng. Abstr.) **(Spa)**

[Inverted carcinoma of kidney pelvis coexisting with transitional cell carcinoma of the bladder. A therapeutic alternative] Diaz Calleja E, et al. **Arch Esp Urol** 1997 Mar; 50(2):189–92 (9 ref.) (Eng. Abstr.) **(Spa)**

[Chronic myelomonocytic leukemia and renal carcinoma: a rare association (letter)] Fernández-Escribano M, et al. **Sangre (Barc)** 1997 Feb;42(1):88–9 (5 ref.) **(Spa)**

CHEMICALLY INDUCED

[Metastatic malignant melanoma in treated non-Hodgkin's lymphoma] Falk S, et al. **Hautarzt** 1996 Sep;47(9):716–8 (21 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

[A case of degenerated diffuse biliary papillomatosis associated with cystic dilatation of the intrahepatic biliary ducts. Value of radiotherapy and review of the literature] Pillet G, et al. **Bull Cancer** 1996 Nov;83(11):957–63 (83 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Re: Is contralateral exploration of the kidney necessary in patients with Wilms tumor? [letter; comment] Paulino AC. **J Urol** 1997 Jun;157(6):2265 (6 ref.) Comment on: J Urol 1996 Aug;156(2 Pt 2):693–5.

Multiple calvarial cavernous haemangiomas: case report and review of the literature. Kumar NA, et al. **Neuroradiology** 1996 May;38 Suppl 1:S83–5 (10 ref.)

Malignant melanoma of the oesophagus—a case report. Chan HS, et al. **Singapore Med J** 1995 Oct;36(5):566–7 (9 ref.)

[The synchronous occurrence of acute myeloid leukemia and kidney carcinoma] Bohle W, et al. **Dtsch Med Wochenschr** 1997 Jun 6;122(23):743–6 (15 ref.) (Eng. Abstr.) **(Ger)**

[After care of breast carcinoma patients—recommendations from the Berlin consensus conference] Hellriegel KP, et al. **Fortschr Med** 1996 Feb 20;114(5):43–5 (0 ref.) **(Ger)**

[Neuroendocrine carcinoma of the ampullar region with oat-cell histological features and adenocarcinoma] Fresno MF, et al. **Rev Esp Enferm Dig** 1997 Jan;89(1):60–4 (24 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Risk of urethral, vaginal and cervical involvement in patients undergoing radical cystectomy for bladder cancer: results of a contemporary cystectomy series from M. D. Anderson Cancer Center. Chen ME, et al. **J Urol** 1997 Jun; 157(6):2120–3 (13 ref.)

ETIOLOGY

Primary intestinal Hodgkin's disease complicating ileal Crohn's disease. Kelly MD, et al. **Aust N Z J Surg** 1997 Jul;67(7):485–9 (38 ref.)

Synchronous signet ring cell carcinoma and squamous cell carcinoma arising in an augmented ileocystoplasty. Case report and review of the literature. Fernandez-Arjona M, et al. **Eur Urol** 1996;29(1):125–8 (14 ref.)

GENETICS

Field cancerization: are multiple primary cancers monoclonal or polyclonal? [editorial] Carey TE. **Ann Med** 1996 Jun; 28(3):183–8 (22 ref.)

Brain tumor-polyposis syndrome: two genetic diseases? Paraf F, et al. **J Clin Oncol** 1997 Jul;15(7):2744–58 (128 ref.)

[Familial multiple cavernous angioma in the brain and spinal cord] Kimura T, et al. **No To Shinkei** 1996 Oct;48(10):955–9 (21 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Periorbital solitary nodule and multiple small papules in a 63-year-old women. Primary mucinous carcinoma (nodule) and syringom (papules). Friednash M, et al. **Arch Dermatol** 1997 Sep;133(9):1161, 1164 (18 ref.)

Multiple, hereditary dome-shaped papules and acrochordons. Birt-Hogg-Dubé syndrome. Haimowitz JE, et al. **Arch Dermatol** 1997 Sep;133(9):1163, 1166 (8 ref.)

Yolk sac tumor of the liver combined with hepatocellular carcinoma. Morinaga S, et al. **Arch Pathol Lab Med** 1996 Jul;120(7):687–90 (20 ref.)

Squamous cell carcinoma arising in a verrucous epidermal nevus. Ichikawa T, et al. **Dermatology** 1996;193(2):135–8 (18 ref.)

Enteric type villoglandular papillary adenocarcinoma of the uterine cervix associated with in situ squamous cell carcinoma. Case report and review of the literature. Skopelitou A, et al. **Eur J Gynaecol Oncol** 1996; 17(4):309–14 (42 ref.)

Coexisting non-functioning pheochromocytoma and renal oncocytoma: a case report and review of the literature. Daskalopoulos G, et al. **Eur J Radiol** 1996 Sep;23(2):138–42 (22 ref.)

Multilocular renal cyst associated with testicular epidermoid cyst. Radhi JM, et al. **Histopathology** 1996 Oct;29(4):377–9

(4 ref.)
Trichoepithelioma with an adjacent basal cell carcinoma, transformation or collision? Wallace ML, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):343–5 (10 ref.)
Quintuple cancers: report of a case with triple cancers in the head and neck. Martin-Granizo R, et al. **J Craniomaxillofac Surg** 1997 Jun;25(3):153–7 (34 ref.)
Multiple early esophageal cancers arising from Barrett's esophagus, and a review of cases of early adenocarcinoma in Barrett's esophagus in Japan. Itatsu T, et al. **J Gastroenterol** 1997 Jun;32(3):389–95 (40 ref.)
Double cancers of the gallbladder and bile duct associated with anomalous choledochopancreatic duct junction. Nakao A, et al. **J Gastroenterol** 1997 Feb;32(1):110–3 (12 ref.)
Gastric ganglioneuroblastoma: a rare finding in an infant with multifocal ganglioneuroblastoma. Sandoval C, et al. **J Pediatr Hematol Oncol** 1996 Nov;18(4):409–12 (19 ref.)
An incidental finding---bilateral multifocal renal oncocytoma. Bender BU, et al. **Nephrol Dial Transplant** 1997 May; 12(5):1034–6 (27 ref.)
Two case reports of breast carcinoma associated with prolactinoma. Strungs I, et al. **Pathology** 1997 Aug; 29(3):320–3 (29 ref.)
Cronkhite–Canada syndrome associated with carcinoma of the sigmoid colon: report of a case. Nakatsubo N, et al. **Surg Today** 1997;27(4):345–8 (28 ref.)
Combined myxoid liposarcoma and angiolipoma of the spermatic cord. Ikinger U, et al. **Urology** 1997 Apr; 49(4):635–7 (15 ref.)
[Symplastic leiomyoma combined with focal adenocarcinoma of the endometrium] Veselinova T, et al. **Akush Ginekol (Sofiia)** 1996;35(3):47–9 (6 ref.) (Eng. Abstr.) **(Bul)**
[Association of a low-grade MALT lymphoma and a slightly differentiated adenocarcinoma of the stomach] Brochériou I, et al. **Ann Pathol** 1997 Apr;17(2):109–12 (12 ref.) (Eng. Abstr.) **(Fre)**
[Neurosarcoma associated with neurofibromatosis 1. Apropos of a case and review of the literature] Ligneau B, et al. **Presse Med** 1997 Mar 29;26(10):458–63 (24 ref.) (Eng. Abstr.) **(Fre)**
[Carcinoma-in-carcinoma metastasis. In situ DNA quantification and immunohistochemical diagnosis] Sperb RA, et al. **Pathologe** 1996 Sep;17(5):385–90 (39 ref.) (Eng. Abstr.) **(Ger)**
[A case of von Recklinghausen's disease complicated by adenocarcinoma of the papilla of Vater] Nagayama K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Feb;94(2):123–8 (16 ref.) **(Jpn)**
[A case of adenosquamous carcinoma of the esophagus, having signet ring cell carcinoma and mucinous adenocarcinoma in the component of well differentiated adenocarcinoma] Tomimatsu H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Sep;93(9):644–9 (18 ref.) **(Jpn)**
[A case of synchronous triple early cancer occurring in the stomach, colon and gallbladder] Yazawa K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Jun;94(6):440–4 (12 ref.) **(Jpn)**

SURGERY

Synchronous lingual granular cell tumor and squamous carcinoma. A case report and review of the literature. Said-al-Naief N, et al. **Arch Otolaryngol Head Neck Surg** 1997 May;123(5):543–7 (48 ref.)
Surgical palliation of colorectal cancer. Sigurdson ER. **Curr Probl Cancer** 1995 Nov–Dec;19(6):348–59 (58 ref.)
Peritumoral B cell infiltrate associated with chronic lymphocytic leukemia obscuring margin evaluation during Mohs micrographic surgery [letter] Humphreys TR, et al. **Dermatol Surg** 1996 Oct;22(10):894–6 (21 ref.)
Multiple meningiomas of the central nervous system without the stigmata of neurofibromatosis. Clinical and therapeutic study. Turgut M, et al. **Neurosurg Rev** 1997;20(2):117–23 (37 ref.)
Primary non-Hodgkin's lymphoma of the sciatic nerve followed by localization in the central nervous system: case report and review of the literature. Roncaroli F, et al. **Neurosurgery** 1997 Mar;40(3):618–21; discussion 621–2 (11 ref.)
[Synchronous bilateral renal cell carcinoma. Renal transplantation after nephrectomy] Lobbedez T, et al. **Presse Med** 1997 Feb 1;26(2):66–9 (12 ref.) (Eng. Abstr.) **(Fre)**
[A case of synchronous triple cancers with curative resection] Matsuoka M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Oct;93(10):732–7 (11 ref.) **(Jpn)**

THERAPY

[Esophageal cancer and multiple primary cancer] Makuuchi H, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(1):1–7 (17 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Testicular ultrasound in Carney complex: report of three cases. Premkumar A, et al. **J Clin Ultrasound** 1997 May; 25(4):211–4 (7 ref.)

NEOPLASMS, MUSCLE TISSUE

PATHOLOGY

Myofibrosarcoma of the breast: review of the literature on myofibroblastic tumors and criteria for defining myofibroblastic differentiation [published erratum appears in Am J Surg Pathol 1997 Jun;21(6):742] Taccagni G, et al. **Am J Surg Pathol** 1997 Apr;21(4):489–96 (27 ref.)
Tumors with smooth muscle differentiation. Spencer JM, et al. **Dermatol Surg** 1996 Sep;22(9):761–8 (61 ref.)

RADIOGRAPHY

Myofibroblastoma of male breast: report of three cases and review of the literature. Pina L, et al. **Eur Radiol** 1997; 7(6):931–4 (38 ref.)

NEOPLASMS, NERVE TISSUE

PATHOLOGY

Gastrointestinal autonomic nerve tumor of the esophagus. A clinicopathologic, immunohistochemical, ultrastructural study of a case and review of the literature. Lam KY, et al. **Cancer** 1996 Oct 15;78(8):1651–9 (29 ref.)
Cutaneous neural heterotopias and related tumors relevant for the dermatopathologist. Argenyi ZB. **Semin Diagn Pathol** 1996 Feb;13(1):60–71 (62 ref.)

NEOPLASMS, NEUROEPITHELIAL

COMPLICATIONS

[Dysembryoplastic neuroepithelial tumors. A benign tumor cause of partial epilepsy in young adults] Lemesle M, et al. **Rev Neurol (Paris)** 1996 Jun–Jul;152(6–7):451–7 (18 ref.) (Eng. Abstr.) **(Fre)**

CONGENITAL

Congenital malignant teratoid neoplasm of the eye and orbit: a case report and review of the literature. Steinkuller PG, et al. **Ophthalmology** 1997 Jan;104(1):38–42 (38 ref.)

IMMUNOLOGY

Nonteratoid medulloepithelioma of the retina with electron microscopic and immunohistochemical characterization. Vadmal M, et al. **Pediatr Pathol Lab Med** 1996 Jul–Aug; 16(4):663–72 (17 ref.)

PATHOLOGY

Congenital malignant teratoid neoplasm of the eye and orbit: a case report and review of the literature. Steinkuller PG, et al. **Ophthalmology** 1997 Jan;104(1):38–42 (38 ref.)

ULTRASTRUCTURE

Nonteratoid medulloepithelioma of the retina with electron microscopic and immunohistochemical characterization. Vadmal M, et al. **Pediatr Pathol Lab Med** 1996 Jul–Aug; 16(4):663–72 (17 ref.)

VETERINARY

Tumours of the nervous system. Cardesa A, et al. **IARC Sci Publ** 1996;(126):427–65 (109 ref.)

NEOPLASMS, OCCULT PRIMARY see **NEOPLASMS, UNKNOWN PRIMARY**

NEOPLASMS, RADIATION-INDUCED

see related
LEUKEMIA, RADIATION-INDUCED
NEOPLASMS, SECOND PRIMARY

Ten years after Chernobyl. Rytömaa T. **Ann Med** 1996 Apr; 28(2):83–7 (48 ref.)
Radiation change in normal organs: an overview of body imaging. Libshitz HI, et al. **Eur Radiol** 1996;6(6):786–95 (82 ref.)
Neovaginal malignant melanoma following surgery and radiation for vulvar squamous cell carcinoma. Lara PN Jr, et al. **Gynecol Oncol** 1997 Jun;65(3):520–2 (18 ref.)
The assessment of doses and effects from intakes of radioactive particles. Harrison JD, et al. **J Anat** 1996 Dec; 189 (Pt 3):521–30 (23 ref.)
Malignant fibrous histiocytoma after radiation for ameloblastoma of the maxilla. Li KK, et al. **J Oral Maxillofac Surg** 1997 Jan;55(1):85–8 (19 ref.)

DIAGNOSIS

High-dose radiation-induced meningiomas following acute lymphoblastic leukemia in children. Salvati M, et al. **Childs Nerv Syst** 1996 May;12(5):266–9 (35 ref.)
Radiation-induced changes in the central nervous system and head and neck. Rabin BM, et al. **Radiographics** 1996 Sep; 16(5):1055–72 (24 ref.)
[Post-radiotherapy multifocal meningioma] Bazin A, et al. **Rev Neurol (Paris)** 1997 Jun;153(5):344–6 (11 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Molecular epidemiology of skin cancers: DNA repair and non-melanocytic skin cancer. Hall J, et al. **Ann Ist Super Sanita** 1996;32(1):43–51 (56 ref.)
Wire codes, magnetic fields, and childhood cancer. Kheifets LI, et al. **Bioelectromagnetics** 1997;18(2):99–110 (30 ref.)
Risk of childhood cancer from fetal irradiation [see comments] Doll R, et al. **Br J Radiol** 1997 Feb;70:130–9 (59 ref.) Comment in: Br J Radiol 1997 Jul;70(835):769–70; discussion 771. Comment in: Br J Radiol 1997 Jul;70(835):770–1.
Childhood cancer 10 years after the Chernobyl accident. Schwenn MR, et al. **Curr Opin Pediatr** 1997 Feb;9(1):51–4 (26 ref.)
Long-term effects of internally deposited alpha-particle emitting radionuclides. Epidemiological, pathological and molecular-biological studies of Danish Thorotrast-administered patients and their offspring. Andersson M. **Dan Med Bull** 1997 Apr;44(2):169–90 (140 ref.)
Assessment of cellular telephone and other radio frequency exposure for epidemiologic research [see comments] Rothman KJ, et al. **Epidemiology** 1996 May;7(3):291–8 (43 ref.) Comment in: Epidemiology 1996 May;7(3):219. Comment in: Epidemiology 1997 Jul;8(4):466–7.
The consequences of the Chernobyl accident one decade after the disaster. Jankowski J. **Int J Occup Med Environ Health** 1996;9(4):365–74 (18 ref.)
Photocarcinogenesis: an overview. Black HS, et al. **J Photochem Photobiol B** 1997 Aug;40(1):29–47 (194 ref.)

ETIOLOGY

Neutrons and carcinogenesis: a cautionary tale. Hall EJ. **Bull Cancer Radiother** 1996;83 Suppl:43s–6s (28 ref.)
Radiation-induced endocrine tumors. Schneider AB, et al. **Cancer Treat Res** 1997;89:141–61 (77 ref.)
Epidemiologic studies of ionizing radiation and cancer: past successes and future challenges. Samet JM. **Environ Health Perspect** 1997 Jun;105 Suppl 4:883–9 (39 ref.)
Radon and cancer. Bochicchio F. **Eur J Cancer Prev** 1996 Oct;5(5):383–4 (12 ref.)
Radiotherapy and second primary tumour. Cartei F. **Eur J Cancer Prev** 1996 Oct;5(5):388–90 (9 ref.)
Extremely low frequency magnetic fields and cancer. Grandolfo M. **Eur J Cancer Prev** 1996 Oct;5(5):379–81 (11 ref.)
Biological mechanisms of radiation carcinogenesis. Trott KR. **Eur J Cancer Prev** 1996 Oct;5(5):377–8 (3 ref.)
Ultraviolet exposure and cancer. Wolf P. **Eur J Cancer Prev** 1996 Oct;5(5):381–3 (7 ref.)
Postirradiation laryngeal osteosarcoma: case report and literature review. Sheen TS, et al. **Head Neck** 1997 Jan; 19(1):57–62 (36 ref.)
Electromagnetic field cancer scares. Deutsch S, et al. **Health Phys** 1997 Aug;73(2):301–9 (13 ref.)
Lethal mutations and genomic instability. Mothersill C, et al. **Int J Radiat Biol** 1997 Jun;71(6):751–8 (57 ref.)
Actinic keratoses. Callen JP, et al. **J Am Acad Dermatol** 1997 Apr;36(4):650–3 (14 ref.)
Therapy with orally administered methoxsalen and ultraviolet A radiation during childhood increases the risk of basal cell carcinoma. The PUVA Follow-up Study. Stern RS, et al. **J Pediatr** 1996 Dec;129(6):915–7 (8 ref.)
Osteochondroma after total body irradiation in bone marrow transplant recipients: report of two cases. Maeda G, et al. **Jpn J Clin Oncol** 1996 Dec;26(6):480–3 (14 ref.)
A diversity of responses displayed by a stochastic model of radiation carcinogenesis allowing for cell death. Yakovlev A, et al. **Math Biosci** 1996 Feb;132(1):1–33 (80 ref.)
The radiological hazards of plutonium. Barnaby F. **Med Confl Surviv** 1997 Jul–Sep;13(3):195–206; discussion 207–8 (18 ref.)
Basal cell carcinoma in a girl after cobalt irradiation to the cranium for acute lymphoblastic leukemia: case report and literature review. Garcia-Silva J, et al. **Pediatr Dermatol** 1996 Jan–Feb;13(1):54–7 (13 ref.)
Photobiology of photocarcinogenesis. de Gruijl FR. **Photochem Photobiol** 1996 Apr;63(4):372–5 (21 ref.)
Relevance of animal models of photocarcinogenesis to humans. Forbes PD. **Photochem Photobiol** 1996 Apr; 63(4):357–62 (39 ref.)
Analysis of rodent photo cocarcinogenicity models for hazard evaluation and risk assessment: industry viewpoint. Kraus AL. **Photochem Photobiol** 1996 Apr;63(4):365–9 (54 ref.)
Signal transduction mechanisms in photocarcinogenesis. Pentland AP. **Photochem Photobiol** 1996 Apr;63(4):379–80 (11 ref.)
Mutagenic lesions in carcinogenesis: induction and repair of pyrimidine dimers. Sutherland BM. **Photochem Photobiol** 1996 Apr;63(4):375–7 (27 ref.)
Oxidant, antioxidant status and photocarcinogenesis: the role of gene activation. Tyrrell RM. **Photochem Photobiol** 1996 Apr;63(4):380–3 (31 ref.)
Cancer risk in relation to radioactivity in tobacco. Kilthau GF. **Radiol Technol** 1996 Jan–Feb;67(3):217–22 (53 ref.)
Need for a European approach to the effects of extremely low-frequency electromagnetic fields on cancer. ELF-EMF European Feasibility Study Group. **Scand J Work Environ Health** 1997 Feb;23(1):5–14 (21 ref.)

Melanoma and sun exposure. Elwood JM. **Semin Oncol** 1996 Dec;23(6):650–66 (69 ref.)

Linear basal cell carcinomas: report of multiple sequential tumors localized to a radiotherapy port and review of the literature. Chopra KF, et al. **Tex Med** 1997 Jul;93(7):57–9 (10 ref.)

Radiation-induced sarcoma following curative radiotherapy for testicular seminoma: case report and brief review of the literature. Stein ME, et al. **Tumori** 1997 May–Jun; 83(3):721–3 (14 ref.)

[131 iodine: medical use. Carcinogenic and genetic effects] Schlumberger M, et al. **Ann Endocrinol (Paris)** 1996; 57(3):166–76 (48 ref.) (Eng. Abstr.) **(Fre)**

[Malignant mesothelioma of the pleura following radiotherapy of Hodgkin disease] Falchero L, et al. **Bull Cancer** 1996 Nov;83(11):964–8 (32 ref.) (Eng. Abstr.) **(Fre)**

[Incidence of malignant soft tissue tumors (sarcomas) after previous radiotherapy] Hernandez-Richter T, et al. **Langenbecks Arch Chir** 1996;381(5):295–8 (19 ref.) (Eng. Abstr.) **(Ger)**

[Risk of secondary neoplasia after treatment of malignant germ cell tumors of the testis] Bokemeyer C, et al. **Med Klin** 1996 Nov 15;91(11):703–10 (51 ref.) **(Ger)**

[Problems evaluating the risk of occupational neoplasms in persons exposed to ionizing radiation] Jankowski J. **Med Pr** 1996;47(6):615–27 (62 ref.) (Eng. Abstr.) **(Pol)**

[Carcinogenic effects of radon in humans (literature review)] Averkina NA. **Med Tr Prom Ekol** 1996;(9):32–6 (20 ref.) (Eng. Abstr.) **(Rus)**

[Exposure to low electromagnetic fields and the carcinogenesis process] Garaj-Vrhovac V. **Arh Hig Rada Toksikol** 1996 Sep;47(3):323–36 (62 ref.) (Eng. Abstr.) **(Scr)**

GENETICS

Genetic alterations in skin cancer. D'errico M, et al. **Ann Ist Super Sanita** 1996;32(1):53–63 (75 ref.)

Radiation-induced bone and soft tissue sarcomas: clinical aspects and molecular biology. Spiro IJ, et al. **Cancer Treat Res** 1997;91:143–55 (107 ref.)

Evidence for a role for genomic instability in radiation-induced mutagenesis. Caron RM, et al. **Radiat Oncol Investig** 1997;5(3):119–23 (15 ref.)

IMMUNOLOGY

A new immunobiological view of radiation-promoted lymphomagenesis. Coggin JH Jr, et al. **Int J Radiat Biol** 1997 Jan;71(1):81–94 (14 ref.)

PATHOLOGY

A diversity of responses displayed by a stochastic model of radiation carcinogenesis allowing for cell death. Yakovlev A, et al. **Math Biosci** 1996 Feb;132(1):1–33 (80 ref.)

PREVENTION & CONTROL

The case for sunscreens. A review of their use in preventing actinic damage and neoplasia. Naylor MF, et al. **Arch Dermatol** 1997 Sep;133(9):1146–54 (50 ref.)

Chemoprevention of ultraviolet radiation-induced skin cancer. Ley RD, et al. **Environ Health Perspect** 1997 Jun; 105 Suppl 4:981–4 (50 ref.)

Chemoprevention of photocarcinogenesis. Agarwal R, et al. **Photochem Photobiol** 1996 Apr;63(4):440–4 (50 ref.)

DNA repair enzymes in prevention of photocarcinogenesis. Yarosh DB, et al. **Photochem Photobiol** 1996 Apr; 63(4):445–7 (25 ref.)

Potassium iodide for thyroid blockade in a reactor accident: administrative policies that govern its use. Becker DV, et al. **Thyroid** 1997 Apr;7(2):193–7 (15 ref.)

SECRETION

An unusual treatment-related complication in a patient with growth hormone-secreting pituitary tumor. Ahmed M, et al. **J Clin Endocrinol Metab** 1997 Sep;82(9):2816–20 (19 ref.)

NEOPLASMS, SECOND PRIMARY

see related
NEOPLASMS, MULTIPLE PRIMARY

Renal cell carcinoma after therapy for neuroblastoma. Donnelly LF, et al. **AJR Am J Roentgenol** 1996 Oct; 167(4):915–7 (8 ref.)

Primary choroidal melanoma in a patient with previous cutaneous melanoma. Scull JJ, et al. **Arch Ophthalmol** 1997 Jun;115(6):796–8 (16 ref.)

Second lung cancers in patients successfully treated for lung cancer. Johnson BE, et al. **Semin Oncol** 1997 Aug; 24(4):492–9 (47 ref.)

The molecular pathogenesis of treatment-induced (secondary) leukemias: foundations for treatment and prevention. Karp JE, et al. **Semin Oncol** 1997 Feb; 24(1):103–13 (89 ref.)

Second ipsilateral breast cancer after modified radical mastectomy: a case report and review of the literature. Miller LA, et al. **Surgery** 1997 Jan;121(1):109–11 (5 ref.)

Secondary acute monocytic leukemia occurring during the treatment of a testicular germ cell tumor. A case report and review of the literature. Nonomura N, et al. **Urol Int** 1997;58(4):239–42 (26 ref.)

[Contralateral breast cancer: metastasis or second primary cancer?] Broët P, et al. **Bull Cancer** 1996 Oct;83(10):870–6 (34 ref.) (Eng. Abstr.) **(Fre)**

[A case of malignant mesothelioma associated intrascrotal mass] Wakasugi E, et al. **Nippon Hinyokika Gakkai Zasshi** 1997 Mar;88(3):443–6 (21 ref.) (Eng. Abstr.) **(Jpn)**

[A case of fibrosarcoma of the ovary] Ikegami A, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Dec; 48(12):1177–9 (12 ref.) **(Jpn)**

[A case of jejunal malignant lymphoma resulting in perforation 2 years after transcatheter arterial embolization for hepatocellular carcinoma] Yokohama A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Aug;93(8):578–82 (21 ref.) **(Jpn)**

CHEMICALLY INDUCED

Tamoxifen and secondary tumours. An update. Wilking N, et al. **Drug Saf** 1997 Feb;16(2):104–17 (151 ref.)

Second primary tumours (SPTs) after chemotherapy. Cartei G, et al. **Eur J Cancer Prev** 1996 Oct;5(5):400–2 (53 ref.)

Second malignancy in hairy cell leukaemia: no evidence of increased incidence after treatment with interferon alpha. Pawson R, et al. **Leuk Lymphoma** 1996 Jun;22(1-2):103–6 (13 ref.)

Growing teratoma syndrome after chemotherapy for germ cell tumors of the ovary. Geisler JP, et al. **Obstet Gynecol** 1994 Oct;84(4 Pt 2):719–21 (9 ref.)

Granulosa cell tumor of the ovary associated with antecedent tamoxifen use. Gherman RB, et al. **Obstet Gynecol** 1994 Oct;84(4 Pt 2):717–9 (11 ref.)

Hematologic complications of rheumatic disease therapies. George CS, et al. **Rheum Dis Clin North Am** 1997 May; 23(2):425–37 (82 ref.)

DIAGNOSIS

[After care of breast carcinoma patients—recommendations from the Berlin consensus conference] Hellriegel KP, et al. **Fortschr Med** 1996 Feb 20;114(5):43–5 (0 ref.) **(Ger)**

DRUG THERAPY

Antiblastic chemotherapy for haematologic malignancies and second tumours. Barillari G, et al. **Eur J Cancer Prev** 1996 Oct;5(5):402–4 (14 ref.)

EPIDEMIOLOGY

Increased incidence of second malignancies associated with small bowel adenocarcinoma. Ripley D, et al. **Can J Gastroenterol** 1997 Jan–Feb;11(1):65–8 (16 ref.)

Myelodysplasia and acute myeloid leukemia occurring after autologous bone marrow transplantation for lymphoma. Traweek ST, et al. **Leuk Lymphoma** 1996 Feb; 20(5–6):365–72 (47 ref.)

Second primary tumors in patients with retinoblastoma. A review of the literature. Moll AC, et al. **Ophthalmic Genet** 1997 Mar;18(1):27–34 (33 ref.)

ETIOLOGY

Hodgkin's disease following solid organ transplantation. Bierman PJ, et al. **Ann Oncol** 1996 Mar;7(3):265–70 (30 ref.)

Myeloid leukemia after hematotoxins. Larson RA, et al. **Environ Health Perspect** 1996 Dec;104 Suppl 6:1303–7 (32 ref.)

Antiblastic chemotherapy for haematologic malignancies and second tumours. Barillari G, et al. **Eur J Cancer Prev** 1996 Oct;5(5):402–4 (14 ref.)

Neovaginal malignant melanoma following surgery and radiation for vulvar squamous cell carcinoma. Lara PN Jr, et al. **Gynecol Oncol** 1997 Jun;65(3):520–2 (18 ref.)

Malignant fibrous histiocytoma after radiation for ameloblastoma of the maxilla. Li KK, et al. **J Oral Maxillofac Surg** 1997 Jan;55(1):85–8 (19 ref.)

Longterm followup and quality of life after hematopoietic stem cell transplantation. Sullivan KM. **J Rheumatol Suppl** 1997 May;48:46–52 (50 ref.)

Primary intracerebral malignant fibrous histiocytoma: immunohistochemical findings and etiopathogenetic considerations. Martinez-Salazar A, et al. **Mod Pathol** 1997 Feb;10(2):149–54 (42 ref.)

Spindle cell carcinoma of the tongue in a long-term survivor of childhood acute lymphoblastic leukemia. Shaw MP, et al. **Pediatr Hematol Oncol** 1997 Jan–Feb;14(1):79–83 (16 ref.)

Suprasellar meningioma subsequent to treatment for a pituitary adenoma: case report. Rao MB, et al. **Surg Neurol** 1997 May;47(5):443–6 (11 ref.)

Linear basal cell carcinomas: report of multiple sequential tumors localized to a radiotherapy port and review of the literature. Chopra KF, et al. **Tex Med** 1997 Jul;93(7):57–9 (10 ref.)

[Incidence of malignant soft tissue tumors (sarcomas) after previous radiotherapy] Hernandez-Richter T, et al. **Langenbecks Arch Chir** 1996;381(5):295–8 (19 ref.) (Eng. Abstr.) **(Ger)**

[Risk of secondary neoplasia after treatment of malignant germ cell tumors of the testis] Bokemeyer C, et al. **Med Klin** 1996 Nov 15;91(11):703–10 (51 ref.) **(Ger)**

[Three cases of secondary acute myeloid leukemia after long-term treatment with oral etoposide] Kikuta T, et al. **Rinsho Ketsueki** 1996 Nov;37(11):1276–82 (15 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Transrearrangements as biomarkers for risk of lymphoid malignancy. Kirsch IR, et al. **Cancer Surv** 1996;28:311–27 (81 ref.)

Chromosome abnormalities in leukaemia: the 11q23 paradigm. Young BD, et al. **Cancer Surv** 1996;28:225–45 (135 ref.)

De novo familial cavernous malformation presenting with hemorrhage 12.5 years after the initial hemorrhagic Ictus: natural history of an infantile form. Tekkök IH, et al. **Pediatr Neurosurg** 1996 Sep;25(3):151–5 (16 ref.)

PATHOLOGY

Malignant endovascular papillary angioendothelioma (Dabska tumor) arising within a deep intramuscular hemangioma. Argani P, et al. **Arch Pathol Lab Med** 1997 Sep;121(9):992–5 (13 ref.)

Pleomorphic medium-sized T-cell lymphoma following Hodgkin's disease (nodular sclerosis type). Gaulier A, et al. **Arch Pathol Lab Med** 1997 Apr;121(4):411–6 (27 ref.)

The growing teratoma syndrome in a nongerminomatous germ cell tumor of the pineal gland: a case report and review. O'Callaghan AM, et al. **Cancer** 1997 Sep 1; 80(5):942–7 (32 ref.)

Burkitt's lymphoma-leukemia in patients treated for Hodgkin's disease. Salloum E, et al. **Cancer Invest** 1996; 14(6):527–33 (47 ref.)

Malignant peripheral nerve sheath tumour with vascular differentiation: a report of four cases. Morphopoulos GD, et al. **Histopathology** 1996 May;28(5):401–10 (41 ref.)

Nasopharyngeal osteosarcoma as second malignant neoplasm in a post-treated unilateral retinoblastoma: report of a case and review of literature. Dubey SP, et al. **Int J Pediatr Otorhinolaryngol** 1996 Feb;34(3):265–71 (14 ref.)

Squamous cell carcinoma associated with a mandibular staple implant. Moxley JE, et al. **J Oral Maxillofac Surg** 1997 Sep;55(9):1020–2 (6 ref.)

Primary intracerebral malignant fibrous histiocytoma: immunohistochemical findings and etiopathogenetic considerations. Martinez-Salazar A, et al. **Mod Pathol** 1997 Feb;10(2):149–54 (42 ref.)

Schwannomatosis: a clinical and pathologic study [see comments] MacCollin M, et al. **Neurology** 1996 Apr; 46(4):1072–9 (40 ref.) Comment in: Neurology 1997 Mar;48(3):787–8.

Symmetrical multifocal liposarcoma. Kulhavy M, et al. **S Afr J Surg** 1997 May;35(2):68–9 (14 ref.)

Ampullary carcinoma in familial adenomatous polyposis: report of a case. Tomita H, et al. **Surg Today** 1996; 26(7):522–6 (16 ref.)

[Malignant histiocytofibroma of the bladder. A case report] Barriol D, et al. **Prog Urol** 1997 Apr;7(2):270–2 (9 ref.) (Eng. Abstr.) **(Fre)**

[Breast carcinoma metastatic to meningioma: review of the literature and description of 2 new cases] Fornelli A, et al. **Pathologica** 1995 Oct;87(5):506–12 (37 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Schwannomatosis: a clinical and pathologic study [see comments] MacCollin M, et al. **Neurology** 1996 Apr; 46(4):1072–9 (40 ref.) Comment in: Neurology 1997 Mar;48(3):787–8.

PREVENTION & CONTROL

Lung cancer chemoprevention and management of carcinoma in situ. Karp DD. **Semin Oncol** 1997 Aug; 24(4):402–10 (76 ref.)

SURGERY

Laparoscopic adrenalectomy for solitary metachronous contralateral adrenal metastasis from renal cell carcinoma. Elashry OM, et al. **J Urol** 1997 Apr;157(4):1217–22 (37 ref.)

[Small-cell sarcoma of the esophagus as a fourth malignancy. Its palliative therapy with argon gas coagulation] Glaser J, et al. **Dtsch Med Wochenschr** 1997 Aug 22; 122(34–35):1037–40 (8 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Anderson JE, et al. **Blood** 1997 Apr 1;89(7):2578–85 (23 ref.)

[Angiosarcoma of the breast. Apropos of 8 cases and review of the literature] Molitor JL, et al. **Bull Cancer** 1997 Feb; 84(2):206–11 (44 ref.) (Eng. Abstr.) **(Fre)**

NEOPLASMS, SQUAMOUS CELL

VETERINARY

Tumours of the lower respiratory tract. Mohr U, et al. **IARC Sci Publ** 1996;(126):189–222 (162 ref.)

NEOPLASMS, SYNCHRONOUS

NEOPLASMS, SYNCHRONOUS see **NEOPLASMS, MULTIPLE PRIMARY**

NEOPLASMS, SYNCHRONOUS MULTIPLE PRIMARY see **NEOPLASMS, MULTIPLE PRIMARY**

NEOPLASMS, THERAPY-RELATED see **NEOPLASMS, SECOND PRIMARY**

NEOPLASMS, TREATMENT-RELATED see **NEOPLASMS, SECOND PRIMARY**

NEOPLASMS, UNKNOWN PRIMARY

A review of Merkel cell carcinoma with emphasis on lymph node disease in the absence of a primary site. Straka JA, et al. **Am J Otolaryngol** 1997 Jan-Feb;18(1):55-65 (106 ref.)

[Metastatic cancers of unknown primary site] Krulik M. **Presse Med** 1996 Nov 16;25(35):1754-8 (28 ref.) (Eng. Abstr.) **(Fre)**

[Squamous cell carcinoma of unknown origin affecting mediastinal lymph nodes] Yodonawa S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec; 34(12):1364-8 (10 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Paraneoplastic cerebellar degeneration. Case report and literature review. Bolla L, et al. **Arch Intern Med** 1997 Jun 9;157(11):1258-62 (33 ref.)

The management of diabetes in patients with advanced cancer. Poulson J. **J Pain Symptom Manage** 1997 Jun; 13(6):339-46 (26 ref.)

DIAGNOSIS

Use of immunocytochemistry in the diagnosis of metastatic carcinoma. Matthews P, et al. **Ann Med** 1996 Aug; 28(4):297-300 (48 ref.)

The dilemma of evaluating and treating cancer of unknown primary site. Markman M. **Cleve Clin J Med** 1997 Feb; 64(2):73-5 (9 ref.)

Is immunostaining with HAM56 antibody useful in identifying ovarian origin of metastatic adenocarcinomas? Cheung AN, et al. **Hum Pathol** 1997 Jan;28(1):91-4 (35 ref.)

Anterior hip pain in the adult: an algorithmic approach to diagnosis. Mansour ES, et al. **J Am Osteopath Assoc** 1997 Jan;97(1):32-8 (29 ref.)

[Diagnosis and therapy of occult primary tumor with lymph node metastases in the area of the head and neck] Jungehülsing M, et al. **HNO** 1997 Jul;45(7):573-83 (108 ref.) **(Ger)**

DRUG THERAPY

[The chemotherapy of metastases of unknown origin] Shparyk IaV, et al. **Lik Sprava** 1996 Jan-Feb;(1-2):45-52 (51 ref.) **(Ukr)**

PATHOLOGY

Metastasis of a malignant melanoma to the region of an impacted mandibular third molar: a case report. Santamaria J, et al. **J Oral Maxillofac Surg** 1997 Sep;55(9):1003-6 (15 ref.)

Clinically-occult mixed cellularity Hodgkin's disease with Charcot-Leyden crystals. Carson HJ, et al. **Leuk Lymphoma** 1996 Sep;23(1-2):153-7 (30 ref.)

Clear cell tumors of unknown nature and origin: a systematic approach to diagnosis. Nappi O, et al. **Semin Diagn Pathol** 1997 Aug;14(3):164-74 (62 ref.)

[Metastatic cervical adenopathies of unknown primary site. Long-term course] Percodani J, et al. **Ann Otolaryngol Chir Cervicofac** 1996;113(4):212-8 (23 ref.) (Eng. Abstr.) **(Fre)**

[Gas gangrene due to Clostridium septicum in a patient with an occult colonic neoplasm. A case report and review of the literature] Sáez Castillo AI, et al. **Gastroenterol Hepatol** 1997 Feb;20(2):55-8 (13 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

The dilemma of evaluating and treating cancer of unknown primary site. Markman M. **Cleve Clin J Med** 1997 Feb; 64(2):73-5 (9 ref.)

NEOPLASMS, VASCULAR TISSUE

PATHOLOGY

Mucocutaneous neoplasms in patients with human immunodeficiency virus infection. Cockerell CJ. **Semin Diagn Pathol** 1996 Feb;13(1):19-39 (131 ref.)

VETERINARY

Tumours of soft tissues. Berman LD. **IARC Sci Publ** 1996; (126):321-49 (79 ref.)

NEOPLASTIC CELLS, CULTURED see **TUMOR CELLS, CULTURED**

NEOPLASTIC ENDOCRINE-LIKE SYNDROMES

see related
ACTH SYNDROME, ECTOPIC

DIAGNOSIS

Masculinizing and feminizing syndromes caused by functioning tumors. Masiakos PT, et al. **Semin Pediatr Surg** 1997 Aug;6(3):147-55 (64 ref.)

Functioning adrenal neoplasms. Sawin RS. **Semin Pediatr Surg** 1997 Aug;6(3):156-63 (52 ref.)

Unusual peptide-secreting tumors in adolescents and children. Schwartz MZ. **Semin Pediatr Surg** 1997 Aug; 6(3):141-6 (19 ref.)

[Radiologic diagnosis of hypophyseal adenomas] Brechtelsbauer D, et al. **Aktuelle Radiol** 1996 Nov; 6(6):301-7 (38 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Pathophysiology and clinical aspects of the ectopic GH-releasing hormone syndrome. Losa M, et al. **Clin Endocrinol (Oxf)** 1997 Aug;47(2):123-35 (93 ref.)

GENETICS

[Molecular biology of incidentally diagnosed adrenal gland space-occupying lesion] Reincke M, et al. **Zentralbl Chir** 1997;122(6):430-7 (42 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Current pathological classification of pituitary adenomas. Saeger W. **Acta Neurochir Suppl (Wien)** 1996;65:1-3 (8 ref.)

Gastrointestinal endocrine tumours. Pathology. Bishop AE, et al. **Baillieres Clin Gastroenterol** 1996 Dec;10(4):555-69 (65 ref.)

Peptide receptors in gut endocrine tumours. de Herder WW, et al. **Baillieres Clin Gastroenterol** 1996 Dec;10(4):571-87 (55 ref.)

[Autonomy and malignancy of thyroid glad tumors. A critical analysis of the literature on the existence of hyperfunctioning follicular and papillary thyroid gland carcinomas] Schröder S, et al. **Pathologe** 1996 Sep; 17(5):349-57 (74 ref.) (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

[Somatostatin receptor scintigraphy. Methodology, indications, results] Eising EG, et al. **Radiologe** 1996 Jan; 36(1):81-8 (33 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Surgical management of gastrointestinal endocrine tumours. Goldstone AP, et al. **Baillieres Clin Gastroenterol** 1996 Dec; 10(4):707-36 (125 ref.)

Intrasellar pituitary gangliocyto-adenoma presenting with acromegaly: case report. Morikawa M, et al. **Neurosurgery** 1997 Mar;40(3):611-4; discussion 614-5 (34 ref.)

[Laparoscopic adrenal gland surgery] Nies C, et al. **Chirurg** 1997 Feb;68(2):99-106 (47 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Gastrointestinal endocrine tumours: medical management. Arnold R, et al. **Baillieres Clin Gastroenterol** 1996 Dec; 10(4):737-59 (120 ref.)

[Management of endocrine pancreatic tumors] Schöber C, et al. **Wien Med Wochenschr** 1997;147(1):18-23 (35 ref.) (Eng. Abstr.) **(Ger)**

NEOPLASTIC GENE EXPRESSION REGULATION see **GENE EXPRESSION REGULATION, NEOPLASTIC**

NEOPLASTIC SYNDROMES, HEREDITARY

DIAGNOSIS

[Effect of molecular diagnostic procedures on surgical therapy of malignant diseases] von Knebel Doeberitz M, et al. **Chirurg** 1996 Oct;67(10):967-79 (73 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Homeosis and polyposis: a tale from the mouse. He TC, et al. **Bioessays** 1997 Jul;19(7):551-5 (39 ref.)

The phakomatoses: recent advances in genetics. MacDonald IM, et al. **Can J Ophthalmol** 1997 Feb;32(1):4-11 (81 ref.)

[Familial ovarian carcinoma] Speiser P. **Wien Med Wochenschr** 1996;146(1-2):10-3 (35 ref.) (Eng. Abstr.) **(Ger)**

[Molecular genetics of hereditary breast carcinoma] Hampl M, et al. **Zentralbl Chir** 1997;122(2):67-73 (76 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Testicular ultrasound in Carney complex: report of three cases. Premkumar A, et al. **J Clin Ultrasound** 1997 May; 25(4):211-4 (7 ref.)

NEOPLASTIC TRANSFORMATION, CELL see **CELL TRANSFORMATION, NEOPLASTIC**

NEOSPORA

CLASSIFICATION

A review of Neospora caninum and neosporosis. Dubey JP, et al. **Vet Parasitol** 1996 Dec 2;67(1-2):1-59 (193 ref.)

NEOSPORA CANINUM see **NEOSPORA**

NEOSTRIATUM

Deep brain stimulation for intractable pain: a 15-year experience. Kumar K, et al. **Neurosurgery** 1997 Apr; 40(4):736-46; discussion 746-7 (64 ref.)

CYTOLOGY

Neostriatal cell subtypes and their functional roles. Kawaguchi Y. **Neurosci Res** 1997 Jan;27(1):1-8 (77 ref.)

PHYSIOLOGY

Synaptic transmission and modulation in the neostriatum. Lovinger DM, et al. **Int Rev Neurobiol** 1996;39:77-111 (151 ref.)

Synaptic plasticity and physiological interactions between dopamine and glutamate in the striatum. Calabresi P, et al. **Neurosci Biobehav Rev** 1997 Jul;21(4):519-23 (60 ref.)

Neostriatal cell subtypes and their functional roles. Kawaguchi Y. **Neurosci Res** 1997 Jan;27(1):1-8 (77 ref.)

The neostriatum beyond the motor function: experimental and clinical evidence. Calabresi P, et al. **Neuroscience** 1997 May;78(1):39-60 (227 ref.)

NEOSYNEPHRINE see **PHENYLEPHRINE**

NEOTOMA see **HESPEROMYINAE**

NEOVASCULARIZATION, PATHOLOGIC

Atherosclerosis and angiogenesis. Its pathophysiological significance in humans as well as in an animal model induced by the gene transfer of vascular endothelial growth factor. Sueishi K, et al. **Ann N Y Acad Sci** 1997 Apr 15; 811:311-22; 322-4 (37 ref.)

Manipulating angiogenesis. From basic science to the bedside. Pepper MS. **Arterioscler Thromb Vasc Biol** 1997 Apr; 17(4):605-19 (166 ref.)

Tumor progression and angiogenesis: cathepsin B & Co. Keppler D, et al. **Biochem Cell Biol** 1996;74(6):799-810 (117 ref.)

Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy. Griffiths L, et al. **Br J Cancer** 1997;76(6):689-93 (55 ref.)

Angiogenesis in breast cancer. Weidner N. **Cancer Treat Res** 1996;83:265-301 (162 ref.)

Tumor cell invasion and angiogenesis in the central nervous system. Bjerkvig R, et al. **Curr Opin Oncol** 1997 May; 9(3):223-9 (68 ref.)

Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Miller JW, et al. **Diabetes Metab Rev** 1997 Mar;13(1):37-50 (119 ref.)

Analysis of the capillary architecture in the precursors of prostate cancer: recent findings and new concepts. Montironi R, et al. **Eur Urol** 1996;30(2):191-200 (43 ref.)

Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. Brown LF, et al. **EXS** 1997;79:233-69 (133 ref.)

Thrombospondin as a regulator of angiogenesis. DiPietro LA. **EXS** 1997;79:295-314 (74 ref.)

Angiogenesis as a biologic and prognostic indicator in human breast carcinoma. Engels K, et al. **EXS** 1997;79:113-56 (311 ref.)

Vascular endothelial growth factor: basic biology and clinical implications. Ferrara N, et al. **EXS** 1997;79:209-32 (142 ref.)

Regulation of capillary formation by laminin and other components of the extracellular matrix. Grant DS, et al. **EXS** 1997;79:317-33 (64 ref.)

Angiogenesis in human gliomas: prognostic and therapeutic implications. Johnson JP, et al. **EXS** 1997;79:29-46 (116 ref.)

Hypoxia and angiogenesis in experimental tumor models: therapeutic implications. Rockwell S, et al. **EXS** 1997; 79:335-60 (107 ref.)

Regulation of angiogenesis by scatter factor. Rosen EM, et al. **EXS** 1997;79:193-208 (93 ref.)

Tumor angiogenesis: functional similarities with tumor invasion. Stetler-Stevenson WG, et al. **EXS** 1997;79:413-8 (27 ref.)

Role of fibrin and plasminogen activators in repair-associated angiogenesis: in vitro studies with human endothelial cells. van Hinsbergh VW, et al. **EXS** 1997;79:391-411 (119 ref.)

The role of vascular cell integrins alpha v beta 3 and alpha v beta 5 in angiogenesis. Varner JA. **EXS** 1997;79:361-90

(243 ref.)
The codependence of angiogenesis and chronic inflammation. Jackson JR, et al. **FASEB J** 1997 May;11(6):457–65 (61 ref.)
The importance of L–arginine metabolism in melanoma: an hypothesis for the role of nitric oxide and polyamines in tumor angiogenesis. Joshi M. **Free Radic Biol Med** 1997; 22(3):573–8 (63 ref.)
Tumour angiogenesis and prognosis. Fox SB. **Histopathology** 1997 Mar;30(3):294–301 (112 ref.)
Tumor angiogenesis and the role of vascular cell integrin alphavbeta3. Varner JA, et al. **Important Adv Oncol** 1996; :69–87 (259 ref.)
Tumoral vascularity as a prognostic factor in cancer. Weidner N, et al. **Important Adv Oncol** 1996;:167–90 (166 ref.)
The role of calcium in the regulation of invasion and angiogenesis. Alessandro R, et al. **In Vivo** 1996 Mar–Apr; 10(2):153–60 (61 ref.)
Mathematical modelling, simulation and prediction of tumour–induced angiogenesis. Chaplain MA, et al. **Invasion Metastasis** 1996;16(4–5):222–34 (62 ref.)
The importance of blood vessels in cancer spread [editorial; comment] Neeman M. **Isr J Med Sci** 1996 Nov; 32(11):1124–6 (20 ref.) Comment on: Isr J Med Sci 1996 Nov;32(11):1086–8.
Endothelial adherens junctions: implications in the control of vascular permeability and angiogenesis. Dejana E. **J Clin Invest** 1996 Nov 1;98(9):1949–53 (32 ref.)
Angiogenesis in ischemic heart disease. Ware JA, et al. **Nat Med** 1997 Feb;3(2):158–64 (64 ref.)
Choroidal neovascularization not associated with age–related macular degeneration. Dolan BJ. **Optom Clin** 1996; 5(1):55–76 (80 ref.)
Possible involvement of VEGF–FLT tyrosine kinase receptor system in normal and tumor angiogenesis. Shibuya M, et al. **Princess Takamatsu Symp** 1994;24:162–70 (23 ref.)
Tumor–associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Pluda JM. **Semin Oncol** 1997 Apr;24(2):203–18 (181 ref.)
Angiogenesis in colorectal cancer. Saclarides TJ. **Surg Clin North Am** 1997 Feb;77(1):253–60 (56 ref.)
Angiogenesis in embryos and ischemic diseases. Breier G, et al. **Thromb Haemost** 1997 Jul;78(1):678–83 (70 ref.)
Current and future strategies to block tumor angiogenesis, invasion, and metastasis. Effert PJ, et al. **World J Urol** 1996; 14(3):131–40 (81 ref.)
Tumor angiogenesis: the pivotal role of vascular endothelial growth factor. Marmé D. **World J Urol** 1996;14(3):166–74 (92 ref.)
[Tumor angiogenesis––prognostic and therapeutic implications] Bairey D, et al. **Harefuah** 1997 Jan 15; 132(2):117–20 (36 ref.) **(Heb)**
[Development of anti tumor agents targeting angiogenesis] Ono M, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(2):178–86 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Secondary neovascularization––one of the steps in the development and progression of breast cancer] Kozlov DV, et al. **Arkh Patol** 1996 Jul–Aug;58(4):72–5 (61 ref.) (Eng. Abstr.) **(Rus)**
[Angiogenesis] Nikolić Lj. **Srp Arh Celok Lek** 1996 May–Jun; 124(5–6):147–9 (28 ref.) (Eng. Abstr.) **(Scc)**
[Angiogenesis in cholesteatoma of the middle ear] Bujía J, et al. **Acta Otorrinolaringol Esp** 1996 May–Jun;47(3):187–92 (31 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Markers of tumor angiogenesis: clinical applications in prognosis and anti–angiogenic therapy. Fox SB, et al. **Invest New Drugs** 1997;15(1):15–28 (174 ref.)
Angiogenic factors as tumor markers. Nguyen M. **Invest New Drugs** 1997;15(1):29–37 (44 ref.)
Assessing tumor angiogenesis using macromolecular MR imaging contrast media. Brasch R, et al. **J Magn Reson Imaging** 1997 Jan–Feb;7(1):68–74 (40 ref.)
Tumor angiogenesis: tutorial on implications for imaging. Passe TJ, et al. **Radiology** 1997 Jun;203(3):593–600 (82 ref.)
[Activation of epidermal melanocytes is independent of epithelial proliferation and vascularization. Immunohistologic study using HMB–45 antibody with review of the literature] Lommel K, et al. **Hautarzt** 1996 Aug;47(8):616–23 (65 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Clinical studies with angiogenesis inhibitors: biological rationale and challenges for their evaluation [editorial; comment] Gasparini G, et al. **Ann Oncol** 1996 Jul;7(5):441–4 (45 ref.) Comment on: Ann Oncol 1996 Jul;7(5):491–6.
Inhibitors of angiogenesis in a clinical perspective. Voest EE. **Anticancer Drugs** 1996 Sep;7(7):723–7 (36 ref.)
Cerebral gliomas. Growth factors and angiogenesis. Weingart JD, et al. **Baillieres Clin Neurol** 1996 Jun;5(2):307–18 (56 ref.)
Antiangiogenis restricted tumor dormancy. Holmgren L. **Cancer Metastasis Rev** 1996 Jun;15(2):241–5 (39 ref.)
Treating cancer by inhibiting angiogenesis: new hopes and potential pitfalls. Rak J, et al. **Cancer Metastasis Rev** 1996 Jun;15(2):231–6 (39 ref.)
A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics––>mechanism(s) of interaction). Teicher BA. **Cancer Metastasis Rev** 1996 Jun;15(2):247–72 (316 ref.)
How to starve a tumor. Taunton J. **Chem Biol** 1997 Jul; 4(7):493–6 (17 ref.)
The modulation of granulomatous tissue and tumour angiogenesis by diclofenac in combination with hyaluronan (HYAL EX–0001). Freemantle C, et al. **Int J Tissue React** 1995;17(4):157–66 (51 ref.)
Development of angiogenesis inhibitors for cancer therapy. Eckhardt SG, et al. **Invest New Drugs** 1997;15(1):1–3 (10 ref.)
An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action. Gradishar WJ. **Invest New Drugs** 1997;15(1):49–59 (103 ref.)
The preclinical evaluation of angiogenesis inhibitors. O'Reilly MS. **Invest New Drugs** 1997;15(1):5–13 (87 ref.)
Matrix metalloproteinase inhibitors. Wojtowicz–Praga SM, et al. **Invest New Drugs** 1997;15(1):61–75 (94 ref.)
Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action. Woltering EA, et al. **Invest New Drugs** 1997;15(1):77–86 (03 ref.)
Angiogenesis as a target for tumor treatment. Gastl G, et al. **Oncology** 1997 May–Jun;54(3):177–84 (69 ref.)
[Angiogenesis and its inhibitors] Ono M, et al. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1585–93 (12 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Angiogenesis: new aspects relating to its initiation and control. Norrby K. **APMIS** 1997 Jun;105(6):417–37 (165 ref.)
Teletherapy in the management of patients with age–related macular degeneration complicated by subfoveal neovascularisation: an overview. Hart PM, et al. **Front Radiat Ther Oncol** 1997;30:229–37 (26 ref.)

GENETICS

Tumor angiogenesis: a physiological process or genetically determined? D'Amore PA, et al. **Cancer Metastasis Rev** 1996 Jun;15(2):205–12 (36 ref.)
Oncogenes as inducers of tumor angiogenesis. Rak J, et al. **Cancer Metastasis Rev** 1995 Dec;14(4):263–77 (85 ref.)
Blood vessel formation: what is its molecular basis? [comment] Folkman J, et al. **Cell** 1996 Dec 27;87(7):1153–5 (20 ref.) Comment on: Cell 1996 Dec 27;87(7):1161–9. Comment on: Cell 1996 Dec 27;87(7):1171–80. Comment on: Cell 1996 Dec 27;87(7):1181–90.
[Correlation of neovascularization and vascular endothelial growth factor in human renal cell carcinoma] Sato K, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(4):389–94 (17 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Vascular endothelial growth factor, a specific regulator of angiogenesis. Ferrara N, et al. **Curr Opin Nephrol Hypertens** 1996 Jan;5(1):35–44 (124 ref.)
Vascular endothelial growth factor and its receptors. Klagsbrun M, et al. **Cytokine Growth Factor Rev** 1996 Oct; 7(3):259–70 (136 ref.)
The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Moses MA. **Stem Cells** 1997;15(3):180–9 (88 ref.)

PATHOLOGY

Vascular endothelial growth factor and ocular neovascularization [comment] Miller JW. **Am J Pathol** 1997 Jul;151(1):13–23 (97 ref.) Comment on: Am J Pathol 1997 Jul;151(1):281–91.
Tumor growth in a defined microcirculation. Christofferson RH, et al. **APMIS** 1997 Jun;105(6):487–96 (34 ref.)
Bladder cancer angiogenesis, its role in recurrence, stage progression and as a therapeutic target. Crew JP, et al. **Cancer Metastasis Rev** 1996 Jun;15(2):221–30 (84 ref.)
Leukocyte–endothelial adhesion and angiogenesis in tumors. Jain RK, et al. **Cancer Metastasis Rev** 1996 Jun; 15(2):195–204 (63 ref.)
The microcirculation in atherogenesis. Lehr HA, et al. **Cardiovasc Res** 1996 Oct;32(4):781–8 (61 ref.)
Prognostic value of angiogenesis in gastro–intestinal tumours. Chung YS, et al. **Eur J Cancer** 1996 Dec;32A(14):2501–5 (37 ref.)
Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Vermeulen PB, et al. **Eur J Cancer** 1996 Dec;32A(14):2474–84 (78 ref.)
Intratumoral vascularity as a prognostic factor in cancers of the urogenital tract. Weidner N. **Eur J Cancer** 1996 Dec; 32A(14):2506–12 (34 ref.)
Cellular mechanisms, interactions, and dynamics of gastric ulcer healing. Tarnawski A, et al. **J Clin Gastroenterol** 1995; 21 Suppl 1:S93–7 (31 ref.)
Angiogenesis in brain tumors; pathobiological and clinical aspects. Wesseling P, et al. **J Neurooncol** 1997 May; 32(3):253–65 (111 ref.)
Clinical perspectives of tumor angiogenesis in pediatric oncology. Schweigerer L. **Klin Padiatr** 1997 Jul–Aug; 209(4):257–64 (92 ref.)

PHYSIOPATHOLOGY

Cell adhesion molecules in angiogenesis. Brooks PC. **Cancer Metastasis Rev** 1996 Jun;15(2):187–94 (54 ref.)
Tumor angiogenesis: a physiological process or genetically determined? D'Amore PA, et al. **Cancer Metastasis Rev** 1996 Jun;15(2):205–12 (36 ref.)
The role of angiogenic growth factors in breast cancer progression. Kern FG, et al. **Cancer Metastasis Rev** 1996 Jun;15(2):213–9 (38 ref.)
REVIEW: the integrin alpha V beta 3: angiogenesis and apoptosis. Varner JA, et al. **Cell Adhes Commun** 1995 Nov; 3(4):367–74 (60 ref.)
The biochemistry of cancer dissemination. Price JT, et al. **Crit Rev Biochem Mol Biol** 1997;32(3):175–253 (643 ref.)
Mechanisms and therapeutic implications of angiogenesis. Bicknell R, et al. **Curr Opin Oncol** 1996 Jan;8(1):60–5 (75 ref.)
Angiogenesis–regulating cytokines: activities and interactions. Pepper MS, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 2):31–67 (200 ref.)
Regulation of tumor angiogenesis by organ–specific cytokines. Singh RK, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 2):1–11 (50 ref.)
Growth factors and diabetic retinopathy. Paques M, et al. **Diabetes Metab** 1997 Apr;23(2):125–30 (43 ref.)
Plasminogen activators and matrix metalloproteinases in angiogenesis. Mignatti P, et al. **Enzyme Protein** 1996; 49(1–3):117–37 (216 ref.)
Role of integrins in angiogenesis. Brooks PC. **Eur J Cancer** 1996 Dec;32A(14):2423–9 (67 ref.)
Role of soluble mediators in angiogenesis. Bussolino F, et al. **Eur J Cancer** 1996 Dec;32A(14):2401–12 (110 ref.)
Angiogenesis and metastasis. Ellis LM, et al. **Eur J Cancer** 1996 Dec;32A(14):2451–60 (119 ref.)
Vascular endothelial growth factor. Ferrara N. **Eur J Cancer** 1996 Dec;32A(14):2413–22 (132 ref.)
New perspectives in clinical oncology from angiogenesis research. Folkman J. **Eur J Cancer** 1996 Dec; 32A(14):2534–9 (60 ref.)
Clinical significance of the determination of angiogenesis in human breast cancer: update of the biological background and overview of the Vicenza studies. Gasparini G. **Eur J Cancer** 1996 Dec;32A(14):2485–93 (75 ref.)
Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Hanahan D, et al. **Eur J Cancer** 1996 Dec;32A(14):2386–93 (44 ref.)
Angiogenesis in primary lung cancer and lung secondaries. Pezzella F, et al. **Eur J Cancer** 1996 Dec;32A(14):2494–500 (34 ref.)
How the extracellular matrix and macrophages contribute to angiogenesis–dependent diseases. Polverini PJ. **Eur J Cancer** 1996 Dec;32A(14):2430–7 (70 ref.)
Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis. Rak J, et al. **Eur J Cancer** 1996 Dec;32A(14):2438–50 (149 ref.)
Clinical significance of the determination of angiogenic factors. Toi M, et al. **Eur J Cancer** 1996 Dec; 32A(14):2513–9 (63 ref.)
Autocrine and paracrine roles of polypeptide growth factors, cytokines and vasogenic substances in normal and tumorous pituitary function and growth: a review. Renner U, et al. **Eur J Endocrinol** 1996 Nov;135(5):515–32 (286 ref.)
Bronchial vascular congestion and angiogenesis. Charan NB, et al. **Eur Respir J** 1997 May;10(5):1173–80 (68 ref.)
Angiogenesis and angiogenesis inhibition: an overview. Folkman J. **EXS** 1997;79:1–8 (39 ref.)
Regulation of angiogenesis in malignant gliomas. Guerin C, et al. **EXS** 1997;79:47–64 (127 ref.)
Fibroblast growth factors as angiogenesis factors: new insights into their mechanism of action. Klein S, et al. **EXS** 1997;79:159–92 (259 ref.)
Role of the macrophage in angiogenesis–dependent diseases. Polverini PJ. **EXS** 1997;79:11–28 (111 ref.)
Regulation of angiogenesis by hypoxic stress: from solid tumours to the ovarian follicle. Neeman M, et al. **Int J Exp Pathol** 1997 Apr;78(2):57–70 (121 ref.)
The role of the pericellular fibrinolytic system in angiogenesis. Fukao H, et al. **Jpn J Physiol** 1997 Apr; 47(2):161–71 (123 ref.)
Tumorangiogenesis: a network of cytokines. Hotfilder M, et al. **Klin Padiatr** 1997 Jul–Aug;209(4):265–70 (108 ref.)
Atherosclerosis as a microvascular disease: impaired angiogenesis mediated by suppressed basic fibroblast growth factor expression. Chen CH, et al. **Proc Assoc Am Physicians** 1997 Jul;109(4):351–61 (59 ref.)
Angiogenesis: a dynamic balance of stimulators and inhibitors. Iruela–Arispe ML, et al. **Thromb Haemost** 1997 Jul;78(1):672–7 (60 ref.)
[Tumoral vascularization: physiopathology and therapeutic prospects] Ortéga N, et al. **Bull Cancer** 1997 Apr; 84(4):391–5 (49 ref.) (Eng. Abstr.) **(Fre)**
[Angiogenesis––principles and significance in urologic tumors] Strohmeyer D, et al. **Urologe A** 1996 Sep; 35(5):357–62 (54 ref.) (Eng. Abstr.) **(Ger)**
[Angiogenesis and its clinical significance] Rodzaj M, et al. **Przegl Lek** 1996;53(10):750–4 (21 ref.) (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

Angiogenesis: new aspects relating to its initiation and control. Norrby K. **APMIS** 1997 Jun;105(6):417–37 (165 ref.)
Breast cancer angiogenesis––new approaches to therapy via

antiangiogenesis, hypoxic activated drugs, and vascular targeting. Harris AL, et al. **Breast Cancer Res Treat** 1996; 38(1):97–108 (52 ref.)

Hitting cancer where it hurts. Sunassee K, et al. **Curr Biol** 1997 May 1;7(5):R282–5 (10 ref.)

Regulation of angiogenesis in malignant gliomas. Guerin C, et al. **EXS** 1997;79:47–64 (127 ref.)

Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. O'Reilly MS. **EXS** 1997;79:273–94 (62 ref.)

Ovarian cancer patients with high CA–125 but no symptoms—should antiangiogenic treatments be considered? Sharma A, et al. **Oncol Res** 1997;9(2):53–4 (13 ref.)

Angiogenesis inhibition in age–related macular degeneration [editorial] D'Amato RJ, et al. **Ophthalmology** 1995 Sep; 102(9):1261–2 (9 ref.)

[Vascularization and perfusion of tumors as target in cancer therapy] Bernsen HJ, et al. **Ned Tijdschr Geneeskd** 1997 Feb 22;141(8):364–8 (25 ref.) (Eng. Abstr.) **(Dut)**

SURGERY

The peril of the pilot study [editorial; comment] Ferris FL 3rd, et al. **Arch Ophthalmol** 1996 Dec;114(12):1506–7 (10 ref.) Comment on: Arch Ophthalmol 1996 Dec;114(12):1456–64.

Macular surgery [published erratum appears in Br J Hosp Med 1996 Apr 17–30;55(8):526] Aylward GW. **Br J Hosp Med** 1996 Feb 7–20;55(3):85–8 (14 ref.)

Surgical removal of choroidal neovascular membranes. Altman BA, et al. **Optom Clin** 1996;5(1):147–59 (33 ref.)

[Evaluating the results of surgery of choroidal neovessels] Nguyen–Khoa JL, et al. **J Fr Ophtalmol** 1997;20(5):350–9 (32 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Anti–angiogenic gene therapy of malignant glioma. Stratmann A, et al. **Acta Neurochir Suppl (Wien)** 1997; 68:105–10 (30 ref.)

We are very spoiled [editorial; comment] Fine SL, et al. **Arch Ophthalmol** 1997 Jul;115(7):915–6 (11 ref.) Comment on: Arch Ophthalmol 1997 Jul;115(7):865–72.

Bladder cancer angiogenesis, its role in recurrence, stage progression and as a therapeutic target. Crew JP, et al. **Cancer Metastasis Rev** 1996 Jun;15(2):221–30 (84 ref.)

Gene therapy of malignant glioma via inhibition of tumor angiogenesis. Plate KH. **Cancer Metastasis Rev** 1996 Jun; 15(2):237–40 (20 ref.)

Antiangiogenesis for cancer therapy. Harris AL. **Lancet** 1997 May;349 Suppl 2:SII13–5 (19 ref.)

NEOVASCULARIZATION, PHYSIOLOGIC

see related

COLLATERAL CIRCULATION

Angiogenesis and the expression of vascular endothelial growth factor in endometrium and placenta. Torry DS, et al. **Am J Reprod Immunol** 1997 Jan;37(1):21–9 (87 ref.)

Angiogenesis: new aspects relating to its initiation and control. Norrby K. **APMIS** 1997 Jun;105(6):417–37 (165 ref.)

Manipulating angiogenesis. From basic science to the bedside. Pepper MS. **Arterioscler Thromb Vasc Biol** 1997 Apr; 17(4):605–19 (166 ref.)

Blood vessel formation: what is its molecular basis? [comment] Folkman J, et al. **Cell** 1996 Dec 27;87(7):1153–5 (20 ref.) Comment on: Cell 1996 Dec 27;87(7):1161–9. Comment on: Cell 1996 Dec 27;87(7):1171–80. Comment on: Cell 1996 Dec 27;87(7):1181–90.

Integrins, angiogenesis and vascular cell survival. Strömblad S, et al. **Chem Biol** 1996 Nov;3(11):881–5 (36 ref.)

Angiogenic gene therapy. A leg to stand on? [editorial; comment] Fox JC, et al. **Circulation** 1996 Dec 15; 94(12):3065–6 (11 ref.) Comment on: Circulation 1996 Dec 15;94(12):3281–90.

A little VEGF goes a long way. Therapeutic angiogenesis by direct injection of vascular endothelial growth factor–encoding plasmid DNA [editorial; comment] Majesky MW. **Circulation** 1996 Dec 15;94(12):3062–4 (17 ref.) Comment on: Circulation 1996 Dec 15;94(12):3281–90.

Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. Brown LF, et al. **EXS** 1997;79:233–69 (133 ref.)

Thrombospondin as a regulator of angiogenesis. DiPietro LA. **EXS** 1997;79:295–314 (74 ref.)

Vascular endothelial growth factor: basic biology and clinical implications. Ferrara N, et al. **EXS** 1997;79:209–32 (142 ref.)

Regulation of capillary formation by laminin and other components of the extracellular matrix. Grant DS, et al. **EXS** 1997;79:317–33 (64 ref.)

Control of angiogenesis by the pericyte: molecular mechanisms and significance. Hirschi KK, et al. **EXS** 1997; 79:419–28 (46 ref.)

Regulation of angiogenesis by scatter factor. Rosen EM, et al. **EXS** 1997;79:193–208 (93 ref.)

Role of fibrin and plasminogen activators in repair–associated angiogenesis: in vitro studies with human endothelial cells. van Hinsbergh VW, et al. **EXS** 1997;79:391–411 (119 ref.)

Vascular development: cellular and molecular regulation. Beck L Jr, et al. **FASEB J** 1997 Apr;11(5):365–73 (67 ref.)

The chick embryo chorioallantoic membrane as a model for in vivo research on angiogenesis. Ribatti D, et al. **Int J Dev Biol** 1996 Dec;40(6):1189–97 (76 ref.)

Vasculogenesis and angiogenesis: extracellular matrix remodeling in coronary collateral arteries and the ischemic heart. Tyagi SC. **J Cell Biochem** 1997 Jun 1;65(3):388–94 (51 ref.)

Endothelial adherens junctions: implications in the control of vascular permeability and angiogenesis. Dejana E. **J Clin Invest** 1996 Nov 1;98(9):1949–53 (32 ref.)

Regulation of vascular morphogenesis by the matricellular protein SPARC. Motamed K, et al. **Kidney Int** 1997 May; 51(5):1383–7 (37 ref.)

A review of the microcirculation of adipose tissue: anatomic, metabolic, and angiogenic perspectives. Crandall DL, et al. **Microcirculation** 1997 Jun;4(2):211–32 (152 ref.)

The role of mechanical stresses in microvascular remodeling. Skalak TC, et al. **Microcirculation** 1996 Jun;3(2):143–65 (198 ref.)

Possible involvement of VEGF–FLT tyrosine kinase receptor system in normal and tumor angiogenesis. Shibuya M, et al. **Princess Takamatsu Symp** 1994;24:162–70 (23 ref.)

Systemic sclerosis. A vascular perspective. LeRoy EC. **Rheum Dis Clin North Am** 1996 Nov;22(4):675–94 (52 ref.)

Angiogenesis in embryos and ischemic diseases. Breier G, et al. **Thromb Haemost** 1997 Jul;78(1):678–83 (70 ref.)

Molecular mechanisms of blood vessel formation. Bussolino F, et al. **Trends Biochem Sci** 1997 Jul;22(7):251–6 (41 ref.)

DRUG EFFECTS

Oestrogen and endothelial cell angiogenic activity. Schnaper HW, et al. **Clin Exp Pharmacol Physiol** 1996 Mar; 23(3):247–50 (20 ref.)

Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. O'Reilly MS. **EXS** 1997;79:273–94 (62 ref.)

An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action. Gradishar WJ. **Invest New Drugs** 1997;15(1):49–59 (103 ref.)

The preclinical evaluation of angiogenesis inhibitors. O'Reilly MS. **Invest New Drugs** 1997;15(1):5–13 (87 ref.)

Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action. Woltering EA, et al. **Invest New Drugs** 1997;15(1):77–86 (03 ref.)

Molecular mechanisms of angiogenesis: experimental models define cellular trafficking of FGF–1. Hicks KK, et al. **P R Health Sci J** 1996 Sep;15(3):179–86 (46 ref.)

PHYSIOLOGY

Cell adhesion molecules in angiogenesis. Brooks PC. **Cancer Metastasis Rev** 1996 Jun;15(2):187–94 (54 ref.)

What, if anything, is an angiogenic factor? Risau W. **Cancer Metastasis Rev** 1996 Jun;15(2):149–51 (25 ref.)

Vascular remodelling and molecular biology: new concepts and therapeutic possibilities. Agrotis A, et al. **Clin Exp Pharmacol Physiol** 1996 May;23(5):363–8 (57 ref.)

Vascular endothelial growth factor, a specific regulator of angiogenesis. Ferrara N, et al. **Curr Opin Nephrol Hypertens** 1996 Jan;5(1):35–44 (124 ref.)

Vascular endothelial growth factor and its receptors. Klagsbrun M, et al. **Cytokine Growth Factor Rev** 1996 Oct; 7(3):259–70 (136 ref.)

Plasminogen activators and matrix metalloproteinases in angiogenesis. Mignatti P, et al. **Enzyme Protein** 1996; 49(1–3):117–37 (216 ref.)

Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Pepper MS, et al. **Enzyme Protein** 1996;49(1–3):138–62 (94 ref.)

Role of integrins in angiogenesis. Brooks PC. **Eur J Cancer** 1996 Dec;32A(14):2423–9 (67 ref.)

Vascular endothelial growth factor. Ferrara N. **Eur J Cancer** 1996 Dec;32A(14):2413–22 (132 ref.)

Autocrine and paracrine roles of polypeptide growth factors, cytokines and vasogenic substances in normal and tumorous pituitary function and growth: a review. Renner U, et al. **Eur J Endocrinol** 1996 Nov;135(5):515–32 (286 ref.)

Angiogenesis and angiogenesis inhibition: an overview. Folkman J. **EXS** 1997;79:1–8 (39 ref.)

Fibroblast growth factors as angiogenesis factors: new insights into their mechanism of action. Klein S, et al. **EXS** 1997;79:159–92 (259 ref.)

Role of the macrophage in angiogenesis–dependent diseases. Polverini PJ. **EXS** 1997;79:11–28 (111 ref.)

Tumor angiogenesis. Petruzzelli GJ. **Head Neck** 1996 May–Jun;18(3):283–91 (49 ref.)

Vascular endothelial growth factor and the endometrium. Smith SK. **Hum Reprod** 1996 Oct;11 Suppl 2:56–61 (43 ref.)

Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans. Biological implications in neovascularization. Rusnati M, et al. **Int J Clin Lab Res** 1996;26(1):15–23 (91 ref.)

Regulation of angiogenesis by hypoxic stress: from solid tumours to the ovarian follicle. Neeman M, et al. **Int J Exp Pathol** 1997 Apr;78(2):57–70 (121 ref.)

The role of the pericellular fibrinolytic system in angiogenesis. Fukao H, et al. **Jpn J Physiol** 1997 Apr; 47(2):161–71 (123 ref.)

Growth factors in angiogenesis: current interest and therapeutic potential. Colville–Nash PR, et al. **Mol Med Today** 1997 Jan;3(1):14–23 (59 ref.)

Mechanisms of angiogenesis. Risau W. **Nature** 1997 Apr 17; 386(6626):671–4 (53 ref.)

Angiogenesis and the fibrinolytic system. Pintucci G, et al. **Semin Thromb Hemost** 1996;22(6):517–24 (124 ref.)

Angiogenesis: a dynamic balance of stimulators and inhibitors. Iruela–Arispe ML, et al. **Thromb Haemost** 1997 Jul;78(1):672–7 (60 ref.)

[Angiogenesis] Nikolić Lj. **Srp Arh Celok Lek** 1996 May–Jun; 124(5–6):147–9 (28 ref.) (Eng. Abstr.) **(Scc)**

NEPHRECTOMY

[Renal transplantectomy] Fernández Aparicio T, et al. **Arch Esp Urol** 1996 Dec;49(10):1079–91 (45 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Arteriovenous fistula following nephrectomy. Kajbafzadeh AM, et al. **Eur Urol** 1997;31(1):112–4 (12 ref.)

Transitional cell carcinoma of the ureteral stump 13 years after nephrectomy for benign disease. Manganelli A, et al. **Urol Int** 1996;56(1):52–4 (17 ref.)

[Severe and unexpected occurrence of water–electrolyte disorders in the postoperative period] Nesa S, et al. **Acta Urol Belg** 1997 Jun;65(2):71–5 (11 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Conservative surgery for renal cell carcinoma. Terrone C, et al. **Ann Urol (Paris)** 1997;31(3):137–44 (55 ref.)

Laparascopic excision of pelvic kidney with single vaginal ectopic ureter. Moores D, et al. **J Pediatr Surg** 1997 Apr; 32(4):634–5 (12 ref.)

Nephron–sparing surgery for renal cell carcinoma. Griffin JH, et al. **Tech Urol** 1996 Spring;2(1):43–7 (14 ref.)

Partial nephrectomy for pediatric renal cell carcinoma: an unusual case presentation. Manion S, et al. **Urology** 1997 Mar;49(3):465–8 (9 ref.)

[Renal oncocytoma: nephrectomy or tumorectomy? Description of five cases and review of the literature] Gabellon S, et al. **Ann Urol (Paris)** 1997;31(3):131–6 (32 ref.) (Eng. Abstr.) **(Fre)**

[Status of organ preserving surgery in renal cell carcinoma] Brkovic D, et al. **Urologe A** 1997 Mar;36(2):103–8 (33 ref.) (Eng. Abstr.) **(Ger)**

[Nephron sparing surgery for renal cell carcinoma] Faris G, et al. **Harefuah** 1996 Nov 15;131(10):438–40 (17 ref.) **(Heb)**

[Laparoscopic surgery for renal carcinomas] Suzuki K, et al. **Gan To Kagaku Ryoho** 1997 Mar;24(5):544–50 (23 ref.) (Eng. Abstr.) **(Jpn)**

NEPHRITIS

COMPLICATIONS

[Acute renal failure in glomerulonephritis and nephrotic syndrome] Furuya R, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):121–3 (14 ref.) **(Jpn)**

IMMUNOLOGY

[Superantigens and glomerulonephritis] Koyama T, et al. **Nippon Naika Gakkai Zasshi** 1997 Apr 10;86(4):695–701 (14 ref.) **(Jpn)**

[Superantigen–related nephritis(SARN)] Kobayashi M, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):167–70 (14 ref.) **(Jpn)**

[Antitubular basement membrane antibody nephritis] Ueda S, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):137–9 (17 ref.) **(Jpn)**

NEPHRITIS, FAMILIAL see **NEPHRITIS, HEREDITARY**

NEPHRITIS, HEREDITARY

DIAGNOSIS

[Progress in diagnosis and treatment of kidney diseases. III. Hereditary kidney diseases and others. 2. Alport syndrome] Harada T, et al. **Nippon Naika Gakkai Zasshi** 1996 Oct 10;85(10):1681–7 (6 ref.) **(Jpn)**

GENETICS

Alport's syndrome. Flinter F. **J Med Genet** 1997 Apr; 34(4):326–30 (61 ref.)

Alport syndrome. Kashtan CE, et al. **Kidney Int** 1996 Nov; 50(5):1445–63 (186 ref.)

Alport syndrome. Kashtan CE. **Kidney Int Suppl** 1997 Mar; 58:S69–71 (28 ref.)

[Hereditary renal diseases and their genetic diagnosis (editorial)] Kääriäinen H, et al. **Duodecim** 1995; 111(15):1398–400 (10 ref.) **(Fin)**

[Alport syndrome] Kawai S, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):87–90 (19 ref.) **(Jpn)**

METABOLISM

Alport syndrome. Kashtan CE, et al. **Kidney Int** 1996 Nov;

50(5):1445–63 (186 ref.)

PHYSIOPATHOLOGY

Alport syndrome. Kashtan CE. **Kidney Int Suppl** 1997 Mar; 58:S69–71 (28 ref.)

THERAPY

Can Alport syndrome be treated by gene therapy? Tryggvason K, et al. **Kidney Int** 1997 May;51(5):1493–9 (43 ref.)

[Progress in diagnosis and treatment of kidney diseases. III. Hereditary kidney diseases and others. 2. Alport syndrome] Harada T, et al. **Nippon Naika Gakkai Zasshi** 1996 Oct 10;85(10):1681–7 (6 ref.) **(Jpn)**

NEPHRITIS, INTERSTITIAL

CHEMICALLY INDUCED

[Interstitial nephropathies of toxic or drug origin. New causes, new prospects] Fillastre JP, et al. **Presse Med** 1997 Mar 29;26(10):477–84 (45 ref.) (Eng. Abstr.) **(Fre)**

[Nephrotoxin-induced tubulointerstitial nephropathies] Kliem V, et al. **Internist (Berl)** 1996 Nov;37(11):1116–28 (96 ref.) **(Ger)**

[Analgesic nephropathy] Pommer W, et al. **Internist (Berl)** 1996 Nov;37(11):1129–36 (65 ref.) **(Ger)**

[Acute, drug-induced tubulointerstitial nephritis] Schlöndorff D, et al. **Internist (Berl)** 1996 Nov;37(11):1084–91 (27 ref.) **(Ger)**

CLASSIFICATION

[Idiopathic tubulointerstitial nephritis (acute, chronic)] Takeda F, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):258–61 (14 ref.) **(Jpn)**

COMPLICATIONS

A case of Sjögren's syndrome associated with Sweet's syndrome. Osawa H, et al. **Clin Rheumatol** 1997 Jan; 16(1):101–5 (16 ref.)

Epstein-Barr virus infection associated with interstitial nephritis and chronic fatigue. López-Navidad A, et al. **Scand J Infect Dis** 1996;28(2):185–7 (20 ref.)

[Acute interstitial nephritis with bone marrow granulomas and uveitis] Akioka Y, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):270–1 (8 ref.) **(Jpn)**

[Tubulointerstitial nephritis and arterial hypertension—their clinical and population significance (editorial)] Mukhin NA, et al. **Ter Arkh** 1997;69(6):5–10 (23 ref.) **(Rus)**

DIAGNOSIS

[Progress in diagnosis and treatment of renal diseases. III. Hereditary kidney diseases and others. 3. Acute interstitial nephritis] Sano M, et al. **Nippon Naika Gakkai Zasshi** 1996 Oct 10;85(10):1688–93 (5 ref.) **(Jpn)**

[Tubulo-interstitial nephropathy; TIN] Inoue S, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):266–9 (8 ref.) **(Jpn)**

DRUG THERAPY

[Progress in diagnosis and treatment of renal diseases. III. Hereditary kidney diseases and others. 3. Acute interstitial nephritis] Sano M, et al. **Nippon Naika Gakkai Zasshi** 1996 Oct 10;85(10):1688–93 (5 ref.) **(Jpn)**

ETIOLOGY

Polyomavirus-induced interstitial nephritis in two renal transplant recipients: case reports and review of the literature. Mathur VS, et al. **Am J Kidney Dis** 1997 May; 29(5):754–8 (9 ref.)

Interstitial nephritis. Dhillon S, et al. **Postgrad Med J** 1997 Mar;73(857):151–5 (33 ref.)

[Tubulointerstitial kidney involvement in systemic diseases] Haas-Wöhrle A, et al. **Internist (Berl)** 1996 Nov; 37(11):1111–5 (36 ref.) **(Ger)**

[Tubulointerstitial kidney diseases in urinary tract infection, reflux and obstruction] Krautzig S, et al. **Internist (Berl)** 1996 Nov;37(11):1096–110 (61 ref.) **(Ger)**

[Uric acid and tubulointerstitial kidney diseases] Wrenger E, et al. **Internist (Berl)** 1996 Nov;37(11):1137–42 (51 ref.) **(Ger)**

[Coping with pathological changes in digestive system and kidney in collagen diseases--special reference to Sjogren's syndrome and interstitial nephritis] Matsumura R, et al. **Nippon Naika Gakkai Zasshi** 1996 Nov 10;85(11):1867–71 (5 ref.) **(Jpn)**

[Tubulointerstitial nephritis induced by chronic bacterial infection] Hirose T. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):278–80 (11 ref.) **(Jpn)**

[Interstitial nephritis associated with neoplasms] Kato N, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):242–7 (22 ref.) **(Jpn)**

[Tubulo-interstitial nephritis associated with abnormal immune system] Kawaguchi K. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):281–3 (9 ref.) **(Jpn)**

[Granulomatous interstitial nephritis] Tateno S, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):262–5 (18 ref.) **(Jpn)**

GENETICS

Expression of genes that promote renal interstitial fibrosis in rats with proteinuria. Eddy AA. **Kidney Int Suppl** 1996 May;54:S49–54 (24 ref.)

IMMUNOLOGY

[Immune complex mediated tubulo-interstitial nephritis] Ehara T, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):284–6 (7 ref.) **(Jpn)**

METABOLISM

Modulation of glomerular sclerosis and interstitial fibrosis by native and modified lipoproteins. Gröne HJ, et al. **Kidney Int Suppl** 1996 May;54:S18–22 (28 ref.)

PATHOLOGY

Phenotypic features of cortical interstitial cells potentially important in fibrosis. Alpers CE, et al. **Kidney Int Suppl** 1996 May;54:S28–31 (37 ref.)

Pathogenesis of chronic renal failure in the primary glomerulopathies, renal vasculopathies, and chronic interstitial nephritides. Bohle A, et al. **Kidney Int Suppl** 1996 May;54:S2–9 (44 ref.)

Significance of tubulointerstitial changes in diabetic renal disease. Ziyadeh FN. **Kidney Int Suppl** 1996 May;54:S10–3 (57 ref.)

[Interstitial changes in kidney transplants] Schindler R, et al. **Internist (Berl)** 1996 Nov;37(11):1152–8 (61 ref.) **(Ger)**

[Interstitial involvement in glomerulonephritis] Strutz F, et al. **Internist (Berl)** 1996 Nov;37(11):1143–51 (80 ref.) **(Ger)**

NEPHRITIS, LUPUS see **LUPUS NEPHRITIS**

NEPHRITIS, TUBULOINTERSTITIAL see **NEPHRITIS, INTERSTITIAL**

NEPHROBLASTOMA

see related
GENES, WILMS' TUMOR

Wilms' tumor in an adult: a case report and review of the literature. Butler D, et al. **J Ky Med Assoc** 1997 May; 95(5):191–6 (23 ref.)

Current issues in the diagnosis and management of Wilms' tumor. Paulino AC. **Oncology (Huntingt)** 1996 Oct; 10(10):1553–65; discussion 1565–71 (90 ref.)

[WAGR syndrome] Teraoka M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):227–8 (14 ref.) **(Jpn)**

[Nephroblastoma] Yokomori K. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):474–7 (16 ref.) **(Jpn)**

COMPLICATIONS

Wilms' tumour presenting as a pulmonary embolism. Ceelen W, et al. **Acta Chir Belg** 1997 Jun;97(3):148–50 (12 ref.)

Wilms tumor associated with polycythemia: case report and review of the literature. Lal A, et al. **J Pediatr Hematol Oncol** 1997 May-Jun;19(3):263–5 (19 ref.)

DIAGNOSIS

Re: Is contralateral exploration of the kidney necessary in patients with Wilms tumor? [letter; comment] Paulino AC. **J Urol** 1997 Jun;157(6):2265 (6 ref.) Comment on: J Urol 1996 Aug;156(2 Pt 2):693–5.

GENETICS

Atypical presentation of Denys-Drash syndrome in a female with a novel Wt1 gene mutation. Machin GA. **Birth Defects Orig Artic Ser** 1996;30(1):269–86 (29 ref.)

Genetics of renal tumours. Fleming S. **Cancer Metastasis Rev** 1997 Jun;16(1-2):127–40 (144 ref.)

Multiple genetic abnormalities of 11p15 in Wilms' tumor. Feinberg AP. **Med Pediatr Oncol** 1996 Nov;27(5):484–9 (61 ref.)

An overview of the clinical and molecular genetics of Wilms' tumor. Grundy P, et al. **Med Pediatr Oncol** 1996 Nov; 27(5):394–7 (53 ref.)

Role of genomic imprinting in Wilms' tumour and overgrowth disorders. Reeve AE. **Med Pediatr Oncol** 1996 Nov;27(5):470–5 (50 ref.)

Beck-Wiedemann syndrome and Wilms' tumour. Ward A. **Mol Hum Reprod** 1997 Feb;3(2):157–68 (184 ref.)

[Genetic alterations associated with pathologic differentiation of Wilms' tumors] Chevalier G, et al. **Bull Cancer** 1997 Mar;84(3):289–303 (127 ref.) (Eng. Abstr.) **(Fre)**

[Molecular genetics of Wilm's tumor] Kaplinsky C, et al. **Harefuah** 1997 May 15;132(10):706–10 (42 ref.) **(Heb)**

[Genetic events and molecular biology of Wilms' tumor] Navajas Gutiérrez A, et al. **An Esp Pediatr** 1997 Feb; 46(2):105–8 (39 ref.) **(Spa)**

PATHOLOGY

Cytodifferentiation of a Wilms' tumor pulmonary metastasis: theoretic and clinical implications. Seemayer TA, et al. **Cancer** 1997 Apr 15;79(8):1629–34 (20 ref.)

New developments in the pathology of Wilms tumor. Beckwith JB. **Cancer Invest** 1997;15(2):153–62 (31 ref.)

Hyperdiploidy and trisomy 12 in the cystic partially differentiated nephroblastoma. de Chadarévian JP, et al. **Hum Pathol** 1996 Sep;27(9):980–1 (5 ref.)

Primary extrarenal Wilms' tumor in the inguinal canal: case report and review of the literature. Arkovitz MS, et al. **J Pediatr Surg** 1996 Jul;31(7):957–9 (15 ref.)

Histological analysis of aggressiveness and responsiveness in Wilms' tumor. Beckwith JB, et al. **Med Pediatr Oncol** 1996 Nov;27(5):422–8 (20 ref.)

Dedifferentiated cystic nephroma with malignant mesenchymoma as the dedifferentiated component. Faria PA, et al. **Pediatr Pathol Lab Med** 1996 Nov-Dec; 16(6):1003–11 (21 ref.)

[Multilocular cystic nephroma, multilocular renal cyst] Komatsu H, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):509–11 (10 ref.) **(Jpn)**

PREVENTION & CONTROL

Screening for Wilms' tumor in children with high-risk congenital syndromes: considerations for an intervention trial. DeBaun MR, et al. **Med Pediatr Oncol** 1996 Nov; 27(5):415–21 (38 ref.)

RADIOTHERAPY

Radiotherapy in Wilms' tumour. Thomas PR. **Ann Acad Med Singapore** 1996 May;25(3):425–8 (21 ref.)

SECONDARY

Cytodifferentiation of a Wilms' tumor pulmonary metastasis: theoretic and clinical implications. Seemayer TA, et al. **Cancer** 1997 Apr 15;79(8):1629–34 (20 ref.)

SURGERY

Current surgical management of Wilms' tumor. Haase GM. **Curr Opin Pediatr** 1996 Jun;8(3):268–75 (65 ref.)

THERAPY

Wilms' tumour. Green DM. **Eur J Cancer** 1997 Mar; 33(3):409–18; discussion 19–20 (130 ref.)

Nephroblastoma. Haase GM, et al. **Semin Pediatr Surg** 1997 Feb;6(1):11–6 (50 ref.)

[Experience in treating Nephroblastomas] Lebedev VI, et al. **Vestn Ross Akad Med Nauk** 1996;(10):13–7 (10 ref.) (Eng. Abstr.) **(Rus)**

VETERINARY

Tumours of the kidney. Tsuda H, et al. **IARC Sci Publ** 1996; (126):223–42 (119 ref.)

NEPHROCALCINOSIS

Nephrocalcinosis. Alon US. **Curr Opin Pediatr** 1997 Apr; 9(2):160–5 (51 ref.)

COMPLICATIONS

Intratubular crystallization events. Kok DJ. **World J Urol** 1997;15(4):219–28 (89 ref.)

NEPHROLITHOTOMY, PERCUTANEOUS see **NEPHROSTOMY, PERCUTANEOUS**

NEPHROLOGY

see related
KIDNEY DISEASES

Endothelin antagonists on the clinical horizon in nephrology. Rabelink TJ, et al. **Curr Opin Nephrol Hypertens** 1996 Sep; 5(5):389–92 (43 ref.)

The hyperfiltration theory: a paradigm shift in nephrology. Brenner BM, et al. **Kidney Int** 1996 Jun;49(6):1774–7 (55 ref.)

The history of salt – aspects of interest to the nephrologist. Ritz E. **Nephrol Dial Transplant** 1996 Jun;11(6):969–75 (7 ref.)

METHODS

Minimal invasive in vivo pharmacology: news of a new method holding promise in nephrology-related research [editorial] Wenzel RR. **Nephrol Dial Transplant** 1997 Apr; 12(4):649–51 (13 ref.)

Acute dialysis and continuous renal replacement: the emergence of new technology involving the nephrologist in the intensive care setting. Yagi N, et al. **Semin Nephrol** 1997 Jul;17(4):306–20 (126 ref.)

TRENDS

The renal epithelial sodium channel: new insights in understanding hypertension. Rossier BC. **Adv Nephrol Necker Hosp** 1996;25:275–86 (38 ref.)

Update on pathogenesis, markers and management of diabetic nephropathy. Mogyorósi A, et al. **Curr Opin Nephrol Hypertens** 1996 May;5(3):243–53 (150 ref.)

Gene targeting in nephrology. Matsusaka T, et al.

NEPHROLOGY

Exp Nephrol 1997 Mar–Apr;5(2):168–73 (40 ref.)

Renal artery stenosis towards the year 2000. Derkx FH, et al. **J Hypertens Suppl** 1996 Dec;14(5):S167–72 (28 ref.)

Latin American nephrology: present state and future concerns. Committee on Nephrology Development and National Problems of the Latin American Society of Nephrology and Hypertension (SLANH). Challú A, et al. **Kidney Int** 1997 Sep;52(3):583–8 (20 ref.)

Nephrology. The year of the pores. Schieppati A, et al. **Lancet** 1996 Dec 21–28;348 Suppl 2:sII13 (5 ref.)

Update in nephrology. Maher MJ, et al. **Med Health R I** 1996 Mar;79(3):110–12 (13 ref.)

Adhesion molecules and the mechanisms of kidney rejection [editorial] de Bustillo EM, et al. **Nephrol Dial Transplant** 1996 Jun;11(6):949–52 (34 ref.)

The year 1995–1996 in review: genetically re–engineering clinical nephrology. Trachtman H. **Pediatr Nephrol** 1997 Jun;11(3):377–81 (27 ref.)

The mechanisms of renal tubule electrolyte and water absorption, 100 years after Carl Ludwig. Greger R. **Pflugers Arch** 1996;432(3 Suppl):R82–6 (31 ref.)

Controversies on glomerular filtration from Ludwig to the present. Steinhausen M, et al. **Pflugers Arch** 1996;432(3 Suppl):R73–81 (79 ref.)

NEPHROMA, MESOBLASTIC

CONGENITAL

Atypical mesoblastic nephroma. A potentially malignant variant of congenital mesoblastic nephroma. Review of literature & report of four cases. Sane SY, et al. **Indian J Cancer** 1996 Mar;33(1):6–11 (26 ref.)

[Congenital mesoblastic nephroma] Maeda M, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):505–8 (20 ref.) **(Jpn)**

PATHOLOGY

Atypical mesoblastic nephroma. A potentially malignant variant of congenital mesoblastic nephroma. Review of literature & report of four cases. Sane SY, et al. **Indian J Cancer** 1996 Mar;33(1):6–11 (26 ref.)

[Mesoblastic nephroma in adults. Apropos of a case and review of the literature] Bouvier R, et al. **Arch Anat Cytol Pathol** 1996;44(1):37–41 (17 ref.) (Eng. Abstr.) **(Fre)**

NEPHRONS

DRUG EFFECTS

Are low osmolality contrast media less nephrotoxic? [editorial] Deray G, et al. **Nephrol Dial Transplant** 1996 Jun;11(6):930–1 (14 ref.)

EMBRYOLOGY

Fetal nephron mass: its control and deficit. Merlet–Bénichou C, et al. **Adv Nephrol Necker Hosp** 1997;26:19–45 (173 ref.)

ENZYMOLOGY

H+, K(+)–ATPASE in the kidney: localization and function in the nephron. Doucet A. **Exp Nephrol** 1997 Jul–Aug; 5(4):271–6 (32 ref.)

Na,K–pump expression and distribution in the nephron. Farman N. **Miner Electrolyte Metab** 1996;22(5–6):272–8 (36 ref.)

PATHOLOGY

Progressive renal failure––inability of podocytes to replicate and the consequences for development of glomerulosclerosis. Kriz W. **Nephrol Dial Transplant** 1996 Sep;11(9):1738–42 (16 ref.)

PHYSIOLOGY

Congenital oligonephropathy: The fetal flaw in essential hypertension? Mackenzie HS, et al. **Kidney Int Suppl** 1996 Jun;55:S30–4 (71 ref.)

NEPHROPATHIA EPIDEMICA see **HANTAVIRUS INFECTIONS**

NEPHROPATHY, IGA see **GLOMERULONEPHRITIS, IGA**

NEPHROPATHY, MEMBRANOUS see **GLOMERULONEPHRITIS, MEMBRANOUS**

NEPHROPATHY, MINIMAL CHANGE see **NEPHROSIS, LIPOID**

NEPHROSCLEROSIS

Nephroangiosclerosis and hypertension: things are not as simple as you might think [editorial] Meyrier A, et al. **Nephrol Dial Transplant** 1996 Nov;11(11):2116–20 (34 ref.)

DIAGNOSIS

Renal vascular lesions in the elderly: nephrosclerosis or atheromatous renal disease? Meyrier A. **Nephrol Dial Transplant** 1996;11 Suppl 9:45–52 (60 ref.)

EPIDEMIOLOGY

Vascular nephropathies and nephrosclerosis: epidemiology and pathophysiology. Meyrier A, et al. **Adv Nephrol Necker Hosp** 1997;26:207–45 (261 ref.)

ETIOLOGY

Is nephroangiosclerosis a hypertension–induced nephropathy? Zuccalà A, et al. **Contrib Nephrol** 1996; 119:110–4 (15 ref.)

[Progress in diagnosis and treatment of renal diseases. II. Nephropathies associated with systemic diseases. 4. Malignant nephrosclerosis] Abe K, et al. **Nippon Naika Gakkai Zasshi** 1996 Oct 10;85(10):1668–73 (4 ref.) **(Jpn)**

[Nephrosclerosis (benign, malignant)] Takebayashi S, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):305–8 (4 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Vasoactive hormones and renal sclerosis. Egido J. **Kidney Int** 1996 Feb;49(2):578–97 (229 ref.)

NEPHROSIS

IMMUNOLOGY

Minimal change nephrosis and allergy. Wardle EN. **Nephron** 1996;74(2):422–3 (24 ref.)

METABOLISM

Lipoprotein metabolism in experimental nephrosis. Marsh JB. **Proc Soc Exp Biol Med** 1996 Nov;213(2):178–86 (78 ref.)

NEPHROSIS, LIPOID

[Minimal change glomerulonephritis] Naito T, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):194–7 (21 ref.) **(Jpn)**

COMPLICATIONS

Childhood nephrotic syndrome in Africa: the steroid question [editorial; comment] Luta M. **East Afr Med J** 1997 Apr; 74(4):205–6 (9 ref.) Comment on: East Afr Med J 1997 Apr;74(4):207–9.

DRUG THERAPY

Childhood nephrotic syndrome in Africa: the steroid question [editorial; comment] Luta M. **East Afr Med J** 1997 Apr; 74(4):205–6 (9 ref.) Comment on: East Afr Med J 1997 Apr;74(4):207–9.

Renal disease. II. The treatment of minimal change nephropathy and focal segmental glomerulosclerosis. Mason PD. **J R Coll Physicians Lond** 1997 Mar–Apr; 31(2):137–41 (20 ref.)

ETIOLOGY

Minimal change nephrotic syndrome with cecum adenocarcinoma. Gandini E, et al. **Clin Nephrol** 1996 Apr; 45(4):268–70 (27 ref.)

PATHOLOGY

Newer glomerular diseases. Abt AB, et al. **Semin Nephrol** 1996 Nov;16(6):501–10 (51 ref.)

PHYSIOPATHOLOGY

Minimal change nephropathy and focal segmental glomerulosclerosis. Mallick NP, et al. **Kidney Int Suppl** 1997 Mar;58:S80–2 (23 ref.)

NEPHROSTOMY, PERCUTANEOUS

Update on interventional uroradiology. Dyer RB, et al. **Urol Clin North Am** 1997 Aug;24(3):623–52 (128 ref.)

Percutaneous nephrostolithotomy. What is its role in 1997? Wolf JS Jr, et al. **Urol Clin North Am** 1997 Feb;24(1):43–58 (64 ref.)

Conservative management of colon injury following percutaneous renal surgery. Gerspach JM, et al. **Urology** 1997 Jun;49(6):831–6 (14 ref.)

INSTRUMENTATION

[Percutaneous therapy of kidney calculi. Current status] Kaldenbach U, et al. **Med Monatsschr Pharm** 1997 Apr; 20(4):90–7 (62 ref.) **(Ger)**

METHODS

[Endoscopic techniques in the treatment of calculi in the upper urinary tract] Hem E. **Tidsskr Nor Laegeforen** 1996 Oct 10;116(24):2893–6 (28 ref.) (Eng. Abstr.) **(Nor)**

NEPHROTIC SYNDROME

[Nephrotic syndrome (primary, secondary)] Ohno I, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):190–3 (17 ref.) **(Jpn)**

BLOOD

Circulating interleukin 2 receptor (IL2R) in nephrotic syndrome. Hulton SA, et al. **Kidney Int Suppl** 1997 Mar; 58:S83–4 (15 ref.)

Insulin–like growth factor–I and insulin–like growth factor–binding proteins in the nephrotic syndrome. Feld SM, et al. **Pediatr Nephrol** 1996 Jun;10(3):355–8 (23 ref.)

CLASSIFICATION

[Primary and secondary glomerular diseases] Arakawa M, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):128–32 (7 ref.) **(Jpn)**

COMPLICATIONS

Acute renal failure in idiopathic nephrotic syndrome. Loghman–Adham M, et al. **Clin Nephrol** 1997 Feb; 47(2):76–80 (29 ref.)

Mesangial lupus nephritis with associated nephrotic syndrome. Stankeviciute N, et al. **J Am Soc Nephrol** 1997 Jul;8(7):1199–204 (13 ref.)

Management of intractable edema in nephrotic syndrome. Glassock RJ. **Kidney Int Suppl** 1997 Mar;58:S75–9 (25 ref.)

Pathogenesis of edema formation in the nephrotic syndrome. Palmer BF, et al. **Kidney Int Suppl** 1997 Jun;59:S21–7 (69 ref.)

A child with nephrotic syndrome and with focal and segmental glomerulosclerosis: do we have to care about associated malformations? Ehrich JH, et al. **Nephrol Dial Transplant** 1996 Oct;11(10):2096–8 (29 ref.)

Thromboembolic risks and complications in nephrotic children. Schlegel N. **Semin Thromb Hemost** 1997; 23(3):271–80 (88 ref.)

[Acute renal failure in glomerulonephritis and nephrotic syndrome] Furuya R, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):121–3 (14 ref.) **(Jpn)**

[Acute myocardial infarction and thromboembolic complications in the nephrotic syndrome] Harada A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):436–9 (24 ref.) **(Jpn)**

CONGENITAL

Congenital nephrotic syndrome. Holmberg C, et al. **Kidney Int Suppl** 1996 Jan;53:S51–6 (42 ref.)

[Congenital nephrotic syndrome] Hattori M, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):175–7 (3 ref.) **(Jpn)**

DIAGNOSIS

Esophageal carcinoma presenting with nephrotic syndrome: association with anti–neutrophil cytoplasmic antibody. Yedidag A, et al. **Am J Gastroenterol** 1997 Feb;92(2):326–8 (20 ref.)

[Progress in diagnosis and treatment of renal diseases. I. Primary glomerular diseases. 3. Nephrotic syndrome] Dohi K, et al. **Nippon Naika Gakkai Zasshi** 1996 Oct 10; 85(10):1639–44 (5 ref.) **(Jpn)**

[Kidney involvement in hereditary osteo–onychodysplasia] Kozlovskaia NL, et al. **Ter Arkh** 1997;69(6):37–9 (13 ref.) (Eng. Abstr.) **(Rus)**

[The nephrotic syndrome in a female patient with hereditary hyperlipidemia type V] Podzolkov VI, et al. **Ter Arkh** 1996; 68(4):27–9 (6 ref.) **(Rus)**

DIET THERAPY

Nutrition in renal disease. Mallat SG. **J Med Liban** 1997; 45(2):90–2 (25 ref.)

DRUG THERAPY

Diuretic combinations in refractory oedema states: pharmacokinetic–pharmacodynamic relationships. Sica DA, et al. **Clin Pharmacokinet** 1996 Mar;30(3):229–49 (132 ref.)

Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults. Tune BM, et al. **J Am Soc Nephrol** 1997 May;8(5):824–32 (50 ref.)

Treatment of idiopathic nephrotic syndrome with cyclosporine A. Meyrier A. **J Nephrol** 1997 Jan–Feb; 10(1):14–24 (76 ref.)

Renal disease. II. The treatment of minimal change nephropathy and focal segmental glomerulosclerosis. Mason PD. **J R Coll Physicians Lond** 1997 Mar–Apr; 31(2):137–41 (20 ref.)

Management of nephrotic syndrome in children: a review. Khan MA, et al. **JPMA J Pak Med Assoc** 1996 May; 46(5):113–6 (32 ref.)

Management of intractable edema in nephrotic syndrome. Glassock RJ. **Kidney Int Suppl** 1997 Mar;58:S75–9 (25 ref.)

Cyclosporine in the therapy of steroid–resistant idiopathic nephrotic syndrome. Niaudet P, et al. **Kidney Int Suppl** 1997 Mar;58:S85–90 (66 ref.)

Use of cyclosporine A in the treatment of refractory nephrotic syndrome in adults. Meyrier A. **Ren Fail** 1996 Sep;18(5):775–84 (42 ref.)

ETIOLOGY

Nephrotic syndrome associated with chronic lymphocytic leukemia resistant to immunosuppressive drugs: remission obtained by splenectomy [see comments] Halimi JM, et

al. **Clin Nephrol** 1996 Apr;45(4):273–6 (19 ref.) Comment in: Clin Nephrol 1997 Feb;47(2):131–3.

Steroid-resistant nephrotic syndrome associated with malignant thymoma. Ishida I, et al. **Clin Nephrol** 1996 Nov; 46(5):340–6 (25 ref.)

Childhood nephrotic syndrome in Africa: the steroid question [editorial; comment] Luta M. **East Afr Med J** 1997 Apr; 74(4):205–6 (9 ref.) Comment on: East Afr Med J 1997 Apr;74(4):207–9.

Clinical spectrum and complications of the nephrotic syndrome. Abrass CK. **J Investig Med** 1997 Apr; 45(4):143–53 (101 ref.)

Acute renal failure and nephrotic syndrome with alpha interferon therapy. Dimitrov Y, et al. **Nephrol Dial Transplant** 1997 Jan;12(1):200–3 (23 ref.)

Nephrotic syndrome in the elderly. Cameron JS. **Semin Nephrol** 1996 Jul;16(4):319–29 (53 ref.)

[A case of nephrotic syndrome after bone marrow transplantation] Yabana M, et al. **Nippon Jinzo Gakkai Shi** 1997 May;39(4):414–20 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Nephrotic syndrome related to chronic graft versus host disease after allogeneic bone marrow transplantation in a patient with malignant lymphoma] Haseyama K, et al. **Rinsho Ketsueki** 1996 Dec;37(12):1383–8 (20 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Circulating interleukin 2 receptor (IL2R) in nephrotic syndrome. Hulton SA, et al. **Kidney Int Suppl** 1997 Mar; 58:S83–4 (15 ref.)

Minimal change nephrosis and allergy. Wardle EN. **Nephron** 1996;74(2):422–3 (24 ref.)

METABOLISM

[Nephrotic syndrome and protein metabolism] Fouque D. **Nephrologie** 1996;17(5):279–82 (24 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

A 51-year-old woman with nephrotic syndrome, hematuria, and renal insufficiency. Fogo A, et al. **Am J Kidney Dis** 1997 May;29(5):806–10 (30 ref.)

Thymoma presenting as nephrotic syndrome—an unusual case report and review of literature. Sirpal YM. **Indian J Cancer** 1995 Jun;32(2):89–92 (12 ref.)

PHYSIOPATHOLOGY

Regulation of renal sodium and water excretion in the nephrotic syndrome and cirrhosis of the liver. Jespersen B. **Dan Med Bull** 1997 Apr;44(2):191–207 (230 ref.)

Proteinuria and albumin homeostasis in the nephrotic syndrome: effect of dietary protein intake. Rodrigo R, et al. **Nutr Rev** 1996 Nov;54(11 Pt 1):337–47 (107 ref.)

[What is new in nephrotic syndrome?] Popović-Rolović M, et al. **Srp Arh Celok Lek** 1996;124 Suppl 1:13–8 (15 ref.) (Eng. Abstr.) **(Scc)**

SURGERY

Nephrotic syndrome associated with chronic lymphocytic leukemia resistant to immunosuppressive drugs: remission obtained by splenectomy [see comments] Halimi JM, et al. **Clin Nephrol** 1996 Apr;45(4):273–6 (19 ref.) Comment in: Clin Nephrol 1997 Feb;47(2):131–3.

THERAPY

Management of recurrent nephrotic syndrome after kidney transplantation in children. Cochat P, et al. **Clin Nephrol** 1996 Jul;46(1):17–20 (27 ref.)

[Clinical application of albumin: a closer look at indications] Smorenburg CH, et al. **Ned Tijdschr Geneeskd** 1997 Apr 12;141(15):719–23 (47 ref.) (Eng. Abstr.) **(Dut)**

[The usefulness of plasmapheresis in a case of nephrotic syndrome in Berger's disease] Pergolini M, et al. **Clin Ter** 1996 Nov;147(11):543–7 (13 ref.) (Eng. Abstr.) **(Ita)**

[Progress in diagnosis and treatment of renal diseases. I. Primary glomerular diseases. 3. Nephrotic syndrome] Dohi K, et al. **Nippon Naika Gakkai Zasshi** 1996 Oct 10; 85(10):1639–44 (5 ref.) **(Jpn)**

[Treatment of nephrotic syndrome] Djukanović LJ. **Srp Arh Celok Lek** 1996;124 Suppl 1:70–4 (42 ref.) (Eng. Abstr.) **(Scc)**

[Therapy of nephrotic syndrome in membranous glomerulonephritis] Kovačević Z, et al. **Vojnosanit Pregl** 1997 Mar-Apr;54(2):161–5 (54 ref.) **(Scr)**

[Modern therapy of idiopathic nephrotic syndrome] Kovačević Z, et al. **Vojnosanit Pregl** 1996 Sep-Oct; 53(5):409–14 (56 ref.) **(Scr)**

NEPHROTIC SYNDROME, MINIMAL CHANGE see **NEPHROSIS, LIPOID**

NEPRILYSIN

ANALYSIS

Endopeptidase-24.11 (neprilysin) and relatives: twenty years on. Turner AJ, et al. **Adv Exp Med Biol** 1996;389:141–8 (34 ref.)

ANTAGONISTS & INHIBITORS

Neutral endopeptidase inhibitors and the pulmonary circulation. Thompson JS, et al. **Gen Pharmacol** 1996 Jun; 27(4):581–5 (50 ref.)

Association of enkephalin catabolism inhibitors and CCK-B antagonists: a potential use in the management of pain and opioid addiction. Roques BP, et al. **Neurochem Res** 1996 Nov;21(11):1397–410 (116 ref.)

IMMUNOLOGY

CD10 in acute leukemias. GEIL (Groupe d'Etude Immunologique des Leucémies). Béné MC, et al. **Haematologica** 1997 Mar-Apr;82(2):205–10 (49 ref.)

NERVE BLOCK

Neural blockade for diagnosis and prognosis. A review [see comments] Hogan QH, et al. **Anesthesiology** 1997 Jan; 86(1):216–41 (266 ref.) Comment in: Anesthesiology 1997 Jan;86(1):4–6.

Neural blockade in chronic and cancer pain. Lamacraft G, et al. **Int Anesthesiol Clin** 1997 Spring;35(2):131–53 (71 ref.)

METHODS

Nerve blocks for regional anesthesia of the face. Kretzschmar JL, et al. **Am Fam Physician** 1997 Apr;55(5):1701–4 (04 ref.)

Treatment of algodystrophy using intravenous guanethidine regional block. Jacquemoud G, et al. **Ann Chir Main** 1982; 1(1):57–64 (16 ref.) **(Eng, Fre)**

Neural blockade for upper-extremity pain. Fouch RA, et al. **Hand Clin** 1996 Nov;12(4):791–800 (33 ref.)

The "ART" mandibular nerve block: a new approach to accomplishing regional anesthesia. Gaum LI, et al. **J Can Dent Assoc** 1997 Jun;63(6):454–9 (18 ref.)

Use of streptomycin-lidocaine injections in the treatment of the cluster-tic syndrome. Clinical perspectives and a case report. Kreiner M. **J Craniomaxillofac Surg** 1996 Oct; 24(5):289–92 (48 ref.)

Verification of sensory block during regional anesthesia. de Leon-Casasola OA. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):126–8 (11 ref.)

[Three-in-one block or femoral nerve block. What should be done and how?] Dupré LJ. **Ann Fr Anesth Reanim** 1996; 15(7):1099–101 (33 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

[Basis and use of neural therapy in diagnosis and treatment] Zohmann A. **Schweiz Arch Tierheilkd** 1997;139(3):117–25 (58 ref.) (Eng. Abstr.) **(Ger)**

NERVE CELLS see **NEURONS**

NERVE COMPRESSION SYNDROMES

Compression neuropathies about the shoulder. Goldberg RS, et al. **Ann Chir Gynaecol** 1996;85(2):159–65 (34 ref.)

Nerve entrapment syndromes [see comments] Nakano KK. **Curr Opin Rheumatol** 1997 Mar;9(2):165–73 (58 ref.) Comment in: Curr Opin Rheumatol 1997 Mar;9(2):133–43.

[Pneumatic tourniquets in orthopedics] Estebe JP, et al. **Ann Fr Anesth Reanim** 1996;15(2):162–78 (211 ref.) (Eng. Abstr.) **(Fre)**

[Compression of the peroneal nerve by a synovial cyst in a 7-year-oldchild] Gayet LE, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(8):762–6 (17 ref.) (Eng. Abstr.) **(Fre)**

[Diagnosis and treatment of entrapment neuropathy] Horiuchi Y. **Nippon Seikeigeka Gakkai Zasshi** 1997 May; 71(5):171–82 (30 ref.) **(Jpn)**

CHEMICALLY INDUCED

[Neurologic sequelae of spinal anesthesia: local anesthetic toxicity] Sakura S, et al. **Masui** 1996 Jul;45(7):846–51 (25 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Cervical angina. Wells P. **Am Fam Physician** 1997 May 1; 55(6):2262–4 (06 ref.)

The piriformis syndrome [see comments] Parziale JR, et al. **Am J Orthop** 1996 Dec;25(12):819–23 (33 ref.) Comment in: Am J Orthop 1997 May;26(5):316, 318.

Irreducible open intertrochanteric hip fracture secondary to entrapment of the sciatic nerve in a child. Wiss DA, et al. **J Orthop Trauma** 1997 Jan;11(1):38–40 (10 ref.)

[Management of trigeminal neuralgia by microvascular decompression] Kuncz A, et al. **Orv Hetil** 1997 Aug 17; 138(33):2051–5 (39 ref.) (Eng. Abstr.) **(Hun)**

[Clinical study in vertiginuous patients suspected of having neurovascular compression syndrome of the eighth cranial nerve] Noguchi Y, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1997 May;100(5):492–8 (28 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Cervical root entrapment. An HS. **Hand Clin** 1996 Nov; 12(4):719–30 (27 ref.)

Radial tunnel syndrome. Barnum M, et al. **Hand Clin** 1996 Nov;12(4):679–89 (45 ref.)

High median nerve entrapments. An obscure cause of upper-extremity pain. Tetro AM, et al. **Hand Clin** 1996 Nov;12(4):691–703 (80 ref.)

Peripheral nerve compression. Gelberman RH, et al. **Instr Course Lect** 1994;43:31–53 (97 ref.)

Electrodiagnostic testing in hand surgery. Campion D. **J Hand Surg [Br]** 1996 Nov;21(6):947–56 (28 ref.)

Presurgical identification of extradural nerve root anomalies by coronal fat-suppressed magnetic resonance imaging: a report of six cases and a review of the literature. Aota Y, et al. **J Spinal Disord** 1997 Apr;10(2):167–75 (19 ref.)

MR features of nerve disorders at the elbow. Rosenberg ZS, et al. **Magn Reson Imaging Clin N Am** 1997 Aug;5(3):545–65 (66 ref.)

The diagnosis and treatment of cervical radiculopathy. Malanga GA. **Med Sci Sports Exerc** 1997 Jul;29(7 Suppl):S236–45 (88 ref.)

Diagnosis and management of common compression and entrapment neuropathies. Campbell WW. **Neurol Clin** 1997 Aug;15(3):549–67 (51 ref.)

Cauda equina histiocytosis X. Lacroix M, et al. **Pediatr Neurol** 1996 Apr;14(3):231–5 (15 ref.)

Neurophysiologic tests in diagnosis of nerve root compression caused by disc herniation. Dvořák J. **Spine** 1996 Dec 15;21(24 Suppl):39S–44S (33 ref.)

[Distal nerve compression of the leg. Clinical and electrophysiologic study] Mabin D. **Neurophysiol Clin** 1997; 27(1):9–24 (113 ref.) (Eng. Abstr.) **(Fre)**

[Postpartum obturator nerve syndrome: case report and review of the nerve compression syndrome during pregnancy and delivery] Lindner A, et al. **Zentralbl Gynakol** 1997;119(3):93–9 (43 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

[Injection therapy in cervical syndromes] Grifka J. **Orthopade** 1996 Nov;25(6):524–32 (26 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Brachial plexus injury due to compression: an alternate mechanism of injury: case report and review of the literature. Desai DC, et al. **Am Surg** 1997 Jun;63(6):487–9 (5 ref.)

Ectasia of the vertebral artery as a cause of isolated pyramidal tract signs: case report and a review of the literature. Moss MS, et al. **Br J Neurosurg** 1996 Oct;10(5):497–9 (13 ref.)

Neuropathy secondary to pigmented villonodular synovitis of the hip. Aboulafia AJ, et al. **Clin Orthop** 1996 Apr; (325):174–80 (19 ref.)

Brachial neuritis presenting as anterior interosseous nerve compression—implications for diagnosis and treatment: a case report. Wong L, et al. **J Hand Surg [Am]** 1997 May; 22(3):536–9 (29 ref.)

Scapular instability associated with brachial plexus irritation: a proposed causative relationship with treatment implications. Langley P. **J Hand Ther** 1997 Jan-Mar; 10(1):35–40 (15 ref.)

Repetitive use and static postures: a source of nerve compression and pain. Novak CB, et al. **J Hand Ther** 1997 Apr-Jun;10(2):151–9 (73 ref.)

Compression of the lateral antebrachial cutaneous nerve by the biceps tendon. Gillingham BL, et al. **J Shoulder Elbow Surg** 1996 Jul-Aug;5(4):330–2 (10 ref.)

Extradural optic nerve decompression for fibrous dysplasia with a favorable visual outcome. Kurimoto M, et al. **Neurol Med Chir (Tokyo)** 1996 Feb;36(2):102–5 (19 ref.)

Extradural tethering effect as one mechanism of radiculopathy complicating posterior decompression of the cervical spinal cord [see comments] Tsuzuki N, et al. **Spine** 1996 Jan 15;21(2):203–11 (14 ref.) Comment in: Spine 1996 Aug 1;21(15):1839–40.

[Cystic compression of the suprascapular nerve. Value of imaging. Apropos of 6 cases and review of the literature] Lévy P, et al. **J Radiol** 1997 Feb;78(2):123–30 (35 ref.) (Eng. Abstr.) **(Fre)**

[Compression of the peroneal nerve by a synovial cyst in a 7-year-oldchild] Gayet LE, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(8):762–6 (17 ref.) (Eng. Abstr.) **(Fre)**

[Synovial cyst of the supracapsular notch of the shoulder with supracapsular nerve compression in a sportsman. Apropos of a case. Review of the literature] Rochwerger A, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996; 82(4):344–7 (12 ref.) (Eng. Abstr.) **(Fre)**

[Acute lumbar disk displacement with nerve root compression. Indications for peridural steroid injection] Schlumpf U, et al. **Schweiz Rundsch Med Prax** 1997 Feb 18;86(8):292–5 (29 ref.) (Eng. Abstr.) **(Ger)**

[Epidemiological and etiopathological aspects of compression neuropathies of the lower limbs caused by adverse occupational factors (review of the literature)] Matveeva OV. **Med Tr Prom Ekol** 1997;(2):34–40 (77 ref.) **(Rus)**

PHYSIOPATHOLOGY

Double-crush syndrome: a critical analysis. Wilbourn AJ, et al. **Neurology** 1997 Jul;49(1):21–9 (84 ref.)

Third cervical nerve root and ganglion compression: clinical syndrome, surgical anatomy, and pathological findings.

Poletti CE. **Neurosurgery** 1996 Nov;39(5):941–8; discussion 948–9 (63 ref.)

Recent data on the pathophysiology of nerve root compression and pain. Boulu P, et al. **Rev Rhum Engl Ed** 1996 May;63(5):358–63 (33 ref.)

RADIOGRAPHY

[Neuroradiologic diagnosis of caudal radiculopathy] Dulić S, et al. **Vojnosanit Pregl** 1997 Jan–Feb;54(1):61–4 (19 ref.) **(Scr)**

SURGERY

Radial tunnel syndrome. Barnum M, et al. **Hand Clin** 1996 Nov;12(4):679–89 (45 ref.)

Third cervical nerve root and ganglion compression: clinical syndrome, surgical anatomy, and pathological findings. Poletti CE. **Neurosurgery** 1996 Nov;39(5):941–8; discussion 948–9 (63 ref.)

Cauda equina histiocytosis X. Lacroix M, et al. **Pediatr Neurol** 1996 Apr;14(3):231–5 (15 ref.)

[The dorsal approach in degeneratively changed cervical spine] Yonenobu K, et al. **Orthopade** 1996 Nov;25(6):533–41 (34 ref.) (Eng. Abstr.) **(Ger)**

[Dunbar's syndrome: clinical reality or physiopathologic hypothesis?] De Cecchis L, et al. **Ann Ital Chir** 1996 Jul–Aug;67(4):501–5 (28 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

High median nerve entrapments. An obscure cause of upper-extremity pain. Tetro AM, et al. **Hand Clin** 1996 Nov;12(4):691–703 (80 ref.)

Peripheral nerve compression. Gelberman RH, et al. **Instr Course Lect** 1994;43:31–53 (97 ref.)

The diagnosis and treatment of cervical radiculopathy. Malanga GA. **Med Sci Sports Exerc** 1997 Jul;29(7 Suppl):S236–45 (88 ref.)

Management of work-related upper-extremity nerve entrapments. Terrono AL, et al. **Orthop Clin North Am** 1996 Oct;27(4):783–93 (101 ref.)

VETERINARY

Conditions of the lumbosacral spinal cord and cauda equina. Ferguson HR. **Semin Vet Med Surg (Small Anim)** 1996 Nov; 11(4):254–8 (15 ref.)

NERVE CONDUCTION see **NEURAL CONDUCTION**

NERVE CROSSOVER see **NERVE TRANSFER**

NERVE DEGENERATION

Delayed neuronal degeneration results from endogenous glutamate excess. Possible role in NP-SLE. Volpe BT. **Ann N Y Acad Sci** 1997 Aug 14;823:185–7 (23 ref.)

Neurotrophic factors as pharmacological agents for the treatment of injured auditory neurons. Van De Water TR, et al. **Ciba Found Symp** 1996;196:149–62; discussion 162–6 (38 ref.)

Spinal instrumentation for degenerative disease. Fessler RG. **Clin Neurosurg** 1996;43:268–74 (8 ref.)

Neurodegenerative disorders: clues from glutamate and energy metabolism. Ikonomidou C, et al. **Crit Rev Neurobiol** 1996;10(2):239–63 (301 ref.)

Mitochondria, free radicals, and neurodegeneration. Beal MF. **Curr Opin Neurobiol** 1996 Oct;6(5):661–6 (45 ref.)

Changes in astrocytic glutamate catabolism enzymes following neuronal degeneration or viral infection. Belin MF, et al. **Glia** 1997 Sep;21(1):154–61 (80 ref.)

Mitochondrial dysfunction in neurodegeneration. Cooper JM, et al. **J Bioenerg Biomembr** 1997 Apr;29(2):175–83 (113 ref.)

Mechanism of 6-hydroxydopamine neurotoxicity. Glinka Y, et al. **J Neural Transm Suppl** 1997;50:55–66 (41 ref.)

Animal model and in vitro studies of anti neurofilament antibodies mediated neurodegeneration in Alzheimer's disease. Oron L, et al. **J Neural Transm Suppl** 1997;49:77–84 (13 ref.)

Long tract degeneration in familial sudanophilic leukodystrophy with prominent spheroids. Yazawa I, et al. **J Neurol Sci** 1997 Apr 15;147(2):185–91 (20 ref.)

The role of chronic self-propagating glial responses in neurodegeneration: implications for long-lived survivors of human immunodeficiency virus. Mrak RE, et al. **J Neurovirol** 1997 Aug;3(4):241–6 (52 ref.)

Ascorbate availability and neurodegeneration in amyotrophic lateral sclerosis. Kok AB. **Med Hypotheses** 1997 Apr; 48(4):281–96 (171 ref.)

Modeling neuronal degeneration in the rodent hippocampus: an approach for studying degenerative neuropathology in dementia. Miguel-Hidalgo JJ, et al. **Methods Find Exp Clin Pharmacol** 1997 Mar;19(2):133–42 (63 ref.)

Transgenic models to assess the pathogenic actions of cytokines in the central nervous system. Campbell IL, et al. **Mol Psychiatry** 1997 Mar;2(2):125–9 (19 ref.)

Astrocytes, brain aging, and neurodegeneration. Schipper HM. **Neurobiol Aging** 1996 May–Jun;17(3):467–80 (109 ref.)

Involvement of phospholipase A2 in neurodegeneration. Farooqui AA, et al. **Neurochem Int** 1997 Jun;30(6):517–22 (48 ref.)

Energy metabolism, oxidative stress and neuronal degeneration in Alzheimer's disease. Sims NR. **Neurodegeneration** 1996 Dec;5(4):435–40 (49 ref.)

Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Litvan I, et al. **Neurology** 1997 Jan;48(1):119–25 (73 ref.)

Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Tatton WG, et al. **Neurology** 1996 Dec;47(6 Suppl 3):S171–83 (205 ref.)

[Progress in the study of ciliary nerotrophic factor] He C, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan;27(1):53–6 (10 ref.) **(Chi)**

[Neurodegenerative disorders and the role of trinucleotide repeat expansion. I. The diseases (see comments)] Kremer HP, et al. **Ned Tijdschr Geneeskd** 1996 Nov 23; 140(47):2325–9 (33 ref.) Comment in: Ned Tijdschr Geneeskd 1997 Feb 22;141(8):400–1. **(Dut)**

[A case of corticobasal degeneration presenting with primary progressive aphasia] Katai S, et al. **Rinsho Shinkeigaku** 1997 Mar;37(3):249–52 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Corticobasal degeneration: symptomatological, brain-imaging and electrophysiological studies] Morimatsu M, et al. **Rinsho Shinkeigaku** 1995 Dec;35(12):1459–62 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Calcium, neuronal death and neurological disease] Jiménez-Jiménez FJ, et al. **Rev Neurol** 1996 Oct; 24(134):1199–209 (280 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Pharmacological characterization of glial cell line-derived neurotrophic factor (GDNF): implications for GDNF as a therapeutic molecule for treating neurodegenerative diseases. Lapchak PA, et al. **Cell Tissue Res** 1996 Nov; 286(2):179–89 (100 ref.)

Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Nicoletti F, et al. **Trends Neurosci** 1996 Jul;19(7):267–71 (74 ref.)

GENETICS

Expanded glutamines and neurodegeneration--a gain of insight. Bates G. **Bioessays** 1996 Mar;18(3):175–8 (33 ref.)

Mouse models of human CAG repeat disorders. Burright EN, et al. **Brain Pathol** 1997 Jul;7(3):965–77 (79 ref.)

Trinucleotide repeat instability: genetic features and molecular mechanisms. La Spada AR. **Brain Pathol** 1997 Jul;7(3):943–63 (146 ref.)

Clinical aspects of CAG repeat diseases. Nance MA. **Brain Pathol** 1997 Jul;7(3):881–900 (188 ref.)

The neuropathology of CAG repeat diseases: review and update of genetic and molecular features. Robitaille Y, et al. **Brain Pathol** 1997 Jul;7(3):901–26 (237 ref.)

Towards gene therapy in the nervous system. Doering LC. **Clin Neurosci** 1995–96;3(5):259–61 (14 ref.)

Adeno-associated virus vectors for gene therapy of neurodegenerative disorders. During MJ, et al. **Clin Neurosci** 1995–96;3(5):292–300 (75 ref.)

Adenovirus for neurodegenerative diseases: in vivo strategies and ex vivo gene therapy using human neural progenitors. Sabaté O, et al. **Clin Neurosci** 1995–96;3(5):317–21 (42 ref.)

Multipotent neural progenitor or stem-like cells may be uniquely suited for therapy for some neurodegenerative conditions. Snyder EY, et al. **Clin Neurosci** 1995–96; 3(5):310–6 (43 ref.)

Neurotoxicity of beta-amyloid and prion peptides. Forloni G. **Curr Opin Neurol** 1996 Dec;9(6):492–500 (111 ref.)

Degenerative ataxias: genetics, pathogenesis and animal models. Kakizuka A. **Curr Opin Neurol** 1997 Aug; 10(4):285–90 (50 ref.)

IMMUNOLOGY

Discovery of new lesions in neurodegenerative diseases with monoclonal antibody techniques: is there a non-amyloid precursor to senile plaques? Dickson DW. **Am J Pathol** 1997 Jul;151(1):7–11 (33 ref.)

The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. McGeer PL, et al. **Brain Res Brain Res Rev** 1995 Sep;21(2):195–218 (308 ref.)

Microglial in neurodegenerative disorders: emphasis on Alzheimer's disease. McRae A, et al. **Gerontology** 1997; 43(1-2):95–108 (100 ref.)

TNF-alpha transgenic and knockout models of CNS inflammation and degeneration. Probert L, et al. **J Neuroimmunol** 1997 Feb;72(2):137–41 (54 ref.)

PHYSIOLOGY

Frontal lobe degeneration of non-Alzheimer type. Structural characteristics, diagnostic criteria and relation to other frontotemporal dementias. Brun A, et al. **Acta Neurol Scand Suppl** 1996;168:28–30 (37 ref.)

Endosome-lysosomes, ubiquitin and neurodegeneration. Mayer RJ, et al. **Adv Exp Med Biol** 1996;389:261–9 (36 ref.)

Metabotropic glutamate receptors and neuronal degeneration in culture. Bruno V, et al. **Adv Neurol** 1996;71:47–51, discussion 51–2 (23 ref.)

Potential of neural "stem-like" cells for gene therapy and repair of the degenerating central nervous system. Snyder EY, et al. **Adv Neurol** 1997;72:121–32 (69 ref.)

Mechanisms of neuronal degeneration: a final common pathway? Troy CM, et al. **Adv Neurol** 1997;72:103–11 (68 ref.)

Apoptosis in neurodegenerative diseases. Nishimoto I, et al. **Adv Pharmacol** 1997;41:337–68 (267 ref.)

The role of vesicular transport proteins in synaptic transmission and neural degeneration. Liu Y, et al. **Annu Rev Neurosci** 1997;20:125–56 (178 ref.)

Hippocampal degeneration inducing impairment of learning in rats: model of dementia? Ishikawa K, et al. **Behav Brain Res** 1997 Feb;83(1-2):39–44 (26 ref.)

Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Billingsley ML, et al. **Biochem J** 1997 May 1;323 (Pt 3):577–91 (216 ref.)

Excitotoxicity and neurodegeneration in amyotrophic lateral sclerosis. Rothstein JD. **Clin Neurosci** 1995–96;3(6):348–59 (79 ref.)

Role of Ca+2 and other second messengers in excitatory amino acid receptor mediated neurodegeneration: clinical perspectives. Schousboe A, et al. **Clin Neurosci** 1997; 4(4):194–8 (87 ref.)

Myoclonus in corticobasal degeneration. Thompson PD. **Clin Neurosci** 1995–96;3(4):203–8 (17 ref.)

The GluR2 hypothesis: Ca(++)-permeable AMPA receptors in delayed neurodegeneration. Bennett MV, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:373–84 (29 ref.)

Neurodegenerative diseases and model systems. Price DL, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:725–38 (200 ref.)

AIDS dementia complex: a complex, slow virus "model" of acquired genetic neurodegenerative disease. Price RW. **Cold Spring Harb Symp Quant Biol** 1996;61:759–70 (90 ref.)

ALS: molecular clues to the jigsaw puzzle of neuronal degeneration. Siddique T. **Cold Spring Harb Symp Quant Biol** 1996;61:699–708 (79 ref.)

Extracellular proteases in neuronal function and degeneration. Strickland S, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:739–45 (33 ref.)

Asymmetric cortical degeneration syndromes. Caselli RJ. **Curr Opin Neurol** 1996 Aug;9(4):276–80 (42 ref.)

Neuropsychology and advances in memory function. Gordon B. **Curr Opin Neurol** 1997 Aug;10(4):306–12 (70 ref.)

Apoptosis in neurodegenerative disorders. Stefanis L, et al. **Curr Opin Neurol** 1997 Aug;10(4):299–305 (78 ref.)

Morphology and neurochemical characteristics of the vulnerable neurons in brain aging and Alzheimer's disease. Hof PR. **Eur Neurol** 1997;37(2):71–81 (90 ref.)

Slowly progressive limb-kinetic apraxia. Otsuki M, et al. **Eur Neurol** 1997;37(2):100–3 (17 ref.)

The role of astroglial cell-derived nitric oxide and prostanoids in neurodegenerative disorders. Mollace V, et al. **Funct Neurol** 1997 May–Aug;12(3-4):199–203 (24 ref.)

Methods of sympathetic degeneration and alteration. Picklo MJ. **J Auton Nerv Syst** 1997 Feb 17;62(3):111–25 (158 ref.)

Neurodegeneration, sleep, and cerebral energy metabolism: a testable hypothesis. Mamelak M. **J Geriatr Psychiatry Neurol** 1997 Jan;10(1):29–32 (42 ref.)

Nitric oxide-mediated mitochondrial damage in the brain: mechanisms and implications for neurodegenerative diseases. Bolaños JP, et al. **J Neurochem** 1997 Jun; 68(6):2227–40 (173 ref.)

Oxidative stress and apoptosis in neurodegeneration. Gorman AM, et al. **J Neurol Sci** 1996 Aug;139 Suppl:45–52 (75 ref.)

Role of amyloid precursor protein in the mechanisms of neurodegeneration in Alzheimer's disease. Masliah E. **Lab Invest** 1997 Sep;77(3):197–209 (164 ref.)

Cytokines secreted by glial cells infected with HTLV-I modulate the expression of matrix metalloproteinases (MMPs) and their natural inhibitor (TIMPs): possible involvement in neurodegenerative processes. Giraudon P, et al. **Mol Psychiatry** 1997 Mar;2(2):107–10, 84 (23 ref.)

Cytokines and acute neurodegeneration. Rothwell NJ. **Mol Psychiatry** 1997 Mar;2(2):120–1 (5 ref.)

Watch for ICE in neurodegeneration. Vasilakos J, et al. **Mol Psychiatry** 1996 Mar;1(1):72–6 (42 ref.)

Inflammatory mechanisms in neurodegeneration and Alzheimer's disease: the role of the complement system. Pasinetti GM. **Neurobiol Aging** 1996 Sep–Oct;17(5):707–16 (157 ref.)

Molecular mechanisms of microglial activation. A. Implications for regeneration and neurodegenerative diseases. Gebicke-Haerter PJ, et al. **Neurochem Int** 1996 Jul;29(1):1–12 (145 ref.)

Functional and molecular differentiation of the dopamine system induced by neonatal denervation. Joyce JN, et al. **Neurosci Biobehav Rev** 1996 Autumn;20(3):453–86 (285 ref.)

The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Lovestone S, et al. **Neuroscience** 1997 May;78(2):309–24 (169 ref.)

The role of microglia in brain injury. Streit WJ. **Neurotoxicology** 1996 Fall–Winter;17(3-4):671–8 (52 ref.)

Apoptosis in development and disease of the nervous system: II. Apoptosis in childhood neurologic disease. Gelbard HA, et al. **Pediatr Neurol** 1997 Feb;16(2):93–7 (57 ref.)

Alterations in apolipoprotein E expression during aging and neurodegeneration. Masliah E, et al. **Prog Neurobiol** 1996 Dec;50(5-6):493–503 (80 ref.)

Tachykinins, neurotrophism and neurodegenerative diseases:

a critical review on the possible role of tachykinins in the aetiology of CNS diseases. Barker R. **Rev Neurosci** 1996 Jul–Sep;7(3):187–214 (270 ref.)
Protein folding, nucleation phenomena and delayed neurodegeneration in Alzheimer's disease. Fox N, et al. **Rev Neurosci** 1996 Jan–Mar;7(1):21–8 (61 ref.)
Apoptosis II: Apoptosis in the pathogenesis and treatment of diseases. Moldoveanu E, et al. **Rom J Morphol Embryol** 1996 Jan–Jun;42(1–2):41–51 (37 ref.)
Mechanism of calcium entry during axon injury and degeneration. LoPachin RM, et al. **Toxicol Appl Pharmacol** 1997 Apr;143(2):233–44 (108 ref.)
Rediscovering an old friend, IGF–I: potential use in the treatment of neurodegenerative diseases. Doré S, et al. **Trends Neurosci** 1997 Aug;20(8):326–31 (64 ref.)

NERVE ENDINGS

see related
PRESYNAPTIC TERMINALS

CHEMISTRY

A supramolecular complex underlying touch sensitivity. Hamill OP, et al. **Trends Neurosci** 1996 Jul;19(7):258–61 (39 ref.)

DRUG EFFECTS

Capsaicin–sensitive sensory nerve terminals with local and systemic efferent functions: facts and scopes of an unorthodox neuroregulatory mechanism. Szolcsányi J. **Prog Brain Res** 1996;113:343–59 (132 ref.)

GROWTH & DEVELOPMENT

Role of protein kinases in nerve terminal maturation and function. Valtorta E, et al. **Biochem Soc Trans** 1996 Aug; 24(3):645–53 (60 ref.)

METABOLISM

SV2proteoglycan: a potential synaptic vesicle transporter and nerve terminal extracellular matrix receptor. Carlson SS. **Perspect Dev Neurobiol** 1996;3(4):373–86 (79 ref.)

PHYSIOLOGY

Atrial receptors and heart volumes. Linden RJ. **Adv Exp Med Biol** 1995;381:125–34 (52 ref.)
Cardiac receptor activity in heart failure: implications for the control of sympathetic nervous outflow. Zucker IH, et al. **Adv Exp Med Biol** 1995;381:109–24 (63 ref.)
Role of protein kinases in nerve terminal maturation and function. Valtorta E, et al. **Biochem Soc Trans** 1996 Aug; 24(3):645–53 (60 ref.)
Genetic analysis of cholinergic nerve terminal function in invertebrates. Baylis HA, et al. **J Neurocytol** 1996 Dec; 25(12):747–62 (100 ref.)
The role of Sec1p–related proteins in vesicle trafficking in the nerve terminal. Pevsner J. **J Neurosci Res** 1996 Jul 15;45(2):89–95 (45 ref.)
Endocytosis at nerve terminals: timing is everything. Ryan TA. **Neuron** 1996 Dec;17(6):1035–7 (25 ref.)
Functional morphology of nociceptive and other fine sensory endings (free nerve endings) in different tissues. Messlinger K. **Prog Brain Res** 1996;113:273–98 (75 ref.)
Purinergic regulation of acetylcholine release. Ribeiro JA, et al. **Prog Brain Res** 1996;109:231–41 (41 ref.)

PHYSIOPATHOLOGY

Neuropeptides in dural fine sensory nerve endings—involvement in neurogenic inflammation? Hanesch U. **Prog Brain Res** 1996;113:299–317 (89 ref.)

NERVE ENDINGS, PRESYNAPTIC see **PRESYNAPTIC TERMINALS**

NERVE ENDINGS, SENSORY see **RECEPTORS, SENSORY**

NERVE FIBERS

DRUG EFFECTS

[Neurotoxicity of intrathecally administrated agents] Malinovsky JM, et al. **Ann Fr Anesth Reanim** 1996; 15(5):647–58 (128 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Innervation of the liver: morphology and function. Tiniakos DG, et al. **Liver** 1996 Jun;16(3):151–60 (125 ref.)

PATHOLOGY

Early diagnosis of functional damage in patients with glaucoma [editorial; comment] Caprioli J. **Arch Ophthalmol** 1997 Jan;115(1):113–4 (31 ref.) Comment on: Arch Ophthalmol 1997 Jan;115(1):26–33.
Mossy fiber reorganization in the epileptic hippocampus. Parent JM, et al. **Curr Opin Neurol** 1997 Apr;10(2):103–9 (50 ref.)

PHYSIOLOGY

Does nerve regeneration restore normal functional patterns in mouse barrel cortex? Bronchti G, et al. **Adv Neurol** 1997; 73:91–8 (24 ref.)
Mossy fiber reorganization and its possible physiological consequences in the dentate gyrus of epileptic humans. Masukawa LM, et al. **Adv Neurol** 1997;72:53–68 (51 ref.)
Neurotransmitters and neuroreceptors in the lower urinary tract. Andersson KE. **Curr Opin Obstet Gynecol** 1996 Oct; 8(5):361–5 (49 ref.)
Seizure–induced molecular changes, sprouting and synaptogenesis of hippocampal mossy fibers. Pollard H, et al. **Epilepsy Res Suppl** 1996;12:355–63 (32 ref.)
Quantifying 2–factor phase relations in non–linear responses from low characteristic–frequency auditory–nerve fibers. Lin T, et al. **Hear Res** 1995 Oct;90(1–2):126–38 (37 ref.)
Spike train analysis. Awiszus F. **J Neurosci Methods** 1997 Jun 27;74(2):155–66 (32 ref.)
The methodology and scope of human microneurography. Gandevia SC, et al. **J Neurosci Methods** 1997 Jun 27; 74(2):123–36 (87 ref.)
Assessing changes in presynaptic inhibition of Ia afferents during movement in humans. Pierrot–Deseilligny E. **J Neurosci Methods** 1997 Jun 27;74(2):189–99 (46 ref.)
The study of normal and abnormal neuromuscular transmission with single fibre electromyography. Stålberg E, et al. **J Neurosci Methods** 1997 Jun 27;74(2):145–54 (31 ref.)
Redistribution of synaptic efficacy: a mechanism to generate infinite synaptic input diversity from a homogeneous population of neurons without changing absolute synaptic efficacies. Markram H, et al. **J Physiol Paris** 1996; 90(3–4):229–32 (12 ref.)
Mossy–fibre sensory input to the cerebellum. Glickstein M. **Prog Brain Res** 1997;114:251–9 (57 ref.)
The functional morphology of thin sensory axons: some principles and problems. Kruger L. **Prog Brain Res** 1996; 113:255–72 (95 ref.)
Reciprocal trophic interactions between climbing fibres and Purkinje cells in the rat cerebellum. Strata P, et al. **Prog Brain Res** 1997;114:263–82 (91 ref.)
Spinal organization of C–fiber afferents related with nociception or non–nociception. Sugiura Y. **Prog Brain Res** 1996;113:320–39 (116 ref.)
The origin and nature of beading: a reversible transformation of the shape of nerve fibers. Ochs S, et al. **Prog Neurobiol** 1997 Aug;52(5):391–426 (161 ref.)
Regeneration of lesioned corticospinal tract fibers in the adult rat spinal cord under experimental conditions. Schwab ME, et al. **Spinal Cord** 1997 Jul;35(7):469–73 (52 ref.)
Regeneration of immature mammalian spinal cord after injury. Nicholls J, et al. **Trends Neurosci** 1996 Jun; 19(6):229–34 (56 ref.)
[Physiology of nociception] Guirimand F, et al. **Ann Fr Anesth Reanim** 1996;15(7):1048–79 (166 ref.) (Eng. Abstr.) **(Fre)**

ULTRASTRUCTURE

Neurofilaments, radial growth of axons, and mechanisms of motor neuron disease. Williamson TL, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:709–23 (73 ref.)
Mossy–fibre sensory input to the cerebellum. Glickstein M. **Prog Brain Res** 1997;114:251–9 (57 ref.)
Cholinergic innervation and receptors in the cerebellum. Jaarsma D, et al. **Prog Brain Res** 1997;114:67–96 (113 ref.)
The origin and nature of beading: a reversible transformation of the shape of nerve fibers. Ochs S, et al. **Prog Neurobiol** 1997 Aug;52(5):391–426 (161 ref.)
The Merkel cell as a possible mechanoreceptor cell. Ogawa H. **Prog Neurobiol** 1996 Jul;49(4):317–34 (79 ref.)
Membrane adhesion in peripheral myelin: good and bad wraps with protein P0. Kirschner DA, et al. **Structure** 1996 Nov 15;4(11):1239–44 (32 ref.)

NERVE FIBERS, MYELINATED

PATHOLOGY

De novo mutation (Arg98–>Cys) of the myelin P0 gene and uncompaction of the major dense line of the myelin sheath in a severe variant of Charcot–Marie–Tooth disease type 1B. Komiyama A, et al. **J Neurol Sci** 1997 Jul; 149(1):103–9 (31 ref.)
Ventriculomegaly, delayed myelination, white matter hypoplasia, and "periventricular" leukomalacia: how are they related? Leviton A, et al. **Pediatr Neurol** 1996 Sep; 15(2):127–36 (163 ref.)

PHYSIOLOGY

Role of polysialic acid in peripheral myelinated axons. Carratù MR, et al. **Microsc Res Tech** 1996 Aug 15; 34(6):489–91 (13 ref.)

NERVE GROWTH FACTOR RECEPTORS see **RECEPTORS, NERVE GROWTH FACTOR**

NERVE GROWTH FACTORS

see related
RECEPTORS, NERVE GROWTH FACTOR
[Netrin and semaphorin] Murakami F. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):571–6 (17 ref.) **(Jpn)**

ANALYSIS

[A sensitive two–site (sandwich) enzyme immunoassay system for measuring nerve growth factor (NGF)] Furukawa S. **Nippon Yakurigaku Zasshi** 1997 May; 109(5):235–41 (16 ref.) (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Orally active NGF synthesis stimulators: potential therapeutic agents in Alzheimer's disease. Yamada K, et al. **Behav Brain Res** 1997 Feb;83(1–2):117–22 (32 ref.)

BIOSYNTHESIS

Orally active NGF synthesis stimulators: potential therapeutic agents in Alzheimer's disease. Yamada K, et al. **Behav Brain Res** 1997 Feb;83(1–2):117–22 (32 ref.)
Neurotrophin and neurotrophin receptors in islet cells. Scharfmann R. **Horm Metab Res** 1997 Jun;29(6):294–6 (13 ref.)

CHEMISTRY

Activity–dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin? Gozes I, et al. **J Mol Neurosci** 1996 Winter;7(4):235–44 (81 ref.)
Does ciliary neurotrophic factor serve a different function in the rat versus the chicken? Finn T, et al. **Perspect Dev Neurobiol** 1996;4(1):91–9 (58 ref.)
[Biochemistry of neurotrophins] Furukawa Y, et al. **Seikagaku** 1996 Jan;68(1):14–30 (93 ref.) **(Jpn)**

DEFICIENCY

Deficient neurotrophic support in the aetiology of diabetic neuropathy. Tomlinson DR, et al. **Diabet Med** 1996 Jul; 13(7):679–81 (28 ref.)
Programmed cell death in neurons: focus on the pathway of nerve growth factor deprivation–induced death of sympathetic neurons. Deshmukh M, et al. **Mol Pharmacol** 1997 Jun;51(6):897–906 (126 ref.)

GENETICS

Novel gene families involved in neural pathfinding. Müller BK, et al. **Curr Opin Genet Dev** 1996 Aug;6(4):469–74 (61 ref.)
Neurotrophin switching: where does it stand? Davies AM. **Curr Opin Neurobiol** 1997 Feb;7(1):110–8 (67 ref.)

ISOLATION & PURIFICATION

Nerve growth factors from snake venoms: chemical properties, mode of action and biological significance. Kostiza T, et al. **Toxicon** 1996 Jul;34(7):787–806 (75 ref.)

METABOLISM

ARIA: a neuromuscular junction neuregulin. Fischbach GD, et al. **Annu Rev Neurosci** 1997;20:429–58 (162 ref.)
Signal transduction by the neurotrophin receptors. Kaplan DR, et al. **Curr Opin Cell Biol** 1997 Apr;9(2):213–21 (79 ref.)
Axons turn as netrins find their receptor. Keynes R, et al. **Neuron** 1996 Dec;17(6):1031–4 (25 ref.)
Neuropeptides, nerve growth factor and the skin. Pincelli C, et al. **Pathol Biol (Paris)** 1996 Dec;44(10):856–9 (49 ref.)
Nerve growth factor: from neurotrophin to neurokine. Levi–Montalcini R, et al. **Trends Neurosci** 1996 Nov; 19(11):514–20 (91 ref.)

PHARMACOKINETICS

Neurotrophin action in the cochlea: implications for cochlear implants. Schindler JS, et al. **Adv Otorhinolaryngol** 1997; 52:8–14 (22 ref.)

PHARMACOLOGY

Pharmacology of neurotrophic factors. Hefti F. **Annu Rev Pharmacol Toxicol** 1997;37:239–67 (229 ref.)
Pharmacological characterization of glial cell line–derived neurotrophic factor (GDNF): implications for GDNF as a therapeutic molecule for treating neurodegenerative diseases. Lapchak PA, et al. **Cell Tissue Res** 1996 Nov; 286(2):179–89 (100 ref.)
Effects of neurotrophins on the survival and regrowth of injured retinal neurons. Aguayo AJ, et al. **Ciba Found Symp** 1996;196:135–44; discussion 144–8 (42 ref.)
Therapeutic potential of the neurotrophins and neurotrophin–CNTF combinations in peripheral neuropathies and motor neuron diseases. Lindsay RM. **Ciba Found Symp** 1996;196:39–48; discussion 48–53 (41 ref.)
Neurotrophic factors as pharmacological agents for the treatment of injured auditory neurons. Van De Water TR, et al. **Ciba Found Symp** 1996;196:149–62; discussion 162–6 (38 ref.)
Nerve growth factor suppresses the tumoral phenotype of human prolactinomas. Missale C, et al. **Horm Res** 1997; 47(4–6):240–4 (29 ref.)
Potential of neurotrophic factors in therapy of Parkinson's disease. Möller JC, et al. **J Neural Transm Suppl** 1996; 48:103–12 (57 ref.)

NERVE GROWTH FACTORS

Experimental neurotrophic factor therapy leads to cortical synaptic remodeling and compensates for behavioral deficits. Cuello AC. **J Psychiatry Neurosci** 1997 Jan; 22(1):46–55 (78 ref.)

The response of motoneurons to neurotrophins. Sendtner M, et al. **Neurochem Res** 1996 Jul;21(7):831–41 (125 ref.)

Neurotrophic factors in the treatment of neurotoxicity: an overview. Apfel SC. **Neurotoxicology** 1996 Fall–Winter; 17(3–4):839–44 (29 ref.)

Development of recombinant human nerve growth factor (rhNGF) as a treatment for peripheral neuropathic disease. Rogers BC. **Neurotoxicology** 1996 Fall–Winter; 17(3–4):865–70 (46 ref.)

Prevention of neuronal apoptotic death by neurotrophic agents and ganglioside GM1: insights and speculations regarding a common mechanism. Ferrari G, et al. **Perspect Dev Neurobiol** 1996;3(2):93–100 (67 ref.)

Effects of trophic factors on the CNS cholinergic phenotype. Cuello AC. **Prog Brain Res** 1996;109:347–58 (59 ref.)

Synaptic modulation by neurotrophic factors. Stoop R, et al. **Prog Brain Res** 1996;109:359–64 (39 ref.)

Neurotrophic factors in peripheral neuropathies: pharmacological strategies. Riaz SS, et al. **Prog Neurobiol** 1996 Jun;49(2):125–43 (160 ref.)

PHYSIOLOGY

Neurotrophic factors: past and future. Moonen G, et al. **Acta Neurol Belg** 1996 Sep;96(3):203–18 (145 ref.)

The role of polypeptide growth factors in recovery from stroke. Kawamata T, et al. **Adv Neurol** 1997;73:377–82 (30 ref.)

Neurotrophic factors and neuronal plasticity: is there a link? Lindholm D. **Adv Neurol** 1997;73:1–6 (52 ref.)

Trophic factors and their role in the postischemic brain. Nikolics K, et al. **Adv Neurol** 1996;71:389–402; discussion 402–3 (153 ref.)

Related mechanisms of action of growth factors and antioxidants in apoptosis: an overview. Oppenheim RW. **Adv Neurol** 1997;72:69–78 (40 ref.)

Neurotrophins and programmed cell death during cerebellar development. Segal RA, et al. **Adv Neurol** 1997;72:79–86 (53 ref.)

The neurotrophins and CNTF: two families of collaborative neurotrophic factors. Ip NY, et al. **Annu Rev Neurosci** 1996; 19:491–515 (137 ref.)

Physiology of the neurotrophins. Lewin GR, et al. **Annu Rev Neurosci** 1996;19:289–317 (203 ref.)

Intracellular signaling pathways activated by neurotrophic factors. Segal RA, et al. **Annu Rev Neurosci** 1996;19:463–89 (208 ref.)

A molecular and cellular theory of depression [see comments] Duman RS, et al. **Arch Gen Psychiatry** 1997 Jul; 54(7):597–606 (91 ref.) Comment in: Arch Gen Psychiatry 1997 Jul;54(7):607–8.

Studies on anterograde trophic interactions based on general muscle properties. Cangiano A, et al. **Arch Ital Biol** 1997 Sep;135(4):331–41 (29 ref.)

Nerve growth factor and the neurotrophic factor hypothesis. Yuen EC, et al. **Brain Dev** 1996 Sep–Oct;18(5):362–8 (63 ref.)

Trophic factors and central nervous system metastasis. Nicolson GL, et al. **Cancer Metastasis Rev** 1995 Dec; 14(4):303–21 (128 ref.)

GDNF: a cytokine at the interface of TGF-betas and neurotrophins. Unsicker K. **Cell Tissue Res** 1996 Nov; 286(2):175–8 (30 ref.)

Neurotrophic factors are required by mature sympathetic neurons for survival, transmission and connectivity. Rush RA, et al. **Clin Exp Pharmacol Physiol** 1997 Aug; 24(8):549–55 (31 ref.)

Nerve growth factor and autoimmune rheumatic diseases. Aloe L, et al. **Clin Exp Rheumatol** 1997 Jul–Aug; 15(4):433–8 (70 ref.)

Gene transfer to the mammalian brain using neural stem cells: a focus on trophic factors, neuroregeneration, and cholinergic neuron systems. Martínez-Serrano A, et al. **Clin Neurosci** 1995–96;3(5):301–9 (97 ref.)

Combination of gene targeting and gene transfer by adenoviral vectors in the analysis of neurotrophin-mediated neuronal plasticity. Griesbeck O, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:77–83 (39 ref.)

Neuregulins as potential drugs for neurological disorders. Marchionni MA, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:459–72 (64 ref.)

Neurotrophins in cortical development. Riddle DR, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:85–93 (78 ref.)

The role of neuregulin (ARIA) at the neuromuscular junction. Rosen KM, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:427–34 (52 ref.)

Neurotrophic factors in brain synaptic plasticity. Nawa H, et al. **Crit Rev Neurobiol** 1997;11(1):91–100 (86 ref.)

Axon guidance: netrin receptors are revealed. Guthrie S. **Curr Biol** 1997 Jan 1;7(1):R6–9 (19 ref.)

Fast actions of neurotrophic factors. Berninger B, et al. **Curr Opin Neurobiol** 1996 Jun;6(3):324–30 (56 ref.)

Neurotrophins and activity-dependent development of the neocortex. Bonhoeffer T. **Curr Opin Neurobiol** 1996 Feb; 6(1):119–26 (56 ref.)

Signalling through the neurotrophin receptor p75NTR. Dechant G, et al. **Curr Opin Neurobiol** 1997 Jun;7(3):413–8 (58 ref.)

Role of neurotrophic factors in neuronal development. Henderson CE. **Curr Opin Neurobiol** 1996 Feb;6(1):64–70 (61 ref.)

The estrogen/neurotrophin connection during neural development: is co-localization of estrogen receptors with the neurotrophins and their receptors biologically relevant? Toran-Allerand CD. **Dev Neurosci** 1996;18(1–2):36–48 (105 ref.)

Visual lateralization in birds: from neurotrophins to cognition? Güntürkün O. **Eur J Morphol** 1997 Oct; 35(4):290–302 (69 ref.)

The semaphorins: a family of axonal guidance molecules? Püschel AW. **Eur J Neurosci** 1996 Jul;8(7):1317–21 (37 ref.)

Molecules making waves in axon guidance. Varela-Echavarría A, et al. **Genes Dev** 1997 Mar 1; 11(5):545–57 (96 ref.)

Determinants of axonal regeneration. Frisén J. **Histol Histopathol** 1997 Jul;12(3):857–68 (157 ref.)

Growth factors and remyelination in the CNS. Woodruff RH, et al. **Histol Histopathol** 1997 Apr;12(2):459–66 (109 ref.)

Activity-dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin? Gozes I, et al. **J Mol Neurosci** 1996 Winter;7(4):235–44 (81 ref.)

Models to study the role of neurotrophic factors in neurodegeneration. Lindholm D. **J Neural Transm Suppl** 1997;49:33–42 (45 ref.)

Neurotrophin signal transduction in medulloblastoma. Chou TT, et al. **J Neurosci Res** 1997 Sep 1;49(5):522–7 (51 ref.)

Neurotrophic activity in cytokine-activated astrocytes. Yoshida K, et al. **Keio J Med** 1997 Jun;46(2):55–60 (50 ref.)

Are neurotrophins synaptotrophins? Snider WD, et al. **Mol Cell Neurosci** 1996 Jun;7(6):433–42 (39 ref.)

Functional roles of neurotrophin 3 in the developing and mature sympathetic nervous system. Zhou XF, et al. **Mol Neurobiol** 1996 Dec;13(3):185–97 (76 ref.)

Programmed cell death in neurons: focus on the pathway of nerve growth factor deprivation-induced death of sympathetic neurons. Deshmukh M, et al. **Mol Pharmacol** 1997 Jun;51(6):897–906 (126 ref.)

Neurotrophin-3 knocks heart off Trk. Srivastava D, et al. **Nat Med** 1996 Oct;2(10):1069–71 (17 ref.)

Gene activation pathways of nerve growth factor signaling: a minireview. Szeberényi J. **Neurobiology (Bp)** 1996; 4(1–2):1–11 (19 ref.)

Neurotrophins and their receptors in nerve injury and repair. Ebadi M, et al. **Neurochem Int** 1997 Apr–May; 30(4–5):347–74 (240 ref.)

Paracrine and autocrine actions of neurotrophic factors. Davies AM. **Neurochem Res** 1996 Jul;21(7):749–53 (57 ref.)

Neurotrophins and the primate central nervous system: a minireview. Hayashi M. **Neurochem Res** 1996 Jul; 21(7):739–47 (89 ref.)

Neurotrophin-4: the odd one out in the neurotrophin family. Ibáñez CF. **Neurochem Res** 1996 Jul;21(7):787–93 (49 ref.)

Neurotrophins live or let die: does p75NTR decide? Carter BD, et al. **Neuron** 1997 Feb;18(2):187–90 (24 ref.)

GDNF in a bind with known orphan: accessory implicated in new twist. Lindsay RM, et al. **Neuron** 1996 Oct; 17(4):571–4 (28 ref.)

Neurotrophins cause a new sensation. Snider WD, et al. **Neuron** 1996 Feb;16(2):229–32 (26 ref.)

Regeneration of injured axons in the adult mammalian central nervous system. Tatagiba M, et al. **Neurosurgery** 1997 Mar; 40(3):541–6; discussion 546–7 (45 ref.)

Does ciliary neurotrophic factor serve a different function in the rat versus the chicken? Finn T, et al. **Perspect Dev Neurobiol** 1996;4(1):91–9 (58 ref.)

Signal transduction pathways activated by ciliary neurotrophic factor and related cytokines. Frank DA, et al. **Perspect Dev Neurobiol** 1996;4(1):3–18 (108 ref.)

Extrinsic signals in the developing nervous system: the role of neurokines during neurogenesis. Heller S, et al. **Perspect Dev Neurobiol** 1996;4(1):19–34 (135 ref.)

Leukemia inhibitory factor and ciliary neurotrophic factor in sensory neuron development. Horton AR, et al. **Perspect Dev Neurobiol** 1996;4(1):35–8 (30 ref.)

The development of cholinergic sympathetic neurons: a role for neuropoietic cytokines? Landis SC. **Perspect Dev Neurobiol** 1996;4(1):53–63 (105 ref.)

Are there more members of the CNTF-GPA family? Shelton DL. **Perspect Dev Neurobiol** 1996;4(1):101–7 (18 ref.)

Do central nervous system neurons require target-derived neurotrophic support for survival throughout adult life and aging? Svendsen CN, et al. **Perspect Dev Neurobiol** 1996; 3(2):133–42 (91 ref.)

Proteoglycans and other repulsive molecules in glial boundaries during development and regeneration of the nervous system. Höke A, et al. **Prog Brain Res** 1996; 108:149–63 (123 ref.)

Sensory afferent processing in multi-responsive DRG neurons. Senba E, et al. **Prog Brain Res** 1996;113:387–410 (160 ref.)

Neurotrophic factors. Thal LJ. **Prog Brain Res** 1996; 109:327–30 (38 ref.)

Molecules relating to the neurogenesis of the sensory ganglion. Tohyama M. **Prog Brain Res** 1996;113:243–52 (15 ref.)

The action of neurotrophins in the development and plasticity of the visual cortex [published erratum appears in Prog Neurobiol 1996 Oct;50(2–3):333] Cellerino A, et al. **Prog Neurobiol** 1996 May;49(1):53–71 (180 ref.)

Tachykinins, neurotrophism and neurodegenerative diseases: a critical review on the possible role of tachykinins in the aetiology of CNS diseases. Barker R. **Rev Neurosci** 1996 Jul–Sep;7(3):187–214 (270 ref.)

Neurotrophins and other growth factors in diabetic neuropathy. Zochodne DW. **Semin Neurol** 1996 Jun; 16(2):153–61 (87 ref.)

The role of neurotrophic factors in regulating the development of inner ear innervation. Fritzsch B, et al. **Trends Neurosci** 1997 Apr;20(4):159–64 (59 ref.)

Nerve growth factor: from neurotrophin to neurokine. Levi-Montalcini R, et al. **Trends Neurosci** 1996 Nov; 19(11):514–20 (91 ref.)

Neurotrophins and activity-dependent plasticity of cortical interneurons. Marty S, et al. **Trends Neurosci** 1997 May; 20(5):198–202 (68 ref.)

Neurotrophic factors in action—new dogs and new tricks. Tolkovsky A. **Trends Neurosci** 1997 Jan;20(1):1–3 (22 ref.)

Participation of nerve growth factor in the regulation of ovarian function. Dissen GA, et al. **Zygote** 1996 Nov; 4(4):309–12 (38 ref.)

Control of ovarian innervation. Gioia L. **Zygote** 1996 Nov; 4(4):295–8 (35 ref.)

[Neurotrophins and the development of the peripheral nervous system] Catala M. **Rev Neurol (Paris)** 1997 Feb; 155(1):73–5 (18 ref.) **(Fre)**

SECRETION

Identity of neurotrophic molecules released from astroglia by vasoactive intestinal peptide. Brenneman DE, et al. **Ann N Y Acad Sci** 1997 Apr 24;814:167–73 (30 ref.)

THERAPEUTIC USE

Therapeutic potential of neurotrophic factors for neurological disorders. Yuen EC, et al. **Ann Neurol** 1996 Sep;40(3):346–54 (79 ref.)

Neurotrophic factors in the treatment of peripheral neuropathy. Apfel SC, et al. **Ciba Found Symp** 1996; 196:98–108; discussion 108–12 (40 ref.)

Development of neurotrophic factor therapy for Alzheimer's disease. Hefti F, et al. **Ciba Found Symp** 1996;196:54–63; discussion 63–9 (36 ref.)

Somatic gene therapy for nervous system disease. Tuszynski MH, et al. **Ciba Found Symp** 1996;196:85–94; discussion 94–7 (51 ref.)

Treatment strategies for neurodegenerative diseases based on trophic factors and cell transplantation techniques. Hoffer B, et al. **J Neural Transm Suppl** 1997;49:1–10 (31 ref.)

Neuronal transplantation and neurotrophic factors in the treatment of Parkinson's disease—update February 1995. Kupsch A, et al. **J Neural Transm Suppl** 1995;46:193–207 (73 ref.)

Experimental neurotrophic factor therapy leads to cortical synaptic remodeling and compensates for behavioral deficits. Cuello AC. **J Psychiatry Neurosci** 1997 Jan; 22(1):46–55 (78 ref.)

Motor neuron growth factors. Elliott JL, et al. **Neurology** 1996 Oct;47(4 Suppl 2):S47–53 (70 ref.)

Neurotrophic factors for experimental treatment of motoneuron disease. Sendtner M. **Prog Brain Res** 1996; 109:365–71 (25 ref.)

Therapeutic potentials for glial cell line-derived neurotrophic factor (GDNF) based upon pharmacological activities in the CNS. Lapchak PA. **Rev Neurosci** 1996 Jul–Sep; 7(3):165–76 (48 ref.)

Axonal sprouting and synaptogenesis in temporal lobe epilepsy: possible pathogenetic and therapeutic roles of neurite growth inhibitory factors. Larner AJ. **Seizure** 1995 Dec;4(4):249–58 (68 ref.)

NERVE NET

Neural assemblies and laminar interactions in the cerebral cortex. Miller R. **Biol Cybern** 1996 Sep;75(3):253–61 (49 ref.)

Connectionist modeling of the recovery of language functions following brain damage. Harley TA. **Brain Lang** 1996 Jan; 52(1):7–24 (71 ref.)

The ascending neuromodulatory systems in learning by reinforcement: comparing computational conjectures with experimental findings. Pennartz CM. **Brain Res Brain Res Rev** 1995 Nov;21(3):219–45 (235 ref.)

Spontaneous signalling in small central neurons: mechanisms and roles of spike-amplitude and spike-interval fluctuations. Arhem P, et al. **Int J Neural Syst** 1996 Sep; 7(4):369–76 (39 ref.)

Can quantum processes control synaptic emission? Beck F. **Int J Neural Syst** 1996 Sep;7(4):343–53 (24 ref.)

Somatic gene transfer approaches to manipulate neural networks. Federoff HJ, et al. **J Neurosci Methods** 1997 Jan;71(1):133–42 (67 ref.)

ANATOMY & HISTOLOGY

[Neural pathways—neural networks] Palkovits M. **Orv Hetil** 1996 Jun 9;137(23):1235–43 (49 ref.) (Eng. Abstr.) **(Hun)**

CYTOLOGY

Control of gap-junctional communication in astrocytic networks. Giaume C, et al. **Trends Neurosci** 1996 Aug;

19(8):319–25 (74 ref.)

EMBRYOLOGY

Phenotypic specification of hindbrain rhombomeres and the origins of rhythmic circuits in vertebrates. Bass AH, et al. **Brain Behav Evol** 1997;50 Suppl 1:3–16 (120 ref.)

[Roles of neuropilin and plexin in the development of nervous system] Fujisawa H. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):584–8 (12 ref.) **(Jpn)**

GROWTH & DEVELOPMENT

Function of a cell adhesion molecule, plexin, in neuron network formation. Fujisawa H, et al. **Dev Neurosci** 1997; 19(1):101–5 (23 ref.)

Development of the prefrontal cortex during adolescence: insights into vulnerable neural circuits in schizophrenia. Lewis DA. **Neuropsychopharmacology** 1997 Jun; 16(6):385–98 (132 ref.)

PHYSIOLOGY

Cortico–thalamic interplay and the security of operation of neural assemblies and temporal chains in the cerebral cortex. Miller R. **Biol Cybern** 1996 Sep;75(3):263–75 (78 ref.)

Semantic category imprecision: a connectionist study of the boundaries of word meanings. Small SL. **Brain Lang** 1997 Apr;57(2):181–94 (31 ref.)

A network of tufted layer 5 pyramidal neurons. Markram H. **Cereb Cortex** 1997 Sep;7(6):523–33 (97 ref.)

The neuroendocrinology of thirst and salt appetite: visceral sensory signals and mechanisms of central integration. Johnson AK, et al. **Front Neuroendocrinol** 1997 Jul; 18(3):292–353 (369 ref.)

Impact of information compression on intellectual activities in the brain. Eriksson JT. **Int J Neural Syst** 1996 Sep; 7(4):543–50 (14 ref.)

Random activity at the microscopic neural level in cortex ("noise") sustains and is regulated by low–dimensional dynamics of macroscopic cortical activity ("chaos"). Freeman WJ. **Int J Neural Syst** 1996 Sep;7(4):473–80 (29 ref.)

The neuronal network for locomotion in the lamprey spinal cord: evidence for the involvement of commissural interneurons. Buchanan JT, et al. **J Physiol Paris** 1995; 89(4–6):221–33 (54 ref.)

Dynamics of functional connectivity in visual cortical networks: an overview. Frégnac Y. **J Physiol Paris** 1996; 90(3–4):113–39 (185 ref.)

Dynamical computational properties of local cortical networks for visual and motor processing: a bayesian framework. Koechlin E, et al. **J Physiol Paris** 1996; 90(3–4):257–62 (17 ref.)

Modulation and dynamic specification of motor rythm–generating circuits in crustacea. Simmers J, et al. **J Physiol Paris** 1995;89(4–6):195–208 (40 ref.)

Neurons, networks, and motor behavior. Katz PS. **Neuron** 1996 Feb;16(2):245–53 (9 ref.)

Linking the family of D2 receptors to neuronal circuits in human brain: insights into schizophrenia. Joyce JN, et al. **Neuropsychopharmacology** 1997 Jun;16(6):375–84 (78 ref.)

Global and serial neurons form A hierarchically arranged interface proposed to underlie memory and cognition. Woolf NJ. **Neuroscience** 1996 Oct;74(3):625–51 (288 ref.)

From conductances to neural network properties: analysis of simple circuits using the hybrid network method. Le Masson G, et al. **Prog Biophys Mol Biol** 1995; 64(2–3):201–20 (51 ref.)

Rostral brain regions contributing to respiratory control. Harper RM, et al. **Prog Brain Res** 1996;107:145–56 (76 ref.)

Networks related to the orbital and medial prefrontal cortex; a substrate for emotional behavior? Price JL, et al. **Prog Brain Res** 1996;107:523–36 (30 ref.)

Growth cone dynamics and activity–dependent processes in neuronal network development. van Pelt J, et al. **Prog Brain Res** 1996;108:333–46 (67 ref.)

Brainstem respiratory networks and cough. Shannon R, et al. **Pulm Pharmacol** 1996 Oct–Dec;9(5–6):343–7 (20 ref.)

Neural representations for action. Decety J. **Rev Neurosci** 1996 Oct–Dec;7(4):285–97 (76 ref.)

Control of gap–junctional communication in astrocytic networks. Giaume C, et al. **Trends Neurosci** 1996 Aug; 19(8):319–25 (74 ref.)

[Frontal–subcortical neuronal circuits] Kischka U, et al. **Fortschr Neurol Psychiatr** 1997 May;65(5):221–31 (133 ref.) (Eng. Abstr.) **(Ger)**

[Neural pathways—neural networks] Palkovits M. **Orv Hetil** 1996 Jun 9;137(23):1235–43 (49 ref.) (Eng. Abstr.) **(Hun)**

NERVE REGENERATION

Survival, regeneration and sprouting of central neurons: the rat septohippocampal projection as a model. Frotscher M, et al. **Anat Anz** 1996 Aug;178(4):311–5 (33 ref.)

Trigeminal neo–neurotization of the paralyzed face. Cheney ML, et al. **Ann Otol Rhinol Laryngol** 1997 Sep;106(9):733–8 (31 ref.)

Exercise training improves functional recovery and motor nerve conduction velocity after sciatic nerve crush lesion in the rat. van Meeteren NL, et al. **Arch Phys Med Rehabil** 1997 Jan;78(1):70–7 (39 ref.)

Nerve regeneration and repair. Danielsen N. **Diabet Med** 1996 Jul;13(7):677–8 (12 ref.)

Nerve fibre regeneration across the peripheral–central transitional zone. Carlstedt T. **J Anat** 1997 Jan;190 (Pt 1):51–6 (40 ref.)

Axonal regeneration through acellular muscle grafts. Hall S. **J Anat** 1997 Jan;190 (Pt 1):57–71 (110 ref.)

Potential treatment modalities for glaucomatous neuropathy: neuroprotection and neuroregeneration. Schwartz M, et al. **J Glaucoma** 1996 Dec;5(6):427–32 (56 ref.)

Degeneration and regeneration of cutaneous sensory nerve formations. Dubový P, et al. **Microsc Res Tech** 1996 Jul 1;34(4):362–75 (110 ref.)

Intrinsic properties and environmental factors in the regeneration of adult cerebellar axons. Rossi F, et al. **Prog Brain Res** 1997;114:283–96 (43 ref.)

[Motor neurons regenerate axons after CNS–injury. Surgery in cases of rotavulsion restore motor functions] Cullheim S, et al. **Lakartidningen** 1996 Dec 4;93(49):4537–41 (20 ref.) **(Swe)**

GENETICS

Principles of neuronal regeneration. Kreutzberg GW. **Acta Neurochir Suppl (Wien)** 1996;66:103–6 (10 ref.)

Use of viral vectors to promote neuroregeneration. Verhaagen J, et al. **Clin Neurosci** 1995–96;3(5):275–83 (59 ref.)

Seizure–induced molecular changes, sprouting and synaptogenesis of hippocampal mossy fibers. Pollard H, et al. **Epilepsy Res Suppl** 1996;12:355–63 (32 ref.)

PHYSIOLOGY

The role of microenvironment in axonal regeneration. Influences of lesion–induced changes and glial implants on the regeneration of the postcommissural fornix. Stichel–Gunkel CC. **Adv Anat Embryol Cell Biol** 1997; 137:I–VII, 1–81 (355 ref.)

Does nerve regeneration restore normal functional patterns in mouse barrel cortex? Bronchti G, et al. **Adv Neurol** 1997; 73:91–8 (24 ref.)

Injury–stimulated neurogenesis in sensory systems. Farbman AI. **Adv Neurol** 1997;72:157–61 (9 ref.)

Compensatory regeneration of the damaged adult human brain: neuroplasticity in a clinical perspective. Goldman S, et al. **Adv Neurol** 1997;73:99–107 (46 ref.)

Long–term response to nerve injury. Gordon T, et al. **Adv Neurol** 1997;72:185–99 (117 ref.)

Mechanisms of reorganization in sensory systems of primates after peripheral nerve injury. Kaas JH, et al. **Adv Neurol** 1997;73:147–58 (122 ref.)

Strategies for clinical and experimental interventions for repair and regeneration in the inner ear. Raphael Y. **Adv Neurol** 1997;72:163–9 (50 ref.)

Retinal regeneration: common principles but a diversity of mechanisms. Raymond PA, et al. **Adv Neurol** 1997; 72:171–84 (110 ref.)

Recovery of vision after partial visual system injury as a model of postlesion neuroplasticity. Sabel BA, et al. **Adv Neurol** 1997;73:251–76 (123 ref.)

Use–dependent structural events in recovery of function. Schallert T, et al. **Adv Neurol** 1997;73:229–38 (32 ref.)

Functional recovery: after the regeneration stops. Stein RB, et al. **Adv Neurol** 1997;72:365–76 (29 ref.)

Gene therapy and the use of stem cells for central nervous system regeneration. Whittemore SR, et al. **Adv Neurol** 1997;72:113–9 (34 ref.)

Central nervous system remyelination clinical application of basic neuroscience principles. Miller DJ, et al. **Brain Pathol** 1996 Jul;6(3):331–44 (101 ref.)

Gene transfer to the mammalian brain using neural stem cells: a focus on trophic factors, neuroregeneration, and cholinergic neuron systems. Martínez–Serrano A, et al. **Clin Neurosci** 1995–96;3(5):301–9 (97 ref.)

Survival of axotomized retinal ganglion cells in adult mammals. Watanabe M, et al. **Clin Neurosci** 1997;4(5):233–9 (87 ref.)

Cell adhesion molecules and neuronal regeneration. Walsh FS, et al. **Curr Opin Cell Biol** 1996 Oct;8(5):707–13 (53 ref.)

Recovery and repair issues after stroke from the scientific perspective. Seil FJ. **Curr Opin Neurol** 1997 Feb; 10(1):49–51 (23 ref.)

Development and regeneration of the nervous system: a role for neurosteroids. Schumacher M, et al. **Dev Neurosci** 1996; 18(1–2):6–21 (135 ref.)

Determinants of axonal regeneration. Frisén J. **Histol Histopathol** 1997 Jul;12(3):857–68 (157 ref.)

Fibroblast growth factor and its implications for developing and regenerating neurons. Grothe C, et al. **Int J Dev Biol** 1996 Feb;40(1):403–10 (86 ref.)

Corneal nerve recovery after photorefractive keratectomy and laser in situ keratomileusis. Latvala T, et al. **Int Ophthalmol Clin** 1996 Fall;36(4):21–7 (38 ref.)

Neurodegenerative disorders with extrapyramidal features—a neuropathological overview. Jellinger KA. **J Neural Transm Suppl** 1995;46:33–57 (144 ref.)

Myelination and axonal regeneration in the central nervous system of mice deficient in the myelin–associated glycoprotein. Bartsch U. **J Neurocytol** 1996 May; 25(5):303–13 (70 ref.)

Long–segment nerve allograft regeneration in the sheep model: experimental study and review of the literature. Strasberg SR, et al. **J Reconstr Microsurg** 1996 Nov; 12(8):529–37 (89 ref.)

Functional implication of secretory proteases derived from microglia in the central nervous system. Kohsaka S, et al. **Keio J Med** 1996 Sep;45(3):263–9 (51 ref.)

Signaling molecules and neuroglial activation in the injured central nervous system. Raivich G, et al. **Keio J Med** 1996 Sep;45(3):239–47 (115 ref.)

The muddle with MAG. Filbin MT. **Mol Cell Neurosci** 1996; 8(2–3):84–92 (56 ref.)

Priming events and retrograde injury signals. A new perspective on the cellular and molecular biology of nerve regeneration. Ambron RT, et al. **Mol Neurobiol** 1996 Aug; 13(1):61–79 (98 ref.)

The cellular and molecular basis of peripheral nerve regeneration. Fu SY, et al. **Mol Neurobiol** 1997 Feb–Apr; 14(1–2):67–116 (462 ref.)

Molecular mechanisms of microglial activation. A. Implications for regeneration and neurodegenerative diseases. Gebicke–Haerter PJ, et al. **Neurochem Int** 1996 Jul;29(1):1–12 (145 ref.)

Peripheral nerve regeneration. Ide C. **Neurosci Res** 1996 Jun; 25(2):101–21 (250 ref.)

Regeneration of injured axons in the adult mammalian central nervous system. Tatagiba M, et al. **Neurosurgery** 1997 Mar; 40(3):541–6; discussion 546–7 (45 ref.)

Proteoglycans and other repulsive molecules in glial boundaries during development and regeneration of the nervous system. Höke A, et al. **Prog Brain Res** 1996; 108:149–63 (123 ref.)

Cellular mechanisms regulating neurite initiation. Lankford KL, et al. **Prog Brain Res** 1996;108:55–81 (231 ref.)

The concept of microglia in relation to central nervous system disease and regeneration. Moore S, et al. **Prog Neurobiol** 1996 Mar–Apr;48(4–5):441–60 (149 ref.)

The role of conduits in nerve repair: a review. Doolabh VB, et al. **Rev Neurosci** 1996 Jan–Mar;7(1):47–84 (214 ref.)

Regeneration of lesioned corticospinal tract fibers in the adult rat spinal cord under experimental conditions. Schwab ME, et al. **Spinal Cord** 1997 Jul;35(7):469–73 (52 ref.)

The c–Jun transcription factor—bipotential mediator of neuronal death, survival and regeneration. Herdegen T, et al. **Trends Neurosci** 1997 May;20(5):227–31 (72 ref.)

Regeneration of immature mammalian spinal cord after injury. Nicholls J, et al. **Trends Neurosci** 1996 Jun; 19(6):229–34 (56 ref.)

[Reversible changes of the neural pathways and receptor functions associated with development and regeneration following nerve injuries] Nabekura J. **Fukuoka Igaku Zasshi** 1997 Jul;88(7):267–73 (7 ref.) **(Jpn)**

[Optic nerve regeneration by nerve transplantation] Fukuda Y. **Nippon Ganka Gakkai Zasshi** 1996 Dec;100(12):956–71 (74 ref.) (Eng. Abstr.) **(Jpn)**

NERVE SHEATH TUMORS

Malignant peripheral nerve sheath tumor arising in a "de novo" ganglioneuroma: a case report and review of the literature. Drago G, et al. **Med Pediatr Oncol** 1997 Mar; 28(3):216–22 (21 ref.)

DIAGNOSIS

Subglottic nerve sheath tumor in a pediatric patient: case report and literature review. Pulli RS, et al. **Head Neck** 1997 Aug;19(5):440–4 (21 ref.)

Malignant peripheral nerve sheath tumor of the orbit in a newborn: a case report and review. Fezza JP, et al. **J Pediatr Ophthalmol Strabismus** 1997 Mar–Apr; 34(2):128–31 (10 ref.)

PATHOLOGY

Soft–tissue perineurioma. Evidence for an abnormality of chromosome 22, criteria for diagnosis, and review of the literature. Giannini C, et al. **Am J Surg Pathol** 1997 Feb; 21(2):164–73 (45 ref.)

Purely epithelioid malignant peripheral nerve sheath tumor of the vulva. Lee YS, et al. **J Korean Med Sci** 1997 Feb; 12(1):78–81 (10 ref.)

SURGERY

Subglottic nerve sheath tumor in a pediatric patient: case report and literature review. Pulli RS, et al. **Head Neck** 1997 Aug;19(5):440–4 (21 ref.)

VETERINARY

Tumours of soft tissues. Berman LD. **IARC Sci Publ** 1996; (126):321–49 (79 ref.)

Tumours of the nervous system. Cardesa A, et al. **IARC Sci Publ** 1996;(126):427–65 (109 ref.)

NERVE TISSUE

EMBRYOLOGY

Fetal neural grafts and repair of the injured spinal cord. Anderson DK, et al. **Brain Pathol** 1995 Oct;5(4):451–57 (58 ref.)

NERVE TISSUE

IMMUNOLOGY

Autoantibodies to nervous system tissue in human and murine systemic lupus erythematosus. Moore PM. **Ann N Y Acad Sci** 1997 Aug 14;823:289–99 (92 ref.)

METABOLISM

Dopaminergic transplants in patients with Parkinson's disease: neuroanatomical correlates of clinical recovery. Kordower JH, et al. **Exp Neurol** 1997 Mar;144(1):41–6 (44 ref.)

Neurocan and phosphacan: two major nervous tissue–specific chondroitin sulfate proteoglycans. Margolis RK, et al. **Perspect Dev Neurobiol** 1996;3(4):273–90 (91 ref.)

PHYSIOLOGY

Intrinsic optical changes in neuronal tissue. Basic mechanisms. Hochman DW. **Neurosurg Clin N Am** 1997 Jul;8(3):393–412 (132 ref.)

TRANSPLANTATION

Dopaminergic transplants in patients with Parkinson's disease: neuroanatomical correlates of clinical recovery. Kordower JH, et al. **Exp Neurol** 1997 Mar;144(1):41–6 (44 ref.)

NERVE TISSUE PROTEIN S 100

BIOSYNTHESIS

A decreased incidence of neuroblastomas in Down's syndrome and overproduction of S–100 b protein. Satge D. **Med Hypotheses** 1996 Apr;46(4):393–9 (47 ref.)

IMMUNOLOGY

Induction of experimental autoimmune encephalomyelitis by CD4+ T cells specific for an astrocyte protein, S100 beta. Kojima K, et al. **J Neural Transm Suppl** 1997;49:43–51 (45 ref.)

PHYSIOLOGY

[Role of S–100 protein in the function of brain cell nuclei] Tiulenev VI, et al. **Ukr Biokhim Zh** 1996 May–Jun; 68(3):3–13 (82 ref.) (Eng. Abstr.) **(Rus)**

NERVE TISSUE PROTEINS

Cardiac hormones: diagnostic and therapeutic potential. Lainchbury JG, et al. **N Z Med J** 1997 Jun 27; 110(1046):219–21 (34 ref.)

[Neurotrophic factors: neuronal death and its protection] Kuno M. **No To Shinkei** 1996 Dec;48(12):1087–98 (100 ref.) **(Jpn)**

[Neuron–specific immunoglobulin superfamily proteins: Cell recognition molecules with neurite extension activities] Watanabe K, et al. **Seikagaku** 1996 Sep;68(9):1548–54 (24 ref.) **(Jpn)**

[Neurotrophins and their receptors] Furukawa Y, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):470–80 (55 ref.) **(Jpn)**

[Neurotrophic factor and cytokine] Hatanaka H. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):464–9 (25 ref.) **(Jpn)**

[Ciliary neurotrophic factor and leukemia inhibitory factor] Matsuoka I. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):496–503 (51 ref.) **(Jpn)**

[Telencephalin, a dendrite–associated cell adhesion molecule with brain segment–specific expression] Mori K, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):555–60 (13 ref.) **(Jpn)**

[Neural proteoglycans: neuroglycan C (NGC), neurocan, and phosphacan] Tokita Y, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):567–70 (17 ref.) **(Jpn)**

ANALYSIS

Endosome–lysosomes, ubiquitin and neurodegeneration. Mayer RJ, et al. **Adv Exp Med Biol** 1996;389:261–9 (36 ref.)

Accumulation of synaptic vesicle proteins and cytoskeletal specializations at the peripheral node of Ranvier. Zimmermann H. **Microsc Res Tech** 1996 Aug 1; 34(5):462–73 (70 ref.)

The postsynaptic density at glutamatergic synapses. Kennedy MB. **Trends Neurosci** 1997 Jun;20(6):264–8 (60 ref.)

ANTAGONISTS & INHIBITORS

Domperidone as a tool to assess the role of dopamine within carotid body chemoreception. Zapata P, et al. **Adv Exp Med Biol** 1996;410:291–7 (36 ref.)

BIOSYNTHESIS

Seizures and the regulation of neurotrophic factor expression: associations with structural plasticity in epilepsy. Gall CM, et al. **Adv Neurol** 1997;72:9–24 (97 ref.)

Regulation of neuronal nitric oxide synthase through alternative transcripts. Brenman JE, et al. **Dev Neurosci** 1997;19(3):224–31 (39 ref.)

Changes in protein expression during neural development analyzed by two–dimensional gel electrophoresis. Geschwind DH, et al. **Electrophoresis** 1996 Nov; 17(11):1677–82 (53 ref.)

(–)–Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. Tatton WG, et al. **J Neural Transm Suppl** 1996;48:45–59 (98 ref.)

Ultrastructural basis for gene expression at the synapse: synapse–associated polyribosome complexes. Steward O, et al. **J Neurocytol** 1996 Dec;25(12):717–34 (51 ref.)

Overexpression of growth–associated proteins in the neurons of adult transgenic mice. Caroni P. **J Neurosci Methods** 1997 Jan;71(1):3–9 (19 ref.)

BLOOD

Cardiac natriuretic peptides as predictors of mortality [editorial; comment] Lainchbury JG, et al. **J Intern Med** 1997 Apr;241(4):257–9 (31 ref.) Comment on: J Intern Med 1997 Apr;241(4):261–8. Comment on: J Intern Med 1997 Apr;241(4):269–75.

CHEMISTRY

Tetanus and botulism neurotoxins: a novel group of zinc–endopeptidases. Tonello F, et al. **Adv Exp Med Biol** 1996;389:251–60 (47 ref.)

Information processing and intracellular 'neural' (protein) networks: considerations regarding the diffusion–based hypothesis of Bray. Agutter PS, et al. **Biol Cell** 1997 Mar; 89(1):13–8 (25 ref.)

Myosin–V: a class of unconventional molecular motors. Larson RE. **Braz J Med Biol Res** 1996 Mar;29(3):309–18 (46 ref.)

Activity–dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin? Gozes I, et al. **J Mol Neurosci** 1996 Winter;7(4):235–44 (81 ref.)

Structural biology of key nervous system proteins. Hucho F, et al. **J Neurochem** 1996 May;66(5):1781–92 (92 ref.)

Activating mechanism of CNTF and related cytokines. Inoue M, et al. **Mol Neurobiol** 1996 Jun;12(3):195–209 (128 ref.)

(S)NO signals: translocation, regulation, and a consensus motif. Stamler JS, et al. **Neuron** 1997 May;18(5):691–6 (60 ref.)

Synaptotagmins: C2–domain proteins that regulate membrane traffic. Südhof TC, et al. **Neuron** 1996 Sep;17(3):379–88 (70 ref.)

Discrete structural domains and cell–specific expression determine functional selectivity of the dopamine and norepinephrine transporters. Buck KJ, et al. **NIDA Res Monogr** 1996;161:154–75 (30 ref.)

Does ciliary neurotrophic factor serve a different function in the rat versus the chicken? Finn T, et al. **Perspect Dev Neurobiol** 1996;4(1):91–9 (58 ref.)

DEFICIENCY

[Deficiency of human ciliary neurotropic factor (CNTF) is not causally related to amyotrophic lateral sclerosis (ALS)] Takahashi R. **Rinsho Shinkeigaku** 1995 Dec;35(12):1543–5 (10 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Fragile X syndrome in humans and mice. Oostra BA. **Acta Genet Med Gemellol (Roma)** 1996;45(1–2):93–108 (79 ref.)

Embryonic lethal abnormal visual RNA–binding proteins involved in growth, differentiation, and posttranscriptional gene expression. Antic D, et al. **Am J Hum Genet** 1997 Aug;61(2):273–8 (59 ref.)

Severe mental retardation and macroorchidism without mutation in the FMR1 gene. Reyniers E, et al. **Am J Med Genet** 1996 Aug 9;64(2):408–12 (26 ref.)

Occurrence and diversity of neuropeptides from the crustacean hyperglycemic hormone family in arthropods. A short review. Soyez D. **Ann N Y Acad Sci** 1997 Apr 24;814:319–23 (28 ref.)

A gene for Parkinson disease. Chase TN. **Arch Neurol** 1997 Sep;54(9):1156–7 (15 ref.)

A new role for the stromal cells in kidney development. Bard J. **Bioessays** 1996 Sep;18(9):705–7 (15 ref.)

Molecular characterization of the protein products of the fragile X syndrome gene and the survival of motor neurons gene. Liu Q, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:689–97 (57 ref.)

Drosophila genetics and the functions of synaptic proteins. Parfitt K, et al. **Cold Spring Harb Symp Quant Biol** 1995; 60:371–7 (46 ref.)

Protein: protein interactions in Alzheimer's disease and the CAG triplet repeat diseases. Strittmatter WJ, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:597–605 (73 ref.)

Genetics of Parkinson's disease. Nussbaum RL, et al. **Hum Mol Genet** 1997;6(10):1687–91 (69 ref.)

Huntington disease: advances in molecular and cell biology. Jones AL, et al. **J Inherit Metab Dis** 1997 Jun;20(2):125–38 (71 ref.)

Variable FMR1 gene methylation of large expansions leads to variable phenotype in three males from one fragile X family. de Vries BB, et al. **J Med Genet** 1996 Dec; 33(12):1007–10 (20 ref.)

The Sec1 family: a novel family of proteins involved in synaptic transmission and general secretion. Halachmi N, et al. **J Neurochem** 1996 Mar;66(3):889–97 (51 ref.)

Antisense oligonucleotides induce functional deletion of ligand gated ion channels in cultured neurons and brain explants. Brussaard AB. **J Neurosci Methods** 1997 Jan; 71(1):55–64 (21 ref.)

Therapeutic strategies for Huntington's disease based on a molecular understanding of the disorder. Haque NS, et al. **Mol Med Today** 1997 Apr;3(4):175–83 (44 ref.)

Single–cell analysis of gene expression in the nervous system. Measurements at the edge of chaos. O'Dowd DK, et al. **Mol Neurobiol** 1996 Dec;13(3):199–211 (41 ref.)

The neurobiology of childhood spinal muscular atrophy. Crawford TO, et al. **Neurobiol Dis** 1996 Apr;3(2):97–110 (120 ref.)

Synaptotagmins: C2–domain proteins that regulate membrane traffic. Südhof TC, et al. **Neuron** 1996 Sep;17(3):379–88 (70 ref.)

Machado–Joseph disease gene products carrying different carboxyl termini. Goto J, et al. **Neurosci Res** 1997 Aug; 28(4):373–7 (12 ref.)

Engrailed, Wnt and Pax genes regulate midbrain–hindbrain development. Joyner AL. **Trends Genet** 1996 Jan; 12(1):15–20 (50 ref.)

The GDNF–RET signalling partnership. Robertson K, et al. **Trends Genet** 1997 Jan;13(1):1–3 (36 ref.)

The DnaJ–like cysteine string protein and exocytotic neurotransmitter release. Buchner E, et al. **Trends Neurosci** 1997 May;20(5):223–7 (28 ref.)

The coming of age of the GDNF family and its receptors: gene delivery in a rat Parkinson model may have clinical implications. Olson L. **Trends Neurosci** 1997 Jul;20(7):277–9 (22 ref.)

[Identification of NPDC–1, gene involved in the control of proliferation and differentiation of neural and glial precursors] Dupont E, et al. **C R Seances Soc Biol Fil** 1997; 191(1):95–104 (34 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Multiple sclerosis: an altered immune response or an altered stress response? van Noort JM. **J Mol Med** 1996 Jun; 74(6):285–96 (49 ref.)

Paraneoplastic encephalomyelitis: an update of the effects of the anti–Hu immune response on the nervous system and tumour [editorial] Voltz RD, et al. **J Neurol Neurosurg Psychiatry** 1997 Aug;63(2):133–6 (49 ref.)

METABOLISM

ARIA: a neuromuscular junction neuregulin. Fischbach GD, et al. **Annu Rev Neurosci** 1997;20:429–58 (162 ref.)

Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Billingsley ML, et al. **Biochem J** 1997 May 1;323 (Pt 3):577–91 (216 ref.)

Mechanical and neuroendocrine regulation of the endocrine heart. de Bold AJ, et al. **Cardiovasc Res** 1996 Jan;31(1):7–18 (154 ref.)

A role of cofilin/destrin in reorganization of actin cytoskeleton in response to stresses and cell stimuli. Yahara I, et al. **Cell Struct Funct** 1996 Oct;21(5):421–4 (34 ref.)

Protein: protein interactions in Alzheimer's disease and the CAG triplet repeat diseases. Strittmatter WJ, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:597–605 (73 ref.)

The natriuretic peptide family. Nakao K, et al. **Curr Opin Nephrol Hypertens** 1996 Jan;5(1):4–11 (73 ref.)

Ca2+ and the regulation of neurotransmitter secretion. Bennett MK. **Curr Opin Neurobiol** 1997 Jun;7(3):316–22 (69 ref.)

beta–Catenin is a target for extracellular signals controlling cadherin function: the neurocan–GalNAcPTase connection. Lilien J, et al. **Curr Top Dev Biol** 1997; 35:161–89 (137 ref.)

Sodium channel expression: a dynamic process in neurons and non–neuronal cells. Black JA, et al. **Dev Neurosci** 1996; 18(3):139–52 (101 ref.)

Pharmacology and regulation of the neuronal dopamine transporter. Reith ME, et al. **Eur J Pharmacol** 1997 Apr 11;324(1):1–10 (92 ref.)

Modulation of amino acid–gated ion channels by protein phosphorylation. Moss SJ, et al. **Int Rev Neurobiol** 1996; 39:1–52 (183 ref.)

Telling axons where to grow: a role for Eph receptor tyrosine kinases in guidance. Brambilla R, et al. **Mol Cell Neurosci** 1995 Dec;6(6):487–95 (65 ref.)

Relationship between multifunctional protein "clusterin" and Alzheimer disease. Choi–Miura NH, et al. **Neurobiol Aging** 1996 Sep–Oct;17(5):717–22 (76 ref.)

Posttranslational arginylation of brain proteins. Hallak ME, et al. **Neurochem Res** 1997 Apr;22(4):467–73 (32 ref.)

Glial cell derived neurotrophic factors and Alzheimer's disease. Patel AJ, et al. **Neurodegeneration** 1996 Dec; 5(4):489–96 (43 ref.)

Regulation of acute and chronic opioid receptor functions by OBCAM, a cell adhesion–like molecule. Loh HH, et al. **NIDA Res Monogr** 1996;161:141–53 (24 ref.)

SV2proteoglycan: a potential synaptic vesicle transporter and nerve terminal extracellular matrix receptor. Carlson SS. **Perspect Dev Neurobiol** 1996;3(4):373–86 (79 ref.)

Neurocan and phosphacan: two major nervous tissue–specific chondroitin sulfate proteoglycans. Margolis RK, et al.

Perspect Dev Neurobiol 1996;3(4):273-90 (91 ref.)
Brevican: a major proteoglycan in adult brain. Yamaguchi Y. **Perspect Dev Neurobiol** 1996;3(4):307-17 (54 ref.)
PDZ domains bind carboxy-terminal sequences of target proteins. Saras J, et al. **Trends Biochem Sci** 1996 Dec; 21(12):455-8 (25 ref.)
The GDNF-RET signalling partnership. Robertson K, et al. **Trends Genet** 1997 Jan;13(1):1-3 (36 ref.)
Detection of protein-protein interactions in the nervous system using the two-hybrid system. Nishimune A, et al. **Trends Neurosci** 1996 Jul;19(7):261-6 (45 ref.)
[Growth factors and neurotrophic factors with relevance to gliomas] Nagashima T. **No To Shinkei** 1997 Mar; 49(3):214-26 (132 ref.) **(Jpn)**
[Activation induces dephosphorylation of cofilin (an actin/PIP2-binding protein) and its translocation to plasma membranes in leukocytes] Suzuki K. **Seikagaku** 1997 Apr; 69(4):254-9 (16 ref.) **(Jpn)**
[Effects of antidepressants on cerebral protein phosphorylation reaction] Miyamoto S, et al. **Seishin Shinkeigaku Zasshi** 1996;98(11):930-7 (25 ref.) **(Jpn)**

PHARMACOLOGY

Pharmacological characterization of glial cell line-derived neurotrophic factor (GDNF): implications for GDNF as a therapeutic molecule for treating neurodegenerative diseases. Lapchak PA, et al. **Cell Tissue Res** 1996 Nov; 286(2):179-89 (100 ref.)
Therapeutic potential of the neurotrophins and neurotrophin-CNTF combinations in peripheral neuropathies and motor neuron diseases. Lindsay RM. **Ciba Found Symp** 1996;196:39-48; discussion 48-53 (41 ref.)
Neurotrophic factors as pharmacological agents for the treatment of injured auditory neurons. Van De Water TR, et al. **Ciba Found Symp** 1996;196:149-62; discussion 162-6 (38 ref.)
Neurotrophic factors and the development of drugs to promote motoneuron survival. Hughes RA, et al. **Clin Exp Pharmacol Physiol** 1996 Oct-Nov;23(10-11):965-9 (43 ref.)
Experimental neurotrophic factor therapy leads to cortical synaptic remodeling and compensates for behavioral deficits. Cuello AC. **J Psychiatry Neurosci** 1997 Jan; 22(1):46-55 (78 ref.)
Neurotrophic factors in the treatment of neurotoxicity: an overview. Apfel SC. **Neurotoxicology** 1996 Fall-Winter; 17(3-4):839-44 (29 ref.)

PHYSIOLOGY

Presynaptic phosphoprotein B-50/GAP-43 in neuronal and synaptic plasticity. Biewenga JE, et al. **Acta Biochim Pol** 1996;43(2):327-38 (121 ref.)
Effects of hypoxia on the intercellular channel activity of cultured glomus cells. Abudara V, et al. **Adv Exp Med Biol** 1996;410:151-8 (18 ref.)
Modulation of voltage-gated Ca2+ channels by O2 tension. Significance for arterial oxygen chemoreception. Franco-Obregón A, et al. **Adv Exp Med Biol** 1996; 410:97-103 (283 ref.)
Restriction of plastic fiber growth after lesions by central nervous system myelin-associated neurite growth inhibitors. Kapfhammer JP. **Adv Neurol** 1997;73:7-27 (180 ref.)
The neurotrophins and CNTF: two families of collaborative neurotrophic factors. Ip NY, et al. **Annu Rev Neurosci** 1996; 19:491-515 (137 ref.)
Intracellular signaling pathways activated by neurotrophic factors. Segal RA, et al. **Annu Rev Neurosci** 1996;19:463-89 (208 ref.)
SNAP-25, enSNAREd in neurotransmission and regulation of behaviour. Wilson MC, et al. **Biochem Soc Trans** 1996 Aug;24(3):670-76 (49 ref.)
Intrinsic neuronal determinants that promote axonal sprouting and elongation. Caroni P. **Bioessays** 1997 Sep; 19(9):767-75 (69 ref.)
Nip and tuck at the neuromuscular junction: a role for proteases in developmental synapse elimination. Chang Q, et al. **Bioessays** 1997 Apr;19(4):271-5 (33 ref.)
Information processing and intracellular 'neural' (protein) networks: considerations regarding the diffusion-based hypothesis of Bray. Agutter PS, et al. **Biol Cell** 1997 Mar; 89(1):13-8 (25 ref.)
Nerve growth factor and the neurotrophic factor hypothesis. Yuen EC, et al. **Brain Dev** 1996 Sep-Oct;18(5):362-8 (63 ref.)
GDNF: a cytokine at the interface of TGF-betas and neurotrophins. Unsicker K. **Cell Tissue Res** 1996 Nov; 286(2):175-8 (30 ref.)
Neurotrophic factors and the development of drugs to promote motoneuron survival. Hughes RA, et al. **Clin Exp Pharmacol Physiol** 1996 Oct-Nov;23(10-11):965-9 (43 ref.)
Drosophila genetics and the functions of synaptic proteins. Parfitt K, et al. **Cold Spring Harb Symp Quant Biol** 1995; 60:371-7 (46 ref.)
Motor proteins: myosin V--the multi-purpose transport motor. Titus MA. **Curr Biol** 1997 May 1;7(5):R301-4 (26 ref.)
Huntington's disease: translating a CAG repeat into a pathogenic mechanism. MacDonald ME, et al. **Curr Opin Neurobiol** 1996 Oct;6(5):638-43 (45 ref.)
Ion channel associated proteins. Sheng M, et al. **Curr Opin Neurobiol** 1996 Oct;6(5):602-8 (63 ref.)
Function of a cell adhesion molecule, plexin, in neuron network formation. Fujisawa H, et al. **Dev Neurosci** 1997; 19(1):101-5 (23 ref.)
NeuroD and neurogenesis. Lee JE. **Dev Neurosci** 1997; 19(1):27-32 (35 ref.)
Brain natriuretic peptide versus atrial natriuretic peptide--physiological and pathophysiological significance in children and adults: a review. Yoshibayashi M, et al. **Eur J Endocrinol** 1996 Sep;135(3):265-8 (22 ref.)
Molecules making waves in axon guidance. Varela-Echavarría A, et al. **Genes Dev** 1997 Mar 1; 11(5):545-57 (96 ref.)
Ependymins: meningeal-derived extracellular matrix proteins at the blood-brain barrier. Hoffmann W, et al. **Int Rev Cytol** 1996;165:121-58 (145 ref.)
Deciphering the function of neurexins at cellular junctions. Littleton JT, et al. **J Cell Biol** 1997 May 19;137(4):793-6 (26 ref.)
Accelerating on a treadmill: ADF/cofilin promotes rapid actin filament turnover in the dynamic cytoskeleton [comment] Theriot JA. **J Cell Biol** 1997 Mar 24; 136(6):1165-8 (28 ref.) Comment on: J Cell Biol 1997 Mar 24;136(6):1307-22. Comment on: J Cell Biol 1997 Mar 24;136(6):1323-32.
Contrasting strategies for anoxic brain survival--glycolysis up or down. Lutz PL, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):411-9 (59 ref.)
Function of metal-ion homeostasis in the cell division cycle, mitochondrial protein processing, sensitivity to mycobacterial infection and brain function. Supek F, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):321-30 (73 ref.)
The role of glutamate transporters in glutamate homeostasis in the brain. Takahashi M, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):401-9 (51 ref.)
Activity-dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin? Gozes I, et al. **J Mol Neurosci** 1996 Winter;7(4):235-44 (81 ref.)
The Sec1 family: a novel family of proteins involved in synaptic transmission and general secretion. Halachmi N, et al. **J Neurochem** 1996 Mar;66(3):889-97 (51 ref.)
Structural biology of key nervous system proteins. Hucho F, et al. **J Neurochem** 1996 May;66(5):1781-92 (92 ref.)
The role of Sec1p-related proteins in vesicle trafficking in the nerve terminal. Pevsner J. **J Neurosci Res** 1996 Jul 15;45(2):89-95 (45 ref.)
Phototransduction cascade and circadian oscillator in chicken pineal gland. Okano T, et al. **J Pineal Res** 1997 Apr; 22(3):145-51 (44 ref.)
Synaptic targeting of ionotropic neurotransmitter receptors. Kirsch J, et al. **Mol Cell Neurosci** 1996;8(2-3):93-8 (50 ref.)
The GDNF receptor: recent progress and unanswered questions. Mason I. **Mol Cell Neurosci** 1996;8(2-3):112-9 (46 ref.)
Priming events and retrograde injury signals. A new perspective on the cellular and molecular biology of nerve regeneration. Ambron RT, et al. **Mol Neurobiol** 1996 Aug; 13(1):61-79 (98 ref.)
The role of the insulin-like growth factors in the central nervous system. D'Ercole AJ, et al. **Mol Neurobiol** 1996 Dec;13(3):227-55 (190 ref.)
The early intracellular signaling pathway for the insulin/insulin-like growth factor receptor family in the mammalian central nervous system. Folli F, et al. **Mol Neurobiol** 1996 Oct;13(2):155-83 (162 ref.)
Activating mechanism of CNTF and related cytokines. Inoue M, et al. **Mol Neurobiol** 1996 Jun;12(3):195-209 (128 ref.)
Inflammatory mechanisms in Alzheimer disease: the role of beta-amyloid/glial interactions. Pachter JS. **Mol Psychiatry** 1997 Mar;2(2):91-5 (58 ref.)
GABA transporter heterogeneity: pharmacology and cellular localization. Borden LA. **Neurochem Int** 1996 Oct; 29(4):335-56 (110 ref.)
Sorting of GABA transporter proteins in polarized cells. Caplan MJ. **Neurochem Int** 1996 Oct;29(4):357-60 (19 ref.)
Biology of glial cell line-derived neurotrophic factor (GDNF): implications for the use of GDNF to treat Parkinson's disease. Lapchak PA, et al. **Neurodegeneration** 1996 Sep;5(3):197-205 (39 ref.)
GDNF in a bind with known orphan: accessory implicated in new twist. Lindsay RM, et al. **Neuron** 1996 Oct; 17(4):571-4 (28 ref.)
Does ciliary neurotrophic factor serve a different function in the rat versus the chicken? Finn T, et al. **Perspect Dev Neurobiol** 1996;4(1):91-9 (58 ref.)
GAP-43: putting constraints on neuronal plasticity. Fishman MC. **Perspect Dev Neurobiol** 1996;4(2-3):193-8 (46 ref.)
Signal transduction pathways activated by ciliary neurotrophic factor and related cytokines. Frank DA, et al. **Perspect Dev Neurobiol** 1996;4(1):3-18 (108 ref.)
Leukemia inhibitory factor and ciliary neurotrophic factor in sensory neuron development. Horton AR, et al. **Perspect Dev Neurobiol** 1996;4(1):35-8 (30 ref.)
Ciliary neurotrophic factor as a motor neuron trophic factor. Kuzis K, et al. **Perspect Dev Neurobiol** 1996;4(1):65-74 (89 ref.)
Calcium and Free Radicals: Mediators of neurotrophic factor and excitatory transmitter-regulated developmental plasticity and cell death. Mattson MP. **Perspect Dev Neurobiol** 1996;3(2):79-91 (101 ref.)
Are there more members of the CNTF-GPA family? Shelton DL. **Perspect Dev Neurobiol** 1996;4(1):101-7 (18 ref.)
Regulation of oligodendrocyte cell survival and differentiation by ciliary neurotrophic factor, leukemia inhibitory factor, oncostatin M, and interleukin-6. Vos JP, et al. **Perspect Dev Neurobiol** 1996;4(1):39-52 (133 ref.)
Non-receptor tyrosine kinases in mammalian neurogenesis. Aizawa S, et al. **Princess Takamatsu Symp** 1994;24:323-37 (67 ref.)
Molecular properties and cellular distribution of cholinergic synaptic proteins. Zimmermann H, et al. **Prog Brain Res** 1996;109:31-40 (53 ref.)
Somatostatin receptors in the central nervous system. Schindler M, et al. **Prog Neurobiol** 1996 Sep;50(1):9-47 (255 ref.)
GAP-43: an intrinsic determinant of neuronal development and plasticity. Benowitz LI, et al. **Trends Neurosci** 1997 Feb;20(2):84-91 (140 ref.)
The DnaJ-like cysteine string protein and exocytotic neurotransmitter release. Buchner E, et al. **Trends Neurosci** 1997 May;20(5):223-7 (28 ref.)
[Progress in the study of ciliary nerotrophic factor] He C, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan;27(1):53-6 (10 ref.) **(Chi)**
[Postsynaptic density proteins related to the expression and modulation of synaptic plasticity] Suzuki T. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Apr; 16(2):53-8 (21 ref.) (Eng. Abstr.) **(Jpn)**
[SC1] Fujii T, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb; 42(3 Suppl):552-4 (20 ref.) **(Jpn)**
[Roles of neuropilin and plexin in the development of nervous system] Fujisawa H. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):584-8 (12 ref.) **(Jpn)**
[Glial cells-derived neurotrophic factors] Nakajima K, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):489-95 (20 ref.) **(Jpn)**
[Neurotrophic factors and synaptic plasticity in the central nervous system] Nawa H, et al. **Tanpakushitsu Kakusan Koso** 1996 Dec;41(16):2513-21 (86 ref.) **(Jpn)**

THERAPEUTIC USE

Therapeutic potential of neurotrophic factors for neurological disorders. Yuen EC, et al. **Ann Neurol** 1996 Sep;40(3):346-54 (79 ref.)
Neurotrophic factors in the treatment of peripheral neuropathy. Apfel SC, et al. **Ciba Found Symp** 1996; 196:98-108; discussion 108-12 (40 ref.)
Development of neurotrophic factor therapy for Alzheimer's disease. Hefti F, et al. **Ciba Found Symp** 1996;196:54-63; discussion 63-9 (36 ref.)
Somatic gene therapy for nervous system disease. Tuszynski MH, et al. **Ciba Found Symp** 1996;196:85-94; discussion 94-7 (51 ref.)
Glial cell line-derived neurotrophic factor: a novel therapeutic approach to treat motor dysfunction in Parkinson's disease. Lapchak PA, et al. **Exp Neurol** 1997 Mar;144(1):29-34 (20 ref.)
Pharmacological activities of glial cell line-derived neurotrophic factor (GDNF): preclinical development and application to the treatment of Parkinson's disease. Lapchak PA, et al. **Exp Neurol** 1997 Jun;145(2 Pt 1):309-21 (65 ref.)
Experimental neurotrophic factor therapy leads to cortical synaptic remodeling and compensates for behavioral deficits. Cuello AC. **J Psychiatry Neurosci** 1997 Jan; 22(1):46-55 (78 ref.)
Neurotrophic factors for experimental treatment of motoneuron disease. Sendtner M. **Prog Brain Res** 1996; 109:365-71 (25 ref.)
Therapeutic potentials for glial cell line-derived neurotrophic factor (GDNF) based upon pharmacological activities in the CNS. Lapchak PA. **Rev Neurosci** 1996 Jul-Sep; 7(3):165-76 (48 ref.)

NERVE TRANSFER

see related
NERVE REGENERATION

METHODS

Neural transplantation. Jones DG, et al. **N Z Med J** 1996 Oct 11;109(1031):369-71 (30 ref.)

NERVE TRANSMITTER SUBSTANCES see **NEUROTRANSMITTERS**

NERVOUS MICE see **MICE, NEUROLOGIC MUTANTS**

NERVOUS SYSTEM

Applications of fourier transform infrared imaging microscopy in neurotoxicity. Lewis EN, et al. **Ann N Y Acad Sci** 1997 May 30;820:234-46; discussion 246-7 (26 ref.)
Herpes simplex virus vectors for gene transfer to the nervous system. Goins WF, et al. **J Neurovirol** 1997 May;3 Suppl 1:S80-8 (91 ref.)

ANATOMY & HISTOLOGY

[Structure and functions of the cutaneous nervous system] Reznik M. **Pathol Biol (Paris)** 1996 Dec;44(10):831-7 (42

ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Cell-adhesion proteins of the immunoglobulin superfamily in the nervous system. Uyemura K, et al. **Essays Biochem** 1996;31:37-48 (30 ref.)

A review of phylogenetic and metabolic relationships between the acylamino acids, N-acetyl-L-aspartic acid and N-acetyl-L-histidine, in the vertebrate nervous system. Baslow MH. **J Neurochem** 1997 Apr;68(4):1335-44 (50 ref.)

Adenosine A2 receptor-mediated excitatory actions on the nervous system. Sebastião AM, et al. **Prog Neurobiol** 1996 Feb;48(3):167-89 (225 ref.)

Neurosteroids: of the nervous system, by the nervous system, for the nervous system. Baulieu EE. **Recent Prog Horm Res** 1997;52:1-32 (107 ref.)

Detection of protein-protein interactions in the nervous system using the two-hybrid system. Nishimune A, et al. **Trends Neurosci** 1996 Jul;19(7):261-6 (45 ref.)

CYTOLOGY

Neural development: instructions for neural diversity. Lillien L. **Curr Biol** 1997 Mar 1;7(3):R168-71 (18 ref.)

Pax genes and their roles in cell differentiation and development. Mansouri A, et al. **Curr Opin Cell Biol** 1996 Dec;8(6):851-7 (78 ref.)

Asymmetric division and polarity of neuroepithelial cells. Huttner WB, et al. **Curr Opin Neurobiol** 1997 Feb; 7(1):29-39 (70 ref.)

Cell culture approaches to understanding the actions of steroid hormones on the insect nervous system. Levine RB, et al. **Dev Neurosci** 1996;18(1-2):73-86 (72 ref.)

Neuronal cell death in the mammalian nervous system: the calmortin hypothesis. Bennett MR, et al. **Gen Pharmacol** 1996 Apr;27(3):407-19 (220 ref.)

The role of Notch in lateral inhibition and cell fate specification [corrected and republished with original paging, article originally printed in Mol Cell Neurosci 1995 Aug;6(4):311-21] Chitnis AB. **Mol Cell Neurosci** 1995 Dec; 6(6):311-21 (73 ref.)

Cell division and the nervous system: regulating the cycle from neural differentiation to death. Ross ME. **Trends Neurosci** 1996 Feb;19(2):62-8 (104 ref.)

[The neuronal theory and new concepts of the structure of the nervous system] Novozhilova AP, et al. **Morfologiia** 1996;110(4):7-16 (74 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Clinical applications of neurotransmitter-receptor studies in geriatric neuropharmacology. Gómez-Vargas M, et al. **Acta Med Okayama** 1996 Aug;50(4):173-90 (148 ref.)

K252a and staurosporine microbial alkaloid toxins as prototype of neurotropic drugs. Lazarovici P, et al. **Adv Exp Med Biol** 1996;391:367-77 (32 ref.)

Recent findings on the mechanisms by which alcohol damages the developing nervous system. West JR. **Alcohol Alcohol Suppl** 1994;2:395-9 (40 ref.)

Neuroprotectant drugs in cisplatin neurotoxicity. Cavaletti G, et al. **Anticancer Res** 1996 Sep-Oct;16(5B):3149-59 (84 ref.)

Oscillation follows drug sensitization: implications. Antelman SM, et al. **Crit Rev Neurobiol** 1996;10(1):101-17 (80 ref.)

The beneficial effects of omega-3 fatty acids: cardiovascular disease and neurodevelopment [editorial] Connor WE. **Curr Opin Lipidol** 1997 Feb;8(1):1-3 (29 ref.)

Individual differences in neural sensitization and the role of context in illness from low-level environmental chemical exposures. Bell IR, et al. **Environ Health Perspect** 1997 Mar; 105 Suppl 2:457-66 (109 ref.)

Neurobehavioral aspects of developmental toxicity testing. Ulbrich B, et al. **Environ Health Perspect** 1996 Apr;104 Suppl 2:407-12 (16 ref.)

Neurophysiological methods in occupational and environmental health: methodology and recent findings. Araki S, et al. **Environ Res** 1997;73(1-2):42-51 (111 ref.)

Neurobehavioral tests as a medical surveillance procedure: applying evaluative criteria. Guirguis S. **Environ Res** 1997; 73(1-2):63-9 (46 ref.)

The Triennial International Symposium on Neurobehavioral Methods: the history and hope. Johnson BL. **Environ Res** 1997;73(1-2):2-8 (17 ref.)

Early manifestations of manganese neurotoxicity in humans: an update. Mergler D, et al. **Environ Res** 1997; 73(1-2):92-100 (52 ref.)

Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Packer L, et al. **Free Radic Biol Med** 1997; 22(1-2):359-78 (215 ref.)

Neuropharmacological profile of non-peptide neurotensin antagonists. Gully D, et al. **Fundam Clin Pharmacol** 1995; 9(6):513-21 (55 ref.)

Neurotoxicity associated with acyclovir in end stage renal failure. Kitching AR, et al. **N Z Med J** 1997 May 9; 110(1043):167-9 (19 ref.)

[Helminth nervous system as a field for anthelmintic action] Boczoń K. **Wiad Parazytol** 1996;42(4):373-9 (26 ref.) (Eng. Abstr.) **(Pol)**

EMBRYOLOGY

Recent findings on the mechanisms by which alcohol damages the developing nervous system. West JR. **Alcohol Alcohol Suppl** 1994;2:395-9 (40 ref.)

Multisite neural tube closure in humans. Van Allen MI. **Birth Defects Orig Artic Ser** 1996;30(1):203-25 (98 ref.)

Programmed cell death in the developing nervous system. Burek MJ, et al. **Brain Pathol** 1996 Oct;6(4):427-46 (156 ref.)

Anti-neural-inhibition: a conserved mechanism for neural induction. Bier E. **Cell** 1997 May 30;89(5):681-4 (21 ref.)

Vertebrate embryonic cells will become nerve cells unless told otherwise. Hemmati-Brivanlou A, et al. **Cell** 1997 Jan 10;88(1):13-7 (25 ref.)

Neural induction and antero-posterior patterning in the amphibian embryo: past, present and future. Gould SE, et al. **Cell Mol Life Sci** 1997 Apr;53(4):319-38 (136 ref.)

Short historical survey of pattern formation in the endo-mesoderm and the neural anlage in the vertebrates: the role of vertical and planar inductive actions. Nieuwkoop PD. **Cell Mol Life Sci** 1997 Apr;53(4):305-18 (133 ref.)

Patterning cascades in the neural tube. Neural development. Placzek M, et al. **Curr Biol** 1996 May 1;6(5):526-9 (17 ref.)

Asymmetric cell division and neurogenesis. Doe CQ. **Curr Opin Genet Dev** 1996 Oct;6(5):562-6 (27 ref.)

Neuregulins and neuregulin receptors in neural development. Gassmann M, et al. **Curr Opin Neurobiol** 1997 Feb; 7(1):87-92 (48 ref.)

Basic helix-loop-helix genes in neural development. Lee JE. **Curr Opin Neurobiol** 1997 Feb;7(1):13-20 (45 ref.)

Development. The end of the beginning? [editorial] Lumsden A, et al. **Curr Opin Neurobiol** 1997 Feb;7(1):3-6 (6 ref.)

Genetics of neural development in zebrafish. Schier AF. **Curr Opin Neurobiol** 1997 Feb;7(1):119-26 (71 ref.)

Neural induction in Xenopus laevis: evidence for the default model. Weinstein DC, et al. **Curr Opin Neurobiol** 1997 Feb; 7(1):7-12 (51 ref.)

Neural induction in amphibians. Grunz H. **Curr Top Dev Biol** 1997;35:191-228 (237 ref.)

Ectodermal patterning in vertebrate embryos. Sasai Y, et al. **Dev Biol** 1997 Feb 1;182(1):5-20 (167 ref.)

NeuroD and neurogenesis. Lee JE. **Dev Neurosci** 1997; 19(1):27-32 (35 ref.)

Molecules making waves in axon guidance. Varela-Echavarría A, et al. **Genes Dev** 1997 Mar 1; 11(5):545-57 (96 ref.)

Neuroectodermal grafting: a new tool for the study of neurodegenerative diseases. Isenmann S, et al. **Histol Histopathol** 1996 Oct;11(4):1063-73 (92 ref.)

Contributions of an orthopteran to the understanding of neuronal pathfinding. Sanchez D, et al. **Immunol Cell Biol** 1995 Dec;73(6):565-74 (55 ref.)

Mechanisms of normal and abnormal neurulation: evidence from embryo culture studies. Fleming A, et al. **Int J Dev Biol** 1997 Apr;41(2):199-212 (159 ref.)

Vertebrate neural induction: inducers, inhibitors, and a new synthesis. Wilson PA, et al. **Neuron** 1997 May;18(5):699-710 (92 ref.)

Non-receptor tyrosine kinases in mammalian neurogenesis. Aizawa S, et al. **Princess Takamatsu Symp** 1994;24:323-37 (67 ref.)

The molecular biology of axon guidance. Tessier-Lavigne M, et al. **Science** 1996 Nov 15;274(5290):1123-33 (120 ref.)

Genetic analysis of axon guidance and mapping in the zebrafish. Karlstrom RO, et al. **Trends Neurosci** 1997 Jan; 20(1):3-8 (48 ref.)

Hematolymphopoietic and inflammatory cytokines in neural development. Mehler MF, et al. **Trends Neurosci** 1997 Aug; 20(8):357-65 (79 ref.)

[Helix-loop-helix transcription factor network regulating mammalian neurogenesis] Kageyama R, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):989-96 (25 ref.) **(Jpn)**

ENZYMOLOGY

Protein tyrosine phosphatases in the nervous system. Naegele JR, et al. **Crit Rev Neurobiol** 1994;9(1):105-14 (97 ref.)

Cyclic GMP-dependent protein kinase and cellular signaling in the nervous system. Wang X, et al. **J Neurochem** 1997 Feb;68(2):443-56 (120 ref.)

GROWTH & DEVELOPMENT

Serotonin as a developmental signal. Whitaker-Azmitia PM, et al. **Behav Brain Res** 1996;73(1-2):19-29 (120 ref.)

Programmed cell death in the developing nervous system. Burek MJ, et al. **Brain Pathol** 1996 Oct;6(4):427-46 (156 ref.)

Neuronal death in developmental models: possible implications in neuropathology. Johnson EM Jr, et al. **Brain Pathol** 1996 Oct;6(4):397-409 (88 ref.)

Roles of platelet-derived growth factor in the developing and mature nervous systems. Valenzuela CF, et al. **Brain Res Brain Res Rev** 1997 Jun;24(1):77-89 (116 ref.)

In vivo development of neuronal structure and function. Cline HT, et al. **Cold Spring Harb Symp Quant Biol** 1996; 61:95-104 (35 ref.)

Cortical plasticity underlying perceptual, motor, and cognitive skill development: implications for neurorehabilitation. Merzenich M, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:1-8 (59 ref.)

Regulation of vertebrate neural cell fate by transcription factors. Bang AG, et al. **Curr Opin Neurobiol** 1996 Feb; 6(1):25-32 (79 ref.)

Synapse maturation and structural plasticity at Drosophila neuromuscular junctions. Budnik V. **Curr Opin Neurobiol** 1996 Dec;6(6):858-67 (80 ref.)

Functions of netrins and semaphorins in axon guidance. Culotti JG, et al. **Curr Opin Neurobiol** 1996 Feb;6(1):81-8 (40 ref.)

Eph receptor tyrosine kinases and their ligands in neural development. Friedman GC, et al. **Curr Opin Neurobiol** 1996 Feb;6(1):127-33 (72 ref.)

Role of neurotrophic factors in neuronal development. Henderson CE. **Curr Opin Neurobiol** 1996 Feb;6(1):64-70 (61 ref.)

Neurogenic genes and vertebrate neurogenesis. Lewis J. **Curr Opin Neurobiol** 1996 Feb;6(1):3-10 (75 ref.)

Schwann cell development, differentiation and myelination. Mirsky R, et al. **Curr Opin Neurobiol** 1996 Feb;6(1):89-96 (70 ref.)

Mechanism of synapse disassembly at the developing neuromuscular junction. Nguyen QT, et al. **Curr Opin Neurobiol** 1996 Feb;6(1):104-12 (68 ref.)

Intrinsic and extrinsic determinants regulating cell fate decision in developing nervous system. Okabe M, et al. **Dev Neurosci** 1997;19(1):9-16 (28 ref.)

Development and regeneration of the nervous system: a role for neurosteroids. Schumacher M, et al. **Dev Neurosci** 1996; 18(1-2):6-21 (135 ref.)

The estrogen/neurotrophin connection during neural development: is co-localization of estrogen receptors with the neurotrophins and their receptors biologically relevant? Toran-Allerand CD. **Dev Neurosci** 1996;18(1-2):36-48 (105 ref.)

Elucidation of the molecular actions of NCAM and structurally related cell adhesion molecules. Baldwin TJ, et al. **J Cell Biochem** 1996 Jun 15;61(4):502-13 (75 ref.)

Overexpression of growth-associated proteins in the neurons of adult transgenic mice. Caroni P. **J Neurosci Methods** 1997 Jan;71(1):3-9 (19 ref.)

Supplemental stimulation of premature infants: a treatment model. Dieter JN, et al. **J Pediatr Psychol** 1997 Jun; 22(3):281-95 (77 ref.)

The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Lovestone S, et al. **Neuroscience** 1997 May;78(2):309-24 (169 ref.)

Lead and neurobehavioral development in gulls: a model for understanding effects in the laboratory and the field. Burger J, et al. **Neurotoxicology** 1997;18(2):495-506 (57 ref.)

Evidence for PCBs as neurodevelopmental toxicants in humans. Jacobson JL, et al. **Neurotoxicology** 1997; 18(2):415-24 (35 ref.)

The cytoskeleton in nerve growth cone motility and axonal pathfinding. Letourneau PC. **Perspect Dev Neurobiol** 1996; 4(2-3):111-23 (85 ref.)

Paternal exposures: impact on reproductive and developmental outcome. An overview. Friedler G. **Pharmacol Biochem Behav** 1996 Dec;55(4):691-700 (135 ref.)

What research with animals is telling us about alcohol-related neurodevelopmental disorder. Hannigan JH. **Pharmacol Biochem Behav** 1996 Dec;55(4):489-99 (207 ref.)

Proteoglycans and other repulsive molecules in glial boundaries during development and regeneration of the nervous system. Höke A, et al. **Prog Brain Res** 1996; 108:149-63 (123 ref.)

IMMUNOLOGY

Autoimmunity and the nervous system. Newsom-Davis J. **Ann Acad Med Singapore** 1996 Mar;25(2):309-14 (20 ref.)

Sixteenth Gaddum Memorial Lecture December 1996. Neuroimmune interactions: the role of cytokines. Rothwell NJ. **Br J Pharmacol** 1997 Jul;121(5):841-7 (62 ref.)

Role of complement in inflammation and injury in the nervous system. Morgan BP, et al. **Exp Clin Immunogenet** 1997;14(1):19-23 (22 ref.)

Human herpes viruses latent infection in the nervous system. Steiner I. **Immunol Rev** 1996 Aug;152:157-73 (110 ref.)

Hematolymphopoietic and inflammatory cytokines in neural development. Mehler MF, et al. **Trends Neurosci** 1997 Aug; 20(8):357-65 (79 ref.)

INJURIES

Long-term response to nerve injury. Gordon T, et al. **Adv Neurol** 1997;72:185-99 (117 ref.)

Role of complement in inflammation and injury in the nervous system. Morgan BP, et al. **Exp Clin Immunogenet** 1997;14(1):19-23 (22 ref.)

Neuropathic pain in the perioperative period. Hayes C, et al. **Int Anesthesiol Clin** 1997 Spring;35(2):67-81 (49 ref.)

Neurotrophins and their receptors in nerve injury and repair. Ebadi M, et al. **Neurochem Int** 1997 Apr-May; 30(4-5):347-74 (240 ref.)

Alterations in apolipoprotein E expression during aging and neurodegeneration. Masliah E, et al. **Prog Neurobiol** 1996 Dec;50(5-6):493-503 (80 ref.)

Focus on neurocritical care. Bleck TP. **Va Med Q** 1996 Spring;123(2):84-9 (13 ref.)

[Nerve injuries during dental and orthodontic interventions. Their causes, incidence, sequelae and legal assessment] Hardt N, et al. **Schweiz Monatsschr Zahnmed** 1996; 106(1):31-44 (41 ref.) **(Ger, Fre)**

METABOLISM

Opiates, glia, and neurotoxicity. Chao CC, et al. **Adv Exp Med Biol** 1996;402:29–33 (20 ref.)

Behavioral and neurophysiological effects of CNS expression of cytokines in transgenic mice. Gold LH, et al. **Adv Exp Med Biol** 1996;402:199–205 (10 ref.)

Bcl-2 gene family in the nervous system. Merry DE, et al. **Annu Rev Neurosci** 1997;20:245–67 (180 ref.)

Dystrophin in the nervous system. Lidov HG. **Brain Pathol** 1996 Jan;6(1):63–77 (111 ref.)

Intermediate filaments in the nervous system: implications in cancer. Ho CL, et al. **Cancer Metastasis Rev** 1996 Dec; 15(4):483–97 (119 ref.)

Extracellular metabolism of nucleotides in the nervous system. Zimmermann H, et al. **J Auton Pharmacol** 1996 Dec;16(6):397–400 (40 ref.)

PAF and PAF acetylhydrolase in the nervous system. Hattori M, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):99–102 (9 ref.)

N-arachidonoylethanolamine (anandamide), an endogenous cannabinoid receptor ligand, and related lipid molecules in the nervous tissues. Sugiura T, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):51–6 (20 ref.)

A review of phylogenetic and metabolic relationships between the acylamino acids, N-acetyl-L-aspartic acid and N-acetyl-L-histidine, in the vertebrate nervous system. Baslow MH. **J Neurochem** 1997 Apr;68(4):1335–44 (50 ref.)

Advances in the immunocytochemical localization of neuroactive substances in the insect nervous system. Nässel DR. **J Neurosci Methods** 1996 Oct 21;69(1):3–23 (102 ref.)

Regulation of gene expression in the nervous system by reactive oxygen and nitrogen species. Merrill JE, et al. **Metab Brain Dis** 1997 Jun;12(2):97–112 (135 ref.)

Mechanisms of transcriptional regulation and neural gene expression. Tamura T, et al. **Neurochem Int** 1996 Dec; 29(6):573–81 (61 ref.)

Cellular immediate-early genes and cell death in the nervous system. Herzog KH, et al. **Neuropathol Appl Neurobiol** 1996 Dec;22(6):484–8 (26 ref.)

The glypican family of heparan sulfate proteoglycans: major cell-surface proteoglycans of the developing nervous system. Lander AD, et al. **Perspect Dev Neurobiol** 1996; 3(4):347–58 (69 ref.)

The VAChT/ChAT "cholinergic gene locus": new aspects of genetic and vesicular regulation of cholinergic function. Erickson JD, et al. **Prog Brain Res** 1996;109:69–82 (50 ref.)

The thrombin receptor in the nervous system. Suidan HS, et al. **Semin Thromb Hemost** 1996;22(2):125–33 (63 ref.)

Identifying changes in gene expression in the nervous system: mRNA differential display. Livesey FJ, et al. **Trends Neurosci** 1996 Mar;19(3):84–8 (20 ref.)

Immune responses to adenovirus vectors in the nervous system. Wood MJ, et al. **Trends Neurosci** 1996 Nov; 19(11):497–501 (47 ref.)

PATHOLOGY

Long-term response to nerve injury. Gordon T, et al. **Adv Neurol** 1997;72:185–99 (117 ref.)

Tissue lesions in AIDS patients involve both the lymphoid and the nervous system. Chiodi F. **AIDS** 1995;9 Suppl A:S41–8 (104 ref.)

Lumbar facet pain: biomechanics, neuroanatomy and neurophysiology. Cavanaugh JM, et al. **J Biomech** 1996 Sep;29(9):1117–29 (54 ref.)

Neuropathology of peroxisomal diseases. Martin JJ. **J Inherit Metab Dis** 1995;18 Suppl 1:19–33 (40 ref.)

T-cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms. Gold R, et al. **Trends Neurosci** 1997 Sep;20(9):399–404 (64 ref.)

PHYSIOLOGY

Neural systems mediating the negative feedback actions of estradiol and progesterone in the ewe. Goodman RL. **Acta Neurobiol Exp (Warsz)** 1996;56(3):727–41 (85 ref.)

Structure and biology of inhibitory glycine receptors. Betz H, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:109–15 (40 ref.)

Region-specific regulation of neurogenesis by VIP and PACAP: direct and indirect modes of action. DiCicco-Bloom E. **Ann N Y Acad Sci** 1996 Dec 26; 805:244–56; discussion 256–8 (30 ref.)

Genetic dissection of signal transduction mechanisms underlying PACAP-like neuropeptide transmission in Drosophila: synergy of cAMP and Ras/Raf pathways. Zhong Y. **Ann N Y Acad Sci** 1996 Dec 26;805:67–79; discussion 79–80 (36 ref.)

The neurotrophins and CNTF: two families of collaborative neurotrophic factors. Ip NY, et al. **Annu Rev Neurosci** 1996; 19:491–515 (137 ref.)

Physiology of the neurotrophins. Lewin GR, et al. **Annu Rev Neurosci** 1996;19:289–317 (203 ref.)

Why do we eat? A neural systems approach. Levine AS, et al. **Annu Rev Nutr** 1997;17:597–619 (139 ref.)

Neural mechanisms of tolerance to the effects of cocaine. Hammer RP Jr, et al. **Behav Brain Res** 1997 Mar; 84(1–2):225–39 (155 ref.)

Serotonergic modulation of behaviour: a phylogenetic overview. Weiger WA. **Biol Rev Camb Philos Soc** 1997 Feb;72(1):61–95 (172 ref.)

The evolution of insect flight: implications for the evolution of the nervous system. Edwards JS. **Brain Behav Evol** 1997 Jul;50(1):8–12 (26 ref.)

The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions. McEwen BS, et al. **Brain Res Brain Res Rev** 1997 Feb;23(1–2):79–133 (485 ref.)

Cellular adhesion molecules in neurology. Marchetti PJ, et al. **Can J Neurol Sci** 1997 Aug;24(3):200–9 (79 ref.)

Neuromodulation of transduction and signal processing in the end organs of taste. Nagai T, et al. **Chem Senses** 1996 Jun;21(3):353–65 (106 ref.)

Neuroregulation of the nose and bronchi. Widdicombe JG. **Clin Exp Allergy** 1996 May;26 Suppl 3:32–5 (20 ref.)

Adenosine and the nervous system: clinical implications. Guieu R, et al. **Clin Neuropharmacol** 1996 Dec;19(6):459–74 (208 ref.)

Neurophysiological aspects of language processing. Friederici AD. **Clin Neurosci** 1997;4(2):64–72 (76 ref.)

Neural mechanisms for heading and structure-from-motion perception. Andersen RA, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:15–25 (61 ref.)

CaMKII function in the nervous system explored from a genetic perspective. Mayford M, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:219–24 (25 ref.)

What words are telling us about the brain. Raichle ME. **Cold Spring Harb Symp Quant Biol** 1996;61:9–14 (25 ref.)

A simple systems approach to neural-immune communication. Clatworthy AL. **Comp Biochem Physiol A Physiol** 1996 Sep;115(1):1–10 (77 ref.)

Hormones, lymphohemopoietic cytokines and the neuroimmune axis. Johnson RW, et al. **Comp Biochem Physiol A Physiol** 1997 Mar;116(3):183–201 (210 ref.)

Opioid and opiate immunoregulatory processes. Stefano GB, et al. **Crit Rev Immunol** 1996;16(2):109–44 (258 ref.)

Oscillation follows drug sensitization: implications. Antelman SM, et al. **Crit Rev Neurobiol** 1996;10(1):101–17 (80 ref.)

Neurobiology of cholecystokinin. Moran TH, et al. **Crit Rev Neurobiol** 1994;9(1):1–28 (321 ref.)

Neurobiology of nitric oxide. Yun HY, et al. **Crit Rev Neurobiol** 1996;10(3–4):291–316 (225 ref.)

DCC's function takes shape in the nervous system. Kolodziej PA. **Curr Opin Genet Dev** 1997 Feb;7(1):87–92 (27 ref.)

Transcriptional control of Hox genes in the vertebrate nervous system. Lufkin T. **Curr Opin Genet Dev** 1996 Oct; 6(5):575–80 (66 ref.)

Biochemistry of cell death. Fraser A, et al. **Curr Opin Neurobiol** 1996 Feb;6(1):71–80 (103 ref.)

Insect visual perception: complex abilities of simple nervous systems. Giurfa M, et al. **Curr Opin Neurobiol** 1997 Aug; 7(4):505–13 (46 ref.)

Sensory hyperacuity in the jamming avoidance response of weakly electric fish. Kawasaki M. **Curr Opin Neurobiol** 1997 Aug;7(4):473–9 (51 ref.)

Neurobehavioural mechanisms of reward and motivation. Robbins TW, et al. **Curr Opin Neurobiol** 1996 Apr; 6(2):228–36 (61 ref.)

Establishment of pathways in the developing neural system. Chiquet M. **Curr Top Microbiol Immunol** 1996;212:229–38 (23 ref.)

Cell culture approaches to understanding the actions of steroid hormones on the insect nervous system. Levine RB, et al. **Dev Neurosci** 1996;18(1–2):73–86 (72 ref.)

Intrinsic and extrinsic determinants regulating cell fate decision in developing nervous system. Okabe M, et al. **Dev Neurosci** 1997;19(1):9–16 (28 ref.)

Steroid receptors and nervous system metamorphosis in insects. Truman JW. **Dev Neurosci** 1996;18(1–2):87–101 (41 ref.)

Another view of GH neuroregulation: lessons from the sheep. Dutour A, et al. **Eur J Endocrinol** 1997 Jun;136(6):553–65 (133 ref.)

Connexins, gap junctions and cell-cell signalling in the nervous system. Bruzzone R, et al. **Eur J Neurosci** 1997 Jan;9(1):1–6 (24 ref.)

Eccentric contractions require unique activation strategies by the nervous system. Enoka RM. **J Appl Physiol** 1996 Dec;81(6):2339–46 (51 ref.)

Neural adaptations with chronic physical activity. Enoka RM. **J Biomech** 1997 May;30(5):447–55 (117 ref.)

Arm movements in monkeys: behavior and neurophysiology. Georgopoulos AP. **J Comp Physiol [A]** 1996 Nov; 179(5):603–12 (46 ref.)

Mast cell interactions with the nervous system: relationship to mechanisms of disease. Dines KC, et al. **J Neuropathol Exp Neurol** 1997 Jun;56(6):627–40 (95 ref.)

The neurobiology of emotional experience. Heilman KM. **J Neuropsychiatry Clin Neurosci** 1997 Summer;9(3):439–48 (85 ref.)

The neural substrates of religious experience. Saver JL, et al. **J Neuropsychiatry Clin Neurosci** 1997 Summer; 9(3):498–510 (145 ref.)

Evidence for nervous system degeneration with advancing age. Lexell J. **J Nutr** 1997 May;127(5 Suppl):1011S–1013S (34 ref.)

Role of glucocorticoids in the neuroregulation of growth hormone secretion. Dieguez C, et al. **J Pediatr Endocrinol Metab** 1996 Jun;9 Suppl 3:255–60 (26 ref.)

Behavioral, neural and cellular components underlying olfactory learning in the honeybee. Menzel R, et al. **J Physiol Paris** 1996;90(5–6):395–8 (36 ref.)

The immune-neuro-endocrine interactions. Tomaszewska D, et al. **J Physiol Pharmacol** 1997 Jun;48(2):139–58 (100 ref.)

Nitric oxide signaling in the nervous system. Brenman JE, et al. **Methods Enzymol** 1996;269:119–29 (78 ref.)

The role of Notch in lateral inhibition and cell fate specification [corrected and republished with original paging, article originally printed in Mol Cell Neurosci 1995 Aug;6(4):311–21] Chitnis AB. **Mol Cell Neurosci** 1995 Dec; 6(6):311–21 (73 ref.)

Nitric oxide in health and disease of the nervous system. Yun HY, et al. **Mol Psychiatry** 1997 Jul;2(4):300–10 (146 ref.)

The utilization of gene targeting to study mammalian neurobiology. Pollock JD. **Neurobiol Dis** 1995 Apr; 2(2):63–78 (106 ref.)

Uridine nucleotide receptors and their ligands: structural, physiological, and pathophysiological aspects, with special emphasis on the nervous system. Heilbronn E, et al. **Neurochem Res** 1997 Aug;22(8):1041–50 (86 ref.)

Programmed cell death in the developing nervous system. Henderson CE. **Neuron** 1996 Oct;17(4):579–85 (26 ref.)

Pre- and postfusion regulation of transmitter release. Rahamimoff R, et al. **Neuron** 1997 Jan;18(1):17–27 (128 ref.)

Reinforcement concept in investigations on simple nervous systems. Balaban PM. **Neurosci Behav Physiol** 1997 Jul-Aug;27(4):435–40 (15 ref.)

Neurophysiological mechanisms of cortical-subcortical interactions in the organization of behavior. Shuvaev VT, et al. **Neurosci Behav Physiol** 1997 May-Jun;27(3):288–96 (29 ref.)

The nerves, the liver, and the route of feeding: an integrated response to nutrient delivery [editorial] Moore MC, et al. **Nutrition** 1996 Apr;12(4):282–4 (25 ref.)

Do theoretical bridges exist between perceptual experience and neurophysiology? Uttal WA. **Perspect Biol Med** 1997 Winter;40(2):280–302 (41 ref.)

Signal transduction pathways activated by ciliary neurotrophic factor and related cytokines. Frank DA, et al. **Perspect Dev Neurobiol** 1996;4(1):3–18 (108 ref.)

Extrinsic signals in the developing nervous system: the role of neurokines during neurogenesis. Heller S, et al. **Perspect Dev Neurobiol** 1996;4(1):19–34 (135 ref.)

Regulation of oligodendrocyte cell survival and differentiation by ciliary neurotrophic factor, leukemia inhibitory factor, oncostatin M, and interleukin-6. Vos JP, et al. **Perspect Dev Neurobiol** 1996;4(1):39–52 (133 ref.)

Endothelial nitric oxide, prostacyclin (PGI2) and tissue plasminogen activator (t-PA): alliance or neutrality? Gryglewski RJ. **Pol J Pharmacol** 1995 Sep-Oct; 47(5):467–72 (22 ref.)

Signals and signs in the nervous system: the dynamic anatomy of electrical activity is probably information-rich. Bullock TH. **Proc Natl Acad Sci U S A** 1997 Jan 7;94(1):1–6 (45 ref.)

Plasticity of the nervous system at the systematic, cellular and molecular levels: a mechanism of chronic pain and hyperalgesia. Zimmermann M, et al. **Prog Brain Res** 1996; 110:233–59 (106 ref.)

Highest level automatisms in the nervous system: a theory of functional principles underlying the highest forms of brain function. Baev KV. **Prog Neurobiol** 1997 Feb; 51(2):129–66 (74 ref.)

The nitric oxide system in insects. Müller U. **Prog Neurobiol** 1997 Feb;51(3):363–81 (146 ref.)

Cytokines which signal through the LIF receptor and their actions in the nervous system. Murphy M, et al. **Prog Neurobiol** 1997 Aug;52(5):355–78 (196 ref.)

Biochemistry, localization and functional roles of ecto-nucleotidases in the nervous system. Zimmermann H. **Prog Neurobiol** 1996 Aug;49(6):589–618 (340 ref.)

Neurosteroids: of the nervous system, by the nervous system, for the nervous system. Baulieu EE. **Recent Prog Horm Res** 1997;52:1–32 (107 ref.)

Some neurophysiologic aspects of consciousness. Bogen JE. **Semin Neurol** 1997 Jun;17(2):95–103 (108 ref.)

The neural basis of aware and unaware forms of memory. Verfaellie M, et al. **Semin Neurol** 1997 Jun;17(2):153–61 (90 ref.)

Thrombin, its receptor and protease nexin I, its potent serpin, in the nervous system. Festoff BW, et al. **Semin Thromb Hemost** 1996;22(3):267–71 (47 ref.)

Vitamin C and nervous tissue. In vivo and in vitro aspects. Katsuki H. **Subcell Biochem** 1996;25:293–311 (133 ref.)

Variation and selection in neural function [letter; comment] Changeux JP. **Trends Neurosci** 1997 Jul;20(7):291–3 (20 ref.) Comment on: Trends Neurosci 1996 Nov;19(11):460–4.

Intrinsic neuromodulation: altering neuronal circuits from within. Katz PS, et al. **Trends Neurosci** 1996 Feb; 19(2):54–61 (72 ref.)

Growth cones and the cues that repel them. Kolodkin AL. **Trends Neurosci** 1996 Nov;19(11):507–13 (64 ref.)

Nerve growth factor: from neurotrophin to neurokine. Levi-Montalcini R, et al. **Trends Neurosci** 1996 Nov; 19(11):514–20 (91 ref.)

Bone morphogenetic proteins in the nervous system. Mehler MF, et al. **Trends Neurosci** 1997 Jul;20(7):309–17 (49 ref.)

Polysialic acid in the vertebrate nervous system: a promoter of plasticity in cell-cell interactions. Rutishauser U, et al. **Trends Neurosci** 1996 Oct;19(10):422–7 (63 ref.)

Variation and selection in neural function [letter; comment] Sporns O. **Trends Neurosci** 1997 Jul;20(7):291; discussion

293 (20 ref.) Comment on: Trends Neurosci 1996 Nov;19(11):460–4.

[Structure and functions of the cutaneous nervous system] Reznik M. **Pathol Biol (Paris)** 1996 Dec;44(10):831–7 (42 ref.) (Eng. Abstr.) **(Fre)**

[Anesthesia mechanisms: nerve excitation and temperature] Suzuki A, et al. **Masui** 1996 Jun;45(6):670–5 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Pain–induced gene expression in the nervous system] Senba E. **Nippon Seikeigeka Gakkai Zasshi** 1996 Jan;70(1):40–50 (30 ref.) **(Jpn)**

[Visualization of neural excitation] Iijima T, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1100–5 (12 ref.) **(Jpn)**

[The concept of reinforcement in research on simple nervous systems] Baladan PM. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 Mar–Apr; 47(2):280–5 (13 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Cytokine action in the nervous system at pathophysiological versus pharmacological concentrations. Plata–Salamán CR. **Adv Exp Med Biol** 1996;402:191–7 (30 ref.)

The prevalence and longitudinal course of PTSD. Implications for the neurobiological models of PTSD. McFarlane AC. **Ann N Y Acad Sci** 1997 Jun 21;821:10–23 (49 ref.)

Neurodevelopmental outcome of hydrocephalus following intra–/periventricular hemorrhage in preterm infants: short– and long–term results. Resch B, et al. **Childs Nerv Syst** 1996 Jan;12(1):27–33 (48 ref.)

Testing the neural sensitization and kindling hypothesis for illness from low levels of environmental chemicals. Bell IR, et al. **Environ Health Perspect** 1997 Mar;105 Suppl 2:539–47 (103 ref.)

Neurological complications of enteric disease [see comments] Wills A, et al. **Gut** 1996 Oct;39(4):501–4 (71 ref.) Comment in: Gut 1997 Jul;41(1):133.

Lumbar facet pain: biomechanics, neuroanatomy and neurophysiology. Cavanaugh JM, et al. **J Biomech** 1996 Sep;29(9):1117–29 (54 ref.)

Neuropathic pain in cancer patients: mechanisms, syndromes, and clinical controversies. Martin LA, et al. **J Pain Symptom Manage** 1997 Aug;14(2):99–117 (179 ref.)

Myocardial, neural and vascular aspects of ischemic preconditioning. Losano G, et al. **Life Sci** 1996; 59(15):1185–92 (61 ref.)

Repetitive CMAPs: mechanisms of neural and synaptic genesis. van Dijk JG, et al. **Muscle Nerve** 1996 Sep; 19(9):1127–33 (51 ref.)

Emotions and disease: from balance of humors to balance of molecules. Sternberg EM. **Nat Med** 1997 Mar;3(3):264–7 (45 ref.)

Windup and central sensitization are not equivalent [editorial] Woolf CJ. **Pain** 1996 Aug;66(2–3):105–8 (51 ref.)

Rett syndrome: neurobiological changes underlying specific symptoms. Wenk GL. **Prog Neurobiol** 1997 Mar; 51(4):383–91 (90 ref.)

Overview of neural mechanisms in asthma. Barnes PJ. **Pulm Pharmacol** 1995 Aug–Oct;8(4–5):151–9 (68 ref.)

An overview of the mechanisms of hyperalgesia. Woolf CJ. **Pulm Pharmacol** 1995 Aug–Oct;8(4–5):161–7 (23 ref.)

RADIATION EFFECTS

[Changes in the nervous system during chronic exposure to ionizing radiation] Niagu AI, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1997;97(2):62–70 (190 ref.) **(Rus)**

VIROLOGY

Human herpes viruses latent infection in the nervous system. Steiner I. **Immunol Rev** 1996 Aug;152:157–73 (110 ref.)

Viruses and behavioural changes: a review of clinical and experimental findings. Mohammed AH, et al. **Rev Neurosci** 1993 Jul–Sep;4(3):267–86 (164 ref.)

NERVOUS SYSTEM DISEASES

Paraneoplastic neurologic syndromes. Hinton RC. **Hematol Oncol Clin North Am** 1996 Aug;10(4):909–25 (97 ref.)

Paraneoplastic syndromes affecting the nervous system. Dalmau JO, et al. **Semin Oncol** 1997 Jun;24(3):318–28 (67 ref.)

[Neurologic diseases of enterovirus infections: polioviruses, coxsackieviruses, echoviruses, and enteroviruses type 68–72] Manki A, et al. **Nippon Rinsho** 1997 Apr; 55(4):849–54 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Acute viral infection] Yasui K. **Nippon Rinsho** 1997 Apr; 55(4):787–94 (35 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

Biochemical markers of neurotoxicity. A review of mechanistic studies and applications. Manzo L, et al. **Hum Exp Toxicol** 1996 Mar;15 Suppl 1:S20–35 (118 ref.)

CHEMICALLY INDUCED

Vasomotor reactions with gold [editorial] Ho M, et al. **Br J Rheumatol** 1997 Feb;36(2):154–6 (15 ref.)

Occupational neurotoxic diseases in Taiwan: a review of the outbreaks and clinical features. Huang CC, et al. **Chang Keng I Hsueh** 1997 Jun;20(2):71–8 (46 ref.)

Irreversible lithium neurotoxicity: an overview. Kores B, et al. **Clin Neuropharmacol** 1997 Aug;20(4):283–99 (84 ref.)

Epidemiological and laboratory evidence of PCB–induced neurotoxicity. Seegal RF. **Crit Rev Toxicol** 1996 Nov; 26(6):709–37 (146 ref.)

Behavioral toxicology, risk assessment, and chlorinated hydrocarbons. Evangelista de Duffard AM, et al. **Environ Health Perspect** 1996 Apr;104 Suppl 2:353–60 (121 ref.)

The assessment of neurobehavioral toxicity: SGOMSEC joint report. Fiedler N, et al. **Environ Health Perspect** 1996 Apr; 104 Suppl 2:179–91 (74 ref.)

Neurobehavioral epidemiology: application in risk assessment. Grandjean P, et al. **Environ Health Perspect** 1996 Apr;104 Suppl 2:397–400 (30 ref.)

Prospective, longitudinal assessment of developmental neurotoxicity. Jacobson JL, et al. **Environ Health Perspect** 1996 Apr;104 Suppl 2:275–83 (68 ref.)

Animal behavioral methods in neurotoxicity assessment: SGOMSEC joint report. Kulig B, et al. **Environ Health Perspect** 1996 Apr;104 Suppl 2:193–204 (107 ref.)

Clinical neurologic indices of toxicity in animals. O'Donoghue JL. **Environ Health Perspect** 1996 Apr;104 Suppl 2:323–30 (13 ref.)

Behavioral effects of lead: commonalities between experimental and epidemiologic data. Rice DC. **Environ Health Perspect** 1996 Apr;104 Suppl 2:337–51 (119 ref.)

Biochemical markers of neurotoxicity. A review of mechanistic studies and applications. Manzo L, et al. **Hum Exp Toxicol** 1996 Mar;15 Suppl 1:S20–35 (118 ref.)

A biochemical perspective of methotrexate neurotoxicity with insight on nonfolate rescue modalities. Quinn CT, et al. **J Investig Med** 1996 Dec;44(9):522–30 (106 ref.)

Solvents and neurotoxicity. White RF, et al. **Lancet** 1997 Apr 26;349(9060):1239–43 (39 ref.)

CANTAB battery: proposed utility in neurotoxicology. Fray PJ, et al. **Neurotoxicol Teratol** 1996 Jul–Aug;18(4):499–504 (33 ref.)

Neurotoxicity of mercury—indicators and effects of low–level exposure: overview. Cranmer M, et al. **Neurotoxicology** 1996 Spring;17(1):9–14 (14 ref.)

Evidence for PCBs as neurodevelopmental toxicants in humans. Jacobson JL, et al. **Neurotoxicology** 1997; 18(2):415–24 (35 ref.)

Structure–activity relationships of potentially neurotoxic PCB congeners in the rat. Kodavanti PR, et al. **Neurotoxicology** 1997;18(2):425–41 (110 ref.)

Neurologic complications of cocaine. Daras M. **NIDA Res Monogr** 1996;163:43–65 (177 ref.)

Similarities in genetic mental retardation and neuroteratogenic syndromes. Adams J. **Pharmacol Biochem Behav** 1996 Dec;55(4):683–90 (75 ref.)

Neurotoxicology and amino acid intake during development: the case of threonine. Castagne V, et al. **Pharmacol Biochem Behav** 1996 Dec;55(4):653–62 (138 ref.)

What research with animals is telling us about alcohol–related neurodevelopmental disorder. Hannigan JH. **Pharmacol Biochem Behav** 1996 Dec;55(4):489–99 (207 ref.)

Monoamine transporters and the neurobehavioral teratology of cocaine. Meyer JS, et al. **Pharmacol Biochem Behav** 1996 Dec;55(4):585–93 (108 ref.)

Cyclosporine neurotoxicity. Hauben M. **Pharmacotherapy** 1996 Jul–Aug;16(4):576–83 (62 ref.)

[Neurologic side–effects of pharmacologic corticoid therapy] Rösener M, et al. **Nervenarzt** 1996 Dec;67(12):983–6 (36 ref.) (Eng. Abstr.) **(Ger)**

[Changes in the nervous system during occupational exposure to manganese in light of the literature] Sinczuk–Walczak H. **Med Pr** 1996;47(6):657–61 (13 ref.) (Eng. Abstr.) **(Pol)**

CLASSIFICATION

[A classification of virus–related neurological disease] Takasu T. **Nippon Rinsho** 1997 Apr;55(4):783–6 (5 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Neurocardiogenic syncope. Somers VK, et al. **Adv Intern Med** 1996;41:399–435 (109 ref.)

Psychiatric and neurocognitive concomitants of systemic lupus erythematosus. Keenan PA, et al. **Ann N Y Acad Sci** 1997 Aug 14;823:69–80 (18 ref.)

The respiratory system. Zifko U, et al. **Baillieres Clin Neurol** 1996 Oct;5(3):477–95 (69 ref.)

Rheumatic manifestations of neurologic and psychiatric diseases. Aviña–Zubieta JA, et al. **Curr Opin Rheumatol** 1997 Jan;9(1):51–5 (30 ref.)

Fluid and electrolyte management in the neurologically–impaired patient. Parobek V, et al. **J Neurosci Nurs** 1996 Oct;28(5):322–8 (12 ref.)

Neurologic manifestations of HIV infection. Simpson DM, et al. **Med Clin North Am** 1996 Nov;80(6):1363–94 (253 ref.)

Dysthymia in neurological disorders. Akiskal HS, et al. **Mol Psychiatry** 1996 Dec;1(6):478–91 (77 ref.)

Dysphagia in pediatric patients with neurologic damage. Arvedson JC. **Semin Neurol** 1996 Dec;16(4):371–86 (83 ref.)

Management of lower gastrointestinal tract dysfunction. Corazziari E, et al. **Semin Neurol** 1996 Sep;16(3):289–96 (72 ref.)

Dysphagic patients with progressive neurologic disease. Groher ME. **Semin Neurol** 1996 Dec;16(4):355–63 (58 ref.)

Dysphagia in neurologic patients in the intensive care unit. Langmore SE. **Semin Neurol** 1996 Dec;16(4):329–40 (144 ref.)

Screening, diagnosis, and management of neurogenic dysphagia. Logemann JA. **Semin Neurol** 1996 Dec; 16(4):319–27 (94 ref.)

Neurologic dysfunction in gastrointestinal disease. Pfeiffer RF. **Semin Neurol** 1996 Sep;16(3):217–26 (124 ref.)

Spinal stenosis and neurogenic claudication. Porter RW. **Spine** 1996 Sep 1;21(17):2046–52 (12 ref.)

[Neuropathology of Rasmussen syndrome] Vajtai I, et al. **Orv Hetil** 1996 Sep 15;137(37):2035–9 (29 ref.) (Eng. Abstr.) **(Hun)**

CONGENITAL

Similarities in genetic mental retardation and neuroteratogenic syndromes. Adams J. **Pharmacol Biochem Behav** 1996 Dec;55(4):683–90 (75 ref.)

DIAGNOSIS

Evaluating the neurocognitive complications of SLE. Lessons from HIV disease. Grant I, et al. **Ann N Y Acad Sci** 1997 Aug 14;823:18–43 (46 ref.)

Advances in neurology. Kennedy CR. **Arch Dis Child** 1996 Sep;75(3):251–5 (45 ref.)

The neurological consultation and neurological syndromes in the intensive care unit [see comments] Bolton CF, et al. **Baillieres Clin Neurol** 1996 Oct;5(3):447–75 (57 ref.) Comment in: Baillieres Clin Neurol 1996 Oct;5(3):645–71.

Molecular genetic advances in neurodegenerative disorders. Aguilera AJ. **Clin Lab Med** 1995 Dec;15(4):915–26 (96 ref.)

Clinical utility of evoked potentials in patients infected with human immunodeficiency virus. Comi G, et al. **Electroencephalogr Clin Neurophysiol Suppl** 1996;46:85–93 (39 ref.)

The neurologic examination. Sturmann K. **Emerg Med Clin North Am** 1997 Aug;15(3):491–506 (9 ref.)

Role of the neurologist in hazard identification and risk assessment. Feldman RG, et al. **Environ Health Perspect** 1996 Apr;104 Suppl 2:227–37 (27 ref.)

Neuropsychological approaches for the detection and evaluation of toxic symptoms. Fiedler N. **Environ Health Perspect** 1996 Apr;104 Suppl 2:239–45 (69 ref.)

Neurogenetic diseases: molecular diagnosis and therapeutic approaches. Muller U, et al. **J Mol Med** 1996 Feb; 74(2):71–84 (110 ref.)

Proposal of diagnostic criteria for human cysticercosis and neurocysticercosis. Del Brutto OH, et al. **J Neurol Sci** 1996 Oct;142(1–2):1–6 (40 ref.)

Neuro–ophthalmology of the pregeniculate afferent visual system. Developments in 1996 (Part I). Balcer LJ, et al. **J Neuroophthalmol** 1997 Mar;17(1):60–71 (87 ref.)

Neuro–ophthalmic manifestations of Lyme disease. Balcer LJ, et al. **J Neuroophthalmol** 1997 Jun;17(2):108–21 (160 ref.)

Distinguishing conversion disorder from neurologic impairment. Parobek VM. **J Neurosci Nurs** 1997 Apr; 29(2):128–34 (17 ref.)

Neurologic manifestations of HIV infection. Simpson DM, et al. **Med Clin North Am** 1996 Nov;80(6):1363–94 (253 ref.)

Dysthymia in neurological disorders. Akiskal HS, et al. **Mol Psychiatry** 1996 Dec;1(6):478–91 (77 ref.)

CANTAB battery: proposed utility in neurotoxicology. Fray PJ, et al. **Neurotoxicol Teratol** 1996 Jul–Aug;18(4):499–504 (33 ref.)

Case history: cornerstone in the neuro–ophthalmic examination. Carr L. **Optom Clin** 1996;5(3–4):17–32 (26 ref.)

Neurodiagnostic techniques. Morriss MC, et al. **Pediatr Rev** 1997 Jun;18(6):192–203 (7 ref.)

Differential diagnoses for nocturnal enuresis. Lettgen B. **Scand J Urol Nephrol Suppl** 1997;183:47–8; discussion 48–9 (6 ref.)

[Immunological diagnosis of paraneoplastic neurologic syndromes] Carpentier AF, et al. **Presse Med** 1996 Nov 30;25(37):1835–8 (9 ref.) (Eng. Abstr.) **(Fre)**

[A look at neurology] Regli F. **Rev Med Suisse Romande** 1997 Aug;117(8):607–11 (29 ref.) **(Fre)**

[A look at neurology] Regli F. **Rev Med Suisse Romande** 1997 Jun;117(6):513–7 (39 ref.) **(Fre)**

[Herpes zoster: follow–up, complications and therapy] Straube A, et al. **Nervenarzt** 1996 Aug;67(8):623–9 (51 ref.) (Eng. Abstr.) **(Ger)**

[Genetic diagnosis of viral diseases in nervous system] Nakamura S, et al. **Nippon Rinsho** 1997 Apr;55(4):833–8 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Central motor conduction time] Uozumi T. **Nippon Rinsho** 1997 Mar;55 Suppl 1:327–9 (7 ref.) **(Jpn)**

[The value of measuring acute phase protein level in pathologic cases with particular attention to nervous system diseases] Kawiak W, et al. **Ann Univ Mariae Curie Sklodowska [Med]** 1995;50:161–5 (26 ref.) (Eng. Abstr.) **(Pol)**

[On work capacity certification among persons with nervous

system dysfunction] Polakowska B. **Med Pr** 1996;47(1):73–6 (11 ref.) (Eng. Abstr.) **(Pol)**

[Changes in blink reflex (OM) after lesions of the nervous system in various locations] Bilińska M, et al. **Neurol Neurochir Pol** 1997 Jan–Feb;31(1):113–22 (20 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Clinical applications of neurotransmitter–receptor studies in geriatric neuropharmacology. Gómez–Vargas M, et al. **Acta Med Okayama** 1996 Aug;50(4):173–90 (148 ref.)

Intravenous immune globulin therapy for neurologic diseases. Dalakas MC. **Ann Intern Med** 1997 May 1;126(9):721–30 (97 ref.)

Therapeutic potential of neurotrophic factors for neurological disorders. Yuen EC, et al. **Ann Neurol** 1996 Sep;40(3):346–54 (79 ref.)

Nervous diseases and Kampo (Japanese herbal) medicine: a new paradigm of therapy against intractable nervous diseases. Sugaya E, et al. **Brain Dev** 1997 Mar;19(2):93–103 (59 ref.)

Pharmacological characterization of glial cell line–derived neurotrophic factor (GDNF): implications for GDNF as a therapeutic molecule for treating neurodegenerative diseases. Lapchak PA, et al. **Cell Tissue Res** 1996 Nov; 286(2):179–89 (100 ref.)

Somatic gene therapy for nervous system disease. Tuszynski MH, et al. **Ciba Found Symp** 1996;196:85–94; discussion 94–7 (51 ref.)

Neuregulins as potential drugs for neurological disorders. Marchionni MA, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:459–72 (64 ref.)

The expanding indications for clozapine. Young CR, et al. **Exp Clin Psychopharmacol** 1997 Aug;5(3):216–34 (235 ref.)

Clozapine therapy in patients with neurologic illness. Sajatovic M, et al. **Int J Psychiatry Med** 1995;25(4):331–44 (60 ref.)

The clinical potential of Deprenyl in neurologic and psychiatric disorders. Kuhn W, et al. **J Neural Transm Suppl** 1996;48:85–93 (51 ref.)

The acetylcholine receptor ligand–gated channel as a molecular target of disease and therapeutic agents. Barrantes FJ. **Neurochem Res** 1997 Apr;22(4):391–400 (68 ref.)

Neurotrophic factors in the treatment of neurotoxicity: an overview. Apfel SC. **Neurotoxicology** 1996 Fall–Winter; 17(3–4):839–44 (29 ref.)

Treatment and prevention of Lyme disease, with emphasis on antimicrobial therapy for neuroborreliosis and vaccination. Wormser GP. **Semin Neurol** 1997 Mar; 17(1):45–52 (91 ref.)

Rediscovering an old friend, IGF-I: potential use in the treatment of neurodegenerative diseases. Doré S, et al. **Trends Neurosci** 1997 Aug;20(8):326–31 (64 ref.)

[Botulin toxin: principles of action and neurological indications] Diederich NJ, et al. **Presse Med** 1997 Feb 1; 26(2):96–100 (42 ref.) **(Fre)**

[Nicardipine and its indications in neurology] Moltó–Jordà JM, et al. **Rev Neurol** 1997 Aug;25(144):1235–41 (55 ref.) (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

Regulation of matrix metalloproteinase expressions in astrocytes, microglia and neurons. Gottschall PE, et al. **Neuroimmunomodulation** 1996 Mar–Jun;3(2–3):69–75 (57 ref.)

EPIDEMIOLOGY

Epidemiological and laboratory evidence of PCB–induced neurotoxicity. Seegal RF. **Crit Rev Toxicol** 1996 Nov; 26(6):709–37 (146 ref.)

Current views on geographic distribution and modes of infection of neurohelminthic diseases. Nishimura K, et al. **J Neurol Sci** 1997 Jan;145(1):5–14 (95 ref.)

Epidemiology of neurocysticercosis in Brazil. Agapejev S. **Rev Inst Med Trop Sao Paulo** 1996 May–Jun;38(3):207–16 (99 ref.)

ETIOLOGY

Neurologic findings in vitamin E deficiency. Tanyel MC, et al. **Am Fam Physician** 1997 Jan;55(1):197–201 (15 ref.)

Reactive oxygen species and the neurodegenerative disorders. Knight JA. **Ann Clin Lab Sci** 1997 Jan–Feb; 27(1):11–25 (93 ref.)

Anti–P antibodies and neuropsychiatric lupus erythematosus. Georgescu L, et al. **Ann N Y Acad Sci** 1997 Aug 14; 823:263–9 (28 ref.)

Evaluating the neurocognitive complications of SLE. Lessons from HIV disease. Grant I, et al. **Ann N Y Acad Sci** 1997 Aug 14;823:18–43 (46 ref.)

Neuropsychiatric systemic lupus erythematosus. Stress, stroke, and seizures. Moore PM. **Ann N Y Acad Sci** 1997 Aug 14;823:1–17 (114 ref.)

Delayed neuronal degeneration results from endogenous glutamate excess. Possible role in NP–SLE. Volpe BT. **Ann N Y Acad Sci** 1997 Aug 14;823:185–7 (23 ref.)

Neurological manifestation of vasculitis: update on immunopathogenic mechanisms and clinical features. Moore PM. **Ann Neurol** 1995 May;37 Suppl 1:S131–41 (118 ref.)

Advances in neurology. Kennedy CR. **Arch Dis Child** 1996 Sep;75(3):251–5 (45 ref.)

Physiological factors predisposing to neurotoxicity. Ray DE. **Arch Toxicol Suppl** 1997;19:219–26 (45 ref.)

Infection in childhood and neurological diseases in adult life. Martyn CN. **Br Med Bull** 1997 Jan;53(1):24–39 (35 ref.)

Peroxisomal bifunctional enzyme deficiency: serial neurophysiological examinations of a case. Akaboshi S, et al. **Brain Dev** 1997 Jun;19(4):295–9 (24 ref.)

Neurological manifestations of tuberous sclerosis complex. Curatolo P. **Childs Nerv Syst** 1996 Sep;12(9):515–21 (34 ref.)

Neurodegenerative disorders: clues from glutamate and energy metabolism. Ikonomidou C, et al. **Crit Rev Neurobiol** 1996;10(2):239–63 (301 ref.)

Paraneoplastic nervous system syndromes. Jaeckle KA. **Curr Opin Oncol** 1996 May;8(3):204–8 (39 ref.)

Clinical utility of evoked potentials in patients infected with human immunodeficiency virus. Comi G, et al. **Electroencephalogr Clin Neurophysiol Suppl** 1996;46:85–93 (39 ref.)

Neurogenic inflammation: with additional discussion of central and perceptual integration of nonneurogenic inflammation. Bascom R, et al. **Environ Health Perspect** 1997 Mar;105 Suppl 2:531–7 (43 ref.)

Fidelity assurance mechanisms of the brain with special reference to its immunogenic CNS compartment: their role in aging and aging–associated neurological disease. Blumenthal HT. **J Gerontol A Biol Sci Med Sci** 1997 Jan; 52(1):B1–9 (96 ref.)

Neurological episodes after minor head injury and trigeminovascular activation. Sakas DE, et al. **Med Hypotheses** 1997 May;48(5):431–5 (48 ref.)

Silicone breast implants and neurologic disorders. Report of the Practice Committee of the American Academy of Neurology. Ferguson JH. **Neurology** 1997 Jun;48(6):1504–7 (16 ref.)

Neuro–ophthalmic manifestations of AIDS. Woods AD, et al. **Optom Clin** 1996;5(3–4):113–52 (198 ref.)

Neurologic complications of HIV infection. Cohen BA. **Prim Care** 1997 Sep;24(3):575–95 (161 ref.)

The nervous system in systemic sclerosis (scleroderma). Clinical features and pathogenetic mechanisms. Cerinic MM, et al. **Rheum Dis Clin North Am** 1996 Nov; 22(4):879–92 (87 ref.)

Neurological paraneoplastic syndromes. Dalmau J, et al. **Springer Semin Immunopathol** 1996;18(1):85–95 (41 ref.)

[Neurologic complications in a case of Werner syndrome] Just A, et al. **Rev Neurol (Paris)** 1996 Oct;152(10):634–6 (11 ref.) (Eng. Abstr.) **(Fre)**

[Transient neurological manifestations disclosing spontaneous acute cervical epidural hematoma] Le Coz P, et al. **Rev Neurol (Paris)** 1997 Jun;153(5):325–30 (37 ref.) (Eng. Abstr.) **(Fre)**

[Neurological aspects of malignant hyperthermia. Clinics, physiopathology, genetics] Serratrice G, et al. **Rev Neurol (Paris)** 1997 Jun;153(5):304–13 (59 ref.) (Eng. Abstr.) **(Fre)**

[Virus–related neurological disorders complicating in compromised hosts] Kimura S. **Nippon Rinsho** 1997 Apr; 55(4):949–53 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Neurotransmitter transporters—a role of the molecular mechanism in nervous system diseases and drug poisoning] Nakamura S, et al. **Nippon Yakurigaku Zasshi** 1996 Sep; 108(3):99–100 (0 ref.) **(Jpn)**

[Cell adhesion proteins in the nervous system: immunoglobulin superfamily—structure, function and involvement in neurological diseases] Yazaki T, et al. **No To Hattatsu** 1996 Nov;28(6):475–83 (26 ref.) (Eng. Abstr.) **(Jpn)**

[Protection of excitotoxicity] Kwak S. **No To Shinkei** 1996 Dec;48(12):1077–85 (35 ref.) **(Jpn)**

[Chronic recurrent polyneuropathy in a patient with autoimmune hemolytic anemia associated with antibodies to gangliosides GM1, GA1, and GD1b] Nomura K, et al. **Rinsho Shinkeigaku** 1995 Oct;35(10):1131–6 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Neuropsychologic effects of occupational exposure to manganese] Bazylewicz–Walczak B. **Med Pr** 1996; 47(6):677–83 (15 ref.) (Eng. Abstr.) **(Pol)**

[Neuropathogenesis of HIV infection] Araújo AD, et al. **Arq Neuropsiquiatr** 1996 Jun;54(2):335–45 (72 ref.) (Eng. Abstr.) **(Por)**

[Oxidant stress—the general mechanism of the damage in nervous system diseases] Zavalishin IA, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(2):111–4 (29 ref.) **(Rus)**

[The etiology of neurological complications after cardiopulmonary bypass surgery] Carrascal Y, et al. **Rev Neurol** 1997 Aug;25(144):1278–84 (49 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Neurogenetic approaches to axon sprouting in the hippocampus. Noebels JL, et al. **Adv Neurol** 1997;72:35–44 (42 ref.)

The CAG/polyglutamine tract diseases: gene products and molecular pathogenesis. Koshy BT, et al. **Brain Pathol** 1997 Jul;7(3):927–42 (157 ref.)

A molecular view of the neurologic porphyrias. Schreiber WE. **Clin Lab Med** 1997 Mar;17(1):73–83 (42 ref.)

Polyglutamine expansions and neurodegenerative diseases. Saudou F, et al. **Cold Spring Harb Symp Quant Biol** 1996; 61:639–47 (46 ref.)

L1–associated diseases: clinical geneticists divide, molecular geneticists unite. Fransen E, et al. **Hum Mol Genet** 1997; 6(10):1625–32 (103 ref.)

Molecular genetics of triplet repeats: unstable expansion of triplet repeats as a new mechanism for neurodegenerative diseases. Tsuji S. **Intern Med** 1997 Jan;36(1):3–8 (36 ref.)

Neurological presentations of mitochondrial diseases. Zeviani M, et al. **J Inherit Metab Dis** 1996;19(4):504–20 (41 ref.)

Unstable expansion of triplet repeats as a new disease mechanism for neurodegenerative diseases. Tsuji S. **Jpn J Hum Genet** 1996 Sep;41(3):279–90 (47 ref.)

Keith R. Porter Lecture, 1996. Of mice and men: genetic disorders of the cytoskeleton. Fuchs E. **Mol Biol Cell** 1997 Feb;8(2):189–203 (111 ref.)

The acetylcholine receptor ligand–gated channel as a molecular target of disease and therapeutic agents. Barrantes FJ. **Neurochem Res** 1997 Apr;22(4):391–400 (68 ref.)

Pathogenesis of neurodegenerative disorders: the role of dynamic mutations. Martin JB. **Neuroreport** 1996 Dec 20; 8(1):i–vii (82 ref.)

Clinical and molecular analysis of neurodegenerative diseases. Abe K. **Tohoku J Exp Med** 1997 Apr;181(4):389–409 (47 ref.)

The TiPS/TINS lecture. Catecholamines: from gene regulation to neuropsychiatric disorders. Mallet J. **Trends Pharmacol Sci** 1996 Apr;17(4):129–35 (69 ref.)

[Neurodegenerative disorders and the role of trinucleotide repeat expansion. II. Molecular genetics] Knoers NV, et al. **Ned Tijdschr Geneeskd** 1996 Nov 23;140(47):2329–33 (23 ref.) **(Dut)**

[Neurodegenerative disorders and the role of trinucleotide repeat expansion. I. The diseases (see comments)] Kremer HP, et al. **Ned Tijdschr Geneeskd** 1996 Nov 23; 140(47):2325–9 (33 ref.) Comment in: Ned Tijdschr Geneeskd 1997 Feb 22;141(8):400–1. **(Dut)**

[Gene therapy of neurologic diseases. Experimental approaches and clinical perspectives] Isenmann S, et al. **Nervenarzt** 1996 Feb;67(2):91–108 (146 ref.) (Eng. Abstr.) **(Ger)**

[Genetic studies in neurology] Lechner–Scott J, et al. **Schweiz Med Wochenschr** 1997 Jun 28;127(26):1141–53 (53 ref.) (Eng. Abstr.) **(Ger)**

[Impact of molecular genetics to clinical neurology] Tsuji S. **Seishin Shinkeigaku Zasshi** 1996;98(9):622–8 (36 ref.) **(Jpn)**

[Trinucleotide repeats and neurologic diseases] Tsuji S. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(15 Suppl):2349–54 (29 ref.) **(Jpn)**

[Triplet repeat expansions in hereditary neurodegenerative diseases] Peñuelas I, et al. **Med Clin (Barc)** 1997 Apr 12; 108(14):542–8 (63 ref.) **(Spa)**

HISTORY

The history of modern spinal traction with particular reference to neural disorders. Shterenshis MV. **Spinal Cord** 1997 Mar;35(3):139–46 (46 ref.)

[Pasteur's neurologic disease] Rumbach L, et al. **Rev Neurol (Paris)** 1996 Oct;152(10):630–3 (35 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

The immune system in neurologic disease: selected recent developments. Toyka KV. **Acta Neurol Belg** 1996 Sep; 96(3):185–8 (18 ref.)

Autoimmunity and the nervous system. Newsom–Davis J. **Ann Acad Med Singapore** 1996 Mar;25(2):309–14 (20 ref.)

Autoantibody–associated sensory neuronopathy and intestinal pseudo–obstruction without detectable neoplasia. Briellmann RS, et al. **Eur Neurol** 1996;36(6):369–73 (26 ref.)

The role of autoimmunity to glutamate receptors in neurological disease. Rogers SW, et al. **Mol Med Today** 1996 Feb;2(2):76–81 (27 ref.)

Immunologic mechanisms in Lyme neuroborreliosis: the potential role of autoimmunity and molecular mimicry. Sigal LH. **Semin Neurol** 1997 Mar;17(1):63–8 (63 ref.)

[Clinical significance and interpretation of immunological tests for nervous system infections] Arasaki K. **Nippon Naika Gakkai Zasshi** 1996 May 10;85(5):682–6 (11 ref.) **(Jpn)**

METABOLISM

Brain tryptophan. Normal and disturbed control. Curzon G. **Adv Exp Med Biol** 1996;398:27–34 (84 ref.)

Mechanisms for nitric oxide–induced cell death: involvement of apoptosis. Nicotera P, et al. **Adv Neuroimmunol** 1995; 5(4):411–20 (58 ref.)

Neurological disease. Muller DP. **Adv Pharmacol** 1997; 38:557–80 (147 ref.)

Profiling of endogenous peptides as a tool for studying development and neurological disease. Slemmon JR, et al. **Biopolymers** 1997;43(2):157–70 (64 ref.)

Oxidative stress and apoptosis in neurodegeneration. Gorman AM, et al. **J Neurol Sci** 1996 Aug;139 Suppl:45–52 (75 ref.)

Protein conformation and disease. Nandi PK. **Vet Res** 1996; 27(4–5):373–82 (61 ref.)

NERVOUS SYSTEM DISEASES

MICROBIOLOGY

Neurologic manifestation and classification of borreliosis. **Haass A**, et al. **Infection** 1996 Nov-Dec;24(6):467-9 (12 ref.)

[Microbes that invade nervous system] Shimada K. **Nippon Naika Gakkai Zasshi** 1996 May 10;85(5):655-8 (12 ref.) **(Jpn)**

PARASITOLOGY

Proposal of diagnostic criteria for human cysticercosis and neurocysticercosis. Del Brutto OH, et al. **J Neurol Sci** 1996 Oct;142(1-2):1-6 (40 ref.)

Current views on geographic distribution and modes of infection of neurohelminthic diseases. Nishimura K, et al. **J Neurol Sci** 1997 Jan;145(1):5-14 (95 ref.)

PATHOLOGY

Huntington's disease and dentatorubral-pallidoluysian atrophy: proteins, pathogenesis and pathology. Ross CA, et al. **Brain Pathol** 1997 Jul;7(3):1003-16 (137 ref.)

AIDS dementia complex: a complex, slow virus "model" of acquired genetic neurodegenerative disease. Price RW. **Cold Spring Harb Symp Quant Biol** 1996;61:759-70 (90 ref.)

Prions of yeast, [PSI] and [URE3], as models for neurodegenerative diseases. Wickner RB, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:541-50 (57 ref.)

Pathogenesis of HIV-1 associated neurodegeneration. Masliah E, et al. **Crit Rev Neurobiol** 1996;10(1):57-67 (79 ref.)

Apoptosis in neurodegenerative disorders. Stefanis L, et al. **Curr Opin Neurol** 1997 Aug;10(4):299-305 (78 ref.)

Models to study the role of neurotrophic factors in neurodegeneration. Lindholm D. **J Neural Transm Suppl** 1997;49:33-42 (45 ref.)

The accumbens: beyond the core-shell dichotomy. Heimer L, et al. **J Neuropsychiatry Clin Neurosci** 1997 Summer; 9(3):354-81 (154 ref.)

Glia: the not so innocent bystanders. Chao CC, et al. **J Neurovirol** 1996 Aug;2(4):234-9 (60 ref.)

AAEM minimonograph #46: neurogenic muscle hypertrophy [see comments] Gutmann L. **Muscle Nerve** 1996 Jul;19(7):811-8 (57 ref.) Comment in: Muscle Nerve 1997 Mar;20(3):390-1.

Pathogenesis of neurodegenerative disorders: the role of dynamic mutations. Martin JB. **Neuroreport** 1996 Dec 20; 8(1):i-vii (82 ref.)

Clinical and MRI evaluation of psychostimulant neurotoxicity. Bartzokis G, et al. **NIDA Res Monogr** 1996; 163:300-17 (39 ref.)

Cocaine addiction as a neurological disorder: implications for treatment. Majewska MD. **NIDA Res Monogr** 1996; 163:1-26 (124 ref.)

Methamphetamine and methylenedioxymethamphetamine neurotoxicity: possible mechanisms of cell destruction. Seiden LS, et al. **NIDA Res Monogr** 1996;163:251-76 (103 ref.)

Apoptosis in development and disease of the nervous system: II. Apoptosis in childhood neurologic disease. Gelbard HA, et al. **Pediatr Neurol** 1997 Feb;16(2):93-7 (57 ref.)

Mechanisms of injury in Lyme neuroborreliosis. Garcia-Monco JC, et al. **Semin Neurol** 1997 Mar; 17(1):57-62 (90 ref.)

Disorders of consciousness: differential diagnosis and neuropathologic features. Giacino JT. **Semin Neurol** 1997 Jun;17(2):105-11 (41 ref.)

[Glial cytoskeletal abnormalities in neurodegenerative diseases] Ikeda K. **No To Shinkei** 1996 Oct;48(10):885-94 (46 ref.) **(Jpn)**

PHYSIOPATHOLOGY

The kynurenine pathway and neurologic disease. Therapeutic strategies. Heyes MP. **Adv Exp Med Biol** 1996;398:125-9 (23 ref.)

Endosome-lysosomes, ubiquitin and neurodegeneration. Mayer RJ, et al. **Adv Exp Med Biol** 1996;389:261-9 (36 ref.)

Murine models of brain aging and age-related neurodegenerative diseases. Jucker M, et al. **Behav Brain Res** 1997 Apr;85(1):1-26 (261 ref.)

Neurodegenerative diseases and model systems. Price DL, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:725-38 (200 ref.)

What neurological syndromes can tell us about human nature: some lessons from phantom limbs, capgras syndrome, and anosognosia. Ramachandran VS. **Cold Spring Harb Symp Quant Biol** 1996;61:115-34 (70 ref.)

Event-related potentials in brain-injured patients with neuropsychological disorders: a review. Viggiano MP. **J Clin Exp Neuropsychol** 1996 Oct;18(5):631-47 (109 ref.)

Fidelity assurance mechanisms of the brain with special reference to its immunogenic CNS compartment: their role in aging and aging-associated neurological disease. Blumenthal HT. **J Gerontol A Biol Sci Med Sci** 1997 Jan; 52(1):B1-9 (96 ref.)

Models to study the role of neurotrophic factors in neurodegeneration. Lindholm D. **J Neural Transm Suppl** 1997;49:33-42 (45 ref.)

Catecholamine phenotyping: clues to the diagnosis, treatment, and pathophysiology of neurogenetic disorders. Goldstein DS, et al. **J Neurochem** 1996 Nov;67(5):1781-90 (87 ref.)

Sleep and neurological diseases. Autret A. **J Neurol** 1997 Apr;244(4 Suppl 1):S1-2 (17 ref.)

Mast cell interactions with the nervous system: relationship to mechanisms of disease. Dines KC, et al. **J Neuropathol Exp Neurol** 1997 Jun;56(6):627-40 (95 ref.)

The limbic system: an anatomic, phylogenetic, and clinical perspective. Mega MS, et al. **J Neuropsychiatry Clin Neurosci** 1997 Summer;9(3):315-30 (101 ref.)

The thalamus and neuropsychiatric illness. Scheibel AB. **J Neuropsychiatry Clin Neurosci** 1997 Summer;9(3):342-53 (94 ref.)

Neuropsychiatric symptoms from the temporolimbic lobes. Trimble MR, et al. **J Neuropsychiatry Clin Neurosci** 1997 Summer;9(3):429-38 (86 ref.)

Neuropathogenesis of HIV-1 infection: interactions between interleukin-1 and transforming growth factor-beta 1. Vitković L. **Mol Psychiatry** 1997 Mar;2(2):111-2 (16 ref.)

Nitric oxide in health and disease of the nervous system. Yun HY, et al. **Mol Psychiatry** 1997 Jul;2(4):300-10 (146 ref.)

Molecular mechanisms of microglial activation. A. Implications for regeneration and neurodegenerative diseases. Gebicke-Haerter PJ, et al. **Neurochem Int** 1996 Jul;29(1):1-12 (145 ref.)

Glycosphingolipids as potential diagnostic markers and/or antigens in neurological disorders. Fredman P, et al. **Neurochem Res** 1997 Aug;22(8):1071-83 (97 ref.)

Sleep and degenerative neurologic disorders. Chokroverty S. **Neurol Clin** 1996 Nov;14(4):807-26 (87 ref.)

Substantia innominata: a notion which impedes clinical-anatomical correlations in neuropsychiatric disorders. Heimer L, et al. **Neuroscience** 1997 Feb; 76(4):957-1006 (562 ref.)

Review of experimental male-mediated behavioral and neurochemical disorders. Nelson BK, et al. **Neurotoxicol Teratol** 1996 Nov-Dec;18(6):611-6 (69 ref.)

Abnormal gait in neurologic disease. Thomann KH, et al. **Optom Clin** 1996;5(3-4):181-92 (9 ref.)

The blood-brain barrier in neuroinflammatory diseases. de Vries HE, et al. **Pharmacol Rev** 1997 Jun;49(2):143-55 (154 ref.)

Management of upper gastrointestinal tract dysfunction. Nowak TV. **Semin Neurol** 1996 Sep;16(3):281-8 (44 ref.)

Lyme disease in children. Shapiro ED, et al. **Semin Neurol** 1997 Mar;17(1):39-44 (63 ref.)

The TiPS/TINS lecture. Catecholamines: from gene regulation to neuropsychiatric disorders. Mallet J. **Trends Pharmacol Sci** 1996 Apr;17(4):129-35 (69 ref.)

[The significance of neurological manifestations from the aspect of aggressology] Aruga T. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):733-8 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Arachidonic acid in physiology and pathology of nervous tissue] Zylińska L, et al. **Postepy Biochem** 1996;42(4):357-63 (49 ref.) **(Pol)**

PREVENTION & CONTROL

Reducing chemotherapy-associated toxicity in elderly cancer patients. Zagonel V, et al. **Cancer Treat Rev** 1996 May; 22(3):223-44 (135 ref.)

[Prevention of virus-related neurological diseases by vaccines] Takahashi M. **Nippon Rinsho** 1997 Apr; 55(4):954-8 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical use of Amifostine (WR-2721) as a preparation protecting healthy tissues from the cytotoxic effects of chemotherapy and radiation therapy] Wrembel-Wargocka J, et al. **Przegl Lek** 1996;53(11):820-5 (15 ref.) (Eng. Abstr.) **(Pol)**

PSYCHOLOGY

Neurologic comorbidity and mania in old age. Shulman KI. **Clin Neurosci** 1997;4(1):37-40 (48 ref.)

Event-related potentials in brain-injured patients with neuropsychological disorders: a review. Viggiano MP. **J Clin Exp Neuropsychol** 1996 Oct;18(5):631-47 (109 ref.)

Clinical and MRI evaluation of psychostimulant neurotoxicity. Bartzokis G, et al. **NIDA Res Monogr** 1996; 163:300-17 (39 ref.)

Some interesting perturbations of the self in neurology. Feinberg TE. **Semin Neurol** 1997 Jun;17(2):129-35 (66 ref.)

REHABILITATION

Cortical plasticity underlying perceptual, motor, and cognitive skill development: implications for neurorehabilitation. Merzenich M, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:1-8 (59 ref.)

The bases of practice--neurological physiotherapy [see comments] Partridge C, et al. **Physiother Res Int** 1996; 1(3):205-8 (13 ref.) Comment in: Physiother Res Int 1996;1(4):265-8. Comment in: Physiother Res Int 1997;2(2):62-4.

A discussion paper on the bases of practice in neurological physiotherapy: a response [comment] [see comments] Shepherd R. **Physiother Res Int** 1996;1(4):265-8 (22 ref.) Comment on: Physiother Res Int 1996;1(3):205-8. Comment in: Physiother Res Int 1997;2(2):62-4.

[Current aspects of neurologic and neurosurgical rehabilitation in ambulatory medicine] Schupp W. **Z Arztl Fortbild (Jena)** 1996 Oct;90(6):501-9 (20 ref.) (Eng. Abstr.) **(Ger)**

[Horseback riding as a means of treatment and rehabilitation in neurology and psychiatry] Gurvich PT. **Zh Nevrol Psikhiatr Im S S Korsakova** 1997;97(8):65-7 (0 ref.) **(Rus)**

SURGERY

Spinal instrumentation for degenerative disease. Fessler RG. **Clin Neurosurg** 1996;43:268-74 (8 ref.)

The role of conduits in nerve repair: a review. Doolabh VB, et al. **Rev Neurosci** 1996 Jan-Mar;7(1):47-84 (214 ref.)

[Radiosurgery] Philippon J, et al. **Rev Neurol (Paris)** 1997 May;153(4):235-8 (13 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Basic aspects of neuroimmunology as they relate to immunotherapeutic targets: present and future prospects. Dalakas MC. **Ann Neurol** 1995 May;37 Suppl 1:S2-13 (91 ref.)

Potential use of herpes simplex virus (HSV) vectors for gene therapy of neurological disorders. Kennedy PG. **Brain** 1997 Jul;120 (Pt 7):1245-59 (80 ref.)

Towards gene therapy in the nervous system. Doering LC. **Clin Neurosci** 1995-96;3(5):259-61 (14 ref.)

Adeno-associated virus vectors for gene therapy of neurodegenerative disorders. During MJ, et al. **Clin Neurosci** 1995-96;3(5):292-300 (75 ref.)

Advances in the development of herpes simplex virus-based gene transfer vectors for the nervous system. Fink DJ, et al. **Clin Neurosci** 1995-96;3(5):284-91 (41 ref.)

Helper virus-free herpes simplex virus-1 plasmid vectors for gene therapy of Parkinson's disease and other neurological disorders. Geller AI, et al. **Exp Neurol** 1997 Mar; 144(1):98-102 (26 ref.)

Transfectable and transplantable postmitotic human neurons: a potential "platform" for gene therapy of nervous system diseases. Trojanowski JQ, et al. **Exp Neurol** 1997 Mar; 144(1):92-7 (36 ref.)

Gene therapy for neurologic disease: benchtop discoveries to bedside applications. 2. The bedside. Maria BL, et al. **J Child Neurol** 1997 Feb;12(2):77-84 (54 ref.)

Neurological gene therapy. Fooks AR, et al. **Sci Prog** 1997; 80 (Pt 2):107-24 (16 ref.)

The principles of gene therapy for the nervous system. Karpati G, et al. **Trends Neurosci** 1996 Feb;19(2):49-54 (68 ref.)

Focus on neurocritical care. Bleck TP. **Va Med Q** 1996 Spring;123(2):84-9 (13 ref.)

[A look at neurology] Regli F. **Rev Med Suisse Romande** 1997 Jun;117(6):513-7 (39 ref.) **(Fre)**

[A look at neurology] Regli F. **Rev Med Suisse Romande** 1997 Aug;117(8):607-11 (29 ref.) **(Fre)**

[Progress of the therapy for virus related neurological disorders] Harukawa H, et al. **Nippon Rinsho** 1997 Apr; 55(4):959-66 (26 ref.) (Eng. Abstr.) **(Jpn)**

[Therapeutic potentials of neurotrophic factors for neurodegenerative disorders] Okazawa H. **No To Shinkei** 1996 Sep;48(9):795-802 (45 ref.) **(Jpn)**

[Phototherapy in neurology and psychiatry] Levin IaI, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996; 96(3):107-12 (100 ref.) **(Rus)**

VETERINARY

Animal models for nervous system disease in systemic lupus erythematosus. Brey RL, et al. **Ann N Y Acad Sci** 1997 Aug 14;823:97-106 (55 ref.)

Neurological and neuropathological observations on the equine neonate. Mayhew IG. **Equine Vet J Suppl** 1988 Sep; (5):28-33 (38 ref.)

Nursing care of the small animal neurological patient. Berry WL, et al. **J S Afr Vet Assoc** 1990 Dec;61(4):188-93 (27 ref.)

Equine degenerative myeloencephalopathy. Miller MM, et al. **Vet Clin North Am Equine Pract** 1997 Apr;13(1):43-52 (31 ref.)

Equine herpesvirus 1 myeloencephalopathy. Wilson WD. **Vet Clin North Am Equine Pract** 1997 Apr;13(1):53-72 (82 ref.)

VIROLOGY

Herpes simplex virus latent infection in the nervous system. Steiner I, et al. **J Neurovirol** 1995 Mar;1(1):19-29 (100 ref.)

Molecular aspects of HTLV-I: relationship to neurological diseases [see comments] Wigdahl B, et al. **J Neurovirol** 1996 Oct;2(5):307-22 (125 ref.) Comment in: J Neurovirol 1996 Oct;2(5):297-8.

[Neurotropic viruses--classification, structure and characteristics] Hotta H. **Nippon Rinsho** 1997 Apr; 55(4):777-82 (7 ref.) (Eng. Abstr.) **(Jpn)**

NERVOUS SYSTEM NEOPLASMS

DIAGNOSIS

Somatostatin and cancer. Robbins RJ. **Metabolism** 1996 Aug; 45(8 Suppl 1):98-100 (41 ref.)

METABOLISM

Intermediate filaments in the nervous system: implications in cancer. Ho CL, et al. **Cancer Metastasis Rev** 1996 Dec;

15(4):483–97 (119 ref.)

PATHOLOGY

Local spread of malignant neuroepithelial tumors. Laerum OD. **Acta Neurochir (Wien)** 1997;139(6):515–22 (91 ref.)

[Von Recklinghausen's disease: experimental models and comparative aspects] Turusov VS, et al. **Arkh Patol** 1996 Sep–Oct;58(5):3–13 (52 ref.) (Eng. Abstr.) **(Rus)**

THERAPY

Gene therapy for neurologic disease: benchtop discoveries to bedside applications. 1. The bench. Maria BL, et al. **J Child Neurol** 1997 Jan;12(1):1–12 (96 ref.)

Somatostatin and cancer. Robbins RJ. **Metabolism** 1996 Aug; 45(8 Suppl 1):98–100 (41 ref.)

NESIDIOBLASTOMA see **ADENOMA, ISLET CELL**

NESIDIOBLASTOSIS see **PANCREATIC DISEASES**

NESIDIOBLASTS see **ISLETS OF LANGERHANS**

NESTED CASE-CONTROL STUDIES see **CASE-CONTROL STUDIES**

NESTED PCR see **POLYMERASE CHAIN REACTION**

NETWORK COMMUNICATION PROTOCOLS see **COMPUTER COMMUNICATION NETWORKS**

NEU PROTO-ONCOGENE PROTEINS see **PROTO-ONCOGENE PROTEINS C-ERBB-2**

NEU RECEPTORS see **PROTO-ONCOGENE PROTEINS C-ERBB-2**

NEURAL ANALYZERS

ANATOMY & HISTOLOGY

[Simulation of the structure and function of the lateral geniculate bodies and visual analyzer system] Radchenko AN. **Fiziol Cheloveka** 1997 Jul–Aug;23(4):28–35 (14 ref.) **(Rus)**

NEURAL CELL ADHESION MOLECULE see **NCAM**

NEURAL CONDUCTION

see related
NEURAL INHIBITION

Idiopathic tibial mononeuropathy with conduction block: an unusual case and review of the literature. Roth LS, et al. **J Foot Ankle Surg** 1997 Mar–Apr;36(2):127–30 (23 ref.)

[F wave conduction study] Kohara N. **Nippon Rinsho** 1997 Mar;55 Suppl 1:426–9 (4 ref.) **(Jpn)**

[Motor nerve conduction study] Ozaki I, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:413–6 (6 ref.) **(Jpn)**

[Measurement of nerve conduction velocity of single or compound nerve action potential using microneurographic technique] Toma S, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:420–5 (5 ref.) **(Jpn)**

[Impulse conduction and synaptic transmission] Haga T. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):203–7 (7 ref.) **(Jpn)**

PHYSIOLOGY

Facts, fallacies, and fancies of nerve conduction studies: twenty-first annual Edward H. Lambert Lecture. Kimura J. **Muscle Nerve** 1997 Jul;20(7):777–87 (65 ref.)

Dynamics of the impulse activity of neurons of the neocortex of monkeys in a visual recognition task after brief oxygen deprivation. Breslav IS. **Neurosci Behav Physiol** 1996 Mar–Apr;26(2):143–52 (69 ref.)

[Central motor conduction time using magnetic and vibratory stimulation in Parkinson's disease, especially in patients with rigidity] Mochio S, et al. **Nippon Rinsho** 1997 Jan; 55(1):173–8 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Central motor conduction time] Uozumi T. **Nippon Rinsho** 1997 Mar;55 Suppl 1:327–9 (7 ref.) **(Jpn)**

NEURAL CREST

Hirschsprung's disease as a neurochristopathy. Martucciello G. **Pediatr Surg Int** 1997;12(1):2–10 (74 ref.)

[Neural crest and multiple endocrinopathies] Pasini A, et al. **C R Seances Soc Biol Fil** 1996;190(5–6):557–67 (22 ref.) (Eng. Abstr.) **(Fre)**

ABNORMALITIES

Cardiac development and perinatal care of infants with neural crest-associated conotruncal defects. Leatherbury L, et al. **Semin Perinatol** 1996 Dec;20(6):473–81 (38 ref.)

CYTOLOGY

Spatial distribution of postotic crest cells defines the head/trunk interface of the vertebrate body: embryological interpretation of peripheral nerve morphology and evolution of the vertebrate head. Kuratani S. **Anat Embryol (Berl)** 1997 Jan;195(1):1–13 (104 ref.)

Receptor tyrosine kinase-dependent neural crest migration in response to differentially localized growth factors. Wehrle-Haller B, et al. **Bioessays** 1997 Apr;19(4):337–45 (73 ref.)

Salamander pigment patterns: how can they be used to study developmental mechanisms and their evolutionary transformation? Parichy DM. **Int J Dev Biol** 1996 Aug; 40(4):871–84 (130 ref.)

Neural crest apoptosis and the establishment of craniofacial pattern: an honorable death. Graham A, et al. **Mol Cell Neurosci** 1996;8(2–3):76–83 (26 ref.)

Neural stem cells are blasting off. Stemple DL, et al. **Neuron** 1997 Jan;18(1):1–4 (26 ref.)

Cellular and molecular biology of neural crest cell lineage determination. Anderson DJ. **Trends Genet** 1997 Jul; 13(7):276–80 (74 ref.)

The extracellular matrix in neural crest–cell migration. Perris R. **Trends Neurosci** 1997 Jan;20(1):23–31 (58 ref.)

[Cells of the neural crest and their derivatives in vertebrates: the mechanisms of migration and its role in tissue formation] Mglinets VA. **Ontogenez** 1997 Jan–Feb; 28(1):18–30 (70 ref.) (Eng. Abstr.) **(Rus)**

EMBRYOLOGY

What insights into the phenomena of cell fate determination and cell migration has the study of the urodele neural crest provided? Epperlein HH, et al. **Int J Dev Biol** 1996 Aug; 40(4):695–707 (89 ref.)

Neural crest cell migration and pigment pattern formation in urodele amphibians. Epperlein HH, et al. **Int J Dev Biol** 1996 Feb;40(1):229–38 (78 ref.)

GROWTH & DEVELOPMENT

Modulations of cellular interactions during development of the neural crest: role of growth factors and adhesion molecules. Duband JL, et al. **Curr Top Microbiol Immunol** 1996;212:207–27 (96 ref.)

PHYSIOLOGY

Patterning the cranial neural crest. Graham A, et al. **Biochem Soc Symp** 1996;62:77–83 (13 ref.)

Human diversity, environmental adaptation and neural crest. Irmak MK, et al. **Med Hypotheses** 1997 May;48(5):407–10 (34 ref.)

Neurocristopathy: its growth and development in 20 years. Bolande RP. **Pediatr Pathol Lab Med** 1997 Jan–Feb; 17(1):1–25 (145 ref.)

NEURAL INHIBITION

The role of inhibition in the hierarchical gating of executed and imagined movements. Berthoz A. **Brain Res Cogn Brain Res** 1996 Mar;3(2):101–13 (112 ref.)

Functional and pharmacological properties of GABA-mediated inhibition in the human neocortex. Avoli M, et al. **Can J Physiol Pharmacol** 1997 May;75(5):526–34 (46 ref.)

Inhibitory cortical phenomena studied with the technique of transcranial stimulation. Berardelli A, et al. **Electroencephalogr Clin Neurophysiol Suppl** 1996;46:343–9 (22 ref.)

Invertebrate presynaptic inhibition and motor control. Clarac F, et al. **Exp Brain Res** 1996 Nov;112(2):163–80 (112 ref.)

Beta innervation and recurrent inhibition: a hypothesis for manipulatory and postural control. Illert M, et al. **Pflugers Arch** 1996;432(3 Suppl):R61–7 (62 ref.)

[Multifocal motor neuropathies with persistent conduction blocks: a form of inflammatory demyelinating neuropathy] Pouget J, et al. **Rev Neurol (Paris)** 1996 May;152(5):370–4 (30 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Cocaine, Neuroleptics, and tardive dyskinesia as paleocortical escape. Howard JS 3rd. **Integr Physiol Behav Sci** 1996 Oct–Dec;31(4):306–14 (33 ref.)

PHYSIOLOGY

Stimulus-driven facilitation and inhibition of visual information processing in environmental and retinotopic representations of space. Shimojo S, et al. **Brain Res Cogn Brain Res** 1996 Dec;5(1–2):11–21 (14 ref.)

Disinhibition and brain rhythms. MacVicar BA. **J Physiol (Lond)** 1997 Apr 15;500 (Pt 2):283 (5 ref.)

Balances between excitatory and inhibitory events in the spinal cord and chronic pain. Dickenson AH. **Prog Brain Res** 1996;110:225–31 (31 ref.)

The basal ganglia: focused selection and inhibition of competing motor programs. Mink JW. **Prog Neurobiol** 1996 Nov;50(4):381–425 (250 ref.)

Cortical dynamics of lateral inhibition: metacontrast masking. Francis G. **Psychol Rev** 1997 Jul;104(3):572–94 (45 ref.)

[Triggered transcranial magnetic stimulation in high cognitive functions] Kammer T, et al. **Fortschr Neurol Psychiatr** 1996 Jun;64(6):205–11 (44 ref.) (Eng. Abstr.) **(Ger)**

NEURAL INTERCONNECTIONS see **NEURAL PATHWAYS**

NEURAL NETWORK MODELS see **NEURAL NETWORKS (COMPUTER)**

NEURAL NETWORKS (ANATOMIC) see **NERVE NET**

NEURAL NETWORKS (COMPUTER)

Keeping in mind the mind: mental functions, networks and neurosurgery. Steiger HJ, et al. **Acta Neurochir (Wien)** 1996;138(8):898–906 (48 ref.)

Dynamic systems and neural networks: modeling in physiology and medicine. Sayegh SI. **Adv Food Nutr Res** 1996;40:323–38 (14 ref.)

Reducing false negatives in clinical practice: the role of neural network technology. Mango LJ. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 2):1114–9 (31 ref.)

Modifiable neuronal connections: an overview for psychiatrists. Jeffery KJ, et al. **Am J Psychiatry** 1997 Feb; 154(2):156–64 (35 ref.)

Can artificial intelligence be of help to psychoanalysis ... or ... vice versa? Rodado J, et al. **Am J Psychoanal** 1996 Dec; 56(4):395–413 (59 ref.)

Opening the black box: the relationship between neural networks and linear discriminant functions. Kemp RA, et al. **Anal Cell Pathol** 1997;14(1):19–30 (14 ref.)

Stimulus configuration, occasion setting, and the hippocampus. Schmajuk NA, et al. **Behav Neurosci** 1997 Apr;111(2):235–57; appendix 258 (90 ref.)

A summary of resource theories from a behavioral perspective. Sanders AF. **Biol Psychol** 1997 Mar 21; 45(1–3):5–18 (50 ref.)

Cognition and life: the autonomy of cognition. Moreno A, et al. **Brain Cogn** 1997 Jun;34(1):107–29 (65 ref.)

Artificial life and higher level cognition. Parisi D. **Brain Cogn** 1997 Jun;34(1):160–84 (60 ref.)

Network models of the basal ganglia. Beiser DG, et al. **Curr Opin Neurobiol** 1997 Apr;7(2):185–90 (38 ref.)

Prediction of N-terminal protein sorting signals. Claros MG, et al. **Curr Opin Struct Biol** 1997 Jun;7(3):394–8 (41 ref.)

Multilayer perceptrons to approximate complex valued functions. Arena P, et al. **Int J Neural Syst** 1995 Dec; 6(4):435–46 (16 ref.)

Remote sensing operations. Badran F, et al. **Int J Neural Syst** 1995 Dec;6(4):447–53 (11 ref.)

Speaker identification using time-delay HMEs. Chen K, et al. **Int J Neural Syst** 1996 Mar;7(1):29–43 (38 ref.)

Can deterministic penalty terms model the effects of synaptic weight noise on network fault-tolerance? Edwards PJ, et al. **Int J Neural Syst** 1995 Dec;6(4):401–16 (41 ref.)

Learning activation rules rather than connection weights. Grundstrom EL, et al. **Int J Neural Syst** 1996 May; 7(2):129–47 (28 ref.)

An application of Hamiltonian neurodynamics using Pontryagin's Maximum (Minimum) Principle. Koshizen T, et al. **Int J Neural Syst** 1995 Dec;6(4):425–33 (29 ref.)

A higher order Bayesian neural network with spiking units. Lansner A, et al. **Int J Neural Syst** 1996 May;7(2):115–28 (54 ref.)

Constructive training methods for feedforward neural networks with binary weights. Mayoraz E, et al. **Int J Neural Syst** 1996 May;7(2):149–66 (42 ref.)

Role of chaos in trial-and-error problem solving by an artificial neural network. Obana I, et al. **Int J Neural Syst** 1996 Mar;7(1):101–8 (20 ref.)

Nonlinear time series analysis by neural networks: a case study [letter] Saxén H. **Int J Neural Syst** 1996 May; 7(2):195–201 (22 ref.)

An attractor neural network model of classical conditioning. Serulnik SD, et al. **Int J Neural Syst** 1996 Mar;7(1):1–18 (42 ref.)

Side effects of normalising radial basis function networks. Shorten R, et al. **Int J Neural Syst** 1996 May;7(2):167–79 (17 ref.)

Noise in models of neurological and psychiatric disorders. Spitzer M, et al. **Int J Neural Syst** 1996 Sep;7(4):355–61 (44 ref.)

Neural networks in petroleum engineering: a case study [letter] Vukelic MA, et al. **Int J Neural Syst** 1996 May; 7(2):187–94 (11 ref.)

On the characteristics of the quadratic order associative memory that uses synchronous update and direct convergence. Wang JH. **Int J Neural Syst** 1996 Mar; 7(1):69–81 (20 ref.)

Nonlinear gated experts for time series: discovering regimes and avoiding overfitting. Weigend AS, et al. **Int J Neural Syst** 1995 Dec;6(4):373–99 (61 ref.)

Comparison of multilayer neural network and Nearest Neighbor Classifiers for handwritten digit recognition. Yan H. **Int J Neural Syst** 1995 Dec;6(4):417–23 (18 ref.)

CNN: a speaker recognition system using a cascaded neural network [letter] Zaki M, et al. **Int J Neural Syst** 1996 May; 7(2):203–12 (29 ref.)

The receptor mosaic hypothesis of the engram: possible relevance of Boolean network modeling. Zoli M, et al. **Int J Neural Syst** 1996 Sep;7(4):363–8 (40 ref.)

Connectionism and developmental psychology. Plunkett K, et al. **J Child Psychol Psychiatry** 1997 Jan;38(1):53–80 (60 ref.)

Fundamentals of feedback control: PID, fuzzy logic, and neural networks. Westenskow DR. **J Clin Anesth** 1997 Sep; 9(6 Suppl):33S–35S (23 ref.)

Advantages and disadvantages of using artificial neural networks versus logistic regression for predicting medical

outcomes. Tu JV. **J Clin Epidemiol** 1996 Nov; 49(11):1225–31 (37 ref.)

Propagation of synchronous spiking activity in feedforward neural networks. Aertsen A, et al. **J Physiol Paris** 1996; 90(3–4):243–7 (19 ref.)

Neural networks in clinical medicine. Penny W, et al. **Med Decis Making** 1996 Oct–Dec;16(4):386–98 (91 ref.)

On neural circuits and cognition. Gazzaniga MS. **Neural Comput** 1995 Jan;7(1):1–12 (36 ref.)

The LHRH–astroglial network of signals as a model to study neuroimmune interactions: assessment of messenger systems and transduction mechanisms at cellular and molecular levels. Marchetti B. **Neuroimmunomodulation** 1996 Jan–Feb;3(1):1–27 (179 ref.)

Cortical dynamics of lateral inhibition: metacontrast masking. Francis G. **Psychol Rev** 1997 Jul;104(3):572–94 (45 ref.)

Optimality: from neural networks to universal grammar. Prince A, et al. **Science** 1997 Mar 14;275(5306):1604–10 (18 ref.)

Machine learning paradigms for pattern recognition and image understanding. Caelli T, et al. **Spat Vis** 1996; 10(1):87–103 (23 ref.)

Displacement field estimation and image segmentation using block matching enhanced by a neural network. Chen YS, et al. **Spat Vis** 1996;10(1):31–50 (19 ref.)

Classical versus artificial neural network analysis [comment] Newey VR. **Ultrasound Obstet Gynecol** 1997 Jul;10(1):5–8 (45 ref.) Comment on: Ultrasound Obstet Gynecol 1997 Jul;10(1):41–7. Comment on: Ultrasound Obstet Gynecol 1997 Jul;10(1):48–53.

Quantitative analysis of multivariate data using artificial neural networks: a tutorial review and applications to the deconvolution of pyrolysis mass spectra. Goodacre R, et al. **Zentralbl Bakteriol** 1996 Aug;284(4):516–39 (114 ref.)

[Neuronal networks and psychopathology] Spitzer M. **Nervenarzt** 1997 Jan;68(1):21–37 (74 ref.) (Eng. Abstr.) **(Ger)**

NEURAL PATHWAYS

The OB protein (leptin) pathway—a link between adipose tissue mass and central neural networks. Campfield LA, et al. **Horm Metab Res** 1996 Dec;28(12):619–32 (96 ref.)

ANATOMY & HISTOLOGY

Static and dynamic organization of motor cortex. Sanes JN, et al. **Adv Neurol** 1997;73:277–96 (88 ref.)

Circuitry and functional aspects of the insular lobe in primates including humans. Augustine JR. **Brain Res Brain Res Rev** 1996 Oct;22(3):229–44 (81 ref.)

The hippocampo–neocortical dialogue. Buzsáki G. **Cereb Cortex** 1996 Mar–Apr;6(2):81–92 (116 ref.)

Trends in the anatomical organization and functional significance of the mammalian thalamus. Macchi G, et al. **Ital J Neurol Sci** 1996 Apr;17(2):105–29 (295 ref.)

The callosal connections of the hierarchically organized somatosensory areas of primates. Manzoni T. **J Neurosurg Sci** 1997 Mar;41(1):1–22 (247 ref.)

Control pathways from the basal ganglia to the orofacial motor system in the lower brainstem. Yasui Y, et al. **Kaibogaku Zasshi** 1996 Jun;71(3):177–82 (22 ref.)

The anatomical basis for the expression of circadian rhythms: the efferent projections of the suprachiasmatic nucleus. Buijs RM. **Prog Brain Res** 1996;111:229–40 (67 ref.)

[Neural pathways—neural networks] Palkovits M. **Orv Hetil** 1996 Jun 9;137(23):1235–43 (49 ref.) (Eng. Abstr.) **(Hun)**

[Neurophysiological basis of acupuncture] Yamamura Y, et al. **Rev Assoc Med Bras** 1995 Jul–Aug;41(4):305–10 (60 ref.) **(Por)**

DRUG EFFECTS

Neuronal mechanisms mediating drug–induced cognition enhancement: cognitive activity as a necessary intervening variable. Sarter M, et al. **Brain Res Cogn Brain Res** 1996 Jun;3(3–4):329–43 (127 ref.)

EMBRYOLOGY

The molecular biology of axon guidance. Tessier–Lavigne M, et al. **Science** 1996 Nov 15;274(5290):1123–33 (120 ref.)

PHYSIOLOGY

Short–term functional plasticity of cortical and thalamic sensory representations and its implication for information processing. Dinse HR, et al. **Adv Neurol** 1997;73:159–78 (78 ref.)

Flexibility in the structure of human information processing. Heinze HJ, et al. **Adv Neurol** 1997;73:359–75 (64 ref.)

Construction of a model demonstrating neural pathways and reflex arcs. Chan V, et al. **Am J Physiol** 1996 Dec;271(6 Pt 3):S14–42 (4 ref.)

Development and expression of hormonal systems regulating aggression. Simon NG, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:8–17 (48 ref.)

Insights into the role of the cholinergic component of the septohippocampal pathway: what have we learned from experimental lesion studies? Hörtnagl H, et al. **Brain Res Bull** 1997;43(3):245–55 (187 ref.)

Processing the head direction cell signal: a review and commentary. Taube JS, et al. **Brain Res Bull** 1996; 40(5–6):477–84; discussion 484–6 (58 ref.)

Impulsivity as a confounding factor in certain animal tests of cognitive function. Bizot JC, et al. **Brain Res Cogn Brain Res** 1996 Jun;3(3–4):243–50 (124 ref.)

Neuropharmacology of timing and time perception. Meck WH. **Brain Res Cogn Brain Res** 1996 Jun;3(3–4):227–42 (130 ref.)

Attention and stimulus processing in the rat. Muir JL. **Brain Res Cogn Brain Res** 1996 Jun;3(3–4):215–25 (77 ref.)

Further developments in the measurement of working memory in rodents. Pontecorvo MJ, et al. **Brain Res Cogn Brain Res** 1996 Jun;3(3–4):205–13 (69 ref.)

Memory procedures, performance and processes in pigeons. White KG, et al. **Brain Res Cogn Brain Res** 1996 Jun; 3(3–4):309–17 (45 ref.)

Sensorimotor processing: charting the frontier. Carpenter RH. **Curr Biol** 1997 Jun 1;7(6):R348–51 (10 ref.)

PKA isoforms, neural pathways, and behaviour: making the connection. Brandon EP, et al. **Curr Opin Neurobiol** 1997 Jun;7(3):397–403 (60 ref.)

Cortical dynamic tuning: the role of intrinsic connections, as revealed by modeling. Lukashin AV. **Curr Opin Neurobiol** 1996 Dec;6(6):765–72 (43 ref.)

Establishment of pathways in the developing neural system. Chiquet M. **Curr Top Microbiol Immunol** 1996;212:229–38 (23 ref.)

A model of selective processing of auditory–nerve inputs by stellate cells of the antero–ventral cochlear nucleus. Lai YC, et al. **J Comput Neurosci** 1994 Aug;1(3):167–94 (43 ref.)

Cognitive graphs, resistive grids, and the hippocampal representation of space. Burgess N, et al. **J Gen Physiol** 1996 Jun;107(6):659–62 (32 ref.)

Anatomy and function of the orbital frontal cortex, I: anatomy, neurocircuitry; and obsessive–compulsive disorder. Zald DH, et al. **J Neuropsychiatry Clin Neurosci** 1996 Spring;8(2):125–38 (119 ref.)

Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence. Maldonado R. **Neurosci Biobehav Rev** 1997 Jan; 21(1):91–104 (137 ref.)

Entrainment pathways and the functional organization of the circadian system. Moore RY. **Prog Brain Res** 1996; 111:103–19 (65 ref.)

Sensori–sensory afferent conditioning with leg movement: gain control in spinal reflex and ascending paths. Brooke JD, et al. **Prog Neurobiol** 1997 Mar;51(4):393–421 (180 ref.)

Spatial, behavioral and sensory correlates of hippocampal CA1 complex spike cell activity: implications for information processing functions. Wiener SI. **Prog Neurobiol** 1996 Jul;49(4):335–61 (104 ref.)

[Neural pathways—neural networks] Palkovits M. **Orv Hetil** 1996 Jun 9;137(23):1235–43 (49 ref.) (Eng. Abstr.) **(Hun)**

RADIONUCLIDE IMAGING

Functional neuroimaging: radiology. Hunter JV. **Curr Opin Neurol** 1996 Feb;9(1):37–41 (42 ref.)

NEURAL TRANSMISSION see **SYNAPTIC TRANSMISSION**

NEURAL TUBE DEFECTS

Folic acid and neural tube defects. Minns RA. **Spinal Cord** 1996 Aug;34(8):460–5 (42 ref.)

COMPLICATIONS

Craniosynostosis in neural tube defects: a theory on its pathogenesis. Martínez–Lage JF, et al. **Surg Neurol** 1996 Nov;46(5):465–9; discussion 469–70 (19 ref.)

[Neural tube dysfunction and cutaneous lesions] Vanaclocha–Vanaclocha V, et al. **Rev Neurol** 1997 Sep;25 Suppl 3:S232–7 (80 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Neural tube defects/alpha–fetoprotein/Down's syndrome screening. Aitken DA, et al. **Curr Opin Obstet Gynecol** 1997 Apr;9(2):113–20 (62 ref.)

MR imaging of the pediatric spine. Byrd SE, et al. **Magn Reson Imaging Clin N Am** 1996 Nov;4(4):797–833 (31 ref.)

Maternal serum screening for fetal genetic disorders. Ross HL, et al. **Obstet Gynecol Clin North Am** 1997 Mar; 24(1):33–47 (51 ref.)

EMBRYOLOGY

Multisite neural tube closure in humans. Van Allen MI. **Birth Defects Orig Artic Ser** 1996;30(1):203–25 (98 ref.)

EPIDEMIOLOGY

A search for environmental and genetic background for neural tube defects: twenty–five years of experience. Pietrzyk JJ. **Cent Eur J Public Health** 1997 Jun;5(2):86–9 (24 ref.)

Myelodysplasia and acute myeloid leukemia occurring after autologous bone marrow transplantation for lymphoma. Traweek ST, et al. **Leuk Lymphoma** 1996 Feb; 20(5–6):365–72 (47 ref.)

ETIOLOGY

Lack of serologic evidence for an association between Cache Valley Virus infection and anencephaly and other neural tube defects in Texas. Edwards JF, et al. **Emerg Infect Dis** 1997 Apr–Jun;3(2):195–7 (19 ref.)

[The main etiopathogenic mechanisms of neurocutaneous diseases] Vicente FJ, et al. **Rev Neurol** 1997 Sep;25 Suppl 3:S214–21 (63 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Genetic analysis of a complex disease. Mayo O. **Alcohol Alcohol Suppl** 1994;2:9–18 (50 ref.)

A search for environmental and genetic background for neural tube defects: twenty–five years of experience. Pietrzyk JJ. **Cent Eur J Public Health** 1997 Jun;5(2):86–9 (24 ref.)

Mice as models of human developmental disorders: natural and artificial mutants. Darling S. **Curr Opin Genet Dev** 1996 Jun;6(3):289–94 (49 ref.)

Inositol prevents expression of a genetic model of neural tube defects in mice. **Nutr Rev** 1997 May;55(5):176–7 (9 ref.)

PREVENTION & CONTROL

Maternal serum screening for fetal Down syndrome: the detection of other pathologies. Saller DN Jr, et al. **Clin Obstet Gynecol** 1996 Dec;39(4):793–800 (12 ref.)

Folic acid to prevent neural tube defects: scientific advances and public health issues. Mills JL, et al. **Curr Opin Obstet Gynecol** 1996 Dec;8(6):394–7 (18 ref.)

Folic acid in the prevention of birth defects. Allen WP. **Curr Opin Pediatr** 1996 Dec;8(6):630–4 (40 ref.)

Folates and the fetus. Eskes TK. **Eur J Obstet Gynecol Reprod Biol** 1997 Feb;71(2):105–11 (44 ref.)

ACOG educational bulletin. Maternal serum screening. Number 228, September 1996 (replaces no. 154, April 1991). Committee on Educational Bulletins of the American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1996 Dec;55(3):299–308 (34 ref.)

Can women live on bread alone? Folic acid supplementation revisited. Page RL 2nd, et al. **J S C Med Assoc** 1997 Feb; 93(2):57–62 (27 ref.)

Folic acid and food fortification: implications for the primary care practitioner. Tinkle M. **Nurse Pract** 1997 Mar; 22(3):105–6, 109, 112–4 (42 ref.)

Folic acid fortification. **Nutr Rev** 1996 Mar;54(3):94–5 (4 ref.)

Inositol prevents expression of a genetic model of neural tube defects in mice. **Nutr Rev** 1997 May;55(5):176–7 (9 ref.)

Preventing neural tube defects. Buehler JW, et al. **Pediatr Ann** 1997 Sep;26(9):535–9 (17 ref.)

Teratology Society Consensus Statement on use of folic acid to reduce the risk of birth defects. Holmes L, et al. **Teratology** 1997 Jun;55(6):381 (3 ref.)

Translation of the advice of the special mixed advisory commission concerning folic acid supplementation for the prevention of neural tube defects. **Verh K Acad Geneeskd Belg** 1996;58(6):635–79; discussion 679–81 (135 ref.) **(Eng, Dut, Fre)**

SURGERY

Surgery of the spine in myelodysplasia. An overview. Rodgers WB, et al. **Clin Orthop** 1997 May;(338):19–35 (91 ref.)

NEURALGIA

COMPLICATIONS

[Glossopharyngeal neuralgia with syncope] Mód G, et al. **Orv Hetil** 1996 Jun 2;137(22):1199–203 (31 ref.) (Eng. Abstr.) **(Hun)**

DIAGNOSIS

Lumbosacral plexus neuropathy: a case report and review of the literature. van Alfen N, et al. **Clin Neurol Neurosurg** 1997 May;99(2):138–41 (16 ref.)

Medical and pharmacologic management of upper extremity neuropathic pain syndromes. Mackin GA. **J Hand Ther** 1997 Apr–Jun;10(2):96–109 (88 ref.)

DRUG THERAPY

Medical and pharmacologic management of upper extremity neuropathic pain syndromes. Mackin GA. **J Hand Ther** 1997 Apr–Jun;10(2):96–109 (88 ref.)

ETIOLOGY

Post–sympathectomy neuralgia: hypotheses on peripheral and central neuronal mechanisms [see comments] Kramis RC, et al. **Pain** 1996 Jan;64(1):1–9 (66 ref.) Comment in: Pain 1996 Sep;67(1):218–20. Comment in: Pain 1997 Apr;70(2–3):290–1.

Epidemiology and management of postherpetic neuralgia. Gershon AA. **Semin Dermatol** 1996 Jun;15(2 Suppl 1):8–13 (33 ref.)

REHABILITATION

Management of pain in persons with spinal cord injury. Ragnarsson KT. **J Spinal Cord Med** 1997 Apr;20(2):186–99 (79 ref.)

SURGERY

[Pain management after post-traumatic brachial plexus lesions. Conservative and surgical therapy possibilities] Carvalho GA, et al. **Orthopade** 1997 Jul;26(7):621-5 (30 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Postherpetic neuralgia: a review [see comments] Hanania MM, et al. **Cancer Invest** 1997;15(2):165-76 (195 ref.) Comment in: Cancer Invest 1997 ;15(2):163-4.

Herpes zoster and postherpetic neuralgia. Optimal treatment. Johnson RW. **Drugs Aging** 1997 Feb;10(2):80-94 (111 ref.)

Epidemiology and management of postherpetic neuralgia. Gershon AA. **Semin Dermatol** 1996 Jun;15(2 Suppl 1):8-13 (33 ref.)

NEURALGIA, GENICULATE see **HERPES ZOSTER OTICUS**

NEURALGIC AMYOTROPHY see **CERVICO-BRACHIAL NEURALGIA**

NEURAMINIDASE

ANTAGONISTS & INHIBITORS

Neuraminidase inhibitors as potential anti-influenza drugs. Bamford MJ. **J Enzyme Inhib** 1996;10(1):1-16 (86 ref.)

CHEMISTRY

Sialidases: structures, biological significance and therapeutic potential. Taylor G. **Curr Opin Struct Biol** 1996 Dec; 6(6):830-7 (54 ref.)

DEFICIENCY

[Two siblings of galactosialidosis with marked progression of cardiac involvement during 10 years] Hisahara S, et al. **Rinsho Shinkeigaku** 1996 Apr;36(4):562-5 (17 ref.) (Eng. Abstr.) **(Jpn)**

NEURASTHENIA

see related
FATIGUE SYNDROME, CHRONIC

NEURENTERIC CYST see **SPINA BIFIDA OCCULTA**

NEURILEMMOMA

Juxta-adrenal malignant schwannoma. Fabbro MA, et al. **Pediatr Surg Int** 1997 Sep;12(7):532-4 (13 ref.)

COMPLICATIONS

Giant intrasacral schwannoma forming a presacral mass: a report of an unusual cause of lumbosacral radiculopathy. Turgut M, et al. **Zentralbl Neurochir** 1996;57(4):201-5 (19 ref.)

DIAGNOSIS

Malignant intestinal schwannoma: a case report and a review of the literature in Japan. Nozu T, et al. **Intern Med** 1995 Nov;34(11):1101-5 (19 ref.)

Intracerebral schwannoma: case report and review. Erongun U, et al. **Neurosurg Rev** 1996;19(4):269-74 (35 ref.)

Radiologic manifestation of spinal accessory neurinoma: a case report. Ohkawa M, et al. **Radiat Med** 1996 Sep-Oct; 14(5):269-73 (16 ref.)

[Retroperitoneal schwannoma. Diagnostic and therapeutic outcome] Krid M, et al. **Acta Urol Belg** 1997 Mar; 65(1):69-72 (18 ref.) (Eng. Abstr.) **(Fre)**

[Intra-parotid neurogenic tumors of the facial nerve. Value of MRI] Fisch-Ponsot C, et al. **J Radiol** 1997 Feb; 78(2):141-4 (14 ref.) (Eng. Abstr.) **(Fre)**

[Extracranial schwannoma of the ENT region. Review of the literature with a case report of benign schwannoma of the base of the tongue] Dreher A, et al. **HNO** 1997 Jun;45(6):468-71 (20 ref.) (Eng. Abstr.) **(Ger)**

[Neurinomas and ependymomas of the cauda equina. A review of the clinical characteristics] Cervoni L, et al. **Minerva Chir** 1997 May;52(5):629-33 (36 ref.) (Eng. Abstr.) **(Ita)**

[Intramedullary cervical neurinoma. A case report and review of the literature] Innocenzi G, et al. **Minerva Chir** 1997 May;52(5):679-82 (15 ref.) (Eng. Abstr.) **(Ita)**

[Diagnosis and treatment of peripheral nerve tumor] Usui M. **Nippon Seikeigeka Gakkai Zasshi** 1997 May; 71(5):161-70 (23 ref.) **(Jpn)**

[Retrovesical schwannosarcoma] Gonzalvo Pérez V, et al. **Actas Urol Esp** 1997 Apr;21(4):416-9 (8 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Malignant peripheral nerve sheath tumour with vascular differentiation: a report of four cases. Morphopoulos GD, et al. **Histopathology** 1996 May;28(5):401-10 (41 ref.)

Schwannoma of the larynx: two case reports and review of the literature. al-Otieschan AT, et al. **J Otolaryngol** 1996 Dec;25(6):412-5 (21 ref.)

Schwannomatosis: a clinical and pathologic study [see comments] MacCollin M, et al. **Neurology** 1996 Apr; 46(4):1072-9 (40 ref.) Comment in: Neurology 1997 Mar;48(3):787-8.

Pancreatic schwannoma: report of two cases and review of the literature. Feldman L, et al. **Pancreas** 1997 Jul; 15(1):99-105 (26 ref.)

[Neurinomas-neurofibromas] Goujon JM, et al. **Neurochirurgie** 1997;43(1):35-8 (9 ref.) (Eng. Abstr.) **(Fre)**

[Laryngeal malignant schwannoma in a 9-year-old boy: report of a clinical case] Dvornik G, et al. **Pathologica** 1996 Dec;88(6):519-21 (10 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Schwannomatosis: a clinical and pathologic study [see comments] MacCollin M, et al. **Neurology** 1996 Apr; 46(4):1072-9 (40 ref.) Comment in: Neurology 1997 Mar;48(3):787-8.

SECONDARY

[Multiple jejuno-ileal metastasis of malignant schwannoma from the leg. Report of a case presenting anemia symptoms and review of the literature] Crespi C, et al. **Minerva Chir** 1996 Oct;51(10):829-33 (12 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Intraparotid facial nerve schwannoma in a child. Kumar BN, et al. **J Laryngol Otol** 1996 Dec;110(12):1169-70 (11 ref.)

Intraparenchymal schwannomas of the central nervous system: an additional case report and review. Beşkonakli E, et al. **Neurosurg Rev** 1997;20(2):139-44 (62 ref.)

Trochlear nerve schwannomas occurring in patients without neurofibromatosis: case report and review of the literature. Santoreneos S, et al. **Neurosurgery** 1997 Jul;41(1):282-7 (21 ref.)

Laparoscopic resection of a pelvic schwannoma. Melvin WS. **Surg Laparosc Endosc** 1996 Dec;6(6):489-91 (12 ref.)

[Retroperitoneal schwannoma. Diagnostic and therapeutic outcome] Krid M, et al. **Acta Urol Belg** 1997 Mar; 65(1):69-72 (18 ref.) (Eng. Abstr.) **(Fre)**

[Giant sacral schwannoma with pelvic extension. Therapeutic strategy. Apropos of a case] Stecken J, et al. **Neurochirurgie** 1996;42(6):294-9 (16 ref.) (Eng. Abstr.) **(Fre)**

[Retroperitoneal schwannoma: report of a clinical case and review of the literature] Ziparo V, et al. **G Chir** 1996 Aug-Sep;17(8-9):399-404 (33 ref.) (Eng. Abstr.) **(Ita)**

[A case report of malignant schwannoma of the chest wall] Morita I, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jan;45(1):46-50 (14 ref.) (Eng. Abstr.) **(Jpn)**

[A case of jugular foramen neurinoma originating from glossopharyngeal nerve] Fukui S, et al. **No Shinkei Geka** 1997 Jan;25(1):47-51 (17 ref.) (Eng. Abstr.) **(Jpn)**

NEURILEMMOMA, ACOUSTIC see **NEUROMA, ACOUSTIC**

NEURINOMA see **NEURILEMMOMA**

NEURINOMA, ACOUSTIC see **NEUROMA, ACOUSTIC**

NEURITE OUTGROWTH FACTOR see **NERVE GROWTH FACTORS**

NEURITES

see related
NERVE GROWTH FACTORS

CHEMISTRY

Cell signalling and CAM-mediated neurite outgrowth. Walsh FS, et al. **Soc Gen Physiol Ser** 1997;52:221-6 (25 ref.)

PHYSIOLOGY

Restriction of plastic fiber growth after lesions by central nervous system myelin-associated neurite growth inhibitors. Kapfhammer JP. **Adv Neurol** 1997;73:7-27 (180 ref.)

Stretch-sensitive ion channels of neuronal growth cones. Pellegrino M, et al. **Arch Ital Biol** 1997 Sep;135(4):319-29 (62 ref.)

Structural plasticity of the adult CNS. Negative control by neurite growth inhibitory signals. Schwab ME. **Int J Dev Neurosci** 1996 Jul;14(4):379-85 (67 ref.)

Neural cell adhesion molecule L1: signaling pathways and growth cone motility. Kamiguchi H, et al. **J Neurosci Res** 1997 Jul 1;49(1):1-8 (81 ref.)

Axonal molecules of the immunoglobulin superfamily bearing a GPI anchor: their role in controlling neurite outgrowth. Faivre-Sarrailh C, et al. **Mol Cell Neurosci** 1997; 9(2):109-15 (51 ref.)

Molecules inhibiting neurite growth: a minireview. Schwab ME. **Neurochem Res** 1996 Jul;21(7):755-61 (92 ref.)

Myelin-associated neurite growth inhibitors: regulators of plastic changes of neural connections in the central nervous system. Kapfhammer JP. **Prog Brain Res** 1996;108:183-202 (61 ref.)

Cellular mechanisms regulating neurite initiation. Lankford KL, et al. **Prog Brain Res** 1996;108:55-81 (231 ref.)

Growth cone dynamics and activity-dependent processes in neuronal network development. van Pelt J, et al. **Prog Brain Res** 1996;108:333-46 (67 ref.)

Cell signalling and CAM-mediated neurite outgrowth. Walsh FS, et al. **Soc Gen Physiol Ser** 1997;52:221-6 (25 ref.)

Schwann cells induce and guide sprouting and reinnervation of neuromuscular junctions. Son YJ, et al. **Trends Neurosci** 1996 Jul;19(7):280-5 (40 ref.)

ULTRASTRUCTURE

Growth cone behaviors during axon guidance in the developing cerebral cortex. Kalil K. **Prog Brain Res** 1996; 108:31-40 (50 ref.)

Retinal axon divergence in the optic chiasm: growth cone behaviors and signalling cells. Mason CA, et al. **Prog Brain Res** 1996;108:95-107 (66 ref.)

NEURITIS

Inflammatory diseases overview [editorial] Coyle PK. **Curr Opin Neurol** 1997 Jun;10(3):245-6 (7 ref.)

COMPLICATIONS

Brachial neuritis presenting as anterior interosseous nerve compression--implications for diagnosis and treatment: a case report. Wong L, et al. **J Hand Surg [Am]** 1997 May; 22(3):536-9 (29 ref.)

ETIOLOGY

The role of inflammatory cytokines in the tissue injury of leprosy. Sarno EN, et al. **Int J Lepr Other Mycobact Dis** 1996 Dec;64(4 Suppl):S69-73; discussion S73-4 (26 ref.)

Inflammatory reaction after brain damage and prospective therapy against damage impending cerebral infarction. Matsuo Y, et al. **Keio J Med** 1996 Sep;45(3):270-4 (18 ref.)

Brachial neuritis following routine childhood immunization for diphtheria, tetanus, and pertussis (DTP): report of two cases and review of the literature. Hamati-Haddad A, et al. **Pediatrics** 1997 Apr;99(4):602-3 (15 ref.)

MICROBIOLOGY

[Microbes that invade nervous system] Shimada K. **Nippon Naika Gakkai Zasshi** 1996 May 10;85(5):655-8 (12 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Neuropeptides in dural fine sensory nerve endings--involvement in neurogenic inflammation? Hanesch U. **Prog Brain Res** 1996;113:299-317 (89 ref.)

NEURITIS, EXPERIMENTAL ALLERGIC

see related
MYELIN P2 PROTEIN

Experimental allergic neuritis (EAN) as a model for the immune-mediated demyelinating neuropathies. Hahn AF. **Rev Neurol (Paris)** 1996 May;152(5):328-32 (48 ref.)

THERAPY

Treatment of inflammatory neuropathy. Hughes RA, et al. **Mult Scler** 1997 Apr;3(2):88-92 (51 ref.)

NEUROBIOLOGY

The problem of gestalt in neurobiology. Sokolov EN. **Neurosci Behav Physiol** 1997 Jul-Aug;27(4):323-32 (33 ref.)

The neurobiology of hepatic encephalopathy. Butterworth RF. **Semin Liver Dis** 1996 Aug;16(3):235-44 (105 ref.)

[The gestalt problem in neurobiology] Sokolov EN. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Mar-Apr; 46(2):229-40 (33 ref.) (Eng. Abstr.) **(Rus)**

HISTORY

One or many arousal systems? Reflections on some of Giuseppe Moruzzi's foresights and insights about the intrinsic regulation of brain activity. Berlucchi G. **Arch Ital Biol** 1997 Jan;135(1):5-14 (38 ref.)

METHODS

Cellular and molecular biology in urogynaecology. Blakeman P, et al. **Curr Opin Obstet Gynecol** 1996 Oct;8(5):357-60 (37 ref.)

Targeted gene disruption: applications in neurobiology. van der Neut R. **J Neurosci Methods** 1997 Jan;71(1):19-27 (93 ref.)

Antisense strategies in neurobiology. Weiss B, et al. **Neurochem Int** 1997 Sep;31(3):321-48 (189 ref.)

NEUROBLASTOMA

Neuroblastoma: an enigmatic disease. Brossard J, et al. **Br Med Bull** 1996 Oct;52(4):787-801 (48 ref.)

Patterns of oncogene activation in human neuroblastoma cells. Corvi R, et al. **J Neurooncol** 1997 Jan;31(1-2):25-31 (38 ref.)

NEUROBLASTOMA

Retinoids and the control of growth/death decisions in human neuroblastoma cell lines. Melino G, et al. **J Neurooncol** 1997 Jan;31(1-2):65-83 (133 ref.)

Neuroblastoma. Black CT, et al. **Semin Pediatr Surg** 1997 Feb;6(1):2-10 (160 ref.)

CHEMISTRY

Comparison of the diagnostic and prognostic value of biological markers in neuroblastoma. Proposal for a common methodology of analysis. SENSE group. Favrot MC, et al. **Ann Oncol** 1996 Aug;7(6):607-11 (50 ref.)

COMPLICATIONS

Development of primary hypothyroidism with antithyroglobulin, antiperoxidase, and blocking-type thyrotropin receptor antibodies after radiation therapy for neuroblastoma. Kikawa Y, et al. **J Pediatr** 1996 Dec; 129(6):909-12 (19 ref.)

A decreased incidence of neuroblastomas in Down's syndrome and overproduction of S-100 b protein. Satge D. **Med Hypotheses** 1996 Apr;46(4):393-9 (47 ref.)

CONGENITAL

Disseminated congenital neuroblastoma involving the placenta. Lynn AA, et al. **Arch Pathol Lab Med** 1997 Jul; 121(7):741-4 (15 ref.)

Rapid growth of a fetal abdominal mass: a case report of congenital neuroblastoma. Shen MR, et al. **J Clin Ultrasound** 1997 Jan;25(1):39-42 (11 ref.)

DIAGNOSIS

Comparison of the diagnostic and prognostic value of biological markers in neuroblastoma. Proposal for a common methodology of analysis. SENSE group. Favrot MC, et al. **Ann Oncol** 1996 Aug;7(6):607-11 (50 ref.)

Prenatally diagnosed neuroblastoma. Acharya S, et al. **Cancer** 1997 Jul 15;80(2):304-10 (46 ref.)

Screening for neuroblastoma. Bernstein ML, et al. **Cancer Treat Res** 1996;86:149-63 (44 ref.)

A review of open biopsy for mediastinal masses. Massie RJ, et al. **J Paediatr Child Health** 1997 Jun;33(3):230-3 (20 ref.)

Biology and treatment of neuroblastoma. Castleberry RP. **Pediatr Clin North Am** 1997 Aug;44(4):919-37 (128 ref.)

DRUG THERAPY

Management of chemotherapy in a pregnancy complicated by a large neuroblastoma. Arango HA, et al. **Obstet Gynecol** 1994 Oct;84(4 Pt 2):665-8 (10 ref.)

GENETICS

Is genomic imprinting involved in the pathogenesis of pseudotriploid neuroblastoma? Haas OA. **Acta Genet Med Gemellol (Roma)** 1996;45(1-2):173-7 (20 ref.)

Biology and genetics of human neuroblastomas. Brodeur GM, et al. **J Pediatr Hematol Oncol** 1997 Mar-Apr; 19(2):93-101 (105 ref.)

New genetic loci in neuroblastoma. Schwab M, et al. **Klin Padiatr** 1997 Jul-Aug;209(4):147-9 (21 ref.)

cDNA subtraction hybridization: a review and an application to neuroblastoma. Swendeman SL, et al. **Semin Pediatr Surg** 1996 Aug;5(3):149-54 (56 ref.)

[Molecular biology markers of neuroblastoma as the basis for a therapy concept] Girgert R, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:1053-5 (9 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

A comparative review of the immunobiology of murine neuroblastoma and human neuroblastoma. Ziegler MM, et al. **Cancer** 1997 May 1;79(9):1757-66 (76 ref.)

METABOLISM

Molecular and functional characterization of angiotensin II AT2 receptor in neuroblastoma N1E-115 cells. Nahmias C, et al. **Adv Exp Med Biol** 1996;396:167-73 (42 ref.)

Production and function of lipid second messengers in proliferating and differentiated neuroblastoma cells. Lang D, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1-3):349-59 (38 ref.)

Inositol trisphosphate/Ca2+ as messengers of bradykinin B2 and muscarinic acetylcholine m1-m4 receptors in neuroblastoma-derived hybrid cells. Noda M, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1-3):175-85 (44 ref.)

New evidence for the occurrence of a glycolipid-mediated signal transduction system. Tsuji S, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1-3):289-94 (9 ref.)

PATHOLOGY

Disseminated congenital neuroblastoma involving the placenta. Lynn AA, et al. **Arch Pathol Lab Med** 1997 Jul; 121(7):741-4 (15 ref.)

Neuroblastoma 4S: a heterogeneous disease with variable risk factors and treatment strategies. van Noesel MM, et al. **Cancer** 1997 Sep 1;80(5):834-43 (63 ref.)

PHYSIOPATHOLOGY

Neuroblastoma and insulin-like growth factor system. New insights and clinical perspectives. Cianfarani S, et al. **Eur J Pediatr** 1997 Apr;156(4):256-61 (65 ref.)

PREVENTION & CONTROL

Newborn screening for neuroblastoma. Parker L. **Curr Opin Pediatr** 1997 Feb;9(1):70-3 (27 ref.)

Screening for neuroblastoma: 20 years and still no answer. Craft AW, et al. **Eur J Cancer** 1996 Aug;32A(9):1540-3 (40 ref.)

RADIOTHERAPY

[Organ preservation in the treatment of malignant solid tumors in children] Saeki M, et al. **Gan To Kagaku Ryoho** 1997 Apr;24(6):666-72 (5 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Renal cell carcinoma after therapy for neuroblastoma. Donnelly LF, et al. **AJR Am J Roentgenol** 1996 Oct; 167(4):915-7 (8 ref.)

ULTRASONOGRAPHY

Rapid growth of a fetal abdominal mass: a case report of congenital neuroblastoma. Shen MR, et al. **J Clin Ultrasound** 1997 Jan;25(1):39-42 (11 ref.)

Prenatal ultrasound characterization of the suprarenal mass: distinction between neuroblastoma and subdiaphragmatic extralobar pulmonary sequestration. Curtis MR, et al. **J Ultrasound Med** 1997 Feb;16(2):75-83 (69 ref.)

Clinical and perinatal sonographic features of congenital adrenal cystic neuroblastoma: a case report with review of the literature. Chen CP, et al. **Ultrasound Obstet Gynecol** 1997 Jul;10(1):68-73 (31 ref.)

NEUROCHEMISTRY

Advances in post mortem molecular neurochemistry and neuropathology: examples from schizophrenia research. Harrison PJ. **Br Med Bull** 1996 Jul;52(3):527-38 (62 ref.)

Nitric oxide actions in neurochemistry. Dawson VL, et al. **Neurochem Int** 1996 Aug;29(2):97-110 (103 ref.)

NEUROCIRCULATORY ASTHENIA

[Does the effort syndrome have a right to be?] Koren W, et al. **Harefuah** 1997 Feb 16;132(4):293-5 (19 ref.) **(Heb)**

[Hyperkinetic beta-adrenergic circulatory state, hyperkinetic heart syndrome] Hayashi T. **Ryoikibetsu Shokogun Shirizu** 1996;(15):505-7 (11 ref.) **(Jpn)**

[Neurocirculatory asthenia] Hayashi T. **Ryoikibetsu Shokogun Shirizu** 1996;(15):543-6 (12 ref.) **(Jpn)**

[Cardiac neurosis] Shimizu H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):564-6 (15 ref.) **(Jpn)**

NEURODERMATITIS

DIAGNOSIS

Pediatric psychocutaneous disorders. Hansen RC. **Curr Opin Pediatr** 1997 Aug;9(4):367-71 (14 ref.)

ETIOLOGY

Lichen simplex chronicus. Jones RO. **Clin Podiatr Med Surg** 1996 Jan;13(1):47-54 (32 ref.)

PSYCHOLOGY

[Psychophysiologic and psychoneuroimmunologic studies in neurodermatitis. Overview and critical evaluation] Buhk H, et al. **Hautarzt** 1997 Jan;48(1):5-11 (24 ref.) (Eng. Abstr.) **(Ger)**

NEURODERMATITIS, ATOPIC see **DERMATITIS, ATOPIC**

NEURODERMATITIS, CIRCUMSCRIBED see **NEURODERMATITIS**

NEURODERMATITIS, DISSEMINATED see **DERMATITIS, ATOPIC**

NEURODERMATITIS, LOCALIZED see **NEURODERMATITIS**

NEUROECTODERMAL TUMOR, MELANOTIC

Melanotic neuroectodermal tumor of infancy in the epididymis. Case report and literature review. Kobayashi T, et al. **Urol Int** 1996;57(4):262-5 (28 ref.)

NEUROECTODERMAL TUMOR, PERIPHERAL

DIAGNOSIS

Small round blue cell tumors in bone: prognostic factors correlated to Ewing's sarcoma and neuroectodermal tumors. Terrier P, et al. **Semin Diagn Pathol** 1996 Aug; 13(3):250-7 (61 ref.)

PATHOLOGY

Malignant peripheral nerve sheath tumour with vascular differentiation: a report of four cases. Morphopoulos GD, et al. **Histopathology** 1996 May;28(5):401-10 (41 ref.)

NEUROECTODERMAL TUMOR, PRIMITIVE

Ewing's sarcoma and peripheral primitive neuroectodermal tumor: an interim report. Batsakis JG, et al. **Ann Otol Rhinol Laryngol** 1996 Oct;105(10):838-43 (32 ref.)

Poor prognosis Ewing's sarcoma and peripheral primitive neuroectodermal tumours (PNET). Maurel J, et al. **Cancer Treat Rev** 1996 Nov;22(6):425-36 (80 ref.)

Ewing's sarcoma and extracranial primitive neuroectodermal tumors. Granowetter L. **Curr Opin Oncol** 1996 Jul; 8(4):305-10 (48 ref.)

CHEMISTRY

Primitive neuroectodermal tumor of the myocardium: a case report, review of the literature, immunohistochemical, and ultrastructural study. Charney DA, et al. **Hum Pathol** 1996 Dec;27(12):1365-9 (26 ref.)

DIAGNOSIS

Primitive neuroectodermal tumor of the kidney confirmed by fluorescence in situ hybridization. Sheaff M, et al. **Am J Surg Pathol** 1997 Apr;21(4):461-8 (20 ref.)

DRUG THERAPY

Chemotherapy for medulloblastomas and primitive neuroectodermal tumors. Cohen BH, et al. **J Neurooncol** 1996 Jul;29(1):55-68 (58 ref.)

GENETICS

Biology of EWS/FLI and related fusion genes in Ewing's sarcoma and primitive neuroectodermal tumor. May WA, et al. **Curr Top Microbiol Immunol** 1997;220:143-50 (35 ref.)

PATHOLOGY

Primary primitive neuroectodermal tumor of the kidney. Case report and review of the literature. Furman J, et al. **Am J Clin Pathol** 1996 Sep;106(3):339-44 (41 ref.)

THERAPY

Gene therapy for PNET. Raffel C. **J Neurooncol** 1996 Jul; 29(1):113-8 (38 ref.)

ULTRASTRUCTURE

Primitive neuroectodermal tumor of the myocardium: a case report, review of the literature, immunohistochemical, and ultrastructural study. Charney DA, et al. **Hum Pathol** 1996 Dec;27(12):1365-9 (26 ref.)

NEUROECTODERMAL TUMORS

DIAGNOSIS

Neuroectodermal cyst may be a rare differential diagnosis of fetal sacrococcygeal teratoma: first case report of a prenatally observed neuroectodermal cyst. Bloechle M, et al. **Ultrasound Obstet Gynecol** 1996 Jan;7(1):64-7 (11 ref.)

PATHOLOGY

Primitive neuroectodermal tumors of the central nervous system. Rorke LB, et al. **Brain Pathol** 1997 Apr;7(2):765-84 (162 ref.)

RADIOTHERAPY

131I-MIBG therapy of neural crest tumours (review). Troncone L, et al. **Anticancer Res** 1997 May-Jun; 17(3B):1823-31 (84 ref.)

THERAPY

The Ewing family of tumors. Ewing's sarcoma and primitive neuroectodermal tumors. Grier HE. **Pediatr Clin North Am** 1997 Aug;44(4):991-1004 (84 ref.)

NEUROEFFECTOR JUNCTION

METABOLISM

Acetylcholine release at motor endplates and autonomic neuroeffector junctions: a comparison. Wessler I. **Pharmacol Res** 1996 Feb;33(2):81-94 (156 ref.)

PHYSIOLOGY

Transmission by post-ganglionic axons of the autonomic nervous system: the importance of the specialized neuroeffector junction. Hirst GD, et al. **Neuroscience** 1996 Jul;73(1):7-23 (144 ref.)

NEUROENDOCRINE SYSTEM see **NEUROSECRETORY**

SYSTEMS

NEUROENDOCRINE TUMORS

Neuroendocrine gastrointestinal tumours. Oberg K. **Ann Oncol** 1996 Jul;7(5):453–63 (119 ref.)

[Somatostatin receptors. A new way to diagnosis and therapy of neuroendocrine tumors] Wängberg B, et al. **Lakartidningen** 1997 Mar 5;94(10):829–30, 835–8 (20 ref.) (Eng. Abstr.) **(Swe)**

CLASSIFICATION

The biological relevance of gastric neuroendocrine tumors. Klöppel G, et al. **Yale J Biol Med** 1996 Jan–Feb;69(1):69–74 (42 ref.)

[Classification of neuroendocrine tumors of the gastrointestinal tract and pancreas and its therapeutic relevance] Höfler H, et al. **Chirurg** 1997 Feb;68(2):107–15 (46 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

A comparison of imaging techniques for the localisation of gastro–enteropancreatic neuroendocrine tumours. Chayvialle JA. **Digestion** 1996;57 Suppl 1:54–6 (12 ref.)

The ultimate biochemical diagnosis of neuroendocrine gastro–enteropancreatic tumours. Faiss S, et al. **Digestion** 1996;57 Suppl 1:48–9 (12 ref.)

The ultimate biochemical diagnosis of gastro–enteropancreatic tumours. Oberg K. **Digestion** 1996; 57 Suppl 1:45–7 (5 ref.)

Approaches to the diagnosis of gut neuroendocrine tumors: the last word (today). Modlin IM, et al. **Gastroenterology** 1997 Feb;112(2):583–90 (23 ref.)

Somatostatin receptor scintigraphy in the diagnosis of neuroendocrine gastroenteropancreatic tumors. Bäder M, et al. **Recent Results Cancer Res** 1996;142:137–62 (66 ref.)

[Neuroendocrine tumors] Schlumberger M, et al. **Ann Endocrinol (Paris)** 1997;58(2):95–9 (17 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Somatostatin analogue treatment of neuroendocrine tumours. de Herder WW, et al. **Postgrad Med J** 1996 Jul; 72(849):403–8 (32 ref.)

Drug therapy in metastatic neuroendocrine tumors of the gastroenteropancreatic system. Faiss S, et al. **Recent Results Cancer Res** 1996;142:193–207 (41 ref.)

GENETICS

Molecular approaches to neuroendocrine pathology. Steel JH, et al. **Cancer Metastasis Rev** 1997 Jun;16(1–2):179–205 (149 ref.)

Familial neuroendocrine tumors as a model of hereditary cancer. Anderson RJ, et al. **Curr Opin Oncol** 1997 Jan; 9(1):45–54 (85 ref.)

[Recent data on molecular genetics of neuroendocrine tumors] Calender A. **Ann Endocrinol (Paris)** 1997; 58(2):113–23 (86 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Gastroenteropancreatic tumours and prohormones. Rehfeld JF, et al. **Scand J Gastroenterol Suppl** 1996;216:39–45 (52 ref.)

PATHOLOGY

Gastrointestinal endocrine tumours. Pathology. Bishop AE, et al. **Baillieres Clin Gastroenterol** 1996 Dec;10(4):555–69 (65 ref.)

Peptide receptors in gut endocrine tumours. de Herder WW, et al. **Baillieres Clin Gastroenterol** 1996 Dec;10(4):571–87 (55 ref.)

Molecular approaches to neuroendocrine pathology. Steel JH, et al. **Cancer Metastasis Rev** 1997 Jun;16(1–2):179–205 (149 ref.)

Applications of immunogold and lectin–gold labeling in tumor research and diagnosis. Roth J, et al. **Histochem Cell Biol** 1996 Jul;106(1):131–48 (117 ref.)

Ovarian neuroendocrine carcinomas of non–small–cell type associated with surface epithelial adenocarcinomas. A study of five cases and review of the literature. Eichhorn JH, et al. **Int J Gynecol Pathol** 1996 Oct;15(4):303–14 (33 ref.)

Spectrum of neuroendocrine differentiation in lung cancer cell lines featured by cytomorphology, markers, and their corresponding tumors. Linnoila RI. **J Cell Biochem Suppl** 1996;24:92–106 (66 ref.)

Neuroendocrine tumors of the lung. Marchevsky AM. **Pathology (Phila)** 1996;4(1):103–23 (59 ref.)

PHYSIOPATHOLOGY

Biological aspects of neuroendocrine gastro–enteropancreatic tumours. Oberg K. **Digestion** 1996;57 Suppl 1:42–4 (5 ref.)

RADIONUCLIDE IMAGING

The current status of meta–iodobenzylguanidine and related agents for the diagnosis of neuro–endocrine tumors. Shapiro B, et al. **Q J Nucl Med** 1995 Dec;39(4 Suppl 1):3–8 (60 ref.)

SECONDARY

Liver transplantation for metastatic neuroendocrine tumors [see comments] Lang H, et al. **Ann Surg** 1997 Apr; 225(4):347–54 (34 ref.) Comment in: Ann Surg 1997 Apr;225(4):345–6.

Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31–case French multicentric report. Le Treut YP, et al. **Ann Surg** 1997 Apr; 225(4):355–64 (33 ref.)

[Diagnosis and therapy of liver metastases of neuroendocrine tumors] Lehnert T, et al. **Chirurg** 1997 Feb;68(2):122–31 (63 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Liver transplantation for metastatic neuroendocrine tumors [see comments] Lang H, et al. **Ann Surg** 1997 Apr; 225(4):347–54 (34 ref.) Comment in: Ann Surg 1997 Apr;225(4):345–6.

Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31–case French multicentric report. Le Treut YP, et al. **Ann Surg** 1997 Apr; 225(4):355–64 (33 ref.)

Surgical management of gastrointestinal endocrine tumours. Goldstone AP, et al. **Baillieres Clin Gastroenterol** 1996 Dec; 10(4):707–36 (125 ref.)

[Surgical relevance of diagnostic imaging of abdominal tumors—decision making in pancreatic tumor] Hopt UT, et al. **Chirurg** 1997 Apr;68(4):325–33 (46 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Gastrointestinal endocrine tumours: medical management. Arnold R, et al. **Baillieres Clin Gastroenterol** 1996 Dec; 10(4):737–59 (120 ref.)

Gut neuroendocrine tumors. Warner RR. **Curr Ther Endocrinol Metab** 1997;6:606–14 (4 ref.)

VETERINARY

Tumours of the lower respiratory tract. Mohr U, et al. **IARC Sci Publ** 1996;(126):189–222 (162 ref.)

NEUROENDOCRINOLOGY

Psychoneuroendoimmunology: the biological basis of the placebo phenomenon? [see comments] Jamison JR. **J Manipulative Physiol Ther** 1996 Sep;19(7):484–7 (47 ref.) Comment in: J Manipulative Physiol Ther 1997 Mar–Apr;20(3):224.

HISTORY

The neuropeptide story. Geoffrey Harris Lecture, Budapest, Hungary, July 1994. de Wied D. **Front Neuroendocrinol** 1997 Jan;18(1):101–13 (52 ref.)

NEUROEPITHELIOMA

Esthesioneuroblastoma: a general review of the cases published since the discovery of the tumour in 1924. Broich G, et al. **Anticancer Res** 1997 Jul–Aug;17(4A):2683–706 (261 ref.)

METABOLISM

Intra– and intercellular calcium signaling in human neuroepithelioma cells. Palmer RK, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):169–74 (6 ref.)

PATHOLOGY

Local spread of malignant neuroepithelial tumors. Laerum OD. **Acta Neurochir (Wien)** 1997;139(6):515–22 (91 ref.)

NEUROFIBRILLARY TANGLES

see related
NEUROFILAMENT PROTEINS

CHEMISTRY

Interaction of aluminum with paired helical filament tau is involved in neurofibrillary pathology of Alzheimer's disease. Shin RW. **Gerontology** 1997;43 Suppl 1:16–23 (60 ref.)

[Neuroimmunology of Alzheimer's disease] Novák M. **Bratisl Lek Listy** 1997 Jun;98(6):303–14 (178 ref.) (Eng. Abstr.) **(Slo)**

METABOLISM

Molecular basis of Alzheimer's disease. Gooch MD, et al. **Am J Health Syst Pharm** 1996 Jul 1;53(13):1545–57; quiz 1603–4 (122 ref.)

Molecular dissection of the neurofibrillary lesions of Alzheimer's disease. Goedert M, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:565–73 (57 ref.)

Protein folding, nucleation phenomena and delayed neurodegeneration in Alzheimer's disease. Fox N, et al. **Rev Neurosci** 1996 Jan–Mar;7(1):21–8 (61 ref.)

PATHOLOGY

The neurochemistry of Alzheimer's disease. Blennow K, et al. **Acta Neurol Scand Suppl** 1996;168:77–86 (129 ref.)

Discovery of new lesions in neurodegenerative diseases with monoclonal antibody techniques: is there a non–amyloid precursor to senile plaques? Dickson DW. **Am J Pathol** 1997 Jul;151(1):7–11 (33 ref.)

Molecular dissection of the neurofibrillary lesions of Alzheimer's disease. Goedert M, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:565–73 (57 ref.)

The neuropathological changes associated with normal brain aging. Hof PR, et al. **Histol Histopathol** 1996 Oct; 11(4):1075–88 (70 ref.)

Oxidative posttranslational modifications in Alzheimer disease. A possible pathogenic role in the formation of senile plaques and neurofibrillary tangles. Smith MA, et al. **Mol Chem Neuropathol** 1996 May–Aug;28(1–3):41–8 (41 ref.)

ULTRASTRUCTURE

An ultrastructural and molecular perspective of the pathological hallmarks of Alzheimer's disease. Sobow T. **Folia Neuropathol** 1996;34(1):55–62 (74 ref.)

[Characterization of glial fibrillary tangles in progressive supranuclear palsy and Alzheimer's disease] Nishimura M. **No To Shinkei** 1996 Oct;48(10):895–903 (32 ref.) **(Jpn)**

NEUROFIBRILS

see related
AMYLOID BETA–PROTEIN

PATHOLOGY

Oxidative stress, mutant SOD1, and neurofilament pathology in transgenic mouse models of human motor neuron disease. Tu PH, et al. **Lab Invest** 1997 Apr;76(4):441–56 (144 ref.)

NEUROFIBROMA

COMPLICATIONS

Right outflow tract obstruction by a pedunculated neurofibroma: case report and literature review. Henderson W, et al. **Can J Cardiol** 1997 Apr;13(4):387–90 (17 ref.)

Isolated colonic neurofibroma manifested by massive lower gastrointestinal bleeding and intussusception. Abramson LP, et al. **South Med J** 1997 Sep;90(9):952–4 (9 ref.)

DIAGNOSIS

[Diagnosis and treatment of peripheral nerve tumor] Usui M. **Nippon Seikeigeka Gakkai Zasshi** 1997 May; 71(5):161–70 (23 ref.) **(Jpn)**

PATHOLOGY

A case of Bednar tumor recurring after 23 years. Mochizuki Y, et al. **J Dermatol** 1996 Sep;23(9):614–8 (17 ref.)

Mesenteric neurofibroma in von Recklinghausen's disease. Kataria R, et al. **J Pediatr Surg** 1997 Jan;32(1):128–9 (9 ref.)

[Neurinomas–neurofibromas] Goujon JM, et al. **Neurochirurgie** 1997;43(1):35–8 (9 ref.) (Eng. Abstr.) **(Fre)**

NEUROFIBROMA, PLEXIFORM

Plexiform neurofibroma involving the genitourinary tract in children: case reports and review of the literature. Nguyen HT, et al. **Urology** 1997 Feb;49(2):257–60 (21 ref.)

COMPLICATIONS

Massive intratumor hemorrhage in facial plexiform neurofibroma. Tung TC, et al. **Head Neck** 1997 Mar; 19(2):158–62 (14 ref.)

PATHOLOGY

Multiple idiopathic mucosal neuromas: a minor form of multiple endocrine neoplasia type 2B or a new entity? Pujol RM, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):349–52 (22 ref.)

NEUROFIBROMATOSIS

Neurofibromatosis. Gabriel KR. **Curr Opin Pediatr** 1997 Feb; 9(1):89–93 (32 ref.)

COMPLICATIONS

Bilateral segmental neurofibromatosis with partial unilateral lentiginosis. Wong SS. **Br J Dermatol** 1997 Mar; 136(3):380–3 (32 ref.)

Dystrophic kyphoscoliosis in neurofibromatosis type I: a report of two cases and review of the literature. Vandenbroucke J, et al. **Eur Spine J** 1997;6(4):273–7 (15 ref.)

SURGERY

Bilateral acoustic neuromas. Anand VT, et al. **Clin Otolaryngol** 1993 Oct;18(5):365–71 (12 ref.)

[Therapy of renovascular hypertension in neurofibromatosis: surgical revascularization versus percutaneous transluminal angioplasty] Türler A, et al. **Vasa** 1996;25(4):368–72 (34 ref.) (Eng. Abstr.) **(Ger)**

NEUROFIBROMATOSIS 1

see related
GENES, NEUROFIBROMATOSIS 1

Neurofibromatosis type 1--an update and review for the primary pediatrician. Goldberg Y, et al. **Clin Pediatr (Phila)** 1996 Nov;35(11):545–61 (31 ref.)

[Neurofibromatosis, von Recklinghausen disease] Fujiwara Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):446–8 (9 ref.) **(Jpn)**

COMPLICATIONS

A case of membranous glomerulonephritis associated with Recklinghausen's neurofibromatosis. Tóth T, et al. **Clin Nephrol** 1996 Apr;45(4):271–2 (10 ref.)

Massive intratumor hemorrhage in facial plexiform neurofibroma. Tung TC, et al. **Head Neck** 1997 Mar; 19(2):158–62 (14 ref.)

Pulmonary manifestations in von Recklinghausen's disease [editorial; comment] Miyamoto K. **Intern Med** 1997 Jun; 36(6):381 (9 ref.) Comment on: Intern Med 1997 Jun;36(6):413–6.

Pancreatic cancer and hypercalcemia associated with von Recklinghausen's disease. Yamamoto M, et al. **J Gastroenterol** 1996 Oct;31(5):728–31 (28 ref.)

Special issues in the management of gliomas in children with neurofibromatosis 1. Pollack IF, et al. **J Neurooncol** 1996 May–Jun;28(2–3):257–68 (64 ref.)

Otolaryngologic manifestations of neurofibromatosis in children. Sobol SE, et al. **J Otolaryngol** 1997 Feb;26(1):13–9 (39 ref.)

Prolonged extreme thrombocytosis associated with neurofibromatosis type 1. Hasle H, et al. **J Pediatr** 1997 Feb;130(2):317–9 (14 ref.)

Orbital and eyelid manifestations of neurofibromatosis: a clinical study and literature review. Farris SR, et al. **Ophthal Plast Reconstr Surg** 1996 Dec;12(4):245–59 (133 ref.)

Endocrinologic disorders and optic pathway gliomas in children with neurofibromatosis type 1. Cnossen MH, et al. **Pediatrics** 1997 Oct;100(4):667–70 (24 ref.)

[Symptomatic arteriovenous fistula in a patient with neurofibromatosis type I] Anegawa S, et al. **No Shinkei Geka** 1997 Apr;25(4):373–8 (25 ref.) (Eng. Abstr.) **(Jpn)**

[Familial astrocytoma associated with von Recklinghausen's disease: report of two cases] Ito Y, et al. **No Shinkei Geka** 1997 Mar;25(3):283–8 (20 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Neurofibromatosis type 1 and type 2: review of the central nervous system and related structures. Inoue Y, et al. **Brain Dev** 1997 Jan;19(1):1–12 (26 ref.)

Neurofibromatosis 1 and 2. Pollack IF, et al. **Brain Pathol** 1997 Apr;7(2):823–36 (99 ref.)

Ophthalmological issues in the neurofibromatoses. Korf BR. **J Pediatr Ophthalmol Strabismus** 1996 Jul–Aug;33(4):255–9 (47 ref.)

The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. Gutmann DH, et al. **JAMA** 1997 Jul 2;278(1):51–7 (66 ref.)

Brain stem involvement in children with neurofibromatosis type 1: role of magnetic resonance imaging and spectroscopy in the distinction from diffuse pontine glioma. Broniscer A, et al. **Neurosurgery** 1997 Feb;40(2):331–7; discussion 337–8 (29 ref.)

Diagnosing neurofibromatosis type I in children. Davis RE. **Nurse Pract** 1997 Apr;22(4):73–6, 79–81 (29 ref.)

ETIOLOGY

[The main etiopathogenic mechanisms of neurocutaneous diseases] Vicente FJ, et al. **Rev Neurol** 1997 Sep;25 Suppl 3:S214–21 (63 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Neurocutaneous syndromes: neurofibromatosis 1, neurofibromatosis 2, and tuberous sclerosis. Korf BR. **Curr Opin Neurol** 1997 Apr;10(2):131–6 (63 ref.)

RNA processing and clinical variability in neurofibromatosis type I (NF1). Skuse GR, et al. **Hum Mol Genet** 1997; 6(10):1707–12 (53 ref.)

Molecular genetics of neurofibromatosis type 1 (NF1). Shen MH, et al. **J Med Genet** 1996 Jan;33(1):2–17 (216 ref.)

Neurofibromatosis and associated tumour suppressor genes. Zwarthoff EC. **Pathol Res Pract** 1996 Jul;192(7):647–57 (109 ref.)

Nf1 gene targeting: toward models and mechanisms. Cichowski K, et al. **Semin Cancer Biol** 1996 Oct;7(5):291–8 (52 ref.)

[Type 1 neurofibromatosis. Molecular and clinical aspects] Schweigerer L. **Hautarzt** 1996 Aug;47(8):591–8 (41 ref.) (Eng. Abstr.) **(Ger)**

[Familial astrocytoma associated with von Recklinghausen's disease: report of two cases] Ito Y, et al. **No Shinkei Geka** 1997 Mar;25(3):283–8 (20 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Mesenteric neurofibroma in von Recklinghausen's disease. Kataria R, et al. **J Pediatr Surg** 1997 Jan;32(1):128–9 (9 ref.)

[Neurinomas–neurofibromas] Goujon JM, et al. **Neurochirurgie** 1997;43(1):35–8 (9 ref.) (Eng. Abstr.) **(Fre)**

[Neurosarcoma associated with neurofibromatosis 1. Apropos of a case and review of the literature] Ligneau B, et al. **Presse Med** 1997 Mar 29;26(10):458–63 (24 ref.) (Eng. Abstr.) **(Fre)**

[A case of von Recklinghausen's disease complicated by adenocarcinoma of the papilla of Vater] Nagayama K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Feb;94(2):123–8 (16 ref.) **(Jpn)**

[Von Recklinghausen's disease: experimental models and comparative aspects] Turusov VS, et al. **Arkh Patol** 1996 Sep–Oct;58(5):3–13 (52 ref.) (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

Psychological aspects of von Recklinghausen neurofibromatosis (NF1) [see comments] Mouridsen SE, et al. **J Med Genet** 1995 Dec;32(12):921–4 (45 ref.) Comment in: J Med Genet 1996 Sep;33(9):806.

Cognitive function and academic performance in neurofibromatosis. 1: consensus statement from the NF1 Cognitive Disorders Task Force. North KN, et al. **Neurology** 1997 Apr;48(4):1121–7 (57 ref.)

NEUROFIBROMATOSIS 1 GENES see **GENES, NEUROFIBROMATOSIS 1**

NEUROFIBROMATOSIS 2

see related
GENES, NEUROFIBROMATOSIS 2

COMPLICATIONS

Meningioangiomatosis is associated with neurofibromatosis 2 but not with somatic alterations of the NF2 gene. Stemmer–Rachamimov AO, et al. **J Neuropathol Exp Neurol** 1997 May;56(5):485–9 (43 ref.)

DIAGNOSIS

Neurofibromatosis type 1 and type 2: review of the central nervous system and related structures. Inoue Y, et al. **Brain Dev** 1997 Jan;19(1):1–12 (26 ref.)

Neurofibromatosis 1 and 2. Pollack IF, et al. **Brain Pathol** 1997 Apr;7(2):823–36 (99 ref.)

Ophthalmological issues in the neurofibromatoses. Korf BR. **J Pediatr Ophthalmol Strabismus** 1996 Jul–Aug;33(4):255–9 (47 ref.)

The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. Gutmann DH, et al. **JAMA** 1997 Jul 2;278(1):51–7 (66 ref.)

Neurofibromatosis type 2: The future holds hope. Ramsden RT. **Rev Laryngol Otol Rhinol (Bord)** 1996;117(3):171–4 (15 ref.)

GENETICS

A point mutation associated with a severe phenotype of neurofibromatosis 2. MacCollin M, et al. **Ann Neurol** 1996 Sep;40(3):440–5 (29 ref.)

Neurofibromatosis 2: loss of merlin's protective spell. Gusella JF, et al. **Curr Opin Genet Dev** 1996 Feb;6(1):87–92 (65 ref.)

Neurocutaneous syndromes: neurofibromatosis 1, neurofibromatosis 2, and tuberous sclerosis. Korf BR. **Curr Opin Neurol** 1997 Apr;10(2):131–6 (63 ref.)

Meningioangiomatosis is associated with neurofibromatosis 2 but not with somatic alterations of the NF2 gene. Stemmer–Rachamimov AO, et al. **J Neuropathol Exp Neurol** 1997 May;56(5):485–9 (43 ref.)

Molecular insights into neurofibromatosis 2. Gutmann DH. **Neurobiol Dis** 1997;3(4):247–61 (83 ref.)

Neurofibromatosis and associated tumour suppressor genes. Zwarthoff EC. **Pathol Res Pract** 1996 Jul;192(7):647–57 (109 ref.)

PATHOLOGY

Cerebral meningioangiomatosis: case report. Tacconi L, et al. **Surg Neurol** 1997 Sep;48(3):255–60 (20 ref.)

[Von Recklinghausen's disease: experimental models and comparative aspects] Turusov VS, et al. **Arkh Patol** 1996 Sep–Oct;58(5):3–13 (52 ref.) (Eng. Abstr.) **(Rus)**

NEUROFIBROMATOSIS 2 GENES see **GENES, NEUROFIBROMATOSIS 2**

NEUROFIBROMATOSIS, ACOUSTIC, BILATERAL see **NEUROFIBROMATOSIS 2**

NEUROFIBROMATOSIS, CENTRAL, NF2 see **NEUROFIBROMATOSIS 2**

NEUROFIBROMATOSIS, PERIPHERAL, NF1 see **NEUROFIBROMATOSIS 1**

NEUROFIBROSARCOMA

PATHOLOGY

[Neurosarcoma associated with neurofibromatosis 1. Apropos of a case and review of the literature] Ligneau B, et al. **Presse Med** 1997 Mar 29;26(10):458–63 (24 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Surgical conditions of the cervical spine. Tomlinson J. **Semin Vet Med Surg (Small Anim)** 1996 Nov;11(4):225–34 (28 ref.)

NEUROFILAMENT PROTEINS

IMMUNOLOGY

Autoimmunity to ion–channels and other proteins in paraneoplastic disorders. Lang B, et al. **Curr Opin Immunol** 1996 Dec;8(6):865–71 (55 ref.)

PHYSIOLOGY

Presynaptic phosphoprotein B–50/GAP–43 in neuronal and synaptic plasticity. Biewenga JE, et al. **Acta Biochim Pol** 1996;43(2):327–38 (121 ref.)

Neuronal intermediate filaments. Lee MK, et al. **Annu Rev Neurosci** 1996;19:187–217 (229 ref.)

Neurofilaments, radial growth of axons, and mechanisms of motor neuron disease. Williamson TL, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:709–23 (73 ref.)

Morphology and neurochemical characteristics of the vulnerable neurons in brain aging and Alzheimer's disease. Hof PR. **Eur Neurol** 1997;37(2):71–81 (90 ref.)

Neurofilamentous swellings and axonal atrophy are of unclear significance to diketone toxicity: commentary on forum position paper [comment] Sickles DW. **Neurotoxicology** 1997;18(1):33–6; discussion 37–40 (15 ref.) Comment on: Neurotoxicology 1997 ;18(1):7–22.

NEUROGLIA

Glial choristoma in the oral cavity: histopathologic and immunohistochemical features. Ide F, et al. **J Oral Pathol Med** 1997 Mar;26(3):147–50 (28 ref.)

Cutaneous neural heterotopias and related tumors relevant for the dermatopathologist. Argenyi ZB. **Semin Diagn Pathol** 1996 Feb;13(1):60–71 (62 ref.)

[Neuroglial heterotopia. Apropos of 8 cases with non–nasofrontal sites] Loundon N, et al. **Ann Otolaryngol Chir Cervicofac** 1997;114(1–2):29–35 (27 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Neuronal and glial localization of NMDA receptors in the cerebral cortex. Conti F, et al. **Mol Neurobiol** 1997 Feb–Apr;14(1–2):1–18 (85 ref.)

CYTOLOGY

The generation of cellular diversity in the cerebral cortex. Price J, et al. **Ciba Found Symp** 1995;193:71–84; discussion 117–26 (13 ref.)

Fractal methods and results in cellular morphology--dimensions, lacunarity and multifractals. Smith TG JR, et al. **J Neurosci Methods** 1996 Nov; 69(2):123–36 (35 ref.)

Stem cells in the central nervous system. McKay R. **Science** 1997 Apr 4;276(5309):66–71 (72 ref.)

[Identification of NPDC–1, gene involved in the control of proliferation and differentiation of neural and glial precursors] Dupont E, et al. **C R Seances Soc Biol Fil** 1997; 191(1):95–104 (34 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Modulation of neuronal and glial cell function by adenosine and neuroprotection in vascular dementia. Rudolphi KA, et al. **Behav Brain Res** 1997 Feb;83(1–2):123–8 (27 ref.)

Assessment of neurotoxicity and "neuroprotection". O'Byrne M, et al. **J Neural Transm Suppl** 1997;50:153–64 (51 ref.)

ENZYMOLOGY

Regulation of inducible nitric oxide synthase expression in human glia: implications for inflammatory central nervous system diseases. Brosnan CF, et al. **Biochem Soc Trans** 1997 May;25(2):679–83 (32 ref.)

IMMUNOLOGY

The central nervous system as an immunocompetent organ: role of glial cells in antigen presentation. Shrikant P, et al. **J Immunol** 1996 Sep 1;157(5):1819–22 (69 ref.)

Cellular immune reactions directed against Toxoplasma gondii with special emphasis on the central nervous system. Däubener W, et al. **Med Microbiol Immunol (Berl)** 1997 Mar;185(4):195–206 (133 ref.)

Inflammatory mechanisms in Alzheimer disease: the role of beta–amyloid/glial interactions. Pachter JS. **Mol Psychiatry** 1997 Mar;2(2):91–5 (58 ref.)

METABOLISM

Regulation of preproenkephalin expression in astrocytes: is there a role for glia-derived opioid peptides in reactive gliosis? McMillian MK, et al. **Crit Rev Neurobiol** 1994; 9(1):91–103 (109 ref.)

Potassium homeostasis and glial energy metabolism. Amédée T, et al. **Glia** 1997 Sep;21(1):46–55 (85 ref.)

Use of fluorocitrate and fluoroacetate in the study of brain metabolism. Fonnum F, et al. **Glia** 1997 Sep;21(1):106–13 (58 ref.)

Glucose transporter proteins in brain: delivery of glucose to neurons and glia. Vannucci SJ, et al. **Glia** 1997 Sep; 21(1):2–21 (140 ref.)

Development and organization of glial cells in Drosophila melanogaster. Giangrande A. **Int J Dev Biol** 1996 Oct; 40(5):917–27 (84 ref.)

Ion channels in neuroglial cells. Oh Y.
Kao Hsiung I Hsueh Ko Hsueh Tsa Chih 1997 Jan;13(1):1–9 (53 ref.)

Glial cell derived neurotrophic factors and Alzheimer's disease. Patel AJ, et al. **Neurodegeneration** 1996 Dec; 5(4):489–96 (43 ref.)

Response of glial cells to ischemia: roles of reactive oxygen species and glutathione. Juurlink BH.
Neurosci Biobehav Rev 1997 Mar;21(2):151–66 (176 ref.)

Endothelial and glial cell interaction in diabetic retinopathy via the function of vascular endothelial growth factor (VEGF). Sueishi K, et al. **Pol J Pharmacol** 1996 May–Jun; 48(3):307–16 (30 ref.)

News on glutamate receptors in glial cells. Steinhäuser C, et al. **Trends Neurosci** 1996 Aug;19(8):339–45 (99 ref.)

[Imaging of calcium signaling in brain glial cells and adrenocortical cells] Kawato S, et al.
Tanpakushitsu Kakusan Koso 1997 May;42(7 Suppl):1227–32 (7 ref.) **(Jpn)**

PATHOLOGY

Malignant supratentorial glial–neuronal neoplasms: report of two cases and review of the literature. McLendon RE, et al. **Arch Pathol Lab Med** 1997 May;121(5):485–92 (45 ref.)

Glia: the not so innocent bystanders. Chao CC, et al.
J Neurovirol 1996 Aug;2(4):234–9 (60 ref.)

PHYSIOLOGY

Microimplantation of glial cells to promote regeneration of a lesioned fiber tract in the adult mammalian brain. Müller HW, et al. **Adv Neurol** 1997;73:29–36 (34 ref.)

Programmed cell death in the developing nervous system. Burek MJ, et al. **Brain Pathol** 1996 Oct;6(4):427–46 (156 ref.)

Axon–glia interactions: building a smart nerve fiber. Waxman SG. **Curr Biol** 1997 Jul 1;7(7):R406–10 (29 ref.)

New views on synapse–glia interactions. Pfrieger FW, et al. **Curr Opin Neurobiol** 1996 Oct;6(5):615–21 (79 ref.)

Periventricular leukomalacia, glial development and myelination. Takashima S, et al. **Early Hum Dev** 1995 Oct 2;43(2):177–84 (40 ref.)

Molecular bases of myelin formation as revealed by investigations on mice deficient in glial cell surface molecules. Martini R, et al. **Glia** 1997 Apr;19(4):298–310 (88 ref.)

Determinants of axonal regeneration. Frisén J.
Histol Histopathol 1997 Jul;12(3):857–68 (157 ref.)

The role of glia in the neuroendocrine hypothalamus: possible implications in hormone secretion. Chowen JA, et al.
Horm Res 1996;45 Suppl 1:15–8 (10 ref.)

Glial lineages and myelination in the central nervous system. Compston A, et al. **J Anat** 1997 Feb;190 (Pt 2):161–200 (360 ref.)

Glial–glial and glial–neuronal interfaces in radiation-induced, glia-depleted spinal cord. Gilmore SA, et al. **J Anat** 1997 Jan;190 (Pt 1):5–21 (51 ref.)

Roles of metabotropic glutamate receptors in glial function and glial–neuronal communication. Winder DG, et al.
J Neurosci Res 1996 Oct 15;46(2):131–7 (63 ref.)

Neuroglial ATF/CREB factors interact with the human immunodeficiency virus type 1 long terminal repeat. Krebs FC, et al. **J Neurovirol** 1997 May;3 Suppl 1:S28–32 (28 ref.)

The role of chronic self-propagating glial responses in neurodegeneration: implications for long-lived survivors of human immunodeficiency virus. Mrak RE, et al.
J Neurovirol 1997 Aug;3(4):241–6 (52 ref.)

Signaling molecules and neuroglial activation in the injured central nervous system. Raivich G, et al. **Keio J Med** 1996 Sep;45(3):239–47 (115 ref.)

Modulation of glial cell signaling by adenosine and pharmacological reinforcement. A neuroprotective strategy? Schubert P, et al. **Mol Chem Neuropathol** 1996 May–Aug;28(1–3):185–90 (19 ref.)

Neurosteroids, with special reference to the effect of progesterone on myelination in peripheral nerves. Baulieu EE, et al. **Mult Scler** 1997 Apr;3(2):105–12 (51 ref.)

Nitric oxide precursor arginine and S-nitrosoglutathione in synaptic and glial function. Do KQ, et al.
Neurochem Int 1996 Sep;29(3):213–24 (94 ref.)

Axon decussation and midline glia in the developing ferret auditory hindbrain. Brunso-Bechtold JK, et al.
Prog Brain Res 1996;108:165–81 (67 ref.)

Proteoglycans and other repulsive molecules in glial boundaries during development and regeneration of the nervous system. Höke A, et al. **Prog Brain Res** 1996; 108:149–63 (123 ref.)

Unilateral containment of retinal axons by tectal glia: a possible role for sulfated proteoglycans. Jhaveri S, et al. **Prog Brain Res** 1996;108:135–48 (104 ref.)

Glia–neuron intercommunications and synaptic plasticity. Vernadakis A. **Prog Neurobiol** 1996 Jun;49(3):185–214 (292 ref.)

Signalling from neurones to glial cells in invertebrates. Coles JA, et al. **Trends Neurosci** 1996 Aug;19(8):358–62 (35 ref.)

The Müller cell: a functional element of the retina. Newman E, et al. **Trends Neurosci** 1996 Aug;19(8):307–12 (58 ref.)

NF-kappa B: a crucial transcription factor for glial and neuronal cell function. O'Neill LA, et al.
Trends Neurosci 1997 Jun;20(6):252–8 (64 ref.)

Glial–neuronal interactions in non-synaptic areas of the brain: studies in the optic nerve. Ransom BR, et al.
Trends Neurosci 1996 Aug;19(8):352–8 (52 ref.)

Voltage-gated Na+ channels in glia: properties and possible functions. Sontheimer H, et al. **Trends Neurosci** 1996 Aug; 19(8):325–31 (67 ref.)

Neurone–glia interactions in the hypothalamus and pituitary. Theodosis DT, et al. **Trends Neurosci** 1996 Aug;19(8):363–7 (46 ref.)

Calcium signalling in glial cells. Verkhratsky A, et al.
Trends Neurosci 1996 Aug;19(8):346–52 (89 ref.)

[Communicating junctions of glial cells in the central nervous system] Giaume C. **Ann Endocrinol (Paris)** 1996; 57(6):487–91 (39 ref.) (Eng. Abstr.) **(Fre)**

[Potassium channels in glial cells] Horio Y, et al.
Nippon Yakurigaku Zasshi 1997 Mar;109(3):103–10 (48 ref.) (Eng. Abstr.) **(Jpn)**

[Ca2+ dynamics in glial cells] Kudo Y.
Nippon Yakurigaku Zasshi 1997 Mar;109(3):111–7 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Interaction between neurons and astrocytes involved in brain regulatory function as assessed by in vitro brain ischemia models] Watanabe Y, et al. **Nippon Yakurigaku Zasshi** 1997 Mar;109(3):119–28 (35 ref.) (Eng. Abstr.) **(Jpn)**

SECRETION

Glia-derived cytokines and the biogenesis of amyloid plaques in Alzheimer's disease. Patel AJ, et al. **Mol Psychiatry** 1997 Mar;2(2):130–2 (20 ref.)

TRANSPLANTATION

The role of microenvironment in axonal regeneration. Influences of lesion-induced changes and glial implants on the regeneration of the postcommissural fornix. Stichel-Gunkel CC. **Adv Anat Embryol Cell Biol** 1997; 137:I–VII, 1–81 (355 ref.)

The use of transplanted glial cells to reconstruct glial environments in the CNS. Blakemore WF, et al.
Brain Pathol 1995 Oct;5(4):443–50 (83 ref.)

Multipotent neural progenitor or stem-like cells may be uniquely suited for therapy for some neurodegenerative conditions. Snyder EY, et al. **Clin Neurosci** 1995–96; 3(5):310–6 (43 ref.)

ULTRASTRUCTURE

Three-dimensional confocal light and electron microscopy of central nervous system tissue and neurons and glia in culture. Turner JN, et al. **Int Rev Exp Pathol** 1996;36:53–72 (88 ref.)

Axoglial dysjunction: a critical appraisal of definition, techniques, and previous results. Giannini C, et al.
Microsc Res Tech 1996 Aug 1;34(5):436–44 (17 ref.)

Clustering sodium channels at the node of Ranvier: close encounters of the axon–glia kind. Salzer JL. **Neuron** 1997 Jun;18(6):843–6 (24 ref.)

VIROLOGY

Neuroglial ATF/CREB factors interact with the human immunodeficiency virus type 1 long terminal repeat. Krebs FC, et al. **J Neurovirol** 1997 May;3 Suppl 1:S28–32 (28 ref.)

Cytokines secreted by glial cells infected with HTLV-I modulate the expression of matrix metalloproteinases (MMPs) and their natural inhibitor (TIMPs): possible involvement in neurodegenerative processes. Giraudon P, et al. **Mol Psychiatry** 1997 Mar;2(2):107–10, 84 (23 ref.)

NEUROHEMAL ORGAN see **NEUROSECRETORY SYSTEMS**

NEUROHUMOR RECEPTORS see **RECEPTORS, NEUROTRANSMITTER**

NEUROHUMORS see **NEUROTRANSMITTERS**

NEUROHYPOPHYSIS see **PITUITARY GLAND, POSTERIOR**

NEUROIMMUNE PROCESSES see **NEUROIMMUNOMODULATION**

NEUROIMMUNOMODULATION

Neuroimmune mechanisms in health and disease: 1. Health. Anisman H, et al. **Can Med Assoc J** 1996 Oct 1; 155(7):867–74 (45 ref.)

Psychoneuroimmunology and its relationship to the differential diagnosis of temporomandibular disorders. Auvenshine RC. **Dent Clin North Am** 1997 Apr; 41(2):279–96 (21 ref.)

Positive and negative immunomodulation by opioid peptides. Roda LG, et al. **Int J Immunopharmacol** 1996 Jan; 18(1):1–16 (167 ref.)

CRH and the immune system. Karalis K, et al.
J Neuroimmunol 1997 Feb;72(2):131–6 (87 ref.)

Passage of cytokines across the blood–brain barrier. Banks WA, et al. **Neuroimmunomodulation** 1995 Jul–Aug; 2(4):241–8 (77 ref.)

The autonomic nervous system as a communication channel between the brain and the immune system. Hori T, et al.
Neuroimmunomodulation 1995 Jul–Aug;2(4):203–15 (101 ref.)

Cytokines and fever. Kluger MJ, et al.
Neuroimmunomodulation 1995 Jul–Aug;2(4):216–23 (52 ref.)

The submandibular gland: a key organ in the neuro–immuno–regulatory network? Sabbadini E, et al.
Neuroimmunomodulation 1995 Jul–Aug;2(4):184–202 (205 ref.)

Brain–periphery connections: do they play a role in mediating the effect of centrally injected interleukin-1 beta on gonadal function? Turnbull A, et al.
Neuroimmunomodulation 1995 Jul–Aug;2(4):224–35 (79 ref.)

Mind–body medicine in primary care. Implications and applications. Lazar JS. **Prim Care** 1996 Mar;23(1):169–82 (71 ref.)

[Is the immune system our sixth sense? Relation between the immune and neuroendocrine systems] Ferenčík M, et al.
Bratisl Lek Listy 1997 Apr;98(4):187–98 (84 ref.) (Eng. Abstr.) **(Slo)**

DRUG EFFECTS

A brief review of immunomodulation caused by acute administration of ethanol: involvement of neuroendocrine pathways. Pruett SB, et al. **Alcohol Alcohol Suppl** 1994; 2:431–7 (44 ref.)

Beta-endorphin and the immune system--possible role in autoimmune diseases. Mørch H, et al. **Autoimmunity** 1995; 21(3):161–71 (96 ref.)

IMMUNOLOGY

Immune system–neuroendocrine dysregulation in spinal cord injury. Cruse JM, et al. **Immunol Res** 1996;15(4):306–14 (46 ref.)

Neuroimmunomodulation: a brief review. Can conditioning of natural killer cell activity reverse cancer and/or aging? Spector NH. **Regul Toxicol Pharmacol** 1996 Aug;24(1 Pt 2):S32–8 (46 ref.)

PHYSIOLOGY

Interdependence of the endocrine and immune systems. Dardenne M, et al. **Adv Neuroimmunol** 1996;6(4):297–307 (73 ref.)

T cell development within the intestinal mucosa: clues to a novel immune–endocrine network? Klein JR.
Adv Neuroimmunol 1996;6(4):397–405 (43 ref.)

Immunomodulation of peripheral lymphocytes by hormones of the hypothalamus–pituitary–thyroid axis. Kruger TE.
Adv Neuroimmunol 1996;6(4):387–95 (63 ref.)

Mechanisms for nitric oxide–induced cell death: involvement of apoptosis. Nicotera P, et al. **Adv Neuroimmunol** 1995; 5(4):411–20 (58 ref.)

Immunoregulatory role of neurotransmitters. Qiu Y, et al.
Adv Neuroimmunol 1996;6(3):223–31 (51 ref.)

Neuroimmune mechanisms in health and disease: 2. Disease. Anisman H, et al. **Can Med Assoc J** 1996 Oct 15; 155(8):1075–82 (63 ref.)

Anti–inflammatory actions of the neuroimmunomodulator alpha–MSH. Lipton JM, et al. **Immunol Today** 1997 Mar; 18(3):140–5 (39 ref.)

Neuroimmune mechanisms in Parkinson's disease. Kuhn W, et al. **J Neural Transm Suppl** 1995;46:229–33 (28 ref.)

The LHRH–astroglial network of signals as a model to study neuroimmune interactions: assessment of messenger systems and transduction mechanisms at cellular and molecular levels. Marchetti B. **Neuroimmunomodulation** 1996 Jan–Feb;3(1):1–27 (179 ref.)

Neuroimmunomodulation via limbic structures--the neuroanatomy of psychoimmunology. Haas HS, et al.
Prog Neurobiol 1997 Feb;51(2):195–222 (426 ref.)

The neuroimmunology of stress from invertebrates to man [published erratum appears in Prog Neurobiol 1996 Jun;49(3):285] Ottaviani E, et al. **Prog Neurobiol** 1996 Mar–Apr;48(4–5):421–40 (103 ref.)

NEUROKININ A

see related
RECEPTORS, NEUROKININ-2

METABOLISM

Tachykinins in the gut. Part I. Expression, release and motor function. Holzer P, et al. **Pharmacol Ther** 1997; 73(3):173–217 (504 ref.)

NEUROKININ A

PHYSIOLOGY

Beta-blocker induced asthma: a role for sensory nerve hyperresponsiveness? [editorial; comment] Belvisi M. **Clin Exp Allergy** 1996 Dec;26(12):1343–6 (29 ref.) Comment on: Clin Exp Allergy 1996 Dec;26(12):1428–35.

Tachykinins in the gut. Part II. Roles in neural excitation, secretion and inflammation. Holzer P, et al. **Pharmacol Ther** 1997;73(3):219–63 (539 ref.)

NEUROKININ A RECEPTORS see **RECEPTORS, NEUROKININ-2**

NEUROKININ-1 RECEPTORS see **RECEPTORS, NEUROKININ-1**

NEUROKININ-2 RECEPTORS see **RECEPTORS, NEUROKININ-2**

NEUROLEPTIC MALIGNANT SYNDROME

[Neuroleptic malignant syndrome, syndrome malin] Takahashi A, et al. **Nippon Rinsho** 1996 Mar;54(3):839–44 (26 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Dysarthric disorders associated with the neuroleptic malignant syndrome. Kozian R, et al. **Pharmacopsychiatry** 1996 Nov;29(6):220–2 (33 ref.)

[Serotonin syndrome: critical review of the literature] Baubet T, et al. **Rev Med Interne** 1997;18(5):380–7 (60 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Neuroleptic malignant syndrome] Bryois C, et al. **Rev Med Suisse Romande** 1996 Sep;116(9):713–7 (17 ref.) **(Fre)**

[Neuroleptic malignant syndrome and acute life-threatening catatonia—two contrasting disease entities?] Heils A, et al. **Fortschr Neurol Psychiatr** 1997 Jan;65(1):8–15 (75 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Risperidone-induced neuroleptic malignant syndrome: a case report and review. Meterissian GB. **Can J Psychiatry** 1996 Feb;41(1):52–4 (9 ref.)

Metoclopramide in a patient with renal failure may be an increased risk of neuroleptic malignant syndrome [letter] Fujita Y, et al. **Intensive Care Med** 1996 Jul;22(7):717 (5 ref.)

Neuroleptic malignant syndrome: case report and review. Dykstra TJ, et al. **J Am Osteopath Assoc** 1997 Jun; 97(6):355–7 (10 ref.)

Neuroleptic malignant syndrome and acute myocardial infarction: case report and review. Freedman MD. **Md Med J** 1997 Aug;46(7):357–9 (18 ref.)

Myoglobinuria, malignant hyperthermia, neuroleptic malignant syndrome and serotonin syndrome. Bertorini TE. **Neurol Clin** 1997 Aug;15(3):649–71 (193 ref.)

NURSING

Catastrophic consequences secondary to psychotropic drugs, Part 1. Keltner NL. **J Psychosoc Nurs Ment Health Serv** 1997 Apr;35(4):41–5 (35 ref.)

PHYSIOPATHOLOGY

Disorders of temperature regulation. Lee-Chiong TL Jr, et al. **Compr Ther** 1995 Dec;21(12):697–704 (25 ref.)

PSYCHOLOGY

[Neuroleptic malignant syndrome from treatment with antidepressives] Heinemann F, et al. **Fortschr Neurol Psychiatr** 1997 May;65(5):208–13 (34 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Neuroleptic malignant syndrome: case report and review. Dykstra TJ, et al. **J Am Osteopath Assoc** 1997 Jun; 97(6):355–7 (10 ref.)

NEUROLEPTICS see **ANTIPSYCHOTIC AGENTS**

NEUROLOGIC EXAMINATION

Neurophysiologic evaluation of cyclosporine toxicity associated with bone marrow transplantation [corrected and republished article originally printed in Acta Neurol Scand 1995 Nov;92(5):423-9] Edwards LL, et al. **Acta Neurol Scand** 1996 Nov;94(5):358–64 (22 ref.)

The assessment of general movements is a valuable technique for the detection of brain dysfunction in young infants. A review. Hadders-Algra M. **Acta Paediatr Suppl** 1996 Oct;416:39–43 (60 ref.)

Neurologic anomalies of Perrault syndrome. Gottschalk ME, et al. **Am J Med Genet** 1996 Nov 11;65(4):274–6 (10 ref.)

Physician and patient-oriented outcomes in progressive neurological disease: which to measure? Hobart JC, et al. **Curr Opin Neurol** 1996 Dec;9(6):441–4 (34 ref.)

Distal, "Tinel-like" percussion paresthesiae, with proximal nerve lesions. Jabre JF. **Electromyogr Clin Neurophysiol** 1996 Apr-May;36(3):175–8 (16 ref.)

The neurologic examination. Sturmann K. **Emerg Med Clin North Am** 1997 Aug;15(3):491–506 (9 ref.)

Preoperative evaluation of the adult neurosurgical patient. Fischer SP. **Int Anesthesiol Clin** 1996 Fall;34(4):21–32 (47 ref.)

Conceptualization of agitation: results based on the Cohen-Mansfield Agitation Inventory and the Agitation Behavior Mapping Instrument. Cohen-Mansfield J. **Int Psychogeriatr** 1996;8 Suppl 3:309–15; discussion 351–4 (45 ref.)

Operative treatment of spontaneous spinal epidural hematomas: a study of the factors determining postoperative outcome. Groen RJ, et al. **Neurosurgery** 1996 Sep;39(3):494–508; discussion 508–9 (22 ref.)

[Differential sciatica pain diagnosis from the neurologic viewpoint] Lindner A, et al. **Med Klin** 1997 Jun 15; 92(6):335–43 (83 ref.) (Eng. Abstr.) **(Ger)**

[Prognosis of traumatic spinal cord lesions. Significance of clinical and electrophysiological findings] Curt A, et al. **Nervenarzt** 1997 Jun;68(6):485–95 (154 ref.) (Eng. Abstr.) **(Ger)**

[Transcranial magnetic stimulation. A diagnostic means from neurology as therapy in psychiatry?] Haag C, et al. **Nervenarzt** 1997 Mar;68(3):274–8 (29 ref.) (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

[Therapy of myasthenia gravis with cholinesterase inhibitors—principles and pharmacologic monitoring] Henze T. **Fortschr Neurol Psychiatr** 1996 Mar;64(3):110–21 (92 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Neurological assessment of the preterm infant. de Vries LS. **Acta Paediatr** 1996 Jul;85(7):765–71 (89 ref.)

Assessing neurologic function in older patients. Crigger N, et al. **Am J Nurs** 1997 Mar;97(3):37–40 (10 ref.)

Physical evaluation of the peripheral nervous system in disorders of pain and dysfunction. Elvey RL. **J Hand Ther** 1997 Apr-Jun;10(2):122–9 (29 ref.)

Case history: cornerstone in the neuro-ophthalmic examination. Carr L. **Optom Clin** 1996;5(3–4):17–32 (26 ref.)

[Proven tests in neurological diagnosis] Oosterhuis HJ. **Ned Tijdschr Geneeskd** 1996 Nov 2;140(44):2171–5 (28 ref.) **(Dut)**

STANDARDS

Fetal habituation: another Pandora's box? Hepper PG. **Dev Med Child Neurol** 1997 Apr;39(4):274–8 (45 ref.)

STATISTICS & NUMERICAL DATA

[Interrater studies of evaluating the reliability of somatic findings] Saur PM, et al. **Rehabilitation (Stuttg)** 1996 Aug; 35(3):150–60 (37 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

[Clinical examination upon suspicion of bovine spongiform encephalopathy (BSE)] Braun U, et al. **Schweiz Arch Tierheilkd** 1997;139(1):35–41 (9 ref.) (Eng. Abstr.) **(Ger)**

NEUROLOGIC MODELS see **MODELS, NEUROLOGICAL**

NEUROLOGY

see related
NERVOUS SYSTEM DISEASES

Central nervous system remyelination clinical application of basic neuroscience principles. Miller DJ, et al. **Brain Pathol** 1996 Jul;6(3):331–44 (101 ref.)

Role of the neurologist in hazard identification and risk assessment. Feldman RG, et al. **Environ Health Perspect** 1996 Apr;104 Suppl 2:227–37 (27 ref.)

The World Health Organization's global initiative on neurology and public health. Janca A, et al. **J Neurol Sci** 1997 Jan;145(1):1–2 (4 ref.)

Neuro-ophthalmology of the pregeniculate afferent visual system. Developments in 1996 (Part II). Balcer LJ, et al. **J Neuroophthalmol** 1997 Jun;17(2):127–42 (217 ref.)

Continuous quality improvement (CQI) in neuropathology. Pearl GS, et al. **J Neuropathol Exp Neurol** 1996 Aug; 55(8):875–9 (22 ref.)

[Impact of molecular genetics to clinical neurology] Tsuji S. **Seishin Shinkeigaku Zasshi** 1996;98(9):622–8 (36 ref.) **(Jpn)**

[Two literary characters in the language of neurology: Pickwick (1)] Navarro FA. **Rev Neurol** 1997 Aug; 25(144):1297–302 (92 ref.) **(Spa)**

[Diet and neurology (I). Basis for nutrition] Picó AM, et al. **Rev Neurol** 1996 Apr;24(128):400–5 (5 ref.) **(Spa)**

HISTORY

Cognitive neurotoxicology: a luxury or necessity? Stollery BT. **Neurotoxicol Teratol** 1996 Jul-Aug;18(4):359–64 (32 ref.)

Centenary of the synapse: from Sherrington to the molecular biology of the synapse and beyond. Shepherd GM, et al. **Trends Neurosci** 1997 Sep;20(9):385–92 (72 ref.)

INSTRUMENTATION

Technology review: nervepace digital electroneurometer. Chaudhry V. **Muscle Nerve** 1997 Sep;20(9):1200–3 (7 ref.)

Cognitive neurotoxicology: a luxury or necessity? Stollery BT. **Neurotoxicol Teratol** 1996 Jul-Aug;18(4):359–64 (32 ref.)

METHODS

Brain-mapping neurotoxicity and neuropathology. Toga AW. **Ann N Y Acad Sci** 1997 May 30;820:1–13 (50 ref.)

Caged compounds: tools for illuminating neuronal responses and connections. Nerbonne JM. **Curr Opin Neurobiol** 1996 Jun;6(3):379–86 (54 ref.)

Methodological considerations in neurobehavioral teratology. Spear LP, et al. **Pharmacol Biochem Behav** 1996 Dec;55(4):455–7 (22 ref.)

[A look at neurology] Regli F. **Rev Med Suisse Romande** 1997 Jun;117(6):513–7 (39 ref.) **(Fre)**

[A look at neurology] Regli F. **Rev Med Suisse Romande** 1997 Aug;117(8):607–11 (29 ref.) **(Fre)**

ORGANIZATION & ADMINISTRATION

A discussion paper on the bases of practice in neurological physiotherapy: a response [comment] [see comments] Shepherd R. **Physiother Res Int** 1996;1(4):265–8 (22 ref.) Comment on: Physiother Res Int 1996;1(3):205–8. Comment in: Physiother Res Int 1997;2(2):62–4.

STANDARDS

Ethical considerations in neuroclinical trials. Macciocchi SN, et al. **Neurosurg Rev** 1997;20(3):161–70 (42 ref.)

TRENDS

What is child neurology? Aicardi J. **Brain Dev** 1995;17 Suppl:17–9 (2 ref.)

Neonatal neurology, past present and future. A window on the brain. Dubowitz LM, et al. **Brain Dev** 1995;17 Suppl:22–30 (34 ref.)

Advances in the genetics of hereditary hypertrophic neuropathy in childhood. Ouvrier RA, et al. **Brain Dev** 1995;17 Suppl:31–8 (66 ref.)

Child neurology in Taiwan, ROC: past, present and future. Shen YZ. **Brain Dev** 1995;17 Suppl:20–1 (2 ref.)

Neuro-ophthalmology update [published erratum appears in Can J Ophthalmol 1996 Jun;31(4):207] Anderson DP. **Can J Ophthalmol** 1996 Feb;31(1):2–10 (30 ref.)

The explosion of neurogenetics [editorial] Hurko O. **Curr Opin Neurol** 1997 Apr;10(2):77–83 (103 ref.)

Introduction: metabolic trafficking comes of age in the decade of the brain. McKenna MC. **Dev Neurosci** 1996; 18(5–6):333–5 (25 ref.)

An overview of novel therapies for Parkinson's disease. Fahn S. **Exp Neurol** 1997 Mar;144(1):21–3 (43 ref.)

Central effects of nitroglycerin in the rat: new perspectives in migraine research. Tassorelli C, et al. **Funct Neurol** 1996 Sep-Oct;11(5):219–23, 227–35 (66 ref.)

Amyotrophic lateral sclerosis: recent advances in understanding disease mechanisms. de Belleroche J, et al. **J Neuropathol Exp Neurol** 1996 Jul;55(7):747–57 (60 ref.)

Neurology. Prions, oestrogens, PCR, and the brain. Portegies P, et al. **Lancet** 1996 Dec 21-28;348 Suppl 2:sII14 (5 ref.)

Current approaches to the treatment of Alzheimer's disease. Wilcock GK. **Neurodegeneration** 1996 Dec;5(4):505–9 (24 ref.)

Contemporary state of reflex theory. Batuev AS. **Neurosci Behav Physiol** 1996 Jul-Aug;26(4):324–8 (18 ref.)

The bases of practice—neurological physiotherapy [see comments] Partridge C, et al. **Physiother Res Int** 1996; 1(3):205–8 (13 ref.) Comment in: Physiother Res Int 1996;1(4):265–8. Comment in: Physiother Res Int 1997;2(2):62–4.

Romanian contribution to stress research. Derevenco P. **Rom J Physiol** 1996 Jan-Dec;33(1–4):101–12 (60 ref.)

[A look at neurology] Regli F. **Rev Med Suisse Romande** 1997 Aug;117(8):607–11 (29 ref.) **(Fre)**

NEUROMA

DIAGNOSIS

Morton's neuroma. Update on diagnosis and imaging. Mendicino SS, et al. **Clin Podiatr Med Surg** 1997 Apr; 14(2):303–11 (40 ref.)

ETIOLOGY

Management of neuromas in the hand. Nath RK, et al. **Hand Clin** 1996 Nov;12(4):745–56 (35 ref.)

SURGERY

Intramedullary neuroma of the cervical spinal cord: case report. Melancia JL, et al. **Neurosurgery** 1996 Sep; 39(3):594–8 (45 ref.)

THERAPY

Management of Morton's neuroma in athletes. Nunan PJ, et al. **Clin Podiatr Med Surg** 1997 Jul;14(3):489–501 (21 ref.)

NEUROMA, ACOUSTIC

DIAGNOSIS

Multicentric eighth cranial nerve schwannoma. Li D, et al. **Arch Otolaryngol Head Neck Surg** 1997 Jun;123(6):650–3 (18 ref.)

Schwannoma in the vestibule and cochlea. Susilawati S, et al. **Australas Radiol** 1997 May;41(2):109–11 (8 ref.)

Sensorineural hearing loss and cerebellopontine angle lesions. Not always an acoustic neuroma—a pictorial essay. Heier LA, et al. **Clin Imaging** 1997 May–Jun;21(3):213–23 (7 ref.)

[Imaging of the labyrinth and vestibular nerve. Clinical significance for differential diagnosis of vestibular diseases] Jäger L, et al. **Nervenarzt** 1997 Jun;68(6):443–58 (42 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Clinical significance of Ki–67 staining index in acoustic neurinoma. Yokoyama M, et al. **Neurol Med Chir (Tokyo)** 1996 Oct;36(10):698–702; discussion 702–3 (27 ref.)

[Neurinomas of the cochlear nerve] Chays A, et al. **Ann Otolaryngol Chir Cervicofac** 1996;113(6):339–47 (29 ref.) (Eng. Abstr.) **(Fre)**

[Acoustic neurinomas with large cystic components: a clinical and pathological study of 3 cases] Asano K, et al. **No Shinkei Geka** 1995 Dec;23(12):1075–82 (27 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

[Large cystic neurinoma: a case report] Miyagi A, et al. **No Shinkei Geka** 1997 Jul;25(7):647–54 (15 ref.) (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY

The best treatment for vestibular schwannoma (acoustic neuroma): microsurgery or radiosurgery? Sekhar LN, et al. **Am J Otol** 1996 Jul;17(4):676–82; discussion 683–9 (34 ref.)

SURGERY

The best treatment for vestibular schwannoma (acoustic neuroma): microsurgery or radiosurgery? Sekhar LN, et al. **Am J Otol** 1996 Jul;17(4):676–82; discussion 683–9 (34 ref.)

Bilateral acoustic neuromas. Anand VT, et al. **Clin Otolaryngol** 1993 Oct;18(5):365–71 (12 ref.)

Hearing preservation in the removal of intracanalicular acoustic neuromas via the retrosigmoid approach. Rowed DW, et al. **J Neurosurg** 1997 Mar;86(3):456–61 (38 ref.)

Acoustic neuromas: results of current surgical management. Gormley WB, et al. **Neurosurgery** 1997 Jul;41(1):50–8; discussion 58–60 (45 ref.)

Management of vestibular schwannomas (acoustic neuromas): the value of neurophysiology for evaluation and prediction of auditory function in 420 cases. Matthies C, et al. **Neurosurgery** 1997 May;40(5):919–29; discussion 929–30 (44 ref.)

Management of 1000 vestibular schwannomas (acoustic neuromas): hearing function in 1000 tumor resections. Samii M, et al. **Neurosurgery** 1997 Feb;40(2):248–60; discussion 260–2 (99 ref.)

Acoustic neuroma update. Kartush JM, et al. **Otolaryngol Clin North Am** 1996 Jun;29(3):377–92 (19 ref.)

[Results of hearing preservation in surgery of vestibular schwannoma. Value of combined retrosigmoid and middle fossa approaches] Louis E, et al. **Neurochirurgie** 1997; 43(1):8–13; discussion 13–4 (26 ref.) (Eng. Abstr.) **(Fre)**

[Gamma knife radiosurgery for acoustic neurinoma: history and present situation] Jokura H, et al. **No To Shinkei** 1996 Feb;48(2):103–11 (39 ref.) **(Jpn)**

NEUROMA, ACOUSTIC, BILATERAL see **NEUROFIBROMATOSIS 2**

NEUROMA, ACOUSTIC, UNILATERAL see **NEUROMA, ACOUSTIC**

NEUROMEDIATOR RECEPTORS see **RECEPTORS, NEUROTRANSMITTER**

NEUROMEDIN B RECEPTORS see **RECEPTORS, BOMBESIN**

NEUROMODULATOR RECEPTORS see **RECEPTORS, NEUROTRANSMITTER**

NEUROMODULATORS see **NEUROTRANSMITTERS**

NEUROMUSCULAR AGENTS

FMRFamide-related peptides (FaRPs) in nematodes: occurrence and neuromuscular physiology. Maule AG, et al. **Parasitology** 1996;113 Suppl:S119–35 (71 ref.)

ADVERSE EFFECTS

[Allergic reactions during anesthesia] Escolano F, et al. **Rev Esp Anestesiol Reanim** 1996 Jan;43(1):17–26 (56 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Neuromuscular physiology and pharmacology of parasitic flatworms. Pax RA, et al. **Parasitology** 1996;113 Suppl:S83–96 (111 ref.)

THERAPEUTIC USE

Botulinum A exotoxin in clinical ophthalmology. Carruthers JD, et al. **Can J Ophthalmol** 1996 Dec;31(7):389–400 (66 ref.)

NEUROMUSCULAR BLOCKADE

see related
NEUROMUSCULAR BLOCKING AGENTS

Drug interactions with neuromuscular blockers. Feldman S, et al. **Drug Saf** 1996 Oct;15(4):261–73 (131 ref.)

Assessment of sedation, analgesia, and neuromuscular blockade in the perioperative period. Habibi S, et al. **Int Anesthesiol Clin** 1996 Summer;34(3):215–41 (68 ref.)

Neuromuscular blockade in the management of cerebral palsy. Koman LA, et al. **J Child Neurol** 1996 Nov;11 Suppl 1:S23–8 (44 ref.)

Neuromuscular blockade: offset anomalies. Are they simply potency-related receptor bonding effects? Midgley JM, et al. **J Pharm Pharmacol** 1997 Apr;49(4):416–20 (42 ref.)

Neuromuscular transmission and its pharmacological blockade. Part 3: Continuous infusion of relaxants and reversal and monitoring of relaxation. Booij LH. **Pharm World Sci** 1997 Feb;19(1):35–44 (152 ref.)

[Clinical evaluation of neuromuscular block] Saitoh Y. **Masui** 1996 Oct;45(10):1198–208 (45 ref.) (Eng. Abstr.) **(Jpn)**

NEUROMUSCULAR BLOCKING AGENTS

The use of neuromuscular-blocking agents in children. Tobias JD. **Pediatr Ann** 1997 Aug;26(8):482–9 (14 ref.)

[The clinical pharmacology of cisatracurium] Mellinghoff H, et al. **Anaesthesist** 1997 Jun;46(6):481–5 (30 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

[Acute muscular weakness during childhood in cases of severe asthma due to the use of corticoids and neuromuscular blockers] Campistol Plana J, et al. **An Esp Pediatr** 1996 Aug;45(2):196–8 (5 ref.) **(Spa)**

METABOLISM

Cholinesterase. Its significance in anaesthetic practice [see comments] Davis L, et al. **Anaesthesia** 1997 Mar; 52(3):244–60 (260 ref.) Comment in: Anaesthesia 1997 Jul;52(7):714.

PHARMACOKINETICS

Drug interactions with neuromuscular blockers. Feldman S, et al. **Drug Saf** 1996 Oct;15(4):261–73 (131 ref.)

PHARMACOLOGY

Good clinical research practice (GCRP) in pharmacodynamic studies of neuromuscular blocking agents. Viby-Mogensen J, et al. **Acta Anaesthesiol Scand** 1996 Jan;40(1):59–74 (48 ref.)

Technical and interpretive problems of peripheral nerve stimulation in monitoring neuromuscular blockade in the intensive care unit. Rudis MI, et al. **Ann Pharmacother** 1996 Feb;30(2):165–72 (4 ref.)

Sedation, analgesia and muscle relaxation and the critically ill patient. Park GR. **Can J Anaesth** 1997 May;44(5 Pt 2):R40–51 (21 ref.) **(Eng, Fre)**

Neuromuscular blocking drugs: onset and intubation. Bevan DR. **J Clin Anesth** 1997 Sep;9(6 Suppl):36S–39S (19 ref.)

Neuromuscular transmission and its pharmacological blockade. Part 2: Pharmacology of neuromuscular blocking agents. Booij LH. **Pharm World Sci** 1997 Feb;19(1):13–34 (301 ref.)

[Acid base changes and muscle relaxants] Ono K, et al. **Masui** 1996 Jan;45(1):2–14 (31 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Cisatracurium besilate. A review of its pharmacology and clinical potential in anaesthetic practice. Bryson HM, et al. **Drugs** 1997 May;53(5):848–66 (66 ref.)

Should ICU patients receive muscle relaxants? Coakley J. **Schweiz Med Wochenschr** 1996 Sep 28;126(39):1644–8 (38 ref.)

[Acute muscular weakness during childhood in cases of severe asthma due to the use of corticoids and neuromuscular blockers] Campistol Plana J, et al. **An Esp Pediatr** 1996 Aug;45(2):196–8 (5 ref.) **(Spa)**

NEUROMUSCULAR BLOCKING AGENTS, COMPETITIVE see **NEUROMUSCULAR**

NONDEPOLARIZING AGENTS

NEUROMUSCULAR DEPOLARIZING AGENTS

[Muscle relaxants] Ota Y. **Masui** 1996 Dec;45 Suppl:S212–9 (9 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

[Myorelaxants in childhood] Gavrilova N. **Khirurgiia (Sofiia)** 1996;49(3):45–50 (30 ref.) **(Bul)**

ADVERSE EFFECTS

Rhabdomyolysis and anesthesia: a report of two cases and review of the literature. Pedrozzi NE, et al. **Pediatr Neurol** 1996 Oct;15(3):254–7 (52 ref.)

[Myoglobinuria following anesthesia with enflurane and succinylcholine in an asthmatic child on theophylline] Shono S, et al. **Masui** 1996 Jan;45(1):91–5 (12 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Neuromuscular transmission and its pharmacological blockade. Part 2: Pharmacology of neuromuscular blocking agents. Booij LH. **Pharm World Sci** 1997 Feb;19(1):13–34 (301 ref.)

Neuromuscular transmission and its pharmacological blockade. Part 3: Continuous infusion of relaxants and reversal and monitoring of relaxation. Booij LH. **Pharm World Sci** 1997 Feb;19(1):35–44 (152 ref.)

[Acid base changes and muscle relaxants] Ono K, et al. **Masui** 1996 Jan;45(1):2–14 (31 ref.) (Eng. Abstr.) **(Jpn)**

NEUROMUSCULAR DISEASES

Chronic motor neuropathies: diagnosis, therapy, and pathogenesis. Kornberg AJ, et al. **Ann Neurol** 1995 May; 37 Suppl 1:S43–50 (88 ref.)

Neuromuscular conditions in the intensive care unit [editorial; comment] Bolton CF. **Intensive Care Med** 1996 Sep; 22(9):841–3 (15 ref.) Comment on: Intensive Care Med 1996 Sep;22(9):849–55. Comment on: Intensive Care Med 1996 Sep;22(9):856–61. Comment on: Intensive Care Med 1996 Sep;22(9):862–6.

CHEMICALLY INDUCED

Serotonin syndrome and drug combinations: focus on MAOI and RIMA. Hilton SE, et al. **Eur Arch Psychiatry Clin Neurosci** 1997;247(3):113–9 (49 ref.)

Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. Lane R, et al. **J Clin Psychopharmacol** 1997 Jun;17(3):208–21 (149 ref.)

Toxic myopathies. George KK, et al. **Neurol Clin** 1997 Aug; 15(3):711–30 (103 ref.)

COMPLICATIONS

Pediatric noninvasive nasal ventilation. Birnkrant DJ, et al. **J Child Neurol** 1997 Jun;12(4):231–6 (31 ref.)

Inflammatory neuromuscular disorders associated with chronic lymphoid leukemia: evidence for clonal B cells within muscle and nerve. Creange A, et al. **J Neurol Sci** 1996 Apr;137(1):35–41 (25 ref.)

External ophthalmoplegia in neuromuscular disorders: case report and review of the literature. Jones KJ, et al. **Neuromuscul Disord** 1997 May;7(3):143–51 (34 ref.)

Heterotopic ossification in neuromuscular disorders. Botte MJ, et al. **Orthopedics** 1997 Apr;20(4):335–41; quiz 342–3 (68 ref.)

Evaluation and treatment of respiratory failure in neuromuscular disease. Teener JW, et al. **Rheum Dis Clin North Am** 1997 May;23(2):277–92 (48 ref.)

CONGENITAL

Congenital neuromuscular diseases presenting in adulthood. Suarez J, et al. **Semin Neurol** 1996 Mar;16(1):47–54 (61 ref.)

DIAGNOSIS

Lumbosacral plexus neuropathy: a case report and review of the literature. van Alfen N, et al. **Clin Neurol Neurosurg** 1997 May;99(2):138–41 (16 ref.)

Approach to generalized weakness and peripheral neuromuscular disease. LoVecchio F, et al. **Emerg Med Clin North Am** 1997 Aug;15(3):605–23 (35 ref.)

Analysis of the electromyographic interference pattern. Sanders DB, et al. **J Clin Neurophysiol** 1996 Sep; 13(5):385–400 (36 ref.)

Quantitative motor unit potential analysis. Stålberg E, et al. **J Clin Neurophysiol** 1996 Sep;13(5):401–22 (105 ref.)

AAEM minimonograph #47: normative data in electrodiagnostic medicine. ff Dorfman LJ, et al. **Muscle Nerve** 1997 Jan;20(1):4–14 (36 ref.)

External ophthalmoplegia in neuromuscular disorders: case report and review of the literature. Jones KJ, et al. **Neuromuscul Disord** 1997 May;7(3):143–51 (34 ref.)

[Dropped head syndrome: diagnostic discussion apropos of 3 cases] Petiot P, et al. **Rev Neurol (Paris)** 1997 May; 153(4):251–5 (15 ref.) (Eng. Abstr.) **(Fre)**

[How reliably does electromyography differentiate

myopathies and neurogenic diseases?] Pfeiffer G. **Nervenarzt** 1996 Feb;67(2):123–32 (60 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

The use of intravenous immunoglobulins in the treatment of neuromuscular disorders. Voltz R, et al. **Curr Opin Neurol** 1996 Oct;9(5):360–6 (72 ref.)

[Treatment of autoimmune neuromuscular diseases with intravenous immunoglobulins] Illa I, et al. **Rev Neurol** 1997 Feb;25(138):263–6 (21 ref.) **(Spa)**

EMBRYOLOGY

[The importance of vitamin B 6 for development of the infant. Human medical and animal experiment studies] Gerster H. **Z Ernahrungswiss** 1996 Dec;35(4):309–17 (50 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Prenatal determinants of motor disorders. Stanley FJ. **Acta Paediatr Suppl** 1997 Jul;422:92–102 (65 ref.)

Trinucleotide-repeat expansions and neurodegenerative disease: a mechanism of pathogenesis. Hannan AJ. **Clin Exp Pharmacol Physiol** 1996 Dec;23(12):1015–20 (48 ref.)

Skeletal malalignments of the lower quarter: correlated and compensatory motions and postures. Riegger-Krugh C, et al. **J Orthop Sports Phys Ther** 1996 Feb;23(2):164–70 (45 ref.)

Endocrine neuromyopathies. Anagnos A, et al. **Neurol Clin** 1997 Aug;15(3):673–96 (117 ref.)

Paraneoplastic neuromuscular syndromes. Levin KH. **Neurol Clin** 1997 Aug;15(3):597–614 (94 ref.)

Neurological complications of severe illness and prolonged mechanical ventilation. Wiles CM. **Thorax** 1996 Aug;51 Suppl 2:S40–4 (27 ref.)

[Peripheral nerve and spinal cord complication in intravenous heroin addiction] Bernasconi A, et al. **Rev Neurol (Paris)** 1996 Nov;152(11):688–94 (53 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Trinucleotide-repeat expansions and neurodegenerative disease: a mechanism of pathogenesis. Hannan AJ. **Clin Exp Pharmacol Physiol** 1996 Dec;23(12):1015–20 (48 ref.)

Update on the genetic bases of disorders with orthopaedic manifestations. Dietz FR, et al. **J Bone Joint Surg Am** 1996 Oct;78(10):1583–98 (99 ref.)

Congenital myopathies. Goebel HH. **Semin Pediatr Neurol** 1996 Jun;3(2):152–61 (72 ref.)

The genetic basis of neuromuscular disorders. Nawrotzki R, et al. **Trends Genet** 1996 Aug;12(8):294–8 (48 ref.)

[Molecular pathogenesis of muscular diseases] Ohlendieck K. **Naturwissenschaften** 1996 Dec;83(12):555–65 (98 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders. van der Meché FG, et al. **Muscle Nerve** 1997 Feb;20(2):136–47 (93 ref.)

METABOLISM

Calcium channels in neurological disease. Greenberg DA. **Ann Neurol** 1997 Sep;42(3):275–82 (64 ref.)

Altered glutamatergic transmission in neurological disorders: from high extracellular glutamate to excessive synaptic efficacy. Obrenovitch TP, et al. **Prog Neurobiol** 1997 Jan; 51(1):39–87 (651 ref.)

PATHOLOGY

Inflammatory neuromuscular disorders associated with chronic lymphoid leukemia: evidence for clonal B cells within muscle and nerve. Creange A, et al. **J Neurol Sci** 1996 Apr;137(1):35–41 (25 ref.)

Calf enlargement in neuromuscular diseases: a quantitative ultrasound study in 350 patients and review of the literature. Reimers CD, et al. **J Neurol Sci** 1996 Nov; 143(1–2):46–56 (75 ref.)

[Cytoplasmic inclusion bodies: a study in several diseases and a review of the literature] Scola RH, et al. **Arq Neuropsiquiatr** 1996 Jun;54(2):245–59 (62 ref.) (Eng. Abstr.) **(Por)**

PHYSIOPATHOLOGY

The study of normal and abnormal neuromuscular transmission with single fibre electromyography. Stålberg E, et al. **J Neurosci Methods** 1997 Jun 27;74(2):145–54 (31 ref.)

Sleep and neuromuscular disorders. Culebras A. **Neurol Clin** 1996 Nov;14(4):791–805 (41 ref.)

[Prolonged muscle weakness in intensive care patients with special attention to the so-called intensive care polyneuromyopathy] Hinder F, et al. **Anaesthesist** 1997 Mar;46(3):211–9 (49 ref.) (Eng. Abstr.) **(Ger)**

[Exteroceptive suppression of activity of the temporal muscle. Principles and applications] Göbel H, et al. **Nervenarzt** 1996 Oct;67(10):846–59 (102 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

HIV-related neurological disability and prospects for rehabilitation. O'Dell MW. **Disabil Rehabil** 1996 Jun; 18(6):285–92 (50 ref.)

Neural signals for command control and feedback in functional neuromuscular stimulation: a review. Hoffer JA, et al. **J Rehabil Res Dev** 1996 Apr;33(2):145–57 (48 ref.)

[Recommendations of Bavarian Muscle Centers of the German Neuromuscular Disease Society for home ventilation of neuromuscular diseases of adult patients] Winterholler M, et al. **Nervenarzt** 1997 Apr;68(4):351–7 (23 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Neuromuscular disorders in critical illness [comment] Zochodne DW, et al. **Baillieres Clin Neurol** 1996 Oct; 5(3):645–71 (111 ref.) Comment on: Baillieres Clin Neurol 1996 Oct;5(3):447–75.

Therapeutic neural effects of electrical stimulation. Daly JJ, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):218–30 (88 ref.)

Immunotherapy in neuromuscular disorders: current and future strategies. Drachman DB. **Muscle Nerve** 1996 Oct; 19(10):1239–51 (69 ref.)

The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders. van der Meché FG, et al. **Muscle Nerve** 1997 Feb;20(2):136–47 (93 ref.)

[Assisted ventilation in chronic neuromuscular diseases. The Vincre Group] Kohler A, et al. **Rev Med Suisse Romande** 1997 Jun;117(6):479–84 (16 ref.) **(Fre)**

ULTRASONOGRAPHY

Calf enlargement in neuromuscular diseases: a quantitative ultrasound study in 350 patients and review of the literature. Reimers CD, et al. **J Neurol Sci** 1996 Nov; 143(1–2):46–56 (75 ref.)

VIROLOGY

HIV-related neurological disability and prospects for rehabilitation. O'Dell MW. **Disabil Rehabil** 1996 Jun; 18(6):285–92 (50 ref.)

NEUROMUSCULAR JUNCTION

see related
NEUROMUSCULAR BLOCKING AGENTS
NEUROMUSCULAR DEPOLARIZING AGENTS
RECEPTORS, CHOLINERGIC

Duchenne muscular dystrophy and the neuromuscular junction: the utrophin link. Gramolini AO, et al. **Bioessays** 1997 Sep;19(9):747–50 (42 ref.)

CHEMISTRY

Syntrophins: modular adapter proteins at the neuromuscular junction and the sarcolemma. Froehner SC, et al. **Soc Gen Physiol Ser** 1997;52:197–207 (49 ref.)

CYTOLOGY

Dynamic roles at the neuromuscular junction. Schwann cells. Balice-Gordon RJ. **Curr Biol** 1996 Sep 1;6(9):1054–6 (11 ref.)

Schwann cells induce and guide sprouting and reinnervation of neuromuscular junctions. Son YJ, et al. **Trends Neurosci** 1996 Jul;19(7):280–5 (40 ref.)

DRUG EFFECTS

Monitoring of neuromuscular transmission by electromyography during anaesthesia. A comparison with mechanomyography in cat and man. Engbaek J. **Dan Med Bull** 1996 Sep;43(4):301–16 (188 ref.)

EMBRYOLOGY

Nip and tuck at the neuromuscular junction: a role for proteases in developmental synapse elimination. Chang Q, et al. **Bioessays** 1997 Apr;19(4):271–5 (33 ref.)

GENETICS

Genetic analysis of postsynaptic differentiation at the vertebrate neuromuscular junction. Sanes JR. **Curr Opin Neurobiol** 1997 Feb;7(1):93–100 (69 ref.)

GROWTH & DEVELOPMENT

Nip and tuck at the neuromuscular junction: a role for proteases in developmental synapse elimination. Chang Q, et al. **Bioessays** 1997 Apr;19(4):271–5 (33 ref.)

Genetic analysis of postsynaptic differentiation at the vertebrate neuromuscular junction. Sanes JR. **Curr Opin Neurobiol** 1997 Feb;7(1):93–100 (69 ref.)

METABOLISM

ARIA: a neuromuscular junction neuregulin. Fischbach GD, et al. **Annu Rev Neurosci** 1997;20:429–58 (162 ref.)

Sequential roles of agrin, MuSK and rapsyn during neuromuscular junction formation. Glass DJ, et al. **Curr Opin Neurobiol** 1997 Jun;7(3):379–84 (45 ref.)

PHYSIOLOGY

Genetic dissection of signal transduction mechanisms underlying PACAP-like neuropeptide transmission in Drosophila: synergy of cAMP and Ras/Raf pathways. Zhong Y. **Ann N Y Acad Sci** 1996 Dec 26;805:67–79; discussion 79–80 (36 ref.)

The drosophila neuromuscular junction: a model system for studying synaptic development and function. Keshishian H, et al. **Annu Rev Neurosci** 1996;19:545–75 (133 ref.)

Morphological adaptations of neuromuscular junctions depend on fiber type. Sieck GC, et al. **Can J Appl Physiol** 1997 Jun;22(3):197–230 (156 ref.)

The receptor tyrosine kinase MuSK is required for neuromuscular junction formation and is a functional receptor for agrin. Glass DJ, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:435–44 (65 ref.)

The role of neuregulin (ARIA) at the neuromuscular junction. Rosen KM, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:427–34 (52 ref.)

The nicotinic acetylcholine receptor at the neuromuscular junction: assembly and tyrosine phosphorylation. Wang ZZ, et al. **Cold Spring Harb Symp Quant Biol** 1996; 61:363–71 (51 ref.)

The state of the union. Neuromuscular junction. Wells DG, et al. **Curr Biol** 1996 Sep 1;6(9):1073–5 (17 ref.)

Synapse maturation and structural plasticity at Drosophila neuromuscular junctions. Budnik V. **Curr Opin Neurobiol** 1996 Dec;6(6):858–67 (80 ref.)

Sequential roles of agrin, MuSK and rapsyn during neuromuscular junction formation. Glass DJ, et al. **Curr Opin Neurobiol** 1997 Jun;7(3):379–84 (45 ref.)

Mechanism of synapse disassembly at the developing neuromuscular junction. Nguyen QT, et al. **Curr Opin Neurobiol** 1996 Feb;6(1):104–12 (68 ref.)

Agrin, laminin beta 2 (s-laminin) and ARIA: their role in neuromuscular development. Ruegg MA. **Curr Opin Neurobiol** 1996 Feb;6(1):97–103 (58 ref.)

Monitoring of neuromuscular transmission by electromyography during anaesthesia. A comparison with mechanomyography in cat and man. Engbaek J. **Dan Med Bull** 1996 Sep;43(4):301–16 (188 ref.)

Neurophysiology and neuropsychiatry of the IBS. Dapoigny M, et al. **Digestion** 1997;58(1):1–9 (38 ref.)

Neuromuscular transmission at an active zone: the secretosome hypothesis. Bennett MR. **J Neurocytol** 1996 Dec;25(12):869–91 (116 ref.)

The study of normal and abnormal neuromuscular transmission with single fibre electromyography. Stålberg E, et al. **J Neurosci Methods** 1997 Jun 27;74(2):145–54 (31 ref.)

Neural signals for command control and feedback in functional neuromuscular stimulation: a review. Hoffer JA, et al. **J Rehabil Res Dev** 1996 Apr;33(2):145–57 (48 ref.)

Intercellular communication that mediates formation of the neuromuscular junction. Daniels MP. **Mol Neurobiol** 1997 Jun;14(3):143–70 (225 ref.)

Age-related changes in neuromuscular innervation. Balice-Gordon RJ. **Muscle Nerve Suppl** 1997;5:S83–7 (24 ref.)

Electromyogram, evoked sensory and motor potentials in neurourology. Vodušek DB. **Neurophysiol Clin** 1997 Jun; 27(3):204–10 (22 ref.)

Rostral brain regions contributing to respiratory control. Harper RM, et al. **Prog Brain Res** 1996;107:145–56 (76 ref.)

Purinergic regulation of acetylcholine release. Ribeiro JA, et al. **Prog Brain Res** 1996;109:231–41 (41 ref.)

Synaptic modulation by neurotrophic factors. Stoop R, et al. **Prog Brain Res** 1996;109:359–64 (39 ref.)

Autonomic neuromuscular transmission at a varicosity. Bennett MR. **Prog Neurobiol** 1996 Dec;50(5–6):505–32 (123 ref.)

Non-adrenergic non-cholinergic (NANC) transmission to smooth muscle: 35 years on. Bennett MR. **Prog Neurobiol** 1997 Jun;52(3):159–95 (261 ref.)

Initiation of contraction in detrusor smooth muscle. Fry CH, et al. **Scand J Urol Nephrol Suppl** 1997;184:7–14 (26 ref.)

The fascination of the Drosophila NMJ. Brunner A, et al. **Trends Genet** 1997 Mar;13(3):85–7 (19 ref.)

[Dynamic joint control training as neuromuscular coordination] Ihara H. **Nippon Seikeigeka Gakkai Zasshi** 1996 Sep;70(9):583–93 (30 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Genes at the junction--candidates for congenital myasthenic syndromes. Vincent A, et al. **Trends Neurosci** 1997 Jan; 20(1):15–22 (32 ref.)

[Tensilon test] Ishihara T. **Nippon Rinsho** 1997 Mar;55 Suppl 1:403–5 (7 ref.) **(Jpn)**

[Repetitive stimulation test] Kano M, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:406–8 (7 ref.) **(Jpn)**

ULTRASTRUCTURE

Ultrastructure of synapses in the first-evolved nervous systems. Westfall IA. **J Neurocytol** 1996 Dec;25(12):735–46 (53 ref.)

The heterogeneity of vesicular acetylcholine storage in cholinergic nerve terminals. Prior C, et al. **Pharmacol Res** 1995 Dec;32(6):345–53 (46 ref.)

NEUROMUSCULAR NONDEPOLARIZING AGENTS

see related

NICOTINIC ANTAGONISTS

Muscle relaxants: a clinical update. Buzello W, et al. **Acta Anaesthesiol Scand Suppl** 1996;109:165–7 (21 ref.)

Mivacurium in infants and children. Goudsouzian NG. **Paediatr Anaesth** 1997;7(3):183–90 (53 ref.)

[Mivacurium in pediatric anesthesia] Hofmockel VR, et al. **Anaesthesiol Reanim** 1996;21(1):11–3 (25 ref.) (Eng. Abstr.) **(Ger)**

[New muscle relaxants. Update on mivacurium, rocuronium and cis-atracurium] Fuchs-Buder T. **Anaesthesist** 1997 Apr;46(4):350–9 (17 ref.) **(Ger)**

[Muscle relaxants] Ota Y. **Masui** 1996 Dec;45 Suppl:S212–9 (9 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Use of intermediate acting muscle relaxants by infusion: the future. Mirakhur RK, et al. **Acta Anaesthesiol Belg** 1997; 48(1):29–34 (33 ref.)

[Myorelaxants in childhood] Gavrilova N. **Khirurgiia (Sofiia)** 1996;49(3):45–50 (30 ref.) **(Bul)**

[New muscle relaxants] Diefenbach C, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Feb; 31(1):2–8 (57 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Acute myopathy associated with combined use of corticosteroids and neuromuscular blocking agents. Fischer JR, et al. **Ann Pharmacother** 1996 Dec;30(12):1437–45 (52 ref.)

Side effects of nondepolarizing muscle relaxants: relationship to their antinicotinic and antimuscarinic actions. Vizi ES, et al. **Pharmacol Ther** 1997;73(2):75–89 (105 ref.)

METABOLISM

Neuromuscular blockade: offset anomalies. Are they simply potency-related receptor bonding effects? Midgley JM, et al. **J Pharm Pharmacol** 1997 Apr;49(4):416–20 (42 ref.)

PHARMACOKINETICS

Clinical pharmacokinetics of rocuronium bromide. Khuenl-Brady KS, et al. **Clin Pharmacokinet** 1996 Sep; 31(3):174–83 (53 ref.)

PHARMACOLOGY

Cisatracurium: a new nondepolarizing neuromuscular blocking agent. Owens CA, et al. **Conn Med** 1996 Aug; 60(8):461–3 (22 ref.)

Neuromuscular transmission and its pharmacological blockade. Part 4: Use of relaxants in paediatric and elderly patients, in obstetrics, and in the intensive care unit. Booij LH. **Pharm World Sci** 1997 Feb;19(1):45–52 (11 ref.)

Neuromuscular transmission and its pharmacological blockade. Part 2: Pharmacology of neuromuscular blocking agents. Booij LH. **Pharm World Sci** 1997 Feb;19(1):13–34 (301 ref.)

[The clinical pharmacology of mivacurium] Diefenbach C, et al. **Anaesthesist** 1997 May;46(5):385–8 (25 ref.) (Eng. Abstr.) **(Ger)**

[Acid base changes and muscle relaxants] Ono K, et al. **Masui** 1996 Jan;45(1):2–14 (31 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Nondepolarizing neuromuscular blocking drugs in the intensive care unit: a clinical review. Reeves ST, et al. **South Med J** 1997 Aug;90(8):769–74 (47 ref.)

NEUROMUSCULAR SPINDLES see **MUSCLE SPINDLES**

NEUROMYELITIS OPTICA

DIAGNOSIS

Central nervous system white matter diseases other than multiple sclerosis. O'Riordan JI. **Curr Opin Neurol** 1997 Jun;10(3):211–4 (41 ref.)

PATHOLOGY

Pediatric Devic's neuromyelitis optica. Jeffery AR, et al. **J Pediatr Ophthalmol Strabismus** 1996 Sep–Oct;33(5):223–9 (37 ref.)

NEURON DEGENERATION see **NERVE DEGENERATION**

NEURON-SPECIFIC ENOLASE see **PHOSPHOPYRUVATE HYDRATASE**

NEURONAL CELL ADHESION MOLECULES see **CELL ADHESION MOLECULES, NEURONAL**

NEURONAL CEROID-LIPOFUSCINOSIS

[Ceroid-lipofuscinosis: recent notions] Chabrol B. **Arch Pediatr** 1997 Jul;4(7):671–5 (9 ref.) (Eng. Abstr.) **(Fre)**

[Batten disease] Eto Y. **Ryoikibetsu Shokogun Shirizu** 1996; (15):241–3 (8 ref.) **(Jpn)**

DIAGNOSIS

Diagnostic (clinical and morphological) criteria for adult neuronal ceroid-lipofuscinosis (Kufs' disease), Hôpital de la Salpétrière 'AFM Institut de Myologie', Paris, France, 5 December 1996. Ruchoux MM, et al. **Neuropathol Appl Neurobiol** 1997 Jun;23(3):262–3 (23 ref.)

EPIDEMIOLOGY

Batten disease in the west of Scotland 1974–1995 including five cases of the juvenile form with granular osmiophilic deposits. Crow YJ, et al. **Neuropediatrics** 1997 Jun; 28(3):140–4 (22 ref.)

GENETICS

The mechanism and functional roles of protein palmitoylation in the nervous system. Bizzozero OA. **Neuropediatrics** 1997 Feb;28(1):23–6 (47 ref.)

The ovine model of neuronal ceroid lipofuscinosis (NCL): its contribution to understanding the pathogenesis of Batten disease. Jolly RD. **Neuropediatrics** 1997 Feb;28(1):60–2 (30 ref.)

The neuronal ceroid-lipofuscinoses. Goebel HH. **Semin Pediatr Neurol** 1996 Dec;3(4):270–8 (62 ref.)

METABOLISM

Lysosomal proteinosis based on decreased degradation of a specific protein, mitochondrial ATP synthase subunit C: Batten disease. Ezaki J, et al. **Adv Exp Med Biol** 1996; 389:121–8 (31 ref.)

The neuronal ceroid lipofuscinoses (Batten disease): a group of lysosomal proteinoses. Palmer DN, et al. **Adv Exp Med Biol** 1996;389:129–36 (55 ref.)

Batten disease and mitochondrial pathways of proteolysis. Tanner AJ, et al. **Biochem Mol Med** 1996 Feb;57(1):1–9 (63 ref.)

PATHOLOGY

Morphologic diagnosis in neuronal ceroid lipofuscinosis. Goebel HH. **Neuropediatrics** 1997 Feb;28(1):67–9 (17 ref.)

Sphingolipid activator proteins (SAPs) in neuronal ceroid lipofuscinoses (NCL). Tyynelä J, et al. **Neuropediatrics** 1997 Feb;28(1):49–52 (41 ref.)

VETERINARY

The mannosidoses and ceroid-lipofuscinoses: experimental studies on two types of storage disease. Jolly RD. **Pathology** 1997 Feb;29(1):51–6 (59 ref.)

NEURONAL PLASTICITY

New perspectives in a gustatory physiology: transduction, development, and plasticity. Stewart RE, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):C1–26 (203 ref.)

In vivo imaging of fatty acid incorporation into brain to examine signal transduction and neuroplasticity involving phospholipids. Rapoport SI, et al. **Ann N Y Acad Sci** 1997 May 30;820:56–73; discussion 73–4 (35 ref.)

Long-term depression in hippocampus. Bear MF, et al. **Annu Rev Neurosci** 1996;19:437–62 (113 ref.)

Intrinsic neuronal determinants that promote axonal sprouting and elongation. Caroni P. **Bioessays** 1997 Sep; 19(9):767–75 (69 ref.)

Plasticity in visual perception and physiology. Gilbert CD. **Curr Opin Neurobiol** 1996 Apr;6(2):269–74 (44 ref.)

Induction of heterosynaptic and homosynaptic LTD in hippocampal sub-regions in vivo. Abraham WC. **J Physiol Paris** 1996;90(5–6):305–6 (13 ref.)

Plasticity of the hippocampal-prefrontal cortex synapses. Jay TM, et al. **J Physiol Paris** 1996;90(5–6):361–6 (19 ref.)

Muscarinic receptors involved in hippocampal plasticity. Segal M, et al. **Life Sci** 1997;60(13–14):1085–91 (37 ref.)

Role of dopamine receptors in the short- and long-term regulation of corticostriatal transmission. Calabresi P, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1997 Apr; 17(2):101–4 (25 ref.)

Reciprocal trophic interactions between climbing fibres and Purkinje cells in the rat cerebellum. Strata P, et al. **Prog Brain Res** 1997;114:263–82 (91 ref.)

Nitric oxide, a neuronal messenger. Its role in the hippocampus neuronal plasticity. Salemme E, et al. **Riv Biol** 1996;89(1):87–107 (37 ref.) **(Eng, Ita)**

Is schizophrenia a lifetime disorder of brain plasticity, growth and aging? DeLisi LE. **Schizophr Res** 1997 Feb 7; 23(2):119–29 (101 ref.)

Synaptic activity and the construction of cortical circuits. Katz LC, et al. **Science** 1996 Nov 15;274(5290):1133–8 (86 ref.)

Sprouting in the hippocampus is layer-specific. Frotscher M, et al. **Trends Neurosci** 1997 May;20(5):218–23 (52 ref.)

Neurotrophins and activity-dependent plasticity of cortical interneurons. Marty S, et al. **Trends Neurosci** 1997 May; 20(5):198–202 (68 ref.)

[Postsynaptic density proteins related to the expression and modulation of synaptic plasticity] Suzuki T. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Apr; 16(2):53–8 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Brain plasticity and the regulating substances] Miyamoto E, et al. **Nippon Yakurigaku Zasshi** 1996 Sep;108(3):157–9 (6 ref.) **(Jpn)**

[Motor reorganization in the motor cortex] Mano Y, et al. **Rinsho Shinkeigaku** 1995 Dec;35(12):1515–7 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Structure and plasticity in the vomeronasal system] Ichikawa M. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(14):2062–9 (15 ref.) **(Jpn)**

[Neurotrophic factors and synaptic plasticity in the central nervous system] Nawa H, et al. **Tanpakushitsu Kakusan Koso** 1996 Dec;41(16):2513–21 (86 ref.) **(Jpn)**

[Neurotrophin and synaptic plasticity] Takei N, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):481–8 (47 ref.) **(Jpn)**

DRUG EFFECTS

Transcription factors: potential roles in drug-induced neuroplasticity. Persico AM, et al. **Rev Neurosci** 1996 Oct-Dec;7(4):233–75 (330 ref.)

GENETICS

Molecular genetic analysis of synaptic plasticity, activity-dependent neural development, learning, and memory in the mammalian brain. Chen C, et al. **Annu Rev Neurosci** 1997;20:157–84 (149 ref.)

Molecular and cellular plasticity in developing epileptic brain. Noebels JL, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:319–26 (34 ref.)

What can genetic models tell us about behavioral plasticity? Sadile AG. **Rev Neurosci** 1993 Jul–Sep;4(3):287–303 (142 ref.)

PHYSIOLOGY

Plasticity of the vestibular system: central compensation and sensory substitution for vestibular deficits. Brandt T, et al. **Adv Neurol** 1997;73:297–309 (51 ref.)

Short-term functional plasticity of cortical and thalamic sensory representations and its implication for information processing. Dinse HR, et al. **Adv Neurol** 1997;73:159–78 (78 ref.)

Seizures and the regulation of neurotrophic factor expression: associations with structural plasticity in epilepsy. Gall CM, et al. **Adv Neurol** 1997;72:9–24 (97 ref.)

Three-dimensional autoradiographic image-processing strategies for the study of brain injury and plasticity. Ginsberg MD, et al. **Adv Neurol** 1997;73:239–50 (24 ref.)

Compensatory regeneration of the damaged adult human brain: neuroplasticity in a clinical perspective. Goldman S, et al. **Adv Neurol** 1997;73:99–107 (46 ref.)

Neurotrophic factors and neuronal plasticity: is there a link? Lindholm D. **Adv Neurol** 1997;73:1–6 (52 ref.)

Recovery of function following lesions of eloquent brain areas. Lüders HO, et al. **Adv Neurol** 1997;73:335–46 (49 ref.)

The functional significance of lesion-induced plasticity of the hippocampal formation. Ramirez JJ. **Adv Neurol** 1997; 73:61–82 (154 ref.)

Mechanisms of compensatory plasticity in the cerebral cortex. Rauschecker JP. **Adv Neurol** 1997;73:137–46 (58 ref.)

Recovery of vision after partial visual system injury as a model of postlesion neuroplasticity. Sabel BA, et al. **Adv Neurol** 1997;73:251–76 (123 ref.)

Plasticity of the human motor cortex. Seitz RJ, et al. **Adv Neurol** 1997;73:321–33 (107 ref.)

Neural plasticity as studied in neuronal cell lines. Wainer BH, et al. **Adv Neurol** 1997;72:133–42 (31 ref.)

Molecular remodeling of neurons in multiple sclerosis: what we know, and what we must ask about brain plasticity in demyelinating diseases. Waxman SG. **Adv Neurol** 1997; 73:109–20 (72 ref.)

Delayed and remote effects of focal cortical infarctions: secondary damage and reactive plasticity. Witte OW, et al. **Adv Neurol** 1997;73:207–27 (139 ref.)

Modifiable neuronal connections: an overview for psychiatrists. Jeffery KJ, et al. **Am J Psychiatry** 1997 Feb; 154(2):156–64 (35 ref.)

Developmental plasticity in neural circuits for a learned behavior. Bottjer SW, et al. **Annu Rev Neurosci** 1997; 20:459–81 (91 ref.)

Function-related plasticity in hypothalamus. Hatton GI. **Annu Rev Neurosci** 1997;20:375–97 (119 ref.)

Visual perceptual learning: a sign of neural plasticity at early stages of visual processing. Fiorentini A, et al. **Arch Ital Biol** 1997 Mar;135(2):157–67 (37 ref.)

Is brain plasticity preserved during aging and in Alzheimer's disease? Mirmiran M, et al. **Behav Brain Res** 1996 Jun; 78(1):43–8 (77 ref.)

Psychobiology of plasticity: effects of training and experience on brain and behavior. Rosenzweig MR, et al. **Behav Brain Res** 1996 Jun;78(1):57–65 (79 ref.)

Sleep states, memory processes and synaptic plasticity. Smith C. **Behav Brain Res** 1996 Jun;78(1):49–56 (71 ref.)

Elementary forms of synaptic plasticity in the visual cortex. Kirkwood A, et al. **Biol Res** 1995;28(1):73–80 (23 ref.)

Neural mechanisms of behavioral plasticity: metamorphosis and learning in Manduca sexta. Weeks JC, et al. **Brain Behav Evol** 1997;50 Suppl 1:69–80 (60 ref.)

NEURONAL PLASTICITY

Evidence for the Hebbian hypothesis in experience-dependent physiological plasticity of neocortex: a critical review. Cruikshank SJ, et al. **Brain Res Brain Res Rev** 1996 Oct;22(3):191–228 (171 ref.)

Melanocortins and lesion-induced plasticity in the CNS: a review. Darlington CL, et al. **Brain Res Brain Res Rev** 1996 Oct;22(3):245–57 (124 ref.)

Sensory regulation of immediate-early gene expression in mammalian visual cortex: implications for functional mapping and neural plasticity. Kaczmarek L, et al. **Brain Res Brain Res Rev** 1997 Apr;23(3):237–56 (169 ref.)

An alternative to the LTP orthodoxy: a plasticity–pathology continuum model. McEachern JC, et al. **Brain Res Brain Res Rev** 1996 Jun;22(1):51–92 (307 ref.)

Functions for interneuronal nets in the hippocampus. Buzsáki G. **Can J Physiol Pharmacol** 1997 May;75(5):508–15 (72 ref.)

Mechanisms controlling neuronal plasticity in somatosensory cortex. Dykes RW. **Can J Physiol Pharmacol** 1997 May; 75(5):535–45 (89 ref.)

Synaptic plasticity in hippocampal interneurons? A commentary. McBain CJ, et al. **Can J Physiol Pharmacol** 1997 May;75(5):488–94 (47 ref.)

Development and plasticity of the inhibitory neocortical circuitry with an emphasis on the rodent barrel field cortex: a review. Micheva KD, et al. **Can J Physiol Pharmacol** 1997 May;75(5):470–8 (70 ref.)

Gonadal steroids and astroglial plasticity. Garcia-Segura LM, et al. **Cell Mol Neurobiol** 1996 Apr;16(2):225–37 (80 ref.)

Gonadal and adrenal steroids regulate neurochemical and structural plasticity of the hippocampus via cellular mechanisms involving NMDA receptors. McEwen BS. **Cell Mol Neurobiol** 1996 Apr;16(2):103–16 (75 ref.)

Potential neuronal mechanisms of estrogen actions in synaptogenesis and synaptic plasticity. Naftolin F, et al. **Cell Mol Neurobiol** 1996 Apr;16(2):213–23 (30 ref.)

Factors that are critical for plasticity in the visual cortex. Daw NW, et al. **Ciba Found Symp** 1995; 193:258–76;discussion 322–4 (35 ref.)

Plasticity in the development of neocortical areas. O'Leary DD, et al. **Ciba Found Symp** 1995;193:214–30; discussion 251–7 (50 ref.)

Injury- and use-related plasticity in the primary sensory cortex of adult mammals: possible relationship to perceptual learning. Irvine DR, et al. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov;23(10–11):939–47 (56 ref.)

Nicotinic receptors and brain plasticity. Changeux JP, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:343–62 (103 ref.)

Combination of gene targeting and gene transfer by adenoviral vectors in the analysis of neurotrophin-mediated neuronal plasticity. Griesbeck O, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:77–83 (39 ref.)

Cortical plasticity underlying perceptual, motor, and cognitive skill development: implications for neurorehabilitation. Merzenich M, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:1–8 (59 ref.)

Functions and roles of glutamate receptors in synaptic transmission and plasticity. Nakanishi S, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:67–75 (39 ref.)

Emotional memory: a search for sites of plasticity. Quirk GJ, et al. **Cold Spring Harb Symp Quant Biol** 1996; 61:247–57 (78 ref.)

Neurotrophic factors in brain synaptic plasticity. Nawa H, et al. **Crit Rev Neurobiol** 1997;11(1):91–100 (86 ref.)

Synaptic plasticity: A molecular mechanism for metaplasticity. Deisseroth K, et al. **Curr Biol** 1995 Dec 1;5(12):1334–8 (30 ref.)

Synaptic plasticity: the basis of particular types of learning. Goda Y, et al. **Curr Biol** 1996 Apr 1;6(4):375–8 (12 ref.)

Synapse maturation and structural plasticity at Drosophila neuromuscular junctions. Budnik V. **Curr Opin Neurobiol** 1996 Dec;6(6):858–67 (80 ref.)

The cerebellum: cortical processing and theory. De Schutter E, et al. **Curr Opin Neurobiol** 1996 Dec;6(6):759–64 (56 ref.)

The role of polysialic acid and other carbohydrate polymers in neural structural plasticity. Fryer HJ, et al. **Curr Opin Neurobiol** 1996 Feb;6(1):113–8 (49 ref.)

Learning perceptual skills: behavioral probes into adult cortical plasticity. Karni A, et al. **Curr Opin Neurobiol** 1997 Aug;7(4):530–5 (71 ref.)

Cyclic nucleotide gated channels as regulators of CNS development and plasticity. Zufall F, et al. **Curr Opin Neurobiol** 1997 Jun;7(3):404–12 (73 ref.)

Mossy fiber reorganization in the epileptic hippocampus. Parent JM, et al. **Curr Opin Neurol** 1997 Apr;10(2):103–9 (50 ref.)

Recovery and repair issues after stroke from the scientific perspective. Seil FJ. **Curr Opin Neurol** 1997 Feb; 10(1):49–51 (23 ref.)

Control of gonadotropin feedback: the possible role of estrogen-induced hypothalamic synaptic plasticity. Horvath TL, et al. **Gynecol Endocrinol** 1997 Apr; 11(2):139–43 (12 ref.)

Intracellular studies of heterosynaptic long-term depression (LTD) in CA1 of hippocampal slices. Barry MF, et al. **Hippocampus** 1996;6(1):3–8 (24 ref.)

Dendritic calcium channels and hippocampal long-term depression. Christie BR, et al. **Hippocampus** 1996;6(1):17–23 (55 ref.)

Associative long-term depression in the hippocampus in vitro. Debanne D, et al. **Hippocampus** 1996;6(1):9–16 (39 ref.)

LTD: many means to how many ends? Kerr DS, et al. **Hippocampus** 1996;6(1):30–4 (41 ref.)

LTD, LTP, and the sliding threshold for long-term synaptic plasticity. Stanton PK. **Hippocampus** 1996;6(1):35–42 (69 ref.)

NMDA receptor-dependent LTD in different subfields of hippocampus in vivo and in vitro. Thiels E, et al. **Hippocampus** 1996;6(1):43–51 (64 ref.)

Homosynaptic LTD and depotentiation: do they differ in name only? Wagner JJ, et al. **Hippocampus** 1996;6(1):24–9 (37 ref.)

Structural plasticity of the adult CNS. Negative control by neurite growth inhibitory signals. Schwab ME. **Int J Dev Neurosci** 1996 Jul;14(4):379–85 (67 ref.)

The neuroplastic phenomenon: a physiologic link between chronic pain and learning. Arnstein PM. **J Neurosci Nurs** 1997 Jun;29(3):179–86 (33 ref.)

Progress in understanding NMDA-receptor-dependent synaptic plasticity in the visual cortex. Bear MF. **J Physiol Paris** 1996;90(3–4):223–7 (39 ref.)

A discussion of activity-dependent forms of synaptic weakening and their possible role in ocular dominance plasticity. Dudek SM. **J Physiol Paris** 1996;90(3–4):167–70 (38 ref.)

Does Hebbian synaptic plasticity explain learning-induced sensory plasticity in adult mammals? Edeline JM. **J Physiol Paris** 1996;90(3–4):271–6 (52 ref.)

Postsynaptic calcium and calcium-dependent processes in synaptic plasticity in the developing visual cortex. Tsumoto T, et al. **J Physiol Paris** 1996;90(3–4):151–6 (21 ref.)

Adenosine and neuronal plasticity. de Mendonça A, et al. **Life Sci** 1997;60(4–5):245–51 (52 ref.)

Synaptic transmission and plasticity in the amygdala. An emerging physiology of fear conditioning circuits. Maren S. **Mol Neurobiol** 1996 Aug;13(1):1–22 (140 ref.)

Putative roles for the inducible transcription factor c-fos in the central nervous system: studies with antisense oligonucleotides. Chiasson BJ, et al. **Neurochem Int** 1997 Sep;31(3):459–75 (136 ref.)

Cholinergic neurotransmission and synaptic plasticity concerning memory processing. Jerusalinsky D, et al. **Neurochem Res** 1997 Apr;22(4):507–15 (91 ref.)

Ca(2+)-dependent routes to Ras: mechanisms for neuronal survival, differentiation, and plasticity? Finkbeiner S, et al. **Neuron** 1996 Feb;16(2):233–6 (16 ref.)

Synaptic economics: competition and cooperation in synaptic plasticity. Miller KD. **Neuron** 1996 Sep;17(3):371–4 (24 ref.)

Hebb's dream: the resurgence of cell assemblies. Nicolelis MA, et al. **Neuron** 1997 Aug;19(2):219–21 (18 ref.)

Synaptic plasticity and physiological interactions between dopamine and glutamate in the striatum. Calabresi P, et al. **Neurosci Biobehav Rev** 1997 Jul;21(4):519–23 (60 ref.)

Windup and central sensitization are not equivalent [editorial] Woolf CJ. **Pain** 1996 Aug;66(2–3):105–8 (51 ref.)

GAP-43: putting constraints on neuronal plasticity. Fishman MC. **Perspect Dev Neurobiol** 1996;4(2–3):193–8 (46 ref.)

Calcium and Free Radicals: Mediators of neurotrophic factor and excitatory transmitter-regulated developmental plasticity and cell death. Mattson MP. **Perspect Dev Neurobiol** 1996;3(2):79–91 (101 ref.)

Glutamate receptors in cortical plasticity: molecular and cellular biology. Kaczmarek L, et al. **Physiol Rev** 1997 Jan; 77(1):217–55 (392 ref.)

NMDA-receptor-dependent synaptic plasticity in the visual cortex. Bear MF. **Prog Brain Res** 1996;108:205–18 (78 ref.)

A new functional role for cerebellar long-term depression. De Schutter E. **Prog Brain Res** 1997;114:529–42 (107 ref.)

The role of excitatory amino acid transmission in development and plasticity of SI barrel cortex. Fox K. **Prog Brain Res** 1996;108:219–34 (56 ref.)

Cellular and molecular correlates to plasticity during recovery from injury in the developing mammalian brain. Ide CF, et al. **Prog Brain Res** 1996;108:365–77 (21 ref.)

Myelin-associated neurite growth inhibitors: regulators of plastic changes of neural connections in the central nervous system. Kapfhammer JP. **Prog Brain Res** 1996;108:183–202 (61 ref.)

Cutaneous polymodal receptors: characteristics and plasticity. Perl ER. **Prog Brain Res** 1996;113:21–37 (49 ref.)

Plasticity of excitatory synaptic transmission in the spinal cord dorsal horn. Randić M. **Prog Brain Res** 1996; 113:463–506 (338 ref.)

Neurobiology of spinal nociception: new concepts. Sandkühler J. **Prog Brain Res** 1996;110:207–24 (50 ref.)

Neural plasticity after brain damage. Spear PD. **Prog Brain Res** 1996;108:391–408 (58 ref.)

Involvement of glutamatergic neurotransmission and protein kinase C in spinal plasticity and the development of chronic pain. Tölle TR, et al. **Prog Brain Res** 1996;110:193–206 (54 ref.)

Plasticity of messenger function in primary afferents following nerve injury—implications for neuropathic pain. Wiesenfeld-Hallin Z, et al. **Prog Brain Res** 1996;110:113–24 (80 ref.)

Plasticity of the nervous system at the systematic, cellular and molecular levels: a mechanism of chronic pain and hyperalgesia. Zimmermann M, et al. **Prog Brain Res** 1996; 110:233–59 (106 ref.)

Metaplasticity: a new vista across the field of synaptic plasticity. Abraham WC, et al. **Prog Neurobiol** 1997 Jul; 52(4):303–23 (138 ref.)

The action of neurotrophins in the development and plasticity of the visual cortex [published erratum appears in Prog Neurobiol 1996 Oct;50(2–3):333] Cellerino A, et al. **Prog Neurobiol** 1996 May;49(1):53–71 (180 ref.)

HB-GAM (heparin-binding growth-associated molecule) and heparin-type glycans in the development and plasticity of neuron-target contacts. Rauvala H, et al. **Prog Neurobiol** 1997 Jun;52(2):127–44 (112 ref.)

Reciprocal trophic interactions in the adult climbing fibre-Purkinje cell system. Rossi F, et al. **Prog Neurobiol** 1995 Nov–Dec;47(4–5):341–69 (188 ref.)

Neural plasticity in cerebellar cultures. Seil FJ. **Prog Neurobiol** 1996 Dec;50(5–6):533–56 (86 ref.)

Neuronal plasticity induced by neonatal monocular (and binocular) enucleation. Toldi J, et al. **Prog Neurobiol** 1996 Feb;48(3):191–218 (200 ref.)

Glia-neuron intercommunications and synaptic plasticity. Vernadakis A. **Prog Neurobiol** 1996 Jun;49(3):185–214 (292 ref.)

The contribution of protein kinases to plastic events in the superior colliculus [see comments] McCrossan D, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Apr; 21(3):487–505 (49 ref.) Comment in: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):373–8.

Protein kinase C in synaptic plasticity: changes in the in situ phosphorylation state of identified pre- and postsynaptic substrates [see comments] Ramakers GM, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Apr; 21(3):455–86 (193 ref.) Comment in: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):373–8.

Plasticity of the afferent innervation of the airways. Kummer W, et al. **Pulm Pharmacol** 1995 Aug–Oct;8(4–5):169–72 (8 ref.)

Associative synaptic plasticity in hippocampus and visual cortex: cellular mechanisms and functional implications. Debanne D. **Rev Neurosci** 1996 Jan–Mar;7(1):29–46 (160 ref.)

GAP-43: an intrinsic determinant of neuronal development and plasticity. Benowitz LI, et al. **Trends Neurosci** 1997 Feb;20(2):84–91 (140 ref.)

Neural cell adhesion molecules in activity-dependent development and synaptic plasticity. Fields RD, et al. **Trends Neurosci** 1996 Nov;19(11):473–80 (95 ref.)

Nitric oxide, the enigmatic neuronal messenger: its role in synaptic plasticity. Hölscher C. **Trends Neurosci** 1997 Jul; 20(7):298–303 (93 ref.)

Polysialic acid in the vertebrate nervous system: a promoter of plasticity in cell–cell interactions. Rutishauser U, et al. **Trends Neurosci** 1996 Oct;19(10):422–7 (63 ref.)

[Dynamic regulation of the NMDA receptor channel subunits in the central nervous system and their involvement in synaptic plasticity and development] Watanabe M. **Kaibogaku Zasshi** 1996 Oct;71(5):517–22 (17 ref.) (Eng. Abstr.) **(Jpn)**

[The general principles of synaptic plasticity in the neocortex, hippocampus and cerebellum] Sil'skiĭ IG. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 Mar–Apr; 47(2):374–92 (73 ref.) (Eng. Abstr.) **(Rus)**

[Neuronal plasticity] Pascual-Castroviejo I. **Rev Neurol** 1996 Nov;24(135):1361–6 (41 ref.) (Eng. Abstr.) **(Spa)**

NEURONS

see related

NEURAL CONDUCTION

Intrinsic neuronal determinants that promote axonal sprouting and elongation. Caroni P. **Bioessays** 1997 Sep; 19(9):767–75 (69 ref.)

Epilepsy and disorders of neuronal migration. I: Introduction. Gordon N. **Dev Med Child Neurol** 1996 Nov;38(11):1053–7 (30 ref.)

Cell vehicles for gene transfer to the brain. Taylor R. **Neuromuscul Disord** 1997 Jul;7(5):343–51 (64 ref.)

[Neurotrophic factors: neuronal death and its protection] Kuno M. **No To Shinkei** 1996 Dec;48(12):1087–98 (100 ref.) **(Jpn)**

[The action of reelin in the layering of cortical neurons in cerebrum] Ogawa M, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):577–83 (19 ref.) **(Jpn)**

[Heterotopia in a 45-year-old man] Segarra Soria MA, et al. **An Med Interna** 1997 Apr;14(4):193–5 (15 ref.) (Eng. Abstr.) **(Spa)**

[Dopaminergic system and neuronal death] Luquin MR, et al. **Rev Neurol** 1997 Aug;25 Suppl 2:S129–40 (88 ref.) (Eng. Abstr.) **(Spa)**

CHEMISTRY

The neurochemistry of Alzheimer's disease. Engelborghs S, et al. **Acta Neurol Belg** 1997 Jun;97(2):67–84 (226 ref.)

The localization of gangliosides in neurons of the central nervous system: the use of anti-ganglioside antibodies. Schwarz A, et al. **Biochim Biophys Acta** 1996 Oct 29; 1286(3):247–67 (334 ref.)

Oxytocin and vasopressin neurones: vive la différence! Hatton GI. **J Physiol (Lond)** 1997 Apr 15;500 (Pt 2):284 (5 ref.)

Nicotinic acetylcholine receptors on hippocampal neurons: distribution on the neuronal surface and modulation of

receptor activity. Albuquerque EX, et al. **J Recept Signal Transduct Res** 1997 Jan-May; 17(1-3):243-66 (50 ref.)

Neuronal and glial localization of NMDA receptors in the cerebral cortex. Conti F, et al. **Mol Neurobiol** 1997 Feb-Apr;14(1-2):1-18 (85 ref.)

Melanotropic peptides in the mammalian brain: the melanin-concentrating hormone. Knigge KM, et al. **Peptides** 1996;17(6):1063-73 (147 ref.)

Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Nicoletti F, et al. **Trends Neurosci** 1996 Jul;19(7):267-71 (74 ref.)

[Neuronal intermediate filament proteins] Bousquet O, et al. **C R Seances Soc Biol Fil** 1996;190(2-3):269-87 (105 ref.) (Eng. Abstr.) **(Fre)**

CYTOLOGY

Environmental and genetic determinants of neural migration and postmigratory survival. Evrard P, et al. **Acta Paediatr Suppl** 1997 Jul;422:20-6 (52 ref.)

Survival, regeneration and sprouting of central neurons: the rat septohippocampal projection as a model. Frotscher M, et al. **Anat Anz** 1996 Aug;178(4):311-5 (33 ref.)

Colocalization of amino acid signal molecules in neurons and endocrine cells. Davanger S. **Anat Embryol (Berl)** 1996 Jul; 194(1):1-12 (192 ref.)

Region-specific regulation of neurogenesis by VIP and PACAP: direct and indirect modes of action. DiCicco-Bloom E. **Ann N Y Acad Sci** 1996 Dec 26; 805:244-56; discussion 256-8 (30 ref.)

VIP and PACAP receptor-mediated actions on cell proliferation and survival. Waschek JA. **Ann N Y Acad Sci** 1996 Dec 26;805:290-300; discussion 300-1 (71 ref.)

Regulatory mechanisms in stem cell biology. Morrison SJ, et al. **Cell** 1997 Feb 7;88(3):287-98 (112 ref.)

Cytomechanics of axonal development. Heidemann SR, et al. **Cell Biochem Biophys** 1995;27(3):135-55 (45 ref.)

Factors regulating the differentiation of neural precursors in the forebrain. Bartlett PF, et al. **Ciba Found Symp** 1995; 193:85-99; discussion 117-26 (22 ref.)

The cell lineage of neuronal subtypes in the mammalian cerebral cortex. Parnavelas JG, et al. **Ciba Found Symp** 1995;193:41-58; discussion 59-70 (35 ref.)

The generation of cellular diversity in the cerebral cortex. Price J, et al. **Ciba Found Symp** 1995;193:71-84; discussion 117-26 (13 ref.)

Cell lineage and patterns of migration in the developing cortex. Walsh C, et al. **Ciba Found Symp** 1995;193:21-40; discussion 59-70 (40 ref.)

Gene transfer to the mammalian brain using neural stem cells: a focus on trophic factors, neuroregeneration, and cholinergic neuron systems. Martínez-Serrano A, et al. **Clin Neurosci** 1995-96;3(5):301-9 (97 ref.)

Cortical development: layers of complexity. Gilmore EC, et al. **Curr Biol** 1997 Apr 1;7(4):R231-4 (23 ref.)

ICE-like proteases execute the neuronal death program. Martinou JC, et al. **Curr Opin Neurobiol** 1996 Oct; 6(5):609-14 (46 ref.)

Viral vectors for modulating gene expression in neurons. Slack RS, et al. **Curr Opin Neurobiol** 1996 Oct;6(5):576-83 (53 ref.)

Breaking the code: regulation of neuronal differentiation by spontaneous calcium transients. Gu X, et al. **Dev Neurosci** 1997;19(1):33-41 (57 ref.)

The transition from proliferation to differentiation in nerve cells: what can we learn from muscle? Piette J. **Exp Cell Res** 1997 Aug 1;234(2):193-204 (117 ref.)

CD15-containing glycoconjugates in the central nervous system. Gocht A, et al. **Histol Histopathol** 1996 Oct; 11(4):1007-28 (133 ref.)

Cytoplasmic mechanisms of axonal and dendritic growth in neurons. Heidemann SR. **Int Rev Cytol** 1996;165:235-96 (354 ref.)

Fractal methods and results in cellular morphology--dimensions, lacunarity and multifractals. Smith TG JR, et al. **J Neurosci Methods** 1996 Nov; 69(2):123-36 (35 ref.)

Mechanisms of neuronal cell death. An overview. Waters CM. **Mol Chem Neuropathol** 1996 May-Aug; 28(1-3):145-51 (41 ref.)

Role of laminin and integrin interactions in growth cone guidance. McKerracher L, et al. **Mol Neurobiol** 1996 Apr; 12(2):95-116 (157 ref.)

Programmed cell death in neurons: focus on the pathway of nerve growth factor deprivation-induced death of sympathetic neurons. Deshmukh M, et al. **Mol Pharmacol** 1997 Jun;51(6):897-906 (126 ref.)

The development of the noradrenergic transmitter phenotype in postganglionic sympathetic neurons. Ernsberger U, et al. **Neurochem Res** 1996 Jul;21(7):823-9 (60 ref.)

Neurotrophins live or let die: does p75NTR decide? Carter BD, et al. **Neuron** 1997 Feb;18(2):187-90 (24 ref.)

Neural stem cells are blasting off. Stemple DL, et al. **Neuron** 1997 Jan;18(1):1-4 (26 ref.)

Vertebrate neural induction: inducers, inhibitors, and a new synthesis. Wilson PA, et al. **Neuron** 1997 May;18(5):699-710 (92 ref.)

Neostriatal cell subtypes and their functional roles. Kawaguchi Y. **Neurosci Res** 1997 Jan;27(1):1-8 (77 ref.)

Does ciliary neurotrophic factor serve a different function in the rat versus the chicken? Finn T, et al. **Perspect Dev Neurobiol** 1996;4(1):91-9 (58 ref.)

The development of cholinergic sympathetic neurons: a role for neuropoietic cytokines? Landis SC. **Perspect Dev Neurobiol** 1996;4(1):53-63 (105 ref.)

Growth cone behaviors during axon guidance in the developing cerebral cortex. Kalil K. **Prog Brain Res** 1996; 108:31-40 (50 ref.)

The unipolar brush cells of the mammalian cerebellum and cochlear nucleus: cytology and microcircuitry. Mugnaini E, et al. **Prog Brain Res** 1997;114:131-50 (71 ref.)

Functional significance of excitatory projections from the precerebellar nuclei to interpositus and dentate nucleus neurons for mediating motor, premotor and parietal cortical inputs. Shinoda Y, et al. **Prog Brain Res** 1997;114:193-207 (49 ref.)

Physiology of transmission at a giant glutamatergic synapse in cerebellum. Slater NT, et al. **Prog Brain Res** 1997; 114:151-63 (47 ref.)

The subependymal zone: "brain marrow". Steindler DA, et al. **Prog Brain Res** 1996;108:349-63 (73 ref.)

Morphological and electrophysiological classification of hypothalamic supraoptic neurons. Armstrong WE. **Prog Neurobiol** 1995 Nov-Dec;47(4-5):291-339 (388 ref.)

Akt signaling: linking membrane events to life and death decisions [comment] Hemmings BA. **Science** 1997 Jan 31; 275(5300):628-30 (25 ref.) Comment on: Science 1997 Jan 31;275(5300):661-5. Comment on: Science 1997 Jan 31;275(5300):665-8.

Stem cells in the central nervous system. McKay R. **Science** 1997 Apr 4;276(5309):66-71 (72 ref.)

Diversity and pattern in the developing spinal cord [published erratum appears in Science 1997 Apr 4;276(5309):21] Tanabe Y, et al. **Science** 1996 Nov 15;274(5290):1115-23 (114 ref.)

Neuroblasts: a model for the asymmetric division of stem cells. Lin H, et al. **Trends Genet** 1997 Jan;13(1):33-9 (48 ref.)

Cold thoughts of death: the role of ICE proteases in neuronal cell death. Schwartz LM, et al. **Trends Neurosci** 1996 Dec; 19(12):555-62 (84 ref.)

Snake venom, fertilization and neurogenesis. Yedvobnick B. **Trends Neurosci** 1996 Dec;19(12):528-30 (17 ref.)

[Neuronal circuit formation of serotonin neuron system] Ueda S. **Kaibogaku Zasshi** 1997 Jun;72(3):187-90 (24 ref.) **(Jpn)**

[Helix-loop-helix transcription factor network regulating mammalian neurogenesis] Kageyama R, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):989-96 (25 ref.) **(Jpn)**

[The neuronal theory and new concepts of the structure of the nervous system] Novozhilova AP, et al. **Morfologiia** 1996;110(4):7-16 (74 ref.) (Eng. Abstr.) **(Rus)**

[The morphofunctional characteristics of the neurons and their connections in the neocortex of man and animals] Okhotin VE, et al. **Usp Fiziol Nauk** 1997 Apr-Jun; 28(2):40-56 (131 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Neuroprotective effects of melatonin. Lipartiti M, et al. **Adv Exp Med Biol** 1996;398:315-21 (28 ref.)

Neuropeptides and neuronal survival: neuroprotective strategy for Alzheimer's disease. Gozes I, et al. **Ann N Y Acad Sci** 1997 Apr 24;814:161-6 (33 ref.)

Functional changes in neuronal systems induced by phencyclidine administration. Nabeshima T, et al. **Ann N Y Acad Sci** 1996 Oct 31;801:29-38 (54 ref.)

Modulation of neuronal and glial cell function by adenosine and neuroprotection in vascular dementia. Rudolphi KA, et al. **Behav Brain Res** 1997 Feb;83(1-2):123-8 (27 ref.)

Effects of neurotrophins on the survival and regrowth of injured retinal neurons. Aguayo AJ, et al. **Ciba Found Symp** 1996;196:135-44; discussion 144-8 (42 ref.)

Growth factor function in the development and maintenance of midbrain dopaminergic neurons: concepts, facts and prospects for TGF-beta. Unsicker K, et al. **Ciba Found Symp** 1996;196:70-80; discussion 80-4 (41 ref.)

Neurotrophic factors as pharmacological agents for the treatment of injured auditory neurons. Van De Water TR, et al. **Ciba Found Symp** 1996;196:149-62; discussion 162-6 (38 ref.)

Therapy of myoclonus. Obeso JA. **Clin Neurosci** 1995-96; 3(4):253-7 (26 ref.)

L-2-chloropropionic acid-induced neurotoxicity in the rat: a valuable model for studying selective neuronal cell death in vivo. Widdowson PS, et al. **Gen Pharmacol** 1997 Aug; 29(2):113-9 (34 ref.)

Techniques for assessing neuroprotective drugs in vitro. Goldberg MP, et al. **Int Rev Neurobiol** 1997;40:69-93 (29 ref.)

Sodium and potassium channel modulators: their role in neuroprotection. Obrenovitch TP. **Int Rev Neurobiol** 1997; 40:109-35 (159 ref.)

NMDA antagonists: their role in neuroprotection. Small DL, et al. **Int Rev Neurobiol** 1997;40:137-71 (229 ref.)

Mechanism of amyloid beta protein induced neuronal cell death: current concepts and future perspectives. Behl C, et al. **J Neural Transm Suppl** 1997;49:125-34 (26 ref.)

The TaClo concept: 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline (TaClo), a new toxin for dopaminergic neurons. Bringmann G, et al. **J Neural Transm Suppl** 1995;46:235-44 (25 ref.)

Assessment of neurotoxicity and "neuroprotection". O'Byrne M, et al. **J Neural Transm Suppl** 1997;50:153-64 (51 ref.)

(-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. Tatton WG, et al. **J Neural Transm Suppl** 1996;48:45-59 (98 ref.)

Antisense oligonucleotides induce functional deletion of ligand gated ion channels in cultured neurons and brain explants. Brussaard AB. **J Neurosci Methods** 1997 Jan; 71(1):55-64 (21 ref.)

Ruthenium red as a tool to study calcium channels, neuronal death and the function of neural pathways. Tapia R, et al. **Neurochem Int** 1997 Feb;30(2):137-47 (59 ref.)

Neuroprotective effects of adenosine in cerebral ischemia: window of opportunity. Sweeney MI. **Neurosci Biobehav Rev** 1997 Mar;21(2):207-17 (132 ref.)

Mercurial-induced alterations in neuronal divalent cation homeostasis. Denny MF, et al. **Neurotoxicology** 1996 Spring;17(1):47-61 (90 ref.)

The relevance of axonal swellings and atrophy to gamma-diketone neurotoxicity: a forum position paper [see comments] LoPachin RM, et al. **Neurotoxicology** 1997; 18(1):7-22 (107 ref.) Comment in: Neurotoxicology 1997 ;18(1):23-4; discussion 37-40. Comment in: Neurotoxicology 1997 ;18(1):25-8; discussion 37-40. Comment in: Neurotoxicology 1997 ;18(1):29-30; discussion 37-10. Comment in: Neurotoxicology 1997 ;18(1):31-2; discussion 37-40. Comment in: Neurotoxicology 1997 ;18(1):33-6; discussion 37-40.

Cellular resistance to methylmercury. Sarafian TA, et al. **Neurotoxicology** 1996 Spring;17(1):27-36 (90 ref.)

Effects of mercurials on ligand- and voltage-gated ion channels: a review. Sirois JE, et al. **Neurotoxicology** 1996 Spring;17(1):63-84 (140 ref.)

Prevention of neuronal apoptotic death by neurotrophic agents and ganglioside GM1: insights and speculations regarding a common mechanism. Ferrari G, et al. **Perspect Dev Neurobiol** 1996;3(2):93-100 (67 ref.)

Neuronal ion channels as the target sites of insecticides. Narahashi T. **Pharmacol Toxicol** 1996 Jul;79(1):1-14 (146 ref.)

Functional and pharmacological properties of human neocortical neurons maintained in vitro. Avoli M, et al. **Prog Neurobiol** 1996 Apr;48(6):519-54 (127 ref.)

The behavioural and neuronal effects of the chronic administration of benzodiazepine anxiolytic and hypnotic drugs. Hutchinson MA, et al. **Prog Neurobiol** 1996 May; 49(1):73-97 (146 ref.)

Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. Schwarting RK, et al. **Prog Neurobiol** 1996 Jun; 49(3):215-66 (596 ref.)

Selective inhibitors of neuronal nitric oxide synthase--is no NOS really good NOS for the nervous system? Moore PK, et al. **Trends Pharmacol Sci** 1997 Jun;18(6):204-11 (120 ref.)

ENZYMOLOGY

PAF-synthesizing enzymes in neural cells during differentiation and in gerbil brain during ischemia. Francescangeli E, et al. **Adv Exp Med Biol** 1996;416:21-7 (48 ref.)

Neuronal Cdc2-like kinase: from cell cycle to neuronal function. Tang D, et al. **Biochem Cell Biol** 1996; 74(4):419-29 (56 ref.)

Regulation of neuronal nitric oxide synthase through alternative transcripts. Brenman JE, et al. **Dev Neurosci** 1997;19(3):224-31 (39 ref.)

Watch for ICE in neurodegeneration. Vasilakos J, et al. **Mol Psychiatry** 1996 Mar;1(1):72-6 (42 ref.)

Regulation of matrix metalloproteinase expressions in astrocytes, microglia and neurons. Gottschall PE, et al. **Neuroimmunomodulation** 1996 Mar-Jun;3(2-3):69-75 (57 ref.)

Targeted deletion of neuronal nitric oxide: a step closer to understanding its functional significance? Good M. **Trends Neurosci** 1996 Mar;19(3):83-4 (11 ref.)

IMMUNOLOGY

[Neuro-immuno-cutaneous system (NICS)] Misery L. **Pathol Biol (Paris)** 1996 Dec;44(10):867-74 (86 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Metabolic aspects of neurovascular coupling. Dirnagl U. **Adv Exp Med Biol** 1997;413:155-9 (35 ref.)

Angiotensin II stimulates protein phosphatase 2A activity in cultured neuronal cells via type 2 receptors in a pertussis toxin sensitive fashion. Huang XC, et al. **Adv Exp Med Biol** 1996;396:209-15 (25 ref.)

Metabolic coupling during activation. A cellular view. Magistretti PJ, et al. **Adv Exp Med Biol** 1997;413:161-6 (32 ref.)

Heterogeneity of angiotensin type 2 (AT2) receptors. Reagan LP, et al. **Adv Exp Med Biol** 1996;396:199-208 (25 ref.)

Target regulation of VIP expression in sympathetic neurons. Habecker BA, et al. **Ann N Y Acad Sci** 1997 Apr 24; 814:198-208 (47 ref.)

Regulation of neuropeptide expression in sympathetic neurons. Paracrine and retrograde influences. Zigmond RE, et al. **Ann N Y Acad Sci** 1997 Apr 24;814:181-97 (90 ref.)

Myosin drives retrograde F-actin flow in neuronal growth cones. Lin CH, et al. **Biol Bull** 1997 Feb;192(1):183-5 (29 ref.)
Intricate regulation of nitric oxide synthesis in neurons. Hu J, et al. **Cell Signal** 1996 Mar;8(3):185-9 (68 ref.)
Disruption of brain cell ion homeostasis in Alzheimer's disease by oxy radicals, and signaling pathways that protect therefrom. Mattson MP, et al. **Chem Res Toxicol** 1997 May; 10(5):507-17 (85 ref.)
A defective herpes simplex virus vector system for gene delivery into the brain: comparison with alternative gene delivery systems and usefulness for gene therapy. Neve RL, et al. **Clin Neurosci** 1995-96;3(5):262-7 (90 ref.)
Neuronal sorting and processing of amyloid precursor protein: implications for Alzheimer's disease. Tienari PJ, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:575-85 (67 ref.)
Molecular mechanisms mediating axon pathway formation. Johansen J, et al. **Crit Rev Eukaryot Gene Expr** 1997; 7(1-2):95-116 (158 ref.)
The molecular biology of neuronal nicotinic acetylcholine receptors. Boyd RT. **Crit Rev Toxicol** 1997 May; 27(3):299-318 (164 ref.)
Retinal development: communication helps you see the light. Wechsler-Reya RJ, et al. **Curr Biol** 1997 Jul 1;7(7):R433-6 (16 ref.)
Ca2+-dependent regulation in neuronal gene expression. Bito H, et al. **Curr Opin Neurobiol** 1997 Jun;7(3):419-29 (139 ref.)
Sodium channel expression: a dynamic process in neurons and non-neuronal cells. Black JA, et al. **Dev Neurosci** 1996; 18(3):139-52 (101 ref.)
A role for astrocytes in glucose delivery to neurons? Forsyth R, et al. **Dev Neurosci** 1996;18(5-6):360-70 (74 ref.)
The time course of loss of dopaminergic neurons and the gliotic reaction surrounding grafts of embryonic mesencephalon to the striatum. Barker RA, et al. **Exp Neurol** 1996 Sep;141(1):79-93 (95 ref.)
Glucose transporter proteins in brain: delivery of glucose to neurons and glia. Vannucci SJ, et al. **Glia** 1997 Sep; 21(1):2-21 (140 ref.)
Fibroblast growth factor and its implications for developing and regenerating neurons. Grothe C, et al. **Int J Dev Biol** 1996 Feb;40(1):403-10 (86 ref.)
Neurogenic nitric oxide (NO) in the regulation of cerebroarterial tone. Toda N, et al. **J Chem Neuroanat** 1996 Jun;10(3-4):259-65 (40 ref.)
Plasmalogen-selective phospholipase A2 and its role in signal transduction. Yang HC, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1-3):9-13 (13 ref.)
The role of neurotransporters in excitotoxicity, neuronal cell death, and other neurodegenerative processes. Lesch KP, et al. **J Mol Med** 1996 Jul;74(7):365-78 (107 ref.)
Development of mesencephalic dopaminergic neurons and the transforming growth factor-beta superfamily. Krieglstein K, et al. **J Neural Transm Suppl** 1995;46:209-16 (32 ref.)
Molecular heterogeneity of neurotransporters: implications for neurodegeneration. Lesch KP, et al. **J Neural Transm Suppl** 1997;49:155-67 (33 ref.)
Plasmid-mediated gene transfer in neurons using the biolistics technique. Biewenga JE, et al. **J Neurosci Methods** 1997 Jan;71(1):67-75 (45 ref.)
Overexpression of growth-associated proteins in the neurons of adult transgenic mice. Caroni P. **J Neurosci Methods** 1997 Jan;71(1):3-9 (19 ref.)
Neuromodulation by Mg2+ and polyamines of excitatory amino acid currents in rodent neurones in culture. Kumamoto E. **Magnes Res** 1996 Dec;9(4):317-27 (50 ref.)
Use of antisense-generating plasmids to probe the function of signal transduction proteins in primary neurons. Abogadie FC, et al. **Methods Mol Biol** 1997;83:217-25 (7 ref.)
Heterologous expression of receptors and signaling proteins in adult mammalian sympathetic neurons by microinjection. Ikeda SR. **Methods Mol Biol** 1997;83:191-202 (15 ref.)
Dopaminergic and GABAergic retinal cell populations in mammals. Nguyen-Legros J, et al. **Microsc Res Tech** 1997 Jan 1;36(1):26-42 (140 ref.)
Neurotrophin receptors and selective loss of cholinergic neurons in Alzheimer disease. Boissière F, et al. **Mol Chem Neuropathol** 1996 May-Aug;28(1-3):219-23 (17 ref.)
Astrocytes and the delivery of glucose from plasma to neurons. Forsyth RJ. **Neurochem Int** 1996 Mar;28(3):231-41 (46 ref.)
Cascade of gene expression induced by Ca2+ signals in neurons. Tsuda M. **Neurochem Int** 1996 Nov;29(5):443-51 (49 ref.)
Retroactive motors. Schnapp BJ. **Neuron** 1997 Apr; 18(4):523-6 (24 ref.)
mRNA localization in neurons: a multipurpose mechanism? Steward O. **Neuron** 1997 Jan;18(1):9-12 (19 ref.)
Measurements of scattering and absorption changes in muscle and brain. Gratton E, et al. **Philos Trans R Soc Lond B Biol Sci** 1997 Jun 29; 352(1354):727-35 (50 ref.)
Gramicidin perforated patch recording and intracellular chloride activity in excitable cells. Akaike N. **Prog Biophys Mol Biol** 1996;65(3):251-64 (40 ref.)
Modulation of acetylcholine release by nitric oxide. Kilbinger H. **Prog Brain Res** 1996;109:219-24 (33 ref.)
Activation of c-fos in the brain. Herrera DG, et al. **Prog Neurobiol** 1996 Oct;50(2-3):83-107 (265 ref.)
25 years since the discovery of presynaptic receptors: present knowledge and future perspectives. Langer SZ. **Trends Pharmacol Sci** 1997 Mar;18(3):95-9 (39 ref.)

PATHOLOGY

Transport of pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier and the prevention of ischemia-induced death of hippocampal neurons. Banks WA, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:270-7; discussion 277-9 (50 ref.)
Endocrine modulators of necrotic neuron death. Chan RS, et al. **Brain Pathol** 1996 Oct;6(4):481-91 (138 ref.)
Mechanisms of neuronal death in Alzheimer's disease. Cotman CW, et al. **Brain Pathol** 1996 Oct;6(4):493-506 (83 ref.)
Similarity of neuronal cell injury and death in AIDS dementia and focal cerebral ischemia: potential treatment with NMDA open-channel blockers and nitric oxide-related species. Lipton SA. **Brain Pathol** 1996 Oct;6(4):507-17 (117 ref.)
Binocularity in prism-reared monkeys. Crawford ML, et al. **Eye** 1996;10 (Pt 2):161-6 (26 ref.)
Mechanisms of nerve cell death: apoptosis or necrosis after cerebral ischaemia. Chalmers-Redman RM, et al. **Int Rev Neurobiol** 1997;40:1-25 (181 ref.)
Neuronal vulnerability in Parkinson's disease. Hirsch EC, et al. **J Neural Transm Suppl** 1997;50:79-88 (36 ref.)
Modulation of control mechanisms of dopamine-induced apoptosis--a future approach to the treatment of Parkinson's disease? Ziv I, et al. **J Neural Transm Suppl** 1997;49:195-202 (21 ref.)
Nigrostriatal neuronal death in Parkinson's disease--a passive or an active genetically-controlled process? Ziv I, et al. **J Neural Transm Suppl** 1997;49:69-76 (26 ref.)
Histopathologic clues to the pathways of neuronal death following ischemia/hypoxia. Rosenblum WI. **J Neurotrauma** 1997 May;14(5):313-26 (47 ref.)
Neurotrophin receptors and selective loss of cholinergic neurons in Alzheimer disease. Boissière F, et al. **Mol Chem Neuropathol** 1996 May-Aug;28(1-3):219-23 (17 ref.)
Ischemic neuronal damage. How does mild hypothermia modulate it? Kataoka K, et al. **Mol Chem Neuropathol** 1996 May-Aug;28(1-3):191-5 (9 ref.)
Neurodegeneration in Alzheimer disease. Is apoptosis involved? Kusiak JW, et al. **Mol Chem Neuropathol** 1996 May-Aug;28(1-3):153-62 (41 ref.)
How do neurons degenerate in transmissible spongiform encephalopathies? Liberski PP. **Mol Chem Neuropathol** 1996 May-Aug;28(1-3):245-9 (10 ref.)
Pathogenic mechanisms of neuronal damage in the AIDS dementia complex. Swingler S. **Mol Pathol** 1997 Apr; 50(2):72-6 (72 ref.)
Mouse Moloney leukemia virus infects microglia but not neurons even though it induces motor neuron disease. Zachary JF, et al. **Mol Psychiatry** 1997 Mar;2(2):104-6 (19 ref.)
Energy metabolism, oxidative stress and neuronal degeneration in Alzheimer's disease. Sims NR. **Neurodegeneration** 1996 Dec;5(4):435-40 (49 ref.)
X-linked malformations of neuronal migration. Dobyns WB, et al. **Neurology** 1996 Aug;47(2):331-9 (65 ref.)
Neuronal damage and its relation to dementia in acquired immunodeficiency syndrome (AIDS). Trillo-Pazos G, et al. **Pathobiology** 1996;64(6):295-307 (126 ref.)
Neuropathology of the gut. Singaram C. **Semin Neurol** 1996 Sep;16(3):227-34 (73 ref.)

PHYSIOLOGY

The development of nerve connections in the peripheral nervous system. Cullheim S. **Acta Paediatr Suppl** 1996 Oct; 416:3-7 (24 ref.)
Transmission and processing of synaptic information in single neurones: an introduction. Kiehn O, et al. **Acta Physiol Scand** 1996 Jul;157(3):367-8 (4 ref.)
Active membrane properties and spatiotemporal synaptic integration in dendrites of vertebrate neurones. Midtgaard J. **Acta Physiol Scand** 1996 Jul;157(3):395-401 (50 ref.)
Can we measure correlates of neuronal activity with non-invasive optical methods? Gratton G, et al. **Adv Exp Med Biol** 1997;413:53-62 (27 ref.)
Neuronal-vascular coupling. A unifying hypothesis. Kuschinsky W. **Adv Exp Med Biol** 1997;413:167-76 (28 ref.)
Taurine deficiency and neuronal migration. Morán J, et al. **Adv Exp Med Biol** 1996;403:519-26 (24 ref.)
Characterization of the volume-activated taurine pathway in cultured cerebellar granule neurons. Pasantes-Morales H, et al. **Adv Exp Med Biol** 1996;403:393-400 (27 ref.)
Novel molecular correlates of neuronal death and regeneration. Chen SC, et al. **Adv Neurol** 1996;71:433-49; discussion 449-50 (166 ref.)
Herpes simplex virus-1 plasmid vectors for gene transfer into neurons. Geller AI. **Adv Neurol** 1997;72:143-8 (35 ref.)
Lesion-induced neuronal reorganization in the spinal cord: morphological aspects. Nacimiento W, et al. **Adv Neurol** 1997;73:37-59 (102 ref.)
Neuronal necrosis and apoptosis: two distinct events induced by exposure to glutamate or oxidative stress. Nicotera P, et al. **Adv Neurol** 1997;72:95-101 (53 ref.)
Related mechanisms of action of growth factors and antioxidants in apoptosis: an overview. Oppenheim RW. **Adv Neurol** 1997;72:69-78 (40 ref.)
Potential of neural "stem-like" cells for gene therapy and repair of the degenerating central nervous system. Snyder EY, et al. **Adv Neurol** 1997;72:121-32 (69 ref.)
Mechanisms of neuronal degeneration: a final common pathway? Troy CM, et al. **Adv Neurol** 1997;72:103-11 (68 ref.)
Neural plasticity as studied in neuronal cell lines. Wainer BH, et al. **Adv Neurol** 1997;72:133-42 (31 ref.)
Gene expression and CREB phosphorylation induced by cAMP and Ca2+ in neuronal cells. Hagiwara M, et al. **Adv Pharmacol** 1996;36:277-85 (11 ref.)
Survival, regeneration and sprouting of central neurons: the rat septohippocampal projection as a model. Frotscher M, et al. **Anat Anz** 1996 Aug;178(4):311-5 (33 ref.)
Pituitary adenylate cyclase-activating polypeptides, PACAP-38 and PACAP-27, regulation of sympathetic neuron catecholamine, and neuropeptide Y expression through activation of type I PACAP/VIP receptor isoforms. Braas KM, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:204-16; discussion 217-8 (47 ref.)
Region-specific regulation of neurogenesis by VIP and PACAP: direct and indirect modes of action. DiCicco-Bloom E. **Ann N Y Acad Sci** 1996 Dec 26; 805:244-56; discussion 256-8 (30 ref.)
Glutamate receptors in the central nervous system. Jonas P. **Ann N Y Acad Sci** 1993 Dec 20;707:126-35 (29 ref.)
The control of fluid-secreting epithelia by VIP. Martin SC, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:133-47; discussion 147-8 (64 ref.)
Interplay of VIP and nitric oxide in the regulation of neuromuscular function in the gut. Murthy KS, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:355-62; discussion 362-3 (27 ref.)
Mating-induced c-fos expression patterns complement and supplement observations after lesions in the male Syrian hamster brain. Newman SW, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:239-59 (44 ref.)
Neural correlates of sensitive periods in avian song learning. Nordeen KW. **Ann N Y Acad Sci** 1997 Jan 15;807:386-400 (109 ref.)
Vasoactive intestinal peptide and nitric oxide: divergent roles in relation to tissue injury. Said SI. **Ann N Y Acad Sci** 1996 Dec 26;805:379-87; discussion 387-8 (60 ref.)
Pituitary adenylate cyclase-activating peptide in sensory and autonomic ganglia: localization and regulation. Sundler F, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:410-26; discussion 427-8 (76 ref.)
Long-term depression in hippocampus. Bear MF, et al. **Annu Rev Neurosci** 1996;19:437-62 (113 ref.)
Information coding in the vertebrate olfactory system. Buck LB. **Annu Rev Neurosci** 1996;19:517-44 (187 ref.)
The significance of neural ensemble codes during behavior and cognition. Deadwyler SA, et al. **Annu Rev Neurosci** 1997;20:217-44 (91 ref.)
Gene transfer to neurons using herpes simplex virus-based vectors. Fink DJ, et al. **Annu Rev Neurosci** 1996;19:265-87 (111 ref.)
Mechanisms and molecules that control growth cone guidance. Goodman CS. **Annu Rev Neurosci** 1996; 19:341-77 (178 ref.)
Vertebrate neural induction. Hemmati-Brivanlou A, et al. **Annu Rev Neurosci** 1997;20:43-60 (70 ref.)
The neurotrophins and CNTF: two families of collaborative neurotrophic factors. Ip NY, et al. **Annu Rev Neurosci** 1996; 19:491-515 (137 ref.)
Active properties of neuronal dendrites. Johnston D, et al. **Annu Rev Neurosci** 1996;19:165-86 (150 ref.)
Neuronal intermediate filaments. Lee MK, et al. **Annu Rev Neurosci** 1996;19:187-217 (229 ref.)
Physiology of the neurotrophins. Lewin GR, et al. **Annu Rev Neurosci** 1996;19:289-317 (203 ref.)
Learning and memory in honeybees: from behavior to neural substrates. Menzel R, et al. **Annu Rev Neurosci** 1996; 19:379-404 (204 ref.)
An urge to explain the incomprehensible: Geoffrey Harris and the discovery of the neural control of the pituitary gland. Raisman G. **Annu Rev Neurosci** 1997;20:533-66 (112 ref.)
Intracellular signaling pathways activated by neurotrophic factors. Segal RA, et al. **Annu Rev Neurosci** 1996;19:463-89 (208 ref.)
Inferotemporal cortex and object vision. Tanaka K. **Annu Rev Neurosci** 1996;19:109-39 (102 ref.)
Synaptic regulation of mesocorticolimbic dopamine neurons. White FJ. **Annu Rev Neurosci** 1996;19:405-36 (191 ref.)
O2-sensing mechanisms in excitable cells: role of plasma membrane K+ channels. Haddad GG, et al. **Annu Rev Physiol** 1997;59:23-42 (73 ref.)
Molecular basis of neuronal biorhythms and paroxysms. Grisar T, et al. **Arch Physiol Biochem** 1996 Oct; 104(6):770-4 (20 ref.)
Electrophysiological studies of 5-hydroxytryptamine receptors on enteric neurons. Galligan JJ. **Behav Brain Res** 1996;73(1-2):199-201 (19 ref.)
Patterns of synaptic and nerve cell pathology in Alzheimer's disease. Lassmann H. **Behav Brain Res** 1996 Jun;78(1):9-14 (61 ref.)
The central regulation of energy homeostasis: roles of neuropeptide Y and other brain peptides. Bing C, et al.

Biochem Soc Trans 1996 May;24(2):559–65 (47 ref.)
Spatial features of calcium-regulated gene expression. Finkbeiner S, et al. **Bioessays** 1997 Aug;19(8):657–60 (26 ref.)
The activation of bulbo-spinal controls by peripheral nociceptive inputs: diffuse noxious inhibitory controls. Villanueva L, et al. **Biol Res** 1995;28(1):113–25 (96 ref.)
Apoptosis: an identical central or collateral mechanism in the development, function and death of neurons [editorial] Mathé G. **Biomed Pharmacother** 1997;51(3):97–100 (43 ref.)
Programmed cell death in the developing nervous system. Burek MJ, et al. **Brain Pathol** 1996 Oct;6(4):427–46 (156 ref.)
Neuronal death in developmental models: possible implications in neuropathology. Johnson EM Jr, et al. **Brain Pathol** 1996 Oct;6(4):397–409 (88 ref.)
Axotomy as an experimental model of neuronal injury and cell death. Koliatsos VE, et al. **Brain Pathol** 1996 Oct; 6(4):447–65 (164 ref.)
Laminin and the mechanism of neuronal outgrowth. Luckenbill-Edds L. **Brain Res Brain Res Rev** 1997 Feb; 23(1–2):1–27 (98 ref.)
The acoustic startle reflex: neurons and connections. Yeomans JS, et al. **Brain Res Brain Res Rev** 1995 Nov; 21(3):301–14 (79 ref.)
Comparison of neuronal activity in the supplementary motor area and primary motor cortex. Tanji J, et al. **Brain Res Cogn Brain Res** 1996 Mar;3(2):143–50 (80 ref.)
Regulatory mechanisms in stem cell biology. Morrison SJ, et al. **Cell** 1997 Feb 7;88(3):287–98 (112 ref.)
Modulation of in vivo neuronal sprouting by serotonin in the adult CNS of the snail. Baker MW, et al. **Cell Mol Neurobiol** 1996 Oct;16(5):561–76 (50 ref.)
From oocyte to neuron: do neurotransmitters function in the same way throughout development? Buznikov GA, et al. **Cell Mol Neurobiol** 1996 Oct;16(5):537–59 (150 ref.)
Potential neuronal mechanisms of estrogen actions in synaptogenesis and synaptic plasticity. Naftolin F, et al. **Cell Mol Neurobiol** 1996 Apr;16(2):213–23 (30 ref.)
Neuronal signal substances in asexual multiplication and development in flatworms. Reuter M, et al. **Cell Mol Neurobiol** 1996 Oct;16(5):591–616 (75 ref.)
Neuronal units linked to microvascular modules in cerebral cortex: response elements for imaging the brain. Woolsey TA, et al. **Cereb Cortex** 1996 Sep–Oct;6(5):647–60 (126 ref.)
Factors affecting neuronal birth and death in the mammalian olfactory epithelium. Calof AL, et al. **Ciba Found Symp** 1996;196:188–205; discussion; 205–10 (47 ref.)
The roles of growth factors and neural activity in the development of the neocortex. Price DJ, et al. **Ciba Found Symp** 1995;193:231–50; discussion 251–7 (35 ref.)
The supply of vasomotor drive to individual classes of sympathetic neuron. McAllen RM, et al. **Clin Exp Hypertens** 1997 Jul–Aug;19(5–6):607–18 (22 ref.)
Limits of parallel processing: excitatory convergence of different information channels on single neurons in striate and extrastriate visual cortices. Dreher B, et al. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov; 23(10–11):913–25 (81 ref.)
Experimental basis for realistic large-scale computer simulation of the enteric nervous system. Furness JB, et al. **Clin Exp Pharmacol Physiol** 1996 Sep;23(9):786–92 (27 ref.)
In vivo development of neuronal structure and function. Cline HT, et al. **Cold Spring Harb Symp Quant Biol** 1996; 61:95–104 (35 ref.)
Nitric oxide, cell multiplication, and cell survival. Peunova N, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:417–26 (54 ref.)
Attention, awareness, and the triangular circuit. LaBerge D. **Conscious Cogn** 1997 Jun–Sep;6(2–3):149–81 (120 ref.)
Neuronal circuit regulation of the hypothalamo–pituitary–adrenocortical stress axis. Herman JP, et al. **Crit Rev Neurobiol** 1996;10(3–4):371–94 (206 ref.)
The role of mesoprefrontal dopamine neurons in stress. Horger BA, et al. **Crit Rev Neurobiol** 1996;10(3–4):395–418 (232 ref.)
Regulation of substantia nigra dopamine neurons. Pucak ML, et al. **Crit Rev Neurobiol** 1994;9(1):67–89 (178 ref.)
The frontal cortex–basal ganglia system in primates. Wise SP, et al. **Crit Rev Neurobiol** 1996;10(3–4):317–56 (443 ref.)
Nongenomic actions of estrogen in the brain: physiological significance and cellular mechanisms. Wong M, et al. **Crit Rev Neurobiol** 1996;10(2):189–203 (114 ref.)
Neurobiology of nitric oxide. Yun HY, et al. **Crit Rev Neurobiol** 1996;10(3–4):291–316 (225 ref.)
Neuronal firing: does function follow form? Connors BW, et al. **Curr Biol** 1996 Dec 1;6(12):1560–2 (16 ref.)
Visual attention: spotlights, highlights and visual awareness. Newsome WT. **Curr Biol** 1996 Apr 1;6(4):357–60 (19 ref.)
Neurophysiology: the changing face of inhibition. Singer W. **Curr Biol** 1996 Apr 1;6(4):395–7 (10 ref.)
Neural coding: The enigma of the brain. Stevens CF, et al. **Curr Biol** 1995 Dec 1;5(12):1370–1 (10 ref.)
Motor proteins: myosin V--the multi-purpose transport motor. Titus MA. **Curr Biol** 1997 May 1;7(5):R301–4 (26 ref.)
Neural development: identical twins separated at birth? Walsh CA. **Curr Biol** 1996 Jan 1;6(1):26–8 (15 ref.)
Calcium regulation of neurotransmitter release: reliably unreliable? Goda Y, et al. **Curr Opin Cell Biol** 1997 Aug; 9(4):513–8 (40 ref.)
Regulation of vertebrate neural cell fate by transcription factors. Bang AG, et al. **Curr Opin Neurobiol** 1996 Feb; 6(1):25–32 (79 ref.)
Structure/function relationships of axon-associated adhesion receptors of the immunoglobulin superfamily. Brümmendorf T, et al. **Curr Opin Neurobiol** 1996 Oct; 6(5):584–93 (80 ref.)
Neuronal progenitors as tools for cell replacement in the nervous system. Brüstle O, et al. **Curr Opin Neurobiol** 1996 Oct;6(5):688–95 (81 ref.)
Ischemia-induced neuronal apoptosis. Choi DW. **Curr Opin Neurobiol** 1996 Oct;6(5):667–72 (55 ref.)
Neurogenesis in the insect central nervous system. Doe CQ, et al. **Curr Opin Neurobiol** 1996 Feb;6(1):18–24 (48 ref.)
Towards the neuronal correlate of visual awareness. Koch C, et al. **Curr Opin Neurobiol** 1996 Apr;6(2):158–64 (56 ref.)
The Notch pathway: democracy and aristocracy in the selection of cell fate. Kopan R, et al. **Curr Opin Neurobiol** 1996 Oct;6(5):594–601 (61 ref.)
The role of positive and negative signals in somite patterning. Lassar AB, et al. **Curr Opin Neurobiol** 1996 Feb;6(1):57–63 (64 ref.)
Rho family GTP-binding proteins in growth cone signalling. Luo L, et al. **Curr Opin Neurobiol** 1997 Feb;7(1):81–6 (43 ref.)
ICE-like proteases execute the neuronal death program. Martinou JC, et al. **Curr Opin Neurobiol** 1996 Oct; 6(5):609–14 (46 ref.)
Paired recordings from neurones. Miles R, et al. **Curr Opin Neurobiol** 1996 Jun;6(3):387–94 (73 ref.)
Head direction cells: properties and functional significance. Muller RU, et al. **Curr Opin Neurobiol** 1996 Apr; 6(2):196–206 (40 ref.)
Caged compounds: tools for illuminating neuronal responses and connections. Nerbonne JM. **Curr Opin Neurobiol** 1996 Jun;6(3):379–86 (54 ref.)
The neural system of language: structure and development. Nobre AC, et al. **Curr Opin Neurobiol** 1997 Apr;7(2):262–8 (58 ref.)
Tripartite signaling of pattern: interactions between Hedgehogs, BMPs and Wnts in the control of vertebrate development. Roelink H. **Curr Opin Neurobiol** 1996 Feb; 6(1):33–40 (78 ref.)
Dopamine neurons and their role in reward mechanisms. Schultz W. **Curr Opin Neurobiol** 1997 Apr;7(2):191–7 (83 ref.)
Ion channel associated proteins. Sheng M, et al. **Curr Opin Neurobiol** 1996 Oct;6(5):602–8 (63 ref.)
Neural basis of utility estimation. Shizgal P. **Curr Opin Neurobiol** 1997 Apr;7(2):198–208 (76 ref.)
Vertebrate neural progenitor cells: subtypes and regulation. Temple S, et al. **Curr Opin Neurobiol** 1996 Feb;6(1):11–7 (65 ref.)
Cellular mechanisms for preservation of timing in central auditory pathways. Trussell LO. **Curr Opin Neurobiol** 1997 Aug;7(4):487–92 (49 ref.)
Neuronal pathfinding and recognition: roles of cell adhesion molecules. Chiba A, et al. **Dev Biol** 1996 Dec 15; 180(2):424–32 (86 ref.)
Regulation of neuronal birth, migration and death in the rat dentate gyrus. Gould E, et al. **Dev Neurosci** 1996; 18(1–2):22–35 (101 ref.)
Cell culture approaches to understanding the actions of steroid hormones on the insect nervous system. Levine RB, et al. **Dev Neurosci** 1996;18(1–2):73–86 (72 ref.)
Signaling pathways that regulate specification of neurons in developing cerebral cortex. Levitt P, et al. **Dev Neurosci** 1997;19(1):6–8 (39 ref.)
Cerebellar afferents to neuroendocrine cells: implications for adaptive responses to simulated weightlessness. Katafuchi T, et al. **Endocr J** 1995 Dec;42(6):729–37 (42 ref.)
Exocytosis in excitable cells: a conserved molecular machinery from yeast to neuron. Lledo PM. **Eur J Endocrinol** 1997 Jul;137(1):1–9 (55 ref.)
The time course of loss of dopaminergic neurons and the gliotic reaction surrounding grafts of embryonic mesencephalon to the striatum. Barker RA, et al. **Exp Neurol** 1996 Sep;141(1):79–93 (95 ref.)
Steroid hormones and excitability in the mammalian brain. Joëls M. **Front Neuroendocrinol** 1997 Jan;18(1):2–48 (235 ref.)
Neuronal cell death in the mammalian nervous system: the calmortin hypothesis. Bennett MR, et al. **Gen Pharmacol** 1996 Apr;27(3):407–19 (220 ref.)
Intracellular and molecular aspects of Ca(2+)-mediated signal transduction in neuronal cells. Račay P, et al. **Gen Physiol Biophys** 1996 Aug;15(4):273–89 (89 ref.)
Control of Ca2+ homeostasis in neuronal cells. Račay P, et al. **Gen Physiol Biophys** 1996 Jun;15(3):193–210 (92 ref.)
Changes in astrocytic glutamate catabolism enzymes following neuronal degeneration or viral infection. Belin MF, et al. **Glia** 1997 Sep;21(1):154–61 (80 ref.)
LTP and spatial learning--where to next? Jeffery KJ. **Hippocampus** 1997;7(1):95–110 (105 ref.)
Cognitive maps beyond the hippocampus. Redish AD, et al. **Hippocampus** 1997;7(1):15–35 (182 ref.)
Role of NPY neurones in GH-dependent feedback signalling to the brain. Chan YY, et al. **Horm Res** 1996;45 Suppl 1:12–4 (10 ref.)
Neuronal basis of amblyopia: a review. Grigg J, et al. **Indian J Ophthalmol** 1996 Jun;44(2):69–76 (40 ref.)
Neuronal laminins and their cellular receptors. Powell SK, et al. **Int J Biochem Cell Biol** 1997 Mar;29(3):401–14 (133 ref.)
Spontaneous signalling in small central neurons: mechanisms and roles of spike-amplitude and spike-interval fluctuations. Arhem P, et al. **Int J Neural Syst** 1996 Sep; 7(4):369–76 (39 ref.)
A low-dimensional, time-resolved and adapting model neuron. Cartling B. **Int J Neural Syst** 1996 Jul;7(3):237–46 (54 ref.)
Random activity at the microscopic neural level in cortex ("noise") sustains and is regulated by low-dimensional dynamics of macroscopic cortical activity ("chaos"). Freeman WJ. **Int J Neural Syst** 1996 Sep;7(4):473–80 (29 ref.)
A higher order Bayesian neural network with spiking units. Lansner A, et al. **Int J Neural Syst** 1996 May;7(2):115–28 (54 ref.)
Role of chaos in trial-and-error problem solving by an artificial neural network. Obana I, et al. **Int J Neural Syst** 1996 Mar;7(1):101–8 (20 ref.)
An attractor neural network model of classical conditioning. Serulnik SD, et al. **Int J Neural Syst** 1996 Mar;7(1):1–18 (42 ref.)
Low-frequency oscillations of visual, auditory and somatosensory cortical neurons evoked by sensory stimulation. Dinse HR, et al. **Int J Psychophysiol** 1997 Jun; 26(1–3):205–27 (31 ref.)
Neuronal coupling in rod-signal pathways of the retina. Vaney DI. **Invest Ophthalmol Vis Sci** 1997 Feb; 38(2):267–73 (24 ref.)
Neuronal nicotinic acetylcholine receptors. Lindstrom J. **Ion Channels** 1996;4:377–450 (270 ref.)
Glial-glial and glial-neuronal interfaces in radiation-induced, glia-depleted spinal cord. Gilmore SA, et al. **J Anat** 1997 Jan;190 (Pt 1):5–21 (51 ref.)
Electrophysiological effects of ATP on brain neurones. Illes P, et al. **J Auton Pharmacol** 1996 Dec;16(6):407–11 (51 ref.)
Why do cats need a dorsal cochlear nucleus? Nelken I, et al. **J Basic Clin Physiol Pharmacol** 1996;7(3):199–220 (74 ref.)
Neurons and receptors in the rostroventrolateral medulla mediating the antihypertensive actions of drugs acting at imidazoline receptors. Reis DJ. **J Cardiovasc Pharmacol** 1996;27 Suppl 3:S11–18 (65 ref.)
Generation of field potentials in the brain. Speckmann EJ. **J Clin Pharmacol** 1997 Jan;37(1 Suppl):8S–10S (10 ref.)
The King Solomon Lectures in Neuroethology. Deciding about motion: linking perception to action. Newsome WT. **J Comp Physiol [A]** 1997 Jul;181(1):5–12 (47 ref.)
Cellular aspects of HIV-1 infection of macrophages leading to neuronal dysfunction in in vitro models for HIV-1 encephalitis. Nottet HS, et al. **J Leukoc Biol** 1997 Jul; 62(1):107–16 (112 ref.)
Transmitter modulation of neuronal calcium channels. Jones SW, et al. **J Membr Biol** 1997 Jan 1;155(1):1–10 (97 ref.)
Clinical implications of the involvement of tPA in neuronal cell death. Tsirka SE. **J Mol Med** 1997 May;75(5):341–7 (52 ref.)
Mechanism of 6-hydroxydopamine neurotoxicity. Glinka Y, et al. **J Neural Transm Suppl** 1997;50:55–66 (41 ref.)
Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites. Hastings TG, et al. **J Neural Transm Suppl** 1997;49:103–10 (37 ref.)
Central nervous system cytokines and their relevance for neurotoxicity and apoptosis. Licinio J. **J Neural Transm Suppl** 1997;49:169–75 (28 ref.)
Developmental and genetic regulation of programmed neuronal death. Weller M, et al. **J Neural Transm Suppl** 1997;50:115–23 (29 ref.)
Molecular mechanisms in synaptic vesicle recycling. Bauerfeind R, et al. **J Neurocytol** 1996 Dec;25(12):701–15 (139 ref.)
Genetic analysis of cholinergic nerve terminal function in invertebrates. Baylis HA, et al. **J Neurocytol** 1996 Dec; 25(12):747–62 (100 ref.)
The role of synapses in cortical computation. Douglas RJ, et al. **J Neurocytol** 1996 Dec;25(12):893–911 (104 ref.)
Ultrastructural view of central catecholaminergic transmission: immunocytochemical localization of synthesizing enzymes, transporters and receptors. Pickel VM, et al. **J Neurocytol** 1996 Dec;25(12):843–56 (141 ref.)
Ultrastructural basis for gene expression at the synapse: synapse-associated polyribosome complexes. Steward O, et al. **J Neurocytol** 1996 Dec;25(12):717–34 (51 ref.)
The methodology and scope of human microneurography. Gandevia SC, et al. **J Neurosci Methods** 1997 Jun 27; 74(2):123–36 (87 ref.)
Roles of metabotropic glutamate receptors in glial function and glial-neuronal communication. Winder DG, et al. **J Neurosci Res** 1996 Oct 15;46(2):131–7 (63 ref.)
The whiplash (hyperextension-flexion) syndrome: a disorder of dorsal root ganglion neurons? [editorial] Waxman SG, et al. **J Neurotrauma** 1996 Dec;13(12):735–9 (60 ref.)
Herpes simplex virus vectors for gene transfer to the nervous system. Goins WF, et al. **J Neurovirol** 1997 May;3 Suppl 1:S80–8 (91 ref.)
An intracellular study of space and time representation in primary visual cortical receptive fields. Frégnac Y, et al. **J Physiol Paris** 1996;90(3–4):189–97 (57 ref.)
Redistribution of synaptic efficacy: a mechanism to generate

infinite synaptic input diversity from a homogeneous population of neurons without changing absolute synaptic efficacies. Markram H, et al. **J Physiol Paris** 1996; 90(3–4):229–32 (12 ref.)

Behavioral, neural and cellular components underlying olfactory learning in the honeybee. Menzel R, et al. **J Physiol Paris** 1996;90(5–6):395–8 (36 ref.)

Model experiments on squid axons and NG108–15 mouse neuroblastoma x rat glioma hybrid cells. Schmitt H, et al. **J Physiol Paris** 1995;89(4–6):181–93 (61 ref.)

Origin and morphogenesis of neurons in the frog cardiac ganglion. Heathcote RD. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1997 Jan; 13(1):36–41 (21 ref.)

ICAM-1 as a potential target for treatments blocking the host response in stroke. Lindsberg PJ. **Keio J Med** 1996 Sep;45(3):254–61; discussion 261–2 (39 ref.)

Muscarinic mechanisms in nerve cells. Brown DA, et al. **Life Sci** 1997;60(13–14):1137–44 (104 ref.)

A brain model with the circuit to convert short-term memory into long-term memory. Wong CW. **Med Hypotheses** 1997 Mar;48(3):221–6 (34 ref.)

Quo vadis: extrasomatic targeting of neuronal mRNAs in mammals. Kindler S, et al. **Mol Cell Endocrinol** 1997 Apr 4;128(1–2):7–10 (22 ref.)

The role of Notch in lateral inhibition and cell fate specification [corrected and republished with original paging, article originally printed in Mol Cell Neurosci 1995 Aug;6(4):311–21] Chitnis AB. **Mol Cell Neurosci** 1995 Dec; 6(6):311–21 (73 ref.)

neurogenins, a novel family of atonal-related bHLH transcription factors, are putative mammalian neuronal determination genes that reveal progenitor cell heterogeneity in the developing CNS and PNS. Sommer L, et al. **Mol Cell Neurosci** 1996;8(4):221–41 (51 ref.)

Nicotinic receptors in the brain. Molecular biology, function, and therapeutics. Vidal C. **Mol Chem Neuropathol** 1996 May–Aug;28(1–3):3–11 (48 ref.)

Mechanisms of neuronal cell death. An overview. Waters CM. **Mol Chem Neuropathol** 1996 May–Aug; 28(1–3):145–51 (41 ref.)

A composite model for establishing the microtubule arrays of the neuron. Baas PW, et al. **Mol Neurobiol** 1996 Apr; 12(2):145–61 (75 ref.)

The role of swelling-induced anion channels during neuronal volume regulation. Basavappa S, et al. **Mol Neurobiol** 1996 Oct;13(2):137–53 (124 ref.)

Role of laminin and integrin interactions in growth cone guidance. McKerracher L, et al. **Mol Neurobiol** 1996 Apr; 12(2):95–116 (157 ref.)

Elevation of intracellular calcium levels in neurons by nicotinic acetylcholine receptors. Rathouz MM, et al. **Mol Neurobiol** 1996 Apr;12(2):117–31 (113 ref.)

Thyroid parafollicular cells. An accessible model for the study of serotonergic neurons. Russo AF, et al. **Mol Neurobiol** 1996 Dec;13(3):257–76 (132 ref.)

The NEURON simulation environment. Hines ML, et al. **Neural Comput** 1997 Aug 15;9(6):1179–209 (38 ref.)

CaM kinase II in long-term potentiation. Fukunaga K, et al. **Neurochem Int** 1996 Apr;28(4):343–58 (151 ref.)

On the mathematical modelling of pain. Britton NF, et al. **Neurochem Res** 1996 Sep;21(9):1133–40 (53 ref.)

Modulatory effects of Gs-coupled excitatory opioid receptor functions on opioid analgesia, tolerance, and dependence. Crain SM, et al. **Neurochem Res** 1996 Nov;21(11):1347–51 (59 ref.)

Paracrine and autocrine actions of neurotrophic factors. Davies AM. **Neurochem Res** 1996 Jul;21(7):749–53 (57 ref.)

Stimulatory effects of opioids on transmitter release and possible cellular mechanisms: overview and original results. Sarne Y, et al. **Neurochem Res** 1996 Nov;21(11):1353–61 (113 ref.)

Making waves in the neocortex. Connors BW, et al. **Neuron** 1997 Mar;18(3):347–9 (24 ref.)

Ca(2+)-dependent routes to Ras: mechanisms for neuronal survival, differentiation, and plasticity? Finkbeiner S, et al. **Neuron** 1996 Feb;16(2):233–6 (16 ref.)

Calcium regulation of gene expression: isn't that spatial? Ginty DD. **Neuron** 1997 Feb;18(2):183–6 (20 ref.)

Neurons, networks, and motor behavior. Katz PS. **Neuron** 1996 Feb;16(2):245–53 (9 ref.)

GDNF in a bind with known orphan: accessory implicated in new twist. Lindsay RM, et al. **Neuron** 1996 Oct; 17(4):571–4 (28 ref.)

PDZs and receptor/channel clustering: rounding up the latest suspects [comment] Sheng M. **Neuron** 1996 Oct;17(4):575–8 (19 ref.) Comment on: Neuron 1996 Oct;17(4):759–67.

How does a vesicle know it is full? [comment] Williams J. **Neuron** 1997 May;18(5):683–6 (15 ref.) Comment on: Neuron 1997 May;18(5):815–26.

The neural coding of stereoscopic depth. Ohzawa I, et al. **Neuroreport** 1997 Feb 10;8(3):iii–xii (36 ref.)

Dynamics of the impulse activity of neurons of the neocortex of monkeys in a visual recognition task after brief oxygen deprivation. Breslav IS. **Neurosci Behav Physiol** 1996 Mar–Apr;26(2):143–52 (69 ref.)

The problem of gestalt in neurobiology. Sokolov EN. **Neurosci Behav Physiol** 1997 Jul–Aug;27(4):323–32 (33 ref.)

Memory, sleep, and dynamic stabilization of neural circuitry: evolutionary perspectives. Kavanau JL. **Neurosci Biobehav Rev** 1996 Summer;20(2):289–311 (236 ref.)

Modulation of dopamine neuronal activity by glutamate receptor subtypes. Meltzer LT, et al. **Neurosci Biobehav Rev** 1997 Jul;21(4):511–8 (96 ref.)

Neostriatal cell subtypes and their functional roles. Kawaguchi Y. **Neurosci Res** 1997 Jan;27(1):1–8 (77 ref.)

Population coding by cell assemblies--what it really is in the brain. Sakurai Y. **Neurosci Res** 1996 Sep;26(1):1–16 (80 ref.)

Modulation of neuronal function by intracellular pH. Takahashi KI, et al. **Neurosci Res** 1996 Jan;24(2):109–16 (29 ref.)

Consciousness in waking and dreaming: the roles of neuronal oscillation and neuromodulation in determining similarities and differences. Kahn D, et al. **Neuroscience** 1997 May; 78(1):13–38 (265 ref.)

A cellular mechanism for the neuronal changes underlying Alzheimer's disease. Vickers JC. **Neuroscience** 1997 Jun; 78(3):629–39 (123 ref.)

Global and serial neurons form A hierarchically arranged interface proposed to underlie memory and cognition. Woolf NJ. **Neuroscience** 1996 Oct;74(3):625–51 (288 ref.)

Stress, glucocorticoids, and mesencephalic dopaminergic neurons: a pathophysiological chain determining vulnerability to psychostimulant abuse. Piazza PV, et al. **NIDA Res Monogr** 1996;163:277–99 (91 ref.)

Cocaine withdrawal alters regulatory elements of dopamine neurons. Pilotte NS, et al. **NIDA Res Monogr** 1996; 163:193–202 (34 ref.)

Role of dopamine receptors in the short- and long-term regulation of corticostriatal transmission. Calabresi P, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1997 Apr; 17(2):101–4 (25 ref.)

Do D2-like dopamine receptors mediate neuronal excitation or inhibition: some functional-behavioural implications. Waddington JL. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1997 Apr; 17(2):111–2 (16 ref.)

Windup and central sensitization are not equivalent [editorial] Woolf CJ. **Pain** 1996 Aug;66(2–3):105–8 (51 ref.)

Expression and function of Enhancer of split bHLH proteins during Drosophila neurogenesis. Bray SJ. **Perspect Dev Neurobiol** 1997;4(4):313–23 (65 ref.)

Genetic control of neural cell apoptosis. Bredesen DE. **Perspect Dev Neurobiol** 1996;3(2):101–9 (90 ref.)

Neurogenesis in Drosophila: an historical perspective and some prospects. Campos-Ortega JA. **Perspect Dev Neurobiol** 1997;4(4):267–71 (51 ref.)

Does ciliary neurotrophic factor serve a different function in the rat versus the chicken? Finn T, et al. **Perspect Dev Neurobiol** 1996;4(1):91–9 (58 ref.)

Extrinsic signals in the developing nervous system: the role of neurokines during neurogenesis. Heller S, et al. **Perspect Dev Neurobiol** 1996;4(1):19–34 (135 ref.)

Molecular mechanisms of directed growth cone motility. Jay DG. **Perspect Dev Neurobiol** 1996;4(2–3):137–45 (67 ref.)

The development of cholinergic sympathetic neurons: a role for neuropoietic cytokines? Landis SC. **Perspect Dev Neurobiol** 1996;4(1):53–63 (105 ref.)

The cytoskeleton in nerve growth cone motility and axonal pathfinding. Letourneau PC. **Perspect Dev Neurobiol** 1996; 4(2–3):111–23 (85 ref.)

Microtubule-associated proteins, phosphorylation gradients, and the establishment of neuronal polarity. Mandell JW, et al. **Perspect Dev Neurobiol** 1996;4(2–3):125–35 (100 ref.)

Calcium and Free Radicals: Mediators of neurotrophic factor and excitatory transmitter-regulated developmental plasticity and cell death. Mattson MP. **Perspect Dev Neurobiol** 1996;3(2):79–91 (101 ref.)

Functional compartmentalization of the neuronal growth cone: determining calcium's place in signaling cascades. Rehder V, et al. **Perspect Dev Neurobiol** 1996;4(2–3):215–26 (57 ref.)

Do central nervous system neurons require target-derived neurotrophic support for survival throughout adult life and aging? Svendsen CN, et al. **Perspect Dev Neurobiol** 1996; 3(2):133–42 (91 ref.)

Changes in neuropeptide phenotype after axotomy of adult peripheral neurons and the role of leukemia inhibitory factor. Zigmond RE, et al. **Perspect Dev Neurobiol** 1996; 4(1):75–90 (146 ref.)

The role of central cholinergic neurons in the regulation of blood pressure and in experimental hypertension. Buccafusco JJ. **Pharmacol Rev** 1996 Jun;48(2):179–211 (293 ref.)

A synaptic basis for memory storage in the cerebral cortex. Bear MF. **Proc Natl Acad Sci U S A** 1996 Nov 26; 93(24):13453–9 (59 ref.)

Signals and signs in the nervous system: the dynamic anatomy of electrical activity is probably information-rich. Bullock TH. **Proc Natl Acad Sci U S A** 1997 Jan 7;94(1):1–6 (45 ref.)

Neural mechanisms for visual memory and their role in attention. Desimone R. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13494–9 (66 ref.)

Regional and cellular fractionation of working memory. Goldman-Rakic PS. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13473–80 (94 ref.)

Memory: recording experience in cells and circuits: diversity in memory research. Goldman-Rakic PS. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13435–7 (24 ref.)

Memory from the dynamics of intrinsic membrane currents. Marder E, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26; 93(24):13481–6 (42 ref.)

Nicotinic acetylcholine receptors on hippocampal neurons: cell compartment-specific expression and modulatory control of channel activity. Albuquerque EX, et al. **Prog Brain Res** 1996;109:111–24 (88 ref.)

Aspects of cerebellar function in relation to locomotor movements. Armstrong DM, et al. **Prog Brain Res** 1997; 114:401–21 (84 ref.)

Role of the locus coeruleus in emotional activation. Aston-Jones G, et al. **Prog Brain Res** 1996;107:379–402 (151 ref.)

Columnar organization in the midbrain periaqueductal gray and the integration of emotional expression. Bandler R, et al. **Prog Brain Res** 1996;107:285–300 (84 ref.)

The neuronal control of micturition and its relation to the emotional motor system. Blok BF, et al. **Prog Brain Res** 1996;107:113–26 (82 ref.)

Effects of trophic factors on the CNS cholinergic phenotype. Cuello AC. **Prog Brain Res** 1996;109:347–58 (59 ref.)

Spinal interneurons and preganglionic neurons in sacral autonomic reflex pathways. deGroat WC, et al. **Prog Brain Res** 1996;107:97–111 (90 ref.)

Neurogenic mechanisms and neuropeptides in chronic pain. Dray A. **Prog Brain Res** 1996;110:85–94 (81 ref.)

The control of forelimb movements by intermediate cerebellum. Ekerot CF, et al. **Prog Brain Res** 1997; 114:423–9 (21 ref.)

Cholinergic innervation and receptors in the cerebellum. Jaarsma D, et al. **Prog Brain Res** 1997;114:67–96 (113 ref.)

Spinal cord reflex organization of sympathetic systems. Jänig W. **Prog Brain Res** 1996;107:43–77 (131 ref.)

The polymodal receptor: bio-warning and defense system. Kumazawa T. **Prog Brain Res** 1996;113:3–18 (129 ref.)

Structure and function of neuronal nicotinic acetylcholine receptors. Lindstrom J, et al. **Prog Brain Res** 1996; 109:125–37 (65 ref.)

Muscarinic receptors and cell signalling. Löffelholz K. **Prog Brain Res** 1996;109:191–4 (33 ref.)

Neurogenic inflammation caused by cutaneous polymodal receptors. Lynn B. **Prog Brain Res** 1996;113:361–8 (43 ref.)

Physiological functions of pontomedullary raphe and medial reticular neurons. Mason P, et al. **Prog Brain Res** 1996; 107:269–82 (130 ref.)

Dentate output channels: motor and cognitive components. Middleton FA, et al. **Prog Brain Res** 1997;114:553–66 (56 ref.)

The unipolar brush cells of the mammalian cerebellum and cochlear nucleus: cytology and microcircuitry. Mugnaini E, et al. **Prog Brain Res** 1997;114:131–50 (71 ref.)

Compartmentalised distribution of GABAA and glutamate receptors in relation to transmitter release sites on the surface of cerebellar neurones. Nusser Z, et al. **Prog Brain Res** 1997;114:109–27 (91 ref.)

Molecular organization of cerebellar glutamate synapses. Ottersen OP, et al. **Prog Brain Res** 1997;114:97–107 (45 ref.)

Meeting the constraints upon behavioral expression through neural and genomic interactive mechanisms. Pfaff DW, et al. **Prog Brain Res** 1996;107:343–54 (48 ref.)

Functional anatomy of nociceptive neurones in rat superior colliculus. Redgrave P, et al. **Prog Brain Res** 1996; 107:403–15 (64 ref.)

Neurophysiology of chronic inflammatory pain: electrophysiological recordings from spinal cord neurons in rats with prolonged acute and chronic unilateral inflammation at the ankle. Schaible HG, et al. **Prog Brain Res** 1996;110:167–76 (56 ref.)

On the role of tachykinins and calcitonin gene-related peptide in the spinal mechanisms of nociception and in the induction and maintenance of inflammation-evoked hyperexcitability in spinal cord neurons (with special reference to nociception in joints). Schaible HG. **Prog Brain Res** 1996;113:423–41 (152 ref.)

Immunolesion by 192IgG-saporin of rat basal forebrain cholinergic system: a useful tool to produce cortical cholinergic dysfunction. Schliebs R, et al. **Prog Brain Res** 1996;109:253–64 (57 ref.)

Functional significance of excitatory projections from the precerebellar nuclei to interpositus and dentate nucleus neurons for mediating motor, premotor and parietal cortical inputs. Shinoda Y, et al. **Prog Brain Res** 1997;114:193–207 (49 ref.)

Physiology of transmission at a giant glutamatergic synapse in cerebellum. Slater NT, et al. **Prog Brain Res** 1997; 114:151–63 (47 ref.)

Growth cone dynamics and activity-dependent processes in neuronal network development. van Pelt J, et al. **Prog Brain Res** 1996;108:333–46 (67 ref.)

Slow synaptic transmission in the spinal dorsal horn. Yoshimura M. **Prog Brain Res** 1996;113:443–62 (149 ref.)

Plasticity of the nervous system at the systematic, cellular and molecular levels: a mechanism of chronic pain and hyperalgesia. Zimmermann M, et al. **Prog Brain Res** 1996; 110:233–59 (106 ref.)

Morphological and electrophysiological classification of hypothalamic supraoptic neurons. Armstrong WE. **Prog Neurobiol** 1995 Nov–Dec;47(4–5):291–339 (388 ref.)

Functional and pharmacological properties of human neocortical neurons maintained in vitro. Avoli M, et al. **Prog Neurobiol** 1996 Apr;48(6):519–54 (127 ref.)

Non-adrenergic non-cholinergic (NANC) transmission to

smooth muscle: 35 years on. Bennett MR. **Prog Neurobiol** 1997 Jun;52(3):159–95 (261 ref.)

Receptors controlling transmitter release from sympathetic neurons in vitro. Boehm S, et al. **Prog Neurobiol** 1997 Feb; 51(3):225–42 (94 ref.)

Neural mechanisms of mammalian olfactory learning. Brennan PA, et al. **Prog Neurobiol** 1997 Mar;51(4):457–81 (160 ref.)

Responses of basal forebrain cholinergic neurons to damage in the adult brain. Henderson Z. **Prog Neurobiol** 1996 Feb; 48(3):219–54 (400 ref.)

The pharmacology of amino–acid responses in septal neurons. Kumamoto E. **Prog Neurobiol** 1997 Jun;52(3):197–259 (425 ref.)

Physiological role of brain endothelin in the central autonomic control: from neuron to knockout mouse. Kuwaki T, et al. **Prog Neurobiol** 1997 Apr;51(5):545–79 (365 ref.)

The microscopic anatomy and physiology of the mammalian saccadic system. Moschovakis AK, et al. **Prog Neurobiol** 1996 Oct;50(2–3):133–254 (699 ref.)

The nitric oxide system in insects. Müller U. **Prog Neurobiol** 1997 Feb;51(3):363–81 (146 ref.)

Neuronal–specific gene expression––the interaction of both positive and negative transcriptional regulators. Quinn JP. **Prog Neurobiol** 1996 Nov;50(4):363–79 (100 ref.)

Role of the central histaminergic neuronal system in the CNS toxicity of the first generation H1–antagonists. Sangalli BC. **Prog Neurobiol** 1997 Jun;52(2):145–57 (98 ref.)

Glia–neuron intercommunications and synaptic plasticity. Vernadakis A. **Prog Neurobiol** 1996 Jun;49(3):185–214 (292 ref.)

The vestibular system as a model of sensorimotor transformations. A combined in vivo and in vitro approach to study the cellular mechanisms of gaze and posture stabilization in mammals. Vibert N, et al. **Prog Neurobiol** 1997 Feb;51(3):243–86 (269 ref.)

Protein kinase C: a memory kinase? [comment] Riedel G. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Apr; 21(3):373–8 (21 ref.) Comment on: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):379–406. Comment on: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):407–25. Comment on: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):427–54. Comment on: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):455–86. Comment on: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):487–505. Comment on: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):507–29. Comment on: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):531–72.

Molecular biology of axon–glia interactions in the peripheral nervous system. Taylor V, et al. **Prog Nucleic Acid Res Mol Biol** 1997;56:225–56 (221 ref.)

Nitric oxide, a neuronal messenger. Its role in the hippocampus neuronal plasticity. Salemme E, et al. **Riv Biol** 1996;89(1):87–107 (37 ref.) **(Eng, Ita)**

A neural substrate of prediction and reward. Schultz W, et al. **Science** 1997 Mar 14;275(5306):1593–9 (37 ref.)

Consciousness and the neurobiology of perceptual binding. Hardcastle VG. **Semin Neurol** 1997 Jun;17(2):163–70 (132 ref.)

Neuroblasts: a model for the asymmetric division of stem cells. Lin H, et al. **Trends Genet** 1997 Jan;13(1):33–9 (48 ref.)

Apoptotic features of selective neuronal death in ischemia, epilepsy and gp 120 toxicity. Charriaut–Marlangue C, et al. **Trends Neurosci** 1996 Mar;19(3):109–14 (87 ref.)

Signalling from neurones to glial cells in invertebrates. Coles JA, et al. **Trends Neurosci** 1996 Aug;19(8):358–62 (35 ref.)

How should brain nuclei be delineated? Consequences for developmental mechanisms and for correlations of area size, neuron numbers and functions of brain nuclei [see comments] Gahr M. **Trends Neurosci** 1997 Feb;20(2):58–62 (38 ref.) Comment in: Trends Neurosci 1997 Aug;20(8):343–4; discussion 345–6. Comment in: Trends Neurosci 1997 Aug;20(8):344; discussion 345–6. Comment in: Trends Neurosci 1997 Aug;20(8):344–5; discussion 345–6. Comment in: Trends Neurosci 1997 Aug;20(8):345; discussion 345–6.

The neural basis of associative reward learning in honeybees. Hammer M. **Trends Neurosci** 1997 Jun;20(6):245–52 (58 ref.)

The c–Jun transcription factor––bipotential mediator of neuronal death, survival and regeneration. Herdegen T, et al. **Trends Neurosci** 1997 May;20(5):227–31 (72 ref.)

Nitric oxide, the enigmatic neuronal messenger: its role in synaptic plasticity. Hölscher C. **Trends Neurosci** 1997 Jul; 20(7):298–303 (93 ref.)

Information processing by graded–potential transmission through tonically active synapses. Juusola M, et al. **Trends Neurosci** 1996 Jul;19(7):292–7 (56 ref.)

Intrinsic neuromodulation: altering neuronal circuits from within. Katz PS, et al. **Trends Neurosci** 1996 Feb; 19(2):54–61 (72 ref.)

Bursts as a unit of neural information: making unreliable synapses reliable [see comments] Lisman JE. **Trends Neurosci** 1997 Jan;20(1):38–43 (74 ref.) Comment in: Trends Neurosci 1997 Jun;20(6):244.

NF–kappa B: a crucial transcription factor for glial and neuronal cell function. O'Neill LA, et al. **Trends Neurosci** 1997 Jun;20(6):252–8 (64 ref.)

Glial–neuronal interactions in non–synaptic areas of the brain: studies in the optic nerve. Ransom BR, et al. **Trends Neurosci** 1996 Aug;19(8):352–8 (52 ref.)

Action potential initiation and backpropagation in neurons of the mammalian CNS. Stuart G, et al. **Trends Neurosci** 1997 Mar;20(3):125–31 (101 ref.)

Neurone–glia interactions in the hypothalamus and pituitary. Theodosis DT, et al. **Trends Neurosci** 1996 Aug;19(8):363–7 (46 ref.)

Neurotrophic factors in action––new dogs and new tricks. Tolkovsky A. **Trends Neurosci** 1997 Jan;20(1):1–3 (22 ref.)

Dual response modes in lateral geniculate neurons: mechanisms and functions. Sherman SM. **Vis Neurosci** 1996 Mar–Apr;13(2):205–13 (68 ref.)

[Neuro–immuno–cutaneous system (NICS)] Misery L. **Pathol Biol (Paris)** 1996 Dec;44(10):867–74 (86 ref.) (Eng. Abstr.) **(Fre)**

[Nitric oxide and carbon monoxide––a new generation of neuronal messengers] Gazit V, et al. **Harefuah** 1996 Jun 16;130(12):854–8 (15 ref.) **(Heb)**

[Neurochemical aspect of brain aging––neuronal death and decreased synaptic functions] Nomura Y. **Hokkaido Igaku Zasshi** 1996 May;71(3):309–14 (21 ref.) (Eng. Abstr.) **(Jpn)**

[The role of tau in neural morphogenesis] Kanai T. **Kaibogaku Zasshi** 1996 Dec;71(6):604–10 (9 ref.) **(Jpn)**

[Neural activity and energy metabolism of brain slices––survival period of neurons during deprivation of oxygen and/or glucose] Okada Y. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Apr; 16(2):65–71 (7 ref.) **(Jpn)**

[Dynamic analysis of neuronal responses by video microscopy: direct visualization of release and acceptance of neuronal signals] Terakawa S. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Apr; 16(2):59–64 (11 ref.) **(Jpn)**

[Interaction between neurons and astrocytes involved in brain regulatory function as assessed by in vitro brain ischemia models] Watanabe Y, et al. **Nippon Yakurigaku Zasshi** 1997 Mar;109(3):119–28 (35 ref.) (Eng. Abstr.) **(Jpn)**

[Cytoskeletons in the signal transduction] Hisanaga S. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):453–63 (72 ref.) **(Jpn)**

[Regulation of cation pump activity in nervous system] Inoue N. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):235–43 (49 ref.) **(Jpn)**

[Roles of protein Ser/Thr phosphatases in regulation of neural cell functions] Kobayashi T, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):439–45 (40 ref.) **(Jpn)**

[The functions of tyrosine kinases in the neuronal tissues] Takayama Y, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb; 42(3 Suppl):431–8 (44 ref.) **(Jpn)**

[Arachidonic acid in physiology and pathology of nervous tissue] Zylińska L, et al. **Postepy Biochem** 1996;42(4):357–63 (49 ref.) **(Pol)**

[The neural activity of thiamine: facts and hypotheses] Parkhomenko IuM, et al. **Ukr Biokhim Zh** 1996 Mar–Apr; 68(2):3–14 (92 ref.) (Eng. Abstr.) **(Rus)**

[The neuronal organization of the amygdala–visceral reflex arch] Baklavadzhian OG, et al. **Usp Fiziol Nauk** 1996 Jul–Sep;27(3):51–77 (193 ref.) (Eng. Abstr) **(Rus)**

[The mechanisms of the integrative activity of neurons] Nikitin VP, et al. **Usp Fiziol Nauk** 1997 Jan–Mar; 28(1):27–46 (84 ref.) (Eng. Abstr.) **(Rus)**

[The morphofunctional characteristics of the neurons and their connections in the neocortex of man and animals] Okhotin VE, et al. **Usp Fiziol Nauk** 1997 Apr–Jun; 28(2):40–56 (131 ref.) (Eng. Abstr.) **(Rus)**

[Gangliosides as neurobiochemical markers] De Luka SR, et al. **Med Pregl** 1996;49(9–10):377–83 (23 ref.) (Eng. Abstr.) **(Scr)**

[Calcium, neuronal death and neurological disease] Jiménez–Jiménez FJ, et al. **Rev Neurol** 1996 Oct; 24(134):1199–209 (280 ref.) (Eng. Abstr.) **(Spa)**

SECRETION

Cellular basis of the GnRH pulse generator. Weiner RI. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Aug;48(8):573–7 (22 ref.)

TRANSPLANTATION

Neural grafting of cholinergic neurons in the hippocampal formation. Tarricone BJ, et al. **Behav Brain Res** 1996 Jan; 74(1–2):25–44 (121 ref.)

Adenovirus for neurodegenerative diseases: in vivo strategies and ex vivo gene therapy using human neural progenitors. Sabaté O, et al. **Clin Neurosci** 1995–96;3(5):317–21 (42 ref.)

Multipotent neural progenitor or stem–like cells may be uniquely suited for therapy for some neurodegenerative conditions. Snyder EY, et al. **Clin Neurosci** 1995–96; 3(5):310–6 (43 ref.)

Neuronal progenitors as tools for cell replacement in the nervous system. Brüstle O, et al. **Curr Opin Neurobiol** 1996 Oct;6(5):688–95 (81 ref.)

Transfectable and transplantable postmitotic human neurons: a potential "platform" for gene therapy of nervous system diseases. Trojanowski JQ, et al. **Exp Neurol** 1997 Mar; 144(1):92–7 (36 ref.)

Neuronal transplantation and neurotrophic factors in the treatment of Parkinson's disease––update February 1995. Kupsch A, et al. **J Neural Transm Suppl** 1995;46:193–207 (73 ref.)

Neural transplantation. Jones DG, et al. **N Z Med J** 1996 Oct 11;109(1031):369–71 (30 ref.)

[Cell transplantation for neuronal and muscular disorders] Kondoh T, et al. **No To Shinkei** 1997 Jun;49(6):507–15 (50 ref.) **(Jpn)**

ULTRASTRUCTURE

Ultrastructure of sympathetic axons and their structural relationship with vascular smooth muscle. Luff SE. **Anat Embryol (Berl)** 1996 Jun;193(6):515–31 (150 ref.)

Stretch–sensitive ion channels of neuronal growth cones. Pellegrino M, et al. **Arch Ital Biol** 1997 Sep;135(4):319–29 (62 ref.)

The neuronal centrosome as a generator of microtubules for the axon. Baas PW. **Curr Top Dev Biol** 1996;33:281–98 (55 ref.)

Three–dimensional confocal light and electron microscopy of central nervous system tissue and neurons and glia in culture. Turner JN, et al. **Int Rev Exp Pathol** 1996;36:53–72 (88 ref.)

The morphology of synapses. Peters A, et al. **J Neurocytol** 1996 Dec;25(12):687–700 (64 ref.)

Ultrastructure of synapses in the first–evolved nervous systems. Westfall IA. **J Neurocytol** 1996 Dec;25(12):735–46 (53 ref.)

Ultrastructure of neuronal circuitry in sympathetic ganglia. Kawai Y. **Microsc Res Tech** 1996 Oct 1;35(2):146–56 (53 ref.)

Signal transduction from membrane to nucleus: the special case for neurons. Johanson SO, et al. **Neurochem Res** 1996 Jul;21(7):779–85 (38 ref.)

Rabies: interactions between neurons and viruses. A review of the history of Negri inclusion bodies. Kristensson K, et al. **Neuropathol Appl Neurobiol** 1996 Jun;22(3):179–87 (30 ref.)

[Current concepts of the neuromorphology and neurochemistry of the striatal cholinergic system and its role in regulating movement] Shapovalova KB. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jul–Aug; 46(4):656–73 (145 ref.) (Eng. Abstr.) **(Rus)**

VIROLOGY

Cellular aspects of HIV–1 infection of macrophages leading to neuronal dysfunction in in vitro models for HIV–1 encephalitis. Nottet HS, et al. **J Leukoc Biol** 1997 Jul; 62(1):107–16 (112 ref.)

Viruses and behavioural changes: a review of clinical and experimental findings. Mohammed AH, et al. **Rev Neurosci** 1993 Jul–Sep;4(3):267–86 (164 ref.)

NEURONS, AFFERENT

see related
RECEPTORS, SENSORY

CYTOLOGY

Sources of afferent fibers from the tongue muscles. Woźniak W, et al. **Folia Morphol (Warsz)** 1996;55(3):129–32 (23 ref.)

[Development of the cutaneous nervous system] Saxod R, et al. **Pathol Biol (Paris)** 1996 Dec;44(10):838–48 (40 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Therapeutic potential of the neurotrophins and neurotrophin–CNTF combinations in peripheral neuropathies and motor neuron diseases. Lindsay RM. **Ciba Found Symp** 1996;196:39–48; discussion 48–53 (41 ref.)

Clinical effects of nedocromil sodium on challenges invoking neuronal mechanisms and on virally induced symptoms. König P. **J Allergy Clin Immunol** 1996 Nov;98(5 Pt 2):S135–40; discussion S140–2 (33 ref.)

Effect of nedocromil sodium on neurogenic mechanisms in vitro. Myers AC, et al. **J Allergy Clin Immunol** 1996 Nov; 98(5 Pt 2):S107–11; discussion S116–7 (12 ref.)

Mechanisms and modulation of capsaicin activity on airway afferent nerves. Fox AJ. **Pulm Pharmacol** 1995 Aug–Oct; 8(4–5):207–15 (64 ref.)

The effect of a peripherally–acting opioid on sensory nerve function. Garland L. **Pulm Pharmacol** 1995 Aug–Oct; 8(4–5):231–6 (9 ref.)

Airway sensory nerves in asthma––targets for therapy? Spina D, et al. **Pulm Pharmacol** 1996 Feb;9(1):1–18 (257 ref.)

Verification of sensory block during regional anesthesia. de Leon–Casasola OA. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):126–8 (11 ref.)

Where is the locus in opioid withdrawal? Christie MJ, et al. **Trends Pharmacol Sci** 1997 Apr;18(4):134–40 (73 ref.)

METABOLISM

Receptor localization in the mammalian dorsal horn and primary afferent neurons. Coggeshall RE, et al. **Brain Res Brain Res Rev** 1997 Jun;24(1):28–66 (341 ref.)

Cytoskeleton: missing links found? Bousquet O, et al. **Curr Biol** 1996 Dec 1;6(12):1563–6 (17 ref.)

NEURONS, AFFERENT

PATHOLOGY

Neuro-ophthalmology of the pregeniculate afferent visual system. Developments in 1996 (Part I). Balcer LJ, et al. **J Neuroophthalmol** 1997 Mar;17(1):60–71 (87 ref.)

PHYSIOLOGY

Reflections on the carotid nerve sensory discharge and coupling between glomus cells. Eyzaguirre C, et al. **Adv Exp Med Biol** 1996;410:159–67 (26 ref.)

Plasticity of the vestibular system: central compensation and sensory substitution for vestibular deficits. Brandt T, et al. **Adv Neurol** 1997;73:297–309 (51 ref.)

Short-term functional plasticity of cortical and thalamic sensory representations and its implication for information processing. Dinse HR, et al. **Adv Neurol** 1997;73:159–78 (78 ref.)

Injury-stimulated neurogenesis in sensory systems. Farbman AI. **Adv Neurol** 1997;72:157–61 (9 ref.)

Mechanisms of reorganization in sensory systems of primates after peripheral nerve injury. Kaas JH, et al. **Adv Neurol** 1997;73:147–58 (122 ref.)

Mechanisms of compensatory plasticity in the cerebral cortex. Rauschecker JP. **Adv Neurol** 1997;73:137–46 (58 ref.)

Mechanism of nonlinear responses of taste cells to mixed tastes. Kashimori Y, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):C405–22 (40 ref.)

Pituitary adenylate cyclase-activating peptide in sensory and autonomic ganglia: localization and regulation. Sundler F, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:410–26; discussion 427–8 (76 ref.)

The molecules of mechanosensation. Garcia-Anoveros J, et al. **Annu Rev Neurosci** 1997;20:567–94 (162 ref.)

Chemical activators of sensory neurons. Wood JN, et al. **Annu Rev Physiol** 1997;59:457–82 (82 ref.)

Sensory afferent neurotransmission in caudal nucleus tractus solitarius—common denominators. Andresen MC, et al. **Chem Senses** 1996 Jun;21(3):387–95 (68 ref.)

Beta-blocker induced asthma: a role for sensory nerve hyperresponsiveness? [editorial; comment] Belvisi M. **Clin Exp Allergy** 1996 Dec;26(12):1343–6 (29 ref.) Comment on: Clin Exp Allergy 1996 Dec;26(12):1428–35.

Silent afferents: a separate class of primary afferents? Michaelis M, et al. **Clin Exp Pharmacol Physiol** 1996 Feb; 23(2):99–105 (79 ref.)

Reflexes mediated by cardiac sympathetic afferents during myocardial ischaemia: role of adenosine. Thames MD, et al. **Clin Exp Pharmacol Physiol** 1996 Aug;23(8):709–14 (33 ref.)

Sensorimotor processing: charting the frontier. Carpenter RH. **Curr Biol** 1997 Jun 1;7(6):R348–51 (10 ref.)

Neurophysiology: neural fingerprints of visual attention. Groh JM, et al. **Curr Biol** 1996 Nov 1;6(11):1406–9 (17 ref.)

Sensory and cognitive functions of the basal ganglia. Brown LL, et al. **Curr Opin Neurobiol** 1997 Apr;7(2):157–63 (65 ref.)

Sensory representation in the cerebellum and control circuits of motion. Arends JJ. **Eur J Morphol** 1997 Oct;35(4):234–45 (94 ref.)

Pigeon basal ganglia: insights into the neuroanatomy underlying telencephalic sensorimotor processes in birds. Veenman CL. **Eur J Morphol** 1997 Oct;35(4):220–33 (138 ref.)

Nociceptors and the peripheral nervous system's role in pain. Greenspan JD. **J Hand Ther** 1997 Apr–Jun;10(2):78–85 (55 ref.)

Sensory neuropathies including painful and toxic neuropathies. Wokke JH, et al. **J Neurol** 1997 Apr; 244(4):209–21 (94 ref.)

Heart rate control during exercise by baroreceptors and skeletal muscle afferents. O'Leary DS. **Med Sci Sports Exerc** 1996 Feb;28(2):210–7 (55 ref.)

Hebb's dream: the resurgence of cell assemblies. Nicolelis MA, et al. **Neuron** 1997 Aug;19(2):219–21 (18 ref.)

Neurotrophins cause a new sensation. Snider WD, et al. **Neuron** 1996 Feb;16(2):229–32 (26 ref.)

Primary afferents and inflammatory hyperexcitability [editorial; comment] Ren K. **Pain** 1996 Sep;67(1):1–2 (15 ref.) Comment on: Pain 1996 Sep;67(1):97–106.

Leukemia inhibitory factor and ciliary neurotrophic factor in sensory neuron development. Horton AR, et al. **Perspect Dev Neurobiol** 1996;4(1):35–8 (30 ref.)

Tachykinins in the gut. Part II. Roles in neural excitation, secretion and inflammation. Holzer P, et al. **Pharmacol Ther** 1997;73(3):219–63 (539 ref.)

Can sensory neurones in culture serve as a model of nociception? [editorial] Vyklický L, et al. **Physiol Res** 1996; 45(1):1–9 (95 ref.)

More sensory competence for nociceptive neurons in culture [comment] Kress M, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24;93(26):14995–7 (35 ref.) Comment on: Proc Natl Acad Sci U S A 1996 Dec 24;93(26):15435–9.

Signal transduction in nociceptive afferent neurons in inflammatory conditions. Bevan S. **Prog Brain Res** 1996; 113:201–13 (54 ref.)

Cellular mechanisms underlying the formation of orderly connections in developing sensory pathways. Erzurumlu RS, et al. **Prog Brain Res** 1996;108:287–301 (85 ref.)

Mossy-fibre sensory input to the cerebellum. Glickstein M. **Prog Brain Res** 1997;114:251–9 (57 ref.)

Interactions of sympathetic and primary afferent neurons following nerve injury and tissue trauma. Jänig W, et al. **Prog Brain Res** 1996;113:161–84 (93 ref.)

The functional morphology of thin sensory axons: some principles and problems. Kruger L. **Prog Brain Res** 1996; 113:255–72 (95 ref.)

Alterations in the functional properties of dorsal root ganglion cells with unmyelinated axons after a chronic nerve constriction in the rat. LaMotte RH, et al. **Prog Brain Res** 1996;110:105–11 (32 ref.)

Peptides and cutaneous polymodal nociceptor neurones. Lawson SN. **Prog Brain Res** 1996;113:369–85 (75 ref.)

Sensory afferent processing in multi-responsive DRG neurons. Senba E, et al. **Prog Brain Res** 1996;113:387–410 (160 ref.)

Spinal organization of C-fiber afferents related with nociception or non-nociception. Sugiura Y. **Prog Brain Res** 1996;113:320–39 (116 ref.)

Sensori-sensory afferent conditioning with leg movement: gain control in spinal reflex and ascending paths. Brooke JD, et al. **Prog Neurobiol** 1997 Mar;51(4):393–421 (180 ref.)

Encoding of tooth loads by human periodontal afferents and their role in jaw motor control. Trulsson M, et al. **Prog Neurobiol** 1996 Jun;49(3):267–84 (89 ref.)

The role of sensory neuropeptides in airway hyperresponsiveness. Baraniuk JN. **Pulm Pharmacol** 1995 Aug-Oct;8(4-5):195–202 (52 ref.)

Plasticity of the afferent innervation of the airways. Kummer W, et al. **Pulm Pharmacol** 1995 Aug-Oct;8(4-5):169–72 (8 ref.)

Cutaneous hyperalgesia and primary afferent sensitization. Meyer RA. **Pulm Pharmacol** 1995 Aug-Oct;8(4-5):187–93 (23 ref.)

Enhancement of afferent nerve excitability in the airways by allergic inflammation. Riccio MM, et al. **Pulm Pharmacol** 1995 Aug-Oct;8(4-5):181–5 (16 ref.)

Cellular mechanisms of inflammatory mediators acting on vagal sensory nerve excitability. Weinreich D. **Pulm Pharmacol** 1995 Aug-Oct;8(4-5):173–9 (5 ref.)

Dynamical representation of odors by oscillating and evolving neural assemblies. Laurent G. **Trends Neurosci** 1996 Nov;19(11):489–96 (48 ref.)

Multiple mechanisms underlying the orientation selectivity of visual cortical neurones. Vidyasagar TR, et al. **Trends Neurosci** 1996 Jul;19(7):272–7 (61 ref.)

[Pulmonary vagal afferents in man] Paleček F. **Cesk Fysiol** 1997 Jun;46(2):57–63 (90 ref.) (Eng. Abstr.) **(Cze)**

[Merkel cell and neuro-cutaneous system] Misery L, et al. **Pathol Biol (Paris)** 1996 Dec;44(10):849–55 (81 ref.) (Eng. Abstr.) **(Fre)**

[What is a nociceptor?] Messlinger K. **Anaesthesist** 1997 Feb; 46(2):142–53 (137 ref.) (Eng. Abstr.) **(Ger)**

[Sensory nerve conduction studies] Hasegawa O. **Nippon Rinsho** 1997 Mar;55 Suppl 1:417–9 (7 ref.) **(Jpn)**

SECRETION

Neurogenic inflammation. A model for studying efferent actions of sensory nerves. McDonald DM, et al. **Adv Exp Med Biol** 1996;410:453–62 (68 ref.)

ULTRASTRUCTURE

Patterns of median nerve sensory innervation to the thumb and index finger: an anatomic study. Jolley BJ, et al. **J Hand Surg [Am]** 1997 Mar;22(2):228–31 (30 ref.)

The Merkel cell as a possible mechanoreceptor cell. Ogawa H. **Prog Neurobiol** 1996 Jul;49(4):317–34 (79 ref.)

NEURONS, EFFERENT

see related
NEUROEFFECTOR JUNCTION

METABOLISM

Review: Ca2+ channel sub-types in peripheral efferent autonomic nerves. Lundy PM, et al. **J Auton Pharmacol** 1996 Oct;16(5):229–41 (146 ref.)

NEURONS, MOTOR see **MOTOR NEURONS**

NEURONS, OLFACTORY RECEPTOR see **OLFACTORY RECEPTOR NEURONS**

NEURONS, SENSORY see **NEURONS, AFFERENT**

NEUROPATHIES, AMYLOID see **AMYLOID NEUROPATHIES**

NEUROPATHIES, HEREDITARY MOTOR AND SENSORY

GENETICS

Advances in the genetics of hereditary hypertrophic neuropathy in childhood. Ouvrier RA, et al. **Brain Dev** 1995;17 Suppl:31–8 (66 ref.)

Deletion of the PMP22 gene and hereditary neuropathy with liability to pressure palsies. Pareyson D, et al. **Curr Opin Neurol** 1996 Oct;9(5):348–54 (58 ref.)

Hereditary neuropathies in children: the contribution of the new genetics. Ouvrier RA. **Semin Pediatr Neurol** 1996 Jun; 3(2):140–51 (57 ref.)

[Molecular biology and genetics of hereditary motor and sensory neuropathies] Stögbauer F, et al. **Nervenarzt** 1996 Dec;67(12):987–97 (119 ref.) (Eng. Abstr.) **(Ger)**

[Recent findings on hereditary peripheral nerve dysfunctions] Yoshimura T. **Fukuoka Igaku Zasshi** 1996 Nov; 87(11):233–6 (3 ref.) **(Jpn)**

[Actual nosology of polyneuropathies in childhood] Férnandez-Alvarez E. **Rev Neurol** 1996 Nov; 24(135):1382–4 (28 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

The pathology of charcot-marie-tooth disease and related disorders. Thomas PK, et al. **Neuropathol Appl Neurobiol** 1996 Aug;22(4):269–84 (116 ref.)

NEUROPATHIES, HEREDITARY SENSORY AND AUTONOMIC

COMPLICATIONS

Oral and maxillofacial manifestations of hereditary sensory neuropathy. Narayanan V. **Br J Oral Maxillofac Surg** 1996 Oct;34(5):446–9 (16 ref.)

GENETICS

Hereditary neuropathies in children: the contribution of the new genetics. Ouvrier RA. **Semin Pediatr Neurol** 1996 Jun; 3(2):140–51 (57 ref.)

NEUROPATHY, TYPE I HEREDITARY MOTOR AND SENSORY see **CHARCOT-MARIE DISEASE**

NEUROPEPTIDE RECEPTORS see **RECEPTORS, NEUROPEPTIDE**

NEUROPEPTIDE Y

see related
RECEPTORS, NEUROPEPTIDE Y

ANTAGONISTS & INHIBITORS

Neuropeptide Y family of hormones: receptor subtypes and antagonists. Balasubramaniam AA. **Peptides** 1997; 18(3):445–57 (159 ref.)

BIOSYNTHESIS

Pituitary adenylate cyclase-activating polypeptides, PACAP-38 and PACAP-27, regulation of sympathetic neuron catecholamine, and neuropeptide Y expression through activation of type I PACAP/VIP receptor isoforms. Braas KM, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:204–16; discussion 217–8 (47 ref.)

BLOOD

[Physiologic and pathologic role of neuropeptide Y] Cichocka E. **Pediatr Pol** 1996 Sep;71(9):807–10 (42 ref.) **(Pol)**

GENETICS

[Physiological functions of neuropeptide Y (NPY) and its gene expression] Higuchi H. **Tanpakushitsu Kakusan Koso** 1997 May;42(6):812–24 (76 ref.) **(Jpn)**

METABOLISM

Neuropeptide Y receptor subtypes. Wan CP, et al. **Life Sci** 1995 Feb 17;56(13):1055–64 (79 ref.)

Neuropeptide Y family of hormones: receptor subtypes and antagonists. Balasubramaniam AA. **Peptides** 1997; 18(3):445–57 (159 ref.)

PHYSIOLOGY

The central regulation of energy homeostasis: roles of neuropeptide Y and other brain peptides. Bing C, et al. **Biochem Soc Trans** 1996 May;24(2):559–65 (47 ref.)

Metabolic actions of neuropeptide Y and their relevance to obesity. Wilding JP. **Biochem Soc Trans** 1996 May; 24(2):576–81 (50 ref.)

Nutritional infertility: the role of the interconnected hypothalamic neuropeptide Y-galanin-opioid network. Kalra SP, et al. **Front Neuroendocrinol** 1996 Oct; 17(4):371–401 (219 ref.)

Neuropeptide Y-related peptides and hypothalamo-pituitary-adrenal axis function. Malendowicz LK, et al. **Histol Histopathol** 1996 Apr;11(2):485–94 (108 ref.)

The loop system between neuropeptide Y and leptin in normal and obese rodents. Rohner-Jeanrenaud F, et al. **Horm Metab Res** 1996 Dec;28(12):642–8 (61 ref.)

Role of NPY neurones in GH-dependent feedback signalling to the brain. Chan YY, et al. **Horm Res** 1996;45 Suppl 1:12–4 (10 ref.)

Neuropeptide Y, the hypothalamus and the regulation of energy homeostasis. Tomaszuk A, et al. **Horm Res** 1996; 46(2):53–8 (40 ref.)

Evidence for a central mechanism of obesity in the Zucker rat: role of neuropeptide Y and leptin. White BD, et al. **Proc Soc Exp Biol Med** 1997 Mar;214(3):222–32 (135 ref.)
Recent developments with neuropeptide Y receptor antagonists. Lundberg JM, et al. **Trends Pharmacol Sci** 1996 Sep;17(9):301–4 (35 ref.)
Peptide YY and neuropeptide Y: two peptides intimately involved in electrolyte homeostasis. Playford RJ, et al. **Trends Pharmacol Sci** 1996 Dec;17(12):436–8 (41 ref.)
[Physiological functions of neuropeptide Y (NPY) and its gene expression] Higuchi H. **Tanpakushitsu Kakusan Koso** 1997 May;42(6):812–24 (76 ref.) **(Jpn)**
[Physiologic and pathologic role of neuropeptide Y] Cichocka E. **Pediatr Pol** 1996 Sep;71(9):807–10 (42 ref.) **(Pol)**

THERAPEUTIC USE

The therapeutic potential of neuropeptide Y. Analgesic, anxiolytic and antihypertensive. Munglani R, et al. **Drugs** 1996 Sep;52(3):371–89 (213 ref.)

NEUROPEPTIDE Y-LIKE IMMUNOREACTIVE PEPTIDE see **NEUROPEPTIDE Y**

NEUROPEPTIDE Y RECEPTORS see **RECEPTORS, NEUROPEPTIDE Y**

NEUROPEPTIDES

see related
RECEPTORS, NEUROPEPTIDE

Neuropeptides and their evolution. Shaw C. **Parasitology** 1996;113 Suppl:S35–45 (47 ref.)
[Tertiary structure and functional sites of bombyxin, an insect insulin-like peptide: comparison with those of insulin] Nagata K, et al. **Tanpakushitsu Kakusan Koso** 1996 Aug; 41(10):1485–96 (54 ref.) **(Jpn)**

ANALYSIS

Nematode FMRFamide-related peptide (FaRP)-systems: occurrence, distribution and physiology. Maule AG, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):927–36 (50 ref.)
Quantitative microscopical methods for the identification and localisation of nerves and neuroendocrine cell markers in mammalian lung. Springall DR, et al. **Microsc Res Tech** 1997 Apr 1;37(1):92–100 (40 ref.)

BIOSYNTHESIS

Ontogeny of PACAP and PACAP receptors in the rat brain: role of PACAP in the cerebellum during development. Gonzalez BJ, et al. **Ann N Y Acad Sci** 1996 Dec 26; 805:302–13; discussion 313–4 (51 ref.)
Neuropeptide genes: targets of activity-dependent signal transduction. MacArthur L, et al. **Peptides** 1996;17(4):721–8 (109 ref.)
Changes in neuropeptide phenotype after axotomy of adult peripheral neurons and the role of leukemia inhibitory factor. Zigmond RE, et al. **Perspect Dev Neurobiol** 1996; 4(1):75–90 (146 ref.)
Sensory afferent processing in multi-responsive DRG neurons. Senba E, et al. **Prog Brain Res** 1996;113:387–410 (160 ref.)

CHEMISTRY

Allatostatins: diversity in structure and function of an insect neuropeptide family. Bendena WG, et al. **Ann N Y Acad Sci** 1997 Apr 24;814:53–66 (56 ref.)
Structural simplification of potent growth hormone-releasing hormone analogs: implications for other members of the VIP/GHRH/PACAP family. Coy DH, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:149–58 (15 ref.)
Speculations on the mechanism of hormone-receptor interactions of the secretin/glucagon family of polypeptide hormones derived from computational structural studies. Momany FA, et al. **Ann N Y Acad Sci** 1996 Dec 26; 805:172–81; discussion 181–3 (18 ref.)
The explosion of structural information on insect neuropeptides. Gäde G. **Fortschr Chem Org Naturst** 1997; 71:1–128 (494 ref.)
Molecular characterization of the inhibitory myotropic peptide leucomyosuppressin. Bendena WG, et al. **Peptides** 1997;18(1):157–63 (56 ref.)
Peptides in the locusts, Locusta migratoria and Schistocerca gregaria. Schoofs L, et al. **Peptides** 1997;18(1):145–56 (152 ref.)

DRUG EFFECTS

[Neuropeptides in dermatologic therapy] Gómez-Bezares P, et al. **Rev Neurol** 1997 Sep;25 Suppl 3:S320–4 (60 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Occurrence and diversity of neuropeptides from the crustacean hyperglycemic hormone family in arthropods. A short review. Soyez D. **Ann N Y Acad Sci** 1997 Apr 24;814:319–23 (28 ref.)
Neuropeptides-immunoreactivity and their mRNA expression in kindling: functional implications for limbic epileptogenesis. Schwarzer C, et al. **Brain Res Brain Res Rev** 1996 Jun;22(1):27–50 (120 ref.)
The impact of physiological stimuli on the expression of corticotropin-releasing hormone (CRH) and other neuropeptide genes. Watts AG. **Front Neuroendocrinol** 1996 Jul;17(3):281–326 (198 ref.)
neurogenins, a novel family of atonal-related bHLH transcription factors, are putative mammalian neuronal determination genes that reveal progenitor cell heterogeneity in the developing CNS and PNS. Sommer L, et al. **Mol Cell Neurosci** 1996;8(4):221–41 (51 ref.)
Neuropeptide genes: targets of activity-dependent signal transduction. MacArthur L, et al. **Peptides** 1996;17(4):721–8 (109 ref.)

IMMUNOLOGY

Neuropeptides-immunoreactivity and their mRNA expression in kindling: functional implications for limbic epileptogenesis. Schwarzer C, et al. **Brain Res Brain Res Rev** 1996 Jun;22(1):27–50 (120 ref.)
Neuroendocrine-immune systems: interactions and regulations. Sterzl I. **Folia Biol (Praha)** 1996;42(1–2):67–9 (13 ref.)
The thymic repertoire of neuroendocrine self-antigens: physiological implications in T-cell life and death. Martens H, et al. **Immunol Today** 1996 Jul;17(7):312–7 (44 ref.)
Epidermal cytokine and neuronal peptide modulation of contact hypersensitivity reactions. Pastore S, et al. **Immunopharmacology** 1996 Mar;31(2–3):117–30 (118 ref.)

METABOLISM

Transport of pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier and the prevention of ischemia-induced death of hippocampal neurons. Banks WA, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:270–7; discussion 277–9 (50 ref.)
Regulation of neuropeptide expression in sympathetic neurons. Paracrine and retrograde influences. Zigmond RE, et al. **Ann N Y Acad Sci** 1997 Apr 24;814:181–97 (90 ref.)
Immunohistochemical localization of neuropeptides and neurotransmitters in the nucleus solitarius. Maley BE. **Chem Senses** 1996 Jun;21(3):367–76 (67 ref.)
Neurotransmitters and neuropeptides in headache. Limmroth V, et al. **Curr Opin Neurol** 1996 Jun;9(3):206–10 (52 ref.)
Neuropeptides and Alzheimer's disease. Gottfries CG, et al. **Eur Neuropsychopharmacol** 1995 Dec;5(4):491–500 (113 ref.)
Intracellular trafficking of prohormones and proneuropeptides: cell type-specific sorting and targeting. Perone MJ, et al. **Exp Physiol** 1997 Jul;82(4):609–28 (137 ref.)
Neuropeptide changes in dementia: pathogenetic implications and diagnostic value. Valenti G. **Gerontology** 1996; 42(5):241–56 (151 ref.)
The study of membrane- or receptor-bound neuropeptides by NMR. Hicks RP. **Methods Mol Biol** 1997;73:185–207 (50 ref.)
Characterization of neuropeptidases using inhibitors. Hooper NM. **Methods Mol Biol** 1997;73:369–81 (14 ref.)
On the release of glutamate and aspartate in the basal ganglia of the rat: interactions with monoamines and neuropeptides. Herrera-Marschitz M, et al. **Neurosci Biobehav Rev** 1997 Jul;21(4):489–95 (73 ref.)
Neuropeptides, nerve growth factor and the skin. Pincelli C, et al. **Pathol Biol (Paris)** 1996 Dec;44(10):856–9 (49 ref.)
Circadian rhythms of neuropeptides in the suprachiasmatic nucleus. Inouye ST. **Prog Brain Res** 1996;111:75–90 (45 ref.)
Neurogenic inflammation caused by cutaneous polymodal receptors. Lynn B. **Prog Brain Res** 1996;113:361–8 (43 ref.)
Behavioral, neurochemical, anatomical and electrophysiological correlates of panic disorder: multiple transmitter interaction and neuropeptide colocalization. Zacharko RM, et al. **Prog Neurobiol** 1995 Nov–Dec; 47(4–5):371–423 (792 ref.)
[Proteolytic enzymes: subcellular localization, properties and participation in neuropeptide metabolism] Vernigora AN, et al. **Biokhimiia** 1996 May;61(5):771–85 (151 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Neuropeptides and neuronal survival: neuroprotective strategy for Alzheimer's disease. Gozes I, et al. **Ann N Y Acad Sci** 1997 Apr 24;814:161–6 (33 ref.)
VIP and PACAP receptor-mediated actions on cell proliferation and survival. Waschek JA. **Ann N Y Acad Sci** 1996 Dec 26;805:290–300; discussion 300–1 (71 ref.)
Effects of GnRH and PACAP on gonadotropin secretion and subunit messenger RNAs. Winters SJ, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:343–52; discussion 352–4 (30 ref.)
Neuropeptides in learning and memory processes. de Wied D. **Behav Brain Res** 1997 Feb;83(1–2):83–90 (76 ref.)
Neuroimmunomodulation in immune privilege: role of neuropeptides in ocular immunosuppression. Taylor AW. **Neuroimmunomodulation** 1996 Jul–Aug;3(4):195–204 (101 ref.)
Serotonin, norepinephrine and associated neuropeptides: effects on somatic motoneuron excitability. White SR, et al. **Prog Brain Res** 1996;107:183–99 (111 ref.)
[Neuromediators in dermatology. Therapeutic prospectives] Claudy A. **Pathol Biol (Paris)** 1996 Dec;44(10):888–94 (69 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Neuropeptides and the puzzle of bone remodeling. State of the art. Konttinen Y, et al. **Acta Orthop Scand** 1996 Dec; 67(6):632–9 (53 ref.)
Allatostatins: diversity in structure and function of an insect neuropeptide family. Bendena WG, et al. **Ann N Y Acad Sci** 1997 Apr 24;814:53–66 (56 ref.)
Neuropeptides and Alzheimer's disease pathology. Bissette G. **Ann N Y Acad Sci** 1997 Apr 24;814:17–29 (72 ref.)
Pituitary adenylate cyclase-activating polypeptides, PACAP-38 and PACAP-27, regulation of sympathetic neuron catecholamine, and neuropeptide Y expression through activation of type I PACAP/VIP receptor isoforms. Braas KM, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:204–16; discussion 217–8 (47 ref.)
Structural simplification of potent growth hormone-releasing hormone analogs: implications for other members of the VIP/GHRH/PACAP family. Coy DH, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:149–58 (15 ref.)
Region-specific regulation of neurogenesis by VIP and PACAP: direct and indirect modes of action. DiCicco-Bloom E. **Ann N Y Acad Sci** 1996 Dec 26; 805:244–56; discussion 256–8 (30 ref.)
Ontogeny of PACAP and PACAP receptors in the rat brain: role of PACAP in the cerebellum during development. Gonzalez BJ, et al. **Ann N Y Acad Sci** 1996 Dec 26; 805:302–13; discussion 313–4 (51 ref.)
Neuropeptides and neuronal survival: neuroprotective strategy for Alzheimer's disease. Gozes I, et al. **Ann N Y Acad Sci** 1997 Apr 24;814:161–6 (33 ref.)
Short- and long-term regulation of tyrosine hydroxylase in chromaffin cells by VIP and PACAP. Haycock JW. **Ann N Y Acad Sci** 1996 Dec 26;805:219–30; discussion 230–1 (34 ref.)
PACAP/VIP receptor subtypes, signal transducers, and effectors in pituitary cells. Hezareh M, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:315–27; discussion 327–8 (41 ref.)
Role of PACAP in the regulation of gastrointestinal motility. Katsoulis S, et al. **Ann N Y Acad Sci** 1996 Dec 26; 805:364–78 (35 ref.)
Signal transduction of PACAP and GLP-1 in pancreatic beta cells. Leech CA, et al. **Ann N Y Acad Sci** 1996 Dec 26; 805:81–92; discussion 92–3 (44 ref.)
Interplay of VIP and nitric oxide in the regulation of neuromuscular function in the gut. Murthy KS, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:355–62; discussion 362–3 (27 ref.)
Brain systems for the mediation of social separation-distress and social-reward. Evolutionary antecedents and neuropeptide intermediaries. Panksepp J, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:78–100 (63 ref.)
Pituitary adenylate cyclase-activating peptide in sensory and autonomic ganglia: localization and regulation. Sundler F, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:410–26; discussion 427–8 (76 ref.)
Genetic dissection of signal transduction mechanisms underlying PACAP-like neuropeptide transmission in Drosophila: synergy of cAMP and Ras/Raf pathways. Zhong Y. **Ann N Y Acad Sci** 1996 Dec 26;805:67–79; discussion 79–80 (36 ref.)
The immune effects of neuropeptides. Berczi I, et al. **Baillieres Clin Rheumatol** 1996 May;10(2):227–57 (217 ref.)
Neuropeptides in learning and memory processes. de Wied D. **Behav Brain Res** 1997 Feb;83(1–2):83–90 (76 ref.)
The central regulation of energy homeostasis: roles of neuropeptide Y and other brain peptides. Bing C, et al. **Biochem Soc Trans** 1996 May;24(2):559–65 (47 ref.)
Neuropeptide control of the cardiovascular system in fish and reptiles. Holmgren S. **Braz J Med Biol Res** 1995 Nov–Dec;28(11–12):1207–16 (43 ref.)
Peptidergic neurohormonal control systems in invertebrates. Nässel DR. **Curr Opin Neurobiol** 1996 Dec;6(6):842–50 (69 ref.)
Gonadal peptides as mediators of development and functional control of the testis: an integrated system with hormones and local environment. Gnessi L, et al. **Endocr Rev** 1997 Aug;18(4):541–609 (844 ref.)
The neuropeptide story. Geoffrey Harris Lecture, Budapest, Hungary, July 1994. de Wied D. **Front Neuroendocrinol** 1997 Jan;18(1):101–13 (52 ref.)
Neuropeptides in the seminal vesicles: locations, binding sites and functional implications. Pinho MS, et al. **Histol Histopathol** 1997 Apr;12(2):503–12 (86 ref.)
Role of selected peptides in the vagal regulation of gastric motor and endocrine pancreatic function. Krowicki ZK. **J Physiol Pharmacol** 1996 Sep;47(3):399–409 (55 ref.)
Changes in renal sympathetic nerve activities in the regulation of body fluid balance with special reference to central neuropeptides in conscious rats. Kannan H. **Jpn J Physiol** 1996 Apr;46(2):111–22 (107 ref.)
The role of neuropeptides in learning and memory: possible mechanisms. Shen Y, et al. **Med Hypotheses** 1995 Dec; 45(6):529–38 (80 ref.)
Neuropeptides responding to leptin. Wolf G. **Nutr Rev** 1997 Mar;55(3):85–8 (20 ref.)
FMRFamide-related peptides (FaRPs) in nematodes:

NEUROPEPTIDES

occurrence and neuromuscular physiology. Maule AG, et al. **Parasitology** 1996;113 Suppl:S119–35 (71 ref.)

Neurogenic mechanisms and neuropeptides in chronic pain. Dray A. **Prog Brain Res** 1996;110:85–94 (81 ref.)

Neuropeptides in dural fine sensory nerve endings—involvement in neurogenic inflammation? Hanesch U. **Prog Brain Res** 1996;113:299–317 (89 ref.)

Peptides and cutaneous polymodal nociceptor neurones. Lawson SN. **Prog Brain Res** 1996;113:369–85 (75 ref.)

Plasticity of messenger function in primary afferents following nerve injury—implications for neuropathic pain. Wiesenfeld-Hallin Z, et al. **Prog Brain Res** 1996;110:113–24 (80 ref.)

Neuropeptides, amines and amino acids in an elementary insect ganglion: functional and chemical anatomy of the unfused abdominal ganglion. Nässel DR. **Prog Neurobiol** 1996 Mar–Apr;48(4–5):325–420 (360 ref.)

Neuropeptide FF, a mammalian neuropeptide with multiple functions [published erratum appears in Prog Neurobiol 1996 Jun;49(3):285] Panula P, et al. **Prog Neurobiol** 1996 Mar–Apr;48(4–5):461–87 (93 ref.)

Neuropeptide abnormalities in anorexia nervosa. Kaye WH. **Psychiatry Res** 1996 Apr 16;62(1):65–74 (75 ref.)

The role of sensory neuropeptides in airway hyperresponsiveness. Baraniuk JN. **Pulm Pharmacol** 1995 Aug–Oct;8(4–5):195–202 (52 ref.)

Neuropeptide modulation of learning and memory processes. Feany MB. **Rev Neurosci** 1996 Apr–Jun;7(2):151–64 (123 ref.)

Endothelin peptides in brain diseases. Nie XJ, et al. **Rev Neurosci** 1996 Jul–Sep;7(3):177–86 (70 ref.)

Gastrointestinal endocrinology. Holst JJ, et al. **Scand J Gastroenterol Suppl** 1996;216:27–38 (74 ref.)

Brain–gut interaction. Gué M, et al. **Semin Neurol** 1996 Sep; 16(3):235–43 (83 ref.)

Ectoenzymes as sites of peptide regulation. Konkoy CS, et al. **Trends Pharmacol Sci** 1996 Aug;17(8):288–94 (41 ref.)

The revolution in insect neuropeptides illustrated by the adipokinetic hormone/red pigment–concentrating hormone family of peptides. Gäde G. **Z Naturforsch [C]** 1996 Sep–Oct;51(9–10):607–17 (86 ref.)

Gut regulatory peptides in young cattle and sheep. Guilloteau P, et al. **Zentralbl Veterinarmed A** 1997 Mar;44(1):1–23 (122 ref.)

[Anders Jahres PRIZE 1996. Current biological and clinical aspects of gastrointestinal hormones] Rehfeld JF. **Nord Med** 1997 Feb;112(2):40–3 (15 ref.) (Eng. Abstr.) **(Dan)**

[Paracrine regulation of anterior pituitary hormones by neuropeptides] Peillon F, et al. **Ann Endocrinol (Paris)** 1997; 58(1):31–8 (67 ref.) (Eng. Abstr.) **(Fre)**

[Stress research between molecular and supra–molecular observations] Oehme P, et al. **Med Monatsschr Pharm** 1996 Sep;19(9):270–4 (7 ref.) **(Ger)**

[Immuno–neuro–endocrine network] Imura H. **Rinsho Byori** 1997 Jun;45(6):505–10 (12 ref.) **(Jpn)**

[The role of the novel hypothalamic peptide PACAP in regulating endocrine functions] Grinevich VV. **Usp Fiziol Nauk** 1997 Jan–Mar;28(1):47–52 (35 ref.) (Eng. Abstr.) **(Rus)**

[Cutaneous innervation: anatomy and physiology. Neuropeptides] Casado–Olea JA. **Rev Neurol** 1997 Sep;25 Suppl 3:S207–13 (31 ref.) (Eng. Abstr.) **(Spa)**

[Role of neuropeptides in dermatology] Sánchez–Carpintero I, et al. **Rev Neurol** 1997 Sep;25 Suppl 3:S222–31 (88 ref.) (Eng. Abstr.) **(Spa)**

SECRETION

Vagal regulation of the gastrointestinal neuroendocrine system. Qian B, et al. **Scand J Gastroenterol** 1996 Jun; 31(6):529–40 (146 ref.)

THERAPEUTIC USE

Basic aspects of vasorelaxant and bronchodilating peptides in clinical use: urodilatin (INN: Ularitide), VIP, and PACAP. Meyer M, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:443–61; discussion 461–3 (104 ref.)

NEUROPHARMACOLOGY

Neuropsychopharmacology: are we ready for a paradigm shift? Meyer RE. **Neuropsychopharmacology** 1996 Mar; 14(3):169–79 (62 ref.)

Neurotoxicology: The Cinderella of neuroscience [see comments] Lotti M. **Neurotoxicology** 1996 Summer; 17(2):313–21 (71 ref.) Comment in: Neurotoxicology 1997;18(1):41–2.

METHODS

The application of neuroimaging techniques to drug development. Tamminga CA, et al. **J Clin Psychiatry** 1997; 58 Suppl 10:3–6 (19 ref.)

NEUROPHYSINS

BIOSYNTHESIS

[Neurophysins and small–cell pulmonary cancer] Pirard F, et al. **Rev Med Liege** 1997;52(1):22–6 (24 ref.) **(Fre)**

PHYSIOLOGY

Neurophysins in central diabetes insipidus. Legros JJ, et al. **Horm Res** 1996;45(3–5):182–6 (18 ref.)

NEUROPHYSIOLOGY

see related
SENSATION

Some reflections on (or by?) grandmother cells [editorial] Rose D. **Perception** 1996;25(8):881–6 (26 ref.)

[Neurophysiological basis of acupuncture] Yamamura Y, et al. **Rev Assoc Med Bras** 1995 Jul–Aug;41(4):305–10 (60 ref.) **(Por)**

METHODS

Paired recordings from neurones. Miles R, et al. **Curr Opin Neurobiol** 1996 Jun;6(3):387–94 (73 ref.)

AAEM minimonograph #47: normative data in electrodiagnostic medicine. ff Dorfman LJ, et al. **Muscle Nerve** 1997 Jan;20(1):4–14 (36 ref.)

Neurophysiological assessment of brain function and maturation: I. A measure of brain adaptation in high risk infants. Scher MS. **Pediatr Neurol** 1997 Apr;16(3):191–8 (100 ref.)

[Sensory nerve conduction studies] Hasegawa O. **Nippon Rinsho** 1997 Mar;55 Suppl 1:417–9 (7 ref.) **(Jpn)**

[Recent advances of clinical neurophysiological studies] Kakigi R. **Nippon Rinsho** 1997 Mar;55 Suppl 1:45–51 (22 ref.) **(Jpn)**

[Motor nerve conduction study] Ozaki I, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:413–6 (6 ref.) **(Jpn)**

NEUROPROTECTIVE AGENTS

Riluzole [see comments] Wokke J. **Lancet** 1996 Sep 21; 348(9030):795–9 (38 ref.) Comment in: Lancet 1996 Dec 14;348(9042):1660; discussion 1660–1. Comment in: Lancet 1996 Dec 14;348(9042):1661.

Modulation of glial cell signaling by adenosine and pharmacological reinforcement. A neuroprotective strategy? Schubert P, et al. **Mol Chem Neuropathol** 1996 May–Aug;28(1–3):185–90 (19 ref.)

Biology of glial cell line–derived neurotrophic factor (GDNF): implications for the use of GDNF to treat Parkinson's disease. Lapchak PA, et al. **Neurodegeneration** 1996 Sep;5(3):197–205 (39 ref.)

The coming of age of the GDNF family and its receptors: gene delivery in a rat Parkinson model may have clinical implications. Olson L. **Trends Neurosci** 1997 Jul;20(7):277–9 (22 ref.)

ADMINISTRATION & DOSAGE

Gene therapeutic strategies for neuroprotection: implications for Parkinson's disease. Bowers WJ, et al. **Exp Neurol** 1997 Mar;144(1):58–68 (114 ref.)

METABOLISM

GDNF: a cytokine at the interface of TGF–betas and neurotrophins. Unsicker K. **Cell Tissue Res** 1996 Nov; 286(2):175–8 (30 ref.)

Role of fibroblast growth factors in neural trauma. Cuevas P, et al. **Neurol Res** 1997 Jun;19(3):254–6 (24 ref.)

GDNF in a bind with known orphan: accessory implicated in new twist. Lindsay RM, et al. **Neuron** 1996 Oct; 17(4):571–4 (28 ref.)

PHARMACOKINETICS

Are metabolites of l–deprenyl (selegiline) useful or harmful? Indications from preclinical research. Yasar S, et al. **J Neural Transm Suppl** 1996;48:61–73 (50 ref.)

PHARMACOLOGY

Neuroprotective efficacy of microvascularly–localized versus brain–penetrating antioxidants. Hall ED, et al. **Acta Neurochir Suppl (Wien)** 1996;66:107–13 (23 ref.)

Neuroprotective effects of melatonin. Lipartiti M, et al. **Adv Exp Med Biol** 1996;398:315–21 (28 ref.)

Neuroprotection by the pyridoindole stobadine: a minireview. Stolc S, et al. **Brain Res Bull** 1997;42(5):335–40 (55 ref.)

Pharmacological characterization of glial cell line–derived neurotrophic factor (GDNF): implications for GDNF as a therapeutic molecule for treating neurodegenerative diseases. Lapchak PA, et al. **Cell Tissue Res** 1996 Nov; 286(2):179–89 (100 ref.)

Perfluorochemical oxygen carriers: potential uses in neurosciences. Sakas DE, et al. **Cerebrovasc Brain Metab Rev** 1996 Fall;8(3):209–29 (172 ref.)

Mechanisms of neuroprotective drug actions. Krieglstein J. **Clin Neurosci** 1997;4(4):184–93 (28 ref.)

Neuroprotection by the metabolic antioxidant alpha–lipoic acid. Packer L, et al. **Free Radic Biol Med** 1997; 22(1–2):359–78 (215 ref.)

Neurotoxic and neuroprotective roles of nitric oxide in cerebral ischaemia. Dalkara T, et al. **Int Rev Neurobiol** 1997;40:319–36 (132 ref.)

Adenosine and neuroprotection. Fredholm BB. **Int Rev Neurobiol** 1997;40:259–80 (130 ref.)

Pharmacology of AMPA antagonists and their role in neuroprotection. Gill R, et al. **Int Rev Neurobiol** 1997; 40:197–232 (186 ref.)

Techniques for assessing neuroprotective drugs in vitro. Goldberg MP, et al. **Int Rev Neurobiol** 1997;40:69–93 (29 ref.)

Techniques for examining neuroprotective drugs in vivo. Green AR, et al. **Int Rev Neurobiol** 1997;40:47–68 (78 ref.)

Nitrone–based free radical traps as neuroprotective agents in cerebral ischaemia and other pathologies. Hensley K, et al. **Int Rev Neurobiol** 1997;40:299–317 (105 ref.)

Calcium antagonists: their role in neuroprotection. Hunter AJ. **Int Rev Neurobiol** 1997;40:95–108 (62 ref.)

GABA and neuroprotection. Lyden PD. **Int Rev Neurobiol** 1997;40:233–58 (80 ref.)

Development of the NMDA ion–channel blocker, aptiganel hydrochloride, as a neuroprotective agent for acute CNS injury. McBurney RN. **Int Rev Neurobiol** 1997;40:173–95 (28 ref.)

Sodium and potassium channel modulators: their role in neuroprotection. Obrenovitch TP. **Int Rev Neurobiol** 1997; 40:109–35 (159 ref.)

NMDA antagonists: their role in neuroprotection. Small DL, et al. **Int Rev Neurobiol** 1997;40:137–71 (229 ref.)

The pharmacology of B–type selective monoamine oxidase inhibitors; milestones in (–)–deprenyl research. Magyar K, et al. **J Neural Transm Suppl** 1996;48:29–43 (65 ref.)

Potential of neurotrophic factors in therapy of Parkinson's disease. Möller JC, et al. **J Neural Transm Suppl** 1996; 48:103–12 (57 ref.)

Assessment of neurotoxicity and "neuroprotection". O'Byrne M, et al. **J Neural Transm Suppl** 1997;50:153–64 (51 ref.)

(–)–Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. Tatton WG, et al. **J Neural Transm Suppl** 1996;48:45–59 (98 ref.)

Cytokine production in the brain following closed head injury: dexanabinol (HU–211) is a novel TNF–alpha inhibitor and an effective neuroprotectant. Shohami E, et al. **J Neuroimmunol** 1997 Feb;72(2):169–77 (60 ref.)

Glutamate, excitotoxicity and amyotrophic lateral sclerosis. Shaw PJ, et al. **J Neurol** 1997 May;244 Suppl 2:S3–14 (130 ref.)

Clinical neuro–protection trials in severe traumatic brain injury: lessons from previous studies. Doppenberg EM, et al. **J Neurotrauma** 1997 Feb;14(2):71–80 (46 ref.)

Neuroprotective signal transduction: relevance to stroke. Mattson MP. **Neurosci Biobehav Rev** 1997 Mar; 21(2):193–206 (127 ref.)

Neuroprotective effects of adenosine in cerebral ischemia: window of opportunity. Sweeney MI. **Neurosci Biobehav Rev** 1997 Mar;21(2):207–17 (132 ref.)

Brain attack. Acute therapeutic interventions. Free radical scavengers and antioxidants. Hall ED. **Neurosurg Clin N Am** 1997 Apr;8(2):195–206 (78 ref.)

Neurotoxic versus neuroprotective actions of endogenous opioid peptides: implications for treatment of CNS injury. Faden AI. **NIDA Res Monogr** 1996;163:318–30 (59 ref.)

Pharmacology of lazaroids and brain energy metabolism: a review. Villa RF, et al. **Pharmacol Rev** 1997 Mar; 49(1):99–136 (274 ref.)

Neuroprotective and anti–amnesic potentials of sigma (sigma) receptor ligands. Maurice T, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Jan; 21(1):69–102 (224 ref.)

Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Nicoletti F, et al. **Trends Neurosci** 1996 Jul;19(7):267–71 (74 ref.)

[Effects of ketamine on CNS–function] Detsch O, et al. **Anaesthesist** 1997 Mar;46 Suppl 1:S20–9 (98 ref.) (Eng. Abstr.) **(Ger)**

[Mechanisms of action of ketamine] Kress HG. **Anaesthesist** 1997 Mar;46 Suppl 1:S8–19 (120 ref.) (Eng. Abstr.) **(Ger)**

[Neuroprotection by ketamine at the cellular level] Pfenninger E, et al. **Anaesthesist** 1997 Mar;46 Suppl 1:S47–54 (64 ref.) (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Piracetam in the treatment of myoclonus: an overview. Van Vleymen B, et al. **Acta Neurol Belg** 1996 Dec;96(4):270–80 (62 ref.)

Sodium channels and therapy of central nervous system diseases. Taylor CP, et al. **Adv Pharmacol** 1997;39:47–98 (300 ref.)

Riluzole: a new agent for amyotrophic lateral sclerosis [see comments] Wagner ML, et al. **Ann Pharmacother** 1997 Jun; 31(6):738–44 (51 ref.) Comment in: Ann Pharmacother 1997 Jun;31(6):779–81.

Modulation of neuronal and glial cell function by adenosine and neuroprotection in vascular dementia. Rudolphi KA, et al. **Behav Brain Res** 1997 Feb;83(1–2):123–8 (27 ref.)

Psychotogenicity and N–methyl–D–aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Kornhuber J, et al. **Biol Psychiatry** 1997 Jan 15;41(2):135–44 (85 ref.)

Intravenous agents and intraoperative neuroprotection. Beyond barbiturates. Cheng MA, et al. **Crit Care Clin** 1997 Jan;13(1):185–99 (90 ref.)

Riluzole for amyotrophic lateral sclerosis. **Drug Ther Bull** 1997 Feb;35(2):11–2 (12 ref.)

Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in

amyotrophic lateral sclerosis. Bryson HM, et al. **Drugs** 1996 Oct;52(4):549–63 (60 ref.)

New directions in the drug treatment of Parkinson's disease. Montastruc JL, et al. **Drugs Aging** 1996 Sep;9(3):169–84 (82 ref.)

Central nervous system resuscitation. McIntosh TK, et al. **Emerg Med Clin North Am** 1997 Aug;15(3):527–50 (279 ref.)

Efficacy and mechanisms of action of the cytoprotective lipid peroxidation inhibitor tirilazad mesylate in subarachnoid haemorrhage. Hall ED. **Eur J Anaesthesiol** 1996 May; 13(3):279–89 (55 ref.)

Neuroprotective therapy for Parkinson's disease. Koller WC. **Exp Neurol** 1997 Mar;144(1):24–8 (42 ref.)

Glial cell line–derived neurotrophic factor: a novel therapeutic approach to treat motor dysfunction in Parkinson's disease. Lapchak PA, et al. **Exp Neurol** 1997 Mar;144(1):29–34 (20 ref.)

Pharmacological activities of glial cell line–derived neurotrophic factor (GDNF): preclinical development and application to the treatment of Parkinson's disease. Lapchak PA, et al. **Exp Neurol** 1997 Jun;145(2 Pt 1):309–21 (65 ref.)

Remacemide hydrochloride: a novel antiepileptic agent. Davies JA. **Gen Pharmacol** 1997 Apr;28(4):499–502 (31 ref.)

Interleukins and cerebral ischaemia. Rothwell NJ, et al. **Int Rev Neurobiol** 1997;40:281–98 (90 ref.)

A review of earlier clinical studies on neuroprotective agents and current approaches. Wahlgren NG. **Int Rev Neurobiol** 1997;40:337–63 (190 ref.)

Therapeutic advances: beta–interferon for multiple sclerosis. Clark W. **J Clin Pharm Ther** 1996 Aug;21(4):195–9 (27 ref.)

The rationale for new therapies in acute ischaemic stroke. Dyker AG, et al. **J Clin Pharm Ther** 1996 Dec;21(6):377–91 (105 ref.)

Neuroprotective drug development in stroke: blood pressure and its impact. McCulloch J. **J Hypertens Suppl** 1996 Dec; 14(5):S131–8 (82 ref.)

Chronic administration of a partial agonist at strychnine–insensitive glycine receptors: a novel experimental approach to the treatment of ischemias. Fossom LH, et al. **J Neural Transm Suppl** 1997;49:235–44 (38 ref.)

New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline. Gerlach M, et al. **J Neural Transm Suppl** 1996;48:7–21 (63 ref.)

The clinical potential of Deprenyl in neurologic and psychiatric disorders. Kuhn W, et al. **J Neural Transm Suppl** 1996;48:85–93 (51 ref.)

Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action. Olanow CW. **J Neural Transm Suppl** 1996;48:75–84 (60 ref.)

TNF–alpha receptor fusion protein prevents experimental auto–immune encephalomyelitis and demyelination in Lewis rats: an overview. Klinkert WE, et al. **J Neuroimmunol** 1997 Feb;72(2):163–8 (44 ref.)

Impact of riluzole on the relationship between patient and physician. Dengler R, et al. **J Neurol** 1997 May;244 Suppl 2:S30–2 (11 ref.)

Pharmacological management of spinal cord injury: current status of drugs designed to augment functional recovery of the injured human spinal cord. Greene KA, et al. **J Spinal Disord** 1996 Oct;9(5):355–66 (130 ref.)

Clinical applications of pharmacologic therapies for spinal cord injury. Zeidman SM, et al. **J Spinal Disord** 1996 Oct; 9(5):367–80 (72 ref.)

Inflammatory reaction after brain damage and prospective therapy against damage impending cerebral infarction. Matsuo Y, et al. **Keio J Med** 1996 Sep;45(3):270–4 (18 ref.)

Attempts to obtain neuroprotection in Parkinson's disease. Olanow CW. **Neurology** 1997 Jul;49(1 Suppl 1):S26–33 (87 ref.)

Selegiline: current perspectives on issues related to neuroprotection and mortality. Olanow CW. **Neurology** 1996 Dec;47(6 Suppl 3):S210–6 (72 ref.)

New pharmacologic strategies for acute neuronal injury. Luer MS, et al. **Pharmacotherapy** 1996 Sep–Oct; 16(5):830–48 (242 ref.)

Therapeutic potentials for glial cell line–derived neurotrophic factor (GDNF) based upon pharmacological activities in the CNS. Lapchak PA. **Rev Neurosci** 1996 Jul–Sep; 7(3):165–76 (48 ref.)

Considerations in the design of clinical trials of neuroprotective therapy in acute stroke. Dorman PJ, et al. **Stroke** 1996 Sep;27(9):1507–15 (85 ref.)

Preventing post–traumatic epilepsy after brain injury: weighing the costs and benefits of anticonvulsant prophylaxis. Hernandez TD. **Trends Pharmacol Sci** 1997 Feb;18(2):59–62 (50 ref.)

The role of glutamic acid in the pathogenesis of stroke and the development of neuroprotective drugs. Evans SM, et al. **West Indian Med J** 1995 Dec;44(4):119–23 (35 ref.)

[Ketamine and neuroprotection. Clinical outlook] Fitzal S. **Anaesthesist** 1997 Mar;46 Suppl 1:S65–70 (48 ref.) (Eng. Abstr.) **(Ger)**

[Effect of ketamine on global cerebral ischemia] Kempski O, et al. **Anaesthesist** 1997 Mar;46 Suppl 1:S61–4 (35 ref.) (Eng. Abstr.) **(Ger)**

[Ketamine racemate and S–(+)–ketamine. Cerebrovascular effects and neuroprotection following focal ischemia] Werner C, et al. **Anaesthesist** 1997 Mar;46 Suppl 1:S55–60 (25 ref.) (Eng. Abstr.) **(Ger)**

[Pharmacotherapy of Alzheimer dementia: therapy of cognitive symptoms--new results of clinical studies] Heidrich A, et al. **Fortschr Neurol Psychiatr** 1997 Mar; 65(3):108–21 (180 ref.) (Eng. Abstr.) **(Ger)**

NEUROPSYCHOLOGICAL TESTS

Naming deficit in herpes simplex encephalitis. Barbarotto R, et al. **Acta Neurol Scand** 1996 Apr;93(4):272–80 (28 ref.)

Neuropsychological features of early Alzheimer's disease: preclinical and clinical stages. Almkvist O. **Acta Neurol Scand Suppl** 1996;165:63–71 (98 ref.)

Measures of psychiatric symptoms in Alzheimer patients: a review. Weiner MF, et al. **Alzheimer Dis Assoc Disord** 1996 Spring;10(1):20–30 (62 ref.)

Performance of PTSD patients on standard tests of memory. Implications for trauma. Wolfe J, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:208–18 (52 ref.)

The agitated brain injured patient. Part 1: Definitions, differential diagnosis, and assessment. Sandel ME, et al. **Arch Phys Med Rehabil** 1996 Jun;77(6):617–23 (64 ref.)

The neuropsychology of obsessive–compulsive disorder: a review and consideration of clinical implications. Tallis F. **Br J Clin Psychol** 1997 Feb;36 (Pt 1):3–20 (130 ref.)

Computerized methods of neuropsychological assessment. Curtis–Prior PB. **Br J Hosp Med** 1996 Nov 6–19; 56(9):445–9 (30 ref.)

Issues in the assessment of cognitive function in dementia. Milberg W. **Brain Cogn** 1996 Jul;31(2):114–32 (42 ref.)

Neurocognitive impairment in schizophrenia and how it affects treatment options [see comments] Bilder RM. **Can J Psychiatry** 1997 Apr;42(3):255–64 (58 ref.) Comment in: Can J Psychiatry 1997 Apr;42(3):247–8.

Neuropsychology and advances in memory function. Gordon B. **Curr Opin Neurol** 1997 Aug;10(4):306–12 (70 ref.)

Neuropsychological approaches for the detection and evaluation of toxic symptoms. Fiedler N. **Environ Health Perspect** 1996 Apr;104 Suppl 2:239–45 (69 ref.)

Neurobehavioral tests as a medical surveillance procedure: applying evaluative criteria. Guirguis S. **Environ Res** 1997; 73(1–2):63–9 (46 ref.)

Neuropsychological evaluation in epilepsy surgery. Loring DW. **Epilepsia** 1997;38 Suppl 4:S18–23 (35 ref.)

Developmental assessment tests: scope and limitations [editorial] Chaudhari S. **Indian Pediatr** 1996 Jul;33(7):541–5 (19 ref.)

Diagnostic classification of neuropsychiatric signs and symptoms in patients with dementia. Caine ED. **Int Psychogeriatr** 1996;8 Suppl 3:273–9; discussion 289–91 (12 ref.)

Theories behind existing scales for rating behavior in dementia. Cummings JL. **Int Psychogeriatr** 1996;8 Suppl 3:293–300 (34 ref.)

Neuropsychiatric assessment and intervention in Alzheimer's disease. Cummings JL. **Int Psychogeriatr** 1996;8 Suppl 1:25–30 (15 ref.)

Cognitive neuropsychology and its application to children. Temple CM. **J Child Psychol Psychiatry** 1997 Jan; 38(1):27–52 (170 ref.)

Cognitive screening instruments in neuropsychiatry: a report of the Committee on Research of the American Neuropsychiatric Association. Malloy PF, et al. **J Neuropsychiatry Clin Neurosci** 1997 Spring;9(2):189–97 (73 ref.)

Forensic issues in the neuropsychiatric evaluation of the patient with mild traumatic brain injury. Silver JM, et al. **J Neuropsychiatry Clin Neurosci** 1997 Winter;9(1):102–13 (120 ref.)

Neuropsychological alterations after split–brain surgery. Sauerwein HC, et al. **J Neurosurg Sci** 1997 Mar;41(1):59–66 (40 ref.)

Neuropsychological and neuroimaging evidence for the involvement of the frontal lobes in depression. Goodwin GM. **J Psychopharmacol (Oxf)** 1997;11(2):115–22 (85 ref.)

Neuropsychologic assessment in surgical treatment of epilepsy. Trenerry MR. **Mayo Clin Proc** 1996 Dec; 71(12):1196–200 (58 ref.)

Tourette syndrome. Neuropsychological tests for obsessive–compulsive disorder and attention deficit hyperactivity disorder. Como PG. **Neurol Clin** 1997 May; 15(2):255–65 (85 ref.)

Symptom dimensions of schizophrenia: a selective integration of neurophysiological and neuropsychological correlates. Aderibigbe YA, et al. **Neuropsychobiology** 1996; 34(4):192–200 (89 ref.)

Neurocognitive functioning in chronic fatigue syndrome. DiPino RK, et al. **Neuropsychol Rev** 1996 Mar;6(1):47–60 (41 ref.)

A review and critique of the process approach in neuropsychological assessment. Erickson RC. **Neuropsychol Rev** 1995 Dec;5(4):223–43 (95 ref.)

Emotional disturbances and their interaction with neuropsychological deficits. Reitan RM, et al. **Neuropsychol Rev** 1997 Mar;7(1):3–19 (67 ref.)

CANTAB battery: proposed utility in neurotoxicology. Fray PJ, et al. **Neurotoxicol Teratol** 1996 Jul–Aug;18(4):499–504 (33 ref.)

The Automated Cognitive Test (ACT) system. Stollery BT. **Neurotoxicol Teratol** 1996 Jul–Aug;18(4):493–7 (18 ref.)

Neuropsychological testing and assessment scales for dementia of the Alzheimer's type. Morgan CD, et al. **Psychiatr Clin North Am** 1997 Mar;20(1):25–43 (69 ref.)

Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Barkley RA. **Psychol Bull** 1997 Jan;121(1):65–94 (400 ref.)

Neuropsychological course after surgery for intracranial aneurysms. A prospective study and a critical review. Stabell KE, et al. **Scand J Psychol** 1997 Jun;38(2):127–37 (49 ref.)

Neuropsychological assessment of developmental learning disabilities in adults. Vincent LC. **Semin Speech Lang** 1996 Aug;17(3):183–200 (110 ref.)

[Proven tests in neurological diagnosis] Oosterhuis HJ. **Ned Tijdschr Geneeskd** 1996 Nov 2;140(44):2171–5 (28 ref.) **(Dut)**

[A critical review of available tools for evaluating memory enhancers in Alzheimer's disease] Poitrenaud J, et al. **Rev Med Interne** 1997;18(1):59–71 (59 ref.) (Eng. Abstr.) **(Fre)**

[Nondeclarative memory—neuropsychological findings and neuroanatomic principles] Daum I, et al. **Fortschr Neurol Psychiatr** 1997 Mar;65(3):122–32 (115 ref.) (Eng. Abstr.) **(Ger)**

[The contribution of neuropsychology to psychiatry] Zihl J. **Fortschr Neurol Psychiatr** 1996 Oct;64(10):403–17 (172 ref.) (Eng. Abstr.) **(Ger)**

[Tests for aphasia, apraxia and agnosia] Hasegawa T, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:318–21 (11 ref.) **(Jpn)**

[Applications of neuropsychology in the medical field: diabetes mellitus as a model of research] Pereda Muñoz M, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 Nov–Dec;24(6):322–30 (32 ref.) (Eng. Abstr.) **(Spa)**

[Normalization of cognitive and functional assessment instruments for dementia (NORMACODEM) (I): objectives, content and population] Peña–Casanova J, et al. **Neurologia** 1997 Feb;12(2):61–8 (98 ref.) (Eng. Abstr.) **(Spa)**

[Mini–mental state examination: proposal of protocol to be used] Giménez–Roldán S, et al. **Rev Neurol** 1997 Apr; 25(140):576–83 (40 ref.) (Eng. Abstr.) **(Spa)**

HISTORY

Cognitive neurotoxicology: a luxury or necessity? Stollery BT. **Neurotoxicol Teratol** 1996 Jul–Aug;18(4):359–64 (32 ref.)

STANDARDS

Symposium on computerized behavioral testing of humans in neurotoxicology research: overview of the proceedings. Anger WK, et al. **Neurotoxicol Teratol** 1996 Jul–Aug; 18(4):347–50 (29 ref.)

STATISTICS & NUMERICAL DATA

Neuropsychological assessment of dementia: state of the art. Almkvist O, et al. **Acta Neurol Scand Suppl** 1996;168:45–9 (45 ref.)

Neuropsychological test performance as an indicator of silent cerebrovascular disease in elderly hypertensives. Kalra L, et al. **Age Ageing** 1994 Nov;23(6):517–23 (68 ref.)

Predicting disability in stroke—a critical review of the literature. Kwakkel G, et al. **Age Ageing** 1996 Nov; 25(6):479–89 (149 ref.)

Assessment of agitation. Cohen–Mansfield J. **Int Psychogeriatr** 1996 Summer;8(2):233–45 (26 ref.)

The Hierarchic Dementia Scale: conceptualization. Cole MG, et al. **Int Psychogeriatr** 1996 Summer;8(2):205–12 (32 ref.)

The Alzheimer's Disease Assessment Scale. Mohs RC. **Int Psychogeriatr** 1996 Summer;8(2):195–203 (21 ref.)

Behavioral pathology in Alzheimer's disease (BEHAVE–AD) rating scale. Reisberg B, et al. **Int Psychogeriatr** 1996;8 Suppl 3:301–8; discussion 351–4 (14 ref.)

Clinical global impressions in Alzheimer's clinical trials. Schneider LS, et al. **Int Psychogeriatr** 1996 Summer; 8(2):277–88; discussion 288–90 (17 ref.)

The Halstead Category Test: a fifty year perspective. Choca JP, et al. **Neuropsychol Rev** 1997 Jun;7(2):61–75 (230 ref.)

[Significance of impartial assessment of geriatric brain diseases] Spiegel R. **Ther Umsch** 1997 Jun;54(6):314–20 (15 ref.) (Eng. Abstr.) **(Ger)**

NEUROPSYCHOLOGY

The neuropsychology of autism. Happé F, et al. **Brain** 1996 Aug;119 (Pt 4):1377–400 (265 ref.)

Clinical and research contributions of the intracarotid amobarbital procedure to neuropsychology. Jones–Gotman M, et al. **Brain Cogn** 1997 Feb;33(1):1–6 (20 ref.)

Reflections on mirror images. Neuropsychology. Walsh V. **Curr Biol** 1996 Sep 1;6(9):1079–81 (16 ref.)

Providing a neuropsychology service for people with multiple sclerosis in an interdisciplinary rehabilitation unit. Thompson SB. **Disabil Rehabil** 1996 Jul;18(7):348–53 (60 ref.)

Affect, attachment, memory: contributions toward psychobiologic integration. Amini F, et al. **Psychiatry** 1996 Fall;59(3):213–39 (113 ref.)

Impaired attention in depressive states: a non–specific deficit? Mialet JP, et al. **Psychol Med** 1996 Sep;26(5):1009–20 (99 ref.)

NEUROPSYCHOLOGY

Obsessive compulsive disorder--a neuropsychiatric illness. Ko SM. **Singapore Med J** 1996 Apr;37(2):186–8 (48 ref.)
[Capgras syndrome: open perspectives for cognitive neuropsychology] Debruille JB, et al. **Can J Psychiatry** 1996 May;41(4):245–50 (37 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Cognitive rehabilitation of chronic alcohol abusers. Allen DN, et al. **Neuropsychol Rev** 1997 Mar;7(1):21–39 (106 ref.)
Emotional disturbances and their interaction with neuropsychological deficits. Reitan RM, et al. **Neuropsychol Rev** 1997 Mar;7(1):3–19 (67 ref.)

NEURORADIOGRAPHY

METHODS

Epilepsy for the neuroradiologist. Fisher RS, et al. **AJNR Am J Neuroradiol** 1997 May;18(5):851–63 (52 ref.)

NEURORECEPTORS see **RECEPTORS, SENSORY**

NEUROREGULATOR RECEPTORS see **RECEPTORS, NEUROTRANSMITTER**

NEUROREGULATORS see **NEUROTRANSMITTERS**

NEUROSCIENCES

Contributions of inhibitory mechanisms to unified theory in neuroscience and psychology. Clark JM. **Brain Cogn** 1996 Feb;30(1):127–52 (104 ref.)
Can cognitive neuroscience illuminate the nature of traumatic childhood memories? Schacter DL, et al. **Curr Opin Neurobiol** 1996 Apr;6(2):207–14 (111 ref.)
Anatomic and physiologic aging: a behavioral neuroscience perspective. Willott JF. **J Am Acad Audiol** 1996 Jun; 7(3):141–51 (60 ref.)
[Psychiatry between neurosciences and psychoanalysis] Dongier M. **Rev Med Liege** 1996 Dec;51(12):763–70 (26 ref.) **(Fre)**

EDUCATION

Dialogue with other sciences: opportunities for mutual gain [editorial] Olds D, et al. **Int J Psychoanal** 1997 Apr;78 (Pt 2):219–25 (48 ref.)

METHODS

Using emerging technologies such as virtual reality and the World Wide Web to contribute to a richer understanding of the brain. Merril JR. **Ann N Y Acad Sci** 1997 May 30; 820:229–33 (0 ref.)
Computerization of Fujimori's method of waveform recognition. A review and methodological considerations for its application to all-night sleep EEG. Uchida S, et al. **J Neurosci Methods** 1996 Jan;64(1):1–12 (60 ref.)
Ethical considerations in clinical neuroscience. Current concepts in neuroclinical trials. Alves WA, et al. **Stroke** 1996 Oct;27(10):1903–9 (44 ref.)
The 'sniffer-patch' technique for detection of neurotransmitter release. Allen TG. **Trends Neurosci** 1997 May;20(5):192–7 (34 ref.)

ORGANIZATION & ADMINISTRATION

The present and the future of sleep research in Asia. Okuma T. **Psychiatry Clin Neurosci** 1995 May;49(2):91–7 (22 ref.)

TRENDS

Neuroscience and human intelligence differences. Deary IJ, et al. **Trends Neurosci** 1997 Aug;20(8):365–71 (82 ref.)
Alzheimer transgenic mouse models come of age. Duff K. **Trends Neurosci** 1997 Jul;20(7):279–80 (11 ref.)
The coming of age of the GDNF family and its receptors: gene delivery in a rat Parkinson model may have clinical implications. Olson L. **Trends Neurosci** 1997 Jul;20(7):277–9 (22 ref.)

NEUROSECRETION

see related
PITUITARY HORMONE-RELEASING HORMONES

NEUROSECRETORY SYSTEMS

see related
NEUROIMMUNOMODULATION

CYTOLOGY

Cerebellar afferents to neuroendocrine cells: implications for adaptive responses to simulated weightlessness. Katafuchi T, et al. **Endocr J** 1995 Dec;42(6):729–37 (42 ref.)
Commentary on the use of immortalized neuroendocrine cell lines for physiological research. Selmanoff M. **Endocrine** 1997 Feb;6(1):1–3 (67 ref.)
Neuroepithelial bodies and solitary neuroendocrine cells in the lungs of amphibia. Goniakowska-Witalińska L. **Microsc Res Tech** 1997 Apr 1;37(1):13–30 (71 ref.)
Functional histology of the neuroendocrine thymus. Moll UM. **Microsc Res Tech** 1997 Aug 1;38(3):300–10 (118 ref.)
Comparative histology of pulmonary neuroendocrine cell system in mammalian lungs. Scheuermann DW. **Microsc Res Tech** 1997 Apr 1;37(1):31–42 (150 ref.)
Ontogeny of neuroepithelial bodies: correlations with mitogenesis and innervation. Sorokin SP, et al. **Microsc Res Tech** 1997 Apr 1;37(1):43–61 (116 ref.)
Quantitative microscopical methods for the identification and localisation of nerves and neuroendocrine cell markers in mammalian lung. Springall DR, et al. **Microsc Res Tech** 1997 Apr 1;37(1):92–100 (40 ref.)
Paraneurons in the gills and airways of fishes. Zaccone G, et al. **Microsc Res Tech** 1997 Apr 1;37(1):4–12 (48 ref.)
Thyroid parafollicular cells. An accessible model for the study of serotonergic neurons. Russo AF, et al. **Mol Neurobiol** 1996 Dec;13(3):257–76 (132 ref.)
Calcium-channel subtypes in the somata and axon terminals of magnocellular neurosecretory cells. Fisher TE, et al. **Trends Neurosci** 1996 Oct;19(10):440–4 (54 ref.)

DRUG EFFECTS

A brief review of immunomodulation caused by acute administration of ethanol: involvement of neuroendocrine pathways. Pruett SB, et al. **Alcohol Alcohol Suppl** 1994; 2:431–7 (44 ref.)
Neuroendocrine responses to serotonergic agonists as indices of the functional status of central serotonin neurotransmission in humans: a preliminary comparative analysis of neuroendocrine endpoints versus other endpoint measures. Murphy DL, et al. **Behav Brain Res** 1996; 73(1-2):209–14 (51 ref.)
Neurohumoral effects of digoxin: a target for further investigation. Gheorghiade M. **Cardiologia** 1996 Oct; 41(10):967–72 (49 ref.)
Dioxins and the Ah receptor: probes to uncover processes in neuroendocrine development. Gasiewicz TA. **Neurotoxicology** 1997;18(2):393–413 (162 ref.)
[Endocrine reactions following S-(+)-ketamine] Adams HA. **Anaesthesist** 1997 Mar;46 Suppl 1:S30–7 (33 ref.) (Eng. Abstr.) **(Ger)**

EMBRYOLOGY

Neuroendocrine regulation of pituitary-adrenal function during fetal life. Brooks AN, et al. **Eur J Endocrinol** 1996 Aug;135(2):153–65 (132 ref.)

GROWTH & DEVELOPMENT

Dioxins and the Ah receptor: probes to uncover processes in neuroendocrine development. Gasiewicz TA. **Neurotoxicology** 1997;18(2):393–413 (162 ref.)

IMMUNOLOGY

Interdependence of the endocrine and immune systems. Dardenne M, et al. **Adv Neuroimmunol** 1996;6(4):297–307 (73 ref.)
T cell development within the intestinal mucosa: clues to a novel immune-endocrine network? Klein JR. **Adv Neuroimmunol** 1996;6(4):397–405 (43 ref.)
Aging, immunity and neuroendocrine hormones. Mosley RL. **Adv Neuroimmunol** 1996;6(4):419–32 (117 ref.)
A brief review of immunomodulation caused by acute administration of ethanol: involvement of neuroendocrine pathways. Pruett SB, et al. **Alcohol Alcohol Suppl** 1994; 2:431–7 (44 ref.)
Psycho-neuro-cytokine/endocrine pathways in immunoregulation during pregnancy. Clark DA, et al. **Am J Reprod Immunol** 1996 Apr;35(4):330–7 (71 ref.)
Neuroendocrine immune responses to inflammation: the concept of the neuroendocrine immune loop. Chikanza IC, et al. **Baillieres Clin Rheumatol** 1996 May;10(2):199–225 (135 ref.)
The neuroendocrine immunology of rheumatoid arthritis . Chikanza IC. **Baillieres Clin Rheumatol** 1996 May; 10(2):273–93 (59 ref.)
Immune system-neuroendocrine dysregulation in spinal cord injury. Cruse JM, et al. **Immunol Res** 1996;15(4):306–14 (46 ref.)
Fighting, fleeing and having fun: the immunology of physical activity. Nehlsen-Cannarella S, et al. **Int J Sports Med** 1997 Mar;18 Suppl 1:S8–21 (152 ref.)

METABOLISM

Intracellular targeting of secretory proteins in neuroendocrine cells. Shennan KI. **Biochem Soc Trans** 1996 May;24(2):535–9 (36 ref.)
Immunogold labelling of neuroendocrine peptides with special reference to antibody specificity and multiple staining techniques. Larsson LI. **Histochem Cell Biol** 1996 Jul;106(1):93–103 (73 ref.)
Human endometrium as a neuroendocrine tissue: expression, regulation and biological roles of endometrial corticotropin-releasing hormone (CRH) and opioid peptides. Zoumakis E, et al. **J Endocrinol Invest** 1997 Mar; 20(3):158–67 (98 ref.)
Neuroendocrine effects of electroconvulsive therapy (ECT). Swartz CM. **Psychopharmacol Bull** 1997;33(2):265–71 (62 ref.)

PATHOLOGY

Pulmonary neuroendocrine cell system in pediatric and adult lung disease. Gosney JR. **Microsc Res Tech** 1997 Apr 1; 37(1):107–13 (76 ref.)

PHYSIOLOGY

Effects of growth hormone on neuroendocrine function. Bartke A, et al. **Acta Neurobiol Exp (Warsz)** 1996; 56(3):833–42 (66 ref.)
Neuroendocrine mechanism mediating fasting-induced suppression of luteinizing hormone secretion in female rats. Maeda K, et al. **Acta Neurobiol Exp (Warsz)** 1996; 56(3):787–96 (43 ref.)
Neuroendocrine regulation of vascular capacitance. Karim F. **Adv Exp Med Biol** 1995;381:81–94 (53 ref.)
Role of the neuroendocrine system in cytokine pathways in inflammatory bowel disease. Ottaway CA. **Aliment Pharmacol Ther** 1996;10 Suppl 2:10–5 (55 ref.)
Overview of dietary sodium effects on and interactions with cardiovascular and neuroendocrine functions. Ely DL. **Am J Clin Nutr** 1997 Feb;65(2 Suppl):594S–605S (163 ref.)
Specific neuroendocrine mechanisms not involving generalized stress mediate social regulation of female reproduction in cooperatively breeding marmoset monkeys. Abbott DH, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:219–38 (106 ref.)
Species diversity and the evolution of behavioral controlling mechanisms. Crews D. **Ann N Y Acad Sci** 1997 Jan 15; 807:1–21 (64 ref.)
New concepts of the neuroendocrine regulation of gonadotropin surges in rats. Levine JE. **Biol Reprod** 1997 Feb;56(2):293–302 (104 ref.)
Coital and estrogen signals: a contrast in the preovulatory neuroendocrine networks of rabbits and rhesus monkeys. Spies HG, et al. **Biol Reprod** 1997 Feb;56(2):310–9 (157 ref.)
Activation of the neuroendocrine response in heart failure: adaptive or maladaptive process? Ferrari R, et al. **Cardiovasc Drugs Ther** 1996 Nov;10 Suppl 2:623–9 (68 ref.)
Plasticity of neuro-endocrine-thymus interactions during aging--a minireview. Fabris N, et al. **Cell Mol Biol (Noisy-le-grand)** 1997 Jun;43(4):529–41 (59 ref.)
Steroid imprinting and modulation of sexual dimorphism in the luteinizing hormone-releasing hormone neuronal system. López FJ, et al. **Cell Mol Neurobiol** 1996 Apr; 16(2):129–41 (30 ref.)
In vivo monitoring of brain neurotransmitter release for the assessment of neuroendocrine interactions. Mas M, et al. **Cell Mol Neurobiol** 1996 Jun;16(3):383–96 (51 ref.)
Biogenesis of neurosecretory vesicles. Huttner WB, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:315–27 (72 ref.)
Commentary on the use of immortalized neuroendocrine cell lines for physiological research. Selmanoff M. **Endocrine** 1997 Feb;6(1):1–3 (67 ref.)
Neuroendocrine asymmetry. Gerendai I, et al. **Front Neuroendocrinol** 1997 Jul;18(3):354–81 (154 ref.)
The neuroendocrinology of thirst and salt appetite: visceral sensory signals and mechanisms of central integration. Johnson AK, et al. **Front Neuroendocrinol** 1997 Jul; 18(3):292–353 (369 ref.)
Neurotensin and neuroendocrine regulation. Rostène WH, et al. **Front Neuroendocrinol** 1997 Apr;18(2):115–73 (346 ref.)
Expression and signal transduction pathways of endothelin receptors in neuroendocrine cells. Stojilkovic SS, et al. **Front Neuroendocrinol** 1996 Jul;17(3):327–69 (224 ref.)
Neuroendocrine activation after myocardial infarction: causes and consequences. Cleland JG, et al. **Heart** 1996 Nov;76(3 Suppl 3):53–9 (68 ref.)
The use of genetic "knockout" mice in behavioral endocrinology research. Nelson RJ. **Horm Behav** 1997 Jun; 31(3):188–96 (55 ref.)
The growth hormone axis: control and effects. Argente J, et al. **Horm Res** 1996;45 Suppl 1:9–11 (10 ref.)
The role of glia in the neuroendocrine hypothalamus: possible implications in hormone secretion. Chowen JA, et al. **Horm Res** 1996;45 Suppl 1:15–8 (10 ref.)
The diffuse neuroendocrine system and extrapineal melatonin. Kvetnoy I, et al. **J Mol Endocrinol** 1997 Feb; 18(1):1–3 (27 ref.)
Antisense oligodeoxynucleotides as specific tools for studying neuroendocrine and behavioral functions: some prospects and problems. Nicot A, et al. **J Neurosci Methods** 1997 Jan;71(1):45–53 (57 ref.)
Behavioral-neuroendocrine-immunologic interactions in myocardial infarction. Goodkin K, et al. **Med Hypotheses** 1997 Mar;48(3):209–14 (45 ref.)
Neuroendocrine and immune system responses with spaceflights. Tipton CM, et al. **Med Sci Sports Exerc** 1996 Aug;28(8):988–98 (78 ref.)
Secretory vesicle pools and rate and kinetics of single vesicle exocytosis in neurosecretory cells. Trifaró JM, et al. **Neurochem Res** 1997 Jul;22(7):831–41 (80 ref.)
Neuroendocrine and autonomous mechanisms underlying thermoregulation in cold environment. Arancibia S, et al. **Neuroendocrinology** 1996 Oct;64(4):257–67 (65 ref.)
Gaseous transmitters and neuroendocrine regulation. Brann DW, et al. **Neuroendocrinology** 1997 Jun;65(6):385–95 (88 ref.)
Neuroendocrine mechanisms of the formation of adaptive behavior. Shalyapina VG, et al. **Neurosci Behav Physiol** 1997 May-Jun;27(3):275–9 (25 ref.)
Neuroendocrine mechanisms mediating awakening of the human gonadotropic axis in puberty. Veldhuis JD.

Pediatr Nephrol 1996 Jun;10(3):304–17 (131 ref.)
Nociceptive, environmental and neuroendocrine factors determining pain behaviour in animals. Aloisi AM, et al. **Prog Brain Res** 1996;110:33–46 (78 ref.)
The neurobiology of the central nucleus of the amygdala in relation to neuroendocrine and autonomic outflow. Bohus B, et al. **Prog Brain Res** 1996;107:447–60 (91 ref.)
The gastrointestinal tract and the lungs. Similarities with particular emphasis on the neuroendocrine cells. Waldum HL, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Mar; 13(1):63–5 (41 ref.)
The neurobiology of stress: understanding regulation of affect during female biological transitions. Dorn LD, et al. **Semin Reprod Endocrinol** 1997 Feb;15(1):19–35 (162 ref.)
Resistance exercise overtraining and overreaching. Neuroendocrine responses. Fry AC, et al. **Sports Med** 1997 Feb;23(2):106–29 (183 ref.)
Somatostatin: the neuroendocrine story. Gillies G. **Trends Pharmacol Sci** 1997 Mar;18(3):87–95 (45 ref.)
[Merit of surgical stress suppression--special reference to epidural and intravenous anesthesia in view of endocrine systems] Ishihara H. **Masui** 1996 Dec;45 Suppl:S51–5 (13 ref.) **(Jpn)**
[Result of biological response to surgical stress] Yuge T. **Masui** 1996 Dec;45 Suppl:S44–8 (14 ref.) **(Jpn)**
[Physiopathology of mucous-membrane immunity system and neuroendocrine regulation] Nakura H, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):694 (0 ref.) **(Jpn)**
[The role of neuroendocrine cells and bombesin neuropeptides in the pathogenesis of smoking related diseases, especially chronic obstructive pulmonary disease] Siemińska A, et al. **Pneumonol Alergol Pol** 1997; 65(1–2):123–8 (32 ref.) **(Pol)**
[Is the immune system our sixth sense? Relation between the immune and neuroendocrine systems] Ferenčík M, et al. **Bratisl Lek Listy** 1997 Apr;98(4):187–98 (84 ref.) (Eng. Abstr.) **(Slo)**

PHYSIOPATHOLOGY

Neuroendocrine response during stress with relation to gender differences. Ježová D, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(3):779–85 (44 ref.)
Neurohormonal perturbations in fibromyalgia. Crofford LJ, et al. **Baillieres Clin Rheumatol** 1996 May;10(2):365–78 (84 ref.)
Neuroendocrine changes in systemic lupus erythematosus and Sjögren's syndrome. Fox RA, et al. **Baillieres Clin Rheumatol** 1996 May;10(2):333–47 (86 ref.)
Neuroendocrine changes in chronic cardiac failure. Nicholls DP, et al. **Basic Res Cardiol** 1996;91 Suppl 1:13–20 (140 ref.)
Hypothalamic disease: neurosecretory dysfunction and parasellar lesions. Bercu BB. **Curr Ther Endocrinol Metab** 1997;6:21–6 (14 ref.)
Human polymodal receptors in pathological conditions. Ochoa J. **Prog Brain Res** 1996;113:185–97 (107 ref.)
The neuroendocrine system and gastrointestinal complications in patients with familial amyloidosis and polyneuropathy. el-Salhy M, et al. **Scand J Gastroenterol** 1997 Sep;32(9):849–54 (55 ref.)
[The functional swings in the neuroendocrine regulation of stress] Shaliapina VG. **Fiziol Zh Im I M Sechenova** 1996 Apr;82(4):9–14 (31 ref.) **(Rus)**

NEUROSES see **NEUROTIC DISORDERS**

NEUROSES, ANXIETY see **ANXIETY DISORDERS**

NEUROSES, PHOBIC see **PHOBIC DISORDERS**

NEUROSES, POST-TRAUMATIC see **STRESS DISORDERS, POST-TRAUMATIC**

NEUROSES, WAR see **COMBAT DISORDERS**

NEUROSIS, DEPRESSIVE see **DEPRESSIVE DISORDER**

NEUROSIS, HYPOCHONDRIACAL see **HYPOCHONDRIASIS**

NEUROSIS, OBSESSIVE-COMPULSIVE see **OBSESSIVE-COMPULSIVE DISORDER**

NEUROSPORA

PHYSIOLOGY

Genetics in rhythm. Iwasaki K, et al. **Trends Genet** 1997 Mar; 13(3):111–5 (50 ref.)

NEUROSPORA CRASSA

GENETICS

The genome and genes of Neurospora crassa. Radford A, et al. **Fungal Genet Biol** 1997 Jun;21(3):258–66 (50 ref.)

NEUROSURGERY

Surgical treatment of Parkinson's disease. Krauss JK, et al. **Am Fam Physician** 1996 Oct;54(5):1621–9 (29 ref.)
Airway management in neuroanaesthesia. Spiekermann BF, et al. **Can J Anaesth** 1996 Aug;43(8):820–34 (93 ref.)
Managed care and managed golf: lessons for neurosurgery in 1995. Dacey RG Jr. **Clin Neurosurg** 1996;43:1–11 (11 ref.)
Basal ganglia: new therapeutic approaches to Parkinson's disease. Graybiel AM. **Curr Biol** 1996 Apr 1;6(4):368–71 (30 ref.)
Postoperative pain management in the neurosurgical patient. Cousins MJ, et al. **Int Anesthesiol Clin** 1996 Fall; 34(4):179–93 (71 ref.)
Preoperative evaluation of the adult neurosurgical patient. Fischer SP. **Int Anesthesiol Clin** 1996 Fall;34(4):21–32 (47 ref.)
Intraoperative neurophysiological monitoring. Lopez JR. **Int Anesthesiol Clin** 1996 Fall;34(4):33–54 (92 ref.)
Hypothermia-associated protection from ischemic brain injury: implications for patient management. Wass CT, et al. **Int Anesthesiol Clin** 1996 Fall;34(4):95–111 (76 ref.)
Desflurane and sevoflurane are valuable additions to the practice of neuroanesthesiology: pro. Baker KZ. **J Neurosurg Anesthesiol** 1997 Jan;9(1):66–8 (24 ref.)
The new inhalational anesthetics desflurane and sevoflurane are valuable additions to the practice of neuroanesthesia: con. Tempelhoff R. **J Neurosurg Anesthesiol** 1997 Jan; 9(1):69–71 (19 ref.)
Global health care and neurosurgeons. Wakai S. **Neurol Med Chir (Tokyo)** 1997 Jun;37(6):483–9; discussion 489–90 (50 ref.)
Application of laser Doppler flowmetry in neurosurgery. Arbit E, et al. **Neurosurg Clin N Am** 1996 Oct;7(4):741–8 (45 ref.)
Basic principles and neurosurgical applications of positron emission tomography. Xiong J, et al. **Neurosurg Clin N Am** 1997 Jul;8(3):293–306 (95 ref.)
What the neurosurgeon needs to know about the coagulation system. Heesen M, et al. **Surg Neurol** 1997 Jan;47(1):32–4 (8 ref.)
[Biological glue in neurosurgery] Dzenis IuL, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1996 Jul–Sep;(3):35–6 (29 ref.) **(Rus)**

EDUCATION

In the realm of ideas: the advent of advanced surgery of the human cerebrum and neurosurgical education. Apuzzo ML. **Acta Neurochir Suppl (Wien)** 1997;69:145–50 (29 ref.)

HISTORY

Historical and basic science review: past, present, and future of nerve repair. Terzis JK, et al. **J Reconstr Microsurg** 1997 Apr;13(3):215–25 (94 ref.)
The isolation and transplantation of the brain. An historical perspective emphasizing the surgical solutions to the design of these classical models. White RJ, et al. **Neurol Res** 1996 Jun;18(3):194–203 (45 ref.)

INSTRUMENTATION

Experimental and clinical standards, and evolution of lasers in neurosurgery. Devaux BC, et al. **Acta Neurochir (Wien)** 1996;138(10):1135–47 (72 ref.)
The role of conduits in nerve repair: a review. Doolabh VB, et al. **Rev Neurosci** 1996 Jan–Mar;7(1):47–84 (214 ref.)
Use of the Horsley-Clarke stereotactic frame in humans. Jensen RL, et al. **Stereotact Funct Neurosurg** 1995; 65(1–4):194–7 (21 ref.)
Endoscopic instruments. Misra M, et al. **Surg Neurol** 1997 Aug;48(2):140–2 (13 ref.)
[Neuroendoscopy and endoscopic neurosurgery] Gaab MR, et al. **Nervenarzt** 1997 Jun;68(6):459–65 (34 ref.) (Eng. Abstr.) **(Ger)**

MANPOWER

Rehabilitation and the neurosurgeon [editorial] Gentleman D. **Br J Neurosurg** 1996 Dec;10(6):537–40 (46 ref.)

METHODS

Innovations in minimalism: intraoperative MRI. Alexander E 3rd, et al. **Clin Neurosurg** 1996;43:338–52 (34 ref.)
Innovation through minimalism: assessing emerging technology in neurosurgery. Awad IA. **Clin Neurosurg** 1996;43:303–16 (35 ref.)
Innovations in surgical approach: lateral cranial base approaches. Day JD, et al. **Clin Neurosurg** 1996;43:72–90 (29 ref.)
Anterior midline approaches to the central skull base. Harsh GR 4th, et al. **Clin Neurosurg** 1996;43:15–43 (41 ref.)
Transcranial orbital surgery. Jane JA Sr, et al. **Clin Neurosurg** 1996;43:53–71 (19 ref.)
Transpetrosal and combination approaches to skull base lesions. Lawton MT, et al. **Clin Neurosurg** 1996;43:91–112 (29 ref.)
Surgical approaches to aneurysms of the upper basilar artery. MacDonald JD, et al. **Clin Neurosurg** 1996;43:127–36 (14 ref.)
Intraoperative cranial navigation. Maciunas RJ. **Clin Neurosurg** 1996;43:353–81 (21 ref.)
Is there a future for percutaneous intradiscal therapy? Maroon JC, et al. **Clin Neurosurg** 1996;43:239–51 (49 ref.)
The transcondylar approach to the lower clivus, foramen magnum and C1–C2. Sen C. **Clin Neurosurg** 1996;43:113–26 (13 ref.)
Innovations in cranial approaches and exposures: anterolateral approaches. Van Loveren HR, et al. **Clin Neurosurg** 1996;43:44–52 (26 ref.)
Treatment of Parkinson's disease. New surgical treatment strategies. Pollak P, et al. **Eur Neurol** 1996;36(6):400–4 (43 ref.)
Stereotactic procedures for molecular neurosurgery. Kelly PJ. **Exp Neurol** 1997 Mar;144(1):157–9 (11 ref.)
Photodynamic therapy in neurosurgery: a review. Kostron H, et al. **J Photochem Photobiol B** 1996 Nov;36(2):157–68 (115 ref.)
A review of stress ulcer prophylaxis in the neurosurgical intensive care unit. Lu WY, et al. **Neurosurgery** 1997 Aug; 41(2):416–25; discussion 425–6 (150 ref.)
Temporary vessel occlusion during intracranial aneurysm repair. Taylor CL, et al. **Neurosurgery** 1996 Nov; 39(5):893–905; discussion 905–6 (133 ref.)
Cellular and molecular neurosurgery: pathways from concept to reality--part I: target disorders and concept approaches to gene therapy of the central nervous system. Zlokovic BV, et al. **Neurosurgery** 1997 Apr;40(4):789–803; discussion 803–4 (99 ref.)
Cellular and molecular neurosurgery: pathways from concept to reality--part II: vector systems and delivery methodologies for gene therapy of the central nervous system. Zlokovic BV, et al. **Neurosurgery** 1997 Apr; 40(4):805–12; discussion 812–3 (51 ref.)
Stereotactic transsylvian, transinsular approach for deep-seated lesions. Heffez DS. **Surg Neurol** 1997 Aug; 48(2):113–24 (16 ref.)
[Image-guided surgery] Gybels J, et al. **Verh K Acad Geneeskd Belg** 1997;59(1):35–57; discussion 57–9 (31 ref.) (Eng. Abstr.) **(Dut)**
[Malignant tumors of the ethmoid region. Neurosurgical techniques] Roux FX, et al. **Neurochirurgie** 1997;43(2):92–9 (28 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

Trauma systems and the neurosurgeon. Brain Trauma Foundation. **J Neurotrauma** 1996 Nov;13(11):647–51 (13 ref.)

TRENDS

Perfluorocarbons: recent developments and implications for neurosurgery. Sakas DE, et al. **J Neurosurg** 1996 Aug; 85(2):248–54 (124 ref.)
Current practices and advances in pediatric neurosurgery. Lawton KH, et al. **Nurs Clin North Am** 1997 Mar; 32(1):73–96 (30 ref.)
Commissural myelotomy revisited [editorial] Gybels J. **Pain** 1997 Mar;70(1):1–2 (12 ref.)
Use of the Horsley-Clarke stereotactic frame in humans. Jensen RL, et al. **Stereotact Funct Neurosurg** 1995; 65(1–4):194–7 (21 ref.)

VETERINARY

Medical care of the neurosurgical patient. Longshore RC, et al. **Semin Vet Med Surg (Small Anim)** 1996 Nov; 11(4):208–17 (36 ref.)

NEUROSYPHILIS

DIAGNOSIS

Neurosyphilis in patients with AIDS. Harris DE, et al. **Neuroimaging Clin N Am** 1997 May;7(2):215–21 (18 ref.)

IMMUNOLOGY

IgG subclasses in neurological disorders. Losy J, et al. **Neurol Neurochir Pol** 1996;30 Suppl 2:17–24 (16 ref.)

NEUROTENDINOUS SPINDLES see **MECHANORECEPTORS**

NEUROTENSIN

ANTAGONISTS & INHIBITORS

Use of nonpeptide antagonists to explore the physiological roles of neurotensin. Focus on brain neurotensin/dopamine interactions. Rostene W, et al. **Ann N Y Acad Sci** 1997 Apr 24;814:125–41 (82 ref.)
Neuropharmacological profile of non-peptide neurotensin antagonists. Gully D, et al. **Fundam Clin Pharmacol** 1995; 9(6):513–21 (55 ref.)

METABOLISM

Neurotensin pathway in the chicken thymus. Atoji Y, et al. **Kaibogaku Zasshi** 1997 Jun;72(3):181–6 (33 ref.)

PHYSIOLOGY

Use of nonpeptide antagonists to explore the physiological roles of neurotensin. Focus on brain neurotensin/dopamine interactions. Rostene W, et al. **Ann N Y Acad Sci** 1997 Apr 24;814:125–41 (82 ref.)
Neurotensin and neuroendocrine regulation. Rostène WH, et al. **Front Neuroendocrinol** 1997 Apr;18(2):115–73 (346 ref.)
[Neurotensin--structure, origin and biological function]

NEUROTENSIN

Kulińska-Niedziela I, et al. **Postepy Hig Med Dosw** 1997; 51(3):329–42 (75 ref.) (Eng. Abstr.) **(Pol)**

NEUROTHEKEOMA

PATHOLOGY

Nerve sheath myxoma of the oral cavity: case report and review. Tiffee JC, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Oct;82(4):423–5 (13 ref.)

NEUROTIC DISORDERS

EPIDEMIOLOGY

The assessment of personality disorders: implications for cognitive and behavior therapy. Van Velzen CJ, et al.
Behav Res Ther 1996 Aug;34(8):655–68 (94 ref.)
Comorbidity and the general neurotic syndrome. Andrews G. **Br J Psychiatry Suppl** 1996 Jun;(30):76–84 (34 ref.)

PSYCHOLOGY

Dysmorphophobia: recent developments of interest to the maxillofacial surgeon. Cunningham SJ, et al.
Br J Oral Maxillofac Surg 1996 Oct;34(5):368–74 (26 ref.)
Bereavement and neurosis. Hagman G.
J Am Acad Psychoanal 1995 Winter;23(4):635–53 (33 ref.)

NEUROTIZATION see **NERVE TRANSFER**

NEUROTOXINS

The kynurenine pathway and neurologic disease. Therapeutic strategies. Heyes MP. **Adv Exp Med Biol** 1996;398:125–9 (23 ref.)
New approaches to imaging based on effects of neurotoxins. Francis PT, et al. **Dement Geriatr Cogn Disord** 1997 Mar–Apr;8(2):117–22 (31 ref.)
Trophic controls on stage transformations of a toxic ambush-predator dinoflagellate. Burkholder JM, et al.
J Eukaryot Microbiol 1997 May–Jun;44(3):200–5 (29 ref.)
Mechanism of amyloid beta protein induced neuronal cell death: current concepts and future perspectives. Behl C, et al. **J Neural Transm Suppl** 1997;49:125–34 (26 ref.)
Central nervous system cytokines and their relevance for neurotoxicity and apoptosis. Licinio J.
J Neural Transm Suppl 1997;49:169–75 (28 ref.)
N-methyl-(R)salsolinol as a dopaminergic neurotoxin: from an animal model to an early marker of Parkinson's disease. Naoi M, et al. **J Neural Transm Suppl** 1997;50:89–105 (49 ref.)
The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Schwarting RK, et al.
Prog Neurobiol 1996 Oct;50(2–3):275–331 (395 ref.)
[Biochemical and pharmacological studies of Clostridium perfringens epsilon-toxin] Nagahama M.
Nippon Saikingaku Zasshi 1996 Oct;51(4):953–62 (20 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Systemic, but not intraparenchymal, administration of 3-nitropropionic acid mimics the neuropathology of Huntington's disease: a speculative explanation. Borlongan CV, et al. **Neurosci Res** 1997 Jul;28(3):185–9 (27 ref.)

ADVERSE EFFECTS

Behavioral toxicology, risk assessment, and chlorinated hydrocarbons. Evangelista de Duffard AM, et al.
Environ Health Perspect 1996 Apr;104 Suppl 2:353–60 (121 ref.)
Role of the neurologist in hazard identification and risk assessment. Feldman RG, et al. **Environ Health Perspect** 1996 Apr;104 Suppl 2:227–37 (27 ref.)
The assessment of neurobehavioral toxicity: SGOMSEC joint report. Fiedler N, et al. **Environ Health Perspect** 1996 Apr; 104 Suppl 2:179–91 (74 ref.)
Neuropsychological approaches for the detection and evaluation of toxic symptoms. Fiedler N.
Environ Health Perspect 1996 Apr;104 Suppl 2:239–45 (69 ref.)
The challenge of mechanism-based modeling in risk assessment for neurobehavioral end points. Hattis D.
Environ Health Perspect 1996 Apr;104 Suppl 2:381–90 (30 ref.)
Behavioral methods and organic solvents: questions and consequences. Iregren A. **Environ Health Perspect** 1996 Apr;104 Suppl 2:361–6 (56 ref.)
Prospective, longitudinal assessment of developmental neurotoxicity. Jacobson JL, et al.
Environ Health Perspect 1996 Apr;104 Suppl 2:275–83 (68 ref.)
Comprehensive neurotoxicity assessment. Kulig BM.
Environ Health Perspect 1996 Apr;104 Suppl 2:317–22 (63 ref.)
Disrupted patterns of behavior in natural populations as an index of ecotoxicity. Peakall DB.
Environ Health Perspect 1996 Apr;104 Suppl 2:331–5 (33 ref.)
Setting exposure standards: a decision process. Tilson HA, et al. **Environ Health Perspect** 1996 Apr;104 Suppl 2:401–5 (23 ref.)
Neurobehavioral aspects of developmental toxicity testing. Ulbrich B, et al. **Environ Health Perspect** 1996 Apr;104 Suppl 2:407–12 (16 ref.)

CHEMISTRY

Structure and function of tetanus and botulinum neurotoxins. Montecucco C, et al. **Q Rev Biophys** 1995 Nov;28(4):423–72 (335 ref.)
Botulinum versus tetanus neurotoxins: why is botulinum neurotoxin but not tetanus neurotoxin a food poison? Singh BR, et al. **Toxicon** 1995 Dec;33(12):1541–7 (48 ref.)

GENETICS

Binding of native kappa-neurotoxins and site-directed mutants to nicotinic acetylcholine receptors. Chiappinelli VA, et al. **Toxicon** 1996 Nov–Dec;34(11–12):1243–56 (41 ref.)

METABOLISM

Excitotoxicity and excitoprotection in vitro. Mattson MP, et al. **Adv Neurol** 1996;71:1–30; discussion 30–5 (267 ref.)
Modulation of 6-hydroxydopamine oxidation by various proteins. Padiglia A, et al. **Biochem Pharmacol** 1997 Apr 25;53(8):1065–8 (32 ref.)
Zinc and Alzheimer's disease: is there a direct link? Cuajungco MP, et al. **Brain Res Brain Res Rev** 1997 Apr; 23(3):219–36 (249 ref.)
Homeostasis of energy conduction, neurotransmitters, cytotoxic compounds and metal ions. Nelson N.
J Exp Biol 1997 Jan;200 (Pt 2):331–3 (21 ref.)
Endogenous neurotoxins relevant to schizophrenia. Smythies J. **J R Soc Med** 1996 Dec;89(12):679–80 (26 ref.)
Excitotoxicity in ALS. Leigh PN, et al. **Neurology** 1996 Dec; 47(6 Suppl 4):S221–7 (87 ref.)
Excitotoxicity hypothesis. Rothstein JD. **Neurology** 1996 Oct; 47(4 Suppl 2):S19–25; discussion S26 (40 ref.)
Binding of native kappa-neurotoxins and site-directed mutants to nicotinic acetylcholine receptors. Chiappinelli VA, et al. **Toxicon** 1996 Nov–Dec;34(11–12):1243–56 (41 ref.)

PHARMACOLOGY

Use of neurotoxins to study Ca2+ channel functions. Cassola AC, et al. **Braz J Med Biol Res** 1996 Dec;29(12):1759–63 (17 ref.)
Recent studies on dendrotoxins and potassium ion channels. Harvey AL. **Gen Pharmacol** 1997 Jan;28(1):7–12 (93 ref.)
[Action mechanisms of botulinum neurotoxins and tetanus neurotoxins] Deloye F, et al. **C R Seances Soc Biol Fil** 1997;191(3):433–50 (85 ref.) (Eng. Abstr.) **(Fre)**
[Effect of neurotoxins on the electrical activity and contraction of the heart muscle] Sauviat MP.
C R Seances Soc Biol Fil 1997;191(3):451–71 (122 ref.) (Eng. Abstr.) **(Fre)**
[Approach to neurotoxicity based on behavioral science] Ando K. **J Toxicol Sci** 1996 Aug;21(3 Appendix):137–42 (8 ref.) **(Jpn)**

POISONING

Cyanobacterial toxins: occurrence, modes of action, health effects and exposure routes. Codd GA, et al.
Arch Toxicol Suppl 1997;19:399–410 (35 ref.)
Neurobehavioral epidemiology: application in risk assessment. Grandjean P, et al. **Environ Health Perspect** 1996 Apr;104 Suppl 2:397–400 (30 ref.)
Evolution of our understanding of methylmercury as a health threat. Watanabe C, et al. **Environ Health Perspect** 1996 Apr;104 Suppl 2:367–79 (69 ref.)

TOXICITY

Economical test methods for developmental neurobehavioral toxicity. Bignami G. **Environ Health Perspect** 1996 Apr;104 Suppl 2:285–98 (12 ref.)
Risk assessment for neurobehavioral toxicity: SGOMSEC joint report. Hattis D, et al. **Environ Health Perspect** 1996 Apr;104 Suppl 2:217–26 (43 ref.)
Animal behavioral methods in neurotoxicity assessment: SGOMSEC joint report. Kulig B, et al.
Environ Health Perspect 1996 Apr;104 Suppl 2:193–204 (107 ref.)
Clinical neurologic indices of toxicity in animals. O'Donoghue JL. **Environ Health Perspect** 1996 Apr;104 Suppl 2:323–30 (13 ref.)
Lessons for neurotoxicology from selected model compounds: SGOMSEC joint report. Rice DC, et al.
Environ Health Perspect 1996 Apr;104 Suppl 2:205–15 (83 ref.)
Nitric oxide neurotoxicity. Dawson VL, et al.
J Chem Neuroanat 1996 Jun;10(3–4):179–90 (100 ref.)
The TaClo concept:
1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline (TaClo), a new toxin for dopaminergic neurons. Bringmann G, et al. **J Neural Transm Suppl** 1995;46:235–44 (25 ref.)
TaClo as a neurotoxic lead: improved synthesis, stereochemical analysis, and inhibition of the mitochondrial respiratory chain. Bringmann G, et al.
J Neural Transm Suppl 1995;46:245–54 (19 ref.)
Mechanism of 6-hydroxydopamine neurotoxicity. Glinka Y, et al. **J Neural Transm Suppl** 1997;50:55–66 (41 ref.)
Assessment of neurotoxicity and "neuroprotection". O'Byrne M, et al. **J Neural Transm Suppl** 1997;50:153–64 (51 ref.)
Toxic models of upper motor neuron disease. Ludolph AC, et al. **J Neurol Sci** 1996 Aug;139 Suppl:53–9 (60 ref.)
Ruthenium red as a tool to study calcium channels, neuronal death and the function of neural pathways. Tapia R, et al. **Neurochem Int** 1997 Feb;30(2):137–47 (59 ref.)
Systemic, but not intraparenchymal, administration of 3-nitropropionic acid mimics the neuropathology of Huntington's disease: a speculative explanation. Borlongan CV, et al. **Neurosci Res** 1997 Jul;28(3):185–9 (27 ref.)
Astrocytes as modulators of mercury-induced neurotoxicity. Aschner M. **Neurotoxicology** 1996 Fall–Winter; 17(3–4):663–9 (59 ref.)
Astrocytes as the site for bioactivation of neurotoxins. Di Monte DA, et al. **Neurotoxicology** 1996 Fall–Winter; 17(3–4):697–703 (32 ref.)
The relevance of axonal swellings and atrophy to gamma-diketone neurotoxicity: a forum position paper [see comments] LoPachin RM, et al. **Neurotoxicology** 1997; 18(1):7–22 (107 ref.) Comment in: Neurotoxicology 1997 ;18(1):23–4; discussion 37–40. Comment in: Neurotoxicology 1997 ;18(1):25–8; discussion 37–40. Comment in: Neurotoxicology 1997 ;18(1):29–30; discussion 37–10. Comment in: Neurotoxicology 1997 ;18(1):31–2; discussion 37–40. Comment in: Neurotoxicology 1997 ;18(1):33–6; discussion 37–40.
Glucocorticoids may enhance oxygen radical-mediated neurotoxicity. McIntosh LJ, et al. **Neurotoxicology** 1996 Fall–Winter;17(3–4):873–82 (106 ref.)
Schwann cells as targets for neurotoxicants. Morell P, et al. **Neurotoxicology** 1996 Fall–Winter;17(3–4):685–95 (42 ref.)
Evidence for delayed neurotoxicity produced by methylmercury. Rice DC. **Neurotoxicology** 1996 Fall–Winter;17(3–4):583–96 (31 ref.)
Neurofilamentous swellings and axonal atrophy are of unclear significance to diketone toxicity: commentary on forum position paper [comment] Sickles DW.
Neurotoxicology 1997;18(1):33–6; discussion 37–40 (15 ref.) Comment on: Neurotoxicology 1997 ;18(1):7–22.
Inorganic lead as a developmental neurotoxicant: some basic issues and the Düsseldorf experience. Winneke G.
Neurotoxicology 1996 Fall–Winter;17(3–4):565–80 (91 ref.)
Neurotoxic versus neuroprotective actions of endogenous opioid peptides: implications for treatment of CNS injury. Faden AI. **NIDA Res Monogr** 1996;163:318–30 (59 ref.)
Structure and function of tetanus and botulinum neurotoxins. Montecucco C, et al. **Q Rev Biophys** 1995 Nov;28(4):423–72 (335 ref.)

NEUROTRANSMITTERS

see related
AUTACOIDS
NEUROIMMUNOMODULATION
RECEPTORS, NEUROTRANSMITTER

Neurobiology of nitric oxide. Yun HY, et al.
Crit Rev Neurobiol 1996;10(3–4):291–316 (225 ref.)
Evolution and overview of classical transmitter molecules and their receptors. Walker RJ, et al. **Parasitology** 1996; 113 Suppl:S3–33 (221 ref.)
Thyroid hormones as neurotransmitters. Dratman MB, et al. **Thyroid** 1996 Dec;6(6):639–47 (35 ref.)
[Neurotransmitter systems in the human brain studied by positron emission tomography] Shinotoh H.
Rinsho Shinkeigaku 1996 Dec;36(12):1313–5 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Cytokines as signal transmitters in the nervous system] Tabira T. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):512–8 (21 ref.) **(Jpn)**

ANALYSIS

The neurochemistry of Alzheimer's disease. Engelborghs S, et al. **Acta Neurol Belg** 1997 Jun;97(2):67–84 (226 ref.)
Colocalization of amino acid signal molecules in neurons and endocrine cells. Davanger S. **Anat Embryol (Berl)** 1996 Jul; 194(1):1–12 (192 ref.)
[Neurotransmitter changes in amyotrophic lateral sclerosis] Barkhatova VP, et al.
Zh Nevropatol Psikhiatr Im S S Korsakova 1996;96(4):78–85 (37 ref.) (Eng. Abstr.) **(Rus)**

ANTAGONISTS & INHIBITORS

Presynaptic inhibition of elicited neurotransmitter release. Wu LG, et al. **Trends Neurosci** 1997 May;20(5):204–12 (73 ref.)

BLOOD

Plasma neurotransmitters and functional illness. Lechin F, et al. **Psychother Psychosom** 1996;65(6):293–318 (203 ref.)
[Tension-type headache: 5-hydroxytryptamine and related substances] Shimomura T. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1342–4 (8 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Insect neuropeptide proctolin and its analogues. An overview of the present literature. Konopińska D. **J Pept Res** 1997 Jun;49(6):457–66 (56 ref.)

IMMUNOLOGY

Immunoregulatory role of neurotransmitters. Qiu Y, et al. **Adv Neuroimmunol** 1996;6(3):223–31 (51 ref.)
Neuroendocrine–immune systems: interactions and regulations. Sterzl I. **Folia Biol (Praha)** 1996;42(1–2):67–9 (13 ref.)
Regulation of the immune response by epidermal cytokines and neurohormones. Luger TA, et al. **J Dermatol Sci** 1996 Oct;13(1):5–10 (51 ref.)

METABOLISM

Neurotransmitters, signal transduction and second-messengers in Alzheimer's disease. Cowburn RF, et al. **Acta Neurol Scand Suppl** 1996;165:25–32 (63 ref.)
Heterogeneity and functional properties of subtypes of sodium-dependent glutamate transporters in the mammalian central nervous system. Robinson MB, et al. **Adv Pharmacol** 1997;37:69–115 (210 ref.)
Neurotransmitter correlates of impulsive aggression in humans. Coccaro EF. **Ann N Y Acad Sci** 1996 Sep 20; 794:82–9 (55 ref.)
Neuroendocrinology of the polycystic ovary syndrome. Soule SG. **Baillieres Clin Endocrinol Metab** 1996 Apr; 10(2):205–19 (59 ref.)
Neurotransmitter and neuromodulator activity in the gustatory zone of the nucleus tractus solitarius. Bradley RM, et al. **Chem Senses** 1996 Jun;21(3):377–85 (55 ref.)
Immunohistochemical localization of neuropeptides and neurotransmitters in the nucleus solitarius. Maley BE. **Chem Senses** 1996 Jun;21(3):367–76 (67 ref.)
ATP as a co-transmitter with noradrenaline in sympathetic nerves—function and fate. Kennedy C, et al. **Ciba Found Symp** 1996;198:223–35; discussion 235–8 (38 ref.)
Challenges in developing P2 purinoceptor-based therapeutics. Williams M. **Ciba Found Symp** 1996; 198:309–21 (53 ref.)
Protein kinase C and transmitter release. Majewski H, et al. **Clin Exp Pharmacol Physiol** 1997 Aug;24(8):619–23 (56 ref.)
Neurohumoral activation in heart failure: role of paraventricular nucleus. Patel KP, et al. **Clin Exp Pharmacol Physiol** 1996 Aug;23(8):722–6 (42 ref.)
Neurotransmitter release - four years of SNARE complexes. Hanson PI, et al. **Curr Opin Neurobiol** 1997 Jun;7(3):310–5 (56 ref.)
Regulation of excitatory and inhibitory neurotransmitter-gated ion channels by protein phosphorylation. Smart TG. **Curr Opin Neurobiol** 1997 Jun; 7(3):358–67 (72 ref.)
Neurotransmitters and neuropeptides in headache. Limmroth V, et al. **Curr Opin Neurol** 1996 Jun;9(3):206–10 (52 ref.)
Neurotransmitters and neuroreceptors in the lower urinary tract. Andersson KE. **Curr Opin Obstet Gynecol** 1996 Oct; 8(5):361–5 (49 ref.)
Depression as a spreading neuronal adjustment disorder. Harro J, et al. **Eur Neuropsychopharmacol** 1996 Aug; 6(3):207–23 (193 ref.)
Synthesis of models for excitable membranes, synaptic transmission and neuromodulation using a common kinetic formalism. Destexhe A, et al. **J Comput Neurosci** 1994 Aug; 1(3):195–230 (119 ref.)
Molecular heterogeneity of neurotransporters: implications for neurodegeneration. Lesch KP, et al. **J Neural Transm Suppl** 1997;49:155–67 (33 ref.)
Balance of transmitter activities in the basal ganglia loops. Schmidt WJ. **J Neural Transm Suppl** 1995;46:67–76 (46 ref.)
Advances in the immunocytochemical localization of neuroactive substances in the insect nervous system. Nässel DR. **J Neurosci Methods** 1996 Oct 21;69(1):3–23 (102 ref.)
Redistribution of synaptic efficacy: a mechanism to generate infinite synaptic input diversity from a homogeneous population of neurons without changing absolute synaptic efficacies. Markram H, et al. **J Physiol Paris** 1996; 90(3–4):229–32 (12 ref.)
Cellular and molecular aspects of monoamine neurotransmitter transporters. Kitayama S, et al. **Jpn J Pharmacol** 1996 Nov;72(3):195–208 (126 ref.)
Functional interaction between serotonin and other neuronal systems: focus on in vivo microdialysis studies. Saito H, et al. **Jpn J Pharmacol** 1996 Mar;70(3):203–5 (221 ref.)
Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Carlsson A, et al. **Life Sci** 1997;61(2):75–94 (67 ref.)
Localization, regulation and functions of neurotransmitters and neuromodulators in cervical sympathetic ganglia. Klimaschewski L, et al. **Microsc Res Tech** 1996 Sep 1; 35(1):44–68 (400 ref.)
Activity-dependent changes in voltage-dependent calcium currents and transmitter release. Lnenicka GA, et al. **Mol Neurobiol** 1997 Feb–Apr;14(1–2):37–66 (94 ref.)
Noradrenaline storing vesicles in sympathetic neurons and their role in neurotransmitter release: an historical overview of controversial issues. De Potter WP, et al. **Neurochem Res** 1997 Aug;22(8):911–9 (74 ref.)
Amino acid neurotransmission: dynamics of vesicular uptake. Fykse EM, et al. **Neurochem Res** 1996 Sep;21(9):1053–60 (68 ref.)
Stimulatory effects of opioids on transmitter release and possible cellular mechanisms: overview and original results. Sarne Y, et al. **Neurochem Res** 1996 Nov;21(11):1353–61 (113 ref.)
Listening to neurotransmitter transporters. Lester HA, et al. **Neuron** 1996 Nov;17(5):807–10 (22 ref.)
Metabolism and inactivation of neurotransmitters in nematodes. Isaac RE, et al. **Parasitology** 1996;113 Suppl:S157–73 (120 ref.)
SV2proteoglycan: a potential synaptic vesicle transporter and nerve terminal extracellular matrix receptor. Carlson SS. **Perspect Dev Neurobiol** 1996;3(4):373–86 (79 ref.)
Compartmentalised distribution of GABAA and glutamate receptors in relation to transmitter release sites on the surface of cerebellar neurones. Nusser Z, et al. **Prog Brain Res** 1997;114:109–27 (91 ref.)
Receptors controlling transmitter release from sympathetic neurons in vitro. Boehm S, et al. **Prog Neurobiol** 1997 Feb; 51(3):225–42 (94 ref.)
Behavioral, neurochemical, anatomical and electrophysiological correlates of panic disorder: multiple transmitter interaction and neuropeptide colocalization. Zacharko RM, et al. **Prog Neurobiol** 1995 Nov–Dec; 47(4–5):371–423 (792 ref.)
Stress versus depression. Lechin F, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Aug; 20(6):899–950 (215 ref.)
Drugs affecting neurotransmitter release in the airways. Spina D. **Pulm Pharmacol** 1995 Aug–Oct;8(4–5):217–25 (117 ref.)
Ion–exchange gel regulates neurotransmitter release through the exocytotic fusion pore. Marszalek P, et al. **Soc Gen Physiol Ser** 1996;51:211–22 (39 ref.)
The 'sniffer-patch' technique for detection of neurotransmitter release. Allen TG. **Trends Neurosci** 1997 May;20(5):192–7 (34 ref.)
Intersynaptic diffusion of neurotransmitter. Barbour B, et al. **Trends Neurosci** 1997 Sep;20(9):377–84 (58 ref.)
The DnaJ-like cysteine string protein and exocytotic neurotransmitter release. Buchner E, et al. **Trends Neurosci** 1997 May;20(5):223–7 (28 ref.)
The calcium channel and the organization of the presynaptic transmitter release face. Stanley EF. **Trends Neurosci** 1997 Sep;20(9):404–9 (54 ref.)
Release of soluble nucleotidases: a novel mechanism for neurotransmitter inactivation? Kennedy C, et al. **Trends Pharmacol Sci** 1997 Aug;18(8):263–6 (30 ref.)
25 years since the discovery of presynaptic receptors: present knowledge and future perspectives. Langer SZ. **Trends Pharmacol Sci** 1997 Mar;18(3):95–9 (39 ref.)
Calcineurin regulation of synaptic function: from ion channels to transmitter release and gene transcription. Yakel JL. **Trends Pharmacol Sci** 1997 Apr;18(4):124–34 (63 ref.)
[Neurotransmitter transporters--a role of the molecular mechanism in nervous system diseases and drug poisoning] Nakamura S, et al. **Nippon Yakurigaku Zasshi** 1996 Sep; 108(3):99–100 (0 ref.) **(Jpn)**
[Rab3A and neurotransmitter release] Fujita Y, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):364–70 (28 ref.) **(Jpn)**
[Molecular mechanisms for neurotransmitter release] Kumakura K. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):261–74 (88 ref.) **(Jpn)**

PHARMACOKINETICS

Drug interactions with vesicular amine transport. Peter D, et al. **NIDA Res Monogr** 1996;161:176–200 (64 ref.)

PHARMACOLOGY

Immunoregulatory role of neurotransmitters. Qiu Y, et al. **Adv Neuroimmunol** 1996;6(3):223–31 (51 ref.)
Cardiovascular pharmacology of purines [editorial] Rongen GA, et al. **Clin Sci (Colch)** 1997 Jan;92(1):13–24 (165 ref.)
Pharmacology of the internal anal sphincter and abnormalities in faecal incontinence. Speakman CT. **Eur J Gastroenterol Hepatol** 1997 May;9(5):442–6 (56 ref.)
Neuromodulation by Mg2+ and polyamines of excitatory amino acid currents in rodent neurones in culture. Kumamoto E. **Magnes Res** 1996 Dec;9(4):317–27 (50 ref.)
The neurobiology of social play behavior in rats. Vanderschuren LJ, et al. **Neurosci Biobehav Rev** 1997 May; 21(3):309–26 (276 ref.)
Behavioral effects of dietary neurotransmitter precursors: basic and clinical aspects. Young SN. **Neurosci Biobehav Rev** 1996 Summer;20(2):313–23 (142 ref.)
Insect neurotransmission: neurotransmitters and their receptors. Osborne RH. **Pharmacol Ther** 1996;69(2):117–42 (429 ref.)
Drugs coordinating and restoring gastrointestinal motility and their effect on selected hypodynamic gastrointestinal disorders in horses and cattle. Steiner A, et al. **Zentralbl Veterinarmed A** 1995 Dec;42(10):613–31 (126 ref.)

PHYSIOLOGY

Carotid chemoreflex. Neural pathways and transmitters. Sapru HN. **Adv Exp Med Biol** 1996;410:357–64 (22 ref.)
Interactions of neurotransmitters and endothelial cells in determining vascular tone. Shepherd JT. **Adv Exp Med Biol** 1995;381:1–13 (94 ref.)
Ethanol as a neurochemical surrogate of conventional reinforcers: the dopamine–opioid link. Di Chiara G, et al. **Alcohol** 1996 Jan–Feb;13(1):13–7 (58 ref.)
Neurobehavioural basis for the pharmacotherapy of alcoholism: current and future directions. Anton RF. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:43–53 (70 ref.)
The role of neurotransmitters in alcohol dependence: animal research. De Witte P. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:13–6 (33 ref.)
Review of neurotransmitters and their role in alcoholism treatment. Erickson CK. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:5–11 (35 ref.)
Alcohol reinforcement and neuropharmacological therapeutics. Lewis MJ. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:17–25 (36 ref.)
Brain sexual dimorphism and sex differences in parental and other social behaviors. De Vries GJ, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:273–86 (89 ref.)
Region-specific regulation of neurogenesis by VIP and PACAP: direct and indirect modes of action. DiCicco-Bloom E. **Ann N Y Acad Sci** 1996 Dec 26; 805:244–56; discussion 256–8 (30 ref.)
Role of PACAP in the regulation of gastrointestinal motility. Katsoulis S, et al. **Ann N Y Acad Sci** 1996 Dec 26; 805:364–78 (35 ref.)
Neurotransmitter release. Matthews G. **Annu Rev Neurosci** 1996;19:219–33 (71 ref.)
Behavioral consequences of abnormal cortical development: insights into developmental disabilities. Berger-Sweeney J, et al. **Behav Brain Res** 1997 Jul;86(2):121–42 (244 ref.)
Psychopharmacology of memory modulation: evidence for multiple interaction among neurotransmitters and hormones. Castellano C, et al. **Behav Brain Res** 1996 May; 77(1–2):1–21 (175 ref.)
Interactions of descending serotonergic systems with other neurotransmitters in the modulation of nociception. Sawynok J, et al. **Behav Brain Res** 1996;73(1–2):63–8 (42 ref.)
Neurobiology. Wilding J, et al. **Br Med Bull** 1997; 53(2):286–306 (77 ref.)
Biogenic amines and aggression: experimental approaches in crustaceans. Huber R, et al. **Brain Behav Evol** 1997;50 Suppl 1:60–8 (45 ref.)
Interleukin-2 as a neuroregulatory cytokine. Hanisch UK, et al. **Brain Res Brain Res Rev** 1995 Nov;21(3):246–84 (469 ref.)
Retrograde messengers, long-term potentiation and memory. Medina JH, et al. **Brain Res Brain Res Rev** 1995 Sep; 21(2):185–94 (113 ref.)
From oocyte to neuron: do neurotransmitters function in the same way throughout development? Buznikov GA, et al. **Cell Mol Neurobiol** 1996 Oct;16(5):537–59 (150 ref.)
Neuromodulation of transduction and signal processing in the end organs of taste. Nagai T, et al. **Chem Senses** 1996 Jun;21(3):353–65 (106 ref.)
The study of neurotransmitter interactions using positron emission tomography and functional coupling. Schloesser R, et al. **Clin Neuropharmacol** 1996 Oct;19(5):371–89 (120 ref.)
The role of mesoprefrontal dopamine neurons in stress. Horger BA, et al. **Crit Rev Neurobiol** 1996;10(3–4):395–418 (232 ref.)
Calcium regulation of neurotransmitter release: reliably unreliable? Goda Y, et al. **Curr Opin Cell Biol** 1997 Aug; 9(4):513–8 (40 ref.)
Peptidergic neurohormonal control systems in invertebrates. Nässel DR. **Curr Opin Neurobiol** 1996 Dec;6(6):842–50 (69 ref.)
Regulation of excitatory and inhibitory neurotransmitter-gated ion channels by protein phosphorylation. Smart TG. **Curr Opin Neurobiol** 1997 Jun; 7(3):358–67 (72 ref.)
Influence of common drugs and related factors on stroke outcome. Goldstein LB. **Curr Opin Neurol** 1997 Feb; 10(1):52–7 (79 ref.)
Molecular and cellular mechanisms of antidepressant drugs. Owens MJ. **Depress Anxiety** 1996–97;4(4):153–9 (35 ref.)
Nuclear magnetic resonance spectroscopy: new insights into the pathophysiology of mood disorders. Soares JC, et al. **Depression** 1996;4(1):14–30 (165 ref.)
Neurocircuitries and neurotransmitter interactions in schizophrenia. Carlsson A. **Int Clin Psychopharmacol** 1995 Sep;10 Suppl 3:21–8 (42 ref.)
Neurotransmitters in the vertebrate retina. Lam DM. **Invest Ophthalmol Vis Sci** 1997 Mar;38(3):553–6 (20 ref.)
Pathogenesis of Tourette's syndrome. Leckman JF, et al. **J Child Psychol Psychiatry** 1997 Jan;38(1):119–42 (225 ref.)
Physiology of the circadian system in animals and humans. Murphy PJ, et al. **J Clin Neurophysiol** 1996 Jan;13(1):2–16 (110 ref.)
Biological basis of generalized anxiety disorder. Brawman-Mintzer O, et al. **J Clin Psychiatry** 1997;58 Suppl 3:16–25; discussion 26 (78 ref.)
Homeostasis of energy conduction, neurotransmitters, cytotoxic compounds and metal ions. Nelson N. **J Exp Biol** 1997 Jan;200 (Pt 2):331–3 (21 ref.)
Platelet-activating factor in the modulation of excitatory amino acid neurotransmitter release and of gene expression. Bazan NG, et al. **J Lipid Mediat Cell Signal** 1996 Sep; 14(1–3):321–30 (49 ref.)
Retrograde messengers and long-term potentiation: a progress report. Williams JH. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):331–9 (55 ref.)
Transmitter modulation of neuronal calcium channels. Jones SW, et al. **J Membr Biol** 1997 Jan 1;155(1):1–10 (97 ref.)
Familial and developmental abnormalities of front lobe function and neurochemistry in schizophrenia. Deakin FW,

et al. **J Psychopharmacol (Oxf)** 1997;11(2):133–42 (110 ref.)
Ocular outflow facility with emphasis on neuronal regulation of intraocular smooth muscles. Suzuki R.
J Smooth Muscle Res 1996 Dec;32(6):229–47 (82 ref.)
Localization, regulation and functions of neurotransmitters and neuromodulators in cervical sympathetic ganglia. Klimaschewski L, et al. **Microsc Res Tech** 1996 Sep 1; 35(1):44–68 (400 ref.)
Regulation of gap junction coupling in the developing neocortex. Rörig B, et al. **Mol Neurobiol** 1996 Jun; 12(3):225–49 (162 ref.)
From acetylcholine to amyloid: neurotransmitters and the pathology of Alzheimer's disease. Nitsch RM.
Neurodegeneration 1996 Dec;5(4):477–82 (44 ref.)
Gaseous transmitters and neuroendocrine regulation. Brann DW, et al. **Neuroendocrinology** 1997 Jun;65(6):385–95 (88 ref.)
Pre- and postfusion regulation of transmitter release. Rahamimoff R, et al. **Neuron** 1997 Jan;18(1):17–27 (128 ref.)
The motornervous system of Ascaris: electrophysiology and anatomy of the neurons and their control by neuromodulators. Davis RE, et al. **Parasitology** 1996;113 Suppl:S97–117 (114 ref.)
FMRFamide-related peptides (FaRPs) in nematodes: occurrence and neuromuscular physiology. Maule AG, et al. **Parasitology** 1996;113 Suppl:S119–35 (71 ref.)
Calcium and Free Radicals: Mediators of neurotrophic factor and excitatory transmitter-regulated developmental plasticity and cell death. Mattson MP.
Perspect Dev Neurobiol 1996;3(2):79–91 (101 ref.)
Actions of neurotransmitters and other messengers on Ca2+ channels and K+ channels in smooth muscle cells. Beech DJ. **Pharmacol Ther** 1997;73(2):91–119 (353 ref.)
The neurobiology of schizophrenia. Littrell RA, et al.
Pharmacotherapy 1996 Nov–Dec;16(6 Pt 2):143S–147S; discussion 166S–168S (19 ref.)
The ventro-medial medullary projections to spinal motoneurons: ultrastructure, transmitters and functional aspects. Holstege JC. **Prog Brain Res** 1996;107:159–81 (167 ref.)
Neurobiology of spinal nociception: new concepts. Sandkühler J. **Prog Brain Res** 1996;110:207–24 (50 ref.)
Cooperative mechanisms of neurotransmitter action in central nervous sensitization. Willis WD, et al. **Prog Brain Res** 1996;110:151–66 (72 ref.)
Non-adrenergic non-cholinergic (NANC) transmission to smooth muscle: 35 years on. Bennett MR.
Prog Neurobiol 1997 Jun;52(3):159–95 (261 ref.)
Multiple regulators of ultrasonic vocalization in the infant rat [published erratum appears in Psychoneuroendocrinology 1996 Jul;21(5):501] Hofer MA.
Psychoneuroendocrinology 1996 Feb;21(2):203–17 (72 ref.)
Evidence that abnormalities of central neurohormonal systems are key to understanding fibromyalgia and chronic fatigue syndrome. Crofford LJ, et al.
Rheum Dis Clin North Am 1996 May;22(2):267–84 (86 ref.)
Nitric oxide, a neuronal messenger. Its role in the hippocampus neuronal plasticity. Salemme E, et al.
Riv Biol 1996;89(1):87–107 (37 ref.) **(Eng, Ita)**
New evidence for neurotransmitter influences on brain development. Levitt P, et al. **Trends Neurosci** 1997 Jun; 20(6):269–74 (86 ref.)
Neurotransmission and the contraction and relaxation of penile erectile tissues. Andersson KE, et al.
World J Urol 1997;15(1):14–20 (72 ref.)
[From inducers of panic attack to neurobiology of panic disorder] Bourin M. **Encephale** 1996 Dec;22 Spec No 5:35–41 (57 ref.) (Eng. Abstr.) **(Fre)**
[Hypertrophy due to left cardiac insufficiency: role of the neurohumoral system] Lerch R, et al.
Schweiz Rundsch Med Prax 1997 Feb 11;86(7):238–41 (32 ref.) (Eng. Abstr.) **(Fre)**
[Neurosteroids--basic principles, anxiolysis and clinical applications] Hartmann A, et al.
Fortschr Neurol Psychiatr 1996 Nov;64(11):444–51 (98 ref.) (Eng. Abstr.) **(Ger)**
[Reflections on the psychobiology of depression] Aldenhoff J. **Nervenarzt** 1997 May;68(5):379–89 (93 ref.) (Eng. Abstr.) **(Ger)**
[Event related brain potentials as indicators of neurochemical dysfunctions in psychiatric patients] Hegerl U, et al.
Nervenarzt 1996 May;67(5):360–8 (67 ref.) (Eng. Abstr.) **(Ger)**
[Neurohumoral regulation in heart failure] Riegger GA, et al. **Z Kardiol** 1996;85 Suppl 6:205–10 (20 ref.) (Eng. Abstr.) **(Ger)**
[Neurotransmitters and ontogenesis of the central nervous system in the human] Retz W, et al.
Z Kinder Jugenpsychiatr 1996 Mar;24(1):34–43 (60 ref.) **(Ger)**
[Neural pathways--neural networks] Palkovits M.
Orv Hetil 1996 Jun 9;137(23):1235–43 (49 ref.) (Eng. Abstr.) **(Hun)**
[Neurotransmission in human brains measured by positron emission tomography (PET)] Yanai K.
Nippon Yakurigaku Zasshi 1997 Jun;109(6):259–70 (33 ref.) (Eng. Abstr.) **(Jpn)**
[The role of the novel hypothalamic peptide PACAP in regulating endocrine functions] Grinevich VV.
Usp Fiziol Nauk 1997 Jan–Mar;28(1):47–52 (35 ref.) (Eng. Abstr.) **(Rus)**
[The integration of neuromediators and hormones in the digestive system] Ovsiannikov VI.
Vestn Ross Akad Med Nauk 1996;(1):33–6 (27 ref.) (Eng. Abstr.) **(Rus)**

SECRETION

Mammalian Unc-13 homologues as possible regulators of neurotransmitter release. Betz A, et al.
Biochem Soc Trans 1996 Aug;24(3):661–6 (18 ref.)
Regulation of the synaptic vesicle cycle in Drosophila. Broadie KS. **Biochem Soc Trans** 1996 Aug;24(3):639–45 (48 ref.)
Role of Rab3a in neurotransmitter and hormone release: a discussion of recent data. Henry JP, et al.
Biochem Soc Trans 1996 Aug;24(3):657–61 (20 ref.)
In vivo monitoring of brain neurotransmitter release for the assessment of neuroendocrine interactions. Mas M, et al.
Cell Mol Neurobiol 1996 Jun;16(3):383–96 (51 ref.)
Ca2+ and the regulation of neurotransmitter secretion. Bennett MK. **Curr Opin Neurobiol** 1997 Jun;7(3):316–22 (69 ref.)
Exocytosis in excitable cells: a conserved molecular machinery from yeast to neuron. Lledo PM.
Eur J Endocrinol 1997 Jul;137(1):1–9 (55 ref.)
[Mechanism of bioactive substance release and the response to various drugs] Izumi F, et al.
Nippon Yakurigaku Zasshi 1996 Sep;108(3):181–2 (0 ref.) **(Jpn)**

THERAPEUTIC USE

Drugs for the treatment of impotence. Garcia-Reboll L, et al. **Drugs Aging** 1997 Aug;11(2):140–51 (98 ref.)

TOXICITY

Excitotoxicity and neurodegeneration in amyotrophic lateral sclerosis. Rothstein JD. **Clin Neurosci** 1995–96;3(6):348–59 (79 ref.)

NEUROTRANSMITTERS, AMINO ACID see **AMINO ACID NEUROTRANSMITTERS**

NEUROTRANSMITTERS, BIOGENIC AMINE see **BIOGENIC AMINE NEUROTRANSMITTERS**

NEUTRALIZATION TESTS

Antibody neutralization of HIV-1. Poignard P, et al.
Immunol Today 1996 May;17(5):239–46 (78 ref.)

METHODS

Neutralization of HIV-1 by antibody. Sattentau QJ.
Curr Opin Immunol 1996 Aug;8(4):540–5 (51 ref.)

NEUTRONS

Neutrons in biology. A perspective. Knott RB, et al.
Basic Life Sci 1996;64:1–15 (117 ref.)
[Proton and neutron radiation in cancer treatment: clinical and economic outcomes] Fleurette F, et al.
Bull Cancer Radiother 1996;83 Suppl:223s–7s (29 ref.)
Neutrons and carcinogenesis: a cautionary tale. Hall EJ.
Bull Cancer Radiother 1996;83 Suppl:43s–6s (28 ref.)

NEUTROPENIA

Timing of treatment for nonneutropenic patients colonized with Candida. Solomkin JS. **Am J Surg** 1996 Dec; 172(6A):44S–48S (62 ref.)
Non-malignant neutropenia. Sievers EL, et al. **Blood Rev** 1996 Jun;10(2):95–100 (42 ref.)
Prevention of infection in neutropenic cancer patients. Klastersky J. **Curr Opin Oncol** 1996 Jul;8(4):270–8 (37 ref.)
Antifungal prophylaxis with itraconazole in neutropenic patients: pharmacological, microbiological and clinical aspects. Glasmacher A, et al. **Mycoses** 1996 Jul–Aug; 39(7–8):249–58 (117 ref.)
[Disorders of neutrophil function] Komiyama A.
Rinsho Ketsueki 1996 Jun;37(6):497–501 (14 ref.) **(Jpn)**

BLOOD

Pathophysiology of Kostmann syndrome: the G-CSF receptor issue. Donadieu J. **Hematol Cell Ther** 1997 Apr; 39(2):102–4 (16 ref.)
[Neutropenia in HIV infection] Moreno García M.
An Med Interna 1997 Apr;14(4):199–208 (188 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. Gonzalez CE, et al. **Clin Infect Dis** 1997 Feb;24(2):192–6 (37 ref.)
Antifungal prophylaxis during neutropenia and immunodeficiency. Lortholary O, et al.
Clin Microbiol Rev 1997 Jul;10(3):477–504 (390 ref.)
Fever in the neutropenic host. Chanock SJ, et al.
Infect Dis Clin North Am 1996 Dec;10(4):777–96 (115 ref.)
Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Walsh TJ, et al. **Infect Dis Clin North Am** 1996 Jun;10(2):365–400 (179 ref.)
Host immunologic augmentation for the control of infection. Wingard JR, et al. **Infect Dis Clin North Am** 1996 Jun; 10(2):345–64 (111 ref.)
A case presentation and review of neutropenic enterocolitis. Kulaylat M, et al. **J Med** 1997;28(1–2):1–19 (63 ref.)
Clostridium septicum infection in children with cyclic neutropenia. Bar-Joseph G, et al. **J Pediatr** 1997 Aug; 131(2):317–9 (14 ref.)
Infections in neutropenic patients I: aetiology. Engervall P, et al. **Med Oncol** 1995 Dec;12(4):251–6 (65 ref.)
Infections in neutropenic patients. II: Management. Engervall P, et al. **Med Oncol** 1996 Mar;13(1):63–9 (74 ref.)
Clinical and laboratory diagnosis of invasive candida infection in neutropenic patients. Kalin M, et al.
Med Oncol 1996 Dec;13(4):223–31 (85 ref.)
Histiocytic necrotizing lymphadenitis, Kikuchi-Fujimoto's disease, associated with systemic lupus erythemotosus. Martínez-Vázquez C, et al. **QJM** 1997 Aug;90(8):531–3 (19 ref.)
Infectious complications of patients undergoing therapy for acute leukemia: current status and future prospects. Chanock SJ, et al. **Semin Oncol** 1997 Feb;24(1):132–40 (65 ref.)
[From epidemiology to therapeutic choices. Infections in patients with neutropenia] Cordonnier C, et al.
Presse Med 1997 Jan 18–25;26(1):45–50 (26 ref.) (Eng. Abstr.) **(Fre)**
[Empirical antimicrobial therapy in neutropenic patients] Maschmeyer G. **Ther Umsch** 1996 Nov;53(11):854–62 (36 ref.) (Eng. Abstr.) **(Ger)**
[The prevention and treatment of fungal infections in the neutropenic patient] Vázquez López ML. **Rev Clin Esp** 1997 Apr;197 Suppl 1:29–34 (26 ref.) **(Spa)**

CONGENITAL

Severe congenital neutropenia terminating in acute myeloid leukemia: disease progression associated with mutations in the granulocyte-colony stimulating factor receptor gene. Touw IP, et al. **Leuk Res** 1996 Aug;20(8):629–31 (20 ref.)

DRUG THERAPY

Administration of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation in children with acute myelogenous leukemia: a note of caution. Calderwood S, et al. **Bone Marrow Transplant** 1996 Jul; 18(1):87–91 (23 ref.)
Empirical treatment of febrile neutropenia: evolution of current therapeutic approaches. Hathorn JW, et al.
Clin Infect Dis 1997 Feb;24 Suppl 2:S256–65 (72 ref.)
Safety of long-term administration of granulocyte colony-stimulating factor for severe chronic neutropenia. Freedman MH. **Curr Opin Hematol** 1997 May;4(3):217–24 (44 ref.)
Use of colony-stimulating factors in the treatment of neutropenia associated with collagen vascular disease. Starkebaum G. **Curr Opin Hematol** 1997 May;4(3):196–9 (46 ref.)
Antibiotic treatment of febrile episodes in neutropenic cancer patients. Clinical and economic considerations. de Lalla F. **Drugs** 1997 May;53(5):789–804 (103 ref.)
Cefpirome. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia. Wiseman LR, et al. **Drugs** 1997 Jul; 54(1):117–40 (134 ref.)
Clinical use of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in neutropenia associated with malignancy. Lifton R, et al.
Hematol Oncol Clin North Am 1996 Aug;10(4):825–39 (49 ref.)
Early empiric antibiotic therapy for febrile neutropenia patients at low risk. Rolston KV, et al.
Infect Dis Clin North Am 1996 Jun;10(2):223–37 (29 ref.)
Empiric antibiotic monotherapy with carbapenems in febrile neutropenia: a review. Cometta A, et al. **J Chemother** 1996 Oct;8(5):375–81 (27 ref.)
Functional features of neutrophils induced by G-CSF and GM-CSF treatment: differential effects and clinical implications. Spiekermann K, et al. **Leukemia** 1997 Apr; 11(4):466–78 (182 ref.)
Empirical treatment of fever in neutropenic children: the role of the carbapenems. International Antimicrobial Therapy Cooperative Group of the European Organisation for Research and Treatment of Cancer and the Gimema Infection Program. Cometta A, et al.
Pediatr Infect Dis J 1996 Aug;15(8):744–8 (37 ref.)
Outpatient antibiotic treatment in low-risk febrile neutropenic cancer patients. Escalante CP, et al.
Support Care Cancer 1996 Sep;4(5):358–63 (18 ref.)
[Antimicrobial therapy in neutropenia] Maschmeyer G, et al. **Dtsch Med Wochenschr** 1997 Jul 4;122(27):864–9 (24 ref.) **(Ger)**
[Preventive antimycotic therapy of neutropenic and immunosuppressed patients] Ruhnke M, et al. **Med Klin** 1997 Jan 15;92(1):28–36 (76 ref.) (Eng. Abstr.) **(Ger)**
[Prevention and treatment of febrile neutropenia] Montemurro F, et al. **Tumori** 1997;83(2 Suppl):S15–9 (30 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Radiotherapy-associated neutropenia and thrombocytopenia: analysis of risk factors and development of a predictive model. Mac Manus M, et al. **Blood** 1997 Apr 1; 89(7):2303–10 (36 ref.)

Neutropenic colitis: a continuing surgical challenge. Williams N, et al. **Br J Surg** 1997 Sep;84(9):1200–5 (88 ref.)

Outpatient antibiotic therapy for febrile episodes in low-risk neutropenic patients with cancer. Escalante CP, et al. **Cancer Invest** 1997;15(3):237–42 (25 ref.)

Fever in the neutropenic host. Chanock SJ, et al. **Infect Dis Clin North Am** 1996 Dec;10(4):777–96 (115 ref.)

Immune deficiency in glycogen storage disease type 1B. Garty BZ, et al. **Isr J Med Sci** 1996 Dec;32(12):1276–81 (40 ref.)

Cutaneous mucormycosis with subsequent visceral dissemination in a child with neutropenia: a case report and review of the pediatric literature. Wirth F, et al. **J Am Acad Dermatol** 1997 Feb;36(2 Pt 2):336–41 (58 ref.)

Outpatient antibiotic treatment in low-risk febrile neutropenic cancer patients. Escalante CP, et al. **Support Care Cancer** 1996 Sep;4(5):358–63 (18 ref.)

GENETICS

Severe congenital neutropenia terminating in acute myeloid leukemia: disease progression associated with mutations in the granulocyte-colony stimulating factor receptor gene. Touw IP, et al. **Leuk Res** 1996 Aug;20(8):629–31 (20 ref.)

IMMUNOLOGY

Controversies in the antibacterial treatment of patients with neutropenia: a matter of comprehension or apprehension? De Pauw BE, et al. **Cancer Invest** 1997;15(1):37–46 (52 ref.)

MICROBIOLOGY

Empirical treatment of febrile neutropenia: evolution of current therapeutic approaches. Hathorn JW, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S256–65 (72 ref.)

PHYSIOPATHOLOGY

[Antifungal prophylaxis in neutropenic cancer patients and in allogeneic bone marrow transplantation] Blau IW, et al. **Mycoses** 1996;39 Suppl 1:81–6 (52 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Schiffer CA. **Blood** 1996 Nov 15;88(10):3675–85 (69 ref.)

THERAPY

Treatment of the neutropenia of Felty syndrome. Rashba EJ, et al. **Blood Rev** 1996 Sep;10(3):177–84 (57 ref.)

Clinical needs for hematopoietic growth factors: old and new. Rusthoven JJ. **Cancer Invest** 1996;14(6):622–34 (163 ref.)

Granulocyte transfusions. Time for a second look. Chanock SJ, et al. **Infect Dis Clin North Am** 1996 Jun;10(2):327–43 (66 ref.)

Biology and therapeutic uses of myeloid hematopoietic growth factors and interferons [see comments] Lau AS, et al. **Pediatr Infect Dis J** 1996 Jul;15(7):563–75 (96 ref.) Comment in: Pediatr Infect Dis J 1997 Feb;16(2):260.

[Azole antifungal agents in the prevention of fungal infections in neutropenic patients and bone marrow graft recipients] Lortholary O, et al. **Ann Med Interne (Paris)** 1997; 148(3):258–67 (106 ref.) (Eng. Abstr.) **(Fre)**

[Integration of G-CSF in prevention and therapy of neutropenic fever] Siegmund R, et al. **Med Klin** 1996 Feb 15;91(2):82–8 (77 ref.) **(Ger)**

[Clinical application of neutrophil hematopoietic factors] Sakurada K. **Nippon Naika Gakkai Zasshi** 1996 Jun 10; 85(6):844–9 (5 ref.) **(Jpn)**

[Chronic neutropenia] Palmblad J, et al. **Nord Med** 1996 Nov; 111(9):304–7 (11 ref.) (Eng. Abstr.) **(Swe)**

NEUTROPHIL-ACTIVATING PEPTIDE, LYMPHOCYTE-DERIVED see **INTERLEUKIN-8**

NEUTROPHIL-ACTIVATING PEPTIDE, MONOCYTE-DERIVED see **INTERLEUKIN-8**

NEUTROPHIL-ACTIVATING PEPTIDES, FIBROBLAST-DERIVED see **INTERLEUKIN-8**

NEUTROPHIL ACTIVATION

Complement in IgA immune-complex-induced neutrophil activation. Zhang W, et al. **Biochem Soc Trans** 1997 May; 25(2):462–6 (28 ref.)

Biosynthesis, processing and sorting of neutrophil proteins: insight into neutrophil granule development. Gullberg U, et al. **Eur J Haematol** 1997 Mar;58(3):137–53 (134 ref.)

New molecular aspects of chronic uraemia and dialysis-related immunocompetent cell activation. Descamps-Latscha B, et al. **Nephrol Dial Transplant** 1996; 11 Suppl 2:121–4 (23 ref.)

[Activation induces dephosphorylation of cofilin (an actin/PIP2-binding protein) and its translocation to plasma membranes in leukocytes] Suzuki K. **Seikagaku** 1997 Apr; 69(4):254–9 (16 ref.) **(Jpn)**

[Activation of neutrophil by cytokines] Yamagoe S, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1086–91 (13 ref.) **(Jpn)**

DRUG EFFECTS

Lipopolysaccharide binding protein participation in cellular activation by LPS. Su GL, et al. **Crit Rev Immunol** 1995; 15(3-4):201–14 (97 ref.)

IMMUNOLOGY

Leukocyte migration and activation in the lungs [editorial; comment] Martin TR. **Eur Respir J** 1997 Apr;10(4):770–1 (15 ref.) Comment on: Eur Respir J 1997 Apr;10(4):795–803.

Intracellular signaling in neutrophil priming and activation. Downey GP, et al. **Semin Cell Biol** 1995 Dec;6(6):345–56 (61 ref.)

[Neutrophil activation by bacterial endotoxins] Klink M, et al. **Postepy Hig Med Dosw** 1996;50(4):333–50 (80 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Leukocyte-endothelial cell interactions evoked by mast cells. Kubes P, et al. **Cardiovasc Res** 1996 Oct;32(4):699–708 (85 ref.)

Molecular mechanisms of leukocyte recruitment in the inflammatory process. Ley K. **Cardiovasc Res** 1996 Oct; 32(4):733–42 (129 ref.)

Mechanisms and consequences of cell activation in the microcirculation. Mazzoni MC, et al. **Cardiovasc Res** 1996 Oct;32(4):709–19 (95 ref.)

The microcirculation in venous hypertension. Smith PD. **Cardiovasc Res** 1996 Oct;32(4):789–95 (59 ref.)

Neutrophil activation by adhesion: mechanisms and pathophysiological implications. Berton G, et al. **Int J Clin Lab Res** 1996;26(3):160–77 (248 ref.)

Initiation of white cell activation during cardiopulmonary bypass: cytokines and receptors. Cameron D. **J Cardiovasc Pharmacol** 1996;27 Suppl 1:S1–5 (12 ref.)

Amplification of the inflammatory response: adhesion molecules associated with platelet/white cell responses. Rinder C, et al. **J Cardiovasc Pharmacol** 1996;27 Suppl 1:S6–12 (41 ref.)

Molecular factors associated with compartmentalization of gingival immune responses and transepithelial neutrophil migration. Tonetti MS. **J Periodontal Res** 1997 Jan;32(1 Pt 2):104–9 (35 ref.)

NEUTROPHIL-DERIVED RELAXANT FACTOR see **ENDOTHELIUM-DERIVED RELAXING FACTOR**

NEUTROPHILIC DERMATOSIS, ACUTE FEBRILE see **SWEET'S SYNDROME**

NEUTROPHILIC ECCRINE HIDRADENITIS see **HIDRADENITIS**

NEUTROPHILIC LEUKEMIA, CHRONIC see **LEUKEMIA, NEUTROPHILIC, CHRONIC**

NEUTROPHILS

The role of the epithelial cell in Escherichia coli induced neutrophil migration into the urinary tract. Agace WW. **Eur Respir J** 1996 Aug;9(8):1713–28 (161 ref.)

[Rheumatoid neutrophilic dermatitis--a rare dermatosis in patients with active rheumatoid arthritis] Mrowietz U, et al. **Hautarzt** 1996 Dec;47(12):921–6 (8 ref.) (Eng. Abstr.) **(Ger)**

[Disorders of neutrophil function] Komiyama A. **Rinsho Ketsueki** 1996 Jun;37(6):497–501 (14 ref.) **(Jpn)**

[Persistent neutrophilic meningitis in a patient with the acquired immunodeficiency syndrome] Marinho SF, et al. **Rev Soc Bras Med Trop** 1997 May-Jun;30(3):241–5 (22 ref.) (Eng. Abstr.) **(Por)**

CHEMISTRY

Granules of the human neutrophilic polymorphonuclear leukocyte. Borregaard N, et al. **Blood** 1997 May 15; 89(10):3503–21 (337 ref.)

CYTOLOGY

Neutrophil transmigration across monolayers of endothelial cells and airway epithelial cells is regulated by different mechanisms. Liu L, et al. **Ann N Y Acad Sci** 1996 Oct 31;796:21–9 (43 ref.)

Platelet-polymorphonuclear leukocyte functional interactions: role of adhesive molecules. Cerletti C, et al. **Haemostasis** 1996 Oct;26 Suppl 4:20–7 (44 ref.)

DRUG EFFECTS

Hypothesis: iron chelation plays a vital role in neutrophilic inflammation. Ghio AJ, et al. **Biometals** 1997 Apr; 10(2):135–42 (88 ref.)

Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals. Anderlini P, et al. **Blood** 1996 Oct 15;88(8):2819–25 (76 ref.)

Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on the bactericidal functions of neutrophils. Pitrak DL. **Curr Opin Hematol** 1997 May;4(3):183–90 (76 ref.)

Pharmacology and pharmacokinetics of LEX 032, a bioengineered serpin: the first of a potential new class of drugs. Sands H, et al. **Drug Metab Rev** 1997 Feb-May; 29(1-2):309–28 (68 ref.)

Purines and neutrophil leukocytes. Fredholm BB. **Gen Pharmacol** 1997 Mar;28(3):345–50 (100 ref.)

Postantibiotic effect and host-bacteria interactions. Shibl AM, et al. **J Antimicrob Chemother** 1995 Dec;36(6):885–7 (23 ref.)

Functional features of neutrophils induced by G-CSF and GM-CSF treatment: differential effects and clinical implications. Spiekermann K, et al. **Leukemia** 1997 Apr; 11(4):466–78 (182 ref.)

[Modulation of the oxidative burst of human neutrophils by pro- and anti-inflammatory cytokines] Gougerot-Podicalo MA, et al. **Pathol Biol (Paris)** 1996 Jan;44(1):36–41 (14 ref.) (Eng. Abstr.) **(Fre)**

[The influence of lead on neutrophils] Hrycek A, et al. **Wiad Lek** 1996;49(7-12):103–6 (13 ref.) (Eng. Abstr.) **(Pol)**

[The effect of heavy metals on neutrophils] Hrycek A, et al. **Wiad Lek** 1996;49(7-12):107–11 (23 ref.) (Eng. Abstr.) **(Pol)**

ENZYMOLOGY

Arginine-specific mono(ADP-ribosyl)transferase activity in human neutrophil polymorphs. A possible link with the assembly of filamentous actin and chemotaxis. Kefalas P, et al. **Adv Exp Med Biol** 1997;419:241–4 (6 ref.)

Activation of 85 kDa PLA2 by eicosanoids in human neutrophils and eosinophils. Wykle RL, et al. **Adv Exp Med Biol** 1996;416:327–31 (16 ref.)

Small GTPase-regulated phospholipase D in granulocytes. Houle MG, et al. **Biochem Cell Biol** 1996;74(4):459–67 (96 ref.)

Activation of the phagocyte NADPH oxidase. Takeshige K, et al. **J Toxicol Sci** 1996 Dec;21(5):291–2 (0 ref.)

Neutrophil proteinases and matrix degradation. The cell biology of pericellular proteolysis. Owen CA, et al. **Semin Cell Biol** 1995 Dec;6(6):367–76 (75 ref.)

[Structure and expression of the human neutrophil elastase gene--regulatory mechanism and its relevance to the respiratory diseases] Yoshimura K, et al. **Nippon Rinsho** 1996 Feb;54(2):396–404 (24 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Neutrophils and allergy. Monteseirín J, et al. **Allergol Immunopathol (Madr)** 1996 Sep-Oct;24(5):193–200 (89 ref.)

Inter-relationship among macrophages, natural killer cells and neutrophils in early stages of Listeria resistance. Unanue ER. **Curr Opin Immunol** 1997 Feb;9(1):35–43 (114 ref.)

Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis. Edwards SW, et al. **Immunol Today** 1997 Jul;18(7):320–4 (46 ref.)

Hyperreactivity of neutrophils and abnormal T cell homeostasis: a new insight for pathogenesis of Behçet's disease. Yamashita N. **Int Rev Immunol** 1997;14(1):11–9 (33 ref.)

Mechanisms of neutrophil-induced parenchymal cell injury. Jaeschke H, et al. **J Leukoc Biol** 1997 Jun;61(6):647–53 (93 ref.)

Lipoxins, leukocyte recruitment and the resolution phase of acute glomerulonephritis. O'Meara YM, et al. **Kidney Int Suppl** 1997 Mar;58:S56–61 (48 ref.)

Neutrophils and the adaptive immune response to Candida albicans. Romani L, et al. **Res Immunol** 1996 Oct-Dec; 147(8-9):512–8 (43 ref.)

Macrophages, NK cells and neutrophils in the cytokine loop of Listeria resistance. Unanue ER. **Res Immunol** 1996 Oct-Dec;147(8-9):499–505 (55 ref.)

Intracellular signaling in neutrophil priming and activation. Downey GP, et al. **Semin Cell Biol** 1995 Dec;6(6):345–56 (61 ref.)

Granulocyte adhesion molecules--structure/function relationships. Dransfield I. **Semin Cell Biol** 1995 Dec; 6(6):337–44 (49 ref.)

[The killing activity method in neutrophils] Kohsaka T, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:204–9 (14 ref.) **(Jpn)**

[Assay of phagocytic activity of neutrophils] Sasada M, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:200–3 (4 ref.) **(Jpn)**

[Assay for locomotion and chemotaxis of neutrophils] Shibata N, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:196–9 (8 ref.) **(Jpn)**

[Activation induces dephosphorylation of cofilin (an actin/PIP2-binding protein) and its translocation to plasma membranes in leukocytes] Suzuki K. **Seikagaku** 1997 Apr; 69(4):254–9 (16 ref.) **(Jpn)**

[Activation of neutrophil by cytokines] Yamagoe S, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1086–91 (13 ref.) **(Jpn)**

METABOLISM

Behçet's disease associated with myelodysplastic syndromes. A case report and a review of the literature. Ohno E, et al. **Cancer** 1997 Jan 15;79(2):262–8 (31 ref.)

NEUTROPHILS

Psoriatic arthritis and hypopyon-iridocyclitis. Possible mechanism of the association of psoriasis and anterior uveitis. Iijima S, et al. **Dermatology** 1996;193(4):295-9 (24 ref.)
Biosynthesis, processing and sorting of neutrophil proteins: insight into neutrophil granule development. Gullberg U, et al. **Eur J Haematol** 1997 Mar;58(3):137-53 (134 ref.)
The microanatomy of calcium stores in human neutrophils: relationship of structure to function. Pettit EJ, et al. **Histol Histopathol** 1997 Apr;12(2):479-90 (61 ref.)
Effects of fluid dynamic forces on vascular cell adhesion. Konstantopoulos K, et al. **J Clin Invest** 1996 Dec 15; 98(12):2661-5 (17 ref.)
Leukocyte responsiveness to substances that activate the respiratory burst is not altered in borderline and essential hypertension. Kopprasch S, et al. **J Hum Hypertens** 1996 Feb;10(2):69-76 (56 ref.)
Activation of the phagocyte NADPH oxidase. Takeshige K, et al. **J Toxicol Sci** 1996 Dec;21(5):291-2 (0 ref.)
Measurement of nitric oxide and hydrogen peroxide production from human neutrophils. Carreras MC, et al. **Methods Enzymol** 1996;269:65-75 (25 ref.)
[Measurement of reactive oxygen species generated from neutrophils] Yoshikawa T, et al. **Nippon Rinsho** 1997 Mar; 55 Suppl 1:210-5 (5 ref.) **(Jpn)**

PATHOLOGY

Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis. Edwards SW, et al. **Immunol Today** 1997 Jul;18(7):320-4 (46 ref.)
Neutrophils and myocardial reperfusion injury. Williams FM. **Pharmacol Ther** 1996;72(1):1-12 (123 ref.)

PHYSIOLOGY

Relationship between biocompatibility and neutrophil function in hemodialysis patients. Vanholder R. **Adv Ren Replace Ther** 1996 Oct;3(4):312-4 (19 ref.)
Biochemistry of inflammatory processes and vascular injury. Role of neutrophils: a review. Belova LA. **Biochemistry (Mosc)** 1997 Jun;62(6):563-70 (38 ref.)
Neutrophil- and glutathione-mediated hepatotoxicity of alpha-naphthylisothiocyanate. Roth RA, et al. **Drug Metab Rev** 1997 Feb-May;29(1-2):153-65 (44 ref.)
Pharmacology and pharmacokinetics of LEX 032, a bioengineered serpin: the first of a potential new class of drugs. Sands H, et al. **Drug Metab Rev** 1997 Feb-May; 29(1-2):309-28 (68 ref.)
Exercise, training, and neutrophil function. Smith JA, et al. **Exerc Immunol Rev** 1997;3:96-116 (97 ref.)
The role of the neutrophil in myocardial ischemia and reperfusion. Frangogiannis NG, et al. **EXS** 1996;76:263-84 (86 ref.)
The role of cyclic nucleotides in neutrophil migration. Elferink JGR, et al. **Gen Pharmacol** 1996 Mar;27(2):387-93 (66 ref.)
Applications of flow cytometry in the study of human neutrophil biology and pathology. Carulli G. **Hematopathol Mol Hematol** 1996;10(1-2):39-61 (87 ref.)
Regulation of neutrophil apoptosis--its biological significance in inflammation and the immune response. Sendo F, et al. **Hum Cell** 1996 Sep;9(3):215-22 (32 ref.)
Exercise immunology and neutrophils. Smith JA. **Int J Sports Med** 1997 Mar;18 Suppl 1:S46-55 (67 ref.)
In vivo, in vitro, and molecular aspects of interleukin-8 and the interleukin-8 receptors. Hoch RC, et al. **J Lab Clin Med** 1996 Aug;128(2):134-45 (97 ref.)
Leukocyte migration in immune complex glomerulonephritis: role of adhesion receptors. Lefkowith JB. **Kidney Int** 1997 May;51(5):1469-75 (54 ref.)
Clinical role of GM-CSF in neutrophil recovery in relation to health care parameters. Hofstra LS, et al. **Med Oncol** 1996 Sep;13(3):177-84 (66 ref.)
Are granulocyte inhibitory proteins contributing to enhanced susceptibility to infections in uraemia? Haag-Weber M, et al. **Nephrol Dial Transplant** 1996;11 Suppl 2:98-100 (20 ref.)
Neutrophil emigration in the lungs. Doerschuk CM, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:141-5 (21 ref.)
A massage for the journey: keeping leukocytes soft and silent [comment] von Andrian UH. **Proc Natl Acad Sci U S A** 1997 May 13;94(10):4825-7 (22 ref.) Comment on: Proc Natl Acad Sci U S A 1997 May 13;94(10):5338-43.
Mechanisms of inflammatory liver injury: adhesion molecules and cytotoxicity of neutrophils. Jaeschke H, et al. **Toxicol Appl Pharmacol** 1996 Aug;139(2):213-26 (98 ref.)
The neutrophil. Function, disorders, and testing. Stickle JE. **Vet Clin North Am Small Anim Pract** 1996 Sep; 26(5):1013-21 (25 ref.)
[Neutrophils and ischemia reperfusion injury] Xing X, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1996 Mar;12(2):138-40 (25 ref.) **(Chi)**
[Adherent reaction among activated platelets, polymorphonuclear cells and vascular endothelial cells under thrombin stimulation or shear stress] Kageoka T, et al. **Rinsho Byori** 1996 Aug;44(8):757-63 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Adhesion molecules and their role in pathogenesis of ARDS] Skiba-Choińska I, et al. **Przegl Lek** 1996;53(8):627-30 (34 ref.) (Eng. Abstr.) **(Pol)**
[The role of the polymorphonuclear neutrophil in the failure of multiple organs and systems] Fontes B, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1996 Jan-Feb;51(1):21-5 (47 ref.) (Eng. Abstr.) **(Por)**

ULTRASTRUCTURE

The microanatomy of calcium stores in human neutrophils: relationship of structure to function. Pettit EJ, et al. **Histol Histopathol** 1997 Apr;12(2):479-90 (61 ref.)

NEVOID BASAL CELL CARCINOMA SYNDROME see **BASAL CELL NEVUS SYNDROME**

NEVOXANTHOENDOTHELIOMA see **XANTHOGRANULOMA, JUVENILE**

NEVUS

COMPLICATIONS

Vitiligo coexistent with nevus depigmentosus. Kang IK, et al. **J Dermatol** 1996 Mar;23(3):187-90 (18 ref.)
Linear sebaceous nevus syndrome: report of a patient with unusual associated abnormalities. Palazzi P, et al. **Pediatr Dermatol** 1996 Jan-Feb;13(1):22-4 (16 ref.)

CONGENITAL

Hair follicle nevus: case report and review of the literature. Davis DA, et al. **Pediatr Dermatol** 1996 Mar-Apr; 13(2):135-8 (24 ref.)

GENETICS

The role of atypical mole syndrome and cutaneous naevi in the development of melanoma. Easton D. **Cancer Surv** 1996;26:237-49 (43 ref.)
Genetics of cutaneous melanoma and nevi. Greene MH. **Mayo Clin Proc** 1997 May;72(5):467-74 (75 ref.)

PATHOLOGY

Mucinous nevus [letter] Rongioletti F, et al. **Arch Dermatol** 1996 Dec;132(12):1522-3 (8 ref.)
Squamous cell carcinoma arising in a verrucous epidermal nevus. Ichikawa T, et al. **Dermatology** 1996;193(2):135-8 (18 ref.)
Porokeratotic eccrine ostial and dermal duct nevus of late onset: more frequent than previously suggested? Valks R, et al. **Dermatology** 1996;193(2):138-40 (17 ref.)
Linear and whorled nevoid hypermelanosis in a boy with mental retardation and congenital defects. Schepis C, et al. **Int J Dermatol** 1996 Sep;35(9):654-5 (10 ref.)
Mucinous nevus: report of two cases and review of the literature. Suhr KB, et al. **J Am Acad Dermatol** 1997 Aug; 37(2 Pt 2):312-3 (4 ref.)
A case of multiple nevoid hypertrichosis. Chang SN, et al. **J Dermatol** 1997 May;24(5):337-41 (10 ref.)
Vitiligo coexistent with nevus depigmentosus. Kang IK, et al. **J Dermatol** 1996 Mar;23(3):187-90 (18 ref.)
Linear sebaceous nevus syndrome: report of a patient with unusual associated abnormalities. Palazzi P, et al. **Pediatr Dermatol** 1996 Jan-Feb;13(1):22-4 (16 ref.)

NEVUS, BLUE

COMPLICATIONS

A case of Cobb syndrome associated with lymphangioma circumscriptum. Shim JH, et al. **Dermatology** 1996; 193(1):45-7 (11 ref.)

PATHOLOGY

Cutaneous metastasis of ocular malignant melanoma. An unusual presentation simulating blue nevi. Wieselthier JS, et al. **Am J Dermatopathol** 1996 Jun;18(3):289-95 (17 ref.)
A pigmented scalp nodule: malignant blue nevus. English JC 3rd, et al. **Cutis** 1996 Jul;58(1):40-2 (6 ref.)
Correlation between the histopathology and the epiluminescence microscopy features of malignant blue nevus. Stanganelli I, et al. **Dermatol Surg** 1996 Oct; 22(10):846-8 (13 ref.)
Cellular blue nevus of the scalp infiltrating the underlying bone: case report and review. Micali G, et al. **Pediatr Dermatol** 1997 May-Jun;14(3):199-203 (17 ref.)

SURGERY

Spinal meningeal melanocytoma: a case report and review of the literature. Sankhla SK, et al. **Br J Neurosurg** 1996 Apr;10(2):205-9 (28 ref.)
Endoscopic polypectomy under laparotomy throughout the alimentary tract for a patient with blue rubber bleb nevus syndrome. Shimada S, et al. **Gastrointest Endosc** 1997 May; 45(5):423-7 (25 ref.)

NEVUS, DYSPLASTIC see **DYSPLASTIC NEVUS SYNDROME**

NEVUS, EPITHELIOID AND SPINDLE CELL

DIAGNOSIS

Superficial spreading melanoma resembling Spitz nevus on the plantar surface [letter] Kato T, et al. **Dermatology** 1996; 193(4):353-4 (17 ref.)

PATHOLOGY

Agminate Spitz naevi occurring in an adult after the excision of a solitary Spitz naevus--report of a case and review of the literature. Sabroe RA, et al. **Clin Exp Dermatol** 1996 May;21(3):197-200 (16 ref.)
Juvenile melanoma (Spitz nevus). Helm KF, et al. **Cutis** 1996 Jul;58(1):35-9 (63 ref.)

NEVUS FLAMMEUS see **PORT-WINE STAIN**

NEVUS, HALO see **NEVUS, PIGMENTED**

NEVUS, MELANOCYTIC see **NEVUS, PIGMENTED**

NEVUS OF OTA

DIAGNOSIS

Dermal melanocytosis: a clinical spectrum. Stanford DG, et al. **Australas J Dermatol** 1996 Feb;37(1):19-25 (35 ref.)

PATHOLOGY

[Clinical contribution to oculo-dermal melanosis or Ota's syndrome] Morra M. **Minerva Oftalmol** 1967 Jul-Aug; 9(4):152-6 (28 ref.) (Eng. Abstr.) **(Ita)**

NEVUS, PIGMENTED

Becker nevus syndrome. Happle R, et al. **Am J Med Genet** 1997 Jan 31;68(3):357-61 (36 ref.)
[Acquired melanocytic nevi in children--a beauty spot or warning sign?] Azizi E, et al. **Harefuah** 1997 Mar 16; 132(6):416-20 (41 ref.) **(Heb)**

COMPLICATIONS

Glaucoma in phakomatosis pigmentovascularis. Teekhasaenee C, et al. **Ophthalmology** 1997 Jan; 104(1):150-7 (66 ref.)
Crouzon disease with acanthosis nigricans and melanocytic nevi. Gines E, et al. **Pediatr Dermatol** 1996 Jan-Feb; 13(1):18-21 (16 ref.)
Phakomatosis pigmentovascularis: report of a case. Mahroughan M, et al. **Pediatr Dermatol** 1996 Jan-Feb; 13(1):36-8 (8 ref.)

CONGENITAL

Giant congenital naevus of the scalp and cranium: case report and review of the literature. Madaree A, et al. **Br J Plast Surg** 1997 Jan;50(1):20-5 (8 ref.)
A study of large congenital melanocytic nevi and associated malignant melanomas: review of cases in the New York University Registry and the world literature. DeDavid M, et al. **J Am Acad Dermatol** 1997 Mar;36(3 Pt 1):409-16 (106 ref.)
Neurocutaneous melanosis: clinical features of large congenital melanocytic nevi in patients with manifest central nervous system melanosis. DeDavid M, et al. **J Am Acad Dermatol** 1996 Oct;35(4):529-38 (104 ref.)

DIAGNOSIS

Dermal melanocytosis: a clinical spectrum. Stanford DG, et al. **Australas J Dermatol** 1996 Feb;37(1):19-25 (35 ref.)
Pigmented lesions of the conjunctiva. Farber M, et al. **J Dermatol** 1996 Nov;23(11):746-50 (8 ref.)
Multiple nodular lesions seen in a patient with neurocutaneous melanosis. Sasaki Y, et al. **J Dermatol** 1996 Nov;23(11):828-31 (11 ref.)
Diagnosis of pigmented skin lesions aided by epiluminescence microscopy. Peck GL. **Md Med J** 1997 May-Jun; 46(5):247-50 (5 ref.)
[Neurocutaneous melanosis] Martínez-Granero MA, et al. **Rev Neurol** 1997 Sep;25 Suppl 3:S265-8 (35 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Eruptive melanocytic nevi after Stevens-Johnson syndrome. Shoji T, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):337-9 (14 ref.)

PATHOLOGY

Hypermelanotic nevus: clinical, histopathologic, and ultrastructural features in 316 cases. Cohen LM, et al. **Am J Dermatopathol** 1997 Feb;19(1):23-30 (9 ref.)
Hair follicle nevus: case report and review. Labandeira J, et al. **Am J Dermatopathol** 1996 Feb;18(1):90-3 (27 ref.)
Dermoscopy (epiluminescence microscopy) of pigmented skin lesions. Current status and evolving trends. Argenyi ZB. **Dermatol Clin** 1997 Jan;15(1):79-95 (43 ref.)
Torpedo maculopathy. Teitelbaum BA, et al. **J Am Optom Assoc** 1997 Jun;68(6):373-6 (12 ref.)

Lentiginous melanocytic hyperplasia overlying dermatofibroma. Toda S, et al. **J Dermatol** 1996 Nov; 23(11):840–4 (13 ref.)
A hamartoma-like mass on the palate? A possible discussion regarding the components of a pigmented naevus and hyperplastic salivary gland. Harada H, et al. **J Laryngol Otol** 1997 Mar;111(3):296–9 (17 ref.)

NEVUS, SPINDLE CELL AND EPITHELIOID see **NEVUS, EPITHELIOID AND SPINDLE CELL**

NEVUS SYNDROME, BASAL CELL see **BASAL CELL NEVUS SYNDROME**

NEVUS SYNDROME, DYSPLASTIC see **DYSPLASTIC NEVUS SYNDROME**

NEW DEVICE APPROVAL see **DEVICE APPROVAL**

NEW DRUG APPROVAL see **DRUG APPROVAL**

NEWBORN INFANT SCREENING see **NEONATAL SCREENING**

NEWBORN INTENSIVE CARE UNITS see **INTENSIVE CARE UNITS, NEONATAL**

NEWCASTLE DISEASE VIRUS

IMMUNOLOGY

Immunogenicity increase of autologous tumor cell vaccines by virus infection and attachment of bispecific antibodies. Haas C, et al. **Cancer Immunol Immunother** 1996 Nov; 43(3):190–4 (41 ref.)

NEWSLETTERS see **PERIODICALS**

NEWSPAPERS

Disasters, the media and social structures: a typology of credibility hierarchy persistence based on a newspaper coverage of the Love Canal and six other disasters. Ploughman P. **Disasters** 1997 Jun;21(2):118–37 (79 ref.)
Gatekeeping through media format: strategies of voice for the HIV-positive via human interest news formats and organizations. Hallett MA, et al. **J Homosex** 1997; 32(3–4):17–36 (25 ref.)
Working with education reporters to advocate for comprehensive school health education. Sofalvi AJ, et al. **J Sch Health** 1997 May;67(5):185–6 (19 ref.)

NEWTS see **SALAMANDRIDAE**

NF-KAPPA B

The NF-kappa B and I kappa B proteins: new discoveries and insights. Baldwin AS Jr. **Annu Rev Immunol** 1996; 14:649–83 (180 ref.)
[NF-kappa B system] Watanabe N, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1198–209 (84 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Biological and biochemical inhibitors of the NF-kappa B/Rel proteins and cytokine synthesis. Beauparlant P, et al. **Cytokine Growth Factor Rev** 1996 Aug;7(2):175–90 (141 ref.)
Antiatherogenic properties of zinc: implications in endothelial cell metabolism. Hennig B, et al. **Nutrition** 1996 Oct; 12(10):711–7 (90 ref.)

DRUG EFFECTS

NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules. Baeuerle PA, et al. **Adv Immunol** 1997;65:111–37 (105 ref.)

GENETICS

Involvement of nuclear factor-kappa B activation in IgE synthesis in human B cells. Yanagihara Y, et al. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 2):S224–9 (38 ref.)
The NF-kappa B/Rel and I kappa B gene families: mediators of immune response and inflammation. Wulczyn FG, et al. **J Mol Med** 1996 Dec;74(12):749–69 (252 ref.)
The involvement of the candidate proto-oncogene NFKB2/lyt-10 in lymphoid malignancies. Neri A, et al. **Leuk Lymphoma** 1996 Sep;23(1–2):43–8 (38 ref.)
NF-kappa B: a pivotal role in asthma and a new target for therapy. Barnes PJ, et al. **Trends Pharmacol Sci** 1997 Feb; 18(2):46–50 (37 ref.)

METABOLISM

Stimulation of NF-kappa B activation and gene expression by platelet-activating factor. Ye RD, et al. **Adv Exp Med Biol** 1996;416:143–51 (18 ref.)
The role of nuclear factor-kappa B in cytokine gene regulation. Blackwell TS, et al. **Am J Respir Cell Mol Biol** 1997 Jul;17(1):3–9 (44 ref.)
Regulation of transcription factor function by proteolysis. Goodbourn S, et al. **Biochem Soc Trans** 1997 May; 25(2):498–502 (49 ref.)
Central role of the transcription factor nuclear factor-kappa B in mesangial cell production of chemokines. Guijarro C, et al. **Contrib Nephrol** 1997;120:210–8 (36 ref.)
Transcription factors in immune-mediated disease. Peltz G. **Curr Opin Biotechnol** 1997 Aug;8(4):467–73 (60 ref.)
Regulation of NF-kappa B and disease control: identification of a novel serine kinase and thioredoxin as effectors for signal transduction pathway for NF-kappa B activation. Okamoto T, et al. **Curr Top Cell Regul** 1997;35:149–61 (74 ref.)
Biological and biochemical inhibitors of the NF-kappa B/Rel proteins and cytokine synthesis. Beauparlant P, et al. **Cytokine Growth Factor Rev** 1996 Aug;7(2):175–90 (141 ref.)
Redox regulation of NF-kappa B activation. Flohé L, et al. **Free Radic Biol Med** 1997;22(6):1115–26 (117 ref.)
The NF-kappa B/Rel and I kappa B gene families: mediators of immune response and inflammation. Wulczyn FG, et al. **J Mol Med** 1996 Dec;74(12):749–69 (252 ref.)
Study of gene regulation by NF-kappa B and AP-1 in response to reactive oxygen intermediates. Müller JM, et al. **Methods** 1997 Mar;11(3):301–12 (90 ref.)
Reactive oxygen intermediates as second messengers of a general pathogen response. Baeuerle PA, et al. **Pathol Biol (Paris)** 1996 Jan;44(1):29–35 (50 ref.)
The ER-overload response: activation of NF-kappa B. Pahl HL, et al. **Trends Biochem Sci** 1997 Feb;22(2):63–7 (37 ref.)
Cell death induction by TNF: a matter of self control. Wallach D. **Trends Biochem Sci** 1997 Apr;22(4):107–9 (29 ref.)

PHYSIOLOGY

NF-IL6 and NF-kappa B in cytokine gene regulation. Akira S, et al. **Adv Immunol** 1997;65:1–46 (215 ref.)
Activate NF-kappa B or die? Baichwal VR, et al. **Curr Biol** 1997 Feb 1;7(2):R94–6 (15 ref.)
Role of nuclear factor-kappa B in atherogenesis. Brand K, et al. **Exp Physiol** 1997 Mar;82(2):297–304 (26 ref.)
Interaction of HTLV-I Tax with the human proteasome: implications for NF-kappa B induction. Béraud C, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S76–84 (88 ref.)
Involvement of nuclear factor-kappa B activation in IgE synthesis in human B cells. Yanagihara Y, et al. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 2):S224–9 (38 ref.)
Cellular and viral protein interactions regulating I kappa B alpha activity during human retrovirus infection. Hiscott J, et al. **J Leukoc Biol** 1997 Jul;62(1):82–92 (80 ref.)
Nuclear factor-kappa-B/steroid hormone receptor interactions as a functional basis of anti-inflammatory action of steroids in reproductive organs. van der Burg B, et al. **Mol Hum Reprod** 1996 Jun;2(6):433–8 (57 ref.)
Transcription factors as activators of gene transcription: AP-1 and NF-kappa B. Adcock IM. **Monaldi Arch Chest Dis** 1997 Apr;52(2):178–86 (49 ref.)
Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. Barnes PJ, et al. **N Engl J Med** 1997 Apr 10;336(15):1066–71 (53 ref.)
Rel/NF-kappaB/IkappaB proteins and cancer. Gilmore TD, et al. **Oncogene** 1996 Oct 3;13(7):1367–78 (171 ref.)
NF-kappa B: a crucial transcription factor for glial and neuronal cell function. O'Neill LA, et al. **Trends Neurosci** 1997 Jun;20(6):252–8 (64 ref.)
[Postsynaptic density proteins related to the expression and modulation of synaptic plasticity] Suzuki T. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Apr; 16(2):53–8 (21 ref.) (Eng. Abstr.) **(Jpn)**

NF1 GENES see **GENES, NEUROFIBROMATOSIS 1**

NF2 GENES see **GENES, NEUROFIBROMATOSIS 2**

NG-MONOMETHYL-L-ARGININE see **OMEGA-N-METHYLARGININE**

NG-NITRO-L-ARGININE METHYL ESTER see **NG-NITROARGININE METHYL ESTER**

NGF RECEPTORS see **RECEPTORS, NERVE GROWTH FACTOR**

NHANES see **NUTRITION SURVEYS**

NIACIN

Tryptophan and niacin nutrition—is there a problem? Bender DA. **Adv Exp Med Biol** 1996;398:565–9 (25 ref.)

DIAGNOSTIC USE

The niacin challenge test in schizophrenia: past, present and future. Lin A, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Aug; 55(1–2):17–9 (15 ref.)

PHARMACOKINETICS

Bioavailability of niacin. van den Berg H. **Eur J Clin Nutr** 1997 Jan;51 Suppl 1:S64–5 (18 ref.)

THERAPEUTIC USE

New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug. Crouse JR 3rd. **Coron Artery Dis** 1996 Apr;7(4):321–6 (47 ref.)
[The role of nicotinic acid in the treatment of atherosclerosis and atherogenic dyslipidemia] Aronov DM. **Klin Med (Mosk)** 1996;74(9):48–52 (25 ref.) **(Rus)**

NIACINAMIDE

ANALOGS & DERIVATIVES

Nicorandil: a potassium channel opening drug for treatment of ischemic heart disease. Goldschmidt M, et al. **J Clin Pharmacol** 1996 Jul;36(7):559–72 (83 ref.)

PHYSIOLOGY

Molecular mechanisms of beta-cell destruction in IDDM: the role of nicotinamide. Gale EA. **Horm Res** 1996;45 Suppl 1:39–43 (22 ref.)

THERAPEUTIC USE

ARCON—current status: summary of a workshop on preclinical and clinical studies. Denekamp J, et al. **Acta Oncol** 1997;36(5):517–25 (0 ref.)
Nicotinamide: potential for the prevention of type 1 diabetes? Gale EA. **Horm Metab Res** 1996 Jul;28(7):361–4 (32 ref.)
Molecular mechanisms of beta-cell destruction in IDDM: the role of nicotinamide. Gale EA. **Horm Res** 1996;45 Suppl 1:39–43 (22 ref.)
Theory and practice of nicotinamide trials in pre-type 1 diabetes. Gale EA. **J Pediatr Endocrinol Metab** 1996 May–Jun;9(3):375–9 (18 ref.)
Prevention and ethics in medicine: the case of diabetes prevention. Nordenfelt L. **J Pediatr Endocrinol Metab** 1996 May–Jun;9(3):381–6 (8 ref.)

NICARDIPINE

THERAPEUTIC USE

Concomitant diseases in elderly hypertensives: the position of nicardipine. Zannad F. **J Hypertens Suppl** 1996 Oct; 14(3):S37–40 (34 ref.)
[Nicardipine and its indications in neurology] Moltó-Jordà JM, et al. **Rev Neurol** 1997 Aug;25(144):1235–41 (55 ref.) (Eng. Abstr.) **(Spa)**

NICERGOLINE

ADVERSE EFFECTS

Lichenoid drug eruption following the Blaschko lines. Muñoz MA, et al. **Dermatology** 1996;193(1):66–7 (10 ref.)

THERAPEUTIC USE

Treatment of impaired cognition with nootropic drugs: nicergoline versus the state of the art. Fariello RG. **Funct Neurol** 1997 May–Aug;12(3–4):221–5 (20 ref.)

NICKEL

Studies and applications of NiTi shape memory alloys in the medical field in China. Dai K, et al. **Biomed Mater Eng** 1996;6(4):233–40 (40 ref.)
On the nature of the biocompatibility and on medical applications of NiTi shape memory and superelastic alloys. Shabalovskaya SA. **Biomed Mater Eng** 1996;6(4):267–89 (39 ref.)

ADVERSE EFFECTS

Nickel dermatitis: how much nickel is safe? Gawkrodger DJ. **Contact Dermatitis** 1996 Nov;35(5):267–71 (27 ref.)
Orthodontic appliances in relation to nickel hypersensitivity. A review. Lindsten R, et al. **J Orofac Orthop** 1997; 58(2):100–8 (23 ref.) **(Eng, Ger)**

TOXICITY

Biochemical and clinical aspects of nickel toxicity. Savolainen H. **Rev Environ Health** 1996 Oct–Dec; 11(4):167–73 (56 ref.)
Carcinogenicity assessment of selected nickel compounds. Oller AR, et al. **Toxicol Appl Pharmacol** 1997 Mar; 143(1):152–66 (120 ref.)

NICOTIANA see **TOBACCO**

NICOTINAMIDE see **NIACINAMIDE**

NICOTINAMIDE-ADENINE DINUCLEOTIDE see **NAD**

NICOTINAMIDE-ADENINE DINUCLEOTIDE PHOSPHATE see **NADP**

NICOTINE

Nicotine dependence in women. Fant RV, et al. **J Am Med Womens Assoc** 1996 Jan–Apr;51(1–2):19–20, 22–4, 28 (74 ref.)

NICOTINE

Recent developments in the pharmacotherapy of substance abuse. O'Brien CP. **J Consult Clin Psychol** 1996 Aug; 64(4):677–86 (57 ref.)

Nicotine addiction. Johnson CR, et al. **J Fla Med Assoc** 1996 Feb;83(2):102–7 (56 ref.)

Immunological approaches to nicotine receptors. Patrick JW, et al. **NIDA Res Monogr** 1996;161:3–19 (70 ref.)

ADMINISTRATION & DOSAGE

Current issues in behavioral and pharmacological approaches to smoking cessation. Hajek P. **Addict Behav** 1996 Nov–Dec;21(6):699–707 (40 ref.)

Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems. Schneider NG, et al. **Clin Pharmacokinet** 1996 Jul; 31(1):65–80 (63 ref.)

The benefits of stopping smoking and the role of nicotine replacement therapy in older patients. Gourlay SG, et al. **Drugs Aging** 1996 Jul;9(1):8–23 (125 ref.)

[Nicotine in neuropsychiatric movement disorders] Erdmann R. **Fortschr Neurol Psychiatr** 1996 Sep;64(9):362–6 (42 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Measuring tobacco withdrawal: a review of self-report questionnaires. Patten CA, et al. **J Subst Abuse** 1996; 8(1):93–113 (75 ref.)

The role of nicotine in smoking-related cardiovascular disease. Benowitz NL. **Prev Med** 1997 Jul–Aug;26(4):412–7 (45 ref.)

Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literature. Dalack GW, et al. **Schizophr Res** 1996 Nov 15;22(2):133–41 (45 ref.)

The maternal and fetal physiologic effects of nicotine. Lambers DS, et al. **Semin Perinatol** 1996 Apr;20(2):115–26 (47 ref.)

[Nicotine and worsening myasthenia] Moreau T, et al. **Rev Neurol (Paris)** 1997 Mar;153(2):141–3 (10 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Individual differences in nicotine kinetics and metabolism in humans. Benowitz NL, et al. **NIDA Res Monogr** 1997; 173:48–64 (32 ref.)

[Metabolism of nicotine--mechanism and clinical effects of toxicity] Szajerka G, et al. **Postepy Hig Med Dosw** 1997; 51(1):23–38 (73 ref.) (Eng. Abstr.) **(Pol)**

PHARMACOKINETICS

Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems. Schneider NG, et al. **Clin Pharmacokinet** 1996 Jul; 31(1):65–80 (63 ref.)

Metabolic bioactivation reactions potentially related to drug toxicities. Castagnoli N Jr, et al. **NIDA Res Monogr** 1997; 173:85–105 (81 ref.)

PHARMACOLOGY

The pharmacology of (–)-nicotine and novel cholinergic channel modulators. Brioni JD, et al. **Adv Pharmacol** 1997; 37:153–214 (298 ref.)

Nicotine and sympathetic neurotransmission. Haass M, et al. **Cardiovasc Drugs Ther** 1997 Jan;10(6):657–65 (55 ref.)

Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. Benowitz NL, et al. **J Am Coll Cardiol** 1997 Jun;29(7):1422–31 (123 ref.)

Attention deficit disorder in adults and nicotine dependence: psychobiological factors in resistance to recovery? Coger RW, et al. **J Psychoactive Drugs** 1996 Jul–Sep;28(3):229–40 (56 ref.)

Nicotine self-administration in animals and humans: similarities and differences. Rose JE, et al. **Psychopharmacology (Berl)** 1997 Mar;130(1):28–40 (108 ref.)

The direct effects of nicotine use on human health. Van Gilder TJ, et al. **Wis Med J** 1997 Feb;96(2):43–8 (39 ref.)

[Nicotine. Actions and interactions] Franken RA, et al. **Arq Bras Cardiol** 1996 Jun;66(6):371–3 (41 ref.) **(Por)**

THERAPEUTIC USE

The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease. Bonapace CR, et al. **Ann Pharmacother** 1997 Jul–Aug;31(7–8):907–13 (32 ref.)

Increased regional cerebral glucose metabolism and semantic memory performance in Alzheimer's disease: a pilot double blind transdermal nicotine positron emission tomography study. Parks RW, et al. **Neuropsychol Rev** 1996 Jun; 6(2):61–79 (79 ref.)

Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Balfour DJ, et al. **Pharmacol Ther** 1996;72(1):51–81 (289 ref.)

The role of cigarettes and nicotine in the onset and treatment of ulcerative colitis. Birtwistle J. **Postgrad Med J** 1996 Dec; 72(854):714–8 (58 ref.)

TOXICITY

[Metabolism of nicotine--mechanism and clinical effects of toxicity] Szajerka G, et al. **Postepy Hig Med Dosw** 1997; 51(1):23–38 (73 ref.) (Eng. Abstr.) **(Pol)**

NICOTINE DEPENDENCE see **TOBACCO USE DISORDER**

NICOTINE USE DISORDER see **TOBACCO USE DISORDER**

NICOTINIC ACETYLCHOLINE RECEPTORS see **RECEPTORS, NICOTINIC**

NICOTINIC ACID see **NIACIN**

NICOTINIC ACIDS

ADMINISTRATION & DOSAGE

Tazarotene gel: efficacy and safety in plaque psoriasis. Weinstein GD. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 3):S33–8 (19 ref.)

ADVERSE EFFECTS

Clinical safety of tazarotene in the treatment of plaque psoriasis. Marks R. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 3):S25–32 (50 ref.)

PHARMACOLOGY

Molecular mechanisms of tazarotene action in psoriasis. Duvic M, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 3):S18–24 (33 ref.)

THERAPEUTIC USE

Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis. Chandraratna RA. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 3):S12–7 (34 ref.)

NICOTINIC AGENTS see **CHOLINERGIC AGENTS**

NICOTINIC AGONISTS

ADMINISTRATION & DOSAGE

Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems. Schneider NG, et al. **Clin Pharmacokinet** 1996 Jul; 31(1):65–80 (63 ref.)

PHARMACOLOGY

Attention deficit disorder in adults and nicotine dependence: psychobiological factors in resistance to recovery? Coger RW, et al. **J Psychoactive Drugs** 1996 Jul–Sep;28(3):229–40 (56 ref.)

Noncompetitive agonism at nicotinic acetylcholine receptors; functional significance for CNS signal transduction. Maelicke A, et al. **J Recept Signal Transduct Res** 1995 Jan–Mar;15(1–4):333–53 (43 ref.)

THERAPEUTIC USE

Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Balfour DJ, et al. **Pharmacol Ther** 1996;72(1):51–81 (289 ref.)

New trends in cholinergic therapy for Alzheimer disease: nicotinic agonists or cholinesterase inhibitors? Giacobini E. **Prog Brain Res** 1996;109:311–23 (72 ref.)

NICOTINIC ANTAGONISTS

METABOLISM

Luminal and non-luminal non-competitive inhibitor binding sites on the nicotinic acetylcholine receptor. Arias HR. **Mol Membr Biol** 1996 Jan–Mar;13(1):1–17 (150 ref.)

PHARMACOLOGY

Luminal and non-luminal non-competitive inhibitor binding sites on the nicotinic acetylcholine receptor. Arias HR. **Mol Membr Biol** 1996 Jan–Mar;13(1):1–17 (150 ref.)

Side effects of nondepolarizing muscle relaxants: relationship to their antinicotinic and antimuscarinic actions. Vizi ES, et al. **Pharmacol Ther** 1997;73(2):75–89 (105 ref.)

NICOTINIC RECEPTORS see **RECEPTORS, NICOTINIC**

NIDATION see **OVUM IMPLANTATION**

NIDDM see **DIABETES MELLITUS, NON-INSULIN-DEPENDENT**

NIEMANN-PICK DISEASE

GENETICS

Biological implications of the Niemann-Pick C mutation. Pentchev PG, et al. **Subcell Biochem** 1997;28:437–51 (58 ref.)

Phenotypic and genetic heterogeneity in Niemann-Pick disease type C: current knowledge and practical implications. Vanier MT. **Wien Klin Wochenschr** 1997 Feb 14;109(3):68–73 (56 ref.)

METABOLISM

Biological implications of the Niemann-Pick C mutation. Pentchev PG, et al. **Subcell Biochem** 1997;28:437–51 (58 ref.)

RADIOGRAPHY

Case report. Pulmonary involvement in Niemann-Pick disease subtype B: CT findings. Ferretti GR, et al. **J Comput Assist Tomogr** 1996 Nov–Dec;20(6):990–2 (9 ref.)

NIF GENES see **GENES, NITROGEN FIXATION**

NIFEDIPINE

Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? [see comments] Grossman E, et al. **JAMA** 1996 Oct 23–30;276(16):1328–31 (65 ref.) Comment in: JAMA 1996 Oct 23–30;276(16):1342–3. Comment in: JAMA 1997 Mar 12;277(10):787; discussion 790–1. Comment in: JAMA 1997 Mar 12;277(10):787–8; discussion 790–1. Comment in: JAMA 1997 Mar 12;277(10):788; discussion 790–1. Comment in: JAMA 1997 Mar 12;277(10):788–9; discussion 790–1. Comment in: JAMA 1997 Mar 12;277(10):789–90; discussion 790–1. Comment in: JAMA 1997 Mar 12;277(10):790; discussion 790–1.

ADVERSE EFFECTS

Calcium channel blockers for hypertension: dissecting the evidence for adverse effects. Opie LH. **Am J Hypertens** 1997 May;10(5 Pt 1):565–77 (84 ref.)

Clinical approaches to male infertility with a case report of possible nifedipine-induced sperm dysfunction. Enders G. **J Am Board Fam Pract** 1997 Mar–Apr;10(2):131–6 (27 ref.)

Surgical treatment of nifedipine-induced gingival hyperplasia. A case report [see comments] Abitbol TE, et al. **N Y State Dent J** 1996 Aug–Sep;62(7):34–7 (24 ref.) Comment in: N Y State Dent J 1996 Dec;62(10):13.

CONTRAINDICATIONS

[Restrictions on the use of short-term action nifedipine in the United States. A review of facts] Fuchs FD. **Arq Bras Cardiol** 1996 Oct;67(4):267–9 (19 ref.) **(Por)**

PHARMACOLOGY

Safety of calcium antagonists: dissecting the evidence. Messerli FH. **Am J Cardiol** 1996 Nov 7;78(9A):19–23 (34 ref.)

THERAPEUTIC USE

The value of nifedipine in the treatment of hypertension, coronary heart disease and myocardial infarction (post-infarction therapy). Schulz J, et al. **Curr Med Res Opin** 1996;13(7):397–408 (25 ref.)

Nifedipine in acute coronary syndromes: Furberg's refrain revisited. Rafflenbeul W. **Eur Heart J** 1996 Aug; 17(8):1147–52 (38 ref.)

Sustained improvement of pulmonary haemodynamics with low-dose of nifedipine in primary pulmonary hypertension [letter] Shimabukuro M, et al. **Eur Heart J** 1996 Dec; 17(12):1911–2 (5 ref.)

Critical appraisal of recent studies on nifedipine and other calcium channel blockers in coronary artery disease and hypertension [see comments] Tijssen JG, et al. **Eur Heart J** 1996 Aug;17(8):1152–7 (18 ref.) Comment in: Eur Heart J 1997 Jan;18(1):168.

Antihypertensive therapy debate: contribution from the Shanghai Trial Of Nifedipine in the Elderly (STONE). Hamet P, et al. **J Hypertens Suppl** 1996 Nov;14(4):S9–14 (63 ref.)

[Nifedipine and coronary insufficiency reasons for controversy] Lièvre M, et al. **Therapie** 1997 Jan–Feb; 52(1):37–45 (49 ref.) (Eng. Abstr.) **(Fre)**

[Nifedipine in ischemic heart disease: a ban on its use or a differential approach to therapy? (see comments)] Martsevich SIu. **Ter Arkh** 1996;68(9):31–5 (20 ref.) (Eng. Abstr.) Comment in: Ter Arkh 1996;68(9):5–7. **(Rus)**

NIFTOLID see **FLUTAMIDE**

NIGHT CARE

METHODS

[Adaptation of insulin therapy in the evening and/or at bedtime. Experience of night hospitalization] Bennis D, et al. **Journ Annu Diabetol Hotel Dieu** 1996;:233–47 (21 ref.) **(Fre)**

[Nocturnal regulation of blood pressure in the diabetic] Julien J. **Journ Annu Diabetol Hotel Dieu** 1996;:267–71 (20 ref.) **(Fre)**

NIGHT TERRORS see **SLEEP DISORDERS**

NIGHTMARES see **DREAMS**

NIMERGOLINE see **NICERGOLINE**

NIMODIPINE

THERAPEUTIC USE

Clinical findings with nimodipine in dementia: test of the calcium hypothesis. Fritze J, et al. **J Neural Transm Suppl** 1995;46:439–53 (87 ref.)

[Piracetam, nimodipine and tacrine in the pharmacologic treatment of dementia: bibliographic review] Ojer Tsakiridu D, et al. **Aten Primaria** 1996 Sep 30;18(5):257–60, 262–4 (31 ref.) **(Spa)**

NIPECOTIC ACIDS

PHARMACOKINETICS

The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Perucca E, et al. **Clin Pharmacokinet** 1996 Jul;31(1):29–46 (120 ref.)

THERAPEUTIC USE

Tiagabine. Shinnar S. **Semin Pediatr Neurol** 1997 Mar; 4(1):24–33 (57 ref.)

NIPPLES

Areolar sebaceous hyperplasia: a case report. Belinchón I, et al. **Cutis** 1996 Jul;58(1):63–4 (8 ref.)

A comprehensive approach to evaluating nipple discharge. Arnold GJ, et al. **Nurse Pract** 1997 Jul;22(7):96–102, 105–11 (16 ref.)

[Barriers in breast feeding: artificial nipples and nipple shields] Mikiel-Kostyra K. **Pediatr Pol** 1996 Feb; 71(2):161–4 (15 ref.) (Eng. Abstr.) **(Pol)**

ABNORMALITIES

Sporadic unilateral intra-areolar polythelia. Report of an additional case and review of the literature [letter] Urbani CE, et al. **Acta Derm Venereol** 1996 Mar;76(2):156 (3 ref.)

Familial polythelia without associated anomalies. Casey HD, et al. **Ann Plast Surg** 1996 Jan;36(1):101–4 (20 ref.)

PATHOLOGY

Erosive adenomatosis of the nipple: a benign imitator of malignant breast disease. Miller L, et al. **Cutis** 1997 Feb; 59(2):91–2 (11 ref.)

PHYSIOLOGY

Breastfeeding: physiological, endocrine and behavioural adaptations caused by oxytocin and local neurogenic activity in the nipple and mammary gland. Uvnäs-Moberg K, et al. **Acta Paediatr** 1996 May;85(5):525–30 (43 ref.)

NIR SPECTROSCOPY see **SPECTROSCOPY, NEAR-INFRARED**

NISIN

BIOSYNTHESIS

Genetics of subtilin and nisin biosyntheses: biosynthesis of lantibiotics. Entian KD, et al. **Antonie Van Leeuwenhoek** 1996 Feb;69(2):109–17 (74 ref.)

Genetic determinants for the biosynthesis of nisin, a bacteriocin produced by Lactococcus lactis. Rodríguez JM, et al. **Microbiologia** 1996 Mar;12(1):61–74 (45 ref.)

[Nisin: conditions for production and isolation of the drug] Baranova IP, et al. **Antibiot Khimioter** 1997;42(3):37–44 (69 ref.) **(Rus)**

CHEMISTRY

Genetics of subtilin and nisin biosyntheses: biosynthesis of lantibiotics. Entian KD, et al. **Antonie Van Leeuwenhoek** 1996 Feb;69(2):109–17 (74 ref.)

PHARMACOLOGY

Applications of the bacteriocin, nisin. Delves-Broughton J, et al. **Antonie Van Leeuwenhoek** 1996 Feb;69(2):193–202 (67 ref.)

NISOLDIPINE

Dihydropyridine calcium antagonists: beneficial or adverse effects in the setting of myocardial ischaemia/reperfusion? Ehring T, et al. **Cardiology** 1997;88 Suppl 1:3–14; discussion 15–6 (117 ref.)

ADMINISTRATION & DOSAGE

Nisoldipine CC: clinical experience in hypertension. Langan J, et al. **Cardiology** 1997;88 Suppl 1:56–62; discussion 63–5 (62 ref.)

PHARMACOKINETICS

Nisoldipine coat-core. A review of its pharmacology and therapeutic efficacy in hypertension. Plosker GL, et al. **Drugs** 1996 Aug;52(2):232–53 (112 ref.)

THERAPEUTIC USE

What does nisoldipine coat core (CC) add to current therapy that is clinically meaningful? Opie LH. **Am J Cardiol** 1997 May 22;79(10A):29–32; discussion 47–8 (40 ref.)

Nisoldipine CC: clinical experience in ischaemic heart disease. Melcher A, et al. **Cardiology** 1997;88 Suppl 1:17–23; discussion 24–5 (30 ref.)

Nisoldipine CC: efficacy and tolerability in hypertension and ischemic heart disease. Fodor JG. **Cardiovasc Drugs Ther** 1997 Jan;10 Suppl 3:873–9 (48 ref.)

Nisoldipine coat-core. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of ischaemic heart disease. Langtry HD, et al. **Drugs** 1997 May;53(5):867–84 (48 ref.)

NISSEN OPERATION see **FUNDOPLICATION**

NISSL DEGENERATION see **NERVE DEGENERATION**

NITRATE REDUCTASES

METABOLISM

Enzyme diversity and mosaic gene organization in denitrification. Zumft WG, et al. **Antonie Van Leeuwenhoek** 1997 Feb;71(1–2):43–58 (139 ref.)

NITRATES

Using peroxynitrite as oxidant with low-density lipoprotein. Patel RP, et al. **Methods Enzymol** 1996;269:375–84 (32 ref.)

ADVERSE EFFECTS

Nitrate as an environmental carcinogen. Cannons A. **J Fla Med Assoc** 1996 Mar;83(3):197–9 (27 ref.)

Food-borne nitrates and nitrites as a cause of methemoglobinemia. Chan TY. **Southeast Asian J Trop Med Public Health** 1996 Mar; 27(1):189–92 (24 ref.)

CHEMICAL SYNTHESIS

Syntheses of pure tetramethylammonium peroxynitrite. Bohle DS, et al. **Methods Enzymol** 1996;269:302–11 (13 ref.)

Syntheses of peroxynitrite: to go with the flow or on solid grounds? Koppenol WH, et al. **Methods Enzymol** 1996; 269:296–302 (24 ref.)

Selecting the most appropriate synthesis of peroxynitrite. Uppu RM, et al. **Methods Enzymol** 1996;269:285–96 (74 ref.)

Synthesis of peroxynitrite by azide-ozone reaction. Uppu RM, et al. **Methods Enzymol** 1996;269:311–21 (21 ref.)

Biphasic synthesis of high concentrations of peroxynitrite using water-insoluble alkyl nitrite and hydrogen peroxide. Uppu RM, et al. **Methods Enzymol** 1996;269:322–9 (25 ref.)

CHEMISTRY

Oxidative damage and tyrosine nitration from peroxynitrite. Beckman JS. **Chem Res Toxicol** 1996 Jul-Aug;9(5):836–44 (79 ref.)

Carbon dioxide: physiological catalyst for peroxynitrite-mediated cellular damage or cellular protectant? Lymar SV, et al. **Chem Res Toxicol** 1996 Jul-Aug;9(5):845–50 (40 ref.)

The discovery of a new organic nitrate: an overview. Benedini F, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 4:S1–5 (27 ref.)

Detection of secondary radicals from peroxynitrite-medicated oxidations by electron spin resonance. Augusto O, et al. **Methods Enzymol** 1996; 269:346–54 (20 ref.)

Reaction of peroxynitrite and hydrogen peroxide to produce singlet molecular oxygen (1deltag). Di Mascio P, et al. **Methods Enzymol** 1996;269:395–400 (20 ref.)

Predicting physical properties of peroxynitrite by quantum mechanics. Hamilton TP, et al. **Methods Enzymol** 1996; 269:329–46 (33 ref.)

Kinetic analysis of reactivity of peroxynitrite with biomolecules. Radi R. **Methods Enzymol** 1996;269:354–66 (26 ref.)

Nitration and hydroxylation of phenolic compounds by peroxynitrite. Ramezanian MS, et al. **Methods Enzymol** 1996;269:195–201 (16 ref.)

Distinguishing reactivities of peroxynitrite and hydroxyl radical. Squadrito GL, et al. **Methods Enzymol** 1996; 269:366–74 (34 ref.)

METABOLISM

Ebselen as a glutathione peroxidase mimic and as a scavenger of peroxynitrite. Sies H, et al. **Adv Pharmacol** 1997; 38:229–46 (105 ref.)

Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Beckman JS, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):C1424–37 (109 ref.)

The metabolism of dietary nitrites and nitrates. Walker R. **Biochem Soc Trans** 1996 Aug;24(3):780–5 (50 ref.)

Possible roles of nitric oxide and peroxynitrite in murine leishmaniasis. Augusto O, et al. **Braz J Med Biol Res** 1996 Jul;29(7):853–62 (55 ref.)

Nitrate reduction to ammonia by enteric bacteria: redundancy, or a strategy for survival during oxygen starvation? Cole J. **FEMS Microbiol Lett** 1996 Feb 1; 136(1):1–11 (49 ref.)

The possible role of peroxynitrite in Alzheimer's disease: a simple hypothesis that could be tested more thoroughly. Van Dyke K. **Med Hypotheses** 1997 May;48(5):375–80 (49 ref.)

Peroxynitrite-dependent tyrosine nitration catalyzed by superoxide dismutase, myeloperoxidase, and horseradish peroxidase. Sampson JB, et al. **Methods Enzymol** 1996; 269:210–18 (23 ref.)

PHARMACOLOGY

DNA strand breakage and activation of poly-ADP ribosyltransferase: a cytotoxic pathway triggered by peroxynitrite. Szabó C. **Free Radic Biol Med** 1996; 21(6):855–69 (218 ref.)

[Physiopathologic and pharmacodynamic rationale for the use of nitrate compounds in cardiac decompensation] Geraci E. **G Ital Cardiol** 1996 Sep;26(9):1073–7 (25 ref.) **(Ita)**

[Endothelial function, nitrate derivatives and cardiac insufficiency] Ledda F. **G Ital Cardiol** 1996 Sep; 26(9):1067–72 (22 ref.) **(Ita)**

PHYSIOLOGY

Peroxynitrite: mediator of the toxic action of nitric oxide. Bartosz G. **Acta Biochim Pol** 1996;43(4):645–59 (123 ref.)

Endogenous N-nitrosation. Hill MJ. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:47–50 (13 ref.)

Peroxynitrite: a two-faced metabolite of nitric oxide. Muijsers RB, et al. **Life Sci** 1997;60(21):1833–45 (139 ref.)

The pathophysiological role of peroxynitrite in shock, inflammation, and ischemia-reperfusion injury. Szabó C. **Shock** 1996 Aug;6(2):79–88 (162 ref.)

THERAPEUTIC USE

Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure. Thadani U. **Cardiovasc Drugs Ther** 1997 Jan;10(6):735–42 (65 ref.)

Oral nitrates: more than symptomatic therapy in coronary artery disease? Thadani U. **Cardiovasc Drugs Ther** 1997 May;11 Suppl 1:213–8 (76 ref.)

Secondary preventive potential of nitrates in ischaemic heart disease. Thadani U. **Eur Heart J** 1996 Dec;17 Suppl F:30–6 (72 ref.)

[Nitric oxide donors in therapy of chronic heart failure] Blasini R, et al. **Internist (Berl)** 1997 May;38(5):448–52 (48 ref.) **(Ger)**

[Nitric oxide in therapy of angina pectoris: nitrates or molsidomine?] Schächinger V, et al. **Internist (Berl)** 1997 May;38(5):438–47 (49 ref.) **(Ger)**

[Nitrate derivatives in heart failure: physiopathological, clinical, and prognostic features] Marra L, et al. **Clin Ter** 1996 Jul-Aug;147(7–8):399–402 (23 ref.) (Eng. Abstr.) **(Ita)**

[Clinical and diagnostic indications for the use of nitrates in dynamic heart defects (decompensation, left ventricular dysfunction without decompensation, etc.] Branzi A. **G Ital Cardiol** 1996 Sep;26(9):1079–84 (19 ref.) **(Ita)**

[Pharmacologic interactions with nitrates in patients with, or at risk of, cardiac decompensation] Filardi PP, et al. **G Ital Cardiol** 1996 Sep;26(9):1085–8 (09 ref.) **(Ita)**

[The role of nitrates in left ventricular insufficiency in patients with acute myocardial infarction] Maggioni AP. **G Ital Cardiol** 1996 Sep;26(9):1095–8 (04 ref.) **(Ita)**

[Effectiveness, tolerance, adverse effects of prolonged therapy with nitrate compounds] Mazzotta G. **G Ital Cardiol** 1996 Sep;26(9):1099–106 (56 ref.) **(Ita)**

TOXICITY

The importance of superoxide in nitric oxide-dependent toxicity: evidence for peroxynitrite-mediated injury. Crow JP, et al. **Adv Exp Med Biol** 1996;387:147–61 (78 ref.)

NITRIC OXIDE

see related

ENDOTHELIUM-DERIVED RELAXING FACTOR

Nitric oxide, the kidney, and hypertension. Lahera V, et al. **Am J Hypertens** 1997 Jan;10(1):129–40 (101 ref.)

Endothelial control of vasomotion and nitric oxide production: a potential target for risk factor management. Harrison DG. **Cardiol Clin** 1996 Feb;14(1):1–15 (68 ref.)

Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task Force. Kharitonov S, et al. **Eur Respir J** 1997 Jul; 10(7):1683–93 (75 ref.)

Nitric oxide in exhaled air. Lundberg JO, et al. **Eur Respir J** 1996 Dec;9(12):2671–80 (71 ref.)

Nitric oxide as antiinflammatory agent. Granger DN, et al. **Methods Enzymol** 1996;269:434–42 (26 ref.)

Nitric oxide inhalation therapy in acute respiratory distress syndrome: intended effects and possible side effects. Rossaint R, et al. **Methods Enzymol** 1996;269:442–53 (55 ref.)

Nitric oxide in the pulmonary circulation. Adnot S, et al. **Monaldi Arch Chest Dis** 1996 Dec;51(6):519–27 (30 ref.)

Nitric oxide in chronic obstructive pulmonary disease.

Barberà JA. **Monaldi Arch Chest Dis** 1996 Dec;51(6):528–32 (28 ref.)

Nitric oxide in exhaled air is a new marker of airway inflammation. Kharitonov SA, et al. **Monaldi Arch Chest Dis** 1996 Dec;51(6):533–7 (50 ref.)

Nitric oxide actions in neurochemistry. Dawson VL, et al. **Neurochem Int** 1996 Aug;29(2):97–110 (103 ref.)

[Uses of nitric oxide in obstetrics and gynecology] He W, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Feb; 31(2):119–21 (23 ref.) **(Chi)**

[Nitric oxide. Basic research and possible clinical use (see comments)] Prónai L, et al. **Orv Hetil** 1996 Aug 4; 137(31):1699–704 (50 ref.) (Eng. Abstr.) Comment in: Orv Hetil 1996 Aug 4;137(31):1699–704. **(Hun)**

[Nitric oxide and the lung] Mikawa K, et al. **Masui** 1996 Dec;45(12):1450–64 (65 ref.) (Eng. Abstr.) **(Jpn)**

[NO and physiopathology] Toda N, et al. **Nippon Yakurigaku Zasshi** 1996 Sep;108(3):178–80 (0 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Phenylephrine and inhaled nitric oxide in adult respiratory distress syndrome. When are two better than one? [editorial; comment] Pearl RG. **Anesthesiology** 1997 Jul;87(1):1–3 (16 ref.) Comment on: Anesthesiology 1997 Jul;87(1):18–25.

Current status of inhaled nitric oxide therapy in the perinatal period. Mupanemunda RH. **Early Hum Dev** 1997 Feb 20; 47(3):247–62 (72 ref.)

Delivery and monitoring of inhaled nitric oxide. Young JD, et al. **Intensive Care Med** 1996 Jan;22(1):77–86 (61 ref.)

Current status of nitric oxide inhalation. Hurford WE. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Dec;33 Suppl:199–204 (32 ref.)

[NO and alternative inhalational therapy approaches in pulmonary hypertension] Walmrath D, et al. **Internist (Berl)** 1997 May;38(5):453–60 (55 ref.) **(Ger)**

[Nitric oxide via inhalation in the newborn infant and the child with acute hypoxemic respiratory failure] Biban P, et al. **Pediatr Med Chir** 1996 May–Jun;18(3):245–51 (44 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

Molecular interactions between nitric oxide and lung surfactant. Hallman M. **Biol Neonate** 1997;71 Suppl 1:44–8 (21 ref.)

Neurotoxic and neuroprotective roles of nitric oxide in cerebral ischaemia. Dalkara T, et al. **Int Rev Neurobiol** 1997;40:319–36 (132 ref.)

ANALYSIS

Nitric oxide: an ancestral immunocyte effector molecule. Franchini A, et al. **Adv Neuroimmunol** 1995;5(4):463–78 (82 ref.)

Nitric oxide determinations: much ado about NO.–thing? [editorial; comment] Moshage H. **Clin Chem** 1997 Apr; 43(4):553–6 (60 ref.) Comment on: Clin Chem 1997 Apr;43(4):657–62.

Measuring expiratory nitric oxide in humans. Byrnes CA, et al. **Methods Enzymol** 1996;269:459–73 (21 ref.)

Measurement of nitric oxide and hydrogen peroxide production from human neutrophils. Carreras MC, et al. **Methods Enzymol** 1996;269:65–75 (25 ref.)

Measuring nitric oxide and superoxide: rate constants for aconitase reactivity. Hausladen A, et al. **Methods Enzymol** 1996;269:37–41 (19 ref.)

Nitric oxide generation from pharmacological nitric oxide donors. Kishnani NS, et al. **Methods Enzymol** 1996; 268:259–65 (27 ref.)

Nitrotyrosine as biomarker for reactive nitrogen species. van der Vliet A, et al. **Methods Enzymol** 1996;269:175–84 (50 ref.)

Nitric oxide as a challenge for the clinical chemistry laboratory. Viinikka L. **Scand J Clin Lab Invest** 1996 Nov; 56(7):577–81 (28 ref.)

ANTAGONISTS & INHIBITORS

Methylene blue: NO panacea [editorial; comment] Schreiber MD. **J Pediatr** 1996 Dec;129(6):790–3 (45 ref.) Comment on: J Pediatr 1996 Dec;129(6):904–8.

BIOSYNTHESIS

Molecular mechanisms regulating nitric oxide biosynthesis: role of xenobiotics in epithelial inflammation. Heck DE. **Adv Exp Med Biol** 1996;387:171–6 (40 ref.)

Molecular biology of nitric oxide synthases. Reduction of complications of cardiopulmonary bypass from platelets and neutrophils by nitric oxide generation from L–arginine and nitric oxide donors. Dewanjee MK. **ASAIO J** 1997 May–Jun;43(3):151–9 (64 ref.)

Use of isolated ocular arteries in vitro to define the pathology of vascular changes in glaucoma. Buckley CH, et al. **Br J Ophthalmol** 1997 Jul;81(7):599–607 (112 ref.)

Intricate regulation of nitric oxide synthesis in neurons. Hu J, et al. **Cell Signal** 1996 Mar;8(3):185–9 (68 ref.)

A proposed mechanism for the cardioprotective effect of oestrogen in women: enhanced endothelial nitric oxide release decreases coronary artery reactivity. Wellman GC, et al. **Clin Exp Pharmacol Physiol** 1996 Mar;23(3):260–6 (70 ref.)

Nitric oxide and shock. Kilbourn RG, et al. **Dis Mon** 1997 May;43(5):277–348 (317 ref.)

Modulation of vascular tone by low density lipoproteins: effects on L–arginine transport and nitric oxide synthesis. Jay MT, et al. **Exp Physiol** 1997 Mar;82(2):349–60 (60 ref.)

Langerhans cells may trigger the psoriatic disease process via production of nitric oxide. Morhenn VB. **Immunol Today** 1997 Sep;18(9):433–6 (53 ref.)

Nitric oxide and bone. Evans DM, et al. **J Bone Miner Res** 1996 Mar;11(3):300–5 (67 ref.)

Endothelial prostaglandin and nitric oxide synthesis in atherogenesis and thrombosis. Wu KK. **J Formos Med Assoc** 1996 Sep;95(9):661–6 (41 ref.)

Potential cellular signaling mechanisms mediating upregulation of endothelial nitric oxide production by estrogen. Kauser K, et al. **J Vasc Res** 1997 May–Jun; 34(3):229–36 (72 ref.)

Molecular and immune mechanisms in the pathogenesis of cardiomyopathy—role of viruses, cytokines, and nitric oxide. Matsumori A. **Jpn Circ J** 1997 Apr;61(4):275–91 (104 ref.)

Commentary on magnesium deficiency, substance P receptor up–regulation and NO overproduction. Weglicki WB, et al. **Magnes Res** 1996 Dec;9(4):331–2 (10 ref.)

Aconitases: a class of metalloproteins highly sensitive to nitric oxide synthesis. Drapier JC, et al. **Methods Enzymol** 1996; 269:26–36 (53 ref.)

The role of nitric oxide synthase pathway on bradykinin–induced bronchoconstriction in guinea–pigs and in man. Ricciardolo FL, et al. **Monaldi Arch Chest Dis** 1996 Dec;51(6):543–7 (52 ref.)

Role of CD23 in NO production by human monocytic cells. Kolb JP, et al. **Res Immunol** 1995 Nov–Dec;146(9):684–9 (52 ref.)

Role of CD69 in NO production by human monocytes. Testi R, et al. **Res Immunol** 1995 Nov–Dec;146(9):682–3 (19 ref.)

Nitric oxide generation by nitric oxide synthase isoforms in transplanted vessels. Akyürek ML, et al. **Transplant Proc** 1997 Sep;29(6):2571–2 (12 ref.)

[Anti–arteriosclerosis effects due to stimulation of endogenous nitric oxide synthesis] Bode–Böger SM, et al. **Internist (Berl)** 1997 May;38(5):461–5 (30 ref.) **(Ger)**

[Increased production of nitric oxide in the immediate and late asthmatic responses in guinea pigs] Uchida Y, et al. **Nippon Rinsho** 1996 Feb;54(2):364–8 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Adult T cell leukemia (ATL)] Matsuzaki H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):135–8 (18 ref.) **(Jpn)**

BLOOD

Nitric oxide binding and the adverse effects of cell–free hemoglobins: what makes us different from earthworms [editorial; comment] Loscalzo J. **J Lab Clin Med** 1997 Jun; 129(6):580–3 (30 ref.) Comment on: J Lab Clin Med 1997 Jun;129(6):603–10.

Commentary on magnesium deficiency and nitric oxide. Rayssiguier Y, et al. **Magnes Res** 1996 Dec;9(4):329–30 (5 ref.)

CHEMISTRY

Reactions of nitric oxide with metalloproteins. Radi R. **Chem Res Toxicol** 1996 Jul–Aug;9(5):828–35 (84 ref.)

No–donors: an emerging class of compounds in medicinal chemistry [published erratum appears in Farmaco 1997 Jan;52(1):71] Gasco A, et al. **Farmaco** 1996 Oct; 51(10):617–35 (171 ref.)

Nitric oxide and metal–catalyzed reactions. Kanner J. **Methods Enzymol** 1996;269:218–29 (42 ref.)

Distinctive chemistries of no–related species. Lipton SA. **Neurochem Int** 1996 Aug;29(2):111–4 (14 ref.)

IMMUNOLOGY

Nitric oxide and macrophage function. MacMicking J, et al. **Annu Rev Immunol** 1997;15:323–50 (190 ref.)

Role of nitric oxide–induced immune suppression in toxoplasmosis during pregnancy and in infection by a virulent strain of Toxoplasma gondii. Candolfi E, et al. **Curr Top Microbiol Immunol** 1996;219:141–54 (61 ref.)

Pro–opiomelanocortin–derived peptides, cytokines, and nitric oxide in immune responses and stress: an evolutionary approach. Ottaviani E, et al. **Int Rev Cytol** 1997;170:79–141 (400 ref.)

Immunological aspects of nitric oxide in HIV–1 infection. Torre D, et al. **Med Hypotheses** 1996 Nov;47(5):405–7 (37 ref.)

[Nitric oxide and macrophages] Drapier JC. **Pathol Biol (Paris)** 1997 Feb;45(2):110–4 (73 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Prostacyclin and nitric oxide–related gene transfer in preventing arterial thrombosis and restenosis. Wu KK. **Agents Actions Suppl** 1997;48:107–23 (35 ref.)

Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Beckman JS, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):C1424–37 (109 ref.)

The role of nitric oxide in the regulation of cellular iron metabolism. Domachowske JB. **Biochem Mol Med** 1997 Feb;60(1):1–7 (59 ref.)

Panax ginseng pharmacology: a nitric oxide link? Gillis CN. **Biochem Pharmacol** 1997 Jul 1;54(1):1–8 (50 ref.)

The role of nitric oxide (NO.) in the carcinogenic process. Tamir S, et al. **Biochim Biophys Acta** 1996 Oct 9; 1288(2):F31–6 (87 ref.)

Microbial and plant metabolism of NO. Payne WJ, et al. **Biofactors** 1997;6(1):47–52 (49 ref.)

Reactive oxygen species and nitric oxide in viral diseases. Peterhans E. **Biol Trace Elem Res** 1997 Jan;56(1):107–16 (75 ref.)

Possible roles of nitric oxide and peroxynitrite in murine leishmaniasis. Augusto O, et al. **Braz J Med Biol Res** 1996 Jul;29(7):853–62 (55 ref.)

Gaseous monoxides: a new class of microvascular regulator in the liver. Suematsu M, et al. **Cardiovasc Res** 1996 Oct; 32(4):679–86 (60 ref.)

Nitric oxide and derived species as toxic agents in stroke, AIDS dementia, and chronic neurodegenerative disorders. Hensley K, et al. **Chem Res Toxicol** 1997 May;10(5):527–32 (64 ref.)

Oxidized lipoproteins and nitric oxide. Jessup W. **Curr Opin Lipidol** 1996 Oct;7(5):274–80 (73 ref.)

Nitric oxide and blood pressure: effects of nitric oxide deficiency. Baylis C, et al. **Curr Opin Nephrol Hypertens** 1996 Jan;5(1):80–8 (109 ref.)

Anti–adhesion molecule and nitric oxide protection strategies in ischemic stroke. Chopp M, et al. **Curr Opin Neurol** 1996 Feb;9(1):68–72 (42 ref.)

Nitric oxide and septic shock. Thiemermann C. **Gen Pharmacol** 1997 Aug;29(2):159–66 (55 ref.)

Nitric oxide and nitric oxide synthase: biology, pathology, localization. Wolf G. **Histol Histopathol** 1997 Jan; 12(1):251–61 (157 ref.)

Endothelial nitric oxide pathway function in the peripheral vasculature of patients with heart failure. Kubo SH, et al. **J Card Fail** 1996 Dec;2(4 Suppl):S217–23 (51 ref.)

The role of the NO pathway in the control of cardiac function. Smith TW, et al. **J Card Fail** 1996 Dec;2(4 Suppl):S141–7 (35 ref.)

The role of nitric oxide in multiple sclerosis [see comments] Parkinson JF, et al. **J Mol Med** 1997 Mar;75(3):174–86 (151 ref.) Comment in: J Mol Med 1997 Mar;75(3):164.

Oscillations and gaseous oxides in invertebrate olfaction. Gelperin A, et al. **J Neurobiol** 1996 May;30(1):110–22 (119 ref.)

Nitric oxide–mediated mitochondrial damage in the brain: mechanisms and implications for neurodegenerative diseases. Bolaños JP, et al. **J Neurochem** 1997 Jun; 68(6):2227–40 (173 ref.)

In vivo ESR measurements of free radical reactions in living mice. Utsumi H, et al. **J Toxicol Sci** 1996 Dec;21(5):293–5 (0 ref.)

Hypertension, the endothelium and the pathogenesis of chronic vascular disease. Haller H. **Kidney Blood Press Res** 1996;19(3–4):166–71 (60 ref.)

Peroxynitrite: a two–faced metabolite of nitric oxide. Muijsers RB, et al. **Life Sci** 1997;60(21):1833–45 (139 ref.)

The osmotic and intrinsic mechanisms of the pharmacological laxative action of oral high doses of magnesium sulphate. Importance of the release of digestive polypeptides and nitric oxide. Izzo AA, et al. **Magnes Res** 1996 Jun; 9(2):133–8 (35 ref.)

Nitric oxide–induced covalent modification of glycolytic enzyme glyceraldehyde–3–phosphate dehydrogenase. Brüne B, et al. **Methods Enzymol** 1996;269:400–7 (18 ref.)

Nitric oxide and cartilage metabolism. Evans CH, et al. **Methods Enzymol** 1996;269:75–88 (61 ref.)

Nitric oxide–cyclic GMP signal transduction system. Hobbs AJ, et al. **Methods Enzymol** 1996;269:134–48 (13 ref.)

Dynamic aspects of nitric oxide metabolism in the circulation and tissues. Inoue M, et al. **Methods Enzymol** 1996; 269:474–9 (17 ref.)

Nitric oxide generation from pharmacological nitric oxide donors. Kishnani NS, et al. **Methods Enzymol** 1996; 268:259–65 (27 ref.)

Detection of nitric oxide interaction with zinc finger proteins. Kröncke KD, et al. **Methods Enzymol** 1996;269:279–84 (26 ref.)

Nitric oxide in platelets. Radomski MW, et al. **Methods Enzymol** 1996;269:88–107 (51 ref.)

Interactions of nitric oxide with cyclooxygenase: in vitro, ex vivo, and in vivo studies. Salvemini D, et al. **Methods Enzymol** 1996;269:12–25 (40 ref.)

Nitric oxide–cyclic GMP pathway in brain slices. Southam E, et al. **Methods Enzymol** 1996;269:129–33 (13 ref.)

Interaction of cytochrome–c oxidase with nitric oxide. Torres J, et al. **Methods Enzymol** 1996;269:3–11 (16 ref.)

Use of L–arginine and its analogs to study nitric oxide pathway in humans. Vallance P. **Methods Enzymol** 1996; 269:453–9 (25 ref.)

Soil microorganisms as controllers of atmospheric trace gases (H2, CO, CH4, OCS, N2O, and NO). Conrad R. **Microbiol Rev** 1996 Dec;60(4):609–40 (602 ref.)

Myocardial infarction and nitric oxide. Bing RJ, et al. **Mol Cell Biochem** 1996 Jul–Aug;160–161:303–6 (30 ref.)

Nitric oxide and inflammation: the answer is blowing in the wind. Lundberg JO, et al. **Nat Med** 1997 Jan;3(1):30–1 (19 ref.)

Role of nitric oxide and superoxide balance in hypoxia–reoxygenation proximal tubular injury. Yaqoob M, et al. **Nephrol Dial Transplant** 1996 Sep;11(9):1738–42 (34 ref.)

Role of nitric oxide and superoxide balance in

hypoxia–reoxygenation proximal tubular injury. Yaqoob M, et al. **Nephrol Dial Transplant** 1996 Sep;11(9):1743–6 (34 ref.)

NO–donors and angina pectoris: more than just symptomatic treatment? Cleophas TJ, et al. **Neth J Med** 1997 Apr; 50(4):180–3 (24 ref.)

Nitric oxide precursor arginine and S–nitrosoglutathione in synaptic and glial function. Do KQ, et al. **Neurochem Int** 1996 Sep;29(3):213–24 (94 ref.)

(S)NO signals: translocation, regulation, and a consensus motif. Stamler JS, et al. **Neuron** 1997 May;18(5):691–6 (60 ref.)

Mechanisms involved in the generation of free radicals. Halliwell B. **Pathol Biol (Paris)** 1996 Jan;44(1):6–13 (68 ref.)

Tetrahydrobiopterin, nitric oxide and regulation of cerebral arterial tone. Kinoshita H, et al. **Prog Neurobiol** 1997 Jul; 52(4):295–302 (77 ref.)

The role of nitric oxide in respiratory disease. Marriott H, et al. **Schweiz Med Wochenschr** 1997 Apr 26;127(17):709–14 (28 ref.)

Dietary L–arginine in renal disease. Peters H, et al. **Semin Nephrol** 1996 Nov;16(6):567–75 (64 ref.)

Hemoglobin–nitric oxide interaction and its implications. Motterlini R, et al. **Transfus Med Rev** 1996 Apr;10(2):77–84 (48 ref.)

Bright and dark sides of nitric oxide in ischemic brain injury. Iadecola C. **Trends Neurosci** 1997 Mar;20(3):132–9 (73 ref.)

[Regulation of cardiac calcium current by cGMP/NO route] Fischmeister R, et al. **C R Seances Soc Biol Fil** 1996; 190(2–3):181–206 (221 ref.) (Eng. Abstr.) **(Fre)**

[Nitrogen monoxide (NO) in the function of the gastrointestinal tract and the liver] Palatka K, et al. **Orv Hetil** 1997 Jun 15;138(24):1555–9 (51 ref.) (Eng. Abstr.) **(Hun)**

PHARMACOKINETICS

Extracellular superoxide dismutase: a regulator of nitric oxide bioavailability. Oury TD, et al. **Lab Invest** 1996 Nov; 75(5):617–36 (144 ref.)

PHARMACOLOGY

Effect of nitric oxide, prostacyclin, and thromboxane on the vasospastic action of hydrogen peroxide on human umbilical artery. Okatani Y, et al. **Acta Obstet Gynecol Scand** 1997 Jul;76(6):515–20 (24 ref.)

Nitric oxide influences dopaminergic processes. Liu Y. **Adv Neuroimmunol** 1996;6(3):259–64 (29 ref.)

Indirect detection of nitric oxide effects: a review. Kiechle FL, et al. **Ann Clin Lab Sci** 1996 Nov–Dec;26(6):501–11 (87 ref.)

Modulation by nitric oxide of metalloprotein regulatory activities. Drapier JC, et al. **Bioessays** 1996 Jul;18(7):549–56 (89 ref.)

N–methyl–D–aspartate receptors, nitric oxide, and ethanol tolerance. Morato GS, et al. **Braz J Med Biol Res** 1996 Nov;29(11):1415–26 (138 ref.)

Nitric oxide and related vasodilators. Young JD. **Can J Anaesth** 1997 May;44(5 Pt 2):R23–33 (46 ref.) **(Eng, Fre)**

Calcium antagonists and endothelial function: focus on nitric oxide and endothelin. Godfraind T, et al. **Cardiovasc Drugs Ther** 1996 Sep;10(4):439–46 (44 ref.)

Medical perspectives of nitric oxide. Wang Z. **Chin Med J (Engl)** 1996 Jan;109(1):60–2 (0 ref.)

A proposed mechanism for the cardioprotective effect of oestrogen in women: enhanced endothelial nitric oxide release decreases coronary artery reactivity. Wellman GC, et al. **Clin Exp Pharmacol Physiol** 1996 Mar;23(3):260–6 (70 ref.)

Synaptic signaling by nitric oxide. Brenman JE, et al. **Curr Opin Neurobiol** 1997 Jun;7(3):374–8 (43 ref.)

No–donors: an emerging class of compounds in medicinal chemistry [published erratum appears in Farmaco 1997 Jan;52(1):71] Gasco A, et al. **Farmaco** 1996 Oct; 51(10):617–35 (171 ref.)

Neurotoxic and neuroprotective roles of nitric oxide in cerebral ischaemia. Dalkara T, et al. **Int Rev Neurobiol** 1997;40:319–36 (132 ref.)

Impact of nitric oxide on renal hemodynamics and glomerular function: modulation by atherogenic lipoproteins? Galle J, et al. **Kidney Blood Press Res** 1996;19(1):2–15 (180 ref.)

The role of nitric oxide synthase pathway on bradykinin–induced bronchoconstriction in guinea–pigs and in man. Ricciardolo FL, et al. **Monaldi Arch Chest Dis** 1996 Dec;51(6):543–7 (52 ref.)

Nitric oxide and lung surfactant. Hallman M, et al. **Semin Perinatol** 1996 Jun;20(3):173–85 (101 ref.)

Nitric oxide, intracellular calcium overload, and cytotoxicity [editorial; comment] Szabó C. **Shock** 1996 Jul;6(1):25–6 (17 ref.) Comment on: Shock 1996 Jul;6(1):19–24.

Nitric oxide supplementation or synthesis block--which is the better approach to treatment of heart disease? Curtis MJ, et al. **Trends Pharmacol Sci** 1997 Jul;18(7):239–44 (63 ref.)

[Cardiovascular effects of arginine and nitric oxide] Faintuch J, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Nov–Dec; 50(6):334–8 (28 ref.) (Eng. Abstr.) **(Por)**

PHYSIOLOGY

Peroxynitrite: mediator of the toxic action of nitric oxide. Bartosz G. **Acta Biochim Pol** 1996;43(4):645–59 (123 ref.)

From Polyplacophora to Cephalopoda: comparative analysis of nitric oxide signalling in mollusca. Moroz LL, et al. **Acta Biol Hung** 1995;46(2–4):169–82 (55 ref.)

Sepsis and nitric oxide. Avontuur JA, et al. **Adv Exp Med Biol** 1996;388:551–67 (128 ref.)

DNA damage and nitric oxide. Keefer LK, et al. **Adv Exp Med Biol** 1996;387:177–85 (30 ref.)

Inhibition of cytochrome P450 enzymes by nitric oxide. Stadler J, et al. **Adv Exp Med Biol** 1996;387:187–93 (43 ref.)

Role of nitric oxide in cell–mediated tumor cytotoxicity. Cifone MG, et al. **Adv Neuroimmunol** 1995;5(4):443–61 (145 ref.)

Induction of nitric oxide in cultured microglia: evidence for a cytoprotective role. Colton CA. **Adv Neuroimmunol** 1995; 5(4):491–503 (57 ref.)

NO–synthase: what can research on invertebrates add to what is already known? Johansson KU, et al. **Adv Neuroimmunol** 1995;5(4):431–42 (77 ref.)

Detection of endothelial cell–derived nitric oxide: current trends and future directions. Magazine HI. **Adv Neuroimmunol** 1995;5(4):479–90 (49 ref.)

Mechanisms for nitric oxide–induced cell death: involvement of apoptosis. Nicotera P, et al. **Adv Neuroimmunol** 1995; 5(4):411–20 (58 ref.)

Nitric oxide in the liver: physiopathological roles. Suzuki H, et al. **Adv Neuroimmunol** 1995;5(4):379–410 (145 ref.)

Neuroprotective and deleterious effects of nitric oxide on focal cerebral ischemia–induced neurone death. Verrecchia C, et al. **Adv Neuroimmunol** 1995;5(4):359–78 (181 ref.)

Nitric oxide and parasitic disease. Clark IA, et al. **Adv Parasitol** 1996;37:1–56 (368 ref.)

Nitric oxide in renal health and disease. Kone BC. **Am J Kidney Dis** 1997 Sep;30(3):311–33 (217 ref.)

A critical role for nitric oxide in intestinal barrier function and dysfunction. Alican I, et al. **Am J Physiol** 1996 Feb; 270(2 Pt 1):G225–37 (106 ref.)

Biosynthesis and homeostatic roles of nitric oxide in the normal kidney. Kone BC, et al. **Am J Physiol** 1997 May; 272(5 Pt 2):F561–78 (222 ref.)

Nitric oxide and pregnancy. Sladek SM, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):R441–63 (256 ref.)

Autotoxicity of nitric oxide in airway disease. Flak TA, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 2):S202–6 (46 ref.)

Chemistry, analysis, and biological roles of S–nitrosothiols. Butler AR, et al. **Anal Biochem** 1997 Jun 15;249(1):1–9 (89 ref.)

Nitric oxide in the vasculature: physiology and pathophysiology. Moncada S. **Ann N Y Acad Sci** 1997 Apr 15;811:60–7; discussion 67–9 (52 ref.)

Interplay of VIP and nitric oxide in the regulation of neuromuscular function in the gut. Murthy KS, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:355–62; discussion 362–3 (27 ref.)

Vasoactive intestinal peptide and nitric oxide: divergent roles in relation to tissue injury. Said SI. **Ann N Y Acad Sci** 1996 Dec 26;805:379–87; discussion 387–8 (60 ref.)

The role of nitric oxide in vascular biology and pathobiology. Dattilo JB, et al. **Ann Vasc Surg** 1997 May;11(3):307–14 (55 ref.)

Nitric oxide and the surgical patient. Identifying therapeutic targets. Tzeng E, et al. **Arch Surg** 1997 Sep;132(9):977–82 (42 ref.)

The L–arginine–nitric oxide pathway: role in atherosclerosis and therapeutic implications. Böger RH, et al. **Atherosclerosis** 1996 Nov 15;127(1):1–11 (120 ref.)

Nitric oxide--biological mediator, modulator and factor of injury: its role in the pathogenesis of atherosclerosis. Radomski MW, et al. **Atherosclerosis** 1995 Dec;118 Suppl:S69–80 (122 ref.)

The influence of oxidized lipoproteins, oxidation products and antioxidants on the release of nitric oxide from the endothelium and the response of platelets to nitric oxide. Bruckdorfer KR, et al. **Biofactors** 1997;6(2):191–9 (49 ref.)

Nitric oxide and the immature kidney. Ballèvre L, et al. **Biol Neonate** 1996;70(1):1–14 (96 ref.)

The potential role of nitric oxide in angiotensin II–receptor blockade. Cachofeiro V, et al. **Blood Press Suppl** 1996; 2:29–35 (49 ref.)

Superoxide, hydrogen peroxide and nitric oxide as signalling molecules: their production and role in disease. Hancock JT. **Br J Biomed Sci** 1997 Mar;54(1):38–46 (110 ref.)

Nitric oxide in critical care medicine. Cuthbertson BH, et al. **Br J Hosp Med** 1995 Dec 13–1996 Jan 16;54(11):579–82 (15 ref.)

The Michael Mason Prize Essay 1997. Nitric oxide and bone: what a gas! Ralston SH. **Br J Rheumatol** 1997 Aug; 36(8):831–8 (87 ref.)

Interleukin–1, nitric oxide and reactive astrocytes. Lee SC, et al. **Brain Behav Immun** 1995 Dec;9(4):345–54 (48 ref.)

Physiological and pathophysiological roles of nitric oxide in the central nervous system. Szabó C. **Brain Res Bull** 1996;41(3):131–41 (223 ref.)

Nitric oxide: a unique biologic mediator [see comments] el–Defrawy SR. **Can J Ophthalmol** 1997 Feb;32(1):12–6 (53 ref.) Comment in: Can J Ophthalmol 1997 Feb;32(1):1–3.

The role of nitric oxide and cell adhesion molecules on the microcirculation in ischaemia–reperfusion. Lefer AM, et al. **Cardiovasc Res** 1996 Oct;32(4):743–51 (70 ref.)

Regulation of cellular thiol redox status by nitric oxide. Padgett CM, et al. **Cell Biochem Biophys** 1995;27(3):157–77 (72 ref.)

Regulation of cyclooxygenase enzymes by nitric oxide. Salvemini D. **Cell Mol Life Sci** 1997 Jul;53(7):576–82 (60 ref.)

Nitric oxide regulation of tissue free radical injury. Rubbo H, et al. **Chem Res Toxicol** 1996 Jul–Aug;9(5):809–20 (135 ref.)

DNA damage by nitric oxide. Tamir S, et al. **Chem Res Toxicol** 1996 Jul–Aug;9(5):821–7 (61 ref.)

Coronary and systemic hemodynamic effects of sustained inhibition of nitric oxide synthesis in conscious dogs. Evidence for cross talk between nitric oxide and cyclooxygenase in coronary vessels. Puybasset L, et al. **Circ Res** 1996 Aug;79(2):343–57 (51 ref.)

Nitric oxide: nature's naturally occurring leukocyte inhibitor [editorial; comment] Lefer AM. **Circulation** 1997 Feb 4; 95(3):553–4 (39 ref.) Comment on: Circulation 1997 Feb 4;95(3):662–8.

What are the molecular mechanisms for the antiproliferative effects of nitric oxide and cGMP in vascular smooth muscle? [editorial; comment] Murad F. **Circulation** 1997 Mar 4;95(5):1101–3 (16 ref.) Comment on: Circulation 1997 Mar 4;95(5):1269–77.

Nitric oxide in sepsis. Payen D, et al. **Clin Chest Med** 1996 Jun;17(2):333–50 (169 ref.)

Nitric oxide: initiator and modulator [editorial; comment] Nijkamp FP, et al. **Clin Exp Allergy** 1997 Apr;27(4):347–50 (39 ref.) Comment on: Clin Exp Allergy 1997 Apr;27(4):358–62.

Recent insights into the regulation of cerebral circulation. Brian JE Jr, et al. **Clin Exp Pharmacol Physiol** 1996 Jun–Jul; 23(6–7):449–57 (111 ref.)

Cardiovascular protection by ginsenosides and their nitric oxide releasing action. Chen X. **Clin Exp Pharmacol Physiol** 1996 Aug;23(8):728–32 (19 ref.)

Role of nitric oxide in the control of glomerular microcirculation. Ito S, et al. **Clin Exp Pharmacol Physiol** 1997 Aug;24(8):578–81 (18 ref.)

Cooperative modulation of gastrointestinal mucosal defence by prostaglandins and nitric oxide. Wallace JL. **Clin Invest Med** 1996 Oct;19(5):346–51 (52 ref.)

Role of oxidants in microbial pathophysiology. Miller RA, et al. **Clin Microbiol Rev** 1997 Jan;10(1):1–18 (334 ref.)

Role of nitric oxide in retinal cell death. Roth S. **Clin Neurosci** 1997;4(5):216–23 (98 ref.)

Role of nitric oxide in immune–mediated diseases [editorial] Cook HT, et al. **Clin Sci (Colch)** 1996 Oct;91(4):375–84 (111 ref.)

Nitric oxide, cell multiplication, and cell survival. Peunova N, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:417–26 (54 ref.)

Evidence for a role of nitric oxide in hypertension and in renal disease in man. Noris M, et al. **Contrib Nephrol** 1996; 119:8–15 (15 ref.)

Just say no to NO., yes? [editorial] Fink MP. **Crit Care Med** 1996 Nov;24(11):1772–4 (30 ref.)

Neurobiology of nitric oxide. Yun HY, et al. **Crit Rev Neurobiol** 1996;10(3–4):291–316 (225 ref.)

Synaptic plasticity: a role for nitric oxide in LTP. Huang EP. **Curr Biol** 1997 Mar 1;7(3):R141–3 (12 ref.)

Lipids and endothelial function: effects of lipid–lowering and other therapeutic interventions. Lüscher TF, et al. **Curr Opin Lipidol** 1996 Aug;7(4):234–40 (67 ref.)

Nitric oxide mediates the cardiovascular instability of haemodialysis patients. Yokokawa K, et al. **Curr Opin Nephrol Hypertens** 1996 Jul;5(4):359–63 (67 ref.)

Maintenance of vascular integrity: role of nitric oxide and other bradykinin mediators. Cosentino F, et al. **Eur Heart J** 1995 Nov;16 Suppl K:4–12 (122 ref.)

Nitric oxide, the biological mediator of the decade: fact or fiction? Singh S, et al. **Eur Respir J** 1997 Mar;10(3):699–707 (112 ref.)

Role of nitric oxide in cell adhesion and locomotion. Goligorsky MS, et al. **Exp Nephrol** 1996 Nov–Dec; 4(6):314–21 (71 ref.)

Disruption of vascular signalling by the reaction of nitric oxide with superoxide: implications for cardiovascular disease. Darley–Usmar V, et al. **Exp Physiol** 1997 Mar; 82(2):305–16 (85 ref.)

Role of nitric oxide in regulation of leucocyte–endothelial cell interactions. Hickey MJ, et al. **Exp Physiol** 1997 Mar; 82(2):339–48 (38 ref.)

Endothelial barrier dysfunction and oxidative stress: roles for nitric oxide? McQuaid KE, et al. **Exp Physiol** 1997 Mar; 82(2):369–76 (30 ref.)

Dysfunction of the endothelial nitric oxide signalling pathway in diabetes and hyperglycaemia. Sobrevia L, et al. **Exp Physiol** 1997 May;82(3):423–52 (188 ref.)

Nitric oxide in coronary artery disease: roles in atherosclerosis, myocardial reperfusion and heart failure. Dusting GJ. **EXS** 1996;76:33–55 (108 ref.)

Nitric oxide: an endogenous cardioprotectant? Pabla R, et al. **EXS** 1996;76:71–85 (57 ref.)

Neural regulation of coronary vascular resistance: role of nitric oxide in reflex cholinergic coronary vasodilation in normal and pathophysiologic states. Zhao G, et al. **EXS** 1996;76:1–19 (94 ref.)

Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression. Ambs S, et al. **FASEB J** 1997 May;11(6):443–8 (89 ref.)

The importance of L–arginine metabolism in melanoma: an

hypothesis for the role of nitric oxide and polyamines in tumor angiogenesis. Joshi M. **Free Radic Biol Med** 1997; 22(3):573–8 (63 ref.)

The role of astroglial cell–derived nitric oxide and prostanoids in neurodegenerative disorders. Mollace V, et al. **Funct Neurol** 1997 May–Aug;12(3–4):199–203 (24 ref.)

"Ottorino Rossi" Award 1997. The biology of nitric oxide. Moncada S. **Funct Neurol** 1997 May–Aug;12(3–4):134–40 (31 ref.)

Resolving the nitric oxide paradox in acute tissue damage [editorial] Billiar TR, et al. **Gastroenterology** 1997 Oct; 113(4):1405–7 (13 ref.)

Superoxide anions, free–radical scavengers, and nitrergic neurotransmission. Gibson A, et al. **Gen Pharmacol** 1997 Apr;28(4):489–93 (37 ref.)

The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Rockey D. **Hepatology** 1997 Jan;25(1):2–5 (43 ref.)

The physiology and pathophysiology of the nitric oxide/superoxide system. Münzel T, et al. **Herz** 1997 Jun; 22(3):158–72 (89 ref.)

Bradykinin and nitric oxide in infectious disease and cancer. Maeda H, et al. **Immunopharmacology** 1996 Jun; 33(1–3):222–30 (34 ref.)

Physiological and clinical importance of nitric oxide. Madan G, et al. **Indian J Med Sci** 1996 Sep;50(9):318–24 (34 ref.)

Nitric oxide and the brain. Pelligrino DA, et al. **Int Anesthesiol Clin** 1996 Fall;34(4):113–32 (106 ref.)

Nitric oxide: biological and clinical perspectives [editorial] Saklayen MG, et al. **Int J Artif Organs** 1996 Nov; 19(11):630–2 (17 ref.)

The role of nitric oxide in sepsis and ARDS: synopsis of a roundtable conference held in Brussels on 18–20 March 1995. Fink MP, et al. **Intensive Care Med** 1996 Feb; 22(2):158–65 (103 ref.)

Physiologic, pathophysiologic, and therapeutic implications for endogenous nitric oxide [see comments] Adams HR. **J Am Vet Med Assoc** 1996 Oct 1;209(7):1297–302 (35 ref.) Comment in: J Am Vet Med Assoc 1997 Apr 1;210(7):888.

Clinical significance of L–arginine—nitric oxide system. Das UN. **J Assoc Physicians India** 1995 Feb;43(2):122–6 (65 ref.)

How can we protect our endothelium? [editorial] Hakim A, et al. **J Assoc Physicians India** 1995 Feb;43(2):85–7 (27 ref.)

Paracrine coronary endothelial modulation of diastolic left ventricular function in man: implications for diastolic heart failure. Paulus WJ. **J Card Fail** 1996 Dec;2(4 Suppl):S155–64 (80 ref.)

Effects of nitric oxide on glutamate–gated channels and other ionic channels. Fagni L, et al. **J Chem Neuroanat** 1996 Jun; 10(3–4):231–40 (55 ref.)

Neurogenic nitric oxide (NO) in the regulation of cerebroarterial tone. Toda N, et al. **J Chem Neuroanat** 1996 Jun;10(3–4):259–65 (40 ref.)

Oxides, onions, and other matters gastrointestinal—1996—a perspective. Kapadia CR. **J Clin Gastroenterol** 1997 Apr; 24(3):133–9 (50 ref.)

Perspectives series: host/pathogen interactions. Mechanisms of nitric oxide–related antimicrobial activity. Fang FC. **J Clin Invest** 1997 Jun 15;99(12):2818–25 (73 ref.)

Cardiovascular derangement in septic shock and nitric oxide [editorial; comment] Lodato RF. **J Crit Care** 1996 Dec; 11(4):151–4 (21 ref.) Comment on: J Crit Care 1996 Dec;11(4):155–66.

Control of the human cardiovascular system by nitric oxide. Vallance P. **J Hum Hypertens** 1996 Jun;10(6):377–81 (31 ref.)

Endothelin and nitric oxide in hepatorenal syndrome: a balance reset. Epstein M, et al. **J Nephrol** 1997 May–Jun; 10(3):120–35 (158 ref.)

Gaseous second messengers in vertebrate olfaction. Broillet MC, et al. **J Neurobiol** 1996 May;30(1):49–57 (65 ref.)

Exploring vascular nitric oxide in health and disease. The Goulstonian Lecture 1996. Vallance P. **J R Coll Physicians Lond** 1997 May–Jun;31(3):321–7 (24 ref.)

Nitric oxide 9 years on. Bhagat K, et al. **J R Soc Med** 1996 Dec;89(12):667–73 (33 ref.)

Role of cross talk between superoxide and NO in the energy metabolism and pathogenesis of vasogenic tissue injury. Inoue M. **J Toxicol Sci** 1996 Dec;21(5):289 (0 ref.)

The role of nitric oxide in cardiac ischemia–reperfusion injury. Nonami Y. **Jpn Circ J** 1997 Feb;61(2):119–32 (69 ref.)

Is nitric oxide really important for regulation of the cerebral circulation? Yes or no? Tanaka K. **Keio J Med** 1996 Mar; 45(1):14–27 (154 ref.)

Nitric oxide and renal autoregulation. Just A. **Kidney Blood Press Res** 1997;20(3):201–4 (60 ref.)

The role of nitric oxide in experimental glomerulonephritis. Ketteler M, et al. **Kidney Blood Press Res** 1996; 19(3–4):177–81 (50 ref.)

Importance of nitric oxide in the control of renal hemodynamics. Baylis C, et al. **Kidney Int** 1996 Jun; 49(6):1727–31 (36 ref.)

Physiology and pathophysiology of nitric oxide. Ignarro LJ. **Kidney Int Suppl** 1996 Jun;55:S2–5 (44 ref.)

Nitric oxide in the juxtaglomerular apparatus. Ito S, et al. **Kidney Int Suppl** 1996 Jun;55:S6–8 (34 ref.)

Insights into the role of nitric oxide in inflammatory arthritis. Cochran FR, et al. **Med Res Rev** 1996 Nov;16(6):547–63 (114 ref.)

Nitric oxide signaling in the nervous system. Brenman JE, et al. **Methods Enzymol** 1996;269:119–29 (78 ref.)

Nitric oxide– and nitric oxide donor–induced relaxation. Ku DD. **Methods Enzymol** 1996;269:107–19 (20 ref.)

Cyclic GMP–dependent protein kinase in nitric oxide signaling. Lincoln TM, et al. **Methods Enzymol** 1996; 269:149–66 (91 ref.)

Nitric oxide and atherosclerosis: possible implications for therapy. Bult H. **Mol Med Today** 1996 Dec;2(12):510–8 (47 ref.)

Nitric oxide: a spatial second messenger. Schulman H. **Mol Psychiatry** 1997 Jul;2(4):296–9 (24 ref.)

Nitric oxide in health and disease of the nervous system. Yun HY, et al. **Mol Psychiatry** 1997 Jul;2(4):300–10 (146 ref.)

Nitric oxide (NO) in renal physiology and pathophysiology [editorial] Baylis C, et al. **Nephrol Dial Transplant** 1996 Oct;11(10):1955–7 (13 ref.)

Nitric oxide and acute renal failure [editorial] [see comments] Peer G, et al. **Nephron** 1996;73(3):375–81 (82 ref.) Comment in: Nephron 1997;76(1):121.

The enigma of potassium ion in the management of dentine hypersensitivity: is nitric oxide the elusive second messenger? McCormack K, et al. **Pain** 1996 Nov;68(1):5–11 (89 ref.)

Nitric oxide in the developing kidney. Solhaug MJ, et al. **Pediatr Nephrol** 1996 Aug;10(4):529–39 (91 ref.)

Interaction of nitric oxide with myogenic and adrenergic vasoconstrictor processes in the control of microcirculatory blood flow. Pohl U, et al. **Pflugers Arch** 1996;432(3 Suppl):R107–10 (46 ref.)

International Union of Pharmacology Nomenclature in Nitric Oxide Research. Moncada S, et al. **Pharmacol Rev** 1997 Jun;49(2):137–42 (58 ref.)

Nitric oxide and the myometrium. Norman J. **Pharmacol Ther** 1996;70(2):91–100 (70 ref.)

Endothelial nitric oxide, prostacyclin (PGI2) and tissue plasminogen activator (t–PA): alliance or neutrality? Gryglewski RJ. **Pol J Pharmacol** 1995 Sep–Oct; 47(5):467–72 (22 ref.)

The role of NMDA receptors and nitric oxide in retinogeniculate development. Cramer KS, et al. **Prog Brain Res** 1996;108:235–44 (84 ref.)

Modulation of acetylcholine release by nitric oxide. Kilbinger H. **Prog Brain Res** 1996;109:219–24 (33 ref.)

Nitric oxide and the developmental remodeling of retinal connections in the brain. Wu HH, et al. **Prog Brain Res** 1996;108:273–86 (81 ref.)

Nitric oxide and fibroblast growth factor in autonomic nervous system: short– and long–term messengers in autonomic pathway and target–organ control. Blottner D. **Prog Neurobiol** 1997 Mar;51(4):423–38 (225 ref.)

The nitric oxide system in insects. Müller U. **Prog Neurobiol** 1997 Feb;51(3):363–81 (146 ref.)

Interaction between nitric oxide and cyclooxygenase pathways. Di Rosa M, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Apr; 54(4):229–38 (127 ref.)

Pathophysiology of the vascular wall: the role of nitric oxide in renal disease. Raij L, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Jan; 54(1):53–8 (83 ref.)

Nitric oxide and asthma. Barnes PJ. **Res Immunol** 1995 Nov–Dec;146(9):698–702 (51 ref.)

Nitric oxide production in human inflammatory processes. Dugas B, et al. **Res Immunol** 1995 Nov–Dec;146(9):661–3 (0 ref.)

Nitric oxide, a vital poison inside the immune and inflammatory network. Dugas B, et al. **Res Immunol** 1995 Nov–Dec;146(9):664–70 (45 ref.)

Immune regulatory role of nitric oxide within the central nervous system. Dugas N, et al. **Res Immunol** 1995 Nov–Dec;146(9):707–10 (27 ref.)

The action of NO and its role in autoimmune diabetes mellitus. Fehsel K, et al. **Res Immunol** 1995 Nov–Dec; 146(9):711–5 (68 ref.)

The antiviral role of nitric oxide. Mannick JB. **Res Immunol** 1995 Nov–Dec;146(9):693–7 (41 ref.)

Nitric oxide, hepatocytes and inflammation. Nussler AK, et al. **Res Immunol** 1995 Nov–Dec;146(9):671–77 (62 ref.)

Nitric oxide in human haematopoiesis. Ouaaz F. **Res Immunol** 1995 Nov–Dec;146(9):678–81 (34 ref.)

Nitric oxide and human infectious diseases. Vouldoukis I, et al. **Res Immunol** 1995 Nov–Dec;146(9):689–92 (31 ref.)

Nitric oxide, a neuronal messenger. Its role in the hippocampus neuronal plasticity. Salemme E, et al. **Riv Biol** 1996;89(1):87–107 (37 ref.) **(Eng, Ita)**

Nitric oxide in learning and memory. Jachimowicz A, et al. **Rocz Akad Med Bialymst** 1996;41(2):161–75 (81 ref.)

Role of oxidative stress in the pathogenesis of acute pancreatitis. Sweiry JH, et al. **Scand J Gastroenterol Suppl** 1996;219:10–5 (47 ref.)

Nitric oxide, intracellular calcium overload, and cytotoxicity [editorial; comment] Szabó C. **Shock** 1996 Jul;6(1):25–6 (17 ref.) Comment on: Shock 1996 Jul;6(1):19–24.

The role of nitric oxide in cardiac surgery. Nonami Y. **Surg Today** 1997;27(7):583–92 (95 ref.)

Nitric oxide in the eye: multifaceted roles and diverse outcomes. Becquet F, et al. **Surv Ophthalmol** 1997 Jul–Aug; 42(1):71–82 (110 ref.)

Targeted deletion of neuronal nitric oxide: a step closer to understanding its functional significance? Good M. **Trends Neurosci** 1996 Mar;19(3):83–4 (11 ref.)

Nitric oxide, the enigmatic neuronal messenger: its role in synaptic plasticity. Hölscher C. **Trends Neurosci** 1997 Jul; 20(7):298–303 (93 ref.)

The cross–talk between nitric oxide and Ca2+: a story with a complex past and a promising future. Clementi E, et al. **Trends Pharmacol Sci** 1997 Aug;18(8):266–9 (39 ref.)

Nitric oxide supplementation or synthesis block—which is the better approach to treatment of heart disease? Curtis MJ, et al. **Trends Pharmacol Sci** 1997 Jul;18(7):239–44 (63 ref.)

Nitric oxide: inducer or suppressor of apoptosis? Nicotera P, et al. **Trends Pharmacol Sci** 1997 Jun;18(6):189–90 (8 ref.)

Nitric oxide, nitrogen metabolism and inflammatory respiratory disease. An hypothesis. Janson L, et al. **Ups J Med Sci** 1997;102(1):21–33 (51 ref.)

Nitric oxide: a review of its role in retinal function and disease. Goldstein IM, et al. **Vision Res** 1996 Sep; 36(18):2979–94 (173 ref.)

[Nitric oxide—a basic mediator of vasodilation and septic shock] Vasilev D, et al. **Khirurgiia (Sofiia)** 1996;49(4):14–6 (35 ref.) (Eng. Abstr.) **(Bul)**

[The participation of nitric oxide in the functions of the central nervous system and the cardiovascular system] Krushkov I, et al. **Mol Med (Sofia)** 1996;1(2):21–7 (15 ref.) (Eng. Abstr.) **(Bul)**

[The retrograde messengers in hippocampal long–term potentiation] Hu ZA, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan;27(1):82–4 (7 ref.) **(Chi)**

[Antiplatelet properties of nitrogen monoxide] Adrie C. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1527–32 (55 ref.) (Eng. Abstr.) **(Fre)**

[Role of nitric oxide in maintaining the mucosal integrity and in inflammatory gastrointestinal diseases] Lamarque D, et al. **Gastroenterol Clin Biol** 1996;20(12):1085–98 (213 ref.) **(Fre)**

[Role of nitric oxic in pregnancy and pre–eclampsia] Boulanger H, et al. **Nephrologie** 1997;18(3):81–90 (117 ref.) (Eng. Abstr.) **(Fre)**

[Kidney and nitric oxide] Dimitrov Y, et al. **Nephrologie** 1997; 18(2):41–6 (42 ref.) (Eng. Abstr.) **(Fre)**

[Role of nitric oxide in the regulation of arterial pressure and renal function] Dussaule JC, et al. **Presse Med** 1996 Nov 23;25(36):1789–93 (22 ref.) (Eng. Abstr.) **(Fre)**

[Role of nitric oxide in respiratory physiology and in the physiopathology of pulmonary diseases] Dinh–Xuan AT. **Rev Mal Respir** 1996;13(4):381–8 (30 ref.) (Eng. Abstr.) **(Fre)**

[Nitric oxide] Bauer M. **Anaesthesist** 1997 May;46(5):441–50 (7 ref.) **(Ger)**

[Nitrogen monoxide: mediator of tissue repair?] Schäffer M, et al. **Dtsch Med Wochenschr** 1997 Mar 14;122(11):339–45 (50 ref.) **(Ger)**

[Endothelial dysfunction and nitrogen monoxide (NO; nitric oxide)] Lüscher TF, et al. **Internist (Berl)** 1997 May; 38(5):411–9 (57 ref.) **(Ger)**

[Formation and effects of nitrogen monoxide (NO) in the vascular system] Schmidt HH, et al. **Internist (Berl)** 1997 May;38(5):406–10 (23 ref.) **(Ger)**

[Nitrogen monoxide. Mediator or marker of chronic inflammation?] Stichtenoth DO. **Internist (Berl)** 1997 May; 38(5):420–6 (49 ref.) **(Ger)**

[Pathogenetic aspects of the L–arginine–NO metabolic pathway in arteriosclerosis and possible therapeutic aspects] Böger RH, et al. **Vasa** 1996;25(4):305–16 (107 ref.) (Eng. Abstr.) **(Ger)**

[Sympathetic nervous system in heart failure: effect of catecholamines and nitric oxide] Drexler H. **Z Kardiol** 1996; 85 Suppl 6:247–52 (30 ref.) (Eng. Abstr.) **(Ger)**

[Nitric oxide and carbon monoxide—a new generation of neuronal messengers] Gazit V, et al. **Harefuah** 1996 Jun 16;130(12):854–8 (15 ref.) **(Heb)**

[Nitric oxide—a small gas molecule with many clinical implications] Sela BA. **Harefuah** 1996 Sep;131(5–6):184–8 (36 ref.) **(Heb)**

[The L–arginine–nitric oxide system: physiology, physiopathology and clinical relevance] Garini G, et al. **Recenti Prog Med** 1997 Feb;88(2):90–9 (74 ref.) (Eng. Abstr.) **(Ita)**

[Inhibitory neuronal control of smooth muscle activity of the gastrointestinal tract] Hata F, et al. **Nippon Yakurigaku Zasshi** 1997 Feb;109(2):61–73 (51 ref.) (Eng. Abstr.) **(Jpn)**

[Function of soluble guanylate cyclase and nitric oxide] Makino R. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):379–84 (55 ref.) **(Jpn)**

[Gaseous monoxides as an endogenous modulator of organ function—application of multifunctional digital microfluorography] Suematsu M, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1075–9 (10 ref.) **(Jpn)**

[Nitric oxide and sepsis] Knobel E. **Arq Bras Cardiol** 1996 Oct;67(4):263–6 (13 ref.) **(Por)**

[Nitric oxide—a novel physiological messenger: possible role in central nervous system pathology] Raevskii KS. **Biull Eksp Biol Med** 1997 May;123(5):484–90 (43 ref.) **(Rus)**

[The role of nitric oxide in cardiology and gastroenterology] Zhuravleva IA, et al. **Klin Med (Mosk)** 1997;75(4):18–21 (33 ref.) **(Rus)**

[The role of nitric oxide in regulating pulmonary functions]

Nevzorova VA, et al. **Ter Arkh** 1997;69(3):68–73 (104 ref.) **(Rus)**

[The functional role of nitric oxide in the central nervous system] Gurin AV. **Usp Fiziol Nauk** 1997 Jan–Mar; 28(1):53–60 (91 ref.) (Eng. Abstr.) **(Rus)**

[Nitric oxide and carbon monoxide—a new class of signal molecules] Markov KhM. **Usp Fiziol Nauk** 1996 Oct–Dec; 27(4):30–43 (107 ref.) (Eng. Abstr.) **(Rus)**

[Nitric oxide in renal physiology and pathology] Markov KhM. **Vestn Ross Akad Med Nauk** 1996;(7):73–8 (61 ref.) **(Rus)**

[The effect of nitric oxide on the regulation of gastric blood flow] Calatayud S, et al. **Gastroenterol Hepatol** 1997 May; 20 Suppl 2:33–6 (50 ref.) **(Spa)**

THERAPEUTIC USE

Pharmacologic approaches to reperfusion injury. Willerson JT. **Adv Pharmacol** 1997;39:291–312 (120 ref.)

Nitric oxide and the lung: an overview. Head CA. **Artif Organs** 1997 Jan;21(1):5–9 (26 ref.)

Advances in the management of respiratory failure. Nitric oxide. Steinhorn RH. **ASAIO J** 1996 May–Jun; 42(3):199–200 (16 ref.)

Clinical aspects of nitric oxide and surfactant replacement. Frostell CG. **Biol Neonate** 1997;71 Suppl 1:39–43 (37 ref.)

Nitric oxide in critical care medicine. Cuthbertson BH, et al. **Br J Hosp Med** 1995 Dec 13–1996 Jan 16;54(11):579–82 (15 ref.)

Current status of inhaled nitric oxide therapy in the perinatal period. Mupanemunda RH. **Early Hum Dev** 1997 Feb 20; 47(3):247–62 (72 ref.)

Gastrointestinal protection by NO from NSAIDs induced injury. Rishi RK, et al. **Indian J Physiol Pharmacol** 1996 Oct;40(4):377–9 (22 ref.)

Nitric oxide and acute respiratory failure. Frostell CG. **Monaldi Arch Chest Dis** 1996 Dec;51(6):538–42 (67 ref.)

Pulmonary hypertension: NO therapy? Adnot S, et al. **Thorax** 1996 Jul;51(7):762–4 (13 ref.)

[Nitric oxide donors in therapy of chronic heart failure] Blasini R, et al. **Internist (Berl)** 1997 May;38(5):448–52 (48 ref.) **(Ger)**

[Soluble guanyl cyclases. Key enzymes for therapeutic applications of the NO principle] Hönicka M, et al. **Internist (Berl)** 1997 May;38(5):427–37 (88 ref.) **(Ger)**

[Nitric oxide in therapy of angina pectoris: nitrates or molsidomine?] Schächinger V, et al. **Internist (Berl)** 1997 May;38(5):438–47 (49 ref.) **(Ger)**

TOXICITY

The importance of superoxide in nitric oxide–dependent toxicity: evidence for peroxynitrite–mediated injury. Crow JP, et al. **Adv Exp Med Biol** 1996;387:147–61 (78 ref.)

Nitric oxide and derived species as toxic agents in stroke, AIDS dementia, and chronic neurodegenerative disorders. Hensley K, et al. **Chem Res Toxicol** 1997 May;10(5):527–32 (64 ref.)

Nitric oxide neurotoxicity. Dawson VL, et al. **J Chem Neuroanat** 1996 Jun;10(3–4):179–90 (100 ref.)

Mutagenicity of nitric oxide in base pair–specific Salmonella tester strains: TA7000 series. Christen S, et al. **Methods Enzymol** 1996;269:267–78 (23 ref.)

Comet assay to detect nitric oxide–dependent DNA damage in mammalian cells. Green MH, et al. **Methods Enzymol** 1996;269:243–66 (52 ref.)

A discussion of mechanisms of NO genotoxicity: implication of inhibition of DNA repair proteins. Laval F, et al. **Rev Physiol Biochem Pharmacol** 1997;131:175–91 (64 ref.)

NITRIC OXIDE, ENDOTHELIUM-DERIVED see **ENDOTHELIUM-DERIVED RELAXING FACTOR**

NITRIC-OXIDE SYNTHASE

ANALYSIS

Nitric oxide synthase expression in cerebral ischemia: neurochemical, immunocytochemical, and molecular approaches. Ross ME, et al. **Methods Enzymol** 1996; 269:408–26 (54 ref.)

ANTAGONISTS & INHIBITORS

Therapeutic strategies for the inhibition of inducible nitric oxide synthase—potential for a novel class of anti–inflammatory agents. Pfeilschifter J, et al. **Cell Biol Int** 1996 Jan;20(1):51–8 (40 ref.)

Nitric oxide: biological and clinical perspectives [editorial] Saklayen MG, et al. **Int J Artif Organs** 1996 Nov; 19(11):630–2 (17 ref.)

Beneficial versus detrimental effects of nitric oxide synthase inhibitors in circulatory shock: lessons learned from experimental and clinical studies. Kilbourn RG, et al. **Shock** 1997 Apr;7(4):235–46 (119 ref.)

Selective inhibitors of neuronal nitric oxide synthase—is no NOS really good NOS for the nervous system? Moore PK, et al. **Trends Pharmacol Sci** 1997 Jun;18(6):204–11 (120 ref.)

[Inhibition of nitric oxide synthase in septic shock. Therapeutic limits and perspectives] Endres S, et al. **Internist (Berl)** 1997 May;38(5):466–9 (17 ref.) **(Ger)**

BIOSYNTHESIS

Immunobiology of picolinic acid. Melillo G, et al. **Adv Exp Med Biol** 1996;398:135–41 (43 ref.)

Regulation of inducible nitric oxide synthase expression in human glia: implications for inflammatory central nervous system diseases. Brosnan CF, et al. **Biochem Soc Trans** 1997 May;25(2):679–83 (32 ref.)

Regulation of expression of the endothelial cell nitric oxide synthase. Harrison DG, et al. **Clin Exp Pharmacol Physiol** 1996 Mar;23(3):251–5 (36 ref.)

Regulation of neuronal nitric oxide synthase through alternative transcripts. Brenman JE, et al. **Dev Neurosci** 1997;19(3):224–31 (39 ref.)

Endothelial nitric oxide synthase expression in heterologous systems. Robinson LJ, et al. **Methods Enzymol** 1996; 269:55–64 (19 ref.)

Pre– and postnatal expression of amino acid neurotransmitters, calcium binding proteins, and nitric oxide synthase in the developing superior colliculus. Mize RR, et al. **Prog Brain Res** 1996;108:313–32 (85 ref.)

Nitric oxide and the pulmonary artery smooth muscle cell. Degnim AC, et al. **Semin Pediatr Surg** 1996 Aug;5(3):160–4 (42 ref.)

Inflammatory cytokines, nitric oxide, and necrotizing enterocolitis. Ford HR, et al. **Semin Pediatr Surg** 1996 Aug; 5(3):155–9 (55 ref.)

[Increased production of nitric oxide in the immediate and late asthmatic responses in guinea pigs] Uchida Y, et al. **Nippon Rinsho** 1996 Feb;54(2):364–8 (15 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Structure–function aspects in the nitric oxide synthases. Stuehr DJ. **Annu Rev Pharmacol Toxicol** 1997;37:339–59 (95 ref.)

DRUG EFFECTS

Physiological and pathophysiological roles of nitric oxide in the central nervous system. Szabó C. **Brain Res Bull** 1996;41(3):131–41 (223 ref.)

GENETICS

Immunobiology of picolinic acid. Melillo G, et al. **Adv Exp Med Biol** 1996;398:135–41 (43 ref.)

Molecular biology and molecular genetics of nitric oxide synthase genes. Nadaud S, et al. **Clin Exp Hypertens** 1996 Feb;18(2):113–43 (88 ref.)

The harmony of the spheres: inducible nitric oxide synthase and related genes in pancreatic beta cells. Eizirik DL, et al. **Diabetologia** 1996 Aug;39(8):875–90 (166 ref.)

Regulation of nitric oxide synthase gene expression by cytokines. Yokoyama M, et al. **J Card Fail** 1996 Dec;2(4 Suppl):S179–85 (25 ref.)

Expression of nitric oxide synthase type II in the spinal cord under conditions producing thermal hyperalgesia. Grzybicki D, et al. **J Chem Neuroanat** 1996 Jun; 10(3–4):221–9 (55 ref.)

Genetic analysis of nitric oxide synthase isoforms: targeted mutation in mice. Huang PL, et al. **J Mol Med** 1996 Aug; 74(8):415–21 (41 ref.)

Modulation of endothelial cell nitric oxide synthase expression. Harrison DG, et al. **Jpn Circ J** 1996 Nov; 60(11):815–21 (36 ref.)

[Transfer of endothelial nitric oxide synthase gene in the purpose of gene therapy for pulmonary arterial hypertension] Setoguchi Y, et al. **Nippon Rinsho** 1996 Feb; 54(2):369–76 (12 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Molecular biology of nitric oxide synthases. Reduction of complications of cardiopulmonary bypass from platelets and neutrophils by nitric oxide generation from L–arginine and nitric oxide donors. Dewanjee MK. **ASAIO J** 1997 May–Jun;43(3):151–9 (64 ref.)

Nitric oxide synthases. Knowles RG. **Biochem Soc Trans** 1996 Aug;24(3):875–8 (8 ref.)

Medical perspectives of nitric oxide. Wang Z. **Chin Med J (Engl)** 1996 Jan;109(1):60–2 (0 ref.)

Derangements of the nitric oxide synthase pathway, L–arginine, and cardiovascular diseases [editorial; comment] Cooke JP, et al. **Circulation** 1997 Jul 15; 96(2):379–82 (37 ref.) Comment on: Circulation 1997 Jul 15;96(2):667–75. Comment on: Circulation 1997 Jul 15;96(2):689–97.

Intrarenal localization of nitric oxide synthase isoforms and soluble guanylyl cyclase. Star RA. **Clin Exp Pharmacol Physiol** 1997 Aug;24(8):607–10 (39 ref.)

Neurobiology of nitric oxide. Yun HY, et al. **Crit Rev Neurobiol** 1996;10(3–4):291–316 (225 ref.)

Nitric oxide synthases in vascular cells. Schini–Kerth VB, et al. **Exp Physiol** 1995 Nov;80(6):885–905 (140 ref.)

Nitric oxide synthase in the pineal gland. López–Figueroa MO, et al. **Histol Histopathol** 1996 Oct;11(4):1089–100 (62 ref.)

Nitric oxide and nitric oxide synthase: biology, pathology, localization. Wolf G. **Histol Histopathol** 1997 Jan; 12(1):251–61 (157 ref.)

Calcium–dependent and calcium–independent activation of the endothelial NO synthase. Fleming I, et al. **J Vasc Res** 1997 May–Jun;34(3):165–74 (57 ref.)

Nitric oxide synthase in models of focal ischemia. Samdani AF, et al. **Stroke** 1997 Jun;28(6):1283–8 (58 ref.)

Current status of platelet NO synthases. Berkels R, et al. **Thromb Res** 1997 Jul 1;87(1):51–5 (30 ref.)

Nitric oxide generation by nitric oxide synthase isoforms in transplanted vessels. Akyürek ML, et al. **Transplant Proc** 1997 Sep;29(6):2571–2 (12 ref.)

[Pulmonary nitric oxide synthase isoform expression and their functional significance] Munakata M. **Nippon Rinsho** 1996 Feb;54(2):358–63 (22 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Induction of cyclo–oxygenase and nitric oxide synthase in inflammation. Appleton I, et al. **Adv Pharmacol** 1996; 35:27–78 (329 ref.)

PHYSIOLOGY

Release of nitric oxide from astroglial cells: a key mechanism in neuroimmune disorders. Mollace V, et al. **Adv Neuroimmunol** 1995;5(4):421–30 (33 ref.)

Biosynthesis and homeostatic roles of nitric oxide in the normal kidney. Kone BC, et al. **Am J Physiol** 1997 May; 272(5 Pt 2):F561–78 (222 ref.)

Nitric oxide synthase: role in the genesis of vascular disease. Cooke JP, et al. **Annu Rev Med** 1997;48:489–509 (116 ref.)

The role of the calcium–dependent enzymes nitric oxide synthase and calpain in hypoxia–induced proximal tubule injury. Edelstein CL, et al. **Ren Fail** 1996 May;18(3):501–11 (73 ref.)

Nitric oxide, a vital poison inside the immune and inflammatory network. Dugas B, et al. **Res Immunol** 1995 Nov–Dec;146(9):664–70 (45 ref.)

Nitric oxide, hepatocytes and inflammation. Nussler AK, et al. **Res Immunol** 1995 Nov–Dec;146(9):671–77 (62 ref.)

[Anti–arteriosclerosis effects due to stimulation of endogenous nitric oxide synthesis] Bode–Böger SM, et al. **Internist (Berl)** 1997 May;38(5):461–5 (30 ref.) **(Ger)**

[Formation and effects of nitrogen monoxide (NO) in the vascular system] Schmidt HH, et al. **Internist (Berl)** 1997 May;38(5):406–10 (23 ref.) **(Ger)**

[Pulmonary nitric oxide synthase isoform expression and their functional significance] Munakata M. **Nippon Rinsho** 1996 Feb;54(2):358–63 (22 ref.) (Eng. Abstr.) **(Jpn)**

NITRILES

see related
CYANIDES

Cysteamine attenuates iminodipropionitrile (IDPN) induced dyskinesia in rats. Tariq M, et al. **Int J Neurosci** 1995 Dec; 83(3–4):165–75 (63 ref.)

ADVERSE EFFECTS

Methyldibromoglutaronitrile (Euxyl K 400): an important "new" allergen in cosmetics. De Groot AC, et al. **J Am Acad Dermatol** 1996 Nov;35(5 Pt 1):743–7 (35 ref.)

METABOLISM

Characterization of cytochrome P450TYR, a multifunctional haem–thiolate N–hydroxylase involved in the biosynthesis of the cyanogenic glucoside dhurrin. Halkier BA, et al. **Drug Metabol Drug Interact** 1995;12(3–4):285–97 (26 ref.)

THERAPEUTIC USE

Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients. Trunet PF, et al. **Acta Oncol** 1996;35 Suppl 5:15–8 (27 ref.)

New aromatase inhibitors for breast cancer. **Drug Ther Bull** 1997 Jul;35(7):55–6 (11 ref.)

Role of new selective aromatase inhibitor in therapy for metastatic breast cancer in postmenopausal women [news] Hannaford M. **Nurse Pract** 1997 Mar;22(3):195–6, 201–2 (21 ref.)

TOXICITY

A mechanistic interpretation of the oncogenicity of chlorothalonil in rodents and an assessment of human relevance. Wilkinson CF, et al. **Regul Toxicol Pharmacol** 1996 Aug;24(1 Pt 1):69–84 (94 ref.)

NITRILOTRIACETIC ACID

ANALYSIS

[Nitrilotriacetic acid (NTA)—properties and environmental behavior. II. Ecotoxicity and biodegradability of NTA in the environment] Malanowska M, et al. **Rocz Panstw Zakl Hig** 1996;47(3):247–56 (15 ref.) (Eng. Abstr.) **(Pol)**

NITRITE REDUCTASES

METABOLISM

Enzyme diversity and mosaic gene organization in denitrification. Zumft WG, et al. **Antonie Van Leeuwenhoek** 1997 Feb;71(1–2):43–58 (139 ref.)

NITRITES

ADMINISTRATION & DOSAGE

NIDA technical review: nitrite inhalants. Haverkos HW, et al. **Biomed Pharmacother** 1996;50(5):228–30 (18 ref.)

ADVERSE EFFECTS

NIDA technical review: nitrite inhalants. Haverkos HW, et al. **Biomed Pharmacother** 1996;50(5):228–30 (18 ref.)

Food–borne nitrates and nitrites as a cause of methemoglobinemia. Chan TY.
Southeast Asian J Trop Med Public Health 1996 Mar; 27(1):189–92 (24 ref.)

METABOLISM

Enzymology of the oxidation of ammonia to nitrite by bacteria. Hooper AB, et al. **Antonie Van Leeuwenhoek** 1997 Feb;71(1–2):59–67 (83 ref.)

The metabolism of dietary nitrites and nitrates. Walker R. **Biochem Soc Trans** 1996 Aug;24(3):780–5 (50 ref.)

NG–NITROARGININE METHYL ESTER

PHARMACOLOGY

Nitric oxide: biological and clinical perspectives [editorial] Saklayen MG, et al. **Int J Artif Organs** 1996 Nov; 19(11):630–2 (17 ref.)

THERAPEUTIC USE

[Inhibition of nitric oxide synthase in septic shock. Therapeutic limits and perspectives] Endres S, et al.
Internist (Berl) 1997 May;38(5):466–9 (17 ref.) **(Ger)**

NITROBACTERACEAE

ENZYMOLOGY

Enzymology of the oxidation of ammonia to nitrite by bacteria. Hooper AB, et al. **Antonie Van Leeuwenhoek** 1997 Feb;71(1–2):59–67 (83 ref.)

METABOLISM

Novel principles in the microbial conversion of nitrogen compounds. Jetten MS, et al. **Antonie Van Leeuwenhoek** 1997 Feb;71(1–2):75–93 (124 ref.)

NITROBENZENES

Nitrobenzene. **IARC Monogr Eval Carcinog Risks Hum** 1996; 65:381–408 (102 ref.)

2–Chloronitrobenzene, 3–chloronitrobenzene and 4–chloronitrobenzene.
IARC Monogr Eval Carcinog Risks Hum 1996;65:263–96 (102 ref.)

NITROFERRICYANIDE see **NITROPRUSSIDE**

NITROFURANS

PHARMACOKINETICS

Reductive activation of nitroheterocyclic compounds. Tocher JH. **Gen Pharmacol** 1997 Apr;28(4):485–7 (27 ref.)

NITROFURANTOIN

ADVERSE EFFECTS

Nitrofurantoin–induced pulmonary toxicity during pregnancy: a report of a case and review of the literature. Boggess KA, et al. **Obstet Gynecol Surv** 1996 Jun; 51(6):367–70 (19 ref.)

NITROGEN

ADMINISTRATION & DOSAGE

Use of a four parameter logistic equation and parameter sharing to evaluate animal responses to graded levels of nitrogen or amino acids. Gahl MJ, et al.
Adv Food Nutr Res 1996;40:157–67 (20 ref.)

Limits and limitations to nitrogen use in farm animals. Oldham JD, et al. **Proc Nutr Soc** 1997 Jul;56(2):525–34 (40 ref.)

ANALYSIS

Protein and nonprotein nitrogen components in human milk, bovine milk, and infant formula: quantitative and qualitative aspects in infant nutrition. Rudloff S, et al.
J Pediatr Gastroenterol Nutr 1997 Mar;24(3):328–44 (191 ref.)

BLOOD

Blood radicals: reactive nitrogen species, reactive oxygen species, transition metal ions, and the vascular system. Darley–Usmar V, et al. **Pharm Res** 1996 May;13(5):649–62 (192 ref.)

METABOLISM

The role of feed protein quality in reducing environmental pollution by lowering nitrogen excretion. III. Strategies of feeding: a review. Hegedüs M. **Acta Vet Hung** 1996; 44(2):153–63 (67 ref.)

Novel principles in the microbial conversion of nitrogen compounds. Jetten MS, et al. **Antonie Van Leeuwenhoek** 1997 Feb;71(1–2):75–93 (124 ref.)

Emerging principles of inorganic nitrogen metabolism in Paracoccus denitrificans and related bacteria. Stouthamer AH, et al. **Antonie Van Leeuwenhoek** 1997 Feb; 71(1–2):33–41 (60 ref.)

Enzyme diversity and mosaic gene organization in denitrification. Zumft WG, et al.
Antonie Van Leeuwenhoek 1997 Feb;71(1–2):43–58 (139 ref.)

Replacing renal function with gastrointestinal nitrogen extraction [editorial] Friedman EA. **ASAIO J** 1996 Nov–Dec;42(6):929–31 (35 ref.)

Regulation of gene expression in the nervous system by reactive oxygen and nitrogen species. Merrill JE, et al. **Metab Brain Dis** 1997 Jun;12(2):97–112 (135 ref.)

Genetic regulation of nitrogen metabolism in the fungi. Marzluf GA. **Microbiol Mol Biol Rev** 1997 Mar;61(1):17–32 (129 ref.)

The biosynthesis of plant alkaloids and nitrogenous microbial metabolites. Herbert RB. **Nat Prod Rep** 1997 Aug; 14(4):359–72 (94 ref.)

The biosynthesis of plant alkaloids and nitrogenous microbial metabolites. Herbert RB. **Nat Prod Rep** 1996 Feb; 13(1):45–58 (117 ref.)

Relationship between nitrogen balance, protein, and energy intake in haemodialysis patients. Alvestrand A, et al.
Nephrol Dial Transplant 1996;11 Suppl 2:130–3 (30 ref.)

Regulation of hepatic nitrogen metabolism in ruminants. Lobley GE, et al. **Proc Nutr Soc** 1997 Jul;56(2):547–63 (57 ref.)

Limits and limitations to nitrogen use in farm animals. Oldham JD, et al. **Proc Nutr Soc** 1997 Jul;56(2):525–34 (40 ref.)

Mathematical modelling of nitrogen flow in growing pigs and lactating sows. Pettigrew JE. **Proc Nutr Soc** 1997 Jul; 56(2):645–56 (27 ref.)

Nitrogen metabolism in gastrointestinal tissue of the pig. van der Meulen J, et al. **Proc Nutr Soc** 1997 Jul;56(2):535–45 (71 ref.)

Coordination of carbon and nitrogen metabolism. Charbit A. **Res Microbiol** 1996 Jul–Sep;147(6–7):513–8 (30 ref.)

Effects of lactulose on nitrogen metabolism. Weber FL Jr. **Scand J Gastroenterol Suppl** 1997;222:83–7 (42 ref.)

Nitric oxide, nitrogen metabolism and inflammatory respiratory disease. An hypothesis. Janson L, et al.
Ups J Med Sci 1997;102(1):21–33 (51 ref.)

PHARMACOKINETICS

Ammonia and glutamine metabolism during liver insufficiency: the role of kidney and brain in interorgan nitrogen exchange. Dejong CH, et al.
Scand J Gastroenterol Suppl 1996;218:61–77 (134 ref.)

PHYSIOLOGY

Reactive oxygen and nitrogen species regulate mitochondrial Ca2+ homeostasis and respiration. Richter C.
Biosci Rep 1997 Feb;17(1):53–66 (106 ref.)

NITROGEN DIOXIDE

ADVERSE EFFECTS

Mediators of inflammation in response to air pollution: a focus on ozone and nitrogen dioxide. Krishna MT, et al.
J R Coll Physicians Lond 1996 Jan–Feb;30(1):61–6 (62 ref.)

ANALYSIS

Nitrotyrosine as biomarker for reactive nitrogen species. van der Vliet A, et al. **Methods Enzymol** 1996;269:175–84 (50 ref.)

NITROGEN FIXATION

see related
GENES, NITROGEN FIXATION

Rhizobium lipo–chitooligosaccharide nodulation factors: signaling molecules mediating recognition and morphogenesis. Dénarié J, et al. **Annu Rev Biochem** 1996; 65:503–35 (185 ref.)

GENETICS

Heterocyst formation. Wolk CP. **Annu Rev Genet** 1996; 30:59–78 (143 ref.)

Environmental regulation of rhizobial symbiotic nitrogen fixation genes. Fischer HM. **Trends Microbiol** 1996 Aug; 4(8):317–20 (27 ref.)

PHYSIOLOGY

Regulation of nitrogen fixation in Azospirillum brasilense. Zhang Y, et al. **FEMS Microbiol Lett** 1997 Jul 15; 152(2):195–204 (69 ref.)

NITROGEN MUSTARD see **MECHLORETHAMINE**

NITROGEN MUSTARD COMPOUNDS

THERAPEUTIC USE

Neoplastic chemotherapy and head and neck cancer [editorial] Jones AS. **J Laryngol Otol** 1997 Jul; 111(7):607–10 (29 ref.)

NITROGEN MUSTARD N–OXIDE see **MECHLORETHAMINE**

NITROGEN OXIDES

PHARMACOLOGY

Clinical studies of effects of nitrogen oxides in healthy and asthmatic subjects. Kjaergaard SK, et al.
Cent Eur J Public Health 1996;4 Suppl:23–6 (18 ref.)

Nitrone–based free radical traps as neuroprotective agents in cerebral ischaemia and other pathologies. Hensley K, et al. **Int Rev Neurobiol** 1997;40:299–317 (105 ref.)

NITROGLYCERIN

DIAGNOSTIC USE

Coronary vein flow velocity changes during transluminal balloon angioplasty: a study using the Doppler guide wire. Manginas A, et al. **Cathet Cardiovasc Diagn** 1997 Jan; 40(1):85–91 (23 ref.)

PHARMACOLOGY

Central effects of nitroglycerin in the rat: new perspectives in migraine research. Tassorelli C, et al. **Funct Neurol** 1996 Sep–Oct;11(5):219–23, 227–35 (66 ref.)

THERAPEUTIC USE

A nonsurgical approach to chronic anal fissure. Scholefield JH, et al. **Hosp Pract (Off Ed)** 1997 Sep 15;32(9):181–6, 188 (10 ref.)

NITROIMIDAZOLES

PHARMACOKINETICS

Reductive activation of nitroheterocyclic compounds. Tocher JH. **Gen Pharmacol** 1997 Apr;28(4):485–7 (27 ref.)

PHARMACOLOGY

Resistance of Helicobacter pylori to antibiotics. Mégraud F. **Aliment Pharmacol Ther** 1997 Apr;11 Suppl 1:43–53 (39 ref.)

4–NITROPHENOL–2–HYDROXYLASE see **CYTOCHROME P–450 CYP2E1**

NITROPRUSSIDE

PHARMACOLOGY

Cell death, survival and proliferation in Tetrahymena thermophila. Effects of insulin, sodium nitroprusside, 8–Bromo cyclic GMP, NG–methyl–L–arginine and methylene blue. Christensen ST, et al. **Cell Biol Int** 1996 Oct;20(10):653–66 (78 ref.)

NITROSAMINES

ADVERSE EFFECTS

Nitrosamines and human cancer: introduction and overview. Magee PN. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:7–10 (33 ref.)

Tobacco–specific nitrosamines. Spiegelhalder B, et al.
Eur J Cancer Prev 1996 Sep;5 Suppl 1:33–8 (38 ref.)

Nitrosamines, alcohol, and gastrointestinal tract cancer: recent epidemiology and experimentation. Chhabra SK, et al. **In Vivo** 1996 May–Jun;10(3):265–84 (221 ref.)

ANALYSIS

N–nitroso compounds in the ambient air of metal factories using metal–working fluids. Fadlallah S, et al.
Bull Environ Contam Toxicol 1996 Dec;57(6):867–74 (22 ref.)

METABOLISM

Mechanisms of nitrosamine bioactivation and carcinogenesis. Yang CS, et al. **Adv Exp Med Biol** 1996;387:385–94 (40 ref.)

TOXICITY

Mechanisms of nitrosamine bioactivation and carcinogenesis. Yang CS, et al. **Adv Exp Med Biol** 1996;387:385–94 (40 ref.)

Approaches to chemoprevention of lung cancer based on carcinogens in tobacco smoke. Hecht SS.
Environ Health Perspect 1997 Jun;105 Suppl 4:955–63 (87 ref.)

NITROSO COMPOUNDS

N-nitroso compounds and man: sources of exposure, endogenous formation and occurrence in body fluids. Tricker AR. **Eur J Cancer Prev** 1997 Jun;6(3):226–68 (330 ref.)

ADVERSE EFFECTS

Environmental exposure to N-nitroso compounds (NNOC) and precursors: an overview. Bartsch H, et al. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:11–7 (54 ref.)

Epidemiology relating N-nitroso compounds to human cancer. Caygill CP. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:125–30 (37 ref.)

N-nitroso compounds in cosmetics, household commodities and cutting fluids. Eisenbrand G, et al. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:41–6 (31 ref.)

Endogenous N-nitrosation. Hill MJ. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:47–50 (13 ref.)

DNA damage studies related to the assessment of the role of N-nitroso compounds in human cancer. Kyrtopoulos SA, et al. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:109–14 (47 ref.)

Inhibition by vitamins C and E of in vivo nitrosation and vitamin C occurrence in the stomach. Mirvish SS. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:131–6 (37 ref.)

N-nitroso compounds, their relevance to human cancer and further prospects for prevention. Reed PI. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:137–47 (75 ref.)

Studies of stable N-nitroso compounds in human gastric juice—a review. Reed PI. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:75–82 (36 ref.)

Haemoglobin adducts of N-nitroso compounds. Richter E. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:115–9 (32 ref.)

Future directions in research of endogenous production on N-nitroso compounds. Stockbrügger RW. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:67–9 (21 ref.)

Environmental exposure to N-nitroso compounds and their precursors. van Maanen JM, et al. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:29–31 (22 ref.)

ANALYSIS

Environmental exposures to N-nitroso compounds and precursors: general review of methods and current status. Challis BC. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:19–26 (75 ref.)

Analytical techniques for total N-nitroso compounds. Pignatelli B, et al. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:51–8 (33 ref.)

Studies of stable N-nitroso compounds in human gastric juice—a review. Reed PI. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:75–82 (36 ref.)

CHEMISTRY

A water soluble C-nitroso-aromatic spin-trap-3,5-dibromo-4-nitrosobenzenesulphonic acid. "The Perkins spin-trap'. Kaur H. **Free Radic Res** 1996 Jun; 24(6):409–20 (63 ref.)

METABOLISM

Chemistry, analysis, and biological roles of S-nitrosothiols. Butler AR, et al. **Anal Biochem** 1997 Jun 15;249(1):1–9 (89 ref.)

Factors controlling endogenous N-nitrosation. Hill MJ. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:71–4 (9 ref.)

N-nitrosation at non-gastric sites. Hill MJ. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:105–8 (12 ref.)

Nitric oxide precursor arginine and S-nitrosoglutathione in synaptic and glial function. Do KQ, et al. **Neurochem Int** 1996 Sep;29(3):213–24 (94 ref.)

PHARMACOKINETICS

Blocking the endogenous formation of N-nitroso compounds and related carcinogens. Bartsch H, et al. **IARC Sci Publ** 1996;(139):189–201 (82 ref.)

NITROSODIETHYLAMINE see **DIETHYLNITROSAMINE**

NITROSOETHYLUREA see **ETHYLNITROSOUREA**

NITROSOMETHYLNITROGUANIDINE see **METHYLNITRONITROSOGUANIDINE**

NITROSOMETHYLUREA see **METHYLNITROSOUREA**

NITROSONITROMETHYLGUANIDINE see **METHYLNITRONITROSOGUANIDINE**

NITROSOUREA COMPOUNDS

METABOLISM

PCNA: structure, functions and interactions. Kelman Z. **Oncogene** 1997 Feb 13;14(6):629–40 (145 ref.)

PHARMACOKINETICS

[The biochemical mechanisms of the action of N-alkyl-N-nitrosoureas. The possible reasons for drug resistance to these compounds] Syrkin AB, et al. **Eksp Klin Farmakol** 1996 Mar-Apr;59(2):69–75 (110 ref.) (Eng. Abstr.) **(Rus)**

NITROUS OXIDE

ADVERSE EFFECTS

Nitrous oxide in the dental environment: assessing the risk, reducing the exposure [published erratum appears in J Am Dent Assoc 1997 Jun;128(6):700] Howard WR. **J Am Dent Assoc** 1997 Mar;128(3):356–60 (22 ref.)

METABOLISM

Soil microorganisms as controllers of atmospheric trace gases (H2, CO, CH4, OCS, N2O, and NO). Conrad R. **Microbiol Rev** 1996 Dec;60(4):609–40 (602 ref.)

[The importance of nitric oxide (NO) in the development of Helicobacter pylori infection] Kopański Z, et al. **Folia Med Cracov** 1996;37(1–2):49–59 (110 ref.) (Eng. Abstr.) **(Pol)**

PHARMACOKINETICS

Concentration and second gas effects: can the accepted explanation be improved? Korman B, et al. **Br J Anaesth** 1997 May;78(5):618–25 (37 ref.)

THERAPEUTIC USE

Role of dopamine mesolimbic system in opioid action of psychotropic analgesic nitrous oxide in alcohol and drug withdrawal. Lichtigfeld FJ, et al. **Clin Neuropharmacol** 1996 Jun;19(3):246–51 (43 ref.)

NIZATIDINE

THERAPEUTIC USE

[Nizatidine++ among the drugs usable in the treatment of acid-dependent gastric diseases] German SV. **Klin Med (Mosk)** 1997;75(5):34–41 (103 ref.) **(Rus)**

NK CELLS see **KILLER CELLS, NATURAL**

NK-1 RECEPTORS see **RECEPTORS, NEUROKININ-1**

NK-2 RECEPTORS see **RECEPTORS, NEUROKININ-2**

NMDA see **N-METHYLASPARTATE**

NMDA RECEPTOR-IONOPHORE COMPLEX see **RECEPTORS, N-METHYL-D-ASPARTATE**

NMDA RECEPTORS see **RECEPTORS, N-METHYL-D-ASPARTATE**

D-NMMA see **OMEGA-N-METHYLARGININE**

L-NMMA see **OMEGA-N-METHYLARGININE**

NMR IMAGING see **MAGNETIC RESONANCE IMAGING**

NMR SPECTROSCOPY see **NUCLEAR MAGNETIC RESONANCE**

NMR TOMOGRAPHY see **MAGNETIC RESONANCE IMAGING**

NO-FAULT INSURANCE see **INSURANCE, LIABILITY**

NO SYNTHASE see **NITRIC-OXIDE SYNTHASE**

NOCARDIA

CLASSIFICATION

Transmission of nocardiosis and molecular typing of Nocardia species: a short review. Provost F, et al. **Eur J Epidemiol** 1997 Feb;13(2):235–8 (35 ref.)

ISOLATION & PURIFICATION

Nocardial infections in bone marrow transplant recipients. Chouciño C, et al. **Clin Infect Dis** 1996 Nov;23(5):1012–9 (41 ref.)

[Mycetoma: report of 3 cases in Falcón State, Venezuela] Pérez-Blanco M, et al. **Invest Clin** 1996 Mar;37(1):61–73 (23 ref.) (Eng. Abstr.) **(Spa)**

NOCARDIA ASTEROIDES

Hypercalcemia in a patient with hypoparathyroidism and Nocardia asteroides infection: a novel observation. Dockrell DH, et al. **Mayo Clin Proc** 1997 Aug;72(8):757–60 (25 ref.)

NOCARDIA INFECTIONS

Nocardiosis. Lerner PI. **Clin Infect Dis** 1996 Jun; 22(6):891–903; quiz 904–5 (27 ref.)

Actinomycosis, nocardiosis, and actinomycetoma. Warren NG. **Dermatol Clin** 1996 Jan;14(1):85–95 (30 ref.)

[Current aspects of pulmonary nocardiosis] Desfemmes-Baleyte T, et al. **Rev Mal Respir** 1996; 13(4):321–5 (25 ref.) (Eng. Abstr.) **(Fre)**

[Nocardia infections] Betriu C. **Enferm Infecc Microbiol Clin** 1997 Mar;15(3):154–60 (64 ref.) **(Spa)**

[Mycetoma: report of 3 cases in Falcón State, Venezuela] Pérez-Blanco M, et al. **Invest Clin** 1996 Mar;37(1):61–73 (23 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Hypercalcemia in a patient with hypoparathyroidism and Nocardia asteroides infection: a novel observation. Dockrell DH, et al. **Mayo Clin Proc** 1997 Aug;72(8):757–60 (25 ref.)

DRUG THERAPY

Update on management of patients with Nocardia infection. Threlkeld SC, et al. **Curr Clin Top Infect Dis** 1997;17:1–23 (120 ref.)

EPIDEMIOLOGY

Transmission of nocardiosis and molecular typing of Nocardia species: a short review. Provost F, et al. **Eur J Epidemiol** 1997 Feb;13(2):235–8 (35 ref.)

Pulmonary infection with Nocardia species: a report of 10 cases and review. Menéndez R, et al. **Eur Respir J** 1997 Jul;10(7):1542–6 (28 ref.)

Nocardiosis in systemic lupus erythematosus. Mok CC, et al. **Semin Arthritis Rheum** 1997 Feb;26(4):675–83 (63 ref.)

IMMUNOLOGY

A case of lymphocutaneous nocardiosis with a review of lymphocutaneous nocardiosis reported in Japan [see comments] Ye Z, et al. **J Dermatol** 1996 Feb;23(2):120–4 (29 ref.) Comment in: J Dermatol 1997 Jan;24(1):68.

MICROBIOLOGY

Transmission of nocardiosis and molecular typing of Nocardia species: a short review. Provost F, et al. **Eur J Epidemiol** 1997 Feb;13(2):235–8 (35 ref.)

PREVENTION & CONTROL

Nocardial infections in bone marrow transplant recipients. Chouciño C, et al. **Clin Infect Dis** 1996 Nov;23(5):1012–9 (41 ref.)

NOCARDIOFORM GROUP

GENETICS

Genetic tools in pathogenic nocardioform actinomycetes. Navas J. **Microbiologia** 1996 Jun;12(2):297–304 (30 ref.)

NOCICEPTION TESTS see **PAIN MEASUREMENT**

NOCICEPTORS

ANATOMY & HISTOLOGY

Neuroanatomy of the pain system and of the pathways that modulate pain. Willis WD, et al. **J Clin Neurophysiol** 1997 Jan;14(1):2–31 (393 ref.)

DRUG EFFECTS

Biochemical aspects of chronic pain and its relationship to treatment. Pleuvry BJ, et al. **Pharmacol Ther** 1996; 71(3):313–24 (128 ref.)

Capsaicin-sensitive sensory nerve terminals with local and systemic efferent functions: facts and scopes of an unorthodox neuroregulatory mechanism. Szolcsányi J. **Prog Brain Res** 1996;113:343–59 (132 ref.)

PHYSIOLOGY

The activation of bulbo-spinal controls by peripheral nociceptive inputs: diffuse noxious inhibitory controls. Villanueva L, et al. **Biol Res** 1995;28(1):113–25 (96 ref.)

Purinergic receptors: their role in nociception and primary afferent neurotransmission. Burnstock G, et al. **Curr Opin Neurobiol** 1996 Aug;6(4):526–32 (63 ref.)

Beta-endorphin in cerebrospinal fluid: relation to nociception. Bach FW. **Dan Med Bull** 1997 Jun; 44(3):274–86 (128 ref.)

Nociceptors and the peripheral nervous system's role in pain. Greenspan JD. **J Hand Ther** 1997 Apr-Jun;10(2):78–85 (55 ref.)

Central nervous system pathways for pain transmission and pain control: issues relevant to the practicing clinician. Robinson AJ. **J Hand Ther** 1997 Apr-Jun;10(2):64–77 (66 ref.)

Descending antinociceptive mechanisms in the brainstem: their role in the animal's defensive system. Harris JA. **J Physiol Paris** 1996;90(1):15–25 (146 ref.)

Comments on Carmody, Pain, 63 (1995) 136 [letter; comment] Raffa RB. **Pain** 1996 Sep;67(1):215–8 (8 ref.) Comment on: Pain 1995 Oct;63(1):136.

Can sensory neurones in culture serve as a model of nociception? [editorial] Vyklický L, et al. **Physiol Res** 1996; 45(1):1–9 (95 ref.)

More sensory competence for nociceptive neurons in culture

NOCICEPTORS

[comment] Kress M, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24;93(26):14995–7 (35 ref.) Comment on: Proc Natl Acad Sci U S A 1996 Dec 24;93(26):15435–9.

Signal transduction in nociceptive afferent neurons in inflammatory conditions. Bevan S. **Prog Brain Res** 1996; 113:201–13 (54 ref.)

Modulations of autonomic functions by somatic nociceptive inputs. Budgell B, et al. **Prog Brain Res** 1996;113:525–39 (57 ref.)

Spinal cord mechanisms of hyperalgesia and allodynia: role of peripheral input from nociceptors. Cervero F. **Prog Brain Res** 1996;113:413–22 (32 ref.)

Visceral polymodal receptors. Gebhart GF. **Prog Brain Res** 1996;113:101–12 (31 ref.)

Role of polymodal receptors in the acupuncture–mediated endogenous pain inhibitory systems. Kawakita K, et al. **Prog Brain Res** 1996;113:507–23 (93 ref.)

The functional morphology of thin sensory axons: some principles and problems. Kruger L. **Prog Brain Res** 1996; 113:255–72 (95 ref.)

The polymodal receptor: bio–warning and defense system. Kumazawa T. **Prog Brain Res** 1996;113:3–18 (129 ref.)

Peptides and cutaneous polymodal nociceptor neurones. Lawson SN. **Prog Brain Res** 1996;113:369–85 (75 ref.)

Neurogenic inflammation caused by cutaneous polymodal receptors. Lynn B. **Prog Brain Res** 1996;113:361–8 (43 ref.)

Physiological functions of pontomedullary raphe and medial reticular neurons. Mason P, et al. **Prog Brain Res** 1996; 107:269–82 (130 ref.)

Group III and IV receptors in skeletal muscle: are they specific or polymodal? Mense S. **Prog Brain Res** 1996; 113:83–100 (75 ref.)

Functional morphology of nociceptive and other fine sensory endings (free nerve endings) in different tissues. Messlinger K. **Prog Brain Res** 1996;113:273–98 (75 ref.)

Modification of nociceptor responses by inflammatory mediators and second messengers implicated in their action––a study in canine testicular polymodal receptors. Mizumura K, et al. **Prog Brain Res** 1996;113:115–41 (149 ref.)

Prostanoid receptors and signal transduction. Narumiya S. **Prog Brain Res** 1996;113:231–41 (70 ref.)

Human polymodal receptors in pathological conditions. Ochoa J. **Prog Brain Res** 1996;113:185–97 (107 ref.)

Cutaneous polymodal receptors: characteristics and plasticity. Perl ER. **Prog Brain Res** 1996;113:21–37 (49 ref.)

Tissue acidosis in nociception and pain. Reeh PW, et al. **Prog Brain Res** 1996;113:143–51 (65 ref.)

Sympathetic modulation of cutaneous polymodal receptors in chronically inflamed and diabetic rats. Sato J, et al. **Prog Brain Res** 1996;113:153–9 (41 ref.)

On the role of tachykinins and calcitonin gene–related peptide in the spinal mechanisms of nociception and in the induction and maintenance of inflammation–evoked hyperexcitability in spinal cord neurons (with special reference to nociception in joints). Schaible HG. **Prog Brain Res** 1996;113:423–41 (152 ref.)

The articular polymodal nociceptor in health and disease. Schmidt RF. **Prog Brain Res** 1996;113:53–81 (111 ref.)

Spinal organization of C–fiber afferents related with nociception or non–nociception. Sugiura Y. **Prog Brain Res** 1996;113:320–39 (116 ref.)

The role of cholecystokinin in nociception, neuropathic pain and opiate tolerance. Wiesenfeld–Hallin Z, et al. **Regul Pept** 1996 Aug 27;65(1):23–8 (59 ref.)

Recent advances in our understanding of pain: how should they affect management? Raffe M. **Semin Vet Med Surg (Small Anim)** 1997 May;12(2):75–9 (17 ref.)

Is there a nociceptive carousel? Urban L, et al. **Trends Pharmacol Sci** 1997 Jul;18(7):223–4 (7 ref.)

[What is a nociceptor?] Messlinger K. **Anaesthesist** 1997 Feb; 46(2):142–53 (137 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Non–nociceptive aspects of persistent musculoskeletal pain. Kramis RC, et al. **J Orthop Sports Phys Ther** 1996 Oct; 24(4):255–67 (66 ref.)

Neurophysiological aspects of angina pectoris. Sylvén C. **Z Kardiol** 1997;86 Suppl 1:95–105 (80 ref.)

NOCTURIA see **URINATION DISORDERS**

NODDING SPASM see **SPASMS, INFANTILE**

NODES OF RANVIER see **RANVIER'S NODES**

NODOSE GANGLION

CHEMISTRY

Neurochemistry of the nodose ganglion. Zhuo H, et al. **Prog Neurobiol** 1997 Jun;52(2):79–107 (321 ref.)

NODULAR ELASTOIDOSIS see **FACIAL DERMATOSES**

NOISE

see related
ACOUSTIC STIMULATION
HEARING LOSS, NOISE–INDUCED

Verbal auditory closure and the speech perception in noise (SPIN) Test. Elliott LL. **J Speech Hear Res** 1995 Dec; 38(6):1363–76 (81 ref.)

ADVERSE EFFECTS

Effects of combined exposure to noise and toxic substances––critical review of the literature. Cary R, et al. **Ann Occup Hyg** 1997 Aug;41(4):455–65 (19 ref.)

A comprehensive strategy for the assessment of noise exposure and risk of hearing impairment. Malchaire J, et al. **Ann Occup Hyg** 1997 Aug;41(4):467–84 (0 ref.)

Noise stress and airway toxicity: a prospect for experimental analysis. Van Raaij MT, et al. **Food Chem Toxicol** 1996 Nov–Dec;34(11–12):1159–61 (15 ref.)

Management of primary blast injury. Argyros GJ. **Toxicology** 1997 Jul 25;121(1):105–15 (57 ref.)

Toxicology of blast overpressure. Elsayed NM. **Toxicology** 1997 Jul 25;121(1):1–15 (76 ref.)

The pathology of primary blast overpressure injury. Mayorga MA. **Toxicology** 1997 Jul 25;121(1):17–28 (44 ref.)

Biological response to blast overpressure: a summary of modeling. Stuhmiller JH. **Toxicology** 1997 Jul 25; 121(1):91–103 (45 ref.)

[The influence of chemical and physical factors in the work environment on the amount of risk for abnormal pregnancy outcome] Makowiec–Dąbrowska T, et al. **Med Pr** 1997; 48(3):239–59 (84 ref.) (Eng. Abstr.) **(Pol)**

NOISE, OCCUPATIONAL

ADVERSE EFFECTS

Unique hearing protection devices––the search for a balance. Gasaway DC. **Occup Health Saf** 1997 Jun;66(6):60–4 (4 ref.)

[The immunomodulating effect of noise (a review of the literature)] Grishina TI, et al. **Med Tr Prom Ekol** 1997; (3):26–9 (31 ref.) **(Rus)**

NOISE, TRANSPORTATION

ADVERSE EFFECTS

A review of health effects of aircraft noise. Morrell S, et al. **Aust N Z J Public Health** 1997 Apr;21(2):221–36 (129 ref.)

NOMA

DIAGNOSIS

Noma neonatorum. Prajapati NC, et al. **Indian Pediatr** 1995 Sep;32(9):1019–21 (9 ref.)

SURGERY

Noma: a review. Adolph HP, et al. **Ann Plast Surg** 1996 Dec;37(6):657–68 (31 ref.)

NOMENCLATURE

Standardization of nomenclature of body composition in weight loss. Roubenoff R, et al. **Am J Clin Nutr** 1997 Jul; 66(1):192–6 (36 ref.)

The best treatment for vestibular schwannoma (acoustic neuroma): microsurgery or radiosurgery? Sekhar LN, et al. **Am J Otol** 1996 Jul;17(4):676–82; discussion 683–9 (34 ref.)

Hilum of the heart. Pauza DH, et al. **Anat Rec** 1997 Jul; 248(3):322–4 (15 ref.)

Uniparental disomy (UPD). Genomic imprinting and a case for new genetics (prenatal and clinical implications: the "Likon" concept). Engel E. **Ann Genet** 1997;40(1):24–34 (74 ref.)

A genome–based receptor nomenclature. Hartig PR. **Ann N Y Acad Sci** 1997 May 30;812:85–91 (30 ref.)

Criteria for the classification of hormone receptors with implications for nomenclature. An impossible task? Lomasney J. **Ann N Y Acad Sci** 1997 May 30;812:48–54 (5 ref.)

How receptor mutagenesis may confirm or confuse receptor classification. Schwartz TW, et al. **Ann N Y Acad Sci** 1997 May 30;812:71–84 (41 ref.)

Terminology of endocrine tumors of the uterine cervix: results of a workshop sponsored by the College of American Pathologists and the National Cancer Institute. Albores–Saavedra J, et al. **Arch Pathol Lab Med** 1997 Jan; 121(1):34–9 (32 ref.)

Descriptors of depression: the importance of agreed definitions. Parker G, et al. **Aust N Z J Psychiatry** 1996 Dec;30(6):819–23 (30 ref.)

Classification and nomenclature of 5–HT receptors: a comment on current issues. Hoyer D, et al. **Behav Brain Res** 1996;73(1–2):263–8 (30 ref.)

Lymphoma classification––the gap between biology and clinical management is closing. Hiddemann W, et al. **Blood** 1996 Dec 1;88(11):4085–9 (15 ref.)

CD antigens 1996. Kishimoto T, et al. **Blood** 1997 May 15; 89(10):3502 (1 ref.)

Comorbidity (psycho) analysed. van Praag HM. **Br J Psychiatry Suppl** 1996 Jun;(30):129–34 (27 ref.)

Definition of tissue–air ratio. Burns JE. **Br J Radiol** 1996; Suppl 25:177–82 (12 ref.)

Anger and hostility in maritally violent men: conceptual distinctions, measurement issues, and literature review. Eckhardt CI, et al. **Clin Psychol Rev** 1997;17(4):333–58 (111 ref.)

The language of death: euthanatos et mors––the science of uncertainty. Koch KA. **Crit Care Clin** 1996 Jan;12(1):1–14 (35 ref.)

Spondyloarthropathies–spondylarthropathies [editorial] Khan MA. **Curr Opin Rheumatol** 1996 Jul;8(4):267–8 (8 ref.)

Nomenclature for factors of the HLA system, 1994. Bodmer JG, et al. **Eur J Immunogenet** 1994 Dec;21(6):485–517 (178 ref.)

Dental erosion. Definition, classification and links. Imfeld T. **Eur J Oral Sci** 1996 Apr;104(2 (Pt 2)):151–5 (59 ref.)

Segmental anatomy of the liver: a review and a proposal for an international working nomenclature. Fasel JH, et al. **Eur Radiol** 1996;6(6):834–7 (37 ref.)

Considerations from the European DNA profiling group (EDNAP) concerning STR nomenclature. Gill P, et al. **Forensic Sci Int** 1997 Jun 23;87(3):185–92 (27 ref.)

DNA recommendations––further report of the DNA Commission of the ISFH regarding the use of short tandem repeat systems. Lincoln PJ. **Forensic Sci Int** 1997 Jun 23; 87(3):181–4 (4 ref.)

Economic evaluation and the shifting balance towards primary care: definitions, evidence and methodological issues. Godber E, et al. **Health Econ** 1997 May–Jun; 6(3):275–94 (45 ref.)

Nomenclature for factors of the HLA System, 1996. Bodmer JG, et al. **Hum Immunol** 1997 Mar;53(1):98–128 (142 ref.)

Gastric epithelial dysplasia and adenoma: historical review and histological criteria for grading. Goldstein NS, et al. **Hum Pathol** 1997 Feb;28(2):127–33 (100 ref.)

On naming H2 haplotypes: functional significance of MHC class Ib alleles. Fischer Lindahl K. **Immunogenetics** 1997; 46(1):53–62 (139 ref.)

Fatigue: a concept analysis. Ream E, et al. **Int J Nurs Stud** 1996 Oct;33(5):519–29 (50 ref.)

How not to clarify concepts in nursing. Paley J. **J Adv Nurs** 1996 Sep;24(3):572–8 (35 ref.)

Comorbidity in ADHD: implications for research, practice, and DSM–V. Jensen PS, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Aug; 36(8):1065–79 (69 ref.)

Terminology of liver anatomy and liver resections: coming to grips with hepatic Babel. Strasberg SM. **J Am Coll Surg** 1997 Apr;184(4):413–34 (26 ref.)

The analytic initiation: the effect of the archetype of initiation on the personal unconscious. Sullivan M. **J Anal Psychol** 1996 Oct;41(4):509–27 (13 ref.)

Corneal topography: a review of terms and concepts. Roberts C. **J Cataract Refract Surg** 1996 Jun;22(5):624–9 (11 ref.)

A unified nomenclature for peroxisome biogenesis factors. Distel B, et al. **J Cell Biol** 1996 Oct;135(1):1–3 (48 ref.)

Clinical review 86: Euthyroid sick syndrome: is it a misnomer? Chopra IJ. **J Clin Endocrinol Metab** 1997 Feb; 82(2):329–34 (98 ref.)

A quantitative definition of exposure and related concepts. Zartarian VG, et al. **J Expo Anal Environ Epidemiol** 1997 Oct–Dec;7(4):411–37 (76 ref.)

MR imaging contrast agents––what's in a name? Mitchell DG. **J Magn Reson Imaging** 1997 Jan–Feb;7(1):1–4 (29 ref.)

Torque: an appraisal of misuse of terminology in chiropractic literature and technique. Harrison DD, et al. **J Manipulative Physiol Ther** 1996 Sep;19(7):454–62 (57 ref.)

Toward an agreement on terminology of nuclear and subnuclear divisions of the motor thalamus. Macchi G, et al. **J Neurosurg** 1997 Jan;86(1):77–92 (93 ref.)

Toward an agreement on terminology of nuclear and subnuclear divisions of the motor thalamus. Macchi G, et al. **J Neurosurg** 1997 Apr;86(4):670–85 (93 ref.)

Anatomic description of conjoined twins: a plea for standardized terminology. Spencer R. **J Pediatr Surg** 1996 Jul;31(7):941–4 (6 ref.)

The semantics of addiction: moving beyond expert models to lay understandings. Quintero G, et al. **J Psychoactive Drugs** 1996 Jul–Sep;28(3):219–28 (66 ref.)

Hyperventilation syndrome: a chimera? [editorial] Bass C. **J Psychosom Res** 1997 May;42(5):421–6 (35 ref.)

Systemic lupus erythematosus: immunopathogenesis and the card game analogy. Isenberg DA. **J Rheumatol Suppl** 1997 May;48:62–6 (27 ref.)

Classification of peripheral T–cell lymphomas: cytogenetic findings support the updated Kiel classification. Schlegelberger B, et al. **Leuk Lymphoma** 1996 Feb; 20(5–6):411–6 (54 ref.)

The lexicon of cutaneous lupus erythematosus––a review and personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus. Sontheimer RD. **Lupus** 1997;6(2):84–95 (90 ref.)

Review paper: coding systems in health care. Cimino JJ. **Methods Inf Med** 1996 Dec;35(4–5):273–84 (73 ref.)

Nomenclature systems for FISH–painted chromosome aberrations. Savage JR, et al. **Mutat Res** 1996 Nov; 366(2):153–61 (11 ref.)

Minisymposium. Definition of death, organ donation and interruption of treatment of Islam. Hassaballah AM. **Nephrol Dial Transplant** 1996 Jun;11(6):964–5 (10 ref.)

5–HT receptor classification and nomenclature: towards a harmonization with the human genome. Hoyer D, et al. **Neuropharmacology** 1997 Apr–May;36(4–5):419–28 (65 ref.)

Standardization of terminology and assessment of functional

characteristics of intestinal urinary reservoirs. Thüroff JW, et al. **Neurourol Urodyn** 1996;15(5):499–511 (6 ref.)

Current terminology and diagnostic classification schemes. Okeson JP.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jan;83(1):61–4 (29 ref.)

New perspectives on the definition of pain [editorial] [see comments] Anand KJ, et al. **Pain** 1996 Sep;67(1):3–6; discussion 209–11 (41 ref.) Comment in: Pain 1997 Apr;70(2–3):293.

The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Mackenzie PI, et al. **Pharmacogenetics** 1997 Aug;7(4):255–69 (58 ref.)

International Union of Pharmacology Nomenclature in Nitric Oxide Research. Moncada S, et al. **Pharmacol Rev** 1997 Jun;49(2):137–42 (58 ref.)

Plant cyclins: a unified nomenclature for plant A–, B– and D–type cyclins based on sequence organization. Renaudin JP, et al. **Plant Mol Biol** 1996 Dec;32(6):1003–18 (63 ref.)

Subclassification and nomenclature of alpha 1– and alpha 2–adrenoceptors. Hieble JP, et al. **Prog Drug Res** 1996; 47:81–130 (207 ref.)

Acute psychoses: a proposed diagnosis for ICD–11 and DSM–V. Susser E, et al. **Psychiatr Q** 1996 Fall; 67(3):165–76 (38 ref.)

The alphabet soup revisited: the chronic interstitial pneumonias in the 1990s. McAdams HP, et al.
Radiographics 1996 Sep;16(5):1009–33; discussion 1033–4 (78 ref.)

Review of the functional anatomy of the cartilages and muscles of the nose. Bruintjes TD, et al. **Rhinology** 1996 Jun;34(2):66–74 (54 ref.)

The standardization of terminology and assessment of functional characteristics of intestinal urinary reservoirs. Thüroff JW, et al. **Scand J Urol Nephrol** 1996 Oct; 30(5):349–56 (6 ref.)

Developmental insanity or dementia praecox: was the wrong concept adopted? O'Connell P, et al. **Schizophr Res** 1997 Feb 7;23(2):97–106 (108 ref.)

Primary bone tumors of the spine. Terminology and surgical staging. Boriani S, et al. **Spine** 1997 May 1;22(9):1036–44 (28 ref.)

HLA: what's in a name? A commentary on HLA nomenclature development over the years. Bodmer WF. **Tissue Antigens** 1997 Mar;49(3 Pt 2):293–6 (5 ref.)

Taxonomic changes and toxinology: systematic revisions of the Asiatic cobras (Naja naja species complex) [see comments] Wüster W. **Toxicon** 1996 Apr;34(4):399–406 (36 ref.) Comment in: Toxicon 1996 Apr;34(4):397–8.

Bacterial polysaccharide synthesis and gene nomenclature. Reeves PR, et al. **Trends Microbiol** 1996 Dec;4(12):495–503 (33 ref.)

Inadequate frameworks for understanding bodily homeostasis. Blessing WW. **Trends Neurosci** 1997 Jun; 20(6):235–9 (44 ref.)

Alignment of receptor nomenclature with the human genome: classification of 5–HT1B and 5–HT1D receptor subtypes. Hartig PR, et al. **Trends Pharmacol Sci** 1996 Mar; 17(3):103–5 (22 ref.)

Dubbing animal diseases with color. Hadlow WJ.
Vet Pathol 1997 Jan;34(1):74–8 (0 ref.)

Pathology and nomenclature of human gastrointestinal neuroendocrine (carcinoid) tumors and related lesions. Klöppel G, et al. **World J Surg** 1996 Feb;20(2):132–41 (88 ref.)

[History and definition of sepsis—do we need new terminology?] Kreymann G, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Feb; 31(1):9–14 (18 ref.) (Eng. Abstr.) **(Ger)**

[What is it called? A formulation and glossary for the finding and understanding of results in HRCT of the lung] Kauczor HU, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996 Nov;165(5):428–37 (88 ref.) (Eng. Abstr.) **(Ger)**

[How to "adjectivize" acute pulmonary embolism? (editorial)] Morpurgo M, et al. **Cardiologia** 1996 Nov;41(11):1029–31 (21 ref.) **(Ita)**

[Applicability of the R.E.A.L. classification of non–Hodgkin's lymphoma in clinical practice] Carbone A. **Pathologica** 1995 Oct;87(5):473–84 (48 ref.) (Eng. Abstr.) **(Ita)**

[Medico–biological definition of major clinical phenomena: syndrome, nosological form, disease] Serov VV.
Biull Eksp Biol Med 1997 Mar;123(3):244–7 (11 ref.) **(Rus)**

[The evolution of th theory of chronic hepatitis: classification, nomenclature, diagnosis and treatment] Tsimmerman IS. **Klin Med (Mosk)** 1996;74(8):19–24 (33 ref.) **(Rus)**

[Definition of the term "complicated cataracts"] Alekseev BN, et al. **Vestn Oftalmol** 1996 Sep–Oct;112(4):26–7 (6 ref.) (Eng. Abstr.) **(Rus)**

[Teaching evolution of the working classification and nomenclature of rheumatism] Nasonova VA.
Vestn Ross Akad Med Nauk 1996;(11):10–4 (9 ref.) **(Rus)**

[The definition and subject of modern epidemiology] Shliakhtenko LI, et al.
Zh Mikrobiol Epidemiol Immunobiol 1997 Jan–Feb;(1):94–9 (40 ref.) **(Rus)**

NON–HODGKIN'S LYMPHOMA see **LYMPHOMA, NON–HODGKIN'S**

NON–OBESE DIABETIC MICE see **MICE, INBRED NOD**

NONAGENARIANS see **AGED, 80 AND OVER**

NONDIRECTIVE THERAPY

Motivational interviewing: research, practice, and puzzles. Miller WR. **Addict Behav** 1996 Nov–Dec;21(6):835–42 (35 ref.)

NONDISJUNCTION, GENETIC

Recombination and nondisjunction in humans and flies. Koehler KE, et al. **Hum Mol Genet** 1996;5 Spec No:1495–504 (54 ref.)

NONHEME IRON PROTEINS

CHEMISTRY

Di–iron–carboxylate proteins. Nordlund P, et al.
Curr Opin Struct Biol 1995 Dec;5(6):758–66 (54 ref.)

NON–HISTONE CHROMOSOMAL PROTEINS see **CHROMOSOMAL PROTEINS, NON–HISTONE**

NONINVASIVE LITHOLAPAXY see **LITHOTRIPSY**

NONLINEAR DYNAMICS

see related
FRACTALS

A criterion of relative degree of chaos or order for open systems. Klimontovich YuL. **Biosystems** 1997; 42(2–3):85–102 (31 ref.)

Containers, mental space and psychodynamics. Rosenbaum B, et al. **Br J Med Psychol** 1996 Dec;69 (Pt 4):281–97 (44 ref.)

Non–linear algorithms for processing biological signals. Cerutti S, et al. **Comput Methods Programs Biomed** 1996 Oct;51(1–2):51–73 (40 ref.)

Using fractals and nonlinear dynamics to determine the physical properties of ion channel proteins. Liebovitch LS, et al. **Crit Rev Neurobiol** 1996;10(2):169–87 (53 ref.)

Nonlinear dynamics and quantitative EEG analysis. Jansen BH. **Electroencephalogr Clin Neurophysiol Suppl** 1996; 45:39–56 (52 ref.)

Fractal geometry, fractal kinetics and chaos en route to biopharmaceutical sciences. Macheras P, et al.
Eur J Drug Metab Pharmacokinet 1996 Apr–Jun; 21(2):77–86 (49 ref.)

Strategic leadership: a view from quantum and chaos theories. McDaniel RR Jr. **Health Care Manage Rev** 1997 Winter;22(1):21–37 (74 ref.)

A nonlinear mathematical model of electrically stimulated skeletal muscle. Dorgan SJ, et al.
IEEE Trans Rehabil Eng 1997 Jun;5(2):179–94 (55 ref.)

Time–varying characteristics of visually induced postural sway. Loughlin PJ, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):416–24 (36 ref.)

A low–dimensional, time–resolved and adapting model neuron. Cartling B. **Int J Neural Syst** 1996 Jul;7(3):237–46 (54 ref.)

Random activity at the microscopic neural level in cortex ("noise") sustains and is regulated by low–dimensional dynamics of macroscopic cortical activity ("chaos"). Freeman WJ. **Int J Neural Syst** 1996 Sep;7(4):473–80 (29 ref.)

Role of chaos in trial–and–error problem solving by an artificial neural network. Obana I, et al.
Int J Neural Syst 1996 Mar;7(1):101–8 (20 ref.)

Nonlinear time series analysis by neural networks: a case study [letter] Saxén H. **Int J Neural Syst** 1996 May; 7(2):195–201 (22 ref.)

Side effects of normalising radial basis function networks. Shorten R, et al. **Int J Neural Syst** 1996 May;7(2):167–79 (17 ref.)

Nonlinear gated experts for time series: discovering regimes and avoiding overfitting. Weigend AS, et al.
Int J Neural Syst 1995 Dec;6(4):373–99 (61 ref.)

The receptor mosaic hypothesis of the engram: possible relevance of Boolean network modeling. Zoli M, et al.
Int J Neural Syst 1996 Sep;7(4):363–8 (40 ref.)

Is there a way from behavior to non–linear brain dynamics? On quantal periods in cognition and the place of alpha in brain resonances. Geissler HG. **Int J Psychophysiol** 1997 Jun;26(1–3):381–93 (31 ref.)

Nonlinear dynamics and multiple sclerosis. Bharanidharan P. **J Neurol Sci** 1997 Aug;149(2):139–40 (10 ref.)

Understanding human sexuality—specifically homosexuality and the paraphilias—in terms of chaos theory and fetal development. Goodman RE. **Med Hypotheses** 1997 Mar; 48(3):237–43 (68 ref.)

Fractals and the birth of Gothic: reflections on the biologic basis of creativity. Goldberger AL. **Mol Psychiatry** 1996 May;1(2):99–104 (33 ref.)

Spirals, chaos, and new mechanisms of wave propagation. Chen PS, et al. **Pacing Clin Electrophysiol** 1997 Feb;20(2 Pt 2):414–21 (66 ref.)

A few selected applications of surface nonlinear optical spectroscopy. Shen YR. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12104–11 (74 ref.)

[Deterministic–chaotic and spectral–functional analysis of heart rate and respiratory movements] Zwiener U, et al. **Pneumologie** 1997 Apr;51 Suppl 2:415–22 (48 ref.) (Eng. Abstr.) **(Ger)**

[Random necessity, transcription initiation, induction of differentiation and need for randomness] Golubev AG.
Biokhimiia 1996 Jul;61(7):1303–19 (88 ref.) (Eng. Abstr.) **(Rus)**

["Determined chaos" and the risk of sudden cardiac death] Parkhomenko AN. **Ter Arkh** 1996;68(4):43–5 (23 ref.) **(Rus)**

NONLYMPHOBLASTIC LEUKEMIA, ACUTE see **LEUKEMIA, NONLYMPHOCYTIC, ACUTE**

NONLYMPHOCYTIC LEUKEMIA, ACUTE see **LEUKEMIA, NONLYMPHOCYTIC, ACUTE**

NONOPIOID ANALGESICS see **ANALGESICS, NON–NARCOTIC**

NONOXYNOL

PHARMACOLOGY

Review: in vitro spermicidal tests. Lee CH. **Contraception** 1996 Sep;54(3):131–47 (151 ref.)

NONPROFIT ORGANIZATIONS see **ORGANIZATIONS, NONPROFIT**

NONSENSE CODON see **CODON, NONSENSE**

NON–SMALL–CELL LUNG CARCINOMA see **CARCINOMA, NON–SMALL–CELL LUNG**

NON–STEROIDAL ANTI–INFLAMMATORY AGENTS see **ANTI–INFLAMMATORY AGENTS, NON–STEROIDAL**

NONSTRUCTURAL PROTEINS, VIRAL see **VIRAL NONSTRUCTURAL PROTEINS**

NONVERBAL COMMUNICATION

Signs and voices: joining a conversation in progress. Stiles WB. **Br J Med Psychol** 1997 Jun;70 (Pt 2):169–76 (35 ref.)

NONYLPHENOXYPOLYETHOXYETHANOLS see **NONOXYNOL**

NOONAN SYNDROME

[Noonan syndrome] Matsuo K.
Ryoikibetsu Shokogun Shirizu 1996;(15):284–6 (5 ref.) **(Jpn)**

COMPLICATIONS

[ORL involvement and Noonan syndrome] Portmann D, et al. **Rev Laryngol Otol Rhinol (Bord)** 1996;117(3):233–6 (23 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Retinitis pigmentosa in a young man with Noonan syndrome: further evidence that Noonan syndrome (NS) and the cardio–facio–cutaneous syndrome (CFC) are variable manifestations of the same entity? [see comments] Lorenzetti ME, et al. **Am J Med Genet** 1996 Oct 16; 65(2):97–9 (17 ref.) Comment in: Am J Med Genet 1996 Oct 16;65(2):100.

GENETICS

Noonan syndrome and its related disorders. Fukushima Y. **Acta Paediatr Jpn** 1996 Feb;38(1):102–4 (6 ref.)

Noonan syndrome: a clinical description emphasizing the cardiac findings. Noonan J, et al. **Acta Paediatr Jpn** 1996 Feb;38(1):76–83 (31 ref.)

NOOTROPIC AGENTS

PHARMACOLOGY

The brain cholinergic system as a target of cognition enhancers. Giovannini MG, et al. **Behav Brain Res** 1997 Feb;83(1–2):1–5 (69 ref.)

Cognitive enhancers and hippocampal long–term potentiation in vitro. Kaneko S, et al. **Behav Brain Res** 1997 Feb; 83(1–2):45–9 (33 ref.)

Interaction of neuromodulatory systems in modulating memory storage. McGaugh JL, et al. **Behav Brain Res** 1997 Feb;83(1–2):31–8 (79 ref.)

Cognitive enhancers in theory and practice: studies of the cholinergic hypothesis of cognitive deficits in Alzheimer's disease. Robbins TW, et al. **Behav Brain Res** 1997 Feb; 83(1–2):15–23 (34 ref.)

Trans–synaptic stimulation of cortical acetylcholine and enhancement of attentional functions: a rational approach for the development of cognition enhancers. Sarter M, et al. **Behav Brain Res** 1997 Feb;83(1–2):7–14 (100 ref.)

NOOTROPIC AGENTS

Nootropics: preclinical results in the light of clinical effects; comparison with tacrine. Mondadori C. **Crit Rev Neurobiol** 1996;10(3–4):357–70 (85 ref.)

THERAPEUTIC USE

Orally active NGF synthesis stimulators: potential therapeutic agents in Alzheimer's disease. Yamada K, et al. **Behav Brain Res** 1997 Feb;83(1–2):117–22 (32 ref.)

Cognition-enhancing drugs in dementia: a guide to the near future. van Reekum R, et al. **Can J Psychiatry** 1997 Jun; 42 Suppl 1:35S–50S (190 ref.)

Nootropics: preclinical results in the light of clinical effects; comparison with tacrine. Mondadori C. **Crit Rev Neurobiol** 1996;10(3–4):357–70 (85 ref.)

Cognition enhancers in age-related cognitive decline. Riedel WJ, et al. **Drugs Aging** 1996 Apr;8(4):245–74 (219 ref.)

Treatment of impaired cognition with nootropic drugs: nicergoline versus the state of the art. Fariello RG. **Funct Neurol** 1997 May–Aug;12(3–4):221–5 (20 ref.)

Enhancing cognition in the intellectually intact. Whitehouse PJ, et al. **Hastings Cent Rep** 1997 May–Jun;27(3):14–22 (19 ref.)

New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline. Gerlach M, et al. **J Neural Transm Suppl** 1996;48:7–21 (63 ref.)

The clinical potential of Deprenyl in neurologic and psychiatric disorders. Kuhn W, et al. **J Neural Transm Suppl** 1996;48:85–93 (51 ref.)

Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action. Olanow CW. **J Neural Transm Suppl** 1996;48:75–84 (60 ref.)

Lines of therapeutics research in Alzheimer's disease. Shvaloff A, et al. **Psychopharmacol Bull** 1996;32(3):343–52 (100 ref.)

[Pharmacotherapy of Alzheimer dementia: therapy of cognitive symptoms--new results of clinical studies] Heidrich A, et al. **Fortschr Neurol Psychiatr** 1997 Mar; 65(3):108–21 (180 ref.) (Eng. Abstr.) **(Ger)**

[Piracetam, nimodipine and tacrine in the pharmacologic treatment of dementia: bibliographic review] Ojer Tsakiridu D, et al. **Aten Primaria** 1996 Sep 30;18(5):257–60, 262–4 (31 ref.) **(Spa)**

NORADRENALINE see **NOREPINEPHRINE**

NOREPINEPHRINE

see related

RECEPTORS, ADRENERGIC

Discrete structural domains and cell-specific expression determine functional selectivity of the dopamine and norepinephrine transporters. Buck KJ, et al. **NIDA Res Monogr** 1996;161:154–75 (30 ref.)

BLOOD

Central and peripheral noradrenalin regulation in eating disorders. Pirke KM. **Psychiatry Res** 1996 Apr 16; 62(1):43–9 (35 ref.)

[Tension-type headache: 5-hydroxytryptamine and related substances] Shimomura T. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1342–4 (8 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSTIC USE

[Pharmacological test] Hirayama M, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:491–3 (8 ref.) **(Jpn)**

METABOLISM

Central noradrenergic hyperactivity early in life: a hypothesis on the origin of morpho-functional brain disorders induced by malnutrition. Soto-Moyano R, et al. **Biol Res** 1995; 28(1):105–11 (80 ref.)

Nicotine and sympathetic neurotransmission. Haass M, et al. **Cardiovasc Drugs Ther** 1997 Jan;10(6):657–65 (55 ref.)

ATP as a co-transmitter with noradrenaline in sympathetic nerves--function and fate. Kennedy C, et al. **Ciba Found Symp** 1996;198:223–35; discussion 235–8 (38 ref.)

Preclinical pharmacology of milnacipran. Briley M, et al. **Int Clin Psychopharmacol** 1996 Sep;11 Suppl 4:9–14 (24 ref.)

Simulated weightlessness to induce chronic hypoactivity of brain norepinephrine for exercise and stress studies. Sothmann M, et al. **Med Sci Sports Exerc** 1997 Jan; 29(1):39–44 (42 ref.)

Noradrenaline storing vesicles in sympathetic neurons and their role in neurotransmitter release: an historical overview of controversial issues. De Potter WP, et al. **Neurochem Res** 1997 Aug;22(8):911–9 (74 ref.)

The development of the noradrenergic transmitter phenotype in postganglionic sympathetic neurons. Ernsberger U, et al. **Neurochem Res** 1996 Jul;21(7):823–9 (60 ref.)

PHARMACOLOGY

Adrenergic regulation of brown adipocyte differentiation. Cannon B, et al. **Biochem Soc Trans** 1996 May;24(2):407–12 (29 ref.)

Catecholamine-induced leukocytosis: early observations, current research, and future directions. Benschop RJ, et al. **Brain Behav Immun** 1996 Jun;10(2):77–91 (103 ref.)

Serotonin, norepinephrine and associated neuropeptides: effects on somatic motoneuron excitability. White SR, et al. **Prog Brain Res** 1996;107:183–99 (111 ref.)

[Hormone-mediated calcium responses of rat and human hepatocytes. Study of multicellular systems by videomicroscopy] Tordjmann T, et al. **Gastroenterol Clin Biol** 1995 Dec;19(12):980–90 (24 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Noradrenergic alterations in posttraumatic stress disorder. Southwick SM, et al. **Ann N Y Acad Sci** 1997 Jun 21; 821:125–41 (115 ref.)

Detection of serotonergic and noradrenergic antidepressants in the rat forced swimming test: the effects of water depth. Detke MJ, et al. **Behav Brain Res** 1996;73(1–2):43–6 (20 ref.)

The serotonergic and noradrenergic systems of the hippocampus: their interactions and the effects of antidepressant treatments. Mongeau R, et al. **Brain Res Brain Res Rev** 1997 Apr;23(3):145–95 (501 ref.)

The biological basis of panic disorder. Krystal JH, et al. **J Clin Psychiatry** 1996;57 Suppl 10:23–31; discussion 32–3 (76 ref.)

Catecholamine regulation of the prefrontal cortex. Arnsten AF. **J Psychopharmacol (Oxf)** 1997;11(2):151–62 (170 ref.)

Noradrenergic mechanisms in the prefrontal cortex. Nutt DJ, et al. **J Psychopharmacol (Oxf)** 1997;11(2):163–8 (45 ref.)

Innervation of the adrenal cortex, its physiological relevance, with primary focus on the noradrenergic transmission. Tóth IE, et al. **Microsc Res Tech** 1997 Mar 15;36(6):534–45 (93 ref.)

Neurotransmission by neurons that use serotonin, noradrenaline, glutamate, glycine, and gamma-aminobutyric acid in the normal and injured spinal cord. Shapiro S. **Neurosurgery** 1997 Jan;40(1):168–76; discussion 177 (109 ref.)

Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Stimmel GL, et al. **Pharmacotherapy** 1997 Jan–Feb;17(1):10–21 (60 ref.)

[Sympathetic nervous system in heart failure: effect of catecholamines and nitric oxide] Drexler H. **Z Kardiol** 1996; 85 Suppl 6:247–52 (30 ref.) (Eng. Abstr.) **(Ger)**

SECRETION

Selective neural regulation of epinephrine and norepinephrine cells in the adrenal medulla — cardiovascular implications. Vollmer RR. **Clin Exp Hypertens** 1996 Aug;18(6):731–51 (75 ref.)

[Noradrenaline secreting glomus jugulare tumor (intracranial pheochromocytoma)] Kudoh Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):595–7 (13 ref.) **(Jpn)**

URINE

Catecholamines in attention-deficit hyperactivity disorder: current perspectives [see comments] Pliszka SR, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Mar;35(3):264–72 (72 ref.) Comment in: J Am Acad Child Adolesc Psychiatry 1997 Jul;36(7):869–70.

L-NORGESTREL see **LEVONORGESTREL**

NORMAL RANGE see **REFERENCE VALUES**

NORMAL SERUM GLOBULIN THERAPY see **IMMUNIZATION, PASSIVE**

NORMAL VALUES see **REFERENCE VALUES**

NORMOBLASTS see **ERYTHROBLASTS**

NORPREGNENES

ADVERSE EFFECTS

Pharmacokinetics of the new progestogens and influence of gestodene and desogestrel on ethinylestradiol metabolism. Stanczyk FZ. **Contraception** 1997 May;55(5):273–82 (38 ref.)

Comments on desogestrel and gestoden (3rd generation progestogens) and the incidence of thromboembolism. Lauritzen C. **Horm Metab Res** 1996 May;28(5):245–7 (11 ref.)

Oral contraceptives and venous thromboembolism. Speroff L. **Int J Gynaecol Obstet** 1996 Jul;54(1):45–50 (22 ref.)

NORTHERN BLOTTING see **BLOTTING, NORTHERN**

NORTRIPTYLINE

THERAPEUTIC USE

Treatment of major depression in later life: a life cycle perspective. Reynolds CF 3rd. **Psychiatr Q** 1997 Fall; 68(3):221–46 (66 ref.)

NORWALK VIRUS

Overview of viral gastroenteritis. Kapikian AZ. **Arch Virol Suppl** 1996;12:7–19 (38 ref.)

Viral gastroenteritis: small round structured viruses, caliciviruses and astroviruses. Part II. The epidemiological perspective. Caul EO. **J Clin Pathol** 1996 Dec; 49(12):959–64 (72 ref.)

[Acute gastroenteritis caused by small round viruses] Haim M, et al. **Harefuah** 1997 Mar 16;132(6):427–31 (45 ref.) **(Heb)**

CLASSIFICATION

Viral gastroenteritis: small round structured viruses, caliciviruses and astroviruses. Part I. The clinical and diagnostic perspective. Caul EO. **J Clin Pathol** 1996 Nov; 49(11):874–80 (58 ref.)

ISOLATION & PURIFICATION

New molecular methods for the detection of hepatitis A and Norwalk viruses in shellfish. Romalde JL. **Microbiologia** 1996 Dec;12(4):547–56 (39 ref.)

NOSE

see related

RHINOPLASTY

Miniature disc battery in the nose: a dangerous foreign body. Alvi A, et al. **Clin Pediatr (Phila)** 1997 Jul;36(7):427–9 (5 ref.)

ABNORMALITIES

Frontonasal malformation and the oculoauriculovertebral spectrum: the oculoauriculofrontonasal syndrome. Casey HD, et al. **Cleft Palate Craniofac J** 1996 Nov;33(6):519–23 (14 ref.)

Fronto-facio-nasal dysplasia. Suthers G, et al. **Clin Dysmorphol** 1997 Jul;6(3):245–9 (10 ref.)

Heminasal aplasia: a case report and review of the literature of the last 25 years. van Kempen AA, et al. **Clin Dysmorphol** 1997 Apr;6(2):147–52 (32 ref.)

Congenital nasal comedones--report of three cases. Piqué E, et al. **Clin Exp Dermatol** 1996 May;21(3):220–1 (6 ref.)

Imaging of facial anomalies. Castillo M, et al. **Curr Probl Diagn Radiol** 1995 Sep–Oct;25(5):169–88 (28 ref.)

[CHARGE association] Tsukahara M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):247–9 (20 ref.) **(Jpn)**

ANATOMY & HISTOLOGY

Review of the functional anatomy of the cartilages and muscles of the nose. Bruintjes TD, et al. **Rhinology** 1996 Jun;34(2):66–74 (54 ref.)

IMMUNOLOGY

The link between the nose and lung, perennial rhinitis and asthma--is it the same disease? Rowe-Jones JM. **Allergy** 1997;52(36 Suppl):20–8 (124 ref.)

INNERVATION

Neuroregulation of the nose and bronchi. Widdicombe JG. **Clin Exp Allergy** 1996 May;26 Suppl 3:32–5 (20 ref.)

PATHOLOGY

Challenge tests in nose and bronchi: pharmacological modulation of rhinitis and asthma. Mygind N, et al. **Clin Exp Allergy** 1996 May;26 Suppl 3:39–43 (35 ref.)

Response of nose and bronchi to exercise in asthma and rhinitis: similarities and differences. Picado C. **Clin Exp Allergy** 1996 May;26 Suppl 3:36–8 (9 ref.)

PHYSIOLOGY

Aging of the normal nose in adults. Edelstein DR. **Laryngoscope** 1996 Sep;106(9 Pt 2):1–25 (132 ref.)

SURGERY

Repair of defects of the nasal ala. Humphreys TR, et al. **Dermatol Surg** 1997 May;23(5):335–49; quiz 350–1 (32 ref.)

Lateral rhinotomy and medial maxillectomy. Weisman R. **Otolaryngol Clin North Am** 1995 Dec;28(6):1145–56 (23 ref.)

NOSE BLEED see **EPISTAXIS**

NOSE DEFORMITIES, ACQUIRED

SURGERY

Repair of defects of the nasal ala. Humphreys TR, et al. **Dermatol Surg** 1997 May;23(5):335–49; quiz 350–1 (32 ref.)

[The deviated nose. Classification and treatment. Apropos of 100 cases] Tomasi M, et al. **Ann Otolaryngol Chir Cervicofac** 1997;114(1–2):41–50 (26 ref.) (Eng. Abstr.) **(Fre)**

NOSE DISEASES

DIAGNOSIS

Nasal tuberculosis in the 20th century. Butt AA. **Am J Med Sci** 1997 Jun;313(6):332–5 (27 ref.)

Ossifying fasciitis of the nose. Innocenzi D, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):357–61 (17 ref.)
Diagnostic nasal endoscopy. Pownell PH, et al. **Plast Reconstr Surg** 1997 Apr;99(5):1451–8 (31 ref.)
Office procedures. Nasopharyngoscopy. Patton DD. **Prim Care** 1997 Jun;24(2):359–74 (18 ref.)
[Modern functional diagnosis of the nose and paranasal sinuses] Deitmer T. **Eur Arch Otorhinolaryngol Suppl** 1996; 1:1–71 (447 ref.) **(Ger)**

EPIDEMIOLOGY

Nasal tuberculosis in the 20th century. Butt AA. **Am J Med Sci** 1997 Jun;313(6):332–5 (27 ref.)

ETIOLOGY

Birth trauma causing nasal vestibular stenosis. Jablon JH, et al. **Arch Otolaryngol Head Neck Surg** 1997 Sep; 123(9):1004–6 (10 ref.)
Cystic lesions of the nasal cavity and the paranasal sinuses: report of two unusual cases. Vele DD, et al. **J Laryngol Otol** 1996 Dec;110(12):1157–60 (7 ref.)

MICROBIOLOGY

Chronic rhinocerebral mucormycosis. Harril WC, et al. **Laryngoscope** 1996 Oct;106(10):1292–7 (23 ref.)

PATHOLOGY

Cranio-facial fibro-osseous dysplasia. A case report and overview of the management of the condition. Delap TG, et al. **Int J Pediatr Otorhinolaryngol** 1996 Oct;37(2):179–91 (37 ref.)

SURGERY

[Endonasal surgery of the paranasal sinuses—concepts, techniques, results, complications and revision interventions] Hosemann W. **Eur Arch Otorhinolaryngol Suppl** 1996;1:155–269 (894 ref.) **(Ger)**

NOSE NEOPLASMS

Esthesioneuroblastoma: a general review of the cases published since the discovery of the tumour in 1924. Broich G, et al. **Anticancer Res** 1997 Jul–Aug;17(4A):2683–706 (261 ref.)

CHEMICALLY INDUCED

Malignant melanoma and levodopa: is there a relationship? Two new cases and a review of the literature. Pfützner W, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):332–6 (68 ref.)
A brief review of formaldehyde carcinogenesis in relation to rat nasal pathology and human health risk assessment. Morgan KT. **Toxicol Pathol** 1997 May–Jun;25(3):291–307 (142 ref.)

CONGENITAL

Congenital midline nasal masses: dermoids, gliomas, and encephaloceles. Fitzpatrick E, et al. **J La State Med Soc** 1996 Mar;148(3):93–6 (16 ref.)
Hair follicle nevus: case report and review of the literature. Davis DA, et al. **Pediatr Dermatol** 1996 Mar–Apr; 13(2):135–8 (24 ref.)

DIAGNOSIS

Vascular leiomyoma of the superior turbinate: first reported case. Nall AV, et al. **Head Neck** 1997 Jan;19(1):63–7 (15 ref.)
Leiomyosarcoma of the nasal cavity. Case report and literature review. Lippert BM, et al. **ORL J Otorhinolaryngol Relat Spec** 1996 Mar–Apr; 58(2):115–20 (49 ref.)
[Imaging of non-osseous malignant tumors of the anterior skull base. Preoperative evaluation] Elkeslassy A, et al. **Neurochirurgie** 1997;43(2):68–75 (47 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Wood dust and nasal cancer risk. A review of the evidence from North America. Blot WJ, et al. **J Occup Environ Med** 1997 Feb;39(2):148–56 (51 ref.)

NURSING

Surgical treatment for intranasal squamous cell carcinoma. McEwen DR, et al. **AORN J** 1996 Jan;63(1):163–75; quiz 176, 179, 181–2 (15 ref.)

PATHOLOGY

Squamous carcinoma of the nasal vestibule: an analysis of five cases and literature review. Taxy JB. **Am J Clin Pathol** 1997 Jun;107(6):698–703 (10 ref.)
Oncocytoma of the nasal cavity: report of a case and review of the literature. Comin CE, et al. **J Laryngol Otol** 1997 Jul;111(7):671–3 (13 ref.)
Microcystic adnexal carcinoma. Kirkland PM, et al. **J Laryngol Otol** 1997 Jul;111(7):674–5 (5 ref.)
Osteoblastoma of the nasal cavity invading the anterior skull base in a young child. Case report. Imai K, et al. **J Neurosurg** 1997 Oct;87(4):625–8 (9 ref.)
Current status and new developments in techniques for imaging the nose and sinuses. Phillips CD. **Otolaryngol Clin North Am** 1997 Jun;30(3):371–87 (66 ref.)
[Two cases of pleomorphic adenoma of the nasal cavity] Wakami S, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Jan;99(1):38–45 (60 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Current status and new developments in techniques for imaging the nose and sinuses. Phillips CD. **Otolaryngol Clin North Am** 1997 Jun;30(3):371–87 (66 ref.)

SECONDARY

Cutaneous metastasis of ocular malignant melanoma. An unusual presentation simulating blue nevi. Wieselthier JS, et al. **Am J Dermatopathol** 1996 Jun;18(3):289–95 (17 ref.)

SURGERY

Bilateral sinonasal papillomas in aplastic maxillary sinuses. Tsue TT, et al. **Am J Otolaryngol** 1997 Jul–Aug;18(4):263–8 (36 ref.)
Surgical treatment for intranasal squamous cell carcinoma. McEwen DR, et al. **AORN J** 1996 Jan;63(1):163–75; quiz 176, 179, 181–2 (15 ref.)
Vascular leiomyoma of the superior turbinate: first reported case. Nall AV, et al. **Head Neck** 1997 Jan;19(1):63–7 (15 ref.)
Inverted papilloma of the nose and paranasal sinuses: a study of 56 cases and review of the literature. Raveh E, et al. **Isr J Med Sci** 1996 Dec;32(12):1163–7 (21 ref.)
[Surgery of primary malignant melanomas of the mucosa of the nasal fossa and facial sinuses] Laccourreye O, et al. **Ann Otolaryngol Chir Cervicofac** 1996;113(3):163–9 (30 ref.) (Eng. Abstr.) **(Fre)**
[Endonasal surgery of the paranasal sinuses—concepts, techniques, results, complications and revision interventions] Hosemann W. **Eur Arch Otorhinolaryngol Suppl** 1996;1:155–269 (894 ref.) **(Ger)**

VETERINARY

Tumours of the nasal cavity. Schuller HM. **IARC Sci Publ** 1996;(126):175–87 (28 ref.)
Retrovirus-associated neoplasms of the respiratory system of sheep and goats. Ovine pulmonary carcinoma and enzootic nasal tumor. DeMartini JC, et al. **Vet Clin North Am Food Anim Pract** 1997 Mar;13(1):55–70 (73 ref.)

VIROLOGY

Survey of sinonasal inverted papillomata for Epstein–Barr virus. Dunn ST, et al. **Head Neck** 1997 Mar;19(2):98–106 (65 ref.)
[Immunophenotype of nasal T-cell lymphoma] Eizuru Y, et al. **Nippon Rinsho** 1997 Feb;55(2):400–3 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Clinical, phenotypic and genotypic aspects of nasal T-cell lymphoma and its causal association with Epstein–Barr virus] Harabuchi Y, et al. **Nippon Rinsho** 1997 Feb; 55(2):394–9 (18 ref.) (Eng. Abstr.) **(Jpn)**

NOSEBLEED see **EPISTAXIS**

NOSOCOMIAL INFECTIONS see **CROSS INFECTION**

NOTIFICATION, DISEASE see **DISEASE NOTIFICATION**

NOTIFICATION, PARTNER see **CONTACT TRACING**

NOTOCHORD

METABOLISM

Neural patterning: A forward role for hedgehog. Lumsden A, et al. **Curr Biol** 1995 Dec 1;5(12):1347–50 (25 ref.)

NOVELTY-SEEKING BEHAVIOR see **EXPLORATORY BEHAVIOR**

NTR GENES see **GENES, NITROGEN FIXATION**

NUCLEAR ACCIDENTS see **ACCIDENTS, RADIATION**

NUCLEAR AND CYTOPLASMIC RECEPTORS see **RECEPTORS, CYTOPLASMIC AND NUCLEAR**

NUCLEAR ENERGY

see related
RADIATION PROTECTION
RADIOACTIVE WASTE

Nuclear energy facilities and cancers. Wakeford R, et al. **Ann Acad Med Singapore** 1996 May;25(3):468–76 (75 ref.)

NUCLEAR ENVELOPE see **NUCLEAR MEMBRANE**

NUCLEAR FACTOR KAPPA B see **NF-KAPPA B**

NUCLEAR FAMILY

Patch test response to house dust mites is positive in children with atopic dermatitis and in their parents. Meglio P, et al. **J Investig Allergol Clin Immunol** 1996 May–Jun; 6(3):190–5 (33 ref.)

NUCLEAR MAGNETIC RESONANCE

see related
MAGNETIC RESONANCE IMAGING

A systematic NMR approach for the determination of the molecular structure of steroidal saponins. Agrawal PK. **Adv Exp Med Biol** 1996;405:299–315 (117 ref.)
NMR structural studies of fumonisin B1 and related compounds from Fusarium moniliforme. Blackwell BA, et al. **Adv Exp Med Biol** 1996;392:75–91 (35 ref.)
Proton and carbon-13 NMR studies of steroids and triterpenes. Cordell GA, et al. **Adv Exp Med Biol** 1996; 405:281–97 (96 ref.)
MRI-MRS of the brain in systemic lupus erythematosus. How do we use it to understand causes of clinical signs? Tanabe J, et al. **Ann N Y Acad Sci** 1997 Aug 14;823:169–84 (53 ref.)
Magnetic resonance spectroscopy and spectroscopic imaging for the study of brain metabolism. Van Zijl PC, et al. **Ann N Y Acad Sci** 1997 May 30;820:75–96 (51 ref.)
Use of 19F NMR to probe protein structure and conformational changes. Danielson MA, et al. **Annu Rev Biophys Biomol Struct** 1996;25:163–95 (98 ref.)
Electron paramagnetic resonance and nuclear magnetic resonance studies of class I ribonucleotide reductase. Gräslund A, et al. **Annu Rev Biophys Biomol Struct** 1996; 25:259–86 (64 ref.)
NMR and x-ray studies of collagen model peptides. Mayo KH. **Biopolymers** 1996;40(4):359–70 (113 ref.)
Isotopic methods for probing organization of cellular metabolism. Sherry AD, et al. **Cell Biochem Funct** 1996 Dec;14(4):259–68 (34 ref.)
Metabolic imaging in the diagnosis of brain tumors. Slosman DO, et al. **Curr Opin Neurol** 1996 Dec;9(6):429–35 (46 ref.)
Nuclear magnetic resonance spectroscopy: new insights into the pathophysiology of mood disorders. Soares JC, et al. **Depression** 1996;4(1):14–30 (165 ref.)
Origins of biological magnetic resonance. Gaffney BJ. **FASEB J** 1996 Oct;10(12):1448–51 (48 ref.)
In vivo hepatic magnetic resonance spectroscopy: clinical or research tool? Jalan R, et al. **J Hepatol** 1996 Sep; 25(3):414–24 (78 ref.)
The application of magnetic resonance spectroscopy to the study of hepatic encephalopathy. Seery JP, et al. **J Hepatol** 1996 Dec;25(6):988–98 (75 ref.)
The role of magnetic resonance spectroscopy in the investigation of lactic acidosis and inborn errors of energy metabolism. Gadian DG, et al. **J Inherit Metab Dis** 1996; 19(4):548–52 (21 ref.)
Magnetic resonance spectroscopy (MRS) in the evaluation of pediatric brain tumors, Part I: Introduction to MRS. Byrd SE, et al. **J Natl Med Assoc** 1996 Oct;88(10):649–54 (15 ref.)
Nuclear magnetic resonance spectroscopy of skeletal muscle and muscle proteins. Yamada T, et al. **Jpn J Physiol** 1996 Jun;46(3):201–13 (87 ref.)
The 13C isotope and nuclear magnetic resonance: unique tools for the study of brain metabolism. Mason GF, et al. **Metab Brain Dis** 1996 Dec;11(4):283–313 (85 ref.)
Spectrometer calibration and experimental setup. Basic principles and procedures. Brereton IM. **Methods Mol Biol** 1997;60:363–410 (65 ref.)
Studies of protein–ligand interactions by NMR. Craik DJ, et al. **Methods Mol Biol** 1997;60:195–232 (61 ref.)
Metal NMR for the study of metalloproteins. Drakenberg T, et al. **Methods Mol Biol** 1997;60:299–323 (67 ref.)
Calculating protein structures from NMR data. Güntert P. **Methods Mol Biol** 1997;60:157–94 (101 ref.)
NMR studies of peptides and proteins associated with membranes. Klassen RB, et al. **Methods Mol Biol** 1997; 60:271–97 (68 ref.)
A case history. NMR studies of the structure of a small protein, omega-conotoxin MVIIA. MacLachlan LK, et al. **Methods Mol Biol** 1997;60:337–62 (38 ref.)
Production and characterization of recombinant proteins for NMR structural studies. Mossakowska DE, et al. **Methods Mol Biol** 1997;60:325–35 (24 ref.)
NMR of paramagnetic proteins. Osborne MJ, et al. **Methods Mol Biol** 1997;60:233–69 (101 ref.)
Data processing in multidimensional NMR. Pelczer I, et al. **Methods Mol Biol** 1997;60:71–155 (388 ref.)
Introduction to the NMR of proteins. Reid DG, et al. **Methods Mol Biol** 1997;60:1–28 (55 ref.)
Double and triple resonance NMR methods for protein assignment. Whitehead B, et al. **Methods Mol Biol** 1997; 60:29–52 (60 ref.)
Protein chemical shifts. Williamson MP, et al. **Methods Mol Biol** 1997;60:53–69 (25 ref.)
NMR spectroscopy of peptides and proteins. Practical considerations. Hinds MG, et al. **Mol Biotechnol** 1997 Jun; 7(3):315–31 (87 ref.)
High-field NMR as a technique for the determination of polysaccharide structures. Mulloy B. **Mol Biotechnol** 1996 Dec;6(3):241–65 (164 ref.)
Magnetic resonance as a tool to study sarcopenia. McCully

NUCLEAR MAGNETIC RESONANCE

K. **Muscle Nerve Suppl** 1997;5:S102–6 (29 ref.)
Introduction to hippocampal spectroscopy. Jackson EF, et al. **Neuroimaging Clin N Am** 1997 Feb;7(1):143–54 (125 ref.)
Localized proton magnetic resonance spectroscopy of cerebral metabolites. Frahm J, et al. **Neuropediatrics** 1996 Apr;27(2):64–9 (30 ref.)
NMR relaxation data of water proton in normal tissues. Akber SF. **Physiol Chem Phys Med NMR** 1996; 28(4):205–38 (234 ref.)
The solution structure of paramagnetic metalloproteins. Bertini I, et al. **Prog Biophys Mol Biol** 1996;66(1):43–80 (148 ref.)
Multinuclear solid-state NMR studies of acidic and non-acidic hydroxyl protons in zeolites. Hunger M. **Solid State Nucl Magn Reson** 1996 Feb;6(1):1–29 (151 ref.)
[Magnetic resonance spectroscopy in the studies of cancer cell biology and anticarcinogen] Si YK. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan;27(1):85–7 (7 ref.) **(Chi)**
[NMR and other physical methods] Akutsu H. **Nippon Rinsho** 1996 Mar;54(3):725–30 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Recent clinical applications of MR medicine as functional medical imaging in the brain and heart] Nishimura T. **Nippon Rinsho** 1997 Jul;55(7):1621–7 (5 ref.) (Eng. Abstr.) **(Jpn)**
[Three dimensional structure of CXC chemokines and its implication for the receptor recognition] Haruyama H, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):982–8 (38 ref.) **(Jpn)**
[Visualization of protein–DNA interactions] Sarai A. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1004–7 (11 ref.) **(Jpn)**
[Conformational ensembles of biopolymers] Suzuki E. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):989–95 (9 ref.) **(Jpn)**
[Structure and ligand recognition of pleckstrin homology domain] Terasawa H, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):996–1003 (49 ref.) **(Jpn)**

DIAGNOSTIC USE

The application of magnetic resonance techniques to the evaluation of the patient with sickle-cell disease. Terk MR, et al. **Biomed Instrum Technol** 1996 Jul–Aug;30(4):349–53 (12 ref.)
Proton magnetic resonance spectroscopy: the new gold standard for diagnosis of clinical and subclinical hepatic encephalopathy? Ross BD, et al. **Dig Dis** 1996;14 Suppl 1:30–9 (23 ref.)
Clinical applications of magnetic resonance spectroscopy. Laxer KD. **Epilepsia** 1997;38 Suppl 4:S13–7 (26 ref.)
[The most rapid detection of ischemic strokes] Kalvach P. **Vnitr Lek** 1997 Jan;43(1):29–33 (18 ref.) **(Cze)**
[Evaluation of dynamic change of cerebral metabolism using of MR spectroscopy] Mashima Y. **Nippon Rinsho** 1997 Mar; 55 Suppl 1:341–4 (6 ref.) **(Jpn)**
[Mapping of cerebral metabolism on cerebral disorders using multi-slice proton magnetic resonance spectroscopic imaging] Tanaka C, et al. **Nippon Rinsho** 1997 Jul; 55(7):1779–84 (4 ref.) (Eng. Abstr.) **(Jpn)**
[Clinical efficacy of three-dimensional chemical shift imaging (3D-CSI)--a study of 3D-CSI in the human heart and its clinical perspectives for the future] Yabe T, et al. **Nippon Rinsho** 1997 Jul;55(7):1839–43 (14 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Is there a different type of MR-contrast in the early phase of functional activation? Hennig J, et al. **Adv Exp Med Biol** 1997;413:35–42 (12 ref.)
The MRT1 based perfusion model. Kwong KK, et al. **Adv Exp Med Biol** 1997;413:27–34 (11 ref.)
New histological and physiological stains derived from diffusion-tensor MR images. Basser PJ. **Ann N Y Acad Sci** 1997 May 30;820:123–38 (45 ref.)
Site-specific dynamics in DNA: experiments. Robinson BH, et al. **Annu Rev Biophys Biomol Struct** 1997;26:629–58 (56 ref.)
Theory and practice of nuclear spin relaxation in proteins. Dayie KT, et al. **Annu Rev Phys Chem** 1996;47:243–82 (147 ref.)
Insights into protein folding from NMR. Dyson HJ, et al. **Annu Rev Phys Chem** 1996;47:369–95 (144 ref.)
31P NMR spectroscopy in oligonucleotide research and development. Hirschbein BL, et al. **Antisense Nucleic Acid Drug Dev** 1997 Feb;7(1):55–61 (16 ref.)
NMR methods for the study of protein structure and dynamics. Kay LE. **Biochem Cell Biol** 1997;75(1):1–15 (41 ref.)
The application of NMR spectroscopy to the study of apoptosis. Bhakoo KK, et al. **Cell Mol Biol (Noisy-le-grand)** 1997 Jul;43(5):621–9 (28 ref.)
NMR perfusion and metabolic imaging and some examples on brain tumours. Bovée WM, et al. **Cell Mol Biol (Noisy-le-grand)** 1997 Jul;43(5):675–89 (41 ref.)
Magentization transfer study of creatine kinase in myocardium. Potential clinical interest of in vivo enzymology. Joubert F, et al. **Cell Mol Biol (Noisy-le-grand)** 1997 Jul;43(5):763–72 (68 ref.)
Nuclear magnetic resonance (NMR) analysis of ligand receptor interactions: the cholinergic system--a model. Fraenkel Y, et al. **Crit Rev Biochem Mol Biol** 1996; 31(4):273–301 (149 ref.)
Magnetic resonance and functional magnetic resonance imaging: tools for the study of human epilepsy. Kuzniecky R. **Curr Opin Neurol** 1997 Apr;10(2):88–91 (24 ref.)
New nuclear magnetic resonance data in epilepsy. Prichard JW. **Curr Opin Neurol** 1997 Apr;10(2):98–102 (34 ref.)
High-resolution NMR of biological solids. McDowell LM, et al. **Curr Opin Struct Biol** 1996 Oct;6(5):624–9 (59 ref.)
Directly coupled HPLC–NMR and its application to drug metabolism. Lindon JC, et al. **Drug Metab Rev** 1997 Aug; 29(3):705–46 (52 ref.)
Phosphorus magnetic resonance spectroscopy of the human heart: current status and clinical implications. Beyerbacht HP, et al. **Eur Heart J** 1996 Aug;17(8):1158–66 (55 ref.)
Diagnosing testicular function using 31P magnetic resonance spectroscopy: a current review. van der Grond J. **Hum Reprod Update** 1995 May;1(3):276–83 (57 ref.)
A new variant of the 3D PFG homonuclear double-quantum experiments with NOESY and TOCSY steps. Dalvit C. **J Magn Reson B** 1996 Aug;112(2):186–9 (21 ref.)
The manipulation of water relaxation and water suppression in biological systems using the water-PRESS pulse sequence. Price WS, et al. **J Magn Reson B** 1996 Aug; 112(2):190–2 (20 ref.)
Multinuclear MR frequency shifts of hydrated ions as a function of applied pressure and temperature. Sarkar SN, et al. **J Magn Reson B** 1996 Aug;112(2):197–9 (12 ref.)
1H nuclear magnetic resonance (NMR) in the elucidation of peptide structure. Guthrie DJ. **Methods Mol Biol** 1997; 73:163–84 (25 ref.)
The study of membrane- or receptor-bound neuropeptides by NMR. Hicks RP. **Methods Mol Biol** 1997;73:185–207 (50 ref.)
Through a magnet, clearly [editorial; comment] **Nat Struct Biol** 1997 Mar;4(3):159–60 (12 ref.) Comment on: Nat Struct Biol 1997 Mar;4(3):167–9.
The other kind of biological NMR--studies of enzyme-substrate interactions. Roberts GC. **Neurochem Res** 1996 Sep;21(9):1117–24 (36 ref.)
Magnetic resonance imaging and spectroscopy of the brain in propionic acidemia: clinical and biochemical considerations. Bergman AJ, et al. **Pediatr Res** 1996 Sep; 40(3):404–9 (30 ref.)
Development and applications of in vivo clinical magnetic resonance spectroscopy. Cox IJ. **Prog Biophys Mol Biol** 1996;65(1–2):45–81 (167 ref.)
Magic angle spinning NMR spectroscopy of membrane proteins. Smith SO, et al. **Q Rev Biophys** 1996 Dec; 29(4):395–449 (213 ref.)
Recent progress in understanding chemical shifts. de Dios AC, et al. **Solid State Nucl Magn Reson** 1996 Apr; 6(2):101–25 (155 ref.)
Magic echoes and NMR imaging of solids. Hafner S, et al. **Solid State Nucl Magn Reson** 1996 Jul;6(4):275–93 (69 ref.)
Characterization of elastomeric materials by NMR-microscopy. Kuhn W, et al. **Solid State Nucl Magn Reson** 1996 Jul;6(4):295–308 (21 ref.)
New applications of simulated annealing in X-ray crystallography and solution NMR. Brünger AT, et al. **Structure** 1997 Mar 15;5(3):325–36 (82 ref.)
Use of deuterium labeling in NMR: overcoming a sizeable problem. Sattler M, et al. **Structure** 1996 Nov 15; 4(11):1245–9 (32 ref.)
[Technical aspect of clinical spectroscopic imaging and its recent development--hardware and software] Inubushi T. **Nippon Rinsho** 1997 Jul;55(7):1655–9 (7 ref.) (Eng. Abstr.) **(Jpn)**

NUCLEAR MATRIX

Dynamic continuity of nuclear and mitotic matrix proteins in the cell cycle. Mancini MA, et al. **J Cell Biochem** 1996 Aug;62(2):158–64 (55 ref.)

CHEMISTRY

Histone modifications, chromatin structure, and the nuclear matrix. Davie JR. **J Cell Biochem** 1996 Aug;62(2):149–57 (39 ref.)

GENETICS

Nuclear matrix, dynamic histone acetylation and transcriptionally active chromatin. Davie JR. **Mol Biol Rep** 1997 Aug;24(3):197–207 (159 ref.)

METABOLISM

Scaffold/matrix-attached regions: topological switches with multiple regulatory functions. Bode J, et al. **Crit Rev Eukaryot Gene Expr** 1996;6(2–3):115–38 (135 ref.)
Nuclear matrix as an anchor for protein kinase CK2 nuclear signalling. Tawfic S, et al. **J Cell Biochem** 1996 Aug; 62(2):165–71 (36 ref.)
Nuclear matrix, dynamic histone acetylation and transcriptionally active chromatin. Davie JR. **Mol Biol Rep** 1997 Aug;24(3):197–207 (159 ref.)
Poly(ADP-ribosyl)ation and nuclear matrix/intermediate filament proteins in renal carcinogenesis. Vamvakas S, et al. **Recent Results Cancer Res** 1997;143:195–208 (60 ref.)
Neutrophil proteinases and matrix degradation. The cell biology of pericellular proteolysis. Owen CA, et al. **Semin Cell Biol** 1995 Dec;6(6):367–76 (75 ref.)

PHYSIOLOGY

Role of the nuclear matrix in breast cancer. Replogle TS, et al. **Cancer Treat Res** 1996;83:127–40 (53 ref.)
The nuclear matrix: a critical appraisal. Martelli AM, et al. **Histol Histopathol** 1996 Oct;11(4):1035–48 (191 ref.)
Dynamic remodeling of nuclear architecture during the cell cycle. Johansen KM. **J Cell Biochem** 1996 Mar 1; 60(3):289–96 (48 ref.)

ULTRASTRUCTURE

The nuclear matrix: a critical appraisal. Martelli AM, et al. **Histol Histopathol** 1996 Oct;11(4):1035–48 (191 ref.)

NUCLEAR MEDICINE

see related

RADIOISOTOPES

Internet in nuclear medicine. Suzuki Y, et al. **Ann Nucl Med** 1997 Feb;11(1):7–13 (13 ref.)
Nuclear medicine and mathematics [see comments] Pedroso de Lima JJ. **Eur J Nucl Med** 1996 Jun;23(6):705–19 (36 ref.) Comment in: Eur J Nucl Med 1997 Feb;24(2):234.
Caring for the older patient, Part I: The relationship of theory to practice. Dowd SB, et al. **J Nucl Med Technol** 1997 Mar;25(1):24–32; quiz 35 (58 ref.)
Dichotomous thinking in nuclear medicine technology. Dowd SB, et al. **J Nucl Med Technol** 1997 Jun;25(2):120–3 (22 ref.)
Caring for the older patient, Part II: Age-related anatomic and physiologic changes and pathologies. Steves AM, et al. **J Nucl Med Technol** 1997 Jun;25(2):86–97; quiz 103, 105 (44 ref.)

INSTRUMENTATION

Radiation safety review for 511-keV emitters in nuclear medicine. Dell MA. **J Nucl Med Technol** 1997 Mar; 25(1):12–7; quiz 33 (6 ref.)

METHODS

Nuclear medicine applications in immunosuppressed patients, "AIDS". Abdel-Dayem HM. **Ann Nucl Med** 1996 Nov; 10(4):369–73 (46 ref.)
The role of nuclear medicine in children. MacKenzie JR. **Br J Hosp Med** 1997 Mar 19–Apr 1;57(6):248–54 (20 ref.)
Nuclear medicine techniques in the evaluation of pharmaceutical formulations. Perkins AC, et al. **Pharm World Sci** 1996 Jun;18(3):97–104 (96 ref.)
The role of nuclear medicine in pulmonary embolism. Galli G, et al. **Rays** 1996 Jul–Sep;21(3):363–77 (62 ref.) **(Eng, Ita)**
Oncologic imaging: interactions of nuclear medicine with CT and MRI using the bone scan as a model. Tryciecky EW, et al. **Semin Nucl Med** 1997 Apr;27(2):142–51 (39 ref.)
The role of nuclear medicine in diagnosis of catheter-related infections. Scheidhauer K, et al. **Zentralbl Bakteriol** 1995 Dec;283(2):154–60 (14 ref.)
[Echocardiography and nuclear medicine: complementary or alternative methods in the study of the ischemic myocardium? (editorial)] La Canna G, et al. **Cardiologia** 1997 Feb;42(2):123–37 (103 ref.) **(Ita)**
[Consensus SOCESP-SBC on nuclear medicine] Camargo EE, et al. **Arq Bras Cardiol** 1995 Nov;65(5):469–74 (40 ref.) **(Por)**

ORGANIZATION & ADMINISTRATION

Managed care and nuclear medicine in the USA. Sy WM. **Ann Nucl Med** 1997 Feb;11(1):1–6 (14 ref.)

TRENDS

Nuclear oncology and the Imagene concept. Urbain JL, et al. **Acta Radiol Suppl** 1997;412:21–8 (71 ref.)
Topics in pulmonary nuclear medicine. Kawakami K. **Ann Nucl Med** 1997 May;11(2):67–73 (12 ref.)
Nuclear medicine at the crossroads. Strauss HW. **Eur J Nucl Med** 1996 Jun;23(6):697–704 (58 ref.)
Advances in pulmonary nuclear medicine. Salvatori M. **Rays** 1997 Jan–Mar;22(1):51–72 (47 ref.) **(Eng, Ita)**

NUCLEAR MEDICINE DEPARTMENT, HOSPITAL

Radioiodine dispensing and usage in a centralized hospital nuclear pharmacy. Hung JC. **Thyroid** 1997 Apr;7(2):289–94 (31 ref.)

NUCLEAR MEMBRANE

CHEMISTRY

Nuclear pores: David and Goliath in nuclear transport. Moore MS. **Curr Biol** 1995 Dec 1;5(12):1339–41 (11 ref.)

GENETICS

Genetic analysis of macromolecular transport across the nuclear envelope. Corbett A, et al. **Exp Cell Res** 1996 Dec 15;229(2):212–6 (54 ref.)

IMMUNOLOGY

Nuclear envelope protein autoantibodies in primary biliary cirrhosis. Courvalin JC, et al. **Semin Liver Dis** 1997 Feb; 17(1):79–90 (88 ref.)

METABOLISM

Effects of tryptophan related compounds on nuclear regulatory control. Possible role in the eosinophilia–myalgia syndrome. Sidransky H, et al. **Adv Exp Med Biol** 1996;398:343–50 (47 ref.)

Nuclear pore-targeting complex and its role on nuclear protein transport. Yoneda Y. **Arch Histol Cytol** 1996 May; 59(2):97–107 (58 ref.)

Nuclear calcium and the regulation of the nuclear pore complex. Perez-Terzic C, et al. **Bioessays** 1997 Sep; 19(9):787–92 (69 ref.)

A look at messenger RNP moving through the nuclear pore. Daneholt B. **Cell** 1997 Mar 7;88(5):585–8 (20 ref.)

A GTPase controlling nuclear trafficking: running the right way or walking RANdomly? Koepp DM, et al. **Cell** 1996 Oct 4;87(1):1–4 (19 ref.)

Nuclear protein import. Görlich D. **Curr Opin Cell Biol** 1997 Jun;9(3):412–9 (68 ref.)

Genetic analysis of macromolecular transport across the nuclear envelope. Corbett A, et al. **Exp Cell Res** 1996 Dec 15;229(2):212–6 (54 ref.)

Regulatory roles of the nuclear envelope. Laskey RA, et al. **Exp Cell Res** 1996 Dec 15;229(2):204–11 (53 ref.)

Nucleocytoplasmic transport of proteins and control of cellular function. Parnaik VK. **Indian J Biochem Biophys** 1996 Jun;33(3):164–7 (22 ref.)

PHYSIOLOGY

Electric fields and the nuclear membrane [letter] Matzke MA, et al. **Bioessays** 1996 Oct;18(10):849–50 (14 ref.)

From nucleoporins to nuclear pore complexes. Doye V, et al. **Curr Opin Cell Biol** 1997 Jun;9(3):401–11 (92 ref.)

Developmental modulation of the nuclear envelope. Liu J, et al. **Curr Top Dev Biol** 1997;35:47–70 (166 ref.)

Nuclear ion channels and regulation of the nuclear pore. Stehno-Bittel L, et al. **Soc Gen Physiol Ser** 1996;51:195–207 (36 ref.)

Inositol 1,4,5-trisphosphate receptor activation and nuclear envelope assembly. Wilson KL, et al. **Soc Gen Physiol Ser** 1996;51:189–93 (14 ref.)

ULTRASTRUCTURE

Life on biomembranes viewed with the atomic force microscope. Oberleithner H, et al. **Wien Klin Wochenschr** 1997 Jun 27;109(12–13):419–23 (19 ref.)

NUCLEAR POLYHEDROSIS VIRUS see **NUCLEOPOLYHEDROVIRUS**

NUCLEAR PORE see **NUCLEAR MEMBRANE**

NUCLEAR POWER PLANTS see **POWER PLANTS**

NUCLEAR PROTEINS

Staining of the nucleolar organizer regions: relevance in hematology. Baatout S. **Blood Rev** 1996 Sep;10(3):185–8 (33 ref.)

Five years on the wings of fork head. Kaufmann E, et al. **Mech Dev** 1996 Jun;57(1):3–20 (137 ref.)

[Transcription factors NF-IL6 and STAT3 involved in cytokine signal transductions] Akira S. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1237–48 (65 ref.) **(Jpn)**

[Structure and function of PAS proteins: Ah receptor, Arnt, and others] Sogawa K, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1288–96 (47 ref.) **(Jpn)**

ANALYSIS

Standardized AgNOR analysis: its usefulness in surgical oncology. Ofner D, et al. **Histochem Cell Biol** 1996 Aug; 106(2):193–6 (32 ref.)

Dynamic organization of pre-mRNA splicing factors. Huang S, et al. **J Cell Biochem** 1996 Aug;62(2):191–7 (53 ref.)

BIOSYNTHESIS

HIN-200: a novel family of IFN-inducible nuclear proteins expressed in leukocytes. Dawson MJ, et al. **J Leukoc Biol** 1996 Sep;60(3):310–6 (47 ref.)

BLOOD

Utilization of nuclear matrix proteins for cancer diagnosis. Keesee SK, et al. **Crit Rev Eukaryot Gene Expr** 1996; 6(2–3):189–214 (197 ref.)

CHEMISTRY

Chromatin architectural proteins and transcription factors: a structural connection. van Holde K, et al. **Bioessays** 1996 Sep;18(9):697–700 (34 ref.)

Photocross-linking of nucleic acids to associated proteins. Meisenheimer KM, et al. **Crit Rev Biochem Mol Biol** 1997; 32(2):101–40 (121 ref.)

Nuclear pores: David and Goliath in nuclear transport. Moore MS. **Curr Biol** 1995 Dec 1;5(12):1339–41 (11 ref.)

Structural and functional analysis of hypoxia-inducible factor 1. Semenza GL, et al. **Kidney Int** 1997 Feb;51(2):553–5 (27 ref.)

The SANT domain: a putative DNA-binding domain in the SWI-SNF and ADA complexes, the transcriptional co-repressor N-CoR and TFIIIB. Aasland R, et al. **Trends Biochem Sci** 1996 Mar;21(3):87–8 (16 ref.)

Regulation of transcription factor localization: fine-tuning of gene expression. Vandromme M, et al. **Trends Biochem Sci** 1996 Feb;21(2):59–64 (42 ref.)

[Nuclear pore-targeting complex/importin family] Imamoto N. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1401–6 (22 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

The nuclear matrix as a target for cancer therapy. Catapano CV, et al. **Ann Oncol** 1996 Sep;7(7):659–66 (90 ref.)

GENETICS

The hypoxic response: huffing and HIFing. Guillemin K, et al. **Cell** 1997 Apr 4;89(1):9–12 (21 ref.)

Lonely no more: p53 finds its kin in a tumor suppressor haven. Oren M. **Cell** 1997 Sep 5;90(5):829–32 (13 ref.)

PAX: developmental control genes in cell growth and differentiation. Stuart ET, et al. **Cell Growth Differ** 1996 Mar;7(3):405–12 (80 ref.)

RNA splicing: unexpected spliceosome diversity. Kreivi JP, et al. **Curr Biol** 1996 Jul 1;6(7):802–5 (9 ref.)

A myogenic switch. Muscle development. Taylor MV. **Curr Biol** 1996 Aug 1;6(8):924–6 (16 ref.)

Partners in time. Circadian rhythms. Van Gelder RN, et al. **Curr Biol** 1996 Mar 1;6(3):244–6 (16 ref.)

Dosage compensation and chromatin structure in Drosophila. Bashaw GJ, et al. **Curr Opin Genet Dev** 1996 Aug; 6(4):496–501 (41 ref.)

Sox genes find their feet. Pevny LH, et al. **Curr Opin Genet Dev** 1997 Jun;7(3):338–44 (70 ref.)

Impact of migration and fitness on the stability of lethal t-haplotype polymorphism in Mus musculus: a computer study. Durand D, et al. **Genetics** 1997 Apr;145(4):1093–108 (38 ref.)

Single-minded--two genes, three chromosomes. Michaud J, et al. **Genome Res** 1997 Jun;7(6):569–71 (37 ref.)

PML, PLZF and NPM genes in the molecular pathogenesis of acute promyelocytic leukemia. Pandolfi PP. **Haematologica** 1996 Sep-Oct;81(5):472–82 (86 ref.)

Huntington disease: advances in molecular and cell biology. Jones AL, et al. **J Inherit Metab Dis** 1997 Jun;20(2):125–38 (71 ref.)

Molecular analysis of infant acute leukemia. Hilden JM, et al. **Leuk Lymphoma** 1997 Apr;25(3–4):191–9 (65 ref.)

Therapeutic strategies for Huntington's disease based on a molecular understanding of the disorder. Haque NS, et al. **Mol Med Today** 1997 Apr;3(4):175–83 (44 ref.)

H-NS: a modulator of environmentally regulated gene expression. Atlung T, et al. **Mol Microbiol** 1997 Apr; 24(1):7–17 (77 ref.)

Engrailed, Wnt and Pax genes regulate midbrain--hindbrain development. Joyner AL. **Trends Genet** 1996 Jan; 12(1):15–20 (50 ref.)

[Regulatory mechanisms of lymphocyte proliferation: roles of Spa-1 gene] Minato N. **Hum Cell** 1996 Mar;9(1):11–6 (7 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Targeted disruption of the IL-6 related genes: gp130 and NF-IL-6. Akira S, et al. **Immunol Rev** 1995 Dec; 148:221–53 (135 ref.)

The interaction of C-reactive protein and serum amyloid P component with nuclear antigens. Du Clos TW. **Mol Biol Rep** 1996;23(3–4):253–60 (40 ref.)

Autoimmune diseases: nuclear autoantigens can be found at the cell-surface. Jordan P, et al. **Mol Biol Rep** 1995–96; 22(1):63–6 (49 ref.)

Autoantibodies against "nuclear dots" in primary biliary cirrhosis. Szostecki C, et al. **Semin Liver Dis** 1997 Feb; 17(1):71–8 (72 ref.)

METABOLISM

Dynamic O-linked glycosylation of nuclear and cytoskeletal proteins. Hart GW. **Annu Rev Biochem** 1997;66:315–35 (190 ref.)

Nuclear pore-targeting complex and its role on nuclear protein transport. Yoneda Y. **Arch Histol Cytol** 1996 May; 59(2):97–107 (58 ref.)

TIF1 alpha: a chromatin-specific mediator for the ligand-dependent activation function AF-2 of nuclear receptors? Le Douarin B, et al. **Biochem Soc Trans** 1997 May;25(2):605–12 (39 ref.)

The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Brown MS, et al. **Cell** 1997 May 2;89(3):331–40 (63 ref.)

A GTPase controlling nuclear trafficking: running the right way or walking RANdomly? Koepp DM, et al. **Cell** 1996 Oct 4;87(1):1–4 (19 ref.)

Nuclear export receptors: from importin to exportin [comment] Ullman KS, et al. **Cell** 1997 Sep 19;90(6):967–70 (21 ref.) Comment on: Cell 1997 Sep 19;90(6):1051–60. Comment on: Cell 1997 Sep 19;90(6):1061–71.

Roles of importin in nuclear protein import. Görlich D, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:695–9 (24 ref.)

Activity of the retinoblastoma family proteins, pRB, p107, and p130, during cellular proliferation and differentiation. Sidle A, et al. **Crit Rev Biochem Mol Biol** 1996 Jun; 31(3):237–71 (197 ref.)

Molecular mechanisms of nuclear protein transport. Moroianu J. **Crit Rev Eukaryot Gene Expr** 1997; 7(1–2):61–72 (128 ref.)

The utilization of nuclear matrix proteins for cancer diagnosis. Replogle-Schwab R, et al. **Crit Rev Eukaryot Gene Expr** 1996;6(2–3):103–13 (77 ref.)

Signalling pathways: jack of all cascades. Cahill MA, et al. **Curr Biol** 1996 Jan 1;6(1):16–9 (17 ref.)

Versatile molecular glue. Transcriptional control. Janknecht R, et al. **Curr Biol** 1996 Aug 1;6(8):951–4 (25 ref.)

Nuclear pores: David and Goliath in nuclear transport. Moore MS. **Curr Biol** 1995 Dec 1;5(12):1339–41 (11 ref.)

Nuclear protein import. Görlich D. **Curr Opin Cell Biol** 1997 Jun;9(3):412–9 (68 ref.)

Nuclear export of proteins and RNAs. Nakielny S, et al. **Curr Opin Cell Biol** 1997 Jun;9(3):420–9 (81 ref.)

Toward the molecular dissection of protein import into nuclei. Panté N, et al. **Curr Opin Cell Biol** 1996 Jun; 8(3):397–406 (65 ref.)

Threshold responses to the dorsal regulatory gradient and the subdivision of primary tissue territories in the Drosophila embryo. Rusch J, et al. **Curr Opin Genet Dev** 1996 Aug;6(4):416–23 (70 ref.)

Role of the Ku autoantigen in V(D)J recombination and double-strand break repair. Chu G. **Curr Top Microbiol Immunol** 1996;217:113–32 (60 ref.)

rag-1 and rag-2: biochemistry and protein interactions. Schatz DG, et al. **Curr Top Microbiol Immunol** 1996; 217:11–29 (27 ref.)

Dynamic changes in nuclear architecture during mitosis: on the role of protein phosphorylation in spindle assembly and chromosome segregation. Nigg EA, et al. **Exp Cell Res** 1996 Dec 15;229(2):174–80 (80 ref.)

The localization of sites containing nascent RNA and splicing factors. Pombo A, et al. **Exp Cell Res** 1996 Dec 15; 229(2):201–3 (14 ref.)

Thermotolerance and heat shock proteins: possible involvement of Ku autoantigen in regulating Hsp70 expression. Li GC, et al. **EXS** 1996;77:425–49 (116 ref.)

O-GlcNAcylation of key nuclear and cytoskeletal proteins: reciprocity with O-phosphorylation and putative roles in protein multimerization. Hart GW, et al. **Glycobiology** 1996 Oct;6(7):711–6 (120 ref.)

Retinoic acid receptors and nuclear orphan receptors in the development of Xenopus laevis. Dreyer C, et al. **Int J Dev Biol** 1996 Feb;40(1):255–62 (55 ref.)

RCC1 in the Ran pathway. Seki T, et al. **J Biochem (Tokyo)** 1996 Aug;120(2):207–14 (50 ref.)

How proteins are transported from cytoplasm to the nucleus. Yoneda Y. **J Biochem (Tokyo)** 1997 May;121(5):811–7 (55 ref.)

Dynamic continuity of nuclear and mitotic matrix proteins in the cell cycle. Mancini MA, et al. **J Cell Biochem** 1996 Aug;62(2):158–64 (55 ref.)

Structural and functional analysis of hypoxia-inducible factor 1. Semenza GL, et al. **Kidney Int** 1997 Feb;51(2):553–5 (27 ref.)

Splicing glue: a role for SR proteins in trans splicing? Bruzik JP. **Microb Pathog** 1996 Sep;21(3):149–55 (65 ref.)

Poly(ADP-ribosyl)ation and nuclear matrix/intermediate filament proteins in renal carcinogenesis. Vamvakas S, et al. **Recent Results Cancer Res** 1997;143:195–208 (60 ref.)

Regulation of transcription factor localization: fine-tuning of gene expression. Vandromme M, et al. **Trends Biochem Sci** 1996 Feb;21(2):59–64 (42 ref.)

[Molecular mechanism of nuclear protein import] Imamoto N. **Seikagaku** 1997 Jun;69(6):383–93 (75 ref.) **(Jpn)**

[Nuclear transport visualized by protein tagging systems including GFP] Kimata Y, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1187–92 (24 ref.) **(Jpn)**

PHYSIOLOGY

NF-IL6 and NF-kappa B in cytokine gene regulation. Akira S, et al. **Adv Immunol** 1997;65:1–46 (215 ref.)

Controlling growth of the wing: vestigial integrates signals from the compartment boundaries. Cohen SM. **Bioessays** 1996 Nov;18(11):855–8 (42 ref.)

Genetic depletion reveals an essential role for an SR protein splicing factor in vertebrate cells. Mount SM. **Bioessays** 1997 Mar;19(3):189–92 (30 ref.)

The small nuclear GTPase Ran: how much does it run? Rush MG, et al. **Bioessays** 1996 Feb;18(2):103–12 (70 ref.)

p300 and CBP as transcriptional regulators and targets of oncogenic events. Eckner R. **Biol Chem** 1996 Nov; 377(11):685–8 (34 ref.)

Cholesterol homeostasis: clipping out a slippery regulator

NUCLEAR PROTEINS

[published erratum appears in Curr Biol 1997 Apr 1;7(4):285] Osborne TF. **Curr Biol** 1997 Mar 1;7(3):R172–4 (11 ref.)

From nucleoporins to nuclear pore complexes. Doye V, et al. **Curr Opin Cell Biol** 1997 Jun;9(3):401–11 (92 ref.)

Nuclear protein import. Görlich D. **Curr Opin Cell Biol** 1997 Jun;9(3):412–9 (68 ref.)

Tying loose ends: roles of Ku and DNA-dependent protein kinase in the repair of double-strand breaks. Lieber MR, et al. **Curr Opin Genet Dev** 1997 Feb;7(1):99–104 (68 ref.)

Huntington's disease: translating a CAG repeat into a pathogenic mechanism. MacDonald ME, et al. **Curr Opin Neurobiol** 1996 Oct;6(5):638–43 (45 ref.)

TLS-CHOP and the role of RNA-binding proteins in oncogenic transformation. Ron D. **Curr Top Microbiol Immunol** 1997;220:131–42 (53 ref.)

Role of the thyroid-specific enhancer-binding protein in transcription, development and differentiation. Kimura S. **Eur J Endocrinol** 1997 Feb;136(2):128–36 (81 ref.)

Regulating adipogenesis. Mandrup S, et al. **J Biol Chem** 1997 Feb 28;272(9):5367–70 (56 ref.)

Ran, a GTPase involved in nuclear processes: its regulators and effectors. Avis JM, et al. **J Cell Sci** 1996 Oct;109 (Pt 10):2423–7 (56 ref.)

Regulation of gene expression by nuclear hormone receptors. Meier CA. **J Recept Signal Transduct Res** 1997 Jan–May; 17(1–3):319–35 (45 ref.)

DNA-PK: at the cross-roads of biochemistry and genetics. Jeggo PA. **Mutat Res** 1997 Jun 9;384(1):1–14 (119 ref.)

The world according to Maf. Motohashi H, et al. **Nucleic Acids Res** 1997 Aug 1;25(15):2953–59 (60 ref.)

Adipocyte differentiation is regulated by a prostaglandin liganded to the nuclear peroxisome proliferator-activated receptor. Wolf G. **Nutr Rev** 1996 Sep;54(9):290–2 (9 ref.)

The multifunctional role of the co-activator CBP in transcriptional regulation. Goldman PS, et al. **Recent Prog Horm Res** 1997;52:103–19; discussion 119–20 (83 ref.)

Coupling signalling pathways to transcriptional control: nuclear factors responsive to cAMP. Tamai KT, et al. **Recent Prog Horm Res** 1997;52:121–39; discussion 139–40 (93 ref.)

[Nuclear pore-targeting complex/importin family] Imamoto N. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1401–6 (22 ref.) (Eng. Abstr.) **(Jpn)**

URINE

The role of nuclear matrix protein 22 in the detection of persistent or recurrent transitional-cell cancer of the bladder. Shelfo SW, et al. **World J Urol** 1997;15(2):107–11 (25 ref.)

NUCLEAR RADIOLOGY see **NUCLEAR MEDICINE**

NUCLEAR REACTOR ACCIDENTS see **ACCIDENTS, RADIATION**

NUCLEAR REACTORS

see related
ACCIDENTS, RADIATION

Childhood thyroid cancer following the Chernobyl accident: a status report [published erratum appears in Endocrinol Metab Clin North Am 1996 Jun;25(2):xi] Becker DV, et al. **Endocrinol Metab Clin North Am** 1996 Mar; 25(1):197–211 (55 ref.)

External radiation and thyroid neoplasia. Sarne D, et al. **Endocrinol Metab Clin North Am** 1996 Mar;25(1):181–95 (48 ref.)

[Technological problems in use of fast reactors for radiotherapy of patients with malignant tumors] Mardynskii IS, et al. **Vestn Rentgenol Radiol** 1997 Jul–Aug;(4):26–9 (11 ref.) (Eng. Abstr.) **(Rus)**

NUCLEAR TRACK DETECTION see **RADIOMETRY**

NUCLEAR TRANS-ACTING FACTOR see **TRANS-ACTIVATORS**

NUCLEAR WARFARE

see related
RADIOACTIVE FALLOUT

Epidemiology of accidental radiation exposures. Cardis E. **Environ Health Perspect** 1996 May;104 Suppl 3:643–9 (64 ref.)

Nuclear war, disaster medicine, and the veterinary profession. Stalheim OH. **J Am Vet Med Assoc** 1997 Apr 15; 210(8):1102–5 (20 ref.)

Profiles of non-cancer diseases in atomic bomb survivors. Kodama K, et al. **World Health Stat Q** 1996;49(1):7–16 (79 ref.)

NUCLEAR WASTE see **RADIOACTIVE WASTE**

NUCLEASES, DNA see **DEOXYRIBONUCLEASES**

NUCLEASES, RNA see **RIBONUCLEASES**

NUCLEIC ACID CONFORMATION

see related
POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL

"Small is beautiful": major modifications in DNA structure or dynamics by small substituents or ligands. Guschlbauer W. **Acta Biochim Pol** 1996;43(1):77–94 (97 ref.)

Hierarchy and dynamics of RNA folding. Brion P, et al. **Annu Rev Biophys Biomol Struct** 1997;26:113–37 (118 ref.)

Visualizing protein-nucleic acid interactions on a large scale with the scanning force microscope. Bustamante C, et al. **Annu Rev Biophys Biomol Struct** 1996;25:395–429 (93 ref.)

Flexibility of RNA. Hagerman PJ. **Annu Rev Biophys Biomol Struct** 1997;26:139–56 (64 ref.)

Modeling DNA in aqueous solutions: theoretical and computer simulation studies on the ion atmosphere of DNA. Jayaram B, et al. **Annu Rev Biophys Biomol Struct** 1996;25:367–94 (151 ref.)

Circular oligonucleotides: new concepts in oligonucleotide design. Kool ET. **Annu Rev Biophys Biomol Struct** 1996; 25:1–28 (80 ref.)

Recent developments in triple-helix regulation of gene expression. Neidle S. **Anticancer Drug Des** 1997 Jul; 12(5):433–42 (46 ref.)

Structural and functional evidence that initiation and elongation of HIV-1 reverse transcription are distinct processes. Lanchy JM, et al. **Biochimie** 1996; 78(11–12):1087–96 (56 ref.)

Structure and function of 10Sa RNA: trans-translation system. Muto A, et al. **Biochimie** 1996;78(11–12):985–91 (41 ref.)

Dimerization of retroviral genomic RNAs: structural and functional implications. Paillart JC, et al. **Biochimie** 1996; 78(7):639–53 (138 ref.)

Conformational flexibility of tRNA: structural changes in yeast tRNA(Asp) upon binding to aspartyl-tRNA synthetase. Rees B, et al. **Biochimie** 1996;78(7):624–31 (31 ref.)

Sequence-dependent DNA structure. Hunter CA. **Bioessays** 1996 Feb;18(2):157–62 (22 ref.)

RNA structure comes of age. Uhlenbeck OC, et al. **Cell** 1997 Sep 5;90(5):833–40 (46 ref.)

Sequence-dependent structural variation in B-DNA. Grzeskowiak K. **Chem Biol** 1996 Oct;3(10):785–90 (38 ref.)

Discriminating among the discriminator bases of tRNAs. Hou YM. **Chem Biol** 1997 Feb;4(2):93–6 (22 ref.)

RNA splicing: out of the loop. Newman A. **Curr Biol** 1997 Jul 1;7(7):R418–20 (15 ref.)

RNA enzymes: putting together a large ribozyme. Tinoco I Jr. **Curr Biol** 1996 Nov 1;6(11):1374–6 (12 ref.)

DNA-protein interactions: IHF--the master bender. Travers A. **Curr Biol** 1997 Apr 1;7(4):R252–4 (27 ref.)

Three-way and four-way junctions in DNA: a conformational viewpoint. Altona C, et al. **Curr Opin Struct Biol** 1996 Jun;6(3):305–16 (67 ref.)

DNA condensation. Bloomfield VA. **Curr Opin Struct Biol** 1996 Jun;6(3):334–41 (73 ref.)

RNA structure: crystal clear? Doudna JA, et al. **Curr Opin Struct Biol** 1997 Jun;7(3):310–6 (62 ref.)

Hammering away at RNA global structure. Hagerman PJ, et al. **Curr Opin Struct Biol** 1996 Jun;6(3):317–21 (21 ref.)

Unusual DNA conformations. Lebrun A, et al. **Curr Opin Struct Biol** 1997 Jun;7(3):348–54 (68 ref.)

Calculations of nucleic acid conformations. Louise-May S, et al. **Curr Opin Struct Biol** 1996 Jun;6(3):289–98 (89 ref.)

Recent solution structures of RNA and its complexes with drugs, peptides and proteins. Ramos A, et al. **Curr Opin Struct Biol** 1997 Jun;7(3):317–23 (59 ref.)

Making DNA do a U-turn: IHF and related proteins. Rice PA. **Curr Opin Struct Biol** 1997 Feb;7(1):86–93 (61 ref.)

RNA structures and folding: from conventional to new issues in structure predictions. Schuster P, et al. **Curr Opin Struct Biol** 1997 Apr;7(2):229–35 (73 ref.)

Oligonucleotide directed triple helix formation. Sun JS, et al. **Curr Opin Struct Biol** 1996 Jun;6(3):327–33 (63 ref.)

In vitro selection of aptamers: the dearth of pure reason. Uphoff KW, et al. **Curr Opin Struct Biol** 1996 Jun; 6(3):281–8 (51 ref.)

Protein-facilitated RNA folding. Weeks KM. **Curr Opin Struct Biol** 1997 Jun;7(3):336–42 (58 ref.)

Double-strand breaks, DNA hairpins, and the mechanism of V(D)J recombination. Steen SB, et al. **Curr Top Microbiol Immunol** 1996;217:61–77 (60 ref.)

Inverted repeats, stem-loops, and cruciforms: significance for initiation of DNA replication. Pearson CE, et al. **J Cell Biochem** 1996 Oct;63(1):1–22 (225 ref.)

Sheared purine x purine pairing in biology. Chou SH, et al. **J Mol Biol** 1997 Apr 18;267(5):1055–67 (75 ref.)

Recognition and manipulation of branched DNA structure by junction-resolving enzymes. White MF, et al. **J Mol Biol** 1997 Jun 27;269(5):647–64 (140 ref.)

Triplex DNA: fundamentals, advances, and potential applications for gene therapy. Chan PP, et al. **J Mol Med** 1997 Apr;75(4):267–82 (128 ref.)

Targeted mutagenesis mediated by the triple helix formation. Glazer PM, et al. **Methods Mol Biol** 1996;57:109–18 (17 ref.)

Recent approaches to probe functional groups in ribonuclease P RNA by modification interference. Hardt WD, et al. **Mol Biol Rep** 1995–96;22(2–3):161–9 (63 ref.)

Analysis of the tertiary structure of bacterial RNase P RNA. Harris ME, et al. **Mol Biol Rep** 1995–96;22(2–3):115–23 (50 ref.)

RNase P as hyperprocessing enzyme: a model for formation of a biologically functional tRNA fragment. Kikuchi Y. **Mol Biol Rep** 1995–96;22(2–3):171–5 (17 ref.)

Enzymatic RNA synthesis and RNase P. Evolutionary aspects. Krupp G. **Mol Biol Rep** 1995–96;22(2–3):177–80 (29 ref.)

Through a magnet, clearly [editorial; comment] **Nat Struct Biol** 1997 Mar;4(3):159–60 (12 ref.) Comment on: Nat Struct Biol 1997 Mar;4(3):167–9.

Trinucleotide repeats associated with human disease. Mitas M. **Nucleic Acids Res** 1997 Jun 15;25(12):2245–54 (93 ref.)

RNA structure and the regulation of gene expression. Klaff P, et al. **Plant Mol Biol** 1996 Oct;32(1–2):89–106 (147 ref.)

From oligonucleotide shapes to genomic SELEX: novel biological regulatory loops. Gold L, et al. **Proc Natl Acad Sci U S A** 1997 Jan 7;94(1):59–64 (42 ref.)

Do basic region-leucine zipper proteins bend their DNA targets ... does it matter? [comment] Hagerman PJ. **Proc Natl Acad Sci U S A** 1996 Sep 17;93(19):9993–6 (45 ref.) Comment on: Proc Natl Acad Sci U S A 1996 Sep 17;93(19):10117–22.

All change at Holliday junction. Lilley DMJ. **Proc Natl Acad Sci U S A** 1997 Sep 2;94(18):9513–5 (27 ref.)

Structure and function of the human immunodeficiency virus leader RNA. Berkhout B. **Prog Nucleic Acid Res Mol Biol** 1996;54:1–34 (182 ref.)

Mismatch base pairs in RNA. Limmer S. **Prog Nucleic Acid Res Mol Biol** 1997;57:1–39 (129 ref.)

Induction of frameshift mutations at hotspot sequences by carcinogen adducts. Burnouf D, et al. **Recent Results Cancer Res** 1997;143:1–20 (42 ref.)

A good turn for DNA: the structure of integration host factor bound to DNA. Ellenberger T, et al. **Structure** 1997 Feb 15;5(2):153–7 (45 ref.)

Pieces of the puzzle: assembling the preinitiation complex of Pol II. Ghosh G, et al. **Structure** 1996 Aug 15;4(8):891–5 (19 ref.)

Secrets of RNA folding revealed. Price S, et al. **Structure** 1996 Oct 15;4(10):1129–32 (30 ref.)

RNA seeing double: close-packing of helices in RNA tertiary structure. Strobel SA, et al. **Trends Biochem Sci** 1997 Jul; 22(7):262–6 (49 ref.)

[DNA, the key to life, before and after the double helix] Ondarza RN. **Gac Med Mex** 1996 May–Jun;132(3):319–26 (20 ref.) **(Spa)**

NUCLEIC ACID HETERODUPLEXES

Nucleotide excision repair in mammalian cells. Wood RD. **J Biol Chem** 1997 Sep 19;272(38):23465–8 (50 ref.)

CHEMISTRY

Unusual DNA conformations. Lebrun A, et al. **Curr Opin Struct Biol** 1997 Jun;7(3):348–54 (68 ref.)

Analysis of open complex formation during RNA polymerase II transcription initiation using heteroduplex templates and potassium permanganate probing. Holstege FC, et al. **Methods** 1997 Jul;12(3):203–11 (46 ref.)

NUCLEIC ACID HYBRIDIZATION

see related
BLOTTING, SOUTHERN

Oligonucleotide micro-arrays for identification of unknown mutations: how far from reality? Ginot F. **Hum Mutat** 1997; 10(1):1–10 (50 ref.)

Yeast colony hybridization. Kleinman MJ. **Methods Mol Biol** 1996;53:189–92 (1 ref.)

METHODS

Molecular epidemiology of human rotaviruses: genogrouping by RNA-RNA hybridization. Nakagomi O, et al. **Arch Virol Suppl** 1996;12:93–8 (18 ref.)

Use of fluorescence in situ hybridization and comparative genomic hybridization in the cytogenetic analysis of testicular germ cell tumors and uveal melanomas. Becher R, et al. **Cancer Genet Cytogenet** 1997 Jan;93(1):22–8 (70 ref.)

Subtractive hybridization, a technique for extraction of DNA sequences distinguishing two closely related genomes: critical analysis. Ermolaeva OD, et al. **Genet Anal** 1996 Jul;13(2):49–58 (35 ref.)

cDNA subtraction hybridization: a review and an application to neuroblastoma. Swendeman SL, et al. **Semin Pediatr Surg** 1996 Aug;5(3):149–54 (56 ref.)

[Possibilities and limits of molecular genetic detection methods in medical microbiology. Wishful thinking and reality] Göbel UB. **Internist (Berl)** 1996 Sep;37(9):919–25 (24 ref.) **(Ger)**

NUCLEIC ACID PRECURSORS

METABOLISM

Protein functions in pre-mRNA splicing. Will CL, et al. **Curr Opin Cell Biol** 1997 Jun;9(3):320–8 (92 ref.)

NUCLEIC ACID PROBES

see related
NUCLEIC ACID HYBRIDIZATION

Analysis of open complex formation during RNA polymerase II transcription initiation using heteroduplex templates and potassium permanganate probing. Holstege FC, et al. **Methods** 1997 Jul;12(3):203–11 (46 ref.)

NUCLEIC ACID REGULATORY SEQUENCES see **REGULATORY SEQUENCES, NUCLEIC ACID**

NUCLEIC ACID REPETITIVE SEQUENCES see **REPETITIVE SEQUENCES, NUCLEIC ACID**

NUCLEIC ACID SYNTHESIS INHIBITORS

ADVERSE EFFECTS

Cutaneous carcinoma during long-term hydroxyurea therapy: a report of 5 cases [letter] Callot-Mellot C, et al. **Arch Dermatol** 1996 Nov;132(11):1395–7 (5 ref.)

A biochemical perspective of methotrexate neurotoxicity with insight on nonfolate rescue modalities. Quinn CT, et al. **J Investig Med** 1996 Dec;44(9):522–30 (106 ref.)

PHARMACOLOGY

[Nucleoside kinases and new types of antitumor nucleosides] Matsuda A. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1594–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

NUCLEIC ACID VACCINES see **VACCINES, DNA**

NUCLEIC ACIDS

ADMINISTRATION & DOSAGE

Development of targeted delivery systems for nucleic acid drugs. Mahato RI, et al. **J Drug Target** 1997;4(6):337–57 (138 ref.)

Role of supplementation of a nucleic acid solution on the intestinal mucosa under total parenteral nutrition. Tsujinaka T, et al. **Nutrition** 1997 Apr;13(4):369–71 (9 ref.)

ANALYSIS

Microfabrication technologies for integrated nucleic acid analysis. Burke DT, et al. **Genome Res** 1997 Mar; 7(3):189–97 (60 ref.)

High-resolution nucleic acid separations by high-performance liquid chromatography. Thayer JR, et al. **Methods Enzymol** 1996;271:147–74 (21 ref.)

CHEMISTRY

Application of peptide nucleic acid in cancer therapy. Knudsen H, et al. **Anticancer Drugs** 1997 Feb;8(2):113–8 (57 ref.)

Photocross-linking of nucleic acids to associated proteins. Meisenheimer KM, et al. **Crit Rev Biochem Mol Biol** 1997; 32(2):101–40 (121 ref.)

Visualizing nucleic acids and their complexes using electron microscopy. Griffith JD, et al. **Curr Opin Struct Biol** 1997 Jun;7(3):362–6 (42 ref.)

Sometimes a great motion: the application of transient electric birefringence to the study of macromolecular structure. Hagerman PJ. **Curr Opin Struct Biol** 1996 Oct;6(5):643–9 (56 ref.)

Nucleic acids. From self-assembly to induced-fit recognition [editorial] Westhof E, et al. **Curr Opin Struct Biol** 1997 Jun;7(3):305–9 (19 ref.)

Interaction of mercury with nucleic acids and their components. Sletten E, et al. **Met Ions Biol Syst** 1997; 34:479–501 (50 ref.)

Fluorescence approaches to study of protein-nucleic acid complexation. Hill JJ, et al. **Methods Enzymol** 1997; 278:390–416 (67 ref.)

Enzymatic labeling of nucleic acids. Temsamani J, et al. **Mol Biotechnol** 1996 Jun;5(3):223–32 (59 ref.)

Nucleic acid crystallography: a view from the nucleic acid database. Berman HM, et al. **Prog Biophys Mol Biol** 1996; 66(3):255–88 (113 ref.)

PNA-nucleic acid complexes. Structure, stability and dynamics. Eriksson M, et al. **Q Rev Biophys** 1996 Dec; 29(4):369–94 (42 ref.)

C-H...O hydrogen bonding in biology. Wahl MC, et al. **Trends Biochem Sci** 1997 Mar;22(3):97–102 (35 ref.)

[Conformational ensembles of biopolymers] Suzuki E. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):989–95 (9 ref.) **(Jpn)**

DRUG EFFECTS

Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification--a role in pathogenesis and antiproliferative chemotherapy. Thornalley PJ. **Gen Pharmacol** 1996 Jun;27(4):565–73 (77 ref.)

GENETICS

[Nucleic acids, specific control agents of gene expression. From chemistry to clinics] Hélène C. **Therapie** 1996 Jul-Aug;51(4):361–2 (9 ref.) **(Fre)**

[DNA vaccination and gene therapy based on transient expression of nucleic acids in human and animal somatic cells] Dababov VG. **Mol Biol (Mosk)** 1997 Mar-Apr; 31(2):209–15 (72 ref.) **(Rus)**

ISOLATION & PURIFICATION

Molecular basis of genetic disease and molecular methods. McPherson RA. **Clin Lab Med** 1995 Dec;15(4):779–94 (54 ref.)

METABOLISM

Visualizing nucleic acids and their complexes using electron microscopy. Griffith JD, et al. **Curr Opin Struct Biol** 1997 Jun;7(3):362–6 (42 ref.)

Nucleic acids. From self-assembly to induced-fit recognition [editorial] Westhof E, et al. **Curr Opin Struct Biol** 1997 Jun;7(3):305–9 (19 ref.)

Escape and migration of nucleic acids between chloroplasts, mitochondria, and the nucleus. Thorsness PE, et al. **Int Rev Cytol** 1996;165:207–34 (112 ref.)

Interaction of mercury with nucleic acids and their components. Sletten E, et al. **Met Ions Biol Syst** 1997; 34:479–501 (50 ref.)

A biopolymer by any other name would bind as well: a comparison of the ligand-binding pockets of nucleic acids and proteins. Marshall KA, et al. **Structure** 1997 Jun 15; 5(6):729–34 (29 ref.)

Lysosomal nucleic acid and phosphate metabolism and related metabolic reactions. Pisoni RL. **Subcell Biochem** 1996;27:295–330 (134 ref.)

[Mitochondrial transport of nucleic acids. Participation of the benzodiazepine receptor] Zorov DB. **Biokhimiia** 1996 Jul;61(7):1320–32 (88 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Application of peptide nucleic acid in cancer therapy. Knudsen H, et al. **Anticancer Drugs** 1997 Feb;8(2):113–8 (57 ref.)

PHYSIOLOGY

Molecular biology and the pediatric surgeon: definitions and basic methodology. Tagge EP, et al. **Semin Pediatr Surg** 1996 Aug;5(3):139–48 (20 ref.)

NUCLEOLAR ORGANIZER see **NUCLEOLUS ORGANIZER REGION**

NUCLEOLAR PROTEINS see **NUCLEAR PROTEINS**

NUCLEOLUS ORGANIZER REGION

Staining of the nucleolar organizer regions: relevance in hematology. Baatout S. **Blood Rev** 1996 Sep;10(3):185–8 (33 ref.)

[Recent progress in the analysis of the intranuclear organization of the animal cell genome by FISH] Okumura K. **Seikagaku** 1997 May;69(5):335–9 (15 ref.) **(Jpn)**

[Nucleolar organizers] Takayama S. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(15 Suppl):2210–8 (49 ref.) **(Jpn)**

PATHOLOGY

[Study of silver binding nucleolar organizer regions (AgNORs) in proliferative lesions of bronchi, colon and thyroid--semiautomatic computer image analysis] Zaczek M. **Folia Med Cracov** 1996;37(1-2):67–88 (82 ref.) (Eng. Abstr.) **(Pol)**

ULTRASTRUCTURE

Standardized AgNOR analysis: its usefulness in surgical oncology. Ofner D, et al. **Histochem Cell Biol** 1996 Aug; 106(2):193–6 (32 ref.)

NUCLEOLYSIS, INTERVERTEBRAL DISK see **INTERVERTEBRAL DISK CHEMOLYSIS**

NUCLEOPOLYHEDROVIRUS

GENETICS

Involvement of host factors in transcription from baculovirus very late promoters -- a review. Hasnain SE, et al. **Gene** 1997 Apr 29;190(1):113–8 (45 ref.)

PHYSIOLOGY

Nucleopolyhedrovirus interactions with their insect hosts. Volkman LE. **Adv Virus Res** 1997;48:313–48 (170 ref.)

NUCLEOPROTEINS

ANALYSIS

The mammalian centromere: its molecular architecture. Mitchell AR. **Mutat Res** 1996 Dec;372(2):153–62 (57 ref.)

METABOLISM

Telomere maintenance without telomerase. Biessmann H, et al. **Chromosoma** 1997 Jul;106(2):63–9 (85 ref.)

NUCLEOSIDASES

CHEMISTRY

DNA glycosylases in the base excision repair of DNA. Krokan HE, et al. **Biochem J** 1997 Jul 1;325 (Pt 1):1–16 (232 ref.)

Precluding uracil from DNA. Vassylyev DG, et al. **Structure** 1996 Dec 15;4(12):1381–5 (18 ref.)

GENETICS

Finding new mutator strains of Escherichia coli--a review. Miller JH, et al. **Gene** 1996 Nov 7;179(1):129–32 (11 ref.)

IMMUNOLOGY

Human CD38, a cell-surface protein with multiple functions. Mehta K, et al. **FASEB J** 1996 Oct;10(12):1408–17 (69 ref.)

METABOLISM

ADP-ribosyl cyclase and CD38. Multi-functional enzymes in Ca+2 signaling. Lee HC, et al. **Adv Exp Med Biol** 1997; 419:411–9 (29 ref.)

DNA glycosylases in the base excision repair of DNA. Krokan HE, et al. **Biochem J** 1997 Jul 1;325 (Pt 1):1–16 (232 ref.)

How do DNA repair proteins locate damaged bases in the genome? Verdine GL, et al. **Chem Biol** 1997 May; 4(5):329–34 (36 ref.)

DNA repair: how yeast repairs radical damage. Cunningham RP. **Curr Biol** 1996 Oct 1;6(10):1230–3 (16 ref.)

DNA glycosylases. Cunningham RP. **Mutat Res** 1997 May 1;383(3):189–96 (45 ref.)

NUCLEOSIDE-DIPHOSPHATE KINASE

[Molecular mechanism of multifunctional protein, NDP kinase/nm 23] Kimura N, et al. **Tanpakushitsu Kakusan Koso** 1997 Apr;42(5):745–60 (102 ref.) **(Jpn)**

GENETICS

[Expression of nm23/NDP kinase and cancer metastasis] Okada K, et al. **Nippon Rinsho** 1996 Mar;54(3):845–53 (23 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Differential gene expression in tumor metastasis: Nm23. Freije JM, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 2):215–32 (62 ref.)

NM23/Nucleoside diphosphate kinase as a transcriptional activator of c-myc. Postel EH. **Curr Top Microbiol Immunol** 1996;213 (Pt 2):233–52 (96 ref.)

NUCLEOSIDE-PHOSPHATE KINASE

GENETICS

PDZ domains: targeting signalling molecules to sub-membranous sites. Ponting CP, et al. **Bioessays** 1997 Jun;19(6):469–79 (88 ref.)

NUCLEOSIDES

ADMINISTRATION & DOSAGE

The well-balanced nucleoside-nucleotide mixture "OG-VI" for special medical purposes. Iwasa Y, et al. **Nutrition** 1997 Apr;13(4):361–4 (17 ref.)

The selection of suitable substrates for hepatic energy metabolism after massive hepatectomy [editorial] Jin MB, et al. **Nutrition** 1997 Apr;13(4):386–7 (6 ref.)

Role of supplementation of a nucleic acid solution on the intestinal mucosa under total parenteral nutrition. Tsujinaka T, et al. **Nutrition** 1997 Apr;13(4):369–71 (9 ref.)

ADVERSE EFFECTS

[Sugar diabetes in AIDS patients treated with antiretroviral nucleoside analogs] Mauvais-Jarvis F, et al. **Journ Annu Diabetol Hotel Dieu** 1997;:43–8 (29 ref.) **(Fre)**

CHEMICAL SYNTHESIS

Some recent trends and progress in nucleoside synthesis. Vorbrüggen H. **Acta Biochim Pol** 1996;43(1):25–36 (22 ref.)

[Highlights from 43 years of chemistry of naturally occurring nitrogen-containing heterocycles. (2). Syntheses and reactions of purines and of their nucleosides (published erratum appears in Yakugaku Zasshi 1996 Dec;116(12):961)] Fujii T, et al. **Yakugaku Zasshi** 1996 May;116(5):355–73 (89 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Some recent trends and progress in nucleoside synthesis. Vorbrüggen H. **Acta Biochim Pol** 1996;43(1):25–36 (22 ref.)

NUCLEOSIDES

METABOLISM

Structure-activity relationships for phosphorylation of nucleoside analogs to monophosphates by nucleoside kinases. Johansson NG, et al. **Acta Biochim Pol** 1996; 43(1):143–60 (77 ref.)

Genetic pharmacomodulation of nucleoside analogues and gene therapy for AIDS and cancer. Guettari N, et al. **Antibiot Chemother** 1996;48:198–204 (21 ref.)

Nucleoside and nucleobase transport systems of mammalian cells. Griffith DA, et al. **Biochim Biophys Acta** 1996 Oct 29;1286(3):153–81 (333 ref.)

Intron-dependent enzymatic formation of modified nucleosides in eukaryotic tRNAs: a review. Grosjean H, et al. **Biochimie** 1997 May;79(5):293–302 (74 ref.)

PHARMACOLOGY

Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Arts EJ, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):527–40 (182 ref.)

Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes. Aquaro S, et al. **J Leukoc Biol** 1997 Jul;62(1):138–43 (39 ref.)

Acyclic nucleosides as antiviral compounds. Freeman S, et al. **Mol Biotechnol** 1996 Apr;5(2):125–37 (94 ref.)

Novel and unusual nucleosides as drugs. Kolb VM. **Prog Drug Res** 1997;48:195–232 (118 ref.)

PHYSIOLOGY

Role of nucleosides and nucleotides in the immune system, gut reparation after injury, and brain function. Yamamoto S, et al. **Nutrition** 1997 Apr;13(4):372–4 (15 ref.)

THERAPEUTIC USE

Rational approaches to resistance: nucleoside analogues. Mayers D. **AIDS** 1996 Nov;10 Suppl 1:S9–13 (32 ref.)

Use of novel beta-L(-)-nucleoside analogues for treatment and prevention of chronic hepatitis B virus infection and hepatocellular carcinoma. Bridges EG, et al. **Prog Liver Dis** 1995;13:231–45 (70 ref.)

TOXICITY

Clinical toxicity of antiretroviral nucleoside analogs. Styrt BA, et al. **Antiviral Res** 1996 Jul;31(3):121–35 (122 ref.)

NUCLEOSOMES

Pushing nucleosomes around. Chromatin. Krude T, et al. **Curr Biol** 1996 May 1;6(5):511–5 (25 ref.)

[Role of yeast global repressors, Bel2 and Tup1, in chromatin-and nucleosome-mediated transcriptional regulation] Harashima S. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1187–97 (31 ref.) **(Jpn)**

[Structure and function of higher eukaryote chromosome] Kaneda Y. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(15 Suppl):2219–29 (36 ref.) **(Jpn)**

CHEMISTRY

Histone structure and the organization of the nucleosome. Ramakrishnan V. **Annu Rev Biophys Biomol Struct** 1997; 26:83–112 (138 ref.)

Archaeal histones, nucleosomes, and transcription initiation. Reeve JN, et al. **Cell** 1997 Jun 27;89(7):999–1002 (18 ref.)

The nucleosomal array: structure/function relationships. Fletcher TM, et al. **Crit Rev Eukaryot Gene Expr** 1996; 6(2–3):149–88 (261 ref.)

Nucleosome assembly: the CAF and the HAT. Kaufman PD. **Curr Opin Cell Biol** 1996 Jun;8(3):369–73 (41 ref.)

GENETICS

Nucleosome DNA sequence pattern revealed by multiple alignment of experimentally mapped sequences. Ioshikhes I, et al. **J Mol Biol** 1996 Sep 20;262(2):129–39 (42 ref.)

Considerations of transcriptional control mechanisms: do TFIID-core promoter complexes recapitulate nucleosome-like functions? Hoffmann A, et al. **Proc Natl Acad Sci U S A** 1997 Aug 19;94(17):8928–35 (127 ref.)

IMMUNOLOGY

Autoimmunity against nucleosomes and lupus nephritis. Van Bruggen MC, et al. **Ann Med Interne (Paris)** 1996; 147(7):485–9 (61 ref.)

Nucleosome-driven autoimmune response in lupus. Pathogenic T helper cell epitopes and costimulatory signals. Datta SK, et al. **Ann N Y Acad Sci** 1997 Apr 5; 815:155–70 (168 ref.)

T helper cells driving pathogenic anti-DNA autoantibody production in lupus: nucleosomal epitopes and CD40 ligand signals. Datta SK, et al. **Lupus** 1997;6(3):333–6 (4 ref.)

Autoantibody to the nucleosome subunit (H2A–H2B)-DNA is an early and ubiquitous feature of lupus-like conditions. Burlingame RW, et al. **Mol Biol Rep** 1996;23(3–4):159–66 (46 ref.)

[Nucleosome as an autoantigen in systemic lupus erythematosus] Gruenbaum E, et al. **Harefuah** 1997 Apr 1;132(7):475–8 (29 ref.) **(Heb)**

METABOLISM

Remodeling chromatin structures for transcription: what happens to the histones? Steger DJ, et al. **Bioessays** 1996 Nov;18(11):875–84 (69 ref.)

The nucleosomal array: structure/function relationships. Fletcher TM, et al. **Crit Rev Eukaryot Gene Expr** 1996; 6(2–3):149–88 (261 ref.)

Where is the globular domain of linker histone located on the nucleosome? Crane-Robinson C. **Trends Biochem Sci** 1997 Mar;22(3):75–7 (22 ref.)

Transcription factors vs nucleosomes: regulation of the PHO5 promoter in yeast. Svaren J, et al. **Trends Biochem Sci** 1997 Mar;22(3):93–7 (50 ref.)

PHYSIOLOGY

Histones, nucleosome, and the roles of chromatin structure in transcriptional control. Wolffe AP. **Biochem Soc Trans** 1997 May;25(2):354–8 (22 ref.)

Nucleosome assembly: the CAF and the HAT. Kaufman PD. **Curr Opin Cell Biol** 1996 Jun;8(3):369–73 (41 ref.)

Nucleosomes and the pathogenesis of lupus nephritis. Berden JH, et al. **Kidney Blood Press Res** 1997;20(3):198–200 (15 ref.)

Signals in eukaryotic DNA promote and influence formation of nucleosome arrays. Stein A. **Prog Nucleic Acid Res Mol Biol** 1996;54:333–81 (121 ref.)

Nucleosomes and lupus [editorial] Gilbert D, et al. **Rev Rhum Engl Ed** 1997 Apr;64(4):210–4 (41 ref.)

Deviant nucleosomes: the functional specialization of chromatin. Wolffe AP, et al. **Trends Genet** 1996 Feb; 12(2):58–62 (31 ref.)

ULTRASTRUCTURE

What determines the folding of the chromatin fiber? van Holde K, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1; 93(20):10548–55 (68 ref.)

5'-NUCLEOTIDASE

T cell signalling through CD73. Resta R, et al. **Cell Signal** 1997 Feb;9(2):131–9 (92 ref.)

DEFICIENCY

[Hemolytic anemia due to abnormalities in erythrocyte nucleotide metabolism] Masuda M, et al. **Nippon Rinsho** 1996 Sep;54(9):2473–7 (15 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Biochemistry, localization and functional roles of ecto-nucleotidases in the nervous system. Zimmermann H. **Prog Neurobiol** 1996 Aug;49(6):589–618 (340 ref.)

PHYSIOLOGY

Autocrine/paracrine control of renal phosphate transport. Friedlander G, et al. **Kidney Int Suppl** 1996 Dec;57:S148–53 (73 ref.)

NUCLEOTIDASES

METABOLISM

Release of soluble nucleotidases: a novel mechanism for neurotransmitter inactivation? Kennedy C, et al. **Trends Pharmacol Sci** 1997 Aug;18(8):263–6 (30 ref.)

NUCLEOTIDE SEQUENCE see **BASE SEQUENCE**

NUCLEOTIDES

see related
BASE SEQUENCE

[Fluorescent nucleotides: their applications for studies on the structure and function of proteins] Hiratsuka T. **Tanpakushitsu Kakusan Koso** 1997 Jan;42(1):64–72 (195 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

The well-balanced nucleoside-nucleotide mixture "OG-VI" for special medical purposes. Iwasa Y, et al. **Nutrition** 1997 Apr;13(4):361–4 (17 ref.)

The selection of suitable substrates for hepatic energy metabolism after massive hepatectomy [editorial] Jin MB, et al. **Nutrition** 1997 Apr;13(4):386–7 (6 ref.)

Role of supplementation of a nucleic acid solution on the intestinal mucosa under total parenteral nutrition. Tsujinaka T, et al. **Nutrition** 1997 Apr;13(4):369–71 (9 ref.)

Dietary nucleotides: a conditional requirement. Van Buren CT, et al. **Nutrition** 1997 May;13(5):470–2 (25 ref.)

BIOSYNTHESIS

Sugars and nucleotides and the biosynthesis of thiamine. David S, et al. **Adv Carbohydr Chem Biochem** 1997; 52:267–309 (84 ref.)

Enzymes of nucleotide synthesis. Smith JL. **Curr Opin Struct Biol** 1995 Dec;5(6):752–7 (37 ref.)

CHEMICAL SYNTHESIS

New insights regarding the potential of the pronucleotide approach in antiviral chemotherapy. Gosselin G, et al. **Acta Biochim Pol** 1996;43(1):196–208 (31 ref.)

CHEMISTRY

Fluorescent nucleotide analogs: synthesis and applications. Jameson DM, et al. **Methods Enzymol** 1997;278:363–90 (75 ref.)

[Modified nucleoside phosphates as precursors of antineoplastic and antiviral compounds in a cell] Arzumanov AA, et al. **Bioorg Khim** 1996 Oct–Nov; 22(10–11):777–94 (127 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Structure-activity relationships for phosphorylation of nucleoside analogs to monophosphates by nucleoside kinases. Johansson NG, et al. **Acta Biochim Pol** 1996; 43(1):143–60 (77 ref.)

The NTP phosphate donor in kinase reactions: is ATP a monopolist? Shugar D. **Acta Biochim Pol** 1996;43(1):9–23 (68 ref.)

Transporters of nucleotide sugars, nucleotide sulfate and ATP in the Golgi apparatus membrane: where next? Hirschberg CB. **Glycobiology** 1997 Mar;7(2):169–71 (40 ref.)

Effects of nucleotides on assembly of the 26S proteasome and degradation of ubiquitin conjugates. Hoffman L, et al. **Mol Biol Rep** 1997 Mar;24(1–2):13–6 (29 ref.)

Transporters of nucleotides and nucleotide derivatives in the endoplasmic reticulum and Golgi apparatus. Hirschberg CB. **Soc Gen Physiol Ser** 1996;51:105–20 (68 ref.)

Transporters of nucleotide sugars, nucleotide sulfate and ATP in the Golgi apparatus. Abeijon C, et al. **Trends Biochem Sci** 1997 Jun;22(6):203–7 (30 ref.)

PHARMACOLOGY

Nucleotide probes of DNA polymerases. Wright GE. **Acta Biochim Pol** 1996;43(1):115–24 (30 ref.)

PHYSIOLOGY

Signaling by extracellular nucleotides. Brake AJ, et al. **Ann Rev Cell Dev Biol** 1996;12:519–41 (111 ref.)

Nucleotide receptors. North RA, et al. **Curr Opin Neurobiol** 1997 Jun;7(3):346–57 (107 ref.)

Role of nucleosides and nucleotides in the immune system, gut reparation after injury, and brain function. Yamamoto S, et al. **Nutrition** 1997 Apr;13(4):372–4 (15 ref.)

Exogenous nucleotides and gastrointestinal immunity. Walker WA. **Transplant Proc** 1996 Oct;28(5):2438–41 (22 ref.)

NUCLEOTIDES, CYCLIC

ANALYSIS

Qualitative and quantitative MS analysis of cyclic nucleotides and related enzymes. Newton RP. **Biochem Soc Trans** 1996 Aug;24(3):938–43 (38 ref.)

METABOLISM

Cooperativity in cyclic nucleotide-gated ion channels [comment] Pugh EN Jr. **J Gen Physiol** 1996 Feb; 107(2):165–7 (20 ref.) Comment on: J Gen Physiol 1996 Feb;107(2):169–81.

PHYSIOLOGY

Calmodulin regulation of cyclic-nucleotide-gated channels. Molday RS. **Curr Opin Neurobiol** 1996 Aug;6(4):445–52 (59 ref.)

Cyclic nucleotide gated channels as regulators of CNS development and plasticity. Zufall F, et al. **Curr Opin Neurobiol** 1997 Jun;7(3):404–12 (73 ref.)

Molecular mechanisms of cyclic nucleotide-gated channels. Zagotta WN. **J Bioenerg Biomembr** 1996 Jun;28(3):269–78 (92 ref.)

NUCLEOTIDYLTRANSFERASES

METABOLISM

Glycobiotechnology: enzymes for the synthesis of nucleotide sugars. Elling L. **Adv Biochem Eng Biotechnol** 1997; 58:89–144 (363 ref.)

Viral and cellular enzymes involved in synthesis of mRNA cap structure. Bisaillon M, et al. **Virology** 1997 Sep 15; 236(1):1–7 (65 ref.)

NUCLEOTOMY, PERCUTANEOUS see **DISKECTOMY, PERCUTANEOUS**

NUCLEUS ACCUMBENS

DRUG EFFECTS

A critique of fixed and progressive ratio schedules used to examine the neural substrates of drug reinforcement. Arnold JM, et al. **Pharmacol Biochem Behav** 1997 Jul; 57(3):441–7 (70 ref.)

Mediation of the discriminative stimulus properties of cocaine by mesocorticolimbic dopamine systems. Callahan PM, et al. **Pharmacol Biochem Behav** 1997 Jul;57(3):601–7 (54 ref.)

Cellular mechanisms underlying reinforcement-related

processing in the nucleus accumbens: electrophysiological studies in behaving animals. Carelli RM, et al. **Pharmacol Biochem Behav** 1997 Jul;57(3):495–504 (55 ref.)

METABOLISM

Neurochemical changes in cocaine withdrawal. Kuhar MJ, et al. **Trends Pharmacol Sci** 1996 Jul;17(7):260–4 (53 ref.)

PATHOLOGY

The accumbens: beyond the core–shell dichotomy. Heimer L, et al. **J Neuropsychiatry Clin Neurosci** 1997 Summer; 9(3):354–81 (154 ref.)

PHYSIOLOGY

Role of dopamine mesolimbic system in opioid action of psychotropic analgesic nitrous oxide in alcohol and drug withdrawal. Lichtigfeld FJ, et al. **Clin Neuropharmacol** 1996 Jun;19(3):246–51 (43 ref.)

The nucleus accumbens and learning and memory. Setlow B. **J Neurosci Res** 1997 Sep 1;49(5):515–21 (56 ref.)

Behavioral functions of nucleus accumbens dopamine: empirical and conceptual problems with the anhedonia hypothesis. Salamone JD, et al. **Neurosci Biobehav Rev** 1997 May;21(3):341–59 (267 ref.)

The nucleus accumbens: gateway for limbic structures to reach the motor system? Groenewegen HJ, et al. **Prog Brain Res** 1996;107:485–511 (157 ref.)

NUCLEUS BASALIS MAGNOCELLULARIS see **SUBSTANTIA INNOMINATA**

NUCLEUS BASALIS OF MEYNERT see **SUBSTANTIA INNOMINATA**

NUCLEUS BASALIS, OLIVARY see **OLIVARY NUCLEUS**

NUCLEUS DENTATUS see **CEREBELLAR NUCLEI**

NUCLEUS SOLITARIUS see **SOLITARY NUCLEUS**

NUDE MICE see **MICE, NUDE**

NULLIPARITY see **PARITY**

NUMERICAL ANALYSIS, COMPUTER-ASSISTED

Electrophoresis between sieving and reptation: an investigation of the role of shape fluctuations in electrophoresis. Völkel AR, et al. **Electrophoresis** 1995 Nov;16(11):2086–93 (24 ref.)

NURSE ADMINISTRATORS

The clinical nurse manager: a literature review. Oroviogoicoechea C. **J Adv Nurs** 1996 Dec;24(6):1273–80 (52 ref.)

The role of the clinical research coordinator in multicenter clinical trials. Pelke S, et al. **J Obstet Gynecol Neonatal Nurs** 1997 May–Jun; 26(3):279–85 (14 ref.)

NURSE ANESTHETISTS

ORGANIZATION & ADMINISTRATION

When will managed care come to anesthesia? Klein JD. **J Health Care Finance** 1997 Spring;23(3):62–86 (61 ref.)

Advanced practice nursing: back to the future. Fitzgerald SM, et al. **J Obstet Gynecol Neonatal Nurs** 1997 Jan–Feb; 26(1):101–7 (30 ref.)

NURSE CLINICIANS

The clinical nurse manager: a literature review. Oroviogoicoechea C. **J Adv Nurs** 1996 Dec;24(6):1273–80 (52 ref.)

Utilizing the clinical nurse specialist to promote interdisciplinary pain management. Cronin Y, et al. **J Fla Med Assoc** 1997 Jan;84(1):46–8 (13 ref.)

Forensic documentation of battered pregnant women. Sheridan DJ. **J Nurse Midwifery** 1996 Nov–Dec; 41(6):467–72 (14 ref.)

Cystic fibrosis nurse specialist: a key role. Dyer J. **J R Soc Med** 1997;90 Suppl 31:21–5 (12 ref.)

Clinical nurse specialists. Berry C. **Wis Med J** 1997 Jun; 96(6):19–20 (6 ref.)

EDUCATION

Conceptualizing advanced nursing practice: curriculum issues to consider in the educational preparation of advanced practice nurses in the UK. Woods LP. **J Adv Nurs** 1997 Apr;25(4):820–8 (37 ref.)

Addressing human immunodeficiency virus/acquired immunodeficiency syndrome in advanced practice nursing education. Nokes KM, et al. **J Prof Nurs** 1997 Sep–Oct; 13(5):294–9 (11 ref.)

LEGISLATION & JURISPRUDENCE

Second licensure for advanced practice: current status. Robinson DL, et al. **Nurse Pract** 1996 Sep;21(9):71–4, 80–2, 88 (25 ref.)

ORGANIZATION & ADMINISTRATION

A literature review of advanced clinical nursing practice in the United States of America. Dunn L. **J Adv Nurs** 1997 Apr;25(4):814–9 (45 ref.)

Advanced practice nursing: back to the future. Fitzgerald SM, et al. **J Obstet Gynecol Neonatal Nurs** 1997 Jan–Feb; 26(1):101–7 (30 ref.)

NURSE MIDWIVES

Cultural competence in the care of abused women. Campbell JC, et al. **J Nurse Midwifery** 1996 Nov–Dec;41(6):457–62 (22 ref.)

Woman abuse. The role of nurse–midwives in assessment. King MC, et al. **J Nurse Midwifery** 1996 Nov–Dec; 41(6):436–41 (13 ref.)

Effective advocacy for domestic violence victims. Role of the nurse–midwife. Orloff LE. **J Nurse Midwifery** 1996 Nov–Dec;41(6):473–94 (74 ref.)

Domestic violence. Implications for the American College of Nurse–Midwives and its members. Paluzzi PA, et al. **J Nurse Midwifery** 1996 Nov–Dec;41(6):430–5 (14 ref.)

The role of nurses and midwives in government. Ralph C, et al. **WHO Reg Publ Eur Ser** 1997;74:167–90 (9 ref.)

EDUCATION

Recent developments in professional midwifery education and credentialing. Fullerton JT, et al. **J Nurse Midwifery** 1996 Jul–Aug;41(4):322–7 (10 ref.)

ORGANIZATION & ADMINISTRATION

Choosing the choices in the USA: examples in the maternity area. Mander R. **J Adv Nurs** 1997 Jun;25(6):1192–7 (24 ref.)

Midwifery, birth centers, and health care reform. Ernst EK. **J Obstet Gynecol Neonatal Nurs** 1996 Jun;25(5):433–9 (10 ref.)

Advanced practice nursing: back to the future. Fitzgerald SM, et al. **J Obstet Gynecol Neonatal Nurs** 1997 Jan–Feb; 26(1):101–7 (30 ref.)

STANDARDS

Nurse–midwife and physician collaboration: improving opportunities to work towards a healthier Wisconsin. VandeVusse L, et al. **Wis Med J** 1997 Jun;96(6):25–9 (20 ref.)

NURSE–PATIENT RELATIONS

Posttraumatic stress disorder: how to support healing. Clark CC. **Am J Nurs** 1997 Aug;97(8):26–32; quiz 33 (10 ref.)

Bakhtin, nursing narratives, and dialogical consciousness. Bowers R, et al. **ANS Adv Nurs Sci** 1997 Mar;19(3):70–7 (28 ref.)

The ethics of compliance: a dialectic. Hess JD. **ANS Adv Nurs Sci** 1996 Sep;19(1):18–27 (24 ref.)

Burns in prisoners: an assessment of problems in handling prisoners in a burns unit. Lee CT, et al. **Burns** 1996 Nov; 22(7):546–8 (5 ref.)

Analysis of the concept of mutuality. Henson RH. **Image J Nurs Sch** 1997 Spring;29(1):77–81 (50 ref.)

Perspective of an institution-based research nurse. Norberg A. **Int Psychogeriatr** 1996;8 Suppl 3:459–63; discussion 469–73 (30 ref.)

The role of communication in nursing care for elderly people: a review of the literature. Caris–Verhallen WM, et al. **J Adv Nurs** 1997 May;25(5):915–33 (76 ref.)

Towards further clarification of the concept 'dignity'. Haddock J. **J Adv Nurs** 1996 Nov;24(5):924–31 (49 ref.)

A concept analysis of trust. Johns JL. **J Adv Nurs** 1996 Jul; 24(1):76–83 (40 ref.)

Exploring the nursing role in pain management from a post-structuralist perspective. Price K, et al. **J Adv Nurs** 1996 Nov;24(5):899–904 (35 ref.)

'Knowing the patient': a review of research on an emerging concept. Radwin LE. **J Adv Nurs** 1996 Jun;23(6):1142–6 (16 ref.)

Protective care–receiving: the active role of care–recipients. Russell CK, et al. **J Adv Nurs** 1997 Mar;25(3):532–40 (14 ref.)

Reinstating the person in the professional: reflections on empathy and aesthetic experience. Smyth T. **J Adv Nurs** 1996 Nov;24(5):932–7 (28 ref.)

Coalescing the theories of two nurse visionaries: Parse and Watson. Walker CA. **J Adv Nurs** 1996 Nov;24(5):988–96 (41 ref.)

Understanding healing: a conceptual analysis. Wendler MC. **J Adv Nurs** 1996 Oct;24(4):836–42 (39 ref.)

A concept analysis of empathy. Wiseman T. **J Adv Nurs** 1996 Jun;23(6):1162–7 (38 ref.)

The trouble with caring: a review of eight arguments against an ethic of care. Crigger NJ. **J Prof Nurs** 1997 Jul–Aug; 13(4):217–21 (36 ref.)

Personal space intrusion and PTSD. Brown P, et al. **J Psychosoc Nurs Ment Health Serv** 1996 Jul;34(7):23–8 (44 ref.)

Managing threatening behavior. The role of talk down and talk up. Maier GJ. **J Psychosoc Nurs Ment Health Serv** 1996 Jun;34(6):25–30 (17 ref.)

Ambulatory surgery. Preoperative assessment and health history interview. Williams GD. **Nurs Clin North Am** 1997 Jun;32(2):395–416 (22 ref.)

Nursing presence: an existential exploration of the concept. Doona ME, et al. **Sch Inq Nurs Pract** 1997 Spring; 11(1):3–16; discussion 17–20 (51 ref.)

Patient satisfaction and the elderly. Owens DJ, et al. **Soc Sci Med** 1996 Jun;42(11):1483–91 (26 ref.)

NURSE–PHYSICIAN RELATIONS see **PHYSICIAN–NURSE RELATIONS**

NURSE PRACTITIONERS

Towards quality and cost–effective health care. Shamian J. **Int Nurs Rev** 1997 May–Jun;44(3):79–84, 90 (69 ref.)

Nursing lecturer/practitioners: can lecturer/practitioners be music to our ears? Rhead M, et al. **J Adv Nurs** 1996 Dec; 24(6):1265–72 (45 ref.)

Urinary incontinence: steps to evaluation, diagnosis, and treatment. Gallo ML, et al. **Nurse Pract** 1997 Feb; 22(2):21–4, 26, 28 passim (26 ref.)

Assisted suicide: nurse practitioners as providers? [see comments] Hall JK. **Nurse Pract** 1996 Oct;21(10):63–6, 71 (43 ref.) Comment in: Nurse Pract 1997 Jan;22(1):13.

Health promotion in HIV: perspectives for practitioners [news] Kitten JH. **Nurse Pract** 1997 Feb;22(2):114–6, 119, 125 (30 ref.)

Evaluating the performance of the APN. Nugent KE, et al. **Nurse Pract** 1997 Apr;22(4):190, 193–4, 197–8 (17 ref.)

Telephone advice: new solutions for old problems. Robinson DL, et al. **Nurse Pract** 1997 Mar;22(3):179–80, 183–6, 189 passim (18 ref.)

Collaborative care between nurse practitioners and primary care physicians. Arcangelo V, et al. **Prim Care** 1996 Mar; 23(1):103–13 (15 ref.)

Mid-level practitioners help physicians meet growing medical needs. Kennedy M. **Wis Med J** 1997 Jun;96(6):8–11 (0 ref.)

Nurse practitioners: the American experience. Nichols BL. **Wis Med J** 1997 Jun;96(6):16–8 (20 ref.)

EDUCATION

Conceptualizing advanced nursing practice: curriculum issues to consider in the educational preparation of advanced practice nurses in the UK. Woods LP. **J Adv Nurs** 1997 Apr;25(4):820–8 (37 ref.)

The clinical reasoning case study: a powerful teaching tool. Ryan–Wenger NA, et al. **Nurse Pract** 1997 May;22(5):66–7, 70, 76–9 passim (36 ref.)

LEGISLATION & JURISPRUDENCE

The psychiatric advanced practice nurse with prescriptive authority: role development, practice issues, and outcomes measurement. Cornwell C, et al. **Arch Psychiatr Nurs** 1997 Apr;11(2):57–65 (36 ref.)

Second licensure for advanced practice: current status. Robinson DL, et al. **Nurse Pract** 1996 Sep;21(9):71–4, 80–2, 88 (25 ref.)

ORGANIZATION & ADMINISTRATION

A deviant comes of age. Ford LC. **Heart Lung** 1997 Mar–Apr;26(2):87–91 (20 ref.)

A literature review of advanced clinical nursing practice in the United States of America. Dunn L. **J Adv Nurs** 1997 Apr;25(4):814–9 (45 ref.)

The emergency nurse practitioner role in major accident and emergency departments: professional issues and the research agenda. Tye CC. **J Adv Nurs** 1997 Aug; 26(2):364–70 (54 ref.)

Advanced practice nursing: back to the future. Fitzgerald SM, et al. **J Obstet Gynecol Neonatal Nurs** 1997 Jan–Feb; 26(1):101–7 (30 ref.)

Expanding the role of the nurse in the Accident and Emergency department. Neades BL. **Postgrad Med J** 1997 Jan;73(855):17–22 (67 ref.)

STANDARDS

Justifying nurse practitioner existence: hard facts to hard figures [see comments] Buppert CK. **Nurse Pract** 1995 Aug; 20(8):43–4, 46–8 (12 ref.) Comment in: Nurse Pract 1996 Jan;21(1):6. Comment in: Nurse Pract 1996 Jan;21(1):6, 9.

NURSERIES

see related
CHILD DAY CARE CENTERS

NURSES

A critical review of the literature on sharps injuries: epidemiology, management of exposures and prevention. Hanrahan A, et al. **J Adv Nurs** 1997 Jan;25(1):144–54 (130 ref.)

Work–related back pain in nurses. Hignett S. **J Adv Nurs** 1996 Jun;23(6):1238–46 (80 ref.)

Power of one: nurses and tobacco control. Gallagher J, et al. **Semin Oncol Nurs** 1996 Nov;12(4):270–5 (14 ref.)

The role of nurses and midwives in government. Ralph C, et al. **WHO Reg Publ Eur Ser** 1997;74:167–90 (9 ref.)

NURSES

PSYCHOLOGY

How to conquer the fear of codes. Badger JM. **Am J Nurs** 1996 Oct;96(10):26–31; quiz 32 (8 ref.)

Is non-judgemental care possible in the context of nurses' attitudes to patients' sexuality? Hayter M. **J Adv Nurs** 1996 Oct;24(4):662–6 (39 ref.)

Mixed messages in nursing research: their contribution to the persisting hiatus between evidence and practice. Hicks C, et al. **J Adv Nurs** 1997 Mar;25(3):595–601 (20 ref.)

Towards a critical theory of mental health nursing. Hopton J. **J Adv Nurs** 1997 Mar;25(3):492–500 (72 ref.)

Labouring the emotions: expanding the remit of nursing work? Phillips S. **J Adv Nurs** 1996 Jul;24(1):139–43 (16 ref.)

Exploring the nursing role in pain management from a post-structuralist perspective. Price K, et al. **J Adv Nurs** 1996 Nov;24(5):899–904 (35 ref.)

[The use of intuition—conceptual aspects and clinical significance] Shemesh-Kigli R. **Harefuah** 1997 Jun 15; 132(12):878–83 (34 ref.) **(Heb)**

STANDARDS

Testing the viability of collaborative interdisciplinary practice in community-focused primary health care: a case study in change. Lundeen SP, et al. **Wis Med J** 1997 Jun; 96(6):30–6 (0 ref.)

NURSES' AIDES

Unlicensed assistive personnel in the perioperative setting. Micheli AJ, et al. **Nurs Clin North Am** 1997 Mar; 32(1):201–13 (24 ref.)

EDUCATION

The nurses' aide: past and future necessity. Edwards M. **J Adv Nurs** 1997 Aug;26(2):237–45 (71 ref.)

ORGANIZATION & ADMINISTRATION

Delegation are you doing it right? [see comments] Parkman CA. **Am J Nurs** 1996 Sep;96(9):42–7; quiz 48 (7 ref.) Comment in: Am J Nurs 1996 Dec;96(12):16.

The nurses' aide: past and future necessity. Edwards M. **J Adv Nurs** 1997 Aug;26(2):237–45 (71 ref.)

UTILIZATION

Survey and critique of studies related to unlicensed assistive personnel from 1975 to 1997, Part 1. Bernreuter ME, et al. **J Nurs Adm** 1997 Jun;27(6):24–9 (50 ref.)

NURSES, HEAD see **NURSING, SUPERVISORY**

NURSES, MALE

PSYCHOLOGY

Men in nursing: issues of gender segregation and hidden advantage. Evans J. **J Adv Nurs** 1997 Aug;26(2):226–31 (30 ref.)

NURSING

see related
ECONOMICS, NURSING
EDUCATION, NURSING
HISTORY OF NURSING

How to provide better care for the postmenopausal woman [see comments] Scura KW, et al. **Am J Nurs** 1997 Apr; 97(4):36–43 (9 ref.) Comment in: Am J Nurs 1997 May;97(5):16.

The barriers and benefits of nursing information systems. Bowles KH. **Comput Nurs** 1997 Jul–Aug;15(4):191–6; quiz 197–8 (42 ref.)

Peer review, authorship, ethics, and conflict of interest. King CR, et al. **Image J Nurs Sch** 1997;29(2):163–7 (47 ref.)

(Ir)reconcilable differences? The debate concerning nursing and technology. Sandelowski M. **Image J Nurs Sch** 1997; 29(2):169–74 (85 ref.)

Clinical ladders: the ups and downs. Buchan J. **Int Nurs Rev** 1997 Mar–Apr;44(2):41–6 (34 ref.)

Developing the nurse as a knowledge worker in health—learning the artistry of practice. Antrobus S. **J Adv Nurs** 1997 Apr;25(4):829–35 (27 ref.)

A critical review of the belief that technology is a neutral object and nurses are its master. Barnard A. **J Adv Nurs** 1997 Jul;26(1):126–31 (57 ref.)

Sexual health promotion and nursing. Irwin R. **J Adv Nurs** 1997 Jan;25(1):170–7 (110 ref.)

Humans, information and science. Jones P. **J Adv Nurs** 1996 Sep;24(3):591–8 (23 ref.)

Advocacy in nursing—a review of the literature. Mallik M. **J Adv Nurs** 1997 Jan;25(1):130–8 (95 ref.)

Books on health policy and health reform: how is nursing represented? Mundt MH. **J Prof Nurs** 1997 Jan–Feb; 13(1):19–27 (47 ref.)

An evolutionary concept analysis of mentoring in nursing. Stewart BM, et al. **J Prof Nurs** 1996 Sep–Oct;12(5):311–21 (83 ref.)

Meta-analysis and public policy: opportunity for nursing impact. Conn VS, et al. **Nurs Outlook** 1996 Nov–Dec; 44(6):267–71 (29 ref.)

Do you have nursing professional liability insurance?—Part I. Byrd CM. **Prog Cardiovasc Nurs** 1997 Spring;12(2):37–9 (7 ref.)

The perceptual aspect of nursing art: sources of accord and discord. Johnson JL. **Sch Inq Nurs Pract** 1996 Winter; 10(4):307–22; discussion 323–7 (55 ref.)

CLASSIFICATION

Classification systems in nursing: formalizing nursing knowledge and implications for nursing information systems. Goossen WT, et al. **Methods Inf Med** 1996 Mar; 35(1):59–71 (65 ref.)

MANPOWER

Sexual orientation: a cultural diversity issue for nursing. Misener TR, et al. **Nurs Outlook** 1997 Jul–Aug;45(4):178–81 (42 ref.)

METHODS

Persuasive communication: marketing health promotion. Stubblefield C. **Nurs Outlook** 1997 Jul–Aug;45(4):173–7 (25 ref.)

ORGANIZATION & ADMINISTRATION

Technology and nursing: an anatomy of definition. Barnard A. **Int J Nurs Stud** 1996 Aug;33(4):433–41 (60 ref.)

An analysis of nursing in context: the effects of current health policy. Antrobus S. **J Adv Nurs** 1997 Mar;25(3):447–53 (36 ref.)

Sexual harassment in nursing. Robbins I, et al. **J Adv Nurs** 1997 Jan;25(1):163–9 (41 ref.)

Strategies for the development of contemporary nursing policy. Jossens MO. **J Prof Nurs** 1997 Jul–Aug;13(4):222–7 (27 ref.)

"It ain't what you do; it's the way that you do it". Beerling A. **WHO Reg Publ Eur Ser** 1997;74:191–206 (7 ref.)

National action plans for nursing and midwifery. Leenders F, et al. **WHO Reg Publ Eur Ser** 1997;74:145–66 (16 ref.)

Nursing up to and beyond the year 2000. Robinson J, et al. **WHO Reg Publ Eur Ser** 1997;74:127–44 (22 ref.)

Nursing in Europe: a resource for better health. Introduction. Salvage J. **WHO Reg Publ Eur Ser** 1997;74:1–11 (5 ref.)

Nursing and midwifery in Europe. Salvage J, et al. **WHO Reg Publ Eur Ser** 1997;74:21–123 (32 ref.)

STANDARDS

Policy matters: critical policy analysis and nursing. Cheek J, et al. **J Adv Nurs** 1997 Apr;25(4):668–72 (23 ref.)

Education for entry into practice: an ethical perspective. Hess JD. **J Prof Nurs** 1996 Sep–Oct;12(5):289–96 (49 ref.)

TRENDS

Nursing ideology: identification and legitimation. Taylor JS. **J Adv Nurs** 1997 Mar;25(3):442–6 (37 ref.)

Changing women's health, changing nursing practice [see comments] Taylor DL, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Nov–Dec; 25(9):791–802 (55 ref.) Comment in: J Obstet Gynecol Neonatal Nurs 1997 Jul–Aug;26(4):373.

Stages of nursing's political development: where we've been and where we ought to go. Cohen SS, et al. **Nurs Outlook** 1996 Nov–Dec;44(6):259–66 (64 ref.)

The preferable future for nursing. Korniewicz DM, et al. **Nurs Outlook** 1997 May–Jun;45(3):108–13 (14 ref.)

NURSING ADMINISTRATION RESEARCH

Managing policy research in nursing. Meerabeau L. **J Adv Nurs** 1996 Sep;24(3):633–9 (40 ref.)

NURSING ASSESSMENT

Elder abuse: what to look for, how to intervene [see comments] Lynch SH. **Am J Nurs** 1997 Jan;97(1):26–32; quiz 33 (10 ref.) Comment in: Am J Nurs 1997 Jul;97(7):17.

Perspectives unifying symptom interpretation. Teel CS, et al. **Image J Nurs Sch** 1997;29(2):175–81 (47 ref.)

Heuristics, servants to intuition, in clinical decision-making. Cioffi J. **J Adv Nurs** 1997 Jul;26(1):203–8 (48 ref.)

'Knowing the patient': a review of research on an emerging concept. Radwin LE. **J Adv Nurs** 1996 Jun;23(6):1142–6 (16 ref.)

Sexuality, sexual abuse. Omissions in admissions? Sharkey VB. **J Adv Nurs** 1997 May;25(5):1025–32 (56 ref.)

Urodynamic tests: client preparation, assessment, and follow-up. Wozniak-Petrofsky J. **Nurse Pract** 1997 Mar; 22(3):70–1, 77–9, 83–4 passim; quiz 90–1 (8 ref.)

METHODS

Assessing neurologic function in older patients. Crigger N, et al. **Am J Nurs** 1997 Mar;97(3):37–40 (10 ref.)

Symptom distress in adult patients with cancer. McClement SE, et al. **Cancer Nurs** 1997 Aug;20(4):236–43 (44 ref.)

Pressure ulcers. Assessment of healing. Ferrell BA. **Clin Geriatr Med** 1997 Aug;13(3):575–86 (24 ref.)

Information-seeking strategies and data utilisation: theory and practice. Roberts J, et al. **Int J Nurs Stud** 1995 Dec; 32(6):601–11 (73 ref.)

Decision making in community nursing: an analysis of the stages of decision making as they relate to community nursing assessment practice. Bryans A, et al. **J Adv Nurs** 1996 Jul;24(1):24–30 (31 ref.)

Social support: a conceptual analysis. Langford CP, et al. **J Adv Nurs** 1997 Jan;25(1):95–100 (53 ref.)

Woman abuse. The role of nurse-midwives in assessment. King MC, et al. **J Nurse Midwifery** 1996 Nov–Dec; 41(6):436–41 (13 ref.)

Assessment and management of chemotherapy-induced mucositis in children. Kennedy L, et al. **J Pediatr Oncol Nurs** 1997 Jul;14(3):164–74; quiz 175–7 (19 ref.)

Assessing American Indian families [see comments] Seideman RY, et al. **MCN Am J Matern Child Nurs** 1996 Nov–Dec; 21(6):274–9 (38 ref.) Comment in: MCN Am J Matern Child Nurs 1997 Mar–Apr;22(2):72, 104.

The clinical reasoning case study: a powerful teaching tool. Ryan-Wenger NA, et al. **Nurse Pract** 1997 May;22(5):66–7, 70, 76–9 passim (36 ref.)

Oral complications from cancer therapy: Part 2—Nursing implications for assessment and treatment. Madeya ML. **Oncol Nurs Forum** 1996 Jun;23(5):808–19 (63 ref.)

Strategies for assessing and fostering hope: the hope assessment guide. Penrod J, et al. **Oncol Nurs Forum** 1997 Jul;24(6):1055–63 (12 ref.)

Criteria for assessment of nausea, vomiting, and retching. Rhodes VA. **Oncol Nurs Forum** 1997 Aug;24(7 Suppl):13–9 (42 ref.)

The physical examination in cancer pain assessment. Portenoy RK. **Semin Oncol Nurs** 1997 Feb;13(1):25–9 (12 ref.)

Measurement issues in the comprehensive assessment of cancer pain. Vallerand AH. **Semin Oncol Nurs** 1997 Feb; 13(1):16–24 (34 ref.)

NURSING CARE

Guarding against adverse drug events. Edwards J. **Am J Nurs** 1997 May;97(5):26–30; quiz 31 (7 ref.)

Utilizing research findings in nursing: policy and practice considerations. Cavanagh SJ, et al. **J Adv Nurs** 1996 Nov; 24(5):1083–8 (48 ref.)

An analysis of the concept 'patient satisfaction' as it relates to contemporary nursing care. Mahon PY. **J Adv Nurs** 1996 Dec;24(6):1241–8 (61 ref.)

The development of parenting: nursing resources. Higley AM, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Oct; 25(8):707–13 (32 ref.)

Nursing implications in the management of superficial bladder cancer. Games J. **Semin Urol Oncol** 1996 Feb;14(1 Suppl 1):36–40 (27 ref.)

CLASSIFICATION

Implications of nursing taxonomies for middle-range theory development. Blegen MA, et al. **ANS Adv Nurs Sci** 1997 Mar;19(3):37–49 (34 ref.)

Nursing classification systems: necessary but not sufficient for representing "what nurses do" for inclusion in computer-based patient record systems [see comments] Henry SB, et al. **J Am Med Inform Assoc** 1997 May–Jun; 4(3):222–32 (48 ref.) Comment in: J Am Med Inform Assoc 1997 May–Jun;4(3):254–5.

METHODS

The nurse's role as patient advocate: obligation or imposition? Willard C. **J Adv Nurs** 1996 Jul;24(1):60–6 (30 ref.)

ORGANIZATION & ADMINISTRATION

Delegation are you doing it right? [see comments] Parkman CA. **Am J Nurs** 1996 Sep;96(9):42–7; quiz 48 (7 ref.) Comment in: Am J Nurs 1996 Dec;96(12):16.

The theory-practice gap in nursing: a new dimension. Hewison A, et al. **J Adv Nurs** 1996 Oct;24(4):754–61 (75 ref.)

Models for community-based long-term care for the elderly in a changing health system. Collins CE, et al. **Nurs Outlook** 1997 Mar–Apr;45(2):59–63 (25 ref.)

The role of nursing in primary health care. Campbell S. **WHO Reg Publ Eur Ser** 1997;74:209–39 (59 ref.)

PSYCHOLOGY

A concept analysis of trust. Johns JL. **J Adv Nurs** 1996 Jul; 24(1):76–83 (40 ref.)

Labouring the emotions: expanding the remit of nursing work? Phillips S. **J Adv Nurs** 1996 Jul;24(1):139–43 (16 ref.)

Methodological issues conducting sensitive research on lesbian and gay men's experience of nursing care. Platzer H, et al. **J Adv Nurs** 1997 Mar;25(3):626–33 (32 ref.)

STANDARDS

British studies which measure patient outcome, 1990–1994. French B. **J Adv Nurs** 1997 Aug;26(2):320–8 (27 ref.)

The pricing of nursing care. Hendricks J, et al. **J Adv Nurs** 1997 Mar;25(3):454–62 (21 ref.)

Quality indicators in clinical nursing: a review of the literature. Idvall E, et al. **J Adv Nurs** 1997 Jan;25(1):6–17 (110 ref.)

Whose outcomes. Patients, providers, or payers? Kleinpell

RM. **Nurs Clin North Am** 1997 Sep;32(3):513–20 (21 ref.)
Nurses at the bedside. Influencing outcomes. Lamb–Havard J. **Nurs Clin North Am** 1997 Sep;32(3):579–87 (7 ref.)
Challenges in measuring patient outcomes. Strickland OL. **Nurs Clin North Am** 1997 Sep;32(3):495–512 (23 ref.)
Measuring nursing. Nielsen GH. **WHO Reg Publ Eur Ser** 1997;74:241–55 (14 ref.)

NURSING CARE PLANS see **PATIENT CARE PLANNING**

NURSING DIAGNOSIS

Using nursing diagnoses to achieve desired outcomes for hemodialysis clients. Lobley LS. **Adv Ren Replace Ther** 1997 Apr;4(2):112–24 (28 ref.)
Spinal epidural abscess: the nurse's role in early detection and intervention. Hoppe B. **Heart Lung** 1996 Nov–Dec; 25(6):463–6 (34 ref.)
Cervical cancer: a developmental perspective. Klemm PR, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Sep; 25(7):629–34 (42 ref.)
Rethinking behavior disorders: whose attention has a deficit? Canuso R. **J Psychosoc Nurs Ment Health Serv** 1997 Apr; 35(4):24–9 (29 ref.)

CLASSIFICATION

Implications of nursing taxonomies for middle-range theory development. Blegen MA, et al. **ANS Adv Nurs Sci** 1997 Mar;19(3):37–49 (34 ref.)

NURSING ECONOMICS see **ECONOMICS, NURSING**

NURSING EDUCATION see **EDUCATION, NURSING**

NURSING EDUCATION, ASSOCIATE see **EDUCATION, NURSING, ASSOCIATE**

NURSING EDUCATION, BACCALAUREATE see **EDUCATION, NURSING, BACCALAUREATE**

NURSING EDUCATION, CONTINUING see **EDUCATION, NURSING, CONTINUING**

NURSING EDUCATION, GRADUATE see **EDUCATION, NURSING, GRADUATE**

NURSING EDUCATION RESEARCH

Role: a concept explored in nursing education. Clifford C. **J Adv Nurs** 1996 Jun;23(6):1135–41 (33 ref.)

METHODS

Continuing pain education in nursing: a literature review. Francke AL, et al. **Int J Nurs Stud** 1996 Oct;33(5):567–78 (37 ref.)

NURSING ETHICS see **ETHICS, NURSING**

NURSING EVALUATION RESEARCH

METHODS

The evaluation of nursing theory: a method for our madness. Dudley–Brown SL. **Int J Nurs Stud** 1997 Feb;34(1):76–83 (21 ref.)
The International Classification for Nursing Practice (ICNP): nursing outcomes. Clark J, et al. **Int Nurs Rev** 1997 Jul–Aug;44(4):121–4 (21 ref.)
A typology of the potential outcomes of maternal–child home visits: a literature analysis. Byrd ME. **Public Health Nurs** 1997 Feb;14(1):3–11 (34 ref.)
Patient satisfaction and the elderly. Owens DJ, et al. **Soc Sci Med** 1996 Jun;42(11):1483–91 (26 ref.)
Measuring nursing. Nielsen GH. **WHO Reg Publ Eur Ser** 1997;74:241–55 (14 ref.)

TRENDS

British studies which measure patient outcome, 1990–1994. French B. **J Adv Nurs** 1997 Aug;26(2):320–8 (27 ref.)

NURSING FACULTY see **FACULTY, NURSING**

NURSING FACULTY PRACTICE

The clinical role of the nurse teacher: a review of the dispute. Lee DT. **J Adv Nurs** 1996 Jun;23(6):1127–34 (40 ref.)

ORGANIZATION & ADMINISTRATION

The practice role in the academic nursing community. Broussard AB, et al. **J Nurs Educ** 1996 Feb;35(2):82–7 (54 ref.)

NURSING, HOLISTIC see **HOLISTIC NURSING**

NURSING, HOME see **HOME NURSING**

NURSING HOMES

Cardiopulmonary resuscitation and do-not-resuscitate orders in the nursing home. Zweig SC. **Arch Fam Med** 1997 Sep–Oct;6(5):424–9 (83 ref.)
Creating a living will. Experience at a multilevel geriatric facility. Levitt D, et al. **Can Fam Physician** 1996 Dec; 42:2413–20 (22 ref.)
Prevalence of cancer in older persons living at home and in institutions. Caranasos GJ. **Clin Geriatr Med** 1997 Feb; 13(1):15–31 (33 ref.)
Falls and fall prevention in the nursing home. Rubenstein LZ, et al. **Clin Geriatr Med** 1996 Nov;12(4):881–902 (86 ref.)
Pain in the nursing home. Stein WM, et al. **Clin Geriatr Med** 1996 Aug;12(3):601–13 (25 ref.)
Methicillin-resistant Staphylococcus aureus in nursing homes. Epidemiology, prevention and management. Bradley SF. **Drugs Aging** 1997 Mar;10(3):185–98 (90 ref.)
Nursing home-acquired pneumonia. Marrie TJ, et al. **Drugs Aging** 1996 May;8(5):338–48 (64 ref.)
Nursing home visits: an efficient system for the busy physician. McCartney RD, et al. **Geriatrics** 1997 May; 52(5):57–60, 65, 69 (17 ref.)
Alcohol and drug misuse in the nursing home. Joseph CL. **Int J Addict** 1995 Nov–Dec;30(13–14):1953–84 (100 ref.)
Hospitalization of nursing home residents: the right rate? [editorial; comment] Lynn J. **J Am Geriatr Soc** 1997 Mar; 45(3):378–9 (8 ref.) Comment on: J Am Geriatr Soc 1997 Mar;45(3):265–9.
Nursing home-acquired pneumonia: avoiding the hospital [editorial; comment] Zimmer JG, et al. **J Am Geriatr Soc** 1997 Mar;45(3):380–1 (14 ref.) Comment on: J Am Geriatr Soc 1997 Mar;45(3):302–6.
Nursing home dentistry. Moncrieff RG. **N Y State Dent J** 1996 Dec;62(10):43–7 (16 ref.)
Lessons from geriatric psychiatry in the long-term care setting. Streim JE, et al. **Psychiatr Q** 1997 Fall; 68(3):281–307 (84 ref.)
A ten-year review of the effect of OBRA-87 on psychotropic prescribing practices in an academic nursing home. Lantz MS, et al. **Psychiatr Serv** 1996 Sep;47(9):951–5 (34 ref.)
Policy issues in the private health sector: examples from long-term care in the U.K. Bartlett HP, et al. **Soc Sci Med** 1996 Sep;43(5):731–7 (37 ref.)
[Family and social aspects in dementia] Bermejo F, et al. **Med Clin (Barc)** 1997 Jun 21;109(4):140–6 (173 ref.) **(Spa)**

MANPOWER

[Current personnel status and qualification requirements in nursing care] Kühnert S, et al. **Z Gerontol Geriatr** 1996 Nov–Dec;29(6):411–7 (7 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

Antimicrobial use in long-term-care facilities. Nicolle LE, et al. **Infect Control Hosp Epidemiol** 1996 Feb;17(2):119–28 (56 ref.)
Nutrition assessment in long-term care facilities. Roubenoff R, et al. **Nutr Rev** 1996 Jan;54(1 Pt 2):S40–2 (8 ref.)

STATISTICS & NUMERICAL DATA

Antimicrobial resistance in long-term-care facilities. Strausbaugh LJ, et al. **Infect Control Hosp Epidemiol** 1996 Feb;17(2):129–40 (65 ref.)
Compression of disability: evidence from the National Long-Term Care Survey. Corder LS. **Nutr Rev** 1996 Jan; 54(1 Pt 2):S9–16 (7 ref.)

TRENDS

Carers of the elderly—knowledge, use of and satisfaction with day care services. Jennings S, et al. **Ir J Med Sci** 1997 Jan–Mar;166(1):28–31 (14 ref.)

NURSING, MATERNAL-CHILD see **MATERNAL-CHILD NURSING**

NURSING METHODOLOGY RESEARCH

Information-seeking strategies and data utilisation: theory and practice. Roberts J, et al. **Int J Nurs Stud** 1995 Dec; 32(6):601–11 (73 ref.)
Loneliness in elderly people: an important area for nursing research. Donaldson JM, et al. **J Adv Nurs** 1996 Nov; 24(5):952–9 (76 ref.)
Social support: a conceptual analysis. Langford CP, et al. **J Adv Nurs** 1997 Jan;25(1):95–100 (53 ref.)

METHODS

Triangulation of communication skills in qualitative research instruments. Begley CM. **J Adv Nurs** 1996 Oct;24(4):688–93 (27 ref.)
Methodological issues conducting sensitive research on lesbian and gay men's experience of nursing care. Platzer H, et al. **J Adv Nurs** 1997 Mar;25(3):626–33 (32 ref.)
Focus on qualitative methods. Qualitative metasynthesis: issues and techniques. Sandelowski M, et al. **Res Nurs Health** 1997 Aug;20(4):365–71 (47 ref.)

NURSING, MILITARY AND NAVAL see **MILITARY NURSING**

NURSING MODELS see **MODELS, NURSING**

NURSING, ONCOLOGIC see **ONCOLOGIC NURSING**

NURSING PROCESS

Serenity as a goal for nursing practice. Roberts KT, et al. **Image J Nurs Sch** 1996 Winter;28(4):359–64 (56 ref.)
Toward a model for nursing informatics. Turley JP. **Image J Nurs Sch** 1996 Winter;28(4):309–13 (26 ref.)
The theory-practice relationship in nursing: an exploration of contemporary discourse. Fealy GM. **J Adv Nurs** 1997 May;25(5):1061–9 (30 ref.)
Nurse-sensitive health care outcomes in acute care settings: an integrative analysis of the literature. Pierce SF. **J Nurs Care Qual** 1997 Apr;11(4):60–72 (56 ref.)
Externalizing the critical thinking in knowledge development and clinical judgment. Facione NC, et al. **Nurs Outlook** 1996 May–Jun;44(3):129–36 (19 ref.)
An implicit world view in technology and its consequences for contemporary life. Ketner KL. **Nurs Outlook** 1996 Nov–Dec;44(6):280–3 (9 ref.)

NURSING PROGRAM EVALUATION see **NURSING EVALUATION RESEARCH**

NURSING PROTOCOLS see **NURSING ASSESSMENT**

NURSING RECORDS

see related
FORMS AND RECORDS CONTROL

Technology assessment. A framework for generating questions useful in evaluating nursing information systems. Manning J, et al. **Comput Nurs** 1997 May–Jun;15(3):141–6 (12 ref.)
The International Classification for Nursing Practice (ICNP): nursing outcomes. Clark J, et al. **Int Nurs Rev** 1997 Jul–Aug;44(4):121–4 (21 ref.)
Nursing classification systems: necessary but not sufficient for representing "what nurses do" for inclusion in computer-based patient record systems [see comments] Henry SB, et al. **J Am Med Inform Assoc** 1997 May–Jun; 4(3):222–32 (48 ref.) Comment in: J Am Med Inform Assoc 1997 May–Jun;4(3):254–5.
Forensic documentation of battered pregnant women. Sheridan DJ. **J Nurse Midwifery** 1996 Nov–Dec; 41(6):467–72 (14 ref.)

NURSING RESEARCH

Nursing research in Taiwan. Shiao SY, et al. **Annu Rev Nurs Res** 1997;15:263–81 (97 ref.)
Nursing science in the global community. Ketefian S, et al. **Image J Nurs Sch** 1997 Spring;29(1):11–5 (27 ref.)
Cultural discourse and the myth of stress in nursing and medicine. Mulhall A. **Int J Nurs Stud** 1996 Oct; 33(5):455–68 (75 ref.)
Informal family caregiving to older people with dementia: research priorities for community psychiatric nursing. Adams T. **J Adv Nurs** 1996 Oct;24(4):703–10 (97 ref.)
Utilizing research findings in nursing: policy and practice considerations. Cavanagh SJ, et al. **J Adv Nurs** 1996 Nov; 24(5):1083–8 (48 ref.)
Intuition: a critical review of the research and rhetoric. King L, et al. **J Adv Nurs** 1997 Jul;26(1):194–202 (41 ref.)
A conceptual foundation for human suffering in nursing care and research. Rodgers BL, et al. **J Adv Nurs** 1997 May; 25(5):1048–53 (47 ref.)
The emergency nurse practitioner role in major accident and emergency departments: professional issues and the research agenda. Tye CC. **J Adv Nurs** 1997 Aug; 26(2):364–70 (54 ref.)
Focus on research utilization. Fitzsimmons L, et al. **J Cardiovasc Nurs** 1995 Jan;9(2):87–94 (30 ref.)
The use of projective techniques in pediatric nursing research from 1984 to 1993. Bellack JP, et al. **J Pediatr Nurs** 1996 Feb;11(1):10–28 (36 ref.)
Multiple authorship: issues and recommendations. Erlen JA, et al. **J Prof Nurs** 1997 Jul–Aug;13(4):262–70 (23 ref.)
Poster presentations: getting your point across. Morin KH. **MCN Am J Matern Child Nurs** 1996 Nov–Dec; 21(6):307–10 (2 ref.)
Ethical dilemmas in maternal–fetal research. Sams L. **MCN Am J Matern Child Nurs** 1997 Mar–Apr;22(2):67–71 (6 ref.)
The mother-headed single-parent family: a feminist critique of the nursing literature [see comments] Ford-Gilboe M, et al. **Nurs Outlook** 1996 Jul–Aug;44(4):173–83 (49 ref.) Comment in: Nurs Outlook 1997 Mar–Apr;45(2):93.
The overemphasis on power analysis. Knapp TR. **Nurs Res** 1996 Nov–Dec;45(6):379–81 (18 ref.)

ECONOMICS

Funding nursing informatics activities. Internet access to announcements of government funding. McCormick KA, et al. **Comput Nurs** 1996 Nov–Dec;14(6):315–22 (10 ref.)

INSTRUMENTATION

Selection and use of content experts for instrument development. Grant JS, et al. **Res Nurs Health** 1997 Jun;

NURSING RESEARCH

20(3):269–74 (25 ref.)

METHODS

Explicating middle-range theory through methodological diversity. Acton GJ, et al. **ANS Adv Nurs Sci** 1997 Mar; 19(3):78–85 (22 ref.)

Single subject experimentation for psychiatric nursing. Elder JH. **Arch Psychiatr Nurs** 1997 Jun;11(3):133–8 (17 ref.)

The contributions of nursing science to social support. Stewart MJ, et al. **Int J Nurs Stud** 1995 Dec;32(6):535–44 (87 ref.)

A review of statistical methods in the Journal of Advanced Nursing. Anthony D. **J Adv Nurs** 1996 Nov;24(5):1089–94 (10 ref.)

Finding your way around qualitative methods in nursing research. Bailey PH. **J Adv Nurs** 1997 Jan;25(1):18–22 (21 ref.)

The problems of researching mixed sex wards. Batcup D. **J Adv Nurs** 1997 May;25(5):1018–24 (71 ref.)

Using triangulation in nursing research. Begley CM. **J Adv Nurs** 1996 Jul;24(1):122–8 (35 ref.)

Integrative nursing research—an important strategy to further the development of nursing science and nursing practice. Kirkevold M. **J Adv Nurs** 1997 May;25(5):977–84 (19 ref.)

Nursing research: our world not theirs? Mulhall A. **J Adv Nurs** 1997 May;25(5):969–76 (63 ref.)

The Delphi method? Crisp J, et al. **Nurs Res** 1997 Mar–Apr; 46(2):116–8 (20 ref.)

Alternative statistical methods to use with survival data. Holt F, et al. **Nurs Res** 1996 Nov–Dec;45(6):345–9 (23 ref.)

Methodological issues in psychoneuroimmunology research. Zeller JM, et al. **Nurs Res** 1996 Sep–Oct;45(5):314–8 (39 ref.)

Interpretive description: a noncategorical qualitative alternative for developing nursing knowledge. Thorne S, et al. **Res Nurs Health** 1997 Apr;20(2):169–77 (51 ref.)

Wilsonian methods of concept analysis: a critique. Hupcey JE, et al. **Sch Inq Nurs Pract** 1996 Fall;10(3):185–210 (50 ref.)

Concept analysis in nursing research: a critical appraisal. Morse JM, et al. **Sch Inq Nurs Pract** 1996 Fall;10(3):253–77 (104 ref.)

ORGANIZATION & ADMINISTRATION

The politics of collaboration as viewed through the lens of a collaborative nursing research project. Beattie J, et al. **J Adv Nurs** 1996 Oct;24(4):682–7 (26 ref.)

Using triangulation in nursing research. Begley CM. **J Adv Nurs** 1996 Jul;24(1):122–8 (35 ref.)

Mixed messages in nursing research: their contribution to the persisting hiatus between evidence and practice. Hicks C, et al. **J Adv Nurs** 1997 Mar;25(3):595–601 (20 ref.)

A re-examination of the experimental design for nursing research. Poole K, et al. **J Adv Nurs** 1996 Jul;24(1):108–14 (64 ref.)

The sabbatical year: letting the fields lay fallow. Tiedje LB, et al. **Nurs Outlook** 1996 Sep–Oct;44(5):235–8 (11 ref.)

Using key informant methods in organizational survey research: assessing for informant bias. Hughes LC, et al. **Res Nurs Health** 1997 Feb;20(1):81–92 (44 ref.)

STANDARDS

How to assess a research study [see comments] Rankin M, et al. **Am J Nurs** 1996 Dec;96(12):32–6; quiz 37 (10 ref.) Comment in: Am J Nurs 1997 Mar;97(3):23.

TRENDS

Themes relating to sexuality that emerged from a discourse analysis of the Nursing Times during 1980–1990. Carr G. **J Adv Nurs** 1996 Jul;24(1):196–212 (129 ref.)

[Nursing research in geriatric nursing. A study of the literature based on 2 scientific specialty periodicals] Flügel K. **Z Gerontol Geriatr** 1996 Nov–Dec;29(6):397–403 (11 ref.) (Eng. Abstr.) **(Ger)**

NURSING RESEARCH, ADMINISTRATIVE see **NURSING ADMINISTRATION RESEARCH**

NURSING RESEARCH, CLINICAL see **CLINICAL NURSING RESEARCH**

NURSING RESEARCH, EDUCATIONAL see **NURSING EDUCATION RESEARCH**

NURSING SCHOOLS see **SCHOOLS, NURSING**

NURSING SERVICE, HOSPITAL

MANPOWER

Survey and critique of studies related to unlicensed assistive personnel from 1975 to 1997, Part 1. Bernreuter ME, et al. **J Nurs Adm** 1997 Jun;27(6):24–9 (50 ref.)

ORGANIZATION & ADMINISTRATION

A focused strategic plan for outcomes evaluation. Stonestreet JS, et al. **Nurs Clin North Am** 1997 Sep;32(3):615–31 (12 ref.)

STANDARDS

Dimensions and indicators of patients' perceived nursing care quality in the hospital setting. Chang K. **J Nurs Care Qual** 1997 Aug;11(6):26–37 (35 ref.)

Nurse-sensitive health care outcomes in acute care settings: an integrative analysis of the literature. Pierce SF. **J Nurs Care Qual** 1997 Apr;11(4):60–72 (56 ref.)

NURSING SERVICES

STANDARDS

Legal and practical impact of clinical practice guidelines on nursing and medical practice. Murphy RN. **Nurse Pract** 1997 Mar;22(3):138, 147–8 (3 ref.)

NURSING STAFF

[Occupational dangers to health of nursing staffs in hemodialysis units] Washio M, et al. **Sangyo Ika Daigaku Zasshi** 1996 Sep 1;18(3):239–45 (20 ref.) (Eng. Abstr.) **(Jpn)**

EDUCATION

Models of differentiated practice and specialization in community nursing: a review of the literature. Jansen PG, et al. **J Adv Nurs** 1996 Nov;24(5):968–80 (89 ref.)

PSYCHOLOGY

Decision making in community nursing: an analysis of the stages of decision making as they relate to community nursing assessment practice. Bryans A, et al. **J Adv Nurs** 1996 Jul;24(1):24–30 (31 ref.)

STANDARDS

Health hazards in nursing and health care: an overview. Rogers B. **Am J Infect Control** 1997 Jun;25(3):248–61 (154 ref.)

NURSING STAFF, HOSPITAL

EDUCATION

The clinical learning environment. Rotem A, et al. **Isr J Med Sci** 1996 Sep;32(9):705–10 (31 ref.)

ORGANIZATION & ADMINISTRATION

Delegation are you doing it right? [see comments] Parkman CA. **Am J Nurs** 1996 Sep;96(9):42–7; quiz 48 (7 ref.) Comment in: Am J Nurs 1996 Dec;96(12):16.

PSYCHOLOGY

Intersubjectivity, social microcosm, and the here-and-now in a support group for nurses. Brandman W. **Arch Psychiatr Nurs** 1996 Dec;10(6):374–8 (8 ref.)

Nurses and physicians evaluate their intensive care experiences. Laubach W, et al. **Heart Lung** 1996 Nov–Dec; 25(6):475–82 (32 ref.)

The politics of collaboration as viewed through the lens of a collaborative nursing research project. Beattie J, et al. **J Adv Nurs** 1996 Oct;24(4):682–7 (26 ref.)

NURSING, SUPERVISORY

ORGANIZATION & ADMINISTRATION

The theory-practice gap in nursing: a new dimension. Hewison A, et al. **J Adv Nurs** 1996 Oct;24(4):754–61 (75 ref.)

NURSING THEORY

see related
MODELS, NURSING

Explicating middle-range theory through methodological diversity. Acton GJ, et al. **ANS Adv Nurs Sci** 1997 Mar; 19(3):78–85 (22 ref.)

Implications of nursing taxonomies for middle-range theory development. Blegen MA, et al. **ANS Adv Nurs Sci** 1997 Mar;19(3):37–49 (34 ref.)

Bakhtin, nursing narratives, and dialogical consciousness. Bowers R, et al. **ANS Adv Nurs Sci** 1997 Mar;19(3):70–7 (28 ref.)

The role of nursing in the rehabilitation of acute stroke patients: toward a unified theoretical perspective. Kirkevold M. **ANS Adv Nurs Sci** 1997 Jun;19(4):55–64 (40 ref.)

The middle-range theory of unpleasant symptoms: an update. Lenz ER, et al. **ANS Adv Nurs Sci** 1997 Mar;19(3):14–27 (53 ref.)

Toward a middle-range theory of resilience. Polk LV. **ANS Adv Nurs Sci** 1997 Mar;19(3):1–13 (42 ref.)

Nursing science in the global community. Ketefian S, et al. **Image J Nurs Sch** 1997 Spring;29(1):11–5 (27 ref.)

Social epistemology, gender and nursing theory. Cash K. **Int J Nurs Stud** 1997 Apr;34(2):137–43 (27 ref.)

The evaluation of nursing theory: a method for our madness. Dudley-Brown SL. **Int J Nurs Stud** 1997 Feb;34(1):76–83 (21 ref.)

The postmodernist hoax and its effects on nursing. Kermode S, et al. **Int J Nurs Stud** 1996 Aug;33(4):375–84 (36 ref.)

Fatigue: a concept analysis. Ream E, et al. **Int J Nurs Stud** 1996 Oct;33(5):519–29 (50 ref.)

The contributions of nursing science to social support. Stewart MJ, et al. **Int J Nurs Stud** 1995 Dec;32(6):535–44 (87 ref.)

The human science basis of psychiatric nursing: theory and practice. Barker PJ, et al. **J Adv Nurs** 1997 Apr;25(4):660–7 (44 ref.)

The theory-practice relationship in nursing: an exploration of contemporary discourse. Fealy GM. **J Adv Nurs** 1997 May;25(5):1061–9 (30 ref.)

The theory-practice gap in nursing: a new dimension. Hewison A, et al. **J Adv Nurs** 1996 Oct;24(4):754–61 (75 ref.)

The politics of phenomenological concepts in nursing. Holmes CA. **J Adv Nurs** 1996 Sep;24(3):579–87 (69 ref.)

Culture, needs and nursing: a critical theory approach. Holmes CA, et al. **J Adv Nurs** 1997 Mar;25(3):463–70 (66 ref.)

Towards a critical theory of mental health nursing. Hopton J. **J Adv Nurs** 1997 Mar;25(3):492–500 (72 ref.)

Integrative nursing research—an important strategy to further the development of nursing science and nursing practice. Kirkevold M. **J Adv Nurs** 1997 May;25(5):977–84 (19 ref.)

Social support: a conceptual analysis. Langford CP, et al. **J Adv Nurs** 1997 Jan;25(1):95–100 (53 ref.)

The art of nursing in a 'postmodern' context. Lister P. **J Adv Nurs** 1997 Jan;25(1):38–44 (50 ref.)

How not to clarify concepts in nursing. Paley J. **J Adv Nurs** 1996 Sep;24(3):572–8 (35 ref.)

Nursing ideology: identification and legitimation. Taylor JS. **J Adv Nurs** 1997 Mar;25(3):442–6 (37 ref.)

Coalescing the theories of two nurse visionaries: Parse and Watson. Walker CA. **J Adv Nurs** 1996 Nov;24(5):988–96 (41 ref.)

A concept analysis of empathy. Wiseman T. **J Adv Nurs** 1996 Jun;23(6):1162–7 (38 ref.)

A middle-range theory of chronotherapeutic intervention for postsurgical pain. Auvil-Novak SE. **Nurs Res** 1997 Mar–Apr;46(2):66–71 (46 ref.)

Older adults' experience of health promotion: a theory for nursing practice. Frenn M. **Public Health Nurs** 1996 Feb; 13(1):65–71 (32 ref.)

Wilsonian methods of concept analysis: a critique. Hupcey JE, et al. **Sch Inq Nurs Pract** 1996 Fall;10(3):185–210 (50 ref.)

Concept development: exploring undocumentedness. Messias DK. **Sch Inq Nurs Pract** 1996 Fall;10(3):235–52 (51 ref.)

Postpartum fatigue: clarifying a concept. Milligan R, et al. **Sch Inq Nurs Pract** 1996 Fall;10(3):279–91 (42 ref.)

Concept analysis in nursing research: a critical appraisal. Morse JM, et al. **Sch Inq Nurs Pract** 1996 Fall;10(3):253–77 (104 ref.)

The pediatric physiologic stress response: a concept analysis. Rosenthal-Dichter CH. **Sch Inq Nurs Pract** 1996 Fall; 10(3):211–34 (58 ref.)

NURSING, TRANSCULTURAL see **TRANSCULTURAL NURSING**

NUTCRACKER ESOPHAGUS see **ESOPHAGEAL MOTILITY DISORDERS**

NUTRITION

see related
DIET
FOOD

Intrauterine nutrition and development. Mancuso S, et al. **Adv Contracept** 1996 Dec;12(4):285–91 (23 ref.)

Nutritional, hormonal, and environmental mechanisms in breast tumorigenesis. Glaspy J. **Adv Exp Med Biol** 1996; 399:27–40 (93 ref.)

Is taurine a preventive nutritional factor of cardiovascular diseases or just a biological marker of nutrition? Yamori Y, et al. **Adv Exp Med Biol** 1996;403:623–9 (26 ref.)

Nutritional approaches to the prevention of prostate cancer progression. Yip I, et al. **Adv Exp Med Biol** 1996;399:173–81 (75 ref.)

Estimation and use of kinetic parameter distributions in metabolism and nutrition. Beltz WF. **Adv Food Nutr Res** 1996;40:265–79 (19 ref.)

Quantitative and conceptual contributions of mathematical modeling to current views on vitamin A metabolism, biochemistry, and nutrition. Green MH, et al. **Adv Food Nutr Res** 1996;40:3–24 (29 ref.)

Microdialysis and ultrafiltration. Janle EM, et al. **Adv Food Nutr Res** 1996;40:183–96 (16 ref.)

Molecular biology in nutrition research: modeling of folate metabolism. Lin BF, et al. **Adv Food Nutr Res** 1996; 40:95–106 (9 ref.)

Analysis of bioperiodicity in physiological responses. Mercer LP, et al. **Adv Food Nutr Res** 1996;40:217–26 (16 ref.)

Mathematical modeling in nutrition: constructing a physiologic compartmental model of the dynamics of beta-carotene metabolism. Novotny JA, et al. **Adv Food Nutr Res** 1996;40:25–54 (39 ref.)

Nutrient-response: a "top down" approach to metabolic control. Schulz AR. **Adv Food Nutr Res** 1996;40:227–41 (23 ref.)

Phytonutrition, phytotherapy, and phytopharmacology. Bland JS. **Altern Ther Health Med** 1996 Nov;2(6):73–6 (24 ref.)
Nutrition during pregnancy. Kolasa KM, et al. **Am Fam Physician** 1997 Jul;56(1):205–12, 216–8 (33 ref.)
Nutrition and the immune system: an introduction. Chandra RK. **Am J Clin Nutr** 1997 Aug;66(2):460S–463S (15 ref.)
Primary care physicians and clinical nutrition: can good medical nutrition care be offered without well-trained physicians in the area? Dutra-de-Oliveira JE, et al. **Am J Clin Nutr** 1997 Jun;65(6 Suppl):2010S–2012S (6 ref.)
Review of nutritional attitudes and counseling practices of primary care physicians. Glanz K. **Am J Clin Nutr** 1997 Jun;65(6 Suppl):2016S–2019S (31 ref.)
Food and nutrition surveillance: an international overview. Jerome NW, et al. **Am J Clin Nutr** 1997 Apr;65(4 Suppl):1198S–1202S (11 ref.)
Nutrition and immunity in the elderly: modification of immune responses with nutritional treatments. Lesourd BM. **Am J Clin Nutr** 1997 Aug;66(2):478S–484S (88 ref.)
Biochemical markers as additional measurements in dietary validity studies: application of the method of triads with examples from the European Prospective Investigation into . Cancer and Nutrition. Ocké MC, et al. **Am J Clin Nutr** 1997 Apr;65(4 Suppl):1240S–1245S (14 ref.)
Synergism of nutrition, infection, and immunity: an overview. Scrimshaw NS, et al. **Am J Clin Nutr** 1997 Aug; 66(2):464S–477S (231 ref.)
Regression calibration method for correcting measurement-error bias in nutritional epidemiology. Spiegelman D, et al. **Am J Clin Nutr** 1997 Apr;65(4 Suppl):1179S–1186S (35 ref.)
Consumer involvement in nutritional issues: the role of information. Vaandrager HW, et al. **Am J Clin Nutr** 1997 Jun;65(6 Suppl):1980S–1984S (21 ref.)
Nutritional factors in Dutch family medicine: an inventory. van Binsbergen JJ. **Am J Clin Nutr** 1997 Jun;65(6 Suppl):1967S–1973S (90 ref.)
Adjustment for total energy intake in epidemiologic studies. Willett WC, et al. **Am J Clin Nutr** 1997 Apr;65(4 Suppl):1220S–1228S; discussion 1229S–1231S (17 ref.)
Hormone-mediated changes in nutrient metabolism in pregnancy: a physiological basis for normal fetal development. Knopp RH. **Ann N Y Acad Sci** 1997 May 28;817:251–71 (46 ref.)
Impact of macronutrient substitutes on the composition of the diet and the U.S. food supply. Morgan R, et al. **Ann N Y Acad Sci** 1997 May 23;819:70–95 (22 ref.)
Carbohydrates and energy balance. Stubbs RJ, et al. **Ann N Y Acad Sci** 1997 May 23;819:44–69 (77 ref.)
The role of fatty acids in gene expression: health implications. Simopoulos AP. **Ann Nutr Metab** 1996;40(6):303–11 (44 ref.)
Applications of mass isotopomer analysis to nutrition research. Brunengraber H, et al. **Annu Rev Nutr** 1997; 17:559–96 (135 ref.)
Development and biomedical testing of military operational rations. Friedl KE, et al. **Annu Rev Nutr** 1997;17:51–75 (110 ref.)
Antioxidants in human health and disease. Halliwell B. **Annu Rev Nutr** 1996;16:33–50 (124 ref.)
Role of nutrition in prevention of the progression of renal disease. Maroni BJ, et al. **Annu Rev Nutr** 1997;17:435–55 (71 ref.)
Comparative nutrition of iron and copper. Winzerling JJ, et al. **Annu Rev Nutr** 1997;17:501–26 (165 ref.)
The epidemic of dieting women: the need for a sociological approach to food and nutrition. Germov J, et al. **Appetite** 1996 Oct;27(2):97–108 (60 ref.)
Nutrition and asthma. Monteleone CA, et al. **Arch Intern Med** 1997 Jan 13;157(1):23–34 (61 ref.)
Nutrition and diabetes. Wahlqvist ML. **Aust Fam Physician** 1997 Apr;26(4):384–9 (54 ref.)
Nutrition for post-exercise recovery. Burke LM. **Aust J Sci Med Sport** 1997 Mar;29(1):3–10 (60 ref.)
Nutritional influences on human adipose-tissue metabolism. Frayn KN, et al. **Biochem Soc Trans** 1996 May;24(2):422–6 (28 ref.)
Endocrine and nutritional modulation of glucose disposal and storage in muscle. Holness MJ, et al. **Biochem Soc Trans** 1997 Feb;25(1):1–7 (23 ref.)
Role of fetal and infant growth in programming metabolism in later life. Desai M, et al. **Biol Rev Camb Philos Soc** 1997 May;72(2):329–48 (111 ref.)
Genetic variation and nutrition. Simopoulos AP. **Biomed Environ Sci** 1996 Sep;9(2–3):124–9 (22 ref.)
Causes and interventions for malnutrition in patients undergoing maintenance dialysis. Fouque D. **Blood Purif** 1997;15(2):112–20 (61 ref.)
Socioeconomic determinants of health. The contribution of nutrition to inequalities in health. James WP, et al. **BMJ** 1997 May 24;314(7093):1545–9 (31 ref.)
Breakfast: a review of associations with measures of dietary intake, physiology and biochemistry. Ruxton CH, et al. **Br J Nutr** 1997 Aug;78(2):199–213 (87 ref.)
Nutrition and cognitive function. Gordon N. **Brain Dev** 1997 Apr;19(3):165–70 (44 ref.)
Using immunological techniques to determine the effect of nutrition on T-cell function. Field CJ. **Can J Physiol Pharmacol** 1996 Jun;74(6):769–77 (64 ref.)
Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 4. Calcium nutrition and osteoporosis [see comments] Murray TM. **Can Med Assoc J** 1996 Oct 1;155(7):935–9 (32 ref.) Comment in: Can Med Assoc J 1997 May 1;156(9):1269.
Metabolic support of the gastrointestinal tract: potential gut protection during intensive cytotoxic therapy. Wilmore DW. **Cancer** 1997 May 1;79(9):1794–803 (72 ref.)
Nutrition and esophageal cancer. Cheng KK, et al. **Cancer Causes Control** 1996 Jan;7(1):33–40 (76 ref.)
Nutrition and endometrial cancer. Hill HA, et al. **Cancer Causes Control** 1996 Jan;7(1):19–32 (64 ref.)
Nutrition and pancreatic cancer. Howe GR, et al. **Cancer Causes Control** 1996 Jan;7(1):69–82 (41 ref.)
Nutrition and breast cancer. Hunter DJ, et al. **Cancer Causes Control** 1996 Jan;7(1):56–68 (123 ref.)
Nutrition, hormones, and breast cancer: is insulin the missing link? [see comments] Kaaks R. **Cancer Causes Control** 1996 Nov;7(6):605–25 (355 ref.) Comment in: Cancer Causes Control 1996 Nov;7(6):569–71.
Nutrition and prostate cancer. Kolonel LN. **Cancer Causes Control** 1996 Jan;7(1):83–44 (91 ref.)
Nutrition and stomach cancer. Kono S, et al. **Cancer Causes Control** 1996 Jan;7(1):41–55 (108 ref.)
Nutrition and bladder cancer. La Vecchia C, et al. **Cancer Causes Control** 1996 Jan;7(1):95–100 (27 ref.)
Nutrition and oral cancer. Marshall JR, et al. **Cancer Causes Control** 1996 Jan;7(1):101–11 (48 ref.)
Nutrition and cervical neoplasia [published erratum appears in Cancer Causes Control 1996 May;7(3):402] Potischman N, et al. **Cancer Causes Control** 1996 Jan;7(1):113–26 (79 ref.)
Nutrition and colorectal cancer. Potter JD. **Cancer Causes Control** 1996 Jan;7(1):127–46 (278 ref.)
Nutrition and laryngeal cancer. Riboli E, et al. **Cancer Causes Control** 1996 Jan;7(1):147–56 (28 ref.)
Nutrition and renal cell cancer. Wolk A, et al. **Cancer Causes Control** 1996 Jan;7(1):5–18 (96 ref.)
Nutrition and lung cancer. Ziegler RG, et al. **Cancer Causes Control** 1996 Jan;7(1):157–77 (161 ref.)
Nutritional influences in early life upon obesity and body proportions. Jackson AA, et al. **Ciba Found Symp** 1996; 201:118–29; discussion 129–37, 188–93 (54 ref.)
Fiber, lipids, and coronary heart disease. A statement for healthcare professionals from the Nutrition Committee, American Heart Association. Van Horn L. **Circulation** 1997 Jun 17;95(12):2701–4 (53 ref.)
Maternal nutrition and the outcome of pregnancy. A renaissance in research. Brown JE, et al. **Clin Perinatol** 1997 Jun;24(2):433–49 (101 ref.)
Nutrition and therapeutics [editorial] Lean ME. **Curr Opin Lipidol** 1996 Dec;7(6):U173–8 (12 ref.)
Nutrition and therapeutics [editorial] Mamo J. **Curr Opin Lipidol** 1997 Apr;8(2):U15–7 (11 ref.)
Translation of the diabetes nutrition recommendations for health care institutions. American Diabetes Association. **Diabetes Care** 1997 Jan;20(1):106–8 (5 ref.)
Translation of the diabetes nutrition recommendations for health care institutions. Schafer RG, et al. **Diabetes Care** 1997 Jan;20(1):96–105 (63 ref.)
High-fat and high-carbohydrate diets and energy balance. Shah M, et al. **Diabetes Care** 1996 Oct;19(10):1142–52 (70 ref.)
A brave new world for nutrition and diabetes. Wheeler ML. **Diabetes Care** 1997 Jan;20(1):109–10 (5 ref.)
Role of nutrition planning in the treatment for obesity. Atkinson RL. **Endocrinol Metab Clin North Am** 1996 Dec; 25(4):955–64 (19 ref.)
Chocolate--divine food, fattening junk or nutritious supplementation? Rössner S. **Eur J Clin Nutr** 1997 Jun; 51(6):341–5 (33 ref.)
Lipid requirements in infants with digestive diseases with references to short bowel syndrome. Goulet O. **Eur J Med Res** 1997 Feb 21;2(2):79–83 (26 ref.)
Nutrition, temperature and homeostasis during perinatal development. Symonds ME, et al. **Exp Physiol** 1995 Nov; 80(6):907–40 (155 ref.)
Oxidative stress, nutrition and health. Experimental strategies for optimization of nutritional antioxidant intake in humans. Halliwell B. **Free Radic Res** 1996 Jul;25(1):57–74 (210 ref.)
Nutritional considerations in inflammatory bowel diseases. Kelly DG, et al. **Gastroenterol Clin North Am** 1995 Sep; 24(3):597–611 (89 ref.)
Corticosteroid-binding globulin during inflammation and burn injury: nutritional modulation and clinical implications. Garrel DR. **Horm Res** 1996;45(3–5):245–51 (54 ref.)
Nutritional regulation of the growth hormone and insulin-like growth factor-binding proteins. Ketelslegers JM, et al. **Horm Res** 1996;45(3–5):252–7 (48 ref.)
Investigations into mechanisms of amino acid supply to the rat embryo using whole-embryo culture. Beckman DA, et al. **Int J Dev Biol** 1997 Apr;41(2):315–8 (23 ref.)
Intrinsic and non-milk extrinsic sugars: does the distinction have analytical or physiological validity? Johnson IT, et al. **Int J Food Sci Nutr** 1996 Mar;47(2):131–40 (43 ref.)
Starch-gum interactions: nutritional and technological implications. Sudhakar V, et al. **Int J Food Sci Nutr** 1996 Mar;47(2):117–29 (90 ref.)
Interrelationships of food, nutrition, diet and health: the National Association of State Universities and Land Grant Colleges White Paper. Bidlack WR. **J Am Coll Nutr** 1996 Oct;15(5):422–33 (52 ref.)
Nutrition, genetics and skeletal development. Matkovic V. **J Am Coll Nutr** 1996 Dec;15(6):556–69 (97 ref.)
Position of the American Dietetic Association: nutrition in comprehensive program planning for persons with developmental disabilities. **J Am Diet Assoc** 1997 Feb; 97(2):189–93 (39 ref.)
Clinical pathway nutrition management for outpatient bone marrow transplantation. Dickson TC. **J Am Diet Assoc** 1997 Jan;97(1):61–3 (14 ref.)
Nutrition, exercise, and healthy aging. Evans WJ, et al. **J Am Diet Assoc** 1997 Jun;97(6):632–8 (44 ref.)
Women in the new world order: where old values command new respect. Finn SC. **J Am Diet Assoc** 1997 May; 97(5):475–80 (43 ref.)
Dietetics and nutrition: impact of scientific advances and development. Gopalan C. **J Am Diet Assoc** 1997 Jul; 97(7):737–41 (33 ref.)
Nutrition and the immune system: a review of nutrient-nutrient interactions. Kubena KS, et al. **J Am Diet Assoc** 1996 Nov;96(11):1156–64; quiz 1165–6 (90 ref.)
Community food systems: working toward a sustainable future. Peters J. **J Am Diet Assoc** 1997 Sep;97(9):955–6 (10 ref.)
Communicating nutrition and dietetics issues: balancing diverse perspectives. Schwartz NE. **J Am Diet Assoc** 1996 Nov;96(11):1137–9 (9 ref.)
Position of the American Dietetic Association: nutrition, aging, and the continuum of care. Weddle D, et al. **J Am Diet Assoc** 1996 Oct;96(10):1048–52 (46 ref.)
Nutrition in patients with severe burns: state of the art. Rodriguez DJ. **J Burn Care Rehabil** 1996 Jan–Feb; 17(1):62–70 (53 ref.)
Early nutritional origins of hypertension: a hypothesis still lacking support. Paneth N, et al. **J Hypertens Suppl** 1996 Dec;14(5):S121–9 (45 ref.)
The story of nutrition [editorial] Hashim SA. **J Med Liban** 1997;45(2):68–72 (0 ref.)
Nutrition in renal disease. Mallat SG. **J Med Liban** 1997; 45(2):90–2 (25 ref.)
Diets of elite athletes: has the discipline of sports nutrition made an impact? Grandjean AC. **J Nutr** 1997 May;127(5 Suppl):874S–877S (21 ref.)
Nutrition and newly emerging viral diseases: an overview. Levander OA. **J Nutr** 1997 May;127(5 Suppl):948S–950S (18 ref.)
Importance of milk and diet on the ontogeny and adaptation of the intestine. Perin NM, et al. **J Pediatr Gastroenterol Nutr** 1997 Apr;24(4):419–25 (76 ref.)
The dietetic and nutritional management of food allergy. Baker HB, et al. **J R Soc Med** 1997;90 Suppl 30:45–50 (8 ref.)
Can women live on bread alone? Folic acid supplementation revisited. Page RL 2nd, et al. **J S C Med Assoc** 1997 Feb; 93(2):57–62 (27 ref.)
Practical issues in nutrition for athletes. Burke L. **J Sports Sci** 1995 Summer;13 Spec No:S83–90 (22 ref.)
Effect of training and nutrition on the development of skeletal muscle. Henriksson J. **J Sports Sci** 1995 Summer;13 Spec No:S25–30 (55 ref.)
Macronutrients and performance. Williams C. **J Sports Sci** 1995 Summer;13 Spec No:S1–10 (88 ref.)
Nutritional ergogenics in athletics. Williams MH. **J Sports Sci** 1995 Summer;13 Spec No:S63–74 (90 ref.)
1997 Jonathan E. Rhoads Lecture. Understanding obesity: the unfinished business. Hirsch J. **JPEN J Parenter Enteral Nutr** 1997 Jul–Aug;21(4):192–5 (7 ref.)
Glutamine-supplemented nutrition [editorial; comment] Smith RJ. **JPEN J Parenter Enteral Nutr** 1997 Jul–Aug; 21(4):183–4 (11 ref.) Comment on: JPEN J Parenter Enteral Nutr 1997 Jul–Aug;21(4):208–14.
Can terathanasia explain the protective effect of folic-acid supplementation on birth defects? Hook EB, et al. **Lancet** 1997 Aug 16;350(9076):513–5 (20 ref.)
Nutrition. But is it food? Katan MB, et al. **Lancet** 1996 Dec 21–28;348 Suppl 2:sII15 (5 ref.)
Physical activity, nutrition, and chronic disease. Blair SN, et al. **Med Sci Sports Exerc** 1996 Mar;28(3):335–49 (202 ref.)
Has improved nutrition contributed to the hip fracture epidemic? Reid IR. **Mol Cell Endocrinol** 1996 Oct 30; 123(2):123–5 (27 ref.)
Plant sources of vitamin A and human nutrition: renewed strategies. **Nutr Rev** 1996 Mar;54(3):89–91 (15 ref.)
Policy: nutrition standards for treatment of pressure ulcers. Chernoff R. **Nutr Rev** 1996 Jan;54(1 Pt 2):S43–4 (1 ref.)
Nutrition in the management of cystic fibrosis. Dowsett J. **Nutr Rev** 1996 Jan;54(1 Pt 1):31–3 (9 ref.)
The nutrition transition: new trends in the global diet. Drewnowski A, et al. **Nutr Rev** 1997 Feb;55(2):31–43 (57 ref.)
Effects of aging and exercise on nutrition needs of the elderly. Evans WJ. **Nutr Rev** 1996 Jan;54(1 Pt 2):S35–9 (27 ref.)
Functional foods: the western perspective. Hasler CM. **Nutr Rev** 1996 Nov;54(11 Pt 2):S6–10 (49 ref.)
The rural elderly: living the good life? Jensen GL. **Nutr Rev** 1996 Jan;54(1 Pt 2):S17–21 (16 ref.)
Nutrition chemoprevention of gastrointestinal cancers: a critical review. Kim YI, et al. **Nutr Rev** 1996 Sep; 54(9):259–79 (119 ref.)

NUTRITION

Nutrition and senescence. Rosenberg IH. **Nutr Rev** 1997 Jan; 55(1 Pt 2):S69–73; discussion S74–7 (20 ref.)

The eastern perspective on functional foods based on traditional Chinese medicine. Weng W, et al. **Nutr Rev** 1996 Nov;54(11 Pt 2):S11–6 (11 ref.)

Nevada's elderly: nutrition screening, risk, and interventions. Wilson D, et al. **Nutr Rev** 1996 Jan;54(1 Pt 2):S45–7 (12 ref.)

Influence of chronic liver disease and chronic renal failure on nutrient metabolism and undernutrition [editorial] Cano N, et al. **Nutrition** 1997 Apr;13(4):381–3 (74 ref.)

Colonic microflora: nutrition and health [editorial] Cummings JH, et al. **Nutrition** 1997 May;13(5):476–8 (21 ref.)

Placenta and growth factors in fetal growth and nutrition [editorial] Garnica AD, et al. **Nutrition** 1997 Apr; 13(4):384–5 (27 ref.)

Influence of nutrition on liver oxidative metabolism. Jorquera F, et al. **Nutrition** 1996 Jun;12(6):442–7 (76 ref.)

Vitamins and immunomodulation in AIDS. Liang B, et al. **Nutrition** 1996 Jan;12(1):1–7 (91 ref.)

Nutritional considerations and management of the child with inflammatory bowel disease. Oliva MM, et al. **Nutrition** 1996 Mar;12(3):151–8 (76 ref.)

Nutrition and outcome in chronic respiratory disease. Schols AM. **Nutrition** 1997 Feb;13(2):161–3 (34 ref.)

A prospective discussion of past international nutrition catastrophes—indications for the future. Swank RL. **Nutrition** 1997 Apr;13(4):344–8 (28 ref.)

Menarche and beyond—do eating and exercise make a difference? Emans SJ. **Pediatr Ann** 1997 Feb;26(2 Suppl):S137–41 (46 ref.)

Gene cloning: studies of nutritional regulation of gene expression. Hesketh JE, et al. **Proc Nutr Soc** 1996 Mar; 55(1B):575–81 (12 ref.)

Nutritional issues for women in developing countries. Walker SP. **Proc Nutr Soc** 1997 Mar;56(1B):345–56 (66 ref.)

Cardiovascular diseases as a growing health problem in developing countries: the role of nutrition in the epidemiologic transition. Pearson TA.
Public Health Rev 1996;24(2):131–46 (29 ref.)

Nutritional and metabolic aspects of postprandial lipemia. Lairon D. **Reprod Nutr Dev** 1996;36(4):345–55 (46 ref.)

Role of glucokinase and glucose-6 phosphatase in the nutritional regulation of endogenous glucose production. Mithieux G. **Reprod Nutr Dev** 1996;36(4):357–62 (23 ref.)

Ergogenic aids: a means to Citius, Altius, Fortius, and Olympic gold? Williams MH. **Res Q Exerc Sport** 1996 Sep; 67(3 Suppl):S58–64 (46 ref.)

Nutrition in short-bowel syndrome. Ladefoged K, et al. **Scand J Gastroenterol Suppl** 1996;216:122–31 (76 ref.)

Nutrition and gastrointestinal disease. O'Keefe SJ.
Scand J Gastroenterol Suppl 1996;220:52–9 (52 ref.)

Roles of diet and physical activity in the prevention of osteoporosis. Anderson JJ, et al.
Scand J Rheumatol Suppl 1996;103:65–74 (43 ref.)

Pathophysiology of hydrops fetalis. Apkon M.
Semin Perinatol 1995 Dec;19(6):437–46 (44 ref.)

Biology and medicine of sailing. An update. Shephard RJ. **Sports Med** 1997 Jun;23(6):350–6 (49 ref.)

Current aspects of epidemiology and nutrition in urinary stone disease. Hesse A, et al. **World J Urol** 1997; 15(3):165–71 (45 ref.)

Historical development of Chinese dietary patterns and nutrition from the ancient to the modern society. Chen JD, et al. **World Rev Nutr Diet** 1996;79:133–53 (23 ref.)

The 'Are' Sport Nutratherapy Program: the rationale for food supplements in sports medicine. Göransson U, et al. **World Rev Nutr Diet** 1997;82:101–21 (61 ref.)

Declaration of Olympia on nutrition and fitness. Ancient Olympia, Greece, May 28–29, 1996. Simopoulos AP.
World Rev Nutr Diet 1997;82:1–12 (5 ref.)

Gene–nutrient interactions in single-gene defects and polygenic diseases: methodologic considerations.
Velázquez A. **World Rev Nutr Diet** 1997;80:145–64 (65 ref.)

[The significance of nutrition for muscular function after surgery] Jensen MB. **Ugeskr Laeger** 1997 Feb 10; 159(7):923–6 (40 ref.) (Eng. Abstr.) **(Dan)**

[Mucoviscidosis. Nutritional management] Munck A, et al. **Presse Med** 1997 May 3–10;26(15):721–6 (33 ref.) **(Fre)**

[Methods of nutrient intake and nutritional status of the elderly in Poland on the basis of the literature from the years 1980–1996] Wierzbicka E, et al.
Rocz Panstw Zakl Hig 1997;48(1):87–102 (62 ref.) (Eng. Abstr.) **(Pol)**

[Feasibility of increasing the longevity of healthy life using rational nutrition] Potemkina NS, et al. **Fiziol Cheloveka** 1996 Sep–Oct;22(5):123–7 (45 ref.) **(Rus)**

[Current concept of scientific pharmacotherapy. Role of nutrition in the regulation of body's vital activity and homeostasis] Kudrin AN. **Vestn Ross Akad Med Nauk** 1996; (12):20–3 (19 ref.) (Eng. Abstr.) **(Rus)**

[Stable isotopes in nutrition research] de Santiago S, et al. **Arch Latinoam Nutr** 1995 Mar;45(1):6–11 (28 ref.) (Eng. Abstr.) **(Spa)**

[Cystic fibrosis: nutritional aspects and recommendations] Nájera Pérez MD, et al. **Nutr Hosp** 1997 Mar–Apr; 12(2):63–72 (60 ref.) (Eng. Abstr.) **(Spa)**

[Nutrition in the etiopathogenesis of cholesterol biliary lithiasis] Encinas Sotillos A, et al. **Rev Esp Enferm Dig** 1996 Jul;88(7):490–6 (62 ref.) **(Spa)**

EDUCATION

Handling nutritional advice in general practice in Norway. Bratland SZ. **Am J Clin Nutr** 1997 Jun;65(6 Suppl):1953S–1956S (2 ref.)

Advice on healthy food as given by Flemish general practitioners. Govaerts F. **Am J Clin Nutr** 1997 Jun;65(6 Suppl):1951S–1952S (3 ref.)

Nutrition coverage on medical licensing examinations in the United States. Hark LA, et al. **Am J Clin Nutr** 1997 Feb; 65(2):568–71 (23 ref.)

Nutrition and general practice: an Australian perspective. Helman A. **Am J Clin Nutr** 1997 Jun;65(6 Suppl):1939S–1942S (24 ref.)

Nutrition in general practice in Italy. Lupo A.
Am J Clin Nutr 1997 Jun;65(6 Suppl):1963S–1966S (35 ref.)

Effectiveness of dietary intervention in general practice. Mant D. **Am J Clin Nutr** 1997 Jun;65(6 Suppl):1933S–1938S (26 ref.)

Media choice in nutrition education of general practitioners. van Woerkum CM. **Am J Clin Nutr** 1997 Jun;65(6 Suppl):2013S–2015S (9 ref.)

Nutrition education in Australian universities: more famine than feast? [editorial] Campbell LV. **Aust N Z J Med** 1996 Oct;26(5):625–6 (7 ref.)

Nutri-action analysis as a research strategy to improve nutrition information, education and communication interventions in Asia. Smitasiri S, et al.
Biomed Environ Sci 1996 Sep;9(2–3):290–5 (13 ref.)

Position of the American Dietetic Association: nutrition education for the public. **J Am Diet Assoc** 1996 Nov; 96(11):1183–7 (40 ref.)

Twenty years of WIC: a review of some effects of the program. Owen AL, et al. **J Am Diet Assoc** 1997 Jul; 97(7):777–82 (30 ref.)

What do consumers really think about dietary fat? Schwartz NE, et al. **J Am Diet Assoc** 1997 Jul;97(7 Suppl):S73–5 (15 ref.)

PHYSIOLOGY

Nutrition and ulcerative colitis. Burke A, et al.
Baillieres Clin Gastroenterol 1997 Mar;11(1):153–74 (118 ref.)

Nutrition during lactation. Hamosh M. **Bibl Nutr Dieta** 1996; (53):23–36 (48 ref.)

Eating frequency: methodological and dietary aspects. Gatenby SJ. **Br J Nutr** 1997 Apr;77 Suppl 1:S7–20 (72 ref.)

Effect of meal frequency and timing on physical performance. Hawley JA, et al. **Br J Nutr** 1997 Apr;77 Suppl 1:S91–103 (82 ref.)

Selenium in health and disease: a review. Foster LH, et al. **Crit Rev Food Sci Nutr** 1997 Apr;37(3):211–28 (122 ref.)

Adaptation of intestinal nutrient transport in health and disease. Part I. Thomson AB, et al. **Dig Dis Sci** 1997 Mar; 42(3):453–69 (254 ref.)

Adaptation of intestinal nutrient transport in health and disease. Part II. Thomson AB, et al. **Dig Dis Sci** 1997 Mar; 42(3):470–88 (271 ref.)

Nutrition and cardiovascular disease. Klör HU, et al.
Eur J Med Res 1997 Jun 16;2(6):243–57 (192 ref.)

Nutritional infertility: the role of the interconnected hypothalamic neuropeptide Y–galanin–opioid network. Kalra SP, et al. **Front Neuroendocrinol** 1996 Oct; 17(4):371–401 (219 ref.)

Adaptive remodelling of intestinal epithelium assessed using stereology: correlation of single cell and whole organ data with nutrient transport. Mayhew TM.
Histol Histopathol 1996 Jul;11(3):729–41 (101 ref.)

Nutritional regulation of IGF-I and IGFBPs. Underwood LE. **J Pediatr Endocrinol Metab** 1996 Jun;9 Suppl 3:303–12 (42 ref.)

Nutrition, body composition, physical activity and growth hormone secretion. Vance ML.
J Pediatr Endocrinol Metab 1996 Jun;9 Suppl 3:299–301 (22 ref.)

The nerves, the liver, and the route of feeding: an integrated response to nutrient delivery [editorial] Moore MC, et al. **Nutrition** 1996 Apr;12(4):282–4 (25 ref.)

Nutrition for improved sports performance. Current issues on ergogenic aids. Clarkson PM. **Sports Med** 1996 Jun; 21(6):393–401 (89 ref.)

[The vasa vasorum of the arteries] Williams JK, et al.
J Mal Vasc 1996;21 Suppl C:266–9 (25 ref.) (Eng. Abstr.) **(Fre)**

[Chronobiology, nutrition and metabolism] Mejean L, et al. **Pathol Biol (Paris)** 1996 Sep;44(7):603–9 (61 ref.) (Eng. Abstr.) **(Fre)**

[The utilization of nutrient substances during wound healing] Mayer NA, et al. **Anesteziol Reanimatol** 1996 Sep–Oct; (5):29–39 (167 ref.) (Eng. Abstr.) **(Rus)**

[Food smell as a problem in trophology] Ugolev DA, et al. **Fiziol Zh Im I M Sechenova** 1996 Mar;82(3):66–73 (33 ref.) **(Rus)**

[Milk in our diet: pro and con. Alternative prophylactic measures] Loranskaia TI, et al. **Klin Med (Mosk)** 1997; 75(2):13–6 (39 ref.) **(Rus)**

[From Pavlov's recording of time and conditioned reflexes to the chronophysiology of human nutrition] Halberg F, et al. **Vestn Ross Akad Med Nauk** 1996;(1):47–51 (34 ref.) (Eng. Abstr.) **(Rus)**

NUTRITION ASSESSMENT

Use of dietetic-specific nutritional diagnostic codes in clinical reasoning relevant to the nutritional management of core clinical outcome indicators in hemodialysis patients. Kelly MP. **Adv Ren Replace Ther** 1997 Apr;4(2):125–35 (87 ref.)

Nutrition in the critical care settings of renal diseases. Moore LW, et al. **Adv Ren Replace Ther** 1996 Jul;3(3):250–60 (32 ref.)

Errors in the interpretation of dietary assessments. Beaton GH, et al. **Am J Clin Nutr** 1997 Apr;65(4 Suppl):1100S–1107S (41 ref.)

Statistical design of calibration studies. Carroll RJ, et al.
Am J Clin Nutr 1997 Apr;65(4 Suppl):1187S–1189S (9 ref.)

Assessments of food-frequency questionnaires in minority populations. Coates RJ, et al. **Am J Clin Nutr** 1997 Apr; 65(4 Suppl):1108S–1115S (46 ref.)

Urinary biochemical markers of dietary intake in the INTERSALT study. Dyer A, et al. **Am J Clin Nutr** 1997 Apr;65(4 Suppl):1246S–1253S (34 ref.)

Culture-specific strategies for capturing local dietary intake patterns. Jerome NW. **Am J Clin Nutr** 1997 Apr;65(4 Suppl):1166S–1167S (1 ref.)

Biochemical markers as additional measurements in studies of the accuracy of dietary questionnaire measurements: conceptual issues. Kaaks RJ. **Am J Clin Nutr** 1997 Apr; 65(4 Suppl):1232S–1239S (29 ref.)

Assessment of dietary intake in rural communities in Africa: experiences in Kenya. Kigutha HN. **Am J Clin Nutr** 1997 Apr;65(4 Suppl):1168S–1172S (9 ref.)

Computer-assisted self-interviewing: a multimedia approach to dietary assessment. Kohlmeier L, et al.
Am J Clin Nutr 1997 Apr;65(4 Suppl):1275S–1281S (32 ref.)

Dietary assessment using a picture-sort approach. Kumanyika SK, et al. **Am J Clin Nutr** 1997 Apr;65(4 Suppl):1123S–1129S (26 ref.)

Biochemical markers as additional measurements in dietary validity studies: application of the method of triads with examples from the European Prospective Investigation into Cancer and Nutrition. Ocké MC, et al. **Am J Clin Nutr** 1997 Apr;65(4 Suppl):1240S–1245S (14 ref.)

Assessing diets of children and adolescents. Rockett HR, et al. **Am J Clin Nutr** 1997 Apr;65(4 Suppl):1116S–1122S (39 ref.)

Dietary studies in countries experiencing a health transition: Mexico and Central America. Romieu I, et al.
Am J Clin Nutr 1997 Apr;65(4 Suppl):1159S–1165S (18 ref.)

Development of culturally competent food-frequency questionnaires. Teufel NI. **Am J Clin Nutr** 1997 Apr;65(4 Suppl):1173S–1178S (31 ref.)

Nutrition screening in old people: its place in a coherent practice of preventive health care. Rush D.
Annu Rev Nutr 1997;17:101–25 (126 ref.)

Evaluation of methodology for nutritional assessment in children: anthropometry, body composition, and energy expenditure. Zemel BS, et al. **Annu Rev Nutr** 1997; 17:211–35 (126 ref.)

Validation of body composition assessment techniques in the dialysis population. Lukaski HC. **ASAIO J** 1997 May–Jun; 43(3):251–5 (31 ref.)

Nutritional monitoring techniques in dialysis. Can routine monitoring impact outcome? Zabetakis PM. **ASAIO J** 1997 May–Jun;43(3):243–5 (20 ref.)

Assessment of the nutritional state of dialysis patients. Kerr PG, et al. **Blood Purif** 1996;14(5):382–7 (25 ref.)

Measuring the adequacy of peritoneal dialysis: is there a link with nutrition and outcome? Gokal R.
Curr Opin Nephrol Hypertens 1996 Nov;5(6):521–6 (58 ref.)

Dietary and exercise assessment in general practice. Little P, et al. **Fam Pract** 1996 Oct;13(5):477–82 (47 ref.)

Nutritional aspects of cancer-related fatigue. Kalman D, et al. **J Am Diet Assoc** 1997 Jun;97(6):650–4 (57 ref.)

Assessing the nutritional status of the elderly: The Mini Nutritional Assessment as part of the geriatric evaluation. Guigoz Y, et al. **Nutr Rev** 1996 Jan;54(1 Pt 2):S59–65 (46 ref.)

Differential display PCR: a new age in nutrition investigation. Harris ED. **Nutr Rev** 1996 Sep;54(9):287–9 (11 ref.)

Nutrition assessment in long-term care facilities. Roubenoff R, et al. **Nutr Rev** 1996 Jan;54(1 Pt 2):S40–2 (8 ref.)

Definition of standardized nutritional assessment and interventional pathways in oncology. Ottery FD.
Nutrition 1996 Jan;12(1 Suppl):S15–9 (21 ref.)

Nutrition in women. Assessment and counseling. Monteleone GP Jr, et al. **Prim Care** 1997 Mar;24(1):37–51 (59 ref.)

Nutrition assessment and dietary guidelines: experience from the Dutch Nutrition Surveillance System. Löwik MR, et al. **Proc Nutr Soc** 1996 Jul;55(2):705–23 (36 ref.)

Screening for nutritional risk. Reilly HM. **Proc Nutr Soc** 1996 Nov;55(3):841–53 (26 ref.)

[Nutrition as prevention of illness in the elderly] Ollenschläger G. **Fortschr Med** 1996 Aug 20; 114(22–23):267–9 (0 ref.) (Eng. Abstr.) **(Ger)**

[Malnutrition in the elderly: the Mini Nutritional Assessment (MNA)] Guigoz Y, et al. **Ther Umsch** 1997 Jun;54(6):345–50 (27 ref.) (Eng. Abstr.) **(Ger)**

[Concept of malabsorption syndrome and nutrition assessment] Takahashi T, et al.
Nippon Naika Gakkai Zasshi 1996 Jul 10;85(7):1022–8 (6 ref.) **(Jpn)**

[Nutritional assessment in elderly] Muto Y, et al.
Nippon Ronen Igakkai Zasshi 1996 Sep;33(9):652–6 (6 ref.)

(Jpn)

NUTRITION DISORDERS

Malnutrition in elderly people. Whitehead C, et al. **Aust N Z J Med** 1997 Feb;27(1):68–74 (53 ref.)
Undernutrition and aging. Aihie Sayer A, et al. **Gerontology** 1997;43(4):203–5 (22 ref.)
Malnutrition in patients with end-stage renal disease: diagnosis, pathophysiology and treatment. Kooman JP, et al. **Neth J Med** 1997 Mar;50(3):120–32 (100 ref.)
Disease and malnutrition in British hospitals. Pennington CR. **Proc Nutr Soc** 1997 Mar;56(1B):393–407 (87 ref.)

BLOOD

Nutritional assessment in pediatric patients: how can the laboratory help? Goldsmith B. **Pediatr Pathol Lab Med** 1996 Jan–Feb;16(1):1–7 (13 ref.)

CLASSIFICATION

Syndromic classification: a process for amplifying information using S-clustering. Rypka EW. **Nutrition** 1996 Nov–Dec;12(11–12):827–9 (7 ref.)

COMPLICATIONS

Integrated management of childhood infections and malnutrition: a global initiative. Campbell H, et al. **Arch Dis Child** 1996 Dec;75(6):468–71 (28 ref.)
Central noradrenergic hyperactivity early in life: a hypothesis on the origin of morpho-functional brain disorders induced by malnutrition. Soto-Moyano R, et al. **Biol Res** 1995; 28(1):105–11 (80 ref.)
Fetal nutrition and cardiovascular disease in later life. Barker DJ. **Br Med Bull** 1997 Jan;53(1):96–108 (54 ref.)
Nutrition and cognitive development. Morley R, et al. **Br Med Bull** 1997 Jan;53(1):123–34 (45 ref.)
Effects of the intrauterine environment on childhood growth. Strauss RS. **Br Med Bull** 1997 Jan;53(1):81–95 (59 ref.)
Reproduction: a global nutritional challenge. Goldberg GR. **Proc Nutr Soc** 1997 Mar;56(1B):319–33 (58 ref.)
[Infection in the elderly—as an immunocompromised host with undernutrition] Toba K. **Nippon Ronen Igakkai Zasshi** 1997 Feb;34(2):106–9 (10 ref.) (Jpn)
[Nutritional disorders and myocardial disease] Masani F, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):36–8 (12 ref.) (Jpn)

DIAGNOSIS

Detection and monitoring of disorders of essential trace elements. Taylor A. **Ann Clin Biochem** 1996 Nov;33 (Pt 6):486–510 (199 ref.)
Nutritional assessment in pediatric patients: how can the laboratory help? Goldsmith B. **Pediatr Pathol Lab Med** 1996 Jan–Feb;16(1):1–7 (13 ref.)
Screening for nutritional risk. Reilly HM. **Proc Nutr Soc** 1996 Nov;55(3):841–53 (26 ref.)
Nutrition assessment and management in pediatric dysphagia. Kovar AJ. **Semin Speech Lang** 1997 Feb;18(1):39–49 (30 ref.)

DIET THERAPY

Nutritional considerations and management of the child with liver disease. Novy MA, et al. **Nutrition** 1997 Mar; 13(3):177–84 (77 ref.)
Role of enteral nutrition in advanced cancer patients: indications and contraindications of the different techniques employed. Ripamonti C, et al. **Tumori** 1996 Jul–Aug; 82(4):302–8 (80 ref.)
[Nutritional therapy in chronic hepatopathy] Caregaro L, et al. **Ann Ital Med Int** 1996 Oct–Dec;11(4):268–74 (46 ref.) (Eng. Abstr.) (Ita)

ECONOMICS

The socio-economic aspects of malnutrition in Sicily. La Grutta A, et al. **Ann Ist Super Sanita** 1995;31(4):441–4 (14 ref.)

EMBRYOLOGY

Insulin resistance as a programmed response to fetal undernutrition [see comments] Phillips DI. **Diabetologia** 1996 Sep;39(9):1119–22 (40 ref.) Comment in: Diabetologia 1996 Sep;39(9):1123–5.

EPIDEMIOLOGY

Vitamin nutritional status in Italy. Maiani G, et al. **Eur J Cancer Prev** 1997 Mar;6 Suppl 1:S3–9 (56 ref.)
Nutritional issues in cancer management. Laviano A, et al. **Nutrition** 1996 May;12(5):358–71 (184 ref.)

ETIOLOGY

Nutrition in acute renal failure patients. Ikizler TA, et al. **Adv Ren Replace Ther** 1997 Apr;4(2 Suppl 1):54–63 (67 ref.)
The socio-economic aspects of malnutrition in Sicily. La Grutta A, et al. **Ann Ist Super Sanita** 1995;31(4):441–4 (14 ref.)
Nutritional monitoring techniques in dialysis. Can routine monitoring impact outcome? Zabetakis PM. **ASAIO J** 1997 May–Jun;43(3):243–5 (20 ref.)
Malnutrition in HIV infection. Babameto G, et al. **Gastroenterol Clin North Am** 1997 Jun;26(2):393–415 (100 ref.)
Malnutrition associated with HIV/AIDS. Part One: Definition and scope, epidemiology, and pathophysiology. Casey KM. **J Assoc Nurses AIDS Care** 1997 May–Jun; 8(3):24–32 (52 ref.)
The story of nutrition [editorial] Hashim SA. **J Med Liban** 1997;45(2):68–72 (0 ref.)
Malnutrition: metabolic changes in children, comparisons with adults. Miller TL. **J Nutr** 1996 Oct;126(10 Suppl):2623S–2631S (62 ref.)
Nutrition in end-stage renal disease. Ikizler TA, et al. **Kidney Int** 1996 Aug;50(2):343–57 (182 ref.)
Nutritional markers and survival in maintenance dialysis patients [editorial] Pollock CA, et al. **Nephron** 1996; 74(4):625–41 (176 ref.)
Influence of chronic liver disease and chronic renal failure on nutrient metabolism and undernutrition [editorial] Cano N, et al. **Nutrition** 1997 Apr;13(4):381–3 (74 ref.)
Nutritional support in advanced pulmonary disease. Thomsen C. **Respir Med** 1997 May;91(5):249–54 (46 ref.)
[Malnutrition in chronic renal insufficiency] Aparicio M, et al. **Presse Med** 1997 Mar 15;26(8):389–95 (25 ref.) (Fre)
[Malnutrition and HIV infection] Rabaud C, et al. **Rev Med Interne** 1996;17(12):992–1002 (112 ref.) (Eng. Abstr.) (Fre)
[Nutrition and HIV infection. I: Causes and sequelae of malnutrition] Schwenk A, et al. **Med Klin** 1996 Jul 15; 91(7):466–71 (103 ref.) (Ger)
[Enteral nutrition in maxillofacial oncology] Garau V, et al. **Minerva Stomatol** 1997 Jul–Aug;46(7–8):415–22 (29 ref.) (Eng. Abstr.) (Ita)
[A case of severe malnutrition due to Ascaris lumbricoides infestation in a boy] Castiglione N, et al. **Pediatr Med Chir** 1996 Nov–Dec;18(6):615–7 (8 ref.) (Eng. Abstr.) (Ita)
[Dysphagia. A common but hidden handicap] Grahn LT. **Lakartidningen** 1996 Nov 20;93(47):4249–51 (9 ref.) (Swe)

IMMUNOLOGY

Nutrition and the immune system: a review of nutrient-nutrient interactions. Kubena KS, et al. **J Am Diet Assoc** 1996 Nov;96(11):1156–64; quiz 1165–6 (90 ref.)

METABOLISM

Role of fetal and infant growth in programming metabolism in later life. Desai M, et al. **Biol Rev Camb Philos Soc** 1997 May;72(2):329–48 (111 ref.)
Pancreatic steatorrhea, malabsorption, and nutrition biochemistry: a comparison of Japanese, European, and American patients with chronic pancreatitis. Nakamura T, et al. **Pancreas** 1997 May;14(4):323–33 (127 ref.)

PHYSIOPATHOLOGY

Reproductive stresses in undernourished and well-nourished women. Prentice AM, et al. **Bibl Nutr Dieta** 1996;(53):1–10 (22 ref.)
Influences of the intrauterine metabolic environment on adult disease: what may we infer from size at birth? Purdy LP, et al. **Diabetologia** 1996 Sep;39(9):1126–30 (46 ref.)
AGA technical review: malnutrition and cachexia, chronic diarrhea, and hepatobiliary disease in patients with human immunodeficiency virus infection. Wilcox CM, et al. **Gastroenterology** 1996 Dec;111(6):1724–52 (311 ref.)
Penalties of hospital undernutrition. Powell-Tuck J. **J R Soc Med** 1997 Jan;90(1):8–11 (50 ref.)
Malnutrition and reactivity to drugs acting in the central nervous system. Almeida SS, et al. **Neurosci Biobehav Rev** 1996 Autumn;20(3):389–402 (168 ref.)

PREVENTION & CONTROL

Common nutritional issues in pediatric and adult critical care medicine. Schears GJ, et al. **Crit Care Clin** 1997 Jul; 13(3):669–90 (195 ref.)
Developing industrial-governmental-academic partnerships to address micronutrient malnutrition. Darnton-Hill I. **Nutr Rev** 1997 Mar;55(3):76–81 (24 ref.)
Nevada's elderly: nutrition screening, risk, and interventions. Wilson D, et al. **Nutr Rev** 1996 Jan;54(1 Pt 2):S45–7 (12 ref.)
[Mucoviscidosis. Nutritional management] Munck A, et al. **Presse Med** 1997 May 3–10;26(15):721–6 (33 ref.) (Fre)
[Nutrition as prevention of illness in the elderly] Ollenschläger G. **Fortschr Med** 1996 Aug 20; 114(22–23):267–9 (0 ref.) (Eng. Abstr.) (Ger)
[Milk in our diet: pro and con. Alternative prophylactic measures] Loranskaia TI, et al. **Klin Med (Mosk)** 1997; 75(2):13–6 (39 ref.) (Rus)
[Enteral jejunostomy prevents malnutrition. The method is safe and practical even for home care] Elgadi A, et al. **Lakartidningen** 1997 Jan 29;94(5):324–6 (20 ref.) (Swe)

THERAPY

Nutritional management of the disabled child: the role of percutaneous endoscopic gastrostomy. Eltumi M, et al. **Dev Med Child Neurol** 1997 Jan;39(1):66–8 (33 ref.)
Malnourished inpatients: overlooked and undertreated. **Drug Ther Bull** 1996 Aug;34(8):57–60 (28 ref.)
Direct button percutaneous endoscopic jejunostomy: successful placement in a patient with severe malnutrition and previous gastric resection. Dumot JA, et al. **Gastrointest Endosc** 1997 Jan;45(1):92–4 (14 ref.)
Nutrition therapy for the cancer patient. Shike M. **Hematol Oncol Clin North Am** 1996 Feb;10(1):221–34 (77 ref.)
Nutritional support. Souba WW. **N Engl J Med** 1997 Jan 2;336(1):41–8 (90 ref.)
Supportive nutritional management of the patient with pancreatic cancer. Ottery F. **Oncology (Huntingt)** 1996 Sep; 10(9 Suppl):26–32 (38 ref.)
A request for a 'sip feed' prescription. James J, et al. **Practitioner** 1996 May;240(1562):281–4, 287–8 (0 ref.)
The management of malnutrition in hospital. Allison SP. **Proc Nutr Soc** 1996 Nov;55(3):855–62 (31 ref.)

NUTRITION DISORDERS, CHILD see **CHILD NUTRITION DISORDERS**

NUTRITION DISORDERS, INFANT see **INFANT NUTRITION DISORDERS**

NUTRITION, ENTERAL see **ENTERAL NUTRITION**

NUTRITION, HOME PARENTERAL see **PARENTERAL NUTRITION, HOME**

NUTRITION LABELING see **FOOD LABELING**

NUTRITION, PARENTERAL see **PARENTERAL NUTRITION**

NUTRITION POLICY

Is there a need to change the American diet? Dwyer J. **Adv Exp Med Biol** 1996;401:189–98 (48 ref.)
The National 5 A Day for Better Health Program. Heimendinger J, et al. **Adv Exp Med Biol** 1996;401:199–206 (29 ref.)
Nutritional implications of dietary phytochemicals. Messina M, et al. **Adv Exp Med Biol** 1996;401:207–12 (16 ref.)
Cholesterol policy and the primary prevention of coronary disease: reflections on clinical and population strategies. Naylor CD, et al. **Annu Rev Nutr** 1996;16:349–82 (188 ref.)
Children on adult diets. Lifshitz F. **Bibl Nutr Dieta** 1996; (53):55–9 (30 ref.)
Position of the American Dietetic Association: nutrition education for the public. **J Am Diet Assoc** 1996 Nov; 96(11):1183–7 (40 ref.)
Communicating nutrition and dietetics issues: balancing diverse perspectives. Schwartz NE. **J Am Diet Assoc** 1996 Nov;96(11):1137–9 (9 ref.)
Folic acid fortification. **Nutr Rev** 1996 Mar;54(3):94–5 (4 ref.)
Policy: nutrition standards for treatment of pressure ulcers. Chernoff R. **Nutr Rev** 1996 Jan;54(1 Pt 2):S43–4 (1 ref.)
Dietary guidelines for infants: a timely reminder. Glinsmann WH, et al. **Nutr Rev** 1996 Feb;54(2 Pt 1):50–7 (39 ref.)
Food fortification in the United States. Mertz W. **Nutr Rev** 1997 Feb;55(2):44–9 (25 ref.)
Codex Alimentarius. Pothisiri P, et al. **Nutr Rev** 1996 Nov; 54(11 Pt 2):S149–51 (4 ref.)
Nutrition policy: priorities for new research. Gibney MJ. **Proc Nutr Soc** 1996 Jul;55(2):661–9 (14 ref.)
Nutrition assessment and dietary guidelines: experience from the Dutch Nutrition Surveillance System. Löwik MR, et al. **Proc Nutr Soc** 1996 Jul;55(2):705–23 (36 ref.)
Consumption implications of agri-food policies. Traill B, et al. **Proc Nutr Soc** 1996 Jul;55(2):649–59 (14 ref.)

LEGISLATION & JURISPRUDENCE

Food control systems in Canada. Smith TM, et al. **Crit Rev Food Sci Nutr** 1997 Apr;37(3):229–51 (19 ref.)

TRENDS

Cottonseed protein: what does the future hold? Alford BB, et al. **Plant Foods Hum Nutr** 1996 Jan;49(1):1–11 (63 ref.)
Food and nutrition policy in the Republic of Ireland: where to from here? Shelley E. **Proc Nutr Soc** 1996 Jul;55(2):641–7 (25 ref.)

NUTRITION SURVEYS

Current food and nutrition situation in south Asian and south-east Asian countries. Gopalan C. **Biomed Environ Sci** 1996 Sep;9(2–3):102–16 (15 ref.)
Vitamin nutritional status in Italy. Maiani G, et al. **Eur J Cancer Prev** 1997 Mar;6 Suppl 1:S3–9 (56 ref.)
Paleolithic nutrition revisited: a twelve-year retrospective on its nature and implications. Eaton SB, et al. **Eur J Clin Nutr** 1997 Apr;51(4):207–16 (98 ref.)
Supply and demand: a framework for explaining variability in dietary intake and its impact on data. Joachim G. **Nutr Health** 1997;11(4):289–99 (26 ref.)
Nutrition surveillance of Ireland. Kelleher C, et al. **Proc Nutr Soc** 1996 Jul;55(2):689–97 (15 ref.)
Integration of nutritional data based on household budget

NUTRITION SURVEYS

surveys in European countries. DAFNE I Group. Data Food Networking. Trichopoulou A, et al. **Proc Nutr Soc** 1996 Jul;55(2):699–704 (8 ref.)

Food variety of adult Melbourne Chinese: a case study of a population in transition. Hsu-Hage BH, et al. **World Rev Nutr Diet** 1996;79:53–69 (54 ref.)

Cultural and nutritional aspects of traditional Korean diet. Kim SH, et al. **World Rev Nutr Diet** 1996;79:109–32 (46 ref.)

The transition of Australian aboriginal diet and nutritional health. Lee A. **World Rev Nutr Diet** 1996;79:1–52 (340 ref.)

[Nutrition in patients treated with antilipemic agents. Survey of 337 patients] Bernard MC, et al. **Presse Med** 1997 Apr 19;26(13):598–602 (13 ref.) (Eng. Abstr.) **(Fre)**

[Nutritional and biochemical studies on vitamin D and its active derivatives] Kobayashi T. **Yakugaku Zasshi** 1996 Jun;116(6):457–72 (29 ref.) (Eng. Abstr.) **(Jpn)**

NUTRITION, TOTAL PARENTERAL see **PARENTERAL NUTRITION, TOTAL**

NUTRITIONAL AVAILABILITY see **NUTRITIVE VALUE**

NUTRITIONAL REQUIREMENTS

Energy and protein requirements during lactation. Dewey KG. **Annu Rev Nutr** 1997;17:19–36 (49 ref.)

Energy sources and requirements of the exercising horse. Harris P. **Annu Rev Nutr** 1997;17:185–210 (96 ref.)

A new look at dietary carbohydrate: chemistry, physiology and health. Paris Carbohydrate Group. Cummings JH, et al. **Eur J Clin Nutr** 1997 Jul;51(7):417–23 (69 ref.)

Age considerations in nutrient needs for bone health: older adults. Heaney RP. **J Am Coll Nutr** 1996 Dec;15(6):575–8 (19 ref.)

Age considerations in nutrient needs for bone health. Miller GD, et al. **J Am Coll Nutr** 1996 Dec;15(6):553–5 (23 ref.)

Relationship between fermentation acid production in the rumen and the requirement for physically effective fiber. Allen MS. **J Dairy Sci** 1997 Jul;80(7):1447–62 (102 ref.)

Creating a system for meeting the fiber requirements of dairy cows. Mertens DR. **J Dairy Sci** 1997 Jul;80(7):1463–81 (112 ref.)

Energy and protein requirements of patients with chronic liver disease. Kondrup J, et al. **J Hepatol** 1997 Jul; 27(1):239–47 (74 ref.)

Interests and values in the Recommended Dietary Allowances and nutritional guidelines for Americans. Kunkel HO. **J Nutr** 1996 Sep;126(9 Suppl):2390S–2397S (47 ref.)

Functional changes appropriate for determining mineral element requirements. Lukaski HC, et al. **J Nutr** 1996 Sep; 126(9 Suppl):2354S–2364S (26 ref.)

How should dietary guidance be given for mineral elements with beneficial actions or suspected of being essential? Nielsen FH. **J Nutr** 1996 Sep;126(9 Suppl):2377S–2385S (25 ref.)

Nutrition and Parkinson's disease. Pandarinath G, et al. **N C Med J** 1997 May–Jun;58(3):186–8 (12 ref.)

Effects of aging and exercise on nutrition needs of the elderly. Evans WJ. **Nutr Rev** 1996 Jan;54(1 Pt 2):S35–9 (27 ref.)

Daily versus weekly: how many iron pills do pregnant women need? [see comments] Galloway R, et al. **Nutr Rev** 1996 Oct;54(10):318–23 (33 ref.) Comment in: Nutr Rev 1997 Apr;55(4):141–2.

Nutrition in acute renal failure. Riella MC. **Ren Fail** 1997 Mar;19(2):237–52 (79 ref.)

[Nutritional requirements for pregnant women] Putet G. **Arch Pediatr** 1997;4(2 Suppl 2):131s–134s (79 ref.) **(Fre)**

[Energy and nutrients needs in athletes. The most common deficiencies] Vega Romero F, et al. **Rev Clin Esp** 1996 Jun;196(6):381–7 (66 ref.) **(Spa)**

[Calcium requirements] Leiva L, et al. **Rev Med Chil** 1996 Aug;124(8 Suppl):29–34 (20 ref.) **(Spa)**

NUTRITIONAL STATUS

Nutrition in acute renal failure patients. Ikizler TA, et al. **Adv Ren Replace Ther** 1997 Apr;4(2 Suppl 1):54–63 (67 ref.)

Community-based nutrition interventions: reaching adolescents from low-income communities. Hinkle AJ. **Ann N Y Acad Sci** 1997 May 28;817:83–93 (13 ref.)

Use of bioelectric impedance analysis and dual-energy X-ray absorptiometry for monitoring the nutritional status of dialysis patients. Dumler F. **ASAIO J** 1997 May–Jun; 43(3):256–60 (38 ref.)

Nutritional status as a predictor of morbidity and mortality in maintenance dialysis patients. Kopple JD. **ASAIO J** 1997 May–Jun;43(3):246–50 (48 ref.)

Nutritional studies on pregnant women in Umbria (Italy). Alberti-Fidanza A, et al. **Bibl Nutr Dieta** 1996;(53):11–22 (14 ref.)

International Federation of Clinical Chemistry. Laboratory assessment of protein-energy status. Shenkin A, et al. **Clin Chim Acta** 1996 Sep 30;253(1–2):S5–59 (163 ref.)

Influence of diet and nutritional status on drug metabolism. Walter-Sack I, et al. **Clin Pharmacokinet** 1996 Jul; 31(1):47–64 (155 ref.)

Transdisciplinarity in the study of undernutrition–infection interactions. Ulijaszek S. **Coll Antropol** 1997 Jun;21(1):3–15 (133 ref.)

Nutritional support of the hospitalized patient. Mizock BA, et al. **Dis Mon** 1997 Jun;43(6):349–426 (298 ref.)

Nutritional status of patients with amyotrophic lateral sclerosis: relation to the proximity of death. **Dysphagia** 1997 Summer;12(3):174–5 (5 ref.)

Vitamin A intake and status. van den Berg H. **Eur J Clin Nutr** 1996 Jul;50 Suppl 3:S7–12 (43 ref.)

Nutritional aspects in cystic fibrosis. Dodge JA, et al. **Eur J Gastroenterol Hepatol** 1996 Aug;8(8):739–43 (57 ref.)

Undernutrition and aging. Aihie Sayer A, et al. **Gerontology** 1997;43(4):203–5 (22 ref.)

Folate nutrition and older adults: challenges and opportunities. Koehler KM, et al. **J Am Diet Assoc** 1997 Feb;97(2):167–73 (57 ref.)

Micronutrient and cytokine interaction in congenital pediatric HIV infection. Cunningham-Rundles S, et al. **J Nutr** 1996 Oct;126(10 Suppl):2674S–2679S (42 ref.)

Nutrition in pediatric HIV infection: setting the research agenda. Nutrition and immune function II: maternal factors influencing transmission. Landers DV. **J Nutr** 1996 Oct; 126(10 Suppl):2637S–2640S (23 ref.)

Nutritional practices of athletes: are they sub-optimal? Hawley JA, et al. **J Sports Sci** 1995 Summer;13 Spec No:S75–81 (73 ref.)

Nutrition in end-stage renal disease. Ikizler TA, et al. **Kidney Int** 1996 Aug;50(2):343–57 (182 ref.)

Assessing the nutritional status of the elderly: The Mini Nutritional Assessment as part of the geriatric evaluation. Guigoz Y, et al. **Nutr Rev** 1996 Jan;54(1 Pt 2):S59–65 (46 ref.)

Nutrition status predicts survival in cirrhosis. Kalman DR, et al. **Nutr Rev** 1996 Jul;54(7):217–9 (14 ref.)

Importance of adequate vitamin A status during iron supplementation. Ribaya-Mercado JD. **Nutr Rev** 1997 Aug; 55(8):306–7 (13 ref.)

Syndromic classification: a process for amplifying information using S-clustering. Rypka EW. **Nutrition** 1996 Nov–Dec;12(11–12):827–9 (7 ref.)

Nutritional assessment in pediatric patients: how can the laboratory help? Goldsmith B. **Pediatr Pathol Lab Med** 1996 Jan–Feb;16(1):1–7 (13 ref.)

The rationale and ultimate limitations of urea kinetic modelling in the estimation of nutritional status. Bargman JM. **Perit Dial Int** 1996 Jul–Aug;16(4):347–51 (24 ref.)

Nutrition in women. Assessment and counseling. Monteleone GP Jr, et al. **Prim Care** 1997 Mar;24(1):37–51 (59 ref.)

Nutrition and poverty in Europe: an overview. Dowler EA, et al. **Proc Nutr Soc** 1997 Mar;56(1A):51–62 (55 ref.)

Adolescent nutritional status in developing countries. Kurz KM. **Proc Nutr Soc** 1996 Mar;55(1B):321–31 (26 ref.)

Disease and malnutrition in British hospitals. Pennington CR. **Proc Nutr Soc** 1997 Mar;56(1B):393–407 (87 ref.)

Early and late nutritional windows for diabetes susceptibility. Petry CJ, et al. **Proc Nutr Soc** 1997 Mar;56(1B):233–42 (34 ref.)

Socio-economic differentials in health: the role of nutrition. Smith GD, et al. **Proc Nutr Soc** 1997 Mar;56(1A):75–90 (75 ref.)

Impact of disease on markers of micronutrient status. Thurnham DI. **Proc Nutr Soc** 1997 Mar;56(1B):421–31 (66 ref.)

Nutritional management of eating disorders. Rock CL, et al. **Psychiatr Clin North Am** 1996 Dec;19(4):701–13 (75 ref.)

Nutrition assessment and management in pediatric dysphagia. Kovar AJ. **Semin Speech Lang** 1997 Feb;18(1):39–49 (30 ref.)

[Enteral nutrition in maxillofacial oncology] Garau V, et al. **Minerva Stomatol** 1997 Jul–Aug;46(7–8):415–22 (29 ref.) (Eng. Abstr.) **(Ita)**

[Methods of nutrient intake and nutritional status of the elderly in Poland on the basis of the literature from the years 1980–1996] Wierzbicka E, et al. **Rocz Panstw Zakl Hig** 1997;48(1):87–102 (62 ref.) (Eng. Abstr.) **(Pol)**

DRUG EFFECTS

The effects of recombinant human erythropoietin on growth and nutritional status. Jabs K. **Pediatr Nephrol** 1996 Jun; 10(3):324–7 (25 ref.)

IMMUNOLOGY

Nutrition in infancy and childhood. Giovannini M, et al. **Monogr Allergy** 1996;32:25–9 (22 ref.)

PHYSIOLOGY

Stress and nutritional influences on GnRH and somatostatin neuronal systems in the ewe. Polkowska J. **Acta Neurobiol Exp (Warsz)** 1996;56(3):797–806 (38 ref.)

Nutrition and cardiovascular disease [editorial] **Indian J Physiol Pharmacol** 1997 Apr;41(2):95–100 (36 ref.)

Heavy exercise, nutrition and immune function: is there a connection? Shephard RJ, et al. **Int J Sports Med** 1995 Nov;16(8):491–7 (102 ref.)

Impact of disease on markers of macronutrient status. Shenkin A. **Proc Nutr Soc** 1997 Mar;56(1B):433–41 (29 ref.)

[Influence of nutrition and physical activity on bone mineralization] Muzzo S, et al. **Rev Med Chil** 1996 Aug; 124(8 Suppl):78–85 (28 ref.) **(Spa)**

NUTRITIONAL SUPPORT

Nutrition in acute renal failure patients. Ikizler TA, et al. **Adv Ren Replace Ther** 1997 Apr;4(2 Suppl 1):54–63 (67 ref.)

Use of dietetic-specific nutritional diagnostic codes in clinical reasoning relevant to the nutritional management of core clinical outcome indicators in hemodialysis patients. Kelly MP. **Adv Ren Replace Ther** 1997 Apr;4(2):125–35 (87 ref.)

Nutrition in the critical care settings of renal diseases. Moore LW, et al. **Adv Ren Replace Ther** 1996 Jul;3(3):250–60 (32 ref.)

Artificial feeding: progresses and problems. Piacentini GL, et al. **Ann Ist Super Sanita** 1995;31(4):411–8 (10 ref.)

The role of nutrition in prevention and healing of pressure ulcers. Thomas DR. **Clin Geriatr Med** 1997 Aug; 13(3):497–511 (75 ref.)

Early nutritional support in critical illness is important. Sax HC. **Crit Care Clin** 1996 Jul;12(3):661–6 (17 ref.)

Nutritional management of the critically ill neurologic patient. Twyman D. **Crit Care Clin** 1997 Jan;13(1):39–49 (30 ref.)

Is there a role for perioperative nutritional support in liver resection? Bothe A Jr, et al. **HPB Surg** 1997;10(3):177–9 (8 ref.)

Review: nutritional support for patients with cirrhosis. Fan ST. **J Gastroenterol Hepatol** 1997 Apr;12(4):282–6 (55 ref.)

Nutritional support of brain-injured patients. Brain Trauma Foundation. **J Neurotrauma** 1996 Nov;13(11):721–9 (41 ref.)

Creation of a specialized nutrition support outcomes research consortium: if not now, when? [see comments] August DA. **JPEN J Parenter Enteral Nutr** 1996 Nov–Dec; 20(6):394–400 (42 ref.) Comment in: JPEN J Parenter Enteral Nutr 1996 Nov–Dec;20(6):383–4.

Clinical practice guidelines in nutrition support: can they be based on randomized clinical trials? Wolfe BM, et al. **JPEN J Parenter Enteral Nutr** 1997 Jan–Feb;21(1):1–6 (35 ref.)

Nutrition and Parkinson's disease. Pandarinath G, et al. **N C Med J** 1997 May–Jun;58(3):186–8 (12 ref.)

Nutritional support. Souba WW. **N Engl J Med** 1997 Jan 2;336(1):41–8 (90 ref.)

Outcomes research methods in nutritional support. August DA. **Nutrition** 1996 Oct;12(10):724–5 (9 ref.)

Artificial nutrition in cancer patients: an outlook from Europe. Bozzetti F. **Nutrition** 1997 May;13(5):486–9 (36 ref.)

Can body composition in multiple organ failure be favorably influenced by feeding? Campbell IT. **Nutrition** 1997 Sep; 13(9 Suppl):79S–83S (56 ref.)

Regulatory climate for therapeutic nutritional claims regarding cachexia. McCamish MA, et al. **Nutrition** 1996 Jan;12(1 Suppl):S63–5 (20 ref.)

A clinical nutritionist's search for meaning: why should we bother to feed the acutely ill, hospitalized patient? [editorial] Mason JB. **Nutrition** 1996 Apr;12(4):279–81 (32 ref.)

Definition of standardized nutritional assessment and interventional pathways in oncology. Ottery FD. **Nutrition** 1996 Jan;12(1 Suppl):S15–9 (21 ref.)

Training for nutrition support dietitians. Skipper A. **Nutrition** 1996 Oct;12(10):730–2 (19 ref.)

Nutritional support in the critically ill: introduction. Takala J. **Nutrition** 1997 Sep;13(9 Suppl):43S–44S (10 ref.)

Adjunctive therapies in nutritional support. Ziegler TR, et al. **Nutrition** 1997 Sep;13(9 Suppl):64S–72S (82 ref.)

Glutamine: from basic science to clinical applications. Ziegler TR, et al. **Nutrition** 1996 Nov–Dec;12(11–12 Suppl):S68–70 (30 ref.)

Supportive nutritional management of the patient with pancreatic cancer. Ottery F. **Oncology (Huntingt)** 1996 Sep; 10(9 Suppl):26–32 (38 ref.)

The role of antioxidants in nutritional support. Fürst P. **Proc Nutr Soc** 1996 Nov;55(3):945–61 (90 ref.)

Nutritional support in advanced pulmonary disease. Thomsen C. **Respir Med** 1997 May;91(5):249–54 (46 ref.)

[Perioperative nutritional therapy and its relevance for postoperative outcome] Müller JM, et al. **Chirurg** 1997 Jun; 68(6):574–82 (44 ref.) (Eng. Abstr.) **(Ger)**

[The postoperative care and treatment in esophageal cancer (4). Postoperative follow up-(recurrence, nutritional management and after-care of IC)] Ide H, et al. **Nippon Geka Gakkai Zasshi** 1996 Jun;97(6):455–9 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Nutritional support in sepsis] Saito H. **Nippon Geka Gakkai Zasshi** 1996 Dec;97(12):1085–90 (32 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Nutrition support is not beneficial and can be harmful in critically ill patients. Marino PL, et al. **Crit Care Clin** 1996 Jul;12(3):667–76 (47 ref.)

ECONOMICS

Clinical economics review: nutritional support. Ofman J, et al. **Aliment Pharmacol Ther** 1997 Jun;11(3):453–71 (159 ref.)

The route of nutritional support in the critically ill: physiological and economical considerations. Frost P, et al. **Nutrition** 1997 Sep;13(9 Suppl):58S–63S (38 ref.)

METHODS

Common nutritional issues in pediatric and adult critical care medicine. Schears GJ, et al. **Crit Care Clin** 1997 Jul; 13(3):669–90 (195 ref.)
Nutritional support of the pediatric intensive care unit patient. Cañete A, et al. **Curr Opin Pediatr** 1996 Jun; 8(3):248–55 (31 ref.)
Nutritional support of the hospitalized patient. Mizock BA, et al. **Dis Mon** 1997 Jun;43(6):349–426 (298 ref.)
The route of nutritional support in the critically ill: physiological and economical considerations. Frost P, et al. **Nutrition** 1997 Sep;13(9 Suppl):58S–63S (38 ref.)

STANDARDS

Nutrition support in clinical practice: review of published data and recommendations for future research directions. National Institutes of Health, American Society for Parenteral and Enteral Nutrition, and American Society for Clinical Nutrition. Klein S, et al.
JPEN J Parenter Enteral Nutr 1997 May–Jun;21(3):133–56 (257 ref.)
Nutritional issues in cancer management. Laviano A, et al. **Nutrition** 1996 May;12(5):358–71 (184 ref.)

NUTRITIVE VALUE

Contrast between immunologic and nutritional properties of food proteins [editorial] Ferguson A. **Nutrition** 1996 Nov–Dec;12(11–12):817–8 (7 ref.)

NUTS

The traditional and emerging role of nuts in healthful diets. Dreher ML, et al. **Nutr Rev** 1996 Aug;54(8):241–5 (19 ref.)

NYCTIPHANES see **CRUSTACEA**

NYCTOHEMERAL RHYTHM see **CIRCADIAN RHYTHM**

NYCTURIA see **URINATION DISORDERS**

NYSTAGMUS

see related
ELECTRONYSTAGMOGRAPHY

CONGENITAL

Multifaceted treatment of congenital nystagmus: a report of 6 cases. Leung V, et al. **Optom Vis Sci** 1996 Feb; 73(2):114–24 (56 ref.)

ETIOLOGY

Whiplash injury. A clinical review with emphasis on neuro-otological aspects. Fischer AJ, et al.
Clin Otolaryngol 1997 Jun;22(3):192–201 (134 ref.)
Monocular vision loss can cause bilateral nystagmus in young children. Good WV, et al. **Dev Med Child Neurol** 1997 Jun;39(6):421–4 (30 ref.)
The relationship between infantile strabismus and latent nystagmus. Kommerell G. **Eye** 1996;10 (Pt 2):274–81 (74 ref.)
Loss of vision alone may result in seesaw nystagmus. May EF, et al. **J Neuroophthalmol** 1997 Jun;17(2):84–5 (8 ref.)

GENETICS

[Albinism. Current clinical and molecular genetic aspects of an important differential congenital nystagmus diagnosis] Lorenz B. **Ophthalmologe** 1997 Jul;94(7):534–44 (46 ref.) **(Ger)**

PHYSIOPATHOLOGY

Eye movements. Averbuch-Heller L, et al.
Curr Opin Neurol 1996 Feb;9(1):26–31 (31 ref.)
See-saw nystagmus in dogs and humans: an international, across-discipline, serendipitous collaboration. Dell'Osso LF. **Neurology** 1996 Dec;47(6):1372–4 (22 ref.)

THERAPY

Medical treatments for abnormal eye movements: pharmacological, optical and immunological strategies. Averbuch-Heller L, et al. **Aust N Z J Ophthalmol** 1997 Feb;25(1):7–13 (36 ref.)
Multifaceted treatment of congenital nystagmus: a report of 6 cases. Leung V, et al. **Optom Vis Sci** 1996 Feb; 73(2):114–24 (56 ref.)

NYSTAGMUS, PHYSIOLOGIC

see related
ELECTRONYSTAGMOGRAPHY

NYSTATIN

ADMINISTRATION & DOSAGE

Characteristics of lipid-based formulations that influence their biological behavior in the plasma of patients. Wasan KM, et al. **Clin Infect Dis** 1996 Nov;23(5):1126–38 (111 ref.)

PHARMACOLOGY

Nystatin-rhodamine B assay for estimating activity of killer toxin from Kluyveromyces lactis. Palková Z, et al.
Methods Mol Biol 1996;53:325–9 (5 ref.)

THERAPEUTIC USE

Clinical use of oral nystatin in the prevention of systemic candidosis in patients at particular risk. Schäfer-Korting M, et al. **Mycoses** 1996 Sep–Oct;39(9–10):329–39 (35 ref.)

OATS

CHEMISTRY

Analysis, heat stability and physiological effects of saponins from oats. Onning G, et al. **Adv Exp Med Biol** 1996; 405:365–75 (49 ref.)

OBESE MICE see **MICE, OBESE**

OBESITY

see related
ANTI-OBESITY AGENTS
APPETITE DEPRESSANTS
DIET, REDUCING
LIPECTOMY
SKINFOLD THICKNESS

Macronutrient substitutes and weight-reduction practices of obese, dieting, and eating-disordered women. Drewnowski A. **Ann N Y Acad Sci** 1997 May 23;819:132–41 (59 ref.)
Management of childhood obesity in pediatric practice. Williams CL, et al. **Ann N Y Acad Sci** 1997 May 28; 817:225–40 (40 ref.)
Obesity as a risk factor for various diseases: necessity of lifestyle changes for healthy aging. Tanaka K, et al.
Appl Human Sci 1996 Jul;15(4):139–48 (76 ref.)
Understanding obesity: the interaction of diet, genetics, and hormones. Rosenfeld CR. **Cleve Clin J Med** 1996 Oct; 63(6):317–9 (16 ref.)
Obesity research continues to spring leaks. Harper ME.
Clin Invest Med 1997 Aug;20(4):239–44 (32 ref.)
Body composition and childhood obesity. Harsha DW, et al. **Endocrinol Metab Clin North Am** 1996 Dec;25(4):871–85 (55 ref.)
The obese strain chicken as a model for human Hashimoto's thyroiditis. Sundick RS, et al.
Exp Clin Endocrinol Diabetes 1996;104 Suppl 3:4–6 (19 ref.)
The OB protein (leptin) pathway—a link between adipose tissue mass and central neural networks. Campfield LA, et al. **Horm Metab Res** 1996 Dec;28(12):619–32 (96 ref.)
Role of the beta3-adrenoceptor in the control of leptin expression. Giacobino JP. **Horm Metab Res** 1996 Dec; 28(12):633–7 (58 ref.)
Regulation of ob gene expression in rodents and humans. Saladin R, et al. **Horm Metab Res** 1996 Dec;28(12):638–41 (41 ref.)
Leptin: genes, concepts and clinical perspective. Considine RV, et al. **Horm Res** 1996;46(6):249–56 (70 ref.)
Obesity and the insulin resistance syndrome. Landsberg L. **Hypertens Res** 1996 Jun;19 Suppl 1:S51–5 (38 ref.)
Obesity. Björntorp P. **Lancet** 1997 Aug 9;350(9075):423–6 (25 ref.)
Obesity update 1996 [clinical conference] [see comments] Utzschneider D. **Md Med J** 1996 Oct;45(10):844–8 (34 ref.) Comment in: Md Med J 1997 Jan;46(1):9–10.
Obesity. Rosenbaum M, et al. **N Engl J Med** 1997 Aug 7; 337(6):396–407 (139 ref.)
Assessment, etiology, and intervention in obesity in children. Keller C, et al. **Nurse Pract** 1996 Sep;21(9):31–6, 38, 41–2 (80 ref.)
[TNF-alpha: molecular tie between obesity and insulin resistance] Peraldi P, et al.
Journ Annu Diabetol Hotel Dieu 1997;:149–59 (52 ref.) **(Fre)**
[Obesity in the adult] Nakano H, et al.
Nippon Ika Daigaku Zasshi 1996 Oct;63(5):431–5 (14 ref.) **(Jpn)**
[Obesity and insulin resistance syndrome] Tokunaga K, et al. **Nippon Rinsho** 1996 Oct;54(10):2679–86 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Obesity and distribution of body fat. Correlation between anthropometric and tomographic data on areas at the abdominal level] Lara Fernández A, et al.
Rev Clin Esp 1996 Jul;196(7):437–45 (41 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

Rapid heparin anticoagulation: use of a weight-based nomogram. Schaefer DC, et al. **Am Fam Physician** 1996 Dec;54(8):2517–21 (14 ref.)
Decreased androgen levels and obesity in men. Vermeulen A. **Ann Med** 1996 Feb;28(1):13–5 (26 ref.)
PAI-1, obesity, insulin resistance and risk of cardiovascular events. Juhan-Vague I, et al. **Thromb Haemost** 1997 Jul; 78(1):656–60 (56 ref.)

COMPLICATIONS

Interrelationships of high fat diets, obesity, hormones, and cancer. Heber D. **Adv Exp Med Biol** 1996;399:13–25 (88 ref.)
Mechanisms of abnormal renal sodium handling in obesity hypertension. Hall JE. **Am J Hypertens** 1997 May;10(5 Pt 2):49S–55S (48 ref.)
Does excess weight cause osteoarthritis and, if so, why? Felson DT. **Ann Rheum Dis** 1996 Sep;55(9):668–70 (23 ref.)
Obesity as a disease. Jung RT. **Br Med Bull** 1997;53(2):307–21 (50 ref.)
Obesity and female reproductive function. Pettigrew R, et al. **Br Med Bull** 1997;53(2):341–58 (47 ref.)
Metabolic consequences of obesity and body fat pattern: lessons from migrant studies. McKeigue PM.
Ciba Found Symp 1996;201:54–64; discussion 64–7, 188–93 (59 ref.)
Obesity and cardiovascular disease. Shaper AG.
Ciba Found Symp 1996;201:90–103; discussion 103–7, 188–93 (41 ref.)
Central nervous system monoamine neurotransmitter turnover in primary and obesity-related human hypertension. Esler M, et al. **Clin Exp Hypertens** 1997 Jul–Aug;19(5–6):577–90 (24 ref.)
Obesity and coronary heart disease. Garrison RJ, et al.
Curr Opin Lipidol 1996 Aug;7(4):199–202 (34 ref.)
Obesity and cardiovascular disease: is body structure a factor? Nielsen S, et al. **Curr Opin Lipidol** 1997 Aug;8(4):200–4 (34 ref.)
Obesity, social class and Western diet: a link to breast cancer prognosis. Stoll BA. **Eur J Cancer** 1996 Jul;32A(8):1293–5 (56 ref.)
Visceral obesity, insulin resistance, and dyslipidemia: contribution of endurance exercise training to the treatment of the plurimetabolic syndrome. Després JP.
Exerc Sport Sci Rev 1997;25:271–300 (125 ref.)
Measurement and long-term health risks of child and adolescent fatness. Power C, et al.
Int J Obes Relat Metab Disord 1997 Jul;21(7):507–26 (93 ref.)
Cardiovascular health risks related to overweight. Ernst ND, et al. **J Am Diet Assoc** 1997 Jul;97(7 Suppl):S47–51 (18 ref.)
Fat, caloric intake, and obesity: lifestyle risk factors for breast cancer. Greenwald P, et al. **J Am Diet Assoc** 1997 Jul;97(7 Suppl):S24–30 (76 ref.)
Obesity-related hypertension: its physiological basis and pharmacological approaches to its treatment. Richards RJ, et al. **J Hum Hypertens** 1996 Sep;10 Suppl 3:S59–64 (60 ref.)
Obesity and weight loss in obstructive sleep apnea: a critical review. Strobel RJ, et al. **Sleep** 1996 Feb;19(2):104–15 (82 ref.)
Physiological regulation of the human growth hormone (GH)-insulin-like growth factor type I (IGF-I) axis: predominant impact of age, obesity, gonadal function, and sleep. Veldhuis JD, et al. **Sleep** 1996 Dec;19(10 Suppl):S221–4 (17 ref.)
Laparoscopic complications in markedly obese urologic patients (a multi-institutional review). Mendoza D, et al. **Urology** 1996 Oct;48(4):562–7 (30 ref.)
[Obesity and hypertension] Müller-Wieland D, et al.
Internist (Berl) 1997 Mar;38(3):237–43 (39 ref.) **(Ger)**
[Obesity and cardiorespiratory disease] Bonsignore G, et al.
Cardiologia 1996 Jul;41(7):613–9 (32 ref.) **(Ita)**
[Obesity, visceral fat obesity syndrome] Nakamura H.
Ryoikibetsu Shokogun Shirizu 1996;(15):63–5 (7 ref.) **(Jpn)**
[Obesity-related hypertension] Ueda Y, et al.
Ryoikibetsu Shokogun Shirizu 1996;(12):163–6 (20 ref.) **(Jpn)**
[Health implications of obesity] Vasiljević N, et al.
Srp Arh Celok Lek 1997 Sep–Oct;125(9–10):299–302 (24 ref.) (Eng. Abstr.) **(Scc)**

DIAGNOSIS

Assessing obesity: classification and epidemiology. Seidell JC, et al. **Br Med Bull** 1997;53(2):238–52 (27 ref.)
Measurement and long-term health risks of child and adolescent fatness. Power C, et al.
Int J Obes Relat Metab Disord 1997 Jul;21(7):507–26 (93 ref.)
Measurement of body fat and fat distribution. Keller C, et al. **J Nurs Meas** 1995 Winter;3(2):159–74 (47 ref.)
[1995 Spanish consensus for the evaluation of obesity and to carry out epidemiologic studies. Spanish Society for the Study of Obesity] **Med Clin (Barc)** 1996 Dec 7; 107(20):782–7 (32 ref.) **(Spa)**

DIET THERAPY

The central role of dietary fat, not carbohydrate, in the insulin resistance syndrome. Purnell JQ, et al.
Curr Opin Lipidol 1997 Feb;8(1):17–22 (71 ref.)
Role of nutrition planning in the treatment for obesity. Atkinson RL. **Endocrinol Metab Clin North Am** 1996 Dec; 25(4):955–64 (19 ref.)
The role of low-fat diets and fat substitutes in body weight management: what have we learned from clinical studies? Astrup A, et al. **J Am Diet Assoc** 1997 Jul;97(7 Suppl):S82–7 (33 ref.)
Nonpharmacologic treatment of obesity. Wood OB, et al.

J Am Pharm Assoc (Wash) 1996 Nov;NS36(11):636–50 (14 ref.)

The usefulness of dietary medium-chain triglycerides in body weight control: fact or fancy? Bach AC, et al. **J Lipid Res** 1996 Apr;37(4):708–26 (222 ref.)

Methods for voluntary weight loss and control. **Nutrition** 1996 Oct;12(10):663–71 (0 ref.)

DRUG THERAPY

Use of drugs in the treatment of obesity. Atkinson RL. **Annu Rev Nutr** 1997;17:383–403 (76 ref.)

The treatment of obesity. A call for prudence and professionalism. Kushner R. **Arch Intern Med** 1997 Mar 24;157(6):602–4 (19 ref.)

Present and future pharmacological approaches. Finer N. **Br Med Bull** 1997;53(2):409–32 (109 ref.)

Effects of troglitazone on insulin sensitivity. Henry RR. **Diabet Med** 1996 Sep;13(9 Suppl 6):S148–50 (9 ref.)

Dexfenfluramine. An updated review of its therapeutic use in the management of obesity. Davis R, et al. **Drugs** 1996 Nov;52(5):696–724 (167 ref.)

Medicating the obese patient. Ryan DH. **Endocrinol Metab Clin North Am** 1996 Dec;25(4):989–1004 (32 ref.)

Pharmacological approaches to intervention. Guy-Grand B. **Int J Obes Relat Metab Disord** 1997 Mar;21 Suppl 1:S22–4 (7 ref.)

Sibutramine—a review of clinical efficacy. Lean ME. **Int J Obes Relat Metab Disord** 1997 Mar;21 Suppl 1:S30–6; discussion 37–9 (18 ref.)

Drug therapy for obesity: an update. Popovich NG, et al. **J Am Pharm Assoc (Wash)** 1997 Jan–Feb;NS37(1):31–9, 56 (34 ref.)

The pharmacologic approach to the treatment of obesity. Weiser M, et al. **J Clin Pharmacol** 1997 Jun;37(6):453–73 (259 ref.)

Long-term pharmacotherapy in the management of obesity. National Task Force on the Prevention and Treatment of Obesity [see comments] **JAMA** 1996 Dec 18; 276(23):1907–15 (117 ref.) Comment in: JAMA 1997 Apr 16;277(15):1201; discussion 1202. Comment in: JAMA 1997 Apr 16;277(15):1201–2; discussion 1202.

ECONOMICS

A review of the economic analysis of obesity. Hughes D, et al. **Br Med Bull** 1997;53(2):253–63 (19 ref.)

The economic and psychosocial consequences of obesity. Rissanen AM. **Ciba Found Symp** 1996;201:194–201; discussion 201–6 (26 ref.)

EPIDEMIOLOGY

Confronting a rising tide of eating disorders and obesity: treatment vs. prevention and policy. Battle EK, et al. **Addict Behav** 1996 Nov–Dec;21(6):755–65 (45 ref.)

Obesity in Singapore [editorial] Cheah JS. **Ann Acad Med Singapore** 1997 Mar;26(2):145–6 (13 ref.)

Obesity in the Caribbean. Forrester T, et al. **Ciba Found Symp** 1996;201:17–26; discussion 26–31, 32–6 (18 ref.)

The epidemiology of obesity. James WP. **Ciba Found Symp** 1996;201:1–11; discussion 11–6, 32–6 (50 ref.)

Obesity and cardiovascular disease. Rexrode KM, et al. **Curr Opin Cardiol** 1996 Sep;11(5):490–5 (51 ref.)

Familial aggregation of obesity, candidate genes and quantitative trait loci. Chagnon YC, et al. **Curr Opin Lipidol** 1997 Aug;8(4):205–11 (51 ref.)

Health hazards of obesity. Bray GA. **Endocrinol Metab Clin North Am** 1996 Dec;25(4):907–19 (46 ref.)

Prevalence of obesity. VanItallie TB. **Endocrinol Metab Clin North Am** 1996 Dec;25(4):887–905 (30 ref.)

Body habitus and coronary heart disease in men. A review with reference to methods of body habitus assessment. Williams SR, et al. **Eur Heart J** 1997 Mar;18(3):376–93 (114 ref.)

Time trends in obesity: an epidemiological perspective. Seidell JC. **Horm Metab Res** 1997 Apr;29(4):155–8 (21 ref.)

Gender-specific aspects of obesity. Legato MJ. **Int J Fertil Womens Med** 1997 May–Jun;42(3):184–97 (162 ref.)

Weight gain in women diagnosed with breast cancer. Demark-Wahnefried W, et al. **J Am Diet Assoc** 1997 May; 97(5):519–26, 529; quiz 527–8 (83 ref.)

Obesity: how can it be controlled? Senior K. **Mol Med Today** 1997 May;3(5):204–6 (23 ref.)

Methods for voluntary weight loss and control: update 1996. Goodrick GK, et al. **Nutrition** 1996 Oct;12(10):672–6 (40 ref.)

ETIOLOGY

Polycystic ovary syndrome: clinical aspects. Conway GS. **Baillieres Clin Endocrinol Metab** 1996 Apr;10(2):263–79 (55 ref.)

Aetiology of obesity. Jebb SA. **Br Med Bull** 1997; 53(2):264–85 (94 ref.)

Neurobiology. Wilding J, et al. **Br Med Bull** 1997; 53(2):286–306 (77 ref.)

Overconsumption as a cause of weight gain: behavioural-physiological interactions in the control of food intake (appetite). Blundell JE, et al. **Ciba Found Symp** 1996;201:138–54; discussion 154–8, 188–93 (69 ref.)

Nutritional influences in early life upon obesity and body proportions. Jackson AA, et al. **Ciba Found Symp** 1996; 201:118–29; discussion 129–37, 188–93 (54 ref.)

Socioeconomic status and obesity. Stunkard AJ. **Ciba Found Symp** 1996;201:174–82; discussion 182–7, 188–93 (28 ref.)

Regulation of energy balance by leptin. Hamann A, et al. **Exp Clin Endocrinol Diabetes** 1996;104(4):293–300 (46 ref.)

Perimenopausal obesity. Milewicz A, et al. **Gynecol Endocrinol** 1996 Aug;10(4):285–91 (68 ref.)

Obesity in children. Environmental and genetic aspects. Guilloume M, et al. **Horm Metab Res** 1996 Nov; 28(11):573–81 (80 ref.)

Obesity results as a consequence of glucocorticoid induced leptin resistance. Ur E, et al. **Horm Metab Res** 1996 Dec; 28(12):744–7 (38 ref.)

Methioninase: a therapeutic for diseases related to altered methionine metabolism and transmethylation: cancer, heart disease, obesity, aging, and Parkinson's disease. Hoffman RM. **Hum Cell** 1997 Mar;10(1):69–80 (117 ref.)

The role of dietary fat in obesity. Golay A, et al. **Int J Obes Relat Metab Disord** 1997 Jun;21 Suppl 3:S2–11 (64 ref.)

Advances in our understanding of the role of the sympathetic nervous system in obesity. Macdonald IA. **Int J Obes Relat Metab Disord** 1995 Dec;19 Suppl 7:S2–S7 (31 ref.)

Dietary fat and human obesity. Ravussin E, et al. **J Am Diet Assoc** 1997 Jul;97(7 Suppl):S42–6 (56 ref.)

The new biology of body weight regulation. Schwartz MW, et al. **J Am Diet Assoc** 1997 Jan;97(1):54–8; quiz 59–60 (41 ref.)

Periods of risk in childhood for the development of adult obesity—what do we need to learn? Dietz WH. **J Nutr** 1997 Sep;127(9):1884S–1886S (29 ref.)

1997 Jonathan E. Rhoads Lecture. Understanding obesity: the unfinished business. Hirsch J. **JPEN J Parenter Enteral Nutr** 1997 Jul–Aug;21(4):192–5 (7 ref.)

The role of tumor necrosis factor-alpha in the pathogenesis of anorexia and bulimia nervosa, cancer cachexia and obesity. Holden RJ, et al. **Med Hypotheses** 1996 Dec; 47(6):423–38 (148 ref.)

Leptin. Meinders AE, et al. **Neth J Med** 1996 Dec; 49(6):247–52 (24 ref.)

Effects of alcohol on energy metabolism and body weight regulation: is alcohol a risk factor for obesity? Suter PM, et al. **Nutr Rev** 1997 May;55(5):157–71 (179 ref.)

Pediatric obesity. An overview of etiology and treatment. Schonfeld-Warden N, et al. **Pediatr Clin North Am** 1997 Apr;44(2):339–61 (157 ref.)

The role of lifestyle in health: the epidemiology and consequences of inactivity. Dietz WH. **Proc Nutr Soc** 1996 Nov;55(3):829–40 (75 ref.)

Eating behaviour, food preferences and dietary intake in relation to obesity and body-weight status. Mela DJ. **Proc Nutr Soc** 1996 Nov;55(3):803–16 (122 ref.)

The role of altered sympathetic nervous system activity in the pathogenesis of obesity. Ravussin E, et al. **Proc Nutr Soc** 1996 Nov;55(3):793–802 (61 ref.)

Evidence for a central mechanism of obesity in the Zucker rat: role of neuropeptide Y and leptin. White BD, et al. **Proc Soc Exp Biol Med** 1997 Mar;214(3):222–32 (135 ref.)

[The molecular pathogenesis of obesity. The physiological and pathophysiological role of leptin] Spitzweg C, et al. **Dtsch Med Wochenschr** 1996 Sep 13;121(37):1134–8 (33 ref.) **(Ger)**

[Etiology of obesity] Weck M, et al. **Internist (Berl)** 1997 Mar;38(3):204–13 (86 ref.) **(Ger)**

[Polymetabolic syndrome] Crepaldi G, et al. **Minerva Endocrinol** 1995 Sep;20(3):155–60 (29 ref.) **(Ita)**

[Endocrinologic problems of the male adolescent] Reina C, et al. **Pediatr Med Chir** 1996 Sep–Oct;18(5 Suppl):9–13 (11 ref.) (Eng. Abstr.) **(Ita)**

[Association of hyperuricemia with hyperlipidemia and obesity] Nakamura H. **Nippon Rinsho** 1996 Dec; 54(12):3289–92 (4 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Lessons from the discovery of leptin: is obesity an endocrine disease? [editorial] Scheen AJ. **Acta Clin Belg** 1996; 51(6):371–6 (51 ref.)

Genes and obesity [editorial] Andersson LB. **Ann Med** 1996 Feb;28(1):5–7 (21 ref.)

Energy balance: role of genetics and activity. Pi-Sunyer FX. **Ann N Y Acad Sci** 1997 May 23;819:29–36 (44 ref.)

Expression of fibrinolytic genes in tissues from human atherosclerotic aneurysms and from obese mice. Samad F, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:350–8; discussion 358–60 (68 ref.)

Hormones and the ob gene product (leptin) in the control of energy balance. Trayhurn P, et al. **Biochem Soc Trans** 1996 May;24(2):565–70 (36 ref.)

Obesity genes and the regulation of body fat content. Weigle DS, et al. **Bioessays** 1996 Nov;18(11):867–74 (79 ref.)

Genetics of obesity in humans: current issues. Bouchard C. **Ciba Found Symp** 1996;201:108–15; discussion 115–7, 188–93 (14 ref.)

Obesity genes. Beales PL, et al. **Clin Endocrinol (Oxf)** 1996 Oct;45(4):373–8 (50 ref.)

Shedding new light on obesity. Appetite regulation. Billington CJ, et al. **Curr Biol** 1996 Aug 1;6(8):920–3 (29 ref.)

Mice as models of human developmental disorders: natural and artificial mutants. Darling S. **Curr Opin Genet Dev** 1996 Jun;6(3):289–94 (49 ref.)

The genetics of obesity. Naggert J, et al. **Curr Opin Genet Dev** 1997 Jun;7(3):398–404 (58 ref.)

Familial aggregation of obesity, candidate genes and quantitative trait loci. Chagnon YC, et al. **Curr Opin Lipidol** 1997 Aug;8(4):205–11 (51 ref.)

Leptin: the tale of an obesity gene. Caro JF, et al. **Diabetes** 1996 Nov;45(11):1455–62 (61 ref.)

The causes of obesity: advances in molecular biology but stagnation on the genetic front. Bouchard C. **Diabetologia** 1996 Dec;39(12):1532–3 (6 ref.)

New insights into obesity genes. Guerre-Millo M, et al. **Diabetologia** 1996 Dec;39(12):1528–31 (45 ref.)

Genetics of obesity in humans and animal models. West DB. **Endocrinol Metab Clin North Am** 1996 Dec;25(4):801–13 (70 ref.)

Lessons from animal models of obesity. York DA. **Endocrinol Metab Clin North Am** 1996 Dec;25(4):781–800 (132 ref.)

Obesity in children. Environmental and genetic aspects. Guilloume M, et al. **Horm Metab Res** 1996 Nov; 28(11):573–81 (80 ref.)

The leptin receptor. Tartaglia LA. **J Biol Chem** 1997 Mar 7;272(10):6093–6 (59 ref.)

Leptin, its receptor and obesity. Misra A, et al. **J Investig Med** 1996 Dec;44(9):540–8 (83 ref.)

Genetics of human obesity: recent results from linkage studies. Bouchard C. **J Nutr** 1997 Sep;127(9):1887S–1890S (18 ref.)

Progress in understanding the genetics of obesity. Bray GA. **J Nutr** 1997 May;127(5 Suppl):940S–942S (36 ref.)

Mapping of mouse obesity genes: A generic approach to a complex trait. Fisler JS, et al. **J Nutr** 1997 Sep; 127(9):1909S–1916S (78 ref.)

Potential role of TNFalpha and lipoprotein lipase as candidate genes for obesity. Kern PA. **J Nutr** 1997 Sep; 127(9):1917S–1922S (43 ref.)

The role of the agouti gene in the yellow obese syndrome. Miltenberger RJ, et al. **J Nutr** 1997 Sep;127(9):1902S–1907S (81 ref.)

Obesity as a pleiotropic effect of gene action. Wolff GL. **J Nutr** 1997 Sep;127(9):1897S–1901S (31 ref.)

Obesity. Jéquier E, et al. **Mol Aspects Med** 1997 Aug; 18(4):247–305 (240 ref.)

Obesity research springs a proton leak [news; comment] Flier JS, et al. **Nat Genet** 1997 Mar;15(3):223–4 (17 ref.) Comment on: Nat Genet 1997 Mar;15(3):269–72.

Leptin: the weight-reducing plasma protein encoded by the obese gene. **Nutr Rev** 1996 Mar;54(3):91–3 (12 ref.)

The new obesity genes. Roberts SB, et al. **Nutr Rev** 1996 Feb;54(2 Pt 1):41–9 (49 ref.)

The human obesity gene map: the 1996 update. Pérusse L, et al. **Obes Res** 1997 Jan;5(1):49–61 (87 ref.)

New insights into the development of obesity: obese genes and the leptin system. Trayhurn P. **Proc Nutr Soc** 1996 Nov;55(3):783–91 (53 ref.)

Genetics of obesity: advances from rodent studies. Chagnon YC, et al. **Trends Genet** 1996 Nov;12(11):441–4 (25 ref.)

[Leptin and genetics of obesity] Clément K, et al. **Journ Annu Diabetol Hotel Dieu** 1997;:161–71 (31 ref.) **(Fre)**

[Euphenic prevention of obesity at the Optimal Family Planning Service in Hungary] Miklós J, et al. **Orv Hetil** 1996 Nov 10;137(45):2517–22 (39 ref.) (Eng. Abstr.) **(Hun)**

[ob protein—product of expressing an obesity gene and some aspects of modern-day endocrinology] Pankov IuA. **Biokhimiia** 1996 Jun;61(6):984–92 (13 ref.) (Eng. Abstr.) **(Rus)**

[Obesity gene and the product of expressing its hormone, leptin] Pankov IuA. **Mol Biol (Mosk)** 1996 Jul–Aug; 30(4):743–7 (13 ref.) **(Rus)**

IMMUNOLOGY

The role of the target organ in the development of autoimmune diseases exemplified in the obese strain (OS) chicken model for human Hashimoto disease. Wick G. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 3:1–4 (27 ref.)

METABOLISM

Effect of fat intake on energy balance. Tataranni PA, et al. **Ann N Y Acad Sci** 1997 May 23;819:37–43 (48 ref.)

Of mice and women: the beta 3-adrenergic receptor leptin and obesity. Bégin-Heick N. **Biochem Cell Biol** 1996; 74(5):615–22 (67 ref.)

Overfeeding, autonomic regulation and metabolic consequences. Scheurink AJ, et al. **Cardiovasc Drugs Ther** 1996 Jun;10 Suppl 1:263–73 (62 ref.)

Obesity and metabolic efficiency. Astrup A. **Ciba Found Symp** 1996;201:159–68; discussion 168–73, 188–93 (52 ref.)

Obesity and physical activity. Ferro-Luzzi A, et al. **Ciba Found Symp** 1996;201:207–21; discussion 221–7 (59 ref.)

Central nervous system monoamine neurotransmitter turnover in primary and obesity-related human hypertension. Esler M, et al. **Clin Exp Hypertens** 1997 Jul-Aug;19(5-6):577-90 (24 ref.)
Antimicrobial dosing in obese patients. Wurtz R, et al. **Clin Infect Dis** 1997 Jul;25(1):112-8 (83 ref.)
Appetite control: Does leptin lighten the problem of obesity? McGarry JD. **Curr Biol** 1995 Dec 1;5(12):1342-4 (23 ref.)
Inhibition of insulin receptor signaling by TNF: potential role in obesity and non-insulin-dependent diabetes mellitus. Skolnik EY, et al. **Cytokine Growth Factor Rev** 1996 Aug; 7(2):161-73 (111 ref.)
Regulation of appetite and body weight. Schwartz MW. **Hosp Pract (Off Ed)** 1997 Jul 15;32(7):109-12, 117-9 (6 ref.)
The role of dietary fat in obesity. Golay A, et al. **Int J Obes Relat Metab Disord** 1997 Jun;21 Suppl 3:S2-11 (64 ref.)
Physical activity and obesity: problems in correcting expenditure for body size. Prentice AM, et al. **Int J Obes Relat Metab Disord** 1996 Jul;20(7):688-91 (18 ref.)
Postprandial lipoprotein metabolism in diabetes mellitus and obesity. Lewis GF. **J Atheroscler Thromb** 1995;2 Suppl 1:S34-5 (4 ref.)
Obesity and metabolic complications: contribution of dehydroepiandrosterone and other steroid hormones. Tchernof A, et al. **J Endocrinol** 1996 Sep;150 Suppl:S155-64 (97 ref.)
Body weight set-points: determination and adjustment. Keesey RE, et al. **J Nutr** 1997 Sep;127(9):1875S-1883S (31 ref.)
Obesity as a pleiotropic effect of gene action. Wolff GL. **J Nutr** 1997 Sep;127(9):1897S-1901S (31 ref.)
Obesity. Jéquir E, et al. **Mol Aspects Med** 1997 Aug; 18(4):247-305 (240 ref.)
Obesity research springs a proton leak [news; comment] Flier JS, et al. **Nat Genet** 1997 Mar;15(3):223-4 (17 ref.) Comment on: Nat Genet 1997 Mar;15(3):269-72.
Defects in substrate oxidation involved in the predisposition to obesity. Astrup A, et al. **Proc Nutr Soc** 1996 Nov; 55(3):817-28 (46 ref.)
Glucose transporters in obesity. Guerre-Millo M. **Proc Nutr Soc** 1996 Mar;55(1B):237-44 (21 ref.)
Regulation of energy balance and adiposity: a model with new approaches. Martínez JA, et al. **Rev Esp Fisiol** 1996 Dec;52(4):255-8 (21 ref.)
[OB protein and its receptor: signal transduction between adipose tissue and central nervous system] Campfield LA, et al. **Journ Annu Diabetol Hotel Dieu** 1997;:131-48 (63 ref.) **(Fre)**
[Metabolic syndrome with vascular risk and arterial hypertension] Wassermann AO, et al. **Medicina (B Aires)** 1996;56(2):183-94 (102 ref.) (Eng. Abstr.) **(Spa)**

MORTALITY

Intentional weight loss: patterns in the general population and its association with morbidity and mortality. Williamson DF. **Int J Obes Relat Metab Disord** 1997 Mar; 21 Suppl 1:S14-9; discussion S20-1 (21 ref.)
[Obesity. Increased mortality caused by arteriosclerotic sequelae and carcinomas] Wirth A. **Internist (Berl)** 1997 Mar;38(3):214-23 (42 ref.) **(Ger)**

PATHOLOGY

The effects of diet, ad libitum overfeeding, and moderate dietary restriction on the rodent bioassay: the uncontrolled variable in safety assessment. Keenan KP, et al. **Toxicol Pathol** 1996 Nov-Dec;24(6):757-68 (49 ref.)

PHYSIOPATHOLOGY

Common biological pathways in eating disorders and obesity. Ericsson M, et al. **Addict Behav** 1996 Nov-Dec; 21(6):733-43 (65 ref.)
Brain Serotonin, Carbohydrate-craving, obesity and depression. Wurtman RJ, et al. **Adv Exp Med Biol** 1996; 398:35-41 (33 ref.)
Role of the brain in energy balance and obesity [editorial] Levin BE, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):R491-500 (143 ref.)
Brown adipose tissue, beta 3-adrenergic receptors, and obesity. Lowell BB, et al. **Annu Rev Med** 1997;48:307-16 (67 ref.)
Regulation of body adiposity and the problem of obesity. Schwartz MW, et al. **Arterioscler Thromb Vasc Biol** 1997 Feb;17(2):233-8 (73 ref.)
Metabolic actions of neuropeptide Y and their relevance to obesity. Wilding JP. **Biochem Soc Trans** 1996 May; 24(2):576-81 (50 ref.)
Obesity and the sympathetic nervous system. Grassi G, et al. **Blood Press Suppl** 1996;1:43-6 (24 ref.)
Overfeeding, autonomic regulation and metabolic consequences. Scheurink AJ, et al. **Cardiovasc Drugs Ther** 1996 Jun;10 Suppl 1:263-73 (62 ref.)
Adipogenesis and obesity: rounding out the big picture. Spiegelman BM, et al. **Cell** 1996 Nov 1;87(3):377-89 (110 ref.)
A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity. Pi-Sunyer FX. **Clin Ther** 1996 Nov-Dec; 18(6):1006-35; discussion 1005 (76 ref.)
Oscillatory insulin secretion: a variable phenotypic marker. Matthews DR. **Diabet Med** 1996 Sep;13(9 Suppl 6):S53-8 (15 ref.)
Pathophysiology and molecular mechanisms of visceral fat syndrome: the Japanese experience. Matsuzawa Y. **Diabetes Metab Rev** 1997 Mar;13(1):3-13 (76 ref.)
The endocrinology of obesity. Smith SR. **Endocrinol Metab Clin North Am** 1996 Dec;25(4):921-42 (186 ref.)
Journey from cachexia to obesity by TNF. Argilés JM, et al. **FASEB J** 1997 Aug;11(10):743-51 (107 ref.)
The loop system between neuropeptide Y and leptin in normal and obese rodents. Rohner-Jeanrenaud F, et al. **Horm Metab Res** 1996 Dec;28(12):642-8 (61 ref.)
The sympathetic nervous system as a target for intervention in obesity. Astrup A. **Int J Obes Relat Metab Disord** 1995 Dec;19 Suppl 7:S24-S28 (24 ref.)
Advances in our understanding of the role of the sympathetic nervous system in obesity. Macdonald IA. **Int J Obes Relat Metab Disord** 1995 Dec;19 Suppl 7:S2-S7 (31 ref.)
Long-term intervention strategies in obesity treatment. Rössner S. **Int J Obes Relat Metab Disord** 1995 Dec;19 Suppl 7:S29-S33 discussion S34-S35 (26 ref.)
Defining success in obesity management. Rössner S. **Int J Obes Relat Metab Disord** 1997 Mar;21 Suppl 1:S2-4 (15 ref.)
Differences in fat balance underlying obesity. Tremblay A. **Int J Obes Relat Metab Disord** 1995 Dec;19 Suppl 7:S10-S14; discussion S15-16 (47 ref.)
Clinical review 90: Leptin and clinical medicine: a new piece in the puzzle of obesity. Bray GA, et al. **J Clin Endocrinol Metab** 1997 Sep;82(9):2771-6 (77 ref.)
Transcription, adipocyte differentiation, and obesity. Auwerx J, et al. **J Mol Med** 1996 Jul;74(7):347-52 (74 ref.)
Physical activity, nutrition, and chronic disease. Blair SN, et al. **Med Sci Sports Exerc** 1996 Mar;28(3):335-49 (202 ref.)
Obesity, diabetes and functions for proopiomelanocortin-derived peptides. Mountjoy KG, et al. **Mol Cell Endocrinol** 1997 Apr 4;128(1-2):171-7 (51 ref.)
Modulation of insulin secretion by feeding behavior and physical activity: possible beneficial effects on obese and aged rats. Carpinelli AR, et al. **Neurosci Biobehav Rev** 1996 Summer;20(2):183-8 (64 ref.)
Leptin: the weight-reducing plasma protein encoded by the obese gene. **Nutr Rev** 1996 Mar;54(3):91-3 (12 ref.)
Glucostatic control of intake and obesity. Astrup A, et al. **Proc Nutr Soc** 1996 Mar;55(1B):485-95 (40 ref.)
Why is the treatment of cancer more successful than that of obesity? Berry EM. **Public Health Rev** 1996;24(2):147-63 (29 ref.)
Effects of exercise training on abdominal obesity and related metabolic complications. Buemann B, et al. **Sports Med** 1996 Mar;21(3):191-212 (218 ref.)
[Leptin—a new weight-loss agent?] Holst JJ. **Nord Med** 1996 Nov;111(9):300-3 (13 ref.) (Eng. Abstr.) **(Dan)**
[Obesity: a frequently neglected pathology] Dubuis JM. **Rev Med Suisse Romande** 1996 Oct;116(10):829-38 (13 ref.) **(Fre)**
[Obesity and lipid metabolism disorders] Wechsler JG. **Internist (Berl)** 1997 Mar;38(3):231-6 (25 ref.) **(Ger)**
[Leptin and its biological and clinical significance. Is leptin and insulin resistance in the X-5H hormonal metabolic syndrome a parallel or causally-linked phenomenon?] Hrnčiar J. **Vnitr Lek** 1997 Feb;43(2):120-4 (21 ref.) (Eng. Abstr.) **(Slo)**
[Insulin as vasoactive hormone. Significance for diabetes, obesity and hypertension] Lind L, et al. **Lakartidningen** 1997 Aug 6;94(32-33):2730-2 (47 ref.) **(Swe)**

PREVENTION & CONTROL

Key issues in the prevention of obesity. Gill TP. **Br Med Bull** 1997;53(2):359-88 (107 ref.)
Coherent, preventive and management strategies for obesity. Bray GA. **Ciba Found Symp** 1996;201:228-46; discussion 246-54 (80 ref.)
Exercise and the metabolic syndrome. Eriksson J, et al. **Diabetologia** 1997 Feb;40(2):125-35 (163 ref.)
Position of the American Dietetic Association: weight management. **J Am Diet Assoc** 1997 Jan;97(1):71-4 (44 ref.)
The impact of obesity on hypertension management in African Americans. Kumanyika SK. **J Health Care Poor Underserved** 1997 Aug;8(3):352-64; discussion 364-5 (31 ref.)
Fear of fatness and adolescent girls: implications for obesity prevention. Flynn MA. **Proc Nutr Soc** 1997 Mar; 56(1B):305-17 (73 ref.)
Physical activity in the prevention and management of obesity. Stich V, et al. **World Rev Nutr Diet** 1997;82:219-28 (68 ref.)

PSYCHOLOGY

The economic and psychosocial consequences of obesity. Rissanen AM. **Ciba Found Symp** 1996;201:194-201; discussion 201-6 (26 ref.)
Fear of fatness and adolescent girls: implications for obesity prevention. Flynn MA. **Proc Nutr Soc** 1997 Mar; 56(1B):305-17 (73 ref.)

SURGERY

Obesity. Nolan JJ, et al. **Curr Ther Endocrinol Metab** 1997; 6:505-9 (10 ref.)
Surgery for obesity. Greenway FL. **Endocrinol Metab Clin North Am** 1996 Dec;25(4):1005-27 (190 ref.)
[Superficial liposuction: a new treatment for lipodystrophies] Adant JP, et al. **Rev Med Liege** 1997;52(7):463-8 (12 ref.) **(Fre)**
[The surgical treatment of obesity] Sedletskiĭ IuI, et al. **Vestn Khir Im I I Grek** 1996;155(6):100-4 (46 ref.) **(Rus)**
[Survey of morbid obesity: current knowledge] Baltasar A. **Rev Neurol** 1996 Apr;24(128):406-11 (32 ref.) **(Spa)**

THERAPY

Future directions in obesity and eating disorders. Foreyt JP, et al. **Addict Behav** 1996 Nov-Dec;21(6):767-78 (105 ref.)
Management of obesity: medical treatment options. Carek PJ, et al. **Am Fam Physician** 1997 Feb 1;55(2):551-8, 561-2 (31 ref.)
Obesity management by life-style strategies. Cowburn G, et al. **Br Med Bull** 1997;53(2):389-408 (92 ref.)
Coherent, preventive and management strategies for obesity. Bray GA. **Ciba Found Symp** 1996;201:228-46; discussion 246-54 (80 ref.)
Office management of the adult obese patient. Kushner RF. **Compr Ther** 1997 Feb;23(2):116-23 (27 ref.)
Obesity. Nolan JJ, et al. **Curr Ther Endocrinol Metab** 1997; 6:505-9 (10 ref.)
Obesity: evaluation and treatment. Blocker WP Jr, et al. **Dis Mon** 1996 Dec;42(12):829-73 (93 ref.)
Behavioral therapy for obesity. Williamson DA, et al. **Endocrinol Metab Clin North Am** 1996 Dec;25(4):943-54 (47 ref.)
Exercise as treatment for obesity. Zachwieja JJ. **Endocrinol Metab Clin North Am** 1996 Dec;25(4):965-88 (113 ref.)
Defining success in obesity management. Rössner S. **Int J Obes Relat Metab Disord** 1997 Mar;21 Suppl 1:S2-4 (15 ref.)
Long-term intervention strategies in obesity treatment. Rössner S. **Int J Obes Relat Metab Disord** 1995 Dec;19 Suppl 7:S29-S33 discussion S34-S35 (26 ref.)
Strategies for weight control success in adults. Keller C, et al. **Nurse Pract** 1997 Mar;22(3):33, 37-8, 40 passim (43 ref.)
Syndrome X. Recognition and management of this metabolic disorder in primary care. Minchoff LE, et al. **Nurse Pract** 1996 Jun;21(6):74-5, 79-80, 83-6 (30 ref.)
Pediatric obesity. An overview of etiology and treatment. Schonfeld-Warden N, et al. **Pediatr Clin North Am** 1997 Apr;44(2):339-61 (157 ref.)
Why is the treatment of cancer more successful than that of obesity? Berry EM. **Public Health Rev** 1996;24(2):147-63 (29 ref.)
Current management of obesity. Cheah JS. **Singapore Med J** 1996 Jun;37(3):299-303 (32 ref.)
Roles of mental health professionals in multidisciplinary medically supervised treatment programs for obesity. Hunter SM, et al. **South Med J** 1997 Jun;90(6):578-86 (76 ref.)
The importance of fat free mass maintenance in weight loss programmes. Marks BL, et al. **Sports Med** 1996 Nov; 22(5):273-81 (45 ref.)
Physical activity in the prevention and management of obesity. Stich V, et al. **World Rev Nutr Diet** 1997;82:219-28 (68 ref.)
[Health risks and economic costs associated with obesity requiring a comprehensive weight reduction program] Hainer V, et al. **Cas Lek Cesk** 1997 Jun 12;136(12):367-72 (45 ref.) (Eng. Abstr.) **(Cze)**
[Strategies in therapy of obesity] Hauner H. **Internist (Berl)** 1997 Mar;38(3):244-50 (30 ref.) **(Ger)**
[Obesity (see comments)] Müller MJ. **Internist (Berl)** 1996 Jan;37(1):101-17; quiz 118 (10 ref.) Comment in: Internist (Berl) 1996 Jun;37(6):647-8; discussion 650-2. **(Ger)**

OBESITY IN DIABETES

BLOOD

The fat mouse: a powerful genetic model to study elevated plasminogen activator inhibitor 1 in obesity/NIDDM. Samad F, et al. **Thromb Haemost** 1997 Jul;78(1):652-5 (44 ref.)

COMPLICATIONS

Therapeutic challenges in the obese diabetic patient with hypertension. Bakris GL, et al. **Am J Med** 1996 Sep 30; 101(3A):33S-46S (205 ref.)
Obesity, non-insulin-dependent diabetes mellitus and the metabolic syndrome. Kopelman PG, et al. **Br Med Bull** 1997;53(2):322-40 (95 ref.)

ETIOLOGY

The origins and consequences of obesity. Diabetes. Björntorp P. **Ciba Found Symp** 1996;201:68-80; discussion 80-9, 188-93 (85 ref.)

OBESITY IN DIABETES

GENETICS

The genetics of human noninsulin-dependent (type 2) diabetes mellitus. Elbein SC. **J Nutr** 1997 Sep; 127(9):1891S-1896S (49 ref.)

[Obesity and type ii diabetes mellitus] Schmülling RM. **Internist (Berl)** 1997 Mar;38(3):224-30 (33 ref.) **(Ger)**

METABOLISM

R.D. Lawrence Lecture 1995 Mrs Sprat's diabetes: some metabolic insights. Coppack SW. **Diabet Med** 1996 Jul; 13(7):616-24 (87 ref.)

[1996 Maurice Dérot Prize. Obesity in diabetes: substrate competition] Felber JP. **Journ Annu Diabetol Hotel Dieu** 1996;:157-65 (28 ref.) **(Fre)**

PHYSIOPATHOLOGY

The benefits of modest weight loss in type II diabetes. Bosello O, et al. **Int J Obes Relat Metab Disord** 1997 Mar;21 Suppl 1:S10-3 (44 ref.)

Obesity, diabetes and functions for proopiomelanocortin-derived peptides. Mountjoy KG, et al. **Mol Cell Endocrinol** 1997 Apr 4;128(1-2):171-7 (51 ref.)

OBESITY, MORBID

see related
GASTROPLASTY
JEJUNOILEAL BYPASS

DIET THERAPY

The protein-sparing modified fast for obesity-related medical problems. Walters JK, et al. **Cleve Clin J Med** 1997 May; 64(5):242-4 (9 ref.)

GENETICS

[Euphenic prevention of obesity at the Optimal Family Planning Service in Hungary] Miklós J, et al. **Orv Hetil** 1996 Nov 10;137(45):2517-22 (39 ref.) (Eng. Abstr.) **(Hun)**

PATHOLOGY

Endoscopic evaluation of the postoperative stomach. Mellinger JD, et al. **Gastrointest Endosc Clin N Am** 1996 Jul;6(3):621-39 (59 ref.)

SURGERY

Surgery for morbid obesity. Desaive C. **Acta Chir Belg** 1996 Sep-Oct;96(5):192-6 (13 ref.)

Surgical treatment for morbid obesity. Kolanowski J. **Br Med Bull** 1997;53(2):433-44 (32 ref.)

Laparoscopic adjustable silicone gastric banding in the treatment of super obesity in the Jeddah area, Saudi Arabia. A preliminary report. Ashy AA, et al. **Int Surg** 1996 Jul-Sep;81(3):289-91 (16 ref.)

Surgical treatment of obesity: who is an appropriate candidate? Balsiger BM, et al. **Mayo Clin Proc** 1997 Jun; 72(6):551-7; quiz 558 (13 ref.)

Gastrointestinal surgery for severe obesity. NIH consensus development conference, March 25-7,1991. **Nutrition** 1996 Jun;12(6):397-404 (0 ref.)

Update: NIH consensus conference. Gastrointestinal surgery for severe obesity. Brolin RE. **Nutrition** 1996 Jun; 12(6):403-4 (13 ref.)

[The treatment of morbid obesity with gastroplasty] Houben JJ, et al. **Rev Med Brux** 1996 Sep;17(4):236-9 (14 ref.) (Eng. Abstr.) **(Fre)**

[Plastic surgery in the treatment of the outcome of intestinal bypass for obesity: a clinical case report] Bernardi C, et al. **G Chir** 1996 Nov-Dec;17(11-12):602-6 (15 ref.) (Eng. Abstr.) **(Ita)**

[Surgical treatment of morbid obesity] Lavrik AS, et al. **Klin Khir** 1997;(1):42-7 (68 ref.) **(Rus)**

OBJECT ATTACHMENT

Object relations couple therapy. Scharff JS, et al. **Am J Psychother** 1997 Spring;51(2):141-73 (75 ref.)

Peptides, steroids, and pair bonding. Carter CS, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:260-72 (33 ref.)

Molecular aspects of monogamy. Insel TR, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:302-16 (44 ref.)

Early learning and the social bond. Keverne EB, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:329-39 (32 ref.)

Affiliation and neuropsychiatric disorders: the deficit syndrome of schizophrenia. Kirkpatrick B. **Ann N Y Acad Sci** 1997 Jan 15;807:455-68 (69 ref.)

Psychobiology of early social attachment in rhesus monkeys. Clinical implications. Kraemer GW. **Ann N Y Acad Sci** 1997 Jan 15;807:401-18 (34 ref.)

Psychobiological consequences of social relationships. Levine S, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:210-8 (58 ref.)

Attachment relationships in New World primates. Mendoza SP, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:203-9 (24 ref.)

Reflective capacity and its significance to the attachment concept of the self. West ML. **Br J Med Psychol** 1997 Mar;70 (Pt 1):17-25 (45 ref.)

Offspring-induced nurturance: animal-human parallels. Stern JM. **Dev Psychobiol** 1997 Jul;31(1):19-37 (114 ref.)

Proposal for a structured assessment of parenting based on attachment theory: theoretical background, description and initial clinical experience. Green JM. **Eur Child Adolesc Psychiatry** 1996 Sep;5(3):133-8 (46 ref.)

Older people and attachment to things, places, pets, and ideas. Cookman CA. **Image J Nurs Sch** 1996 Fall;28(3):227-31 (56 ref.)

Attachment disruption in anorexia nervosa and bulimia nervosa: a review of theory and empirical research. O'Kearney R. **Int J Eat Disord** 1996 Sep;20(2):115-27 (74 ref.)

Dead babies and the birth of desire: maternal erotic transferences and countertransferences. Wrye HK. **J Am Acad Psychoanal** 1996 Spring;24(1):75-94 (14 ref.)

The primal scene: variations on a theme. Knafo D, et al. **J Am Psychoanal Assoc** 1996;44(2):549-69 (41 ref.)

Epilogue: bridging the gap between research on attachment and psychopathology. del Carmen R, et al. **J Consult Clin Psychol** 1996 Apr;64(2):291-4 (33 ref.)

Attachment relationships among children with aggressive behavior problems: the role of disorganized early attachment patterns. Lyons-Ruth K. **J Consult Clin Psychol** 1996 Feb;64(1):64-73 (92 ref.)

Introduction to the special section on attachment and psychopathology: 2. Overview of the field of attachment. Main M. **J Consult Clin Psychol** 1996 Apr;64(2):237-43 (50 ref.)

Adolescent attachment and psychopathology. Rosenstein DS, et al. **J Consult Clin Psychol** 1996 Apr;64(2):244-53 (45 ref.)

Beyond insecurity: a reconceptualization of attachment disorders of infancy. Zeanah CH. **J Consult Clin Psychol** 1996 Feb;64(1):42-52 (85 ref.)

Attachment transition, addiction and therapeutic bonding--an integrative approach. Höfler DZ, et al. **J Subst Abuse Treat** 1996 Nov-Dec;13(6):511-9 (56 ref.)

Cooperative care of young in mammals. König B. **Naturwissenschaften** 1997 Mar;84(3):95-104 (95 ref.)

Affect, attachment, memory: contributions toward psychobiologic integration. Amini F, et al. **Psychiatry** 1996 Fall;59(3):213-39 (113 ref.)

OBJECT RELATIONS see **OBJECT ATTACHMENT**

OBLIGATION, SOCIAL see **SOCIAL RESPONSIBILITY**

OBSERVATION

Early-stage prostate cancer. When is observation appropriate? Albertsen PC. **Hematol Oncol Clin North Am** 1996 Jun;10(3):611-25 (40 ref.)

METHODS

Communication, accrual to clinical trials, and the physician-patient relationship: implications for training programs. Ruckdeschel JC, et al. **J Cancer Educ** 1996 Summer;11(2):73-9 (51 ref.)

OBSERVER BIAS see **OBSERVER VARIATION**

OBSERVER VARIATION

Medical examiner variability. Hinchcliffe R. **J Laryngol Otol** 1997 Jan;111(1):8-14 (25 ref.)

Unified measurement of observer performance in detecting and localizing target objects on images. Swensson RG. **Med Phys** 1996 Oct;23(10):1709-25 (62 ref.)

[Interrater reliability of instruments for the evaluation of needs of bedridden persons: a review of the international literature] Kliebsch U, et al. **Soz Praventivmed** 1996; 41(5):303-14 (32 ref.) (Eng. Abstr.) **(Ger)**

OBSESSIVE-COMPULSIVE DISORDER

Neuropsychiatric disorders of childhood: Tourette's syndrome as a model. Cohen DJ, et al. **Acta Paediatr Suppl** 1997 Jul;422:106-11 (28 ref.)

Obsessive-compulsive disorder. Warnock JK, et al. **Dermatol Clin** 1996 Jul;14(3):465-72 (54 ref.)

Selections from current literature: obsessive compulsive disorder. Levine N. **Fam Pract** 1997 Jun;14(3):258-61 (28 ref.)

New developments in obsessive-compulsive disorder research: implications for clinical management. Sasson Y, et al. **Int Clin Psychopharmacol** 1996 Dec;11 Suppl 5:3-12 (88 ref.)

Increased writing activity in neurological conditions: a review and clinical study. van Vugt P, et al. **J Neurol Neurosurg Psychiatry** 1996 Nov;61(5):510-4 (22 ref.)

Obsessive compulsive disorder--a neuropsychiatric illness. Ko SM. **Singapore Med J** 1996 Apr;37(2):186-8 (48 ref.)

[Compulsive syndromes in children and adolescents. Often a curse for the whole family] Ivarsson T. **Lakartidningen** 1997 Feb 5;94(6):420-2, 427 (38 ref.) **(Swe)**

COMPLICATIONS

The course and prognosis of Tourette syndrome. Bruun RD, et al. **Neurol Clin** 1997 May;15(2):291-8 (38 ref.)

Tics and fits. The current status of Gilles de la Tourette syndrome and its relationship with epilepsy. Rickards H. **Seizure** 1995 Dec;4(4):259-66 (77 ref.)

[Clinical considerations regarding co-morbidity in childhood and adolescent anxiety disorders] Ballesteros Alcalde MC, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 Nov-Dec;24(6):339-52 (45 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Morbid jealousy as a variant of obsessive-compulsive disorder. Parker G, et al. **Aust N Z J Psychiatry** 1997 Feb; 31(1):133-8 (16 ref.)

Obsessive-compulsive disorder in children and adolescents: a review of the past 10 years. March JS, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Oct; 35(10):1265-73 (95 ref.)

Obsessive-compulsive disorder: diagnosis and treatment in the primary care setting. Gedenk M, et al. **J Am Board Fam Pract** 1997 Sep-Oct;10(5):349-56 (34 ref.)

Tourette syndrome. Neuropsychological tests for obsessive-compulsive disorder and attention deficit hyperactivity disorder. Como PG. **Neurol Clin** 1997 May; 15(2):255-65 (85 ref.)

[Perfectionism: conceptual and clinical aspects] Todorov C, et al. **Can J Psychiatry** 1996 Jun;41(5):291-8 (29 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder. Carpenter LL, et al. **Drug Saf** 1996 Aug;15(2):116-34 (156 ref.)

Refining treatment approaches in obsessive-compulsive disorder. Fineberg N. **Int Clin Psychopharmacol** 1996 Dec; 11 Suppl 5:13-22 (58 ref.)

Obsessive-compulsive disorder-related disorders: the role of selective serotonergic reuptake inhibitors. Hollander E. **Int Clin Psychopharmacol** 1996 Dec;11 Suppl 5:75-87 (61 ref.)

Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors [published erratum appears in Int Clin Psychopharmacol 1997 Mar;12(2):126] Lane RM. **Int Clin Psychopharmacol** 1996 Dec;11 Suppl 5:31-61 (266 ref.)

Long-term management of obsessive-compulsive disorder. Montgomery SA. **Int Clin Psychopharmacol** 1996 Dec;11 Suppl 5:23-9 (35 ref.)

Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions. Goodman WK, et al. **J Clin Psychiatry** 1997;58 Suppl 5:32-49 (200 ref.)

Tourette syndrome. Medical and surgical treatment of obsessive-compulsive disorder. Rapoport JL, et al. **Neurol Clin** 1997 May;15(2):421-8 (41 ref.)

Pharmacokinetic and pharmacodynamic drug interactions with polypharmacotherapy of treatment-resistant affective and obsessive-compulsive disorders. Carson SW. **Psychopharmacol Bull** 1996;32(4):555-68 (59 ref.)

Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder. Laird LK. **Psychopharmacol Bull** 1996;32(4):569-78 (83 ref.)

[The treatment of the resistant obsessive-compulsive disorder: an update] Crespo Facorro B, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1997 Jan-Feb;25(1):61-9 (106 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Three cases of symptom change in Tourette's syndrome and obsessive-compulsive disorder associated with paediatric cerebral malignancies. Peterson BS, et al. **J Neurol Neurosurg Psychiatry** 1996 Nov;61(5):497-505 (48 ref.)

PATHOLOGY

Anatomy and function of the orbital frontal cortex, II: Function and relevance to obsessive-compulsive disorder. Zald DH, et al. **J Neuropsychiatry Clin Neurosci** 1996 Summer;8(3):249-61 (115 ref.)

PHYSIOPATHOLOGY

Bipolar disorders, dystonia, and compulsion after dysfunction of the cerebellum, dentatorubrothalamic tract, and substantia nigra. Lauterbach EC. **Biol Psychiatry** 1996 Oct 15;40(8):726-30 (65 ref.)

The neuropsychology of obsessive-compulsive disorder: a review and consideration of clinical implications. Tallis F. **Br J Clin Psychol** 1997 Feb;36 (Pt 1):3-20 (130 ref.)

Anatomy and function of the orbital frontal cortex, II: Function and relevance to obsessive-compulsive disorder. Zald DH, et al. **J Neuropsychiatry Clin Neurosci** 1996 Summer;8(3):249-61 (115 ref.)

Anatomy and function of the orbital frontal cortex, I: anatomy, neurocircuitry; and obsessive-compulsive disorder. Zald DH, et al. **J Neuropsychiatry Clin Neurosci** 1996 Spring;8(2):125-38 (119 ref.)

PSYCHOLOGY

[Body dysmorphic disorder as an obsessive-compulsive spectrum disorder] Díaz Mársá M, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 Nov-Dec;24(6):331-7 (35 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Tourette syndrome. Medical and surgical treatment of obsessive-compulsive disorder. Rapoport JL, et al. **Neurol Clin** 1997 May;15(2):421-8 (41 ref.)

THERAPY

A review of cognitive behavioral and pharmacological treatment of body dysmorphic disorder. Neziroglu F, et al. **Behav Modif** 1997 Jul;21(3):324-40 (50 ref.)

Treatment of obsessive-compulsive disorder in children and adolescents. A review of the literature. Thomsen PH. **Eur Child Adolesc Psychiatry** 1996 Jun;5(2):55-66 (100 ref.)

Obsessive-compulsive disorder: adding value to treatment through patient support groups. Broatch JW. **Int Clin Psychopharmacol** 1996 Dec;11 Suppl 5:89-94 (21 ref.)

New developments in behaviour therapy for obsessive-compulsive disorder. Greist JH. **Int Clin Psychopharmacol** 1996 Dec;11 Suppl 5:63-73 (79 ref.)

Obsessive-compulsive disorder: diagnosis and treatment in the primary care setting. Gedenk M, et al. **J Am Board Fam Pract** 1997 Sep-Oct;10(5):349-56 (34 ref.)

OBSTETRICAL ANALGESIA see **ANALGESIA, OBSTETRICAL**

OBSTETRICAL FORCEPS

Failed trial of vacuum or forceps--maternal and fetal outcome. Revah A, et al. **Am J Obstet Gynecol** 1997 Jan; 176(1 Pt 1):200-4 (11 ref.)

Case report: unilateral combined facial nerve and brachial plexus palsies in a neonate following a midlevel forceps delivery. de Chalain TM, et al. **Ann Plast Surg** 1997 Feb; 38(2):187-90 (27 ref.)

ADVERSE EFFECTS

Forceps and vacuum injuries to the cornea: histopathologic features of twelve cases and review of the literature. Honig MA, et al. **Cornea** 1996 Sep;15(5):463-72 (27 ref.)

OBSTETRICAL NURSING

Nurse advocacy for selective versus routine episiotomy [see comments] Maier JS, et al. **J Obstet Gynecol Neonatal Nurs** 1997 Mar-Apr; 26(2):155-61 (52 ref.) Comment in: J Obstet Gynecol Neonatal Nurs 1997 Jul-Aug;26(4):373.

OBSTETRICS

see related
PREGNANCY COMPLICATIONS

Recent evolution within obstetrics. Nordic experience since the 1970s, as evidenced by statistics (editorial). Bergsjø P. **Acta Obstet Gynecol Scand** 1997 Aug;76(7):613-8 (11 ref.)

Responding to the ethical challenges posed by the business tools of managed care in the practice of obstetrics and gynecology. Chervenak FA, et al. **Am J Obstet Gynecol** 1996 Sep;175(3 Pt 1):523-7 (10 ref.)

Obstetrics in general practice. A rural perspective. Gillett JM. **Aust Fam Physician** 1997 Mar;26(3):263-9 (6 ref.)

What should obstetricians be doing about the Barker hypothesis? Fraser R Sr, et al. **Br J Obstet Gynaecol** 1997 Jun;104(6):645-7 (16 ref.)

Adolescent obstetrics and gynecology: children having children--can it be controlled? Plouffe L Jr, et al. **Curr Opin Obstet Gynecol** 1996 Oct;8(5):335-8 (21 ref.)

General obstetrics--prevention: the perinatal medicine of the future [editorial] Queenan JT. **Curr Opin Obstet Gynecol** 1996 Dec;8(6):391-3 (16 ref.)

Obstetric and gynecologic emergencies. Nadel E, et al. **Emerg Med Clin North Am** 1997 May;15(2):389-97 (49 ref.)

Ethical issues in obstetrics. Samsioe G, et al. **Int J Fertil Menopausal Stud** 1996 May-Jun;41(3):284-7 (2 ref.)

Genetic counseling in perinatal medicine. Milunsky JM, et al. **Obstet Gynecol Clin North Am** 1997 Mar;24(1):1-17 (63 ref.)

Relevance of molecular medicine to clinical obstetrics and gynecology. Cohen DP, et al. **Obstet Gynecol Surv** 1997 Jan;52(1):73-80 (29 ref.)

EDUCATION

Preparing obstetricians and gynecologists for capitation. Huey JR Jr, et al. **Clin Obstet Gynecol** 1997 Jun; 40(2):427-36 (12 ref.)

LEGISLATION & JURISPRUDENCE

Liability risks in gynaecology and obstetrics under German and Austrian law. Bernat E. **Med Law** 1995;14(5-6):413-23 (63 ref.)

METHODS

Amnioinfusion. Hofmeyr GJ, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Feb;64(2):159-65 (57 ref.)

ORGANIZATION & ADMINISTRATION

The spectrum of managed care model types. Fabius R. **Clin Obstet Gynecol** 1997 Jun;40(2):391-4 (0 ref.)

Preparing obstetricians and gynecologists for capitation. Huey JR Jr, et al. **Clin Obstet Gynecol** 1997 Jun; 40(2):427-36 (12 ref.)

Obstetrics/gynecology network development. Krieg KA. **Clin Obstet Gynecol** 1997 Jun;40(2):446-52 (5 ref.)

Obstetrician/gynecologist as primary care physician in managed health care. Pritzker J. **Clin Obstet Gynecol** 1997 Jun;40(2):402-13 (21 ref.)

Looking down the prospectoscope: obstetrics/gynecology in the year 2000 and beyond. Sanfilippo J. **Clin Obstet Gynecol** 1997 Jun;40(2):395-401 (0 ref.)

Managed care in obstetrics. Devoe LD. **Curr Opin Obstet Gynecol** 1997 Aug;9(4):258-61 (17 ref.)

The managed care of early pregnancy problems. Draycott T, et al. **Curr Opin Obstet Gynecol** 1997 Aug;9(4):262-6 (32 ref.)

Managed care in obstetrics. Richman RS. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):329-32 (33 ref.)

-Resistance to changes of medical procedures in obstetrics. The role of mass media and community medicine] Basevi V, et al. **Epidemiol Prev** 1994 Dec;18(61):194-9 (26 ref.) **(Ita)**

STANDARDS

Audit in obstetrics. Maresh MM, et al. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):296-9 (19 ref.)

High-risk obstetrics, medicolegal problems. Herczeg J. **Eur J Obstet Gynecol Reprod Biol** 1997 Feb;71(2):181-5 (14 ref.)

[Medical consensus practice guidelines in gynecology-obstetrics] Lansac J. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(2):124-30 (3 ref.) **(Fre)**

TRENDS

Operative vaginal delivery--year 2000 [see comments] Hankins GD, et al. **Am J Obstet Gynecol** 1996 Aug; 175(2):275-82 (25 ref.) Comment in: Am J Obstet Gynecol 1997 Jan;176(1 Pt 1):259.

Obstetrics. Judgment day in utero. Kent AP, et al. **Lancet** 1996 Dec 21-28;348 Suppl 2:sII16 (5 ref.)

OBTURATOR HERNIA see **HERNIA, OBTURATOR**

OBTURATOR NERVE

INJURIES

[Postpartum obturator nerve syndrome: case report and review of the nerve compression syndrome during pregnancy and delivery] Lindner A, et al. **Zentralbl Gynakol** 1997;119(3):93-9 (43 ref.) (Eng. Abstr.) **(Ger)**

OCCIPITAL BONE

ABNORMALITIES

An anatomic variation of the stylomastoid foramen. Celik HH, et al. **Bull Assoc Anat (Nancy)** 1997 Mar;81(252):17-8 (3 ref.)

Occipital plagiocephaly: deformation or lambdoid synostosis? II. A unifying theory regarding pathogenesis [see comments] Dias MS, et al. **Pediatr Neurosurg** 1996; 24(2):69-73 (28 ref.) Comment in: Pediatr Neurosurg 1996 Sep;25(3):164.

INJURIES

Posttraumatic intradiploic arachnoid cyst of the posterior fossa. Martínez-Lage JF, et al. **Childs Nerv Syst** 1997 May; 13(5):293-6 (15 ref.)

Occipital condyle fractures. Tuli S, et al. **Neurosurgery** 1997 Aug;41(2):368-76; discussion 376-7 (42 ref.)

OCCIPITAL LOBE

BLOOD SUPPLY

Arteriovenous malformation associated with pleomorphic xanthoastrocytoma. Lee TT, et al. **Acta Neurochir (Wien)** 1996;138(5):590-1 (5 ref.)

PHYSIOLOGY

Cellular basis of pontine ponto-geniculo-occipital wave generation and modulation. Datta S. **Cell Mol Neurobiol** 1997 Jun;17(3):341-65 (172 ref.)

Study of human occipital alpha rhythm: the alphon hypothesis and alpha suppression. Williamson SJ, et al. **Int J Psychophysiol** 1997 Jun;26(1-3):63-76 (35 ref.)

PHYSIOPATHOLOGY

Occipital-parietal encephalopathy: a new name for an old syndrome. Pavlakis SG, et al. **Pediatr Neurol** 1997 Feb; 16(2):145-8 (11 ref.)

SURGERY

Solitary Langerhans cell histiocytosis lesion of the parieto-occipital lobe: a case report and review of the literature. Bergmann M, et al. **Clin Neurol Neurosurg** 1997 Feb;99(1):50-5 (42 ref.)

OCCLUDING JUNCTIONS see **TIGHT JUNCTIONS**

OCCLUSAL ADJUSTMENT

The role of occlusal adjustment in the management of temporomandibular disorders. Kirveskari P. . **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jan;83(1):87-90 (24 ref.)

OCCLUSAL EQUILIBRATION see **OCCLUSAL ADJUSTMENT**

OCCLUSAL SPLINTS

Dentistry's role in obstructive sleep apnoea. Review and case report. Miles PG, et al. **Aust Dent J** 1996 Aug;41(4):248-51 (18 ref.)

An overview of bruxism and its management. Attanasio R. **Dent Clin North Am** 1997 Apr;41(2):229-41 (91 ref.)

Intraoral orthotic therapy. Attanasio R. **Dent Clin North Am** 1997 Apr;41(2):309-24 (105 ref.)

[Treatment of obstructive sleep apnea syndrome using a mandibular advancement prosthesis: review of the literature] Lockhart R, et al. **Rev Stomatol Chir Maxillofac** 1996 Dec;97(6):365-73 (56 ref.) (Eng. Abstr.) **(Fre)**

OCCLUSIVE DRESSINGS

Should we use occlusive dressings in the treatment of acute wounds? Lotti T, et al. **Int J Dermatol** 1997 Feb;36(2):97-9 (10 ref.)

OCCULT BLOOD

see related
MELENA

Screening for colorectal cancer with the fecal occult blood test: a background paper. American College of Physicians. Ransohoff DF, et al. **Ann Intern Med** 1997 May 15; 126(10):811-22 (82 ref.)

Fecal occult blood testing for colorectal cancer. Can we afford to do this? Ahlquist DA. **Gastroenterol Clin North Am** 1997 Mar;26(1):41-55 (73 ref.)

Fecal occult blood testing for colorectal cancer. Can we afford not to do this? Bond JH. **Gastroenterol Clin North Am** 1997 Mar;26(1):57-70 (51 ref.)

Rare causes of occult small intestinal bleeding, including aortoenteric fistulas, small bowel tumors, and small bowel ulcers. Bashir RM, et al. **Gastrointest Endosc Clin N Am** 1996 Oct;6(4):709-38 (238 ref.)

Occult gastrointestinal bleeding. General overview and approach. Mujica VR, et al. **Gastrointest Endosc Clin N Am** 1996 Oct;6(4):833-45 (43 ref.)

Decision making in colorectal cancer screening [editorial] Trowers E Jr, et al. **J Natl Med Assoc** 1997 Jan;89(1):9-12 (32 ref.)

Screening for colorectal cancer by immunochemical fecal occult blood testing. Saito H. **Jpn J Cancer Res** 1996 Oct; 87(10):1011-24 (89 ref.)

[Sensitivity of immunochemical occult blood testing in detecting early colorectal cancer] Saito H. **Nippon Rinsho** 1996 May;54(5):1421-4 (8 ref.) (Eng. Abstr.) **(Jpn)**

OCCULT PRIMARY NEOPLASMS see **NEOPLASMS, UNKNOWN PRIMARY**

OCCULT SPINA BIFIDA see **SPINA BIFIDA OCCULTA**

OCCULT SPINAL DYSRAPHISM see **SPINA BIFIDA OCCULTA**

OCCULTISM

The differential diagnosis of ritual abuse allegations. Bernet W, et al. **J Forensic Sci** 1997 Jan;42(1):32-8 (69 ref.)

[Sects, sectarisms and authentic spiritual pathways: can we learn to discern between them in order to counsel?] Wulliemier F. **Rev Med Suisse Romande** 1997 Jun; 117(6):525-33 (24 ref.) **(Fre)**

OCCUPATIONAL DERMATITIS see **DERMATITIS, OCCUPATIONAL**

OCCUPATIONAL AIR POLLUTANTS see **AIR POLLUTANTS, OCCUPATIONAL**

OCCUPATIONAL DISEASES

see related
ACCIDENTS, OCCUPATIONAL

Occupational lung disease. Schwartz DA, et al. **Adv Intern Med** 1997;42:269–312 (161 ref.)

Treatment of occupationally acquired low back pain. Daniels JM 2nd. **Am Fam Physician** 1997 Feb 1;55(2):587–96, 601–2 (21 ref.)

Nonspecific work–related upper extremity disorders [see comments] Downs DG. **Am Fam Physician** 1997 Mar; 55(4):1296–302 (22 ref.) Comment in: Am Fam Physician 1997 Mar;55(4):1029–30.

ABC of work related disorders. Working with an occupational health department. Adisesh A, et al. **BMJ** 1996 Oct 19;313(7063):999–1002 (0 ref.)

ABC of work related disorders. Absence from work. Briner RB. **BMJ** 1996 Oct 5;313(7061):874–7 (0 ref.)

ABC of work related disorders. Legal aspects. Davidson MJ. **BMJ** 1996 Nov 2;313(7065):1136–40 (0 ref.)

ABC of work related disorders. Women at work. Kapadia LH. **BMJ** 1996 Oct 26;313(7064):1073–6 (0 ref.)

ABC of work related disorders. Stress at work. von Onciul J. **BMJ** 1996 Sep 21;313(7059):745–8 (0 ref.)

Occupational stress and the law: some current issues for employers. Howard GS. **Br J Hosp Med** 1996 May 1–14; 55(9):563–6 (9 ref.)

Care of the professional voice. Irving RM, et al. **Clin Otolaryngol** 1997 Jun;22(3):202–5 (23 ref.)

Update on hypersensitivity pneumonitis. Craig TJ, et al. **Compr Ther** 1996 Sep;22(9):559–64 (24 ref.)

Sports–related and other soft–tissue injuries, tendinitis, bursitis, and occupation–related syndromes [see comments] Biundo JJ Jr, et al. **Curr Opin Rheumatol** 1997 Mar; 9(2):151–4 (20 ref.) Comment in: Curr Opin Rheumatol 1997 Mar;9(2):133–43.

Experimental research into the pathogenesis of cobalt/hard metal lung disease. Lison D, et al. **Eur Respir J** 1996 May; 9(5):1024–8 (21 ref.)

Occupational reproductive hazards. Paul M. **Lancet** 1997 May 10;349(9062):1385–8 (0 ref.)

Occupational asthma. Venables KM, et al. **Lancet** 1997 May 17;349(9063):1465–9 (36 ref.)

Repetitive strain injuries [see comments] Yassi A. **Lancet** 1997 Mar 29;349(9056):943–7 (29 ref.) Comment in: Lancet 1997 Jun 7;349(9066):1700–1. Comment in: Lancet 1997 Jun 7;349(9066):1701. Comment in: Lancet 1997 Jun 7;349(9066):1701–2.

A study of occupational asthma in New Jersey. Hudgins JF, et al. **N J Med** 1996 Jan;93(1):32–4 (18 ref.)

Cardiovascular disease among firefighters. Melius JM. **Occup Med** 1995 Oct–Dec;10(4):821–7 (45 ref.)

Pulmonary effects of firefighting. Scannell CH, et al. **Occup Med** 1995 Oct–Dec;10(4):789–801 (42 ref.)

Noise and hearing loss in firefighting. Tubbs RL. **Occup Med** 1995 Oct–Dec;10(4):843–56 (38 ref.)

Shoulder pain in the work place. Curtis AS, et al. **Orthop Clin North Am** 1996 Oct;27(4):763–81 (42 ref.)

Occupational soft–tissue and tendon disorders. Kasdan ML, et al. **Orthop Clin North Am** 1996 Oct;27(4):795–803 (20 ref.)

Occupational disorders of the foot and ankle. Trepman E, et al. **Orthop Clin North Am** 1996 Oct;27(4):815–29 (37 ref.)

Occupational knee injuries. Westrich GH, et al. **Orthop Clin North Am** 1996 Oct;27(4):805–14 (25 ref.)

Psychiatric illness in female physicians. Are high rates of depression an occupational hazard? North CS, et al. **Postgrad Med** 1997 May;101(5):233–6, 239–40, 242 (20 ref.)

Comparison of soybean epidemic asthma and occupational asthma. Antó JM, et al. **Thorax** 1996 Jul;51(7):743–9 (39 ref.)

[Progresses in occupational diseases in China, 1996] Ren Y, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Dec;76(12):931–2 (0 ref.) **(Chi)**

[Gulf War syndrome––more than meets the eye] Vidan A, et al. **Harefuah** 1996 Jul;131(1–2):27–30 (22 ref.) **(Heb)**

[Occupational dangers to health of nursing staffs in hemodialysis units] Washio M, et al. **Sangyo Ika Daigaku Zasshi** 1996 Sep 1;18(3):239–45 (20 ref.) (Eng. Abstr.) **(Jpn)**

CHEMICALLY INDUCED

Methyl iodide poisoning: report of two cases. Hermouet C, et al. **Am J Ind Med** 1996 Dec;30(6):759–64 (26 ref.)

Exposure to organic solvents and breast cancer in women: a hypothesis. Labrèche FP, et al. **Am J Ind Med** 1997 Jul; 32(1):1–14 (125 ref.)

Dose response relationship between occupational PAH exposure and lung cancer––an overview. Bolm–Audorff U. **Cent Eur J Public Health** 1996;4 Suppl:40 (42 ref.)

Interactive effects of polycyclic aromatic hydrocarbons and iron oxides particles. Epidemiological and fundamental aspects. Haguenoer JM, et al. **Cent Eur J Public Health** 1996;4 Suppl:41–5 (42 ref.)

Occupational neurotoxic diseases in Taiwan: a review of the outbreaks and clinical features. Huang CC, et al. **Chang Keng I Hsueh** 1997 Jun;20(2):71–8 (46 ref.)

Toxicology and epidemiology of 1,3–butadiene. Himmelstein MW, et al. **Crit Rev Toxicol** 1997 Jan;27(1):1–108 (239 ref.)

Does benzene cause multiple myeloma? An analysis of the published case–control literature. Bezabeh S, et al. **Environ Health Perspect** 1996 Dec;104 Suppl 6:1393–8 (28 ref.)

Clinical features of hematopoietic malignancies and related disorders among benzene–exposed workers in China. Benzene Study Group. Linet MS, et al. **Environ Health Perspect** 1996 Dec;104 Suppl 6:1353–64 (116 ref.)

Polycyclic aromatic hydrocarbons and cancer in man. Mastrangelo G, et al. **Environ Health Perspect** 1996 Nov; 104(11):1166–70 (33 ref.)

Cancer risk in the work place, including asbestos. Nicholson WJ. **Eur J Cancer Prev** 1996 Oct;5(5):393–6 (5 ref.)

Printing processes and printing inks. **IARC Monogr Eval Carcinog Risks Hum** 1996;65:33–147 (272 ref.)

Assessment of the health effects of trichloroethylene. Kaneko T, et al. **Ind Health** 1997 Jul;35(3):301–24 (97 ref.)

Silica–associated systemic erythematosus lupus or mineral dust lupus? Masson C, et al. **Lupus** 1997;6(1):1–3 (8 ref.)

Bilateral optic neuritis in occupational exposure to trichloroethylene. Abecia E, et al. **Med Lav** 1996 Sep–Oct; 87(5):432–6 (25 ref.)

Interpretation and use of occupational exposure limits for chronic disease agents. Hewett P. **Occup Med** 1996 Jul–Sep; 11(3):561–90 (125 ref.)

Epidemiology of occupational carcinogens and mutagens. Ruder AM. **Occup Med** 1996 Jul–Sep;11(3):487–512 (103 ref.)

Occupational toxicology: test methods and approaches for the pharmaceutical industry. Sprague G, et al. **Occup Med** 1997 Jan–Mar;12(1):119–29 (13 ref.)

Monitoring the pesticide–exposed worker. Wilson BW, et al. **Occup Med** 1997 Apr–Jun;12(2):347–63 (55 ref.)

Hydrogen sulphide. Guidotti TL. **Occup Med (Oxf)** 1996 Oct; 46(5):367–71 (45 ref.)

Lung cancer rates in carbon–black workers are discordant with predictions from rat bioassay data. Valberg PA, et al. **Regul Toxicol Pharmacol** 1996 Oct;24(2 Pt 1):155–70 (67 ref.)

Occupational and environmental renal disease. Wedeen RP. **Semin Nephrol** 1997 Jan;17(1):46–53 (35 ref.)

Butadiene epidemiology: a summary of results and outstanding issues. Acquavella JF. **Toxicology** 1996 Oct 28;113(1–3):148–56 (30 ref.)

[Hepatotoxic occupational risk factors] Tomei F, et al. **Minerva Med** 1996 Dec;87(12):585–98 (96 ref.) (Eng. Abstr.) **(Ita)**

[Epidemiology of lung cancer in former poison–gas workers and molecular approaches to lung cancer] Yamakido M. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:8–12 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Problems of environmental exposure to toxic effects of glutaraldehyde in medicine] Leszczyszyn J, et al. **Med Pr** 1997;48(3):335–40 (39 ref.) (Eng. Abstr.) **(Pol)**

[Changes in the nervous system during occupational exposure to manganese in light of the literature] Sinczuk–Walczak H. **Med Pr** 1996;47(6):657–61 (13 ref.) (Eng. Abstr.) **(Pol)**

[The reactive airways dysfunction syndrome induced by glue (letter)] Alvarez MJ, et al. **Med Clin (Barc)** 1996 Apr 6; 106(13):517–8 (5 ref.) **(Spa)**

COMPLICATIONS

Lead and cancer––association or causation? [editorial] Vainio H. **Scand J Work Environ Health** 1997 Feb;23(1):1–3 (24 ref.)

Disability resulting from occupational low back pain. Part II: What do we know about secondary prevention? A review of the scientific evidence on prevention after disability begins. Frank JW, et al. **Spine** 1996 Dec 15; 21(24):2918–29 (73 ref.)

DIAGNOSIS

ABC of work related disorders. Investigating suspected occupational illness and evaluating the workplace. Palmer K, et al. **BMJ** 1996 Sep 28;313(7060):809–11 (0 ref.)

Serial peak expiratory flow measurement in the diagnosis of occupational asthma. Gannon PF, et al. **Eur Respir J Suppl** 1997 Feb;24:57S–63S (32 ref.)

Diagnosis and treatment of organophosphate and carbamate intoxication. Wagner SL. **Occup Med** 1997 Apr–Jun; 12(2):239–49 (44 ref.)

Respiratory symptoms. Burge S. **Occup Med (Oxf)** 1997 Jan; 47(1):55–6 (6 ref.)

Chronic fatigue syndrome and occupational health. Mounstephen A, et al. **Occup Med (Oxf)** 1997 May; 47(4):217–27 (83 ref.)

Biomonitoring of occupational exposures to cytostatic anticancer drugs. Bos RP, et al. **Rev Environ Health** 1997 Jan–Mar;12(1):43–58 (104 ref.)

[Comments on the revision of the Königstein instructional pamphlet (see comments)] Plath P. **HNO** 1996 Aug; 44(8):431–9 (11 ref.) (Eng. Abstr.) Comment in: HNO 1997 May;45(5):356–8; discussion 358–9. **(Ger)**

[Glaucoma and aircraft pilot fitness] Schwartz R, et al. **Ophthalmologe** 1996 Feb;93(1):76–9 (18 ref.) (Eng. Abstr.) **(Ger)**

[Diagnostic problems and prophylaxis of paraoccupational diseases of the spine] Iżycki J. **Med Pr** 1996;47(6):651–5 (31 ref.) (Eng. Abstr.) **(Pol)**

ECONOMICS

Compensation for hearing loss. Dobie RA. **Audiology** 1996 Jan–Feb;35(1):1–7 (20 ref.)

EPIDEMIOLOGY

Risk of HIV infection in health care workers. Fahrner R. **AIDS Clin Rev** 1997–98;:93–107 (15 ref.)

Methodological challenges to the study of occupational injury––an international epidemiology workshop. Courtney TK, et al. **Am J Ind Med** 1997 Aug;32(2):103–5 (15 ref.)

Lung cancer and asbestos exposure: asbestosis is not necessary. Egilman D, et al. **Am J Ind Med** 1996 Oct; 30(4):398–406 (55 ref.)

Design factors in epidemiologic cohort studies of work–related low back injury or pain. Kraus JF, et al. **Am J Ind Med** 1997 Aug;32(2):153–63 (50 ref.)

Alternative approaches to analytical designs in occupational injury epidemiology. Mittleman MA, et al. **Am J Ind Med** 1997 Aug;32(2):129–41 (58 ref.)

Epidemiology of occupation and coronary heart disease: research agenda. Steenland K. **Am J Ind Med** 1996 Oct; 30(4):495–9 (31 ref.)

Venous insufficiency at work. Hobson J. **Angiology** 1997 Jul; 48(7):577–82 (19 ref.)

Nuclear energy facilities and cancers. Wakeford R, et al. **Ann Acad Med Singapore** 1996 May;25(3):468–76 (75 ref.)

Occupationally acquired infections in health care workers. Part II [published erratum appears in Ann Intern Med 1997 Apr 1;126(7):588] Sepkowitz KA. **Ann Intern Med** 1996 Dec 1;125(11):917–28 (279 ref.)

Inferences from occupational asthma. Cullinan P, et al. **Ciba Found Symp** 1997;206:160–8; discussion 168–72 (30 ref.)

Cancer mortality among petroleum refinery and chemical manufacturing workers in Texas. Cooper SP, et al. **J Environ Pathol Toxicol Oncol** 1997;16(1):1–14 (65 ref.)

Evidence for silica's neoplastic risk among workers and derivation of cancer risk assessment. Goldsmith DF. **J Expo Anal Environ Epidemiol** 1997 Jul–Sep;7(3):291–301 (46 ref.)

Occupational and geographical factors in the epidemiology of malignant mesothelioma. Ross D, et al. **Monaldi Arch Chest Dis** 1995 Dec;50(6):459–63 (47 ref.)

Application of meta–analysis in reviewing occupational cohort studies. Wong O, et al. **Occup Environ Med** 1996 Dec;53(12):793–800 (29 ref.)

Chronic occupational respiratory disease. Attfield MD, et al. **Occup Med** 1996 Jul–Sep;11(3):451–65 (53 ref.)

Epidemiology of occupational cancer. Bang KM. **Occup Med** 1996 Jul–Sep;11(3):467–85 (110 ref.)

Epidemiology of pesticide poisonings in the United States, with special reference to occupational cases. Blondell J. **Occup Med** 1997 Apr–Jun;12(2):209–20 (38 ref.)

Epidemiology of occupational disorders of the upper extremity. Cherniack MG. **Occup Med** 1996 Jul–Sep; 11(3):513–30 (90 ref.)

Epidemiology of work–related musculoskeletal disorders. Hales TR, et al. **Orthop Clin North Am** 1996 Oct; 27(4):679–709 (243 ref.)

Metal workers and repairmen at risk for prostate cancer: a review. van der Gulden JW. **Prostate** 1997 Feb 1; 30(2):107–16 (93 ref.)

Lung cancer rates in carbon–black workers are discordant with predictions from rat bioassay data. Valberg PA, et al. **Regul Toxicol Pharmacol** 1996 Oct;24(2 Pt 1):155–70 (67 ref.)

Quantification of historical exposures in occupational cohort studies [see comments] Stewart PA, et al. **Scand J Work Environ Health** 1996 Dec;22(6):405–14 (42 ref.) Comment in: Scand J Work Environ Health 1996 Dec;22(6):401–3.

[Occupational medicine significance of hepatitis C in health care employees] Hofmann F, et al. **Gesundheitswesen** 1997 Jul;59(7):452–60 (58 ref.) (Eng. Abstr.) **(Ger)**

[Environmental and occupational diseases] Baur X, et al. **Pneumologie** 1996 Sep;50 Suppl 2:604–6 (15 ref.) **(Ger)**

[Risk of hepatitis C virus infection in medical occupations] Kaufmann M, et al. **Versicherungsmedizin** 1997 Aug 1; 49(4):132–4 (21 ref.) (Eng. Abstr.) **(Ger)**

[Epidemiology of stress fractures from an occupational health viewpoint] Bräunlich A, et al. **Z Orthop Ihre Grenzgeb** 1996 Nov–Dec;134(6):553–61 (67 ref.) (Eng. Abstr.) **(Ger)**

[Work–related diseases––a medical problem or a social problem?] Iżycki J. **Med Pr** 1996;47(1):55–62 (37 ref.) (Eng. Abstr.) **(Pol)**

[Laboratory animals as a cause of occupational allergy] Krakowiak A, et al. **Med Pr** 1996;47(5):523–31 (55 ref.) (Eng. Abstr.) **(Pol)**

[Risk of neoplastic disease in workers from petroleum refineries and in persons employed in fuel distribution] Pepłońska B. **Med Pr** 1995;46(6):603–17 (37 ref.) (Eng. Abstr.) **(Pol)**

[An attempt to identify an increased incidence of occupational laryngeal diseases in teachers] Wośkowiak G. **Med Pr** 1996;47(5):519–22 (14 ref.) (Eng. Abstr.) **(Pol)**

ETHNOLOGY

Women, alcohol and work: interactions of gender, ethnicity and occupational culture. Ames GM, et al. **Soc Sci Med** 1996 Dec;43(11):1649–63 (100 ref.)

ETIOLOGY

Review on buckwheat allergy. Wieslander G. **Allergy** 1996 Oct;51(10):661–5 (25 ref.)

Cardiovascular disease and occupational exposure to environmental tobacco smoke. Aviado DM. **Am Ind Hyg Assoc J** 1996 Mar;57(3):285–94 (75 ref.)

What to do about softwood? A review of respiratory effects and recommendations regarding exposure limits. Demers PA, et al. **Am J Ind Med** 1997 Apr;31(4):385–98 (72 ref.)

Is self-reported pain an appropriate outcome measure in ergonomic–epidemiologic studies of work-related musculoskeletal disorders? Schierhout GH, et al. **Am J Ind Med** 1996 Jul;30(1):93–8 (45 ref.)

Chrysotile asbestos is the main cause of pleural mesothelioma. Smith AH, et al. **Am J Ind Med** 1996 Sep;30(3):252–66 (113 ref.)

Health effects of working in pulp and paper mills: malignant diseases [see comments] Torén K, et al. **Am J Ind Med** 1996 Feb;29(2):123–30 (48 ref.) Comment in: Am J Ind Med 1996 Nov;30(5):641.

Health effects of working in pulp and paper mills: exposure, obstructive airways diseases, hypersensitivity reactions, and cardiovascular diseases. Torén K, et al. **Am J Ind Med** 1996 Feb;29(2):111–22 (75 ref.)

Occupationally acquired HIV: the vulnerability of health care workers under workers' compensation laws. Tereskerz PM, et al. **Am J Public Health** 1997 Sep;87(9):1558–62 (36 ref.)

Latex allergy: an emerging clinical and occupational health problem. Kam PC, et al. **Anaesthesia** 1997 Jun;52(6):570–5 (45 ref.)

Occupational transmission of tuberculosis: implications for anesthesiologists. Tait AR. **Anesth Analg** 1997 Aug; 85(2):444–51 (74 ref.)

Occupationally acquired infections in health care workers. Part I. Sepkowitz KA. **Ann Intern Med** 1996 Nov 15; 125(10):826–34 (202 ref.)

Occupational activity and the risk of hip osteoarthritis. Cooper C, et al. **Ann Rheum Dis** 1996 Sep;55(9):680–2 (20 ref.)

Stress in the workplace. Cooper CL. **Br J Hosp Med** 1996 May 1–14;55(9):559–63 (22 ref.)

Occupational medicine and rheumatic diseases [editorial] Harrington JM. **Br J Rheumatol** 1997 Feb;36(2):153–4 (12 ref.)

Back pain in the workplace. Ratti N, et al. **Br J Rheumatol** 1997 Feb;36(2):260–4 (26 ref.)

Managing latex allergy in patients and health care workers. Melton AL. **Cleve Clin J Med** 1997 Feb;64(2):76–82 (60 ref.)

Aetiology of occupational asthma. Cullinan P, et al. **Clin Exp Allergy** 1997 May;27 Suppl 1:41–6 (29 ref.)

Mechanisms of occupational asthma. Maestrelli P, et al. **Clin Exp Allergy** 1997 May;27 Suppl 1:47–54 (83 ref.)

Occupational asthma. Dykewicz MS. **Compr Ther** 1997 Feb; 23(2):141–7 (7 ref.)

Occupational lung disease and the role of peptide growth factors. Brody AR. **Curr Opin Pulm Med** 1997 May; 3(3):203–8 (37 ref.)

Special problems of the asthmatic patient. Wallace JM, et al. **Curr Opin Pulm Med** 1997 Jan;3(1):72–9 (60 ref.)

Nearwork-induced transient myopia: a critical review. Ong E, et al. **Doc Ophthalmol** 1995;91(1):57–85 (64 ref.)

The role of oxygen free radicals in occupational and environmental lung diseases. Vallyathan V, et al. **Environ Health Perspect** 1997 Feb;105 Suppl 1:165–77 (147 ref.)

Occupational risk factors for gastric cancer: an overview. Cocco P, et al. **Epidemiol Rev** 1996;18(2):218–34 (231 ref.)

Type I allergies to latex and the aeroallergenic problem. Heese A, et al. **Eur J Surg Suppl** 1997;(579):19–22 (14 ref.)

Adverse effects of colophony. Keira T, et al. **Ind Health** 1997;35(1):1–7 (63 ref.)

Kienböck's disease. I. Anatomy and Etiology. Fredericks TK, et al. **Int J Occup Med Environ Health** 1997;10(1):11–7 (21 ref.)

Chemical toxicity and reactive oxygen species. Parke DV, et al. **Int J Occup Med Environ Health** 1996;9(4):331–40 (45 ref.)

Repetitive upper-extremity motions in the workplace are not hazardous [see comments] Hadler NM. **J Hand Surg [Am]** 1997 Jan;22(1):19–29 (47 ref.) Comment in: J Hand Surg [Am] 1997 Jan;22(1):1.

Repetitive strain in the workplace [see comments] Mackinnon SE, et al. **J Hand Surg [Am]** 1997 Jan;22(1):2–18 (118 ref.) Comment in: J Hand Surg [Am] 1997 Jan;22(1):1.

Wood dust and nasal cancer risk. A review of the evidence from North America. Blot WJ, et al. **J Occup Environ Med** 1997 Feb;39(2):148–56 (51 ref.)

The influence of personal variables on work-related low-back disorders and implications for future research. Dempsey PG, et al. **J Occup Environ Med** 1997 Aug; 39(8):748–59 (99 ref.)

Whole-body vibration exposure and occupational work-hardening [editorial] Wasserman DE, et al. **J Occup Environ Med** 1997 May;39(5):403–7 (56 ref.)

Multiple chemical sensitivity: state of the art symposium. The role of chemical allergens. Bernstein DI. **Regul Toxicol Pharmacol** 1996 Aug;24(1 Pt 2):S28–31 (18 ref.)

The impact of occupation on self-reported cardiovascular morbidity in western Germany: gender differences. Helmert U, et al. **Rev Environ Health** 1997 Jan–Mar; 12(1):25–42 (41 ref.)

Occupation as a risk factor for knee disorders. Jensen LK, et al. **Scand J Work Environ Health** 1996 Jun;22(3):165–75 (72 ref.)

Back pain in the workplace. What you lift or how you lift matters far less than whether you lift or when [editorial] Hadler NM. **Spine** 1997 May 1;22(9):935–40 (41 ref.)

Occupational and chronic obstructive pulmonary disease (COPD) [see comments] Hendrick DJ. **Thorax** 1996 Sep; 51(9):947–55 (60 ref.) Comment in: Thorax 1997 Apr;52(4):399–400.

[Occupational environment and strain induced gout. A review of epidemiological studies of the connection between occupational environment and coxarthrosis] Bøggild H, et al. **Ugeskr Laeger** 1997 Jul 7;159(28):4370–6 (38 ref.) (Eng. Abstr.) **(Dan)**

[Epicondylitis and tenosynovitis or peritendinitis as an occupational disease] Kivi P, et al. **Duodecim** 1995; 111(17):1703–7 (8 ref.) **(Fin)**

[Room air allergens: clinical significance, detection and prevention] Müsken H. **Pneumologie** 1996 Feb;50(2):168–76 (119 ref.) **(Ger)**

[List of potential etiological agents in occupationally-induced asthmatic diseases] Nowak D. **Pneumologie** 1996 Dec; 50(12):875–88 (258 ref.) **(Ger)**

[Sick building syndrome] Brede-Weisflog B. **Versicherungsmedizin** 1996 Oct 1;48(5):170–4 (17 ref.) (Eng. Abstr.) **(Ger)**

[Neuropsychologic effects of occupational exposure to manganese] Bazylewicz-Walczak B. **Med Pr** 1996; 47(6):677–83 (15 ref.) (Eng. Abstr.) **(Pol)**

[Hazards to workers' health caused by work-related psychosocial factors--a challenge to occupational health services] Dudek B, et al. **Med Pr** 1996;47(1):63–72 (12 ref.) (Eng. Abstr.) **(Pol)**

[Problems evaluating the risk of occupational neoplasms in persons exposed to ionizing radiation] Jankowski J. **Med Pr** 1996;47(6):615–27 (62 ref.) (Eng. Abstr.) **(Pol)**

[Occupational immediate allergy to latex. I. Introduction, epidemiology and clinical findings] Pałczyński C, et al. **Med Pr** 1997;48(3):317–23 (15 ref.) (Eng. Abstr.) **(Pol)**

[Eye fatigue during work with computer monitors] Salomon E, et al. **Med Pr** 1997;48(3):341–6 (39 ref.) **(Pol)**

[Documentation problems for occupationally related neoplastic diseases] Szeszenia-Dąbrowska N. **Med Pr** 1997; 48(2):189–95 (2 ref.) (Eng. Abstr.) **(Pol)**

[Epidemiological and etiopathological aspects of compression neuropathies of the lower limbs caused by adverse occupational factors (review of the literature)] Matveeva OV. **Med Tr Prom Ekol** 1997;(2):34–40 (77 ref.) **(Rus)**

GENETICS

Molecular biomarkers of occupational lung cancer. Talaska G, et al. **Yonsei Med J** 1996 Feb;37(1):1–18 (61 ref.)

IMMUNOLOGY

Mechanisms of occupational asthma. Maestrelli P, et al. **Clin Exp Allergy** 1997 May;27 Suppl 1:47–54 (83 ref.)

[Allergic and irritative disease caused by gloves in the health setting and their prevention. Consensus document of the Italian Preventive Society of Health Laboratories (news)] **Med Lav** 1996 Jul–Aug;87(4):350–9 (0 ref.) **(Ita)**

MORTALITY

Cancer mortality among petroleum refinery and chemical manufacturing workers in Texas. Cooper SP, et al. **J Environ Pathol Toxicol Oncol** 1997;16(1):1–14 (65 ref.)

Death due to asthma at workplace in a diphenylmethane diisocyanate-sensitized subject. Carino M, et al. **Respiration** 1997;64(1):111–3 (16 ref.)

PATHOLOGY

Osteoarthrosis of the knee and physical load from occupation. Vingård E. **Ann Rheum Dis** 1996 Sep;55(9):677–9 (23 ref.)

PHYSIOPATHOLOGY

Vibration syndrome and autonomic nervous system. Sakakibara H, et al. **Cent Eur J Public Health** 1995;3 Suppl:11–4 (56 ref.)

Occupational diseases–a mini review. Ficarra BJ. **J Med** 1996; 27(1–2):7–19 (7 ref.)

PREVENTION & CONTROL

New recommendations for prophylaxis after HIV exposure. Perlmutter BL, et al. **Am Fam Physician** 1997 Feb 1; 55(2):507–12, 515–7 (22 ref.)

Outcome studies in industry: cost-effectiveness of cumulative trauma disorder prevention. Mitchell CS. **Am J Ind Med** 1996 Jun;29(6):689–96 (34 ref.)

Review of applicability of existing functional status measures to the study of workers with musculoskeletal disorders of the neck and upper limb. Stock SR, et al. **Am J Ind Med** 1996 Jun;29(6):679–88 (102 ref.)

Design and conduct of occupational injury intervention studies: a review of evaluation strategies. Zwerling C, et al. **Am J Ind Med** 1997 Aug;32(2):164–79 (105 ref.)

Managing latex allergy in patients and health care workers. Melton AL. **Cleve Clin J Med** 1997 Feb;64(2):76–82 (60 ref.)

A new trend in the study of low back pain in workplaces. Yamamoto S. **Ind Health** 1997 Apr;35(2):173–85 (120 ref.)

Work-related back pain in nurses. Hignett S. **J Adv Nurs** 1996 Jun;23(6):1238–46 (80 ref.)

TB and dentistry. Younai FS, et al. **N Y State Dent J** 1997 Jan;63(1):49–53 (29 ref.)

Industrial hygiene in the pharmaceutical industry. Guest I, et al. **Occup Med** 1997 Jan–Mar;12(1):81–94 (35 ref.)

Hazard communication: challenges in the pharmaceutical industry. Hayes EP. **Occup Med** 1997 Jan–Mar; 12(1):95–105 (7 ref.)

Occupational health issues in the pharmaceutical research and development process. Klees JE, et al. **Occup Med** 1997 Jan–Mar;12(1):5–27 (155 ref.)

Setting occupational exposure limits for pharmaceuticals. Naumann BD, et al. **Occup Med** 1997 Jan–Mar;12(1):67–80 (62 ref.)

Occupational ergonomics and injury prevention. Stobbe TJ. **Occup Med** 1996 Jul–Sep;11(3):531–43 (37 ref.)

Health hazard labeling for hazard communication in the pharmaceutical industry. Sussman RG, et al. **Occup Med** 1997 Jan–Mar;12(1):107–17 (12 ref.)

Surveillance and intervention studies on respiratory cancers in asbestos-exposed workers. Merler E, et al. **Scand J Work Environ Health** 1997 Apr;23(2):83–92 (86 ref.)

Disability resulting from occupational low back pain. Part I: What do we know about primary prevention? A review of the scientific evidence on prevention before disability begins. Frank JW, et al. **Spine** 1996 Dec 15;21(24):2908–17 (80 ref.)

[The prevention of infection in oral medicine] Vassal S, et al. **Rev Stomatol Chir Maxillofac** 1997 Sep;98(3):216–9 (19 ref.) **(Fre)**

[Post-exposure drug prevention of HIV infection] Rave K, et al. **Med Klin** 1996 Sep 15;91(9):589–99 (99 ref.) **(Ger)**

[Biomarkers of hepatotoxic effects: their usefulness in occupational medicine] Indulski JA, et al. **Med Pr** 1997; 48(2):177–87 (34 ref.) (Eng. Abstr.) **(Pol)**

[Diagnostic problems and prophylaxis of paraoccupational diseases of the spine] Iżycki J. **Med Pr** 1996;47(6):651–5 (31 ref.) (Eng. Abstr.) **(Pol)**

[Mercury as an allergic factor] Kieć-Swierczyńska M. **Med Pr** 1996;47(1):77–81 (33 ref.) (Eng. Abstr.) **(Pol)**

[Post-occupational exposure HIV infection in health workers: an update and preventive measures] Boaventura JL. **Acta Med Port** 1997 Jun–Jul;10(6–7):469–78 (38 ref.) (Eng. Abstr.) **(Por)**

PSYCHOLOGY

Psychosocial aspects of coronary artery disease related to military patients. Grenier JL, et al. **Can J Psychiatry** 1997 Mar;42(2):176–84 (88 ref.)

Models of shiftwork and health: an examination of the influence of stress on shiftwork theory. Taylor E, et al. **Hum Factors** 1997 Mar;39(1):67–82 (58 ref.)

Understanding vicarious traumatization. Blair DT, et al. **J Psychosoc Nurs Ment Health Serv** 1996 Nov;34(11):24–30 (54 ref.)

Occupational stress in contemporary fire service. Gist R, et al. **Occup Med** 1995 Oct–Dec;10(4):763–87 (53 ref.)

Occupational stress management programmes: a practical overview of published effect studies. van der Hek H, et al. **Occup Med (Oxf)** 1997 Apr;47(3):133–41 (53 ref.)

Sick building syndrome, work factors and occupational stress. Crawford JO, et al. **Scand J Work Environ Health** 1996 Aug;22(4):243–50 (71 ref.)

Women, alcohol and work: interactions of gender, ethnicity and occupational culture. Ames GM, et al. **Soc Sci Med** 1996 Dec;43(11):1649–63 (100 ref.)

[Is drug dependence an occupational risk for physicians?] Schifferdecker M, et al. **Fortschr Med** 1996 Oct 20; 114(29):372–3, 376 (20 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

[Significance of isthmic spondylolisthesis in expert assessment of occupational disease of the lumbar spine] Grosser V, et al. **Unfallchirurg** 1996 Jul;99(7):470–6 (16 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

Prognosis of nonspecific work-related musculoskeletal disorders of the neck and upper extremity. Cole DC, et al. **Am J Ind Med** 1996 Jun;29(6):657–68 (46 ref.)

Rehabilitation intervention for patients with upper extremity dysfunction: challenges of outcome evaluation. Stiens SA, et al. **Am J Ind Med** 1996 Jun;29(6):590–601 (72 ref.)

Industrial rehabilitation medicine. 4. Strategies for disability management. Rondinelli RD, et al. **Arch Phys Med Rehabil** 1997 Mar;78(3 Suppl):S21–8 (54 ref.)

Industrial rehabilitation medicine. 2. Case studies in occupational low back pain. Scheer SJ, et al. **Arch Phys Med Rehabil** 1997 Mar;78(3 Suppl):S10–5 (72 ref.)

Randomized controlled trials in industrial low back pain relating to return to work. Part 2. Discogenic low back pain. Scheer SJ, et al. **Arch Phys Med Rehabil** 1996 Nov; 77(11):1189–97 (79 ref.)

Randomized controlled trials in industrial low back pain. Part

3. Subacute/chronic pain interventions. Scheer SJ, et al. **Arch Phys Med Rehabil** 1997 Apr;78(4):414–23 (65 ref.)

Regional back pain: predicament at home, nemesis at work [editorial] [see comments] Hadler NM. **J Occup Environ Med** 1996 Oct;38(10):973–8 (54 ref.) Comment in: J Occup Environ Med 1996 Oct;38(10):979–80.

Rehabilitation of acute and subacute low back and neck pain in the work-injured patient. Hartigan C, et al. **Orthop Clin North Am** 1996 Oct;27(4):841–60 (61 ref.)

A team approach to reduce disability in work-related disorders. Millender LH, et al. **Orthop Clin North Am** 1996 Oct;27(4):669–77 (68 ref.)

THERAPY

Diagnosis and treatment of organophosphate and carbamate intoxication. Wagner SL. **Occup Med** 1997 Apr–Jun;12(2):239–49 (44 ref.)

The case management approach to work-related injuries. Brain GF, et al. **Orthop Clin North Am** 1996 Oct;27(4):831–40 (19 ref.)

Occupational disorders and the management of chronic pain. Polatin PB, et al. **Orthop Clin North Am** 1996 Oct;27(4):881–90 (73 ref.)

Management of work-related upper-extremity nerve entrapments. Terrono AL, et al. **Orthop Clin North Am** 1996 Oct;27(4):783–93 (101 ref.)

Occupational asthma: a GP's guide. Burge PS. **Practitioner** 1997 Jan;241(1570):28, 32–4 (3 ref.)

Snakebite by the bushmaster (Lachesis muta) in Brazil: case report and review of the literature. Jorge MT, et al. **Toxicon** 1997 Apr;35(4):545–54 (33 ref.)

VIROLOGY

Risk of HIV infection in health care workers. Fahrner R. **AIDS Clin Rev** 1997–98;:93–107 (15 ref.)

New recommendations for prophylaxis after HIV exposure. Perlmutter BL, et al. **Am Fam Physician** 1997 Feb 1;55(2):507–12, 515–7 (22 ref.)

Hepatitis C virus infection in healthcare workers. Surgical Infection Society. Howard RJ, et al. **J Am Coll Surg** 1997 May;184(5):540–52 (114 ref.)

OCCUPATIONAL EXPOSURE

see related
AIR POLLUTANTS, OCCUPATIONAL
MULTIPLE CHEMICAL SENSITIVITY

HIV infection: challenges for dialysis personnel. Bradley-Springer L. **Adv Ren Replace Ther** 1996 Oct;3(4):293–7 (35 ref.)

New recommendations for prophylaxis after HIV exposure. Perlmutter BL, et al. **Am Fam Physician** 1997 Feb 1;55(2):507–12, 515–7 (22 ref.)

Cardiovascular disease and occupational exposure to environmental tobacco smoke. Aviado DM. **Am Ind Hyg Assoc J** 1996 Mar;57(3):285–94 (75 ref.)

Lung cancer and asbestos exposure: asbestosis is not necessary. Egilman D, et al. **Am J Ind Med** 1996 Oct;30(4):398–406 (55 ref.)

Exposure to organic solvents and breast cancer in women: a hypothesis. Labrèche FP, et al. **Am J Ind Med** 1997 Jul;32(1):1–14 (125 ref.)

Measurement methods and strategies for non-infectious microbial components in bioaerosols at the workplace. Eduard W. **Analyst** 1996 Sep;121(9):1197–201 (34 ref.)

Assessment of human risks from exposure to low toxicity occupational dusts. Soutar CA, et al. **Ann Occup Hyg** 1997 Apr;41(2):123–33 (32 ref.)

The future of dental amalgam: a review of the literature. Part 2: Mercury exposure in dental practice. Eley BM. **Br Dent J** 1997 Apr 26;182(8):293–7 (38 ref.)

Safety among health-care workers in the NHS. Bojanowski LM. **Br J Hosp Med** 1997 Jan 15–Feb 5;57(1–2):47–8 (5 ref.)

Dose response relationship between occupational PAH exposure and lung cancer—an overview. Bolm-Audorff U. **Cent Eur J Public Health** 1996;4 Suppl:40 (42 ref.)

Evaluation of the white finger risk prediction model in ISO 5349 suggests need for prospective studies. Gemne G, et al. **Cent Eur J Public Health** 1996 May;4(2):137–9 (23 ref.)

Interactive effects of polycyclic aromatic hydrocarbons and iron oxides particles. Epidemiological and fundamental aspects. Haguenoer JM, et al. **Cent Eur J Public Health** 1996;4 Suppl:41–5 (42 ref.)

Comparison of clinical picture between Yusho/Yucheng cases and occupational PCB poisoning cases. Ikeda M. **Chemosphere** 1996 Feb;32(3):559–66 (53 ref.)

Laboratory probing of oncogenes from human liquid and solid specimens as markers of exposure to toxicants. Nelson E. **Crit Rev Toxicol** 1996 Sep;26(5):483–549 (397 ref.)

Does benzene cause multiple myeloma? An analysis of the published case-control literature. Bezabeh S, et al. **Environ Health Perspect** 1996 Dec;104 Suppl 6:1393–8 (28 ref.)

Behavioral methods and organic solvents: questions and consequences. Iregren A. **Environ Health Perspect** 1996 Apr;104 Suppl 2:361–6 (56 ref.)

Clinical features of hematopoietic malignancies and related disorders among benzene-exposed workers in China. Benzene Study Group. Linet MS, et al. **Environ Health Perspect** 1996 Dec;104 Suppl 6:1353–64 (116 ref.)

The biological exposure indices: a key component in protecting workers from toxic chemicals. Morgan MS. **Environ Health Perspect** 1997 Feb;105 Suppl 1:105–15 (63 ref.)

The central nervous system and exposure to toluene: a risk characterization. Greenberg MM. **Environ Res** 1997 Jan;72(1):1–7 (57 ref.)

Neurobehavioral tests as a medical surveillance procedure: applying evaluative criteria. Guirguis S. **Environ Res** 1997;73(1–2):63–9 (46 ref.)

Overview of benzene-induced aplastic anaemia. Smith MT. **Eur J Haematol Suppl** 1996;60:107–10 (48 ref.)

Complex mixtures: hazard identification and risk assessment. Fay RM, et al. **Food Chem Toxicol** 1996 Nov–Dec;34(11–12):1175–6 (5 ref.)

Occupational exposure. Sterzl-Eckert H, et al. **Food Chem Toxicol** 1996 Nov–Dec;34(11–12):1177–8 (1 ref.)

Dry cleaning. **IARC Monogr Eval Carcinog Risks Hum** 1995;63:33–71 (119 ref.)

Multiple exposure to solvents in the workplace. Alessio L. **Int Arch Occup Environ Health** 1996;69(1):1–4 (29 ref.)

Critical evaluation and review of cadmium concentrations in blood for use in occupational health according to the TRACY protocol. Herber RF, et al. **Int Arch Occup Environ Health** 1997;69(6):372–8 (26 ref.)

Occupational exposure to HIV: new recommendations for treating health care workers. Goldschmidt RH, et al. **J Am Board Fam Pract** 1996 Nov–Dec;9(6):455–8 (10 ref.)

Stillbirth after occupational exposure to N-methyl-2-pyrrolidone. A case report and review of the literature [see comments] Solomon GM, et al. **J Occup Environ Med** 1996 Jul;38(7):705–13 (58 ref.) Comment in: J Occup Environ Med 1997 May;39(5):393–4.

HIV post-exposure prophylaxis: complex issues in health care worker management [editorial] Ball RT Jr. **J S C Med Assoc** 1996 Oct;92(10):437–40 (6 ref.)

A recommended occupational exposure limit for formaldehyde based on irritation. Paustenbach D, et al. **J Toxicol Environ Health** 1997 Feb 21;50(3):217–63 (209 ref.)

Occupational reproductive hazards. Paul M. **Lancet** 1997 May 10;349(9062):1385–8 (0 ref.)

Risks and issues for the health care worker in the human immunodeficiency virus era. Weiss SH. **Med Clin North Am** 1997 Mar;81(2):555–75 (208 ref.)

Update on recommendations for HIV postexposure prophylaxis. Grodesky MJ. **Nurse Pract** 1996 Dec;21(12 Pt 1):74, 77–8 (6 ref.)

Importance of causation for interpreting occupational epidemiology research: a case study of quartz and cancer. Goldsmith DF. **Occup Med** 1996 Jul–Sep;11(3):433–49 (76 ref.)

Interpretation and use of occupational exposure limits for chronic disease agents. Hewett P. **Occup Med** 1996 Jul–Sep;11(3):561–90 (125 ref.)

Epidemiology of reproductive hazards in the workplace. Lemasters GK. **Occup Med** 1996 Jul–Sep;11(3):545–60 (80 ref.)

Basic occupational epidemiologic measures. Marsh GM. **Occup Med** 1996 Jul–Sep;11(3):421–31 (34 ref.)

Pneumoconiosis in carbon black workers [published erratum appears in Sangyo Ika Daigaku Zasshi 1996 Dec 1;18(4):307] Szozda R. **Sangyo Ika Daigaku Zasshi** 1996 Sep 1;18(3):223–8 (29 ref.)

Biogenic amorphous silica. Rabovsky J. **Scand J Work Environ Health** 1995;21 Suppl 2:108–10 (31 ref.)

The urinary excretion of solvents and gases for the biological monitoring of occupational exposure: a review. Gobba F, et al. **Sci Total Environ** 1997 Jun 20;199(1–2):3–12 (46 ref.)

Low back pain disorders and exposure to whole-body vibration in the workplace. Bovenzi M. **Semin Perinatol** 1996 Feb;20(1):38–53 (61 ref.)

Pregnancy outcome: physical activities inside versus outside the workplace. Clapp JF 3rd. **Semin Perinatol** 1996 Feb;20(1):70–6 (46 ref.)

Practical approach to measurement and evaluation of exposure to whole-body vibration in the workplace. Thalheimer E. **Semin Perinatol** 1996 Feb;20(1):77–89 (21 ref.)

Mechanical stress reduction during seated jolt/vibration exposure. Wilder DG, et al. **Semin Perinatol** 1996 Feb;20(1):54–60 (85 ref.)

Battery of neurobehavioral tests recommended to ATSDR: solvent-induced deficits in microelectronic workers. Hudnell HK, et al. **Toxicol Ind Health** 1996 Mar–Apr;12(2):235–43 (6 ref.)

Biologic markers of exposure: current status and future research needs. Vine MF. **Toxicol Ind Health** 1996 Mar–Apr;12(2):189–200 (38 ref.)

[The effect of the factors of the working and living environment on oxidative/antioxidative balance (a review)] Vangelova K. **Probl Khig** 1996;21:27–36 (41 ref.) (Eng. Abstr.) **(Bul)**

[Exposure to endotoxins in the environment. Occurrence and health hazards] Rix BA. **Ugeskr Laeger** 1997 Apr 21;159(17):2529–33 (36 ref.) (Eng. Abstr.) **(Dan)**

[After accidental exposure to blood. What should be done?] Vayssettes JC, et al. **Presse Med** 1997 Apr 5;26(11):517–9 (25 ref.) **(Fre)**

[Latex allergy—it concerns all of us. Primary, secondary and tertiary prevention from the viewpoint of occupational medicine] Drexler H, et al. **Dtsch Med Wochenschr** 1996 Sep 27;121(39):1198–203 (17 ref.) **(Ger)**

[Occupational exposure of medical personnel to chemical factors affecting fertility] Sitarek K, et al. **Med Pr** 1997;48(2):215–21 (36 ref.) (Eng. Abstr.) **(Pol)**

[The influence of lead on neutrophils] Hrycek A, et al. **Wiad Lek** 1996;49(7–12):103–6 (13 ref.) (Eng. Abstr.) **(Pol)**

ADVERSE EFFECTS

Contact dermatitis in the textile industry: a review of 72 patients. Soni BP, et al. **Am J Contact Dermat** 1996 Dec;7(4):226–30 (21 ref.)

Monitoring occupational exposure to cancer chemotherapy drugs. Baker ES, et al. **Am J Health Syst Pharm** 1996 Nov 15;53(22):2713–23 (146 ref.)

Health effects of working in pulp and paper mills: exposure, obstructive airways diseases, hypersensitivity reactions, and cardiovascular diseases. Torén K, et al. **Am J Ind Med** 1996 Feb;29(2):111–22 (75 ref.)

Health effects of working in pulp and paper mills: malignant diseases [see comments] Torén K, et al. **Am J Ind Med** 1996 Feb;29(2):123–30 (48 ref.) Comment in: Am J Ind Med 1996 Nov;30(5):641.

Occupational medicine and rheumatic diseases [editorial] Harrington JM. **Br J Rheumatol** 1997 Feb;36(2):153–4 (12 ref.)

Epidemiology and pathogenesis of non-specific low back pain: what does the epidemiology tell us? Riihimäki H. **Bull Hosp Jt Dis** 1996;55(4):197–8 (14 ref.)

Occupational skin diseases. Halkier-Sørensen L. **Contact Dermatitis** 1996;35(1 Suppl):1–120 (342 ref.)

Toxicology and epidemiology of 1,3-butadiene. Himmelstein MW, et al. **Crit Rev Toxicol** 1997 Jan;27(1):1–108 (239 ref.)

Common dermatologic manifestations of cutaneous exposure to petroleum and its derivatives. Beasley KL, et al. **Cutis** 1996 Jul;58(1):59–62 (13 ref.)

Occupational risk factors for gastric cancer: an overview. Cocco P, et al. **Epidemiol Rev** 1996;18(2):218–34 (231 ref.)

Cancer risk in the work place, including asbestos. Nicholson WJ. **Eur J Cancer Prev** 1996 Oct;5(5):393–6 (5 ref.)

In search of dose-response relationships of solvent mixtures to neurobehavioural effects in paint manufacturing and painters. Seeber A, et al. **Food Chem Toxicol** 1996 Nov-Dec;34(11–12):1113–20 (22 ref.)

Distinguishing passive contamination from active cocaine consumption: assessing the occupational exposure of narcotics officers to cocaine. Mieczkowski T. **Forensic Sci Int** 1997 Jan 17;84(1–3):87–111 (47 ref.)

Drinking habits and occupational exposure to xenobiotics: a review. Bisio S, et al. **G Ital Med Lav** 1995 Jan–Nov;17(1–6):37–40 (32 ref.)

Proposal for hand-arm vibration exposure limits adopted for Japanese workers operating hand-held vibration tools. Mirbod SM, et al. **Int Arch Occup Environ Health** 1997;69(6):418–22 (25 ref.)

Effect of occupational exposure to opiates on the respiratory system. Górski P, et al. **Int J Occup Med Environ Health** 1996;9(3):245–53 (48 ref.)

Occupational exposure and malignant lymphoma. Persson B. **Int J Occup Med Environ Health** 1996;9(4):309–21 (119 ref.)

Occupational exposure to mercury in dentistry and dentist mortality. McComb D. **J Can Dent Assoc** 1997 May;63(5):372–6 (30 ref.)

Evidence for silica's neoplastic risk among workers and derivation of cancer risk assessment. Goldsmith DF. **J Expo Anal Environ Epidemiol** 1997 Jul–Sep;7(3):291–301 (46 ref.)

Hazards to the orthopaedic trauma surgeon: occupational exposure to tuberculosis. Risk reduction, testing, and treatment (a review article). Esterhai JL Jr, et al. **J Orthop Trauma** 1996;10(5):366–70 (24 ref.)

An evaluation of the use of bronchopulmonary lavage in the treatment of plutonium oxide inhalation. Dean MR. **J R Nav Med Serv** 1997;82(3):188–96 (27 ref.)

Occupational and geographical factors in the epidemiology of malignant mesothelioma. Ross D, et al. **Monaldi Arch Chest Dis** 1995 Dec;50(6):459–63 (47 ref.)

Diagnostics of hand-arm system disorders in workers who use vibrating tools. Gemne G. **Occup Environ Med** 1997 Feb;54(2):90–5 (95 ref.)

Does occupational exposure to iron promote infection? Palmer K, et al. **Occup Environ Med** 1997 Aug;54(8):529–34 (52 ref.)

Occupational exposure to dust: inflammation and ischaemic heart disease. Sjögren B. **Occup Environ Med** 1997 Jul;54(7):466–9 (49 ref.)

Reproductive health hazards in the pharmaceutical industry. Clement JD. **Occup Med** 1997 Jan–Mar;12(1):131–43 (61 ref.)

Pesticide exposure assessment of workers and their families. Fenske RA. **Occup Med** 1997 Apr–Jun;12(2):221–37 (95 ref.)

The risk of cancer in firefighters. Golden AL, et al. **Occup Med** 1995 Oct–Dec;10(4):803–20 (73 ref.)

Respiratory health hazards and lung function in wildland firefighters. Harrison R, et al. **Occup Med** 1995 Oct–Dec;10(4):857–70 (41 ref.)

Chronic neurologic effects of pesticide overexposure. Keifer

MC, et al. **Occup Med** 1997 Apr-Jun;12(2):291-304 (82 ref.)
Occupational health issues in the pharmaceutical research and development process. Klees JE, et al. **Occup Med** 1997 Jan-Mar;12(1):5-27 (155 ref.)
Reproductive hazards and firefighters. McDiarmid MA, et al. **Occup Med** 1995 Oct-Dec;10(4):829-41 (84 ref.)
Reproductive and developmental effects of occupational pesticide exposure: the epidemiologic evidence. Sever LE, et al. **Occup Med** 1997 Apr-Jun;12(2):305-25 (101 ref.)
Pesticides and cancer. Zahm SH, et al. **Occup Med** 1997 Apr-Jun;12(2):269-89 (195 ref.)
Occupational exposure to electromagnetic fields and adult leukaemia: a review of the epidemiological evidence. Feychting M. **Radiat Environ Biophys** 1996 Nov; 35(4):237-42 (32 ref.)
Toxicological risk assessment of worker exposure to pesticides: some general principles. de Raat WK, et al. **Regul Toxicol Pharmacol** 1997 Jun;25(3):204-10 (27 ref.)
Death due to asthma at workplace in a diphenylmethane diisocyanate-sensitized subject. Carino M, et al. **Respiration** 1997;64(1):111-3 (16 ref.)
Biomonitoring of occupational exposures to cytostatic anticancer drugs. Bos RP, et al. **Rev Environ Health** 1997 Jan-Mar;12(1):43-58 (104 ref.)
Recombinant DNA technology: a 20-year occupational health retrospective. Cohen R, et al. **Rev Environ Health** 1996 Jul-Sep;11(3):149-65 (58 ref.)
Cancer risk assessment for crystalline silica to implement California's hot spots act. Collins JF, et al. **Scand J Work Environ Health** 1995;21 Suppl 2:99-103 (35 ref.)
Policy development for compensating workers exposed to crystalline silica in Ontario, Canada. Elinson L, et al. **Scand J Work Environ Health** 1995;21 Suppl 2:111-4 (14 ref.)
Comparative cancer potency for silica from extrapolations of human and animal findings. Goldsmith DF, et al. **Scand J Work Environ Health** 1995;21 Suppl 2:104-7 (27 ref.)
Asbestos, asbestosis, pleural plaques and lung cancer. Hillerdal G, et al. **Scand J Work Environ Health** 1997 Apr; 23(2):93-103 (153 ref.)
Assessment of silicosis risk for occupational exposure to crystalline silica. Rice FL, et al. **Scand J Work Environ Health** 1995;21 Suppl 2:87-90 (27 ref.)
Asbestos exposure, asbestosis, and asbestos-attributable lung cancer [see comments] Jones RN, et al. **Thorax** 1996 Aug; 51 Suppl 2:S9-15 (41 ref.) Comment in: Thorax 1997 Mar;52(3):306.
[List of potential etiological agents in occupationally-induced asthmatic diseases] Nowak D. **Pneumologie** 1996 Dec; 50(12):875-88 (258 ref.) **(Ger)**
[Cytogenetic indicators of genotoxicity in subjects occupationally exposed to antineoplastic drugs] Forni A, et al. **Med Lav** 1996 May-Jun;87(3):222-9 (34 ref.) (Eng. Abstr.) **(Ita)**
[Pathological effects due to antineoplastic drugs in workers engaged in their production, preparation or administration] Merler E, et al. **Med Lav** 1996 May-Jun;87(3):207-21 (42 ref.) (Eng. Abstr.) **(Ita)**
[The influence of chemical and physical factors in the work environment on the amount of risk for abnormal pregnancy outcome] Makowiec-Dąbrowska T, et al. **Med Pr** 1997; 48(3):239-59 (84 ref.) (Eng. Abstr.) **(Pol)**
[Health hazards in hospital personnel related to use of ethylene oxide in sterilization processes] Tyras H. **Med Pr** 1997;48(3):325-33 (48 ref.) (Eng. Abstr.) **(Pol)**

ANALYSIS

A comprehensive strategy for the assessment of noise exposure and risk of hearing impairment. Malchaire J, et al. **Ann Occup Hyg** 1997 Aug;41(4):467-84 (0 ref.)
Occupational chronic exposure to organic solvents. XVI. Ambient and biological monitoring of workers exposed to toluene. Angerer J, et al. **Int Arch Occup Environ Health** 1997;69(2):91-6 (38 ref.)
Proposal for hand-arm vibration exposure limits adopted for Japanese workers operating hand-held vibration tools. Mirbod SM, et al. **Int Arch Occup Environ Health** 1997; 69(6):418-22 (25 ref.)
Variability and consistency of electric and magnetic field occupational exposure measurements [published erratum appears in J Expo Anal Environ Epidemiol 1996 Oct-Dec;6(4):527] Bracken TD, et al. **J Expo Anal Environ Epidemiol** 1996 Jul-Sep;6(3):355-74 (27 ref.)
Quantification of historical exposures in occupational cohort studies [see comments] Stewart PA, et al. **Scand J Work Environ Health** 1996 Dec;22(6):405-14 (42 ref.) Comment in: Scand J Work Environ Health 1996 Dec;22(6):401-3.
[Criteria and methods for the study of occupational exposure to antineoplastic agents] Apostoli P, et al. **Med Lav** 1996 May-Jun;87(3):230-54 (60 ref.) (Eng. Abstr.) **(Ita)**

PREVENTION & CONTROL

Risk assessment and exposure control in an occupational setting. Packham CL. **Curr Probl Dermatol** 1996;25:133-44 (0 ref.)
Occupational hazards of operating: opportunities for improvement. Davis MS. **Infect Control Hosp Epidemiol** 1996 Oct;17(10):691-3 (16 ref.)
A critical review of the literature on sharps injuries: epidemiology, management of exposures and prevention. Hanrahan A, et al. **J Adv Nurs** 1997 Jan;25(1):144-54 (130 ref.)
Nitrous oxide in the dental environment: assessing the risk, reducing the exposure [published erratum appears in J Am Dent Assoc 1997 Jun;128(6):700] Howard WR. **J Am Dent Assoc** 1997 Mar;128(3):356-60 (22 ref.)
Prevention of risks from occupational exposure to antineoplastic drugs. Consensus document. Alessio L, et al. **Med Lav** 1996 May-Jun;87(3):194-206 (0 ref.) **(Eng, Ita)**
Generic strategies for protecting worker health and safety. OSHA's general duty clause and hazard communications standard. Baram M. **Occup Med** 1996 Jan-Mar;11(1):69-77 (46 ref.)
Establishing guidance for the handling and containment of new chemical entities and chemical intermediates in the pharmaceutical industry. Olson MJ, et al. **Occup Med** 1997 Jan-Mar;12(1):49-65 (7 ref.)
Control of biologic hazards. Stave GM. **Occup Med** 1996 Jan-Mar;11(1):79-85 (9 ref.)
Recombinant DNA technology: a 20-year occupational health retrospective. Cohen R, et al. **Rev Environ Health** 1996 Jul-Sep;11(3):149-65 (58 ref.)

STANDARDS

Investigation into the impact of introducing workplace aerosol standards based on the inhalable fraction. Werner MA, et al. **Analyst** 1996 Sep;121(9):1207-14 (22 ref.)
Generic strategies for protecting worker health and safety. OSHA's general duty clause and hazard communications standard. Baram M. **Occup Med** 1996 Jan-Mar;11(1):69-77 (46 ref.)
Setting occupational exposure limits for pharmaceuticals. Naumann BD, et al. **Occup Med** 1997 Jan-Mar;12(1):67-80 (62 ref.)
[The problem of hygienic standardization of commercial electric and magnetic fields in Russia and other countries] Rubtsova NB. **Aviakosm Ekolog Med** 1997;31(1):4-8 (26 ref.) (Eng. Abstr.) **(Rus)**
[A comparative analysis of the existing standards for exposure to ultraviolet radiation] Strzhizhovskiĭ AD. **Usp Fiziol Nauk** 1997 Apr-Jun;28(2):94-106 (40 ref.) (Eng. Abstr.) **(Rus)**

STATISTICS & NUMERICAL DATA

Methodological limitations in the study of video display terminal use and upper extremity musculoskeletal disorders. Gerr F, et al. **Am J Ind Med** 1996 Jun;29(6):649-56 (38 ref.)
Design factors in epidemiologic cohort studies of work-related low back injury or pain. Kraus JF, et al. **Am J Ind Med** 1997 Aug;32(2):153-63 (50 ref.)
Alternative approaches to analytical designs in occupational injury epidemiology. Mittleman MA, et al. **Am J Ind Med** 1997 Aug;32(2):129-41 (58 ref.)

OCCUPATIONAL HEALTH

Treatment of allergic rhinitis: effect on occupation productivity and work force costs. Fireman P. **Allergy Asthma Proc** 1997 Mar-Apr;18(2):63-7 (10 ref.)
Occupational and environmental health in Turkmenistan and Uzbekistan. Reynolds SJ. **Am Ind Hyg Assoc J** 1996 Dec; 57(12):1096-102 (16 ref.)
Assessment of autonomic neurotoxicity in occupational and environmental health as determined by ECG R-R interval variability: a review. Murata K, et al. **Am J Ind Med** 1996 Aug;30(2):155-63 (82 ref.)
Workplace organizational correlates of lost-time accident rates in manufacturing. Shannon HS, et al. **Am J Ind Med** 1996 Mar;29(3):258-68 (17 ref.)
Health hazards in nursing and health care: an overview. Rogers B. **Am J Infect Control** 1997 Jun;25(3):248-61 (154 ref.)
Industrial hygiene. Harper M, et al. **Anal Chem** 1997 Jun 15;69(12):307R-327R (814 ref.)
Investigation into the impact of introducing workplace aerosol standards based on the inhalable fraction. Werner MA, et al. **Analyst** 1996 Sep;121(9):1207-14 (22 ref.)
Air traffic controller shiftwork: what are the implications for aviation safety? A review. Luna TD. **Aviat Space Environ Med** 1997 Jan;68(1):69-79 (142 ref.)
Managing fatigue in operational settings 2: An integrated approach. Rosekind MR, et al. **Behav Med** 1996 Winter; 21(4):166-70 (7 ref.)
ABC of work related disorders. Working with an occupational health department. Adisesh A, et al. **BMJ** 1996 Oct 19;313(7063):999-1002 (0 ref.)
ABC of work related disorders. Assessing fitness for work. Davies W. **BMJ** 1996 Oct 12;313(7062):934-8 (8 ref.)
ABC of work related disorders. Women at work. Kapadia LH. **BMJ** 1996 Oct 26;313(7064):1073-6 (0 ref.)
ABC of work related disorders. Investigating suspected occupational illness and evaluating the workplace. Palmer K, et al. **BMJ** 1996 Sep 28;313(7060):809-11 (0 ref.)
Safety among health-care workers in the NHS. Bojanowski LM. **Br J Hosp Med** 1997 Jan 15-Feb 5;57(1-2):47-8 (5 ref.)
Frontiers of occupational health. New vaccines, new prophylactic regimens, and management of the HIV-infected worker. Beekmann SE, et al. **Infect Dis Clin North Am** 1997 Jun;11(2):313-29 (87 ref.)
School injuries in an occupational health perspective: what do we learn from community based epidemiological studies? Laflamme L, et al. **Inj Prev** 1997 Mar;3(1):50-6 (30 ref.)
Critical evaluation and review of cadmium concentrations in blood for use in occupational health according to the TRACY protocol. Herber RF, et al. **Int Arch Occup Environ Health** 1997;69(6):372-8 (26 ref.)
Ethical problems in the relationship between health and work. Berlinguer G, et al. **Int J Health Serv** 1996; 26(1):147-71 (39 ref.)
A strategic response to the occupational health establishment. Sass R. **Int J Health Serv** 1996;26(2):355-70 (11 ref.)
Defining total corporate health and safety costs--significance and impact. Review and recommendations. Brady W, et al. **J Occup Environ Med** 1997 Mar;39(3):224-31 (23 ref.)
Generic strategies for protecting worker health and safety. OSHA's general duty clause and hazard communications standard. Baram M. **Occup Med** 1996 Jan-Mar;11(1):69-77 (46 ref.)
Firefighters: fitness for duty. Gerkin D. **Occup Med** 1995 Oct-Dec;10(4):871-6 (12 ref.)
Industrial hygiene in the pharmaceutical industry. Guest I, et al. **Occup Med** 1997 Jan-Mar;12(1):81-94 (35 ref.)
Occupational health services and OSHA compliance. Jones DL. **Occup Med** 1996 Jan-Mar;11(1):57-68 (9 ref.)
Occupational health issues in the pharmaceutical research and development process. Klees JE, et al. **Occup Med** 1997 Jan-Mar;12(1):5-27 (155 ref.)
Setting occupational exposure limits for pharmaceuticals. Naumann BD, et al. **Occup Med** 1997 Jan-Mar;12(1):67-80 (62 ref.)
Establishing guidance for the handling and containment of new chemical entities and chemical intermediates in the pharmaceutical industry. Olson MJ, et al. **Occup Med** 1997 Jan-Mar;12(1):49-65 (7 ref.)
Occupational ergonomics and injury prevention. Stobbe TJ. **Occup Med** 1996 Jul-Sep;11(3):531-43 (37 ref.)
Chronic fatigue syndrome and occupational health. Mounstephen A, et al. **Occup Med (Oxf)** 1997 May; 47(4):217-27 (83 ref.)
Ergonomics and body mechanics in the work place. Gassett RS, et al. **Orthop Clin North Am** 1996 Oct;27(4):861-79 (99 ref.)
Health status assessment in the occupational health setting. Jette DU, et al. **Orthop Clin North Am** 1996 Oct; 27(4):891-902 (42 ref.)
Low back and cervical spine disorders. Rainville J, et al. **Orthop Clin North Am** 1996 Oct;27(4):729-46 (80 ref.)
Toxicological considerations in environmental audit studies. Jaffery FN, et al. **Qual Assur** 1997 Jan-Mar;5(1):19-26 (7 ref.)
Integrating quality, safety, and environment management systems. Winder C. **Qual Assur** 1997 Jan-Mar;5(1):27-48 (11 ref.)
The application of ergonomics in the work environment of general surgeons. Berguer R. **Rev Environ Health** 1997 Apr-Jun;12(2):99-106 (56 ref.)
Recombinant DNA technology: a 20-year occupational health retrospective. Cohen R, et al. **Rev Environ Health** 1996 Jul-Sep;11(3):149-65 (58 ref.)
Environmental health in the health-care professions: biological, physical, psychic, and social health hazards. Hofmann F, et al. **Rev Environ Health** 1996 Jan-Jun; 11(1-2):41-55 (104 ref.)
Nursing implications in the management of superficial bladder cancer. Games J. **Semin Urol Oncol** 1996 Feb;14(1 Suppl 1):36-40 (27 ref.)
Psychosocial work environment in human service organizations: a conceptual analysis and development of the demand-control model. Söderfeldt B, et al. **Soc Sci Med** 1996 May;42(9):1217-26 (50 ref.)
Clothing and exercise. II. Influence of clothing during exercise/work in environmental extremes. Pascoe DD, et al. **Sports Med** 1994 Aug;18(2):94-108 (92 ref.)
Alcohol and the workplace. Henderson M, et al. **WHO Reg Publ Eur Ser** 1996;67:1-100 (233 ref.)
[Follow-up system within industrial corporations for patients with glucose intolerance] Atsumi Y. **Nippon Rinsho** 1996 Oct;54(10):2761-4 (3 ref.) **(Jpn)**
[Total health promotion plan for laborers--physical exercise and bone metabolism] Niwa S, et al. **Nippon Seikeigeka Gakkai Zasshi** 1996 Jan;70(1):17-27 (8 ref.) **(Jpn)**
[Legionella infection in occupational and environmental health] Fujii J, et al. **Sangyo Ika Daigaku Zasshi** 1996 Mar 1;18(1):61-76 (16 ref.) (Eng. Abstr.) **(Jpn)**
[The practical theory of occupational health planning: Part One--The theoretical background of the target population setting and needs assessment procedures (OPST research report 2)] Jahng DJ, et al. **Sangyo Ika Daigaku Zasshi** 1996 Sep 1;18(3):193-201 (5 ref.) (Eng. Abstr.) **(Jpn)**
[The practical theory of occupational health planning: Part Two--The theoretical background from the priority setting procedure to the post project appraisal making procedure (OPST research report 3)] Jahng DJ, et al. **Sangyo Ika Daigaku Zasshi** 1996 Sep 1;18(3):203-11 (17

ref.) (Eng. Abstr.) **(Jpn)**

[Occupational dangers to health of nursing staffs in hemodialysis units] Washio M, et al. **Sangyo Ika Daigaku Zasshi** 1996 Sep 1;18(3):239–45 (20 ref.) (Eng. Abstr.) **(Jpn)**

[The problem of hygienic standardization of commercial electric and magnetic fields in Russia and other countries] Rubtsova NB. **Aviakosm Ekolog Med** 1997;31(1):4–8 (26 ref.) (Eng. Abstr.) **(Rus)**

LEGISLATION & JURISPRUDENCE

ABC of work related disorders. Legal aspects. Davidson MJ. **BMJ** 1996 Nov 2;313(7065):1136–40 (0 ref.)

Ethical, social, and legal issues surrounding studies of susceptible populations and individuals. Soskolne CL. **Environ Health Perspect** 1997 Jun;105 Suppl 4:837–41 (68 ref.)

Occupational and environmental medicine in New York State. de la Hoz RE, et al. **Int Arch Occup Environ Health** 1997;70(1):1–8 (13 ref.)

Injury, death, and the deregulation fetish: the politics of occupational safety regulation in U.K. manufacturing industries. Tombs S. **Int J Health Serv** 1996;26(2):309–29 (73 ref.)

Health and safety problems associated with long working hours: a review of the current position. Spurgeon A, et al. **Occup Environ Med** 1997 Jun;54(6):367–75 (76 ref.)

Hazard communication: challenges in the pharmaceutical industry. Hayes EP. **Occup Med** 1997 Jan–Mar; 12(1):95–105 (7 ref.)

Occupational health issues under employment discrimination law. Stillman NG, et al. **Occup Med** 1996 Jan–Mar; 11(1):41–55 (93 ref.)

Health hazard labeling for hazard communication in the pharmaceutical industry. Sussman RG, et al. **Occup Med** 1997 Jan–Mar;12(1):107–17 (12 ref.)

STATISTICS & NUMERICAL DATA

Design and conduct of occupational injury intervention studies: a review of evaluation strategies. Zwerling C, et al. **Am J Ind Med** 1997 Aug;32(2):164–79 (105 ref.)

OCCUPATIONAL HEALTH NURSING

ORGANIZATION & ADMINISTRATION

Occupational health nursing in the pharmaceutical industry. Campbell KN, et al. **Occup Med** 1997 Jan–Mar;12(1):169–78 (29 ref.)

OCCUPATIONAL HEALTH SERVICES

Health promotion and disease prevention in the worksite. Lusk SL. **Annu Rev Nurs Res** 1997;15:187–213 (94 ref.)

ABC of work related disorders. Legal aspects. Davidson MJ. **BMJ** 1996 Nov 2;313(7065):1136–40 (0 ref.)

Occupational stress in contemporary fire service. Gist R, et al. **Occup Med** 1995 Oct–Dec;10(4):763–87 (53 ref.)

ECONOMICS

Outcome studies in industry: cost–effectiveness of cumulative trauma disorder prevention. Mitchell CS. **Am J Ind Med** 1996 Jun;29(6):689–96 (34 ref.)

ORGANIZATION & ADMINISTRATION

Onsite clinical services in the era of managed health care. Larkin GN. **Occup Med** 1997 Jan–Mar;12(1):145–54 (11 ref.)

Partnering occupational medicine and the pharmaceutical business. Levin BK, et al. **Occup Med** 1997 Jan–Mar; 12(1):155–62 (4 ref.)

[Work–related diseases––a medical problem or a social problem?] Iżycki J. **Med Pr** 1996;47(1):55–62 (37 ref.) (Eng. Abstr.) **(Pol)**

TRENDS

[Hazards to workers' health caused by work–related psychosocial factors––a challenge to occupational health services] Dudek B, et al. **Med Pr** 1996;47(1):63–72 (12 ref.) (Eng. Abstr.) **(Pol)**

OCCUPATIONAL MEDICINE

see related
OCCUPATIONAL DISEASES
OCCUPATIONAL HEALTH SERVICES
PROTECTIVE DEVICES

Industrial rehabilitation medicine. 1. Why is industrial rehabilitation medicine unique? Robinson JP, et al. **Arch Phys Med Rehabil** 1997 Mar;78(3 Suppl):S3–9 (81 ref.)

Incorporating occupational medicine methodology into military fitness for duty and readiness issues. Popper SE. **Aviat Space Environ Med** 1997 Aug;68(8):740–5 (28 ref.)

Occupational medicine and rheumatic diseases [editorial] Harrington JM. **Br J Rheumatol** 1997 Feb;36(2):153–4 (12 ref.)

Neurophysiological methods in occupational and environmental health: methodology and recent findings. Araki S, et al. **Environ Res** 1997;73(1–2):42–51 (111 ref.)

Prevalence of hereditary hemochromatosis in a Massachusetts corporation: is Celtic origin a risk factor? Smith BN, et al. **Hepatology** 1997 Jun;25(6):1439–46 (53 ref.)

A selective overview of occupational psychiatry. Greenfield DP, et al. **N J Med** 1996 Jan;93(1):28–30 (17 ref.)

Applications of occupational epidemiology. Bang KM. **Occup Med** 1996 Jul–Sep;11(3):381–91 (41 ref.)

Occupational epidemiologic study design and application. Blair A, et al. **Occup Med** 1996 Jul–Sep;11(3):403–19 (112 ref.)

Management of behavioral dysfunction: a corporate physician's perspective. Farid I. **Occup Med** 1996 Oct–Dec; 11(4):599–615 (27 ref.)

Collection of occupational epidemiologic data: the use of surrogate respondents to provide occupational histories. Henneberger PK. **Occup Med** 1996 Jul–Sep;11(3):393–401 (28 ref.)

Licensing, practice, and malpractice in occupational medicine. Rischitelli DG. **Occup Med** 1996 Jan–Mar; 11(1):121–35 (51 ref.)

A guide to spirometry as applied to occupational health. White N, et al. **S Afr Med J** 1996 Jul;86(7):807–13 (39 ref.)

[The development of the occupational physician support system––OPST research report] Jahng DJ. **Sangyo Ika Daigaku Zasshi** 1996 Sep 1;18(3):185–92 (8 ref.) **(Jpn)**

[Identity of the occupational medicine physician] Grzesik J. **Med Pr** 1997;48(1):69–74 (0 ref.) (Eng. Abstr.) **(Pol)**

[Occupational diseases features and priorities in internal medicine] Berliner GB. **Klin Med (Mosk)** 1997;75(3):64–5 (0 ref.) **(Rus)**

EDUCATION

Occupational medicine in Austria. Wolf C, et al. **Int Arch Occup Environ Health** 1997;69(3):151–6 (0 ref.)

[Analysis of education processes in areas of public health and occupational medicine. Introductory premises and hypotheses] Boczkowski A, et al. **Med Pr** 1997;48(1):61–7 (9 ref.) (Eng. Abstr.) **(Pol)**

HISTORY

Occupational medicine in Canada in 1996. Guidotti TL, et al. **Occup Med (Oxf)** 1997 Jan;47(1):45–51 (11 ref.)

The industrial panopticon: mining and the medical construction of migrant African labour in South Africa, 1900–1950. Butchart A. **Soc Sci Med** 1996 Jan;42(2):185–97 (63 ref.)

METHODS

Time to pregnancy: a measure of reproductive function in either sex. Asclepios Project. Joffe M. **Occup Environ Med** 1997 May;54(5):289–95 (20 ref.)

The ABCs of psychiatric disability evaluations. Perlo S. **Occup Med** 1996 Oct–Dec;11(4):747–65 (45 ref.)

[Biomarkers of hepatotoxic effects: their usefulness in occupational medicine] Indulski JA, et al. **Med Pr** 1997; 48(2):177–87 (34 ref.) (Eng. Abstr.) **(Pol)**

ORGANIZATION & ADMINISTRATION

What is the strategic value of occupational and environmental medicine? Observations from the United States and Australia. Emmett EA. **J Occup Environ Med** 1996 Nov; 38(11):1124–34 (41 ref.)

STANDARDS

Study of business ethics in occupational medicine. Philipp R, et al. **Occup Environ Med** 1997 May;54(5):351–6 (30 ref.)

TRENDS

Occupational and environmental medicine in New York State. de la Hoz RE, et al. **Int Arch Occup Environ Health** 1997;70(1):1–8 (13 ref.)

OCCUPATIONAL NOISE see **NOISE, OCCUPATIONAL**

OCCUPATIONAL SAFETY see **OCCUPATIONAL HEALTH**

OCCUPATIONAL SAFETY AND HEALTH ADMINISTRATION (U.S.) see **UNITED STATES OCCUPATIONAL SAFETY AND HEALTH ADMINISTRATION**

OCCUPATIONAL THERAPY

Acknowledging a spiritual dimension in occupational therapy practice. Christiansen C. **Am J Occup Ther** 1997 Mar; 51(3):169–72 (34 ref.)

Faculty practice in an age of entrepreneurship: can occupational therapy educators add yet another role? Hanson C, et al. **Am J Occup Ther** 1997 May;51(5):388–92 (22 ref.)

Predictors of functional outcome among adolescents and young adults with psychotic disorders. Henry AD, et al. **Am J Occup Ther** 1996 Mar;50(3):171–81 (97 ref.)

Competency beliefs and occupational role behavior among adolescents: explication of the personal causation construct. Henry AD, et al. **Am J Occup Ther** 1997 Apr;51(4):267–76 (80 ref.)

Occupation as spiritual activity. Howard BS, et al. **Am J Occup Ther** 1997 Mar;51(3):181–5 (31 ref.)

Religious orientation and pain management. Low JF. **Am J Occup Ther** 1997 Mar;51(3):215–9 (22 ref.)

Why the profession of occupational therapy will flourish in the 21st century. The 1996 Eleanor Clarke Slagle Lecture. Nelson DL. **Am J Occup Ther** 1997 Jan;51(1):11–24 (51 ref.)

Therapeutic occupation: a definition. Nelson DL. **Am J Occup Ther** 1996 Nov–Dec;50(10):775–82 (21 ref.)

A Copernican revolution in clinical ethics: engagement versus disengagement. Van Amburg R. **Am J Occup Ther** 1997 Mar;51(3):186–90 (20 ref.)

Legitimizing occupational therapy's knowledge. Wood W. **Am J Occup Ther** 1996 Sep;50(8):626–34 (90 ref.)

The value of studying occupation: an example with primate play [published erratum appears in Am J Occup Ther 1996 Sep;50(8):638] Wood W. **Am J Occup Ther** 1996 May; 50(5):327–37 (60 ref.)

Stress experiences of occupational therapists in mental health practice arenas: a review of the literature. Sweeney G, et al. **Int J Soc Psychiatry** 1996 Summer;42(2):132–40 (35 ref.)

ECONOMICS

Occupational therapy practice: focusing on occupational performance. Baum CM, et al. **Am J Occup Ther** 1997 Apr; 51(4):277–88 (39 ref.)

EDUCATION

Process over person?: occupational therapy students' fieldwork experiences of people in psychiatric settings. Lyons M. **Disabil Rehabil** 1996 Apr;18(4):197–204 (51 ref.)

LEGISLATION & JURISPRUDENCE

An overview of professional liability in occupational therapy. Ranke BA, et al. **Am J Occup Ther** 1997 Sep;51(8):671–80 (17 ref.)

METHODS

Right–hemispheric activation approaches to neglect rehabilitation poststroke. Lin KC. **Am J Occup Ther** 1996 Jul–Aug;50(7):504–15 (114 ref.)

Job analysis in occupational therapy: stepping into the complex world of business and industry. Lysaght R. **Am J Occup Ther** 1997 Jul–Aug;51(7):569–75 (31 ref.)

Prenatal cocaine exposure and mother–infant interaction: implications for occupational therapy intervention. Miller H. **Am J Occup Ther** 1997 Feb;51(2):119–31 (100 ref.)

Art: an occupation with promise for developing empathy. Peloquin SM. **Am J Occup Ther** 1996 Sep;50(8):655–61 (34 ref.)

Latex sensitivity in children with spina bifida: implications for occupational therapy practitioners. Scoggin AE, et al. **Am J Occup Ther** 1997 Jul–Aug;51(7):608–11 (21 ref.)

ORGANIZATION & ADMINISTRATION

Should we trade person–centered service for a consumer–based model? Peloquin SM. **Am J Occup Ther** 1997 Jul–Aug;51(7):612–5 (26 ref.)

OCCUPATIONS

see related
HEALTH OCCUPATIONS
WORKPLACE

The impact of occupation on self–reported cardiovascular morbidity in western Germany: gender differences. Helmert U, et al. **Rev Environ Health** 1997 Jan–Mar; 12(1):25–42 (41 ref.)

Occupation as a risk factor for knee disorders. Jensen LK, et al. **Scand J Work Environ Health** 1996 Jun;22(3):165–75 (72 ref.)

CLASSIFICATION

Psychosocial work environment in human service organizations: a conceptual analysis and development of the demand–control model. Söderfeldt B, et al. **Soc Sci Med** 1996 May;42(9):1217–26 (50 ref.)

OCEANOGRAPHY

see related
MARINE BIOLOGY

OCHRATOXINS

ANALYSIS

The effects of processing on the occurrence of ochratoxin A in cereals. Alldrick AJ. **Food Addit Contam** 1996;13 Suppl:27–8 (8 ref.)

Fate of ochratoxin A on processing of meat products. Gareis M. **Food Addit Contam** 1996;13 Suppl:35–7 (6 ref.)

Sampling and analysis for ochratoxin A in foods. Gilbert J. **Food Addit Contam** 1996;13 Suppl:17–8 (3 ref.)

Ochratoxin A in animal feed––effects of processing. Scudamore KA. **Food Addit Contam** 1996;13 Suppl:39–42 (14 ref.)

Fate of ochratoxin A during breadmaking. Subirade I. **Food Addit Contam** 1996;13 Suppl:25–6 (3 ref.)

Analytical methodology and regulations for ochratoxin A. Van Egmond HP. **Food Addit Contam** 1996;13 Suppl:11–3

(8 ref.)
Fate of ochratoxin A (OTA) during processing of coffee. Cooperative work by PEC (Physiological Effects of Coffee committee). Viani R. **Food Addit Contam** 1996;13 Suppl:29–33 (15 ref.)

BIOSYNTHESIS

Mode of formation of ochratoxin A. Moss MO. **Food Addit Contam** 1996;13 Suppl:5–9 (27 ref.)

CHEMISTRY

Effects of processing and detoxification treatments on ochratoxin A: introduction. Scott PM. **Food Addit Contam** 1996;13 Suppl:19–21 (18 ref.)

POISONING

Nephrotoxicity of ochratoxin A. Pleština R. **Food Addit Contam** 1996;13 Suppl:49–50 (9 ref.)

TOXICITY

Is ochratoxin a nephrotoxic in human beings? Godin M, et al. **Adv Nephrol Necker Hosp** 1997;26:181–206 (123 ref.)
Aspartame as a preventive agent of chronic toxic effects of ochratoxin A in experimental animals. Creppy EE, et al. **Food Addit Contam** 1996;13 Suppl:51–2 (6 ref.)
Mechanistic approaches to ochratoxin toxicity. Dirheimer G. **Food Addit Contam** 1996;13 Suppl:45–8 (28 ref.)
Risk assessment of ochratoxin A: an update. Kuiper-Goodman T. **Food Addit Contam** 1996;13 Suppl:53–7 (13 ref.)
Carcinogenicity and kinetic aspects of ochratoxin A. Schlatter C, et al. **Food Addit Contam** 1996;13 Suppl:43–4 (6 ref.)
Renal toxicodynamics of ochratoxin A: a pathophysiological approach. Gekle M, et al. **Kidney Blood Press Res** 1996; 19(5):225–35 (74 ref.)

OCHRONOSIS

COMPLICATIONS

Ochronotic arthropathy: the black hip. Case report and review of the literature. Dom K, et al. **Acta Orthop Belg** 1997 Jun;63(2):122–5 (5 ref.)

DIAGNOSIS

Alkaptonuric ochronosis: report of two affected brothers. Gutzmer R, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):305–7 (16 ref.)

OCKELBO VIRUS see **ALPHAVIRUS**

OCTANOLS see **ALCOHOLS, OCTYL**

OCTODON see **RODENTIA**

OCTOGENARIANS see **AGED, 80 AND OVER**

OCTOPUS VENOMS see **MOLLUSK VENOMS**

OCTREOTIDE

ADMINISTRATION & DOSAGE

Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Gillis JC, et al. **Drugs** 1997 Apr;53(4):681–99 (71 ref.)
[Indications for the use of somatostatin and octreotide in digestive pathology] Zan S, et al. **Minerva Gastroenterol Dietol** 1996 Jun;42(2):107–14 (38 ref.) (Eng. Abstr.) **(Ita)**
[Analgesic effects of natural growth hormone release inhibitors and their synthetic analogs. Intraspinal administration] Beltrutti D, et al. **Minerva Med** 1997 Jan–Feb;88(1–2):39–47 (86 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

Role of intestinal transit in the pathogenesis of gallbladder stones. Dowling RH, et al. **Can J Gastroenterol** 1997 Jan–Feb;11(1):57–64 (81 ref.)

ANALOGS & DERIVATIVES

Radiolabeled somatostatin analog scintigraphy in oncology and immune diseases: an overview. Kwekkeboom DJ, et al. **Eur Radiol** 1997;7(7):1103–9 (37 ref.)

DIAGNOSTIC USE

Somatostatin analogue in the localization and treatment of bronchial carcinoid tumours. Temeck BK, et al. **Surg Oncol** 1996 Oct–Dec;5(5–6):195–200 (27 ref.)
[Cushing syndrome disclosing bronchial neuroendocrine carcinoma: value of scintigraphy with octreotide] Vallette S, et al. **Rev Med Interne** 1997;18(2):138–43 (14 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOKINETICS

Internalisation of isotope-coupled somatostatin analogues. Hofland LJ, et al. **Digestion** 1996;57 Suppl 1:2–6 (32 ref.)
Studies on radiolabeled somatostatin analogues in rats and in patients. Breeman WA, et al. **Q J Nucl Med** 1996 Sep; 40(3):209–20 (93 ref.)

PHARMACOLOGY

Effects of somatostatin analogues on human gastrointestinal motility. Camilleri M. **Digestion** 1996;57 Suppl 1:90–2 (10 ref.)

THERAPEUTIC USE

Is octreotide a new hope for enterocutaneous and external pancreatic fistulas closure? Martineau P, et al. **Am J Surg** 1996 Oct;172(4):386–95 (76 ref.)
Octreotide in hyperinsulinism. Barrons RW. **Ann Pharmacother** 1997 Feb;31(2):239–41 (20 ref.)
Octreotide or vasopressin for bleeding esophageal varices. Law AW, et al. **Ann Pharmacother** 1997 Feb;31(2):237–8 (15 ref.)
Octreotide in the management of treatment-related diarrhoea. Baillie-Johnson HR. **Anticancer Drugs** 1996 Jan; 7 Suppl 1:11–5 (43 ref.)
Octreotide therapy in carcinoid disease. Bax ND, et al. **Anticancer Drugs** 1996 Jan;7 Suppl 1:17–22 (35 ref.)
Therapeutic potential of octreotide in the treatment of liver metastases. Davies N, et al. **Anticancer Drugs** 1996 Jan;7 Suppl 1:23–31 (41 ref.)
Octreotide in malignant intestinal obstruction. Pandha HS, et al. **Anticancer Drugs** 1996 Jan;7 Suppl 1:5–10 (23 ref.)
Use of octreotide in the acute management of bleeding esophageal varices. Sadowski DC. **Can J Gastroenterol** 1997 May–Jun;11(4):339–43 (39 ref.)
Somatostatin analogues and pancreatic fistulas. Bassi C, et al. **Digestion** 1996;57 Suppl 1:94–6 (9 ref.)
The role of somatostatin analogues in the treatment of refractory diarrhoea. Farthing MJ. **Digestion** 1996;57 Suppl 1:107–13 (52 ref.)
The place of octreotide in the medical management of the dumping syndrome. Scarpignato C. **Digestion** 1996;57 Suppl 1:114–8 (37 ref.)
Metabolic aspects of acromegaly and its treatment. Quabbe HJ, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):61–2 (25 ref.)
Somatostatin analogs in ectopic corticotropin production. von Werder K, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):129–31 (16 ref.)
Somatostatin and its analogues in G.I. tract, liver and pancreatic disorders. Dhar A, et al. **Trop Gastroenterol** 1995 Jul–Sep;16(3):3–7 (22 ref.)
[Treatment with octreotide of stenosing cystic dystrophy on heterotopic pancreas of the duodenal wall] de Parades V, et al. **Gastroenterol Clin Biol** 1996;20(6–7):601–4 (12 ref.) (Eng. Abstr.) **(Fre)**
[Menetrier disease associated with ulcerative colitis. Response to the treatment with octreotide. Review of the diagnostic criteria and etiopathogenesis] Ojeda E, et al. **Gastroenterol Hepatol** 1997 Apr;20(4):175–9 (20 ref.) (Eng. Abstr.) **(Spa)**
[The therapeutic applications of octreotide] Carrera-Hueso FJ, et al. **Med Clin (Barc)** 1996 Apr 6;106(13):505–16 (239 ref.) **(Spa)**

OCULAR DISPARITY see **VISION DISPARITY**

OCULAR HERPES ZOSTER VIRUS see **HERPESVIRUS 3, HUMAN**

OCULAR HYPERTENSION

COMPLICATIONS

Early diagnosis of functional damage in patients with glaucoma [editorial; comment] Caprioli J. **Arch Ophthalmol** 1997 Jan;115(1):113–4 (31 ref.) Comment on: Arch Ophthalmol 1997 Jan;115(1):26–33.

DIAGNOSIS

[Informative value of psychophysical examinations aside from conventional white-white perimetry] Lachenmayr B. **Ophthalmologe** 1996 Aug;93(4):389–95 (81 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. Balfour JA, et al. **Drugs Aging** 1997 May; 10(5):384–403 (81 ref.)
Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension. Patel SS, et al. **Drugs Aging** 1996 Nov;9(5):363–78 (83 ref.)
Timolol hemihydrate: a new formulation of timolol for the treatment of glaucoma. Stewart WC. **J Ocul Pharmacol Ther** 1996 Summer;12(2):225–37 (30 ref.)
Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Alm A, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S105–10 (23 ref.)
Clinical dose-regimen studies with latanoprost, a new ocular hypotensive PGF2 alpha analogue. Diestelhorst M, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S77–81 (28 ref.)
Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Walters TR. **Surv Ophthalmol** 1996 Nov;41 Suppl 1:S19–26 (26 ref.)

PHYSIOPATHOLOGY

Impact of intraocular pressure on venous outflow from the globe: a hypothesis regarding IOP-dependent vascular damage in normal-tension and hypertensive glaucoma. Bito LZ. **J Glaucoma** 1996 Apr;5(2):127–34 (40 ref.)

THERAPY

Management of the failing glaucoma filter. Shingleton BJ. **Ophthalmic Surg Lasers** 1996 Jun;27(6):445–51 (39 ref.)

OCULAR HYPOTENSION

ETIOLOGY

Postsurgical hypotony: relationship to fistulization, inflammation, chorioretinal lesions, and the vitreous. Schubert HD. **Surv Ophthalmol** 1996 Sep–Oct;41(2):97–125 (331 ref.)

THERAPY

Management of the failing glaucoma filter. Shingleton BJ. **Ophthalmic Surg Lasers** 1996 Jun;27(6):445–51 (39 ref.)

OCULAR HYPOTONY see **OCULAR HYPOTENSION**

OCULAR INFECTIONS see **EYE INFECTIONS**

OCULAR INFECTIONS, BACTERIAL see **EYE INFECTIONS, BACTERIAL**

OCULAR INFECTIONS, FUNGAL see **EYE INFECTIONS, FUNGAL**

OCULAR INFECTIONS, PARASITIC see **EYE INFECTIONS, PARASITIC**

OCULAR INFECTIONS, VIRAL see **EYE INFECTIONS, VIRAL**

OCULAR LARVA MIGRANS see **LARVA MIGRANS**

OCULAR MOTILITY DISORDERS

COMPLICATIONS

Ocular neuromyotonia in Graves dysthyroid orbitopathy. Chung SM, et al. **Arch Ophthalmol** 1997 Mar;115(3):365–70 (31 ref.)
Juvenile progressive scoliosis and congenital horizontal gaze palsy. Thomsen M, et al. **J Pediatr Orthop B** 1996 Summer; 5(3):185–9 (22 ref.)
[Diplopia of muscular origin. Etiology, diagnosis and treatment] Kapranova AS. **Vestn Oftalmol** 1997 Mar–Apr; 113(2):45–7 (67 ref.) **(Rus)**

DIAGNOSIS

Paraneoplastic ophthalmological syndromes. Constantinescu A. **Oftalmologia** 1996 Jul–Sep;40(3):214–8 (7 ref.)
[Diagnosis and clinical assessment of abnormal eye movements] Shimizu N. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1351–5 (9 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Botulinum A exotoxin in clinical ophthalmology. Carruthers JD, et al. **Can J Ophthalmol** 1996 Dec;31(7):389–400 (66 ref.)

ETIOLOGY

Cerebral ocular motor signs. Pierrot-Deseilligny C, et al. **J Neurol** 1997 Feb;244(2):65–70 (46 ref.)
Intracranial hypertension. Kabat AG. **Optom Clin** 1996; 5(3–4):153–79 (51 ref.)

PHYSIOPATHOLOGY

Opsoclonus. Averbuch-Heller L, et al. **Semin Neurol** 1996 Mar;16(1):21–6 (38 ref.)

THERAPY

International Symposium for Therapy of Ocular Motility and Related Visual Disturbances. Kaminski HJ, et al. **Neurology** 1997 May;48(5):1178–84 (72 ref.)

OCULAR PROSTHESIS see **EYE, ARTIFICIAL**

OCULAR REFRACTION see **REFRACTION, OCULAR**

OCULAR TENSION see **INTRAOCULAR PRESSURE**

OCULAR TORTICOLLIS see **OCULAR MOTILITY DISORDERS**

OCULAR TOXOPLASMOSIS see **TOXOPLASMOSIS, OCULAR**

OCULAR TUBERCULOSIS see **TUBERCULOSIS,**

OCULAR TUBERCULOSIS

OCULAR

OCULOAURICULOVERTEBRAL SYNDROME see **GOLDENHAR SYNDROME**

OCULOCEREBRORENAL SYNDROME

[Lowe syndrome] Asami T, et al.
Ryoikibetsu Shokogun Shirizu 1997;(16 Pt 1):616–9 (7 ref.) **(Jpn)**

OCULOMOTOR MUSCLES

[Isolated blow out fracture of the medial wall of the orbit with medial rectus entrapment. Apropos of 3 cases] Gerard M, et al. **J Fr Ophtalmol** 1996;19(10):591–6 (15 ref.) (Eng. Abstr.) **(Fre)**

[Effects of external orbital radiotherapy on the oculomotor muscle in Graves disease] Maalouf T, et al.
J Fr Ophtalmol 1996;19(12):748–54 (20 ref.) (Eng. Abstr.) **(Fre)**

[Use of botulinum toxin in ophthalmology: current concepts and problems] Tapiero B, et al. **J Fr Ophtalmol** 1997; 20(2):134–45 (21 ref.) **(Fre)**

[Mitochondrial anomalies in oculopharyngeal muscular dystrophy] de Seze J, et al. **Rev Neurol (Paris)** 1997 Jun; 153(5):335–8 (19 ref.) (Eng. Abstr.) **(Fre)**

ABNORMALITIES

Aplasia of the inferior rectus muscle. A case report and review of the literature. Taylor RH, et al.
Ophthalmology 1997 Mar;104(3):415–8 (15 ref.)

INNERVATION

Blepharospasm: an Australian survey. Daly K.
Int J Rehabil Res 1997 Mar;20(1):41–50 (15 ref.)

PHYSIOLOGY

Eye-centering: the basic ocular motor reflex--literature review, observations and hypotheses. Jampel RS, et al.
Curr Eye Res 1996 Aug;15(8):890–8 (41 ref.)

Ocular outflow facility with emphasis on neuronal regulation of intraocular smooth muscles. Suzuki R.
J Smooth Muscle Res 1996 Dec;32(6):229–47 (82 ref.)

Effect of oculomotor and other visual skills on reading performance: a literature review. Kulp MT, et al.
Optom Vis Sci 1996 Apr;73(4):283–92 (122 ref.)

[Intraocular smooth muscle physiology relating to pathogenesis and therapy of glaucoma] Suzuki R.
J Smooth Muscle Res 1996 Oct;32(5):175–94 (68 ref.) **(Jpn)**

[The interoceptive properties of the vestibular apparatus (a systems analysis of vestibular-oculomotor interaction)] Ianov IuK, et al. **Usp Fiziol Nauk** 1996 Oct–Dec; 27(4):63–72 (22 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

[Electromyogram in extraocular muscle] Hayashi T.
Nippon Rinsho 1997 Mar;55 Suppl 1:397–9 (6 ref.) **(Jpn)**

[Diplopia of muscular origin. Etiology, diagnosis and treatment] Kapranova AS. **Vestn Oftalmol** 1997 Mar–Apr; 113(2):45–7 (67 ref.) **(Rus)**

SURGERY

The aponeurotic approach for the correction of blepharoptosis. Shovlin JP. **Int Ophthalmol Clin** 1997 Summer;37(3):133–50 (30 ref.)

OCULOMOTOR NERVE

Neurogenic diplopia: paralysis of cranial nerves III, IV, and VI. Sowka J. **Optom Clin** 1996;5(3–4):53–76 (46 ref.)

PATHOLOGY

The ocular motor nerves. Miller NR. **Curr Opin Neurol** 1996 Feb;9(1):21–5 (43 ref.)

Cranial nerves III, IV, and VI. Laine FJ.
Top Magn Reson Imaging 1996 Apr;8(2):111–30 (61 ref.)

PHYSIOLOGY

[The interoceptive properties of the vestibular apparatus (a systems analysis of vestibular-oculomotor interaction)] Ianov IuK, et al. **Usp Fiziol Nauk** 1996 Oct–Dec; 27(4):63–72 (22 ref.) (Eng. Abstr.) **(Rus)**

OCULOMOTOR NERVE PALSY see **OCULOMOTOR NERVE PARALYSIS**

OCULOMOTOR NERVE PARALYSIS

COMPLICATIONS

[Optic neuropathies and peripheral oculomotor disorders in patients with AIDS] Torras-Sanvicens J, et al.
Rev Neurol 1996 Dec;24(136):1605–13 (44 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

[Difficulty in eye opening following left hemispheric infarction-- causative lesion and pathophysiology of abnormalities of the eye and eyelids movements] Waragai M, et al. **Rinsho Shinkeigaku** 1996 Apr;36(4):577–83 (16 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

The ocular motor nerves. Miller NR. **Curr Opin Neurol** 1996 Feb;9(1):21–5 (43 ref.)

OCULOMOTOR PARALYSIS see **OPHTHALMOPLEGIA**

OCULOMYCOSIS see **EYE INFECTIONS, FUNGAL**

OCYTOCIN see **OXYTOCIN**

ODDI'S SPHINCTER

see related
CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE
SPHINCTEROTOMY, ENDOSCOPIC

Defining sphincter of oddi dysfunction. Funch-Jensen P.
Gastrointest Endosc Clin N Am 1996 Jan;6(1):107–115 (53 ref.)

Therapy of sphincter of Oddi dysfunction. Kalloo AN, et al. **Gastrointest Endosc Clin N Am** 1996 Jan;6(1):117–25 (53 ref.)

Sphincter of Oddi dysfunction. Lehman GA, et al.
Int J Pancreatol 1996 Aug;20(1):11–25 (102 ref.)

[The diagnosis of dyskinesias of Oddi's sphincter] Sauerbruch T, et al. **Dtsch Med Wochenschr** 1997 Apr 25; 122(17):547–50 (33 ref.) **(Ger)**

PHYSIOLOGY

Sphincter of Oddi motility. Funch-Jensen P, et al.
Scand J Gastroenterol Suppl 1996;216:46–51 (70 ref.)

PHYSIOPATHOLOGY

Sphincter of Oddi manometry. Hogan WJ, et al.
Gastrointest Endosc 1997 Mar;45(3):342–8 (74 ref.)

Biliary tract dysmotility and sphincter of Oddi dyskinesia. van Berge-Henegouwen GP, et al. **Neth J Med** 1997 Apr; 50(4):174–9 (32 ref.)

ODONTOBLASTS

CYTOLOGY

Cell biology of calcified tissues: experimental models of differentiation and mechanisms by which local and systemic factors exert their effects. Boyan BD, et al.
Connect Tissue Res 1996;35(1–4):63–70 (54 ref.)

ODONTOCLASTS see **OSTEOCLASTS**

ODONTOGENESIS

[The role of syndecan and tenascine during tooth development. Review o the literature] Bucci P, et al.
Minerva Stomatol 1996 Jun;45(6):259–66 (15 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

The genetic control of early tooth development. Maas R, et al. **Crit Rev Oral Biol Med** 1997;8(1):4–39 (312 ref.)

PHYSIOLOGY

Effects of preterm birth on oral growth and development. Seow WK. **Aust Dent J** 1997 Apr;42(2):85–91 (33 ref.)

Extracellular matrix proteins of dentine. Butler WT, et al. **Ciba Found Symp** 1997;205:107–15; discussion 115–7 (28 ref.)

Tooth morphogenesis and the differentiation of ameloblasts. Thesleff I, et al. **Ciba Found Symp** 1997;205:3–12; discussion 12–7 (39 ref.)

Some methods of assessing postnatal craniofaciodental growth: a retrospective of personal research. Sarnat BG. **Cleft Palate Craniofac J** 1997 Mar;34(2):159–72 (57 ref.)

ODONTOGENIC CYST, CALCIFYING

PATHOLOGY

Central epithelial odontogenic ghost cell tumour. A case report. Junquera LM, et al.
Ann Otolaryngol Chir Cervicofac 1997;114(3):76–9 (24 ref.)

ODONTOGENIC CYSTS

DIAGNOSIS

[Odontogenic keratocysts--their imaging via MRT] Wildberger JE, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1997 Aug;167(2):207–9 (8 ref.) **(Ger)**

PATHOLOGY

Per[cyst]ent growth: the odontogenic keratocyst 40 years on. Browne RM. **Ann R Coll Surg Engl** 1996 Sep;78(5):426–33 (103 ref.)

Gingival cyst of the adult: a review and a report of eight cases. Bell RC, et al. **J Can Dent Assoc** 1997 Jul–Aug; 63(7):533–5 (7 ref.)

Odontogenic keratocysts: review of the literature and report of a case. Blanchard SB. **J Periodontol** 1997 Mar; 68(3):306–11 (29 ref.)

Glandular odontogenic cyst: report of a case and review of the literature. Ramer M, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jul;84(1):54–7 (21 ref.)

[The keratocyst or epidermoid cyst: the current state of understanding apropos of a case with intracranial involvement] Franc C, et al.
Rev Stomatol Chir Maxillofac 1996 Oct;97(5):270–82 (134 ref.) (Eng. Abstr.) **(Fre)**

[Mucoepidermoid carcinoma and mucoepidermoid cyst of the jaw bones in the same patient. A clinical case and discussion of their histogenesis] Tanda F, et al.
Minerva Stomatol 1996 Dec;45(12):599–603 (9 ref.) (Eng. Abstr.) **(Ita)**

ODONTOGENIC TUMOR, SQUAMOUS see **AMELOBLASTOMA**

ODONTOGENIC TUMORS

PATHOLOGY

Adenomatoid odontogenic tumour: an unusual cause of gingival swelling in a 3-year-old patient. Kearns GJ, et al. **Br Dent J** 1996 Nov 23;181(10):380–2 (24 ref.)

Squamous odontogenic tumor (SOT): a benign neoplasm of the periodontium. A review of 36 reported cases. Philipsen HP, et al. **J Clin Periodontol** 1996 Oct;23(10):922–6 (32 ref.)

Clear cell ameloblastoma or odontogenic carcinoma. A case report. Marí A, et al. **J Craniomaxillofac Surg** 1995 Dec; 23(6):387–90 (18 ref.)

An asymptomatic enlargement of the mandible causing marked root resorption [clinical conference] Stoll C, et al.
J Oral Maxillofac Surg 1997 Jul;55(7):740–6 (43 ref.)

Central odontogenic fibroma current concepts. Gardner DG.
J Oral Pathol Med 1996 Nov;25(10):556–61 (24 ref.)

Clear cell odontogenic carcinoma in the mandible: histochemical and immunohistochemical observations with a review of the literature. Muramatsu T, et al.
J Oral Pathol Med 1996 Oct;25(9):516–21 (20 ref.)

Mixed odontogenic tumours and odontomas. Considerations on interrelationship. Review of the literature and presentation of 134 new cases of odontomas. Philipsen HP, et al. **Oral Oncol** 1997 Mar;33(2):86–99 (129 ref.)

Extraosseous calcifying epithelial odontogenic tumor: report of two cases and review of the literature. Houston GD, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 May;83(5):577–83 (30 ref.)

Clear cell tumors of the salivary glands, jaws, and oral mucosa. Maiorano E, et al. **Semin Diagn Pathol** 1997 Aug; 14(3):203–12 (80 ref.)

SURGERY

Surgical treatment of central epithelial ghost cell tumor. Limongelli WA, et al. **N Y State Dent J** 1997 Aug–Sep; 63(7):42–6 (9 ref.)

VETERINARY

Tumours of the bone. Pour PM. **IARC Sci Publ** 1996; (126):385–426 (84 ref.)

Ameloblastic fibromas and related tumors in cattle. Gardner DG. **J Oral Pathol Med** 1996 Mar;25(3):119–24 (29 ref.)

Case of calcifying epithelial odontogenic tumour in a dog. Ishikawa T, et al. **J Small Anim Pract** 1996 Dec; 37(12):597–9 (13 ref.)

ODONTOID PROCESS

Synovial cyst and degeneration of the transverse ligament: an unusual cause of high cervical myelopathy. Case report. Fransen P, et al. **J Neurosurg** 1997 Jun;86(6):1027–30 (17 ref.)

Ganglion cyst of the odontoid process. Case report and review of the literature. Tabaddor K, et al. **Spine** 1996 Sep 1;21(17):2019–22 (26 ref.)

INJURIES

Typical and atypical fractures of the odontoid process in young children. Report of two cases and a review of the literature. Schippers N, et al. **Acta Neurochir (Wien)** 1996; 138(5):524–30 (38 ref.)

Odontoid fractures in the child with neurological injury. Direct anterior osteosynthesis with a cortico-spongious screw and literature review. Godard J, et al.
Childs Nerv Syst 1997 Feb;13(2):105–7 (14 ref.)

Treatment protocol for fractures of the odontoid process. Chiba K, et al. **J Spinal Disord** 1996 Aug;9(4):267–76 (25 ref.)

PATHOLOGY

Juvenile avascular necrosis of the odontoid process. A review on the etiology of os odontoideum and absentia odontoidei. Heick A. **Dan Med Bull** 1996 Sep;43(4):363–6 (20 ref.)

SURGERY

Primary hemangiopericytoma in the axis bone: case report and review of literature. Lin YJ, et al. **Neurosurgery** 1996 Aug;39(2):397–9; discussion 399–400 (32 ref.)

ODORANT RECEPTORS see **RECEPTORS, ODORANT**

ODORS

see related
AROMATHERAPY
SMELL

Special transformation processes using fungal spores and immobilized cells. Larroche C, et al. **Adv Biochem Eng Biotechnol** 1997;55:179–220 (324 ref.)

Prospects for the bioengineering of isoprenoid biosynthesis. McCaskill D, et al. **Adv Biochem Eng Biotechnol** 1997; 55:107–46 (225 ref.)

Glycoconjugated aroma compounds: occurrence, role and biotechnological transformation. Winterhalter P, et al. **Adv Biochem Eng Biotechnol** 1997;55:73–105 (288 ref.)

Excision of subcutaneous tissue for the treatment of axillary osmidrosis. Tung TC, et al. **Br J Plast Surg** 1997 Jan; 50(1):61–6 (15 ref.)

Cognitive processes in odorant mixture assessment. Booth DA. **Chem Senses** 1995 Dec;20(6):639–43 (19 ref.)

Odour plumes and odour-mediated flight in insects. Cardé RT. **Ciba Found Symp** 1996;200:54–66; discussion 66–70 (46 ref.)

Odours for host-finding mosquitoes. Costantini C. **Ciba Found Symp** 1996;200:124–31 (48 ref.)

A search for components in human body odour that attract females of Aedes aegypti. Geier M, et al. **Ciba Found Symp** 1996;200:132–44; discussion 144–8, 178–83 (35 ref.)

Synthesis and future challenges: the response of mosquitoes to host odours. Takken W. **Ciba Found Symp** 1996; 200:302–12; discussion 312–20 (52 ref.)

Volatile flavor release from foods during eating. Taylor AJ. **Crit Rev Food Sci Nutr** 1996 Dec;36(8):765–84 (75 ref.)

Olfactory information processing in the brain: encoding chemical and temporal features of odors. Christensen TA, et al. **J Neurobiol** 1996 May;30(1):82–91 (68 ref.)

Dynamical representation of odors by oscillating and evolving neural assemblies. Laurent G. **Trends Neurosci** 1996 Nov;19(11):489–96 (48 ref.)

ANALYSIS

GC/olfactometry. Acree TE. **Anal Chem** 1997 Mar 1; 69(5):170A–175A (28 ref.)

[The long path toward "odorless garlic"] Koch HP. **Pharm Unserer Zeit** 1996 Jul;25(4):186–91 (44 ref.) **(Ger)**

OFFICE AUTOMATION

[Computer applications in ophthalmology] Kuchenbecker J, et al. **Ophthalmologe** 1997 Mar;94(3):248–60 (42 ref.) **(Ger)**

OFFICE MANAGEMENT

Occupational dermatitis—what's new? Office environment. Wahlberg JE. **Clin Dermatol** 1997 Jul–Aug;15(4):587–92 (38 ref.)

Office laboratory procedures, office economics, patient and parent education, and urinary tract infection. Ey JL, et al. **Curr Opin Pediatr** 1995 Dec;7(6):741–54 (83 ref.)

OFFICE NURSING

Safe handling of cytotoxic drugs in the physician's office: a procedure manual model. Carmignani SS, et al. **Oncol Nurs Forum** 1997 Jan–Feb;24(1 Suppl):41–8 (31 ref.)

OFFICE SURGERY see **AMBULATORY SURGERY**

OFFICE VISITS

Reconsidering sore throats. Part 2: Alternative approach and practical office tool [see comments] McIsaac WJ, et al. **Can Fam Physician** 1997 Mar;43:495–500 (40 ref.) Comment in: Can Fam Physician 1997 May;43:843, 845. Comment in: Can Fam Physician 1997 Jul;43:1207–8.

Attitudes and access: advancing the rights of people with disabilities [editorial; comment] Peat M. **Can Med Assoc J** 1997 Mar 1;156(5):657–9 (8 ref.) Comment on: Can Med Assoc J 1997 Mar 1;156(5):647–56.

Office procedures. Endometrial biopsy. Apgar BS, et al. **Prim Care** 1997 Jun;24(2):303–26 (61 ref.)

Office procedures. No-scalpel vasectomy. Davis LE, et al. **Prim Care** 1997 Jun;24(2):433–61 (29 ref.)

Office procedures. Obstetric ultrasonography. Deutchman ME, et al. **Prim Care** 1997 Jun;24(2):407–31 (35 ref.)

Office procedures. Colposcopy. Ferris DG. **Prim Care** 1997 Jun;24(2):241–67 (8 ref.)

Office procedures. Exercise testing. Fowler GC, et al. **Prim Care** 1997 Jun;24(2):375–406 (22 ref.)

Office procedures. Flexible sigmoidoscopy. Harper MB, et al. **Prim Care** 1997 Jun;24(2):341–57 (25 ref.)

Office procedures. Cryotherapy of dermal abnormalities. Jester DM. **Prim Care** 1997 Jun;24(2):269–80 (12 ref.)

Office procedures. Education, training, and proficiency of procedural skills. Miller MD. **Prim Care** 1997 Jun; 24(2):231–40 (7 ref.)

Office procedures. Electrosurgical loop excision of the cervix. Newkirk GR. **Prim Care** 1997 Jun;24(2):281–302 (26 ref.)

Office procedures. Esophagogastroduodenoscopy. Norris TE. **Prim Care** 1997 Jun;24(2):327–40 (26 ref.)

Office procedures. Nasopharyngoscopy. Patton DD. **Prim Care** 1997 Jun;24(2):359–74 (18 ref.)

[White coat hypertension] Matsubayashi K. **Ryoikibetsu Shokogun Shirizu** 1996;(12):151–4 (13 ref.) **(Jpn)**

[White coat hypertension] Chaves Júnior H. **Arq Bras Cardiol** 1996 Aug;67(2):139–42 (26 ref.) **(Por)**

OFFSPRING OF IMPAIRED PARENTS see **CHILD OF IMPAIRED PARENTS**

OFLOXACIN

ADVERSE EFFECTS

Seizures associated with ofloxacin therapy. Traeger SM, et al. **Clin Infect Dis** 1995 Dec;21(6):1504–6 (7 ref.)

PHARMACOKINETICS

The clinical pharmacokinetics of levofloxacin. Fish DN, et al. **Clin Pharmacokinet** 1997 Feb;32(2):101–19 (78 ref.)

[Pharmacokinetic properties of ofloxacin (review of the literature] Iakovlev VP. **Antibiot Khimioter** 1996; 41(9):24–32 (69 ref.) **(Rus)**

PHARMACOLOGY

[Antimicrobial activity and action mechanism of ofloxacin] Padeĭskaia EN. **Antibiot Khimioter** 1996;41(9):13–23 (66 ref.) **(Rus)**

THERAPEUTIC USE

Treatment of multidrug-resistant tuberculosis in Thailand. Maranetra KN. **Chemotherapy** 1996;42 Suppl 3:10–5; discussion 30–3 (11 ref.)

Treatment of multidrug-resistant tuberculosis in China. Zhang LX. **Chemotherapy** 1996;42 Suppl 3:16–9; discussion 30–3 (8 ref.)

New generations of quinolones: with particular attention to levofloxacin. Ambrose PG, et al. **Conn Med** 1997 May; 61(5):269–72 (11 ref.)

[Ten-year experience with the use of ofloxacin (Tarivid®). New treatment regimens] Navashin SM, et al. **Antibiot Khimioter** 1996;41(9):99–103 (22 ref.) **(Rus)**

OGILVIE DISEASE see **COLONIC PSEUDO-OBSTRUCTION**

6-OHDA see **OXIDOPAMINE**

OIL, IODIZED see **IODIZED OIL**

OILS

Oleaginous microorganisms: an assessment of the potential. Leman J. **Adv Appl Microbiol** 1997;43:195–243 (230 ref.)

OILS, PLANT see **PLANT OILS**

OILS, VEGETABLE see **PLANT OILS**

OILS, VOLATILE

see related
AROMATHERAPY

OINTMENTS

Efficacy of protective creams and/or gels. Lachapelle JM. **Curr Probl Dermatol** 1996;25:182–92 (34 ref.)

PHARMACOKINETICS

Percutaneous penetration (dermatopharmacokinetics) in evaluating barrier creams. Zhai H, et al. **Curr Probl Dermatol** 1996;25:193–205 (24 ref.)

PHARMACOLOGY

Moisturizers in the prevention of contact dermatitis. Hannuksela M. **Curr Probl Dermatol** 1996;25:214–20 (31 ref.)

OK-432 see **PICIBANIL**

OKA VARICELLA VACCINE see **CHICKENPOX VACCINE**

OKADAIC ACID

BLOOD

Okadaic acid-like toxin in systemic lupus erythematosus patients: hypothesis for toxin-induced pathology, immune dysregulation, and transactivation of herpesviruses. Mitchell TM. **Med Hypotheses** 1996 Sep;47(3):217–25 (102 ref.)

OKM5 ANTIGEN see **ANTIGENS, CD36**

OLD AGE HOMES see **HOMES FOR THE AGED**

OLDEST OLD see **AGED, 80 AND OVER**

OLEANDOCETIN see **TROLEANDOMYCIN**

OLEFINS see **ALKENES**

OLFACTION see **SMELL**

OLFACTORY BULB

PHYSIOLOGY

Information coding in the vertebrate olfactory system. Buck LB. **Annu Rev Neurosci** 1996;19:517–44 (187 ref.)

Olfaction, GABAergic neurotransmission in the olfactory bulb, and intermale aggression in mice: modulation by steroids. Guillot PV, et al. **Behav Genet** 1996 Sep; 26(5):497–504 (65 ref.)

Multiple factors shape development of olfactory glomeruli: insights from an insect model system. Oland LA, et al. **J Neurobiol** 1996 May;30(1):92–109 (136 ref.)

Functional role of receptor neurons in encoding olfactory information. Trotier D, et al. **J Neurobiol** 1996 May; 30(1):58–66 (40 ref.)

Olfactory recognition memory. Keverne EB, et al. **J Physiol Paris** 1996;90(5–6):399–401 (13 ref.)

Neural mechanisms of mammalian olfactory learning. Brennan PA, et al. **Prog Neurobiol** 1997 Mar;51(4):457–81 (160 ref.)

Dynamical representation of odors by oscillating and evolving neural assemblies. Laurent G. **Trends Neurosci** 1996 Nov;19(11):489–96 (48 ref.)

[Clinical olfaction tests] Ishimaru T, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:484–6 (8 ref.) **(Jpn)**

[The sexual dimorphism of the accessory olfactory system] Guillermón A, et al. **Ontogenez** 1996 Sep–Oct;27(5):341–8 (56 ref.) **(Rus)**

OLFACTORY CORTEX see **OLFACTORY PATHWAYS**

OLFACTORY MUCOSA

see related
VOMERONASAL ORGAN

PATHOLOGY

Neurogenesis and cell death in olfactory epithelium. Calof AL, et al. **J Neurobiol** 1996 May;30(1):67–81 (76 ref.)

PHYSIOLOGY

Gaseous second messengers in vertebrate olfaction. Broillet MC, et al. **J Neurobiol** 1996 May;30(1):49–57 (65 ref.)

Molecular mechanisms of olfactory processing in the mammalian olfactory epithelium. Hatt H. **ORL J Otorhinolaryngol Relat Spec** 1996 Jul–Aug; 58(4):183–94 (56 ref.)

OLFACTORY NERVE

PATHOLOGY

Magnetic resonance imaging of the olfactory apparatus. Castillo M, et al. **Top Magn Reson Imaging** 1996 Apr; 8(2):80–6 (7 ref.)

OLFACTORY PATHWAYS

Olfactory control of mosquito behaviour. Davis EE. **Ciba Found Symp** 1996;200:48–53 (12 ref.)

ANATOMY & HISTOLOGY

The cranial nerves of the Senegal bichir, Polypterus senegalus [osteichthyes: actinopterygii: cladistia]. Piotrowski T, et al. **Brain Behav Evol** 1996;47(2):55–102 (66 ref.)

CYTOLOGY

Factors affecting neuronal birth and death in the mammalian olfactory epithelium. Calof AL, et al. **Ciba Found Symp** 1996;196:188–205; discussion; 205–10 (47 ref.)

GROWTH & DEVELOPMENT

Developmental anatomy of the primary olfactory pathway in the opossum Monodelphis domestica. Chuah MI, et al. **Histol Histopathol** 1997 Jul;12(3):799–806 (46 ref.)

PATHOLOGY

Magnetic resonance imaging of the olfactory apparatus. Castillo M, et al. **Top Magn Reson Imaging** 1996 Apr; 8(2):80–6 (7 ref.)

PHYSIOLOGY

Information coding in the vertebrate olfactory system. Buck

OLFACTORY PATHWAYS

LB. **Annu Rev Neurosci** 1996;19:517–44 (187 ref.)
Mechanisms of olfactory discrimination: converging evidence for common principles across phyla. Hildebrand JG, et al. **Annu Rev Neurosci** 1997;20:595–631 (237 ref.)
Sorting signals and targeting of infectious agents through axons: an annotation to the 100 years' birth of the name "axon". Kristensson K. **Brain Res Bull** 1996;41(6):327–33 (68 ref.)
Synchronous oscillations in neuronal systems: mechanisms and functions. Gray CM. **J Comput Neurosci** 1994 Jun; 1(1–2):11–38 (164 ref.)
Olfactory information processing in the brain: encoding chemical and temporal features of odors. Christensen TA, et al. **J Neurobiol** 1996 May;30(1):82–91 (68 ref.)
Functional organization of olfactory system. Shipley MT, et al. **J Neurobiol** 1996 May;30(1):123–76 (390 ref.)
Information processing in mammalian olfactory system. Sullivan SL, et al. **J Neurobiol** 1996 May;30(1):20–36 (171 ref.)
The orbitofrontal cortex. Rolls ET. **Philos Trans R Soc Lond B Biol Sci** 1996 Oct 29; 351(1346):1433–43; discussion 1443–4 (103 ref.)
Dynamical representation of odors by oscillating and evolving neural assemblies. Laurent G. **Trends Neurosci** 1996 Nov;19(11):489–96 (48 ref.)
[Clinical olfaction tests] Ishimaru T, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:484–6 (8 ref.) **(Jpn)**
[An olfactory memory formed in the vomeronasal system] Kaba H. **Tanpakushitsu Kakusan Koso** 1996 Nov; 41(14):2077–83 (29 ref.) **(Jpn)**

SURGERY

Surgical treatment of anterior basal meningiomas. DeMonte F. **J Neurooncol** 1996 Sep;29(3):239–48 (31 ref.)

OLFACTORY RECEPTOR NEURONS

see related
RECEPTORS, ODORANT

CHEMISTRY

Scentsational ion channels. Firestein S. **Neuron** 1996 Nov; 17(5):803–6 (20 ref.)

CYTOLOGY

Neurogenesis and cell death in olfactory epithelium. Calof AL, et al. **J Neurobiol** 1996 May;30(1):67–81 (76 ref.)

PHYSIOLOGY

Information coding in the vertebrate olfactory system. Buck LB. **Annu Rev Neurosci** 1996;19:517–44 (187 ref.)
Olfactory receptors, vomeronasal receptors, and the organization of olfactory information. Bargmann CI. **Cell** 1997 Aug 22;90(4):585–7 (17 ref.)
Perireceptor events in olfaction. Pelosi P. **J Neurobiol** 1996 May;30(1):3–19 (99 ref.)
Second messenger signaling in olfactory transduction. Restrepo D, et al. **J Neurobiol** 1996 May;30(1):37–48 (111 ref.)
Information processing in mammalian olfactory system. Sullivan SL, et al. **J Neurobiol** 1996 May;30(1):20–36 (171 ref.)
Functional role of receptor neurons in encoding olfactory information. Trotier D, et al. **J Neurobiol** 1996 May; 30(1):58–66 (40 ref.)
Scentsational ion channels. Firestein S. **Neuron** 1996 Nov; 17(5):803–6 (20 ref.)

ULTRASTRUCTURE

Ultrastructural aspects of olfactory signaling. Menco BP. **Chem Senses** 1997 Jun;22(3):295–311 (128 ref.)

OLFACTORY RECEPTOR PROTEINS see **RECEPTORS, ODORANT**

OLFACTORY TRACT see **OLFACTORY PATHWAYS**

OLFACTORY TUBERCLE see **OLFACTORY PATHWAYS**

OLIGOCHAETA

IMMUNOLOGY

Earthworm immunity. Cooper EL. **Prog Mol Subcell Biol** 1996;15:10–45 (201 ref.)

OLIGODENDROBLASTOMA see **OLIGODENDROGLIOMA**

OLIGODENDROCYTES see **OLIGODENDROGLIA**

OLIGODENDROGLIA

CYTOLOGY

Origins of spinal cord oligodendrocytes: possible developmental and evolutionary relationships with motor neurons. Richardson WD, et al. **Dev Neurosci** 1997; 19(1):58–68 (44 ref.)
Regulation of oligodendrocyte cell survival and differentiation by ciliary neurotrophic factor, leukemia inhibitory factor, oncostatin M, and interleukin-6. Vos JP, et al. **Perspect Dev Neurobiol** 1996;4(1):39–52 (133 ref.)

DRUG EFFECTS

On the track of cell survival pharmaceuticals in the oligodendrocyte type-2 astrocyte lineage. Noble M, et al. **Perspect Dev Neurobiol** 1996;3(2):121–31 (125 ref.)

METABOLISM

Relationship of iron to oligodendrocytes and myelination. Connor JR, et al. **Glia** 1996 Jun;17(2):83–93 (92 ref.)

PATHOLOGY

The Norton Lecture: a review of the oligodendrocyte in the multiple sclerosis lesion. Raine CS. **J Neuroimmunol** 1997 Aug;77(2):135–52 (123 ref.)

PHYSIOLOGY

Regulation of oligodendrocyte development and CNS myelination by growth factors: prospects for therapy of demyelinating disease. McMorris FA, et al. **Brain Pathol** 1996 Jul;6(3):313–29 (170 ref.)
Pericytes in the microvasculature. Hirschi KK, et al. **Cardiovasc Res** 1996 Oct;32(4):687–98 (144 ref.)
Proteolipid protein: is it more than just a structural component of myelin? Knapp PE. **Dev Neurosci** 1996; 18(4):297–308 (128 ref.)
Origins of spinal cord oligodendrocytes: possible developmental and evolutionary relationships with motor neurons. Richardson WD, et al. **Dev Neurosci** 1997; 19(1):58–68 (44 ref.)
The pathobiology of the oligodendrocyte. Ludwin SK. **J Neuropathol Exp Neurol** 1997 Feb;56(2):111–24 (113 ref.)
Development and differentiation of oligodendrocytes. Yamada M, et al. **Jpn J Physiol** 1996 Apr;46(2):105–10 (57 ref.)
To what extent is oligodendrocyte progenitor migration a limiting factor in the remyelination of multiple sclerosis lesions? Franklin RJ, et al. **Mult Scler** 1997 Apr;3(2):84–7 (29 ref.)
The reactions of the oligodendrocyte. Ludwin SK. **Mult Scler** 1996 Dec;2(5):241–3 (24 ref.)
Do oligodendrocytes divide? Norton WT. **Neurochem Res** 1996 Apr;21(4):495–503 (121 ref.)
On the track of cell survival pharmaceuticals in the oligodendrocyte type-2 astrocyte lineage. Noble M, et al. **Perspect Dev Neurobiol** 1996;3(2):121–31 (125 ref.)
Oligodendrocyte origins. Miller RH. **Trends Neurosci** 1996 Mar;19(3):92–6 (37 ref.)

TRANSPLANTATION

Understanding the molecular basis of cell migration; implications for clinical therapy in multiple sclerosis. Milner R. **Clin Sci (Colch)** 1997 Feb;92(2):113–22 (57 ref.)
Transplanting oligodendrocyte progenitors into the adult CNS. Franklin RJ, et al. **J Anat** 1997 Jan;190 (Pt 1):23–33 (52 ref.)

OLIGODENDROGLIOMA

[Intraventricular oligodendroglioma. Description of 2 cases] Romero Z, et al. **Invest Clin** 1996 Mar;37(1):51–9 (31 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Clear cell ependymoma: a mimic of oligodendroglioma: clinicopathologic and ultrastructural considerations. Min KW, et al. **Am J Surg Pathol** 1997 Jul;21(7):820–6 (20 ref.)

SURGERY

Tumors and approaches to the lateral ventricles. Introduction and overview. Piepmeier JM. **J Neurooncol** 1996 Dec; 30(3):267–74 (36 ref.)

OLIGODEOXYRIBONUCLEOTIDE PRIMERS see **DNA PRIMERS**

OLIGODEOXYRIBONUCLEOTIDES

GENETICS

Use of codon cassette mutagenesis for saturation mutagenesis. Kegler-Ebo DM, et al. **Methods Mol Biol** 1996;57:297–310 (14 ref.)

METABOLISM

Oligonucleotide micro-arrays for identification of unknown mutations: how far from reality? Ginot F. **Hum Mutat** 1997; 10(1):1–10 (50 ref.)

PHARMACOKINETICS

Controversies in the cellular pharmacology of oligodeoxynucleotides. Stein CA. **Antisense Nucleic Acid Drug Dev** 1997 Jun;7(3):207–9 (18 ref.)

PHARMACOLOGY

Inhibition of HIV-1 replication by targeting the Rev protein. Nakaya T, et al. **Leukemia** 1997 Apr;11 Suppl 3:134–7 (24 ref.)

OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE see **OLIGONUCLEOTIDES, ANTISENSE**

OLIGOHYDRAMNIOS

DIAGNOSIS

Clinical assessment of amniotic fluid. Moore TR. **Clin Obstet Gynecol** 1997 Jun;40(2):303–13 (52 ref.)

ETIOLOGY

[Changes in the amniotic fluid volume in fetal structural anomalies] Khaidar A, et al. **Akush Ginekol (Sofiia)** 1997; 36(1):18–21 (20 ref.) **(Bul)**

THERAPY

Clinical role of amnio-infusion. Ouzounian JG, et al. **Baillieres Clin Obstet Gynaecol** 1996 Jun;10(2):259–72 (56 ref.)
Therapeutic interventions for oligohydramnios: amnioinfusion and maternal hydration. Kilpatrick SJ. **Clin Obstet Gynecol** 1997 Jun;40(2):328–36 (39 ref.)
Amnioinfusion. Hofmeyr GJ, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Feb;64(2):159–65 (57 ref.)

ULTRASONOGRAPHY

Oligohydramnios: sonographic diagnosis and clinical implications. Hill LM. **Clin Obstet Gynecol** 1997 Jun; 40(2):314–27 (55 ref.)

OLIGONUCLEOTIDE-DIRECTED MUTAGENESIS see **MUTAGENESIS, SITE-DIRECTED**

OLIGONUCLEOTIDE PRIMERS see **DNA PRIMERS**

OLIGONUCLEOTIDE PROBES

see related
NUCLEIC ACID HYBRIDIZATION

OLIGONUCLEOTIDES

ANALYSIS

Qualitative and quantitative measurements of oligonucleotides in gene therapy: Part I. In vitro models. Tewary HK, et al. **J Pharm Biomed Anal** 1997 Apr; 15(7):857–73 (77 ref.)
Qualitative and quantitative measurements of oligonucleotides in gene therapy: Part II in vivo models. Tewary HK, et al. **J Pharm Biomed Anal** 1997 May; 15(8):1127–35 (36 ref.)
[Detection of undegraded oligonucleotides in living cells by fluorescence resonance energy transfer] Hirano K, et al. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(14):2139–43 (11 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

Recent progress in oligonucleotide synthesis. Pfleiderer W, et al. **Acta Biochim Pol** 1996;43(1):37–44 (27 ref.)

CHEMISTRY

Circular oligonucleotides: new concepts in oligonucleotide design. Kool ET. **Annu Rev Biophys Biomol Struct** 1996; 25:1–28 (80 ref.)
31P NMR spectroscopy in oligonucleotide research and development. Hirschbein BL, et al. **Antisense Nucleic Acid Drug Dev** 1997 Feb;7(1):55–61 (16 ref.)
An oligonucleotide analog approach to the decoding region of 16S rRNA. Stern S, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11–12):899–905 (19 ref.)
A hitchhiker's guide to antisense and nonantisense biochemical pathways. Branch AD. **Hepatology** 1996 Dec; 24(6):1517–29 (136 ref.)

GENETICS

Construction of linker-scanning mutations using PCR. Harlow PP, et al. **Methods Mol Biol** 1996;57:287–95 (19 ref.)
Construction of linker-scanning mutations by oligonucleotide ligation. Hobson GM, et al. **Methods Mol Biol** 1996; 57:279–85 (7 ref.)

PHARMACOKINETICS

Oligonucleotides and polynucleotides as biologically active compounds. Vlassov VV, et al. **Prog Nucleic Acid Res Mol Biol** 1997;57:95–143 (336 ref.)
Pharmacokinetics of 99mTc-labeled oligonucleotides. Hnatowich DJ. **Q J Nucl Med** 1996 Sep;40(3):202–8 (31 ref.)

PHARMACOLOGY

Oligonucleotides and polynucleotides as biologically active compounds. Vlassov VV, et al.
Prog Nucleic Acid Res Mol Biol 1997;57:95–143 (336 ref.)
[Specific control of gene expression by oligonucleotides: from chemistry to clinical aspects] Hélène C. **Ann Pharm Fr** 1997;55(3):95–103 (34 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

[Application of decoy strategy] Morishita R, et al.
Nippon Rinsho 1996 Sep;54(9):2583–90 (18 ref.) (Eng. Abstr.) **(Jpn)**

OLIGONUCLEOTIDES, ANTISENSE

Ex vivo bone marrow purging with oligonucleotides. Bergan RC. **Antisense Nucleic Acid Drug Dev** 1997 Jun;7(3):251–5 (21 ref.)
Morpholino antisense oligomers: design, preparation, and properties. Summerton J, et al.
Antisense Nucleic Acid Drug Dev 1997 Jun;7(3):187–95 (41 ref.)
Strategy for designing specific antisense oligonucleotide sequences. Mitsuhashi M. **J Gastroenterol** 1997 Apr; 32(2):282–7 (37 ref.)
Antisense and the kidney. Oberbauer R, et al.
Kidney Blood Press Res 1996;19(5):221–4 (19 ref.)
Use of antisense-generating plasmids to probe the function of signal transduction proteins in primary neurons. Abogadie FC, et al. **Methods Mol Biol** 1997;83:217–25 (7 ref.)
Nuclear application of antisense oligonucleotides by microinjection and ballistomagnetic transfer to identify G protein heterotrimers activating phospholipase C. Kalkbrenner F, et al. **Methods Mol Biol** 1997;83:203–16 (16 ref.)
Antisense strategies in neurobiology. Weiss B, et al.
Neurochem Int 1997 Sep;31(3):321–48 (189 ref.)
Development of antisense and antigene oligonucleotide analogs. Miller PS. **Prog Nucleic Acid Res Mol Biol** 1996; 52:261–91 (126 ref.)
[Development of gene delivery system by using DNA complexes and their application to antisense drug] Sato T, et al. **Nippon Rinsho** 1996 Oct;54(10):2857–66 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Specific regulation of gene expression in brain by antisense oligodeoxynucleotides] Yoshikawa M, et al.
Nippon Yakurigaku Zasshi 1997 Apr;109(4):187–91 (10 ref.) (Eng. Abstr.) **(Jpn)**

CHEMICAL SYNTHESIS

Natural antisense RNA/target RNA interactions: possible models for antisense oligonucleotide drug design. Delihas N, et al. **Nat Biotechnol** 1997 Aug;15(8):751–3 (55 ref.)

CHEMISTRY

Recent advances in capillary electrophoresis of DNA fragments and PCR products in poly(n-substituted acrylamides). Righetti PG, et al. **Anal Biochem** 1997 Jan 15;244(2):195–207 (82 ref.)
Identification and characterization of second-generation antisense oligonucleotides. Dean NM, et al.
Antisense Nucleic Acid Drug Dev 1997 Jun;7(3):229–33 (19 ref.)
Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors. Altmann KH, et al.
Biochem Soc Trans 1996 Aug;24(3):630–7 (46 ref.)
A hitchhiker's guide to antisense and nonantisense biochemical pathways. Branch AD. **Hepatology** 1996 Dec; 24(6):1517–29 (136 ref.)

DIAGNOSTIC USE

[Prerequisites for diagnostic use of antisense oligonucleotides in nuclear medicine] Hildebrandt M, et al.
Nuklearmedizin 1996 Aug;35(4):126–31 (39 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Perturbing gene expression with oligodeoxynucleotides: research and potential therapeutic applications. Gewirtz AM. **Mt Sinai J Med** 1996 Oct–Nov;63(5–6):372–80 (14 ref.)
Making (anti)sense of non-coding sequence conservation. Lipman DJ. **Nucleic Acids Res** 1997 Sep 15;25(18):3580–3 (54 ref.)
[Gene-directed biologically active substances (antisense oligonucleotides and their derivatives)] Knorre DG.
Bioorg Khim 1997 Jan;23(1):3–17 (104 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Oligonucleotide analogs might be designed to bind to m-RNA. Crooke ST. **Anticancer Drug Des** 1997 Jul; 12(5):311–3 (13 ref.)
Ribonuclease H-mediated antisense effects in intact human leukaemia cells. Tidd DM. **Biochem Soc Trans** 1996 Aug; 24(3):619–23 (21 ref.)
Targeting RNA structures by antisense oligonucleotides. Toulmé JJ, et al. **Biochimie** 1996;78(7):663–73 (85 ref.)

PHARMACOKINETICS

Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Geary RS, et al.
Anticancer Drug Des 1997 Jul;12(5):383–93 (23 ref.)
Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase. Henry SP, et al. **Anticancer Drug Des** 1997 Jul;12(5):409–20 (38 ref.)
Pharmacology of therapeutic oligonucleotides. Diasio RB, et al. **Antisense Nucleic Acid Drug Dev** 1997 Jun;7(3):239–43 (30 ref.)
Pharmacokinetics of antisense analogues in the central nervous system. Szklarczyk A, et al. **Neurochem Int** 1997 Sep;31(3):413–23 (43 ref.)
Pharmacokinetics of 99mTc-labeled oligonucleotides. Hnatowich DJ. **Q J Nucl Med** 1996 Sep;40(3):202–8 (31 ref.)

PHARMACOLOGY

Antisense oligonucleotides for in vivo studies of angiotensin receptors. Phillips MI, et al. **Adv Exp Med Biol** 1996; 396:79–92 (42 ref.)
Advances in understanding the pharmacological properties of antisense oligonucleotides. Crooke ST.
Adv Pharmacol 1997;40:1–49 (222 ref.)
Towards genomic drug therapy with antisense oligonucleotides. Lönnberg H, et al. **Ann Med** 1996 Dec; 28(6):511–22 (88 ref.)
Targeting c-myc in leukemia. Calabretta B, et al.
Anticancer Drug Des 1997 Jul;12(5):373–81 (31 ref.)
In vitro and in vivo activity of antisense inhibitors of ras: potential for clinical development. Cowsert LM.
Anticancer Drug Des 1997 Jul;12(5):359–71 (59 ref.)
Oligonucleotide analogs might be designed to bind to m-RNA. Crooke ST. **Anticancer Drug Des** 1997 Jul; 12(5):311–3 (13 ref.)
Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Geary RS, et al.
Anticancer Drug Des 1997 Jul;12(5):383–93 (23 ref.)
Antisense oligonucleotide inhibitors of isozymes of protein kinase C: in vitro and in vivo activity, and clinical development as anti-cancer therapeutics. McGraw K, et al. **Anticancer Drug Des** 1997 Jul;12(5):315–26 (42 ref.)
First- and second-generation antisense inhibitors targeted to human c-raf kinase: in vitro and in vivo studies. Monia BP. **Anticancer Drug Des** 1997 Jul;12(5):327–39 (46 ref.)
Antisense-protein kinase A: a single-gene-based therapeutic approach. Cho-Chung YS, et al.
Antisense Nucleic Acid Drug Dev 1997 Jun;7(3):217–23 (20 ref.)
Protein kinase A-directed antisense restrains cancer growth: sequence-specific inhibition of gene expression.
Cho-Chung YS. **Antisense Nucleic Acid Drug Dev** 1996 Fall;6(3):237–44 (52 ref.)
Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors. Altmann KH, et al.
Biochem Soc Trans 1996 Aug;24(3):630–7 (46 ref.)
Antisense oligonucleotides as inhibitors of signal transduction: development from research tools to therapeutic agents. Dean NM, et al. **Biochem Soc Trans** 1996 Aug;24(3):623–9 (41 ref.)
Ribonuclease H-mediated antisense effects in intact human leukaemia cells. Tidd DM. **Biochem Soc Trans** 1996 Aug; 24(3):619–23 (21 ref.)
Antisense regulation of oncogenes in human cancer. Mukhopadhyay T, et al. **Crit Rev Oncog** 1996;7(3–4):151–90 (251 ref.)
Experience with antisense oligodeoxynucleotides in renal cells. Ganz MB, et al. **Exp Nephrol** 1997 May–Jun; 5(3):175–9 (14 ref.)
Promise and problems of Bcl-2 antisense therapy [editorial; comment] Reed JC. **J Natl Cancer Inst** 1997 Jul 16; 89(14):988–90 (36 ref.) Comment on: J Natl Cancer Inst 1997 Jul 16;89(14):1027–36.
Antisense oligonucleotides induce functional deletion of ligand gated ion channels in cultured neurons and brain explants. Brussaard AB. **J Neurosci Methods** 1997 Jan; 71(1):55–64 (21 ref.)
Antisense oligodeoxynucleotides as specific tools for studying neuroendocrine and behavioral functions: some prospects and problems. Nicot A, et al. **J Neurosci Methods** 1997 Jan;71(1):45–53 (57 ref.)
Antisense oligonucleotides in psychopharmacology and behaviour: promises and pitfalls. Robinson ES, et al.
J Psychopharmacol (Oxf) 1997;11(3):259–69 (100 ref.)
Antisense strategies in dopamine receptor pharmacology. Weiss B, et al. **Life Sci** 1997;60(7):433–55 (110 ref.)
DNA antisense strategies in the study of receptors for vasoactive peptides, and of growth and wound-healing factors. D'Orléans-Juste P, et al. **Mol Cell Biochem** 1997 Jul;172(1–2):199–211 (77 ref.)
Putative roles for the inducible transcription factor c-fos in the central nervous system: studies with antisense oligonucleotides. Chiasson BJ, et al. **Neurochem Int** 1997 Sep;31(3):459–75 (136 ref.)
On the role of c-fos expression in striatal transmission. The antisense oligonucleotide approach. Sommer W, et al.
Neurochem Int 1997 Sep;31(3):425–36 (50 ref.)
Antisense oligonucleotides as therapeutics for malignant diseases. Ho PT, et al. **Semin Oncol** 1997 Apr;24(2):187–202 (103 ref.)
In vivo studies with antisense oligonucleotides. Akhtar S, et al. **Trends Pharmacol Sci** 1997 Jan;18(1):12–8 (61 ref.)
[The "antisense" strategy: a new approach in the development of antineoplastic substances and gene therapy] Hélène C.
J Pharm Belg 1997 Mar–Apr;52(2):79–85 (29 ref.) **(Fre)**

THERAPEUTIC USE

Antisense inhibition of virus infections. Kilkuskie RE, et al.
Adv Pharmacol 1997;40:437–83 (181 ref.)
Developing oligonucleotide therapeutics for human leukemia. Gewirtz AM. **Anticancer Drug Des** 1997 Jul;12(5):341–58 (54 ref.)
Proof of mechanism of antisense drugs. Crooke ST.
Antisense Nucleic Acid Drug Dev 1996 Summer;6(2):145–7 (21 ref.)
Recruiting the 2-5A system for antisense therapeutics. Torrence PF, et al. **Antisense Nucleic Acid Drug Dev** 1997 Jun;7(3):203–6 (7 ref.)
Anti-sense and gene therapy approaches to the treatment of lymphomas. Devereux S, et al.
Baillieres Clin Haematol 1996 Dec;9(4):819–34 (86 ref.)
Antisense approaches to the gene therapy of cancer--'Recnac'. Gibson I. **Cancer Metastasis Rev** 1996 Sep;15(3):287–99 (73 ref.)
Antisense therapy. Narayanan R, et al. **Curr Opin Oncol** 1996 Nov;8(6):509–15 (66 ref.)
Therapeutic intervention in glomerulonephritis by oligonucleotides. Kashihara N, et al. **Exp Nephrol** 1997 Mar–Apr;5(2):126–31 (29 ref.)
Recent status of the antisense oligonucleotide approaches in oncology. Ma L, et al. **Fundam Clin Pharmacol** 1996; 10(2):97–115 (170 ref.)
Gene and other biological therapies for vascular diseases. Stephan D, et al. **Fundam Clin Pharmacol** 1997;11(2):97–110 (85 ref.)
A hitchhiker's guide to antisense and nonantisense biochemical pathways. Branch AD. **Hepatology** 1996 Dec; 24(6):1517–29 (136 ref.)
Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants. von Weizsäcker F, et al. **Hepatology** 1997 Aug;26(2):251–5 (72 ref.)
Anti-HIV therapy with antisense oligonucleotides and ribozymes: realistic approaches or expensive myths? Akhtar S, et al. **J Antimicrob Chemother** 1996 Aug;38(2):159–65 (64 ref.)
Combination of antisense oligonucleotide and low-dose chemotherapy in hematological malignancies. Benner E, et al. **J Pharmacol Toxicol Methods** 1997 Jun;37(4):229–35 (34 ref.)
Antisense strategy: biological utility and prospects in the treatment of hematological malignancies. Warzocha K, et al. **Leuk Lymphoma** 1997 Jan;24(3–4):267–81 (101 ref.)
Progress in antisense therapeutics. Crooke ST.
Med Res Rev 1996 Jul;16(4):319–44 (183 ref.)
Antisense technology and prospects for therapy of viral infections and cancer. Wagner RW, et al.
Mol Med Today 1997 Jan;3(1):31–8 (36 ref.)
Antisense oligonucleotides for central nervous system tumors. Hall WA, et al. **Neurosurgery** 1996 Feb; 38(2):376–83 (24 ref.)
Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine. Oberbauer R. **Wien Klin Wochenschr** 1997 Jan 31;109(2):40–6 (34 ref.)
[Prospects of a more selective chemotherapy with antisense oligonucleotides] Le Doan T, et al.
Ann Med Interne (Paris) 1996;147(8):542–52 (133 ref.) **(Fre)**
[Prospects for antisense therapy of human leukemias] Maekawa T. **Hum Cell** 1996 Mar;9(1):17–24 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Perspectives of antisense therapy] Matysiak W, et al.
Pol Arch Med Wewn .996 Jul;96(1):84–9 (49 ref.) **(Pol)**
[The significance of specific oligonucleotides in clinical medicine and their use in the treatment of patients with infective diseases] Bojić I. **Vojnosanit Pregl** 1996 Sep–Oct; 53(5):399–408 (94 ref.) **(Scr)**

TOXICITY

Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides. Henry SP, et al.
Anticancer Drug Des 1997 Jul;12(5):395–408 (37 ref.)
Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase. Henry SP, et al. **Anticancer Drug Des** 1997 Jul;12(5):409–20 (38 ref.)

OLIGOPEPTIDES

Growth hormone-releasing peptides: clinical and basic aspects. Argente J, et al. **Horm Res** 1996;46(4–5):155–9 (36 ref.)
Oligopeptides as osmotic agents for peritoneal dialysis. Wang T, et al. **Perit Dial Int** 1997;17 Suppl 2:S75–9 (39 ref.)
Prevention of cancer metastasis in mice with

OLIGOPEPTIDES

fibronectin-related substances. Azuma I, et al. **Princess Takamatsu Symp** 1994;24:125-41 (70 ref.)

Angiopeptin--an immunological review. Motomura N, et al. **Transpl Immunol** 1996 Jun;4(2):99-104 (72 ref.)

CHEMISTRY

Ligand function of antigenized antibodies expressing the RGD motif. Billetta R, et al. **Chem Immunol** 1997;65:159-78 (53 ref.)

Structures, assays and receptors for locust adipokinetic hormones. Goldsworthy GJ, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 Aug; 117(4):483-96 (136 ref.)

Insect neuropeptide proctolin and its analogues. An overview of the present literature. Konopińska D. **J Pept Res** 1997 Jun;49(6):457-66 (56 ref.)

DIAGNOSTIC USE

Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency. Pombo M, et al. **J Pediatr Endocrinol Metab** 1996 Jun;9 Suppl 3:333-8 (35 ref.)

Evaluation of pituitary GH reserve with GHRP-6. Popovic V, et al. **J Pediatr Endocrinol Metab** 1996 Jun;9 Suppl 3:289-98 (23 ref.)

GENETICS

[Resistance to activated protein C by mutation of the factor V gene. Most frequent blood coagulation defect in venous thromboses] Peus D, et al. **Hautarzt** 1997 Feb;48(2):84-8 (41 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Renal assimilation of oligopeptides: physiological mechanisms and metabolic importance. Adibi SA. **Am J Physiol** 1997 May;272(5 Pt 1):E723-36 (92 ref.)

Structures, assays and receptors for locust adipokinetic hormones. Goldsworthy GJ, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 Aug; 117(4):483-96 (136 ref.)

Antiflammins: endogenous nonapeptides with regulatory effect on inflammation. Moreno JJ. **Gen Pharmacol** 1997 Jan;28(1):23-6 (41 ref.)

Biologically active pyroglutamyl N-terminal oligopeptides: parts of larger molecules? Elgjo K, et al. **Physiol Chem Phys Med NMR** 1995;27(4):351-3 (17 ref.)

PHARMACOLOGY

Structure-based design of peptides that inhibit IgE binding to its high-affinity receptor Fc epsilon RI. McDonnell JM, et al. **Biochem Soc Trans** 1997 May;25(2):387-92 (34 ref.)

Development of new anticancer drugs in Japan--tubulin-interacting agents. Tsukagoshi S. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:94-9 (5 ref.)

Preclinical studies on the broad-spectrum neuropeptide growth factor antagonist G. Jones DA, et al. **Gen Pharmacol** 1997 Feb;28(2):183-9 (22 ref.)

The dermorphin peptide family. Melchiorri P, et al. **Gen Pharmacol** 1996 Oct;27(7):1099-107 (95 ref.)

Insect neurotransmission: neurotransmitters and their receptors. Osborne RH. **Pharmacol Ther** 1996;69(2):117-42 (429 ref.)

PHYSIOLOGY

RGD and other recognition sequences for integrins. Ruoslahti E. **Ann Rev Cell Dev Biol** 1996;12:697-715 (103 ref.)

Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis. Zöller B, et al. **Annu Rev Med** 1997;48:45-58 (102 ref.)

Neuropeptide FF, a mammalian neuropeptide with multiple functions [published erratum appears in Prog Neurobiol 1996 Jun;49(3):285] Panula P, et al. **Prog Neurobiol** 1996 Mar-Apr;48(4-5):461-87 (93 ref.)

The revolution in insect neuropeptides illustrated by the adipokinetic hormone/red pigment-concentrating hormone family of peptides. Gäde G. **Z Naturforsch [C]** 1996 Sep-Oct;51(9-10):607-17 (86 ref.)

[RGD-dependent and -independent binding domains of fibronectin to GPIIb/IIIa] Mohri H. **Rinsho Byori** 1997 Feb;Suppl 104:80-8 (35 ref.) **(Jpn)**

THERAPEUTIC USE

Therapeutic potential of RGD peptides in acute renal injury. Goligorsky MS, et al. **Kidney Int** 1997 May;51(5):1487-92 (48 ref.)

OLIGORIBONUCLEOTIDES

CHEMISTRY

From oligonucleotide shapes to genomic SELEX: novel biological regulatory loops. Gold L, et al. **Proc Natl Acad Sci U S A** 1997 Jan 7;94(1):59-64 (42 ref.)

METABOLISM

Recruiting the 2-5A system for antisense therapeutics. Torrence PF, et al. **Antisense Nucleic Acid Drug Dev** 1997 Jun;7(3):203-6 (7 ref.)

OLIGORIBONUCLEOTIDES, ANTISENSE see **OLIGONUCLEOTIDES, ANTISENSE**

OLIGOSACCHARIDES

Glycobiology and medicine: an introduction. Axford J. **J R Soc Med** 1997 May;90(5):260-4 (53 ref.)

Oligosaccharides with beneficial health effects: a Japanese perspective. Oku T. **Nutr Rev** 1996 Nov;54(11 Pt 2):S59-66 (32 ref.)

Functional effects of food components and the gastrointestinal system: chicory fructooligosaccharides. Roberfroid MB. **Nutr Rev** 1996 Nov;54(11 Pt 2):S38-42 (20 ref.)

[Abnormalities of N-linked oligosaccharide moieties of glycoproteins in patients with myotonic dystrophy] Ito K, et al. **Rinsho Shinkeigaku** 1995 Dec;35(12):1484-5 (4 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

HPLC of oligosaccharides in glycobiology. Lo-Guidice JM, et al. **Biomed Chromatogr** 1996 Nov-Dec;10(6):290-6 (65 ref.)

The analysis of complex carbohydrates: relevance of values obtained in vitro. Champ MM. **Proc Nutr Soc** 1996 Nov; 55(3):863-80 (52 ref.)

BIOSYNTHESIS

Complexity in O-linked oligosaccharide biosynthesis engendered by multiple polypeptide N-acetylgalactosaminyltransferases. Marth JD. **Glycobiology** 1996 Oct;6(7):701-5 (60 ref.)

The role of the lipid matrix in the biosynthesis of dolichyl-linked oligosaccharides. Schutzbach JS. **Glycoconj J** 1997 Feb;14(2):175-82 (77 ref.)

[The structural and functional characteristics of the dolichol cycle enzymes] Shpakov AO, et al. **Tsitologiia** 1996; 38(9):889-913 (154 ref.) (Eng. Abstr.) **(Rus)**

CHEMICAL SYNTHESIS

Thioglycosides as glycosyl donors in oligosaccharide synthesis. Garegg PJ. **Adv Carbohydr Chem Biochem** 1997; 52:179-205 (189 ref.)

Some contributions of chemical synthesis to glycobiology: an organic chemist's point of view. Garegg PJ. **Med Res Rev** 1996 Jul;16(4):345-64 (63 ref.)

Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. Walenga JM, et al. **Thromb Res** 1997 Apr 1;86(1):1-36 (141 ref.)

CHEMISTRY

Steroid and triterpenoid oligoglycosides of marine origin. Minale L, et al. **Adv Exp Med Biol** 1996;404:335-56 (63 ref.)

Identification of oligosaccharides by matrix-assisted laser desorption ionization and electrospray MS. Harvey DJ, et al. **Biochem Soc Trans** 1996 Aug;24(3):905-12 (40 ref.)

Rapid, sensitive sequencing of oligosaccharides from glycoproteins. Rudd PM, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):488-97 (50 ref.)

Structure and dynamics of oligosaccharides: NMR and modeling studies. Peters T, et al. **Curr Opin Struct Biol** 1996 Oct;6(5):710-20 (82 ref.)

"Unusual" modifications and variations of vertebrate oligosaccharides: are we missing the flowers for the trees? Varki A. **Glycobiology** 1996 Oct;6(7):707-10 (60 ref.)

Oligosaccharide sequencing technology. Rudd PM, et al. **Nature** 1997 Jul 10;388(6638):205-7 (27 ref.)

METABOLISM

Insulin second messengers. Strålfors P. **Bioessays** 1997 Apr; 19(4):327-35 (79 ref.)

Engineered cell surfaces: fertile ground for molecular landscaping. Mahal LK, et al. **Chem Biol** 1997 Jun; 4(6):415-22 (59 ref.)

Signalling events elicited in plants by defined oligosaccharide structures. Promé JC. **Curr Opin Struct Biol** 1996 Oct; 6(5):671-8 (48 ref.)

Is there evidence for phospho-oligosaccharides as insulin mediators? Field MC. **Glycobiology** 1997 Mar;7(2):161-8 (65 ref.)

Do the binding properties of oligosaccharides in milk protect human infants from gastrointestinal bacteria? Newburg DS. **J Nutr** 1997 May;127(5 Suppl):980S-984S (18 ref.)

Expression of sialosyl-T and disialosyl-T antigens in erythroid cells. Muroi K, et al. **Leuk Lymphoma** 1997 May; 25(5-6):403-14 (31 ref.)

Oligosaccharins, brassinolides, and jasmonates: nontraditional regulators of plant growth, development, and gene expression. Creelman RA, et al. **Plant Cell** 1997 Jul; 9(7):1211-23 (160 ref.)

Fermentation of non-digestible oligosaccharides by human colonic bacteria. Gibson GR, et al. **Proc Nutr Soc** 1996 Nov;55(3):899-912 (93 ref.)

PHARMACOLOGY

Inhibitory effect of oleanene-type triterpene oligoglycosides on ethanol absorption: the structure-activity relationships. Yoshikawa M, et al. **Adv Exp Med Biol** 1996;404:207-18 (40 ref.)

Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. Walenga JM, et al. **Thromb Res** 1997 Apr 1;86(1):1-36 (141 ref.)

THERAPEUTIC USE

Anti-adhesion therapy. Cornejo CJ, et al. **Adv Pharmacol** 1997;39:99-142 (200 ref.)

[New approach for the absorbent therapy of verotoxin-producing Escherichia coli infection] Takeda T, et al. **Nippon Rinsho** 1997 Mar;55(3):751-7 (10 ref.) **(Jpn)**

OLIGOSPERMIA

ETIOLOGY

[Iatrogenic obstructive azoospermia] Bellorofonte C, et al. **Arch Ital Urol Androl** 1996 Dec;68(5):359-62 (12 ref.) (Eng. Abstr.) **(Ita)**

[Surgical therapy of obstructive azoospermia: microsurgery] Fenice O, et al. **Arch Ital Urol Androl** 1996 Dec; 68(5):379-88 (29 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

The azoospermic factor on the Y chromosome. Shinka T, et al. **Acta Paediatr Jpn** 1996 Aug;38(4):399-404 (34 ref.)

[Azoospermia and genetic mutations: implications for the methods of in vitro fertilization] Rocchietti March M, et al. **Minerva Endocrinol** 1996 Dec;21(4):123-31 (19 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Microsurgical aspects of the treatment of azoospermia. The BMFT Study Group for Microsurgery. Weidner W, et al. **Int J Androl** 1995 Dec;18 Suppl 2:63-6 (32 ref.)

[Surgical therapy of obstructive azoospermia: microsurgery] Fenice O, et al. **Arch Ital Urol Androl** 1996 Dec; 68(5):379-88 (29 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

New therapeutic possibilities handling residual azoospermia. Schoysman R, et al. **Acta Eur Fertil** 1995 Jul-Aug; 26(4):131-6 (21 ref.)

Azoospermia and intracytoplasmic sperm injection. Ubaldi F, et al. **Acta Eur Fertil** 1995 Jan-Feb;26(1):21-4 (16 ref.)

Assisted reproductive technology in the management of azoospermic men--the Austrian experience. Lunglmayr G, et al. **Andrologia** 1996;28 Suppl 1:83-6 (28 ref.)

OLIGURIA

THERAPY

Reversing oliguria in critically ill patients. DePriest J. **Postgrad Med** 1997 Sep;102(3):245-6, 251-2, 258 passim (20 ref.)

OLIVARY NUCLEUS

ANATOMY & HISTOLOGY

Cerebellar nuclei: the olivary connection. Ruigrok TJ. **Prog Brain Res** 1997;114:167-92 (74 ref.)

PHYSIOLOGY

Signal processing in the C2 module of the flocculus and its role in head movement control. De Zeeuw CI, et al. **Prog Brain Res** 1997;114:299-320 (86 ref.)

Intrinsic properties and environmental factors in the regeneration of adult cerebellar axons. Rossi F, et al. **Prog Brain Res** 1997;114:283-96 (43 ref.)

Cerebellar nuclei: the olivary connection. Ruigrok TJ. **Prog Brain Res** 1997;114:167-92 (74 ref.)

Some organizing principles for the control of movement based on olivocerebellar physiology. Welsh JP, et al. **Prog Brain Res** 1997;114:449-61 (57 ref.)

OLIVOPONTOCEREBELLAR ATROPHY

DIAGNOSIS

[MRI of degenerative extrapyramidal syndromes. Parkinson disease, progressive supranuclear palsy and multiple system atrophy] Elkeslassy A, et al. **J Neuroradiol** 1996 Dec; 23(3):157-63 (14 ref.) (Eng. Abstr.) **(Fre)**

OLIVOPONTOCEREBELLAR DEGENERATION see **OLIVOPONTOCEREBELLAR ATROPHY**

OLLIER'S DISEASE see **ENCHONDROMATOSIS**

OMEGA-3 FATTY ACIDS see **FATTY ACIDS, OMEGA-3**

OMEGA PROTEIN see **DNA TOPOISOMERASE**

OMENTUM

Ovarian fibromatosis, ascites and omental fibrosis. Scurry J, et al. **Histopathology** 1996 Jan;28(1):81–4 (6 ref.)
Omental herniation through a 5–mm laparoscopic cannula site. Toub DB, et al. **J Am Assoc Gynecol Laparosc** 1994 Aug;1(4 Pt 1):413–4 (4 ref.)
Colon carcinoma discovered in an adolescent during inguinal hernia repair. LeClair LL, et al. **J Am Osteopath Assoc** 1997 Feb;97(2):100–1 (11 ref.)
Primary leiomyosarcoma arising in the lesser sac: report of a case. Kimura H, et al. **Surg Today** 1997;27(7):672–5 (10 ref.)
[A case of an omental cyst] Kolarov I, et al. **Khirurgiia (Sofiia)** 1996;49(4):49–51 (0 ref.) **(Bul)**
[Primary omental torsion in children: report of 2 cases and review of the literature] Pesce C, et al. **Pediatr Med Chir** 1996 Jul–Aug;18(4):403–5 (16 ref.) (Eng. Abstr.) **(Ita)**

ABNORMALITIES

Strangulation ileus resulting from encasement of a loop of the small intestine by the great omentum, caused by abnormal adhesion. Kimura H, et al. **J Gastroenterol** 1996 Oct;31(5):714–6 (8 ref.)

BLOOD SUPPLY

Residents' corner. Answer to case of the month #46. Torsion and infarction of the greater omentum. Garant M, et al. **Can Assoc Radiol J** 1997 Apr;48(2):130–2 (6 ref.)
An aneurysm of the right gastroepiploic artery. Funahashi S, et al. **J Cardiovasc Surg (Torino)** 1997 Aug;38(4):385–8 (11 ref.)
Total arterial myocardial revascularization [editorial] Calafiore AM. **Thorac Cardiovasc Surg** 1997 Jun; 45(3):105–8 (17 ref.)

PATHOLOGY

Does primary omental pregnancy exist? Berghella V, et al. **Gynecol Obstet Invest** 1996;42(2):133–6 (18 ref.)
[Hairy cell leukemia with specific omental involvement] Volkova MA, et al. **Ter Arkh** 1996;68(7):79–82 (26 ref.) **(Rus)**

PHYSIOLOGY

Role of omentum–associated lymphoid tissue in the progression of peritoneal carcinomatosis. Shimotsuma M, et al. **Cancer Treat Res** 1996;82:147–54 (21 ref.)

TRANSPLANTATION

Free gastro–omental flap reconstruction of the complex, irradiated pharyngeal wound. Carlson GW, et al. **Head Neck** 1997 Jan;19(1):68–71 (11 ref.)
Physical barriers in adhesion prevention. Saravelos HG, et al. **J Reprod Med** 1996 Jan;41(1):42–51 (75 ref.)

OMEPRAZOLE

ADMINISTRATION & DOSAGE

Helicobacter pylori: new developments and treatments. Veldhuyzen van Zanten SJ, et al. **Can Med Assoc J** 1997 Jun 1;156(11):1565–74 (112 ref.)
Clarithromycin and omeprazole as helicobacter pylori eradication therapy in patients with H. pylori–associated gastric disorders. Markham A, et al. **Drugs** 1996 Jan; 51(1):161–78 (67 ref.)

ANALOGS & DERIVATIVES

Lansoprazole and omeprazole in the treatment of acid peptic disorders [see comments] Blum RA. **Am J Health Syst Pharm** 1996 Jun 15;53(12):1401–15 (174 ref.) Comment in: Am J Health Syst Pharm 1996 Dec 1;53(23):2882, 2884.
Lansoprazole: a proton pump inhibitor. Garnett WR. **Ann Pharmacother** 1996 Dec;30(12):1425–36 (108 ref.)
Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Andersson T. **Clin Pharmacokinet** 1996 Jul; 31(1):9–28 (170 ref.)
Drug interactions with proton pump inhibitors. Unge P, et al. **Drug Saf** 1997 Mar;16(3):171–9 (115 ref.)
Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid–related disorders. Langtry HD, et al. **Drugs** 1997 Sep;54(3):473–500 (205 ref.)
A case study: evaluation of results and selection of additional studies. Furihata C. **J Toxicol Sci** 1996 Dec;21(5):465–7 (15 ref.)
Lansoprazole: a comprehensive review. Zimmermann AE, et al. **Pharmacotherapy** 1997 Mar–Apr;17(2):308–26 (184 ref.)
[Helicobacter pylori eradication: modified triple therapy with lansoprazole] Müller P, et al. **Fortschr Med** 1996 Dec 20; 114(35–36):497–9 (17 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Drug interactions with proton pump inhibitors. Unge P, et al. **Drug Saf** 1997 Mar;16(3):171–9 (115 ref.)

PHARMACOKINETICS

Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Andersson T. **Clin Pharmacokinet** 1996 Jul; 31(1):9–28 (170 ref.)

PHARMACOLOGY

Lansoprazole and omeprazole in the treatment of acid peptic disorders [see comments] Blum RA. **Am J Health Syst Pharm** 1996 Jun 15;53(12):1401–15 (174 ref.) Comment in: Am J Health Syst Pharm 1996 Dec 1;53(23):2882, 2884.

THERAPEUTIC USE

The impact of omeprazole and laparoscopy upon hiatal hernia and reflux esophagitis. McKenzie D, et al. **J Am Coll Surg** 1996 Oct;183(4):413–8 (46 ref.)
Eradication of Helicobacter pylori: omeprazole in combination with antibiotics. Axon AT, et al. **Scand J Gastroenterol Suppl** 1996;215:82–9 (58 ref.)
[Intravenous omeprazole versus ranitidine in the treatment of hemorrhagic duodenal ulcer: a prospective randomized study] Cardi M, et al. **Ann Chir** 1997;51(2):136–9 (32 ref.) (Eng. Abstr.) **(Fre)**
[What is the current therapeutic role of omeprazole in gastroduodenal ulcer disease?] Gisbert JP, et al. **Rev Esp Enferm Dig** 1997 Feb;89(2):116–23 (131 ref.) **(Spa)**

TOXICITY

A case study: evaluation of results and selection of additional studies. Furihata C. **J Toxicol Sci** 1996 Dec;21(5):465–7 (15 ref.)

OMP PROTEINS see **BACTERIAL OUTER MEMBRANE PROTEINS**

OMPHALOCELE see **HERNIA, UMBILICAL**

OMPHALOMESENTERIC DUCT see **VITELLINE DUCT**

ONCHOCERCA VOLVULUS

IMMUNOLOGY

Immunopathology of onchocerciasis: a role for eosinophils in onchocercal dermatitis and keratitis. Pearlman E. **Chem Immunol** 1997;66:26–40 (62 ref.)

ONCHOCERCIASIS

DIAGNOSIS

Molecular approaches to the diagnosis of onchocerciasis. Bradley JE, et al. **Adv Parasitol** 1996;37:57–106 (171 ref.)

DRUG THERAPY

Treatment of onchocerciasis. Van Laethem Y, et al. **Drugs** 1996 Dec;52(6):861–9 (51 ref.)

IMMUNOLOGY

Immunopathology of onchocerciasis: a role for eosinophils in onchocercal dermatitis and keratitis. Pearlman E. **Chem Immunol** 1997;66:26–40 (62 ref.)

ONCOCYTOMA see **ADENOMA, OXYPHILIC**

ONCOGENE PRODUCTS see **ONCOGENE PROTEINS**

ONCOGENE PROTEIN P21(RAS)

CHEMISTRY

Intermediate trapping and laue X–ray diffraction: potential for enzyme mechanism, dynamics, and inhibitor screening. Stoddard BL. **Pharmacol Ther** 1996;70(3):215–56 (95 ref.)
[Inhibitors of isoprenylation of ras p21] Yoshimatsu K. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1495–502 (30 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

[Inhibitors of isoprenylation of ras p21] Yoshimatsu K. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1495–502 (30 ref.) (Eng. Abstr.) **(Jpn)**

ONCOGENE PROTEIN P190(BCR–ABL) see **FUSION PROTEINS, BCR–ABL**

ONCOGENE PROTEIN P210(BCR–ABL) see **FUSION PROTEINS, BCR–ABL**

ONCOGENE PROTEIN PP60(SRC) see **ONCOGENE PROTEIN PP60(V–SRC)**

ONCOGENE PROTEIN PP60(V–SRC)

METABOLISM

DNA tumor viruses and Src family tyrosine kinases, an intimate relationship. Messerschmitt AS, et al. **Virology** 1997 Jan 20;227(2):271–80 (100 ref.)

ONCOGENE PROTEINS

[Myb: structure and regulation of activity] Ishii S. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1320–7 (29 ref.) **(Jpn)**

ANALYSIS

Bcl–1/cyclin D1 in malignant lymphoma. de Boer CJ, et al. **Ann Oncol** 1997;8 Suppl 2:109–17 (145 ref.)
Relevance of cyclin D1 and other molecular markers to cancer chemoprevention. Weinstein IB. **J Cell Biochem Suppl** 1996;25:23–8 (19 ref.)
Immunohistochemical detection and gene amplification of cyclin D1 in mammary infiltrating ductal carcinoma. Frierson HF Jr, et al. **Mod Pathol** 1996 Jul;9(7):725–30 (38 ref.)
[Cyclin D1: from the study of the cell cycle to the histopathologic diagnosis] Barbareschi M, et al. **Pathologica** 1996 Jun;88(3):236–8 (9 ref.) **(Ita)**

ANTAGONISTS & INHIBITORS

Oncogene products as therapeutic targets for cancer. Huang PS, et al. **Curr Opin Oncol** 1997 Jan;9(1):94–100 (83 ref.)

BIOSYNTHESIS

PRAD1/Cyclin D1 gene overexpression in mantle cell lymphoma. Oka K, et al. **Leuk Lymphoma** 1996 Mar; 21(1–2):37–42 (50 ref.)

BLOOD

[Oncoproteins and anti–oncoproteins in blood serum as biomarkers of early health effects induced by occupational and environmental carcinogens] Lutz W, et al. **Med Pr** 1996;47(5):511–8 (29 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Oncoprotein networks. Hunter T. **Cell** 1997 Feb 7; 88(3):333–46 (126 ref.)
Implication of cyclin D1 in malignant lymphoma. Callanan M, et al. **Crit Rev Oncog** 1996;7(3–4):191–203 (89 ref.)
The function of BCR/ABL and related proto–oncogenes. Gotoh A, et al. **Curr Opin Hematol** 1997 Jan;4(1):3–11 (98 ref.)
PRAD1/Cyclin D1 gene overexpression in mantle cell lymphoma. Oka K, et al. **Leuk Lymphoma** 1996 Mar; 21(1–2):37–42 (50 ref.)
Immunohistochemical detection and gene amplification of cyclin D1 in mammary infiltrating ductal carcinoma. Frierson HF Jr, et al. **Mod Pathol** 1996 Jul;9(7):725–30 (38 ref.)
[Analysis of the p16INK4, p15INK4B genes abnormality and the amplification of cyclin D1 gene in esophageal cancer] Takamura H, et al. **Nippon Rinsho** 1996 Apr;54(4):1043–8 (16 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Oncoprotein signalling and mitosis. Laird AD, et al. **Cell Signal** 1997 May–Jun;9(3–4):249–55 (126 ref.)
The VAV family of signal transduction molecules. Bustelo XR. **Crit Rev Oncog** 1996;7(1–2):65–88 (114 ref.)
Tumor genes and their proteins in cytologic and surgical specimens: relevance and detection systems. Leong AS, et al. **Diagn Cytopathol** 1995 Dec;13(5):411–22 (109 ref.)
Cyclin D1 in mammary carcinoma. Barnes DM. **J Pathol** 1997 Mar;181(3):267–9 (31 ref.)
Cyclin D1 overexpression in malignant lymphomas. Nakamura S, et al. **Pathol Int** 1997 Jul;47(7):421–9 (75 ref.)

PHYSIOLOGY

Catching a Gli–mpse of Hedgehog. Ruiz i Altaba A. **Cell** 1997 Jul 25;90(2):193–6 (20 ref.)
Cyclin D1/PRAD1 as a central target in oncogenesis. Hosokawa Y, et al. **J Lab Clin Med** 1996 Mar;127(3):246–52 (67 ref.)
Recent progress on the role of Axl, a receptor tyrosine kinase, in malignant transformation of myeloid leukemias. Neubauer A, et al. **Leuk Lymphoma** 1997 Mar;25(1–2):91–6 (23 ref.)
New insights into the control of cell growth; the role of the AxI family. Crosier KE, et al. **Pathology** 1997 May; 29(2):131–5 (43 ref.)

ONCOGENE PROTEINS, FUSION

GENETICS

The PML nuclear compartment and cancer. Doucas V, et al. **Biochim Biophys Acta** 1996 Dec 9;1288(3):M25–9 (38 ref.)
Characterisation of the PML/RAR alpha rearrangement associated with t(15;17) acute promyelocytic leukaemia. Grimwade D, et al. **Curr Top Microbiol Immunol** 1997; 220:81–112 (153 ref.)
Biology of EWS/FLI and related fusion genes in Ewing's sarcoma and primitive neuroectodermal tumor. May WA, et al. **Curr Top Microbiol Immunol** 1997;220:143–50 (35 ref.)
Chromosome translocation–mediated conversion of a tumor

ONCOGENE PROTEINS, FUSION

suppressor gene into a dominant oncogene: fusion of EWS1 to WT1 in desmoplastic small round cell tumors. Rauscher FJ 3rd. **Curr Top Microbiol Immunol** 1997;220:151–62 (47 ref.)

The biological significance of the multidrug resistance gene MRP in inversion 16 leukemias. Kuss BJ, et al. **Leuk Lymphoma** 1996 Feb;20(5–6):357–64 (34 ref.)

PHYSIOLOGY

Fusions involving paired box and fork head family transcription factors in the pediatric cancer alveolar rhabdomyosarcoma. Barr FG. **Curr Top Microbiol Immunol** 1997;220:113–29 (68 ref.)

E2A–Pbx1 induces growth, blocks differentiation, and interacts with other homeodomain proteins regulating normal differentiation. Kamps MP. **Curr Top Microbiol Immunol** 1997;220:25–43 (68 ref.)

E2A–HLF chimeric transcription factors in pro–B cell acute lymphoblastic leukemia. Look AT. **Curr Top Microbiol Immunol** 1997;220:45–53 (54 ref.)

TLS–CHOP and the role of RNA–binding proteins in oncogenic transformation. Ron D. **Curr Top Microbiol Immunol** 1997;220:131–42 (53 ref.)

ONCOGENE PROTEINS, VIRAL

GENETICS

[Genetic alterations associated with pathologic differentiation of Wilms' tumors] Chevalier G, et al. **Bull Cancer** 1997 Mar;84(3):289–303 (127 ref.) (Eng. Abstr.) **(Fre)**

[Sequence analysis of the carboxy terminal of the Epstein–Barr virus LMP–1 oncogene in Epstein–Barr virus associated disorders] Itakura O, et al. **Nippon Rinsho** 1997 Feb;55(2):467–72 (15 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

The oncogenic role of human papillomavirus proteins. Barbosa MS. **Crit Rev Oncog** 1996;7(1–2):1–18 (155 ref.)

Molecular mechanisms of virus–induced carcinogenesis: the interaction of viral factors with cellular tumor suppressor proteins. Hoppe–Seyler F, et al. **J Mol Med** 1995 Nov; 73(11):529–38 (96 ref.)

The disruption of cell cycle checkpoints by papillomavirus oncoproteins contributes to anogenital neoplasia. Galloway DA, et al. **Semin Cancer Biol** 1996 Dec;7(6):309–15 (49 ref.)

Mechanism of HPV E6 proteins in cellular transformation. Huibregtse JM, et al. **Semin Cancer Biol** 1996 Dec; 7(6):317–26 (85 ref.)

Are particular Epstein–Barr virus strains linked to disease? Jenkins PJ, et al. **Semin Cancer Biol** 1996 Aug;7(4):209–15 (52 ref.)

Interactions of the human papillomavirus E7 protein with cell cycle regulators. Jones DL, et al. **Semin Cancer Biol** 1996 Dec;7(6):327–37 (66 ref.)

THERAPEUTIC USE

The development of therapeutic vaccines of the management of malignant melanoma. Dalgleish AG, et al. **Cancer Surv** 1996;26:289–319 (158 ref.)

ONCOGENES

Genetic linkage studies for the identification of cancer–related genes. Brancolini V, et al. **Ann Ist Super Sanita** 1996;32(1):173–80 (45 ref.)

Genetic alterations in gastric cancer. Ranzani GN. **Ann Ist Super Sanita** 1996;32(1):101–10 (75 ref.)

Oncogenes and onco–suppressor genes in female genital cancer. Koffa M, et al. **Ann N Y Acad Sci** 1997 Jun 17; 816:347–55 (58 ref.)

Oncogenic role of the Y chromosome. McDonough PG. **Ann N Y Acad Sci** 1997 Jun 17;816:356–61 (17 ref.)

Contribution of oncogenes and tumor suppressor genes to myeloid leukemia. Wolff L. **Biochim Biophys Acta** 1997 Jun 7;1332(3):F67–104 (352 ref.)

Oncogenes as inducers of tumor angiogenesis. Rak J, et al. **Cancer Metastasis Rev** 1995 Dec;14(4):263–77 (85 ref.)

Tissue reconstitution, or transgenic mammary gland, technique for modeling breast cancer development. Edwards PA. **Cancer Treat Res** 1996;83:23–36 (41 ref.)

Oncogene–initiated aberrant signaling engenders the metastatic phenotype: synergistic transcription factor interactions are targets for cancer therapy. Denhardt DT. **Crit Rev Oncog** 1996;7(3–4):261–91 (238 ref.)

Oncogenes and cell proliferation [editorial] Broach JR, et al. **Curr Opin Genet Dev** 1997 Feb;7(1):1–6 (14 ref.)

Role of oncogenes in resistance and killing by cancer therapeutic agents. el–Deiry WS. **Curr Opin Oncol** 1997 Jan;9(1):79–87 (122 ref.)

Molecular genetics and molecular biology advances in brain tumors. James CD, et al. **Curr Opin Oncol** 1996 May; 8(3):188–95 (64 ref.)

Developments in cytogenetics and oncogenes in acute leukemia. Strout MP, et al. **Curr Opin Oncol** 1997 Jan; 9(1):8–17 (76 ref.)

Chromosome translocation–mediated conversion of a tumor suppressor gene into a dominant oncogene: fusion of EWS1 to WT1 in desmoplastic small round cell tumors. Rauscher FJ 3rd. **Curr Top Microbiol Immunol** 1997;220:151–62 (47 ref.)

Control of differentiation, transformation, and apoptosis in granulosa cells by oncogenes, oncoviruses, and tumor suppressor genes. Amsterdam A, et al. **Endocr Rev** 1997 Aug;18(4):435–61 (367 ref.)

Molecular pathogenesis of thyroid cancer: the significance of oncogenes, tumor suppressor genes, and genomic instability. Farid NR. **Exp Clin Endocrinol Diabetes** 1996; 104 Suppl 4:1–12 (111 ref.)

The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias. Lo Coco F, et al. **Haematologica** 1997 May–Jun;82(3):364–70 (66 ref.)

Regulation of hematopoietic cell proliferation and differentiation by the myb oncogene family of transcription factors. Golay J, et al. **Int J Clin Lab Res** 1996;26(1):24–32 (95 ref.)

Chromosomal abnormalities and oncogenes. Mitani K. **Int J Hematol** 1996 Feb;63(2):81–93 (74 ref.)

Regulation of apoptosis by oncogenes. Green DR, et al. **J Cell Biochem** 1996 Jan;60(1):33–8 (25 ref.)

Oncogene alterations in primary, recurrent, and metastatic human bone tumors. Pompetti F, et al. **J Cell Biochem** 1996 Oct;63(1):37–50 (37 ref.)

BCL–2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. Reed JC, et al. **J Cell Biochem** 1996 Jan;60(1):23–32 (55 ref.)

Regulation of nuclear oncogenes expressed in lung cancer cell lines. Sabichi AL, et al. **J Cell Biochem Suppl** 1996; 24:218–27 (31 ref.)

Viruses and oncogenes in brain tumors. Archer GE, et al. **J Neurovirol** 1997 May;3 Suppl 1:S76–7 (7 ref.)

Cancer genes and molecular oncology in the clinic. Caldas C, et al. **Lancet** 1997 May;349 Suppl 2:SII16–8 (32 ref.)

Overexpression of the MDM2 oncogene in leukemia and lymphoma. Watanabe T, et al. **Leuk Lymphoma** 1996 May; 21(5–6):391–7, color plates XVI following 5 (49 ref.)

Oncogenic mechanisms mediated by DNA methylation. Laird PW. **Mol Med Today** 1997 May;3(5):223–9 (40 ref.)

The human chromosome 22–located genes and malignancies of the central nervous system. Dumanski JP. **Neuropathol Appl Neurobiol** 1996 Oct;22(5):412–7 (57 ref.)

Tumour suppressive properties of the adenovirus 5 E1A oncogene. Mymryk JS. **Oncogene** 1996 Oct 17;13(8):1581–9 (153 ref.)

Oncogenes and tumor suppressor genes in cutaneous malignant melanoma. Albino AP, et al. **Photochem Photobiol** 1996 Apr;63(4):412–8 (79 ref.)

Oncogenes and tumor suppressor genes in photocarcinogenesis. Ananthaswamy HN, et al. **Photochem Photobiol** 1996 Apr;63(4):428–32 (36 ref.)

One decade of comparative molecular carcinogenesis. Goodrow TL. **Prog Clin Biol Res** 1996;395:57–80 (137 ref.)

Analysis of genetic factors and molecular mechanisms in the development of hereditary and carcinogen–induced tumors of Xiphophorus. Schartl A, et al. **Recent Results Cancer Res** 1997;143:225–35 (24 ref.)

Complementation tagging of cooperating oncogenes in knockout mice. Allen JD, et al. **Semin Cancer Biol** 1996 Oct;7(5):299–306 (36 ref.)

Molecular and immunopathology studies of oncogenes and tumor–suppressor genes in bladder cancer. Cordon–Cardo C, et al. **World J Urol** 1997;15(2):112–9 (72 ref.)

[Clinical significance of ovarian cancer related oncogenes and tumor suppressor genes] Neng J, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Dec;30(12):756–8 (31 ref.) **(Chi)**

[Cytogenetic abnormalities, genetic alterations, and applications for genetic diagnosis in breast cancer] Tsukamoto K, et al. **Nippon Rinsho** 1996 Dec; 54(12):3389–97 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Detection of genetic alterations in human cancer] Shimizu K. **Seikagaku** 1997 May;69(5):311–23 (37 ref.) **(Jpn)**

[Regulation mechanism of specific expression of tumor marker gene during carcinogenesis] Imagawa M. **Yakugaku Zasshi** 1996 Jul;116(7):505–18 (29 ref.) (Eng. Abstr.) **(Jpn)**

[Diagnostic and prognostic significance of oncogenes in pulmonary carcinoma] Anđelić G, et al. **Vojnosanit Pregl** 1996 Sep–Oct;53(5):393–7 (44 ref.) **(Scr)**

GENETICS

Anti–oncogene ribozymes for cancer gene therapy. Irie A, et al. **Adv Pharmacol** 1997;40:207–57 (350 ref.)

The cat and mouse games that genes, viruses, and cells play. Weinberg RA. **Cell** 1997 Mar 7;88(5):573–5 (20 ref.)

Oncogenes and antioncogenes in the development of HPV associated tumors. Crawford L, et al. **Clin Dermatol** 1997 Mar–Apr;15(2):207–15 (96 ref.)

The interaction of oncogene and tumour suppressor gene defects with cytotoxic drugs: its role in the improvement of selective toxicity and the development of new drugs in clinical oncology. Petty RD. **Clin Oncol (R Coll Radiol)** 1996;8(3):186–9 (27 ref.)

Oncogenes and growth factor receptors as diagnostic and prognostic markers in precancers and cancers of the oral mucosa. Burkhardt A. **Curr Top Pathol** 1996;90:223–39 (136 ref.)

Patterns of oncogene activation in human neuroblastoma cells. Corvi R, et al. **J Neurooncol** 1997 Jan;31(1–2):25–31 (38 ref.)

Fusion of the EWS1 and WT1 genes as a result of the t(11;22)(p13;q12) translocation in desmoplastic small round cell tumors. Benjamin LE, et al. **Med Pediatr Oncol** 1996 Nov;27(5):434–9 (34 ref.)

Studies of oncogene activation and tumor suppressor gene inactivation in normal and neoplastic rodent tissue. Buzard GS. **Mutat Res** 1996 Sep;365(1–3):43–58 (111 ref.)

Oncogenes in gynecologic oncology. Maxwell GL, et al. **Obstet Gynecol Surv** 1996 Dec;51(12):710–7 (124 ref.)

The role of ras GTPase activating protein in human tumorigenesis. Friedman E. **Pathobiology** 1995;63(6):348–50 (21 ref.)

[Oncogenesis of T–cell prolymphocytic leukemia (editorial)] Stern MH. **Pathol Biol (Paris)** 1996 Oct;44(8):689–93 (16 ref.) (Eng. Abstr.) **(Fre)**

[Oncogenes and tumor suppressor genes in head and neck squamous cell carcinomas] Maestro R, et al. **Acta Otorhinolaryngol Ital** 1996 Jun;16(3 Suppl 54):21–6 (56 ref.) **(Ita)**

[Oncogenes and oncosuppressor role in head and neck carcinomas] Pastore A, et al. **Acta Otorhinolaryngol Ital** 1996 Jun;16(3 Suppl 54):31–8 (92 ref.) **(Ita)**

[Neurologic diseases due to alterations in oncogenes and tumor suppressing genes] Bello MJ, et al. **Neurologia** 1995 Dec;10 Suppl 1:20–31 (110 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Targeted tumor cytotoxicity mediated by intracellular single–chain anti–oncogene antibodies. Curiel DT. **Adv Pharmacol** 1997;40:51–84 (76 ref.)

PHYSIOLOGY

Tumour–suppressor genes in prostatic oncogenesis: a positional approach. Bookstein R, et al. **Br J Urol** 1997 Mar;79 Suppl 1:28–36 (73 ref.)

Oncogenic regulation and function of keratins 8 and 18. Oshima RG, et al. **Cancer Metastasis Rev** 1996 Dec; 15(4):445–71 (221 ref.)

Oncogenic role of heterotrimeric G proteins. Vallar L. **Cancer Surv** 1996;27:325–38 (74 ref.)

Tumor genes and their proteins in cytologic and surgical specimens: relevance and detection systems. Leong AS, et al. **Diagn Cytopathol** 1995 Dec;13(5):411–22 (109 ref.)

Binding of MAR–DNA elements by mutant p53: possible implications for its oncogenic functions. Deppert W. **J Cell Biochem** 1996 Aug;62(2):172–80 (42 ref.)

ONCOGENIC VIRUSES

see related
TUMOR VIRUS INFECTIONS

PATHOGENICITY

Avian tumor viruses: persistent and evolving pathogens. Witter RL. **Acta Vet Hung** 1997;45(3):251–66 (37 ref.)

PHYSIOLOGY

Molecular mechanisms of virus–induced carcinogenesis: the interaction of viral factors with cellular tumor suppressor proteins. Hoppe–Seyler F, et al. **J Mol Med** 1995 Nov; 73(11):529–38 (96 ref.)

How viral oncogenes make the cell cycle. Jansen–Dürr P. **Trends Genet** 1996 Jul;12(7):270–5 (52 ref.)

p53 and tumour viruses: catching the guardian off–guard. Neil JC, et al. **Trends Microbiol** 1997 Mar;5(3):115–20 (69 ref.)

ONCOGENS see **CARCINOGENS**

ONCOLOGIC NURSING

The silent ones: a review of sampling issues and biases pertinent to the area of pediatric oncology procedural pain. Williams HA. **J Pediatr Oncol Nurs** 1996 Jan;13(1):31–9 (76 ref.)

New chemotherapy treatment options and implications for nursing care [published erratum appears in Oncol Nurs Forum 1997 Apr;24(3):442] Berg DT. **Oncol Nurs Forum** 1997 Jan–Feb;24(1 Suppl):5–12 (36 ref.)

Nurse and patient satisfaction with three types of venous access devices. Dearborn P, et al. **Oncol Nurs Forum** 1997 Jan–Feb;24(1 Suppl):34–40 (47 ref.)

Intravenous drug compatibility: a challenge for the oncology nurse. Eisenberg S. **Oncol Nurs Forum** 1997 Jun; 24(5):859–69 (54 ref.)

Immunologic advances in monoclonal antibody therapy: implications for oncology nursing. Karius D, et al. **Oncol Nurs Forum** 1997 Apr;24(3):483–94; QUIZ 495–6 (74 ref.)

Quality of life and the cancer experience: the state–of–the–knowledge. King CR, et al. **Oncol Nurs Forum** 1997 Jan–Feb;24(1):27–41 (138 ref.)

Rehabilitation of the cancer patient at home. Blesch KS. **Semin Oncol Nurs** 1996 Aug;12(3):219–25 (51 ref.)

Selected issues in quality improvement and risk management. Chapman AH, et al. **Semin Oncol Nurs** 1996 Aug; 12(3):231–7 (20 ref.)

Home infusion therapy. Gorski LA, et al. **Semin Oncol Nurs** 1996 Aug;12(3):193–201 (30 ref.)

Ethical considerations in home care of the oncology patient. Haddad AM. **Semin Oncol Nurs** 1996 Aug;12(3):226–30 (14

ref.)
The oncology nurse's role in cancer risk assessment and counseling. MacDonald DJ. **Semin Oncol Nurs** 1997 May; 13(2):123–8 (21 ref.)
Role of the oncology nurse in home care: family-centered practice. McEnroe LE. **Semin Oncol Nurs** 1996 Aug; 12(3):188–92 (20 ref.)
Pain management in home care. Magrum LC, et al. **Semin Oncol Nurs** 1996 Aug;12(3):202–18 (53 ref.)
The blood cell transplant program. Nelson JP. **Semin Oncol Nurs** 1997 Aug;13(3):208–15 (23 ref.)
Diseases treated with blood cell transplants. Yoder LH. **Semin Oncol Nurs** 1997 Aug;13(3):164–71 (60 ref.)
Nursing implications in the management of superficial bladder cancer. Games J. **Semin Urol Oncol** 1996 Feb;14(1 Suppl 1):36–40 (27 ref.)

EDUCATION

Current review of cancer nursing in Hong Kong. Mak JM. **Cancer Nurs** 1997 Jun;20(3):197–200 (22 ref.)

METHODS

The power of humor and play as nursing interventions for a child with cancer: a case report. Frankenfield PK. **J Pediatr Oncol Nurs** 1996 Jan;13(1):15–20 (21 ref.)
Nursing challenges of caring for patients with HIV-related malignancies. Moran TA. **Oncology (Huntingt)** 1996 Oct; 10(10):1509–16; discussion 1523–4, 1527 (55 ref.)

ORGANIZATION & ADMINISTRATION

Current review of cancer nursing in Hong Kong. Mak JM. **Cancer Nurs** 1997 Jun;20(3):197–200 (22 ref.)

STANDARDS

Hospice nursing. McNally JC, et al. **Semin Oncol Nurs** 1996 Aug;12(3):238–43 (19 ref.)

ONCOLOGY, MEDICAL see **MEDICAL ONCOLOGY**

ONCOLOGY, RADIATION see **RADIATION ONCOLOGY**

ONCOLYTIC VIRUSES see **VIRUSES**

ONCOPROTEINS see **ONCOGENE PROTEINS**

ONCORHYNCHUS GORBUSCHA see **SALMON**

ONCORHYNCHUS MYKISS

PHYSIOLOGY

Dimethyl formamide (DMFA) and ethylene glycol (EG) are estrogenic in rainbow trout. Ren L, et al. **Chem Biol Interact** 1996 Sep 27;102(1):63–7 (6 ref.)

ONCORHYNCHUS NERKA see **SALMON**

ONCORHYNCHUS TSHAWYTSCHA see **SALMON**

ONCORNAVIRUSES see **RETROVIRIDAE**

ONCOVIRINAE see **RETROVIRIDAE**

ONCOVIRUSES see **RETROVIRIDAE**

ONCOVIRUSES, TYPE C see **RETROVIRIDAE**

ONDANSETRON

ADMINISTRATION & DOSAGE

[Prevention of postoperative nausea and vomiting with single and repeat administration of ondansetron--review of the literature on different administration forms] Saur P, et al. **Anaesthesiol Reanim** 1996;21(5):131–5 (30 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOKINETICS

Clinical pharmacokinetics of ondansetron. A review. Simpson KH, et al. **J Pharm Pharmacol** 1996 Aug; 48(8):774–81 (60 ref.)

PHARMACOLOGY

Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. Wilde MI, et al. **Drugs** 1996 Nov;52(5):773–94 (185 ref.)

ONDINE'S CURSE see **SLEEP APNEA SYNDROMES**

ONIONS see **ALLIUM**

ONLAYS see **INLAYS**

ONYCHOMYCOSIS

Nail infections. Midgley G, et al. **Dermatol Clin** 1996 Jan; 14(1):41–49 (25 ref.)

DIAGNOSIS

Onychomycosis. Hoffman AF, et al. **Clin Podiatr Med Surg** 1996 Jan;13(1):13–29 (67 ref.)

DRUG THERAPY

Onychomycosis. Going for cure. Gupta AK, et al. **Can Fam Physician** 1997 Feb;43:299–305 (49 ref.)
Newer systemic antifungal drugs for the treatment of onychomycosis. Chiritescu MM, et al. **Clin Podiatr Med Surg** 1996 Oct;13(4):741–58 (758 ref.)
Current management of onychomycosis. An overview. Gupta AK, et al. **Dermatol Clin** 1997 Jan;15(1):121–35 (157 ref.)
Oral antifungal drug interactions. Katz HI, et al. **Dermatol Clin** 1997 Jul;15(3):535–44 (92 ref.)
Onychomycosis—treatment, relapse and re-infection. Hull PR. **Dermatology** 1997;194 Suppl 1:7–9 (18 ref.)
Oral terbinafine (Lamisil) in the treatment of fungal infections of the skin and nails. Roberts DT. **Dermatology** 1997;194 Suppl 1:37–9 (13 ref.)
Treatment of onychomycosis and tinea pedis with intermittent itraconazole therapy. Del Rosso JQ. **J Am Osteopath Assoc** 1996 Oct;96(10):607–9 (19 ref.)
Advances in the treatment of superficial fungal infections: focus on onychomycosis and dry tinea pedis. Del Rosso JQ. **J Am Osteopath Assoc** 1997 Jun;97(6):339–46 (48 ref.)

EPIDEMIOLOGY

Epidemiology and ecology of onychomycosis. Summerbell RC. **Dermatology** 1997;194 Suppl 1:32–6 (12 ref.)

MICROBIOLOGY

Uncommon clinical patterns of Fusarium nail infection: report of three cases. Baran R, et al. **Br J Dermatol** 1997 Mar;136(3):424–7 (23 ref.)
Epidemiology and ecology of onychomycosis. Summerbell RC. **Dermatology** 1997;194 Suppl 1:32–6 (12 ref.)

PATHOLOGY

Childhood white superficial onychomycosis caused by Trichophyton rubrum: report of seven cases and review of the literature. Ploysangam T, et al. **J Am Acad Dermatol** 1997 Jan;36(1):29–32 (23 ref.)

OOCYTE DONATION

Endometrial preparation: lessons from oocyte donation. Younis JS, et al. **Fertil Steril** 1996 Dec;66(6):873–84 (89 ref.)
Information access and donated gametes: how much do we know about who wants to know? Broderick P, et al. **Hum Reprod** 1995 Dec;10(12):3338–41 (40 ref.)
In quest of the perfect analogy for using in vitro fertilization patients as oocyte donors. Nisker JA. **Womens Health Issues** 1997 Jul–Aug;7(4):241–7 (31 ref.)

LEGISLATION & JURISPRUDENCE

What are the effects of anonymity and secrecy on the welfare of the child in gamete donation? Shenfield F, et al. **Hum Reprod** 1997 Feb;12(2):392–5 (28 ref.)

METHODS

Pregnancy wastage and reproductive aging: the oocyte donation model. Sauer MV. **Curr Opin Obstet Gynecol** 1996 Jun;8(3):226–9 (42 ref.)

STANDARDS

Ethical considerations of assisted reproductive technologies. The Ethics Committee of the American Society for Reproductive Medicine. **Fertil Steril** 1997 May;67(5 Suppl 1):i–iii, 1S–9S (0 ref.)

VETERINARY

Transvaginal aspiration. Squires EL, et al. **Vet Clin North Am Equine Pract** 1996 Apr;12(1):13–29 (42 ref.)

OOCYTES

Cryopreservation of human oocytes: a review of current problems and perspectives. Bernard A, et al. **Hum Reprod Update** 1996 May–Jun;2(3):193–207 (105 ref.)
Advances in production of embryos in vitro from juvenile and prepubertal oocytes from the calf and lamb. Armstrong DT, et al. **Reprod Fertil Dev** 1997;9(3):333–9 (24 ref.)
Intracytoplasmic sperm injection for treatment of the infertile male. Kim ED, et al. **Tex Med** 1997 Jul;93(7):50–6 (41 ref.)

CYTOLOGY

DNA repair by oocytes. Ashwood-Smith MJ, et al. **Mol Hum Reprod** 1996 Jan;2(1):46–51 (47 ref.)
Potential effects of age-associated oxidative stress on mammalian oocytes/embryos. Tarín JJ. **Mol Hum Reprod** 1996 Oct;2(10):717–24 (122 ref.)
[The roles of the Mos-MAPK pathway in oocyte meiosis and cellular transformation] Sagata N. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1847–55 (62 ref.) **(Jpn)**

DRUG EFFECTS

Direct non-genomic effects of follicular steroids on maturing human oocytes: oestrogen versus androgen antagonism. Tesarik J, et al. **Hum Reprod Update** 1997 Mar–Apr; 3(2):95–100 (20 ref.)
[Mini-review: oocyte activation mechanisms. Different models, comparison: marine invertebrate and mammal] Ciapa B, et al. **Contracept Fertil Sex** 1996 Jul–Aug; 24(7–8):564–70 (47 ref.) (Eng. Abstr.) **(Fre)**
[Oocyte maturation. From animal experiments to human reproduction techniques] Lefèvre B. **Contracept Fertil Sex** 1996 Jul–Aug;24(7–8):559–63 (34 ref.) (Eng. Abstr.) **(Fre)**

GROWTH & DEVELOPMENT

Development of oocyte banks and systems for the in-vitro development of oocytes: future directions for the treatment of infertility. Carroll J. **Hum Reprod** 1996 Sep;11 Suppl 1:159–68; discussion 169–71 (39 ref.)
Low density lipoprotein receptor gene family members mediate yolk deposition. Bujo H, et al. **J Nutr** 1997 May; 127(5 Suppl):801S–804S (29 ref.)
Mammalian oocyte growth and development in vitro. Eppig JJ, et al. **Mol Reprod Dev** 1996 Jun;44(2):260–73 (156 ref.)
Follicular dominance and oocyte maturation. Campbell BK, et al. **Zygote** 1996 Nov;4(4):327–34 (60 ref.)
Influence of granulosa cells and of different somatic cell types on mammalian oocyte development in vitro. Cecconi S, et al. **Zygote** 1996 Nov;4(4):305–7 (34 ref.)
Intra-ovarian regulation of oocyte developmental competence in cattle. Gandolfi F. **Zygote** 1996 Nov; 4(4):323–6 (37 ref.)
Antral follicles confer developmental competence on oocytes. Moor RM, et al. **Zygote** 1996 Nov;4(4):289–93 (11 ref.)
[Oocyte maturation. From animal experiments to human reproduction techniques] Lefèvre B. **Contracept Fertil Sex** 1996 Jul–Aug;24(7–8):559–63 (34 ref.) (Eng. Abstr.) **(Fre)**
[In vitro oocyte maturation in domestic ruminants] Mermillod P, et al. **Contracept Fertil Sex** 1996 Jul–Aug;24(7–8):552–8 (36 ref.) (Eng. Abstr.) **(Fre)**
[Status of development and areas of employment of in vitro production of cattle embryos] Lucas-Hahn A, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Aug–Sep; 103(8–9):306–11 (26 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Elementary events of InsP3-induced Ca2+ liberation in Xenopus oocytes: hot spots, puffs and blips. Parker I, et al. **Cell Calcium** 1996 Aug;20(2):105–21 (44 ref.)
RNA localization and the development of asymmetry during Drosophila oogenesis. Grünert S, et al. **Curr Opin Genet Dev** 1996 Aug;6(4):395–402 (59 ref.)
Coupling transcription to translation: a novel site for the regulation of eukaryotic gene expression. Wolffe AP, et al. **Int J Biochem Cell Biol** 1996 Mar;28(3):247–57 (103 ref.)
Vitellogenin receptors: oocyte-specific members of the low-density lipoprotein receptor supergene family. Schneider WJ. **Int Rev Cytol** 1996;166:103–37 (119 ref.)
Regulation of calcium spiking in mammalian oocytes through a combination of inositol trisphosphate-dependent entry and release. Berridge MJ. **Mol Hum Reprod** 1996 Jun; 2(6):386–8 (25 ref.)
How and why spermatozoa cause calcium oscillations in mammalian oocytes. Swann K, et al. **Mol Hum Reprod** 1996 Jun;2(6):388–90 (42 ref.)
Mechanism of calcium oscillations in human oocytes: a two-store model. Tesarik J, et al. **Mol Hum Reprod** 1996 Jun;2(6):383–6 (38 ref.)

PHYSIOLOGY

The human oocyte. Genetic aspects. Plachot M. **Ann Genet** 1997;40(2):115–20 (28 ref.)
Translational regulation of maternal mRNA. Hake LE, et al. **Biochim Biophys Acta** 1997 Feb 22;1332(1):M31–8 (45 ref.)
Synthesis and function of Mos: the control switch of vertebrate oocyte meiosis. Gebauer F, et al. **Bioessays** 1997 Jan;19(1):23–8 (61 ref.)
What does Mos do in oocytes and somatic cells? Sagata N. **Bioessays** 1997 Jan;19(1):13–21 (70 ref.)
Establishment of polarities in the oocyte of Xenopus laevis: the provisional axial symmetry of the full-grown oocyte of Xenopus laevis. Ubbels GA. **Cell Mol Life Sci** 1997 Apr; 53(4):382–409 (186 ref.)
From oocyte to neuron: do neurotransmitters function in the same way throughout development? Buznikov GA, et al. **Cell Mol Neurobiol** 1996 Oct;16(5):537–59 (150 ref.)
Follicular development and oocyte maturation in hypogonadotrophic women employing recombinant follicle-stimulating hormone: the role of oestradiol. Fauser BC. **Hum Reprod Update** 1997 Mar–Apr;3(2):101–8 (57 ref.)
Oestrogens and follicular and oocyte development. Pellicer A. **Hum Reprod Update** 1997 Mar–Apr;3(2):93–4 (23 ref.)
Direct non-genomic effects of follicular steroids on maturing human oocytes: oestrogen versus androgen antagonism. Tesarik J, et al. **Hum Reprod Update** 1997 Mar–Apr; 3(2):95–100 (20 ref.)
Ion channels and membrane receptors in follicle-enclosed

OOCYTES

Xenopus oocytes. Arellano RO, et al. **Ion Channels** 1996; 4:203–59 (130 ref.)
Treatment of polycystic ovary patients undergoing IVF. Barri PN, et al. **J Assist Reprod Genet** 1997 Jan;14(1):10–2 (17 ref.)
Egg maturation and fertilization in marsupials. Breed WG. **Reprod Fertil Dev** 1996;8(4):617–43 (46 ref.)
Coordination of nuclear and cytoplasmic oocyte maturation in eutherian mammals. Eppig JJ. **Reprod Fertil Dev** 1996; 8(4):485–9 (48 ref.)
Cytoplasmic maturation of the marsupial oocyte during the periovulatory period. Mate KE. **Reprod Fertil Dev** 1996; 8(4):509–19 (63 ref.)
17 alpha,20 beta–dihydroxy–4–pregnen–3–one, a maturation–inducing hormone in fish oocytes: mechanisms of synthesis and action. Nagahama Y. **Steroids** 1997 Jan; 62(1):190–6 (46 ref.)
Maturation and fertilization of equine oocytes. Squires EL. **Vet Clin North Am Equine Pract** 1996 Apr;12(1):31–45 (36 ref.)
Endocrine and paracrine regulation of cumulus expansion. Salustri A, et al. **Zygote** 1996 Nov;4(4):313–5 (13 ref.)
[Physiological mechanisms of oocyte activation] Ozil JP. **Contracept Fertil Sex** 1996 Jul–Aug;24(7–8):571–6 (38 ref.) (Eng. Abstr.) **(Fre)**
[Participation of the follicular fluid in follicular development, oocyte maturation and spermatic function] Durán Reyes G, et al. **Ginecol Obstet Mex** 1997 Aug;65:349–56 (34 ref.) (Eng. Abstr.) **(Spa)**

TRANSPLANTATION

[Oocyte donation: ethical aspects related to the donor] Englert Y, et al. **Contracept Fertil Sex** 1997 Mar;25(3):251–7 (34 ref.) (Eng. Abstr.) **(Fre)**

ULTRASTRUCTURE

Mitosis in the human embryo: the vital role of the sperm centrosome (centriole). Sathananthan AH. **Histol Histopathol** 1997 Jul;12(3):827–56 (86 ref.)
Ultrastructure of the human egg. Sathananthan AH. **Hum Cell** 1997 Mar;10(1):21–38 (44 ref.)
A comparison of oocyte organelles in Monodelphis domestica with those of other marsupials and eutherians. Kress A. **Reprod Fertil Dev** 1996;8(4):521–33 (90 ref.)
Mammalian oocyte organelles with special reference to pleomorphic mitochondria and vacuole formation in marsupials. Ullmann SL, et al. **Reprod Fertil Dev** 1996; 8(4):491–508 (117 ref.)

OOGENESIS

Germ cell development in Drosophila. Williamson A, et al. **Ann Rev Cell Dev Biol** 1996;12:365–91 (122 ref.)
Egg maturation and fertilization in marsupials. Breed WG. **Reprod Fertil Dev** 1996;8(4):617–43 (46 ref.)
Coordination of nuclear and cytoplasmic oocyte maturation in eutherian mammals. Eppig JJ. **Reprod Fertil Dev** 1996; 8(4):485–9 (48 ref.)
Cytoplasmic maturation of the marsupial oocyte during the periovulatory period. Mate KE. **Reprod Fertil Dev** 1996; 8(4):509–19 (63 ref.)

PHYSIOLOGY

Multiple signaling pathways establish both the individuation and the polarity of the oocyte follicle in Drosophila. Morgan MM, et al. **Arch Insect Biochem Physiol** 1996; 33(3–4):211–30 (83 ref.)
RNA localization and the development of asymmetry during Drosophila oogenesis. Grünert S, et al. **Curr Opin Genet Dev** 1996 Aug;6(4):395–402 (59 ref.)
Paradigms to study signal transduction pathways in Drosophila. Engstrom L, et al. **Curr Top Dev Biol** 1997; 35:229–61 (111 ref.)
In vitro maturation of buffalo oocytes: role of insulin and its interaction with gonadotrophins. Totey SM, et al. **J Reprod Fertil Suppl** 1996;50:113–9 (45 ref.)
Maturation and fertilization of equine oocytes. Squires EL. **Vet Clin North Am Equine Pract** 1996 Apr;12(1):31–45 (36 ref.)

OOMYCETES

PHYSIOLOGY

Geographical spread of bacterial and fungal diseases of crustaceans. Alderman DJ. **Rev Sci Tech** 1996 Jun; 15(2):603–32 (59 ref.)

OOPHORECTOMY see **OVARIECTOMY**

OOPHORITIS

ETIOLOGY

Elucidation of autoimmune disease mechanism based on testicular and ovarian autoimmune disease models. Tung KS. **Horm Metab Res** 1995 Dec;27(12):539–43 (38 ref.)

IMMUNOLOGY

Mechanisms of autoimmune disease in the testis and ovary. Tung KS, et al. **Hum Reprod Update** 1995 Jan;1(1):35–50 (114 ref.)

PATHOLOGY

[Oophoritis due to cytomegalovirus in a female AIDS patient (letter)] Ortiz–Rey JA, et al. **Med Clin (Barc)** 1997 Mar 8;108(9):357–8 (10 ref.) **(Spa)**

OPEN–ANGLE GLAUCOMA see **GLAUCOMA, OPEN–ANGLE**

OPEN BITE see **MALOCCLUSION**

OPERATING ROOM NURSING

MANPOWER

Unlicensed assistive personnel in the perioperative setting. Micheli AJ, et al. **Nurs Clin North Am** 1997 Mar; 32(1):201–13 (24 ref.)

OPERATING ROOMS

Asepsis in ophthalmic operating room. Sharma S, et al. **Indian J Ophthalmol** 1996 Sep;44(3):173–7 (6 ref.)

ORGANIZATION & ADMINISTRATION

The operating rooms: cost center management in a managed care environment. DeRiso B, et al. **Int Anesthesiol Clin** 1995 Fall;33(4):133–50 (11 ref.)
Surgical process scheduling: a structured review. Blake JT, et al. **J Soc Health Syst** 1997;5(3):17–30 (39 ref.)

STATISTICS & NUMERICAL DATA

Sexual harassment and hostile environments in the perioperative area. Kaye J. **AORN J** 1996 Feb;63(2):443–6, 448–9 (51 ref.)

OPERATIONAL AUDIT see **MANAGEMENT AUDIT**

OPERATIONS RESEARCH

see related
DECISION THEORY
GAME THEORY

OPERON

Translational regulation of infC operon in Bacillus stearothermophilus. Pediconi D, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1071–8 (25 ref.)
Distribution, diversity and evolution of the bacterial mercury resistance (mer) operon. Osborn AM, et al. **FEMS Microbiol Rev** 1997 Apr;19(4):239–62 (173 ref.)
How is osmotic regulation of transcription of the Escherichia coli proU operon achieved? A review and a model. Gowrishankar J, et al. **Genetica** 1996 May;97(3):363–78 (140 ref.)
[The operon after 25 years (editorial)] Jacob F. **C R Acad Sci III** 1997 Mar;320(3):199–206 (23 ref.) **(Fre)**

GENETICS

The dlt operon in the biosynthesis of D–alanyl–lipoteichoic acid in Lactobacillus casei. Neuhaus FC, et al. **Microb Drug Resist** 1996 Spring;2(1):77–84 (44 ref.)
Antitermination of transcription of catabolic operons. Rutberg B. **Mol Microbiol** 1997 Feb;23(3):413–21 (71 ref.)
Catabolite repression control in the Pseudomonads. Collier DN, et al. **Res Microbiol** 1996 Jul–Sep;147(6–7):551–61 (41 ref.)
Epigenetic phase variation of the pap operon in Escherichia coli. van der Woude M, et al. **Trends Microbiol** 1996 Jan; 4(1):5–9 (39 ref.)

PHYSIOLOGY

Selfish operons and speciation by gene transfer. Lawrence JG. **Trends Microbiol** 1997 Sep;5(9):355–9 (25 ref.)

OPHTHALMIA see **ENDOPHTHALMITIS**

OPHTHALMIC ARTERY

[The late results of the surgical treatment of gigantic carotid–ophthalmic aneurysms of the internal carotid artery (2 cases)] Tropinskaia OF, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1996 Oct–Dec; (4):35–7 (10 ref.) **(Rus)**

OPHTHALMIC SOLUTIONS

Cardiovascular effects of commonly used ophthalmic medications. Shiuey Y, et al. **Clin Cardiol** 1996 Jan;19(1):5–8 (23 ref.)

ADVERSE EFFECTS

Mechanisms of failure in glaucoma filtering surgery: a consequence of antiglaucomatous drugs? Baudouin C. **Int J Clin Pharmacol Res** 1996;16(1):29–41 (39 ref.)
[Adverse effects of local use of beta–blockaders in glaucoma. A literature review and a survey of reports to the adverse drug reaction authority 1986–95] Nygaard HA, et al. **Tidsskr Nor Laegeforen** 1997 May 30;117(14):2019–21 (31 ref.) (Eng. Abstr.) **(Nor)**

POISONING

Eye drops––the hidden poison. Jones AL, et al. **Scott Med J** 1996 Aug;41(4):110–2 (32 ref.)

THERAPEUTIC USE

A guide to ophthalmic pharmacy medicines in the United Kingdom. Doughty MJ. **Ophthalmic Physiol Opt** 1997 Mar; 17 Suppl 1:S2–8 (44 ref.)

OPHTHALMODYNAMOMETRY

[Ophthalmodynamometry. Current aspects] Zolog I. **Oftalmologia** 1997;41(1):5–7 (9 ref.) (Eng. Abstr.) **(Rum)**

OPHTHALMOLOGY

see related
EYE DISEASES
VISION

Do we understand the effects of 'managed care' in ophthalmology? A review and analysis. Asch S, et al. **Arch Ophthalmol** 1997 Apr;115(4):531–6 (48 ref.)
Asepsis in ophthalmic operating room. Sharma S, et al. **Indian J Ophthalmol** 1996 Sep;44(3):173–7 (6 ref.)
Neuro–ophthalmology of the pregeniculate afferent visual system. Developments in 1996 (Part II). Balcer LJ, et al. **J Neuroophthalmol** 1997 Jun;17(2):127–42 (217 ref.)
Ophthalmological monitoring of patients taking antimalarials: preferred practice patterns. Easterbrook M, et al. **J Rheumatol** 1997 Jul;24(7):1390–2 (21 ref.)
[The pediatric physician and consultation in ophthalmology] Boles Carenini B, et al. **Minerva Pediatr** 1995 Dec; 47(12):493–504 (46 ref.) **(Ita)**

INSTRUMENTATION

[Computer applications in ophthalmology] Kuchenbecker J, et al. **Ophthalmologe** 1997 Mar;94(3):248–60 (42 ref.) **(Ger)**
[New communication media for ophthalmology] Spallek G, et al. **Ophthalmologe** 1996 Oct;93(5):596–603 (15 ref.) (Eng. Abstr.) **(Ger)**

METHODS

An appraisal of the accuracy of Littmann's method of determining the real dimension of a retinal object. Barr DB. **Acta Ophthalmol Scand Suppl** 1995;(216):1–12 (38 ref.)
The revolution in molecular genetics and its impact on ophthalmology. Della NG. **Aust N Z J Ophthalmol** 1996 May;24(2):85–95 (86 ref.)
Neuroimaging techniques for the ophthalmologist. Gans M. **Can J Ophthalmol** 1997 Jun;32(4):277–81 (11 ref.)
The role of the therapeutic contact lens in the management of recurrent corneal erosions: a review of treatment strategies. Liu C, et al. **CLAO J** 1996 Jan;22(1):79–82 (42 ref.)
Assessing retinal/neural function in the presence of ocular media opacities. McGraw PV, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Apr;234(4):280–3 (24 ref.)
Optic disc evaluation in glaucoma. Sekhar GC. **Indian J Ophthalmol** 1996 Dec;44(4):235–9 (8 ref.)
Ophthalmologic examination in systemic toxicity studies: an overview. Kuiper B, et al. **Lab Anim** 1997 Apr;31(2):177–83 (31 ref.)
Ophthalmic fluorescein angiography. Cavallerano AA. **Optom Clin** 1996;5(1):1–23 (46 ref.)
Clinical applications of fundus reflection densitometry. Liem AT, et al. **Surv Ophthalmol** 1996 Jul–Aug;41(1):37–50 (108 ref.)
[Anesthesia in ophthalmology] Stefăniu I, et al. **Oftalmologia** 1996 Oct–Dec;40(4):340–8 (5 ref.) (Eng. Abstr.) **(Rum)**

ORGANIZATION & ADMINISTRATION

Ophthalmology and the Internet [editorial] Lindstrom RL. **J Cataract Refract Surg** 1996 Nov;22(9):1127–9 (11 ref.)

TRENDS

AIDS and ophthalmology: a period of transition [editorial; comment] Jabs DA, et al. **Am J Ophthalmol** 1997 Aug; 124(2):227–33 (42 ref.) Comment on: Am J Ophthalmol 1997 Aug;124(2):141–57. Comment on: Am J Ophthalmol 1997 Aug;124(2):158–67. Comment on: Am J Ophthalmol 1997 Aug;124(2):168–80. Comment on: Am J Ophthalmol 1997 Aug;124(2):190–8. Comment on: Am J Ophthalmol 1997 Aug;124(2):199–205. Comment on: Am J Ophthalmol 1997 Aug;124(2):234–9.
Progress in thyroid–associated ophthalmopathy. Wall J, et al. **Autoimmunity** 1995;22(3):191–5 (41 ref.)
Neuro–ophthalmology update [published erratum appears in Can J Ophthalmol 1996 Jun;31(4):207] Anderson DP. **Can J Ophthalmol** 1996 Feb;31(1):2–10 (30 ref.)
Update in cataract and refractive surgery. MacInnis BJ. **Can J Ophthalmol** 1996 Apr;31(3):111–2 (14 ref.)
Levels of evidence and interventional ophthalmology. Sharma S. **Can J Ophthalmol** 1997 Aug;32(5):359–62 (18

ref.)
Dry eye: pharmacological approaches, effects, and progress. Gilbard JP. **CLAO J** 1996 Apr;22(2):141–5 (25 ref.)
The genetics of retinoblastoma and current diagnostic testing. Smith BJ, et al. **J Pediatr Ophthalmol Strabismus** 1996 Mar–Apr;33(2):120–3 (20 ref.)

OPHTHALMOPATHY, INFILTRATIVE see **GRAVES' DISEASE**

OPHTHALMOPATHY, THYROID–ASSOCIATED see **GRAVES' DISEASE**

OPHTHALMOPLEGIA

COMPLICATIONS

External ophthalmoplegia in neuromuscular disorders: case report and review of the literature. Jones KJ, et al. **Neuromuscul Disord** 1997 May;7(3):143–51 (34 ref.)
Surgical management of strabismus associated with chronic progressive external ophthalmoplegia. Wallace DK, et al. **Ophthalmology** 1997 Apr;104(4):695–700 (40 ref.)
[A case of atypical Miller–Fisher syndrome treated with intravenous immunoglobulins (letter)] Auzou P, et al. **Ann Med Interne (Paris)** 1996;147(6):458–9 (12 ref.) **(Fre)**
[Guillain–Barré syndrome and Fisher syndrome] Kusunoki S, et al. **Nippon Rinsho** 1997 Apr;55(4):940–4 (20 ref.) (Eng. Abstr.) **(Jpn)**

CONGENITAL

Diagnosis of a masked bilateral congenital superior oblique palsy. Evens PA, et al. **Bull Soc Belge Ophtalmol** 1996; 261:47–51 (11 ref.)

DIAGNOSIS

Diagnosis of a masked bilateral congenital superior oblique palsy. Evens PA, et al. **Bull Soc Belge Ophtalmol** 1996; 261:47–51 (11 ref.)
Myasthenia gravis and the Miller–Fisher variant of Guillain–Barré syndrome. Newsom–Davis J. **Curr Opin Neurol** 1997 Feb;10(1):18–21 (23 ref.)
External ophthalmoplegia in neuromuscular disorders: case report and review of the literature. Jones KJ, et al. **Neuromuscul Disord** 1997 May;7(3):143–51 (34 ref.)

DRUG THERAPY

[Use of botulinum toxin in ophthalmology] Huber A. **Klin Monatsbl Augenheilkd** 1997 May;210(5):289–92 (28 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Whiplash injury. A clinical review with emphasis on neuro–otological aspects. Fischer AJ, et al. **Clin Otolaryngol** 1997 Jun;22(3):192–201 (134 ref.)
Bilateral pseudo–internuclear ophthalmoplegia in myasthenia gravis. Ito K, et al. **ORL J Otorhinolaryngol Relat Spec** 1997 Mar–Apr; 59(2):122–6 (18 ref.)
[Unusual manifestation of Horton's disease: apropos of 2 case reports] Boschi A, et al. **Bull Soc Belge Ophtalmol** 1995; 259:189–95 (21 ref.) (Eng. Abstr.) **(Fre)**
[A case of relapsing Guillain–Barré syndrome following Miller Fisher syndrome] Mochizuki A, et al. **Rinsho Shinkeigaku** 1996 May;36(5):675–9 (18 ref.) (Eng. Abstr.) **(Jpn)**
[Acute bilateral ophthalmoplegia and nasopharyngeal neoplasms] Marcos Martínez L, et al. **An Med Interna** 1996 Sep;13(9):441–2 (7 ref.) (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

Chronic rhinocerebral mucormycosis. Harril WC, et al. **Laryngoscope** 1996 Oct;106(10):1292–7 (23 ref.)

OPHTHALMOPLEGIA, CHRONIC PROGRESSIVE EXTERNAL

GENETICS

Autosomal dominant chronic progressive external ophthalmoplegia: a tale of two genomes [editorial; comment] Shoubridge EA. **Ann Neurol** 1996 Nov; 40(5):693–4 (15 ref.) Comment on: Ann Neurol 1996 Nov;40(5):707–13.

OPHTHALMOSCOPY

Funduscopy versus photographic assessment of cytomegalovirus retinitis progression: a clinician's perspective. Migdal C. **AIDS** 1996 Dec;10 Suppl 4:S19–23 (4 ref.)

METHODS

Leber's hereditary optic neuropathy: historical and contemporary considerations. Kleiner L, et al. **Optom Clin** 1996;5(3–4):77–112 (210 ref.)
The scanning laser ophthalmoscope. Sharp PF, et al. **Phys Med Biol** 1997 May;42(5):951–66 (80 ref.)

OPIATE DEPENDENCE see **NARCOTIC DEPENDENCE**

OPIATES see **NARCOTICS**

OPIATES, ENDOGENOUS see **OPIOID PEPTIDES**

OPIOID ANALGESICS see **ANALGESICS, OPIOID**

OPIOID ANTAGONISTS see **NARCOTIC ANTAGONISTS**

OPIOID PEPTIDES

see related
RECEPTORS, OPIOID

CHEMISTRY

The hemorphins: a new class of opioid peptides derived from the blood protein hemoglobin. Nyberg F, et al. **Biopolymers** 1997;43(2):147–56 (63 ref.)
Opioid peptides derived from hemoglobin: hemorphins. Zhao Q, et al. **Biopolymers** 1997;43(2):75–98 (60 ref.)
[Endomorphins in pain relief. New endogenous peptides a sensational discovery] Nyberg F. **Lakartidningen** 1997 Sep 3;94(36):3019–21 (15 ref.) **(Swe)**

IMMUNOLOGY

Pro–opiomelanocortin–derived peptides, cytokines, and nitric oxide in immune responses and stress: an evolutionary approach. Ottaviani E, et al. **Int Rev Cytol** 1997;170:79–141 (400 ref.)

METABOLISM

Milk protein–derived opioid receptor ligands. Teschemacher H, et al. **Biopolymers** 1997;43(2):99–117 (171 ref.)
Opioid and opiate immunoregulatory processes. Stefano GB, et al. **Crit Rev Immunol** 1996;16(2):109–44 (258 ref.)
Human endometrium as a neuroendocrine tissue: expression, regulation and biological roles of endometrial corticotropin–releasing hormone (CRH) and opioid peptides. Zoumakis E, et al. **J Endocrinol Invest** 1997 Mar; 20(3):158–67 (98 ref.)
Orphan receptors and their natural ligands. Civelli O, et al. **J Recept Signal Transduct Res** 1997 Jan–May; 17(1–3):545–50 (49 ref.)
The orphan opioid receptor and its endogenous ligand--nociceptin/orphanin FQ. Henderson G, et al. **Trends Pharmacol Sci** 1997 Aug;18(8):293–300 (67 ref.)
[New possible pathways for melanogenesis: opiomelanins] Rosei MA, et al. **Recenti Prog Med** 1997 Mar;88(3):134–9 (13 ref.) (Eng. Abstr.) **(Ita)**

PHARMACOLOGY

Peptide and nonpeptide ligands for opioid receptors. Misicka A. **Acta Pol Pharm** 1995 Sep–Oct;52(5):349–63 (128 ref.)
Positive and negative immunomodulation by opioid peptides. Roda LG, et al. **Int J Immunopharmacol** 1996 Jan; 18(1):1–16 (167 ref.)
Neurotoxic versus neuroprotective actions of endogenous opioid peptides: implications for treatment of CNS injury. Faden AI. **NIDA Res Monogr** 1996;163:318–30 (59 ref.)

PHYSIOLOGY

Ethanol as a neurochemical surrogate of conventional reinforcers: the dopamine–opioid link. Di Chiara G, et al. **Alcohol** 1996 Jan–Feb;13(1):13–7 (58 ref.)
Implication of the endogenous opioid system in excessive ethanol consumption. Gianoulakis C, et al. **Alcohol** 1996 Jan–Feb;13(1):19–23 (33 ref.)
Endogenous opioids and alcohol dependence: opioid alkaloids and the propensity to drink alcoholic beverages. Reid LD. **Alcohol** 1996 Jan–Feb;13(1):5–11 (52 ref.)
Alcohol addiction (alcoholism) and the opioid system. Terenius L. **Alcohol** 1996 Jan–Feb;13(1):31–4 (19 ref.)
Use of serotonin (5–HT) and opiate–based drugs in the pharmacotherapy of alcohol dependence: an overview of the preclinical data. Lê AD, et al. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:27–32 (55 ref.)
Neuromodulatory role of opioidergic system on hypothalamus–pituitary–gonadal axis during puberty. Genazzani AD, et al. **Ann N Y Acad Sci** 1997 Jun 17; 816:76–82 (29 ref.)
Regulation of masculine sexual behavior: involvement of brain opioids and dopamine. van Furth WR, et al. **Brain Res Brain Res Rev** 1995 Sep;21(2):162–84 (312 ref.)
Regulation of preproenkephalin expression in astrocytes: is there a role for glia–derived opioid peptides in reactive gliosis? McMillian MK, et al. **Crit Rev Neurobiol** 1994; 9(1):91–103 (109 ref.)
Autistic disorder and the endogenous opioid system. Sher L. **Med Hypotheses** 1997 May;48(5):413–4 (17 ref.)
The placebo effect on mood and behavior: the role of the endogenous opioid system. Sher L. **Med Hypotheses** 1997 Apr;48(4):347–9 (32 ref.)
Cocaine effects on dopamine and opioid peptide neural systems: implications for human cocaine abuse. Hurd YL. **NIDA Res Monogr** 1996;163:94–116 (114 ref.)
Endogenous opiates: 1995. Olson GA, et al. **Peptides** 1996; 17(8):1421–66 (583 ref.)
Role of opioids in the physiologic and pathophysiologic control of the cerebral circulation. Armstead WM. **Proc Soc Exp Biol Med** 1997 Mar;214(3):210–21 (123 ref.)
Studies on the opioid mechanism in Tetrahymena. Renaud FL, et al. **Prog Mol Subcell Biol** 1996;17:29–39 (27 ref.)
The neurobiology of placebo analgesia: from endogenous opioids to cholecystokinin. Benedetti F, et al. **Prog Neurobiol** 1997 Jun;52(2):109–25 (135 ref.)
Mothers and their infants: peptide–mediated physiological, behavioral and affective changes during suckling. Blass EM. **Regul Pept** 1996 Oct 8;66(1–2):109–12 (28 ref.)
[Endogenous opioid peptides and the immune system] Peramo F, et al. **Rev Esp Anestesiol Reanim** 1997 Apr; 44(4):150–3 (43 ref.) (Eng. Abstr.) **(Spa)**

TOXICITY

Neurotoxic versus neuroprotective actions of endogenous opioid peptides: implications for treatment of CNS injury. Faden AI. **NIDA Res Monogr** 1996;163:318–30 (59 ref.)

OPIOID RECEPTORS see **RECEPTORS, OPIOID**

OPIOID RECEPTORS, DELTA see **RECEPTORS, OPIOID, DELTA**

OPIOID RECEPTORS, KAPPA see **RECEPTORS, OPIOID, KAPPA**

OPIOID RECEPTORS, MU see **RECEPTORS, OPIOID, MU**

OPIOID RECEPTORS, SIGMA see **RECEPTORS, SIGMA**

OPIOIDS see **NARCOTICS**

OPISTHORCHIASIS

Endoscopy and biliary parasites. Bhargava DK. **Gastrointest Endosc Clin N Am** 1996 Jan;6(1):139–52 (65 ref.)

PARASITOLOGY

Liver and intestinal flukes. Liu LX, et al. **Gastroenterol Clin North Am** 1996 Sep;25(3):627–36 (41 ref.)

OPIUM

Opium revisited: a brief review of its nature, composition, non–medical use and relative risks. Kalant H. **Addiction** 1997 Mar;92(3):267–77 (57 ref.)

OPOSSUMS

ANATOMY & HISTOLOGY

A comparison of oocyte organelles in Monodelphis domestica with those of other marsupials and eutherians. Kress A. **Reprod Fertil Dev** 1996;8(4):521–33 (90 ref.)

GROWTH & DEVELOPMENT

Developmental anatomy of the primary olfactory pathway in the opossum Monodelphis domestica. Chuah MI, et al. **Histol Histopathol** 1997 Jul;12(3):799–806 (46 ref.)

PHYSIOLOGY

Didelphid behavior. Kimble DP. **Neurosci Biobehav Rev** 1997 May;21(3):361–9 (67 ref.)
Possum biocontrol: prospects for fertility regulation. Cowan PE. **Reprod Fertil Dev** 1996;8(4):655–60 (38 ref.)
Gamete biology of the new world marsupial, the grey short–tailed opossum, Monodelphis domestica. Moore HD. **Reprod Fertil Dev** 1996;8(4):605–15 (38 ref.)

OPPENHEIM–ZIEHEN DISEASE see **DYSTONIA MUSCULORUM DEFORMANS**

OPPENHEIM'S DISEASE see **NEUROMUSCULAR DISEASES**

OPPORTUNISTIC INFECTIONS

Recent advances in the management of opportunistic fungal infections. Sanchez JL, et al. **Compr Ther** 1996 Nov; 22(11):703–12 (85 ref.)
Pulmonary fungal infections in immunocompromised children. Shenep JL, et al. **Curr Opin Pediatr** 1997 Jun; 9(3):213–8 (34 ref.)
Co–infection of Toxoplasma gondii with other pathogens: pathogenicity and chemotherapy in animal models. Lacroix C, et al. **Curr Top Microbiol Immunol** 1996;219:223–33 (33 ref.)
Rhodococcus equi: an emerging opportunistic pathogen. Mosser DM, et al. **Trends Microbiol** 1996 Jan;4(1):29–33 (50 ref.)
[Rhodococcus equi--a newly recognized opportunistic pathogen in man] Votava M, et al. **Epidemiol Mikrobiol Imunol** 1997 May;46(2):58–66 (58 ref.) (Eng. Abstr.) **(Cze)**
[Virus–related neurological disorders complicating in compromised hosts] Kimura S. **Nippon Rinsho** 1997 Apr; 55(4):949–53 (24 ref.) (Eng. Abstr.) **(Jpn)**

OPPORTUNISTIC INFECTIONS

COMPLICATIONS

Infectious complications of human T cell leukemia/lymphoma virus type I infection [see comments] Marsh BJ. **Clin Infect Dis** 1996 Jul;23(1):138–45 (87 ref.) Comment in: Clin Infect Dis 1997 May;24(5):1026.

Malignant otitis externa in HIV and AIDS. Hern JD, et al. **J Laryngol Otol** 1996 Aug;110(8):770–5 (37 ref.)

Clostridium septicum infection in children with cyclic neutropenia. Bar-Joseph G, et al. **J Pediatr** 1997 Aug; 131(2):317–9 (14 ref.)

Capnocytophaga meningitis in a cancer patient. Kim JO, et al. **Pediatr Infect Dis J** 1996 Jul;15(7):636–7 (11 ref.)

Hepatosplenic abscess caused by Curvularia boedijn in a patient with acute monocytic leukemia. Shigemori M, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1128–9 (11 ref.)

Lethal disseminated Fusarium infection with sinus involvement in the immunocompromised host: case report and review of the literature. Rombaux P, et al. **Rhinology** 1996 Dec;34(4):237–41 (27 ref.)

Disseminated Blastoschizomyces capitatus infection in acute myeloblastic leukaemia. Report of three cases. Sanz MA, et al. **Support Care Cancer** 1996 Jul;4(4):291–3 (14 ref.)

[Coping with opportunistic mycoses in patients with collagen diseases] Kono S. **Nippon Naika Gakkai Zasshi** 1996 Nov 10;85(11):1889–94 (5 ref.) **(Jpn)**

DIAGNOSIS

Cutaneous alternariosis: role of corticosteroid-induced cutaneous fragility. Machet L, et al. **Dermatology** 1996; 193(4):342–4 (17 ref.)

Central nervous system infection due to Clostridium septicum: a case report and review of the literature. Cheng YT, et al. **Infection** 1997 May–Jun;25(3):171–4 (14 ref.)

Subcutaneous phaeohypomycosis caused by Scytalidium dimidiatum in the foot of an immunosuppressed host. Rockett MS, et al. **J Foot Ankle Surg** 1996 Jul–Aug; 35(4):350–4 (25 ref.)

Respiratory syncytial virus bronchiolitis in a girl undergoing chemotherapy for acute lymphoblastic leukemia: an immunologic study of local secretion. Tsutsumi H, et al. **Pediatr Infect Dis J** 1996 Jul;15(7):635–6 (12 ref.)

DRUG THERAPY

Controversies in the antibacterial treatment of patients with neutropenia: a matter of comprehension or apprehension? De Pauw BE, et al. **Cancer Invest** 1997;15(1):37–46 (52 ref.)

Therapeutic outcome in invasive aspergillosis. Denning DW. **Clin Infect Dis** 1996 Sep;23(3):608–15 (110 ref.)

Home intravenous antibiotic therapy: practical aspects in children. Leaver J, et al. **J R Soc Med** 1997;90 Suppl 31:26–33 (5 ref.)

Home intravenous antibiotic therapy: practical aspects in adults. Phillips AM. **J R Soc Med** 1997;90 Suppl 31:34–6 (14 ref.)

Treatment of fungal and other opportunistic infections in immunocompromised patients. Wade JC. **Leukemia** 1997 May;11 Suppl 4:S38–9 (7 ref.)

Infections in neutropenic patients. II: Management. Engervall P, et al. **Med Oncol** 1996 Mar;13(1):63–9 (74 ref.)

[Prevention, diagnosis and therapy of infections in patients with malignant diseases] Hiddemann W, et al. **Internist (Berl)** 1996 Dec;37(12):1212–24 (56 ref.) **(Ger)**

[Therapy of infections in patients with acute leukemia] Hiddemann W, et al. **Med Klin** 1997 Jul 15;92(7):406–9 (18 ref.) (Eng. Abstr.) **(Ger)**

[Preventive antimycotic therapy of neutropenic and immunosuppressed patients] Ruhnke M, et al. **Med Klin** 1997 Jan 15;92(1):28–36 (76 ref.) (Eng. Abstr.) **(Ger)**

[Antifungal resistance in opportunistic pathogenic fungi (I). Polyenes and fluorocytosine] Martínez-Suárez JV, et al. **Enferm Infecc Microbiol Clin** 1996 Jun–Jul;14(6):384–9 (43 ref.) **(Spa)**

EPIDEMIOLOGY

Nocardiosis in systemic lupus erythematosus. Mok CC, et al. **Semin Arthritis Rheum** 1997 Feb;26(4):675–83 (63 ref.)

ETIOLOGY

Pulmonary mucormycosis in diabetic renal allograft recipients. Latif S, et al. **Am J Kidney Dis** 1997 Mar; 29(3):461–4 (26 ref.)

Tuberculosis in bone marrow transplant recipients: report of two cases and review of the literature. Martino R, et al. **Bone Marrow Transplant** 1996 Oct;18(4):809–12 (19 ref.)

Opportunistic infections in oncologic patients. Emmanouilides C, et al. **Hematol Oncol Clin North Am** 1996 Aug;10(4):841–60 (83 ref.)

Oral lesions in organ transplant patients. Seymour RA, et al. **J Oral Pathol Med** 1997 Aug;26(7):297–304 (99 ref.)

Acinetobacter pericarditis with tamponade in a patient with systemic lupus erythematosus. Lam SM, et al. **Lupus** 1997; 6(5):480–3 (13 ref.)

Lipids and immune function. Garnacho Montero J, et al. **Nutr Hosp** 1996 Jul–Aug;11(4):230–7 (87 ref.)

[Opportunistic lymphoma] Katano H, et al. **Nippon Rinsho** 1997 Feb;55(2):441–5 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Pneumocystis carinii pneumonia in patients with a solid organ transplant (editorial; comment)] Muñoz P. **Rev Clin Esp** 1997 Jan;197(1):1–3 (14 ref.) Comment on: Rev Clin Esp 1997 Jan;197(1):31–4. **(Spa)**

[Pneumocystis carinii pneumonia in patients with a solid organ transplant: a report of 5 cases (see comments)] Ruiz Ruiz J, et al. **Rev Clin Esp** 1997 Jan;197(1):31–4 (59 ref.) (Eng. Abstr.) Comment in: Rev Clin Esp 1997 Jan;197(1):1–3. **(Spa)**

IMMUNOLOGY

Opportunistic infections in the cardiac transplant patient. Thaler SJ, et al. **Curr Opin Cardiol** 1996 Mar;11(2):191–203 (95 ref.)

[Diseases of the lung and respiratory tract in disorders of immunodeficiency in childhood and adolescence] Roesler J, et al. **Pneumologie** 1996 Nov;50(11):745–51 (37 ref.) **(Ger)**

MICROBIOLOGY

Achromobacter xylosoxidans bacteremia: report of four cases and review of the literature. Duggan JM, et al. **Clin Infect Dis** 1996 Sep;23(3):569–76 (64 ref.)

Burkholderia cepacia: medical, taxonomic and ecological issues. Govan JR, et al. **J Med Microbiol** 1996 Dec; 45(6):395–407 (129 ref.)

Two case reports and review of vascular catheter-associated bacteremia caused by nontuberculous Mycobacterium species. Rodgers GL, et al. **Pediatr Infect Dis J** 1996 Mar; 15(3):260–4 (50 ref.)

[New gram-positive opportunistic bacteria: pathogenic role and treatment] Philippon A, et al. **Presse Med** 1997 May 17;26(16):778–86 (31 ref.) (Eng. Abstr.) **(Fre)**

[Bacteremia caused by Alcaligenes (Achromobacter) xylosoxidans. Description of 3 cases and review of the literature] Ramos JM, et al. **Enferm Infecc Microbiol Clin** 1996 Aug–Sep;14(7):436–40 (38 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Fungal infections. Chimelli L, et al. **Brain Pathol** 1997 Jan; 7(1):613–27 (90 ref.)

Free-living, amphizoic and opportunistic amebas. Martinez AJ, et al. **Brain Pathol** 1997 Jan;7(1):583–98 (100 ref.)

[Diagnosis of cytomegalovirus disease in biopsy and surgical material. Methods and clinical relevance] Seifert G. **Pathologe** 1997 May;18(3):207–17 (163 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Prevention of infection in neutropenic cancer patients. Klastersky J. **Curr Opin Oncol** 1996 Jul;8(4):270–8 (37 ref.)

Late infections following allogeneic bone marrow transplantation: suggested strategies for prophylaxis. Roy V, et al. **Leuk Lymphoma** 1997 Jun;26(1–2):1–15 (77 ref.)

Prophylactic strategies to meet infectious complications in fludarabine-treated CLL. Südhoff T, et al. **Leukemia** 1997 Apr;11 Suppl 2:S38–41 (38 ref.)

Treatment of fungal and other opportunistic infections in immunocompromised patients. Wade JC. **Leukemia** 1997 May;11 Suppl 4:S38–9 (7 ref.)

Clinical use of oral nystatin in the prevention of systemic candidosis in patients at particular risk. Schäfer-Korting M, et al. **Mycoses** 1996 Sep–Oct;39(9–10):329–39 (35 ref.)

[Current status of vaccination and antibiotic prophylaxis in splenectomy. II: Children] Funk EM, et al. **Chirurg** 1997 Jun;68(6):591–5 (28 ref.) (Eng. Abstr.) **(Ger)**

[The current status of vaccination and antibiotic prophylaxis in splenectomy. I: Adults] Funk EM, et al. **Chirurg** 1997 Jun;68(6):586–90 (25 ref.) (Eng. Abstr.) **(Ger)**

[Pneumococcal vaccination--why so rare?] Persili SA, et al. **Schweiz Rundsch Med Prax** 1997 Jul 2;86(27–28):1097–100 (34 ref.) (Eng. Abstr.) **(Ger)**

[Empirical antimicrobial therapy in neutropenic patients] Maschmeyer G. **Ther Umsch** 1996 Nov;53(11):854–62 (36 ref.) (Eng. Abstr.) **(Ger)**

[Vaccination of chronically ill children] Zielen S, et al. **Z Arztl Fortbild Qualitatssich** 1997 Jun;91(3):213–7 (23 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Intracerebral Aspergillus abscess: case report and review of the literature. Artico M, et al. **Neurosurg Rev** 1997; 20(2):135–8 (34 ref.)

THERAPY

Use of intravenous immunoglobulin to prevent or treat infections in persons with immune deficiency. Lee ML, et al. **Annu Rev Med** 1997;48:93–102 (112 ref.)

[Integration of G-CSF in prevention and therapy of neutropenic fever] Siegmund R, et al. **Med Klin** 1996 Feb 15;91(2):82–8 (77 ref.) **(Ger)**

[Risk of infection and wound healing disorders in dialysis patients] Zimmermann J, et al. **Zentralbl Chir** 1996;121 Suppl:58–60 (14 ref.) **(Ger)**

TRANSMISSION

[The problem of viral hepatitis in transplantation medicine] Tillmann HL, et al. **Internist (Berl)** 1996 Mar;37(3):240–9 (149 ref.) **(Ger)**

VETERINARY

Opportunistic infections associated with retroviral infections in cats. Lappin MR. **Semin Vet Med Surg (Small Anim)** 1995 Nov;10(4):244–50 (71 ref.)

OPPORTUNISTIC INFECTIONS, AIDS-RELATED see **AIDS-RELATED OPPORTUNISTIC INFECTIONS**

OPPORTUNISTIC INFECTIONS, HIV-RELATED see **AIDS-RELATED OPPORTUNISTIC INFECTIONS**

OPSIN

GENETICS

Opsin genes. Maden BE. **Essays Biochem** 1995;29:87–111 (58 ref.)

Molecular evolution of retinal and nonretinal opsins. Yokoyama S. **Genes Cells** 1996 Sep;1(9):787–94 (46 ref.)

METABOLISM

The patterning and onset of opsin expression in vertebrate retinae. Cepko CL. **Curr Opin Neurobiol** 1996 Aug; 6(4):542–6 (32 ref.)

PHYSIOLOGY

Phototransduction cascade and circadian oscillator in chicken pineal gland. Okano T, et al. **J Pineal Res** 1997 Apr; 22(3):145–51 (44 ref.)

OPSOCLONUS see **OCULAR MOTILITY DISORDERS**

OPSONINS

see related
PHAGOCYTOSIS

PHARMACOLOGY

Mechanism and computer simulation of immune complex formation, opsonization, and clearance. Head M, et al. **J Lab Clin Med** 1996 Jul;128(1):61–74 (42 ref.)

PHYSIOLOGY

The role of immunoproteins in the survival of liposomes in the circulation. Devine DV, et al. **Crit Rev Ther Drug Carrier Syst** 1997;14(2):105–31 (146 ref.)

OPTIC ATROPHY

GENETICS

[PEHO syndrome (progressive encephalopathy, edema, hypsarrhythmia. optic atrophy)] Hollódy K, et al. **Orv Hetil** 1997 Feb 16;138(7):425–8 (7 ref.) (Eng. Abstr.) **(Hun)**

THERAPY

[Electrostimulation as a treatment method in partial atrophy of the optic nerve and retinal diseases] Rogatina EV. **Vestn Oftalmol** 1997 Jan–Feb;113(1):41–3 (51 ref.) **(Rus)**

OPTIC ATROPHY, HEREDITARY

Leber's hereditary optic neuropathy: historical and contemporary considerations. Kleiner L, et al. **Optom Clin** 1996;5(3–4):77–112 (210 ref.)

GENETICS

Leber hereditary optic neuropathy: how do mitochondrial DNA mutations cause degeneration of the optic nerve? Howell N. **J Bioenerg Biomembr** 1997 Apr;29(2):165–73 (57 ref.)

METABOLISM

Mitochondrial disorders in neuro–ophthalmology. Riordan-Eva P, et al. **Curr Opin Neurol** 1996 Feb;9(1):1–4 (20 ref.)

PATHOLOGY

Clinical spectrum of Leber's hereditary optic neuropathy. Kerrison JB, et al. **Clin Neurosci** 1997;4(5):295–301 (81 ref.)

OPTIC CHIASM

Optic chiasmatic-hypothalamic glioma. Alshail E, et al. **Brain Pathol** 1997 Apr;7(2):799–806 (49 ref.)

Hemidystonia as presenting symptom of an optic glioma. Vandertop WP, et al. **Childs Nerv Syst** 1997 May; 13(5):289–92 (22 ref.)

Orbital disease, optic nerve and chiasm. Cockerham KP, et al. **Curr Opin Neurol** 1997 Feb;10(1):22–30 (45 ref.)

An integrated approach to the treatment of chiasmatic-hypothalamic gliomas. Garvey M, et al. **J Neurooncol** 1996 May–Jun;28(2–3):167–83 (75 ref.)

[Surgical treatment of chiasmal gliomas in children] Helcl F. **Bratisl Lek Listy** 1997 Mar;98(3):166–9 (20 ref.) (Eng. Abstr.) **(Cze)**

ABNORMALITIES

Chiasmal crossing defects in disorders of binocular vision. Apkarian P. **Eye** 1996;10 (Pt 2):222–32 (73 ref.)
The albino retina: an abnormality that provides insight into normal retinal development. Jeffery G. **Trends Neurosci** 1997 Apr;20(4):165–9 (37 ref.)

ANATOMY & HISTOLOGY

A comparison of eutherian and marsupial optic chiasms: a brief review. Guillery RW. **Rev Bras Biol** 1995 Dec;55 Suppl 1:1–10 (31 ref.)

BLOOD SUPPLY

Recurrent chiasmal apoplexy due to cavernous malformation. Warner JE, et al. **J Neuroophthalmol** 1996 Jun;16(2):99–106 (33 ref.)

PHYSIOPATHOLOGY

The anterior visual pathways—Part II. Sadun AA, et al. **J Neuroophthalmol** 1996 Sep;16(3):212–22 (340 ref.)

SURGERY

Optochiasmatic tuberculoma—case report and review. Kadioglu HH, et al. **Zentralbl Neurochir** 1996;57(1):30–6 (25 ref.)

ULTRASTRUCTURE

Retinal axon divergence in the optic chiasm: growth cone behaviors and signalling cells. Mason CA, et al. **Prog Brain Res** 1996;108:95–107 (66 ref.)

OPTIC DISK

The significance of optic disc hemorrhages in glaucoma. Gordon J, et al. **J Glaucoma** 1997 Feb;6(1):62–4 (15 ref.)
Optic disk edema with a macular star. Brazis PW, et al. **Mayo Clin Proc** 1996 Dec;71(12):1162–6 (66 ref.)

ABNORMALITIES

[Vitrectomy-laser-gas for treating optic disk pits complicated by serous macular detachment] Taiel-Sartral M, et al. **J Fr Ophtalmol** 1996;19(10):603–9 (31 ref.) (Eng. Abstr.) **(Fre)**

BLOOD SUPPLY

Intraocular pressure and circulation at the disc in glaucoma. Hitchings RA. **Acta Ophthalmol Scand Suppl** 1997; (220):15–20; discussion 20–2 (63 ref.)
Anterior ischemic optic neuropathy. Hayreh SS. **Clin Neurosci** 1997;4(5):251–63 (48 ref.)
Ischemic optic neuropathy: models for mechanism of disease. Potarazu SV. **Clin Neurosci** 1997;4(5):264–9 (22 ref.)
Current perspectives on nonarteritic anterior ischemic optic neuropathy. Kellett SC, et al. **J Am Optom Assoc** 1997 Jul;68(7):413–24 (34 ref.)
Anterior ischemic optic neuropathy and activated protein C resistance. A case report and review of the literature. Worrall BB, et al. **J Neuroophthalmol** 1997 Sep;17(3):162–5 (52 ref.)
Blood supply of the optic nerve head. Hayreh SS. **Ophthalmologica** 1996;210(5):285–95 (48 ref.)

PATHOLOGY

Optic disc evaluation in glaucoma. Sekhar GC. **Indian J Ophthalmol** 1996 Dec;44(4):235–9 (8 ref.)

PHYSIOLOGY

Mr. Chips: an ideal-observer model of reading. Legge GE, et al. **Psychol Rev** 1997 Jul;104(3):524–53 (130 ref.)

PHYSIOPATHOLOGY

The optic nerve head in glaucomatous optic neuropathy. Hernandez MR, et al. **Arch Ophthalmol** 1997 Mar; 115(3):389–95 (64 ref.)

RADIOGRAPHY

Multiple evanescent white dot syndrome--an uncommon cause for an enlarged blind spot. Fong KS, et al. **Ann Acad Med Singapore** 1996 Nov;25(6):866–8 (13 ref.)

ULTRASTRUCTURE

The three-dimensional structure of the connective tissue in the lamina cribrosa of the human optic nerve head. Birch M, et al. **Ophthalmologica** 1997;211(3):183–91 (24 ref.)

OPTIC LOBE

CYTOLOGY

Daily rhythms in cells of the fly's optic lobe: taking time out from the circadian clock. Meinertzhagen IA, et al. **Trends Neurosci** 1996 Jul;19(7):285–91 (62 ref.)

OPTIC NERVE

Sarcoid masquerading as optic nerve sheath meningioma [see comments] Ing EB, et al. **Mayo Clin Proc** 1997 Jan; 72(1):38–43 (32 ref.) Comment in: Mayo Clin Proc 1997 Aug;72(8):791.

BLOOD SUPPLY

Embryology, anatomy, and histology of the optic nerve vasculature. Orgül S, et al. **J Glaucoma** 1996 Aug; 5(4):285–94 (66 ref.)
Glaucoma, capillaries and pericytes. 1. Blood flow regulation. Anderson DR. **Ophthalmologica** 1996;210(5):257–62 (82 ref.)

EMBRYOLOGY

Embryology, anatomy, and histology of the optic nerve vasculature. Orgül S, et al. **J Glaucoma** 1996 Aug; 5(4):285–94 (66 ref.)
The chronotopic reordering of optic axons. Reese BE. **Perspect Dev Neurobiol** 1996;3(3):233–42 (70 ref.)

PATHOLOGY

Early diagnosis of functional damage in patients with glaucoma [editorial; comment] Caprioli J. **Arch Ophthalmol** 1997 Jan;115(1):113–4 (31 ref.) Comment on: Arch Ophthalmol 1997 Jan;115(1):26–33.
Glaucomatous optic nerve cupping as an optic neuropathy. Anderson DR, et al. **Clin Neurosci** 1997;4(5):274–8 (37 ref.)
Magnetic resonance imaging in optic neuropathy. Moseley I, et al. **Clin Neurosci** 1997;4(5):302–19 (217 ref.)
The optic nerve. Miller NR. **Curr Opin Neurol** 1996 Feb; 9(1):5–15 (97 ref.)
Leber hereditary optic neuropathy: how do mitochondrial DNA mutations cause degeneration of the optic nerve? Howell N. **J Bioenerg Biomembr** 1997 Apr;29(2):165–73 (57 ref.)
Imaging evaluation of the optic nerve and visual pathway including cranial nerves affecting the visual pathway. Weber AL, et al. **Neuroimaging Clin N Am** 1996 Feb; 6(1):143–77 (162 ref.)
MRI of optic nerve enlargement in optic neuritis. Cornblath WT, et al. **Neurology** 1997 Apr;48(4):821–5 (15 ref.)
Surgically verified case of optic sheath nerve meningocele: case report with review of the literature. Lunardi P, et al. **Neurosurg Rev** 1997;20(3):201–5 (21 ref.)
Orbit and optic nerve. Villablanca P, et al. **Top Magn Reson Imaging** 1996 Apr;8(2):87–110 (75 ref.)
[Invasion of the optic nerve in undifferentiated retinoblastoma] Florescu M, et al. **Oftalmologia** 1996 Oct-Dec;40(4):354–6 (7 ref.) (Eng. Abstr.) **(Rum)**

PHYSIOLOGY

Retinal ganglion cell anatomy and physiology after section of the optic nerve in mice overexpressing bcl-2. Ratto GM, et al. **Adv Neurol** 1997;72:87–94 (20 ref.)
Studying the snail's clock at better than a snail's pace. Block GD. **Braz J Med Biol Res** 1996 Jan;29(1):71–5 (26 ref.)
Electrophysiology of retina and optic nerve: effects of changes in serum glucose and of exogenous adenosine in vitro. Niemeyer G, et al. **Electroencephalogr Clin Neurophysiol Suppl** 1996;46:141–6 (22 ref.)
Potential treatment modalities for glaucomatous neuropathy: neuroprotection and neuroregeneration. Schwartz M, et al. **J Glaucoma** 1996 Dec;5(6):427–32 (56 ref.)
Glial-neuronal interactions in non-synaptic areas of the brain: studies in the optic nerve. Ransom BR, et al. **Trends Neurosci** 1996 Aug;19(8):352–8 (52 ref.)
[Optic nerve regeneration by nerve transplantation] Fukuda Y. **Nippon Ganka Gakkai Zasshi** 1996 Dec;100(12):956–71 (74 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Ischemic injury of optic nerve axons: the nuts and bolts. Fern R, et al. **Clin Neurosci** 1997;4(5):246–50 (32 ref.)
Assessing retinal/neural function in the presence of ocular media opacities. McGraw PV, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Apr;234(4):280–3 (24 ref.)
The anterior visual pathways--Part II. Sadun AA, et al. **J Neuroophthalmol** 1996 Sep;16(3):212–22 (340 ref.)

SURGERY

Extradural optic nerve decompression for fibrous dysplasia with a favorable visual outcome. Kurimoto M, et al. **Neurol Med Chir (Tokyo)** 1996 Feb;36(2):102–5 (19 ref.)
Powered instrumentation in orbital and optic nerve decompression. Chow JM, et al. **Otolaryngol Clin North Am** 1997 Jun;30(3):467–78 (24 ref.)

ULTRASTRUCTURE

Retinal ganglion cell anatomy and physiology after section of the optic nerve in mice overexpressing bcl-2. Ratto GM, et al. **Adv Neurol** 1997;72:87–94 (20 ref.)
The three-dimensional structure of the connective tissue in the lamina cribrosa of the human optic nerve head. Birch M, et al. **Ophthalmologica** 1997;211(3):183–91 (24 ref.)

OPTIC NERVE DISEASES

Optic nerve disease: an introduction. Bodis-Wollner I. **Clin Neurosci** 1997;4(5):213–5 (13 ref.)

DIAGNOSIS

Hemidystonia as presenting symptom of an optic glioma. Vandertop WP, et al. **Childs Nerv Syst** 1997 May; 13(5):289–92 (22 ref.)
Magnetic resonance imaging in optic neuropathy. Moseley I, et al. **Clin Neurosci** 1997;4(5):302–19 (217 ref.)
Orbital disease, optic nerve and chiasm. Cockerham KP, et al. **Curr Opin Neurol** 1997 Feb;10(1):22–30 (45 ref.)
Imaging evaluation of the optic nerve and visual pathway including cranial nerves affecting the visual pathway. Weber AL, et al. **Neuroimaging Clin N Am** 1996 Feb; 6(1):143–77 (162 ref.)
Surgically verified case of optic sheath nerve meningocele: case report with review of the literature. Lunardi P, et al. **Neurosurg Rev** 1997;20(3):201–5 (21 ref.)
Evidence of optic pathway gliomas after previously negative neuroimaging. Massry GG, et al. **Ophthalmology** 1997 Jun; 104(6):930–5 (35 ref.)
Orbit and optic nerve. Villablanca P, et al. **Top Magn Reson Imaging** 1996 Apr;8(2):87–110 (75 ref.)

EPIDEMIOLOGY

Epidemic optic and peripheral neuropathy in Cuba: a unique geopolitical public health problem. Hedges TR 3rd, et al. **Surv Ophthalmol** 1997 Jan-Feb;41(4):341–53 (54 ref.)

ETIOLOGY

Glaucomatous optic nerve cupping as an optic neuropathy. Anderson DR, et al. **Clin Neurosci** 1997;4(5):274–8 (37 ref.)
Endocrinologic disorders and optic pathway gliomas in children with neurofibromatosis type 1. Cnossen MH, et al. **Pediatrics** 1997 Oct;100(4):667–70 (24 ref.)
[Dysthyroid optic neuropathy. Apropos of 2 cases] Domenjöd M, et al. **J Fr Ophtalmol** 1996;19(8–9):543–50 (22 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Infectious optic neuropathy. March GA Jr, et al. **Int Ophthalmol Clin** 1996 Summer;36(3):197–205 (52 ref.)

PATHOLOGY

The optic nerve. Miller NR. **Curr Opin Neurol** 1996 Feb; 9(1):5–15 (97 ref.)

PHYSIOPATHOLOGY

The optic nerve head in glaucomatous optic neuropathy. Hernandez MR, et al. **Arch Ophthalmol** 1997 Mar; 115(3):389–95 (64 ref.)

PREVENTION & CONTROL

Potential treatment modalities for glaucomatous neuropathy: neuroprotection and neuroregeneration. Schwartz M, et al. **J Glaucoma** 1996 Dec;5(6):427–32 (56 ref.)

SURGERY

Successful surgical removal of an asymptomatic optic nerve hemangioblastoma in von Hippel-Lindau disease. Raila FA, et al. **J Neuroimaging** 1997 Jan;7(1):48–50 (23 ref.)
[Restoration of vision after surgical treatment of traumatic optic neuropathy of an uncommon type. Case report and literature review] Haninec P, et al. **Cesk Slov Oftalmol** 1996 Sep;52(4):249–52 (15 ref.) (Eng. Abstr.) **(Cze)**

OPTIC NEURITIS

Optic neuritis in a child. Williams JR. **Pediatr Emerg Care** 1996 Jun;12(3):210–2 (11 ref.)

CHEMICALLY INDUCED

Bilateral optic neuritis in occupational exposure to trichloroethylene. Abecia E, et al. **Med Lav** 1996 Sep-Oct; 87(5):432–6 (25 ref.)

DIAGNOSIS

MRI of optic nerve enlargement in optic neuritis. Cornblath WT, et al. **Neurology** 1997 Apr;48(4):821–5 (15 ref.)
[Differential diagnostic considerations on retrobulbar neuritis] Killer HE, et al. **Nervenarzt** 1996 Oct; 67(10):815–20 (36 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

[Optic neuritis and measles infection] Inokuchi N, et al. **Nippon Rinsho** 1997 Apr;55(4):861–4 (6 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

The optic nerve. Miller NR. **Curr Opin Neurol** 1996 Feb; 9(1):5–15 (97 ref.)

OPTIC NEUROPATHY, ISCHEMIC

Ischemic optic neuropathy: models for mechanism of disease. Potarazu SV. **Clin Neurosci** 1997;4(5):264–9 (22 ref.)
Current perspectives on nonarteritic anterior ischemic optic neuropathy. Kellett SC, et al. **J Am Optom Assoc** 1997 Jul;68(7):413–24 (34 ref.)

OPTIC NEUROPATHY, ISCHEMIC

COMPLICATIONS

Anterior ischemic optic neuropathy and activated protein C resistance. A case report and review of the literature. Worrall BB, et al. **J Neuroophthalmol** 1997 Sep;17(3):162–5 (52 ref.)

ETIOLOGY

Anterior ischemic optic neuropathy. Hayreh SS. **Clin Neurosci** 1997;4(5):251–63 (48 ref.)

Anterior ischemic optic neuropathy following neck dissection. Strome SE, et al. **Head Neck** 1997 Mar; 19(2):148–52 (12 ref.)

Posterior ischemic optic neuropathy associated with migraine. Lee AG, et al. **Headache** 1996 Sep;36(8):506–10 (12 ref.)

PHYSIOPATHOLOGY

Ischemic injury of optic nerve axons: the nuts and bolts. Fern R, et al. **Clin Neurosci** 1997;4(5):246–50 (32 ref.)

[The role of hemodynamic conditions in the posterior eye segment on genesis and development of glaucomatous neuropathy] Niżankowska MH. **Klin Oczna** 1996 Mar; 98(3):241–7 (75 ref.) (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

Medical cardiovascular treatment trials: relevant to medical ophthalmology in 1997? Dodson PM, et al. **Eye** 1997;11 (Pt 1):3–11 (70 ref.)

OPTIC PAPILLA see **OPTIC DISK**

OPTIC TECTUM see **SUPERIOR COLLICULUS**

OPTICAL ILLUSIONS

PHYSIOLOGY

Cortical dynamics of three-dimensional figure-ground perception of two-dimensional pictures. Grossberg S. **Psychol Rev** 1997 Jul;104(3):618–58 (180 ref.)

Mach bands: how many models are possible? Recent experimental findings and modeling attempts. Pessoa L. **Vision Res** 1996 Oct;36(19):3205–27 (115 ref.)

OPTICAL READERS see **AUTOMATIC DATA PROCESSING**

OPTICS

see related
VISION

Can we measure correlates of neuronal activity with non-invasive optical methods? Gratton G, et al. **Adv Exp Med Biol** 1997;413:53–62 (27 ref.)

Vascular regulation at sub millimeter range. Sources of intrinsic signals for high resolution optical imaging. Malonek D, et al. **Adv Exp Med Biol** 1997;413:215–20 (18 ref.)

Spatial resolution enhancement through time gated measurements. Sölkner G, et al. **Adv Exp Med Biol** 1997; 413:75–83 (22 ref.)

Functional neuroimaging. Optical approaches. Villringer A. **Adv Exp Med Biol** 1997;413:1–18 (83 ref.)

Optical detection of single molecules. Nie S, et al. **Annu Rev Biophys Biomol Struct** 1997;26:567–96 (151 ref.)

Anisotropic activation spread in heart cell monolayers assessed by high-resolution optical mapping. Role of tissue discontinuities. Fast VG, et al. **Circ Res** 1996 Jul; 79(1):115–27 (49 ref.)

Optical mapping approaches to molecular genomics. Schwartz DC, et al. **Curr Opin Biotechnol** 1997 Feb; 8(1):70–4 (32 ref.)

Imaging exocytosis and endocytosis. Betz WJ, et al. **Curr Opin Neurobiol** 1996 Jun;6(3):365–71 (49 ref.)

Imaging calcium dynamics in dendritic spines. Denk W, et al. **Curr Opin Neurobiol** 1996 Jun;6(3):372–8 (63 ref.)

Optical methods to evaluate the contractile function of unloaded isolated cardiac myocytes. Delbridge LM, et al. **J Mol Cell Cardiol** 1997 Jan;29(1):11–25 (68 ref.)

Intraoperative optical imaging of epileptiform and functional activity. Haglund MM. **Neurosurg Clin N Am** 1997 Jul; 8(3):413–20 (26 ref.)

Intrinsic optical changes in neuronal tissue. Basic mechanisms. Hochman DW. **Neurosurg Clin N Am** 1997 Jul;8(3):393–412 (132 ref.)

Enhanced optical imaging of human gliomas and tumor margins. Haglund MM, et al. **Neurosurgery** 1996 Feb; 38(2):308–17 (58 ref.)

The refractive group. Campbell C. **Optom Vis Sci** 1997 Jun; 74(6):381–7 (13 ref.)

Meridional profiles of variance-covariance of symmetric dioptric power: classes of variation that are uniform across the meridians of the eye. Harris WF. **Optom Vis Sci** 1997 Jun;74(6):397–413 (44 ref.)

Invariance of ophthalmic properties under spherocylindrical transposition. Harris WF. **Optom Vis Sci** 1997 Jun; 74(6):459–62 (9 ref.)

Dioptric power: its nature and its representation in three- and four-dimensional space [see comments] Harris WF. **Optom Vis Sci** 1997 Jun;74(6):349–66 (84 ref.) Comment in: Optom Vis Sci 1997 Jun;74(6):339–41.

Wavefronts and their propagation in astigmatic optical systems. Harris WF. **Optom Vis Sci** 1996 Sep;73(9):606–12 (31 ref.)

Equivalent dioptric power asymmetry relations for thick astigmatic systems [see comments] Keating MP. **Optom Vis Sci** 1997 Jun;74(6):388–92 (11 ref.) Comment in: Optom Vis Sci 1997 Jun;74(6):339–41.

Clinical refraction in three-dimensional dioptric space revisited [see comments] Raasch T. **Optom Vis Sci** 1997 Jun;74(6):376–80 (28 ref.) Comment in: Optom Vis Sci 1997 Jun;74(6):339–41.

A few selected applications of surface nonlinear optical spectroscopy. Shen YR. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12104–11 (74 ref.)

Third-generation synchrotron radiation X-ray optics. Freund AK. **Structure** 1996 Feb 15;4(2):121–5 (5 ref.)

Monitoring secretion in real time: capacitance, amperometry and fluorescence compared. Angleson JK, et al. **Trends Neurosci** 1997 Jul;20(7):281–7 (57 ref.)

[Optical tweezers: their principle and applications] Miyata H. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1170–2 (15 ref.) **(Jpn)**

INSTRUMENTATION

Oxygen electrodes and optodes and their application in vivo. Lübbers DW. **Adv Exp Med Biol** 1996;388:13–34 (84 ref.)

Lasers, optical systems and safety in ophthalmology: a review. Fankhauser F, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Aug;234(8):473–87 (56 ref.)

OPTOMETRY

[Image methods in the development of optometry] Shelepin IuE, et al. **Med Tekh** 1996 Jul–Aug;(4):41–3 (6 ref.) (Eng. Abstr.) **(Rus)**

LEGISLATION & JURISPRUDENCE

Glaucoma—a clinicolegal review. Classé JG. **J Am Optom Assoc** 1997 Jun;68(6):389–94 (21 ref.)

Release of contact lens prescriptions: an update. Classé JG. **J Am Optom Assoc** 1997 Feb;68(2):125–9 (4 ref.)

Liability for pediatric care. Classé JG. **Optom Clin** 1996; 5(2):161–85 (66 ref.)

METHODS

Optometric management of patients with Alzheimer's disease. Baker DR, et al. **J Am Optom Assoc** 1997 Aug;68(8):483–94 (59 ref.)

The refractive group. Campbell C. **Optom Vis Sci** 1997 Jun; 74(6):381–7 (13 ref.)

Dioptric power: its nature and its representation in three- and four-dimensional space [see comments] Harris WF. **Optom Vis Sci** 1997 Jun;74(6):349–66 (84 ref.) Comment in: Optom Vis Sci 1997 Jun;74(6):339–41.

Reliability of and comparisons among methods of measuring dissociated phoria. Schroeder TL, et al. **Optom Vis Sci** 1996 Jun;73(6):389–97 (31 ref.)

Biosocial consequences of poverty: associated visual problems. Solan HA, et al. **Optom Vis Sci** 1997 Apr; 74(4):185–9 (44 ref.)

ORGANIZATION & ADMINISTRATION

Vision, learning and dyslexia. A joint organizational policy statement of the American Academy of Optometry and the American Optometric Association. **J Am Optom Assoc** 1997 May;68(5):284–6 (29 ref.)

Medicaid, managed care and optometry: a review. Soroka M. **J Am Optom Assoc** 1996 Jun;67(6):335–42 (16 ref.)

Optometry and the World Wide Web. Herse P. **Optom Vis Sci** 1996 Jun;73(6):435–6 (7 ref.)

STANDARDS

Meeting the vision care needs of aircraft pilots. Asmus TL, et al. **J Am Optom Assoc** 1997 Feb;68(2):116–24 (15 ref.)

STATISTICS & NUMERICAL DATA

Impact of using weighted versus unweighted measures to assess optometry faculty productivity in research. Doughty MJ, et al. **J Am Optom Assoc** 1996 Jul;67(7):410–20 (28 ref.)

TRENDS

The future of Medicare and managed care: implications for optometry. Soroka M. **J Am Optom Assoc** 1997 Mar; 68(3):147–54 (12 ref.)

ORAL CHARACTER see **PSYCHOANALYTIC THEORY**

ORAL HEALTH

see related
MOUTH DISEASES

Infant nutrition: implication for somatic growth, adult onset diseases, and oral health. Sonis A, et al. **Curr Opin Pediatr** 1997 Jun;9(3):289–97 (53 ref.)

Oral health care for the cancer patient. Scully C, et al. **Eur J Cancer B Oral Oncol** 1996 Sep;32B(5):281–92 (282 ref.)

[The importance of oral and dental health] Huttunen J. **Duodecim** 1995;111(14):1326–7 (18 ref.) **(Fin)**

[Survey on oral health of university students: examination on tooth conditions using panoramic X-ray films] Susami T, et al. **Kokubyo Gakkai Zasshi** 1996 Sep;63(3):459–67 (31 ref.) (Eng. Abstr.) **(Jpn)**

[The effect of smoking on the general somatic and stomatological status of the population] Alimskiĭ AV, et al. **Stomatologiia (Mosk)** 1996;75(2):70–9 (168 ref.) **(Rus)**

ORAL HEMORRHAGE

ETIOLOGY

Mandibular metastatic hepatocellular carcinoma: a case involving severe postbiopsy hemorrhage. Ashar A, et al. **J Oral Maxillofac Surg** 1997 Jun;55(6):547–52 (36 ref.)

ORAL HYGIENE

see related
DENTAL DEVICES, HOME CARE
TOOTHBRUSHING

[Importance of the masticatory mucosa in the maintenance of healthy peri-implant soft tissues. Review of the literature] Francetti L, et al. **Minerva Stomatol** 1997 Jul–Aug;46(7–8):399–405 (38 ref.) (Eng. Abstr.) **(Ita)**

METHODS

Assessment and management of chemotherapy-induced mucositis in children. Kennedy L, et al. **J Pediatr Oncol Nurs** 1997 Jul;14(3):164–74; quiz 175–7 (19 ref.)

ORAL MEDICINE

see related
DENTISTRY
MOUTH DISEASES

[The prevention of infection in oral medicine] Vassal S, et al. **Rev Stomatol Chir Maxillofac** 1997 Sep;98(3):216–9 (19 ref.) **(Fre)**

ORAL MUCOSA see **MOUTH MUCOSA**

ORAL REHYDRATION THERAPY see **FLUID THERAPY**

ORAL SUBMUCOUS FIBROSIS

Oral submucous fibrosis. A review. Cox SC, et al. **Aust Dent J** 1996 Oct;41(5):294–9 (61 ref.)

ORAL TOBACCO see **TOBACCO, SMOKELESS**

ORAL ULCER

see related
NOMA
STOMATITIS, APHTHOUS

Mouth ulcers: how can you help? Hale L, et al. **Practitioner** 1997 Feb;241(1571):86–90 (8 ref.)

PATHOLOGY

Recurrent scarring ulcers of the oral mucosa. Sutton disease (periadenitis mucosa necrotica recurrens. Chung JY, et al. **Arch Dermatol** 1997 Sep;133(9):1162–3, 1165–6 (6 ref.)

ORBICULARIS OCULI REFLEX see **BLINKING**

ORBIT

Fractional cryosurgery. A new technique for basal cell carcinoma of the eyelids and periorbital area. Gonçalves JC. **Dermatol Surg** 1997 Jun;23(6):475–81 (26 ref.)

Anatomy and function of the orbital frontal cortex, I: anatomy, neurocircuitry; and obsessive-compulsive disorder. Zald DH, et al. **J Neuropsychiatry Clin Neurosci** 1996 Spring;8(2):125–38 (119 ref.)

[Effects of external orbital radiotherapy on the oculomotor muscle in Graves disease] Maalouf T, et al. **J Fr Ophtalmol** 1996;19(12):748–54 (20 ref.) (Eng. Abstr.) **(Fre)**

ANATOMY & HISTOLOGY

Normal computed tomography and magnetic resonance imaging anatomy of the globe, orbit, and visual pathways. Hesselink JR, et al. **Neuroimaging Clin N Am** 1996 Feb; 6(1):15–27 (16 ref.)

BLOOD SUPPLY

Vascular lesions in the orbit. Forbes G. **Neuroimaging Clin N Am** 1996 Feb;6(1):113–22 (22 ref.)

Successful surgical treatment of intraorbital arteriovenous malformations: case report. Hieu PD, et al. **Neurosurgery** 1997 Mar;40(3):626–31 (14 ref.)

INJURIES

Enophthalmos revisited. Longaker MT, et al.

Clin Plast Surg 1997 Jul;24(3):531–7 (11 ref.)
Asystole after inadvertent intubation of the orbit. Green JG, et al. **J Oral Maxillofac Surg** 1997 Aug;55(8):856–9 (43 ref.)
Growing fracture of the orbital roof. Jamjoom ZA. **Surg Neurol** 1997 Aug;48(2):184–8 (15 ref.)

PATHOLOGY

High-resolution MR imaging of the eye and orbit. Hosten N, et al. **Front Radiat Ther Oncol** 1997;30:8–19 (37 ref.)
Extramedullary blast crisis in chronic myeloid leukemia. Specchia G, et al. **Leuk Res** 1996 Nov–Dec;20(11–12):905–8 (28 ref.)
Graves' disease of the orbit. Weber AL, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):61–72 (34 ref.)
Management of the eye in the treatment of sinonasal cancers. McCary WS, et al. **Otolaryngol Clin North Am** 1995 Dec; 28(6):1231–8 (27 ref.)
Orbitofascial conidiobolomycosis in a child. al-Hajjar S, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1130–2 (15 ref.)
[Adenocarcinoma of the meibomian gland with invasion of the orbit] Cernea P, et al. **Oftalmologia** 1997;41(1):44–6 (10 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

The orbitofrontal cortex. Rolls ET. **Philos Trans R Soc Lond B Biol Sci** 1996 Oct 29; 351(1346):1433–43; discussion 1443–4 (103 ref.)

RADIATION EFFECTS

Acute and late side effects of radiotherapy for ocular disease: an overview. Alberti W. **Front Radiat Ther Oncol** 1997; 30:281–6 (23 ref.)

SURGERY

Transcranial orbital surgery. Jane JA Sr, et al. **Clin Neurosurg** 1996;43:53–71 (19 ref.)
Current treatment of post-traumatic deformities. Residual orbital, adnexal, and soft-tissue abnormalities. Spinelli HM, et al. **Clin Plast Surg** 1997 Jul;24(3):519–30 (47 ref.)
The suborbicularis oculi fat in aesthetic and reconstructive surgery. Hoenig JA, et al. **Int Ophthalmol Clin** 1997 Summer;37(3):179–91 (20 ref.)
Complications of hydroxyapatite orbital implants. A review of 100 consecutive cases and a comparison of Dexon mesh (polyglycolic acid) with scleral wrapping. Oestreicher JH, et al. **Ophthalmology** 1997 Feb;104(2):324–9 (20 ref.)
Powered instrumentation in orbital and optic nerve decompression. Chow JM, et al. **Otolaryngol Clin North Am** 1997 Jun;30(3):467–78 (24 ref.)
Concepts in orbital reconstruction. Howard G, et al. **Otolaryngol Clin North Am** 1997 Aug;30(4):541–62 (44 ref.)

ORBIT EVISCERATION

see related
EYE EVISCERATION

ORBITAL DISEASES

[Recent interdisciplinary diagnosis and therapy of endocrine orbitopathy] Kahaly G, et al. **Dtsch Med Wochenschr** 1997 Jan 3;122(1–2):27–32 (19 ref.) **(Ger)**

DIAGNOSIS

Orbital disease, optic nerve and chiasm. Cockerham KP, et al. **Curr Opin Neurol** 1997 Feb;10(1):22–30 (45 ref.)
Paraorbital lesions. Sanchez R, et al. **Eur J Radiol** 1996 Mar; 22(1):53–67 (30 ref.)
Survey of CT and MR imaging of the orbit. Weber AL, et al. **Eur J Radiol** 1996 Mar;22(1):42–52 (28 ref.)
Pediatric orbital and visual pathway lesions. Barnes PD, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):179–98 (86 ref.)
Vascular lesions in the orbit. Forbes G. **Neuroimaging Clin N Am** 1996 Feb;6(1):113–22 (22 ref.)
Clinical signs and symptoms requiring computed tomography and magnetic resonance imaging evaluation. Levin LA. **Neuroimaging Clin N Am** 1996 Feb;6(1):1–14 (38 ref.)
Benign and malignant tumors of the orbital cavity including the lacrimal gland. Warner MA, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):123–42 (109 ref.)
Lymphoproliferative disease of the orbit. Weber AL, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):93–111 (51 ref.)
Orbit and optic nerve. Villablanca P, et al. **Top Magn Reson Imaging** 1996 Apr;8(2):87–110 (75 ref.)

ETIOLOGY

Orbital emphysema and the medial orbital wall: a review of the literature with particular reference to that associated with indirect trauma and possible blindness. Muhammad JK, et al. **J Craniomaxillofac Surg** 1996 Aug;24(4):245–50 (44 ref.)
Orbital complications of sinusitis. Jabor MA, et al. **J La State Med Soc** 1997 Apr;149(4):105–8 (13 ref.)
Orbital and eyelid manifestations of neurofibromatosis: a clinical study and literature review. Farris SR, et al. **Ophthal Plast Reconstr Surg** 1996 Dec;12(4):245–59 (133 ref.)
Orbital compression syndrome in sickle cell disease. Curran EL, et al. **Ophthalmology** 1997 Oct;104(10):1610–5 (18 ref.)
[Orbital hydatid cyst. Apropos of a case] Benjelloun A, et al. **Ann Radiol (Paris)** 1996;39(3):131–4 (20 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Potential sources for orbital cellulitis. Rumelt S, et al. **Int Ophthalmol Clin** 1996 Summer;36(3):207–21 (55 ref.)
Asymptomatic posterior orbital cellulitis resulting from ethmoid/maxillary sinusitis. Filips RF, et al. **J Am Optom Assoc** 1997 Jan;68(1):55–60 (18 ref.)
Oral botryomycosis: a case report. Devaiah AK, et al. **J Laryngol Otol** 1997 Jan;111(1):77–9 (15 ref.)
Orbital infections in patients with human immunodeficiency virus infection. Kronish JW, et al. **Ophthalmology** 1996 Sep; 103(9):1483–92 (39 ref.)
Recovery from rhinocerebral mucormycosis with carotid artery occlusion: a pediatric case and review of the literature. Shah PD, et al. **Pediatr Infect Dis J** 1997 Jan; 16(1):68–71 (27 ref.)

PARASITOLOGY

Extrapulmonary Dirofilaria immitis–like infections in the Western Hemisphere [published erratum appears in Am J Surg Pathol 1996 Sep;20(9):1160] Gutierrez Y, et al. **Am J Surg Pathol** 1996 Mar;20(3):299–305 (45 ref.)

PATHOLOGY

Atypical choristomatous cysts of the orbit. West JA, et al. **Aust N Z J Ophthalmol** 1997 May;25(2):117–23 (14 ref.)
The spectrum of orbital aspergillosis: a clinicopathological review. Levin LA, et al. **Surv Ophthalmol** 1996 Sep–Oct; 41(2):142–54 (119 ref.)

SURGERY

Transcranial orbital surgery. Jane JA Sr, et al. **Clin Neurosurg** 1996;43:53–71 (19 ref.)
Extended applications of endoscopic sinus surgery—the territorial imperative [editorial] Lund VJ. **J Laryngol Otol** 1997 Apr;111(4):313–5 (13 ref.)
Surgical methods and approaches in the treatment of orbital disease. Rubin PA, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):239–55 (68 ref.)

ORBITAL FRACTURES

COMPLICATIONS

Enophthalmos revisited. Longaker MT, et al. **Clin Plast Surg** 1997 Jul;24(3):531–7 (11 ref.)
Orbital emphysema and the medial orbital wall: a review of the literature with particular reference to that associated with indirect trauma and possible blindness. Muhammad JK, et al. **J Craniomaxillofac Surg** 1996 Aug;24(4):245–50 (44 ref.)
[Isolated blow out fracture of the medial wall of the orbit with medial rectus entrapment. Apropos of 3 cases] Gerard M, et al. **J Fr Ophtalmol** 1996;19(10):591–6 (15 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Radiologic assessment of trauma and foreign bodies of the eye and orbit. Lustrin ES, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):219–37 (40 ref.)

SURGERY

Strategies for the treatment of enophthalmos. Grant MP, et al. **Clin Plast Surg** 1997 Jul;24(3):539–50 (17 ref.)

ORBITAL GRANULOMA, PLASMA CELL see **GRANULOMA, PLASMA CELL, ORBITAL**

ORBITAL MYOSITIS see **GRANULOMA, PLASMA CELL, ORBITAL**

ORBITAL NEOPLASMS

see related
EYE NEOPLASMS
[Ocular sites of acute leukemias] Berthou C, et al. **J Fr Ophtalmol** 1996;19(6–7):470–8 (45 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

An unusual cause of proptosis: orbital solitary fibrous tumor: case report. Ramdial PK, et al. **Neurosurgery** 1996 May; 38(5):1040–3 (15 ref.)
Chewing-induced visual impairment from a dumbbell dermoid cyst. Emerick GT, et al. **Ophthal Plast Reconstr Surg** 1997 Mar;13(1):57–61 (11 ref.)

CONGENITAL

Congenital orbital teratoma: a clinicopathologic case report. Bilgiç S, et al. **Ophthal Plast Reconstr Surg** 1997 Jun; 13(2):142–6 (17 ref.)

DIAGNOSIS

Strategies for diagnosis and management of infiltrative orbital lesion. Bacskulin A, et al. **Front Radiat Ther Oncol** 1997; 30:165–71 (11 ref.)
Malignant peripheral nerve sheath tumor of the orbit in a newborn: a case report and review. Fezza JP, et al. **J Pediatr Ophthalmol Strabismus** 1997 Mar–Apr; 34(2):128–31 (10 ref.)
Pediatric orbital and visual pathway lesions. Barnes PD, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):179–98 (86 ref.)
Vascular lesions in the orbit. Forbes G. **Neuroimaging Clin N Am** 1996 Feb;6(1):113–22 (22 ref.)
Clinical signs and symptoms requiring computed tomography and magnetic resonance imaging evaluation. Levin LA. **Neuroimaging Clin N Am** 1996 Feb;6(1):1–14 (38 ref.)
Benign and malignant tumors of the orbital cavity including the lacrimal gland. Warner MA, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):123–42 (109 ref.)
Lymphoproliferative disease of the orbit. Weber AL, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):93–111 (51 ref.)
MRI of mesenchymal chondrosarcoma of the orbit: case report and review of the literature. Shinaver CN, et al. **Neuroradiology** 1997 Apr;39(4):296–301 (22 ref.)
[Primary extradural meningioma of the orbits: a report of a patient and review of the literature] Spraul CW, et al. **Klin Monatsbl Augenheilkd** 1996 Nov;209(5):322–7 (41 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Intracranial chondromyxoid fibroma. Report of a case and review of the literature. Wolf DA, et al. **Arch Pathol Lab Med** 1997 Jun;121(6):626–30 (23 ref.)
Plasmacytoma of the eye and orbit. Adkins JW, et al. **Int Ophthalmol** 1996–97;20(6):339–43 (11 ref.)
Congenital orbital teratoma: a clinicopathologic case report. Bilgiç S, et al. **Ophthal Plast Reconstr Surg** 1997 Jun; 13(2):142–6 (17 ref.)
Hodgkin's disease of the orbit with intracranial extension. Sahjpaul R, et al. **Ophthalmic Surg Lasers** 1996 Mar; 27(3):239–42 (16 ref.)
Epibulbar granular cell tumor. Report of a case and review of the literature. Charles NC, et al. **Ophthalmology** 1997 Sep;104(9):1454–6 (18 ref.)
Congenital malignant teratoid neoplasm of the eye and orbit: a case report and review of the literature. Steinkuller PG, et al. **Ophthalmology** 1997 Jan;104(1):38–42 (38 ref.)
Management of the eye in the treatment of sinonasal cancers. McCary WS, et al. **Otolaryngol Clin North Am** 1995 Dec; 28(6):1231–8 (27 ref.)

SECONDARY

Metastatic adenocarcinoma of the prostate to the orbit as a presenting symptom. Gonzalez CM, et al. **J Urol** 1997 Feb;157(2):625 (4 ref.)
[Orbital metastases of melanoma of the choroid. Value of imaging] Menif E, et al. **J Radiol** 1997 May;78(5):385–7 (10 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Fronto–ethmoidal and orbital osteomas with intracranial extension. Report of two cases. Maiuri F, et al. **J Neurosurg Sci** 1996 Mar;40(1):65–70 (24 ref.)
Surgical methods and approaches in the treatment of orbital disease. Rubin PA, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):239–55 (68 ref.)
Reconstruction of the orbit. Spinelli HM, et al. **Surg Oncol Clin N Am** 1997 Jan;6(1):45–69 (68 ref.)

THERAPY

Strategies for diagnosis and management of infiltrative orbital lesion. Bacskulin A, et al. **Front Radiat Ther Oncol** 1997; 30:165–71 (11 ref.)

ORBITAL SIMULATION see **SPACE SIMULATION**

ORCHIDECTOMY see **ORCHIECTOMY**

ORCHIECTOMY

Management of seminoma of the testis: recommendations based on treatment results. Morgan G, et al. **Aust N Z J Surg** 1997 Jan;67(1):15–20 (26 ref.)
Total androgen blockade for prostate cancer: the end does not justify the means. Javle M, et al. **Cancer Treat Res** 1996;88:201–10 (61 ref.)
Combined androgen blockade in the treatment of advanced prostate cancer—an overview. The Scandinavian Prostatic Cancer Group. Iversen P. **Scand J Urol Nephrol** 1997 Jun; 31(3):249–54 (33 ref.)
[A case of aphallia] Nakaigawa N, et al. **Hinyokika Kiyo** 1996 Sep;42(9):695–7 (10 ref.) (Eng. Abstr.) **(Jpn)**

HISTORY

From mutilation to medication: the history of orchidectomy. Glass JM, et al. **Br J Urol** 1997 Sep;80(3):373–8 (39 ref.)

METHODS

[Orchidectomy in testicular cancer. Variant techniques and tactics] Houdelette P, et al. **Ann Urol (Paris)** 1996; 30(5):264–8 (19 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Fantasies and facts of the testes. van Basten JP, et al.

ORCHIECTOMY

Br J Urol 1996 Nov;78(5):756–62 (63 ref.)

ORCHITIS

ETIOLOGY

Elucidation of autoimmune disease mechanism based on testicular and ovarian autoimmune disease models. Tung KS. **Horm Metab Res** 1995 Dec;27(12):539–43 (38 ref.)

Orchitis due to vasculitis in autoimmune diseases. Pannek J, et al. **Scand J Rheumatol** 1997;26(3):151–4 (40 ref.)

IMMUNOLOGY

Mechanisms of autoimmune disease in the testis and ovary. Tung KS, et al. **Hum Reprod Update** 1995 Jan;1(1):35–50 (114 ref.)

MICROBIOLOGY

[[Brucellar orchiepididymitis with abscess] González Sánchez FJ, et al. **Arch Esp Urol** 1997 Apr;50(3):289–92 (14 ref.) (Eng. Abstr.) **(Spa)**

ORF see **ECTHYMA, CONTAGIOUS**

ORF VIRUS

IMMUNOLOGY

The immune and inflammatory response to orf virus. Haig DM, et al. **Comp Immunol Microbiol Infect Dis** 1997 Jun; 20(3):197–204 (33 ref.)

ORGAN CULTURE

see related
CELLS, CULTURED
TISSUE CULTURE

METHODS

Organ culture: the method of choice for preservation of human donor corneas. Pels L. **Br J Ophthalmol** 1997 Jul; 81(7):523–5 (37 ref.)

Human pilosebaceous culture. Kealey T, et al. **Methods Mol Biol** 1997;75:101–15 (20 ref.)

ORGAN DONORS see **TISSUE DONORS**

ORGAN FAILURE, MULTIPLE see **MULTIPLE ORGAN FAILURE**

ORGAN PRESERVATION

Reperfusion injury after liver preservation for transplantation. Lemasters JJ, et al. **Annu Rev Pharmacol Toxicol** 1997;37:327–38 (89 ref.)

Preservation injury: mechanisms, prevention and consequences. Jaeschke H. **J Hepatol** 1996 Nov; 25(5):774–80 (78 ref.)

Transplantation-induced injuries of the intestinal muscularis and its innervation: from preservation to chronic rejection. Bauer AJ. **Transplant Proc** 1996 Oct;28(5):2539–41 (11 ref.)

Reperfusion injury. Grinyó JM. **Transplant Proc** 1997 Feb–Mar;29(1–2):59–62 (67 ref.)

METHODS

Organ culture: the method of choice for preservation of human donor corneas. Pels L. **Br J Ophthalmol** 1997 Jul; 81(7):523–5 (37 ref.)

Failure patterns of cryopreserved vein grafts in liver transplantation. Kuang AA, et al. **Transplantation** 1996 Sep 27;62(6):742–7 (21 ref.)

Portal vein thrombosis and stenosis in pediatric liver transplantation. Millis JM, et al. **Transplantation** 1996 Sep 27;62(6):748–54 (24 ref.)

[Disinfection of human donor corneas during preparation and preservation] Hagenah M, et al. **Klin Monatsbl Augenheilkd** 1996 Jul;209(1):1–6; discussion 1 (58 ref.) (Eng. Abstr.) **(Ger)**

ORGAN PROCUREMENT

see related
TISSUE DONORS

Evolving concepts in autologous blood procurement and transfusion: case reports of perisurgical anemia complicated by myocardial infarction. Goodnough LT, et al. **Am J Med** 1996 Aug 26;101(2A):33S–37S (30 ref.)

Psychosocial and ethical issues in surgical approaches to end-stage lung disease. Manzetti JD, et al. **Clin Chest Med** 1997 Jun;18(2):383–90 (50 ref.)

Ethical and policy issues in altruistic living and cadaveric organ donation. Spital A. **Clin Transplant** 1997 Apr; 11(2):77–87 (93 ref.)

Bone marrow transplantation using unrelated donors for haematological malignancies. Ringdén O. **Med Oncol** 1997 Mar;14(1):11–22 (116 ref.)

[Problems related to organ transplantation as an allocation of scarce medical resources: a review] Hagihara A, et al. **Nippon Eiseigaku Zasshi** 1996 Oct;51(3):648–56 (45 ref.) (Eng. Abstr.) **(Jpn)**

[Practical aspects of organ procurement for transplant] Vaz ML, et al. **Rev Assoc Med Bras** 1995 Nov–Dec;41(6):401–5 (7 ref.) **(Por)**

ECONOMICS

Bodily integrity and the sale of human organs. Wilkinson S, et al. **J Med Ethics** 1996 Dec;22(6):334–9 (12 ref.)

Nephrarious goings on. Kidney sales and moral arguments [see comments] Richards JR. **J Med Philos** 1996 Aug; 21(4):375–416 (15 ref.) Comment in: J Med Philos 1996 Aug;21(4):357–73.

LEGISLATION & JURISPRUDENCE

Is it time to abandon brain death? Truog RD. **Hastings Cent Rep** 1997 Jan–Feb;27(1):29–37 (47 ref.)

The Swedish Transplant Acts: sociological considerations on bodies and giving. Machado N. **Soc Sci Med** 1996 Jan; 42(2):159–68 (48 ref.)

[Organ donation: legal principles, procedures, organization] Gubernatis G. **Internist (Berl)** 1996 Mar;37(3):217–28 (32 ref.) **(Ger)**

METHODS

In situ splitting of cadaveric livers. The ultimate expansion of a limited donor pool. Rogiers X, et al. **Ann Surg** 1996 Sep;224(3):331–9; discussion 339–41 (26 ref.)

Contemporary criteria for cadaveric organ donation in renal transplantation: the need for better selection parameters. Taylor RJ, et al. **World J Urol** 1996;14(4):225–9 (23 ref.)

ORGANIZATION & ADMINISTRATION

Ethical issues in organ procurement: a review for intensivists. Arnold RM, et al. **Crit Care Clin** 1996 Jan;12(1):29–48 (133 ref.)

The potential organ donor pool: international figures. Miranda B, et al. **Transplant Proc** 1997 Feb–Mar; 29(1–2):1604–6 (25 ref.)

Donor screening: an overview of current regulation and practices in Europe. Tjabbes H. **Transplant Proc** 1996 Oct; 28(5):2950–2 (0 ref.)

STANDARDS

Donor criteria and evaluation. Frost AE. **Clin Chest Med** 1997 Jun;18(2):231–7 (22 ref.)

Liver graft-transmitted glioblastoma multiforme. A case report and experience with 13 multiorgan donors suffering from primary cerebral neoplasia [see comments] Jonas S, et al. **Transpl Int** 1996;9(4):426–9 (16 ref.) Comment in: Transpl Int 1997;10(1):83–4.

STATISTICS & NUMERICAL DATA

Selection and management of cardiac allograft donors. Novitzky D. **Curr Opin Cardiol** 1996 Mar;11(2):174–82 (51 ref.)

[Kidney donation by the elderly--an emergency solution?] Waleczek H, et al. **Chirurg** 1996 Sep;67(9):907–14 (48 ref.) (Eng. Abstr.) **(Ger)**

ORGAN PROCUREMENT FOUNDATIONS see **ORGAN PROCUREMENT**

ORGAN PROCUREMENT SYSTEMS see **ORGAN PROCUREMENT**

ORGAN RETRIEVAL see **ORGAN PROCUREMENT**

ORGAN SPECIFICITY

How organ-specific is the migration of 'naive' and 'memory' T cells? Westermann J, et al. **Immunol Today** 1996 Jun; 17(6):278–82 (65 ref.)

Benzidine mechanistic data and risk assessment: species- and organ-specific metabolic activation. Whysner J, et al. **Pharmacol Ther** 1996;71(1–2):107–26 (146 ref.)

[Molecular mechanism of tissue-specific actions of oestrogen] Kato S. **Seikagaku** 1997 Jan;69(1):30–6 (20 ref.) **(Jpn)**

DRUG EFFECTS

Selective protein covalent binding and target organ toxicity. Cohen SD, et al. **Toxicol Appl Pharmacol** 1997 Mar; 143(1):1–12 (99 ref.)

Selected lesions of dioxin in laboratory rodents. Mann PC. **Toxicol Pathol** 1997 Jan–Feb;25(1):72–9 (25 ref.)

IMMUNOLOGY

Signal minus 1: a key factor in immunological tolerance to tissue-specific self antigens? Parish CR. **Immunol Cell Biol** 1996 Jun;74(3):278–85 (50 ref.)

PHYSIOLOGY

[The "rapidity" factor in the specific immunity response after oral vaccination] Negretti F. **Minerva Med** 1997 Apr; 88(4):127–41 (82 ref.) (Eng. Abstr.) **(Ita)**

ORGAN SURVIVAL see **TISSUE SURVIVAL**

ORGAN TEMPERATURE see **BODY TEMPERATURE**

ORGAN TRANSPLANTATION

see related
TRANSPLANTATION IMMUNOLOGY

An update on new immunosuppressive drugs undergoing preclinical and clinical trials: potential applications in organ transplantation. First MR. **Am J Kidney Dis** 1997 Feb; 29(2):303–17 (138 ref.)

Immunosuppressive agents in clinical trials in transplantation. Halloran PF. **Am J Med Sci** 1997 May;313(5):283–8 (39 ref.)

Role of extracellular matrix proteins in organ transplantation. Kupiec-Weglinski JW, et al. **Arch Immunol Ther Exp (Warsz)** 1997;45(1):7–13 (46 ref.)

Role of alfacalcidiol on bone quality and immunomodulation in autoimmune disease and organ transplantation. Dequeker J, et al. **Calcif Tissue Int** 1997 Jan;60(1):128–9 (14 ref.)

The use of other drugs to allow a lower dosage of cyclosporin to be used. Therapeutic and pharmacoeconomic considerations. Jones TE. **Clin Pharmacokinet** 1997 May; 32(5):357–67 (100 ref.)

Xenogeneic organ transplantation. Squinto SP. **Curr Opin Biotechnol** 1996 Dec;7(6):641–5 (26 ref.)

Xenotransplantation. Cozzi E, et al. **Curr Opin Nephrol Hypertens** 1996 Nov;5(6):514–8 (48 ref.)

Lymphoproliferative disorders in organ transplant recipients. Vanrenterghem Y. **Eur Radiol** 1997;7(5):665–7 (14 ref.)

Ethical dichotomies in organ transplantation. A time for bridge building. Surman OS, et al. **Gen Hosp Psychiatry** 1996 Nov;18(6 Suppl):13S–19S (29 ref.)

Xenograft rejection: molecular mechanisms and therapeutic prospects. Azimzadeh A, et al. **Hematol Cell Ther** 1996 Aug;38(4):331–43 (123 ref.)

Killer cell inhibitory receptor interactions with HLA class I molecules: implications for alloreactivity and transplantation. Young NT, et al. **Hum Immunol** 1997 Jan; 52(1):1–11 (109 ref.)

Prophylaxis against CMV infection in transplant patients. Griffiths PD. **J Antimicrob Chemother** 1997 Mar; 39(3):299–301 (29 ref.)

New immunosuppressive drugs in organ transplantation. Hughes SE, et al. **J Clin Pharmacol** 1996 Dec; 36(12):1081–92 (140 ref.)

Trauma management in solid organ transplant recipients. Barone GW, et al. **J Emerg Med** 1997 Mar–Apr; 15(2):169–76 (12 ref.)

Gene therapy in transplantation. Hullett DA. **J Heart Lung Transplant** 1996 Sep;15(9):857–62 (52 ref.)

Oral lesions in organ transplant patients. Seymour RA, et al. **J Oral Pathol Med** 1997 Aug;26(7):297–304 (99 ref.)

Brain death and organ donation. Wig N, et al. **Natl Med J India** 1997 May–Jun;10(3):120–5 (27 ref.)

Therapeutic approach to organ transplantation. Strom TB, et al. **Nephrol Dial Transplant** 1996 Jun;11(6):1176–81 (44 ref.)

The role of cell migration and microchimerism in the induction of tolerance after solid organ transplantation. Jindal RM, et al. **Postgrad Med J** 1997 Mar;73(857):146–50 (39 ref.)

Sarcoidosis and transplantation. Padilla ML, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1997 Mar;14(1):16–22 (25 ref.)

Changing patterns in organ donation in Eurotransplant, 1990–1994. Cohen B, et al. **Transpl Int** 1997;10(1):1–6 (9 ref.)

Role of PCR in the diagnosis and management of CMV in solid organ recipients: what is the predictive value for the development of disease and should PCR be used to guide antiviral therapy? Abecassis MM, et al. **Transplant Proc** 1996 Dec;28(6 Suppl 2):2–4 (18 ref.)

Immunosuppressive drugs and pregnancy: experimental and clinical data. Albengres E, et al. **Transplant Proc** 1997 Aug; 29(5):2461–6 (14 ref.)

Xenotransplantation: a possible option for the future. Bach FH. **Transplant Proc** 1997 Sep;29(6):2651–2 (7 ref.)

Purchasing transplants in the NHS. Edwards B. **Transplant Proc** 1997 Sep;29(6):2725–6 (6 ref.)

Xenotransplantation: ethical acceptability. Kennedy I. **Transplant Proc** 1997 Sep;29(6):2729–30 (0 ref.)

Extracellular matrix proteins and their interactions with the cellular repertoire of transplant recipients. Kupiec-Weglinski JW, et al. **Transplant Proc** 1997 Sep; 29(6):2601–2 (10 ref.)

Combination protocols for prevention of CMV disease in the high risk transplant patient. Martin M. **Transplant Proc** 1996 Dec;28(6 Suppl 2):12–3 (5 ref.)

Defining an optimal regimen for cytomegalovirus prophylaxis in organ transplant recipients. Paya CV. **Transplant Proc** 1996 Dec;28(6 Suppl 2):9–11 (22 ref.)

The Bellagio Task Force report on transplantation, bodily integrity, and the International Traffic in Organs. Rothman DJ, et al. **Transplant Proc** 1997 Sep;29(6):2739–45 (38 ref.)

Xenotransplantation--scientific aspects. White DJ. **Transplant Proc** 1997 Sep;29(6):2727–8 (0 ref.)

Rationale for the use of antioxidant vitamins in clinical organ transplantation. Lehr HA, et al. **Transplantation** 1996 Nov 15;62(9):1197–9 (47 ref.)

Measuring transplant patients' compliance with immunosuppressive therapy. De Geest S, et al. **West J Nurs Res** 1996 Oct;18(5):595–605 (45 ref.)

Hematologic problems and organ transplantation.

Dmitrewski J, et al. **World J Surg** 1996 Nov-Dec; 20(9):1160-5 (43 ref.)
[Monoclonal antibodies and transplantation] Hourmant M. **Nephrologie** 1996;17(8):435-40 (64 ref.) (Eng. Abstr.) **(Fre)**
[Pregnancy after organ transplantation] Chevalier P, et al. **Presse Med** 1996 Nov 9;25(34):1643-8 (29 ref.) (Eng. Abstr.) **(Fre)**
[The combined grafts of the kidney and another organ] **Prog Urol** 1996 Oct;6(5):813-30 (157 ref.) **(Fre)**
[The problem of viral hepatitis in transplantation medicine] Tillmann HL, et al. **Internist (Berl)** 1996 Mar;37(3):240-9 (149 ref.) **(Ger)**
[Pathogenesis of post-transplantation osteopathy] Hofbauer LC, et al. **Wien Med Wochenschr** 1996;146(12):253-7 (46 ref.) (Eng. Abstr.) **(Ger)**
[Pregnancy after organ transplantation] Many A, et al. **Harefuah** 1996 Sep;131(5-6):173-6 (28 ref.) **(Heb)**
[Ethical questions concerning organ transplantation, with special reference to Great Britain] Széll KI, et al. **Orv Hetil** 1997 Jun 22;138(25):1635-40 (52 ref.) (Eng. Abstr.) **(Hun)**
[Problems related to organ transplantation as an allocation of scarce medical resources: a review] Hagihara A, et al. **Nippon Eiseigaku Zasshi** 1996 Oct;51(3):648-56 (45 ref.) (Eng. Abstr.) **(Jpn)**
[Transplantation of animal organs (xenotransplantation). Status and future development] Fiane AE, et al. **Tidsskr Nor Laegeforen** 1997 Mar 20;117(8):1071-6 (65 ref.) (Eng. Abstr.) **(Nor)**
[Prospects for clinical transplantation of the testis as an organ and as a tissue] Bozhedomov VA, et al. **Biull Eksp Biol Med** 1994 Apr;117(4):400-4 (71 ref.) **(Rus)**

ADVERSE EFFECTS

Risks of transfusion and organ and tissue transplantation: practical concerns that drive practical policies. DeChristopher PJ, et al. **Am J Clin Pathol** 1997 Apr;107(4 Suppl 1):S2-11 (39 ref.)
Immunomodulation in transplantation with photopheresis. Barr ML. **Artif Organs** 1996 Aug;20(8):971-3 (12 ref.)
Infections due to dematiaceous fungi in organ transplant recipients: case report and review. Singh N, et al. **Clin Infect Dis** 1997 Mar;24(3):369-74 (35 ref.)
Infections in solid-organ transplant recipients. Patel R, et al. **Clin Microbiol Rev** 1997 Jan;10(1):86-124 (800 ref.)
Post-transplant diabetes mellitus. The role of immunosuppression. Jindal RM, et al. **Drug Saf** 1997 Apr; 16(4):242-57 (126 ref.)
Management of cytomegalovirus infection in solid-organ transplant recipients. Murray BM. **Immunol Invest** 1997 Jan-Feb;26(1-2):243-55 (51 ref.)
Post-transplant Kaposi's sarcoma. Gotti E, et al. **J Am Soc Nephrol** 1997 Jan;8(1):130-7 (98 ref.)
Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton. Epstein S. **J Bone Miner Res** 1996 Jan;11(1):1-7 (73 ref.)
Immunologic barriers to xenotransplantation. Lin SS, et al. **J Heart Lung Transplant** 1996 Jun;15(6):547-55 (72 ref.)
Cytomegalovirus infections in transplant patients. Ljungman P. **Scand J Infect Dis Suppl** 1996;100:59-63 (35 ref.)
Molecular pathology of posttransplantation lymphoproliferative disorders. Chadburn A, et al. **Semin Diagn Pathol** 1997 Feb;14(1):15-26 (62 ref.)
Hyperlipidemia in solid organ transplantation. Kobashigawa JA, et al. **Transplantation** 1997 Feb 15;63(3):331-8 (86 ref.)
[Aspergillus lung pathology in transplant patients] Kaiser L, et al. **Rev Mal Respir** 1996 Nov;13(5 Suppl):S93-101 (75 ref.) (Eng. Abstr.) **(Fre)**
[Lymphoproliferative syndromes associated to the Epstein Barr virus in organ transplants] Hidalgo M, et al. **Med Clin (Barc)** 1996 Sep 14;107(8):310-6 (116 ref.) **(Spa)**
[Characteristics of non-bacterial infections in solid organ transplantation] Cisterna Cancer R, et al. **Rev Clin Esp** 1995 Oct;195 Spec No:37-43 (57 ref.) **(Spa)**
[Pneumocystis carinii pneumonia in patients with a solid organ transplant (editorial; comment)] Muñoz P. **Rev Clin Esp** 1997 Jan;197(1):1-3 (14 ref.) Comment on: Rev Clin Esp 1997 Jan;197(1):31-4. **(Spa)**
[Pneumocystis carinii pneumonia in patients with a solid organ transplant: a report of 5 cases (see comments)] Ruiz Ruiz J, et al. **Rev Clin Esp** 1997 Jan;197(1):31-4 (59 ref.) (Eng. Abstr.) Comment in: Rev Clin Esp 1997 Jan;197(1):1-3. **(Spa)**

ECONOMICS

Economics of transplantation in the 21st century: new scientific opportunities but greater economic problems. Buxton MJ. **Transplant Proc** 1997 Sep;29(6):2723-4 (6 ref.)

LEGISLATION & JURISPRUDENCE

The Swedish Transplant Acts: sociological considerations on bodies and giving. Machado N. **Soc Sci Med** 1996 Jan; 42(2):159-68 (48 ref.)
[Organ donation: legal principles, procedures, organization] Gubernatis G. **Internist (Berl)** 1996 Mar;37(3):217-28 (32 ref.) **(Ger)**

MORTALITY

Chronic allograft failure: the clinical problem. Nagano H, et al. **Am J Med Sci** 1997 May;313(5):305-9 (48 ref.)

PATHOLOGY

Molecular pathology of posttransplantation lymphoproliferative disorders. Chadburn A, et al. **Semin Diagn Pathol** 1997 Feb;14(1):15-26 (62 ref.)
Classification of the posttransplant lymphoproliferative disorders: from the past to the present. Swerdlow SH. **Semin Diagn Pathol** 1997 Feb;14(1):2-7 (21 ref.)

PHYSIOLOGY

Will tolerance become a clinical reality? Aradhye S, et al. **Am J Med Sci** 1997 May;313(5):310-4 (40 ref.)
Cyclosporin pharmacokinetics in paediatric transplant recipients. Cooney GF, et al. **Clin Pharmacokinet** 1997 Jun; 32(6):481-95 (81 ref.)
Chimerism and transplantation tolerance: cause and effect. Wood K, et al. **Immunol Today** 1996 Dec;17(12):584-7; discussion 588 (35 ref.)
Cytokines and organ transplantation. A review. Pirenne J, et al. **Nucl Med Biol** 1994 Apr;21(3):545-55 (28 ref.)
[Diagnosis and follow-up of post-transplantation osteopathies] Seibel MJ. **Acta Med Austriaca** 1997;24(1):1-4 (44 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Posttraumatic stress symptoms and medical procedures in children. Wintgens A, et al. **Can J Psychiatry** 1997 Aug; 42(6):611-6 (44 ref.)
Psychosocial assessment of organ transplant candidates and the Americans with Disabilities Act. Orentlicher D. **Gen Hosp Psychiatry** 1996 Nov;18(6 Suppl):5S-12S (24 ref.)
Studying the quality of life after organ transplantation: research problems and solutions. Joralemon D, et al. **Soc Sci Med** 1997 May;44(9):1259-69 (100 ref.)

STATISTICS & NUMERICAL DATA

Children and organ donation in the United Kingdom: a literature review. Baxter RC. **J Pediatr Nurs** 1996 Apr; 11(2):136-41 (40 ref.)
Kaposi's sarcoma in transplant recipients. Penn I. **Transplantation** 1997 Sep 15;64(5):669-73 (52 ref.)
[Transplantation today] Mühlbacher F. **Radiologe** 1997 Mar; 37(3):191-6 (23 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

Update in transplantation 1995. Helderman JH, et al. **Clin Transpl** 1995;:323-50 (272 ref.)
Transplantation. Beware: shifting paradigms ahead. Morris RE. **Lancet** 1996 Dec 21-28;348 Suppl 2:sII26 (5 ref.)
The prospects for xenotransplantation. Warrens AN, et al. **QJM** 1996 Dec;89(12):885-91 (28 ref.)
Classification of the posttransplant lymphoproliferative disorders: from the past to the present. Swerdlow SH. **Semin Diagn Pathol** 1997 Feb;14(1):2-7 (21 ref.)

ORGAN TRANSPLANTS see **ORGAN TRANSPLANTATION**

ORGANELLES

[Caveola--an old but new organelle] Fujimoto T. **Kaibogaku Zasshi** 1996 Dec;71(6):611-4 (9 ref.) **(Jpn)**

ENZYMOLOGY

Ribonuclease P from plant nuclei and photosynthetic organelles. Schön A. **Mol Biol Rep** 1995-96;22(2-3):139-45 (41 ref.)

GENETICS

Organelle structure, function, and inheritance in yeast: a role for fatty acid synthesis? Schneiter R, et al. **Cell** 1997 Feb 21;88(4):431-4 (13 ref.)
Organelle genomes: going, going, gone! Palmer JD. **Science** 1997 Feb 7;275(5301):790-1 (22 ref.)
Bonsai genomics: sequencing the smallest eukaryotic genomes. McFadden GI, et al. **Trends Genet** 1997 Feb; 13(2):46-9 (16 ref.)

METABOLISM

The neuronal ceroid lipofuscinoses (Batten disease): a group of lysosomal proteinoses. Palmer DN, et al. **Adv Exp Med Biol** 1996;389:129-36 (55 ref.)
Endosymbiotic interactions in anaerobic protozoa. Hackstein JH, et al. **Antonie Van Leeuwenhoek** 1997 Feb;71(1-2):151-8 (52 ref.)
Agonist-releasable intracellular calcium stores and the phenomenon of store-dependent calcium entry. A novel hypothesis based on calcium stores in organelles of the endo- and exocytotic apparatus. Bode HP, et al. **Biochem Pharmacol** 1996 Apr 26;51(8):993-1001 (71 ref.)
Superoxide generation in relation to dehydration and rehydration. Navari-Izzo F, et al. **Biochem Soc Trans** 1996 May;24(2):447-51 (47 ref.)
Intracellular targeting of secretory proteins in neuroendocrine cells. Shennan KI. **Biochem Soc Trans** 1996 May;24(2):535-9 (36 ref.)
Intracellular transport of the low-density lipoprotein receptor. Soutar AK. **Biochem Soc Trans** 1996 May; 24(2):547-52 (41 ref.)
The molecular mechanism of organelle transport along microtubules: the identification and characterization of KIFs (kinesin superfamily proteins). Hirokawa N. **Cell Struct Funct** 1996 Oct;21(5):357-67 (36 ref.)
Microtubule motor complexes moving membranous organelles. Sheetz MP. **Cell Struct Funct** 1996 Oct; 21(5):369-73 (31 ref.)
Molecular machinery mediating vesicle budding, docking and fusion. Söllner TH, et al. **Cell Struct Funct** 1996 Oct; 21(5):407-12 (69 ref.)
Actin-based organelle movement. Simon VR, et al. **Experientia** 1996 Dec 15;52(12):1117-22 (70 ref.)
Variations on the intracellular transport theme: maturing cisternae and trafficking tubules. Mironov AA, et al. **J Cell Biol** 1997 Aug 11;138(3):481-4 (39 ref.)
Do intracellular organelles have any role in transport of bile acids by hepatocytes? Erlinger S. **J Hepatol** 1996;24 Suppl 1:88-93 (33 ref.)
The structure and biogenesis of plant oil bodies: the role of the ER membrane and the oleosin class of proteins. Napier JA, et al. **Plant Mol Biol** 1996 Aug;31(5):945-56 (68 ref.)

PHYSIOLOGY

Factors regulating organelles transport along microtubules. Lopez LA. **Biocell** 1996 Dec;20(3):313-6 (27 ref.)
Formation of secretory vesicles in the biosynthetic pathway. Urbé S, et al. **Biochim Biophys Acta** 1997 Aug 21; 1358(1):6-22 (143 ref.)
Protein transports: the nonclassical ins and outs. Cleves AE. **Curr Biol** 1997 May 1;7(5):R318-20 (10 ref.)
Organelle origins: energy-producing symbionts in early eukaryotes?. Sogin ML. **Curr Biol** 1997 May 1;7(5):R315-7 (11 ref.)

ULTRASTRUCTURE

A comparison of oocyte organelles in Monodelphis domestica with those of other marsupials and eutherians. Kress A. **Reprod Fertil Dev** 1996;8(4):521-33 (90 ref.)
Mammalian oocyte organelles with special reference to pleomorphic mitochondria and vacuole formation in marsupials. Ullmann SL, et al. **Reprod Fertil Dev** 1996; 8(4):491-508 (117 ref.)

ORGANIC BRAIN SYNDROME, NONPSYCHOTIC see **ORGANIC MENTAL DISORDERS**

ORGANIC BRAIN SYNDROME, PSYCHOTIC see **ORGANIC MENTAL DISORDERS, PSYCHOTIC**

ORGANIC BRAIN SYNDROME, SUBSTANCE-INDUCED see **ORGANIC MENTAL DISORDERS, SUBSTANCE-INDUCED**

ORGANIC FOOD see **HEALTH FOOD**

ORGANIC HALLUCINOSIS see **ORGANIC MENTAL DISORDERS, PSYCHOTIC**

ORGANIC MENTAL DISORDERS

DIAGNOSIS

Neuropsychiatric consequences of stroke. Robinson RG. **Annu Rev Med** 1997;48:217-29 (56 ref.)
Caffeine and its effect on persons with mental disorders. Simmons DH. **Arch Psychiatr Nurs** 1996 Apr;10(2):116-22 (37 ref.)
Pathological laughing and crying. Dark FL, et al. **Aust N Z J Psychiatry** 1996 Aug;30(4):472-9 (46 ref.)
Postconcussion symptoms. Gasquoine PG. **Neuropsychol Rev** 1997 Jun;7(2):77-85 (75 ref.)
[The contribution of neuropsychology to psychiatry] Zihl J. **Fortschr Neurol Psychiatr** 1996 Oct;64(10):403-17 (172 ref.) (Eng. Abstr.) **(Ger)**
[Value of computerized tomography and magnetic resonance tomography in psychiatric diagnosis] Schlegel S, et al. **Nervenarzt** 1997 Jan;68(1):1-10 (95 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Use of stimulants in the medically ill. Masand PS, et al. **Psychiatr Clin North Am** 1996 Sep;19(3):515-47 (129 ref.)
[The treatment of depression in central nervous system disorders] Schmitt L, et al. **Encephale** 1995 Dec;21 Spec No 4:15-8 (27 ref.) **(Fre)**

ETIOLOGY

Neuropsychiatric complications after temporal lobe limbic system surgery. Gabriel EM, et al. **Neuroimaging Clin N Am** 1997 Feb;7(1):155-64 (62 ref.)
Psychiatric presentations of medical illness. Marsh CM. **Psychiatr Clin North Am** 1997 Mar;20(1):181-204 (54 ref.)

IMMUNOLOGY

[Role of the cytokine network in the CNS and psychiatric disorders] Müller N. **Nervenarzt** 1997 Jan;68(1):11-20 (117

ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

The neuropsychology of obsessive-compulsive disorder: a review and consideration of clinical implications. Tallis F. **Br J Clin Psychol** 1997 Feb;36 (Pt 1):3-20 (130 ref.)

Corticotropin-releasing factor receptors: physiology, pharmacology, biochemistry and role in central nervous system and immune disorders. De Souza EB. **Psychoneuroendocrinology** 1995;20(8):789-819 (144 ref.)

[Neuronal networks and psychopathology] Spitzer M. **Nervenarzt** 1997 Jan;68(1):21-37 (74 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Psychiatric manifestations of multiple sclerosis: a review [see comments] Rodgers J, et al. **Can J Psychiatry** 1996 Sep; 41(7):441-5 (41 ref.) Comment in: Can J Psychiatry 1997 Apr;42(3):324-5.

Depression in Parkinson's disease. Murray JB. **J Psychol** 1996 Nov;130(6):659-67 (52 ref.)

Poststroke depression: prevalence, course, and associated factors. Hosking SG, et al. **Neuropsychol Rev** 1996 Sep; 6(3):107-33 (66 ref.)

Assessment of depression in patients with brain pathology: the case of stroke. Spencer KA, et al. **Psychol Bull** 1997 Sep;122(2):132-52 (120 ref.)

[Psychiatric sequelae of craniocerebral trauma--a review of the literature] Supprian T, et al. **Psychiatr Prax** 1996 Jul; 23(4):161-7 (73 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

Consumerism for neurobiological disorders. An assessment. Peschel RE, et al. **Int J Technol Assess Health Care** 1996 Fall;12(4):644-56 (40 ref.)

ORGANIC MENTAL DISORDERS, DRUG-INDUCED see **ORGANIC MENTAL DISORDERS, SUBSTANCE-INDUCED**

ORGANIC MENTAL DISORDERS, PSYCHOTIC

DIAGNOSIS

Neuropsychiatric consequences of stroke. Robinson RG. **Annu Rev Med** 1997;48:217-29 (56 ref.)

Severe mental illness and HIV-related medical and neuropsychiatric sequelae. McDaniel JS, et al. **Clin Psychol Rev** 1997;17(3):311-25 (85 ref.)

Chronic subdural hematoma in the elderly: a case report. Elie M, et al. **J Geriatr Psychiatry Neurol** 1996 Apr; 9(2):100-1 (12 ref.)

Psychiatric illnesses in the elderly: a review. Jenike MA. **J Geriatr Psychiatry Neurol** 1996 Apr;9(2):57-82 (125 ref.)

Mechanism of disinhibition after brain lesions. Starkstein SE, et al. **J Nerv Ment Dis** 1997 Feb;185(2):108-14 (36 ref.)

Symptom dimensions of schizophrenia: a selective integration of neurophysiological and neuropsychological correlates. Aderibigbe YA, et al. **Neuropsychobiology** 1996; 34(4):192-200 (89 ref.)

Time course of cerebral ventricular enlargement in schizophrenia supports the hypothesis of its neurodevelopmental nature. Vita A, et al. **Schizophr Res** 1997 Jan 17;23(1):25-30 (32 ref.)

[Antiphospholipid syndrome and psychosis] Clervoy P, et al. **Encephale** 1997 Mar-Apr;23(2):105-7 (14 ref.) (Eng. Abstr.) **(Fre)**

[Neurologic and psychiatric symptoms of legionella infection. Case report and overview of the clinical spectrum] Plaschke M, et al. **Nervenarzt** 1997 Apr;68(4):342-5 (30 ref.) (Eng. Abstr.) **(Ger)**

[Organically-induced delusional syndrome in psittacosis] Hain C, et al. **Psychiatr Prax** 1997 Jul;24(4):198-9 (10 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

The treatment of psychotic disorders in late life. Thorpe L. **Can J Psychiatry** 1997 Jun;42 Suppl 1:19S-27S (116 ref.)

ETIOLOGY

Transient postictal psychosis associated with a course of ECT. Zwil AS, et al. **Convuls Ther** 1997 Mar;13(1):32-6 (23 ref.)

Psychiatric presentations of medical illness. Marsh CM. **Psychiatr Clin North Am** 1997 Mar;20(1):181-204 (54 ref.)

GENETICS

A critical review of genetic studies of schizophrenia. I. Epidemiological and brain studies. Portin P, et al. **Acta Psychiatr Scand** 1997 Jan;95(1):1-5 (55 ref.)

PATHOLOGY

Neuropathology of the cerebellum in schizophrenia--an update: 1996 and future directions. Katsetos CD, et al. **Biol Psychiatry** 1997 Aug 1;42(3):213-24 (160 ref.)

Neuropathology of psychotic symptoms in Alzheimer's disease. Bondareff W. **Int Psychogeriatr** 1996;8 Suppl 3:233-7; discussion 269-72 (8 ref.)

PHYSIOPATHOLOGY

The case for a psychological perspective on late-onset psychosis. Hassett A. **Aust N Z J Psychiatry** 1997 Feb; 31(1):68-75 (76 ref.)

Restlessness: the anatomy of a neuropsychiatric symptom. Sachdev P, et al. **Aust N Z J Psychiatry** 1996 Feb; 30(1):38-53 (100 ref.)

Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Kornhuber J, et al. **Biol Psychiatry** 1997 Jan 15;41(2):135-44 (85 ref.)

Bipolar disorders, dystonia, and compulsion after dysfunction of the cerebellum, dentatorubrothalamic tract, and substantia nigra. Lauterbach EC. **Biol Psychiatry** 1996 Oct 15;40(8):726-30 (65 ref.)

Disturbances of one-carbon metabolism in neuropsychiatric disorders: a review. Smythies JR, et al. **Biol Psychiatry** 1997 Jan 15;41(2):230-3 (35 ref.)

Biological determinants of difficult to treat patients with schizophrenia. Sharma T, et al. **Br J Psychiatry Suppl** 1996 Dec;(31):5-9 (45 ref.)

Neonatal insult to the hippocampal region and schizophrenia: a review and a putative animal model. Beauregard M, et al. **Can J Psychiatry** 1996 Sep;41(7):446-56 (145 ref.)

[Neurodevelopmental models of schizophrenia] Verdoux H. **Encephale** 1996 Oct;22 Spec No 3:85-90 (56 ref.) **(Fre)**

PSYCHOLOGY

Cerebellar arachnoid cyst in a firesetter: the weight of organic lesions in arson. Heidrich A, et al. **J Psychiatry Neurosci** 1996 May;21(3):202-6 (35 ref.)

[Psychiatric sequelae of craniocerebral trauma--a review of the literature] Supprian T, et al. **Psychiatr Prax** 1996 Jul; 23(4):161-7 (73 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

[Non-motor symptoms of Parkinson disease. Significant impact on quality of life--using possible treatments] Müller T, et al. **Fortschr Med** 1997 May 20;115(14):45-8 (0 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

[Pathogenicity of Borna disease virus in psychiatric and neurologic disorders of humans. Current status of research and critical comments] Bechter K, et al. **Nervenarzt** 1997 May;68(5):425-30 (33 ref.) (Eng. Abstr.) **(Ger)**

ORGANIC MENTAL DISORDERS, SUBSTANCE-INDUCED

DIAGNOSIS

Cannabis and the brain [see comments] Castle DJ, et al. **Aust N Z J Psychiatry** 1996 Apr;30(2):179-83 (28 ref.) Comment in: Aust N Z J Psychiatry 1997 Apr;31(2):304-5.

Serotonin syndrome and drug combinations: focus on MAOI and RIMA. Hilton SE, et al. **Eur Arch Psychiatry Clin Neurosci** 1997;247(3):113-9 (49 ref.)

ETIOLOGY

Psychiatric presentations of medical illness. Marsh CM. **Psychiatr Clin North Am** 1997 Mar;20(1):181-204 (54 ref.)

[Adverse psychological drug effects. Methodological problems in detection and examples from clinical practice] Hollweg M, et al. **Med Monatsschr Pharm** 1997 Feb; 20(2):36-43 (57 ref.) **(Ger)**

ORGANIZATION AND ADMINISTRATION, HOSPITAL see **HOSPITAL ADMINISTRATION**

ORGANIZATIONAL AFFILIATION

Management retention contracts in health care affiliations. Leroux CG. **Health Care Manage Rev** 1997 Spring; 22(2):49-54 (0 ref.)

ORGANIZATIONAL CHANGE see **ORGANIZATIONAL INNOVATION**

ORGANIZATIONAL CULTURE

Living systems theory as a paradigm for organizational behavior: understanding humans, organizations, and social processes. Vancouver JB. **Behav Sci** 1996 Jul;41(3):165-204 (200 ref.)

A model to create "organizational readiness" for the successful implementation of quality management systems. Penland T. **Int J Qual Health Care** 1997 Feb;9(1):69-72 (10 ref.)

Military psychiatry: a cross-cultural perspective. Kutz DL. **Mil Med** 1996 Feb;161(2):78-83 (19 ref.)

Machiavellianism and management: a review of single-nation studies exclusive of the USA and cross-national studies. Corzine JB. **Psychol Rep** 1997 Feb;80(1):291-304 (46 ref.)

ORGANIZATIONAL DECISION MAKING see **DECISION MAKING, ORGANIZATIONAL**

ORGANIZATIONAL EFFICIENCY see **EFFICIENCY, ORGANIZATIONAL**

ORGANIZATIONAL INNOVATION

Commentary: change. Middleman EL, et al. **Am J Med Qual** 1997 Spring;12(1):44-7 (6 ref.)

Reason and protest in the new urban public health movement: an observation on the sociological analysis of political discourse in the 'healthy city'. Milewa T, et al. **Br J Sociol** 1996 Dec;47(4):657-70 (40 ref.)

Antecedents of the people and organizational aspects of medical informatics: review of the literature. Lorenzi NM, et al. **J Am Med Inform Assoc** 1997 Mar-Apr;4(2):79-93 (156 ref.)

A manual on manners and courtesies for the shared care of patients. Stoeckle JD, et al. **J Clin Ethics** 1997 Spring; 8(1):22-33 (19 ref.)

Preventive care. Steps toward implementation. Sifri R, et al. **Prim Care** 1996 Mar;23(1):127-40 (28 ref.)

Obstacles to community health promotion. Guldan GS. **Soc Sci Med** 1996 Sep;43(5):689-95 (26 ref.)

The changing roles of health care personnel in health and health care management. Hunter DJ. **Soc Sci Med** 1996 Sep;43(5):799-808 (31 ref.)

ORGANIZATIONAL MODELS see **MODELS, ORGANIZATIONAL**

ORGANIZATIONAL POLICY

Alcohol policy and aviation safety. Cook CC. **Addiction** 1997 Jul;92(7):793-804 (36 ref.)

ORGANIZATIONS

see related
SOCIETIES

[Collaboration between non-governmental organizations and governments for health sector reform] Dickson K. **Rev Panam Salud Publica** 1997 Apr;1(4):324-9 (9 ref.) (Eng. Abstr.) **(Spa)**

ORGANIZATIONS, NONPROFIT

ECONOMICS

From health services to medical markets: the commodity transformation of medical production and the nonprofit sector. Imershein AW, et al. **Int J Health Serv** 1996; 26(2):221-38 (44 ref.)

Charity and community: the role of nonprofit ownership in a managed health care system. Schlesinger M, et al. **J Health Polit Policy Law** 1996 Winter;21(4):697-751 (114 ref.)

ORGANIZATION & ADMINISTRATION

State policy issues in nonprofit conversions. Butler PA. **Health Aff (Millwood)** 1997 Mar-Apr;16(2):69-84 (38 ref.)

State experience in regulating a changing health care system. Shriber D. **Health Aff (Millwood)** 1997 Mar-Apr; 16(2):48-68 (38 ref.)

ORGANOCHLORINE INSECTICIDES see **INSECTICIDES, ORGANOCHLORINE**

ORGANOGENESIS see **FETAL DEVELOPMENT**

ORGANOMETALLIC COMPOUNDS

[Weitz' aminium salt initiated electron transfer reactions and application to the synthesis of natural products] Takeya T, et al. **Yakugaku Zasshi** 1997 Jun;117(6):353-67 (21 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSTIC USE

Gd-DPTA enhanced MRI in Bell's palsy and herpes zoster oticus: an overview and implications for future studies. Jonsson L, et al. **Acta Otolaryngol (Stockh)** 1995 Sep; 115(5):577-84 (56 ref.)

Venous aneurysms: MR diagnosis with the "layered gadolinium" sign. Krinsky G, et al. **J Comput Assist Tomogr** 1997 Jul-Aug;21(4):623-7 (12 ref.)

Dynamic breath-hold 3D gadolinium-enhanced MRI of intraarterial masses: findings in two patients. Krinsky G, et al. **J Comput Assist Tomogr** 1997 Jul-Aug;21(4):631-4 (9 ref.)

"Dural tail" adjacent to a giant posterior cerebral artery aneurysm: case report and review of the literature. Good CD, et al. **Neuroradiology** 1997 Aug;39(8):577-80 (25 ref.)

PHARMACOKINETICS

Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. Tofts PS. **J Magn Reson Imaging** 1997 Jan-Feb; 7(1):91-101 (56 ref.)

THERAPEUTIC USE

The actions of bismuth in the treatment of Helicobacter pylori infection. Lambert JR, et al. **Aliment Pharmacol Ther** 1997 Apr;11 Suppl 1:27-33 (62 ref.)

[Eradication of Helicobacter pylori infection. A new therapy

standard for duodenal ulcer] Caspary WF, et al. **Internist (Berl)** 1996 Dec;37(12):1204–11 (41 ref.) **(Ger)**

ORGANOPHOSPHATE INSECTICIDE ANTAGONISTS see **CHOLINESTERASE REACTIVATORS**

ORGANOPHOSPHATE INSECTICIDES see **INSECTICIDES, ORGANOPHOSPHATE**

ORGANOPHOSPHORUS COMPOUNDS

see related
CHOLINESTERASE INHIBITORS
CHOLINESTERASE REACTIVATORS
INSECTICIDES, ORGANOPHOSPHATE

The use of organic compounds of phosphorus in clinical dentistry. Nicholson JW, et al. **Biomaterials** 1996 Nov; 17(21):2023–30 (67 ref.)

Etoposide phosphate: what, why, where, and how? Schacter L. **Semin Oncol** 1996 Dec;23(6 Suppl 13):1–7 (27 ref.)

DIAGNOSTIC USE

Diagnostic and prognostic role of 99mTc–Tetrofosmin in breast cancer. Mansi L, et al. **Q J Nucl Med** 1997 Sep; 41(3):239–50 (70 ref.)

IMMUNOLOGY

Direct presentation of non–peptide prenyl pyrophosphate antigens to human gamma delta T cells. Morita CT, et al. **Res Immunol** 1996 Jun;147(5):347–53 (44 ref.)

METABOLISM

Constitution of the metabolic type of streptomycetes during the first hours of cultivation. Janeček J, et al. **Folia Microbiol (Praha)** 1997;42(2):75–96 (120 ref.)

Metabotropic GABA(B) receptors cloned at last. Bowery NG. **Trends Pharmacol Sci** 1997 Apr;18(4):103 (6 ref.)

PHARMACOKINETICS

Cidofovir. Lea AP, et al. **Drugs** 1996 Aug;52(2):225–230; discussion 231 (8 ref.)

PHARMACOLOGY

Etoposide phosphate, the water soluble prodrug of etoposide. Witterland AH, et al. **Pharm World Sci** 1996 Oct; 18(5):163–70 (38 ref.)

POISONING

The role of excitotoxicity in organophosphorous nerve agents central poisoning. Solberg Y, et al. **Trends Pharmacol Sci** 1997 Jun;18(6):183–5 (37 ref.)

THERAPEUTIC USE

Cidofovir [editorial; comment] Jabs DA. **Arch Ophthalmol** 1997 Jun;115(6):785–6 (19 ref.) Comment on: Arch Ophthalmol 1997 Jun;115(6):733–7. Comment on: Arch Ophthalmol 1997 Jun;115(6):801–2.

Cidofovir. Lea AP, et al. **Drugs** 1996 Aug;52(2):225–230; discussion 231 (8 ref.)

New therapies for cytomegalovirus retinitis. Schwartz DM. **Int Ophthalmol Clin** 1996 Spring;36(2):1–9 (35 ref.)

Management strategies for patients with cytomegalovirus retinitis. Hardy WD. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 1:S7–12 (19 ref.)

Clinical experience with cidofovir in the treatment of cytomegalovirus retinitis. Lalezari JP, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 1:S27–31 (16 ref.)

Cidofovir: a new therapy for cytomegalovirus retinitis. Lalezari JP. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 1:S22–6 (25 ref.)

Etoposide phosphate, the water soluble prodrug of etoposide. Witterland AH, et al. **Pharm World Sci** 1996 Oct; 18(5):163–70 (38 ref.)

The potential of acyclic nucleoside phosphonates as broad–spectrum antiviral agents. Naesens L, et al. **Postepy Biochem** 1995;41(5 Suppl):347–51 (44 ref.)

Sarah Cannon Cancer Center Consensus Conference on Novel Developments with Podophyllotoxin Therapy. **Semin Oncol** 1996 Dec;23(6 Suppl 13):1–60 (0 ref.)

Early studies of etoposide phosphate, a water–soluble prodrug. Budman DR. **Semin Oncol** 1996 Dec;23(6 Suppl 13):8–14 (40 ref.)

TOXICITY

Hypothesis for synergistic toxicity of organophosphorus poisoning–induced cholinergic crisis and anaphylactoid reactions. Cowan FM, et al. **J Appl Toxicol** 1996 Jan–Feb; 16(1):25–33 (79 ref.)

ORGANOPLATINUM COMPOUNDS

ADMINISTRATION & DOSAGE

Platinum dose–intensity. Los G. **J Infus Chemother** 1996 Spring;6(2):64–8 (47 ref.)

ORGANOSELENIUM COMPOUNDS

PHARMACOLOGY

Recent results in the organosulfur and organoselenium chemistry of genus Allium and Brassica plants. Relevance for cancer prevention. Block E. **Adv Exp Med Biol** 1996; 401:155–69 (75 ref.)

Ebselen as a glutathione peroxidase mimic and as a scavenger of peroxynitrite. Sies H, et al. **Adv Pharmacol** 1997; 38:229–46 (105 ref.)

ORGANOTECHNETIUM COMPOUNDS

DIAGNOSTIC USE

Sensitivity, specificity, and positive predictive value of technetium 99–HMPAO SPECT in discriminating Alzheimer's disease from other dementias. Masterman DL, et al. **J Geriatr Psychiatry Neurol** 1997 Jan;10(1):15–21 (50 ref.)

The rim sign in hepatic abscess: case report and review of the literature. McDonald KL, et al. **J Nucl Med** 1997 Aug; 38(8):1282–3 (7 ref.)

The evaluation of acute pyelonephritis and renal scarring with technetium 99m–dimercaptosuccinic acid renal scintigraphy: evolving concepts and future directions. Rushton HG. **Pediatr Nephrol** 1997 Feb;11(1):108–20 (102 ref.)

Diagnostic and prognostic role of 99mTc–Tetrofosmin in breast cancer. Mansi L, et al. **Q J Nucl Med** 1997 Sep; 41(3):239–50 (70 ref.)

Brain single–photon emission CT with HMPAO and safety of thrombolytic therapy in acute ischemic stroke. Proceedings of the meeting of the SPECT Safe Thrombolysis Study Collaborators and the members of the Brain Imaging Council of the Society of Nuclear Medicine. Alexandrov AV, et al. **Stroke** 1997 Sep;28(9):1830–4 (32 ref.)

[99m technetium–dimercaptosuccinic acid renal scan in urinary tract infection in infancy and childhood] Aladjem M, et al. **Harefuah** 1997 Jun 1;132(11):796–8 (25 ref.) **(Heb)**

PHARMACOKINETICS

Pharmacokinetics of 99mTc–labeled oligonucleotides. Hnatowich DJ. **Q J Nucl Med** 1996 Sep;40(3):202–8 (31 ref.)

ORGANOTHIOPHOSPHATE INSECTICIDE ANTAGONISTS see **CHOLINESTERASE REACTIVATORS**

ORGANOTHIOPHOSPHATE INSECTICIDES see **INSECTICIDES, ORGANOTHIOPHOSPHATE**

ORGANOTHIOPHOSPHORUS COMPOUNDS

see related
CHOLINESTERASE INHIBITORS
CHOLINESTERASE REACTIVATORS
INSECTICIDES, ORGANOTHIOPHOSPHATE

ORGANOTIN COMPOUNDS

TOXICITY

Ecotoxicology of organotin compounds. Fent K. **Crit Rev Toxicol** 1996 Jan;26(1):1–117 (428 ref.)

ORGANUM VOMERONASALE see **VOMERONASAL ORGAN**

ORGASM

PHYSIOLOGY

[The epileptic attacks of orgasm] Badalian LO, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996; 96(2):96–100 (30 ref.) **(Rus)**

ORI REGION see **REPLICATION ORIGIN**

ORIENTAL MEDICINE, TRADITIONAL see **MEDICINE, ORIENTAL TRADITIONAL**

ORIENTAL SORE see **LEISHMANIASIS, CUTANEOUS**

ORIENTATION

Visual attention: control, representation, and time course. Egeth HE, et al. **Annu Rev Psychol** 1997;48:269–97 (110 ref.)

Evidence of a global oblique effect in human extrafoveal vision. Pointer JS. **Perception** 1996;25(5):523–30 (20 ref.)

Neural mechanisms of visual orienting responses. Sprague JM. **Prog Brain Res** 1996;112:1–15 (110 ref.)

Representation of space in blind persons: vision as a spatial sense? Thinus–Blanc C, et al. **Psychol Bull** 1997 Jan; 121(1):20–42 (150 ref.)

The CODE theory of visual attention: an integration of space–based and object–based attention. Logan GD. **Psychol Rev** 1996 Oct;103(4):603–49 (140 ref.)

PHYSIOLOGY

The neuroethology of cognitive maps: contributions from research on the hippocampus and homing pigeon navigation. Casini G, et al. **Arch Ital Biol** 1997 Jan; 135(1):73–92 (69 ref.)

Spatial orientation perception and reflexive eye movements––a perspective, an overview, and some clinical implications. Guedry FE. **Brain Res Bull** 1996; 40(5–6):505–12 (77 ref.)

Processing the head direction cell signal: a review and commentary. Taube JS, et al. **Brain Res Bull** 1996; 40(5–6):477–84; discussion 484–6 (58 ref.)

Orienting a spatial attention––its reflexive, compensatory, and voluntary mechanisms. Hikosaka O, et al. **Brain Res Cogn Brain Res** 1996 Dec;5(1–2):1–9 (32 ref.)

New perspectives on the mechanisms for orientation selectivity. Sompolinsky H, et al. **Curr Opin Neurobiol** 1997 Aug;7(4):514–22 (50 ref.)

Models of orientation and ocular dominance columns in the visual cortex: a critical comparison. Erwin E, et al. **Neural Comput** 1995 May;7(3):425–68 (83 ref.)

Are there sex differences in hemispatial visual neglect after unilateral stroke? McGlone J, et al. **Neuropsychiatry Neuropsychol Behav Neurol** 1997 Apr; 10(2):125–34 (57 ref.)

Orienting reaction in invertebrates. Shuranova ZP, et al. **Neurosci Behav Physiol** 1996 Sep–Dec;26(5):406–15 (48 ref.)

Lateralization of brain mechanisms underlying automatic and controlled forms of spatial orienting of attention. Gainotti G. **Neurosci Biobehav Rev** 1996 Winter;20(4):617–22 (48 ref.)

Place cells and place navigation. Bures J, et al. **Proc Natl Acad Sci U S A** 1997 Jan 7;94(1):343–50 (63 ref.)

ORIENTATION PROGRAMS, EMPLOYEE see **INSERVICE TRAINING**

ORIGIN OF LIFE see **BIOGENESIS**

ORIGIN OF REPLICATION see **REPLICATION ORIGIN**

ORMOND'S DISEASE see **RETROPERITONEAL FIBROSIS**

ORNITHINE CARBAMOYLTRANSFERASE

DEFICIENCY

The ornithine transcarbamylase (OTC) gene: mutations in 50 Japanese families with OTC deficiency. Matsuda I, et al. **Am J Med Genet** 1997 Sep 5;71(4):378–83 (37 ref.)

GENETICS

The ornithine transcarbamylase (OTC) gene: mutations in 50 Japanese families with OTC deficiency. Matsuda I, et al. **Am J Med Genet** 1997 Sep 5;71(4):378–83 (37 ref.)

ORNITHINE CARBOXY–LYASE see **ORNITHINE DECARBOXYLASE**

ORNITHINE DECARBOXYLASE

ANTAGONISTS & INHIBITORS

Antizyme–dependent degradation of ornithine decarboxylase. Hayashi S. **Essays Biochem** 1995;30:37–47 (22 ref.)

METABOLISM

[Is ornithine decarboxylase a unique non–ubiquitinated protein degraded by 26S proteasome?] Manteuffel–Cymborowska M. **Postepy Biochem** 1996; 42(2):113–20 (65 ref.) **(Pol)**

ORNITHOSIS

Psittacosis. Is contact with birds causing your patient's pneumonia? Kirchner JT. **Postgrad Med** 1997 Aug; 102(2):181–2, 187–8, 193–4 (17 ref.)

Psittacosis. Gregory DW, et al. **Semin Respir Infect** 1997 Mar;12(1):7–11 (10 ref.)

DIAGNOSIS

[Organically–induced delusional syndrome in psittacosis] Hain C, et al. **Psychiatr Prax** 1997 Jul;24(4):198–9 (10 ref.) (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

Chlamydiae as pathogens: new species and new issues. Peeling RW, et al. **Emerg Infect Dis** 1996 Oct–Dec; 2(4):307–19 (78 ref.)

ORNITHOSIS

PATHOLOGY

Gestational psittacosis: case report and literature review. Hyde SR, et al. **Mod Pathol** 1997 Jun;10(6):602–7 (16 ref.)

RADIOGRAPHY

Psittacosis pneumonia: a case report and review of the literature. Riantawan P, et al. **J Med Assoc Thai** 1996 Jan; 79(1):55–9 (20 ref.)

OROANTRAL FISTULA

SURGERY

Anteriorly based palatal flap for closure of large oroantral fistula. Salins PC, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Sep;82(3):253–6 (11 ref.)

OROPHARYNGEAL NEOPLASMS

DIAGNOSIS

[Modern imaging methods in diagnosis of tumors of the oropharynx and mouth cavity] Lenz M. **Rontgenpraxis** 1996 Nov;49(11):286–96 (28 ref.) **(Ger)**

ETIOLOGY

Alcohol-containing mouthwashes and oropharyngeal cancer: a spurious association due to underascertainment of confounders? Shapiro S, et al. **Am J Epidemiol** 1996 Dec 15;144(12):1091–5 (19 ref.)

GENETICS

p53 alterations in progenitor lesions of the bronchus, esophagus, oral cavity, and colon. Bennett WP.
Cancer Detect Prev 1995;19(6):503–11 (109 ref.)

PATHOLOGY

Clear cell tumors of the salivary glands, jaws, and oral mucosa. Maiorano E, et al. **Semin Diagn Pathol** 1997 Aug; 14(3):203–12 (80 ref.)

RADIOTHERAPY

Altered fractionated radiation therapy for head and neck carcinomas—A Massachusetts General Hospital experience. Wang CC. **Ann Acad Med Singapore** 1996 May; 25(3):335–40 (21 ref.)

OROPHARYNX

MICROBIOLOGY

The diagnosis of oropharyngeal gonorrhoea. Barlow D.
Genitourin Med 1997 Feb;73(1):16–7 (18 ref.)

PATHOLOGY

[Atrophy of the oro-pharyngeal mucosa caused by vitamin B12 and folic acid deficiency. Etiopathologic aspects and clinico-therapeutic problems] Bottero A, et al.
Minerva Stomatol 1997 Jul–Aug;46(7–8):359–74 (99 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Laser utilization in the oral pharynx. Rathfoot CJ, et al.
Otolaryngol Clin North Am 1996 Dec;29(6):963–72 (13 ref.)

OROYA FEVER see **BARTONELLA INFECTIONS**

ORPHAN DRUG PRODUCTION

ECONOMICS

[Orphan drugs: problem of public health and economic stakes] Brandissou S, et al. **Therapie** 1996 Nov–Dec; 51(6):647–53 (40 ref.) (Eng. Abstr.) **(Fre)**

ORTHO-AMINOBENZOIC ACIDS see **ANTHRANILIC ACIDS**

ORTHO,PARA-DDD see **MITOTANE**

ORTHODONTIC APPLIANCE DESIGN

Prosthodontic considerations when using implants for orthodontic anchorage. Goodacre CJ, et al.
J Prosthet Dent 1997 Feb;77(2):162–70 (34 ref.)

ORTHODONTIC APPLIANCES

see related
DENTAL BONDING

Biomechanical considerations for orthodontic treatment of adults. Lindauer SJ, et al. **Dent Clin North Am** 1996 Oct; 40(4):811–36 (42 ref.)
Clinical application of magnets in orthodontics and biological implications: a review. Darendeliler MA, et al.
Eur J Orthod 1997 Aug;19(4):431–42 (89 ref.)

ADVERSE EFFECTS

Orthodontic appliances in relation to nickel hypersensitivity. A review. Lindsten R, et al. **J Orofac Orthop** 1997; 58(2):100–8 (23 ref.) **(Eng, Ger)**

ORTHODONTIC APPLIANCES, FUNCTIONAL

Orthopedics in orthodontics: Part I, Fiction or reality--a review of the literature [see comments] Aelbers CM, et al. **Am J Orthod Dentofacial Orthop** 1996 Nov;110(5):513–9 (101 ref.) Comment in: Am J Orthod Dentofacial Orthop 1997 Jun;111(6):16A.
Predicting functional appliance treatment outcome in Class II malocclusions--a review. Barton S, et al.
Am J Orthod Dentofacial Orthop 1997 Sep;112(3):282–6 (31 ref.)
Orthopedics in orthodontics: Fiction or reality. A review of the literature--Part II [see comments] Dermaut LR, et al. **Am J Orthod Dentofacial Orthop** 1996 Dec; 110(6):667–71 (77 ref.) Comment in: Am J Orthod Dentofacial Orthop 1997 Jun;111(6):16A.

ORTHODONTIC BRACKETS

Clinical characteristics and properties of ceramic brackets: A comprehensive review. Karamouzos A, et al.
Am J Orthod Dentofacial Orthop 1997 Jul;112(1):34–40 (61 ref.)
Esthetic orthodontic appliances and bonding concerns for adults. Sinha PK, et al. **Dent Clin North Am** 1997 Jan; 41(1):89–109 (72 ref.)
Orthodontic bonding with glass ionomer cement--a review. Millett DT, et al. **Eur J Orthod** 1996 Aug;18(4):385–99 (81 ref.)
Relative friction minimization in fixed orthodontic bracket appliances. Schlegel V. **J Biomech** 1996 Apr;29(4):483–91 (24 ref.)

ORTHODONTIC RETAINERS

Retention and stability considerations for adult patients. Kahl-Nieke B. **Dent Clin North Am** 1996 Oct;40(4):961–94 (75 ref.)

ORTHODONTIC SPACE CLOSURE

Combined orthodontic and prosthetic therapy. Special considerations. Shroff B, et al. **Dent Clin North Am** 1996 Oct;40(4):911–43 (17 ref.)
Optimal orthodontic space closure in adult patients. Siatkowski RE. **Dent Clin North Am** 1996 Oct;40(4):837–73 (17 ref.)

ORTHODONTIC WIRES

A review of contemporary archwires: their properties and characteristics. Kusy RP. **Angle Orthod** 1997;67(3):197–207 (63 ref.)
Studies and applications of NiTi shape memory alloys in the medical field in China. Dai K, et al.
Biomed Mater Eng 1996;6(4):233–40 (40 ref.)

ORTHODONTICS

[Digital image processing in orthodontics] Tourné L.
Rev Belge Med Dent 1996;51(4):239–56 (62 ref.) (Eng. Abstr.) **(Fre)**
[Nerve injuries during dental and orthodontic interventions. Their causes, incidence, sequelae and legal assessment] Hardt N, et al. **Schweiz Monatsschr Zahnmed** 1996; 106(1):31–44 (41 ref.) **(Ger, Fre)**
[The practical problems in the orthodontic treatment of middle-aged and elderly patients with mental diseases] Shvartszaid EE. **Stomatologiia (Mosk)** 1996;75(4):48–53 (58 ref.) (Eng. Abstr.) **(Rus)**

TRENDS

Orthognathic surgery in China: past, present and future. Zhang Z, et al. **Chin Med J (Engl)** 1996 Nov;109(11):888–9 (12 ref.)

ORTHODONTICS, CORRECTIVE

Surgical-orthodontic correction of adult facial deformities. Blanchaert R, et al. **Dent Clin North Am** 1996 Oct; 40(4):945–59 (26 ref.)
The importance of determination of jaw position in orthodontic diagnosis and treatment planning for adult patients. Chang FH, et al. **Dent Clin North Am** 1997 Jan; 41(1):49–66 (24 ref.)
Esthetic considerations in orthodontic treatment of adults. Margolis MJ. **Dent Clin North Am** 1997 Jan;41(1):29–48 (19 ref.)
The role of extraction in stability of orthodontic treatment. Kahl-Nieke B. **J Orofac Orthop** 1996 Oct;57(5):272–87 (54 ref.) **(Eng, Ger)**

ADVERSE EFFECTS

Orthodontic treatment and temporomandibular disorders: is there a relationship? Part 1: Clinical studies. McNamara JA Jr, et al. **J Orofac Orthop** 1997;58(2):74–89 (89 ref.) **(Eng, Ger)**
Orthodontic treatment and temporomandibular disorder: is there a relationship? Part 2: Clinical implications. Türp JC, et al. **J Orofac Orthop** 1997;58(3):136–43 (39 ref.) **(Eng, Ger)**
Orthodontic treatment and temporomandibular disorders. McNamara JA Jr.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jan;83(1):107–17 (90 ref.)

INSTRUMENTATION

Prosthodontic considerations when using implants for orthodontic anchorage. Goodacre CJ, et al.
J Prosthet Dent 1997 Feb;77(2):162–70 (34 ref.)

METHODS

Retention and stability considerations for adult patients. Kahl-Nieke B. **Dent Clin North Am** 1996 Oct;40(4):961–94 (75 ref.)
Treatment planning considerations for adult patients. Kuhlberg AJ, et al. **Dent Clin North Am** 1997 Jan; 41(1):17–27 (35 ref.)
Biomechanical considerations for orthodontic treatment of adults. Lindauer SJ, et al. **Dent Clin North Am** 1996 Oct; 40(4):811–36 (42 ref.)
Effective orthodontics: achieving objectives, avoiding misadventures. Shellhart WC, et al. **J Am Dent Assoc** 1997 Jan;128(1):97–104 (15 ref.)

ORTHODONTICS, INTERCEPTIVE

Open bite: a review of etiology and management. Ngan P, et al. **Pediatr Dent** 1997 Mar–Apr;19(2):91–8 (76 ref.)

ORTHOMYXOVIRIDAE

[Mechanism of the induction of apoptosis by influenza virus infection] Takizawa T. **Nippon Rinsho** 1996 Jul; 54(7):1836–41 (19 ref.) (Eng. Abstr.) **(Jpn)**
[Ecology of influenza viruses: are we prepared for the emergence of the next pandemic of influenza] Kida H. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(2):145–53 (30 ref.) **(Jpn)**
[Functions of influenza virus RNA polymerase subunits] Nakada S. **Uirusu** 1995 Dec;45(2):125–43 (58 ref.) **(Jpn)**
[The evolution of influenza viruses] Nakajima K, et al.
Uirusu 1996 Jun;46(1):23–34 (44 ref.) **(Jpn)**
[Molecular dissection of the influenza virus RNA polymerase] Toyoda T. **Uirusu** 1996 Dec;46(2):131–43 (67 ref.) **(Jpn)**

ENZYMOLOGY

A multi-functional enzyme with RNA polymerase and RNase activities: molecular anatomy of influenza virus RNA polymerase. Ishihama A. **Biochimie** 1996; 78(11–12):1097–102 (46 ref.)
Neuraminidase inhibitors as potential anti-influenza drugs. Bamford MJ. **J Enzyme Inhib** 1996;10(1):1–16 (86 ref.)

GENETICS

The molecular anatomy of influenza virus RNA polymerase. Honda A, et al. **Biol Chem** 1997 Jun;378(6):483–8 (54 ref.)
Molecular evolution of influenza viruses. Scholtissek C.
Virus Genes 1995;11(2–3):209–15 (40 ref.)
[Influenza: interspecies transmissions and viral rearrangement] Manuguerra JC, et al.
Bull Acad Natl Med 1997 Mar 18;181(3):421–30 (13 ref.) (Eng. Abstr.) **(Fre)**
[Influenza, a special form of zoonosis] Rott R.
Berl Munch Tierarztl Wochenschr 1997 Jul–Aug; 110(7–8):241–6 (19 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Virus versus antibody. Colman PM. **Structure** 1997 May 15; 5(5):591–3 (19 ref.)
Recent structural solutions for antibody neutralization of viruses. Stewart PL, et al. **Trends Microbiol** 1997 Jun; 5(6):229–33 (36 ref.)

PATHOGENICITY

Cellular proteases involved in the pathogenicity of human immunodeficiency and influenza viruses. Kido H, et al.
Adv Exp Med Biol 1996;389:233–40 (24 ref.)

PHYSIOLOGY

Membrane fusion: the influenza paradigm. White JM.
Cold Spring Harb Symp Quant Biol 1995;60:581–8 (55 ref.)

ULTRASTRUCTURE

[Iscom (Immuno Stimulating Complex)-vaccine of equine influenza virus--transmission electron microscopic investigation and literature review] Brügmann M, et al.
DTW Dtsch Tierarztl Wochenschr 1997 Jun;104(6):196–202 (61 ref.) (Eng. Abstr.) **(Ger)**

ORTHOMYXOVIRUS TYPE A see **INFLUENZA A VIRUS**

ORTHOMYXOVIRUS TYPE A, HUMAN see

INFLUENZA A VIRUS, HUMAN

ORTHOMYXOVIRUSES TYPE B see **INFLUENZA B VIRUS**

ORTHOPANTOMOGRAPHY see **RADIOGRAPHY, PANORAMIC**

ORTHOPEDIC EQUIPMENT

[Pneumatic tourniquets in orthopedics] Estebe JP, et al. **Ann Fr Anesth Reanim** 1996;15(2):162–78 (211 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Instrumentation and techniques in equine fracture fixation. Auer JA, et al. **Vet Clin North Am Equine Pract** 1996 Aug; 12(2):283–302 (40 ref.)

ORTHOPEDIC FIXATION DEVICES

MR imaging of soft tissues adjacent to orthopaedic hardware: techniques to minimize susceptibility artefact. Eustace S, et al. **Clin Radiol** 1997 Aug;52(8):589–94 (9 ref.)

VETERINARY

Instrumentation and techniques in equine fracture fixation. Auer JA, et al. **Vet Clin North Am Equine Pract** 1996 Aug; 12(2):283–302 (40 ref.)

ORTHOPEDIC MANIPULATION see **MANIPULATION, ORTHOPEDIC**

ORTHOPEDIC SURGERY see **ORTHOPEDICS**

ORTHOPEDICS

Cost–effectiveness of preoperative autologous blood donation for orthopedic and cardiac surgeries. AuBuchon JP. **Am J Med** 1996 Aug 26;101(2A):38S–42S (11 ref.)

Prudent strategies for red blood cell conservation in orthopedic surgery. deAndrade JR. **Am J Med** 1996 Aug 26;101(2A):16S–21S (09 ref.)

Cigarette smoking and its orthopedic consequences. Kwiatkowski TC, et al. **Am J Orthop** 1996 Sep;25(9):590–7 (112 ref.)

Preparing manuscripts for publication in The Journal of Bone and Joint Surgery: a view from the former editor of the British volume. Apley AG. **Instr Course Lect** 1994;43:573–7 (3 ref.)

Practical implementation of the computer–based medical record in orthopaedic surgery. Branson PJ, et al. **Instr Course Lect** 1994;43:613–23 (5 ref.)

Orthopaedic surgery on the HIV–positive patient: complications and outcome. Luck JV Jr. **Instr Course Lect** 1994;43:543–9 (36 ref.)

Statistical analysis as related to hand surgery [see comments] Szabo RM. **J Hand Surg [Am]** 1997 May;22(3):376–85 (19 ref.) Comment in: J Hand Surg [Am] 1997 May;22(3):375.

Hazards to the orthopaedic trauma surgeon: occupational exposure to tuberculosis. Risk reduction, testing, and treatment (a review article). Esterhai JL Jr, et al. **J Orthop Trauma** 1996;10(5):366–70 (24 ref.)

Planning the design phase of a clinical study. Madison M. **J Orthop Trauma** 1997 Jan;11(1):63–7 (19 ref.)

Unique management needs of pediatric spinal cord injury patients: orthopedic problems in the child with spinal cord injury. Betz RR. **J Spinal Cord Med** 1997 Jan;20(1):14–6 (15 ref.)

Low–molecular–weight heparin: from the bench to the orthopedic patient. Turpie AG. **Orthopedics** 1997 Feb;20 Suppl:10–3 (12 ref.)

Perisurgical use of epoetin alfa in orthopedic surgery patients. Adamson J. **Semin Hematol** 1997 Apr;33(2 Suppl 2):55–8; discussion 59 (11 ref.)

Epoetin alfa as an adjuvant to autologous blood donation. Beris P. **Semin Hematol** 1996 Apr;33(2 Suppl 2):27–9; discussion 30 (3 ref.)

Potential of epoetin alfa in patients in autologous blood donation programs for orthopedic surgery. McClelland B. **Semin Hematol** 1996 Apr;33(2 Suppl 2):2–3; discussion 4 (10 ref.)

Potential of epoetin alfa in patients in autologous blood donation programs for orthopedic surgery. McClelland B. **Semin Hematol** 1997 Apr;33(2 Suppl 2):2–3; discussion 4 (10 ref.)

Epoetin alfa for autologous blood donation in patients with rheumatoid arthritis and concomitant anemia. Mercuriali F. **Semin Hematol** 1996 Apr;33(2 Suppl 2):18–20; discussion 21 (9 ref.)

Post discharge clinically overt venous thromboembolism in orthopaedic surgery patients with negative venography--an overview analysis. Ricotta S, et al. **Thromb Haemost** 1996 Dec;76(6):887–92 (56 ref.)

[Progresses in orthopedics in China, 1996] Chen Z, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Dec;76(12):905–7 (0 ref.) **(Chi)**

[Thrombosis in trauma and orthopedic surgery. Prevention, diagnosis, therapy] Haas S. **Unfallchirurg** 1997 Apr; 100(4):307–19 (10 ref.) **(Ger)**

[Adverse reaction of drugs in the field of orthopaedic surgery] Azuma T. **Nippon Seikeigeka Gakkai Zasshi** 1997 Feb;71(2):106–11 (13 ref.) **(Jpn)**

[Diagnostic imaging of the orthopaedic diseases with special emphasis on magnetic resonance technology] Miyasaka K. **Nippon Seikeigeka Gakkai Zasshi** 1997 Jan;71(1):1–10 (5 ref.) **(Jpn)**

[Clinical application and merits of ultrasonography in orthopedic field] Semoto Y. **Nippon Seikeigeka Gakkai Zasshi** 1996 Jul;70(7):366–79 (19 ref.) **(Jpn)**

EDUCATION

Education in orthopaedic trauma. Chapman MW. **Clin Orthop** 1997 Jun;(339):7–19 (20 ref.)

Clinicians teaching orthopaedics: effective strategies. Meals RA, et al. **Instr Course Lect** 1997;46:583–94 (38 ref.)

The use of computer technology to improve the effectiveness of orthopaedic presentations. Russell JA, et al. **Instr Course Lect** 1997;46:595–610 (27 ref.)

HISTORY

Were the Hunter brothers wrong? Can surgical treatment repair articular cartilage? Buckwalter JA. **Iowa Orthop J** 1997;17:1–13 (75 ref.)

LEGISLATION & JURISPRUDENCE

[Forensic medical implications of vascular injuries in orthopedic surgery] Natali J. **J Mal Vasc** 1996 Nov; 21(4):206–15 (9 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Physeal surgery: indications and operative treatment. Guille JT, et al. **Am J Orthop** 1997 May;26(5):323–32 (57 ref.)

The future of anterior cruciate ligament restoration. Dye SF. **Clin Orthop** 1996 Apr;(325):130–9 (46 ref.)

Anterior cruciate ligament surgery 1996. State of the art? Fu FH, et al. **Clin Orthop** 1996 Apr;(325):19–24 (45 ref.)

Geriatrics for orthopaedists. Brummel–Smith K. **Instr Course Lect** 1997;46:409–16 (39 ref.)

Advanced imaging in orthopaedics: current pitfalls and new applications. Potter HG, et al. **Instr Course Lect** 1997; 46:521–9 (38 ref.)

Treatment of adolescent Blount disease by asymmetric physeal distraction. de Pablos J, et al. **J Pediatr Orthop** 1997 Jan–Feb;17(1):54–8 (30 ref.)

[Bone grafts in orthopedic surgery] Tsuriel S, et al. **Harefuah** 1996 Nov 15;131(10):427–31 (37 ref.) **(Heb)**

[Surgical treatment for recurrent dislocation and subluxation of the shoulder joint] Yamamoto R. **Nippon Seikeigeka Gakkai Zasshi** 1997 Feb;71(2):112–24 (30 ref.) **(Jpn)**

[Transplantation in orthopedic surgery and traumatology] Cara JA, et al. **Rev Med Univ Navarra** 1994 Oct–Dec; 38(4):207–11 (15 ref.) (Eng. Abstr.) **(Spa)**

STANDARDS

Outcomes research in orthopaedics. Keller RB, et al. **Instr Course Lect** 1994;43:599–611 (23 ref.)

STATISTICS & NUMERICAL DATA

Survey of use of thromboprophylaxis for routine total hip replacement by British orthopaedic surgeons. Francis RM, et al. **Br J Hosp Med** 1997 May 7–20;57(9):427–31 (36 ref.)

TRENDS

Orthopaedics. Healing of bones, cartilages, tendons, and ligaments: a new era. Buckwalter JA, et al. **Lancet** 1996 Dec 21–28;348 Suppl 2:sII18 (5 ref.)

Trends in orthopedic sports medicine for the 21st century. Magee MJ, et al. **Md Med J** 1996 Aug;45(8):678–81 (11 ref.)

Epoetin alfa: new directions in orthopedic surgery. Beris P. **Semin Hematol** 1996 Apr;33(2 Suppl 2):60–2; discussion 63 (7 ref.)

[Current problems and future trends of polymeric biomaterials for orthopaedic surgery] Ikada Y. **Nippon Seikeigeka Gakkai Zasshi** 1996 Jan;70(1):28–39 (28 ref.) **(Jpn)**

VETERINARY

Instrumentation and techniques in equine fracture fixation. Auer JA, et al. **Vet Clin North Am Equine Pract** 1996 Aug; 12(2):283–302 (40 ref.)

Instrumentation and techniques for treating orthopedic infections in horses. Baxter GM. **Vet Clin North Am Equine Pract** 1996 Aug;12(2):303–35 (70 ref.)

ORTHOPOXVIRUS

IMMUNOLOGY

Controlling orthopoxvirus infections--200 years after Jenner's revolutionary immunization. Niemialtowski MG, et al. **Arch Immunol Ther Exp (Warsz)** 1996;44(5–6):373–8 (36 ref.)

ORTHOPSYCHIATRY

see related
MENTAL HEALTH

ORTHOPTERA

PHYSIOLOGY

Vision: simple stereopsis. Collett TS. **Curr Biol** 1996 Nov 1;6(11):1392–5 (14 ref.)

ORTHOSES see **ORTHOTIC DEVICES**

ORTHOSIS see **ORTHOTIC DEVICES**

ORTHOTIC DEVICES

Shoes and insoles for patients with rheumatoid foot disease. Grifka JK. **Clin Orthop** 1997 Jul;(340):18–25 (15 ref.)

Evaluation of a rehabilitative pedorthic: plantar pressure alterations with scaphoid pad application. Abu–Faraj ZO, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):328–36 (36 ref.)

The potential for ambulation by severely handicapped cerebral palsy patients. Stallard J, et al. **Prosthet Orthot Int** 1996 Aug;20(2):122–8 (28 ref.)

An update on orthotic devices for the lumbar spine based on a review of the literature. Calmels P, et al. **Rev Rhum Engl Ed** 1996 Apr;63(4):285–91 (52 ref.)

STANDARDS

Pressure–relieving strategies for preventing and treating pressure sores. Remsburg RE, et al. **Clin Geriatr Med** 1997 Aug;13(3):513–41 (95 ref.)

ORTHOVANADATE see **VANADATES**

ORYCTES VIRUSES see **BACULOVIRIDAE**

ORYZA see **RICE**

ORYZAVIRUS see **REOVIRIDAE**

ORYZOMYS see **HESPEROMYINAE**

OS TRIGONUM see **TALUS**

OSCILLATORS, ENDOGENOUS see **BIOLOGICAL CLOCKS**

OSGOOD–SCHLATTER DISEASE see **OSTEOCHONDRITIS**

OSLER–RENDU DISEASE see **TELANGIECTASIA, HEREDITARY HEMORRHAGIC**

OSLER–VAQUEZ DISEASE see **POLYCYTHEMIA VERA**

OSMIUM COMPOUNDS

Osmium ammine: review of current applications to visualize DNA in electron microscopy. Biggiogera M, et al. **Biol Cell** 1996;87(3):121–32 (38 ref.)

The osmium ammine–SO2 staining method for studying the in situ configuration of viral genomes in ultrathin sections of DNA virus infected cells. Puvion–Dutilleul F, et al. **Biol Cell** 1996;87(3):133–41 (33 ref.)

OSMOLALITY see **OSMOLAR CONCENTRATION**

OSMOLAR CONCENTRATION

[Regulation of osmolyte transporter gene expression by tonicity] Takenaka M, et al. **Nippon Rinsho** 1996 Oct; 54(10):2821–8 (25 ref.) (Eng. Abstr.) **(Jpn)**

[Proline biosynthesis and water stress tolerance in plants] Yoshiba Y, et al. **Tanpakushitsu Kakusan Koso** 1997 May; 42(6):842–55 (63 ref.) **(Jpn)**

OSMOLARITY see **OSMOLAR CONCENTRATION**

OSMOREGULATION see **WATER–ELECTROLYTE BALANCE**

OSMOTIC DIURETICS see **DIURETICS, OSMOTIC**

OSMOTIC FRAGILITY

[Osmotic fragility test] Fujii H. **Nippon Rinsho** 1997 Mar;55 Suppl 1:153–5 (2 ref.) **(Jpn)**

OSSEOINTEGRATED DENTAL IMPLANTATION see **DENTAL IMPLANTATION, ENDOSSEOUS**

OSSEOINTEGRATION

see related
ARTHROPLASTY
BONE SUBSTITUTES
DENTAL IMPLANTATION, ENDOSSEOUS
HIP PROSTHESIS

OSSEOINTEGRATION

The role of implant surface characteristics in the healing of bone. Kieswetter K, et al. **Crit Rev Oral Biol Med** 1996; 7(4):329–45 (121 ref.)

OSSICULAR REPLACEMENT PROSTHESIS

Practical use of total and partial ossicular replacement prostheses in ossiculoplasty. Slater PW, et al. **Laryngoscope** 1997 Sep;107(9):1193–8 (16 ref.)

[Will there ever exist the ideal auditive prosthesis for the reconstructive surgery of the middle ear?] Garzón Calles JA. **An Otorrinolaringol Ibero Am** 1996;23(1):35–52 (96 ref.) (Eng. Abstr.) **(Spa)**

OSSIFICATION, HETEROTOPIC

see related
SYNOSTOSIS

Heterotopic ossification of the elbow. Summerfield SL, et al. **J Shoulder Elbow Surg** 1997 May–Jun;6(3):321–32 (92 ref.)

DIAGNOSIS

Ossifying fasciitis of the nose. Innocenzi D, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):357–61 (17 ref.)

ETIOLOGY

Heterotopic ossification after severe burns: a report of three cases and review of the literature. Richards AM, et al. **Burns** 1997 Feb;23(1):64–8 (39 ref.)

Heterotopic bone formation within a missile track. Morasch MD, et al. **J Accid Emerg Med** 1996 May;13(3):227–9 (13 ref.)

Heterotopic ossification in neuromuscular disorders. Botte MJ, et al. **Orthopedics** 1997 Apr;20(4):335–41; quiz 342–3 (68 ref.)

PATHOLOGY

Heterotopic bone formation in the gastrointestinal tract. Haque S, et al. **Arch Pathol Lab Med** 1996 Jul;120(7):666–70 (26 ref.)

Longitudinal epiphyseal bracket: associated foot deformities with implications for treatment. Sobel E, et al. **J Am Podiatr Med Assoc** 1996 Apr;86(4):147–55 (23 ref.)

Ossifying fibromyxoid tumor of soft parts: a case report and review. Barrett TL, et al. **J Cutan Pathol** 1996 Aug; 23(4):378–80 (8 ref.)

Stromal bone formation in pleomorphic adenoma of minor salivary gland origin. Takeda Y, et al. **J Nihon Univ Sch Dent** 1996 Jul;38(2):102–4 (6 ref.)

Bone formation within a choroid plexus papilloma. Doran SE, et al. **Pediatr Neurosurg** 1995;23(4):216–8 (18 ref.)

[Bone metaplasia in adenomatous intestinal polyp. Report of a case and review of the literature] Cavazza A, et al. **Pathologica** 1996 Dec;88(6):511–3 (17 ref.) (Eng. Abstr.) **(Ita)**

RADIOGRAPHY

Ossification of a rectal tumor: CT evaluation. Beauchamp NJ, et al. **J Comput Assist Tomogr** 1997 Jul–Aug; 21(4):671–3 (8 ref.)

Neonatal mucolipidosis II (I-cell disease) with dysharmonic epiphyseal ossification and butterfly vertebral body. Herman TE, et al. **J Perinatol** 1996 Sep–Oct;16(5):400–2 (16 ref.)

REHABILITATION

Heterotopic ossification after severe burns: a report of three cases and review of the literature. Richards AM, et al. **Burns** 1997 Feb;23(1):64–8 (39 ref.)

SURGERY

Heterotopic ossification. Naraghi FF, et al. **Orthopedics** 1996 Feb;19(2):145–51 (76 ref.)

OSSIFICATION OF POSTERIOR LONGITUDINAL LIGAMENT

SURGERY

[Anterior decompression for cervical myelopathy caused by ossification of the posterior longitudinal ligament--anterior floating method of OPLL] Yamaura I. **Nippon Seikeigeka Gakkai Zasshi** 1996 May;70(5):296–310 (27 ref.) **(Jpn)**

[Pathogenesis and surgical management of ossification of the posterior longitudinal ligament in the cervical spine] Nakagawa H, et al. **No Shinkei Geka** 1996 Mar;24(3):205–10 (29 ref.) **(Jpn)**

OSSIFICATION, PATHOLOGIC see **OSSIFICATION, HETEROTOPIC**

OSSIFICATION, PHYSIOLOGIC see **OSTEOGENESIS**

OSTEITIS

[SAPHO syndrome: common denominator for various bone and skin diseases] Jahangier ZN, et al. **Ned Tijdschr Geneeskd** 1997 Apr 19;141(16):764–9 (37 ref.) (Eng. Abstr.) **(Dut)**

DIAGNOSIS

[The Calmette-Guérin bacillus (BCG). An agent to consider in pediatric infection] Marcelino F, et al. **Acta Med Port** 1996 Oct–Dec;9(10–12):397–400 (12 ref.) (Eng. Abstr.) **(Por)**

PATHOLOGY

Chronic diffuse sclerosing osteomyelitis of the mandible or mandibular location of S.A.P.H.O. syndrome. García-Marín F, et al. **Acta Stomatol Belg** 1996 Jun; 93(2):65–71 (31 ref.)

RADIOGRAPHY

A 42-year-old woman with low back pain. McGrory BJ, et al. **Am J Orthop** 1996 Sep;25(9):653–4, 657–8 (14 ref.)

SURGERY

Benign necrotizing osteitis of the external auditory meatus. Kumar BN, et al. **J Laryngol Otol** 1997 Mar;111(3):269–70 (7 ref.)

[Bone and joint infections] Schneider U, et al. **Unfallchirurg** 1996 Oct;99(10):789–800 (8 ref.) **(Ger)**

OSTEITIS DEFORMANS

Paget's disease of bone: clinical, pathogenetic and therapeutic aspects. Papapoulos SE. **Baillieres Clin Endocrinol Metab** 1997 Apr;11(1):117–43 (87 ref.)

Paget's disease of bone. Fraser WD. **Curr Opin Rheumatol** 1997 Jul;9(4):347–54 (68 ref.)

Paget's disease of bone. Ooi CG, et al. **Postgrad Med J** 1997 Feb;73(856):69–74 (60 ref.)

[Paget's disease of bone] Okumura Y. **Ryoikibetsu Shokogun Shirizu** 1996;(15):354–6 (12 ref.) **(Jpn)**

COMPLICATIONS

Paget's disease of bone: complications and treatment. Alexandre C. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):99S–102S (16 ref.)

Chondrosarcoma as a complicating factor in Paget's disease of bone. Brandolini F, et al. **Skeletal Radiol** 1997 Aug; 26(8):497–500 (16 ref.)

DRUG THERAPY

The management of Paget's disease of bone. Delmas PD, et al. **N Engl J Med** 1997 Feb 20;336(8):558–66 (71 ref.)

Paget's disease of bone: complications and treatment. Alexandre C. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):99S–102S (16 ref.)

Optimizing the treatment of Paget's disease of bone [editorial] Reginster JY, et al. **Rev Rhum Engl Ed** 1997 Apr; 64(4):207–9 (14 ref.)

Calcitonin. Sewell KL. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):56S–62S (23 ref.)

[Guidelines for improved therapeutic strategy in patients with Paget's osteitis deformans] Ringe JD, et al. **Z Rheumatol** 1996 Jul–Aug;55(4):256–9 (8 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Paget bone disease involving young adults in 3 generations of a Korean family. Kim GS, et al. **Medicine (Baltimore)** 1997 May;76(3):157–69 (50 ref.)

PATHOLOGY

Paget's disease and osteoclast biology. Roodman GD. **Bone** 1996 Sep;19(3):209–12 (40 ref.)

SURGERY

[Paget disease of the jaws. Review of the subject. Clinical-therapeutic considerations] Russo A, et al. **Minerva Stomatol** 1996 Jul–Aug;45(7–8):349–54 (12 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Paget's disease of bone. Seton M, et al. **Curr Ther Endocrinol Metab** 1997;6:568–72 (7 ref.)

OSTEITIS FIBROSA DISSEMINATA see **FIBROUS DYSPLASIA OF BONE**

OSTEO-ONYCHODYSPLASIA, HEREDITARY see **NAIL-PATELLA SYNDROME**

OSTEOARTHRITIS

Monograph series on aging-related diseases: IX. Osteoarthritis. Rottensten K. **Chronic Dis Can** 1996; 17(3–4):92–107 (209 ref.)

Mechanisms of joint destruction, pain and disability in osteoarthritis. Pinals RS. **Drugs** 1996;52 Suppl 3:14–20 (34 ref.)

Osteoarthritis. Creamer P, et al. **Lancet** 1997 Aug 16; 350(9076):503–8 (76 ref.)

Osteoarthritis. March LM. **Med J Aust** 1997 Jan 20; 166(2):98–103 (39 ref.)

Recent advances in osteoarthritis. Lim KK, et al. **Singapore Med J** 1996 Apr;37(2):189–93 (38 ref.)

Osteoarthritis in elderly knees. Handy JR. **South Med J** 1996 Nov;89(11):1031–5 (40 ref.)

CLASSIFICATION

Definitions of osteoarthritis in the knee and hand. Jacobson LT. **Ann Rheum Dis** 1996 Sep;55(9):656–8 (23 ref.)

Reliability of radiographic grading of osteoarthritis of the hip and knee. Sun Y, et al. **Scand J Rheumatol** 1997; 26(3):155–65 (38 ref.)

COMPLICATIONS

Aggressive polyfibromatosis: a 10 year follow-up. Lee YC, et al. **Australas J Dermatol** 1996 Nov;37(4):205–7 (13 ref.)

Nonpharmacological approaches to pain in osteoarthritis. Available options. Perrot S, et al. **Drugs** 1996;52 Suppl 3:21–6 (97 ref.)

Pain management in osteoarthritis: the role of COX-2 inhibitors. Lane NE. **J Rheumatol** 1997 Jul;24 Suppl 49:20–4 (30 ref.)

Large osteoarthritic bone cyst of the facet joint causing low back pain and sciatica. Shirado O, et al. **Orthopedics** 1997 May;20(5):472–5 (13 ref.)

[Combination of two diseases of knee joint] Mochul'skiĭ AS, et al. **Vestn Rentgenol Radiol** 1997 Jul–Aug;(4):36–7 (6 ref.) **(Rus)**

DIAGNOSIS

Quantitative radiography in osteoarthritis: analysis. Hochberg MC. **Baillieres Clin Rheumatol** 1996 Aug;10(3):421–8 (55 ref.)

Quantitative radiography in osteoarthritis: plain radiographs. Ravaud P. **Baillieres Clin Rheumatol** 1996 Aug;10(3):409–14 (23 ref.)

Reliability and validity of clinical outcome measurements of osteoarthritis of the hip and knee--a review of the literature. Sun Y, et al. **Clin Rheumatol** 1997 Mar; 16(2):185–98 (65 ref.)

Diagnosis of osteoarthritis. Guidelines and current pitfalls. Bálint G, et al. **Drugs** 1996;52 Suppl 3:1–13 (113 ref.)

Therapeutic approaches to osteoarthritis. Block JA, et al. **Hosp Pract (Off Ed)** 1997 Feb 15;32(2):159–64 (6 ref.)

Multifocal osteoarthritis due to Candida albicans in a neonate: serum level monitoring of liposomal amphotericin B and literature review. Evdoridou J, et al. **Infection** 1997 Mar–Apr;25(2):112–6 (29 ref.)

Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. Bellamy N, et al. **J Rheumatol** 1997 Apr;24(4):799–802 (6 ref.)

Cartilage imaging in osteoarthritis. Blackburn WD Jr, et al. **Semin Arthritis Rheum** 1996 Feb;25(4):273–81 (65 ref.)

Osteoarthritis. Preidler KW, et al. **Semin Roentgenol** 1996 Jul;31(3):208–19 (73 ref.)

Current status of imaging of articular cartilage. Hodler J, et al. **Skeletal Radiol** 1996 Nov;25(8):703–9 (41 ref.)

[Recommendations of the Consensus Conference on Imaging of mechanical and degenerative pathology of a non-operated shoulder] Caroit M, et al. **J Radiol** 1997 Apr; 78(4):321–4 (0 ref.) **(Fre)**

[Arthritis: imaging and therapy. Past, present and future] Jewell F, et al. **Radiologe** 1996 Aug;36(8):646–56 (102 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Potential of tetracyclines to modify cartilage breakdown in osteoarthritis [see comments] Ryan ME, et al. **Curr Opin Rheumatol** 1996 May;8(3):238–47 (76 ref.) Comment in: Curr Opin Rheumatol 1996 May;8(3):235–7.

Pharmacology and clinical experience with tramadol in osteoarthritis. Katz WA. **Drugs** 1996;52 Suppl 3:39–47 (49 ref.)

Meloxicam. Noble S, et al. **Drugs** 1996 Mar;51(3):424–30; discussion 431–32 (43 ref.)

Current pharmacological treatment of osteoarthritis. Wollheim FA. **Drugs** 1996;52 Suppl 3:27–38 (97 ref.)

Multifocal osteoarthritis due to Candida albicans in a neonate: serum level monitoring of liposomal amphotericin B and literature review. Evdoridou J, et al. **Infection** 1997 Mar–Apr;25(2):112–6 (29 ref.)

A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the knee, with an emphasis on trial methodology. Towheed TE, et al. **Semin Arthritis Rheum** 1997 Apr;26(5):755–70 (103 ref.)

ECONOMICS

Economic evaluation of the management of pain in osteoarthritis. Tugwell P. **Drugs** 1996;52 Suppl 3:48–58 (36 ref.)

Socioeconomic evaluation of rheumatoid arthritis and osteoarthritis: a literature review. Rothfuss J, et al. **Semin Arthritis Rheum** 1997 Apr;26(5):771–9 (79 ref.)

ENZYMOLOGY

Upregulation of enzymatic activity by interleukin-1 in osteoarthritis. Chevalier X. **Biomed Pharmacother** 1997; 51(2):58–62 (34 ref.)

EPIDEMIOLOGY

The occurrence of osteoarthritis outside Europe. Croft P. **Ann Rheum Dis** 1996 Sep;55(9):661–4 (14 ref.)

Prognosis of osteoarthritis. Hochberg MC. **Ann Rheum Dis** 1996 Sep;55(9):685–8 (37 ref.)

Sex hormones and the risk of osteoarthritis in women: epidemiological evidence. Nevitt MC, et al. **Ann Rheum Dis** 1996 Sep;55(9):673–6 (47 ref.)

Occurrence of osteoarthritis of the peripheral joints in European populations. Petersson IF. **Ann Rheum Dis** 1996 Sep;55(9):659–61 (32 ref.)

Osteoarthritis in ankle and knee joints. Huch K, et al. **Semin Arthritis Rheum** 1997 Feb;26(4):667–74 (67 ref.)

[Incidence and prevalence of cox- and gonarthrosis in the general population] Sun Y, et al. **Z Orthop Ihre Grenzgeb** 1997 May-Jun;135(3):184–92 (49 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Ochronotic arthropathy: the black hip. Case report and review of the literature. Dom K, et al. **Acta Orthop Belg** 1997 Jun;63(2):122–5 (5 ref.)

Does excess weight cause osteoarthritis and, if so, why? Felson DT. **Ann Rheum Dis** 1996 Sep;55(9):668–70 (23 ref.)

Physical activity at leisure and risk of osteoarthritis. Lane NE. **Ann Rheum Dis** 1996 Sep;55(9):682–4 (23 ref.)

Obstetric and gynaecoiogical factors in susceptibility to peripheral joint osteoarthritis. Silman AJ, et al. **Ann Rheum Dis** 1996 Sep;55(9):671–3 (19 ref.)

Osteoarthrosis of the knee and physical load from occupation. Vingård E. **Ann Rheum Dis** 1996 Sep;55(9):677–9 (23 ref.)

Hyperostotic and destructive osteoarthritis in a patient with vitamin A intoxication syndrome: a case report. Romero JB, et al. **Bull Hosp Jt Dis** 1996;54(3):169–74 (65 ref.)

Cumulative trauma disorders. Higgs PE, et al. **Clin Plast Surg** 1996 Jul;23(3):421–33 (34 ref.)

Does participation in sports cause osteoarthritis? Buckwalter JA, et al. **Iowa Orthop J** 1997;17:80–9 (73 ref.)

Development and progression of osteoarthritis [editorial] Hochberg MC. **J Rheumatol** 1996 Sep;23(9):1497–9 (23 ref.)

Does running exercise cause osteoarthritis? Lahr DD. **Md Med J** 1996 Aug;45(8):641–4 (18 ref.)

Pathogenesis and treatment of osteoarthritis. Kraus VB. **Med Clin North Am** 1997 Jan;81(1):85–112 (170 ref.)

Joint pain and weather. A critical review of the literature. Quick DC. **Minn Med** 1997 Mar;80(3):25–9 (24 ref.)

Sport practice and osteoarthritis of the limbs. Lequesne MG, et al. **Osteoarthritis Cartilage** 1997 Mar;5(2):75–86 (68 ref.)

[Sports activity and risk of arthrosis] Gross P, et al. **Schweiz Med Wochenschr** 1997 Jun 7;127(23):967–77 (60 ref.) (Eng. Abstr.) **(Ger)**

[Pathogenesis and pathologic anatomy of degenerative knee joint disease] Kotela I. **Przegl Lek** 1996;53(3):178–80 (19 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Unravelling the molecular genetics of osteoarthrosis. Vikkula M, et al. **Ann Med** 1996 Aug;28(4):301–4 (25 ref.)

Genetics of osteoarthritis. Cicuttini FM, et al. **Ann Rheum Dis** 1996 Sep;55(9):665–7 (46 ref.)

Can mutated genes cause common osteoarthritis? [editorial] Prockop DJ, et al. **Br J Rheumatol** 1997 Aug;36(8):827–9 (21 ref.)

IMMUNOLOGY

Total joint arthroplasty and the immune response. Toumbis CA, et al. **Semin Arthritis Rheum** 1997 Aug;27(1):44–7 (47 ref.)

METABOLISM

Inverse relationship osteoarthritis–osteoporosis: what is the evidence? What are the consequences? [editorial] Dequeker J, et al. **Br J Rheumatol** 1996 Sep;35(9):813–8 (49 ref.)

Bone density and local growth factors in generalized osteoarthritis. Dequeker J, et al. **Microsc Res Tech** 1997 May 15;37(4):358–71 (100 ref.)

The interaction of the zone of calcified cartilage and subchondral bone in osteoarthritis. Oegema TR Jr, et al. **Microsc Res Tech** 1997 May 15;37(4):324–32 (75 ref.)

PATHOLOGY

Articular cartilage chondrons: form, function and failure. Poole CA. **J Anat** 1997 Jul;191 (Pt 1):1–13 (48 ref.)

The involvement of subchondral mineralized tissues in osteoarthrosis: quantitative microscopic evidence. Burr DB, et al. **Microsc Res Tech** 1997 May 15;37(4):343–57 (100 ref.)

Scanning electron microscopy of "fibrillated" and "malacic" human articular cartilage: technical considerations. Clark JM, et al. **Microsc Res Tech** 1997 May 15;37(4):299–313 (55 ref.)

Bone density and local growth factors in generalized osteoarthritis. Dequeker J, et al. **Microsc Res Tech** 1997 May 15;37(4):358–71 (100 ref.)

Advances in the microscopy of osteoarthritis. Gardner DL, et al. **Microsc Res Tech** 1997 May 15;37(4):245–70 (250 ref.)

Cartilage and subchondral bone interaction in osteoarthrosis of human knee joint: a histological and histomorphometric study. Matsui H, et al. **Microsc Res Tech** 1997 May 15; 37(4):333–42 (22 ref.)

The interaction of the zone of calcified cartilage and subchondral bone in osteoarthritis. Oegema TR Jr, et al. **Microsc Res Tech** 1997 May 15;37(4):324–32 (75 ref.)

PHYSIOPATHOLOGY

Cartilage repair. A critical review [see comments] Messner K, et al. **Acta Orthop Scand** 1996 Oct;67(5):523–9 (58 ref.) Comment in: Acta Orthop Scand 1997 Apr;68(2):186–91.

Glucocorticoids and Th-1, Th-2 type cytokines in rheumatoid arthritis, osteoarthritis, asthma, atopic dermatitis and AIDS. Norbiato G, et al. **Clin Exp Rheumatol** 1997 May-Jun;15(3):315–23 (79 ref.)

Muscle weakness in osteoarthritis. O'Reilly S, et al. **Curr Opin Rheumatol** 1997 May;9(3):259–62 (28 ref.)

Impaired proprioception and osteoarthritis. Sharma L, et al. **Curr Opin Rheumatol** 1997 May;9(3):253–8 (64 ref.)

Implications of increased bone density in osteoarthritis. Hamerman D, et al. **J Bone Miner Res** 1996 Sep; 11(9):1205–8 (53 ref.)

Static and dynamic balance responses in persons with bilateral knee osteoarthritis. Wegener L, et al. **J Orthop Sports Phys Ther** 1997 Jan;25(1):13–8 (50 ref.)

Development and progression of osteoarthritis [editorial] Hochberg MC. **J Rheumatol** 1996 Sep;23(9):1497–9 (23 ref.)

Arthroplasty for arthritis and rotator cuff deficiency. Collins DN, et al. **Orthop Clin North Am** 1997 Apr;28(2):225–39 (59 ref.)

Cytokines in osteoarthritis: mediators or markers of joint destruction? Westacott CI, et al. **Semin Arthritis Rheum** 1996 Feb;25(4):254–72 (140 ref.)

RADIOGRAPHY

Quantitative radiography in osteoarthritis: microfocal radiography. Buckland-Wright JC. **Baillieres Clin Rheumatol** 1996 Aug;10(3):415–20 (18 ref.)

Quantitative radiography in osteoarthritis: computerized measurement of radiographic knee and hip joint space. Conrozier T, et al. **Baillieres Clin Rheumatol** 1996 Aug; 10(3):429–33 (13 ref.)

Plain radiography in the evaluation of knee osteoarthritis. Mazzuca S. **Curr Opin Rheumatol** 1997 May;9(3):263–7 (36 ref.)

Reliability of radiographic grading of osteoarthritis of the hip and knee. Sun Y, et al. **Scand J Rheumatol** 1997; 26(3):155–65 (38 ref.)

[Clinical aspects and therapy of degenerative joint diseases] Puhl W, et al. **Rontgenpraxis** 1997 Jun;50(6):142–9 (87 ref.) **(Ger)**

RADIONUCLIDE IMAGING

The use of scintigraphy to detect increased osseous metabolic activity about the knee. Dye SF, et al. **Instr Course Lect** 1994;43:453–69 (73 ref.)

SURGERY

Arthroscopic debridement versus arthroplasty in the osteoarthritic knee. Jackson RW, et al. **J Arthroplasty** 1997 Jun;12(4):465–9; discussion 469–70 (13 ref.)

Total joint arthroplasty and the immune response. Toumbis CA, et al. **Semin Arthritis Rheum** 1997 Aug;27(1):44–7 (47 ref.)

[Surgical fusion of the subtalar joint—changing concepts in changing times] Fellmann J, et al. **Z Orthop Ihre Grenzgeb** 1996 Jul-Aug;134(4):341–5 (35 ref.) (Eng. Abstr.) **(Ger)**

[Twenty-eight years' treatments using high tibial osteotomy with development of Y-blade plate and postoperative repair of degenerated cartilage in the osteoarthritic knee] Koshino T. **Nippon Seikeigeka Gakkai Zasshi** 1996 Dec; 70(12):817–25 (29 ref.) **(Jpn)**

THERAPY

Gene therapy for arthritis: principles and clinical practice. Kang R, et al. **Biochem Soc Trans** 1997 May;25(2):533–7 (37 ref.)

Cartilage as a target organ in arthritis: new approaches. Rothschild BM. **Compr Ther** 1996 Nov;22(11):727–30 (18 ref.)

Therapeutic approaches to osteoarthritis. Block JA, et al. **Hosp Pract (Off Ed)** 1997 Feb 15;32(2):159–64 (6 ref.)

Conservative management of spinal osteoarthritis with glucosamine sulfate and chiropractic treatment. Gottlieb MS. **J Manipulative Physiol Ther** 1997 Jul-Aug; 20(6):400–14 (157 ref.)

[Treatment of infectious osteoarthritis in children] Barthes X, et al. **Arch Pediatr** 1997 May;4(5):460–3 (18 ref.) (Eng. Abstr.) **(Fre)**

[Possibilities of gene therapy in traumatic and degenerative articular lesions. Current status of experimental and initial clinical applications] Gerich TG, et al. **Orthopade** 1997 May;26(5):450–8 (92 ref.) (Eng. Abstr.) **(Ger)**

[Conservative treatment of degenerative changes in the knee joint] Kotela I. **Przegl Lek** 1996;53(3):185–7 (17 ref.) (Eng. Abstr.) **(Pol)**

ULTRASONOGRAPHY

[Ultrasound diagnosis of rheumatic/inflammatory joint diseases] Manger B, et al. **Z Arztl Fortbild Qualitatssich** 1997 Jul;91(4):341–5 (12 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Review of pathogenesis and treatment of degenerative joint disease. McIlwraith CW, et al. **Equine Vet J Suppl** 1988 Sep;(6):3–11 (117 ref.)

Use of carprofen for the treatment of pain and inflammation in dogs. Fox SM, et al. **J Am Vet Med Assoc** 1997 May 15;210(10):1493–8 (60 ref.)

Mechanisms of action of anti-inflammatory medications used for the treatment of osteoarthritis [see comments] Johnston SA, et al. **J Am Vet Med Assoc** 1997 May 15; 210(10):1486–92 (102 ref.) Comment in: J Am Vet Med Assoc 1997 May 15;210(10):1417–8.

The pathophysiology and medical management of canine osteoarthritis. Vaughan-Scott T, et al. **J S Afr Vet Assoc** 1997 Mar;68(1):21–5 (40 ref.)

Chronic pain: osteoarthritis and cancer. Kyles AE, et al. **Semin Vet Med Surg (Small Anim)** 1997 May;12(2):122–32 (77 ref.)

Outcome assessment in clinical trials involving medical management of osteoarthritis in small animals. Budsberg SC. **Vet Clin North Am Small Anim Pract** 1997 Jul; 27(4):815–23 (29 ref.)

Diagnostic imaging of osteoarthritis. Carrig CB. **Vet Clin North Am Small Anim Pract** 1997 Jul; 27(4):777–814 (127 ref.)

Surgical treatment of osteoarthritis. Cook JL, et al. **Vet Clin North Am Small Anim Pract** 1997 Jul;27(4):931–44 (85 ref.)

Clinical evaluation of the osteoarthritic patient. Harari J. **Vet Clin North Am Small Anim Pract** 1997 Jul;27(4):725–34 (27 ref.)

Management of osteoarthritis in cats. Hardie EM. **Vet Clin North Am Small Anim Pract** 1997 Jul;27(4):945–53 (23 ref.)

Nonsteroidal anti-inflammatory drugs and corticosteroids for the management of canine osteoarthritis. Johnston SA, et al. **Vet Clin North Am Small Anim Pract** 1997 Jul; 27(4):841–62 (135 ref.)

Osteoarthritis. Joint anatomy, physiology, and pathobiology. Johnston SA. **Vet Clin North Am Small Anim Pract** 1997 Jul;27(4):699–723 (102 ref.)

Slow-acting, disease-modifying osteoarthritis agents. McNamara PS, et al. **Vet Clin North Am Small Anim Pract** 1997 Jul;27(4):863–81 (109 ref.)

Acquired conditions that lead to osteoarthritis in the dog. Martinez SA, et al. **Vet Clin North Am Small Anim Pract** 1997 Jul;27(4):759–75 (41 ref.)

Congenital conditions that lead to osteoarthritis in the dog. Martinez SA. **Vet Clin North Am Small Anim Pract** 1997 Jul;27(4):735–58 (54 ref.)

The role of exercise and physical modalities in the treatment of osteoarthritis. Millis DL, et al. **Vet Clin North Am Small Anim Pract** 1997 Jul;27(4):913–30 (33 ref.)

Nutritional management of osteoarthritis. Richardson DC, et al. **Vet Clin North Am Small Anim Pract** 1997 Jul; 27(4):883–911 (118 ref.)

OSTEOARTHRITIS, HIP

DIAGNOSIS

[Imaging of hip joint cartilage and its significance for the intertrochanteric transposition osteotomies in coxarthrosis] Bernd L, et al. **Z Orthop Ihre Grenzgeb** 1996 Jul-Aug; 134(4):366–70 (41 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

[Incidence and prevalence of cox- and gonarthrosis in the general population] Sun Y, et al. **Z Orthop Ihre Grenzgeb** 1997 May-Jun;135(3):184–92 (49 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Occupational activity and the risk of hip osteoarthritis. Cooper C, et al. **Ann Rheum Dis** 1996 Sep;55(9):680–2 (20 ref.)

The contralateral hip in slipped capital femoral epiphysis. Hägglund G. **J Pediatr Orthop B** 1996 Summer;5(3):158–61 (20 ref.)

[Occupational environment and strain induced gout. A review of epidemiological studies of the connection between occupational environment and coxarthrosis] Bøggild H, et al. **Ugeskr Laeger** 1997 Jul 7;159(28):4370–6 (38 ref.) (Eng. Abstr.) **(Dan)**

SURGERY

[Total hip replacement in the elderly patient: indications and results] Rodriguez A, et al. **Rev Med Liege** 1997 Apr; 52(4):278–84 (27 ref.) **(Fre)**

OSTEOARTHRITIS, HIP

THERAPY

[Arthroses of the hip joint and their treatment. Developments and progress in the area of conservative and surgical therapy] Mittelmeier W, et al. **Fortschr Med** 1997 Jun 30; 115(18):34–9 (0 ref.) (Eng. Abstr.) **(Ger)**

OSTEOARTHROPATHY, PRIMARY HYPERTROPHIC

DIAGNOSIS

[Psoriatic onycho-pachydermo-periostitis (POPP)] Schröder K, et al. **Hautarzt** 1997 Jul;48(7):500–3 (17 ref.) (Eng. Abstr.) **(Ger)**

OSTEOARTHROPATHY, SECONDARY HYPERTROPHIC

CLASSIFICATION

Hypertrophic osteoarthropathy. Martínez-Lavín M. **Curr Opin Rheumatol** 1997 Jan;9(1):83–6 (17 ref.)

COMPLICATIONS

Primary digital clubbing associated with palmoplantar keratoderma. Barraud-Klenovsek MM, et al. **Dermatology** 1997;194(3):302–5 (15 ref.)

Hypertrophic osteoarthropathy and intrathoracic Hodgkin disease of childhood. Kebudi R, et al. **Med Pediatr Oncol** 1997 Dec;29(6):578–81 (15 ref.)

DIAGNOSIS

Clubbing, arthralgia and haemoptysis in a patient with metastatic carcinoma of the breast [letter] Gregory RK, et al. **Ann Oncol** 1996 Sep;7(7):756–7 (4 ref.)

Unilateral lower limb hypertrophic osteoarthropathy due to aortic graft infection and aortoenteric fistula. Martínez JI, et al. **Eur J Vasc Endovasc Surg** 1996 Nov;12(4):497–500 (23 ref.)

Osteoarthropathy versus osteomyelitis: does magnetic resonance imaging help? Naftulin KA, et al. **J Am Podiatr Med Assoc** 1996 Apr;86(4):164–9 (28 ref.)

ETIOLOGY

Hypertrophic pulmonary osteoarthropathy in pulmonary metastasis—a case report. Aderaye G. **Ethiop Med J** 1996 Oct;34(4):251–4 (13 ref.)

MICROBIOLOGY

Hypertrophic osteoarthropathy associated with Pneumocystis carinii pneumonia and human immunodeficiency virus infection. Gunnarsson G, et al. **Clin Infect Dis** 1996 Mar;22(3):590–1 (9 ref.)

VETERINARY

Hypertrophic osteopathy (Marie's disease) in Equidae: a review of twenty-four cases. Mair TS, et al. **Equine Vet J** 1996 Jul;28(4):256–62 (31 ref.)

OSTEOARTHROSIS see **OSTEOARTHRITIS**

OSTEOARTHROSIS DEFORMANS see **OSTEOARTHRITIS**

OSTEOBLASTOMA

COMPLICATIONS

[Scoliosis of sudden evolution due to lumbar osteoblastoma] Amaral J de S, et al. **Acta Med Port** 1997 May;10(5):417–22 (16 ref.) (Eng. Abstr.) **(Por)**

DIAGNOSIS

Osteoblastoma of the calvaria: report of two cases diagnosed with MRI and clinical review. Cervoni L, et al. **Neurosurg Rev** 1997;20(1):51–4 (16 ref.)

PATHOLOGY

Aggressive osteoblastoma with focal malignant transformation and development of pulmonary metastases. A case report with a review of literature. Kunze E, et al. **Gen Diagn Pathol** 1996 May;141(5–6):377–92 (41 ref.)

Osteoblastoma of the nasal cavity invading the anterior skull base in a young child. Case report. Imai K, et al. **J Neurosurg** 1997 Oct;87(4):625–8 (9 ref.)

RADIOGRAPHY

Osteoblastoma. Ruggieri P, et al. **Orthopedics** 1996 Jul; 19(7):621–4 (18 ref.)

SURGERY

Osteoblastoma. Ruggieri P, et al. **Orthopedics** 1996 Jul; 19(7):621–4 (18 ref.)

OSTEOBLASTS

CYTOLOGY

Cell biology of calcified tissues: experimental models of differentiation and mechanisms by which local and systemic factors exert their effects. Boyan BD, et al. **Connect Tissue Res** 1996;35(1–4):63–70 (54 ref.)

Guanine nucleotide binding-protein coupled signaling pathway regulation of osteoblast-mediated bone formation [editorial] Quarles LD, et al. **J Bone Miner Res** 1996 Oct; 11(10):1375–83 (118 ref.)

DRUG EFFECTS

Alcohol-induced bone disease: impact of ethanol on osteoblast proliferation. Klein RF. **Alcohol Clin Exp Res** 1997 May;21(3):392–9 (112 ref.)

METABOLISM

Insulin-like growth factor binding protein proteolysis in bone cell models. Conover CA. **Prog Growth Factor Res** 1995; 6(2–4):301–9 (13 ref.)

PATHOLOGY

Growth factors mediate glucocorticoid receptor function and dexamethasone-induced regression of osteoblastic lesions in hormone refractory prostate cancer. Koutsilieris M, et al. **Anticancer Res** 1997 May-Jun;17(3A):1461–5 (29 ref.)

PHYSIOLOGY

Underlying mechanisms at the bone-surface interface during regeneration. Schwartz Z, et al. **J Periodontal Res** 1997 Jan;32(1 Pt 2):166–71 (36 ref.)

[Cellular basis of bone tissue development] Rosselot G, et al. **Rev Med Chil** 1996 Aug;124(8 Suppl):15–20 (25 ref.) **(Spa)**

OSTEOCALCIN

ANALYSIS

Biochemical markers of skeletal growth in children. Branca F. **Bibl Nutr Dieta** 1996;(53):90–102 (39 ref.)

Strategies for developing human osteocalcin standards: a critical evaluation. Houben R, et al. **Scand J Clin Lab Invest Suppl** 1997;227:100–4 (24 ref.)

BLOOD

New developments in biochemical markers for osteoporosis. Garnero P, et al. **Calcif Tissue Int** 1996;59 Suppl 1:S2–9 (79 ref.)

Biochemical markers of bone turnover in osteoporosis. Delmas PD, et al. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):31S–36S (70 ref.)

Strategies for developing human osteocalcin standards: a critical evaluation. Houben R, et al. **Scand J Clin Lab Invest Suppl** 1997;227:100–4 (24 ref.)

GENETICS

The osteocalcin gene: a model for multiple parameters of skeletal-specific transcriptional control. Stein GS, et al. **Mol Biol Rep** 1997 Aug;24(3):185–96 (102 ref.)

METABOLISM

The osteocalcin gene: a model for multiple parameters of skeletal-specific transcriptional control. Stein GS, et al. **Mol Biol Rep** 1997 Aug;24(3):185–96 (102 ref.)

PHYSIOLOGY

Skeletal functions of vitamin K-dependent proteins: not just for clotting anymore. Booth SL. **Nutr Rev** 1997 Jul; 55(7):282–4 (15 ref.)

Function of the bone protein osteocalcin: definitive evidence. Wolf G. **Nutr Rev** 1996 Oct;54(10):332–3 (12 ref.)

OSTEOCHONDRITIS

Bilateral osteochondritis dissecans of the elbow in a female pitcher. Williamson LR, et al. **J Fam Pract** 1996 Nov; 43(5):489–93 (22 ref.)

COMPLICATIONS

Anterior knee pain syndromes in the adolescent. Stanitski CL. **Instr Course Lect** 1994;43:211–20 (77 ref.)

DIAGNOSIS

Kienböck's disease. II. Risk factors, diagnosis, and ergonomic interventions. Fredericks TK, et al. **Int J Occup Med Environ Health** 1997;10(2):147–57 (49 ref.)

ETIOLOGY

Kienböck's disease. II. Risk factors, diagnosis, and ergonomic interventions. Fredericks TK, et al. **Int J Occup Med Environ Health** 1997;10(2):147–57 (49 ref.)

Kienböck's disease. I. Anatomy and Etiology. Fredericks TK, et al. **Int J Occup Med Environ Health** 1997;10(1):11–7 (21 ref.)

Aetiology of Kienböck's disease. Watson HK, et al. **J Hand Surg [Br]** 1997 Feb;22(1):5–7 (24 ref.)

RADIOGRAPHY

Radiologic study of patellar height in Osgood-Schlatter disease. Aparicio G, et al. **J Pediatr Orthop** 1997 Jan-Feb; 17(1):63–6 (14 ref.)

RADIONUCLIDE IMAGING

Bone scan findings in Kienböck's disease. A case report with atypical findings and literature review. Stuckey SL, et al. **Clin Nucl Med** 1997 Jul;22(7):481–3 (8 ref.)

SURGERY

A 32-year follow-up of lunate excision for Kienbock's disease: a case report and a review of results from excision and other treatment methods. Wheatley MJ, et al. **Ann Plast Surg** 1996 Sep;37(3):322–5 (83 ref.)

OSTEOCHONDRITIS DISSECANS

Osteochondritis dissecans of the distal femur and patella. Obedian RS, et al. **Clin Sports Med** 1997 Jan;16(1):157–74 (69 ref.)

ETIOLOGY

[Osteochondrosis dissecans] Bruns J. **Orthopade** 1997 Jun; 26(6):573–84 (7 ref.) **(Ger)**

VETERINARY

Congenital conditions that lead to osteoarthritis in the dog. Martinez SA. **Vet Clin North Am Small Anim Pract** 1997 Jul;27(4):735–58 (54 ref.)

OSTEOCHONDRODYSPLASIAS

Humero-spinal dysostosis: report of the fourth case with emphasis on generalized skeletal involvement, abnormal craniofacial features, and mitral valve thickening. Hall BD. **J Pediatr Orthop B** 1997 Jan;6(1):11–4 (3 ref.)

COMPLICATIONS

Malignant B-cell lymphoma in an infant with severe combined immunodeficiency with short-limbed skeletal dysplasia. van den Berg H, et al. **Acta Paediatr** 1997 Jul; 86(7):778–80 (10 ref.)

DIAGNOSIS

Clinical approach still has an important role in constitutional bone diseases [editorial] Maroteaux P, et al. **J Pediatr Orthop B** 1997 Jan;6(1):1–6 (22 ref.)

Antenatal sonographic diagnosis of thanatophoric dysplasia: a report of three cases and a review of the literature with special emphasis on the differential diagnosis. Schild RL, et al. **Ultrasound Obstet Gynecol** 1996 Jul;8(1):62–7 (22 ref.)

EMBRYOLOGY

[Prenatal diagnosis of orthopedic anomalies] Ganel A, et al. **Harefuah** 1997 May 1;132(9):649–52 (29 ref.) **(Heb)**

GENETICS

Mutations in SOX9 cause both autosomal sex reversal and campomelic dysplasia. Foster JW. **Acta Paediatr Jpn** 1996 Aug;38(4):405–11 (26 ref.)

Unravelling the molecular genetics of osteoarthrosis. Vikkula M, et al. **Ann Med** 1996 Aug;28(4):301–4 (25 ref.)

Receptors for parathyroid hormone and parathyroid hormone-related peptide: from molecular cloning to definition of diseases. Jüppner H, et al. **Curr Opin Nephrol Hypertens** 1996 Jul;5(4):300–6 (62 ref.)

Molecular genetic basis of the human chondrodysplasias. Horton WA. **Endocrinol Metab Clin North Am** 1996 Sep; 25(3):683–97 (65 ref.)

Molecular genetics of the human chondrodysplasias–1995. Horton WA. **Eur J Hum Genet** 1995;3(6):357–73 (76 ref.)

Heritable diseases of the skeleton. Part II: Molecular insights into skeletal development-matrix components and their homeostasis. Mundlos S, et al. **FASEB J** 1997 Mar; 11(4):227–33 (73 ref.)

Heritable diseases of the skeleton. Part I: Molecular insights into skeletal development-transcription factors and signaling pathways. Mundlos S, et al. **FASEB J** 1997 Feb; 11(2):125–32 (60 ref.)

Progressive pseudorheumatoid dysplasia: report of a family and review. el-Shanti HE, et al. **J Med Genet** 1997 Jul; 34(7):559–63 (24 ref.)

Murine models of human genetic skeletal disorders. Li Y, et al. **Matrix Biol** 1997 May;16(2):49–52 (22 ref.)

PATHOLOGY

Abnormal bone development: histopathology of skeletal dysplasias. Gilbert-Barness E, et al. **Birth Defects Orig Artic Ser** 1996;30(1):103–56 (149 ref.)

Benign and malignant cartilage tumors of bone and joint: their anatomic and theoretical basis with an emphasis on radiology, pathology and clinical biology. I. The intramedullary cartilage tumors. Brien EW, et al. **Skeletal Radiol** 1997 Jun;26(6):325–53 (41 ref.)

OSTEOCHONDROMA

COMPLICATIONS

Rupture of a popliteal artery pseudo-aneurysm secondary to a fibular osteochondroma. Ballaro A, et al. **Eur J Vasc Endovasc Surg** 1997 Aug;14(2):151-2 (5 ref.)

ETIOLOGY

Osteochondroma after total body irradiation in bone marrow transplant recipients: report of two cases. Maeda G, et al. **Jpn J Clin Oncol** 1996 Dec;26(6):480-3 (14 ref.)

PATHOLOGY

Malignant transformation of a multiple cartilaginous exostosis--a case report. Willms R, et al. **Int Orthop** 1997; 21(2):133-6 (26 ref.)

RADIOGRAPHY

Paraarticular osteochondroma of the knee: report of 2 cases and review of the literature. Reith JD, et al. **Clin Orthop** 1997 Jan;(334):225-32 (17 ref.)

THERAPY

Popliteal artery pseudoaneurysm caused by an osteochondroma--a traditional medicine massage sequelae. Kalinga MJ, et al. **Singapore Med J** 1996 Aug;37(4):443-5 (8 ref.)

OSTEOCHONDROMAS, MULTIPLE see **EXOSTOSES, MULTIPLE HEREDITARY**

OSTEOCHONDROMATOSIS

PATHOLOGY

Dedifferentiated chondrosarcoma in patients with multiple osteochondromatosis: report of a case and review of the literature. Kilpatrick SE, et al. **Skeletal Radiol** 1997 Jun; 26(6):370-4 (21 ref.)

OSTEOCHONDROMATOSIS, SYNOVIAL see **CHONDROMATOSIS, SYNOVIAL**

OSTEOCHONDROSIS see **OSTEOCHONDRITIS**

OSTEOCLASTIC BONE LOSS see **BONE RESORPTION**

OSTEOCLASTS

Advances in bone biology: the osteoclast. Roodman GD. **Endocr Rev** 1996 Aug;17(4):308-32 (233 ref.)

IMMUNOLOGY

Osteoclast differentiation antigen. Kukita T, et al. **Histol Histopathol** 1996 Jul;11(3):821-30 (91 ref.)

METABOLISM

Molecular mechanisms of bone resorption: therapeutic implications. Baron R. **Rev Rhum Engl Ed** 1996 Nov; 63(10):633-8 (34 ref.)

Journey across the osteoclast [comment] Mostov K, et al. **Science** 1997 Apr 11;276(5310):219-20 (17 ref.) Comment on: Science 1997 Apr 11;276(5310):266-9. Comment on: Science 1997 Apr 11;276(5310):270-3.

PATHOLOGY

"Osteoclastic" giant cell carcinoma of the pancreas. Report of a case with aspiration cytology. Mullick SS, et al. **Acta Cytol** 1996 Sep-Oct;40(5):975-9 (23 ref.)

Paget's disease and osteoclast biology. Roodman GD. **Bone** 1996 Sep;19(3):209-12 (40 ref.)

Osteoclasts, macrophages, and the molecular mechanisms of bone resorption. Teitelbaum SL, et al. **J Leukoc Biol** 1997 Apr;61(4):381-8 (67 ref.)

Mixed osteoclastic/pleomorphic-type giant cell tumor of the pancreas with ductal adenocarcinoma: histochemical and immunohistochemical study with review of the literature. Watanabe M, et al. **Pancreas** 1997 Aug;15(2):201-8 (28 ref.)

Sarcomatoid hepatocellular carcinoma with osteoclast-like giant cells: case report and immunohistochemical observations. Sasaki A, et al. **Pathol Int** 1997 May; 47(5):318-24 (30 ref.)

Leiomyosarcoma with osteoclast-like giant cells of the spermatic cord. A case report and review of the literature. Konety BR, et al. **Urol Int** 1996;56(4):259-62 (14 ref.)

[Cell biology of osteoclasts and molecular mechanisms of bone resorption] Amling M, et al. **Pathologe** 1996 Sep; 17(5):358-67 (76 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Pathophysiology and management of bone disease in multiple myeloma. Niesvizky R, et al. **Cancer Invest** 1997; 15(1):85-90 (69 ref.)

Mechanism and regulation of bone resorption by osteoclasts. Katunuma N. **Curr Top Cell Regul** 1997;35:179-92 (12 ref.)

Molecular aspects of osteoclast function. Hall TJ, et al. **Inflamm Res** 1996 Jan;45(1):1-9 (115 ref.)

Regulation of osteoclast function. Suda T, et al. **J Bone Miner Res** 1997 Jun;12(6):869-79 (103 ref.)

Role of c-Src in cellular events associated with colony-stimulating factor-1-induced spreading in osteoclasts. Insogna K, et al. **Mol Reprod Dev** 1997 Jan; 46(1):104-8 (22 ref.)

The osteoclast and osteoporosis. Teitelbaum SI. **Mt Sinai J Med** 1996 Oct-Nov;63(5-6):399-402 (17 ref.)

OSTEOCYTES

CYTOLOGY

Osteocyte density and histomorphometric parameters in cancellous bone of the proximal femur in five mammalian species. Mullender MG, et al. **J Orthop Res** 1996 Nov; 14(6):972-9 (35 ref.)

METABOLISM

The structure of bone tissues and the cellular control of their deposition. Marotti G. **Ital J Anat Embryol** 1996 Oct-Dec; 101(4):25-79 (178 ref.)

ULTRASTRUCTURE

The structure of bone tissues and the cellular control of their deposition. Marotti G. **Ital J Anat Embryol** 1996 Oct-Dec; 101(4):25-79 (178 ref.)

OSTEOGENESIS

Interpreting elbow radiographs in children. Fick DS, et al. **Am Fam Physician** 1997 Mar;55(4):1278-82 (14 ref.)

Mechanical and electrical interactions in bone remodeling. Spadaro JA. **Bioelectromagnetics** 1997;18(3):193-202 (78 ref.)

Callotasis lengthening: a review of some technical aspects. Maffulli N. **Bull Hosp Jt Dis** 1996;54(4):249-54 (85 ref.)

Roles of cartilage matrix proteins, chondromodulin-I and -II, in endochondral bone formation: a review. Suzuki F. **Connect Tissue Res** 1996;35(1-4):303-7 (21 ref.)

GENETICS

The function of adipocytes in the bone marrow stroma: an update. Gimble JM, et al. **Bone** 1996 Nov;19(5):421-8 (108 ref.)

PHYSIOLOGY

Role of CSF-1 in bone and bone marrow development. Cecchini MG, et al. **Mol Reprod Dev** 1997 Jan;46(1):75-83; discussion 83-4 (32 ref.)

Clinical usefulness of markers of bone degradation and formation. Demers LM. **Scand J Clin Lab Invest Suppl** 1997;227:12-20 (28 ref.)

[Bone induction using bone growth factors: bone morphogenetic proteins] Den Boer FC, et al. **Ned Tijdschr Geneeskd** 1996 Nov 30;140(48):2390-4 (40 ref.) **(Dut)**

[Molecular aspects of osteogenic phenomena] Martínez J, et al. **Rev Med Chil** 1996 Aug;124(8 Suppl):21-8 (41 ref.) **(Spa)**

[Cellular basis of bone tissue development] Rosselot G, et al. **Rev Med Chil** 1996 Aug;124(8 Suppl):15-20 (25 ref.) **(Spa)**

OSTEOGENESIS IMPERFECTA

Osteogenesis imperfecta. Tosi LL. **Curr Opin Pediatr** 1997 Feb;9(1):94-9 (33 ref.)

Fragile bone syndrome associated with craniognathic fibro-osseous lesions and abnormal modeling of the tubular bones: report of two cases and review of the literature. Nishimura G, et al. **Skeletal Radiol** 1996 Nov;25(8):717-22 (6 ref.)

COMPLICATIONS

Bruck syndrome (osteogenesis imperfecta with congenital joint contractures): review and report on the first North American case. McPherson E, et al. **Am J Med Genet** 1997 May 2;70(1):28-31 (4 ref.)

Hearing loss (in nonoperated ears) in relation to age in osteogenesis imperfecta type I. Garretsen AJ, et al. **Ann Otol Rhinol Laryngol** 1997 Jul;106(7 Pt 1):575-82 (23 ref.)

Transient osteoporosis and osteogenesis imperfecta. A case report. Noorda RJ, et al. **Clin Orthop** 1997 Apr; (337):249-55 (48 ref.)

Two new case-reports of reflex sympathetic dystrophy syndrome in patients with osteogenesis imperfecta. Review of the literature [letter] Bouvier M, et al. **Rev Rhum Engl Ed** 1997 Mar;64(3):202-4 (14 ref.)

[Osteogenesis imperfecta] Oku S. **Ryoikibetsu Shokogun Shirizu** 1996;(15):108-11 (18 ref.) **(Jpn)**

DIAGNOSIS

Non-accidental injury: confusion with temporary brittle bone disease and mild osteogenesis imperfecta. Ablin DS, et al. **Pediatr Radiol** 1997 Feb;27(2):111-3 (18 ref.)

Non-accidental injury or brittle bones. Chapman S, et al. **Pediatr Radiol** 1997 Feb;27(2):106-10 (41 ref.)

Two new case-reports of reflex sympathetic dystrophy syndrome in patients with osteogenesis imperfecta. Review of the literature [letter] Bouvier M, et al. **Rev Rhum Engl Ed** 1997 Mar;64(3):202-4 (14 ref.)

GENETICS

Osteogenesis imperfecta and other heritable disorders of bone. Paterson CR. **Baillieres Clin Endocrinol Metab** 1997 Apr;11(1):195-213 (94 ref.)

METABOLISM

Osteogenesis imperfecta--where next? [editorial] Smith R. **J Bone Joint Surg Br** 1997 Mar;79(2):177-8 (10 ref.)

PATHOLOGY

Osteogenesis imperfecta Type IIA and pulmonary hypoplasia with normal alveolar development. Thibeault DW, et al. **Pediatr Pulmonol** 1995 Nov;20(5):301-6 (23 ref.)

SURGERY

Spinal fusion in situ in osteogenesis imperfecta. Livesley PJ, et al. **Int Orthop** 1996;20(1):43-6 (19 ref.)

OSTEOLYSIS

DRUG THERAPY

[Bisphosphonates in anti-osteolytic therapy of metastasizing breast carcinoma] Diel IJ, et al. **Zentralbl Gynakol** 1996; 118(10):582-6 (20 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Post-traumatic osteolysis of the distal clavicle. Reber P, et al. **Arch Orthop Trauma Surg** 1996;115(2):120-2 (17 ref.)

Pathophysiology and management of bone disease in multiple myeloma. Niesvizky R, et al. **Cancer Invest** 1997; 15(1):85-90 (69 ref.)

Causes and treatment of bone pain of malignant origin [see comments] Thürlimann B, et al. **Drugs** 1996 Mar; 51(3):383-98 (72 ref.) Comment in: Drugs 1996 Sep;52(3):475.

Polyethylene wear and osteolysis following total knee replacement. Ayers DC. **Instr Course Lect** 1997;46:205-13 (31 ref.)

Osteolysis caused by polymethylmethacrylate (PMMA). Eftekhar NS. **Instr Course Lect** 1994;43:263-75 (53 ref.)

Osteolysis due to particle wear debris following total hip arthroplasty: the role of high-density polyethylene. Wroblewski BM. **Instr Course Lect** 1994;43:289-94 (12 ref.)

PHYSIOPATHOLOGY

Role of parathyroid hormone-related peptide in hypercalcemia of malignancy and the development of osteolytic metastases. de Vernejoul MC. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):119S-123S (36 ref.)

PREVENTION & CONTROL

Current concepts in orthopaedic biomaterials and implant fixation. Friedman RJ, et al. **Instr Course Lect** 1994; 43:233-55 (193 ref.)

THERAPY

Pathophysiology and management of bone disease in multiple myeloma. Niesvizky R, et al. **Cancer Invest** 1997; 15(1):85-90 (69 ref.)

Causes and treatment of bone pain of malignant origin [see comments] Thürlimann B, et al. **Drugs** 1996 Mar; 51(3):383-98 (72 ref.) Comment in: Drugs 1996 Sep;52(3):475.

OSTEOLYSIS, ESSENTIAL

Idiopathic multicentric osteolysis principally affecting the phalanges of the hands and feet. Downing ND, et al. **J Hand Surg [Br]** 1996 Oct;21(5):656-9 (16 ref.)

PATHOLOGY

Severe Hajdu-Cheney syndrome with upper airway obstruction. Crifasi PA, et al. **Am J Med Genet** 1997 Jun 13;70(3):261-6 (39 ref.)

OSTEOLYSIS, IDIOPATHIC MULTICENTRIC see **OSTEOLYSIS, ESSENTIAL**

OSTEOLYSIS, MASSIVE see **OSTEOLYSIS, ESSENTIAL**

OSTEOMA

CLASSIFICATION

Cranial osteomas: their classification and management. Report on a giant osteoma and review of the literature. Haddad FS, et al. **Surg Neurol** 1997 Aug;48(2):143-7 (32 ref.)

DIAGNOSIS

[Osteoma of the mastoid: apropos of 2 cases] Guérin N, et al. **Rev Laryngol Otol Rhinol (Bord)** 1996;117(2):127-32 (30

OSTEOMA

ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Fronto-ethmoid osteoma: the place of surgery. Hehar SS, et al. **J Laryngol Otol** 1997 Apr;111(4):372–5 (18 ref.)

Fronto-ethmoidal and orbital osteomas with intracranial extension. Report of two cases. Maiuri F, et al. **J Neurosurg Sci** 1996 Mar;40(1):65–70 (24 ref.)

Cranial osteomas: their classification and management. Report on a giant osteoma and review of the literature. Haddad FS, et al. **Surg Neurol** 1997 Aug;48(2):143–7 (32 ref.)

OSTEOMA, GIANT OSTEOID see **OSTEOBLASTOMA**

OSTEOMA, OSTEOID

PATHOLOGY

Osteoid osteoma with a multicentric nidus. Gonzalez G, et al. **Int Orthop** 1996;20(1):61–3 (7 ref.)

Osteoid osteoma of the vertebral body with extension across the intervertebral disc. Hurtgen KL, et al. **J Manipulative Physiol Ther** 1996 Feb;19(2):118–23 (31 ref.)

RADIOGRAPHY

Osteoid osteoma of the carpus. Case reports and a review of the literature. Lisanti M, et al. **Acta Orthop Belg** 1996 Dec;62(4):195–9 (27 ref.)

Osteoid osteoma of the clavicle. Shaffrey CI, et al. **J Shoulder Elbow Surg** 1997 Jul–Aug;6(4):396–9 (20 ref.)

SURGERY

Osteoid osteoma of the clavicle. Shaffrey CI, et al. **J Shoulder Elbow Surg** 1997 Jul–Aug;6(4):396–9 (20 ref.)

OSTEOMALACIA

Osteomalacia. Francis RM, et al. **Baillieres Clin Endocrinol Metab** 1997 Apr;11(1):145–63 (70 ref.)

CHEMICALLY INDUCED

Antacid-induced osteomalacia. Boutsen Y, et al. **Clin Rheumatol** 1996 Jan;15(1):75–80 (29 ref.)

COMPLICATIONS

Musculoskeletal manifestations of osteomalacia. Reginato AJ. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):107S–113S (71 ref.)

DIAGNOSIS

Bone disease in moderate renal failure: cause, nature and prevention. Bushinsky DA. **Annu Rev Med** 1997;48:167–76 (46 ref.)

ETIOLOGY

Acquired osteomalacia. Bell NH, et al. **Curr Ther Endocrinol Metab** 1997;6:530–3 (9 ref.)

Hepatic osteodystrophy: a review. Idilman R, et al. **Hepatogastroenterology** 1997 Mar–Apr;44(14):574–81 (15 ref.)

[Osteopathia in chronic inflammatory intestinal disease] Neef B, et al. **Dtsch Med Wochenschr** 1997 Feb 14;122(7):195–9 (33 ref.) **(Ger)**

[Renal osteomalacia] Eguchi J, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):17–20 (12 ref.) **(Jpn)**

GENETICS

Genetic rickets and osteomalacia. Weisman Y, et al. **Curr Ther Endocrinol Metab** 1997;6:527–9 (6 ref.)

PHYSIOPATHOLOGY

Phosphatonin—a new phosphaturetic hormone? (lessons from tumour-induced osteomalacia and X-linked hypophosphataemia) [editorial] Kumar R. **Nephrol Dial Transplant** 1997 Jan;12(1):11–3 (9 ref.)

THERAPY

Acquired osteomalacia. Bell NH, et al. **Curr Ther Endocrinol Metab** 1997;6:530–3 (9 ref.)

Genetic rickets and osteomalacia. Weisman Y, et al. **Curr Ther Endocrinol Metab** 1997;6:527–9 (6 ref.)

OSTEOMYELITIS

Update on the diagnosis and management of osteomyelitis. Mader JT, et al. **Clin Podiatr Med Surg** 1996 Oct; 13(4):701–24 (87 ref.)

Osteomyelitis [see comments] Lew DP, et al. **N Engl J Med** 1997 Apr 3;336(14):999–1007 (62 ref.) Comment in: N Engl J Med 1997 Aug 7;337(6):428; discussion 429. Comment in: N Engl J Med 1997 Aug 7;337(6):428–9.

COMPLICATIONS

Epidermoid carcinoma complicating chronic osteomyelitis of the femur. Blidi M, et al. **Rev Rhum Engl Ed** 1996 Jan; 63(1):62–4 (6 ref.)

DIAGNOSIS

Chronic diffuse sclerosing osteomyelitis of the mandible or mandibular location of S.A.P.H.O. syndrome. García-Marín F, et al. **Acta Stomatol Belg** 1996 Jun; 93(2):65–71 (31 ref.)

Bacterial osteomyelitis in adults: evolving considerations in diagnosis and treatment. Hass DW, et al. **Am J Med** 1996 Nov;101(5):550–61 (117 ref.)

Salmonella braenderup sacroiliac osteomyelitis in a nonsickle cell patient: case report. Hunt BK, et al. **Bull Hosp Jt Dis** 1996;55(2):86–7 (9 ref.)

Salmonella osteomyelitis in a patient with human immunodeficiency virus infection [letter] Belzunegui J, et al. **Clin Rheumatol** 1997 May;16(3):319–20 (10 ref.)

Imaging in the diagnosis of musculoskeletal infections in children. Mandell GA. **Curr Probl Pediatr** 1996 Aug; 26(7):218–37 (46 ref.)

A practical guide to the diagnosis and management of bone and joint infections. Mader JT, et al. **Drugs** 1997 Aug; 54(2):253–64 (64 ref.)

Chronic recurrent multifocal osteomyelitis (C.R.M.O.). A case report and review of literature. Meyer zu Reckendorf G, et al. **Eur J Pediatr Surg** 1996 Oct;6(5):312–5 (18 ref.)

Osteoarthropathy versus osteomyelitis: does magnetic resonance imaging help? Naftulin KA, et al. **J Am Podiatr Med Assoc** 1996 Apr;86(4):164–9 (28 ref.)

Cost effectiveness of magnetic resonance imaging in diagnosing Pseudomonas aeruginosa infection after puncture wound. Lau LS, et al. **J Foot Ankle Surg** 1997 Jan–Feb;36(1):36–43 (23 ref.)

Radiologic case study. Tuberculous osteomyelitis and arthritis. Wright T, et al. **Orthopedics** 1996 Aug; 19(8):699–702 (16 ref.)

MRI in chronic recurrent multifocal osteomyelitis. Jurik AG, et al. **Skeletal Radiol** 1997 Apr;26(4):230–8 (38 ref.)

Candida osteomyelitis and disc space infection of the lumbar spine. Munk PL, et al. **Skeletal Radiol** 1997 Jan;26(1):42–6 (17 ref.)

[Chronic recurrent multifocal osteomyelitis. A diagnosis to be called to mind] Saint-Martin C, et al. **J Radiol** 1997 Feb;78(2):111–4 (17 ref.) (Eng. Abstr.) **(Fre)**

[Diagnostic imaging of acute and chronic osteomyelitis] Bohndorf K. **Radiologe** 1996 Oct;36(10):786–94 (16 ref.) (Eng. Abstr.) **(Ger)**

[Osteomyelitis. Clinical aspects, diagnosis and therapy] Schwameis E, et al. **Radiologe** 1996 Oct;36(10):823–33 (29 ref.) (Eng. Abstr.) **(Ger)**

[Diagnostic imaging in osteomyelitis. Characteristics in childhood] Wandl-Vergesslich KA, et al. **Radiologe** 1996 Oct;36(10):805–12 (20 ref.) (Eng. Abstr.) **(Ger)**

[The SAPHO syndrome and ulcerative colitis (letter)] Sanjuán Portugal F, et al. **An Med Interna** 1997 Apr; 14(4):210–1 (9 ref.) **(Spa)**

DRUG THERAPY

Antibiotic-impregnated cement and beads for orthopedic infections. Wininger DA, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2675–9 (49 ref.)

Local treatment of bone and soft tissue infections with the collagen-gentamicin sponge. Stemberger A, et al. **Eur J Surg Suppl** 1997;(578):17–26 (80 ref.)

Clinical features and antibiotic treatment of septic arthritis and osteomyelitis due to Yersinia enterocolitica. Crowe M, et al. **J Med Microbiol** 1996 Oct;45(4):302–9 (55 ref.)

[Oral antibiotic treatment of chronic osteomyelitis in adults] Javaloyas de Morlius M. **Med Clin (Barc)** 1996 Oct 12; 107(12):472–6 (58 ref.) **(Spa)**

ETIOLOGY

Vertebral osteomyelitis in diabetes mellitus [editorial; comment] Toyota T. **Intern Med** 1997 Jun;36(6):382–3 (12 ref.) Comment on: Intern Med 1997 Jun;36(6):443–5.

Acute hematogenous osteomyelitis in intravenous drug users. Fox IM, et al. **J Foot Ankle Surg** 1997 Jul–Aug;36(4):301–5 (13 ref.)

Oral complications associated with sickle cell anemia: a review and case report. Kelleher M, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Aug;82(2):225–8 (13 ref.)

[Brucellosis of the pubic symphysis. Apropos of a case. Review of the literature] Mansoori D, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(8):753–6 (30 ref.) (Eng. Abstr.) **(Fre)**

[Pyogenic osteomyelitis after a plantar puncture wound: analysis of a series of 8 cases] Morales M, et al. **Enferm Infecc Microbiol Clin** 1996 Oct;14(8):479–82 (17 ref.) (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

Bone and joint infections caused by gram-negative bacteria. Kučišec-Tepeš N. **Acta Med Croatica** 1996;50(1):37–44 (39 ref.)

Osteomyelitis of the base of the skull secondary to Aspergillus. Kountakis SE, et al. **Am J Otolaryngol** 1997 Jan–Feb;18(1):19–22 (19 ref.)

Mycobacterium fortuitum infection of the sternum. Review of the literature and case illustration. Samuels LE, et al. **Arch Surg** 1996 Dec;131(12):1344–6 (7 ref.)

Vertebral osteomyelitis due to Capnocytophaga species in immunocompetent patients: report of two cases and review. Duong M, et al. **Clin Infect Dis** 1996 Jun;22(6):1099–101 (15 ref.)

Vertebral osteomyelitis due to Roseomonas species: case report and review of the evaluation of vertebral osteomyelitis. Nahass RG, et al. **Clin Infect Dis** 1995 Dec; 21(6):1474–6 (13 ref.)

Tubercular sternal osteomyelitis and mediastinitis after open heart surgery. Aggarwal B, et al. **Indian Heart J** 1997 May–Jun;49(3):313–4 (4 ref.)

Cost effectiveness of magnetic resonance imaging in diagnosing Pseudomonas aeruginosa infection after puncture wound. Lau LS, et al. **J Foot Ankle Surg** 1997 Jan–Feb;36(1):36–43 (23 ref.)

Musculoskeletal infections in patients with human immunodeficiency virus infection. Vassilopoulos D, et al. **Medicine (Baltimore)** 1997 Jul;76(4):284–94 (129 ref.)

Eikenella corrodens skull infection: a case report with review of the literature. Arana E, et al. **Surg Neurol** 1997 Apr; 47(4):389–91 (9 ref.)

Candida albicans osteomyelitis in a liver transplant recipient: a case report and review of the literature. Jonnalagadda S, et al. **Transplantation** 1996 Oct 27;62(8):1182–4 (19 ref.)

[Osteomyelitis by Salmonella enteritidis and sickle cell hemoglobinopathy. Report of a case and review of the literature] Pierrotti LC, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1996 May–Jun; 51(3):96–8 (8 ref.) (Eng. Abstr.) **(Por)**

PATHOLOGY

Skull base osteomyelitis. Malignant external otitis. Slattery WH 3rd, et al. **Otolaryngol Clin North Am** 1996 Oct; 29(5):795–806 (30 ref.)

[Osteomyelitis. A pathomorphologic overview] Lang S. **Radiologe** 1996 Oct;36(10):781–5 (3 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Two cases of chronic recurrent multifocal osteomyelitis: radiological and scintigraphic findings. Tan BS, et al. **Australas Radiol** 1996 Nov;40(4):437–41 (15 ref.)

[Radiological changes in chronic recurrent multifocal osteomyelitis] Jurik AG. **Ugeskr Laeger** 1997 Jul 21; 159(30):4623–7 (35 ref.) (Eng. Abstr.) **(Dan)**

[Chronic recurrent multifocal osteomyelitis in children] Quelquejay C, et al. **J Radiol** 1997 Feb;78(2):115–21 (22 ref.) (Eng. Abstr.) **(Fre)**

RADIONUCLIDE IMAGING

Scintigraphy and ultrasonography in differentiating osteomyelitis from bone infarction in sickle cell disease. Rifai A, et al. **Acta Radiol** 1997 Jan;38(1):139–43 (12 ref.)

Three-phase bone scan in osteomyelitis and other musculoskeletal disorders. Sutter CW, et al. **Am Fam Physician** 1996 Oct;54(5):1639–47 (26 ref.)

Two cases of chronic recurrent multifocal osteomyelitis: radiological and scintigraphic findings. Tan BS, et al. **Australas Radiol** 1996 Nov;40(4):437–41 (15 ref.)

[Nuclear medicine diagnosis of osteomyelitis] Leitha T. **Radiologe** 1996 Oct;36(10):813–22 (42 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Bilateral total calcanectomy for the treatment of chronic refractory osteomyelitis. Naftulin KA, et al. **J Am Podiatr Med Assoc** 1997 Mar;87(3):141–3 (9 ref.)

Eikenella corrodens skull infection: a case report with review of the literature. Arana E, et al. **Surg Neurol** 1997 Apr; 47(4):389–91 (9 ref.)

[Infected pseudarthrosis] Ekkernkamp A, et al. **Unfallchirurg** 1996 Dec;99(12):914–24 (61 ref.) (Eng. Abstr.) **(Ger)**

[Bone and joint infections] Schneider U, et al. **Unfallchirurg** 1996 Oct;99(10):789–800 (8 ref.) **(Ger)**

THERAPY

Bacterial osteomyelitis in adults: evolving considerations in diagnosis and treatment. Hass DW, et al. **Am J Med** 1996 Nov;101(5):550–61 (117 ref.)

Is instillation drainage for the treatment of infected joints, bones and soft tissues still up to date? Schmidt J, et al. **Arch Orthop Trauma Surg** 1996;115(3–4):149–52 (16 ref.)

Pott's puffy tumor due to Haemophilus influenzae: case report and review. Verbon A, et al. **Clin Infect Dis** 1996 Dec;23(6):1305–7 (15 ref.)

A practical guide to the diagnosis and management of bone and joint infections. Mader JT, et al. **Drugs** 1997 Aug; 54(2):253–64 (64 ref.)

ULTRASONOGRAPHY

Scintigraphy and ultrasonography in differentiating osteomyelitis from bone infarction in sickle cell disease. Rifai A, et al. **Acta Radiol** 1997 Jan;38(1):139–43 (12 ref.)

OSTEONECROSIS

CHEMICALLY INDUCED

Avascular necrosis following extensive chemotherapy and dexamethasone treatment in a patient with advanced ovarian cancer: case report and review of the literature. Gogas H, et al. **Gynecol Oncol** 1996 Dec;63(3):379–81 (19 ref.)

COMPLICATIONS

Osteonecrosis and human immunodeficiency virus infection. Rademaker J, et al. **J Rheumatol** 1997 Mar;24(3):601–4 (35 ref.)

DIAGNOSIS

Imaging of avascular necrosis of bone. Imhof H, et al. **Eur Radiol** 1997;7(2):180–6 (30 ref.)

MRI of avascular necrosis of bone. Bluemke DA, et al. **Top Magn Reson Imaging** 1996 Aug;8(4):231–46 (91 ref.)

[MRI of the joints] Haltiala T, et al. **Duodecim** 1995; 111(16):1553–64 (21 ref.) **(Fin)**

[Avascular bone necrosis] Tomczak R, et al. **Rontgenpraxis** 1997 Jun;50(6):155–7 (18 ref.) **(Ger)**

ETIOLOGY

Fracture–dislocation of the neck of the talus in a ten–year–old child: a case report and review of the literature. Pereles TR, et al. **Bull Hosp Jt Dis** 1996;55(2):88–91 (13 ref.)

Osteonecrosis following meningococcemia and disseminated intravascular coagulation in an adult: case report and review. Campbell WN, et al. **Clin Infect Dis** 1997 Mar; 24(3):452–5 (12 ref.)

Juvenile avascular necrosis of the odontoid process. A review on the etiology of os odontoideum and absentia odontoidei. Heick A. **Dan Med Bull** 1996 Sep;43(4):363–6 (20 ref.)

Concepts of etiology and early pathogenesis of osteonecrosis. Jones JP Jr. **Instr Course Lect** 1994;43:499–512 (143 ref.)

Idiopathic avascular necrosis of a vertebral body. Case report and literature review. Chou LH, et al. **Spine** 1997 Aug 15;22(16):1928–32 (18 ref.)

PREVENTION & CONTROL

Open total talus dislocation: case report and review of the literature. Palomo–Traver JM, et al. **J Orthop Trauma** 1997 Jan;11(1):45–9 (19 ref.)

OSTEONECTIN

PHYSIOLOGY

Regulation of vascular morphogenesis by the matricellular protein SPARC. Motamed K, et al. **Kidney Int** 1997 May; 51(5):1383–7 (37 ref.)

Terms of attachment: SPARC and tumorigenesis [news] Sage EH. **Nat Med** 1997 Feb;3(2):144–6 (15 ref.)

OSTEOPATHIC MANIPULATION see **MANIPULATION, ORTHOPEDIC**

OSTEOPATHIC MEDICINE

Update on osteopathic medical concepts and the lymphatic system. Degenhardt BF, et al. **J Am Osteopath Assoc** 1996 Feb;96(2):97–100 (31 ref.)

Osteopathic medical considerations of reflex sympathetic dystrophy. Nelson KE. **J Am Osteopath Assoc** 1997 May; 97(5):286–9 (30 ref.)

The controversy of cranial bone motion. Rogers JS, et al. **J Orthop Sports Phys Ther** 1997 Aug;26(2):95–103 (50 ref.)

EDUCATION

Osteopathic medical education: the introduction of managed care principles into our undergraduate curriculum. Musser AE, et al. **J Am Osteopath Assoc** 1996 Oct;96(10):627–30 (46 ref.)

An osteopathic prescription for medical education reform: Part 2. Specialty mix and community integration. Ross–Lee B, et al. **J Am Osteopath Assoc** 1997 Aug;97(8):463–8 (18 ref.)

Transforming osteopathic medical education. Ross–Lee B, et al. **J Am Osteopath Assoc** 1996 Aug;96(8):473–8 (25 ref.)

METHODS

Repositioning maneuver for benign paroxysmal positional vertigo (BPPV). Brooks JG, et al. **J Am Osteopath Assoc** 1997 May;97(5):277–9 (10 ref.)

OSTEOPATHY see **OSTEOPATHIC MEDICINE**

OSTEOPENIA see **BONE DISEASES, METABOLIC**

OSTEOPETROSIS

Animal models of osteopetrosis: the impact of recent molecular developments on novel strategies for therapeutic intervention. Popoff SN, et al. **Mol Med Today** 1996 Aug; 2(8):349–58 (39 ref.)

PHYSIOPATHOLOGY

Macrophage differentiation and granulomatous inflammation in osteopetrotic mice (op/op) defective in the production of CSF–1. Naito M, et al. **Mol Reprod Dev** 1997 Jan; 46(1):85–91 (13 ref.)

OSTEOPHYTOSIS, SPINAL see **SPINAL OSTEOPHYTOSIS**

OSTEOPOIKILOSIS

DIAGNOSIS

Mixed sclerosing bone dystrophy. Report of a case and review of the literature. Belzunegui J, et al. **Clin Rheumatol** 1996 Jul;15(4):378–81 (16 ref.)

OSTEOPOROSIS

The osteoporosis revolution. Raisz LG. **Ann Intern Med** 1997 Mar 15;126(6):458–62 (56 ref.)

Bone loss in men [editorial] Gennari C, et al. **Calcif Tissue Int** 1996 Jan;58(1):1–3 (52 ref.)

The importance of genetic and nutritional factors in responses to vitamin D and its analogs in osteoporotic patients. Nakamura T. **Calcif Tissue Int** 1997 Jan;60(1):119–23 (38 ref.)

Active vitamin D metabolites in glucocorticoid–induced osteoporosis. Ringe JD. **Calcif Tissue Int** 1997 Jan; 60(1):124–7 (47 ref.)

Report from the Danish Medical Research Council and the Danish Hospital Institute. Consensus statement on osteoporosis. **Int J Technol Assess Health Care** 1996 Summer;12(3):524–5 (0 ref.)

Osteoporosis: prevention, detection and treatment. Watts NB. **J Med Assoc Ga** 1997 Sep;86(3):224–6 (16 ref.)

Osteoporosis. Sambrook PN. **Med J Aust** 1996 Sep 16; 165(6):332–6 (17 ref.)

Osteoporosis: a view into the next century. Kanis JA. **Neth J Med** 1997 May;50(5):198–203 (9 ref.)

Osteoporosis in pregnancy. Khovidhunkit W, et al. **Osteoporos Int** 1996;6(5):345–54 (92 ref.)

[Animal models of osteoporosis: status and prospect] Wu B. **Yao Hsueh Hsueh Pao** 1996;31(4):316–20 (36 ref.) **(Chi)**

[Gynecological management of osteoporosis and prevention of osteoporotic fracture] Minaguchi H. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Aug; 48(8):563–72 (23 ref.) **(Jpn)**

[Osteoporosis] Luk'ianchikov VS, et al. **Klin Med (Mosk)** 1997;75(6):20–3 (17 ref.) **(Rus)**

BLOOD

New developments in biochemical markers for osteoporosis. Garnero P, et al. **Calcif Tissue Int** 1996;59 Suppl 1:S2–9 (79 ref.)

CHEMICALLY INDUCED

Corticosteroid–induced osteoporosis. Adachi JD. **Am J Med Sci** 1997 Jan;313(1):41–9 (78 ref.)

Glucocorticoid–induced osteoporosis: pathogenesis, prevention and treatment. Gulko PS, et al. **Clin Exp Rheumatol** 1996 Mar–Apr;14(2):199–206 (82 ref.)

Corticosteroid–induced bone loss. Prevention and management. Picado C, et al. **Drug Saf** 1996 Nov; 15(5):347–59 (125 ref.)

Corticosteroid–induced osteoporosis. **Drug Ther Bull** 1996 Nov;34(11):84–6 (30 ref.)

Clinical review 83: Mechanisms of glucocorticoid action in bone: implications to glucocorticoid–induced osteoporosis. Canalis E. **J Clin Endocrinol Metab** 1996 Oct;81(10):3441–7 (85 ref.)

Corticosteroid induced osteoporosis. Sambrook PN. **J Rheumatol Suppl** 1996 Aug;45:19–22 (27 ref.)

Heparin–induced osteoporosis in pregnancy. Nelson–Piercy C. **Lupus** 1997;6(6):500–4 (37 ref.)

Is there cyclosporine A–induced bone disease? Callegari PE. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):103S–106S (19 ref.)

Osteoporotic vertebral fractures in a man under high–dose inhaled glucocorticoid therapy. A case–report with a review of the literature. Laroche M, et al. **Rev Rhum Engl Ed** 1997 Apr;64(4):267–70 (16 ref.)

Glucocorticoid–induced osteoporosis: prevention and treatment. Werth VP. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):84S–88S (44 ref.)

[Osteoporosis induced either by unfractionated heparin or by low molecular weight heparin] Chigot P, et al. **J Mal Vasc** 1996;21(3):121–5 (18 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

Defining osteopenias and osteoporoses: another view (with insights from a new paradigm). Frost HM. **Bone** 1997 May; 20(5):385–91 (76 ref.)

COMPLICATIONS

Age–related bone loss and senile osteoporosis: evidence for both secondary hyperparathyroidism and skeletal growth factor deficiency in the elderly. Boonen S, et al. **Aging (Milano)** 1995 Dec;7(6):414–22 (90 ref.)

Epidemiology and predictors of fractures associated with osteoporosis. Lips P. **Am J Med** 1997 Aug 18; 103(2A):3S–8S; discussion 8S–11S (41 ref.)

The consequences of osteoporosis in the elderly [see comments] Mykyta LJ. **Aust Fam Physician** 1997 Feb; 26(2):115–21 (26 ref.) Comment in: Aust Fam Physician 1997 Apr;26(4):475.

Clinical guidelines for the treatment of osteoporosis in Japan. Fujita T. **Calcif Tissue Int** 1996;59 Suppl 1:34–7 (15 ref.)

Transient osteoporosis and osteogenesis imperfecta. A case report. Noorda RJ, et al. **Clin Orthop** 1997 Apr; (337):249–55 (48 ref.)

Water fluoridation and osteoporotic fracture. Hillier S, et al. **Community Dent Health** 1996 Sep;13 Suppl 2:63–8 (23 ref.)

Relationship between osteoporosis and arthritis and effect of corticosteroids and other drugs on bone. Henderson NK, et al. **Curr Opin Rheumatol** 1996 Jul;8(4):365–9 (43 ref.)

Endocrine disorders and osteoporosis. Rosen CJ. **Curr Opin Rheumatol** 1997 Jul;9(4):355–61 (45 ref.)

Biomechanical considerations of hip and spine fractures in osteoporotic bone. Hayes WC, et al. **Instr Course Lect** 1997; 46:431–8 (59 ref.)

The female athlete triad. Grooms AM. **J Fla Med Assoc** 1996 Aug–Sep;83(7):479–81 (20 ref.)

Epidemiology of hip fracture: the MEDOS study. Mediterranean Osteoporosis Study. Lyritis GP. **Osteoporos Int** 1996;6 Suppl 3:11–5 (19 ref.)

Osteoporotic vertebral fractures in a man under high–dose inhaled glucocorticoid therapy. A case–report with a review of the literature. Laroche M, et al. **Rev Rhum Engl Ed** 1997 Apr;64(4):267–70 (16 ref.)

Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. Halbreich U, et al. **Schizophr Bull** 1996;22(3):447–54 (61 ref.)

[Fractures in osteoporosis as a social, economic and therapeutic problem] Dutka J, et al. **Przegl Lek** 1997; 54(3):194–200 (22 ref.) (Eng. Abstr.) **(Pol)**

DIAGNOSIS

Osteoporosis: prevention, diagnosis, and management. Deal CL. **Am J Med** 1997 Jan 27;102(1A):35S–39S (23 ref.)

Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 2. The use of bone density measurement in the diagnosis and management of osteoporosis. Sturtridge W, et al. **Can Med Assoc J** 1996 Oct 1;155(7):924–9 (24 ref.)

Osteoporosis: diagnosis and treatment. Lane JM, et al. **Instr Course Lect** 1997;46:445–58 (141 ref.)

Bone density measurement—a systematic review. A report from SBU, the Swedish Council on Technology Assessment in Health Care. **J Intern Med Suppl** 1997; 739:1–60 (148 ref.)

The prevention and management of osteoporosis. Consensus statement. Australian National Consensus Conference 1996. **Med J Aust** 1997 Jul 7;167 Suppl:S1–15 (60 ref.)

Rationale and clinical indications for bone density measurements. Cooper C. **Osteoporos Int** 1996;6 Suppl 2:6–8 (20 ref.)

Assessment of bone density and bone loss. Eastell R. **Osteoporos Int** 1996;6 Suppl 2:3–5 (6 ref.)

New perspectives on bone densitometry. Ring F. **Przegl Lek** 1997;54(4):226–9 (8 ref.)

Osteoporosis 1995. Basic diagnosis and therapeutic elements for a national consensus proposal. Sao Paulo, Brazil, May 12–13, 1995. **Rev Paul Med** 1995 Jul–Aug;113(4 Suppl):1–64 (83 ref.) **(Eng, Por)**

Biochemical markers of bone turnover in osteoporosis. Delmas PD, et al. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):31S–36S (70 ref.)

Practical use of bone densitometry. Falasca GF, et al. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):26S–30S (18 ref.)

Interpretation of bone densitometry. Genant HK. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):20S–25S (81 ref.)

Osteoporosis in men. Haddad JG. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):81S–83S (17 ref.)

Normal bone, osteoporosis and the rheumatologist. Simon LS, et al. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):3S–9S (65 ref.)

Clinical utility of bone mass measurements in adults: consensus of an international panel. The Society for Clinical Densitometry. Miller PD, et al. **Semin Arthritis Rheum** 1996 Jun;25(6):361–72 (67 ref.)

Peripheral measurement techniques for the assessment of osteoporosis. Glüer CC, et al. **Semin Nucl Med** 1997 Jul; 27(3):229–47 (147 ref.)

[Bone metabolism and disorders] Raue F, et al. **Internist (Berl)** 1996 May;37(5):539–49 (8 ref.) **(Ger)**

[Osteoporosis—diagnosis and therapy] Ziegler R. **Med Klin** 1996 Feb 15;91 Suppl 1:29–33 (12 ref.) **(Ger)**

[Pediatric aspects of osteoporosis] Lorenc RS. **Pediatr Pol** 1996 Feb;71(2):83–92 (59 ref.) (Eng. Abstr.) **(Pol)**

[Radiologic diagnosis and densitometry of osteoporosis] Czerwiński E. **Przegl Lek** 1997;54(4):220–5 (22 ref.) (Eng. Abstr.) **(Pol)**

[Clinical diagnosis of osteoporosis] Hoszowski K. **Przegl Lek** 1997;54(4):215–9 (12 ref.) (Eng. Abstr.) **(Pol)**

[Difficulties in the interpretation of bone densitometric measurements] Korczyk P, et al. **Przegl Lek** 1997;

54(4):250–1, 254–5 (12 ref.) (Eng. Abstr.) **(Pol)**
[Usefulness of bone densitometry, quantitative computed tomography and quantitative ultrasound in diagnosis and monitoring of osteoporosis treatment] Lorenc RS. **Przegl Lek** 1997;54(4):243–8 (21 ref.) (Eng. Abstr.) **(Pol)**
[Physical aspects of selected densitometry methods used in the diagnosis of osteoporosis] Rokita E. **Przegl Lek** 1997; 54(4):230–6 (14 ref.) (Eng. Abstr.) **(Pol)**
[Differential diagnosis of osteoporosis] Sieradzki J. **Przegl Lek** 1997;54(4):260–2 (14 ref.) (Eng. Abstr.) **(Pol)**

DIET THERAPY

Medical nutrition therapy for patients with osteoporosis. Packard PT, et al. **J Am Diet Assoc** 1997 Apr;97(4):414–7 (41 ref.)

DRUG THERAPY

Osteoporosis treatment: focusing the target [editorial] Sartori L, et al. **Aging (Milano)** 1996 Aug;8(4):219–20 (12 ref.)
Osteoporosis: trials and tribulations. Seeman E. **Am J Med** 1997 Aug 18;103(2A):74S–87S; discussion 87S–89S (67 ref.)
Bisphosphonate therapy [see comments] Licata AA. **Am J Med Sci** 1997 Jan;313(1):17–22 (70 ref.) Comment in: Am J Med Sci 1997 Jan;313(1):1.
Sustained-release sodium fluoride in the management of established postmenopausal osteoporosis. Pak CY, et al. **Am J Med Sci** 1997 Jan;313(1):23–32 (30 ref.)
Calcitonin. Silverman SL. **Am J Med Sci** 1997 Jan; 313(1):13–6 (26 ref.)
Bisphosphonates: preclinical aspects and use in osteoporosis. Fleisch HA. **Ann Med** 1997 Feb;29(1):55–62 (49 ref.)
Current and potential future drug treatments for osteoporosis [see comments] Patel S. **Ann Rheum Dis** 1996 Oct; 55(10):700–14 (162 ref.) Comment in: Ann Rheum Dis 1997 Apr;56(4):280.
PTHrP(1–36) as a skeletal anabolic agent for the treatment of osteoporosis. Stewart AF. **Bone** 1996 Oct;19(4):303–6 (41 ref.)
Does growth hormone treatment prevent corticosteroid-induced osteoporosis? Tanaka H, et al. **Bone** 1996 Jun;18(6):493–4 (28 ref.)
Rationale for active vitamin D analog therapy in senile osteoporosis. Akesson K, et al. **Calcif Tissue Int** 1997 Jan; 60(1):100–5 (40 ref.)
Is there a differential response to alfacalcidol and vitamin D in the treatment of osteoporosis? Francis RM. **Calcif Tissue Int** 1997 Jan;60(1):111–4 (43 ref.)
Vitamin D analogs: from renal bone disease to osteoporosis. Kanis JA. **Calcif Tissue Int** 1997 Jan;60(1):106–10 (42 ref.)
Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 6. Use of bisphosphonates in the treatment of osteoporosis. Hodsman A, et al. **Can Med Assoc J** 1996 Oct 1;155(7):945–8 (34 ref.)
Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 8. Vitamin D metabolites and analogs in the treatment of osteoporosis. Jones G, et al. **Can Med Assoc J** 1996 Oct 1;155(7):955–61 (47 ref.)
Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 7. Fluoride therapy for osteoporosis. Murray TM, et al. **Can Med Assoc J** 1996 Oct 1;155(7):949–54 (52 ref.)
Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 9. Calcitonin in the treatment of osteoporosis. Siminoski K, et al. **Can Med Assoc J** 1996 Oct 1;155(7):962–5 (27 ref.)
Growth hormone and the maintenance of adult bone mineral density. Inzucchi SE, et al. **Clin Endocrinol (Oxf)** 1996 Dec; 45(6):665–73 (80 ref.)
Glucocorticoid-induced osteoporosis: pathogenesis, prevention and treatment. Gulko PS, et al. **Clin Exp Rheumatol** 1996 Mar–Apr;14(2):199–206 (82 ref.)
How to manage patients on long-term oral corticosteroids: recommendations from available guidelines [editorial] Pal B. **Clin Exp Rheumatol** 1997 Jul–Aug;15(4):341–2 (8 ref.)
Relationship between osteoporosis and arthritis and effect of corticosteroids and other drugs on bone. Henderson NK, et al. **Curr Opin Rheumatol** 1996 Jul;8(4):365–9 (43 ref.)
Bisphosphonates in the treatment of osteoporosis. Bell NH, et al. **Endocrine** 1997 Apr;6(2):203–6 (17 ref.)
Use of estrogen for prevention and treatment of osteoporosis. Marcus R. **Endocrine** 1997 Apr;6(2):207–11 (29 ref.)
Bisphosphonates: mechanisms of action and clinical use in osteoporosis—an update. Fleisch H. **Horm Metab Res** 1997 Mar;29(3):145–50 (51 ref.)
Responsiveness of endpoints in osteoporosis clinical trials. Wells G, et al. **J Rheumatol** 1997 Jun;24(6):1230–3 (14 ref.)
Current treatment options for osteoporosis. Adachi JD. **J Rheumatol Suppl** 1996 Aug;45:11–4 (14 ref.)
Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis. McCarty MF. **Med Hypotheses** 1997 Aug; 49(2):123–31 (108 ref.)
Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Brumsen C, et al. **Medicine (Baltimore)** 1997 Jul;76(4):266–83 (83 ref.)
Update on pharmacologic therapies for osteoporosis. Kessenich CR. **Nurse Pract** 1996 Aug;21(8):19–24 (19 ref.)
Alendronate treatment for osteoporosis: a review of the clinical evidence. Selby P. **Osteoporos Int** 1996;6(6):419–26 (47 ref.)
Alendronate—a new bisphosphonate. Selby PL. **Osteoporos Int** 1996;6 Suppl 2:21–3 (7 ref.)
Fluoride and osteoporosis: an overview [editorial] Briançon D. **Rev Rhum Engl Ed** 1997 Feb;64(2):78–81 (32 ref.)
Bisphosphonates in the treatment of osteoporosis. Hochberg MC. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):53S–55S (13 ref.)
Fluoride therapy for bone disease. Orcel P, et al. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):63S–69S (47 ref.)
Calcium and vitamin D in the prevention and treatment of osteoporosis. Orcel P. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):70S–74S (50 ref.)
New bisphosphonates for the treatment of osteoporosis: concerns and hopes [editorial] Reginster JY. **Rev Rhum Engl Ed** 1996 Jul–Sep;63(7–8):461–4 (36 ref.)
Calcium supplementation for the prevention and treatment of osteoporosis. Roux C. **Rev Rhum Engl Ed** 1995 Dec; 62(11):729–32 (28 ref.)
Glucocorticoid-induced osteoporosis: prevention and treatment. Werth VP. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):84S–88S (44 ref.)
[Bisphosphonates in osteoporosis; a reevaluation (see comments)] Papapoulos SE, et al. **Ned Tijdschr Geneeskd** 1996 Nov 30;140(48):2394–8 (28 ref.) Comment in: Ned Tijdschr Geneeskd 1997 Feb 22;141(8):399. **(Dut)**
[Basic aspects of osteoporosis therapy with active vitamin D metabolites] Schacht E. **Med Klin** 1996 Feb 15;91 Suppl 1:34–7 (17 ref.) **(Ger)**
[Alendronate—a new drug for treatment of osteoporosis] Pluskiewicz W, et al. **Chir Narzadow Ruchu Ortop Pol** 1997; 62(1):73–7 (17 ref.) (Eng. Abstr.) **(Pol)**
[Pharmacotherapy of osteoporosis: prospects of bisphosphonates] Nasonov EL, et al. **Klin Med (Mosk)** 1996;74(9):16–22 (77 ref.) **(Rus)**
[The place of Miacalcic (synthetic salmon calcitonin) in the treatment and prevention of osteoporosis] Nasonov EL, et al. **Ter Arkh** 1997;69(5):86–8 (67 ref.) **(Rus)**

EPIDEMIOLOGY

Osteoporosis—an update. Samsioe G. **Acta Obstet Gynecol Scand** 1997 Mar;76(3):189–99 (97 ref.)
The epidemiology and pathogenesis of osteoporosis. Center J, et al. **Baillieres Clin Endocrinol Metab** 1997 Apr; 11(1):23–62 (272 ref.)
Male osteoporosis. Peris P, et al. **Curr Opin Rheumatol** 1996 Jul;8(4):357–64 (96 ref.)
Clinical epidemiology and osteoporosis. Measures and their interpretation. Sowers M. **Endocrinol Metab Clin North Am** 1997 Mar;26(1):219–31 (47 ref.)
The epidemiology of osteoporosis. Hawker GA. **J Rheumatol Suppl** 1996 Aug;45:2–5 (20 ref.)
Epidemiology of osteoporosis. Scott JC. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):10S–14S (62 ref.)
[Epidemiology of osteoporosis] Bonjour JP, et al. **Schweiz Med Wochenschr** 1997 Apr 19;127(16):659–67 (50 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Alcohol, cytokines, and estrogen in the control of bone remodeling. Kimble RB. **Alcohol Clin Exp Res** 1997 May; 21(3):385–91 (85 ref.)
Alcohol-induced bone disease: impact of ethanol on osteoblast proliferation. Klein RF. **Alcohol Clin Exp Res** 1997 May;21(3):392–9 (112 ref.)
Alcohol, osteoporosis, and bone regulating hormones. Sampson HW. **Alcohol Clin Exp Res** 1997 May;21(3):400–3 (45 ref.)
Osteoporosis and systemic lupus erythematosus: etiology and treatment strategies. Segal LG, et al. **Ann Med Interne (Paris)** 1996;147(4):281–9 (43 ref.)
The epidemiology and pathogenesis of osteoporosis. Center J, et al. **Baillieres Clin Endocrinol Metab** 1997 Apr; 11(1):23–62 (272 ref.)
Secondary osteoporosis. Reid DM, et al. **Baillieres Clin Endocrinol Metab** 1997 Apr;11(1):83–99 (125 ref.)
Calcium intake, calcium absorption, and osteoporosis [editorial] Fujita T. **Calcif Tissue Int** 1996 Apr;58(4):215 (7 ref.)
Vitamin D deficiency and osteoporosis: the role of vitamin D deficiency and treatment with vitamin D and analogues in the prevention of osteoporosis-related fractures. Lips P. **Eur J Clin Invest** 1996 Jun;26(6):436–42 (50 ref.)
Strategies to protect bone mass in the older patient with epilepsy. Cohen A, et al. **Geriatrics** 1997 Aug;52(8):70, 75–8, 81 (26 ref.)
Hepatic osteodystrophy: a review. Idilman R, et al. **Hepatogastroenterology** 1997 Mar–Apr;44(14):574–81 (15 ref.)
Injury of an extremity as a risk factor for the development of osteoporosis. Järvinen M, et al. **J Bone Joint Surg Am** 1997 Feb;79(2):263–76 (88 ref.)
Osteoporosis in India—the nutritional hypothesis. Gupta A. **Natl Med J India** 1996 Nov–Dec;9(6):268–74 (71 ref.)
Secondary amenorrhea leading to osteoporosis: incidence and prevention. McGee C. **Nurse Pract** 1997 May;22(5):38, 41–5, 48 passim (40 ref.)
[Clinical case of the month. Osteoporosis and beta-thalassemia] Halkin V, et al. **Rev Med Liege** 1997 Mar; 52(3):138–41 (29 ref.) **(Fre)**
[Osteopathia in chronic inflammatory intestinal disease] Neef B, et al. **Dtsch Med Wochenschr** 1997 Feb 14;122(7):195–9 (33 ref.) **(Ger)**
[Pathogenesis of post-transplantation osteopathy] Hofbauer LC, et al. **Wien Med Wochenschr** 1996;146(12):253–7 (46 ref.) (Eng. Abstr.) **(Ger)**
[Thyroid and osteoporosis] Földes J, et al. **Orv Hetil** 1996 Jun 23;137(25):1347–54 (50 ref.) (Eng. Abstr.) **(Hun)**
[Involutional osteoporosis. Reflections on the problem (editorial)] Passeri M, et al. **Recenti Prog Med** 1996 Dec; 87(12):600–8 (28 ref.) **(Ita)**
[Osteoporosis in rheumatoid arthritis] Haugeberg G. **Tidsskr Nor Laegeforen** 1997 Feb 20;117(5):651–4 (46 ref.) (Eng. Abstr.) **(Nor)**
[The role of locally synthesized growth factors and cytokines in pathogenesis of osteoporosis] Pindel B, et al. **Chir Narzadow Ruchu Ortop Pol** 1996;61(5):487–91 (16 ref.) (Eng. Abstr.) **(Pol)**
[Hypercalciuria and its consequences] Konopielko Z. **Pediatr Pol** 1996 Aug;71(8):695–700 (29 ref.) (Eng. Abstr.) **(Pol)**
[Calcium deficiency as on of the risk factors of osteoporosis] Brzóska MM, et al. **Postepy Hig Med Dosw** 1997; 51(1):55–74 (86 ref.) (Eng. Abstr.) **(Pol)**
[Osteoporosis during development—selected problems] Chlebna-Sokół D. **Przegl Lek** 1997;54(4):276–8 (20 ref.) (Eng. Abstr.) **(Pol)**
[Osteoporosis: the rheumatological perspectives (editorial)] Nasonov EL, et al. **Ter Arkh** 1997;69(5):5–9 (53 ref.) **(Rus)**
[Risk factors in osteoporosis: clinical and epidemiologic evidence] Parra-Cabrera MS, et al. **Gac Med Mex** 1994 Jul–Aug;130(4):231–40 (105 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Osteoporosis. Ralston SH. **BMJ** 1997 Aug 23; 315(7106):469–72 (18 ref.)
Beyond one gene–one disease: alternative strategies for deciphering genetic determinants of osteoporosis [editorial] Rogers J, et al. **Calcif Tissue Int** 1997 Mar;60(3):225–8 (33 ref.)
Vitamin D receptor gene variants: implications for therapy. Eisman JA. **Curr Opin Genet Dev** 1996 Jun;6(3):361–5 (53 ref.)
The genetics of osteoporosis. Ralston SH. **QJM** 1997 Apr; 90(4):247–51 (38 ref.)
Has the gene for osteoporosis really been identified? Marcelli C. **Rev Rhum Engl Ed** 1996 Jun;63(6):445–9 (52 ref.)
Vitamin D receptor gene polymorphisms and osteoporosis. van Leeuwen JP, et al. **Steroids** 1996 Apr;61(4):154–6 (28 ref.)
Genetics of osteoporosis. Kelly PJ, et al. **World Rev Nutr Diet** 1997;80:126–44 (66 ref.)

METABOLISM

Biochemical markers of bone remodeling. Kleerekoper M. **Am J Med Sci** 1996 Dec;312(6):270–7 (35 ref.)
Prediction of fracture risk. I: Bone density. Miller PD, et al. **Am J Med Sci** 1996 Dec;312(6):257–9 (14 ref.)
Prediction of fracture risk. II: Other risk factors. Ross PD. **Am J Med Sci** 1996 Dec;312(6):260–9 (172 ref.)
Inverse relationship osteoarthritis–osteoporosis: what is the evidence? What are the consequences? [editorial] Dequeker J, et al. **Br J Rheumatol** 1996 Sep;35(9):813–8 (49 ref.)
Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 4. Calcium nutrition and osteoporosis [see comments] Murray TM. **Can Med Assoc J** 1996 Oct 1;155(7):935–9 (32 ref.) Comment in: Can Med Assoc J 1997 May 1;156(9):1269.
Is nutrition important in osteoporosis? Prentice A. **Proc Nutr Soc** 1997 Mar;56(1B):357–67 (74 ref.)
Age-related changes in IGFBP-4 and IGFBP-5 levels in human serum and bone: implications for bone loss with aging. Mohan S, et al. **Prog Growth Factor Res** 1995; 6(2–4):465–73 (27 ref.)
[New drugs with positive effects on bones] Zofková I, et al. **Cas Lek Cesk** 1997 Jul 30;136(15):459–63 (74 ref.) (Eng. Abstr.) **(Cze)**
[Calcium metabolism and osteoporosis] Matsumoto T. **Nippon Naika Gakkai Zasshi** 1997 Mar 10;86(3):380–4 (15 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Corticosteroid-induced osteoporosis. Adachi JD. **Am J Med Sci** 1997 Jan;313(1):41–9 (78 ref.)
Pathophysiology of osteoporosis. Heaney RP. **Am J Med Sci** 1996 Dec;312(6):251–6 (24 ref.)
Consensus of an international panel on the clinical utility of bone mass measurements in the detection of low bone mass in the adult population. Miller PD, et al.

Calcif Tissue Int 1996 Apr;58(4):207–14 (80 ref.)
Pregnancy and lactation as risk factors for subsequent bone loss and osteoporosis. Sowers M. **J Bone Miner Res** 1996 Aug;11(8):1052–60 (90 ref.)
Bone density measurement––a systematic review. A report from SBU, the Swedish Council on Technology Assessment in Health Care. **J Intern Med Suppl** 1997; 739:1–60 (148 ref.)
Menopause and osteoporosis: theoretical aspects. Effects of pluriform practices for present day health care and for women. Klinge I. **J Psychosom Obstet Gynaecol** 1997 Jun; 18(2):105–12 (26 ref.)
The role of vitamin D in the pathogenesis and treatment of osteoporosis. Gallagher JC. **J Rheumatol Suppl** 1996 Aug;45:15–8 (25 ref.)
Mechanisms of bone loss. Murray TM.
J Rheumatol Suppl 1996 Aug;45:6–10 (16 ref.)
Physical activity, nutrition, and chronic disease. Blair SN, et al. **Med Sci Sports Exerc** 1996 Mar;28(3):335–49 (202 ref.)
The osteoclast and osteoporosis. Teitelbaum SI.
Mt Sinai J Med 1996 Oct–Nov;63(5–6):399–402 (17 ref.)
Smoking and the human vertebral column: a review of the impact of cigarette use on vertebral bone metabolism and spinal fusion. Hadley MN, et al. **Neurosurgery** 1997 Jul; 41(1):116–24 (138 ref.)
Osteoporosis in men: a review. Ybarra J, et al.
Nurs Clin North Am 1996 Dec;31(4):805–13 (39 ref.)
Pathogenesis of the osteoporoses. Axelrod DW.
Rev Rhum Engl Ed 1997 Jun 30;64(6 Suppl):15S–19S (16 ref.)
Growth factors and bone formation in osteoporosis: roles for IGF-I and TGF-beta. Marie P. **Rev Rhum Engl Ed** 1997 Jan;64(1):44–53 (95 ref.)
[Diagnosis and follow-up of post-transplantation osteopathies] Seibel MJ. **Acta Med Austriaca** 1997;24(1):1–4 (44 ref.) (Eng. Abstr.) **(Ger)**
[Osteoporosis of the lumbar spine] Villiger PM, et al.
Schweiz Rundsch Med Prax 1996 Oct 22;85(43):1354–9 (15 ref.) (Eng. Abstr.) **(Ger)**
[Biochemical markers for bone activity and osteoporosis] Antognozzi G, et al. **Riv Eur Sci Med Farmacol** 1995 Nov–Dec;17(6):237–41 (34 ref.) (Eng. Abstr.) **(Ita)**
[Osteoporosis during development––selected problems] Chlebna-Sokół D. **Przegl Lek** 1997;54(4):276–8 (20 ref.) (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

Vertebral fractures associated with osteoporosis: patient management. Tamayo-Orozco J, et al. **Am J Med** 1997 Aug 18;103(2A):44S–48S; discussion 48S–50S (20 ref.)
Calcitonin. Silverman SL. **Am J Med Sci** 1997 Jan; 313(1):13–6 (26 ref.)
Intake of dietary calcium to reduce the incidence of osteoporosis. Council on Scientific Affairs, American Medical Association. **Arch Fam Med** 1997 Sep–Oct; 6(5):495–9 (73 ref.)
Current bone mineral density data on bisphosphonates in postmenopausal osteoporosis. McClung MR. **Bone** 1996 Nov;19(5 Suppl):195S–198S (35 ref.)
Diagnostics: the correlation of bone mineral density and biochemical markers to fracture risk––where do we go from here? Clinical practice guidelines for the prevention and treatment of osteoporosis and osteopenia. Indianapolis, Indiana, September 7–8, 1995. The Osteoporosis Global Medical Conference. **Calcif Tissue Int** 1996;59 Suppl 1:S1–37 (0 ref.)
Practice guidelines for the treatment of osteoporosis. Prince RL. **Calcif Tissue Int** 1996;59 Suppl 1:S20–3 (7 ref.)
Harmonization of clinical practice guidelines for the prevention and treatment of osteoporosis and osteopenia in Europe: a difficult challenge. Reginster JL.
Calcif Tissue Int 1996;59 Suppl 1:S24–9 (17 ref.)
Osteoporosis prevention and treatment: its relevance to breast cancer patients. Hodsman AB. **Can J Oncol** 1995 Dec;5 Suppl 1:28–32 (33 ref.)
Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 1. Introduction [published erratum appears in Can Med Assoc J 1997 Jan 1;156(1):23] Hanley DA, et al. **Can Med Assoc J** 1996 Oct 1; 155(7):921–3 (0 ref.)
Corticosteroid-induced bone loss. Prevention and management. Picado C, et al. **Drug Saf** 1996 Nov; 15(5):347–59 (125 ref.)
Prevention and management of osteoporosis. Current trends and future prospects. Compston JE. **Drugs** 1997 May; 53(5):727–35 (61 ref.)
Use of estrogen for prevention and treatment of osteoporosis. Marcus R. **Endocrine** 1997 Apr;6(2):207–11 (29 ref.)
Strategies to protect bone mass in the older patient with epilepsy. Cohen A, et al. **Geriatrics** 1997 Aug;52(8):70, 75–8, 81 (26 ref.)
Alternatives to estrogen replacement therapy for preventing osteoporosis. Haines ST, et al.
J Am Pharm Assoc (Wash) 1996 Dec;NS36(12):707–15 (60 ref.)
Hormone therapy and phytoestrogens. Lien LL, et al.
J Clin Pharm Ther 1996 Apr;21(2):101–11 (27 ref.)
Menopause and osteoporosis: theoretical aspects. Effects of pluriform practices for present day health care and for women. Klinge I. **J Psychosom Obstet Gynaecol** 1997 Jun; 18(2):105–12 (26 ref.)
An anthropological perspective on optimizing calcium consumption for the prevention of osteoporosis. Nelson DA. **Osteoporos Int** 1996;6(4):325–8 (47 ref.)
Osteoporosis in women. Bowman MA, et al. **Prim Care** 1997 Mar;24(1):27–36 (63 ref.)
Is nutrition important in osteoporosis? Prentice A.
Proc Nutr Soc 1997 Mar;56(1B):357–67 (74 ref.)
Calcium supplementation for the prevention and treatment of osteoporosis. Roux C. **Rev Rhum Engl Ed** 1995 Dec; 62(11):729–32 (28 ref.)
Roles of diet and physical activity in the prevention of osteoporosis. Anderson JJ, et al.
Scand J Rheumatol Suppl 1996;103:65–74 (43 ref.)
Recent progress in the prevention of osteoporosis. To screen or not to screen? Sørensen OH, et al.
Scand J Rheumatol Suppl 1996;103:25–9 (38 ref.)
Exercise for osteoporosis––is walking enough? The case for site specificity and resistive exercise. Swezey RL. **Spine** 1996 Dec 1;21(23):2809–13 (27 ref.)
[Thiazide diuretics and calcium metabolism: role in renal lithiasis and osteoporosis] Suárez Fernández C, et al.
An Med Interna 1996 Aug;13(8):401–6 (52 ref.) (Eng. Abstr.) **(Spa)**
[Nutrition and osteoporosis: a consolidated relationship] Luna López V, et al. **Med Clin (Barc)** 1997 Sep 6;109(7):271–5 (30 ref.) **(Spa)**

RADIOGRAPHY

DXA scanning. Truscott JG, et al.
Baillieres Clin Rheumatol 1996 Nov;10(4):679–98 (50 ref.)
Single and dual energy X-ray absorptiometry. Adams JE.
Eur Radiol 1997;7 Suppl 2:S20–31 (143 ref.)
Radiological diagnosis of osteoporosis. Grampp S, et al.
Eur Radiol 1997;7 Suppl 2:S11–9 (76 ref.)
[X-ray and radionuclide methods in the diagnosis of osteoporosis] Shiraliev OK, et al.
Vestn Rentgenol Radiol 1996 Nov–Dec;(6):51–4 (46 ref.) **(Rus)**

RADIONUCLIDE IMAGING

Bone densitometry: patients receiving prolonged steroid therapy. Erlichman M, et al. **Health Technol Assess** 1996 Sep;(9):i–vi, 1–31 (198 ref.)

REHABILITATION

Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 5. Physical activity as therapy for osteoporosis. Prior JC, et al.
Can Med Assoc J 1996 Oct 1;155(7):940–4 (40 ref.)
[Rehabilitation in osteoporosis] Frańczuk B, et al.
Przegl Lek 1997;54(4):289–91 (10 ref.) (Eng. Abstr.) **(Pol)**

THERAPY

Osteoporosis: prevention, diagnosis, and management. Deal CL. **Am J Med** 1997 Jan 27;102(1A):35S–39S (23 ref.)
Therapy of osteoporosis: calcium, vitamin D, and exercise. Reid IR. **Am J Med Sci** 1996 Dec;312(6):278–86 (74 ref.)
The management of osteoporosis. Reid IR.
Baillieres Clin Endocrinol Metab 1997 Apr;11(1):63–81 (94 ref.)
Development of clinical practice guidelines for prevention and treatment of osteoporosis. Johnston CC Jr.
Calcif Tissue Int 1996;59 Suppl 1:S30–3 (13 ref.)
Osteoporosis: diagnosis and treatment. Lane JM, et al.
Instr Course Lect 1997;46:445–58 (141 ref.)
Growth factors as potential therapeutic agents in osteoporosis. Mundy GR. **Instr Course Lect** 1997;46:495–8 (31 ref.)
The prevention and management of osteoporosis. Consensus statement. Australian National Consensus Conference 1996. **Med J Aust** 1997 Jul 7;167 Suppl:S1–15 (60 ref.)
Who are candidates for prevention and treatment for osteoporosis? **Osteoporos Int** 1997;7(1):1–6 (36 ref.)
Role and evolution of therapeutic options. Keen RW, et al.
Osteoporos Int 1996;6 Suppl 2:16–20 (29 ref.)
Current therapies and future directions in osteoporosis management. Sibilia V, et al. **Pharmacol Res** 1996 Nov–Dec;34(5–6):237–45 (126 ref.)
Osteoporosis 1995. Basic diagnosis and therapeutic elements for a national consensus proposal. Sao Paulo, Brazil, May 12–13, 1995. **Rev Paul Med** 1995 Jul–Aug;113(4 Suppl):1–64 (83 ref.) **(Eng, Por)**
Managing osteoporotic fractures: minimizing pain and disability. Von Feldt JM. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):78S–80S (13 ref.)
Prevention of osteoporotic fractures: possibilities, the role of exercise, and limitations. Fries JF.
Scand J Rheumatol Suppl 1996;103:6–10; discussion 11–2 (12 ref.)
Overview of role of BMD measurements in managing osteoporosis. Ryan PJ. **Semin Nucl Med** 1997 Jul; 27(3):197–209 (52 ref.)
[How I treat...senile osteoporosis] Reginster JY.
Rev Med Liege 1997 Apr;52(4):267–9 (27 ref.) **(Fre)**
[Involutional osteoporosis––etiopathogenesis and treatment] Skalska A, et al. **Folia Med Cracov** 1996;37(1–2):15–28 (51 ref.) (Eng. Abstr.) **(Pol)**
[Prevention and treatment of osteoporosis] Pumarino H, et al. **Rev Med Chil** 1996 Aug;124(8 Suppl):69–77 (40 ref.) **(Spa)**

ULTRASONOGRAPHY

EC Biomed1 Concerted Action "Assessment of Bone Quality in Osteoporosis": clinical ultrasound consensus workshop 5–6 October 1994, Hull, UK. Langton CM.
Clin Rheumatol 1997 Jan;16(1):113–4 (0 ref.)
Definition consensus workshop for the ultrasonic assessment of bone 15th December 1995 (Paris). Langton CM, et al.
Clin Rheumatol 1997 Jan;16(1):115–6 (0 ref.)
The clinical role of BUA for the assessment of osteoporosis: a new hypothesis. Langton CM. **Clin Rheumatol** 1996 Jul; 15(4):414–5 (15 ref.)
The epidemiology of quantitative ultrasound: a review of the relationships with bone mass, osteoporosis and fracture risk. Gregg EW, et al. **Osteoporos Int** 1997;7(2):89–99 (84 ref.)
The role of ultrasound in the assessment of osteoporosis: a review. Njeh CF, et al. **Osteoporos Int** 1997;7(1):7–22 (128 ref.)

OSTEOPOROSIS, AGE-RELATED see **OSTEOPOROSIS**

OSTEOPOROSIS, POST-TRAUMATIC see **REFLEX SYMPATHETIC DYSTROPHY**

OSTEOPOROSIS, POSTMENOPAUSAL

Current concepts in osteoporosis. Lenchik L, et al.
AJR Am J Roentgenol 1997 Apr;168(4):905–11 (88 ref.)
Osteoporosis. Sambrook PN. **Med J Aust** 1996 Sep 16; 165(6):332–6 (17 ref.)

COMPLICATIONS

Osteoporotic vertebral fractures in postmenopausal women. Millard PS, et al. **Am Fam Physician** 1997 Mar; 55(4):1315–22 (26 ref.)
Epidemiology and predictors of fractures associated with osteoporosis. Lips P. **Am J Med** 1997 Aug 18; 103(2A):3S–8S; discussion 8S–11S (41 ref.)

DIAGNOSIS

Bone densitometry in the clinical practice. Passariello R, et al. **Eur Radiol** 1997;7 Suppl 2:S2–10 (79 ref.)
[Osteoporosis––diagnosis and therapy] Ziegler R.
Med Klin 1996 Feb 15;91 Suppl 1:29–33 (12 ref.) **(Ger)**

DRUG THERAPY

Bisphosphonate therapy [see comments] Licata AA.
Am J Med Sci 1997 Jan;313(1):17–22 (70 ref.) Comment in: Am J Med Sci 1997 Jan;313(1):1.
Sustained-release sodium fluoride in the management of established postmenopausal osteoporosis. Pak CY, et al.
Am J Med Sci 1997 Jan;313(1):23–32 (30 ref.)
Miscellaneous and experimental agents. Reginster JY.
Am J Med Sci 1997 Jan;313(1):33–40 (111 ref.)
Calcitonin. Silverman SL. **Am J Med Sci** 1997 Jan; 313(1):13–6 (26 ref.)
Current bone mineral density data on bisphosphonates in postmenopausal osteoporosis. McClung MR. **Bone** 1996 Nov;19(5 Suppl):195S–198S (35 ref.)
Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 3. Effects of ovarian hormone therapy on skeletal and extraskeletal tissues in women [see comments] Josse RG. **Can Med Assoc J** 1996 Oct 1;155(7):929–34 (28 ref.) Comment in: Can Med Assoc J 1997 Jun 1;156(11):1530, 1532.
Alendronate. A review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis. Jeal W, et al. **Drugs** 1997 Mar;53(3):415–34 (70 ref.)
Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis. Plosker GL, et al.
Drugs Aging 1996 May;8(5):378–400 (146 ref.)
Slow-release sodium fluoride in osteoporosis. Pak CY, et al. **J Bone Miner Res** 1996 May;11(5):561–4 (16 ref.)
PTH: a future role in the management of osteoporosis? [editorial] Reeve J. **J Bone Miner Res** 1996 Apr;11(4):440–5 (92 ref.)
Clodronate and osteoporosis. Kanis JA, et al. **Maturitas** 1996 May;23 Suppl:S81–6 (26 ref.)
Osteoporosis. Current pharmacologic options for prevention and treatment. Isenbarger DW, et al. **Postgrad Med** 1997 Jan;101(1):129–32, 136–7, 141–2 (21 ref.)
Estrogen and the prevention and treatment of osteoporosis. Battistini M. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):44S–49S (47 ref.)
Calcitonin. Sewell KL. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):56S–62S (23 ref.)
[Basic aspects of osteoporosis therapy with active vitamin D metabolites] Schacht E. **Med Klin** 1996 Feb 15;91 Suppl 1:34–7 (17 ref.) **(Ger)**
[Postmenopausal osteoporosis: therapeutic approaches] Affinito P, et al. **Minerva Ginecol** 1997 Mar;49(3):109–20 (99 ref.) (Eng. Abstr.) **(Ita)**
[Diphosphonates: and alternative to estrogen therapy in

postmenopausal osteoporosis. Experience with alendronate] Buffo L, et al. **Minerva Ginecol** 1996 Jun;48(6):263–72 (32 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

The menopause and the skeleton: key issues. Kanis JA. **Baillieres Clin Obstet Gynaecol** 1996 Sep;10(3):469–81 (23 ref.)

Bone insufficiency fractures as an inaugural manifestation of primary hyperparathyroidism. Lafforgue P, et al. **Rev Rhum Engl Ed** 1996 Jul–Sep;63(7–8):475–9 (26 ref.)

METABOLISM

Biochemical markers in osteoporosis. Kanis JA. **Scand J Clin Lab Invest Suppl** 1997;227:6–11 (23 ref.)

PATHOLOGY

Bone microdamage and skeletal fragility in osteoporotic and stress fractures. Burr DB, et al. **J Bone Miner Res** 1997 Jan;12(1):6–15 (67 ref.)

PHYSIOPATHOLOGY

The pathophysiology and treatment of postmenopausal osteoporosis. An evidence-based approach to estrogen replacement therapy. Rosen CJ, et al. **Endocrinol Metab Clin North Am** 1997 Jun;26(2):295–311 (69 ref.)

Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. Pacifici R. **J Bone Miner Res** 1996 Aug; 11(8):1043–51 (99 ref.)

[Osteoporosis of the elderly person] Rivier E. **Rev Med Suisse Romande** 1996 Sep;116(9):743–50 (45 ref.) **(Fre)**

[Osteoporosis of the lumbar spine] Villiger PM, et al. **Schweiz Rundsch Med Prax** 1996 Oct 22;85(43):1354–9 (15 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Estrogen therapy and osteoporosis: principles & practice [see comments] Notelovitz M. **Am J Med Sci** 1997 Jan; 313(1):2–12 (121 ref.) Comment in: Am J Med Sci 1997 Jan;313(1):1.

Miscellaneous and experimental agents. Reginster JY. **Am J Med Sci** 1997 Jan;313(1):33–40 (111 ref.)

Calcitonin. Silverman SL. **Am J Med Sci** 1997 Jan; 313(1):13–6 (26 ref.)

European and North American Experience with HRT for the prevention of osteoporosis. Eriksen EF, et al. **Bone** 1996 Nov;19(5 Suppl):179S–183S (46 ref.)

Estrogens, the menopause, and osteoporosis. Kanis JA. **Bone** 1996 Nov;19(5 Suppl):185S–190S (26 ref.)

Bone preservation and the menopause [published erratum appears in Br J Hosp Med 1997 Apr 2–15;57(7):352] Fraser WD. **Br J Hosp Med** 1997 Mar 5–18;57(5):212–4 (20 ref.)

The effects of oestrogen deficiency on the skeleton and its prevention. Fogelman I. **Br J Obstet Gynaecol** 1996 Oct; 103 Suppl 14:5–9 (55 ref.)

Osteoporosis prevention and treatment. Pharmacological management and treatment implications. Sankaran SK. **Drugs Aging** 1996 Dec;9(6):472–7 (31 ref.)

The brittle bone: how to save women from osteoporosis. Rozenberg S, et al. **Int J Fertil Womens Med** 1997 Mar–Apr;42(2):101–6 (38 ref.)

Hormone replacement therapy and osteoporosis. Christiansen C. **Maturitas** 1996 May;23 Suppl:S71–6 (38 ref.)

Estrogen and bone metabolism. Väänänen HK, et al. **Maturitas** 1996 May;23 Suppl:S65–9 (27 ref.)

Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments. Ankjaer-Jensen A, et al. **Osteoporos Int** 1996;6(4):265–75 (43 ref.)

Hormone replacement therapy in the prevention and treatment of osteoporosis. Delmas PD. **Osteoporos Int** 1997; 7 Suppl 1:S3–7 (47 ref.)

Gonadal hormone substitutes. Purdie DW. **Osteoporos Int** 1997;7 Suppl 1:S61–3 (5 ref.)

Osteoporosis. Current pharmacologic options for prevention and treatment. Isenbarger DW, et al. **Postgrad Med** 1997 Jan;101(1):129–32, 136–7, 141–2 (21 ref.)

Osteoporosis in women. Bowman MA, et al. **Prim Care** 1997 Mar;24(1):27–36 (63 ref.)

[The effect of hormone replacement therapy on bone mineral content and on fractures] Eiken PA. **Ugeskr Laeger** 1997 Jan 27;159(5):570–6 (40 ref.) (Eng. Abstr.) **(Dan)**

[Estrogens and prevention of postmenopausal osteoporosis] Chaouat D. **Ann Med Interne (Paris)** 1996;147(6):432–40 (105 ref.) **(Fre)**

[Evaluation of the preventive role of estro-progestogens and non-hormonal therapies in postmenopausal osteoporosis] Reginster JY. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(7):677–83 (81 ref.) (Eng. Abstr.) **(Fre)**

[Prevention of postmenopausal osteoporosis: estrogens and nonhormonal drugs] Reginster JY. **Rev Med Liege** 1996 Oct;51(10):649–53 (25 ref.) **(Fre)**

RADIOGRAPHY

Lateral dual X-ray absorptiometry of the lumbar spine: current status [editorial] Jergas M, et al. **Bone** 1997 Apr; 20(4):311–4 (39 ref.)

THERAPY

Estrogen therapy and osteoporosis: principles & practice [see comments] Notelovitz M. **Am J Med Sci** 1997 Jan; 313(1):2–12 (121 ref.) Comment in: Am J Med Sci 1997 Jan;313(1):1.

Osteoporosis: the need for comprehensive treatment guidelines. Abbott TA 3d, et al. **Clin Ther** 1996 Jan–Feb; 18(1):127–49; discussion 126 (106 ref.)

Postmenopausal osteoporosis. Ettinger B. **Curr Ther Endocrinol Metab** 1997;6:639–44 (12 ref.)

[Prevention and treatment during the postmenopausal period] Klimek R. **Przegl Lek** 1997;54(4):279–83 (8 ref.) (Eng. Abstr.) **(Pol)**

OSTEOPOROSIS, SENILE see **OSTEOPOROSIS**

OSTEOSARCOMA

Osteosarcoma and other tumors of bone. Mertens WC, et al. **Curr Opin Oncol** 1997 Jul;9(4):360–5 (47 ref.)

Osteosarcoma and other tumors of bone. Mertens WC, et al. **Curr Opin Oncol** 1996 Jul;8(4):299–304 (51 ref.)

Primary osteosarcoma of the spermatic cord with synchronous bilateral renal cell carcinoma. Beiswanger JC, et al. **Urology** 1997 Jun;49(6):957–9 (14 ref.)

[Primary spinal osteosarcomas] Khalfallah M, et al. **Neurochirurgie** 1997;43(1):28–34 (56 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Osteosarcomatosis with Rothmund-Thomson syndrome. el-Khoury JM, et al. **Br J Radiol** 1997 Feb;70:215–8 (11 ref.)

Primary osteosarcoma of the L2 lamina presenting as "silent" paraplegia: case report and review of the literature. Korovessis P, et al. **Eur Spine J** 1995;4(6):375–8 (18 ref.)

DIAGNOSIS

An unusual presentation of telangiectatic osteosarcoma. Simon RG, et al. **Am J Orthop** 1996 May;25(5):375–9 (19 ref.)

Osteosarcoma of the scaphoid. A case report and review of the literature. Marcuzzi A, et al. **J Bone Joint Surg Br** 1996 Sep;78(5):699–701 (8 ref.)

[Physiopathology and therapy of patients with osteosarcoma] Iwamoto Y. **Fukuoka Igaku Zasshi** 1996 Jul;87(7):151–5 (6 ref.) **(Jpn)**

DRUG THERAPY

Chemotherapy for osteosarcoma and Ewing's sarcoma. Saeter G, et al. **Acta Orthop Scand Suppl** 1997 Feb; 273:120–5 (51 ref.)

The role of corrected QT interval in the cardiologic follow-up of young patients treated with Adriamycin. Ferrari S, et al. **J Chemother** 1996 Jun;8(3):232–6 (8 ref.)

Effect of chemotherapy on survival of craniofacial osteosarcoma: a systematic review of 201 patients. Smeele LE, et al. **J Clin Oncol** 1997 Jan;15(1):363–7 (27 ref.)

Melatonin in osteosarcoma: an effective drug? Panzer A. **Med Hypotheses** 1997 Jun;48(6):523–5 (36 ref.)

[L-MTP-PE--a potential antineoplastic agent] Dzierzbicka K, et al. **Postepy Hig Med Dosw** 1997;51(2):227–36 (37 ref.) (Eng. Abstr.) **(Pol)**

ETIOLOGY

Postirradiation laryngeal osteosarcoma: case report and literature review. Sheen TS, et al. **Head Neck** 1997 Jan; 19(1):57–62 (36 ref.)

MORTALITY

Effect of chemotherapy on survival of craniofacial osteosarcoma: a systematic review of 201 patients. Smeele LE, et al. **J Clin Oncol** 1997 Jan;15(1):363–7 (27 ref.)

PATHOLOGY

Low-grade central osteosarcoma resembling fibrous dysplasia. A report of two cases. Franceschina MJ, et al. **Am J Orthop** 1997 Jun;26(6):432–40 (14 ref.)

Osteosarcoma metastatic to the ovary: a case report and review of the literature. Eltabbakh GH, et al. **Int J Gynecol Pathol** 1997 Jan;16(1):76–8 (13 ref.)

Osteogenic sarcoma of the jaws: factors influencing prognosis. August M, et al. **Int J Oral Maxillofac Surg** 1997 Jun;26(3):198–204 (24 ref.)

Nasopharyngeal osteosarcoma as second malignant neoplasm in a post-treated unilateral retinoblastoma: report of a case and review of literature. Dubey SP, et al. **Int J Pediatr Otorhinolaryngol** 1996 Feb;34(3):265–71 (14 ref.)

Maxillary chondroblastic sarcoma: presentation of two cases and a literature review. Altuwairgi O, et al. **J Oral Maxillofac Surg** 1996 Nov;54(11):1357–64 (65 ref.)

PHYSIOPATHOLOGY

[Insulin-like growth factor in normalcy and in osteogenic sarcoma] KushlinskiiNE, et al. **Vopr Onkol** 1996;42(6):7–12 (39 ref.) **(Rus)**

SECONDARY

Osteosarcoma metastatic to the ovary: a case report and review of the literature. Eltabbakh GH, et al. **Int J Gynecol Pathol** 1997 Jan;16(1):76–8 (13 ref.)

[Extraosseus osteogenic sarcoma: report of a case with atypical secondary involvement of the lung] Pezzullo L, et al. **Radiol Med (Torino)** 1997 Mar;93(3):296–8 (16 ref.) **(Ita)**

SURGERY

Endoprosthetic replacement following limb-sparing resection for bone sarcoma. Damron TA. **Semin Surg Oncol** 1997 Jan–Feb;13(1):3–10 (35 ref.)

THERAPY

Successful treatment of spinal osteosarcoma with radiation and chemotherapy. Hershey A, et al. **Orthopedics** 1996 Jul; 19(7):617–8 (7 ref.)

Osteosarcoma. Meyers PA, et al. **Pediatr Clin North Am** 1997 Aug;44(4):973–89 (81 ref.)

VETERINARY

Canine osteosarcoma: amputation and chemotherapy. Berg J. **Vet Clin North Am Small Anim Pract** 1996 Jan; 26(1):111–21 (29 ref.)

Canine osteosarcoma: amputation and chemoimmunotherapy. MacEwen EG, et al. **Vet Clin North Am Small Anim Pract** 1996 Jan;26(1):123–33 (50 ref.)

Limb-sparing surgery versus amputation for dogs with bone tumors. Straw RC, et al. **Vet Clin North Am Small Anim Pract** 1996 Jan;26(1):135–43 (28 ref.)

OSTEOSCLEROSIS

COMPLICATIONS

Osteosclerotic myeloma and 'POEMS' syndrome. Schey S. **Blood Rev** 1996 Jun;10(2):75–80 (50 ref.)

RADIOGRAPHY

A 42-year-old woman with low back pain. McGrory BJ, et al. **Am J Orthop** 1996 Sep;25(9):653–4, 657–8 (14 ref.)

OSTEOSCLEROSIS FRAGILIS see **OSTEOPETROSIS**

OSTEOSYNTHESIS, FRACTURE see **FRACTURE FIXATION, INTERNAL**

OSTEOSYNTHESIS, FRACTURE, INTRAMEDULLARY see **FRACTURE FIXATION, INTRAMEDULLARY**

OSTEOTOMY

ADVERSE EFFECTS

Complications of distal first metatarsal osteotomies. Hanft J. **Clin Podiatr Med Surg** 1996 Jul;13(3):355–65 (21 ref.)

Peripheral facial palsy after sagittal split ramus osteotomy for setback of the mandible. A case report. Sakashita H, et al. **Int J Oral Maxillofac Surg** 1996 Jun;25(3):182–3 (11 ref.)

Perioperative morbidity in maxillofacial orthopaedic surgery: a retrospective study. Van de Perre JP, et al. **J Craniomaxillofac Surg** 1996 Oct;24(5):263–70 (123 ref.)

METHODS

Translocation of the fifth finger by intracarpal osteotomy. Le Viet D. **Ann Chir Main** 1982;1(1):45–56 (9 ref.) **(Eng, Fre)**

Clinical results of rotational osteotomy for treatment of avascular necrosis of the femoral head. Belal MA, et al. **Arch Orthop Trauma Surg** 1996;115(2):80–4 (16 ref.)

Sagittal ramus split osteotomy: literature review and suggested modification of technique. Wyatt WM. **Br J Oral Maxillofac Surg** 1997 Apr;35(2):137–41 (23 ref.)

Laterally closing metatarsal head osteotomy in the correction of a medially overlapping digit. Berens TA. **Clin Podiatr Med Surg** 1996 Apr;13(2):293–307 (7 ref.)

Displacement osteotomy for the treatment of digital transverse plane deformities. Goforth WP, et al. **Clin Podiatr Med Surg** 1996 Apr;13(2):279–92 (16 ref.)

Research perspectives in first metatarsal osteotomy and fixation stability. Landsman AS, et al. **Clin Podiatr Med Surg** 1996 Jul;13(3):575–87 (34 ref.)

Alternatives to the closing base wedge osteotomy. Martin DE, et al. **Clin Podiatr Med Surg** 1996 Jul;13(3):515–31 (14 ref.)

Angular surgical corrections for hallux valgus. Pagliano JW. **Clin Podiatr Med Surg** 1997 Jul;14(3):427–45 (21 ref.)

Modified Austin procedure for correction of hallux valgus. Trnka HJ, et al. **Foot Ankle Int** 1997 Mar;18(3):119–27 (28 ref.)

Bioresorbable implants: applications in orthopaedic surgery. Blasier RD, et al. **Instr Course Lect** 1997;46:531–46 (64 ref.)

Hallux valgus. Coughlin MJ. **Instr Course Lect** 1997; 46:357–91 (151 ref.)

Temperature rise during drilling through bone. Abouzgia

MB, et al. **Int J Oral Maxillofac Implants** 1997 May–Jun; 12(3):342–53 (31 ref.)
Bone grafting for reconstructive osteotomies of the foot. Alter SA, et al. **J Foot Ankle Surg** 1996 Sep–Oct; 35(5):418–27 (39 ref.)
Role of osteotomy in the treatment of slipped capital femoral epiphysis. Crawford AH. **J Pediatr Orthop B** 1996 Spring; 5(2):102–9 (55 ref.)
[Kirner's disease: surgical treatment] Mantero R. **Ann Chir Main** 1982;1(1):88–91 (13 ref.) (Eng. Abstr.) **(Fre)**
[Austin's horizontal V-shaped sliding osteotomy of the metatarsal head [Chevron-osteotomy) in the treatment of hallux valgus] Steinböck G. **Orthopade** 1996 Aug; 25(4):308–16 (62 ref.) (Eng. Abstr.) **(Ger)**
[Twenty-eight years' treatments using high tibial osteotomy with development of Y-blade plate and postoperative repair of degenerated cartilage in the osteoarthritic knee] Koshino T. **Nippon Seikeigeka Gakkai Zasshi** 1996 Dec; 70(12):817–25 (29 ref.) **(Jpn)**

VETERINARY

Treatment of recurrent otitis media that developed after total ear canal ablation and lateral bulla osteotomy in dogs: nine cases (1986–1994). Smeak DD, et al. **J Am Vet Med Assoc** 1996 Sep 1;209(5):937–42 (17 ref.)

OSTERREICHER SYNDROME see **NAIL–PATELLA SYNDROME**

OSTERTAGIA

IMMUNOLOGY

The genetic basis of resistance to Ostertagia circumcincta in lambs. Stear MJ, et al. **Vet J** 1997 Sep;154(2):111–9 (65 ref.)

OSTERTAGIA OSTERTAGI see **OSTERTAGIA**

OSTERTAGIASIS

VETERINARY

The genetic basis of resistance to Ostertagia circumcincta in lambs. Stear MJ, et al. **Vet J** 1997 Sep;154(2):111–9 (65 ref.)

OSTOMY

NURSING

Essential elements of ostomy care. Bradley M, et al. **Am J Nurs** 1997 Jul;97(7):38–45; quiz 46 (6 ref.)

OTA'S NEVUS see **NEVUS OF OTA**

OTC DRUGS see **DRUGS, NON-PRESCRIPTION**

OTITIS EXTERNA

COMPLICATIONS

Malignant otitis externa in HIV and AIDS. Hern JD, et al. **J Laryngol Otol** 1996 Aug;110(8):770–5 (37 ref.)
Skull base osteomyelitis. Malignant external otitis. Slattery WH 3rd, et al. **Otolaryngol Clin North Am** 1996 Oct; 29(5):795–806 (30 ref.)

DIAGNOSIS

Malignant otitis externa. Hickham M, et al. **J La State Med Soc** 1996 Dec;148(12):511–3 (19 ref.)
Malignant external otitis as the presentation of childhood acute lymphocytic leukemia. Pacini DL, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1132–4 (21 ref.)

DRUG THERAPY

Malignant external otitis as the presentation of childhood acute lymphocytic leukemia. Pacini DL, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1132–4 (21 ref.)

PHYSIOPATHOLOGY

Otitis externa. Bojrab DI, et al. **Otolaryngol Clin North Am** 1996 Oct;29(5):761–82 (38 ref.)

VETERINARY

Antimicrobial therapy of skin and ear infections. Dowling PM. **Can Vet J** 1996 Nov;37(11):695–9 (6 ref.)

OTITIS INTERNA see **LABYRINTHITIS**

OTITIS MEDIA

Otitis media and its relation to allergic rhinitis. Fireman P. **Allergy Asthma Proc** 1997 May–Jun;18(3):135–43 (46 ref.)
Acute otitis media. Deka RC. **Indian Pediatr** 1996 Oct; 33(10):832–6 (18 ref.)

COMPLICATIONS

Otitis media and eustachian tube dysfunction: connection to allergic rhinitis. Fireman P. **J Allergy Clin Immunol** 1997 Feb;99(2):S787–97 (95 ref.)

DIAGNOSIS

Diagnosing otitis media: a workshop. Stool S, et al. **Compr Ther** 1996 Dec;22(12):776–81 (9 ref.)
Otitis media and sinusitis: similar diseases. Parsons DS, et al. **Otolaryngol Clin North Am** 1996 Feb;29(1):11–25 (28 ref.)
Acute otitis media in children. Rosenfeld JA, et al. **Prim Care** 1996 Dec;23(4):677–86 (40 ref.)

DRUG THERAPY

Antimicrobials for acute otitis media? A review from the International Primary Care Network. Froom J, et al. **BMJ** 1997 Jul 12;315(7100):98–102 (58 ref.)
The antibiotic treatment of acute otitis media and sinusitis in children. Cohen R. **Diagn Microbiol Infect Dis** 1997 Jan–Feb;27(1–2):35–9 (19 ref.)
An evidence-based approach to treating otitis media. Rosenfeld RM. **Pediatr Clin North Am** 1996 Dec; 43(6):1165–81 (86 ref.)
Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media. Block SL. **Pediatr Infect Dis J** 1997 Apr;16(4):449–56 (39 ref.)
Acute otitis media in pediatrics: are there rational issues for empiric therapy? Boccazzi A, et al. **Pediatr Infect Dis J** 1997 Mar;16(3 Suppl):S65–9 (19 ref.)
Shortened course of antibiotic therapy for acute otitis media, sinusitis and tonsillopharyngitis. Pichichero ME, et al. **Pediatr Infect Dis J** 1997 Jul;16(7):680–95 (144 ref.)
Acute otitis media in children. Rosenfeld JA, et al. **Prim Care** 1996 Dec;23(4):677–86 (40 ref.)
[Treatment of acute otitis media in children. Some questions] del Castillo Martín F. **Enferm Infecc Microbiol Clin** 1997 Apr;15(4):212–7 (95 ref.) **(Spa)**

ECONOMICS

Management of otitis media in the era of managed care. Klein JO, et al. **Adv Pediatr Infect Dis** 1996;12:351–86 (98 ref.)

ETIOLOGY

Acute otitis media. Maxson S, et al. **Pediatr Rev** 1996 Jun; 17(6):191–5; quiz 196 (18 ref.)

IMMUNOLOGY

Immunologic evaluation of the child with recurrent otitis media. Church JA. **Ear Nose Throat J** 1997 Jan;76(1):31–4, 42 (21 ref.)
New vaccines for the prevention of pneumococcal infections. Käyhty H, et al. **Emerg Infect Dis** 1996 Oct–Dec; 2(4):289–98 (74 ref.)

MICROBIOLOGY

Otitis media and mastoiditis due to Mycobacterium fortuitum: case report, review of four cases, and a cautionary note. Plemmons RM, et al. **Clin Infect Dis** 1996 Jun;22(6):1105–6 (10 ref.)
Tuberculosis of the ear and a Nepalese experience [letter] Friedman I, et al. **J Laryngol Otol** 1997 Apr;111(4):408 (9 ref.)
Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media. Block SL. **Pediatr Infect Dis J** 1997 Apr;16(4):449–56 (39 ref.)

PHYSIOPATHOLOGY

New concepts in the pathophysiology and management of middle ear disease in childhood. Pelton SI. **Drugs** 1996;52 Suppl 2:62–6; discussion 66–7 (25 ref.)
Pathogenesis of otitis media: role of eustachian tube. Bluestone CD. **Pediatr Infect Dis J** 1996 Apr;15(4):281–91 (110 ref.)

PREVENTION & CONTROL

New prospects in the prevention of otitis media. Heikkinen T, et al. **Ann Med** 1996 Feb;28(1):23–30 (87 ref.)
New vaccines for the prevention of pneumococcal infections. Käyhty H, et al. **Emerg Infect Dis** 1996 Oct–Dec; 2(4):289–98 (74 ref.)
A community-based nursing approach to the prevention of otitis media. Curry MD, et al. **J Community Health Nurs** 1997;14(2):81–110 (164 ref.)

SURGERY

Choice, advice and assessment of patients for ear surgery. Browning GG. **J R Soc Med** 1996 Oct;89(10):571–6 (6 ref.)
Care of the child with tympanostomy tubes. Isaacson G, et al. **Pediatr Clin North Am** 1996 Dec;43(6):1183–93 (64 ref.)

THERAPY

Management of otitis media in the era of managed care. Klein JO, et al. **Adv Pediatr Infect Dis** 1996;12:351–86 (98 ref.)
Upper respiratory tract infections – otitis media, sinusitis and pharyngitis. Oh HM. **Singapore Med J** 1995 Aug; 36(4):428–31 (23 ref.)

VETERINARY

Treatment of recurrent otitis media that developed after total ear canal ablation and lateral bulla osteotomy in dogs: nine cases (1986–1994). Smeak DD, et al. **J Am Vet Med Assoc** 1996 Sep 1;209(5):937–42 (17 ref.)
Otitis media and interna and temporohyoid osteoarthropathy. Blythe LL. **Vet Clin North Am Equine Pract** 1997 Apr; 13(1):21–42 (24 ref.)

OTITIS MEDIA, PURULENT see **OTITIS MEDIA, SUPPURATIVE**

OTITIS MEDIA, SECRETORY see **OTITIS MEDIA WITH EFFUSION**

OTITIS MEDIA, SEROUS see **OTITIS MEDIA WITH EFFUSION**

OTITIS MEDIA, SUPPURATIVE

COMPLICATIONS

Luc's abscess—a rare complication of middle-ear infection. Knappe MV, et al. **J Laryngol Otol** 1997 May;111(5):461–4 (8 ref.)

PHYSIOPATHOLOGY

Eustachian tube dysfunction. Monsell EM, et al. **Otolaryngol Clin North Am** 1996 Jun;29(3):437–44 (23 ref.)

OTITIS MEDIA WITH EFFUSION

COMPLICATIONS

Complications of chronic otitis media. Nissen AJ, et al. **Ear Nose Throat J** 1996 May;75(5):284–92 (19 ref.)
Otitis media and eustachian tube dysfunction: connection to allergic rhinitis. Fireman P. **J Allergy Clin Immunol** 1997 Feb;99(2):S787–97 (95 ref.)
[Paranasal sinuses, middle ear, and allergy] Mogi G. **Arerugi** 1995 Dec;44(12):1355–60 (21 ref.) **(Jpn)**

DIAGNOSIS

Ehlers–Danlos syndrome: aural manifestations and treatment. Thomas DM, et al. **Am J Otolaryngol** 1996 Nov–Dec; 17(6):432–3 (10 ref.)
Chronic otitis media with effusion. Poehlman GS. **Prim Care** 1996 Dec;23(4):687–99 (27 ref.)

DRUG THERAPY

Management of otitis media with effusion in young children. Paap CM. **Ann Pharmacother** 1996 Nov;30(11):1291–7 (19 ref.)
Chronic otitis media with effusion. Poehlman GS. **Prim Care** 1996 Dec;23(4):687–99 (27 ref.)
[Antibiotics in otitis media with effusion (see comments)] Grote JJ. **Ned Tijdschr Geneeskd** 1997 Jan 11;141(2):76–7 (15 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1997 Feb 22;141(8):401–2. Comment in: Ned Tijdschr Geneeskd 1997 Apr 5;141(14):702. **(Dut)**

ETIOLOGY

Otitis serosa: a food allergy? Høst A. **Monogr Allergy** 1996; 32:195–7 (9 ref.)

PHYSIOPATHOLOGY

Relapsing infective-phlogistic pathology of Waldeyer's ring and its relationship with secretory otitis media. Passali D, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;523:138–41 (10 ref.)
Eustachian tube dysfunction. Monsell EM, et al. **Otolaryngol Clin North Am** 1996 Jun;29(3):437–44 (23 ref.)
[Acute otitis media with effusion: an overview of the pathogenesis and recommendations for therapy] Linder T, et al. **Schweiz Med Wochenschr** 1996 Dec 28; 126(51–52):2223–33 (43 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[Acute otitis media with effusion: an overview of the pathogenesis and recommendations for therapy] Linder T, et al. **Schweiz Med Wochenschr** 1996 Dec 28; 126(51–52):2223–33 (43 ref.) (Eng. Abstr.) **(Ger)**

OTOACOUSTIC EMISSIONS, SPONTANEOUS

Otoacoustic emissions. Probst R, et al. **Adv Otorhinolaryngol** 1997;53:182–204 (55 ref.)
Neonatal hearing screening. Oudesluys-Murphy AM, et al. **Eur J Pediatr** 1996 Jun;155(6):429–35 (51 ref.)

OTOCONIA see **OTOLITHIC MEMBRANE**

OTOLARYNGOLOGY

see related
OTORHINOLARYNGOLOGIC DISEASES

Asthma: an important disease to otolaryngologists—Part I: Suspecting and diagnosing asthma. Gordon BR.

OTOLARYNGOLOGY

Ear Nose Throat J 1996 Feb;75(2):97–101 (29 ref.)
The use of systemic steroids in otolaryngology. Nadel DM. **Ear Nose Throat J** 1996 Aug;75(8):502–5, 509–10, 511–2 passim (57 ref.)
Argon laser and Gherini–Causse Endo–Otoprobe in otologic surgery. Vincent R, et al. **Ear Nose Throat J** 1996 Dec; 75(12):770, 773–8, 780 (22 ref.)

EDUCATION

[Digital image processing in rhinologic education and graduate education] Keerl R, et al.
Eur Arch Otorhinolaryngol Suppl 1996;1:297–315 (68 ref.) **(Ger)**

METHODS

The perceptual evaluation of voice disorders. De Bodt MS, et al. **Acta Otorhinolaryngol Belg** 1996;50(4):283–91 (40 ref.)
Perioperative psychosocial interventions for autistic children undergoing ENT surgery. Seid M, et al.
Int J Pediatr Otorhinolaryngol 1997 Jun 20;40(2–3):107–13 (11 ref.)

STATISTICS & NUMERICAL DATA

Evidence based medicine in otolaryngology [editorial] Gibbin KP. **J Laryngol Otol** 1997 May;111(5):415–7 (15 ref.)

TRENDS

Recent advances. Otorhinolaryngology. Werner JA, et al. **BMJ** 1997 Aug 9;315(7104):354–7 (37 ref.)
Recent advances of otology in China. Wang L, et al. **Chin Med J (Engl)** 1996 Oct;109(10):743–6 (12 ref.)
Trends in randomized controlled trials in ENT: a 30–year review. Ah–See KW, et al. **J Laryngol Otol** 1997 Jul; 111(7):611–3 (9 ref.)
Otolaryngology. Making the deaf hear and the dumb speak. Callanan V, et al. **Lancet** 1996 Dec 21–28;348 Suppl 2:sII19 (5 ref.)

OTOLITHIC MEMBRANE

ANATOMY & HISTOLOGY

[The structural variability of the otolithic apparatus and the problem of motion sickness] Lychakov DV.
Zh Evol Biokhim Fiziol 1996 Sep–Oct;32(5):629–42 (66 ref.) **(Rus)**

OTOLITHS see **OTOLITHIC MEMBRANE**

OTOLOGY see **OTOLARYNGOLOGY**

OTORHINOLARYNGOLOGIC DISEASES

see related
EAR DISEASES
LARYNGEAL DISEASES
NOSE DISEASES
PHARYNGEAL DISEASES

Diagnosis and tranosis and treatment of ENT infections. Bates G, et al. **Practitioner** 1996 May;240(1562):336–40 (14 ref.)
[Progresses in otorhinolaryngology in China, 1996] Liu C, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Dec;76(12):928–9 (0 ref.) **(Chi)**

DIAGNOSIS

Eye, ear, nose, and throat. Pfaff JA, et al.
Emerg Med Clin North Am 1997 May;15(2):327–40 (59 ref.)
Imaging of otolaryngologic manifestations of HIV infection. Fischbein NJ, et al. **Neuroimaging Clin N Am** 1997 May; 7(2):375–99 (100 ref.)
[Cat scratch disease. An overview for the ENT physician] Dreher A, et al. **Laryngorhinootologie** 1996 Jul;75(7):403–7 (25 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

[ORL infections. 10th consensus conference on anti–infectious therapeutics. Under the collaboration of the French Societies of Infectious Diseases, of ORL and of Pediatrics] **Arch Pediatr** 1997 Feb;4(2):188–94 (0 ref.) **(Fre)**

EPIDEMIOLOGY

High prevalence of opportunistic infections in the head and neck related to human immunodeficiency virus. A prospective study of the distribution of otorhinolaryngologic disorders in 250 patients. Riederer AP, et al. **Infection** 1996 Nov–Dec;24(6):440–6 (43 ref.)
[Tuberculosis of the otorhinolaryngologic region: laryngeal and extra–laryngeal forms] Fortún J, et al.
Enferm Infecc Microbiol Clin 1996 Jun–Jul;14(6):352–6 (41 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

[Minimally invasive ENT surgery. Progress due to modern technology] Plinkert PK, et al. **HNO** 1996 Jun; 44(6):288–301 (64 ref.) (Eng. Abstr.) **(Ger)**
[Nosocomial infections in head and neck surgery. 1] Vössing M, et al. **HNO** 1996 Feb;44(2):61–7 (58 ref.) (Eng. Abstr.) **(Ger)**
[Local anesthesia in operations of the head–neck area] Grevers G, et al. **Laryngorhinootologie** 1996 Jul;75(7):433–6 (10 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Eye, ear, nose, and throat. Pfaff JA, et al.
Emerg Med Clin North Am 1997 May;15(2):327–40 (59 ref.)

VIROLOGY

High prevalence of opportunistic infections in the head and neck related to human immunodeficiency virus. A prospective study of the distribution of otorhinolaryngologic disorders in 250 patients. Riederer AP, et al. **Infection** 1996 Nov–Dec;24(6):440–6 (43 ref.)
Human immunodeficiency virus in otolaryngology [editorial] Youngs R. **J Laryngol Otol** 1997 Mar;111(3):209–11 (30 ref.)

OTORHINOLARYNGOLOGIC NEOPLASMS

PSYCHOLOGY

[Medical consultation with curable cancer patients] de Maddalena H. **HNO** 1996 Nov;44(11):645–54 (17 ref.) **(Ger)**
[Research in psychosocial aspects of ENT tumor surgery (excluding laryngectomy): 4–part analysis of the literature. 3: Results of research] Kollbrunner J, et al. **HNO** 1997 Jul;45(7):523–32 (0 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

[Psychosocial aspects of ENT tumor surgery (excluding laryngectomy). 2: Analysis of empirical studies (see comments)] Kollbrunner J, et al. **HNO** 1997 Jun; 45(6):433–41 (0 ref.) (Eng. Abstr.) Comment in: HNO 1997 Jun;45(6):424. **(Ger)**
[Nosocomial infections in head and neck surgery. 1] Vössing M, et al. **HNO** 1996 Feb;44(2):61–7 (58 ref.) (Eng. Abstr.) **(Ger)**
[Local anesthesia in operations of the head–neck area] Grevers G, et al. **Laryngorhinootologie** 1996 Jul;75(7):433–6 (10 ref.) (Eng. Abstr.) **(Ger)**

OTORHINOLARYNGOLOGY see **OTOLARYNGOLOGY**

OTOSCLEROSIS

DRUG THERAPY

Etidronate for the the neurotologic symptoms of otosclerosis: preliminary study. Brookler KH, et al.
Ear Nose Throat J 1997 Jun;76(6):371–6, 379–81 (144 ref.)

ETIOLOGY

Tympanosclerosis. Wielinga EW, et al. **Clin Otolaryngol** 1993 Oct;18(5):341–9 (76 ref.)

PHYSIOPATHOLOGY

Tympanosclerosis. Wielinga EW, et al. **Clin Otolaryngol** 1993 Oct;18(5):341–9 (76 ref.)

SURGERY

Choice, advice and assessment of patients for ear surgery. Browning GG. **J R Soc Med** 1996 Oct;89(10):571–6 (6 ref.)

OTOSPONGIOSIS see **OTOSCLEROSIS**

OUABAIN

METABOLISM

Search for an endogenous mammalian cardiotonic factor. Nakanishi K, et al. **Adv Exp Med Biol** 1996;404:219–24 (11 ref.)
Endogenous ouabain: role in the pathogenesis of hypertension. Blaustein MP. **Kidney Int** 1996 Jun; 49(6):1748–53 (41 ref.)

OUTBREAKS see **DISEASE OUTBREAKS**

OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE)

Assessment issues and domains in the prediction of relapse. Donovan DM. **Addiction** 1996 Dec;91 Suppl:S29–36 (22 ref.)
Assessing health and quality of life outcomes in dialysis: a report on an Institute of Medicine workshop. Rettig RA, et al. **Am J Kidney Dis** 1997 Jul;30(1):140–55 (85 ref.)
Computer aids to treatment in psychiatry. Kirkby KC, et al. **Aust N Z J Psychiatry** 1996 Feb;30(1):142–5 (20 ref.)
Psychotherapy outcome research in child psychiatric disorders. Pearsall DF. **Can J Psychiatry** 1997 Aug; 42(6):595–601 (62 ref.)
Outcomes and process in genetic counselling. Clarke A, et al. **Clin Genet** 1996 Dec;50(6):462–9 (63 ref.)
Introducing Critical Appraisal to studies of animal models investigating novel therapies in sepsis. Piper RD, et al. **Crit Care Med** 1996 Dec;24(12):2059–70 (111 ref.)
Outcomes–oriented research and managed care. Chelmow D. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):293–5 (15 ref.)
Interventions for caregivers of patients with Alzheimer's disease: a review and analysis of content, process, and outcomes. Bourgeois MS, et al. **Int J Aging Hum Dev** 1996; 43(1):35–92 (117 ref.)
An industrial process view of information delivery to support clinical decision making: implications for systems design and process measures. Elson RB, et al.
J Am Med Inform Assoc 1997 Jul–Aug;4(4):266–78 (95 ref.)
The evolving role of outcomes measurement and management in healthcare. Licciardone JC.
J Am Osteopath Assoc 1997 May;97(5):290–2 (17 ref.)
Evaluating outcomes in ethics consultation research. Fox E, et al. **J Clin Ethics** 1996 Summer;7(2):127–38 (47 ref.)
Patient–focused models of care. Pence M.
J Obstet Gynecol Neonatal Nurs 1997 May–Jun;26(3):320–6 (18 ref.)
Electronic communication with patients. Evaluation of distance medicine technology. Balas EA, et al. **JAMA** 1997 Jul 9;278(2):152–9 (93 ref.)
The role of cost–effectiveness analysis in health and medicine. Panel on Cost–Effectiveness in Health and Medicine [see comments] Russell LB, et al. **JAMA** 1996 Oct 9; 276(14):1172–7 (51 ref.) Comment in: JAMA 1996 Oct 9;276(14):1180.
Recommendations for reporting cost–effectiveness analyses. Panel on Cost–Effectiveness in Health and Medicine [see comments] Siegel JE, et al. **JAMA** 1996 Oct 23–30; 276(16):1339–41 (17 ref.) Comment in: JAMA 1997 Feb 5;277(5):375.
Recommendations of the Panel on Cost–effectiveness in Health and Medicine. Weinstein MC, et al. **JAMA** 1996 Oct 16;276(15):1253–8 (23 ref.)
The outcomes of very low birth weight infants: are we asking the right questions? McCormick MC. **Pediatrics** 1997 Jun; 99(6):869–76 (89 ref.)
Principles for assessment of patient outcomes in mental health care. Smith GR Jr, et al. **Psychiatr Serv** 1997 Aug; 48(8):1033–6 (14 ref.)
Quality of mental health service care: the forgotten pathway from process to outcome. Brugha TS, et al.
Soc Psychiatry Psychiatr Epidemiol 1996 Mar;31(2):89–98 (72 ref.)
A conceptual framework for the study of early readmission as an indicator of quality of care. Ashton CM, et al.
Soc Sci Med 1996 Dec;43(11):1533–41 (39 ref.)
[Quality evaluation in endoscopy] Riemann JF, et al.
Internist (Berl) 1996 Aug;37(8):830–8 (27 ref.) **(Ger)**
[Goals in rehabilitation: assessment and outcome evaluation] Meier–Baumgartner HP, et al. **Ther Umsch** 1997 Jun; 54(6):337–9 (22 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

The consequence of production loss or increased costs of production. Koopmanschap MA, et al. **Med Care** 1996 Dec; 34(12 Suppl):DS59–68 (22 ref.)
The proper role for discounting. Search in progress. Lipscomb J. **Med Care** 1996 Dec;34(12 Suppl):DS119–23 (15 ref.)

ORGANIZATION & ADMINISTRATION

Managed care in benign gynecology. Gambone JC, et al. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):314–8 (11 ref.)
Evaluation in clinical practice: problems, precedents and principles. McIntyre N. **J Eval Clin Pract** 1995 Sep; 1(1):5–13 (24 ref.)
Outcomes management in women's health. Houston S, et al. **J Obstet Gynecol Neonatal Nurs** 1997 May–Jun; 26(3):342–50 (19 ref.)
Achieving outcomes through organizational redesign. Strong A, et al. **Nurs Clin North Am** 1997 Sep;32(3):603–14 (16 ref.)

STANDARDS

Early detection and intervention in schizophrenia: research. McGlashan TH. **Schizophr Bull** 1996;22(2):327–45 (34 ref.)

STATISTICS & NUMERICAL DATA

Alcohol treatment outcome methodology: state of the art 1989–1993. Breslin FC, et al. **Addict Behav** 1997 Mar–Apr; 22(2):145–55 (75 ref.)
Basics of stratifying for severity of illness. Gross PA.
Infect Control Hosp Epidemiol 1996 Oct;17(10):675–86 (57 ref.)
The impact of immunization control activities on measles outbreaks in middle and low income countries. Aylward RB, et al. **Int J Epidemiol** 1997 Jun;26(3):662–9 (68 ref.)
Survival analysis in observational studies. Bull K, et al.
Stat Med 1997 May 15;16(9):1041–74 (31 ref.)

TRENDS

Acute renal failure in the 21st century: recommendations for management and outcomes assessment. DuBose TD Jr, et al. **Am J Kidney Dis** 1997 May;29(5):793–9 (31 ref.)

OUTCOME ASSESSMENT (HEALTH CARE)

Alcoholism treatment outcome studies, 1980–1992: the nature of the research. Floyd AS, et al. **Addict Behav** 1996 Jul–Aug;21(4):413–28 (16 ref.)

Redefining success in eating disorders. Miller PM. **Addict Behav** 1996 Nov–Dec;21(6):745–54 (40 ref.)

Outcomes research in Helicobacter pylori infection. Fendrick AM. **Aliment Pharmacol Ther** 1997 Apr;11 Suppl 1:95–101 (19 ref.)

Improving the quality of outcomes research involving pharmaceutical services. Holdford DA, et al. **Am J Health Syst Pharm** 1997 Jun 15;54(12):1434–42 (109 ref.)

Hypertension and outcomes research. From clinical trials to clinical epidemiology. Psaty BM, et al. **Am J Hypertens** 1996 Feb;9(2):178–83 (38 ref.)

Outcome studies in industry: cost–effectiveness of cumulative trauma disorder prevention. Mitchell CS. **Am J Ind Med** 1996 Jun;29(6):689–96 (34 ref.)

Is self–reported pain an appropriate outcome measure in ergonomic–epidemiologic studies of work–related musculoskeletal disorders? Schierhout GH, et al. **Am J Ind Med** 1996 Jul;30(1):93–8 (45 ref.)

Unilateral vs. bilateral carpal tunnel: challenges and approaches. Stanek EJ 3rd, et al. **Am J Ind Med** 1996 Jun; 29(6):669–78 (14 ref.)

Rehabilitation intervention for patients with upper extremity dysfunction: challenges of outcome evaluation. Stiens SA, et al. **Am J Ind Med** 1996 Jun;29(6):590–601 (72 ref.)

Modeling case mix adjustment of stroke rehabilitation outcomes. Segal ME, et al. **Am J Phys Med Rehabil** 1997 Mar–Apr;76(2):154–61 (74 ref.)

Measuring anaesthetic outcomes. Lee A, et al. **Anaesth Intensive Care** 1996 Dec;24(6):685–93 (82 ref.)

Costs, outcomes, and patient satisfaction by provider type for patients with rheumatic and musculoskeletal conditions: a critical review of the literature and proposed methodologic standards [see comments] Solomon DH, et al. **Ann Intern Med** 1997 Jul 1;127(1):52–60 (35 ref.) Comment in: Ann Intern Med 1997 Jul 1;127(1):72–4.

Clinical outcomes assessment in multiple sclerosis. Rudick R, et al. **Ann Neurol** 1996 Sep;40(3):469–79 (47 ref.)

Peering into the 'black box'. Measuring outcomes of managed care. Pincus HA, et al. **Arch Gen Psychiatry** 1996 Oct; 53(10):870–7 (55 ref.)

Can we achieve accountability for long–term outcomes? Batterham RW, et al. **Arch Phys Med Rehabil** 1996 Dec; 77(12):1219–25 (76 ref.)

Postacute neurorehabilitation: roles and responsibilities within a national information system. Evans RW. **Arch Phys Med Rehabil** 1997 Aug;78(8 Suppl 4):S17–25 (38 ref.)

Functional outcome measures to assess interventions for spasticity. Hinderer SR, et al. **Arch Phys Med Rehabil** 1996 Oct;77(10):1083–9 (54 ref.)

Patient outcomes used by advanced practice psychiatric nurses to evaluate effectiveness of practice. Barrell LM, et al. **Arch Psychiatr Nurs** 1997 Aug;11(4):184–97 (13 ref.)

Preventable death studies: an inappropriate tool for evaluating trauma systems. Kelly AM, et al. **Aust N Z J Surg** 1997 Sep;67(9):591–2 (25 ref.)

A critical review of marital therapy outcome research [see comments] Wesley S, et al. **Can J Psychiatry** 1996 Sep; 41(7):421–8 (22 ref.) Comment in: Can J Psychiatry 1996 Sep;41(7):419–20. Comment in: Can J Psychiatry 1997 Apr;42(3):323–4.

Assessing health–related quality of life in patients with genitourinary malignancies. Litwin MS. **Cancer Treat Res** 1996;88:249–64 (94 ref.)

Use of cardiac markers as assessed by outcomes analysis. Wu AH. **Clin Biochem** 1997 Jun;30(4):339–50 (87 ref.)

Outcomes assessment in hand surgery. What's new? Amadio PC. **Clin Plast Surg** 1997 Jan;24(1):191–4 (24 ref.)

Reliability and validity of clinical outcome measurements of osteoarthritis of the hip and knee—a review of the literature. Sun Y, et al. **Clin Rheumatol** 1997 Mar; 16(2):185–98 (65 ref.)

Economic outcomes and costs in the treatment of schizophrenia. Knapp M, et al. **Clin Ther** 1997 Jan–Feb; 19(1):128–38; discussion 126–7 (32 ref.)

Skewed distributions—new outcome measures. Spencer AJ. **Community Dent Oral Epidemiol** 1997 Feb;25(1):52–9 (47 ref.)

ICU scoring systems allow prediction of patient outcomes and comparison of ICU performance. Becker RB, et al. **Crit Care Clin** 1996 Jul;12(3):503–14 (53 ref.)

Does pulmonary artery catheter use change outcome? Yes. Del Guercio LR. **Crit Care Clin** 1996 Jul;12(3):553–7 (14 ref.)

Does increasing oxygen delivery improve outcome? Yes. Kelly KM. **Crit Care Clin** 1996 Jul;12(3):635–44 (42 ref.)

Do pulmonary artery catheters improve patient outcome? No. Leibowitz AB. **Crit Care Clin** 1996 Jul;12(3):559–68 (39 ref.)

Does increasing oxygen delivery improve outcome in the critically ill? No. Ronco JJ, et al. **Crit Care Clin** 1996 Jul; 12(3):645–59 (47 ref.)

ICU scoring systems do not allow prediction of patient outcomes or comparison of ICU performance. Sherck JP, et al. **Crit Care Clin** 1996 Jul;12(3):515–23 (41 ref.)

Measuring effectiveness and outcomes of interventions for renal disease. Powe NR. **Curr Opin Nephrol Hypertens** 1996 May;5(3):230–5 (37 ref.)

Health assessment in the rheumatic diseases of childhood. Duffy CM, et al. **Curr Opin Rheumatol** 1997 Sep;9(5):440–7 (49 ref.)

Outcome in pediatric rheumatic disease. Graham TB, et al. **Curr Opin Rheumatol** 1997 Sep;9(5):434–9 (32 ref.)

Defining outcomes in older patients with cardiovascular disease. Pashos CL. **Drugs Aging** 1997 Apr;10(4):243–8 (36 ref.)

Application of clinical trials to the care of patients with bladder cancer. Hall RR. **Eur Urol** 1997;31 Suppl 1:42–6 (29 ref.)

An assessment of the use of costs and quality of life as outcomes in endoscopic research. Sahai AV, et al. **Gastrointest Endosc** 1997 Aug;46(2):113–8 (75 ref.)

Who is holding whom accountable for quality? [see comments] Gosfield AG. **Health Aff (Millwood)** 1997 May–Jun;16(3):26–40 (21 ref.) Comment in: Health Aff (Millwood) 1997 May–Jun;16(3):41–3.

The impact of age on cost–effectiveness ratios and its control in decision making. Baltussen R, et al. **Health Econ** 1996 May–Jun;5(3):227–39 (40 ref.)

Health promotion community development and the tyranny of individualism. Shiell A, et al. **Health Econ** 1996 May–Jun;5(3):241–7 (61 ref.)

Outcomes research in orthopaedics. Keller RB, et al. **Instr Course Lect** 1994;43:599–611 (23 ref.)

Outcome assessment after fracture in the elderly. Skovron ML, et al. **Instr Course Lect** 1997;46:439–43 (19 ref.)

"My patients are sicker": adjusting outcomes by severity of illness. Hopkins DS. **Int Anesthesiol Clin** 1995 Fall; 33(4):33–47 (15 ref.)

Monitoring and analysis of outcome studies. Lagasse RS. **Int Anesthesiol Clin** 1996 Summer;34(3):263–77 (37 ref.)

Defining value in health care: outcomes. Macario A. **Int Anesthesiol Clin** 1995 Fall;33(4):15–31 (76 ref.)

The International Classification for Nursing Practice (ICNP): nursing outcomes. Clark J, et al. **Int Nurs Rev** 1997 Jul–Aug;44(4):121–4 (21 ref.)

Measuring outcomes in Alzheimer's disease. Montgomery RJ. **Int Psychogeriatr** 1996;8 Suppl 1:13–6 (13 ref.)

Outcomes research: an overview. Faust HB, et al. **J Am Acad Dermatol** 1997 Jun;36(6 Pt 1):999–1006 (47 ref.)

Functional outcomes for the patient with burn injuries. Staley M, et al. **J Burn Care Rehabil** 1996 Jul–Aug;17(4):362–8 (38 ref.)

Outcome assessment in cardiac rehabilitation. Health–related quality of life and economic evaluation. Oldridge NB. **J Cardiopulm Rehabil** 1997 May–Jun;17(3):179–94 (169 ref.)

Anesthesia information–management systems: their role in risk–versus cost assessment and outcomes research. Gibby GL. **J Cardiothorac Vasc Anesth** 1997 Apr;11(2 Suppl 1):2–5; discussion 24–5 (22 ref.)

Outcome of anorexia nervosa in the younger patient. Steinhausen HC. **J Child Psychol Psychiatry** 1997 Mar; 38(3):271–6 (40 ref.)

Demystifying the concept of ethnicity for psychotherapy researchers. Alvidrez J, et al. **J Consult Clin Psychol** 1996 Oct;64(5):903–8 (50 ref.)

Effective practice. Hunter DJ. **J Eval Clin Pract** 1995 Nov; 1(2):131–4 (12 ref.)

Measuring the effects of casemix on outcomes. Orchard C. **J Eval Clin Pract** 1996 May;2(2):111–21 (80 ref.)

Internal medicine residency training and outcomes [see comments] Griffith CH 3rd, et al. **J Gen Intern Med** 1997 Jun;12(6):390–6 (53 ref.) Comment in: J Gen Intern Med 1997 Jun;12(6):399–400.

Outcomes research in chiropractic: the state of the art and recommendations for the chiropractic research agenda. Nyiendo J, et al. **J Manipulative Physiol Ther** 1997 Mar–Apr;20(3):185–200 (77 ref.)

Modern management of spinal disorders. Waddell G. **J Manipulative Physiol Ther** 1995 Nov–Dec;18(9):590–6 (14 ref.)

Health outcomes research on Hispanics/Latinos. Giachello AL. **J Med Syst** 1996 Oct;20(5):235–54 (41 ref.)

Hispanic/Latino health outcomes research. Introduction to special issue. Gray J, et al. **J Med Syst** 1996 Oct; 20(5):229–33 (23 ref.)

Selecting patients with ischemic cardiomyopathy for medical treatment, revascularization, or heart transplantation. Beller GA. **J Nucl Cardiol** 1997 Mar–Apr;4(2 Pt 2):S152–7 (27 ref.)

Nurse–sensitive health care outcomes in acute care settings: an integrative analysis of the literature. Pierce SF. **J Nurs Care Qual** 1997 Apr;11(4):60–72 (56 ref.)

Methods of clinical evaluation of dental restorative materials. Knibbs PJ. **J Oral Rehabil** 1997 Feb;24(2):109–23 (174 ref.)

Validation of dental implant systems through a review of literature supplied by system manufacturers. Eckert SE, et al. **J Prosthet Dent** 1997 Mar;77(3):271–9 (157 ref.)

Outcome measures in palliative care for advanced cancer patients: a review. Hearn J, et al. **J Public Health Med** 1997 Jun;19(2):193–9 (22 ref.)

Systematic literature review: outcome measures for child and adolescent mental health services. Hunter J, et al. **J Public Health Med** 1996 Jun;18(2):197–206 (90 ref.)

Healthcare outcomes management and quality improvement. al–Assaf AF. **J R Soc Health** 1996 Aug;116(4):245–52 (47 ref.)

The assessment of disability and handicap in musculoskeletal disease. McFarlane AC, et al. **J Rheumatol** 1997 May; 24(5):985–9 (16 ref.)

Creation of a specialized nutrition support outcomes research consortium: if not now, when? [see comments] August DA. **JPEN J Parenter Enteral Nutr** 1996 Nov–Dec; 20(6):394–400 (42 ref.) Comment in: JPEN J Parenter Enteral Nutr 1996 Nov–Dec;20(6):383–4.

Outcome analysis: considerations for an electronic health record. Dolin RH. **MD Comput** 1997 Jan–Feb;14(1):50–6 (64 ref.)

Rehabilitation care and outcomes from the patient's perspective. Kramer AM. **Med Care** 1997 Jun;35(6 Suppl):JS48–57; discussion JS58–63 (20 ref.)

Can clinical practice guidelines increase the cost–effectiveness of geriatric rehabilitation? Stason WB. **Med Care** 1997 Jun;35(6 Suppl):JS68–77; discussion JS78–83 (2 ref.)

The relationship between descriptive and valuational quality–of–life measures in patients with intermittent claudication. Bosch JL, et al. **Med Decis Making** 1996 Jul–Sep;16(3):217–25 (29 ref.)

A criticism of healthy–years equivalents [see comments] Wakker P. **Med Decis Making** 1996 Jul–Sep;16(3):207–14 (30 ref.) Comment in: Med Decis Making 1996 Jul–Sep;16(3):215–6.

Estimating the risks of cardiac surgery [editorial; comment] Dobb GJ. **Med J Aust** 1997 Apr 21;166(8):397–8 (18 ref.) Comment on: Med J Aust 1997 Apr 21;166(8):408–11.

What drives outcomes for emotional and behavioral disorders in children and adolescents? Burns BJ. **New Dir Ment Health Serv** 1996 Fall;(71):89–102 (44 ref.)

Outcomes of psychiatric rehabilitation service delivery. Cook JA, et al. **New Dir Ment Health Serv** 1996 Fall;(71):33–47 (74 ref.)

How will mental health outcomes data be used in private systems. Feldman J. **New Dir Ment Health Serv** 1996 Fall; (71):103–9 (10 ref.)

Using outcomes measurement to improve quality and value. Nelson EC. **New Dir Ment Health Serv** 1996 Fall; (71):111–24 (25 ref.)

Ethnic minority populations and mental health outcomes. Snowden LR. **New Dir Ment Health Serv** 1996 Fall; (71):79–87 (41 ref.)

Whose outcomes. Patients, providers, or payers? Kleinpell RM. **Nurs Clin North Am** 1997 Sep;32(3):513–20 (21 ref.)

Challenges in measuring patient outcomes. Strickland OL. **Nurs Clin North Am** 1997 Sep;32(3):495–512 (23 ref.)

Outcomes research methods in nutritional support. August DA. **Nutrition** 1996 Oct;12(10):724–5 (9 ref.)

Outcomes research as an integral part of practice. Gottschlich MM. **Nutrition** 1997 Feb;13(2):168–70 (23 ref.)

Multidimensional measures of outcomes research. Voss AC, et al. **Nutrition** 1996 Mar;12(3):220–1 (3 ref.)

Assessment of physical and behavioral outcomes of treatment. LeResche L. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jan;83(1):82–6 (26 ref.)

Overview of health–related quality–of–life measures for pediatric patients: application in the assessment of pharmacotherapeutic and pharmacoeconomic outcomes. Marra CA, et al. **Pharmacotherapy** 1996 Sep–Oct; 16(5):879–88 (81 ref.)

Strategies to evaluate quality clinical outcomes. Shinn JA. **Prog Cardiovasc Nurs** 1997 Winter;12(1):44–6 (2 ref.)

A typology of the potential outcomes of maternal–child home visits: a literature analysis. Byrd ME. **Public Health Nurs** 1997 Feb;14(1):3–11 (34 ref.)

The problem of quality of life [editorial] Hunt SM. **Qual Life Res** 1997 Apr;6(3):205–12 (54 ref.)

Quality of life as an outcome measure in evaluating mental health services: a review of the empirical evidence. Barry MM, et al. **Soc Psychiatry Psychiatr Epidemiol** 1997 Jan; 32(1):38–47 (32 ref.)

QALYs and mental health care. Chisholm D, et al. **Soc Psychiatry Psychiatr Epidemiol** 1997 Feb;32(2):68–75 (44 ref.)

Measuring the quality of life of severely mentally ill people using the Lancashire Quality of Life Profile. Oliver JP, et al. **Soc Psychiatry Psychiatr Epidemiol** 1997 Feb; 32(2):76–83 (24 ref.)

Composite outcome measures in alcoholism treatment research: problems and potentialities. Zweben A, et al. **Subst Use Misuse** 1996 Nov;31(13):1783–805 (36 ref.)

[Contributions of epidemiology to therapeutic decisions in psychiatry] Hardy P. **Encephale** 1996 Jul–Aug;22(4):264–9 (39 ref.) (Eng. Abstr.) **(Fre)**

[Outcomes research exemplified by infection] Witthaut R, et al. **Internist (Berl)** 1996 Dec;37(12):1249–59 (35 ref.) **(Ger)**

[Patient satisfaction—artefact or social reality?] Leimkühler AM, et al. **Nervenarzt** 1996 Sep;67(9):765–73 (54 ref.) (Eng. Abstr.) **(Ger)**

[Medical performance: ethical and conceptual issues] Widder J. **Wien Klin Wochenschr** 1996;108(19):621–6 (30 ref.) (Eng. Abstr.) **(Ger)**

[Investigation methods in clinical cardiology. VI. Evaluation of results (outcomes) and its clinical relevance in cardiology: with a special reference to the quality of life] Brotons Cuixart C, et al. **Rev Esp Cardiol** 1997 Mar; 50(3):192–200 (44 ref.) (Eng. Abstr.) **(Spa)**

OUTCOME ASSESSMENT (HEALTH CARE)

CLASSIFICATION

Implications of nursing taxonomies for middle-range theory development. Blegen MA, et al. **ANS Adv Nurs Sci** 1997 Mar;19(3):37-49 (34 ref.)

ECONOMICS

The use of claims databases for outcomes research: rationale, challenges, and strategies. Motheral BR, et al. **Clin Ther** 1997 Mar-Apr;19(2):346-66 (74 ref.)

Outcomes research and cost-effectiveness analysis in radiology. Hunink MG. **Eur Radiol** 1996;6(5):615-20 (37 ref.)

Proper preference-based outcome measures in economic evaluations of pharmaceutical interventions. Gafni A. **Med Care** 1996 Dec;34(12 Suppl):DS48-58 (59 ref.)

ORGANIZATION & ADMINISTRATION

British studies which measure patient outcome, 1990-1994. French B. **J Adv Nurs** 1997 Aug;26(2):320-8 (27 ref.)

Case mix adjustment in comparative audit. Hayes C, et al. **J Eval Clin Pract** 1995 Nov;1(2):105-11 (37 ref.)

Monitoring outcomes in routine practice: defining appropriate measurement criteria. Long AF, et al. **J Eval Clin Pract** 1996 Feb;2(1):71-8 (22 ref.)

Getting there from here: evidentiary quandaries of the US outcomes movement. Tanenbaum S. **J Eval Clin Pract** 1995 Nov;1(2):97-103 (26 ref.)

Disablement outcomes in geriatric rehabilitation. Jette AM. **Med Care** 1997 Jun;35(6 Suppl):JS28-37; discussion JS38-44 (25 ref.)

Toward collaborative mental health outcomes systems. Campbell J. **New Dir Ment Health Serv** 1996 Fall; (71):69-78 (45 ref.)

Nurses at the bedside. Influencing outcomes. Lamb-Havard J. **Nurs Clin North Am** 1997 Sep;32(3):579-87 (7 ref.)

The role of the Agency for Health Care Policy and Research (AHCPR) in improving outcomes of care. McCormick KA, et al. **Nurs Clin North Am** 1997 Sep;32(3):521-42 (14 ref.)

Outcomes research. Clues to quality and organizational effectiveness? Mark BA, et al. **Nurs Clin North Am** 1997 Sep;32(3):589-601 (24 ref.)

The benefits of continuous performance measurement. Nadzam DM, et al. **Nurs Clin North Am** 1997 Sep; 32(3):543-59 (13 ref.)

A focused strategic plan for outcomes evaluation. Stonestreet JS, et al. **Nurs Clin North Am** 1997 Sep;32(3):615-31 (12 ref.)

Measuring nursing. Nielsen GH. **WHO Reg Publ Eur Ser** 1997;74:241-55 (14 ref.)

STANDARDS

What meta-analyses have and have not taught us about psychotherapy effects: a review and future directions. Matt GE, et al. **Clin Psychol Rev** 1997;17(1):1-32 (114 ref.)

Outcome measurement in economic evaluation [see comments] Johannesson M, et al. **Health Econ** 1996 Jul-Aug;5(4):279-96 (73 ref.) Comment in: Health Econ 1997 Jan-Feb;6(1):91-3.

Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. Bellamy N, et al. **J Rheumatol** 1997 Apr;24(4):799-802 (6 ref.)

Assessing clinical outcomes: the community functioning of persons with serious mental illness. Dickerson FB. **Psychiatr Serv** 1997 Jul;48(7):897-902 (51 ref.)

STATISTICS & NUMERICAL DATA

International comparisons of critical care outcome and resource consumption. Angus DC, et al. **Crit Care Clin** 1997 Apr;13(2):389-407 (85 ref.)

The dilemma of factitious demographic distinctions in psychological research. Beutler LE, et al. **J Consult Clin Psychol** 1996 Oct;64(5):892-902 (50 ref.)

Methodological issues of randomized controlled trials for the evaluation of reproductive health interventions. Villar J, et al. **Prev Med** 1996 May-Jun;25(3):365-75 (53 ref.)

TRENDS

What are outcomes? Mullins CD, et al. **J Am Pharm Assoc (Wash)** 1996 Jan;NS36(1):39-49 (46 ref.)

Psychiatric interventions in the medically ill. Outcome and effectiveness research. Saravay SM. **Psychiatr Clin North Am** 1996 Sep;19(3):467-80 (66 ref.)

OUTCOME MEASUREMENT ERRORS see **BIAS (EPIDEMIOLOGY)**

OUTCOMES RESEARCH see **OUTCOME ASSESSMENT (HEALTH CARE)**

OUTER MEMBRANE PROTEINS, BACTERIAL see **BACTERIAL OUTER MEMBRANE PROTEINS**

OUTPATIENT CARE see **AMBULATORY CARE**

OUTPATIENT CLINICS, HOSPITAL

see related
AMBULATORY CARE

Teaching in the outpatient clinic. Practical tips. McGee SR, et al. **J Gen Intern Med** 1997 Apr;12 Suppl 2:S34-40 (29 ref.)

OUTPATIENT HEALTH SERVICES see **AMBULATORY CARE**

OUTPATIENT INFUSION THERAPY see **HOME INFUSION THERAPY**

OUTPATIENT MONITORING see **MONITORING, AMBULATORY**

OUTPATIENT SURGERY see **AMBULATORY SURGERY**

OUTPATIENTS

Outpatient antibiotic therapy for febrile episodes in low-risk neutropenic patients with cancer. Escalante CP, et al. **Cancer Invest** 1997;15(3):237-42 (25 ref.)

Meaningful linkage practices: challenges and opportunities. Boyer CA. **New Dir Ment Health Serv** 1997 Spring; (73):87-101 (54 ref.)

[Safe use of anesthetic drugs outside the operating room] Rudich Z, et al. **Harefuah** 1996 Jun 2;130(11):784-6 (11 ref.) **(Heb)**

[The conservative treatment for lumbar disc herniation] Maruo S. **Nippon Seikeigeka Gakkai Zasshi** 1996 Oct; 70(10):673-84 (40 ref.) **(Jpn)**

[White coat hypertension] Matsubayashi K. **Ryoikibetsu Shokogun Shirizu** 1996;(12):151-4 (13 ref.) **(Jpn)**

[Programmed complex for automated prophylactic check-ups of chronic outpatients. Communication 1. Tasks and fundamentals] Lapochkin VI, et al. **Vestn Oftalmol** 1997 Mar-Apr;113(2):32-4 (0 ref.) (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

Incorporating outpatient perceptions into definitions of quality. Hart M. **J Adv Nurs** 1996 Dec;24(6):1234-40 (36 ref.)

OVALOCYTOSIS, HEREDITARY see **ELLIPTOCYTOSIS, HEREDITARY**

OVARIAN CYCLE see **MENSTRUAL CYCLE**

OVARIAN CYSTS

see related
OVARIAN HYPERSTIMULATION SYNDROME

Hyperreactio luteinalis complicating a normal singleton pregnancy. Lambers DS, et al. **Am J Perinatol** 1996 Nov; 13(8):491-4 (15 ref.)

COMPLICATIONS

Salmonella enteritidis in an endometriotic ovarian cyst. Burgmans JP, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Apr;72(2):207-11 (18 ref.)

ETIOLOGY

Neonatal ovarian cysts: pathogenesis, diagnosis and management. Schmahmann S, et al. **Pediatr Radiol** 1997 Feb;27(2):101-5 (23 ref.)

PATHOLOGY

Malignant struma ovarii. A case report and review of the literature. Berghella V, et al. **Gynecol Obstet Invest** 1997; 43(1):68-72 (20 ref.)

SURGERY

Laparoscopic surgery for ovarian cysts. Audebert AJ. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):261-5 (20 ref.)

[Laparoscopic surgery in benign ovarian cysts] Feng F, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Jun;31(6):375-7 (20 ref.) **(Chi)**

ULTRASONOGRAPHY

Fetal ovarian torsion appearing as a solid abdominal mass. Katz VL, et al. **J Perinatol** 1996 Jul-Aug;16(4):302-4 (37 ref.)

Office management of ovarian cysts. Magrina JF, et al. **Mayo Clin Proc** 1997 Jul;72(7):653-6 (35 ref.)

Sonographic evaluation of ovarian masses and its therapeutical implications [editorial] Osmers R. **Ultrasound Obstet Gynecol** 1996 Oct;8(4):217-22 (60 ref.)

[The role of transvaginal ultrasonography in the screening of ovarian tumors] De Rosa G, et al. **Minerva Ginecol** 1997 Jun;49(6):243-9 (47 ref.) (Eng. Abstr.) **(Ita)**

VETERINARY

Ovarian follicular cysts in dairy cows. Garverick HA. **J Dairy Sci** 1997 May;80(5):995-1004 (98 ref.)

OVARIAN DISEASES

COMPLICATIONS

Acute small bowel obstruction caused by endometriosis. Martín-Duce A, et al. **Eur J Surg** 1996 Sep;162(9):747-9 (41 ref.)

DIAGNOSIS

[Ovarian torsion in pregnancy with a dermoid] Forstner R, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Jan;166(1):84-6 (9 ref.) **(Ger)**

ETIOLOGY

Perspectives on ovarian dysfunction and autoimmunity. Moncayo HE, et al. **Horm Metab Res** 1995 Dec; 27(12):544-6 (35 ref.)

GENETICS

Hereditary ovarian cancer. Langston AA, et al. **Curr Opin Obstet Gynecol** 1997 Feb;9(1):3-7 (50 ref.)

THERAPY

Occult ovarian failure. Healy DL. **Curr Ther Endocrinol Metab** 1997;6:226-7 (6 ref.)

ULTRASONOGRAPHY

Ovarian ultrasound. Pilling DW. **Br J Hosp Med** 1997 Jan 15-Feb 5;57(1-2):15-8 (14 ref.)

Regarding the best approach to the pyosalpinx [comment] Parsons AK. **Ultrasound Obstet Gynecol** 1996 Jun; 7(6):398-400 (20 ref.) Comment on: Ultrasound Obstet Gynecol 1996 Jun;7(6):435-8. Comment on: Ultrasound Obstet Gynecol 1996 Jun;7(6):439-42.

OVARIAN FAILURE, PREMATURE

Premature ovarian failure. Barlow DH. **Baillieres Clin Obstet Gynaecol** 1996 Sep;10(3):361-84 (142 ref.)

Premature ovarian failure. Conway GS. **Curr Opin Obstet Gynecol** 1997 Jun;9(3):202-6 (51 ref.)

Premature ovarian failure. Davis SR. **Maturitas** 1996 Feb; 23(1):1-8 (28 ref.)

CHEMICALLY INDUCED

Primary care issues for the breast cancer survivor. Bines J, et al. **Compr Ther** 1997 Sep;23(9):605-11 (48 ref.)

IMMUNOLOGY

Is premature ovarian failure an autoimmune disease? Wheatcroft N, et al. **Autoimmunity** 1997;25(3):157-65 (48 ref.)

Premature ovarian failure and ovarian autoimmunity. Hoek A, et al. **Endocr Rev** 1997 Feb;18(1):107-34 (318 ref.)

OVARIAN FUNCTION TESTS

METHODS

[LH-RH test, clomiphene test, Premarin test, and Kaufmann test] Shimizu Y, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:397-408 (11 ref.) **(Jpn)**

OVARIAN HYPERSTIMULATION SYNDROME

Spontaneous ovarian hyperstimulation syndrome in four consecutive pregnancies. Olatunbosun OA, et al. **Clin Exp Obstet Gynecol** 1996;23(3):127-32 (10 ref.)

[The ovarian hyperstimulation syndrome] Vasiljević M, et al. **Srp Arh Celok Lek** 1996 Jul-Aug;124(7-8):197-200 (22 ref.) (Eng. Abstr.) **(Scc)**

BLOOD

[Ovarian hyper stimulation syndrome and thrombosis] Goto K, et al. **Rinsho Ketsueki** 1996 Sep;37(9):799-807 (27 ref.) **(Jpn)**

IMMUNOLOGY

The immune system in severe ovarian hyperstimulation syndrome. Orvieto R, et al. **Isr J Med Sci** 1996 Dec; 32(12):1180-2 (15 ref.)

METABOLISM

Treatment of polycystic ovary patients undergoing IVF. Barri PN, et al. **J Assist Reprod Genet** 1997 Jan;14(1):10-2 (17 ref.)

PHYSIOPATHOLOGY

The pathophysiology of ovarian hyperstimulation syndrome--views and ideas. Elchalal U, et al. **Hum Reprod** 1997 Jun;12(6):1129-37 (103 ref.)

PREVENTION & CONTROL

The treatment of patients with polycystic ovaries undergoing

IVF. Franks S. **J Assist Reprod Genet** 1997 Jan;14(1):12–4 (12 ref.)
In vitro fertilization treatment in patients with polycystic ovaries. Shulman A, et al. **J Assist Reprod Genet** 1997 Jan; 14(1):7–10 (19 ref.)
Prevention and treatment of ovarian hyperstimulation syndrome. Dourron NE, et al. **Semin Reprod Endocrinol** 1996 Nov;14(4):355–65 (94 ref.)

THERAPY

Prevention and treatment of ovarian hyperstimulation syndrome. Dourron NE, et al. **Semin Reprod Endocrinol** 1996 Nov;14(4):355–65 (94 ref.)
[Ovarian hyperstimulation syndrome—prevention and treatment] Grønlund LA, et al. **Ugeskr Laeger** 1996 Dec 9;158(50):7205–9 (34 ref.) (Eng. Abstr.) **(Dan)**

OVARIAN NEOPLASMS

see related
KRUKENBERG TUMOR
PSEUDOMYXOMA PERITONEI

Ovarian malignancies in adolescence. Fotiou SK. **Ann N Y Acad Sci** 1997 Jun 17;816:338–46 (48 ref.)
Ovarian cancer, from the laboratory to the clinic: challenges for the future. Kaye SB. **Ann Oncol** 1996 Jan;7(1):9–13 (26 ref.)
Ovarian Cancer. Jacobs A. **Clin Symp** 1996;48(2):2–32 (18 ref.)
Two synchronous primary tumors of the ovary and kidney: a case report. Balat O, et al. **Eur J Gynaecol Oncol** 1996; 17(4):257–9 (9 ref.)
An evaluation of prognostic factors in advanced ovarian cancer. Brinkhuis M, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Dec;63(2):115–24 (150 ref.)
Stage IIIC ovarian leiomyosarcoma in a premenopausal woman with multiple recurrences: prolonged survival with surgical therapy. Rasmussen CC, et al. **Gynecol Oncol** 1997 Sep;66(3):519–25 (21 ref.)
Diagnosis and management of malignant germ cell ovarian tumors in young females. Zalel Y, et al. **Int J Gynaecol Obstet** 1996 Oct;55(1):1–10 (64 ref.)
An update on the diagnosis and treatment of common malignant ovarian tumors. Gallup DG. **J Med Assoc Ga** 1997 Sep;86(3):181–5 (33 ref.)
Epithelial ovarian carcinoma [see comments] Kristensen GB, et al. **Lancet** 1997 Jan 11;349(9045):113–7 (76 ref.) Comment in: Lancet 1997 Mar 22;349(9055):878.
Primary malignant melanoma of the ovary. Boscaino A, et al. **Pathologica** 1995 Dec;87(6):685–8 (11 ref.)
Ovarian cancer. Current outlook on this deadly disease. Nahhas WA. **Postgrad Med** 1997 Sep;102(3):112–20 (17 ref.)
[Progresses in gynecology in China, 1996] Lang J. **Chung Hua I Hsueh Tsa Chih** 1996 Dec;76(12):916–7 (0 ref.) **(Chi)**

BLOOD SUPPLY

Ovarian cancer patients with high CA–125 but no symptoms—should antiangiogenic treatments be considered? Sharma A, et al. **Oncol Res** 1997;9(2):53–4 (13 ref.)
Doppler indices in tumors—resolution of a dilemma? [comment] Cosgrove D, et al. **Ultrasound Obstet Gynecol** 1997 Jul;10(1):9–11 (13 ref.) Comment on: Ultrasound Obstet Gynecol 1997 Jul;10(1):41–7. Comment on: Ultrasound Obstet Gynecol 1997 Jul;10(1):48–53.

CHEMICALLY INDUCED

Fertility drugs and ovarian cancer. Artini PG, et al. **Gynecol Endocrinol** 1997 Feb;11(1):59–68 (88 ref.)
Ovarian cancer after successful ovulation induction: a case report. Hull ME, et al. **J Reprod Med** 1996 Jan;41(1):52–4 (16 ref.)
Granulosa cell tumor of the ovary associated with antecedent tamoxifen use. Gherman RB, et al. **Obstet Gynecol** 1994 Oct;84(4 Pt 2):717–9 (11 ref.)
Ovulation induction and ovarian malignancy. Beltsos AN, et al. **Semin Reprod Endocrinol** 1996 Nov;14(4):367–74 (76 ref.)

COMPLICATIONS

Palmar fasciitis and polyarthritis associated with ovarian carcinoma in a young patient. A case report and review of the literature. Vinker S, et al. **Clin Rheumatol** 1996 Sep; 15(5):495–7 (12 ref.)
Spontaneous arterial thrombosis with an advanced ovarian malignancy. Minjarez DA, et al. **Gynecol Oncol** 1997 Jan; 64(1):176–9 (18 ref.)
Ovarian fibromatosis, ascites and omental fibrosis. Scurry J, et al. **Histopathology** 1996 Jan;28(1):81–4 (6 ref.)
Ovarian cancer and unilateral naevoid telangiectasia: a rare association. Pranteda G, et al. **J Exp Clin Cancer Res** 1997 Mar;16(1):71–3 (15 ref.)
An unusual case of urinary incontinence, ataxia–telangiectasia, and metastatic dysgerminoma: case report and review of the literature. deVries CR, et al. **Urology** 1997 Sep;50(3):453–5 (15 ref.)

DIAGNOSIS

Abdominal mass in a young woman. Pitfalls and delayed diagnosis. Case report. Barrenetxea G, et al. **Eur J Gynaecol Oncol** 1996;17(6):507–9 (17 ref.)
Successful outcome of a 9 week pregnancy managed by bilateral salpingo–oophorectomy for ovarian cancer: case report. Colavita M, et al. **Eur J Gynaecol Oncol** 1996; 17(6):522–3 (7 ref.)
Squamous cell carcinoma in mature cystic teratoma in a young woman: a diagnostic and management dilemma. Comerci JT Jr, et al. **Eur J Gynaecol Oncol** 1996; 17(6):501–3 (22 ref.)
Malignant struma ovarii. A case report and review of the literature. Berghella V, et al. **Gynecol Obstet Invest** 1997; 43(1):68–72 (20 ref.)
Underestimation of ovarian pathology: a review. Guida M, et al. **J Chemother** 1997 Apr;9(2):135–7 (10 ref.)
Immunoreactive inhibin, müllerian inhibitory substance, and activin as biochemical markers for juvenile granulosa cell tumors. Silverman LA, et al. **J Pediatr** 1996 Dec; 129(6):918–21 (20 ref.)
Implantation metastasis of ovarian cancer after third–look laparoscopy. Gungor M, et al. **JPMA J Pak Med Assoc** 1996 May;46(5):111–2 (6 ref.)
[Pure embryonal carcinoma of the ovary. A review of the literature apropos of a case] Hulewicz G, et al. **Bull Cancer** 1996 Sep;83(9):718–24 (40 ref.) (Eng. Abstr.) **(Fre)**
[Ovarian torsion in pregnancy with a dermoid] Forstner R, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Jan;166(1):84–6 (9 ref.) **(Ger)**
[Early detection and preoperative diagnosis of ovarian carcinoma] Kainz C. **Wien Med Wochenschr** 1996; 146(1–2):2–7 (30 ref.) (Eng. Abstr.) **(Ger)**
[Problems and contradictions in the screening of ovarian cancer] Bucchi L. **Epidemiol Prev** 1995 Dec;19(65):304–9 (24 ref.) **(Ita)**
[Early cancer in the uterus and ovaries] Fujimura M, et al. **Nippon Rinsho** 1996 May;54(5):1400–4 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Value of CA 125 as a tumor marker in ovarian carcinoma] Barrios CH, et al. **Rev Assoc Med Bras** 1995 Sep–Oct; 41(5):329–32 (33 ref.) (Eng. Abstr.) **(Por)**

DRUG THERAPY

High–dose chemotherapy with autologous stem cell support for the treatment of advanced ovarian cancer—initial experience in Uppsala and Turku. Grenman S, et al. **Acta Obstet Gynecol Scand** 1997 Apr;76(4):363–8 (31 ref.)
Intraperitoneal chemotherapy in the treatment of ovarian cancer. Markman M. **Ann Med** 1996 Aug;28(4):293–6 (19 ref.)
How many more nails to seal the coffin of dose intensity? [editorial] McGuire WP. **Ann Oncol** 1997 Apr;8(4):311–3 (13 ref.)
The role of chemotherapy in the management of celomic epithelial carcinoma of the ovary. Thigpen T, et al. **Cancer Invest** 1997;15(3):277–87 (36 ref.)
The role of high–dose chemotherapy in the management of advanced ovarian cancer. Fennelly D. **Curr Opin Oncol** 1996 Sep;8(5):415–25 (69 ref.)
Paclitaxel and docetaxel in breast and ovarian cancer. **Drug Ther Bull** 1997 Jun;35(6):43–6 (34 ref.)
Gemcitabine in ovarian cancer: an overview of safety and efficacy. Kaufmann M, et al. **Eur J Cancer** 1997 Jan;33 Suppl 1:S31–3 (14 ref.)
Remission of recurrent mixed germ cell tumor of the ovary after treatment with vincristine, carboplatin, fluorouracil, and ifosfamide: a case report and review of the literature. Balat O, et al. **Eur J Gynaecol Oncol** 1996;17(5):342–4 (20 ref.)
Platinum based chemotherapy to treat recurrent Sertoli–Leydig cell ovarian carcinoma during pregnancy. Tomlinson MW, et al. **Eur J Gynaecol Oncol** 1997; 18(1):44–6 (18 ref.)
Clinical trials in patients with epithelial ovarian cancer: past, present and future. Vermorken JB, et al. **Eur J Surg Oncol** 1996 Oct;22(5):455–66 (87 ref.)
Individualized chemotherapeutic regimen for each histological subtype of ovarian carcinoma. Shimizu Y. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:61–9 (14 ref.)
Primary ovarian non–Hodgkin's lymphoma: outcome after treatment with combination chemotherapy. Dimopoulos MA, et al. **Gynecol Oncol** 1997 Mar;64(3):446–50 (20 ref.)
Avascular necrosis following extensive chemotherapy and dexamethasone treatment in a patient with advanced ovarian cancer: case report and review of the literature. Gogas H, et al. **Gynecol Oncol** 1996 Dec;63(3):379–81 (19 ref.)
Growing teratoma syndrome after chemotherapy for germ cell tumors of the ovary. Geisler JP, et al. **Obstet Gynecol** 1994 Oct;84(4 Pt 2):719–21 (9 ref.)
Ovarian cancer patients with high CA–125 but no symptoms—should antiangiogenic treatments be considered? Sharma A, et al. **Oncol Res** 1997;9(2):53–4 (13 ref.)
Prevention of cis–platinum nephrotoxicity in a high–risk patient. Donadio C, et al. **Ren Fail** 1996 Jul;18(4):691–5 (9 ref.)
New options for the treatment of advanced ovarian cancer. Dunton CJ. **Semin Oncol** 1997 Feb;24(1 Suppl 5):S5–2–S5–11 (65 ref.)
Gemcitabine in cisplatin–resistant ovarian cancer. Lund B, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 10):72–6 (20 ref.)
Current status and future directions of platinum/paclitaxel–based chemotherapy of ovarian cancer. Markman M. **Semin Oncol** 1997 Aug;24(4 Suppl 11):S11–24–S11–27 (17 ref.)
Paclitaxel with carboplatin for the treatment of ovarian cancer. Neijt JP, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 15):2–4 (12 ref.)
Chemotherapy of advanced ovarian cancer: current status and future directions. Ozols RF, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2–1–S2–9 (49 ref.)
Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony–stimulating factor? Saltz L, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 5):S5–26–S5–30 (24 ref.)
Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma. ten Bokkel Huinink W, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 5):S5–19–S5–25 (25 ref.)
[Drug therapy of ovarian carcinoma] Dittrich C. **Wien Med Wochenschr** 1996;146(1–2):23–34 (93 ref.) (Eng. Abstr.) **(Ger)**
[Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities] du Bois A, et al. **Zentralbl Gynakol** 1997;119(7):299–323 (330 ref.) (Eng. Abstr.) **(Ger)**
[Chemotherapy for recurrent or advanced persistent epithelial ovarian cancer] Edelman DZ, et al. **Harefuah** 1996 Jul;131(1–2):31–6 (48 ref.) **(Heb)**

EPIDEMIOLOGY

Dietary factors and cancers of breast, endometrium, and ovary: strategies for modifying fat intake in African American women. Hargreaves MK, et al. **Am J Obstet Gynecol** 1997 Jun;176(6):S255–64 (134 ref.)
Estrogen action in human ovarian cancer. Clinton GM, et al. **Crit Rev Oncol Hematol** 1997 Jan;25(1):1–9 (96 ref.)
Hormone replacement therapy and the risk of reproductive cancers. Swan SH. **J Psychosom Obstet Gynaecol** 1997 Jun; 18(2):165–74 (47 ref.)
Does physical activity reduce risk of estrogen–dependent cancer in women? Kramer MM, et al. **Med Sci Sports Exerc** 1996 Mar;28(3):322–34 (117 ref.)
Ovarian intraepithelial neoplasia and ovarian cancer. Gershenson DM, et al. **Obstet Gynecol Clin North Am** 1996 Jun;23(2):475–543 (314 ref.)
[Transitional cell tumor of the ovary. Revision of a 20–year surgical material of the department of pathology at the Mexico General Hospital] Alcántara Vázquez A, et al. **Ginecol Obstet Mex** 1997 Aug;65:339–43 (32 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

The impact of parity, infertility and treatment with fertility drugs on the risk of ovarian cancer. A survey. Mosgaard BJ, et al. **Acta Obstet Gynecol Scand** 1997 Feb;76(2):89–95 (28 ref.)
Is tubal sterilization associated with an increased risk of subsequent hysterectomy but a decreased risk of ovarian cancer? A review of recent literature. Chi IC. **Adv Contracept** 1996 Jun;12(2):77–99 (64 ref.)
Ovarian surface epithelium, ovulation and carcinogenesis. Murdoch WJ. **Biol Rev Camb Philos Soc** 1996 Nov; 71(4):529–43 (128 ref.)
Krukenberg syndrome as a natural manifestation of tumor cell entrapment. Sugarbaker PH, et al. **Cancer Treat Res** 1996;82:163–91 (85 ref.)
Steroid hormones and cancer: (III) observations from human subjects. Miller WR, et al. **Eur J Surg Oncol** 1997 Apr; 23(2):163–77; quiz 177–8, 183 (228 ref.)
Ovarian stimulation and ovarian tumours: a critical reappraisal. Tarlatzis BC, et al. **Hum Reprod Update** 1995 May;1(3):284–301 (121 ref.)

GENETICS

Role of BRCA1 mutation screening in the management of familial ovarian cancer. Berchuck A, et al. **Am J Obstet Gynecol** 1996 Sep;175(3 Pt 1):738–46 (61 ref.)
The role of apoptosis in gynaecological malignancies. Sheets EE, et al. **Ann Med** 1997 Apr;29(2):121–6 (53 ref.)
Molecular approaches to diagnosis and management of ovarian cancer. Katso RM, et al. **Cancer Metastasis Rev** 1997 Jun;16(1–2):81–107 (268 ref.)
The genetics of ovarian cancer: concepts in testing and counseling. Hartenbach EM, et al. **Curr Opin Obstet Gynecol** 1996 Oct;8(5):339–42 (16 ref.)
Issues in the genetic assessment of predispositions for familial breast and ovarian cancer. Mark HF, et al. **Cytobios** 1996; 87(351):229–35 (21 ref.)
Overexpression of the oncogene c–erbB–2 (HER2/neu) in ovarian cancer: a new prognostic factor. Meden H, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Feb;71(2):173–9 (36 ref.)
From bench to bedside... but when? Eng C. **Genome Res** 1997 Jul;7(7):669–72 (29 ref.)
Hereditary ovarian cancer: molecular genetics and clinical implications. Boyd J, et al. **Gynecol Oncol** 1997 Feb; 64(2):196–206 (152 ref.)
The relationship between borderline ovarian tumors and

epithelial ovarian carcinoma: epidemiologic, pathologic, and molecular aspects. Link CJ Jr, et al. **Gynecol Oncol** 1996 Mar;60(3):347–54 (64 ref.)

Molecular biology of human ovarian cancer. Chow SN, et al. **Int Surg** 1996 Apr–Jun;81(2):152–7 (85 ref.)

The biology of ovarian cancer of epithelial origin. Rabinerson D, et al. **Isr J Med Sci** 1996 Nov;32(11):1128–33 (55 ref.)

Genetic susceptibility testing for breast and ovarian cancer: a progress report. Biesecker BB, et al. **J Am Med Womens Assoc** 1997 Winter;52(1):22–7 (82 ref.)

Molecular genetic events in the development and progression of ovarian cancer in humans. Chuaqui RF, et al. **Mol Med Today** 1997 May;3(5):207–13 (49 ref.)

Genetic susceptibility to breast and ovarian cancer. Skolnick MH, et al. **Pathol Biol (Paris)** 1997 Mar;45(3):245–9 (27 ref.)

Recent advances in the molecular genetics of hereditary breast and ovarian cancer. Lancaster JM, et al. **Prog Clin Biol Res** 1997;396:31–51 (136 ref.)

Predisposition testing for breast and ovarian cancer susceptibility. Calzone KA. **Semin Oncol Nurs** 1997 May; 13(2):82–90 (61 ref.)

HER-2/neu signal transduction in human breast and ovarian cancer. Reese DM, et al. **Stem Cells** 1997;15(1):1–8 (85 ref.)

[Candidate genes for the familial forms of breast and ovarian carcinomas (BRCA)] Markov A. **Mol Med (Sofia)** 1996; 1(1):17–20 (19 ref.) **(Bul)**

[The p53 tumor suppressor gene and ovarian cancer] Li G, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Nov; 30(11):698–701 (18 ref.) **(Chi)**

[Clinical significance of ovarian cancer related oncogenes and tumor suppressor genes] Neng J, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Dec;30(12):756–8 (31 ref.) **(Chi)**

[Germ-line mutation of BRCA1 in patients with breast and/or ovarian cancer in high risk families in Northern France] Peyrat JP, et al. **Bull Cancer** 1997 Jan;84(1):41–6 (34 ref.) (Eng. Abstr.) **(Fre)**

[Familial ovarian carcinoma] Speiser P. **Wien Med Wochenschr** 1996;146(1–2):10–3 (35 ref.) (Eng. Abstr.) **(Ger)**

[Familial ovarian cancer] Ben David Y, et al. **Harefuah** 1997 Jun 15;132(12):858–61 (15 ref.) **(Heb)**

[Familial ovarian cancer--detection of the responsible genes] Menczer J. **Harefuah** 1997 Jan 15;132(2):100–3 (41 ref.) **(Heb)**

[Ovarian granulosa cell tumor of juvenile type associated with pregnancy. Clinical case and review of the literature] Bognoni V, et al. **Minerva Ginecol** 1997 Jun;49(6):283–7 (34 ref.) (Eng. Abstr.) **(Ita)**

[Genetic testing of BRCA1 for familial ovarian cancers] Takano M, et al. **Gan To Kagaku Ryoho** 1997 Feb; 24(4):439–42 (19 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

The value of cancer antigen 125 (CA 125) during treatment and follow-up of patients with ovarian cancer. de Bruijn HW, et al. **Curr Opin Obstet Gynecol** 1997 Feb;9(1):8–13 (64 ref.)

[Advances in the research of anti-idiotypic antibody against ovarian cancer] Zhang X, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Sep;31(9):571–4 (26 ref.) **(Chi)**

METABOLISM

Estrogen action in human ovarian cancer. Clinton GM, et al. **Crit Rev Oncol Hematol** 1997 Jan;25(1):1–9 (96 ref.)

Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary. Geisler JP, et al. **Gynecol Oncol** 1996 Mar;60(3):424–7 (18 ref.)

PATHOLOGY

Premenarchal ovarian serous borderline tumor: a case report and review of the literature. Seoud M, et al. **Acta Obstet Gynecol Scand** 1996 Sep;75(8):762–4 (17 ref.)

Malignant ovarian neoplasms. The place of conservative surgery. Tserkezoglou AJ. **Ann N Y Acad Sci** 1997 Jun 17;816:362–8 (16 ref.)

Initial surgical management of advanced epithelial ovarian cancer. Benjamin I, et al. **Cancer Invest** 1997;15(3):270–6 (35 ref.)

Molecular approaches to diagnosis and management of ovarian cancer. Katso RM, et al. **Cancer Metastasis Rev** 1997 Jun;16(1–2):81–107 (268 ref.)

Current status of staging laparotomy in colorectal and ovarian cancer. Boente MP, et al. **Cancer Treat Res** 1996; 82:337–57 (60 ref.)

Growth factors in human ovarian cancer. Westermann AM, et al. **Cancer Treat Rev** 1997 Mar;23(2):113–31 (137 ref.)

Germ cell tumors of the ovary. Talerman A. **Curr Opin Obstet Gynecol** 1997 Feb;9(1):44–7 (18 ref.)

Malignant germ cell tumours in childhood. Pinkerton CR. **Eur J Cancer** 1997 May;33(6):895–901; discussion 901–2 (15 ref.)

Cauda equina metastasis from ovarian malignancy. Rivano C, et al. **Eur J Gynaecol Oncol** 1996;17(5):397–9 (13 ref.)

Individualized chemotherapeutic regimen for each histological subtype of ovarian carcinoma. Shimizu Y. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:61–9 (14 ref.)

Small cell carcinoma of the ovary, hypercalcemic type. A case report with immunohistochemical, ultrastructural and cytophotometric analysis and review of the literature. Förster C, et al. **Gen Diagn Pathol** 1997 Jun; 142(5–6):365–70 (16 ref.)

Significance of lymph node sampling in epithelial carcinoma of the ovary. Carnino F, et al. **Gynecol Oncol** 1997 Jun; 65(3):467–72 (25 ref.)

Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary. Geisler JP, et al. **Gynecol Oncol** 1996 Mar;60(3):424–7 (18 ref.)

Fine-needle aspiration in the diagnosis of metastatic ovarian cancer to the breast. Hennigan CA, et al. **Gynecol Oncol** 1997 Mar;64(3):533–40 (32 ref.)

Recurrent granulosa cell tumor of the ovary 37 years after initial diagnosis: a case report and review of the literature. Hines JF, et al. **Gynecol Oncol** 1996 Mar;60(3):484–8 (33 ref.)

Ovarian carcinoma metastatic to the choroid of the eye. Kushner DM, et al. **Gynecol Oncol** 1997 Jun;65(3):517–9 (6 ref.)

The relationship between borderline ovarian tumors and epithelial ovarian carcinoma: epidemiologic, pathologic, and molecular aspects. Link CJ Jr, et al. **Gynecol Oncol** 1996 Mar;60(3):347–54 (64 ref.)

Is immunostaining with HAM56 antibody useful in identifying ovarian origin of metastatic adenocarcinomas? Cheung AN, et al. **Hum Pathol** 1997 Jan;28(1):91–4 (35 ref.)

Oncological implications in the replacement of ovarian tissue [see comments] Shaw J, et al. **Hum Reprod** 1997 Mar; 12(3):403–5 (16 ref.) Comment in: Hum Reprod 1997 Mar;12(3):403.

Bone metastasis in epithelial ovarian carcinoma. Dinh TV, et al. **Int J Gynaecol Obstet** 1996 Feb;52(2):173–6 (10 ref.)

Malignant melanoma arising in mature ovarian cystic teratoma (dermoid cyst). Report of two cases and literature analysis. Davis GL. **Int J Gynecol Pathol** 1996 Oct; 15(4):356–62 (50 ref.)

Ovarian neuroendocrine carcinomas of non-small-cell type associated with surface epithelial adenocarcinomas. A study of five cases and review of the literature. Eichhorn JH, et al. **Int J Gynecol Pathol** 1996 Oct;15(4):303–14 (33 ref.)

Osteosarcoma metastatic to the ovary: a case report and review of the literature. Eltabbakh GH, et al. **Int J Gynecol Pathol** 1997 Jan;16(1):76–8 (13 ref.)

Symposium: ovarian tumors of borderline malignancy. Silva EG, et al. **Int J Gynecol Pathol** 1996 Oct;15(4):281–302 (62 ref.)

Recent advances in the pathology of ovarian tumors. Young RH, et al. **Mod Pathol** 1995 Dec;8(9):930–59 (167 ref.)

Ovarian intraepithelial neoplasia and ovarian cancer. Gershenson DM, et al. **Obstet Gynecol Clin North Am** 1996 Jun;23(2):475–543 (314 ref.)

Small cell carcinoma of the ovary: a case report of large cell variant. Fukunaga M, et al. **Pathol Int** 1997 Apr; 47(4):250–5 (18 ref.)

[Struma ovarii--a rare tumor in gynecological practice] Popov I, et al. **Akush Ginekol (Sofiia)** 1996;35(4):41–5 (26 ref.) (Eng. Abstr.) **(Bul)**

[Borderline ovarian tumors. Current data] Duvillard P. **Ann Pathol** 1996 Nov;16(5):396–405 (102 ref.) **(Fre)**

[Struma ovarii or malignant ovarian goiter. A case] Barrande G, et al. **Presse Med** 1997 Jun 7;26(19):900–2 (21 ref.) (Eng. Abstr.) **(Fre)**

[Prognostic factors in ovarian carcinoma] Sliutz G. **Wien Med Wochenschr** 1996;146(1–2):14–7 (56 ref.) (Eng. Abstr.) **(Ger)**

[Current status of the management of patients with malignant ovarian cancer in Hungary] Szánthó A, et al. **Orv Hetil** 1997 Feb 16;138(7):405–11 (42 ref.) (Eng. Abstr.) **(Hun)**

[Malignant Brenner's tumor of the ovary: description of a case] Pantaleone U, et al. **Pathologica** 1995 Dec;87(6):715–8 (10 ref.) (Eng. Abstr.) **(Ita)**

[A case of solitary metastatic splenic tumor of ovarian carcinoma] Kobayashi A, et al. **Gan To Kagaku Ryoho** 1997 Aug;24(10):1341–5 (7 ref.) (Eng. Abstr.) **(Jpn)**

[A case of fibrosarcoma of the ovary] Ikegami A, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Dec; 48(12):1177–9 (12 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Endometriosis--a disease because it is characterized by bleeding. Brosens IA. **Am J Obstet Gynecol** 1997 Feb; 176(2):263–7 (25 ref.)

Ovarian tumors with endocrine manifestations. Rao BR, et al. **Curr Ther Endocrinol Metab** 1997;6:260–2 (6 ref.)

Molecular genetic events in the development and progression of ovarian cancer in humans. Chuaqui RF, et al. **Mol Med Today** 1997 May;3(5):207–13 (49 ref.)

PREVENTION & CONTROL

The genetics of ovarian cancer: an assessment of current screening protocols and recommendations for counseling families at risk. Bombard AT, et al. **Clin Obstet Gynecol** 1996 Dec;39(4):860–72 (47 ref.)

Early cancer detection programmes for women at high risk for breast and ovarian cancer: a proposal of practical guidelines. Beckmann MW, et al. **Eur J Cancer Prev** 1996 Dec;5(6):468–75 (87 ref.)

Prophylactic oophorectomy: a century-long dilemma. Piver MS, et al. **Hum Reprod** 1997 Feb;12(2):205–6 (28 ref.)

Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium [see comments] Burke W, et al. **JAMA** 1997 Mar 26;277(12):997–1003 (120 ref.) Comment in: JAMA 1997 Jul 23–30;278(4):289–90; discussion 290. Comment in: JAMA 1997 Jul 23–30;278(4):290.

Screening for ovarian cancer. Guidozzi F. **Obstet Gynecol Surv** 1996 Nov;51(11):696–701 (42 ref.)

Predisposition testing for breast and ovarian cancer susceptibility. Calzone KA. **Semin Oncol Nurs** 1997 May; 13(2):82–90 (61 ref.)

RADIOGRAPHY

Recurrent granulosa cell tumor of the ovary 37 years after initial diagnosis: a case report and review of the literature. Hines JF, et al. **Gynecol Oncol** 1996 Mar;60(3):484–8 (33 ref.)

RADIOTHERAPY

Is there a place for whole abdominal radiotherapy in the management of ovarian cancer? Morton GC, et al. **Ann Acad Med Singapore** 1996 May;25(3):429–36 (68 ref.)

Radioimmunotherapy of ovarian cancer with radiolabelled monoclonal antibodies: biological basis, present status and future perspectives. Bombardieri E, et al. **Anticancer Res** 1997 May–Jun;17(3B):1719–29 (90 ref.)

Is abdomino-pelvic radiation therapy the optimal treatment for completely resected stage I and II high risk ovarian cancer? Fyles A, et al. **Eur J Cancer** 1997 Jan;33(1):12–9 (53 ref.)

Apoptosis and response to radiation: implications for radiation therapy. Meyn RE. **Oncology (Huntingt)** 1997 Mar;11(3):349–56; discussion 356, 361, 365 (45 ref.)

SECONDARY

Case report: Krukenberg tumours arising from a primary duodenojejunal adenocarcinoma. Loke TK, et al. **Clin Radiol** 1997 Feb;52(2):154–5 (12 ref.)

Osteosarcoma metastatic to the ovary: a case report and review of the literature. Eltabbakh GH, et al. **Int J Gynecol Pathol** 1997 Jan;16(1):76–8 (13 ref.)

[Primary and secondary ovarian tumors in patients with colorectal carcinoma. Thoughts on preventive oophorectomy] Bedó E. **Orv Hetil** 1996 Oct 13; 137(41):2249–51 (28 ref.) (Eng. Abstr.) **(Hun)**

SURGERY

Malignant ovarian neoplasms. The place of conservative surgery. Tserkezoglou AJ. **Ann N Y Acad Sci** 1997 Jun 17;816:362–8 (16 ref.)

Initial surgical management of advanced epithelial ovarian cancer. Benjamin I, et al. **Cancer Invest** 1997;15(3):270–6 (35 ref.)

Abdominal mass in a young woman. Pitfalls and delayed diagnosis. Case report. Barrenetxea G, et al. **Eur J Gynaecol Oncol** 1996;17(6):507–9 (17 ref.)

Successful outcome of a 9 week pregnancy managed by bilateral salpingo-oophorectomy for ovarian cancer: case report. Colavita M, et al. **Eur J Gynaecol Oncol** 1996; 17(6):522–3 (7 ref.)

Clinical trials in patients with epithelial ovarian cancer: past, present and future. Vermorken JB, et al. **Eur J Surg Oncol** 1996 Oct;22(5):455–66 (87 ref.)

Preoperative sonographic evaluation and laparoscopic management of persistent adnexal masses: a 1994 review. Hulka JF, et al. **J Am Assoc Gynecol Laparosc** 1994 May; 1(3):197–205 (67 ref.)

A trend toward more conservative surgery in gynecologic oncology. Menczer J. **Obstet Gynecol Surv** 1996 Oct; 51(10):628–36 (143 ref.)

Germ cell tumors. Rescorla FJ. **Semin Pediatr Surg** 1997 Feb; 6(1):29–37 (95 ref.)

[Negative second-look laparatomy in ovarian cancers. Survival analysis and prognostic factors from 64 cases treated at the Gustave Roussy Institute] Pautier P, et al. **Bull Cancer** 1997 Feb;84(2):147–54 (37 ref.) (Eng. Abstr.) **(Fre)**

[Surgical therapy of ovarian carcinoma] Sevelda P. **Wien Med Wochenschr** 1996;146(1–2):18–22 (22 ref.) (Eng. Abstr.) **(Ger)**

[Endoscopic cancer surgery--uterine and ovarian cancer] Tsubata K, et al. **Gan To Kagaku Ryoho** 1997 Mar; 24(5):551–5 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical significance and subject of second look operation] Yakushiji M, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Aug;48(8):761–8 (19 ref.) **(Jpn)**

[The treatment of refractory ovarian cancer] Shparyk IaV, et al. **Lik Sprava** 1996 Oct–Dec;(10–12):41–7 (50 ref.) **(Ukr)**

THERAPY

High-dose chemotherapy with autologous stem cell support in advanced ovarian cancer. Grénman SE, et al. **Ann Med** 1996 Apr;28(2):151–8 (64 ref.)

The management of granulosa cell tumor of the ovary--a case history. Verhagen CA, et al. **Ann Oncol** 1996 Jul; 7(5):521–4 (20 ref.)

The role of high-dose chemotherapy with hematopoietic stem cell support in the treatment of patients with epithelial ovarian carcinoma. Hussein AM. **Cancer Invest** 1997; 15(3):288–95 (50 ref.)

Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes. Freedman RS, et al. **Cancer Treat Res** 1996;82:115–46 (114 ref.)

The value of cancer antigen 125 (CA 125) during treatment and follow-up of patients with ovarian cancer. de Bruijn HW, et al. **Curr Opin Obstet Gynecol** 1997 Feb;9(1):8–13 (64 ref.)

Taxanes in ovarian cancer treatment. Seetalarom K, et al. **Curr Opin Obstet Gynecol** 1997 Feb;9(1):14–20 (46 ref.)

Germ cell tumors of the ovary. Talerman A. **Curr Opin Obstet Gynecol** 1997 Feb;9(1):44–7 (18 ref.)

High-dose chemotherapy for the treatment of breast and ovarian cancer [see comments] Cagnoni PJ, et al. **Curr Opin Oncol** 1997 Mar;9(2):122–5 (32 ref.) Comment in: Curr Opin Oncol 1997 Mar;9(2):115–6.

Ovarian tumors with endocrine manifestations. Rao BR, et al. **Curr Ther Endocrinol Metab** 1997;6:260–2 (6 ref.)

Gene therapy and ovarian cancer: a review. Barnes MN, et al. **Obstet Gynecol** 1997 Jan;89(1):145–55 (104 ref.)

[Advances in the therapy of malignant ovarian germ cell tumors] Hong W. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Jul;31(7):437–40 (23 ref.) **(Chi)**

[Carboplatin and cyclophosphamide in stage Ic–IV ovarian carcinoma: retrospective study of 101 cases] Petit T, et al. **Bull Cancer** 1996 Jul;83(7):566–72 (31 ref.) (Eng. Abstr.) **(Fre)**

[Ovarian adenocarcinomas: current strategies] Varette C. **Presse Med** 1997 Mar 15;26(8):384–8 (29 ref.) **(Fre)**

[Current aspects of ovarian carcinoma] Dietl J. **Geburtshilfe Frauenheilkd** 1996 Jul;56(7):331–44 (255 ref.) (Eng. Abstr.) **(Ger)**

[After-care and palliative therapeutic measures in ovarian carcinoma] Kurz C, et al. **Wien Med Wochenschr** 1996; 146(1–2):34–7 (12 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

The status of ultrasound and color Doppler imaging for the early detection of ovarian carcinoma. Karlan BY. **Cancer Invest** 1997;15(3):265–9 (29 ref.)

Transvaginal sonography as a screening method for the detection of early ovarian cancer. DePriest PD, et al. **Gynecol Oncol** 1997 Jun;65(3):408–14 (27 ref.)

Preoperative sonographic evaluation and laparoscopic management of persistent adnexal masses: a 1994 review. Hulka JF, et al. **J Am Assoc Gynecol Laparosc** 1994 May; 1(3):197–205 (67 ref.)

Classical versus artificial neural network analysis [comment] Newey VR. **Ultrasound Obstet Gynecol** 1997 Jul;10(1):5–8 (45 ref.) Comment on: Ultrasound Obstet Gynecol 1997 Jul;10(1):41–7. Comment on: Ultrasound Obstet Gynecol 1997 Jul;10(1):48–53.

Sonographic evaluation of ovarian masses and its therapeutical implications [editorial] Osmers R. **Ultrasound Obstet Gynecol** 1996 Oct;8(4):217–22 (60 ref.)

[A preoperative diagnostic concept for determining the extent of laparoscopic surgery of the adnexa] Hesseling M, et al. **Gynakol Geburtshilfliche Rundsch** 1997;37(1):5–13 (49 ref.) (Eng. Abstr.) **(Ger)**

[The role of transvaginal ultrasonography in the screening of ovarian tumors] De Rosa G, et al. **Minerva Ginecol** 1997 Jun;49(6):243–9 (47 ref.) (Eng. Abstr.) **(Ita)**

[Epidermoid carcinoma originating from a mature cystic ovarian teratoma. Report of two cases and review of the literature] Pérez Sanchez VM, et al. **Ginecol Obstet Mex** 1997 Jul;65:296–9 (11 ref.) (Eng. Abstr.) **(Spa)**

OVARIECTOMY

Prophylactic oophorectomy: a century-long dilemma. Piver MS, et al. **Hum Reprod** 1997 Feb;12(2):205–6 (28 ref.)

Regression of uterine low-grade smooth-muscle tumors metastatic to the lung after oophorectomy. Abu-Rustum NR, et al. **Obstet Gynecol** 1997 May;89(5 Pt 2):850–2 (13 ref.)

Hormonal approaches to breast cancer treatment and prevention: an overview. Vogel CL. **Semin Oncol** 1996 Aug;23(4 Suppl 9):2–9 (41 ref.)

Is it time to develop an optimal endocrine therapy for premenopausal patients with axillary node positive and negative breast cancer? Bilimoria MM, et al. **Semin Surg Oncol** 1996 Sep–Oct;12(5):339–45 (44 ref.)

[Indications for castration in women treated for breast cancer] Chapet S, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(5):445–50 (44 ref.) (Eng. Abstr.) **(Fre)**

[Primary and secondary ovarian tumors in patients with colorectal carcinoma. Thoughts on preventive oophorectomy] Bedó E. **Orv Hetil** 1996 Oct 13; 137(41):2249–51 (28 ref.) (Eng. Abstr.) **(Hun)**

ADVERSE EFFECTS

[Urinary incontinence in castrated bitches. 2. Diagnosis and treatment] Arnold S. **Schweiz Arch Tierheilkd** 1997; 139(7):319–24 (27 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Laparoscopic management of gynecological malignancies. Kadar N. **Curr Opin Obstet Gynecol** 1997 Aug;9(4):247–55 (52 ref.)

OVARY

see related

OVARIECTOMY

Preservation of reproductive function before therapy for cancer: new options involving sperm and ovary cryopreservation [editorial] Opsahl MS, et al. **Cancer J Sci Am** 1997 Jul–Aug;3(4):189–91 (12 ref.)

Cryopreservation of ovarian tissue. Potential "reproductive insurance" for women at risk of early ovarian failure. Wood CE, et al. **Med J Aust** 1997 Apr 7;166(7):366–9 (50 ref.)

BLOOD SUPPLY

Absence of flow in ovarian vein by time-of-flight magnetic resonance angiography without evidence of thrombosis. Rizk B, et al. **Clin Imaging** 1997 May–Jun;21(3):203–6 (11 ref.)

The first three weeks assessed by transvaginal color Doppler. Kupešić S. **J Perinat Med** 1996;24(4):301–17 (61 ref.)

DRUG EFFECTS

Prevention of gonadal damage during cytotoxic therapy. Blumenfeld Z, et al. **Ann Med** 1997 Jun;29(3):199–206 (76 ref.)

Assisted conception following poor ovarian response to gonadotrophin stimulation. Keay SD, et al. **Br J Obstet Gynaecol** 1997 May;104(5):521–7 (78 ref.)

Ovarian stimulation for assisted reproduction. Meldrum DR. **Curr Opin Obstet Gynecol** 1996 Jun;8(3):166–70 (33 ref.)

Biological activity of hormones in preovulatory follicular fluid and serum of women undergoing ovarian stimulation. Andersen CY. **Dan Med Bull** 1997 Jun;44(3):257–73 (180 ref.)

Clinical applications of growth hormone for ovarian stimulation. Homburg R, et al. **Hum Reprod Update** 1995 May;1(3):264–75 (42 ref.)

Role of the cytokines in the hypothalamic-pituitary-adrenal and gonadal axes. Spangelo BL, et al. **Neuroimmunomodulation** 1995 Sep–Oct;2(5):299–312 (159 ref.)

[Pharmacologic suppression of the ovarian function and its clinical usefulness] Kershenovich Sefchovich R, et al. **Ginecol Obstet Mex** 1997 Aug;65:344–8 (24 ref.) (Eng. Abstr.) **(Spa)**

GROWTH & DEVELOPMENT

Development of the hypothalamic-pituitary-ovarian axis. Apter D. **Ann N Y Acad Sci** 1997 Jun 17;816:9–21 (57 ref.)

Ovarian aging. Maroulis GB. **Ann N Y Acad Sci** 1997 Jun 17;816:22–6 (28 ref.)

Expression of follicle stimulating hormone-receptor mRNA during gonadal development. O'Shaughnessy PJ, et al. **Mol Cell Endocrinol** 1996 Dec 20;125(1–2):169–75 (46 ref.)

IMMUNOLOGY

Review: cytokine involvement in ovarian processes. Terranova PF, et al. **Am J Reprod Immunol** 1997 Jan; 37(1):50–63 (121 ref.)

Production of ovarian cytokines and their role in ovulation in the mammalian ovary. Machelon V, et al. **Eur Cytokine Netw** 1997 Jun;8(2):137–43 (72 ref.)

Immunological aspects of ovarian function: role of the cytokines. Vinatier D, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Dec;63(2):155–68 (185 ref.)

INNERVATION

Control of ovarian innervation. Gioia L. **Zygote** 1996 Nov; 4(4):295–8 (35 ref.)

METABOLISM

AT2 receptor expression in ovaries: a review. Nielsen AH, et al. **Adv Exp Med Biol** 1996;396:183–7 (26 ref.)

Characterization of the AT2 receptor on rat ovarian granulosa cells. Tanaka M, et al. **Adv Exp Med Biol** 1996; 396:175–82 (27 ref.)

The role of cytochrome P450 17 alpha-hydroxylase and 3 beta-hydroxysteroid dehydrogenase in the integration of gonadal and adrenal steroidogenesis via the delta 5 and delta 4 pathways of steroidogenesis in mammals. Conley AJ, et al. **Biol Reprod** 1997 Apr;56(4):789–99 (147 ref.)

Presence and function of growth factors in the avian ovary. van Nassauw L, et al. **Eur J Morphol** 1997 Jul;35(3):171–80 (59 ref.)

In vitro fertilization treatment in patients with polycystic ovaries. Shulman A, et al. **J Assist Reprod Genet** 1997 Jan; 14(1):7–10 (19 ref.)

The molecular pharmacology of ovarian steroid receptors. Vegeto E, et al. **Vitam Horm** 1996;52:99–128 (129 ref.)

[Role of extragonadal estrogens and hormonal carcinogenesis] Bershtein LM. **Vestn Ross Akad Med Nauk** 1997;(8):54–8 (41 ref.) **(Rus)**

PATHOLOGY

Apoptosis: a programmed cell death involved in ovarian and uterine physiology. Vinatier D, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Aug;67(2):85–102 (282 ref.)

Gonadal cell apoptosis: hormone-regulated cell demise. Billig H, et al. **Hum Reprod Update** 1996 Mar–Apr;2(2):103–17 (167 ref.)

PHYSIOLOGY

Hypothalamic-pituitary-ovarian axis and mood. Toren P, et al. **Biol Psychiatry** 1996 Nov 15;40(10):1051–5 (52 ref.)

Ovarian surface epithelium, ovulation and carcinogenesis. Murdoch WJ. **Biol Rev Camb Philos Soc** 1996 Nov; 71(4):529–43 (128 ref.)

Prostaglandins and their receptors: implications for ovarian physiology. Olofsson JI, et al. **Biol Signals** 1996 Mar–Apr; 5(2):90–100 (103 ref.)

Activin and follistatin as local regulators in the human ovary. Peng C, et al. **Biol Signals** 1996 Mar–Apr;5(2):81–9 (51 ref.)

Physiological cell death in endocrine-dependent tissues: an ovarian perspective. Martimbeau S, et al. **Clin Endocrinol (Oxf)** 1997 Mar;46(3):241–54 (169 ref.)

Biological activity of hormones in preovulatory follicular fluid and serum of women undergoing ovarian stimulation. Andersen CY. **Dan Med Bull** 1997 Jun;44(3):257–73 (180 ref.)

Manipulation of human ovarian function: physiological concepts and clinical consequences. Fauser BC, et al. **Endocr Rev** 1997 Feb;18(1):71–106 (412 ref.)

Overview of ovarian follicular development: considerations for the toxicologist. Hirshfield AN. **Environ Mol Mutagen** 1997;29(1):10–5 (17 ref.)

Physiological effects of ovarian hormones: clinical aspects and compliance. Ottesen B, et al. **Eur Heart J** 1996 Aug; 17 Suppl D:20–6 (48 ref.)

Dendritic cells and macrophages in the pituitary and the gonads. Evidence for their role in the fine regulation of the reproductive endocrine response. Hoek A, et al. **Eur J Endocrinol** 1997 Jan;136(1):8–24 (193 ref.)

Presence and function of growth factors in the avian ovary. van Nassauw L, et al. **Eur J Morphol** 1997 Jul;35(3):171–80 (59 ref.)

Immunological aspects of ovarian function: role of the cytokines. Vinatier D, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Dec;63(2):155–68 (185 ref.)

The ovarian renin-angiotensin system in reproductive physiology. Yoshimura Y. **Front Neuroendocrinol** 1997 Jul; 18(3):247–91 (235 ref.)

Perspectives on ovarian dysfunction and autoimmunity. Moncayo HE, et al. **Horm Metab Res** 1995 Dec; 27(12):544–6 (35 ref.)

Sex differentiation and ovarian function. An overview. Tsutsumi O, et al. **Horm Res** 1996;46 Suppl 1:1–5 (66 ref.)

Role of growth hormone in ovarian physiology and onset of puberty. Sharara FI, et al. **J Soc Gynecol Investig** 1997 Jan–Feb;4(1):2–7 (82 ref.)

Gonadotropins and ovarian gonadotropin receptors during the perimenopausal transition period. Vihko KK. **Maturitas** 1996 May;23 Suppl:S19–22 (26 ref.)

Interference with follicle stimulating hormone regulation of human ovarian function. Fauser BC. **Mol Hum Reprod** 1996 May;2(5):327–34 (92 ref.)

Ovarian control of very low sperm/egg ratios at the commencement of mammalian fertilisation to avoid polyspermy. Hunter RH. **Mol Reprod Dev** 1996 Jul; 44(3):417–22 (73 ref.)

Cytokines in the ovary: pathophysiology and potential for pharmacological intervention. Norman RJ, et al. **Pharmacol Ther** 1996;69(3):219–36 (166 ref.)

Participation of nerve growth factor in the regulation of ovarian function. Dissen GA, et al. **Zygote** 1996 Nov; 4(4):309–12 (38 ref.)

Intra-ovarian regulation of oocyte developmental competence in cattle. Gandolfi F. **Zygote** 1996 Nov; 4(4):323–6 (37 ref.)

Control of ovarian innervation. Gioia L. **Zygote** 1996 Nov; 4(4):295–8 (35 ref.)

[Ovarian renin-angiotensin system] Wu X, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Jul;31(7):434–6 (17 ref.) **(Chi)**

[The ovarian renin-angiotensin-aldosterone system] Pizzo A, et al. **Minerva Ginecol** 1996 Dec;48(12):539–44 (33 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Apoptosis: a programmed cell death involved in ovarian and uterine physiology. Vinatier D, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Aug;67(2):85–102 (282 ref.)

Ovarian function in fragile X carriers [editorial] Fryns JP. **Genet Couns** 1996;7(4):245–7 (14 ref.)

Ovarian stimulation and ovarian tumours: a critical reappraisal. Tarlatzis BC, et al. **Hum Reprod Update** 1995 May;1(3):284–301 (121 ref.)

Pathophysiology of ovarian steroid secretion in polycystic ovary syndrome. Barnes RB. **Semin Reprod Endocrinol** 1997 May;15(2):159–68 (61 ref.)

Adrenal involvement in polycystic ovary syndrome.

OVARY

Gonzalez F. **Semin Reprod Endocrinol** 1997 May; 15(2):137–57 (129 ref.)

TRANSPLANTATION

Oncological implications in the replacement of ovarian tissue [see comments] Shaw J, et al. **Hum Reprod** 1997 Mar; 12(3):403–5 (16 ref.) Comment in: Hum Reprod 1997 Mar;12(3):403.

ULTRASTRUCTURE

Ultrastructural aspects of the remodeling process of the Corpus albicans in the recent postmenopausal period. Focchi GR, et al. **Rev Paul Med** 1996 May–Jun; 114(3):1173–6 (12 ref.)

OVER-THE-COUNTER DRUGS see **DRUGS, NON-PRESCRIPTION**

OVERDENTURE see **DENTURE, OVERLAY**

OVERDOSE

Poisoning and overdose. Giorgi DF, et al. **Mt Sinai J Med** 1997 Sep–Oct;64(4–5):283–91 (32 ref.)

BLOOD

[Digitoxin overdose with reversible thrombocytopenia] Dahmen KG, et al. **Med Klin** 1996 Dec 15;91(12):791–5 (35 ref.) **(Ger)**

MORTALITY

Fatal heroin 'overdose': a review. Darke S, et al. **Addiction** 1996 Dec;91(12):1765–72 (50 ref.)

[Suicide and psychotropic drugs] Lejoyeux M, et al. **Encephale** 1996 Dec;22 Spec No 4:40–5 (34 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Poisoning and drug overdose. Vernon DD, et al. **Crit Care Clin** 1997 Jul;13(3):647–67 (136 ref.)

Diagnosis and management of opioid– and benzodiazepine–induced comatose overdose in children. Perry HE, et al. **Curr Opin Pediatr** 1996 Jun;8(3):243–7 (36 ref.)

Managing self-harm: the legal issues. **Drug Ther Bull** 1997 Jun;35(6):41–3 (25 ref.)

Acute caffeine ingestion fatalities: management issues. Shum S, et al. **Vet Hum Toxicol** 1997 Aug;39(4):228–30 (13 ref.)

OVEREATING see **HYPERPHAGIA**

OVERPOPULATION see **POPULATION DENSITY**

OVERUSE SYNDROME see **CUMULATIVE TRAUMA DISORDERS**

OVERUTILIZATION OF HEALTH SERVICES see **HEALTH SERVICES MISUSE**

OVIDUCTS, MAMMALIAN see **FALLOPIAN TUBES**

OVINE-CAPRINE LENTIVIRUSES see **LENTIVIRUSES, OVINE-CAPRINE**

OVIPOSITION

Olfactory control of mosquito behaviour. Davis EE. **Ciba Found Symp** 1996;200:48–53 (12 ref.)

The role of mosquito olfaction in oviposition site location and in the avoidance of unsuitable hosts. Pickett JA, et al. **Ciba Found Symp** 1996;200:109–19; discussion 119–23, 178–83 (42 ref.)

GENETICS

Direct and correlated responses to long–term selection for increased body weight and egg production in turkeys. Nestor KE, et al. **Poult Sci** 1996 Oct;75(10):1180–91 (54 ref.)

OVOCYTES see **OOCYTES**

OVOMUCIN

[Development of HPLC packing materials for drug analysis and their applications] Haginaka J. **Yakugaku Zasshi** 1996 Jun;116(6):473–90 (46 ref.) (Eng. Abstr.) **(Jpn)**

OVOMUCOID see **OVOMUCIN**

OVULATION

The probability of conception on different days of the cycle with respect to ovulation: an overview. Ferreira–Poblete A. **Adv Contracept** 1997 Jun–Sep;13(2–3):83–95 (14 ref.)

Circulating and ovarian IGF binding proteins: potential roles in normo–ovulatory cycles and in polycystic ovarian syndrome. Giudice LC, et al. **Prog Growth Factor Res** 1995; 6(2–4):397–408 (48 ref.)

Hormones of oestrus and ovulation and their manipulation in marsupials. Hinds LA, et al. **Reprod Fertil Dev** 1996; 8(4):661–72 (56 ref.)

Cytoplasmic maturation of the marsupial oocyte during the periovulatory period. Mate KE. **Reprod Fertil Dev** 1996; 8(4):509–19 (63 ref.)

[Awareness of ovulation time and sex determination in Biblical times] Ben–Noun L. **Harefuah** 1997 May 15; 132(10):726–7 (18 ref.) **(Heb)**

DRUG EFFECTS

Dose relationship between GnRH antagonists and pituitary suppression. Rivier J, et al. **Hum Reprod** 1996 Nov;11 Suppl 3:133–47 (74 ref.)

IMMUNOLOGY

Immune modulators in the context of the ovulatory process: a role for interleukin–1. Adashi EY. **Am J Reprod Immunol** 1996 Mar;35(3):190–4 (49 ref.)

Production of ovarian cytokines and their role in ovulation in the mammalian ovary. Machelon V, et al. **Eur Cytokine Netw** 1997 Jun;8(2):137–43 (72 ref.)

PHYSIOLOGY

Gonadotropin–releasing hormone requirements for ovulation. Karsch FJ, et al. **Biol Reprod** 1997 Feb;56(2):303–9 (62 ref.)

Ovarian surface epithelium, ovulation and carcinogenesis. Murdoch WJ. **Biol Rev Camb Philos Soc** 1996 Nov; 71(4):529–43 (128 ref.)

Potential roles of tumor necrosis factor–alpha in follicular development, ovulation, and the life span of the corpus luteum. Terranova PF. **Domest Anim Endocrinol** 1997 Jan; 14(1):1–15 (104 ref.)

Manipulation of human ovarian function: physiological concepts and clinical consequences. Fauser BC, et al. **Endocr Rev** 1997 Feb;18(1):71–106 (412 ref.)

Ovulation induction in the ovulatory woman. Silverberg KM. **Semin Reprod Endocrinol** 1996 Nov;14(4):339–44 (28 ref.)

Post–partum anoestrus in dairy cows: a review. Opsomer G, et al. **Vet Q** 1996 Jun;18(2):68–75 (133 ref.)

Participation of nerve growth factor in the regulation of ovarian function. Dissen GA, et al. **Zygote** 1996 Nov; 4(4):309–12 (38 ref.)

OVULATION DETECTION

INSTRUMENTATION

Approaches for incorporating ovulation detection devices and home kits into learning NFP--implications for service delivery. Kirkman RJ. **Adv Contracept** 1997 Jun–Sep; 13(2–3):269–72 (6 ref.)

METHODS

Prediction and detection of the fertile phase of the menstrual cycle: an overview. Martinez AR. **Adv Contracept** 1997 Jun–Sep;13(2–3):131–8 (8 ref.)

Monitoring reproductive hormones to detect the fertile period: development of Persona--the first home use system. May K. **Adv Contracept** 1997 Jun–Sep;13(2–3):139–41 (0 ref.)

[Temperature graph] Belaisch J. **Contracept Fertil Sex** 1996 Jan;24(1):15–7 (16 ref.) **(Fre)**

VETERINARY

Post–partum anoestrus in dairy cows: a review. Opsomer G, et al. **Vet Q** 1996 Jun;18(2):68–75 (133 ref.)

OVULATION INDUCTION

see related
OVARIAN HYPERSTIMULATION SYNDROME

Ovarian stimulation in assisted reproduction. Gips H, et al. **Andrologia** 1996;28 Suppl 1:3–7 (16 ref.)

Heterotopic pregnancy after ovulation induction and assisted reproductive technologies: a literature review from 1971 to 1993. Tal J, et al. **Fertil Steril** 1996 Jul;66(1):1–12 (77 ref.)

Role of different GnRH agonist regimens in pituitary suppression and the outcome of controlled ovarian hyperstimulation. Filicori M, et al. **Hum Reprod** 1996 Nov; 11 Suppl 3:123–32 (52 ref.)

Roles of follicle stimulating hormone and luteinizing hormone in controlled ovarian hyperstimulation. Hillier SG. **Hum Reprod** 1996 Nov;11 Suppl 3:113–21 (28 ref.)

Development, pharmacology and clinical experience with clomiphene citrate. Dickey RP, et al. **Hum Reprod Update** 1996 Nov–Dec;2(6):483–506 (108 ref.)

The role of growth hormone (GH), GH–receptor and GH–binding protein in reproduction and ovulation induction. Blumenfeld Z, et al. **J Pediatr Endocrinol Metab** 1996 Mar–Apr;9(2):145–62 (82 ref.)

Ovarian cancer after successful ovulation induction: a case report. Hull ME, et al. **J Reprod Med** 1996 Jan;41(1):52–4 (16 ref.)

Physiologic basis of ovulation induction. Erickson GF. **Semin Reprod Endocrinol** 1996 Nov;14(4):287–97 (287 ref.)

Ovulation induction in the nonestrogenized patient. Hurst BS. **Semin Reprod Endocrinol** 1996 Nov;14(4):299–308 (71 ref.)

Ovulation induction in the estrogenized anovulatory patient. Kettel LM, et al. **Semin Reprod Endocrinol** 1996 Nov; 14(4):309–15 (57 ref.)

Evaluation and treatment of low responders. Scott RT Jr. **Semin Reprod Endocrinol** 1996 Nov;14(4):317–37 (63 ref.)

ADVERSE EFFECTS

Ovarian stimulation and ovarian tumours: a critical reappraisal. Tarlatzis BC, et al. **Hum Reprod Update** 1995 May;1(3):284–301 (121 ref.)

Ovulation induction for infertility is it safe or not? Anderson SM, et al. **S D J Med** 1996 Nov;49(11):419–21 (14 ref.)

Ovulation induction and ovarian malignancy. Beltsos AN, et al. **Semin Reprod Endocrinol** 1996 Nov;14(4):367–74 (76 ref.)

Reproductive toxicity of ovulation induction. Tucker KE. **Semin Reprod Endocrinol** 1996 Nov;14(4):345–53 (79 ref.)

[GnRH analog protocols revisited I--advantages and doubts] Hugues JN, et al. **Contracept Fertil Sex** 1997 Jun; 25(6):445–56 (116 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Surgical ovulation induction: the role of ovarian diathermy in polycystic ovary syndrome. Donesky BW, et al. **Baillieres Clin Endocrinol Metab** 1996 Apr;10(2):293–309 (83 ref.)

Polycystic ovary syndrome: induction of ovulation. Homburg R. **Baillieres Clin Endocrinol Metab** 1996 Apr;10(2):281–92 (50 ref.)

Biological activity of hormones in preovulatory follicular fluid and serum of women undergoing ovarian stimulation. Andersen CY. **Dan Med Bull** 1997 Jun;44(3):257–73 (180 ref.)

Growth hormone cotreatment with gonadotropins in ovulation induction. Artini PG, et al. **J Endocrinol Invest** 1996 Dec;19(11):763–79 (128 ref.)

The evolution of new agents for ovulation induction. Gast MJ. **Semin Reprod Endocrinol** 1996 Nov;14(4):375–89 (79 ref.)

Surgical approaches to ovulation induction. Shanti A, et al. **Semin Reprod Endocrinol** 1997 May;15(2):183–91 (64 ref.)

Ovulation induction in the ovulatory woman. Silverberg KM. **Semin Reprod Endocrinol** 1996 Nov;14(4):339–44 (28 ref.)

[Intra–uterine inseminations with hyperstimulation in male infertility] Delépine B, et al. **Contracept Fertil Sex** 1996 Dec;24(12):891–6 (21 ref.) (Eng. Abstr.) **(Fre)**

[GnRH analog protocols revisited I--advantages and doubts] Hugues JN, et al. **Contracept Fertil Sex** 1997 Jun; 25(6):445–56 (116 ref.) (Eng. Abstr.) **(Fre)**

[Prevention of multiple pregnancy by induction of single ovulation] Aono T. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Aug; 48(8):666–71 (10 ref.) **(Jpn)**

TRENDS

The evolution of new agents for ovulation induction. Gast MJ. **Semin Reprod Endocrinol** 1996 Nov;14(4):375–89 (79 ref.)

OVUM

see related
GRAAFIAN FOLLICLE

CYTOLOGY

Can developmentally significant spatial patterning of the egg be discounted in mammals? Gardner RL. **Hum Reprod Update** 1996 Jan–Feb;2(1):3–27 (226 ref.)

IMMUNOLOGY

Contraceptive vaccines. Jones WR. **Baillieres Clin Obstet Gynaecol** 1996 Apr;10(1):69–86 (65 ref.)

PHYSIOLOGY

Cyclic ADP–ribose and calcium signaling in eggs. Lee HC. **Biol Signals** 1996 Mar–Apr;5(2):101–10 (58 ref.)

The cortical reaction and development of activation competence in mammalian oocytes. Ducibella T. **Hum Reprod Update** 1996 Jan–Feb;2(1):29–42 (169 ref.)

Ovarian control of very low sperm/egg ratios at the commencement of mammalian fertilisation to avoid polyspermy. Hunter RH. **Mol Reprod Dev** 1996 Jul; 44(3):417–22 (73 ref.)

What marsupial gametes disclose about gamete function in eutherian mammals. Bedford JM. **Reprod Fertil Dev** 1996; 8(4):569–80 (65 ref.)

Egg maturation and fertilization in marsupials. Breed WG. **Reprod Fertil Dev** 1996;8(4):617–43 (46 ref.)

OVUM DONATION see **OOCYTE DONATION**

OVUM IMPLANTATION

Response to "Germ–line therapy to cure mitochondrial disease: protocol and ethics of in vitro ovum nuclear transplantation" by Donald S. Rubenstein, David C. Thomasma, Eric A. Schon, and Michael J. Zinaman (CQ Vol 4, No 3). Bacchetta MD, et al. **Camb Q Healthc Ethics** 1996 Summer;5(3):450–7 (10 ref.)

Biology and genetics of implantation. Schultz GA, et al.

Dev Genet 1997;21(1):1-5 (59 ref.)
The effects of assisted hatching on the hatching process and implantation. Mandelbaum J. **Hum Reprod** 1996 Sep;11 Suppl 1:43-50; discussion 51-5 (33 ref.)
The cytoskeleton of uterine epithelial cells: a new player in uterine receptivity and the plasma membrane transformation. Murphy CR. **Hum Reprod Update** 1995 Nov;1(6):567-80 (171 ref.)
Hormonal and non-hormonal agents at implantation as targets for contraception. Nie GY, et al. **Reprod Fertil Dev** 1997;9(1):65-76 (114 ref.)

DRUG EFFECTS

Hormonal requirement for blastocyst implantation and a new approach for anti-implantation strategy. Ghosh D, et al. **Indian J Physiol Pharmacol** 1997 Apr;41(2):101-8 (54 ref.)

GENETICS

Molecular genetics of implantation in the mouse. Rinkenberger JL, et al. **Dev Genet** 1997;21(1):6-20 (156 ref.)

IMMUNOLOGY

The interleukin-1 system and human implantation. Simón C, et al. **Am J Reprod Immunol** 1997 Jan;37(1):64-72 (51 ref.)
Immunology of human implantation: an evolutionary perspective. Loke YW, et al. **Hum Reprod** 1996 Feb; 11(2):283-6 (34 ref.)

PHYSIOLOGY

Epithelial-mesenchymal transition during trophoblast differentiation. Vićovac L, et al. **Acta Anat (Basel)** 1996; 156(3):202-16 (157 ref.)
Uterine pinopodes in peri-implantation human endometrium. Clinical relevance. Nikas G, et al. **Ann N Y Acad Sci** 1997 Jun 17;816:129-42 (59 ref.)
Intrauterine signaling and embryonic implantation. Barkai U, et al. **Biol Signals** 1996 Mar-Apr;5(2):111-21 (134 ref.)
Integrins and reproductive physiology: expression and modulation in fertilization, embryogenesis, and implantation. Sueoka K, et al. **Fertil Steril** 1997 May; 67(5):799-811 (100 ref.)
Implantation of the human embryo. Lopata A. **Hum Reprod** 1996 Sep;11 Suppl 1:175-84; discussion 193-5 (31 ref.)
Trophoblast migration during human placental implantation. Burrows TD, et al. **Hum Reprod Update** 1996 Jul-Aug; 2(4):307-21 (128 ref.)
Cytokines in implantation. Chard T. **Hum Reprod Update** 1995 Jul;1(4):385-96 (134 ref.)
Expression pattern of different gap junction connexins is related to embryo implantation. Grümmer R, et al. **Int J Dev Biol** 1996 Feb;40(1):361-7 (35 ref.)
Oncofetal fibronectin: new insight into the physiology of implantation and labor. Dunn PA, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Nov-Dec; 25(9):753-7 (24 ref.)
Molecular basis of embryo implantation. Fukuda MN. **Keio J Med** 1996 Mar;45(1):37-43 (29 ref.)
Potential molecular mechanisms for the contraceptive control of implantation. Simón C. **Mol Hum Reprod** 1996 Jul; 2(7):475-9 (74 ref.)
Cytokines-adhesion molecules-invasive proteinases. The missing paracrine/autocrine link in embryonic implantation? Simón C, et al. **Mol Hum Reprod** 1996 Jun; 2(6):405-24 (262 ref.)
The cell biology of human implantation. Aplin JD. **Placenta** 1996 Jul-Aug;17(5-6):269-75 (93 ref.)
[Granulated CD56 lymphocytes of decidual tissue] Calatayud S, et al. **Pathol Biol (Paris)** 1995 Nov;43(9):788-98 (101 ref.) (Eng. Abstr.) **(Fre)**
[The early placental trophoblast. I. Normal development and endometrial and non-tumor-induced disorders] Horn LC, et al. **Zentralbl Gynakol** 1996;118(9):487-97 (65 ref.) (Eng. Abstr.) **(Ger)**
[The early placental trophoblast. II. Tumorous disorders of trophoblast development] Horn LC, et al. **Zentralbl Gynakol** 1996;118(11):591-7 (36 ref.) (Eng. Abstr.) **(Ger)**

OVUM PROTEINS see **EGG PROTEINS**

OVUM-SPERM INTERACTIONS see **SPERM-OVUM INTERACTIONS**

OWNERSHIP

see related
INTELLECTUAL PROPERTY

Public policy issues in nonprofit conversions: an overview. Claxton G, et al. **Health Aff (Millwood)** 1997 Mar-Apr; 16(2):9-28 (44 ref.)
Conversion of HMOs and hospitals: what's at stake? [see comments] Gray BH. **Health Aff (Millwood)** 1997 Mar-Apr;16(2):29-47 (43 ref.) Comment in: Health Aff (Millwood) 1997 Jul-Aug;16(4):284-6.

LEGISLATION & JURISPRUDENCE

State policy issues in nonprofit conversions. Butler PA. **Health Aff (Millwood)** 1997 Mar-Apr;16(2):69-84 (38 ref.)
State experience in regulating a changing health care system. Shriber D. **Health Aff (Millwood)** 1997 Mar-Apr; 16(2):48-68 (38 ref.)
It's my body and I'll die if I want to: a property-based argument in support of assisted suicide. Friedman RF. **J Contemp Health Law Policy** 1995 Fall;12(1):183-213 (210 ref.)

STANDARDS

Dog bite prevention: responsible pet ownership and animal safety. Cornwell JM. **J Am Vet Med Assoc** 1997 Apr 15; 210(8):1147-8 (10 ref.)

OXADIAZOLES

PHARMACOLOGY

GR127935: a potent and selective 5-HT1D receptor antagonist. Skingle M, et al. **Behav Brain Res** 1996; 73(1-2):157-61 (23 ref.)

OXALATES

see related
HYPEROXALURIA
HYPEROXALURIA, PRIMARY

METABOLISM

Oxalate transport and calcium oxalate renal stone disease [editorial] Verkoelen CF, et al. **Urol Res** 1996;24(4):183-91 (77 ref.)
Ion exchangers mediating NaCl transport in the proximal tubule. Aronson PS. **Wien Klin Wochenschr** 1997 Jun 27; 109(12-13):435-40 (58 ref.)

PHARMACOKINETICS

Alterations in intestinal transport of oxalate in disease states. Hatch M, et al. **Scanning Microsc** 1995;9(4):1121-6; discussion 1126 (43 ref.)
Dietary oxalate and its intestinal absorption. Holmes RP, et al. **Scanning Microsc** 1995;9(4):1109-18; discussion 1118-20 (53 ref.)

OXALURIA see **HYPEROXALURIA**

OXALURIA, PRIMARY see **HYPEROXALURIA, PRIMARY**

OXAZEPAM

Oxazepam. **IARC Monogr Eval Carcinog Risks Hum** 1996; 66:115-42 (102 ref.)

PHARMACOLOGY

On mouse pups and their lactating dams: behavioral consequences of early exposure to oxazepam and interacting factors. Laviola G. **Pharmacol Biochem Behav** 1996 Dec;55(4):459-74 (130 ref.)

OXAZINES

CHEMISTRY

The discovery of a new organic nitrate: an overview. Benedini F, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 4:S1-5 (27 ref.)

OXAZOLES

[Synthetic 2-amino alcohol derivatives as chiral auxiliaries] Ishizuka T. **Yakugaku Zasshi** 1997 Jun;117(6):339-52 (35 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Imidazoline receptor agonist drugs: a new approach to the treatment of systemic hypertension. Yu A, et al. **J Clin Pharmacol** 1996 Feb;36(2):98-111 (100 ref.)
Oxazolidinones: new antibacterial agents. Ford CW, et al. **Trends Microbiol** 1997 May;5(5):196-200 (30 ref.)

THERAPEUTIC USE

Metal-independent putative superoxide dismutase mimics in chemistry, biology, and medicine. Ahmad N, et al. **Ecotoxicol Environ Saf** 1996 Jul;34(2):141-4 (37 ref.)
Emerging preclinical and clinical profile of 311C90: a poster review and discussion. Ferrari MD. **Eur Neurol** 1996;36 Suppl 2:19-23 (23 ref.)
311C90: increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists. Ferrari MD. **Neurology** 1997 Mar;48(3 Suppl 3):S21-4 (15 ref.)
Increasing the options for effective migraine management. Goadsby PJ, et al. **Neurology** 1997 Mar;48(3 Suppl 3):S1-3 (16 ref.)

OXIDANTS

see related
ANTIOXIDANTS

Oxidants and antioxidants in viral diseases: disease mechanisms and metabolic regulation. Peterhans E. **J Nutr** 1997 May;127(5 Suppl):962S-965S (41 ref.)

ADMINISTRATION & DOSAGE

Nightguard vital bleaching: current concepts and research. Haywood VB. **J Am Dent Assoc** 1997 Apr;128 Suppl:19S-25S (31 ref.)
The effect of dietary fat, antioxidants, and pro-oxidants on blood lipids, lipoproteins, and atherosclerosis. Kwiterovich PO Jr. **J Am Diet Assoc** 1997 Jul;97(7 Suppl):S31-41 (75 ref.)

ADVERSE EFFECTS

Advanced glycation end products, oxidant stress and vascular lesions. Chappey O, et al. **Eur J Clin Invest** 1997 Feb; 27(2):97-108 (107 ref.)

CHEMISTRY

An oxidant sensor at the plasma membrane. Knebel A, et al. **Adv Exp Med Biol** 1996;387:57-62 (36 ref.)

METABOLISM

Oxidant mechanisms in toxic acute renal failure. Baliga R, et al. **Am J Kidney Dis** 1997 Mar;29(3):465-77 (84 ref.)
Pathways for oxidation of low density lipoprotein by myeloperoxidase: tyrosyl radical, reactive aldehydes, hypochlorous acid and molecular chlorine. Heinecke JW. **Biofactors** 1997;6(2):145-55 (44 ref.)
Oxidative stress: oxidants and antioxidants. Sies H. **Exp Physiol** 1997 Mar;82(2):291-5 (19 ref.)
Hypochlorous acid and its pharmacological antagonism: an update picture. Lapenna D, et al. **Gen Pharmacol** 1996 Oct; 27(7):1145-7 (30 ref.)
Mechanisms involved in the generation of free radicals. Halliwell B. **Pathol Biol (Paris)** 1996 Jan;44(1):6-13 (68 ref.)
Iron-sulfur clusters as biosensors of oxidants and iron [published erratum appears in Trends Biochem Sci 1996 Jul;21(7):246] [see comments] Rouault TA, et al. **Trends Biochem Sci** 1996 May;21(5):174-7 (48 ref.) Comment in: Trends Biochem Sci 1996 Aug;21(8):282-3.
[The effect of the factors of the working and living environment on oxidative/antioxidative balance (a review)] Vangelova K. **Probl Khig** 1996;21:27-36 (41 ref.) (Eng. Abstr.) **(Bul)**
[Oxidant stress--the general mechanism of the damage in nervous system diseases] Zavalishin IA, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(2):111-4 (29 ref.) **(Rus)**

PHARMACOLOGY

Oxidants as stimulators of signal transduction. Suzuki YJ, et al. **Free Radic Biol Med** 1997;22(1-2):269-85 (184 ref.)
DNA strand breakage and activation of poly-ADP ribosyltransferase: a cytotoxic pathway triggered by peroxynitrite. Szabó C. **Free Radic Biol Med** 1996; 21(6):855-69 (218 ref.)
Vitamin C: antioxidant or pro-oxidant in vivo? Halliwell B. **Free Radic Res** 1996 Nov;25(5):439-54 (182 ref.)

TOXICITY

Role of oxidants/antioxidants in smoking-induced lung diseases. Rahman I, et al. **Free Radic Biol Med** 1996; 21(5):669-81 (155 ref.)
The effect of peroxides and free radicals on body tissues. Floyd RA. **J Am Dent Assoc** 1997 Apr;128 Suppl:37S-40S (8 ref.)
Toxicological considerations of tooth bleaching using peroxide-containing agents. Li Y. **J Am Dent Assoc** 1997 Apr;128 Suppl:31S-36S (58 ref.)
Influence of oxygen radical injury on DNA methylation [see comments] Cerda S, et al. **Mutat Res** 1997 Apr; 386(2):141-52 (136 ref.) Comment in: Mutat Res 1997 Apr;386(2):103-5.

OXIDANTS, PHOTOCHEMICAL

ADVERSE EFFECTS

Cosmic radiation and ozone. Hack M. **Eur J Cancer Prev** 1996 Oct;5(5):378-9 (4 ref.)
Controlled human studies of ozone exposure. Bylin G. **Scand J Work Environ Health** 1996;22 Suppl 3:52-71 (113 ref.)
Epidemiologic studies on ozone. Nyberg F, et al. **Scand J Work Environ Health** 1996;22 Suppl 3:72-98 (144 ref.)

TOXICITY

Toxic oxidant species and their impact on the pulmonary surfactant system. Putman E, et al. **Lung** 1997;175(2):75-103 (156 ref.)

OXIDASES see **OXIDOREDUCTASES**

OXIDATION-REDUCTION

see related
ANTIOXIDANTS
OXIDANTS

Redox modulation of tyrosine phosphorylation-dependent

OXIDATION-REDUCTION

signal transduction pathways. Monteiro HP, et al. **Free Radic Biol Med** 1996;21(3):323–33 (106 ref.)

Redox regulation of transcriptional activators. Sun Y, et al. **Free Radic Biol Med** 1996;21(3):335–48 (133 ref.)

A common export pathway for proteins binding complex redox cofactors? Berks BC. **Mol Microbiol** 1996 Nov; 22(3):393–404 (90 ref.)

Role of uncoupled and non-coupled oxidations in maintenance of safely low levels of oxygen and its one-electron reductants. Skulachev VP. **Q Rev Biophys** 1996 May;29(2):169–202 (166 ref.)

A simple unified explanation of the red–ox and acid–base concepts. Macarulla JM. **Rev Esp Fisiol** 1996 Mar; 52(1):59–64 (2 ref.)

[Redox regulation of cellular signaling] Suzuki Y. **Seikagaku** 1997 Mar;69(3):187–91 (15 ref.) **(Jpn)**

OXIDATIVE BURST see **RESPIRATORY BURST**

OXIDATIVE PHOSPHORYLATION

see related
UNCOUPLING AGENTS

Mitochondrial oxidative phosphorylation changes in the life span. Molecular aspects and physiopathological implications. Papa S. **Biochim Biophys Acta** 1996 Sep 12; 1276(2):87–105 (243 ref.)

Evidence for physiological down-regulation of brain oxidative phosphorylation in Alzheimer's disease. Chandrasekaran K, et al. **Exp Neurol** 1996 Nov;142(1):80–8 (103 ref.)

Maternal inheritance and the evaluation of oxidative phosphorylation diseases. Shoffner JM. **Lancet** 1996 Nov 9;348(9037):1283–8 (35 ref.)

Brain energy metabolism, cognitive function and down-regulated oxidative phosphorylation in Alzheimer disease. Rapoport SI, et al. **Neurodegeneration** 1996 Dec; 5(4):473–6 (27 ref.)

[Mitochondrial cytopathies (editorial)] Rötig A. **Pathol Biol (Paris)** 1996 Apr;44(4):229–31 (11 ref.) **(Fre)**

DRUG EFFECTS

[Biological role and mechanisms of realization of the Crabtree effect in rapidly proliferating cells. The role of Ca2+ ions] Evtodienko IuV, et al. **Biokhimiia** 1996 Nov; 61(11):1995–2004 (65 ref.) (Eng. Abstr.) **(Rus)**

OXIDATIVE STRESS

Intramolecular ADP-ribose transfer reactions and calcium signalling. Potential role of 2'-phospho-cyclic ADP-ribose in oxidative stress. Vu CQ, et al. **Adv Exp Med Biol** 1997; 419:381–8 (31 ref.)

Protective action of nitrone-based free radical traps against oxidative damage to the central nervous system. Floyd RA. **Adv Pharmacol** 1997;38:361–78 (71 ref.)

Potential use of iron chelators against oxidative damage. Galey JB. **Adv Pharmacol** 1997;38:167–203 (141 ref.)

Role of oxidative stress and antioxidant therapy in alcoholic and nonalcoholic liver diseases. Lieber CS. **Adv Pharmacol** 1997;38:601–28 (188 ref.)

Oxidative stress and antioxidant function in relation to risk for cataract. Taylor A, et al. **Adv Pharmacol** 1997;38:515–36 (91 ref.)

Oxidative stress in cystic fibrosis: does it occur and does it matter? van der Vliet A, et al. **Adv Pharmacol** 1997; 38:491–513 (155 ref.)

Novel indices of oxidant stress in cardiovascular disease: specific analysis of F2-isoprostanes. Praticò D, et al. **Agents Actions Suppl** 1997;48:25–41 (61 ref.)

Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Repine JE, et al. **Am J Respir Crit Care Med** 1997 Aug;156(2 Pt 1):341–57 (296 ref.)

Chronic immune stimulation, oxidative stress, and apoptosis in HIV infection. Baier-Bitterlich G, et al. **Biochem Pharmacol** 1997 Mar 21;53(6):755–63 (123 ref.)

How knockout mouse lines will be used to study the role of drug-metabolizing enzymes and their receptors during reproduction and development, and in environmental toxicity, cancer, and oxidative stress. Nebert DW, et al. **Biochem Pharmacol** 1997 Feb 7;53(3):249–54 (44 ref.)

Oxidative stress and responses in Arabidopsis thaliana and Oryza sativa subjected to chilling and salinity stress. Burdon RH, et al. **Biochem Soc Trans** 1996 May; 24(2):469–72 (17 ref.)

Cytosolic calcium and oxidative plant stress. Price A, et al. **Biochem Soc Trans** 1996 May;24(2):479–83 (48 ref.)

Ascorbate metabolism in relation to oxidative stress. Smirnoff N, et al. **Biochem Soc Trans** 1996 May;24(2):472–8 (50 ref.)

Free oxygen radicals and surfactant. Bracci R. **Biol Neonate** 1997;71 Suppl 1:23–7 (35 ref.)

Cu,Zn-superoxide dismutase gene dosage and cell resistance to oxidative stress: a review. Peskin AV. **Biosci Rep** 1997 Feb;17(1):85–9 (54 ref.)

8-Epi PGF2 alpha: specific analysis of an isoeicosanoid as an index of oxidant stress in vivo. Delanty N, et al. **Br J Clin Pharmacol** 1996 Jul;42(1):15–9 (40 ref.)

Oxidative stress in acute intermittent porphyria and lead poisoning may be triggered by 5-aminolevulinic acid. Bechara EJ. **Braz J Med Biol Res** 1996 Jul;29(7):841–51 (78 ref.)

Reactive oxygen metabolites and arterial thrombosis. Ambrosio G, et al. **Cardiovasc Res** 1997 Jun;34(3):445–52 (58 ref.)

beta-Amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease. Butterfield DA. **Chem Res Toxicol** 1997 May;10(5):495–506 (113 ref.)

Mitochondria, free radicals, and neurodegeneration. Beal MF. **Curr Opin Neurobiol** 1996 Oct;6(5):661–6 (45 ref.)

Regulation of bacterial responses to oxidative stress. Rosner JL, et al. **Curr Top Cell Regul** 1997;35:163–77 (66 ref.)

Oxidative stress and platelet activation in diabetes mellitus. Catella-Lawson F, et al. **Diabetes Res Clin Pract** 1996 Feb; 30 Suppl:13–8 (40 ref.)

The impact of oxidative stress on eukaryotic iron metabolism. Rouault TA, et al. **EXS** 1996;77:183–97 (58 ref.)

Transcriptional regulators of oxidative stress-inducible genes in prokaryotes and eukaryotes. Storz G, et al. **EXS** 1996; 77:239–54 (88 ref.)

Oxidative stress hypothesis in Alzheimer's disease. Markesbery WR. **Free Radic Biol Med** 1997;23(1):134–47 (155 ref.)

Oxidative stress during viral infection: a review. Schwarz KB. **Free Radic Biol Med** 1996;21(5):641–9 (76 ref.)

Aging and oxidative stress: modulation by dietary restriction. Yu BP. **Free Radic Biol Med** 1996;21(5):651–68 (164 ref.)

Oxidative stress, nutrition and health. Experimental strategies for optimization of nutritional antioxidant intake in humans. Halliwell B. **Free Radic Res** 1996 Jul;25(1):57–74 (210 ref.)

High cardiovascular mortality in postcommunist countries: participation of oxidative stress? Ginter E. **Int J Vitam Nutr Res** 1996;66(3):183–9 (33 ref.)

Nutritional implications in vascular endothelial cell metabolism. Hennig B, et al. **J Am Coll Nutr** 1996 Aug; 15(4):345–58 (138 ref.)

The effect of peroxides and free radicals on body tissues. Floyd RA. **J Am Dent Assoc** 1997 Apr;128 Suppl:37S–40S (8 ref.)

Role of oxidative stress and antioxidants in male infertility. Sikka SC, et al. **J Androl** 1995 Nov–Dec;16(6):464–81 (16 ref.)

Protein oxidation in aging, disease, and oxidative stress. Berlett BS, et al. **J Biol Chem** 1997 Aug 15;272(33):20313–6 (49 ref.)

Cancer risk and oxidative DNA damage in man [published erratum appears in J Mol Med 1997 Jan;75(1):67–8] Loft S, et al. **J Mol Med** 1996 Jun;74(6):297–312 (167 ref.)

Dietary modulation of oxidative stress in alcoholic liver disease in rats. Porta EA. **J Nutr** 1997 May;127(5 Suppl):912S–915S (32 ref.)

Oxidative stress, mutant SOD1, and neurofilament pathology in transgenic mouse models of human motor neuron disease. Tu PH, et al. **Lab Invest** 1997 Apr;76(4):441–56 (144 ref.)

Cardiomyopathies and oxidative stress. Romero-Alvira D, et al. **Med Hypotheses** 1996 Aug;47(2):137–44 (89 ref.)

The heat shock/oxidative stress connection. Relevance to Alzheimer disease. Pappolla MA, et al. **Mol Chem Neuropathol** 1996 May–Aug;28(1–3):21–34 (57 ref.)

Oxidative posttranslational modifications in Alzheimer disease. A possible pathogenic role in the formation of senile plaques and neurofibrillary tangles. Smith MA, et al. **Mol Chem Neuropathol** 1996 May–Aug;28(1–3):41–8 (41 ref.)

Potential effects of age-associated oxidative stress on mammalian oocytes/embryos. Tarín JJ. **Mol Hum Reprod** 1996 Oct;2(10):717–24 (122 ref.)

Amyloid beta-peptide and oxidative cellular injury in Alzheimer's disease. Mark RJ, et al. **Mol Neurobiol** 1996 Jun;12(3):211–24 (91 ref.)

Influence of oxygen radical injury on DNA methylation [see comments] Cerda S, et al. **Mutat Res** 1997 Apr; 386(2):141–52 (136 ref.) Comment in: Mutat Res 1997 Apr;386(2):103–5.

Energy metabolism, oxidative stress and neuronal degeneration in Alzheimer's disease. Sims NR. **Neurodegeneration** 1996 Dec;5(4):435–40 (49 ref.)

Oxidative stress and the pathogenesis of Parkinson's disease. Jenner P, et al. **Neurology** 1996 Dec;47(6 Suppl 3):S161–70 (128 ref.)

Oxidative stress and liver disease. Kaplowitz N, et al. **Prog Liver Dis** 1996;14:131–59 (148 ref.)

Oxidative injury and potential use of antioxidants in schizophrenia. Mahadik SP, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Aug; 55(1–2):45–54 (117 ref.)

Free radical pathology in schizophrenia: a review. Reddy RD, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Aug;55(1–2):33–43 (137 ref.)

Exploring the role of oxygen in Fanconi's anemia. Liebetrau W, et al. **Recent Results Cancer Res** 1997;143:353–67 (31 ref.)

Role of oxidative stress in the pathogenesis of acute pancreatitis. Sweiry JH, et al. **Scand J Gastroenterol Suppl** 1996;219:10–5 (47 ref.)

Role of oxidant stress in the adult respiratory distress syndrome: evaluation of a novel antioxidant strategy in a porcine model of endotoxin-induced acute lung injury. Gonzalez PK, et al. **Shock** 1996;6 Suppl 1:S23–6 (54 ref.)

[Oxidative stress: value of its demonstration in medical biology and problems posed by the choice of a marker] Favier A. **Ann Biol Clin (Paris)** 1997 Jan–Feb;55(1):9–16 (25 ref.) (Eng. Abstr.) **(Fre)**

[Free radicals: concepts, associated diseases, defense system and oxidative stress] Ferreira AL, et al. **Rev Assoc Med Bras** 1997 Jan–Mar;43(1):61–8 (54 ref.) **(Por)**

[Changes in DNA induced by oxidative stress] Roche E, et al. **Med Clin (Barc)** 1996 Feb 3;106(4):144–53 (114 ref.) **(Spa)**

[Dopaminergic system and neuronal death] Luquin MR, et al. **Rev Neurol** 1997 Aug;25 Suppl 2:S129–40 (88 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

The neurochemistry of Parkinson's disease--comments on present and future developments. Hucho F. **J Neural Transm Suppl** 1995;46:59–65 (22 ref.)

GENETICS

Redox signaling and gene control in the Escherichia coli soxRS oxidative stress regulon--a review. Demple B. **Gene** 1996 Nov 7;179(1):53–7 (25 ref.)

Regulation of the oxidative stress protective enzymes, catalase and superoxide dismutase in Xanthomonas--a review. Loprasert S, et al. **Gene** 1996 Nov 7;179(1):33–7 (25 ref.)

PHYSIOLOGY

Neuronal necrosis and apoptosis: two distinct events induced by exposure to glutamate or oxidative stress. Nicotera P, et al. **Adv Neurol** 1997;72:95–101 (53 ref.)

GSH transport in mitochondria: defense against TNF-induced oxidative stress and alcohol-induced defect. Fernández-Checa JC, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):G7–17 (85 ref.)

Exercise, oxidative stress, and antioxidants. Ji LL. **Am J Sports Med** 1996;24(6 Suppl):S20–4 (42 ref.)

Oxidative stress: animal adaptations in nature. Storey KB. **Braz J Med Biol Res** 1996 Dec;29(12):1715–33 (85 ref.)

Oxidative stress associated with exercise, psychological stress and life-style factors. Møller P, et al. **Chem Biol Interact** 1996 Sep 27;102(1):17–36 (171 ref.)

Two-stage gene regulation of the superoxide stress response soxRS system in Escherichia coli. Nunoshiba T. **Crit Rev Eukaryot Gene Expr** 1996;6(4):377–89 (92 ref.)

Oxidative stress in clinical situations--fact or fiction? Pincemail J, et al. **Eur J Anaesthesiol** 1996 May; 13(3):219–34 (151 ref.)

Free radicals, oxidative damage and degenerative diseases [editorial] Giacosa A, et al. **Eur J Cancer Prev** 1996 Oct; 5(5):307–12 (35 ref.)

Exercise, free radical generation and vitamins. Giuliani A, et al. **Eur J Cancer Prev** 1997 Mar;6 Suppl 1:S55–67 (163 ref.)

Endothelial barrier dysfunction and oxidative stress: roles for nitric oxide? McQuaid KE, et al. **Exp Physiol** 1997 Mar; 82(2):369–76 (30 ref.)

Oxidative stress: oxidants and antioxidants. Sies H. **Exp Physiol** 1997 Mar;82(2):291–5 (19 ref.)

Oxidative stress and living cells. Gille G, et al. **Folia Microbiol (Praha)** 1995;40(2):131–52 (149 ref.)

Iron homeostasis, oxidative stress, and DNA damage. Meneghini R. **Free Radic Biol Med** 1997;23(5):783–92 (74 ref.)

Oxidative damage and fibrogenesis. Poli G, et al. **Free Radic Biol Med** 1997;22(1–2):287–305 (219 ref.)

Antioxidants in peripheral nerve. Romero FJ. **Free Radic Biol Med** 1996;20(7):925–32 (112 ref.)

Isoprostanes--prostaglandin-like compounds formed in vivo independently of cyclooxygenase: use as clinical indicators of oxidant damage. Awad JA, et al. **Gastroenterol Clin North Am** 1996 Jun;25(2):409–27 (76 ref.)

Homocysteine, oxidative stress, and vascular disease [see comments] Welch GN, et al. **Hosp Pract (Off Ed)** 1997 Jun 15;32(6):81–2, 85, 88–92 (13 ref.) Comment in: Hosp Pract (Off Ed) 1997 Aug 15;32(8):44.

Muscle cell and oxidative damage in aging: a century of hypothesis and personal contribution. Montanari G, et al. **Int J Tissue React** 1996;18(1):33–41 (55 ref.)

Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. Becker BN, et al. **J Am Soc Nephrol** 1997 Mar;8(3):475–86 (136 ref.)

Reactive oxygen species and antioxidants in inflammatory diseases. Chapple IL. **J Clin Periodontol** 1997 May; 24(5):287–96 (103 ref.)

Oxidative stress and apoptosis in neurodegeneration. Gorman AM, et al. **J Neurol Sci** 1996 Aug;139 Suppl:45–52 (75 ref.)

Yeast metallothionein gene expression in response to metals and oxidative stress. Liu XD, et al. **Methods** 1997 Mar; 11(3):289–99 (56 ref.)

The molecular defences against reactive oxygen species in yeast. Moradas-Ferreira P, et al. **Mol Microbiol** 1996 Feb; 19(4):651–8 (50 ref.)

Can cysteine direct tyrosine in signal transduction for environment-oriented gene control? Nakashima I. **Nagoya J Med Sci** 1996 Mar;59(1–2):1–10 (72 ref.)

Oxidative stress caused by glycation of Cu,Zn-superoxide dismutase and its effects on intracellular components. Fujii J, et al. **Nephrol Dial Transplant** 1996;11 Suppl 5:34–40 (36 ref.)

Mechanisms involved in the generation of free radicals.

Halliwell B. **Pathol Biol (Paris)** 1996 Jan;44(1):6–13 (68 ref.)
Oxidative stress in Parkinson's disease and other neurodegenerative disorders. Jenner P. **Pathol Biol (Paris)** 1996 Jan;44(1):57–64 (51 ref.)
Role of DNA repair enzymes in the cellular resistance to oxidative stress. Laval J. **Pathol Biol (Paris)** 1996 Jan; 44(1):14–24 (92 ref.)
Oxidative stress in malaria; implications for prevention and therapy. Postma NS, et al. **Pharm World Sci** 1996 Aug; 18(4):121–9 (124 ref.)
Superoxide dismutase and pulmonary oxygen toxicity. Tsan MF. **Proc Soc Exp Biol Med** 1997 Feb;214(2):107–13 (82 ref.)
Interrelationships between astrocyte function, oxidative stress and antioxidant status within the central nervous system. Peuchen S, et al. **Prog Neurobiol** 1997 Jul;52(4):261–81 (311 ref.)
Oxidative damage to DNA: formation, measurement, and biological significance. Cadet J, et al. **Rev Physiol Biochem Pharmacol** 1997;131:1–87 (405 ref.)
The pathophysiological role of peroxynitrite in shock, inflammation, and ischemia–reperfusion injury. Szabó C. **Shock** 1996 Aug;6(2):79–88 (162 ref.)
Markers of platelet activation and oxidant stress in atherothrombotic disease. FitzGerald GA, et al. **Thromb Haemost** 199/ Jul;78(1):280–4 (68 ref.)
[Alcohol and free radicals: from basic research to clinical prospects] Nordmann R, et al. **Ann Gastroenterol Hepatol (Paris)** 1996 May–Jun; 32(3):128–33; discussion 133–4 (41 ref.) (Eng. Abstr.) **(Fre)**
[Oxidative stress and apoptosis] Mathieu J, et al. **Ann Pharm Fr** 1996;54(5):193–201 (88 ref.) (Eng. Abstr.) **(Fre)**
[Role of oxidative stress in aging] Remacle J, et al. **Pathol Biol (Paris)** 1996 Jan;44(1):65–76 (64 ref.) (Eng. Abstr.) **(Fre)**
[The role of oxidative stress in the pathogenesis of diabetic macroangiopathy] Przybyś W. **Pol Arch Med Wewn** 1996 Oct;96(4):386–94 (49 ref.) **(Pol)**
[Adaptation mechanisms of cells and removal of damage due to oxidative stress] Farbiszewski R, et al. **Postepy Hig Med Dosw** 1996;50(6):613–20 (45 ref.) (Eng. Abstr.) **(Pol)**
[Role of glutathione containing amino acids in the correction of body's dysadaptation states] Pavlov VA. **Probl Tuberk** 1997;(3):51–3 (10 ref.) (Eng. Abstr.) **(Rus)**
[Oxidant stress—the general mechanism of the damage in nervous system diseases] Zavalishin IA, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(2):111–4 (29 ref.) **(Rus)**
[Oxidative stress and molecular biology in ulcerative colitis and cancer] Romero Alvira D, et al. **Rev Esp Enferm Dig** 1997 Jun;89(6):463–73 (134 ref.) **(Spa)**

OXIDES

see related
CYCLIC N-OXIDES

OXIDIZING AGENTS see **OXIDANTS**

OXIDOPAMINE

The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Schwarting RK, et al. **Prog Neurobiol** 1996 Oct;50(2–3):275–331 (395 ref.)

METABOLISM

Modulation of 6-hydroxydopamine oxidation by various proteins. Padiglia A, et al. **Biochem Pharmacol** 1997 Apr 25;53(8):1065–8 (32 ref.)

PHARMACOLOGY

Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. Schwarting RK, et al. **Prog Neurobiol** 1996 Jun; 49(3):215–66 (596 ref.)

TOXICITY

Mechanism of 6-hydroxydopamine neurotoxicity. Glinka Y, et al. **J Neural Transm Suppl** 1997;50:55–66 (41 ref.)

OXIDOREDUCTASES

[Structure and evolution of enzymes involved in fatty acid oxidation] Sato S, et al. **Seikagaku** 1996 Nov; 68(11):1692–703 (105 ref.) **(Jpn)**

ANALYSIS

Methods for chromatographic and electrophoretic separation and assay of NADP oxidoreductases. Toribio F, et al. **J Chromatogr B Biomed Appl** 1996 Sep 20;684(1–2):1–23 (214 ref.)

BLOOD

Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits. Milano G, et al. **Ther Drug Monit** 1996 Aug;18(4):335–40 (41 ref.)

CHEMISTRY

NAD-binding domains of dehydrogenases. Lesk AM. **Curr Opin Struct Biol** 1995 Dec;5(6):775–83 (24 ref.)
[Cytochrome bd: structure and properties] Borisov VB. **Biokhimiia** 1996 May;61(5):786–99 (93 ref.) (Eng. Abstr.) **(Rus)**

DEFICIENCY

Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy. Morrison GB, et al. **Oncol Nurs Forum** 1997 Jan–Feb;24(1):83–8 (22 ref.)
Hyperhomocysteinaemia and associated disease. Bakker RC, et al. **Pharm World Sci** 1997 Jun;19(3):126–32 (83 ref.)

GENETICS

Abnormal cholesterol biosynthesis in the Smith–Lemli–Opitz syndrome. Salen G, et al. **J Lipid Res** 1996 Jun; 37(6):1169–80 (64 ref.)
Molecular basis of polymorphic drug metabolism. Daly AK. **J Mol Med** 1995 Nov;73(11):539–53 (210 ref.)

ISOLATION & PURIFICATION

Purification and characterization of glutathione-dependent dehydroascorbate reductase from rat liver. Maellaro E, et al. **Methods Enzymol** 1997;279:30–5 (13 ref.)

METABOLISM

Investigation of the carbon- and sulfur-oxidizing capabilities of microorganisms by active-site modeling. Holland HL. **Adv Appl Microbiol** 1997;44:125–65 (90 ref.)
Nicotinoprotein alcohol/aldehyde oxidoreductases. Enzymes with bound NAD(P) as cofactor. Piersma SR, et al. **Adv Exp Med Biol** 1997;414:425–34 (29 ref.)
Oxidoreductase-type enzymes and redox proteins involved in fermentative metabolisms of hyperthermophilic Archaea. Adams MW, et al. **Adv Protein Chem** 1996;48:101–80 (210 ref.)
Enzyme diversity and mosaic gene organization in denitrification. Zumft WG, et al. **Antonie Van Leeuwenhoek** 1997 Feb;71(1–2):43–58 (139 ref.)
Studies on non-haem ferrous-dependent oxygenases and oxidases. Barlow JN, et al. **Biochem Soc Trans** 1997 Feb; 25(1):86–90 (30 ref.)
Possible mechanism for late gestational development of the antioxidant enzymes in the fetal rat lung. Frank L, et al. **Biol Neonate** 1996;70(2):116–27 (57 ref.)
In situ heterogeneity of peroxisomal oxidase activities: an update. Van den Munckhof RJ. **Histochem J** 1996 Jun; 28(6):401–29 (348 ref.)
[The effect of Maillard reaction products on enzyme reactions] Schumacher D, et al. **Z Ernahrungswiss** 1996 Sep;35(3):213–25 (108 ref.) (Eng. Abstr.) **(Ger)**
[Cytochrome bd: structure and properties] Borisov VB. **Biokhimiia** 1996 May;61(5):786–99 (93 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Succinate: quinone oxidoreductases. Variations on a conserved theme. Hägerhäll C. **Biochim Biophys Acta** 1997 Jun 13;1320(2):107–41 (188 ref.)
The 5 alpha-reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders. Chen W, et al. **Dermatology** 1996;193(3):177–84 (58 ref.)
The roles of the thiol:protein disulfide oxidoreductases in membrane and secretory protein synthesis within the lumen of the endoplasmic reticulum. Holtzman JL. **J Investig Med** 1997 Feb;45(2):28–34 (52 ref.)
Metabolism of steroids in the brain: a new insight into the role of 5alpha-reductase and aromatase in brain differentiation and functions. Negri-Cesi P, et al. **J Steroid Biochem Mol Biol** 1996 Aug;58(5–6):455–66 (116 ref.)

OXIDOREDUCTASES, N-DEMETHYLATING

ANTAGONISTS & INHIBITORS

Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies. Greenblatt DJ, et al. **J Clin Pharmacol** 1996 Sep;36(9):792–8 (51 ref.)

METABOLISM

Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. Wilkinson GR. **J Pharmacokinet Biopharm** 1996 Oct;24(5):475–90 (38 ref.)

OXIDOREDUCTASES, O-DEMETHYLATING

DEFICIENCY

Low frequency of dextromethorphan O-demethylation deficiency in a Chinese population [letter] Lane HY, et al. **Clin Pharmacol Ther** 1996 Dec;60(6):696–8 (19 ref.)

OXIDOREDUCTASES, NADH, NADPH see **NADH, NADPH OXIDOREDUCTASES**

OXIMES

DIAGNOSTIC USE

Sensitivity, specificity, and positive predictive value of technetium 99-HMPAO SPECT in discriminating Alzheimer's disease from other dementias. Masterman DL, et al. **J Geriatr Psychiatry Neurol** 1997 Jan;10(1):15–21 (50 ref.)
Brain single-photon emission CT with HMPAO and safety of thrombolytic therapy in acute ischemic stroke. Proceedings of the meeting of the SPECT Safe Thrombolysis Study Collaborators and the members of the Brain Imaging Council of the Society of Nuclear Medicine. Alexandrov AV, et al. **Stroke** 1997 Sep;28(9):1830–4 (32 ref.)

THERAPEUTIC USE

Pharmacological effects of oximes: how relevant are they? van Helden HP, et al. **Arch Toxicol** 1996;70(12):779–86 (44 ref.)

OXIMETRY

Pulse oximetry and supplemental oxygen during gastrointestinal endoscopy: a critical review [see comments] Holm C, et al. **Endoscopy** 1996 Oct;28(8):703–11 (85 ref.) Comment in: Endoscopy 1996 Oct;28(8):718–21.
Pulse oximetry—physiological considerations. Hanson MA, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Mar;72 Suppl:S3–8 (10 ref.)
Physio-optical considerations in the design of fetal pulse oximetry sensors. Mannheimer PD, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Mar;72 Suppl:S9–19 (26 ref.)
Accuracy of fetal pulse oximetry and pitfalls in measurements. Nijland R, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Mar;72 Suppl:S21–7 (50 ref.)
Continuous intra-arterial blood gas monitoring. Venkatesh B, et al. **Intensive Care Med** 1996 Aug;22(8):818–28 (67 ref.)
Fetal pulse oximetry during labor: issues and recommendations for clinical use. Saling E. **J Perinat Med** 1996;24(5):467–78 (25 ref.)
Fetal oximetry monitoring: a new wonder or another mirage? Lurie S, et al. **Obstet Gynecol Surv** 1996 Aug;51(8):498–502 (29 ref.)
[Pulse oximetry in pediatrics] Carbajal R. **Arch Pediatr** 1996 Nov;3(11):1129–35 (33 ref.) (Eng. Abstr.) **(Fre)**
[Assessment of pulse oximetry readings] Kimura T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:35–8 (8 ref.) **(Jpn)**

METHODS

Fetal pulse oximetry. Luttkus AK, et al. **Baillieres Clin Obstet Gynaecol** 1996 Jun;10(2):295–306 (28 ref.)
Continuous measurement of cardiac output by the Fick principle in infants and children: comparison with the thermodilution method. Wippermann CF, et al. **Intensive Care Med** 1996 May;22(5):467–71 (20 ref.)
Jugular bulb oximetry for the monitoring of cerebral blood flow and metabolism. Mayberg TS, et al. **Neurosurg Clin N Am** 1996 Oct;7(4):755–65 (71 ref.)

STANDARDS

Simultaneous measurement of total hemoglobin and its derivatives in blood using CO-oximeters: analytical principles; their application in selecting analytical wavelengths and reference methods; a comparison of the results of the choices made. Brunelle JA, et al. **Scand J Clin Lab Invest Suppl** 1996;224:47–69 (34 ref.)

OXIMETRY, TRANSCUTANEOUS see **BLOOD GAS MONITORING, TRANSCUTANEOUS**

2-OXO ACID CARBOXY-LYASE see **PYRUVATE DECARBOXYLASE**

6-OXO-PGF1 ALPHA see **6-KETOPROSTAGLANDIN F1 ALPHA**

OXOPROPANAL see **PYRUVALDEHYDE**

6-OXOPROSTAGLANDIN F1 ALPHA see **6-KETOPROSTAGLANDIN F1 ALPHA**

OXOQUINOLINES see **QUINOLONES**

3-OXOSTEROID ISOMERASES see **STEROID ISOMERASES**

OXYBATE SODIUM see **SODIUM OXYBATE**

OXYCEPHALY see **CRANIOSYNOSTOSES**

OXYCHLOROCHIN see **HYDROXYCHLOROQUINE**

OXYCHLOROQUINE see **HYDROXYCHLOROQUINE**

OXYGEN

see related
ANOXEMIA
ANOXIA

Fire hazard in oxygen-enriched atmospheres at low barometric pressures. West JB.
Aviat Space Environ Med 1997 Feb;68(2):159-62 (6 ref.)

Free oxygen radicals and surfactant. Bracci R.
Biol Neonate 1997;71 Suppl 1:23-7 (35 ref.)

Oxygen free radicals and platelet activation. Iuliano L, et al. **Free Radic Biol Med** 1997;22(6):999-1006 (76 ref.)

Primary aromatic amines: their N-oxidative bioactivation. Hlavica P, et al. **Hum Exp Toxicol** 1997 Aug;16(8):441-8 (81 ref.)

Control of mitochondrial and cellular respiration by oxygen. Gnaiger E, et al. **J Bioenerg Biomembr** 1995 Dec; 27(6):583-96 (62 ref.)

Effects of air and oxygen on parenteral nutrition admixtures--an underrated risk? Allwood MC, et al. **Nutrition** 1996 Mar;12(3):222-3 (19 ref.)

[Oxygen and vital signs] Irita K. **Fukuoka Igaku Zasshi** 1996 Dec;87(12):253-9 (2 ref.) **(Jpn)**

[Complete genome sequence of a cyanobacterium Synechocystis sp. PCC 6803, the oxygenic photosynthetic prokaryote] Ikeuchi M. **Tanpakushitsu Kakusan Koso** 1996 Dec;41(16):2579-83 (9 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Advanced fluorocarbon-based systems for oxygen and drug delivery, and diagnosis. Riess JG, et al.
Artif Cells Blood Substit Immobil Biotechnol 1997 Jan-Mar; 25(1-2):43-52 (36 ref.)

ADVERSE EFFECTS

Oxygen venous embolism after the use of hydrogen peroxide during lumbar discectomy. Despond O, et al.
Can J Anaesth 1997 Apr;44(4):410-3 (18 ref.)

ANALYSIS

Oxygen electrodes and optodes and their application in vivo. Lübbers DW. **Adv Exp Med Biol** 1996;388:13-34 (84 ref.)

Oxygen dependent quenching of phosphorescence: a status report. Wilson DF, et al. **Adv Exp Med Biol** 1996;388:101-7 (38 ref.)

Rapid monitoring of gastrointestinal intraluminal PCO2 as an end-organ perfusion index [editorial; comment] Tao W, et al. **Crit Care Med** 1997 Sep;25(9):1458-9 (28 ref.) Comment on: Crit Care Med 1997 Sep;25(9):1575-8.

BLOOD

PO2 affinities, heme proteins, and reactive oxygen intermediates involved in intracellular signal cascades for sensing oxygen. Acker H. **Adv Exp Med Biol** 1996; 410:59-64 (36 ref.)

Mechanisms of carotid chemoreceptor resetting after birth. In vitro studies. Carroll JL, et al. **Adv Exp Med Biol** 1996; 410:73-7 (19 ref.)

Modulation of voltage-gated Ca2+ channels by O2 tension. Significance for arterial oxygen chemoreception. Franco-Obregón A, et al. **Adv Exp Med Biol** 1996; 410:97-103 (283 ref.)

Linking cerebral blood oxygenation to human brain function. Current issues for human neuroscience by magnetic resonance neuroimaging. Kleinschmidt A, et al.
Adv Exp Med Biol 1997;413:221-33 (39 ref.)

Carotid chemoreflex. Neural pathways and transmitters. Sapru HN. **Adv Exp Med Biol** 1996;410:357-64 (22 ref.)

Prolegomena. Chemoreception upstream of transmitters. Torrance RW. **Adv Exp Med Biol** 1996;410:13-38 (49 ref.)

Domperidone as a tool to assess the role of dopamine within carotid body chemoreception. Zapata P, et al.
Adv Exp Med Biol 1996;410:291-7 (36 ref.)

Theoretical predictions of end-capillary PO2 in muscles of athletic and nonathletic animals at VO2max. Roy TK, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):H721-37 (72 ref.)

A 'BOLD' new approach to renal oxygen economy [editorial; comment] Kone BC. **Circulation** 1996 Dec 15;94(12):3067-8 (17 ref.) Comment on: Circulation 1996 Dec 15;94(12):3271-5.

Evaluation of the newborn's blood gas status. National Academy of Clinical Biochemistry. Brouillette RT, et al. **Clin Chem** 1997 Jan;43(1):215-21 (32 ref.)

Current status of the multicenter randomized clinical trial on fetal oxygen saturation monitoring in the United States. Dildy GA, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Mar;72 Suppl:S43-50 (47 ref.)

Pulse oximetry--physiological considerations. Hanson MA, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Mar;72 Suppl:S3-8 (10 ref.)

Measurement of maximal and submaximal anaerobic performance capacity: concluding chapter. Rusko HK, et al. **Int J Sports Med** 1996 Jul;17 Suppl 2:S125-9 (29 ref.)

Oxygen and carbon dioxide transport in vertebrate erythrocytes: an evolutionary change in the role of membrane transport. Nikinmaa M. **J Exp Biol** 1997 Jan;200 (Pt 2):369-80 (118 ref.)

The interaction of pulmonary ventilation and the right-left shunt on arterial oxygen levels. Wang T, et al.
J Exp Biol 1996 Oct;199 (Pt 10):2121-9 (28 ref.)

Oxygen transport deficits in systemic disease and implications for physical therapy. Dean E. **Phys Ther** 1997 Feb; 77(2):187-202 (120 ref.)

Acute hypoxic pulmonary vasoconstriction: a model of oxygen sensing. Michelakis ED, et al. **Physiol Res** 1995; 44(6):361-7 (45 ref.)

Blood gases and hypothermia: some theoretical and practical considerations. Kofstad J.
Scand J Clin Lab Invest Suppl 1996;224:21-6 (8 ref.)

Definition, significance and measurement of quantities pertaining to the oxygen carrying properties of human blood. Zijlstra WG, et al.
Scand J Clin Lab Invest Suppl 1996;224:27-45 (69 ref.)

[Maximizing O2-transport in critical illness. A rational therapeutic concept?] Forst H. **Anaesthesist** 1997 Jan; 46(1):46-52 (75 ref.) (Eng. Abstr.) **(Ger)**

[Oxygen supply and acid-base status in extreme anemia] Zander R.
Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Oct; 31(8):492-4 (30 ref.) **(Ger)**

[PO2-affinity of oxygen-sensitive intracellular signal cascades] Acker H. **Pneumologie** 1997 Apr;51 Suppl 2:403-5 (22 ref.) (Eng. Abstr.) **(Ger)**

[Assessment of pulse oximetry readings] Kimura T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:35-8 (8 ref.) **(Jpn)**

CHEMISTRY

Molecular modeling of singlet-oxygen binding to anthraquinones in relation to the peroxidating activity of antitumor anthraquinone drugs. Liwo A, et al.
Acta Biochim Pol 1995;42(4):445-56 (47 ref.)

Reaction of peroxynitrite and hydrogen peroxide to produce singlet molecular oxygen (1deltag). Di Mascio P, et al.
Methods Enzymol 1996;269:395-400 (20 ref.)

DIAGNOSTIC USE

[Cerebral perfusion and oxygen metabolism in Parkinson's disease: positron emission tomographic study using oxygen-15-labeled CO2 and O2] Tanaka M, et al.
Nippon Rinsho 1997 Jan;55(1):218-21 (9 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Metabolic aspects of neurovascular coupling. Dirnagl U.
Adv Exp Med Biol 1997;413:155-9 (35 ref.)

Cerebral oxygenation states as revealed by near-infrared spectrophotometry. Tamura M, et al.
Adv Exp Med Biol 1997;413:91-6 (22 ref.)

Carbon monoxide excretion, not oxygen secretion? Torrance RW. **Adv Exp Med Biol** 1996;410:335-9 (11 ref.)

Vascularization, blood flow, oxygenation, tissue pH, and bioenergetic status of human breast cancer. Vaupel P.
Adv Exp Med Biol 1997;411:243-54 (40 ref.)

Light-harvesting complexes in oxygenic photosynthesis: diversity, control, and evolution. Grossman AR, et al.
Annu Rev Genet 1995;29:231-88 (368 ref.)

O2-sensing mechanisms in excitable cells: role of plasma membrane K+ channels. Haddad GG, et al.
Annu Rev Physiol 1997;59:23-42 (73 ref.)

Oxygen processing in photosynthesis. Foyer CH.
Biochem Soc Trans 1996 May;24(2):427-33 (61 ref.)

Mechanisms of oxygen taxis in bacteria. Grishanin RN, et al. **Biosci Rep** 1997 Feb;17(1):77-83 (28 ref.)

Oxygen deficit: a measure of the anaerobic energy production during intense exercise? [see comments] Bangsbo J. **Can J Appl Physiol** 1996 Oct;21(5):350-63; discussion 364-9 (26 ref.) Comment in: Can J Appl Physiol 1996 Oct;21(5):347-9.

Is the maximal accumulated oxygen deficit an adequate measure of the anaerobic capacity? [see comments] Medbø JI. **Can J Appl Physiol** 1996 Oct;21(5):370-83; discussion 384-8 (37 ref.) Comment in: Can J Appl Physiol 1996 Oct;21(5):347-9.

Microvascular and tissue oxygen distribution. Intaglietta M, et al. **Cardiovasc Res** 1996 Oct;32(4):632-43 (78 ref.)

Oxygen sensing and signal transduction in metabolic defense against hypoxia: lessons from vertebrate facultative anaerobes. Hochachka PW, et al.
Comp Biochem Physiol A Physiol 1997 Sep;118(1):23-9 (40 ref.)

Oxygen sensors in the organism: examples of regulation under altitude hypoxia in mammals. Richalet JP.
Comp Biochem Physiol A Physiol 1997 Sep;118(1):9-14 (16 ref.)

Oxygen delivery in critical illness. Baigorri F, et al.
Crit Care Clin 1996 Oct;12(4):971-94 (91 ref.)

Oxygen transport and oxygen metabolism in shock and critical illness. Invasive and noninvasive monitoring of circulatory dysfunction and shock. Shoemaker WC.
Crit Care Clin 1996 Oct;12(4):939-69 (55 ref.)

Determination of oxygen delivery and consumption versus cardiac index and oxygen extraction ratio. Vincent JL.
Crit Care Clin 1996 Oct;12(4):995-1006 (29 ref.)

The use of hyperventilation and its impact on cerebral ischemia in the treatment of traumatic brain injury. Yundt KD, et al. **Crit Care Clin** 1997 Jan;13(1):163-84 (85 ref.)

Near-infrared spectroscopy for the in vivo study of cerebral hemodynamics and oxygenation. du Plessis AJ.
Curr Opin Pediatr 1995 Dec;7(6):632-9 (37 ref.)

Cellular and molecular physiology of Escherichia coli in the adaptation to aerobic environments. Iuchi S, et al.
J Biochem (Tokyo) 1996 Dec;120(6):1055-63 (50 ref.)

Pathophysiological changes in cerebral circulation, oxidative metabolism and blood-brain barrier in patients with acute liver failure. Tailored cerebral oxygen utilization. Larsen FS, et al. **J Hepatol** 1997 Jul;27(1):231-8 (65 ref.)

Pathological aspects of active oxygens/free radicals. Nakazawa H, et al. **Jpn J Physiol** 1996 Feb;46(1):15-32 (135 ref.)

Erythropoietin gene regulation depends on heme-dependent oxygen sensing and assembly of interacting transcription factors. Huang LE, et al. **Kidney Int** 1997 Feb;51(2):548-52 (34 ref.)

Oxygen sensing by ion channels. López-Barneo J, et al.
Kidney Int 1997 Feb;51(2):454-61 (43 ref.)

Oxygen regulated gene expression: erythropoietin as a model system. Ratcliffe PJ, et al. **Kidney Int** 1997 Feb;51(2):514-26 (79 ref.)

Diversity of response in vascular smooth muscle cells to changes in oxygen tension. Weir EK, et al. **Kidney Int** 1997 Feb;51(2):462-6 (41 ref.)

Gastrointestinal tonometry: a monitor of regional dysoxia. Gutierrez G, et al. **New Horiz** 1996 Nov;4(4):413-9 (52 ref.)

Role of uncoupled and non-coupled oxidations in maintenance of safely low levels of oxygen and its one-electron reductants. Skulachev VP. **Q Rev Biophys** 1996 May;29(2):169-202 (166 ref.)

Cellular mechanisms of oxygen chemoreception in the carotid body. Gonzalez C, et al. **Respir Physiol** 1995 Dec; 102(2-3):137-47 (38 ref.)

[Free radicals and surgical stress] Yukioka T, et al.
Nippon Geka Gakkai Zasshi 1996 Sep;97(9):716-20 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Erythrocyte pyruvate kinase--an enzyme that may have an influence on oxygen transport to tissues] Dąbrowska A. **Postepy Hig Med Dosw** 1997;51(3):305-18 (69 ref.) (Eng. Abstr.) **(Pol)**

[Anti-oxidants, free radicals, and health. A chemical, organic, and physical approach] Ballester M. **Med Clin (Barc)** 1996 Oct 19;107(13):509-15 (64 ref.) **(Spa)**

PHARMACOKINETICS

Perfluorochemical oxygen carriers: potential uses in neurosciences. Sakas DE, et al.
Cerebrovasc Brain Metab Rev 1996 Fall;8(3):209-29 (172 ref.)

Fetal chemoreception: a developing story. Teitel DF.
Reprod Fertil Dev 1996;8(3):471-82 (121 ref.)

Pathophysiology of hydrops fetalis. Apkon M.
Semin Perinatol 1995 Dec;19(6):437-46 (44 ref.)

[General principles of oxygen transport in the venous wall] Michel CC. **J Mal Vasc** 1996;21 Suppl C:239-44 (11 ref.) (Eng. Abstr.) **(Fre)**

[Is hypoxia a stimulus for structural and metabolic changes in skeletal muscles?] Nemirovskaia TL, et al.
Fiziol Cheloveka 1997 Jan-Feb;23(1):123-30 (65 ref.) **(Rus)**

[Role of myoglobin in supplying oxygen to tissues] Vasil'eva VO, et al. **Ukr Biokhim Zh** 1996 Jul-Aug;68(4):45-55 (81 ref.) (Eng. Abstr.) **(Ukr)**

PHARMACOLOGY

Regulation of tyrosine hydroxylase mRNA stability by oxygen in PC12 cells. Czyzyk-Krzeska MF, et al.
Adv Exp Med Biol 1996;410:143-50 (20 ref.)

Regulation of ionic conductances and gene expression by hypoxia in an oxygen sensitive cell line. Millhorn DE, et al. **Adv Exp Med Biol** 1996;410:135-42 (17 ref.)

PHYSIOLOGY

Intracellular acidosis potentiates carotid chemoreceptor responses to hypoxia in the absence of CO2-HCO3-. Iturriaga R. **Adv Exp Med Biol** 1996;410:211-6 (20 ref.)

A new measurement of tissue capillarity: the capillary-to-fibre perimeter exchange index. Hepple RT. **Can J Appl Physiol** 1997 Feb;22(1):11-22 (40 ref.)

Role of reactive oxygen species in cardiovascular aging. Muscari C, et al. **Mol Cell Biochem** 1996 Jul-Aug; 160-161:159-66 (72 ref.)

Hypoxic alterations in cellular signal transduction in shock and sepsis. West MA, et al. **New Horiz** 1996 May; 4(2):168-78 (89 ref.)

Oxygen-sensing by ion channels and the regulation of cellular functions. López-Barneo J. **Trends Neurosci** 1996 Oct; 19(10):435-40 (46 ref.)

[Regulation of gene expression by oxygen] Nagao M, et al. **Tanpakushitsu Kakusan Koso** 1996 Dec;41(16):2522-31 (49 ref.) **(Jpn)**

THERAPEUTIC USE

ARCON--current status: summary of a workshop on preclinical and clinical studies. Denekamp J, et al. **Acta Oncol** 1997;36(5):517-25 (0 ref.)
Advances in the management of respiratory failure. Aqueous preparations of oxygen. Spears JR. **ASAIO J** 1996 May-Jun;42(3):196-8 (14 ref.)
Oxygen and cancer. Dunn T. **N C Med J** 1997 Mar-Apr; 58(2):140-3 (13 ref.)
Heliox in children with airway obstruction. Tobias JD. **Pediatr Emerg Care** 1997 Feb;13(1):29-32 (14 ref.)
Sleep-related hypoxaemia in chronic obstructive pulmonary disease: causes, consequences and treatment. Weitzenblum E, et al. **Respiration** 1997;64(3):187-93 (42 ref.)

TOXICITY

A possible role of slips in cytochrome C oxidase in the antioxygen defense system of the cell. Papa S, et al. **Biosci Rep** 1997 Feb;17(1):23-31 (33 ref.)
Glucocorticoids may enhance oxygen radical-mediated neurotoxicity. McIntosh LJ, et al. **Neurotoxicology** 1996 Fall-Winter;17(3-4):873-82 (106 ref.)
Superoxide dismutase and pulmonary oxygen toxicity. Tsan MF.. **Proc Soc Exp Biol Med** 1997 Feb;214(2):107-13 (82 ref.)

OXYGEN CONSUMPTION

Theoretical predictions of end-capillary PO2 in muscles of athletic and nonathletic animals at VO2max. Roy TK, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):H721-37 (72 ref.)
New aspects of altitude training. Rusko HR. **Am J Sports Med** 1996;24(6 Suppl):S48-52 (29 ref.)
Blood flow measurements in lower limb arteries using duplex ultrasound. Hussain ST. **Ann R Coll Surg Engl** 1997 Sep; 79(5):323-30 (25 ref.)
Monitoring of cerebral hemodynamics with jugular bulb catheters. Feldman Z, et al. **Crit Care Clin** 1997 Jan; 13(1):51-77 (76 ref.)
Does increasing oxygen delivery improve outcome? Yes. Kelly KM. **Crit Care Clin** 1996 Jul;12(3):635-44 (42 ref.)
Does increasing oxygen delivery improve outcome in the critically ill? No. Ronco JJ, et al. **Crit Care Clin** 1996 Jul; 12(3):645-59 (47 ref.)
Determination of oxygen delivery and consumption versus cardiac index and oxygen extraction ratio. Vincent JL. **Crit Care Clin** 1996 Oct;12(4):995-1006 (29 ref.)
Thyroid hormone and gene expression in the regulation of mitochondrial respiratory function. Pillar TM, et al. **Eur J Endocrinol** 1997 Mar;136(3):231-9 (75 ref.)
Continuous measurement of cardiac output by the Fick principle in infants and children: comparison with the thermodilution method. Wippermann CF, et al. **Intensive Care Med** 1996 May;22(5):467-71 (20 ref.)
A 33-yr follow-up of peak oxygen uptake and related variables of former physical education students. Astrand PO, et al. **J Appl Physiol** 1997 Jun;82(6):1844-52 (28 ref.)
Control of mitochondrial and cellular respiration by oxygen. Gnaiger E, et al. **J Bioenerg Biomembr** 1995 Dec; 27(6):583-96 (62 ref.)
Tissue oxygenation and routine nursing procedures in critically ill patients. Jesurum J. **J Cardiovasc Nurs** 1997 Jul;11(4):12-30 (72 ref.)
A model for the coupling between cerebral blood flow and oxygen metabolism during neural stimulation. Buxton RB, et al. **J Cereb Blood Flow Metab** 1997 Jan;17(1):64-72 (53 ref.)
Oxygen and renal metabolism. Epstein FH. **Kidney Int** 1997 Feb;51(2):381-5 (30 ref.)
Heterogeneities and profiles of oxygen pressure in brain and kidney as examples of the pO2 distribution in the living tissue. Lübbers DW, et al. **Kidney Int** 1997 Feb;51(2):372-80 (40 ref.)
1996 J.B. Wolffe Memorial Lecture. Challenging beliefs: ex Africa semper aliquid novi. Noakes TD. **Med Sci Sports Exerc** 1997 May;29(5):571-90 (118 ref.)
Enhancement of perioperative tissue perfusion as a therapeutic strategy for major surgery. Boyd O, et al. **New Horiz** 1996 Nov;4(4):453-65 (59 ref.)
Invasive and noninvasive oxygen consumption and hemodynamic monitoring in elderly surgical patients. Yu M. **New Horiz** 1996 Nov;4(4):443-52 (111 ref.)
Oxidative metabolism in muscle. Ferrari M, et al. **Philos Trans R Soc Lond B Biol Sci** 1997 Jun 29; 352(1354):677-83 (72 ref.)
Role of uncoupled and non-coupled oxidations in maintenance of safely low levels of oxygen and its one-electron reductants. Skulachev VP. **Q Rev Biophys** 1996 May;29(2):169-202 (166 ref.)
Significance of the velocity at VO2max and time to exhaustion at this velocity. Billat LV, et al. **Sports Med** 1996 Aug;22(2):90-108 (87 ref.)
[Oxygen and vital signs] Irita K. **Fukuoka Igaku Zasshi** 1996 Dec;87(12):253-9 (2 ref.) **(Jpn)**
[Evaluation of oxidative metabolism in the myocardium] Kudoh T. **Nippon Rinsho** 1997 Mar;55 Suppl 1:648-50 (9 ref.) **(Jpn)**
[Cerebral perfusion and oxygen metabolism in Parkinson's disease: positron emission tomographic study using oxygen-15-labeled CO2 and O2] Tanaka M, et al. **Nippon Rinsho** 1997 Jan;55(1):218-21 (9 ref.) (Eng. Abstr.) **(Jpn)**
[The biological design of the oxygen transport system in mammals and the law of symmorphism] Ivanov KP. **Zh Obshch Biol** 1996 Nov-Dec;57(6):699-717 (75 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

The Crabtree effect: a new look at the old problem. Wojtczak L. **Acta Biochim Pol** 1996;43(2):361-8 (37 ref.)
Dobutamine and the oxygen uptake/supply relationship in sepsis: from global to regional--nothing is simple and easy [comment] Vogt J, et al. **Intensive Care Med** 1997 Jul; 23(7):715-7 (33 ref.) Comment on: Intensive Care Med 1997 Jul;23(7):732-7.

PHYSIOLOGY

What determines cardiac oxygen consumption and how is it regulated? van Beek JH, et al. **Adv Exp Med Biol** 1996; 388:265-74 (27 ref.)
Oxygen transport in tumors: characteristics and clinical implications. Vaupel P. **Adv Exp Med Biol** 1996;388:341-51 (39 ref.)
Advances in the management of respiratory failure. Aqueous preparations of oxygen. Spears JR. **ASAIO J** 1996 May-Jun;42(3):196-8 (14 ref.)
Reactive oxygen and nitrogen species regulate mitochondrial Ca2+ homeostasis and respiration. Richter C. **Biosci Rep** 1997 Feb;17(1):53-66 (106 ref.)
Superoxide production by the mitochondrial respiratory chain. Turrens JF. **Biosci Rep** 1997 Feb;17(1):3-8 (38 ref.)
The role of CO2/pH chemoreceptors in ventilatory control. Milsom WK. **Braz J Med Biol Res** 1995 Nov-Dec; 28(11-12):1147-60 (113 ref.)
Oxygen transfer in fish: morphological and molecular adjustments. Val AL. **Braz J Med Biol Res** 1995 Nov-Dec; 28(11-12):1119-27 (53 ref.)
Oxygen delivery and consumption during sepsis. Chittock DR, et al. **Clin Chest Med** 1996 Jun;17(2):263-78 (109 ref.)
Oxygen delivery in critical illness. Baigorri F, et al. **Crit Care Clin** 1996 Oct;12(4):971-94 (91 ref.)
Importance of the kinetic characterization of liver cell metabolic reactions to the design of hybrid liver support devices. Catapano G, et al. **Int J Artif Organs** 1996 Nov; 19(11):670-6 (19 ref.)
Oxygen efficiency and the control of energy flow in animals and humans. Ketelaars JJ, et al. **J Anim Sci** 1996 Dec; 74(12):3036-51 (87 ref.)
Fatty acid oxidation in the heart. Grynberg A, et al. **J Cardiovasc Pharmacol** 1996;28 Suppl 1:S11-7 (21 ref.)
Oxygen and cancer. Dunn T. **N C Med J** 1997 Mar-Apr; 58(2):140-3 (13 ref.)
Cellular energy utilization and molecular origin of standard metabolic rate in mammals. Rolfe DF, et al. **Physiol Rev** 1997 Jul;77(3):731-58 (221 ref.)
[NADPH oxidase--a specialized enzyme complex for the formation of active oxygen metabolites] Kliubin IV, et al. **Tsitologiia** 1997;39(4-5):320-40 (291 ref.) (Eng. Abstr.) **(Rus)**

OXYGEN DEFICIENCY see **ANOXIA**

OXYGEN INHALATION THERAPY

Does increasing oxygen delivery improve outcome? Yes. Kelly KM. **Crit Care Clin** 1996 Jul;12(3):635-44 (42 ref.)
Does increasing oxygen delivery improve outcome in the critically ill? No. Ronco JJ, et al. **Crit Care Clin** 1996 Jul; 12(3):645-59 (47 ref.)
Pulse oximetry and supplemental oxygen during gastrointestinal endoscopy: a critical review [see comments] Holm C, et al. **Endoscopy** 1996 Oct;28(8):703-11 (85 ref.) Comment in: Endoscopy 1996 Oct;28(8):718-21.
Perfluorochemical respiratory gas carriers: applications in medicine and biotechnology. Lowe KC. **Sci Prog** 1997;80 (Pt 2):169-93 (89 ref.)
[Maximizing O2-transport in critical illness. A rational therapeutic concept?] Forst H. **Anaesthesist** 1997 Jan; 46(1):46-52 (75 ref.) (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

[Liquid ventilation with perfluorocarbons (see comments)] Quintel M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Oct; 31(8):461-9 (72 ref.) (Eng. Abstr.) Comment in: Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Oct;31(8):459-60. **(Ger)**

METHODS

Domiciliary oxygen therapy. Leach RM, et al. **Br J Hosp Med** 1994 Jan 19-Feb 1;51(1-2):47-54 (33 ref.)
Home oxygen and ventilation therapies in pediatric patients. Voter KZ, et al. **Curr Opin Pediatr** 1996 Jun;8(3):221-5 (30 ref.)
Helium-oxygen therapy in the emergency department. McGee DL, et al. **J Emerg Med** 1997 May-Jun;15(3):291-6 (37 ref.)
Long-term oxygen therapy: how can maximum benefit be achieved? Ström K. **Monaldi Arch Chest Dis** 1997 Jun; 52(3):249-52 (31 ref.)
[Home oxygen therapy with transtracheal catheter] Díaz Lobato S, et al. **Rev Clin Esp** 1996 Dec;196(12):846-50 (63 ref.) **(Spa)**

OXYGEN ISOTOPES

Total energy expenditure of free-living humans can be estimated with the doubly labeled water method. Wong WW. **Adv Food Nutr Res** 1996;40:171-80 (23 ref.)
Stable isotopes and bioelectrical impedance for measuring body composition in infants born small for gestational age. Davies PS. **Horm Res** 1997;48 Suppl 1:50-5 (30 ref.)

OXYGEN PARTIAL PRESSURE DETERMINATION, TRANSCUTANEOUS see **BLOOD GAS MONITORING, TRANSCUTANEOUS**

OXYGEN RADIOISOTOPES

DIAGNOSTIC USE

[Cerebral perfusion and oxygen metabolism in Parkinson's disease: positron emission tomographic study using oxygen-15-labeled CO2 and O2] Tanaka M, et al. **Nippon Rinsho** 1997 Jan;55(1):218-21 (9 ref.) (Eng. Abstr.) **(Jpn)**

OXYGEN SPECIES, REACTIVE see **REACTIVE OXYGEN SPECIES**

OXYGENASES

CHEMISTRY

Structure-function analysis of the bacterial aromatic ring-hydroxylating dioxygenases. Butler CS, et al. **Adv Microb Physiol** 1997;38:47-84 (140 ref.)
The iron form of methane mono-oxygenase and its mode of action. Dalton H, et al. **Biochem Soc Trans** 1997 Feb; 25(1):69-74 (27 ref.)
Model complexes of di-iron sites in methane mono-oxygenase and ribonucleotide reductase: structure and reactivity. Fontecave M, et al. **Biochem Soc Trans** 1997 Feb;25(1):65-9 (36 ref.)
Di-iron-carboxylate proteins. Nordlund P, et al. **Curr Opin Struct Biol** 1995 Dec;5(6):758-66 (54 ref.)
The flavin-containing monooxygenase system. Gasser R. **Exp Toxicol Pathol** 1996 Jul;48(5):467-70 (40 ref.)

METABOLISM

Exploring the catalytic mechanism of the extradiol catechol dioxygenases. Bugg TD, et al. **Biochem Soc Trans** 1997 Feb;25(1):81-5 (22 ref.)
The iron form of methane mono-oxygenase and its mode of action. Dalton H, et al. **Biochem Soc Trans** 1997 Feb; 25(1):69-74 (27 ref.)
Model complexes of di-iron sites in methane mono-oxygenase and ribonucleotide reductase: structure and reactivity. Fontecave M, et al. **Biochem Soc Trans** 1997 Feb;25(1):65-9 (36 ref.)

PHYSIOLOGY

Structure-function analysis of the bacterial aromatic ring-hydroxylating dioxygenases. Butler CS, et al. **Adv Microb Physiol** 1997;38:47-84 (140 ref.)
The flavin-containing monooxygenase system. Gasser R. **Exp Toxicol Pathol** 1996 Jul;48(5):467-70 (40 ref.)

OXYGENATION, EXTRACORPOREAL MEMBRANE see **EXTRACORPOREAL MEMBRANE OXYGENATION**

OXYGENATION, HYPERBARIC see **HYPERBARIC OXYGENATION**

OXYGENATORS

Performance evaluation of blood-gas exchange devices. Fried DW. **Int Anesthesiol Clin** 1996 Spring;34(2):47-60 (31 ref.)
Blood-gas exchange devices. Voorhees ME, et al. **Int Anesthesiol Clin** 1996 Spring;34(2):29-45 (60 ref.)
Oxygenator anatomy and function. Wegner JA. **J Cardiothorac Vasc Anesth** 1997 May;11(3):275-81 (38 ref.)

STANDARDS

Clinical strategies in intravascular gas exchange. Sim KM, et al. **Artif Organs** 1996 Jul;20(7):807-10 (11 ref.)

OXYGENATORS, MEMBRANE

Advances in the management of respiratory failure. Intracorporeal membrane gas exchange: will it still prevail? Zwischenberger JB, et al. **ASAIO J** 1996 May-Jun; 42(3):207-8 (11 ref.)
[The membrane oxygenator] Thomas A. **Bull Acad Natl Med** 1996 Oct;180(7):1627-39; discussion 1639-41 (10 ref.) (Eng. Abstr.) **(Fre)**

OXYHEMOGLOBINS

PHYSIOLOGY

Definition, significance and measurement of quantities

OXYHEMOGLOBINS

pertaining to the oxygen carrying properties of human blood. Zijlstra WG, et al.
Scand J Clin Lab Invest Suppl 1996;224:27–45 (69 ref.)

OXYNEURINE see **BETAINE**

OXYNTIC CELLS see **PARIETAL CELLS, GASTRIC**

OXYNTOMODULIN see **ENTEROGLUCAGON**

OXYPROLINE see **HYDROXYPROLINE**

OXYTETRACYCLINE

THERAPEUTIC USE

Gastritis and Helicobacter pylori: forty years of antibiotic therapy. Lieber CS. **Digestion** 1997;58(3):203–10 (62 ref.)
Extralabel use of oxytetracycline. Martin-Jimenez T, et al.
J Am Vet Med Assoc 1997 Jul 1;211(1):42–4 (3 ref.)

OXYTOCICS

ADVERSE EFFECTS

Bone and tissue changes following prostaglandin therapy in neonates. Kaufman MB, et al. **Ann Pharmacother** 1996 Mar; 30(3):269–74, 277 (29 ref.)

PHARMACOLOGY

Induction of cyclo-oxygenase and nitric oxide synthase in inflammation. Appleton I, et al. **Adv Pharmacol** 1996; 35:27–78 (329 ref.)
The prevention of post partum haemorrhage: optimising routine management of the third stage of labour. Prendiville WJ. **Eur J Obstet Gynecol Reprod Biol** 1996 Oct; 69(1):19–24 (22 ref.)
Mechanisms of drugs that affect uterine motility. Sultatos LG. **J Nurse Midwifery** 1997 Jul–Aug;42(4):367–70 (13 ref.)

STANDARDS

Instability of (methyl)ergometrine in tropical climates: an overview. Hogerzeil HV, et al.
Eur J Obstet Gynecol Reprod Biol 1996 Oct;69(1):25–9 (19 ref.)

THERAPEUTIC USE

Chemotherapeutic induction of labour. A rational approach. Xenakis EM, et al. **Drugs** 1997 Jul;54(1):61–8 (71 ref.)
The role of oral (methyl)ergometrine in the prevention of postpartum haemorrhage [see comments] de Groot AN. **Eur J Obstet Gynecol Reprod Biol** 1996 Oct;69(1):31–6 (19 ref.) Comment in: Eur J Obstet Gynecol Reprod Biol 1996 Oct;69(1):3–4.

OXYTOCIN

see related
OXYTOCICS
RECEPTORS, OXYTOCIN

GENETICS

Gene targeting approaches to neuroendocrinology: oxytocin, maternal behavior, and affiliation. Young LJ, et al.
Horm Behav 1997 Jun;31(3):221–31 (34 ref.)

PHARMACOLOGY

Analogies between oxytocin systems of the uterus and brain. Caldwell JD, et al. **Horm Metab Res** 1996 Feb;28(2):65–74 (100 ref.)

PHYSIOLOGY

Breastfeeding: physiological, endocrine and behavioural adaptations caused by oxytocin and local neurogenic activity in the nipple and mammary gland. Uvnäs-Moberg K, et al. **Acta Paediatr** 1996 May;85(5):525–30 (43 ref.)
A neurobiological basis of social attachment. Insel TR.
Am J Psychiatry 1997 Jun;154(6):726–35 (84 ref.)
Integrative functions of lactational hormones in social behavior and stress management. Carter CS, et al.
Ann N Y Acad Sci 1997 Jan 15;807:164–74 (78 ref.)
Peptides, steroids, and pair bonding. Carter CS, et al.
Ann N Y Acad Sci 1997 Jan 15;807:260–72 (33 ref.)
Molecular aspects of monogamy. Insel TR, et al.
Ann N Y Acad Sci 1997 Jan 15;807:302–16 (44 ref.)
Oxytocin control of maternal behavior. Regulation by sex steroids and offspring stimuli. Pedersen CA.
Ann N Y Acad Sci 1997 Jan 15;807:126–45 (65 ref.)
Physiological and endocrine effects of social contact. Uvnäs-Moberg K. **Ann N Y Acad Sci** 1997 Jan 15; 807:146–63 (90 ref.)
Regulatory mechanisms of oxytocin-mediated sociosexual behavior. Witt DM. **Ann N Y Acad Sci** 1997 Jan 15; 807:287–301 (80 ref.)
A speculative review of parturition in the mare. Thorburn GD. **Equine Vet J Suppl** 1993 Apr;(14):41–9 (72 ref.)
Oxytocin and the control of LH. Evans JJ. **J Endocrinol** 1996 Nov;151(2):169–74 (75 ref.)
Oxytocin and vasopressin neurones: vive la différence! Hatton GI. **J Physiol (Lond)** 1997 Apr 15;500 (Pt 2):284 (5 ref.)
Central nervous system actions of oxytocin and modulation of behavior in humans. McCarthy MM, et al.
Mol Med Today 1997 Jun;3(6):269–75 (49 ref.)
Behavioral consequences of intracerebral vasopressin and oxytocin: focus on learning and memory. Engelmann M, et al. **Neurosci Biobehav Rev** 1996 Autumn;20(3):341–58 (219 ref.)
Oxytocin and its receptor in pregnancy and parturition: current concepts and clinical implications. Zeeman GG, et al. **Obstet Gynecol** 1997 May;89(5 Pt 2):873–83 (107 ref.)
Role of oxytocin in the neuroadaptation to drugs of abuse. Sarnyai Z, et al. **Psychoneuroendocrinology** 1994; 19(1):85–117 (100 ref.)
Central inhibition of salt appetite by oxytocin in rats. Stricker EM, et al. **Regul Pept** 1996 Oct 8;66(1–2):83–5 (25 ref.)
[The role of oxytocin and vasopressin in the regulation of mammalian reproduction] Grinevich VV, et al.
Morfologiia 1997;111(2):17–27 (96 ref.) (Eng. Abstr.) **(Rus)**

SECRETION

Neurohypophysial peptides. Histaminergic regulation and function in adenohypophysial secretion. Kjaer A.
Dan Med Bull 1996 Dec;43(5):391–406 (188 ref.)

THERAPEUTIC USE

Oxytocin and its receptor in pregnancy and parturition: current concepts and clinical implications. Zeeman GG, et al. **Obstet Gynecol** 1997 May;89(5 Pt 2):873–83 (107 ref.)

OXYTOCIN RECEPTORS see **RECEPTORS, OXYTOCIN**

OXYTRICHA

GENETICS

Internal eliminated segments (IESs) of Oxytrichidae. Prescott DM, et al. **J Eukaryot Microbiol** 1996 Nov–Dec; 43(6):432–41 (22 ref.)

OXYURIDA

DRUG EFFECTS

[The results of micromorphological and histochemical studies of the musculocutaneous sac of nematodes in the suborder Oxyurata after anthelmintic exposure] Bogoiavlenskii IuK, et al. **Med Parazitol (Mosk)** 1996 Jul–Sep;(3):57–62 (15 ref.) (Eng. Abstr.) **(Rus)**

OXYURIS VERMICULARIS see **ENTEROBIUS**

OXYVANADIUM see **VANADATES**

OYSTERS

[Some examples of introductions and transfers of mollusks] Grizel H. **Rev Sci Tech** 1996 Jun;15(2):401–8 (11 ref.) (Eng. Abstr.) **(Fre)**
[International trade in bivalve mollusks and the current situation in France and in Europe] Le Borgne Y.
Rev Sci Tech 1996 Jun;15(2):491–8 (6 ref.) (Eng. Abstr.) **(Fre)**

OZENA see **RHINITIS, ATROPHIC**

OZONE

Tropospheric air pollution: ozone, airborne toxics, polycyclic aromatic hydrocarbons, and particles. Finlayson-Pitts BJ, et al. **Science** 1997 May 16;276(5315):1045–52 (193 ref.)

ADVERSE EFFECTS

Ozone, airways and allergic airways disease. Krishna MT, et al. **Clin Exp Allergy** 1995 Dec;25(12):1150–8 (82 ref.)
Cosmic radiation and ozone. Hack M. **Eur J Cancer Prev** 1996 Oct;5(5):378–9 (4 ref.)
Noise stress and airway toxicity: a prospect for experimental analysis. Van Raaij MT, et al. **Food Chem Toxicol** 1996 Nov–Dec;34(11–12):1159–61 (15 ref.)
Mediators of inflammation in response to air pollution: a focus on ozone and nitrogen dioxide. Krishna MT, et al.
J R Coll Physicians Lond 1996 Jan–Feb;30(1):61–6 (62 ref.)
Controlled human studies of ozone exposure. Bylin G.
Scand J Work Environ Health 1996;22 Suppl 3:52–71 (113 ref.)
Epidemiologic studies on ozone. Nyberg F, et al.
Scand J Work Environ Health 1996;22 Suppl 3:72–98 (144 ref.)
Genotoxicity and carcinogenicity of ozone. Victorin K.
Scand J Work Environ Health 1996;22 Suppl 3:42–51 (81 ref.)

PHARMACOKINETICS

Absorption and metabolic fate of ozone--the molecular basis of ozone-induced toxicity. Cotgreave IA.
Scand J Work Environ Health 1996;22 Suppl 3:15–26 (95 ref.)

PHARMACOLOGY

Ozone alters T-helper cell mediated bronchial hyperreactivity and resistance to bacterial infection. Steerenberg PA, et al. **Exp Toxicol Pathol** 1996 Nov; 48(6):497–9 (12 ref.)
The effects of ozone on antioxidant responses in plants. Sharma YK, et al. **Free Radic Biol Med** 1997;23(3):480–8 (53 ref.)
Ozone as a bioregulator. Pharmacology and toxicology of ozonetherapy today [see comments] Bocci V.
J Biol Regul Homeost Agents 1996 Apr–Sep;10(2–3):31–53 (198 ref.) Comment in: J Biol Regul Homeost Agents 1996 Apr–Sep;10(2–3):29.

THERAPEUTIC USE

Ozone as a bioregulator. Pharmacology and toxicology of ozonetherapy today [see comments] Bocci V.
J Biol Regul Homeost Agents 1996 Apr–Sep;10(2–3):31–53 (198 ref.) Comment in: J Biol Regul Homeost Agents 1996 Apr–Sep;10(2–3):29.
Ozonotherapy. Madej P, et al. **Mater Med Pol** 1995 Apr–Jun; 27(2):53–6 (38 ref.)
[Aspects of using ozone in medicine] Idov IE.
Anesteziol Reanimatol 1997 Jan–Feb;(1):90–4 (66 ref.) **(Rus)**

TOXICITY

Some consequences of ozone exposure on health. Paz C.
Arch Med Res 1997 Summer;28(2):163–70 (96 ref.)
Plant defence systems and ozone. Schraudner M, et al.
Biochem Soc Trans 1996 May;24(2):456–61 (50 ref.)
Ozone-induced toxicity in experimental animals and isolated cell systems. Gustafsson LE, et al.
Scand J Work Environ Health 1996;22 Suppl 3:27–41 (93 ref.)

P0 GLYCOPROTEIN see **MYELIN P0 PROTEIN**

P0 PROTEIN see **MYELIN P0 PROTEIN**

P1 PHAGE see **BACTERIOPHAGE P1**

P1 PURINOCEPTORS see **RECEPTORS, PURINERGIC P1**

P2 PROTEIN see **MYELIN P2 PROTEIN**

P2 PURINOCEPTORS see **RECEPTORS, PURINERGIC P2**

P21(C-HA-RAS) see **PROTO-ONCOGENE PROTEIN P21(RAS)**

P21(C-KI-RAS) see **PROTO-ONCOGENE PROTEIN P21(RAS)**

P21(C-RAS) see **PROTO-ONCOGENE PROTEIN P21(RAS)**

P21(N-RAS) see **PROTO-ONCOGENE PROTEIN P21(RAS)**

P21(RAS) see **PROTO-ONCOGENE PROTEIN P21(RAS)**

P21(V-HA-RAS) see **ONCOGENE PROTEIN P21(RAS)**

P21(V-KI-RAS) see **ONCOGENE PROTEIN P21(RAS)**

P34CDC2 PROTEIN see **PROTEIN P34CDC2**

P39(C-JUN) see **PROTO-ONCOGENE PROTEINS C-JUN**

P40 T-CELL GROWTH FACTOR see **INTERLEUKIN-9**

P40(TAX) see **GENE PRODUCTS, TAX**

P53 GENES see **GENES, P53**

P53 PROTEIN see **PROTEIN P53**

P55(C-FOS) see **PROTO-ONCOGENE PROTEINS C-FOS**

P62(C-MYC) see **PROTO-ONCOGENE PROTEINS C-MYC**

P105-RB PROTEIN see **RETINOBLASTOMA PROTEIN**

P145(C-KIT) see **PROTO-ONCOGENE PROTEINS C-KIT**

P150,95 ANTIGEN see **ANTIGEN P150,95**

P185(C-NEU) see **PROTO-ONCOGENE PROTEINS C-ERBB-2**

P300 EVENT-RELATED POTENTIALS see **EVENT-RELATED POTENTIALS, P300**

P-ANCA see **ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC**

P-CADHERINS see **CADHERINS**

P-CELL STIMULATING FACTOR see **INTERLEUKIN-3**

P-GLYCOPROTEIN

see related
DRUG RESISTANCE, MULTIPLE

Biophysical aspects of P-glycoprotein-mediated multidrug resistance. Wadkins RM, et al. **Int Rev Cytol** 1997; 171:121-65 (124 ref.)

[Multidrug resistance protein (MRP)] Abe T, et al. **Nippon Rinsho** 1997 May;55(5):1077-82 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular mechanisms for drug transport by MDR1/P-glycoprotein] Ueda K. **Tanpakushitsu Kakusan Koso** 1997 Jun;42(8):1263-72 (45 ref.) **(Jpn)**

ANALYSIS

Assays for the analysis of P-glycoprotein in acute myeloid leukemia and CD34 subsets of AML blasts. Sonneveld P, et al. **Leukemia** 1997 Jul;11(7):1160-5 (47 ref.)

[Advances in the research on multidrug resistance genes] Gao Z, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1996 Jun; 25(3):185-7 (12 ref.) **(Chi)**

[Detection of P-glycoprotein and its clinical significance] Tanigawa N, et al. **Nippon Rinsho** 1997 May;55(5):1064-8 (21 ref.) (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Sikic BI, et al. **Cancer Chemother Pharmacol** 1997;40 Suppl:S13-9 (67 ref.)

Cellular drug efflux and reversal therapy of cancer. Wigler PW. **J Bioenerg Biomembr** 1996 Jun;28(3):279-84 (28 ref.)

BIOSYNTHESIS

Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion. Barrand MA, et al. **Gen Pharmacol** 1997 May;28(5):639-45 (44 ref.)

CLASSIFICATION

Proton-dependent multidrug efflux systems. Paulsen IT, et al. **Microbiol Rev** 1996 Dec;60(4):575-608 (326 ref.)

GENETICS

Genetic analysis of the multidrug transporter. Gottesman MM, et al. **Annu Rev Genet** 1995;29:607-49 (258 ref.)

P-glycoprotein multidrug resistance and cancer. Bosch I, et al. **Biochim Biophys Acta** 1996 Oct 9;1288(2):F37-54 (352 ref.)

Multidrug resistance: molecular mechanisms and clinical relevance. Ling V. **Cancer Chemother Pharmacol** 1997;40 Suppl:S3-8 (36 ref.)

Hepatic canalicular membrane 4: expression of the multidrug resistance genes in the liver. Silverman JA, et al. **FASEB J** 1997 Apr;11(5):308-13 (55 ref.)

Improved retroviral vectors for hematopoietic stem cell protection and in vivo selection. Baum C, et al. **J Hematother** 1996 Aug;5(4):323-9 (40 ref.)

Detection of multidrug resistance gene expression in multiple myeloma. Dalton WS. **Leukemia** 1997 Jul;11(7):1166-9 (13 ref.)

IMMUNOLOGY

Monoclonal antibodies specific for P-glycoprotein. Okochi E, et al. **Leukemia** 1997 Jul;11(7):1119-23 (43 ref.)

[Overcoming of multidrug resistance by anti-P-glycoprotein monoclonal antibody] Nokihara H, et al. **Nippon Rinsho** 1997 May;55(5):1128-34 (22 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Influence of bile salts on hepatic mdr2 P-glycoprotein expression. Frijters CM, et al. **Adv Enzyme Regul** 1996; 36:351-63 (38 ref.)

Cell-volume regulation: P-glycoprotein--a cautionary tale. Wine JJ, et al. **Curr Biol** 1996 Nov 1;6(11):1410-2 (28 ref.)

Membrane proteins which exhibit multiple topological orientations. Levy D. **Essays Biochem** 1996;31:49-60 (21 ref.)

Cellular resistance to anthracyclines. Nielsen D, et al. **Gen Pharmacol** 1996 Mar;27(2):251-5 (30 ref.)

Altered drug translocation mediated by the MDR protein: direct, indirect, or both? Roepe PD, et al. **J Bioenerg Biomembr** 1996 Dec;28(6):541-55 (77 ref.)

Multidrug resistance in leukemias and its reversal. Malayeri R, et al. **Leuk Lymphoma** 1996 Nov;23(5-6):451-8 (89 ref.)

Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Stein WD. **Physiol Rev** 1997 Apr;77(2):545-90 (260 ref.)

Pharmacokinetic modeling of multidrug resistance P-glycoprotein transport of gamma-emitting substrates. Bae KT, et al. **Q J Nucl Med** 1997 Jun;41(2):101-10 (53 ref.)

[MDR (Multiple Drug Resistant) type of resistance to chemotherapy in clinical practice] Oudard S, et al. **Bull Cancer** 1996 Aug;83(8):609-18 (79 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

P-glycoprotein-mediated multidrug resistance: experimental and clinical strategies for its reversal. Ford JM, et al. **Cancer Treat Res** 1996;87:3-38 (236 ref.)

P-glycoprotein and multidrug resistance. Gottesman MM, et al. **Curr Opin Genet Dev** 1996 Oct;6(5):610-7 (65 ref.)

Hepatic canalicular membrane 1: The role of mdr2 P-glycoprotein in hepatobiliary lipid transport. Elferink RP, et al. **FASEB J** 1997 Jan;11(1):19-28 (59 ref.)

The functional role of P-glycoprotein in the blood-brain barrier. van Asperen J, et al. **J Pharm Sci** 1997 Aug; 86(8):881-4 (24 ref.)

Proton-dependent multidrug efflux systems. Paulsen IT, et al. **Microbiol Rev** 1996 Dec;60(4):575-608 (326 ref.)

P-glycoprotein mediated multidrug resistance and its implications for pathology. Trambas CM, et al. **Pathology** 1997 May;29(2):122-30 (117 ref.)

Secretion of organic anions by hepatocytes: involvement of homologues of the multidrug resistance protein. Müller M, et al. **Semin Liver Dis** 1996 May;16(2):211-20 (137 ref.)

P-glycoprotein, multidrug resistance and protein kinase C. Fine RL, et al. **Stem Cells** 1996 Jan;14(1):47-55 (50 ref.)

Genetic dissection of the function of mammalian P-glycoproteins. Borst P, et al. **Trends Genet** 1997 Jun; 13(6):217-22 (46 ref.)

Natural functions of bacterial multidrug transporters. Neyfakh AA. **Trends Microbiol** 1997 Aug;5(8):309-13 (41 ref.)

[The role of P-glycoprotein in the liver] Kusuhara H, et al. **Nippon Rinsho** 1997 May;55(5):1069-76 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Antibiotic extrusion and multidrug resistance] Nakae T. **Nippon Rinsho** 1997 May;55(5):1173-8 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Tissue distribution of the multidrug-resistance gene product P-glycoprotein and its physiological function] Tsuji A, et al. **Nippon Rinsho** 1997 May;55(5):1059-63 (22 ref.) (Eng. Abstr.) **(Jpn)**

P SELECTIN see **P-SELECTIN**

PABA see **4-AMINOBENZOIC ACID**

PACEMAKER, ARTIFICIAL

Cardiac pacemaker: 15 years of "new" interpretation. DiFrancesco D. **Acta Cardiol** 1995;50(6):413-27 (50 ref.)

American College of Cardiology/American Heart Association guidelines for pacemaker implantation after acute myocardial infarction. What is persistent advanced block at the atrioventricular node? [editorial] Barold SS. **Am J Cardiol** 1997 Sep 15;80(6):770-4 (41 ref.)

Contemporary issues in rate-adaptive pacing. Barold SS, et al. **Clin Cardiol** 1997 Aug;20(8):726-9 (35 ref.)

Advances in pacing for the patient with sick sinus syndrome. Alagona P Jr. **Curr Opin Cardiol** 1997 Jan;12(1):3-11 (114 ref.)

The treatment of atrial fibrillation: pharmacologic and nonpharmacologic strategies. Viskin S, et al. **Curr Probl Cardiol** 1997 Feb;22(2):37-108 (229 ref.)

Pacemakers. Ferguson TB Jr. **Curr Probl Surg** 1997 Jan; 34(1):1-108 (130 ref.)

ICD-antiarrhythmic drug and ICD-pacemaker interactions. Brode SE, et al. **J Cardiovasc Electrophysiol** 1997 Jul; 8(7):830-42 (100 ref.)

Ionic mechanisms of the cardiac pacemaker potential. Noma A. **Jpn Heart J** 1996 Sep;37(5):673-82 (29 ref.)

Cardiac pacing [see comments] Morley-Davies A, et al. **Lancet** 1997 Jan 4;349(9044):41-6 (56 ref.) Comment in: Lancet 1997 Mar 15;349(9054):807.

Dual-chamber pacing for cardiomyopathies: a 1996 clinical perspective. Nishimura RA, et al. **Mayo Clin Proc** 1996 Nov;71(11):1077-87 (47 ref.)

Energy parameters in cardiac pacing should be abandoned. Barold SS, et al. **Pacing Clin Electrophysiol** 1997 Jan;20(1 Pt 1):112-21 (88 ref.)

State of the science: pacemaker and defibrillator interference from wireless communication devices [see comments] Hayes DL, et al. **Pacing Clin Electrophysiol** 1996 Oct; 19(10):1419-30 (42 ref.) Comment in: Pacing Clin Electrophysiol 1996 Oct;19(10):1407-9.

[Recent advances in cardiac pacing] Godin JF, et al. **Ann Cardiol Angeiol (Paris)** 1996 Oct;45(8):430-8 (33 ref.) (Eng. Abstr.) **(Fre)**

[Risk factors for pacemaker disorders] Wilke A, et al. **Dtsch Med Wochenschr** 1997 Apr 18;122(16):517-22 (55 ref.) **(Ger)**

[Interventional treatment methods in atrial fibrillation] Osswald S. **Schweiz Med Wochenschr** 1996 Oct 12; 126(41):1732-8 (34 ref.) (Eng. Abstr.) **(Ger)**

[Combined therapy with transvenous cardioverter/defibrillator and anti-bradycardia pacemaker systems] Sticherling C, et al. **Z Kardiol** 1997 Feb; 86(2):105-12 (23 ref.) (Eng. Abstr.) **(Ger)**

[Pacemaker implantation in 7 days or less old of early neonates] Tadokoro T, et al. **Rinsho Kyobu Geka** 1989 Oct; 9(5):490-3 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Pacing failure] Kuzawa Y. **Ryoikibetsu Shokogun Shirizu** 1996;(12):486-9 (8 ref.) **(Jpn)**

[Pacemaker syndrome] Mitsui T. **Ryoikibetsu Shokogun Shirizu** 1996;(12):490-3 (6 ref.) **(Jpn)**

[Endless loop tachycardia] Ohnishi S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):529-31 (12 ref.) **(Jpn)**

[Safety rules for patients with artificial cardiac pacemaker] Costa R, et al. **Rev Assoc Med Bras** 1996 Jul-Sep; 42(3):185-96 (39 ref.) (Eng. Abstr.) **(Por)**

[Endocarditis in patients with endocardial catheters; role of transesophageal echocardiography for its detection (report of 4 clinical cases)] Galrinho A, et al. **Rev Port Cardiol** 1996 Sep;15(9):649-55, 613 (18 ref.) (Eng. Abstr.) **(Por)**

[The runaway pacemaker syndrome during electrical ventricular stimulation of the heart] Kozlov VL, et al. **Ter Arkh** 1997;69(4):40-1 (9 ref.) (Eng. Abstr.) **(Rus)**

[Pacemaker in bradycardias is sometimes not necessary. Seponation of carbamazepine should be considered] Kennebäck G. **Lakartidningen** 1997 Mar 12;94(11):947-8 (9 ref.) **(Swe)**

ADVERSE EFFECTS

Systemic infection related to endocarditis on pacemaker leads: clinical presentation and management. Klug D, et al. **Circulation** 1997 Apr 15;95(8):2098-107 (36 ref.)

[Acute relapsing pericarditis induced by screw-in atrial pacing lead. Apropos of 3 cases] Jacques B, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11):1389-95 (18 ref.) (Eng. Abstr.) **(Fre)**

[Cross stimulation] Nakamura Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):530-3 (11 ref.) **(Jpn)**

[The pacemaker syndrome] Leandro J, et al. **Acta Med Port** 1997 Jan;10(1):81-5 (37 ref.) (Eng. Abstr.) **(Por)**

CONTRAINDICATIONS

Physiological pacing for elderly patients: exploit the benefits but don't overdo it. Hargreaves MR, et al. **Age Ageing** 1994 Nov;23(6):441-4 (23 ref.)

PSYCHOLOGY

Pacemaker therapy: how do patients cope with the icon of modern antibradycard treatment? [editorial] Schüppel R, et al. **Int J Artif Organs** 1997 Jan;20(1):7-11 (46 ref.)

TRENDS

Bipolar leads for use with permanently implantable cardiac pacing systems: a review of limitations of traditional and coaxial configurations and the development and testing of new conductor, insulation, and electrode designs. Tyers GF, et al. **J Invest Surg** 1997 Jan-Apr;10(1-2):1-15 (80 ref.)

PACEMAKERS, BIOLOGICAL see **BIOLOGICAL CLOCKS**

PACHYDERMOPERIOSTOSIS see **OSTEOARTHROPATHY, PRIMARY HYPERTROPHIC**

PACIFIC ISLAND AMERICANS see **ASIAN AMERICANS**

PACIFIERS see **INFANT CARE**

PACING, CARDIAC, ARTIFICIAL see **CARDIAC PACING, ARTIFICIAL**

PACINIAN CORPUSCLES

METABOLISM

Immunohistochemistry of human cutaneous Meissner and pacinian corpuscles. Vega JA, et al. **Microsc Res Tech** 1996 Jul 1;34(4):351-61 (110 ref.)

PACKAGE INSERTS see **PRODUCT LABELING**

PACKAGE INSERTS, DRUG see **DRUG LABELING**

PACKAGING, PRODUCT see **PRODUCT PACKAGING**

PACKAGING, VIRAL see **VIRUS ASSEMBLY**

PACKED RED-CELL VOLUME see **HEMATOCRIT**

PACLITAXEL

The clinical development of paclitaxel: a successful collaboration of academia, industry and the National Cancer Institute. Donehower RC. **Stem Cells** 1996 Jan; 14(1):25-8 (2 ref.)

ADMINISTRATION & DOSAGE

Intraperitoneal taxol. Markman M. **Cancer Treat Res** 1996; 81:1-5 (20 ref.)

Alternative formulations of paclitaxel. Terwogt JM, et al. **Cancer Treat Rev** 1997 Mar;23(2):87-95 (32 ref.)

Paclitaxel dose intensity. Reed E, et al. **J Infus Chemother** 1996 Spring;6(2):59-63 (33 ref.)

Paclitaxel-based combination chemotherapy for breast cancer. Hortobagyi GN. **Oncology (Huntingt)** 1997 Mar; 11(3 Suppl 2):29-37 (54 ref.)

The taxanes: dosing and scheduling considerations. Rowinsky

EK. **Oncology (Huntingt)** 1997 Mar;11(3 Suppl 2):7–19 (88 ref.)
The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer. Bunn PA Jr. **Semin Oncol** 1996 Dec;23(6 Suppl 16):18–25 (34 ref.)
Paclitaxel combinations as front-line and salvage chemotherapy regimens in advanced breast cancer. Conte PF, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 15):39–42 (10 ref.)
Paclitaxel and doxorubicin in metastatic breast cancer. Gehl J, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 15):35–8 (17 ref.)
Paclitaxel via 1-hour infusion: clinical experience. Greco FA, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):91–3 (7 ref.)
Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review. Holmes FA. **Semin Oncol** 1996 Oct;23(5 Suppl 11):46–56 (55 ref.)
Paclitaxel combination therapy in the treatment of metastatic breast cancer. Holmes FA. **Semin Oncol** 1996 Oct;23(5 Suppl 12):29–39 (56 ref.)
Optimal dosing of paclitaxel and doxorubicin in metastatic breast cancer. Hortobagyi GN, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 3):S4–7 (20 ref.)
Paclitaxel with carboplatin for the treatment of ovarian cancer. Neijt JP, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 15):2–4 (12 ref.)
Chemotherapy of advanced ovarian cancer: current status and future directions. Ozols RF, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2–1–S2–9 (49 ref.)
Paclitaxel and carboplatin for advanced breast cancer. Perez EA, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 11):41–5 (38 ref.)
Preoperative paclitaxel plus carboplatin for patients with intermediate-risk non-small cell lung cancer. Ruckdeschel JC. **Semin Oncol** 1996 Dec;23(6 Suppl 16):62–7 (65 ref.)
High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer. Socinski MA, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12–45–S12–51 (51 ref.)
The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tumors. Bokemeyer C, et al. **World J Urol** 1996;14(6):354–9 (37 ref.)

ADVERSE EFFECTS

Case report of anaphylaxis from cisplatin/paclitaxel and a review of their hypersensitivity reaction profiles. Ciesielski-Carlucci C, et al. **Am J Clin Oncol** 1997 Aug; 20(4):373–5 (14 ref.)
Paclitaxel-induced radiation recall dermatitis [letter] Bokemeyer C, et al. **Ann Oncol** 1996 Sep;7(7):755–6 (7 ref.)
Generalized pustular dermatosis following paclitaxel therapy [letter] Weinberg JM, et al. **Int J Dermatol** 1997 Jul; 36(7):559–60 (8 ref.)

ANALOGS & DERIVATIVES

Docetaxel. A review of its role in breast cancer treatment. Antoine EC, et al. **Am J Clin Oncol** 1997 Aug;20(4):429–32 (38 ref.)
The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Rowinsky EK. **Annu Rev Med** 1997;48:353–74 (117 ref.)
The scientific rationale for developing taxoids. Aapro M. **Anticancer Drugs** 1996 Aug;7 Suppl 2:33–6 (18 ref.)
The clinical rationale for developing docetaxel (Taxotere). Armand JP. **Anticancer Drugs** 1996 Aug;7 Suppl 2:37–9 (13 ref.)
Optimal use of docetaxel (Taxotere): maximizing its potential. Burris HA. **Anticancer Drugs** 1996 Aug;7 Suppl 2:25–8 (6 ref.)
Taxoids in combination chemotherapy for metastatic breast cancer. Dieras V, et al. **Anticancer Drugs** 1996 Aug;7 Suppl 2:47–52 (33 ref.)
Treatment of patients with liver metastases. Fumoleau P. **Anticancer Drugs** 1996 Aug;7 Suppl 2:21–3 (24 ref.)
Treatment of advanced breast cancer: current status. Piccart M. **Anticancer Drugs** 1996 Aug;7 Suppl 2:5–7 (15 ref.)
Biotransformation of taxoids by human cytochromes P450: structure-activity relationship. Monsarrat B, et al. **Bull Cancer** 1997 Feb;84(2):125–33 (59 ref.)
Docetaxel: a review of its pharmacology and clinical activity. Trudeau ME. **Can J Oncol** 1996 Jun;6(1):443–57 (110 ref.)
Taxanes in ovarian cancer treatment. Seetalarom K, et al. **Curr Opin Obstet Gynecol** 1997 Feb;9(1):14–20 (46 ref.)
Metastatic breast cancer. Kennedy MJ. **Curr Opin Oncol** 1996 Nov;8(6):485–90 (32 ref.)
Paclitaxel and docetaxel in breast and ovarian cancer. **Drug Ther Bull** 1997 Jun;35(6):43–6 (34 ref.)
Taxotere. Renick-Ettinger A. **J Pediatr Oncol Nurs** 1996 Jan;13(1):43–5 (10 ref.)
Docetaxel (Taxotere) for advanced breast cancer. **Med Lett Drugs Ther** 1996 Sep 27;38(984):87–8 (0 ref.)
Docetaxel in breast cancer and a rationale for combination therapy. Hortobágyi G. **Oncology (Huntingt)** 1997 Jun;11(6 Suppl 6):11–5 (21 ref.)
The international experience with docetaxel in the treatment of breast cancer. Ravdin PM. **Oncology (Huntingt)** 1997 Mar;11(3 Suppl 2):38–42 (30 ref.)
The taxanes: dosing and scheduling considerations. Rowinsky EK. **Oncology (Huntingt)** 1997 Mar;11(3 Suppl 2):7–19 (88 ref.)
Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects. D'Andrea GM, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 13):S13–27–S13–44 (109 ref.)
Future perspectives of docetaxel (Taxotere) in front-line therapy. Piccart MJ, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 10):S10–27–S10–33 (41 ref.)
Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer. Ravdin PM. **Semin Oncol** 1997 Aug;24(4 Suppl 10):S10–18–S10–21 (26 ref.)
Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy. Valero V. **Semin Oncol** 1997 Aug;24(4 Suppl 13):S13–11–S13–18 (39 ref.)
The taxoids: same roots, different drugs. Von Hoff DD. **Semin Oncol** 1997 Aug;24(4 Suppl 13):S13–3–S13–10 (53 ref.)
[Development of a new tubulin-interacting agent, docetaxel (taxotere) in Japan] Tsukagoshi S. **Gan To Kagaku Ryoho** 1997 Jul;24(9):1167–74 (14 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Taxol biosynthesis: an update. Hezari M, et al. **Planta Med** 1997 Aug;63(4):291–5 (42 ref.)

CHEMISTRY

Alternative formulations of paclitaxel. Terwogt JM, et al. **Cancer Treat Rev** 1997 Mar;23(2):87–95 (32 ref.)

METABOLISM

The transport and binding of taxol. Parekh H, et al. **Gen Pharmacol** 1997 Aug;29(2):167–72 (47 ref.)

PHARMACOKINETICS

Biotransformation of taxoids by human cytochromes P450: structure-activity relationship. Monsarrat B, et al. **Bull Cancer** 1997 Feb;84(2):125–33 (59 ref.)
A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel. Calvert AH. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2–85–S2–90 (43 ref.)
Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function. Panday VR, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 11):S11–34–S11–38 (37 ref.)

PHARMACOLOGY

The scientific rationale for developing taxoids. Aapro M. **Anticancer Drugs** 1996 Aug;7 Suppl 2:33–6 (18 ref.)
Paclitaxel (Taxol): mechanisms of Resistance. Casazza AM, et al. **Cancer Treat Res** 1996;87:149–71 (107 ref.)
HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Baselga J, et al. **Oncology (Huntingt)** 1997 Mar;11(3 Suppl 2):43–8 (47 ref.)
Mobilization of peripheral blood progenitor cells with paclitaxel-based chemotherapy. Shea TC. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2–105–S2–107 (17 ref.)

THERAPEUTIC USE

The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Rowinsky EK. **Annu Rev Med** 1997;48:353–74 (117 ref.)
Taxoids in combination chemotherapy for metastatic breast cancer. Dieras V, et al. **Anticancer Drugs** 1996 Aug;7 Suppl 2:47–52 (33 ref.)
Taxanes in ovarian cancer treatment. Seetalarom K, et al. **Curr Opin Obstet Gynecol** 1997 Feb;9(1):14–20 (46 ref.)
Metastatic breast cancer. Kennedy MJ. **Curr Opin Oncol** 1996 Nov;8(6):485–90 (32 ref.)
Paclitaxel and docetaxel in breast and ovarian cancer. **Drug Ther Bull** 1997 Jun;35(6):43–6 (34 ref.)
Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin. Klaassen U, et al. **J Infus Chemother** 1996 Summer;6(3):127–32 (34 ref.)
Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview. Hájek R, et al. **Neoplasma** 1996; 43(3):141–54 (158 ref.)
Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New Zealand. Bishop JF, et al. **Oncology (Huntingt)** 1997 Apr; 11(4 Suppl 3):19–23 (43 ref.)
Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experience. Seidman AD, et al. **Oncology (Huntingt)** 1997 Mar;11(3 Suppl 2):20–8 (62 ref.)
The Fox Chase Cancer Center and Free University Hospital Investigators' Workshop and Consensus Conference on Paclitaxel. Part 4: Breast Cancer II. Marrakech, Morocco, January 18–20, 1996 and St Croix, US Virgin Islands, March 13–16, 1996. **Semin Oncol** 1997 Feb;24(1 Suppl 3):S1–49, quiz S50–5 (0 ref.)
The Fox Chase Cancer Center and Free University Hospital Investigators' Workshop and Consensus Conference on Paclitaxel. Part 1: Lung Cancer. Puerto Rico, March 12–16, 1997. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12–1–S12–162; quiz S12–163–S12–173 (0 ref.)
The Fox Chase Cancer Center and Free University Hospital Investigators' Workshop and Consensus Conference on Paclitaxel. Part 1: Breast Cancer I. **Semin Oncol** 1996 Oct; 23(5 Suppl 11):1–70 (0 ref.)
The Fox Chase Cancer Center and Free University Hospital Investigators' Workshop and Consensus Conference on Paclitaxel. Part 3: Gynecologic malignancies, head and neck cancer, and other tumor types. Marrakech, Morocco, January 18–20, 1996 and St Croix, Virgin Islands, March 13–16, 1996. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2–1–S2–120; quiz S2–121–S2–123 (0 ref.)
Paclitaxel in head and neck and other cancers: future prospects. Aisner J, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2–113–S2–115 (21 ref.)
Defining the role of paclitaxel in lung cancer: summary of recent studies and implications for future directions. Bunn PA Jr. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12–153–S12–162 (63 ref.)
Paclitaxel in head and neck cancer and other tumor types: chairmen's introduction. Cortés-Funes H, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2–51–S2–57 (48 ref.)
Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects. D'Andrea GM, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 13):S13–27–S13–44 (109 ref.)
The University of Texas M.D. Anderson Cancer Center experience with paclitaxel in breast cancer. Hortobagyi GN, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 3):S30–3 (17 ref.)
The role of paclitaxel in the management of patients with carcinoma of the cervix. Thigpen T, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2–41–S2–46 (46 ref.)
Simultaneous paclitaxel and radiotherapy: initial clinical experience in lung cancer and other malignancies. Vogt HG, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12–101–S12–105 (15 ref.)
The taxoids: same roots, different drugs. Von Hoff DD. **Semin Oncol** 1997 Aug;24(4 Suppl 13):S13–3–S13–10 (53 ref.)
[Taxol in bronchial carcinoma] Gatzemeier U. **Med Klin** 1996 Dec 15;91 Suppl 2:1–6 (41 ref.) **(Ger)**
[Paclitaxel in therapy of breast carcinoma. Value and perspectives] Klaassen U, et al. **Med Klin** 1996 Dec 15;91 Suppl 2:7–10 (31 ref.) **(Ger)**

PACS (RADIOLOGY) see **RADIOLOGY INFORMATION SYSTEMS**

PADUTIN see **KALLIKREIN**

PAECILOMYCES

["Sergeantella"--a morphological index of erythrodieresis or a result of degradation by fungi of the genus Paecilomyces] Grigor'ev GI. **Ter Arkh** 1995;67(12):53–5 (27 ref.) (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Paecilomyces sinusitis in an immunocompromised adult patient: case report and review. Gucalp R, et al. **Clin Infect Dis** 1996 Aug;23(2):391–3 (10 ref.)

PATHOGENICITY

Complicated soft tissue infection with prepatellar bursitis caused by Paecilomyces lilacinus in an immunocompetent host: case report and review. Westenfeld F, et al. **J Clin Microbiol** 1996 Jun;34(6):1559–62 (29 ref.)

PAF-ACETHER see **PLATELET ACTIVATING FACTOR**

PAGET'S DISEASE, EXTRAMAMMARY

COMPLICATIONS

Extramammary Paget's disease of the axilla with an underlying apocrine carcinoma [letter] [see comments] Morgan JM, et al. **Acta Derm Venereol** 1996 Mar; 76(2):173–4 (8 ref.) Comment in: Acta Derm Venereol 1997 Jan;77(1):78.

DIAGNOSIS

A case of triple extramammary Paget's disease. Koseki S, et al. **J Dermatol** 1997 Aug;24(8):535–8 (8 ref.)
Uncommon cutaneous neoplasms. Harrington AC, et al. **Md Med J** 1997 May-Jun;46(5):255–62 (48 ref.)

DRUG THERAPY

[Chemotherapy for advanced adenocarcinoma of the skin: experience with combination chemotherapy and a review of the literature] Yamazaki N. **Gan To Kagaku Ryoho** 1997 Jan;24(1):30–6 (15 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Extramammary Paget's disease of the vulva: metastases to the bone marrow in the absence of an underlying adenocarcinoma--case report and literature review. Cappuccini F, et al. **Gynecol Oncol** 1997 Jul;66(1):146–50 (14 ref.)

PAGET'S DISEASE, MAMMARY

PATHOLOGY

Paget's disease of the male breast. Desai DC, et al. **Am Surg** 1996 Dec;62(12):1068–72 (32 ref.)

Erosive adenomatosis of the nipple: a benign imitator of malignant breast disease. Miller L, et al. **Cutis** 1997 Feb; 59(2):91–2 (11 ref.)

PAGET'S DISEASE OF BONE see **OSTEITIS DEFORMANS**

PAGET'S DISEASE OF BREAST see **PAGET'S DISEASE, MAMMARY**

PAHO see **PAN AMERICAN HEALTH ORGANIZATION**

PAI-1 see **PLASMINOGEN ACTIVATOR INHIBITOR 1**

PAI-3 see **PROTEIN C INHIBITOR**

PAIN

see related
ANALGESIA
ANALGESICS
HYPERALGESIA
PAIN INSENSITIVITY, CONGENITAL
PALLIATIVE CARE

Factitious sickle cell acute painful episodes: a secondary type of Munchausen syndrome. Ballas SK. **Am J Hematol** 1996 Dec;53(4):254–8 (7 ref.)

Why do people tend to overpredict pain? On the asymmetries between underpredictions and overpredictions of pain. Arntz A. **Behav Res Ther** 1996 Jul;34(7):545–54 (35 ref.)

Geriatric pain. Pain perceptions in the old. Harkins SW. **Clin Geriatr Med** 1996 Aug;12(3):435–59 (64 ref.)

Analgesic drugs for neuropathic and sympathetically maintained pain. Lipman AG. **Clin Geriatr Med** 1996 Aug; 12(3):501–15 (30 ref.)

The behavioral–cognitive model of pain. Manetto C, et al. **Clin Geriatr Med** 1996 Aug;12(3):461–71 (41 ref.)

Pain in cognitively impaired older persons. Parmelee PA. **Clin Geriatr Med** 1996 Aug;12(3):473–87 (56 ref.)

Invasive modalities for the diagnosis and treatment of pain in the elderly [published erratum appears in Clin Geriatr Med 1996 Nov;12(4):X] Prager JP. **Clin Geriatr Med** 1996 Aug;12(3):549–61 (18 ref.)

Infracalcaneal heel pain in the athlete. Agostinelli J, et al. **Clin Podiatr Med Surg** 1997 Jul;14(3):503–9 (14 ref.)

Musculoskeletal pain in children. Sherry DD. **Curr Opin Rheumatol** 1997 Sep;9(5):465–70 (59 ref.)

A conceptual foundation for human suffering in nursing care and research. Rodgers BL, et al. **J Adv Nurs** 1997 May; 25(5):1048–53 (47 ref.)

Anterior hip pain in the adult: an algorithmic approach to diagnosis. Mansour ES, et al. **J Am Osteopath Assoc** 1997 Jan;97(1):32–8 (29 ref.)

Pain mechanisms involved in musculoskeletal disorders. Sluka KA. **J Orthop Sports Phys Ther** 1996 Oct; 24(4):240–54 (105 ref.)

Shoulder pain in the work place. Curtis AS, et al. **Orthop Clin North Am** 1996 Oct;27(4):763–81 (42 ref.)

New perspectives on the definition of pain [editorial] [see comments] Anand KJ, et al. **Pain** 1996 Sep;67(1):3–6; discussion 209–11 (41 ref.) Comment in: Pain 1997 Apr;70(2–3):293.

More sensory competence for nociceptive neurons in culture [comment] Kress M, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24;93(26):14995–7 (35 ref.) Comment on: Proc Natl Acad Sci U S A 1996 Dec 24;93(26):15435–9.

Temporomandibular pain and dysfunction syndrome. History, physical examination, and treatment. Marbach JJ. **Rheum Dis Clin North Am** 1996 Aug;22(3):477–98 (84 ref.)

[Tourniquet pain: anatomic–physiological notes and clinical aspects] Ramaioli F, et al. **Minerva Anestesiol** 1996 Jul–Aug;62(7–8):265–70 (36 ref.) (Eng. Abstr.) **(Ita)**

[Pain–induced gene expression in the nervous system] Senba E. **Nippon Seikeigeka Gakkai Zasshi** 1996 Jan;70(1):40–50 (30 ref.) **(Jpn)**

[The role of "passing processes": is it disease or not?] Shmurin RI. **Klin Med (Mosk)** 1997;75(2):68–70 (10 ref.) **(Rus)**

CLASSIFICATION

Classification of pain following spinal cord injury. Siddall PJ, et al. **Spinal Cord** 1997 Feb;35(2):69–75 (44 ref.)

[Assessment of chronic pain in elderly patients] Nikolaus T. **Ther Umsch** 1997 Jun;54(6):340–4 (56 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Hematuria–loin pain syndrome: its existence as a discrete clinicopathological entity cannot be supported. Hall R, et al. **Clin J Pain** 1997 Jun;13(2):171–7 (35 ref.)

Depression in the patient with chronic pain. Ruoff GE. **J Fam Pract** 1996 Dec;43(6 Suppl):S25–33; discussion S34 (53 ref.)

The impact of dementia on the pain experience. Farrell MJ, et al. **Pain** 1996 Sep;67(1):7–15 (66 ref.)

Diagnosing addictive disease in chronic pain patients [see comments] Miotto K, et al. **Psychosomatics** 1996 May–Jun; 37(3):223–35 (66 ref.) Comment in: Psychosomatics 1997 Mar–Apr;38(2):158–9.

DIAGNOSIS

Management of common shoulder problems. Binder A. **Br J Hosp Med** 1996 Jul 10–Aug 20;56(2–3):66–72 (22 ref.)

Clinical differential diagnosis of shoulder pain. Turner–Stokes L. **Br J Hosp Med** 1996 Jul 10–Aug 20;56(2–3):73–7 (3 ref.)

Anterior knee pain: a review. Cutbill JW, et al. **Clin J Sport Med** 1997 Jan;7(1):40–5 (77 ref.)

Evaluation of the patient presenting with a painful wrist. Young VL, et al. **Clin Plast Surg** 1996 Jul;23(3):361–8 (12 ref.)

Diagnostic imaging of heel pain and plantar fasciitis. DiMarcangelo MT, et al. **Clin Podiatr Med Surg** 1997 Apr; 14(2):281–301 (47 ref.)

Pearls, pitfalls, and updates for pain management. Martin JJ, et al. **Emerg Med Clin North Am** 1997 May;15(2):399–415 (95 ref.)

Clinical neurophysiology laboratory tests to assess the nociceptive system in humans. Dotson RM. **J Clin Neurophysiol** 1997 Jan;14(1):32–45 (74 ref.)

The integration of pain sciences into clinical practice. Gifford LS, et al. **J Hand Ther** 1997 Apr–Jun;10(2):86–95 (89 ref.)

The anatomical basis for spinal pain syndromes. Bogduk N. **J Manipulative Physiol Ther** 1995 Nov–Dec;18(9):603–5 (27 ref.)

Sciatic pain and piriformis syndrome. Douglas S. **Nurse Pract** 1997 May;22(5):166–8, 170, 172 passim (18 ref.)

Chronic pain in elderly people. Gagliese L, et al. **Pain** 1997 Mar;70(1):3–14 (82 ref.)

The physical examination in cancer pain assessment. Portenoy RK. **Semin Oncol Nurs** 1997 Feb;13(1):25–9 (12 ref.)

Measurement issues in the comprehensive assessment of cancer pain. Vallerand AH. **Semin Oncol Nurs** 1997 Feb; 13(1):16–24 (34 ref.)

[The "pedrada" ("coup–de–fouet") syndrome. A possibility to be considered in acute leg pain] Toscano F, et al. **Minerva Chir** 1997 Apr;52(4):489–91 (12 ref.) (Eng. Abstr.) **(Ita)**

[Criteria for the evaluation of neonatal pain] Ghizzi C, et al. **Pediatr Med Chir** 1996 Nov–Dec;18(6):591–5 (21 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Cancer pain management. Bruera E, et al. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 2):146–53 (68 ref.)

Update on spinal cord pharmacology in pain. Eisenach J. **Acta Anaesthesiol Scand Suppl** 1997;110:124–6 (21 ref.)

Analgesic effect of bisphosphonates on bone pain in breast cancer patients: a review article. Strang P. **Acta Oncol** 1996; 35 Suppl 5:50–4 (30 ref.)

Treating chronic pain [published erratum appears in Am Fam Physician 1997 Apr;55(5):1586] Montauk SL, et al. **Am Fam Physician** 1997 Mar;55(4):1151–60, 1165–6 (15 ref.)

Opioid treatment of chronic nonmalignant pain. Stein C. **Anesth Analg** 1997 Apr;84(4):912–4 (30 ref.)

alpha(2)–adrenergic agonists for regional anesthesia. A clinical review of clonidine (1984–1995). Eisenach JC, et al. **Anesthesiology** 1996 Sep;85(3):655–74 (169 ref.)

Acute pain management: operative or medical procedures and trauma. Follin SL, et al. **Ann Pharmacother** 1997 Sep; 31(9):1068–76 (63 ref.)

Use of gabapentin in pain management. Wetzel CH, et al. **Ann Pharmacother** 1997 Sep;31(9):1082–3 (8 ref.)

Novel pharmacological strategies for analgesia. Perkins M, et al. **Ann Rheum Dis** 1996 Oct;55(10):715–22 (93 ref.)

Towards better pain treatment in cancer. Dellemijn PL, et al. **Anticancer Drugs** 1996 Jan;7(1):3–26 (300 ref.)

Treating acute pain in hospital. McQuay H, et al. **BMJ** 1997 May 24;314(7093):1531–5 (31 ref.)

Management of chronic non–malignant pain. Andersen S, et al. **Br J Clin Pract** 1996 Sep;50(6):324–30 (27 ref.)

Analgesia and analgesic drugs in paediatrics. Ball AJ, et al. **Br J Hosp Med** 1996 May 1–14;55(9):586–90 (27 ref.)

Palliative medicine in the elderly. Cleary JF, et al. **Cancer** 1997 Oct 1;80(7):1335–47 (56 ref.)

Opioid analgesic drugs in the elderly. Forman WB. **Clin Geriatr Med** 1996 Aug;12(3):489–500 (44 ref.)

Nonsteroidal anti–inflammatory drugs, traditional opioids, and tramadol: contrasting therapies for the treatment of chronic pain. Aronson MD. **Clin Ther** 1997 May–Jun; 19(3):420–32; discussion 367–8 (38 ref.)

A risk–benefit assessment of tramadol in the management of pain. Radbruch L, et al. **Drug Saf** 1996 Jul;15(1):8–29 (128 ref.)

Current guidelines for the treatment of acute pain in children. Bhatt–Mehta V. **Drugs** 1996 May;51(5):760–76 (160 ref.)

Aceclofenac. A review of its pharmacodynamic properties and therapeutic potential in the treatment of rheumatic disorders and in pain management. Brogden RN, et al. **Drugs** 1996 Jul;52(1):113–24 (52 ref.)

Opioid analgesics: comparative features and prescribing guidelines. Cherny NI. **Drugs** 1996 May;51(5):713–37 (210 ref.)

Peppers and pain. The promise of capsaicin. Fusco BM, et al. **Drugs** 1997 Jun;53(6):909–14 (37 ref.)

Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Gillis JC, et al. **Drugs** 1997 Jan;53(1):139–88 (293 ref.)

Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Jeal W, et al. **Drugs** 1997 Jan;53(1):109–38 (105 ref.)

Pearls, pitfalls, and updates for pain management. Martin JJ, et al. **Emerg Med Clin North Am** 1997 May;15(2):399–415 (95 ref.)

Managing chronic neuropathic pain with implanted anesthetic reservoirs. Monsivais JJ, et al. **Hand Clin** 1996 Nov;12(4):781–6 (8 ref.)

Nonopioid and opioid analgesic pharmacotherapy of cancer pain. Cherny NI, et al. **Hematol Oncol Clin North Am** 1996 Feb;10(1):79–102 (125 ref.)

Adjuvant analgesic agents. Portenoy RK. **Hematol Oncol Clin North Am** 1996 Feb;10(1):103–19 (66 ref.)

Acute pain management in pediatric patients. Walker SM. **Int Anesthesiol Clin** 1997 Spring;35(2):105–30 (126 ref.)

Capsaicin—an effective topical treatment in pain. Markovits E, et al. **Int J Dermatol** 1997 Jun;36(6):401–4 (24 ref.)

Carotenoids in cancer, mastalgia, and AIDS: prevention and treatment—an overview. Santamaria L, et al. **J Environ Pathol Toxicol Oncol** 1996;15(2–4):89–95 (46 ref.)

Opioids for chronic non–malignant pain. Conigliaro DA. **J Fla Med Assoc** 1996 Dec;83(10):708–11 (30 ref.)

Pain and symptom management in cancer patients. Kori S. **J Fla Med Assoc** 1996 Dec;83(10):679–94 (75 ref.)

Pediatric pain management. Lederhaas G. **J Fla Med Assoc** 1997 Jan;84(1):37–40 (31 ref.)

Pain management for the AIDS patient. Lefkowitz M. **J Fla Med Assoc** 1996 Dec;83(10):701–4 (21 ref.)

Epidural opioid therapy for chronic nonmalignant pain: critique of current experience. Bedder MD. **J Pain Symptom Manage** 1996 Jun;11(6):353–6 (14 ref.)

Epidural and subarachnoid administration of opioids for nonmalignant pain: technical issues, current approaches and novel treatments. Hassenbusch SJ. **J Pain Symptom Manage** 1996 Jun;11(6):357–62 (23 ref.)

Clinical realities and economic considerations: economics of intrathecal therapy. Hassenbusch SJ, et al. **J Pain Symptom Manage** 1997 Sep;14(3 Suppl):S36–48 (12 ref.)

Clinical realities and economic considerations: patient selection in intrathecal therapy. Krames ES, et al. **J Pain Symptom Manage** 1997 Sep;14(3 Suppl):S3–13 (31 ref.)

Intraspinal opioid therapy for chronic nonmalignant pain: current practice and clinical guidelines. Krames ES. **J Pain Symptom Manage** 1996 Jun;11(6):333–52 (78 ref.)

Clinical realities and economic considerations: efficacy of intrathecal pain therapy. Paice JA, et al. **J Pain Symptom Manage** 1997 Sep;14(3 Suppl):S14–26 (36 ref.)

Pediatric palliative medicine: obstacles to overcome. Liben S. **J Palliat Care** 1996 Autumn;12(3):24–8 (39 ref.)

Attitudes and beliefs about medication and pain management in children. McGrath PJ, et al. **J Palliat Care** 1996 Autumn; 12(3):46–50 (22 ref.)

Conscious sedation of pediatric oncology patients for painful procedures: development and implementation of a clinical practice protocol. Macpherson CF, et al. **J Pediatr Oncol Nurs** 1997 Jan;14(1):33–42; quiz 43–4 (16 ref.)

Pain management in osteoarthritis: the role of COX–2 inhibitors. Lane NE. **J Rheumatol** 1997 Jul;24 Suppl 49:20–4 (30 ref.)

Pain management. Foster RL. **J Soc Pediatr Nurs** 1996 Jul–Sep;1(2):93–4 (16 ref.)

Ketorolac: an alternative for the management of acute pain. Burke SM. **MCN Am J Matern Child Nurs** 1997 Jan–Feb; 22(1):56 (6 ref.)

The use of oral opioids in patients with chronic non–cancer pain. Management strategies [see comments] Graziotti PJ, et al. **Med J Aust** 1997 Jul 7;167(1):30–4 (20 ref.) Comment in: Med J Aust 1997 Jul 7;167(1):9–10.

Role of opioids in chronic non–cancer pain [editorial; comment] Molloy AR, et al. **Med J Aust** 1997 Jul 7; 167(1):9–10 (14 ref.) Comment on: Med J Aust 1997 Jul 7;167(1):26–9. Comment on: Med J Aust 1997 Jul 7;167(1):30–4.

Opiates for chronic nonmalignant pain? [see comments] Grosshandler S, et al. **N C Med J** 1996 Sep–Oct; 57(5):288–90 (7 ref.) Comment in: N C Med J 1997 Jan–Feb;58(1):8.

Association of enkephalin catabolism inhibitors and CCK–B antagonists: a potential use in the management of pain and opioid addiction. Roques BP, et al. **Neurochem Res** 1996 Nov;21(11):1397–410 (116 ref.)

Burn management. Psychosocial interventions: pharmacologic and psychologic modalities. Davis ST, et al. **Nurs Clin North Am** 1997 Jun;32(2):331–42 (56 ref.)

Correcting misconceptions about pain assessment and use of opioid analgesics: educational strategies aimed at public concerns. McCaffery M, et al. **Nurs Outlook** 1996 Jul–Aug; 44(4):184–90 (28 ref.)

Pharmacologic approaches to chronic pain in the older adult. Dellasega C, et al. **Nurse Pract** 1997 May;22(5):20–4, 26, 31–2 passim; quiz 36–7 (21 ref.)

Paracetamol with and without codeine in acute pain: a quantitative systematic review. Moore A, et al. **Pain** 1997

Apr;70(2-3):193-201 (18 ref.)
Ketamine in cancer pain: an update. Mercadante S. **Palliat Med** 1996 Jul;10(3):225-30 (35 ref.)
Sedation and analgesia for minor pediatric procedures. Algren JT, et al. **Pediatr Emerg Care** 1996 Dec;12(6):435-41 (6 ref.)
Biochemical aspects of chronic pain and its relationship to treatment. Pleuvry BJ, et al. **Pharmacol Ther** 1996; 71(3):313-24 (128 ref.)
NSAIDs revisited: selection, monitoring, and safe use. Amadio P Jr, et al. **Postgrad Med** 1997 Feb;101(2):257-60, 263-7, 270-1 (20 ref.)
Alternative neuraxial pain management techniques. Abram SE. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):129-34 (59 ref.)
Future directions for outcome research in acute pain management: design of clinical trials. Carpenter RL. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):137-8 (11 ref.)
Consensus statement on acute pain management. Carpenter RL, et al. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):152-6 (0 ref.)
New agents to clinical practice: introduction to clinical trials. Eisenach JC. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):135-6 (14 ref.)
Cost-effectiveness and cost/benefit ratio of acute pain management. Rauck RL. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):139-43 (18 ref.)
Trigger points and tender points: one and the same? Does injection treatment help? Borg-Stein J, et al. **Rheum Dis Clin North Am** 1996 May;22(2):305-22 (62 ref.)
Chronic pain states: pathophysiology and medical therapy. Garcia J, et al. **Semin Arthritis Rheum** 1997 Aug;27(1):1-16 (53 ref.)
Innovations in pharmacologic therapies. Miaskowski C. **Semin Oncol Nurs** 1997 Feb;13(1):30-5 (44 ref.)
Injection techniques and use in the treatment of sports injuries. Scott WA. **Sports Med** 1996 Dec;22(6):406-16 (64 ref.)
Should bisphosphonates be standard therapy for bone pain? Paterson AH. **Support Care Cancer** 1997 May;5(3):200-4 (21 ref.)
[Transdermal opioid administration: the pain plaster] Vecht CJ, et al. **Ned Tijdschr Geneeskd** 1997 Apr 26;141(17):821-3 (10 ref.) (Eng. Abstr.) **(Dut)**
[Analgesia controlled by the patient in pediatrics] Colcanap O, et al. **Arch Pediatr** 1996 Oct;3(10):1032-7 (43 ref.) (Eng. Abstr.) **(Fre)**
[Use of opiates for chronic pain] Larue F. **Bull Acad Natl Med** 1996 Nov;180(8):1967-78; discussion 1979-85 (27 ref.) (Eng. Abstr.) **(Fre)**
[Role of amphetamines in cancerology : a review of the literature] Reich MG, et al. **Bull Cancer** 1996 Nov; 83(11):891-900 (66 ref.) (Eng. Abstr.) **(Fre)**
[The complexity of physiopharmacologic aspects of pain] Besson JM. **Drugs** 1997;53 Suppl 2:1-9 (12 ref.) (Eng. Abstr.) **(Fre)**
[Review of current pharmacologic treatment of pain] Brasseur L. **Drugs** 1997;53 Suppl 2:10-7 (41 ref.) (Eng. Abstr.) **(Fre)**
[Tramadol in acute pain] Lehmann KA. **Drugs** 1997;53 Suppl 2:25-33 (32 ref.) (Eng. Abstr.) **(Fre)**
[Treatment of pain at a community pharmacy] Malonne H, et al. **J Pharm Belg** 1996 Nov-Dec;51(6):305-15 (0 ref.) (Eng. Abstr.) **(Fre)**
[Analgesic in pediatrics. Drugs for pain relief in children] Fournier-Charrière E, et al. **Presse Med** 1997 Jun 7; 26(19):925-32 (28 ref.) (Eng. Abstr.) **(Fre)**
[Pain therapy in ophthalmology] Wölfelschneider P, et al. **Klin Monatsbl Augenheilkd** 1996 Nov;209(5):261-8 (50 ref.) (Eng. Abstr.) **(Ger)**
[Treatment of pain in oncology] De Conno F, et al. **Tumori** 1997;83(2 Suppl):S20-4 (49 ref.) (Eng. Abstr.) **(Ita)**
[The problem of opioid tolerance and dependence during clinical use thereof] Osipova NA. **Anesteziol Reanimatol** 1996 Jul-Aug;(4):17-21 (26 ref.) (Eng. Abstr.) **(Rus)**
[New aspects of learning addictive effects of narcotic analgesics] Zvartau EE, et al. **Anesteziol Reanimatol** 1996 Jul-Aug;(4):13-6 (20 ref.) **(Rus)**

ECONOMICS

Cost-effectiveness and cost/benefit ratio of acute pain management. Rauck RL. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):139-43 (18 ref.)

EPIDEMIOLOGY

The association between external weather conditions and pain and stiffness in women with rheumatoid arthritis. Drane D, et al. **J Rheumatol** 1997 Jul;24(7):1309-16 (23 ref.)
Gender variations in clinical pain experience. Unruh AM. **Pain** 1996 May-Jun;65(2-3):123-67 (235 ref.)

ETIOLOGY

Transient synovitis of the hip in children. Hart JJ. **Am Fam Physician** 1996 Oct;54(5):1587-91, 1595-6 (20 ref.)
The painful foot, Part II: Common rearfoot deformities. Van Wyngarden TM. **Am Fam Physician** 1997 May 1; 55(6):2207-12 (07 ref.)
Is self-reported pain an appropriate outcome measure in ergonomic-epidemiologic studies of work-related musculoskeletal disorders? Schierhout GH, et al. **Am J Ind Med** 1996 Jul;30(1):93-8 (45 ref.)
Symptom distress in adult patients with cancer. McClement SE, et al. **Cancer Nurs** 1997 Aug;20(4):236-43 (44 ref.)
Analysis of recent literature concerning relaxation and imagery interventions for cancer pain. Wallace KG. **Cancer Nurs** 1997 Apr;20(2):79-87 (45 ref.)
Diagnostic imaging of heel pain and plantar fasciitis. DiMarcangelo MT, et al. **Clin Podiatr Med Surg** 1997 Apr; 14(2):281-301 (47 ref.)
Shoulder pain in golf. Jobe FW, et al. **Clin Sports Med** 1996 Jan;15(1):55-63 (15 ref.)
Correlation of clinical pain symptoms with histopathological changes of the dental pulp: a review. Ngassapa D. **East Afr Med J** 1996 Dec;73(12):779-81 (28 ref.)
Physical examination of the wrist. Watson HK, et al. **Hand Clin** 1997 Feb;13(1):17-34 (6 ref.)
Clinicopathologic correlates of common cancer pain syndromes. Caraceni A. **Hematol Oncol Clin North Am** 1996 Feb;10(1):57-78 (64 ref.)
Reflex sympathetic dystrophy and pain dysfunction in the lower extremity. Lindenfeld TN, et al. **Instr Course Lect** 1997;46:261-8 (51 ref.)
Magnetic resonance imaging studies of the shoulder: diagnosis of lesions of the rotator cuff. Recht MP, et al. **Instr Course Lect** 1994;43:483-92 (50 ref.)
Anterior knee pain syndromes in the adolescent. Stanitski CL. **Instr Course Lect** 1994;43:211-20 (77 ref.)
The reflex sympathetic dystrophy syndrome: a review with special reference to chronic pain and motor impairments. Ribbers G, et al. **Int J Rehabil Res** 1995 Dec;18(4):277-95 (78 ref.)
Nonossifying fibroma. Four cases and review of the literature. Glockenberg A, et al. **J Am Podiatr Med Assoc** 1997 Feb;87(2):66-9 (8 ref.)
Three decades of pain research and its control. Dubner R. **J Dent Res** 1997 Mar;76(3):730-3 (30 ref.)
Pain after injury: some basic mechanisms. Yaksh TL. **J Fla Med Assoc** 1997 Jan;84(1):16-9 (19 ref.)
Congenital absence of the scaphoid without other congenital abnormality: a case report. Kuz JE, et al. **J Hand Surg [Am]** 1997 May;22(3):489-91 (7 ref.)
Physical evaluation of the peripheral nervous system in disorders of pain and dysfunction. Elvey RL. **J Hand Ther** 1997 Apr-Jun;10(2):122-9 (29 ref.)
The integration of pain sciences into clinical practice. Gifford LS, et al. **J Hand Ther** 1997 Apr-Jun;10(2):86-95 (89 ref.)
Repetitive use and static postures: a source of nerve compression and pain. Novak CB, et al. **J Hand Ther** 1997 Apr-Jun;10(2):151-9 (73 ref.)
The influence of the mobility in the cervicothoracic spine and the upper ribs (shoulder girdle) on the mobility of the scapulohumeral joint. Sobel JS, et al. **J Manipulative Physiol Ther** 1996 Sep;19(7):469-74 (16 ref.)
Herniated intervertebral disc without pain. Gorman WF, et al. **J Okla State Med Assoc** 1997 May-Jun;90(5):185-90 (38 ref.)
Genital pain associated with genital retraction: a case of Koro syndrome. Wilson S, et al. **J Pain Symptom Manage** 1997 Mar;13(3):176-8 (8 ref.)
Inflammatory cloacogenic polyp: an unrecognized cause of hematochezia and tenesmus in childhood. Poon KK, et al. **J Pediatr** 1997 Feb;130(2):327-9 (13 ref.)
Joint pain and weather. A critical review of the literature. Quick DC. **Minn Med** 1997 Mar;80(3):25-9 (24 ref.)
Muscle pain, fatigue, and fasciulations. Kincaid JC. **Neurol Clin** 1997 Aug;15(3):697-709 (23 ref.)
Wound care pain management. Rook JL. **Nurse Pract** 1997 Mar;22(3):122-6, 131, 134-6 (66 ref.)
Chronic abacterial prostatitis--a urological chronic pain syndrome? Egan KJ, et al. **Pain** 1997 Feb;69(3):213-8 (35 ref.)
Malignant bone pain: pathophysiology and treatment. Mercadante S. **Pain** 1997 Jan;69(1-2):1-18 (166 ref.)
Episodic pain associated with a tumor in the parietal operculum: a case report and literature review. Potagas C, et al. **Pain** 1997 Aug;72(1-2):201-8 (70 ref.)
Ketamine in cancer pain: an update. Mercadante S. **Palliat Med** 1996 Jul;10(3):225-30 (35 ref.)
Patellofemoral malalignment. Goldberg B. **Pediatr Ann** 1997 Jan;26(1):32-5 (39 ref.)
Three common causes of childhood hip pain. Koop S, et al. **Pediatr Clin North Am** 1996 Oct;43(5):1053-66 (23 ref.)
Heel pain as the inaugural manifestation of metastatic prostate cancer [letter] Gisserot O, et al. **Rev Rhum Engl Ed** 1996 Dec;63(11):870-1 (8 ref.)
Psychological medicine, pain, and musculoskeletal disorders. Merskey H. **Rheum Dis Clin North Am** 1996 Aug; 22(3):623-37 (48 ref.)
The dynias. Wesselmann U, et al. **Semin Neurol** 1996 Mar; 16(1):63-74 (162 ref.)
International efforts in cancer pain relief. Coyne PJ. **Semin Oncol Nurs** 1997 Feb;13(1):57-62 (29 ref.)
Cancer pain education for patients. Ferrell BR, et al. **Semin Oncol Nurs** 1997 Feb;13(1):42-8 (37 ref.)
The use of computers in cancer pain management. Frandsen JL. **Semin Oncol Nurs** 1997 Feb;13(1):49-56 (21 ref.)
The physical examination in cancer pain assessment. Portenoy RK. **Semin Oncol Nurs** 1997 Feb;13(1):25-9 (12 ref.)
Measurement issues in the comprehensive assessment of cancer pain. Vallerand AH. **Semin Oncol Nurs** 1997 Feb; 13(1):16-24 (34 ref.)
Central pain of spinal origin. Bowsher D. **Spinal Cord** 1996 Dec;34(12):707-10 (38 ref.)
Intraradicular, intervertebral disc herniation. A case report. Finkel HZ. **Spine** 1997 May 1;22(9):1028-9 (8 ref.)
[Vulvodynia--sensitivity to touch of the vulva] Paavonen J. **Duodecim** 1995;111(13):1237-41 (21 ref.) **(Fin)**
[Pain syndromes in AIDS] Wesselmann U. **Anaesthesist** 1996 Nov;45(11):1004-14 (52 ref.) (Eng. Abstr.) **(Ger)**
[Minimum requirements in medical expert assessment of occupational disability of patients with chronic nonspecific pain] Raspe HH. **Versicherungsmedizin** 1997 Aug 1; 49(4):118-25 (31 ref.) (Eng. Abstr.) **(Ger)**
[Mechanism of arthritic pain] Yokota T. **Ryumachi** 1996 Oct; 36(5):783-90 (29 ref.) **(Jpn)**
[Pain syndrome in differential diagnosis of infectious diseases] Bogomolova BP. **Klin Med (Mosk)** 1996;74(9):75-7 (0 ref.) **(Rus)**
[Central pain] Polushkina NR, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996; 96(5):108-12 (48 ref.) **(Rus)**

NURSING

The middle-range theory of unpleasant symptoms: an update. Lenz ER, et al. **ANS Adv Nurs Sci** 1997 Mar;19(3):14-27 (53 ref.)
Analysis of recent literature concerning relaxation and imagery interventions for cancer pain. Wallace KG. **Cancer Nurs** 1997 Apr;20(2):79-87 (45 ref.)
Continuing pain education in nursing: a literature review. Francke AL, et al. **Int J Nurs Stud** 1996 Oct;33(5):567-78 (37 ref.)
Exploring the nursing role in pain management from a post-structuralist perspective. Price K, et al. **J Adv Nurs** 1996 Nov;24(5):899-904 (35 ref.)
Nurses' knowledge of pain assessment and management: how much progress have we made? McCaffery M, et al. **J Pain Symptom Manage** 1997 Sep;14(3):175-88 (39 ref.)
The silent ones: a review of sampling issues and biases pertinent to the area of pediatric oncology procedural pain. Williams HA. **J Pediatr Oncol Nurs** 1996 Jan;13(1):31-9 (76 ref.)

PATHOLOGY

[Anatomical route of pain in premature newborn infants] Hamon I. **Arch Pediatr** 1996 Oct;3(10):1006-12 (27 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Beta-endorphin in the brain. A role in nociception. Bach FW. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 2):133-40 (59 ref.)
Opioids in the brain: supraspinal mechanisms in pain control. Jensen TS. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 2):123-32 (61 ref.)
Mechanisms of central pain. Xu XJ, et al. **Acta Anaesthesiol Scand Suppl** 1997;110:127-8 (9 ref.)
Endogenous kynurenine derivatives and pain. Weil-Fugazza J. **Adv Exp Med Biol** 1996;398:83-7 (27 ref.)
Neural blockade for diagnosis and prognosis. A review [see comments] Hogan QH, et al. **Anesthesiology** 1997 Jan; 86(1):216-41 (266 ref.) Comment in: Anesthesiology 1997 Jan;86(1):4-6.
Interactions of descending serotonergic systems with other neurotransmitters in the modulation of nociception. Sawynok J, et al. **Behav Brain Res** 1996;73(1-2):63-8 (42 ref.)
Do fetuses feel pain? Reflex responses do not necessarily signify pain. Lloyd-Thomas AR, et al. **BMJ** 1996 Sep 28; 313(7060):797-8 (21 ref.)
ATP receptors in sickness, pain and death. Brake A, et al. **Chem Biol** 1996 Apr;3(4):229-32 (23 ref.)
Biological barriers to paediatric pain management. Andrews K, et al. **Clin J Pain** 1997 Jun;13(2):138-43 (75 ref.)
Vulvar vestibulitis syndrome: a critical review. Bergeron S, et al. **Clin J Pain** 1997 Mar;13(1):27-42 (80 ref.)
Peripheral pain mechanisms. Cesare P, et al. **Curr Opin Neurobiol** 1997 Aug;7(4):493-9 (65 ref.)
Anterior knee pain in adolescents and young adults [see comments] Johnson RP. **Curr Opin Rheumatol** 1997 Mar; 9(2):159-64 (20 ref.) Comment in: Curr Opin Rheumatol 1997 Mar;9(2):133-43.
Chronic wrist pain [see comments] Ko EH, et al. **Curr Opin Rheumatol** 1997 Mar;9(2):155-8 (24 ref.) Comment in: Curr Opin Rheumatol 1997 Mar;9(2):133-43.
The pharmacology of excitatory and inhibitory amino acid-mediated events in the transmission and modulation of pain in the spinal cord. Dickenson AH, et al. **Gen Pharmacol** 1997 May;28(5):633-8 (62 ref.)
Neurobiology of pain. Siddall PJ, et al. **Int Anesthesiol Clin** 1997 Spring;35(2):1-26 (112 ref.)
Basic science and conservative care of patellofemoral dysfunction: a review of the literature. Banovetz JM, et al. **Iowa Orthop J** 1996;16:88-96 (63 ref.)
Lumbar facet pain: biomechanics, neuroanatomy and neurophysiology. Cavanaugh JM, et al. **J Biomech** 1996 Sep;29(9):1117-29 (54 ref.)
Neuroanatomy of the pain system and of the pathways that modulate pain. Willis WD, et al. **J Clin Neurophysiol** 1997 Jan;14(1):2-31 (393 ref.)
Pain--it's all in your head: a philosophical essay. Brand P. **J Hand Ther** 1997 Apr-Jun;10(2):59-63 (5 ref.)
Nociceptors and the peripheral nervous system's role in pain.

Greenspan JD. **J Hand Ther** 1997 Apr–Jun;10(2):78–85 (55 ref.)

Central nervous system pathways for pain transmission and pain control: issues relevant to the practicing clinician. Robinson AJ. **J Hand Ther** 1997 Apr–Jun;10(2):64–77 (66 ref.)

Sensory neuropathies including painful and toxic neuropathies. Wokke JH, et al. **J Neurol** 1997 Apr; 244(4):209–21 (94 ref.)

The neuroplastic phenomenon: a physiologic link between chronic pain and learning. Arnstein PM. **J Neurosci Nurs** 1997 Jun;29(3):179–86 (33 ref.)

Neuropathic pain in cancer patients: mechanisms, syndromes, and clinical controversies. Martin LA, et al. **J Pain Symptom Manage** 1997 Aug;14(2):99–117 (179 ref.)

Galanin receptors: involvement in feeding, pain, depression and Alzheimer's disease. Kask K, et al. **Life Sci** 1997; 60(18):1523–33 (110 ref.)

On the mathematical modelling of pain. Britton NF, et al. **Neurochem Res** 1996 Sep;21(9):1133–40 (53 ref.)

Application of focused ultrasound for research on pain. ab Ithel Davies I, et al. **Pain** 1996 Sep;67(1):17–27 (37 ref.)

Pain and its persistence in herpes zoster. Dworkin RH, et al. **Pain** 1996 Oct;67(2–3):241–51 (126 ref.)

The medullary subnucleus reticularis dorsalis (SRD) as a key link in both the transmission and modulation of pain signals. Villanueva L, et al. **Pain** 1996 Oct;67(2–3):231–40 (109 ref.)

Windup and central sensitization are not equivalent [editorial] Woolf CJ. **Pain** 1996 Aug;66(2–3):105–8 (51 ref.)

System theory of pain and of opiate analgesia: no tolerance to opiates. Colpaert FC. **Pharmacol Rev** 1996 Sep; 48(3):355–402 (408 ref.)

The effects of pain on opioid tolerance: how do we resolve the controversy? Gutstein HB. **Pharmacol Rev** 1996 Sep; 48(3):403–7; discussion 409–11 (23 ref.)

Can sensory neurones in culture serve as a model of nociception? [editorial] Vyklický L, et al. **Physiol Res** 1996; 45(1):1–9 (95 ref.)

Nociceptive, environmental and neuroendocrine factors determining pain behaviour in animals. Aloisi AM, et al. **Prog Brain Res** 1996;110:33–46 (78 ref.)

Involvement of the spino-parabrachio -amygdaloid and -hypothalamic pathways in the autonomic and affective emotional aspects of pain. Bernard JF, et al. **Prog Brain Res** 1996;107:243–55 (80 ref.)

Signal transduction in nociceptive afferent neurons in inflammatory conditions. Bevan S. **Prog Brain Res** 1996; 113:201–13 (54 ref.)

Spinal cord mechanisms of hyperalgesia and allodynia: role of peripheral input from nociceptors. Cervero F. **Prog Brain Res** 1996;113:413–22 (32 ref.)

From acute to chronic pain: mechanisms and hypotheses. Cervero F, et al. **Prog Brain Res** 1996;110:3–15 (61 ref.)

Limbic processes and the affective dimension of pain. Chapman CR. **Prog Brain Res** 1996;110:63–81 (72 ref.)

Balances between excitatory and inhibitory events in the spinal cord and chronic pain. Dickenson AH. **Prog Brain Res** 1996;110:225–31 (31 ref.)

Neurogenic mechanisms and neuropeptides in chronic pain. Dray A. **Prog Brain Res** 1996;110:85–94 (81 ref.)

Peripheral opioid analgesia--facts and mechanisms. Herz A. **Prog Brain Res** 1996;110:95–104 (47 ref.)

Interactions of sympathetic and primary afferent neurons following nerve injury and tissue trauma. Jänig W, et al. **Prog Brain Res** 1996;113:161–84 (93 ref.)

Role of polymodal receptors in the acupuncture-mediated endogenous pain inhibitory systems. Kawakita K, et al. **Prog Brain Res** 1996;113:507–23 (93 ref.)

Alterations in the functional properties of dorsal root ganglion cells with unmyelinated axons after a chronic nerve constriction in the rat. LaMotte RH, et al. **Prog Brain Res** 1996;110:105–11 (32 ref.)

Physiological functions of pontomedullary raphe and medial reticular neurons. Mason P, et al. **Prog Brain Res** 1996; 107:269–82 (130 ref.)

The possible role of substance P in eliciting and modulating deep somatic pain. Mense S, et al. **Prog Brain Res** 1996; 110:125–35 (55 ref.)

Functional morphology of nociceptive and other fine sensory endings (free nerve endings) in different tissues. Messlinger K. **Prog Brain Res** 1996;113:273–98 (75 ref.)

Functional anatomy of nociceptive neurones in rat superior colliculus. Redgrave P, et al. **Prog Brain Res** 1996; 107:403–15 (64 ref.)

Tissue acidosis in nociception and pain. Reeh PW, et al. **Prog Brain Res** 1996;113:143–51 (65 ref.)

Neurobiology of spinal nociception: new concepts. Sandkühler J. **Prog Brain Res** 1996;110:207–24 (50 ref.)

Neurophysiology of chronic inflammatory pain: electrophysiological recordings from spinal cord neurons in rats with prolonged acute and chronic unilateral inflammation at the ankle. Schaible HG, et al. **Prog Brain Res** 1996;110:167–76 (56 ref.)

Spinal organization of C-fiber afferents related with nociception or non-nociception. Sugiura Y. **Prog Brain Res** 1996;113:320–39 (116 ref.)

Involvement of glutamatergic neurotransmission and protein kinase C in spinal plasticity and the development of chronic pain. Tölle TR, et al. **Prog Brain Res** 1996;110:193–206 (54 ref.)

Plasticity of messenger function in primary afferents following nerve injury--implications for neuropathic pain. Wiesenfeld-Hallin Z, et al. **Prog Brain Res** 1996;110:113–24 (80 ref.)

Cooperative mechanisms of neurotransmitter action in central nervous sensitization. Willis WD, et al. **Prog Brain Res** 1996;110:151–66 (72 ref.)

Slow synaptic transmission in the spinal dorsal horn. Yoshimura M. **Prog Brain Res** 1996;113:443–62 (149 ref.)

Plasticity of the nervous system at the systematic, cellular and molecular levels: a mechanism of chronic pain and hyperalgesia. Zimmermann M, et al. **Prog Brain Res** 1996; 110:233–59 (106 ref.)

The organization and function of endogenous antinociceptive systems. Sandkühler J. **Prog Neurobiol** 1996 Sep; 50(1):49–81 (172 ref.)

Recent data on the pathophysiology of nerve root compression and pain. Boulu P, et al. **Rev Rhum Engl Ed** 1996 May;63(5):358–63 (33 ref.)

Chronic pain states: pathophysiology and medical therapy. Garcia J, et al. **Semin Arthritis Rheum** 1997 Aug;27(1):1–16 (53 ref.)

Animal models in pain research. Stanley KL, et al. **Semin Oncol Nurs** 1997 Feb;13(1):3–9 (23 ref.)

Spinal pain mechanisms. Siddall PJ, et al. **Spine** 1997 Jan 1;22(1):98–104 (20 ref.)

[Physiology of nociception] Guirimand F, et al. **Ann Fr Anesth Reanim** 1996;15(7):1048–79 (166 ref.) (Eng. Abstr.) **(Fre)**

[Anatomical route of pain in premature newborn infants] Hamon I. **Arch Pediatr** 1996 Oct;3(10):1006–12 (27 ref.) (Eng. Abstr.) **(Fre)**

[The complexity of physiopharmacologic aspects of pain] Besson JM. **Drugs** 1997;53 Suppl 2:1–9 (12 ref.) (Eng. Abstr.) **(Fre)**

[Pain treatment: current status and perspectives] Buchser E, et al. **Rev Med Suisse Romande** 1997 Mar;117(3):175–84 (10 ref.) **(Fre)**

[N-methyl-D-aspartate (NMDA) receptor and pain] Yamamoto T. **Masui** 1996 Nov;45(11):1312–8 (24 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Adenosine for pain control. Sollevi A. **Acta Anaesthesiol Scand Suppl** 1997;110:135–6 (14 ref.)

Neuraxial implants for pain control. Muir A, et al. **Int Anesthesiol Clin** 1997 Spring;35(2):171–96 (112 ref.)

Acute pain and the obstetric patient: recent developments in analgesia for labor and delivery. Ward ME. **Int Anesthesiol Clin** 1997 Spring;35(2):83–103 (115 ref.)

Perioperative pain management. Levy BS, et al. **J Am Assoc Gynecol Laparosc** 1995 Aug;2(4):381–7 (24 ref.)

Psychological influences on pain perception and non-pharmacologic approaches to the treatment of pain. DePalma MT, et al. **J Hand Ther** 1997 Apr–Jun; 10(2):183–91 (68 ref.)

Anesthesiology. Second of two parts. Wiklund RA, et al. **N Engl J Med** 1997 Oct 23;337(17):1215–9 (151 ref.)

Wound care pain management. Rook JL. **Nurse Pract** 1997 Mar;22(3):122–6, 131, 134–6 (66 ref.)

How to measure and reduce the burden of zoster-associated pain. Wood MJ. **Scand J Infect Dis Suppl** 1996;100:55–8 (18 ref.)

International efforts in cancer pain relief. Coyne PJ. **Semin Oncol Nurs** 1997 Feb;13(1):57–62 (29 ref.)

Cancer pain education for patients. Ferrell BR, et al. **Semin Oncol Nurs** 1997 Feb;13(1):42–8 (37 ref.)

The use of computers in cancer pain management. Frandsen JL. **Semin Oncol Nurs** 1997 Feb;13(1):49–56 (21 ref.)

[Topical anesthesia with the EMLA cream: application in pediatric urology] Xavier B, et al. **Actas Urol Esp** 1996 Nov–Dec;20(10):883–5 (15 ref.) (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Managing spiritual distress in patients with advanced cancer pain. Georgesen J, et al. **Cancer Nurs** 1996 Oct;19(5):376–83 (20 ref.)

Chronic pain-associated depression: antecedent or consequence of chronic pain? A review. Fishbain DA, et al. **Clin J Pain** 1997 Jun;13(2):116–37 (129 ref.)

Psychological barriers to optimal pain management in infants and children. McGrath PJ, et al. **Clin J Pain** 1996 Jun; 12(2):135–41 (42 ref.)

Pain in the newborn, a possible new starting point. McIntosh N. **Eur J Pediatr** 1997 Mar;156(3):173–7 (75 ref.)

Psychiatric aspects of cancer pain. Reynolds PT, et al. **J Fla Med Assoc** 1996 Dec;83(10):705–7 (14 ref.)

Pain—it's all in your head: a philosophical essay. Brand P. **J Hand Ther** 1997 Apr–Jun;10(2):59–63 (5 ref.)

Psychological influences on pain perception and non-pharmacologic approaches to the treatment of pain. DePalma MT, et al. **J Hand Ther** 1997 Apr–Jun; 10(2):183–91 (68 ref.)

Pain in the family [editorial] Bebbington P, et al. **J Psychosom Res** 1996 May;40(5):451–6 (45 ref.)

The association between external weather conditions and pain and stiffness in women with rheumatoid arthritis. Drane D, et al. **J Rheumatol** 1997 Jul;24(7):1309–16 (23 ref.)

Sexual abuse during childhood and adolescence and its effects on the physical and emotional quality of life of the survivor: a review of the literature. Wood DP. **Mil Med** 1996 Oct; 161(10):582–7 (38 ref.)

Advances in comprehensive pain management. Koenig TW, et al. **Psychiatr Clin North Am** 1996 Sep;19(3):589–611 (165 ref.)

Psychological medicine, pain, and musculoskeletal disorders. Merskey H. **Rheum Dis Clin North Am** 1996 Aug; 22(3):623–37 (48 ref.)

RADIONUCLIDE IMAGING

Scrotal pathology as the cause for hip pain. Diagnostic findings on bone scintigraphy. Sheafor DH, et al. **Clin Nucl Med** 1997 May;22(5):287–91 (25 ref.)

RADIOTHERAPY

Unsealed source therapy of painful bone metastases: an update. McEwan AJ. **Semin Nucl Med** 1997 Apr; 27(2):165–82 (127 ref.)

REHABILITATION

Fibromyalgia and the disability dilemma. A new era in understanding a complex, multidimensional pain syndrome [see comments] Bennett RM. **Arthritis Rheum** 1996 Oct; 39(10):1627–34 (85 ref.) Comment in: Arthritis Rheum 1997 Jun;40(6):1184–5.

The role of physical medicine and rehabilitation in pain management. Nguyen DM. **Clin Geriatr Med** 1996 Aug; 12(3):517–29 (59 ref.)

Nonpharmacological approaches to pain in osteoarthritis. Available options. Perrot S, et al. **Drugs** 1996;52 Suppl 3:21–6 (97 ref.)

Rehabilitation of the painful upper extremity. Haines BL. **Hand Clin** 1996 Nov;12(4):801–16 (68 ref.)

Pain management programs in hand therapy: a literature review and appraisal. Doleys DM, et al. **J Hand Ther** 1997 Apr–Jun;10(2):175–82 (72 ref.)

Implementation of neck/shoulder rehabilitation in primary health care clinics. Jordan A, et al. **J Manipulative Physiol Ther** 1996 Jan;19(1):36–40 (25 ref.)

Management of pain in persons with spinal cord injury. Ragnarsson KT. **J Spinal Cord Med** 1997 Apr;20(2):186–99 (79 ref.)

[Musculoskeletal pain disorders] Klockars M. **Duodecim** 1995; 111(17):1671–4 (10 ref.) **(Fin)**

[Treatment and rehabilitation of chronic pain patients] Hildebrandt J. **Anaesthesist** 1997 Jun;46(6):516–27 (98 ref.) (Eng. Abstr.) **(Ger)**

[Long-term pain therapy] Hildebrandt J, et al. **Chirurg** 1996 Jul;67(7):681–7 (28 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Treatment of chronic pain by "wrapping" intact nerves with pedicle and free flaps. Jones NF. **Hand Clin** 1996 Nov; 12(4):765–72 (23 ref.)

Treating the chronic pain of cancerous CNS tumors. Friehs GM. **Med Health R I** 1996 Jun;79(6):218–23 (33 ref.)

THERAPY

Religious orientation and pain management. Low JF. **Am J Occup Ther** 1997 Mar;51(3):215–9 (22 ref.)

Patellofemoral pain syndrome. A critical review of the clinical trials on nonoperative therapy. Arroll B, et al. **Am J Sports Med** 1997 Mar–Apr;25(2):207–12 (32 ref.)

Management strategies for chronic pain. Justins DM. **Ann Rheum Dis** 1996 Sep;55(9):588–96 (105 ref.)

Management of common shoulder problems. Binder A. **Br J Hosp Med** 1996 Jul 10–Aug 20;56(2–3):66–72 (22 ref.)

Management of groin pain in athletes. Fricker PA. **Br J Sports Med** 1997 Jun;31(2):97–101 (22 ref.)

Ethical issues in pain management. Borneman T, et al. **Clin Geriatr Med** 1996 Aug;12(3):615–28 (45 ref.)

Multidisciplinary pain clinics for older people. Do they have a role? Helme RD, et al. **Clin Geriatr Med** 1996 Aug; 12(3):563–82 (19 ref.)

Family and caregiver involvement in pain management. Juarez G, et al. **Clin Geriatr Med** 1996 Aug;12(3):531–47 (48 ref.)

Pain in the nursing home. Stein WM, et al. **Clin Geriatr Med** 1996 Aug;12(3):601–13 (25 ref.)

Biological barriers to paediatric pain management. Andrews K, et al. **Clin J Pain** 1997 Jun;13(2):138–43 (75 ref.)

Psychological barriers to optimal pain management in infants and children. McGrath PJ, et al. **Clin J Pain** 1996 Jun; 12(2):135–41 (42 ref.)

Anterior knee pain: a review. Cutbill JW, et al. **Clin J Sport Med** 1997 Jan;7(1):40–5 (77 ref.)

Management of sickle pain. Ballas SK. **Curr Opin Hematol** 1997 Mar;4(2):104–11 (59 ref.)

Pain management in the pediatric intensive care unit. Chambliss CR, et al. **Curr Opin Pediatr** 1997 Jun; 9(3):246–53 (54 ref.)

Reducing pain during procedures. Liebelt EL. **Curr Opin Pediatr** 1996 Oct;8(5):436–41 (22 ref.)

Causes and treatment of bone pain of malignant origin [see comments] Thürlimann B, et al. **Drugs** 1996 Mar; 51(3):383–98 (72 ref.) Comment in: Drugs 1996 Sep;52(3):475.

Neural blockade for upper-extremity pain. Fouch RA, et al. **Hand Clin** 1996 Nov;12(4):791–800 (33 ref.)

Management of painful paraneoplastic syndromes. Brady AM. **Hematol Oncol Clin North Am** 1996 Aug;10(4):801–9 (58 ref.)

Invasive techniques in the management of cancer pain.

Cherny NI, et al. **Hematol Oncol Clin North Am** 1996 Feb; 10(1):121–37 (105 ref.)

Pain and symptom control. Patient rights and physician responsibilities. Emanuel EJ. **Hematol Oncol Clin North Am** 1996 Feb;10(1):41–56 (34 ref.)

Psychological approaches to the management of pain in patients with advanced cancer. Loscalzo M. **Hematol Oncol Clin North Am** 1996 Feb;10(1):139–55 (59 ref.)

Perspectives in pancreatic pain. Salim AS. **HPB Surg** 1997; 10(5):269–77 (27 ref.)

Laparoscopic treatment of symptomatic endometriosis. Pouly JL, et al. **Hum Reprod** 1996 Nov;11 Suppl 3:67–88 (88 ref.)

Neural blockade in chronic and cancer pain. Lamacraft G, et al. **Int Anesthesiol Clin** 1997 Spring;35(2):131–53 (71 ref.)

Cognitive–behavioral programs: theory and application. Nicholas M, et al. **Int Anesthesiol Clin** 1997 Spring; 35(2):155–70 (29 ref.)

Recent trends in the management of acute pain in children. Litman RS. **J Am Osteopath Assoc** 1996 May;96(5):290–6 (44 ref.)

Stimulation of the central and peripheral nervous system for the control of pain. Stanton–Hicks M, et al. **J Clin Neurophysiol** 1997 Jan;14(1):46–62 (150 ref.)

Utilizing the clinical nurse specialist to promote interdisciplinary pain management. Cronin Y, et al. **J Fla Med Assoc** 1997 Jan;84(1):46–8 (13 ref.)

Types of pain treatment facilities referral selection criteria: are they medically and cost effective? Rosomoff HL, et al. **J Fla Med Assoc** 1997 Jan;84(1):41–5 (17 ref.)

The role of physical agents in modulating pain. Fedorczyk J. **J Hand Ther** 1997 Apr–Jun;10(2):110–21 (90 ref.)

Transcutaneous electrical nerve stimulation for the control of pain in musculoskeletal disorders. Robinson AJ. **J Orthop Sports Phys Ther** 1996 Oct;24(4):208–26 (83 ref.)

Cognitive behavioral control of arthritis pain. Keefe FJ, et al. **Med Clin North Am** 1997 Jan;81(1):277–90 (38 ref.)

Pain control. Sidebotham DA, et al. **N Z Med J** 1997 Mar 14;110(1039):65–7 (27 ref.)

Management of the pediatric burn patient. Cortiella J, et al. **Nurs Clin North Am** 1997 Jun;32(2):311–29 (33 ref.)

Primary care management of chronic musculoskeletal pain [see comments] Davis AE. **Nurse Pract** 1996 Aug;21(8):72, 75, 79–82, passim (44 ref.) Comment in: Nurse Pract 1996 Dec;21(12 Pt 1):8, 13.

Occupational disorders and the management of chronic pain. Polatin PB, et al. **Orthop Clin North Am** 1996 Oct; 27(4):881–90 (73 ref.)

An assessment of the efficacy of physical therapy and physical modalities for the control of chronic musculoskeletal pain. Feine JS, et al. **Pain** 1997 May; 71(1):5–23 (91 ref.)

Chronic pain in elderly people. Gagliese L, et al. **Pain** 1997 Mar;70(1):3–14 (82 ref.)

Pain following spinal cord injury: the clinical problem and experimental studies. Yezierski RP. **Pain** 1996 Dec; 68(2–3):185–94 (76 ref.)

Anesthesia and pain management in pediatric burn patients. Beushausen T, et al. **Pediatr Surg Int** 1997 Jul; 12(5–6):327–33 (75 ref.)

American Society of Regional Anesthesia Future Directions of Acute Pain Management. Consensus conference. Orlando, Florida, May 31–June 2, 1996. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):1–159 (0 ref.)

Animal models in pain research. Stanley KL, et al. **Semin Oncol Nurs** 1997 Feb;13(1):3–9 (23 ref.)

Enhanced limb salvage for peripheral vascular disease with the use of spinal cord stimulation. Huber SJ, et al. **W V Med J** 1996 Mar–Apr;92(2):89–91 (14 ref.)

[Treatment of pain in children burns] Latarjet J, et al. **Arch Pediatr** 1997 Mar;4(3):278–84 (25 ref.) (Eng. Abstr.) **(Fre)**

[Electrotherapy of pain] Dumoulin J, et al. **J Belge Med Phys Rehabil** 1980;3(3):231–8 (15 ref.) **(Fre)**

[Treatment and rehabilitation of chronic pain patients] Hildebrandt J. **Anaesthesist** 1997 Jun;46(6):516–27 (98 ref.) (Eng. Abstr.) **(Ger)**

[Basis and use of neural therapy in diagnosis and treatment] Zohmann A. **Schweiz Arch Tierheilkd** 1997;139(3):117–25 (58 ref.) (Eng. Abstr.) **(Ger)**

[The importance of acute pain units] Stolik–Dollberg O, et al. **Harefuah** 1997 May 1;132(9):653–5 (20 ref.) **(Heb)**

[Plasmapheresis and pain] Betaneli AM, et al. **Vestn Khir Im I I Grek** 1997;156(2):120–21 (6 ref.) **(Rus)**

VETERINARY

Cosmetic tail docking of dogs [see comments] Wansbrough RK. **Aust Vet J** 1996 Jul;74(1):59–63 (11 ref.) Comment in: Aust Vet J 1996 Dec;74(6):476–7.

Nonsteroidal anti–inflammatory analgesics in pain management in dogs and cats [published erratum appears in Can Vet J 1997 Mar;38(3):133] Mathews KA. **Can Vet J** 1996 Sep;37(9):539–45 (17 ref.)

Use of carprofen for the treatment of pain and inflammation in dogs. Fox SM, et al. **J Am Vet Med Assoc** 1997 May 15;210(10):1493–8 (60 ref.)

Management of pain in the critically ill patient. Faggella AM. **Semin Vet Med Surg (Small Anim)** 1997 May;12(2):115–21 (28 ref.)

Management of acute and surgical pain. Hellyer PW. **Semin Vet Med Surg (Small Anim)** 1997 May;12(2):106–14 (55 ref.)

Chronic pain: osteoarthritis and cancer. Kyles AE, et al. **Semin Vet Med Surg (Small Anim)** 1997 May;12(2):122–32 (77 ref.)

Principles of analgesic drug therapy. Papich MG. **Semin Vet Med Surg (Small Anim)** 1997 May;12(2):80–93 (111 ref.)

Recent advances in our understanding of pain: how should they affect management? Raffe M. **Semin Vet Med Surg (Small Anim)** 1997 May;12(2):75–9 (17 ref.)

[Suffering and misfortune––the beginning of comprehension] Winckler C, et al. **DTW Dtsch Tierarztl Wochenschr** 1997 Feb;104(2):43–6 (25 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

Pain in human immunodeficiency virus disease. Newshan G. **Semin Oncol Nurs** 1997 Feb;13(1):36–41 (27 ref.)

PAIN ASSESSMENT see **PAIN MEASUREMENT**

PAIN CENTERS see **PAIN CLINICS**

PAIN CLINICS

Multidisciplinary pain clinics for older people. Do they have a role? Helme RD, et al. **Clin Geriatr Med** 1996 Aug; 12(3):563–82 (19 ref.)

Types of pain treatment facilities referral selection criteria: are they medically and cost effective? Rosomoff HL, et al. **J Fla Med Assoc** 1997 Jan;84(1):41–5 (17 ref.)

Pain clinics. Crook J, et al. **Rheum Dis Clin North Am** 1996 Aug;22(3):599–611 (74 ref.)

PAIN, FACIAL see **FACIAL PAIN**

PAIN INSENSITIVITY, CONGENITAL

COMPLICATIONS

Osteoarticular manifestations of congenital insensitivity to pain with anhydrosis. Szöke G, et al. **Int Orthop** 1996; 20(2):107–10 (22 ref.)

Charcot spinal arthropathy in congenital insensitivity to pain. Igram CM, et al. **Orthopedics** 1996 Mar;19(3):251–55 (44 ref.)

PAIN, INTRACTABLE

see related
PALLIATIVE CARE

Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re–186–HEDP. De Klerk JM, et al. **Anticancer Res** 1997 May–Jun;17(3B):1773–7 (21 ref.)

Complex regional pain syndrome. Colton AM, et al. **J Foot Ankle Surg** 1996 Jul–Aug;35(4):284–96 (42 ref.)

Pathophysiology of joint pain. Perrot S, et al. **Rev Rhum Engl Ed** 1996 Jul–Sep;63(7–8):485–92 (88 ref.)

DRUG THERAPY

Bisphosphonates for controlling pain from metastatic bone disease [see comments] Diener KM. **Am J Health Syst Pharm** 1996 Aug 15;53(16):1917–27 (67 ref.) Comment in: Am J Health Syst Pharm 1996 Aug 15;53(16):1907.

Ketorolac continuous infusion: a case report and review of the literature [see comments] Middleton RK, et al. **J Pain Symptom Manage** 1996 Sep;12(3):190–4 (15 ref.) Comment in: J Pain Symptom Manage 1997 Jun;13(6):315–6.

Intractable pain in children with terminal cancer. Collins JJ. **J Palliat Care** 1996 Autumn;12(3):29–34 (43 ref.)

How should we use transdermal fentanyl (TF) for pain management in palliative care patients? Fainsinger RL, et al. **J Palliat Care** 1996 Spring;12(1):48–53 (30 ref.)

Refractory symptoms and terminal sedation of children: ethical issues and practical management. Kenny NP, et al. **J Palliat Care** 1996 Autumn;12(3):40–5 (22 ref.)

The management of cancer pain. Rhodes DJ, et al. **Md Med J** 1997 Mar;46(3):141–6 (13 ref.)

Current status of patient–controlled analgesia in cancer patients. Ripamonti C, et al. **Oncology (Huntingt)** 1997 Mar; 11(3):373–80, 383–4; discussion 384–6 (102 ref.)

Pain management in home care. Magrum LC, et al. **Semin Oncol Nurs** 1996 Aug;12(3):202–18 (53 ref.)

[Malignant bone pain] Thomsen CB, et al. **Ugeskr Laeger** 1997 Apr 14;159(16):2364–9 (40 ref.) (Eng. Abstr.) **(Dan)**

ETIOLOGY

Bisphosphonates for controlling pain from metastatic bone disease [see comments] Diener KM. **Am J Health Syst Pharm** 1996 Aug 15;53(16):1917–27 (67 ref.) Comment in: Am J Health Syst Pharm 1996 Aug 15;53(16):1907.

Anterior knee pain in the military population. Chang PC, et al. **Ann Acad Med Singapore** 1997 Jan;26(1):60–3 (12 ref.)

Non–nociceptive aspects of persistent musculoskeletal pain. Kramis RC, et al. **J Orthop Sports Phys Ther** 1996 Oct; 24(4):255–67 (66 ref.)

Current status of patient–controlled analgesia in cancer patients. Ripamonti C, et al. **Oncology (Huntingt)** 1997 Mar; 11(3):373–80, 383–4; discussion 384–6 (102 ref.)

PSYCHOLOGY

Psychological factors in disabling low back pain: causes or consequences? Simmonds MJ, et al. **Disabil Rehabil** 1996 Apr;18(4):161–8 (94 ref.)

RADIOGRAPHY

Radiologic case study. Tuberculous osteomyelitis and arthritis. Wright T, et al. **Orthopedics** 1996 Aug; 19(8):699–702 (16 ref.)

REHABILITATION

Management of pain in brachial plexus lesions. Frampton V. **J Hand Ther** 1996 Oct–Dec;9(4):339–43 (23 ref.)

Pain in arthritis and musculoskeletal disorders: the role of coping skills training and exercise interventions. Keefe FJ, et al. **J Orthop Sports Phys Ther** 1996 Oct;24(4):279–90 (43 ref.)

SURGERY

Surgical interruption of a midline dorsal column visceral pain pathway. Case report and review of the literature. Nauta HJ, et al. **J Neurosurg** 1997 Mar;86(3):538–42 (20 ref.)

THERAPY

Spinal cord stimulation [editorial] Simpson BA. **Br J Neurosurg** 1997 Feb;11(1):5–11 (65 ref.)

Pain management at the end of life. Dickey NW. **J Orthop Sports Phys Ther** 1996 Oct;24(4):237–9 (11 ref.)

Deep brain stimulation for intractable pain: a 15–year experience. Kumar K, et al. **Neurosurgery** 1997 Apr; 40(4):736–46; discussion 746–7 (64 ref.)

Managing osteoporotic fractures: minimizing pain and disability. Von Feldt JM. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):78S–80S (13 ref.)

[Recommendations for a successful cancer pain management in adults and children] Krakowski I, et al. **Bull Cancer** 1996 Nov;83 Suppl 1:9s–79s (340 ref.) **(Fre)**

[Pain in cancer patients. Practical attitude] Pichard–Léandri E. **J Chir (Paris)** 1997 May;134(1):14–21 (29 ref.) (Eng. Abstr.) **(Fre)**

PAIN MEASUREMENT

see related
PAIN THRESHOLD
SENSORY THRESHOLDS

Assessment of pain in herpes zoster: lessons learned from antiviral trials. Dworkin RH, et al. **Antiviral Res** 1997 Jan; 33(2):73–85 (43 ref.)

Clinical neurophysiology laboratory tests to assess the nociceptive system in humans. Dotson RM. **J Clin Neurophysiol** 1997 Jan;14(1):32–45 (74 ref.)

Pain assessment in children. Morton NS. **Paediatr Anaesth** 1997;7(4):267–72 (20 ref.)

Chronic pain in elderly people. Gagliese L, et al. **Pain** 1997 Mar;70(1):3–14 (82 ref.)

Comments on Carmody, Pain, 63 (1995) 136 [letter; comment] Raffa RB. **Pain** 1996 Sep;67(1):215–8 (8 ref.) Comment on: Pain 1995 Oct;63(1):136.

Quantitative experimental assessment of pain and hyperalgesia in animals and underlying neural mechanisms. Carstens E. **Prog Brain Res** 1996;110:17–31 (73 ref.)

DRUG EFFECTS

New insights into the site and mode of antinociceptive action of flurbiprofen enantiomers. Geisslinger G, et al. **J Clin Pharmacol** 1996 Jun;36(6):513–20 (85 ref.)

METHODS

Pain assessment in seriously ill patients: its importance and need for technical improvement [editorial; comment] Lasch K, et al. **Crit Care Med** 1996 Dec;24(12):1943–4 (15 ref.) Comment on: Crit Care Med 1996 Dec;24(12):1953–61.

Development of a scale for patient rating of wrist pain and disability. MacDermid JC. **J Hand Ther** 1996 Apr–Jun; 9(2):178–83 (37 ref.)

Nurses' knowledge of pain assessment and management: how much progress have we made? McCaffery M, et al. **J Pain Symptom Manage** 1997 Sep;14(3):175–88 (39 ref.)

Correcting misconceptions about pain assessment and use of opioid analgesics: educational strategies aimed at public concerns. McCaffery M, et al. **Nurs Outlook** 1996 Jul–Aug; 44(4):184–90 (28 ref.)

The physical examination in cancer pain assessment. Portenoy RK. **Semin Oncol Nurs** 1997 Feb;13(1):25–9 (12 ref.)

Measurement issues in the comprehensive assessment of cancer pain. Vallerand AH. **Semin Oncol Nurs** 1997 Feb; 13(1):16–24 (34 ref.)

[Criteria for the evaluation of neonatal pain] Ghizzi C, et al. **Pediatr Med Chir** 1996 Nov–Dec;18(6):591–5 (21 ref.) (Eng. Abstr.) **(Ita)**

NURSING

Factors affecting the assessment of postoperative pain: a literature review. Allcock N. **J Adv Nurs** 1996 Dec; 24(6):1144–51 (42 ref.)

STATISTICS & NUMERICAL DATA

Pain in the newborn, a possible new starting point. McIntosh N. **Eur J Pediatr** 1997 Mar;156(3):173–7 (75 ref.)

[Assessment of chronic pain in elderly patients] Nikolaus T. **Ther Umsch** 1997 Jun;54(6):340–4 (56 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Through a glass darkly: using behavior to assess pain. Hansen B. **Semin Vet Med Surg (Small Anim)** 1997 May;12(2):61–74 (70 ref.)

PAIN, POSTOPERATIVE

Role of peridural fibrosis in the failed back: a review. Robertson JT. **Eur Spine J** 1996;5 Suppl 1:S2–6 (22 ref.)

DRUG THERAPY

Side effects of opioids in postoperative pain treatment. Camu F. **Acta Anaesthesiol Belg** 1996;47(3):105–9 (28 ref.)

Timing of perioperative non-steroidal anti-inflammatory drug treatment. Camu F, et al. **Acta Anaesthesiol Belg** 1996; 47(3):125–8 (25 ref.)

Efficacy of nonsteroidal antiinflammatory drugs in postoperative pain. Joris J. **Acta Anaesthesiol Belg** 1996; 47(3):115–23 (72 ref.)

Pain relief and clinical outcome: from opioids to balanced analgesia. Kehlet H. **Acta Anaesthesiol Belg** 1996; 47(3):111–4 (19 ref.)

Analgesic efficacy of ketorolac. Wheatley RG. **Acta Anaesthesiol Belg** 1996;47(3):135–42 (38 ref.)

Managing postoperative pain in the elderly. Pasero CL, et al. **Am J Nurs** 1996 Oct;96(10):38–45; quiz 46 (19 ref.)

Peri-operative use of nonsteroidal anti-inflammatory drugs in children: analgesic efficacy and bleeding. Rømsing J, et al. **Anaesthesia** 1997 Jul;52(7):673–83 (40 ref.)

Nausea and vomiting in the postoperative patient–controlled analgesia environment. Woodhouse A, et al. **Anaesthesia** 1997 Aug;52(8):770–5 (46 ref.)

Preliminary risk–benefit analysis of ropivacaine in labour and following surgery. Cederholm I. **Drug Saf** 1997 Jun; 16(6):391–402 (60 ref.)

Ketorolac for postoperative pain management in children. Forrest JB, et al. **Drug Saf** 1997 May;16(5):309–29 (113 ref.)

Advances in acute pain management. Barratt SM. **Int Anesthesiol Clin** 1997 Spring;35(2):27–47 (170 ref.)

Postoperative pain management in the neurosurgical patient. Cousins MJ, et al. **Int Anesthesiol Clin** 1996 Fall; 34(4):179–93 (71 ref.)

Postoperative opioid analgesia: time for a reconsideration? Kehlet H, et al. **J Clin Anesth** 1996 Sep;8(6):441–5 (54 ref.)

New concepts in postoperative pain management: is there more beyond pain control? de Leon–Casasola OA. **J Fla Med Assoc** 1996 Dec;83(10):695–700 (72 ref.)

Postoperative pain management. d'Amours RH, et al. **J Orthop Sports Phys Ther** 1996 Oct;24(4):227–36 (65 ref.)

Postoperative pain management. Tobias JD. **Pediatr Ann** 1997 Aug;26(8):490–500 (23 ref.)

Masked mischief. Bromage PR. **Reg Anesth** 1996 Nov–Dec; 21(6 Suppl):62–3 (6 ref.)

Postoperative pain management in opioid–tolerant patients. de Leon–Casasola OA. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):114–6 (22 ref.)

Organizing postoperative accelerated recovery programs. Kehlet H. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):149–51 (20 ref.)

[Treatment of pain with peridural administration of opioids (see comments)] Chrubasik S, et al. **Chirurg** 1996 Jul; 67(7):665–70 (24 ref.) (Eng. Abstr.) Comment in: Chirurg 1997 Jan;68(1):94–5. **(Ger)**

[Postoperative pain therapy in inpatient treatment] Holthausen U, et al. **Chirurg** 1996 Jul;67(7):671–80 (30 ref.) (Eng. Abstr.) **(Ger)**

[The problem of opioid tolerance and dependence during clinical use thereof] Osipova NA. **Anesteziol Reanimatol** 1996 Jul–Aug;(4):17–21 (26 ref.) (Eng. Abstr.) **(Rus)**

[The problem of acute pain in postoperative period] Malinovskii NN, et al. **Khirurgiia (Mosk)** 1996;(5):30–5 (41 ref.) (Eng. Abstr.) **(Rus)**

ETIOLOGY

Postmastectomy pain syndromes. Kwekkeboom K. **Cancer Nurs** 1996 Feb;19(1):37–43 (24 ref.)

Neuropathic pain in the perioperative period. Hayes C, et al. **Int Anesthesiol Clin** 1997 Spring;35(2):67–81 (49 ref.)

Stem loosening and thigh pain in THA: are they related to prosthesis stiffness? Mishra AK, et al. **Orthopedics** 1997 Jan;20(1):58–61; quiz 62–3 (36 ref.)

Pain relief from intra-articular morphine after knee surgery: a qualitative systematic review. Kalso E, et al. **Pain** 1997 Jun;71(2):127–34 (47 ref.)

The immune-suppressive nature of pain. Page GG, et al. **Semin Oncol Nurs** 1997 Feb;13(1):10–5 (50 ref.)

IMMUNOLOGY

The immune-suppressive nature of pain. Page GG, et al. **Semin Oncol Nurs** 1997 Feb;13(1):10–5 (50 ref.)

NURSING

Managing postoperative pain in the elderly. Pasero CL, et al. **Am J Nurs** 1996 Oct;96(10):38–45; quiz 46 (19 ref.)

Factors affecting the assessment of postoperative pain: a literature review. Allcock N. **J Adv Nurs** 1996 Dec; 24(6):1144–51 (42 ref.)

Perioperative pain management in children. Keuren KV, et al. **Nurs Clin North Am** 1997 Mar;32(1):31–44 (48 ref.)

A middle-range theory of chronotherapeutic intervention for postsurgical pain. Auvil-Novak SE. **Nurs Res** 1997 Mar–Apr;46(2):66–71 (46 ref.)

PATHOLOGY

Masked mischief. Bromage PR. **Reg Anesth** 1996 Nov–Dec; 21(6 Suppl):62–3 (6 ref.)

PREVENTION & CONTROL

Postoperative epidural opioid analgesia: what are the choices? [see comments] de Leon–Casasola OA, et al. **Anesth Analg** 1996 Oct;83(4):867–75 (69 ref.) Comment in: Anesth Analg 1997 Jun;84(6):1390–1.

Perioperative pain management. Levy BS, et al. **J Am Assoc Gynecol Laparosc** 1995 Aug;2(4):381–7 (24 ref.)

Postoperative pain management. Tobias JD. **Pediatr Ann** 1997 Aug;26(8):490–500 (23 ref.)

[Surgical treatment of inguinal hernia. Which criteria to be used for assessment?] Fingerhut A, et al. **Ann Chir** 1996; 50(9):832–7 (62 ref.) **(Fre)**

[Inguinal hernia: contribution of randomized studies over the last 10 years] Parc Y, et al. **Ann Chir** 1996;50(9):827–31 (18 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Optimizing postoperative pain management [see comments] Carpenter RL. **Am Fam Physician** 1997 Sep 1;56(3):835–44, 847–50 (23 ref.) Comment in: Am Fam Physician 1997 Sep 1;56(3):726, 731–2.

Randomization is important in studies with pain outcomes: systematic review of transcutaneous electrical nerve stimulation in acute postoperative pain. Carroll D, et al. **Br J Anaesth** 1996 Dec;77(6):798–803 (52 ref.)

Acute pain--guidelines for care. Sandler AN. **Can J Anaesth** 1997 May;44(5 Pt 2):R137–45 (28 ref.) **(Eng, Fre)**

Postoperative pain management in the frail elderly. Egbert AM. **Clin Geriatr Med** 1996 Aug;12(3):583–99 (120 ref.)

Pain relief following cardiac surgery: a review. Taylor A, et al. **Ir J Med Sci** 1996 Jan–Mar;165(1):1–9 (68 ref.)

Effects of relaxation and music on postoperative pain: a review. Good M. **J Adv Nurs** 1996 Nov;24(5):905–14 (51 ref.)

American Society of Regional Anesthesia Future Directions of Acute Pain Management. Consensus conference. Orlando, Florida, May 31–June 2, 1996. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):1–159 (0 ref.)

Effect of pain relief on the surgical stress response. Kehlet H. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):35–7 (3 ref.)

[Postoperative analgesia after surgery of the knee] Fletcher D. **Cah Anesthesiol** 1996;44(3):253–9 (74 ref.) (Eng. Abstr.) **(Fre)**

[Postoperative pain therapy. II.] Jage J, et al. **Anaesthesist** 1997 Feb;46(2):161–73 (110 ref.) **(Ger)**

[Postoperative pain therapy. I.] Jage J, et al. **Anaesthesist** 1997 Jan;46(1):65–77 (0 ref.) **(Ger)**

[Intra- and postoperative catheter epidural analgesia. Combination of epidural analgesia and general anesthesia] Seeling W, et al. **Anaesthesist** 1997 Mar;46(3):237–52 (13 ref.) **(Ger)**

[The importance of acute pain units] Stolik-Dollberg O, et al. **Harefuah** 1997 May 1;132(9):653–5 (20 ref.) **(Heb)**

VETERINARY

Management of acute and surgical pain. Hellyer PW. **Semin Vet Med Surg (Small Anim)** 1997 May;12(2):106–14 (55 ref.)

PAIN RECEPTORS see **NOCICEPTORS**

PAIN RELIEF UNITS see **PAIN CLINICS**

PAIN THRESHOLD

Mechanisms of touch-evoked pain (allodynia): a new model. Cervero F, et al. **Pain** 1996 Nov;68(1):13–23 (85 ref.)

DRUG EFFECTS

How to measure and reduce the burden of zoster-associated pain. Wood MJ. **Scand J Infect Dis Suppl** 1996;100:55–8 (18 ref.)

PHYSIOLOGY

Pain management at the end of life. Dickey NW. **J Orthop Sports Phys Ther** 1996 Oct;24(4):237–9 (11 ref.)

[Exteroceptive suppression of activity of the temporal muscle. Principles and applications] Göbel H, et al. **Nervenarzt** 1996 Oct;67(10):846–59 (102 ref.) (Eng. Abstr.) **(Ger)**

PAINT

ADVERSE EFFECTS

In search of dose-response relationships of solvent mixtures to neurobehavioural effects in paint manufacturing and painters. Seeber A, et al. **Food Chem Toxicol** 1996 Nov–Dec;34(11–12):1113–20 (22 ref.)

PAIR BOND

A neurobiological basis of social attachment. Insel TR. **Am J Psychiatry** 1997 Jun;154(6):726–35 (84 ref.)

PAIRED-ASSOCIATE LEARNING

PHYSIOLOGY

A cognitive neuroscience view of schizophrenic thought disorder. Spitzer M. **Schizophr Bull** 1997;23(1):29–50 (110 ref.)

PALATAL EXPANSION TECHNIQUE

Surgically-assisted maxillary expansion. Woods M, et al. **Aust Dent J** 1997 Feb;42(1):38–42 (25 ref.)

PALATAL NEOPLASMS

PATHOLOGY

Angiocentric T-cell lymphoma presenting as lethal midline granuloma. Lee PY, et al. **Int J Dermatol** 1997 Jun; 36(6):419–27 (37 ref.)

Pleomorphic adenoma of the palate in children: report of a case. López-Cedrún JL, et al. **Int J Oral Maxillofac Surg** 1996 Jun;25(3):206–7 (11 ref.)

Sialadenoma papilliferum of the hard palate: a case report and review of literature. Asahina I, et al. **J Oral Maxillofac Surg** 1997 Sep;55(9):1000–3 (25 ref.)

[Warthin tumor of the palate: an unusual location] Chiapasco M, et al. **Minerva Stomatol** 1996 Dec;45(12):605–10 (25 ref.) (Eng. Abstr.) **(Ita)**

PALATE

Anteriorly based palatal flap for closure of large oroantral fistula. Salins PC, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Sep;82(3):253–6 (11 ref.)

PATHOLOGY

Angiocentric T-cell lymphoma presenting as lethal midline granuloma. Lee PY, et al. **Int J Dermatol** 1997 Jun; 36(6):419–27 (37 ref.)

Palatal juvenile xanthogranuloma. A case report. Tagawa T, et al. **Int J Oral Maxillofac Surg** 1996 Dec;25(6):453–4 (10 ref.)

A hamartoma-like mass on the palate? A possible discussion regarding the components of a pigmented naevus and hyperplastic salivary gland. Harada H, et al. **J Laryngol Otol** 1997 Mar;111(3):296–9 (17 ref.)

Glial choristoma in the oral cavity: histopathologic and immunohistochemical features. Ide F, et al. **J Oral Pathol Med** 1997 Mar;26(3):147–50 (28 ref.)

Mucosal calcified nodule of the hard palate in an infant: case report and review of the literature. Afzal MN, et al. **Pediatr Pathol Lab Med** 1997 Jul–Aug;17(4):611–5 (10 ref.)

SURGERY

Surgically-assisted maxillary expansion. Woods M, et al. **Aust Dent J** 1997 Feb;42(1):38–42 (25 ref.)

PALATE, SOFT

ANATOMY & HISTOLOGY

Properties of tissues surrounding the upper airway. Schwab RJ. **Sleep** 1996 Dec;19(10 Suppl):S170–4 (25 ref.)

PHYSIOLOGY

Properties of tissues surrounding the upper airway. Schwab RJ. **Sleep** 1996 Dec;19(10 Suppl):S170–4 (25 ref.)

SURGERY

An unusual appearance of velopharyngeal closure in a post-uvulopalatopharyngoplasty patient. Yanagisawa E, et al. **Ear Nose Throat J** 1997 Jan;76(1):14–5 (5 ref.)

The surgical treatment of snoring [see comments] Harries PG, et al. **J Laryngol Otol** 1996 Dec;110(12):1103–4 (9 ref.) Comment in: J Laryngol Otol 1997 Jun;111(6):598.

Critical analysis of the results of surgery in the treatment of snoring, upper airway resistance syndrome (UARS), and obstructive sleep apnea (OSA). Pépin JL, et al. **Sleep** 1996 Nov;19(9 Suppl):S90–100 (92 ref.)

PALATINE TONSIL see **TONSIL**

PALATOPHARYNGEAL INCOMPETENCE see **VELOPHARYNGEAL INSUFFICIENCY**

PALEONTOLOGY

see related
MUMMIES

Assessing the reliability of paleodemographic fertility estimators using simulated skeletal distributions. Paine RR, et al. **Am J Phys Anthropol** 1996 Oct;101(2):151–9 (38 ref.)

The limits of palaeontological knowledge: finding the gold among the dross. Knoll AH, et al. **Ciba Found Symp** 1996; 202:198–209; discussion 210–3 (43 ref.)

[Morphology of the Neanderthal thumb. Apropos of 6 cases and a review of the literature] Oberlin C, et al. **Ann Chir Main Memb Super** 1997;16(1):58–65 (11 ref.) **(Fre)**

PALEOSTRIATUM see **GLOBUS PALLIDUS**

PALESTINIANS see **ARABS**

PALLIATIVE CARE

Palliative treatment of bone metastases. Nielsen OS. **Acta Oncol** 1996;35 Suppl 5:58–60 (16 ref.)

Palliative use of ionizing radiations. Parker RG. **Acta Oncol** 1996;35(8):981–7 (69 ref.)

Treatment of metastatic carcinoma of the prostate. Goethuys H, et al. **Am J Clin Oncol** 1997 Feb;20(1):40–5 (47 ref.)

Endoscopic Nd:YAG laser treatment of inoperable lower gastrointestinal cancer. Tai LS, et al. **Ann Acad Med Singapore** 1996 Sep;25(5):712–6 (39 ref.)

Consultation in palliative medicine. Weissman DE. **Arch Intern Med** 1997 Apr 14;157(7):733–7 (24 ref.)

Interventional radiology in palliative medicine. Morgan RA, et al. **Br J Hosp Med** 1997 Feb 5–18;57(3):69–75 (9 ref.)

The role of palliative thoracic radiotherapy in non-small cell lung cancer. Brundage MD, et al. **Can J Oncol** 1996 Feb; 6 Suppl 1:25–32 (24 ref.)

Palliative radiation therapy in the United States. Coia LR. **Can J Oncol** 1996 Feb;6 Suppl 1:62–8; discussion 84 (14 ref.)

The role of palliative radiotherapy in advanced head and neck cancer. Hodson DI, et al. **Can J Oncol** 1996 Feb;6 Suppl 1:54–60 (36 ref.)

The role of palliative radiotherapy for bone metastases. Kirkbride P, et al. **Can J Oncol** 1996 Feb;6 Suppl 1:33–8 (27 ref.)

The role of palliative radiotherapy for brain metastases. Paszat L, et al. **Can J Oncol** 1996 Feb;6 Suppl 1:48–53 (37 ref.)

The role of radiotherapy in the management of pelvic recurrence of rectal cancer. Wong R, et al. **Can J Oncol** 1996 Feb;6 Suppl 1:39–47 (18 ref.)

Palliative medicine in the elderly. Cleary JF, et al. **Cancer** 1997 Oct 1;80(7):1335–47 (56 ref.)

The dilemma of evaluating and treating cancer of unknown primary site. Markman M. **Cleve Clin J Med** 1997 Feb; 64(2):73–5 (9 ref.)

Pulmonary rehabilitation and surgery for end-stage lung disease. Kesten S. **Clin Chest Med** 1997 Jun;18(2):173–81 (55 ref.)

Psychosocial and ethical issues in surgical approaches to end-stage lung disease. Manzetti JD, et al. **Clin Chest Med** 1997 Jun;18(2):383–90 (50 ref.)

Radiotherapy for painful bone metastases: a systematic review. McQuay HJ, et al. **Clin Oncol (R Coll Radiol)** 1997; 9(3):150–4 (24 ref.)

The role of supportive care in quality of life. Warr D, et al. **Curr Opin Oncol** 1996 Jul;8(4):279–83 (24 ref.)

Advances in palliative care for the patient with scleroderma. Herrick AL. **Curr Opin Rheumatol** 1996 Nov;8(6):555–60 (27 ref.)

Surgical palliation of incurable urologic cancer. Alagiri M, et al. **Curr Probl Cancer** 1995 Nov–Dec;19(6):360–71 (55 ref.)

Surgical palliation of upper gastrointestinal cancer. Eisenberg BL. **Curr Probl Cancer** 1995 Nov–Dec;19(6):338–47 (40 ref.)

Radiotherapy for palliation of symptoms in incurable cancer. Hoegler D. **Curr Probl Cancer** 1997 May–Jun;21(3):129–83 (140 ref.)

Surgical palliation of colorectal cancer. Sigurdson ER. **Curr Probl Cancer** 1995 Nov–Dec;19(6):348–59 (58 ref.)

Endoscopic palliation for esophageal cancer. Lee JG, et al. **Dig Dis** 1997 Jan–Apr;15(1–2):100–12 (55 ref.)

The management of patients with advanced cancer (II). Heys SD, et al. **Eur J Surg Oncol** 1997 Jun;23(3):257–63 (69 ref.)

Surgical management of patients with advanced cancer (I). Smith IC, et al. **Eur J Surg Oncol** 1997 Apr;23(2):178–82 (58 ref.)

Hormonal treatment in advanced non-small cell lung cancer: fact or fiction? Vansteenkiste JF, et al. **Eur Respir J** 1996 Aug;9(8):1707–12 (48 ref.)

Palliative medicine and the medical oncologist. Defining the purview of care. Cherny NI, et al. **Hematol Oncol Clin North Am** 1996 Feb;10(1):1–20 (137 ref.)

Laparoscopic treatment of pancreatic disorders: diagnosis and staging, palliation of cancer and treatment of pancreatic pseudocysts. Targarona EM, et al. **Int Surg** 1996 Jan–Mar; 81(1):1–5 (38 ref.)

Methodologic issues in effectiveness research on palliative cancer care: a systematic review. Rinck GC, et al. **J Clin Oncol** 1997 Apr;15(4):1697–707 (59 ref.)

Radiation palliation of cervical cancer. Spanos WJ Jr, et al. **J Natl Cancer Inst Monogr** 1996;(21):127–30 (8 ref.)

A multicenter evaluation of cancer pain control by palliative care teams. Higginson IJ, et al. **J Pain Symptom Manage** 1997 Jul;14(1):29–35 (41 ref.)

Opioid therapy for chronic nonmalignant pain: a review of the critical issues. Portenoy RK. **J Pain Symptom Manage** 1996 Apr;11(4):203–17 (169 ref.)

Practical use of rectal medications in palliative care [see comments] Warren DE. **J Pain Symptom Manage** 1996 Jun; 11(6):378–87 (37 ref.) Comment in: J Pain Symptom Manage 1997 May;13(5):250. Comment in: J Pain Symptom Manage 1997 May;13(5):250–1. Comment in: J Pain Symptom Manage 1997 Jun;13(6):313–4. Comment in: J Pain Symptom Manage 1997 Jun;13(6):314–5.

Development and evaluation of a protocol to manage fecal incontinence in the patient with cancer. Beddar SA, et al. **J Palliat Care** 1997 Summer;13(2):27–38 (106 ref.)

How should we use transdermal fentanyl (TF) for pain management in palliative care patients? Fainsinger RL, et al. **J Palliat Care** 1996 Spring;12(1):48–53 (30 ref.)

Home care of the dying child. Goldman A. **J Palliat Care** 1996 Autumn;12(3):16–9 (27 ref.)

An international perspective on palliative care for children. Martinson I. **J Palliat Care** 1996 Autumn;12(3):13–5 (15 ref.)

Palliative care: a fragment towards its philosophy [editorial] Roy DJ. **J Palliat Care** 1997 Spring;13(1):3–4 (14 ref.)

A modern tragedy: needless suffering with cancer pain. de Jong RH. **J S C Med Assoc** 1996 Oct;92(10):432–6 (7 ref.)

Palliative care in undergraduate medical education. Status report and future directions [see comments] Billings JA, et al. **JAMA** 1997 Sep 3;278(9):733–8 (95 ref.) Comment in: JAMA 1997 Sep 3;278(9):761–3.

Palliative care: an update on "terminal restlessness". Burke AL. **Med J Aust** 1997 Jan 6;166(1):39–42 (37 ref.)

Palliative management of the patient with advanced pancreatic cancer. Walsh D. **Oncology (Huntingt)** 1996 Sep; 10(9 Suppl):40–4 (31 ref.)

On the dorsal columns: translating basic research hypotheses to the clinic [editorial] Berkley KJ. **Pain** 1997 Apr; 70(2–3):103–7 (35 ref.)

Chronic pain in elderly people. Gagliese L, et al. **Pain** 1997 Mar;70(1):3–14 (82 ref.)

Paracetamol with and without codeine in acute pain: a quantitative systematic review. Moore A, et al. **Pain** 1997 Apr;70(2–3):193–201 (18 ref.)

Selecting an approach and design in qualitative research. Payne S. **Palliat Med** 1997 May;11(3):249–52 (22 ref.)

Fatal rupture of an acquired aneurysm of the pulmonary artery: rare complication after surgical palliation of tricuspid atresia. Boubaker A, et al. **Pediatr Cardiol** 1997 Sep–Oct;18(5):392–5 (9 ref.)

Palliative medicine and HIV/AIDS. O'Neill JF, et al. **Prim Care** 1997 Sep;24(3):607–15 (18 ref.)

Psychological medicine, pain, and musculoskeletal disorders. Merskey H. **Rheum Dis Clin North Am** 1996 Aug; 22(3):623–37 (48 ref.)

Ivemark syndrome. A case with successful surgical intervention. Tkebuchava T, et al. **Scand Cardiovasc J** 1997; 31(3):173–5 (8 ref.)

Quality of life in advanced prostate cancer. Fosså SD. **Semin Oncol** 1996 Dec;23(6 Suppl 14):32–4 (15 ref.)

Southwest Oncology Group studies in hormone-refractory prostate cancer. Hussain MH, et al. **Semin Oncol** 1996 Dec; 23(6 Suppl 14):24–7 (13 ref.)

Overview of Canadian trials in hormonally resistant prostate cancer. Moore MJ, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 14):15–9 (7 ref.)

Palliative radiotherapy in prostate cancer. Catton CN, et al. **Semin Urol Oncol** 1997 Feb;15(1):65–72 (70 ref.)

Supportive care in the patient with hormone refractory prostate cancer. Esper PS, et al. **Semin Urol Oncol** 1997 Feb;15(1):56–64 (35 ref.)

Other chemotherapy regimens including mitoxantrone and suramin. Siu LL, et al. **Semin Urol Oncol** 1997 Feb; 15(1):20–7 (38 ref.)

When to treat dehydration in a terminally ill patient? Fainsinger RL, et al. **Support Care Cancer** 1997 May; 5(3):205–11 (54 ref.)

Dyspnea: assessment and treatment [see comments] Farncombe M. **Support Care Cancer** 1997 Mar;5(2):94–9 (18 ref.) Comment in: Support Care Cancer 1997 Mar;5(2):77–9.

Palliative treatment of malignant pericardial effusion: report of two cases and a review of the literature. Sharma A, et al. **Support Care Cancer** 1996 Jul;4(4):317–9 (17 ref.)

[Palliative care--objectives and accomplishments of the Association for the Development of Palliative Care] Kermarec J. **Bull Acad Natl Med** 1996 Nov;180(8):1951–64; discussion 1964–5 (13 ref.) (Eng. Abstr.) **(Fre)**

[Palliative and supportive care: at the frontiers of medical omnipotence] Stiefel F, et al. **Rev Med Suisse Romande** 1997 Mar;117(3):191–5 (24 ref.) (Eng. Abstr.) **(Fre)**

[Minimally invasive surgery and tumor surgery--palliative laparoscopic techniques] Saeger HD, et al. **Chirurg** 1997 Mar;68(3):225–30 (25 ref.) (Eng. Abstr.) **(Ger)**

[Progress and perspectives in palliative therapy of breast carcinoma] Verlag GT. **Dtsch Med Wochenschr** 1996 Dec 6;121(49 Suppl):1–8 (0 ref.) **(Ger)**

[Esophageal carcinoma: downstaging or stent?] Grund KE, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996; 113:755–8 (15 ref.) (Eng. Abstr.) **(Ger)**

[Palliative therapy of inoperable malignant occlusive jaundice--stent implantation or biliodigestive anastomosis] Truong S, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:762–6 (20 ref.) (Eng. Abstr.) **(Ger)**

[Patient education--support--help with decisions: ethical aspects in treatment of amyotrophic lateral sclerosis] Meran JG, et al. **Wien Med Wochenschr** 1996;146(9–10):190–4 (21 ref.) (Eng. Abstr.) **(Ger)**

[Possibilities of palliative radiotherapy] Berndt-Skorka R. **Z Arztl Fortbild Qualitatssich** 1997 Mar;91(2):145–8 (10 ref.) (Eng. Abstr.) **(Ger)**

[Exercise rehabilitation in patients with heart failure--palliation or disease modification?] Ponikowski P, et al. **Pol Arch Med Wewn** 1996 Jun;95(6):565–71 (59 ref.) **(Pol)**

[Intestinal obstruction in cancer patients. Palliative treatment] Costa I, et al. **Acta Med Port** 1997 May;10(5):381–5 (30 ref.) (Eng. Abstr.) **(Por)**

[Palliative irradiation in the treatment of breast carcinoma] Borojević N, et al. **Srp Arh Celok Lek** 1996 Sep–Oct; 124(9–10):255–9 (18 ref.) (Eng. Abstr.) **(Scc)**

METHODS

The aetiology and management of hepatic metastases. Hugh TJ, et al. **Aust N Z J Surg** 1997 Jul;67(7):400–9 (90 ref.)

The palliative therapy of advanced prostate cancer, with particular reference to the results of recent European clinical trials. Newling DW. **Br J Urol** 1997 Mar;79 Suppl 1:72–81 (63 ref.)

Medical management of intestinal obstruction in terminal care. Frank C. **Can Fam Physician** 1997 Feb;43:259–65 (29 ref.)

Organ preservation. An effective and safe form of cancer treatment. Balducci L, et al. **Clin Geriatr Med** 1997 Feb; 13(1):185–201 (38 ref.)

Symptomatic management of the older person with cancer. Sheehan DC, et al. **Clin Geriatr Med** 1997 Feb;13(1):203–19 (66 ref.)

Minimally invasive therapy for advanced oesophageal malignancy. Tan BS, et al. **Clin Radiol** 1996 Dec; 51(12):828–36 (76 ref.)

Self-expanding metal stents for palliation of stenosing tumors of the esophagus and cardia: a critical review. Ell C, et al. **Endoscopy** 1997 Jun;29(5):392–8 (40 ref.)

The ethics of death-hastening or death-causing palliative analgesic administration to the terminally ill [see comments] Cavanaugh TA. **J Pain Symptom Manage** 1996 Oct; 12(4):248–54 (18 ref.) Comment in: J Pain Symptom Manage 1997 Jul;14(1):2. Comment in: J Pain Symptom Manage 1997 Jul;14(1):2–4.

Pediatric palliative care: building the model, bridging the gaps. Frager G. **J Palliat Care** 1996 Autumn;12(3):9–12 (17 ref.)

Ethical aspects of pediatric palliative care. Levetown M. **J Palliat Care** 1996 Autumn;12(3):35–9 (47 ref.)

Pediatric palliative medicine: obstacles to overcome. Liben S. **J Palliat Care** 1996 Autumn;12(3):24–8 (39 ref.)

Attitudes and beliefs about medication and pain management in children. McGrath PJ, et al. **J Palliat Care** 1996 Autumn; 12(3):46–50 (22 ref.)

Management of malignant biliary obstruction: nonoperative and palliative techniques. Shapiro MJ. **Oncology (Huntingt)** 1995 Jun;9(6):493–6, 499; discussion 499–500, 503 (35 ref.)

Trigger points and tender points: one and the same? Does injection treatment help? Borg-Stein J, et al. **Rheum Dis Clin North Am** 1996 May;22(2):305–22 (62 ref.)

Unsealed source therapy of painful bone metastases: an update. McEwan AJ. **Semin Nucl Med** 1997 Apr; 27(2):165–82 (127 ref.)

Transhiatal esophagectomy for esophageal cancer. Pinotti HW, et al. **Semin Surg Oncol** 1997 Jul–Aug;13(4):253–8 (38 ref.)

Palliative radiotherapy. Siegel S, et al. **Vet Clin North Am Small Anim Pract** 1997 Jan;27(1):149–55 (25 ref.)

[Delirium in palliative care] Rivier E, et al. **Rev Med Suisse Romande** 1997 Mar;117(3):185–9 (24 ref.) **(Fre)**

[Small-cell sarcoma of the esophagus as a fourth malignancy. Its palliative therapy with argon gas coagulation] Glaser J, et al. **Dtsch Med Wochenschr** 1997 Aug 22; 122(34–35):1037–40 (8 ref.) (Eng. Abstr.) **(Ger)**

[Terminal care medicine--basic principles and perspectives] Knupp B, et al. **Med Klin** 1997 Feb 15;92(2):106–11 (53 ref.) **(Ger)**

[Palliative therapy of carcinomas of the biliary system] Lersch C, et al. **Med Klin** 1997 Jul 15;92(7):401–5 (52 ref.) (Eng. Abstr.) **(Ger)**

[After-care and palliative therapeutic measures in ovarian carcinoma] Kurz C, et al. **Wien Med Wochenschr** 1996; 146(1–2):34–7 (12 ref.) (Eng. Abstr.) **(Ger)**

[Non-resectable neoplasms of the biliary duct: palliative surgery vs non-surgical management] Tocchi A, et al. **G Chir** 1996 Aug–Sep;17(8–9):408–12 (43 ref.) (Eng. Abstr.) **(Ita)**

STANDARDS

Quality of life assessment and HIV infection: a review. Vanhems P, et al. **Eur J Epidemiol** 1996 Jun;12(3):221–8 (33 ref.)
Outcome measures in palliative care for advanced cancer patients: a review. Hearn J, et al. **J Public Health Med** 1997 Jun;19(2):193–9 (22 ref.)

TRENDS

New concepts in pain management and in the application of low-power laser for relief of cervicothoracic pain syndromes [editorial] Lee G, et al. **Am Heart J** 1996 Dec; 132(6):1329–34 (27 ref.)
Palliative radiotherapy in Canada. Dixon P. **Can J Oncol** 1996 Feb;6 Suppl 1:74–83; discussion 84 (7 ref.)
Palliative radiotherapy in the UK. Priestman TJ. **Can J Oncol** 1996 Feb;6 Suppl 1:69–73; discussion 84 (14 ref.)
Advances in hospice care. Leland JY, et al. **Clin Geriatr Med** 1997 May;13(2):381–401 (73 ref.)
An update on the clinical use of methadone for cancer pain. Ripamonti C, et al. **Pain** 1997 Apr;70(2–3):109–15 (70 ref.)
[Palliative medicine] Klaschik E, et al. **Anaesthesist** 1997 Mar; 46(3):177–85 (29 ref.) (Eng. Abstr.) **(Ger)**

PALLIATIVE TREATMENT see **PALLIATIVE CARE**

PALMITATES

METABOLISM

Palmitoylation: a post-translational modification that regulates signalling from G-protein coupled receptors. Morello JP, et al. **Biochem Cell Biol** 1996;74(4):449–57 (70 ref.)

PALMITIC ACID

METABOLISM

Reversible palmitoylation of signaling proteins. Mumby SM. **Curr Opin Cell Biol** 1997 Apr;9(2):148–54 (60 ref.)

PALMITOYL COA DEACYLASE see **PALMITOYL-COA HYDROLASE**

PALMITOYL-COA HYDROLASE

GENETICS

The mechanism and functional roles of protein palmitoylation in the nervous system. Bizzozero OA. **Neuropediatrics** 1997 Feb;28(1):23–6 (47 ref.)

PALMITOYL COENZYME A HYDROLASE see **PALMITOYL-COA HYDROLASE**

PALMITOYL THIOESTERASE see **PALMITOYL-COA HYDROLASE**

PALMOPLANTAR KERATODERMA see **KERATODERMA, PALMOPLANTAR**

PALMOPLANTARIS PUSTULOSIS see **PSORIASIS**

PALPATION

[Nonpalpable lesions of breast carcinoma in elderly patients] Caruso U, et al. **Minerva Chir** 1997 May;52(5):619–24 (23 ref.) (Eng. Abstr.) **(Ita)**

PALSY, PROGRESSIVE SUPRANUCLEAR see **SUPRANUCLEAR PALSY, PROGRESSIVE**

PAMPHLETS

[Comments on the revision of the Königstein instructional pamphlet (see comments)] Plath P. **HNO** 1996 Aug; 44(8):431–9 (11 ref.) (Eng. Abstr.) Comment in: HNO 1997 May;45(5):356–8; discussion 358–9. **(Ger)**

PAN see **CHIMPANSEE TROGLODYTES**

PAN AMERICAN HEALTH ORGANIZATION

Strategies of the Pan American Health Organization/World Health Organization for the control of iron deficiency in Latin America. Freire WB. **Nutr Rev** 1997 Jun;55(6):183–8 (15 ref.)

PANAX see **GINSENG**

PANCOAST'S SYNDROME

THERAPY

Pancoast (superior sulcus) tumors. Detterbeck FC. **Ann Thorac Surg** 1997 Jun;63(6):1810–8 (52 ref.)
Management of carcinoma of the superior pulmonary sulcus. Johnson DE, et al. **Oncology (Huntingt)** 1997 Jun; 11(6):781–5; discussion 785–6 (27 ref.)

PANCREAS

see related
PANCREATECTOMY
PANCREATICOJEJUNOSTOMY

Aberrant pancreas in the gallbladder wall. Kondi-Paphiti A, et al. **Eur Radiol** 1997;7(7):1064–6 (14 ref.)
Endoscopic resection of heterotopic pancreas of the minor duodenal papilla: case report and review of the literature. Lucena JF, et al. **Gastrointest Endosc** 1997 Jul;46(1):69–72 (25 ref.)
Pancreatitis caused by a gastric duplication communicating with an aberrant pancreatic lobe. Moss RL, et al. **J Pediatr Surg** 1996 May;31(5):733–6 (14 ref.)
[Treatment with octreotide of stenosing cystic dystrophy on heterotopic pancreas of the duodenal wall] de Parades V, et al. **Gastroenterol Clin Biol** 1996;20(6–7):601–4 (12 ref.) (Eng. Abstr.) **(Fre)**
[Progress in instrument used for diagnosis of obstructive jaundice. 4. MRCP] Akahane M. **Nippon Naika Gakkai Zasshi** 1997 Apr 10;86(4):602–7 (5 ref.) **(Jpn)**

ABNORMALITIES

Annular pancreas and obstructive jaundice. Benger JR, et al. **Am J Gastroenterol** 1997 Apr;92(4):713–4 (7 ref.)
Inherited causes of exocrine pancreatic dysfunction. Durie PR. **Can J Gastroenterol** 1997 Mar;11(2):145–52 (47 ref.)
Inherited and congenital disorders of the exocrine pancreas. Durie PR. **Gastroenterologist** 1996 Sep;4(3):169–87 (85 ref.)
Diagnosis of annular pancreas by endoscopic ultrasound. Gress F, et al. **Gastrointest Endosc** 1996 Oct;44(4):485–9 (27 ref.)
Combined percutaneous-endoscopic therapy for recurrent pancreatitis and pancreas divisum. Spiess SE, et al. **Gastrointest Endosc** 1997 Feb;45(2):188–91 (14 ref.)
[Duodenum preserving resection of the head of the pancrease in therapy of pancreas divisum] Widmaier U, et al. **Chirurg** 1997 Feb;68(2):180–6 (23 ref.) (Eng. Abstr.) **(Ger)**
[Annular pancreas. Report of a case and review of the literature] Jotz GP, et al. **Arq Gastroenterol** 1996 Jan–Mar; 33(1):29–31 (13 ref.) (Eng. Abstr.) **(Por)**

ANATOMY & HISTOLOGY

Overview of MnDPDP as a pancreas-specific contrast agent for MR imaging [see comments] Ahlström H, et al. **Acta Radiol** 1997 Jul;38(4 Pt 2):660–4 (18 ref.) Comment in: Acta Radiol 1997 Jul;38(4 Pt 2):623–5.
Histology of the exocrine pancreas. Motta PM, et al. **Microsc Res Tech** 1997 Jun 1–15;37(5–6):384–98 (50 ref.)
Lymphatic system of the pancreas. O'Morchoe CC. **Microsc Res Tech** 1997 Jun 1–15;37(5–6):456–77 (95 ref.)
[The structure and histotopography of the gastroenteropancreatic endocrine system in teleost fish] Shirkina NI. **Morfologiia** 1995;108(3):78–83 (66 ref.) **(Rus)**

BLOOD SUPPLY

Microcirculation in pancreatic function. Wayland H. **Microsc Res Tech** 1997 Jun 1–15;37(5–6):418–33 (30 ref.)
[Quantitative measurement of the blood flow in the pancreas] Taniguchi H, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:206–9 (14 ref.) **(Jpn)**

CYTOLOGY

Pancreatic development and maturation of the islet B cell. Studies of pluripotent islet cultures. Madsen OD, et al. **Eur J Biochem** 1996 Dec 15;242(3):435–45 (125 ref.)

DRUG EFFECTS

Ethanol induced acinar cell injury. Apte MV, et al. **Alcohol Alcohol Suppl** 1994;2:365–8 (39 ref.)

EMBRYOLOGY

Molecular insights into the development of the pancreas. Debas HT. **Am J Surg** 1997 Sep;174(3):227–31 (10 ref.)
The non-human primate endocrine pancreas: development, regeneration potential and metaplasia. Wolfe-Coote S, et al. **Cell Biol Int** 1996 Feb;20(2):95–101 (28 ref.)
The beta cell transcription factors and development of the pancreas. Sander M, et al. **J Mol Med** 1997 May; 75(5):327–40 (129 ref.)
Development of pancreas. Böck P, et al. **Microsc Res Tech** 1997 Jun 1–15;37(5–6):374–83 (50 ref.)

ENZYMOLOGY

Structure and function of pancreatic lipase and colipase. Lowe ME. **Annu Rev Nutr** 1997;17:141–58 (74 ref.)
Pancreatic procarboxypeptidases: oligomeric structures and activation processes revisited. Ventura S, et al. **Biol Chem** 1997 Mar-Apr;378(3–4):161–5 (31 ref.)
Stimulus-secretion coupling of pancreatic digestive enzyme secretion. Williams JA, et al. **Digestion** 1997;58 Suppl 1:42–5 (16 ref.)
Intracellular transport of pancreatic enzymes. Cook LJ, et al. **Scand J Gastroenterol Suppl** 1996;219:1–5 (16 ref.)

INJURIES

Ethanol induced acinar cell injury. Apte MV, et al. **Alcohol Alcohol Suppl** 1994;2:365–8 (39 ref.)
Pancreatic emergencies. Siegel MJ, et al. **Radiol Clin North Am** 1997 Jul;35(4):815–30, 814 (51 ref.)

METABOLISM

Chloride channels and cystic fibrosis of the pancreas. Gray MA, et al. **Biosci Rep** 1995 Dec;15(6):531–41 (41 ref.)
Acute phase reaction of the exocrine pancreas. Dagorn JC. **Digestion** 1997;58 Suppl 1:50–2 (4 ref.)
Analysis of calcium oscillations in pancreatic acinar cells. Elliott AC, et al. **Digestion** 1997;58 Suppl 2:69–74 (15 ref.)
Phosphorylation and desensitization of the pancreatic cholecystokinin-A receptor. Willems PH, et al. **Digestion** 1997;58 Suppl 2:75–80 (33 ref.)

PATHOLOGY

Ancillary studies in FNA of liver and pancreas. Silverman JF, et al. **Diagn Cytopathol** 1995 Dec;13(5):396–410 (151 ref.)
Magnetic resonance cholangiopancreatography. Mehta SN, et al. **Gastrointest Endosc Clin N Am** 1997 Apr;7(2):247–70 (66 ref.)
Magnetic resonance cholangiopancreatography. Bearcroft PW, et al. **Gut** 1997 Aug;41(2):135–7 (27 ref.)
Operative vs non-operative management in sterile necrotizing pancreatitis. Bradley EL 3rd. **HPB Surg** 1997; 10(3):188–91 (8 ref.)
Redifferentiation and apoptosis of pancreatic cells during acute pancreatitis. Iovanna JL. **Int J Pancreatol** 1996 Oct; 20(2):77–84 (88 ref.)
Adenosquamous carcinoma of the pancreas. Makiyama K, et al. **J Gastroenterol** 1995 Dec;30(6):798–802 (18 ref.)
Morphology of the exocrine pancreas related to pancreatitis. Bockman DE. **Microsc Res Tech** 1997 Jun 1–15; 37(5–6):509–19 (40 ref.)
Models of exocrine pancreatic pathologies: a microscopical point of view. Grondin G, et al. **Microsc Res Tech** 1997 Feb 15;36(4):324–36 (20 ref.)
What to do about sterile pancreatic necrosis? Warshaw AL. **Pancreas** 1996 Oct;13(3):223–5 (13 ref.)
Fine-needle aspiration of the pancreas. Hughes JH, et al. **Pathology (Phila)** 1996;4(2):389–407 (66 ref.)
The pancreas and peripancreatic area. Ranchod M, et al. **Pathology (Phila)** 1996;3(2):379–87 (20 ref.)
Fine-needle aspiration of the liver and pancreas: a cytology primer for radiologists. Dodd LG, et al. **Radiology** 1997 Apr;203(1):1–9 (58 ref.)
MR imaging techniques for evaluation of the pancreas. Outwater EK, et al. **Top Magn Reson Imaging** 1996 Oct; 8(5):248–64 (98 ref.)
MR imaging of pancreatic disorders. Outwater EK, et al. **Top Magn Reson Imaging** 1996 Oct;8(5):265–89 (115 ref.)
[Evaluation of the biliary system and pancreatic duct using MR cholangiopancreatography] Hanaoka H, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:187–9 (8 ref.) **(Jpn)**
[Current approach to pancreatic necrosis] Chebli JM, et al. **Arq Gastroenterol** 1995 Oct-Dec;32(4):178–85 (56 ref.) (Eng. Abstr.) **(Por)**

PHYSIOLOGY

Gap junction involvement in secretion: the pancreas experience. Meda P. **Clin Exp Pharmacol Physiol** 1996 Dec; 23(12):1053–7 (42 ref.)
Microcirculation in pancreatic function. Wayland H. **Microsc Res Tech** 1997 Jun 1–15;37(5–6):418–33 (30 ref.)
Effect of aging on the gastrointestinal tract and the pancreas. Majumdar AP, et al. **Proc Soc Exp Biol Med** 1997 Jun; 215(2):134–44 (138 ref.)

PHYSIOPATHOLOGY

Exocrine pancreatic function in cystic fibrosis. Guy-Crotte O, et al. **Eur J Gastroenterol Hepatol** 1996 Aug;8(8):755–9 (35 ref.)

RADIOGRAPHY

Diagnostic features on images in primary small cell carcinoma of the pancreas. Namieno T, et al. **Am J Gastroenterol** 1997 Feb;92(2):319–22 (22 ref.)

RADIONUCLIDE IMAGING

[Quantitative measurement of the blood flow in the pancreas] Taniguchi H, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:206–9 (14 ref.) **(Jpn)**

SECRETION

Physiological mechanisms of cholecystokinin action on pancreatic secretion. Owyang C. **Am J Physiol** 1996 Jul; 271(1 Pt 1):G1–7 (71 ref.)
The control of fluid-secreting epithelia by VIP. Martin SC, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:133–47; discussion 147–8 (64 ref.)
Gap junction involvement in secretion: the pancreas experience. Meda P. **Clin Exp Pharmacol Physiol** 1996 Dec; 23(12):1053–7 (42 ref.)
Regulation of human pancreatic secretion. Adler G. **Digestion** 1997;58 Suppl 1:39–41 (26 ref.)
The physiological role of histamine in the exocrine pancreas.

Singh J, et al. **Inflamm Res** 1997 May;46(5):159–65 (95 ref.)
[Pancreatic resection and secretory function of it's remaining part] Agaev BA, et al. **Khirurgiia (Mosk)** 1997;(5):68–71 (58 ref.) **(Rus)**

SURGERY

Simple technique for pancreatogastrostomy and the histological findings of pancreatogastric anastomosis. Yamamoto J, et al. **Arch Surg** 1997 Jul;132(7):785–8 (08 ref.)
Combined percutaneous-endoscopic therapy for recurrent pancreatitis and pancreas divisum. Spiess SE, et al. **Gastrointest Endosc** 1997 Feb;45(2):188–91 (14 ref.)
Jejunum or stomach for the pancreatic anastomosis after pancreaticoduodenectomy. Warshaw AL. **HPB Surg** 1997; 10(3):191–3 (4 ref.)
The pancreas and peripancreatic area. Ranchod M, et al. **Pathology (Phila)** 1996;3(2):379–87 (20 ref.)
[Complications of two types of pancreatic anastomosis after pancreaticoduodenectomy] Andivot T, et al. **Ann Chir** 1996;50(6):431–7 (37 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Diagnostic features on images in primary small cell carcinoma of the pancreas. Namieno T, et al. **Am J Gastroenterol** 1997 Feb;92(2):319–22 (22 ref.)

PANCREAS, ARTIFICIAL ENDOCRINE see **INSULIN INFUSION SYSTEMS**

PANCREAS, ENDOCRINE see **ISLETS OF LANGERHANS**

PANCREAS TRANSPLANTATION

Cyclosporine-associated thrombotic microangiopathy/hemolytic uremic syndrome following kidney and kidney-pancreas transplantation [see comments] Young BA, et al. **Am J Kidney Dis** 1996 Oct;28(4):561–71 (62 ref.) Comment in: Am J Kidney Dis 1997 May;29(5):813–4.
Successful pregnancy after combined renal-pancreas transplantation: a case report and literature review. Skannal DG, et al. **Am J Perinatol** 1996 Aug;13(6):383–7 (21 ref.)
Update on the status of pancreas-kidney transplantation. Pelletier RP, et al. **Curr Opin Nephrol Hypertens** 1996 Nov; 5(6):504–7 (30 ref.)
Pancreas transplantation as a treatment for diabetes: indications and outcome. Sutherland DE. **Curr Ther Endocrinol Metab** 1997;6:496–9 (31 ref.)
Perspectives in pancreatic and islet cell transplantation for the therapy of IDDM. Calafiore R. **Diabetes Care** 1997 May;20(5):889–96 (62 ref.)
Impact of pancreas transplantation on diabetic secondary complications and quality of life. Landgraf R. **Diabetologia** 1996 Dec;39(12):1415–24 (112 ref.)
Pancreas and islet transplantation: current progresses, problems and perspectives. Secchi A, et al. **Horm Metab Res** 1997 Jan;29(1):1–8 (45 ref.)
Small bowel and pancreas transplantation. Pollard S. **Transplant Proc** 1997 Sep;29(6):2721–2 (0 ref.)
[Islet cell and pancreas transplantation in diabetes: status 1996] Bretzel RG. **Ther Umsch** 1996 Dec;53(12):889–901 (51 ref.) (Eng. Abstr.) **(Ger)**
[Infections in kidney and pancreas transplantation] Casanova D, et al. **Enferm Infecc Microbiol Clin** 1997 May;15 Suppl 2:104–11 (44 ref.) **(Spa)**

ADVERSE EFFECTS

Urological complications of pancreatic transplantation. Hickey DP, et al. **J Urol** 1997 Jun;157(6):2042–8 (81 ref.)

METHODS

[Pancreas transplantation--between experiment and clinical method] Klempnauer J, et al. **Internist (Berl)** 1996 Mar; 37(3):289–94 (23 ref.) **(Ger)**

TRENDS

Organ transplantation in Taiwan. Lee CJ. **Artif Organs** 1996 Dec;20(12):1270–3 (10 ref.)
[The future of kidney and pancreas transplantation] **Prog Urol** 1996 Oct;6(5):831–41 (64 ref.) **(Fre)**

PANCREATECTOMY

see related
PANCREATICOJEJUNOSTOMY

Anaesthetic management of a neonate with nesidioblastosis. Bellwoar C, et al. **Paediatr Anaesth** 1996;6(1):61–3 (12 ref.)
[Adjuvant therapies in combination with pancreatectomy for carcinoma of the pancreas] Ishikawa O, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1635–41 (34 ref.) (Eng. Abstr.) **(Jpn)**
[Pancreatic resection and secretory function of it's remaining part] Agaev BA, et al. **Khirurgiia (Mosk)** 1997;(5):68–71 (58 ref.) **(Rus)**

METHODS

Organ-preserving surgery in pancreatic diseases. Uhl W, et al. **Digestion** 1997;58 Suppl 1:107–13 (55 ref.)
Appleby operation for carcinoma of the body and tail of the pancreas. Kimura W, et al. **Hepatogastroenterology** 1997 Mar-Apr;44(14):387–93 (20 ref.)
[Duodenum preserving resection of the head of the pancrease in therapy of pancreas divisum] Widmaier U, et al. **Chirurg** 1997 Feb;68(2):180–6 (23 ref.) (Eng. Abstr.) **(Ger)**

MORTALITY

[Surgical treatment of pancreatic cancer and its prognosis-long-term therapeutic results after resection] Ohashi O, et al. **Gan To Kagaku Ryoho** 1996 Oct; 23(12):1629–34 (11 ref.) (Eng. Abstr.) **(Jpn)**

PANCREATIC ALPHA CELLS see **ISLETS OF LANGERHANS**

PANCREATIC BETA CELLS see **ISLETS OF LANGERHANS**

PANCREATIC CHOLERA see **VIPOMA**

PANCREATIC CYST

DIAGNOSIS

Duodenum-preserving resection of the head of the pancreas: the significance as a diagnostic therapy of the lesion in the pancreatic head. Watanabe Y, et al. **HPB Surg** 1996; 9(2):107–11 (7 ref.)
[Pancreatic cystic lesions of difficult diagnosis] Hammel P, et al. **Presse Med** 1996 Nov 23;25(36):1794–800 (27 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Cystic endometriosis of the upper abdominal organs. Report on three cases and review of the literature. Verbeke C, et al. **Pathol Res Pract** 1996 Mar;192(3):300–4; discussion 305 (28 ref.)

RADIOGRAPHY

[Mucinous ductal ectasia of the pancreas] Angella S, et al. **J Chir (Paris)** 1996 Nov;133(7):337–41 (12 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Management of pancreatic lesions in von Hippel-Lindau disease. Cheng TY, et al. **World J Surg** 1997 Mar-Apr; 21(3):307–12 (24 ref.)
[Cyst, pseudocyst or carcinoma? Space-occupying lesions of the pancreas in childhood and adolescence] Hümmer HP, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996; 113:1034–9 (10 ref.) (Eng. Abstr.) **(Ger)**

PANCREATIC CYSTIC FIBROSIS see **CYSTIC FIBROSIS**

PANCREATIC DELTA CELLS see **ISLETS OF LANGERHANS**

PANCREATIC DISEASES

see related
HYPERINSULINISM

[Pancreatic diseases] Kozu T, et al. **Nippon Naika Gakkai Zasshi** 1996 Jul 10;85(7):1110–3 (5 ref.) **(Jpn)**

COMPLICATIONS

Hepatobiliary tract and pancreatic disorders in celiac disease. Freeman HJ. **Can J Gastroenterol** 1997 Jan-Feb;11(1):77–81 (79 ref.)
Rheumatic features of gastrointestinal tract, hepatic, and pancreatic diseases. Ramos-Remus C, et al. **Curr Opin Rheumatol** 1997 Jan;9(1):56–61 (68 ref.)
Overview and consensus statement on diabetes in tropical areas. Tripathy BB, et al. **Diabetes Metab Rev** 1997 Mar; 13(1):63–76 (76 ref.)
The pancreas in AIDS. Cappell MS. **Gastroenterol Clin North Am** 1997 Jun;26(2):337–65 (267 ref.)
[Pancreatic diseases and jaundice] Kimura K, et al. **Nippon Naika Gakkai Zasshi** 1997 Apr 10;86(4):629–33 (5 ref.) **(Jpn)**
[Impaired glucose tolerance in liver and pancreas disease] Nagasaka Y, et al. **Nippon Rinsho** 1996 Oct;54(10):2720–4 (21 ref.) (Eng. Abstr.) **(Jpn)**

CONGENITAL

Inherited and congenital disorders of the exocrine pancreas. Durie PR. **Gastroenterologist** 1996 Sep;4(3):169–87 (85 ref.)

DIAGNOSIS

Novel approaches to the diagnosis of pancreatic disease in childhood. Couper RT. **Can J Gastroenterol** 1997 Mar; 11(2):153–6 (38 ref.)
Diagnosis of annular pancreas by endoscopic ultrasound. Gress F, et al. **Gastrointest Endosc** 1996 Oct;44(4):485–9 (27 ref.)
Glucagonoma associated with calculous pancreatitis. Mao C, et al. **HPB Surg** 1996;9(2):77–81 (24 ref.)
Laparoscopic treatment of pancreatic disorders: diagnosis and staging, palliation of cancer and treatment of pancreatic pseudocysts. Targarona EM, et al. **Int Surg** 1996 Jan-Mar; 81(1):1–5 (38 ref.)
Fine-needle aspiration of the pancreas. Hughes JH, et al. **Pathology (Phila)** 1996;4(2):389–407 (66 ref.)
MR imaging techniques for evaluation of the pancreas. Outwater EK, et al. **Top Magn Reson Imaging** 1996 Oct; 8(5):248–64 (98 ref.)
MR pancreatography: technique and applications. Takehara Y. **Top Magn Reson Imaging** 1996 Oct;8(5):290–301 (54 ref.)
[Review of the 1996 literature: roentgen diagnosis of the pancreas] Brambs HJ, et al. **Rontgenpraxis** 1997 Jul; 50(7):189–98 (43 ref.) **(Ger)**
[The role of endoscopy in the diagnosis and treatment of pancreatic diseases] Martins Júnior EV, et al. **Rev Assoc Med Bras** 1996 Oct-Dec;42(4):245–52 (93 ref.) **(Por)**

DRUG THERAPY

Somatostatin and its analogues in G.I. tract, liver and pancreatic disorders. Dhar A, et al. **Trop Gastroenterol** 1995 Jul-Sep;16(3):3–7 (22 ref.)

GENETICS

Inherited causes of exocrine pancreatic dysfunction. Durie PR. **Can J Gastroenterol** 1997 Mar;11(2):145–52 (47 ref.)
Inherited and congenital disorders of the exocrine pancreas. Durie PR. **Gastroenterologist** 1996 Sep;4(3):169–87 (85 ref.)

IMMUNOLOGY

Hyperexpression of GAD in the islets may be relevant but is it sufficient to induce autoimmune insulitis? [comment] Pozzilli P, et al. **Diabetologia** 1997 Mar;40(3):357–61 (28 ref.) Comment on: Diabetologia 1997 Mar;40(3):352–6.

METABOLISM

Pancreatic steatorrhea, malabsorption, and nutrition biochemistry: a comparison of Japanese, European, and American patients with chronic pancreatitis. Nakamura T, et al. **Pancreas** 1997 May;14(4):323–33 (127 ref.)
Pancreatic B-cell dysfunction and glucose toxicity in non-insulin-dependent diabetes. Flatt PR, et al. **Proc Nutr Soc** 1997 Mar;56(1B):243–62 (75 ref.)

MICROBIOLOGY

Pancreatic infections. Stephan RN, et al. **Gastroenterologist** 1996 Sep;4(3):163–8 (39 ref.)

PATHOLOGY

Ancillary studies in FNA of liver and pancreas. Silverman JF, et al. **Diagn Cytopathol** 1995 Dec;13(5):396–410 (151 ref.)

PHYSIOPATHOLOGY

Inherited causes of exocrine pancreatic dysfunction. Durie PR. **Can J Gastroenterol** 1997 Mar;11(2):145–52 (47 ref.)

PREVENTION & CONTROL

The management of internal pancreatic fistula--a collective review. Levy RD, et al. **S Afr J Surg** 1996 Nov;34(4):175–7 (41 ref.)

RADIOGRAPHY

Total fat replacement of the pancreas: case report and review of the literature. Rosseel F, et al. **J Belge Radiol** 1996 Nov; 79(5):199–200 (14 ref.)

SURGERY

Organ-preserving surgery in pancreatic diseases. Uhl W, et al. **Digestion** 1997;58 Suppl 1:107–13 (55 ref.)
Sphincterotomy techniques and risks. Shields SJ, et al. **Gastrointest Endosc Clin N Am** 1996 Jan;6(1):17–42 (80 ref.)
Anaesthetic management of a neonate with nesidioblastosis. Bellwoar C, et al. **Paediatr Anaesth** 1996;6(1):61–3 (12 ref.)
Management of pancreatic lesions in von Hippel-Lindau disease. Cheng TY, et al. **World J Surg** 1997 Mar-Apr; 21(3):307–12 (24 ref.)
[The role of endoscopy in the diagnosis and treatment of pancreatic diseases] Martins Júnior EV, et al. **Rev Assoc Med Bras** 1996 Oct-Dec;42(4):245–52 (93 ref.) **(Por)**

THERAPY

Interventional and surgical treatment of pancreatic abscess. Mithöfer K, et al. **World J Surg** 1997 Feb;21(2):162–8 (62 ref.)
[Endoscopic management of pancreatic diseases] Holstege A, et al. **Internist (Berl)** 1996 Aug;37(8):800–16 (137 ref.) **(Ger)**

ULTRASONOGRAPHY

Evaluation of pancreatic disease by endoscopic ultrasonography. Tenner SM, et al. **Am J Gastroenterol** 1997 Jan;92(1):18–26 (64 ref.)
Endoscopic ultrasonography in upper gastrointestinal and

pancreatic disease. Rösch T. **Digestion** 1997;58 Suppl 1:76–8 (0 ref.)
The role of endoscopic ultrasound in pancreatic disorders. Brugge WR. **Int J Pancreatol** 1996 Aug;20(1):1–10 (52 ref.)

VETERINARY

Immunization with viral antigens: infectious pancreatic necrosis. Christie KE. **Dev Biol Stand** 1997;90:191–9 (54 ref.)

PANCREATIC DUCTS

ABNORMALITIES

Left-sided gallbladder with anomalies of the intrahepatic portal vein and anomalous junction of the pancreaticobiliary ductal system: a case report. Ogawa T, et al. **Hepatogastroenterology** 1995 Sep–Oct;42(5):645–9 (13 ref.)
Endoscopic stenting of minor papilla for symptomatic pancreas divisum. Bhasin DK, et al.
Indian J Gastroenterol 1997 Jan;16(1):30–1 (7 ref.)
Double cancers of the gallbladder and bile duct associated with anomalous choledochopancreatic duct junction. Nakao A, et al. **J Gastroenterol** 1997 Feb;32(1):110–3 (12 ref.)
[Carcinoma of the gallbladder in anomalous pancreaticoliliary ductal junction] Chijiiwa K, et al.
Nippon Geka Gakkai Zasshi 1996 Aug;97(8):599–605 (25 ref.) (Eng. Abstr.) **(Jpn)**
[Symptoms, diagnosis and treatment of pancreaticobiliary maljunction associated with congenital cystic dilatation of bile duct] Funabiki T, et al.
Nippon Geka Gakkai Zasshi 1996 Aug;97(8):582–8 (18 ref.) (Eng. Abstr.) **(Jpn)**
[Congenital dilatation and stricture of the bile duct as a cause of primary intrahepatic calculi] Matsumoto Y, et al.
Nippon Geka Gakkai Zasshi 1996 Aug;97(8):611–7 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Pancreatico-biliary maljunction and congenital dilatation of bile duct] Okada A. **Nippon Geka Gakkai Zasshi** 1996 Aug; 97(8):589–93 (18 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD SUPPLY

Morphology of the pancreatic duct system in mammals. Egerbacher M, et al. **Microsc Res Tech** 1997 Jun 1–15; 37(5–6):407–17 (52 ref.)

DRUG EFFECTS

Clinical perspectives of a sonographic secretin test. Glaser J. **Z Gastroenterol** 1997 Jul;35(7):579–83 (23 ref.)

PATHOLOGY

Endoscopic biliopancreatic balloon dilation. Tytgat GN, et al. **Endoscopy** 1996 May;28(4):367–71 (25 ref.)
MR pancreatography: technique and applications. Takehara Y. **Top Magn Reson Imaging** 1996 Oct;8(5):290–301 (54 ref.)

RADIOGRAPHY

A case of intraductal papillary tumor of pancreas associated with mucinous ductal ectasia. Baek IS, et al.
Korean J Intern Med 1997 Jan;12(1):100–4 (11 ref.)

SURGERY

Endoscopic resection of heterotopic pancreas of the minor duodenal papilla: case report and review of the literature. Lucena JF, et al. **Gastrointest Endosc** 1997 Jul;46(1):69–72 (25 ref.)

ULTRASONOGRAPHY

[Evaluation of pancreatic function with intraductal ultrasonography (IDUS)] Fujimoto M, et al.
Nippon Rinsho 1997 Apr;55 Suppl 2:210–3 (9 ref.) **(Jpn)**

ULTRASTRUCTURE

Morphology of the pancreatic duct system in mammals. Egerbacher M, et al. **Microsc Res Tech** 1997 Jun 1–15; 37(5–6):407–17 (52 ref.)

PANCREATIC ELASTASE see **PANCREATOPEPTIDASE**

PANCREATIC FISTULA

Pancreatic fistulas: etiology, consequences, and treatment. Kozarek RA, et al. **Gastroenterologist** 1996 Dec;4(4):238–44 (25 ref.)

DRUG THERAPY

Is octreotide a new hope for enterocutaneous and external pancreatic fistulas closure? Martineau P, et al.
Am J Surg 1996 Oct;172(4):386–95 (76 ref.)
Somatostatin analogues and pancreatic fistulas. Bassi C, et al. **Digestion** 1996;57 Suppl 1:94–6 (9 ref.)

PREVENTION & CONTROL

The management of internal pancreatic fistula—a collective review. Levy RD, et al. **S Afr J Surg** 1996 Nov;34(4):175–7 (41 ref.)

SURGERY

[Conservative treatment of postoperative pancreatic fistula. Role of interventional radiology] Aldrighetti L, et al.
Minerva Chir 1996 Oct;51(10):839–48 (30 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Surgical management and treatment of pancreatic fistulas. Ridgeway MG, et al. **Surg Clin North Am** 1996 Oct; 76(5):1159–73 (42 ref.)

PANCREATIC FUNCTION TESTS

METHODS

[Evaluation of pancreatic function with intraductal ultrasonography (IDUS)] Fujimoto M, et al.
Nippon Rinsho 1997 Apr;55 Suppl 2:210–3 (9 ref.) **(Jpn)**
[Tolbutamide, glucagon, leucine and arginine tolerance test] Hosaka T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:423–7 (10 ref.) **(Jpn)**
[Secretin test (S-test)] Oyama H, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:197–201 (4 ref.) **(Jpn)**
[PFD test (bentiromide test, BT-PABA test)] Oyama H, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:202–5 (6 ref.) **(Jpn)**
[Somatostatin stimulation test] Sakai Y, et al.
Nippon Rinsho 1997 Apr;55 Suppl 2:428–31 (6 ref.) **(Jpn)**

PANCREATIC HORMONES

BIOSYNTHESIS

Regulation of islet hormone gene expression by incretin hormones. Fehmann HC, et al.
Exp Clin Endocrinol Diabetes 1995;103 Suppl 2:56–65 (60 ref.)

METABOLISM

Gastroenteropancreatic tumours and prohormones. Rehfeld JF, et al. **Scand J Gastroenterol Suppl** 1996;216:39–45 (52 ref.)

PHYSIOLOGY

Regulation of net hepatic glucose uptake: interaction of neural and pancreatic mechanisms. Moore MC, et al.
Reprod Nutr Dev 1996;36(4):399–406 (30 ref.)
[Cardiovascular complications of pancreatis diseases] Gyöngyösi M, et al. **Orv Hetil** 1997 Jul 27;138(30):1897–901 (57 ref.) (Eng. Abstr.) **(Hun)**

PANCREATIC ISLETS TRANSPLANTATION see **ISLETS OF LANGERHANS TRANSPLANTATION**

PANCREATIC JUICE

see related
CHYMOTRYPSIN
TRYPSIN

SECRETION

The physiological role of histamine in the exocrine pancreas. Singh J, et al. **Inflamm Res** 1997 May;46(5):159–65 (95 ref.)

PANCREATIC NECROSIS VIRUS, INFECTIOUS see **INFECTIOUS PANCREATIC NECROSIS VIRUS**

PANCREATIC NEOPLASMS

High fat diet, lipid peroxidation, and pancreatic carcinogenesis. Zhang J, et al. **Adv Exp Med Biol** 1996; 399:165–72 (53 ref.)
Pancreatic adenocarcinoma in the pregnant patient: case report and review of the literature. Blackbourne LH, et al. **Cancer** 1997 May 1;79(9):1776–9 (21 ref.)
Recent advances in diagnosis and therapy of neuroendocrine tumors of the gastrointestinal tract. Pelley RJ, et al.
Curr Opin Oncol 1997 Jan;9(1):68–74 (74 ref.)
Pancreatic adenocarcinoma. Howard TJ.
Curr Probl Cancer 1996 Sep–Oct;20(5):281–328 (193 ref.)
Endoscopy in the management of malignant obstructive jaundice. Kozarek RA. **Gastrointest Endosc Clin N Am** 1996 Jan;6(1):153–76 (65 ref.)
Adenosquamous carcinoma of the pancreas. Makiyama K, et al. **J Gastroenterol** 1995 Dec;30(6):798–802 (18 ref.)
Pancreatic carcinoma. Rosewicz S, et al. **Lancet** 1997 Feb 15;349(9050):485–9 (86 ref.)
Incidental detection of cystic neoplasms of the pancreas. Gorin AD, et al. **Md Med J** 1997 Feb;46(2):79–82 (15 ref.)
Gastrointestinal endocrine tumors. Krejs GJ.
Scand J Gastroenterol Suppl 1996;220:121–3 (20 ref.)
[Cystadenocarcinoma of the pancreas. Case report and review of the literature] Cavalli S, et al. **G Chir** 1997 Apr; 18(4):193–200 (84 ref.) (Eng. Abstr.) **(Ita)**
[Apudomas: nosographic and physiopathological aspects] Bruzzese A, et al. **Minerva Chir** 1996 May;51(5):313–20 (19 ref.) (Eng. Abstr.) **(Ita)**
[Treatment of liver metastasis of endocrine tumors of the pancreas] Orozco Zepeda H. **Rev Gastroenterol Mex** 1997 Jan–Mar;62(1):50–6 (28 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

The use of chromogranin, synaptophysin and islet amyloid polypeptide as markers for neuroendocrine tumours. Stridsberg M. **Ups J Med Sci** 1995;100(3):169–99 (186 ref.)

CLASSIFICATION

The case for parallel classification of biliary tract and pancreatic neoplasms. Longnecker DS, et al.
Mod Pathol 1996 Aug;9(8):828–37 (64 ref.)
[Stage classification for pancreatic cancer: its difference between Japan and UICC] Kobari M, et al.
Nippon Shokakibyo Gakkai Zasshi 1997 Jan;94(1):1–7 (6 ref.) **(Jpn)**

COMPLICATIONS

Emphysematous cholecystitis after endoscopic wallstent placement complicated by distal migration of the stent. Takasaki M, et al. **Endoscopy** 1995 Nov;27(9):704–6 (10 ref.)
Common bile duct obstruction caused by multiple myeloma of the pancreas. Abu-Hammour AM, et al.
Gastrointest Endosc 1996 Nov;44(5):606–8 (18 ref.)
Pancreatic cancer and hypercalcemia associated with von Recklinghausen's disease. Yamamoto M, et al.
J Gastroenterol 1996 Oct;31(5):728–31 (28 ref.)
Supportive nutritional management of the patient with pancreatic cancer. Ottery F. **Oncology (Huntingt)** 1996 Sep; 10(9 Suppl):26–32 (38 ref.)
[Surgery in malignant obstructive jaundice: laparoscopic surgery—the future?] Schlumpf R, et al.
Schweiz Med Wochenschr 1997 May 10;127(19):834–8 (21 ref.) (Eng. Abstr.) **(Ger)**
[Cardiovascular complications of pancreatis diseases] Gyöngyösi M, et al. **Orv Hetil** 1997 Jul 27;138(30):1897–901 (57 ref.) (Eng. Abstr.) **(Hun)**
[A case of ulcerative colitis with minute gastric cancer and intraductal papillary adenoma of the pancreas] Yamamoto T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Aug; 94(8):532–7 (12 ref.) **(Jpn)**
[Facial erythema and pancreatic glucagonoma] Erce C, et al. **Rev Esp Enferm Dig** 1997 Feb;89(2):137–8 (14 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Ki-ras mutations and the carcinoembryonic antigen level in fine needle aspirates of the pancreas. Pinto MM, et al.
Acta Cytol 1997 Mar–Apr;41(2):427–34 (26 ref.)
AIDS-related non-Hodgkin's lymphoma of the pancreas. Jones WF, et al. **Am J Gastroenterol** 1997 Feb;92(2):335–8 (29 ref.)
Diagnostic features on images in primary small cell carcinoma of the pancreas. Namieno T, et al.
Am J Gastroenterol 1997 Feb;92(2):319–22 (22 ref.)
Gastrointestinal endocrine tumours. Glucagonomas. Frankton S, et al. **Baillieres Clin Gastroenterol** 1996 Dec; 10(4):697–705 (19 ref.)
Gastrointestinal endocrine tumours. Insulinoma. Grant CS. **Baillieres Clin Gastroenterol** 1996 Dec;10(4):645–71 (75 ref.)
Gastrointestinal endocrine tumours. Gastrinoma. Jensen RT. **Baillieres Clin Gastroenterol** 1996 Dec;10(4):603–43 (220 ref.)
Vasoactive intestinal polypeptide-secreting tumours: biology and therapy. Park SK, et al.
Baillieres Clin Gastroenterol 1996 Dec;10(4):673–96 (130 ref.)
Diagnostic workup of patients with suspected pancreatic carcinoma: the University of California-Los Angeles approach. Gloor B, et al. **Cancer** 1997 May 1;79(9):1780–6 (32 ref.)
A comparison of imaging techniques for the localisation of gastro-enteropancreatic neuroendocrine tumours. Chayvialle JA. **Digestion** 1996;57 Suppl 1:54–6 (12 ref.)
The ultimate biochemical diagnosis of neuroendocrine gastro-enteropancreatic tumours. Faiss S, et al.
Digestion 1996;57 Suppl 1:48–9 (12 ref.)
The ultimate biochemical diagnosis of gastro-enteropancreatic tumours. Oberg K. **Digestion** 1996; 57 Suppl 1:45–7 (5 ref.)
Standards and perspectives in the diagnosis and treatment of pancreatic adenocarcinoma. Sulkowski U. **Digestion** 1996;57 Suppl 1:34–5 (9 ref.)
MRI of pancreatic tumors. Kelekis NL, et al. **Eur Radiol** 1997;7(6):875–86 (60 ref.)
Glucagonoma associated with calculous pancreatitis. Mao C, et al. **HPB Surg** 1996;9(2):77–81 (24 ref.)
Glucagonoma and pseudoglucagonoma syndromes. Schwartz RA. **Int J Dermatol** 1997 Feb;36(2):81–9 (119 ref.)
Molecular diagnosis of pancreas carcinoma. Chu TM.
J Clin Lab Anal 1997;11(4):225–31 (84 ref.)
Pancreatic cancer and hypercalcemia associated with von Recklinghausen's disease. Yamamoto M, et al.
J Gastroenterol 1996 Oct;31(5):728–31 (28 ref.)
Diagnosis and treatment of pancreatic and ampullary cancer. Murr MM, et al. **J Med Liban** 1995;43(4):200–7 (55 ref.)
A case of intraductal papillary tumor of pancreas associated with mucinous ductal ectasia. Baek IS, et al.
Korean J Intern Med 1997 Jan;12(1):100–4 (11 ref.)
Errors and pitfalls in diagnostic cytology of abdominal organs. Silverman JF. **Monogr Pathol** 1997;(39):147–70 (107

ref.)
Use of calcium provocative test in the diagnosis of gastroenteropancreatic endocrine tumors. Vezzadini C, et al. **Panminerva Med** 1996 Dec;38(4):255–8 (14 ref.)
Somatostatin receptor scintigraphy in the diagnosis of neuroendocrine gastroenteropancreatic tumors. Bäder M, et al. **Recent Results Cancer Res** 1996;142:137–62 (66 ref.)
Papillary cystic tumor of the pancreas in children. Yang YJ, et al. **Scand J Gastroenterol** 1996 Dec;31(12):1223–7 (18 ref.)
Unusual peptide-secreting tumors in adolescents and children. Schwartz MZ. **Semin Pediatr Surg** 1997 Aug; 6(3):141–6 (19 ref.)
Clinical relevance of serological markers in the detection and follow-up of pancreatic adenocarcinoma. Audisio RA, et al. **Surg Oncol** 1996 Apr;5(2):49–63 (171 ref.)
Enteric duplication presenting as cystic tumors of the pancreas. Spivak H, et al. **Surgery** 1997 May;121(5):597–600 (8 ref.)
MR imaging of pancreatic disorders. Outwater EK, et al. **Top Magn Reson Imaging** 1996 Oct;8(5):265–89 (115 ref.)
[Cystic and papillary tumor of the pancreas: diagnostic and developmental uncertainties. Apropos of a case] Le Borgne J, et al. **Chirurgie** 1997;122(1):31–4 (23 ref.) (Eng. Abstr.) **(Fre)**
[Review of the 1996 literature: roentgen diagnosis of the pancreas] Brambs HJ, et al. **Rontgenpraxis** 1997 Jul; 50(7):189–98 (43 ref.) **(Ger)**
[Diagnosis and differential diagnosis of pancreatic carcinoma] Mössner J. **Schweiz Rundsch Med Prax** 1997 Mar 4; 86(10):397–400 (36 ref.) (Eng. Abstr.) **(Ger)**
[Controversies in timing of preoperative staging of pancreatic carcinomas] Covarelli P, et al. **G Chir** 1997 Jan–Feb; 18(1–2):65–8 (19 ref.) (Eng. Abstr.) **(Ita)**
[Cystic-papillary neoplasm of the pancreas: a case report in childhood] Fabbro MA, et al. **Pediatr Med Chir** 1996 Nov–Dec;18(6):607–10 (15 ref.) (Eng. Abstr.) **(Ita)**
[Current diagnosis and treatment of early pancreatic cancer] Ryu S, et al. **Nippon Rinsho** 1996 May;54(5):1390–4 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Topical diagnosis of insulinomas] Egorov AV, et al. **Khirurgiia (Mosk)** 1996;(3):71–4 (70 ref.) **(Rus)**
[A case of carcinoid of the pancreas] Budiak VA, et al. **Lik Sprava** 1996 Mar–Apr;(3–4):166–7 (6 ref.) **(Rus)**
[Pancreatic cancer, difficult to diagnose. Few early symptoms, often normal laboratory values] Persson B. **Lakartidningen** 1997 May 21;94(21):1980–2 (29 ref.) **(Swe)**

DRUG THERAPY

Antitumorigenic effects of limonene and perillyl alcohol against pancreatic and breast cancer. Crowell PL, et al. **Adv Exp Med Biol** 1996;401:131–6 (23 ref.)
Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: results of a feasibility study. Prott FJ, et al. **Br J Cancer** 1997;75(4):597–601 (29 ref.)
Adjuvant hyperthermic intraperitoneal chemotherapy for adenocarcinoma of the pancreas. Ettinghausen SE, et al. **Cancer Treat Res** 1996;81:227–37 (69 ref.)
Control of growth in neuroendocrine gastro–enteropancreatic tumours. Arnold R, et al. **Digestion** 1996;57 Suppl 1:69–71 (19 ref.)
The role of somatostatin analogues in the treatment of gastro–enteropancreatic endocrine tumours. Bajetta E, et al. **Digestion** 1996;57 Suppl 1:72–6 (11 ref.)
Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Noble S, et al. **Drugs** 1997 Sep;54(3):447–72 (119 ref.)
Adjuvant chemotherapy in pancreatic cancer. Bramhall SR, et al. **Int J Pancreatol** 1997 Feb;21(1):59–63 (24 ref.)
Chemotherapy in advanced pancreatic cancer. Dippold W, et al. **Int J Pancreatol** 1997 Feb;21(1):39–41 (12 ref.)
Octreotide combined with goserelin in the therapy of advanced pancreatic cancer—results of a pilot study and review of the literature. Fazeny B, et al. **J Cancer Res Clin Oncol** 1997;123(1):45–52 (39 ref.)
Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. Spitz FR, et al. **J Clin Oncol** 1997 Mar;15(3):928–37 (44 ref.)
CPT-11: the European clinical development. Terret C, et al. **J Infus Chemother** 1996 Summer;6(3):152–7 (44 ref.)
New developments in chemotherapy for patients with advanced pancreatic cancer. Rothenberg ML. **Oncology (Huntingt)** 1996 Sep;10(9 Suppl):18–22 (25 ref.)
Drug therapy in metastatic neuroendocrine tumors of the gastroenteropancreatic system. Faiss S, et al. **Recent Results Cancer Res** 1996;142:193–207 (41 ref.)
Chemotherapy for patients with adenocarcinoma of the pancreas. Riess H, et al. **Recent Results Cancer Res** 1996; 142:415–24 (39 ref.)
[Primary granulocytic sarcoma of the pancreas: efficacy of early treatment with intensive chemotherapy] Moreau P, et al. **Rev Med Interne** 1996;17(8):677–9 (12 ref.) (Eng. Abstr.) **(Fre)**
[Chemotherapy for pancreatic cancer] Sakata Y, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1647–50 (19 ref.) (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application. Bramhall SR. **Int J Pancreatol** 1997 Feb; 21(1):1–12 (100 ref.)

EPIDEMIOLOGY

Nutrition and pancreatic cancer. Howe GR, et al. **Cancer Causes Control** 1996 Jan;7(1):69–82 (41 ref.)
Insulinoma and other islet-cell tumors. Service FJ. **Cancer Treat Res** 1997;89:335–46 (43 ref.)
A rare case of pancreatic lipoma. Merli M, et al. **Hepatogastroenterology** 1996 May–Jun;43(9):734–6 (10 ref.)
Pancreatic adenocarcinoma: epidemiology and genetics. Flanders TY, et al. **J Med Genet** 1996 Nov;33(11):889–98 (121 ref.)
[The risk factors for pancreatic cancer] Gullo L, et al. **Recenti Prog Med** 1996 Jun;87(6):262–6 (56 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Etiologic links between chronic pancreatitis and pancreatic cancer. Andrén-Sandberg A, et al. **Scand J Gastroenterol** 1997 Feb;32(2):97–103 (87 ref.)
[The search of risk factors for pancreatic cancer: practice, patience and paradigms] Porta M, et al. **Gastroenterol Hepatol** 1997 May;20(5):259–73 (141 ref.) **(Spa)**

GENETICS

Tracking the MEN1 gene. Ebrahimi SA, et al. **Am J Surg** 1997 Sep;174(3):266–70 (23 ref.)
Molecular diagnosis of pancreas carcinoma. Chu TM. **J Clin Lab Anal** 1997;11(4):225–31 (84 ref.)
Pancreatic adenocarcinoma: epidemiology and genetics. Flanders TY, et al. **J Med Genet** 1996 Nov;33(11):889–98 (121 ref.)
Molecular oncology in pancreatic cancer. Gansauge S, et al. **J Mol Med** 1996 Jun;74(6):313–20 (97 ref.)
[Familial exocrine pancreatic carcinoma] Bartsch D, et al. **Dtsch Med Wochenschr** 1997 Mar 21;122(12):378–82 (53 ref.) **(Ger)**
[Genetic changes in cancer of the exocrine pancreas] Real FX. **Gastroenterol Hepatol** 1996 Dec;19(10):534–41 (89 ref.) **(Spa)**

METABOLISM

Neurotrophin-Trk receptor interactions in neoplasia: a possible role in interstitial and perineural invasion in ductal pancreatic cancer. Miknyoczki SJ, et al. **Crit Rev Oncog** 1996;7(1–2):89–100 (109 ref.)
Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors. Friess H, et al. **J Mol Med** 1996 Jan;74(1):35–42 (120 ref.)
Gastroenteropancreatic tumours and prohormones. Rehfeld JF, et al. **Scand J Gastroenterol Suppl** 1996;216:39–45 (52 ref.)
[A case of alpha-fetoprotein-producing pancreatic carcinoma--review of 41 cases reported in Japan] Shimizu E, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Dec; 93(12):921–6 (20 ref.) **(Jpn)**

MORTALITY

[Surgical treatment of pancreatic cancer and its prognosis-long-term therapeutic results after resection] Ohashi O, et al. **Gan To Kagaku Ryoho** 1996 Oct; 23(12):1629–34 (11 ref.) (Eng. Abstr.) **(Jpn)**

NURSING

Managing patients with pancreatic cancer. McEwen DR, et al. **AORN J** 1996 Nov;64(5):716–35; quiz 737–44 (48 ref.)

PATHOLOGY

"Osteoclastic" giant cell carcinoma of the pancreas. Report of a case with aspiration cytology. Mullick SS, et al. **Acta Cytol** 1996 Sep–Oct;40(5):975–9 (23 ref.)
The preoperative staging of pancreatic adenocarcinoma. Rivera JA, et al. **Adv Surg** 1996;30:97–122 (90 ref.)
Solid and papillary neoplasm of the pancreas: radiological-pathological study of five cases and review of the literature. Dong PR, et al. **Clin Radiol** 1996 Oct; 51(10):702–5 (27 ref.)
Fine-needle aspiration cytology of islet cell tumors. Collins BT, et al. **Diagn Cytopathol** 1996 Jul;15(1):37–45 (22 ref.)
Solid and cystic tumor of the pancreas--case report. Maestri L, et al. **Eur J Pediatr Surg** 1996 Aug;6(4):238–40 (5 ref.)
Pancreatic endocrine tumour: a 22-year clinico-pathological experience with morphological, immunohistochemical observation and a review of the literature. Lam KY, et al. **Eur J Surg Oncol** 1997 Feb;23(1):36–42 (46 ref.)
Cutaneous metastases from pancreatic cancer. Miyahara M, et al. **Int J Pancreatol** 1996 Oct;20(2):127–30 (17 ref.)
Pancreatoblastoma: a histochemical and immunohistochemical analysis. Hua C, et al. **J Clin Pathol** 1996 Nov;49(11):952–4 (10 ref.)
Anaplastic Ki-1-positive large cell lymphoma of the pancreas: a case report and review of the literature. Maruyama H, et al. **Jpn J Clin Oncol** 1997 Feb;27(1):51–7 (25 ref.)
Pancreatic schwannoma: report of two cases and review of the literature. Feldman L, et al. **Pancreas** 1997 Jul; 15(1):99–105 (26 ref.)
Mixed osteoclastic/pleomorphic-type giant cell tumor of the pancreas with ductal adenocarcinoma: histochemical and immunohistochemical study with review of the literature. Watanabe M, et al. **Pancreas** 1997 Aug;15(2):201–8 (28 ref.)
The pancreas and peripancreatic area. Ranchod M, et al. **Pathology (Phila)** 1996;3(2):379–87 (20 ref.)
Prognostic factors in pancreatic carcinoma. Compton CC, et al. **Surg Oncol Clin N Am** 1997 Jul;6(3):533–54 (153 ref.)
Pancreatic nodal metastases: biologic significance and therapeutic considerations. Yeo CJ, et al. **Surg Oncol Clin N Am** 1996 Jan;5(1):145–57 (37 ref.)
[Pathologic study with immunohistochemistry of 61 pancreatic endocrine tumors in 16 patients suffering from multiple endocrine neoplasia type I (MEN I). Review of the literature] Heymann MF, et al. **Ann Pathol** 1996; 16(3):167–73 (45 ref.) (Eng. Abstr.) **(Fre)**
[Growth inhibition of human pancreatic cancer by farnesyl transferase inhibitor] Kainuma O, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1657–9 (6 ref.) (Eng. Abstr.) **(Jpn)**
[A new strategy for the therapy of pancreatic cancer by proton pump inhibitor] Ohta T, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1660–4 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Inhibitory effect of FOY-305 on liver metastasis of the pancreatic cancer] Ohta T, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1669–72 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Application for therapeutic use of deuterium oxide (D2O) against human pancreatic cancer] Omori H, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1665–8 (5 ref.) (Eng. Abstr.) **(Jpn)**
[Metastatic tumor to the penis from lung and pancreas cancer: report of two cases] Danno S, et al. **Hinyokika Kiyo** 1997 Jan;43(1):61–3 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Stage classification for pancreatic cancer: its difference between Japan and UICC] Kobari M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Jan;94(1):1–7 (6 ref.) **(Jpn)**
[A case of leiomyosarcoma of the pancreas] Tanaka Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Sep; 93(9):676–80 (10 ref.) **(Jpn)**
[Glucagonoma: case report and literature review] das Neves MM, et al. **Arq Gastroenterol** 1996 Jul–Sep;33(3):167–72 (31 ref.) (Eng. Abstr.) **(Por)**

PHYSIOPATHOLOGY

Biological aspects of neuroendocrine gastro-enteropancreatic tumours. Oberg K. **Digestion** 1996;57 Suppl 1:42–4 (5 ref.)
Islet cell tumors. Stabile BE. **Gastroenterologist** 1997 Sep; 5(3):213–32 (161 ref.)
The role of cytokines in pancreatic cancer. Schmielau J, et al. **Int J Pancreatol** 1996 Jun;19(3):157–63 (41 ref.)

PREVENTION & CONTROL

[The role of screening for carcinoma of the pancreas] Amikura K, et al. **Nippon Rinsho** 1996 May;54(5):1431–4 (21 ref.) (Eng. Abstr.) **(Jpn)**

PSYCHOLOGY

Supportive care of the patient with pancreatic cancer: the role of the oncology social worker. Kennedy VN. **Oncology (Huntingt)** 1996 Sep;10(9 Suppl):35–7 (9 ref.)
Supportive care of the patient with pancreatic cancer: role of the psycho-oncologist. Passik SD. **Oncology (Huntingt)** 1996 Sep;10(9 Suppl):33–4 (11 ref.)

RADIOGRAPHY

Solid and papillary neoplasm of the pancreas: radiological-pathological study of five cases and review of the literature. Dong PR, et al. **Clin Radiol** 1996 Oct; 51(10):702–5 (27 ref.)
CT of pancreatic neoplasms. Part II: The unusual tumors. Stephens DH. **Curr Probl Diagn Radiol** 1997 Mar–Apr; 26(2):81–106 (113 ref.)
CT of pancreatic neoplasms. Part I: Adenocarcinoma. Stephens DH. **Curr Probl Diagn Radiol** 1997 Mar–Apr; 26(2):59–80 (45 ref.)
[Contrast enhanced CT] Kohno A, et al. **Nippon Rinsho** 1996 May;54(5):1249–54 (14 ref.) (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY

Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: results of a feasibility study. Prott FJ, et al. **Br J Cancer** 1997;75(4):597–601 (29 ref.)
Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. Spitz FR, et al. **J Clin Oncol** 1997 Mar;15(3):928–37 (44 ref.)
Role of radiation therapy in the management of the patient with pancreatic cancer. Abrams RA. **Oncology (Huntingt)** 1996 Sep;10(9 Suppl):13–7 (40 ref.)
Brachytherapy and pancreatic cancer. Bodner WR, et al. **Semin Surg Oncol** 1997 May–Jun;13(3):204–7 (21 ref.)
[Intraoperative radiotherapy in cancers of the pancreas and

in recurrent colorectal cancers] Houry S, et al. **Ann Chir** 1996;50(6):438–44 (31 ref.) (Eng. Abstr.) **(Fre)**

[Present state and future of radiation therapy for pancreatic cancer] Kato H, et al. **Gan To Kagaku Ryoho** 1996 Oct; 23(12):1642–6 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Effect of etoposide on a human pancreatic cancer cell line exposed to high dose X-ray irradiation] Mizumoto K, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1673–5 (3 ref.) (Eng. Abstr.) **(Jpn)**

[New therapeutic approach to pancreatic cancer by monoclonal antibodies] Sawada T, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1654–6 (10 ref.) (Eng. Abstr.) **(Jpn)**

SECONDARY

Solitary metastatic tumors to the pancreas: a case report and review of the literature [see comments] Robbins EG 2nd, et al. **Am J Gastroenterol** 1996 Nov;91(11):2414–7 (37 ref.) Comment in: Am J Gastroenterol 1997 May;92(5):914–5.

Renal cell carcinoma of the spindle cell type with metastasis to the pancreas: a case report. Zhao B, et al. **Jpn J Clin Oncol** 1997 Feb;27(1):58–61 (34 ref.)

[Kidney cancer and pancreatic metastases. Report of 3 cases] Masson J, et al. **Prog Urol** 1996 Jun;6(3):443–6 (17 ref.) (Eng. Abstr.) **(Fre)**

SECRETION

Gastrin-producing tumors. Jensen RT. **Cancer Treat Res** 1997;89:293–334 (201 ref.)

SURGERY

Endoscopic pancreatic intervention. Liguory C, et al. **Abdom Imaging** 1997 Sep–Oct;22(5):489–95 (42 ref.)

Simple technique for pancreatogastrostomy and the histological findings of pancreatogastric anastomosis. Yamamoto J, et al. **Arch Surg** 1997 Jul;132(7):785–8 (08 ref.)

Pancreatoblastoma in children. Case report and review of the literature. Willnow U, et al. **Eur J Pediatr Surg** 1996 Dec;6(6):369–72 (47 ref.)

Appleby operation for carcinoma of the body and tail of the pancreas. Kimura W, et al. **Hepatogastroenterology** 1997 Mar–Apr;44(14):387–93 (20 ref.)

A desmoid tumor of the pancreas. Sporadic intra-abdominal desmoids revisited. Bruce JM, et al. **Int J Pancreatol** 1996 Jun;19(3):197–203 (56 ref.)

Laparoscopic treatment of pancreatic disorders: diagnosis and staging, palliation of cancer and treatment of pancreatic pseudocysts. Targarona EM, et al. **Int Surg** 1996 Jan–Mar; 81(1):1–5 (38 ref.)

Pancreatic cancer. The need for critical reassessment [editorial] Gudjonsson B. **J Clin Gastroenterol** 1996 Jul; 23(1):2–6 (35 ref.)

Surgical management of pancreatic cancer. Hoffman JP, et al. **Oncology (Huntingt)** 1996 Sep;10(9 Suppl):9–12 (33 ref.)

The pancreas and peripancreatic area. Ranchod M, et al. **Pathology (Phila)** 1996;3(2):379–87 (20 ref.)

Pancreatic adenocarcinoma: why and when should it be resected? Ravichandran D, et al. **Postgrad Med J** 1997 Aug; 73(862):469–75 (58 ref.)

Pancreatic nodal metastases: biologic significance and therapeutic considerations. Yeo CJ, et al. **Surg Oncol Clin N Am** 1996 Jan;5(1):145–57 (37 ref.)

Spindle cell stromal tumor of the pancreas: treatment by pancreatoduodenectomy. Owen CH, et al. **Surgery** 1997 Jul;122(1):105–11 (22 ref.)

Management of carcinoid tumors of the stomach, duodenum, and pancreas. Akerström G. **World J Surg** 1996 Feb; 20(2):173–82 (128 ref.)

Papillary cystic and solid tumor of the pancreas. Merkle EM, et al. **Z Gastroenterol** 1996 Nov;34(11):743–6 (27 ref.)

[Surgical relevance of diagnostic imaging of abdominal tumors--decision making in pancreatic tumor] Hopt UT, et al. **Chirurg** 1997 Apr;68(4):325–33 (46 ref.) (Eng. Abstr.) **(Ger)**

[Special diagnostic and therapeutic aspects of insulinoma] Röher HD, et al. **Chirurg** 1997 Feb;68(2):116–21 (25 ref.) (Eng. Abstr.) **(Ger)**

[Principles and value of lymph node excision in tumors of the pancreatobiliary system] Schumpelick V, et al. **Chirurg** 1996 Sep;67(9):900–6 (68 ref.) (Eng. Abstr.) **(Ger)**

[Cyst, pseudocyst or carcinoma? Space-occupying lesions of the pancreas in childhood and adolescence] Hümmer HP, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996; 113:1034–9 (10 ref.) (Eng. Abstr.) **(Ger)**

[Treatment of the residual pancreatic stump after pancreatoduodenectomy: pancreatogastrostomy] Catania G, et al. **G Chir** 1996 Aug–Sep;17(8–9):425–30 (54 ref.) (Eng. Abstr.) **(Ita)**

[Controversies in timing of preoperative staging of pancreatic carcinomas] Covarelli P, et al. **G Chir** 1997 Jan–Feb; 18(1–2):65–8 (19 ref.) (Eng. Abstr.) **(Ita)**

[New etiopathogenic, clinical and therapeutic findings in multiple endocrine neoplasia type 1] Tomassetti P, et al. **Minerva Gastroenterol Dietol** 1996 Sep;42(3):133–43 (53 ref.) (Eng. Abstr.) **(Ita)**

[Selective thermocoagulation of unresectable malignant tumors using radiofrequency] Nakagawa A, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1651–3 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Cancer of the head of the pancreas with a unique evolution] Angelescu N, et al. **Chirurgia (Bucur)** 1996 May–Jun; 45(3):129–32 (15 ref.) (Eng. Abstr.) **(Rum)**

[Analgesia in pancreatic cancer. Achievements and perspectives] Shalimov SO, et al. **Klin Khir** 1997;(1):38–42 (53 ref.) **(Ukr)**

THERAPY

Standards and perspectives in the diagnosis and treatment of pancreatic adenocarcinoma. Sulkowski U. **Digestion** 1996;57 Suppl 1:34–5 (9 ref.)

Results of adjuvant therapy in resected pancreatic cancer. Andrén-Sandberg A, et al. **Int J Pancreatol** 1997 Feb; 21(1):31–8 (55 ref.)

Adjuvant therapy of pancreatic cancer using monoclonal antibodies and immune response modifiers. Friess H, et al. **Int J Pancreatol** 1997 Feb;21(1):43–52 (66 ref.)

Multimodal therapies in ductal pancreatic cancer. The future. Link KH, et al. **Int J Pancreatol** 1997 Feb;21(1):71–83 (86 ref.)

Treatment of pancreatic cancer: current limitations, future possibilities. Blackstock AW, et al. **Oncology (Huntingt)** 1996 Mar;10(3):301–7; discussion: 308–23 (87 ref.)

Palliative management of the patient with advanced pancreatic cancer. Walsh D. **Oncology (Huntingt)** 1996 Sep; 10(9 Suppl):40–4 (31 ref.)

Signal transduction as target of gene therapy. Moelling K, et al. **Recent Results Cancer Res** 1996;142:63–71 (18 ref.)

[Endoscopic management of pancreatic diseases] Holstege A, et al. **Internist (Berl)** 1996 Aug;37(8):800–16 (137 ref.) **(Ger)**

[Management of endocrine pancreatic tumors] Schöber C, et al. **Wien Med Wochenschr** 1997;147(1):18–23 (35 ref.) (Eng. Abstr.) **(Ger)**

[Adjuvant therapies in combination with pancreatectomy for carcinoma of the pancreas] Ishikawa O, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1635–41 (34 ref.) (Eng. Abstr.) **(Jpn)**

[Adoptive immunotherapy for pancreatic cancer, using MUC1 specific CTL] Masaki Y, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1679–80 (3 ref.) (Eng. Abstr.) **(Jpn)**

[Multidisciplinary treatment of obstructive jaundice in malignant diseases] Ryu M, et al. **Nippon Naika Gakkai Zasshi** 1997 Apr 10;86(4):646–51 (10 ref.) **(Jpn)**

ULTRASONOGRAPHY

Intra-abdominal ectopic thyroid presenting as a pancreatic tumour. Seelig MH, et al. **Eur J Surg** 1997 Jul;163(7):549–51 (18 ref.)

The role of laparoscopy and ultrasonography in pancreatic head carcinoma. Beger HG, et al. **HPB Surg** 1997; 10(3):186–8 (2 ref.)

[Evolution of ultrasonographic diagnosis for early cancer] Kitamra T, et al. **Nippon Rinsho** 1996 May;54(5):1236–40 (6 ref.) (Eng. Abstr.) **(Jpn)**

VETERINARY

Tumours of the pancreas. Pour PM, et al. **IARC Sci Publ** 1996;(126):149–73 (29 ref.)

PANCREATIC POLYPEPTIDE

CHEMISTRY

Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide. Larhammar D. **Regul Pept** 1996 Sep 16;65(3):165–74 (64 ref.)

PANCREATIC PSEUDOCYST

SURGERY

Laparoscopic treatment of pancreatic disorders: diagnosis and staging, palliation of cancer and treatment of pancreatic pseudocysts. Targarona EM, et al. **Int Surg** 1996 Jan–Mar; 81(1):1–5 (38 ref.)

[Cyst, pseudocyst or carcinoma? Space-occupying lesions of the pancreas in childhood and adolescence] Hümmer HP, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996; 113:1034–9 (10 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Endoscopic management of pancreatic pseudocysts. Lo SK, et al. **Gastroenterologist** 1997 Mar;5(1):10–25 (76 ref.)

Endoscopic treatment of pancreatic pseudocysts. Kozarek RA. **Gastrointest Endosc Clin N Am** 1997 Apr;7(2):271–83 (41 ref.)

PANCREATICODUODENECTOMY

Jejunum or stomach for the pancreatic anastomosis after pancreaticoduodenectomy. Warshaw AL. **HPB Surg** 1997; 10(3):191–3 (4 ref.)

Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. Spitz FR, et al. **J Clin Oncol** 1997 Mar;15(3):928–37 (44 ref.)

Spindle cell stromal tumor of the pancreas: treatment by pancreatoduodenectomy. Owen CH, et al. **Surgery** 1997 Jul;122(1):105–11 (22 ref.)

[Preservation of the pylorus in duodenopancreatectomy] Partensky C, et al. **Ann Chir** 1996;50(7):517–23 (53 ref.) (Eng. Abstr.) **(Fre)**

[Emergency pancreaticoduodenal resection in closed abdominal trauma] Dolgushin NE, et al. **Vestn Khir Im I I Grek** 1996;155(2):58–9 (17 ref.) **(Rus)**

[Pancreatoduodenectomy in the treatment of carcinoma of Vater's ampulla] Morales-Linares JC, et al. **Rev Invest Clin** 1996 May–Jun;48(3):185–9 (25 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

[Complications of two types of pancreatic anastomosis after pancreaticoduodenectomy] Andivot T, et al. **Ann Chir** 1996;50(6):431–7 (37 ref.) (Eng. Abstr.) **(Fre)**

[Conservative treatment of postoperative pancreatic fistula. Role of interventional radiology] Aldrighetti L, et al. **Minerva Chir** 1996 Oct;51(10):839–48 (30 ref.) (Eng. Abstr.) **(Ita)**

METHODS

Alternative techniques for performing the Whipple operation. Yeo CJ, et al. **Adv Surg** 1996;30:293–310 (80 ref.)

Duodenum-preserving resection of the head of the pancreas: the significance as a diagnostic therapy of the lesion in the pancreatic head. Watanabe Y, et al. **HPB Surg** 1996; 9(2):107–11 (7 ref.)

[Treatment of the residual pancreatic stump after pancreatoduodenectomy: pancreatogastrostomy] Catania G, et al. **G Chir** 1996 Aug–Sep;17(8–9):425–30 (54 ref.) (Eng. Abstr.) **(Ita)**

TRENDS

Evolution and current status of the Whipple procedure: an update for gastroenterologists. Strasberg SM, et al. **Gastroenterology** 1997 Sep;113(3):983–94 (75 ref.)

PANCREATICOJEJUNOSTOMY

ADVERSE EFFECTS

Jejunum or stomach for the pancreatic anastomosis after pancreaticoduodenectomy. Warshaw AL. **HPB Surg** 1997; 10(3):191–3 (4 ref.)

PANCREATITIS

Acute pancreatitis. Greenfeld JI, et al. **Curr Opin Pediatr** 1997 Jun;9(3):260–4 (23 ref.)

Acute pancreatitis: overview. Imrie CW. **Eur J Gastroenterol Hepatol** 1997 Feb;9(2):103–5 (9 ref.)

Assessment of severity and prognosis in acute pancreatitis. Larvin M. **Eur J Gastroenterol Hepatol** 1997 Feb; 9(2):122–30 (73 ref.)

Does acute alcoholic pancreatitis exist without preexisting chronic pancreatitis? Hanck C, et al. **Scand J Gastroenterol** 1997 Jul;32(7):625–6 (28 ref.)

Chronic pancreatitis. Pedersen NT, et al. **Scand J Gastroenterol Suppl** 1996;216:52–8 (75 ref.)

[Acute pancreatitis in childhood--new perspectives] Weizman Z. **Harefuah** 1997 Jun 1;132(11):765–8 (38 ref.) **(Heb)**

[Chronic pancreatitis] **Policlinico [Prat]** 1970 Dec 14; 77(50):1639–40 (00 ref.) **(Ita)**

[Acute pancreatitis] Arenas Miravé JI, et al. **Rev Esp Enferm Dig** 1996 Dec;88(12):851–64 (177 ref.) **(Spa)**

CHEMICALLY INDUCED

Review article: drug-induced pancreatitis. McArthur KE. **Aliment Pharmacol Ther** 1996 Feb;10(1):23–38 (132 ref.)

Perindopril-induced acute pancreatitis. Gallego-Rojo FJ, et al. **Dig Dis Sci** 1997 Aug;42(8):1789–91 (13 ref.)

Drug-induced pancreatitis. Wilmink T, et al. **Drug Saf** 1996 Jun;14(6):406–23 (327 ref.)

Drug-associated pancreatitis: facts and fiction. Rünzi M, et al. **Pancreas** 1996 Jul;13(1):100–9 (176 ref.)

[A case report of drug induced hepatitis and pancreatitis] Shimizu A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 May;94(5):351–5 (19 ref.) **(Jpn)**

CLASSIFICATION

Classification of acute pancreatitis and the role of prognostic factors in assessing severity of disease. Imrie CW. **Schweiz Med Wochenschr** 1997 May 10;127(19):798–804 (25 ref.)

[Fibrocalculous pancreatic diabetes] Mohan V. **Journ Annu Diabetol Hotel Dieu** 1996;:99–109 (47 ref.) **(Fre)**

COMPLICATIONS

Arterial complications of pancreatitis and their radiological management. Sawlani V, et al. **Australas Radiol** 1996 Nov; 40(4):381–6 (14 ref.)

Unusual presentation of primary sclerosing cholangitis. Pineau BC, et al. **Can J Gastroenterol** 1997 Jan–Feb; 11(1):45–8 (34 ref.)

The role of surgery in the major early complications of severe acute pancreatitis. Bassi C, et al.

Eur J Gastroenterol Hepatol 1997 Feb;9(2):131–6 (27 ref.)
Chronic pancreatitis: a complication of sarcoidosis? Boruchowicz A, et al. **Eur J Gastroenterol Hepatol** 1996 Nov;8(11):1125–7 (25 ref.)
Management of the later complications of severe acute pancreatitis – pseudocyst, abscess and fistula. Wilson C. **Eur J Gastroenterol Hepatol** 1997 Feb;9(2):117–21 (28 ref.)
The timing of endoscopic sphincterotomy in gallstone acute pancreatitis. Wilson PG, et al. **Eur J Gastroenterol Hepatol** 1997 Feb;9(2):137–44 (64 ref.)
Antibiotics and pancreatitis. Foxx-Orenstein A, et al. **Gastroenterologist** 1997 Jun;5(2):157–64 (63 ref.)
Perspectives in pancreatic pain. Salim AS. **HPB Surg** 1997; 10(5):269–77 (27 ref.)
Etiologic links between chronic pancreatitis and pancreatic cancer. Andrén-Sandberg A, et al. **Scand J Gastroenterol** 1997 Feb;32(2):97–103 (87 ref.)
Late outcome after acute pancreatitis: functional impairment and gastrointestinal tract complications. Fernández-Cruz L, et al. **World J Surg** 1997 Feb;21(2):169–72 (32 ref.)
[Gastroduodenal arterial aneurysm and chronic pancreatitis. A case and review of the literature] Benoit L, et al. **Ann Chir** 1996;50(10):918–20 (17 ref.) (Eng. Abstr.) **(Fre)**
[Cardiovascular complications of pancreatis diseases] Gyöngyösi M, et al. **Orv Hetil** 1997 Jul 27;138(30):1897–901 (57 ref.) (Eng. Abstr.) **(Hun)**
[Colonic stricture due to acute pancreatitis--the examination of our cases and the past reports in Japan] Miyazaki R, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Oct; 93(10):775–9 (20 ref.) **(Jpn)**
[Biliary microlithiasis and its association with acute idiopathic pancreatitis] Kohut M, et al. **Pol Arch Med Wewn** 1996 Dec;96(6):590–6 (33 ref.) **(Pol)**
[Local infectious complications in acute pancreatitis] de Górgolas Hernández-Mora M, et al. **Rev Clin Esp** 1996 Aug;196(8):542–7 (55 ref.) **(Spa)**

DIAGNOSIS

Diagnosis and management of acute pancreatitis. Steinberg WM. **Cleve Clin J Med** 1997 Apr;64(4):182–6 (17 ref.)
Support of the diagnosis of pancreatitis by enzyme tests--old problems, new techniques. Tietz NW. **Clin Chim Acta** 1997 Jan 3;257(1):85–98 (35 ref.)
Diagnosis and prevention of post-ERCP pancreatitis [editorial; comment] Tittobello A. **Endoscopy** 1997 May; 29(4):285–7 (40 ref.) Comment on: Endoscopy 1997 May;29(4):252–7.
The role of imaging in acute pancreatitis. Chalmers AG. **Eur J Gastroenterol Hepatol** 1997 Feb;9(2):106–16 (35 ref.)
Magnetic resonance cholangiopancreatography. Bearcroft PW, et al. **Gut** 1997 Aug;41(2):135–7 (27 ref.)
Glucagonoma associated with calculous pancreatitis. Mao C, et al. **HPB Surg** 1996;9(2):77–81 (24 ref.)
Diagnostic criteria for chronic pancreatitis by the Japan Pancreas Society. Homma T, et al. **Pancreas** 1997 Jul; 15(1):14–5 (3 ref.)
Pancreatitis. Evaluation and treatment. Dragonetti GC, et al. **Prim Care** 1996 Sep;23(3):525–34 (37 ref.)
Pancreatic emergencies. Siegel MJ, et al. **Radiol Clin North Am** 1997 Jul;35(4):815–30, 814 (51 ref.)
Systemic lupus erythematosus (SLE) presenting as acute pancreatitis--a case report. Leong KP, et al. **Singapore Med J** 1996 Jun;37(3):323–4 (18 ref.)
MR imaging of pancreatic disorders. Outwater EK, et al. **Top Magn Reson Imaging** 1996 Oct;8(5):265–89 (115 ref.)
Diagnostic standards for acute pancreatitis. Ranson JH. **World J Surg** 1997 Feb;21(2):136–42 (69 ref.)
[Acute hemorrhagic pancreatitis] Varlet C, et al. **Presse Med** 1996 Oct 19;25(31):1453–8 (28 ref.) (Eng. Abstr.) **(Fre)**
[Diagnosis and treatment of chronic pancreatitis] Kashima K. **Nippon Naika Gakkai Zasshi** 1997 Mar 10;86(3):406–10 (5 ref.) **(Jpn)**
[Acute fatty liver of pregnancy complicated by pancreatitis] Castañón-González JA, et al. **Gac Med Mex** 1997 May-Jun;133(3):253–8 (26 ref.) (Eng. Abstr.) **(Spa)**
[Acute pancreatitis in Caroli's syndrome] García Valriberas R, et al. **Rev Esp Enferm Dig** 1997 Feb;89(2):133–6 (16 ref.) (Eng. Abstr.) **(Spa)**
[Laboratory diagnosis of acute pancreatitis. Amylase analysis is still the leading one, but a "urinary strip" is on its way to be marketed] Andrén-Sandberg A, et al. **Lakartidningen** 1997 Jun 25;94(26–27):2451–3 (17 ref.) **(Swe)**

DRUG THERAPY

Lexipafant (BB-882), a potent PAF antagonist in acute pancreatitis. Curtis LD. **Adv Exp Med Biol** 1996;416:361–3 (16 ref.)
The use of lexipafant in the treatment of acute pancreatitis. McKay C, et al. **Adv Exp Med Biol** 1996;416:365–70 (34 ref.)
A critical review of antibiotic prophylaxis in severe acute pancreatitis. Barie PS. **Am J Surg** 1996 Dec; 172(6A):38S–43S (31 ref.)

ENZYMOLOGY

Intracellular transport of pancreatic enzymes. Cook LJ, et al. **Scand J Gastroenterol Suppl** 1996;219:1–5 (16 ref.)
[The role of intracellular activation of enzymes in pathogenesis of acute pancreatitis--literature review] Król R, et al. **Przegl Lek** 1997;54(1):67–9 (34 ref.) (Eng. Abstr.) **(Pol)**

EPIDEMIOLOGY

Tropical pancreatitis. Ramesh H. **Indian J Gastroenterol** 1997 Jan;16(1):20–5 (64 ref.)

ETIOLOGY

Alcohol-associated diabetes mellitus. A review of the impact of alcohol consumption on carbohydrate metabolism. Greenhouse L, et al. **Arch Fam Med** 1996 Apr;5(4):229–33 (29 ref.)
Severe juvenile dermatomyositis complicated by pancreatitis. See Y, et al. **Br J Rheumatol** 1997 Aug;36(8):912–6 (36 ref.)
Duodenal obstruction from congenital bands: an unusual cause of pancreatitis. Just JD, et al. **Can J Gastroenterol** 1996 Nov-Dec;10(7):449–50 (17 ref.)
Acute pancreatitis in childhood: research of pathogenesis and clinical implications. Weizman Z. **Can J Gastroenterol** 1997 Apr;11(3):249–53 (37 ref.)
Pathogenesis of acute pancreatitis. Steer ML. **Digestion** 1997; 58 Suppl 1:46–9 (16 ref.)
Intraluminal duodenal diverticulum causing recurrent acute pancreatitis: case report and review of the literature. al-Mulhim AA, et al. **Eur J Gastroenterol Hepatol** 1997 Apr;9(4):397–401 (46 ref.)
Pancreatitis in children--experience with 43 cases. Yeung CY, et al. **Eur J Pediatr** 1996 Jun;155(6):458–63 (42 ref.)
Can a bezoar cause acute pancreatitis? Katapadi M, et al. **J Clin Gastroenterol** 1997 Mar;24(2):120–1 (12 ref.)
[Acute and chronic pancreatitis in the elderly patient] Van Steenbergen W. **Tijdschr Gerontol Geriatr** 1996 Oct; 27(5):191–6 (47 ref.) (Eng. Abstr.) **(Dut)**
[Pancreatic involvement, ascites and diarrhea in idiopathic hypereosinophilic syndrome] Bellaiche G, et al. **Gastroenterol Clin Biol** 1997;21(6–7):519–22 (49 ref.) (Eng. Abstr.) **(Fre)**
[Chronic pancreatitis: an extraintestinal manifestation of hemorrhagic rectocolitis?] Lederman E, et al. **Gastroenterol Clin Biol** 1997;21(1):71–3 (18 ref.) (Eng. Abstr.) **(Fre)**
[Acute pancreatitis in rheumatoid purpura. Apropos of 2 cases] Lévy-Weil FE, et al. **Rev Med Interne** 1997; 18(1):54–8 (14 ref.) (Eng. Abstr.) **(Fre)**
[Acute pancreatitis: inflammatory response of the body] Jakab L. **Orv Hetil** 1996 Sep 29;137(39):2141–7 (49 ref.) (Eng. Abstr.) **(Hun)**
[Experience with endoscopic diagnosis and treatment of acute biliary pancreatitis] Zágoni T, et al. **Orv Hetil** 1997 Jun 8;138(23):1497–9 (46 ref.) (Eng. Abstr.) **(Hun)**

METABOLISM

Lithostathine: place in chronic pancreatitis, pathogenesis. Laugier R, et al. **Acta Gastroenterol Belg** 1996 Jul-Sep; 59(3):188–90 (40 ref.)
Pancreatic steatorrhea, malabsorption, and nutrition biochemistry: a comparison of Japanese, European, and American patients with chronic pancreatitis. Nakamura T, et al. **Pancreas** 1997 May;14(4):323–33 (127 ref.)

MICROBIOLOGY

Infectious causes of acute pancreatitis. Parenti DM, et al. **Pancreas** 1996 Nov;13(4):356–71 (238 ref.)
What to do about sterile pancreatic necrosis? Warshaw AL. **Pancreas** 1996 Oct;13(3):223–5 (13 ref.)
[Local infectious complications in acute pancreatitis] de Górgolas Hernández-Mora M, et al. **Rev Clin Esp** 1996 Aug;196(8):542–7 (55 ref.) **(Spa)**

PARASITOLOGY

Infectious causes of acute pancreatitis. Parenti DM, et al. **Pancreas** 1996 Nov;13(4):356–71 (238 ref.)

PATHOLOGY

Redifferentiation and apoptosis of pancreatic cells during acute pancreatitis. Iovanna JL. **Int J Pancreatol** 1996 Oct; 20(2):77–84 (88 ref.)
Morphology of the exocrine pancreas related to pancreatitis. Bockman DE. **Microsc Res Tech** 1997 Jun 1–15; 37(5–6):509–19 (40 ref.)
Chronic fibrosing pancreatitis in childhood: report of a case and literature review. Lewin-Smith MR, et al. **Pediatr Pathol Lab Med** 1996 Jul-Aug;16(4):681–90 (19 ref.)

PHYSIOPATHOLOGY

Severe acute pancreatitis: pathophysiologic mechanisms underlying pancreatic necrosis and remote organ damage. Dugernier T, et al. **Acta Gastroenterol Belg** 1996 Jul-Sep; 59(3):178–85 (33 ref.)
Pancreatitis and cytokines. Van Laethem JL, et al. **Acta Gastroenterol Belg** 1996 Jul-Sep;59(3):186–7 (23 ref.)
The diagnosis and management of fluid collections associated with pancreatitis. Baron TH, et al. **Am J Med** 1997 Jun; 102(6):555–63 (44 ref.)
Cholelithiasis, cholecystitis, and pancreatitis. Moscati RM. **Emerg Med Clin North Am** 1996 Nov;14(4):719–37 (33 ref.)
Acute pancreatitis: assessment and management. Skaife P, et al. **Postgrad Med J** 1996 May;72(847):277–83 (35 ref.)
Circulating endotoxin, tumour necrosis factor-alpha, and their natural antagonists in the pathophysiology of acute pancreatitis. De Beaux AC, et al. **Scand J Gastroenterol Suppl** 1996;219:43–6 (18 ref.)
Platelet-activating factor. Kingsnorth AN. **Scand J Gastroenterol Suppl** 1996;219:28–31 (21 ref.)
Circulating mediators in acute pancreatitis as predictors of severity. Larvin M. **Scand J Gastroenterol Suppl** 1996; 219:16–9 (15 ref.)
Mononuclear phagocyte activation and acute pancreatitis. McKay C, et al. **Scand J Gastroenterol Suppl** 1996;219:32–6 (37 ref.)
Activation of human granulocyte type 1-prophospholipase A2. Rae D, et al. **Scand J Gastroenterol Suppl** 1996;219:24–7 (20 ref.)
Protease-antiprotease interactions and the rationale for therapeutic protease inhibitors. Schmid S, et al. **Scand J Gastroenterol Suppl** 1996;219:47–50 (29 ref.)
Interleukins in acute pancreatitis. Schölmerich J. **Scand J Gastroenterol Suppl** 1996;219:37–42 (28 ref.)
Role of oxidative stress in the pathogenesis of acute pancreatitis. Sweiry JH, et al. **Scand J Gastroenterol Suppl** 1996;219:10–5 (47 ref.)
Ischaemia-reperfusion mechanisms in acute pancreatitis. Toyama MT, et al. **Scand J Gastroenterol Suppl** 1996; 219:20–3 (24 ref.)
Natural course of acute pancreatitis. Beger HG, et al. **World J Surg** 1997 Feb;21(2):130–5 (48 ref.)
[Physiopathology of chronic calcifying pancreatitis] Bernard JP. **Journ Annu Diabetol Hotel Dieu** 1996;:69–77 (36 ref.) **(Fre)**
[Physiopathology of lung injury in acute pancreatitis] Alves Júnior A, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1996 Nov-Dec;51(6):232–8 (53 ref.) (Eng. Abstr.) **(Por)**

PREVENTION & CONTROL

Diagnosis and prevention of post-ERCP pancreatitis [editorial; comment] Tittobello A. **Endoscopy** 1997 May; 29(4):285–7 (40 ref.) Comment on: Endoscopy 1997 May;29(4):252–7.
Transpapillary stenting of proximal biliary strictures: does biliary sphincterotomy reduce the risk of postprocedure pancreatitis? Tarnasky PR, et al. **Gastrointest Endosc** 1997 Jan;45(1):46–51 (27 ref.)

RADIOGRAPHY

CT of pancreatitis with renal and juxtarenal manifestations. Farman J, et al. **Clin Imaging** 1997 May-Jun;21(3):183–8 (9 ref.)

SURGERY

Endoscopic pancreatic intervention. Liguory C, et al. **Abdom Imaging** 1997 Sep-Oct;22(5):489–95 (42 ref.)
Endoscopic retrograde cholangiopancreatography and laparoscopic cholecystectomy. Brady PG, et al. **Dig Dis** 1996 Nov-Dec;14(6):371–81 (47 ref.)
The role of surgery in the major early complications of severe acute pancreatitis. Bassi C, et al. **Eur J Gastroenterol Hepatol** 1997 Feb;9(2):131–6 (27 ref.)
The timing of endoscopic sphincterotomy in gallstone acute pancreatitis. Wilson PG, et al. **Eur J Gastroenterol Hepatol** 1997 Feb;9(2):137–44 (64 ref.)
Current approach to the surgical management of chronic pancreatitis. Ho HS, et al. **Gastroenterologist** 1997 Jun; 5(2):128–36 (63 ref.)
Combined percutaneous-endoscopic therapy for recurrent pancreatitis and pancreas divisum. Spiess SE, et al. **Gastrointest Endosc** 1997 Feb;45(2):188–91 (14 ref.)
Endoscopic stenting of minor papilla for symptomatic pancreas divisum. Bhasin DK, et al. **Indian J Gastroenterol** 1997 Jan;16(1):30–1 (7 ref.)
Pancreatitis caused by a gastric duplication communicating with an aberrant pancreatic lobe. Moss RL, et al. **J Pediatr Surg** 1996 May;31(5):733–6 (14 ref.)
[Endoscopic treatment in acute biliary pancreatitis (editorial)] Prat F, et al. **Presse Med** 1996 Nov 9;25(34):1620–2 (11 ref.) (Eng. Abstr.) **(Fre)**
[Duodenum preserving resection of the head of the pancreas in therapy of pancreas divisum] Widmaier U, et al. **Chirurg** 1997 Feb;68(2):180–6 (23 ref.) (Eng. Abstr.) **(Ger)**
[Surgical therapy of severe acute pancreatitis] Uhl W, et al. **Schweiz Med Wochenschr** 1997 May 10;127(19):805–11 (37 ref.) (Eng. Abstr.) **(Ger)**
[Acute pancreatitis--is endoscopic papillotomy a reliable therapy?] van Husen N. **Wien Med Wochenschr** 1997; 147(1):6–9 (26 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Diagnosis and management of acute pancreatitis. Steinberg WM. **Cleve Clin J Med** 1997 Apr;64(4):182–6 (17 ref.)
Management of the later complications of severe acute pancreatitis – pseudocyst, abscess and fistula. Wilson C. **Eur J Gastroenterol Hepatol** 1997 Feb;9(2):117–21 (28 ref.)
Operative vs non-operative management in sterile necrotizing pancreatitis. Bradley EL 3rd. **HPB Surg** 1997; 10(3):188–91 (8 ref.)
Clinical update: management of acute pancreatitis. Haber PS,

et al. **J Gastroenterol Hepatol** 1997 Mar;12(3):189–97 (99 ref.)
Enteral nutrition in acute pancreatitis. Karamitsios N, et al. **Nutr Rev** 1997 Jul;55(7):279–82 (25 ref.)
What to do about sterile pancreatic necrosis? Warshaw AL. **Pancreas** 1996 Oct;13(3):223–5 (13 ref.)
Acute pancreatitis: assessment and management. Skaife P, et al. **Postgrad Med J** 1996 May;72(847):277–83 (35 ref.)
Acute pancreatitis: nonsurgical management. Tenner S, et al. **World J Surg** 1997 Feb;21(2):143–8 (68 ref.)
[Acute pancreatitis treated in a surgery ward. Apropos of 57 cases] Benchimol D, et al. **J Chir (Paris)** 1996 Jul; 133(5):208–13 (43 ref.) (Eng. Abstr.) **(Fre)**
[Method and application limitations of decision support systems in acute pancreatitis] De Bernardinis M, et al. **Minerva Chir** 1996 Jun;51(6):451–9 (36 ref.) (Eng. Abstr.) **(Ita)**
[The medical therapy of chronic pancreatitis. Problems, progress and outlook] Dobrilla G, et al. **Recenti Prog Med** 1996 Oct;87(10):500–7 (70 ref.) (Eng. Abstr.) **(Ita)**
[Diagnosis and treatment of chronic pancreatitis] Kashima K. **Nippon Naika Gakkai Zasshi** 1997 Mar 10;86(3):406–10 (5 ref.) **(Jpn)**
[Endoscopic treatment of chronic pancreatitis] Jarosz M, et al. **Pol Arch Med Wewn** 1997 Jan;97(1):62–8 (47 ref.) **(Pol)**

ULTRASONOGRAPHY

Clinical perspectives of a sonographic secretin test. Glaser J. **Z Gastroenterol** 1997 Jul;35(7):579–83 (23 ref.)

PANCREATITIS, ACUTE NECROTIZING

COMPLICATIONS

Infected pancreatic necrosis complicated by multiple organ failure. Dominioni L, et al. **Hepatogastroenterology** 1997 Jul–Aug;44(16):968–74 (22 ref.)

ETIOLOGY

[Etiology, pathogenesis and pathophysiology of acute pancreatitis] Rünzi M, et al. **Schweiz Med Wochenschr** 1997 May 17;127(20):849–53 (8 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Surgical treatment of infected necrosis. Rau B, et al. **World J Surg** 1997 Feb;21(2):155–61 (71 ref.)
[Surgical therapy of severe acute pancreatitis] Uhl W, et al. **Schweiz Med Wochenschr** 1997 May 10;127(19):805–11 (37 ref.) (Eng. Abstr.) **(Ger)**

PANCREATITIS, ALCOHOLIC

Does acute alcoholic pancreatitis exist without preexisting chronic pancreatitis? Hanck C, et al. **Scand J Gastroenterol** 1997 Jul;32(7):625–6 (28 ref.)

COMPLICATIONS

Recurrent pericardial effusion as a result of chronic pancreatitis. Successful treatment with somatostatin. Schoonjans R, et al. **J Clin Gastroenterol** 1996 Oct; 23(3):224–7 (20 ref.)

ETIOLOGY

An overview of extrapancreatic factors in the pathogenesis of alcoholic pancreatitis. Korsten MA, et al. **Alcohol Alcohol Suppl** 1994;2:377–84 (54 ref.)
Evaluation of etiological hypotheses and a study of early lesions in alcoholic pancreatitis. Pitchumoni CS. **Alcohol Alcohol Suppl** 1994;2:359–63 (23 ref.)
[Experience with endoscopic diagnosis and treatment of acute biliary pancreatitis] Zágoni T, et al. **Orv Hetil** 1997 Jun 8;138(23):1497–9 (46 ref.) (Eng. Abstr.) **(Hun)**
[Pathogenesis of chronic alcoholic pancreatitis] Tanaka T, et al. **Nippon Geka Gakkai Zasshi** 1996 Aug;97(8):693–7 (29 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Evaluation of etiological hypotheses and a study of early lesions in alcoholic pancreatitis. Pitchumoni CS. **Alcohol Alcohol Suppl** 1994;2:359–63 (23 ref.)

PANCREATODUODENECTOMY see **PANCREATICODUODENECTOMY**

PANCREATOJEJUNOSTOMY see **PANCREATICOJEJUNOSTOMY**

PANCREATOPEPTIDASE

PHYSIOLOGY

Elastase and cell matrix interactions in the pathobiology of vascular disease. Rabinovitch M. **Acta Paediatr Jpn** 1995 Dec;37(6):657–66 (45 ref.)

TOXICITY

Formation and growth of aortic aneurysms induced by adventitial elastolysis. White JV, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:97–120 (14 ref.)

PANCREOZYMIN see **CHOLECYSTOKININ**

PANCREOZYMIN RECEPTORS see **RECEPTORS, CHOLECYSTOKININ**

PANCYTOPENIA

CHEMICALLY INDUCED

Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis: comment on the article by Gutierrez-Ureña et al [letter; comment] Berthelot JM, et al. **Arthritis Rheum** 1997 Jan;40(1):193–4; discussion 195–6 (27 ref.) Comment on: Arthritis Rheum 1996 Feb;39(2):272–6.
[Pancytopenia and Pneumocystis carinii pneumonia associated with low dose methotrexate pulse therapy for rheumatoid arthritis—case report and review of literature] Kitsuwa S, et al. **Ryumachi** 1996 Jun;36(3):551–8 (43 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

[Dyskeratosis congenita. Genetic hematologic-immunologic systemic disease with pancytopenia] Sölder B, et al. **Klin Padiatr** 1996 Nov–Dec;208(6):344–9 (50 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Splenic hematopoiesis after granulocyte-colony stimulating factor therapy in a lupus patient [letter] Tsoi WC, et al. **Am J Hematol** 1996 Dec;53(4):283–4 (4 ref.)

PANDAS, GREATER see **CARNIVORA**

PANDAS, LESSER see **CARNIVORA**

PANENCEPHALITIS, SUBACUTE SCLEROSING see **SUBACUTE SCLEROSING PANENCEPHALITIS**

PANIC

Fear, panic, anxiety, and disorders of emotion. Barlow DH, et al. **Nebr Symp Motiv** 1996;43:251–328 (100 ref.)
Psychosocial factors and asthma. Bosley CM, et al. **Respir Med** 1996 Sep;90(8):453–7 (32 ref.)
[Panic disorder and panic attack] Abbar M. **Encephale** 1996 Dec;22 Spec No 5:13–8 (32 ref.) (Eng. Abstr.) **(Fre)**
[Panic attack and panic disorder in the child and adolescent] Braconnier A. **Encephale** 1996 Dec;22 Spec No 5:19–24 (16 ref.) (Eng. Abstr.) **(Fre)**
[Ethology of panic disorders] Cyrulnik B. **Encephale** 1996 Dec;22 Spec No 5:42–5 (10 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Placebo response in anxiety disorders. Piercy MA, et al. **Ann Pharmacother** 1996 Sep;30(9):1013–9 (47 ref.)

PHYSIOLOGY

[From inducers of panic attack to neurobiology of panic disorder] Bourin M. **Encephale** 1996 Dec;22 Spec No 5:35–41 (57 ref.) (Eng. Abstr.) **(Fre)**

PANIC ATTACKS see **PANIC DISORDER**

PANIC DISORDER

Panic attacks and panic disorder. Katerndahl DA. **J Fam Pract** 1996 Sep;43(3):275–82 (56 ref.)
The neuroanatomy of 5-HT dysregulation and panic disorder. Grove G, et al. **J Neuropsychiatry Clin Neurosci** 1997 Spring;9(2):198–207 (62 ref.)
Diagnosis and treatment of panic disorder and generalized anxiety in primary care. Valente SM. **Nurse Pract** 1996 Aug;21(8):26, 32–4, 37–8, passim (30 ref.)
Panic disorder. When symptoms have no apparent physical cause. Katerndahl DA. **Postgrad Med** 1997 Jan; 101(1):147–50, 153–4, 159–60 passim (39 ref.)

COMPLICATIONS

Managing recurrent nonischemic chest pain in the emergency department. Tueth MJ. **Am J Emerg Med** 1997 Mar; 15(2):170–2 (33 ref.)
Comorbidity and its effects on panic disorder. Marshall JR. **Bull Menninger Clin** 1996 Spring;60(2 Suppl A):A39–53 (63 ref.)
Panic disorder and medical comorbidity: a review of the medical and psychiatric literature. Zaubler TS, et al. **Bull Menninger Clin** 1996 Spring;60(2 Suppl A):A12–38 (122 ref.)
Unexplained chest pain: when is it panic disorder? Fleet RP, et al. **Clin Cardiol** 1997 Mar;20(3):187–94 (68 ref.)

DIAGNOSIS

The panic-agoraphobic spectrum: a descriptive approach to the assessment and treatment of subtle symptoms. Cassano GB, et al. **Am J Psychiatry** 1997 Jun;154(6 Suppl):27–38 (108 ref.)
Panic disorder: diagnosis and treatment in emergency medicine. Zun LS. **Ann Emerg Med** 1997 Jul;30(1):92–6 (34 ref.)
The nature and assessment of catastrophic thoughts in panic disorder. Cox BJ. **Behav Res Ther** 1996 Apr;34(4):363–74 (55 ref.)
Panic attack syndrome [see comments] Prabhu SS, et al. **Indian Pediatr** 1996 May;33(5):409–11 (9 ref.) Comment in: Indian Pediatr 1996 Oct;33(10):869–70.
The assessment of panic using self-report: a comprehensive survey of validated instruments. Bouchard S, et al. **J Anxiety Disord** 1997 Jan–Feb;11(1):89–111 (73 ref.)
Panic disorder in the medical setting. Ballenger JC. **J Clin Psychiatry** 1997;58 Suppl 2:13–7; discussion 18–9 (47 ref.)
Panic disorder: diagnosis, epidemiology, and clinical course. Hirschfeld RM. **J Clin Psychiatry** 1996;57 Suppl 10:3–8; discussion 9–10 (26 ref.)
Panic disorder: relationship to high medical utilization, unexplained physical symptoms, and medical costs. Katon W. **J Clin Psychiatry** 1996;57 Suppl 10:11–8; discussion 19–22 (38 ref.)
Long-term course and outcome of panic disorder. Pollack MH, et al. **J Clin Psychiatry** 1997;58 Suppl 2:57–60 (23 ref.)
[Panic disorder and panic attack] Abbar M. **Encephale** 1996 Dec;22 Spec No 5:13–8 (32 ref.) (Eng. Abstr.) **(Fre)**
[Panic attack and panic disorder in the child and adolescent] Braconnier A. **Encephale** 1996 Dec;22 Spec No 5:19–24 (16 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Panic disorder and social phobia: possible implications of comorbid depression for drug therapy. Lydiard RB. **Anxiety** 1996;2(2):61–70 (90 ref.)
Integrating pharmacotherapy and psychotherapy: an emerging field of study. Beitman BD. **Bull Menninger Clin** 1996 Spring;60(2):160–73 (29 ref.)
An integrated treatment approach to panic disorder. Craske MG. **Bull Menninger Clin** 1996 Spring;60(2 Suppl A):A87–104 (68 ref.)
Placebo response in the treatment of panic disorder. Hirschfeld RM. **Bull Menninger Clin** 1996 Spring;60(2 Suppl A):A76–86 (20 ref.)
The pharmacotherapy of panic disorder. Rosenbaum JF, et al. **Bull Menninger Clin** 1996 Spring;60(2 Suppl A):A54–75 (119 ref.)
Developments in the drug treatment of panic disorder: what is the place of the selective serotonin reuptake inhibitors? Westenberg HG. **J Affect Disord** 1996 Sep 9;40(1–2):85–93 (56 ref.)
Use of benzodiazepines in panic disorder. Davidson JR. **J Clin Psychiatry** 1997;58 Suppl 2:26–8; discussion 29–31 (21 ref.)
Antidepressants in panic disorder. Jefferson JW. **J Clin Psychiatry** 1997;58 Suppl 2:20–4; discussion 24–5 (64 ref.)
The role of SSRIs in panic disorder. Sheehan DV, et al. **J Clin Psychiatry** 1996;57 Suppl 10:51–8; discussion 59–60 (65 ref.)
Description of antipanic therapy in a prospective longitudinal study. Yonkers KA, et al. **J Clin Psychopharmacol** 1996 Jun;16(3):223–32 (59 ref.)
[Pharmacotherapy of panic disorder] Bougerol T, et al. **Encephale** 1996 Dec;22 Spec No 5:46–53 (53 ref.) (Eng. Abstr.) **(Fre)**
[Panic disorder] Heinzl S. **Med Monatsschr Pharm** 1996 Mar; 19(3):79–80 (2 ref.) **(Ger)**

EPIDEMIOLOGY

Comorbidity of depression and panic disorder. Gorman JM, et al. **J Clin Psychiatry** 1996;57 Suppl 10:34–41; discussion 42–3 (63 ref.)
Panic disorder: diagnosis, epidemiology, and clinical course. Hirschfeld RM. **J Clin Psychiatry** 1996;57 Suppl 10:3–8; discussion 9–10 (26 ref.)
Alcohol and substance abuse in panic disorder. Marshall JR. **J Clin Psychiatry** 1997;58 Suppl 2:46–9; discussion 49–50 (38 ref.)
[Epidemiology of panic disorder] Rouillon F. **Encephale** 1996 Dec;22 Spec No 5:25–34 (112 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Panic attacks caused by temporal tumors: an exemplary new case and a review. Kellner M, et al. **Depress Anxiety** 1996–97;4(5):243–5 (23 ref.)
Panic disorder: a bioself-psychological perspective. Miliora MT, et al. **J Am Acad Psychoanal** 1996 Summer; 24(2):217–56 (106 ref.)
Hyperventilation syndrome: a chimera? [editorial] Bass C. **J Psychosom Res** 1997 May;42(5):421–6 (35 ref.)

NURSING

New hope for a disabling condition. Cognitive-behavioral approaches to panic disorder. Wakefield M, et al.

J Psychosoc Nurs Ment Health Serv 1997 Mar;35(3):12–20 (31 ref.)

PHYSIOPATHOLOGY

Testing the suffocation false alarm theory of panic disorder [see comments] Klein DF. **Anxiety** 1994;1(1):1–7 (38 ref.) Comment in: Anxiety 1994–95;1(3):144–8.

Hoigne's syndrome, kindling, and panic disorder. Araszkiewicz A, et al. **Depress Anxiety** 1996–97;4(3):139–43 (45 ref.)

Toward an integrated neurobiology of panic disorder. Goddard AW, et al. **J Clin Psychiatry** 1997;58 Suppl 2:4–11; discussion 11–2 (57 ref.)

The biological basis of panic disorder. Krystal JH, et al. **J Clin Psychiatry** 1996;57 Suppl 10:23–31; discussion 32–3 (76 ref.)

Behavioral, neurochemical, anatomical and electrophysiological correlates of panic disorder: multiple transmitter interaction and neuropeptide colocalization. Zacharko RM, et al. **Prog Neurobiol** 1995 Nov–Dec; 47(4–5):371–423 (792 ref.)

Predator-elicited flight responses in Swiss-Webster mice: an experimental model of panic attacks. Griebel G, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Feb; 20(2):185–205 (85 ref.)

[From inducers of panic attack to neurobiology of panic disorder] Bourin M. **Encephale** 1996 Dec;22 Spec No 5:35–41 (57 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

The nature and assessment of catastrophic thoughts in panic disorder. Cox BJ. **Behav Res Ther** 1996 Apr;34(4):363–74 (55 ref.)

Behavioral, neurochemical, anatomical and electrophysiological correlates of panic disorder: multiple transmitter interaction and neuropeptide colocalization. Zacharko RM, et al. **Prog Neurobiol** 1995 Nov–Dec; 47(4–5):371–423 (792 ref.)

[Ethology of panic disorders] Cyrulnik B. **Encephale** 1996 Dec;22 Spec No 5:42–5 (10 ref.) (Eng. Abstr.) **(Fre)**

[The psychophysiological specificity problem in panic attacks] Siniachkin MS, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(3):113–9 (154 ref.) **(Rus)**

THERAPY

Benzodiazepines and exposure-based cognitive behavior therapies for panic disorder: conclusions from combined treatment trials. Spiegel DA, et al. **Am J Psychiatry** 1997 Jun;154(6):773–81 (77 ref.)

Panic disorder: diagnosis and treatment in emergency medicine. Zun LS. **Ann Emerg Med** 1997 Jul;30(1):92–6 (34 ref.)

Course and outcome in panic disorder: a review of recent follow-up studies. Roy-Byrne PP, et al. **Anxiety** 1994–95; 1(4):151–60 (41 ref.)

On the need for standardization in panic disorder treatment research: survey of the literature, 1980–1992. Weise RE, et al. **Anxiety** 1996;2(6):257–64 (95 ref.)

Integrating pharmacotherapy and psychotherapy: an emerging field of study. Beitman BD. **Bull Menninger Clin** 1996 Spring;60(2):160–73 (29 ref.)

An integrated treatment approach to panic disorder. Craske MG. **Bull Menninger Clin** 1996 Spring;60(2 Suppl A):A87–104 (68 ref.)

Behavioral treatment of panic disorder in children and adolescents. Griegel LE. **Curr Opin Pediatr** 1996 Aug; 8(4):355–60 (22 ref.)

Panic disorder: a bioself-psychological perspective. Miliora MT, et al. **J Am Acad Psychoanal** 1996 Summer; 24(2):217–56 (106 ref.)

Cognitive-behavioral therapy for panic disorder: current status. Barlow DH. **J Clin Psychiatry** 1997;58 Suppl 2:32–6; discussion 36–7 (26 ref.)

Issues in the assessment of treatment response in panic disorder with special reference to fluvoxamine. Ninan PT. **J Clin Psychiatry** 1997;58 Suppl 5:24–31 (39 ref.)

Treatment-resistant panic disorder. Rosenbaum JF. **J Clin Psychiatry** 1997;58 Suppl 2:61–4; discussion 65 (20 ref.)

Clinical issues in the long-term treatment of panic disorder. Rosenbaum JF, et al. **J Clin Psychiatry** 1996;57 Suppl 10:44–8; discussion 49–50 (22 ref.)

Cognitive-behavior therapy versus pharmacotherapy: Now that the jury's returned its verdict, it's time to present the rest of the evidence [see comments] Jacobson NS, et al. **J Consult Clin Psychol** 1996 Feb;64(1):74–80 (45 ref.) Comment in: J Consult Clin Psychol 1996 Feb;64(1):81–7.

Long-term outcome of panic disorder treatment. A review of the literature. Milrod B, et al. **J Nerv Ment Dis** 1996 Dec;184(12):723–30 (44 ref.)

The place of selective serotonin reuptake inhibitors in the treatment of panic disorder. DeVane CL. **Pharmacotherapy** 1997 Mar–Apr;17(2):282–92 (65 ref.)

[The role of psychotherapy in managing panic disorder] Cottraux J. **Encephale** 1996 Dec;22 Spec No 5:54–60 (53 ref.) (Eng. Abstr.) **(Fre)**

[Panic disorder and its psychological treatment] Margraf J, et al. **Naturwissenschaften** 1996 Sep;83(9):401–13 (137 ref.) (Eng. Abstr.) **(Ger)**

PANNICULITIS

PATHOLOGY

Subcutaneous panniculitic T-cell lymphoma. Wang CY, et al. **Int J Dermatol** 1996 Jan;35(1):1–8 (34 ref.)

Panniculitis: recent developments and observations. White WL, et al. **Semin Cutan Med Surg** 1996 Dec;15(4):278–99 (114 ref.)

PANNICULITIS, LUPUS ERYTHEMATOSUS

DIAGNOSIS

Uncommon cutaneous manifestations of lupus erythematosus. Mascaro JM, et al. **Lupus** 1997;6(2):122–31 (84 ref.)

PANNICULITIS, NODULAR NONSUPPURATIVE

DIAGNOSIS

Recognizing Weber-Christian disease. Khan GA, et al. **Tenn Med** 1996 Dec;89(12):447–9 (10 ref.)

DRUG THERAPY

Successful treatment of severe cytophagic histiocytic panniculitis with cyclosporine A. Ostrov BE, et al. **Semin Arthritis Rheum** 1996 Jun;25(6):404–13 (44 ref.)

PATHOLOGY

[Scrotal panniculitis due to cold: a pseudo-tumoral lesion in the prepubertal child. Report of a case] Versini P, et al. **Ann Pathol** 1996 Sep;16(4):282–4 (16 ref.) (Eng. Abstr.) **(Fre)**

PANNICULITIS, PERITONEAL

DIAGNOSIS

[Mesenteric panniculitis simulating Crohn disease] Rosa I, et al. **Gastroenterol Clin Biol** 1996;20(10):905–8 (21 ref.) (Eng. Abstr.) **(Fre)**

[Mesenteric panniculitis. Aspects in x-ray computed tomography and MRI] Saadate-Arab M, et al. **J Radiol** 1997 Apr;78(4):305–8 (15 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Retractile mesenteritis: to treat or not to treat. Koornstra JJ, et al. **Hepatogastroenterology** 1997 Mar–Apr; 44(14):408–10 (16 ref.)

ULTRASONOGRAPHY

Sonographic detection of mesenteric panniculitis: case report and literature review. Catalano O, et al. **J Clin Ultrasound** 1997 Mar–Apr;25(3):141–4 (10 ref.)

PANNICULITIS, SUBACUTE NODULAR MIGRATORY see **PANNICULITIS**

PANOPHTHALMITIS

PREVENTION & CONTROL

[Infectious complications of cataract-implant surgery] Galand A, et al. **Bull Soc Belge Ophtalmol** 1996;260:67–9 (10 ref.) (Eng. Abstr.) **(Fre)**

PANORAMIC RADIOGRAPHY see **RADIOGRAPHY, PANORAMIC**

PANTOMOGRAPHY see **RADIOGRAPHY, PANORAMIC**

PANTOTHENIC ACID

ANALOGS & DERIVATIVES

Measurement of pantothenic acid and hopantenic acid by gas chromatography-mass spectroscopy. Banno K. **Methods Enzymol** 1997;279:213–9 (16 ref.)

ANALYSIS

Measurement of pantothenic acid and hopantenic acid by gas chromatography-mass spectroscopy. Banno K. **Methods Enzymol** 1997;279:213–9 (16 ref.)

PHARMACOKINETICS

Bioavailability of pantothenic acid. van den Berg H. **Eur J Clin Nutr** 1997 Jan;51 Suppl 1:S62–3 (15 ref.)

PAP-I see **ANNEXIN V**

PAPAIN

CHEMISTRY

Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. Turk B, et al. **Biol Chem** 1997 Mar–Apr;378(3–4):141–50 (137 ref.)

METABOLISM

Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. Turk B, et al. **Biol Chem** 1997 Mar–Apr;378(3–4):141–50 (137 ref.)

PAPANICOLAOU SMEAR see **VAGINAL SMEARS**

PAPAVER

see related
OPIUM

PAPAVERETUM see **OPIUM**

PAPAVERINE

ADMINISTRATION & DOSAGE

Technical considerations on intra-arterial papaverine hydrochloride for cerebral vasospasm. Mathis JM, et al. **Neuroradiology** 1997 Feb;39(2):90–8 (31 ref.)

PAPER

Hemicellulases in the bleaching of chemical pulps. Suurnäkki A, et al. **Adv Biochem Eng Biotechnol** 1997;57:261–87 (140 ref.)

Health effects of working in pulp and paper mills: malignant diseases [see comments] Torén K, et al. **Am J Ind Med** 1996 Feb;29(2):123–30 (48 ref.) Comment in: Am J Ind Med 1996 Nov;30(5):641.

Health effects of working in pulp and paper mills: exposure, obstructive airways diseases, hypersensitivity reactions, and cardiovascular diseases. Torén K, et al. **Am J Ind Med** 1996 Feb;29(2):111–22 (75 ref.)

Microbiology and biodegradation of resin acids in pulp mill effluents: a minireview. Liss SN, et al. **Can J Microbiol** 1997 Jul;43(7):599–611 (100 ref.)

Perspectives on Canadian field studies examining the potential of pulp and paper mill effluent to affect fish reproduction. Kovacs TG, et al. **J Toxicol Environ Health** 1997 Jul;51(4):305–52 (77 ref.)

PAPILLARY MUSCLES

see related
CHORDAE TENDINEAE

[A case report of mitral valve papillary fibroelastoma leading to embolic stroke] Shirota K, et al. **Kyobu Geka** 1996 Jul; 49(7):571–4 (18 ref.) (Eng. Abstr.) **(Jpn)**

[A case of scheduled mitral valve replacement for mitral regurgitation caused by papillary muscle rupture after acute myocardial infarction] Minakata K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):639–44 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Mitral valve replacement and coronary artery bypass grafting for postinfarction mitral papillary muscle rupture] Sasaki Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 May;44(5):697–701 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Mitral regurgitation due to papillary muscle rupture after myocardial infarction] Okada M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):381–4 (11 ref.) **(Jpn)**

[Papillary muscle dysfunction, rupture of posterior papillary muscle] Tekaoka K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):435–7 (14 ref.) **(Jpn)**

DRUG EFFECTS

[Acute toxic actions of mercury on the cardiovascular system] Vassallo DV, et al. **Arq Bras Cardiol** 1996 Jul; 67(1):39–45 (40 ref.) **(Por)**

PHYSIOPATHOLOGY

[Syndrome of papillary muscle dysfunction] Koshiji T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):431–4 (16 ref.) **(Jpn)**

ULTRASONOGRAPHY

The vital role of papillary muscles in mitral and ventricular function: echocardiographic insights [see comments] Madu EC, et al. **Clin Cardiol** 1997 Feb;20(2):93–8 (30 ref.) Comment in: Clin Cardiol 1997 May;20(5):506.

PAPILLEDEMA

see related
OPHTHALMOSCOPY

PAPILLOMA

see related
WARTS

Recurrent respiratory papillomatosis. Bauman NM, et al. **Pediatr Clin North Am** 1996 Dec;43(6):1385–401 (103 ref.)

COMPLICATIONS

[A case of degenerated diffuse biliary papillomatosis associated with cystic dilatation of the intrahepatic biliary ducts. Value of radiotherapy and review of the literature] Pillet G, et al. **Bull Cancer** 1996 Nov;83(11):957–63 (83

ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Recurrent respiratory papillomatosis. Kashima HK, et al. **Obstet Gynecol Clin North Am** 1996 Sep;23(3):699–706 (20 ref.)

GENETICS

Hyperdiploid karyotype in a choroid plexus papilloma. Roland B, et al. **Cancer Genet Cytogenet** 1996 Sep; 90(2):130–1 (9 ref.)

Genetic susceptibility to tumor progression in mouse skin carcinogenesis. Stern MC, et al. **Prog Clin Biol Res** 1996; 395:47–55 (19 ref.)

[Detection of human papillomavirus gene sequences in laryngeal tumors and premalignant changes by polymerase chain reaction] Czeglédy J, et al. **Orv Hetil** 1997 Jul 27; 138(30):1891–5 (28 ref.) (Eng. Abstr.) **(Hun)**

PATHOLOGY

Benign papilloma of the cervix in childhood: immunohistochemical findings and review of the literature. Schmedding A, et al. **Eur J Pediatr** 1997 Apr;156(4):320–2 (18 ref.)

Sialadenoma papilliferum of the hard palate: a case report and review of literature. Asahina I, et al. **J Oral Maxillofac Surg** 1997 Sep;55(9):1000–3 (25 ref.)

Intraepithelial lesions of the urinary bladder with a discussion of the histogenesis of urothelial neoplasia. Amin MB, et al. **Semin Diagn Pathol** 1997 May;14(2):84–97 (57 ref.)

[Esophageal squamous cell papilloma. Report of 3 cases. Diagnostic aspects] Ferrari AP, et al. **Rev Assoc Med Bras** 1995 Jul–Aug;41(4):266–70 (17 ref.) (Eng. Abstr.) **(Por)**

PHYSIOPATHOLOGY

Recurrent laryngeal papillomatosis. Retrospective analysis of 95 patients and review of the literature [editorial] Mahnke CG, et al. **Otolaryngol Pol** 1996;50(6):567–78 (61 ref.)

PREVENTION & CONTROL

Role of cesarean section in prevention of recurrent respiratory papillomatosis—is there one? Kosko JR, et al. **Int J Pediatr Otorhinolaryngol** 1996 Mar;35(1):31–8 (26 ref.)

SURGERY

[The treatment of juvenile laryngeal papillomatosis with argon plasma coagulation] Bergler W, et al. **Dtsch Med Wochenschr** 1997 Aug 22;122(34–35):1033–6 (19 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[Molecular-biological aspects of juvenile respiratory papillomatosis and its combined treatment] Gerain V, et al. **Vestn Otorinolaringol** 1996 Jul–Aug;(4):3–8 (44 ref.) (Eng. Abstr.) **(Rus)**

VETERINARY

Tumours of the urinary bladder, renal pelvis, ureter and urethra. Fukushima S, et al. **IARC Sci Publ** 1996; (126):243–59 (39 ref.)

Tumours of the nasal cavity. Schuller HM. **IARC Sci Publ** 1996;(126):175–87 (28 ref.)

VIROLOGY

The rabbit viral skin papillomas and carcinomas: a model for the immunogenetics of HPV-associated carcinogenesis. Breitburd F, et al. **Clin Dermatol** 1997 Mar–Apr; 15(2):237–47 (111 ref.)

Survey of sinonasal inverted papillomata for Epstein–Barr virus. Dunn ST, et al. **Head Neck** 1997 Mar;19(2):98–106 (65 ref.)

[High-risk HPV types in oral and laryngeal papilloma and leukoplakia] Arndt O, et al. **Laryngorhinootologie** 1997 Mar; 76(3):142–9 (58 ref.) (Eng. Abstr.) **(Ger)**

PAPILLOMA, CHOROID PLEXUS see **GLIOMA**

PAPILLOMA, INTRADUCTAL

SURGERY

[Diffuse bile duct papillomatosis: high rate of recurrence and risk of malignant transformation] Brönnimann S, et al. **Chirurg** 1996 Jan;67(1):93–7 (28 ref.) (Eng. Abstr.) **(Ger)**

PAPILLOMA, INVERTED

PATHOLOGY

Intracranial inverting papilloma. Miller PJ, et al. **Head Neck** 1996 Sep–Oct;18(5):450–3; discussion 454 (26 ref.)

The prognostic value of a primary inverted papilloma of the urinary tract. Witjes JA, et al. **J Urol** 1997 Oct; 158(4):1500–5 (84 ref.)

Intraepithelial lesions of the urinary bladder with a discussion of the histogenesis of urothelial neoplasia. Amin MB, et al. **Semin Diagn Pathol** 1997 May;14(2):84–97 (57 ref.)

[Inverted papilloma of the posterior urethra: a case report] Nozawa M, et al. **Hinyokika Kiyo** 1996 Jul;42(7):533–5 (16 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

Bilateral sinonasal papillomas in aplastic maxillary sinuses. Tsue TT, et al. **Am J Otolaryngol** 1997 Jul–Aug;18(4):263–8 (36 ref.)

Inverted papilloma of the nose and paranasal sinuses: a study of 56 cases and review of the literature. Raveh E, et al. **Isr J Med Sci** 1996 Dec;32(12):1163–7 (21 ref.)

PAPILLOMA, SHOPE see **TUMOR VIRUS INFECTIONS**

PAPILLOMA, SQUAMOUS CELL see **PAPILLOMA**

PAPILLOMATOSIS see **PAPILLOMA**

PAPILLOMAVIRUS

see related

CONDYLOMATA ACUMINATA

Role of HPV in cutaneous premalignant and malignant tumors. Pfister H, et al. **Clin Dermatol** 1997 May–Jun; 15(3):335–47 (101 ref.)

Molecular methods for the detection of human papillomavirus infection. Lörincz AT. **Obstet Gynecol Clin North Am** 1996 Sep;23(3):707–30 (73 ref.)

Genital HPV infections in children and adolescents. Moscicki AB. **Obstet Gynecol Clin North Am** 1996 Sep;23(3):675–97 (84 ref.)

The role of human papillomavirus in anogenital cancer. Pfister H. **Obstet Gynecol Clin North Am** 1996 Sep; 23(3):579–95 (110 ref.)

CLASSIFICATION

Papillomavirus and HPV typing. de Villiers EM. **Clin Dermatol** 1997 Mar–Apr;15(2):199–206 (83 ref.)

GENETICS

Heterogeneity of papillomaviruses. Myers G, et al. **Semin Cancer Biol** 1996 Dec;7(6):349–58 (48 ref.)

[Organization and structure of genomes in Papilloma viruses] Dziabaszewska E. **Postepy Biochem** 1997;43(1):18–24 (56 ref.) **(Pol)**

IMMUNOLOGY

Immunology of papillomavirus infection. Frazer IH. **Curr Opin Immunol** 1996 Aug;8(4):484–91 (89 ref.)

Immunologic responses to human papillomavirus infection. Gissmann L. **Obstet Gynecol Clin North Am** 1996 Sep; 23(3):625–39 (108 ref.)

Papillomavirus-like particles and HPV vaccine development. Schiller JT, et al. **Semin Cancer Biol** 1996 Dec;7(6):373–82 (65 ref.)

PATHOGENICITY

Papillomaviruses and potential copathogens. DiPaolo JA, et al. **Toxicol Lett** 1996 Nov;88(1–3):1–7 (25 ref.)

PHYSIOLOGY

Synthesis, properties and applications of papillomavirus-like particles. Sapp M, et al. **Intervirology** 1996;39(1–2):49–53 (30 ref.)

PAPILLOMAVIRUS, BOVINE

IMMUNOLOGY

Vaccination against papillomavirus in cattle. Campo MS. **Clin Dermatol** 1997 Mar–Apr;15(2):275–83 (51 ref.)

Multiplicity of uses of monoclonal antibodies that define papillomavirus linear immunodominant epitopes. Jenson AB, et al. **Immunol Res** 1997 Feb;16(1):115–9 (22 ref.)

PAPILLOMAVIRUS, HUMAN

Cervical carcinoma: role of imaging. Yu KK, et al. **Abdom Imaging** 1997 Mar–Apr;22(2):208–15 (50 ref.)

Issues in the management of human papillomavirus genital disease [see comments] Verdon ME. **Am Fam Physician** 1997 Apr;55(5):1813–6, 1819, 1822 (34 ref.) Comment in: Am Fam Physician 1997 Apr;55(5):1545–6, 1548.

Therapeutic approaches to genital warts. Beutner KR, et al. **Am J Med** 1997 May 5;102(5A):28–37 (63 ref.)

Clinical presentation and natural course of anogenital warts. Handsfield HH. **Am J Med** 1997 May 5;102(5A):16–20 (13 ref.)

Epidemiology of genital human papillomavirus infection. Koutsky L. **Am J Med** 1997 May 5;102(5A):3–8 (40 ref.)

Counseling patients with genital warts. Reitano M. **Am J Med** 1997 May 5;102(5A):38–43 (15 ref.)

Diagnosis of human papillomavirus genital tract infection. Trofatter KF Jr. **Am J Med** 1997 May 5;102(5A):21–7 (25 ref.)

The impact of the human immunodeficiency virus on the human papillomavirus epidemic. Chopra KF, et al. **Arch Dermatol** 1997 May;133(5):629–33 (50 ref.)

Human papillomavirus and bladder cancer. Lopez-Beltran A, et al. **Biomed Pharmacother** 1997;51(6–7):252–7 (34 ref.)

The causal link between HPV and cervical cancer and its implications for prevention of cervical cancer. Muñoz N, et al. **Bull Pan Am Health Organ** 1996 Dec;30(4):362–77 (59 ref.)

A possible role for human papillomaviruses in head and neck cancer. Steinberg BM, et al. **Cancer Metastasis Rev** 1996 Mar;15(1):91–112 (178 ref.)

HPV infections and immunosuppression. Bouwes Bavinck JN, et al. **Clin Dermatol** 1997 May–Jun;15(3):427–37 (155 ref.)

Human papillomaviruses: general features. Favre M, et al. **Clin Dermatol** 1997 Mar–Apr;15(2):181–98 (164 ref.)

Therapy of anogenital HPV-induced lesions. Gross G, et al. **Clin Dermatol** 1997 May–Jun;15(3):457–70 (127 ref.)

Human papillomavirus infection in women. Special aspects of infectious diseases in women. Jablonska S, et al. **Clin Dermatol** 1997 Jan–Feb;15(1):67–79 (109 ref.)

Cutaneous and genital HPV-associated lesions in HIV-infected patients. Palefsky JM. **Clin Dermatol** 1997 May–Jun;15(3):439–47 (75 ref.)

HPV-associated diseases of oral mucosa. Praetorius F. **Clin Dermatol** 1997 May–Jun;15(3):399–413 (100 ref.)

Cervical and vaginal HPV infections. Schneider A. **Clin Dermatol** 1997 May–Jun;15(3):389–98 (120 ref.)

Role of human papillomaviruses in cancer of the respiratory and upper digestive tract. Snijders PJ, et al. **Clin Dermatol** 1997 May–Jun;15(3):415–25 (112 ref.)

Human papilloma virus—H.P.V. condyloma. Current studies in diagnosis, treatment and prognosis. Garrido JL. **Clin Exp Obstet Gynecol** 1996;23(2):99–102 (24 ref.)

The roles of the human major histocompatibility complex and human papillomavirus infection in cervical intraepithelial neoplasia and cervical cancer. Odunsi KO, et al. **Clin Oncol (R Coll Radiol)** 1997;9(1):4–13 (115 ref.)

Pathobiology of vulvar squamous neoplasia. Crum CP, et al. **Curr Opin Obstet Gynecol** 1997 Feb;9(1):63–9 (50 ref.)

Cervical pathology. Herrington CS. **Curr Opin Obstet Gynecol** 1997 Feb;9(1):57–62 (54 ref.)

Human papillomavirus vaccines. Vonka V. **Folia Biol (Praha)** 1996;42(3):73–8 (50 ref.)

The role of vaccines in the control of STDs: HPV vaccines. Frazer IH. **Genitourin Med** 1996 Dec;72(6):398–403 (65 ref.)

Role of cesarean section in prevention of recurrent respiratory papillomatosis—is there one? Kosko JR, et al. **Int J Pediatr Otorhinolaryngol** 1996 Mar;35(1):31–8 (26 ref.)

Human papillomavirus-associated tumors of the skin and mucosa. Majewski S, et al. **J Am Acad Dermatol** 1997 May; 36(5 Pt 1):659–85; quiz 686–8 (272 ref.)

Anal human papillomavirus and anal cancer. Tilston P. **J Clin Pathol** 1997 Aug;50(8):625–34 (108 ref.)

Analysis of cytokine profiles in patients with human papillomavirus-associated neoplasms [editorial; comment] Wu TC, et al. **J Natl Cancer Inst** 1997 Feb 5;89(3):185–7 (33 ref.) Comment on: J Natl Cancer Inst 1997 Feb 5;89(3):245–50.

Cervical human papillomavirus infection and intraepithelial neoplasia: a review. Mitchell MF, et al. **J Natl Cancer Inst Monogr** 1996;(21):17–25 (84 ref.)

Recurrent respiratory papillomatosis. Bauman NM, et al. **Pediatr Clin North Am** 1996 Dec;43(6):1385–401 (103 ref.)

Congenital papillomas and papillomatoses associated with the human papilloma virus (HPV)–report on 5 cases. Dias EP, et al. **Rev Paul Med** 1995 Jul–Aug;113(4):957–63 (63 ref.)

HLA control in the progression of human papillomavirus infections. Breitburd F, et al. **Semin Cancer Biol** 1996 Dec; 7(6):359–71 (120 ref.)

Mechanism of HPV E6 proteins in cellular transformation. Huibregtse JM, et al. **Semin Cancer Biol** 1996 Dec; 7(6):317–26 (85 ref.)

Interactions of the human papillomavirus E7 protein with cell cycle regulators. Jones DL, et al. **Semin Cancer Biol** 1996 Dec;7(6):327–37 (66 ref.)

[HIV, HPV and cervical pathology] Quéreux C, et al. **Contracept Fertil Sex** 1997 Feb;25(2):120–4 (29 ref.) **(Fre)**

[Primary carcinoma of Bartholin's glands with HPV 18 detection] Schwarzlos G, et al. **Zentralbl Gynakol** 1997; 119(3):133–5 (17 ref.) (Eng. Abstr.) **(Ger)**

[Follow-up of high risk, human papillomavirus (HPV)-positive patients with cancer of the uterine cervix] Hernádi Z, et al. **Orv Hetil** 1997 May 18;138(20):1249–53 (29 ref.) (Eng. Abstr.) **(Hun)**

CLASSIFICATION

Papillomavirus and HPV typing. de Villiers EM. **Clin Dermatol** 1997 Mar–Apr;15(2):199–206 (83 ref.)

Anogenital warts in prepubertal children: pathogenesis, HPV typing and management [editorial] Armstrong DK, et al. **Int J STD AIDS** 1997 Feb;8(2):78–81 (34 ref.)

Human papillomavirus infection and invasive cervical neoplasia: a study of prevalence and morphology. Zehbe I, et al. **J Pathol** 1997 Mar;181(3):270–5 (44 ref.)

[High-risk HPV types in oral and laryngeal papilloma and leukoplakia] Arndt O, et al. **Laryngorhinootologie** 1997 Mar; 76(3):142–9 (58 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Human papillomavirus and human disease. Beutner KR, et al. **Am J Med** 1997 May 5;102(5A):9–15 (36 ref.)

PAPILLOMAVIRUS, HUMAN

Human papillomavirus and other risk factors for cervical cancer. Bosch FX, et al. **Biomed Pharmacother** 1997; 51(6-7):268-75 (36 ref.)

Oncogenes and antioncogenes in the development of HPV associated tumors. Crawford L, et al. **Clin Dermatol** 1997 Mar-Apr;15(2):207-15 (96 ref.)

Human papillomavirus biology. Lowy DR, et al. **J Natl Cancer Inst Monogr** 1996;(21):141-3 (27 ref.)

The genetic program of genital human papillomaviruses in infection and cancer. Turek LP, et al. **Obstet Gynecol Clin North Am** 1996 Dec;23(4):735-58 (151 ref.)

Control of papillomavirus DNA replication and transcription. Desaintes C, et al. **Semin Cancer Biol** 1996 Dec;7(6):339-47 (76 ref.)

[Anti-papillomavirus immunologic response and natural history of cervical lesions] Vinatier D, et al. **Contracept Fertil Sex** 1997 May;25(5):339-47 (88 ref.) **(Fre)**

GROWTH & DEVELOPMENT

In vitro experimental systems for HPV: epithelial raft cultures for investigations of viral reproduction and pathogenesis and for genetic analyses of viral proteins and regulatory sequences. Chow LT, et al. **Clin Dermatol** 1997 Mar-Apr; 15(2):217-27 (63 ref.)

IMMUNOLOGY

DNA vaccines for bacteria and viruses. Ulmer JB, et al. **Adv Exp Med Biol** 1996;397:49-53 (15 ref.)

The current status of therapeutic HPV vaccine. van Driel WJ, et al. **Ann Med** 1996 Dec;28(6):471-7 (72 ref.)

The rabbit viral skin papillomas and carcinomas: a model for the immunogenetics of HPV-associated carcinogenesis. Breitburd F, et al. **Clin Dermatol** 1997 Mar-Apr; 15(2):237-47 (111 ref.)

Humoral immune response to human papillomavirus infection. Carter JJ, et al. **Clin Dermatol** 1997 Mar-Apr; 15(2):249-59 (89 ref.)

Cellular immunity in cutaneous and genital HPV infections. Malejczyk J, et al. **Clin Dermatol** 1997 Mar-Apr; 15(2):261-74 (131 ref.)

Immunology of papillomavirus infection. Frazer IH. **Curr Opin Immunol** 1996 Aug;8(4):484-91 (89 ref.)

Human papillomavirus vaccines for cervical cancer. Tindle RW. **Curr Opin Immunol** 1996 Oct;8(5):643-50 (63 ref.)

Papillomavirus-like particles for serology and vaccine development. Kirnbauer R. **Intervirology** 1996; 39(1-2):54-61 (82 ref.)

Human papillomavirus immunology and vaccine prospects. Steller MA, et al. **J Natl Cancer Inst Monogr** 1996; (21):145-8 (28 ref.)

[Role of macrophages in papillomavirus infections] Bianchi A, et al. **Pathol Biol (Paris)** 1997 Feb;45(2):165-8 (25 ref.) (Eng. Abstr.) **(Fre)**

[Immunologic aspects of infections with papillomaviruses. Prospects for a vaccine] Höpfl R, et al. **Hautarzt** 1996 Oct; 47(10):739-43 (42 ref.) (Eng. Abstr.) **(Ger)**

ISOLATION & PURIFICATION

Genital viral infections. Studies on human papillomavirus and Epstein-Barr virus. Voog E. **Acta Derm Venereol Suppl (Stockh)** 1996;198:1-55 (232 ref.)

HPV-11- and HPV-16-associated oral verrucous carcinoma. Lübbe J, et al. **Dermatology** 1996;192(3):217-21 (35 ref.)

Papillary squamous cell carcinoma of the uterine cervix: report of a case with HPV 16 DNA and brief review. Ollayos CW, et al. **Gynecol Oncol** 1996 Dec;63(3):388-91 (20 ref.)

Molecular diagnosis of persistent human papilloma virus infections. Wieland U, et al. **Intervirology** 1996;39(3):145-57 (96 ref.)

In situ PCR to cells and to wax sections. An alternative to in situ hybridization for the detection of low copies of human papillomavirus and cytomegalovirus DNA. Mougin C, et al. **Methods Mol Biol** 1997;71:77-97 (44 ref.)

Human papillomavirus, integration and cervical carcinogenesis: a clinicopathological perspective. Cooper K, et al. **Mol Pathol** 1997 Feb;50(1):1-3 (37 ref.)

Human papillomavirus expression in oral mucosa, premalignant conditions, and squamous cell carcinoma: a retrospective review of the literature [see comments] Miller CS, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Jul;82(1):57-68 (99 ref.) Comment in: Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Feb;83(2):187-8.

Virus infection and cancer risk in transplant recipients. McGregor JM, et al. **Trends Microbiol** 1996 Jan;4(1):2-3 (14 ref.)

[Genital infection with human papillomavirus (HPV): viral screening and typing, importance of in situ hybridization] Walker F, et al. **Ann Pathol** 1996 Nov;16(5):364-73 (76 ref.) **(Fre)**

[Detection of human papillomavirus gene sequences in laryngeal tumors and premalignant changes by polymerase chain reaction] Czeglédy J, et al. **Orv Hetil** 1997 Jul 27; 138(30):1891-5 (28 ref.) (Eng. Abstr.) **(Hun)**

[Clinical usefulness of the detection and classification of human papilloma viruses using polymerase chain reaction (PCR)] **Gac Med Mex** 1994 Jul-Aug;130(4):273-5 (0 ref.) **(Spa)**

PATHOGENICITY

Human papillomaviruses and cervical cancer. Villa LL. **Adv Cancer Res** 1997;71:321-41 (174 ref.)

Papillomavirus infections--a major cause of human cancers. zur Hausen H. **Biochim Biophys Acta** 1996 Oct 9; 1288(2):F55-78 (415 ref.)

Tissue xenografts as a model system for study of the pathogenesis of papillomaviruses. Howett MK, et al. **Clin Dermatol** 1997 Mar-Apr;15(2):229-36 (53 ref.)

Some etio-pathogenetic factors in laryngeal carcinogenesis. Sugár J, et al. **J Environ Pathol Toxicol Oncol** 1996; 15(2-4):195-9 (26 ref.)

PHYSIOLOGY

The role of papillomaviruses in human non-melanoma skin cancer. McGregor JM, et al. **Cancer Surv** 1996;26:219-36 (94 ref.)

The oncogenic role of human papillomavirus proteins. Barbosa MS. **Crit Rev Oncog** 1996;7(1-2):1-18 (155 ref.)

Human epithelial cells immortalized by human papilloma viruses. Zheng J, et al. **Crit Rev Oncog** 1995;6(3-6):235-50 (128 ref.)

The disruption of cell cycle checkpoints by papillomavirus oncoproteins contributes to anogenital neoplasia. Galloway DA, et al. **Semin Cancer Biol** 1996 Dec;7(6):309-15 (49 ref.)

PAPILLON-LEFEVRE DISEASE

COMPLICATIONS

Preservation of permanent teeth in a patient with Papillon-Lefèvre syndrome by professional tooth-cleaning. Kim JB, et al. **ASDC J Dent Child** 1997 May-Jun; 64(3):222-6 (20 ref.)

PAPIO

Baboons as an animal model for genetic studies of common human disease. Rogers J, et al. **Am J Hum Genet** 1997 Sep;61(3):489-93 (41 ref.)

IMMUNOLOGY

Xenotransplantation of baboon bone marrow cells: a historical review of the protocols as a possible treatment modality for HIV/AIDS. Relf MV. **J Assoc Nurses AIDS Care** 1996 Sep-Oct;7(5):27-35 (38 ref.)

PAPOVAVIRIDAE

ISOLATION & PURIFICATION

Progressive multifocal leukoencephalopathy during cyclosporine treatment. A case report. Gentile S, et al. **Ital J Neurol Sci** 1996 Oct;17(5):363-6 (20 ref.)

PAPOVAVIRIDAE INFECTIONS

Issues in the management of human papillomavirus genital disease [see comments] Verdon ME. **Am Fam Physician** 1997 Apr;55(5):1813-6, 1819, 1822 (34 ref.) Comment in: Am Fam Physician 1997 Apr;55(5):1545-6, 1548.

Human papillomavirus and cancers of the upper aerodigestive tract: a review of epidemiological and experimental evidence. Franceschi S, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Jul;5(7):567-75 (104 ref.)

HPV infections and immunosuppression. Bouwes Bavinck JN, et al. **Clin Dermatol** 1997 May-Jun;15(3):427-37 (155 ref.)

HPV-associated diseases of oral mucosa. Praetorius F. **Clin Dermatol** 1997 May-Jun;15(3):399-413 (100 ref.)

Cervical and vaginal HPV infections. Schneider A. **Clin Dermatol** 1997 May-Jun;15(3):389-98 (120 ref.)

Anogenital warts in prepubertal children: pathogenesis, HPV typing and management [editorial] Armstrong DK, et al. **Int J STD AIDS** 1997 Feb;8(2):78-81 (34 ref.)

Human papillomavirus-associated tumors of the skin and mucosa. Majewski S, et al. **J Am Acad Dermatol** 1997 May; 36(5 Pt 1):659-85; quiz 686-8 (272 ref.)

Human papillomatous virus infection update: impact on women's health. Carson S. **Nurse Pract** 1997 Apr; 22(4):24-5, 28-30, 35-7 (23 ref.)

Clinical manifestations and natural history of genital human papillomavirus infections. Campion MJ, et al. **Obstet Gynecol Clin North Am** 1996 Dec;23(4):783-809 (63 ref.)

HPV infection and disease in men. Palefsky JM, et al. **Obstet Gynecol Clin North Am** 1996 Dec;23(4):895-916 (43 ref.)

[Human JC and BK polyomavirus infection] Pérez Gracia MT, et al. **Med Clin (Barc)** 1996 Jan 20;106(2):69-75 (123 ref.) **(Spa)**

COMPLICATIONS

Polyomavirus-induced interstitial nephritis in two renal transplant recipients: case reports and review of the literature. Mathur VS, et al. **Am J Kidney Dis** 1997 May; 29(5):754-8 (9 ref.)

Papillomavirus infections--a major cause of human cancers. zur Hausen H. **Biochim Biophys Acta** 1996 Oct 9; 1288(2):F55-78 (415 ref.)

Cutaneous and genital HPV-associated lesions in HIV-infected patients. Palefsky JM. **Clin Dermatol** 1997 May-Jun;15(3):439-47 (75 ref.)

Role of HPV in cutaneous premalignant and malignant tumors. Pfister H, et al. **Clin Dermatol** 1997 May-Jun; 15(3):335-47 (101 ref.)

Role of human papillomaviruses in cancer of the respiratory and upper digestive tract. Snijders PJ, et al. **Clin Dermatol** 1997 May-Jun;15(3):415-25 (112 ref.)

HPV-11- and HPV-16-associated oral verrucous carcinoma. Lübbe J, et al. **Dermatology** 1996;192(3):217-21 (35 ref.)

Progressive multifocal leukoencephalopathy during cyclosporine treatment. A case report. Gentile S, et al. **Ital J Neurol Sci** 1996 Oct;17(5):363-6 (20 ref.)

Anal human papillomavirus and anal cancer. Tilston P. **J Clin Pathol** 1997 Aug;50(8):625-34 (108 ref.)

Considerations on a possible viral etiology for B-precursor acute lymphoblastic leukemia of childhood. Smith M. **J Immunother** 1997 Mar;20(2):89-100 (122 ref.)

Human papillomavirus infection and invasive cervical neoplasia: a study of prevalence and morphology. Zehbe I, et al. **J Pathol** 1997 Mar;181(3):270-5 (44 ref.)

Human papillomavirus, integration and cervical carcinogenesis: a clinicopathological perspective. Cooper K, et al. **Mol Pathol** 1997 Feb;50(1):1-3 (37 ref.)

The role of human papillomavirus in anogenital cancer. Pfister H. **Obstet Gynecol Clin North Am** 1996 Sep; 23(3):579-95 (110 ref.)

Recurrent respiratory papillomatosis. Bauman NM, et al. **Pediatr Clin North Am** 1996 Dec;43(6):1385-401 (103 ref.)

[HIV, HPV and cervical pathology] Quéreux C, et al. **Contracept Fertil Sex** 1997 Feb;25(2):120-4 (29 ref.) **(Fre)**

CONGENITAL

Congenital papillomas and papillomatoses associated with the human papilloma virus (HPV)-report on 5 cases. Dias EP, et al. **Rev Paul Med** 1995 Jul-Aug;113(4):957-63 (63 ref.)

DIAGNOSIS

Cervical carcinoma: role of imaging. Yu KK, et al. **Abdom Imaging** 1997 Mar-Apr;22(2):208-15 (50 ref.)

Genital viral infections. Studies on human papillomavirus and Epstein-Barr virus. Voog E. **Acta Derm Venereol Suppl (Stockh)** 1996;198:1-55 (232 ref.)

Clinical presentation and natural course of anogenital warts. Handsfield HH. **Am J Med** 1997 May 5;102(5A):16-20 (13 ref.)

Diagnosis of human papillomavirus genital tract infection. Trofatter KF Jr. **Am J Med** 1997 May 5;102(5A):21-7 (25 ref.)

Human papillomavirus infection in women. Special aspects of infectious diseases in women. Jablonska S, et al. **Clin Dermatol** 1997 Jan-Feb;15(1):67-79 (109 ref.)

Virus-host interactions and diagnosis of human polyomavirus-associated disease. Dörries K. **Intervirology** 1996;39(3):165-75 (75 ref.)

Molecular diagnosis of persistent human papilloma virus infections. Wieland U, et al. **Intervirology** 1996;39(3):145-57 (96 ref.)

Clinical role of HPV testing. Cox JT. **Obstet Gynecol Clin North Am** 1996 Dec;23(4):811-51 (153 ref.)

Molecular methods for the detection of human papillomavirus infection. Lörincz AT. **Obstet Gynecol Clin North Am** 1996 Sep;23(3):707-30 (73 ref.)

Genital HPV infections in children and adolescents. Moscicki AB. **Obstet Gynecol Clin North Am** 1996 Sep;23(3):675-97 (84 ref.)

[Genital infection with human papillomavirus (HPV): viral screening and typing, importance of in situ hybridization] Walker F, et al. **Ann Pathol** 1996 Nov;16(5):364-73 (76 ref.) **(Fre)**

EPIDEMIOLOGY

Epidemiology of genital human papillomavirus infection. Koutsky L. **Am J Med** 1997 May 5;102(5A):3-8 (40 ref.)

The impact of the human immunodeficiency virus on the human papillomavirus epidemic. Chopra KF, et al. **Arch Dermatol** 1997 May;133(5):629-33 (50 ref.)

Anogenital papillomavirus infection and neoplasia in immunodeficient women. Wright TC Jr, et al. **Obstet Gynecol Clin North Am** 1996 Dec;23(4):861-93 (79 ref.)

ETIOLOGY

Tissue xenografts as a model system for study of the pathogenesis of papillomaviruses. Howett MK, et al. **Clin Dermatol** 1997 Mar-Apr;15(2):229-36 (53 ref.)

GENETICS

Oncogenes and antioncogenes in the development of HPV associated tumors. Crawford L, et al. **Clin Dermatol** 1997 Mar-Apr;15(2):207-15 (96 ref.)

The genetic program of genital human papillomaviruses in infection and cancer. Turek LP, et al. **Obstet Gynecol Clin North Am** 1996 Dec;23(4):735-58 (151

ref.)

IMMUNOLOGY

The rabbit viral skin papillomas and carcinomas: a model for the immunogenetics of HPV-associated carcinogenesis. Breitburd F, et al. **Clin Dermatol** 1997 Mar-Apr; 15(2):237-47 (111 ref.)

Humoral immune response to human papillomavirus infection. Carter JJ, et al. **Clin Dermatol** 1997 Mar-Apr; 15(2):249-59 (89 ref.)

Cellular immunity in cutaneous and genital HPV infections. Malejczyk J, et al. **Clin Dermatol** 1997 Mar-Apr; 15(2):261-74 (131 ref.)

Immunology of papillomavirus infection. Frazer IH. **Curr Opin Immunol** 1996 Aug;8(4):484-91 (89 ref.)

Analysis of cytokine profiles in patients with human papillomavirus-associated neoplasms [editorial; comment] Wu TC, et al. **J Natl Cancer Inst** 1997 Feb 5;89(3):185-7 (33 ref.) Comment on: J Natl Cancer Inst 1997 Feb 5;89(3):245-50.

Immunologic responses to human papillomavirus infection. Gissmann L. **Obstet Gynecol Clin North Am** 1996 Sep; 23(3):625-39 (108 ref.)

HLA control in the progression of human papillomavirus infections. Breitburd F, et al. **Semin Cancer Biol** 1996 Dec; 7(6):359-71 (120 ref.)

[Anti-papillomavirus immunologic response and natural history of cervical lesions] Vinatier D, et al. **Contracept Fertil Sex** 1997 May;25(5):339-47 (88 ref.) **(Fre)**

[Role of macrophages in papillomavirus infections] Bianchi A, et al. **Pathol Biol (Paris)** 1997 Feb;45(2):165-8 (25 ref.) (Eng. Abstr.) **(Fre)**

[Immunologic aspects of infections with papillomaviruses. Prospects for a vaccine] Höpfl R, et al. **Hautarzt** 1996 Oct; 47(10):739-43 (42 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Tissue effects and host response. The key to the rational triage of cervical neoplasia. Ferenczy A, et al. **Obstet Gynecol Clin North Am** 1996 Dec;23(4):759-82 (50 ref.)

Papillomaviruses and potential copathogens. DiPaolo JA, et al. **Toxicol Lett** 1996 Nov;88(1-3):1-7 (25 ref.)

[Primary carcinoma of Bartholin's glands with HPV 18 detection] Schwarzlos G, et al. **Zentralbl Gynakol** 1997; 119(3):133-5 (17 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Vaccination against papillomavirus in cattle. Campo MS. **Clin Dermatol** 1997 Mar-Apr;15(2):275-83 (51 ref.)

Papillomavirus-like particles for serology and vaccine development. Kirnbauer R. **Intervirology** 1996; 39(1-2):54-61 (82 ref.)

Synthesis, properties and applications of papillomavirus-like particles. Sapp M, et al. **Intervirology** 1996;39(1-2):49-53 (30 ref.)

PSYCHOLOGY

Counseling patients with genital warts. Reitano M. **Am J Med** 1997 May 5;102(5A):38-43 (15 ref.)

THERAPY

Therapeutic approaches to genital warts. Beutner KR, et al. **Am J Med** 1997 May 5;102(5A):28-37 (63 ref.)

The current status of therapeutic HPV vaccine. van Driel WJ, et al. **Ann Med** 1996 Dec;28(6):471-7 (72 ref.)

Therapy of anogenital HPV-induced lesions. Gross G, et al. **Clin Dermatol** 1997 May-Jun;15(3):457-70 (127 ref.)

Therapeutic approaches to papillomavirus infections. Baker GE, et al. **Dermatol Clin** 1997 Apr;15(2):331-40 (71 ref.)

TRANSMISSION

Role of cesarean section in prevention of recurrent respiratory papillomatosis--is there one? Kosko JR, et al. **Int J Pediatr Otorhinolaryngol** 1996 Mar;35(1):31-8 (26 ref.)

VIROLOGY

New aspects in the pathogenesis of polyomavirus-induced disease. Dörries K. **Adv Virus Res** 1997;48:205-61 (204 ref.)

Human papillomavirus and human disease. Beutner KR, et al. **Am J Med** 1997 May 5;102(5A):9-15 (36 ref.)

In vitro experimental systems for HPV: epithelial raft cultures for investigations of viral reproduction and pathogenesis and for genetic analyses of viral proteins and regulatory sequences. Chow LT, et al. **Clin Dermatol** 1997 Mar-Apr; 15(2):217-27 (63 ref.)

Pathobiology of vulvar squamous neoplasia. Crum CP, et al. **Curr Opin Obstet Gynecol** 1997 Feb;9(1):63-9 (50 ref.)

Cervical pathology. Herrington CS. **Curr Opin Obstet Gynecol** 1997 Feb;9(1):57-62 (54 ref.)

Cervical human papillomavirus infection and intraepithelial neoplasia: a review. Mitchell MF, et al. **J Natl Cancer Inst Monogr** 1996;(21):17-25 (84 ref.)

In situ PCR to cells and to wax sections. An alternative to in situ hybridization for the detection of low copies of human papillomavirus and cytomegalovirus DNA. Mougin C, et al. **Methods Mol Biol** 1997;71:77-97 (44 ref.)

Virus infection and cancer risk in transplant recipients. McGregor JM, et al. **Trends Microbiol** 1996 Jan;4(1):2-3 (14 ref.)

[Follow-up of high risk, human papillomavirus (HPV)-positive patients with cancer of the uterine cervix] Hernádi Z, et al. **Orv Hetil** 1997 May 18;138(20):1249-53 (29 ref.) (Eng. Abstr.) **(Hun)**

PAPP-D see **PLACENTAL LACTOGEN**

PAPULOSQUAMOUS DISORDERS see **SKIN DISEASES, PAPULOSQUAMOUS**

PARA-AMINOBENZOIC ACID see **4-AMINOBENZOIC ACID**

PARA-BROMDYLAMINE see **BROMPHENIRAMINE**

PARA-DIHYDROXYBENZENES see **HYDROQUINONES**

PARACENTESIS

Induced tolerance and chimaerism in human fetuses using coelocentesis: a medical opportunity to avert genetic disease? Edwards RG, et al. **Hum Reprod Update** 1995 Jul; 1(4):419-27 (70 ref.)

Management of ascites. Paracentesis as a guide. Habeeb KS, et al. **Postgrad Med** 1997 Jan;101(1):191-2, 195-200 (15 ref.)

PARACETAMOL see **ACETAMINOPHEN**

PARACHUTING see **AVIATION**

PARACOCCIDIOIDES

ISOLATION & PURIFICATION

Paracoccidioidomycosis: case report and review. Manns BJ, et al. **Clin Infect Dis** 1996 Nov;23(5):1026-32 (40 ref.)

PATHOGENICITY

Virulence factors of medically important fungi. Hogan LH, et al. **Clin Microbiol Rev** 1996 Oct;9(4):469-88 (326 ref.)

PARACOCCIDIOIDOMYCOSIS

Paracoccidioidomycosis: case report and review. Manns BJ, et al. **Clin Infect Dis** 1996 Nov;23(5):1026-32 (40 ref.)

DIAGNOSIS

Thoracic intraspinal Paracoccidioidomycosis. Case report. Pacheco RA, et al. **Arq Neuropsiquiatr** 1996 Sep; 54(3):474-8 (10 ref.)

PARACOCCUS DENITRIFICANS

CHEMISTRY

Protein structure: proton-pumping oxidases. Gennis RB, et al. **Curr Biol** 1996 Jan 1;6(1):36-8 (10 ref.)

ENZYMOLOGY

[Structure of cytochrome c oxidase from Paracoccus denitrificans at 2.8A resolution] Iwata S. **Tanpakushitsu Kakusan Koso** 1996 Jul;41(9):1343-52 (14 ref.) **(Jpn)**

METABOLISM

Emerging principles of inorganic nitrogen metabolism in Paracoccus denitrificans and related bacteria. Stouthamer AH, et al. **Antonie Van Leeuwenhoek** 1997 Feb; 71(1-2):33-41 (60 ref.)

PARADENTIUM see **PERIODONTIUM**

PARADOXICAL SLEEP see **SLEEP, REM**

PARAGANGLIOMA

[Bladder paraganglioma. Report of a case and review of the Spanish literature] Chesa Ponce N, et al. **Actas Urol Esp** 1997 Jan;21(1):52-6 (15 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Intrasellar paraganglioma: report of a case in a sibship of von Hippel-Lindau disease. Scheithauer BW, et al. **Neurosurgery** 1996 Feb;38(2):395-9 (26 ref.)

PATHOLOGY

Thyroid paraganglioma: a clinicopathologic and immunohistochemical study of three cases. LaGuette J, et al. **Am J Surg Pathol** 1997 Jul;21(7):748-53 (36 ref.)

Subglottic paraganglioma. Peterson KL, et al. **Head Neck** 1997 Jan;19(1):54-6 (8 ref.)

Nonfunctioning malignant paraganglioma of the posterior mediastinum with spinal cord compression. A case report. Noorda RJ, et al. **Spine** 1996 Jul 15;21(14):1703-9 (61 ref.)

RADIONUCLIDE IMAGING

Malignant paraganglioma of the prostate: case report, depiction by meta-iodobenzylguanidine scintigraphy and review of the literature. Shapiro B, et al. **Q J Nucl Med** 1997 Mar;41(1):36-41 (37 ref.)

RADIOTHERAPY

[Branchial paraganglioma. A case of carotid paraganglioma and review of the literature] Haddad Z, et al. **J Mal Vasc** 1996;21(5):315-9 (23 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Subglottic paraganglioma. Peterson KL, et al. **Head Neck** 1997 Jan;19(1):54-6 (8 ref.)

[Cervical sympathetic paraganglioma] Mickley V, et al. **Chirurg** 1996 Feb;67(2):199-201 (15 ref.) (Eng. Abstr.) **(Ger)**

PARAGANGLIOMA, CAROTID BODY see **CAROTID BODY TUMOR**

PARAGANGLIOMA, EXTRA-ADRENAL

DRUG THERAPY

Combination chemotherapy for malignant paraganglioma. Kimura S, et al. **Intern Med** 1997 Jan;36(1):35-9 (21 ref.)

PATHOLOGY

[Latero-cervical tumors: apropos of a case of paraganglioma of the vagus nerve (letter)] Lefebvre P, et al. **Ann Med Interne (Paris)** 1996;147(6):459-62 (20 ref.) **(Fre)**

PARAGANGLIOMA, GANGLIOCYTIC see **PARAGANGLIOMA**

PARAGANGLIOMA, NONCHROMAFFIN see **PARAGANGLIOMA, EXTRA-ADRENAL**

PARAGONIMIASIS

Pulmonary paragonimiasis. Kagawa FT. **Semin Respir Infect** 1997 Jun;12(2):149-58 (59 ref.)

PARAIMMUNOGLOBULINEMIAS see **PARAPROTEINEMIAS**

PARAINFLUENZA VIRUS 3, BOVINE see **PARAMYXOVIRUS**

PARALLAX, OCULAR see **VISION DISPARITY**

PARALYSIS

Accessory nerve palsy and serratus palsy. Vastamäki M. **Ann Chir Gynaecol** 1996;85(2):167-71 (14 ref.)

[Periodic paralysis, myotonia] Kinoshita M, et al. **Nippon Rinsho** 1996 Mar;54(3):834-8 (12 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Femoral nerve palsy associated with an associated posterior wall transverse acetabular fracture. Hardy SL. **J Orthop Trauma** 1997 Jan;11(1):40-2 (6 ref.)

Neurogenic diplopia: paralysis of cranial nerves III, IV, and VI. Sowka J. **Optom Clin** 1996;5(3-4):53-76 (46 ref.)

DIAGNOSIS

Disseminated mucormycosis presenting with lower extremity weakness. von Pohle WR. **Eur Respir J** 1996 Aug; 9(8):1751-3 (10 ref.)

Hopkins syndrome associated with Mycoplasma infection. Acharya AB, et al. **Pediatr Neurol** 1997 Jan;16(1):54-5 (15 ref.)

[Evaluation of central paralysis] Imamura Y, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:322-6 (11 ref.) **(Jpn)**

ETIOLOGY

Sciatic nerve palsy following childbirth [see comments] Silva M, et al. **Anaesthesia** 1996 Dec;51(12):1144-8 (53 ref.) Comment in: Anaesthesia 1997 Jun;52(6):605-6.

Monoplegia following obstetric epidural anaesthesia. Loo CC, et al. **Ann Acad Med Singapore** 1997 Mar;26(2):232-4 (10 ref.)

Case report: unilateral combined facial nerve and brachial plexus palsies in a neonate following a midlevel forceps delivery. de Chalain TM, et al. **Ann Plast Surg** 1997 Feb; 38(2):187-90 (27 ref.)

Nerve paralysis after surgery in the submandibular triangle: review of University of Tokyo Hospital experience. Ichimura K, et al. **Head Neck** 1997 Jan;19(1):48-53 (19 ref.)

Hypokalaemic thyrotoxic periodic paralysis: case report and review of an Oriental syndrome. van Dam GM, et al. **Neth J Med** 1996 Aug;49(2):90-7 (76 ref.)

Persistent serratus anterior paralysis after fracture of an

PARALYSIS

anterior cervical bone graft. Smith MD, et al. **Orthopedics** 1996 Jul;19(7):611–3 (16 ref.)
Neurologic safety in spinal deformity surgery. Winter RB. **Spine** 1997 Jul 1;22(13):1527–33 (49 ref.)
[Emergencies in neurological patients] Maire P. **Schweiz Rundsch Med Prax** 1997 Feb 18;86(8):286–91 (23 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Autosomal dominant late-onset leukoencephalopathy. Clinical report of a new Italian family. Quattrocolo G, et al. **Eur Neurol** 1997;37(1):53–61 (26 ref.)
Hypokalemic periodic paralysis: an autosomal dominant muscle disorder caused by mutations in a voltage-gated calcium channel. Lapie P, et al. **Neuromuscul Disord** 1997 Jun;7(4):234–40 (68 ref.)
Channelopathies: ion channel disorders of muscle as a paradigm for paroxysmal disorders of the nervous system. Ptáček LJ. **Neuromuscul Disord** 1997 Jun;7(4):250–5 (56 ref.)

METABOLISM

Cellular sodium pumps in hypokalaemic periodic muscle paralysis. Taylor EA, et al. **Clin Sci (Colch)** 1996 Sep; 91(3):261–4 (28 ref.)
Periodic paralysis and voltage-gated ion channels [editorial] Fontaine B, et al. **Kidney Int** 1996 Jan;49(1):9–18 (107 ref.)

PHYSIOPATHOLOGY

Motor control physiology below spinal cord injury: residual volitional control of motor units in paretic and paralyzed muscles. Dimitrijevic MR, et al. **Adv Neurol** 1997;72:335–45 (32 ref.)

REHABILITATION

New control strategies for neuroprosthetic systems. Crago PE, et al. **J Rehabil Res Dev** 1996 Apr;33(2):158–72 (40 ref.)

SURGERY

[Shoulder arthrodesis in deltoid paralysis] Kohn D, et al. **Orthopade** 1997 Jul;26(7):630–3 (21 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[Gastrointestinal tract paralysis in surgery and methods for its treatment] Smirnova VI, et al. **Anesteziol Reanimatol** 1995 Nov–Dec;(6):71–3 (39 ref.) **(Rus)**

VETERINARY

Hyperkalemic periodic paralysis. Naylor JM. **Vet Clin North Am Equine Pract** 1997 Apr;13(1):129–44 (31 ref.)

PARALYSIS AGITANS see **PARKINSON DISEASE**

PARALYSIS, BULBAR

GENETICS

Ponto-bulbar palsy with deafness (Vialetto-Van Laere syndrome). Puri V, et al. **Indian Pediatr** 1996 Feb; 33(2):140–2 (12 ref.)
[X chromosomal bulbospinal neuropathy (X-BSN, Kennedy syndrome): an illness with repetitive triplet sequences. Case report, differential diagnosis and molecular genetics aspects] Abel A, et al. **Nervenarzt** 1996 Dec;67(12):1011–9 (44 ref.) (Eng. Abstr.) **(Ger)**

PARALYSIS, FAMILIAL PERIODIC

CLASSIFICATION

[Periodic palsies and myotonias are ion channel diseases (editorial)] Fontaine B, et al. **Rev Neurol (Paris)** 1996 Oct; 152(10):579–86 (39 ref.) **(Fre)**

COMPLICATIONS

[A case of potassium-sensitive periodic paralysis with cardiac dysrhythmia] Nakamagoe K, et al. **Rinsho Shinkeigaku** 1997 Mar;37(3):239–42 (14 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Ion channel mutations in periodic paralysis and related myotonic diseases. Brown RH Jr. **Ann N Y Acad Sci** 1993 Dec 20;707:305–16 (51 ref.)
Channelopathies: the nondystrophic myotonias and periodic paralyses. Lehmann-Horn F, et al. **Semin Pediatr Neurol** 1996 Jun;3(2):122–39 (114 ref.)

PHYSIOPATHOLOGY

Sodium channel defects in myotonia and periodic paralysis. Cannon SC. **Annu Rev Neurosci** 1996;19:141–64 (78 ref.)

PARALYSIS, GENERAL see **NEUROSYPHILIS**

PARALYSIS, PSEUDOBULBAR see **PARALYSIS**

PARALYTIC ILEUS see **INTESTINAL PSEUDO-OBSTRUCTION**

PARAMAGNETIC RESONANCE see **ELECTRON SPIN RESONANCE SPECTROSCOPY**

PARAMECIUM

GENETICS

Whatever happened to paramecium genetics? Preer JR Jr. **Genetics** 1997 Feb;145(2):217–25 (65 ref.)
Epigenetic regulation of programmed genomic rearrangements in Paramecium aurelia. Meyer E, et al. **J Eukaryot Microbiol** 1996 Nov–Dec;43(6):453–61 (28 ref.)

PARAMEDICAL PERSONNEL see **ALLIED HEALTH PERSONNEL**

PARAMEDICS see **ALLIED HEALTH PERSONNEL**

PARAMEDICS, EMERGENCY see **EMERGENCY MEDICAL TECHNICIANS**

PARAMYOCLONUS MULTIPLEX see **MYOCLONUS**

PARAMYOSIN see **TROPOMYOSIN**

PARAMYXOVIRIDAE

ENZYMOLOGY

Role of cellular kinases in the gene expression of nonsegmented negative strand RNA viruses. De BP, et al. **Biol Chem** 1997 Jun;378(6):489–93 (29 ref.)

GENETICS

Role of cellular kinases in the gene expression of nonsegmented negative strand RNA viruses. De BP, et al. **Biol Chem** 1997 Jun;378(6):489–93 (29 ref.)

PARAMYXOVIRUS

Gene transfer into the glomerulus by the hemagglutinating virus of Japan-liposome method. Imai E, et al. **Exp Nephrol** 1997 Mar–Apr;5(2):112–7 (30 ref.)
[Untold part of my Sendai virus research] Honma M. **Uirusu** 1996 Dec;46(2):179–84 (11 ref.) **(Jpn)**
[Molecular evolution of paramyxoviruses] Ito Y. **Uirusu** 1996 Jun;46(1):35–41 (31 ref.) **(Jpn)**

PATHOGENICITY

Cellular proteases involved in the pathogenicity of human immunodeficiency and influenza viruses. Kido H, et al. **Adv Exp Med Biol** 1996;389:233–40 (24 ref.)

PARAMYXOVIRUS 1, AVIAN see **NEWCASTLE DISEASE VIRUS**

PARANASAL SINUS DISEASES

DIAGNOSIS

Paraorbital lesions. Sanchez R, et al. **Eur J Radiol** 1996 Mar; 22(1):53–67 (30 ref.)
Paranasal sinus disease in patients with cystic fibrosis. Nishioka GJ, et al. **Otolaryngol Clin North Am** 1996 Feb; 29(1):193–205 (37 ref.)
Imaging of paranasal sinus disease. Bangert BA. **Pediatr Clin North Am** 1997 Jun;44(3):681–99 (55 ref.)
Bone marrow transplantation in children. Imaging assessment of complications. Benya EC, et al. **Pediatr Clin North Am** 1997 Jun;44(3):741–61 (30 ref.)
[Modern functional diagnosis of the nose and paranasal sinuses] Deitmer T. **Eur Arch Otorhinolaryngol Suppl** 1996; 1:1–71 (447 ref.) **(Ger)**

ETIOLOGY

Cystic lesions of the nasal cavity and the paranasal sinuses: report of two unusual cases. Vele DD, et al. **J Laryngol Otol** 1996 Dec;110(12):1157–60 (7 ref.)
Bone marrow transplantation in children. Imaging assessment of complications. Benya EC, et al. **Pediatr Clin North Am** 1997 Jun;44(3):741–61 (30 ref.)
[Sinus mucoceles. Apropos of 5 cases] Kpemissi E, et al. **Ann Otolaryngol Chir Cervicofac** 1996;113(3):179–82 (18 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Criteria for the diagnosis of sinus mycetoma. deShazo RD, et al. **J Allergy Clin Immunol** 1997 Apr;99(4):475–85 (29 ref.)

PHYSIOPATHOLOGY

[Applications of modern image data processing in clinico-rhinologic research] Weber R, et al. **Eur Arch Otorhinolaryngol Suppl** 1996;1:271–96 (332 ref.) **(Ger)**

SURGERY

Functional endoscopic sinus surgery. Swift AC. **Br J Hosp Med** 1996 May 1–14;55(9):554–8 (24 ref.)
Pneumosinus dilatans of the maxillary sinus: a report of two cases. Breidahl AF, et al. **Br J Plast Surg** 1997 Jan; 50(1):33–9 (22 ref.)
Laser use in the paranasal sinuses. Rathfoot CJ, et al. **Otolaryngol Clin North Am** 1996 Dec;29(6):943–8 (13 ref.)
[Endonasal surgery of the paranasal sinuses--concepts, techniques, results, complications and revision interventions] Hosemann W. **Eur Arch Otorhinolaryngol Suppl** 1996;1:155–269 (894 ref.) **(Ger)**

PARANASAL SINUS NEOPLASMS

DIAGNOSIS

[Imaging of non-osseous malignant tumors of the anterior skull base. Preoperative evaluation] Elkeslassy A, et al. **Neurochirurgie** 1997;43(2):68–75 (47 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Management of anterior ethmoid and frontal sinus tumors. Catalano PJ, et al. **Otolaryngol Clin North Am** 1995 Dec; 28(6):1157–74 (26 ref.)
Sphenoid and sellar tumors. Isaacs RS, et al. **Otolaryngol Clin North Am** 1995 Dec;28(6):1191–229 (77 ref.)
Management of the eye in the treatment of sinonasal cancers. McCary WS, et al. **Otolaryngol Clin North Am** 1995 Dec; 28(6):1231–8 (27 ref.)
Craniofacial approaches to sinus malignancy. Osguthorpe JD, et al. **Otolaryngol Clin North Am** 1995 Dec;28(6):1239–57 (36 ref.)
Radiation therapy for sinus malignancies. Parsons JT, et al. **Otolaryngol Clin North Am** 1995 Dec;28(6):1259–68 (14 ref.)
Current status and new developments in techniques for imaging the nose and sinuses. Phillips CD. **Otolaryngol Clin North Am** 1997 Jun;30(3):371–87 (66 ref.)

RADIOGRAPHY

Choanal polyp of sphenoidal origin. Report of two cases. Eloy P, et al. **Acta Otorhinolaryngol Belg** 1996;50(3):183–9 (22 ref.)
The radiographic evaluation of sinonasal tumors: an overview. Mosesson RE, et al. **Otolaryngol Clin North Am** 1995 Dec;28(6):1097–115 (37 ref.)
Current status and new developments in techniques for imaging the nose and sinuses. Phillips CD. **Otolaryngol Clin North Am** 1997 Jun;30(3):371–87 (66 ref.)
[Sinus involvement in a patient with human immunodeficiency virus infection] Carratalá C, et al. **Rev Clin Esp** 1997 Jun;197(6):447–8 (9 ref.) **(Spa)**

RADIOTHERAPY

[Role of radiotherapy in the treatment of epitheliomas of the anterior skull base] Housset M, et al. **Neurochirurgie** 1997;43(2):85–7 (15 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

Metastatic follicular thyroid carcinoma to the paranasal sinuses: a case report and review. Altman KW, et al. **J Laryngol Otol** 1997 Jul;111(7):647–51 (22 ref.)

SURGERY

Bilateral sinonasal papillomas in aplastic maxillary sinuses. Tsue TT, et al. **Am J Otolaryngol** 1997 Jul–Aug;18(4):263–8 (36 ref.)
Inverted papilloma of the nose and paranasal sinuses: a study of 56 cases and review of the literature. Raveh E, et al. **Isr J Med Sci** 1996 Dec;32(12):1163–7 (21 ref.)
Fronto-ethmoid osteoma: the place of surgery. Hehar SS, et al. **J Laryngol Otol** 1997 Apr;111(4):372–5 (18 ref.)
Fronto-ethmoidal and orbital osteomas with intracranial extension. Report of two cases. Maiuri F, et al. **J Neurosurg Sci** 1996 Mar;40(1):65–70 (24 ref.)
Management of anterior ethmoid and frontal sinus tumors. Catalano PJ, et al. **Otolaryngol Clin North Am** 1995 Dec; 28(6):1157–74 (26 ref.)
Reconstruction of midfacial and anterior skull-base defects. Hochman M. **Otolaryngol Clin North Am** 1995 Dec; 28(6):1269–77 (13 ref.)
Sphenoid and sellar tumors. Isaacs RS, et al. **Otolaryngol Clin North Am** 1995 Dec;28(6):1191–229 (77 ref.)
Craniofacial approaches to sinus malignancy. Osguthorpe JD, et al. **Otolaryngol Clin North Am** 1995 Dec;28(6):1239–57 (36 ref.)
Radiation therapy for sinus malignancies. Parsons JT, et al. **Otolaryngol Clin North Am** 1995 Dec;28(6):1259–68 (14 ref.)
Endonasal surgery for nasal wall tumors. Rice DH. **Otolaryngol Clin North Am** 1995 Dec;28(6):1117–25 (26 ref.)
[Surgery of primary malignant melanomas of the mucosa of the nasal fossa and facial sinuses] Laccourreye O, et al.

Ann Otolaryngol Chir Cervicofac 1996;113(3):163–9 (30 ref.) (Eng. Abstr.) **(Fre)**

[Trans-facial approaches of cancers of the ethmoid] Brasnu D, et al. **Neurochirurgie** 1997;43(2):88–91 (18 ref.) (Eng. Abstr.) **(Fre)**

[Malignant tumors of the ethmoid region. Neurosurgical techniques] Roux FX, et al. **Neurochirurgie** 1997;43(2):92–9 (28 ref.) (Eng. Abstr.) **(Fre)**

[Endonasal surgery of the paranasal sinuses—concepts, techniques, results, complications and revision interventions] Hosemann W.
Eur Arch Otorhinolaryngol Suppl 1996;1:155–269 (894 ref.) **(Ger)**

PARANASAL SINUSES

ABNORMALITIES

Anatomic variation in pediatric chronic sinusitis: a CT study. Lusk RP, et al. **Otolaryngol Clin North Am** 1996 Feb; 29(1):75–91 (25 ref.)

ANATOMY & HISTOLOGY

Functional anatomy of the paranasal sinuses. Miller AJ, et al. **J La State Med Soc** 1997 Mar;149(3):85–90 (20 ref.)

[Anatomic orientation in paranasal endoscopic surgery] Bernal Sprekelsen M. **Acta Otorrinolaringol Esp** 1996 Sep–Oct;47(5):337–41 (7 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Management of anterior ethmoid and frontal sinus tumors. Catalano PJ, et al. **Otolaryngol Clin North Am** 1995 Dec; 28(6):1157–74 (26 ref.)

Management of the eye in the treatment of sinonasal cancers. McCary WS, et al. **Otolaryngol Clin North Am** 1995 Dec; 28(6):1231–8 (27 ref.)

Craniofacial approaches to sinus malignancy. Osguthorpe JD, et al. **Otolaryngol Clin North Am** 1995 Dec;28(6):1239–57 (36 ref.)

Radiation therapy for sinus malignancies. Parsons JT, et al. **Otolaryngol Clin North Am** 1995 Dec;28(6):1259–68 (14 ref.)

Current status and new developments in techniques for imaging the nose and sinuses. Phillips CD.
Otolaryngol Clin North Am 1997 Jun;30(3):371–87 (66 ref.)

RADIOGRAPHY

Nasal and paranasal sinus imaging. Benson ML, et al.
J Belge Radiol 1997 Apr;80(2):89–91 (19 ref.)

The radiographic evaluation of sinonasal tumors: an overview. Mosesson RE, et al.
Otolaryngol Clin North Am 1995 Dec;28(6):1097–115 (37 ref.)

Current status and new developments in techniques for imaging the nose and sinuses. Phillips CD.
Otolaryngol Clin North Am 1997 Jun;30(3):371–87 (66 ref.)

SECRETION

Radiation therapy for sinus malignancies. Parsons JT, et al. **Otolaryngol Clin North Am** 1995 Dec;28(6):1259–68 (14 ref.)

SURGERY

Complications and medicolegal aspects of endoscopic sinus surgery. Lund VJ, et al. **J R Soc Med** 1997 Aug;90(8):422–8 (41 ref.)

Computer-assisted endoscopic sinus surgery. An international review. Anon JB, et al.
Otolaryngol Clin North Am 1997 Jun;30(3):389–401 (23 ref.)

Management of anterior ethmoid and frontal sinus tumors. Catalano PJ, et al. **Otolaryngol Clin North Am** 1995 Dec; 28(6):1157–74 (26 ref.)

Reconstruction of midfacial and anterior skull-base defects. Hochman M. **Otolaryngol Clin North Am** 1995 Dec; 28(6):1269–77 (13 ref.)

Craniofacial approaches to sinus malignancy. Osguthorpe JD, et al. **Otolaryngol Clin North Am** 1995 Dec;28(6):1239–57 (36 ref.)

Endonasal surgery for nasal wall tumors. Rice DH.
Otolaryngol Clin North Am 1995 Dec;28(6):1117–25 (26 ref.)

[The role of endoscopic surgery in the treatment of chronic inflammation of paranasal sinuses] Krzeski A, et al.
Otolaryngol Pol 1996;50(1):37–45 (15 ref.) (Eng. Abstr.) **(Pol)**

[Anatomic orientation in paranasal endoscopic surgery] Bernal Sprekelsen M. **Acta Otorrinolaringol Esp** 1996 Sep-Oct;47(5):337–41 (7 ref.) (Eng. Abstr.) **(Spa)**

PARANEOPLASTIC SYNDROMES

Autoimmune central nervous system paraneoplastic disorders: mechanisms, diagnosis, and therapeutic options. Dropcho EJ. **Ann Neurol** 1995 May;37 Suppl 1:S102–13 (141 ref.)

Paraneoplastic primary lateral sclerosis and amyotrophic lateral sclerosis [comment] Rowland LP. **Ann Neurol** 1997 Jun;41(6):703–5 (32 ref.) Comment on: Ann Neurol 1997 Jun;41(6):722–30.

Paraneoplastic nervous system syndromes. Jaeckle KA.
Curr Opin Oncol 1996 May;8(3):204–8 (39 ref.)

Paraneoplastic neurologic syndromes. Hinton RC.
Hematol Oncol Clin North Am 1996 Aug;10(4):909–25 (97 ref.)

Endocrinopathy and ectopic hormones in malignancy. Keffer JH. **Hematol Oncol Clin North Am** 1996 Aug;10(4):811–23 (52 ref.)

Paraneoplastic neurologic syndromes. Hirose G.
Intern Med 1996 Dec;35(12):925–9 (24 ref.)

Idiopathic hypothalamic dysfunction: a paraneoplastic syndrome? Nunn K, et al. **J Child Neurol** 1997 Jun; 12(4):276–81 (27 ref.)

Mucocutaneous paraneoplastic syndromes. Cohen PR, et al. **Semin Oncol** 1997 Jun;24(3):334–59 (87 ref.)

Paraneoplastic syndromes affecting the nervous system. Dalmau JO, et al. **Semin Oncol** 1997 Jun;24(3):318–28 (67 ref.)

Paraneoplastic syndromes of the kidney. Maesaka JK, et al. **Semin Oncol** 1997 Jun;24(3):373–81 (81 ref.)

Endocrine/metabolic syndromes of cancer. Odell WD.
Semin Oncol 1997 Jun;24(3):299–317 (186 ref.)

Hematological paraneoplastic syndromes. Staszewski H.
Semin Oncol 1997 Jun;24(3):329–33 (23 ref.)

[Pseudo-Still disease and deep neoplasm] Routier G, et al. **Rev Med Interne** 1997;18(1):47–9 (4 ref.) (Eng. Abstr.) **(Fre)**

[Cancer-associated retinopathy] Ohguro H, et al.
Nippon Ganka Gakkai Zasshi 1997 Apr;101(4):283–7 (45 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Carcinoma and the peripheral nervous system. Hughes R, et al. **J Neurol** 1996 May;243(5):371–6 (32 ref.)

Neurological paraneoplastic syndromes. Dalmau J, et al.
Springer Semin Immunopathol 1995;18(1):85–95 (41 ref.)

[Hematological paraneoplasias in breast cancer] Kozlov DV, et al. **Klin Med (Mosk)** 1997;75(1):14–6 (41 ref.) **(Rus)**

DIAGNOSIS

Paraneoplastic syndromes affecting the central nervous system. Posner JB, et al. **Annu Rev Med** 1997;48:157–66 (35 ref.)

Paraneoplastic ophthalmological syndromes. Constantinescu A. **Oftalmologia** 1996 Jul–Sep;40(3):214–8 (7 ref.)

Paraneoplastic manifestations of renal cell carcinoma. Gold PJ, et al. **Semin Urol Oncol** 1996 Nov;14(4):216–22 (46 ref.)

[Immunological diagnosis of paraneoplastic neurologic syndromes] Carpentier AF, et al. **Presse Med** 1996 Nov 30;25(37):1835–8 (9 ref.) (Eng. Abstr.) **(Fre)**

[Erythema elevatum diutinum. A rare dermatosis with a broad spectrum of associated illnesses] Gerbig AW, et al. **Hautarzt** 1997 Feb;48(2):113–7 (25 ref.) (Eng. Abstr.) **(Ger)**

[The clinical pictures of rheumatological involvement in neoplasms] Dipasquale G. **Riv Med Aeronaut Spaz** 1975 Oct–Dec;38(4):547–60 (27 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Paraneoplastic cerebellar degeneration. Case report and literature review. Bolla L, et al. **Arch Intern Med** 1997 Jun 9;157(11):1258–62 (33 ref.)

Paraneoplastic syndromes associated with small cell lung cancer. Marchioli CC, et al. **Chest Surg Clin N Am** 1997 Feb;7(1):65–80 (99 ref.)

Paraneoplastic subacute cutaneous lupus erythematosus: report of a case associated with cancer of the lung. Brenner S, et al. **Dermatology** 1997;194(2):172–4 (12 ref.)

Paraneoplastic syndromes of gynecologic neoplasms. Ashour AA, et al. **J Clin Oncol** 1997 Mar;15(3):1272–82 (138 ref.)

Paraneoplastic neuromuscular syndromes. Levin KH.
Neurol Clin 1997 Aug;15(3):597–614 (94 ref.)

Hodgkin's disease associated with neurologic paraneoplastic syndrome. Vickers SM, et al. **South Med J** 1997 Aug; 90(8):839–44 (39 ref.)

Neurological paraneoplastic syndromes. Dalmau J, et al.
Springer Semin Immunopathol 1996;18(1):85–95 (41 ref.)

[Mucocele of the appendix with pseudomyxoma peritonei—a rare cause of a paraneoplastic syndrome] Pollack T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Mar;166(3):266–8 (13 ref.) **(Ger)**

[Malignant hypercalcemia with and without bone metastasis] Millán Núñez-Cortés J, et al. **Rev Clin Esp** 1996 Jun; 196(6):388–91 (14 ref.) **(Spa)**

IMMUNOLOGY

Cancer-induced retinal hypersensitivity. Thirkill CE.
Br J Biomed Sci 1996 Sep;53(3):227–34 (110 ref.)

The immunopharmacology of the opsoclonus-myoclonus syndrome. Pranzatelli MR. **Clin Neuropharmacol** 1996 Feb; 19(1):1–47 (285 ref.)

Autoimmunity to ion-channels and other proteins in paraneoplastic disorders. Lang B, et al.
Curr Opin Immunol 1996 Dec;8(6):865–71 (55 ref.)

Autoantibody-associated sensory neuronopathy and intestinal pseudo-obstruction without detectable neoplasia. Briellmann RS, et al. **Eur Neurol** 1996;36(6):369–73 (26 ref.)

Immunologic dysfunction in cancer. Kavanaugh DY, et al. **Hematol Oncol Clin North Am** 1996 Aug;10(4):927–51 (234 ref.)

Paraneoplastic encephalomyelitis: an update of the effects of the anti-Hu immune response on the nervous system and tumour [editorial] Voltz RD, et al.
J Neurol Neurosurg Psychiatry 1997 Aug;63(2):133–6 (49 ref.)

Autoimmune phenomena in patients with myelodysplastic syndromes. Enright H, et al. **Leuk Lymphoma** 1997 Feb; 24(5–6):483–9 (33 ref.)

PATHOLOGY

Paraneoplastic pemphigus. Anhalt GJ. **Adv Dermatol** 1997; 12:77–96; discussion 97 (49 ref.)

Undifferentiated carcinoma of the nasopharynx and leukemoid reaction: report of case with literature review. Saussez S, et al. **J Laryngol Otol** 1997 Jan;111(1):66–9 (12 ref.)

[Reactive angioendotheliomatosis in chronic lymphatic leukemia] Schmidt K, et al. **Hautarzt** 1996 Jul;47(7):550–5 (33 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Cachexia and anorexia in malignancy. Albrecht JT, et al. **Hematol Oncol Clin North Am** 1996 Aug;10(4):791–800 (87 ref.)

Hypercalcemia and electrolyte disturbances in malignancy. Barri YM, et al. **Hematol Oncol Clin North Am** 1996 Aug; 10(4):775–90 (111 ref.)

Paraneoplastic syndromes: mechanisms. Hall TC.
Semin Oncol 1997 Jun;24(3):269–76 (30 ref.)

THERAPY

Management of painful paraneoplastic syndromes. Brady AM. **Hematol Oncol Clin North Am** 1996 Aug;10(4):801–9 (58 ref.)

PARANOID DISORDER, SHARED see **SHARED PARANOID DISORDER**

PARAPARESIS, TROPICAL SPASTIC

HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP): a chronic progressive neurologic disease associated with immunologically mediated damage to the central nervous system. Levin MC, et al. **J Neurovirol** 1997 Apr;3(2):126–40 (97 ref.)

[Important nervous system infections—human T-lymphotrophic virus type I-associated myelopathy/tropical spastic paraparesis] Izichi S, et al.
Nippon Naika Gakkai Zasshi 1996 May 10;85(5):716–9 (5 ref.) **(Jpn)**

[Multiple sclerosis viewed from the point of HTLV-I associated myelopathy] Osame M, et al.
Rinsho Shinkeigaku 1995 Dec;35(12):1498–500 (8 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Tropical spastic paraparesis/HTLV-I-associated myelopathy in Brazil. Araújo A de Q, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996;13 Suppl 1:S33–7 (39 ref.)

Tropical spastic paraparesis/HTLV-I-associated myelopathy in Europe and in Africa: clinical and epidemiologic aspects. Touzé E, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996;13 Suppl 1:S38–45 (71 ref.)

HTLV-I associated myelopathy (HAM): review and recent studies. Osame M, et al. **Leukemia** 1997 Apr;11 Suppl 3:63–4 (17 ref.)

ETIOLOGY

HAM/TSP: recent perspectives in Japan. Ijichi S, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996;13 Suppl 1:S26–32 (61 ref.)

[Isolated spastic paraparesis disclosing Krabbe disease in adult age] Bataillard M, et al. **Rev Neurol (Paris)** 1997 Jun; 153(5):347–50 (20 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

HTLV-I associated myelopathy: a case of viral-induced auto-immunity. Oger J, et al. **Autoimmunity** 1995; 21(3):151–9 (83 ref.)

An HTLV-I/II vaccine: from animal models to clinical trials? de Thé G, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996;13 Suppl 1:S191–8 (48 ref.)

Cellular immune responses to HTLV-I: immunopathogenic role in HTLV-I-associated neurologic disease. Jacobson S. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S100–6 (46 ref.)

PHYSIOPATHOLOGY

Cytokines secreted by glial cells infected with HTLV-I modulate the expression of matrix metalloproteinases (MMPs) and their natural inhibitor (TIMPs): possible involvement in neurodegenerative processes. Giraudon P, et al. **Mol Psychiatry** 1997 Mar;2(2):107–10, 84 (23 ref.)

[Physiopathology and therapy of HTLV-I-associated myelopathy] Kira J. **Fukuoka Igaku Zasshi** 1996 Jan; 87(1):1–7 (3 ref.) **(Jpn)**

[Neurophysiological studies of minamata disease with

HTLV-I associated myelopathy--a case report] Nakanishi R, et al. **Rinsho Shinkeigaku** 1996 Sep;36(9):1060-4 (12 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Vaccine against human T cell leukemia-lymphoma virus type I: progress and prospects. Bomford R, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):403-5 (34 ref.)

THERAPY

The promiscuous IL-2/IL-15 receptor: a target for immunotherapy of HTLV-I-associated disorders. Waldmann TA. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S179-85 (43 ref.)

[Physiopathology and therapy of HTLV-I-associated myelopathy] Kira J. **Fukuoka Igaku Zasshi** 1996 Jan; 87(1):1-7 (3 ref.) **(Jpn)**

VIROLOGY

Pathogenesis of chronic progressive myelopathy associated with human T-cell lymphotropic virus type I. Höllsberg P. **Acta Neurol Scand Suppl** 1997;169:86-93 (62 ref.)

HTLV-I associated myelopathy: a case of viral-induced auto-immunity. Oger J, et al. **Autoimmunity** 1995; 21(3):151-9 (83 ref.)

Virological aspects of tropical spastic paraparesis/HTLV-I associated myelopathy and HTLV-I infection [see comments] Gessain A. **J Neurovirol** 1996 Oct;2(5):299-306 (80 ref.) Comment in: J Neurovirol 1996 Oct;2(5):297-8.

HAM/TSP and ATL: persistent paradoxes and new hypotheses. Xu X, et al. **J Neurovirol** 1996 Apr;2(2):60-9 (120 ref.)

[HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP)] Ijichi S, et al. **Nippon Rinsho** 1997 Apr; 55(4):926-33 (42 ref.) (Eng. Abstr.) **(Jpn)**

PARAPHILIAS

see related
SEX OFFENSES

Understanding human sexuality--specifically homosexuality and the paraphilias--in terms of chaos theory and fetal development. Goodman RE. **Med Hypotheses** 1997 Mar; 48(3):237-43 (68 ref.)

DIAGNOSIS

Scientific status of the concept of continuing emotional propensity for sexually aberrant acts. Lanyon RI. **J Am Acad Psychiatry Law** 1997;25(1):59-67 (36 ref.)

PARAPLEGIA

COMPLICATIONS

Electrodiagnostic study of carpal tunnel syndrome in wheelchair basketball players. Jackson DL, et al. **Clin J Sport Med** 1996 Jan;6(1):27-31 (21 ref.)

Major risk factors for pressure ulcers in the spinal cord disabled: a literature review. Byrne DW, et al. **Spinal Cord** 1996 May;34(5):255-63 (190 ref.)

ETIOLOGY

Paraplegia complicating intraaortic balloon pumping [letter] Hurlé A, et al. **Ann Thorac Surg** 1997 Apr;63(4):1217-8 (5 ref.)

A rare intrahepatic portacaval tubular shunt in a patient with spastic paraparesis. Ardic S, et al. **Australas Radiol** 1997 May;41(2):181-4 (17 ref.)

Neurological complications in segmental spinal instrumentation: analysis of 750 patients. Cervellati S, et al. **Eur Spine J** 1996;5(3):161-6 (25 ref.)

Primary osteosarcoma of the L2 lamina presenting as "silent" paraplegia: case report and review of the literature. Korovessis P, et al. **Eur Spine J** 1995;4(6):375-8 (18 ref.)

[Paraplegia following coeliac plexus block by anterior approach under direct vision] Kinoshita H, et al. **Masui** 1996 Oct;45(10):1244-6 (8 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Pure hereditary spastic paraplegia. Reid E. **J Med Genet** 1997 Jun;34(6):499-503 (52 ref.)

PHYSIOPATHOLOGY

Paraplegic locomotion: a review. Nene AV, et al. **Spinal Cord** 1996 Sep;34(9):507-24 (106 ref.)

REHABILITATION

FES standing: control by handle reactions of leg muscle stimulation (CHRELMS). Donaldson N de N, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):280-4 (12 ref.)

Transcutaneous functional neuromuscular stimulation of certain traumatic complete thoracic paraplegics for independent short-distance ambulation. Graupe D, et al. **Neurol Res** 1997 Jun;19(3):323-33 (16 ref.)

PARAPLEGIA, SPASTIC see **PARAPLEGIA**

PARAPLEGIA, SPASTIC, HEREDITARY see **SPASTIC PARAPLEGIA, HEREDITARY**

PARAPROTEINEMIAS

Plasma cell dyscrasias. Nishimoto N, et al. **Adv Immunol** 1997; 64:219-81 (296 ref.)

[Abnormality of immunoglobulin (hyperimmunoglobulinemia E syndrome)] Sugiyama H. **Ryoikibetsu Shokogun Shirizu** 1996;(15):155-7 (6 ref.) **(Jpn)**

CHEMICALLY INDUCED

When should the clinician suspect a drug-induced blood dyscrasia, and how should he proceed? Heimpel H. **Eur J Haematol Suppl** 1996;60:11-5 (35 ref.)

Pharmacogenetics and blood dyscrasias. Spielberg SP. **Eur J Haematol Suppl** 1996;60:93-7 (41 ref.)

COMPLICATIONS

Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. Latov N. **Ann Neurol** 1995 May;37 Suppl 1:S32-42 (157 ref.)

Schnitzler's syndrome: report of a new case and a review of the literature. Puddu P, et al. **Clin Exp Rheumatol** 1997 Jan-Feb;15(1):91-5 (32 ref.)

Gammopathy-related crystal-storing histiocytosis, pseudo- and pseudo-pseudo-Gaucher cells. Critical commentary and mini-review [comment] Schaefer HE. **Pathol Res Pract** 1996 Nov;192(11):1152-62 (95 ref.) Comment on: Pathol Res Pract 1996 Nov;192(11):1148-51.

[Triclonal gammopathy and malignant immunoproliferative syndrome] Grosbois B, et al. **Rev Med Interne** 1997; 18(6):470-3 (25 ref.) (Eng. Abstr.) **(Fre)**

[Peripheral neuropathies associated with IgM monoclonal gammopathy: clinical and electrophysiological aspects] Léger JM, et al. **Rev Neurol (Paris)** 1996 May;152(5):394-9 (37 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Toward understanding the molecular pathogenesis of monoclonal immunoglobulin light-chain deposition [editorial] Bellotti V, et al. **Nephrol Dial Transplant** 1996 Sep;11(9):1708-11 (18 ref.)

Paraproteins and complement depletion: pathogenesis and clinical syndromes. Pascual M, et al. **Semin Hematol** 1997 Jan;34(1 Suppl 1):40-8 (75 ref.)

IMMUNOLOGY

Immune mechanisms leading to drug-induced blood dyscrasias. Claas FH. **Eur J Haematol Suppl** 1996;60:64-8 (23 ref.)

IgE lambda monoclonal gammopathy and amyloidosis. Jako JM, et al. **Int Arch Allergy Immunol** 1997 Apr;112(4):415-21 (49 ref.)

Idiotype-specific T cells in multiple myeloma: targets for an immunotherapeutic intervention? Yi Q, et al. **Med Oncol** 1996 Mar;13(1):1-7 (70 ref.)

PATHOLOGY

Monoclonal corneal gammopathy: topographic considerations. Sekundo W, et al. **Ger J Ophthalmol** 1996 Sep;5(5):262-7 (29 ref.)

Morphological changes at paranodes in IgM paraproteinaemic neuropathy. Jacobs JM. **Microsc Res Tech** 1996 Aug 15;34(6):544-53 (59 ref.)

New insights in the clinical biology of multiple myeloma. Bataille R. **Semin Hematol** 1997 Jan;34(1 Suppl 1):23-8 (48 ref.)

PHYSIOPATHOLOGY

Monoclonal gammopathy of undetermined significance and solitary plasmacytoma. Implications for progression to overt multiple myeloma. Kyle RA. **Hematol Oncol Clin North Am** 1997 Feb;11(1):71-87 (54 ref.)

THERAPY

Biology and therapy of immunoglobulin deposition diseases. Dhodapkar MV, et al. **Hematol Oncol Clin North Am** 1997 Feb;11(1):89-110 (109 ref.)

[Treatment of peripheral neuropathies associated with IgM anti-myelin monoclonal gammopathy] Mariette X, et al. **Rev Neurol (Paris)** 1996 May;152(5):413-6 (23 ref.) (Eng. Abstr.) **(Fre)**

PARAPSYCHOLOGY

Hauntings and poltergeist-like episodes as a confluence of conventional phenomena: a general hypothesis. Houran J, et al. **Percept Mot Skills** 1996 Dec;83(3 Pt 2):1307-16 (80 ref.)

PARAQUAT

POISONING

Homicidal poisoning by paraquat. Stephens BG, et al. **Am J Forensic Med Pathol** 1997 Mar;18(1):33-9 (3 ref.)

PARASITE-HOST RELATIONS see **HOST-PARASITE RELATIONS**

PARASITES

see related
ANTHELMINTICS
ANTI-INFECTIVE AGENTS
ANTIPROTOZOAL AGENTS
FOOD PARASITOLOGY
HOST-PARASITE RELATIONS

Parasites as host [corrected] evolutionary prints: insights into host evolution from parasitological data [published erratum appears in Int J Parasitol 1996 Oct;26(10):1137] Thomas F, et al. **Int J Parasitol** 1996 Jul;26(7):677-86 (59 ref.)

CLASSIFICATION

Molecular genetic approaches to parasite identification: their value in diagnostic parasitology and systematics. McManus DP, et al. **Int J Parasitol** 1996 Jul;26(7):687-704 (151 ref.)

How many parasite species are there: are we close to answers? Poulin R. **Int J Parasitol** 1996 Oct;26(10):1127-9 (7 ref.)

DRUG EFFECTS

The mechanisms of action of antiprotozoal and anthelmintic drugs in man. Frayha GJ, et al. **Gen Pharmacol** 1997 Feb; 28(2):273-99 (132 ref.)

[Development of resistance to antiparasitic agents in parasites pathogenic to animals] Daugschies A. **DTW Dtsch Tierarztl Wochenschr** 1996 Jul;103(7):260-3 (52 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Fitness of parasites: pathology and selection. Combes C. **Int J Parasitol** 1997 Jan;27(1):1-10 (45 ref.)

Finding genetic markers for complex phenotypic traits in parasites. Lymbery AJ. **Int J Parasitol** 1996 Jan;26(1):7-17 (70 ref.)

GROWTH & DEVELOPMENT

The evolution of life history strategies in parasitic animals. Poulin R. **Adv Parasitol** 1996;37:107-34 (109 ref.)

ISOLATION & PURIFICATION

Application of molecular biology in veterinary parasitology. Prichard R. **Vet Parasitol** 1997 Jul 31;71(2-3):155-75 (102 ref.)

PARASITOLOGY

Hijacking the cell: parasites in the driver's seat. Beverley SM. **Cell** 1996 Nov 29;87(5):787-9 (17 ref.)

PATHOGENICITY

Fitness of parasites: pathology and selection. Combes C. **Int J Parasitol** 1997 Jan;27(1):1-10 (45 ref.)

Models of parasite virulence. Frank SA. **Q Rev Biol** 1996 Mar;71(1):37-78 (105 ref.)

Virulence and transmissibility of pathogens: what is the relationship? Lipsitch M, et al. **Trends Microbiol** 1997 Jan; 5(1):31-7 (69 ref.)

PHYSIOLOGY

Glycoconjugate cross-talk in metastatic cancer cells, leucocytes, parasites and bacteria. Leroy A, et al. **Biochem Soc Trans** 1997 Feb;25(1):228-34 (48 ref.)

[Stability of epidemic process in context of biological system] Savilov ED. **Vestn Ross Akad Med Nauk** 1997;(8):29-32 (24 ref.) (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

The cytoskeleton of protozoan parasites. Tilney LG, et al. **Curr Opin Cell Biol** 1996 Feb;8(1):43-8 (25 ref.)

PARASITIC DISEASES

SCID mice and the study of parasitic disease. Seydel KB, et al. **Clin Microbiol Rev** 1996 Apr;9(2):126-34 (98 ref.)

Infectious causes of acute pancreatitis. Parenti DM, et al. **Pancreas** 1996 Nov;13(4):356-71 (238 ref.)

[Parasitic infections in AIDS] Rogowska-Szadkowska D. **Wiad Parazytol** 1996;42(2):145-57 (40 ref.) (Eng. Abstr.) **(Pol)**

COMPLICATIONS

Infections in solid-organ transplant recipients. Patel R, et al. **Clin Microbiol Rev** 1997 Jan;10(1):86-124 (800 ref.)

Rheumatic manifestations of tropical diseases. Adebajo AO. **Curr Opin Rheumatol** 1996 Jan;8(1):85-9 (30 ref.)

DIAGNOSIS

Molecular diagnosis of microbial infections. Blum HE. **Biologicals** 1996 Sep;24(3):193-5 (10 ref.)

[Molecular diagnosis of infectious and parasitic diseases] Said-Fernández S, et al. **Gac Med Mex** 1996 May-Jun;

132(3):295–318 (135 ref.) **(Spa)**

DRUG THERAPY

Chemotherapy of parasitic diseases. Current status and new directions. Liu Y. **Chin Med J (Engl)** 1996 Aug; 109(8):579–82 (28 ref.)

The mechanisms of action of antiprotozoal and anthelmintic drugs in man. Frayha GJ, et al. **Gen Pharmacol** 1997 Feb; 28(2):273–99 (132 ref.)

ENZYMOLOGY

Nongenetic variation, genetic-environmental interactions and altered gene expression. II. Disease, parasite and pollution effects. Poly WJ.
Comp Biochem Physiol B Biochem Mol Biol 1997 May; 117(1):61–74 (202 ref.)

EPIDEMIOLOGY

Finding genetic markers for complex phenotypic traits in parasites. Lymbery AJ. **Int J Parasitol** 1996 Jan;26(1):7–17 (70 ref.)

[Stability of epidemic process in context of biological system] Savilov ED. **Vestn Ross Akad Med Nauk** 1997;(8):29–32 (24 ref.) (Eng. Abstr.) **(Rus)**

ETIOLOGY

Nitric oxide and parasitic disease. Clark IA, et al.
Adv Parasitol 1996;37:1–56 (368 ref.)

Sex differences in parasite infections: patterns and processes. Zuk M, et al. **Int J Parasitol** 1996 Oct;26(10):1009–23 (133 ref.)

GENETICS

Immunology and genetics of zoonotic infections involving parasites. Wakelin D.
Comp Immunol Microbiol Infect Dis 1996 Sep;19(4):255–65 (41 ref.)

IMMUNOLOGY

Initiation and regulation of CD4+ T-cell function in host-parasite models. Jankovic D, et al. **Chem Immunol** 1996;63:51–65 (67 ref.)

Immunology and genetics of zoonotic infections involving parasites. Wakelin D.
Comp Immunol Microbiol Infect Dis 1996 Sep;19(4):255–65 (41 ref.)

TNF-alpha and genetic susceptibility to parasitic disease. Goldfeld AE, et al. **Exp Parasitol** 1996 Nov;84(2):300–3 (17 ref.)

Zoonoses: a personal perspective on the Jennerian principle of cross-protective immunity. Nelson GS.
J Med Microbiol 1997 Jan;46(1):6–11, 28–33 (228 ref.)

METABOLISM

Role of oxidants in microbial pathophysiology. Miller RA, et al. **Clin Microbiol Rev** 1997 Jan;10(1):1–18 (334 ref.)

PARASITOLOGY

Regulation of host cell function by glycosylphosphatidylinositols of the parasitic protozoa. Schofield L, et al. **Immunol Cell Biol** 1996 Dec;74(6):555–63 (103 ref.)

PHYSIOPATHOLOGY

Fitness of parasites: pathology and selection. Combes C.
Int J Parasitol 1997 Jan;27(1):1–10 (45 ref.)

Parasitic effects on host life-history traits: a review of recent studies. Michalakis Y, et al. **Parasite** 1994 Dec;1(4):291–4 (20 ref.)

PREVENTION & CONTROL

Prospects for integration of novel parasite control options into grazing systems. Barger IA. **Int J Parasitol** 1996 Aug-Sep;26(8–9):1001–7 (23 ref.)

Antigen delivery strategies for mucosal vaccines. Husband AJ, et al. **Int J Parasitol** 1996 Aug-Sep;26(8–9):825–34 (86 ref.)

Occupational health issues in the pharmaceutical research and development process. Klees JE, et al. **Occup Med** 1997 Jan-Mar;12(1):5–27 (155 ref.)

Progress toward the development of vaccines against parasitic diseases: a review based on studies performed by participants of the Laveran seminar. Liance M. **Parasite** 1994 Sep;1(3):197–203 (38 ref.)

Integrated control of tropical animal parasitoses. Uilenberg G. **Trop Anim Health Prod** 1996 Nov;28(4):257–65 (17 ref.)

[Prevention of parasitic infections (excluding toxoplasmosis) in immunocompromised patients] Hennequin C.
Ann Med Interne (Paris) 1997;148(3):240–5 (44 ref.) (Eng. Abstr.) **(Fre)**

[Prevention of opportunistic infections in HIV seropositive patients. Prevention of parasitic infections] Casassus P, et al. **Presse Med** 1997 Mar 8;26(7):334–9 (55 ref.) (Eng. Abstr.) **(Fre)**

[Integrated control of tropical parasitic diseases in animals] Uilenberg G. **Rev Elev Med Vet Pays Trop** 1996;49(2):124–9 (17 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Incidence of Armillifer armillatus (pentastome) calcification in the abdomen. Nzeh DA, et al. **Cent Afr J Med** 1996 Jan;42(1):29–31 (08 ref.)

TRANSMISSION

Virulence and transmissibility of pathogens: what is the relationship? Lipsitch M, et al. **Trends Microbiol** 1997 Jan; 5(1):31–7 (69 ref.)

Irradiation as a cold pasteurization process of food [published erratum appears in Vet Parasitol 1997 Jul 15;71(1):65] Loaharanu P. **Vet Parasitol** 1996 Aug;64(1–2):71–82 (56 ref.)

Marine parasitology with special reference to Japanese fisheries and mariculture. Ogawa K. **Vet Parasitol** 1996 Aug;64(1–2):95–105 (36 ref.)

VETERINARY

Immunization against parasitic diseases of fish. Woo PT.
Dev Biol Stand 1997;90:233–41 (62 ref.)

Some relationships between age, immune responsiveness and resistance to parasites in ruminants. Colditz IG, et al.
Int J Parasitol 1996 Aug-Sep;26(8–9):869–77 (30 ref.)

How many parasite species are there: are we close to answers? Poulin R. **Int J Parasitol** 1996 Oct;26(10):1127–9 (7 ref.)

Husbandry and diseases of camelids. Fowler ME.
Rev Sci Tech 1996 Mar;15(1):155–69 (18 ref.)

Infectious and parasitic disease of captive reptiles and amphibians, with special emphasis on husbandry practices which prevent or promote diseases. Ippen R, et al.
Rev Sci Tech 1996 Mar;15(1):43–54 (1 ref.)

Dealing with infectious and parasitic diseases in safari parks, roadside menageries, exotic animal auctions and rehabilitation centres. Porter SL. **Rev Sci Tech** 1996 Mar; 15(1):227–36 (20 ref.)

Special challenges of maintaining wild animals in captivity in Australia and New Zealand: prevention of infectious and parasitic diseases. Schultz DJ, et al. **Rev Sci Tech** 1996 Mar;15(1):289–308 (53 ref.)

Husbandry practices as related to infectious and parasitic diseases of farmed ratites. Tully TN, et al.
Rev Sci Tech 1996 Mar;15(1):73–89 (33 ref.)

Infectious and parasitic diseases of captive carnivores, with special emphasis on the black-footed ferret (Mustela nigripes). Williams ES, et al. **Rev Sci Tech** 1996 Mar; 15(1):91–114 (154 ref.)

Integrated control of tropical animal parasitoses. Uilenberg G. **Trop Anim Health Prod** 1996 Nov;28(4):257–65 (17 ref.)

Recent advances in the laboratory diagnosis of equine parasitic diseases. Granstrom DE.
Vet Clin North Am Equine Pract 1995 Dec;11(3):437–42 (22 ref.)

Detection of animal pathogens by using the polymerase chain reaction (PCR). Rodriguez JM. **Vet J** 1997 May; 153(3):287–305 (232 ref.)

Vaccination against worm parasites of animals. Emery DL. **Vet Parasitol** 1996 Aug;64(1–2):31–45 (93 ref.)

Wildlife parasites: lessons for parasite control in livestock. Malan FS, et al. **Vet Parasitol** 1997 Jul 31;71(2–3):137–53 (69 ref.)

Communications: technology transfer in the developed world. Murrell KD. **Vet Parasitol** 1996 Aug;64(1–2):107–20 (19 ref.)

Marine parasitology with special reference to Japanese fisheries and mariculture. Ogawa K. **Vet Parasitol** 1996 Aug;64(1–2):95–105 (36 ref.)

Sense or nonsense? Traditional methods of animal parasitic disease control. Schillhorn van Veen TW. **Vet Parasitol** 1997 Jul 31;71(2–3):177–94 (61 ref.)

The effect of parasites on wildlife. Borgsteede FH.
Vet Q 1996;18 Suppl 3:S138–40 (18 ref.)

Diseases of freshwater fish. Haenen OL. **Vet Q** 1996;18 Suppl 3:S132–3 (24 ref.)

Using molecular tools for diagnosis in veterinary parasitology. Comes AM, et al. **Vet Res** 1996; 27(4–5):333–42 (52 ref.)

[Integrated control of tropical parasitic diseases in animals] Uilenberg G. **Rev Elev Med Vet Pays Trop** 1996;49(2):124–9 (17 ref.) (Eng. Abstr.) **(Fre)**

[Parasite control and its effect on the environment] Liebisch A. **DTW Dtsch Tierarztl Wochenschr** 1996 Jul; 103(7):268–73 (20 ref.) (Eng. Abstr.) **(Ger)**

["Arbitrarily primed PCR". Or: chance in the service of science] Felleisen R, et al. **Schweiz Arch Tierheilkd** 1996; 138(3):139–43 (14 ref.) (Eng. Abstr.) **(Ger)**

[Vaccines against parasitic diseases of domestic animals] Eckert J, et al. **Tierarztl Prax** 1996 Aug;24(4):322–9 (50 ref.) (Eng. Abstr.) **(Ger)**

[Parasitic infections and herd fertility. An overview] Ilchmann G, et al. **Tierarztl Prax** 1997 Apr;25(2):130–2 (17 ref.) (Eng. Abstr.) **(Ger)**

PARASITIC EYE INFECTIONS see **EYE INFECTIONS, PARASITIC**

PARASITIC INTESTINAL DISEASES see **INTESTINAL DISEASES, PARASITIC**

PARASITIC LIVER DISEASES see **LIVER DISEASES, PARASITIC**

PARASITIC LUNG DISEASES see **LUNG DISEASES, PARASITIC**

PARASITIC PREGNANCY COMPLICATIONS see **PREGNANCY COMPLICATIONS, PARASITIC**

PARASITIC SKIN DISEASES see **SKIN DISEASES, PARASITIC**

PARASITICIDES see **ANTIPARASITIC AGENTS**

PARASITOLOGY

Communications: technology transfer in the developed world. Murrell KD. **Vet Parasitol** 1996 Aug;64(1–2):107–20 (19 ref.)

METHODS

Phylogenetic tree-building. Morrison DA. **Int J Parasitol** 1996 Jun;26(6):589–617 (150 ref.)

Alternatives to animal experimentation in parasitology. Eckert J. **Vet Parasitol** 1997 Jul 31;71(2–3):99–120 (142 ref.)

Application of molecular biology in veterinary parasitology. Prichard R. **Vet Parasitol** 1997 Jul 31;71(2–3):155–75 (102 ref.)

PARASYMPATHETIC-BLOCKING AGENTS see **PARASYMPATHOLYTICS**

PARASYMPATHETIC FIBERS, POSTGANGLIONIC

PHYSIOPATHOLOGY

Postganglionic cholinergic dysautonomia with incomplete recovery: a clinical, neurophysiological and immunological case study. Baron R, et al. **J Neurol** 1996 Jan;243(1):18–24 (46 ref.)

PARASYMPATHETIC GANGLIA see **GANGLIA, PARASYMPATHETIC**

PARASYMPATHETIC NERVOUS SYSTEM

see related
PARASYMPATHOLYTICS
PARASYMPATHOMIMETICS

Hypothesis for synergistic toxicity of organophosphorus poisoning-induced cholinergic crisis and anaphylactoid reactions. Cowan FM, et al. **J Appl Toxicol** 1996 Jan-Feb; 16(1):25–33 (79 ref.)

DRUG EFFECTS

The brain cholinergic system as a target of cognition enhancers. Giovannini MG, et al. **Behav Brain Res** 1997 Feb;83(1–2):1–5 (69 ref.)

INJURIES

A case of gustatory rhinorrhoea. Franceschini SS, et al.
Rhinology 1997 Mar;35(1):41–3 (15 ref.)

PHYSIOLOGY

Autonomic neural control of cardiac function: modulation by adenosine and adenosine 5'-triphosphate. Pelleg A, et al. **Am J Cardiol** 1997 Jun 19;79(12A):11–4 (72 ref.)

Neural grafting of cholinergic neurons in the hippocampal formation. Tarricone BJ, et al. **Behav Brain Res** 1996 Jan; 74(1–2):25–44 (121 ref.)

PHYSIOPATHOLOGY

Cognitive enhancers in theory and practice: studies of the cholinergic hypothesis of cognitive deficits in Alzheimer's disease. Robbins TW, et al. **Behav Brain Res** 1997 Feb; 83(1–2):15–23 (34 ref.)

Postganglionic cholinergic dysautonomia with incomplete recovery: a clinical, neurophysiological and immunological case study. Baron R, et al. **J Neurol** 1996 Jan;243(1):18–24 (46 ref.)

PARASYMPATHOLYTICS

see related
ANTIPARKINSON AGENTS
ANTI-ULCER AGENTS
MUSCARINIC ANTAGONISTS

DIAGNOSTIC USE

Prognostic value of dobutamine-atropine stress echocardiography for peri-operative and late cardiac events in patients scheduled for vascular surgery. Poldermans D, et al. **Eur Heart J** 1997 Jun;18 Suppl D:D86–96 (56 ref.)

ECONOMICS

[Costs of drug treatment of neurologic diseases: Parkinson disease, dystonia, epilepsy] Dodel RC, et al. **Med Klin** 1996 Jul 15;91(7):479–85 (64 ref.) (Eng. Abstr.) **(Ger)**

PARASYMPATHOLYTICS

PHARMACOLOGY

Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Wagstaff AJ, et al. **Drugs** 1997 Mar;53(3):435–52 (112 ref.)

POISONING

Systemic toxicity from ocular homatropine. Reilly KM, et al. **Acad Emerg Med** 1996 Sep;3(9):868–71 (15 ref.)

Hyoscyamus falezlez C: a poisonous plant of north Africa. el Bahri L, et al. **Vet Hum Toxicol** 1996 Oct;38(5):378–9 (19 ref.)

THERAPEUTIC USE

Potassium channel activation: a potential therapeutic approach? Lawson K. **Pharmacol Ther** 1996;70(1):39–63 (301 ref.)

Management of nonobstructive idiopathic feline lower urinary tract disease. Kruger JM, et al. **Vet Clin North Am Small Anim Pract** 1996 May; 26(3):571–88 (65 ref.)

[Current potentialities of Buscopan in clinical practice] Sheptulin AA. **Klin Med (Mosk)** 1997;75(8):55–7 (31 ref.) **(Rus)**

PARASYMPATHOMIMETICS

see related
CHOLINESTERASE INHIBITORS
MUSCARINIC AGONISTS

Cisapride. Mangal N, et al. **Indian Pediatr** 1995 Oct; 32(10):1124–6 (9 ref.)

POISONING

Cisapride poisoning. Gibly RL, et al. **Vet Hum Toxicol** 1997 Aug;39(4):231–3 (17 ref.)

PARASYSTOLE

[Parasystole] Kawaguchi H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):465–7 (7 ref.) **(Jpn)**

[Ventricular parasystole] Sakagami S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):318–20 (10 ref.) **(Jpn)**

PHYSIOPATHOLOGY

[Ventricular parasystole] Inukai M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):468–70 (13 ref.) **(Jpn)**

PARATHION

POISONING

[Fatal food poisoning by parathion] Laynez Bretones F, et al. **Med Clin (Barc)** 1997 Feb 15;108(6):224–5 (17 ref.) (Eng. Abstr.) **(Spa)**

PARATHYROID DISEASES

COMPLICATIONS

Giant mediastinal parathyroid cyst: an unusual cause of hypercalcemic crisis—case report and review of the literature. Gurbuz AT, et al. **Surgery** 1996 Nov; 120(5):795–800 (43 ref.)

DIAGNOSIS

Imaging of the parathyroid glands. Loevner LA. **Semin Ultrasound CT MR** 1996 Dec;17(6):563–75 (55 ref.)

[Two patients with mediastinal parathyroid cysts] Hirano H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 Jan; 35(1):82–8 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Parathyroid cyst presenting as a mediastinal tumor] Shishido M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Aug; 34(8):894–7 (11 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Percutaneous ethanol injection therapy in the treatment of thyroid and parathyroid diseases. Bennedbaek FN, et al. **Eur J Endocrinol** 1997 Mar;136(3):240–50 (71 ref.)

METABOLISM

Calcium-sensing receptors and associated pathological conditions [editorial] Drüeke TB. **Rev Rhum Engl Ed** 1996 May;63(5):305–8 (28 ref.)

PHYSIOPATHOLOGY

Mineral metabolism: new aspects and perspectives [editorial] Drüeke TB. **Curr Opin Nephrol Hypertens** 1996 Jul; 5(4):297–9 (16 ref.)

PARATHYROID GLANDS

see related
PARATHYROIDECTOMY

ANATOMY & HISTOLOGY

[Topographic anatomy and arterial vascularization of the parathyroid glands. Practical application] Abboud B. **Presse Med** 1996 Sep 7;25(25):1156–61 (30 ref.) (Eng. Abstr.) **(Fre)**

CYTOLOGY

Regulation of parathyroid cell proliferation. Silver J, et al. **Curr Opin Nephrol Hypertens** 1997 Jul;6(4):321–6 (55 ref.)

Allotransplantation of cultured human parathyroid cells: present status and perspectives. Tolloczko T, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):998–1000 (25 ref.)

DRUG EFFECTS

Molecular basis for the management of secondary hyperparathyroidism in chronic renal failure. Fukagawa M, et al. **Artif Organs** 1995 Dec;19(12):1210–4 (25 ref.)

METABOLISM

Calcium-receptor-regulated parathyroid and renal function. Brown EM, et al. **Bone** 1997 Apr;20(4):303–9 (50 ref.)

The scent of an ion: calcium-sensing and its roles in health and disease. Hebert SC, et al. **Curr Opin Nephrol Hypertens** 1996 Jan;5(1):45–53 (79 ref.)

The parathyroid calcium receptor: a novel therapeutic target for treating hyperparathyroidism. Nemeth EF, et al. **Pediatr Nephrol** 1996 Jun;10(3):275–9 (30 ref.)

PATHOLOGY

Imaging of the parathyroid in chronic renal failure: diagnostic and therapeutic aspects. Fukagawa M, et al. **Curr Opin Nephrol Hypertens** 1997 Jul;6(4):349–55 (74 ref.)

Molecular mechanisms of parathyroid hyperplasia and neoplasia. Brandi ML. **Horm Res** 1997;47(4–6):194–8 (32 ref.)

The hyperparathyroidism of chronic renal failure: a disorder of growth. Parfitt AM. **Kidney Int** 1997 Jul;52(1):3–9 (90 ref.)

Ultrasonographic intervention of parathyroid hyperplasia in chronic dialysis patients: a theoretical approach. Fukagawa M, et al. **Nephrol Dial Transplant** 1996;11 Suppl 3:125–9 (32 ref.)

Parathyroid gland. Ranchod M. **Pathology (Phila)** 1996; 3(2):405–16 (28 ref.)

Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Tominaga Y, et al. **Semin Surg Oncol** 1997 Mar–Apr;13(2):78–86 (68 ref.)

PHYSIOLOGY

Effect of phosphate on the parathyroid gland: direct and indirect? Rodriguez M, et al. **Curr Opin Nephrol Hypertens** 1996 Jul;5(4):321–8 (44 ref.)

Calcium, phosphate, vitamin D, and the parathyroid. Marks KH, et al. **Pediatr Nephrol** 1996 Jun;10(3):364–7 (32 ref.)

PHYSIOPATHOLOGY

In vivo studies of parathyroid gland function in secondary hyperparathyroidism. Salusky IB, et al. **Adv Nephrol Necker Hosp** 1996;25:289–302 (43 ref.)

The parathyroid-bone axis in uremia: new insights into old questions. Hory B, et al. **Curr Opin Nephrol Hypertens** 1997 Jan;6(1):40–8 (94 ref.)

Parathyroid pathophysiology in uraemia. Cunningham J. **Nephrol Dial Transplant** 1996;11 Suppl 3:106–10 (46 ref.)

Parathyroid gland function in secondary hyperparathyroidism. Salusky IB, et al. **Pediatr Nephrol** 1996 Jun;10(3):359–63 (26 ref.)

RADIONUCLIDE IMAGING

Parathyroid scintigraphy. Prekeges JL, et al. **J Nucl Med Technol** 1997 Mar;25(1):59–65 (28 ref.)

[Recent progress in radionuclide imaging of parathyroid glands] Jeanguillaume C, et al. **Ann Endocrinol (Paris)** 1997; 58(2):143–51 (34 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Surgery of the parathyroid glands. Rice DH. **Otolaryngol Clin North Am** 1996 Aug;29(4):693–9 (20 ref.)

Parathyroid gland. Ranchod M. **Pathology (Phila)** 1996; 3(2):405–16 (28 ref.)

ULTRASONOGRAPHY

Ultrasonographic intervention of parathyroid hyperplasia in chronic dialysis patients: a theoretical approach. Fukagawa M, et al. **Nephrol Dial Transplant** 1996;11 Suppl 3:125–9 (32 ref.)

PARATHYROID HORMONE RECEPTORS see **RECEPTORS, PARATHYROID HORMONE**

PARATHYROID HORMONES

see related
HYPOPARATHYROIDISM

Diagnostic and therapeutic aspects of calciotropic hormones. Cormier C, et al. **Curr Opin Rheumatol** 1997 Jul;9(4):370–6 (40 ref.)

BIOSYNTHESIS

New insights into the regulation of parathyroid hormone synthesis and secretion in chronic renal failure. Silver J, et al. **Nephrol Dial Transplant** 1996;11 Suppl 3:2–5 (30 ref.)

BLOOD

Combined measurements of ionized calcium and intact parathyroid hormone in blood. Rudnicki PM. **Dan Med Bull** 1996 Feb;43(1):58–67 (188 ref.)

Determination of circulating parathyroid hormone levels and differential diagnosis of hypercalcemia. Rizzoli R, et al. **Nucl Med Biol** 1994 Apr;21(3):337–47 (21 ref.)

DIAGNOSTIC USE

[PTH infusion test] Yamamoto M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:307–9 (4 ref.) **(Jpn)**

METABOLISM

Peripheral metabolism of parathyroid hormone. Studies with isolated perfused kidneys and livers from normal and uremic rats. Daugaard H. **Dan Med Bull** 1996 Jun; 43(3):203–15 (143 ref.)

PHARMACOLOGY

Interaction between insulin-like growth factor I, growth hormone, parathyroid hormone, 1 alpha,25-dihydroxyvitamin D3 and steroids on epiphyseal chondrocytes [see comments] Klaus G, et al. **Acta Paediatr Suppl** 1996 Oct;417:69–71 (28 ref.) Comment in: Acta Paediatr Suppl 1996 Oct;417 :80.

PHYSIOLOGY

Alcohol, osteoporosis, and bone regulating hormones. Sampson HW. **Alcohol Clin Exp Res** 1997 May;21(3):400–3 (45 ref.)

Parathyroid-hormone-related peptides. A new class of multifunctional proteins. Roskams T, et al. **Am J Pathol** 1997 Mar;150(3):779–85 (91 ref.)

Parathyroid hormone-related peptide and hypercalcemia of malignancy. Goltzman D, et al. **Cancer Treat Res** 1997; 89:193–215 (96 ref.)

Regulation of renal phosphate handling: recent findings. Friedlander G. **Curr Opin Nephrol Hypertens** 1996 Jul; 5(4):316–20 (29 ref.)

Physiological and pathological roles of parathyroid hormone-related peptide. Guise TA, et al. **Curr Opin Nephrol Hypertens** 1996 Jul;5(4):307–15 (126 ref.)

Effect of phosphate on the parathyroid gland: direct and indirect? Rodriguez M, et al. **Curr Opin Nephrol Hypertens** 1996 Jul;5(4):321–8 (44 ref.)

Parathyroid hormone dynamics in vivo. Schwarz P. **Dan Med Bull** 1996 Feb;43(1):11–20 (76 ref.)

The endothelin-parathyroid hormone-related protein vasoactive peptide system in human endometrium: modulation by transforming growth factor-beta. Casey ML, et al. **Hum Reprod** 1996 Oct;11 Suppl 2:62–82 (116 ref.)

Renal brush border membrane Na/Pi-cotransport: molecular aspects in PTH-dependent and dietary regulation. Murer H, et al. **Kidney Int** 1996 Jun;49(6):1769–73 (44 ref.)

An update on the discovery, pathophysiological actions, clinical manifestations and possible physiology of parathyroid related peptide. Alcantara A, et al. **P R Health Sci J** 1997 Mar;16(1):15–22 (19 ref.)

Abnormal skeletal response to parathyroid hormone and the expression of its receptor in chronic uremia. Drüeke TB. **Pediatr Nephrol** 1996 Jun;10(3):348–50 (23 ref.)

SECRETION

The scent of an ion: calcium-sensing and its roles in health and disease. Hebert SC, et al. **Curr Opin Nephrol Hypertens** 1996 Jan;5(1):45–53 (79 ref.)

In vivo assessments of calcium-regulated parathyroid hormone release in secondary hyperparathyroidism [editorial] Goodman WG, et al. **Kidney Int** 1996 Dec; 50(6):1834–44 (77 ref.)

THERAPEUTIC USE

PTHrP(1-36) as a skeletal anabolic agent for the treatment of osteoporosis. Stewart AF. **Bone** 1996 Oct;19(4):303–6 (41 ref.)

PTH: a future role in the management of osteoporosis? [editorial] Reeve J. **J Bone Miner Res** 1996 Apr;11(4):440–5 (92 ref.)

PARATHYROID NEOPLASMS

Detection and management of parathyroid tumors. Hodin RA, et al. **Curr Opin Oncol** 1997 Jan;9(1):75–8 (23 ref.)

Functioning parathyroid carcinoma: clinicopathologic features and rational treatment. Obara T, et al. **Semin Surg Oncol** 1997 Mar–Apr;13(2):134–41 (65 ref.)

COMPLICATIONS

Clinical image. Recurrent hyperparathyroidism caused by a parathyroid cystic adenoma: localization by MRI. Santos E, et al. **J Comput Assist Tomogr** 1996 Nov–Dec;

20(6):996–8 (21 ref.)
Bone insufficiency fractures as an inaugural manifestation of primary hyperparathyroidism. Lafforgue P, et al. **Rev Rhum Engl Ed** 1996 Jul–Sep;63(7–8):475–9 (26 ref.)

DIAGNOSIS

Parathyroid carcinoma. Sandelin K. **Cancer Treat Res** 1997; 89:183–92 (59 ref.)

ETIOLOGY

Parathyroid carcinoma in patients with chronic renal failure on maintenance hemodialysis. Miki H, et al. **Surgery** 1996 Nov;120(5):897–901 (10 ref.)

GENETICS

Multiple endocrine neoplasia type I. Clinical genetics and diagnosis. Skogseid B. **Cancer Treat Res** 1997;89:383–406 (64 ref.)
Molecular mechanisms of parathyroid hyperplasia and neoplasia. Brandi ML. **Horm Res** 1997;47(4–6):194–8 (32 ref.)

PATHOLOGY

Pathology of parathyroid tumors. Grimelius L, et al. **Semin Surg Oncol** 1997 Mar–Apr;13(2):142–54 (62 ref.)

SURGERY

[Parathyroidectomy under local anesthesia. First two cases in Lebanon and review of the literature] Abboud B, et al. **J Med Liban** 1997;45(2):107–11 (31 ref.) (Eng. Abstr.) **(Fre)**
[New strategies in the surgery of primary hyperparathyroidism] Demard F, et al. **Rev Laryngol Otol Rhinol (Bord)** 1996;117(3):203–14 (25 ref.) (Eng. Abstr.) **(Fre)**
[Primary hyperthyroidism 1996] Schweizer I, et al. **Schweiz Med Wochenschr** 1997 Feb 15;127(7):243–53 (58 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Parathyroid carcinoma. Shane E. **Curr Ther Endocrinol Metab** 1997;6:565–8 (6 ref.)

VETERINARY

Tumours of the endocrine glands. Schmidt RE, et al. **IARC Sci Publ** 1996;(126):307–20 (50 ref.)

PARATHYROIDECTOMY

Current management of patients with hyperparathyroidism. Clark OH. **Adv Surg** 1996;30:179–87 (16 ref.)
Biochemical aberrations in a dialysis patient following parathyroidectomy. Cruz DN, et al. **Am J Kidney Dis** 1997 May;29(5):759–62 (6 ref.)
Surgery of the parathyroid glands. Rice DH. **Otolaryngol Clin North Am** 1996 Aug;29(4):693–9 (20 ref.)
[New strategies in the surgery of primary hyperparathyroidism] Demard F, et al. **Rev Laryngol Otol Rhinol (Bord)** 1996;117(3):203–14 (25 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Surgical treatment of parathyroid disease. Scott-Coombes DM, et al. **Br J Hosp Med** 1997 May 21–Jun 3; 57(10):488–91 (20 ref.)
[Parathyroidectomy under local anesthesia. First two cases in Lebanon and review of the literature] Abboud B, et al. **J Med Liban** 1997;45(2):107–11 (31 ref.) (Eng. Abstr.) **(Fre)**

PARATOPES see **BINDING SITES, ANTIBODY**

PARATUBERCULOSIS

COMPLICATIONS

Mycobacterium paratuberculosis and Crohn's disease. Engstrand L. **Scand J Infect Dis Suppl** 1995;98:27–9 (21 ref.)

DIAGNOSIS

Molecular techniques in the diagnosis and control of paratuberculosis in cattle. Thoen CO, et al. **J Am Vet Med Assoc** 1996 Aug 15;209(4):734–7 (35 ref.)
Diagnosis of paratuberculosis. Collins MT. **Vet Clin North Am Food Anim Pract** 1996 Jul;12(2):357–71 (53 ref.)
Paratuberculosis and molecular biology [editorial; comment] Clarke CJ. **Vet J** 1997 May;153(3):245–7 (12 ref.) Comment on: Vet J 1997 May;153(3):260–86.
The contribution of molecular biology to Mycobacterium avium subspecies Paratuberculosis research [see comments] Stevenson K, et al. **Vet J** 1997 May;153(3):269–86 (165 ref.) Comment in: Vet J 1997 May;153(3):245–7.
[Mycobacterium paratuberculosis--an etiological agent in Crohn disease?] Andersen J, et al. **Ugeskr Laeger** 1997 Jan 6;159(2):159–63 (40 ref.) **(Dan)**

DRUG THERAPY

Treatment of clinical paratuberculosis in cattle. St Jean G. **Vet Clin North Am Food Anim Pract** 1996 Jul;12(2):417–30 (51 ref.)

ECONOMICS

Economic impact of paratuberculosis. Hutchinson LJ. **Vet Clin North Am Food Anim Pract** 1996 Jul;12(2):373–81 (21 ref.)

EPIDEMIOLOGY

Relationship between soil type and Mycobacterium paratuberculosis. Johnson-Ifearulundu YJ, et al. **J Am Vet Med Assoc** 1997 Jun 15;210(12):1735–40 (44 ref.)
Paratuberculosis in small ruminants, deer, and South American camelids. Stehman SM. **Vet Clin North Am Food Anim Pract** 1996 Jul;12(2):441–55 (56 ref.)

ETIOLOGY

Mycobacteria on trial: guilty or innocent in the pathogenesis of Crohn's disease? Travis SP. **Eur J Gastroenterol Hepatol** 1995 Dec;7(12):1173–6 (26 ref.)

IMMUNOLOGY

Immunology: resistance to paratuberculosis. Chiodini RJ. **Vet Clin North Am Food Anim Pract** 1996 Jul;12(2):313–43 (122 ref.)

PATHOLOGY

The pathology and pathogenesis of paratuberculosis in ruminants and other species. Clarke CJ. **J Comp Pathol** 1997 Apr;116(3):217–61 (262 ref.)
Preclinical and clinical manifestations of paratuberculosis (including pathology). Whitlock RH, et al. **Vet Clin North Am Food Anim Pract** 1996 Jul;12(2):345–56 (39 ref.)

PREVENTION & CONTROL

Molecular techniques in the diagnosis and control of paratuberculosis in cattle. Thoen CO, et al. **J Am Vet Med Assoc** 1996 Aug 15;209(4):734–7 (35 ref.)
Farm-specific approach to paratuberculosis (Johne's disease) control. Rossiter CA, et al. **Vet Clin North Am Food Anim Pract** 1996 Jul;12(2):383–415 (55 ref.)
Johne's disease eradication and control: regulatory implications. Sockett DC. **Vet Clin North Am Food Anim Pract** 1996 Jul;12(2):431–40 (16 ref.)

TRANSMISSION

Paratuberculosis: a potential zoonosis? Chiodini RJ, et al. **Vet Clin North Am Food Anim Pract** 1996 Jul;12(2):457–67 (25 ref.)
Transmission of paratuberculosis. Sweeney RW. **Vet Clin North Am Food Anim Pract** 1996 Jul;12(2):305–12 (35 ref.)

PARATYPHOID VACCINE see **TYPHOID-PARATYPHOID VACCINES**

PARAVENTRICULAR HYPOTHALAMIC NUCLEUS

PHYSIOLOGY

Metabolic actions of neuropeptide Y and their relevance to obesity. Wilding JP. **Biochem Soc Trans** 1996 May; 24(2):576–81 (50 ref.)
Neuronal circuit regulation of the hypothalamo-pituitary-adrenocortical stress axis. Herman JP, et al. **Crit Rev Neurobiol** 1996;10(3–4):371–94 (206 ref.)
Electrophysiology of suprachiasmatic nucleus projections to hypothalamic paraventricular nucleus neurons. Hermes ML, et al. **Prog Brain Res** 1996;111:241–52 (46 ref.)
The paraventricular nucleus of the hypothalamus and the functional neuroanatomy of visceromotor responses to stress. Sawchenko PE, et al. **Prog Brain Res** 1996; 107:201–22 (104 ref.)

PHYSIOPATHOLOGY

Novel estrogen feedback sites associated with stress-induced suppression of luteinizing hormone secretion in female rats. Maeda K, et al. **Cell Mol Neurobiol** 1996 Jun;16(3):311–24 (32 ref.)
Neurohumoral activation in heart failure: role of paraventricular nucleus. Patel KP, et al. **Clin Exp Pharmacol Physiol** 1996 Aug;23(8):722–6 (42 ref.)

PARENT-CHILD RELATIONS

Parental influence on children's socialization to gender roles. Witt SD. **Adolescence** 1997 Summer;32(126):253–9 (42 ref.)
Integrating social-skills training interventions with parent training and family-focused support to prevent conduct disorder in high-risk populations. The Fast Track Multisite Demonstration Project. The Conduct Problems Prevention Research Group. Bierman KL. **Ann N Y Acad Sci** 1996 Sep 20;794:256–64 (21 ref.)
Parent-adolescent communication in nondistressed families. Riesch SK. **Annu Rev Nurs Res** 1997;15:123–52 (130 ref.)
Crossing the line from physical discipline to child abuse: how much is too much? Whipple EE, et al. **Child Abuse Negl** 1997 May;21(5):431–44 (75 ref.)
Unique issues of the adopted child: helping parents talk openly and honestly with their child and the community. Smit EM. **J Psychosoc Nurs Ment Health Serv** 1996 Jul; 34(7):29–36 (22 ref.)
Latchkey children. Leung AK, et al. **J R Soc Health** 1996 Dec;116(6):356–9 (32 ref.)
Psychiatric sequelae in seriously ill children and their families. Stuber ML. **Psychiatr Clin North Am** 1996 Sep; 19(3):481–93 (71 ref.)
Parenting the prematurely born child: pathways of influence. Miles MS, et al. **Semin Perinatol** 1997 Jun;21(3):254–66 (105 ref.)
Children of Holocaust survivors: separation obstacles, attachments, and anxiety. Zilberfein F. **Soc Work Health Care** 1996;23(3):35–55 (30 ref.)
[Apropos of families where parents are battered by their children] Laurent A. **Arch Pediatr** 1997 May;4(5):468–72 (13 ref.) (Eng. Abstr.) **(Fre)**
[Treatment failures and analysis of resistance in behavior therapy exemplified by a parent-child program for the treatment of hyperkinetic and oppositional children] Dopfner M, et al. **Prax Kinderpsychol Kinderpsychiatr** 1996 Jan;45(1):10–19 (0 ref.) (Eng. Abstr.) **(Ger)**

PARENT, SINGLE see **SINGLE PARENT**

PARENTAL IMPRINTING see **GENOMIC IMPRINTING**

PARENTERAL FEEDING see **PARENTERAL NUTRITION**

PARENTERAL FEEDING, HOME see **PARENTERAL NUTRITION, HOME**

PARENTERAL HYPERALIMENTATION see **PARENTERAL NUTRITION, TOTAL**

PARENTERAL INFUSIONS see **INFUSIONS, PARENTERAL**

PARENTERAL NUTRITION

see related
FAT EMULSIONS, INTRAVENOUS

Enteral or parenteral nutrition? Pro-parenteral. Wernerman J. **Acta Anaesthesiol Scand Suppl** 1997;110:148–50 (14 ref.)
Principles and practice of parenteral nutrition in the neonatal period. Yu VY. **Acta Med Port** 1997 Feb–Mar; 10(2–3):185–96 (200 ref.)
Reappraisal of indispensable amino acids. Design of parenteral synthetic dipeptides: synthesis and characterization. Fürst P, et al. **Ann Nutr Metab** 1997; 41(1):1–9 (47 ref.)
Design of parenteral synthetic dipeptides for clinical nutrition: in vitro and in vivo utilization. Fürst P, et al. **Ann Nutr Metab** 1997;41(1):10–21 (64 ref.)
Parenteral nutrition in low-birth-weight infants. Heird WC, et al. **Annu Rev Nutr** 1996;16:471–99 (115 ref.)
Advances in parenteral nutrition. Collier S, et al. **Curr Opin Pediatr** 1996 Oct;8(5):476–82 (65 ref.)
How often can we justify parenteral nutrition in terminally ill cancer patients? Fainsinger RL, et al. **J Palliat Care** 1997 Spring;13(1):48–51 (21 ref.)
Effects of air and oxygen on parenteral nutrition admixtures--an underrated risk? Allwood MC, et al. **Nutrition** 1996 Mar;12(3):222–3 (19 ref.)
Parenteral glutamine supply in intensive care patients. Griffiths RD, et al. **Nutrition** 1996 Nov–Dec;12(11–12 Suppl):S73–5 (22 ref.)
Development of an intravenous glutamine supply through dipeptide technology. Langer K. **Nutrition** 1996 Nov–Dec; 12(11–12 Suppl):S76–7 (8 ref.)
A request for a 'sip feed' prescription. James J, et al. **Practitioner** 1996 May;240(1562):281–4, 287–8 (0 ref.)
The management of malnutrition in hospital. Allison SP. **Proc Nutr Soc** 1996 Nov;55(3):855–62 (31 ref.)
Effects of parenteral nutrients on gastrointestinal motility and secretion. Masclee AA, et al. **Scand J Gastroenterol Suppl** 1996;218:50–5 (81 ref.)
The metabolic distinctiveness of emulsified lipid particles in the bloodstream and its clinical implications. Iriyama K. **Surg Today** 1996;26(9):673–8 (48 ref.)
[Surgical metabolism] Jauch KW. **Chirurg** 1997 Jun; 68(6):551–8 (27 ref.) (Eng. Abstr.) **(Ger)**
[Parenteral nutrition in the perioperative period] Pawlowski W. **Pol Tyg Lek** 1996 Apr;51(14–18):246–8 (44 ref.) **(Pol)**
[The role of glutamine in nutrition in clinical practice] Campos FG, et al. **Arq Gastroenterol** 1996 Apr–Jun; 33(2):86–92 (47 ref.) (Eng. Abstr.) **(Por)**
[Preoperative parenteral nutrition] Sloventantor VIu, et al. **Vestn Ross Akad Med Nauk** 1996;(5):31–5 (47 ref.) (Eng. Abstr.) **(Rus)**
[Parenteral nutrition] Llubiá-Maristany C. **Rev Esp Anestesiol Reanim** 1996 Dec;43(10):364–70 (18 ref.)

PARENTERAL NUTRITION

(Spa)

METHODS

Parenteral use of medium-chain triglycerides: a reappraisal. Ulrich H, et al. **Nutrition** 1996 Apr;12(4):231-8 (82 ref.)

[Use of parenteral feeding in the multimodality treatment of Crohn's disease and nonspecific ulcerative colitis] Sloventantor VI, et al. **Vestn Ross Akad Med Nauk** 1996; (9):40-4 (58 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

[Approximation of a proposal of therapeutic criteria for parenteral nutrition] Font Noguera I, et al. **Nutr Hosp** 1996 Nov-Dec;11(6):309-16 (52 ref.) (Eng. Abstr.) **(Spa)**

PARENTERAL NUTRITION, HOME

Nutrition in short-bowel syndrome. Ladefoged K, et al. **Scand J Gastroenterol Suppl** 1996;216:122-31 (76 ref.)

STANDARDS

Clinical pathways in home nutrition support. Ireton-Jones C, et al. **J Am Diet Assoc** 1997 Sep;97(9):1003-7 (13 ref.)

TRENDS

Home parenteral nutrition in adults: new trends raise new questions [editorial] Van Gossum A, et al. **Nutrition** 1997 May;13(5):479-80 (16 ref.)

Current status of home parenteral nutrition in the United States. Howard L, et al. **Transplant Proc** 1996 Oct; 28(5):2691-5 (6 ref.)

PARENTERAL NUTRITION, TOTAL

Proinflammatory cytokines, nutritional support, and the cachexia syndrome: interactions and therapeutic options. Moldawer LL, et al. **Cancer** 1997 May 1;79(9):1828-39 (119 ref.)

The evolution of clinical nutrition in the critical care of the neonate. Cotter R. **Equine Vet J Suppl** 1988 Sep;(5):17-8 (16 ref.)

Studies on the regulation of food intake using rat total parenteral nutrition as a model. Opara EI, et al. **Neurosci Biobehav Rev** 1996 Autumn;20(3):413-43 (206 ref.)

Lipids and immune function. Garnacho Montero J, et al. **Nutr Hosp** 1996 Jul-Aug;11(4):230-7 (87 ref.)

The well-balanced nucleoside-nucleotide mixture "OG-VI" for special medical purposes. Iwasa Y, et al. **Nutrition** 1997 Apr;13(4):361-4 (17 ref.)

Role of supplementation of a nucleic acid solution on the intestinal mucosa under total parenteral nutrition. Tsujinaka T, et al. **Nutrition** 1997 Apr;13(4):369-71 (9 ref.)

Interactions related to trace elements in parenteral nutrition. Harraki B, et al. **Pharm Acta Helv** 1995 Dec;70(4):269-78 (71 ref.)

Novel lipid sources in parenteral and enteral nutrition. Bistrian BR. **Proc Nutr Soc** 1997 Mar;56(1B):471-7 (40 ref.)

The value of peri-operative nutrition in the sick patient. Heys SD, et al. **Proc Nutr Soc** 1997 Mar;56(1B):443-57 (69 ref.)

Nutritional management of patients with gastrointestinal fistulas. Meguid MM, et al. **Surg Clin North Am** 1996 Oct; 76(5):1035-80 (114 ref.)

Is there a role for parenteral feeding in clinical medicine? Phinney SD, et al. **West J Med** 1996 Feb;164(2):130-6 (46 ref.)

[Parenteral nutrition therapy. Energy and non-energy actions of carbohydrates and fats] Schricker T, et al. **Anaesthesist** 1997 May;46(5):371-84 (72 ref.) (Eng. Abstr.) **(Ger)**

[Tumor cachexia--a special entity and therapeutic sequelae] Heberer M. **Chirurg** 1997 Jun;68(6):568-73 (51 ref.) (Eng. Abstr.) **(Ger)**

[Pathophysiology, clinical aspects and therapy of short bowel syndrome] Krähenbühl L, et al. **Chirurg** 1997 Jun; 68(6):559-67 (50 ref.) (Eng. Abstr.) **(Ger)**

[Nutrition for patients with craniocerebral trauma] Dörr F, et al. **Zentralbl Neurochir** 1997;58(2):88-90 (19 ref.) **(Ger)**

[Enteral nutrition in maxillofacial oncology] Garau V, et al. **Minerva Stomatol** 1997 Jul-Aug;46(7-8):415-22 (29 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

Parenteral nutrition-associated cholestasis. Teitelbaum DH. **Curr Opin Pediatr** 1997 Jun;9(3):270-5 (49 ref.)

Hepatobiliary toxicity of total parenteral nutrition in adults. Bashir RM, et al. **Gastroenterol Clin North Am** 1995 Dec; 24(4):1003-25 (187 ref.)

Hepatobiliary complications of parenteral nutrition. Gaddipati K, et al. **Gastroenterologist** 1996 Jun;4(2):98-106 (91 ref.)

Essential nature of choline with implications for total parenteral nutrition. Shronts EP. **J Am Diet Assoc** 1997 Jun;97(6):639-46, 649; quiz 647-8 (61 ref.)

Leuconostoc bacteremia in an infant with short-gut syndrome: case report and literature review. Dhodapkar KM, et al. **Mayo Clin Proc** 1996 Dec;71(12):1171-4 (24 ref.)

Management of catheter-related bacteremia and fungemia in patients on total parenteral nutrition. Widmer AF. **Nutrition** 1997 Apr;13(4 Suppl):18S-25S (84 ref.)

TPN-induced fulminant beriberi: a report on our experience and a review of the literature. Kitamura K, et al. **Surg Today** 1996;26(10):769-76 (45 ref.)

[Hansenula anomala fungemia in a patient undergoing IVH-treatment with ascending colon carcinoma] Sumitomo M, et al. **Kansenshogaku Zasshi** 1996 Feb; 70(2):198-205 (27 ref.) (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

Stephen L. Gans Visiting Guest Lecture: central venous catheters for parenteral nutrition: a double-edged sword. Lloyd DA. **J Pediatr Surg** 1997 Jul;32(7):943-8 (11 ref.)

Right atrial thrombus as a complication of total parenteral nutrition in pregnancy. Turrentine MA, et al. **Obstet Gynecol** 1994 Oct;84(4 Pt 2):675-7 (13 ref.)

METHODS

[Glutamine supplemented nutrition in clinical practice--use of glutamine-containing dipeptides (see comments)] Fürst P, et al. **Infusionsther Transfusionsmed** 1995 Oct; 22(5):317-24 (56 ref.) (Eng. Abstr.) Comment in: Infusionsther Transfusionsmed 1996 Apr;23(2):98-9. **(Ger)**

PARENTERALLY-TRANSMITTED NON-A, NON-B HEPATITIS see **HEPATITIS C**

PARENTING

see related

CHILD REARING

Parenting the prematurely born child. Holditch-Davis D, et al. **Annu Rev Nurs Res** 1997;15:3-34 (92 ref.)

Sibling rivalry in the 1990s. Renshaw DC. **Compr Ther** 1996 Jul;22(7):415-9 (11 ref.)

Proposal for a structured assessment of parenting based on attachment theory: theoretical background, description and initial clinical experience. Green JM. **Eur Child Adolesc Psychiatry** 1996 Sep;5(3):133-8 (46 ref.)

Two-generation programs: design, cost, and short-term effectiveness. St. Pierre RG, et al. **Future Child** 1995 Winter;5(3):76-93 (35 ref.)

Parenting in an era of genetics. McGee G. **Hastings Cent Rep** 1997 Mar-Apr;27(2):16-22 (15 ref.)

The development of parenting: nursing resources. Higley AM, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Oct; 25(8):707-13 (32 ref.)

Background and overview of mental health and substance abuse treatment systems: meeting the needs of women who are pregnant or parenting. Grella CE. **J Psychoactive Drugs** 1996 Oct-Dec;28(4):319-43 (236 ref.)

The effects of dual diagnosis on pregnancy and parenting. Mallouh C. **J Psychoactive Drugs** 1996 Oct-Dec; 28(4):367-80 (98 ref.)

The early parenting of twins. Thomas JG. **Mil Med** 1996 Apr;161(4):233-5 (18 ref.)

A review of the outcomes of parental use of nonabusive or customary physical punishment [see comments] Larzelere RE. **Pediatrics** 1996 Oct;98(4 Pt 2):824-8 (37 ref.) Comment in: Pediatrics 1996 Oct;98(4 Pt 2):828-31.

ETHNOLOGY

A conceptual model for studying parenting behaviors in immigrant populations. Foss GF. **ANS Adv Nurs Sci** 1996 Dec;19(2):74-87 (66 ref.)

PSYCHOLOGY

Crossing the line from physical discipline to child abuse: how much is too much? Whipple EE, et al. **Child Abuse Negl** 1997 May;21(5):431-44 (75 ref.)

Lesbian motherhood: the impact on child development and family functioning. Brewaeys A, et al. **J Psychosom Obstet Gynaecol** 1997 Mar;18(1):1-16 (82 ref.)

Parental investment theory and gender differences in the evolution of inhibition mechanisms. Bjorklund DF, et al. **Psychol Bull** 1996 Sep;120(2):163-88 (200 ref.)

Parenting the prematurely born child: pathways of influence. Miles MS, et al. **Semin Perinatol** 1997 Jun;21(3):254-66 (105 ref.)

[The contribution of fathers to the individuation process in adolescence] Shulman S. **Prax Kinderpsychol Kinderpsychiatr** 1997 May-Jun; 46(5):321-37 (41 ref.) (Eng. Abstr.) **(Ger)**

PARENTS

see related

CHILD OF IMPAIRED PARENTS
SINGLE PARENT

Parental discretion in refusal of treatment for newborns. A real but limited right. Paris JJ, et al. **Clin Perinatol** 1996 Sep;23(3):573-81 (21 ref.)

Parental issues in the treatment of chronic infantile eczema. Koblenzer PJ. **Dermatol Clin** 1996 Jul;14(3):423-7 (10 ref.)

Travel with infants and children. Foster JA, et al. **Emerg Med Clin North Am** 1997 Feb;15(1):71-92 (31 ref.)

Adolescents as research subjects without permission of their parents or guardians: ethical considerations. Levine RJ. **J Adolesc Health** 1995 Nov;17(5):287-97 (23 ref.)

Parenting and the best interests of minors. Downie RS, et al. **J Med Philos** 1997 Jun;22(3):219-31 (9 ref.)

Alcohol and other drugs: the scope of the problem among pregnant and parenting women in California. Young N. **J Psychoactive Drugs** 1997 Jan-Mar;29(1):3-22 (122 ref.)

Sudden infant death syndrome and parental smoking--a literature review. Golding J. **Paediatr Perinat Epidemiol** 1997 Jan;11(1):67-77 (29 ref.)

Supporting relatives following a cot death. Phillips BM. **Postgrad Med J** 1996 Nov;72(853):648-52 (13 ref.)

EDUCATION

Family processes and child risk for injury. Peterson L, et al. **Behav Res Ther** 1997 Mar;35(3):179-90 (70 ref.)

Early intervention for young children with developmental delay: the Portage approach. Cameron RJ. **Child Care Health Dev** 1997 Jan;23(1):11-27 (51 ref.)

Two-generation programs: design, cost, and short-term effectiveness. St. Pierre RG, et al. **Future Child** 1995 Winter;5(3):76-93 (35 ref.)

Childbirth education in the 1990s and beyond. Zwelling E. **J Obstet Gynecol Neonatal Nurs** 1996 Jun;25(5):425-32 (49 ref.)

Standards of care for acutely ill children with asthma. Andersen CL, et al. **MCN Am J Matern Child Nurs** 1996 Nov-Dec;21(6):280-7 (18 ref.)

PSYCHOLOGY

The management of late fetal death: a guide to comprehensive care. Fox R, et al. **Br J Obstet Gynaecol** 1997 Jan; 104(1):4-10 (31 ref.)

Coping strategies of immigrant parents: directions for family therapy. Strier DR. **Fam Process** 1996 Sep;35(3):363-76 (46 ref.)

Genetic dilemmas and the child's right to an open future. Davis DS. **Hastings Cent Rep** 1997 Mar-Apr;27(2):7-15 (30 ref.)

Parenting in an era of genetics. McGee G. **Hastings Cent Rep** 1997 Mar-Apr;27(2):16-22 (15 ref.)

Facilitating perinatal grieving between the mother and the father. Wallerstedt C, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Jun;25(5):389-94 (35 ref.)

Relating parent and family functioning to the psychological adjustment of children with chronic health conditions: what have we learned? What do we need to know? Drotar D. **J Pediatr Psychol** 1997 Apr;22(2):149-65 (88 ref.)

Unique issues of the adopted child: helping parents talk openly and honestly with their child and the community. Smit EM. **J Psychosoc Nurs Ment Health Serv** 1996 Jul; 34(7):29-36 (22 ref.)

Parental coping with childhood hospitalization: a theoretical framework to guide research and clinical interventions. Melnyk BM. **Matern Child Nurs J** 1995 Oct-Dec; 23(4):123-31 (51 ref.)

Consultation with the specialist. The vulnerable child. Leslie LK, et al. **Pediatr Rev** 1996 Sep;17(9):323-6 (9 ref.)

Parenting a technology assisted infant: coping with occupational stress. Murphy KE. **Soc Work Health Care** 1997;24(3-4):113-26 (32 ref.)

[Should fetal reduction be used in triplet pregnancies?] Nisand I. **Contracept Fertil Sex** 1997 Jun;25(6):423-8 (41 ref.) **(Fre)**

PARESIS

ETIOLOGY

Transient paraparesis after postdural puncture spinal hematoma in a patient receiving ketorolac. Gerancher JC, et al. **Anesthesiology** 1997 Feb;86(2):490-4 (26 ref.)

Neurological sequelae following a high voltage electrical burn. Ratnayake B, et al. **Burns** 1996 Nov;22(7):574-7 (23 ref.)

VIROLOGY

Segmental zoster paresis of limbs. Merchut MP, et al. **Electromyogr Clin Neurophysiol** 1996 Sep;36(6):369-75 (21 ref.)

PARESTHESIA

ETIOLOGY

Lumbosacral plexus neuropathy: a case report and review of the literature. van Alfen N, et al. **Clin Neurol Neurosurg** 1997 May;99(2):138-41 (16 ref.)

PHYSIOPATHOLOGY

Distal, "Tinel-like" percussion paresthesiae, with proximal nerve lesions. Jabre JF. **Electromyogr Clin Neurophysiol** 1996 Apr-May;36(3):175-8 (16 ref.)

Mechanisms of paresthesiae, dysesthesiae, and hyperesthesiae: role of Na+ channel heterogeneity. Rizzo MA, et al. **Eur Neurol** 1996;36(1):3-12 (44 ref.)

PARETIC NEUROSYPHILIS see **NEUROSYPHILIS**

PARIETAL BONE

[A giant-cell tumor of the parietal skull bones in childhood

(a clinical case)] Govenko FS, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1996 Jul-Sep;(3):37-9 (28 ref.) **(Rus)**

PATHOLOGY

Cellular blue nevus of the scalp infiltrating the underlying bone: case report and review. Micali G, et al. **Pediatr Dermatol** 1997 May-Jun;14(3):199-203 (17 ref.)

SURGERY

Ewing's sarcoma of the skull in an infant. A case report and review. Hadfield MG, et al. **Pediatr Neurosurg** 1996 Aug; 25(2):100-4 (64 ref.)

PARIETAL CELLS, GASTRIC

see related
GASTRIC ACID

CYTOLOGY

Differentiation of oxyntic cells and cell-matrix interactions during avian gastric gland morphogenesis. Koenig CS, et al. **Biol Res** 1994;27(3-4):177-92 (53 ref.)

METABOLISM

Roles of gastric GATA DNA-binding proteins. Maeda M, et al. **J Exp Biol** 1996 Mar;199 (Pt 3):513-20 (54 ref.)

MICROBIOLOGY

Helicobacter pylori and its interaction with chief and parietal cells. Cave DR. **Yale J Biol Med** 1996 Jan-Feb;69(1):91-8 (44 ref.)

PHYSIOLOGY

Gastric oxyntic cell structure as related to secretory activity. Ogata T. **Histol Histopathol** 1997 Jul;12(3):739-54 (0 ref.)

The role of gastric mast cells, enterochromaffin-like cells and parietal cells in the regulation of acid secretion. Kurbel S, et al. **Med Hypotheses** 1995 Dec;45(6):539-42 (22 ref.)

Rab proteins in gastric parietal cells: evidence for the membrane recycling hypothesis. Calhoun BC, et al. **Yale J Biol Med** 1996 Jan-Feb;69(1):1-8 (46 ref.)

SECRETION

Signal transduction and activation of acid secretion in the parietal cell. Urushidani T, et al. **J Membr Biol** 1997 Sep 15;159(2):99-111 (119 ref.)

ULTRASTRUCTURE

Gastric oxyntic cell structure as related to secretory activity. Ogata T. **Histol Histopathol** 1997 Jul;12(3):739-54 (0 ref.)

PARIETAL LOBE

Episodic pain associated with a tumor in the parietal operculum: a case report and literature review. Potagas C, et al. **Pain** 1997 Aug;72(1-2):201-8 (70 ref.)

Intracranial metastases as the first manifestation of prostate cancer. Sutton MA, et al. **Urology** 1996 Nov;48(5):789-93 (28 ref.)

[A case of the immediate efficacy of chemotherapy in a female patient with a glioblastoma] Kobiakov GL, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1996 Oct-Dec; (4):39-41 (22 ref.) **(Rus)**

ANATOMY & HISTOLOGY

Premotor and parietal cortex: corticocortical connectivity and combinatorial computations. Wise SP, et al. **Annu Rev Neurosci** 1997;20:25-42 (72 ref.)

BLOOD SUPPLY

Focal brain dysfunction in a 41-year old man with familial alternating hemiplegia. Dangond F, et al. **Eur Arch Psychiatry Clin Neurosci** 1997;247(1):35-41 (37 ref.)

PHYSIOLOGY

Multimodal representation of space in the posterior parietal cortex and its use in planning movements. Andersen RA, et al. **Annu Rev Neurosci** 1997;20:303-30 (72 ref.)

Premotor and parietal cortex: corticocortical connectivity and combinatorial computations. Wise SP, et al. **Annu Rev Neurosci** 1997;20:25-42 (72 ref.)

Spatial representations for action in parietal cortex. Colby CL, et al. **Brain Res Cogn Brain Res** 1996 Dec; 5(1-2):105-15 (34 ref.)

Parietal cortex area 5 and visuomotor behavior. Kalaska JF. **Can J Physiol Pharmacol** 1996 Apr;74(4):483-98 (69 ref.)

Perceptual and cognitive visual functions of parietal and temporal cortices in the cat. Lomber SG, et al. **Cereb Cortex** 1996 Sep-Oct;6(5):673-95 (86 ref.)

Parietal cortex: from sight to action. Rizzolatti G, et al. **Curr Opin Neurobiol** 1997 Aug;7(4):562-7 (51 ref.)

The TINS Lecture. The parietal association cortex in depth perception and visual control of hand action. Sakata H, et al. **Trends Neurosci** 1997 Aug;20(8):350-7 (75 ref.)

PHYSIOPATHOLOGY

Occipital-parietal encephalopathy: a new name for an old syndrome. Pavlakis SG, et al. **Pediatr Neurol** 1997 Feb; 16(2):145-8 (11 ref.)

SURGERY

Solitary Langerhans cell histiocytosis lesion of the parieto-occipital lobe: a case report and review of the literature. Bergmann M, et al. **Clin Neurol Neurosurg** 1997 Feb;99(1):50-5 (42 ref.)

PARITY

Childbearing and mortality from cancer of the corpus uteri. Løchen ML, et al. **Acta Obstet Gynecol Scand** 1997 Apr; 76(4):373-7 (36 ref.)

The impact of parity, infertility and treatment with fertility drugs on the risk of ovarian cancer. A survey. Mosgaard BJ, et al. **Acta Obstet Gynecol Scand** 1997 Feb;76(2):89-95 (28 ref.)

Multiparous species present problems (and possibilities) to developmentalists. Zorrilla EP. **Dev Psychobiol** 1997 Mar; 30(2):141-50 (49 ref.)

[Value of the systematic uterine Doppler in the primiparous woman. A series of 315 cases] Soutif C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(8):819-23 (17 ref.) (Eng. Abstr.) **(Fre)**

PARKINSON DISEASE

see related
ANTIPARKINSON AGENTS
LEWY BODIES

Parkinson's disease: from etiology to treatment. Mizuno Y, et al. **Intern Med** 1995 Nov;34(11):1045-54 (139 ref.)

Parkinson's disease. Nadeau SE. **J Am Geriatr Soc** 1997 Feb; 45(2):233-40 (27 ref.)

Parkinson's disease: diagnosis, pathology, and treatment. Sethi KD. **J Med Assoc Ga** 1997 Apr;86(2):89-96 (46 ref.)

Pathophysiology, assessment, and treatment of Parkinson's disease. Tapper VJ. **Nurse Pract** 1997 Jul;22(7):76-8, 80, 85 passim (27 ref.)

Parkinson's disease. Playfer JR. **Postgrad Med J** 1997 May; 73(859):257-84 (41 ref.)

Lewy body disease. Smith TA, et al. **South Med J** 1996 Dec; 89(12):1174-80 (68 ref.)

Parkinson's disease. Diagnosis and treatment. Ng DC. **West J Med** 1996 Oct;165(4):234-40 (26 ref.)

[Recent progress in development of psychotropic drugs (3)--Antiparkinsonian agents applied in the treatment of Parkinson's disease or are under investigation for patients or model animals] Nomoto M. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Aug; 16(4):113-22 (41 ref.) (Eng. Abstr.) **(Jpn)**

[Diffuse Lewy body disease] Ishikawa A. **Nippon Rinsho** 1997 Jan;55(1):144-8 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Neural mechanisms for the clinical syndromes of Parkinson's disease] Kato M. **Nippon Rinsho** 1997 Jan;55(1):26-31 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Concept and diagnostic criteria of Parkinson's disease and parkinsonism] Mizuno Y. **Nippon Rinsho** 1997 Jan; 55(1):16-20 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical classifications of Parkinson's disease] Murata M, et al. **Nippon Rinsho** 1997 Jan;55(1):21-5 (17 ref.) (Eng. Abstr.) **(Jpn)**

[New therapeutic strategy for Parkinson's disease based on pharmacological profiles] Ogawa N. **Nippon Rinsho** 1997 Jan;55(1):43-51 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Vascular parkinsonism] Yamanouchi H. **Nippon Rinsho** 1997 Jan;55(1):106-11 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical characteristics and trends in research of Parkinson's disease and parkinsonism in Japan] Yanagisawa N. **Nippon Rinsho** 1997 Jan;55(1):9-15 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Definition and nosological concept of juvenile parkinsonism] Yokochi M, et al. **Nippon Rinsho** 1997 Jan;55(1):72-81 (41 ref.) (Eng. Abstr.) **(Jpn)**

[Diffuse Lewy body disease] Kosaka K. **Rinsho Shinkeigaku** 1995 Dec;35(12):1455-6 (10 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Disorders of posture, balance, and gait in Parkinson's disease. Rogers MW. **Clin Geriatr Med** 1996 Nov;12(4):825-45 (85 ref.)

Cognitive-motor dysfunction in Parkinson's disease. Brown RG, et al. **Eur Neurol** 1996;36 Suppl 1:24-31 (38 ref.)

Clinicophysiological features of akinesia. Imai H. **Eur Neurol** 1996;36 Suppl 1:9-12 (103 ref.)

Glial cell line-derived neurotrophic factor: a novel therapeutic approach to treat motor dysfunction in Parkinson's disease. Lapchak PA, et al. **Exp Neurol** 1997 Mar;144(1):29-34 (20 ref.)

New aspects of pathology in Parkinson's disease with concomitant incipient Alzheimer's disease. Braak H, et al. **J Neural Transm Suppl** 1996;48:1-6 (24 ref.)

Cognitive deficits in Parkinson's disease. Dubois B, et al. **J Neurol** 1997 Jan;244(1):2-8 (86 ref.)

Anxiety and Parkinson's disease. Richard IH, et al. **J Neuropsychiatry Clin Neurosci** 1996 Fall;8(4):383-92 (81 ref.)

Managing the late complications of Parkinson's disease. Waters CH. **Neurology** 1997 Jul;49(1 Suppl 1):S49-57 (77 ref.)

Drugs inducing or aggravating parkinsonism: a review. Martí-Massó JF, et al. **Therapie** 1996 Sep-Oct;51(5):568-77 (130 ref.)

[Respiratory disorders in movement disorders] Jiménez Jiménez FJ, et al. **Med Clin (Barc)** 1996 Sep 21;107(9):342-6 (69 ref.) **(Spa)**

[Depression and Parkinson's disease: neurobiologic foundations and therapeutic management] Giménez-Roldán S, et al. **Neurologia** 1996 Nov; 11(9):332-40 (51 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Early intervention in Parkinson's disease: epidemiologic considerations. Tanner CM. **Ann Epidemiol** 1996 Sep; 6(5):438-41 (14 ref.)

The dementias: nosological and clinical factors related to diagnosis. Stuss DT, et al. **Brain Cogn** 1996 Jul;31(2):99-113 (100 ref.)

Dementia with Lewy bodies. Kosaka K, et al. **Curr Opin Neurol** 1996 Aug;9(4):271-5 (43 ref.)

Spectrum of memory dysfunction in degenerative disease. Perry RJ, et al. **Curr Opin Neurol** 1996 Aug;9(4):281-5 (60 ref.)

Early detection of Parkinson's disease. Implications for treatment. Di Paola R, et al. **Drugs Aging** 1996 Sep; 9(3):159-68 (97 ref.)

Early diagnosis in Parkinson's disease--limitation of biochemical markers and instrumental methods. Kraus PH. **J Neural Transm Suppl** 1996;48:23-8 (9 ref.)

Epidemiological, genetic, pharmacological, kinesiological, nuclear medical (IBZM-SPECT), standard and functional MRI studies on Parkinson's disease and related disorders and economic evaluation of Parkinson's disease therapy--clinical projects in the BMFT-research program Munich: "Parkinson's disease and other basal ganglia disorders". Oertel WH, et al. **J Neural Transm Suppl** 1995; 46:325-37 (40 ref.)

Issues in the early diagnosis of Parkinson's disease. Koller WC, et al. **Neurology** 1997 Jul;49(1 Suppl 1):S10-25 (161 ref.)

[MRI of degenerative extrapyramidal syndromes. Parkinson disease, progressive supranuclear palsy and multiple system atrophy] Elkeslassy A, et al. **J Neuroradiol** 1996 Dec; 23(3):157-63 (14 ref.) (Eng. Abstr.) **(Fre)**

[Atypical Parkinson syndrome] Wenning GK, et al. **Nervenarzt** 1997 Feb;68(2):102-15 (142 ref.) (Eng. Abstr.) **(Ger)**

[Parkinson disease--diagnosis and treatment] Kanazawa I. **Nippon Naika Gakkai Zasshi** 1997 Mar 10;86(3):425-8 (2 ref.) **(Jpn)**

[Magnetic resonance spectroscopy in Parkinson's disease and multiple system atrophy] Aotsuka A, et al. **Nippon Rinsho** 1997 Jan;55(1):249-54 (12 ref.) (Eng. Abstr.) **(Jpn)**

[The use of magnetic resonance imaging (MRI) and single photon emission computing tomography (SPECT) for the differential diagnosis of Parkinson's disease and other neurodegenerative disorders presenting as parkinsonism] Kohira I. **Nippon Rinsho** 1997 Jan;55(1):39-42 (5 ref.) (Eng. Abstr.) **(Jpn)**

[PET study using 6-[18F]-fluorodopa in Parkinson's disease] Nagasawa H, et al. **Nippon Rinsho** 1997 Jan;55(1):213-7 (15 ref.) (Eng. Abstr.) **(Jpn)**

[The role of magnetic resonance spectroscopic imaging in patients with Parkinson's disease] Naruse S, et al. **Nippon Rinsho** 1997 Jan;55(1):262-4 (4 ref.) (Eng. Abstr.) **(Jpn)**

[PET and SPECT in Parkinson's disease] Blesa R. **Rev Neurol** 1997 Aug;25 Suppl 2:S147-50 (43 ref.) (Eng. Abstr.) **(Spa)**

[Parkinsonian syndromes in children] Chutorian A. **Rev Neurol** 1997 Jun;25(142):954-65 (81 ref.) **(Spa)**

DIET THERAPY

Nutrition and Parkinson's disease. Pandarinath G, et al. **N C Med J** 1997 May-Jun;58(3):186-8 (12 ref.)

DRUG THERAPY

Clozapine for the treatment of psychosis in Parkinson's disease: a review. Auzou P, et al. **Acta Neurol Scand** 1996 Nov;94(5):329-36 (76 ref.)

Retrospective study of selegiline-antidepressant drug interactions and a review of the literature. Ritter JL, et al. **Ann Clin Psychiatry** 1997 Mar;9(1):7-13 (37 ref.)

Selegiline and mortality in Parkinson's disease [see comments] Olanow CW, et al. **Ann Neurol** 1996 Dec;40(6):841-5 (36 ref.) Comment in: Ann Neurol 1997 Feb;41(2):282-3.

Current developments in neurology, Part II: Advances in the pharmacotherapy of Alzheimer disease, Parkinson's disease, and stroke. Gidal BE, et al. **Ann Pharmacother** 1996 Dec;30(12):1446-51 (53 ref.)

(-)Deprenyl (selegiline) in Parkinson's disease: a pharmacologist's comment [letter] Knoll J. **Biomed Pharmacother** 1996;50(6-7):315-7 (29 ref.)

Growth factor function in the development and maintenance of midbrain dopaminergic neurons: concepts, facts and prospects for TGF-beta. Unsicker K, et al. **Ciba Found Symp** 1996;196:70-80; discussion 80-4 (41 ref.)

Controversies in the treatment of Parkinson's disease. Hely MA, et al. **Curr Opin Neurol** 1996 Aug;9(4):308–13 (43 ref.)
Drug treatment of Parkinson's disease in the 1990s. Achievements and future possibilities. Hughes AJ. **Drugs** 1997 Feb;53(2):195–205 (65 ref.)
Gastrointestinal motility problems in patients with Parkinson's disease. Effects of antiparkinsonian treatment and guidelines for management. Jost WH. **Drugs Aging** 1997 Apr;10(4):249–58 (77 ref.)
Using liquid levodopa in the treatment of Parkinson's disease. A practical guide. Kurth MC. **Drugs Aging** 1997 May; 10(5):332–40 (40 ref.)
New directions in the drug treatment of Parkinson's disease. Montastruc JL, et al. **Drugs Aging** 1996 Sep;9(3):169–84 (82 ref.)
Treatment of Parkinson's disease. Advances in the pharmacological therapy. Ghika J. **Eur Neurol** 1996; 36(6):396–9 (33 ref.)
Management of motor fluctuations in Parkinson's disease. Koller WC. **Eur Neurol** 1996;36 Suppl 1:43–8 (48 ref.)
Motor fluctuations in levodopa treatment: clinical pharmacology. Stocchi F, et al. **Eur Neurol** 1996;36 Suppl 1:38–42 (38 ref.)
An overview of novel therapies for Parkinson's disease. Fahn S. **Exp Neurol** 1997 Mar;144(1):21–3 (43 ref.)
New strategies with dopaminergic drugs: modified formulations of levodopa and novel agonists. Goetz CG. **Exp Neurol** 1997 Mar;144(1):17–20 (45 ref.)
Problems with current pharmacologic treatment of Parkinson's disease. Hurtig HI. **Exp Neurol** 1997 Mar; 144(1):10–6 (61 ref.)
Neuroprotective therapy for Parkinson's disease. Koller WC. **Exp Neurol** 1997 Mar;144(1):24–8 (42 ref.)
Pharmacological activities of glial cell line–derived neurotrophic factor (GDNF): preclinical development and application to the treatment of Parkinson's disease. Lapchak PA, et al. **Exp Neurol** 1997 Jun;145(2 Pt 1):309–21 (65 ref.)
Impaired absorption of oral levodopa: a major cause for response fluctuations in Parkinson's disease. Djaldetti R, et al. **Isr J Med Sci** 1996 Dec;32(12):1224–7 (26 ref.)
Twenty-five years of amantadine therapy in Parkinson's disease. Danielczyk W. **J Neural Transm Suppl** 1995; 46:399–405 (34 ref.)
Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy. Fischer PA. **J Neural Transm Suppl** 1995;46:381–9 (29 ref.)
New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline. Gerlach M, et al. **J Neural Transm Suppl** 1996;48:7–21 (63 ref.)
Amantadine in Parkinson's disease: pro and contra. Greulich W, et al. **J Neural Transm Suppl** 1995;46:415–21 (27 ref.)
The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (–)-deprenyl research. Magyar K, et al. **J Neural Transm Suppl** 1996;48:29–43 (65 ref.)
Potential of neurotrophic factors in therapy of Parkinson's disease. Möller JC, et al. **J Neural Transm Suppl** 1996; 48:103–12 (57 ref.)
Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action. Olanow CW. **J Neural Transm Suppl** 1996;48:75–84 (60 ref.)
Modulation of control mechanisms of dopamine–induced apoptosis—a future approach to the treatment of Parkinson's disease? Ziv I, et al. **J Neural Transm Suppl** 1997;49:195–202 (21 ref.)
Amine precursor amino acid therapy: from neurochemical basis to clinical aspects. Nakajima T. **Neurochem Res** 1996 Feb;21(2):251–8 (52 ref.)
Newer therapies for Parkinson's disease. Korczyn AD, et al. **Neurol Neurochir Pol** 1996;30 Suppl 2:105–11 (22 ref.)
Is levodopa toxic? Fahn S. **Neurology** 1996 Dec;47(6 Suppl 3):S184–95 (154 ref.)
Selegiline monotherapy in the treatment of Parkinson's disease. Koller WC. **Neurology** 1996 Dec;47(6 Suppl 3):S196–9 (38 ref.)
Role of selegiline in combination therapy of Parkinson's disease. Myllylä VV, et al. **Neurology** 1996 Dec;47(6 Suppl 3):S200–9 (145 ref.)
Selegiline: current perspectives on issues related to neuroprotection and mortality. Olanow CW. **Neurology** 1996 Dec;47(6 Suppl 3):S210–6 (72 ref.)
Attempts to obtain neuroprotection in Parkinson's disease. Olanow CW. **Neurology** 1997 Jul;49(1 Suppl 1):S26–33 (87 ref.)
Contemporary approaches to the pharmacotherapeutic management of Parkinson's disease: an overview. Stern MB. **Neurology** 1997 Jul;49(1 Suppl 1):S2–9 (97 ref.)
Pharmacologic profile of ropinirole: a nonergoline dopamine agonist. Tulloch IF. **Neurology** 1997 Jul;49(1 Suppl 1):S58–62 (35 ref.)
The role of dopamine agonists in early Parkinson's disease. Watts RL. **Neurology** 1997 Jul;49(1 Suppl 1):S34–48 (87 ref.)
Glutamate antagonists and Parkinson's disease: a review of clinical data. Montastruc JL, et al. **Neurosci Biobehav Rev** 1997 Jul;21(4):477–80 (33 ref.)
The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders. Gassen M, et al. **Pharmacol Toxicol** 1997 Apr;80(4):159–66 (76 ref.)
Parkinson's disease: prospects for improved drug therapy. Hagan JJ, et al. **Trends Pharmacol Sci** 1997 May; 18(5):156–63 (76 ref.)
[Nicotine in neuropsychiatric movement disorders] Erdmann R. **Fortschr Neurol Psychiatr** 1996 Sep;64(9):362–6 (42 ref.) (Eng. Abstr.) **(Ger)**
[Parkinson disease—diagnosis and treatment] Kanazawa I. **Nippon Naika Gakkai Zasshi** 1997 Mar 10;86(3):425–8 (2 ref.) **(Jpn)**
[Treatment of Parkinson's disease with multiple drugs] Kuno S. **Nippon Rinsho** 1997 Jan;55(1):59–64 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Problems of long-term levodopa therapy in Parkinson's disease] Nakamura Y. **Nippon Rinsho** 1997 Jan;55(1):65–71 (26 ref.) (Eng. Abstr.) **(Jpn)**
[Treatment and prognosis of juvenile parkinsonism—L-dopa responsiveness] Takubo H. **Nippon Rinsho** 1997 Jan; 55(1):101–5 (23 ref.) (Eng. Abstr.) **(Jpn)**
[Guidelines of drug therapies for Parkinson's disease] Yanagisawa N. **Nippon Rinsho** 1997 Jan;55(1):52–7 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Pharmacological therapy of complicated Parkinson's disease] Jiménez-Jiménez FJ, et al. **Rev Neurol** 1997 Aug; 25 Suppl 2:S170–9 (249 ref.) (Eng. Abstr.) **(Spa)**
[Neuroprotective and neurorestorative therapy in Parkinson's disease] Jiménez-Jiménez FJ, et al. **Rev Neurol** 1997 Aug; 25 Suppl 2:S185–93 (207 ref.) (Eng. Abstr.) **(Spa)**
[Initial treatment of Parkinson's disease] Kulisevsky J, et al. **Rev Neurol** 1997 Aug;25 Suppl 2:S163–9 (42 ref.) (Eng. Abstr.) **(Spa)**
[Treatment of parkinsonism. Views on the recommendations issued by the Medical Products Agency] Olsson JE. **Lakartidningen** 1997 Mar 5;94(10):819–22 (20 ref.) **(Swe)**

ECONOMICS

[Costs of drug treatment of neurologic diseases: Parkinson disease, dystonia, epilepsy] Dodel RC, et al. **Med Klin** 1996 Jul 15;91(7):479–85 (64 ref.) (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

Tyrosine hydroxylase: human isoforms, structure and regulation in physiology and pathology. Nagatsu T. **Essays Biochem** 1995;30:15–35 (45 ref.)

EPIDEMIOLOGY

Early intervention in Parkinson's disease: epidemiologic considerations. Tanner CM. **Ann Epidemiol** 1996 Sep; 6(5):438–41 (14 ref.)
Parkinson's disease in populations of African origin: a review. Richards M, et al. **Neuroepidemiology** 1996;15(4):214–21 (52 ref.)
[Epidemiological characteristics of Parkinson's disease in various areas in the world] Zhang ZQ, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1996 Feb; 17(1):47–51 (15 ref.) **(Chi)**

ETHNOLOGY

Ethnicity and movement disorders. Eastham JH, et al. **Mt Sinai J Med** 1996 Oct-Nov;63(5-6):314–9 (33 ref.)

ETIOLOGY

Methioninase: a therapeutic for diseases related to altered methionine metabolism and transmethylation: cancer, heart disease, obesity, aging, and Parkinson's disease. Hoffman RM. **Hum Cell** 1997 Mar;10(1):69–80 (117 ref.)
Parkinson's disease: from etiology to treatment. Mizuno Y, et al. **Intern Med** 1995 Nov;34(11):1045–54 (139 ref.)
The etiology of Parkinson's disease with emphasis on the MPTP story. Langston JW. **Neurology** 1996 Dec;47(6 Suppl 3):S153–60 (66 ref.)
[Current aspects of the etiology of Parkinson disease (editorial)] Fuhr P. **Schweiz Rundsch Med Prax** 1997 Jan 14;86(3):34–6 (33 ref.) **(Ger)**
[Brain tumor and parkinsonism] Kondo T. **Nippon Rinsho** 1997 Jan;55(1):118–22 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Parkinsonism in Alzheimer's disease] Odawara T, et al. **Nippon Rinsho** 1997 Jan;55(1):149–52 (18 ref.) (Eng. Abstr.) **(Jpn)**
[The molecular genetic and toxicological-ecological bases of the etiology and pathogenesis of Parkinson's diseases (parkinsonism)] Iakimovskii AF, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1997;97(4):69–73 (52 ref.) **(Rus)**
[Neurochemistry of Parkinson's disease and parkinsonism plus] Pascual J, et al. **Rev Neurol** 1997 Aug;25 Suppl 2:S141–6 (40 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Conference Participants. Foster NL, et al. **Ann Neurol** 1997 Jun; 41(6):706–15 (41 ref.)
A gene for Parkinson disease. Chase TN. **Arch Neurol** 1997 Sep;54(9):1156–7 (15 ref.)
Is Parkinson's disease inherited? Hawkes CH. **Br J Hosp Med** 1997 Feb 19-Mar 4;57(4):130–3 (42 ref.)
Familial juvenile parkinsonism. Yokochi M. **Eur Neurol** 1997; 38 Suppl 1:29–33 (15 ref.)
Targets for gene therapy of Parkinson's disease: growth factors, signal transduction, and promoters. During MJ, et al. **Exp Neurol** 1997 Mar;144(1):74–81 (65 ref.)
Genetics of Parkinson's disease. Nussbaum RL, et al. **Hum Mol Genet** 1997;6(10):1687–91 (69 ref.)
GTP cyclohydrolase I gene, dystonia, juvenile parkinsonism, and Parkinson's disease. Nagatsu T, et al. **J Neural Transm Suppl** 1997;49:203–9 (30 ref.)
Disinhibition–dementia–parkinsonism–amyotrophy complex (DDPAC) is a non-Alzheimer's frontotemporal dementia. Wilhelmsen KC. **J Neural Transm Suppl** 1997;49:269–75 (35 ref.)
Nigrostriatal neuronal death in Parkinson's disease—a passive or an active genetically-controlled process? Ziv I, et al. **J Neural Transm Suppl** 1997;49:69–76 (26 ref.)
Retinoids: from hindbrain patterning to Parkinson disease. Eichele G. **Trends Genet** 1997 Sep;13(9):343–5 (25 ref.)
[Atypical familial parkinsonian syndromes. Parkinson diseases or specific entities?] Taussig D, et al. **Presse Med** 1997 Mar 1;26(6):290–6 (25 ref.) (Eng. Abstr.) **(Fre)**
[Clinical characteristics and linkage analysis of autosomal recessive form of juvenile parkinsonism(AR-JP)] Saito M, et al. **Nippon Rinsho** 1997 Jan;55(1):83–8 (22 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Neuroimmune mechanisms in Parkinson's disease. Kuhn W, et al. **J Neural Transm Suppl** 1995;46:229–33 (28 ref.)

METABOLISM

Nuclear microscope analysis in Alzheimer's and Parkinson's disease: A review. Watt F. **Cell Mol Biol (Noisy-le-grand)** 1996 Feb;42(1):17–26 (34 ref.)
Pharmacokinetic optimisation in the treatment of Parkinson's disease [published erratum appears in Clin Pharmacokinet 1996 Aug;31(2):110] Contin M, et al. **Clin Pharmacokinet** 1996 Jun;30(6):463–81 (196 ref.)
Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease. Elsworth JD, et al. **Exp Neurol** 1997 Mar;144(1):4–9 (44 ref.)
Mechanism of 6-hydroxydopamine neurotoxicity. Glinka Y, et al. **J Neural Transm Suppl** 1997;50:55–66 (41 ref.)
The neurochemistry of Parkinson's disease—comments on present and future developments. Hucho F. **J Neural Transm Suppl** 1995;46:59–65 (22 ref.)
N-methyl-(R)salsolinol as a dopaminergic neurotoxin: from an animal model to an early marker of Parkinson's disease. Naoi M, et al. **J Neural Transm Suppl** 1997;50:89–105 (49 ref.)
IBZM- and CIT-SPECT of the dopaminergic system in parkinsonism. Tissingh G, et al. **J Neural Transm Suppl** 1997;50:31–7 (38 ref.)
GTP cyclohydrolase I gene, tetrahydrobiopterin, and tyrosine hydroxylase gene: their relations to dystonia and parkinsonism. Nagatsu T, et al. **Neurochem Res** 1996 Feb; 21(2):245–50 (47 ref.)
Oxidative stress and the pathogenesis of Parkinson's disease. Jenner P, et al. **Neurology** 1996 Dec;47(6 Suppl 3):S161–70 (128 ref.)
Oxidative stress in Parkinson's disease and other neurodegenerative disorders. Jenner P. **Pathol Biol (Paris)** 1996 Jan;44(1):57–64 (51 ref.)
[Metabolic, cerebral and neuropsychological characterization of Parkinson syndromes] Salmon E, et al. **Rev Med Liege** 1996 Sep;51(9):566–70 (20 ref.) **(Fre)**
[Glucose metabolism and blood flow studies in 2 cases with juvenile Parkinson's disease] Shibasaki T. **Nippon Rinsho** 1997 Jan;55(1):95–100 (15 ref.) (Eng. Abstr.) **(Jpn)**
[PET study of dopamine metabolism and dopamine D2 receptor in juvenile parkinsonism] Tanji H, et al. **Nippon Rinsho** 1997 Jan;55(1):89–94 (25 ref.) (Eng. Abstr.) **(Jpn)**

MORTALITY

Selegiline and mortality in Parkinson's disease [see comments] Olanow CW, et al. **Ann Neurol** 1996 Dec;40(6):841–5 (36 ref.) Comment in: Ann Neurol 1997 Feb;41(2):282–3.

NURSING

Stereotactic pallidotomy for treatment of Parkinson's disease. Eller TW, et al. **AORN J** 1997 May;65(5):903–4, 907–16; quiz 917–20 (16 ref.)

PATHOLOGY

The cholinergic system in Alzheimer's disease and dementia with Lewy bodies: from animal models to neuropathological data. Liberini P. **Funct Neurol** 1997 May-Aug;12(3-4):153–7 (18 ref.)
Nigral and extranigral pathology in Parkinson's disease. Braak H, et al. **J Neural Transm Suppl** 1995;46:15–31 (87 ref.)
Neuronal vulnerability in Parkinson's disease. Hirsch EC, et al. **J Neural Transm Suppl** 1997;50:79–88 (36 ref.)
The relationship of Alzheimer-type pathology to dementia in Parkinson's disease. Jendroska K. **J Neural Transm Suppl** 1997;49:23–31 (66 ref.)
Modulation of control mechanisms of dopamine–induced apoptosis—a future approach to the treatment of Parkinson's disease? Ziv I, et al. **J Neural Transm Suppl** 1997;49:195–202 (21 ref.)
Nigrostriatal neuronal death in Parkinson's disease—a passive or an active genetically-controlled process? Ziv I, et al.

J Neural Transm Suppl 1997;49:69–76 (26 ref.)

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. McKeith LG, et al. **Neurology** 1996 Nov;47(5):1113–24 (49 ref.)

Re–evaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states. Levy R, et al. **Neuroscience** 1997 Jan;76(2):335–43 (68 ref.)

[Neuropathology of the basal ganglia in Parkinson's disease with a special reference to its responsible lesion] Tanaka J, et al. **Nippon Rinsho** 1997 Jan;55(1):32–8 (23 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Kaufmann H. **Clin Auton Res** 1996 Apr;6(2):125–6 (1 ref.)

Visual electrophysiology in Parkinson's disease: PERG, VEP and visual P300. Bodis–Wollner I. **Clin Electroencephalogr** 1997 Jul;28(3):143–7 (26 ref.)

Serotonin, dopamine, and motor effects in Parkinson's disease. Miyawaki E, et al. **Clin Neuropharmacol** 1997 Aug; 20(4):300–10 (103 ref.)

Parkinson's disease: biology and aetiology. Temlett JA. **Curr Opin Neurol** 1996 Aug;9(4):303–7 (86 ref.)

The role of glutamate in the pathophysiology of Parkinson's disease. Blandini F, et al. **Funct Neurol** 1996 Jan–Feb; 11(1):3–15 (95 ref.)

Neurodegeneration, sleep, and cerebral energy metabolism: a testable hypothesis. Mamelak M. **J Geriatr Psychiatry Neurol** 1997 Jan;10(1):29–32 (42 ref.)

Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. Gerlach M, et al. **J Neural Transm** 1996;103(8–9):987–1041 (267 ref.)

rCBF SPECT in Parkinson's disease patients with mental dysfunction. Bissessur S, et al. **J Neural Transm Suppl** 1997; 50:25–30 (38 ref.)

Contributions of positron emission tomography to elucidating the pathogenesis of idiopathic parkinsonism and dopa responsive dystonia. Calne DB, et al. **J Neural Transm Suppl** 1997;50:47–52 (21 ref.)

Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites. Hastings TG, et al. **J Neural Transm Suppl** 1997;49:103–10 (37 ref.)

Pathophysiology of movement disorders studied using PET. Leenders KL. **J Neural Transm Suppl** 1997;50:39–46 (12 ref.)

Sleep disorder related to Parkinson's disease. Partinen M. **J Neurol** 1997 Apr;244(4 Suppl 1):S3–6 (25 ref.)

The natural history of Parkinson's disease. Poewe WH, et al. **Neurology** 1996 Dec;47(6 Suppl 3):S146–52 (49 ref.)

Contribution of frontostriatal function to sequence learning in Parkinson's disease: evidence for dissociable systems. Dominey PF, et al. **Neuroreport** 1997 Mar 24;8(5):iii–ix (48 ref.)

Dopamine/glutamate interactions in Parkinson's disease. Lange KW, et al. **Neurosci Biobehav Rev** 1997 Jul; 21(4):393–400 (75 ref.)

The unilateral 6–hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Schwarting RK, et al. **Prog Neurobiol** 1996 Oct;50(2–3):275–331 (395 ref.)

Gastrointestinal dysfunction in Parkinson's disease. Quigley EM. **Semin Neurol** 1996 Sep;16(3):245–50 (58 ref.)

[Clinical features and current principles in medical treatment] Destée A. **Neurochirurgie** 1997;43 Suppl 1:52–8 (0 ref.) **(Fre)**

[Static contrast sensitivity in idiopathic Parkinson disease] Ingster–Moati I, et al. **Rev Neurol (Paris)** 1996 Dec; 152(12):738–43 (25 ref.) (Eng. Abstr.) **(Fre)**

[Neurodegeneration: aging and dementia. Etiopathogenic role of electron transport disorders. Therapeutic possibilities] Klivényi P, et al. **Orv Hetil** 1997 Feb 9; 138(6):331–5 (43 ref.) (Eng. Abstr.) **(Hun)**

[Objective measurement of motor activity in Parkinson's disease by actigraphy. Clinical assessment of akinesia] Fujikane M, et al. **Nippon Rinsho** 1997 Jan;55(1):153–7 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Impaired associated movement in Parkinson's disease] Kawakami O, et al. **Nippon Rinsho** 1997 Jan;55(1):179–84 (15 ref.) (Eng. Abstr.) **(Jpn)**

[A physiological study on instability in Parkinson's disease] Mitoma H. **Nippon Rinsho** 1997 Jan;55(1):168–72 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Central motor conduction time using magnetic and vibratory stimulation in Parkinson's disease, especially in patients with rigidity] Mochio S, et al. **Nippon Rinsho** 1997 Jan; 55(1):173–8 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Clinicophysiological study of tremor in Parkinson's disease: quantitative tremor–based assessment of motor count using actigraphy] Mochio S, et al. **Nippon Rinsho** 1997 Jan; 55(1):158–62 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Glucose metabolism and blood flow studies in 2 cases with juvenile Parkinson's disease] Shibasaki T. **Nippon Rinsho** 1997 Jan;55(1):95–100 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Parkinson's disease: diagnosis, treatment and prognosis] Tohgi H, et al. **Nippon Ronen Igakkai Zasshi** 1996 Dec; 33(12):911–5 (13 ref.) **(Jpn)**

[Pathophysiology of involuntary movements in adults] Hashimoto T, et al. **No To Hattatsu** 1997 May;29(3):193–8 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Movement–related cortical potentials (MRCPs) and voluntary movement––clinical usefulness of MRCPs] Washimi Y, et al. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1525–7 (10 ref.) (Eng. Abstr.) **(Jpn)**

PSYCHOLOGY

Management of psychiatric symptoms of Parkinson's disease. Miyoshi K, et al. **Eur Neurol** 1996;36 Suppl 1:49–8 (28 ref.)

Depression in Parkinson's disease. Murray JB. **J Psychol** 1996 Nov;130(6):659–67 (52 ref.)

[Metabolic, cerebral and neuropsychological characterization of Parkinson syndromes] Salmon E, et al. **Rev Med Liege** 1996 Sep;51(9):566–70 (20 ref.) **(Fre)**

[Memory disturbances in Parkinson's disease] Ringendahl H. **Fortschr Neurol Psychiatr** 1996 Feb;64(2):43–8 (91 ref.) (Eng. Abstr.) **(Ger)**

[Cognitive impairment in Parkinson's disease—a visual event–related potential study] Tachibana H. **Nippon Rinsho** 1997 Jan;55(1):189–94 (22 ref.) (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE IMAGING

Biological imaging and the molecular basis of dopaminergic diseases. Barrio JR, et al. **Biochem Pharmacol** 1997 Aug 1;54(3):341–8 (94 ref.)

Advances in imaging Parkinson's disease [editorial] Brooks DJ. **Curr Opin Neurol** 1997 Aug;10(4):327–31 (67 ref.)

rCBF SPECT in Parkinson's disease patients with mental dysfunction. Bissessur S, et al. **J Neural Transm Suppl** 1997; 50:25–30 (38 ref.)

Contributions of positron emission tomography to elucidating the pathogenesis of idiopathic parkinsonism and dopa responsive dystonia. Calne DB, et al. **J Neural Transm Suppl** 1997;50:47–52 (21 ref.)

Pathophysiology of movement disorders studied using PET. Leenders KL. **J Neural Transm Suppl** 1997;50:39–46 (12 ref.)

IBZM– and CIT–SPECT of the dopaminergic system in parkinsonism. Tissingh G, et al. **J Neural Transm Suppl** 1997;50:31–7 (38 ref.)

[Role of positron emission tomography in the evaluation of new treatments of Parkinson's disease] Remy P, et al. **Rev Neurol (Paris)** 1997 May;153(4):283–5 (17 ref.) **(Fre)**

[18F–fluorodeoxyglucose positron emission tomography in Parkinson's disease] Arahata Y, et al. **Nippon Rinsho** 1997 Jan;55(1):222–6 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Muscarinic cholinergic receptor imaging of parkinsonian brain using 11C–NMPB and PET] Asahina M, et al. **Nippon Rinsho** 1997 Jan;55(1):233–7 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Evaluation of benzodiazepine receptor in the cerebral cortex of Parkinson's disease using 123I–iomazenil SPECT] Kawabata K, et al. **Nippon Rinsho** 1997 Jan;55(1):244–8 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Striatal dopamine D2 receptor in Parkinson disease and its related disorders assessed by C–11 NMSP and PET] Momose T, et al. **Nippon Rinsho** 1997 Jan;55(1):227–32 (4 ref.) (Eng. Abstr.) **(Jpn)**

[Cerebral perfusion and oxygen metabolism in Parkinson's disease: positron emission tomographic study using oxygen–15–labeled CO2 and O2] Tanaka M, et al. **Nippon Rinsho** 1997 Jan;55(1):218–21 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Neurotransmitter systems in the human brain studied by positron emission tomography] Shinotoh H. **Rinsho Shinkeigaku** 1996 Dec;36(12):1313–5 (9 ref.) (Eng. Abstr.) **(Jpn)**

REHABILITATION

[Non–motor symptoms of Parkinson disease. Significant impact on quality of life––using possible treatments] Müller T, et al. **Fortschr Med** 1997 May 20;115(14):45–8 (0 ref.) (Eng. Abstr.) **(Ger)**

[Current therapy of idiopathic Parkinson disease. 1: Diagnosis, therapeutic guidelines, standard pharmacotherapy and physical therapy] Müller T, et al. **Fortschr Med** 1997 May 10;115(13):28, 31–4 (0 ref.) (Eng. Abstr.) **(Ger)**

[Current therapy of idiopathic Parkinson disease. 2: Recent and alternative therapies] Müller T, et al. **Fortschr Med** 1997 May 10;115(13):37–41 (0 ref.) (Eng. Abstr.) **(Ger)**

[The Parkinson patient in expert social medicine assessment with special reference to the nursing care law] Semsch–Poppe B, et al. **Gesundheitswesen** 1996 Dec; 58(12):635–40 (18 ref.) (Eng. Abstr.) **(Ger)**

[Effect of early diagnosis and therapy on prognosis of Parkinson syndrome] Werner M, et al. **Versicherungsmedizin** 1997 Aug 1;49(4):126–31 (16 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Controversies in pallidal surgery. Hariz MI. **Acta Neurochir Suppl (Wien)** 1997;68:1–10 (88 ref.)

Surgical treatment of Parkinson's disease. Krauss JK, et al. **Am Fam Physician** 1996 Oct;54(5):1621–9 (29 ref.)

Stereotactic pallidotomy for treatment of Parkinson's disease. Eller TW, et al. **AORN J** 1997 May;65(5):903–4, 907–16; quiz 917–20 (16 ref.)

Parkinson's disease, trophic factors, and adrenal medullary chromaffin cell grafting: basic and clinical studies. Date I. **Brain Res Bull** 1996;40(1):1–19 (223 ref.)

The role of pallidotomy in Parkinson's disease and dystonia. Vitek JL, et al. **Curr Opin Neurol** 1997 Aug;10(4):332–9 (56 ref.)

Treatment of Parkinson's disease. New surgical treatment strategies. Pollak P, et al. **Eur Neurol** 1996;36(6):400–4 (43 ref.)

Surgical control of akinesia in Parkinson's disease. Shima F, et al. **Eur Neurol** 1996;36 Suppl 1:55–61 (24 ref.)

From transplants to gene therapy for Parkinson's disease. Freeman TB. **Exp Neurol** 1997 Mar;144(1):47–50 (19 ref.)

Dopaminergic transplants in patients with Parkinson's disease: neuroanatomical correlates of clinical recovery. Kordower JH, et al. **Exp Neurol** 1997 Mar;144(1):41–6 (44 ref.)

Pallidal and thalamic surgery for Parkinson's disease. Tasker RR, et al. **Exp Neurol** 1997 Mar;144(1):35–40 (21 ref.)

Surgical intervention and anesthetic management of the patient with Parkinson's disease. Mason LJ, et al. **Int Anesthesiol Clin** 1996 Fall;34(4):133–50 (75 ref.)

Pallidotomy: a surgical intervention for control of Parkinson's disease. Gilbert M, et al. **J Neurosci Nurs** 1996 Aug;28(4):215–6, 221 (10 ref.)

Pallidotomy, editorial review [editorial] Fernandez PM, et al. **Neurol Res** 1997 Feb;19(1):25–34 (85 ref.)

Fetal nigral transplantation as a therapy for Parkinson's disease. Olanow CW, et al. **Trends Neurosci** 1996 Mar; 19(3):102–9 (81 ref.)

[Neurosurgical methods in treatment of Parkinson disease. Current status] Diederich NJ, et al. **Nervenarzt** 1997 Jun; 68(6):466–76 (140 ref.) (Eng. Abstr.) **(Ger)**

[Stereotactic pallidotomy––effective surgery for Parkinson's disease] Spiegelman R. **Harefuah** 1996 Nov 1;131(9):324–6 (8 ref.) **(Heb)**

[Adrenal transplantation and Parkinson's disease] Luquin MR, et al. **Rev Med Univ Navarra** 1994 Oct–Dec; 38(4):174–80 (38 ref.) (Eng. Abstr.) **(Spa)**

[Surgical therapy of Parkinson's disease] Luquin MR. **Rev Neurol** 1997 Aug;25 Suppl 2:S180–4 (45 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. Stocchi F, et al. **Clin Neuropharmacol** 1997 Apr;20(2):95–115 (146 ref.)

Basal ganglia: new therapeutic approaches to Parkinson's disease. Graybiel AM. **Curr Biol** 1996 Apr 1;6(4):368–71 (30 ref.)

Dopamine neurotransmission and treatments for Parkinson's disease in the molecular biology era. Ogawa N. **Eur Neurol** 1997;38 Suppl 1:2–5 (39 ref.)

Treatment of Parkinson's disease. Symptomatic cell therapies: cells as biological minipumps. Zurn AD, et al. **Eur Neurol** 1996;36(6):405–8 (40 ref.)

Practical aspects of the development of ex vivo and in vivo gene therapy for Parkinson's disease. Bankiewicz KS, et al. **Exp Neurol** 1997 Mar;144(1):147–56 (62 ref.)

Gene therapeutic strategies for neuroprotection: implications for Parkinson's disease. Bowers WJ, et al. **Exp Neurol** 1997 Mar;144(1):58–68 (114 ref.)

Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease. Elsworth JD, et al. **Exp Neurol** 1997 Mar;144(1):4–9 (44 ref.)

Development of an HSV–based vector for the treatment of Parkinson's disease. Fink DJ, et al. **Exp Neurol** 1997 Mar; 144(1):103–21 (87 ref.)

From transplants to gene therapy for Parkinson's disease. Freeman TB. **Exp Neurol** 1997 Mar;144(1):47–50 (19 ref.)

Helper virus–free herpes simplex virus–1 plasmid vectors for gene therapy of Parkinson's disease and other neurological disorders. Geller AI, et al. **Exp Neurol** 1997 Mar; 144(1):98–102 (26 ref.)

Adenovirus–mediated gene transfer to the central nervous system for Parkinson's disease. Horellou P, et al. **Exp Neurol** 1997 Mar;144(1):131–8 (68 ref.)

Gene therapy for Parkinson's disease: an approach to the prevention or palliation of levodopa–associated motor complications. Mouradian MM, et al. **Exp Neurol** 1997 Mar; 144(1):51–7 (65 ref.)

Application of ex vivo gene therapy in the treatment of Parkinson's disease. Raymon HK, et al. **Exp Neurol** 1997 Mar;144(1):82–91 (87 ref.)

Gene therapy approaches to Parkinson's disease: preclinical to clinical trials, or what steps to take to get there from here? Redmond DE Jr. **Exp Neurol** 1997 Mar;144(1):160–7 (72 ref.)

Current trends in the pharmacologic and surgical treatment of Parkinson's disease. Galler RM, et al. **J Am Osteopath Assoc** 1996 Apr;96(4):228–32 (25 ref.)

Neuronal transplantation and neurotrophic factors in the treatment of Parkinson's disease––update February 1995. Kupsch A, et al. **J Neural Transm Suppl** 1995;46:193–207 (73 ref.)

The current significance of physiotherapeutic measures in the treatment of Parkinson's disease. Ulm G. **J Neural Transm Suppl** 1995;46:455–60 (23 ref.)

Fetal tissue transplantation for the treatment of Parkinson's disease: a review of the literature. Chisholm AH. **J Neurosci Nurs** 1996 Oct;28(5):329–38 (34 ref.)

Pathophysiology and management of idiopathic Parkinson's

disease. Lusis SA. **J Neurosci Nurs** 1997 Feb;29(1):24–31 (51 ref.)

Controlled release of proteins to tissue transplants for the treatment of neurodegenerative disorders. Mahoney MJ, et al. **J Pharm Sci** 1996 Dec;85(12):1276–81 (46 ref.)

Prospects for gene therapy in Parkinson's disease. Freese A, et al. **Mov Disord** 1996 Sep;11(5):469–88 (112 ref.)

Managing the late complications of Parkinson's disease. Waters CH. **Neurology** 1997 Jul;49(1 Suppl 1):S49–57 (77 ref.)

The coming of age of the GDNF family and its receptors: gene delivery in a rat Parkinson model may have clinical implications. Olson L. **Trends Neurosci** 1997 Jul;20(7):277–9 (22 ref.)

[Clinical features and current principles in medical treatment] Destée A. **Neurochirurgie** 1997;43 Suppl 1:52–8 (0 ref.) **(Fre)**

[Parkinson disease: interrogations and solutions] Allain H, et al. **Presse Med** 1997 Jun 7;26(19):909–15 (58 ref.) (Eng. Abstr.) **(Fre)**

[Cell transplantation for neuronal and muscular disorders] Kondoh T, et al. **No To Shinkei** 1997 Jun;49(6):507–15 (50 ref.) **(Jpn)**

PARKINSON DISEASE, POSTENCEPHALITIC

see related
ENCEPHALITIS, EPIDEMIC

PARKINSON DISEASE, SYMPTOMATIC

[Drug-induced parkinsonism] Kuzuhara S. **Nippon Rinsho** 1997 Jan;55(1):112–7 (15 ref.) (Eng. Abstr.) **(Jpn)**

CHEMICALLY INDUCED

Drug-induced movement disorders. Jiménez-Jiménez FJ, et al. **Drug Saf** 1997 Mar;16(3):180–204 (643 ref.)

Movement disorders associated with the serotonin selective reuptake inhibitors. Leo RJ. **J Clin Psychiatry** 1996 Oct; 57(10):449–54 (86 ref.)

Experimental models and behavioural tests used in the study of Parkinson's disease. Mokrý J. **Physiol Res** 1995; 44(3):143–50 (40 ref.)

Drugs inducing or aggravating parkinsonism: a review. Marti-Massó JF, et al. **Therapie** 1996 Sep-Oct;51(5):568–77 (130 ref.)

DIAGNOSIS

[Atypical Parkinson syndrome] Wenning GK, et al. **Nervenarzt** 1997 Feb;68(2):102–15 (142 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Novel approaches to the symptomatic treatment of parkinsonian syndromes: alternatives and adjuncts to dopamine-replacement. Brotchie JM. **Curr Opin Neurol** 1997 Aug;10(4):340–5 (45 ref.)

Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents--preclinical studies. Danysz W, et al. **Neurosci Biobehav Rev** 1997 Jul;21(4):455–68 (151 ref.)

Reversal of parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission: potential mechanisms of action. Mitchell IJ, et al. **Neurosci Biobehav Rev** 1997 Jul;21(4):469–75 (63 ref.)

ETIOLOGY

Non-Parkinson akinetic-rigid syndromes. Riley DE, et al. **Curr Opin Neurol** 1996 Aug;9(4):321–6 (86 ref.)

Dopamine and serotonin receptors: amino acid sequences, and clinical role in neuroleptic parkinsonism. Seeman P, et al. **Jpn J Pharmacol** 1996 Jul;71(3):187–204 (140 ref.)

METABOLISM

N-methyl-(R)salsolinol as a dopaminergic neurotoxin: from an animal model to an early marker of Parkinson's disease. Naoi M, et al. **J Neural Transm Suppl** 1997;50:89–105 (49 ref.)

IBZM- and CIT-SPECT of the dopaminergic system in parkinsonism. Tissingh G, et al. **J Neural Transm Suppl** 1997;50:31–7 (38 ref.)

GTP cyclohydrolase I gene, tetrahydrobiopterin, and tyrosine hydroxylase gene: their relations to dystonia and parkinsonism. Nagatsu T, et al. **Neurochem Res** 1996 Feb; 21(2):245–50 (47 ref.)

[Metabolic, cerebral and neuropsychological characterization of Parkinson syndromes] Salmon E, et al. **Rev Med Liege** 1996 Sep;51(9):566–70 (20 ref.) **(Fre)**

PHYSIOPATHOLOGY

Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. Gerlach M, et al. **J Neural Transm** 1996;103(8–9):987–1041 (267 ref.)

Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease. Blanchet PJ, et al. **Neurosci Biobehav Rev** 1997 Jul;21(4):447–53 (80 ref.)

Species differences in the role of excitatory amino acids in experimental parkinsonism. Fornai F, et al. **Neurosci Biobehav Rev** 1997 Jul;21(4):401–15 (156 ref.)

Stimulation of basal and L-DOPA-induced motor activity by glutamate antagonists in animal models of Parkinson's disease. Starr MS, et al. **Neurosci Biobehav Rev** 1997 Jul; 21(4):437–46 (69 ref.)

PSYCHOLOGY

Experimental models and behavioural tests used in the study of Parkinson's disease. Mokrý J. **Physiol Res** 1995; 44(3):143–50 (40 ref.)

RADIONUCLIDE IMAGING

IBZM- and CIT-SPECT of the dopaminergic system in parkinsonism. Tissingh G, et al. **J Neural Transm Suppl** 1997;50:31–7 (38 ref.)

PARKINSONIAN SYNDROME see **PARKINSON DISEASE, SYMPTOMATIC**

PAROTID DISEASES

Parotid lipomatosis. Holland AJ, et al. **J Pediatr Surg** 1996 Oct;31(10):1422–3 (18 ref.)

DIAGNOSIS

Differential diagnosis of parotid masses in HIV positive men: report of five cases and review. Seddon BM, et al. **Int J STD AIDS** 1996 May-Jun;7(3):224–7 (11 ref.)

[Intraparotid lymphoepithelial cysts and the human immunodeficiency virus] Rivas Lacarte MP, et al. **Rev Clin Esp** 1997 Jun;197(6):417–9 (13 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Dysgenetic polycystic disease of the parotid gland: report of case. Ficarra G, et al. **J Oral Maxillofac Surg** 1996 Oct; 54(10):1246–9 (15 ref.)

PATHOLOGY

[Juvenile xanthogranuloma localized in the parotid gland] Moukassa D, et al. **Ann Pathol** 1997 Apr;17(2):113–5 (14 ref.) (Eng. Abstr.) **(Fre)**

VIROLOGY

Differential diagnosis of parotid masses in HIV positive men: report of five cases and review. Seddon BM, et al. **Int J STD AIDS** 1996 May-Jun;7(3):224–7 (11 ref.)

PAROTID GLAND

ABNORMALITIES

Monolateral aplasia of the parotid gland. Almadori G, et al. **Ann Otol Rhinol Laryngol** 1997 Jun;106(6):522–5 (35 ref.)

BLOOD SUPPLY

The 'turkey wattle' sign revisited: diagnosing parotid vascular malformations in the adult. Saeed WR, et al. **Br J Plast Surg** 1997 Jan;50(1):43–6 (22 ref.)

CYTOLOGY

Immunocytochemical studies of cell differentiation during rat salivary gland development. Hand AR, et al. **Eur J Morphol** 1996 Aug;34(3):149–54 (25 ref.)

The significance of lamellated structure of Golgi apparatus in parotid acinar cells. Yamashina S, et al. **Eur J Morphol** 1996 Aug;34(3):229–32 (11 ref.)

EMBRYOLOGY

Immunocytochemical studies of cell differentiation during rat salivary gland development. Hand AR, et al. **Eur J Morphol** 1996 Aug;34(3):149–54 (25 ref.)

METABOLISM

Changes in intracellular Ca2+ concentration produced by the alteration of intracellular pH in rat parotid acinar cells. Nishiguchi H, et al. **Jpn J Physiol** 1997 Feb;47(1):41–9 (32 ref.)

SURGERY

The 'turkey wattle' sign revisited: diagnosing parotid vascular malformations in the adult. Saeed WR, et al. **Br J Plast Surg** 1997 Jan;50(1):43–6 (22 ref.)

PAROTID NEOPLASMS

Pleomorphic adenoma of the parotid. Wolf IS, et al. **Am Fam Physician** 1997 Jul;56(1):185–92 (25 ref.)

DIAGNOSIS

Pictorial review: MR imaging of parotid tumours. Soler R, et al. **Clin Radiol** 1997 Apr;52(4):269–75 (13 ref.)

Diagnosis and treatment of parotid tumours. Kamal SA, et al. **J Laryngol Otol** 1997 Apr;111(4):316–21 (27 ref.)

[Intra-parotid neurogenic tumors of the facial nerve. Value of MRI] Fisch-Ponsot C, et al. **J Radiol** 1997 Feb; 78(2):141–4 (14 ref.) (Eng. Abstr.) **(Fre)**

ETHNOLOGY

Lymphoepithelial carcinoma of salivary glands. Abdulla AK, et al. **Head Neck** 1996 Nov-Dec;18(6):577–81 (23 ref.)

PATHOLOGY

Role of fine needle aspiration cytology in the management of the discrete parotid lump. McGurk M, et al. **Ann R Coll Surg Engl** 1997 May;79(3):198–202 (27 ref.)

Polymorphous low-grade adenocarcinoma of parotid gland. Merchant WJ, et al. **Br J Oral Maxillofac Surg** 1996 Aug; 34(4):328–30 (11 ref.)

Basal cell adenocarcinoma of the salivary glands. Report of seven cases and review of the literature. Muller S, et al. **Cancer** 1996 Dec 15;78(12):2471–7 (26 ref.)

A cytologic, immunocytochemical and ultrastructural study of a malignant parotid gland myoepithelioma. Sironi M, et al. **Cytopathology** 1997 Feb;8(1):53–62 (16 ref.)

Lymphoepithelioma-like salivary gland carcinoma in Taiwan: a clinicopathological study of nine cases demonstrating a strong association with Epstein-Barr virus. Kuo T, et al. **Histopathology** 1997 Jul;31(1):75–82 (22 ref.)

Metastatic carcinoma of the prostate presenting as parotid tumour. Simpson RH, et al. **Histopathology** 1997 Jan; 30(1):70–4 (14 ref.)

Mucoepidermoid carcinoma with cutaneous presentation. Yen A, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):340–2 (17 ref.)

Capillary haemangioma of the parotid in an adult: an unusual case and a review of the literature. Hughes RG, et al. **J Laryngol Otol** 1997 Jun;111(6):588–9 (13 ref.)

Salivary duct carcinoma: a clinicopathologic study of three cases with a review of the literature. Minamiguchi S, et al. **Pathol Int** 1996 Aug;46(8):614–22 (22 ref.)

[Tumors of the parotid gland] Tresserra L, et al. **Rev Stomatol Chir Maxillofac** 1997 Sep;98(3):220–30 (37 ref.) (Eng. Abstr.) **(Fre)**

[Primary salivary gland tumors in lymph nodes of the parotid gland. Report of 3 cases and review of the literature] Seifert G. **Pathologe** 1997 Mar;18(2):141–6 (54 ref.) (Eng. Abstr.) **(Ger)**

[Effects of TNM extension and histopathological type of the tumor on long-term survival rates of parotid and submandibular gland cancer] Konno A, et al. **Gan To Kagaku Ryoho** 1997 Aug;24(10):1347–53 (10 ref.) (Eng. Abstr.) **(Jpn)**

[A case of malignant oncocytoma of the parotid gland] Nakagawa M, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Jan;99(1):1–5 (14 ref.) (Eng. Abstr.) **(Jpn)**

SECONDARY

Cutaneous squamous cell carcinoma metastatic to the parotid gland in a transplant patient. Christiansen TN, et al. **Clin Transplant** 1996 Dec;10(6 Pt 1):561–3 (23 ref.)

Metastatic carcinoma of the prostate presenting as parotid tumour. Simpson RH, et al. **Histopathology** 1997 Jan; 30(1):70–4 (14 ref.)

[Two cases of melanoma metastasis. Description and review of the literature] Zanon C, et al. **Minerva Chir** 1996 Nov; 51(11):979–82 (8 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Diagnosis and treatment of parotid tumours. Kamal SA, et al. **J Laryngol Otol** 1997 Apr;111(4):316–21 (27 ref.)

Intraparotid facial nerve schwannoma in a child. Kumar BN, et al. **J Laryngol Otol** 1996 Dec;110(12):1169–70 (11 ref.)

[Malignant tumors of the parotid gland. Apropos of 60 cases] Coiffier T, et al. **Ann Otolaryngol Chir Cervicofac** 1996; 113(7–8):419–24 (26 ref.) (Eng. Abstr.) **(Fre)**

[Epithelioid sarcoma of the parotid region] Johannssen V, et al. **Laryngorhinootologie** 1996 Sep;75(9):556–9 (29 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Salivary duct carcinoma: clinical characteristics and treatment strategies. Guzzo M, et al. **Head Neck** 1997 Mar; 19(2):126–33 (29 ref.)

[Squamous cell carcinoma of the parotid gland in children] Higuchi S, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Jul; 99(7):999–1003 (25 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

A cytologic, immunocytochemical and ultrastructural study of a malignant parotid gland myoepithelioma. Sironi M, et al. **Cytopathology** 1997 Feb;8(1):53–62 (16 ref.)

VIROLOGY

Lymphoepithelioma-like salivary gland carcinoma in Taiwan: a clinicopathological study of nine cases demonstrating a strong association with Epstein-Barr virus. Kuo T, et al. **Histopathology** 1997 Jul;31(1):75–82 (22 ref.)

PAROTITIS

DIAGNOSIS

Submasseteric abscess caused by a dentigerous cyst

mimicking a parotitis: report of two cases. Mandel L. **J Oral Maxillofac Surg** 1997 Sep;55(9):996–9 (17 ref.)

ETIOLOGY

A case of swollen parotid gland. Ros SP, et al. **Pediatr Emerg Care** 1996 Jun;12(3):205–6 (6 ref.)

PAROXETINE

ADVERSE EFFECTS

A review of the psychomotor effects of paroxetine. Hawley CJ, et al. **Int Clin Psychopharmacol** 1997 Jan;12(1):13–8 (24 ref.)

THERAPEUTIC USE

Depression: making the diagnosis and using SSRIs in the older patient. Reynolds CF 3rd. **Geriatrics** 1996 Oct; 51(10):28–34 (25 ref.)

Antidepressants in the treatment of premature ejaculation. Balon R. **J Sex Marital Ther** 1996 Summer;22(2):85–96 (51 ref.)

PARROTS

Functional anatomy of forebrain vocal control pathways in the budgerigar (Melopsittacus undulatus). Brauth SE, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:368–85 (32 ref.)

Audio–vocal learning in budgerigars. Hall WS, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:352–67 (58 ref.)

PARSONAGE–TURNER SYNDROME see **CERVICO–BRACHIAL NEURALGIA**

PARTIAL MASTECTOMY see **MASTECTOMY, SEGMENTAL**

PARTIAL MONOSOMY see **CHROMOSOME DELETION**

PARTIAL THROMBOPLASTIN TIME

[Tests for the intrinsic clotting pathways] Fukue H, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:129–31 (4 ref.) **(Jpn)**

PARTICLE ACCELERATORS

see related
RADIOSURGERY

Modelling clinical accelerator beams: a review. Ebert MA, et al. **Australas Phys Eng Sci Med** 1996 Sep;19(3):131–50 (148 ref.)

PARTICLE–INDUCED X–RAY EMISSION SPECTROMETRY see **SPECTROMETRY, X–RAY EMISSION**

PARTICLE INTERACTIONS, ELEMENTARY see **ELEMENTARY PARTICLE INTERACTIONS**

PARTICLE SIZE

Genome size in bacteria. Trevors JT. **Antonie Van Leeuwenhoek** 1996 May;69(4):293–303 (73 ref.)

PARTNER NOTIFICATION see **CONTACT TRACING**

PARTURIENT PARESIS

PREVENTION & CONTROL

Strategies for preventing milk fever in dairy cattle. Horst RL, et al. **J Dairy Sci** 1997 Jul;80(7):1269–80 (108 ref.)

PARTURITION see **LABOR**

PARVALBUMINS

METABOLISM

Calcium–binding proteins in primate basal ganglia. Parent A, et al. **Neurosci Res** 1996 Aug;25(4):309–34 (156 ref.)

PARVOVIRIDAE

IMMUNOLOGY

Rheumatic manifestations due to human parvovirus B19. A report of four cases. Golstein MA, et al. **Rev Rhum Engl Ed** 1996 Dec;63(11):854–8 (21 ref.)

ISOLATION & PURIFICATION

Parvovirus B19 infection and rheumatic diseases. Caramaschi P, et al. **Rev Rhum Engl Ed** 1996 Dec;63(11):846–53 (103 ref.)

PHYSIOLOGY

Epizootiology, distribution and the impact on international trade of two penaeid shrimp viruses in the Americas. Lightner DV. **Rev Sci Tech** 1996 Jun;15(2):579–601 (80 ref.)

PARVOVIRIDAE INFECTIONS

Infections caused by parvovirus B19. Chinea B, et al. **Bol Asoc Med P R** 1996 Jan–Mar;88(1–3):20–6 (26 ref.)

Pure red cell aplasia due to parvovirus B19 infection in solid organ transplantation. Ahsan N, et al. **Clin Transplant** 1997 Aug;11(4):265–70 (26 ref.)

Infection by parvovirus B 19 during pregnancy: a review. Levy R, et al. **Obstet Gynecol Surv** 1997 Apr;52(4):254–9 (55 ref.)

COMPLICATIONS

Parvovirus B19 in HIV infection: a treatable cause of anemia. Fuller A, et al. **Pathology** 1996 Aug;28(3):277–80 (20 ref.)

Parvovirus B19 infection and rheumatic diseases. Caramaschi P, et al. **Rev Rhum Engl Ed** 1996 Dec;63(11):846–53 (103 ref.)

Rheumatic manifestations due to human parvovirus B19. A report of four cases. Golstein MA, et al. **Rev Rhum Engl Ed** 1996 Dec;63(11):854–8 (21 ref.)

[Cutaneous vasculitis disclosing parvovirus B19 infection (letter)] Andrès E, et al. **Ann Med Interne (Paris)** 1997; 148(1):107–8 (9 ref.) **(Fre)**

[Acute blood spoliation: an unrecognized hemolytic factor allowing clinical expression of erythroblastopenia caused by parvoviruses B19 in healthy subjects (letter)] Join–Lambert O, et al. **Ann Med Interne (Paris)** 1996; 147(7):516–8 (9 ref.) **(Fre)**

[A case with petechiae due to human parvovirus B19] Shimada Y, et al. **Kansenshogaku Zasshi** 1996 Sep; 70(9):976–80 (21 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Parvovirus B19 in human disease. Brown KE, et al. **Annu Rev Med** 1997;48:59–67 (30 ref.)

New molecular diagnostic tests for two congenital forms of anemia. Auerbach AD, et al. **J Clin Lab Anal** 1997; 11(1):17–22 (27 ref.)

ETIOLOGY

Parvovirus B19 infection in a liver transplant recipient: case report and review in organ transplant recipients. Chang FY, et al. **Clin Transplant** 1996 Jun;10(3):243–7 (36 ref.)

IMMUNOLOGY

Aplastic anemia in a cardiac transplant recipient. Thio K, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1139, 1141–2 (11 ref.)

Parvoviruses and bone marrow failure. Brown KE, et al. **Stem Cells** 1996 Mar;14(2):151–63 (95 ref.)

TRANSMISSION

Human parvovirus B19 and blood products. Prowse C, et al. **Vox Sang** 1997;72(1):1–10 (128 ref.)

VETERINARY

Rodent parvovirus infections. Jacoby RO, et al. **Lab Anim Sci** 1996 Aug;46(4):370–80 (89 ref.)

VIROLOGY

Prevalence of parvovirus B19 infection in patients infected with human immunodeficiency virus. van Elsacker–Neile AM, et al. **Clin Infect Dis** 1996 Dec;23(6):1255–60 (28 ref.)

PARVOVIRUS

GENETICS

Autonomous parvovirus and densovirus gene vectors. Corsini J, et al. **Adv Virus Res** 1996;47:303–51 (206 ref.)

PARVOVIRUS B19, HUMAN

see related
ERYTHEMA INFECTIOSUM

Parvovirus B19 in human disease. Brown KE, et al. **Annu Rev Med** 1997;48:59–67 (30 ref.)

Infections caused by parvovirus B19. Chinea B, et al. **Bol Asoc Med P R** 1996 Jan–Mar;88(1–3):20–6 (26 ref.)

Pure red cell aplasia due to parvovirus B19 infection in solid organ transplantation. Ahsan N, et al. **Clin Transplant** 1997 Aug;11(4):265–70 (26 ref.)

Parvovirus B19 infection in a liver transplant recipient: case report and review in organ transplant recipients. Chang FY, et al. **Clin Transplant** 1996 Jun;10(3):243–7 (36 ref.)

Infection by parvovirus B 19 during pregnancy: a review. Levy R, et al. **Obstet Gynecol Surv** 1997 Apr;52(4):254–9 (55 ref.)

Parvovirus B19 in HIV infection: a treatable cause of anemia. Fuller A, et al. **Pathology** 1996 Aug;28(3):277–80 (20 ref.)

Human parvovirus B19 and blood products. Prowse C, et al. **Vox Sang** 1997;72(1):1–10 (128 ref.)

[Cutaneous vasculitis disclosing parvovirus B19 infection (letter)] Andrès E, et al. **Ann Med Interne (Paris)** 1997; 148(1):107–8 (9 ref.) **(Fre)**

[Acute blood spoliation: an unrecognized hemolytic factor allowing clinical expression of erythroblastopenia caused by parvoviruses B19 in healthy subjects (letter)] Join–Lambert O, et al. **Ann Med Interne (Paris)** 1996; 147(7):516–8 (9 ref.) **(Fre)**

[A case with petechiae due to human parvovirus B19] Shimada Y, et al. **Kansenshogaku Zasshi** 1996 Sep; 70(9):976–80 (21 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

New molecular diagnostic tests for two congenital forms of anemia. Auerbach AD, et al. **J Clin Lab Anal** 1997; 11(1):17–22 (27 ref.)

IMMUNOLOGY

Papular–purpuric gloves–and–socks syndrome. Vargas–Diez E, et al. **Int J Dermatol** 1996 Sep;35(9):626–32 (25 ref.)

Aplastic anemia in a cardiac transplant recipient. Thio K, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1139, 1141–2 (11 ref.)

ISOLATION & PURIFICATION

Prevalence of parvovirus B19 infection in patients infected with human immunodeficiency virus. van Elsacker–Neile AM, et al. **Clin Infect Dis** 1996 Dec;23(6):1255–60 (28 ref.)

PATHOGENICITY

Parvoviruses and bone marrow failure. Brown KE, et al. **Stem Cells** 1996 Mar;14(2):151–63 (95 ref.)

PARVOVIRUS INFECTIONS see **PARVOVIRIDAE INFECTIONS**

PARVOVIRUSES, INSECT see **DENSOVIRUS**

PASSIVE ADDICTION, NEONATAL see **NEONATAL ABSTINENCE SYNDROME**

PASSIVE ANTIBODY TRANSFER see **IMMUNIZATION, PASSIVE**

PASSIVE MOTION THERAPY, CONTINUOUS see **MOTION THERAPY, CONTINUOUS PASSIVE**

PASSIVE RANGE OF MOTION see **RANGE OF MOTION, ARTICULAR**

PASSIVE SMOKING see **TOBACCO SMOKE POLLUTION**

PASSIVE TRANSFER OF IMMUNITY see **IMMUNIZATION, PASSIVE**

PASTES see **OINTMENTS**

PASTEURELLA

IMMUNOLOGY

Immunization with bacterial antigens: pasteurellosis. Romalde JL, et al. **Dev Biol Stand** 1997;90:167–77 (42 ref.)

PASTEURELLA INFECTIONS

Pasteurella multocida pneumonia. Klein NC, et al. **Semin Respir Infect** 1997 Mar;12(1):54–6 (19 ref.)

DIAGNOSIS

Pasteurella multocida epiglottitis. Wine N, et al. **Arch Otolaryngol Head Neck Surg** 1997 Jul;123(7):759–61 (10 ref.)

[Pasteurella multocida: infections in man] Stepanshin IuG, et al. **Antibiot Khimioter** 1997;42(1):37–44 (61 ref.) (Eng. Abstr.) **(Rus)**

ETIOLOGY

Pasteurella multocida infectious arthritis with acute gout after a cat bite. Butt TS, et al. **J Rheumatol** 1997 Aug; 24(8):1649–52 (56 ref.)

Pasteurella multocida endocarditis: report of a case and review of the literature. Genne D, et al. **Scand J Infect Dis** 1996;28(1):95–7 (19 ref.)

IMMUNOLOGY

Restricted B–cell responses to microbial challenge of the respiratory tract. Walker J, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):197–204 (28 ref.)

VETERINARY

Immunization with bacterial antigens: pasteurellosis. Romalde JL, et al. **Dev Biol Stand** 1997;90:167–77 (42 ref.)

PASTEURELLA MULTOCIDA

Pasteurella multocida epiglottitis. Wine N, et al. **Arch Otolaryngol Head Neck Surg** 1997 Jul;123(7):759–61 (10 ref.)

Pasteurella multocida endocarditis: report of a case and review of the literature. Genne D, et al. **Scand J Infect Dis** 1996;28(1):95–7 (19 ref.)

Pasteurella multocida pneumonia. Klein NC, et al. **Semin Respir Infect** 1997 Mar;12(1):54–6 (19 ref.)

PASTEURELLA MULTOCIDA

[Pasteurella multocida: infections in man] Stepanshin IuG, et al. **Antibiot Khimioter** 1997;42(1):37–44 (61 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Restricted B-cell responses to microbial challenge of the respiratory tract. Walker J, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):197–204 (28 ref.)

ISOLATION & PURIFICATION

Pasteurella multocida infectious arthritis with acute gout after a cat bite. Butt TS, et al. **J Rheumatol** 1997 Aug; 24(8):1649–52 (56 ref.)

PASTEURELLA PESTIS see **YERSINIA PESTIS**

PASTEURELLA TULARENSIS see **FRANCISELLA TULARENSIS**

PASTEURELLOSIS see **PASTEURELLA INFECTIONS**

PASTORAL CARE

Spiritual issues and bioethics in the intensive care unit: the role of the chaplain. Wagner JT, et al. **Crit Care Clin** 1996 Jan;12(1):15–27 (09 ref.)

Towards a rhetoric of spirituality in mental health care. Nolan P, et al. **J Adv Nurs** 1997 Aug;26(2):289–94 (27 ref.)

Physicians' collaboration with chaplains: difficulties and benefits. Thiel MM, et al. **J Clin Ethics** 1997 Spring; 8(1):94–103 (23 ref.)

The spiritual dimension of hospice: the secularization of an ideal. Bradshaw A. **Soc Sci Med** 1996 Aug;43(3):409–19 (44 ref.)

ORGANIZATION & ADMINISTRATION

Posttraumatic stress, mental health professionals, and the clergy: a need for collaboration, training, and research. Weaver AJ, et al. **J Trauma Stress** 1996 Oct;9(4):847–56 (54 ref.)

Radicalizing recovery: addiction, spirituality, and politics. Morell C. **Soc Work** 1996 May;41(3):306–12 (34 ref.)

STANDARDS

[Sects, sectarisms and authentic spiritual pathways: can we learn to discern between them in order to counsel?] Wulliemier F. **Rev Med Suisse Romande** 1997 Jun; 117(6):525–33 (24 ref.) **(Fre)**

PATCH-CLAMP TECHNIQUES

Induced membrane hypo/hyper-mechanosensitivity: a limitation of patch-clamp recording. Hamill OP, et al. **Annu Rev Physiol** 1997;59:621–31 (51 ref.)

Functional and molecular analysis of glutamate-gated channels by patch-clamp and RT-PCR at the single cell level. Audinat E, et al. **Neurochem Int** 1996 Feb; 28(2):119–36 (49 ref.)

Gramicidin perforated patch recording and intracellular chloride activity in excitable cells. Akaike N. **Prog Biophys Mol Biol** 1996;65(3):251–64 (40 ref.)

[Possible applications of the "patch-clamp" method in anesthesiologic research; comment] Bräu ME, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Nov; 31(9):537–42 (21 ref.) (Eng. Abstr.) Comment on: Anasthesiol Intensivmed Notfallmed Schmer 1996 Nov;31(9):535–6. **(Ger)**

[Patch clamp] Hashimoto T, et al. **Nippon Rinsho** 1996 Mar; 54(3):704–10 (9 ref.) (Eng. Abstr.) **(Jpn)**

STANDARDS

Action potentials recorded with patch-clamp amplifiers: are they genuine? Magistretti J, et al. **Trends Neurosci** 1996 Dec;19(12):530–4 (25 ref.)

PATCH TESTS

Patch testing in systemic drug eruptions. Bruynzeel DP, et al. **Clin Dermatol** 1997 Jul–Aug;15(4):479–84 (87 ref.)

Photopatch testing. Isaksson M, et al. **Clin Dermatol** 1997 Jul–Aug;15(4):615–8 (39 ref.)

A personal critique of diagnostic patch testing. Kligman AM. **Clin Dermatol** 1996 Jan–Feb;14(1):35–40 (33 ref.)

The spectrum of cutaneous patch-test reactions in patients with atopic dermatitis. Hanifin JM, et al. **Clin Rev Allergy Immunol** 1996 Summer;14(2):225–40 (56 ref.)

Technical and ethical problems associated with patch testing. Storrs FJ. **Clin Rev Allergy Immunol** 1996 Summer; 14(2):185–98 (37 ref.)

Patch tests in children: a review of 14 years experience. Katsarou A, et al. **Contact Dermatitis** 1996 Jan;34(1):70–1 (9 ref.)

What is new in clinical research in contact dermatitis. Cohen DE, et al. **Dermatol Clin** 1997 Jan;15(1):137–48 (53 ref.)

Patch test response to house dust mites is positive in children with atopic dermatitis and in their parents. Meglio P, et al. **J Investig Allergol Clin Immunol** 1996 May–Jun; 6(3):190–5 (33 ref.)

[Dental materials--problem substances in allergologic diagnosis? II: Patch test diagnosis and relevance evaluation of selected dental material groups] Richter G. **Hautarzt** 1996 Nov;47(11):844–9 (50 ref.) (Eng. Abstr.) **(Ger)**

[Skin test for delayed type hypersensitivity] Haida M. **Nippon Rinsho** 1997 Mar;55 Suppl 1:222–5 (6 ref.) **(Jpn)**

INSTRUMENTATION

Patch tests: evaluation by instrumental methods. De Boer EM, et al. **Clin Dermatol** 1996 Jan–Feb;14(1):41–50 (68 ref.)

METHODS

Guidelines for measurement of skin colour and erythema. A report from the Standardization Group of the European Society of Contact Dermatitis. Fullerton A, et al. **Contact Dermatitis** 1996 Jul;35(1):1–10 (32 ref.)

1- versus 2- and 3-day diagnostic patch testing. Manuskiatti W, et al. **Contact Dermatitis** 1996 Oct;35(4):197–200 (20 ref.)

STANDARDS

Stochastic resonance and angry back syndrome: noisy skin. Rietschel RL. **Am J Contact Dermat** 1996 Sep;7(3):152–4 (13 ref.)

Proposal for a revised international standard series of patch tests. Lachapelle JM, et al. **Contact Dermatitis** 1997 Mar; 36(3):121–3 (8 ref.)

PATELLA

Aneurysmal bone cyst of the patella. Castro MD, et al. **Am J Orthop** 1996 Oct;25(10):717–9 (13 ref.)

Osteochondritis dissecans of the distal femur and patella. Obedian RS, et al. **Clin Sports Med** 1997 Jan;16(1):157–74 (69 ref.)

Intraosseous ganglion of the patella. Tam W, et al. **Skeletal Radiol** 1996 Aug;25(6):588–91 (25 ref.)

ABNORMALITIES

Congenital conditions that lead to osteoarthritis in the dog. Martinez SA. **Vet Clin North Am Small Anim Pract** 1997 Jul;27(4):735–58 (54 ref.)

INJURIES

Medial retinacular complex injury in acute patellar dislocation: MR findings and surgical implications. Spritzer CE, et al. **AJR Am J Roentgenol** 1997 Jan;168(1):117–22 (25 ref.)

Anterior knee pain in the military population. Chang PC, et al. **Ann Acad Med Singapore** 1997 Jan;26(1):60–3 (12 ref.)

Fractures of the patella. Carpenter JE, et al. **Instr Course Lect** 1994;43:97–108 (37 ref.)

RADIOGRAPHY

Radiologic study of patellar height in Osgood-Schlatter disease. Aparicio G, et al. **J Pediatr Orthop** 1997 Jan–Feb; 17(1):63–6 (14 ref.)

SURGERY

Fractures of the patella. Carpenter JE, et al. **Instr Course Lect** 1994;43:97–108 (37 ref.)

PATELLAR LIGAMENT

see related
ANTERIOR CRUCIATE LIGAMENT
MEDIAL COLLATERAL LIGAMENT, KNEE
POSTERIOR CRUCIATE LIGAMENT

INJURIES

Medial retinacular complex injury in acute patellar dislocation: MR findings and surgical implications. Spritzer CE, et al. **AJR Am J Roentgenol** 1997 Jan;168(1):117–22 (25 ref.)

Late patellar tendon ruptures after removal of the central third for anterior cruciate ligament reconstruction. A report of two cases. Marumoto JM, et al. **Am J Sports Med** 1996 Sep–Oct;24(5):698–701 (31 ref.)

Avulsion of the patellar ligament with combined fracture luxation of the proximal tibial epiphysis: case report and review of the literature. Perez Carro L. **J Orthop Trauma** 1996;10(5):355–8 (8 ref.)

TRANSPLANTATION

Anatomic endoscopic ACL reconstruction with autogenous patellar tendon graft. Clancy WG Jr. **Orthopedics** 1997 May;20(5):397, 399–400 (5 ref.)

PATENCY, VASCULAR see **VASCULAR PATENCY**

PATENT MEDICINES see **DRUGS, NON-PRESCRIPTION**

PATENTS

Going beyond the native: protecting DNA and protein patents. Chahine KG. **Nat Biotechnol** 1997 Feb;15(2):183–6 (11 ref.)

Norms for patents concerning human and other life forms. Guenin LM. **Theor Med** 1996 Sep;17(3):279–314 (53 ref.)

LEGISLATION & JURISPRUDENCE

The case for patenting medical procedures. Garris JJ. **Am J Law Med** 1996;22(1):85–108 (235 ref.)

Structure and function in gene patenting. Eisenberg RS. **Nat Genet** 1997 Feb;15(2):125–30 (65 ref.)

PATERNAL EXPOSURE

see related
MATERNAL EXPOSURE

Review of experimental male-mediated behavioral and neurochemical disorders. Nelson BK, et al. **Neurotoxicol Teratol** 1996 Nov–Dec;18(6):611–6 (69 ref.)

ADVERSE EFFECTS

Paternal exposures and the question of birth defects. Poynor DH, et al. **J Fla Med Assoc** 1997 Jun–Jul;84(5):323–6 (38 ref.)

PATERNITY

see related
DNA FINGERPRINTING

The Y chromosome in forensic analysis and paternity testing. Jobling MA, et al. **Int J Legal Med** 1997;110(3):118–24 (32 ref.)

Use of DNA identification for forensic and paternity analysis. Baird ML. **J Clin Lab Anal** 1996;10(6):350–8 (34 ref.)

[Determination of biological paternity yesterday and today] Sieglová Z, et al. **Cas Lek Cesk** 1996 Jul 14;135(14):439–44 (32 ref.) (Eng. Abstr.) **(Cze)**

PATEY MASTECTOMY see **MASTECTOMY, MODIFIED RADICAL**

PATHOGEN-FREE ORGANISMS see **SPECIFIC PATHOGEN-FREE ORGANISMS**

PATHOGENS, BLOOD-BORNE see **BLOOD-BORNE PATHOGENS**

PATHOLOGICAL WASTE see **MEDICAL WASTE**

PATHOLOGY

The pathologist's workstation. Aller RD. **Clin Lab Med** 1997 Jun;17(2):201–28 (22 ref.)

Digital imaging as a teaching tool for pathologists. Weinberg DS. **Clin Lab Med** 1997 Jun;17(2):229–44 (23 ref.)

Lectin activities of cytokines and growth factors: function and implications for pathology. Zanetta JP, et al. **Histol Histopathol** 1996 Oct;11(4):1101–8 (67 ref.)

Introduction: human pathology within the broad scope of comparative pathology. Kaiser HE. **In Vivo** 1996 Mar–Apr; 10(2):125–30 (78 ref.)

Overview of current Internet resources for molecular pathology. Killeen AA. **J Clin Lab Anal** 1996;10(6):375–9 (0 ref.)

Continuous quality improvement (CQI) in neuropathology. Pearl GS, et al. **J Neuropathol Exp Neurol** 1996 Aug; 55(8):875–9 (22 ref.)

As you like it. Ghadially FN. **Ultrastruct Pathol** 1997 May–Jun;21(3):211–26 (38 ref.)

WAAP and Pfizer Award for excellence in veterinary parasitology research. Pursuing life cycles and transmission of cyst-forming coccidia of animals and humans. Dubey JP. **Vet Parasitol** 1996 Aug;64(1–2):13–20 (41 ref.)

[Contribution of pathology in procedures for medically assisted reproduction] Ceresa-Manoux A, et al. **Ann Pathol** 1996 Nov;16(5):392–4 (10 ref.) **(Fre)**

LEGISLATION & JURISPRUDENCE

Medicolegal issues. An anatomic pathologist's perspective. Roth LM. **Am J Clin Pathol** 1996 Oct;106(4 Suppl 1):S18–24 (17 ref.)

Problems in consideration of rodent hepatocarcinogenesis for regulatory purposes. Moch RW, et al. **Toxicol Pathol** 1996 Jan–Feb;24(1):138–45 (28 ref.)

PATHOLOGY, CLINICAL

Errors and pitfalls in diagnostic cytology: new techniques applied to cytopathology. Ross JS. **Monogr Pathol** 1997; (39):94–117 (75 ref.)

Dilemmas and solutions for the pathologist and clinician encountering religious views of the autopsy [see comments] Davis GJ, et al. **South Med J** 1996 Nov;89(11):1041–4 (29 ref.) Comment in: South Med J 1996 Nov;89(11):1125–6.

[Sensitivity, specificity and predictive value in laboratory tests] Takagi Y, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:5–10 (4 ref.) **(Jpn)**

[Development of the clinical laboratory examination with a progress of high technology] Wakamatsu H. **Nippon Rinsho** 1997 Mar;55 Suppl 1:11–28 (6 ref.) **(Jpn)**

[From handmade to laboratory system] Kanno T. **Rinsho Byori** 1997 Mar;45(3):203–5 (4 ref.) **(Jpn)**

[Practical subjects of reference interval] Kanno T. **Rinsho Byori** 1996 Mar;44(3):241–4 (3 ref.) (Eng. Abstr.)

(Jpn)

[Reference intervals, discussed again] Kawai T. **Rinsho Byori** 1996 Mar;44(3):237-40 (5 ref.) (Eng. Abstr.) (Jpn)

EDUCATION

[A need for undergraduate education for laboratory medicine in medical schools] Yamanaka M. **Rinsho Byori** 1996 Aug; 44(8):709-14 (10 ref.) (Eng. Abstr.) (Jpn)

LEGISLATION & JURISPRUDENCE

Papanicolaou smear 5-year retrospective review: what is required by the Clinical Laboratory Improvement Amendments of 1988? Davey DD. **Arch Pathol Lab Med** 1997 Mar;121(3):296-8 (11 ref.)

Guidelines for experts reviewing Papanicolaou smear litigation cases. Frable WJ. **Arch Pathol Lab Med** 1997 Mar; 121(3):331-4 (12 ref.)

Implications of mandating amended reports following retrospective review of Papanicolaou smears. Freedman LF. **Arch Pathol Lab Med** 1997 Mar;121(3):299-300 (0 ref.)

Liability issues with the Papanicolaou smear: general legal background. Kline TJ. **Arch Pathol Lab Med** 1997 Mar; 121(3):250-2 (14 ref.)

Liability issues with the Papanicolaou smear: an insurance industry perspective. Scott MD. **Arch Pathol Lab Med** 1997 Mar;121(3):239-40 (0 ref.)

An overview of consumer protection act--remedial aspects in laboratory services. Thergaonkar A, et al. **Indian J Pathol Microbiol** 1996 Jul;39(3):237-50 (39 ref.)

Environmental Protection Agency risk assessment--process and toxicologic pathology. Copley MP. **Toxicol Pathol** 1997 Jan-Feb;25(1):68-71 (3 ref.)

Food and Drug Administration risk assessment--process and toxicologic pathology. Moch RW, et al. **Toxicol Pathol** 1997 Jan-Feb;25(1):61-7 (12 ref.)

METHODS

Digital imaging in anatomic pathology. O'Brien MJ, et al. **Am J Clin Pathol** 1996 Oct;106(4 Suppl 1):S25-32 (15 ref.)

Automation of the Papanicolaou smear: a technology assessment perspective. Linder J. **Arch Pathol Lab Med** 1997 Mar;121(3):282-6 (30 ref.)

Environmental Protection Agency risk assessment--process and toxicologic pathology. Copley MP. **Toxicol Pathol** 1997 Jan-Feb;25(1):68-71 (3 ref.)

ORGANIZATION & ADMINISTRATION

Clinical cytology in Russia: a brief review. Shabalova IP, et al. **Cytopathology** 1996 Feb;7(1):54-5 (0 ref.)

STANDARDS

Quality assessment in anatomic pathology in the cost-conscious era. Zarbo RJ. **Am J Clin Pathol** 1996 Oct; 106(4 Suppl 1):S3-10 (58 ref.)

College of American Pathologists Conference XXX on quality and liability issues with the Papanicolaou smear: summation. Austin RM. **Arch Pathol Lab Med** 1997 Mar; 121(3):341-2 (21 ref.)

Does a zero error standard exist for the Papanicolaou smear? A pathologist's perspective. Frable WJ. **Arch Pathol Lab Med** 1997 Mar;121(3):301-10 (42 ref.)

American Society of Cytopathology Laboratory Accreditation Program. Gupta PK, et al. **Arch Pathol Lab Med** 1997 Mar;121(3):260-3 (25 ref.)

Strategies for reducing Papanicolaou smear screening errors: principles derived from data and experience with quality control. Krieger PA. **Arch Pathol Lab Med** 1997 Mar; 121(3):277-81 (5 ref.)

The false-negative fraction for Papanicolaou smears: how often are "abnormal" smears not detected by a "standard" screening cytologist? Naryshkin S. **Arch Pathol Lab Med** 1997 Mar;121(3):270-2 (10 ref.)

Cytopathology laboratory improvement programs of the College of American Pathologists: Laboratory Accreditation Program (CAP LAP) and Performance Improvement Program in Cervicovaginal Cytology (CAP PAP). Nielsen ML. **Arch Pathol Lab Med** 1997 Mar; 121(3):256-9 (26 ref.)

Health Care Financing Administration/American Society for Cytotechnology inspections: government assessment of cytology laboratory practice under the regulations of the Clinical Laboratory Improvement Amendments of 1988. Triol JH, et al. **Arch Pathol Lab Med** 1997 Mar; 121(3):264-6 (3 ref.)

Liability issues with the Papanicolaou smear: a defense lawyer's perspective. Varner CD. **Arch Pathol Lab Med** 1997 Mar;121(3):315-20 (50 ref.)

False negatives in focused rescreening of Papanicolaou smears: how frequently are 'abnormal' cells detected in retrospective review of smears preceding cancer or high-grade intraepithelial neoplasia? Wilbur DC. **Arch Pathol Lab Med** 1997 Mar;121(3):273-6 (12 ref.)

Internal quality control for cervical cytopathology laboratories [editorial; comment] [see comments] Coleman DV. **Cytopathology** 1996 Feb;7(1):1-3 (7 ref.) Comment on: Cytopathology 1996 Feb;7(1):4-9. Comment in: Cytopathology 1996 Aug;7(4):296-7.

Clinical hematology. In-clinic analysis, quality control, reference values, and system selection. Knoll JS, et al. **Vet Clin North Am Small Anim Pract** 1996 Sep; 26(5):981-1002 (21 ref.)

TRENDS

Angiogenesis: new aspects relating to its initiation and control. Norrby K. **APMIS** 1997 Jun;105(6):417-37 (165 ref.)

Human monocytic and granulocytic ehrlichioses. Discovery and diagnosis of emerging tick-borne infections and the critical role of the pathologist. Walker DH, et al. **Arch Pathol Lab Med** 1997 Aug;121(8):785-91 (50 ref.)

Diagnostic molecular pathology in the twenty-first century. Kiechle FL. **Clin Lab Med** 1996 Mar;16(1):213-22 (84 ref.)

PATHOLOGY, ORAL

EDUCATION

New aspects of oral viral diseases. Scully C. **Curr Top Pathol** 1996;90:29-96 (648 ref.)

Importance of proliferation markers in oral pathology. Warnakulasuriya KA, et al. **Curr Top Pathol** 1996;90:147-77 (105 ref.)

STANDARDS

Oral exfoliative cytology: review of methods of assessment. Ogden GR, et al. **J Oral Pathol Med** 1997 May;26(5):201-5 (63 ref.)

TRENDS

New aspects of oral viral diseases. Scully C. **Curr Top Pathol** 1996;90:29-96 (648 ref.)

PATHOLOGY, SURGICAL

Second opinions in surgical pathology [see comments] Leslie KO, et al. **Am J Clin Pathol** 1996 Oct;106(4 Suppl 1):S58-64 (17 ref.) Comment in: Am J Clin Pathol 1997 Apr;107(4):497-8.

METHODS

Evaluating radical prostatectomy specimens: therapeutic and prognostic importance. Bostwick DG, et al. **Virchows Arch** 1997 Jan;430(1):1-16 (92 ref.)

STANDARDS

Recommendations for the reporting of tissues removed as part of the surgical treatment of cutaneous melanoma. Association of Directors of Anatomic and Surgical Pathology. **Virchows Arch** 1997 Aug;431(2):79-81 (7 ref.)

TRENDS

Intraoperative consultation: introduction and general principles. Ranchod M. **Pathology (Phila)** 1996;3(2):259-71 (7 ref.)

Technical aspects of intraoperative diagnosis. Ranchod M. **Pathology (Phila)** 1996;3(2):273-84 (4 ref.)

PATIENT ABANDONMENT see REFUSAL TO TREAT

PATIENT ACCEPTANCE OF HEALTH CARE

The effects of HIV counseling and testing on risk-related practices and help-seeking behavior. Wolitski RJ, et al. **AIDS Educ Prev** 1997 Jun;9(3 Suppl):52-67 (45 ref.)

Typical and atypical clinical signs and symptoms of myocardial infarction and delayed seeking of professional care among blacks. Lee HO. **Am J Crit Care** 1997 Jan; 6(1):7-13; quiz 14-5 (56 ref.)

Risk factor control and perceptions of risk factors in patients with coronary heart disease. Battegay E, et al. **Blood Press Suppl** 1997;1:17-22 (40 ref.)

The challenge for women with a drug-abusing family member: the Jamaican perspective. Boyce-Reid K. **Bull Narc** 1995;47(1-2):23-30 (11 ref.)

Mothers' help seeking as care initiated in a social context. Pridham KF. **Image J Nurs Sch** 1997 Spring;29(1):65-70 (39 ref.)

Issues and recommendations for the recruitment and retention of older ethnic minority adults into clinical research. Areán PA, et al. **J Consult Clin Psychol** 1996 Oct;64(5):875-80 (38 ref.)

Psychotropic drug use by women: could violence account for the gender difference? Mazza D, et al. **J Psychosom Obstet Gynaecol** 1996 Dec;17(4):229-34 (43 ref.)

When do the "dollars" make sense? Toward a conceptual framework for contingent valuation studies in health care. O'Brien B, et al. **Med Decis Making** 1996 Jul-Sep; 16(3):288-99 (49 ref.)

Helping heart attack victims to save their own lives [editorial; comment] Langton PE, et al. **Med J Aust** 1997 Mar 3; 166(5):228-9 (9 ref.) Comment on: Med J Aust 1997 Mar 3;166(5):233-6.

Help-seeking by substance abusers: the role of harm reduction and behavioral-economic approaches to facilitate treatment entry and retention. Marlatt GA, et al. **NIDA Res Monogr** 1997;165:44-84 (147 ref.)

Barriers to cancer treatment: a review of published research. Guidry JJ, et al. **Oncol Nurs Forum** 1996 Oct;23(9):1393-8 (18 ref.)

Daily symptoms and responses in adults: a review. Burman ME. **Public Health Nurs** 1996 Aug;13(4):294-301 (57 ref.)

Services for adults who have experienced child sexual assault: improving agency response. Gibbons J. **Soc Sci Med** 1996 Dec;43(12):1755-63 (48 ref.)

Treatment seeking for malaria: a review of recent research. McCombie SC. **Soc Sci Med** 1996 Sep;43(6):933-45 (90 ref.)

Heroin addicts in the community and in treatment compared for severity of problems and need for help. Eland-Goossensen A, et al. **Subst Use Misuse** 1997 Aug; 32(10):1313-30 (24 ref.)

[In times of survival, the right of silence] Métraux JC. **Rev Med Suisse Romande** 1997 May;117(5):419-23 (7 ref.) (Fre)

ETHNOLOGY

Heart disease and associated risk factors among Hawaiians: culturally responsive strategies. Mokuau N, et al. **Health Soc Work** 1995 Feb;20(1):46-51 (20 ref.)

White, red and black: colour classification and illness management in Northern Ghana. Kirby JP. **Soc Sci Med** 1997 Jan;44(2):215-30 (38 ref.)

Help-seeking among Asian and Pacific Americans: a multiperspective analysis. Yamashiro G, et al. **Soc Work** 1997 Mar;42(2):176-86 (41 ref.)

PATIENT ADMISSION

see related
PATIENT READMISSION

The effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on mediators and moderators of setting effects. Finney JW, et al. **Addiction** 1996 Dec;91(12):1773-96; discussion 1803-20 (72 ref.)

Postpartum psychiatric disorder: who should be admitted and to which hospital? Barnett B, et al. **Aust N Z J Psychiatry** 1996 Dec;30(6):709-14 (29 ref.)

Severe personality disorders. Treatment issues and selection for in-patient psychotherapy [see comments] Norton K, et al. **Br J Psychiatry** 1996 Jun;168(6):723-31 (29 ref.) Comment in: Br J Psychiatry 1996 Oct;169(4):524. Comment in: Br J Psychiatry 1996 Dec;169(6):792-3. Comment in: Br J Psychiatry 1997 Jan;170:90-1.

Consultation to residential psychosocial rehabilitation agencies. Kupers TA. **Community Ment Health J** 1996 Aug; 32(4):403-13; discussion 415-8 (32 ref.)

Cognitive therapy with inpatients. Stuart S, et al. **Gen Hosp Psychiatry** 1997 Jan;19(1):42-50 (48 ref.)

The social worker's record of the hospitalized patient: a physician's perspective. Benbassat J. **Isr J Psychiatry Relat Sci** 1996;33(4):246-52 (27 ref.)

Integrating substance abuse treatment for the seriously mentally ill into inpatient psychiatric treatment. Bradizza CM, et al. **J Subst Abuse Treat** 1997 Mar-Apr;14(2):103-11 (34 ref.)

[Inpatient pneumologic rehabilitation of adults: goals--diagnostic and therapeutic standards--research needs] Bergmann KC, et al. **Pneumologie** 1997 May; 51(5):523-32 (87 ref.) (Ger)

[Mother-child treatment in psychiatry. I: Overview of experiences up to now] Hartmann HP. **Psychiatr Prax** 1997 Mar;24(2):56-60 (56 ref.) (Eng. Abstr.) (Ger)

[The trauma patient: open hospital choice? (editorial)] Leutenegger A, et al. **Swiss Surg** 1997;3(4):136-41 (27 ref.) (Eng. Abstr.) (Ger)

[Nonpharmacologic and rehabilitation aspects in inpatient settings] Gatterer G, et al. **Wien Med Wochenschr** 1996; 146(21-22):559-65 (46 ref.) (Eng. Abstr.) (Ger)

[Fungal infection in patients admitted to the intensive care unit] León Gil C, et al. **Rev Clin Esp** 1997 Apr;197 Suppl 1:17-28 (86 ref.) (Spa)

TRENDS

Swimming against the tide? A review of the therapeutic community. Schimmel P. **Aust N Z J Psychiatry** 1997 Feb; 31(1):120-7 (31 ref.)

PATIENT ADVOCACY

Change, co-option and the community sector. Altman D. **AIDS** 1995;9 Suppl A:S239-43 (28 ref.)

The patient advocate. Jennings RH Jr. **Am J Obstet Gynecol** 1997 Aug;177(2):251-5 (15 ref.)

The end-of-life sequence. Waisel DB, et al. **Anesthesiology** 1997 Sep;87(3):676-86 (68 ref.)

On the tension between individual health rights and public health responsibilities [editorial] Short S. **Aust N Z J Public Health** 1997 Jun;21(3):246-7 (12 ref.)

Ethical issues in clinical trials in oncology. Markman M. **Cleve Clin J Med** 1997 May;64(5):275-7 (4 ref.)

Is there a duty to die? Hardwig J. **Hastings Cent Rep** 1997 Mar-Apr;27(2):34-42 (9 ref.)

Pain and symptom control. Patient rights and physician responsibilities. Emanuel EJ. **Hematol Oncol Clin North Am** 1996 Feb;10(1):41-56 (34 ref.)

The rights of psychiatric patients in the light of the principles

announced by the United Nations: a recognition of the right to consent to treatment? Gendreau C. **Int J Law Psychiatry** 1997 Spring;20(2):259–78 (77 ref.)

Guidelines for adolescent health research: issues of race and class. Jenkins RR, et al. **J Adolesc Health** 1995 Nov; 17(5):314–22 (43 ref.)

A concept analysis of consent. Brennan M. **J Adv Nurs** 1997 Mar;25(3):477–84 (37 ref.)

Advocacy in nursing--a review of the literature. Mallik M. **J Adv Nurs** 1997 Jan;25(1):130–8 (95 ref.)

The nurse's role as patient advocate: obligation or imposition? Willard C. **J Adv Nurs** 1996 Jul;24(1):60–6 (30 ref.)

Voiceless and vulnerable: dementia patients without surrogates in an era of capitation [editorial; comment] Meier DE. **J Am Geriatr Soc** 1997 Mar;45(3):375–7 (22 ref.) Comment on: J Am Geriatr Soc 1997 Mar;45(3):369–74.

A feminist standpoint for genetics. Mahowald MB. **J Clin Ethics** 1996 Winter;7(4):333–40 (28 ref.)

Human experimentation. Protecting patient autonomy through informed consent. Tuthill KA. **J Leg Med** 1997 Jun;18(2):221–50 (180 ref.)

Exercising restraint: autonomy, welfare and elderly patients. Dodds S. **J Med Ethics** 1996 Jun;22(3):160–3 (13 ref.)

Effective advocacy for domestic violence victims. Role of the nurse–midwife. Orloff LE. **J Nurse Midwifery** 1996 Nov–Dec;41(6):473–94 (74 ref.)

Can suicide intervention in hospice be ethical? McGee EM. **J Palliat Care** 1997 Spring;13(1):27–33 (50 ref.)

Sexually transmitted diseases and unwanted pregnancies in chronically ill psychiatric patients [editorial] [see comments] Coverdale JH, et al. **Med J Aust** 1997 Mar 3; 166(5):231–2 (10 ref.) Comment in: Med J Aust 1997 Jun 16;166(12):665–6. Comment in: Med J Aust 1997 Jun 16;166(12):666. Comment in: Med J Aust 1997 Jun 16;166(12):666–7.

Patient's autonomy vs doctor's professional integrity. Tsukamoto Y. **Med Law** 1996;15(2):195–9 (11 ref.)

Advocacy and managed behavioral health care. Shore MF. **New Dir Ment Health Serv** 1996 Winter;(72):59–64 (2 ref.)

Mandatory treatment: an examination of therapeutic jurisprudence. Winick BJ. **New Dir Ment Health Serv** 1997 Fall;(75):27–34 (33 ref.)

Ethical issues relative to autonomy and personal control in independent and cognitively impaired elders. Rice VH, et al. **Nurs Outlook** 1997 Jan–Feb;45(1):27–34 (34 ref.)

Considerations for research on consumer empowerment and psychosocial interventions. Corrigan PW, et al. **Psychiatr Serv** 1997 Mar;48(3):347–52 (59 ref.)

Quality of care and cost–containment in managed mental health: policy, education, research, advocacy. Dana RH, et al. **Psychol Rep** 1996 Dec;79(3 Pt 2):1395–422 (125 ref.)

Empowering patients: issues and strategies. Anderson JM. **Soc Sci Med** 1996 Sep;43(5):697–705 (42 ref.)

Responsibilities and rights in the promotion of health: differing positions of the individual and the state. Bell NK. **Soc Sci Med** 1996 Sep;43(5):775–82 (16 ref.)

Should social work clients have the right to effective treatment? Myers LL, et al. **Soc Work** 1997 May; 42(3):288–98 (56 ref.)

Engagement and suffering in responsible caregiving: on overcoming maleficience in health care. Schultz DS, et al. **Theor Med** 1996 Sep;17(3):189–207 (17 ref.)

When patients ask about assisted suicide. A viewpoint from Oregon. Lee MA, et al. **West J Med** 1996 Oct;165(4):205–8 (23 ref.)

LEGISLATION & JURISPRUDENCE

Developing issues under the Massachusetts 'Physician Profile' Act. Donohue JP. **Am J Law Med** 1997; 23(1):115–58 (367 ref.)

Procedural protections for patients in capitated health plans. Kinney ED. **Am J Law Med** 1996;22(2–3):301–30 (0 ref.)

Legal issues in pediatric gynecology. May JW. **Clin Obstet Gynecol** 1997 Mar;40(1):241–53 (19 ref.)

Guidelines for adolescent health research: legal perspectives. English A. **J Adolesc Health** 1995 Nov;17(5):277–86 (86 ref.)

Treatment decisions for patients without surrogates: rethinking policies for a vulnerable population [see comments] Miller TE, et al. **J Am Geriatr Soc** 1997 Mar; 45(3):369–74 (35 ref.) Comment in: J Am Geriatr Soc 1997 Mar;45(3):375–7.

Patients' rights in England and the United States of America: The Patient's Charter and the New Jersey Patient Bill of Rights: a comparison. Silver MH. **J Med Ethics** 1997 Aug; 23(4):213–20 (16 ref.)

Maternal–fetal conflict: court–ordered cesarean section. Lindgren K. **J Obstet Gynecol Neonatal Nurs** 1996 Oct; 25(8):653–6 (23 ref.)

Female genital mutilation: balancing intolerance of the practice with tolerance of culture. Bashir LM. **J Womens Health** 1997 Feb;6(1):11–4 (12 ref.)

Making decisions about medical treatment for mentally incapable adults in the UK. Luttrell S. **Lancet** 1997 Sep 27;350(9082):950–3 (27 ref.)

Deaths, dying and the euthanasia debate in Australia [editorial; comment] van der Weyden MB. **Med J Aust** 1997 Feb 17;166(4):173–4 (17 ref.) Comment on: Med J Aust 1997 Feb 17;166(4):191–6.

Respect for the patient's integrity and self–determination--an ethical imperative called upon in the Swedish Health and Medical Care Act. Margareta A. **Med Law** 1996; 15(2):189–93 (9 ref.)

Right to privacy and confidentiality of medical records. Tilton SH. **Occup Med** 1996 Jan–Mar;11(1):17–29 (106 ref.)

New rights for deaf patients; new responsibilities for mental hospitals. Raifman LJ, et al. **Psychiatr Q** 1996 Fall; 67(3):209–20 (18 ref.)

The status of genetic material and genetic information in The Netherlands. de Witte JI, et al. **Soc Sci Med** 1997 Jul; 45(1):45–9 (32 ref.)

[The practice of placing under psychiatric observation] Boxho P. **Rev Med Liege** 1997 May;52(5):345–51 (24 ref.) **(Fre)**

[Are we legally allowed to administer blood for lifesaving to a patient who refuses it?] Shimasaki H, et al. **Masui** 1997 Apr;46(4):556–9 (24 ref.) (Eng. Abstr.) **(Jpn)**

PATIENT APPOINTMENTS see **APPOINTMENTS AND SCHEDULES**

PATIENT CARE EPISODES see **EPISODE OF CARE**

PATIENT CARE PLANNING

see related
AFTERCARE
CONSUMER PARTICIPATION

Caring for demented patients. Norberg A. **Acta Neurol Scand Suppl** 1996;165:105–8 (13 ref.)

Effectiveness of individualized neurodevelopmental care in the newborn intensive care unit (NICU). Als H, et al. **Acta Paediatr Suppl** 1996 Oct;416:21–30 (60 ref.)

Strategies for driving cessation in Alzheimer Disease. Friedland RP. **Alzheimer Dis Assoc Disord** 1997 Jun;11 Suppl 1:73–5 (8 ref.)

Elder abuse: what to look for, how to intervene [see comments] Lynch SH. **Am J Nurs** 1997 Jan;97(1):26–32; quiz 33 (10 ref.) Comment in: Am J Nurs 1997 Jul;97(7):17.

Multidisciplinary management controversies in laryngeal cancer. Goh C, et al. **Ann Acad Med Singapore** 1996 May; 25(3):405–12 (54 ref.)

Implications of nursing taxonomies for middle–range theory development. Blegen MA, et al. **ANS Adv Nurs Sci** 1997 Mar;19(3):37–49 (34 ref.)

How does evidence that is available affect decisions with an individual patient? Woolf AD. **Baillieres Clin Rheumatol** 1997 Feb;11(1):1–12 (17 ref.)

Self–management plans: uses and limitations. Partridge MR. **Br J Hosp Med** 1996 Feb 7–20;55(3):120–2 (11 ref.)

An approach to planning services for bulimia nervosa [editorial] Treasure JL, et al. **Br J Psychiatry** 1996 Nov; 169(5):551–4 (19 ref.)

Screening for failure to thrive--what are we looking for? Wright CM, et al. **Child Care Health Dev** 1996 Jul; 22(4):223–34 (20 ref.)

Perioperative management in lung transplantation. Simpson KP, et al. **Clin Chest Med** 1997 Jun;18(2):277–84 (38 ref.)

Computer assisted knee surgery: diagnostics and planning of knee surgery. Sati M, et al. **Comput Aided Surg** 1997; 2(2):108–23 (49 ref.)

The importance of determination of jaw position in orthodontic diagnosis and treatment planning for adult patients. Chang FH, et al. **Dent Clin North Am** 1997 Jan; 41(1):49–66 (24 ref.)

Treatment planning considerations for adult patients. Kuhlberg AJ, et al. **Dent Clin North Am** 1997 Jan; 41(1):17–27 (35 ref.)

Exercise at midlife: how and why to prescribe it for sedentary patients. Gunnarsson OT, et al. **Geriatrics** 1997 May; 52(5):71–2, 77–80; quiz 81 (20 ref.)

'Maintaining the balance'--nursing care of patients with chronic heart failure. Jaarsma T, et al. **Int J Nurs Stud** 1997 Jun;34(3):213–21 (32 ref.)

Perspective of an institution–based research nurse. Norberg A. **Int Psychogeriatr** 1996;8 Suppl 3:459–63; discussion 469–73 (30 ref.)

Patient participation: a concept analysis. Cahill J. **J Adv Nurs** 1996 Sep;24(3):561–71 (82 ref.)

Take control of high–cost asthma [see comments] Flaum M, et al. **J Asthma** 1997;34(1):5–14 (18 ref.) Comment in: J Asthma 1997 ;34(1):1–3.

Adherence to medication, diet, and activity recommendations: from assessment to maintenance. Burke LE, et al. **J Cardiovasc Nurs** 1995 Jan;9(2):62–79 (97 ref.)

The nursing management of women experiencing preterm labor: clinical guidelines and why they are needed. Jones DP, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Sep; 25(7):569–92 (56 ref.)

Standards of care for acutely ill children with asthma. Andersen CL, et al. **MCN Am J Matern Child Nurs** 1996 Nov–Dec;21(6):280–7 (18 ref.)

Services for epilepsy in the United Kingdom. Chadwick D, et al. **Neurology** 1997 Jun;48(6 Suppl 8):S3–7 (15 ref.)

Perspectives of epilepsy care in the United States: children and the developmentally disabled. Clancy RR. **Neurology** 1997 Jun;48(6 Suppl 8):S33–8 (25 ref.)

Patterns of care for patients with epilepsy in France. Dulac O, et al. **Neurology** 1997 Jun;48(6 Suppl 8):S30–2 (4 ref.)

Perspectives on epilepsy care in Denmark. Gram L. **Neurology** 1997 Jun;48(6 Suppl 8):S16–9 (14 ref.)

Perspectives of epilepsy care in Norway. Henriksen O. **Neurology** 1997 Jun;48(6 Suppl 8):S20–4 (5 ref.)

Epilepsy care in Germany: a clinical perspective. Schmidt D. **Neurology** 1997 Jun;48(6 Suppl 8):S25–9 (15 ref.)

Patterns of epilepsy care in Japan. Seino M, et al. **Neurology** 1997 Jun;48(6 Suppl 8):S8–15 (16 ref.)

Care of adults with epilepsy in the United States. Willmore LJ. **Neurology** 1997 Jun;48(6 Suppl 8):S39–43 (12 ref.)

Management of the burn wound. Jordan BS, et al. **Nurs Clin North Am** 1997 Jun;32(2):251–73 (69 ref.)

Preconception care: a health promotion opportunity [see comments] Perry LE. **Nurse Pract** 1996 Nov;21(11):24–6, 32, 34 passim (27 ref.) Comment in: Nurse Pract 1997 Mar;22(3):14.

[The value of scores for therapy planning and therapy evaluation in individual intensive care patients--basic principles] Neugebauer E, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:293–8 (13 ref.) (Eng. Abstr.) **(Ger)**

[Questionnaires on preoperative evaluation of patients] Irita K, et al. **Masui** 1996 Dec;45 Suppl:S147–54 (9 ref.) **(Jpn)**

CLASSIFICATION

How NIC describes MCH nursing. Eganhouse DJ, et al. **MCN Am J Matern Child Nurs** 1996 Sep–Oct;21(5):247–52 (22 ref.)

ECONOMICS

Rethinking patient placement: the human service matrix model for matching services to needs. McGee MD, et al. **J Subst Abuse Treat** 1997 Mar–Apr;14(2):141–8 (75 ref.)

STANDARDS

Treating acute pain in hospital. McQuay H, et al. **BMJ** 1997 May 24;314(7093):1531–5 (31 ref.)

Professional prospects in clinical pharmacology. An experience within the hospital. Vallano A. **Methods Find Exp Clin Pharmacol** 1996;18 Suppl C:9–13 (8 ref.)

PATIENT CARE TEAM

Tobacco cessation interventions in health care settings: rationale, model, outcomes. Lichtenstein E, et al. **Addict Behav** 1996 Nov–Dec;21(6):709–20 (45 ref.)

The hemodialysis patient: object of diagnosis or part of the treatment team? Burnell MS. **Adv Ren Replace Ther** 1997 Apr;4(2):145–51 (22 ref.)

The pharmacological treatment of alcohol dependence: needs and possibilities. Mann K. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:55–8 (30 ref.)

Team decision–making in rehabilitation: a commentary [see comments] Unsworth C. **Am J Phys Med Rehabil** 1996 Nov–Dec;75(6):483–6 (24 ref.) Comment in: Am J Phys Med Rehabil 1997 Jul–Aug;76(4):348.

Multidisciplinary management controversies in laryngeal cancer. Goh C, et al. **Ann Acad Med Singapore** 1996 May; 25(3):405–12 (54 ref.)

Management of adults with congenital heart disease: an increasing problem. Somerville J. **Annu Rev Med** 1997; 48:283–93 (9 ref.)

Assisted suicide and euthanasia: what about the clinical issues? [see comments] Kelly BJ, et al. **Aust N Z J Psychiatry** 1996 Feb;30(1):3–8 (34 ref.) Comment in: Aust N Z J Psychiatry 1996 Aug;30(4):557–8.

What is the psychiatrist's role in drugs and alcohol? Pols RG, et al. **Aust N Z J Psychiatry** 1996 Aug;30(4):540–8; discussion 548–9 (99 ref.)

An approach to planning services for bulimia nervosa [editorial] Treasure JL, et al. **Br J Psychiatry** 1996 Nov; 169(5):551–4 (19 ref.)

Psychosocial rehabilitation and psychiatry: what are the boundaries? Bachrach LL. **Can J Psychiatry** 1996 Feb; 41(1):28–35 (55 ref.)

Posttraumatic stress disorder and motor vehicle accidents: a multidisciplinary overview [see comments] Kuch K, et al. **Can J Psychiatry** 1996 Sep;41(7):429–34 (69 ref.) Comment in: Can J Psychiatry 1997 Mar;42(2):210.

MULTIFIT: a new approach to risk factor modification. DeBusk RF. **Cardiol Clin** 1996 Feb;14(1):143–57 (20 ref.)

Vascular stents and stent grafts: a vascular surgeon's view. Taylor PR. **Cardiovasc Intervent Radiol** 1997 Jan–Feb; 20(1):1–4 (37 ref.)

Consultation to residential psychosocial rehabilitation agencies. Kupers TA. **Community Ment Health J** 1996 Aug; 32(4):403–13; discussion 415–8 (32 ref.)

Providing a neuropsychology service for people with multiple sclerosis in an interdisciplinary rehabilitation unit. Thompson SB. **Disabil Rehabil** 1996 Jul;18(7):348–53 (60 ref.)

General principles in child liaison consultation service: a literature review. Ortiz P. **Eur Child Adolesc Psychiatry** 1997 Mar;6(1):1–6 (46 ref.)

Competing demands in psychosocial care. A model for the identification and treatment of depressive disorders in primary care [see comments] Klinkman MS. **Gen Hosp Psychiatry** 1997 Mar;19(2):98–111 (116 ref.) Comment in: Gen Hosp Psychiatry 1997 Mar;19(2):79–81.

Chronic fatigue syndrome. A practical guide to assessment and management. Sharpe M, et al. **Gen Hosp Psychiatry** 1997 May;19(3):185–99 (128 ref.)

Perioperative psychosocial interventions for autistic children

undergoing ENT surgery. Seid M, et al. **Int J Pediatr Otorhinolaryngol** 1997 Jun 20;40(2-3):107-13 (11 ref.)

The social worker's record of the hospitalized patient: a physician's perspective. Benbassat J. **Isr J Psychiatry Relat Sci** 1996;33(4):246-52 (27 ref.)

Cervical pregnancy--a forgotten entity in family practice. Acosta DA. **J Am Board Fam Pract** 1997 Jul-Aug; 10(4):290-5 (33 ref.)

Practitioner review: assessment and treatment of sleep disorders in children and adolescents. Stores G. **J Child Psychol Psychiatry** 1996 Nov;37(8):907-25 (100 ref.)

Early detection of developmental problems: strategies for monitoring young children in the practice setting [see comments] Squires J, et al. **J Dev Behav Pediatr** 1996 Dec; 17(6):420-7 (77 ref.) Comment in: J Dev Behav Pediatr 1997 Feb;18(1):72-3.

Utilizing the clinical nurse specialist to promote interdisciplinary pain management. Cronin Y, et al. **J Fla Med Assoc** 1997 Jan;84(1):46-8 (13 ref.)

Primary care paradigm for management of sarcoidosis, Part 1. Young RC Jr, et al. **J Natl Med Assoc** 1997 Mar; 89(3):181-90 (53 ref.)

A multicenter evaluation of cancer pain control by palliative care teams. Higginson IJ, et al. **J Pain Symptom Manage** 1997 Jul;14(1):29-35 (41 ref.)

Miscarriage as a traumatic event: a review of the literature and new implications for intervention. Lee C, et al. **J Psychosom Res** 1996 Mar;40(3):235-44 (60 ref.)

Psychosocial factors and physical illness in primary care: promoting the biopsychosocial model in medical practice [editorial] Zimmermann C, et al. **J Psychosom Res** 1996 Apr;40(4):351-8 (60 ref.)

Unique management needs of pediatric spinal cord injury patients: psychosocial issues. Anderson CJ. **J Spinal Cord Med** 1997 Jan;20(1):21-4 (35 ref.)

Unique management needs of pediatric spinal cord injury patients: medical issues. Vogel LC. **J Spinal Cord Med** 1997 Jan;20(1):17-20 (49 ref.)

Integrating substance abuse treatment for the seriously mentally ill into inpatient psychiatric treatment. Bradizza CM, et al. **J Subst Abuse Treat** 1997 Mar-Apr;14(2):103-11 (34 ref.)

Care of collegiate athletes. Brandon TA, et al. **Md Med J** 1996 Aug;45(8):669-75 (31 ref.)

Concepts and controversies in the treatment of brain metastases. Chougule PB. **Med Health R I** 1996 Jun; 79(6):214-7 (35 ref.)

Multidisciplinary approach to malignant gliomas. Saris S. **Med Health R I** 1996 Jun;79(6):210-3 (11 ref.)

Management of the pediatric burn patient. Cortiella J, et al. **Nurs Clin North Am** 1997 Jun;32(2):311-29 (33 ref.)

Shared care for diabetes. A systematic review. Greenhalgh PM. **Occas Pap R Coll Gen Pract** 1994 Oct;(67):i-viii, 1-35 (117 ref.)

A team approach to reduce disability in work-related disorders. Millender LH, et al. **Orthop Clin North Am** 1996 Oct;27(4):669-77 (68 ref.)

Chronic sinusitis: a medical or surgical disease? Parsons DS. **Otolaryngol Clin North Am** 1996 Feb;29(1):1-9 (19 ref.)

Advances in comprehensive pain management. Koenig TW, et al. **Psychiatr Clin North Am** 1996 Sep;19(3):589-611 (165 ref.)

Use of stimulants in the medically ill. Masand PS, et al. **Psychiatr Clin North Am** 1996 Sep;19(3):515-47 (129 ref.)

Psychiatric aspects of rheumatology. Moran MG. **Psychiatr Clin North Am** 1996 Sep;19(3):575-87 (53 ref.)

Psychiatric aspects of cardiovascular disease. Shapiro PA. **Psychiatr Clin North Am** 1996 Sep;19(3):613-29 (70 ref.)

Chronic fatigue syndrome. Sharpe M. **Psychiatr Clin North Am** 1996 Sep;19(3):549-73 (122 ref.)

New antidepressant drugs and the treatment of depression in the medically ill patient. Stoudemire A. **Psychiatr Clin North Am** 1996 Sep;19(3):495-514 (85 ref.)

Delirium. Advances in diagnosis, pathophysiology, and treatment. Trzepacz PT. **Psychiatr Clin North Am** 1996 Sep;19(3):429-48 (149 ref.)

Multidisciplinary approach to venous thromboembolism. Marano P, et al. **Rays** 1996 Jul-Sep;21(3):481-99 (48 ref.) **(Eng, Ita)**

Issues in the linkage of alcohol and domestic violence services. Collins JJ, et al. **Recent Dev Alcohol** 1997; 13:387-405 (91 ref.)

A behavioral diagnostic paradigm for integrating behavior-analytic and psychopharmacological interventions for people with a dual diagnosis. Pyles DA, et al. **Res Dev Disabil** 1997 May-Jun;18(3):185-214 (60 ref.)

Multidisciplinary group programs to treat fibromyalgia patients. Bennett RM. **Rheum Dis Clin North Am** 1996 May; 22(2):351-67 (59 ref.)

Interhospital and intrahospital transfer of the critically ill patient. Tan TK. **Singapore Med J** 1997 Jun;38(6):244-8 (20 ref.)

Problems in accurate medical diagnosis of depression in female patients. Floyd BJ. **Soc Sci Med** 1997 Feb; 44(3):403-12 (60 ref.)

Roles of mental health professionals in multidisciplinary medically supervised treatment programs for obesity. Hunter SM, et al. **South Med J** 1997 Jun;90(6):578-86 (76 ref.)

The challenge and the promise of clinical suicidology. Jobes DA. **Suicide Life Threat Behav** 1995 Winter;25(4):437-49 (43 ref.)

The multidisciplinary melanoma center. Sagebiel RW. **Surg Clin North Am** 1996 Dec;76(6):1433-9 (6 ref.)

Orthopaedic management of juvenile chronic arthritis (JCA). Pahle JA. **Z Rheumatol** 1996 Nov-Dec;55(6):376-87 (23 ref.)

[Psychopathology and cognitive neurosciences: theoretical conflicts and experimental paradigms] Jouvent R, et al. **Encephale** 1997 Jun;23 Spec No 3:9-14 (30 ref.) (Eng. Abstr.) **(Fre)**

[Clinical criteria for choosing an antidepressive drug] Manus A. **Encephale** 1995 Dec;21 Spec No 4:19-21 (26 ref.) **(Fre)**

[Evaluation of suicidal risk in emergency service] König F, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Dec;31(10):615-20 (35 ref.) (Eng. Abstr.) **(Ger)**

[Management of craniocerebral trauma in a neurosurgery center] Gilsbach JM, et al. **Chirurg** 1996 Nov; 67(11):1114-22 (39 ref.) (Eng. Abstr.) **(Ger)**

[Long-term pain therapy] Hildebrandt J, et al. **Chirurg** 1996 Jul;67(7):681-7 (28 ref.) (Eng. Abstr.) **(Ger)**

[Postoperative pain therapy in inpatient treatment] Holthausen U, et al. **Chirurg** 1996 Jul;67(7):671-80 (30 ref.) (Eng. Abstr.) **(Ger)**

[Alcoholism as chronic disease: a challenge for the physician] Kruse G. **Fortschr Med** 1996 Oct 20;114(29):369-71 (0 ref.) (Eng. Abstr.) **(Ger)**

[Sexual problems--possible counseling by the general physician] Loewit K. **Fortschr Med** 1996 Oct 30; 114(30):387-92 (9 ref.) (Eng. Abstr.) **(Ger)**

[Evaluation of measures for improving patient management in diabetes] Trautner C, et al. **Gesundheitswesen** 1996 Sep; 58 Suppl 2:139-43 (11 ref.) (Eng. Abstr.) **(Ger)**

[Peripheral arterial occlusive disease. Diagnosis and modern conservative therapy] Zinnagl N. **Hautarzt** 1996 Jan; 47(1):70-8 (11 ref.) **(Ger)**

[Medical consultation with curable cancer patients] de Maddalena H. **HNO** 1996 Nov;44(11):645-54 (17 ref.) **(Ger)**

[Anorexia and bulimia nervosa] Csef H. **Internist (Berl)** 1997 Jul;38(7):721-31 (10 ref.) **(Ger)**

[Surgical preparedness in coronary interventions] Meinertz T, et al. **Internist (Berl)** 1997 Jan;38(1):53-5 (5 ref.) **(Ger)**

[Differential diagnostic concepts in sleep medicine and their particular significance for the internist] Peter JH. **Internist (Berl)** 1996 May;37(5):454-62 (33 ref.) **(Ger)**

[Quality management in diagnosis and therapy of colorectal carcinoma] Hermanek P. **Leber Magen Darm** 1996 Jan; 26(1):20-4 (14 ref.) (Eng. Abstr.) **(Ger)**

[Psychiatry of elderly patients. A consensus statement] **Nervenarzt** 1997 Jan;68(1):80-3 (0 ref.) **(Ger)**

[Family therapy and work with relatives in various psychiatric diseases] Wiedemann G, et al. **Nervenarzt** 1996 Jul;67(7):524-44 (182 ref.) (Eng. Abstr.) **(Ger)**

[Current status of interdisciplinary therapy of stage III non-small-cell bronchial carcinoma] Manegold C, et al. **Pneumologie** 1996 Oct;50(10):735-41 (52 ref.) **(Ger)**

[Disorders of eating behavior--early detection and treatment possibilities in general practice] Buddeberg-Fischer B. **Schweiz Rundsch Med Prax** 1997 Jul 30;86(31-32):1209-12 (5 ref.) (Eng. Abstr.) **(Ger)**

[Differential diagnosis and therapy of delirium] Radanov BP. **Ther Umsch** 1997 Jul;54(7):372-5 (11 ref.) (Eng. Abstr.) **(Ger)**

[Perioperative hygiene in trauma surgery] Kasperczyk WJ, et al. **Unfallchirurg** 1996 Jul;99(7):460-5 (22 ref.) (Eng. Abstr.) **(Ger)**

[Self-induced injuries--surgical aspects] Katzer A, et al. **Unfallchirurgie** 1997 Jun;23(3):105-13 (48 ref.) (Eng. Abstr.) **(Ger)**

[Risk of hepatitis C virus infection in medical occupations] Kaufmann M, et al. **Versicherungsmedizin** 1997 Aug 1; 49(4):132-4 (21 ref.) (Eng. Abstr.) **(Ger)**

[The physically ill patient needs psychotherapy] Barolin GS. **Wien Med Wochenschr** 1996;146(12):245-52 (19 ref.) (Eng. Abstr.) **(Ger)**

[After-care and palliative therapeutic measures in ovarian carcinoma] Kurz C, et al. **Wien Med Wochenschr** 1996; 146(1-2):34-7 (12 ref.) (Eng. Abstr.) **(Ger)**

[Rehabilitation as interdisciplinary responsibility--the medical specialty "physical and rehabilitative medicine"] Gehrk A. **Z Arztl Fortbild (Jena)** 1996 Oct;90(6):471-8 (7 ref.) (Eng. Abstr.) **(Ger)**

[Rehabilitation in asthmatic diseases] Lübcke P. **Z Arztl Fortbild (Jena)** 1996 Oct;90(6):495-500 (17 ref.) (Eng. Abstr.) **(Ger)**

[Substance dependence. Information, diagnosis and therapy--encouragement for pragmatic treatment] Salloch-Vogel RR, et al. **Z Arztl Fortbild (Jena)** 1996 Jun; 90(4):279-94 (0 ref.) (Eng. Abstr.) **(Ger)**

[Pharmacopsychiatric guidelines for treatment of alcohol withdrawal syndrome] Schröder-Rosenstock K, et al. **Z Arztl Fortbild (Jena)** 1996 Jun;90(4):301-6 (29 ref.) (Eng. Abstr.) **(Ger)**

[Current aspects of neurologic and neurosurgical rehabilitation in ambulatory medicine] Schupp W. **Z Arztl Fortbild (Jena)** 1996 Oct;90(6):501-9 (20 ref.) (Eng. Abstr.) **(Ger)**

[Psychological contributions to rehabilitation in ambulatory health care] Vogel H. **Z Arztl Fortbild (Jena)** 1996 Oct; 90(6):519-25 (23 ref.) (Eng. Abstr.) **(Ger)**

[Cardiologic rehabilitation. An orienting overview] Weidemann H. **Z Arztl Fortbild (Jena)** 1996 Oct; 90(6):479-86 (8 ref.) (Eng. Abstr.) **(Ger)**

[Possibilities of therapy and rehabilitation of patients with urinary incontinence] Zermann DH, et al. **Z Arztl Fortbild (Jena)** 1996 Oct;90(6):533-7 (19 ref.) (Eng. Abstr.) **(Ger)**

[Gastroenterologic and hepatologic rehabilitation today--on changes in indications and contents] Zillessen E. **Z Arztl Fortbild (Jena)** 1996 Oct;90(6):487-93 (19 ref.) (Eng. Abstr.) **(Ger)**

[Management of children with oncologic illnesses. Cooperation between the family physician and the clinic] Schwabe D. **Z Arztl Fortbild Qualitatssich** 1997 Jun; 91(3):267-75 (20 ref.) (Eng. Abstr.) **(Ger)**

[Cardiosurgical stand-by and acute interventions after interventional cardiologic procedures] Oelert H. **Z Kardiol** 1996;85 Suppl 6:303-8 (24 ref.) (Eng. Abstr.) **(Ger)**

[Current surgical therapy of breast carcinoma and subsequent requirements for histopathologic diagnosis] Schönfelder M. **Zentralbl Chir** 1997;122(2):74-8 (17 ref.) (Eng. Abstr.) **(Ger)**

[Errors in trauma team work] Hirshberg A, et al. **Harefuah** 1996 Dec 1;131(11):506-7 (9 ref.) **(Heb)**

ECONOMICS

Occupational therapy practice: focusing on occupational performance. Baum CM, et al. **Am J Occup Ther** 1997 Apr; 51(4):277-88 (39 ref.)

Rethinking patient placement: the human service matrix model for matching services to needs. McGee MD, et al. **J Subst Abuse Treat** 1997 Mar-Apr;14(2):141-8 (75 ref.)

[Psychosomatic rehabilitation] Lamprecht F. **Z Arztl Fortbild (Jena)** 1996 Oct;90(6):511-7 (13 ref.) (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

Partnership and collaboration: rhetoric and reality. Morrison T. **Child Abuse Negl** 1996 Feb;20(2):127-40 (37 ref.)

[Legal implications, patient education responsibilities for referring and treating physicians] Ulsenheimer K. **Z Kardiol** 1996 Aug;85(8):529-36 (29 ref.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Integration or evolution: women's health as a model for interdisciplinary change in medical education. Nelson M, et al. **Acad Med** 1997 Sep;72(9):737-40 (14 ref.)

Shared care: a review of the literature. Hampson JP, et al. **Fam Pract** 1996 Jun;13(3):264-79 (230 ref.)

Effective teamwork in rehabilitation. Bakheit AM. **Int J Rehabil Res** 1996 Dec;19(4):301-6 (27 ref.)

Critical incident stress debriefing and the community health nurse. Hollister R. **J Community Health Nurs** 1996; 13(1):43-9 (11 ref.)

Administrative and technical support of ambulatory infusional cancer chemotherapy (ICC). Moore C, et al. **J Infus Chemother** 1996 Fall;6(4):161-3 (6 ref.)

Marriage and family therapists and the clergy: a need for clinical collaboration, training, and research. Weaver AJ, et al. **J Marital Fam Ther** 1997 Jan;23(1):13-25 (86 ref.)

Ancillary services in rheumatology. Jones G, et al. **Med J Aust** 1997 Apr 21;166(8):434-9 (34 ref.)

Health professional decision-making in the ICU: a review of the evidence. Cook DJ. **New Horiz** 1997 Feb;5(1):15-9 (46 ref.)

The trauma team--a system of initial trauma care [see comments] Adedeji OA, et al. **Postgrad Med J** 1996 Oct; 72(852):587-93 (72 ref.) Comment in: Postgrad Med J 1997 Mar;73(857):190.

The blood cell transplant program. Nelson JP. **Semin Oncol Nurs** 1997 Aug;13(3):208-15 (23 ref.)

STANDARDS

Relationships between primary care physicians and consultants in managed care. Brett AS. **J Clin Ethics** 1997 Spring;8(1):60-5 (13 ref.)

STATISTICS & NUMERICAL DATA

The impact of HIV infection on medical services in drug abuse treatment programs. Selwyn PA. **J Subst Abuse Treat** 1996 Sep-Oct;13(5):397-410; discussion 439 (85 ref.)

[Occupational medicine significance of hepatitis C in health care employees] Hofmann F, et al. **Gesundheitswesen** 1997 Jul;59(7):452-60 (58 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

Clinical practice issues in consultation-liaison psychiatry. Wright M, et al. **Aust N Z J Psychiatry** 1996 Apr; 30(2):238-45 (66 ref.)

Psychotherapy integration: its implications for psychiatry. Albeniz A, et al. **Br J Psychiatry** 1996 Nov;169(5):563-70 (20 ref.)

Elucidating mental disorder in liaison psychiatry: the Johns Hopkins "perspectives" [editorial] Lobo A. **J Psychosom Res** 1996 Jul;41(1):7-11 (29 ref.)

Consultation-liaison psychiatry in the managed care arena. Gonzales JJ, et al. **Psychiatr Clin North Am** 1996 Sep;

19(3):449–66 (53 ref.)
Psychiatric interventions in the medically ill. Outcome and effectiveness research. Saravay SM.
Psychiatr Clin North Am 1996 Sep;19(3):467–80 (66 ref.)
Geriatric psychiatry in primary care. A focus on ambulatory settings. Woolley DC. **Psychiatr Clin North Am** 1997 Mar; 20(1):241–60 (98 ref.)
Psychiatry in medical practice. Implications for the education of primary care physicians in the era of managed care: Part 2. Stoudemire A. **Psychosomatics** 1997 Jan–Feb; 38(1):1–9 (74 ref.)
[Quality assurance in phoniatrics. Recommendation for standardization of clinical voice evaluation (see comments)] Friedrich G. **HNO** 1996 Jul;44(7):401–16 (65 ref.)
Comment in: HNO 1996 Aug;44(8):423. **(Ger)**

PATIENT-CENTERED CARE

Margaret Holroyd Prize Essay. A patient-centred approach to evaluation and treatment in rheumatoid arthritis: the development of a clinical tool to measure patient-perceived handicap. Carr AJ. **Br J Rheumatol** 1996 Oct;35(10):921–32 (114 ref.)
Facing future challenges in general practice: a clinical method with computer support. Purves IN. **Fam Pract** 1996 Dec;13(6):536–43 (62 ref.)
Organizing care for patients with chronic illness. Wagner EH, et al. **Milbank Q** 1996;74(4):511–44 (121 ref.)

ORGANIZATION & ADMINISTRATION

Integrated care pathways. Kitchiner D, et al.
Arch Dis Child 1996 Aug;75(2):166–8 (23 ref.)
Children at risk: we shall overcome. Shelov SP.
Arch Pediatr Adolesc Med 1997 Sep;151(9):931–6 (8 ref.)
Renewing the National Health Service: Labour's agenda for a healthier Britain. **Int J Health Serv** 1996;26(2):269–308 (0 ref.)
Towards a critical theory of mental health nursing. Hopton J. **J Adv Nurs** 1997 Mar;25(3):492–500 (72 ref.)
Drug treatment for women: traditional models and new directions. Kearney MH.
J Obstet Gynecol Neonatal Nurs 1997 Jul–Aug;26(4):459–68 (52 ref.)
Patient-focused models of care. Pence M.
J Obstet Gynecol Neonatal Nurs 1997 May–Jun;26(3):320–6 (18 ref.)

STANDARDS

Evaluation of brain injury related behavioral disturbances in community mental health centers. McAllister TW.
Community Ment Health J 1997 Aug;33(4):341–58; discussion 359–64 (96 ref.)
Whose outcomes. Patients, providers, or payers? Kleinpell RM. **Nurs Clin North Am** 1997 Sep;32(3):513–20 (21 ref.)

PATIENT COMPLIANCE

see related
PATIENT DROPOUTS
TREATMENT REFUSAL

Compliance to a low-salt diet. Luft FC, et al.
Am J Clin Nutr 1997 Feb;65(2 Suppl):698S–703S (30 ref.)
Compliance with treatment regimens in chronic asymptomatic diseases. Miller NH. **Am J Med** 1997 Feb 17;102(2A):43–9 (49 ref.)
Nonadherence in asthmatic patients: is there a solution to the problem? Bender B, et al.
Ann Allergy Asthma Immunol 1997 Sep;79(3):177–85; quiz 185–6 (67 ref.)
Oral contraceptive compliance during adolescence. Serfaty D. **Ann N Y Acad Sci** 1997 Jun 17;816:422–31 (11 ref.)
Adherence to therapy in tuberculosis. Cohen FL.
Annu Rev Nurs Res 1997;15:153–84 (80 ref.)
Medication compliance as a feature in drug development. Kastrissios H, et al. **Annu Rev Pharmacol Toxicol** 1997; 37:451–75 (92 ref.)
The ethics of compliance: a dialectic. Hess JD.
ANS Adv Nurs Sci 1996 Sep;19(1):18–27 (24 ref.)
Aids to compliance with medication. Corlett AJ. **BMJ** 1996 Oct 12;313(7062):926–9 (5 ref.)
Improving treatment compliance among adolescent suicide attempters. Spirito A. **Crisis** 1996;17(4):152–4 (18 ref.)
The role of patient participation in the doctor visit. Implications for adherence to diabetes care. Golin CE, et al. **Diabetes Care** 1996 Oct;19(10):1153–64 (134 ref.)
Adherence in diabetes: can we define it and can we measure it? McNabb WL. **Diabetes Care** 1997 Feb;20(2):215–8 (30 ref.)
Compliance and outcomes in patients with asthma. Cochrane GM. **Drugs** 1996;52 Suppl 6:12–9 (44 ref.)
Progestogen intolerance and compliance with hormone replacement therapy in menopausal women. Panay N, et al. **Hum Reprod Update** 1997 Mar–Apr;3(2):159–71 (73 ref.)
Patient compliance: recognition of factors involved and suggestions for promoting compliance with therapeutic regimens. Cameron C. **J Adv Nurs** 1996 Aug;24(2):244–50 (45 ref.)
Compliance during treatment with antidepressants. Demyttenaere K. **J Affect Disord** 1997 Mar;43(1):27–39 (88 ref.)
Compliance/adherence and care management in HIV disease. Crespo-Fierro M. **J Assoc Nurses AIDS Care** 1997 Jul–Aug;8(4):43–54 (80 ref.)
Adherence to medication, diet, and activity recommendations: from assessment to maintenance. Burke LE, et al. **J Cardiovasc Nurs** 1995 Jan;9(2):62–79 (97 ref.)
Adherence in AIDS clinical trials: a framework for clinical research and clinical care. Ickovics JR, et al.
J Clin Epidemiol 1997 Apr;50(4):385–91 (58 ref.)
The assessment of refill compliance using pharmacy records: methods, validity, and applications. Steiner JF, et al.
J Clin Epidemiol 1997 Jan;50(1):105–16 (61 ref.)
Failure to comply: a therapeutic dilemma and the bane of clinical trials. Gibaldi M. **J Clin Pharmacol** 1996 Aug; 36(8):674–82 (49 ref.)
The problem of compliance to cholesterol altering therapy. Insull W. **J Intern Med** 1997 Apr;241(4):317–25 (24 ref.)
Involuntary confinement for tuberculosis control: the Jewish view. Rosner F. **Mt Sinai J Med** 1996 Jan;63(1):44–8 (27 ref.)
From compliance to alliance. A quarter century of research. Blackwell B. **Neth J Med** 1996 Apr;48(4):140–9 (38 ref.)
Medication noncompliance. Olfson M, et al.
New Dir Ment Health Serv 1997 Spring;(73):39–49 (36 ref.)
Tailoring interventions to clients: effects on engagement and retention. Beutler LE, et al. **NIDA Res Monogr** 1997; 165:85–109 (104 ref.)
Enhancing retention in clinical trials of psychosocial treatments: practical strategies. Carroll KM.
NIDA Res Monogr 1997;165:4–24 (52 ref.)
Stages of change: interactions with treatment compliance and involvement. DiClemente CC, et al. **NIDA Res Monogr** 1997;165:131–56 (71 ref.)
From the initial clinic contact to aftercare: a brief review of effective strategies for retaining cocaine abusers in treatment. Higgins ST, et al. **NIDA Res Monogr** 1997; 165:25–43 (35 ref.)
Factors associated with treatment continuation: implications for the treatment of drug dependence. Kolden GG, et al. **NIDA Res Monogr** 1997;165:110–30 (47 ref.)
Back to basics: fundamental cognitive therapy skills for keeping drug-dependent individuals in treatment. Liese BS, et al. **NIDA Res Monogr** 1997;165:207–32 (39 ref.)
The role of family and significant others in the engagement and retention of drug-dependent individuals. Stanton MD. **NIDA Res Monogr** 1997;165:157–80 (89 ref.)
Drug compliance in pediatrics. Clinical and research issues. Matsui DM. **Pediatr Clin North Am** 1997 Feb;44(1):1–14 (71 ref.)
Maximizing drug compliance in the elderly. Tips for staying on top of your patients' medication use. Ennis KJ, et al. **Postgrad Med** 1997 Sep;102(3):211–3, 218, 223–4 (13 ref.)
Compliance in rheumatoid arthritis and the role of formal patient education. Brus H, et al. **Semin Arthritis Rheum** 1997 Feb;26(4):702–10 (77 ref.)
Measuring transplant patients' compliance with immunosuppressive therapy. De Geest S, et al.
West J Nurs Res 1996 Oct;18(5):595–605 (45 ref.)
[Evaluation of the risk-benefit ratio of hormonal replacement therapy for menopause and susceptible elements in maximizing compliance] Lopes P, et al.
J Gynecol Obstet Biol Reprod (Paris) 1996;25(7):694–8 (21 ref.) (Eng. Abstr.) **(Fre)**
[Hormone substitution in postmenopause. Administration mode, regimen and compliance] Keller PJ.
Zentralbl Gynakol 1997;119(6):260–4 (19 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Should we pay the patient? Review of financial incentives to enhance patient compliance. Giuffrida A, et al. **BMJ** 1997 Sep 20;315(7110):703–7 (64 ref.)
Towards the improvement of compliance: the significance of psycho-education and new antipsychotic drugs. Gaebel W. **Int Clin Psychopharmacol** 1997 Feb;12 Suppl 1:S37–42 (48 ref.)
What can we achieve by implementing a compliance-improvement program? Kane JM.
Int Clin Psychopharmacol 1997 Feb;12 Suppl 1:S43–6 (21 ref.)
Adherence: a matter of self-efficacy and power. Buchmann WF. **J Adv Nurs** 1997 Jul;26(1):132–7 (11 ref.)
Patient adherence in chronic illness: personality and coping in context. Wiebe JS, et al. **J Pers** 1996 Dec;64(4):815–35 (95 ref.)

PATIENT COOPERATION see **PATIENT COMPLIANCE**

PATIENT DATA PRIVACY see **CONFIDENTIALITY**

PATIENT DISCHARGE

Challenges in ambulatory surgery: discharge criteria. Boey WK. **Ann Acad Med Singapore** 1995 Nov;24(6):906–9 (13 ref.)
Early release after cardiac surgery. Keon WJ, et al.
Coron Artery Dis 1997 Mar–Apr;8(3–4):235–41 (24 ref.)
Early release following cardiac surgery. Keon WJ, et al.
Curr Opin Cardiol 1996 Nov;11(6):599–602 (20 ref.)
Congenital diaphragmatic hernia: what happens after discharge? D'Agostino JA.
MCN Am J Matern Child Nurs 1997 Sep–Oct;22(5):263–6 (20 ref.)
Discharge planning in psychiatric units in general hospitals. Olfson M, et al. **New Dir Ment Health Serv** 1997 Spring; (73):75–85 (26 ref.)
[Nutritional needs of the preterm infant after hospital discharge] Zuppa AA, et al. **Minerva Pediatr** 1997 Mar; 49(3):79–88 (45 ref.) (Eng. Abstr.) **(Ita)**

LEGISLATION & JURISPRUDENCE

The politics of "Drive-through deliveries": putting early postpartum discharge on the legislative agenda. Declercq E, et al. **Milbank Q** 1997;75(2):175–202 (69 ref.)

STANDARDS

Ethical dilemmas in discharge planning for patients with Alzheimer's disease. Cummings SM, et al.
Health Soc Work 1997 May;22(2):101–8 (39 ref.)

PATIENT DROPOUTS

Back to basics: fundamental cognitive therapy skills for keeping drug-dependent individuals in treatment. Liese BS, et al. **NIDA Res Monogr** 1997;165:207–32 (39 ref.)
[Patients leaving psychiatric hospitals without permission] Naveh S, et al. **Harefuah** 1996 May 15;130(10):699–701 (15 ref.) **(Heb)**
[Syndrome of dropout and premature termination at psychiatric clinics--reasons and characteristics] Shamir D, et al. **Harefuah** 1996 Jul;131(1–2):39–42 (25 ref.) **(Heb)**

PATIENT DUMPING see **PATIENT TRANSFER**

PATIENT EDUCATION

Issues of medication compliance and the elderly. Atkin PA, et al. **Adverse Drug React Toxicol Rev** 1996 Jun; 15(2):109–18 (61 ref.)
Providing asthma education in primary care practice. Stoloff SW, et al. **Am Fam Physician** 1997 Jul;56(1):117–26, 131–4, 142 (31 ref.)
Research on the effects of pharmacist-patient communication in institutions and ambulatory care sites, 1969–1994. De Young M. **Am J Health Syst Pharm** 1996 Jun 1; 53(11):1277–91 (66 ref.)
The physician's role in minimizing prehospital delay in patients at high risk for acute myocardial infarction: recommendations from the National Heart Attack Alert Program. Working Group on Educational Strategies To Prevent Prehospital Delay in Patients at High Risk for Acute Myocardial Infarction. Dracup K, et al.
Ann Intern Med 1997 Apr 15;126(8):645–51 (61 ref.)
A preventive ethics approach to counseling patients about clinical futility in the primary care setting. Doukas DJ, et al. **Arch Fam Med** 1996 Nov–Dec;5(10):589–92 (35 ref.)
Prostate cancer screening: what general practitioners and patients need to know. Boyden A. **Aust Fam Physician** 1996 Sep;25(9 Suppl 2):S86–90 (28 ref.)
Good performance of vaccination by education. Peltola H. **Biologicals** 1997 Jun;25(2):237–9 (9 ref.)
Patient educational material in the management of low back pain in primary care. Burton AK, et al.
Bull Hosp Jt Dis 1996;55(3):138–41 (24 ref.)
Moderate drinking and health. Implications of recent evidence. Ashley MJ, et al. **Can Fam Physician** 1997 Apr; 43:687–94 (85 ref.)
Asthma in the elderly: the importance of patient education. Anderson CJ, et al. **Compr Ther** 1996 Jun;22(6):375–83 (26 ref.)
Medication reduction strategies. Courtney DL.
Compr Ther 1996 May;22(5):318–23 (11 ref.)
Asthma patient education: a primer for the primary care physician. Oppedisano R, et al. **Compr Ther** 1996 Nov; 22(11):695–702 (19 ref.)
Advice for selected breast-feeding issues. Thureen PJ, et al. **Compr Ther** 1996 Dec;22(12):802–5 (11 ref.)
Training and professional development in diabetes care. Apfel J, et al. **Diabet Med** 1996 Sep;13(9 Suppl 4):S65–76 (9 ref.)
The potential for lifestyle change to influence the progression of impaired glucose tolerance to non-insulin-dependent diabetes mellitus. Bourn DM. **Diabet Med** 1996 Nov; 13(11):938–45 (55 ref.)
Report of the Patients and Carers Group. Hill J, et al.
Diabet Med 1996 Sep;13(9 Suppl 4):S60–4 (8 ref.)
Medical limitations to wilderness travel. Backer H.
Emerg Med Clin North Am 1997 Feb;15(1):17–41 (73 ref.)
Traveler's diarrhea. Larson SC.
Emerg Med Clin North Am 1997 Feb;15(1):179–89 (15 ref.)
General medical advice for travelers. Reyes I, et al.
Emerg Med Clin North Am 1997 Feb;15(1):1–16 (73 ref.)
High-altitude medicine. Zafren K, et al.
Emerg Med Clin North Am 1997 Feb;15(1):191–222 (201 ref.)
Towards the improvement of compliance: the significance of psycho-education and new antipsychotic drugs. Gaebel W. **Int Clin Psychopharmacol** 1997 Feb;12 Suppl 1:S37–42 (48 ref.)
What can we achieve by implementing a compliance-improvement program? Kane JM.
Int Clin Psychopharmacol 1997 Feb;12 Suppl 1:S43–6 (21 ref.)
Asymptomatic shedding of herpes simplex virus from the genital tract: uncertainty and its consequences for patient

management. The Herpes Simplex Virus Advisory Panel [editorial] Barton SE, et al. **Int J STD AIDS** 1996 Jul; 7(4):229–32 (13 ref.)

Penetrating BB shot head wound in an asymptomatic 9-year-old girl: the ultimate teaching moment. Johnson NA. **J Am Board Fam Pract** 1997 Mar–Apr;10(2):125–30 (14 ref.)

New OTC drugs and devices: a selective review. Newton GD, et al. **J Am Pharm Assoc (Wash)** 1997 Mar–Apr; NS37(2):165–76 (14 ref.)

Naproxen sodium. Sutton LB. **J Am Pharm Assoc (Wash)** 1996 Nov;NS36(11):663–7 (15 ref.)

Continence for women: evidence-based practice. Sampselle CM, et al. **J Obstet Gynecol Neonatal Nurs** 1997 Jul–Aug; 26(4):375–85 (29 ref.)

Epilepsy education: a nursing perspective. Hausman SV, et al. **Mayo Clin Proc** 1996 Nov;71(11):1114–7 (17 ref.)

Standards of care for acutely ill children with asthma. Andersen CL, et al. **MCN Am J Matern Child Nurs** 1996 Nov–Dec;21(6):280–7 (18 ref.)

Physical activity: counseling adults and older adults. **Nurse Pract** 1997 Apr;22(4):159–60; 165–6; 171; passim (25 ref.)

Strategies to improve cancer education materials. Doak LG, et al. **Oncol Nurs Forum** 1996 Sep;23(8):1305–12 (69 ref.)

Compliance in rheumatoid arthritis and the role of formal patient education. Brus H, et al. **Semin Arthritis Rheum** 1997 Feb;26(4):702–10 (77 ref.)

How should a man with testicular cancer be counseled and what information is available to him? Reiker PP. **Semin Urol Oncol** 1996 Feb;14(1):17–22 (16 ref.)

Educational and behavioral interventions for back pain in primary care. Turner JA. **Spine** 1996 Dec 15;21(24):2851–7; discussion 2858–9 (48 ref.)

[Sects, sectarisms and authentic spiritual pathways: can we learn to discern between them in order to counsel?] Wulliemier F. **Rev Med Suisse Romande** 1997 Jun; 117(6):525–33 (24 ref.) **(Fre)**

[Medical consultation with curable cancer patients] de Maddalena H. **HNO** 1996 Nov;44(11):645–54 (17 ref.) **(Ger)**

[Patient education--support--help with decisions: ethical aspects in treatment of amyotrophic lateral sclerosis] Meran JG, et al. **Wien Med Wochenschr** 1996;146(9–10):190–4 (21 ref.) (Eng. Abstr.) **(Ger)**

[Safety rules for patients with artificial cardiac pacemaker] Costa R, et al. **Rev Assoc Med Bras** 1996 Jul–Sep; 42(3):185–96 (39 ref.) (Eng. Abstr.) **(Por)**

[The effect of the education of bronchial asthma patients on the course of the disease] Bulkina LS, et al. **Ter Arkh** 1996; 68(12):30–5 (91 ref.) (Eng. Abstr.) **(Rus)**

ECONOMICS

[The anxious patient during magnetic resonance tomography (MRI) examination. Health care economic aspects of patient education] Goyen M, et al. **Z Arztl Fortbild Qualitatssich** 1997 Jul;91(4):319–22 (21 ref.) (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

The legal and ethical implications of gag clauses in physician contracts. Martin JA, et al. **Am J Law Med** 1996; 22(4):433–76 (351 ref.)

[Consent and patient education in anesthesia. Legal principles and forensic consequences] Biermann E. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jul; 32(7):427–52 (108 ref.) **(Ger)**

[Legal implications, patient education responsibilities for referring and treating physicians] Ulsenheimer K. **Z Kardiol** 1996 Aug;85(8):529–36 (29 ref.) **(Ger)**

METHODS

Interventions to reduce the impact of chronic disease: community-based arthritis patient education. Goeppinger J, et al. **Annu Rev Nurs Res** 1997;15:101–22 (63 ref.)

Educational assessment and teaching of older clients with pressure ulcers. Ayello EA, et al. **Clin Geriatr Med** 1997 Aug;13(3):483–96 (20 ref.)

How to prepare cancer patients for potentially threatening medical procedures: consensus guidelines. NSW Cancer Council Cancer Education Research Program. Schofield MJ, et al. **J Cancer Educ** 1996 Fall;11(3):153–8 (16 ref.)

Systemic lupus erythematosus: immunopathogenesis and the card game analogy. Isenberg DA. **J Rheumatol Suppl** 1997 May;48:62–6 (27 ref.)

Interactive educational simulators in diabetes care. Lehmann ED. **Med Inf (Lond)** 1997 Jan–Mar;22(1):47–76 (90 ref.)

Patient teaching in ambulatory surgery. Lancaster KA. **Nurs Clin North Am** 1997 Jun;32(2):417–27 (18 ref.)

Care of the pediatric patient in ambulatory surgery. Lancaster KA. **Nurs Clin North Am** 1997 Jun;32(2):441–55 (19 ref.)

Group education for rheumatoid arthritis patients. Taal E, et al. **Semin Arthritis Rheum** 1997 Jun;26(6):805–16 (56 ref.)

Cancer pain education for patients. Ferrell BR, et al. **Semin Oncol Nurs** 1997 Feb;13(1):42–8 (37 ref.)

[Role of education in the patient with chronic diseases: example of asthma and chronic obstructive lung disease] Uldry C, et al. **Rev Med Suisse Romande** 1997 May; 117(5):433–7 (28 ref.) **(Fre)**

[Hemi-neglect syndrome. Clinical characteristics and reeducation management] Seniów J, et al. **Neurol Neurochir Pol** 1997 Jan–Feb;31(1):123–33 (18 ref.) (Eng. Abstr.) **(Pol)**

ORGANIZATION & ADMINISTRATION

Patient education for behavior change: help from the Transtheoretical and Harm Reduction models. Bradley-Springer L. **J Assoc Nurses AIDS Care** 1996;7 Suppl 1:23–33; discussion 34–40 (18 ref.)

Childbirth education in the 1990s and beyond. Zwelling E. **J Obstet Gynecol Neonatal Nurs** 1996 Jun;25(5):425–32 (49 ref.)

STANDARDS

Medical guidelines for air travel. Aerospace Medical Association, Air Transport Medicine Committee, Alexandria, Va. **Aviat Space Environ Med** 1996 Oct;67(10 Suppl):B1–16 (62 ref.)

Patient education in rheumatology [see comments] Lorish CD, et al. **Curr Opin Rheumatol** 1997 Mar;9(2):106–11 (21 ref.) Comment in: Curr Opin Rheumatol 1997 Mar;9(2):87–9.

TRENDS

A practical guide to patient education and information giving. Hill J. **Baillieres Clin Rheumatol** 1997 Feb;11(1):109–27 (53 ref.)

Childbirth education in the 1990s and beyond. Zwelling E. **J Obstet Gynecol Neonatal Nurs** 1996 Jun;25(5):425–32 (49 ref.)

PATIENT-FAMILY LODGING see **HOUSING**

PATIENT-FOCUSED CARE see **PATIENT-CENTERED CARE**

PATIENT IDENTIFICATION SYSTEMS

METHODS

Practical methods to improve transfusion safety by using novel blood unit and patient identification systems. Wenz B, et al. **Am J Clin Pathol** 1997 Apr;107(4 Suppl 1):S12–6 (26 ref.)

PATIENT ISOLATION

STANDARDS

Isolation [published erratum appears in Infect Control Hosp Epidemiol 1997 Apr;18(4):236] Edmond M. **Infect Control Hosp Epidemiol** 1997 Jan;18(1):58–64 (12 ref.)

PATIENT MONITORING see **MONITORING, PHYSIOLOGIC**

PATIENT NONCOMPLIANCE see **TREATMENT REFUSAL**

PATIENT OMBUDSMEN see **PATIENT ADVOCACY**

PATIENT OUTCOME ASSESSMENT see **OUTCOME ASSESSMENT (HEALTH CARE)**

PATIENT PARTICIPATION

The hemodialysis patient: object of diagnosis or part of the treatment team? Burnell MS. **Adv Ren Replace Ther** 1997 Apr;4(2):145–51 (22 ref.)

Making decisions about end-stage renal disease treatment: a review of theories and issues. Pfettscher SA. **Adv Ren Replace Ther** 1997 Jan;4(1):81–8 (62 ref.)

Physician recommendations and patient autonomy: finding a balance between physician power and patient choice. Quill TE, et al. **Ann Intern Med** 1996 Nov 1;125(9):763–9 (46 ref.)

Self-management plans: uses and limitations. Partridge MR. **Br J Hosp Med** 1996 Feb 7–20;55(3):120–2 (11 ref.)

Ethics in the doctor-patient relationship. Smith DH. **Crit Care Clin** 1996 Jan;12(1):179–97 (35 ref.)

Shifting attention from objective risk factors to patients' self-assessed health resources: a clinical model for general practice. Hollnagel H, et al. **Fam Pract** 1995 Dec; 12(4):423–9 (50 ref.)

Analysis of the concept of mutuality. Henson RH. **Image J Nurs Sch** 1997 Spring;29(1):77–81 (50 ref.)

Implications of the Patient Self-Determination Act: guidelines for involving adolescents in medical decision making. Mccabe MA, et al. **J Adolesc Health** 1996 Nov; 19(5):319–24 (33 ref.)

Patient participation: a concept analysis. Cahill J. **J Adv Nurs** 1996 Sep;24(3):561–71 (82 ref.)

Protective care-receiving: the active role of care-recipients. Russell CK, et al. **J Adv Nurs** 1997 Mar;25(3):532–40 (14 ref.)

Evidence-based medicine and "médecine d'observation". Vandenbroucke JP. **J Clin Epidemiol** 1996 Dec; 49(12):1335–8 (10 ref.)

Communication through interpreters in healthcare: ethical dilemmas arising from differences in class, culture, language, and power [see comments] Kaufert JM, et al. **J Clin Ethics** 1997 Spring;8(1):71–87 (47 ref.) Comment in: J Clin Ethics 1997 Spring;8(1):88–93.

From what's neutral to what's meaningful: reflections on a study of medical interpreters [see comments] Solomon MZ. **J Clin Ethics** 1997 Spring;8(1):88–93 (11 ref.) Comment in: J Clin Ethics 1997 Spring;8(1):71–87.

Patient decision-making: medical ethics and mediation. Craig YJ. **J Med Ethics** 1996 Jun;22(3):164–7 (24 ref.)

From compliance to alliance. A quarter century of research. Blackwell B. **Neth J Med** 1996 Apr;48(4):140–9 (38 ref.)

Stages of change: interactions with treatment compliance and involvement. DiClemente CC, et al. **NIDA Res Monogr** 1997;165:131–56 (71 ref.)

Toward a theory of social pharmacology: the actor-spectator paradox applied to the psychotropic prescribing process. Lilja J, et al. **Subst Use Misuse** 1997 Jul;32(9):1175–215 (38 ref.)

Personalized surgery for rectal tumours: the patient's opinion counts. Audisio RA, et al. **Support Care Cancer** 1997 Jan; 5(1):17–21 (77 ref.)

Freedom and democracy in health care ethics: is the cart before the horse? Meaney ME. **Theor Med** 1996 Dec; 17(4):399–414 (21 ref.)

Listening or telling? Thoughts on responsibility in clinical ethics consultation. Zaner RM. **Theor Med** 1996 Sep; 17(3):255–77 (74 ref.)

[The trauma patient: open hospital choice? (editorial)] Leutenegger A, et al. **Swiss Surg** 1997;3(4):136–41 (27 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Involving children and adolescents in medical decision making: developmental and clinical considerations. McCabe MA. **J Pediatr Psychol** 1996 Aug;21(4):505–16 (48 ref.)

Considerations for research on consumer empowerment and psychosocial interventions. Corrigan PW, et al. **Psychiatr Serv** 1997 Mar;48(3):347–52 (59 ref.)

PATIENT PREFERENCE see **PATIENT SATISFACTION**

PATIENT READMISSION

Forensic conditional release programs and outcomes in three states. Wiederanders MR, et al. **Int J Law Psychiatry** 1997 Spring;20(2):249–57 (19 ref.)

Predictors of receipt of aftercare and recidivism among persons with severe mental illness: a review. Klinkenberg WD, et al. **Psychiatr Serv** 1996 May;47(5):487–96 (117 ref.)

A conceptual framework for the study of early readmission as an indicator of quality of care. Ashton CM, et al. **Soc Sci Med** 1996 Dec;43(11):1533–41 (39 ref.)

PATIENT RECRUITMENT see **PATIENT SELECTION**

PATIENT REFUSAL OF TREATMENT see **TREATMENT REFUSAL**

PATIENT REPRESENTATIVES see **PATIENT ADVOCACY**

PATIENT SATISFACTION

see related
PATIENT ACCEPTANCE OF HEALTH CARE

Should we trade person-centered service for a consumer-based model? Peloquin SM. **Am J Occup Ther** 1997 Jul–Aug;51(7):612–5 (26 ref.)

Costs, outcomes, and patient satisfaction by provider type for patients with rheumatic and musculoskeletal conditions: a critical review of the literature and proposed methodologic standards [see comments] Solomon DH, et al. **Ann Intern Med** 1997 Jul 1;127(1):52–60 (35 ref.) Comment in: Ann Intern Med 1997 Jul 1;127(1):72–4.

Physician and patient evaluation of hypertension-related risks and benefits from treatment. Hedner T, et al. **Blood Press Suppl** 1997;1:26–34 (54 ref.)

The patient perspective. What should a new anti-asthma agent provide? Osman L. **Drugs** 1996;52 Suppl 6:29–35 (40 ref.)

Methods of measuring patient satisfaction in health care organizations. Ford RC, et al. **Health Care Manage Rev** 1997 Spring;22(2):74–89 (41 ref.)

Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome. Awad AG, et al. **Int Clin Psychopharmacol** 1996 May;11 Suppl 2:55–9 (28 ref.)

Involving clients in clinical audits of mental health services. Balogh R, et al. **Int J Qual Health Care** 1995 Dec; 7(4):343–53 (74 ref.)

An analysis of the concept 'patient satisfaction' as it relates to contemporary nursing care. Mahon PY. **J Adv Nurs** 1996 Dec;24(6):1241–8 (61 ref.)

Consumer satisfaction with dental care: where have we been, where are we going? Kress G, et al. **J Am Coll Dent** 1997 Spring;64(1):9–15 (50 ref.)

User involvement in clinical audit: a review of developments and issues of good practice. Kelson M. **J Eval Clin Pract** 1996 May;2(2):97–109 (109 ref.)

Dimensions and indicators of patients' perceived nursing care quality in the hospital setting. Chang K. **J Nurs Care Qual** 1997 Aug;11(6):26–37 (35 ref.)

PATIENT SATISFACTION

Rehabilitation care and outcomes from the patient's perspective. Kramer AM. **Med Care** 1997 Jun;35(6 Suppl):JS48–57; discussion JS58–63 (20 ref.)
Patient satisfaction and quality of care. Jackson JL, et al. **Mil Med** 1997 Apr;162(4):273–7 (79 ref.)
Marketing: applications in a military health care setting. Roark GA, et al. **Mil Med** 1997 Aug;162(8):543–7 (18 ref.)
Nurse and patient satisfaction with three types of venous access devices. Dearborn P, et al. **Oncol Nurs Forum** 1997 Jan–Feb;24(1 Suppl):34–40 (47 ref.)
Current status of patient–controlled analgesia in cancer patients. Ripamonti C, et al. **Oncology (Huntingt)** 1997 Mar; 11(3):373–80, 383–4; discussion 384–6 (102 ref.)
Assessing pharmacotherapy outcomes: a model for clinicians. Gleason PP, et al. **Pharmacotherapy** 1996 Nov–Dec; 16(6):1142–53 (102 ref.)
The next medical revolution should be quality. Friedenberg RM. **Radiology** 1997 Jul;204(1):31A–34A (14 ref.)
Patient satisfaction and the elderly. Owens DJ, et al. **Soc Sci Med** 1996 Jun;42(11):1483–91 (26 ref.)
[Patient satisfaction--artefact or social reality?] Leimkühler AM, et al. **Nervenarzt** 1996 Sep;67(9):765–73 (54 ref.) (Eng. Abstr.) **(Ger)**
[Investigation methods in clinical cardiology. VI. Evaluation of results (outcomes) and its clinical relevance in cardiology: with a special reference to the quality of life] Brotons Cuixart C, et al. **Rev Esp Cardiol** 1997 Mar; 50(3):192–200 (44 ref.) (Eng. Abstr.) **(Spa)**

PATIENT SCHEDULES see **APPOINTMENTS AND SCHEDULES**

PATIENT SELECTION

The use and abuse of upper digestive endoscopy. Axon AT. **Acta Gastroenterol Belg** 1997 Apr–Jun;60(2):172–5 (17 ref.)
Continuous renal replacement therapies in the acute renal failure setting: current concepts. Mehta RL. **Adv Ren Replace Ther** 1997 Apr;4(2 Suppl 1):81–92 (92 ref.)
Prosthetic selection in total knee arthroplasty. Vince KG. **Am J Knee Surg** 1996 Spring;9(2):76–82 (54 ref.)
Do dying patients really need i.v. fluids? [see comments] Zerwekh JV. **Am J Nurs** 1997 Mar;97(3):26–30; quiz 31 (9 ref.) Comment in: Am J Nurs 1997 May;97(5):16.
Evidence–based assessment of the benefit of revascularisation in coronary disease: beyond the randomised trials. French JK, et al. **Aust N Z J Med** 1996 Aug;26(4):490–4 (39 ref.)
Injury risk for research subjects with spina bifida occulta in a repeated impact study: a case review. Albano JP, et al. **Aviat Space Environ Med** 1996 Aug;67(8):767–9 (15 ref.)
Indications and restrictions of fluoroquinolone use in children. Green SD. **Br J Hosp Med** 1996 Oct 16–Nov 5;56(8):420–3 (23 ref.)
How does hormone replacement therapy affect the longevity of women with different risk profiles? Frank J, et al. **Can Fam Physician** 1997 Aug;43:1371–3 (5 ref.)
Cardiopulmonary exercise testing for heart transplant candidate selection. Mancini DM. **Cardiologia** 1997 Jun; 42(6):579–84 (22 ref.)
Liver transplantation in children: advances in patient selection, technique and immunosuppression. Emond JC. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1997 Jul–Aug;38(4):249–54 (20 ref.)
The dilemma of evaluating and treating cancer of unknown primary site. Markman M. **Cleve Clin J Med** 1997 Feb; 64(2):73–5 (9 ref.)
Donor criteria and evaluation. Frost AE. **Clin Chest Med** 1997 Jun;18(2):231–7 (22 ref.)
Donor considerations in living–related donor lung transplantation. Mallory GB Jr, et al. **Clin Chest Med** 1997 Jun;18(2):239–44 (24 ref.)
Psychosocial and ethical issues in surgical approaches to end–stage lung disease. Manzetti JD, et al. **Clin Chest Med** 1997 Jun;18(2):383–90 (50 ref.)
Indications. Unilateral, bilateral, heart–lung, and lobar transplant procedures. Patterson GA. **Clin Chest Med** 1997 Jun;18(2):225–30 (18 ref.)
Patient selection, evaluation, and preoperative management for lung transplant candidates. Smith CM. **Clin Chest Med** 1997 Jun;18(2):183–97 (123 ref.)
Evaluation and preoperative management of lung volume reduction surgery candidates. Yusen RD, et al. **Clin Chest Med** 1997 Jun;18(2):199–224 (154 ref.)
Cancer surgery in the elderly. Berger DH, et al. **Clin Geriatr Med** 1997 Feb;13(1):119–41 (84 ref.)
Hormone replacement therapy in the elderly. Miller KL. **Clin Obstet Gynecol** 1996 Dec;39(4):912–32 (66 ref.)
Graft selection in anterior cruciate ligament revision surgery. Ritchie JR, et al. **Clin Orthop** 1996 Apr;(325):65–77 (58 ref.)
Bioethics for clinicians: 13. Resource allocation. McKneally MF, et al. **CMAJ** 1997 Jul 15;157(2):163–7 (31 ref.)
Selection and management of candidates for heart transplantation. Stevenson LW. **Curr Opin Cardiol** 1996 Mar;11(2):166–73 (54 ref.)
Medical limitations to wilderness travel. Backer H. **Emerg Med Clin North Am** 1997 Feb;15(1):17–41 (73 ref.)
Selection criteria and programmes for pulmonary rehabilitation in COPD patients. Rehabilitation and Chronic Care Scientific Group of the European Respiratory Society. Donner CF, et al. **Eur Respir J** 1997 Mar;10(3):744–57 (97 ref.)
Critical factors in the determination of focus group size. Tang KC, et al. **Fam Pract** 1995 Dec;12(4):474–5 (13 ref.)
Psychosocial assessment of organ transplant candidates and the Americans with Disabilities Act. Orentlicher D. **Gen Hosp Psychiatry** 1996 Nov;18(6 Suppl):5S–12S (24 ref.)
Ethical dichotomies in organ transplantation. A time for bridge building. Surman OS, et al. **Gen Hosp Psychiatry** 1996 Nov;18(6 Suppl):13S–19S (29 ref.)
Seizure control: how to use the new antiepileptic drugs in older patients. Haider A, et al. **Geriatrics** 1996 Sep; 51(9):42–5 (16 ref.)
Is it time to abandon brain death? Truog RD. **Hastings Cent Rep** 1997 Jan–Feb;27(1):29–37 (47 ref.)
Inhibition of the renin–angiotensin system after acute myocardial infarction--treat first, select later? Hall AS, et al. **Heart** 1996 Nov;76(3 Suppl 3):73–8 (31 ref.)
What is the optimal patient selection for combined androgen ablative and radiation therapy? The role of combined modality staging. D'Amico AV. **Hematol Oncol Clin North Am** 1996 Jun;10(3):643–51 (13 ref.)
Prostate cancer. Who is best benefited by external beam radiation therapy? Hartford AC, et al. **Hematol Oncol Clin North Am** 1996 Jun;10(3):595–610 (65 ref.)
Who is best benefited by radical prostatectomy? Nadler RB, et al. **Hematol Oncol Clin North Am** 1996 Jun;10(3):581–93 (39 ref.)
Hospitalization of nursing home residents: the right rate? [editorial; comment] Lynn J. **J Am Geriatr Soc** 1997 Mar; 45(3):378–9 (8 ref.) Comment on: J Am Geriatr Soc 1997 Mar;45(3):265–9.
Communication, accrual to clinical trials, and the physician–patient relationship: implications for training programs. Ruckdeschel JC, et al. **J Cancer Educ** 1996 Summer;11(2):73–9 (51 ref.)
Clinical trials in sepsis: where do we stand? [see comments] Vincent JL. **J Crit Care** 1997 Mar;12(1):3–6 (17 ref.) Comment in: J Crit Care 1997 Mar;12(1):1–2.
Types of pain treatment facilities referral selection criteria: are they medically and cost effective? Rosomoff HL, et al. **J Fla Med Assoc** 1997 Jan;84(1):41–5 (17 ref.)
Time for integration of predictive factors for selection of breast cancer patients who need postoperative radiation therapy? [editorial; comment] Bergh J. **J Natl Cancer Inst** 1997 May 7;89(9):605–7 (31 ref.) Comment on: J Natl Cancer Inst 1997 May 7;89(9):639–45.
Selecting patients with ischemic cardiomyopathy for medical treatment, revascularization, or heart transplantation. Beller GA. **J Nucl Cardiol** 1997 Mar–Apr;4(2 Pt 2):S152–7 (27 ref.)
Nurse advocacy for selective versus routine episiotomy [see comments] Maier JS, et al. **J Obstet Gynecol Neonatal Nurs** 1997 Mar–Apr; 26(2):155–61 (52 ref.) Comment in: J Obstet Gynecol Neonatal Nurs 1997 Jul–Aug;26(4):373.
Clinical realities and economic considerations: patient selection in intrathecal therapy. Krames ES, et al. **J Pain Symptom Manage** 1997 Sep;14(3 Suppl):S3–13 (31 ref.)
How often can we justify parenteral nutrition in terminally ill cancer patients? Fainsinger RL, et al. **J Palliat Care** 1997 Spring;13(1):48–51 (21 ref.)
Meckel's diverticulum: should it be excised prophylactically in service personnel? Farrar MJ. **J R Army Med Corps** 1994 Feb;140(1):42–4 (09 ref.)
Choosing appropriate patients with systemic sclerosis for treatment by autologous stem cell transplantation. Clements PJ, et al. **J Rheumatol Suppl** 1997 May;48:85–8 (13 ref.)
Opportunities with combined modality therapy for selective organ preservation in muscle–invasive bladder cancer. Colvett KT, et al. **J Surg Oncol** 1996 Nov;63(3):201–8 (67 ref.)
Reference values for serum selenium in various areas–evaluated according to the TRACY protocol. Alfthan G, et al. **J Trace Elem Med Biol** 1996 Jun; 10(2):77–87 (81 ref.)
The role of MR imaging in the selection of therapy for prostate cancer. D'Amico AV. **Magn Reson Imaging Clin N Am** 1996 Aug;4(3):471–9 (26 ref.)
Surgical treatment of obesity: who is an appropriate candidate? Balsiger BM, et al. **Mayo Clin Proc** 1997 Jun; 72(6):551–7; quiz 558 (13 ref.)
Lung transplantation: selection of patients and analysis of outcome. Peters SG, et al. **Mayo Clin Proc** 1997 Jan; 72(1):85–8 (24 ref.)
Continuous electronic fetal monitoring: does it belong in low–risk births? Supplee RB, et al. **MCN Am J Matern Child Nurs** 1996 Nov–Dec;21(6):301–6 (30 ref.)
Preventing harm in resuscitation medicine. Ardagh M. **N Z Med J** 1997 Apr 11;110(1041):113–5 (28 ref.)
Cesarean delivery for fetal malformations. Kuller JA, et al. **Obstet Gynecol Surv** 1996 Jun;51(6):371–5 (28 ref.)
Surgical management of lung metastases: selection factors and results. Dresler CM, et al. **Oncology (Huntingt)** 1996 May;10(5):649–55; discussion 655–6, 659 (52 ref.)
Tonsillectomy and adenoidectomy. Changing indications. Deutsch ES. **Pediatr Clin North Am** 1996 Dec; 43(6):1319–38 (102 ref.)
Which route for hysterectomy? Evidence–based outcomes guide selection. Kovac SR. **Postgrad Med** 1997 Sep; 102(3):153–8 (16 ref.)
Coronary artery stenting: indications and cost implications. Cohen EA, et al. **Prog Cardiovasc Dis** 1996 Sep–Oct; 39(2):83–110 (169 ref.)
A guide to successfully recruiting patients for cardiovascular clinical trials. DeSantis P, et al. **Prog Cardiovasc Nurs** 1997 Summer;12(3):24–31 (8 ref.)
Pitfalls in coronary stenting. A review of current strategies. Thomas MR. **S Afr Med J** 1997 Jun;87 Suppl 3:C167–70 (24 ref.)
Patient selection and predicting response to recombinant human erythropoietin in anemic cancer patients. Henry DH 3d, et al. **Semin Hematol** 1996 Jan;33(1 Suppl 1):2–5 (17 ref.)
Axillary dissection: when and how radical? Morrow M. **Semin Surg Oncol** 1996 Sep–Oct;12(5):321–7 (51 ref.)
Breast cancer in older women: screening and selection of locoregional therapy. Sener SF. **Semin Surg Oncol** 1996 Sep–Oct;12(5):328–31 (24 ref.)
Identification of candidates for prevention of venous thromboembolism. Gensini GF, et al. **Semin Thromb Hemost** 1997;23(1):55–67 (150 ref.)
[Indications for heart transplantation (excluding emergencies)] Cohen–Solal A, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89 Spec No 6:15–22 (51 ref.) (Eng. Abstr.) **(Fre)**
[Cervical dysplasia: is there a role for hysterectomy?] Boulanger J, et al. **Contracept Fertil Sex** 1996 Dec; 24(12):904–7 (13 ref.) (Eng. Abstr.) **(Fre)**
[Endometrial cancer: total simple hysterectomy or radical hysterectomy? Abdominal or vaginal route?] Elhage A, et al. **Contracept Fertil Sex** 1996 Nov;24(11):830–3 (18 ref.) (Eng. Abstr.) **(Fre)**
[Should fetal reduction be used in triplet pregnancies?] Nisand I. **Contracept Fertil Sex** 1997 Jun;25(6):423–8 (41 ref.) **(Fre)**
[Indications for castration in women treated for breast cancer] Chapet S, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(5):445–50 (44 ref.) (Eng. Abstr.) **(Fre)**
[Current indications for liver transplantation in adults] Elnakadi I, et al. **J Med Liban** 1996;44(2):80–5 (30 ref.) **(Fre)**
[Indications for blood transfusion] Naman RE. **J Med Liban** 1995;43(2):72–82 (68 ref.) **(Fre)**
[Chemotherapy in elderly patients with bronchogenic cancers] Souquet PJ, et al. **Rev Mal Respir** 1996; 13(4):327–33 (55 ref.) (Eng. Abstr.) **(Fre)**
[Comparative analysis of indications and results of percutaneous coronary angioplasties according to age] Nellessen E, et al. **Rev Med Liege** 1997 Apr;52(4):230–6 (18 ref.) **(Fre)**
[Total hip replacement in the elderly patient: indications and results] Rodriguez A, et al. **Rev Med Liege** 1997 Apr; 52(4):278–84 (27 ref.) **(Fre)**
[Criteria for choosing a hearing aid] Mudry A. **Rev Med Suisse Romande** 1997 Jun;117(6):509–12 (16 ref.) **(Fre)**
[Selection of patients with pulmonary emphysema for surgical volume reduction] Russi EW. **Wien Med Wochenschr** 1996;146(23):582–5 (11 ref.) (Eng. Abstr.) **(Ger)**
[Integration of therapeutic options and the candidates for treatment: the ABC of the post–infarction period] Ambrosioni E, et al. **Ann Ital Med Int** 1996 Oct;11 Suppl 2:132S–138S (40 ref.) (Eng. Abstr.) **(Ita)**
[Evolution and recent trends in patient selection and reconstruction method for chronic aortic dissection] Yasuda K, et al. **Nippon Geka Gakkai Zasshi** 1996 Oct; 97(10):906–15 (30 ref.) (Eng. Abstr.) **(Jpn)**
[Surgery for intractable epilepsy—selection and presurgical evaluation] Yagi K. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1356–60 (9 ref.) (Eng. Abstr.) **(Jpn)**
[In an infertile woman, does the presence of one or several myomas of less than three cm in diameter justify a myomectomy?] Lopes P. **Contracept Fertil Sex** 1997 May; 25(5):350–1 (6 ref.) **(Spa)**

PATIENT SIMULATION

The use of standardized patients in research in general practice. Beullens J, et al. **Fam Pract** 1997 Feb;14(1):58–62 (36 ref.)
Professional shopping of hospital services: an analysis of sub rosa investigative methods in determination of quality. Komarek AG. **J Nurs Care Qual** 1996 Oct;11(1):44–55 (18 ref.)

PATIENT TRANSFER

Acute dissecting aortic aneurysm in an operational environment. Henning KS. **Mil Med** 1997 Aug;162(8):573–4 (5 ref.)

ORGANIZATION & ADMINISTRATION

Total facility evacuation at Helena Regional Medical Center. Vasudevan P, et al. **J Ark Med Soc** 1997 Jul;94(2):76–7 (0 ref.)

Chronic illness in adolescents: transfer or transition to adult services? Sawyer SM, et al. **J Paediatr Child Health** 1997 Apr;33(2):88–90 (22 ref.)

STANDARDS

Interhospital and intrahospital transfer of the critically ill patient. Tan TK. **Singapore Med J** 1997 Jun;38(6):244–8 (20 ref.)

PATIENTS

see related
INPATIENTS
OUTPATIENTS

Lessons from medicine and nursing for pharmacist–patient communication. Landis NT. **Am J Health Syst Pharm** 1996 Jun 1;53(11):1306–14 (66 ref.)

The abusive patient: where do you draw the line? [see comments] Zollo MB, et al. **Am J Nurs** 1997 Feb; 97(2):31–5; quiz 36 (10 ref.) Comment in: Am J Nurs 1997 Apr;97(4):20.

Medical ethics under managed care: how can the patient survive? Webb MS. **Ann Plast Surg** 1996 Sep;37(3):233–44 (49 ref.)

Managing latex allergy in patients and health care workers. Melton AL. **Cleve Clin J Med** 1997 Feb;64(2):76–82 (60 ref.)

PATIENTS' RIGHTS see **PATIENT ADVOCACY**

PATIENTS' ROOMS

ORGANIZATION & ADMINISTRATION

The problems of researching mixed sex wards. Batcup D. **J Adv Nurs** 1997 May;25(5):1018–24 (71 ref.)

PATIENTS' VISITORS see **VISITORS TO PATIENTS**

PATTERN RECOGNITION

Decision support techniques for the interpretation of quantitative amino acid data. Briddon A. **Ann Clin Biochem** 1996 May;33 (Pt 3):227–33 (26 ref.)

Reflections on mirror images. Neuropsychology. Walsh V. **Curr Biol** 1996 Sep 1;6(9):1079–81 (16 ref.)

PATTERN RECOGNITION, VISUAL

Critical bits and the Rorschach response process. Exner JE Jr. **J Pers Assess** 1996 Dec;67(3):464–77 (15 ref.)

Evidence of a global oblique effect in human extrafoveal vision. Pointer JS. **Perception** 1996;25(5):523–30 (20 ref.)

The CODE theory of visual attention: an integration of space-based and object-based attention. Logan GD. **Psychol Rev** 1996 Oct;103(4):603–49 (140 ref.)

Raster-scan cathode-ray tubes for vision research—limits of resolution in space, time and intensity, and some solutions. Bach M, et al. **Spat Vis** 1997;10(4):403–14 (48 ref.)

PHYSIOLOGY

The primate temporal pole: its putative role in object recognition and memory. Nakamura K, et al. **Behav Brain Res** 1996 May;77(1–2):53–77 (290 ref.)

Stimulus configuration, occasion setting, and the hippocampus. Schmajuk NA, et al. **Behav Neurosci** 1997 Apr;111(2):235–57; appendix 258 (90 ref.)

Functional imagining of human visual recognition. Kanwisher N, et al. **Brain Res Cogn Brain Res** 1996 Dec; 5(1–2):55–67 (39 ref.)

Functional anatomy of object recognition in humans: evidence from positron emission tomography and functional magnetic resonance imaging. Bly BM, et al. **Curr Opin Neurol** 1997 Feb;10(1):5–9 (27 ref.)

The neuropsychology of object constancy. Turnbull OH, et al. **J Int Neuropsychol Soc** 1997 May;3(3):288–98 (109 ref.)

High level object recognition without an anterior inferior temporal lobe. Biederman I, et al. **Neuropsychologia** 1997 Mar;35(3):271–87 (64 ref.)

Cortical dynamics of boundary segmentation and reset: persistence, afterimages, and residual traces. Francis G, et al. **Perception** 1996;25(5):543–67 (60 ref.)

Invariant face and object recognition in the visual system. Wallis G, et al. **Prog Neurobiol** 1997 Feb;51(2):167–94 (113 ref.)

Cortical dynamics of three-dimensional figure-ground perception of two-dimensional pictures. Grossberg S. **Psychol Rev** 1997 Jul;104(3):618–58 (180 ref.)

Machine learning paradigms for pattern recognition and image understanding. Caelli T, et al. **Spat Vis** 1996; 10(1):87–103 (23 ref.)

PAVOR NOCTURNUS see **SLEEP DISORDERS**

PC12 CELLS

DRUG EFFECTS

Regulation of tyrosine hydroxylase mRNA stability by oxygen in PC12 cells. Czyzyk-Krzeska MF, et al. **Adv Exp Med Biol** 1996;410:143–50 (20 ref.)

Regulation of ionic conductances and gene expression by hypoxia in an oxygen sensitive cell line. Millhorn DE, et al. **Adv Exp Med Biol** 1996;410:135–42 (17 ref.)

ENZYMOLOGY

N-acetylaspartylglutamate acetoxymethyl triester (NAAG.AM) as a tool for loading the neuropeptides NAAG and succinimidyl-NAAG into intact cells: effect on [3H]-dopamine exocytosis. Brovia V, et al. **Braz J Med Biol Res** 1996 Feb;29(2):249–58 (28 ref.)

PCBS see **POLYCHLORINATED BIPHENYLS**

PCNA see **PROLIFERATING CELL NUCLEAR ANTIGEN**

PCP see **PHENCYCLIDINE**

PCR see **POLYMERASE CHAIN REACTION**

PDGF RECEPTORS see **RECEPTORS, PLATELET-DERIVED GROWTH FACTOR**

PEAK EXPIRATORY FLOW RATE

A practical guide for peak expiratory flow monitoring in asthma patients. Jain P, et al. **Cleve Clin J Med** 1997 Apr; 64(4):195–202 (42 ref.)

Peak flow meters and spirometers in general practice. **Drug Ther Bull** 1997 Jul;35(7):52–5 (20 ref.)

Serial peak expiratory flow measurement in the diagnosis of occupational asthma. Gannon PF, et al. **Eur Respir J Suppl** 1997 Feb;24:57S–63S (32 ref.)

Paediatric prediction equations for PEF (growth, ageing, gender, race and health). Le Souef PN. **Eur Respir J Suppl** 1997 Feb;24:75S–79S (48 ref.)

Peak expiratory flow: conclusions and recommendations of a Working Party of the European Respiratory Society. Quanjer PH, et al. **Eur Respir J Suppl** 1997 Feb;24:2S–8S (74 ref.)

Peak expiratory flow monitoring in pediatric asthma: is there a role? [see comments] Sly PD. **J Asthma** 1996;33(5):277–87 (35 ref.) Comment in: J Asthma 1996;33(5):275–6.

[Peak-flow monitoring in asthmatic patients: indications and therapeutic implications of the measurements with reference to the 'traffic-light system' (published erratum appears in Schweiz Rundsch Med Prax 1997 Jan 14;86(3):64)] Rothe TB. **Schweiz Rundsch Med Prax** 1996 Nov 26;85(48):1542–9 (40 ref.) (Eng. Abstr.) **(Ger)**

[Chronopharmacology and chronotherapy for asthma by using PEF] Burioka N, et al. **Nippon Rinsho** 1996 Nov; 54(11):2956–61 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Comparison of asthma score and peak flow rate (PEF) monitoring] Okada C. **Nippon Rinsho** 1996 Nov; 54(11):2939–43 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Histopathological changes and hyperresponsiveness in asthmatic airways: relationship to peak expiratory flow] Sugiyama K, et al. **Nippon Rinsho** 1996 Nov;54(11):2944–8 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Effectiveness of PEF monitoring in chronic management of asthma patients] Takishima T, et al. **Nippon Rinsho** 1996 Nov;54(11):2919–26 (13 ref.) (Eng. Abstr.) **(Jpn)**

[The brittle asthmatic and the morning dipper] Tamura G. **Nippon Rinsho** 1996 Nov;54(11):2949–55 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Comparison of different types of peak flow meter and reference values for peak expiratory flow (PEF) for healthy Japanese subjects] Tsukioka K. **Nippon Rinsho** 1996 Nov; 54(11):2927–32 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Self-assessment of peak expiratory flow] Tsukioka K. **Nippon Rinsho** 1997 Apr;55 Suppl 2:31–4 (7 ref.) **(Jpn)**

PHYSIOLOGY

Changes in peak expiratory flow in healthy subjects and in patients with obstructive lung disease. Brand PL, et al. **Eur Respir J Suppl** 1997 Feb;24:69S–71S (57 ref.)

PEANUTS

[Allergic reactions to peanuts and soya. The life-threatening/fatal cases can be prevented] Kjellman NI, et al. **Lakartidningen** 1997 Jul 23;94(30–31):2633–4 (11 ref.) **(Swe)**

ADVERSE EFFECTS

Peanut allergy: recent advances and unresolved issues. Hourihane JO. **J R Soc Med** 1997;90 Suppl 30:40–4 (33 ref.)

IMMUNOLOGY

Peanut hypersensitivity. IgE binding characteristics of a recombinant Ara h I protein. Stanley JS, et al. **Adv Exp Med Biol** 1996;409:213–6 (13 ref.)

PEAT see **SOIL**

PEAT THERAPY see **MUD THERAPY**

PECAM-1 see **ANTIGENS, CD31**

PECTEN OCULI see **RETINAL VESSELS**

PECTINS

CHEMISTRY

Chemistry and uses of pectin—a review. Thakur BR, et al. **Crit Rev Food Sci Nutr** 1997 Feb;37(1):47–73 (229 ref.)

METABOLISM

Regulation of pectinolysis in Erwinia chrysanthemi. Hugouvieux-Cotte-Pattat N, et al. **Annu Rev Microbiol** 1996;50:213–57 (154 ref.)

THERAPEUTIC USE

[Possible mechanisms of the antimicrobial action of pectin in acute infectious diarrhea] Potievskiĭ EG. **Antibiot Khimioter** 1996;41(7–8):40–2 (12 ref.) **(Rus)**

[The therapeutic and therapeutic-prophylactic action of pectins] Tverskoĭ LA, et al. **Lik Sprava** 1995 Sep–Dec; (9–12):10–6 (57 ref.) **(Rus)**

PECTORAL NERVES see **THORACIC NERVES**

PECTUS EXCAVATUM see **FUNNEL CHEST**

PEDIATRIC DENTISTRY

see related
DENTAL CARE FOR CHILDREN

METHODS

Emergency management of oral trauma in children. Nelson LP, et al. **Curr Opin Pediatr** 1997 Jun;9(3):242–5 (15 ref.)

PEDIATRIC INTENSIVE CARE UNITS see **INTENSIVE CARE UNITS, PEDIATRIC**

PEDIATRIC NURSING

see related
MATERNAL-CHILD NURSING

The silent ones: a review of sampling issues and biases pertinent to the area of pediatric oncology procedural pain. Williams HA. **J Pediatr Oncol Nurs** 1996 Jan;13(1):31–9 (76 ref.)

Legal issues in nonrelated infant adoption: nursing implications. Lobar SL, et al. **J Soc Pediatr Nurs** 1997 Jul–Sep;2(3):116–24; quiz 125–6 (29 ref.)

Ethical issues in pediatric perioperative nursing. Hamblet Berlandi JL. **Nurs Clin North Am** 1997 Mar;32(1):153–68 (39 ref.)

EDUCATION

The use of projective techniques in pediatric nursing research from 1984 to 1993. Bellack JP, et al. **J Pediatr Nurs** 1996 Feb;11(1):10–28 (36 ref.)

Education for the nursing of children and their families: standards and guidelines for prelicensure and early professional education [published erratum appears in J Pediatr Nurs 1997 Apr;12(2):132] Pridham KF, et al. **J Pediatr Nurs** 1996 Oct;11(5):273–80 (29 ref.)

METHODS

Pediatric sedation. Essentials for the perioperative nurse. Algren CL, et al. **Nurs Clin North Am** 1997 Mar;32(1):17–30 (49 ref.)

Streamlining the perioperative process. LaRosa-Nash P, et al. **Nurs Clin North Am** 1997 Mar;32(1):141–51 (24 ref.)

STANDARDS

Standards to prevent complications of urinary catheterization in children: should and should-knots. Carlson D, et al. **J Soc Pediatr Nurs** 1997 Jan–Mar;2(1):37–41 (11 ref.)

TRENDS

Advances in pediatric anesthesia. Burns LS. **Nurs Clin North Am** 1997 Mar;32(1):45–71 (159 ref.)

Current practices and advances in pediatric neurosurgery. Lawton KH, et al. **Nurs Clin North Am** 1997 Mar; 32(1):73–96 (30 ref.)

PEDIATRIC PSYCHOLOGY see **CHILD PSYCHOLOGY**

PEDIATRICS

Advances in pediatric pharmacology and toxicology. Berlin CM Jr. **Adv Pediatr** 1997;44:545–74 (81 ref.)

Use of animal models in pediatric research. Harroff HH Jr. **Adv Pediatr** 1997;44:453–89 (75 ref.)

Recent advances. Paediatrics—I: Infancy and early childhood. Pearn J. **BMJ** 1997 Mar 15;314(7083):801–5 (63 ref.)

Paediatric anaesthesia [see comments] Russell SC, et al. **BMJ** 1997 Jan 18;314(7075):201–3 (35 ref.) Comment in: BMJ 1997 Apr 19;314(7088):1203.

Analgesia and analgesic drugs in paediatrics. Ball AJ, et al. **Br J Hosp Med** 1996 May 1–14;55(9):586–90 (27 ref.)

Sedation, analgesia, and anesthesia issues in the pediatric patient. Goad RN, et al. **Clin Podiatr Med Surg** 1997 Jan; 14(1):131–48 (30 ref.)

PEDIATRICS

Usefulness of preoperative testing in pediatric podiatric surgery. Does it influence clinical decisions? Harris EJ. **Clin Podiatr Med Surg** 1997 Jan;14(1):149–78 (15 ref.)

The primary care physician's role in evaluating the pediatric amputee. O'Neal ML, et al. **Compr Ther** 1997 Aug; 23(8):546–53 (20 ref.)

Neonatal and pediatric critical care: ethical decision making. Cooper R, et al. **Crit Care Clin** 1996 Jan;12(1):149–64 (53 ref.)

Office laboratory procedures, office economics, patient and parent education, and urinary tract infection. Ey JL, et al. **Curr Opin Pediatr** 1995 Dec;7(6):741–54 (83 ref.)

Pediatrics. A potpourri of clinical pearls. Barkin RM. **Emerg Med Clin North Am** 1997 May;15(2):381–8 (18 ref.)

Future of paediatric cardiology and its patients [see comments] Somerville J. **Eur Heart J** 1997 Feb; 18(2):198–207 (6 ref.) Comment in: Eur Heart J 1997 Feb;18(2):184–6.

Safety of stable isotope use. Koletzko B, et al. **Eur J Pediatr** 1997 Aug;156 Suppl 1:S12–7 (49 ref.)

Glucose, the brain and the paediatric endocrinologist. Aynsley-Green A. **Horm Res** 1996 Jul;46(1):8–25 (88 ref.)

Outpatient liver biopsy in children: a medical position statement of the North American Society for Pediatric Gastroenterology and Nutrition. Fox VL, et al. **J Pediatr Gastroenterol Nutr** 1996 Oct;23(3):213–6 (20 ref.)

Pediatric HIV infection. Wiznia AA, et al. **Med Clin North Am** 1996 Nov;80(6):1309–36 (206 ref.)

Problems with resistance in pediatric intensive care. Toltzis P, et al. **New Horiz** 1996 Aug;4(3):353–60 (74 ref.)

Care of the pediatric patient in ambulatory surgery. Lancaster KA. **Nurs Clin North Am** 1997 Jun;32(2):441–55 (19 ref.)

Pharmacological considerations for the pediatric patient. Blaho K, et al. **Optom Clin** 1996;5(2):61–90 (97 ref.)

Pediatric primary care vision examination. Ryan JB. **Optom Clin** 1996;5(2):1–34 (64 ref.)

Pediatric growth and development. Winbery S, et al. **Optom Clin** 1996;5(2):35–59 (47 ref.)

Noninvasive methods for drug measurement in pediatrics. Bailey B, et al. **Pediatr Clin North Am** 1997 Feb;44(1):15–26 (74 ref.)

Future directions in interventional pediatric radiology. Chait P. **Pediatr Clin North Am** 1997 Jun;44(3):763–82 (88 ref.)

Pharmacogenetics in pediatrics. Implications for practice. Leeder JS, et al. **Pediatr Clin North Am** 1997 Feb; 44(1):55–77 (113 ref.)

Drug compliance in pediatrics. Clinical and research issues. Matsui DM. **Pediatr Clin North Am** 1997 Feb;44(1):1–14 (71 ref.)

The ethical boundaries of drug research in pediatrics. Rowell M, et al. **Pediatr Clin North Am** 1997 Feb;44(1):27–40 (47 ref.)

Sedation and analgesia for minor pediatric procedures. Algren JT, et al. **Pediatr Emerg Care** 1996 Dec;12(6):435–41 (6 ref.)

Pediatric oncology in Argentina: a historical overview. Diez B, et al. **Pediatr Hematol Oncol** 1997 Jul–Aug;14(4):299–305 (11 ref.)

Poisonous plants: when they are a threat to children. Lawrence RA. **Pediatr Rev** 1997 May;18(5):162–8 (7 ref.)

Pediatricians and gay and lesbian youth [see comments] Perrin EC. **Pediatr Rev** 1996 Sep;17(9):311–8 (24 ref.) Comment in: Pediatr Rev 1996 Sep;17(9):299.

Breastfeeding update. 2: Clinical lactation management. Powers NG, et al. **Pediatr Rev** 1997 May;18(5):147–61 (9 ref.)

Gifted and talented children: issues for pediatricians. Robinson NM, et al. **Pediatr Rev** 1996 Dec;17(12):427–34 (7 ref.)

Gene therapy in pediatric surgery. Brandt ML. **Semin Pediatr Surg** 1996 Aug;5(3):197–205 (78 ref.)

Molecular biology and the pediatric surgeon: definitions and basic methodology. Tagge EP, et al. **Semin Pediatr Surg** 1996 Aug;5(3):139–48 (20 ref.)

Specialized studies in pediatric dysphagia. Lefton-Greif MA, et al. **Semin Speech Lang** 1996 Nov;17(4):311–29; quiz 330 (68 ref.)

[Progresses in pediatrics in China, 1996] Hu Y. **Chung Hua I Hsueh Tsa Chih** 1996 Dec;76(12):920–2 (0 ref.) **(Chi)**

[Locoregional anesthesia in children: benefit/risk ratio] Ecoffey C. **Chirurgie** 1997;122(1):39–42 (23 ref.) (Eng. Abstr.) **(Fre)**

[The introduction to molecular biology and its application go pediatrics (4): study of mutations in DNA amplified by PCR] Castaño L, et al. **An Esp Pediatr** 1997 Mar; 46(3):305–10 (7 ref.) **(Spa)**

[Evaluation of statistical procedures in the original articles of "Anales Espanõles de Pediatría": comparison of two different periods (1989–90 and 1994–95)] González de Dios J, et al. **An Esp Pediatr** 1996 Oct;45(4):351–60 (35 ref.) **(Spa)**

EDUCATION

Medical education--addressing the needs of the dying child. Charlton R. **Palliat Med** 1996 Jul;10(3):240–6 (79 ref.)

Obtaining a faculty position in academic emergency medicine. Simon HK, et al. **Pediatr Emerg Care** 1997 Apr; 13(2):130–3 (9 ref.)

LEGISLATION & JURISPRUDENCE

Legal issues in pediatric gynecology. May JW. **Clin Obstet Gynecol** 1997 Mar;40(1):241–53 (19 ref.)

Liability for pediatric care. Classé JG. **Optom Clin** 1996; 5(2):161–85 (66 ref.)

MANPOWER

The pediatrician's role in caring for the developmentally disabled child. Liptak GS. **Pediatr Rev** 1996 Jun; 17(6):203–10; quiz 211 (16 ref.)

METHODS

Dialysis support in the pediatric intensive care unit. Parekh RS, et al. **Adv Ren Replace Ther** 1996 Oct;3(4):326–36 (46 ref.)

The role of nuclear medicine in children. MacKenzie JR. **Br J Hosp Med** 1997 Mar 19–Apr 1;57(6):248–54 (20 ref.)

Recognition and management of the ill child. Lavelle JM, et al. **Compr Ther** 1995 Dec;21(12):711–18 (7 ref.)

Acute respiratory distress syndrome in children. Beaufils F, et al. **Curr Opin Pediatr** 1997 Jun;9(3):207–12 (47 ref.)

Pain management in the pediatric intensive care unit. Chambliss CR, et al. **Curr Opin Pediatr** 1997 Jun; 9(3):246–53 (54 ref.)

Management of the suicidal child or adolescent in the emergency department. Press BR, et al. **Curr Opin Pediatr** 1997 Jun;9(3):237–41 (24 ref.)

Pulmonary fungal infections in immunocompromised children. Shenep JL, et al. **Curr Opin Pediatr** 1997 Jun; 9(3):213–8 (34 ref.)

The role of the pediatrician in smoking prevention. Sockrider MM. **Curr Opin Pediatr** 1997 Jun;9(3):225–9 (39 ref.)

Sedation and anesthesia for pediatric bronchoscopy. Tobias JD. **Curr Opin Pediatr** 1997 Jun;9(3):198–206 (23 ref.)

Pediatric peritonsillar abscess: management guidelines. Herzon FS, et al. **Curr Probl Pediatr** 1996 Sep;26(8):270–8 (45 ref.)

Pet Therapy Program. Proposal for the US Department of Health and Human Services. 1996 Secretary's Award. Teeter LM. **J Am Vet Med Assoc** 1997 May 15; 210(10):1435–8 (7 ref.)

Biofeedback with children and adolescents: clinical observations and patient perspectives. Culbert TP, et al. **J Dev Behav Pediatr** 1996 Oct;17(5):342–50 (148 ref.)

Quality of life assessment in children: a review of conceptual and methodological issues in multidimensional health status measures. Pal DK. **J Epidemiol Community Health** 1996 Aug;50(4):391–6 (35 ref.)

Chronic illness in adolescents: transfer or transition to adult services? Sawyer SM, et al. **J Paediatr Child Health** 1997 Apr;33(2):88–90 (22 ref.)

Preparation and intraoperative management of the pediatric patient. Hata T. **Pediatr Ann** 1997 Aug;26(8):471–81; quiz 501–3 (28 ref.)

Emergence and recovery from anesthesia for pediatrics patients in the post-anesthesia care unit. Lee B, et al. **Pediatr Ann** 1997 Aug;26(8):461–9 (19 ref.)

The preoperative evaluation of the pediatric patient. Rasmussen GE. **Pediatr Ann** 1997 Aug;26(8):455–60 (15 ref.)

The use of neuromuscular-blocking agents in children. Tobias JD. **Pediatr Ann** 1997 Aug;26(8):482–9 (14 ref.)

Postoperative pain management. Tobias JD. **Pediatr Ann** 1997 Aug;26(8):490–500 (23 ref.)

Toward an integrated program for patient care in pediatric infections. Schaad UB. **Pediatr Infect Dis J** 1997 Mar;16(3 Suppl):S34–8 (17 ref.)

Preschool development. Part 2: Psychosocial/behavioral development. Sturner RA, et al. **Pediatr Rev** 1997 Oct; 18(10):327–36 (13 ref.)

Paediatric life support. An advisory statement by the Paediatric Life Support Working Group of the International Liaison Committee on Resuscitation. Nadkarni V, et al. **Resuscitation** 1997 Apr;34(2):115–27 (69 ref.)

[Introduction to molecular biology and application to pediatrics (1): basic concepts] Castaño L, et al. **An Esp Pediatr** 1996 Sep;45(3):315–20 (5 ref.) **(Spa)**

ORGANIZATION & ADMINISTRATION

Children at risk: we shall overcome. Shelov SP. **Arch Pediatr Adolesc Med** 1997 Sep;151(9):931–6 (8 ref.)

The ED on line: computerization of the pediatric emergency department. Endom EE, et al. **Pediatr Emerg Care** 1996 Aug;12(4):301–4 (4 ref.)

[The pediatric physician and consultation in ophthalmology] Boles Carenini B, et al. **Minerva Pediatr** 1995 Dec; 47(12):493–504 (46 ref.) **(Ita)**

STANDARDS

Pediatric guidelines: help or hindrance? Homer CJ, et al. **Curr Opin Pediatr** 1996 Oct;8(5):430–5 (41 ref.)

Physical abuse of children: an update. Sirotnak AP, et al. **Del Med J** 1997 Jul;69(7):335–43 (20 ref.)

Microbiology testing and the pediatrician's office. Rogers WO, et al. **Pediatr Infect Dis J** 1997 Apr;16(4):339–45 (13 ref.)

TRENDS

Pediatric hepatology: present and future. Zancan L. **Acta Genet Med Gemellol (Roma)** 1996;45(3):377–82 (8 ref.)

Future prospects for evidence-based child health. Gilbert R, et al. **Arch Dis Child** 1996 Dec;75(6):465–8 (42 ref.)

Recent advances in paediatrics. II--Childhood and adolescence. Pearn J. **BMJ** 1997 Apr 12; 314(7087):1099–102 (51 ref.)

Ethical problems in prenatal diagnosis: pediatric considerations. Lenard G. **Brain Dev** 1995;17 Suppl:44–7 (14 ref.)

The genetics of retinoblastoma and current diagnostic testing. Smith BJ, et al. **J Pediatr Ophthalmol Strabismus** 1996 Mar-Apr;33(2):120–3 (20 ref.)

Pediatric hematology and oncology in Cameroon, Africa: past and future perspectives. Abena Obama MT. **Pediatr Hematol Oncol** 1996 Jul–Aug;13(4):315–7 (5 ref.)

Key developments of the year in paediatrics. Sajjanhar T. **Practitioner** 1997 Jun;241(1575):329–30 (3 ref.)

PEDICULOSIS

THERAPY

Head lice in schoolchildren. Ibarra J, et al. **Arch Dis Child** 1996 Dec;75(6):471–3 (29 ref.)

PEDICULUS

CLASSIFICATION

[The taxonomy of human head and body lice] Chirov PA, et al. **Med Parazitol (Mosk)** 1997 Apr–Jun;(2):38–40 (26 ref.) (Eng. Abstr.) **(Rus)**

PEDIOCOCCUS

CHEMISTRY

Purification of bacteriocins of lactic acid bacteria: problems and pointers. Carolissen-Mackay V, et al. **Int J Food Microbiol** 1997 Jan;34(1):1–16 (65 ref.)

PEDODONTICS see **PEDIATRIC DENTISTRY**

PEEP see **POSITIVE-PRESSURE RESPIRATION**

PEEP, INTRINSIC see **POSITIVE-PRESSURE RESPIRATION, INTRINSIC**

PEEP, OCCULT see **POSITIVE-PRESSURE RESPIRATION, INTRINSIC**

PEER GROUP

On the importance of peer influence for adolescent drug use: commonly neglected considerations. Bauman KE, et al. **Addiction** 1996 Feb;91(2):185–98 (116 ref.)

Full inclusion and students with autism. Mesibov GB, et al. **J Autism Dev Disord** 1996 Jun;26(3):337–46 (14 ref.)

The developmental course of violence and aggression. Mechanisms of family and peer influence. Pettit GS. **Psychiatr Clin North Am** 1997 Jun;20(2):283–99 (47 ref.)

PEER REVIEW, GRANTS see **PEER REVIEW, RESEARCH**

PEER REVIEW, HEALTH CARE

METHODS

Guidelines for internal peer review in the cardiac catheterization laboratory. Laboratory Performance Standards Committee, Society for Cardiac Angiography and Interventions. Heupler FA Jr, et al. **Cathet Cardiovasc Diagn** 1997 Jan;40(1):21–32 (74 ref.)

PEER REVIEW ORGANIZATIONS see **PROFESSIONAL REVIEW ORGANIZATIONS**

PEER REVIEW, PUBLISHING see **PEER REVIEW, RESEARCH**

PEER REVIEW, RESEARCH

Value of peer review of pathology in soft tissue sarcomas. Harris M, et al. **Cancer Treat Res** 1997;91:1–8 (13 ref.)

How to "peer review" a medical journal manuscript [editorial] Salasche SJ. **Dermatol Surg** 1997 Jun;23(6):423–8 (17 ref.)

Peer review, authorship, ethics, and conflict of interest. King CR, et al. **Image J Nurs Sch** 1997;29(2):163–7 (47 ref.)

Reference values for serum selenium in various areas-evaluated according to the TRACY protocol. Alfthan G, et al. **J Trace Elem Med Biol** 1996 Jun; 10(2):77–87 (81 ref.)

METHODS

Selection and use of content experts for instrument development. Grant JS, et al. **Res Nurs Health** 1997 Jun; 20(3):269–74 (25 ref.)

PELIOSIS HEPATIS

DIAGNOSIS

[Illnesses caused by Bartonella. Cat-scratch disease, bacillary angiomatosis, bacillary peliosis hepatis, endocarditis] Nadal D, et al. **Internist (Berl)** 1996 Sep;37(9):890–4 (35 ref.) **(Ger)**

PELIZAEUS-MERZBACHER DISEASE see **CEREBRAL SCLEROSIS, DIFFUSE**

PELLETS, DRUG see **DRUG IMPLANTS**

PELVIC BONES

Malignant transformation of a multiple cartilaginous exostosis--a case report. Willms R, et al. **Int Orthop** 1997; 21(2):133–6 (26 ref.)

Imaging of pelvic trauma: the role of CT with multiplanar and three-dimensional reconstruction. Noh HM, et al. **J South Orthop Assoc** 1996 Summer;5(2):111–25 (38 ref.)

ABNORMALITIES

The pelvic digit: five new examples of an unusual anomaly. Granieri GF, et al. **Skeletal Radiol** 1996 Nov;25(8):723–6 (8 ref.)

INJURIES

Blunt abdominal trauma and severe pelvic rupture. What to do? Hötker U, et al. **Acta Chir Belg** 1997 Apr;97(2):65–8 (16 ref.)

Indications and techniques of external fixation of the injured pelvis. Bircher MD. **Injury** 1996;27 Suppl 2:B3–19 (12 ref.)

Late reconstruction after pelvic ring injuries. Gautier E, et al. **Injury** 1996;27 Suppl 2:B39–46 (24 ref.)

Internal fixation of pelvic ring disruptions. Routt ML Jr, et al. **Injury** 1996;27 Suppl 2:B20–30 (32 ref.)

Disruption of the pelvic ring during spontaneous childbirth. A case report. Pennig D, et al. **J Bone Joint Surg Br** 1997 May;79(3):438–40 (8 ref.)

Pelvic and bladder trauma: a case report and subject review. Wright DG, et al. **J Orthop Trauma** 1996;10(5):351–4 (28 ref.)

Pelvic fracture urethral injuries: evaluation of various methods of management [see comments] Koraitim MM. **J Urol** 1996 Oct;156(4):1288–91 (27 ref.) Comment in: J Urol 1997 Aug;158(2):550.

Evaluation of pelvic fractures. Clinical and radiologic. MacLeod M, et al. **Orthop Clin North Am** 1997 Jul; 28(3):299–319 (15 ref.)

Practical management of venous thromboembolism following pelvic fractures. Montgomery KD, et al. **Orthop Clin North Am** 1997 Jul;28(3):397–404 (56 ref.)

Stabilization of pelvic ring disruptions. Routt ML Jr, et al. **Orthop Clin North Am** 1997 Jul;28(3):369–88 (43 ref.)

Biomechanics of pelvic fixation. Simonian PT, et al. **Orthop Clin North Am** 1997 Jul;28(3):351–67 (100 ref.)

Management of pelvic fractures with concomitant urologic injuries. Taffet R. **Orthop Clin North Am** 1997 Jul; 28(3):389–96 (47 ref.)

Assessment and management of pelvic fracture in the hemodynamically unstable patient. Wolinsky PR. **Orthop Clin North Am** 1997 Jul;28(3):321–9 (58 ref.)

External fixation for pelvic ring disruptions. Yang AP, et al. **Orthop Clin North Am** 1997 Jul;28(3):331–44 (11 ref.)

Pelvic and acetabular trauma. Hunter JC, et al. **Radiol Clin North Am** 1997 May;35(3):559–90 (55 ref.)

[Perineal injuries in complicated pelvic trauma] David A, et al. **Swiss Surg** 1996;(1):4–9 (35 ref.) (Eng. Abstr.) **(Ger)**

[Injuries of the pelvic ring] Culemann U, et al. **Unfallchirurg** 1997 Jun;100(6):487–96 (14 ref.) **(Ger)**

PATHOLOGY

Treatment of metastatic adenocarcinoma of the pelvis and the extremities. Aaron AD. **J Bone Joint Surg Am** 1997 Jun;79(6):917–32 (130 ref.)

RADIONUCLIDE IMAGING

Scrotal pathology as the cause for hip pain. Diagnostic findings on bone scintigraphy. Sheafor DH, et al. **Clin Nucl Med** 1997 May;22(5):287–91 (25 ref.)

PELVIC EXENTERATION

Pelvic exenteration for locally advanced rectal carcinoma: factors predicting improved survival Meterissian SH, et al. **Surgery** 1997 May;121(5):479–87 (31 ref.)

METHODS

Exenterative surgery. Vergote IB. **Curr Opin Obstet Gynecol** 1997 Feb;9(1):25–8 (34 ref.)

PELVIC FLOOR

Continence for women: evidence-based practice. Sampselle CM, et al. **J Obstet Gynecol Neonatal Nurs** 1997 Jul–Aug; 26(4):375–85 (29 ref.)

The pelvic floor muscles: muscle thickness in healthy and urinary-incontinent women measured by perineal ultrasonography with reference to the effect of pelvic floor training. Estrogen receptor studies. Bernstein IT. **Neurourol Urodyn** 1997;16(4):237–75 (145 ref.)

INJURIES

Occult obstetric trauma and anal incontinence. Sultan AH, et al. **Eur J Gastroenterol Hepatol** 1997 May;9(5):423–7 (32 ref.)

[Pelvic floor reconstruction after traumatic childbirth damage] Franz HB, et al. **Zentralbl Chir** 1996;121(8):688–91 (20 ref.) (Eng. Abstr.) **(Ger)**

INNERVATION

Morphology and neuropathology of the pelvic floor in patients with stress incontinence. Morley R, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1996;7(1):3–12 (63 ref.)

SURGERY

Fascia--defects and repair. Monga A. **Curr Opin Obstet Gynecol** 1996 Oct;8(5):366–71 (38 ref.)

Laparoscopic colposuspension and pelvic floor repair. Vancaillie TG. **Curr Opin Obstet Gynecol** 1997 Aug; 9(4):244–6 (19 ref.)

PELVIC HORN SYNDROME see **NAIL-PATELLA SYNDROME**

PELVIC INFECTION see **ADNEXITIS**

PELVIC INFLAMMATORY DISEASE see **ADNEXITIS**

PELVIC NEOPLASMS

COMPLICATIONS

Pelvic lipoma causing venous obstruction syndrome. Acheson A, et al. **Eur J Vasc Endovasc Surg** 1997 Aug; 14(2):149–50 (6 ref.)

DIAGNOSIS

[A voluminous prevesical hemangiopericytoma. A clinical case report] Donnola G, et al. **Minerva Chir** 1997 May; 52(5):673–8 (31 ref.) (Eng. Abstr.) **(Ita)**

[Idiopathic retroperitoneal fibrosis simulating pelvic tumor with distal ureter infiltration. Report of a case] Luján Galán M, et al. **Arch Esp Urol** 1997 Apr;50(3):299–302 (10 ref.) (Eng. Abstr.) **(Spa)**

RADIOTHERAPY

The role of radiotherapy in the management of pelvic recurrence of rectal cancer. Wong R, et al. **Can J Oncol** 1996 Feb;6 Suppl 1:39–47 (18 ref.)

SECONDARY

The role of radiotherapy in the management of pelvic recurrence of rectal cancer. Wong R, et al. **Can J Oncol** 1996 Feb;6 Suppl 1:39–47 (18 ref.)

SURGERY

The assessment and surgical management of recurrent pelvic cancer of the female genitalia. Monaghan JM. **Br J Urol** 1997 Jul;80 Suppl 1:62–5 (10 ref.)

Pelvic surgery after radiotherapy. Mundy AR. **Br J Urol** 1997 Jul;80 Suppl 1:66–8 (0 ref.)

Laparoscopic resection of a pelvic schwannoma. Melvin WS. **Surg Laparosc Endosc** 1996 Dec;6(6):489–91 (12 ref.)

[Plastic surgery defect coverage in the area of the pelvis and trunk] Germann G, et al. **Chirurg** 1997 May; 68(5):469–76 (26 ref.) (Eng. Abstr.) **(Ger)**

PELVIC PAIN

Chronic pelvic pain [see comments] Ryder RM. **Am Fam Physician** 1996 Nov 15;54(7):2225–32, 2237 (12 ref.) Comment in: Am Fam Physician 1996 Nov 15;54(7):2187–8, 2193.

Sociopsychological factors in chronic pelvic pain: a review. Fry RP, et al. **J Psychosom Res** 1997 Jan;42(1):1–15 (53 ref.)

Chronic postpartum pelvic pain treated by surgical stabilization. Shuler TE, et al. **Orthopedics** 1996 Aug; 19(8):687–9 (16 ref.)

DIAGNOSIS

Chronic gynecologic pain. Stewart DE. **Gen Hosp Psychiatry** 1996 Jul;18(4):230–7 (30 ref.)

DRUG THERAPY

[Analgesics in the treatment of chronic pelvic pain] Erny R, et al. **Contracept Fertil Sex** 1996 Oct;24(10):732–8 (2 ref.) **(Fre)**

ETIOLOGY

Chronic pelvic pain in women--gastroenterological, gynaecological or psychological? Kamm MA. **Int J Colorectal Dis** 1997;12(2):57–62 (59 ref.)

Adhesion controversies: pelvic pain as a cause of adhesions, crystalloids in preventing them. Duffy DM, et al. **J Reprod Med** 1996 Jan;41(1):19–26 (66 ref.)

Chronic pelvic pains represent the most prominent urogenital symptoms of "chronic prostatitis". Krieger JN, et al. **Urology** 1996 Nov;48(5):715–21; discussion 721–2 (39 ref.)

[Cavernous hemangioma of the rectum: an uncommon cause of pelvic pain. Apropos of 2 cases] Lautard M, et al. **Chirurgie** 1997;122(2):149–52 (18 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Psychological aspects of chronic pelvic pain. Savidge CJ, et al. **J Psychosom Res** 1997 May;42(5):433–44 (56 ref.)

[Chronic pelvic pain: searching for the "psychological factor".] Dellenbach P, et al. **Contracept Fertil Sex** 1996 Nov;24(11):791–9 (59 ref.) **(Fre)**

SURGERY

Advanced laparoscopic procedures for pelvic pain and dysmenorrhoea. Daniell JF, et al. **Baillieres Clin Obstet Gynaecol** 1995 Dec;9(4):795–808 (42 ref.)

Surgical interruption of a midline dorsal column visceral pain pathway. Case report and review of the literature. Nauta HJ, et al. **J Neurosurg** 1997 Mar;86(3):538–42 (20 ref.)

On the dorsal columns: translating basic research hypotheses to the clinic [editorial] Berkley KJ. **Pain** 1997 Apr; 70(2–3):103–7 (35 ref.)

THERAPY

Chronic gynecologic pain. Stewart DE. **Gen Hosp Psychiatry** 1996 Jul;18(4):230–7 (30 ref.)

Evaluation and management of chronic pelvic pain. Duleba AJ, et al. **J Am Assoc Gynecol Laparosc** 1996 Feb; 3(2):205–27 (153 ref.)

PELVIC PLEXUS see **HYPOGASTRIC PLEXUS**

PELVIS

see related
ADNEXITIS
PELVIC EXENTERATION

Inflammatory pseudotumor presenting as fever of unknown origin. Fisher RG, et al. **Clin Infect Dis** 1995 Dec; 21(6):1492–4 (18 ref.)

Internal iliac artery embolization in the management of pelvic bleeding [editorial; comment] Wells I. **Clin Radiol** 1996 Dec;51(12):825–7 (22 ref.) Comment on: Clin Radiol 1996 Dec;51(12):865–8.

Pelvic mass in 46-year old man. Flórez J, et al. **Postgrad Med J** 1997 Jun;73(860):371–3 (12 ref.)

[Idiopathic retroperitoneal fibrosis localizing in pelvic cavity: a case report] Touge H, et al. **Hinyokika Kiyo** 1996 Aug; 42(8):577–81 (13 ref.) (Eng. Abstr.) **(Jpn)**

ABNORMALITIES

Unilateral pulmonary hypoplasia with bifid ureter and pelvis. Prasad R, et al. **Indian J Chest Dis Allied Sci** 1996 Jul–Sep; 38(3):205–9 (9 ref.)

ANATOMY & HISTOLOGY

The anatomical substrate for a difference in surgical approach to rectal cancer in male and female patients. Verschueren RC, et al. **Anticancer Res** 1997 Jan–Feb;17(1B):637–41 (18 ref.)

Laparoscopic anatomy and dissection of the pelvis. Kadar N. **Baillieres Clin Obstet Gynaecol** 1997 Mar;11(1):37–60 (8 ref.)

Surgical anatomy and dissection techniques for laparoscopic surgery. Kadar N. **Curr Opin Obstet Gynecol** 1996 Aug; 8(4):266–77 (9 ref.)

BLOOD SUPPLY

Spiral CT angiography of the abdomen and pelvis: interventional applications. Brink JA. **Abdom Imaging** 1997 Jul–Aug;22(4):365–72 (26 ref.)

[MR angiography of the pelvic-leg blood vessels: current status and perspectives] Vosshenrich R, et al. **Aktuelle Radiol** 1997 Jan;7(1):14–8 (24 ref.) (Eng. Abstr.) **(Ger)**

[Early stent-induced thrombosis in the pelvic circulation: a complication in APC resistance] Lenglinger FX, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Mar;166(3):260–2 (11 ref.) **(Ger)**

[Pelvic arteriovenous malformation] Toma M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):466–8 (11 ref.) **(Jpn)**

INJURIES

Traumatic spondylopelvic dissociation. A case report and literature review [see comments] Bents RT, et al. **Spine** 1996 Aug 1;21(15):1814–9 (25 ref.) Comment in: Spine 1997 Jun 1;22(11):1276.

Damage control for devastating pelvic and extremity injuries. Henry SM, et al. **Surg Clin North Am** 1997 Aug; 77(4):879–95 (47 ref.)

PELVIS

PATHOLOGY

Optimization of sequences for MRI of the abdomen and pelvis. Lomas DJ. **Clin Radiol** 1997 Jun;52(6):412–28 (78 ref.)

MR imaging of the pediatric pelvis. Boechat MI. **Magn Reson Imaging Clin N Am** 1996 Nov;4(4):679–96 (72 ref.)

MR imaging of the female pelvis. Lipson SA, et al. **Radiol Clin North Am** 1996 Nov;34(6):1157–82 (67 ref.)

RADIATION EFFECTS

[Plastic surgery defect coverage in the area of the pelvis and trunk] Germann G, et al. **Chirurg** 1997 May; 68(5):469–76 (26 ref.) (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

False-positive radioiodine uptake in the abdomen and the pelvis: radioiodine retention in the kidneys and review of the literature. Bakheet SM, et al. **Clin Nucl Med** 1996 Dec; 21(12):932–7 (25 ref.)

SURGERY

Laparoscopic anatomy and dissection of the pelvis. Kadar N. **Baillieres Clin Obstet Gynaecol** 1997 Mar;11(1):37–60 (8 ref.)

Female adult reconstructive urology. N'Dow J, et al. **Br J Urol** 1997 Jul;80 Suppl 1:69–78 (84 ref.)

ULTRASONOGRAPHY

The contribution of pelvic ultrasonography to the diagnostic process in pediatric and adolescent gynecology. Arbel-DeRowe Y, et al. **J Pediatr Adolesc Gynecol** 1997 Feb;10(1):3–12 (50 ref.)

PEMOLINE

ADVERSE EFFECTS

Pemoline-associated hepatic failure: a critical analysis of the literature. Shevell M, et al. **Pediatr Neurol** 1997 Jan; 16(1):14–6 (22 ref.)

POISONING

Pemoline induced acute choreoathetosis: case report and review of the literature. Stork CM, et al. **J Toxicol Clin Toxicol** 1997;35(1):105–8 (22 ref.)

PEMPHIGOID, BENIGN MUCOUS MEMBRANE

DIAGNOSIS

[Pemphigoid of the mucous membranes. The clinical, histopathological and immunological aspects and current therapeutic concepts] Carrozzo M, et al. **Minerva Stomatol** 1996 Oct;45(10):455–63 (73 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Ocular cicatricial pemphigoid and ocular manifestations of pemphigus vulgaris. Smith RJ, et al. **Int Ophthalmol Clin** 1997 Spring;37(2):63–75 (35 ref.)

PEMPHIGOID, BULLOUS

CHEMICALLY INDUCED

Bullous pemphigoid after treatment with furosemide. Koch CA, et al. **Cutis** 1996 Nov;58(5):340–4 (21 ref.)

COMPLICATIONS

Dermatitis herpetiformis and bullous pemphigoid: a developing association confirmed by immunoelectronmicroscopy. Setterfield J, et al. **Br J Dermatol** 1997 Feb;136(2):253–6 (21 ref.)

Bullous pemphigoid and multiple sclerosis: a report of three cases and review of the literature. Kirtschig G, et al. **Clin Exp Dermatol** 1995 Nov;20(6):449–53 (41 ref.)

DIAGNOSIS

Bullous scabies [letter] Veraldi S, et al. **Acta Derm Venereol** 1996 Mar;76(2):167–8 (11 ref.)

Localized bullous pemphigoid of the vulva. Urano S. **J Dermatol** 1996 Aug;23(8):580–2 (11 ref.)

[Pemphigus and pemphigoid. A review and case reports] von Arx T, et al. **Schweiz Monatsschr Zahnmed** 1996; 106(9):796–811 (39 ref.) **(Ger, Fre)**

ETIOLOGY

Localised bullous pemphigoid following radiotherapy [letter] Cliff S, et al. **Acta Derm Venereol** 1996 Jul;76(4):330–1 (15 ref.)

IMMUNOLOGY

Pemphigoid nodularis: a report of three cases and review of the literature. Cliff S, et al. **Br J Dermatol** 1997 Mar; 136(3):398–401 (14 ref.)

The desmosome and hemidesmosome in cutaneous autoimmunity. Lin MS, et al. **Clin Exp Immunol** 1997 Jan; 107 Suppl 1:9–15 (55 ref.)

PEMPHIGOID, CICATRICIAL see **PEMPHIGOID, BENIGN MUCOUS MEMBRANE**

PEMPHIGUS

COMPLICATIONS

Ocular cicatricial pemphigoid and ocular manifestations of pemphigus vulgaris. Smith RJ, et al. **Int Ophthalmol Clin** 1997 Spring;37(2):63–75 (35 ref.)

A case of pemphigus vulgaris with esophageal involvement. Amichai B, et al. **J Dermatol** 1996 Mar;23(3):214–5 (8 ref.)

DIAGNOSIS

A case of localized pemphigus foliaceus. Yamamoto S, et al. **J Dermatol** 1996 Dec;23(12):893–5 (12 ref.)

[Pemphigus and pemphigoid. A review and case reports] von Arx T, et al. **Schweiz Monatsschr Zahnmed** 1996; 106(9):796–811 (39 ref.) **(Ger, Fre)**

ETIOLOGY

[Brazilian pemphigus foliaceus (fogo selvagem)] Kunte C, et al. **Hautarzt** 1997 Apr;48(4):228–33 (44 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

The desmosome and hemidesmosome in cutaneous autoimmunity. Lin MS, et al. **Clin Exp Immunol** 1997 Jan; 107 Suppl 1:9–15 (55 ref.)

Pemphigus: from immunofluorescence to molecular biology. Nishikawa T, et al. **J Dermatol Sci** 1996 Apr;12(1):1–9 (39 ref.)

Frontiers in keratodermas: pushing the envelope. Christiano AM. **Trends Genet** 1997 Jun;13(6):227–33 (45 ref.)

PATHOLOGY

Paraneoplastic pemphigus. Anhalt GJ. **Adv Dermatol** 1997; 12:77–96; discussion 97 (49 ref.)

Transition from pemphigus vulgaris to pemphigus foliaceus [letter] Chang SN, et al. **Br J Dermatol** 1997 Aug; 137(2):303–5 (9 ref.)

VIROLOGY

Viruses in pemphigus: a casual or causal relationship? Ruocco V, et al. **Int J Dermatol** 1996 Nov;35(11):782–4 (51 ref.)

PEMPHIGUS, BENIGN FAMILIAL

COMPLICATIONS

Hailey-Hailey disease with acrokeratosis verruciformis Hopf [letter] Yakis G, et al. **Acta Derm Venereol** 1996 Mar; 76(2):157 (4 ref.)

GENETICS

Pemphigus vulgaris in two MHC-haploidentical brothers [letter] Revenga-Arranz F, et al. **Dermatology** 1996; 193(1):71–2 (10 ref.)

PEMPHIGUS VULGARIS see **PEMPHIGUS**

PENICILLAMINE

ADVERSE EFFECTS

Bronchiolitis obliterans in a patient with localized scleroderma treated with D-penicillamine. Boehler A, et al. **Eur Respir J** 1996 Jun;9(6):1317–9 (28 ref.)

Penicillamine-induced bullous dermatoses. Bialy-Golan A, et al. **J Am Acad Dermatol** 1996 Nov;35(5 Pt 1):732–42 (113 ref.)

Penicillamine-induced degenerative dermatoses: report of a case and brief review of such dermatoses. Iozumi K, et al. **J Dermatol** 1997 Jul;24(7):458–65 (37 ref.)

[D-penicillamine nephropathy] Ohno I. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):523–5 (17 ref.) **(Jpn)**

THERAPEUTIC USE

Penicillamine. Munro R, et al. **Br J Rheumatol** 1997 Jan; 36(1):104–9 (54 ref.)

PENICILLANIC ACID

ANALOGS & DERIVATIVES

Piperacillin/tazobactam: a critical review of the evolving clinical literature. Sanders WE Jr, et al. **Clin Infect Dis** 1996 Jan;22(1):107–23 (67 ref.)

[Development of beta-lactamase inhibitors] Hyodo A, et al. **Nippon Rinsho** 1997 May;55(5):1272–80 (20 ref.) (Eng. Abstr.) **(Jpn)**

PENICILLIN G, BENZATHINE

THERAPEUTIC USE

[Syphilis in HIV infected individuals] Frisoli Junior A, et al. **Rev Assoc Med Bras** 1996 Jan-Mar;42(1):46–50 (45 ref.) **(Por)**

PENICILLIN G, PROCAINE

ADVERSE EFFECTS

Hoigne's syndrome, kindling, and panic disorder. Araszkiewicz A, et al. **Depress Anxiety** 1996–97;4(3):139–43 (45 ref.)

PENICILLIN, PHENOXYMETHYL see **PENICILLIN V**

PENICILLIN RESISTANCE

The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: current antibiotic therapy in the 1990s. Bradley JS, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S213–21 (58 ref.)

Penicillin-resistant pneumococci in adult disease with special reference to AIDS patients. Bouza E, et al. **Microb Drug Resist** 1995 Spring;1(1):9–28 (241 ref.)

Epidemiology of pneumococcal serotypes and conjugate vaccine formulations. Butler JC. **Microb Drug Resist** 1997 Summer;3(2):125–9 (44 ref.)

Epidemiology of penicillin resistant pneumococci in Iceland. Kristinsson KG. **Microb Drug Resist** 1995 Summer; 1(2):121–5 (21 ref.)

Antibiotic resistant Streptococcus pneumoniae. Minton EJ, et al. **Thorax** 1996 Aug;51 Suppl 2:S45–50 (57 ref.)

GENETICS

Genetics and molecular biology of beta-lactam-resistant pneumococci. Coffey TJ, et al. **Microb Drug Resist** 1995 Spring;1(1):29–34 (39 ref.)

Intrinsic penicillin resistance in enterococci. Fontana R, et al. **Microb Drug Resist** 1996 Summer;2(2):209–13 (30 ref.)

[Penicillin-resistant mechanisms of Streptococcus pneumoniae] Ubukata K, et al. **Nippon Rinsho** 1997 May; 55(5):1213–8 (6 ref.) **(Jpn)**

PENICILLIN V

THERAPEUTIC USE

Streptococcal pharyngitis: is penicillin still the right choice? Pichichero ME. **Compr Ther** 1996 Dec;22(12):782–7 (37 ref.)

PENICILLINS

Bacterial DD-transpeptidases and penicillin. Jamin M, et al. **Essays Biochem** 1995;29:1–24 (37 ref.)

ADVERSE EFFECTS

Penicillin allergy. **Drug Ther Bull** 1996 Nov;34(11):87–8 (17 ref.)

[Cholestatic hepatitis caused by amoxycillin-clavulanic acid. Report of a new case] Bustamante Balén M, et al. **Gastroenterol Hepatol** 1997 Apr;20(4):187–9 (14 ref.) (Eng. Abstr.) **(Spa)**

CHEMISTRY

Penicillin and beyond: evolution, protein fold, multimodular polypeptides, and multiprotein complexes. Ghuysen JM, et al. **Microb Drug Resist** 1996 Summer;2(2):163–75 (42 ref.)

PHARMACOLOGY

The emerging role of multi-drug-resistant Streptococcus pneumoniae--a cause for concern [editorial] Koay B, et al. **Clin Otolaryngol** 1996 Aug;21(4):289–91 (36 ref.)

Effect of antimicrobial use and other risk factors on antimicrobial resistance in pneumococci. Kristinsson KG. **Microb Drug Resist** 1997 Summer;3(2):117–23 (70 ref.)

THERAPEUTIC USE

Piperacillin/tazobactam: a critical review of the evolving clinical literature. Sanders WE Jr, et al. **Clin Infect Dis** 1996 Jan;22(1):107–23 (67 ref.)

Streptococcal pharyngitis: is penicillin still the right choice? Pichichero ME. **Compr Ther** 1996 Dec;22(12):782–7 (37 ref.)

The antibiotic treatment of acute otitis media and sinusitis in children. Cohen R. **Diagn Microbiol Infect Dis** 1997 Jan-Feb;27(1-2):35–9 (19 ref.)

Meningitis in older patients: how to diagnose and treat a deadly infection. Miller LG, et al. **Geriatrics** 1997 Aug; 52(8):43–4, 47–50, 55 (21 ref.)

Penicillin-resistant pneumococci in adult disease with special reference to AIDS patients. Bouza E, et al. **Microb Drug Resist** 1995 Spring;1(1):9–28 (241 ref.)

Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media. Block SL. **Pediatr Infect Dis J** 1997 Apr;16(4):449–56 (39 ref.)

PENICILLIUM

ISOLATION & PURIFICATION

Penicillium marneffei infection in a non-HIV infected child. Kwan EY, et al. **J Paediatr Child Health** 1997 Jun; 33(3):267-71 (34 ref.)

PATHOGENICITY

Pathology of Penicillium marneffei. An emerging acquired immunodeficiency syndrome-related pathogen. Cooper CR Jr, et al. **Arch Pathol Lab Med** 1997 Aug;121(8):798-804 (44 ref.)

Infection due to Penicillium marneffei, an emerging pathogen: review of 155 reported cases [see comments] Duong TA. **Clin Infect Dis** 1996 Jul;23(1):125-30 (42 ref.) Comment in: Clin Infect Dis 1997 May;24(5):1026.

PENILE DISEASES

HPV infection and disease in men. Palefsky JM, et al. **Obstet Gynecol Clin North Am** 1996 Dec;23(4):895-916 (43 ref.)

COMPLICATIONS

Granulomatous lymphangitis of the penile skin as a cause of penile swelling in children. Mor Y, et al. **J Urol** 1997 Aug;158(2):591-2 (12 ref.)

DIAGNOSIS

Latent and subclinical HPV external anogenital infection. Barrasso R. **Clin Dermatol** 1997 May-Jun;15(3):349-53 (22 ref.)

Dermatoses of the glans penis and prepuce. English JC 3rd, et al. **J Am Acad Dermatol** 1997 Jul;37(1):1-24; quiz 25-6 (352 ref.)

MR imaging of scrotal, testicular, and penile diseases. Sica GT, et al. **Magn Reson Imaging Clin N Am** 1996 Aug; 4(3):545-63 (27 ref.)

ETIOLOGY

Late glans hypervascularization subsequent to penile prosthesis implantation after revascularization operation. Kayigil O, et al. **J Urol** 1997 Aug;158(2):541 (4 ref.)

PATHOLOGY

Pearly penile papules [comment] Oates JK. **Genitourin Med** 1997 Apr;73(2):137-8 (13 ref.) Comment on: Genitourin Med 1997 Apr;73(2):136.

SURGERY

[Topical anesthesia with the EMLA cream: application in pediatric urology] Xavier B, et al. **Actas Urol Esp** 1996 Nov-Dec;20(10):883-5 (15 ref.) (Eng. Abstr.) **(Spa)**

PENILE ERECTION

Has the efficacy of penile arterial by-pass surgery in the treatment of arteriogenic erectile dysfunction been determined? Vickers KE, et al. **Int J Impot Res** 1996 Dec; 8(4):247-51; discussion 251-3 (24 ref.)

[Sexuality--an important factor for quality of life. Who should treat erectile dysfunction?] Hedelin H, et al. **Lakartidningen** 1997 Jul 9;94(28-29):2548-52 (5 ref.) **(Swe)**

DRUG EFFECTS

Drugs for the treatment of impotence. Garcia-Reboll L, et al. **Drugs Aging** 1997 Aug;11(2):140-51 (98 ref.)

The influence of medication on erectile function. Meinhardt W, et al. **Int J Impot Res** 1997 Mar;9(1):17-26 (105 ref.)

[Drug treatment of sexual disorders in men (see comments)] Slob AK, et al. **Ned Tijdschr Geneeskd** 1996 Oct 12; 140(41):2029-32 (33 ref.) Comment in: Ned Tijdschr Geneeskd 1996 Dec 14;140(50):2528. **(Dut)**

[Pharmacological therapy in erectile dysfunction--current standards and new viewpoint] Schultheiss D, et al. **Wien Med Wochenschr** 1997;147(4-5):102-4 (33 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Organic erectile dysfunction. Lewis RW. **Curr Ther Endocrinol Metab** 1997;6:366-70 (9 ref.)

Vascular control mechanisms in penile erection: phylogeny and the inevitability of multiple and overlapping systems. Adams MA, et al. **Int J Impot Res** 1997 Jun;9(2):85-91 (30 ref.)

Integrative erectile biology: the role of signal transduction and cell-to-cell communication in coordinating corporal smooth muscle tone and penile erection. Christ GJ, et al. **Int J Impot Res** 1997 Jun;9(2):69-84 (65 ref.)

Androgens and penile erection: a review. Mills TM, et al. **J Androl** 1996 Nov-Dec;17(6):633-8 (45 ref.)

Evaluation of erectile dysfunction and sleep-related erections [see comments] Moore CA, et al. **J Psychosom Res** 1997 Jun;42(6):531-9 (32 ref.) Comment in: J Psychosom Res 1997 Jun;42(6):515-6.

Cardiovascular disease and sleep-related erections [see comments] Rosen RC, et al. **J Psychosom Res** 1997 Jun; 42(6):517-30 (25 ref.) Comment in: J Psychosom Res 1997 Jun;42(6):515-6.

Sleep-related erectile activity. Hirshkowitz M, et al. **Neurol Clin** 1996 Nov;14(4):721-37 (90 ref.)

Neurotransmission and the contraction and relaxation of penile erectile tissues. Andersson KE, et al. **World J Urol** 1997;15(1):14-20 (72 ref.)

The "syncytial tissue triad": a model for understanding how gap junctions participate in the local control of penile erection. Christ GJ. **World J Urol** 1997;15(1):36-44 (49 ref.)

Spinal control of penile erection. Rampin O, et al. **World J Urol** 1997;15(1):2-13 (181 ref.)

The effects of testosterone on the cavernous tissue and erectile function. Shabsigh R. **World J Urol** 1997;15(1):21-6 (62 ref.)

[The physiology of erection] Hora M, et al. **Cas Lek Cesk** 1997 Jun 12;136(12):363-6 (15 ref.) (Eng. Abstr.) **(Cze)**

[The peripheral pharmacology of erection] Guiliano F, et al. **Prog Urol** 1997 Feb;7(1):24-33 (105 ref.) (Eng. Abstr.) **(Fre)**

[Central nervous system control of erection] Rampin O, et al. **Prog Urol** 1997 Feb;7(1):17-23 (65 ref.) (Eng. Abstr.) **(Fre)**

[Nocturnal penile tumescence] Takanami M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:393-6 (6 ref.) **(Jpn)**

PENILE INDURATION

[La Peyronie disease. Historical, epidemiological, physiopathological data. Diagnostic and therapeutic approaches] Chevallier D, et al. **Rev Med Interne** 1997;18 Suppl 1:41s-45s (30 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

[Radical surgical treatment of Peironie disease by excision of the plaque and dermal graft allowing conservation of erection] Austoni E, et al. **Ann Urol (Paris)** 1996; 30(4):204-12 (19 ref.) (Eng. Abstr.) **(Fre)**

[Surgical treatment of La Peyronie's disease] Grisoni V, et al. **Prog Urol** 1996 Dec;6(6):963-73 (46 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

[Is there a renaissance of conservative therapy in plastic penile induration?] Schubert J, et al. **Wien Med Wochenschr** 1997;147(4-5):99-101 (24 ref.) (Eng. Abstr.) **(Ger)**

PENILE NEOPLASMS

[Epidermoid carcinoma of the penis. Review of 30 cases] Fernández Gómez JM, et al. **Arch Esp Urol** 1997 Apr; 50(3):243-52 (20 ref.) (Eng. Abstr.) **(Spa)**

[Review of 42 cases of penile carcinoma] Portillo Martín JA, et al. **Arch Esp Urol** 1996 May;49(4):365-73 (26 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

[Malignant lymphoma of the penis: report of two cases] Kuwahara Y, et al. **Hinyokika Kiyo** 1997 May;43(5):371-4 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Verrucous carcinoma of the penis. A report of 6 new cases and a review of the diagnostic and therapeutic aspects] Clemente Ramos LM, et al. **Actas Urol Esp** 1997 Apr; 21(4):372-6 (31 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Up-to-date management of carcinoma of the penis. Pizzocaro G, et al. **Eur Urol** 1997;32(1):5-15 (49 ref.)

ETIOLOGY

Carcinoma in situ of the penis in a 76-year-old circumcised man. Cold CJ, et al. **J Fam Pract** 1997 Apr;44(4):407-10 (33 ref.)

PATHOLOGY

Penile basal cell carcinoma with eccrine differentiation. Chang YT, et al. **Clin Exp Dermatol** 1995 Nov;20(6):487-9 (20 ref.)

Carcinoma penis in a young boy. A case report. Hemal AK, et al. **Indian J Cancer** 1996 Jun;33(2):108-10 (7 ref.)

Penile verrucous carcinoma in a 37-year-old circumcised man. Kanik AB, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):329-31 (13 ref.)

SECONDARY

[Metastatic tumor to the penis from lung and pancreas cancer: report of two cases] Danno S, et al. **Hinyokika Kiyo** 1997 Jan;43(1):61-3 (11 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

Up-to-date management of carcinoma of the penis. Pizzocaro G, et al. **Eur Urol** 1997;32(1):5-15 (49 ref.)

[Verrucous carcinoma of the penis: local excision with the Mohs micrographic technique] Muro Vidaurre I, et al. **Arch Esp Urol** 1996 Nov;49(9):959-64 (39 ref.) (Eng. Abstr.) **(Spa)**

VIROLOGY

Anogenital premalignant and malignant tumors (including Buschke-Löwenstein tumors). Grussendorf-Conen EI. **Clin Dermatol** 1997 May-Jun;15(3):377-88 (95 ref.)

Human papillomavirus-associated tumors of the skin and mucosa. Majewski S, et al. **J Am Acad Dermatol** 1997 May; 36(5 Pt 1):659-85; quiz 686-8 (272 ref.)

PENILE PROSTHESIS

ADVERSE EFFECTS

Late glans hypervascularization subsequent to penile prosthesis implantation after revascularization operation. Kayigil O, et al. **J Urol** 1997 Aug;158(2):541 (4 ref.)

PENIS

see related

CIRCUMCISION

Lymphedema due to chronic penile strangulation: a case report. Tanabe N, et al. **J Dermatol** 1996 Sep;23(9):648-51 (15 ref.)

ABNORMALITIES

Femoral hypoplasia-unusual facies syndrome with bifid hallux, absent tibia, and macrophallus: a report of a Bedouin baby. Sabry MA, et al. **J Med Genet** 1996 Feb;33(2):165-7 (9 ref.)

Penis and bladder agenesis in a living male neonate. Kaefer M, et al. **J Urol** 1997 Apr;157(4):1439-40 (6 ref.)

Megalourethra: a report of four cases and review of the literature. Sharma AK, et al. **Pediatr Surg Int** 1997 Jul; 12(5-6):458-60 (29 ref.)

Distal urethral duplication--a case report and literature review. Singh G, et al. **Scand J Urol Nephrol** 1996 Apr; 30(2):149-51 (5 ref.)

[Micropenis in children: etiology, diagnosis and therapy] Massa GG, et al. **Ned Tijdschr Geneeskd** 1997 Mar 15; 141(11):511-5 (20 ref.) (Eng. Abstr.) **(Dut)**

[A case of aphallia] Nakaigawa N, et al. **Hinyokika Kiyo** 1996 Sep;42(9):695-7 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Duplication of the penis] Pivnev AA, et al. **Arkh Anat Gistol Embriol** 1968 Nov;55(11):81-2 (6 ref.) **(Rus)**

BLOOD SUPPLY

High-flow priapism--recurrence after initially successful selective coil embolization: case report. Millward SF, et al. **Can Assoc Radiol J** 1997 Apr;48(2):105-7 (11 ref.)

Has the efficacy of penile arterial by-pass surgery in the treatment of arteriogenic erectile dysfunction been determined? Vickers KE, et al. **Int J Impot Res** 1996 Dec; 8(4):247-51; discussion 251-3 (24 ref.)

Radiologic evaluation of penile arterial anatomy in arteriogenic impotence. Wahl SI, et al. **Int J Impot Res** 1997 Jun;9(2):93-7 (23 ref.)

Use of radioactive tracers in the evaluation of penile hemodynamics: history, methodology and measurements. Zuckier LS. **Int J Impot Res** 1997 Jun;9(2):99-108 (52 ref.)

Late glans hypervascularization subsequent to penile prosthesis implantation after revascularization operation. Kayigil O, et al. **J Urol** 1997 Aug;158(2):541 (4 ref.)

Post-traumatic priapism treated with selective cavernosal artery ligation. Shapiro RH, et al. **Urology** 1997 Apr; 49(4):638-43 (15 ref.)

[Percutaneous superselective bilateral embolization for the therapy of traumatic juvenile arterial priapism] Rilinger N, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Mar;166(3):263-5 (10 ref.) **(Ger)**

[Post-traumatic priapism in a 10-year-old boy] Sperling H, et al. **Urologe A** 1997 Mar;36(2):162-4 (11 ref.) (Eng. Abstr.) **(Ger)**

CYTOLOGY

Integrative erectile biology: the role of signal transduction and cell-to-cell communication in coordinating corporal smooth muscle tone and penile erection. Christ GJ, et al. **Int J Impot Res** 1997 Jun;9(2):69-84 (65 ref.)

INJURIES

Re: Circumcision: successful glanular reconstruction and survival following traumatic amputation [letter; comment] Van Howe RS. **J Urol** 1997 Aug;158(2):550 (16 ref.) Comment on: J Urol 1996 Aug;156(2 Pt 2):842-4.

Post-traumatic priapism treated with selective cavernosal artery ligation. Shapiro RH, et al. **Urology** 1997 Apr; 49(4):638-43 (15 ref.)

[Penile injuries] Prunet D, et al. **Prog Urol** 1996 Dec; 6(6):987-93 (23 ref.) (Eng. Abstr.) **(Fre)**

[Surgical treatment of fracture of the corpus cavernosum and the urethra: review of the literature and report of 2 cases] Rubio Briones J, et al. **Arch Esp Urol** 1996 Jun; 49(5):499-506 (26 ref.) (Eng. Abstr.) **(Spa)**

INNERVATION

[Assessment of sensory thresholds of the penile dorsal nerve as screening technique for neurologic lesion in impotence] Salinas Casado J, et al. **Arch Esp Urol** 1997 Mar;

50(2):173–82 (20 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Crohn's disease of the prepuce in a 12-year-old boy: a case report and review of the literature. Phillips SS, et al. **Pediatr Pathol Lab Med** 1997 May–Jun;17(3):497–502 (24 ref.)

PHYSIOLOGY

Vascular control mechanisms in penile erection: phylogeny and the inevitability of multiple and overlapping systems. Adams MA, et al. **Int J Impot Res** 1997 Jun;9(2):85–91 (30 ref.)

Integrative erectile biology: the role of signal transduction and cell–to–cell communication in coordinating corporal smooth muscle tone and penile erection. Christ GJ, et al. **Int J Impot Res** 1997 Jun;9(2):69–84 (65 ref.)

De virginibus puerisque: the function of the human foreskin considered from an evolutionary perspective. Cox G. **Med Hypotheses** 1995 Dec;45(6):617–21 (18 ref.)

The "syncytial tissue triad": a model for understanding how gap junctions participate in the local control of penile erection. Christ GJ. **World J Urol** 1997;15(1):36–44 (49 ref.)

Multiple types of ion channels in cavernous smooth muscle. Noack T, et al. **World J Urol** 1997;15(1):45–9 (12 ref.)

The effects of testosterone on the cavernous tissue and erectile function. Shabsigh R. **World J Urol** 1997;15(1):21–6 (62 ref.)

Signal transduction in cavernous smooth muscle. Stief CG, et al. **World J Urol** 1997;15(1):27–31 (29 ref.)

PHYSIOPATHOLOGY

[Nocturnal penile tumescence] Takanami M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:393–6 (6 ref.) **(Jpn)**

[Assessment of sensory thresholds of the penile dorsal nerve as screening technique for neurologic lesion in impotence] Salinas Casado J, et al. **Arch Esp Urol** 1997 Mar; 50(2):173–82 (20 ref.) (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

Radiologic evaluation of penile arterial anatomy in arteriogenic impotence. Wahl SI, et al. **Int J Impot Res** 1997 Jun;9(2):93–7 (23 ref.)

RADIONUCLIDE IMAGING

Use of radioactive tracers in the evaluation of penile hemodynamics: history, methodology and measurements. Zuckier LS. **Int J Impot Res** 1997 Jun;9(2):99–108 (52 ref.)

[Radioisotope penography] Shirai M. **Nippon Rinsho** 1997 Apr;55 Suppl 2:390–2 (10 ref.) **(Jpn)**

SURGERY

Neonatal circumcision: anatomic contraindications [see comments] Redman JF, et al. **J Ark Med Soc** 1997 Jul; 94(2):73–5 (5 ref.) Comment in: J Ark Med Soc 1997 Jul;94(2):60–2.

Re: Circumcision: successful glanular reconstruction and survival following traumatic amputation [letter; comment] Van Howe RS. **J Urol** 1997 Aug;158(2):550 (16 ref.) Comment on: J Urol 1996 Aug;156(2 Pt 2):842–4.

[Surgical treatment of fracture of the corpus cavernosum and the urethra: review of the literature and report of 2 cases] Rubio Briones J, et al. **Arch Esp Urol** 1996 Jun; 49(5):499–506 (26 ref.) (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Ultrasound evaluation of the penis for assessment of impotence. Connolly JA, et al. **J Clin Ultrasound** 1996 Oct; 24(8):481–6 (31 ref.)

PENIS, ARTIFICIAL see **PENILE PROSTHESIS**

PENSIONS

A theory of technophysio evolution, with some implications for forecasting population, health care costs, and pension costs [published erratum appears in Demography 1997 May;34(2):170] Fogel RW, et al. **Demography** 1997 Feb; 34(1):49–66 (119 ref.)

The welfare state, pensions, privatization: the case of Social Security in the United States. Du Boff RB. **Int J Health Serv** 1997;27(1):1–23 (23 ref.)

STATISTICS & NUMERICAL DATA

Pension benefits among the aged: conflicting measures, unequal distributions. Woods JR. **Soc Secur Bull** 1996 Fall; 59(3):3–30 (30 ref.)

PENTAGASTRIN

see related
GASTROINTESTINAL AGENTS

PENTAMIDINE

ADVERSE EFFECTS

[Sinus bradycardia secondary to systemic pentamidine] Izquierdo Patrón M, et al. **Rev Esp Cardiol** 1996 Dec; 49(12):919–20 (7 ref.) (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

Treatment of Pneumocystis carinii pneumonia in adults with AIDS. Deresinski SC. **Semin Respir Infect** 1997 Jun; 12(2):79–97 (142 ref.)

PENTAMIDINE ISETHIONATE see **PENTAMIDINE**

PENTANUCLEOTIDE REPEATS see **MICROSATELLITE REPEATS**

PENTETATES see **DTPA**

PENTHANIL see **DTPA**

PENTOSAN POLYSULFATE see **PENTOSAN SULFURIC POLYESTER**

PENTOSAN SULFURIC POLYESTER

ADVERSE EFFECTS

[Cerebral infarction as first manifestation of thrombocytopenia caused by pentosan polysulfate (letter)] Gironell A, et al. **Med Clin (Barc)** 1997 Apr 26;108(16):636 (10 ref.) **(Spa)**

PENTOSE PHOSPHATE SHUNT see **PENTOSEPHOSPHATE PATHWAY**

PENTOSE SHUNT see **PENTOSEPHOSPHATE PATHWAY**

PENTOSEPHOSPHATE PATHWAY

[Pentose phosphate pathway] Kizaki Z, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:234–8 (12 ref.) **(Jpn)**

PHYSIOLOGY

Regulation of and intervention into the oxidative pentose phosphate pathway and adenine nucleotide metabolism in the heart. Zimmer HG. **Mol Cell Biochem** 1996 Jul–Aug; 160–161:101–9 (49 ref.)

PENTOSTATIN

Pharmacology of purine nucleoside analogues. Plunkett W, et al. **Hematol Cell Ther** 1996 Dec;38 Suppl 2:S67–74 (77 ref.)

THERAPEUTIC USE

Purine analogues in the management of lymphoproliferative diseases. Johnson SA. **Clin Oncol (R Coll Radiol)** 1996; 8(5):289–96 (107 ref.)

Clinical experience with 2'-deoxycoformycin. Catovsky D. **Hematol Cell Ther** 1996 Dec;38 Suppl 2:S103–7 (25 ref.)

Perspectives on purine analogues. Cheson BD. **Hematol Cell Ther** 1996 Dec;38 Suppl 2:S109–16 (104 ref.)

Adverse and beneficial immunological effects of purine nucleoside analogues. Dighiero G. **Hematol Cell Ther** 1996 Dec;38 Suppl 2:S75–81 (98 ref.)

Present status of purine analogs in the therapy of chronic lymphocytic leukemias. Bergmann L. **Leukemia** 1997 Apr; 11 Suppl 2:S29–34 (77 ref.)

PENTOXIFYLLINE

PHARMACOLOGY

Pentoxifylline: its influence on the interaction of blood cells with the vessel wall. Seiffge D. **Atherosclerosis** 1997 Jun; 131 Suppl:S27–8 (9 ref.)

Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Windmeier C, et al. **Gen Pharmacol** 1997 Aug;29(2):181–96 (195 ref.)

THERAPEUTIC USE

Clinical experience with pentoxifylline. Labs KH, et al. **Atherosclerosis** 1997 Jun;131 Suppl:S37–9 (15 ref.)

Pentoxifylline: brief review and rationale for its possible use in the treatment of autism. Gupta S, et al. **J Child Neurol** 1996 Nov;11(6):501–4 (44 ref.)

PENTYMAL see **AMOBARBITAL**

PEOPLE WITH DISABILITIES see **DISABLED**

PEPSIN see **PEPSIN A**

PEPSIN A

ADVERSE EFFECTS

Peptic activity and gastroduodenal mucosal damage. Raufman JP. **Yale J Biol Med** 1996 Jan–Feb;69(1):85–90 (27 ref.)

SECRETION

Long-term effects of Helicobacter pylori infection on acid and pepsin secretion. Halter F, et al. **Yale J Biol Med** 1996 Jan–Feb;69(1):99–104 (39 ref.)

PEPSINOGEN

GENETICS

[Gene analysis of acid proteases] Azuma T. **Nippon Rinsho** 1996 Apr;54(4):1149–54 (12 ref.) (Eng. Abstr.) **(Jpn)**

PEPTIC ULCER

see related
ANTI-ULCER AGENTS
GASTRECTOMY
ZOLLINGER-ELLISON SYNDROME

Peptic ulcer disease in the 1990s: an Asian perspective. Fock KM. **J Gastroenterol Hepatol** 1997 Jun;12(6):S23–8 (64 ref.)

Peptic ulcer disease: paradigms lost. Sarner A, et al. **Mt Sinai J Med** 1996 Oct–Nov;63(5–6):387–98 (177 ref.)

[Erosive lesions of gastroduodenal mucosa: etiology, pathogenesis, clinical features, treatment] Maev IV, et al. **Klin Med (Mosk)** 1997;75(6):57–61 (40 ref.) **(Rus)**

[Erosive gastroduodenal ulcers] Vodolagin VD. **Klin Med (Mosk)** 1997;75(5):11–3 (14 ref.) (Eng. Abstr.) **(Rus)**

CHEMICALLY INDUCED

Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: where we stand. Graham DY. **Am J Gastroenterol** 1996 Oct;91(10):2080–6 (92 ref.)

New NSAIDs and gastroduodenal damage. Folco GC. **Ital J Gastroenterol** 1996 Dec;28 Suppl 4:28–9 (10 ref.)

Gastrointestinal effects of NSAIDs. Difficulties in detection and management. Pearson SP, et al. **Postgrad Med** 1996 Nov;100(5):131–2, 135–6, 141–3 (20 ref.)

Non-steroidal anti-inflammatory drug gastropathy: causes and treatment. Hawkey CJ. **Scand J Gastroenterol Suppl** 1996;220:124–7 (34 ref.)

[Digestive and extra-digestive complications of nonsteroidal anti-inflammatory drugs. Preventive and curative strategies] Sternon J, et al. **Rev Med Brux** 1997 Apr; 18(2):52–8 (43 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Gastric outlet obstruction. Khullar SK, et al. **Gastrointest Endosc Clin N Am** 1996 Jul;6(3):585–603 (82 ref.)

[Clinical protocols in digestive system hemorrhage caused by peptic ulcer] Ruiz del Arbol Olmos L, et al. **Rev Esp Enferm Dig** 1996 Nov;88(11):785–98 (137 ref.) **(Spa)**

DIAGNOSIS

Approach to the patient with unexplained chest pain. Katz PO, et al. **Compr Ther** 1997 Apr;23(4):249–53 (21 ref.)

Helicobacter pylori in peptic ulcer disease: report of an NIH consensus conference [see comments] Berg AO. **J Am Board Fam Pract** 1996 May–Jun;9(3):205–7 (4 ref.) Comment in: J Am Board Fam Pract 1996 Sep–Oct;9(5):392.

[Infections caused by Helicobacter pylori] Stock I, et al. **Med Monatsschr Pharm** 1997 Jan;20(1):2–8 (10 ref.) **(Ger)**

[A case of isolated jejunal ulcer and review of the literature] Schmulson Wasserman MJ, et al. **Rev Invest Clin** 1995 Nov–Dec;47(6):477–80 (16 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Review article: clinical aspects of Helicobacter pylori eradication therapy in peptic ulcer disease. Penston JG. **Aliment Pharmacol Ther** 1996 Aug;10(4):469–86 (200 ref.)

Treatment strategies for Helicobacter pylori infection. Damianos AJ, et al. **Am Fam Physician** 1997 Jun; 55(8):2765–74, 2784–6 (34 ref.)

Peptic ulcer disease: defining the treatment strategies in the era of Helicobacter pylori. Hunt RH. **Am J Gastroenterol** 1997 Apr;92(4 Suppl):36S–40S; discussion 40S–43S (56 ref.)

Lansoprazole and omeprazole in the treatment of acid peptic disorders [see comments] Blum RA. **Am J Health Syst Pharm** 1996 Jun 15;53(12):1401–15 (174 ref.) Comment in: Am J Health Syst Pharm 1996 Dec 1;53(23):2882, 2884.

Lansoprazole: a proton pump inhibitor. Garnett WR. **Ann Pharmacother** 1996 Dec;30(12):1425–36 (108 ref.)

Pathogenesis and treatment of acid peptic disorders: comparison of proton pump inhibitors with other antiulcer agents. Sanders SW. **Clin Ther** 1996 Jan–Feb;18(1):2–34; discussion 1 (178 ref.)

Helicobacter pylori and peptic ulcer disease: issues for primary care providers. Taniguchi DK, et al. **Compr Ther** 1996 Jul;22(7):434–9 (20 ref.)

Clarithromycin and omeprazole as helicobacter pylori eradication therapy in patients with H. pylori–associated gastric disorders. Markham A, et al. **Drugs** 1996 Jan; 51(1):161–78 (67 ref.)

Treatment of peptic ulcer in the elderly. Proton pump inhibitors and histamine H2 receptor antagonists. Lazzaroni

M, et al. **Drugs Aging** 1996 Oct;9(4):251–61 (72 ref.)
Triple therapy as a cure for Helicobacter pylori infection. Bardhan KD. **Eur J Gastroenterol Hepatol** 1996 Oct;8 Suppl 1:S27–30 (36 ref.)
Proton-pump inhibitors are the treatment of choice in acid-related disease. Brunner G. **Eur J Gastroenterol Hepatol** 1996 Oct;8 Suppl 1:S9–13 (42 ref.)
The changing role of H2-receptor antagonists in acid-related diseases. Lamers CB. **Eur J Gastroenterol Hepatol** 1996 Oct;8 Suppl 1:S3–7 (38 ref.)
Pantoprazole, a new proton-pump inhibitor, has a precise and predictable profile of activity. Parsons ME. **Eur J Gastroenterol Hepatol** 1996 Oct;8 Suppl 1:S15–20 (45 ref.)
How to achieve a near 100% cure rate for H. pylori infection in peptic ulcer patients. A personal viewpoint. de Boer WA. **J Clin Gastroenterol** 1996 Jun;22(4):313–6 (28 ref.)
Managing acid peptic disease in the Helicobacter pylori era. Marshall BJ. **J Clin Gastroenterol** 1995;21 Suppl 1:S155–9 (14 ref.)
The clinical relevance of chronopharmacology in therapeutics. Lemmer B. **Pharmacol Res** 1996 Feb; 33(2):107–15 (65 ref.)
Proton pump inhibitors and acid-related diseases. Sachs G. **Pharmacotherapy** 1997 Jan–Feb;17(1):22–37 (112 ref.)
Helicobacter pylori infection. The importance of eradication in patients with gastric disease. Bonagura AF, et al. **Postgrad Med** 1996 Nov;100(5):115–6, 119–20, 123–4 passim (13 ref.)
Helicobacter pylori eradication: therapy other than with bismuth or proton-pump inhibitors. Korman MG. **Scand J Gastroenterol Suppl** 1996;220:41–3 (25 ref.)
Pooled analysis of anti-Helicobacter pylori treatment regimens. Unge P, et al. **Scand J Gastroenterol Suppl** 1996; 220:27–40 (307 ref.)
pH, healing rate and symptom relief in acid-related diseases. Huang JQ, et al. **Yale J Biol Med** 1996 Mar–Apr; 69(2):159–74 (123 ref.)
[Anti-ulcer agents. Recommendations and medical references. Agence Nationale pour le Développement de l'Evaluation Médicale] **Gastroenterol Clin Biol** 1996; 20(11):991–1008 (211 ref.) **(Fre)**
[Helicobacter pylori eradication: triple therapy versus dual therapy] Dammann HG. **Fortschr Med** 1996 Feb 10; 114(4):34–8 (34 ref.) (Eng. Abstr.) **(Ger)**
[Helicobacter pylori eradication: modified triple therapy with lansoprazole] Müller P, et al. **Fortschr Med** 1996 Dec 20; 114(35–36):497–9 (17 ref.) (Eng. Abstr.) **(Ger)**
[Peptic ulcer and reparants] Maiorov VM, et al. **Klin Med (Mosk)** 1996;74(4):71–2 (9 ref.) **(Rus)**
[Modern principles of drug therapy of peptic ulcer] Sheptulin AA. **Klin Med (Mosk)** 1996;74(8):17–9 (20 ref.) **(Rus)**
[What is the current therapeutic role of omeprazole in gastroduodenal ulcer disease?] Gisbert JP, et al. **Rev Esp Enferm Dig** 1997 Feb;89(2):116–23 (131 ref.) **(Spa)**

ECONOMICS

Clinical economics review: Helicobacter pylori-associated peptic ulcer disease. Bodger K, et al. **Aliment Pharmacol Ther** 1997 Apr;11(2):273–82 (52 ref.)

EPIDEMIOLOGY

[Epidemiology and risk factors of gastroduodenal ulcer] Kreiss C, et al. **Chirurg** 1996 Jan;67(1):7–13 (89 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Current management of patients with stress ulceration. O'Keefe G, et al. **Adv Surg** 1996;30:155–77 (95 ref.)
Review: Helicobacter pylori. Current issues and new directions. Forbes GM. **J Gastroenterol Hepatol** 1997 Jun; 12(6):419–24 (51 ref.)
Use of animal models in peptic ulcer disease. Weiner H. **Psychosom Med** 1996 Nov–Dec;58(6):524–45 (259 ref.)
pH, healing rate and symptom relief in acid-related diseases. Huang JQ, et al. **Yale J Biol Med** 1996 Mar–Apr; 69(2):159–74 (123 ref.)
[Ulcerous disease and gastritis at the time of Helicobacter pylori] **Therapie** 1996 May–Jun;51(3):309–18 (0 ref.) **(Fre)**

IMMUNOLOGY

[Immune responses of IgG, IgA and anti-CagA IgG to Helicobacter pylori in dyspeptic and peptic ulcer patients] Tamássy K, et al. **Orv Hetil** 1997 Apr 20;138(16):985–8 (27 ref.) (Eng. Abstr.) **(Hun)**

METABOLISM

Acid secretion and Helicobacter pylori. Sachs G, et al. **Digestion** 1997;58 Suppl 1:8–13 (16 ref.)
Inflammatory mediators in gastrointestinal defense and injury. Wallace JL, et al. **Proc Soc Exp Biol Med** 1997 Mar;214(3):192–203 (139 ref.)

MICROBIOLOGY

Helicobacter pylori and peptic ulcer disease: evolution to revolution to resolution [see comments] Pattison CP, et al. **AJR Am J Roentgenol** 1997 Jun;168(6):1415–20 (70 ref.) Comment in: AJR Am J Roentgenol 1997 Jun;168(6):1403. Comment in: AJR Am J Roentgenol 1997 Jun;168(6):1421–2.
Helicobacter pylori and the risk and management of associated diseases: gastritis, ulcer disease, atrophic gastritis and gastric cancer. Kuipers EJ. **Aliment Pharmacol Ther** 1997 Apr;11 Suppl 1:71–88 (193 ref.)
Treatment strategies for Helicobacter pylori infection. Damianos AJ, et al. **Am Fam Physician** 1997 Jun; 55(8):2765–74, 2784–6 (34 ref.)
Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: where we stand. Graham DY. **Am J Gastroenterol** 1996 Oct;91(10):2080–6 (92 ref.)
Helicobacter pylori and acid peptic disorders of the esophagus: is it conceivable? Vicari J, et al. **Am J Gastroenterol** 1997 Jul;92(7):1097–102 (63 ref.)
Helicobacter pylori: new developments and treatments. Veldhuyzen van Zanten SJ, et al. **Can Med Assoc J** 1997 Jun 1;156(11):1565–74 (112 ref.)
Helicobacter pylori and peptic ulcer disease: issues for primary care providers. Taniguchi DK, et al. **Compr Ther** 1996 Jul;22(7):434–9 (20 ref.)
Helicobacter pylori infection in ulcer pathogenesis. Malfertheiner P, et al. **Digestion** 1997;58 Suppl 1:17–20 (35 ref.)
Prospects for the development of a vaccine against Helicobacter pylori. Telford JL, et al. **Drugs** 1996 Dec; 52(6):799–804 (36 ref.)
How to treat Helicobacter pylori infection--should treatment strategies be based on testing bacterial susceptibility? A personal viewpoint. de Boer WA, et al. **Eur J Gastroenterol Hepatol** 1996 Jul;8(7):709–16 (59 ref.)
Current European concepts in the management of Helicobacter pylori infection--the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG). Malfertheiner P, et al. **Eur J Gastroenterol Hepatol** 1997 Jan;9(1):1–2 (0 ref.)
Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group. **Gut** 1997 Jul;41(1):8–13 (50 ref.)
The clinical relevance of strain types of Helicobacter pylori. Atherton JC. **Gut** 1997 Jun;40(6):701–3 (36 ref.)
Helicobacter pylori infection [editorial; comment] Patwari AK. **Indian Pediatr** 1996 Nov;33(11):899–903 (7 ref.) Comment on: Indian Pediatr 1996 Nov;33(11):905–9.
How to achieve a near 100% cure rate for H. pylori infection in peptic ulcer patients. A personal viewpoint. de Boer WA. **J Clin Gastroenterol** 1996 Jun;22(4):313–6 (28 ref.)
Review: eradication of Helicobacter pylori. Problems and recommendations. Huang JQ, et al. **J Gastroenterol Hepatol** 1997 Aug;12(8):590–8 (78 ref.)
Pathogenesis to prescription: progress in understanding and treating acid related disorders. Hunt RH. **J R Nav Med Serv** 1996 Summer;82(2):122–33 (125 ref.)
Helicobacter pylori infection. The importance of eradication in patients with gastric disease. Bonagura AF, et al. **Postgrad Med** 1996 Nov;100(5):115–6, 119–20, 123–4 passim (13 ref.)
The infectious etiology of peptic ulcer disease. Diagnosis and implications for therapy. Brooks MJ, et al. **Prim Care** 1996 Sep;23(3):443–54 (39 ref.)
Immune and inflammatory responses to Helicobacter pylori infection. Crabtree JE. **Scand J Gastroenterol Suppl** 1996; 215:3–10 (78 ref.)
Helicobacter pylori eradication: therapy other than with bismuth or proton-pump inhibitors. Korman MG. **Scand J Gastroenterol Suppl** 1996;220:41–3 (25 ref.)
Long-term consequences of Helicobacter pylori eradication: clinical aspects. Labenz J, et al. **Scand J Gastroenterol Suppl** 1996;215:111–5 (35 ref.)
Pooled analysis of anti-Helicobacter pylori treatment regimens. Unge P, et al. **Scand J Gastroenterol Suppl** 1996; 220:27–40 (307 ref.)
Helicobacter pylori and peptic ulcer disease. Van der Hulst RW, et al. **Scand J Gastroenterol Suppl** 1996;220:10–8 (118 ref.)
[Progresses in gastroenterology in China, 1996] Fan D, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Dec;76(12):887–8 (0 ref.) **(Chi)**
[Infection with Helicobacter pylori, the end in sight?] Loffeld RJ. **Ned Tijdschr Geneeskd** 1996 Dec 7;140(49):2440–1 (20 ref.) **(Dut)**
[Ulcer disease and gastritis in time of Helicobacter pylori. Société Nationale Française de Gastro-entérologie et. Société Française de Chirurgie Digestive. Société Française d'Endoscopie Digestive. Société Française de Microbiologie. Société de Pathologie Infectieuse de Langue Française. Groupe d'Etude Français des Helicobacter.] **Gastroenterol Clin Biol** 1996;20(11):1009–12 (0 ref.) **(Fre)**
[Helicobacter pylori and ulcer disease (see comments)] Rácz I. **Orv Hetil** 1996 Jul 7;137(27):1459–67 (50 ref.) (Eng. Abstr.) Comment in: Orv Hetil 1996 Dec 29;137(52):2947–8. **(Hun)**

MORTALITY

Mortality after gastric surgery for peptic ulceration [comment] Venables CW. **Eur J Gastroenterol Hepatol** 1997 Jan;9(1):13–4 (13 ref.) Comment on: Eur J Gastroenterol Hepatol 1997 Jan;9(1):33–40.

PATHOLOGY

Endoscopic evaluation of the postoperative stomach. Mellinger JD, et al. **Gastrointest Endosc Clin N Am** 1996 Jul;6(3):621–39 (59 ref.)
[The problem of regeneration of the gastrointestinal tract mucosa in erosive-ulcerous lesions] Potkhin PP, et al. **Arkh Patol** 1997 Mar–Apr;59(2):68–71 (47 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Pathophysiology of Helicobacter pylori-induced gastritis and peptic ulcer disease. Peek RM Jr, et al. **Am J Med** 1997 Feb;102(2):200–7 (93 ref.)
Peptic ulcer pathophysiology: acid, bicarbonate, and mucosal function. Højgaard L, et al. **Scand J Gastroenterol Suppl** 1996;216:10–5 (62 ref.)
[Aggressive factors in the physiopathology of peptic ulcer. Recent findings] Testino G. **Recenti Prog Med** 1996 Jun; 87(6):285–9 (15 ref.) (Eng. Abstr.) **(Ita)**

PREVENTION & CONTROL

Gastroprotective properties of ebrotidine. A review. Slomiany BL, et al. **Arzneimittelforschung** 1997 Apr; 47(4A):459–67 (49 ref.)
Steroid therapy and H2-receptor antagonists: pharmacoeconomic implications. Marcus P, et al. **Clin Pharmacol Ther** 1997 May;61(5):503–8 (18 ref.)
[Prevention and therapy of NSAID-induced ulcers: fact versus myth] Fried M, et al. **Schweiz Med Wochenschr** 1996 Sep 14;126(37):1569–72 (15 ref.) (Eng. Abstr.) **(Ger)**
[The eradication of Helicobacter pylori and the prevention of ulcer recurrence. The certainties and the open problems] Dobrilla G. **Recenti Prog Med** 1996 Jun;87(6):290–300 (60 ref.) (Eng. Abstr.) **(Ita)**

PSYCHOLOGY

The personality pattern in peptic ulcer disease. Jess P. **Dan Med Bull** 1996 Sep;43(4):330–5 (109 ref.)

SURGERY

Mortality after gastric surgery for peptic ulceration [comment] Venables CW. **Eur J Gastroenterol Hepatol** 1997 Jan;9(1):13–4 (13 ref.) Comment on: Eur J Gastroenterol Hepatol 1997 Jan;9(1):33–40.
[Evaluating elective surgical procedures in ulcer surgery] Becker HD, et al. **Chirurg** 1996 Jan;67(1):14–9 (30 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Current management of patients with stress ulceration. O'Keefe G, et al. **Adv Surg** 1996;30:155–77 (95 ref.)
Peptic disease: can we afford current management? Fletcher DR. **Aust N Z J Surg** 1997 Feb–Mar;67(2–3):75–80 (39 ref.)
Are ulcer healing and prophylaxis studies appropriately analysed? Eriksson SA. **Eur J Gastroenterol Hepatol** 1995 Dec;7(12):1195–8 (3 ref.)
[Gastroduodenal ulcers in intensive care units] Raynard B, et al. **Presse Med** 1996 Oct 19;25(31):1448–52 (28 ref.) (Eng. Abstr.) **(Fre)**
[The current methods in the nontraditional therapy of peptic ulcer (a review of the literature and the authors' own data)] Filippov IuA, et al. **Lik Sprava** 1996 Oct–Dec; (10–12):14–20 (28 ref.) **(Rus)**

PEPTIC ULCER HEMORRHAGE

DRUG THERAPY

[Intravenous omeprazole versus ranitidine in the treatment of hemorrhagic duodenal ulcer: a prospective randomized study] Cardi M, et al. **Ann Chir** 1997;51(2):136–9 (32 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Stress-related mucosal damage. What to do or not to do. Goldin GF, et al. **Gastrointest Endosc Clin N Am** 1996 Jul;6(3):505–26 (106 ref.)
Ulcer bleeding and perforation: non-steroidal anti-inflammatory drugs or Helicobacter pylori. Svanes C, et al. **Scand J Gastroenterol Suppl** 1996;220:128–31 (43 ref.)

SURGERY

Surgical approach in severe bleeding peptic ulcer. Legrand MJ, et al. **Acta Gastroenterol Belg** 1996 Oct–Dec; 59(4):240–4 (38 ref.)
[Ulcer surgery '96--choice of methods in an emergency] Röher HD, et al. **Chirurg** 1996 Jan;67(1):20–5 (28 ref.) (Eng. Abstr.) **(Ger)**
[Changes in the body of patients with peptic ulcer after acute hemorrhage] Desiaterik VI. **Klin Khir** 1996;(10):47–50 (24 ref.) **(Rus)**

THERAPY

Peptic ulcer bleeding: perspectives on some common dilemmas. Choudari CP. **Cleve Clin J Med** 1996 Nov–Dec; 63(7):381–6; quiz 419 (32 ref.)
A practical guide to the management of bleeding ulcers. Villanueva C, et al. **Drugs** 1997 Mar;53(3):389–403 (113

PEPTIC ULCER HEMORRHAGE

ref.)
Therapeutic modalities for treatment of peptic ulcer bleeding. Lee JG, et al. **Gastroenterologist** 1997 Mar;5(1):26–40 (97 ref.)
A review on treatment of bleeding peptic ulcer: a collaborative task of gastroenterologist and surgeon. Kolkman JJ, et al. **Scand J Gastroenterol Suppl** 1996; 218:16–25 (100 ref.)
[Endoscopic treatment of digestive system diseases. 1. Selection of endoscopic hemostasis applied to hemorrhage of the digestive system] Takahashi H, et al. **Nippon Naika Gakkai Zasshi** 1996 Sep 10;85(9):1432–7 (16 ref.) **(Jpn)**

PEPTIC ULCER PERFORATION

COMPLICATIONS

Liver penetration by a duodenal ulcer. Padda SS, et al. **Am J Gastroenterol** 1997 Feb;92(2):352–4 (12 ref.)
Perforated duodenal ulcer in a pediatric patient with eosinophilic gastroenteritis. Deslandres C, et al. **Can J Gastroenterol** 1997 Apr;11(3):208–12 (28 ref.)

DIAGNOSIS

[A giant ulcer of the stomach with perforation into the liver simulating cancer] Kovalenko VL, et al. **Vestn Khir Im I I Grek** 1996;155(6):82–3 (7 ref.) **(Rus)**

SURGERY

[Ulcer surgery '96—choice of methods in an emergency] Röher HD, et al. **Chirurg** 1996 Jan;67(1):20–5 (28 ref.) (Eng. Abstr.) **(Ger)**

PEPTIDASE INHIBITORS see **PROTEASE INHIBITORS**

PEPTIDE ANTIBIOTICS see **ANTIBIOTICS, PEPTIDE**

PEPTIDE CHAIN ELONGATION

see related
PEPTIDE ELONGATION FACTORS
PROTEIN SYNTHESIS INHIBITORS

The elongating ribosome: structural and functional aspects. Nierhaus KH, et al. **Biochem Cell Biol** 1995 Nov–Dec; 73(11–12):1011–21 (24 ref.)
The elongation phase of protein synthesis. Czworkowski J, et al. **Prog Nucleic Acid Res Mol Biol** 1996;54:293–332 (232 ref.)

PHYSIOLOGY

A complex profile of protein elongation: translating chemical energy into molecular movement. Abel K, et al. **Structure** 1996 Mar 15;4(3):229–38 (41 ref.)

PEPTIDE CHAIN INITIATION

see related
PEPTIDE INITIATION FACTORS
PROTEIN SYNTHESIS INHIBITORS

A pseudoknot is required for efficient translational initiation and regulation of the Escherichia coli rpsO gene coding for ribosomal protein S15. Ehresmann C, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1131–40 (34 ref.)
Escherichia coli initiator tRNA: structure–function relationships and interactions with the translational machinery. Mangroo D, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1023–31 (51 ref.)
RNA–protein interactions in regulation of picornavirus RNA translation. Belsham GJ, et al. **Microbiol Rev** 1996 Sep; 60(3):499–511 (159 ref.)
Functional importance of RNA interactions in selection of translation initiation codons. Sprengart ML, et al. **Mol Microbiol** 1997 Apr;24(1):19–28 (57 ref.)
Regulation of translational initiation during cellular responses to stress. Brostrom CO, et al. **Prog Nucleic Acid Res Mol Biol** 1998;58:79–125 (203 ref.)
Role of translation initiation factor eIF–2B in the regulation of protein synthesis in mammalian cells. Kimball SR, et al. **Prog Nucleic Acid Res Mol Biol** 1996;54:165–96 (106 ref.)
eIF4G: a multipurpose ribosome adapter? [published erratum appears in Science 1997 Mar 14;275(5306):1553] Hentze MW. **Scicnce** 1997 Jan 24;275(5299):500–1 (12 ref.)

PEPTIDE CHAIN TERMINATION

see related
PEPTIDE TERMINATION FACTORS

Termination of translation in eukaryotes. Kisselev LL, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1079–86 (34 ref.)
Upstream stimulators for recoding. Larsen B, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1123–9 (45 ref.)
Regulation of translation termination: conserved structural motifs in bacterial and eukaryotic polypeptide release factors. Nakamura Y, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1113–22 (38 ref.)
Translational termination efficiency in both bacteria and mammals is regulated by the base following the stop codon. Tate WP, et al. **Biochem Cell Biol** 1995 Nov–Dec; 73(11–12):1095–103 (42 ref.)
Dual functions of ribosome recycling factor in protein biosynthesis: disassembling the termination complex and preventing translational errors. Janosi L, et al. **Biochimie** 1996;78(11–12):959–69 (50 ref.)
The translational stop signal: codon with a context, or extended factor recognition element? Tate WP, et al. **Biochimie** 1996;78(11–12):945–52 (32 ref.)
Emerging understanding of translation termination. Nakamura Y, et al. **Cell** 1996 Oct 18;87(2):147–50 (20 ref.)

GENETICS

Hidden infidelities of the translational stop signal. Tate WP, et al. **Prog Nucleic Acid Res Mol Biol** 1996;52:293–335 (157 ref.)

PEPTIDE ELONGATION FACTOR TU

CHEMISTRY

The ternary complex of aminoacylated tRNA and EF–Tu–GTP. Recognition of a bond and a fold. Nissen P, et al. **Biochimie** 1996;78(11–12):921–33 (62 ref.)
A complex profile of protein elongation: translating chemical energy into molecular movement. Abel K, et al. **Structure** 1996 Mar 15;4(3):229–38 (41 ref.)
[Three-dimensional structure and function of ribosomal elongation factors: new data and new questions] Chirgadze IuN. **Mol Biol (Mosk)** 1996 Jul–Aug;30(4):773–85 (24 ref.) **(Rus)**

GENETICS

Antibiotic resistance mechanisms of mutant EF–Tu species in Escherichia coli. Kraal B, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1167–77 (36 ref.)
Elongation factor Tu, a GTPase triggered by codon recognition on the ribosome: mechanism and GTP consumption. Rodnina MV, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1221–7 (42 ref.)

METABOLISM

tRNA–ribosome interactions. Ehrenberg M, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1049–54 (35 ref.)
The ternary complex of EF–Tu and its role in protein biosynthesis. Clark BF, et al. **Curr Opin Struct Biol** 1997 Feb;7(1):110–6 (48 ref.)
Placental isoferritin–associated p43 in pregnancy and breast cancer. Minireview. Rosen HR. **Neoplasma** 1996; 43(6):357–62 (21 ref.)

PEPTIDE ELONGATION FACTORS

CHEMISTRY

Regulatory GTPases. Hilgenfeld R. **Curr Opin Struct Biol** 1995 Dec;5(6):810–7 (80 ref.)
Ribosomal proteins and elongation factors. Liljas A, et al. **Curr Opin Struct Biol** 1995 Dec;5(6):721–7 (59 ref.)
A complex profile of protein elongation: translating chemical energy into molecular movement. Abel K, et al. **Structure** 1996 Mar 15;4(3):229–38 (41 ref.)
[Three-dimensional structure and function of ribosomal elongation factors: new data and new questions] Chirgadze IuN. **Mol Biol (Mosk)** 1996 Jul–Aug;30(4):773–85 (24 ref.) **(Rus)**

ULTRASTRUCTURE

Crystallographic studies of elongation factor G. Liljas A, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1209–16 (35 ref.)

PEPTIDE FRAGMENTS

ANALYSIS

Distribution of GLP–1 and PACAP receptors in human tissues. Wei Y, et al. **Acta Physiol Scand** 1996 Jul; 157(3):355–7 (7 ref.)
Appreciating the complexity of MHC class II peptide binding: lysozyme peptide and I–Ak. Nelson CA, et al. **Immunol Rev** 1996 Jun;151:81–105 (57 ref.)
PP3 component of bovine milk: a phosphorylated whey glycoprotein. Girardet JM, et al. **J Dairy Res** 1996 May; 63(2):333–50 (79 ref.)
Assays of type I procollagen domains and collagen fragments: problems to be solved and future trends. Risteli J, et al. **Scand J Clin Lab Invest Suppl** 1997;227:105–13 (26 ref.)
[N–terminal peptide of type III procollagen in serum and bronchoalveolar fluid as a marker of collagen metabolism in chronic interstitial lung diseases] Siemińska A. **Przegl Lek** 1996;53(7):574–8 (45 ref.) (Eng. Abstr.) **(Pol)**

BIOSYNTHESIS

Endoprotease regulation of miniglucagon production. Bataille D, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:1–8; discussion 8–9 (12 ref.)
Synthesis and biochemical characterization of proglucagon–related peptides. Yanaihara N, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:20–9; discussion 29–30 (31 ref.)
Active fragments of angiotensin II: enzymatic pathways of synthesis and biological effects. Ardaillou R. **Curr Opin Nephrol Hypertens** 1997 Jan;6(1):28–34 (73 ref.)

BLOOD

Collagen: scaffold for repair or execution. Jensen LT, et al. **Cardiovasc Res** 1997 Mar;33(3):535–9 (35 ref.)

CHEMISTRY

Primary structure and biological activity of hemoglobin–related hypothalamic peptides. Galoyan AA. **Biopolymers** 1997;43(2):135–7 (30 ref.)
Hemoglobin as a source of endogenous bioactive peptides: the concept of tissue–specific peptide pool. Ivanov VT, et al. **Biopolymers** 1997;43(2):171–88 (60 ref.)
Biochemical properties of regulatory peptides derived from milk proteins. Meisel H. **Biopolymers** 1997;43(2):119–28 (79 ref.)
The hemorphins: a new class of opioid peptides derived from the blood protein hemoglobin. Nyberg F, et al. **Biopolymers** 1997;43(2):147–56 (63 ref.)
Antihypertensive peptides derived from food proteins. Yamamoto N. **Biopolymers** 1997;43(2):129–34 (67 ref.)
Opioid peptides derived from hemoglobin: hemorphins. Zhao Q, et al. **Biopolymers** 1997;43(2):75–98 (60 ref.)
Recent advances in multiple antigen peptides. Tam JP. **J Immunol Methods** 1996 Sep 13;196(1):17–32 (107 ref.)
Association of complementary fragments and the elucidation of protein folding pathways. de Prat–Gay G. **Protein Eng** 1996 Oct;9(10):843–7 (75 ref.)
Assays of type I procollagen domains and collagen fragments: problems to be solved and future trends. Risteli J, et al. **Scand J Clin Lab Invest Suppl** 1997;227:105–13 (26 ref.)
[Biologically active peptide fragments of functional proteins produced by proteolysis in vitro] Filippova MM, et al. **Bioorg Khim** 1997 May;23(5):388–409 (168 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Glucagon and GLP–1 receptors: lessons from chimeric ligands and receptors. Hjorth SA, et al. **Acta Physiol Scand** 1996 Jul;157(3):343–5 (12 ref.)
Lack of correlation between V3 amino acid sequence and syncytium–inducing capacity of some HIV ,ype 1 isolates [letter] Sabri F, et al. **AIDS Res Hum Retroviruses** 1996 Jul 1;12(10):855–8 (25 ref.)

IMMUNOLOGY

Needles in haystacks: identifying specific peptide antigens for T cells. Shastri N. **Curr Opin Immunol** 1996 Apr; 8(2):271–7 (56 ref.)
The role of polymorphic donor peptides in allograft recognition and rejection. Fabre JW. **Immunol Rev** 1996 Dec;154:21–43 (79 ref.)
Recent advances in multiple antigen peptides. Tam JP. **J Immunol Methods** 1996 Sep 13;196(1):17–32 (107 ref.)
Partial activation of foreign antigen specific T lymphocytes by a self peptide: possible roles of altered peptide ligands in regulating T lymphocyte mediated immune response. Cao W, et al. **J Mol Med** 1996 Oct;74(10):573–82 (104 ref.)
Bone marrow–derived dendritic cells serve as potent adjuvants for peptide–based antitumor vaccines. Mayordomo JI, et al. **Stem Cells** 1997;15(2):94–103 (59 ref.)
Identification of potential CTL epitopes of bovine RSV using allele–specific peptide motifs from bovine MHC class I molecules. Gaddum RM, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):211–9 (50 ref.)

ISOLATION & PURIFICATION

Des(1–3)IGF–I: a truncated form of insulin–like growth factor–I. Ballard FJ, et al. **Int J Biochem Cell Biol** 1996 Oct;28(10):1085–7 (12 ref.)

METABOLISM

Glucagon and GLP–1 receptors: lessons from chimeric ligands and receptors. Hjorth SA, et al. **Acta Physiol Scand** 1996 Jul;157(3):343–5 (12 ref.)
Angiotensin receptor heterogeneity in the dorsal medulla oblongata as defined by angiotensin–(1–7). Diz DI, et al. **Adv Exp Med Biol** 1996;396:225–35 (65 ref.)
Lysosomal proteinosis based on decreased degradation of a specific protein, mitochondrial ATP synthase subunit C: Batten disease. Ezaki J, et al. **Adv Exp Med Biol** 1996; 389:121–8 (31 ref.)
The N–end rule pathway of protein degradation. Varshavsky A. **Genes Cells** 1997 Jan;2(1):13–28 (75 ref.)
Biochemical markers of bone turnover. Crofton PM, et al. **Horm Res** 1996;45 Suppl 1:55–8 (10 ref.)
Appreciating the complexity of MHC class II peptide binding: lysozyme peptide and I–Ak. Nelson CA, et al. **Immunol Rev** 1996 Jun;151:81–105 (57 ref.)
An etiological role of amyloidogenic carboxyl–terminal fragments of the beta–amyloid precursor protein in Alzheimer's disease. Suh YH. **J Neurochem** 1997 May; 68(5):1781–91 (121 ref.)
Studies of the release of immunoreactive galanin and

dynorphin A(1–8) in the spinal cord of the rat. Duggan AW, et al. **Prog Brain Res** 1996;110:137–47 (74 ref.)
[Biologically active peptide fragments of functional proteins produced by proteolysis in vitro] Filippova MM, et al. **Bioorg Khim** 1997 May;23(5):388–409 (168 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

On the effects of glucagon–like peptide–1 on blood glucose regulation in normal and diabetic subjects. Holst JJ, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:729–36 (54 ref.)
Primary structure and biological activity of hemoglobin–related hypothalamic peptides. Galoyan AA. **Biopolymers** 1997;43(2):135–7 (30 ref.)
Hemoglobin as a source of endogenous bioactive peptides: the concept of tissue–specific peptide pool. Ivanov VT, et al. **Biopolymers** 1997;43(2):171–88 (60 ref.)
Biochemical properties of regulatory peptides derived from milk proteins. Meisel H. **Biopolymers** 1997;43(2):119–28 (79 ref.)
Antihypertensive peptides derived from food proteins. Yamamoto N. **Biopolymers** 1997;43(2):129–34 (67 ref.)
Ularitide: from renal natriuretic peptide to clinical trials. Meyer M, et al. **Curr Opin Nephrol Hypertens** 1996 Jul; 5(4):364–8 (40 ref.)
Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. O'Reilly MS. **EXS** 1997;79:273–94 (62 ref.)
Counterregulatory actions of angiotensin–(1–7). Ferrario CM, et al. **Hypertension** 1997 Sep;30(3 Pt 2):535–41 (63 ref.)
Oral growth hormone secretagogues—better than Alice in Wonderland's growth elixir? [editorial; comment] Saenger P. **J Clin Endocrinol Metab** 1996 Aug;81(8):2773–5 (28 ref.)
Comment on: J Clin Endocrinol Metab 1996 Aug;81(8):2776–82.

PHYSIOLOGY

Molecular mechanism underlying glucagon–like peptide 1 induced calcium mobilization from internal stores in insulin–secreting beta TC3 cells. Gromada J, et al. **Acta Physiol Scand** 1996 Jul;157(3):349–51 (7 ref.)
Glucagon, glucagon–like peptide–1 and their receptors: an introduction. Holst JJ. **Acta Physiol Scand** 1996 Jul; 157(3):309–15 (65 ref.)
In vitro insulinomimetic [corrected] effects of GLP–1 in liver, muscle and fat [published erratum appears in Acta Physiol Scand 1996 Nov;158(3):297] Valverde I, et al. **Acta Physiol Scand** 1996 Jul;157(3):359–60 (11 ref.)
Protein kinase A–directed antisense restrains cancer growth: sequence–specific inhibition of gene expression. Cho–Chung YS. **Antisense Nucleic Acid Drug Dev** 1996 Fall;6(3):237–44 (52 ref.)
Central glucagon–like peptide–I in the control of feeding. Gunn I, et al. **Biochem Soc Trans** 1996 May;24(2):581–4 (22 ref.)
Active fragments of angiotensin II: enzymatic pathways of synthesis and biological effects. Ardaillou R. **Curr Opin Nephrol Hypertens** 1997 Jan;6(1):28–34 (73 ref.)
The aminoterminal propeptide of type III procollagen. Studies on physiology and pathophysiology. Jensen LT. **Dan Med Bull** 1997 Feb;44(1):70–8 (109 ref.)
Human studies with glucagon–like–peptide–1: potential of the gut hormone for clinical use. Byrne MM, et al. **Diabet Med** 1996 Oct;13(10):854–60 (70 ref.)
GLP–1 in NIDDM. Holst JJ. **Diabet Med** 1996 Sep;13(9 Suppl 6):S156–60 (48 ref.)
Therapeutic potential of glucagon–like peptide 1 in type 2 diabetes. Nauck M. **Diabet Med** 1996 Sep;13(9 Suppl 5):S39–43 (33 ref.)
Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. O'Reilly MS. **EXS** 1997;79:273–94 (62 ref.)
Disruption of cytokine signaling in lymphoid development: unique contributions of the common cytokine gamma chain and the Jak3 kinase. Eynon EE, et al. **J Interferon Cytokine Res** 1996 Sep;16(9):677–84 (32 ref.)
Nutrient–induced secretion and metabolic effects of glucose–dependent insulinotropic polypeptide and glucagon–like peptide–1. Knapper JM, et al. **Proc Nutr Soc** 1996 Mar;55(1B):291–305 (82 ref.)
The renal paracrine peptide system—possible urologic implications of urodilatin. Meyer M, et al. **World J Urol** 1996;14(6):375–9 (49 ref.)
[New approach for the studies on Alzheimer's disease: a beta 1–42 and acetylcholine] Hoshi M. **Seikagaku** 1997 Mar; 69(3):181–7 (19 ref.) **(Jpn)**

THERAPEUTIC USE

Basic aspects of vasorelaxant and bronchodilating peptides in clinical use: urodilatin (INN: Ularitide), VIP, and PACAP. Meyer M, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:443–61; discussion 461–3 (104 ref.)
The ACTH(4–9) analog ORG 2766 and recovery after brain damage in animal models—a review. van Rijzingen IM, et al. **Behav Brain Res** 1996 Jan;74(1–2):1–15 (135 ref.)
Use of peptides to selectively modulate CD4+ T–cell responses. Hetzel C, et al. **Biochem Soc Trans** 1997 May; 25(2):398–403 (49 ref.)
Clinical trials of Hirulog in patients undergoing high–risk percutaneous transluminal coronary angioplasty. Bittl JA. **Coron Artery Dis** 1996 Jun;7(6):449–54 (64 ref.)
Direct thrombin inhibitors in cardiovascular disease. Catella–Lawson F. **Coron Artery Dis** 1997 Feb;8(2):105–11 (34 ref.)
Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes. Maraganore JM, et al. **Coron Artery Dis** 1996 Jun;7(6):438–48 (38 ref.)
Human studies with glucagon–like–peptide–1: potential of the gut hormone for clinical use. Byrne MM, et al. **Diabet Med** 1996 Oct;13(10):854–60 (70 ref.)
Therapeutic potential of glucagon–like peptide 1 in type 2 diabetes. Nauck M. **Diabet Med** 1996 Sep;13(9 Suppl 5):S39–43 (33 ref.)
Prevention of cancer metastasis in mice with fibronectin–related substances. Azuma I, et al. **Princess Takamatsu Symp** 1994;24:125–41 (70 ref.)
Second generation, B–domain deleted recombinant factor VIII. Berntorp E. **Thromb Haemost** 1997 Jul;78(1):256–60 (33 ref.)
Immunomodulation by HLA class I–derived peptides. Krensky AM, et al. **Transplant Proc** 1996 Dec;28(6):3026–8 (14 ref.)
[Immune intervention by peptides having a MHC class II binding motif—application of MHC blockers to autoimmune disease models] Nihira S. **Nippon Rinsho** 1997 Jun;55(6):1525–30 (21 ref.) (Eng. Abstr.) **(Jpn)**

PEPTIDE HORMONE RECEPTORS see **RECEPTORS, PEPTIDE**

PEPTIDE HYDROLASE INHIBITORS see **PROTEASE INHIBITORS**

PEPTIDE HYDROLASES

ADVERSE EFFECTS

[Side effects of mesotherapy] Doutre MS, et al. **Therapie** 1997 Mar–Apr;52(2):93–6 (15 ref.) **(Fre)**

BIOSYNTHESIS

Effects of nucleotides on assembly of the 26S proteasome and degradation of ubiquitin conjugates. Hoffman L, et al. **Mol Biol Rep** 1997 Mar;24(1–2):13–6 (29 ref.)

CHEMISTRY

Eubacterial proteasomes. Lupas A, et al. **Mol Biol Rep** 1997 Mar;24(1–2):125–31 (50 ref.)
The 26S proteasome: subunits and functions. Tanaka K, et al. **Mol Biol Rep** 1997 Mar;24(1–2):3–11 (39 ref.)

GENETICS

Expression of subunits of the 19S complex and of the PA28 activator in rat skeletal muscle. Attaix D, et al. **Mol Biol Rep** 1997 Mar;24(1–2):95–8 (30 ref.)

METABOLISM

Proteases and glycosyl hydrolases from hyperthermophilic microorganisms. Bauer MW, et al. **Adv Protein Chem** 1996; 48:271–310 (150 ref.)
The proteolytic systems of lactic acid bacteria. Kunji ER, et al. **Antonie Van Leeuwenhoek** 1996 Oct;70(2–4):187–221 (186 ref.)
Are bacterial proteases important virulence factors? Lantz MS. **J Periodontal Res** 1997 Jan;32(1 Pt 2):126–32 (47 ref.)
Proteolytic degradation of host hemoglobin by schistosomes. Brindley PJ, et al. **Mol Biochem Parasitol** 1997 Oct; 89(1):1–9 (57 ref.)
Regulation of proteasome structure and function. Rivett AJ, et al. **Mol Biol Rep** 1997 Mar;24(1–2):99–102 (33 ref.)
The 26S proteasome: a dynamic structure. Seeger M, et al. **Mol Biol Rep** 1997 Mar;24(1–2):83–8 (38 ref.)
[Is ornithine decarboxylase a unique non–ubiquitinated protein degraded by 26S proteasome?] Manteuffel–Cymborowska M. **Postepy Biochem** 1996; 42(2):113–20 (65 ref.) **(Pol)**
[The role of Porphyromonas gingivalis proteinases in periodontitis] Polanowska J, et al. **Postepy Hig Med Dosw** 1997;51(2):149–69 (68 ref.) (Eng. Abstr.) **(Pol)**
[The role of proteolytic enzymes in the pathogenesis of primary glomerulonephritis] Senatorski G, et al. **Postepy Hig Med Dosw** 1997;51(2):139–48 (33 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Immunomodulation by proteolytic enzymes [editorial] Lehmann PV. **Nephrol Dial Transplant** 1996 Jun; 11(6):952–5 (12 ref.)

PEPTIDE INITIATION FACTORS

GENETICS

Conservation and diversity in the structure of translation initiation factor EIF3 from humans and yeast. Hershey JW, et al. **Biochimie** 1996;78(11–12):903–7 (24 ref.)
Translational regulation of yeast GCN4. A window on factors that control initiator–trna binding to the ribosome. Hinnebusch AG. **J Biol Chem** 1997 Aug 29;272(35):21661–4 (61 ref.)

METABOLISM

Intracellular signalling pathways regulating initiation factor eIF4E phosphorylation during the activation of cell growth. Morley SJ. **Biochem Soc Trans** 1997 May; 25(2):503–9 (65 ref.)
Messenger RNA translation in prokaryotes: GTPase centers associated with translational factors. Laalami S, et al. **Biochimie** 1996;78(7):577–89 (192 ref.)
Translational controls impinging on the 5'–untranslated region and initiation factor proteins. Jackson RJ, et al. **Curr Opin Genet Dev** 1997 Apr;7(2):233–41 (72 ref.)
eIF4G: a multipurpose ribosome adapter? [published erratum appears in Science 1997 Mar 14;275(5306):1553] Hentze MW. **Science** 1997 Jan 24;275(5299):500–1 (12 ref.)

PHYSIOLOGY

The role of eIF4 in cell proliferation. Flynn A, et al. **Cancer Surv** 1996;27:293–310 (71 ref.)

PEPTIDE LIBRARY

Structural and mechanistic determinants of affinity and specificity of ligands discovered or engineered by phage display. Katz BA. **Annu Rev Biophys Biomol Struct** 1997; 26:27–45 (98 ref.)
Bacteriophage display and discovery of peptide leads for drug development. Lowman HB. **Annu Rev Biophys Biomol Struct** 1997;26:401–24 (67 ref.)
Therapeutic peptides and peptidomimetics. Kieber–Emmons T, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):435–41 (56 ref.)
Phage display of combinatorial antibody libraries. Rader C, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):503–8 (47 ref.)
Combinatorial protein design: strategies for screening protein libraries. Zhao H, et al. **Curr Opin Struct Biol** 1997 Aug; 7(4):480–5 (49 ref.)
The potential of combinatorial peptide libraries for the identification of inhibitors of TNF–alpha mediated cytotoxicity in vitro. Partidos CD, et al. **Immunol Lett** 1997 Jun 1;57(1–3):113–6 (16 ref.)
Sequence–selective nonmacrocyclic two–armed receptors for peptides. Nestler HP. **Mol Divers** 1996 Oct;2(1–2):35–40 (18 ref.)
[Libraries as tools to explore the specificities of molecular interactions] Udaka K. **Seikagaku** 1997 May;69(5):339–43 (15 ref.) **(Jpn)**

PEPTIDE MAPPING

see related
PEPTIDE FRAGMENTS

Current challenges and future applications for protein maps and post–translational vector maps in proteome projects. Wilkins MR, et al. **Electrophoresis** 1996 May;17(5):830–8 (74 ref.)
Detection of pathological changes of proteins by peptide mapping after protein digestion by use of oriented immobilized proteinases. Turková J, et al. **J Mol Recognit** 1996 Sep–Dec;9(5–6):360–3 (15 ref.)
Mapping of HCG–receptor complexes. Remy JJ, et al. **Mol Cell Endocrinol** 1996 Dec 20;125(1–2):79–91 (51 ref.)

METHODS

New horizons in sequence analysis. Hubbard TJ. **Curr Opin Struct Biol** 1997 Apr;7(2):190–3 (33 ref.)
Trace analysis peptide mapping by high–performance displacement chromatography. Frenz J. **Methods Enzymol** 1996;271:486–504 (40 ref.)
Reversed–phase peptide mapping of glycoproteins using liquid chromatography/electrospray ionization–mass spectrometry. Hancock WS, et al. **Methods Enzymol** 1996; 271:403–27 (34 ref.)
Analytical peptide mapping of recombinant DNA–derived proteins by reversed–phase high–performance liquid chromatography. Hoff ER, et al. **Methods Enzymol** 1996; 271:51–68 (32 ref.)
Applications of capillary zone electrophoresis to peptide mapping. Rickard EC, et al. **Methods Enzymol** 1996; 271:237–64 (49 ref.)

PEPTIDE PEPTIDOHYDROLASE INHIBITORS see **PROTEASE INHIBITORS**

PEPTIDE PEPTIDOHYDROLASES

Virus–encoded proteinases of the picornavirus super–group. Ryan MD, et al. **J Gen Virol** 1997 Apr;78 (Pt 4):699–723 (179 ref.)
Growth factors, proteases and protease inhibitors in the maternal–fetal dialogue. Lala PK, et al. **Placenta** 1996 Nov; 17(8):545–55 (135 ref.)
[New function of proteases and protease inhibitors—aiming for development of new drug design] Yamamoto K, et al. **Nippon Yakurigaku Zasshi** 1996 Sep;108(3):135–7 (0 ref.) **(Jpn)**

BIOSYNTHESIS

[Collagenolytic enzymes synthesized by microorganisms] Demina NS, et al. **Mikrobiologiia** 1996 May–Jun; 65(3):293–304 (83 ref.) (Eng. Abstr.) **(Rus)**

PEPTIDE PEPTIDOHYDROLASES

BLOOD

Amyotrophic lateral sclerosis and antibodies to voltage-gated calcium channels--new doubts [editorial; comment] Vincent A, et al. **Ann Neurol** 1996 Nov;40(5):691-3 (15 ref.) Comment on: Ann Neurol 1996 Nov;40(5):695-700. Comment on: Ann Neurol 1996 Nov;40(5):701-6.

CHEMISTRY

Membrane protein secretases. Hooper NM, et al. **Biochem J** 1997 Jan 15;321 (Pt 2):265-79 (164 ref.)

Bypassing the ribosome: peptide synthesis without translation. Murphy A, et al. **Essays Biochem** 1996;31:61-75 (29 ref.)

Nonconventional protease catalysis in frozen aqueous solutions. Hänsler M, et al. **J Pept Sci** 1996 Sep-Oct; 2(5):279-89 (48 ref.)

Design of profluorescent protease substrates guided by exciton theory. Packard BZ, et al. **Methods Enzymol** 1997; 278:15-23 (65 ref.)

GENETICS

Regulation of programmed cell death by interleukin-1 beta-converting enzyme family of proteases. Miura M, et al. **Adv Exp Med Biol** 1996;389:165-72 (57 ref.)

Control of gene expression by proteolysis. Pahl HL, et al. **Curr Opin Cell Biol** 1996 Jun;8(3):340-7 (70 ref.)

ISOLATION & PURIFICATION

Separation of proteases: old and new approaches. Ibrahim-Granet O, et al. **J Chromatogr B Biomed Appl** 1996 Sep 20;684(1-2):239-63 (161 ref.)

METABOLISM

Proteinases from pollen and pests. Travis J, et al. **Acta Biochim Pol** 1996;43(3):411-7 (23 ref.)

Proteolytic cleavage of connectin/titin. Suzuki A, et al. **Adv Biophys** 1996;33:53-64 (48 ref.)

Endoprotease regulation of miniglucagon production. Bataille D, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:1-8; discussion 8-9 (12 ref.)

Proteases and their targets in Escherichia coli. Gottesman S. **Annu Rev Genet** 1996;30:465-506 (264 ref.)

Non-conventional enzyme catalysis: application of proteases and zymogens in biotransformations. Jakubke HD, et al. **Biol Chem** 1996 Jul-Aug;377(7-8):455-64 (49 ref.)

Retroviral proteases: structure, function and inhibition from a non-anticipated viral enzyme to the target of a most promising HIV therapy. von der Helm K. **Biol Chem** 1996 Dec;377(12):765-74 (97 ref.)

Pathogenic mechanisms induced by microbial proteases in microbial infections. Maeda H, et al. **Biol Chem Hoppe Seyler** 1996 Apr;377(4):217-26 (90 ref.)

Thermostable proteases. Daniel RM, et al. **Biotechnol Genet Eng Rev** 1996;13:51-100 (221 ref.)

Casein and peptide degradation in lactic acid bacteria. Mierau I, et al. **Biotechnol Genet Eng Rev** 1997;14:279-301 (125 ref.)

Description of two classes of proteinases from enamel extracellular matrix cleaving a recombinant amelogenin. Moradian-Oldak J, et al. **Connect Tissue Res** 1996; 35(1-4):231-8 (26 ref.)

Protein degradation: de-ubiquitinate to decide your fate. Kalderon D. **Curr Biol** 1996 Jun 1;6(6):662-5 (12 ref.)

Focalized proteolysis: spatial and temporal regulation of extracellular matrix degradation at the cell surface. Basbaum CB, et al. **Curr Opin Cell Biol** 1996 Oct;8(5):731-8 (63 ref.)

Control of gene expression by proteolysis. Pahl HL, et al. **Curr Opin Cell Biol** 1996 Jun;8(3):340-7 (70 ref.)

Proteases associated with invadopodia, and their role in degradation of extracellular matrix. Chen WT. **Enzyme Protein** 1996;49(1-3):59-71 (83 ref.)

Bypassing the ribosome: peptide synthesis without translation. Murphy A, et al. **Essays Biochem** 1996;31:61-75 (29 ref.)

Probing the partly folded states of proteins by limited proteolysis. Fontana A, et al. **Fold Des** 1997;2(2):R17-26 (105 ref.)

Structure-function relationship of type-IV prepilin peptidase of Pseudomonas aeruginosa--a review. Lory S, et al. **Gene** 1997 Jun 11;192(1):117-21 (26 ref.)

Protein quality control: triage by chaperones and proteases. Gottesman S, et al. **Genes Dev** 1997 Apr 1;11(7):815-23 (70 ref.)

Hypothesis: MHC class I, rather than just a flagpole for CD8+ T cells is also a protease in its own right. Müllbacher A. **Immunol Cell Biol** 1997 Jun;75(3):310-7 (61 ref.)

Acquired carbapenemases. Livermore DM. **J Antimicrob Chemother** 1997 Jun;39(6):673-6 (32 ref.)

The peptidolytic capacity of the spirochete system. Mäkinen KK, et al. **Med Microbiol Immunol (Berl)** 1996 May; 185(1):1-10 (78 ref.)

Characterization of neuropeptidases using inhibitors. Hooper NM. **Methods Mol Biol** 1997;73:369-81 (14 ref.)

Role of microbial proteases in pathogenesis. Maeda H. **Microbiol Immunol** 1996;40(10):685-99 (81 ref.)

Protein degradation by the proteasome and dissection of its in vivo importance with synthetic inhibitors. Goldberg AL, et al. **Mol Biol Rep** 1997 Mar;24(1-2):69-75 (32 ref.)

Regulation of proteasome structure and function. Rivett AJ, et al. **Mol Biol Rep** 1997 Mar;24(1-2):99-102 (33 ref.)

Proteinases and myocardial extracellular matrix turnover. Tyagi SC. **Mol Cell Biochem** 1997 Mar;168(1-2):1-12 (90 ref.)

Cell membrane-bound proteases: not "only" proteolysis. Sedo A, et al. **Physiol Res** 1996;45(3):169-76 (70 ref.)

Measurement of muscle proteolysis and the impact on muscle wasting. Nissen S. **Proc Nutr Soc** 1997 Jul;56(2):793-9 (26 ref.)

Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases. Fowlkes JL, et al. **Prog Growth Factor Res** 1995;6(2-4):255-63 (26 ref.)

Neutrophil proteinases and matrix degradation. The cell biology of pericellular proteolysis. Owen CA, et al. **Semin Cell Biol** 1995 Dec;6(6):367-76 (75 ref.)

Protease-activated G protein-coupled receptors on human platelets and endothelial cells. Brass LF, et al. **Thromb Haemost** 1997 Jul;78(1):234-41 (89 ref.)

Molecular crosstalk between adhesion receptors and proteolytic cascades in vascular remodelling. Preissner KT, et al. **Thromb Haemost** 1997 Jul;78(1):88-95 (114 ref.)

ATP-dependent proteases that also chaperone protein biogenesis. Suzuki CK, et al. **Trends Biochem Sci** 1997 Apr; 22(4):118-23 (48 ref.)

[The effect of Maillard reaction products on enzyme reactions] Schumacher D, et al. **Z Ernahrungswiss** 1996 Sep;35(3):213-25 (108 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Control of apoptosis by proteases. Thornberry NA, et al. **Adv Pharmacol** 1997;41:155-77 (152 ref.)

Effects of placental proteases on maternal and fetal blood pressure in normal pregnancy and preeclampsia. Mizutani S, et al. **Am J Hypertens** 1996 Jun;9(6):591-7 (39 ref.)

Nip and tuck at the neuromuscular junction: a role for proteases in developmental synapse elimination. Chang Q, et al. **Bioessays** 1997 Apr;19(4):271-5 (33 ref.)

Extracellular proteases in neuronal function and degeneration. Strickland S, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:739-45 (33 ref.)

The role of protein degradation in mitochondrial function and biogenesis. Rep M, et al. **Curr Genet** 1996 Nov; 30(5):367-80 (170 ref.)

Proteases in apoptosis. Zhivotovsky B, et al. **Experientia** 1996 Oct 31;52(10-11):968-78 (96 ref.)

The human sperm acrosome reaction: physiology and regulatory mechanisms. An update. Brucker C, et al. **Hum Reprod Update** 1995 Jan;1(1):51-62 (103 ref.)

Cytokines-adhesion molecules-invasive proteinases. The missing paracrine/autocrine link in embryonic implantation? Simón C, et al. **Mol Hum Reprod** 1996 Jun; 2(6):405-24 (262 ref.)

Insulin-like growth factor binding protein (IGFBP) proteases: functional regulators of cell growth. Rajah R, et al. **Prog Growth Factor Res** 1995;6(2-4):273-84 (49 ref.)

Protease-antiprotease interactions and the rationale for therapeutic protease inhibitors. Schmid S, et al. **Scand J Gastroenterol Suppl** 1996;219:47-50 (29 ref.)

The role of inflammatory cells and their proteases in extravascular fibrinolysis. Heiden M, et al. **Semin Thromb Hemost** 1996;22(6):497-501 (68 ref.)

Ectoenzymes as sites of peptide regulation. Konkoy CS, et al. **Trends Pharmacol Sci** 1996 Aug;17(8):288-94 (41 ref.)

The role of cell adhesion molecules and proteases in tumor invasion and metastasis. Bussemakers MJ, et al. **World J Urol** 1996;14(3):151-6 (63 ref.)

[Proteinase/antiproteinase balance in patients with cystic fibrosis] Welte T. **Pneumologie** 1996 Dec;50 Suppl 3:838-40 (16 ref.) **(Ger)**

[Proteases participating in metamorphosis of flesh fly (Sarcophaga peregrina)] Homma K. **Seikagaku** 1997 Apr; 69(4):259-64 (14 ref.) **(Jpn)**

[Spatial resolution of proteolytic reactions in brain ischemia and Alzheimer's disease] Saido TC. **Seikagaku** 1996 Sep; 68(9):1507-22 (73 ref.) **(Jpn)**

SECRETION

Functional implication of secretory proteases derived from microglia in the central nervous system. Kohsaka S, et al. **Keio J Med** 1996 Sep;45(3):263-9 (51 ref.)

Influence of high-dose antithrombin concentrate therapy on the release of cellular proteinases, cytokines, and soluble adhesion molecules in acute inflammation. Jochum M. **Semin Hematol** 1995 Oct;32(4 Suppl 2):19-32 (8 ref.)

PEPTIDE RECEPTORS see **RECEPTORS, PEPTIDE**

PEPTIDE SYNTHETASES

ANTAGONISTS & INHIBITORS

Exploitation of folate and antifolate polyglutamylation to achieve selective anticancer chemotherapy. McGuire JJ, et al. **Invest New Drugs** 1996;14(3):317-23 (28 ref.)

GENETICS

Molecular biology in nutrition research: modeling of folate metabolism. Lin BF, et al. **Adv Food Nutr Res** 1996; 40:95-106 (9 ref.)

METABOLISM

Molecular biology in nutrition research: modeling of folate metabolism. Lin BF, et al. **Adv Food Nutr Res** 1996; 40:95-106 (9 ref.)

Thiol template peptide synthesis systems in bacteria and fungi. Zocher R, et al. **Adv Microb Physiol** 1997;38:85-131 (120 ref.)

Role of folylpolygutamate synthetase (FPGS) in antifolate chemotherapy; a biochemical and clinical update. Synold TW, et al. **Leuk Lymphoma** 1996 Mar;21(1-2):9-15 (56 ref.)

Molecular interplay of murein synthases and murein hydrolases in Escherichia coli. Höltje JV. **Microb Drug Resist** 1996 Spring;2(1):99-103 (43 ref.)

PEPTIDE TERMINATION FACTORS

CHEMISTRY

Regulation of translation termination: conserved structural motifs in bacterial and eukaryotic polypeptide release factors. Nakamura Y, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11-12):1113-22 (38 ref.)

GENETICS

Termination of translation in eukaryotes. Kisselev LL, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11-12):1079-86 (34 ref.)

METABOLISM

Polypeptide chain release factors. Buckingham RH, et al. **Mol Microbiol** 1997 May;24(3):449-56 (54 ref.)

PHYSIOLOGY

Emerging understanding of translation termination. Nakamura Y, et al. **Cell** 1996 Oct 18;87(2):147-50 (20 ref.)

PEPTIDES

see related

AMINO ACID SEQUENCE

Adrenomedullin: view on a novel vasodilatory peptide with natriuretic properties. Massart PE, et al. **Acta Cardiol** 1996; 51(3):259-69 (53 ref.)

The CAG/polyglutamine tract diseases: gene products and molecular pathogenesis. Koshy BT, et al. **Brain Pathol** 1997 Jul;7(3):927-42 (157 ref.)

B27 polymorphism and peptide repertoire. Parham P. **Clin Rheumatol** 1996 Jan;15 Suppl 1:72-3 (20 ref.)

On the failure of de novo-designed peptides as biocatalysts. Corey MJ, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15; 93(21):11428-34 (114 ref.)

[Protein- and peptide-derived radiopharmaceuticals] Arano Y. **Kaku Igaku** 1996 Oct;33(10):1111-8 (27 ref.) (Eng. Abstr.) **(Jpn)**

[Vasoactive intestinal contractor (VIC)/mouse ET-2 and VIC receptor: biological activity, gene expression, and specific receptor] Saida K, et al. **Nippon Rinsho** 1996 Apr; 54(4):1115-21 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Peptide binding motif for HLA class I and autoimmune disease] Sakaguchi T, et al. **Nippon Rinsho** 1997 Jun; 55(6):1397-402 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Huntington's disease: trinucleotide disease or polyglutamine disease?] Ide K, et al. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1540-1 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Addition of sugar chains to peptide using endoglycosidase] Yamamoto K. **Seikagaku** 1996 Nov;68(11):1713-7 (14 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Kleiman NS. **Am J Cardiol** 1997 Aug 18; 80(4A):29B-33B (17 ref.)

Targeted delivery of peptides, proteins, and genes by receptor-mediated endocytosis. Kato Y, et al. **Crit Rev Ther Drug Carrier Syst** 1997;14(3):287-331 (156 ref.)

Systemic delivery of peptides and proteins across absorptive mucosae. Sayani AP, et al. **Crit Rev Ther Drug Carrier Syst** 1996;13(1-2):85-184 (323 ref.)

Advances and opportunities in delivery of therapeutic proteins and peptides. Banakar UV. **J Biomater Appl** 1997 Apr;11(4):377-429 (128 ref.)

Strategies for delivery of peptides utilizing absorption-enhancing agents. Fix JA. **J Pharm Sci** 1996 Dec;85(12):1282-5 (10 ref.)

Transdermal peptide delivery using electroporation. Potts RO, et al. **Pharm Biotechnol** 1997;10:213-38 (50 ref.)

ADVERSE EFFECTS

Cardiac tamponade following stent implantation with adjuvant platelet IIb/IIIa receptor inhibitor administration. Bottner RK, et al. **Cathet Cardiovasc Diagn** 1997 Apr; 40(4):380-2 (4 ref.)

Could schizophrenia be reasonably explained by Dohan's hypothesis on genetic interaction with a dietary peptide overload? Reichelt KL, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Oct; 20(7):1083-114 (205 ref.)

ANALYSIS

Analysis of derivatized peptides using high-performance liquid chromatography and capillary electrophoresis. De Antonis KM, et al. **Adv Chromatogr** 1997;37:425-52 (52 ref.)

Separation and analysis of peptides and proteins. Hühmer AF, et al. **Anal Chem** 1997 Jun 15;69(12):29R-57R (512 ref.)

Profiling of endogenous peptides as a tool for studying development and neurological disease. Slemmon JR, et al. **Biopolymers** 1997;43(2):157-70 (64 ref.)

Protein and peptide analysis by capillary zone electrophoresis and micellar electrokinetic chromatography. Szökö E. **Electrophoresis** 1997 Jan;18(1):74-81 (99 ref.)

Immunogold labelling of neuroendocrine peptides with special reference to antibody specificity and multiple staining techniques. Larsson LI. **Histochem Cell Biol** 1996 Jul;106(1):93-103 (73 ref.)

Mass spectrometry in the analysis of peptides and proteins, past and present. Roepstorff P. **Methods Mol Biol** 1996; 61:1-7 (16 ref.)

Benzophenone photoprobes for phosphoinositides, peptides and drugs. Prestwich GD, et al. **Photochem Photobiol** 1997 Feb;65(2):222-34 (95 ref.)

Direct identification of tumor-associated peptide antigens. Engelhard VH. **Springer Semin Immunopathol** 1996; 18(2):171-83 (83 ref.)

BIOSYNTHESIS

Formation of lipids, peptides and cytokines. Monteseirín J, et al. **Allergol Immunopathol (Madr)** 1996 Sep-Oct; 24(5):211-8 (110 ref.)

Synthesis of prenylated peptides and peptide esters. Naider FR, et al. **Biopolymers** 1997;43(1):3-14 (60 ref.)

Generation, intracellular transport and loading of peptides associated with MHC class I molecules. Koopmann JO, et al. **Curr Opin Immunol** 1997 Feb;9(1):80-8 (90 ref.)

Peptide antigen production by the proteasome: complexity provides efficiency. Groettrup M, et al. **Immunol Today** 1996 Sep;17(9):429-35 (75 ref.)

Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? Yewdell JW, et al. **J Immunol** 1996 Sep 1;157(5):1823-6 (21 ref.)

Enzymatic generation of complex peptides. Kleinkauf H, et al. **Prog Drug Res** 1997;48:27-53 (83 ref.)

BLOOD

Royal College of Physicians of Edinburgh/Royal College of Obstetricians and Gynaecologists consensus conference on anti-D prophylaxis 7 & 8 April 1997. Urbaniak SJ. **Transfus Med** 1997 Jun;7(2):143-4 (0 ref.)

[Are all animal and human organs and tissues endocrine in nature and are they secreting peptide hormones into blood?] Pankov IuA. **Vopr Med Khim** 1996 Jul-Sep;42(3):179-84 (13 ref.) (Eng. Abstr.) **(Rus)**

CHEMICAL SYNTHESIS

Synthesis, physicochemical and biological properties of poly-alpha-amino acids--the simplest of protein models. Katchalski-Katzir E. **Acta Biochim Pol** 1996;43(1):217-26 (35 ref.)

Perspectives on the synthesis and application of triple-helical, collagen-model peptides. Fields GB, et al. **Biopolymers** 1996;40(4):345-57 (70 ref.)

Design of peptide and polypeptide vaccines. Ben-Yedidia T, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):442-8 (66 ref.)

Bypassing the ribosome: peptide synthesis without translation. Murphy A, et al. **Essays Biochem** 1996;31:61-75 (29 ref.)

Proteinogenic amino acids labelled with 15N and/or 13C for application in peptide synthesis: a short review with a comprehensive list of published derivatives. Ragnarsson U. **J Pept Sci** 1995 May-Jun;1(3):149-56 (50 ref.)

CHEMISTRY

Synthesis, physicochemical and biological properties of poly-alpha-amino acids--the simplest of protein models. Katchalski-Katzir E. **Acta Biochim Pol** 1996;43(1):217-26 (35 ref.)

Supramolecular assembly using helical peptides. Fujita K, et al. **Adv Biophys** 1997;34:127-37 (20 ref.)

Primary structural motifs of Conus peptides. Cruz LJ. **Adv Exp Med Biol** 1996;391:155-67 (62 ref.)

Advances in tryptophan analysis in peptides and proteins. Molnár-Perl I. **Adv Exp Med Biol** 1996;398:635-48 (88 ref.)

Propeptide-mediated folding in subtilisin: the intramolecular chaperone concept. Shinde U, et al. **Adv Exp Med Biol** 1996;379:147-54 (35 ref.)

Methods to estimate the conformation of proteins and polypeptides from circular dichroism data. Greenfield NJ. **Anal Biochem** 1996 Mar 1;235(1):1-10 (44 ref.)

D-amino acids in animal peptides. Kreil G. **Annu Rev Biochem** 1997;66:337-45 (53 ref.)

Structural and mechanistic determinants of affinity and specificity of ligands discovered or engineered by phage display. Katz BA. **Annu Rev Biophys Biomol Struct** 1997; 26:27-45 (98 ref.)

M-factor, a farnesylated mating factor from the fission yeast Schizosaccharomyces pombe. Davey J. **Biochem Soc Trans** 1996 Aug;24(3):718-23 (48 ref.)

Analysis of hydrophobic proteins and peptides by electrospray ionization MS. Fearnley IM, et al. **Biochem Soc Trans** 1996 Aug;24(3):912-7 (16 ref.)

Chalcogen-analogs of amino acids. Their use in X-ray crystallographic and folding studies of peptides and proteins. Besse D, et al. **Biol Chem** 1997 Mar-Apr; 378(3-4):211-8 (40 ref.)

Use of the chemical structure of peptides as the starting point to design nonpeptide agonists and antagonists at peptide receptors: examples with cholecystokinin and tachykinins. Horwell DC. **Bioorg Med Chem** 1996 Oct;4(10):1573-6 (24 ref.)

The use of collagen-based model peptides to investigate platelet-reactive sequences in collagen. Barnes MJ, et al. **Biopolymers** 1996;40(4):383-97 (82 ref.)

Biophysical studies of lipopeptide-membrane interactions. Epand RM. **Biopolymers** 1997;43(1):15-24 (54 ref.)

NMR and x-ray studies of collagen model peptides. Mayo KH. **Biopolymers** 1996;40(4):359-70 (113 ref.)

Human matrix metalloproteinase specificity studies using collagen sequence-based synthetic peptides. Nagase H, et al. **Biopolymers** 1996;40(4):399-416 (101 ref.)

Bone marrow immunoregulatory peptides (myelopeptides): isolation, structure, and functional activity. Petrov RV, et al. **Biopolymers** 1997;43(2):139-46 (25 ref.)

Accommodating structurally diverse peptides in proteins. Wilkinson AJ. **Chem Biol** 1996 Jul;3(7):519-24 (23 ref.)

Therapeutic peptides and peptidomimetics. Kieber-Emmons T, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):435-41 (56 ref.)

Minimized proteins. Cunningham BC, et al. **Curr Opin Struct Biol** 1997 Aug;7(4):457-62 (23 ref.)

Interest of epitopic dissection in immunoanalysis of proteins and peptides: review of theoretical and practical aspects. Niccoli P, et al. **Eur J Clin Chem Clin Biochem** 1996 Sep; 34(9):741-8 (19 ref.)

Adding backbone to protein folding: why proteins are polypeptides. Honig B, et al. **Fold Des** 1996;1(1):R17-20 (35 ref.)

Surface-induced dissociation: an effective tool to probe structure, energetics and fragmentation mechanisms of protonated peptides. Dongré AR, et al. **J Mass Spectrom** 1996 Apr;31(4):339-50 (67 ref.)

Structure and functions of channel-forming peptides: magainins, cecropins, melittin and alamethicin. Bechinger B. **J Membr Biol** 1997 Apr 1;156(3):197-211 (262 ref.)

Fluorescence studies of zinc finger peptides and proteins. Eis PS. **Methods Enzymol** 1997;278:330-43 (32 ref.)

Peptide characterization by mass spectrometry. Gillece-Castro BL, et al. **Methods Enzymol** 1996; 271:427-48 (63 ref.)

Analysis of peptides by high-performance liquid chromatography. Mant CT, et al. **Methods Enzymol** 1996; 271:3-50 (129 ref.)

1H nuclear magnetic resonance (NMR) in the elucidation of peptide structure. Guthrie DJ. **Methods Mol Biol** 1997; 73:163-84 (25 ref.)

NMR studies of peptides and proteins associated with membranes. Klassen RB, et al. **Methods Mol Biol** 1997; 60:271-97 (68 ref.)

A case history. NMR studies of the structure of a small protein, omega-conotoxin MVIIA. MacLachlan LK, et al. **Methods Mol Biol** 1997;60:337-62 (38 ref.)

Charged derivatives for peptide sequencing using a magnetic sector instrument. Zaia J. **Methods Mol Biol** 1996;61:29-41 (29 ref.)

Penicillin and beyond: evolution, protein fold, multimodular polypeptides, and multiprotein complexes. Ghuysen JM, et al. **Microb Drug Resist** 1996 Summer;2(2):163-75 (42 ref.)

NMR spectroscopy of peptides and proteins. Practical considerations. Hinds MG, et al. **Mol Biotechnol** 1997 Jun; 7(3):315-31 (87 ref.)

Sequence-selective nonmacrocyclic two-armed receptors for peptides. Nestler HP. **Mol Divers** 1996 Oct;2(1-2):35-40 (18 ref.)

Oral controlled release technology for peptides: status and future prospects. Fix JA. **Pharm Res** 1996 Dec; 13(12):1760-4 (33 ref.)

Applications of the ion-pair concept to hydrophilic substances with special emphasis on peptides. Quintanar-Guerrero D, et al. **Pharm Res** 1997 Feb; 14(2):119-27 (53 ref.)

Acidic chromatin peptides. Molecular models and biological activity. Lugaro G, et al. **Physiol Chem Phys Med NMR** 1995;27(4):345-9 (8 ref.)

Rational design, analysis, and potential utility of GM-CSF antagonists. Monfardini C, et al. **Proc Assoc Am Physicians** 1996 Nov;108(6):420-31 (55 ref.)

Circular permutation of polypeptide chains: implications for protein folding and stability. Heinemann U, et al. **Prog Biophys Mol Biol** 1995;64(2-3):121-43 (98 ref.)

Design of alpha-helical peptides: their role in protein folding and molecular biology. Parthasarathy R, et al. **Prog Biophys Mol Biol** 1995;64(1):1-54 (205 ref.)

Conformation and design of peptides with alpha,beta-dehydro-amino acid residues. Singh TP, et al. **Prog Biophys Mol Biol** 1996;66(2):141-65 (96 ref.)

PNA-nucleic acid complexes. Structure, stability and dynamics. Eriksson M, et al. **Q Rev Biophys** 1996 Dec; 29(4):369-94 (42 ref.)

PR-39, a proline-rich peptide antibiotic from pig, and FALL-39, a tentative human counterpart. Agerberth B, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1-4):127-31 (19 ref.)

DIAGNOSTIC USE

Radiolabeled peptides and other ligands for receptors overexpressed in tumor cells for imaging neoplasms. McAfee JG, et al. **Nucl Med Biol** 1996 Aug;23(6):673-6 (36 ref.)

Pharmacokinetic considerations in the development of peptide-based imaging agents. Lister-James J, et al. **Q J Nucl Med** 1997 Jun;41(2):111-8 (17 ref.)

GENETICS

Comparison of functional peptide encoded in the Escherichia coli 23S rRNA with other peptides involved in cis-regulation of translation. Tenson T, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11-12):1061-70 (40 ref.)

Expanded glutamines and neurodegeneration--a gain of insight. Bates G. **Bioessays** 1996 Mar;18(3):175-8 (33 ref.)

Toward understanding the molecular pathology of Huntington's disease. Wellington CL, et al. **Brain Pathol** 1997 Jul;7(3):979-1002 (188 ref.)

Toward understanding polyglutamine-induced neurological disease in spinocerebellar ataxia type 1. Orr HT, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:649-57 (47 ref.)

Polyglutamine expansions and neurodegenerative diseases. Saudou F, et al. **Cold Spring Harb Symp Quant Biol** 1996; 61:639-47 (46 ref.)

Regulation of salivary-gland-specific gene expression. Ann DK, et al. **Crit Rev Oral Biol Med** 1997;8(3):244-52 (62 ref.)

Is it possible to construct phylogenetic trees using polypeptide hormone sequences? Dores RM, et al. **Gen Comp Endocrinol** 1996 Jul;103(1):1-12 (78 ref.)

Selection of proteins and peptides from libraries displayed on filamentous bacteriophage. McGregor D. **Mol Biotechnol** 1996 Oct;6(2):155-62 (54 ref.)

Trefoil peptides in the defense of the gastrointestinal tract. Plaut AG. **N Engl J Med** 1997 Feb 13;336(7):506-7 (4 ref.)

IMMUNOLOGY

Immunomodulation with T cell reactive peptides. Wallner BP, et al. **Adv Exp Med Biol** 1996;409:231-40 (47 ref.)

Peptide induced anergy of human allergen-specific T cells. Yssel H, et al. **Adv Exp Med Biol** 1996;409:405-10 (30 ref.)

Recognition of tumor-associated antigens by T-lymphocytes: perspectives for peptide-based vaccines. Cerottini JC, et al. **Ann Oncol** 1996 Apr;7(4):339-42 (52 ref.)

Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Sloan-Lancaster J, et al. **Annu Rev Immunol** 1996;14:1-27 (81 ref.)

Antigenic peptides and autoimmunity. Sinigaglia F, et al. **APMIS** 1997 Feb;105(2):81-8 (38 ref.)

Immunology: keeping mother at bay. Parham P. **Curr Biol** 1996 Jun 1;6(6):638-41 (18 ref.)

Generation, intracellular transport and loading of peptides associated with MHC class I molecules. Koopmann JO, et al. **Curr Opin Immunol** 1997 Feb;9(1):80-8 (90 ref.)

Peptide-based cancer vaccines. Melief CJ, et al. **Curr Opin Immunol** 1996 Oct;8(5):651-7 (66 ref.)

Different roles of D-amino acids in immune phenomena. Sela M, et al. **FASEB J** 1997 May;11(6):449-56 (79 ref.)

Peptide-MHC complexes assembled following multiple pathways: an opportunity for the design of vaccines and therapeutic molecules. Corradin G, et al. **Hum Immunol** 1997 May;54(2):137-47 (106 ref.)

Minor histocompatibility antigens: from T cell recognition to peptide identification [editorial] Goulmy E. **Hum Immunol** 1997 Apr 15;54(1):8-14 (63 ref.)

How HLA-DM affects the peptide repertoire bound to HLA-DR molecules. Vogt AB, et al. **Hum Immunol** 1997 May;54(2):170-9 (69 ref.)

In thymic selection, peptide diversity gives and takes away. Bevan MJ. **Immunity** 1997 Aug;7(2):175-8 (16 ref.)

MHC class I-restricted CTL responses to exogenous antigens. Jondal M, et al. **Immunity** 1996 Oct;5(4):295-302 (140 ref.)

Peptide-mediated regulation of the allergic immune response. Hoyne GF, et al. **Immunol Cell Biol** 1996 Apr;74(2):180-6 (88 ref.)

Peptide binding function and the paradox of HLA disease associations. Hughes AL, et al. **Immunol Cell Biol** 1996 Oct;74(5):444-8 (31 ref.)

Class I HLA-restricted cytotoxic T lymphocyte responses against malaria--elucidation on the basis of HLA peptide binding motifs. Doolan DL, et al. **Immunol Res** 1996; 15(4):280-305 (180 ref.)

T-cell recognition of self peptides as tumor rejection antigens. Kawakami Y, et al. **Immunol Res** 1996; 15(3):179-90 (51 ref.)

Peptide selection for presentation by HLA class I: a role for the human transporter associated with antigen processing? van Endert PM. **Immunol Res** 1996; 15(4):265-79 (34 ref.)

The role of peptide specificity in MHC class I-restricted allogeneic responses. Frelinger JA, et al. **Immunol Rev** 1996 Dec;154:45-58 (48 ref.)

Presentation of HLA class I-derived peptides: potential involvement in allorecognition and HLA-B27-associated

arthritis. Parham P. **Immunol Rev** 1996 Dec;154:137–54 (70 ref.)
The role of endogenous peptides in the direct pathway of alloreactivity to human MHC class II molecules expressed on CHO cells. Pawelec G, et al. **Immunol Rev** 1996 Dec; 154:155–73 (53 ref.)
(Altered) self peptides and the regulation of self reactivity in the peripheral T cell pool. Van Eden W, et al. **Immunol Rev** 1996 Feb;149:55–73 (44 ref.)
Indirect T-cell allorecognition: perspectives for peptide-based therapy in transplantation. Benichou G, et al. **Immunol Today** 1997 Feb;18(2):67–71 (34 ref.)
How HLA-DM edits the MHC class II peptide repertoire: survival of the fittest? Kropshofer H, et al. **Immunol Today** 1997 Feb;18(2):77–82 (35 ref.)
Could endogenous self-peptides presented by dendritic cells initiate rheumatoid arthritis? Thomas R, et al. **Immunol Today** 1996 Dec;17(12):559–64 (39 ref.)
Structure of HLA molecules and immunosuppressive effects of HLA derived peptides. Krensky AM, et al. **Int Rev Immunol** 1996;13(3):173–85 (56 ref.)
Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? Yewdell JW, et al. **J Immunol** 1996 Sep 1;157(5):1823–6 (21 ref.)
The influence of two distinct alloresponse pathways on the design of peptide-based strategies for allograft tolerance. Benichou G, et al. **Res Immunol** 1996 Jul–Aug; 147(6):377–87 (50 ref.)
The nature of the peptide/MHC ligand involved in positive selection. Hogquist KA, et al. **Semin Immunol** 1996 Apr; 8(2):63–8 (31 ref.)
Endogenous peptides associated with MHC class II and selection of CD4 T cells. Rudensky AY. **Semin Immunol** 1995 Dec;7(6):399–409 (84 ref.)
Antigen analogs as tools to study T-cell activation function and activation. Sette A, et al. **Semin Immunol** 1996 Apr; 8(2):103–8 (29 ref.)
The effect of endogenous altered peptide ligands on peripheral T-cell responses. Vidal K, et al. **Semin Immunol** 1996 Apr;8(2):117–22 (44 ref.)
Tumor antigens and tumor vaccines: peptides as immunogens. Slingluff CL Jr. **Semin Surg Oncol** 1996 Nov–Dec; 12(6):446–53 (89 ref.)
Direct identification of tumor-associated peptide antigens. Engelhard VH. **Springer Semin Immunopathol** 1996; 18(2):171–83 (83 ref.)

ISOLATION & PURIFICATION

Purification of heat shock protein–peptide complexes for use in vaccination against cancers and intracellular pathogens. Srivastava PK. **Methods** 1997 Jun;12(2):165–71 (24 ref.)

METABOLISM

Mechanism of class I assembly with beta 2 microglobulin and loading with peptide. Hansen TH, et al. **Adv Immunol** 1997;64:105–37 (170 ref.)
Antigen-specific T-cell receptors and their reactions with complexes formed by peptides with major histocompatibility complex proteins. Eisen HN, et al. **Adv Protein Chem** 1996;49:1–56 (227 ref.)
Cellular and molecular mechanisms of renal peptide transport. Daniel H, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):F1–8 (72 ref.)
Modular peptide recognition domains in eukaryotic signaling. Kuriyan J, et al. **Annu Rev Biophys Biomol Struct** 1997; 26:259–88 (102 ref.)
The proteolytic systems of lactic acid bacteria. Kunji ER, et al. **Antonie Van Leeuwenhoek** 1996 Oct;70(2–4):187–221 (186 ref.)
The extrinsic polypeptides of Photosystem II. Seidler A. **Biochim Biophys Acta** 1996 Nov 12;1277(1–2):35–60 (247 ref.)
Peptide binding by class I and class II MHC molecules. Batalia MA, et al. **Biopolymers** 1997;43(4):281–302 (74 ref.)
Peptide binding and antigen presentation by class II histocompatibility glycoproteins. Jensen PE. **Biopolymers** 1997;43(4):303–22 (160 ref.)
Casein and peptide degradation in lactic acid bacteria. Mierau I, et al. **Biotechnol Genet Eng Rev** 1997;14:279–301 (125 ref.)
Structure-function analysis of the cloned opiate receptors: peptide and small molecule interactions. Blake AD, et al. **Chem Biol** 1996 Dec;3(12):967–72 (28 ref.)
Kinesis of polypeptide during GroEL-mediated folding. Horwich AL, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:435–40 (35 ref.)
Molecular chaperones: clasping the prize. Gething MJ. **Curr Biol** 1996 Dec 1;6(12):1573–6 (19 ref.)
Kinase connections on the cellular intranet. Signalling pathways. Pelech SL. **Curr Biol** 1996 May 1;6(5):551–4 (19 ref.)
Bypassing the ribosome: peptide synthesis without translation. Murphy A, et al. **Essays Biochem** 1996;31:61–75 (29 ref.)
Polypeptide translocation machinery of the yeast endoplasmic reticulum. Lyman SK, et al. **Experientia** 1996 Dec 15;52(12):1042–9 (63 ref.)
Rolling in the clover: trefoil factor family (TFF)-domain peptides, cell migration and cancer. Wright NA, et al. **FEBS Lett** 1997 May 19;408(2):121–3 (20 ref.)
Heavy metal detoxification in higher plants--a review. Zenk MH. **Gene** 1996 Nov 7;179(1):21–30 (40 ref.)
Biochemical markers of bone turnover. Crofton PM, et al. **Horm Res** 1996;45 Suppl 1:55–8 (10 ref.)
In thymic selection, peptide diversity gives and takes away. Bevan MJ. **Immunity** 1997 Aug;7(2):175–8 (16 ref.)
How HLA-DM edits the MHC class II peptide repertoire: survival of the fittest? Kropshofer H, et al. **Immunol Today** 1997 Feb;18(2):77–82 (35 ref.)
Why do superantigens care about peptides? Woodland DL, et al. **Immunol Today** 1997 Jan;18(1):18–22 (52 ref.)
Tyrosine protein kinase assays. Boutin JA. **J Chromatogr B Biomed Appl** 1996 Sep 20;684(1–2):179–99 (160 ref.)
Function and molecular structure of brush border membrane peptide/H+ symporters. Daniel H. **J Membr Biol** 1996 Dec;154(3):197–203 (68 ref.)
How structural features influence the biomembrane permeability of peptides. Burton PS, et al. **J Pharm Sci** 1996 Dec;85(12):1336–40 (55 ref.)
Quorum sensing by peptide pheromones and two-component signal-transduction systems in Gram-positive bacteria. Kleerebezem M, et al. **Mol Microbiol** 1997 Jun; 24(5):895–904 (38 ref.)
Peptides and growth factors in non-small cell lung cancer. Moody TW. **Peptides** 1996;17(3):545–55 (151 ref.)
Models for investigation of peptide and protein transport across cultured mammalian respiratory epithelial barriers. Kim KJ, et al. **Pharm Biotechnol** 1996;8:325–46 (155 ref.)
Phosphorylation of acidic peptides by protein kinase CKII. Cardellini E, et al. **Physiol Chem Phys Med NMR** 1995; 27(4):363–8 (6 ref.)
Intracellular organelles involved in antigen processing and the binding of peptides to class II MHC molecules. Harding CV. **Semin Immunol** 1995 Dec;7(6):355–60 (77 ref.)
[Heart failure and circulatory peptides] Hirata Y. **Nippon Naika Gakkai Zasshi** 1994 Jan 10;83(1):9–15 (8 ref.) **(Jpn)**
[Coupled transbilayer transport of peptides, lipids, and ions mediated by a peptide–lipid supramolecular complex pore] Matsuzaki K, et al. **Seikagaku** 1997 Feb;69(2):119–22 (14 ref.) **(Jpn)**
[Leukotriene A4 hydrolase: a bifunctional enzyme acts toward two different types of cellular compounds, lipids and peptides] Minami M, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(6):825–33 (42 ref.) **(Jpn)**
[Biochemical basis of enteral nutrition] Freitas O, et al. **Arch Latinoam Nutr** 1995 Jun;45(2):84–9 (67 ref.) (Eng. Abstr.) **(Por)**

PHARMACOKINETICS

Pharmacokinetics of allergens after local administration. Falagiani P, et al. **Allergy** 1997;52(33 Suppl):17–21 (17 ref.)
Oral delivery of antibodies. Future pharmacokinetic trends. Reilly RM, et al. **Clin Pharmacokinet** 1997 Apr; 32(4):313–23 (53 ref.)
Hepatobiliary elimination of certain peptide-mimicking drugs: linear hydrophobic and hydrophilic renin-inhibitors and hydrophobic cyclopeptides. Ziegler K, et al. **J Hepatol** 1996;24 Suppl 1:47–52 (22 ref.)
Current concepts in intestinal peptide absorption. Fricker G, et al. **J Pept Sci** 1996 Jul–Aug;2(4):195–211 (209 ref.)
The blood–brain barrier: principles for targeting peptides and drugs to the central nervous system. Begley DJ. **J Pharm Pharmacol** 1996 Feb;48(2):136–46 (47 ref.)
Chemical approaches to improve the oral bioavailability of peptidergic molecules. Samanen J, et al. **J Pharm Pharmacol** 1996 Feb;48(2):119–35 (68 ref.)
Passage of peptides across the blood-brain barrier: pathophysiological perspectives. Banks WA, et al. **Life Sci** 1996;59(23):1923–43 (181 ref.)
Some approaches to improve bioavailability of peptides and proteins through oral and other mucosal routes. Vyas SP, et al. **Pharmazie** 1997 May;52(5):339–45 (67 ref.)
Pharmacokinetic considerations in the development of peptide-based imaging agents. Lister-James J, et al. **Q J Nucl Med** 1997 Jun;41(2):111–8 (17 ref.)
Small peptides radiolabeled with 99mTc. Lister-James J, et al. **Q J Nucl Med** 1996 Sep;40(3):221–33 (34 ref.)
Receptor ligands. Signore A. **Q J Nucl Med** 1995 Dec;39(4 Suppl 1):83–5 (8 ref.)

PHARMACOLOGY

Clinical pharmacology of eptifibatide. Phillips DR, et al. **Am J Cardiol** 1997 Aug 18;80(4A):11B–20B (70 ref.)
Application of peptide nucleic acid in cancer therapy. Knudsen H, et al. **Anticancer Drugs** 1997 Feb;8(2):113–8 (57 ref.)
Bone marrow immunoregulatory peptides (myelopeptides): isolation, structure, and functional activity. Petrov RV, et al. **Biopolymers** 1997;43(2):139–46 (25 ref.)
Selective peptidic and peptidomimetic inhibitors of Candida albicans myristoylCoA: protein N-myristoyltransferase: a new approach to antifungal therapy. Sikorski JA, et al. **Biopolymers** 1997;43(1):43–71 (58 ref.)
Selection of biologically active peptides by phage display of random peptide libraries. Cortese R, et al. **Curr Opin Biotechnol** 1996 Dec;7(6):616–21 (41 ref.)
Synthetic peptides derived from human MHC class I sequences delay allograft rejection in rodents and inhibit cell-mediated cytotoxicity in vivo and in vitro. Cuturi MC, et al. **Immunol Rev** 1996 Dec;154:5–20 (56 ref.)
The responses of mature T cells are not necessarily antagonized by their positively selecting peptide. Ignatowicz L, et al. **J Immunol** 1996 Sep 1;157(5):1827–31 (33 ref.)
New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis. Arnon R, et al. **J Neurol** 1996 Apr;243(4 Suppl 1):S8–13 (28 ref.)
Trefoil peptides: what are they and what do they do? Playford RJ. **J R Coll Physicians Lond** 1997 Jan–Feb; 31(1):37–41 (25 ref.)
Receptor biology of the melanocortins, a family of neuroimmunomodulatory peptides. Tatro JB. **Neuroimmunomodulation** 1996 Sep–Oct;3(5):259–84 (224 ref.)
Antigen analogs as tools to study T-cell activation function and activation. Sette A, et al. **Semin Immunol** 1996 Apr; 8(2):103–8 (29 ref.)
The effect of endogenous altered peptide ligands on peripheral T-cell responses. Vidal K, et al. **Semin Immunol** 1996 Apr;8(2):117–22 (44 ref.)
[Molecular action mechanisms and membrane recognition of membrane-acting antimicrobial peptides] Matsuzaki K. **Yakugaku Zasshi** 1997 May;117(5):253–64 (30 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

The role of polypeptide growth factors in recovery from stroke. Kawamata T, et al. **Adv Neurol** 1997;73:377–82 (30 ref.)
Peptidergic mechanisms of action in the suprachiasmatic nucleus. Huhman KL, et al. **Ann N Y Acad Sci** 1997 Apr 24;814:300–4 (40 ref.)
Endogenous vertebrate antibiotics. Defensins, protegrins, and other cysteine-rich antimicrobial peptides. Lehrer RI, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:228–39 (55 ref.)
Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Sloan-Lancaster J, et al. **Annu Rev Immunol** 1996;14:1–27 (81 ref.)
Regulatory peptides in the control of metabolism during starvation and exercise. Buchanan KD, et al. **Biochem Soc Trans** 1996 May;24(2):591–3 (25 ref.)
Pancreatic B-cells as mediators of metabolic effects of regulatory peptides. Flatt PR. **Biochem Soc Trans** 1996 May;24(2):570–5 (33 ref.)
Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: a peptide superfamily. Wimalawansa SJ. **Crit Rev Neurobiol** 1997;11(2–3):167–239 (606 ref.)
Insect physiology: the emerging story of ecdysis. Hesterlee S, et al. **Curr Biol** 1996 Jun 1;6(6):648–50 (9 ref.)
Adrenomedullin--physiological regulator of the cardiovascular system or biochemical curiosity? Kitamura K, et al. **Curr Opin Nephrol Hypertens** 1997 Jan;6(1):80–7 (89 ref.)
Adrenomedullin: a new peptide involved in cardiorenal homeostasis? Edwards RM, et al. **Exp Nephrol** 1997 Jan–Feb;5(1):18–22 (25 ref.)
Different roles of D-amino acids in immune phenomena. Sela M, et al. **FASEB J** 1997 May;11(6):449–56 (79 ref.)
Guanylin: where it's at! Why's it there? [editorial; comment] Semrad CE. **Gastroenterology** 1997 Sep;113(3):1036–8 (29 ref.) Comment on: Gastroenterology 1997 Sep;113(3):1000–6. Comment on: Gastroenterology 1997 Sep;113(3):1007–14.
Peptide hormone regulation of islet cells. D'Alessio D. **Horm Metab Res** 1997 Jun;29(6):297–300 (32 ref.)
Peptide growth factors and preimplantation development. Kane MT, et al. **Hum Reprod Update** 1997 Mar–Apr; 3(2):137–57 (363 ref.)
Knob proteins in falciparum malaria. Sharma YD. **Indian J Med Res** 1997 Aug;106:53–62 (55 ref.)
Peptide regulation of intestinal glucose absorption. Bird AR, et al. **J Anim Sci** 1996 Oct;74(10):2523–40 (267 ref.)
Bioactive peptides in digesta that regulate gastrointestinal function and intake. Froetschel MA. **J Anim Sci** 1996 Oct; 74(10):2500–8 (87 ref.)
Adrenomedullin: a new modulator of vascular tone. Kangawa K, et al. **J Card Fail** 1996 Dec;2(4 Suppl):S135–40 (28 ref.)
Franz Volhard Lecture 1996. Sodium transport inhibitors and hypertension. de Wardener HE. **J Hypertens Suppl** 1996 Dec;14(5):S9–18 (101 ref.)
Adrenomedullin: a new hypotensive peptide. Kangawa K, et al. **J Hypertens Suppl** 1996 Dec;14(5):S105–10 (29 ref.)
Peptide growth factors and the adrenal cortex. Ho MM, et al. **Microsc Res Tech** 1997 Mar 15;36(6):558–68 (183 ref.)
Peptide growth factors: clinical and therapeutic strategies [editorial] Di Silverio F, et al. **Minerva Urol Nefrol** 1997 Jun;49(2):63–72 (43 ref.)
Trefoil peptides in the defense of the gastrointestinal tract. Plaut AG. **N Engl J Med** 1997 Feb 13;336(7):506–7 (4 ref.)
Polypeptide growth factors in the nucleus: a review of function and translocation. Levine JE, et al. **Neuroimmunomodulation** 1995 Sep–Oct;2(5):290–8 (72 ref.)
Regulation of oligodendrocyte cell survival and differentiation by ciliary neurotrophic factor, leukemia inhibitory factor, oncostatin M, and interleukin-6. Vos JP, et al. **Perspect Dev Neurobiol** 1996;4(1):39–52 (133 ref.)
Acidic chromatin peptides. Molecular models and biological activity. Lugaro G, et al.

Physiol Chem Phys Med NMR 1995;27(4):345–9 (8 ref.)
Polypeptide signaling for plant defensive genes exhibits analogies to defense signaling in animals. Bergey DR, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12053–8 (44 ref.)
Adrenomedullin: a novel cardiovascular regulatory peptide. Hanna FW, et al. **QJM** 1996 Dec;89(12):881–4 (26 ref.)
The role of anchoring protein RACK1 in PKC activation in the ageing rat brain. Battaini F, et al. **Trends Neurosci** 1997 Sep;20(9):410–5 (72 ref.)
Peptide YY and neuropeptide Y: two peptides intimately involved in electrolyte homeostasis. Playford RJ, et al. **Trends Pharmacol Sci** 1996 Dec;17(12):436–8 (41 ref.)
Signal transduction pathways combining peptide hormones and steroidogenesis. Waterman MR, et al. **Vitam Horm** 1996;52:129–48 (62 ref.)
[The intestinal hormone glucagon-like peptide 1 (GLP-1): from experiment to the clinic] Göke B, et al. **Z Gastroenterol** 1997 Apr;35(4):285–94 (62 ref.) (Eng. Abstr.) **(Ger)**
[Heart failure and circulatory peptides] Hirata Y. **Nippon Naika Gakkai Zasshi** 1994 Jan 10;83(1):9–15 (8 ref.) **(Jpn)**

SECRETION

Unusual peptide-secreting tumors in adolescents and children. Schwartz MZ. **Semin Pediatr Surg** 1997 Aug; 6(3):141–6 (19 ref.)

THERAPEUTIC USE

Clinical experience with treatment of allergies with T cell epitope containing peptides. Norman PS. **Adv Exp Med Biol** 1996;409:457–61 (13 ref.)
Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. Harrington RA. **Am J Cardiol** 1997 Aug 18; 80(4A):34B–38B (27 ref.)
Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Tcheng JE. **Am J Cardiol** 1997 Aug 18;80(4A):21B–28B (15 ref.)
Copolymer 1: from basic research to clinical application. Teitelbaum D, et al. **Cell Mol Life Sci** 1997 Jan;53(1):24–8 (22 ref.)
Therapeutic peptides and peptidomimetics. Kieber-Emmons T, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):435–41 (56 ref.)
Newer versus older treatments for relapsing-remitting multiple sclerosis. Weinstock-Guttman B, et al. **Drug Saf** 1996 Feb;14(2):121–30 (22 ref.)
Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor. Ohman EM, et al. **Eur Heart J** 1995 Nov;16 Suppl L:50–5 (35 ref.)
Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. Nauck MA, et al. **Exp Clin Endocrinol Diabetes** 1997;105(4):187–95 (81 ref.)
The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections. Arnon R. **Immunol Lett** 1996 Apr;50(1–2):1–15 (67 ref.)
Indirect T-cell allorecognition: perspectives for peptide-based therapy in transplantation. Benichou G, et al. **Immunol Today** 1997 Feb;18(2):67–71 (34 ref.)
Cop 1 as a candidate drug for multiple sclerosis. Teitelbaum D, et al. **J Neural Transm Suppl** 1997;49:85–91 (29 ref.)
A review of the clinical efficacy profile of copolymer 1: new U.S. phase III trial data. Johnson KP. **J Neurol** 1996 Apr; 243(4 Suppl 1):S3–7 (15 ref.)
Immunomodulatory peptides with high binding affinity for class II MHC molecules for the prevention of graft-versus-host disease. Schlegel PG, et al. **Leuk Lymphoma** 1996 Sep;23(1–2):11–6 (47 ref.)
[Modern "antiplatelet agents" in unstable angina] Vahanian A, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1521–6 (27 ref.) (Eng. Abstr.) **(Fre)**
[Cancer vaccine therapy using peptides derived from tumor-rejection antigens] Akiyoshi T. **Gan To Kagaku Ryoho** 1997 Mar;24(5):511–9 (38 ref.) (Eng. Abstr.) **(Jpn)**

PEPTIDES, CYCLIC

CHEMICAL SYNTHESIS

A review of the design, synthesis and biological activity of the bicyclic hexapeptide tachykinin NK2 antagonist MEN 10627. Quartara L, et al. **Regul Pept** 1996 Aug 27;65(1):55–9 (29 ref.)

CHEMISTRY

Cyclopeptide alkaloids [published erratum appears in Nat Prod Rep 1997 Aug;14(4):432] Gournelis DC, et al. **Nat Prod Rep** 1997 Feb;14(1):75–82 (75 ref.)
[Tentoxin: structure-activity relationship. Application to the study of its action on chloroplast ATP-synthase] André F, et al. **C R Seances Soc Biol Fil** 1997;191(3):401–32 (124 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Lipopeptide inhibitors of fungal glucan synthase. Kurtz MB, et al. **J Med Vet Mycol** 1997 Mar-Apr;35(2):79–86 (52 ref.)
[Endothelial receptor antagonists] Bornkessel B. **Med Monatsschr Pharm** 1997 Jul;20(7):174–6 (3 ref.) **(Ger)**

THERAPEUTIC USE

[Lanreotide++: a new therapeutic option in acromegaly] Díez JJ. **Med Clin (Barc)** 1996 Sep 7;107(7):257–69 (200 ref.) **(Spa)**

PEPTIDOGLYCAN

BIOSYNTHESIS

Biosynthesis of bacterial peptidoglycan. Kłoszewska M. **Acta Microbiol Pol** 1996;45(2):119–30 (17 ref.)
Bacterial cell surface carbohydrates: structure and assembly. Hancock IC. **Biochem Soc Trans** 1997 Feb;25(1):183–7 (40 ref.)
Molecular interplay of murein synthases and murein hydrolases in Escherichia coli. Höltje JV. **Microb Drug Resist** 1996 Spring;2(1):99–103 (43 ref.)

METABOLISM

Peptidoglycan as a barrier to transenvelope transport. Dijkstra AJ, et al. **J Bacteriol** 1996 Oct;178(19):5555–62 (102 ref.)
beta-Lactamase induction in gram-negative bacteria is intimately linked to peptidoglycan recycling. Normark S. **Microb Drug Resist** 1995 Summer;1(2):111–4 (25 ref.)
The convergence of murein recycling research with beta-lactamase research. Park JT. **Microb Drug Resist** 1996 Spring;2(1):105–12 (20 ref.)

PEPTIDYL-DIPEPTIDASE A

BIOSYNTHESIS

Tissue repair and angiotensin II generated at sites of healing. Weber KT, et al. **Basic Res Cardiol** 1997 Apr;92(2):75–8 (10 ref.)

BLOOD

Effects of early captopril treatment and its removal on plasma angiotensin converting enzyme (ACE) activity and arginine vasopressin in hypertensive rats (SHR) and normotensive rats (WKY). Zhang L, et al. **Clin Exp Hypertens** 1996 Feb; 18(2):201–26 (51 ref.)

DEFICIENCY

Lessons from angiotensin-converting enzyme-deficient mice. Esther CR Jr, et al. **Curr Opin Nephrol Hypertens** 1996 Nov;5(6):463–7 (48 ref.)

GENETICS

Molecular biology and genetics of the angiotensin-I-converting enzyme: potential implications in cardiovascular diseases [see comments] Villard E, et al. **Cardiovasc Res** 1996 Dec;32(6):999–1007 (83 ref.) Comment in: Cardiovasc Res 1996 Dec;32(6):998.
Angiotensin-converting enzyme gene polymorphism. What to do about all the confusion [editorial] [see comments] Singer DR, et al. **Circulation** 1996 Aug 1;94(3):236–9 (43 ref.) Comment in: Circulation 1997 Aug 5;96(3):1050–2.
Genetics of angiotensin I-converting enzyme. Costerousse O, et al. **Clin Exp Hypertens** 1997 Jul-Aug;19(5–6):659–69 (54 ref.)
Hypothesis: an angiotensin converting enzyme genotype, present in one in three caucasians, is associated with increased mortality rate [published erratum appears in Clin Exp Pharmacol Physiol 1996 May;23(5):447] Morris BJ. **Clin Exp Pharmacol Physiol** 1996 Jan;23(1):1–10 (81 ref.)
The role of angiotensin I-converting enzyme gene polymorphism in renal disease. Schmidt S, et al. **Curr Opin Nephrol Hypertens** 1996 Nov;5(6):552–5 (26 ref.)
Genetics of the renin-angiotensin system and renal disease: a progress report. Schmidt S, et al. **Curr Opin Nephrol Hypertens** 1997 Mar;6(2):146–51 (57 ref.)
Angiotensin I converting enzyme gene polymorphism and coronary heart disease. Cambien F, et al. **Eur Heart J** 1995 Nov;16 Suppl K:13–22 (84 ref.)
The role of genetic variants in angiotensin I converting enzyme, angiotensinogen and the angiotensin II type-1 receptor in the pathophysiology of heart muscle disease. Raynolds MV, et al. **Eur Heart J** 1995 Nov;16 Suppl K:23–30 (85 ref.)
Diabetic nephropathy: the ACE hypothesis. Marre M. **J Diabetes Complications** 1996 May-Jun;10(3):126–8 (28 ref.)
Angiotensin I-converting enzyme insertion/deletion polymorphism: potential significance in nephrology. Kitamura H, et al. **Kidney Int Suppl** 1996 Jun;55:S101–3 (21 ref.)
[The polymorphism of the angiotensin I-converting enzyme gene and its association with ischemic cardiopathy] Calviño Santos R, et al. **Rev Esp Cardiol** 1996 Dec;49(12):863–8 (36 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Angiotensin-converting enzyme-independent pathways of angiotensin II formation in human tissues and cardiovascular diseases. Urata H, et al. **Blood Press Suppl** 1996;2:22–8 (49 ref.)
Angiotensin I converting enzyme and chymase in cardiovascular tissues. Nishimura H, et al. **Kidney Int Suppl** 1996 Jun;55:S18–23 (63 ref.)

PEPTIDYL TRANSFERASES

CHEMISTRY

Antibiotic inhibition of the movement of tRNA substrates through a peptidyl transferase cavity. Porse BT, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11–12):877–85 (47 ref.)

METABOLISM

Histidine 229 in protein L2 is apparently essential for 50S peptidyl transferase activity. Cooperman BS, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11–12):1087–94 (43 ref.)
Peptidyl transferase and beyond. Wower J, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11–12):1041–7 (45 ref.)
Movement of the 3'-end of tRNA through the peptidyl transferase centre and its inhibition by antibiotics. Kirillov S, et al. **FEBS Lett** 1997 Apr 14;406(3):223–33 (165 ref.)

PEPTIDYL TRANSLOCASES see **PEPTIDYL TRANSFERASES**

PEPTONES

[Production of free bile acids by bacterial deconjugation from conjugated bile acids derived from peptone in a medium] Morotomi M, et al. **Nippon Saikingaku Zasshi** 1996 Oct; 51(4):1043–7 (3 ref.) (Eng. Abstr.) **(Jpn)**

PEPTOSTREPTOCOCCUS

ISOLATION & PURIFICATION

Deep neck infections. Marra S, et al. **Am J Otolaryngol** 1996 Sep-Oct;17(5):287–98 (15 ref.)
[The detection of Peptostreptococcus asaccharolyticus and Bacillus cereus in clinical materials from a child who died of sepsis with a fulminant clinical course] Beleva S, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Nov-Dec; (6):16–20 (11 ref.) (Eng. Abstr.) **(Rus)**

PERCA see **PERCH**

PERCEPTION

see related
SENSATION

The topology of perceptive functions as a corollary of the theorem of existence in closed spaces. Bounias M, et al. **Biosystems** 1997;42(2–3):191–205 (56 ref.)
How much work can a quale do? [comment] Banks WP. **Conscious Cogn** 1996 Sep;5(3):368–80 (36 ref.) Comment on: Conscious Cogn 1996 Sep;5(3):327–58.
The importance of a consideration of qualia to imagery and cognition [see comments] Hubbard TL. **Conscious Cogn** 1996 Sep;5(3):327–58 (100 ref.) Comment in: Conscious Cogn 1996 Sep;5(3):359–67. Comment in: Conscious Cogn 1996 Sep;5(3):368–80.
Current awareness: spotlight on consciousness. The 1996 Ronnie Mac Keith lecture. Cowey A. **Dev Med Child Neurol** 1997 Jan;39(1):54–62 (50 ref.)
Privileged knowledge and mothers' "perceptions": the case of breast-feeding and insufficient milk in Bangladesh. Zeitlyn S, et al. **Med Anthropol Q** 1997 Mar;11(1):56–68 (17 ref.)
Misconceptions about classical psychophysics and the measurement of response bias. Gardner RM. **Percept Mot Skills** 1997 Apr;84(2):587–94 (19 ref.)
The perceptual aspect of nursing art: sources of accord and discord. Johnson JL. **Sch Inq Nurs Pract** 1996 Winter; 10(4):307–22; discussion 323–7 (55 ref.)
Effort perception in children. Lamb KL, et al. **Sports Med** 1997 Mar;23(3):139–48 (43 ref.)

PHYSIOLOGY

Paradoxical functional facilitation in brain-behaviour research. A critical review [see comments] Kapur N. **Brain** 1996 Oct;119 (Pt 5):1775–90 (156 ref.) Comment in: Brain 1997 Jul;120 (Pt 7):1261–4.
Spatial orientation perception and reflexive eye movements—a perspective, an overview, and some clinical implications. Guedry FE. **Brain Res Bull** 1996; 40(5–6):505–12 (77 ref.)
Processing the head direction cell signal: a review and commentary. Taube JS, et al. **Brain Res Bull** 1996; 40(5–6):477–84; discussion 484–6 (58 ref.)
Neuropharmacology of timing and time perception. Meck WH. **Brain Res Cogn Brain Res** 1996 Jun;3(3–4):227–42 (130 ref.)
Injury- and use-related plasticity in the primary sensory cortex of adult mammals: possible relationship to perceptual learning. Irvine DR, et al. **Clin Exp Pharmacol Physiol** 1996

PERCEPTION

Oct-Nov;23(10-11):939-47 (56 ref.)
Information coding in the mammalian olfactory system. Buck LB. **Cold Spring Harb Symp Quant Biol** 1996;61:147-55 (57 ref.)
Cortical plasticity underlying perceptual, motor, and cognitive skill development: implications for neurorehabilitation. Merzenich M, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:1-8 (59 ref.)
The molecular biology of olfactory perception. Mombaerts P, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:135-45 (41 ref.)
Learning perceptual skills: behavioral probes into adult cortical plasticity. Karni A, et al. **Curr Opin Neurobiol** 1997 Aug;7(4):530-5 (71 ref.)
The binding problem. Treisman A. **Curr Opin Neurobiol** 1996 Apr;6(2):171-8 (104 ref.)
Perception of physical exertion: methods, mediators, and applications. Robertson RJ, et al. **Exerc Sport Sci Rev** 1997; 25:407-52 (246 ref.)
Impact of information compression on intellectual activities in the brain. Eriksson JT. **Int J Neural Syst** 1996 Sep; 7(4):543-50 (14 ref.)
The King Solomon Lectures in Neuroethology. Deciding about motion: linking perception to action. Newsome WT. **J Comp Physiol [A]** 1997 Jul;181(1):5-12 (47 ref.)
Outlining a brain model of mental imaging abilities. Faw B. **Neurosci Biobehav Rev** 1997 May;21(3):283-8 (63 ref.)
Do theoretical bridges exist between perceptual experience and neurophysiology? Uttal WA. **Perspect Biol Med** 1997 Winter;40(2):280-302 (41 ref.)
A proposed reorganization of the cortical input-output system. Tamai Y. **Prog Brain Res** 1996;112:373-84 (27 ref.)
High-frequency brain activity: its possible role in attention, perception and language processing. Pulvermüller F, et al. **Prog Neurobiol** 1997 Aug;52(5):427-45 (130 ref.)
[Cognition and feelings--on the neurobiology of the perception-emotion connection] Emrich HM. **Geburtshilfe Frauenheilkd** 1996 Jan;56(1):M6-8 (10 ref.) **(Ger)**

PERCEPTION, SOCIAL see **SOCIAL PERCEPTION**

PERCEPTRONS see **NEURAL NETWORKS (COMPUTER)**

PERCEPTUAL DEFENSE

Cognitive behaviour therapy territory model: effective disputing approach. Lam D. **J Adv Nurs** 1997 Jun; 25(6):1205-9 (8 ref.)
Cognitive bias in the anxiety disorders. McNally RJ. **Nebr Symp Motiv** 1996;43:211-50 (95 ref.)

PERCEPTUAL DISORDERS

DIAGNOSIS

Sensory-perceptual abnormalities in autism: a case for more research? O'Neill M, et al. **J Autism Dev Disord** 1997 Jun; 27(3):283-93 (35 ref.)

ETIOLOGY

[Vision in Alzheimer's disease] Ceccaldi M. **Rev Neurol (Paris)** 1996 Jun-Jul;152(6-7):441-6 (57 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Blindsight and consciousness. Natsoulas T. **Am J Psychol** 1997 Spring;110(1):1-33 (75 ref.)
Does stereopsis matter in humans? Fielder AR, et al. **Eye** 1996;10 (Pt 2):233-8 (45 ref.)
Pulfrich revisited. Diaper CJ. **Surv Ophthalmol** 1997 May-Jun;41(6):493-9 (64 ref.)

PERCEPTUAL DISTORTION

see related
PERCEPTUAL DISORDERS
Cognitive distortions in sex offenders: an integrative review. Ward T, et al. **Clin Psychol Rev** 1997;17(5):479-507 (160 ref.)

PERCEPTUAL MASKING

PHYSIOLOGY

Cortical dynamics of lateral inhibition: metacontrast masking. Francis G. **Psychol Rev** 1997 Jul;104(3):572-94 (45 ref.)
[Masking as a result of matched filtration in the human visual system] Krasil'nikov NN, et al. **Fiziol Cheloveka** 1996 Sep-Oct;22(5):99-103 (10 ref.) **(Rus)**

PERCEPTUAL MOTOR PERFORMANCE see **PSYCHOMOTOR PERFORMANCE**

PERCH

METABOLISM

Biochemical adjustments to hypoxia by Amazon cichlids. Almeida-Val VM, et al. **Braz J Med Biol Res** 1995 Nov-Dec;28(11-12):1257-63 (27 ref.)

PERCHLORIC ACID

DIAGNOSTIC USE

[In vivo test of thyroid radioactive iodide uptake, pertechnetate 99m uptake and thyroid scintigraphy] Ochi Y, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:317-20 (5 ref.) **(Jpn)**

PERCHLOROETHYLENE see **TETRACHLOROETHYLENE**

PERCUSSION

VETERINARY

[High-pitched percussion noise (PING) as a leading symptom] Martig J. **Schweiz Arch Tierheilkd** 1996; 138(7):351-2 (3 ref.) **(Ger)**

PERCUTANEOUS ADMINISTRATION see **ADMINISTRATION, CUTANEOUS**

PERCUTANEOUS ATHERECTOMY see **ATHERECTOMY**

PERCUTANEOUS ELECTRIC NERVE STIMULATION see **TRANSCUTANEOUS ELECTRIC NERVE STIMULATION**

PERCUTANEOUS NEPHROLITHOTOMY see **NEPHROSTOMY, PERCUTANEOUS**

PERCUTANEOUS NEPHROSTOMY see **NEPHROSTOMY, PERCUTANEOUS**

PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY see **ANGIOPLASTY, BALLOON**

PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY see **ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY**

PERCUTANEOUS TRANSLUMINAL LASER ANGIOPLASTY see **ANGIOPLASTY, BALLOON, LASER-ASSISTED**

PERCUTANEOUS ULTRASONIC LITHOTRIPSY see **LITHOTRIPSY**

PERFLUOROCARBONS see **FLUOROCARBONS**

PERFUME

ADVERSE EFFECTS

Allergic contact dermatitis to fragrance: a review. Scheinman PL. **Am J Contact Dermat** 1996 Jun;7(2):65-76 (92 ref.)
Contact allergens--what's new? Fragrances. Nethercott JR, et al. **Clin Dermatol** 1997 Jul-Aug;15(4):499-504 (45 ref.)
Adverse reactions to fragrances. A clinical review. de Groot AC, et al. **Contact Dermatitis** 1997 Feb;36(2):57-86 (264 ref.)
[Contact allergy for perfume ingredients in cosmetics and toilet articles] de Groot AC. **Ned Tijdschr Geneeskd** 1997 Mar 22;141(12):571-4 (10 ref.) (Eng. Abstr.) **(Dut)**

PERFUSION

Retrograde cerebral perfusion (RCP) in aortic arch surgery: efficacy and possible mechanisms of brain protection. Bavaria JE, et al. **Semin Thorac Cardiovasc Surg** 1997 Jul; 9(3):222-32 (55 ref.)

INSTRUMENTATION

Experimental methods in hepatology. Guidelines of the German Association for the Study of the Liver (GASL). Liver perfusion--technique and applications. vom Dahl S, et al. **Z Gastroenterol** 1997 Mar;35(3):221-6 (58 ref.)

METHODS

Twenty years of myocardial perfusion imaging 1976-1996: anything new for the clinical cardiologist? van der Wall EE, et al. **Eur Heart J** 1996 Jul;17(7):987-90 (25 ref.)
Brain protection. Svensson LG. **J Card Surg** 1997 Mar-Apr; 12(2 Suppl):326-9; discussion 329-30 (30 ref.)
Intermittent antegrade/selective cerebral perfusion during circulatory arrest for repair of the aortic arch. Maas C, et al. **Perfusion** 1997 Mar;12(2):127-32 (12 ref.)
Isolated perfused liver. Brouwer KL, et al. **Pharm Biotechnol** 1996;8:161-92 (140 ref.)

PERFUSION, PULSATILE see **PULSATILE FLOW**

PERFUSION PUMPS see **INFUSION PUMPS**

PERFUSION PUMPS, IMPLANTABLE see **INFUSION PUMPS, IMPLANTABLE**

PERFUSION, REGIONAL

Mortality, major amputation rates, and leukopenia after isolated limb perfusion with phenylalanine mustard for the treatment of melanoma. Taber SW, et al. **Ann Surg Oncol** 1997 Jul-Aug;4(5):440-5 (30 ref.)
Treatment of peritoneal carcinomatosis by continuous hyperthermic peritoneal perfusion with cisplatin. Alexander HR, et al. **Cancer Treat Res** 1996;81:41-50 (34 ref.)
Isolated limb perfusion for malignant melanoma. Alexander HR Jr, et al. **Semin Surg Oncol** 1996 Nov-Dec;12(6):416-28 (85 ref.)
Theoretic and experimental aspects of regional liver infusion. August DA. **Surg Oncol Clin N Am** 1996 Apr;5(2):399-409 (36 ref.)
Clinical and preclinical trials of isolated liver perfusion for advanced liver tumors: primary liver tumors. Lowy AM, et al. **Surg Oncol Clin N Am** 1996 Apr;5(2):429-41 (18 ref.)
Isolated liver perfusion for liver metastases: pharmacokinetic advantage? Ravikumar TS, et al. **Surg Oncol Clin N Am** 1996 Apr;5(2):443-9 (22 ref.)
Regional chemotherapy approaches for primary and metastatic liver tumors. Venook AP, et al. **Surg Oncol Clin N Am** 1996 Apr;5(2):411-427 (96 ref.)
Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma. Walther MM, et al. **World J Urol** 1996;14 Suppl 1:S2-7 (49 ref.)

ADVERSE EFFECTS

Compartment syndrome after isolated perfusion of the leg: a case report. Chan PS, et al. **Am J Orthop** 1997 May; 26(5):369-70 (7 ref.)

METHODS

Thirty-five years of isolated limb perfusion for melanoma: indications and results. Vrouenraets BC, et al. **Br J Surg** 1996 Oct;83(10):1319-28 (131 ref.)
Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. Dedrick RL, et al. **J Natl Cancer Inst** 1997 Apr 2;89(7):480-7 (61 ref.)

PERIADENITIS MUCOSA NECROTICA RECURRENS see **STOMATITIS, APHTHOUS**

PERIANAL GLAND NEOPLASMS see **ANAL GLAND NEOPLASMS**

PERIANEURYSMAL FIBROSIS, INFLAMMATORY see **RETROPERITONEAL FIBROSIS**

PERIAORTITIS, CHRONIC see **RETROPERITONEAL FIBROSIS**

PERIAPICAL DISEASES

ETIOLOGY

[Periapical lesions of mixed etiology: bacterial and foreign body] Bruno E, et al. **Minerva Stomatol** 1996 Dec; 45(12):563-8 (13 ref.) (Eng. Abstr.) **(Ita)**

PERIAPICAL GRANULOMA

COMPLICATIONS

Pediatric facial fistula. Unkel JH, et al. **Pediatr Emerg Care** 1997 Feb;13(1):21-3 (18 ref.)

PERIAPICAL PERIODONTITIS, CHRONIC NONSUPPURATIVE see **PERIAPICAL GRANULOMA**

PERIAPICAL TISSUE

[Periapical lesions of mixed etiology: bacterial and foreign body] Bruno E, et al. **Minerva Stomatol** 1996 Dec; 45(12):563-8 (13 ref.) (Eng. Abstr.) **(Ita)**

PERIAQUEDUCTAL GRAY

Deep brain stimulation for intractable pain: a 15-year experience. Kumar K, et al. **Neurosurgery** 1997 Apr; 40(4):736-46; discussion 746-7 (64 ref.)

PHYSIOLOGY

Columnar organization in the midbrain periaqueductal gray and the integration of emotional expression. Bandler R, et al. **Prog Brain Res** 1996;107:285-300 (84 ref.)
A concept for the final common pathway of vocalization and lordosis behavior in the cat. VanderHorst VG, et al. **Prog Brain Res** 1996;107:327-42 (83 ref.)

PERIARTERITIS NODOSA see **POLYARTERITIS NODOSA**

PERIARTHRITIS

ETIOLOGY

[Epicondylitis and tenosynovitis or peritendinitis as an occupational disease] Kivi P, et al. **Duodecim** 1995; 111(17):1703-7 (8 ref.) **(Fin)**

PERICARDIAL CYST see **MEDIASTINAL CYST**

PERICARDIAL EFFUSION

see related
CARDIAC TAMPONADE

The management of malignant pleural and pericardial effusions. Fiocco M, et al.
Hematol Oncol Clin North Am 1997 Apr;11(2):253–65 (50 ref.)

[Hydropericardium] Amano M, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):566–8 (7 ref.) **(Jpn)**

[Hemopericardium] Nakamura H, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):561–3 (18 ref.) **(Jpn)**

[Chylopericardium] Ogawa K, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):594–6 (18 ref.) **(Jpn)**

DIAGNOSIS

[Primary chylopericardium—stepwise diagnosis and therapy of a differential diagnostically important illness] Kentsch M, et al. **Z Kardiol** 1997 Jun;86(6):417–22 (25 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Pericardial tamponade from Kaposi's sarcoma: role of early pericardial window. Vijay V, et al. **Am Heart J** 1996 Oct; 132(4):897–9 (6 ref.)

Hepatitis C-associated cryoglobulinemia presenting with pericardial effusion. Safadi R, et al. **Am J Gastroenterol** 1997 Apr;92(4):710–2 (10 ref.)

Malignant pericardial effusion [see comments] Shepherd FA. **Curr Opin Oncol** 1997 Mar;9(2):170–4 (28 ref.) Comment in: Curr Opin Oncol 1997 Mar;9(2):147–8.

Recurrent pericardial effusion as a result of chronic pancreatitis. Successful treatment with somatostatin. Schoonjans R, et al. **J Clin Gastroenterol** 1996 Oct; 23(3):224–7 (20 ref.)

MICROBIOLOGY

Afebrile spontaneous pneumopyopericardium. Tsai WC, et al. **Int J Cardiol** 1996 Apr 19;54(1):69–72 (6 ref.)

PATHOLOGY

Cytology of pleural, peritoneal and pericardial fluids in children. A 40-year summary. Wong JW, et al.
Acta Cytol 1997 Mar–Apr;41(2):467–73 (13 ref.)

SURGERY

Pericardial tamponade from Kaposi's sarcoma: role of early pericardial window. Vijay V, et al. **Am Heart J** 1996 Oct; 132(4):897–9 (6 ref.)

Primary idiopathic chylopericardium—a case report and review of the literature. Svedjeholm R, et al.
Eur J Cardiothorac Surg 1997 Feb;11(2):387–90 (22 ref.)

Palliative treatment of malignant pericardial effusion: report of two cases and a review of the literature. Sharma A, et al. **Support Care Cancer** 1996 Jul;4(4):317–9 (17 ref.)

[Ultrasound-guided pericardial drainage. Experience in 34 consecutive patients] Vayre F, et al. **Presse Med** 1997 Jun 28;26(22):1036–9 (16 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Direct demonstration of an air–fluid interface by two-dimensional echocardiography: a new diagnostic sign of hydropneumopericardium. Antonini-Canterin F, et al. **J Am Soc Echocardiogr** 1996 Mar–Apr;9(2):187–9 (7 ref.)

PERICARDIAL WINDOW TECHNIQUES

Pericardial tamponade from Kaposi's sarcoma: role of early pericardial window. Vijay V, et al. **Am Heart J** 1996 Oct; 132(4):897–9 (6 ref.)

Laparoscopic transdiaphragmatic diagnostic pericardial window in the hemodynamically stable patient with penetrating chest trauma. A brief report. McMahon DJ, et al. **Surg Endosc** 1997 May;11(5):474–5 (9 ref.)

METHODS

Palliative treatment of malignant pericardial effusion: report of two cases and a review of the literature. Sharma A, et al. **Support Care Cancer** 1996 Jul;4(4):317–9 (17 ref.)

PERICARDIECTOMY

[Anesthetic managements for pericardiectomy of three patients with constrictive pericarditis] Kurokawa S, et al. **Masui** 1997 Apr;46(4):515–20 (8 ref.) (Eng. Abstr.) **(Jpn)**

PERICARDIOSTOMY see **PERICARDIAL WINDOW TECHNIQUES**

PERICARDIOTOMY see **PERICARDIECTOMY**

PERICARDITIS

Endocarditis, pericarditis, and myocarditis. Zales VR, et al. **Pediatr Ann** 1997 Feb;26(2):116–21 (14 ref.)

[Bacterial pericarditis (purulent pericarditis, tuberculous pericarditis)] Ashizawa N, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):520–3 (19 ref.) **(Jpn)**

[Pericardial disease] Baba K, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):564–5 (4 ref.) **(Jpn)**

[Rheumatic pericarditis] Fujikawa S.
Ryoikibetsu Shokogun Shirizu 1996;(13):615–7 (6 ref.) **(Jpn)**

[Myopericarditis] Shibata T, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):531–4 (14 ref.) **(Jpn)**

[Idiopathic pericarditis] Sumimoto T, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):591–3 (9 ref.) **(Jpn)**

[Infective pericarditis] Suzuki S, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):498–501 (7 ref.) **(Jpn)**

[Pericarditis (acute, subacute, chronic)] Toda G, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):550–3 (8 ref.) **(Jpn)**

[Intrapericardial abscess, pericardial abscess] Yuasa N.
Ryoikibetsu Shokogun Shirizu 1996;(13):546–9 (22 ref.) **(Jpn)**

CHEMICALLY INDUCED

[Pericarditis in chronic inflammatory bowel disease: underlying disease or side effects of therapy? Clinical problem solving] Kupferschmidt H, et al.
Schweiz Med Wochenschr 1996 Dec 14;126(50):2184–90 (74 ref.) (Eng. Abstr.) **(Ger)**

[Drug-induced pericarditis] Ohnishi A, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):612–4 (22 ref.) **(Jpn)**

CLASSIFICATION

A new classification for pericarditis associated with meningococcal infection. Finkelstein Y, et al.
Eur J Pediatr 1997 Aug;156(8):585–8 (53 ref.)

COMPLICATIONS

Bacterial pericarditis and cardiac tamponade in patients infected with human immunodeficiency virus type 1: case report and review. Scerpella EG, et al. **Clin Infect Dis** 1995 Dec;21(6):1518–9 (4 ref.)

Fatal Listeria meningitis, endocarditis and pericarditis in a patient with haemochromatosis. Manso C, et al.
Scand J Infect Dis 1997;29(3):308–9 (14 ref.)

DIAGNOSIS

Pseudomonas pericarditis and tamponade in an infant with human immunodeficency virus infection. Tumaliuan JA, et al. **Arch Pediatr Adolesc Med** 1997 Feb;151(2):207–8 (9 ref.)

Abnormalities of the S–T segment—Part II. Hurst JW.
Clin Cardiol 1997 Jul;20(7):595–600 (10 ref.)

Pneumococcal pericarditis—out of sight, out of mind? McMechan SR, et al. **Clin Cardiol** 1996 Oct;19(10):829–30 (5 ref.)

[Asymptomatic pericarditis] Kuriyama I.
Ryoikibetsu Shokogun Shirizu 1996;(13):609–11 (11 ref.) **(Jpn)**

DRUG THERAPY

[Colchicine treatment for recurrent pericarditis] Rodríguez Blanco VM, et al. **An Med Interna** 1997 Feb;14(2):98–100 (24 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Salmonella pericarditis and empyema: a case report. Yang CH, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Sep; 56(3):199–204 (25 ref.)

Pericardial involvement in acute myocardial infarction in the post-thrombolytic era: clinical meaning and value. Correale E, et al. **Clin Cardiol** 1997 Apr;20(4):327–31 (37 ref.)

Thoracic complications in uremic patients and in patients undergoing dialytic treatment: state of the art. Gavelli G, et al. **Eur Radiol** 1997;7(5):708–17 (76 ref.)

Acinetobacter pericarditis with tamponade in a patient with systemic lupus erythematosus. Lam SM, et al. **Lupus** 1997; 6(5):480–3 (13 ref.)

[Acute relapsing pericarditis induced by screw-in atrial pacing lead. Apropos of 3 cases] Jacques B, et al.
Arch Mal Coeur Vaiss 1996 Nov;89(11):1389–95 (18 ref.) (Eng. Abstr.) **(Fre)**

[Traumatic pericarditis] Hamada O, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):495–7 (20 ref.) **(Jpn)**

[Radiation-induced pericarditis] Horimoto M.
Ryoikibetsu Shokogun Shirizu 1996;(13):597–9 (26 ref.) **(Jpn)**

[Inflammatory bowel disease] Iizuka B, et al.
Ryoikibetsu Shokogun Shirizu 1996;(15):398–405 (55 ref.) **(Jpn)**

[Pericarditis in rheumatoid arthritis] Kunitomi T, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):602–4 (21 ref.) **(Jpn)**

[Pericarditis in collagen vascular diseases] Matsumoto Y.
Ryoikibetsu Shokogun Shirizu 1996;(13):511–4 (15 ref.) **(Jpn)**

[Postmyocardial infarction syndrome] Shimizu M.
Ryoikibetsu Shokogun Shirizu 1996;(12):692–5 (14 ref.) **(Jpn)**

[Uremic pericarditis] Tsuzuki K, et al.
Ryoikibetsu Shokogun Shirizu 1997;(16 Pt 1):60–2 (3 ref.) **(Jpn)**

METABOLISM

[Cholesterol pericarditis] Ito T.
Ryoikibetsu Shokogun Shirizu 1996;(13):515–9 (14 ref.) **(Jpn)**

[Metabolic pericarditis (uremia, myxedema)] Katoh S, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):585–8 (17 ref.) **(Jpn)**

MICROBIOLOGY

Candida pericarditis: clinical profile and treatment. Rabinovici R, et al. **Ann Thorac Surg** 1997 Apr;63(4):1200–4 (31 ref.)

A new classification for pericarditis associated with meningococcal infection. Finkelstein Y, et al.
Eur J Pediatr 1997 Aug;156(8):585–8 (53 ref.)

Mycoplasma-associated pericarditis. Farraj RS, et al.
Mayo Clin Proc 1997 Jan;72(1):33–6 (19 ref.)

Aspergillus endocarditis, myocarditis and pericarditis complicating necrotizing fasciitis. Case report and subject review. Sergi C, et al. **Virchows Arch** 1996 Oct; 429(2–3):177–80 (44 ref.)

[Salmonella enteritidis pericarditis. Apropos of a case and review of the literature] Victor F, et al.
Arch Mal Coeur Vaiss 1997 Feb;90(2):301–3 (10 ref.) (Eng. Abstr.) **(Fre)**

[Fungal pericarditis] Ashizawa N, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):535–8 (12 ref.) **(Jpn)**

[Mycoplasma pericarditis] Baba K, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):600–1 (5 ref.) **(Jpn)**

[Spirochetal pericarditis] Ueyama C, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):582–4 (11 ref.) **(Jpn)**

PARASITOLOGY

[Protozoal pericarditis] Seto S, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):508–10 (8 ref.) **(Jpn)**

[Parasitic pericarditis] Toda G, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):502–4 (12 ref.) **(Jpn)**

PATHOLOGY

[Localized pericarditis] Kuwajima M.
Ryoikibetsu Shokogun Shirizu 1996;(13):505–7 (13 ref.) **(Jpn)**

RADIOGRAPHY

[X-ray diagnosis of pericarditis] Vishniakova MV, et al.
Vestn Rentgenol Radiol 1997 Jan–Feb;(1):39–44 (16 ref.) **(Rus)**

VIROLOGY

[Viral pericarditis] Suzuki S, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):491–4 (12 ref.) **(Jpn)**

PERICARDITIS, CONSTRICTIVE

[Pericardial calcification] Lee CW, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):569–71 (12 ref.) **(Jpn)**

[(Subacute) effusive-constrictive pericarditis] Tamura T.
Ryoikibetsu Shokogun Shirizu 1996;(13):539–41 (7 ref.) **(Jpn)**

[Chronic constrictive pericarditis] Tamura T.
Ryoikibetsu Shokogun Shirizu 1996;(13):605–8 (16 ref.) **(Jpn)**

[The late appearance of chronic constrictive pericarditis] Tamura T, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (13):589–90 (7 ref.) **(Jpn)**

SURGERY

[Anesthetic managements for pericardiectomy of three patients with constrictive pericarditis] Kurokawa S, et al. **Masui** 1997 Apr;46(4):515–20 (8 ref.) (Eng. Abstr.) **(Jpn)**

PERICARDITIS, TUBERCULOUS

DIAGNOSIS

Tuberculous pericarditis. Kutoloski KS, et al.
J Am Osteopath Assoc 1996 Apr;96(4):253–6 (12 ref.)

PERICARDIUM

see related
PERICARDIECTOMY

A case report and review: the gross, histological and immunohistochemical characteristics of a carcinoma of ectopic thyroid in a dog. Constantino-Casas P, et al. **Br Vet J** 1996 Nov;152(6):669-72 (10 ref.)

Pericardial heart disease. Hoit BD. **Curr Probl Cardiol** 1997 Jul;22(7):353-400 (131 ref.)

Carpentier pericardial valve. Cosgrove DM. **Semin Thorac Cardiovasc Surg** 1996 Jul;8(3):269-75 (36 ref.)

[A case of primary anterior mediastinal liposarcoma with a heterotopic mass in the pericardium of the same histology] Kiyama H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Dec;44(12):2191-5 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Pericardial disease] Baba K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):564-5 (4 ref.) **(Jpn)**

ABNORMALITIES

Congenital absence of the left pericardium with extreme intrathoracic displacement of the heart. Case report and review of the literature. Gersbach P, et al. **Eur J Cardiothorac Surg** 1996;10(6):473-6 (16 ref.)

[Congenital absence and defects of the left pericardium] Matsuo S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):178-81 (9 ref.) **(Jpn)**

[Congenital pericardial defect (complete and incomplete)] Tokushima T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):190-2 (14 ref.) **(Jpn)**

ANATOMY & HISTOLOGY

Pericardial reflection around the venous aspect of the heart. Chaffanjon P, et al. **Surg Radiol Anat** 1997;19(1):17-21 (19 ref.)

METABOLISM

[Deposition of subepicardial fat] Iwasaka T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):524-7 (25 ref.) **(Jpn)**

PATHOLOGY

Intrapericardial thymoma: report of two incidental autopsy cases and review of the literature. Mirra M, et al. **Arch Pathol Lab Med** 1997 Jan;121(1):59-63 (17 ref.)

Magnetic resonance imaging of cardiac and pericardial disease. Croisille P, et al. **J Belge Radiol** 1997 Jun;80(3):133-6 (15 ref.)

[Pericardium--radiologic diagnosis] Kopsa W, et al. **Radiologe** 1997 May;37(5):378-87 (28 ref.) (Eng. Abstr.) **(Ger)**

[Leukemic infiltration of the pericardium] Shibata K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):289-90 (6 ref.) **(Jpn)**

[Pericardial fibrosis] Teraoka K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):576-8 (15 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Pericardial space exploration for ventricular tachycardia mapping: should the countdown begin? [comment] Strickberger SA. **J Cardiovasc Electrophysiol** 1996 Jun;7(6):537-8 (4 ref.) Comment on: J Cardiovasc Electrophysiol 1996 Jun;7(6):531-6.

TRANSPLANTATION

Surgical treatment of emphysema using bovine pericardium strips. Allen GM. **AORN J** 1996 Feb;63(2):373, 376-80, 383-4, passim 388 (14 ref.)

PERICEMENTITIS see **PERIODONTITIS**

PERIDINIUM see **DINOFLAGELLIDA**

PERILYMPH

Update on idiopathic perilymphatic fistulas. Kohut RI, et al. **Otolaryngol Clin North Am** 1996 Apr;29(2):343-52 (15 ref.)

PERIMENOPAUSAL BONE LOSS see **OSTEOPOROSIS, POSTMENOPAUSAL**

PERIMENOPAUSE see **PREMENOPAUSE**

PERIMETRY

[Objective measurement of visual field by using visual evoked potentials] Tobimatsu S. **Nippon Rinsho** 1997 Mar;55 Suppl 1:450-3 (6 ref.) **(Jpn)**

INSTRUMENTATION

[Computerized static perimetry] Kaucsár E. **Oftalmologia** 1996 Oct-Dec;40(4):420-8 (40 ref.) (Eng. Abstr.) **(Rum)**

METHODS

Early diagnosis of functional damage in patients with glaucoma [editorial; comment] Caprioli J. **Arch Ophthalmol** 1997 Jan;115(1):113-4 (31 ref.) Comment on: Arch Ophthalmol 1997 Jan;115(1):26-33.

[Informative value of psychophysical examinations aside from conventional white-white perimetry] Lachenmayr B. **Ophthalmologe** 1996 Aug;93(4):389-95 (81 ref.) (Eng. Abstr.) **(Ger)**

PERINATAL CARE

General obstetrics--prevention: the perinatal medicine of the future [editorial] Queenan JT. **Curr Opin Obstet Gynecol** 1996 Dec;8(6):391-3 (16 ref.)

A birth father and adoption in the perinatal setting. Menard BJ. **Soc Work Health Care** 1997;24(3-4):153-63 (18 ref.)

ORGANIZATION & ADMINISTRATION

Maternal and child health services in India with special focus on perinatal services. Singh M, et al. **J Perinatol** 1997 Jan-Feb;17(1):65-9 (28 ref.)

PERINATAL MORTALITY see **INFANT MORTALITY**

PERINATAL NURSING see **NEONATAL NURSING**

PERINATOLOGY

see related
FETAL DISEASES
INFANT, NEWBORN, DISEASES
MATERNAL-CHILD NURSING
PERINATAL CARE
PREGNANCY COMPLICATIONS

Fetal and perinatal medicine. Soothill P. **Br J Hosp Med** 1996 Aug 21-Sep 3;56(4):141-4 (10 ref.)

Perinatology: an end and a beginning. Rossdale PD. **Equine Vet J Suppl** 1988 Sep;(5):19-24 (61 ref.)

Ethical dilemmas in maternal-fetal research. Sams L. **MCN Am J Matern Child Nurs** 1997 Mar-Apr;22(2):67-71 (6 ref.)

Genetic counseling in perinatal medicine. Milunsky JM, et al. **Obstet Gynecol Clin North Am** 1997 Mar;24(1):1-17 (63 ref.)

METHODS

Conceptualization, measurement, and use of gestational age. I. Clinical and public health practice. Alexander GR, et al. **J Perinatol** 1996 Jan-Feb;16(1):53-9 (57 ref.)

STANDARDS

Randomized controlled trials and systematic reviews: a foundation for evidence-based perinatal medicine. Ohlsson A. **Acta Paediatr** 1996 Jun;85(6):647-55 (100 ref.)

TRENDS

An effective model for reorganization of perinatal services in a metropolitan area: a descriptive analysis and historical perspective. Pollack LD. **J Perinatol** 1996 Jan-Feb;16(1):3-8 (30 ref.)

PERINEUM

Perineal and perirectal sarcomas: report of two cases. Kessler KJ, et al. **Dis Colon Rectum** 1996 Apr;39(4):468-72 (27 ref.)

Aggressive angiomyxoma of the perineum in a man. Hong RD, et al. **J Urol** 1997 Mar;157(3):959-60 (3 ref.)

INJURIES

Burns of the female genitalia and perineum. Weiler-Mithoff EM, et al. **Burns** 1996 Aug;22(5):390-5 (28 ref.)

[The advantages, disadvantages and sequelae of episiotomy and spontaneous tears of the perineum] Dimitrov A. **Akush Ginekol (Sofiia)** 1996;35(4):30-4 (28 ref.) **(Bul)**

[Post-traumatic priapism in a 10-year-old boy] Sperling H, et al. **Urologe A** 1997 Mar;36(2):162-4 (11 ref.) (Eng. Abstr.) **(Ger)**

[Pelvic floor reconstruction after traumatic childbirth damage] Franz HB, et al. **Zentralbl Chir** 1996;121(8):688-91 (20 ref.) (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

Anal and perianal tuberculosis: a report of three cases in 10 years. Chung CC, et al. **J R Coll Surg Edinb** 1997 Jun;42(3):189-90 (6 ref.)

PATHOLOGY

Port site metastasis after laparoscopic-assisted vaginal hysterectomy for endometrial cancer: possible mechanisms and prevention. Wang PH, et al. **Gynecol Oncol** 1997 Jul;66(1):151-5 (26 ref.)

SURGERY

The difficult perineal wound. Del Pino A, et al. **Surg Clin North Am** 1997 Feb;77(1):155-74 (110 ref.)

Reconstruction of the abdomen and perineum in cancer surgery. Fix RJ, et al. **Surg Oncol Clin N Am** 1997 Jan;6(1):115-32 (11 ref.)

Reconstruction of the perineum after tumor surgery. McCraw JB, et al. **Surg Oncol Clin N Am** 1997 Jan;6(1):177-89 (17 ref.)

ULTRASONOGRAPHY

The pelvic floor muscles: muscle thickness in healthy and urinary-incontinent women measured by perineal ultrasonography with reference to the effect of pelvic floor training. Estrogen receptor studies. Bernstein IT. **Neurourol Urodyn** 1997;16(4):237-75 (145 ref.)

PERINEURIUM see **PERIPHERAL NERVES**

PERINEURONAL SATELLITE CELLS see **OLIGODENDROGLIA**

PERIODIC DISEASE

COMPLICATIONS

Peritoneal mesothelioma in recurrent familial peritonitis. Gentiloni N, et al. **J Clin Gastroenterol** 1997 Jun;24(4):276-9 (20 ref.)

DIAGNOSIS

[Hyperimmunoglobulinemia D--a new periodic syndrome with features simulating familial Mediterranean fever] Livneh A, et al. **Harefuah** 1996 Oct;131(7-8):283-4 (18 ref.) **(Heb)**

EPIDEMIOLOGY

The changing face of familial Mediterranean fever. Livneh A, et al. **Semin Arthritis Rheum** 1996 Dec;26(3):612-27 (175 ref.)

PERIODICALS

More informative abstracts revisited. Haynes RB, et al. **Cleft Palate Craniofac J** 1996 Jan;33(1):1-9 (41 ref.)

Enlivening basic-science learning with current journal articles. Beresford WA. **Clin Anat** 1996;9(4):273-6 (9 ref.)

How to write a paper. Driscoll P. **J Accid Emerg Med** 1997 Mar;14(2):65-9 (20 ref.)

A review of statistical methods in the Journal of Advanced Nursing. Anthony D. **J Adv Nurs** 1996 Nov;24(5):1089-94 (10 ref.)

The journal club. Valentini RP, et al. **Postgrad Med J** 1997 Feb;73(856):81-5 (19 ref.)

Reviews of venomous snake systematics in Toxicon [letter; comment] Wüster W, et al. **Toxicon** 1996 Apr;34(4):397-8 (1 ref.) Comment on: Toxicon 1996 Apr;34(4):399-406.

Citation analysis for measuring the value of scientific publications: quality assessment tool or comedy of errors? [see comments] Schoonbaert D, et al. **Trop Med Int Health** 1996 Dec;1(6):739-52 (71 ref.) Comment in: Trop Med Int Health 1996 Dec;1(6):737.

[Medical publishing--dissemination of knowledge or personal promotion?] Nylenna M. **Tidsskr Nor Laegeforen** 1996 Dec 10;116(30):3652-5 (29 ref.) (Eng. Abstr.) **(Nor)**

[Evaluation of statistical procedures in the original articles of "Anales Espanôles de Pediatría": comparison of two different periods (1989-90 and 1994-95)] González de Dios J, et al. **An Esp Pediatr** 1996 Oct;45(4):351-60 (35 ref.) **(Spa)**

HISTORY

Implementing the concepts of William Farr: the contributions of Alexander D. Langmuir to Public Health Surveillance and Communications. Thacker SB, et al. **Am J Epidemiol** 1996 Oct 15;144(8 Suppl):S23-8 (42 ref.)

STANDARDS

Design issues addressed in published evaluations of adolescent HIV-risk reduction interventions: a review [see comments] Stanton B, et al. **J Adolesc Health** 1996 Jun;18(6):387-96 (61 ref.) Comment in: J Adolesc Health 1996 Jun;18(6):379.

Critical appraisal meets clinical reality: evaluating evidence in the literature using canine hemangiosarcoma as an example. Bonnett B, et al. **Vet Clin North Am Small Anim Pract** 1996 Jan;26(1):39-61 (53 ref.)

STATISTICS & NUMERICAL DATA

Forty years of randomised trials in the New Zealand Medical Journal. Neal B, et al. **N Z Med J** 1996 Oct 11;109(1031):372-3 (6 ref.)

TRENDS

Themes relating to sexuality that emerged from a discourse analysis of the Nursing Times during 1980-1990. Carr G. **J Adv Nurs** 1996 Jul;24(1):196-212 (129 ref.)

The Journal of Human Hypertension: looking back over 10 years of research and thinking of the future [editorial] Beevers DG, et al. **J Hum Hypertens** 1997 Jan;11(1):1-5 (36 ref.)

PERIODICITY

see related
BIOLOGICAL CLOCKS
CIRCADIAN RHYTHM

Analysis of bioperiodicity in physiological responses. Mercer

LP, et al. **Adv Food Nutr Res** 1996;40:217–26 (16 ref.)
Periodic syndromes of childhood. Arav-Boger R, et al. **Adv Pediatr** 1997;44:389–428 (155 ref.)
Entrainment and the cranial rhythmic impulse. McPartland JM, et al. **Altern Ther Health Med** 1997 Jan;3(1):40–5 (80 ref.)
Development of VIP agonists and antagonists with tissue and receptor specificity: effects on behavioral maturation, sexual function, and the biologic clock. Gozes I, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:159–69; discussion 169–71 (60 ref.)
Periodic vestibulocerebellar ataxia, an autosomal dominant ataxia with defective smooth pursuit, is genetically distinct from other autosomal dominant ataxias. Damji KF, et al. **Arch Neurol** 1996 Apr;53(4):338–44 (42 ref.)
Molecular basis of neuronal biorhythms and paroxysms. Grisar T, et al. **Arch Physiol Biochem** 1996 Oct; 104(6):770–4 (20 ref.)
Dynamic internal coordination in different frequency ranges. Rittweger J, et al. **Boll Soc Ital Biol Sper** 1996 Jan–Feb; 72(1–2):45–63 (24 ref.)
Cultural aspects of meals and meal frequency. Chiva M. **Br J Nutr** 1997 Apr;77 Suppl 1:S21–8 (23 ref.)
Eating frequency: methodological and dietary aspects. Gatenby SJ. **Br J Nutr** 1997 Apr;77 Suppl 1:S7–20 (72 ref.)
The phenomenon of rapid cycling in bipolar mood disorders: a review. Persad E, et al. **Can J Psychiatry** 1996 Feb; 41(1):23–7 (57 ref.)
Cellular sodium pumps in hypokalaemic periodic muscle paralysis. Taylor EA, et al. **Clin Sci (Colch)** 1996 Sep; 91(3):261–4 (28 ref.)
The cell cycle and V(D)J recombination. Desiderio S, et al. **Curr Top Microbiol Immunol** 1996;217:45–59 (60 ref.)
Rhythms of cellular immediate-early gene expression: more than just an early response. Carter DA. **Exp Physiol** 1997 Mar;82(2):237–44 (31 ref.)
Positive feedback as a general mechanism for sustaining rhythmic and non-rhythmic activity. Roberts A, et al. **J Physiol Paris** 1995;89(4–6):241–8 (33 ref.)
Hypokalemic periodic paralysis: an autosomal dominant muscle disorder caused by mutations in a voltage-gated calcium channel. Lapie P, et al. **Neuromuscul Disord** 1997 Jun;7(4):234–40 (68 ref.)
Channelopathies: ion channel disorders of muscle as a paradigm for paroxysmal disorders of the nervous system. Ptáček LJ. **Neuromuscul Disord** 1997 Jun;7(4):250–5 (56 ref.)
Episodic pain associated with a tumor in the parietal operculum: a case report and literature review. Potagas C, et al. **Pain** 1997 Aug;72(1–2):201–8 (70 ref.)
Fractal variability versus pathologic periodicity: complexity loss and stereotypy in disease. Goldberger AL. **Perspect Biol Med** 1997 Summer;40(4):543–61 (42 ref.)
The genetics of sporadic breast cancer. Brenner AJ, et al. **Prog Clin Biol Res** 1997;396:63–82 (82 ref.)
Human cortical oscillations: a neuromagnetic view through the skull. Hari R, et al. **Trends Neurosci** 1997 Jan;20(1):44–9 (59 ref.)
Bursts as a unit of neural information: making unreliable synapses reliable [see comments] Lisman JE. **Trends Neurosci** 1997 Jan;20(1):38–43 (74 ref.) Comment in: Trends Neurosci 1997 Jun;20(6):244.
Hyperkalemic periodic paralysis. Naylor JM. **Vet Clin North Am Equine Pract** 1997 Apr;13(1):129–44 (31 ref.)
[Periodic paralysis, myotonia] Kinoshita M, et al. **Nippon Rinsho** 1996 Mar;54(3):834–8 (12 ref.) (Eng. Abstr.) **(Jpn)**
[The periodic action of cold and body resistance] Barbarash NA. **Usp Fiziol Nauk** 1996 Oct–Dec;27(4):116–32 (101 ref.) (Eng. Abstr.) **(Rus)**
[The nonspecific mechanisms of CNS adaptation to intermittent stimuli, EEG spectral structure and the optimal parameters of rhythmic sensory actions] Fedotchev AI, et al. **Usp Fiziol Nauk** 1996 Oct–Dec;27(4):44–62 (173 ref.) (Eng. Abstr.) **(Rus)**
[Stability of epidemic process in context of biological system] Savilov ED. **Vestn Ross Akad Med Nauk** 1997;(8):29–32 (24 ref.) (Eng. Abstr.) **(Rus)**
[Age-related changes in the effect of catecholamines on spontaneous periodic motor activity in rat pups] Bursian AV. **Zh Evol Biokhim Fiziol** 1996 May–Jun;32(3):292–301 (38 ref.) (Eng. Abstr.) **(Rus)**
[New data on the characteristics of sleep and the organization of the wakefulness-sleep cycle in cold-blooded vertebrates] Karmanova IG. **Zh Evol Biokhim Fiziol** 1996 Jul–Aug; 32(4):511–35 (10 ref.) **(Rus)**

PERIODONTAL CYST

PATHOLOGY

The buccal bifurcation cyst: a prospective study of treatment outcomes in 44 sites. Pompura JR, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Feb;83(2):215–21 (23 ref.)

PERIODONTAL DISEASES

COMPLICATIONS

The influence of endodontic treatment upon periodontal wound healing. Chen SY, et al. **J Clin Periodontol** 1997 Jul;24(7):449–56 (98 ref.)
Periodontal disease and cardiovascular disease. Beck J, et al. **J Periodontol** 1996 Oct;67(10 Suppl):1123–37 (68 ref.)
Relationships between periodontal disease and bacterial pneumonia. Scannapieco FA, et al. **J Periodontol** 1996 Oct; 67(10 Suppl):1114–22 (87 ref.)
The role of osteopenia in oral bone loss and periodontal disease. Wactawski-Wende J, et al. **J Periodontol** 1996 Oct; 67(10 Suppl):1076–84 (108 ref.)

DIAGNOSIS

Rapid diagnosis of periodontal infections: findings in AIDS patients. Zambon JJ. **Immunol Invest** 1997 Jan–Feb; 26(1–2):55–65 (45 ref.)

DRUG THERAPY

Antimicrobial treatment of periodontal diseases disturbs the human ecology: a review. Edlund C, et al. **J Chemother** 1996 Oct;8(5):331–41 (65 ref.)
Systemic antibiotics in periodontics. **J Periodontol** 1996 Aug; 67(8):831–8 (63 ref.)

ENZYMOLOGY

Structure and function of a novel arginine-specific cysteine proteinase (argingipain) as a major periodontal pathogenic factor from porphyromonas gingivalis. Yamamoto K, et al. **Adv Exp Med Biol** 1996;389:33–42 (38 ref.)

EPIDEMIOLOGY

Position paper: epidemiology of periodontal diseases. American Academy of Periodontology. **J Periodontol** 1996 Sep;67(9):935–45 (164 ref.)

ETIOLOGY

Factors affecting IL-1-mediated collagen metabolism by fibroblasts and the pathogenesis of periodontal disease: a review of the literature. Havemose-Poulsen A, et al. **Crit Rev Oral Biol Med** 1997;8(2):217–36 (206 ref.)
Periodontal manifestations of systemic diseases and their management. Michelberger D, et al. **J Can Dent Assoc** 1996 Apr;62(4):313–4, 317–21 (50 ref.)
Tobacco smoking and periodontal diseases. Qandil R, et al. **J Can Dent Assoc** 1997 Mar;63(3):187–92, 194–5 (60 ref.)
Medications as risk factors for periodontal disease. Ciancio SG. **J Periodontol** 1996 Oct;67(10 Suppl):1055–9 (66 ref.)
Current view of risk factors for periodontal diseases. Genco RJ. **J Periodontol** 1996 Oct;67(10 Suppl):1041–9 (66 ref.)
The influence of anatomic and iatrogenic root surface characteristics on bacterial colonization and periodontal destruction: a review. Leknes KN. **J Periodontol** 1997 Jun; 68(6):507–16 (106 ref.)
Clinical significance of tooth morphology correlated with periodontal disease-I. Hou GL, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1997 Apr; 13(4):200–12 (75 ref.)
[Etiopathogenic hypotheses on dental ankylosis] Belcastro S, et al. **Minerva Stomatol** 1997 Mar;46(3):109–13 (9 ref.) (Eng. Abstr.) **(Ita)**
[Saliva and periodontal disease] Giuliana G, et al. **Minerva Stomatol** 1996 Mar;45(3):101–11 (46 ref.) (Eng. Abstr.) **(Ita)**

IMMUNOLOGY

Life and death in the three millimeter pocket. McKay M. **Technol Health Care** 1996 Sep;4(3):305–9 (7 ref.)

METABOLISM

[New findings on pathogenic mechanisms of collagen fiber damage during development of periodontal diseases] Bokor M. **Med Pregl** 1997 May–Jun;50(5–6):201–5 (33 ref.) (Eng. Abstr.) **(Scr)**

MICROBIOLOGY

Potential of diagnostic microbiology for treatment and prognosis of dental caries and periodontal diseases. Baehni PC, et al. **Crit Rev Oral Biol Med** 1996;7(3):259–77 (135 ref.)
Human oral microbial ecology and dental caries and periodontal diseases. Liljemark WF, et al. **Crit Rev Oral Biol Med** 1996;7(2):180–98 (196 ref.)
Microbiology of caries and periodontal diseases. Marsh PD. **Fogorv Sz** 1997 Apr;90 Spec No:29–36 (20 ref.)
Rapid diagnosis of periodontal infections: findings in AIDS patients. Zambon JJ. **Immunol Invest** 1997 Jan–Feb; 26(1–2):55–65 (45 ref.)
Alterations in phagocyte function and periodontal infection. Daniel MA, et al. **J Periodontol** 1996 Oct;67(10 Suppl):1070–5 (47 ref.)
Bacterial transmission in periodontal diseases: a critical review. Greenstein G, et al. **J Periodontol** 1997 May; 68(5):421–31 (84 ref.)
Taxonomy and identification of periodontopathogenic bacteria and related species. Thaller MC, et al. **New Microbiol** 1997 Apr;20(2):161–76 (115 ref.)
Lost in the pocket: the current status of periodontal diagnosis. Lavine WS, et al. **Technol Health Care** 1996 Sep; 4(3):317–22 (47 ref.)
The role of Actinobacillus actinomycetemcomitans in the pathogenesis of periodontal disease. Meyer DH, et al. **Trends Microbiol** 1997 Jun;5(6):224–8 (51 ref.)

PATHOLOGY

Squamous odontogenic tumor (SOT): a benign neoplasm of the periodontium. A review of 36 reported cases. Philipsen HP, et al. **J Clin Periodontol** 1996 Oct;23(10):922–6 (32 ref.)

PHYSIOPATHOLOGY

Children, adolescents and periodontal diseases. Dibart S. **J Dent** 1997 Mar;25(2):79–89 (132 ref.)

PREVENTION & CONTROL

Supportive care after active periodontal treatment: a review. Echeverría JJ, et al. **J Clin Periodontol** 1996 Oct; 23(10):898–905 (110 ref.)

SURGERY

Lasers in periodontics. **J Periodontol** 1996 Aug;67(8):826–30 (79 ref.)
[Barrier membrane technique in oral medicine] Yao H, et al. **Chung Hua Kou Chiang Hsueh Tsa Chih** 1995 Jul; 30(4):250–2 (20 ref.) **(Chi)**
[Periodontal surgery and guided tissue regeneration. Advancements in outcome:—concepts—means—applications] Servera C, et al. **Rev Stomatol Chir Maxillofac** 1997 Sep;98(3):207–15 (24 ref.) **(Fre)**

THERAPY

Orthodontic procedures improving periodontal prognosis. Diedrich PR. **Dent Clin North Am** 1996 Oct;40(4):875–87 (29 ref.)
Evidence-based periodontal treatment. Highlights from the 1996 World Workshop in Periodontics. Jeffcoat MK, et al. **J Am Dent Assoc** 1997 Jun;128(6):713–24 (19 ref.)
Periodontal management of patients with cardiovascular diseases. American Academy of Periodontology. **J Periodontol** 1996 Jun;67(6):627–35 (94 ref.)
Response to periodontal therapy in diabetics and smokers. Grossi SG, et al. **J Periodontol** 1996 Oct;67(10 Suppl):1094–102 (60 ref.)
[Progresses in stomatology in China, 1996] Zhang K. **Chung Hua I Hsueh Tsa Chih** 1996 Dec;76(12):929–31 (0 ref.) **(Chi)**

PERIODONTAL INDEX

Periodontal probing. Hefti AF. **Crit Rev Oral Biol Med** 1997; 8(3):336–56 (113 ref.)
Suitability of gingival indices for use in therapeutic trials. Is bleeding a sine qua non? Barnett ML. **J Clin Periodontol** 1996 Jun;23(6):582–6 (38 ref.)
Gingival recession. Reappraisal of an enigmatic condition and a new index for monitoring. Smith RG. **J Clin Periodontol** 1997 Mar;24(3):201–5 (39 ref.)
Indices to measure gingival bleeding. Newbrun E. **J Periodontol** 1996 Jun;67(6):555–61 (65 ref.)

PERIODONTAL LIGAMENT

see related
GUIDED TISSUE REGENERATION

CYTOLOGY

Fibroblast heterogeneity in the periodontium and other tissues. Phipps RP, et al. **J Periodontal Res** 1997 Jan;32(1 Pt 2):159–65 (58 ref.)

PHYSIOLOGY

Is fibroblast heterogeneity relevant to the health, diseases, and treatments of periodontal tissues? Lekic PC, et al. **Crit Rev Oral Biol Med** 1997;8(3):253–68 (122 ref.)

PERIODONTITIS

CLASSIFICATION

Periodontitis vs. peri-implantitis: the same disease? The same treatment? Meffert RM. **Crit Rev Oral Biol Med** 1996; 7(3):278–91 (130 ref.)

DIAGNOSIS

Periodontal disease diagnosis: current status and future developments. Chapple IL. **J Dent** 1997 Jan;25(1):3–15 (98 ref.)

DRUG THERAPY

Subgingival delivery of therapeutic agents in the treatment of periodontal diseases. Soskolne WA. **Crit Rev Oral Biol Med** 1997;8(2):164–74 (64 ref.)
[Subgingival irrigation: a heresy?] Bouclin R, et al.

PERIODONTITIS

J Can Dent Assoc 1996 Apr;62(4):358–62 (52 ref.) (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

Porphyromonas gingivalis proteinases in periodontitis, a review. Potempa J, et al. **Acta Biochim Pol** 1996; 43(3):455–65 (77 ref.)

Cytokines modulate routes of collagen breakdown. Review with special emphasis on mechanisms of collagen degradation in the periodontium and the burst hypothesis of periodontal disease progression. van der Zee E, et al. **J Clin Periodontol** 1997 May;24(5):297–305 (146 ref.)

ETIOLOGY

The effects of smoking on periodontal structures: a literature review. Bouclin R, et al. **J Can Dent Assoc** 1997 May; 63(5):356, 360–3 (59 ref.)

IMMUNOLOGY

Cell-mediated immune system regulation in periodontal diseases. Mathur A, et al. **Crit Rev Oral Biol Med** 1997; 8(1):76–89 (104 ref.)

Cytokine-inducing components of periodontopathogenic bacteria. Wilson M, et al. **J Periodontal Res** 1996 Aug; 31(6):393–407 (117 ref.)

METABOLISM

Reactive oxygen species and antioxidants in inflammatory diseases. Chapple IL. **J Clin Periodontol** 1997 May; 24(5):287–96 (103 ref.)

MICROBIOLOGY

Can one acquire periodontal bacteria and periodontitis from a family member? Asikainen S, et al. **J Am Dent Assoc** 1997 Sep;128(9):1263–71 (37 ref.)

The challenge of growing oral spirochaetes. Wardle HM. **J Med Microbiol** 1997 Feb;46(2):104–16 (77 ref.)

Porphyromonas gingivalis proteinases as virulence factors in the development of periodontitis. Travis J, et al. **J Periodontal Res** 1997 Jan;32(1 Pt 2):120–5 (37 ref.)

Cytokine-inducing components of periodontopathogenic bacteria. Wilson M, et al. **J Periodontal Res** 1996 Aug; 31(6):393–407 (117 ref.)

Microbiological response to mechanical treatment in combination with adjunctive therapy. A review of the literature. Bollen CM, et al. **J Periodontol** 1996 Nov; 67(11):1143–58 (118 ref.)

[The role of Porphyromonas gingivalis proteinases in periodontitis] Polanowska J, et al. **Postepy Hig Med Dosw** 1997;51(2):149–69 (68 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

Short-chain carboxylic-acid-stimulated, PMN-mediated gingival inflammation. Niederman R, et al. **Crit Rev Oral Biol Med** 1997;8(3):269–90 (144 ref.)

PSYCHOLOGY

Emotional stress effects on immunity, gingivitis and periodontitis. Breivik T, et al. **Eur J Oral Sci** 1996 Aug; 104(4 (Pt 1)):327–34 (74 ref.)

THERAPY

The effect of periodontal therapy in diabetics. Results after 5 years. Westfelt E, et al. **J Clin Periodontol** 1996 Feb; 23(2):92–100 (33 ref.)

Microbiological response to mechanical treatment in combination with adjunctive therapy. A review of the literature. Bollen CM, et al. **J Periodontol** 1996 Nov; 67(11):1143–58 (118 ref.)

PERIODONTITIS, APICAL, CHRONIC NONSUPPURATIVE see **PERIAPICAL GRANULOMA**

PERIODONTIUM

INNERVATION

Encoding of tooth loads by human periodontal afferents and their role in jaw motor control. Trulsson M, et al. **Prog Neurobiol** 1996 Jun;49(3):267–84 (89 ref.)

MICROBIOLOGY

Can one acquire periodontal bacteria and periodontitis from a family member? Asikainen S, et al. **J Am Dent Assoc** 1997 Sep;128(9):1263–71 (37 ref.)

PATHOLOGY

[Smoking and the periodontium (I). History and clinical aspects. A review of the literature] Brochut PF, et al. **Schweiz Monatsschr Zahnmed** 1997;107(8):672–86 (89 ref.) **(Fre, Ger)**

PHYSIOLOGY

Periodontal tissue engineering by growth factors. Giannobile WV. **Bone** 1996 Jul;19(1 Suppl):23S–37S (117 ref.)

Biochemistry of periodontal connective tissues and their regeneration: a current perspective. Narayanan AS, et al. **Connect Tissue Res** 1996;34(3):191–201 (91 ref.)

Tissue engineering, morphogenesis, and regeneration of the periodontal tissues by bone morphogenetic proteins. Ripamonti U, et al. **Crit Rev Oral Biol Med** 1997; 8(2):154–63 (86 ref.)

SURGERY

Soft tissue management in endodontic surgery. Peters LB, et al. **Dent Clin North Am** 1997 Jul;41(3):513–28 (24 ref.)

PERIODONTIUM, APICAL see **PERIAPICAL TISSUE**

PERIOPERATIVE NURSING

see related
OPERATING ROOM NURSING
POSTANESTHESIA NURSING

Surgical treatment of emphysema using bovine pericardium strips. Allen GM. **AORN J** 1996 Feb;63(2):373, 376–80, 383–4, passim 388 (14 ref.)

Arthroscopic repairs of triangular fibrocartilage complex tears. Baehser-Griffith P, et al. **AORN J** 1997 Jul; 66(1):101–2, 105–11, quiz 112, 115, 117–8 (23 ref.)

Collagen injection therapy for type III stress urinary incontinence. Bartholomew B, et al. **AORN J** 1996 Jul; 64(1):75–83, 85–6 (28 ref.)

Timing of perioperative antibiotic administration [see comments] Butts JD, et al. **AORN J** 1997 Jan;65(1):109–15 (22 ref.) Comment in: AORN J 1997 May;65(5):888.

Blood administration in perioperative settings. Craig V, et al. **AORN J** 1997 Jul;66(1):133–8, 140–3 (55 ref.)

Pediatric tonsillectomy and adenoidectomy procedures. Derkay CS, et al. **AORN J** 1995 Dec;62(6):887–904; quiz 906–10 (36 ref.)

Bilateral lung volume reduction surgery for treatment of emphysema. Dickey DM. **AORN J** 1996 Feb;63(2):355–64, 367, 372; quiz 406, 409–14 (26 ref.)

Malignant hyperthermia. Dunn D. **AORN J** 1997 Apr; 65(4):728, 731, passim; quiz 755–8, 760–2 (40 ref.)

Stereotactic pallidotomy for treatment of Parkinson's disease. Eller TW, et al. **AORN J** 1997 May;65(5):903–4, 907–16; quiz 917–20 (16 ref.)

Surgical treatment of pheochromocytomas. Gavaghan M. **AORN J** 1997 Jun;65(6):1041–51 passim; quiz 1072–80 (64 ref.)

Bilateral lung volume reduction surgery. Graling PR, et al. **AORN J** 1996 Feb;63(2):389–90, 392, 394 passim (10 ref.)

Pial synangiosis for treatment of Moyamoya syndrome in children. Hannon KE. **AORN J** 1996 Oct;64(4):540–54; quiz 557–60 (40 ref.)

Pediatric dental rehabilitation procedures in the OR. Haskins DR. **AORN J** 1996 Oct;64(4):573–9 (23 ref.)

Perioperative nursing care of patients with craniofacial injuries. Hayes KM, et al. **AORN J** 1996 Sep;64(3):385–98; quiz 407–10, 413–4 (44 ref.)

Treatment of depression with outpatient electroconvulsive therapy. Irvin SM. **AORN J** 1997 Mar;65(3):573–8, 581–2 (44 ref.)

Sexual harassment and hostile environments in the perioperative area. Kaye J. **AORN J** 1996 Feb;63(2):443–6, 448–9 (51 ref.)

A guide to salivary gland disorders. McEwen DR, et al. **AORN J** 1997 Mar;65(3):554–6, 559–67; quiz 568–9, 571–2 (36 ref.)

Management of alcoholic cirrhosis of the liver. McEwen DR. **AORN J** 1996 Aug;64(2):209–16, 218–20, 222–3 passim (64 ref.)

Managing patients with pancreatic cancer. McEwen DR, et al. **AORN J** 1996 Nov;64(5):716–35; quiz 737–44 (48 ref.)

Surgical treatment for intranasal squamous cell carcinoma. McEwen DR, et al. **AORN J** 1996 Jan;63(1):163–75; quiz 176, 179, 181–2 (15 ref.)

Liver-kidney transplantation for Budd-Chiari syndrome. Ronk LL, et al. **AORN J** 1996 Aug;64(2):196–201, 203–6 (27 ref.)

Triple arthrodesis. Schramm CA, et al. **AORN J** 1996 Jul; 64(1):31–52; quiz 54–61 (22 ref.)

Transoral resection of spinal cord tumors and posterior cervical spine stabilization. Walton PG, et al. **AORN J** 1997 Jan;65(1):48–50, 52–9, 62–8; quiz 69–74 (45 ref.)

Management of retrohepatic venous injuries with atrial caval shunts. Weber S, et al. **AORN J** 1996 Sep;64(3):376–7, 380–2 (14 ref.)

Marfan's syndrome and surgical repair of ascending aortic aneurysms. Wieczorek P, et al. **AORN J** 1996 Dec; 64(6):895–913; quiz 916–8, 921–2 (46 ref.)

Cryosurgical ablation of unresectable hepatic tumors [published erratum appears in AORN J 1996 Nov;64(5):686] Zuro LM, et al. **AORN J** 1996 Aug;64(2):231–6, 239–44; quiz 244–6, 248–50 (37 ref.)

The ambulatory surgical nurse. Evolution, competency, and vision. Brockway PM. **Nurs Clin North Am** 1997 Jun; 32(2):387–94 (14 ref.)

Ethical issues in pediatric perioperative nursing. Hamblet Berlandi JL. **Nurs Clin North Am** 1997 Mar;32(1):153–68 (39 ref.)

Ambulatory surgery. Care of the special needs patient. Litwack K. **Nurs Clin North Am** 1997 Jun;32(2):457–68 (10 ref.)

METHODS

Pediatric sedation. Essentials for the perioperative nurse. Algren CL, et al. **Nurs Clin North Am** 1997 Mar;32(1):17–30 (49 ref.)

Patient teaching in ambulatory surgery. Lancaster KA. **Nurs Clin North Am** 1997 Jun;32(2):417–27 (18 ref.)

Streamlining the perioperative process. LaRosa-Nash P, et al. **Nurs Clin North Am** 1997 Mar;32(1):141–51 (24 ref.)

Ambulatory surgery. Preoperative assessment and health history interview. Williams GD. **Nurs Clin North Am** 1997 Jun;32(2):395–416 (22 ref.)

TRENDS

Advances in pediatric anesthesia. Burns LS. **Nurs Clin North Am** 1997 Mar;32(1):45–71 (159 ref.)

Current practices and advances in pediatric neurosurgery. Lawton KH, et al. **Nurs Clin North Am** 1997 Mar; 32(1):73–96 (30 ref.)

PERIOSTEUM

PHYSIOLOGY

Periosteum: its relation to pediatric fractures. Jacobsen FS. **J Pediatr Orthop B** 1997 Apr;6(2):84–90 (94 ref.)

TRANSPLANTATION

Lower eyelid reconstruction using pedicled skin flap and palatal mucoperiosteum. Perry MJ, et al. **Dermatol Surg** 1997 May;23(5):395–7; discussion 397–8 (10 ref.)

PERIPHERAL ANGIOPATHIES see **PERIPHERAL VASCULAR DISEASES**

PERIPHERAL CATHETERIZATION see **CATHETERIZATION, PERIPHERAL**

PERIPHERAL EQUIPMENT, COMPUTER see **COMPUTER PERIPHERALS**

PERIPHERAL NERVE DISEASES see **PERIPHERAL NERVOUS SYSTEM DISEASES**

PERIPHERAL NERVE NEOPLASMS

COMPLICATIONS

Giant intrasacral schwannoma forming a presacral mass: a report of an unusual cause of lumbosacral radiculopathy. Turgut M, et al. **Zentralbl Neurochir** 1996;57(4):201–5 (19 ref.)

DIAGNOSIS

Case report: magnetic resonance imaging of primary lymphoma of the cauda equina. Ooi GC, et al. **Br J Radiol** 1996 Nov;69(827):1057–60 (13 ref.)

Pictorial review: imaging of peripheral nerve tumours. Beggs I. **Clin Radiol** 1997 Jan;52(1):8–17 (49 ref.)

Intraneural capillary hemangioma of the cauda equina. Mastronardi L, et al. **Eur Spine J** 1997;6(4):278–80 (13 ref.)

Carcinoma and the peripheral nervous system. Hughes R, et al. **J Neurol** 1996 May;243(5):371–6 (32 ref.)

Malignant peripheral nerve sheath tumor of the orbit in a newborn: a case report and review. Fezza JP, et al. **J Pediatr Ophthalmol Strabismus** 1997 Mar–Apr; 34(2):128–31 (10 ref.)

[Neurinomas and ependymomas of the cauda equina. A review of the clinical characteristics] Cervoni L, et al. **Minerva Chir** 1997 May;52(5):629–33 (36 ref.) (Eng. Abstr.) **(Ita)**

[Diagnosis and treatment of peripheral nerve tumor] Usui M. **Nippon Seikeigeka Gakkai Zasshi** 1997 May; 71(5):161–70 (23 ref.) **(Jpn)**

ETIOLOGY

Management of neuromas in the hand. Nath RK, et al. **Hand Clin** 1996 Nov;12(4):745–56 (35 ref.)

PATHOLOGY

Soft-tissue perineurioma. Evidence for an abnormality of chromosome 22, criteria for diagnosis, and review of the literature. Giannini C, et al. **Am J Surg Pathol** 1997 Feb; 21(2):164–73 (45 ref.)

Malignant peripheral nerve sheath tumour with vascular differentiation: a report of four cases. Morphopoulos GD, et al. **Histopathology** 1996 May;28(5):401–10 (41 ref.)

Gastrointestinal autonomic nerve tumor with giant abscess. A case report and literature review. Honda K, et al. **J Clin Gastroenterol** 1997 Jun;24(4):280–5 (12 ref.)

Schwannomatosis: a clinical and pathologic study [see comments] MacCollin M, et al. **Neurology** 1996 Apr; 46(4):1072–9 (40 ref.) Comment in: Neurology 1997 Mar;48(3):787–8.

PHYSIOPATHOLOGY

Schwannomatosis: a clinical and pathologic study [see comments] MacCollin M, et al. **Neurology** 1996 Apr; 46(4):1072–9 (40 ref.) Comment in: Neurology 1997 Mar;48(3):787–8.

RADIOGRAPHY

Malignant autonomic nerve tumor of the duodenum. Jain KA, et al. **AJR Am J Roentgenol** 1997 Jun;168(6):1461-3 (8 ref.)

SECONDARY

Cauda equina metastasis from ovarian malignancy. Rivano C, et al. **Eur J Gynaecol Oncol** 1996;17(5):397-9 (13 ref.)

SURGERY

Spinal meningeal melanocytoma: a case report and review of the literature. Sankhla SK, et al. **Br J Neurosurg** 1996 Apr;10(2):205-9 (28 ref.)

Primary non-Hodgkin's lymphoma of the sciatic nerve followed by localization in the central nervous system: case report and review of the literature. Roncaroli F, et al. **Neurosurgery** 1997 Mar;40(3):618-21; discussion 621-2 (11 ref.)

VETERINARY

Tumours of the nervous system. Cardesa A, et al. **IARC Sci Publ** 1996;(126):427-65 (109 ref.)

PERIPHERAL NERVES

see related
NERVE FIBERS

ANATOMY & HISTOLOGY

Anatomic predilection of the spondyloarthropathies(-)a case of the nerves? Segal AH. **J Rheumatol** 1996 Mar; 23(3):491-4 (60 ref.)

CHEMISTRY

Molecular specializations at nodes and paranodes in peripheral nerve. Scherer SS. **Microsc Res Tech** 1996 Aug 1;34(5):452-61 (102 ref.)

Peripheral nerve immunohistochemistry in diabetic neuropathy. Younger DS, et al. **Semin Neurol** 1996 Jun; 16(2):139-42 (48 ref.)

DRUG EFFECTS

The effect of a peripherally-acting opioid on sensory nerve function. Garland L. **Pulm Pharmacol** 1995 Aug-Oct; 8(4-5):231-6 (9 ref.)

EMBRYOLOGY

neurogenins, a novel family of atonal-related bHLH transcription factors, are putative mammalian neuronal determination genes that reveal progenitor cell heterogeneity in the developing CNS and PNS. Sommer L, et al. **Mol Cell Neurosci** 1996;8(4):221-41 (51 ref.)

INJURIES

Advances in peripheral nerve repair. Watchmaker GP, et al. **Clin Plast Surg** 1997 Jan;24(1):63-73 (108 ref.)

Nerve injury and repair in the foot and ankle. Santi MD, et al. **Foot Ankle Int** 1996 Jul;17(7):425-39 (108 ref.)

The physiological and metabolic consequences of muscle denervation. Frostick SP. **Int Angiol** 1995 Sep;14(3):278-87 (92 ref.)

Priming events and retrograde injury signals. A new perspective on the cellular and molecular biology of nerve regeneration. Ambron RT, et al. **Mol Neurobiol** 1996 Aug; 13(1):61-79 (98 ref.)

Plasticity of messenger function in primary afferents following nerve injury--implications for neuropathic pain. Wiesenfeld-Hallin Z, et al. **Prog Brain Res** 1996;110:113-24 (80 ref.)

Peripheral nerve injury. Welch JA. **Semin Vet Med Surg (Small Anim)** 1996 Nov;11(4):273-84 (36 ref.)

METABOLISM

Antioxidants in peripheral nerve. Romero FJ. **Free Radic Biol Med** 1996;20(7):925-32 (112 ref.)

Receptor-mediated phosphoinositide metabolism in peripheral nerve and cultured Schwann cells. Eichberg J, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1-3):187-95 (26 ref.)

Metabolic alterations of peripheral nerve in diabetes. Sima AA. **Semin Neurol** 1996 Jun;16(2):129-37 (76 ref.)

Cholesterol and myelin. Snipes GJ, et al. **Subcell Biochem** 1997;28:173-204 (170 ref.)

PATHOLOGY

Impairment of central and peripheral myelin in mitochondrial diseases. Kalman B, et al. **Mult Scler** 1997 Jan;2(6):267-78 (112 ref.)

Utility of skin biopsy in diabetic neuropathy. Kennedy WR, et al. **Semin Neurol** 1996 Jun;16(2):163-71 (40 ref.)

PHYSIOLOGY

Technical and interpretive problems of peripheral nerve stimulation in monitoring neuromuscular blockade in the intensive care unit. Rudis MI, et al. **Ann Pharmacother** 1996 Feb;30(2):165-72 (4 ref.)

Nerve regeneration and repair. Danielsen N. **Diabet Med** 1996 Jul;13(7):677-8 (12 ref.)

Role of polysialic acid in peripheral myelinated axons. Carratù MR, et al. **Microsc Res Tech** 1996 Aug 15; 34(6):489-91 (13 ref.)

The cellular and molecular basis of peripheral nerve regeneration. Fu SY, et al. **Mol Neurobiol** 1997 Feb-Apr; 14(1-2):67-116 (462 ref.)

Neurosteroids, with special reference to the effect of progesterone on myelination in peripheral nerves. Baulieu EE, et al. **Mult Scler** 1997 Apr;3(2):105-12 (51 ref.)

Peripheral nerve regeneration. Ide C. **Neurosci Res** 1996 Jun; 25(2):101-21 (250 ref.)

Spinal cord mechanisms of hyperalgesia and allodynia: role of peripheral input from nociceptors. Cervero F. **Prog Brain Res** 1996;113:413-22 (32 ref.)

Maturation of the mammalian dorsal root entry zone--from entry to no entry. Golding J, et al. **Trends Neurosci** 1997 Jul;20(7):303-8 (53 ref.)

[Motor nerve conduction study] Ozaki I, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:413-6 (6 ref.) **(Jpn)**

[Measurement of nerve conduction velocity of single or compound nerve action potential using microneurographic technique] Toma S, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:420-5 (5 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Peripheral nerve involvement in merosin-deficient congenital muscular dystrophy and dy mouse. Matsumura K, et al. **Neuromuscul Disord** 1997 Jan;7(1):7-12 (50 ref.)

Post-sympathectomy neuralgia: hypotheses on peripheral and central neuronal mechanisms [see comments] Kramis RC, et al. **Pain** 1996 Jan;64(1):1-9 (66 ref.) Comment in: Pain 1996 Sep;67(1):218-20. Comment in: Pain 1997 Apr;70(2-3):290-1.

SURGERY

Current principles in microsurgical nerve repair. Hausamen JE, et al. **Br J Oral Maxillofac Surg** 1996 Apr;34(2):143-57 (51 ref.)

Advances in peripheral nerve repair. Watchmaker GP, et al. **Clin Plast Surg** 1997 Jan;24(1):63-73 (108 ref.)

Nerve injury and repair in the foot and ankle. Santi MD, et al. **Foot Ankle Int** 1996 Jul;17(7):425-39 (108 ref.)

Treatment of chronic pain by "wrapping" intact nerves with pedicle and free flaps. Jones NF. **Hand Clin** 1996 Nov; 12(4):765-72 (23 ref.)

The treatment of epineural scarring with allograft vein wrapping. Masear VR, et al. **Hand Clin** 1996 Nov; 12(4):773-9 (28 ref.)

Historical and basic science review: past, present, and future of nerve repair. Terzis JK, et al. **J Reconstr Microsurg** 1997 Apr;13(3):215-25 (94 ref.)

Laser(-assisted) nerve repair. A review. Menovsky T, et al. **Neurosurg Rev** 1995;18(4):225-35 (67 ref.)

TRANSPLANTATION

Vascularized nerve grafts. A review. Terzis JK, et al. **Int Angiol** 1995 Sep;14(3):264-77 (53 ref.)

[Nerve transfer (neurotization) for functional reconstruction of arm functions in cervical root avulsions] Nikkhah G, et al. **Orthopade** 1997 Jul;26(7):606-11 (21 ref.) (Eng. Abstr.) **(Ger)**

[Nerve transplantation and neurolysis of the brachial plexus after post-traumatic lesions] Nikkhah G, et al. **Orthopade** 1997 Jul;26(7):612-20 (24 ref.) (Eng. Abstr.) **(Ger)**

[Optic nerve regeneration by nerve transplantation] Fukuda Y. **Nippon Ganka Gakkai Zasshi** 1996 Dec;100(12):956-71 (74 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

Node-paranode regions as local degradative centres in alpha-motor axons. Gatzinsky KP. **Microsc Res Tech** 1996 Aug 15;34(6):492-506 (117 ref.)

Accumulation of synaptic vesicle proteins and cytoskeletal specializations at the peripheral node of Ranvier. Zimmermann H. **Microsc Res Tech** 1996 Aug 1; 34(5):462-73 (70 ref.)

PERIPHERAL NERVOUS SYSTEM

see related
NEURAL PATHWAYS

DRUG EFFECTS

The effect of naloxone on spontaneous and evoked dopamine release in the central and peripheral nervous systems. Feigenbaum JJ, et al. **Life Sci** 1996;59(24):2009-19 (128 ref.)

Mechanisms of action of central and peripheral antitussive drugs. Bolser DC. **Pulm Pharmacol** 1996 Oct-Dec; 9(5-6):357-64 (78 ref.)

EMBRYOLOGY

Hoxb-8 gain-of-function transgenic mice exhibit alterations in the peripheral nervous system. Fanarraga ML, et al. **J Neurosci Methods** 1997 Jan;71(1):11-8 (19 ref.)

Embryonic development of Schwann cells: multiple roles for neuregulins along the pathway. Topilko P, et al. **Mol Cell Neurosci** 1996;8(2-3):71-5 (46 ref.)

Molecular biology of axon-glia interactions in the peripheral nervous system. Taylor V, et al. **Prog Nucleic Acid Res Mol Biol** 1997;56:225-56 (221 ref.)

GROWTH & DEVELOPMENT

The development of nerve connections in the peripheral nervous system. Cullheim S. **Acta Paediatr Suppl** 1996 Oct; 416:3-7 (24 ref.)

[Neurotrophins and the development of the peripheral nervous system] Catala M. **Rev Neurol (Paris)** 1997 Feb; 155(1):73-5 (18 ref.) **(Fre)**

IMMUNOLOGY

Brain-periphery connections: do they play a role in mediating the effect of centrally injected interleukin-1 beta on gonadal function? Turnbull A, et al. **Neuroimmunomodulation** 1995 Jul-Aug;2(4):224-35 (79 ref.)

INJURIES

Mechanisms of reorganization in sensory systems of primates after peripheral nerve injury. Kaas JH, et al. **Adv Neurol** 1997;73:147-58 (122 ref.)

Axonal regeneration through acellular muscle grafts. Hall S. **J Anat** 1997 Jan;190 (Pt 1):57-71 (110 ref.)

METABOLISM

Presynaptic 5-HT auto- and heteroreceptors in the human central and peripheral nervous system. Göthert M, et al. **Behav Brain Res** 1996;73(1-2):89-92 (24 ref.)

Vascular permeability in the peripheral autonomic and somatic nervous systems: controversial aspects and comparisons with the blood-brain barrier. Kiernan JA. **Microsc Res Tech** 1996 Oct 1;35(2):122-36 (239 ref.)

Origin of cholesterol in myelin. Morell P, et al. **Neurochem Res** 1996 Apr;21(4):463-70 (31 ref.)

Free D-aspartate and D-serine in the mammalian brain and periphery. Hashimoto A, et al. **Prog Neurobiol** 1997 Jul; 52(4):325-53 (351 ref.)

PHYSIOLOGY

Axotomy as an experimental model of neuronal injury and cell death. Koliatsos VE, et al. **Brain Pathol** 1996 Oct; 6(4):447-65 (164 ref.)

Progesterone as a neurosteroid: actions within the nervous system. Baulieu EE, et al. **Cell Mol Neurobiol** 1996 Apr; 16(2):143-54 (50 ref.)

Nociceptors and the peripheral nervous system's role in pain. Greenspan JD. **J Hand Ther** 1997 Apr-Jun;10(2):78-85 (55 ref.)

Noninvasive measures of central and peripheral activation in human muscle fatigue. Kent-Braun JA. **Muscle Nerve Suppl** 1997;5:S98-101 (12 ref.)

Non-adrenergic non-cholinergic (NANC) transmission to smooth muscle: 35 years on. Bennett MR. **Prog Neurobiol** 1997 Jun;52(3):159-95 (261 ref.)

PHYSIOPATHOLOGY

Peripheral pain mechanisms. Cesare P, et al. **Curr Opin Neurobiol** 1997 Aug;7(4):493-9 (65 ref.)

SURGERY

[Polymer biomaterials (polyphosphazenes) in the repair of peripheral nervous system] Nicoli Aldini N, et al. **Ann Ital Chir** 1996 Nov-Dec;67(6):843-8 (35 ref.) (Eng. Abstr.) **(Ita)**

PERIPHERAL NERVOUS SYSTEM DISEASES

see related
NEUROMUSCULAR DISEASES
SPINAL CORD DISEASES

Nerve entrapment syndromes [see comments] Nakano KK. **Curr Opin Rheumatol** 1997 Mar;9(2):165-73 (58 ref.) Comment in: Curr Opin Rheumatol 1997 Mar;9(2):133-43.

Diabetes and the nervous system. Harati Y. **Endocrinol Metab Clin North Am** 1996 Jun;25(2):325-59 (295 ref.)

[Variety in radicular symptoms and signs at the lumbosacral region] Hasue M. **Nippon Seikeigeka Gakkai Zasshi** 1996 Jan;70(1):1-6 (28 ref.) **(Jpn)**

CHEMICALLY INDUCED

The concept and target of promotion of axonopathies. Lotti M. **Arch Toxicol Suppl** 1997;19:331-6 (45 ref.)

Central and peripheral neurotoxic effects of chronic methyl bromide intoxication. De Haro L, et al. **J Toxicol Clin Toxicol** 1997;35(1):29-34 (13 ref.)

Chronic neurologic effects of pesticide overexposure. Keifer MC, et al. **Occup Med** 1997 Apr-Jun;12(2):291-304 (82 ref.)

COMPLICATIONS

Idiopathic eosinophilic myositis associated with vasculitis and symmetrical polyneuropathy. Espino-Montoro A, et al. **Br J Rheumatol** 1997 Feb;36(2):276-9 (18 ref.)

Brachial plexus injury in association with fracture-dislocation

of the shoulder. Yip KM, et al. **Bull Hosp Jt Dis** 1996; 55(2):92–4 (8 ref.)

Peripheral neuropathy in HIV. Sadler M, et al. **Int J STD AIDS** 1997 Jan;8(1):16–21; quiz 22 (45 ref.)

Neurally mediated syncope and syncope due to autonomic failure: differences and similarities. Kaufmann H. **J Clin Neurophysiol** 1997 May;14(3):183–96 (73 ref.)

Physical evaluation of the peripheral nervous system in disorders of pain and dysfunction. Elvey RL. **J Hand Ther** 1997 Apr–Jun;10(2):122–9 (29 ref.)

Neuropathy associated with "benign" anti–myelin–associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases. Ellie E, et al. **J Neurol** 1996 Jan; 243(1):34–43 (43 ref.)

Autonomic neuropathy, I. Clinical features, investigation, pathophysiology, and treatment. McDougall AJ, et al. **J Neurol Sci** 1996 May;137(2):79–88 (78 ref.)

Autonomic neuropathy, II: Specific peripheral neuropathies. McDougall AJ, et al. **J Neurol Sci** 1996 Jun;138(1–2):1–13 (156 ref.)

Peripheral neuropathy in polyarteritis nodosa. Said G. **Springer Semin Immunopathol** 1996;18(1):75–84 (44 ref.)

[Peripheral neuropathies associated with IgM monoclonal gammopathy: clinical and electrophysiological aspects] Léger JM, et al. **Rev Neurol (Paris)** 1996 May;152(5):394–9 (37 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Physical evaluation of the peripheral nervous system in disorders of pain and dysfunction. Elvey RL. **J Hand Ther** 1997 Apr–Jun;10(2):122–9 (29 ref.)

Evaluation and management of polyneuropathy: a practical approach. Petit J, et al. **Nurse Pract** 1997 May;22(5):131–3, 136–8, 141–3 passim (32 ref.)

Recognizing peripheral neuropathy. How to read the clues to an underlying cause. Morgenlander JC. **Postgrad Med** 1997 Sep;102(3):71–2, 75, 80 (1 ref.)

The brachial plexus. Mukherji SK, et al. **Semin Ultrasound CT MR** 1996 Dec;17(6):519–38 (44 ref.)

[Electrophysiologic study, diagnosis and cases of acquired sensory polyneuropathy] Maisonobe T, et al. **Neurophysiol Clin** 1996;26(4):202–15 (74 ref.) (Eng. Abstr.) **(Fre)**

[Diagnosis of monogenic diseases of the peripheral nervous system] Haupt A, et al. **Dtsch Med Wochenschr** 1996 Nov 22;121(47):1469–72 (13 ref.) **(Ger)**

DRUG THERAPY

Neurotrophic factors in the treatment of peripheral neuropathy. Apfel SC, et al. **Ciba Found Symp** 1996; 196:98–108; discussion 108–12 (40 ref.)

Cytomegalovirus polyradiculopathy treated successfully with foscarnet [letter] Corral I, et al. **Eur J Clin Microbiol Infect Dis** 1996 May;15(5):428–9 (10 ref.)

Bangkok Workshop on Leprosy Research. Treatment of reactions and nerve damage. Naafs B. **Int J Lepr Other Mycobact Dis** 1996 Dec;64(4 Suppl):S21–8 (34 ref.)

Development of recombinant human nerve growth factor (rhNGF) as a treatment for peripheral neuropathic disease. Rogers BC. **Neurotoxicology** 1996 Fall–Winter; 17(3–4):865–70 (46 ref.)

Neurotrophic factors in peripheral neuropathies: pharmacological strategies. Riaz SS, et al. **Prog Neurobiol** 1996 Jun;49(2):125–43 (160 ref.)

EPIDEMIOLOGY

Nerve abscess in children and adults leprosy patients: analysis of 145 cases and review of the literature. Salafia A, et al. **Acta Leprol** 1996;10(1):45–50 (40 ref.)

ETIOLOGY

Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. Latov N. **Ann Neurol** 1995 May;37 Suppl 1:S32–42 (157 ref.)

Systemic lupus erythematosus with ischemic peripheral neuropathy and lupus anticoagulant: response to intravenous prostaglandin E1. Yoshikawa Y, et al. **Cutis** 1996 Dec;58(6):393–6 (8 ref.)

Cytokines and peripheral nerve disorders. Créange A, et al. **Eur Cytokine Netw** 1997 Jun;8(2):145–51 (84 ref.)

Brachial plexopathy secondary to anticoagulant–induced hematoma as a complication of axillary arteriography. Shoup DW, et al. **J Am Osteopath Assoc** 1997 Feb; 97(2):102–5 (18 ref.)

Carcinoma and the peripheral nervous system. Hughes R, et al. **J Neurol** 1996 May;243(5):371–6 (32 ref.)

Acquired peripheral neuropathy. Chalk CH. **Neurol Clin** 1997 Aug;15(3):501–28 (104 ref.)

Acute peripheral neuropathy in adults. Guillain–Barré syndrome and related disorders. Pascuzzi RM, et al. **Neurol Clin** 1997 Aug;15(3):529–47 (71 ref.)

Endocrinologic causes of peripheral neuropathy. Pins and needles in a stocking–and–glove pattern and other symptoms. Perkins AT, et al. **Postgrad Med** 1997 Sep; 102(3):81–2, 90–2, 102–6 (21 ref.)

Molecular pathogenesis of peripheral neuropathy. Trapp BD, et al. **Rev Neurol (Paris)** 1996 May;152(5):314–9 (48 ref.)

[Sensorimotor polyneuropathy in a flare–up of Crohn disease] Duval L, et al. **Rev Med Interne** 1997;18(3):230–2 (14 ref.) (Eng. Abstr.) **(Fre)**

[Involvements of the peripheral nervous system and primary Gougerot–Sjögren syndrome] Rodier G, et al. **Rev Med Interne** 1996;17(7):558–62 (30 ref.) (Eng. Abstr.) **(Fre)**

[Rubella virus] Abe T, et al. **Nippon Rinsho** 1997 Apr; 55(4):865–9 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Uremic neuropathy] Maeda K. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):63–5 (20 ref.) **(Jpn)**

GENETICS

Molecular mechanisms for Charcot–Marie–Tooth disease and related demyelinating peripheral neuropathies. Warner LE, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:659–71 (115 ref.)

[Diagnosis of monogenic diseases of the peripheral nervous system] Haupt A, et al. **Dtsch Med Wochenschr** 1996 Nov 22;121(47):1469–72 (13 ref.) **(Ger)**

IMMUNOLOGY

Monoclonal gammopathy and neuropathy. Notermans NC. **Curr Opin Neurol** 1996 Oct;9(5):334–7 (20 ref.)

Cytokines and peripheral nerve disorders. Créange A, et al. **Eur Cytokine Netw** 1997 Jun;8(2):145–51 (84 ref.)

Immunologically induced electrophysiological dysfunction: implications for inflammatory diseases of the CNS and PNS. Köller H, et al. **Prog Neurobiol** 1997 May;52(1):1–26 (250 ref.)

Autoimmune responses in peripheral nerve. Hartung HP, et al. **Springer Semin Immunopathol** 1996;18(1):97–123 (237 ref.)

[Anti–ganglioside antibodies and peripheral neuropathies] Humbel RL, et al. **Rev Med Liege** 1996 May;51(5):368–75 (84 ref.) **(Fre)**

[Anti–glycoconjugate antibodies and dysglobulinemic or dysimmune peripheral neuropathies] Steck AJ, et al. **Rev Neurol (Paris)** 1996 May;152(5):400–4 (27 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Progressive systemic sclerosis associated with multiple mononeuropathy. Nitta Y, et al. **Dermatology** 1996; 193(1):22–6 (19 ref.)

Morphological changes at paranodes in IgM paraproteinaemic neuropathy. Jacobs JM. **Microsc Res Tech** 1996 Aug 15;34(6):544–53 (59 ref.)

[Peripheral neuropathies in childhood: a neuropathological approach] Chimelli L. **Arq Neuropsiquiatr** 1996 Sep; 54(3):510–8 (29 ref.) (Eng. Abstr.) **(Por)**

PHYSIOPATHOLOGY

F–waves in clinical neurophysiology: a review, methodological issues and overall value in peripheral neuropathies. Panayiotopoulos CP, et al. **Electroencephalogr Clin Neurophysiol** 1996 Oct; 101(5):365–74 (75 ref.)

Sensory neuropathies including painful and toxic neuropathies. Wokke JH, et al. **J Neurol** 1997 Apr; 244(4):209–21 (94 ref.)

Immunologically induced electrophysiological dysfunction: implications for inflammatory diseases of the CNS and PNS. Köller H, et al. **Prog Neurobiol** 1997 May;52(1):1–26 (250 ref.)

Pure motor hand weakness. Lewis RA. **Semin Neurol** 1996 Mar;16(1):75–81 (48 ref.)

Peripheral nervous system Lyme borreliosis. Logigian EL. **Semin Neurol** 1997 Mar;17(1):25–30 (0 ref.)

[Neurologic signs and symptoms in viral infections—disease involving meninges, central nervous system or peripheral nerve system] Araga S, et al. **Nippon Rinsho** 1997 Apr; 55(4):805–8 (24 ref.) (Eng. Abstr.) **(Jpn)**

REHABILITATION

Management of pain in brachial plexus lesions. Frampton V. **J Hand Ther** 1996 Oct–Dec;9(4):339–43 (23 ref.)

THERAPY

The use of self infused intravenous immunoglobulin home therapy in the treatment of acquired chronic demyelinating neuropathies. Sewell WA, et al. **J Neurol Neurosurg Psychiatry** 1997 Jul;63(1):106–9 (18 ref.)

Evaluation and management of polyneuropathy: a practical approach. Petit J, et al. **Nurse Pract** 1997 May;22(5):131–3, 136–8, 141–3 passim (32 ref.)

[Treatment of peripheral neuropathies associated with IgM anti–myelin monoclonal gammopathy] Mariette X, et al. **Rev Neurol (Paris)** 1996 May;152(5):413–6 (23 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Peripheral nerve injury. Welch JA. **Semin Vet Med Surg (Small Anim)** 1996 Nov;11(4):273–84 (36 ref.)

PERIPHERAL RESISTANCE see **VASCULAR RESISTANCE**

PERIPHERAL STEM CELL TRANSPLANTATION see **HEMATOPOIETIC STEM CELL TRANSPLANTATION**

PERIPHERAL T-CELL LYMPHOMA see **LYMPHOMA, T-CELL, PERIPHERAL**

PERIPHERAL VASCULAR DISEASES

Quality of life assessment in peripheral arterial disease. Hiatt WR. **Atherosclerosis** 1997 Jun;131 Suppl:S35–6 (7 ref.)

Management of peripheral arterial disease in patients with end–stage renal failure. Koskas F, et al. **Nephrol Dial Transplant** 1997 Mar;12(3):604–7 (9 ref.)

CHEMICALLY INDUCED

Vascular complications of injecting drug misuse [see comments] Woodburn KR, et al. **Br J Surg** 1996 Oct; 83(10):1329–34 (40 ref.) Comment in: Br J Surg 1997 Apr;84(4):582–3.

Sexual dysfunction in nonseminoma testicular cancer patients is related to chemotherapy–induced angiopathy. van Basten JP, et al. **J Clin Oncol** 1997 Jun;15(6):2442–8 (55 ref.)

COMPLICATIONS

Modified lipoproteins, cytokines and macrovascular disease in non–insulin–dependent diabetes mellitus. Lopes–Virella MF, et al. **Ann Med** 1996 Aug;28(4):347–54 (78 ref.)

Enhanced limb salvage for peripheral vascular disease with the use of spinal cord stimulation. Huber SJ, et al. **W V Med J** 1996 Mar–Apr;92(2):89–91 (14 ref.)

DIAGNOSIS

MR angiography of the peripheral vasculature. Schmiedl UP, et al. **Semin Ultrasound CT MR** 1996 Aug;17(4):404–11 (36 ref.)

[Cardiac evaluation in arteritis] Le Feuvre C, et al. **J Mal Vasc** 1996;21(5):271–6 (45 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Diabetes mellitus and peripheral vascular disease: is aspirin effective in preventing vascular events? [see comments] Cimminiello C, et al. **Diabetologia** 1996 Nov;39(11):1402–4 (26 ref.) Comment in: Diabetologia 1996 Nov;39(11):1405–6. Comment in: Diabetologia 1996 Nov;39(11):1407–8.

State of the art—treatment of peripheral occlusive arterial disease (POAD) with drugs vs. vascular reconstruction or amputation. Haustein KO. **Int J Clin Pharmacol Ther** 1997 Jul;35(7):266–74 (101 ref.)

[Use of antithrombotic agents in peripheral arterial diseases] Wütschert R, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1551–5 (23 ref.) (Eng. Abstr.) **(Fre)**

ECONOMICS

Socioeconomic impact of peripheral vascular disease. Drummond M. **Atherosclerosis** 1997 Jun;131 Suppl:S33–4 (7 ref.)

EPIDEMIOLOGY

Epidemiology of peripheral vascular disease. Fowkes FG. **Atherosclerosis** 1997 Jun;131 Suppl:S29–31 (16 ref.)

ETIOLOGY

Fibrinogen, fibrin turnover, endothelial products and vascular surgery. Woodburn KR, et al. **Br J Surg** 1997 Aug;84(8):1059–64 (87 ref.)

Dyslipidemia in peripheral vascular disease. Vigna GB, et al. **Curr Opin Lipidol** 1996 Aug;7(4):254–9 (81 ref.)

Abnormal membrane concentrations of 20 and 22–carbon essential fatty acids: a common link between risk factors and coronary and peripheral vascular disease? Horrobin DF. **Prostaglandins Leukot Essent Fatty Acids** 1995 Dec; 53(6):385–96 (157 ref.)

PHYSIOPATHOLOGY

Vibration syndrome and autonomic nervous system. Sakakibara H, et al. **Cent Eur J Public Health** 1995;3 Suppl:11–4 (56 ref.)

RADIOGRAPHY

Peripheral magnetic resonance imaging. Round ME, et al. **Tex Heart Inst J** 1996;23(2):155–61 (18 ref.)

RADIONUCLIDE IMAGING

Noninvasive evaluation of patients with peripheral vascular disease scheduled to undergo surgery: dobutamine stress echocardiography versus myocardial perfusion imaging [see comments] Kovács A, et al. **Am J Card Imaging** 1996 Apr;10(2):133–42 (58 ref.) Comment in: Am J Card Imaging 1996 Apr;10(2):117–9.

RADIOTHERAPY

Management of peripheral vascular disease: innovative approaches using radiation therapy. Nori D, et al.

Int J Radiat Oncol Biol Phys 1996 Nov 1;36(4):847–56 (71 ref.)

SURGERY

Current concepts: amputation surgery in peripheral vascular disease. Pinzur MS. **Instr Course Lect** 1997;46:501–9 (24 ref.)

State of the art--treatment of peripheral occlusive arterial disease (POAD) with drugs vs. vascular reconstruction or amputation. Haustein KO. **Int J Clin Pharmacol Ther** 1997 Jul;35(7):266–74 (101 ref.)

Results of revascularization for peripheral arterial insufficiency in chronic renal failure patients. Donayre CE. **Semin Vasc Surg** 1996 Sep;9(3):253–61 (34 ref.)

[Simultaneous surgical revascularization for myocardial and peripheral vascular ischemia] Saga T, et al. **Kyobu Geka** 1996 Aug;49(9):745–9 (14 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Angiogenic gene therapy. A leg to stand on? [editorial; comment] Fox JC, et al. **Circulation** 1996 Dec 15; 94(12):3065–6 (11 ref.) Comment on: Circulation 1996 Dec 15;94(12):3281–90.

Treatment of peripheral arterial and venous diseases. Navarro F, et al. **Coron Artery Dis** 1996 Sep;7(9):649–55 (35 ref.)

Intravascular ultrasound guidance for peripheral vascular interventions. Scoccianti M, et al. **J Endovasc Surg** 1994 Sep;1:71–80 (43 ref.)

Reporting standards for clinical evaluation of new peripheral arterial revascularization devices. Technology Assessment Committee. Sacks D, et al. **J Vasc Interv Radiol** 1997 Jan–Feb;8(1 Pt 1):137–49 (77 ref.)

[Gene therapy in peripheral vascular disease. A future therapeutic method?] Wahlberg E, et al. **Lakartidningen** 1997 Apr 2;94(14):1276–8, 1283 (79 ref.) **(Swe)**

ULTRASONOGRAPHY

Noninvasive evaluation of patients with peripheral vascular disease scheduled to undergo surgery: dobutamine stress echocardiography versus myocardial perfusion imaging [see comments] Kovács A, et al. **Am J Card Imaging** 1996 Apr;10(2):133–42 (58 ref.) Comment in: Am J Card Imaging 1996 Apr;10(2):117–9.

Intravascular ultrasound guidance for peripheral vascular interventions. Scoccianti M, et al. **J Endovasc Surg** 1994 Sep;1:71–80 (43 ref.)

PERIPHLEBITIS see **PHLEBITIS**

PERIPLANETA

PHYSIOLOGY

The molting gland of the cockroach Periplaneta americana: secretory activity and its regulation. Richter K, et al. **Gen Pharmacol** 1997 Jul;29(1):17–21 (32 ref.)

PERIPLANETA AMERICANA see **COCKROACHES**

PERISTALTIC PUMPS, IMPLANTABLE see **INFUSION PUMPS, IMPLANTABLE**

PERITONEAL CAVITY

see related
ASCITIC FLUID
LAPAROSCOPY

Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. Dedrick RL, et al. **J Natl Cancer Inst** 1997 Apr 2;89(7):480–7 (61 ref.)

Clinical problem of intraperitoneal postsurgical adhesion formation following general surgery and the use of adhesion prevention barriers. DeCherney AH, et al. **Surg Clin North Am** 1997 Jun;77(3):671–88 (80 ref.)

PATHOLOGY

The peritoneal fibroblast and the control of peritoneal inflammation. Jörres A, et al. **Kidney Int Suppl** 1996 Nov; 56:S22–7 (50 ref.)

Activation of inflammation and leukocyte recruitment into the peritoneal cavity. Topley N, et al. **Kidney Int Suppl** 1996 Nov;56:S17–21 (44 ref.)

[The peritoneal environment: physiopathogenesis of endometriosis] Corchado Gómez A, et al. **Ginecol Obstet Mex** 1997 Apr;65:123–5 (20 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Residual renal function, peritoneal transport characteristics and dialysis adequacy in peritoneal dialysis. Heimbürger O. **Kidney Int Suppl** 1996 Nov;56:S47–55 (111 ref.)

Preservation of peritoneal membrane function. Krediet RT, et al. **Kidney Int Suppl** 1996 Nov;56:S62–8 (123 ref.)

Peritoneal membrane morphology and function. Nagy JA. **Kidney Int Suppl** 1996 Nov;56:S2–11 (127 ref.)

PHYSIOPATHOLOGY

Use of intraperitoneal pressure, ultrafiltration and purification dwell times for individual peritoneal dialysis prescription in children. Fischbach M, et al. **Clin Nephrol** 1996 Jul; 46(1):14–6 (11 ref.)

PERITONEAL DIALYSIS

see related
DIALYSIS SOLUTIONS
KIDNEY, ARTIFICIAL

Interpreting glycosylated hemoglobin in diabetic patients on peritoneal dialysis. Tzamaloukas AH. **Adv Perit Dial** 1996; 12:171–5 (40 ref.)

Epidemiological perspective on infections in chronic dialysis patients. Bloembergen WE, et al. **Adv Ren Replace Ther** 1996 Jul;3(3):201–7 (35 ref.)

Dialysis support in the pediatric intensive care unit. Parekh RS, et al. **Adv Ren Replace Ther** 1996 Oct;3(4):326–36 (46 ref.)

Disposal of dialysate in HIV-positive patients: an update. Scheel PJ Jr, et al. **Adv Ren Replace Ther** 1996 Oct; 3(4):298–301 (25 ref.)

Biocompatibility of peritoneal dialysis solutions and host defense. Topley N. **Adv Ren Replace Ther** 1996 Oct; 3(4):309–11 (8 ref.)

Peritoneal dialysis for patients with diabetes and end-stage renal disease: sorting out the biases? [editorial] Finkelstein FO, et al. **ASAIO J** 1996 Jan–Feb;42(1):1–3 (24 ref.)

Use of intraperitoneal pressure, ultrafiltration and purification dwell times for individual peritoneal dialysis prescription in children. Fischbach M, et al. **Clin Nephrol** 1996 Jul; 46(1):14–6 (11 ref.)

Urea volume estimates in peritoneal dialysis: pitfalls and corrections [editorial] Tzamaloukas AH, et al. **Int J Artif Organs** 1996 Jun;19(6):321–4 (25 ref.)

Residual renal function, peritoneal transport characteristics and dialysis adequacy in peritoneal dialysis. Heimbürger O. **Kidney Int Suppl** 1996 Nov;56:S47–55 (111 ref.)

Osmotic agents in peritoneal dialysis. Vanholder RC, et al. **Kidney Int Suppl** 1996 Nov;56:S86–91 (41 ref.)

Low or high calcium dialysate solutions in peritoneal dialysis? Weinreich T. **Kidney Int Suppl** 1996 Nov;56:S92–6 (42 ref.)

New strategies for peritoneal dialysis fluids. Gokal R. **Nephrol Dial Transplant** 1997;12 Suppl 1:74–7 (39 ref.)

Peritoneal dialysis and haemodialysis: are they comparable? Prichard SS. **Nephrol Dial Transplant** 1997;12 Suppl 1:65–7 (18 ref.)

Adequacy of peritoneal dialysis is more than Kt/V. Ronco C. **Nephrol Dial Transplant** 1997;12 Suppl 1:68–73 (10 ref.)

N-acetylglucosamine: a new osmotic solute in peritoneal dialysis solutions. Breborowicz A, et al. **Perit Dial Int** 1997; 17 Suppl 2:S80–3 (20 ref.)

Long-term outcomes of peritoneal dialysis. Cancarini GC, et al. **Perit Dial Int** 1997;17 Suppl 2:S115–8 (16 ref.)

Advanced glycosylation end products in peritoneal tissue with different solutions. Dobbie JW. **Perit Dial Int** 1997; 17 Suppl 2:S27–30 (32 ref.)

The peritoneal dialysis system: importance of each component. Flessner MF. **Perit Dial Int** 1997;17 Suppl 2:S91–7 (39 ref.)

Peritoneal dialysis is a real clinical option. Giangrande AC, et al. **Perit Dial Int** 1997;17 Suppl 2:S149–54 (25 ref.)

Detrimental effects of peritoneal dialysis solutions upon in vivo and in situ exposed mesothelium. Gotloib L, et al. **Perit Dial Int** 1997;17 Suppl 2:S13–6 (38 ref.)

Peritoneal dialysis solution biocompatibility: inhibitory mechanisms and recent studies with bicarbonate-buffered solutions. Jörres A, et al. **Perit Dial Int** 1997;17 Suppl 2:S42–6 (53 ref.)

Impact of different dialysis solutions on solute and water transport. Krediet RT, et al. **Perit Dial Int** 1997;17 Suppl 2:S17–26 (87 ref.)

The impact of residual renal function on the adequacy of peritoneal dialysis. Lameire N, et al. **Perit Dial Int** 1997; 17 Suppl 2:S102–10 (73 ref.)

Factors affecting peritoneal efficiency in different treatment schedules. Nolph KD. **Perit Dial Int** 1997;17 Suppl 2:S98–101 (19 ref.)

Icodextrin: overview of clinical experience [see comments] Peers E, et al. **Perit Dial Int** 1997 Jan–Feb;17(1):22–6 (28 ref.) Comment in: Perit Dial Int 1997 Jan–Feb;17(1):9–10.

Integration of peritoneal dialysis in active uremia treatment. Ronco C, et al. **Perit Dial Int** 1997;17 Suppl 2:S155–60 (9 ref.)

Future clinical research with icodextrin-containing solutions. Shockley TR, et al. **Perit Dial Int** 1997;17 Suppl 2:S70–4 (43 ref.)

In vitro biocompatibility of bicarbonate-based peritoneal dialysis solutions. Topley N. **Perit Dial Int** 1997 Jan–Feb; 17(1):42–7 (45 ref.)

Oligopeptides as osmotic agents for peritoneal dialysis. Wang T, et al. **Perit Dial Int** 1997;17 Suppl 2:S75–9 (39 ref.)

Peritoneal dialysis: an evolving understanding. McCusker FX, et al. **Semin Nephrol** 1997 May;17(3):226–38 (72 ref.)

[Peritoneum as a dialysis membrane. I. Physiology] Grzybowski A, et al. **Przegl Lek** 1996;53(7):565–73 (146 ref.) (Eng. Abstr.) **(Pol)**

ADVERSE EFFECTS

Peritoneal catheter exit-site and tunnel infections. Piraino B. **Adv Ren Replace Ther** 1996 Jul;3(3):222–7 (56 ref.)

Peritonitis in peritoneal dialysis patients: an overview. Tzamaloukas AH. **Adv Ren Replace Ther** 1996 Jul; 3(3):232–6 (24 ref.)

Nutritional status as a predictor of morbidity and mortality in maintenance dialysis patients. Kopple JD. **ASAIO J** 1997 May–Jun;43(3):246–50 (48 ref.)

Nutritional monitoring techniques in dialysis. Can routine monitoring impact outcome? Zabetakis PM. **ASAIO J** 1997 May–Jun;43(3):243–5 (20 ref.)

Peritonitis: finding success by evaluating the failures [editorial] Korbet SM. **Int J Artif Organs** 1996 Dec; 19(12):695–6 (15 ref.)

Buffers: bicarbonate, lactate and pyruvate. Feriani M. **Kidney Int Suppl** 1996 Nov;56:S75–80 (61 ref.)

Cardiovascular diseases in peritoneal dialysis patients: the size of the problem. Lameire N, et al. **Kidney Int Suppl** 1996 Nov;56:S28–36 (71 ref.)

Limitations of peritoneal dialysis. Ronco C. **Kidney Int Suppl** 1996 Nov;56:S69–74 (25 ref.)

Biocompatibility of peritoneal dialysis treatment. Di Paolo N, et al. **Nephrol Dial Transplant** 1997;12 Suppl 1:78–83 (40 ref.)

Current approach to exit-site infections in patients on peritoneal dialysis. Twardowski ZJ, et al. **Nephrol Dial Transplant** 1997 Jun;12(6):1284–95 (46 ref.)

Cytotoxicity of peritoneal dialysis fluid – is it related to glucose breakdown products? [editorial] Wieslander AP. **Nephrol Dial Transplant** 1996 Jun;11(6):958–9 (7 ref.)

Evidence for the presence of chronic inflammation during peritoneal dialysis: therapeutic implications. Breborowicz A, et al. **Perit Dial Int** 1997;17 Suppl 2:S37–41 (55 ref.)

INSTRUMENTATION

The Cruz catheter and its functional characteristics. Cruz C. **Perit Dial Int** 1997;17 Suppl 2:S146–8 (9 ref.)

Silver-coated catheters in peritoneal dialysis. Dasgupta MK. **Perit Dial Int** 1997;17 Suppl 2:S142–5 (17 ref.)

[Peritoneum as a dialysis membrane. II. Pathology] Grzybowski A, et al. **Przegl Lek** 1997;54(1):52–61 (114 ref.) (Eng. Abstr.) **(Pol)**

METHODS

Automated peritoneal dialysis: new implications for pharmacists. Brophy DF, et al. **Ann Pharmacother** 1997 Jun;31(6):756–64 (47 ref.)

Acute peritoneal dialysis: how to do it. Barton IK, et al. **Br J Hosp Med** 1997 Feb 19–Mar 4;57(4):134–6 (0 ref.)

Adequacy of peritoneal dialysis. Blake PG. **Curr Opin Nephrol Hypertens** 1996 Nov;5(6):492–6 (41 ref.)

Solute clearance approach to adequacy of peritoneal dialysis [see comments] Burkart JM, et al. **Perit Dial Int** 1996 Sep–Oct;16(5):457–70 (80 ref.) Comment in: Perit Dial Int 1996 Sep–Oct;16(5):432–3.

[Peritoneal dialysis in children] Fischbach M. **Arch Pediatr** 1997 Jan;4(1):81–9 (48 ref.) (Eng. Abstr.) **(Fre)**

MORTALITY

Nutritional status as a predictor of morbidity and mortality in maintenance dialysis patients. Kopple JD. **ASAIO J** 1997 May–Jun;43(3):246–50 (48 ref.)

NURSING

Nursing interventions related to peritonitis. Prowant BF. **Adv Ren Replace Ther** 1996 Jul;3(3):237–9 (9 ref.)

Nursing interventions related to peritoneal catheter exit-site infections. Prowant BF. **Adv Ren Replace Ther** 1996 Jul; 3(3):228–31 (32 ref.)

PSYCHOLOGY

Withdrawal from dialysis: a review with an emphasis on the black experience. Leggat JE Jr, et al. **Adv Ren Replace Ther** 1997 Jan;4(1):22–9 (44 ref.)

STANDARDS

Making long-term peritoneal dialysis possible [editorial] Dombros NV, et al. **Int J Artif Organs** 1997 Mar; 20(3):129–33 (24 ref.)

Peritoneal dialysis access [editorial] Eklund BH. **Int J Artif Organs** 1996 Jul;19(7):381–3 (30 ref.)

STATISTICS & NUMERICAL DATA

[Replacement treatment of chronic renal insufficiency. Current perspectives (editorial)] Ortuño Mirete J. **Rev Clin Esp** 1997 May;197(5):306–16 (97 ref.) **(Spa)**

TRENDS

ESRD modality selection into the 21st century: the importance of non medical factors. Nissenson AR, et al. **ASAIO J** 1997 May–Jun;43(3):143–50 (25 ref.)

The future of peritoneal dialysis: problems and hopes. Cancarini GC. **Nephrol Dial Transplant** 1997;12 Suppl 1:84–8 (28 ref.)

PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY

Acute renal failure in the pediatric patient. Mendley SR, et al. **Adv Ren Replace Ther** 1997 Apr;4(2 Suppl 1):93–101 (29 ref.)

Clinical pharmacokinetics during continuous ambulatory

peritoneal dialysis. Taylor CA 3rd, et al. **Clin Pharmacokinet** 1996 Oct;31(4):293–308 (104 ref.)

Impact of hypertension in CAPD patients. Enia G. **Contrib Nephrol** 1996;119:147–51 (10 ref.)

Measuring the adequacy of peritoneal dialysis: is there a link with nutrition and outcome? Gokal R. **Curr Opin Nephrol Hypertens** 1996 Nov;5(6):521–6 (58 ref.)

Thoracic complications in uremic patients and in patients undergoing dialytic treatment: state of the art. Gavelli G, et al. **Eur Radiol** 1997;7(5):708–17 (76 ref.)

Hypertension in the dialysis population: no easy answers [editorial] Salem MM. **Int J Artif Organs** 1996 Dec; 19(12):693–4 (15 ref.)

The rationale and ultimate limitations of urea kinetic modelling in the estimation of nutritional status. Bargman JM. **Perit Dial Int** 1996 Jul–Aug;16(4):347–51 (24 ref.)

Advanced glycosylation end products in peritoneal tissue with different solutions. Dobbie JW. **Perit Dial Int** 1997; 17 Suppl 2:S27–30 (32 ref.)

Bicarbonate-buffered CAPD solutions: from clinical trials to clinical practice. Feriani M. **Perit Dial Int** 1997;17 Suppl 2:S51–5 (30 ref.)

Icodextrin's effects on peritoneal transport [see comments] Krediet RT, et al. **Perit Dial Int** 1997 Jan–Feb;17(1):35–41 (34 ref.) Comment in: Perit Dial Int 1997 Jan–Feb;17(1):9–10.

The impact of residual renal function on the adequacy of peritoneal dialysis. Lameire N, et al. **Perit Dial Int** 1997; 17 Suppl 2:S102–10 (73 ref.)

Plasticizers in renal failure: aspects of metabolism and toxicity. Mettang T, et al. **Perit Dial Int** 1997;17 Suppl 2:S31–6 (34 ref.)

Factors affecting peritoneal efficiency in different treatment schedules. Nolph KD. **Perit Dial Int** 1997;17 Suppl 2:S98–101 (19 ref.)

Future clinical research with icodextrin-containing solutions. Shockley TR, et al. **Perit Dial Int** 1997;17 Suppl 2:S70–4 (43 ref.)

[Clinical and kinetic evaluation of continuous ambulatory peritoneal dialysis (CAPD)] Grzegorzewska A, et al. **Przegl Lek** 1996;53(8):619–22 (17 ref.) (Eng. Abstr.) **(Pol)**

ADVERSE EFFECTS

Sclerosing encapsulating peritonitis associated with continuous ambulatory peritoneal dialysis: surgical management. Smith L, et al. **Am J Kidney Dis** 1997 Mar; 29(3):456–60 (17 ref.)

Fungal peritonitis in continuous ambulatory peritoneal dialysis [editorial] Saran R, et al. **Int J Artif Organs** 1996 Aug;19(8):441–5 (55 ref.)

Hypertension and left ventricular hypertrophy in the CAPD patient. Amann K, et al. **Kidney Int Suppl** 1996 Nov; 56:S37–40 (35 ref.)

Inflammatory changes in vivo during CAPD: what can the effluent tell us? Ho-Dac-Pannekeet MM, et al. **Kidney Int Suppl** 1996 Nov;56:S12–6 (58 ref.)

Preservation of peritoneal membrane function. Krediet RT, et al. **Kidney Int Suppl** 1996 Nov;56:S62–8 (123 ref.)

Abnormalities of lipoprotein metabolism in CAPD patients. Wheeler DC. **Kidney Int Suppl** 1996 Nov;56:S41–6 (54 ref.)

Nonocclusive mesenteric infarction in continuous ambulatory peritoneal dialysis. Korzets Z, et al. **Nephron** 1996; 74(2):415–8 (15 ref.)

Role of imbalance of intracavity fibrin formation and removal in the pathogenesis of peritoneal lesions in CAPD [editorial] Dobbie JW, et al. **Perit Dial Int** 1997 Mar–Apr; 17(2):121–4 (41 ref.)

Is CAPD atherogenic? [editorial] Siamopoulos KC, et al. **Perit Dial Int** 1997 May–Jun;17(3):227–31 (61 ref.)

Disconnect systems in children undergoing continuous ambulatory peritoneal dialysis. Aguilar A, et al. **Transplant Proc** 1996 Dec;28(6):3388 (7 ref.)

[Peritoneal dialysis: peritonitis and catheter infections] Bergeron E, et al. **Ann Chir** 1996;50(8):606–12 (37 ref.) (Eng. Abstr.) **(Fre)**

[Viral hepatitis type B and C in patients with chronic renal failure treated with dialysis] Niemczyk S. **Pol Arch Med Wewn** 1996 Nov;96(5):484–9 (37 ref.) **(Pol)**

[Non-infectious complications during treatment with continuous peritoneal dialysis (CAPD)] Bętkowska-Prokop A. **Przegl Lek** 1997;54(2):115–21 (46 ref.) (Eng. Abstr.) **(Pol)**

ECONOMICS

The costs of dialysis in Italy. Piccoli G, et al. **Nephrol Dial Transplant** 1997;12 Suppl 1:33–44 (46 ref.)

HISTORY

Birth and evolution of the "Y" set. Buoncristiani U. **ASAIO J** 1996 Jan–Feb;42(1):8–11 (26 ref.)

INSTRUMENTATION

The Cruz catheter and its functional characteristics. Cruz C. **Perit Dial Int** 1997;17 Suppl 2:S146–8 (9 ref.)

MORTALITY

Cardiovascular factors influencing survival in dialysis patients. Alpert MA. **Adv Perit Dial** 1996;12:110–9 (57 ref.)

Is peritoneal dialysis the preferred modality in the diabetic patient? Kraus MA, et al. **Adv Perit Dial** 1996;12:89–92 (10 ref.)

Comparison of long-term survival between hemodialysis and peritoneal dialysis. Maiorca R, et al. **Adv Perit Dial** 1996; 12:79–88 (34 ref.)

STANDARDS

Making long-term peritoneal dialysis possible [editorial] Dombros NV, et al. **Int J Artif Organs** 1997 Mar; 20(3):129–33 (24 ref.)

TRENDS

Current issues of continuous ambulatory peritoneal dialysis. Kawaguchi Y, et al. **Artif Organs** 1995 Dec;19(12):1204–9 (17 ref.)

PERITONEAL DISEASES

The relevance of asymptomatic endometriosis. Thomas EJ. **Hum Reprod** 1996 Nov;11 Suppl 3:103–9 (8 ref.)

COMPLICATIONS

Strangulation ileus resulting from encasement of a loop of the small intestine by the great omentum, caused by abnormal adhesion. Kimura H, et al. **J Gastroenterol** 1996 Oct;31(5):714–6 (8 ref.)

Adhesion controversies: pelvic pain as a cause of adhesions, crystalloids in preventing them. Duffy DM, et al. **J Reprod Med** 1996 Jan;41(1):19–26 (66 ref.)

DRUG THERAPY

Medical treatment of symptomatic endometriosis. Cirkel U. **Hum Reprod** 1996 Nov;11 Suppl 3:89–101 (40 ref.)

ETIOLOGY

Peritoneal and pleural infection following placement of an internal biliary stent for a large bile leak. Weiss K, et al. **Am J Gastroenterol** 1997 Feb;92(2):347–8 (9 ref.)

Theories on the pathogenesis of endometriosis. van der Linden PJ. **Hum Reprod** 1996 Nov;11 Suppl 3:53–65 (63 ref.)

PHYSIOPATHOLOGY

Endometriosis—a disease because it is characterized by bleeding. Brosens IA. **Am J Obstet Gynecol** 1997 Feb; 176(2):263–7 (25 ref.)

Pathophysiology of adhesion formation and strategies for prevention. Gomel V, et al. **J Reprod Med** 1996 Jan; 41(1):35–41 (65 ref.)

PREVENTION & CONTROL

Effects of postoperative intraperitoneal chemotherapy on peritoneal wound healing and adhesion formation. Jacquet P, et al. **Cancer Treat Res** 1996;82:327–35 (39 ref.)

Pathophysiology of adhesion formation and strategies for prevention. Gomel V, et al. **J Reprod Med** 1996 Jan; 41(1):35–41 (65 ref.)

Efficacy of Interceed in adhesion prevention in gynecologic surgery: a review of 13 clinical studies. Larsson B. **J Reprod Med** 1996 Jan;41(1):27–34 (40 ref.)

Physical barriers in adhesion prevention. Saravelos HG, et al. **J Reprod Med** 1996 Jan;41(1):42–51 (75 ref.)

[The pathophysiology and treatment of severe intra-abdominal abscess] Shinagawa N. **Nippon Geka Gakkai Zasshi** 1996 Dec;97(12):1048–53 (5 ref.) (Eng. Abstr.) **(Jpn)**

PERITONEAL EFFUSION see **ASCITIC FLUID**

PERITONEAL FLUID see **ASCITIC FLUID**

PERITONEAL INFUSIONS see **INFUSIONS, PARENTERAL**

PERITONEAL MACROPHAGES see **MACROPHAGES, PERITONEAL**

PERITONEAL NEOPLASMS

Pseudomyxoma peritonei syndrome. Sugarbaker PH, et al. **Adv Surg** 1996;30:233–80 (35 ref.)

Papillary serous carcinoma of the peritoneum. Chew S, et al. **J Obstet Gynaecol** 1995 Aug;21(4):341–7 (17 ref.)

[Solitary fibrous mesothelioma of the peritoneum. Considerations of a clinical case in our observation] Cebrelli C, et al. **Minerva Chir** 1996 Nov;51(11):993–5 (17 ref.) (Eng. Abstr.) **(Ita)**

CHEMICALLY INDUCED

Malignant peritoneal mesothelioma following asbestos exposure. Manavoğlu O, et al. **J Environ Pathol Toxicol Oncol** 1996;15(2–4):191–4 (27 ref.)

COMPLICATIONS

Ovarian fibromatosis, ascites and omental fibrosis. Scurry J, et al. **Histopathology** 1996 Jan;28(1):81–4 (6 ref.)

Peritoneal mesothelioma in recurrent familial peritonitis. Gentiloni N, et al. **J Clin Gastroenterol** 1997 Jun; 24(4):276–9 (20 ref.)

[Mucocele of the appendix with pseudomyxoma peritonei—a rare cause of a paraneoplastic syndrome] Pollack T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Mar;166(3):266–8 (13 ref.) **(Ger)**

DIAGNOSIS

Cystic mesothelioma of the peritoneum. Moriwaki Y, et al. **J Gastroenterol** 1996 Dec;31(6):868–74 (24 ref.)

Unusual tumors of the appendix and pseudomyxoma peritonei. Carr NJ, et al. **Semin Diagn Pathol** 1996 Nov; 13(4):314–25 (83 ref.)

Primary leiomyosarcoma arising in the lesser sac: report of a case. Kimura H, et al. **Surg Today** 1997;27(7):672–5 (10 ref.)

[Diffuse peritoneal leiomyomatosis. A clinical case report] Borsellino G, et al. **Minerva Ginecol** 1997 Jan–Feb; 49(1–2):53–7 (28 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Treatment of peritoneal carcinomatosis by continuous hyperthermic peritoneal perfusion with cisplatin. Alexander HR, et al. **Cancer Treat Res** 1996;81:41–50 (34 ref.)

Intraoperative hyperthermic lavage with cisplatin for peritoneal carcinomatosis and sarcomatosis. Stephens AD, et al. **Cancer Treat Res** 1996;81:15–30 (35 ref.)

Peritoneal carcinomatosis: natural history and rational therapeutic interventions using intraperitoneal chemotherapy. Sugarbaker PH. **Cancer Treat Res** 1996; 81:149–68 (42 ref.)

Arterial infusion chemotherapy for peritoneal and liver metastasis in gastric cancer. Kitamura M, et al. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:45–51 (14 ref.)

[A case of peritoneum malignant mesothelioma responding to arterial infusion chemotherapy] Tohda G, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Jun;94(6):445–9 (10 ref.) **(Jpn)**

ETIOLOGY

Role of omentum-associated lymphoid tissue in the progression of peritoneal carcinomatosis. Shimotsuma M, et al. **Cancer Treat Res** 1996;82:147–54 (21 ref.)

Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. Sugarbaker PH. **Cancer Treat Res** 1996; 82:79–100 (32 ref.)

Pathology of malignant mesothelioma. Attanoos RL, et al. **Histopathology** 1997 May;30(5):403–18 (120 ref.)

PATHOLOGY

Cytology of pleural, peritoneal and pericardial fluids in children. A 40-year summary. Wong JW, et al. **Acta Cytol** 1997 Mar–Apr;41(2):467–73 (13 ref.)

Mesenteric pleomorphic liposarcoma in an adolescent. Pawel BR, et al. **Arch Pathol Lab Med** 1997 Feb;121(2):173–6 (15 ref.)

Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Jacquet P, et al. **Cancer Treat Res** 1996;82:359–74 (53 ref.)

Pathology of peritoneal mesothelioma. Kass ME. **Cancer Treat Res** 1996;81:213–25 (28 ref.)

Metastatic inefficiency: intravascular and intraperitoneal implantation of cancer cells. Weiss L. **Cancer Treat Res** 1996;82:1–11 (34 ref.)

Columnar cells in smears from pseudomyxoma peritonei [letter] Gu M, et al. **Diagn Cytopathol** 1997 Feb;16(2):182–3 (13 ref.)

Pathology of malignant mesothelioma. Attanoos RL, et al. **Histopathology** 1997 May;30(5):403–18 (120 ref.)

Mesenteric neurofibroma in von Recklinghausen's disease. Kataria R, et al. **J Pediatr Surg** 1997 Jan;32(1):128–9 (9 ref.)

Unusual tumors of the appendix and pseudomyxoma peritonei. Carr NJ, et al. **Semin Diagn Pathol** 1996 Nov; 13(4):314–25 (83 ref.)

[Pathogenesis of puncture-site metastases after laparoscopy] Reymond MA, et al. **Zentralbl Chir** 1997;122(5):387–94 (75 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Radiology of peritoneal carcinomatosis. Archer AG, et al. **Cancer Treat Res** 1996;82:263–88 (18 ref.)

SECONDARY

Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes. Freedman RS, et al. **Cancer Treat Res** 1996;82:115–46 (114 ref.)

Arterial infusion chemotherapy for peritoneal and liver metastasis in gastric cancer. Kitamura M, et al. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:45–51 (14 ref.)

Significance of lymph node sampling in epithelial carcinoma of the ovary. Carnino F, et al. **Gynecol Oncol** 1997 Jun; 65(3):467–72 (25 ref.)

Colon carcinoma discovered in an adolescent during inguinal hernia repair. LeClair LL, et al. **J Am Osteopath Assoc** 1997 Feb;97(2):100–1 (11 ref.)

Colorectal cancer and peritoneal carcinomatosis. Cintron JR, et al. **Semin Surg Oncol** 1996 Jul–Aug;12(4):267–78 (17 ref.)
Intracranial germinoma metastasizing via a ventriculo–peritoneal shunt. Wong KT, et al. **Singapore Med J** 1996 Aug;37(4):441–2 (13 ref.)
[Mechanism of peritoneal metastasis and the possibility of therapeutic agents] Sowa M, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(10):1269–74 (13 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Pseudomyxoma peritonei syndrome. Sugarbaker PH, et al. **Adv Surg** 1996;30:233–80 (35 ref.)
Peritoneal mesothelioma: treatment approach based on natural history. Averbach AM, et al. **Cancer Treat Res** 1996;81:193–211 (80 ref.)
Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes. Freedman RS, et al. **Cancer Treat Res** 1996;82:115–46 (114 ref.)
Clinical determinants of treatment failure in patients with pseudomyxoma peritonei. Sugarbaker PH, et al. **Cancer Treat Res** 1996;81:121–32 (20 ref.)
Pseudomyxoma peritonei. Sugarbaker PH. **Cancer Treat Res** 1996;81:105–19 (79 ref.)

ULTRASONOGRAPHY

[Imaging of peritoneal mesotheliomas] Lewin M, et al. **J Radiol** 1996 Sep;77(9):649–56 (39 ref.) (Eng. Abstr.) **(Fre)**

PERITONEOSCOPY see **LAPAROSCOPY**

PERITONEUM

see related
ASCITIC FLUID
LAPAROSCOPY

DRUG EFFECTS

Cytotoxicity of peritoneal dialysis fluid – is it related to glucose breakdown products? [editorial] Wieslander AP. **Nephrol Dial Transplant** 1996 Jun;11(6):958–9 (7 ref.)

EMBRYOLOGY

The anatomy and embryological origins of the fascia of Denonvilliers: a medico–historical debate. van Ophoven A, et al. **J Urol** 1997 Jan;157(1):3–9 (45 ref.)

IMMUNOLOGY

Peritoneal defences and peritoneum–associated lymphoid tissue. Heel KA, et al. **Br J Surg** 1996 Aug;83(8):1031–6 (59 ref.)

METABOLISM

Role of imbalance of intracavity fibrin formation and removal in the pathogenesis of peritoneal lesions in CAPD [editorial] Dobbie JW, et al. **Perit Dial Int** 1997 Mar–Apr; 17(2):121–4 (41 ref.)
Icodextrin's effects on peritoneal transport [see comments] Krediet RT, et al. **Perit Dial Int** 1997 Jan–Feb;17(1):35–41 (34 ref.) Comment in: Perit Dial Int 1997 Jan–Feb;17(1):9–10.

PATHOLOGY

Sclerosing encapsulating peritonitis associated with continuous ambulatory peritoneal dialysis: surgical management. Smith L, et al. **Am J Kidney Dis** 1997 Mar; 29(3):456–60 (17 ref.)
Biocompatibility of peritoneal dialysis treatment. Di Paolo N, et al. **Nephrol Dial Transplant** 1997;12 Suppl 1:78–83 (40 ref.)
[Peritoneum as a dialysis membrane. II. Pathology] Grzybowski A, et al. **Przegl Lek** 1997;54(1):52–61 (114 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

[Peritoneum as a dialysis membrane. I. Physiology] Grzybowski A, et al. **Przegl Lek** 1996;53(7):565–73 (146 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

Peritonitis: pathophysiology and local defense mechanisms. Heemken R, et al. **Hepatogastroenterology** 1997 Jul–Aug; 44(16):927–36 (20 ref.)

SECRETION

Surfactant protein A and lamellar bodies: a homologous secretory function of peritoneum, synovium, and lung. Dobbie JW. **Perit Dial Int** 1996 Nov–Dec;16(6):574–81 (43 ref.)

SURGERY

The role of growth factors in peritoneal healing: transforming growth factor beta (TGF–beta). Chegini N. **Eur J Surg Suppl** 1997;(577):17–23 (41 ref.)
Biochemical events in peritoneal tissue repair. diZerega GS. **Eur J Surg Suppl** 1997;(577):10–6 (44 ref.)
The role of fibrinolysis in adhesion formation. Holmdahl L. **Eur J Surg Suppl** 1997;(577):24–31 (44 ref.)
Adhesions: pathogenesis and prevention–panel discussion and summary. Holmdahl L, et al. **Eur J Surg Suppl** 1997;(577):56–62 (57 ref.)

PERITONITIS

Spontaneous bacterial peritonitis: an indication for liver transplantation? Bac DJ. **Scand J Gastroenterol Suppl** 1996; 218:38–42 (43 ref.)

CHEMICALLY INDUCED

Sclerosing encapsulating peritonitis after intraperitoneal use of povidone iodine. Keating JP, et al. **Aust N Z J Surg** 1997 Oct;67(10):742–4 (19 ref.)

COMPLICATIONS

Peritoneal mesothelioma in recurrent familial peritonitis. Gentiloni N, et al. **J Clin Gastroenterol** 1997 Jun; 24(4):276–9 (20 ref.)
The small intestine as the origin of bacteremia in acute diffuse peritonitis. Peregudov SI, et al. **Nutr Hosp** 1996 Nov–Dec; 11(6):317–20 (8 ref.)

DIAGNOSIS

Idiopathic sclerosing encapsulating peritonitis. Eldar S, et al. **Eur J Surg** 1996 Jul;162(7):575–8 (36 ref.)
Prognostic indices in peritonitis. Ohmann C, et al. **Hepatogastroenterology** 1997 Jul–Aug;44(16):937–46 (53 ref.)
Leiomyosarcoma of the colon presenting as acute suppurative peritonitis. Iwasa K, et al. **Surg Today** 1997;27(4):337–44 (44 ref.)
[The diagnosis and surgical treatment of postoperative peritonitis] Shugaev AI, et al. **Vestn Khir Im I I Grek** 1996; 155(2):114–6 (42 ref.) **(Rus)**
[Peritonitis chronica fibrosa encapsulans] Svintsov EL. **Vestn Khir Im I I Grek** 1997;156(2):119–20 (7 ref.) **(Rus)**

DRUG THERAPY

Fungal peritonitis in continuous ambulatory peritoneal dialysis [editorial] Saran R, et al. **Int J Artif Organs** 1996 Aug;19(8):441–5 (55 ref.)
[Adjuvant therapy of peritonitis with taurolidine. Modulation of mediator liberation] Staubach KH. **Langenbecks Arch Chir** 1997;382(4 Suppl 1):S26–30 (17 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Disconnect systems in children undergoing continuous ambulatory peritoneal dialysis. Aguilar A, et al. **Transplant Proc** 1996 Dec;28(6):3388 (7 ref.)

ETIOLOGY

Peritonitis in peritoneal dialysis patients: an overview. Tzamaloukas AH. **Adv Ren Replace Ther** 1996 Jul; 3(3):232–6 (24 ref.)
Peritonitis: update on pathophysiology, clinical manifestations, and management. Johnson CC, et al. **Clin Infect Dis** 1997 Jun;24(6):1035–45; quiz 1046–7 (98 ref.)
Noncandidal fungal peritonitis in patients with AIDS: report of three cases and review. Spindel SJ, et al. **Clin Infect Dis** 1997 Feb;24(2):279–80 (10 ref.)
Peritonitis: finding success by evaluating the failures [editorial] Korbet SM. **Int J Artif Organs** 1996 Dec; 19(12):695–6 (15 ref.)
[Spontaneous ascites infections] Lata J. **Vnitr Lek** 1996 Nov; 42(11):789–91 (20 ref.) (Eng. Abstr.) **(Cze)**
[Peritoneal dialysis: peritonitis and catheter infections] Bergeron E, et al. **Ann Chir** 1996;50(8):606–12 (37 ref.) (Eng. Abstr.) **(Fre)**
[A case of jejunal malignant lymphoma resulting in perforation 2 years after transcatheter arterial embolization for hepatocellular carcinoma] Yokohama A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Aug;93(8):578–82 (21 ref.) **(Jpn)**
[Ascitic peritonitis] Didenko VM, et al. **Vestn Khir Im I I Grek** 1996;155(2):111–3 (35 ref.) **(Rus)**

MICROBIOLOGY

Campylobacter jejuni peritonitis in a patient with liver cirrhosis. Vermeij CG, et al. **Eur J Gastroenterol Hepatol** 1996 Dec;8(12):1219–21 (9 ref.)
Animal models for intra–abdominal infection. Sayek I. **Hepatogastroenterology** 1997 Jul–Aug;44(16):923–6 (22 ref.)
[Importance of mycoses in intra–abdominal infections] Blinzler L, et al. **Langenbecks Arch Chir** 1997;382(4 Suppl 1):S5–8 (16 ref.) (Eng. Abstr.) **(Ger)**

NURSING

Nursing interventions related to peritonitis. Prowant BF. **Adv Ren Replace Ther** 1996 Jul;3(3):237–9 (9 ref.)

PATHOLOGY

Sclerosing encapsulating peritonitis after intraperitoneal use of povidone iodine. Keating JP, et al. **Aust N Z J Surg** 1997 Oct;67(10):742–4 (19 ref.)
Inflammatory changes in vivo during CAPD: what can the effluent tell us? Ho–Dac–Pannekeet MM, et al. **Kidney Int Suppl** 1996 Nov;56:S12–6 (58 ref.)
The peritoneal fibroblast and the control of peritoneal inflammation. Jörres A, et al. **Kidney Int Suppl** 1996 Nov; 56:S22–7 (50 ref.)
Activation of inflammation and leukocyte recruitment into the peritoneal cavity. Topley N, et al. **Kidney Int Suppl** 1996 Nov;56:S17–21 (44 ref.)
[Spontaneous bacterial peritonitis and primary hepatic lymphoma in a female patient with human immunodeficiency virus infection (letter)] Sancho JM, et al. **Med Clin (Barc)** 1997 Feb 15;108(6):238 (7 ref.) **(Spa)**

PHYSIOPATHOLOGY

Peritonitis: pathophysiology and local defense mechanisms. Heemken R, et al. **Hepatogastroenterology** 1997 Jul–Aug; 44(16):927–36 (20 ref.)
Cellular and molecular mechanisms of TNF protection in septic peritonitis. Echtenacher B, et al. **J Inflamm** 1995–96; 47(1–2):85–9 (24 ref.)
[Intestinal bacterial translocation] Llovet JM, et al. **Gastroenterol Hepatol** 1996 Aug–Sep;19(7):374–82 (110 ref.) **(Spa)**

PREVENTION & CONTROL

Making long–term peritoneal dialysis possible [editorial] Dombros NV, et al. **Int J Artif Organs** 1997 Mar; 20(3):129–33 (24 ref.)
[Primary prophylaxis of spontaneous bacterial peritonitis (editorial)] Soriano G, et al. **Gastroenterol Hepatol** 1997 Jun–Jul;20(6):312–4 (24 ref.) **(Spa)**

SURGERY

Sclerosing encapsulating peritonitis associated with continuous ambulatory peritoneal dialysis: surgical management. Smith L, et al. **Am J Kidney Dis** 1997 Mar; 29(3):456–60 (17 ref.)
Idiopathic sclerosing encapsulating peritonitis. Eldar S, et al. **Eur J Surg** 1996 Jul;162(7):575–8 (36 ref.)
Surgical treatment of severe intra–abdominal infection. van Goor H. **Hepatogastroenterology** 1997 Jul–Aug; 44(16):975–81 (90 ref.)
[Peritonitis—an unaging problem in surgery] Korukov B. **Khirurgiia (Sofiia)** 1996;49(2):47–50 (0 ref.) **(Bul)**
[Therapy of peritonitis today. Surgical management and adjuvant therapy strategies] Reith HB. **Langenbecks Arch Chir** 1997;382(4 Suppl 1):S14–7 (23 ref.) (Eng. Abstr.) **(Ger)**
[Urgent medical situation and therapeutic strategy in patients undergoing digestive cancer surgery (inflammation, stenosis, hemorrhage)] Mizobuchi N, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(3):279–84 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Current principles of the surgical treatment of postoperative peritonitis] Saenko VF, et al. **Klin Khir** 1996;(6):4–9 (12 ref.) **(Rus)**
[The diagnosis and surgical treatment of postoperative peritonitis] Shugaev AI, et al. **Vestn Khir Im I I Grek** 1996; 155(2):114–6 (42 ref.) **(Rus)**

PERITONITIS, TUBERCULOUS see **TUBERCULOSIS, PERITONEAL**

PERITONSILLAR ABSCESS

Supraglottic airway infections. Millan SB, et al. **Prim Care** 1996 Dec;23(4):741–58 (106 ref.)

ETIOLOGY

Peritonsillar abscess—an unusual presentation of Kawasaki disease. Ravi KV, et al. **J Laryngol Otol** 1997 Jan; 111(1):73–4 (8 ref.)

THERAPY

Pediatric peritonsillar abscess: management guidelines. Herzon FS, et al. **Curr Probl Pediatr** 1996 Sep;26(8):270–8 (45 ref.)

PERIVASCULAR OLIGODENDROGLIA see **OLIGODENDROGLIA**

PERIVENTRICULAR LEUKOMALACIA see **LEUKOMALACIA, PERIVENTRICULAR**

PERMEABILITY

Endothelial permeability for macromolecules. Mechanistic aspects of pathophysiological modulation. van Hinsbergh WM. **Arterioscler Thromb Vasc Biol** 1997 Jun;17(6):1018–23 (61 ref.)
Round window membrane. Structure function and permeability: a review. Goycoolea MV, et al. **Microsc Res Tech** 1997 Feb 1;36(3):201–11 (60 ref.)

PERMEABILITY, CAPILLARY

PERMEABILITY, CAPILLARY see **CAPILLARY PERMEABILITY**

PERMEABILITY, CELL MEMBRANE see **CELL MEMBRANE PERMEABILITY**

PERMEABILITY, MICROVASCULAR see **CAPILLARY PERMEABILITY**

PERMEASES

CHEMISTRY

Helix packing in polytopic membrane proteins: the lactose permease of Escherichia coli. Kaback HR, et al. **Curr Opin Struct Biol** 1997 Aug;7(4):537–42 (57 ref.)

GENETICS

Transcription factors vs nucleosomes: regulation of the PHO5 promoter in yeast. Svaren J, et al. **Trends Biochem Sci** 1997 Mar;22(3):93–7 (50 ref.)

METABOLISM

Transport bicycles [comment] Karlin A. **Proc Natl Acad Sci U S A** 1997 May 27;94(11):5508–9 (23 ref.) Comment on: Proc Natl Acad Sci U S A 1997 May 27;94(11):5539–43.

PERONEAL NERVE

Neural fibrolipoma of the foot: a case report. Donley BG, et al. **Foot Ankle Int** 1996 Nov;17(11):712–3 (8 ref.)

[Compression of the peroneal nerve by a synovial cyst in a 7–year–oldchild] Gayet LE, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(8):762–6 (17 ref.) (Eng. Abstr.) **(Fre)**

INJURIES

Neurovascular complications following total knee replacement: causes, treatment, and prevention. Johanson NA. **Instr Course Lect** 1997;46:181–4 (15 ref.)

PEROPERATIVE CARE see **INTRAOPERATIVE CARE**

PEROPERATIVE COMPLICATIONS see **INTRAOPERATIVE COMPLICATIONS**

PEROPERATIVE PERIOD see **INTRAOPERATIVE PERIOD**

PEROXIDASE

IMMUNOLOGY

Development of primary hypothyroidism with antithyroglobulin, antiperoxidase, and blocking–type thyrotropin receptor antibodies after radiation therapy for neuroblastoma. Kikawa Y, et al. **J Pediatr** 1996 Dec; 129(6):909–12 (19 ref.)

[A case of Grave's disease with MPO–ANCA–associated glomerulonephritis during propylthiouracil (PTU) therapy following interstitial pneumonitis] Saeki T, et al. **Nippon Jinzo Gakkai Shi** 1997 Mar;39(2):167–71 (15 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Pathways for oxidation of low density lipoprotein by myeloperoxidase: tyrosyl radical, reactive aldehydes, hypochlorous acid and molecular chlorine. Heinecke JW. **Biofactors** 1997;6(2):145–55 (44 ref.)

The mechanism of the hypochlorite–induced lipid peroxidation. Panasenko OM. **Biofactors** 1997;6(2):181–90 (44 ref.)

Peroxynitrite–dependent tyrosine nitration catalyzed by superoxide dismutase, myeloperoxidase, and horseradish peroxidase. Sampson JB, et al. **Methods Enzymol** 1996; 269:210–18 (23 ref.)

PEROXIDASE–ANTIPEROXIDASE COMPLEX TECHNIQUE see **IMMUNOENZYME TECHNIQUES**

PEROXIDASE–LABELED ANTIBODY TECHNIQUE see **IMMUNOENZYME TECHNIQUES**

PEROXIDASES

DEFICIENCY

Life without KatG. Zhang Y. **Trends Microbiol** 1996 Nov; 4(11):415–6 (15 ref.)

DRUG EFFECTS

Cyclooxygenase–2 inhibitors: a new class of anti–inflammatory agents that spare the gastrointestinal tract. Masferrer JL, et al. **Gastroenterol Clin North Am** 1996 Jun;25(2):363–72 (35 ref.)

Pain management in osteoarthritis: the role of COX–2 inhibitors. Lane NE. **J Rheumatol** 1997 Jul;24 Suppl 49:20–4 (30 ref.)

Outcome of specific COX–2 inhibition in rheumatoid arthritis. Lipsky PE, et al. **J Rheumatol** 1997 Jul;24 Suppl 49:9–14 (21 ref.)

METABOLISM

Biosynthesis of halogenated metabolites by bacteria. van Pée KH. **Annu Rev Microbiol** 1996;50:375–99 (120 ref.)

Gaseous pollutants and plant defence mechanisms. Wellburn AR, et al. **Biochem Soc Trans** 1996 May;24(2):461–4 (15 ref.)

Use of transgenic plants to study antioxidant defenses. Allen RD, et al. **Free Radic Biol Med** 1997;23(3):473–9 (39 ref.)

The role of peroxidase in mammalian melanogenesis: a review. Okun MR. **Physiol Chem Phys Med NMR** 1996; 28(2):91–100; discussion 100–1 (58 ref.)

PHYSIOLOGY

New directions in cyclooxygenase research and their implications for NSAID–gastropathy. Flower RJ. **Ital J Gastroenterol** 1996 Dec;28 Suppl 4:23–7 (26 ref.)

The discovery and function of COX–2. Needleman P, et al. **J Rheumatol** 1997 Jul;24 Suppl 49:6–8 (23 ref.)

SECRETION

[EPO release from eosinophils] Hirai K. **Nippon Rinsho** 1997 Mar;55 Suppl 1:219–21 (8 ref.) **(Jpn)**

PEROXIDES

see related
BENZOYL PEROXIDE
LIPID PEROXIDES

ADMINISTRATION & DOSAGE

Nightguard vital bleaching: current concepts and research. Haywood VB. **J Am Dent Assoc** 1997 Apr;128 Suppl:19S–25S (31 ref.)

ADVERSE EFFECTS

Biological properties of peroxide–containing tooth whiteners. Li Y. **Food Chem Toxicol** 1996 Sep;34(9):887–904 (212 ref.)

BLOOD

[Selenium, glutathione peroxidase, peroxides and platelet functions] Vitoux D, et al. **Ann Biol Clin (Paris)** 1996; 54(5):181–7 (35 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Molecular modeling of singlet–oxygen binding to anthraquinones in relation to the peroxidating activity of antitumor anthraquinone drugs. Liwo A, et al. **Acta Biochim Pol** 1995;42(4):445–56 (47 ref.)

TOXICITY

The effect of peroxides and free radicals on body tissues. Floyd RA. **J Am Dent Assoc** 1997 Apr;128 Suppl:37S–40S (8 ref.)

Toxicological considerations of tooth bleaching using peroxide–containing agents. Li Y. **J Am Dent Assoc** 1997 Apr;128 Suppl:31S–36S (58 ref.)

PEROXISOMAL DISORDERS

[Peroxisomal disorders] Yajima S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):75–7 (14 ref.) **(Jpn)**

[Peroxisomal hereditary diseases] Chandoga J, et al. **Bratisl Lek Listy** 1997 Jan;98(1):32–42 (104 ref.) (Eng. Abstr.) **(Slo)**

CLASSIFICATION

Biochemistry of peroxisomes in health and disease. Singh I. **Mol Cell Biochem** 1997 Feb;167(1–2):1–29 (308 ref.)

COMPLICATIONS

Peroxisomal bifunctional enzyme deficiency: serial neurophysiological examinations of a case. Akaboshi S, et al. **Brain Dev** 1997 Jun;19(4):295–9 (24 ref.)

DIAGNOSIS

Diagnostic work–up of a peroxisomal patient. Leroy JG, et al. **J Inherit Metab Dis** 1995;18 Suppl 1:214–22 (49 ref.)

Clinical approach to inherited peroxisomal disorders. Poggi–Travert F, et al. **J Inherit Metab Dis** 1995;18 Suppl 1:1–18 (42 ref.)

X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy. van Geel BM, et al. **J Neurol Neurosurg Psychiatry** 1997 Jul;63(1):4–14 (139 ref.)

[Keratotic neurocutaneous syndromes] Tercedor J, et al. **Rev Neurol** 1997 Sep;25 Suppl 3:S238–42 (34 ref.) (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

Peroxisomal disorders: overview. Moser HW, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:427–41 (100 ref.)

GENETICS

Pathogenetic mechanisms in peroxisomal disorders. Moser HW. **Curr Opin Neurol** 1996 Dec;9(6):473–6 (41 ref.)

Peroxisomal disorders. Moser HW. **Semin Pediatr Neurol** 1996 Dec;3(4):298–304 (54 ref.)

HISTORY

Peroxisomal diseases: a microscopist looks through the retrospectroscope. Goldfischer S. **Ann N Y Acad Sci** 1996 Dec 27;804:424–6 (9 ref.)

METABOLISM

Secondary alterations of human hepatocellular peroxisomes. De Craemer D. **J Inherit Metab Dis** 1995;18 Suppl 1:181–213 (124 ref.)

Polyunsaturated fatty acids in the developing human brain, erythrocytes and plasma in peroxisomal disease: therapeutic implications. Martinez M. **J Inherit Metab Dis** 1995;18 Suppl 1:61–75 (19 ref.)

On the molecular etiology of decreased arachidonic (20:4n–6), docosapentaenoic (22:5n–6) and docosahexaenoic (22:6n–3) acids in Zellweger syndrome and other peroxisomal disorders. Infante JP, et al. **Mol Cell Biochem** 1997 Mar;168(1–2):101–15 (167 ref.)

Biochemistry of peroxisomes in health and disease. Singh I. **Mol Cell Biochem** 1997 Feb;167(1–2):1–29 (308 ref.)

PATHOLOGY

Approaches to studies on peroxisome biogenesis and human peroxisome–deficient disorders. Fujiki Y. **Ann N Y Acad Sci** 1996 Dec 27;804:491–501 (43 ref.)

Secondary alterations of human hepatocellular peroxisomes. De Craemer D. **J Inherit Metab Dis** 1995;18 Suppl 1:181–213 (124 ref.)

Neuropathology of peroxisomal diseases. Martin JJ. **J Inherit Metab Dis** 1995;18 Suppl 1:19–33 (40 ref.)

THERAPY

Polyunsaturated fatty acids in the developing human brain, erythrocytes and plasma in peroxisomal disease: therapeutic implications. Martinez M. **J Inherit Metab Dis** 1995;18 Suppl 1:61–75 (19 ref.)

PEROXISOMES see **MICROBODIES**

PERPHENAZINE

THERAPEUTIC USE

[Pharmacological treatment of delusional depression] Amore M, et al. **Minerva Psichiatr** 1996 Mar;37(1):29–33 (28 ref.) (Eng. Abstr.) **(Ita)**

PERSIAN GULF SYNDROME

DIAGNOSIS

A review of Gulf War illness. Coker WJ. **J R Nav Med Serv** 1996 Summer;82(2):141–6 (11 ref.)

PERSISTENT COMMON ATRIOVENTRICULAR CANAL see **ENDOCARDIAL CUSHION DEFECTS**

PERSISTENT FETAL CIRCULATION SYNDROME

[Persistent pulmonary hypertension in newborn infants] Pedersen CM, et al. **Ugeskr Laeger** 1997 Jul 7; 159(28):4377–82 (40 ref.) (Eng. Abstr.) **(Dan)**

PERSISTENT OSTIUM PRIMUM see **ENDOCARDIAL CUSHION DEFECTS**

PERSISTENT PULMONARY HYPERTENSION OF NEWBORN see **PERSISTENT FETAL CIRCULATION SYNDROME**

PERSISTENT VEGETATIVE STATE

Persistent vegetative state: important considerations for the neuroscience nurse. Ozuna J. **J Neurosci Nurs** 1996 Jun; 28(3):199–203 (20 ref.)

Persistent vegetative state. Zeman A. **Lancet** 1997 Sep 13; 350(9080):795–9 (36 ref.)

PHYSIOPATHOLOGY

Post–traumatic apallic syndrome following head injury. Part 1: clinical characteristics. Grossman P, et al. **Disabil Rehabil** 1996 Jan;18(1):1–20 (211 ref.)

REHABILITATION

Post–traumatic apallic syndrome following head injury. Part 2: Treatment. Grossman P, et al. **Disabil Rehabil** 1996 Feb; 18(2):57–68 (68 ref.)

PERSONAL EXPENDITURES see **FINANCING, PERSONAL**

PERSONAL LIABILITY see **LIABILITY, LEGAL**

PERSONAL SATISFACTION

Gain in the caregiving experience: where are we? What next? Kramer BJ. **Gerontologist** 1997 Apr;37(2):218–32 (86 ref.)

Complaints and complaining: functions, antecedents, and consequences. Kowalski RM. **Psychol Bull** 1996 Mar; 119(2):179–96 (169 ref.)

PERSONAL SPACE

Personal space intrusion and PTSD. Brown P, et al. **J Psychosoc Nurs Ment Health Serv** 1996 Jul;34(7):23–8 (44 ref.)

PERSONALITY

The personality pattern in peptic ulcer disease. Jess P. **Dan Med Bull** 1996 Sep;43(4):330–5 (109 ref.)

Context and consistency: the Canadian connection. Council JR. **Int J Clin Exp Hypn** 1997 Jul;45(3):204–11 (28 ref.)

Convergence in understanding hypnosis? Perhaps, but perhaps not quite so fast. Kihlstrom JF. **Int J Clin Exp Hypn** 1997 Jul;45(3):324–32 (28 ref.)

Why scientific hypnosis needs psychoanalysis (or something like it). Nash MR. **Int J Clin Exp Hypn** 1997 Jul; 45(3):291–300 (32 ref.)

The trait and process of resilience. Jacelon CS. **J Adv Nurs** 1997 Jan;25(1):123–9 (25 ref.)

Illness behaviour, personality traits, anxiety, and depression in patients with Menière's disease. Savastano M, et al. **J Otolaryngol** 1996 Oct;25(5):329–33 (12 ref.)

This I have learned from over 40 years of personality research. Epstein S. **J Pers** 1997 Mar;65(1):3–32 (75 ref.)

The interactional context of problem–, emotion–, and relationship–focused coping: the role of the big five personality factors. O'Brien TB, et al. **J Pers** 1996 Dec; 64(4):775–813 (100 ref.)

Personality and coping: three generations of research. Suls J, et al. **J Pers** 1996 Dec;64(4):711–35 (92 ref.)

Coping and personality: third time's the charm? Suls J, et al. **J Pers** 1996 Dec;64(4):993–1005 (43 ref.)

Positive illusions and coping with adversity. Taylor SE, et al. **J Pers** 1996 Dec;64(4):873–98 (80 ref.)

Patient adherence in chronic illness: personality and coping in context. Wiebe JS, et al. **J Pers** 1996 Dec;64(4):815–35 (95 ref.)

A guide to constructs of control. Skinner EA. **J Pers Soc Psychol** 1996 Sep;71(3):549–70 (120 ref.)

Intelligence, personality, and interests: evidence for overlapping traits. Ackerman PL, et al. **Psychol Bull** 1997 Mar;121(2):219–45 (210 ref.)

Social consequences of experiential openness. McCrae RR. **Psychol Bull** 1996 Nov;120(3):323–37 (143 ref.)

Personality and endogenous/major depression: an empirical approach to typus melancholicus. 1. Theoretical issues. Stanghellini G, et al. **Psychopathology** 1997;30(3):119–29 (60 ref.)

A nonhuman primate model of excessive alcohol intake. Personality and neurobiological parallels of type I– and type II–like alcoholism. Higley JD, et al. **Recent Dev Alcohol** 1997;13:191–219 (177 ref.)

[Psychosocial factors in Crohn disease—an overview] Enck P, et al. **Z Gastroenterol** 1996 Oct;34(10):708–13 (62 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Experience Producing Drive Theory: how genes drive experience and shape personality. Bouchard TJ Jr. **Acta Paediatr Suppl** 1997 Jul;422:60–4 (41 ref.)

PHYSIOLOGY

Psychological stress, neuroimmunomodulation, and susceptibility to infectious diseases in animals and man: a review. Biondi M, et al. **Psychother Psychosom** 1997; 66(1):3–26 (271 ref.)

PERSONALITY ASSESSMENT

Assessment issues and domains in the prediction of relapse. Donovan DM. **Addiction** 1996 Dec;91 Suppl:S29–36 (22 ref.)

Conceptual and methodological issues in the assessment of shame and guilt. Tangney JP. **Behav Res Ther** 1996 Sep; 34(9):741–54 (85 ref.)

Conceptualization of agitation: results based on the Cohen–Mansfield Agitation Inventory and the Agitation Behavior Mapping Instrument. Cohen–Mansfield J. **Int Psychogeriatr** 1996;8 Suppl 3:309–15; discussion 351–4 (45 ref.)

Assessment of insight in psychotic disorders. Fennig S, et al. **Isr J Psychiatry Relat Sci** 1996;33(3):175–87 (42 ref.)

"Cleaning–up cognition" in triple–response fear assessment through individualized functional behavior analysis. Forsyth JP, et al. **J Behav Ther Exp Psychiatry** 1996 Jun; 27(2):87–98 (60 ref.)

Mental defenses and posttraumatic stress disorder: assessment of criminal intent. Sparr LF. **J Trauma Stress** 1996 Jul; 9(3):405–25 (100 ref.)

The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Cummings JL. **Neurology** 1997 May; 48(5 Suppl 6):S10–6 (62 ref.)

[Health related quality of life and subjective health. Overview of the status of research for new evaluation criteria in medicine] Bullinger M. **Psychother Psychosom Med Psychol** 1997 Mar–Apr; 47(3–4):76–91 (165 ref.) (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

Issues on functional analysis in behavioral assessment. Cone JD. **Behav Res Ther** 1997 Mar;35(3):259–75 (85 ref.)

Behavioral pathology in Alzheimer's disease (BEHAVE–AD) rating scale. Reisberg B, et al. **Int Psychogeriatr** 1996;8 Suppl 3:301–8; discussion 351–4 (14 ref.)

Structural equation modeling: basic concepts and applications in personality assessment research. Crowley SL, et al. **J Pers Assess** 1997 Jun;68(3):508–31 (44 ref.)

The influence of culture on psychiatric assessment: the Vietnamese refugee. Phan T, et al. **Psychiatr Serv** 1997 Jan;48(1):86–90 (59 ref.)

The Interview for Recent Life Events. Paykel ES. **Psychol Med** 1997 Mar;27(2):301–10 (95 ref.)

Psychiatric assessment instruments developed by the World Health Organization. Sartorius N, et al. **Soc Psychiatry Psychiatr Epidemiol** 1996 Mar;31(2):55–69 (59 ref.)

[Tools for clinical evaluation of affective temperaments] Hantouche EG, et al. **Encephale** 1997 Jan;23 Spec No 1:27–34 (16 ref.) (Eng. Abstr.) **(Fre)**

[The Bern Coping Forms BEFO—an instrument for self– and observer rating of coping with illness] Heim E, et al. **Rehabilitation (Stuttg)** 1996 Nov;35(4):XXXI–XLI (60 ref.) (Eng. Abstr.) **(Ger)**

[Emotionality, age and aging—research perspectives, methodological approaches and empirical results] Kruse A, et al. **Ther Umsch** 1997 Jun;54(6):326–36 (43 ref.) (Eng. Abstr.) **(Ger)**

PERSONALITY DEVELOPMENT

see related
SOCIALIZATION

Key issues in the development of aggression and violence from childhood to early adulthood. Loeber R, et al. **Annu Rev Psychol** 1997;48:371–410 (240 ref.)

The concept of "self". Gilhotra J. **Aust N Z J Psychiatry** 1995 Dec;29(4):598–603 (20 ref.)

The psychology of self: an update. Meares R. **Aust N Z J Psychiatry** 1996 Jun;30(3):312–6 (15 ref.)

The concept of resilience. Wolff S. **Aust N Z J Psychiatry** 1995 Dec;29(4):565–74 (61 ref.)

An ethological approach to self–injury [editorial] [see comments] Jones IH, et al. **Br J Psychiatry** 1996 Sep; 169(3):263–7 (21 ref.) Comment in: Br J Psychiatry 1997 Feb;170:192–3.

Childhood emotional abuse. Thompson AE, et al. **Br J Psychiatry** 1996 Feb;168(2):143–8 (23 ref.)

Symbolic aspects of confabulation following brain injury: influence of premorbid personality. Weinstein EA. **Bull Menninger Clin** 1996 Summer;60(3):331–50 (39 ref.)

Is Mr Pac Man eating our children? A review of the effect of video games on children. Emes CE. **Can J Psychiatry** 1997 May;42(4):409–14 (38 ref.)

A person–oriented approach in research on developmental psychopathology. Bergman LR, et al. **Dev Psychopathol** 1997 Spring;9(2):291–319 (120 ref.)

Epigenetic approaches to developmental psychopathology. Goldsmith HH, et al. **Dev Psychopathol** 1997 Spring; 9(2):365–87 (105 ref.)

Conceptualizing psychopathology: the importance of developmental profiles. Kagan J. **Dev Psychopathol** 1997 Spring;9(2):321–34 (27 ref.)

The Hubble hypothesis and the developmentalist's dilemma. Richters JE. **Dev Psychopathol** 1997 Spring;9(2):193–9 (120 ref.)

Integrating nature and nurture: implications of person–environment correlations and interactions for developmental psychopathology. Rutter M, et al. **Dev Psychopathol** 1997 Spring;9(2):335–64 (270 ref.)

Psychopathology as an outcome of development. Sroufe LA. **Dev Psychopathol** 1997 Spring;9(2):251–68 (95 ref.)

When is development disordered? Developmental psychopathology and the harmful dysfunction analysis of mental disorder. Wakefield JC. **Dev Psychopathol** 1997 Spring;9(2):269–90 (52 ref.)

The long–term outcome of childhood empathy disorders. Gillberg C. **Eur Child Adolesc Psychiatry** 1996;5 Suppl 1:52–6 (51 ref.)

Recent undesirable life events: their influence on subsequent psychopathology. Goodyer IM. **Eur Child Adolesc Psychiatry** 1996;5 Suppl 1:33–7 (29 ref.)

The psychopathic personality in a longitudinal perspective. Klinteberg B. **Eur Child Adolesc Psychiatry** 1996;5 Suppl 1:57–63 (66 ref.)

Long–term outcomes of early childhood programs: analysis and recommendations. Gomby DS, et al. **Future Child** 1995 Winter;5(3):6–24 (60 ref.)

Long–term effects of early childhood programs on social outcomes and delinquency. Yoshikawa H. **Future Child** 1995 Winter;5(3):51–75 (83 ref.)

Life–span perspective of personality in dementia. Kolanowski AM, et al. **Image J Nurs Sch** 1996 Winter;28(4):315–20 (69 ref.)

The aim of psychoanalysis in theory and in practice [see comments] Steiner J. **Int J Psychoanal** 1996 Dec;77 (Pt 6):1073–83 (29 ref.) Comment in: Int J Psychoanal 1997 Jun;78 (Pt 3):580–3.

Importance of nonshared environmental factors for childhood and adolescent psychopathology. Pike A, et al. **J Am Acad Child Adolesc Psychiatry** 1996 May; 35(5):560–70 (59 ref.)

Archaic sadism. Chessick RD. **J Am Acad Psychoanal** 1996 Winter;24(4):605–18 (37 ref.)

Trait anxiety: it's not what you think it is. Reiss S. **J Anxiety Disord** 1997 Mar–Apr;11(2):201–14 (36 ref.)

Attachment relationships among children with aggressive behavior problems: the role of disorganized early attachment patterns. Lyons–Ruth K. **J Consult Clin Psychol** 1996 Feb;64(1):64–73 (92 ref.)

Beyond insecurity: a reconceptualization of attachment disorders of infancy. Zeanah CH. **J Consult Clin Psychol** 1996 Feb;64(1):42–52 (85 ref.)

Schools, families, and early adolescents: what are we doing wrong and what can we do instead? Eccles JS, et al. **J Dev Behav Pediatr** 1996 Aug;17(4):267–76 (65 ref.)

Addressing developmental needs of pregnant adolescents. Drake P. **J Obstet Gynecol Neonatal Nurs** 1996 Jul–Aug; 25(6):518–24 (18 ref.)

Television violence and its effect on children. Johnson MO. **J Pediatr Nurs** 1996 Apr;11(2):94–9 (31 ref.)

What language reveals about children's categories of personhood. Budwig N, et al. **New Dir Child Dev** 1995 Fall;(69):21–32 (25 ref.)

Reflections on the authority of the past in psychoanalytic thinking. Chodorow NJ. **Psychoanal Q** 1996 Jan; 65(1):32–51 (33 ref.)

Anna Freud's contributions to our knowledge of child development. An overview. Yorke C. **Psychoanal Study Child** 1996;51:7–24 (46 ref.)

Early identification of chronic offenders: who is the fledgling psychopath? Lynam DR. **Psychol Bull** 1996 Sep; 120(2):209–34 (240 ref.)

Alcohol, drugs, and violence in children's lives. Miller BA, et al. **Recent Dev Alcohol** 1997;13:357–85 (120 ref.)

[Perfectionism: conceptual and clinical aspects] Todorov C, et al. **Can J Psychiatry** 1996 Jun;41(5):291–8 (29 ref.) (Eng. Abstr.) **(Fre)**

[The emotional development of children] Fegert JM, et al. **Gesundheitswesen** 1997 Jan;59(1):1–9 (34 ref.) (Eng. Abstr.) **(Ger)**

[Life change event—life history—life plant: psychopathologic and forensic aspects] Janzarik W. **Nervenarzt** 1996 Jul;67(7):545–51 (15 ref.) (Eng. Abstr.) **(Ger)**

[Reflections on the cause and consequences of exposure to violent presentations in children] Rauchfleisch U. **Prax Kinderpsychol Kinderpsychiatr** 1997 Jul–Aug; 46(6):435–44 (27 ref.) (Eng. Abstr.) **(Ger)**

[The contribution of fathers to the individuation process in adolescence] Shulman S. **Prax Kinderpsychol Kinderpsychiatr** 1997 May–Jun; 46(5):321–37 (41 ref.) (Eng. Abstr.) **(Ger)**

[Factitious disorders: psychopathologic markers, biographic background and therapy follow–up] Lauer G. **Psychiatr Prax** 1996 Jan;23(1):37–9 (16 ref.) (Eng. Abstr.) **(Ger)**

PERSONALITY DISORDER, ANTISOCIAL see **ANTISOCIAL PERSONALITY DISORDER**

PERSONALITY DISORDER, BORDERLINE see **BORDERLINE PERSONALITY DISORDER**

PERSONALITY DISORDER, SCHIZOTYPAL see **SCHIZOTYPAL PERSONALITY DISORDER**

PERSONALITY DISORDERS

ABC of mental health. Disorders of personality. Marlowe M, et al. **BMJ** 1997 Jul 19;315(7101):176–9 (0 ref.)

COMPLICATIONS

Comorbidity and binge eating disorder. Mitchell JE, et al. **Addict Behav** 1995 Nov–Dec;20(6):725–32 (39 ref.)

Comorbidity and its effects on panic disorder. Marshall JR. **Bull Menninger Clin** 1996 Spring;60(2 Suppl A):A39–53 (63 ref.)

Antisocial personality disorder, sexual sadism, malignant narcissism, and serial murder. Geberth VJ, et al. **J Forensic Sci** 1997 Jan;42(1):49–60 (54 ref.)

The Sonda Project: prevention, prediction, and psychological disorder. Buscema M. **Subst Use Misuse** 1997 Jul; 32(9):1053–153 (315 ref.)

DIAGNOSIS

The concept and boundaries of personality disorders. López–Ibor JJ Jr. **Am J Psychiatry** 1997 Jun;154(6 Suppl):20–5 (38 ref.)

The assessment of personality disorders: implications for cognitive and behavior therapy. Van Velzen CJ, et al. **Behav Res Ther** 1996 Aug;34(8):655–68 (94 ref.)

Personality dimensions and depression: review and commentary [see comments] Enns MW, et al. **Can J Psychiatry** 1997 Apr;42(3):274–84 (105 ref.) Comment in: Can J Psychiatry 1997 Apr;42(3):249–50.

PERSONALITY DISORDERS

Personality disorders and culture: contemporary clinical views (Part A). Alarcón RD, et al. **Cult Divers Ment Health** 1995;1(1):3–17 (104 ref.)

Personality disorders and culture: contemporary clinical views (Part B). Alarcón RD, et al. **Cult Divers Ment Health** 1995;1(2):79–91 (81 ref.)

A personality disorder of excessive power strivings. Charny IW. **Isr J Psychiatry Relat Sci** 1997;34(1):3–15; discussion 16–7 (38 ref.)

Prospects for the assessment of normal and abnormal interpersonal behavior. Wiggins JS, et al. **J Pers Assess** 1997 Feb;68(1):110–26 (92 ref.)

Invited essay: the challenge of differentiating normal and disordered personality. Strack S, et al. **J Personal Disord** 1997 Summer;11(2):105–22 (86 ref.)

DRUG THERAPY

Psychopharmacologic treatment of pathologic aggression. Fava M. **Psychiatr Clin North Am** 1997 Jun;20(2):427–51 (176 ref.)

EPIDEMIOLOGY

The assessment of personality disorders: implications for cognitive and behavior therapy. Van Velzen CJ, et al. **Behav Res Ther** 1996 Aug;34(8):655–68 (94 ref.)

PREVENTION & CONTROL

The Sonda Project: prevention, prediction, and psychological disorder. Buscema M. **Subst Use Misuse** 1997 Jul; 32(9):1053–153 (315 ref.)

PSYCHOLOGY

An overview of depression-prone personality traits and the role of interpersonal sensitivity. Boyce P, et al. **Aust N Z J Psychiatry** 1996 Feb;30(1):90–103 (99 ref.)

The psychology of self: an update. Meares R. **Aust N Z J Psychiatry** 1996 Jun;30(3):312–6 (15 ref.)

Identifying narcissistic personality disorders in preadolescents. Guilé JM. **Can J Psychiatry** 1996 Aug; 41(6):343–9 (38 ref.)

Cloninger's tridimensional theory of personality and psychopathology: applications to substance use disorders. Howard MO, et al. **J Stud Alcohol** 1997 Jan;58(1):48–66 (55 ref.)

Personality and endogenous/major depression: an empirical approach to typus melancholicus. 1. Theoretical issues. Stanghellini G, et al. **Psychopathology** 1997;30(3):119–29 (60 ref.)

[Impulsiveness and impulse control. On the psychological and psychopathological conceptualization] Herpertz S, et al. **Nervenarzt** 1997 Mar;68(3):171–83 (106 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Long-term psychotherapy in borderline and narcissistic disorders: when is it necessary? Beatson JA. **Aust N Z J Psychiatry** 1995 Dec;29(4):591–7 (37 ref.)

Severe personality disorders. Treatment issues and selection for in-patient psychotherapy [see comments] Norton K, et al. **Br J Psychiatry** 1996 Jun;168(6):723–31 (29 ref.) Comment in: Br J Psychiatry 1996 Oct;169(4):524. Comment in: Br J Psychiatry 1996 Dec;169(6):792–3. Comment in: Br J Psychiatry 1997 Jan;170:90–1.

PERSONALITY INVENTORY

Self-rating procedures in the evaluation of antidepressants. Möller HJ, et al. **Psychopathology** 1995;28(6):291–306 (82 ref.)

STANDARDS

Stability and change in personality assessment: the revised NEO Personality Inventory in the year 2000. Costa PT Jr, et al. **J Pers Assess** 1997 Feb;68(1):86–94 (26 ref.)

Prospects for the assessment of normal and abnormal interpersonal behavior. Wiggins JS, et al. **J Pers Assess** 1997 Feb;68(1):110–26 (92 ref.)

STATISTICS & NUMERICAL DATA

A review of research on the Alcohol Use Disorders Identification Test (AUDIT). Allen JP, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):613–9 (31 ref.)

Suggestibility or hypnosis: what do our scales really measure? Kirsch I. **Int J Clin Exp Hypn** 1997 Jul;45(3):212–25 (36 ref.)

What this field needs is a good nomological network. Nadon R. **Int J Clin Exp Hypn** 1997 Jul;45(3):314–23 (24 ref.)

Have the hypnotic susceptibility scales outlived their usefulness? Woody EZ. **Int J Clin Exp Hypn** 1997 Jul; 45(3):226–38 (24 ref.)

The Geriatric Depression Scale: a review of its development and utility. Montorio I, et al. **Int Psychogeriatr** 1996 Spring; 8(1):103–12 (50 ref.)

The mismeasure of coping by checklist. Coyne JC, et al. **J Pers** 1996 Dec;64(4):959–91 (70 ref.)

Cloninger's tridimensional theory of personality and psychopathology: applications to substance use disorders. Howard MO, et al. **J Stud Alcohol** 1997 Jan;58(1):48–66 (55 ref.)

Measuring tobacco withdrawal: a review of self-report questionnaires. Patten CA, et al. **J Subst Abuse** 1996; 8(1):93–113 (75 ref.)

SCAN and the PSE tradition. Wing J. **Soc Psychiatry Psychiatr Epidemiol** 1996 Mar;31(2):50–4 (42 ref.)

[Quantitative psychopathology of affect and emotion. Review of evaluation scales and emotion induction methods] Garcia C, et al. **Encephale** 1997 Mar–Apr;23(2):119–30 (129 ref.) (Eng. Abstr.) **(Fre)**

[Tools for clinical evaluation of affective temperaments] Hantouche EG, et al. **Encephale** 1997 Jan;23 Spec No 1:27–34 (16 ref.) (Eng. Abstr.) **(Fre)**

[The Bern Coping Forms BEFO--an instrument for self- and observer rating of coping with illness] Heim E, et al. **Rehabilitation (Stuttg)** 1996 Nov;35(4):XXXI–XLI (60 ref.) (Eng. Abstr.) **(Ger)**

PERSONNEL ADMINISTRATION, HOSPITAL

STANDARDS

Delegation are you doing it right? [see comments] Parkman CA. **Am J Nurs** 1996 Sep;96(9):42–7; quiz 48 (7 ref.) Comment in: Am J Nurs 1996 Dec;96(12):16.

PERSONNEL, HOSPITAL

Occupational dermatitis--what's new? Hospital workers. Wrangsjö K, et al. **Clin Dermatol** 1997 Jul–Aug;15(4):573–8 (59 ref.)

The new era of hospital epidemiology: what you need to succeed. Simmons BP, et al. **Clin Infect Dis** 1996 Mar; 22(3):550–3 (12 ref.)

Occupational hazards of operating: opportunities for improvement. Davis MS. **Infect Control Hosp Epidemiol** 1996 Oct;17(10):691–3 (16 ref.)

[After accidental exposure to blood. What should be done?] Vayssettes JC, et al. **Presse Med** 1997 Apr 5;26(11):517–9 (25 ref.) **(Fre)**

[Health hazards in hospital personnel related to use of ethylene oxide in sterilization processes] Tyras H. **Med Pr** 1997;48(3):325–33 (48 ref.) (Eng. Abstr.) **(Pol)**

EDUCATION

A substance abuse consultation service. Enhancing the care of hospitalized substance abusers and providing training in addiction psychiatry. McDuff DR, et al. **Am J Addict** 1997 Summer;6(3):256–65 (43 ref.)

Demand for post-qualifying professional education in the health care sector in England. Calpin-Davies PJ. **J Adv Nurs** 1996 Oct;24(4):800–9 (33 ref.)

PSYCHOLOGY

Humor in the emergency room: a social work perspective. van Wormer K, et al. **Health Soc Work** 1997 May; 22(2):87–92 (17 ref.)

PERSONNEL, HOSPITAL, ORGANIZATION AND ADMINISTRATION see **PERSONNEL ADMINISTRATION, HOSPITAL**

PERSONNEL MANAGEMENT

see related
PERSONNEL ADMINISTRATION, HOSPITAL

Sexual harassment in nursing. Robbins I, et al. **J Adv Nurs** 1997 Jan;25(1):163–9 (41 ref.)

TRENDS

The changing roles of health care personnel in health and health care management. Hunter DJ. **Soc Sci Med** 1996 Sep;43(5):799–808 (31 ref.)

PERSONNEL RECRUITMENT see **PERSONNEL SELECTION**

PERSONNEL SELECTION

[Performance capacity of elderly workers--internal and external influencing factors] Dittmann-Kohli F, et al. **Z Gerontol Geriatr** 1996 Sep–Oct;29(5):323–7 (47 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Recruiting and retaining clinician-educators. Lessons learned from three programs. Osborn LM, et al. **J Gen Intern Med** 1997 Apr;12 Suppl 2:S83–9 (31 ref.)

PERSONNEL STAFFING AND SCHEDULING

ORGANIZATION & ADMINISTRATION

Changing schedules: shiftwork. Knauth P. **Chronobiol Int** 1997 Mar;14(2):159–71 (24 ref.)

Does a full-time, 24-hour intensivist improve care and efficiency? Carlson RW, et al. **Crit Care Clin** 1996 Jul; 12(3):525–51 (63 ref.)

Human resource policies and older workers in Japan. Clark RL, et al. **Gerontologist** 1996 Oct;36(5):627–36 (26 ref.)

PERSONNEL TURNOVER

Turning job finders into job keepers. Hershey AM, et al. **Future Child** 1997 Spring;7(1):74–86 (39 ref.)

Management retention contracts in health care affiliations. Leroux CG. **Health Care Manage Rev** 1997 Spring; 22(2):49–54 (0 ref.)

PERSUASION see **PERSUASIVE COMMUNICATION**

PERSUASIVE COMMUNICATION

see related
SUGGESTION

Attitudes and attitude change. Petty RE, et al. **Annu Rev Psychol** 1997;48:609–47 (270 ref.)

Communication, accrual to clinical trials, and the physician-patient relationship: implications for training programs. Ruckdeschel JC, et al. **J Cancer Educ** 1996 Summer;11(2):73–9 (51 ref.)

Persuasive communication: marketing health promotion. Stubblefield C. **Nurs Outlook** 1997 Jul–Aug;45(4):173–7 (25 ref.)

Shaping perceptions to motivate healthy behavior: the role of message framing. Rothman AJ, et al. **Psychol Bull** 1997 Jan;121(1):3–19 (125 ref.)

PERTECHNETATE SODIUM see **SODIUM PERTECHNETATE TC 99M**

PERTHES DISEASE see **LEGG-PERTHES DISEASE**

PERTUSSIGEN see **PERTUSSIS TOXINS**

PERTUSSIS see **WHOOPING COUGH**

PERTUSSIS TOXINS

[Properties and action of Bordetella dermonecrotizing toxin] Horiguchi Y. **Nippon Saikingaku Zasshi** 1996 Oct; 51(4):963–72 (43 ref.) **(Jpn)**

IMMUNOLOGY

New vaccines against bacterial toxins. Rappuoli R, et al. **Adv Exp Med Biol** 1996;397:55–60 (30 ref.)

PHARMACOLOGY

Signalling functions and biochemical properties of pertussis toxin-resistant G-proteins. Fields TA, et al. **Biochem J** 1997 Feb 1;321 (Pt 3):561–71 (242 ref.)

PERTUSSIS VACCINE

New vaccines against bacterial toxins. Rappuoli R, et al. **Adv Exp Med Biol** 1996;397:55–60 (30 ref.)

European Union research strategies on vaccines. Hansen B. **Dev Biol Stand** 1997;89:29–36 (17 ref.)

The United States research strategy on pertussis. La Montagne JR. **Dev Biol Stand** 1997;89:25–8 (6 ref.)

Epidemiological determinants of pertussis. Miller E, et al. **Dev Biol Stand** 1997;89:15–23 (16 ref.)

A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned [see comments] Schneerson R, et al. **Lancet** 1996 Nov 9;348(9037):1289–92 (38 ref.) Comment in: Lancet 1997 Jan 11;349(9045):136; discussion 137–8. Comment in: Lancet 1997 Jan 11;349(9045):136–7; discussion 137–8. Comment in: Lancet 1997 Jan 11;349(9045);137; discussion 137–8.

Pertussis vaccination in the United States--new developments and recommendations. Guris D, et al. **Pediatr Ann** 1997 Jun;26(6):372–7 (23 ref.)

Combination vaccines consisting of acellular pertussis vaccines. Edwards KM, et al. **Pediatr Infect Dis J** 1997 Apr;16(4 Suppl):S97–102 (24 ref.)

Pertussis: current concepts of pathogenesis and prevention. Hewlett EL. **Pediatr Infect Dis J** 1997 Apr;16(4 Suppl):S78–84 (72 ref.)

ADMINISTRATION & DOSAGE

The acellular pertussis vaccine trials: an interpretation. Plotkin SA, et al. **Pediatr Infect Dis J** 1997 May; 16(5):508–17; discussion 517–9 (46 ref.)

IMMUNOLOGY

Historical review of pertussis and the classical vaccine. Cherry JD. **J Infect Dis** 1996 Nov;174 Suppl 3:S259–63 (35 ref.)

Acellular pertussis vaccine composed of genetically inactivated pertussis toxin. Peppoloni S, et al. **Physiol Chem Phys Med NMR** 1995;27(4):355–61 (21 ref.)

THERAPEUTIC USE

Adult pertussis: a salesman's dream--and an epidemiologist's nightmare. Fine PE. **Biologicals** 1997 Jun;25(2):195–8 (22 ref.)

An overview of the status of acellular pertussis vaccines in practice. Lopez AL, et al. **Drugs** 1997 Aug;54(2):189–96

(45 ref.)

PERVASIVE CHILD DEVELOPMENT DISORDERS see **CHILD DEVELOPMENT DISORDERS, PERVASIVE**

PES CAVUS see **FOOT DEFORMITIES**

PES PLANUS see **FLATFOOT**

PESSARIES, INTRACERVICAL see **INTRAUTERINE DEVICES**

PESSARIES, INTRAUTERINE see **INTRAUTERINE DEVICES**

PEST CONTROL

Ecological implications of control strategies: arthropods of domestic and production animals. Petney TN. **Int J Parasitol** 1997 Feb;27(2):155–65 (121 ref.)

Managing problem wildlife in the 'Old World': a veterinary perspective. Artois M. **Reprod Fertil Dev** 1997;9(1):17–25 (98 ref.)

Australian and New Zealand mammal species considered to be pests or problems. Cowan PE, et al. **Reprod Fertil Dev** 1997;9(1):27–36 (61 ref.)

METHODS

Head lice in schoolchildren. Ibarra J, et al. **Arch Dis Child** 1996 Dec;75(6):471–3 (29 ref.)

Modelling immunocontraception in disseminating systems. Barlow ND. **Reprod Fertil Dev** 1997;9(1):51–60 (14 ref.)

A bait-delivered immunocontraceptive vaccine for the European red fox (Vulpes vulpes) by the year 2002? Bradley MP, et al. **Reprod Fertil Dev** 1997;9(1):111–6 (20 ref.)

Case studies in wildlife immunocontraception: wild and feral equids and white-tailed deer. Kirkpatrick JF, et al. **Reprod Fertil Dev** 1997;9(1):105–10 (21 ref.)

Immunocontraception in rodents: a review of the development of a sperm-based immunocontraceptive vaccine for the grey squirrel (Sciurus carolinensis). Moore HD, et al. **Reprod Fertil Dev** 1997;9(1):125–9 (33 ref.)

Ethical aspects and dilemmas of fertility control of unwanted wildlife: an animal welfarist's perspective. Oogjes G. **Reprod Fertil Dev** 1997;9(1):163–7 (8 ref.)

Can foxes be controlled by reducing their fertility? Pech R, et al. **Reprod Fertil Dev** 1997;9(1):41–50 (28 ref.)

Progress towards using recombinant myxoma virus as a vector for fertility control in rabbits. Robinson AJ, et al. **Reprod Fertil Dev** 1997;9(1):77–83 (43 ref.)

Fertility control of mammal pests and the conservation of endangered marsupials. Sinclair AR. **Reprod Fertil Dev** 1997;9(1):1–16 (59 ref.)

Neither human nor natural: ethics and feral animals. Singer P. **Reprod Fertil Dev** 1997;9(1):157–62 (7 ref.)

Development and use of virus-vectored immunocontraception. Williams CK. **Reprod Fertil Dev** 1997;9(1):169–78 (23 ref.)

STANDARDS

Ecotoxicology for risk assessment in arid zones: some key issues. Everts JW. **Arch Environ Contam Toxicol** 1997 Jan; 32(1):1–10 (123 ref.)

PEST CONTROL, BIOLOGICAL

The insecticidal proteins of Bacillus thuringiensis. Kumar PA, et al. **Adv Appl Microbiol** 1996;42:1–43 (311 ref.)

The utility of strains of morphological group II Bacillus. Singer S. **Adv Appl Microbiol** 1996;42:219–61 (65 ref.)

Lectins and biocontrol. Inbar J, et al. **Crit Rev Biotechnol** 1997;17(1):1–20 (126 ref.)

The prospects for biological control of the free-living stages of nematode parasites of livestock. Waller PJ, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):915–25 (81 ref.)

Transgenic plants: an emerging approach to pest control. Estruch JJ, et al. **Nat Biotechnol** 1997 Feb;15(2):137–41 (52 ref.)

Possum biocontrol: prospects for fertility regulation. Cowan PE. **Reprod Fertil Dev** 1996;8(4):655–60 (38 ref.)

Biological control. Aspects of biological control--with special reference to arthropods, protozoans and helminths of domesticated animals. Grønvold J, et al. **Vet Parasitol** 1996 Aug;64(1–2):47–64 (61 ref.)

METHODS

Adverse assessments of Gambusia affinis: an alternate view for mosquito control practitioners [published erratum appears in J Am Mosq Control Assoc 1996 Dec;12(4):752] [see comments] Rupp HR. **J Am Mosq Control Assoc** 1996 Jun;12(2 Pt 1):155–9; discussion 160–6 (25 ref.) Comment in: J Am Mosq Control Assoc 1997 Mar;13(1):101.

PESTICIDE RESIDUES

An operational perspective on measuring aerosol cloud dynamics. Burkett DA, et al. **J Am Mosq Control Assoc** 1996 Jun;12(2 Pt 2):380–3 (4 ref.)

Overview of meteorological measurements for aerial spray modeling. Rafferty JE, et al. **J Am Mosq Control Assoc** 1996 Jun;12(2 Pt 2):364–7 (7 ref.)

Atmospheric stability and the dispersion of pesticides. Thistle HW. **J Am Mosq Control Assoc** 1996 Jun;12(2 Pt 2):359–63 (5 ref.)

Limits for pesticide residues in infant foods: a safety-based proposal. Schilter B, et al. **Regul Toxicol Pharmacol** 1996 Oct;24(2 Pt 1):126–40 (96 ref.)

ADVERSE EFFECTS

FIFRA Subdivision F testing Guidelines: are these tests adequate to detect potential hormonal activity for crop protection chemicals? Federal Insecticide, Fungicide, and Rodenticide Act. Stevens JT, et al. **J Toxicol Environ Health** 1997 Apr 11;50(5):415–31 (35 ref.)

An overview of some reproductive toxicology studies conducted at Health Canada. Foster WG, et al. **Toxicol Ind Health** 1996 May–Aug;12(3–4):447–59 (77 ref.)

ANALYSIS

Annual variation of insecticides in precipitation in rural Japan. Kawata K, et al. **Bull Environ Contam Toxicol** 1996 Dec;57(6):853–8 (15 ref.)

Control and intake of pesticide residues during 1981–1993 in Finland. Penttilä PL, et al. **Food Addit Contam** 1996 Aug–Sep;13(6):609–21 (45 ref.)

Strategies for chromatographic analysis of pesticide residues in water. Balinova A. **J Chromatogr A** 1996 Nov 22; 754(1–2):125–35 (125 ref.)

Occurrence and determination of pesticides in natural and treated waters. Biziuk M, et al. **J Chromatogr A** 1996 Nov 22;754(1–2):103–23 (431 ref.)

Applications of liquid chromatography-mass spectrometry interfacing systems in food analysis: pesticide, drug and toxic substance residues. Careri M, et al. **J Chromatogr A** 1996 Mar 15;727(2):153–84 (162 ref.)

Chromatographic methods for the determination of pyrethrin and pyrethroid pesticide residues in crops, foods and environmental samples. Chen ZM, et al. **J Chromatogr A** 1996 Nov 22;754(1–2):367–95 (226 ref.)

Screening and analysis of polar pesticides in environmental monitoring programmes by coupled-column liquid chromatography and gas chromatography-mass spectrometry. Hogendoorn EA, et al. **J Chromatogr A** 1996 Nov 22;754(1–2):49–60 (37 ref.)

Official multiresidue methods of pesticide analysis in vegetables, fruits and soil. Motohashi N, et al. **J Chromatogr A** 1996 Nov 22;754(1–2):333–46 (64 ref.)

Chromatographic techniques in the analysis of organochlorine pesticide residues. Mukherjee I, et al. **J Chromatogr A** 1996 Nov 22;754(1–2):33–42 (87 ref.)

Pesticide residue analysis in foodstuffs applying capillary gas chromatography with atomic emission detection state-of-the-art use of modified multimethod S19 of the Deutsche forschungsgemeinschaft and automated large-volume injection with programmed-temperature vaporization and solvent venting. Stan HJ, et al. **J Chromatogr A** 1996 Oct 25;750(1–2):369–90 (33 ref.)

Determination of cereal herbicide residues in environmental samples by gas chromatography. Tadeo JL, et al. **J Chromatogr A** 1996 Nov 22;754(1–2):347–65 (189 ref.)

Pesticide residue analyses in plant material by chromatographic methods: clean-up procedures and selective detectors. Tekel J, et al. **J Chromatogr A** 1996 Nov 22;754(1–2):397–410 (99 ref.)

Determination of pesticide residues in fruit and vegetables. Torres CM, et al. **J Chromatogr A** 1996 Nov 22; 754(1–2):301–31 (185 ref.)

Recent advances in the residue analysis of N-methylcarbamate pesticides. Yang SS, et al. **J Chromatogr A** 1996 Nov 22;754(1–2):3–16 (117 ref.)

Organochlorine insecticide residues in African Fauna: 1971–1995. Wiktelius S, et al. **Rev Environ Contam Toxicol** 1997;151:1–37 (100 ref.)

[Enzyme immunoassay with monoclonal antibody for environmental contaminants] Nakata M, et al. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(14):2132–8 (7 ref.) **(Jpn)**

POISONING

Identification of pesticide poisoning in wildlife. Brown P, et al. **J Chromatogr A** 1996 Nov 22;754(1–2):463–78 (43 ref.)

PESTICIDES

Is sustainable development a practical possibility given the continued use of plant protection products?—the scientific view. Herrchen M, et al. **Arch Toxicol Suppl** 1997;19:167–76 (17 ref.)

Ecological implications of control strategies: arthropods of domestic and production animals. Petney TN. **Int J Parasitol** 1997 Feb;27(2):155–65 (121 ref.)

State pesticide regulatory programs: themes and variations. Arne KH. **Occup Med** 1997 Apr–Jun;12(2):371–85 (33 ref.)

ADVERSE EFFECTS

Genotoxic effects of pesticides. de Bertoldi M. **Eur J Cancer Prev** 1996 Oct;5(5):397–9 (24 ref.)

Low-level chemical sensitivity: current perspectives. Ashford NA, et al. **Int Arch Occup Environ Health** 1996; 68(6):367–76 (28 ref.)

FIFRA Subdivision F testing Guidelines: are these tests adequate to detect potential hormonal activity for crop protection chemicals? Federal Insecticide, Fungicide, and Rodenticide Act. Stevens JT, et al. **J Toxicol Environ Health** 1997 Apr 11;50(5):415–31 (35 ref.)

Pesticide exposure assessment of workers and their families. Fenske RA. **Occup Med** 1997 Apr–Jun;12(2):221–37 (95 ref.)

Chronic neurologic effects of pesticide overexposure. Keifer MC, et al. **Occup Med** 1997 Apr–Jun;12(2):291–304 (82 ref.)

Skin reactions to pesticides. O'Malley MA. **Occup Med** 1997 Apr–Jun;12(2):327–45 (81 ref.)

A clinical historical overview of pesticide health issues. Schuman SH, et al. **Occup Med** 1997 Apr–Jun;12(2):203–7 (15 ref.)

Monitoring the pesticide-exposed worker. Wilson BW, et al. **Occup Med** 1997 Apr–Jun;12(2):347–63 (55 ref.)

Pesticides and cancer. Zahm SH, et al. **Occup Med** 1997 Apr–Jun;12(2):269–89 (195 ref.)

Is working in greenhouses healthy? Evidence concerning the toxic risks that might affect greenhouse workers. Illing HP. **Occup Med (Oxf)** 1997 Jul;47(5):281–93 (70 ref.)

ANALYSIS

Impaired immunity in harbour seals [Phoca vitulina] fed environmentally contaminated herring. de Swart RL, et al. **Vet Q** 1996;18 Suppl 3:S127–8 (12 ref.)

CHEMISTRY

Chemical structure of descriptors with an active hydrogen atom in certain bioregulators. Kurchii BA. **Ukr Biokhim Zh** 1996 Jan–Feb;68(1):3–13 (29 ref.)

ECONOMICS

Regulations and risk assessments on the ecotoxicological impact from the use of plant protection products in the European Union--an industry viewpoint. Punja N. **Arch Toxicol Suppl** 1997;19:177–85 (4 ref.)

PHARMACOLOGY

Pesticides: multiple mechanisms of demasculinization. LeBlanc GA, et al. **Mol Cell Endocrinol** 1997 Jan 3; 126(1):1–5 (72 ref.)

POISONING

Identification of pesticide poisoning in wildlife. Brown P, et al. **J Chromatogr A** 1996 Nov 22;754(1–2):463–78 (43 ref.)

Clinical evaluation of pesticide exposure and poisonings. O'Malley M. **Lancet** 1997 Apr 19;349(9059):1161–6 (51 ref.)

Epidemiology of pesticide poisonings in the United States, with special reference to occupational cases. Blondell J. **Occup Med** 1997 Apr–Jun;12(2):209–20 (38 ref.)

Emerging issues in pesticide health studies. Fleming LE, et al. **Occup Med** 1997 Apr–Jun;12(2):387–97 (106 ref.)

Reproductive and developmental effects of occupational pesticide exposure: the epidemiologic evidence. Sever LE, et al. **Occup Med** 1997 Apr–Jun;12(2):305–25 (101 ref.)

An estimate of the incidence of pesticide poisoning in Hong Kong. Chan TY, et al. **Vet Hum Toxicol** 1996 Oct; 38(5):362–4 (12 ref.)

[Nephropathy induced by non-drug chemical agents] Miyazaki K, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):577–9 (15 ref.) **(Jpn)**

TOXICITY

Repeated acquisition and the assessment of centrally acting compounds. Cohn J, et al. **Brain Res Cogn Brain Res** 1996 Jun;3(3–4):183–91 (60 ref.)

Biomarkers of human exposure to pesticides. Anwar WA. **Environ Health Perspect** 1997 Jun;105 Suppl 4:801–6 (79 ref.)

Regulations for combined effects of pollutants: consequences from risk assessment in aquatic toxicology. Altenburger R, et al. **Food Chem Toxicol** 1996 Nov–Dec; 34(11–12):1155–7 (19 ref.)

Immunotoxicity of pesticides: perspectives and trends. Banerjee BD, et al. **Indian J Exp Biol** 1996 Aug; 34(8):723–33 (45 ref.)

Toxicity testing of pesticides sold in the United States. Keifer MC, et al. **Occup Med** 1997 Apr–Jun;12(2):365–70 (4 ref.)

Toxicological risk assessment of worker exposure to pesticides: some general principles. de Raat WK, et al. **Regul Toxicol Pharmacol** 1997 Jun;25(3):204–10 (27 ref.)

Pesticides hazards in developing countries. Koh D, et al. **Sci Total Environ** 1996 Sep;188 Suppl 1:S78–85 (21 ref.)

Green revolution agriculture and chemical hazards. Pimentel D. **Sci Total Environ** 1996 Sep;188 Suppl 1:S86–98 (93 ref.)

Environmental Protection Agency risk assessment--process and toxicologic pathology. Copley MP. **Toxicol Pathol** 1997 Jan–Feb;25(1):68–71 (3 ref.)

PESTIVIRUS

Molecular characterization of pestiviruses. Meyers G, et al. **Adv Virus Res** 1996;47:53–118 (173 ref.)

PESTIVIRUS

CLASSIFICATION

Pestiviruses--taxonomic perspectives. Horzinek MC. **Arch Virol Suppl** 1991;3:1–5 (21 ref.)

Molecular characterization of positive-strand RNA viruses: pestiviruses and the porcine reproductive and respiratory syndrome virus (PRRSV). Thiel HJ, et al. **Arch Virol Suppl** 1993;7:41–52 (33 ref.)

ISOLATION & PURIFICATION

[Pestiviruses] Sergeev OV. **Vopr Virusol** 1997 Jan–Feb; 42(1):5–10 (60 ref.) **(Rus)**

PESTIVIRUS, BOVINE see **DIARRHEA VIRUS, BOVINE VIRAL**

PESTIVIRUS INFECTIONS

VIROLOGY

Molecular characterization of pestiviruses. Meyers G, et al. **Adv Virus Res** 1996;47:53–118 (173 ref.)

PET-HUMAN BONDING see **BONDING, HUMAN-PET**

PET SCAN see **TOMOGRAPHY, EMISSION-COMPUTED**

PETECHIAE see **PURPURA**

PETIT MAL EPILEPSY see **EPILEPSY, ABSENCE**

PETIT MAL STATUS see **STATUS EPILEPTICUS**

PETROLATUM, LIQUID see **MINERAL OIL**

PETROLEUM

Burns with inhalation injury and petrol aspiration in adolescents seeking euphoria through hydrocarbon inhalation. Sheridan RL. **Burns** 1996 Nov;22(7):566–7 (18 ref.)

Neural networks in petroleum engineering: a case study [letter] Vukelic MA, et al. **Int J Neural Syst** 1996 May; 7(2):187–94 (11 ref.)

ADVERSE EFFECTS

Common dermatologic manifestations of cutaneous exposure to petroleum and its derivatives. Beasley KL, et al. **Cutis** 1996 Jul;58(1):59–62 (13 ref.)

Cancer mortality among petroleum refinery and chemical manufacturing workers in Texas. Cooper SP, et al. **J Environ Pathol Toxicol Oncol** 1997;16(1):1–14 (65 ref.)

[Risk of neoplastic disease in workers from petroleum refineries and in persons employed in fuel distribution] Pepłońska B. **Med Pr** 1995;46(6):603–17 (37 ref.) (Eng. Abstr.) **(Pol)**

[Hygienic aspects of health of children living in areas with developed gas chemical industries (review)] Savin VP, et al. **Gig Sanit** 1996 Jul–Aug;(4):24–7 (45 ref.) **(Rus)**

METABOLISM

Beyond TPH: health-based evaluation of petroleum hydrocarbon exposures. Hutcheson MS, et al. **Regul Toxicol Pharmacol** 1996 Aug;24(1 Pt 1):85–101 (90 ref.)

POISONING

Liquefied petroleum gas (LPG) poisoning: report of two cases and review of the literature. Fukunaga T, et al. **Forensic Sci Int** 1996 Oct 25;82(3):193–200 (16 ref.)

Toxicopathology of oilfield poisoning in cattle: a review. Coppock RW, et al. **Vet Hum Toxicol** 1996 Feb;38(1):36–42 (45 ref.)

TOXICITY

A proposed approach to study the toxicology of complex mixtures of petroleum products: the integrated use of QSAR, lumping analysis and PBPK/PD modeling. Verhaar HJ, et al. **Environ Health Perspect** 1997 Feb;105 Suppl 1:179–95 (73 ref.)

PETROUS BONE

Cranial fasciitis presenting as an external auditory canal mass. Clapp CG, et al. **Arch Otolaryngol Head Neck Surg** 1997 Feb;123(2):223–5 (4 ref.)

Cemento-ossifying fibroma of the petromastoid region: case report and review of the literature. Brademann G, et al. **J Laryngol Otol** 1997 Feb;111(2):152–5 (28 ref.)

[Cholesterol granuloma of the petrous apex--etiology, diagnosis and therapy] Lorenz KJ, et al. **Laryngorhinootologie** 1996 Dec;75(12):775–82 (33 ref.) (Eng. Abstr.) **(Ger)**

PETROUS PYRAMID see **PETROUS BONE**

PETS see **ANIMALS, DOMESTIC**

PEUTZ-JEGHERS SYNDROME

PATHOLOGY

Peutz-Jeghers syndrome and the hamartomatous polyposis syndromes: radiologic-pathologic correlation. Cho GJ, et al. **Radiographics** 1997 May-Jun;17(3):785–91 (16 ref.)

RADIOGRAPHY

Peutz-Jeghers syndrome and the hamartomatous polyposis syndromes: radiologic-pathologic correlation. Cho GJ, et al. **Radiographics** 1997 May-Jun;17(3):785–91 (16 ref.)

PEYER'S PATCHES

Review: Peyer's patches. Heel KA, et al. **J Gastroenterol Hepatol** 1997 Feb;12(2):122–36 (168 ref.)

IMMUNOLOGY

Postrearrangement diversification processes in gut-associated lymphoid tissues. Reynaud CA, et al. **Curr Top Microbiol Immunol** 1996;212:7–15 (28 ref.)

PHYSIOLOGY

Nanoparticles and microparticles for drug and vaccine delivery. Kreuter J. **J Anat** 1996 Dec;189 (Pt 3):503–5 (24 ref.)

The intestinal uptake of particles and the implications for drug and antigen delivery. O'Hagan DT. **J Anat** 1996 Dec; 189 (Pt 3):477–82 (38 ref.)

Particle uptake and translocation across epithelial membranes. Thomas NW, et al. **J Anat** 1996 Dec;189 (Pt 3):487–90 (17 ref.)

PEYRONIE'S DISEASE see **PENILE INDURATION**

PF1 PHAGE see **INOVIRUS**

PF 4 see **PLATELET FACTOR 4**

PFEIFFER SYNDROME see **ACROCEPHALOSYNDACTYLIA**

PGD2 see **PROSTAGLANDIN D2**

PGE RECEPTORS see **RECEPTORS, PROSTAGLANDIN E**

PGE1 see **ALPROSTADIL**

PGE2 see **DINOPROSTONE**

PGE2ALPHA see **DINOPROSTONE**

PGE2 RECEPTORS see **RECEPTORS, PROSTAGLANDIN E**

PGF SYNETHETIC see **PROSTAGLANDINS F, SYNTHETIC**

PGF2 see **DINOPROST**

PGF2ALPHA see **DINOPROST**

PGH SYNTHASE see **PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE**

PGI2 see **EPOPROSTENOL**

PGX see **EPOPROSTENOL**

PH see **HYDROGEN-ION CONCENTRATION**

PH1 CHROMOSOME see **PHILADELPHIA CHROMOSOME**

PHACOEMULSIFICATION

ADVERSE EFFECTS

Consultation section. How would you handle a tear in the posterior capsule, detected at the end of phacoemulsification, with the cortex intact and no vitreous loss? [see comments] **J Cataract Refract Surg** 1997 Jan–Feb; 23(1):12–8 (9 ref.) Comment in: J Cataract Refract Surg 1997 May;23(4):462.

INSTRUMENTATION

Bimanual irrigation/aspiration. Brauweiler P. **J Cataract Refract Surg** 1996 Oct;22(8):1013–6 (7 ref.)

METHODS

Stop, chop, chop, and stuff. Vasavada AR, et al. **J Cataract Refract Surg** 1996 Jun;22(5):526–9 (5 ref.)

Comparison of phacoemulsification and planned extracapsular extraction. Ohrloff C, et al. **Ophthalmologica** 1997;211(1):8–12 (24 ref.)

VETERINARY

Cataract surgery in the horse: a review of six cases. Whitley RD, et al. **Equine Vet J Suppl** 1990 Sep;(10):85–90 (26 ref.)

PHAGE ATTACHMENT SITES see **ATTACHMENT SITES (MICROBIOLOGY)**

PHAGE FD see **INOVIRUS**

PHAGE IKE see **INOVIRUS**

PHAGE LAMBDA see **BACTERIOPHAGE LAMBDA**

PHAGE MU see **BACTERIOPHAGE MU**

PHAGE MU 1 see **BACTERIOPHAGE MU**

PHAGE MU 2 see **RNA PHAGES**

PHAGE P1 see **BACTERIOPHAGE P1**

PHAGE PF1 see **INOVIRUS**

PHAGE RECEPTORS see **RECEPTORS, VIRUS**

PHAGE T3 see **BACTERIOPHAGE T3**

PHAGE T4 see **BACTERIOPHAGE T4**

PHAGE TYPING see **BACTERIOPHAGE TYPING**

PHAGES see **BACTERIOPHAGES**

PHAGES, RNA see **RNA PHAGES**

PHAGOCYTE BACTERICIDAL DYSFUNCTION

[Chronic granulomatous disease (CGD): dysfunction of the neutrophil granulocyte NADPH-oxidase enzyme system] Német K, et al. **Orv Hetil** 1997 Feb 16;138(7):397–401 (20 ref.) (Eng. Abstr.) **(Hun)**

ETIOLOGY

Immune deficiency in glycogen storage disease type 1B. Garty BZ, et al. **Isr J Med Sci** 1996 Dec;32(12):1276–81 (40 ref.)

GENETICS

[Recent findings on the molecular basis of congenital, hereditary phagocytic dysfunctions--with special reference to genetic abnormality of Chediak-Higashi syndrome] Yasui K. **Nihon Rinsho Meneki Gakkai Kaishi** 1997 Jun; 20(3):145–51 (18 ref.) **(Jpn)**

PHAGOCYTES

DRUG EFFECTS

Action of cyclosporin A on mononuclear phagocytes. Losa García JE, et al. **J Investig Allergol Clin Immunol** 1996 Jul-Aug;6(4):222–31 (97 ref.)

[Effect of contemporary chemotherapeutic drugs on phagocyte activity and the immune response] Nikitin AV, et al. **Antibiot Khimioter** 1996;41(7–8):49–56 (14 ref.) **(Rus)**

ENZYMOLOGY

Assembly of the phagocyte NADPH oxidase: molecular interaction of oxidase proteins. DeLeo FR, et al. **J Leukoc Biol** 1996 Dec;60(6):677–91 (156 ref.)

IMMUNOLOGY

IgA antibody as a non-inflammatory regulator of immunity. Russell MW, et al. **Biochem Soc Trans** 1997 May; 25(2):466–70 (45 ref.)

[Platelet activating factor--role in regulating the functional activity of the mononuclear phagocyte system] Shebzukhov IuV, et al. **Vopr Med Khim** 1996 Oct-Dec;42(4):278–83 (67 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

[Signal transduction by Rac small G proteins in phagocytes] Dorseuil O, et al. **C R Seances Soc Biol Fil** 1997; 191(2):237–46 (49 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis? Burmester GR, et al. **Arthritis Rheum** 1997 Jan;40(1):5–18 (178 ref.)

Phagocyte implications in advanced atherosclerosis. de Prost D, et al. **Atherosclerosis** 1997 Jun;131 Suppl:S19–21 (6 ref.)

Phagocyte recognition of apoptotic cells. Savill J. **Biochem Soc Trans** 1996 Nov;24(4):1065–9 (29 ref.)

Mononuclear phagocytes and dendritic leukocytes in the skin. Milon G, et al. **Clin Dermatol** 1996 Sep-Oct;14(5):465–70 (65 ref.)

Recognition of apoptotic cells by phagocytes. Hart SP, et al. **Experientia** 1996 Oct 31;52(10–11):950–6 (35 ref.)

Priming study of human phagocytes oxidative burst by using flow cytometry. Elbim C, et al. **Hematol Cell Ther** 1996

Dec;38(6):527–35 (58 ref.)
Pathogenetic role of phagocytic abnormalities in human virus immunodeficiency infection: possible therapeutical approaches. A review. Covelli V, et al. **Immunopharmacol Immunotoxicol** 1997 May;19(2):147–64 (76 ref.)
Alterations in phagocyte function and periodontal infection. Daniel MA, et al. **J Periodontol** 1996 Oct;67(10 Suppl):1070–5 (47 ref.)
Interactions between professional phagocytes and Brucella spp. Liautard JP, et al. **Microbiologia** 1996 Jun; 12(2):197–206 (36 ref.)
Mononuclear phagocyte activation and acute pancreatitis. McKay C, et al. **Scand J Gastroenterol Suppl** 1996;219:32–6 (37 ref.)

SECRETION

Out of the phagocyte or into its phagosome: signalling to secretion. Tapper H. **Eur J Haematol** 1996 Sep; 57(3):191–201 (116 ref.)

VIROLOGY

The HIV–1 associated dementia complex: a metabolic encephalopathy fueled by viral replication in mononuclear phagocytes. Zheng J, et al. **Curr Opin Neurol** 1997 Aug; 10(4):319–25 (77 ref.)

PHAGOCYTOSIS

Cellular effects of particles—impact of dissolution on toxicity of man-made mineral fibers. Luoto K, et al. **Cent Eur J Public Health** 1996;4 Suppl:29–32 (40 ref.)
Mechanisms of phagocytosis. Allen LA, et al. **Curr Opin Immunol** 1996 Feb;8(1):36–40 (41 ref.)
Phagocytosis and intracellular digestion of collagen, its role in turnover and remodelling. Everts V, et al. **Histochem J** 1996 Apr;28(4):229–45 (135 ref.)
Mechanism and computer simulation of immune complex formation, opsonization, and clearance. Head M, et al. **J Lab Clin Med** 1996 Jul;128(1):61–74 (42 ref.)
Zucker rat (fa/fa), a model for the study of immune function in type–II diabetes mellitus: effect of exercise and caloric restriction on the phagocytic activity of macrophages. Plotkin BJ, et al. **Lab Anim Sci** 1996 Dec;46(6):682–4 (17 ref.)
Interactions between professional phagocytes and Brucella spp. Liautard JP, et al. **Microbiologia** 1996 Jun; 12(2):197–206 (36 ref.)
[The killing activity method in neutrophils] Kohsaka T, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:204–9 (14 ref.) **(Jpn)**
[Assay of phagocytic activity of neutrophils] Sasada M, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:200–3 (4 ref.) **(Jpn)**
[An improved phagocytic plaque method using gram-negative bacilli] Tomiya Y, et al. **Nippon Saikingaku Zasshi** 1996 Oct;51(4):1049–53 (6 ref.) (Eng. Abstr.) **(Jpn)**
[Strategies of Histoplasma capsulatum for evading the cytocidal mechanisms of phagocytes] Taylor ML, et al. **Rev Invest Clin** 1995 Nov–Dec;47(6):499–506 (50 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Mechanisms for recognition and phagocytosis of apoptotic lymphocytes by macrophages. Schlegel RA, et al. **Adv Exp Med Biol** 1996;406:21–8 (26 ref.)
Mechanisms of antigen uptake for presentation. Lanzavecchia A. **Curr Opin Immunol** 1996 Jun;8(3):348–54 (93 ref.)

PHYSIOLOGY

Vesicular transport of microorganisms in macrophages. Alvarez-Dominguez C. **Biocell** 1996 Dec;20(3):355–65 (29 ref.)
Tyrosine phosphorylation and Fcgamma receptor-mediated phagocytosis. Strzelecka A, et al. **FEBS Lett** 1997 Jan 2; 400(1):11–4 (51 ref.)

PHAGOLYSOSOMES see **PHAGOSOMES**

PHAGOSOMES

see related
PHAGOCYTOSIS

METABOLISM

Structural aspects of autophagy. Seglen PO, et al. **Adv Exp Med Biol** 1996;389:103–11 (19 ref.)

PHYSIOLOGY

Out of the phagocyte or into its phagosome: signalling to secretion. Tapper H. **Eur J Haematol** 1996 Sep; 57(3):191–201 (116 ref.)
Characterization of the Mycobacterium tuberculosis phagosome. Clemens DL. **Trends Microbiol** 1996 Mar; 4(3):113–8 (39 ref.)

PHALLIC STAGE see **PSYCHOSEXUAL DEVELOPMENT**

PHALLOIDINE

TOXICITY

New aspects of amanitin and phalloidin poisoning. Faulstich H, et al. **Adv Exp Med Biol** 1996;391:309–14 (11 ref.)

PHANTOM LIMB

DRUG THERAPY

[Epiduritis after long-term pain therapy with an epidural catheter—review of the literature with a current case report] Michel H, et al. **Anaesthesiol Reanim** 1997; 22(3):69–79 (105 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Postmastectomy pain syndromes. Kwekkeboom K. **Cancer Nurs** 1996 Feb;19(1):37–43 (24 ref.)
Increased phantom limb pain as an initial symptom of spinal-neoplasia [published erratum appears in J Pain Symptom Manage 1997 Sep;14(3):135] Chang VT, et al. **J Pain Symptom Manage** 1997 Jun;13(6):362–4 (18 ref.)

PHYSIOPATHOLOGY

What neurological syndromes can tell us about human nature: some lessons from phantom limbs, capgras syndrome, and anosognosia. Ramachandran VS. **Cold Spring Harb Symp Quant Biol** 1996;61:115–34 (70 ref.)
Noise in models of neurological and psychiatric disorders. Spitzer M, et al. **Int J Neural Syst** 1996 Sep;7(4):355–61 (44 ref.)

SURGERY

[Pain management after post-traumatic brachial plexus lesions. Conservative and surgical therapy possibilities] Carvalho GA, et al. **Orthopade** 1997 Jul;26(7):621–5 (30 ref.) (Eng. Abstr.) **(Ger)**

PHANTOMS, IMAGING

Phase-derivative analysis in MR angiography: reduced Venc dependency and improved vessel wall detection in laminar and disturbed flow. Hoogeveen RM, et al. **J Magn Reson Imaging** 1997 Mar–Apr;7(2):321–30 (32 ref.)
Computational dosimetry and treatment planning for boron neutron capture therapy. Nigg DW, et al. **J Neurooncol** 1997 May;33(1–2):93–104 (32 ref.)
Measurements of scattering and absorption changes in muscle and brain. Gratton E, et al. **Philos Trans R Soc Lond B Biol Sci** 1997 Jun 29; 352(1354):727–35 (50 ref.)

PHANTOMS, RADIOGRAPHIC see **PHANTOMS, IMAGING**

PHANTOMS, RADIOLOGIC see **PHANTOMS, IMAGING**

PHARMACEUTIC AIDS (PRESERVATIVES) see **PRESERVATIVES, PHARMACEUTICAL**

PHARMACEUTICAL ECONOMICS see **ECONOMICS, PHARMACEUTICAL**

PHARMACEUTICAL SERVICES

Clinical laboratory tests: application to daily practice. Cannon B, et al. **J Am Pharm Assoc (Wash)** 1996 Nov; NS36(11):668–79; quiz 679–81 (13 ref.)
New OTC drugs and devices: a selective review. Newton GD, et al. **J Am Pharm Assoc (Wash)** 1997 Mar–Apr; NS37(2):165–76 (14 ref.)
Cancer-related issues for women. Rospond RM. **J Am Pharm Assoc (Wash)** 1996 Nov;NS36(11):655–60 (26 ref.)
Naproxen sodium. Sutton LB. **J Am Pharm Assoc (Wash)** 1996 Nov;NS36(11):663–7 (15 ref.)

ORGANIZATION & ADMINISTRATION

Lipid management: an opportunity for pharmacy service. Schoen MD. **J Am Pharm Assoc (Wash)** 1996 Oct; NS36(10):609–19; quiz 619–21 (21 ref.)

STANDARDS

Improving the quality of outcomes research involving pharmaceutical services. Holdford DA, et al. **Am J Health Syst Pharm** 1997 Jun 15;54(12):1434–42 (109 ref.)

TRENDS

Pharmaceutical care in The Netherlands. History, definition and projects. van Mil JW, et al. **Pharm World Sci** 1996 Dec;18(6):237–40 (5 ref.)

PHARMACIES

Research on the effects of pharmacist-patient communication in institutions and ambulatory care sites, 1969–1994. De Young M. **Am J Health Syst Pharm** 1996 Jun 1; 53(11):1277–91 (66 ref.)
Efforts of pharmacy to reduce antibiotic resistance. Klem C, et al. **New Horiz** 1996 Aug;4(3):377–84 (66 ref.)
Saliva as a specimen for therapeutic drug monitoring in pharmacies [editorial; comment] Zuidema J, et al. **Pharm World Sci** 1996 Dec;18(6):193–4 (9 ref.) Comment on: Pharm World Sci 1996 Dec;18(6):211–6.
Puerto Rican elders and botanical shops: a community resource or liability? Delgado M. **Soc Work Health Care** 1996;23(1):67–81 (25 ref.)

ORGANIZATION & ADMINISTRATION

Automated medication dispensing devices. Glover DG. **J Am Pharm Assoc (Wash)** 1997 May–Jun;NS37(3):353–8; quiz 358–60 (4 ref.)

PHARMACISTS

Research on the effects of pharmacist-patient communication in institutions and ambulatory care sites, 1969–1994. De Young M. **Am J Health Syst Pharm** 1996 Jun 1; 53(11):1277–91 (66 ref.)
Lessons from medicine and nursing for pharmacist-patient communication. Landis NT. **Am J Health Syst Pharm** 1996 Jun 1;53(11):1306–14 (66 ref.)
Pediatric HIV infection: a primer for pharmacists. Cohen LG, et al. **J Am Pharm Assoc (Wash)** 1996 Oct; NS36(10):580–95 (72 ref.)
Pharmaceutical care for rural patients: ominous trends. Gangeness DE. **J Am Pharm Assoc (Wash)** 1997 Jan–Feb; NS37(1):62–5, 84 (21 ref.)
Alzheimer's disease: an overview for the pharmacist. McGuffey EC. **J Am Pharm Assoc (Wash)** 1997 May–Jun; NS37(3):347–52 (28 ref.)
Diagnostic imaging: an overview for the pharmacist. Shaw SM. **J Am Pharm Assoc (Wash)** 1997 Jan–Feb; NS37(1):99–106; quiz 106–8 (10 ref.)
What pharmacists should know about herbal remedies. Tyler VE. **J Am Pharm Assoc (Wash)** 1996 Jan;NS36(1):29–37 (25 ref.)
The involvement of pharmacists in professional and clinical audit in the UK: a review and assessment of their potential role. Panton R, et al. **J Eval Clin Pract** 1996 Aug;2(3):193–8 (53 ref.)
Community care of asthma: the pharmacist as counsellor? Chrystyn H. **J Pharm Pharmacol** 1997 May;49 Suppl 3:51–4 (37 ref.)

TRENDS

What are outcomes? Mullins CD, et al. **J Am Pharm Assoc (Wash)** 1996 Jan;NS36(1):39–49 (46 ref.)

PHARMACOECONOMICS see **ECONOMICS, PHARMACEUTICAL**

PHARMACOEPIDEMIOLOGY

Pharmaceutical decisionmaking: pharmacoepidemiology or pharmacoeconomics—who's in the driver's seat? Zito JM, et al. **Psychopharmacol Bull** 1995;31(4):735–44 (40 ref.)

PHARMACOGENETICS

Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Linder MW, et al. **Clin Chem** 1997 Feb;43(2):254–66 (118 ref.)
Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype. Llerena A, et al. **Eur J Drug Metab Pharmacokinet** 1996 Apr–Jun; 21(2):129–38 (54 ref.)
Pharmacogenetics and blood dyscrasias. Spielberg SP. **Eur J Haematol Suppl** 1996;60:93–7 (41 ref.)
Extensions to quantitative trait locus mapping in experimental organisms. Schork NJ, et al. **Hypertension** 1996 Dec; 28(6):1104–11 (58 ref.)
Psychopharmacogenetic basis of medication-induced movement disorders. Tu JB. **Int Clin Psychopharmacol** 1997 Jan;12(1):1–12 (126 ref.)
Interpatient variability: genetic predisposition and other genetic factors. West WL, et al. **J Clin Pharmacol** 1997 Jul;37(7):635–48 (76 ref.)
Ethnicity and pharmacogenetics. Smith MW, et al. **Mt Sinai J Med** 1996 Oct–Nov;63(5–6):285–90 (75 ref.)
Pharmacogenetics in pediatrics. Implications for practice. Leeder JS, et al. **Pediatr Clin North Am** 1997 Feb; 44(1):55–77 (113 ref.)
The evolving science of pharmacogenetics: clinical and ethnic perspectives. Lin KM, et al. **Psychopharmacol Bull** 1996;32(2):205–17 (134 ref.)
Biochemical individuality: the next generation. Calabrese EJ. **Regul Toxicol Pharmacol** 1996 Aug;24(1 Pt 2):S58–67 (52 ref.)
[Pharmacogenetics: pharmacokinetics and clinical implications] Blardi P. **Recenti Prog Med** 1997 Jan; 88(1):46–55 (38 ref.) (Eng. Abstr.) **(Ita)**
[Clinical significance of the pharmacogenetics in psychiatric and neurological syndromes] Milejski P, et al. **Neurol Neurochir Pol** 1996 Nov–Dec;30(6):997–1007 (28 ref.) (Eng. Abstr.) **(Pol)**

PHARMACOGENETICS

TRENDS

[Value and applications of pharmacogenetics in oncology and hematology] Albin N, et al. **Bull Cancer** 1997 Jun; 84(6):643–51 (79 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOGNOSY

Academic research: policies and practice. Bertha SL. **J Ethnopharmacol** 1996 Apr;51(1–3):59–73 (7 ref.)

Natural products research: perspectives from a major pharmaceutical company. Borris RP. **J Ethnopharmacol** 1996 Apr;51(1–3):29–38 (3 ref.)

Medicinal plant genetic resources and international cooperation: the Brazilian perspective. Elisabetsky E, et al. **J Ethnopharmacol** 1996 Apr;51(1–3):111–9; discussion 119–20 (19 ref.)

Biological diversity, indigenous knowledge, drug discovery and intellectual property rights: creating reciprocity and maintaining relationships. King SR, et al. **J Ethnopharmacol** 1996 Apr;51(1–3):45–57 (25 ref.)

Biodiversity prospecting and benefit-sharing: perspectives from the field. Soejarto DD. **J Ethnopharmacol** 1996 Apr; 51(1–3):1–15 (56 ref.)

Coral reefs, forests, and thermal vents: the worldwide exploration of nature for novel antitumor agents. Cragg GM, et al. **Semin Oncol** 1997 Apr;24(2):156–63 (22 ref.)

LEGISLATION & JURISPRUDENCE

The position of intellectual property rights in drug discovery and development from natural products. Boyd MR. **J Ethnopharmacol** 1996 Apr;51(1–3):17–25; discussion 25–7 (12 ref.)

Interests and policies of the state of Sarawak, Malaysia regarding intellectual property rights for plant derived drugs. Chung FJ. **J Ethnopharmacol** 1996 Apr; 51(1–3):201–4 (1 ref.)

Rules and regulations on the collection in Cameroon of biological materials for biological testing and drug discovery. Jato JG, et al. **J Ethnopharmacol** 1996 Apr; 51(1–3):121–5 (8 ref.)

Tanzania's policy on biodiversity prospecting and drug discovery programs. Mahunnah RL, et al. **J Ethnopharmacol** 1996 Apr;51(1–3):221–8 (13 ref.)

Legal issues in sharing the benefits of biodiversity prospecting. Mays TD, et al. **J Ethnopharmacol** 1996 Apr; 51(1–3):93–102; discussion 102–9 (14 ref.)

Collection of biological materials in biodiversity prospecting in India: problems and solutions. Mehrotra BN. **J Ethnopharmacol** 1996 Apr;51(1–3):161–5 (0 ref.)

Research, valorization and exploitation of biological resources for medicinal purposes in the Malagasy Republic (Madagascar). Randimbivololona F. **J Ethnopharmacol** 1996 Apr;51(1–3):195–200 (10 ref.)

PHARMACOKINETICS

Pharmacology in space: pharmacokinetics. Saivin S, et al. **Adv Space Biol Med** 1997;6:107–21 (26 ref.)

Bioelectrical impedance analysis measurements for drug pharmacokinetics. Zarowitz BJ. **Am J Clin Nutr** 1996 Sep; 64(3 Suppl):519S–523S (40 ref.)

Extrapolation from animals to man. The integration of pharmacokinetics and pharmacodynamics. Campbell DB. **Ann N Y Acad Sci** 1996 Oct 31;801:116–35 (80 ref.)

Effects of food on drug absorption. Welling PG. **Annu Rev Nutr** 1996;16:383–415 (222 ref.)

Toxicokinetics of endogenous substances: a neglected issue. Marzo A. **Arzneimittelforschung** 1996 Jan;46(1):1–10 (79 ref.)

Pharmacokinetics of inhaled drugs. Lipworth BJ. **Br J Clin Pharmacol** 1996 Dec;42(6):697–705 (55 ref.)

Aging and pharmacology. Vestal RE. **Cancer** 1997 Oct 1; 80(7):1302–10 (49 ref.)

Membrane transport as a determinant of the hepatic elimination of drugs and metabolites. Evans AM. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov;23(10–11):970–4 (32 ref.)

Sparse drug concentration data analysis using a population approach: a valuable tool in clinical pharmacology. McLachlan AJ. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov;23(10–11):995–9 (39 ref.)

Permeability of myocardial capillaries to hydrophilic drugs: the paracellular pathway. Morgan DJ. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov;23(10–11):975–9 (32 ref.)

Renal transport of drugs: specificity and molecular mechanisms. Somogyi A. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov;23(10–11):986–9 (22 ref.)

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Bertz RJ, et al. **Clin Pharmacokinet** 1997 Mar;32(3):210–58 (681 ref.)

Relevance of the application of pharmacokinetic–pharmacodynamic modelling concepts in drug development. The "wooden shoe" paradigm. Breimer DD, et al. **Clin Pharmacokinet** 1997 Apr;32(4):259–67 (35 ref.)

Responsive polymeric drug delivery systems. Meeting the patient's needs. D'Emanuele A. **Clin Pharmacokinet** 1996 Oct;31(4):241–5 (31 ref.)

Bayesian forecasting in paediatric populations. Fernández de Gatta MM, et al. **Clin Pharmacokinet** 1996 Nov; 31(5):325–30 (59 ref.)

Pharmacokinetic rationale for chemotherapeutic drugs combined with intra-arterial degradable starch microspheres (Spherex). Johansson CJ. **Clin Pharmacokinet** 1996 Sep;31(3):231–40 (44 ref.)

Principles of drug administration in renal insufficiency. Lam YW, et al. **Clin Pharmacokinet** 1997 Jan;32(1):30–57 (118 ref.)

Integrating pharmacokinetics into point-of-care information systems. Leader WG, et al. **Clin Pharmacokinet** 1996 Sep; 31(3):165–73 (39 ref.)

Pharmacokinetic changes in the elderly. Do they contribute to drug abuse and dependence? Ozdemir V, et al. **Clin Pharmacokinet** 1996 Nov;31(5):372–85 (144 ref.)

Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective. Samara E, et al. **Clin Pharmacokinet** 1997 Apr;32(4):294–312 (133 ref.)

Clinical pharmacokinetics during continuous ambulatory peritoneal dialysis. Taylor CA 3rd, et al. **Clin Pharmacokinet** 1996 Oct;31(4):293–308 (104 ref.)

The use of population pharmacokinetics in drug development [see comments] Vozeh S, et al. **Clin Pharmacokinet** 1996 Feb;30(2):81–93 (39 ref.) Comment in: Clin Pharmacokinet 1996 Aug;31(2):164.

Concepts, properties, and applications of linear systems to describe distribution, identify input, and control endogenous substances and drugs in biological systems. Verotta D. **Crit Rev Biomed Eng** 1996;24(2–3):73–139 (119 ref.)

Structural identifiability of PBPK models: practical consequences for modeling strategies and study designs. Slob W, et al. **Crit Rev Toxicol** 1997 May;27(3):261–72 (22 ref.)

Drug metabolism: from experiments to regulatory aspects. Garattini S. **Drug Metab Rev** 1997 Aug;29(3):853–86 (168 ref.)

Application of metabolism and pharmacokinetic studies to the drug discovery process. Humphrey MJ. **Drug Metab Rev** 1996 Aug;28(3):473–89 (32 ref.)

Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity. Matzke GR, et al. **Drug Saf** 1997 Mar;16(3):205–31 (236 ref.)

Drug administration in chronic liver disease. Westphal JF, et al. **Drug Saf** 1997 Jul;17(1):47–73 (225 ref.)

Drug chirality and its clinical significance. Hutt AJ, et al. **Drugs** 1996;52 Suppl 5:1–12 (78 ref.)

Purpose and guidelines for toxicokinetic studies within the National Toxicology Program. Buchanan JR, et al. **Environ Health Perspect** 1997 May;105(5):468–71 (4 ref.)

The importance of understanding pharmacokinetics for equine veterinarians [editorial] Davis LE. **Equine Vet J Suppl** 1992 Feb;(11):3–4 (11 ref.)

Practical uses of individual pharmacokinetic parameters in drug development and clinical practice: examples and simulations. Bjornsson TD. **Eur J Drug Metab Pharmacokinet** 1997 Jan–Mar;22(1):1–14 (8 ref.)

Gender differences in pharmacokinetics. Gleiter CH, et al. **Eur J Drug Metab Pharmacokinet** 1996 Apr–Jun; 21(2):123–8 (69 ref.)

Pharmacoeconomics: where is the link with pharmacokinetics and biopharmaceutics? Peys F. **Eur J Drug Metab Pharmacokinet** 1996 Apr–Jun; 21(2):189–200 (29 ref.)

The relevance of pharmacokinetics in the development of biotechnology products. Toon S. **Eur J Drug Metab Pharmacokinet** 1996 Apr–Jun; 21(2):93–103 (71 ref.)

Application of physiologically based pharmacokinetic modelling to combination toxicology. Simmons JE. **Food Chem Toxicol** 1996 Nov–Dec;34(11–12):1067–73 (32 ref.)

Genetic predisposition to drug-induced liver disease. Fontana RJ, et al. **Gastroenterol Clin North Am** 1995 Dec; 24(4):811–38 (172 ref.)

Hemodynamic surrogate end-points in phase I studies? De Mey C. **Int J Clin Pharmacol Ther** 1997 Apr;35(4):175–9 (18 ref.)

Systematic screening for pharmacokinetic interactions during drug development. Fuhr U, et al. **Int J Clin Pharmacol Ther** 1996 Apr;34(4):139–51 (97 ref.)

Targeting of drugs and delivery systems to specific sites in the gastrointestinal tract. Fell JT. **J Anat** 1996 Dec;189 (Pt 3):517–9 (12 ref.)

Elimination of drugs and toxins during cardiopulmonary bypass. Rosen DA, et al. **J Cardiothorac Vasc Anesth** 1997 May;11(3):337–40 (38 ref.)

Validation of liquid chromatographic and gas chromatographic methods. Applications to pharmacokinetics. Bressolle F, et al. **J Chromatogr B Biomed Appl** 1996 Nov 8;686(1):3–10 (16 ref.)

Grapefruits and drugs: when is statistically significant clinically significant? [editorial; comment] Abernethy DR. **J Clin Invest** 1997 May 15;99(10):2297–8 (14 ref.) Comment on: J Clin Invest 1997 May 15;99(10):2545–53.

The correlation between pharmacodynamics and pharmacokinetics: basics of pharmacokinetics--pharmacodynamics modeling. Cawello W, et al. **J Clin Pharmacol** 1997 Jan;37(1 Suppl):65S–69S (9 ref.)

Use of probe drugs as predictors of drug metabolism in humans. Kivistö KT, et al. **J Clin Pharmacol** 1997 Jan;37(1 Suppl):40S–48S (54 ref.)

Interpatient variability: genetic predisposition and other genetic factors. West WL, et al. **J Clin Pharmacol** 1997 Jul;37(7):635–48 (76 ref.)

Drug traffic in the hepatobiliary system. Groothuis GM, et al. **J Hepatol** 1996;24 Suppl 1:3–28 (252 ref.)

Drug elimination in chronic liver diseases. Huet PM, et al. **J Hepatol** 1997;26 Suppl 2:63–72 (40 ref.)

We may not measure the correct intestinal wall permeability coefficient of drugs: alternative absorptive clearance concept [see comments] Chiou WL. **J Pharmacokinet Biopharm** 1995 Jun;23(3):323–31 (42 ref.) Comment in: J Pharmacokinet Biopharm 1995 Jun;23(3):333–7.

Strategic proposals for avoiding toxic interactions with drugs for clinical use during development and after marketing of a new drug: pharmacokinetic consideration. Sugiyama Y, et al. **J Toxicol Sci** 1996 Dec;21(5):309–16 (10 ref.)

Future prospects for toxicokinetics: its ability to predict drug adverse events in humans. Sugiyama Y, et al. **J Toxicol Sci** 1996 Dec;21(5):511–6 (12 ref.)

Basic principles and techniques of pharmacokinetic modeling. Riviere JE. **J Zoo Wildl Med** 1997 Mar;28(1):3–19 (20 ref.)

Population-based approach to the assessment of pharmacokinetic–pharmacodynamic data. Trocóniz IF. **Methods Find Exp Clin Pharmacol** 1996;18 Suppl C:51–2 (4 ref.)

Toxicokinetics in the National Toxicology Program. Goehl TJ. **NIDA Res Monogr** 1997;173:273–304 (20 ref.)

Prescribing for children: issues in pediatric pharmacology. Niederhauser VP. **Nurse Pract** 1997 Mar;22(3):16–8, 23, 26–8 passim (21 ref.)

Review of theoretical passive drug absorption models: historical background, recent developments and limitations. Camenisch G, et al. **Pharm Acta Helv** 1996 Nov; 71(5):309–27 (114 ref.)

General principles in the characterization and use of model systems for biopharmaceutical studies. Borchardt RT, et al. **Pharm Biotechnol** 1996;8:1–11 (51 ref.)

Application of microdialysis in pharmacokinetic studies. Elmquist WF, et al. **Pharm Res** 1997 Mar;14(3):267–88 (182 ref.)

Gastrointestinal drug absorption: is it time to consider heterogeneity as well as homogeneity? Macheras P, et al. **Pharm Res** 1997 Jul;14(7):842–7 (48 ref.)

Evaluation of orally administered highly variable drugs and drug formulations. Shah VP, et al. **Pharm Res** 1996 Nov; 13(11):1590–4 (0 ref.)

Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution. Takakura Y, et al. **Pharm Res** 1996 Jun;13(6):820–31 (66 ref.)

Nuclear medicine techniques in the evaluation of pharmaceutical formulations. Perkins AC, et al. **Pharm World Sci** 1996 Jun;18(3):97–104 (96 ref.)

Pharmacokinetics, science or fiction? Rescigno A. **Pharmacol Res** 1996 Apr–May;33(4–5):227–33 (19 ref.)

Fit fluctuating blood drug concentration: a beginner's first note. Wu G. **Pharmacol Res** 1996 Jun;33(6):379–83 (24 ref.)

The use of microdialysis in pharmacokinetics and pharmacodynamics. Johansen MJ, et al. **Pharmacotherapy** 1997 May–Jun;17(3):464–81 (98 ref.)

A review of the effects of plasmapheresis on drug clearance. Kale-Pradhan PB, et al. **Pharmacotherapy** 1997 Jul–Aug; 17(4):684–95 (90 ref.)

Physiological parameter values for physiologically based pharmacokinetic models. Brown RP, et al. **Toxicol Ind Health** 1997 Jul–Aug;13(4):407–84 (253 ref.)

Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Mahmood I, et al. **Xenobiotica** 1996 Sep;26(9):887–95 (41 ref.)

Pharmacokinetics and pharmacodynamics in toxicology. Smith DA. **Xenobiotica** 1997 May;27(5):513–25 (46 ref.)

[Pharmacogenetics: pharmacokinetics and clinical implications] Blardi P. **Recenti Prog Med** 1997 Jan; 88(1):46–55 (38 ref.) (Eng. Abstr.) **(Ita)**

[Pharmacokinetic activity of drugs and circadian rhythm] Shinoda H, et al. **Nippon Yakurigaku Zasshi** 1996 Sep; 108(3):152–4 (0 ref.) **(Jpn)**

PHARMACOLOGY

see related
DRUGS

Extrapolation from animals to man. The integration of pharmacokinetics and pharmacodynamics. Campbell DB. **Ann N Y Acad Sci** 1996 Oct 31;801:116–35 (80 ref.)

Transgenic animals as new approaches in pharmacological studies. Wei LN. **Annu Rev Pharmacol Toxicol** 1997; 37:119–41 (110 ref.)

Modern role of pharmacology in health sciences: assessing and accessing traditional medicines. Smith CM. **Braz J Med Biol Res** 1996 May;29(5):563–8 (19 ref.)

Bias against the null hypothesis in maternal-fetal pharmacology and toxicology. Koren G. **Clin Pharmacol Ther** 1997 Jul;62(1):1–5 (21 ref.)

Application of metabolism and pharmacokinetic studies to the drug discovery process. Humphrey MJ. **Drug Metab Rev** 1996 Aug;28(3):473–89 (32 ref.)

Drug chirality and its clinical significance. Hutt AJ, et al. **Drugs** 1996;52 Suppl 5:1–12 (78 ref.)

Mechanisms, chemical structures and drug metabolism. Pohl LR, et al. **Eur J Haematol Suppl** 1996;60:98–104 (45 ref.)
International Union of Pharmacology. XII. Classification of opioid receptors. Dhawan BN, et al. **Pharmacol Rev** 1996 Dec;48(4):567–92 (350 ref.)
The use of microdialysis in pharmacokinetics and pharmacodynamics. Johansen MJ, et al. **Pharmacotherapy** 1997 May–Jun;17(3):464–81 (98 ref.)
The role of radiopharmacological imaging in streamlining the drug development process. Campbell DB. **Q J Nucl Med** 1997 Jun;41(2):163–9 (32 ref.)
Pharmacokinetics and pharmacodynamics in toxicology. Smith DA. **Xenobiotica** 1997 May;27(5):513–25 (46 ref.)
[Particulars about pharmacotherapy in the elderly patient] Scheen AJ. **Rev Med Liege** 1997 Apr;52(4):201–4 (17 ref.) **(Fre)**
[Statistical analysis of pharmacological preclinical tests] Matsumoto K, et al. **Nippon Yakurigaku Zasshi** 1996 Sep; 108(3):186–8 (3 ref.) **(Jpn)**
[Cell membrane transport proteins: cross point of pharmacology and molecular biology] Shigekawa S, et al. **Nippon Yakurigaku Zasshi** 1996 Sep;108(3):160–2 (6 ref.) **(Jpn)**

ECONOMICS

Pharmacoeconomics and therapeutic drug monitoring. Bootman JL, et al. **Pharm World Sci** 1997 Aug;19(4):178–81 (32 ref.)

METHODS

In vivo EPR: an effective new tool for studying pathophysiology, physiology and pharmacology. Mäder K, et al. **Appl Radiat Isot** 1996 Nov–Dec;47(11–12):1663–7 (46 ref.)
Sparse drug concentration data analysis using a population approach: a valuable tool in clinical pharmacology. McLachlan AJ. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov;23(10–11):995–9 (39 ref.)
Relevance of the application of pharmacokinetic–pharmacodynamic modelling concepts in drug development. The "wooden shoe' paradigm. Breimer DD, et al. **Clin Pharmacokinet** 1997 Apr;32(4):259–67 (35 ref.)
The correlation between pharmacodynamics and pharmacokinetics: basics of pharmacokinetics—pharmacodynamics modeling. Cawello W, et al. **J Clin Pharmacol** 1997 Jan;37(1 Suppl):65S–69S (9 ref.)
Minimal invasive in vivo pharmacology: news of a new method holding promise in nephrology-related research [editorial] Wenzel RR. **Nephrol Dial Transplant** 1997 Apr; 12(4):649–51 (13 ref.)

STATISTICS & NUMERICAL DATA

Pharmacologic quantitation. Patil PN. **Indian J Exp Biol** 1996 Jul;34(7):615–33 (150 ref.)

TRENDS

Modern pharmaceutical biotechnology. Situation worldwide and in Germany 1995. Schlumberger HD, et al. **Arzneimittelforschung** 1997 Jan;47(1):106–10 (7 ref.)
Reflections from distant cuvettes. Vesell ES. **Drug Metab Rev** 1996 Nov;28(4):493–511 (32 ref.)
Reduction of the central nervous system adverse effects associated with antihistamines in the management of allergic disorders: strategies and progress. Gengo FM. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 3):S319–25 (31 ref.)
Natural products in drug discovery and development. Cragg GM, et al. **J Nat Prod** 1997 Jan;60(1):52–60 (38 ref.)
Bioequivalence and generic prescribing: a pharmacy view. Calvert RT. **J Pharm Pharmacol** 1996 Jan;48(1):9–10 (9 ref.)
Chirality: a major issue in veterinary pharmacology. Landoni MF, et al. **J Vet Pharmacol Ther** 1996 Feb;19(1):82–4 (17 ref.)
Applications of pharmacokinetic/pharmacodynamic research in rational drug development. Danhof M. **Methods Find Exp Clin Pharmacol** 1996;18 Suppl C:53–4 (12 ref.)
Population-based approach to the assessment of pharmacokinetic–pharmacodynamic data. Trocóniz IF. **Methods Find Exp Clin Pharmacol** 1996;18 Suppl C:51–2 (4 ref.)
Laboratory animal science, welfare and ethics in pharmacology and toxicology. Svendsen O, et al. **Pharmacol Toxicol** 1997 Jan;80(1):3–5 (14 ref.)

PHARMACOLOGY, CLINICAL

Aging and pharmacology. Vestal RE. **Cancer** 1997 Oct 1; 80(7):1302–10 (49 ref.)
The challenge of in-hospital medication use: an opportunity for clinical pharmacology. Atkinson AJ Jr, et al. **Clin Pharmacol Ther** 1996 Oct;60(4):363–7 (18 ref.)
Hemodynamic surrogate end-points in phase I studies? De Mey C. **Int J Clin Pharmacol Ther** 1997 Apr;35(4):175–9 (18 ref.)

EDUCATION

[Present problems and improvement strategy in education of clinical pharmacology and pharmacy] Nakano S, et al. **Nippon Yakurigaku Zasshi** 1996 Sep;108(3):189–91 (0 ref.) **(Jpn)**

INSTRUMENTATION

Polysomnography in drug development. Dietrich B. **J Clin Pharmacol** 1997 Jan;37(1 Suppl):70S–78S (81 ref.)

METHODS

Usefulness, usability, and quality criteria for noninvasive methods in cardiovascular clinical pharmacology. de Mey C, et al. **J Clin Pharmacol** 1997 Jan;37(1 Suppl):11S–20S (109 ref.)
Optimization of methods and models in clinical pharmacology. Gerloff J. **J Clin Pharmacol** 1997 Jan;37(1 Suppl):4S–7S (10 ref.)
Use of probe drugs as predictors of drug metabolism in humans. Kivistö KT, et al. **J Clin Pharmacol** 1997 Jan;37(1 Suppl):40S–48S (54 ref.)
Pharmacodynamic models to evaluate antithrombotics in clinical pharmacology. Müller TH. **J Clin Pharmacol** 1997 Jan;37(1 Suppl):49S–58S (77 ref.)

TRENDS

Professional prospects in clinical pharmacology. An experience within the hospital. Vallano A. **Methods Find Exp Clin Pharmacol** 1996;18 Suppl C:9–13 (8 ref.)
Dementia drug development: use of information systems to harmonize global drug development. Whitehouse PJ, et al. **Psychopharmacol Bull** 1997;33(1):129–33 (19 ref.)

PHARMACOPOEIAS

[On the revision of microbial tests in the Pharmacopoeia of Japan] Mise K. **Eisei Shikenjo Hokoku** 1994;(112):206–8 (2 ref.) (Eng. Abstr.) **(Jpn)**

STANDARDS

[Determination of crude drugs in the pharmacopoeia] Suzuki H, et al. **Eisei Shikenjo Hokoku** 1996;(114):145–6 (0 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOTHERAPY see **DRUG THERAPY**

PHARMACY

see related
COMMUNITY PHARMACY SERVICES
EDUCATION, PHARMACY
LEGISLATION, PHARMACY
PHARMACY SERVICE, HOSPITAL
PRESCRIPTIONS, DRUG
TECHNOLOGY, PHARMACEUTICAL

INSTRUMENTATION

Automated medication dispensing devices. Glover DG. **J Am Pharm Assoc (Wash)** 1997 May–Jun;NS37(3):353–8; quiz 358–60 (4 ref.)

STANDARDS

Clinical pharmacy: is it a credible academic discipline? Walker R. **Pharm Acta Helv** 1996 Nov;71(5):367–71 (1 ref.)

STATISTICS & NUMERICAL DATA

The assessment of refill compliance using pharmacy records: methods, validity, and applications. Steiner JF, et al. **J Clin Epidemiol** 1997 Jan;50(1):105–16 (61 ref.)

PHARMACY EDUCATION see **EDUCATION, PHARMACY**

PHARMACY SERVICE, CLINICAL see **PHARMACY SERVICE, HOSPITAL**

PHARMACY SERVICE, HOSPITAL

Research on the effects of pharmacist–patient communication in institutions and ambulatory care sites, 1969–1994. De Young M. **Am J Health Syst Pharm** 1996 Jun 1; 53(11):1277–91 (66 ref.)
Radioiodine dispensing and usage in a centralized hospital nuclear pharmacy. Hung JC. **Thyroid** 1997 Apr;7(2):289–94 (31 ref.)

ECONOMICS

Economic evaluations of clinical pharmacy services—1988–1995. The Publications Committee of the American College of Clinical Pharmacy. Schumock GT, et al. **Pharmacotherapy** 1996 Nov–Dec;16(6):1188–208 (110 ref.)

ORGANIZATION & ADMINISTRATION

The impact of clinical pharmacists on psychiatric patients. Jenkins MH, et al. **Pharmacotherapy** 1996 Jul–Aug; 16(4):708–14 (40 ref.)

STANDARDS

Monitoring occupational exposure to cancer chemotherapy drugs. Baker ES, et al. **Am J Health Syst Pharm** 1996 Nov 15;53(22):2713–23 (146 ref.)
Clinical pharmacy: is it a credible academic discipline? Walker R. **Pharm Acta Helv** 1996 Nov;71(5):367–71 (1 ref.)

PHARYNGEAL DISEASES

Laryngopharyngeal reflux: a modern day "great masquerader". Hawkins BL. **J Ky Med Assoc** 1997 Sep; 95(9):379–85 (19 ref.)

DIAGNOSIS

The diagnosis of oropharyngeal gonorrhoea. Barlow D. **Genitourin Med** 1997 Feb;73(1):16–7 (18 ref.)
Office procedures. Nasopharyngoscopy. Patton DD. **Prim Care** 1997 Jun;24(2):359–74 (18 ref.)

PATHOLOGY

Torsion of the palatine tonsil. Prikas KG, et al. **J Laryngol Otol** 1996 Sep;110(9):891–2 (2 ref.)

SURGERY

Free gastro-omental flap reconstruction of the complex, irradiated pharyngeal wound. Carlson GW, et al. **Head Neck** 1997 Jan;19(1):68–71 (11 ref.)
[Use of CO2 laser in endoscopic treatment of Zenker's pharyngo-esophageal diverticula. Experience apropos of 33 cases] Hamoir M, et al. **Ann Otolaryngol Chir Cervicofac** 1997;114(1–2):7–12 (30 ref.) (Eng. Abstr.) **(Fre)**

PHARYNGEAL DIVERTICULUM see **ZENKER'S DIVERTICULUM**

PHARYNGEAL MUSCLES

[Mitochondrial anomalies in oculopharyngeal muscular dystrophy] de Seze J, et al. **Rev Neurol (Paris)** 1997 Jun; 153(5):335–8 (19 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Motor control of the pharyngeal musculature and implications for the pathogenesis of obstructive sleep apnea. Horner RL. **Sleep** 1996 Dec;19(10):827–53 (272 ref.)

PHARYNGEAL NEOPLASMS

Human papillomavirus and cancers of the upper aerodigestive tract: a review of epidemiological and experimental evidence. Franceschi S, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Jul;5(7):567–75 (104 ref.)

COMPLICATIONS

Melkersson-Rosenthal syndrome with malignant pharyngeal lymphoma [letter] Kanda A, et al. **J Dermatol** 1996 Sep; 23(9):658–9 (6 ref.)

DIAGNOSIS

Liposarcoma of the retropharyngeal space: review of the literature. Prince ME, et al. **J Otolaryngol** 1997 Apr; 26(2):139–42 (20 ref.)

EPIDEMIOLOGY

Cancers of the oral cavity and pharynx in the United States: an epidemiologic overview. Swango PA. **J Public Health Dent** 1996 Fall;56(6):309–18 (33 ref.)

PATHOLOGY

Solitary fibrous tumor of the parapharyngeal space: a case report and review of the literature. Gangopadhyay K, et al. **Ear Nose Throat J** 1996 Oct;75(10):681–4 (19 ref.)
Lymphoepithelial carcinoma of the larynx and hypopharynx: study of eight cases with relationship to Epstein–Barr virus and p53 gene alterations, and review of the literature. MacMillan C, et al. **Hum Pathol** 1996 Nov;27(11):1172–9 (44 ref.)
Pharyngeal lipoma with cartilaginous metaplasia (chondrolipoma): a case report and literature review. Nwaorgu OG, et al. **J Laryngol Otol** 1997 Jul;111(7):656–8 (11 ref.)

PREVENTION & CONTROL

Detecting, diagnosing, and preventing oral cancer. Shugars DC, et al. **Nurse Pract** 1997 Jun;22(6):105, 109–10, 113–5 passim (20 ref.)

RADIOGRAPHY

Papillary carcinoma of the thyroid metastatic to the parapharyngeal space. Sirotnak JJ, et al. **Ear Nose Throat J** 1997 May;76(5):342–4 (9 ref.)

SECONDARY

Papillary carcinoma of the thyroid metastatic to the parapharyngeal space. Sirotnak JJ, et al.

PHARYNGEAL NEOPLASMS

Ear Nose Throat J 1997 May;76(5):342–4 (9 ref.)

SURGERY

[Laryngectomies and pharyngo–laryngectomies with tracheo–laryngo–pharyngeal shunt of Pearson type. Technique, indications and preliminary results] Laccourreye O, et al. **Ann Otolaryngol Chir Cervicofac** 1996;113(5):261–8 (34 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Current status of larynx preservation trials. Lefebvre JL, et al. **Curr Opin Oncol** 1996 May;8(3):209–14 (55 ref.)

PHARYNGECTOMY

METHODS

[Laryngectomies and pharyngo–laryngectomies with tracheo–laryngo–pharyngeal shunt of Pearson type. Technique, indications and preliminary results] Laccourreye O, et al. **Ann Otolaryngol Chir Cervicofac** 1996;113(5):261–8 (34 ref.) (Eng. Abstr.) **(Fre)**

PHARYNGITIS

DIAGNOSIS

An approach to diagnosing the acute sore throat. Perkins A. **Am Fam Physician** 1997 Jan;55(1):131–8, 141–2 (25 ref.)

Reconsidering sore throats. Part 2: Alternative approach and practical office tool [see comments] McIsaac WJ, et al. **Can Fam Physician** 1997 Mar;43:495–500 (40 ref.) Comment in: Can Fam Physician 1997 May;43:843, 845. Comment in: Can Fam Physician 1997 Jul;43:1207–8.

Reconsidering sore throats. Part I: Problems with current clinical practice [see comments] McIsaac WJ, et al. **Can Fam Physician** 1997 Mar;43:485–93 (62 ref.) Comment in: Can Fam Physician 1997 May;43:843, 845. Comment in: Can Fam Physician 1997 Jul;43:1207–8.

Sore throat management in general practice. Little P, et al. **Fam Pract** 1996 Jun;13(3):317–21 (52 ref.)

Management of a deep space infection of the neck in a patient with Glanzmann's thrombasthenia. Kirita T, et al. **J Oral Maxillofac Surg** 1997 Aug;55(8):882–5 (9 ref.)

Severe sore throat as a presenting symptom of adult onset Still's disease: a case series and review of the literature. Nguyen KH, et al. **J Rheumatol** 1997 Mar;24(3):592–7 (63 ref.)

Management of group A streptococcus pharyngitis with a second–generation rapid strep screen: Strep A OIA. Badgett JT, et al. **Microb Drug Resist** 1996 Fall;2(3):371–6 (54 ref.)

Pharyngitis. Middleton DB. **Prim Care** 1996 Dec; 23(4):719–39 (52 ref.)

[How to recognize streptococcal pharyngitis? (editorial)] Ghanassia JP, et al. **Arch Pediatr** 1996 Aug;3(8):749–51 (17 ref.) **(Fre)**

DRUG THERAPY

Reconsidering sore throats. Part I: Problems with current clinical practice [see comments] McIsaac WJ, et al. **Can Fam Physician** 1997 Mar;43:485–93 (62 ref.) Comment in: Can Fam Physician 1997 May;43:843, 845. Comment in: Can Fam Physician 1997 Jul;43:1207–8.

Reconsidering sore throats. Part 2: Alternative approach and practical office tool [see comments] McIsaac WJ, et al. **Can Fam Physician** 1997 Mar;43:495–500 (40 ref.) Comment in: Can Fam Physician 1997 May;43:843, 845. Comment in: Can Fam Physician 1997 Jul;43:1207–8.

Streptococcal pharyngitis: is penicillin still the right choice? Pichichero ME. **Compr Ther** 1996 Dec;22(12):782–7 (37 ref.)

Current concepts in the management of pharyngitis. Smith DS. **Compr Ther** 1996 Dec;22(12):806–9 (3 ref.)

Optimum treatment of streptococcal pharyngitis. Scaglione F, et al. **Drugs** 1997 Jan;53(1):86–97 (106 ref.)

Sore throat management in general practice. Little P, et al. **Fam Pract** 1996 Jun;13(3):317–21 (52 ref.)

The role of macrolides in Streptococcus pyogenes pharyngitis. Schito GC, et al. **J Antimicrob Chemother** 1997 May;39(5):562–5 (34 ref.)

Shortened course of antibiotic therapy for acute otitis media, sinusitis and tonsillopharyngitis. Pichichero ME, et al. **Pediatr Infect Dis J** 1997 Jul;16(7):680–95 (144 ref.)

Macrolides in the management of streptococcal pharyngitis/tonsillitis. Tarlow MJ. **Pediatr Infect Dis J** 1997 Apr;16(4):444–8 (24 ref.)

Pharyngitis. Middleton DB. **Prim Care** 1996 Dec; 23(4):719–39 (52 ref.)

ETIOLOGY

An approach to diagnosing the acute sore throat. Perkins A. **Am Fam Physician** 1997 Jan;55(1):131–8, 141–2 (25 ref.)

Exudative pharyngitis possibly due to Corynebacterium pseudodiphtheriticum, a new challenge in the differential diagnosis of diphtheria [see comments] Izurieta HS, et al. **Emerg Infect Dis** 1997 Jan–Mar;3(1):65–8 (44 ref.) Comment in: Emerg Infect Dis 1997 Apr–Jun;3(2):242–3.

Sore throat after sore throat after sore throat. Are you asking the critical questions? Pichichero ME. **Postgrad Med** 1997 Jan;101(1):205–6, 209–12, 215–8, passim (22 ref.)

MICROBIOLOGY

An approach to diagnosing the acute sore throat. Perkins A. **Am Fam Physician** 1997 Jan;55(1):131–8, 141–2 (25 ref.)

Current concepts in the management of pharyngitis. Smith DS. **Compr Ther** 1996 Dec;22(12):806–9 (3 ref.)

Fatal Streptococcus viridans descending mediastinitis: case report and review of the literature. Berlot G, et al. **Eur J Emerg Med** 1997 Jun;4(2):111–4 (10 ref.)

[Streptococcal pharyngitis] Romero J, et al. **Enferm Infecc Microbiol Clin** 1995 Dec;13(10):611–27 (204 ref.) **(Spa)**

PREVENTION & CONTROL

Management of healthcare workers with pharyngitis or suspected streptococcal infections. Weber DJ, et al. **Infect Control Hosp Epidemiol** 1996 Nov;17(11):753–61 (95 ref.)

THERAPY

Upper respiratory tract infections – otitis media, sinusitis and pharyngitis. Oh HM. **Singapore Med J** 1995 Aug; 36(4):428–31 (23 ref.)

PHARYNGO–CONJUNCTIVAL FEVER see **ADENOVIRUS INFECTIONS, HUMAN**

PHARYNGOESOPHAGEAL DIVERTICULUM see **ZENKER'S DIVERTICULUM**

PHARYNX

see related
PHARYNGECTOMY

Full intrusion of a tooth after facial trauma. Tung TC, et al. **J Trauma** 1997 Aug;43(2):357–9 (7 ref.)

ANATOMY & HISTOLOGY

Properties of tissues surrounding the upper airway. Schwab RJ. **Sleep** 1996 Dec;19(10 Suppl):S170–4 (25 ref.)

METABOLISM

Effect of ventilatory drive on upper airway patency in humans during NREM sleep. Badr MS. **Respir Physiol** 1996 Jan;103(1):1–10 (33 ref.)

PATHOLOGY

Upper aerodigestive tract. Ranchod M. **Pathology (Phila)** 1996;3(2):299–304 (5 ref.)

PHYSIOLOGY

Properties of tissues surrounding the upper airway. Schwab RJ. **Sleep** 1996 Dec;19(10 Suppl):S170–4 (25 ref.)

PHYSIOPATHOLOGY

The pharyngeal critical pressure. The whys and hows of using nasal continuous positive airway pressure diagnostically. Gold AR, et al. **Chest** 1996 Oct; 110(4):1077–88 (48 ref.)

How and why should we stabilize the upper airway? Hoffstein V. **Sleep** 1996 Nov;19(9 Suppl):S57–60 (30 ref.)

[Pharyngoesophageal dysfunction: report of case and review of literature] Félix VN, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1996 May–Jun; 51(3):103–5 (17 ref.) (Eng. Abstr.) **(Por)**

SURGERY

An unusual appearance of velopharyngeal closure in a post–uvulopalatopharyngoplasty patient. Yanagisawa E, et al. **Ear Nose Throat J** 1997 Jan;76(1):14–5 (5 ref.)

The surgical treatment of snoring [see comments] Harries PG, et al. **J Laryngol Otol** 1996 Dec;110(12):1103–4 (9 ref.) Comment in: J Laryngol Otol 1997 Jun;111(6):598.

Concepts in pharyngoesophageal reconstruction. Haller JR. **Otolaryngol Clin North Am** 1997 Aug;30(4):655–61 (14 ref.)

Upper aerodigestive tract. Ranchod M. **Pathology (Phila)** 1996;3(2):299–304 (5 ref.)

Critical analysis of the results of surgery in the treatment of snoring, upper airway resistance syndrome (UARS), and obstructive sleep apnea (OSA). Pépin JL, et al. **Sleep** 1996 Nov;19(9 Suppl):S90–100 (92 ref.)

PHASE I CLINICAL TRIALS see **CLINICAL TRIALS, PHASE I**

PHASE II CLINICAL TRIALS see **CLINICAL TRIALS, PHASE II**

PHASE III CLINICAL TRIALS see **CLINICAL TRIALS, PHASE III**

PHASEOLUS see **LEGUMES**

PHENACETIN O–DEALKYLASE see **CYTOCHROME P–450 CYP1A2**

PHENADONE see **METHADONE**

PHENANTHROLINES

Oxidative chemical nucleases. Perrin DM, et al. **Prog Nucleic Acid Res Mol Biol** 1996;52:123–51 (77 ref.)

PHENANTOIN see **PHENYTOIN**

PHENAZINES

CHEMISTRY

The Gram stain after more than a century. Popescu A, et al. **Biotech Histochem** 1996 May;71(3):145–51 (60 ref.)

PHENAZOCINE

ANALOGS & DERIVATIVES

[Neuropharmacological effects of sigma receptor ligands: anxiolytic, anti–amnesic and neuroprotective effects] Amano M, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Jun; 16(3):73–84 (103 ref.) (Eng. Abstr.) **(Jpn)**

PHENAZOPYRIDINE

POISONING

Protracted methemoglobinemia after phenazopyridine overdose in an infant. Christensen CM, et al. **J Clin Pharmacol** 1996 Feb;36(2):112–6 (11 ref.)

THERAPEUTIC USE

Phenazopyridine in urinary tract infections. Zelenitsky SA, et al. **Ann Pharmacother** 1996 Jul–Aug;30(7–8):866–8 (10 ref.)

PHENBENZORPHAN see **PHENAZOCINE**

PHENCYCLIDINE

PHARMACOLOGY

Functional changes in neuronal systems induced by phencyclidine administration. Nabeshima T, et al. **Ann N Y Acad Sci** 1996 Oct 31;801:29–38 (54 ref.)

The behavioral and neurochemical effects of phenyclidine in humans and animals: some implications for modeling psychosis. Steinpresis RE. **Behav Brain Res** 1996 Jan; 74(1–2):45–55 (195 ref.)

[Neuropharmacological effects of sigma receptor ligands: anxiolytic, anti–amnesic and neuroprotective effects] Amano M, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Jun; 16(3):73–84 (103 ref.) (Eng. Abstr.) **(Jpn)**

PHENEMAL see **PHENOBARBITAL**

PHENETHYLAMINES

CHEMISTRY

beta–Phenylethylamines and the isoquinoline alkaloids. Bentley KW. **Nat Prod Rep** 1997 Aug;14(4):387–411 (462 ref.)

PHARMACOLOGY

Plant phenolic amines: potential effects on sympathoadrenal medullary, hypothalamic–pituitary–adrenal, and hypothalamic–pituitary–gonadal function in ruminants. Vera–Avila HR, et al. **Domest Anim Endocrinol** 1996 Jul; 13(4):285–96 (74 ref.)

Dofetilide versus quinidine for atrial flutter: viva la difference!? [editorial; comment] Olshansky B. **J Cardiovasc Electrophysiol** 1996 Sep;7(9):828–32 (18 ref.) Comment on: J Cardiovasc Electrophysiol 1996 Sep;7(9):809–27.

beta–Phenylethylamines and the isoquinoline alkaloids. Bentley KW. **Nat Prod Rep** 1997 Aug;14(4):387–411 (462 ref.)

PHENETHYLAZOCINE see **PHENAZOCINE**

PHENOBARBITAL

PHARMACOLOGY

Phenobarbital induction of cytochrome P450 genes in primary hepatocyte and transgenic models. Omiecinski CJ. **J Toxicol Sci** 1996 Dec;21(5):279–81 (4 ref.)

THERAPEUTIC USE

[Neonatal seizures: the beginning and interruption of the treatment] Koenigsberger MR, et al. **Rev Neurol** 1997 May; 25(141):706–8 (28 ref.) (Eng. Abstr.) **(Spa)**

TOXICITY

Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion. Whysner J, et al. **Pharmacol Ther** 1996; 71(1–2):153–91 (214 ref.)

PHENOBARBITONE see **PHENOBARBITAL**

PHENOL RED see **PHENOLSULFONPHTHALEIN**

PHENOLOXIDASE see **MONOPHENOL MONOOXYGENASE**

PHENOLS

ADMINISTRATION & DOSAGE

Deep chemical peeling. Matarasso SL, et al. **Semin Cutan Med Surg** 1996 Sep;15(3):155–61 (33 ref.)

ANALYSIS

Bioactive ingredients: antioxidants and polyphenols in tea. Dreosti IE. **Nutr Rev** 1996 Nov;54(11 Pt 2):S51–8 (62 ref.)

[Methods of determination of phenol and its derivatives in biological media (literature review)] Runova OB, et al. **Klin Lab Diagn** 1996 Sep–Oct;(5):15–9 (62 ref.) **(Rus)**

CHEMISTRY

Nitration and hydroxylation of phenolic compounds by peroxynitrite. Ramezanian MS, et al. **Methods Enzymol** 1996;269:195–201 (16 ref.)

METABOLISM

The sensing of plant signal molecules by Agrobacterium: genetic evidence for direct recognition of phenolic inducers by the VirA protein. Lee YW, et al. **Gene** 1996 Nov 7; 179(1):83–8 (20 ref.)

PHARMACOLOGY

Polyphenols as inhibitors of carcinogenesis. Yang CS, et al. **Environ Health Perspect** 1997 Jun;105 Suppl 4:971–6 (72 ref.)

Natural polyphenols (vegetable tannins) as drugs: possible modes of action. Haslam E. **J Nat Prod** 1996 Feb; 59(2):205–15 (60 ref.)

[Cardio–protective effect of red wine as reflected in the literature] Lugasi A, et al. **Orv Hetil** 1997 Mar 16; 138(11):673–8 (50 ref.) (Eng. Abstr.) **(Hun)**

POISONING

Campho–Phenique ingestion: an intentional overdose. Lahoud CA, et al. **South Med J** 1997 Jun;90(6):647–8 (11 ref.)

THERAPEUTIC USE

Cancer chemoprevention by polyphenols in green tea and artichoke. Agarwal R, et al. **Adv Exp Med Biol** 1996; 401:35–50 (107 ref.)

Plant phenolics as potential cancer prevention agents. Newmark HL. **Adv Exp Med Biol** 1996;401:25–34 (42 ref.)

Effects of tea on carcinogenesis in animal models and humans. Yang CS, et al. **Adv Exp Med Biol** 1996;401:51–61 (82 ref.)

PHENOLSULFONPHTHALEIN

DIAGNOSTIC USE

[Phenolsulfonphthalein test] Kimura M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:605–7 (3 ref.) **(Jpn)**

PHENOPROMIN see **AMPHETAMINE**

PHENOTHIAZINES

ADVERSE EFFECTS

[Torsades de pointe with spiramycine and metiquazine therapy. Apropos of a case] Verdun F, et al. **Arch Mal Coeur Vaiss** 1997 Jan;90(1):103–6 (10 ref.) (Eng. Abstr.) **(Fre)**

TOXICITY

Review of the genotoxic properties of chlorpromazine and related phenothiazines. Gocke E. **Mutat Res** 1996 Oct; 366(1):9–21 (78 ref.)

PHENOTYPE

see related
SOMATOTYPES

Diagnosis of Alzheimer's disease: defining genetic profiles (genotype vs phenotype). Cacabelos R. **Acta Neurol Scand Suppl** 1996;165:72–84 (104 ref.)

Phenotypic specification of hindbrain rhombomeres and the origins of rhythmic circuits in vertebrates. Bass AH, et al. **Brain Behav Evol** 1997;50 Suppl 1:3–16 (120 ref.)

Mating assortment and the liability to substance abuse. Vanyukov MM, et al. **Drug Alcohol Depend** 1996 Sep; 42(1):1–10 (100 ref.)

Alzheimer's disease: phenotypes and genotypes. Sorbi S, et al. **Funct Neurol** 1997 May–Aug;12(3–4):147–51 (13 ref.)

A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Crawley JN, et al. **Horm Behav** 1997 Jun;31(3):197–211 (200 ref.)

V3 vasopressin receptor and corticotropic phenotype in pituitary and nonpituitary tumors. de Keyzer Y, et al. **Horm Res** 1997;47(4–6):259–62 (18 ref.)

Nerve growth factor suppresses the tumoral phenotype of human prolactinomas. Missale C, et al. **Horm Res** 1997; 47(4–6):240–4 (29 ref.)

Genotype and phenotype in cystic fibrosis. Tsui LC, et al. **Hosp Pract (Off Ed)** 1997 Jun 15;32(6):115–8, 123–9, 134, passim (9 ref.)

Non–syndromic dominant sensorineural hearing loss: from a few phenotypes to many genotypes. Stinckens C, et al. **Int J Pediatr Otorhinolaryngol** 1997 Jan 3;38(3):237–45 (47 ref.)

Annotation: behavioural phenotypes: a window onto the biology of behaviour. Flint J. **J Child Psychol Psychiatry** 1996 May;37(4):355–67 (160 ref.)

Phenotypic features of cortical interstitial cells potentially important in fibrosis. Alpers CE, et al. **Kidney Int Suppl** 1996 May;54:S28–31 (37 ref.)

Phenotypic modulation of renal cells during experimental and clinical renal scarring. el Nahas AM, et al. **Kidney Int Suppl** 1996 May;54:S23–7 (52 ref.)

The development of the noradrenergic transmitter phenotype in postganglionic sympathetic neurons. Ernsberger U, et al. **Neurochem Res** 1996 Jul;21(7):823–9 (60 ref.)

Phenotypic and genetic heterogeneity in Niemann–Pick disease type C: current knowledge and practical implications. Vanier MT. **Wien Klin Wochenschr** 1997 Feb 14;109(3):68–73 (56 ref.)

Genetic, metabolic, and dietary influences on the atherogenic lipoprotein phenotype. Krauss RM. **World Rev Nutr Diet** 1997;80:22–43 (110 ref.)

[Genetic and phenotypic polymorphisms in carcinogen–metabolizing enzymes and cancer susceptibility] Watanabe M. **Nippon Rinsho** 1996 Aug; 54(8):2261–75 (60 ref.) (Eng. Abstr.) **(Jpn)**

[Genes, heredity and illness. A critical review of the concepts of genotypes and phenotypes] López de Munain A, et al. **Rev Neurol** 1996 Mar;24(127):320–4 (11 ref.) **(Spa)**

PHENOXAZOLE see **PEMOLINE**

PHENOXYBENZAMINE

ADMINISTRATION & DOSAGE

[Premedication in pheochromocytoma] Förster G, et al. **Zentralbl Chir** 1997;122(6):454–9 (29 ref.) (Eng. Abstr.) **(Ger)**

PHENTANYL see **FENTANYL**

PHENTERMINE

PHARMACOLOGY

The fenfluramine/phentermine combination for weight loss [letter] Garrett SD, et al. **Nurse Pract** 1997 Aug;22(8):166, 168, 170 (13 ref.)

PHENTOLAMINE

DIAGNOSTIC USE

[Regitine test] Takasaki I, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:363–6 (12 ref.) **(Jpn)**

PHENYLALANINE

ANALOGS & DERIVATIVES

Modulation of insulin secretion in non–insulin–dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166. Kikuchi M. **Diabet Med** 1996 Sep;13(9 Suppl 6):S151–5 (15 ref.)

BLOOD

Tetrahydrobiopterin and inherited hyperphenylalaninemias. Blau N, et al. **Turk J Pediatr** 1996 Jan–Mar;38(1):19–35 (102 ref.)

PHENYLALANINE AMMONIA-LYASE

CHEMISTRY

Enzymatic catalysis by Friedel–Crafts–type reactions. Rétey J. **Naturwissenschaften** 1996 Oct;83(10):439–47 (40 ref.)

METABOLISM

Enzymatic catalysis by Friedel–Crafts–type reactions. Rétey J. **Naturwissenschaften** 1996 Oct;83(10):439–47 (40 ref.)

PHENYLALANINE HYDROXYLASE

DEFICIENCY

The influence of mutations of enzyme activity and phenylalanine tolerance in phenylalanine hydroxylase deficiency. Güttler F, et al. **Eur J Pediatr** 1996 Jul;155 Suppl 1:S6–10 (27 ref.)

GENETICS

The phenylalanine hydroxylase locus: a marker for the history of phenylketonuria and human genetic diversity. PAH Mutation Analysis Consortium. Scriver CR, et al. **Ciba Found Symp** 1996;197:73–90; discussion 90–6 (60 ref.)

ISOLATION & PURIFICATION

Analysis of human specificity in AFLP systems APOB, PAH, and D1S80. Latorra D, et al. **Forensic Sci Int** 1996 Nov 11;83(1):15–25 (22 ref.)

PHENYLALANINE MUSTARD see **MELPHALAN**

PHENYLALANINE-SPECIFIC TRNA see **RNA, TRANSFER, PHE**

PHENYLAMINES see **ANILINE COMPOUNDS**

PHENYLBARBITAL see **PHENOBARBITAL**

PHENYLCARBAMIDES see **PHENYLUREA COMPOUNDS**

PHENYLCARBINOLS see **BENZYL ALCOHOLS**

PHENYLEPHRINE

ADMINISTRATION & DOSAGE

Phenylephrine and inhaled nitric oxide in adult respiratory distress syndrome. When are two better than one? [editorial; comment] Pearl RG. **Anesthesiology** 1997 Jul;87(1):1–3 (16 ref.) Comment on: Anesthesiology 1997 Jul;87(1):18–25.

PHENYLETHYLAMINES see **PHENETHYLAMINES**

PHENYLISOHYDANTOIN see **PEMOLINE**

PHENYLKETONURIA

DRUG THERAPY

Evidence for the importance of dopamine for prefrontal cortex functions early in life. Diamond A. **Philos Trans R Soc Lond B Biol Sci** 1996 Oct 29; 351(1346):1483–93; discussion 1494 (109 ref.)

GENETICS

The phenylalanine hydroxylase locus: a marker for the history of phenylketonuria and human genetic diversity. PAH Mutation Analysis Consortium. Scriver CR, et al. **Ciba Found Symp** 1996;197:73–90; discussion 90–6 (60 ref.)

The influence of mutations of enzyme activity and phenylalanine tolerance in phenylalanine hydroxylase deficiency. Güttler F, et al. **Eur J Pediatr** 1996 Jul;155 Suppl 1:S6–10 (27 ref.)

PHYSIOPATHOLOGY

A prefrontal dysfunction model of early–treated phenylketonuria. Welsh MC. **Eur J Pediatr** 1996 Jul;155 Suppl 1:S87–9 (33 ref.)

Evidence for the importance of dopamine for prefrontal cortex functions early in life. Diamond A. **Philos Trans R Soc Lond B Biol Sci** 1996 Oct 29; 351(1346):1483–93; discussion 1494 (109 ref.)

THERAPY

Gene therapy for phenylketonuria. Eisensmith RC, et al. **Eur J Pediatr** 1996 Jul;155 Suppl 1:S16–9 (18 ref.)

Somatic gene therapy for phenylketonuria and other hepatic deficiencies. Eisensmith RC, et al. **J Inherit Metab Dis** 1996;19(4):412–23 (30 ref.)

PHENYLMETHANOLS see **BENZYL ALCOHOLS**

PHENYLUREA COMPOUNDS

THERAPEUTIC USE

Antitumor diarylsulfonylureas: novel agents with unfulfilled promise. Houghton PJ, et al. **Invest New Drugs** 1996; 14(3):271–80 (34 ref.)

PHENYTOIN

Phenytoin. **IARC Monogr Eval Carcinog Risks Hum** 1996; 66:175–237 (306 ref.)

ANALOGS & DERIVATIVES

Safety of fosphenytoin sodium [see comments] Fierro LS, et al. **Am J Health Syst Pharm** 1996 Nov 15;53(22):2707–12 (53 ref.) Comment in: Am J Health Syst Pharm 1996 Nov 15;53(22):2702. Comment in: Am J Health Syst Pharm 1997 Feb 15;54(4):441–2. Comment in: Am J Health Syst Pharm 1997 Feb 15;54(4):442. Comment in: Am J Health Syst Pharm 1997 Feb 15;54(4):442, 445.

Fosphenytoin (Cerebyx). Browne TR. **Clin Neuropharmacol** 1997 Feb;20(1):1–12 (51 ref.)

Fosphenytoin: a novel phenytoin prodrug. Boucher BA. **Pharmacotherapy** 1996 Sep–Oct;16(5):777–91 (60 ref.)

PHENYTOIN

PHARMACOKINETICS

Erythrocytes and the transport of drugs and endogenous compounds. Highley MS, et al. **Pharm Res** 1996 Feb; 13(2):186–95 (50 ref.)

PHARMACOLOGY

Basis of the antiseizure action of phenytoin. Tunnicliff G. **Gen Pharmacol** 1996 Oct;27(7):1091–7 (105 ref.)

[Antiepileptic drugs: mechanism of action] Mercadé Cerdá JM. **Neurologia** 1996 Dec;11 Suppl 4:93–9 (31 ref.) (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

Phenytoin in wound healing. Anstead GM, et al. **Ann Pharmacother** 1996 Jul–Aug;30(7–8):768–75 (71 ref.)

Phenytoin as an alternative treatment for preeclampsia. Lucas LS, et al. **J Obstet Gynecol Neonatal Nurs** 1997 May–Jun; 26(3):263–9 (9 ref.)

[The diagnosis and treatment of partial epilepsy in childhood and adolescence] Martínez Bermejo Z, et al. **Neurologia** 1996 Dec;11 Suppl 4:58–71 (178 ref.) (Eng. Abstr.) **(Spa)**

PHEOCHROMOCYTOMA

see related
MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A
MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B

An unusual case of spontaneous rupture of a clinically "silent" phaeochromocytoma. Sapienza P, et al. **Anticancer Res** 1997 Jan–Feb;17(1B):717–20 (24 ref.)

Pheochromocytoma: issues in diagnosis & treatment. Young WF Jr. **Compr Ther** 1997 May;23(5):319–26 (28 ref.)

Diagnosis and management of pheochromocytoma. Kenady DE, et al. **Curr Opin Oncol** 1997 Jan;9(1):61–7 (21 ref.)

Phaeochromocytoma in Northern Ireland: a 21 year review. Beatty OL, et al. **Eur J Surg** 1996 Sep;162(9):695–702 (41 ref.)

Extra-adrenal pheochromocytoma. Atiyeh BA, et al. **J Nephrol** 1997 Jan–Feb;10(1):25–9 (32 ref.)

Hormonal and humeral considerations in hypertensive disease. Zimmerman RS. **Med Clin North Am** 1997 Sep; 81(5):1213–30 (147 ref.)

[Pheochromocytoma] Satoh A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):11–4 (16 ref.) **(Jpn)**

DIAGNOSIS

Pheochromocytoma in a long-term hemodialysis patient, discovered as an adrenal incidentaloma. Asaka S, et al. **Intern Med** 1997 Jun;36(6):403–7 (18 ref.)

Pheochromocytoma. Francis IR, et al. **Radiol Clin North Am** 1996 Nov;34(6):1101–12 (48 ref.)

Malignant pheochromocytoma in multiple endocrine neoplasia type 2B syndrome. Case report and review of the literature. Scopsi L, et al. **Tumori** 1996 Sep–Oct; 82(5):480–4 (36 ref.)

[Clinical and endocrine diagnosis of pheochromocytoma] Lehnert H, et al. **Zentralbl Chir** 1997;122(6):447–53 (14 ref.) (Eng. Abstr.) **(Ger)**

[Imaging methods in diagnosis of pheochromocytoma] Neumann K, et al. **Zentralbl Chir** 1997;122(6):438–42 (15 ref.) (Eng. Abstr.) **(Ger)**

[Bilateral adrenal pheochromocytoma. A clinical case and review of the literature] Piazza D, et al. **Minerva Chir** 1997 May;52(5):667–72 (17 ref.) (Eng. Abstr.) **(Ita)**

[A case of asymptomatic posterior mediastinal pheochromocytoma diagnosed during the procedure of video-assisted thoracic surgery (VATS)] Yajima H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Feb;45(2):155–60 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Malignant pheochromocytoma--progress in diagnosis and therapy] Sworczak K, et al. **Pol Arch Med Wewn** 1996 Jul;96(1):68–74 (43 ref.) **(Pol)**

[The characteristics of the course and diagnostic difficulties in pheochromocytoma in young people] Solun MN, et al. **Ter Arkh** 1996;68(4):80–2 (8 ref.) **(Rus)**

DRUG THERAPY

[Case of malignant pheochromocytoma with successful control of systemic metastasis with CVD chemotherapy] Minami T, et al. **Nippon Naika Gakkai Zasshi** 1996 Dec 10;85(12):2078–80 (10 ref.) **(Jpn)**

GENETICS

[A case of ectopic familial pheochromocytoma] Nakada J, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Aug; 87(8):1060–3 (11 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Coexisting non-functioning pheochromocytoma and renal oncocytoma: a case report and review of the literature. Daskalopoulos G, et al. **Eur J Radiol** 1996 Sep;23(2):138–42 (22 ref.)

Multiple endocrine neoplasia type 2B (mucosal neuroma syndrome, Wagenmann-Froboese syndrome). Morrison PJ, et al. **J Med Genet** 1996 Sep;33(9):779–82 (31 ref.)

RADIONUCLIDE IMAGING

Radioiodinated metaiodobenzylguanidine scintigraphy for pheochromocytoma. A false-positive case of adrenocortical adenoma and literature review. Sone H, et al. **Horm Res** 1996;46(3):138–42 (27 ref.)

[Nuclear medicine diagnosis of pheochromocytoma] Farahati J, et al. **Zentralbl Chir** 1997;122(6):443–6 (21 ref.) (Eng. Abstr.) **(Ger)**

RADIOTHERAPY

[Therapeutic possibilities in metastatic pheochromocytoma] Vierhapper H, et al. **Zentralbl Chir** 1997;122(6):494–7 (28 ref.) (Eng. Abstr.) **(Ger)**

SECONDARY

[Case of malignant pheochromocytoma with successful control of systemic metastasis with CVD chemotherapy] Minami T, et al. **Nippon Naika Gakkai Zasshi** 1996 Dec 10;85(12):2078–80 (10 ref.) **(Jpn)**

SECRETION

[Noradrenaline secreting glomus jugulare tumor (intracranial pheochromocytoma)] Kudoh Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):595–7 (13 ref.) **(Jpn)**

SURGERY

Surgical treatment of pheochromocytomas. Gavaghan M. **AORN J** 1997 Jun;65(6):1041–51 passim; quiz 1072–80 (64 ref.)

[Anesthesia-resuscitation in surgery for pheochromocytoma] Tavernier B, et al. **Ann Chir** 1997;51(4):352–60 (84 ref.) (Eng. Abstr.) **(Fre)**

[Premedication in pheochromocytoma] Förster G, et al. **Zentralbl Chir** 1997;122(6):454–9 (29 ref.) (Eng. Abstr.) **(Ger)**

[Conventional operation for therapy of incidentaloma] Simon D, et al. **Zentralbl Chir** 1997;122(6):473–6 (29 ref.) (Eng. Abstr.) **(Ger)**

[Anesthetic management in pheochromocytoma] Strecker U, et al. **Zentralbl Chir** 1997;122(6):460–6 (44 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Pheochromocytoma. Bravo EL. **Curr Ther Endocrinol Metab** 1997;6:195–7 (5 ref.)

VETERINARY

Pheochromocytoma in dogs and cats. Maher ER Jr, et al. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):359–80 (46 ref.)

PHEOCHROMOCYTOMA CELL LINE see **PC12 CELLS**

PHERESIS see **BLOOD COMPONENT REMOVAL**

PHEROMONES

Olfactory basis of host location by mosquitoes and other haematophagous Diptera. Cork A. **Ciba Found Symp** 1996; 200:71–84; discussion 84–8 (78 ref.)

A search for components in human body odour that attract females of Aedes aegypti. Geier M, et al. **Ciba Found Symp** 1996;200:132–44; discussion 144–8, 178–83 (35 ref.)

CHEMISTRY

M-factor, a farnesylated mating factor from the fission yeast Schizosaccharomyces pombe. Davey J. **Biochem Soc Trans** 1996 Aug;24(3):718–23 (48 ref.)

METABOLISM

The multiple role of the pheromone-binding protein in olfactory transduction. Ziegelberger G. **Ciba Found Symp** 1996;200:267–75; discussion 275–80 (41 ref.)

Quorum sensing by peptide pheromones and two-component signal-transduction systems in Gram-positive bacteria. Kleerebezem M, et al. **Mol Microbiol** 1997 Jun; 24(5):895–904 (38 ref.)

PHYSIOLOGY

The pheromonal role of cuticular hydrocarbons in Drosophila melanogaster. Ferveur JF. **Bioessays** 1997 Apr; 19(4):353–8 (70 ref.)

When is a butterfly like an elephant? Kelly DR. **Chem Biol** 1996 Aug;3(8):595–602 (118 ref.)

Peripheral mechanisms of pheromone reception in moths. Kaissling KE. **Chem Senses** 1996 Apr;21(2):257–68 (66 ref.)

Central mechanisms of pheromone information processing. Mustaparta H. **Chem Senses** 1996 Apr;21(2):269–75 (34 ref.)

Biological responsiveness to pheromones provides fundamental and unique insight into olfactory function. Sorensen PW. **Chem Senses** 1996 Apr;21(2):245–56 (86 ref.)

Pheromone signalling and polarized morphogenesis in yeast. Leberer E, et al. **Curr Opin Genet Dev** 1997 Feb;7(1):59–66 (60 ref.)

Pheromone transduction in the vomeronasal organ. Liman ER. **Curr Opin Neurobiol** 1996 Aug;6(4):487–93 (63 ref.)

The induction of cell polarity by pheromone in Saccharomyces cerevisiae. Dorer R, et al. **Harvey Lect** 1994–95;90:95–104 (20 ref.)

Olfactory recognition memory. Keverne EB, et al. **J Physiol Paris** 1996;90(5–6):399–401 (13 ref.)

Streptococcal competence for genetic transformation: regulation by peptide pheromones. Morrison DA. **Microb Drug Resist** 1997 Spring;3(1):27–37 (86 ref.)

Ciliate pheromones. Luporini P, et al. **Prog Mol Subcell Biol** 1996;17:80–104 (59 ref.)

The role of pheromones in bacterial interactions. Wirth R, et al. **Trends Microbiol** 1996 Mar;4(3):96–103 (70 ref.)

PHEROMONES, SEXUAL see **SEX ATTRACTANTS**

PHIALAPHORA JEANSELMEI see **EXOPHIALA**

PHIALOPHORA GOUGEROTII see **EXOPHIALA**

PHILADELPHIA CHROMOSOME

see related
ONCOGENE PROTEINS, FUSION

Clinical and biological aspects of Philadelphia-negative/BCR-negative chronic myeloid leukemia. Costello R, et al. **Leuk Lymphoma** 1997 Apr; 25(3–4):225–32 (45 ref.)

PHILOSOPHY

Philosophy of science and physiology education. Refinetti R. **Am J Physiol** 1997 Jun;272(6 Pt 3):S31–5 (30 ref.)

What postmodernism can do for psychoanalysis: a guide to the postmodern vision. Shawver L. **Am J Psychoanal** 1996 Dec;56(4):371–94 (67 ref.)

The origin and formulation of Chinese character: an introduction to confucianism and its influence on Chinese behavior patterns. Huang DD, et al. **Cult Divers Ment Health** 1996;2(1):35–42 (24 ref.)

A postmodern perspective on feminist gerontology. Ray RE. **Gerontologist** 1996 Oct;36(5):674–80 (64 ref.)

Geographies of responsibility. Walker M. **Hastings Cent Rep** 1997 Jan–Feb;27(1):38–44 (15 ref.)

The politics of phenomenological concepts in nursing. Holmes CA. **J Adv Nurs** 1996 Sep;24(3):579–87 (69 ref.)

The application of postmodern thought to the clinical practice of psychoanalytic psychotherapy. Chessick RD. **J Am Acad Psychoanal** 1996 Fall;24(3):385–407 (46 ref.)

An east Asian perspective of mind–body [see comments] Nagatomo S, et al. **J Med Philos** 1996 Aug;21(4):439–66 (26 ref.) Comment in: J Med Philos 1996 Aug;21(4):357–73.

[On teaching philosophy at medical higher educational establishments] Sarkisov DS, et al. **Vestn Ross Akad Med Nauk** 1997;(7):57–9 (0 ref.) **(Rus)**

PHILOSOPHY, MEDICAL

Unity and diversity in psychiatry: some philosophical issues. Dewhurst D, et al. **Aust N Z J Psychiatry** 1996 Jun; 30(3):382–8; discussion 388–91 (20 ref.)

From EBM to CSM: the evolution of context-sensitive medicine [editorial] Greenhalgh T, et al. **J Eval Clin Pract** 1997 Apr;3(2):105–8 (30 ref.)

Logical limits of randomized controlled trials. Sleigh JW. **J Eval Clin Pract** 1997 Apr;3(2):145–8 (5 ref.)

Genetic testing in children. Clayton EW. **J Med Philos** 1997 Jun;22(3):233–51 (29 ref.)

Adolescent parents and medical decision-making. De Ville K. **J Med Philos** 1997 Jun;22(3):253–70 (52 ref.)

Parenting and the best interests of minors. Downie RS, et al. **J Med Philos** 1997 Jun;22(3):219–31 (9 ref.)

Palliative care: a fragment towards its philosophy [editorial] Roy DJ. **J Palliat Care** 1997 Spring;13(1):3–4 (14 ref.)

Medicalization of women's third age. Kaufert PA, et al. **J Psychosom Obstet Gynaecol** 1997 Jun;18(2):81–6 (7 ref.)

The social construction of menopause as risk. Palmlund I. **J Psychosom Obstet Gynaecol** 1997 Jun;18(2):87–94 (61 ref.)

Medicalization of menopause and public health. Rueda Martinez de Santos JR. **J Psychosom Obstet Gynaecol** 1997 Jun;18(2):175–80 (20 ref.)

Variation among quality-of-life surveys. Theory and practice. Hornberger J, et al. **Med Care** 1996 Dec;34(12 Suppl):DS23–33 (81 ref.)

Assigning values to intermediate health states for cost-utility analysis: theory and practice. Cohen BJ. **Med Decis Making** 1996 Oct–Dec;16(4):376–85 (56 ref.)

Recent work on consciousness: philosophical, theoretical, and empirical. Churchland PM, et al. **Semin Neurol** 1997 Jun; 17(2):179–86 (17 ref.)

Beyond the orthodox: heresy in medicine and the social sciences from a cross-cultural perspective. Gürsoy A. **Soc Sci Med** 1996 Sep;43(5):577–99 (156 ref.)

Can phronesis save the life of medical ethics? Beresford EB. **Theor Med** 1996 Sep;17(3):209–24 (42 ref.)

About signs and symptoms: can semiotics expand the view of clinical medicine? Nessa J. **Theor Med** 1996 Dec; 17(4):363–77 (54 ref.)

[Philosophical principles of psychopathology] Wienbruch U. **Fortschr Neurol Psychiatr** 1996 Oct;64(10):375–81 (42 ref.) (Eng. Abstr.) **(Ger)**

[Axioms of systematic progress in medicine] Bauer AW. **Internist (Berl)** 1997 Apr;38(4):299–306 (42 ref.) **(Ger)**

HISTORY

The last physician? "The parable of the last physician". Geppert CM. **Pharos** 1997 Spring;60(2):15–20 (15 ref.)

PHILOSOPHY, NURSING

The postmodernist hoax and its effects on nursing. Kermode S, et al. **Int J Nurs Stud** 1996 Aug;33(4):375–84 (36 ref.)

Developing the nurse as a knowledge worker in health--learning the artistry of practice. Antrobus S. **J Adv Nurs** 1997 Apr;25(4):829–35 (27 ref.)

What is philosophy of nursing? Edwards SD. **J Adv Nurs** 1997 May;25(5):1089–93 (16 ref.)

The theory-practice relationship in nursing: an exploration of contemporary discourse. Fealy GM. **J Adv Nurs** 1997 May;25(5):1061–9 (30 ref.)

Dementia and personhood: a focus for care? Jenkins D, et al. **J Adv Nurs** 1996 Jul;24(1):84–90 (26 ref.)

The professional imagination: narrative and the symbolic boundaries between medicine and nursing. May C, et al. **J Adv Nurs** 1997 May;25(5):1094–100 (43 ref.)

The problem of arriving at a phenomenological description of memory loss. Moyle W, et al. **J Adv Nurs** 1997 Jul; 26(1):120–5 (31 ref.)

Husserl, phenomenology and nursing. Paley J. **J Adv Nurs** 1997 Jul;26(1):187–93 (35 ref.)

A re-examination of the experimental design for nursing research. Poole K, et al. **J Adv Nurs** 1996 Jul;24(1):108–14 (64 ref.)

Health promotion ideology and nursing education. Rush KL. **J Adv Nurs** 1997 Jun;25(6):1292–8 (29 ref.)

Nursing ideology: identification and legitimation. Taylor JS. **J Adv Nurs** 1997 Mar;25(3):442–6 (37 ref.)

Looking at discourse in a literature review of nursing texts. Traynor M. **J Adv Nurs** 1996 Jun;23(6):1155–61 (46 ref.)

Is caring the ethical ideal? Warelow PJ. **J Adv Nurs** 1996 Oct;24(4):655–61 (56 ref.)

Understanding healing: a conceptual analysis. Wendler MC. **J Adv Nurs** 1996 Oct;24(4):836–42 (39 ref.)

Community-based nursing versus community health nursing: what does it all mean? Zotti ME, et al. **Nurs Outlook** 1996 Sep-Oct;44(5):211–7 (25 ref.)

The perceptual aspect of nursing art: sources of accord and discord. Johnson JL. **Sch Inq Nurs Pract** 1996 Winter; 10(4):307–22; discussion 323–7 (55 ref.)

PHIMOSIS

THERAPY

Phimosis: is circumcision necessary? Dewan PA, et al. **J Paediatr Child Health** 1996 Aug;32(4):285–9 (41 ref.)

PHLEBITIS

COMPLICATIONS

The role of granulomatous phlebitis and thrombosis in the pathogenesis of cirrhosis and portal hypertension in sarcoidosis. Moreno-Merlo F, et al. **Hepatology** 1997 Sep; 26(3):554–60 (29 ref.)

ETIOLOGY

[Cerebral thrombophlebitis, sural phlebitis, pulmonary embolisms and protein S deficiencies] Bostroem H, et al. **Rev Neurol (Paris)** 1996 Dec;152(12):755–8 (26 ref.) (Eng. Abstr.) **(Fre)**

PHLEBOTOMUS

PHYSIOLOGY

Breeding habitats of vector sandflies and their control in India. Sivagnaname N, et al. **J Commun Dis** 1997 Jun; 29(2):153–9 (57 ref.)

PHLEBOTOMY

ADVERSE EFFECTS

Cutaneous mucormycosis with subsequent visceral dissemination in a child with neutropenia: a case report and review of the pediatric literature. Wirth F, et al. **J Am Acad Dermatol** 1997 Feb;36(2 Pt 2):336–41 (58 ref.)

PHLEBOVIRUS

CLASSIFICATION

[Argas and arbovirus update] Vermeil C, et al. **Bull Soc Pathol Exot** 1996;89(5):363–5 (16 ref.) (Eng. Abstr.) **(Fre)**

PHLEGMASIA ALBA DOLENS see **THROMBOPHLEBITIS**

PHLEGMON see **CELLULITIS**

PHLORHIZIN

ANALOGS & DERIVATIVES

Prospects for the production and use of new improved dietary oestrogens for cardioprotection. Ridgway TJ, et al. **Biochem Soc Trans** 1997 Feb;25(1):59–63 (28 ref.)

METABOLISM

Novel bioconversions for the production of designer antioxidant and colourant flavonoids using polyphenol oxidases. Ridgway T, et al. **Biotechnol Genet Eng Rev** 1997; 14:165–90 (117 ref.)

THERAPEUTIC USE

Prospects for the production and use of new improved dietary oestrogens for cardioprotection. Ridgway TJ, et al. **Biochem Soc Trans** 1997 Feb;25(1):59–63 (28 ref.)

PHOBIA, SCHOOL see **PHOBIC DISORDERS**

PHOBIA, SOCIAL see **PHOBIC DISORDERS**

PHOBIAS see **PHOBIC DISORDERS**

PHOBIC DISORDERS

Children's nighttime fears. King N, et al. **Clin Psychol Rev** 1997;17(4):431–43 (44 ref.)

COMPLICATIONS

Comorbidity and its effects on panic disorder. Marshall JR. **Bull Menninger Clin** 1996 Spring;60(2 Suppl A):A39–53 (63 ref.)

DIAGNOSIS

The neurobiology of social phobia. Potts NL, et al. **Int Clin Psychopharmacol** 1996 Jun;11 Suppl 3:43–8 (37 ref.)

The measurement of disability. Sheehan DV, et al. **Int Clin Psychopharmacol** 1996 Jun;11 Suppl 3:89–95 (13 ref.)

[Disorders of assertiveness and social anxiety] Azaïs F, et al. **Ann Med Psychol (Paris)** 1995 Dec;153(10):667–75 (33 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Panic disorder and social phobia: possible implications of comorbid depression for drug therapy. Lydiard RB. **Anxiety** 1996;2(2):61–70 (90 ref.)

Moclobemide. An update of its pharmacological properties and therapeutic use [published erratum appears in Drugs 1996 Dec;52(6):869] Fulton B, et al. **Drugs** 1996 Sep; 52(3):450–74 (115 ref.)

Issues in the design of trials for the evaluation of psychopharmacological treatments for social phobia. Liebowitz MR, et al. **Int Clin Psychopharmacol** 1996 Jun; 11 Suppl 3:49–53 (22 ref.)

Moclobemide in the treatment of social phobia. Nutt D, et al. **Int Clin Psychopharmacol** 1996 Jun;11 Suppl 3:77–82 (22 ref.)

The pharmacotherapy of social phobia. Pollack MH, et al. **Int Clin Psychopharmacol** 1996 Jun;11 Suppl 3:71–5 (40 ref.)

Role of serotonin drugs in the treatment of social phobia. Tancer ME, et al. **J Clin Psychiatry** 1997;58 Suppl 5:50–4 (39 ref.)

EPIDEMIOLOGY

Comorbidity and social phobia: clinical and epidemiological issues. Lépine JP, et al. **Int Clin Psychopharmacol** 1996 Jun; 11 Suppl 3:35–41 (39 ref.)

ETIOLOGY

[Body dysmorphic disorder as an obsessive-compulsive spectrum disorder] Díaz Márslá M, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 Nov-Dec;24(6):331–7 (35 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

The neurobiology of social phobia. Potts NL, et al. **Int Clin Psychopharmacol** 1996 Jun;11 Suppl 3:43–8 (37 ref.)

Blushing and social phobia: a neuroethological speculation. Stein DJ, et al. **Med Hypotheses** 1997 Jul;49(1):101–8 (81 ref.)

PSYCHOLOGY

Quality of life in anxiety and social phobia. Bech P, et al. **Int Clin Psychopharmacol** 1996 Jun;11 Suppl 3:97–100 (28 ref.)

In defense of weight phobia as the central organizing motive in anorexia nervosa: historical and cultural arguments for a culture-sensitive psychological conception. Habermas T. **Int J Eat Disord** 1996 May;19(4):317–34 (73 ref.)

Blushing and social phobia: a neuroethological speculation. Stein DJ, et al. **Med Hypotheses** 1997 Jul;49(1):101–8 (81 ref.)

THERAPY

On the need for standardization in panic disorder treatment research: survey of the literature, 1980–1992. Weise RE, et al. **Anxiety** 1996;2(6):257–64 (95 ref.)

Issues in the design of trials for the evaluation of psychosocial treatments for social phobia. Heimberg RG, et al. **Int Clin Psychopharmacol** 1996 Jun;11 Suppl 3:55–64 (45 ref.)

Non-drug treatment for social phobia. van Dyck R. **Int Clin Psychopharmacol** 1996 Jun;11 Suppl 3:65–70 (45 ref.)

Tailor-made and standardized therapy: complementary tasks in behavior therapy. A contrarian view. Schulte D. **J Behav Ther Exp Psychiatry** 1996 Jun;27(2):119–26 (31 ref.)

Treatment of childhood Phobias. King NJ, et al. **J Child Psychol Psychiatry** 1997 May;38(4):389–400 (115 ref.)

PHOBIC NEUROSES see **PHOBIC DISORDERS**

PHOBOS see **MARS**

PHOCOMELIA see **ECTROMELIA**

PHOEBE see **SATURN**

PHONATION

PHYSIOLOGY

Phonetography in voice diagnoses. Heylen LG, et al. **Acta Otorhinolaryngol Belg** 1996;50(4):299–308 (54 ref.)

Aerodynamic measurements of voice production. Raes JP, et al. **Acta Otorhinolaryngol Belg** 1996;50(4):293–8 (22 ref.)

PHONATION DISORDERS see **VOICE DISORDERS**

PHONETICS

Language acquisition: the acquisition of linguistic structure in normal and special populations. McDonald JL. **Annu Rev Psychol** 1997;48:215–41 (105 ref.)

A critical review of PET studies of phonological processing. Poeppel D. **Brain Lang** 1996 Dec;55(3):317–51; discussion 352–85 (66 ref.)

Behavioral and electrophysiological indices of voicing-cue discrimination: laterality patterns and development. Simos PG, et al. **Brain Lang** 1997 Mar;57(1):122–50 (84 ref.)

PHONOCARDIOGRAPHY

Digital signal processing of the phonocardiogram: review of the most recent advancements. Durand LG, et al. **Crit Rev Biomed Eng** 1995;23(3–4):163–219 (187 ref.)

[Phonocardiogram] Amano K. **Nippon Rinsho** 1997 Mar;55 Suppl 1:560–5 (5 ref.) **(Jpn)**

[Interventional phonocardiogram] Amano K. **Nippon Rinsho** 1997 Mar;55 Suppl 1:566–8 (5 ref.) **(Jpn)**

PHORBOL ESTERS

PHARMACOLOGY

Protein kinase D: a novel target for diacylglycerol and phorbol esters. Rozengurt E, et al. **Biochem Soc Trans** 1997 May;25(2):565–71 (49 ref.)

PHORIAS see **STRABISMUS**

PHOSGENE

ADVERSE EFFECTS

Acute lung injury after phosgene inhalation. Lim SC, et al. **Korean J Intern Med** 1996 Jan;11(1):87–92 (18 ref.)

PHOSPHATASES see **PHOSPHORIC MONOESTER HYDROLASES**

PHOSPHATE DIABETES see **HYPOPHOSPHATEMIA, FAMILIAL**

PHOSPHATES

see related
HYPOPHOSPHATEMIA

Treatment options in struvite stones. Wang LP, et al. **Urol Clin North Am** 1997 Feb;24(1):149–62 (149 ref.)

ADMINISTRATION & DOSAGE

Complications of Fleet enema administration and suggested guidelines for use in the pediatric emergency department. Harrington L, et al. **Pediatr Emerg Care** 1997 Jun; 13(3):225–6 (18 ref.)

ADVERSE EFFECTS

Severe hyperphosphatemia following phosphate administration for bowel preparation in patients with renal failure: two cases and a review of the literature. Fine A, et al. **Am J Kidney Dis** 1997 Jan;29(1):103–5 (11 ref.)

PHOSPHATES

Oral Fleet Phospho-Soda laxative-induced hyperphosphatemia and hypocalcemic tetany in an adult: report of a case. Vukasin P, et al. **Dis Colon Rectum** 1997 Apr;40(4):497-9 (11 ref.)

Complications of Fleet enema administration and suggested guidelines for use in the pediatric emergency department. Harrington L, et al. **Pediatr Emerg Care** 1997 Jun; 13(3):225-6 (18 ref.)

BLOOD

Severe hyperphosphatemia following phosphate administration for bowel preparation in patients with renal failure: two cases and a review of the literature. Fine A, et al. **Am J Kidney Dis** 1997 Jan;29(1):103-5 (11 ref.)

Disorders of plasma phosphate and indications for its measurement. Crook M, et al. **Ann Clin Biochem** 1996 Sep; 33 (Pt 5):376-96 (249 ref.)

Severe hyperphosphatemia and hypocalcemia: a dilemma in patient management. Sutters M, et al. **J Am Soc Nephrol** 1996 Oct;7(10):2056-61 (31 ref.)

Hyperostosis with hyperphosphatemia: evidence of familial occurrence and association with tumoral calcinosis. Narchi H. **Pediatrics** 1997 May;99(5):745-8 (9 ref.)

METABOLISM

Bone biology. Ng KW, et al. **Baillieres Clin Endocrinol Metab** 1997 Apr;11(1):1-22 (104 ref.)

Basic helix-loop-helix transcription factors and the cross-regulation of sulphate and phosphate metabolism in yeast. Crowther DJ, et al. **Biochem Soc Trans** 1996 May; 24(2):354-9 (53 ref.)

Modeling of the actomyosin ATPase activity. Origin of the initial phosphate burst and implications of the phosphate release kinetics. Stein LA. **Cell Biochem Biophys** 1995-96; 27(2):63-96 (14 ref.)

Regulation of renal phosphate handling: recent findings. Friedlander G. **Curr Opin Nephrol Hypertens** 1996 Jul; 5(4):316-20 (29 ref.)

Cellular and molecular mechanisms of renal phosphate transport. Tenenhouse HS. **J Bone Miner Res** 1997 Feb; 12(2):159-64 (64 ref.)

Molecular regulation of renal phosphate transport. Levi M, et al. **J Membr Biol** 1996 Nov;154(1):1-9 (73 ref.)

Molecular mechanisms in the regulation of renal proximal tubular Na/phosphate cotransport. Murer H, et al. **Kidney Blood Press Res** 1996;19(3-4):151-4 (27 ref.)

Autocrine/paracrine control of renal phosphate transport. Friedlander G, et al. **Kidney Int Suppl** 1996 Dec;57:S148-53 (73 ref.)

A view of type I and II Na+/P(i) transporters through microelectrodes [editorial] Busch AE. **Nephrol Dial Transplant** 1997 Apr;12(4):638-40 (11 ref.)

Phosphatonin--a new phosphaturetic hormone? (lessons from tumour-induced osteomalacia and X-linked hypophosphataemia) [editorial] Kumar R. **Nephrol Dial Transplant** 1997 Jan;12(1):11-3 (9 ref.)

Cellular mechanisms in renal tubular transport of divalent inorganic anions. Murer H, et al. **Nephrologie** 1996; 17(7):365-9 (33 ref.)

A molecular view of proximal tubular inorganic phosphate (Pi) reabsorption and of its regulation. Murer H, et al. **Pflugers Arch** 1997 Feb;433(4):379-89 (107 ref.)

Lysosomal nucleic acid and phosphate metabolism and related metabolic reactions. Pisoni RL. **Subcell Biochem** 1996;27:295-330 (134 ref.)

Signaling phosphate starvation. Lenburg ME, et al. **Trends Biochem Sci** 1996 Oct;21(10):383-7 (42 ref.)

[Regulation and physiopathology of phosphate transport] Friedlander G. **Nephrologie** 1996;17(7):371-5 (35 ref.) (Eng. Abstr.) **(Fre)**

[Fractional tubular reabsorption of phosphate] Akatsu T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:310-2 (9 ref.) **(Jpn)**

PHARMACOLOGY

[Mini review: a factor enhanced the antibacterial effect of beta-lactams on methicillin-resistant Staphylococcus aureus] Tajima Y. **Rinsho Byori** 1996 Nov;44(11):1093-9 (6 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Cellular and molecular mechanisms of renal phosphate transport. Tenenhouse HS. **J Bone Miner Res** 1997 Feb; 12(2):159-64 (64 ref.)

Calcium, phosphate, vitamin D, and the parathyroid. Marks KH, et al. **Pediatr Nephrol** 1996 Jun;10(3):364-7 (32 ref.)

Muscle contraction and fatigue. The role of adenosine 5'-diphosphate and inorganic phosphate. McLester JR Jr. **Sports Med** 1997 May;23(5):287-305 (124 ref.)

URINE

Profound hypophosphatemia and isolated hyperphosphaturia in two cases of multiple myeloma. Dash T, et al. **Am J Kidney Dis** 1997 Mar;29(3):445-8 (19 ref.)

PHOSPHATES, INORGANIC see **PHOSPHATES**

PHOSPHATIDAL COMPOUNDS see **PLASMALOGENS**

PHOSPHATIDATE PHOSPHATASE

METABOLISM

Molecular properties of enzymes involved in diacylglycerol and phosphatidate metabolism. Kanoh H, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1-3):245-50 (18 ref.)

Phosphatidate phosphatases of mammals, yeast, and higher plants. Kocsis MG, et al. **Lipids** 1996 Aug;31(8):785-802 (163 ref.)

PHOSPHATIDATE PHOSPHOHYDROLASE see **PHOSPHATIDATE PHOSPHATASE**

PHOSPHATIDES see **PHOSPHOLIPIDS**

PHOSPHATIDIC ACIDS

METABOLISM

Regulation of Raf-1 kinase by interaction with the lipid second messenger, phosphatidic acid. Ghosh S, et al. **Biochem Soc Trans** 1997 May;25(2):561-5 (19 ref.)

Phosphatidic acid: a lipid messenger involved in intracellular and extracellular signalling. English D. **Cell Signal** 1996 Aug;8(5):341-7 (98 ref.)

PHOSPHATIDYLCHOLINES

Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations? Mehta J. **Leuk Res** 1997 Mar;21(3):183-8 (33 ref.)

BLOOD

[Hereditary high red cell membrane phosphatidylcholine hemolytic anemia (HPCHA)] Terada H. **Nippon Rinsho** 1996 Sep;54(9):2502-6 (18 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

A new phase in phosphatidylcholines [comment] O'Leary TJ, et al. **Biophys J** 1996 Dec;71(6):2915-6 (9 ref.) Comment on: Biophys J 1996 Dec;71(6):3186-98.

METABOLISM

Hydration properties of lamellar and non-lamellar phases of phosphatidylcholine and phosphatidylethanolamine. McIntosh TJ. **Chem Phys Lipids** 1996 Jul 15;81(2):117-31 (120 ref.)

Phosphatidylcholine hydrolysis and protein kinase C activation for intracellular signaling network. Nakamura S. **J Lipid Mediat Cell Signal** 1996 Sep;14(1-3):197-202 (16 ref.)

Muscarinic activation of phosphatidylcholine hydrolysis. Klein J, et al. **Prog Brain Res** 1996;109:201-8 (57 ref.)

PHYSIOLOGY

Nuclear diacylglycerol, the cell cycle, the enzymes and a red herring (or how we came to love phosphatidylcholine). Divecha N, et al. **Biochem Soc Trans** 1997 May;25(2):571-5 (22 ref.)

Phosphatidylcholine signaling in response to CSF-1. Jackowski S, et al. **Mol Reprod Dev** 1997 Jan;46(1):24-30 (23 ref.)

PHOSPHATIDYLETHANOLAMINES

METABOLISM

Hydration properties of lamellar and non-lamellar phases of phosphatidylcholine and phosphatidylethanolamine. McIntosh TJ. **Chem Phys Lipids** 1996 Jul 15;81(2):117-31 (120 ref.)

PHARMACOLOGY

[L-MTP-PE--a potential antineoplastic agent] Dzierzbicka K, et al. **Postepy Hig Med Dosw** 1997;51(2):227-36 (37 ref.) (Eng. Abstr.) **(Pol)**

PHOSPHATIDYLGLYCEROLS

Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations? Mehta J. **Leuk Res** 1997 Mar;21(3):183-8 (33 ref.)

PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE see **PHOSPHATIDYLINOSITOL 4,5-DIPHOSPHATE**

PHOSPHATIDYLINOSITOL 4,5-DIPHOSPHATE

METABOLISM

The control of inositol lipid hydrolysis. Katan M. **Cancer Surv** 1996;27:199-211 (67 ref.)

PHOSPHATIDYLINOSITOL PHOSPHATES

BIOSYNTHESIS

Polyphosphoinositide synthesis and platelet shape change. Hartwig JH, et al. **Curr Opin Hematol** 1997 Sep;4(5):351-6 (45 ref.)

PHOSPHATIDYLINOSITOLS

ANALYSIS

Benzophenone photoprobes for phosphoinositides, peptides and drugs. Prestwich GD, et al. **Photochem Photobiol** 1997 Feb;65(2):222-34 (95 ref.)

METABOLISM

Inositol lipid cycle and autonomous nuclear signalling. Cocco L, et al. **Adv Enzyme Regul** 1996;36:101-14 (32 ref.)

The phosphatidylinositol 4-phosphate 5-kinase family. Loijens JC, et al. **Adv Enzyme Regul** 1996;36:115-40 (90 ref.)

Phosphoinositides as spatial regulators of membrane traffic. Martin TF. **Curr Opin Neurobiol** 1997 Jun;7(3):331-8 (62 ref.)

Phosphatidylinositol transfer proteins: requirements in phospholipase C signaling and in regulated exocytosis. Cockcroft S. **FEBS Lett** 1997 Jun 23;410(1):44-8 (31 ref.)

The human sperm acrosome reaction: physiology and regulatory mechanisms. An update. Brucker C, et al. **Hum Reprod Update** 1995 Jan;1(1):51-62 (103 ref.)

Growth factor-dependent phosphoinositide signalling. Hsuan JJ, et al. **Int J Biochem Cell Biol** 1997 Mar;29(3):415-35 (204 ref.)

Receptor-mediated phosphoinositide metabolism in peripheral nerve and cultured Schwann cells. Eichberg J, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1-3):187-95 (26 ref.)

Poly-phosphoinositide-mediated messengers in focal cerebral ischemia and reperfusion. Sun GY, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1-3):137-45 (19 ref.)

Acute regulation of the receptor-mediated phosphoinositide signal transduction pathway. Willars GB, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1-3):157-68 (35 ref.)

Cell-to-cell transfer of glycosylphosphatidylinositol-anchored membrane proteins during sperm maturation. Kirchhoff C, et al. **Mol Hum Reprod** 1996 Mar;2(3):177-84 (77 ref.)

Signalling through the lipid products of phosphoinositide-3-OH kinase. Toker A, et al. **Nature** 1997 Jun 12;387(6634):673-6 (47 ref.)

Phosphoinositide signaling in human brain. Pacheco MA, et al. **Prog Neurobiol** 1996 Oct;50(2-3):255-73 (65 ref.)

[Screening of phosphatidylinositol turnover inhibitors and regulation of cell cycle progression] Umezawa K, et al. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1578-84 (27 ref.) (Eng. Abstr.) **(Jpn)**

[New members of regulating phosphoinositide metabolism] Ijuin T. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):385-93 (18 ref.) **(Jpn)**

[Phosphatidylinositol-specific phospholipase C isozymes and regulation of their activity] Pawelczyk T. **Postepy Biochem** 1996;42(3):290-8 (151 ref.) **(Pol)**

PHARMACOLOGY

Phosphoinositides as spatial regulators of membrane traffic. Martin TF. **Curr Opin Neurobiol** 1997 Jun;7(3):331-8 (62 ref.)

PHYSIOLOGY

Modulation of serotonin2A/2C receptors and these receptor-linked phosphoinositide system by ethanol. Pandey SC, et al. **Behav Brain Res** 1996;73(1-2):235-8 (26 ref.)

Inositol phosphates and inositol phospholipids: how big is the iceberg? Woodcock EA. **Mol Cell Endocrinol** 1997 Mar 14;127(1):1-10 (108 ref.)

Role of Drosophila TRP in inositide-mediated Ca2+ entry. Minke B, et al. **Mol Neurobiol** 1996 Apr;12(2):163-80 (83 ref.)

Cell-surface GPI expression in Protozoa. The connection with the PI system. Kovács P. **Prog Mol Subcell Biol** 1996; 17:105-18 (53 ref.)

PHOSPHATIDYLSERINES

METABOLISM

Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. Reutelingsperger CP, et al. **Cell Mol Life Sci** 1997 Jun; 53(6):527-32 (58 ref.)

PHARMACOLOGY

A review of phosphatidylserine pharmacological and clinical effects. Is phosphatidylserine a drug for the ageing brain? Pepeu G, et al. **Pharmacol Res** 1996 Feb;33(2):73-80 (71 ref.)

PHYSIOLOGY

Regulatory mechanisms in maintenance and modulation of transmembrane lipid asymmetry: pathophysiological implications. Bevers EM, et al. **Lupus** 1996 Oct;5(5):480–7 (101 ref.)

PHOSPHOADENOSINE PHOSPHOSULFATE

METABOLISM

Sulfation and sulfotransferases 5: the importance of 3'-phosphoadenosine 5'-phosphosulfate (PAPS) in the regulation of sulfation. Klaassen CD, et al. **FASEB J** 1997 May;11(6):404–18 (116 ref.)

PHOSPHODIESTERASE ANTAGONISTS see **PHOSPHODIESTERASE INHIBITORS**

PHOSPHODIESTERASE INHIBITORS

PHARMACOLOGY

Intracellular targeting, interaction with Src homology 3 (SH3) domains and rolipram-detected conformational switches in cAMP-specific PDE4A phosphodiesterase. Houslay MD, et al. **Biochem Soc Trans** 1997 May; 25(2):374–81 (50 ref.)

Anti-inflammatory effects of theophylline and selective phosphodiesterase inhibitors. Banner KH, et al. **Clin Exp Allergy** 1996 Mar;26 Suppl 2:2–9 (99 ref.)

Phosphodiesterase inhibitors and endothelin as modulators of respiratory neurotransmission. Fernandes LB. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov;23(10–11):980–2 (35 ref.)

Phosphodiesterase inhibitors: knockout drops? Raeburn D, et al. **J Pharm Pharmacol** 1997 May;49 Suppl 3:19–24 (22 ref.)

Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Teixeira MM, et al. **Trends Pharmacol Sci** 1997 May;18(5):164–71 (101 ref.)

THERAPEUTIC USE

Pharmacologic intervention for acute low cardiac output. Marchetti A, et al. **Adv Card Surg** 1996;7:31–64 (91 ref.)

Pentoxifylline: brief review and rationale for its possible use in the treatment of autism. Gupta S, et al. **J Child Neurol** 1996 Nov;11(6):501–4 (44 ref.)

[Theophylline and selective phosphodiesterase inhibitor in therapy of obstructive respiratory tract diseases] Rabe KF, et al. **Pneumologie** 1997 Mar;51(3):303–16 (140 ref.) **(Ger)**

[Future aspects of new cardiotonic drugs] Hori M, et al. **Nippon Naika Gakkai Zasshi** 1994 Jan 10;83(1):59–63 (5 ref.) **(Jpn)**

PHOSPHODIESTERASES see **PHOSPHORIC DIESTER HYDROLASES**

PHOSPHOENOLPYRUVATE

METABOLISM

The versatility of phosphoenolpyruvate and its vinyl ether products in biosynthesis. Walsh CT, et al. **Chem Biol** 1996 Feb;3(2):83–91 (38 ref.)

PHOSPHOENOLPYRUVATE CARBOXYKINASES

CHEMISTRY

Structure and mechanism of phosphoenolpyruvate carboxykinase [published erratum appears in J Biol Chem 1997 Aug 15;272(33):20962] Matte A, et al. **J Biol Chem** 1997 Mar 28;272(13):8105–8 (70 ref.)

GENETICS

Regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression. Hanson RW, et al. **Annu Rev Biochem** 1997;66:581–611 (145 ref.)

Regulation of gene transcription by fatty acids, fibrates and prostaglandins: the phosphoenolpyruvate carboxykinase gene as a model. Forest C, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Jul; 57(1):47–56 (66 ref.)

PHOSPHOENOLPYRUVATE HEXOSE PHOSPHOTRANSFERASES see **PHOSPHOENOLPYRUVATE SUGAR PHOSPHOTRANSFERASE SYSTEM**

PHOSPHOENOLPYRUVATE SUGAR PHOSPHOTRANSFERASE SYSTEM

GENETICS

A voyage along the bases: novel phosphotransferase genes revealed by in silico analyses of the Escherichia coli genome. Reizer J, et al. **Res Microbiol** 1996 Jul–Sep; 147(6–7):458–71 (61 ref.)

METABOLISM

Modular multidomain phosphoryl transfer proteins of bacteria. Reizer J, et al. **Curr Opin Struct Biol** 1997 Jun; 7(3):407–15 (51 ref.)

The phosphoenolpyruvate:sugar phosphotransferase system of oral streptococci and its role in the control of sugar metabolism. Vadeboncoeur C, et al. **FEMS Microbiol Rev** 1997 Feb;19(3):187–207 (107 ref.)

Coordination of carbon and nitrogen metabolism. Charbit A. **Res Microbiol** 1996 Jul–Sep;147(6–7):513–8 (30 ref.)

CcpA and HPr(ser-P): mediators of catabolite repression in Bacillus subtilis. Chauvaux S. **Res Microbiol** 1996 Jul–Sep; 147(6–7):518–22 (20 ref.)

Enzyme I: the first protein and potential regulator of the bacterial phosphoenolpyruvate: glycose phosphotransferase system. Chauvin F, et al. **Res Microbiol** 1996 Jul–Sep; 147(6–7):471–9 (24 ref.)

Life in mucus: sugar metabolism in Haemophilus influenzae. Macfadyen LP, et al. **Res Microbiol** 1996 Jul–Sep; 147(6–7):541–51 (49 ref.)

Inducer exclusion and the regulation of sugar transport. Saier MH Jr, et al. **Res Microbiol** 1996 Jul–Sep;147(6–7):482–9 (55 ref.)

Regulation of carbohydrate transport in Lactococcus and Lactobacillus. Ye J. **Res Microbiol** 1996 Jul–Sep; 147(6–7):523–7 (31 ref.)

6-PHOSPHOFRUCTOKINASE

METABOLISM

Regulatory properties and the development of structure in phosphofructokinase. Hofer HW. **Arch Biol Med Exp (Santiago)** 1987;20(3–4):359–70 (51 ref.)

PHOSPHOGLUCOSE ISOMERASE see **GLUCOSEPHOSPHATE ISOMERASE**

PHOSPHOGLYCERALDEHYDE DEHYDROGENASE see **GLYCERALDEHYDEPHOSPHATE DEHYDROGENASE**

PHOSPHOGLYCERIDES see **GLYCEROPHOSPHATES**

PHOSPHOHEXOSE ISOMERASE see **GLUCOSEPHOSPHATE ISOMERASE**

PHOSPHOHYDROLASES see **PHOSPHORIC MONOESTER HYDROLASES**

PHOSPHOINOSITIDES see **PHOSPHATIDYLINOSITOLS**

PHOSPHOLIPASE A1 see **PHOSPHOLIPASES A**

PHOSPHOLIPASE A2 see **PHOSPHOLIPASES A**

PHOSPHOLIPASE C

ANTAGONISTS & INHIBITORS

[Phospholipase C inhibitor] Homma Y, et al. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1611–7 (14 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Protein kinase C and phospholipase C: bilayer interactions and regulation. Hurley JH, et al. **Curr Opin Struct Biol** 1997 Aug;7(4):557–65 (69 ref.)

Phospholipase C-gamma1: regulation of enzyme function and role in growth factor-dependent signal transduction. Kamat A, et al. **Cytokine Growth Factor Rev** 1997 Jun; 8(2):109–17 (86 ref.)

Structural views of phosphoinositide-specific phospholipase C: signalling the way ahead. Williams RL, et al. **Structure** 1996 Dec 15;4(12):1387–94 (80 ref.)

METABOLISM

Inositol lipid cycle and autonomous nuclear signalling. Cocco L, et al. **Adv Enzyme Regul** 1996;36:101–14 (32 ref.)

Regulation of insulin secretion by phospholipase C. Zawalich WS, et al. **Am J Physiol** 1996 Sep;271(3 Pt 1):E409–16 (64 ref.)

Regulation of eukaryotic phosphatidylinositol-specific phospholipase C and phospholipase D. Singer WD, et al. **Annu Rev Biochem** 1997;66:475–509 (316 ref.)

Nuclear diacylglycerol, the cell cycle, the enzymes and a red herring (or how we came to love phosphatidylcholine). Divecha N, et al. **Biochem Soc Trans** 1997 May;25(2):571–5 (22 ref.)

Calcium signalling: sphingosine kinase versus phospholipase C? Beaven MA. **Curr Biol** 1996 Jul 1;6(7):798–801 (14 ref.)

Phosphatidylinositol transfer proteins: requirements in phospholipase C signaling and in regulated exocytosis. Cockcroft S. **FEBS Lett** 1997 Jun 23;410(1):44–8 (31 ref.)

Regulation of phosphoinositide-specific phospholipase C isozymes. Rhee SG, et al. **J Biol Chem** 1997 Jun 13; 272(24):15045–8 (50 ref.)

Nuclear application of antisense oligonucleotides by microinjection and ballistomagnetic transfer to identify G protein heterotrimers activating phospholipase C. Kalkbrenner F, et al. **Methods Mol Biol** 1997;83:203–16 (16 ref.)

Activation, cellular redistribution and enhanced degradation of the G proteins Gq and G11 by endogenously expressed and transfected phospholipase C-coupled muscarinic m1 acetylcholine receptors. Mullaney I, et al. **Prog Brain Res** 1996;109:181–7 (44 ref.)

Participation of small GTP-binding proteins in m3 muscarinic acetylcholine receptor signalling to phospholipase D and C. Rümenapp U, et al. **Prog Brain Res** 1996;109:209–16 (42 ref.)

G16 as a universal G protein adapter: implications for agonist screening strategies. Milligan G, et al. **Trends Pharmacol Sci** 1996 Jul;17(7):235–7 (26 ref.)

[Phosphatidylinositol-specific phospholipase C isozymes and regulation of their activity] Pawelczyk T. **Postepy Biochem** 1996;42(3):290–8 (151 ref.) **(Pol)**

PHYSIOLOGY

The control of inositol lipid hydrolysis. Katan M. **Cancer Surv** 1996;27:199–211 (67 ref.)

Phospholipase C-gamma1: regulation of enzyme function and role in growth factor-dependent signal transduction. Kamat A, et al. **Cytokine Growth Factor Rev** 1997 Jun; 8(2):109–17 (86 ref.)

PHOSPHOLIPASE D

BLOOD

Small GTPase-regulated phospholipase D in granulocytes. Houle MG, et al. **Biochem Cell Biol** 1996;74(4):459–67 (96 ref.)

METABOLISM

Regulation of eukaryotic phosphatidylinositol-specific phospholipase C and phospholipase D. Singer WD, et al. **Annu Rev Biochem** 1997;66:475–509 (316 ref.)

New developments in phospholipase D. Exton JH. **J Biol Chem** 1997 Jun 20;272(25):15579–82 (77 ref.)

Regulation of phospholipase D by low molecular weight GTP-binding proteins. Kanaho Y, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):223–7 (15 ref.)

Phospholipase D: role in signal transduction and membrane traffic. Liscovitch M. **J Lipid Mediat Cell Signal** 1996 Sep; 14(1–3):215–21 (38 ref.)

Phospholipase D: enzymology, mechanisms of regulation, and function. Exton JH. **Physiol Rev** 1997 Apr;77(2):303–20 (231 ref.)

Participation of small GTP-binding proteins in m3 muscarinic acetylcholine receptor signalling to phospholipase D and C. Rümenapp U, et al. **Prog Brain Res** 1996;109:209–16 (42 ref.)

Phospholipase D: regulation by GTPases and protein kinase C and physiological relevance. Cockcroft S. **Prog Lipid Res** 1996 Dec;35(4):345–70 (270 ref.)

Evidence for a Ras/Ral signaling cascade. Feig LA, et al. **Trends Biochem Sci** 1996 Nov;21(11):438–41 (49 ref.)

PHYSIOLOGY

Exploration of the possible roles of phospholipase D and protein kinase C in the mechanism of ischemic preconditioning in the myocardium. Eskildsen-Helmond YE, et al. **Ann N Y Acad Sci** 1996 Sep 30;793:210–25 (79 ref.)

Phospholipase D: enzymology, mechanisms of regulation, and function. Exton JH. **Physiol Rev** 1997 Apr;77(2):303–20 (231 ref.)

PHOSPHOLIPASES

ANTAGONISTS & INHIBITORS

[Intracellular signal transmission of low density lipoprotein receptors in human monocytes] Balogh Z, et al. **Orv Hetil** 1997 Sep 7;138(36 Suppl 2):2318–21 (30 ref.) (Eng. Abstr.) **(Hun)**

PHYSIOLOGY

Cell signalling through guanine-nucleotide-binding regulatory proteins (G proteins) and phospholipases. Exton JH. **Eur J Biochem** 1997 Jan 15;243(1–2):10–20 (110 ref.)

Bacterial phospholipases and their role in virulence [see comments] Songer JG. **Trends Microbiol** 1997 Apr; 5(4):156–61 (65 ref.) Comment in: Trends Microbiol 1997 Jul;5(7):265.

PHOSPHOLIPASES A

Structure, function and regulation of Ca2+-sensitive cytosolic phospholipase A2 (cPLA2). Kramer RM, et al. **FEBS Lett** 1997 Jun 23;410(1):49–53 (44 ref.)

CHEMISTRY

Functional and structural features of plasma platelet-activating factor acetylhydrolase. Tjoelker LW, et al. **Adv Exp Med Biol** 1996;416:107–11 (10 ref.)

Phospholipase A2--a structural review. Arni RK, et al.

Toxicon 1996 Aug;34(8):827–41 (90 ref.)
Crystallization of bothropstoxin II isolated from the venom of Bothrops jararacussu. Bortoleto RK, et al. **Toxicon** 1996 May;34(5):614–7 (24 ref.)

GENETICS

Genetic basis of disease: studies of eicosanoids, and some complex disease traits. Tay A. **Clin Sci (Colch)** 1996 Sep; 91(3):264–6 (22 ref.)
A reassessment of the low molecular weight phospholipase A2 gene family in mammals. Tischfield JA.
J Biol Chem 1997 Jul 11;272(28):17247–50 (53 ref.)
The growing phospholipase A2 superfamily of signal transduction enzymes. Dennis EA. **Trends Biochem Sci** 1997 Jan;22(1):1–2 (26 ref.)

IMMUNOLOGY

Allergen dose dependent cytokine production regulates specific IgE and IgG antibody production. Blaser K.
Adv Exp Med Biol 1996;409:295–303 (16 ref.)
A role for secretory phospholipase A2 and C–reactive protein in the removal of injured cells. Hack CE, et al.
Immunol Today 1997 Mar;18(3):111–5 (49 ref.)

METABOLISM

Platelet–activating factor acetylhydrolase activity in human follicular fluid. Narahara H, et al. **Adv Exp Med Biol** 1996; 416:121–7 (27 ref.)
Binding proteins on synaptic membranes for certain phospholipases A2 with presynaptic toxicity. Tzeng MC, et al. **Adv Exp Med Biol** 1996;391:271–8 (46 ref.)
Activation of 85 kDa PLA2 by eicosanoids in human neutrophils and eosinophils. Wykle RL, et al.
Adv Exp Med Biol 1996;416:327–31 (16 ref.)
Characterization of plasmalogen–selective phospholipase A2 from bovine brain. Yang HC, et al. **Adv Exp Med Biol** 1996;416:309–13 (12 ref.)
Plasmalogens, phospholipases A2 and signal transduction. Farooqui AA, et al. **Brain Res Brain Res Rev** 1995 Sep; 21(2):152–61 (87 ref.)
Dopamine–1 receptor G–protein coupling and the involvement of phospholipase A2 in dopamine–1 receptor mediated cellular signaling mechanisms in the proximal tubules of SHR. Hussain T, et al. **Clin Exp Hypertens** 1997 Jan–Feb;19(1–2):131–40 (31 ref.)
Phospholipase A2 in mesangial cells: control mechanisms and functional importance. Pfeilschifter J, et al.
Exp Nephrol 1997 May–Jun;5(3):189–93 (30 ref.)
Structure, function and regulation of Ca2+–sensitive cytosolic phospholipase A2 (cPLA2). Kramer RM, et al. **FEBS Lett** 1997 Jun 23;410(1):49–53 (44 ref.)
Properties and regulation of cytosolic phospholipase A2. Leslie CC. **J Biol Chem** 1997 Jul 4;272(27):16709–12 (77 ref.)
Platelet–activating factor acetylhydrolases. Stafforini DM, et al. **J Biol Chem** 1997 Jul 18;272(29):17895–8 (55 ref.)
PAF and PAF acetylhydrolase in the nervous system. Hattori M, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):99–102 (9 ref.)
Cytosolic phospholipase A2 (cPLA2) and lipid mediator release in the brain. Kramer RM, et al.
J Lipid Mediat Cell Signal 1996 Sep;14(1–3):3–7 (14 ref.)
Plasmalogen–selective phospholipase A2 and its role in signal transduction. Yang HC, et al.
J Lipid Mediat Cell Signal 1996 Sep;14(1–3):9–13 (13 ref.)
Phospholipase A2 and its role in brain tissue. Farooqui AA, et al. **J Neurochem** 1997 Sep;69(3):889–901 (106 ref.)
Involvement of phospholipase A2 in neurodegeneration. Farooqui AA, et al. **Neurochem Int** 1997 Jun;30(6):517–22 (48 ref.)
Acute mechanical hyperalgesia in the rat can be produced by coactivation of spinal ionotropic AMPA and metabotropic glutamate receptors, activation of phospholipase A2 and generation of cyclooxygenase products. Meller ST, et al. **Prog Brain Res** 1996;110:177–92 (69 ref.)
Activation of human granulocyte type I–prophospholipase A2. Rae D, et al. **Scand J Gastroenterol Suppl** 1996;219:24–7 (20 ref.)
[Diversity of phospholipases A2 and their functions] Bereziat G. **C R Seances Soc Biol Fil** 1996;190(4):409–16 (21 ref.) (Eng. Abstr.) **(Fre)**
[Role of type II secreted phospholipase A2 in inflammatory processes] Jacques C, et al. **C R Seances Soc Biol Fil** 1996; 190(4):437–43 (40 ref.) (Eng. Abstr.) **(Fre)**
[Coupling of seven transmembrane domains receptors cytosolic PLA2: role of G proteins and protein kinases] Masliah J, et al. **C R Seances Soc Biol Fil** 1996; 190(4):417–23 (28 ref.) (Eng. Abstr.) **(Fre)**
[Phospholipase A2 and inflammation] Murakami M, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Dec;19(6):561–3 (10 ref.) **(Jpn)**

PHYSIOLOGY

The prevention of necrotizing enterocolitis. The role of platelet–activating factor acetylhydrolase. Muguruma K, et al. **Adv Exp Med Biol** 1996;416:129–33 (29 ref.)
Functional and structural features of plasma platelet–activating factor acetylhydrolase. Tjoelker LW, et al. **Adv Exp Med Biol** 1996;416:107–11 (10 ref.)
Potential involvement of type II phospholipase A2 in atherosclerosis. Hurt–Camejo E, et al. **Atherosclerosis** 1997 Jul 11;132(1):1–8 (91 ref.)
Regulation of rat kidney mesangial cell phospholipase A2. Hack N, et al. **Clin Exp Pharmacol Physiol** 1996 Jan; 23(1):71–5 (46 ref.)
Regulatory functions of phospholipase A2. Murakami M, et al. **Crit Rev Immunol** 1997;17(3–4):225–83 (436 ref.)
Function and inhibition of intracellular calcium–independent phospholipase A2. Balsinde J, et al. **J Biol Chem** 1997 Jun 27;272(26):16069–72 (44 ref.)
Roles of phospholipases A2 in brain cell and tissue injury associated with ischemia and excitotoxicity [corrected and republished article originally printed in J Lipid Mediat Cell Signal 1996 Sep; 14(1–3):15–23] Bonventre JV.
J Lipid Mediat Cell Signal 1997 Jul;16(3):199–208 (56 ref.)
Roles of phospholipases A2 in brain cell and tissue injury associated with ischemia and excitotoxicity [corrected and republished in J Lipid Mediat Cell Signal 1997 Jul;16(3):199–208] Bonventre JV.
J Lipid Mediat Cell Signal 1996 Sep;14(1–3):15–23 (55 ref.)

SECRETION

[Role of type II secreted phospholipase A2 in inflammatory processes] Jacques C, et al. **C R Seances Soc Biol Fil** 1996; 190(4):437–43 (40 ref.) (Eng. Abstr.) **(Fre)**
[A family of receptors for secretory phospholipases A2] Lambeau G, et al. **C R Seances Soc Biol Fil** 1996; 190(4):425–35 (42 ref.) (Eng. Abstr.) **(Fre)**

PHOSPHOLIPID ETHERS

PHARMACOLOGY

Protein kinase C inhibition by ET–18–OCH3 and related analogs. A target for cancer chemotherapy. Pauig SB, et al. **Adv Exp Med Biol** 1996;416:173–80 (49 ref.)

PHOSPHOLIPIDS

see related
ANTIBODIES, ANTIPHOSPHOLIPID
ANTIPHOSPHOLIPID SYNDROME

Lupus anticoagulants and thrombosis: the role of phospholipids. Esmon NL, et al. **Haematologica** 1997 Jul–Aug;82(4):474–7 (32 ref.)

ANALYSIS

Phospholipid–rich particles in commercial parenteral fat emulsions. An overview. Bach AC, et al.
Prog Lipid Res 1996;35(2):133–53 (232 ref.)

BIOSYNTHESIS

Genetic regulation of phospholipid biosynthesis in Saccharomyces cerevisiae. Greenberg ML, et al.
Microbiol Rev 1996 Mar;60(1):1–20 (230 ref.)

BLOOD

Phospholipid binding plasma proteins required for antiphospholipid antibody detection--an overview. McIntyre JA, et al. **Am J Reprod Immunol** 1997 Jan; 37(1):101–10 (86 ref.)
Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Zwaal RF, et al. **Blood** 1997 Feb 15;89(4):1121–32 (196 ref.)

CHEMISTRY

Molecular and physicochemical aspects of local anesthetic–membrane interaction. de–Paula E, et al.
Braz J Med Biol Res 1996 Jul;29(7):877–94 (199 ref.)
SDS–digested freeze–fracture replica labeling electron microscopy to study the two–dimensional distribution of integral membrane proteins and phospholipids in biomembranes: practical procedure, interpretation and application. Fujimoto K. **Histochem Cell Biol** 1997 Feb; 107(2):87–96 (30 ref.)
Molecular dynamics simulation of hydrated phospholipid bilayers. Kothekar V. **Indian J Biochem Biophys** 1996 Dec; 33(6):431–47 (122 ref.)
Molecular species analysis of phospholipids. Olsson NU, et al. **J Chromatogr B Biomed Appl** 1997 May 9;692(2):245–56 (122 ref.)

IMMUNOLOGY

Autoantibody screening for infertility: explaining the unexplained? Hatasaka HH, et al. **J Reprod Immunol** 1997 Sep;34(2):137–53 (30 ref.)

METABOLISM

Psoralen photosensitization: damages to nucleic acid and membrane lipid components. Caffieri S, et al.
Acta Biochim Pol 1996;43(1):241–6 (31 ref.)
Advances with phospholipid signalling as a target for anticancer drug development. Powis G, et al.
Acta Biochim Pol 1995;42(4):395–403 (51 ref.)
In vivo imaging of fatty acid incorporation into brain to examine signal transduction and neuroplasticity involving phospholipids. Rapoport SI, et al. **Ann N Y Acad Sci** 1997 May 30;820:56–73; discussion 73–4 (35 ref.)
Phospholipid transfer proteins revisited. Wirtz KW.
Biochem J 1997 Jun 1;324 (Pt 2):353–60 (95 ref.)
Rho is only ARF the story. Phospholipid signalling. Frohman MA, et al. **Curr Biol** 1996 Aug 1;6(8):945–7 (24 ref.)
Cationic lipophilic drugs: mechanisms of action, potential consequences, and reversibility. Kacew S, et al.
Drug Metab Rev 1997 Feb–May;29(1–2):355–68 (88 ref.)
Lysophosphatidic acid as a phospholipid mediator: pathways of synthesis. Gaits F, et al. **FEBS Lett** 1997 Jun 23; 410(1):54–8 (57 ref.)
Regulation of proliferation and apoptosis by Ras and Rho GTPases through specific phospholipid–dependent signaling. Lacal JC. **FEBS Lett** 1997 Jun 23;410(1):73–7 (59 ref.)
Tissue factor pathway inhibitor: regulation of its inhibitory activity by phospholipid surfaces. Lindhout T, et al.
Haemostasis 1996 Oct;26 Suppl 4:89–97 (23 ref.)
Effects of acid phospholipids on ARF activities: potential roles in membrane traffic. Kahn RA, et al.
J Lipid Mediat Cell Signal 1996 Sep;14(1–3):209–14 (22 ref.)
Phospholipid metabolism in Alzheimer's disease and in a human cholinergic cell. Kanfer JN, et al.
J Lipid Mediat Cell Signal 1996 Sep;14(1–3):361–3 (7 ref.)
Molecular properties of enzymes involved in diacylglycerol and phosphatidate metabolism. Kanoh H, et al.
J Lipid Mediat Cell Signal 1996 Sep;14(1–3):245–50 (18 ref.)
Apolipoprotein–mediated removal of cellular cholesterol and phospholipids. Oram JF, et al. **J Lipid Res** 1996 Dec; 37(12):2473–91 (164 ref.)
Antibodies against phospholipids other than cardiolipin: potential roles for both phospholipid and protein. Rauch J, et al. **Lupus** 1996 Oct;5(5):498–502 (62 ref.)
Possible relevance of phospholipid abnormalities and genetic interactions in psychiatric disorders: the relationship between dyslexia and schizophrenia. Horrobin DF, et al.
Med Hypotheses 1995 Dec;45(6):605–13 (70 ref.)
Membrane phospholipid alterations in Alzheimer's disease: deficiency of ethanolamine plasmalogens. Farooqui AA, et al. **Neurochem Res** 1997 Apr;22(4):523–7 (48 ref.)
Insulin–sensitive phospholipid signaling systems and glucose transport: an update. Farese RV.
Proc Soc Exp Biol Med 1996 Oct;213(1):1–12 (103 ref.)
The niacin challenge test in schizophrenia: past, present and future. Lin A, et al.
Prostaglandins Leukot Essent Fatty Acids 1996 Aug; 55(1–2):17–9 (15 ref.)
31P magnetic resonance spectroscopy studies in schizophrenia. Williamson PC, et al.
Prostaglandins Leukot Essent Fatty Acids 1996 Aug; 55(1–2):115–8 (19 ref.)
Hepatocellular transport and secretion of biliary phospholipids. Cohen DE. **Semin Liver Dis** 1996 May; 16(2):191–200 (68 ref.)
Has nature designed the cholesterol side chain for optimal interaction with phospholipids? Bittman R.
Subcell Biochem 1997;28:145–71 (85 ref.)
Cationic amphiphilic drug–induced phospholipidosis. Halliwell WH. **Toxicol Pathol** 1997 Jan–Feb;25(1):53–60 (87 ref.)
[Coupled transbilayer transport of peptides, lipids, and ions mediated by a peptide–lipid supramolecular complex pore] Matsuzaki K, et al. **Seikagaku** 1997 Feb;69(2):119–22 (14 ref.) **(Jpn)**
[Ca(2+)–phospholipid–dependent protein kinases and their role in regulating metabolic processes] Ostapchenko LI. **Ukr Biokhim Zh** 1995 Nov–Dec;67(6):3–11 (84 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Pharmacology of apolipoprotein A–I. Andersson LO.
Curr Opin Lipidol 1997 Aug;8(4):225–8 (18 ref.)

PHYSIOLOGY

Molecular basis for membrane phospholipid diversity: why are there so many lipids? Dowhan W.
Annu Rev Biochem 1997;66:199–232 (195 ref.)
Nuclear magnetic resonance spectroscopy: new insights into the pathophysiology of mood disorders. Soares JC, et al.
Depression 1996;4(1):14–30 (165 ref.)
Physiopathological significance of catalytic phospholipids in the generation of thrombin. Dachary–Prigent J, et al.
Semin Thromb Hemost 1996;22(2):157–64 (58 ref.)
[Signal transduction in the cell. Phospholipids as messenger molecules] Barańska J, et al. **Postepy Biochem** 1996; 42(2):140–5 (43 ref.) **(Pol)**

THERAPEUTIC USE

Heterocyclic alkylphospholipids with an improved therapeutic range. Hilgard P, et al. **Adv Exp Med Biol** 1996; 416:157–64 (6 ref.)

PHOSPHOMONOESTERASES see **PHOSPHORIC MONOESTER HYDROLASES**

PHOSPHONOFORMATE see **FOSCARNET**

PHOSPHONOFORMIC ACID see **FOSCARNET**

PHOSPHONOMYCIN see **FOSFOMYCIN**

PHOSPHOPROTEIN PHOSPHATASE

BLOOD

Non-receptor protein tyrosine kinases and phosphatases in human platelets. Jackson SP, et al. **Thromb Haemost** 1996 Nov;76(5):640-50 (151 ref.)

CHEMISTRY

Modular peptide recognition domains in eukaryotic signaling. Kuriyan J, et al. **Annu Rev Biophys Biomol Struct** 1997; 26:259-88 (102 ref.)

Calcineurin: not just a simple protein phosphatase. Guerini D. **Biochem Biophys Res Commun** 1997 Jun 18;235(2):271-5 (50 ref.)

Protein phosphatases: structures and implications. Jia Z. **Biochem Cell Biol** 1997;75(1):17-26 (57 ref.)

Protein phosphatases. Barford D. **Curr Opin Struct Biol** 1995 Dec;5(6):728-34 (64 ref.)

Calcineurin-immunosuppressor complexes. Stoddard BL, et al. **Curr Opin Struct Biol** 1996 Dec;6(6):770-5 (39 ref.)

Molecular mechanisms of the protein serine/threonine phosphatases. Barford D. **Trends Biochem Sci** 1996 Nov; 21(11):407-12 (54 ref.)

GENETICS

Cdc25 protein phosphatases in cell proliferation. Draetta G, et al. **Biochim Biophys Acta** 1997 Apr 18;1332(2):M53-63 (79 ref.)

Cell cycle: on target with Myc. Zörnig M, et al. **Curr Biol** 1996 Dec 1;6(12):1553-6 (22 ref.)

METABOLISM

Angiotensin II stimulates protein phosphatase 2A activity in cultured neuronal cells via type 2 receptors in a pertussis toxin sensitive fashion. Huang XC, et al. **Adv Exp Med Biol** 1996;396:209-15 (25 ref.)

Modulation of the calcium sensitivity of the smooth muscle contractile apparatus: molecular mechanisms, pharmacological and pathophysiological implications. Savineau JP, et al. **Fundam Clin Pharmacol** 1997; 11(4):289-99 (103 ref.)

Dissection of protein kinase and phosphatase targeting interactions. Scott JD. **Soc Gen Physiol Ser** 1997;52:227-39 (36 ref.)

Molecular mechanisms of the protein serine/threonine phosphatases. Barford D. **Trends Biochem Sci** 1996 Nov; 21(11):407-12 (54 ref.)

Novel protein serine/threonine phosphatases: variety is the spice of life. Cohen PT. **Trends Biochem Sci** 1997 Jul; 22(7):245-51 (55 ref.)

More on target with protein phosphorylation: conferring specificity by location. Faux MC, et al. **Trends Biochem Sci** 1996 Aug;21(8):312-5 (48 ref.)

Protein aspartate phosphatases control the output of two-component signal transduction systems. Perego M, et al. **Trends Genet** 1996 Mar;12(3):97-101 (29 ref.)

[Serine/threonine phosphoprotein phosphatases in brain tissue] Zylińska L, et al. **Postepy Biochem** 1995;41(4):276-82 (52 ref.) **(Pol)**

PHYSIOLOGY

Novel protein phosphatases that may participate in cell signaling. Cohen PT, et al. **Adv Pharmacol** 1996;36:67-89 (74 ref.)

Calcineurin: not just a simple protein phosphatase. Guerini D. **Biochem Biophys Res Commun** 1997 Jun 18;235(2):271-5 (50 ref.)

Regulation of vascular smooth muscle contraction. The roles of Ca2+, protein kinase C and myosin light chain phosphatase. Takuwa Y. **Jpn Heart J** 1996 Nov; 37(6):793-813 (116 ref.)

Molecular mechanisms of the protein serine/threonine phosphatases. Barford D. **Trends Biochem Sci** 1996 Nov; 21(11):407-12 (54 ref.)

Calcineurin regulation of synaptic function: from ion channels to transmitter release and gene transcription. Yakel JL. **Trends Pharmacol Sci** 1997 Apr;18(4):124-34 (63 ref.)

Yeast protein serine/threonine phosphatases: multiple roles and diverse regulation. Stark MJ. **Yeast** 1996 Dec; 12(16):1647-75 (200 ref.)

[Calcineurin-mediated signalling important for growth regulation in yeast] Hirata D, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1695-703 (40 ref.) **(Jpn)**

[Phosphoprotein phosphatases and signal transduction in plant cells] Oka A, et al. **Tanpakushitsu Kakusan Koso** 1997 Apr;42(5):736-43 (48 ref.) **(Jpn)**

PHOSPHOPROTEIN PHOSPHOHYDROLASE see **PHOSPHOPROTEIN PHOSPHATASE**

PHOSPHOPROTEIN PP53 see **PROTEIN P53**

PHOSPHOPROTEINS

[Interferon] Tanaka H. **Gan To Kagaku Ryoho** 1997 Sep; 24(11):1471-6 (51 ref.) (Eng. Abstr.) **(Jpn)**

[The function of the transcription factor, IRF family, in the interferon system] Harada H. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1273-81 (32 ref.) **(Jpn)**

ANALYSIS

PP3 component of bovine milk: a phosphorylated whey glycoprotein. Girardet JM, et al. **J Dairy Res** 1996 May; 63(2):333-50 (79 ref.)

Visualization of protein kinase activities in single cells by antibodies against phosphorylated vimentin and GFAP. Inagaki N, et al. **Neurochem Res** 1996 Jul;21(7):795-800 (30 ref.)

BIOSYNTHESIS

Lithostathine: place in chronic pancreatitis, pathogenesis. Laugier R, et al. **Acta Gastroenterol Belg** 1996 Jul-Sep; 59(3):188-90 (40 ref.)

CHEMISTRY

Proteins P1, P2, and P0, components of the eukaryotic ribosome stalk. New structural and functional aspects. Remacha M, et al. **Biochem Cell Biol** 1995 Nov-Dec; 73(11-12):959-68 (49 ref.)

Tyrosines 113, 128, and 145 of SLP-76 are required for optimal augmentation of NFAT promoter activity. Fang N, et al. **J Immunol** 1996 Nov 1;157(9):3769-73 (16 ref.)

GENETICS

Role of the cyclin-dependent kinase 4 and 6 inhibitor gene family p15, p16, p18 and p19 in leukemia and lymphoma. Siebert R, et al. **Leuk Lymphoma** 1996 Nov;23(5-6):505-20 (107 ref.)

New developments in congenital lipoid adrenal hyperplasia and steroidogenic acute regulatory protein [published erratum appears in Pediatr Clin North Am 1997 Jun;44(3):viii] Saenger P. **Pediatr Clin North Am** 1997 Apr; 44(2):397-421 (95 ref.)

Regulation of expression of the steroidogenic acute regulatory protein (StAR) gene: a central role for steroidogenic factor 1 [published erratum appears in Steroids 1997 Apr;62(4):395] Sugawara T, et al. **Steroids** 1997 Jan;62(1):5-9 (12 ref.)

IMMUNOLOGY

Stimulation of gamma delta T cells by phosphoantigens. Fournié JJ, et al. **Res Immunol** 1996 Jun;147(5):338-47 (60 ref.)

METABOLISM

Cellular regulation by protein phosphorylation: a historical overview. Fischer EH. **Biofactors** 1997;6(3):367-74 (42 ref.)

Participation of annexins in protein phosphorylation. Rothhut B. **Cell Mol Life Sci** 1997 Jun;53(6):522-6 (51 ref.)

Activity of the retinoblastoma family proteins, pRB, p107, and p130, during cellular proliferation and differentiation. Sidle A, et al. **Crit Rev Biochem Mol Biol** 1996 Jun; 31(3):237-71 (197 ref.)

Threshold responses to the dorsal regulatory gradient and the subdivision of primary tissue territories in the Drosophila embryo. Rusch J, et al. **Curr Opin Genet Dev** 1996 Aug;6(4):416-23 (70 ref.)

Molecular analysis of the fyn-complex: cloning of SKAP55 and SLAP-130, two novel adaptor proteins which associate with fyn and may participate in the regulation of T cell receptor-mediated signaling. Schraven B, et al. **Immunol Lett** 1997 Jun 1;57(1-3):165-9 (26 ref.)

Interactions between the components of the human NADPH oxidase: intrigues in the phox family. Leusen JH, et al. **J Lab Clin Med** 1996 Nov;128(5):461-76 (158 ref.)

Twinkle, twinkle little StAR, how we wonder what you are [comment] Estabrook RW, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13552-4 (12 ref.) Comment on: Proc Natl Acad Sci U S A 1996 Nov 26;93(24):13731-6.

Molecular architecture of tight junctions: occludin and ZO-1. Tsukita S, et al. **Soc Gen Physiol Ser** 1997;52:69-76 (27 ref.)

Regulation of expression of the steroidogenic acute regulatory protein (StAR) gene: a central role for steroidogenic factor 1 [published erratum appears in Steroids 1997 Apr;62(4):395] Sugawara T, et al. **Steroids** 1997 Jan;62(1):5-9 (12 ref.)

[ERM (ezrin/radixin/moesin) as crosslinkers between actin filaments and plasma membranes] Tsukita S. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1899-905 (44 ref.) **(Jpn)**

PHYSIOLOGY

Presynaptic phosphoprotein B-50/GAP-43 in neuronal and synaptic plasticity. Biewenga JE, et al. **Acta Biochim Pol** 1996;43(2):327-38 (121 ref.)

Insulin receptor/IRS-1/PI 3-kinase signaling system in corticosteroid-induced insulin resistance. Folli F, et al. **Acta Diabetol** 1996 Sep;33(3):185-92 (82 ref.)

IRF-1: the transcription factor linking the interferon response and oncogenesis. Taniguchi T, et al. **Biochim Biophys Acta** 1997 Aug 8;1333(1):M9-17 (58 ref.)

The IRS-signalling system during insulin and cytokine action. Yenush L, et al. **Bioessays** 1997 Jun;19(6):491-500 (81 ref.)

A StAR search: implications in controlling steroidgenesis. Stocco DM. **Biol Reprod** 1997 Feb;56(2):328-36 (116 ref.)

ERM (ezrin/radixin/moesin) family: from cytoskeleton to signal transduction. Tsukita S, et al. **Curr Opin Cell Biol** 1997 Feb;9(1):70-5 (42 ref.)

The steroidogenic acute regulatory (StAR) protein two years later. An update. Stocco DM. **Endocrine** 1997 Apr; 6(2):99-109 (146 ref.)

Tyrosine phosphorylation of p130Cas in cell adhesion and transformation. Nojima Y, et al. **Hum Cell** 1996 Sep; 9(3):169-74 (19 ref.)

IRF-1 and IRF-2 as regulators of the interferon system and cell growth. Taniguchi T. **Indian J Biochem Biophys** 1995 Oct;32(5):235-9 (33 ref.)

Interferon regulatory factors: growth control and histone gene regulation--it's not just interferon anymore. Vaughan PS, et al. **J Mol Med** 1997 May;75(5):348-59 (128 ref.)

The role of the steroidogenic acute regulatory protein in steroidogenesis. Stocco DM, et al. **Steroids** 1997 Jan; 62(1):29-36 (87 ref.)

PHAS/4E-BPs as regulators of mRNA translation and cell proliferation. Lawrence JC Jr, et al. **Trends Biochem Sci** 1997 Sep;22(9):345-9 (46 ref.)

[Transcriptional regulation of factor IX promoter by HNF 4, ARP 1 and COUP] Naka H. **Rinsho Byori** 1997 Feb; Suppl 104:107-16 (13 ref.) **(Jpn)**

PHOSPHOPYRUVATE HYDRATASE

CHEMISTRY

Structural and mechanistic studies of enolase. Reed GH, et al. **Curr Opin Struct Biol** 1996 Dec;6(6):736-43 (27 ref.)

DIAGNOSTIC USE

[Value of tumor markers for screening and diagnosis (except prognostic and surveillance values) in primary bronchial cancers] Grivaux M. **Rev Mal Respir** 1997 Apr;14 Suppl 3:S15-9 (41 ref.) **(Fre)**

[Neuron specific enolase] Milleron B. **Rev Mal Respir** 1997 Apr;14 Suppl 3:S36-7 (12 ref.) **(Fre)**

[Value of serial tumor markers for the detection of recurrences] Quoix E. **Rev Mal Respir** 1997 Apr;14 Suppl 3:S27-9 (32 ref.) **(Fre)**

[Which tumor markers should be used in primary bronchial cancers?] Schuller MP, et al. **Rev Mal Respir** 1997 Apr; 14 Suppl 3:S9-14 (29 ref.) **(Fre)**

[Value of tumor markers in surveillance of primary bronchial cancers and to evaluate therapy] Sculier JP. **Rev Mal Respir** 1997 Apr;14 Suppl 3:S23-6 (29 ref.) **(Fre)**

[Value of serial tumor markers for determining the prognosis and predicting treatment response and survival] Souquet PJ. **Rev Mal Respir** 1997 Apr;14 Suppl 3:S20-2 (23 ref.) **(Fre)**

PHOSPHORESCENCE see **LUMINESCENCE**

PHOSPHORIBOSYL PYROPHOSPHATE AMIDOTRANSFERASE see **AMIDOPHOSPHORIBOSYLTRANSFERASE**

PHOSPHORIBOSYL PYROPHOSPHATE SYNTHETASE see **RIBOSE-PHOSPHATE PYROPHOSPHOKINASE**

PHOSPHORIC DIESTER HYDROLASE INHIBITORS see **PHOSPHODIESTERASE INHIBITORS**

PHOSPHORIC DIESTER HYDROLASES

CHEMISTRY

Intracellular targeting, interaction with Src homology 3 (SH3) domains and rolipram-detected conformational switches in cAMP-specific PDE4A phosphodiesterase. Houslay MD, et al. **Biochem Soc Trans** 1997 May; 25(2):374-81 (50 ref.)

Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Souness JE, et al. **Cell Signal** 1997 May-Jun;9(3-4):227-36 (66 ref.)

GENETICS

Intracellular targeting, interaction with Src homology 3 (SH3) domains and rolipram-detected conformational switches in cAMP-specific PDE4A phosphodiesterase. Houslay MD, et al. **Biochem Soc Trans** 1997 May; 25(2):374-81 (50 ref.)

METABOLISM

Phosphodiesterase 4 and tolerance to beta 2-adrenoceptor agonists in asthma. Giembycz MA. **Trends Pharmacol Sci** 1996 Sep;17(9):331-6 (62 ref.)

Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Teixeira MM, et al. **Trends Pharmacol Sci** 1997 May;18(5):164-71 (101 ref.)

PHOSPHORIC MONOESTER HYDROLASES

Anchoring and scaffold proteins for kinases and phosphatases. Lester LB, et al. **Recent Prog Horm Res** 1997; 52:409–29; discussion 429–30 (98 ref.)

ANTAGONISTS & INHIBITORS

Inositol monophosphatase inhibitors--lithium mimetics? Atack JR. **Med Res Rev** 1997 Mar;17(2):215–24 (32 ref.)

CHEMISTRY

The MutT proteins or "Nudix" hydrolases, a family of versatile, widely distributed, "housecleaning" enzymes. Bessman MJ, et al. **J Biol Chem** 1996 Oct 11; 271(41):25059–62 (47 ref.)

DRUG EFFECTS

Inositol monophosphatase, the putative therapeutic target for lithium. Atack JR. **Brain Res Brain Res Rev** 1996 Aug; 22(2):183–90 (60 ref.)

GENETICS

The family of inositol and phosphatidylinositol polyphosphate 5-phosphatases. Drayer AL, et al. **Biochem Soc Trans** 1996 Nov;24(4):1001–5 (36 ref.)

Novel gene families involved in neural pathfinding. Müller BK, et al. **Curr Opin Genet Dev** 1996 Aug;6(4):469–74 (61 ref.)

The role of the mutT gene of Escherichia coli in maintaining replication fidelity. Fowler RG, et al. **FEMS Microbiol Rev** 1997 Aug;21(1):43–54 (90 ref.)

METABOLISM

The road less travelled: taming phosphatases. Widlanski TS, et al. **Chem Biol** 1997 Jul;4(7):489–92 (17 ref.)

MutT-related error avoidance mechanism for DNA synthesis. Sekiguchi M. **Genes Cells** 1996 Feb;1(2):139–45 (37 ref.)

The MutT proteins or "Nudix" hydrolases, a family of versatile, widely distributed, "housecleaning" enzymes. Bessman MJ, et al. **J Biol Chem** 1996 Oct 11; 271(41):25059–62 (47 ref.)

PHYSIOLOGY

Regulation of second messengers by the inositol polyphosphate 5-phosphatases. Mitchell CA, et al. **Biochem Soc Trans** 1996 Nov;24(4):994–1000 (40 ref.)

The emerging field of receptor-mediated inhibitory signaling: SHP or SHIP? Scharenberg AM, et al. **Cell** 1996 Dec 13; 87(6):961–4 (16 ref.)

SHIP, a new player in cytokine-induced signalling. Liu L, et al. **Leukemia** 1997 Feb;11(2):181–4 (38 ref.)

SECRETION

Stimulus-secretion coupling of pancreatic digestive enzyme secretion. Williams JA, et al. **Digestion** 1997;58 Suppl 1:42–5 (16 ref.)

PHOSPHORUS

see related
ORGANOPHOSPHORUS COMPOUNDS

Stimulable phosphor plates in chest radiology. Tylén U. **Eur Radiol** 1997;7 Suppl 3:S83–6 (16 ref.)

BLOOD

Benefits of calcitriol therapy and serum phosphorus control in dogs and cats with chronic renal failure. Both are essential to prevent of suppress toxic hyperparathyroidism. Nagode LA, et al. **Vet Clin North Am Small Anim Pract** 1996 Nov; 26(6):1293–330 (236 ref.)

METABOLISM

Phosphorus economy in a healthy man. Pilarczyk M. **Ann Univ Mariae Curie Sklodowska [Med]** 1995;50:111–3 (4 ref.)

Metabolism of micro-organisms responsible for enhanced biological phosphorus removal from wastewater. Use of dynamic enrichment cultures. van Loosdrecht MC, et al. **Antonie Van Leeuwenhoek** 1997 Feb;71(1–2):109–16 (34 ref.)

Pathophysiology of calcium, phosphorus, and magnesium metabolism in animals. Rosol TJ, et al. **Vet Clin North Am Small Anim Pract** 1996 Sep; 26(5):1155–84 (127 ref.)

[Role of phosphorus in hyperparathyroidism secondary to non-dialysed adult chronic renal insufficiency] Combe C, et al. **Nephrologie** 1996;17(3):149–56 (68 ref.) (Eng. Abstr.) **(Fre)**

[Normal phosphorus and calcium metabolism during pregnancy and breast feeding] Koeger AC, et al. **Rev Med Interne** 1997 Jul;18(7):533–45 (30 ref.) (Eng. Abstr.) **(Fre)**

[Pathological phosphorus and calcium metabolism during pregnancy and breast feeding] Koeger AC, et al. **Rev Med Interne** 1997 Jul;18(7):546–52 (36 ref.) (Eng. Abstr.) **(Fre)**

[Regulation of calcium and phosphorus metabolism] Burrows R. **Rev Med Chil** 1996 Aug;124(8 Suppl):9–14 (15 ref.) **(Spa)**

PHOSPHORUS, DIETARY

ADMINISTRATION & DOSAGE

Adaptation to changes in dietary phosphorus intake in health and in renal failure. Loghman-Adham M. **J Lab Clin Med** 1997 Feb;129(2):176–88 (153 ref.)

METABOLISM

Renal brush border membrane Na/Pi-cotransport: molecular aspects in PTH-dependent and dietary regulation. Murer H, et al. **Kidney Int** 1996 Jun;49(6):1769–73 (44 ref.)

PHARMACOKINETICS

Mechanisms of intestinal phosphorus absorption and availability of dietary phosphorus in pigs. Schröder B, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Jun; 103(6):209–14 (87 ref.)

PHOSPHORUS METABOLISM DISORDERS

CHEMICALLY INDUCED

Oral Fleet Phospho-Soda laxative-induced hyperphosphatemia and hypocalcemic tetany in an adult: report of a case. Vukasin P, et al. **Dis Colon Rectum** 1997 Apr;40(4):497–9 (11 ref.)

GENETICS

Benign familial hyperphosphatasemia: a report of two families and review of the literature. Crespo-Peña M, et al. **Clin Exp Rheumatol** 1997 Jul-Aug;15(4):425–31 (36 ref.)

PHOSPHORUS RADIOISOTOPES

ADVERSE EFFECTS

Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias". Najean Y, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:111–9 (42 ref.)

DIAGNOSTIC USE

[Influenced factors of nuclease P1-enhanced 32 P-postlabeling method] Chang P, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1996 Mar; 30(2):111–3 (22 ref.) **(Chi)**

METABOLISM

Detection of DNA modifications by the 32P-postlabelling assay. Phillips DH. **Mutat Res** 1997 Aug 1;378(1–2):1–12 (100 ref.)

PHOSPHORYLASE B

METABOLISM

[Structure, regulation, and denaturation of muscle glycogen phosphorylase b] Livanova NB, et al. **Biokhimiia** 1996 Nov; 61(11):2005–17 (81 ref.) (Eng. Abstr.) **(Rus)**

PHOSPHORYLASE KINASE

DEFICIENCY

[Exercise intolerance caused by muscular phosphorylase kinase deficiency. Contribution of in vivo metabolic studies] Laforêt P, et al. **Rev Neurol (Paris)** 1996 Jun-Jul; 152(6–7):458–64 (27 ref.) (Eng. Abstr.) **(Fre)**

PHOSPHORYLCHOLINE, ACETYL GLYCERYL ETHER
see **PLATELET ACTIVATING FACTOR**

PHOSPHOTRANSFERASES

[Nucleoside kinases and new types of antitumor nucleosides] Matsuda A. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1594–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Role of cellular kinases in the gene expression of nonsegmented negative strand RNA viruses. De BP, et al. **Biol Chem** 1997 Jun;378(6):489–93 (29 ref.)

A comparative review of the sites of histoenzymatic dephosphorylating activities and of gene expression in developing limb buds of mammalian and avian species. Milaire J. **Eur J Morphol** 1997 Jul;35(3):143–69 (193 ref.)

METABOLISM

The NTP phosphate donor in kinase reactions: is ATP a monopolist? Shugar D. **Acta Biochim Pol** 1996;43(1):9–23 (68 ref.)

Enzymes in mineralizing systems: state of the art. Golub EE. **Connect Tissue Res** 1996;35(1–4):183–8 (66 ref.)

Modular multidomain phosphoryl transfer proteins of bacteria. Reizer J, et al. **Curr Opin Struct Biol** 1997 Jun; 7(3):407–15 (51 ref.)

Signal transduction via the histidyl-aspartyl phosphorelay. Egger LA, et al. **Genes Cells** 1997 Mar;2(3):167–84 (148 ref.)

PHYSIOLOGY

Role of cellular kinases in the gene expression of nonsegmented negative strand RNA viruses. De BP, et al. **Biol Chem** 1997 Jun;378(6):489–93 (29 ref.)

PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR)

Phosphatidylinositol 3-kinase related kinases. Abraham RT. **Curr Opin Immunol** 1996 Jun;8(3):412–8 (69 ref.)

Heterogeneity of diacylglycerol kinase in terms of molecular structure, biochemical characteristics and gene expression localization in the brain. Goto K, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):251–7 (7 ref.)

Phosphoinositide 3-kinases: a conserved family of signal transducers. Vanhaesebroeck B, et al. **Trends Biochem Sci** 1997 Jul;22(7):267–72 (53 ref.)

[Phosphatidylinositol 3-kinase and low molecular weight GTP-binding proteins] Kodaki T. **Seikagaku** 1996 Nov; 68(11):1704–8 (23 ref.) **(Jpn)**

[Phosphoinositide 3-kinase] Hazeki O. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):394–402 (113 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Advances with phospholipid signalling as a target for anticancer drug development. Powis G, et al. **Acta Biochim Pol** 1995;42(4):395–403 (51 ref.)

CHEMISTRY

The phosphatidylinositol 4-phosphate 5-kinase family. Loijens JC, et al. **Adv Enzyme Regul** 1996;36:115–40 (90 ref.)

The sugar kinase/heat shock protein 70/actin superfamily: implications of conserved structure for mechanism. Hurley JH. **Annu Rev Biophys Biomol Struct** 1996;25:137–62 (75 ref.)

[PI3-kinase superfamily: structures and functions] Kimura K, et al. **Seikagaku** 1996 May;68(5):362–7 (15 ref.) **(Jpn)**

GENETICS

[Diverse structures of diacylglycerol kinase gene family] Sakane F. **Seikagaku** 1997 Mar;69(3):176–81 (15 ref.) **(Jpn)**

METABOLISM

Structure-activity relationships for phosphorylation of nucleoside analogs to monophosphates by nucleoside kinases. Johansson NG, et al. **Acta Biochim Pol** 1996; 43(1):143–60 (77 ref.)

Insulin receptor/IRS-1/PI 3-kinase signaling system in corticosteroid-induced insulin resistance. Folli F, et al. **Acta Diabetol** 1996 Sep;33(3):185–92 (82 ref.)

The phosphatidylinositol 4-phosphate 5-kinase family. Loijens JC, et al. **Adv Enzyme Regul** 1996;36:115–40 (90 ref.)

Phosphoinositide 3-kinase activation and platelet function. Rittenhouse SE. **Blood** 1996 Dec 15;88(12):4401–14 (109 ref.)

Calcium signalling: sphingosine kinase versus phospholipase C? Beaven MA. **Curr Biol** 1996 Jul 1;6(7):798–801 (14 ref.)

Signalling enzymes: bursting with potential. Braselmann S, et al. **Curr Biol** 1997 Aug 1;7(8):R470–3 (22 ref.)

Responses to DNA damage and regulation of cell cycle checkpoints by the ATM protein kinase family. Hoekstra MF. **Curr Opin Genet Dev** 1997 Apr;7(2):170–5 (48 ref.)

The recognition of DNA damage. Jackson SP. **Curr Opin Genet Dev** 1996 Feb;6(1):19–25 (66 ref.)

Role of PI 3-kinase and SH-PTP2 in insulin action. Kasuga M. **Diabet Med** 1996 Sep;13(9 Suppl 6):S87–9 (23 ref.)

Inhibitory effect of wortmannin on phosphatidylinositol 3-kinase-mediated cellular events. Hazeki O, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):259–61 (8 ref.)

Molecular properties of enzymes involved in diacylglycerol and phosphatidate metabolism. Kanoh H, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):245–50 (18 ref.)

The role of phosphoinositide 3-kinase in insulin signalling. Shepherd PR, et al. **J Mol Endocrinol** 1996 Dec; 17(3):175–84 (92 ref.)

BCR/ABL regulation of PI-3 kinase activity. Calabretta B, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):473–6 (41 ref.)

Signalling through the lipid products of phosphoinositide-3-OH kinase. Toker A, et al. **Nature** 1997 Jun 12;387(6634):673–6 (47 ref.)

PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Marte BM, et al. **Trends Biochem Sci** 1997 Sep;22(9):355–8 (41 ref.)

PHYSIOLOGY

Regulation of 'signalling diacylglycerol' in cells: the importance of diacylglycerol kinase. Hodgkin MN, et al. **Biochem Soc Trans** 1996 Nov;24(4):991–4 (15 ref.)
The study of phosphoinositide 3-kinase function. Vanhaesebroeck B, et al. **Cancer Surv** 1996;27:249–70 (110 ref.)
PI3K: downstream AKTion blocks apoptosis. Franke TF, et al. **Cell** 1997 Feb 21;88(4):435–7 (20 ref.)
Using structure to define the function of phosphoinositide 3-kinase family members. Domin J, et al. **FEBS Lett** 1997 Jun 23;410(1):91–5 (78 ref.)
Regulating integrin-mediated adhesion: one more function for PI 3-kinase? Shimizu Y, et al. **Immunol Today** 1996 Dec;17(12):565–73 (82 ref.)
PI 3-kinase: a pivotal pathway in T-cell activation? Ward SG, et al. **Immunol Today** 1996 Apr;17(4):187–97 (116 ref.)
[PI3-kinase superfamily: structures and functions] Kimura K, et al. **Seikagaku** 1996 May;68(5):362–7 (15 ref.) **(Jpn)**

PHOSPHOTRANSFERASES, ATP see **PHOSPHOTRANSFERASES**

PHOSPHOTRANSFERASES (NITROGENOUS GROUP ACCEPTOR)

METABOLISM

Enzyme I: the first protein and potential regulator of the bacterial phosphoenolpyruvate: glycose phosphotransferase system. Chauvin F, et al. **Res Microbiol** 1996 Jul–Sep; 147(6–7):471–9 (24 ref.)

PHOSPHOTRANSFERASES (OTHER SUBSTITUTED PHOSPHATE GROUPS) see **TRANSFERASES (OTHER SUBSTITUTED PHOSPHATE GROUPS)**

PHOSPHOTRANSFERASES (PHOSPHATE GROUP ACCEPTOR)

[World smallest motor, ATP synthase] Yoshida M, et al. **Tanpakushitsu Kakusan Koso** 1997 Jul;42(9):1396–406 (21 ref.) **(Jpn)**

GENETICS

The ovine model of neuronal ceroid lipofuscinosis (NCL): its contribution to understanding the pathogenesis of Batten disease. Jolly RD. **Neuropediatrics** 1997 Feb;28(1):60–2 (30 ref.)

PHOSPHOTYROSINE

Inhibition of protein tyrosine phosphorylation in endothelial cells: relationship to antiproliferative action of genistein. Koroma BM, et al. **Biochem Soc Trans** 1997 Feb; 25(1):35–40 (37 ref.)

CHEMISTRY

Structure and function of the phosphotyrosine binding (PTB) domain. Zhou MM, et al. **Prog Biophys Mol Biol** 1995; 64(2–3):221–35 (53 ref.)

METABOLISM

Structure and function of the phosphotyrosine binding (PTB) domain. Zhou MM, et al. **Prog Biophys Mol Biol** 1995; 64(2–3):221–35 (53 ref.)

PHOSPHOTYROSINE PHOSPHATASE see **PROTEIN-TYROSINE-PHOSPHATASE**

PHOTIC STIMULATION

ALBERT: a real-time visual feedback computer tool for professional vocal development. Rossiter D, et al. **J Voice** 1996 Dec;10(4):321–36 (79 ref.)

METHODS

Cerebral activity during visual stimulation: a positron emission tomography and functional magnetic resonance imaging study. Schiefer U, et al. **Ger J Ophthalmol** 1996 Mar;5(2):109–17 (63 ref.)

PHOTOAGING OF SKIN see **SKIN AGING**

PHOTOALLERGY see **DERMATITIS, PHOTOALLERGIC**

PHOTOBIOLOGY

see related
LIGHT
PHOTOCHEMISTRY
PHOTOSYNTHESIS

Interrelationship of photocarcinogenicity, photomutagenicity and phototoxicity. Loveday KS. **Photochem Photobiol** 1996 Apr;63(4):369–72 (26 ref.)

METHODS

Benzophenone photoprobes for phosphoinositides, peptides and drugs. Prestwich GD, et al. **Photochem Photobiol** 1997 Feb;65(2):222–34 (95 ref.)

PHOTOCHEMICAL REACTION CENTER, BACTERIAL see **PHOTOSYNTHETIC REACTION CENTER, BACTERIAL**

PHOTOCHEMICAL REACTION CENTER, PLANT see **PHOTOSYNTHETIC REACTION CENTER, PLANT**

PHOTOCHEMISTRY

METHODS

Photocross-linking of nucleic acids to associated proteins. Meisenheimer KM, et al. **Crit Rev Biochem Mol Biol** 1997; 32(2):101–40 (121 ref.)
Caged compounds: tools for illuminating neuronal responses and connections. Nerbonne JM. **Curr Opin Neurobiol** 1996 Jun;6(3):379–86 (54 ref.)
[Current methods for processing of radiographic medical films] Koveshnikov AI. **Vestn Rentgenol Radiol** 1997 Jul-Aug;(4):44–9 (3 ref.) **(Rus)**

TRENDS

Photothermal beam deflection calorimetry in solution photochemistry: recent progress and future prospects. Falvey DE. **Photochem Photobiol** 1997 Jan;65(1):4–9 (34 ref.)

PHOTOCHEMOTHERAPY

Biochemical aspects of psoralen photochemotherapy. Moor AC, et al. **Clin Dermatol** 1996 Jul–Aug;14(4):353–65 (121 ref.)
Current status of photodynamic therapy in dermatology. Bissonnette R, et al. **Dermatol Clin** 1997 Jul;15(3):507–19 (91 ref.)
Esophageal varices obliterated by photodynamic therapy for coexisting early esophageal carcinoma. Ido K, et al. **Gastrointest Endosc** 1997 May;45(5):420–3 (8 ref.)
Photodynamic therapy with systemic administration of photosensitizers in dermatology. Calzavara-Pinton PG, et al. **J Photochem Photobiol B** 1996 Nov;36(2):225–31 (35 ref.)
Purpurins and benzochlorins as sensitizers for photodynamic therapy. Garbo GM. **J Photochem Photobiol B** 1996 Jul; 34(2–3):109–16 (64 ref.)
PDT light dosimetry revisited. Grossweiner LI. **J Photochem Photobiol B** 1997 Apr;38(2–3):258–68 (35 ref.)
Photophysical and photobiological processes in the photodynamic therapy of tumours. Ochsner M. **J Photochem Photobiol B** 1997 May;39(1):1–18 (172 ref.)
Role of delivery vehicles for photosensitizers in the photodynamic therapy of tumours. Reddi E. **J Photochem Photobiol B** 1997 Feb;37(3):189–95 (50 ref.)
Photodynamic therapy: a promising new modality for the treatment of cancer. Schuitmaker JJ, et al. **J Photochem Photobiol B** 1996 Jun;34(1):3–12 (99 ref.)
Photodynamic therapy in lung cancer. A review. Sutedja TG, et al. **J Photochem Photobiol B** 1996 Nov; 36(2):199–204 (63 ref.)
Topical photodynamic therapy in dermatology. Szeimies RM, et al. **J Photochem Photobiol B** 1996 Nov;36(2):213–9 (43 ref.)
The concept of laser phototherapy. Castro DJ, et al. **Otolaryngol Clin North Am** 1996 Dec;29(6):1011–29 (84 ref.)
The biology of photodynamic therapy. Moore JV, et al. **Phys Med Biol** 1997 May;42(5):913–35 (175 ref.)
Practical aspects of photodynamic therapy for superficial bladder carcinoma. Manyak MJ. **Tech Urol** 1995 Summer; 1(2):84–93 (25 ref.)
Correlation of subcellular and intratumoral photosensitizer localization with ultrastructural features after photodynamic therapy. Peng Q, et al. **Ultrastruct Pathol** 1996 Mar-Apr;20(2):109–129 (200 ref.)
[Photochemotherapy in the treatment of carcinoma of the vocal cords of early stage (Tis, T1)] Delbove H, et al. **Ann Otolaryngol Chir Cervicofac** 1996;113(3):155–61 (29 ref.) (Eng. Abstr.) **(Fre)**
[Systemic therapy of psoriasis] Altmeyer P, et al. **Dtsch Med Wochenschr** 1996 Dec 20;121(51–52):1605–7 (14 ref.) **(Ger)**
[Photodynamic therapy of gastrointestinal malignant tumors] Haddad R, et al. **Harefuah** 1996 Jun 2;130(11):765–9 (43 ref.) **(Heb)**
[Photodynamic therapy for bronchogenic carcinoma] Kato H, et al. **Nippon Geka Gakkai Zasshi** 1997 Jan;98(1):36–40 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Phototherapy, photochemotherapy, and various photosensitizers] Colussi VC, et al. **Rev Assoc Med Bras** 1996 Oct–Dec;42(4):229–36 (45 ref.) **(Por)**

INSTRUMENTATION

Systems for light application and dosimetry in photodynamic therapy. Beyer W. **J Photochem Photobiol B** 1996 Nov; 36(2):153–6 (19 ref.)

METHODS

5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Peng Q, et al. **Cancer** 1997 Jun 15;79(12):2282–308 (225 ref.)
Natural products derived from plants as potential drugs for the photodynamic destruction of tumor cells. Ebermann R, et al. **J Photochem Photobiol B** 1996 Nov;36(2):95–7 (15 ref.)
Tumour photosensitizers: approaches to enhance the selectivity and efficiency of photodynamic therapy. Jori G. **J Photochem Photobiol B** 1996 Nov;36(2):87–93 (42 ref.)
Surgery and laser therapy. Lawrence CM. **J R Coll Physicians Lond** 1997 Jul–Aug;31(4):369–73 (25 ref.)
New applications in photodynamic therapy. Introduction. Levy JG, et al. **Photochem Photobiol** 1996 Nov;64(5):737–9 (20 ref.)
5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research. Peng Q, et al. **Photochem Photobiol** 1997 Feb;65(2):235–51 (234 ref.)
Photodynamic treatment of rheumatoid and inflammatory arthritis. Trauner KB, et al. **Photochem Photobiol** 1996 Nov;64(5):740–50 (124 ref.)
[Photodynamic therapy at the threshold of clinical use in disseminated dermatoses] Boehncke WH, et al. **Hautarzt** 1996 Nov;47(11):825–31 (48 ref.) (Eng. Abstr.) **(Ger)**
[Photodynamic therapy (PDT)] Wolf P. **Hautarzt** 1997 Feb; 48(2):137–48; quiz 148 (10 ref.) **(Ger)**

TRENDS

Perspectives in cutaneous photodynamic sensitization. Ortel B, et al. **J Photochem Photobiol B** 1996 Nov;36(2):209–11 (14 ref.)

UTILIZATION

Photodynamic therapy in neurosurgery: a review. Kostron H, et al. **J Photochem Photobiol B** 1996 Nov;36(2):157–68 (115 ref.)

PHOTOCHEMOTHERAPY, EXTRACORPOREAL see **PHOTOPHERESIS**

PHOTOCHEMOTHERAPY, HEMATOPORPHYRIN see **HEMATOPORPHYRIN PHOTORADIATION**

PHOTODENSITOMETRY see **DENSITOMETRY, X-RAY**

PHOTODERMATITIS see **PHOTOSENSITIVITY DISORDERS**

PHOTODYNAMIC THERAPY see **PHOTOCHEMOTHERAPY**

PHOTOGRAPHY

see related
MOTION PICTURES

Pediatric penile swelling. Harrison BP. **Acad Emerg Med** 1996 Apr;3(4):384, 87, 88 (12 ref.)
Diagnosis of nonmelanoma skin cancer. Brodland DG. **Clin Dermatol** 1995 Nov–Dec;13(6):551–7 (6 ref.)
Principles of reconstruction following excision of nonmelanoma skin cancer. Fazio MJ, et al. **Clin Dermatol** 1995 Nov–Dec;13(6):601–16 (29 ref.)
Comparison of treatment modalities for squamous cell carcinoma. Geisse JK. **Clin Dermatol** 1995 Nov–Dec; 13(6):621–6 (31 ref.)
Radiation therapy for skin neoplasms. Parker RG. **Clin Dermatol** 1995 Nov–Dec;13(6):579–88 (51 ref.)
Corneal endothelial photography. Three-year revision. American Academy of Ophthalmology. **Ophthalmology** 1997 Aug;104(8):1360–5 (41 ref.)

METHODS

Photographic documentation of hair growth in androgenetic alopecia. Canfield D. **Dermatol Clin** 1996 Oct;14(4):713–21 (6 ref.)
Narrow Band Imaging and fluorescence and its role in wound pattern documentation. Schneider RE, et al. **J Biol Photogr** 1996 Jul;64(3):67–75 (74 ref.)

PHOTOKERATECTOMY see **KERATECTOMY, PHOTOREFRACTIVE, EXCIMER LASER**

PHOTOMETRY

Physiological influence on ocular photometry. A review. DeMel T, et al. **Ophthalmic Res** 1996;28 Suppl 2:1–4 (16 ref.)
[High speed and high precision multipoint photometric system] Miyakawa A, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1163–6 (9 ref.) **(Jpn)**

METHODS

Transcutaneous bilirubinometry: its role in the assessment of neonatal jaundice. Dai J, et al. **Clin Biochem** 1997 Feb; 30(1):1–9 (67 ref.)
[Tyndall automatized photometry (PAT) in ophthalmology] Guex-Crosier Y, et al. **J Fr Ophtalmol** 1997;20(5):391–404

PHOTOMETRY

(95 ref.) **(Fre)**

TRENDS

Frederic Ives Medal paper. History and current status of a physiologically based system of photometry and colorimetry. Boynton RM. **J Opt Soc Am A** 1996 Aug; 13(8):1609–21 (50 ref.)

PHOTONS

Photobiology of microorganisms: how photosensors catch a photon to initialize signalling. Hellingwerf KJ, et al. **Mol Microbiol** 1996 Aug;21(4):683–93 (76 ref.)

Photon upmanship: why multiphoton imaging is more than a gimmick. Denk W, et al. **Neuron** 1997 Mar;18(3):351–7 (39 ref.)

[Near-field optical microscopy using Evanescent-photons] Inouye Y, et al. **Tanpakushitsu Kakusan Koso** 1997 May; 42(7 Suppl):1167–9 (15 ref.) **(Jpn)**

THERAPEUTIC USE

Conversion of PDD for photon beams from one SSD to another and calculation of TAR, TMR and TPR. Burns JE. **Br J Radiol** 1996;Suppl 25:153–7 (12 ref.)

The normalized peak scatter factor and normalized scatter functions for high energy photon beams. Day MJ, et al. **Br J Radiol** 1996;Suppl 25:168–76 (18 ref.)

PHOTOPERIOD

Melatonin as a chemical indicator of environmental light–dark cycle. Zawilska JB. **Acta Neurobiol Exp (Warsz)** 1996;56(3):757–67 (65 ref.)

Illuminating flowers: CONSTANS induces LEAFY expression. Blázquez MA. **Bioessays** 1997 Apr;19(4):277–9 (21 ref.)

Influence of melatonin and photoperiod on animal and human reproduction. Cagnacci A, et al. **J Endocrinol Invest** 1996 Jun;19(6):382–411 (419 ref.)

Comparative genetics of flowering time. Laurie DA. **Plant Mol Biol** 1997 Sep;35(1–2):167–77 (64 ref.)

PHOTOPHERESIS

Immunomodulation in transplantation with photopheresis. Barr ML. **Artif Organs** 1996 Aug;20(8):971–3 (12 ref.)

Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis. Rook AH, et al. **Clin Exp Immunol** 1997 Jan;107 Suppl 1:16–20 (35 ref.)

Reversal of acute renal allograft rejection by extracorporeal photopheresis: a case presentation and review of the literature. Wolfe JT, et al. **J Clin Apheresis** 1996;11(1):36–41 (26 ref.)

Clinical and mechanistic aspects of photopheresis. van Iperen HP, et al. **J Photochem Photobiol B** 1997 Jun;39(2):99–109 (123 ref.)

PHOTOPROTEINS see **LUMINESCENT PROTEINS**

PHOTORADIATION see **LIGHT**

PHOTORADIATION, HEMATOPORPHYRIN see **HEMATOPORPHYRIN PHOTORADIATION**

PHOTORADIATION THERAPY see **PHOTOTHERAPY**

PHOTORECEPTORS

see related
RETINAL PIGMENTS

CHEMISTRY

The phytochromes: a biochemical mechanism of signaling in sight? Quail PH. **Bioessays** 1997 Jul;19(7):571–9 (56 ref.)

CYTOLOGY

The interphotoreceptor matrix, a space in sight. Mieziewska K. **Microsc Res Tech** 1996 Dec 15;35(6):463–71 (104 ref.)

METABOLISM

Plant photomorphogenesis: a green light for cryptochrome research. Whitelam G. **Curr Biol** 1995 Dec 1;5(12):1351–3 (7 ref.)

Lipid metabolism in photoreceptor membranes: regulation and mechanisms. Giusto NM, et al. **Neurochem Res** 1997 Apr;22(4):445–53 (58 ref.)

PHYSIOLOGY

Cell physiology of the pineal body. Marchiafava PL, et al. **Arch Ital Biol** 1997 Mar;135(2):183–94 (73 ref.)

The roles of trp and calcium in regulating photoreceptor function in Drosophila. Minke B, et al. **Curr Opin Neurobiol** 1996 Aug;6(4):459–66 (67 ref.)

Retinoic acid. A key molecule for eye and photoreceptor development. Hyatt GA, et al. **Invest Ophthalmol Vis Sci** 1997 Jul;38(8):1471–5 (14 ref.)

Characterization and possible roles of fibroblast growth factors in retinal photoreceptor cells. Hicks D. **Keio J Med** 1996 Sep;45(3):140–54 (130 ref.)

Vitamin A, visual pigments, and visual receptors in Drosophila. Lee RD, et al. **Microsc Res Tech** 1996 Dec 15;35(6):418–30 (96 ref.)

Role of Drosophila TRP in inositide-mediated Ca2+ entry. Minke B, et al. **Mol Neurobiol** 1996 Apr;12(2):163–80 (83 ref.)

Dark adaptation in vertebrate photoreceptors. Fain GL, et al. **Trends Neurosci** 1996 Nov;19(11):502–7 (84 ref.)

Regulation of sensitivity in vertebrate rod photoreceptors by calcium. Koutalos Y, et al. **Trends Neurosci** 1996 Feb; 19(2):73–81 (80 ref.)

Modelling the spatio-temporal modulation response of ganglion cells with difference-of-Gaussians receptive fields: relation to photoreceptor response kinetics. Donner K, et al. **Vis Neurosci** 1996 Jan–Feb;13(1):173–86 (67 ref.)

[Physiological roles of rhodopsin phosphorylation and dephosphorylation and its relationship with retinitis pigmentosa] Oguro H. **Nippon Ganka Gakkai Zasshi** 1996 Aug;100(8):575–81 (49 ref.) (Eng. Abstr.) **(Jpn)**

TRANSPLANTATION

Transplantation of retinal pigment epithelial, photoreceptor and other cells as treatment for retinal degeneration. Litchfield TM, et al. **Exp Eye Res** 1997 May;64(5):655–66 (130 ref.)

PHOTORECEPTORS, CONE see **CONES (RETINA)**

PHOTORECEPTORS, INVERTEBRATE

CYTOLOGY

Cell-cell interactions during neural development: multiple types of lateral inhibitions involved in Drosophila eye development. Sawamoto K, et al. **Neurosci Res** 1996 Nov; 26(3):205–14 (90 ref.)

PHOTORECEPTORS, RETINAL see **PHOTORECEPTORS**

PHOTORECEPTORS, ROD see **RODS (RETINA)**

PHOTORECEPTORS, VERTEBRATE see **PHOTORECEPTORS**

PHOTOSENSITIVITY DISORDERS

Photosensitivity in the pediatric patient. Garzon MC, et al. **Curr Opin Pediatr** 1997 Aug;9(4):377–87 (101 ref.)

Drug photosensitivity, idiopathic photodermatoses, and sunscreens. González E, et al. **J Am Acad Dermatol** 1996 Dec;35(6):871–85; quiz 886–7 (139 ref.)

CHEMICALLY INDUCED

Do steroidal saponins have a role in hepatogenous photosensitization diseases of sheep? Flåøyen A. **Adv Exp Med Biol** 1996;405:395–403 (51 ref.)

DIAGNOSIS

Phototesting and photoprotection in LE. Walchner M, et al. **Lupus** 1997;6(2):167–74 (80 ref.)

ETIOLOGY

Photosensitivity reaction to intravenously administered fluorescein. Lentner A, et al. **Photodermatol Photoimmunol Photomed** 1995 Aug; 11(4):178–9 (21 ref.)

IMMUNOLOGY

Photosensitivity and autoantibodies to Sm, Ro, and La in a patient with silicosis [letter] Vidaller A, et al. **Int J Dermatol** 1996 Sep;35(9):679–80 (10 ref.)

METABOLISM

The involvement of serotonin (5-hydroxytryptamine) in photosensitive epilepsy. Anyanwu E, et al. **J Basic Clin Physiol Pharmacol** 1994 Jul–Dec; 5(3–4):179–206 (55 ref.)

PATHOLOGY

Histology of high-energy pulsed CO2 laser resurfacing. Alster TS, et al. **Semin Cutan Med Surg** 1996 Sep; 15(3):189–93 (11 ref.)

PHYSIOPATHOLOGY

Animal models of cutaneous lupus erythematosus and lupus erythematosus photosensitivity. Furukawa F. **Lupus** 1997; 6(2):193–202 (88 ref.)

THERAPY

Managing PLE and actinic prurigo. Grabczyska SA, et al. **Practitioner** 1997 Feb;241(1571):74, 77, 79 (6 ref.)

PHOTOSENSITIZERS see **PHOTOSENSITIZING AGENTS**

PHOTOSENSITIZING AGENTS

see related
HEMATOPORPHYRIN PHOTORADIATION
PHOTOCHEMOTHERAPY
PUVA THERAPY

[Photosensitization and photoprotection by some drugs, metabolites and other compounds] Lozovskaia EL, et al. **Biofizika** 1997 May–Jun;42(3):549–57 (23 ref.) (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

Photodynamic therapy with systemic administration of photosensitizers in dermatology. Calzavara-Pinton PG, et al. **J Photochem Photobiol B** 1996 Nov;36(2):225–31 (35 ref.)

ADVERSE EFFECTS

[Drugs and light] Tønnesen HH. **Tidsskr Nor Laegeforen** 1997 Jun 30;117(17):2481–3 (18 ref.) (Eng. Abstr.) **(Nor)**

ANALYSIS

Correlation of subcellular and intratumoral photosensitizer localization with ultrastructural features after photodynamic therapy. Peng Q, et al. **Ultrastruct Pathol** 1996 Mar–Apr;20(2):109–129 (200 ref.)

CHEMISTRY

Structure and biodistribution relationships of photodynamic sensitizers. Boyle RW, et al. **Photochem Photobiol** 1996 Sep; 64(3):469–85 (77 ref.)

Benzophenone photoprobes for phosphoinositides, peptides and drugs. Prestwich GD, et al. **Photochem Photobiol** 1997 Feb;65(2):222–34 (95 ref.)

PHARMACOKINETICS

Structure and biodistribution relationships of photodynamic sensitizers. Boyle RW, et al. **Photochem Photobiol** 1996 Sep; 64(3):469–85 (77 ref.)

PHARMACOLOGY

Psoralen photosensitization: damages to nucleic acid and membrane lipid components. Caffieri S, et al. **Acta Biochim Pol** 1996;43(1):241–6 (31 ref.)

Lysosomes and microtubules as targets for photochemotherapy of cancer. Berg K, et al. **Photochem Photobiol** 1997 Mar;65(3):403–9 (93 ref.)

5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research. Peng Q, et al. **Photochem Photobiol** 1997 Feb;65(2):235–51 (234 ref.)

Oxidative DNA damage induced by dioxetanes, photosensitizing ketones, and photo-fenton reagents. Adam W, et al. **Recent Results Cancer Res** 1997;143:21–34 (40 ref.)

THERAPEUTIC USE

Purpurins and benzochlorins as sensitizers for photodynamic therapy. Garbo GM. **J Photochem Photobiol B** 1996 Jul; 34(2–3):109–16 (64 ref.)

Tumour photosensitizers: approaches to enhance the selectivity and efficiency of photodynamic therapy. Jori G. **J Photochem Photobiol B** 1996 Nov;36(2):87–93 (42 ref.)

Photophysical and photobiological processes in the photodynamic therapy of tumours. Ochsner M. **J Photochem Photobiol B** 1997 May;39(1):1–18 (172 ref.)

[Photodynamic therapy of gastrointestinal malignant tumors] Haddad R, et al. **Harefuah** 1996 Jun 2;130(11):765–9 (43 ref.) **(Heb)**

[Phototherapy, photochemotherapy, and various photosensitizers] Colussi VC, et al. **Rev Assoc Med Bras** 1996 Oct–Dec;42(4):229–36 (45 ref.) **(Por)**

TOXICITY

Assessment of the phototoxicity risk of new drugs. Miranda MA. **Arch Toxicol Suppl** 1997;19:249–58 (30 ref.)

Validation of in vitro methods to single out photoirritants using mechanistically based tests. Pape WJ. **Arch Toxicol Suppl** 1997;19:239–47 (13 ref.)

PHOTOSYNTHESIS

Tyrosyl radicals in enzyme catalysis: some properties and a focus on photosynthetic water oxidation. Babcock GT, et al. **Acta Chem Scand** 1997 May;51(5):533–40 (49 ref.)

Molecular handling of photosynthetic proteins for molecular assembly construction. Miyake J, et al. **Adv Biophys** 1997; 34:109–26 (102 ref.)

Oxygen processing in photosynthesis. Foyer CH. **Biochem Soc Trans** 1996 May;24(2):427–33 (61 ref.)

Structure-function relationships in the dual-function photosynthetic-respiratory electron-transport assembly of cyanobacteria (blue-green algae). Peschek GA. **Biochem Soc Trans** 1996 Aug;24(3):729–33 (44 ref.)

Plants, CO2 and photosynthesis in the 21st century. Griffin KL, et al. **Chem Biol** 1996 Apr;3(4):245–54 (61 ref.)

Ribonuclease P from plant nuclei and photosynthetic organelles. Schön A. **Mol Biol Rep** 1995–96;22(2–3):139–45 (41 ref.)

Carotenoids in photosynthesis. Frank HA, et al. **Photochem Photobiol** 1996 Mar;63(3):257–264 (76 ref.)
[Complete genome sequence of a cyanobacterium Synechocystis sp. PCC 6803, the oxygenic photosynthetic prokaryote] Ikeuchi M. **Tanpakushitsu Kakusan Koso** 1996 Dec;41(16):2579–83 (9 ref.) **(Jpn)**
[Sensors and photoelectric devises using photosynthetic proteins] Miyake J, et al. **Tanpakushitsu Kakusan Koso** 1996 Oct;41(13):2050–4 (11 ref.) **(Jpn)**
[Photochemical reaction centers] Satoh K. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(2):110–20 (26 ref.) **(Jpn)**

GENETICS

Chlamydomonas reinhardtii as the photosynthetic yeast. Rochaix JD. **Annu Rev Genet** 1995;29:209–30 (100 ref.)
The evolution of the Calvin cycle from prokaryotic to eukaryotic chromosomes: a case study of functional redundancy in ancient pathways through endosymbiosis. Martin W, et al. **Curr Genet** 1997 Jul;32(1):1–18 (158 ref.)

PHYSIOLOGY

Advanced EPR spectroscopy on electron transfer processes in photosynthesis and biomimetic model systems. Levanon H, et al. **Annu Rev Biophys Biomol Struct** 1997;26:495–540 (223 ref.)
Light-harvesting complexes in oxygenic photosynthesis: diversity, control, and evolution. Grossman AR, et al. **Annu Rev Genet** 1995;29:231–88 (368 ref.)

PHOTOSYNTHETIC REACTION CENTER, BACTERIAL

[How does, bacteriorhodopsin convert light into energy?] Kandori H, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb; 42(2):101–9 (41 ref.) **(Jpn)**
[Photochemical reaction centers] Satoh K. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(2):110–20 (26 ref.) **(Jpn)**

CHEMISTRY

Molecular handling of photosynthetic proteins for molecular assembly construction. Miyake J, et al. **Adv Biophys** 1997; 34:109–26 (102 ref.)
Light-harvesting mechanisms in purple photosynthetic bacteria. Isaacs NW, et al. **Curr Opin Struct Biol** 1995 Dec; 5(6):794–7 (22 ref.)
A dawning light: the beginnings of an understanding of the photosynthetic reaction center. Ichiye T. **Structure** 1996 Sep 15;4(9):1009–12 (20 ref.)

GENETICS

Genetic analysis of the form and function of photosystem I and photosystem II. Pakrasi HB. **Annu Rev Genet** 1995; 29:755–76 (83 ref.)

PHOTOSYNTHETIC REACTION CENTER, PLANT

A current assessment of photosystem II structure. Nicholson WV, et al. **Biosci Rep** 1996 Apr;16(2):159–87 (126 ref.)

CHEMISTRY

How does photosystem 2 split water? The structural basis of efficient energy conversion. Rögner M, et al. **Trends Biochem Sci** 1996 Feb;21(2):44–9 (41 ref.)

GENETICS

Genetic analysis of the form and function of photosystem I and photosystem II. Pakrasi HB. **Annu Rev Genet** 1995; 29:755–76 (83 ref.)

METABOLISM

The extrinsic polypeptides of Photosystem II. Seidler A. **Biochim Biophys Acta** 1996 Nov 12;1277(1–2):35–60 (247 ref.)
How does photosystem 2 split water? The structural basis of efficient energy conversion. Rögner M, et al. **Trends Biochem Sci** 1996 Feb;21(2):44–9 (41 ref.)

PHOTOSYSTEM I REACTION CENTER see **PHOTOSYNTHETIC REACTION CENTER, PLANT**

PHOTOSYSTEM II REACTION CENTER see **PHOTOSYNTHETIC REACTION CENTER, PLANT**

PHOTOTHERAPY

Bright light: a countermeasure for jet lag? Samel A, et al. **Chronobiol Int** 1997 Mar;14(2):173–83 (40 ref.)
The influence of mineral water solutions in phototherapy. Boer J. **Clin Dermatol** 1996 Nov–Dec;14(6):665–73 (48 ref.)
Recent advances in the treatment of psoriasis. Guzzo C. **Dermatol Clin** 1997 Jan;15(1):59–68 (76 ref.)
Progress in phototherapy. de Araújo MC, et al. **Rev Paul Med** 1996 Mar–Apr;114(2):1134–40 (33 ref.)
[Systemic therapy of psoriasis] Altmeyer P, et al. **Dtsch Med Wochenschr** 1996 Dec 20;121(51–52):1605–7 (14 ref.) **(Ger)**
[Phototherapy of jet lag, night work and sleep disorders] Bjorvatn B, et al. **Tidsskr Nor Laegeforen** 1997 Jun 30; 117(17):2489–92 (33 ref.) (Eng. Abstr.) **(Nor)**
[Phototherapy. An alternative for seasonal affective disorders or sleep disorders] Holsten F, et al. **Tidsskr Nor Laegeforen** 1997 Jun 30;117(17):2484–8 (68 ref.) (Eng. Abstr.) **(Nor)**
[Phototherapy, photochemotherapy, and various photosensitizers] Colussi VC, et al. **Rev Assoc Med Bras** 1996 Oct–Dec;42(4):229–36 (45 ref.) **(Por)**
[Phototherapy in neurology and psychiatry] Levin Ial, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996; 96(3):107–12 (100 ref.) **(Rus)**
[Seasonal affective disorder and light therapy] Matías J, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 Jul–Aug;24(4):204–8 (50 ref.) (Eng. Abstr.) **(Spa)**

METHODS

Rhythm and blues: the theory and treatment of seasonal affective disorder. Dalgleish T, et al. **Br J Clin Psychol** 1996 May;35 (Pt 2):163–82 (140 ref.)
Jaundice in the healthy term neonate: when is treatment indicated? Bland HE. **Curr Probl Pediatr** 1996 Nov–Dec; 26(10):355–63 (40 ref.)
[Clinical implications of high blood viscosity and its reduction bu photo-hemotherapy] Karandashov VI, et al. **Klin Med (Mosk)** 1997;75(8):19–23 (37 ref.) (Eng. Abstr.) **(Rus)**

PHOTOTOXICITY see **DERMATITIS, PHOTOTOXIC**

PHOTOTRANSDUCTION

GENETICS

The genetics of phototransduction and circadian rhythms in Arabidopsis. Millar AJ, et al. **Bioessays** 1997 Mar; 19(3):209–14 (41 ref.)

PHYSIOLOGY

A fundamental step–transition in retinal function at low light intensities. Morgan IG, et al. **Aust N Z J Ophthalmol** 1997 May;25 Suppl 1:S70–2 (15 ref.)
Bilirubin, REM sleep, and phototransduction of environmental time cues. A hypothesis. Oren DA. **Chronobiol Int** 1997 May;14(3):319–29 (75 ref.)
Neuronal coupling in rod–signal pathways of the retina. Vaney DI. **Invest Ophthalmol Vis Sci** 1997 Feb; 38(2):267–73 (24 ref.)
Lights out: deactivation of the phototransduction cascade. Scott K, et al. **Trends Biochem Sci** 1997 Sep;22(9):350–4 (51 ref.)
[The molecular mechanism of visual transduction] Cruce M, et al. **Oftalmologia** 1996 Jul–Sep;40(3):201–9 (10 ref.) (Eng. Abstr.) **(Rum)**

PHRENIC NERVE

PHYSIOLOGY

Rostral brain regions contributing to respiratory control. Harper RM, et al. **Prog Brain Res** 1996;107:145–56 (76 ref.)

PHTHALAZINES

THERAPEUTIC USE

Aldose reductase inhibitors: the end of an era or the need for different trial designs? Pfeifer MA, et al. **Diabetes** 1997 Sep;46 Suppl 2:S82–9 (59 ref.)
[Inhibitor of chemical mediator release] Fujimura M. **Nippon Rinsho** 1996 Nov;54(11):3029–33 (8 ref.) (Eng. Abstr.) **(Jpn)**

PHTHALIC ACIDS

ADVERSE EFFECTS

para-Aramid fibrils. **IARC Monogr Eval Carcinog Risks Hum** 1997;68:409–39 (68 ref.)

PHTHALIC ANHYDRIDES

ADVERSE EFFECTS

Review of trimellitic anhydride (TMA) induced respiratory response. Grammer LC, et al. **Allergy Asthma Proc** 1997 Jul–Aug;18(4):235–7 (14 ref.)

IMMUNOLOGY

Review of trimellitic anhydride (TMA) induced respiratory response. Grammer LC, et al. **Allergy Asthma Proc** 1997 Jul–Aug;18(4):235–7 (14 ref.)

PHTHALIMIDES

PHARMACOLOGY

[Novel biological response modifiers: phthalimides with TNF-alpha production regulating activity] Miyachi H, et al. **Yakugaku Zasshi** 1997 Feb;117(2):91–107 (49 ref.) (Eng. Abstr.) **(Jpn)**

PHTHIRAPTERA see **LICE**

PHYLLODES TUMOR

PATHOLOGY

[Phyllodes tumors of the breast. Forty one cases] Matar N, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(1):32–6 (33 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

[Phyllodes tumors of the breast. Forty one cases] Matar N, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(1):32–6 (33 ref.) (Eng. Abstr.) **(Fre)**

PHYLLOQUINONE see **PHYTONADIONE**

PHYLLOQUINONE REDUCTASE see **NAD(P)H DEHYDROGENASE (QUINONE)**

PHYLOGENY

The super-repeats of titin/connectin and their interactions: glimpses at sarcomeric assembly. Gautel M. **Adv Biophys** 1996;33:27–37 (61 ref.)
Phylogeny of the tissue cyst-forming coccidia. Tenter AM, et al. **Adv Parasitol** 1997;39:69–139 (250 ref.)
There is no highly conserved embryonic stage in the vertebrates: implications for current theories of evolution and development. Richardson MK, et al. **Anat Embryol (Berl)** 1997 Aug;196(2):91–106 (81 ref.)
Molecular diversity of voltage-dependent calcium channel. Mori Y, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:87–108 (92 ref.)
Serotonergic modulation of behaviour: a phylogenetic overview. Weiger WA. **Biol Rev Camb Philos Soc** 1997 Feb;72(1):61–95 (172 ref.)
Phenotypic specification of hindbrain rhombomeres and the origins of rhythmic circuits in vertebrates. Bass AH, et al. **Brain Behav Evol** 1997;50 Suppl 1:3–16 (120 ref.)
On the role played by ontogenetic remodeling and functional transformation in the evolution of terrestrial hearing. Fritzsch B. **Brain Behav Evol** 1997 Jul;50(1):38–49 (75 ref.)
Evolution of gnathostome lateral line ontogenies. Northcutt RG. **Brain Behav Evol** 1997 Jul;50(1):25–37 (70 ref.)
Genome size, secondary simplification, and the evolution of the brain in salamanders. Roth G, et al. **Brain Behav Evol** 1997 Jul;50(1):50–9 (60 ref.)
The telencephalon of tetrapods in evolution. Striedter GF. **Brain Behav Evol** 1997;49(4):179–213 (160 ref.)
Phylogenetic analysis. Hillis DM. **Curr Biol** 1997 Mar 1; 7(3):R129–31 (7 ref.)
Defusing the Cambrian 'explosion'? Morris SC. **Curr Biol** 1997 Feb 1;7(2):R71–4 (13 ref.)
Whither microbiology? Phylogenetic trees. Woese CR. **Curr Biol** 1996 Sep 1;6(9):1060–3 (10 ref.)
Origin and evolution of mitochondria: what have we learnt from red algae? Leblanc C, et al. **Curr Genet** 1997 Mar; 31(3):193–207 (100 ref.)
Searching for regulatory elements in human noncoding sequences. Duret L, et al. **Curr Opin Struct Biol** 1997 Jun; 7(3):399–406 (48 ref.)
Modular multidomain phosphoryl transfer proteins of bacteria. Reizer J, et al. **Curr Opin Struct Biol** 1997 Jun; 7(3):407–15 (51 ref.)
Legionella-like amebal pathogens--phylogenetic status and possible role in respiratory disease. Adeleke A, et al. **Emerg Infect Dis** 1996 Jul–Sep;2(3):225–30 (35 ref.)
Phylogenetic analysis of membrane trafficking proteins: a family reunion and secondary structure predictions. Terrian DM, et al. **Eur J Cell Biol** 1997 Jul;73(3):198–204 (13 ref.)
Phylogenetic characterization of bacteria in the subsurface microbial culture collection. Balkwill DL, et al. **FEMS Microbiol Rev** 1997 Jul;20(3–4):201–16 (68 ref.)
The hemopoietic system: a phylogenetic approach. Galíndez EJ, et al. **Histol Histopathol** 1997 Jul;12(3):823–6 (48 ref.)
Phylogenetic analysis of the evolution of lactose digestion in adults. Holden C, et al. **Hum Biol** 1997 Oct;69(5):605–28 (108 ref.)
The significance of immune suppression in normal self tolerance. McCullagh P. **Immunol Rev** 1996 Feb;149:127–53 (63 ref.)
Evolutionary patterns in ontogenetic transformation: from laws to regularities. Alberch P, et al. **Int J Dev Biol** 1996 Aug;40(4):845–58 (78 ref.)
Direct development in the lungless salamanders: what are the consequences for developmental biology, evolution and phylogenesis? Wake DB, et al. **Int J Dev Biol** 1996 Aug; 40(4):859–69 (118 ref.)
Phylogenetic tree-building. Morrison DA. **Int J Parasitol** 1996 Jun;26(6):589–617 (150 ref.)
Using our brains [editorial] Wolf S. **Integr Physiol Behav Sci** 1996 Jul–Sep;31(3):195–201 (21 ref.)
The phylogeny and molecular epidemiology of human T-cell lymphotropic virus type II. Heneine W. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S236–41 (17 ref.)
Phylogenetic relationships of Bacillus thuringiensis

delta-endotoxin family proteins and their functional domains. Bravo A. **J Bacteriol** 1997 May;179(9):2793-801 (54 ref.)
A reappraisal of early hominid phylogeny. Strait DS, et al. **J Hum Evol** 1997 Jan;32(1):17-82 (202 ref.)
A myosin family reunion. Sellers JR, et al. **J Muscle Res Cell Motil** 1996 Feb;17(1):7-22 (112 ref.)
Ancestral relationships of the major eukaryotic lineages. Sogin ML, et al. **Microbiologia** 1996 Mar;12(1):17-28 (37 ref.)
A possible role for the alpha 1-->3 galactosyl epitope and the natural anti-gal antibody in oncogenesis. Gollogly L, et al. **Neoplasma** 1996;43(5):285-9 (27 ref.)
The organization and structure of immunoglobulin and T-cell receptor genes in the most phylogenetically distant jawed vertebrates: evolutionary implications. Litman GW, et al. **Res Immunol** 1996 May;147(4):226-33 (36 ref.)
A molecular view of microbial diversity and the biosphere. Pace NR. **Science** 1997 May 2;276(5313):734-40 (52 ref.)
Strand asymmetries in DNA evolution. Francino MP, et al. **Trends Genet** 1997 Jun;13(6):240-5 (47 ref.)
Zooflagellate phylogeny and classification. Cavalier-Smith T. **Tsitologiia** 1995;37(11):1010-29 (95 ref.)
Progress in understanding the phylogeny of flagellates. Sleigh MA. **Tsitologiia** 1995;37(11):985-1009 (82 ref.)
The position of flagellated protists in the system of lower eukaryotes. Starobogatov YI. **Tsitologiia** 1995; 37(11):1030-7 (18 ref.)
[Immune response of fishes with respect to phylogenetic aspects] Ahne W. **Tierarztl Prax** 1996 Feb;24(1):88-95 (27 ref.) (Eng. Abstr.) **(Ger)**
[Mechanisms of calcification and molecular phylogeny of Rubisco genes in coccolithophorid algae] Fujiwara S. **Seikagaku** 1996 Aug;68(8):1445-8 (8 ref.) **(Jpn)**
[Characteristics features of the ultrastructure of liver cells in various morphological types of animals and their significance] Kalashnikova MM. **Biull Eksp Biol Med** 1996 Jun;121(6):604-9 (27 ref.) **(Rus)**

PHYSCOMITRELLA see **MOSSES**

PHYSIATRY see **PHYSICAL MEDICINE**

PHYSICAL CONDITIONING, ANIMAL

High calcium diet reduces blood pressure in exercised and nonexercised hypertensive rats. Sallinen K, et al. **Am J Hypertens** 1996 Feb;9(2):144-56 (53 ref.)
Theoretical predictions of end-capillary PO2 in muscles of athletic and nonathletic animals at VO2max. Roy TK, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):H721-37 (72 ref.)
Exercise and immunity: a review with emphasis on the horse. Hines MT, et al. **J Vet Intern Med** 1996 Sep-Oct; 10(5):280-9 (122 ref.)
The role of exercise and physical modalities in the treatment of osteoarthritis. Millis DL, et al. **Vet Clin North Am Small Anim Pract** 1997 Jul;27(4):913-30 (33 ref.)

PHYSIOLOGY

Preparing for and competing in the heat: the human perspective. Maughan RJ, et al. **Equine Vet J Suppl** 1995 Nov;(20):8-15 (86 ref.)
Antiarrhythmic mechanisms during exercise. Paterson DJ. **J Appl Physiol** 1996 Jun;80(6):1853-62 (100 ref.)
Effects of acute physical exercise on central serotonergic systems. Chaouloff F. **Med Sci Sports Exerc** 1997 Jan; 29(1):58-62 (39 ref.)
Brain monoamines, exercise, and behavioral stress: animal models. Dishman RK. **Med Sci Sports Exerc** 1997 Jan; 29(1):63-74 (76 ref.)
Upper respiratory causes of exercise intolerance. Beard W. **Vet Clin North Am Equine Pract** 1996 Dec;12(3):435-55 (42 ref.)
Exercise intolerance in endurance horses. Flaminio MJ, et al. **Vet Clin North Am Equine Pract** 1996 Dec;12(3):565-80 (57 ref.)
Metabolic causes of equine exercise intolerance. Foreman JH. **Vet Clin North Am Equine Pract** 1996 Dec;12(3):537-54 (90 ref.)
Skeletal origins of exercise intolerance in horses. Gaughan EM. **Vet Clin North Am Equine Pract** 1996 Dec; 12(3):517-35 (26 ref.)
Evaluation of young or unproven horses for potential exercise intolerance. Hendrickson DA. **Vet Clin North Am Equine Pract** 1996 Dec;12(3):607-12 (15 ref.)
Exercise intolerance and poor performance in western performance and sprint horses. Kobluk CN, et al. **Vet Clin North Am Equine Pract** 1996 Dec;12(3):581-606 (49 ref.)
Diagnostic approach to exercise intolerance in racehorses. Lilich JD, et al. **Vet Clin North Am Equine Pract** 1996 Dec;12(3):555-64 (15 ref.)
Cardiovascular causes of exercise intolerance. Mitten LA. **Vet Clin North Am Equine Pract** 1996 Dec;12(3):473-94 (89 ref.)
Testing methods for exercise intolerance in horses. Parente EJ. **Vet Clin North Am Equine Pract** 1996 Dec;12(3):421-33 (35 ref.)
Muscular causes of exercise intolerance in horses. Valberg SJ. **Vet Clin North Am Equine Pract** 1996 Dec; 12(3):495-515 (52 ref.)

PHYSICAL CONDITIONING, HUMAN see **PHYSICAL FITNESS**

PHYSICAL EDUCATION AND TRAINING

A 33-yr follow-up of peak oxygen uptake and related variables of former physical education students. Astrand PO, et al. **J Appl Physiol** 1997 Jun;82(6):1844-52 (28 ref.)
Nutritional practices of athletes: are they sub-optimal? Hawley JA, et al. **J Sports Sci** 1995 Summer;13 Spec No:S75-81 (73 ref.)
Effect of training and nutrition on the development of skeletal muscle. Henriksson J. **J Sports Sci** 1995 Summer;13 Spec No:S25-30 (55 ref.)
Adaptation to training and performance in elite athletes. Keul J, et al. **Res Q Exerc Sport** 1996 Sep;67(3 Suppl):S29-36 (45 ref.)
Interactions of physical training and heat acclimation. The thermophysiology of exercising in a hot climate. Aoyagi Y, et al. **Sports Med** 1997 Mar;23(3):173-210 (311 ref.)
Use of blood lactate measurements for prediction of exercise performance and for control of training. Recommendations for long-distance running. Billat LV. **Sports Med** 1996 Sep; 22(3):157-75 (138 ref.)
Resistance exercise overtraining and overreaching. Neuroendocrine responses. Fry AC, et al. **Sports Med** 1997 Feb;23(2):106-29 (183 ref.)
Endothelium-medicated control of the coronary circulation. Exercise training-induced vascular adaptations. Laughlin MH, et al. **Sports Med** 1996 Oct;22(4):228-50 (162 ref.)

METHODS

The athletic trainer's perspective. George FJ. **Clin Sports Med** 1997 Jul;16(3):361-74 (33 ref.)
Overtraining: consequences and prevention. Eichner ER. **J Sports Sci** 1995 Summer;13 Spec No:S41-8 (123 ref.)
How much is too much? Performance aspects of overtraining. Kuipers H. **Res Q Exerc Sport** 1996 Sep;67(3 Suppl):S65-9 (34 ref.)
Key factors in success of altitude training for swimming. Miyashita M. **Res Q Exerc Sport** 1996 Sep;67(3 Suppl):S76-8 (10 ref.)

PHYSICAL EFFORT see **EXERTION**

PHYSICAL ENDURANCE

The relationship between power output and endurance: a brief review. Morton RH, et al. **Eur J Appl Physiol** 1996; 73(6):491-502 (102 ref.)

DRUG EFFECTS

Caffeine and endurance performance. Tarnopolsky MA. **Sports Med** 1994 Aug;18(2):109-25 (149 ref.)

PHYSIOLOGY

The immune response to prolonged cardiorespiratory exercise. Nieman DC. **Am J Sports Med** 1996;24(6 Suppl):S98-103 (79 ref.)
Mitochondrial biogenesis in skeletal muscle in response to endurance exercises. Freyssenet D, et al. **Arch Physiol Biochem** 1996;104(2):129-41 (114 ref.)
Physiological implications of altitude training for endurance performance at sea level: a review. Bailey DM, et al. **Br J Sports Med** 1997 Sep;31(3):183-90 (111 ref.)
Effect of altered reproductive function and lowered testosterone levels on bone density in male endurance athletes. Bennell KL, et al. **Br J Sports Med** 1996 Sep; 30(3):205-8 (59 ref.)
Physiologic consequences of training. Charlton GA, et al. **Cardiol Clin** 1997 Aug;15(3):345-54 (59 ref.)
The power athlete. Longhurst JC, et al. **Cardiol Clin** 1997 Aug;15(3):413-29 (115 ref.)
Outer limits of the athlete's heart, the effect of gender, and relevance to the differential diagnosis with primary cardiac diseases. Pelliccia A, et al. **Cardiol Clin** 1997 Aug; 15(3):381-96 (88 ref.)
The morphologic consequences of systemic training. Shapiro LM. **Cardiol Clin** 1997 Aug;15(3):373-9 (34 ref.)
The clinical value of serum ferritin tests in endurance athletes. Garza D, et al. **Clin J Sport Med** 1997 Jan;7(1):46-53 (54 ref.)
Mechanisms of exercise intolerance in congestive heart failure. Harrington D, et al. **Curr Opin Cardiol** 1997 May; 12(3):224-32 (86 ref.)
Interactions between muscle glycogen and blood glucose during exercise. Hargreaves M. **Exerc Sport Sci Rev** 1997; 25:21-39 (112 ref.)
Effects of endurance exercise on adipose tissue metabolism. Nicklas BJ. **Exerc Sport Sci Rev** 1997;25:77-103 (125 ref.)
Perception of physical exertion: methods, mediators, and applications. Robertson RJ, et al. **Exerc Sport Sci Rev** 1997; 25:407-52 (246 ref.)
Physiology of aerobic fitness/endurance. Chandler TJ. **Instr Course Lect** 1994;43:11-5 (11 ref.)
Training and overtraining: an overview and experimental results in endurance sports. Lehmann MJ, et al. **J Sports Med Phys Fitness** 1997 Mar;37(1):7-17 (51 ref.)
Work-exhaustion time relationships and the critical power concept. A critical review. Vandewalle H, et al. **J Sports Med Phys Fitness** 1997 Jun;37(2):89-102 (55 ref.)
Diet composition and the performance of high-intensity exercise. Maughan RJ, et al. **J Sports Sci** 1997 Jun; 15(3):265-75 (67 ref.)
American College of Sports Medicine position stand. Heat and cold illnesses during distance running. Armstrong LE, et al. **Med Sci Sports Exerc** 1996 Dec;28(12):i-x (97 ref.)
Plasma glucose metabolism during exercise: effect of endurance training in humans. Coggan AR. **Med Sci Sports Exerc** 1997 May;29(5):620-7 (36 ref.)
Training enhanced hepatic gluconeogenesis: the importance for glucose homeostasis during exercise. Donovan CM, et al. **Med Sci Sports Exerc** 1997 May;29(5):628-34 (58 ref.)
Effect of endurance training on ammonia and amino acid metabolism in humans. Graham TE, et al. **Med Sci Sports Exerc** 1997 May;29(5):646-53 (57 ref.)
The male reproductive system and endurance exercise. Hackney AC. **Med Sci Sports Exerc** 1996 Feb;28(2):180-9 (61 ref.)
Adaptive strategies of respiratory muscles in response to endurance exercise. Powers SK, et al. **Med Sci Sports Exerc** 1996 Sep;28(9):1115-22 (54 ref.)
The effect of endurance training on reproductive function in male runners. A 'volume threshold' hypothesis. De Souza MJ, et al. **Sports Med** 1997 Jun;23(6):357-74 (79 ref.)
Carbohydrate-loading and exercise performance. An update. Hawley JA, et al. **Sports Med** 1997 Aug;24(2):73-81 (43 ref.)
Exercise intolerance in endurance horses. Flaminio MJ, et al. **Vet Clin North Am Equine Pract** 1996 Dec;12(3):565-80 (57 ref.)
Micronutrients: effects of variation in [Hb] and iron deficiency on physical performance. Ekblom B. **World Rev Nutr Diet** 1997;82:122-30 (64 ref.)

PHYSICAL EXAMINATION

Weighing the evidence: the Canadian experience. Goldbloom RB. **Am J Clin Nutr** 1997 Feb;65(2 Suppl):584S-586S (6 ref.)
Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians. Coley CM, et al. **Ann Intern Med** 1997 Mar 1;126(5):394-406 (181 ref.)
Diagnosing syncope. Part 1: Value of history, physical examination, and electrocardiography. Clinical Efficacy Assessment Project of the American College of Physicians. Linzer M, et al. **Ann Intern Med** 1997 Jun 15;126(12):989-96 (34 ref.)
Predictive value of signs and symptoms in the diagnosis of subarachnoid hemorrhage among stroke patients. Talavera JO, et al. **Arch Med Res** 1996 Autumn;27(3):353-7 (28 ref.)
Additional thoughts on the physical examination of the wrist. Nelson DL. **Hand Clin** 1997 Feb;13(1):35-7 (6 ref.)
Physical examination of the wrist. Watson HK, et al. **Hand Clin** 1997 Feb;13(1):17-34 (6 ref.)
Physical diagnosis in the 1990s. Art of artifact? Mangione S, et al. **J Gen Intern Med** 1996 Aug;11(8):490-3 (34 ref.)
Preparticipation physical examinations. Sanders B, et al. **J Orthop Sports Phys Ther** 1996 Feb;23(2):149-63 (48 ref.)
Is this patient pregnant? Can you reliably rule in or rule out early pregnancy by clinical examination? Bastian LA, et al. **JAMA** 1997 Aug 20;278(7):586-91 (21 ref.)
Does this patient have an abnormal systolic murmur? [see comments] Etchells E, et al. **JAMA** 1997 Feb 19; 277(7):564-71 (78 ref.) Comment in: JAMA 1997 Feb 19;277(7):572. Comment in: JAMA 1997 May 28;277(20):1593-4; discussion 1594. Comment in: JAMA 1997 May 28;277(20):1594.
The preparticipation athletic examination: a closer look. Krowchuk DP. **Pediatr Ann** 1997 Jan;26(1):37-49 (34 ref.)
History and physical examination in patients with herniated lumbar discs. Andersson GB, et al. **Spine** 1996 Dec 15;21(24 Suppl):10S-18S (25 ref.)
Use of prostate-specific antigen, Gleason score, and digital rectal examination in staging patients with newly diagnosed prostate cancer. Rees MA, et al. **Urol Clin North Am** 1997 May;24(2):379-88 (68 ref.)
[Pre-anesthesiologic preparation for urologic operations. I: Screening for anesthesia] Wilhelm W, et al. **Urologe A** 1996 Sep;35(5):W427-36 (0 ref.) **(Ger)**
[Relative significance of clinical examinations, imaging techniques and EMG] Ganel A. **Harefuah** 1997 Feb 2; 132(3):225-9 (29 ref.) **(Heb)**

ADVERSE EFFECTS

Digital rectal examination during early acute MI [editorial] Lee JR, et al. **Hosp Pract (Off Ed)** 1997 Sep 15;32(9):15-6 (11 ref.)

METHODS

The 'turkey wattle' sign revisited: diagnosing parotid vascular malformations in the adult. Saeed WR, et al. **Br J Plast Surg** 1997 Jan;50(1):43-6 (22 ref.)
Pressure ulcer assessment. Maklebust J. **Clin Geriatr Med** 1997 Aug;13(3):455-81 (62 ref.)
Physical examination of the prepubertal girl. Hairston L. **Clin Obstet Gynecol** 1997 Mar;40(1):127-34 (10 ref.)
Digital rectal examination during early acute MI [editorial]

Lee JR, et al. **Hosp Pract (Off Ed)** 1997 Sep 15;32(9):15–6 (11 ref.)
Spinal stenosis: history and physical examination. Mirkovic S, et al. **Instr Course Lect** 1994;43:435–40 (41 ref.)
The physical examination in cancer pain assessment. Portenoy RK. **Semin Oncol Nurs** 1997 Feb;13(1):25–9 (12 ref.)
[Clinical studies in suspected hip dysplasia or dislocation] Parsch K. **Orthopade** 1997 Jan;26(1):7–13 (48 ref.) (Eng. Abstr.) **(Ger)**
[Immuno-physiological and hematological aspects of flight certification examination] Goranchuk VV, et al. **Aviakosm Ekolog Med** 1996;30(1):54–7 (12 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

Evidence-based diagnosis. Fowler PB. **J Eval Clin Pract** 1997 Apr;3(2):153–9 (3 ref.)

VETERINARY

[Clinical examination upon suspicion of bovine spongiform encephalopathy (BSE)] Braun U, et al. **Schweiz Arch Tierheilkd** 1997;139(1):35–41 (9 ref.) (Eng. Abstr.) **(Ger)**

PHYSICAL EXAMINATION, PREADMISSION see **DIAGNOSTIC TESTS, ROUTINE**

PHYSICAL FITNESS

see related
EXERCISE

Physical activity, physical fitness and longevity. Lee IM, et al. **Aging (Milano)** 1997 Feb-Apr;9(1–2):2–11 (42 ref.)
Incorporating occupational medicine methodology into military fitness for duty and readiness issues. Popper SE. **Aviat Space Environ Med** 1997 Aug;68(8):740–5 (28 ref.)
ABC of work related disorders. Assessing fitness for work. Davies W. **BMJ** 1996 Oct 12;313(7062):934–8 (8 ref.)
Physical activity among persons with disabilities--a public health perspective. Heath GW, et al. **Exerc Sport Sci Rev** 1997;25:195–234 (233 ref.)
Evidence for an interaction between calcium intake and physical activity on changes in bone mineral density. Specker BL. **J Bone Miner Res** 1996 Oct;11(10):1539–44 (47 ref.)
Guidelines for school and community programs to promote lifelong physical activity among young people. National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and prevention. **J Sch Health** 1997 Aug;67(6):202–19 (276 ref.)
Care of collegiate athletes. Brandon TA, et al. **Md Med J** 1996 Aug;45(8):669–75 (31 ref.)
Physical activity, nutrition, and chronic disease. Blair SN, et al. **Med Sci Sports Exerc** 1996 Mar;28(3):335–49 (202 ref.)
Does physical activity reduce risk of estrogen-dependent cancer in women? Kramer MM, et al. **Med Sci Sports Exerc** 1996 Mar;28(3):322–34 (117 ref.)
Firefighters: fitness for duty. Gerkin D. **Occup Med** 1995 Oct-Dec;10(4):871–6 (12 ref.)
Physical activity, health, and well-being. An international scientific consensus conference, Québec City, May 19–21, 1995. Consensus statement. **Res Q Exerc Sport** 1995 Dec; 66(4):v–viii (0 ref.)
Tracking of physical activity and physical fitness across the lifespan. Malina RM. **Res Q Exerc Sport** 1996 Sep;67(3 Suppl):S48–57 (64 ref.)
Descriptive epidemiology of health-related physical activity and fitness. Oja P. **Res Q Exerc Sport** 1995 Dec; 66(4):303–12 (29 ref.)
Physical activity and fitness for health and longevity. Paffenbarger RS Jr, et al. **Res Q Exerc Sport** 1996 Sep; 67(3 Suppl):S11–28 (68 ref.)
Physical activity and health: dose-response issues. Pate RR. **Res Q Exerc Sport** 1995 Dec;66(4):313–7 (39 ref.)
Physical activity and physical fitness as protection against premature disease or death. Andersen LB. **Scand J Med Sci Sports** 1995 Dec;5(6):318–28 (137 ref.)
Applications of methods and techniques in the study of aerobic fitness during pregnancy. Wiswell RA. **Semin Perinatol** 1996 Aug;20(4):213–21 (54 ref.)
Walking to health. Morris JN, et al. **Sports Med** 1997 May; 23(5):306–32 (196 ref.)
Declaration of Olympia on nutrition and fitness. Ancient Olympia, Greece, May 28–29, 1996. Simopoulos AP. **World Rev Nutr Diet** 1997;82:1–12 (5 ref.)
[Is exercise beneficial? (see comments)] Andersen LB, et al. **Ugeskr Laeger** 1997 Mar 3;159(10):1413–6 (13 ref.) Comment in: Ugeskr Laeger 1997 Jun 30;159(27):4283–4. **(Dan)**

PHYSIOLOGY

Exercise for the older woman: choosing the right prescription. Taunton JE, et al. **Br J Sports Med** 1997 Mar; 31(1):5–10 (75 ref.)
Physiology of aerobic fitness/endurance. Chandler TJ. **Instr Course Lect** 1994;43:11–5 (11 ref.)
Effects of exercise on appetite control: implications for energy balance. King NA, et al. **Med Sci Sports Exerc** 1997 Aug;29(8):1076–89 (110 ref.)
How much physical activity should we do? The case for moderate amounts and intensities of physical activity. Blair SN, et al. **Res Q Exerc Sport** 1996 Jun;67(2):193–205 (58 ref.)
Physical activity and health: atherosclerotic, metabolic, and hypertensive diseases. Bouchard C, et al. **Res Q Exerc Sport** 1995 Dec;66(4):268–75 (70 ref.)
Exercise and physical health: musculoskeletal health and functional capabilities. Vuori I. **Res Q Exerc Sport** 1995 Dec;66(4):276–85 (75 ref.)
Finnish research project on aging workers in 1981–1992. Tuomi K, et al. **Scand J Work Environ Health** 1997;23 Suppl 1:7–11 (33 ref.)
Effects of exercise on blood coagulation, fibrinolysis and platelet aggregation. el-Sayed MS. **Sports Med** 1996 Nov; 22(5):282–98 (121 ref.)
[Indications and performance of a 6 minute treadmill test in pneumology] Kirsten D, et al. **Pneumologie** 1997 Jan; 51(1):33–5 (17 ref.) (Eng. Abstr.) **(Ger)**
[Physical fitness in the elderly] Zenker TK. **Rehabilitation (Stuttg)** 1996 Nov;35(4):233–6 (24 ref.) (Eng. Abstr.) **(Ger)**
[New aspects in the evaluation of cardiologic fitness in sport activities. From the Bethesda Conference in 1994 to the Italian COCIS in 1996. Cardiologic Organizational Committee for Cardiovascular Fitness in Sport] Naccarella F, et al. **G Ital Cardiol** 1996 Dec;26(12):1507–39 (296 ref.) **(Ita)**
[Effects of physical conditioning on ambulatory blood pressure monitoring in normotensive and hypertensive patients] Lima EG, et al. **Arq Bras Cardiol** 1996 Sep; 67(3):185–8 (26 ref.) **(Por)**
[Evaluation of the physical performance of flying personnel] Vlasov VV. **Aviakosm Ekolog Med** 1996;30(5):54–7 (15 ref.) (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

The biopsychosocial disease consequence model in rehabilitation: model development in the Finnish 'work hardening' programme for chronic pain. Talo S, et al. **Int J Rehabil Res** 1996 Jun;19(2):93–109 (35 ref.)

PHYSICAL MAPPING (GENETICS) see **RESTRICTION MAPPING**

PHYSICAL MEDICINE

see related
BIOMECHANICS

Rehabilitation and chiropractic practice. Liebenson C. **J Manipulative Physiol Ther** 1996 Feb;19(2):134–40 (50 ref.)
[Rehabilitation as interdisciplinary responsibility--the medical specialty "physical and rehabilitative medicine"] Gehrk A. **Z Arztl Fortbild (Jena)** 1996 Oct;90(6):471–8 (7 ref.) (Eng. Abstr.) **(Ger)**

METHODS

The role of physical medicine and rehabilitation in pain management. Nguyen DM. **Clin Geriatr Med** 1996 Aug; 12(3):517–29 (59 ref.)

PHYSICAL STIMULATION

Feeling force: mechanical transduction by vertebrates and invertebrates. Gillespie PG. **Chem Biol** 1996 Apr;3(4):223–7 (19 ref.)

METHODS

Post-traumatic apallic syndrome following head injury. Part 2: Treatment. Grossman P, et al. **Disabil Rehabil** 1996 Feb; 18(2):57–68 (68 ref.)
Multidisciplinary research of multimodal stimulation of premature infants: an integrated review of the literature. Mueller CR. **Matern Child Nurs J** 1996 Jan-Mar; 24(1):18–31 (31 ref.)

PHYSICAL THERAPY

Physiotherapy for patients with soft tissue shoulder disorders: a systematic review of randomised clinical trials. van der Heijden GJ, et al. **BMJ** 1997 Jul 5;315(7099):25–30 (45 ref.)
Heterotopic ossification after severe burns: a report of three cases and review of the literature. Richards AM, et al. **Burns** 1997 Feb;23(1):64–8 (39 ref.)
Rehabilitation of foot and ankle injuries. Losito JM, et al. **Clin Podiatr Med Surg** 1997 Jul;14(3):533–57 (39 ref.)
Posteroanterior spinal mobilization: state of the art review and discussion. Björnsdóttir SV, et al. **Disabil Rehabil** 1997 Feb;19(2):39–46 (40 ref.)
The integration of pain sciences into clinical practice. Gifford LS, et al. **J Hand Ther** 1997 Apr-Jun;10(2):86–95 (89 ref.)
The current significance of physiotherapeutic measures in the treatment of Parkinson's disease. Ulm G. **J Neural Transm Suppl** 1995;46:455–60 (23 ref.)
Physical therapy: a critique [see comments] Feine JS, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jan;83(1):123–7 (38 ref.) Comment in: Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jul;84(1):3.
Physical medicine modalities and trigger point injections in the management of temporomandibular disorders and assessing treatment outcome. Murphy GJ. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jan;83(1):118–22 (79 ref.)
An assessment of the efficacy of physical therapy and physical modalities for the control of chronic musculoskeletal pain. Feine JS, et al. **Pain** 1997 May; 71(1):5–23 (91 ref.)
Screening for psychological factors in patients with low back problems: Waddell's nonorganic signs. Scalzitti DA. **Phys Ther** 1997 Mar;77(3):306–12 (36 ref.)
Health status measures: strategies and analytic methods for assessing change scores. Stratford PW, et al. **Phys Ther** 1996 Oct;76(10):1109–23 (33 ref.)
The use and interpretation of the Friedman test in the analysis of ordinal-scale data in repeated measures designs. Sheldon MR, et al. **Physiother Res Int** 1996;1(4):221–8 (28 ref.)
Manual therapy in the treatment of neck pain. Gross AR, et al. **Rheum Dis Clin North Am** 1996 Aug;22(3):579–98 (60 ref.)
Physical therapy for musculoskeletal syndromes. Guccione AA. **Rheum Dis Clin North Am** 1996 Aug;22(3):551–62 (53 ref.)
[Current therapy of idiopathic Parkinson disease. I: Diagnosis, therapeutic guidelines, standard pharmacotherapy and physical therapy] Müller T, et al. **Fortschr Med** 1997 May 10;115(13):28, 31–4 (0 ref.) (Eng. Abstr.) **(Ger)**
[Physiotherapy in the treatment of urinary incontinence in elderly women] Bø K. **Tidsskr Nor Laegeforen** 1997 Aug 10;117(18):2623–6 (43 ref.) (Eng. Abstr.) **(Nor)**
[Reactive arthritis and its treatment with physical factors] Grigor'eva VD, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1997 May-Jun; (3):39–41 (52 ref.) **(Rus)**
[The effect of physical factors on the active transport of sodium ions across cell membranes] Tereshin SIu. **Vopr Kurortol Fizioter Lech Fiz Kult** 1997 Mar-Apr; (2):41–3 (31 ref.) **(Rus)**

INSTRUMENTATION

[Value of various intra- and extraoral therapeutic procedures for treatment of obstructive sleep apnea and snoring] Schönhofer B, et al. **Med Klin** 1997 Mar 15;92(3):167–74 (35 ref.) (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

An overview of professional liability in occupational therapy. Ranke BA, et al. **Am J Occup Ther** 1997 Sep;51(8):671–80 (17 ref.)

METHODS

Systemic sclerosis (scleroderma): an integrated challenge in rehabilitation. Casale R, et al. **Arch Phys Med Rehabil** 1997 Jul;78(7):767–73 (91 ref.)
Rehabilitation after hip fracture in the elderly. The Hospital for Joint Diseases Protocol. Koval KJ, et al. **Bull Hosp Jt Dis** 1997;56(1):60–2 (9 ref.)
Nonoperative management of urinary incontinence. Nygaard IE. **Curr Opin Obstet Gynecol** 1996 Oct;8(5):347–50 (26 ref.)
Physical therapy interventions for patients with movement disorders due to cerebral palsy. Barry MJ. **J Child Neurol** 1996 Nov;11 Suppl 1:S51–60 (101 ref.)
Psychological influences on pain perception and non-pharmacologic approaches to the treatment of pain. DePalma MT, et al. **J Hand Ther** 1997 Apr-Jun; 10(2):183–91 (68 ref.)
Pain management programs in hand therapy: a literature review and appraisal. Doleys DM, et al. **J Hand Ther** 1997 Apr-Jun;10(2):175–82 (72 ref.)
The role of physical agents in modulating pain. Fedorczyk J. **J Hand Ther** 1997 Apr-Jun;10(2):110–21 (90 ref.)
Reflex sympathetic dystrophy: the clinician's perspective. Hardy MA, et al. **J Hand Ther** 1997 Apr-Jun;10(2):137–50 (153 ref.)
Anterior-inferior capsular length insufficiency in the painful shoulder. Hjelm R, et al. **J Orthop Sports Phys Ther** 1996 Mar;23(3):216–22 (14 ref.)
Oxygen transport deficits in systemic disease and implications for physical therapy. Dean E. **Phys Ther** 1997 Feb; 77(2):187–202 (120 ref.)
Physical therapy implications following the TRAM procedure. Monteiro M. **Phys Ther** 1997 Jul;77(7):765–70 (20 ref.)
Evaluation of postural stability in children: current theories and assessment tools. Westcott SL, et al. **Phys Ther** 1997 Jun;77(6):629–45 (117 ref.)
The role of exercise and physical modalities in the treatment of osteoarthritis. Millis DL, et al. **Vet Clin North Am Small Anim Pract** 1997 Jul;27(4):913–30 (33 ref.)
[Spasticity--treatment in children] Truscelli D. **J Belge Med Phys Rehabil** 1980;3(2):158–68 (0 ref.) **(Fre)**
[Physical therapy in low back pain] Muff L, et al. **Schweiz Rundsch Med Prax** 1996 Sep 10;85(37):1116–22 (18 ref.) (Eng. Abstr.) **(Ger)**
[Nonpharmacologic and rehabilitation aspects in inpatient settings] Gatterer G, et al. **Wien Med Wochenschr** 1996; 146(21–22):559–65 (46 ref.) (Eng. Abstr.) **(Ger)**
[Laser physiotherapy of stomatological diseases] Prokhonchukov AA, et al. **Stomatologiia (Mosk)** 1995;

PHYSICAL THERAPY

74(6):23–31 (21 ref.) (Eng. Abstr.) **(Rus)**

ORGANIZATION & ADMINISTRATION

Should general practitioners refer patients directly to physical therapists? Robert G, et al. **Br J Gen Pract** 1997 May; 47(418):314–8 (26 ref.)

Evidence based medicine--implications for physiotherapy? [see comments] Partridge C. **Physiother Res Int** 1996; 1(2):69–73 (14 ref.) Comment in: Physiother Res Int 1997;2(1):59.

A discussion paper on the bases of practice in neurological physiotherapy: a response [comment] [see comments] Shepherd R. **Physiother Res Int** 1996;1(4):265–8 (22 ref.) Comment on: Physiother Res Int 1996;1(3):205–8. Comment in: Physiother Res Int 1997;2(2):62–4.

STATISTICS & NUMERICAL DATA

[Interrater studies of evaluating the reliability of somatic findings] Saur PM, et al. **Rehabilitation (Stuttg)** 1996 Aug; 35(3):150–60 (37 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

The bases of practice--neurological physiotherapy [see comments] Partridge C, et al. **Physiother Res Int** 1996; 1(3):205–8 (13 ref.) Comment in: Physiother Res Int 1996;1(4):265–8. Comment in: Physiother Res Int 1997;2(2):62–4.

PHYSICALLY CHALLENGED see **DISABLED**

PHYSICALLY HANDICAPPED see **DISABLED**

PHYSICIAN ASSISTANTS

ORGANIZATION & ADMINISTRATION

Expanding the physician-substitute concept to oral health care practitioners. Nielsen-Thompson N, et al. **J Public Health Policy** 1997;18(1):80–97 (63 ref.)

STANDARDS

Physician assistants (PAs) provide quality care. Falligant L. **Wis Med J** 1997 Jun;96(6):13–4 (9 ref.)

PHYSICIAN-ASSISTED SUICIDE see **SUICIDE, ASSISTED**

PHYSICIAN EXECUTIVES

EDUCATION

Leadership and organizational skills in academic medicine. Bogdewic SP, et al. **Fam Med** 1997 Apr;29(4):262–5 (47 ref.)

ORGANIZATION & ADMINISTRATION

The physician executive: role in the adaptation of American medicine. Schneller ES, et al. **Health Care Manage Rev** 1997 Spring;22(2):90–6 (46 ref.)

PHYSICIAN-HOSPITAL ORGANIZATIONS see **HOSPITAL-PHYSICIAN JOINT VENTURES**

PHYSICIAN-HOSPITAL RELATIONS see **HOSPITAL-PHYSICIAN RELATIONS**

PHYSICIAN IMPAIRMENT

Physician impairment by substance abuse. O'Connor PG, et al. **Med Clin North Am** 1997 Jul;81(4):1037–52 (49 ref.)

The portrayal of the doctor in non-medical literature: the impaired doctor. Posen S. **Med J Aust** 1997 Jan 6; 166(1):48–51 (34 ref.)

LEGISLATION & JURISPRUDENCE

Medical practitioners and fitness to practise. Chowdhury JR. **J Indian Med Assoc** 1996 Aug;94(8):306–8 (14 ref.)

PSYCHOLOGY

Treatment of the mentally ill physician. Myers MF. **Can J Psychiatry** 1997 Aug;42(6):12 p. (43 ref.) **(Eng, Fre)**

[Is drug dependence an occupational risk for physicians?] Schifferdecker M, et al. **Fortschr Med** 1996 Oct 20; 114(29):372–3, 376 (20 ref.) (Eng. Abstr.) **(Ger)**

[Drug dependence among physicians] Schifferdecker M, et al. **Z Arztl Fortbild (Jena)** 1996 Jun;90(4):295–300 (39 ref.) (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

[Physicians as patients--on the problem of the mentally ill physician] Loevenich A, et al. **Fortschr Neurol Psychiatr** 1996 Sep;64(9):344–52 (47 ref.) (Eng. Abstr.) **(Ger)**

PHYSICIAN INCENTIVE PLANS

ORGANIZATION & ADMINISTRATION

Creating incentives for the delivery of services. Hyde PS. **New Dir Ment Health Serv** 1996 Winter;(72):25–34 (19 ref.)

PHYSICIAN-NURSE RELATIONS

The professional imagination: narrative and the symbolic boundaries between medicine and nursing. May C, et al. **J Adv Nurs** 1997 May;25(5):1094–100 (43 ref.)

Nurse-midwife and physician collaboration: improving opportunities to work towards a healthier Wisconsin. VandeVusse L, et al. **Wis Med J** 1997 Jun;96(6):25–9 (20 ref.)

PHYSICIAN-PATIENT RELATIONS

see related
TRUTH DISCLOSURE

Physician-patient communication in the emergency department. Part 2: Communication strategies for specific situations. SAEM Task Force on Physician-Patient Communication. **Acad Emerg Med** 1996 Dec;3(12):1146–53 (48 ref.)

Making decisions about end-stage renal disease treatment: a review of theories and issues. Pfettscher SA. **Adv Ren Replace Ther** 1997 Jan;4(1):81–8 (62 ref.)

The legal and ethical implications of gag clauses in physician contracts. Martin JA, et al. **Am J Law Med** 1996; 22(4):433–76 (351 ref.)

Drug interactions among the elderly [news] Liaw ST. **Aust Fam Physician** 1997 Apr;26(4):355–7 (29 ref.)

Assisting sexually abused adults. Practical guide to interviewing patients. Leach MM, et al. **Can Fam Physician** 1996 Jan;42:82–6 (22 ref.)

Ethics in the doctor-patient relationship. Smith DH. **Crit Care Clin** 1996 Jan;12(1):179–97 (35 ref.)

Confidentiality issues in the adolescent population. Proimos J. **Curr Opin Pediatr** 1997 Aug;9(4):325–8 (30 ref.)

The role of patient participation in the doctor visit. Implications for adherence to diabetes care. Golin CE, et al. **Diabetes Care** 1996 Oct;19(10):1153–64 (134 ref.)

Ethical and legal implications of managed care. Hall RC. **Gen Hosp Psychiatry** 1997 May;19(3):200–8 (88 ref.)

The patient as moral agent in psychotherapy. Chazan R. **Isr J Psychiatry Relat Sci** 1997;34(1):26–36 (27 ref.)

Play and game as metaphor for technique. Cohen MC. **J Am Acad Psychoanal** 1996 Spring;24(1):61–73 (25 ref.)

Compromised consent: deficiencies in the consent process for genetic testing. Andrews LB. **J Am Med Womens Assoc** 1997 Winter;52(1):39–42, 44 (34 ref.)

Communication, accrual to clinical trials, and the physician-patient relationship: implications for training programs. Ruckdeschel JC, et al. **J Cancer Educ** 1996 Summer;11(2):73–9 (51 ref.)

Discussing futility with patients and families. Dunn PM, et al. **J Gen Intern Med** 1996 Nov;11(11):689–93 (33 ref.)

Communication and the medical interview. Strategies for learning and teaching. Kaplan CB, et al. **J Gen Intern Med** 1997 Apr;12 Suppl 2:S49–55 (24 ref.)

Medical practitioners and fitness to practise. Chowdhury JR. **J Indian Med Assoc** 1996 Aug;94(8):306–8 (14 ref.)

Medical practice and social authority [see comments] Pippin RB. **J Med Philos** 1996 Aug;21(4):417–37 (19 ref.) Comment in: J Med Philos 1996 Aug;21(4):357–73.

Impact of riluzole on the relationship between patient and physician. Dengler R, et al. **J Neurol** 1997 May;244 Suppl 2:S30–2 (11 ref.)

Reappraising reassurance--the role of investigations [editorial] Howard LM, et al. **J Psychosom Res** 1996 Oct; 41(4):307–11 (26 ref.)

The erosion of medical privacy today. Katze J. **Md Med J** 1997 Aug;46(7):345–9 (0 ref.)

Informed consent and disclosure in the physician-patient relationship: expanding obligations for physicians in the United States. LeBlang TR. **Med Law** 1995;14(5–6):429–44 (46 ref.)

Physician virtues and communicating with patients. Gilligan T, et al. **New Horiz** 1997 Feb;5(1):6–14 (53 ref.)

Resolving conflicts surrounding end-of-life care. Prendergast TJ. **New Horiz** 1997 Feb;5(1):62–71 (33 ref.)

Dying, death, and grief. Helping patients and their families through the process. Krigger KW, et al. **Postgrad Med** 1997 Mar;101(3):263–70 (8 ref.)

When your patient is a batterer. What you need to know before treating perpetrators of domestic violence. Mintz HA, et al. **Postgrad Med** 1997 Apr;101(4):219–21, 225–8 (15 ref.)

A patient who keeps giving expensive gifts. Champ R, et al. **Practitioner** 1995 Dec;239(1557):695–8 (0 ref.)

Easier communication with children. Kai J, et al. **Practitioner** 1997 Jun;241(1575):346–9 (2 ref.)

Humor in medicine. Wender RC. **Prim Care** 1996 Mar; 23(1):141–54 (23 ref.)

Hearing the patient's 'voice': toward a social poetics in diagnostic interviews. Katz AM, et al. **Soc Sci Med** 1996 Sep;43(6):919–31 (32 ref.)

Toward a theory of social pharmacology: the actor-spectator paradox applied to the psychotropic prescribing process. Lilja J, et al. **Subst Use Misuse** 1997 Jul;32(9):1175–215 (38 ref.)

Personalized surgery for rectal tumours: the patient's opinion counts. Audisio RA, et al. **Support Care Cancer** 1997 Jan; 5(1):17–21 (77 ref.)

Empathy as a hermeneutic practice. More ES. **Theor Med** 1996 Sep;17(3):243–54 (31 ref.)

Engagement and suffering in responsible caregiving: on overcoming maleficience in health care. Schultz DS, et al. **Theor Med** 1996 Sep;17(3):189–207 (17 ref.)

What's happened to the healing process? Goldberg RM. **W V Med J** 1997 Jul–Aug;93(4):172–3 (0 ref.)

Reproductive health and blurred professional boundaries. Chavkin W, et al. **Womens Health Issues** 1996 Mar–Apr; 6(2):89–96 (46 ref.)

[Methaphors and understanding of diseases] Mabeck CE, et al. **Ugeskr Laeger** 1996 Dec 16;158(51):7384–7 (12 ref.) (Eng. Abstr.) **(Dan)**

[Management of patients afflicted with chronic maladies. Difficulties and obstacles from the standpoint of the patients, from the standpoint of the doctors, from the standpoint of the institution] Assal JP, et al. **Journ Annu Diabetol Hotel Dieu** 1996;:175–83 (10 ref.) **(Fre)**

["Doctor shopping" in fertility medicine] Strauss B. **Arch Gynecol Obstet** 1996;259 Suppl 1:S24–32 (25 ref.) **(Ger)**

[Medical consultation with curable cancer patients] de Maddalena H. **HNO** 1996 Nov;44(11):645–54 (17 ref.) **(Ger)**

[Self-reflection, interpersonal behavior and psychoanalytic ethics] Bürgy M. **Psychother Psychosom Med Psychol** 1997 May;47(5):181–6 (32 ref.) (Eng. Abstr.) **(Ger)**

[Patient education--support--help with decisions: ethical aspects in treatment of amyotrophic lateral sclerosis] Meran JG, et al. **Wien Med Wochenschr** 1996;146(9–10):190–4 (21 ref.) (Eng. Abstr.) **(Ger)**

[Responsibility for the individual or the whole? Ethical considerations on medical responsibility] Vollmann J, et al. **Z Arztl Fortbild (Jena)** 1996 Oct;90(6):527–32 (22 ref.) (Eng. Abstr.) **(Ger)**

[Sexual relations between doctors and patients: state of the art] Witztum E, et al. **Harefuah** 1996 Oct;131(7–8):257–9 (18 ref.) **(Heb)**

[An approach concentrated on the individual--possibilities of use in general medical practice] Leksowski W. **Wiad Lek** 1996;49(1–6):15–23 (24 ref.) (Eng. Abstr.) **(Pol)**

[Should a doctor be insistence in proposing surgery for cancer?] Fedorov VD. **Khirurgiia (Mosk)** 1997;(2):13–7 (10 ref.) (Eng. Abstr.) **(Rus)**

[Biomedical ethics as a form of professional defense of physician's personality] Siluianova IV. **Vestn Ross Akad Med Nauk** 1997;(8):40–3 (5 ref.) (Eng. Abstr.) **(Rus)**

[Is psychotherapy in depression efficient? Physician-patient relations are significant for therapeutic results] Cullberg J. **Lakartidningen** 1996 Nov 27;93(48):4405–6 (6 ref.) **(Swe)**

PHYSICIAN REFUSAL TO TREAT see **REFUSAL TO TREAT**

PHYSICIAN SHORTAGE AREA see **MEDICALLY UNDERSERVED AREA**

PHYSICIANS

The demented driver: the doctor's dilemma. Fitten LJ. **Alzheimer Dis Assoc Disord** 1997 Jun;11 Suppl 1:57–61 (15 ref.)

Rural physicians, rural networks, and free market health care in the 1990s. Rosenthal TC, et al. **Arch Fam Med** 1997 Jul–Aug;6(4):319–23 (59 ref.)

How to get a job in medicine: 1. Scriven P. **Br J Hosp Med** 1996 May 1–14;55(9):546–8 (0 ref.)

The new era of hospital epidemiology: what you need to succeed. Simmons BP, et al. **Clin Infect Dis** 1996 Mar; 22(3):550–3 (12 ref.)

A manual on manners and courtesies for the shared care of patients. Stoeckle JD, et al. **J Clin Ethics** 1997 Spring; 8(1):22–33 (19 ref.)

The Canadian health care crisis and how to survive it: can cost effectiveness save Canadian doctors? Innes G. **J Emerg Med** 1997 May–Jun;15(3):410–5 (19 ref.)

Time management: a review for physicians. Brunicardi FC, et al. **J Natl Med Assoc** 1996 Sep;88(9):581–7 (29 ref.)

Clinicians' attitudes about prolonged use of opioids and the issue of patient heterogeneity. Turk DC. **J Pain Symptom Manage** 1996 Apr;11(4):218–30 (51 ref.)

The migration offshore of U.S. medical technology innovation--what it means for U.S. physicians. Loarie TM. **J Refract Surg** 1997 Mar–Apr;13(2):176–84 (81 ref.)

Management of behavioral dysfunction: a corporate physician's perspective. Farid I. **Occup Med** 1996 Oct–Dec; 11(4):599–615 (27 ref.)

Collaborative care between nurse practitioners and primary care physicians. Arcangelo V, et al. **Prim Care** 1996 Mar; 23(1):103–13 (15 ref.)

Legal forum. Economic credentialing of physicians. New criteria and evaluation of physicians. Riley DW. **Spine** 1996 Jan 1;21(1):141–6 (45 ref.)

[Does a physician's apron protect against nosocomial infection?] Grys E, et al. **Ginekol Pol** 1996 Jun;67(6):309–12 (12 ref.) (Eng. Abstr.) **(Pol)**

[Knowledge and opinions of physicians on acquired immunodeficiency syndrome] González López E. **Med Clin (Barc)** 1996 Nov 16;107(17):664–8 (85 ref.) **(Spa)**

[The characteristics of the diagnostic activities of the physician and therapist] Vitenko IS. **Lik Sprava** 1996 Jan–Feb;(1–2):188–91 (12 ref.) **(Ukr)**

LEGISLATION & JURISPRUDENCE

Capitation, disease management, and physician liability. Frenkel M. **J Health Care Finance** 1997 Spring;23(3):87–90 (0 ref.)

Physician, protect thyself: minimizing the risk of employee embezzlement. Streitfeld R. **Med Health R I** 1997 Jul; 80(7):229–31 (3 ref.)

PSYCHOLOGY

Nurses and physicians evaluate their intensive care experiences. Laubach W, et al. **Heart Lung** 1996 Nov–Dec; 25(6):475–82 (32 ref.)

Scientific knowledge in medicine: a new clinical epistemology? Marshall T. **J Eval Clin Pract** 1997 Apr; 3(2):133–8 (16 ref.)

Evidence–based medicine: why all the fuss? This is why [editorial] Miles A, et al. **J Eval Clin Pract** 1997 Apr; 3(2):83–6 (19 ref.)

Discussing futility with patients and families. Dunn PM, et al. **J Gen Intern Med** 1996 Nov;11(11):689–93 (33 ref.)

Informatics: a physician's view. Welsh F. **J Health Care Finance** 1997 Spring;23(3):37–43 (17 ref.)

Impact of riluzole on the relationship between patient and physician. Dengler R, et al. **J Neurol** 1997 May;244 Suppl 2:S30–2 (11 ref.)

Prescription drug abuse. A question of balance. Parran T Jr. **Med Clin North Am** 1997 Jul;81(4):967–78 (16 ref.)

The psychology of good judgment: frequency formats and simple algorithms [see comments] Gigerenzer G. **Med Decis Making** 1996 Jul–Sep;16(3):273–80 (32 ref.) Comment in: Med Decis Making 1997 Apr–Jun;17(2):233.

How convergence of research paradigms can improve research on diagnostic judgment. Hammond KR. **Med Decis Making** 1996 Jul–Sep;16(3):281–7 (30 ref.)

The acceptance of decision–support systems. van Bemmel JH. **Technol Health Care** 1996 Aug;4(2):137–45 (24 ref.)

[Biomedical ethics as a form of professional defense of physician's personality] Siluianova IV. **Vestn Ross Akad Med Nauk** 1997;(8):40–3 (5 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

Developing issues under the Massachusetts Physician Profile' Act. Donohue JP. **Am J Law Med** 1997; 23(1):115–58 (367 ref.)

The performance of doctors. I: Professionalism and self regulation in a changing world. Irvine D. **BMJ** 1997 May 24;314(7093):1540–2 (21 ref.)

The performance of doctors. II: Maintaining good practice, protecting patients from poor performance [see comments] Irvine D. **BMJ** 1997 May 31;314(7094):1613–5 (11 ref.) Comment in: BMJ 1997 May 31;314(7094):1568.

Who is an interventional cardiologist? Bottner RK, et al. **Cathet Cardiovasc Diagn** 1997 Jun;41(2):120–3 (6 ref.)

SUPPLY & DISTRIBUTION

Are there too many physicians? O'Neil EH. **Hosp Pract (Off Ed)** 1997 Sep 15;32(9):146–8 (5 ref.)

Laboratories and the health care marketplace: the limits of state workforce policy [see comments] Sparer MS. **J Health Polit Policy Law** 1997 Jun;22(3):789–814 (39 ref.) Comment in: J Health Polit Policy Law 1997 Jun;22(3):879–96. Comment in: J Health Polit Policy Law 1997 Jun;22(3):897–906.

Downsizing the physician workforce [see comments] McClendon BJ, et al. **Public Health Rep** 1997 May–Jun; 112(3):231–9 (48 ref.) Comment in: Public Health Rep 1997 May–Jun;112(3):219–21.

PHYSICIANS' ASSISTANTS see **PHYSICIAN ASSISTANTS**

PHYSICIANS' EXTENDERS see **PHYSICIAN ASSISTANTS**

PHYSICIANS, FAMILY

HIV and the primary care physician in Japan. Asai A. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 2:S30–4 (21 ref.)

The physician and the Internet. Wang KK, et al. **Mayo Clin Proc** 1997 Jan;72(1):66–71 (05 ref.)

[Cancer prevention by general practitioners in the Rhône area: a declarative survey] Garcia–Giannoli H, et al. **Bull Cancer** 1996 Oct;83(10):853–63 (39 ref.) (Eng. Abstr.) **(Fre)**

[The role of the general practitioner seen from a perspective of family medicine. Competence about dementia should be developed] Olafsdóttir M, et al. **Lakartidningen** 1997 Mar 12;94(11):957–60 (21 ref.) **(Swe)**

EDUCATION

The allergist as an educator: an evolving relationship between specialty and primary care clinicians [editorial] Squillace SP, et al. **Ann Allergy Asthma Immunol** 1996 Nov; 77(5):341–4 (16 ref.)

STANDARDS

Nurse–midwife and physician collaboration: improving opportunities to work towards a healthier Wisconsin. VandeVusse L, et al. **Wis Med J** 1997 Jun;96(6):25–9 (20 ref.)

PHYSICIANS' OFFICES

STANDARDS

Making our offices universally accessible: guidelines for physicians [see comments] Jones KE, et al. **Can Med Assoc J** 1997 Mar 1;156(5):647–56 (64 ref.) Comment in: Can Med Assoc J 1997 Mar 1;156(5):657–9.

PHYSICIAN'S PRACTICE PATTERNS

Treatment of spinal injuries. On relating anatomical facts to clinical practice. Crock HV. **Acta Orthop Scand** 1997 Aug; 68(4):315–8 (13 ref.)

Review of nutritional attitudes and counseling practices of primary care physicians. Glanz K. **Am J Clin Nutr** 1997 Jun;65(6 Suppl):2016S–2019S (31 ref.)

Nutrition support in clinical practice: review of published data and recommendations for future research directions. Summary of a conference sponsored by the National Institutes of Health, American Society for Parenteral and Enteral Nutrition, and American Society for Clinical Nutrition. Klein S, et al. **Am J Clin Nutr** 1997 Sep; 66(3):683–706 (257 ref.)

Managed care, managing uncertainty. Mirvis DM, et al. **Arch Intern Med** 1997 Feb 24;157(4):385–8 (38 ref.)

Personal paper. Beliefs and evidence in changing clinical practice. Grol R. **BMJ** 1997 Aug 16;315(7105):418–21 (30 ref.)

Variations in breast cancer treatment by patient and provider characteristics. Ayanian JZ, et al. **Breast Cancer Res Treat** 1996;40(1):65–74 (33 ref.)

Reconsidering sore throats. Part I: Problems with current clinical practice [see comments] McIsaac WJ, et al. **Can Fam Physician** 1997 Mar;43:485–93 (62 ref.) Comment in: Can Fam Physician 1997 May;43:843, 845. Comment in: Can Fam Physician 1997 Jul;43:1207–8.

Translating guidelines into practice. A systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines [see comments] Davis DA, et al. **CMAJ** 1997 Aug 15; 157(4):408–16 (61 ref.) Comment in: CMAJ 1997 Aug 15;157(4):403–4.

Does good science make good medicine? Incorporating evidence into practice is complicated by the fact that clinical practice is as much art as science [editorial] Kenny NP. **CMAJ** 1997 Jul 1;157(1):33–6 (18 ref.)

Why psychiatrists in India prescribe so many drugs. Nunley M. **Cult Med Psychiatry** 1996 Jun;20(2):165–97 (91 ref.)

Worldwide similarities and differences in the foregoing of life–sustaining treatments [editorial; comment] Sprung CL, et al. **Intensive Care Med** 1996 Oct;22(10):1003–5 (37 ref.) Comment on: Intensive Care Med 1996 Oct;22(10):1015–9. Comment on: Intensive Care Med 1996 Oct;22(10):1020–5.

Resuscitation decisions in the elderly: a discussion of current thinking. Bruce–Jones PN. **J Med Ethics** 1996 Oct; 22(5):286–91 (62 ref.)

Ophthalmological monitoring of patients taking antimalarials: preferred practice patterns. Easterbrook M, et al. **J Rheumatol** 1997 Jul;24(7):1390–2 (21 ref.)

Trials of providing costing information to general practitioners: a systematic review. Beilby JJ, et al. **Med J Aust** 1997 Jul 21;167(2):89–92 (34 ref.)

Overdrugging and undertreatment in primary health care. Huebscher R. **Nurs Outlook** 1997 Jul–Aug;45(4):161–6 (40 ref.)

Preventive care. Steps toward implementation. Sifri R, et al. **Prim Care** 1996 Mar;23(1):127–40 (28 ref.)

Drug administration practices in medical imaging: a survey. Tortorici M, et al. **Radiol Technol** 1997 May–Jun; 68(5):379–85 (11 ref.)

Strategies and practice for use of nonsteroidal anti–inflammatory drugs. Peloso PM. **Scand J Rheumatol Suppl** 1996;105:29–43; discussion 44–6 (32 ref.)

Ethics committees and achievement of good clinical practice. Glasa J, et al. **Therapie** 1996 Jul–Aug;51(4):369–72 (31 ref.)

Modifying physicians' transfusion practice. Eisenstaedt RS. **Transfus Med Rev** 1997 Jan;11(1):27–37 (69 ref.)

An emerging public health perspective on domestic violence: implications for Wisconsin physicians and health care organizations. Dunham NC, et al. **Wis Med J** 1997 Jan; 96(1):46–50 (21 ref.)

[The impact of clinical trials in arterial hypertension in clinical practice] Pessina AC, et al. **Cardiologia** 1997 Jul; 42(7):687–91 (28 ref.) **(Ita)**

[An approach concentrated on the individual—possibilities of use in general medical practice] Leksowski W. **Wiad Lek** 1996;49(1–6):15–23 (24 ref.) (Eng. Abstr.) **(Pol)**

[Health and Disease as clinician sees them] Malov IS. **Klin Med (Mosk)** 1997;75(1):16–8 (11 ref.) **(Rus)**

ECONOMICS

Cost–effectiveness and cost containment. A physician's primer. Bishof RO, et al. **Prim Care** 1996 Mar;23(1):115–26 (22 ref.)

LEGISLATION & JURISPRUDENCE

Medical malpractice arbitration: a primer for Texas physicians. Fraser JJ Jr. **Tex Med** 1997 Jan;93(1):76–80 (44 ref.)

ORGANIZATION & ADMINISTRATION

Sore throat management in general practice. Little P, et al. **Fam Pract** 1996 Jun;13(3):317–21 (52 ref.)

The telephone in primary care. Studdiford JS III, et al. **Prim Care** 1996 Mar;23(1):83–102 (76 ref.)

STANDARDS

Evidence–based medicine, practice variations and clinical freedom. Hampton JR. **J Eval Clin Pract** 1997 Apr; 3(2):123–31 (38 ref.)

[Rating control in the working program on phthisiology] Kolomiets VM, et al. **Probl Tuberk** 1997;(2):56–8 (0 ref.) **(Rus)**

[Phthisiologist's qualification certification by using tests and personal computers] Kopylova IF, et al. **Probl Tuberk** 1997; (2):59–62 (4 ref.) **(Rus)**

STATISTICS & NUMERICAL DATA

Prevalence of potentially inappropriate long term prescribing in general practice in the United Kingdom, 1980–95: systematic literature review [published erratum appears in BMJ 1997 Mar 1;314(7081):651] Buetow SA, et al. **BMJ** 1996 Nov 30;313(7069):1371–4 (111 ref.)

Physician preferences in the diagnosis and treatment of Lyme disease in the United States. Ziska MH, et al. **Infection** 1996 Mar–Apr;24(2):182–6 (29 ref.)

TRENDS

Clinical practice issues in consultation–liaison psychiatry. Wright M, et al. **Aust N Z J Psychiatry** 1996 Apr; 30(2):238–45 (66 ref.)

How can clinicians incorporate research advances into practice? Larson EB. **J Gen Intern Med** 1997 Apr;12 Suppl 2:S20–4 (13 ref.)

PHYSICIAN'S ROLE

Alternative medicine and the family physician [see comments] Gordon JS. **Am Fam Physician** 1996 Nov 15; 54(7):2205–12, 2218–20 (37 ref.) Comment in: Am Fam Physician 1996 Nov 15;54(7):2184, 2187. Comment in: Am Fam Physician 1997 May 1;55(6):2079; discussion 2083–4. Comment in: Am Fam Physician 1997 May 1;55(6):2080; discussion 2083–4. Comment in: Am Fam Physician 1997 May 1;55(6):2080, 2082; discussion 2083–4. Comment in: Am Fam Physician 1997 May 1;55(6):2083; discussion 2083–4.

Handling nutritional advice in general practice in Norway. Bratland SZ. **Am J Clin Nutr** 1997 Jun;65(6 Suppl):1953S–1956S (2 ref.)

Challenges to prevention in Dutch general practice. Drenthen T. **Am J Clin Nutr** 1997 Jun;65(6 Suppl):1943S–1945S (12 ref.)

Advice on healthy food as given by Flemish general practitioners. Govaerts F. **Am J Clin Nutr** 1997 Jun;65(6 Suppl):1951S–1952S (3 ref.)

Nutrition and general practice: an Australian perspective. Helman A. **Am J Clin Nutr** 1997 Jun;65(6 Suppl):1939S–1942S (24 ref.)

Nutrition in general practice in Italy. Lupo A. **Am J Clin Nutr** 1997 Jun;65(6 Suppl):1963S–1966S (35 ref.)

Management of the cardiac transplant recipient: roles of the transplant cardiologist and primary care physician. Wagoner LE. **Am J Med Sci** 1997 Sep;314(3):173–84 (110 ref.)

Encouraging patients to become more physically active: the physician's role. Andersen RE, et al. **Ann Intern Med** 1997 Sep 1;127(5):395–400 (36 ref.)

The physician's role in minimizing prehospital delay in patients at high risk for acute myocardial infarction: recommendations from the National Heart Attack Alert Program. Working Group on Educational Strategies To Prevent Prehospital Delay in Patients at High Risk for Acute Myocardial Infarction. Dracup K, et al. **Ann Intern Med** 1997 Apr 15;126(8):645–51 (61 ref.)

Physician recommendations and patient autonomy: finding a balance between physician power and patient choice. Quill TE, et al. **Ann Intern Med** 1996 Nov 1;125(9):763–9 (46 ref.)

Recognizing bedside rationing: clear cases and tough calls [see comments] Ubel PA, et al. **Ann Intern Med** 1997 Jan 1;126(1):74–80 (28 ref.) Comment in: Ann Intern Med 1997 Jun 1;126(11):921; discussion 921–2.

PHYSICIAN'S ROLE

In their own hands: adolescents' refusals of medical treatment. Traugott I, et al. **Arch Pediatr Adolesc Med** 1997 Sep;151(9):922–7 (31 ref.)
What is the psychiatrist's role in drugs and alcohol? Pols RG, et al. **Aust N Z J Psychiatry** 1996 Aug;30(4):540–8; discussion 548–9 (99 ref.)
Our strength for tomorrow: valuing our children. Levitt C, et al. **Can Fam Physician** 1997 Sep;43:1585–94 (30 ref.) **(Eng, Fre)**
Bioethics for clinicians: 11. Euthanasia and assisted suicide. Lavery JV, et al. **Can Med Assoc J** 1997 May 15; 156(10):1405–8 (43 ref.)
School-based health promotion: the physician as advocate. Mackie JW, et al. **Can Med Assoc J** 1997 May 1; 156(9):1301–5 (36 ref.)
Barriers to lifestyle change, and the need to develop an integrated approach to prevention. Ockene IS, et al. **Cardiol Clin** 1996 Feb;14(1):159–69 (54 ref.)
The interventional vascular access sheath--the legacy of Donald T. Desilets, M.D. (1935–1996) [editorial; comment] Grollman JH Jr. **Cathet Cardiovasc Diagn** 1997 Jan;40(1):84 (12 ref.) Comment on: Cathet Cardiovasc Diagn 1997 Jan;40(1):81–3.
Bioethics for clinicians: 13. Resource allocation. McKneally MF, et al. **CMAJ** 1997 Jul 15;157(2):163–7 (31 ref.)
The role of the pediatrician in smoking prevention. Sockrider MM. **Curr Opin Pediatr** 1997 Jun;9(3):225–9 (39 ref.)
Chronic gynecologic pain. Stewart DE. **Gen Hosp Psychiatry** 1996 Jul;18(4):230–7 (30 ref.)
Conceptions and misconceptions. Decisions about pregnancy. Stotland NL. **Gen Hosp Psychiatry** 1996 Jul;18(4):238–43 (11 ref.)
Smoking cessation: a four-step plan to help older patients quit. Boyd NR. **Geriatrics** 1996 Nov;51(11):52–7; quiz 58 (21 ref.)
The physician executive: role in the adaptation of American medicine. Schneller ES, et al. **Health Care Manage Rev** 1997 Spring;22(2):90–6 (46 ref.)
Pain and symptom control. Patient rights and physician responsibilities. Emanuel EJ. **Hematol Oncol Clin North Am** 1996 Feb;10(1):41–56 (34 ref.)
Is there a role for physician-assisted suicide in cancer? Yes. McKhann CF. **Important Adv Oncol** 1996;:267–79 (20 ref.)
Is there a role for physician-assisted suicide in cancer? No. Siegler M. **Important Adv Oncol** 1996;:281–91 (72 ref.)
How clinicians can affect patient smoking behavior through community involvement and clinical practice. Epps RP, et al. **J Am Med Womens Assoc** 1996 Jan–Apr;51(1–2):43–7 (8 ref.)
The clinician-educator--present and future roles. Branch WT, et al. **J Gen Intern Med** 1997 Apr;12 Suppl 2:S1–4 (24 ref.)
Preventing firearm violence: a physician's guide. Hunt DK. **J Gen Intern Med** 1996 Nov;11(11):694–701 (94 ref.)
The doctor as businessman: the changing politics of a cultural icon. Stone DA. **J Health Polit Policy Law** 1997 Apr; 22(2):533–56 (43 ref.)
Torture and medical profession--an overview. Umesh MS. **J Indian Med Assoc** 1996 Jul;94(7):257–8, 261 (17 ref.)
Economic analyses, the medical commons, and patients' dilemmas: what is the physician's role? Wynia MK. **J Investig Med** 1997 Feb;45(2):35–43 (62 ref.)
Medical examiner variability. Hinchcliffe R. **J Laryngol Otol** 1997 Jan;111(1):8–14 (25 ref.)
The role of chiropractors in the delivery of interdisciplinary health care in rural areas. Hawk C, et al. **J Manipulative Physiol Ther** 1996 Feb;19(2):82–91 (65 ref.)
Medical practice and social authority [see comments] Pippin RB. **J Med Philos** 1996 Aug;21(4):417–37 (19 ref.) Comment in: J Med Philos 1996 Aug;21(4):357–73.
The role of the generalist in the care of the substance-abusing patient. Lewis DC. **Med Clin North Am** 1997 Jul; 81(4):831–43 (71 ref.)
The role of the general practitioner in the treatment of schizophrenia: general principles. Carr VJ. **Med J Aust** 1997 Jan 20;166(2):91–4 (34 ref.)
Resolving conflicts surrounding end-of-life care. Prendergast TJ. **New Horiz** 1997 Feb;5(1):62–71 (33 ref.)
Supportive care of the patient with pancreatic cancer: role of the psycho-oncologist. Passik SD. **Oncology (Huntingt)** 1996 Sep;10(9 Suppl):33–4 (11 ref.)
Medicolegal aspects of neurotology. Hart CW, et al. **Otolaryngol Clin North Am** 1996 Jun;29(3):503–20 (29 ref.)
The pediatrician's role in caring for the developmentally disabled child. Liptak GS. **Pediatr Rev** 1996 Jun; 17(6):203–10; quiz 211 (16 ref.)
Breastfeeding update. 2: Clinical lactation management. Powers NG, et al. **Pediatr Rev** 1997 May;18(5):147–61 (9 ref.)
The last physician? "The parable of the last physician". Geppert CM. **Pharos** 1997 Spring;60(2):15–20 (15 ref.)
As fiduciaries physicians hold in trust: life, death, and money--and least of those is money. Kjellstrand CM. **Ren Fail** 1996 May;18(3):417–23 (32 ref.)
Hydrops fetalis: role of the geneticist. Steiner RD. **Semin Perinatol** 1995 Dec;19(6):516–24 (70 ref.)
Promoting ethics [editorial] Khoo CY. **Singapore Med J** 1996 Oct;37(5):457–63 (25 ref.)
Ethics and the police surgeon: compromise or conflict? Kelly K, et al. **Soc Sci Med** 1996 Jun;42(11):1569–75 (44 ref.)
Dilemmas and solutions for the pathologist and clinician encountering religious views of the autopsy [see comments] Davis GJ, et al. **South Med J** 1996 Nov;89(11):1041–4 (29 ref.) Comment in: South Med J 1996 Nov;89(11):1125–6.
Roles of mental health professionals in multidisciplinary medically supervised treatment programs for obesity. Hunter SM, et al. **South Med J** 1997 Jun;90(6):578–86 (76 ref.)
Toward a theory of social pharmacology: the actor–spectator paradox applied to the psychotropic prescribing process. Lilja J, et al. **Subst Use Misuse** 1997 Jul;32(9):1175–215 (38 ref.)
Wound healing and wound infection. What surgeons and anesthesiologists can do. Hunt TK, et al. **Surg Clin North Am** 1997 Jun;77(3):587–606 (69 ref.)
[Pediatrician and uprooted children (editorial)] Berthier M, et al. **Arch Pediatr** 1997 Jul;4(7):607–14 (45 ref.) **(Fre)**
[Sects, sectarisms and authentic spiritual pathways: can we learn to discern between them in order to counsel?] Wulliemier F. **Rev Med Suisse Romande** 1997 Jun; 117(6):525–33 (24 ref.) **(Fre)**
[Alcohol at the wheel--medical psychological expert assessment. Laboratory data and abstinence--prognosis--responsibilities of the family physician] Müller-Wickop J, et al. **Fortschr Med** 1996 Oct 20;114(29):374–6 (4 ref.) **(Ger)**
[The role of the pathologist in the diagnosis and monitoring of Wilson's disease] Faa G. **Pathologica** 1996 Apr; 88(2):102–10 (31 ref.) (Eng. Abstr.) **(Ita)**
[The role of the pulmonologist in pulmonary infection (editorial)] Dorca J. **Arch Bronconeumol** 1997 May; 33(5):210–2 (21 ref.) **(Spa)**
[The role of the general practitioner seen from a perspective of family medicine. Competence about dementia should be developed] Olafsdóttir M, et al. **Lakartidningen** 1997 Mar 12;94(11):957–60 (21 ref.) **(Swe)**

PHYSICIANS, WOMEN

PSYCHOLOGY

Psychiatric illness in female physicians. Are high rates of depression an occupational hazard? North CS, et al. **Postgrad Med** 1997 May;101(5):233–6, 239–40, 242 (20 ref.)

STATISTICS & NUMERICAL DATA

The underrepresentation of Hispanic women in the health professions. Zambrana RE. **J Am Med Womens Assoc** 1996 Aug–Oct;51(4):147–52 (13 ref.)

PHYSICS

Dynamical energy systems and modern physics: fostering the science and spirit of complementary and alternative medicine. Schwartz GE, et al. **Altern Ther Health Med** 1997 May;3(3):46–56 (53 ref.)
On the physics of momentum in ballistics: can the human body be displaced or knocked down by a small arms projectile? Karger B, et al. **Int J Legal Med** 1996; 109(3):147–9 (9 ref.)
Physics in medicine: a potential unfolding in the radiological sciences. Jacobson JI. **Panminerva Med** 1997 Jun; 39(2):111–27 (15 ref.)

METHODS

Optical trapping and manipulation of neutral particles using lasers. Ashkin A. **Proc Natl Acad Sci U S A** 1997 May 13;94(10):4853–60 (155 ref.)

PHYSIOGNOMY

see related
FACIAL EXPRESSION

PHYSIOLOGIC AVAILABILITY see **BIOLOGICAL AVAILABILITY**

PHYSIOLOGY

Dynamic systems and neural networks: modeling in physiology and medicine. Sayegh SI. **Adv Food Nutr Res** 1996;40:323–38 (14 ref.)
High altitude medicine and physiology in the former Soviet Union. Gippenreiter E, et al. **Aviat Space Environ Med** 1996 Jun;67(6):576–84 (103 ref.)
Human physiology in space. Vernikos J. **Bioessays** 1996 Dec; 18(12):1029–37 (50 ref.)
Developmental biology of the heart: is there a role for the physiologist? Rudolph AM. **Semin Perinatol** 1996 Dec; 20(6):589–95 (22 ref.)

EDUCATION

Philosophy of science and physiology education. Refinetti R. **Am J Physiol** 1997 Jun;272(6 Pt 3):S31–5 (30 ref.)

HISTORY

Starling: the formulation of his hypothesis of microvascular fluid exchange and its significance after 100 years. Michel CC. **Exp Physiol** 1997 Jan;82(1):1–30 (73 ref.)
The Otto Loewi Lecture. Loewi's discovery and the XXI century. Karczmar AG. **Prog Brain Res** 1996;109:1–27, xvii (108 ref.)
The pivotal role of John S. Edkins in the discovery of gastrin. Modlin IM, et al. **World J Surg** 1997 Feb;21(2):226–34 (35 ref.)
[Waking mechanisms: multiple networks in the mesencephalic reticular formation] Jouvet M. **Arch Physiol Biochem** 1996 Oct;104(6):762–9 (26 ref.) (Eng. Abstr.) **(Fre)**
[Animal respiration as a combustion phenomenon. A historical overview] de Micheli A. **Arch Inst Cardiol Mex** 1996 Nov–Dec;66(6):519–24 (20 ref.) **(Spa)**

METHODS

In vivo EPR: an effective new tool for studying pathophysiology, physiology and pharmacology. Mäder K, et al. **Appl Radiat Isot** 1996 Nov–Dec;47(11–12):1663–7 (46 ref.)
Gene targeting in embryonic stem cells: the new physiology and metabolism. Moreadith RW, et al. **J Mol Med** 1997 Mar;75(3):208–16 (81 ref.)
Optical investigations of physiology: a study of intrinsic and extrinsic biomedical contrast. Chance B, et al. **Philos Trans R Soc Lond B Biol Sci** 1997 Jun 29; 352(1354):707–16 (30 ref.)
[Significance of exercise in clinical physiological function test] Miyazato I, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:52–8 (12 ref.) **(Jpn)**

TRENDS

The mechanisms of renal tubule electrolyte and water absorption, 100 years after Carl Ludwig. Greger R. **Pflugers Arch** 1996;432(3 Suppl):R82–6 (31 ref.)
Controversies on glomerular filtration from Ludwig to the present. Steinhausen M, et al. **Pflugers Arch** 1996;432(3 Suppl):R73–81 (79 ref.)

PHYSIOLOGY, COMPARATIVE

[Surface law and allometric analysis of functions] Günther B, et al. **Rev Med Chil** 1996 Oct;124(10):1261–72 (25 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOTHERAPY see **PHYSICAL THERAPY**

PHYSOSTIGMINE

THERAPEUTIC USE

[Physostigmine. From the God's judgment bean to modern antidote and therapeutic agent] Walter K, et al. **Med Monatsschr Pharm** 1996 Sep;19(9):252–60 (45 ref.) **(Ger)**

PHYTAGGLUTININS see **LECTINS**

PHYTIC ACID

PHARMACOLOGY

IP6: a novel anti-cancer agent. Shamsuddin AM, et al. **Life Sci** 1997;61(4):343–54 (68 ref.)

PHYTIN see **PHYTIC ACID**

PHYTOCHROME

[Phytochrome: a plant sensor for environmental light conditions] Tokutomi S. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(2):121–8 (31 ref.) **(Jpn)**

CHEMISTRY

The phytochromes: a biochemical mechanism of signaling in sight? Quail PH. **Bioessays** 1997 Jul;19(7):571–9 (56 ref.)

METABOLISM

Light modulation of vegetative development. Chory J. **Plant Cell** 1997 Jul;9(7):1225–34 (100 ref.)

PHYSIOLOGY

From seed germination to flowering, light controls plant development via the pigment phytochrome. Chory J, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12066–71 (63 ref.)

PHYTOHORMONES see **PLANT GROWTH REGULATORS**

PHYTOMASTIGOPHOREA

ULTRASTRUCTURE

Cortical structure and function in euglenoids with reference to trypanosomes, ciliates, and dinoflagellates. Bouck GB, et al. **Int Rev Cytol** 1996;169:267–318 (193 ref.)

PHYTOMENADIONE see **PHYTONADIONE**

PHYTOMITOGENS see **LECTINS**

PHYTONADIONE

ADMINISTRATION & DOSAGE

Does intramuscular vitamin K1 act as an unintended depot preparation? Loughnan PM, et al. **J Paediatr Child Health** 1996 Jun;32(3):251–4 (46 ref.)

ADVERSE EFFECTS

Pseudoscleroderma secondary to phytomenadione (vitamin K1) injections: Texier's disease. Pang BK, et al. **Australas J Dermatol** 1996 Feb;37(1):44–7 (11 ref.)

DEFICIENCY

The riddle of vitamin K1 deficit in the newborn. Israels LG, et al. **Semin Perinatol** 1997 Feb;21(1):90–6 (54 ref.)

PHARMACOLOGY

Dietary vitamin K1 and stability of oral anticoagulation: proposal of a diet with constant vitamin K1 content. Booth SL, et al. **Thromb Haemost** 1997 Mar;77(3):504–9 (63 ref.)

PHYTOPHAGINEAE see **PLANT VIRUSES**

PHYTOPHTHORA

PATHOGENICITY

The oxidative burst protects plants against pathogen attack: mechanism and role as an emergency signal for plant bio–defence––a review. Doke N, et al. **Gene** 1996 Nov 7; 179(1):45–51 (40 ref.)

PHYTOREOVIRUS see **REOVIRIDAE**

PHYTOSTEROLS

ADMINISTRATION & DOSAGE

Dietary phytosterols as cholesterol–lowering agents in humans. Jones PJ, et al. **Can J Physiol Pharmacol** 1997 Mar;75(3):217–27 (40 ref.)

BLOOD

Phytosterolaemia: diagnosis, characterization and therapeutical approaches [editorial] Lütjohann D, et al. **Ann Med** 1997 Jun;29(3):181–4 (59 ref.)

THERAPEUTIC USE

Phytochemicals and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Howard BV, et al. **Circulation** 1997 Jun 3; 95(11):2591–3 (25 ref.)

PHYTOTHERAPY see **MEDICINE, HERBAL**

PIA MATER

CYTOLOGY

Ganglionic axons in motor roots and pia mater. Hildebrand C, et al. **Prog Neurobiol** 1997 Feb;51(2):89–128 (276 ref.)

PATHOLOGY

Primary diffuse leptomeningeal gliomatosis with signs of increased intracranial pressure and progressive meningeal enhancement on MRI. Park JS, et al. **J Neuroimaging** 1996 Oct;6(4):250–4 (16 ref.)

SURGERY

Pial synangiosis for treatment of Moyamoya syndrome in children. Hannon KE. **AORN J** 1996 Oct;64(4):540–54; quiz 557–60 (40 ref.)

PIAL VEIN see **CEREBRAL VEINS**

PICA

Pica: are you hungry for the facts? Federman DG, et al. **Conn Med** 1997 Apr;61(4):207–9 (10 ref.)

COMPLICATIONS

Celiac disease in childhood presenting with pica: case report. Santos JA, et al. **Wis Med J** 1996 Aug;95(8):581–2 (9 ref.)

PICHIA

METABOLISM

Large–scale production in Pichia pastoris of the recombinant vaccine Gavac against cattle tick. Canales M, et al. **Vaccine** 1997 Mar;15(4):414–22 (27 ref.)

PICIBANIL

ADMINISTRATION & DOSAGE

Successful treatment of molluscum contagiosum in the immunosuppressed adult with topical injection of streptococcal preparation OK–432. Inui S, et al. **J Dermatol** 1996 Sep;23(9):628–30 (19 ref.)

PICK'S DISEASE OF BRAIN see **DEMENTIA, PRESENILE**

PICK'S DISEASE OF HEART see **PERICARDITIS, CONSTRICTIVE**

PICKWICKIAN SYNDROME

[Two literary characters in the language of neurology: Pickwick (1)] Navarro FA. **Rev Neurol** 1997 Aug; 25(144):1297–302 (92 ref.) **(Spa)**

PICOBIRNAVIRUS

Picobirnavirus, a novel group of undescribed viruses of mammals and birds: a minireview. Chandra R. **Acta Virol** 1997 Feb;41(1):59–62 (18 ref.)

PICODNAVIRUSES see **PARVOVIRIDAE**

PICOLINIC ACIDS

PHARMACOLOGY

Immunobiology of picolinic acid. Melillo G, et al. **Adv Exp Med Biol** 1996;398:135–41 (43 ref.)

Chromium picolinate. Reading SA. **J Fla Med Assoc** 1996 Jan;83(1):29–31 (25 ref.)

PICORNAVIRIDAE

ENZYMOLOGY

Virus–encoded proteinases of the picornavirus super–group. Ryan MD, et al. **J Gen Virol** 1997 Apr;78 (Pt 4):699–723 (179 ref.)

GENETICS

RNA–protein interactions in regulation of picornavirus RNA translation. Belsham GJ, et al. **Microbiol Rev** 1996 Sep; 60(3):499–511 (159 ref.)

PHYSIOLOGY

The regulation of gene expression in neurotrophic viruses. Roos RP. **J Neurovirol** 1997 May;3 Suppl 1:S25–7 (15 ref.)

Epizootiology, distribution and the impact on international trade of two penaeid shrimp viruses in the Americas. Lightner DV. **Rev Sci Tech** 1996 Jun;15(2):579–601 (80 ref.)

PICORNAVIRIDAE INFECTIONS

COMPLICATIONS

The role of respiratory viruses in asthma. Busse WW, et al. **Ciba Found Symp** 1997;206:208–13; discussion 213–9 (27 ref.)

[ICAM–1 and allergic inflammation] Canonica GW. **Allerg Immunol (Paris)** 1997 Mar;29(3):77–9; discussion 84 (17 ref.) (Eng. Abstr.) **(Fre)**

[Respiratory inflammation] Holgate ST. **Allerg Immunol (Paris)** 1997 Mar;29(3):75–6; discussion 82 (11 ref.) (Eng. Abstr.) **(Fre)**

PICORNAVIRUS INFECTIONS see **PICORNAVIRIDAE INFECTIONS**

PICTURE ARCHIVING AND COMMUNICATION SYSTEMS see **RADIOLOGY INFORMATION SYSTEMS**

PICTURE ARCHIVING, RADIOLOGIC see **RADIOLOGY INFORMATION SYSTEMS**

PIEBALDISM

see related
WAARDENBURG'S SYNDROME

PATHOLOGY

Piebaldism, Waardenburg syndrome, and related disorders of melanocyte development. Spritz RA. **Semin Cutan Med Surg** 1997 Mar;16(1):15–23 (59 ref.)

PIERRE ROBIN SYNDROME

DIAGNOSIS

[Robin sequence] Dudkiewicz Z, et al. **Pediatr Pol** 1996 Sep; 71(9):811–5 (18 ref.) **(Pol)**

PIG SKIN DRESSINGS see **BIOLOGICAL DRESSINGS**

PIGEONS

[Circovirus infections in pigeons] Soike D. **Tierarztl Prax** 1997 Jan;25(1):52–4 (15 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

The neuroethology of cognitive maps: contributions from research on the hippocampus and homing pigeon navigation. Casini G, et al. **Arch Ital Biol** 1997 Jan; 135(1):73–92 (69 ref.)

Memory procedures, performance and processes in pigeons. White KG, et al. **Brain Res Cogn Brain Res** 1996 Jun; 3(3–4):309–17 (45 ref.)

Separate channels for visuomotor transformations in the pigeon. Jäger R. **Eur J Morphol** 1997 Oct;35(4):277–89 (70 ref.)

Visual sensation during pecking in pigeons. Ostheim J. **Eur J Morphol** 1997 Oct;35(4):269–76 (36 ref.)

Pigeon basal ganglia: insights into the neuroanatomy underlying telencephalic sensorimotor processes in birds. Veenman CL. **Eur J Morphol** 1997 Oct;35(4):220–33 (138 ref.)

Behavioral morphology of the pigeon's peck: ingestion, prehension and cognition. Zeigler HP. **Eur J Morphol** 1997 Oct;35(4):255–68 (31 ref.)

PIGMENT EPITHELIUM OF EYE

CYTOLOGY

Actin–dependent pigment granule transport in retinal pigment epithelial cells. Burnside B, et al. **Biol Bull** 1997 Feb;192(1):181–2 (7 ref.)

Differentiation and transdifferentiation of the retinal pigment epithelium. Zhao S, et al. **Int Rev Cytol** 1997;171:225–66 (199 ref.)

The interphotoreceptor matrix, a space in sight. Mieziewska K. **Microsc Res Tech** 1996 Dec 15;35(6):463–71 (104 ref.)

METABOLISM

Lipofuscin of the retinal pigment epithelium: a review. Kennedy CJ, et al. **Eye** 1995;9 (Pt 6):763–71 (72 ref.)

PATHOLOGY

Adenocarcinoma of the iris pigment epithelium. Spraul CW, et al. **Arch Ophthalmol** 1996 Dec;114(12):1512–7 (35 ref.)

Adenocarcinoma of the retinal pigment epithelium: a diagnostic and therapeutic challenge. Finger PT, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Aug;234 Suppl 1:S22–7 (23 ref.)

Torpedo maculopathy. Teitelbaum BA, et al. **J Am Optom Assoc** 1997 Jun;68(6):373–6 (12 ref.)

Tumor–associated retinal pigment epithelial tears. Leys AM, et al. **Retina** 1997;17(3):258–60 (5 ref.)

RADIATION EFFECTS

Stress–wave–induced injury to retinal pigment epithelium cells in vitro. Douki T, et al. **Lasers Surg Med** 1996; 19(3):249–59 (33 ref.)

TRANSPLANTATION

Transplantation of retinal pigment epithelial, photoreceptor and other cells as treatment for retinal degeneration. Litchfield TM, et al. **Exp Eye Res** 1997 May;64(5):655–66 (130 ref.)

Retinal cell transplantation in the macula: new techniques. Gouras P, et al. **Vision Res** 1996 Dec;36(24):4121–5 (31 ref.)

[Retinal pigment epithelial cell transplantation: perspective] Tamai M. **Nippon Ganka Gakkai Zasshi** 1996 Dec; 100(12):982–1006 (152 ref.) (Eng. Abstr.) **(Jpn)**

[New techniques for retinal surgery. Cell transplantation, a future therapeutic method?] Nystrand A. **Lakartidningen** 1997 Apr 23;94(17):1617–20, 1623 (10 ref.) **(Swe)**

PIGMENTARY RETINOPATHY see **RETINITIS PIGMENTOSA**

PIGMENTATION

see related
SKIN PIGMENTATION

Dubbing animal diseases with color. Hadlow WJ. **Vet Pathol** 1997 Jan;34(1):74–8 (0 ref.)

GENETICS

Pattern formation in colour on butterfly wings. French V. **Curr Opin Genet Dev** 1997 Aug;7(4):524–9 (30 ref.)

Homologous pigmentation mutations in human, mouse and other model organisms. Jackson IJ. **Hum Mol Genet** 1997; 6(10):1613–24 (122 ref.)

PHYSIOLOGY

The interaction of agouti signal protein and melanocyte stimulating hormone to regulate melanin formation in mammals. Furumura M, et al. **Pigment Cell Res** 1996 Aug; 9(4):191–203 (135 ref.)

Zinc in pigmented cells and structures, interactions and possible roles. Borovanský J. **Sb Lek** 1994;95(4):309–320 (102 ref.)

PIGMENTATION DISORDERS

Dyschromatosis. Urabe K, et al. **Semin Cutan Med Surg** 1997 Mar;16(1):81–5 (20 ref.)

PIGMENTATION DISORDERS

CHEMICALLY INDUCED

Minocycline-induced intraoral pharmacogenic pigmentation: case reports and review of the literature. Westbury LW, et al. **J Periodontol** 1997 Jan;68(1):84–91 (78 ref.)
Minocycline-induced scleral pigmentation. Fraunfelder FT, et al. **Ophthalmology** 1997 Jun;104(6):936–8 (11 ref.)

CLASSIFICATION

Phacomatosis pigmentokeratotica: a melanocytic-epidermal twin nevus syndrome [letter] Happle R, et al. **Am J Med Genet** 1996 Nov 11;65(4):363–5 (18 ref.)

COMPLICATIONS

Sporadic hypomelanosis of Ito with focal hypertrichosis in a 16-month-old girl. Ballmer-Weber BK, et al. **Dermatology** 1996;193(1):63–4 (14 ref.)
Hypomelanosis of Ito and brain abnormalities: MRI findings and literature review. Steiner J, et al. **Pediatr Radiol** 1996 Nov;26(11):763–8 (36 ref.)

DIAGNOSIS

Oral pigmentation representing Laugier-Hunziker syndrome. Mowad CM, et al. **Cutis** 1997 Jul;60(1):37–9 (9 ref.)
Linear atrophoderma of Moulin: treatment with Potaba. Artola Igarza JL, et al. **Dermatology** 1996;193(4):345–7 (7 ref.)
Malignant melanoma: differential diagnosis of pigmented lesions. Le AD, et al. **J Fla Med Assoc** 1997 Mar; 84(3):166–74 (45 ref.)
Yellow nail syndrome. Hershko A, et al. **Postgrad Med J** 1997 Aug;73(862):466–8 (31 ref.)

DRUG THERAPY

Linear atrophoderma of Moulin: treatment with Potaba. Artola Igarza JL, et al. **Dermatology** 1996;193(4):345–7 (7 ref.)

ETIOLOGY

Prurigo pigmentosa, ketonemia and diabetes mellitus. Kobayashi T, et al. **Dermatology** 1996;192(1):78–80 (16 ref.)

GENETICS

Sporadic hypomelanosis of Ito with focal hypertrichosis in a 16-month-old girl. Ballmer-Weber BK, et al. **Dermatology** 1996;193(1):63–4 (14 ref.)
The genetics of pigmentation: from fancy genes to complex traits. Barsh GS. **Trends Genet** 1996 Aug;12(8):299–305 (53 ref.)
[Dyscromic neurocutaneous syndromes] Sola-Casas MA, et al. **Rev Neurol** 1997 Sep;25 Suppl 3:S259–64 (23 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

The color of the human eye: a review of morphologic correlates and of some conditions that affect iridial pigmentation. Imesch PD, et al. **Surv Ophthalmol** 1997 Feb; 41 Suppl 2:S117–23 (46 ref.)

PATHOLOGY

Phacomatosis pigmentokeratotica: a melanocytic-epidermal twin nevus syndrome [letter] Happle R, et al. **Am J Med Genet** 1996 Nov 11;65(4):363–5 (18 ref.)
Piebaldism, Waardenburg syndrome, and related disorders of melanocyte development. Spritz RA. **Semin Cutan Med Surg** 1997 Mar;16(1):15–23 (59 ref.)

SURGERY

Laser treatment of hypertrophic scars, keloids, and striae. Alster TS. **Dermatol Clin** 1997 Jul;15(3):419–29 (86 ref.)
Laser treatment of pigmented lesions. Goldberg DJ. **Dermatol Clin** 1997 Jul;15(3):397–407 (43 ref.)
[Q-switched ruby laser in dermatologic therapy. Use and indications] Michel S, et al. **Hautarzt** 1997 Jul;48(7):462–70 (81 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

[The etiology and diagnosis of "black spot disease" of fish] Kurochkin IuV, et al. **Parazitologiia** 1996 Mar-Apr; 30(2):117–25 (93 ref.) (Eng. Abstr.) **(Rus)**

PIGMENTS

CHEMISTRY

Photobiology of microorganisms: how photosensors catch a photon to initialize signalling. Hellingwerf KJ, et al. **Mol Microbiol** 1996 Aug;21(4):683–93 (76 ref.)

GENETICS

Mutants of Arabidopsis as tools to understand the regulation of phenylpropanoid pathway and UVB protection mechanisms. Bharti AK, et al. **Photochem Photobiol** 1997 May;65(5):765–76 (104 ref.)

METABOLISM

Biochemical basis of lipofuscin, ceroid, and age pigment-like fluorophores. Yin D. **Free Radic Biol Med** 1996; 21(6):871–88 (187 ref.)

PHYSIOLOGY

Pigment cell research: what directions? Prota G. **Pigment Cell Res** 1997 Feb-Apr;10(1-2):5–11 (27 ref.)

RADIATION EFFECTS

Chromophores in human skin. Young AR. **Phys Med Biol** 1997 May;42(5):789–802 (60 ref.)

PIGS see **SWINE**

PILAR CYST see **EPIDERMAL CYST**

PILI, BACTERIAL see **FIMBRIAE, BACTERIAL**

PILI, COMMON see **FIMBRIAE, BACTERIAL**

PILI, CONJUGATIVE see **PILI, SEX**

PILI, SEX

see related
CONJUGATION, GENETIC

IMMUNOLOGY

Questions about gonococcal pilus phase- and antigenic variation. Seifert HS. **Mol Microbiol** 1996 Aug;21(3):433–40 (54 ref.)

PILOCARPINE

POISONING

Eye drops—the hidden poison. Jones AL, et al. **Scott Med J** 1996 Aug;41(4):110–2 (32 ref.)

THERAPEUTIC USE

The pilocarpine paradox [editorial; comment] Ritch R. **J Glaucoma** 1996 Aug;5(4):225–7 (33 ref.) Comment on: J Glaucoma 1996 Aug;5(4):228–32.
The additive intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents. Hoyng PF, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S93–8 (43 ref.)

PILOMATRIXOMA

DIAGNOSIS

Mimics of pilomatrixomas in fine-needle aspirates. Sánchez Sánchez C, et al. **Diagn Cytopathol** 1996 Feb;14(1):75–83 (28 ref.)

PATHOLOGY

Mimics of pilomatrixomas in fine-needle aspirates. Sánchez Sánchez C, et al. **Diagn Cytopathol** 1996 Feb;14(1):75–83 (28 ref.)

PILONIDAL CYST see **PILONIDAL SINUS**

PILONIDAL SINUS

COMPLICATIONS

Multimodality treatment of squamous cell carcinoma complicating pilonidal disease. Kulaylat MN, et al. **Am Surg** 1996 Nov;62(11):922–9 (59 ref.)

SURGERY

[Plastic surgery by the Limberg-Dufourmentel method in the treatment of a pilonidal sinus. The anatomicosurgical considerations and an emblematic case] Cervelli V, et al. **Minerva Chir** 1997 May;52(5):659–62 (18 ref.) (Eng. Abstr.) **(Ita)**

PINDOLOL

ANALOGS & DERIVATIVES

[Pharmacological characteristics of the long-acting beta-blocker "bopindolol"] Nagatomo T, et al. **Nippon Yakurigaku Zasshi** 1997 Jan;109(1):1–12 (51 ref.) (Eng. Abstr.) **(Jpn)**

PINEAL BODY

[Primary germ cell tumors of the central nervous system] Losa F, et al. **Neurologia** 1997 Jun-Jul;12(6):249–54 (30 ref.) (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

Nitric oxide synthase in the pineal gland. López-Figueroa MO, et al. **Histol Histopathol** 1996 Oct;11(4):1089–100 (62 ref.)
The melatonin rhythm-generating enzyme: molecular regulation of serotonin N-acetyltransferase in the pineal gland. Klein DC, et al. **Recent Prog Horm Res** 1997; 52:307–57; discussion 357–8 (72 ref.)

IMMUNOLOGY

[The pineal gland and the immune system] Braczkowski R, et al. **Pol Tyg Lek** 1996 Jun;51(23–26):355–6 (32 ref.) **(Pol)**

INNERVATION

Neural control of the pineal gland. Moore RY. **Behav Brain Res** 1996;73(1–2):125–30 (36 ref.)

PATHOLOGY

The growing teratoma syndrome in a nongerminomatous germ cell tumor of the pineal gland: a case report and review. O'Callaghan AM, et al. **Cancer** 1997 Sep 1; 80(5):942–7 (32 ref.)

PHYSIOLOGY

Cell physiology of the pineal body. Marchiafava PL, et al. **Arch Ital Biol** 1997 Mar;135(2):183–94 (73 ref.)
Neural control of the pineal gland. Moore RY. **Behav Brain Res** 1996;73(1–2):125–30 (36 ref.)
Components and connections of the circadian timing system in mammals. Reuss S. **Cell Tissue Res** 1996 Sep; 285(3):353–78 (280 ref.)
Theoretical considerations on the nature of the pineal 'ageing clock'. Pierpaoli W, et al. **Gerontology** 1997;43(1–2):20–5 (15 ref.)
The pineal gland and reproduction. Aleandri V, et al. **Hum Reprod Update** 1996 May-Jun;2(3):225–35 (115 ref.)
Comparative aspects of the pineal/melatonin system of poikilothermic vertebrates. Filadelfi AM, et al. **J Pineal Res** 1996 May;20(4):175–86 (161 ref.)
Phototransduction cascade and circadian oscillator in chicken pineal gland. Okano T, et al. **J Pineal Res** 1997 Apr; 22(3):145–51 (44 ref.)
Signal transduction molecules in the rat pineal organ: Ca2+, pCREB, and ICER. Korf HW, et al. **Naturwissenschaften** 1996 Dec;83(12):535–43 (44 ref.)
[The role of the pineal body in the endocrine control of puberty] Aleandri V, et al. **Minerva Ginecol** 1997 Jan-Feb; 49(1–2):43–8 (51 ref.) (Eng. Abstr.) **(Ita)**
[The participation of the epiphysis in the anti-stress protection of the brain] Arushanian EB. **Usp Fiziol Nauk** 1996 Jul-Sep;27(3):31–50 (153 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Influence of the pineal gland on the expression of experimental allergic encephalomyelitis: possible relationship to the aquisition of multiple sclerosis. Sandyk R. **Int J Neurosci** 1997 Jun;90(1–2):129–33 (32 ref.)
The pineal gland, cataplexy, and multiple sclerosis. Sandyk R. **Int J Neurosci** 1995 Dec;83(3–4):153–63 (139 ref.)

RADIATION EFFECTS

Phototransduction cascade and circadian oscillator in chicken pineal gland. Okano T, et al. **J Pineal Res** 1997 Apr; 22(3):145–51 (44 ref.)

SECRETION

Gonadal steroid modulation of neuroendocrine transduction: a transynaptic view. Alonso-Solís R, et al. **Cell Mol Neurobiol** 1996 Jun;16(3):357–82 (94 ref.)
[Melatonin in humans: a biochemical marker of the circadian clock and an endogenous synchronizer] Claustrat B, et al. **Neurophysiol Clin** 1995;25(6):351–9 (43 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Cavernous haemangioma of the pineal region. Lombardi D, et al. **Acta Neurochir (Wien)** 1996;138(6):678–83 (16 ref.)
Radiosurgery for pineal tumors: is biopsy indicated? Chasan CB, et al. **Stereotact Funct Neurosurg** 1996;66 Suppl 1:157–63 (12 ref.)

PINEAL GLAND see **PINEAL BODY**

PINOCYTOSIS

IMMUNOLOGY

Mechanisms of antigen uptake for presentation. Lanzavecchia A. **Curr Opin Immunol** 1996 Jun;8(3):348–54 (93 ref.)

PINWORMS see **ENTEROBIUS**

PIP2 see **PHOSPHATIDYLINOSITOL 4,5-DIPHOSPHATE**

PIPECOLIC ACIDS

THERAPEUTIC USE

Argatroban: a synthetic thrombin inhibitor of low relative molecular mass. Fitzgerald D, et al. **Coron Artery Dis** 1996 Jun;7(6):455–8 (33 ref.)
Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Lewis BE, et al. **Semin Thromb Hemost** 1997;23(2):197–202 (35 ref.)

PIPERACILLIN

[Development of beta-lactamase inhibitors] Hyodo A, et al. **Nippon Rinsho** 1997 May;55(5):1272–80 (20 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Piperacillin/tazobactam: a critical review of the evolving clinical literature. Sanders WE Jr, et al. **Clin Infect Dis** 1996 Jan;22(1):107–23 (67 ref.)

PIPERAZINES

ADVERSE EFFECTS

Headache induced by serotonergic agonists—a key to the interpretation of migraine pathogenesis? Panconesi A, et al. **Cephalalgia** 1997 Feb;17(1):3–14 (147 ref.)

Zopiclone: is there any dependence and abuse potential? Lader M. **J Neurol** 1997 Apr;244(4 Suppl 1):S18–22 (31 ref.)

PHARMACOLOGY

GR127935: a potent and selective 5-HT1D receptor antagonist. Skingle M, et al. **Behav Brain Res** 1996; 73(1–2):157–61 (23 ref.)

[A new approach to innovating selective anxiolytics: pharmacological profile of a novel 5-HT1A agonist (tandospirone)] Sasa M. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1997 Apr; 17(2):53–9 (33 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Grepafloxacin. Wagstaff AJ, et al. **Drugs** 1997 May; 53(5):817–24; discussion 825–7 (39 ref.)

PIPERIDINES

Remifentanil: when and how to use it. Servin F. **Eur J Anaesthesiol Suppl** 1997 May;15:41–4 (24 ref.)

Cisapride. Mangal N, et al. **Indian Pediatr** 1995 Oct; 32(10):1124–6 (9 ref.)

[New intravenous anesthetics. Remifentanil, S(+)-ketamine, eltanolone and target controlled infusion] Albrecht S, et al. **Anaesthesist** 1996 Dec;45(12):1129–41 (85 ref.) (Eng. Abstr.) **(Ger)**

[Is remifentanil an ideal opioid for anesthesiologic management in the 21st century?] Scholz J, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Dec; 31(10):592–607 (96 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSTIC USE

[Muscarinic cholinergic receptor imaging of parkinsonian brain using 11C-NMPB and PET] Asahina M, et al. **Nippon Rinsho** 1997 Jan;55(1):233–7 (10 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOKINETICS

The pharmacokinetics of remifentanil. Michelsen LG, et al. **J Clin Anesth** 1996 Dec;8(8):679–82 (16 ref.)

PHARMACOLOGY

Cisapride. Drug interactions of clinical significance. Bedford TA, et al. **Drug Saf** 1996 Sep;15(3):167–75 (31 ref.)

A preclinical overview of ebastine. Studies on the pharmacological properties of a novel histamine H1 receptor antagonist. Roberts DJ. **Drugs** 1996;52 Suppl 1:8–14 (9 ref.)

Brofaromine—a review of its pharmacological properties and therapeutic use. Volz HP, et al. **J Neural Transm** 1996; 103(1–2):217–45 (99 ref.)

Applications of pharmacokinetic/pharmacodynamic research in rational drug development. Danhof M. **Methods Find Exp Clin Pharmacol** 1996;18 Suppl C:53–4 (12 ref.)

[Effect of quinine on the multiple drug resistance and intracellular distribution of pirarubicin in LR73 tumor cells: a comparative study with verapamil and S9788 by confocal laser microspectrofluorometry] Belhoussine R, et al. **Bull Cancer** 1997 Apr;84(4):343–9 (39 ref.) (Eng. Abstr.) **(Fre)**

POISONING

Cisapride poisoning. Gibly RL, et al. **Vet Hum Toxicol** 1997 Aug;39(4):231–3 (17 ref.)

THERAPEUTIC USE

Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166. Kikuchi M. **Diabet Med** 1996 Sep;13(9 Suppl 6):S151–5 (15 ref.)

Remifentanil. Patel SS, et al. **Drugs** 1996 Sep;52(3):417–27; discussion 428 (53 ref.)

Donepezil. Bryson HM, et al. **Drugs Aging** 1997 Mar; 10(3):234–9; discussion 240–1 (26 ref.)

Brofaromine—a review of its pharmacological properties and therapeutic use. Volz HP, et al. **J Neural Transm** 1996; 103(1–2):217–45 (99 ref.)

Glutamate antagonists and Parkinson's disease: a review of clinical data. Montastruc JL, et al. **Neurosci Biobehav Rev** 1997 Jul;21(4):477–80 (33 ref.)

[Pharmacologic and clinical differentiation of prokinetic drugs] May B, et al. **Leber Magen Darm** 1996 Jul; 26(4):193–8 (52 ref.) (Eng. Abstr.) **(Ger)**

PIPOBROMAN

ADVERSE EFFECTS

Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias". Najean Y, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:111–9 (42 ref.)

PIRACETAM

PHARMACOLOGY

Nootropics: preclinical results in the light of clinical effects; comparison with tacrine. Mondadori C. **Crit Rev Neurobiol** 1996;10(3–4):357–70 (85 ref.)

THERAPEUTIC USE

Piracetam in the treatment of myoclonus: an overview. Van Vleymen B, et al. **Acta Neurol Belg** 1996 Dec;96(4):270–80 (62 ref.)

[Piracetam, nimodipine and tacrine in the pharmacologic treatment of dementia: bibliographic review] Ojer Tsakiridu D, et al. **Aten Primaria** 1996 Sep 30;18(5):257–60, 262–4 (31 ref.) **(Spa)**

PIRENZEPINE

ADVERSE EFFECTS

[A case report of drug induced hepatitis and pancreatitis] Shimizu A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 May;94(5):351–5 (19 ref.) **(Jpn)**

ANALOGS & DERIVATIVES

Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Fulton B, et al. **Drugs** 1997 Feb; 53(2):281–98 (71 ref.)

The new generation of antipsychotic drugs. Tamminga CA, et al. **Int Clin Psychopharmacol** 1996 May;11 Suppl 2:73–6 (15 ref.)

In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. Bymaster FP, et al. **J Clin Psychiatry** 1997;58 Suppl 10:28–36 (59 ref.)

Side effect profiles of new antipsychotic agents. Casey DE. **J Clin Psychiatry** 1996;57 Suppl 11:40–5; discussion 46–52 (30 ref.)

Olanzapine and the new generation of antipsychotic agents: patterns of use. Glazer WM. **J Clin Psychiatry** 1997;58 Suppl 10:18–21 (30 ref.)

Behavioral pharmacology of olanzapine: a novel antipsychotic drug. Moore NA, et al. **J Clin Psychiatry** 1997;58 Suppl 10:37–44 (28 ref.)

Olanzapine: a new atypical antipsychotic. Littrell K, et al. **J Psychosoc Nurs Ment Health Serv** 1996 Aug;34(8):41–6 (16 ref.)

Olanzapine: a new typical antipsychotic drug. Meltzer HY, et al. **Neuropsychopharmacology** 1996 Feb;14(2):83–5 (21 ref.)

PIROPLASMA see **BABESIA**

PIROPLASMOSIS see **BABESIOSIS**

PIROXICAM

ANALOGS & DERIVATIVES

Tenoxicam-associated hepatic injury: a case report and review. Katsinelos P, et al. **Eur J Gastroenterol Hepatol** 1997 Apr;9(4):403–6 (24 ref.)

PIT AND FISSURE SEALANTS

Dental sealants. ADA Council on Access, Prevention and Interprofessional Relations; ADA Council on Scientific Affairs. **J Am Dent Assoc** 1997 Apr;128(4):485–8 (24 ref.)

Glass ionomer as fissure sealant—a critical review. Simonsen RJ. **J Public Health Dent** 1996;56(3 Spec No):146–9; discussion 161–3 (21 ref.)

THERAPEUTIC USE

Pit and fissure sealant application: updating the technique. Waggoner WF, et al. **J Am Dent Assoc** 1996 Mar; 127(3):351–61, quiz 391–2 (92 ref.)

The impact of recent changes in the epidemiology of dental caries on guidelines for the use of dental sealants [see comments] Brown LJ, et al. **J Public Health Dent** 1995; 55(5 Spec No):274–91 (102 ref.) Comment in: J Public Health Dent 1995;55(5 Spec No):292–301. Comment in: J Public Health Dent 1995;55(5 Spec No):302–11.

The impact of recent changes in the epidemiology of dental caries on guidelines for the use of dental sealants: epidemiologic perspectives [comment] Rozier RG. **J Public Health Dent** 1995;55(5 Spec No):292–301 (85 ref.) Comment on: J Public Health Dent 1995;55(5 Spec No):274–91.

The impact of recent changes in the epidemiology of dental caries on guidelines for the use of dental sealants: clinical perspectives [comment] Söderholm KJ. **J Public Health Dent** 1995;55(5 Spec No):302–11 (84 ref.) Comment on: J Public Health Dent 1995;55(5 Spec No):274–91.

PIT VIPER VENOMS see **CROTALID VENOMS**

PITHECINAE see **CEBIDAE**

PITUITARY ADENOMA, PROLACTIN-SECRETING see **PROLACTINOMA**

PITUITARY-ADRENAL FUNCTION TESTS

METHODS

[Metopiron test] Horiba N, et al. **Nippon Rinsho** 1997 Apr; 55 Suppl 2:268–71 (3 ref.) **(Jpn)**

[Lysine-vasopressin test] Horiba N, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:272–4 (5 ref.) **(Jpn)**

[Insulin-induced hypoglycemia test] Horiba N, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:275–8 (3 ref.) **(Jpn)**

PITUITARY-ADRENAL SYSTEM

Sensitization of the hypothalamic-pituitary-adrenal axis in posttraumatic stress disorder. Yehuda R. **Ann N Y Acad Sci** 1997 Jun 21;821:57–75 (83 ref.)

CYTOLOGY

The hypothalamic-pituitary axis: co-development of two organs. Treier M, et al. **Curr Opin Cell Biol** 1996 Dec; 8(6):833–43 (82 ref.)

DRUG EFFECTS

Role of prostaglandins in the stimulation of the hypothalamic-pituitary-adrenal axis by adrenergic and neurohormone systems. Bugajski J. **J Physiol Pharmacol** 1996 Dec;47(4):559–75 (78 ref.)

The role of the hypothalamic-pituitary-adrenocortical axis in memory-related effects of anxiolytics. Korneyev AY. **Neurobiol Learn Mem** 1997 Jan;67(1):1–13 (162 ref.)

Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Lipworth BJ, et al. **Thorax** 1997 May;52(5):476–82 (49 ref.)

[Biological mechanisms of drug-resistant depression] Suwalska A, et al. **Psychiatr Pol** 1996 Sep-Oct;30(5):713–29 (56 ref.) (Eng. Abstr.) **(Pol)**

EMBRYOLOGY

The hypothalamic-pituitary axis: co-development of two organs. Treier M, et al. **Curr Opin Cell Biol** 1996 Dec; 8(6):833–43 (82 ref.)

Foetal endocrine maturation. Challis JR, et al. **Equine Vet J Suppl** 1993 Apr;(14):35–40 (51 ref.)

Neuroendocrine regulation of pituitary-adrenal function during fetal life. Brooks AN, et al. **Eur J Endocrinol** 1996 Aug;135(2):153–65 (132 ref.)

IMMUNOLOGY

CRH and the immune system. Karalis K, et al. **J Neuroimmunol** 1997 Feb;72(2):131–6 (87 ref.)

METABOLISM

Regulation of the hypothalmic-pituitary-adrenal axis and vasopressin secretion. Role of angiotensin II. Aguilera G, et al. **Adv Exp Med Biol** 1996;396:105–12 (29 ref.)

The neuroendocrinology of depression and chronic stress. Checkley S. **Br Med Bull** 1996 Jul;52(3):597–617 (122 ref.)

PHYSIOLOGY

Immune modulation of the hypothalamic-pituitary-adrenal axis. Cytokines and gases in the hypothalamus. Grossman A, et al. **Ann N Y Acad Sci** 1997 Aug 14;823:225–33 (17 ref.)

The hypothalamic-pituitary-adrenal axis and the female reproductive system. Magiakou MA, et al. **Ann N Y Acad Sci** 1997 Jun 17;816:42–56 (69 ref.)

The three-way interactions between the hypothalamic-pituitary-adrenal and gonadal axes and the immune system. Torpy DJ, et al. **Baillieres Clin Rheumatol** 1996 May;10(2):181–98 (102 ref.)

Serotonin receptors involved in regulation of pituitary-adrenocortical function in rats. Fuller RW. **Behav Brain Res** 1996;73(1–2):215–9 (33 ref.)

Regulation of the HPA axis by cytokines. Turnbull AV, et al. **Brain Behav Immun** 1995 Dec;9(4):253–75 (289 ref.)

Brain-corticosteroid hormone dialogue: slow and persistent. de Kloet ER, et al. **Cell Mol Neurobiol** 1996 Jun; 16(3):345–56 (52 ref.)

Neuronal circuit regulation of the

hypothalamo-pituitary-adrenocortical stress axis. Herman JP, et al. **Crit Rev Neurobiol** 1996;10(3-4):371-94 (206 ref.)

Dose-response aspects in the clinical assessment of the hypothalamo-pituitary-adrenal axis, and the low-dose adrenocorticotropin test. Oelkers W. **Eur J Endocrinol** 1996 Jul;135(1):27-33 (41 ref.)

Psychoneuroimmunology: searching for the main deteriorating psychobehavioral factor. Rotenberg VS, et al. **Genet Soc Gen Psychol Monogr** 1996 Aug;122(3):329-46 (72 ref.)

Neuropeptide Y-related peptides and hypothalamo-pituitary-adrenal axis function. Malendowicz LK, et al. **Histol Histopathol** 1996 Apr;11(2):485-94 (108 ref.)

Mortyn Jones Memorial Lecture--1995. Calcium checks cyclic AMP--corticosteroid feedback in adenohypophysial corticotrophs. Antoni FA. **J Neuroendocrinol** 1996 Sep; 8(9):659-72 (153 ref.)

A diurnal rhythm of stimulatory input to the hypothalamo-pituitary-adrenal system as revealed by timed intrahypothalamic administration of the vasopressin V1 antagonist. Kalsbeek A, et al. **J Neurosci** 1996 Sep 1; 16(17):5555-65 (80 ref.)

Lipocortin I: a second messenger of glucocorticoid action in the hypothalamo-pituitary-adrenocortical axis. Buckingham JC, et al. **Mol Med Today** 1997 Jul; 3(7):296-302 (39 ref.)

Seminars in medicine of the Beth Israel Deaconess Medical Center. Neuroendocrine responses to starvation and weight loss. Schwartz MW, et al. **N Engl J Med** 1997 Jun 19; 336(25):1802-11 (87 ref.)

Hypothalamic-pituitary-adrenal responses to brief social separation. Hennessy MB. **Neurosci Biobehav Rev** 1997 Jan; 21(1):11-29 (148 ref.)

A view on noradrenergic, hypothalamic-pituitary-adrenal axis and extrahypothalamic corticotrophin-releasing factor function in anxiety and affective disorders: the reduced growth hormone response to clonidine. Coplan JD, et al. **Psychopharmacol Bull** 1997;33(2):193-204 (93 ref.)

Impact of social environment characteristics on neuroendocrine regulation. Seeman TE, et al. **Psychosom Med** 1996 Sep-Oct;58(5):459-71 (159 ref.)

Evidence that abnormalities of central neurohormonal systems are key to understanding fibromyalgia and chronic fatigue syndrome. Crofford LJ, et al. **Rheum Dis Clin North Am** 1996 May;22(2):267-84 (86 ref.)

Stress and behaviorally induced reproductive dysfunction in primates. Cameron JL. **Semin Reprod Endocrinol** 1997 Feb; 15(1):37-45 (56 ref.)

[Biological response to surgical stress--endocrine response] Sakai T. **Masui** 1996 Dec;45 Suppl:S25-30 (14 ref.) **(Jpn)**

[Endocrine response to surgical stress] Saito H. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):701-7 (23 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

The hypothalamic-pituitary-adrenal axis in autoimmunity. Harbuz MS, et al. **Ann N Y Acad Sci** 1997 Aug 14; 823:214-24 (47 ref.)

The relationship of endogenous cortisol to psychiatric disorder: a review. Kiraly SJ, et al. **Can J Psychiatry** 1997 May;42(4):415-20 (85 ref.)

Biological basis of generalized anxiety disorder. Brawman-Mintzer O, et al. **J Clin Psychiatry** 1997;58 Suppl 3:16-25; discussion 26 (78 ref.)

Does prenatal stress impair coping and regulation of hypothalamic-pituitary-adrenal axis? Weinstock M. **Neurosci Biobehav Rev** 1997 Jan;21(1):1-10 (128 ref.)

The hypothalamic-pituitary-adrenal axis in anorexia nervosa. Licinio J, et al. **Psychiatry Res** 1996 Apr 16;62(1):75-83 (50 ref.)

A neuroendocrine role in cocaine reinforcement. Goeders NE. **Psychoneuroendocrinology** 1997 May;22(4):237-59 (180 ref.)

[Limbic-hypothalamic-pituitary-adrenal axis in depression: literature review] Twardowska K, et al. **Psychiatr Pol** 1996 Sep-Oct;30(5):741-55 (46 ref.) (Eng. Abstr.) **(Pol)**

SECRETION

[Metopiron test] Horiba N, et al. **Nippon Rinsho** 1997 Apr; 55 Suppl 2:268-71 (3 ref.) **(Jpn)**

PITUITARY DISEASES

Lymphocytic adenohypophysitis and lymphocytic infundibuloneurohypophysitis. Hashimoto K, et al. **Endocr J** 1997 Feb;44(1):1-10 (107 ref.)

DIAGNOSIS

Diagnostic strategies in pediatric imaging. Adamsbaum C, et al. **Horm Res** 1996;46(4-5):165-9 (30 ref.)

Role of the new growth hormone-releasing secretagogues in the diagnosis of some hypothalamopituitary pathologies. Casanueva FF, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):123-6 (25 ref.)

MRI of pituitary abscess: two cases and review of the literature. Wolansky LJ, et al. **Neuroradiology** 1997 Jul; 39(7):499-503 (35 ref.)

The evaluation and management of subclinical pituitary disease. Soule SG, et al. **Postgrad Med J** 1996 May; 72(847):258-62 (29 ref.)

[Intra-sellar non-adenomatous expansive process] Rohmer V, et al. **Ann Endocrinol (Paris)** 1997;58(1):11-9 (70 ref.) (Eng. Abstr.) **(Fre)**

[Diffuse symptoms in hypophyseal diseases are frequent. Patients are few, but the treatment is highly cost-effective] Werner S. **Lakartidningen** 1997 Mar 12;94(11):968-72 (3 ref.) **(Swe)**

ETIOLOGY

[Lymphocytic infundibulo-hypophysitis with diabetes insipidus as a new clinical entity: a case report and review of the literature] Miyagi K, et al. **No Shinkei Geka** 1997 Feb;25(2):169-75 (23 ref.) (Eng. Abstr.) **(Jpn)**

[The pituitary specific transcription factor Pit-1/GHF-1 and PIT1 abnormality] Tatsumi K, et al. **Rinsho Byori** 1997 Jul;45(7):656-9 (20 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Pit-1: clinical aspects. Pfäffle R, et al. **Horm Res** 1996;45 Suppl 1:25-8 (10 ref.)

PATHOLOGY

Lymphocytic and granulomatous hypophysitis: experience with nine cases. Honegger J, et al. **Neurosurgery** 1997 Apr; 40(4):713-22; discussion 722-3 (41 ref.)

PHYSIOPATHOLOGY

Molecular biology of pituitary development and disease. Bedford FK, et al. **Horm Res** 1996;45 Suppl 1:19-21 (9 ref.)

Spontaneous resolution of a pituitary mass: probable lymphocytic hypophysitis. Menon PS, et al. **J Assoc Physicians India** 1996 Sep;44(9):653-5 (20 ref.)

Hyperfunction and hypofunction in the anterior pituitary. Romeo JH. **Nurs Clin North Am** 1996 Dec;31(4):769-78 (30 ref.)

RADIOGRAPHY

Pituitary abscess: a series of six cases. Jain KC, et al. **Br J Neurosurg** 1997 Apr;11(2):139-43 (15 ref.)

MR imaging and CT of pituitary abscess: case report and review. Kabuto M, et al. **Neurol Res** 1996 Dec;18(6):495-8 (22 ref.)

PITUITARY FUNCTION TESTS

Growth hormone secretion assessment in the diagnosis of short stature. Audí L, et al. **J Pediatr Endocrinol Metab** 1996 Jun;9 Suppl 3:313-24 (74 ref.)

Evaluation of pituitary function in children using growth hormone secretagogues. Bercu BB, et al. **J Pediatr Endocrinol Metab** 1996 Jun;9 Suppl 3:325-32 (12 ref.)

ADVERSE EFFECTS

[Acute pituitary necrosis after multiple pituitary stimulation test] Vergély N, et al. **Presse Med** 1996 Nov 30; 25(37):1827-9 (28 ref.) (Eng. Abstr.) **(Fre)**

METHODS

[L-dopa and dopamine loading test] Azuma K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:252-5 (7 ref.) **(Jpn)**

[Bromocriptine loading test] Azuma K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:256-8 (6 ref.) **(Jpn)**

[TRH test] Azuma K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:245-8 (8 ref.) **(Jpn)**

[Metoclopramide, sulpiride, and chlorpromazine loading test] Azuma K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:249-51 (9 ref.) **(Jpn)**

[Oral glucose loading test] Inoue K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:238-40 (6 ref.) **(Jpn)**

[GRH test] Inoue K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:217-8 (7 ref.) **(Jpn)**

[Insulin induced hypoglycemic test] Inoue K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:219-22 (9 ref.) **(Jpn)**

[Arginine test] Inoue K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:223-4 (5 ref.) **(Jpn)**

[Carter-Robbins test] Kimura T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:291-4 (5 ref.) **(Jpn)**

[LH-RH (loading) test] Miyake A, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:259-61 (0 ref.) **(Jpn)**

[Clomiphene challenge test] Miyake A, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:262-4 (1 ref.) **(Jpn)**

[Pitressin test and DDAVP test] Ohta M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:303-6 (6 ref.) **(Jpn)**

[Water deprivation and water load test] Ota K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:295-8 (4 ref.) **(Jpn)**

[Clinical studies in antidiuretic hormone secretion] Shoji M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:299-302 (3 ref.) **(Jpn)**

[Bromocriptine provocative test] Takeda S, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:234-7 (8 ref.) **(Jpn)**

[Glucagon-propranolol provocative test] Takeda S, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:225-8 (9 ref.) **(Jpn)**

[L-dopa provocative test] Takeda S, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:229-33 (10 ref.) **(Jpn)**

[TRH provocative test] Takeda S, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:241-4 (11 ref.) **(Jpn)**

PITUITARY GLAND

see related
HYPOPHYSECTOMY

CYTOLOGY

Cell-specific mechanisms of estrogen receptor in the pituitary gland. Demay F, et al. **Cell Biol Toxicol** 1996 Dec; 12(4-6):317-24 (45 ref.)

Dendritic cells and macrophages in the pituitary and the gonads. Evidence for their role in the fine regulation of the reproductive endocrine response. Hoek A, et al. **Eur J Endocrinol** 1997 Jan;136(1):8-24 (193 ref.)

DRUG EFFECTS

Plant phenolic amines: potential effects on sympathoadrenal medullary, hypothalamic-pituitary-adrenal, and hypothalamic-pituitary-gonadal function in ruminants. Vera-Avila HR, et al. **Domest Anim Endocrinol** 1996 Jul; 13(4):285-96 (74 ref.)

Dose relationship between GnRH antagonists and pituitary suppression. Rivier J, et al. **Hum Reprod** 1996 Nov;11 Suppl 3:133-47 (74 ref.)

ENZYMOLOGY

The biosynthetic processing and secretion of endogenous carboxypeptidase H in mouse pituitary cells. Mains RE, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:10-8; discussion 18-9 (51 ref.)

GROWTH & DEVELOPMENT

The role of early environmental events in regulating neuroendocrine development. Moms, pups, stress, and glucocorticoid receptors. Francis D, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:136-52 (81 ref.)

Molecular biology of pituitary development and disease. Bedford FK, et al. **Horm Res** 1996;45 Suppl 1:19-21 (9 ref.)

INNERVATION

Architecture of the mammalian pituitary cholinergic system with observations on a putative blood acetylcholine sensor [published erratum appears in Histol Histopathol 1996 Jul;11(3):831] Caffe AR. **Histol Histopathol** 1996 Apr; 11(2):537-51 (64 ref.)

METABOLISM

GnRH signaling in goldfish pituitary cells. Chang JP, et al. **Biol Signals** 1996 Mar-Apr;5(2):70-80 (33 ref.)

Cell-specific mechanisms of estrogen receptor in the pituitary gland. Demay F, et al. **Cell Biol Toxicol** 1996 Dec; 12(4-6):317-24 (45 ref.)

Cytokines in the hypophysis: a comparative look at interleukin-6 in the porcine anterior pituitary gland. Abraham EJ, et al. **Comp Biochem Physiol A Physiol** 1997 Mar;116(3):203-7 (30 ref.)

Post-translational processing of proopiomelanocortin in the pituitary and in the brain. Castro MG, et al. **Crit Rev Neurobiol** 1997;11(1):35-57 (175 ref.)

Corticotropin-releasing factor in antinociception and inflammation. Schäfer M, et al. **Eur J Pharmacol** 1997 Mar 26;323(1):1-10 (152 ref.)

V3 vasopressin receptor and corticotropic phenotype in pituitary and nonpituitary tumors. de Keyzer Y, et al. **Horm Res** 1997;47(4-6):259-62 (18 ref.)

Evaluation of pituitary GH reserve with GHRP-6. Popovic V, et al. **J Pediatr Endocrinol Metab** 1996 Jun;9 Suppl 3:289-98 (23 ref.)

Cytokines: autocrine and paracrine roles in the anterior pituitary. Arzt E, et al. **Neuroimmunomodulation** 1996 Jan-Feb;3(1):28-34 (88 ref.)

Atrial natriuretic peptide in brain and pituitary gland. Gutkowska J, et al. **Physiol Rev** 1997 Apr;77(2):465-515 (468 ref.)

Neuroendocrine effects of cytokines in the rat. Rivier C. **Rev Neurosci** 1993 Jul-Sep;4(3):223-37 (157 ref.)

Different regulation of thyroid hormone transport in liver and pituitary: its possible role in the maintenance of low T3 production during nonthyroidal illness and fasting in man. Everts ME, et al. **Thyroid** 1996 Aug;6(4):359-68 (79 ref.)

PATHOLOGY

Pituitary adenomas: current methods of diagnosis and treatment. Buatti JM, et al. **Oncology (Huntingt)** 1997 Jun; 11(6):791-6; discussion 798, 803-4 (43 ref.)

[Intra-sellar non-adenomatous expansive process] Rohmer V, et al. **Ann Endocrinol (Paris)** 1997;58(1):11-9 (70 ref.) (Eng. Abstr.) **(Fre)**

[Acute pituitary necrosis after multiple pituitary stimulation test] Vergély N, et al. **Presse Med** 1996 Nov 30; 25(37):1827-9 (28 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

An urge to explain the incomprehensible: Geoffrey Harris and the discovery of the neural control of the pituitary

gland. Raisman G. **Annu Rev Neurosci** 1997;20:533–66 (112 ref.)
Studies of gonadotropin-releasing hormone (GnRH) action using GnRH receptor-expressing pituitary cell lines. Kaiser UB, et al. **Endocr Rev** 1997 Feb;18(1):46–70 (191 ref.)
Pituitary cytokine and growth factor expression and action. Ray D, et al. **Endocr Rev** 1997 Apr;18(2):206–28 (357 ref.)
Autocrine and paracrine roles of polypeptide growth factors, cytokines and vasogenic substances in normal and tumorous pituitary function and growth: a review. Renner U, et al. **Eur J Endocrinol** 1996 Nov;135(5):515–32 (286 ref.)
Pit-1: clinical aspects. Pfäffle R, et al. **Horm Res** 1996;45 Suppl 1:25–8 (10 ref.)
Neurone–glia interactions in the hypothalamus and pituitary. Theodosis DT, et al. **Trends Neurosci** 1996 Aug;19(8):363–7 (46 ref.)

PHYSIOPATHOLOGY

Management of canine pituitary-dependent hyperadrenocorticism with l-deprenyl (Anipryl). Bruyette DS, et al. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):273–86 (34 ref.)

SECRETION

Effect of histone-H2A (H–H2A), platelet activating factor (PAF) and pregnancy specific protein B (PSPB) on secretion of prostaglandins E and F2 alpha (PGE; PGF2 alpha) by bovine endometrium and H–H2A on basal secretion of luteinizing hormone (LH) by bovine pituitary cells in vitro. Weems CW, et al. **Chin J Physiol** 1996; 39(3):147–54 (53 ref.)

SURGERY

Cushing's disease: pituitary microsurgery. Hardy J.
Curr Ther Endocrinol Metab 1997;6:63–5 (14 ref.)

ULTRASTRUCTURE

Nuclear effects of the cAMP pathway activation in somatotrophs. Bertherat J. **Horm Res** 1997;47(4–6):245–50 (48 ref.)

PITUITARY GLAND, ANTERIOR

Cholestasis and hypoglycemia: manifestations of congenital anterior hypopituitarism. Choo-Kang LR, et al.
J Clin Endocrinol Metab 1996 Aug;81(8):2786–9 (11 ref.)

CYTOLOGY

Protein sorting and secretory granule formation in prolactin-producing cells in the anterior pituitary. Ozawa H. **Kaibogaku Zasshi** 1997 Feb;72(1):13–24 (62 ref.)

INNERVATION

Direct neural regulation of the mammalian anterior pituitary. Ju G. **Chin Med J (Engl)** 1996 Jan;109(1):44–6 (8 ref.)

METABOLISM

Dual expression of p80 type I and p68 type II interleukin-I receptors on anterior pituitary cells synthesizing growth hormone. French RA, et al. **Endocrinology** 1996 Sep; 137(9):4027–36 (84 ref.)
A senescent pattern of pituitary function during critical illness and dopamine treatment. Van den Berghe GH, et al.
Verh K Acad Geneeskd Belg 1996;58(4):383–411 (178 ref.)
[Paracrine regulation of anterior pituitary hormones by neuropeptides] Peillon F, et al. **Ann Endocrinol (Paris)** 1997; 58(1):31–8 (67 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Diagnosis & management of pituitary tumors. Weinstein J, et al. **Compr Ther** 1997 Sep;23(9):594–604 (66 ref.)
Pituitary corticotroph macrotumors. Diagnosis and treatment. Ihle SL.
Vet Clin North Am Small Anim Pract 1997 Mar; 27(2):287–97 (58 ref.)

PHYSIOLOGY

PACAP/VIP receptor subtypes, signal transducers, and effectors in pituitary cells. Hezareh M, et al.
Ann N Y Acad Sci 1996 Dec 26;805:315–27; discussion 327–8 (41 ref.)
Effects of GnRH and PACAP on gonadotropin secretion and subunit messenger RNAs. Winters SJ, et al.
Ann N Y Acad Sci 1996 Dec 26;805:343–52; discussion 352–4 (30 ref.)
Neurotensin and neuroendocrine regulation. Rostène WH, et al. **Front Neuroendocrinol** 1997 Apr;18(2):115–73 (346 ref.)
Novel perspectives on pituitary and brain angiotensinogen. Sernia C, et al. **Front Neuroendocrinol** 1997 Apr; 18(2):174–208 (179 ref.)
Ain't misbehavin': reflections on the functional differences among anterior pituitary cells. Schwartz J, et al.
Mol Cell Endocrinol 1996 Oct 14;123(1):1–6 (44 ref.)

PHYSIOPATHOLOGY

Spontaneous resolution of a pituitary mass: probable lymphocytic hypophysitis. Menon PS, et al.
J Assoc Physicians India 1996 Sep;44(9):653–5 (20 ref.)

SECRETION

Neurohypophysial peptides. Histaminergic regulation and function in adenohypophysial secretion. Kjaer A.
Dan Med Bull 1996 Dec;43(5):391–406 (188 ref.)
Oxytocin and the control of LH. Evans JJ. **J Endocrinol** 1996 Nov;151(2):169–74 (75 ref.)
New insights into the regulation of somatotrope function using genetic and transgenic models. Frohman LA.
Metabolism 1996 Aug;45(8 Suppl 1):1–3 (14 ref.)
[Bromocriptine loading test] Azuma K, et al.
Nippon Rinsho 1997 Apr;55 Suppl 2:256–8 (6 ref.) **(Jpn)**
[TRH test] Azuma K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:245–8 (8 ref.) **(Jpn)**

PITUITARY GLAND, POSTERIOR

PHYSIOLOGY

Neurohypophysial peptides. Histaminergic regulation and function in adenohypophysial secretion. Kjaer A.
Dan Med Bull 1996 Dec;43(5):391–406 (188 ref.)
Molecular evolution of fish neurohypophysial hormones: neutral and selective evolutionary mechanisms. Acher R.
Gen Comp Endocrinol 1996 May;102(2):157–72 (59 ref.)
Central nervous system actions of oxytocin and modulation of behavior in humans. McCarthy MM, et al.
Mol Med Today 1997 Jun;3(6):269–75 (49 ref.)

SECRETION

[Clinical studies in antidiuretic hormone secretion] Shoji M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:299–302 (3 ref.) **(Jpn)**

PITUITARY GLYCOPROTEIN HORMONE, ALPHA SUBUNIT see **GLYCOPROTEIN HORMONES, ALPHA SUBUNIT**

PITUITARY GONADOTROPIN RECEPTORS see **RECEPTORS, GONADOTROPIN**

PITUITARY GROWTH HORMONE see **SOMATOTROPIN**

PITUITARY GROWTH HORMONES, RECOMBINANT see **SOMATOTROPINS, RECOMBINANT**

PITUITARY HORMONE RECEPTORS see **RECEPTORS, PITUITARY HORMONE**

PITUITARY HORMONE-REGULATING HORMONE RECEPTORS see **RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE**

PITUITARY HORMONE RELEASE INHIBITING HORMONES

see related
RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE

PITUITARY HORMONE-RELEASING HORMONE RECEPTORS see **RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE**

PITUITARY HORMONE-RELEASING HORMONES

see related
RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE

PHYSIOLOGY

[Molecular biological analysis of hypothalamic-hypophyseal hormones] Mori M, et al. **Nippon Naika Gakkai Zasshi** 1997 Mar 10;86(3):385–90 (7 ref.) **(Jpn)**

PITUITARY HORMONES

see related
HYPOPITUITARISM
RECEPTORS, PITUITARY HORMONE
Cell biology of somatolactin. Kaneko T. **Int Rev Cytol** 1996; 169:1–24 (57 ref.)
Melanotropic peptides in the mammalian brain: the melanin-concentrating hormone. Knigge KM, et al.
Peptides 1996;17(6):1063–73 (147 ref.)

CHEMISTRY

Glycosylation is the structural basis for changes in polymorphism and immunoreactivity of pituitary glycoprotein hormones. Zerfaoui M, et al.
Eur J Clin Chem Clin Biochem 1996 Sep;34(9):749–53 (12 ref.)

DEFICIENCY

Replacement therapy: arginine vasopressin (AVP), growth hormone (GH), cortisol, thyroxine, testosterone and estrogen. Mitchell DH, et al. **J Neurosci Nurs** 1996 Jun; 28(3):140–52; quiz 152–4 (67 ref.)

GENETICS

Glycosylation is the structural basis for changes in polymorphism and immunoreactivity of pituitary glycoprotein hormones. Zerfaoui M, et al.
Eur J Clin Chem Clin Biochem 1996 Sep;34(9):749–53 (12 ref.)

IMMUNOLOGY

Immunomodulation of peripheral lymphocytes by hormones of the hypothalamus–pituitary–thyroid axis. Kruger TE.
Adv Neuroimmunol 1996;6(4):387–95 (63 ref.)
Dynamic regulation of intestinal immunity by hormones of the hypothalamus–pituitary–thyroid axis. Wang J.
Adv Neuroimmunol 1996;6(4):407–17 (51 ref.)

PHYSIOLOGY

Dynamic regulation of intestinal immunity by hormones of the hypothalamus–pituitary–thyroid axis. Wang J.
Adv Neuroimmunol 1996;6(4):407–17 (51 ref.)
MIF re-discovered: pituitary hormone and glucocorticoid-induced regulator of cytokine production. Bucala R. **Cytokine Growth Factor Rev** 1996 Jun;7(1):19–24 (31 ref.)
Molecular evolution of fish neurohypophysial hormones: neutral and selective evolutionary mechanisms. Acher R.
Gen Comp Endocrinol 1996 May;102(2):157–72 (59 ref.)
[Molecular biological analysis of hypothalamic-hypophyseal hormones] Mori M, et al. **Nippon Naika Gakkai Zasshi** 1997 Mar 10;86(3):385–90 (7 ref.) **(Jpn)**

THERAPEUTIC USE

Hypopituitarism. Oelkers WK.
Curr Ther Endocrinol Metab 1997;6:27–31 (7 ref.)
Replacement therapy: arginine vasopressin (AVP), growth hormone (GH), cortisol, thyroxine, testosterone and estrogen. Mitchell DH, et al. **J Neurosci Nurs** 1996 Jun; 28(3):140–52; quiz 152–4 (67 ref.)

PITUITARY HORMONES, ANTERIOR

BIOSYNTHESIS

[Paracrine regulation of anterior pituitary hormones by neuropeptides] Peillon F, et al. **Ann Endocrinol (Paris)** 1997; 58(1):31–8 (67 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune response. Bucala R. **FASEB J** 1996 Dec;10(14):1607–13 (46 ref.)

PHYSIOLOGY

Novel insights into the molecular mechanisms of human thyrotropin action: structural, physiological, and therapeutic implications for the glycoprotein hormone family. Grossmann M, et al. **Endocr Rev** 1997 Aug; 18(4):476–501 (236 ref.)

SECRETION

Ain't misbehavin': reflections on the functional differences among anterior pituitary cells. Schwartz J, et al.
Mol Cell Endocrinol 1996 Oct 14;123(1):1–6 (44 ref.)
[Paracrine regulation of anterior pituitary hormones by neuropeptides] Peillon F, et al. **Ann Endocrinol (Paris)** 1997; 58(1):31–8 (67 ref.) (Eng. Abstr.) **(Fre)**

PITUITARY HORMONES, POSTERIOR

see related
NEUROPHYSINS

PITUITARY IRRADIATION

TRENDS

[Pituitary radiotherapy. Current data and future prospects] Cortet-Rudelli C, et al. **Ann Endocrinol (Paris)** 1997; 58(1):21–9 (44 ref.) (Eng. Abstr.) **(Fre)**

PITUITARY NEOPLASMS

Diagnosis & management of pituitary tumors. Weinstein J, et al. **Compr Ther** 1997 Sep;23(9):594–604 (66 ref.)
Nerve growth factor suppresses the tumoral phenotype of human prolactinomas. Missale C, et al. **Horm Res** 1997; 47(4–6):240–4 (29 ref.)
Nonfunctioning adenomas of the pituitary. Liuzzi A, et al.
Metabolism 1996 Aug;45(8 Suppl 1):80–2 (16 ref.)

CLASSIFICATION

[Classification, pathology and molecular biology of pituitary adenoma] Tapar K, et al. **Arkh Patol** 1997 May–Jun; 59(3):7–17 (22 ref.) (Eng. Abstr.) **(Rus)**

PITUITARY NEOPLASMS

COMPLICATIONS

Clusterlike headache in a patient with a pituitary adenoma. With a review of the literature. Milos P, et al. **Headache** 1996 Mar;36(3):184–8 (29 ref.)

A pituitary mass and hypopituitarism: improvement after corticosteroid therapy. Shimon I, et al. **Isr J Med Sci** 1997 Jan;33(1):58–62 (28 ref.)

Etiology of an unusual visual field deficit associated with a craniopharyngioma: case report. Huang PP, et al. **Ophthalmologica** 1997;211(4):256–62 (24 ref.)

Hyperthyroidism caused by an ectopic TSH-secreting pituitary tumor. Cooper DS, et al. **Thyroid** 1996 Aug; 6(4):337–43 (50 ref.)

DIAGNOSIS

Approach to the incidentally discovered pituitary mass. Molitch ME. **Cancer Treat Res** 1997;89:73–90 (83 ref.)

Pituitary adenomas: current methods of diagnosis and treatment. Buatti JM, et al. **Oncology (Huntingt)** 1997 Jun; 11(6):791–6; discussion 798, 803–4 (43 ref.)

The evaluation and management of subclinical pituitary disease. Soule SG, et al. **Postgrad Med J** 1996 May; 72(847):258–62 (29 ref.)

Giant posterior fossa cystic craniopharyngiomas presenting with hearing loss. Report of three cases and review of the literature. Connolly ES Jr, et al. **Surg Neurol** 1997 Mar; 47(3):291–9 (32 ref.)

[Intra-sellar non-adenomatous expansive process] Rohmer V, et al. **Ann Endocrinol (Paris)** 1997;58(1):11–9 (70 ref.) (Eng. Abstr.) **(Fre)**

[Hypophyseal adenomas: functional and tumor evaluation and therapeutic approaches] Tielmans D, et al. **Rev Med Interne** 1996;17(11):901–9 (31 ref.) (Eng. Abstr.) **(Fre)**

[Radiologic diagnosis of hypophyseal adenomas] Brechtelsbauer D, et al. **Aktuelle Radiol** 1996 Nov; 6(6):301–7 (38 ref.) (Eng. Abstr.) **(Ger)**

[Diffuse symptoms in hypophyseal diseases are frequent. Patients are few, but the treatment is highly cost-effective] Werner S. **Lakartidningen** 1997 Mar 12;94(11):968–72 (3 ref.) **(Swe)**

DRUG THERAPY

A pituitary mass and hypopituitarism: improvement after corticosteroid therapy. Shimon I, et al. **Isr J Med Sci** 1997 Jan;33(1):58–62 (28 ref.)

[Quinagolide and macroprolactinomas a progress?] Jaquet P. **Ann Endocrinol (Paris)** 1997;58(2):83–5 (35 ref.) **(Fre)**

[Treatment of macroprolactinomas with quinagolide (Norprolac)] Tabarin A, et al. **Ann Endocrinol (Paris)** 1997; 58(2):87–94 (30 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Cyclic AMP and calcium in the transduction of hypothalamic neurohormone action in human pituitary tumors. Spada A, et al. **Horm Res** 1997;47(4–6):235–9 (38 ref.)

Genetic basis of endocrine disease: pituitary tumor pathogenesis. Shimon I, et al. **J Clin Endocrinol Metab** 1997 Jun;82(6):1675–81 (104 ref.)

GENETICS

Molecular biology of growth-hormone-secreting human pituitary tumours: biochemical consequences and potential clinical significance. Adams EF, et al. **Acta Neurochir Suppl (Wien)** 1996;65:7–10 (18 ref.)

Molecular pathophysiology of acromegaly. Melmed S. **Acta Paediatr Suppl** 1996 Oct;417:45–8 (28 ref.)

Multiple endocrine neoplasia type I. Clinical genetics and diagnosis. Skogseid B. **Cancer Treat Res** 1997;89:383–406 (64 ref.)

Abnormal transduction mechanisms in pituitary adenomas. Barlier A, et al. **Horm Res** 1997;47(4–6):227–34 (61 ref.)

Tumour suppressor genes in the pathogenesis of human pituitary tumours. Clayton RN, et al. **Horm Res** 1997; 47(4–6):185–93 (22 ref.)

Genetic basis of endocrine disease: pituitary tumor pathogenesis. Shimon I, et al. **J Clin Endocrinol Metab** 1997 Jun;82(6):1675–81 (104 ref.)

GS protein mutations and pituitary tumors: functional correlates and possible therapeutic implications. Faglia G, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):117–9 (18 ref.)

Gs protein mutations and the pathogenesis and function of pituitary tumors. Harris PE. **Metabolism** 1996 Aug;45(8 Suppl 1):120–2 (23 ref.)

[Homeoproteins and pituitary adenoma] Barlier A, et al. **Ann Endocrinol (Paris)** 1997;58(1):3–10 (34 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Gonadotroph adenomas. Snyder PJ. **Curr Ther Endocrinol Metab** 1997;6:56–8 (4 ref.)

V3 vasopressin receptor and corticotropic phenotype in pituitary and nonpituitary tumors. de Keyzer Y, et al. **Horm Res** 1997;47(4–6):259–62 (18 ref.)

Pit-1 gene expression in human pituitary adenomas. Pellegrini-Bouiller I, et al. **Horm Res** 1997;47(4–6):251–8 (43 ref.)

Hyperthyroidism caused by an ectopic TSH-secreting pituitary tumor. Cooper DS, et al. **Thyroid** 1996 Aug; 6(4):337–43 (50 ref.)

PATHOLOGY

Proliferation parameters for pituitary adenomas. Buchfelder M, et al. **Acta Neurochir Suppl (Wien)** 1996;65:18–21 (20 ref.)

Molecular biological research in pituitary adenomas from the pathologists' view. Kovacs K. **Acta Neurochir Suppl (Wien)** 1996;65:4–6 (8 ref.)

Current pathological classification of pituitary adenomas. Saeger W. **Acta Neurochir Suppl (Wien)** 1996;65:1–3 (8 ref.)

PHYSIOPATHOLOGY

Autocrine and paracrine roles of polypeptide growth factors, cytokines and vasogenic substances in normal and tumorous pituitary function and growth: a review. Renner U, et al. **Eur J Endocrinol** 1996 Nov;135(5):515–32 (286 ref.)

GS protein mutations and pituitary tumors: functional correlates and possible therapeutic implications. Faglia G, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):117–9 (18 ref.)

Gs protein mutations and the pathogenesis and function of pituitary tumors. Harris PE. **Metabolism** 1996 Aug;45(8 Suppl 1):120–2 (23 ref.)

Cellular abnormalities in pituitary tumors. Spada A, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):46–8 (24 ref.)

RADIOTHERAPY

Radiotherapy for pituitary adenomas: an endocrinologist's perspective. O'Halloran DJ, et al. **Clin Oncol (R Coll Radiol)** 1996;8(2):79–84 (58 ref.)

Suprasellar meningioma subsequent to treatment for a pituitary adenoma: case report. Rao MB, et al. **Surg Neurol** 1997 May;47(5):443–6 (11 ref.)

[Pituitary radiotherapy. Current data and future prospects] Cortet-Rudelli C, et al. **Ann Endocrinol (Paris)** 1997; 58(1):21–9 (44 ref.) (Eng. Abstr.) **(Fre)**

SECRETION

Prolactinomas. Katznelson L, et al. **Cancer Treat Res** 1997; 89:41–55 (40 ref.)

Growth hormone- and growth-hormone-releasing hormone-producing tumors. Shimon I, et al. **Cancer Treat Res** 1997;89:1–24 (78 ref.)

Gonadotroph and other clinically nonfunctioning pituitary adenomas. Snyder PJ. **Cancer Treat Res** 1997;89:57–72 (39 ref.)

Thyrotropin-secreting pituitary tumors. Beck-Peccoz P, et al. **Endocr Rev** 1996 Dec;17(6):610–38 (377 ref.)

An unusual treatment-related complication in a patient with growth hormone-secreting pituitary tumor. Ahmed M, et al. **J Clin Endocrinol Metab** 1997 Sep;82(9):2816–20 (19 ref.)

Adrenocorticotropin-producing pituitary carcinoma with liver metastasis. Lormeau B, et al. **J Endocrinol Invest** 1997 Apr;20(4):230–6 (23 ref.)

Thyrotropin-secreting pituitary adenomas. Beck-Peccoz P, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):75–9 (28 ref.)

[Thyreotropic adenoma: review of the literature. Apropos of 2 cases] Prévost G, et al. **Ann Endocrinol (Paris)** 1996; 57(3):194–202 (40 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Primary intrasellar mixed germ-cell tumor with precocious puberty and diabetes insipidus. Cho DY, et al. **Childs Nerv Syst** 1997 Jan;13(1):42–6 (14 ref.)

Craniopharyngioma: transsphenoidal surgery. Laws ER Jr. **Curr Ther Endocrinol Metab** 1997;6:35–8 (6 ref.)

Surgical management of pituitary tumors. Wilson CB. **J Clin Endocrinol Metab** 1997 Aug;82(8):2381–5 (4 ref.)

Surgical therapy of pituitary adenomas. Giovanelli M, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):115–6 (7 ref.)

Stereotactic radiosurgery of pituitary adenomas. Motti ED, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):111–4 (11 ref.)

Surgical management of craniopharyngiomas: a review. Samii M, et al. **Neurol Med Chir (Tokyo)** 1997 Feb;37(2):141–9 (39 ref.)

Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Ciric I, et al. **Neurosurgery** 1997 Feb; 40(2):225–36; discussion 236–7 (101 ref.)

Intrasellar pituitary gangliocyto-adenoma presenting with acromegaly: case report. Morikawa M, et al. **Neurosurgery** 1997 Mar;40(3):611–4; discussion 614–5 (34 ref.)

Giant posterior fossa cystic craniopharyngiomas presenting with hearing loss. Report of three cases and review of the literature. Connolly ES Jr, et al. **Surg Neurol** 1997 Mar; 47(3):291–9 (32 ref.)

[New etiopathogenic, clinical and therapeutic findings in multiple endocrine neoplasia type 1] Tomassetti P, et al. **Minerva Gastroenterol Dietol** 1996 Sep;42(3):133–43 (53 ref.) (Eng. Abstr.) **(Ita)**

[Endoscope assisted transsphenoidal approach for pituitary adenomas] Kitano M, et al. **No Shinkei Geka** 1997 Mar; 25(3):197–203 (14 ref.) **(Jpn)**

THERAPY

Pituitary adenomas. Andrews DW. **Curr Opin Oncol** 1997 Jan;9(1):55–60 (59 ref.)

Prolactinoma. Schlechte JA. **Curr Ther Endocrinol Metab** 1997;6:45–7 (5 ref.)

Nonfunctioning pituitary adenoma. Vance ML. **Curr Ther Endocrinol Metab** 1997;6:33–5 (4 ref.)

New modalities in treating pituitary adenomas. Jackson I, et al. **Med Health R I** 1996 Jun;79(6):224–8 (15 ref.)

Recent management of pituitary adenomas. Teramoto A. **Nippon Ika Daigaku Zasshi** 1996 Aug;63(4):255–8 (8 ref.)

Pituitary adenomas: current methods of diagnosis and treatment. Buatti JM, et al. **Oncology (Huntingt)** 1997 Jun; 11(6):791–6; discussion 798, 803–4 (43 ref.)

VETERINARY

Tumours of the endocrine glands. Schmidt RE, et al. **IARC Sci Publ** 1996;(126):307–20 (50 ref.)

Pituitary corticotroph macrotumors. Diagnosis and treatment. Ihle SL. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):287–97 (58 ref.)

PITYRIASIS

COMPLICATIONS

Pityriasis rubra pilaris and focal acantholytic dyskeratosis. Cowen P, et al. **Australas J Dermatol** 1997 Feb;38(1):40–1 (5 ref.)

PATHOLOGY

Pityriasis rotunda. Pinto GM, et al. **Cutis** 1996 Dec; 58(6):406–8 (20 ref.)

PITYRIASIS LICHENOIDES

Mucha-Habermann disease and its febrile ulceronecrotic variant. Tsuji T, et al. **Cutis** 1996 Aug;58(2):123–31 (70 ref.)

PHYSIOPATHOLOGY

Febrile ulceronecrotic Mucha-Habermann disease: a case report and review of the literature. Suárez J, et al. **Dermatology** 1996;192(3):277–9 (11 ref.)

PITYRIASIS LICHENOIDES CHRONICA see **PITYRIASIS LICHENOIDES**

PITYRIASIS LICHENOIDES ET VARIOLIFORMIS ACUTA see **PITYRIASIS LICHENOIDES**

PITYRIASIS ROSEA

DIAGNOSIS

Pityriasis. Wyndham M. **Practitioner** 1997 Jun;241(1575):358 (0 ref.)

PITYRIASIS RUBRA PILARIS

ETIOLOGY

Dermatomyositis with a pityriasis rubra pilaris-like eruption: a little-known distinctive cutaneous manifestation of dermatomyositis. Requena L, et al. **Br J Dermatol** 1997 May;136(5):768–71 (23 ref.)

PITYRIASIS VERSICOLOR see **TINEA VERSICOLOR**

PITYROSPORUM see **MALASSEZIA**

PIXE see **SPECTROMETRY, X-RAY EMISSION**

PIZOTIFEN see **PIZOTYLINE**

PIZOTYLINE

THERAPEUTIC USE

[Familial erythermalgia treated with pizotifen] Guillet MH, et al. **Ann Dermatol Venereol** 1995;122(11–12):777–9 (31 ref.) (Eng. Abstr.) **(Fre)**

PLACEBO EFFECT

Placebo effect and placebo concept: a critical methodological and conceptual analysis of reports on the magnitude of the placebo effect. Kienle GS, et al. **Altern Ther Health Med** 1996 Nov;2(6):39–54 (167 ref.)

The placebo effect in cardiovascular disease. Bienenfeld L, et al. **Am Heart J** 1996 Dec;132(6):1207–21 (79 ref.)

Placebo response in anxiety disorders. Piercy MA, et al. **Ann Pharmacother** 1996 Sep;30(9):1013–9 (47 ref.)

The kinetics and dynamics of responses to placebo. Weiner M, et al. **Clin Pharmacol Ther** 1996 Sep;60(3):247–54 (50 ref.)

The uncontrollable placebo effect. Hróbjartsson A. **Eur J Clin Pharmacol** 1996;50(5):345–8 (24 ref.)

Does a placebo-effect exist in clinical trials on multiple sclerosis? Review of the literature. La Mantia L, et al. **Ital J Neurol Sci** 1996 Apr;17(2):135–9 (28 ref.)

Psychoneuroendoimmunology: the biological basis of the placebo phenomenon? [see comments] Jamison JR. **J Manipulative Physiol Ther** 1996 Sep;19(7):484–7 (47 ref.)

Comment in: J Manipulative Physiol Ther 1997 Mar-Apr;20(3):224.
The placebogenic phenomenon: art in psychiatric nursing. **Blair DT. J Psychosoc Nurs Ment Health Serv** 1996 Aug; 34(8):11-5 (24 ref.)
The neurobiology of placebo analgesia: from endogenous opioids to cholecystokinin. Benedetti F, et al. **Prog Neurobiol** 1997 Jun;52(2):109-25 (135 ref.)

PLACEBOS

Placebo effect and placebo concept: a critical methodological and conceptual analysis of reports on the magnitude of the placebo effect. Kienle GS, et al. **Altern Ther Health Med** 1996 Nov;2(6):39-54 (167 ref.)
Provoking nonepileptic seizures: the ethics of deceptive diagnostic testing. Burack JH, et al. **Hastings Cent Rep** 1997 Jul-Aug;27(4):24-33 (25 ref.)
Phase III trials: specific problems associated with the use of a placebo control group. Cleophas TJ, et al. **Int J Clin Pharmacol Ther** 1997 Feb;35(2):47-50 (32 ref.)
Placebos in clinical practice and research. De Deyn PP, et al. **J Med Ethics** 1996 Jun;22(3):140-6 (40 ref.)
The placebo effect on mood and behavior: the role of the endogenous opioid system. Sher L. **Med Hypotheses** 1997 Apr;48(4):347-9 (32 ref.)
[Contemporary opinion on placebo] Bogdanik T. **Przegl Lek** 1996;53(6):481-5 (20 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Placebo response in anxiety disorders. Piercy MA, et al. **Ann Pharmacother** 1996 Sep;30(9):1013-9 (47 ref.)

PLACENTA

see related
MATERNAL-FETAL EXCHANGE
UTEROPLACENTAL CIRCULATION
Adult placenta: heparin bonded extracorporeal life support systems. Golding LA. **ASAIO J** 1996 Jan-Feb;42(1):16-8 (24 ref.)

BLOOD SUPPLY

Angiogenesis and the expression of vascular endothelial growth factor in endometrium and placenta. Torry DS, et al. **Am J Reprod Immunol** 1997 Jan;37(1):21-9 (87 ref.)
The control of blood flow to the placenta. Poston L. **Exp Physiol** 1997 Mar;82(2):377-87 (48 ref.)
Placental transporter activity and expression in relation to fetal growth. Sibley C, et al. **Exp Physiol** 1997 Mar; 82(2):389-402 (56 ref.)
Endothelial dysfunction in preeclampsia. Part I: Primary prevention. Therapeutic perspectives. Dekker GA, et al. **J Perinat Med** 1996;24(2):99-117 (145 ref.)
Conflicting data on intervillous circulation in early pregnancy. Kurjak A, et al. **J Perinat Med** 1997; 25(3):225-36 (40 ref.)
Structure and permeability of human placental microvasculature. Leach L, et al. **Microsc Res Tech** 1997 Jul 1-15;38(1-2):137-44 (49 ref.)

CHEMISTRY

Is placenta a good indicator of cadmium and lead exposure? Lagerkvist BI, et al. **Arch Environ Health** 1996 Sep-Oct; 51(5):389-94 (16 ref.)
Location of insulin receptors in the placenta and its progenitor tissues. Desoye G, et al. **Microsc Res Tech** 1997 Jul 1-15;38(1-2):63-75 (80 ref.)

CYTOLOGY

The fibrinoids of the human placenta: origin, composition and functional relevance. Kaufmann P, et al. **Anat Anz** 1996 Dec;178(6):485-501 (117 ref.)
Reliability of trans-cervical recovery of placental cells from the lower uterine pole using a minimally invasive procedure. Evidence based on fetal sexing and analysis of recovered cell populations. Miller D, et al. **Early Hum Dev** 1996 Dec 30;47 Suppl:S99-102 (6 ref.)
Stereology and its impact on our understanding of human placental functional morphology. Mayhew TM, et al. **Microsc Res Tech** 1997 Jul 1-15;38(1-2):195-205 (15 ref.)

DRUG EFFECTS

Placental transfer of selected substances of abuse. Little BB, et al. **Semin Perinatol** 1996 Apr;20(2):147-53 (52 ref.)

ENZYMOLOGY

Effects of placental proteases on maternal and fetal blood pressure in normal pregnancy and preeclampsia. Mizutani S, et al. **Am J Hypertens** 1996 Jun;9(6):591-7 (39 ref.)
11 beta-Hydroxysteroid dehydrogenases: tissue-specific dictators of glucocorticoid action. Benediktsson R, et al. **Essays Biochem** 1996;31:23-36 (20 ref.)
Expression and regulation of 17 beta-hydroxysteroid dehydrogenase type 1. Peltoketo H, et al. **J Endocrinol** 1996 Sep;150 Suppl:S21-30 (59 ref.)

IMMUNOLOGY

Role of placental cytokines and inflammation in vertical transmission of HIV infection. Shearer WT, et al. **Acta Paediatr Suppl** 1997 Jun;421:33-8 (30 ref.)
Placental interferons. Bazer FW, et al. **Am J Reprod Immunol** 1996 Apr;35(4):297-308 (109 ref.)
Placental expression of HLA class I genes. Le Bouteiller P, et al. **Am J Reprod Immunol** 1996 Mar;35(3):216-25 (60 ref.)
Maternal anti-placental cell-mediated reactivity and spontaneous abortions. Raghupathy R. **Am J Reprod Immunol** 1997 Jun;37(6):478-84 (62 ref.)
Contraceptive vaccines. Jones WR. **Baillieres Clin Obstet Gynaecol** 1996 Apr;10(1):69-86 (65 ref.)
The great balancing acts. The pregnant woman, placenta, fetus, and infectious agents. Nahmias AJ, et al. **Clin Perinatol** 1997 Jun;24(2):497-521 (104 ref.)
Traffic of leukocytes through the maternofetal placental interface and its possible consequences. Papadogiannakis N. **Curr Top Microbiol Immunol** 1997;222:141-57 (137 ref.)
The structural basis of maternal-fetal immune interactions in the human placenta. Redline RW. **Curr Top Microbiol Immunol** 1997;222:25-44 (122 ref.)
Immunobiology of the trophoblast: mechanisms by which placental tissues evade maternal recognition and rejection. Torry DS, et al. **Curr Top Microbiol Immunol** 1997; 222:127-40 (78 ref.)
Immunobiology of human uteroplacental macrophages--friend and foe? Vince GS, et al. **Placenta** 1996 May;17(4):191-9 (106 ref.)

INNERVATION

Human placental cholinergic system. Sastry BV. **Biochem Pharmacol** 1997 Jun 1;53(11):1577-86 (116 ref.)

METABOLISM

Placental expression of HLA class I genes. Le Bouteiller P, et al. **Am J Reprod Immunol** 1996 Mar;35(3):216-25 (60 ref.)
Angiogenesis and the expression of vascular endothelial growth factor in endometrium and placenta. Torry DS, et al. **Am J Reprod Immunol** 1997 Jan;37(1):21-9 (87 ref.)
Protein metabolism in pregnancy. Robinson S, et al. **Baillieres Clin Endocrinol Metab** 1996 Oct;10(4):571-87 (56 ref.)
Confined placental mosaicism. Kalousek DK, et al. **J Med Genet** 1996 Jul;33(7):529-33 (45 ref.)
Heterogeneity of corticotropin-releasing factor (CRF). Yasuda N, et al. **Jpn J Physiol** 1997 Apr;47(2):147-59 (132 ref.)
Mechanism of glucose transport across the human and rat placental barrier: a review. Takata K, et al. **Microsc Res Tech** 1997 Jul 1-15;38(1-2):145-52 (70 ref.)
Placental transfer of inorganic ions and water. Stulc J. **Physiol Rev** 1997 Jul;77(3):805-36 (297 ref.)

PATHOLOGY

The fibrinoids of the human placenta: origin, composition and functional relevance. Kaufmann P, et al. **Anat Anz** 1996 Dec;178(6):485-501 (117 ref.)
Maternal melanoma metastatic to the placenta: a case report and review of the literature. Baergen RN, et al. **Arch Pathol Lab Med** 1997 May;121(5):508-11 (26 ref.)
Disseminated congenital neuroblastoma involving the placenta. Lynn AA, et al. **Arch Pathol Lab Med** 1997 Jul; 121(7):741-4 (15 ref.)
From delivery suite to laboratory: optimizing returns from placental examination in medico-legal defence. Khong TY. **Aust N Z J Obstet Gynaecol** 1997 Feb;37(1):1-5 (46 ref.)
Clinicopathologic implications of placental pathology. Altshuler G, et al. **Clin Obstet Gynecol** 1996 Sep; 39(3):549-70 (70 ref.)
Postpartum examination of the placenta. Kaplan CG. **Clin Obstet Gynecol** 1996 Sep;39(3):535-48 (18 ref.)
Gestational psittacosis: case report and literature review. Hyde SR, et al. **Mod Pathol** 1997 Jun;10(6):602-7 (16 ref.)
Placental teratoma. A case report and review of the literature. Wang L, et al. **Pathol Res Pract** 1995 Dec;191(12):1267-70; discussion 1270 (21 ref.)
Malignancy metastatic to the products of conception: a case report with literature review. Ackerman J, et al. **Pediatr Pathol Lab Med** 1997 Jul-Aug;17(4):577-86 (71 ref.)
Placental pathology in systemic lupus erythematosus and phospholipid antibody syndrome. Salafia CM, et al. **Rheum Dis Clin North Am** 1997 Feb;23(1):85-97 (72 ref.)
[Primary nontrophoblastic tumors of the placenta] Fiutowski M, et al. **Ginekol Pol** 1996 Oct;67(10):515-9 (30 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Placentas and foetal health. Collins MH. **Equine Vet J Suppl** 1993 Apr;(14):8-11 (24 ref.)
Engine and radiator: fetal and placental interactions for heat dissipation. Schröder HJ, et al. **Exp Physiol** 1997 Mar; 82(2):403-14 (40 ref.)
Placental transporter activity and expression in relation to fetal growth. Sibley C, et al. **Exp Physiol** 1997 Mar; 82(2):389-402 (56 ref.)
Trophoblast migration during human placental implantation. Burrows TD, et al. **Hum Reprod Update** 1996 Jul-Aug; 2(4):307-21 (128 ref.)
The role of the placenta in fetal nutrition and growth [see comments] Garnica AD, et al. **J Am Coll Nutr** 1996 Jun; 15(3):206-22 (203 ref.) Comment in: J Am Coll Nutr 1996 Jun;15(3):197-8.
Placenta and growth factors in fetal growth and nutrition [editorial] Garnica AD, et al. **Nutrition** 1997 Apr; 13(4):384-5 (27 ref.)
Placental transfer of inorganic ions and water. Stulc J. **Physiol Rev** 1997 Jul;77(3):805-36 (297 ref.)
Inhibin, activin and follistatin in the human placenta--a new family of regulatory proteins. Petraglia F. **Placenta** 1997 Jan;18(1):3-8 (57 ref.)

PHYSIOPATHOLOGY

Role of the placenta in perinatal pathology (revisited). Altshuler G. **Pediatr Pathol Lab Med** 1996 Mar-Apr; 16(2):207-33 (101 ref.)
Angiotensin mediated interaction of fetal kidney and placenta in the control of fetal arterial pressure and its role in hydrops fetalis. Faber JJ, et al. **Placenta** 1997 May; 18(4):313-26 (43 ref.)

SURGERY

Surgery of the placenta and umbilical cord. De Lia JE. **Clin Obstet Gynecol** 1996 Sep;39(3):607-25 (64 ref.)

ULTRASONOGRAPHY

Ultrasound of the placenta. Kuhlmann RS, et al. **Clin Obstet Gynecol** 1996 Sep;39(3):519-34 (58 ref.)

ULTRASTRUCTURE

Structure and function in the ruminant synepitheliochorial placenta: central role of the trophoblast binucleate cell in deer. Wooding FB, et al. **Microsc Res Tech** 1997 Jul 1-15; 38(1-2):88-99 (27 ref.)
Confined placental mosaicism for trisomies 2, 3, 7, 8, 9, 16, and 22: their incidence, likely origins, and mechanisms for cell lineage compartmentalization. Wolstenholme J. **Prenat Diagn** 1996 Jun;16(6):511-24 (51 ref.)

PLACENTA ACCRETA

ULTRASONOGRAPHY

[Ultrasonic diagnosis of placenta percreta. Apropos of a case with hemorrhagic complication] Durand-Réville M, et al. **J Radiol** 1997 Apr;78(4):313-6 (10 ref.) (Eng. Abstr.) **(Fre)**

PLACENTA DISEASES

COMPLICATIONS

Diaplacental infections with ruminant pestiviruses. Osburn BI, et al. **Arch Virol Suppl** 1991;3:71-8 (27 ref.)
Thrombophilia and fetal loss. Brenner B, et al. **Blood Rev** 1997 Jun;11(2):72-9 (82 ref.)
Placental causes of fetal malformation. Craven C, et al. **Clin Obstet Gynecol** 1996 Sep;39(3):588-606 (34 ref.)
[Preeclampsia resulting from placental defects: biology to clinical considerations] Maquoi E, et al. **Rev Med Liege** 1997;52(7):478-84 (20 ref.) **(Fre)**
[Uterine rupture and placenta percreta in the second trimester. Presentation of a case] Bernal-Martínez S, et al. **Ginecol Obstet Mex** 1996 Oct;64:482-3 (24 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Pseudoxanthoma elasticum and pregnancy. Yoles A, et al. **Cutis** 1996 Aug;58(2):161-4 (15 ref.)
Clinical biological features of Ballantyne syndrome and the role of placental hydrops. Carbillon L, et al. **Obstet Gynecol Surv** 1997 May;52(5):310-4 (27 ref.)

PATHOLOGY

Clinicopathologic implications of placental pathology. Altshuler G, et al. **Clin Obstet Gynecol** 1996 Sep; 39(3):549-70 (70 ref.)
Malignancy metastatic to the products of conception: a case report with literature review. Ackerman J, et al. **Pediatr Pathol Lab Med** 1997 Jul-Aug;17(4):577-86 (71 ref.)
Embolism of fetal brain tissue to the lungs and the placenta. Baergen RN, et al. **Pediatr Pathol Lab Med** 1997 Jan-Feb; 17(1):159-67 (25 ref.)

PHYSIOPATHOLOGY

Sudden infant death syndrome and placental disorders: the thyroid-selenium link. Reid GM, et al. **Med Hypotheses** 1997 Apr;48(4):317-24 (66 ref.)

PLACENTA PRAEVIA

EPIDEMIOLOGY

[Placenta praevia. A review of contradictory opinions on its incidence. The importance of ultrasonic study] Ruseva R, et al. **Akush Ginekol (Sofiia)** 1996;35(1-2):43-5 (12 ref.)

PLACENTA PRAEVIA

(Eng. Abstr.) **(Bul)**

ETIOLOGY

The association of cigarette smoking with placenta previa and abruptio placentae. Andres RL. **Semin Perinatol** 1996 Apr;20(2):154–9 (43 ref.)

ULTRASONOGRAPHY

[Placenta praevia. A review of contradictory opinions on its incidence. The importance of ultrasonic study] Ruseva R, et al. **Akush Ginekol (Sofiia)** 1996;35(1–2):43–5 (12 ref.) (Eng. Abstr.) **(Bul)**

PLACENTA, RETAINED

ETIOLOGY

Bovine retained placenta: aetiology, pathogenesis and economic loss. Laven RA, et al. **Vet Rec** 1996 Nov 9; 139(19):465–71 (112 ref.)

VETERINARY

Bovine retained placenta: aetiology, pathogenesis and economic loss. Laven RA, et al. **Vet Rec** 1996 Nov 9; 139(19):465–71 (112 ref.)

Treatment of bovine retained placenta and its effects. Peters AR, et al. **Vet Rec** 1996 Nov 30;139(22):535–9 (78 ref.)

PLACENTAL ANTICOAGULANT PROTEIN I see **ANNEXIN V**

PLACENTAL ANTICOAGULANT PROTEINS see **ANNEXINS**

PLACENTAL FUNCTION TESTS

METHODS

[Placental function test] Watanabe H, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:414–7 (10 ref.) **(Jpn)**

PLACENTAL INSUFFICIENCY

COMPLICATIONS

[Long-term consequences of fetal nutrition] Rey J, et al. **Arch Pediatr** 1997 Apr;4(4):359–66 (59 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Assessment of the fetal circulatory state in uteroplacental insufficiency by Doppler ultrasound: which vessels are the most practicable? Gembruch U. **Ultrasound Obstet Gynecol** 1996 Aug;8(2):77–81 (56 ref.)

PLACENTAL LACTOGEN

see related
RECEPTORS, SOMATOTROPIN

CHEMISTRY

Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen, and related proteins in mammals. Goffin V, et al. **Endocr Rev** 1996 Aug;17(4):385–410 (244 ref.)

GENETICS

Hormonal and cell-specific regulation of the human growth hormone and chorionic somatomammotropin genes. Eberhardt NL, et al. **Prog Nucleic Acid Res Mol Biol** 1996; 54:127–63 (180 ref.)

PHYSIOLOGY

Adaptation of islets of Langerhans to pregnancy: beta-cell growth, enhanced insulin secretion and the role of lactogenic hormones. Sorenson RL, et al. **Horm Metab Res** 1997 Jun;29(6):301–7 (59 ref.)

[Human placental lactogen] Fang JB, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan;27(1):50–1 (9 ref.) **(Chi)**

PLACENTAL PROTEINS see **PREGNANCY PROTEINS**

PLACENTAL-SITE TROPHOBLASTIC TUMOR see **TROPHOBLASTIC TUMOR, PLACENTAL SITE**

PLACENTAL VILLI see **CHORIONIC VILLI**

PLACENTATION

IMMUNOLOGY

Immunology of human placental implantation: clinical implications of our current understanding. Loke YW, et al. **Mol Med Today** 1997 Apr;3(4):153–9 (35 ref.)

Uterine natural killer cells in species with epitheliochorial placentation. Engelhardt H, et al. **Nat Immun** 1996–97; 15(1):53–69 (95 ref.)

PHYSIOLOGY

The biology of the twinning process: how placentation influences outcome. Benirschke K. **Semin Perinatol** 1995 Oct;19(5):342–50 (26 ref.)

[The early placental trophoblast. I. Normal development and endometrial and non-tumor-induced disorders] Horn LC, et al. **Zentralbl Gynakol** 1996;118(9):487–97 (65 ref.) (Eng. Abstr.) **(Ger)**

PLACENTOMA, NORMAL see **PLACENTA**

PLACENTOME see **PLACENTA**

PLAGUE

Plague—a review. Ranga S, et al. **Indian J Pathol Microbiol** 1995 Apr;38(2):213–22 (26 ref.)

Plague pneumonia disease caused by Yersinia pestis. Cleri DJ, et al. **Semin Respir Infect** 1997 Mar;12(1):12–23 (65 ref.)

ETIOLOGY

Yersinia pestis—etiologic agent of plague. Perry RD, et al. **Clin Microbiol Rev** 1997 Jan;10(1):35–66 (315 ref.)

PREVENTION & CONTROL

[Genetic research on plague pathogen in plague control] Anisimov PI, et al. **Genetika** 1996 Jun;32(6):725–9 (36 ref.) (Eng. Abstr.) **(Rus)**

TRANSMISSION

[The mechanism of the existence of Yersinia pestis in nature] Nersesov V, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Jan–Feb;(1):102–6 (25 ref.) **(Rus)**

PLANETARY EVOLUTION see **EVOLUTION, PLANETARY**

PLANETS

see related
EXTRATERRESTRIAL ENVIRONMENT

Habitable zones around low mass stars and the search for extraterrestrial life. Kasting JF. **Orig Life Evol Biosph** 1997 Jun;27(1–3):291–307 (51 ref.)

PLANNED PARENTHOOD see **FAMILY PLANNING**

PLANNING, HEALTH AND WELFARE see **HEALTH PLANNING**

PLANNING, HEALTH FACILITY see **HEALTH FACILITY PLANNING**

PLANNING TECHNIQUES

see related
HEALTH PLANNING
SOCIAL PLANNING

A focused strategic plan for outcomes evaluation. Stonestreet JS, et al. **Nurs Clin North Am** 1997 Sep;32(3):615–31 (12 ref.)

PLANNING THEORIES see **PLANNING TECHNIQUES**

PLANT AGGLUTININS see **LECTINS**

PLANT DISEASES

The plant response in pathogenesis, symbiosis, and wounding: variations on a common theme? Baron C, et al. **Annu Rev Genet** 1995;29:107–29 (129 ref.)

Plant pathology: many roads lead to resistance. Boyes DC, et al. **Curr Biol** 1996 Jun 1;6(6):634–7 (25 ref.)

The oxidative burst protects plants against pathogen attack: mechanism and role as an emergency signal for plant bio-defence—a review. Doke N, et al. **Gene** 1996 Nov 7; 179(1):45–51 (40 ref.)

Recent advances in systemic acquired resistance research—a review. Hunt MD, et al. **Gene** 1996 Nov 7;179(1):89–95 (50 ref.)

Are biological antagonists an alternative to synthetic fungicides for preventing postharvest diseases of fruits and vegetables? Droby S, et al. **Rev Environ Health** 1996 Jan-Jun;11(1–2):71–7 (47 ref.)

Molecular intimacy between proteins specifying plant-pathogen recognition. Parker JE, et al. **Trends Biochem Sci** 1997 Aug;22(8):291–6 (49 ref.)

ETIOLOGY

Pathogenesis-related functions of plant beta-1,3-glucanases investigated by antisense transformation—a review. Beffa R, et al. **Gene** 1996 Nov 7;179(1):97–103 (50 ref.)

Host-selective toxins: agents of compatibility. Walton JD. **Plant Cell** 1996 Oct;8(10):1723–33 (60 ref.)

Alien introgression in rice. Brar DS, et al. **Plant Mol Biol** 1997 Sep;35(1–2):35–47 (45 ref.)

GENETICS

Resistance gene-dependent plant defense responses. Hammond-Kosack KE, et al. **Plant Cell** 1996 Oct; 8(10):1773–91 (150 ref.)

Alien introgression in rice. Brar DS, et al. **Plant Mol Biol** 1997 Sep;35(1–2):35–47 (45 ref.)

The molecular basis of disease resistance in rice. Ronald PC. **Plant Mol Biol** 1997 Sep;35(1–2):179–86 (53 ref.)

MICROBIOLOGY

Saponin detoxification by plant pathogenic fungi. Osbourn AE, et al. **Adv Exp Med Biol** 1996;404:547–55 (44 ref.)

Breaking and entering: host penetration by the fungal rice blast pathogen Magnaporthe grisea. Howard RJ, et al. **Annu Rev Microbiol** 1996;50:491–512 (98 ref.)

Molecular and biochemical basis of the interaction between tomato and its fungal pathogen Cladosporium fulvum. de Wit PJ, et al. **Antonie Van Leeuwenhoek** 1997 Feb; 71(1–2):137–41 (27 ref.)

The type III (Hrp) secretion pathway of plant pathogenic bacteria: trafficking harpins, Avr proteins, and death. Alfano JR, et al. **J Bacteriol** 1997 Sep;179(18):5655–62 (89 ref.)

Recognition of bacterial avirulence proteins occurs inside the plant cell: a general phenomenon in resistance to bacterial diseases? Bonas U, et al. **Plant J** 1997 Jul;12(1):1–7 (40 ref.)

The molecular basis of disease resistance in rice. Ronald PC. **Plant Mol Biol** 1997 Sep;35(1–2):179–86 (53 ref.)

Signaling in plant-microbe interactions. Baker B, et al. **Science** 1997 May 2;276(5313):726–33 (133 ref.)

Spiroplasmas: infectious agents of plants, arthropods and vertebrates. Bové JM. **Wien Klin Wochenschr** 1997 Aug 8;109(14–15):604–12 (70 ref.)

Non-cultivable phytopathogenic mycoplasmas: characterization, detection and perspectives for control. Garnier M. **Wien Klin Wochenschr** 1997 Aug 8; 109(14–15):613–7 (46 ref.)

PARASITOLOGY

Nematode pathogenesis and resistance in plants. Williamson VM, et al. **Plant Cell** 1996 Oct;8(10):1735–45 (90 ref.)

VIROLOGY

Plant hormones and plant virus diseases. The auxins. Pennazio S, et al. **New Microbiol** 1996 Oct;19(4):369–78 (87 ref.)

Plant virus proteins involved in natural vector transmission. Gray SM. **Trends Microbiol** 1996 Jul;4(7):259–64 (55 ref.)

PLANT DNA see **DNA, PLANT**

PLANT EMBRYOS see **SEEDS**

PLANT EPIDERMIS

GROWTH & DEVELOPMENT

Epidermal cell fate and patterning in leaves. Larkin JC, et al. **Plant Cell** 1997 Jul;9(7):1109–20 (65 ref.)

PLANT EXTRACTS

Sesquiterpene lactone allergy. Warshaw EM, et al. **Am J Contact Dermat** 1996 Mar;7(1):1–23 (97 ref.)

ADVERSE EFFECTS

1,2,3-Trithiane-5-carboxylic acid, a first contact allergen from Asparagus officinalis (Liliaceae). Hausen BM, et al. **Am J Contact Dermat** 1996 Mar;7(1):41–6 (32 ref.)

Adult respiratory distress syndrome induced by a Chinese medicine, Kamisyoyo-san [see comments] Shiota Y, et al. **Intern Med** 1996 Jun;35(6):494–6 (10 ref.) Comment in: Intern Med 1996 Jun;35(6):433.

Safety issues in herbal medicine: implications for the health professions [see comments] Drew AK, et al. **Med J Aust** 1997 May 19;166(10):538–41 (38 ref.) Comment in: Med J Aust 1997 May 19;166(10):516–7.

ANALYSIS

Screening of medicinal plants used by the Garifuna of eastern Nicaragua for bioactive compounds. Coe FG, et al. **J Ethnopharmacol** 1996 Jul 26;53(1):29–50 (71 ref.)

Plant products in perfumes and cosmetics. White IR. **Semin Dermatol** 1996 Jun;15(2):78–82 (9 ref.)

CHEMISTRY

Steroid saponins from fenugreek and some of their biological properties. Sauvaire Y, et al. **Adv Exp Med Biol** 1996; 405:37–46 (21 ref.)

Natural products derived from plants as potential drugs for the photodynamic destruction of tumor cells. Ebermann R, et al. **J Photochem Photobiol B** 1996 Nov;36(2):95–7 (15 ref.)

Diterpenoids. Hanson JR. **Nat Prod Rep** 1996 Feb;13(1):59–71 (244 ref.)

[Chemical study of Indonesian medicinal plants] Shibuya H, et al. **Yakugaku Zasshi** 1996 Dec;116(12):911–27 (47 ref.) (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

Ritual and medicinal plants of the Ese'ejas of the Amazonian rainforest (Madre de Dios, Perú). Desmarchelier C, et al. **J Ethnopharmacol** 1996 May;52(1):45–51 (20 ref.)

PHARMACOKINETICS

Pharmacokinetic evaluation of herbal remedies. Basic introduction, applicability, current status and regulatory needs. De Smet PA, et al. **Clin Pharmacokinet** 1997 Jun; 32(6):427–36 (106 ref.)

PHARMACOLOGY

Stimulation of the specific immune system by mistletoe extracts. Fischer S, et al. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S33–7 (32 ref.)

How to study the pharmacology of medicinal plants in underdeveloped countries. Brito AR. **J Ethnopharmacol** 1996 Nov;54(2–3):131–8 (34 ref.)

Natural products as a resource for new drugs. Clark AM. **Pharm Res** 1996 Aug;13(8):1133–44 (39 ref.)

THERAPEUTIC USE

Phytotherapy for the prostate. Buck AC. **Br J Urol** 1996 Sep;78(3):325–36 (59 ref.)

Natural origins of gynecologic treatment. Haefner HK, et al. **Compr Ther** 1997 Jul;23(7):455–66 (84 ref.)

Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Plosker GL, et al. **Drugs Aging** 1996 Nov;9(5):379–95 (86 ref.)

Euphorbium: modern research on its active principle, resiniferatoxin, revives an ancient medicine. Appendino G, et al. **Life Sci** 1997;60(10):681–96 (87 ref.)

Nature's own pharmacy: the diabetes perspective. Gray AM, et al. **Proc Nutr Soc** 1997 Mar;56(1B):507–17 (61 ref.)

Triaga Brasilica: renewed interest in a seventeenth-century panacea. Pereira NA, et al. **Toxicon** 1996 May;34(5):511–6 (10 ref.)

Plants as a source of antimalarial drugs. Kirby GC. **Trop Doct** 1997;27 Suppl 1:7–11 (34 ref.)

[Drug therapy of benign prostatic hyperplasia] Vahlensieck W Jr, et al. **Fortschr Med** 1996 Nov 10;114(31):407–11 (0 ref.) (Eng. Abstr.) **(Ger)**

[Phytotherapy of benign prostatic hyperplasia] Bracher F. **Urologe A** 1997 Jan;36(1):10–7 (27 ref.) (Eng. Abstr.) **(Ger)**

[St John's wort against depression in favour again] Nordfors M, et al. **Lakartidningen** 1997 Jun 18;94(25):2365–7 (20 ref.) (Eng. Abstr.) **(Swe)**

TOXICITY

Assessment of cassia gum. Hallagan JB, et al. **Food Chem Toxicol** 1997 Jun;35(6):625–32 (35 ref.)

PLANT EXTRACTS, CHINESE see **DRUGS, CHINESE HERBAL**

PLANT GALLS see **PLANT TUMORS**

PLANT GENE EXPRESSION REGULATION see **GENE EXPRESSION REGULATION, PLANT**

PLANT GENES see **GENES, PLANT**

PLANT GENOME see **GENOME, PLANT**

PLANT GROWTH REGULATORS

Hormones and the cytoskeleton of animals and plants. De Loof A, et al. **Int Rev Cytol** 1996;166:1–58 (342 ref.)

CHEMISTRY

Brassinosteroids. Fujioka S, et al. **Nat Prod Rep** 1997 Feb; 14(1):1–10 (105 ref.)

Chemical structure of descriptors with an active hydrogen atom in certain bioregulators. Kurchii BA. **Ukr Biokhim Zh** 1996 Jan–Feb;68(1):3–13 (29 ref.)

METABOLISM

Plant hormones: brassinosteroids in the spotlight. Clouse SD. **Curr Biol** 1996 Jun 1;6(6):658–61 (14 ref.)

Plant tropisms: the ins and outs of auxin. Estelle M. **Curr Biol** 1996 Dec 1;6(12):1589–91 (10 ref.)

Recent advances in systemic acquired resistance research--a review. Hunt MD, et al. **Gene** 1996 Nov 7;179(1):89–95 (50 ref.)

Oligosaccharins, brassinolides, and jasmonates: nontraditional regulators of plant growth, development, and gene expression. Creelman RA, et al. **Plant Cell** 1997 Jul; 9(7):1211–23 (160 ref.)

PHYSIOLOGY

Phyto-oestrogens and Western diseases. Adlercreutz H, et al. **Ann Med** 1997 Apr;29(2):95–120 (356 ref.)

Plant cell walls and the control of growth. McQueen-Mason S. **Biochem Soc Trans** 1997 Feb;25(1):204–14 (60 ref.)

BRI-ghtening the pathway to steroid hormone signaling events in plants [comment] Ecker JR. **Cell** 1997 Sep 5; 90(5):825–7 (18 ref.) Comment on: Cell 1997 Sep 5;90(5):929–38.

Plant steroid hormones emerge from the dark. Hooley R. **Trends Genet** 1996 Aug;12(8):281–3 (14 ref.)

[Regulation of plant MAP kinase cascade by environmental stresses and plant hormones] Ichimura K, et al. **Tanpakushitsu Kakusan Koso** 1997 Apr;42(5):706–16 (53 ref.) **(Jpn)**

PLANT HORMONES see **PLANT GROWTH REGULATORS**

PLANT LEAVES

Designing leaves. Plant morphogenesis. Jackson D. **Curr Biol** 1996 Aug 1;6(8):917–9 (14 ref.)

Nutritional and economic benefits of Leucaena and Gliricidia as feed supplements for small ruminants in humid West Africa. Jabbar MA, et al. **Trop Anim Health Prod** 1997 Feb;29(1):35–47 (44 ref.)

GENETICS

QTL analysis to study the association between leaf size and abscisic acid accumulation in droughted rice leaves and comparisons across cereals. Quarrie SA, et al. **Plant Mol Biol** 1997 Sep;35(1–2):155–65 (45 ref.)

GROWTH & DEVELOPMENT

Epidermal cell fate and patterning in leaves. Larkin JC, et al. **Plant Cell** 1997 Jul;9(7):1109–20 (65 ref.)

Leaf morphogenesis in flowering plants. Poethig RS. **Plant Cell** 1997 Jul;9(7):1077–87 (80 ref.)

PLANT OILS

Minor constituents of rice bran oil as functional foods. de Deckere EA, et al. **Nutr Rev** 1996 Nov;54(11 Pt 2):S120–6 (81 ref.)

[Mediterranean diet in Spain. Legend or reality? (I). Study of 7 countries. Various elements of the Mediterranean diet: olive oil and red wine] Alvarez-Sala Walther LA, et al. **Rev Clin Esp** 1996 Aug;196(8):548–56 (106 ref.) **(Spa)**

ADVERSE EFFECTS

Toxicologists versus toxicological disasters: toxic oil syndrome, clinical aspects. Gómez de la Cámara A, et al. **Arch Toxicol Suppl** 1997;19:31–40 (40 ref.)

Immunological aspects of the toxic oil syndrome. Lahoz C, et al. **Arch Toxicol Suppl** 1997;19:65–73 (35 ref.)

Epidemiology of the toxic oil syndrome. Philen RM, et al. **Arch Toxicol Suppl** 1997;19:41–52 (25 ref.)

PHARMACOLOGY

Rice bran oil and human health. Sugano M, et al. **Biomed Environ Sci** 1996 Sep;9(2–3):242–6 (24 ref.)

Olive oil, monounsaturated fatty acids and cancer. Gerber M. **Cancer Lett** 1997 Mar 19;114(1–2):91–2 (10 ref.)

Dietary fatty acids in athero-thrombogenesis: influence of palm oil ingestion. de Bosch NB, et al. **Haemostasis** 1996 Oct;26 Suppl 4:46–54 (35 ref.)

Rice bran oil and cholesterol metabolism. Sugano M, et al. **J Nutr** 1997 Mar;127(3):521S–524S (27 ref.)

POISONING

The eosinophilia-myalgia syndrome and the toxic oil syndrome. Pursuing parallels. Hertzman PA. **Adv Exp Med Biol** 1996;398:339–42 (8 ref.)

Comparison of clinical picture between Yusho/Yucheng cases and occupational PCB poisoning cases. Ikeda M. **Chemosphere** 1996 Feb;32(3):559–66 (53 ref.)

Clinicoepidemiological, toxicological, and safety evaluation studies on argemone oil. Das M, et al. **Crit Rev Toxicol** 1997 May;27(3):273–97 (137 ref.)

[15 years of research on toxic oil syndrome (editorial)] Pestaña A. **Med Clin (Barc)** 1997 Mar 22;108(11):421–3 (34 ref.) **(Spa)**

TOXICITY

Clinicoepidemiological, toxicological, and safety evaluation studies on argemone oil. Das M, et al. **Crit Rev Toxicol** 1997 May;27(3):273–97 (137 ref.)

PLANT PHOTOSYNTHETIC PROTEIN COMPLEXES see **PHOTOSYNTHETIC REACTION CENTER, PLANT**

PLANT PHOTOSYNTHETIC REACTION CENTER see **PHOTOSYNTHETIC REACTION CENTER, PLANT**

PLANT POISONING

Hyoscyamus falezlez C: a poisonous plant of north Africa. el Bahri L, et al. **Vet Hum Toxicol** 1996 Oct;38(5):378–9 (19 ref.)

Plant exposures: a state profile of the most common species. Krenzelok EP, et al. **Vet Hum Toxicol** 1996 Aug; 38(4):289–98 (30 ref.)

ETIOLOGY

Mandrake toxicity. A case of mistaken identity. Frasca T, et al. **Arch Intern Med** 1997 Sep 22;157(17):2007–9 (21 ref.)

The dangers of jimson weed and its abuse by teenagers in the Kanawha Valley of West Virginia. Dewitt MS, et al. **W V Med J** 1997 Jul–Aug;93(4):182–5 (9 ref.)

PLANT PROTEINS

Pyrularia thionin. Physical properties, binding to phospholipid bilayers and cellular responses. Vernon LP. **Adv Exp Med Biol** 1996;391:279–91 (64 ref.)

Recent advances in the uses and applications of ribosome-inactivating proteins from plants. Girbés T, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 Jun;42(4):461–71 (122 ref.)

The Hsf world: classification and properties of plant heat stress transcription factors. Nover L, et al. **Cell Stress Chaperones** 1996 Dec;1(4):215–23 (58 ref.)

The biology of plant proteins. Day PR. **Crit Rev Food Sci Nutr** 1996;36 Suppl:S39–47 (29 ref.)

Sulfation and sulfotransferases 6: Biochemistry and molecular biology of plant sulfotransferases. Varin L, et al. **FASEB J** 1997 Jun;11(7):517–25 (44 ref.)

Plant cyclins: a unified nomenclature for plant A–, B– and D–type cyclins based on sequence organization. Renaudin JP, et al. **Plant Mol Biol** 1996 Dec;32(6):1003–18 (63 ref.)

[Sensors and photoelectric devises using photosynthetic proteins] Miyake J, et al. **Tanpakushitsu Kakusan Koso** 1996 Oct;41(13):2050–4 (11 ref.) **(Jpn)**

BIOSYNTHESIS

Illuminating flowers: CONSTANS induces LEAFY expression. Blázquez MA. **Bioessays** 1997 Apr;19(4):277–9 (21 ref.)

Recent advances in systemic acquired resistance research--a review. Hunt MD, et al. **Gene** 1996 Nov 7;179(1):89–95 (50 ref.)

Pollen embryogenesis. Reynolds TL. **Plant Mol Biol** 1997 Jan;33(1):1–10 (56 ref.)

CHEMISTRY

One century of protein crystallography: the phycobiliproteins. Betz M. **Biol Chem** 1997 Mar–Apr; 378(3–4):167–76 (64 ref.)

Structures and functions of annexins in plants. Delmer DP, et al. **Cell Mol Life Sci** 1997 Jun;53(6):546–53 (39 ref.)

Arabinogalactan proteins: a family of cell-surface and extracellular matrix plant proteoglycans. Bacic A, et al. **Essays Biochem** 1996;31:91–101 (29 ref.)

Characterization of Mal d 1, the 18-kD major apple allergen, at the molecular level. Vieths S, et al. **Monogr Allergy** 1996; 32:63–72 (28 ref.)

GENETICS

Genetic modification of proteins in food. Day PR. **Crit Rev Food Sci Nutr** 1996;36 Suppl:S49–67 (76 ref.)

Plant meristems: cell signalling keeps the balance. Hudson A, et al. **Curr Biol** 1997 Jul 1;7(7):R427–9 (10 ref.)

Plant evolution: the dominance of maize. Kellogg EA. **Curr Biol** 1997 Jul 1;7(7):R411–3 (15 ref.)

Flower development: repressing reproduction. Weigel D. **Curr Biol** 1997 Jun 1;7(6):R373–5 (14 ref.)

Pathogenesis-related functions of plant beta-1,3-glucanases investigated by antisense transformation--a review. Beffa R, et al. **Gene** 1996 Nov 7;179(1):97–103 (50 ref.)

The molecular basis of disease resistance in rice. Ronald PC. **Plant Mol Biol** 1997 Sep;35(1–2):179–86 (53 ref.)

Perspectives of plant cold tolerance: physiology and molecular responses. Kaye C, et al. **Sci Prog** 1995;78 (Pt 4):271–99 (174 ref.)

Molecular intimacy between proteins specifying plant-pathogen recognition. Parker JE, et al. **Trends Biochem Sci** 1997 Aug;22(8):291–6 (49 ref.)

[Molecular mechanisms of self-incompatibility in Brassica] Takayama S, et al. **Tanpakushitsu Kakusan Koso** 1997 Jul; 42(9):1386–95 (41 ref.) **(Jpn)**

IMMUNOLOGY

The function of allergens may determine allergenicity. Bufe A, et al. **Adv Exp Med Biol** 1996;409:399–402 (18 ref.)

Peanut hypersensitivity. IgE binding characteristics of a recombinant Ara h I protein. Stanley JS, et al. **Adv Exp Med Biol** 1996;409:213–6 (13 ref.)

The use of antibodies to study the architecture and developmental regulation of plant cell walls. Knox JP. **Int Rev Cytol** 1997;171:79–120 (203 ref.)

ISOLATION & PURIFICATION

Phytocystatins and their target enzymes-molecular cloning, expression and possible functions. Arai S, et al. **Adv Exp Med Biol** 1996;389:73–8 (31 ref.)

METABOLISM

Import and routing of nucleus-encoded chloroplast proteins. Cline K, et al. **Ann Rev Cell Dev Biol** 1996;12:1–26 (105 ref.)

Molecular and biochemical basis of the interaction between tomato and its fungal pathogen Cladosporium fulvum. de Wit PJ, et al. **Antonie Van Leeuwenhoek** 1997 Feb; 71(1–2):137–41 (27 ref.)

Developmental regulation of respiratory activity and protein import in plant mitochondria. Wood CK, et al.

PLANT PROTEINS

Biochem Soc Trans 1996 Aug;24(3):746–9 (23 ref.)
Plant cell enlargement and the action of expansins. Cosgrove DJ. **Bioessays** 1996 Jul;18(7):533–40 (62 ref.)
Molecular dissection of the mechanism of protein import into chloroplasts. Tian F, et al.
Cold Spring Harb Symp Quant Biol 1995;60:629–36 (43 ref.)
Plant hormones: brassinosteroids in the spotlight. Clouse SD. **Curr Biol** 1996 Jun 1;6(6):658–61 (14 ref.)
Plant tropisms: the ins and outs of auxin. Estelle M. **Curr Biol** 1996 Dec 1;6(12):1589–91 (10 ref.)
Plant photomorphogenesis: a green light for cryptochrome research. Whitelam G. **Curr Biol** 1995 Dec 1;5(12):1351–3 (7 ref.)
Morphogenesis on the move: cell–to–cell trafficking of plant regulatory proteins. Jackson D, et al.
Curr Opin Genet Dev 1997 Aug;7(4):495–500 (40 ref.)
Heavy metal detoxification in higher plants—a review. Zenk MH. **Gene** 1996 Nov 7;179(1):21–30 (40 ref.)
Protein translocation at the envelope and thylakoid membranes of chloroplasts. Kouranov A, et al.
J Biol Chem 1996 Dec 6;271(49):31009–12 (53 ref.)
Basal and activated in vitro transcription in plants by RNA polymerase II and III. Fan H, et al. **Methods Enzymol** 1996; 273:268–77 (12 ref.)
Light modulation of vegetative development. Chory J. **Plant Cell** 1997 Jul;9(7):1225–34 (100 ref.)
Protein stability and degradation in chloroplasts. Adam Z. **Plant Mol Biol** 1996 Dec;32(5):773–83 (120 ref.)
Transport of proteins in eukaryotic cells: more questions ahead. Bar–Peled M, et al. **Plant Mol Biol** 1996 Oct; 32(1–2):223–49 (283 ref.)
Plasmodesmal cell–to–cell transport of proteins and nucleic acids. Mezitt LA, et al. **Plant Mol Biol** 1996 Oct; 32(1–2):251–73 (112 ref.)
The structure and biogenesis of plant oil bodies: the role of the ER membrane and the oleosin class of proteins. Napier JA, et al. **Plant Mol Biol** 1996 Aug;31(5):945–56 (68 ref.)
Protein import into plant mitochondria. Whelan J, et al.
Plant Mol Biol 1997 Mar;33(5):771–89 (195 ref.)
Oleosins and oil bodies in seeds and other organs. Huang AH. **Plant Physiol** 1996 Apr;110(4):1055–61 (27 ref.)

PHARMACOLOGY

Protease inhibitors and carcinogenesis: a review. Clawson GA. **Cancer Invest** 1996;14(6):597–608 (114 ref.)

PHYSIOLOGY

Illuminating flowers: CONSTANS induces LEAFY expression. Blázquez MA. **Bioessays** 1997 Apr;19(4):277–9 (21 ref.)
Polypeptide signaling for plant defensive genes exhibits analogies to defense signaling in animals. Bergey DR, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12053–8 (44 ref.)
Creeping walls, softening fruit, and penetrating pollen tubes: the growing roles of expansins [comment] Cosgrove DJ. **Proc Natl Acad Sci U S A** 1997 May 27;94(11):5504–5 (18 ref.) Comment on: Proc Natl Acad Sci U S A 1997 May 27;94(11):5955–60.
Signaling in plant–microbe interactions. Baker B, et al. **Science** 1997 May 2;276(5313):726–33 (133 ref.)
MYB transcription factors in plants. Martin C, et al.
Trends Genet 1997 Feb;13(2):67–73 (55 ref.)

STANDARDS

Cottonseed protein: what does the future hold? Alford BB, et al. **Plant Foods Hum Nutr** 1996 Jan;49(1):1–11 (63 ref.)

THERAPEUTIC USE

Decelerating gastric emptying: therapeutic possibilities in type 2 diabetes. Phillips WT, et al. **Diabet Med** 1996 Sep; 13(9 Suppl 5):S44–8 (13 ref.)

PLANT RNA see **RNA, PLANT**

PLANT ROOTS

Cell signaling in root development. Scheres B.
Curr Opin Genet Dev 1997 Aug;7(4):501–6 (27 ref.)

GROWTH & DEVELOPMENT

Building a root: the control of patterning and morphogenesis during root development. Schiefelbein JW, et al.
Plant Cell 1997 Jul;9(7):1089–98 (60 ref.)

MICROBIOLOGY

Osmoadaptation by rhizosphere bacteria. Miller KJ, et al.
Annu Rev Microbiol 1996;50:101–36 (167 ref.)
Signal transduction in Rhizobium–induced nodule formation. Geurts R, et al. **Plant Physiol** 1996 Oct;112(2):447–53 (42 ref.)
Biogenesis of the peribacteroid membrane in root nodules. Verma DP, et al. **Trends Microbiol** 1996 Sep;4(9):364–8 (40 ref.)

PARASITOLOGY

Manipulation of host gene expression by root–knot nematodes. Bird DM. **J Parasitol** 1996 Dec;82(6):881–8 (56 ref.)
Nematode pathogenesis and resistance in plants. Williamson VM, et al. **Plant Cell** 1996 Oct;8(10):1735–45 (90 ref.)

PLANT SHOOTS

GENETICS

Genetic control of shoot and flower meristem behavior. Liljegren SJ, et al. **Curr Opin Cell Biol** 1996 Dec;8(6):865–9 (35 ref.)

GROWTH & DEVELOPMENT

Flower development: repressing reproduction. Weigel D.
Curr Biol 1997 Jun 1;7(6):R373–5 (14 ref.)
Last exit: senescence, abscission, and meristem arrest in Arabidopsis. Bleecker AB, et al. **Plant Cell** 1997 Jul; 9(7):1169–79 (50 ref.)

PLANT STEROLS see **PHYTOSTEROLS**

PLANT STRUCTURAL GENES see **GENES, STRUCTURAL, PLANT**

PLANT TUMORS

MICROBIOLOGY

Genetics of Ustilago maydis, a fungal pathogen that induces tumors in maize. Banuett F. **Annu Rev Genet** 1995; 29:179–208 (111 ref.)
The sensing of plant signal molecules by Agrobacterium: genetic evidence for direct recognition of phenolic inducers by the VirA protein. Lee YW, et al. **Gene** 1996 Nov 7; 179(1):83–8 (20 ref.)

PLANT VIRUSES

GENETICS

Comparison of the replication of positive–stranded RNA viruses of plants and animals. Buck KW.
Adv Virus Res 1996;47:159–251 (543 ref.)
Replicase–mediated resistance to plant virus disease. Palukaitis P, et al. **Adv Virus Res** 1997;48:349–77 (93 ref.)
Plant pathogenic RNAs and RNA catalysis. Symons RH. **Nucleic Acids Res** 1997 Jul 15;25(14):2683–9 (71 ref.)
Gene expression from viral RNA genomes. Maia IG, et al. **Plant Mol Biol** 1996 Oct;32(1–2):367–91 (203 ref.)
Interplay of tRNA–like structures from plant viral RNAs with partners of the translation and replication machineries [comment] Giegé R. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12078–81 (43 ref.) Comment on: Proc Natl Acad Sci U S A 1996 Oct 29;93(22):12212–6.

PHYSIOLOGY

Plant virus proteins involved in natural vector transmission. Gray SM. **Trends Microbiol** 1996 Jul;4(7):259–64 (55 ref.)

PLANTAR ULCER see **FOOT ULCER**

PLANTARIS MUSCLE see **MUSCLE, SKELETAL**

PLANTS

see related
HERBICIDES
POLLEN
SEEDS

Phytonutrition, phytotherapy, and phytopharmacology. Bland JS. **Altern Ther Health Med** 1996 Nov;2(6):73–6 (24 ref.)
Oxidative burst: an early plant response to pathogen infection. Wojtaszek P. **Biochem J** 1997 Mar 15;322 (Pt 3):681–92 (144 ref.)
Subcellular targeting and purification of recombinant proteins in plant production systems. Moloney MM, et al.
Biotechnol Genet Eng Rev 1997;14:321–36 (63 ref.)
Tropical rainforests: diversity begets diversity. Mayer AL, et al. **Curr Biol** 1997 Jul 1;7(7):R430–2 (10 ref.)
Uses of biotechnology in modifying plant lipids. Budziszewski GJ, et al. **Lipids** 1996 Jun;31(6):557–69 (121 ref.)
Is working in greenhouses healthy? Evidence concerning the toxic risks that might affect greenhouse workers. Illing HP. **Occup Med (Oxf)** 1997 Jul;47(5):281–93 (70 ref.)
Plant–derived immunocontraceptive vaccines. Smith G, et al. **Reprod Fertil Dev** 1997;9(1):85–9 (31 ref.)
Current topics in plant dermatitis. Lovell CR.
Semin Dermatol 1996 Jun;15(2):113–21 (91 ref.)
Dermatitis in florists. Rycroft RJ. **Semin Dermatol** 1996 Jun; 15(2):83–6 (18 ref.)
Compositae allergy. Wrangsjö K, et al. **Semin Dermatol** 1996 Jun;15(2):87–94 (49 ref.)
[Heavy metals in the soil–plant–man system (review)] Mudryĭ IV. **Gig Sanit** 1997 Jan–Feb;(1):14–7 (23 ref.) **(Rus)**

ANATOMY & HISTOLOGY

Creating phyllotaxis: the stack–and–drag model. Van Der Linden FM. **Math Biosci** 1996 Apr 1;133(1):21–50 (63 ref.)

CHEMISTRY

Estrogens, phytoestrogens, and breast cancer. Clarke R, et al. **Adv Exp Med Biol** 1996;401:63–85 (141 ref.)
Triterpenoid saponins from a Siberian chemorace of the Thalictrum genus. Semenov AA, et al.
Adv Exp Med Biol 1996;405:193–207 (26 ref.)
Plant K+ channels: structure, activity and function. Chérel I, et al. **Biochem Soc Trans** 1996 Nov;24(4):964–71 (50 ref.)
Oncogene– and tumor–suppressor gene–related proteins in plants and fungi. Loidl A, et al. **Crit Rev Oncog** 1996; 7(1–2):49–64 (93 ref.)
Plant phenolic amines: potential effects on sympathoadrenal medullary, hypothalamic–pituitary–adrenal, and hypothalamic–pituitary–gonadal function in ruminants. Vera–Avila HR, et al. **Domest Anim Endocrinol** 1996 Jul; 13(4):285–96 (74 ref.)
Brassinosteroids. Fujioka S, et al. **Nat Prod Rep** 1997 Feb; 14(1):1–10 (105 ref.)
Cyclopeptide alkaloids [published erratum appears in Nat Prod Rep 1997 Aug;14(4):432] Gournelis DC, et al.
Nat Prod Rep 1997 Feb;14(1):75–82 (75 ref.)
Diterpenoids. Hanson JR. **Nat Prod Rep** 1996 Feb;13(1):59–71 (244 ref.)
Plant sources of vitamin A and human nutrition: renewed strategies. **Nutr Rev** 1996 Mar;54(3):89–91 (15 ref.)
Plant cyclins: a unified nomenclature for plant A–, B– and D–type cyclins based on sequence organization. Renaudin JP, et al. **Plant Mol Biol** 1996 Dec;32(6):1003–18 (63 ref.)
Physiologically–active compounds in plant foods: an overview. Rhodes MJ. **Proc Nutr Soc** 1996 Mar; 55(1B):371–84 (41 ref.)
Betaine ether–linked glycerolipids: chemistry and biology. Dembitsky VM. **Prog Lipid Res** 1996 Mar;35(1):1–51 (202 ref.)
Plant allergens: a chemical perspective. Rowan MG.
Semin Dermatol 1996 Jun;15(2):103–12 (19 ref.)

CYTOLOGY

Transduction of Ca2+ signals in plant cells and compartmentalization of the Ca2+ signal. Trewavas A, et al. **Biochem Soc Trans** 1996 Nov;24(4):971–4 (24 ref.)
The GS–X pump in plant, yeast, and animal cells: structure, function, and gene expression. Ishikawa T, et al.
Biosci Rep 1997 Apr;17(2):189–207 (100 ref.)
Cell–cell interactions during plant development. Hake S, et al. **Genes Dev** 1997 May 1;11(9):1087–97 (112 ref.)
The use of antibodies to study the architecture and developmental regulation of plant cell walls. Knox JP.
Int Rev Cytol 1997;171:79–120 (203 ref.)
Biology of plant cells in microgravity and under clinostating. Kordyum EL. **Int Rev Cytol** 1997;171:1–78 (299 ref.)
Cell model systems in plant cytoskeleton studies. Sonobe S.
Int Rev Cytol 1997;175:1–27 (141 ref.)
[Measurement of plant bio–cell: towards the elucidation of systemic response mechanism in plant] Matsuoka H, et al.
Tanpakushitsu Kakusan Koso 1997 Apr;42(5):784–9 (10 ref.) **(Jpn)**

DRUG EFFECTS

Response of higher plants to lead contaminated environment. Singh RP, et al. **Chemosphere** 1997 Jun;34(11):2467–93 (147 ref.)
The effects of ozone on antioxidant responses in plants. Sharma YK, et al. **Free Radic Biol Med** 1997;23(3):480–8 (53 ref.)
Brefeldin A effects in plant and fungal cells: something new about vesicle trafficking? Satiat–Jeunemaitre B, et al.
J Microsc 1996 Feb;181 (Pt 2):162–77 (75 ref.)
Rubber tire leachates in the aquatic environment. Evans JJ.
Rev Environ Contam Toxicol 1997;151:67–115 (125 ref.)

EMBRYOLOGY

Acquisition of identity in the developing leaf. Sylvester AW, et al. **Ann Rev Cell Dev Biol** 1996;12:257–304 (166 ref.)
Models of biological pattern formation: common mechanism in plant and animal development. Meinhardt H.
Int J Dev Biol 1996 Feb;40(1):123–34 (82 ref.)

ENZYMOLOGY

Proteinases from pollen and pests. Travis J, et al.
Acta Biochim Pol 1996;43(3):411–7 (23 ref.)
Plant glutathione S–transferases and herbicide detoxification. Neuefeind T, et al. **Biol Chem** 1997 Mar–Apr; 378(3–4):199–205 (55 ref.)
Hydroxynitrile lyases of higher plants. Wajant H, et al.
Biol Chem 1996 Oct;377(10):611–7 (52 ref.)
Plant cytochromes P450: an overview. Durst F, et al.
Drug Metabol Drug Interact 1995;12(3–4):171–87 (67 ref.)
Diversity and evolution of plant P450 and P450–reductases. Durst F, et al. **Drug Metabol Drug Interact** 1995; 12(3–4):189–206 (30 ref.)
Characterization of cytochrome P450TYR, a multifunctional haem–thiolate N–hydroxylase involved in the biosynthesis of the cyanogenic glucoside dhurrin. Halkier BA, et al.
Drug Metabol Drug Interact 1995;12(3–4):285–97 (26 ref.)
Cytochrome P–450 in plant/insect interactions: geraniol 10–hydroxylase and the biosynthesis of iridoid monoterpenoids. Hallahan DL, et al.
Drug Metabol Drug Interact 1995;12(3–4):369–82 (44 ref.)
Cytochrome P450 limonene hydroxylases of Mentha species.

Lupien S, et al. **Drug Metabol Drug Interact** 1995; 12(3–4):245–60 (62 ref.)
Plants as hosts for heterologous cytochrome P450 expression. O'Keefe DP. **Drug Metabol Drug Interact** 1995; 12(3–4):383–9 (13 ref.)
Cytochrome P450–dependent oxidation of fatty acids. Salaün JP, et al. **Drug Metabol Drug Interact** 1995;12(3–4):261–83 (67 ref.)
Cytochromes P450 in phenylpropanoid metabolism. Werck–Reichhart D. **Drug Metabol Drug Interact** 1995; 12(3–4):221–43 (118 ref.)
Plant–type ferredoxin–NADP+ reductases: a basal structural framework and a multiplicity of functions. Arakaki AK, et al. **FASEB J** 1997 Feb;11(2):133–40 (63 ref.)
The role of endoxyloglucan transferase in the organization of plant cell walls. Nishitani K. **Int Rev Cytol** 1997; 173:157–206 (180 ref.)
Ribonuclease P from plant nuclei and photosynthetic organelles. Schön A. **Mol Biol Rep** 1995–96;22(2–3):139–45 (41 ref.)
Unraveling DNA helicases from plant cells. Tuteja N. **Plant Mol Biol** 1997 Apr;33(6):947–52 (47 ref.)
New hope for old dreams: evidence that plant cellulose synthase genes have finally been identified [comment] Haigler CH, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12082–5 (28 ref.) Comment on: Proc Natl Acad Sci U S A 1996 Oct 29;93(22):12637–42.
[Regulation of plant MAP kinase cascade by environmental stresses and plant hormones] Ichimura K, et al. **Tanpakushitsu Kakusan Koso** 1997 Apr;42(5):706–16 (53 ref.) **(Jpn)**
[Phosphoprotein phosphatases and signal transduction in plant cells] Oka A, et al. **Tanpakushitsu Kakusan Koso** 1997 Apr;42(5):736–43 (48 ref.) **(Jpn)**

GENETICS

Nuclear extrachromosomal DNA of higher plants. Buchowicz J. **Acta Biochim Pol** 1997;44(1):13–9 (50 ref.)
Genetically engineered plants for quality improvement. Brar DS, et al. **Biotechnol Genet Eng Rev** 1996;13:167–79 (41 ref.)
Genetic control of cell division patterns in developing plants. Meyerowitz EM. **Cell** 1997 Feb 7;88(3):299–308 (84 ref.)
Significance of circadian gene expression in higher plants. Beator J, et al. **Chronobiol Int** 1996 Nov;13(5):319–39 (128 ref.)
Plant pathology: many roads lead to resistance. Boyes DC, et al. **Curr Biol** 1996 Jun 1;6(6):634–7 (25 ref.)
Epigenetic phenomena: paramutation and gene silencing in plants. Martienssen R. **Curr Biol** 1996 Jul 1;6(7):810–3 (14 ref.)
Cell–cell interactions: taking cues from the neighbors. Weigel D, et al. **Curr Biol** 1996 Jan 1;6(1):10–2 (10 ref.)
Turned on by stress. Plant retrotransposons. Wessler SR. **Curr Biol** 1996 Aug 1;6(8):959–61 (17 ref.)
Post–transcriptional gene silencing in plants. Depicker A, et al. **Curr Opin Cell Biol** 1997 Jun;9(3):373–82 (57 ref.)
Control of flowering time in plants. Amasino RM. **Curr Opin Genet Dev** 1996 Aug;6(4):480–7 (63 ref.)
Plants as hosts for heterologous cytochrome P450 expression. O'Keefe DP. **Drug Metabol Drug Interact** 1995; 12(3–4):383–9 (13 ref.)
Floral symmetry. Coen ES. **EMBO J** 1996 Dec 16; 15(24):6777–88 (67 ref.)
Molecular mapping and tagging of genes in crop plants. Sharma RP, et al. **Genetica** 1996 May;97(3):313–20 (36 ref.)
Plants and the logic of development. Meyerowitz EM. **Genetics** 1997 Jan;145(1):5–9 (44 ref.)
Genetic engineering in plants. Simoens C, et al. **Hum Reprod Update** 1995 Nov;1(6):523–42 (111 ref.)
Basal and activated in vitro transcription in plants by RNA polymerase II and III. Fan H, et al. **Methods Enzymol** 1996; 273:268–77 (12 ref.)
Recognition of bacterial avirulence proteins occurs inside the plant cell: a general phenomenon in resistance to bacterial diseases? Bonas U, et al. **Plant J** 1997 Jul;12(1):1–7 (40 ref.)
Control of mRNA stability in higher plants. Abler ML, et al. **Plant Mol Biol** 1996 Oct;32(1–2):63–78 (99 ref.)
The plant translational apparatus. Browning KS. **Plant Mol Biol** 1996 Oct;32(1–2):107–44 (352 ref.)
Translation in plants—rules and exceptions. Fütterer J, et al. **Plant Mol Biol** 1996 Oct;32(1–2):159–89 (375 ref.)
Comparative genetics of flowering time. Laurie DA. **Plant Mol Biol** 1997 Sep;35(1–2):167–77 (64 ref.)
RNA editing in plant mitochondria and chloroplasts. Maier RM, et al. **Plant Mol Biol** 1996 Oct;32(1–2):343–65 (113 ref.)
Plant mRNA 3'–end formation. Rothnie HM. **Plant Mol Biol** 1996 Oct;32(1–2):43–61 (133 ref.)
Splicing of precursors to mRNA in higher plants: mechanism, regulation and sub–nuclear organisation of the spliceosomal machinery. Simpson GG, et al. **Plant Mol Biol** 1996 Oct; 32(1–2):1–41 (307 ref.)
Seed banks and molecular maps: unlocking genetic potential from the wild. Tanksley SD, et al. **Science** 1997 Aug 22; 277(5329):1063–6 (22 ref.)
Molecular intimacy between proteins specifying plant–pathogen recognition. Parker JE, et al. **Trends Biochem Sci** 1997 Aug;22(8):291–6 (49 ref.)
The adventures of the Ty1–copia group of retrotransposons in plants. Kumar A. **Trends Genet** 1996 Feb;12(2):41–3 (26 ref.)
Genetic analysis of coevolution between plants and their natural enemies. Rausher MD. **Trends Genet** 1996 Jun; 12(6):212–7 (56 ref.)
DNA methylation and plant development [see comments] Richards EJ. **Trends Genet** 1997 Aug;13(8):319–23 (39 ref.) Comment in: Trends Genet 1997 Aug;13(8):293–5.
[A glucocorticoid–mediated transcriptional induction system in higher plants] Aoyama T. **Tanpakushitsu Kakusan Koso** 1996 Dec;41(16):2559–63 (14 ref.) **(Jpn)**
[High resolution mapping of genes by imaging methods using the interna] Fukui K, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(6):881–7 (22 ref.) **(Jpn)**
[Molecular bases of cytoplasmic male sterility in higher plants] Jańska H, et al. **Postepy Biochem** 1996;42(3):253–9 (86 ref.) **(Pol)**
[Molecular markers in plant genetics and plant breeding] Marczewski W. **Postepy Biochem** 1995;41(4):237–43 (8 ref.) **(Pol)**
[Cytogenetic patterns in synapsis of meiotic chromosomes in animals and plants] Bogdanov IuF, et al. **Genetika** 1996 Nov;32(11):1474–93 (95 ref.) (Eng. Abstr.) **(Rus)**
[Molecular markers in genetic mapping of plants] Malyshev SV, et al. **Mol Biol (Mosk)** 1997 Mar–Apr;31(2):197–208 (92 ref.) **(Rus)**

GROWTH & DEVELOPMENT

Plant cell walls and the control of growth. McQueen–Mason S. **Biochem Soc Trans** 1997 Feb;25(1):204–14 (60 ref.)
Illuminating flowers: CONSTANS induces LEAFY expression. Blázquez MA. **Bioessays** 1997 Apr;19(4):277–9 (21 ref.)
Genetic control of cell division patterns in developing plants. Meyerowitz EM. **Cell** 1997 Feb 7;88(3):299–308 (84 ref.)
Designing leaves. Plant morphogenesis. Jackson D. **Curr Biol** 1996 Aug 1;6(8):917–9 (14 ref.)
Cell–cell interactions: taking cues from the neighbors. Weigel D, et al. **Curr Biol** 1996 Jan 1;6(1):10–2 (10 ref.)
Control of flowering time in plants. Amasino RM. **Curr Opin Genet Dev** 1996 Aug;6(4):480–7 (63 ref.)
Plant development: local control, global patterning. Meyerowitz EM. **Curr Opin Genet Dev** 1996 Aug; 6(4):475–9 (31 ref.)
Cell–cell interactions during plant development. Hake S, et al. **Genes Dev** 1997 May 1;11(9):1087–97 (112 ref.)
Plants and the logic of development. Meyerowitz EM. **Genetics** 1997 Jan;145(1):5–9 (44 ref.)
Light modulation of vegetative development. Chory J. **Plant Cell** 1997 Jul;9(7):1225–34 (100 ref.)
Relaxation in a high–stress environment: the molecular bases of extensible cell walls and cell enlargement. Cosgrove DJ. **Plant Cell** 1997 Jul;9(7):1031–41 (110 ref.)
The excessive production of indole–3–acetic acid and its significance in studies of the biosynthesis of this regulator of plant growth and development. Kawaguchi M, et al. **Plant Cell Physiol** 1996 Dec;37(8):1043–8 (56 ref.)
Polyamines: small molecules triggering pathways in plant growth and development. Walden R, et al. **Plant Physiol** 1997 Apr;113(4):1009–13 (29 ref.)
DNA methylation and plant development [see comments] Richards EJ. **Trends Genet** 1997 Aug;13(8):319–23 (39 ref.) Comment in: Trends Genet 1997 Aug;13(8):293–5.

IMMUNOLOGY

The plant response in pathogenesis, symbiosis, and wounding: variations on a common theme? Baron C, et al. **Annu Rev Genet** 1995;29:107–29 (129 ref.)
Signal transduction in plant immunity. Shirasu K, et al. **Curr Opin Immunol** 1996 Feb;8(1):3–7 (55 ref.)
Signal perception and transduction in plant defense responses. Yang Y, et al. **Genes Dev** 1997 Jul 1;11(13):1621–39 (239 ref.)
Genetic dissection of acquired resistance to disease. Delaney TP. **Plant Physiol** 1997 Jan;113(1):5–12 (47 ref.)
How flowering plants discriminate between self and non–self pollen to prevent inbreeding. Kao TH, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12059–65 (32 ref.)
Sacrifice in the face of foes: pathogen–induced programmed cell death in plants. Mittler R, et al. **Trends Microbiol** 1996 Jan;4(1):10–15 (37 ref.)

METABOLISM

Import and routing of nucleus–encoded chloroplast proteins. Cline K, et al. **Ann Rev Cell Dev Biol** 1996;12:1–26 (105 ref.)
Mechanism and potential applications of bio–ligninolytic systems in a CELSS. Sarikaya A, et al. **Appl Biochem Biotechnol** 1997 Feb–Mar;62(2–3):131–49 (43 ref.)
The origin of the oxidative burst in plants. Bolwell GP. **Biochem Soc Trans** 1996 May;24(2):438–42 (50 ref.)
Peroxisomes as a source of superoxide and hydrogen peroxide in stressed plants. del Río LA, et al. **Biochem Soc Trans** 1996 May;24(2):434–8 (43 ref.)
Oxygen processing in photosynthesis. Foyer CH. **Biochem Soc Trans** 1996 May;24(2):427–33 (61 ref.)
Role of NAD(+)–dependent 'malic' enzyme and pyruvate dehydrogenase complex in leaf metabolism. Hill S, et al. **Biochem Soc Trans** 1996 Aug;24(3):743–6 (15 ref.)
A specific porin is involved in the malate shuttle of leaf peroxisomes. Reumann S, et al. **Biochem Soc Trans** 1996 Aug;24(3):754–7 (17 ref.)
Developmental regulation of respiratory activity and protein import in plant mitochondria. Wood CK, et al. **Biochem Soc Trans** 1996 Aug;24(3):746–9 (23 ref.)
Plant cell enlargement and the action of expansins. Cosgrove DJ. **Bioessays** 1996 Jul;18(7):533–40 (62 ref.)
Microbial and plant metabolism of NO. Payne WJ, et al. **Biofactors** 1997;6(1):47–52 (49 ref.)
Plant glutathione S–transferases and herbicide detoxification. Neuefeind T, et al. **Biol Chem** 1997 Mar–Apr; 378(3–4):199–205 (55 ref.)
Phytoremediation of soil metals. Chaney RL, et al. **Curr Opin Biotechnol** 1997 Jun;8(3):279–84 (63 ref.)
Signalling events elicited in plants by defined oligosaccharide structures. Promé JC. **Curr Opin Struct Biol** 1996 Oct; 6(5):671–8 (48 ref.)
Influence of microorganisms on the environmental fate of radionuclides. Gadd GM. **Endeavour** 1996;20(4):150–6 (50 ref.)
Heavy metal detoxification in higher plants—a review. Zenk MH. **Gene** 1996 Nov 7;179(1):21–30 (40 ref.)
Proteoglycans and related components in plant cells. Nothnagel EA. **Int Rev Cytol** 1997;174:195–291 (296 ref.)
Plants as a source of salt. Aliotta G, et al. **Kidney Int Suppl** 1997 Jun;59:S114–7 (16 ref.)
Biotin synthesis in higher plants. Baldet P, et al. **Methods Enzymol** 1997;279:327–39 (23 ref.)
Plant mitochondrial RNase P. Marchfelder A. **Mol Biol Rep** 1995–96;22(2–3):151–6 (29 ref.)
Molecular components and biochemistry of electron transport in plant plasma membranes (review). Döring O, et al. **Mol Membr Biol** 1996 Jul–Sep;13(3):127–42 (246 ref.)
The biosynthesis of C5–C25 terpenoid compounds. Dewick PM. **Nat Prod Rep** 1997 Apr;14(2):111–44 (260 ref.)
The excessive production of indole–3–acetic acid and its significance in studies of the biosynthesis of this regulator of plant growth and development. Kawaguchi M, et al. **Plant Cell Physiol** 1996 Dec;37(8):1043–8 (56 ref.)
Molecular chaperones and protein folding in plants. Boston RS, et al. **Plant Mol Biol** 1996 Oct;32(1–2):191–222 (344 ref.)
The structure and biogenesis of plant oil bodies: the role of the ER membrane and the oleosin class of proteins. Napier JA, et al. **Plant Mol Biol** 1996 Aug;31(5):945–56 (68 ref.)
Proteolysis in plants: mechanisms and functions. Vierstra RD. **Plant Mol Biol** 1996 Oct;32(1–2):275–302 (221 ref.)
Carbohydrate control of gene expression in higher plants. Graham IA. **Res Microbiol** 1996 Jul–Sep;147(6–7):572–80 (85 ref.)
The role of iron in plant host–pathogen interactions. Expert D, et al. **Trends Microbiol** 1996 Jun;4(6):232–7 (44 ref.)
[Plant acetyl–CoA carboxylases: strategy for survival] Sasaki Y. **Seikagaku** 1996 May;68(5):335–44 (58 ref.) **(Jpn)**
[Proline biosynthesis and water stress tolerance in plants] Yoshiba Y, et al. **Tanpakushitsu Kakusan Koso** 1997 May; 42(6):842–55 (63 ref.) **(Jpn)**

MICROBIOLOGY

Microorganisms and enzymes involved in the degradation of plant fiber cell walls. Kuhad RC, et al. **Adv Biochem Eng Biotechnol** 1997;57:45–125 (676 ref.)
Resistance gene–dependent plant defense responses. Hammond–Kosack KE, et al. **Plant Cell** 1996 Oct; 8(10):1773–91 (150 ref.)
Agrobacterium–plant cell DNA transport: have virulence proteins, will travel. Sheng J, et al. **Plant Cell** 1996 Oct; 8(10):1699–710 (55 ref.)
Signaling in plant–microbe interactions. Baker B, et al. **Science** 1997 May 2;276(5313):726–33 (133 ref.)
The role of iron in plant host–pathogen interactions. Expert D, et al. **Trends Microbiol** 1996 Jun;4(6):232–7 (44 ref.)

PARASITOLOGY

Lectins and biocontrol. Inbar J, et al. **Crit Rev Biotechnol** 1997;17(1):1–20 (126 ref.)

PHYSIOLOGY

Galactolipase and chilling sensitivity of plants. Kaniuga Z. **Acta Biochim Pol** 1997;44(1):21–35 (81 ref.)
Plant gravitropic response. Merkys A, et al. **Adv Space Biol Med** 1997;6:213–30 (56 ref.)
Replicase–mediated resistance to plant virus disease. Palukaitis P, et al. **Adv Virus Res** 1997;48:349–77 (93 ref.)
Free radical formation in non–photosynthetic plant tissue—an overview. Hendry GA, et al. **Biochem Soc Trans** 1996 May;24(2):484–8 (14 ref.)
Free radicals and metabolism associated with the acquisition and loss of desiccation tolerance in developing seeds. Leprince O, et al. **Biochem Soc Trans** 1996 May;24(2):451–5 (18 ref.)
Superoxide generation in relation to dehydration and rehydration. Navari–Izzo F, et al. **Biochem Soc Trans** 1996 May;24(2):447–51 (47 ref.)
Cytosolic calcium and oxidative plant stress. Price A, et al. **Biochem Soc Trans** 1996 May;24(2):479–83 (48 ref.)
Plant defence systems and ozone. Schraudner M, et al. **Biochem Soc Trans** 1996 May;24(2):456–61 (50 ref.)
Ascorbate metabolism in relation to oxidative stress. Smirnoff

N, et al. **Biochem Soc Trans** 1996 May;24(2):472–8 (50 ref.)
Gaseous pollutants and plant defence mechanisms. Wellburn AR, et al. **Biochem Soc Trans** 1996 May;24(2):461–4 (15 ref.)
Functional transformation of microbodies in higher plant cells. Nishimura M, et al. **Cell Struct Funct** 1996 Oct; 21(5):387–93 (42 ref.)
Plants, CO2 and photosynthesis in the 21st century. Griffin KL, et al. **Chem Biol** 1996 Apr;3(4):245–54 (61 ref.)
Cloning in silico. Cutler S, et al. **Curr Biol** 1997 Feb 1; 7(2):R108–11 (14 ref.)
Making asymmetric flowers. Running MP. **Curr Biol** 1997 Feb 1;7(2):R89–91 (10 ref.)
Signalling pathways: a common theme in plants and animals? Wilson I, et al. **Curr Biol** 1997 Mar 1;7(3):R175–8 (10 ref.)
The role of lipochitooligosaccharides in root nodule organogenesis and plant cell growth. Schultze M, et al. **Curr Opin Genet Dev** 1996 Oct;6(5):631–8 (76 ref.)
Transcriptional activation of plant defense genes. Zhu Q, et al. **Curr Opin Genet Dev** 1996 Oct;6(5):624–30 (76 ref.)
Gametes and fertilization in flowering plants. Southworth D. **Curr Top Dev Biol** 1996;34:259–79 (76 ref.)
Nuclear organization in plants. Shaw PJ. **Essays Biochem** 1996;31:77–89 (31 ref.)
Hormones and the cytoskeleton of animals and plants. De Loof A, et al. **Int Rev Cytol** 1996;166:1–58 (342 ref.)
Salt tolerance in plants and microorganisms: toxicity targets and defense responses. Serrano R. **Int Rev Cytol** 1996; 165:1–52 (264 ref.)
Plant intercellular communication via plasmodesmata. McLean BG, et al. **Plant Cell** 1997 Jul;9(7):1043–54 (120 ref.)
The plant ER: a dynamic organelle composed of a large number of discrete functional domains. Staehelin LA. **Plant J** 1997 Jun;11(6):1151–65 (114 ref.)
Comparative genetics of flowering time. Laurie DA. **Plant Mol Biol** 1997 Sep;35(1–2):167–77 (64 ref.)
Pollen embryogenesis. Reynolds TL. **Plant Mol Biol** 1997 Jan;33(1):1–10 (56 ref.)
Roles of higher plant K+ channels. Maathuis FJ, et al. **Plant Physiol** 1997 Aug;114(4):1141–9 (70 ref.)
Genetic analysis of abscisic acid signal transduction. Merlot S, et al. **Plant Physiol** 1997 Jul;114(3):751–7 (46 ref.)
The role of cytochrome P450 monooxygenases in plant–insect interactions. Schuler MA. **Plant Physiol** 1996 Dec;112(4):1411–9 (47 ref.)
Creeping walls, softening fruit, and penetrating pollen tubes: the growing roles of expansins [comment] Cosgrove DJ. **Proc Natl Acad Sci U S A** 1997 May 27;94(11):5504–5 (18 ref.) Comment on: Proc Natl Acad Sci U S A 1997 May 27;94(11):5955–60.
Programmed cell death: a way of life for plants. Greenberg JT. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12094–7 (59 ref.)
Second-hand chloroplasts and the case of the disappearing nucleus. Palmer JD, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):7432–5 (55 ref.)
Perspectives of plant cold tolerance: physiology and molecular responses. Kaye C, et al. **Sci Prog** 1995;78 (Pt 4):271–99 (174 ref.)
Plant steroid hormones emerge from the dark. Hooley R. **Trends Genet** 1996 Aug;12(8):281–3 (14 ref.)
MYB transcription factors in plants. Martin C, et al. **Trends Genet** 1997 Feb;13(2):67–73 (55 ref.)
Something in the air: volatile signals in plant defence. Mur LA, et al. **Trends Microbiol** 1997 Aug;5(8):297–300 (16 ref.)
[Measurement of plant bio-cell: towards the elucidation of systemic response mechanism in plant] Matsuoka H, et al. **Tanpakushitsu Kakusan Koso** 1997 Apr;42(5):784–9 (10 ref.) **(Jpn)**
[Phosphoprotein phosphatases and signal transduction in plant cells] Oka A, et al. **Tanpakushitsu Kakusan Koso** 1997 Apr;42(5):736–43 (48 ref.) **(Jpn)**
[Phytochrome: a plant sensor for environmental light conditions] Tokutomi S. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(2):121–8 (31 ref.) **(Jpn)**
[Plant respiratory chains] Rychter AM. **Postepy Biochem** 1996;42(3):268–76 (102 ref.) **(Pol)**
[The comparative structural-functional characteristics of the cytoskeleton of animals and higher plants] Vasil'ev AE. **Zh Obshch Biol** 1996 May-Jun;57(3):293–325 (269 ref.) (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Light signal transduction in plants. Staub JM, et al. **Photochem Photobiol** 1996 Dec;64(6):897–905 (109 ref.)
Light modulation of vegetative development. Chory J. **Plant Cell** 1997 Jul;9(7):1225–34 (100 ref.)

ULTRASTRUCTURE

[The comparative structural-functional characteristics of the cytoskeleton of animals and higher plants] Vasil'ev AE. **Zh Obshch Biol** 1996 May-Jun;57(3):293–325 (269 ref.) (Eng. Abstr.) **(Rus)**

VIROLOGY

Resistance gene-dependent plant defense responses. Hammond-Kosack KE, et al. **Plant Cell** 1996 Oct; 8(10):1773–91 (150 ref.)

PLANTS, EDIBLE

Dietary phytoestrogens. Kurzer MS, et al. **Annu Rev Nutr** 1997;17:353–81 (181 ref.)
An analysis of the food plants and drug plants of native North America. Moerman DE. **J Ethnopharmacol** 1996 May; 52(1):1–22 (69 ref.)
[Ecological and food safety considerations about products of vegetable origin] Tapia de Daza MS, et al. **Arch Latinoam Nutr** 1994 Dec;44(4):232–41 (75 ref.) (Eng. Abstr.) **(Spa)**

CHEMISTRY

Is there a need to change the American diet? Dwyer J. **Adv Exp Med Biol** 1996;401:189–98 (48 ref.)
Do steroidal saponins have a role in hepatogenous photosensitization diseases of sheep? Flåøyen A. **Adv Exp Med Biol** 1996;405:395–403 (51 ref.)
Nutritional implications of dietary phytochemicals. Messina M, et al. **Adv Exp Med Biol** 1996;401:207–12 (16 ref.)
Phyto-oestrogens and Western diseases. Adlercreutz H, et al. **Ann Med** 1997 Apr;29(2):95–120 (356 ref.)
Pesticide residue analyses in plant material by chromatographic methods: clean-up procedures and selective detectors. Tekel J, et al. **J Chromatogr A** 1996 Nov 22;754(1–2):397–410 (99 ref.)
[Natural toxic substances in food] Pokorný J. **Cas Lek Cesk** 1997 May 7;136(9):267–70 (34 ref.) (Eng. Abstr.) **(Cze)**
[Natural flavonoids as dietary antioxidants and biologically active additives] Tiukavkina NA, et al. **Vopr Pitan** 1996; (2):33–8 (55 ref.) (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Chromatographic methods for amylases. Brena BM, et al. **J Chromatogr B Biomed Appl** 1996 Sep 20;684(1–2):217–37 (123 ref.)

GENETICS

Opportunities for the genetic manipulation of antioxidants in plant foods. Mullineaux PM, et al. **Biochem Soc Trans** 1996 Aug;24(3):829–35 (22 ref.)
Genetic modification of proteins in food. Day PR. **Crit Rev Food Sci Nutr** 1996;36 Suppl:S49–67 (76 ref.)
Assessment of the allergenic potential of foods derived from genetically engineered crop plants. Metcalfe DD, et al. **Crit Rev Food Sci Nutr** 1996;36 Suppl:S165–86 (118 ref.)
[Transgenic foods--advantages and risks] Mannhalter C. **Wien Klin Wochenschr** 1997 Jan 31;109(2):33–9 (20 ref.) **(Ger)**

IMMUNOLOGY

Assessment of the allergenic potential of foods derived from genetically engineered crop plants. Metcalfe DD, et al. **Crit Rev Food Sci Nutr** 1996;36 Suppl:S165–86 (118 ref.)

METABOLISM

The role of cardenolides in a crucifer-insect relationship. Renwick JA. **Adv Exp Med Biol** 1996;405:111–21 (52 ref.)
Opportunities for the genetic manipulation of antioxidants in plant foods. Mullineaux PM, et al. **Biochem Soc Trans** 1996 Aug;24(3):829–35 (22 ref.)
Plant limitations to fiber digestion and utilization. Buxton DR, et al. **J Nutr** 1997 May;127(5 Suppl):814S–818S (22 ref.)
The use of 14C-labelled substrates to study plant cell wall breakdown in the gastrointestinal tract. Buchanan CJ, et al. **Proc Nutr Soc** 1996 Nov;55(3):927–36 (39 ref.)

PLANTS, MEDICINAL

see related
ALKALOIDS
PHARMACOGNOSY
PLANT EXTRACTS

Indole alkaloids and other constituents from the plant Securidaca longipedunculata fres. Wróbel JT, et al. **Adv Exp Med Biol** 1996;398:685–9 (7 ref.)
Medical marijuana and its use by the immunocompromised. McPartland JM, et al. **Altern Ther Health Med** 1997 May; 3(3):39–45 (101 ref.)
Phytotherapy for the prostate. Buck AC. **Br J Urol** 1996 Sep;78(3):325–36 (59 ref.)
Modern role of pharmacology in health sciences: assessing and accessing traditional medicines. Smith CM. **Braz J Med Biol Res** 1996 May;29(5):563–8 (19 ref.)
Herbal products in Canada. How safe are they? [see comments] Kozyrskyj A. **Can Fam Physician** 1997 Apr; 43:697–702 (26 ref.) Comment in: Can Fam Physician 1997 Jun;43:1047.
Natural origins of gynecologic treatment. Haefner HK, et al. **Compr Ther** 1997 Jul;23(7):455–66 (84 ref.)
From plant to patient: an ethnomedical approach to the identification of new drugs for the treatment of NIDDM. Oubré AY, et al. **Diabetologia** 1997 May;40(5):614–7 (23 ref.)
Peppers and pain. The promise of capsaicin. Fusco BM, et al. **Drugs** 1997 Jun;53(6):909–14 (37 ref.)
Hepatotoxicity of herbal remedies: insights into the intricacies of plant-animal warfare and cell death [editorial; comment] Kaplowitz N. **Gastroenterology** 1997 Oct;113(4):1408–12 (19 ref.) Comment on: Gastroenterology 1997 Oct;113(4):1334–46.
How to study the pharmacology of medicinal plants in underdeveloped countries. Brito AR. **J Ethnopharmacol** 1996 Nov;54(2–3):131–8 (34 ref.)
Interests and policies of the state of Sarawak, Malaysia regarding intellectual property rights for plant derived drugs. Chung FJ. **J Ethnopharmacol** 1996 Apr; 51(1–3):201–4 (1 ref.)
Ritual and medicinal plants of the Ese'ejas of the Amazonian rainforest (Madre de Dios, Perú). Desmarchelier C, et al. **J Ethnopharmacol** 1996 May;52(1):45–51 (20 ref.)
Biodiversity prospecting in Nigeria: seeking equity and reciprocity in intellectual property rights through partnership arrangements and capacity building. Iwu MM. **J Ethnopharmacol** 1996 Apr;51(1–3):209–19 (4 ref.)
An analysis of the food plants and drug plants of native North America. Moerman DE. **J Ethnopharmacol** 1996 May; 52(1):1–22 (69 ref.)
Research, valorization and exploitation of biological resources for medicinal purposes in the Malagasy Republic (Madagascar). Randimbivololona F. **J Ethnopharmacol** 1996 Apr;51(1–3):195–200 (10 ref.)
Medicinal plants used in the Barros Area, Badajoz Province, Spain. Vázquez FM, et al. **J Ethnopharmacol** 1997 Jan; 55(2):81–5 (25 ref.)
Hepatotoxicity of herbal remedies. Larrey D. **J Hepatol** 1997; 26 Suppl 1:47–51 (56 ref.)
Euphorbium: modern research on its active principle, resiniferatoxin, revives an ancient medicine. Appendino G, et al. **Life Sci** 1997;60(10):681–96 (87 ref.)
Puerto Rican elders and botanical shops: a community resource or liability? Delgado M. **Soc Work Health Care** 1996;23(1):67–81 (25 ref.)
Compounds with anti-HIV activity from plants. Houghton PJ. **Trans R Soc Trop Med Hyg** 1996 Nov-Dec;90(6):601–4 (19 ref.)
Medicinal plants and the control of protozoal disease, with particular reference to malaria. Kirby GC. **Trans R Soc Trop Med Hyg** 1996 Nov-Dec;90(6):605–9 (41 ref.)
Novel anthelmintic compounds and molluscicides from medicinal plants. Whitfield PJ. **Trans R Soc Trop Med Hyg** 1996 Nov-Dec;90(6):596–600 (46 ref.)
Prospects for plant anthelmintics in tropical veterinary medicine. Hammond JA, et al. **Vet Res Commun** 1997 Apr; 21(3):213–28 (40 ref.)
[Pharmacovigilance off the beaten track: herbal surveillance or pharmacovigilance of medicinal plants] Castot A, et al. **Therapie** 1997 Mar-Apr;52(2):97–103 (41 ref.) (Eng. Abstr.) **(Fre)**
[Bradycardiac atrial fibrillation after consuming herbal tea] Brustbauer R, et al. **Dtsch Med Wochenschr** 1997 Jul 25; 122(30):930–2 (12 ref.) (Eng. Abstr.) **(Ger)**
[Phytotherapy of benign prostatic hyperplasia] Bracher F. **Urologe A** 1997 Jan;36(1):10–7 (27 ref.) (Eng. Abstr.) **(Ger)**
[Chemical constituents of original plants of Cimicifugae rhizoma in Chinese medicine] Sakurai N, et al. **Yakugaku Zasshi** 1996 Nov;116(11):850–65 (75 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

New cardioactive steroid saponins and other glycosides from Mexican Tribulus cistoides. Achenbach H, et al. **Adv Exp Med Biol** 1996;404:357–70 (17 ref.)
New biologically active steroidal and triterpenoid glycosides from medicinal plants. Aquino R, et al. **Adv Exp Med Biol** 1996;404:401–14 (30 ref.)
Acylated saponins from Crocosmia plants. Asada Y, et al. **Adv Exp Med Biol** 1996;404:459–69 (12 ref.)
Commercial utilization of plant-derived saponins: an overview of medicinal, pharmaceutical, and industrial applications. Balandrin MF. **Adv Exp Med Biol** 1996; 404:1–14 (43 ref.)
Triterpene saponins from plants of the flora of Turkey. Calis I, et al. **Adv Exp Med Biol** 1996;404:485–500 (44 ref.)
Search for molluscicidal and antifungal saponins from tropical plants. Hostettmann K, et al. **Adv Exp Med Biol** 1996;404:117–28 (18 ref.)
Anti-tumor-promoting activities or triterpenoid glycosides; cancer chemoprevention by saponins. Konoshima T. **Adv Exp Med Biol** 1996;404:87–100 (11 ref.)
Steroidal saponins from the Liliaceae plants and their biological activities. Mimaki Y, et al. **Adv Exp Med Biol** 1996;404:101–10 (29 ref.)
Saponins from the compositae plants: structures of the saponins from Aster scaber Thunb. Nagao T, et al. **Adv Exp Med Biol** 1996;404:297–307 (8 ref.)
Steroidal glycoalkaloids: nature and consequences of bioactivity. Roddick JG. **Adv Exp Med Biol** 1996; 404:277–95 (131 ref.)
Molecular structures of saponins from Quillaja saponaria Molina. van Setten DC, et al. **Adv Exp Med Biol** 1996; 404:185–93 (30 ref.)
Bioactive triterpenoid and steroid saponins from medicinal plants in southwest China. Yang CR, et al. **Adv Exp Med Biol** 1996;404:225–38 (20 ref.)
Plant hallucinogens: springboards for psychotherapeutic drug discovery. McKenna DJ. **Behav Brain Res** 1996;

73(1-2):109-16 (45 ref.)
Vascular effects of selected antihypertensive drugs derived from traditional medicinal herbs. Kwan CY. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S297-9 (12 ref.)
Acetogenins from Annonaceae. Cavé A, et al. **Fortschr Chem Org Naturst** 1997;70:81-288 (245 ref.)
Sesquiterpenoids from Thapsia species and medicinal chemistry of the thapsigargins. Christensen SB, et al. **Fortschr Chem Org Naturst** 1997;71:129-67 (84 ref.)
Withania somnifera Dunal (Ashwagandha): potential plant source of a promising drug for cancer chemotherapy and radiosensitization. Devi PU. **Indian J Exp Biol** 1996 Oct; 34(10):927-32 (41 ref.)
Natural polyphenols (vegetable tannins) as drugs: possible modes of action. Haslam E. **J Nat Prod** 1996 Feb; 59(2):205-15 (60 ref.)
Natural products as a resource for new drugs. Clark AM. **Pharm Res** 1996 Aug;13(8):1133-44 (39 ref.)
NCDEU update. Natural product formulations available in europe for psychotropic indications. Cott J. **Psychopharmacol Bull** 1995;31(4):745-51 (45 ref.)
Herbal remedies. Menke J. **S D J Med** 1997 Jun;50(6):207-8 (6 ref.)
[Progress in the studies on medicinal plants of the genus Zanthoxylum Linn] Sun XW, et al. **Yao Hsueh Hsueh Pao** 1996;31(3):231-40 (67 ref.) **(Chi)**
[Plant procyanidine: occurance, classification and pharmacologic actions] Kaul R. **Pharm Unserer Zeit** 1996 Jul;25(4):175-85 (60 ref.) **(Ger)**
[Chemical study of Indonesian medicinal plants] Shibuya H, et al. **Yakugaku Zasshi** 1996 Dec;116(12):911-27 (47 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Medicinal plant genetic resources and international cooperation: the Brazilian perspective. Elisabetsky E, et al. **J Ethnopharmacol** 1996 Apr;51(1-3):111-9; discussion 119-20 (19 ref.)

METABOLISM

Pharmacokinetic evaluation of herbal remedies. Basic introduction, applicability, current status and regulatory needs. De Smet PA, et al. **Clin Pharmacokinet** 1997 Jun; 32(6):427-36 (106 ref.)
Enzymology of indole alkaloid biosynthesis in Catharanthus roseus. Misra N, et al. **Indian J Biochem Biophys** 1996 Aug; 33(4):261-73 (121 ref.)
Screening of medicinal plants used by the Garífuna of eastern Nicaragua for bioactive compounds. Coe FG, et al. **J Ethnopharmacol** 1996 Jul 26;53(1):29-50 (71 ref.)

PLANTS, TOXIC

see related
PLANT POISONING

Mandrake toxicity. A case of mistaken identity. Frasca T, et al. **Arch Intern Med** 1997 Sep 22;157(17):2007-9 (21 ref.)
Phytodermatitis. Lovell CR. **Clin Dermatol** 1997 Jul-Aug; 15(4):607-13 (75 ref.)
Poisonings: food, fish, shellfish. Mines D, et al. **Emerg Med Clin North Am** 1997 Feb;15(1):157-77 (65 ref.)
Hepatotoxicity of herbal remedies: insights into the intricacies of plant-animal warfare and cell death [editorial; comment] Kaplowitz N. **Gastroenterology** 1997 Oct;113(4):1408-12 (19 ref.) Comment on: Gastroenterology 1997 Oct;113(4):1334-46.
Poisonous plants: when they are a threat to children. Lawrence RA. **Pediatr Rev** 1997 May;18(5):162-8 (7 ref.)
[Recent results on the pharmacodynamics of Strychnos malgaches alkaloids] Rasoanaivo P, et al. **Sante** 1996 Jul-Aug;6(4):249-53 (23 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Plant toxins. The essences of diversity and a challenge to research. Manners GD. **Adv Exp Med Biol** 1996;391:9-35 (137 ref.)
Investigations of molluscicidal saponins from the Endod plant Phytolacca dodecandra. Thiilborg ST, et al. **Adv Exp Med Biol** 1996;404:151-64 (52 ref.)

CLASSIFICATION

Plant exposures: a state profile of the most common species. Krenzelok EP, et al. **Vet Hum Toxicol** 1996 Aug; 38(4):289-98 (30 ref.)

PLANTS, TRANSGENIC

Food biotechnology's challenge to cultural integrity and individual consent. Thompson PB. **Hastings Cent Rep** 1997 Jul-Aug;27(4):34-8 (5 ref.)
Transgenic plants: an emerging approach to pest control. Estruch JJ, et al. **Nat Biotechnol** 1997 Feb;15(2):137-41 (52 ref.)
[Questions about transgenic foods--importance and/or dangers-- importance of research on unexpected cross-reactions] Sabbah A. **Allerg Immunol (Paris)** 1996 Oct;28(8):288-9 (0 ref.) **(Fre)**
[Transgenic foods--advantages and risks] Mannhalter C. **Wien Klin Wochenschr** 1997 Jan 31;109(2):33-9 (20 ref.) **(Ger)**

ENZYMOLOGY

Modification of flower colour via manipulation of P450 gene expression in transgenic plants. Holton TA. **Drug Metabol Drug Interact** 1995;12(3-4):359-68 (28 ref.)

GENETICS

Modification of flower colour via manipulation of P450 gene expression in transgenic plants. Holton TA. **Drug Metabol Drug Interact** 1995;12(3-4):359-68 (28 ref.)
Transgene inheritance in plants genetically engineered by microprojectile bombardment. Pawlowski WP, et al. **Mol Biotechnol** 1996 Aug;6(1):17-30 (86 ref.)
RNA as a target and an initiator of post-transcriptional gene silencing in transgenic plants. Baulcombe DC. **Plant Mol Biol** 1996 Oct;32(1-2):79-88 (56 ref.)
[Transposon tagging using transgenic plants] Izawa T, et al. **Tanpakushitsu Kakusan Koso** 1996 Jul;41(9):1415-21; discussion 1397-8 (15 ref.) **(Jpn)**

METABOLISM

Manipulation of glutathione metabolism in transgenic plants. Creissen G, et al. **Biochem Soc Trans** 1996 May;24(2):465-9 (28 ref.)
Use of transgenic plants to study antioxidant defenses. Allen RD, et al. **Free Radic Biol Med** 1997;23(3):473-9 (39 ref.)

PLAQUE THERAPY, RADIOISOTOPE see **BRACHYTHERAPY**

PLASMA

[Plasma-derived products: therapeutic biological products] Folléa G, et al. **Transfus Clin Biol** 1997;4(2):227-40 (40 ref.) (Eng. Abstr.) **(Fre)**
[Therapy with blood and blood products] Kreienbühl G. **Urologe A** 1996 Jan;35(1):69-85 (46 ref.) **(Ger)**
[Use of blood preparations for patients of perioperative period] Takaori M. **Masui** 1996 Dec;45 Suppl:S173-8 (16 ref.) **(Jpn)**
[Reality and clinical application of blood coagulation factor preparations] Sakuragawa N. **Nippon Naika Gakkai Zasshi** 1996 Jun 10;85(6):811-7 (5 ref.) **(Jpn)**

VIROLOGY

Issues in the development of medical products based on human plasma. Josić D, et al. **J Chromatogr B Biomed Appl** 1997 Jul 4;694(2):253-69 (50 ref.)
Viral infectivity of albumin and plasma protein fraction. Erstad BL. **Pharmacotherapy** 1996 Nov-Dec; 16(6):996-1001 (47 ref.)
[Viral attenuation of labile blood products] Folléa G, et al. **Transfus Clin Biol** 1996;3(2):113-23 (84 ref.) (Eng. Abstr.) **(Fre)**

PLASMA CELL ANTIGENS PC-1 see **ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE**

PLASMA CELL DYSCRASIAS see **PARAPROTEINEMIAS**

PLASMA CELL GRANULOMA see **GRANULOMA, PLASMA CELL**

PLASMA CELL GRANULOMA, ORBITAL see **GRANULOMA, PLASMA CELL, ORBITAL**

PLASMA CELL GRANULOMA, PULMONARY see **GRANULOMA, PLASMA CELL, PULMONARY**

PLASMA-CELL LEUKEMIA see **LEUKEMIA, PLASMACYTIC**

PLASMA CELLS

CHEMISTRY

DNA cell content studies in multiple myeloma. San Miguel JF, et al. **Leuk Lymphoma** 1996 Sep;23(1-2):33-41 (45 ref.)

CYTOLOGY

Regulation of B-cell commitment to plasma cells or to memory B cells. Liu YJ, et al. **Semin Immunol** 1997 Aug; 9(4):235-40 (56 ref.)

IMMUNOLOGY

Regulation of B-cell commitment to plasma cells or to memory B cells. Liu YJ, et al. **Semin Immunol** 1997 Aug; 9(4):235-40 (56 ref.)
Long-term humoral immunity against viruses: revisiting the issue of plasma cell longevity [see comments] Slifka MK, et al. **Trends Microbiol** 1996 Oct;4(10):394-400 (63 ref.) Comment in: Trends Microbiol 1997 May;5(5):180-1.

METABOLISM

Expression of adhesion molecules in malignant plasma cells in multiple myeloma: comparison with normal plasma cells and functional significance. Helfrich MH, et al. **Blood Rev** 1997 Mar;11(1):28-38 (89 ref.)
Molecular regulation of human IgE synthesis. Worm M, et al. **J Mol Med** 1997 Jun;75(6):440-7 (68 ref.)

PATHOLOGY

Lymphoplasmacyte-rich meningioma with clinical resemblance to inflammatory pseudotumor. Report of two cases. Yamaki T, et al. **J Neurosurg** 1997 May;86(5):898-904 (22 ref.)

PHYSIOLOGY

[The role of cytokines in differentiation and function of normal and pathologic plasmacytes] Usnarska-Zubkiewicz L. **Pol Arch Med Wewn** 1996 Oct;96(4):395-405 (162 ref.) **(Pol)**

PLASMA EXCHANGE

Treatment of glomerulonephritis in microscopic polyangiitis and Churg-Strauss syndrome. Indications of plasma exchanges, Meta-analysis of 2 randomized studies on 140 patients, 32 with glomerulonephritis. Guillevin L, et al. **Ann Med Interne (Paris)** 1997;148(3):198-204 (17 ref.)
Still a role for plasma exchange in rapidly progressive glomerulonephritis? Levy JB, et al. **J Nephrol** 1997 Jan-Feb;10(1):7-13 (57 ref.)
[Respective indications of plasma exchange and high-dose immunoglobulins in polyradiculoneuritis and myasthenia gravis] Raphaël JC, et al. **Presse Med** 1996 Oct 19; 25(31):1516-22 (31 ref.) (Eng. Abstr.) **(Fre)**
[Treatment of Guillain-Barré syndrome by plasma exchange: proposal of a therapeutic strategy] Raphael JC, et al. **Rev Neurol (Paris)** 1996 May;152(5):359-64 (42 ref.) (Eng. Abstr.) **(Fre)**
[Which patients should be treated with plasma exchange? Indications for plasma exchange therapy] Cala S. **Lijec Vjesn** 1996 Nov-Dec;118(11-12):286-90 (35 ref.) (Eng. Abstr.) **(Scr)**

STANDARDS

Current status in extracorporeal immunomodulation: immune disorders. Bosch T. **Artif Organs** 1996 Aug;20(8):902-5 (22 ref.)

PLASMA FLOW, RENAL, EFFECTIVE see **RENAL PLASMA FLOW, EFFECTIVE**

PLASMA MEMBRANE see **CELL MEMBRANE**

PLASMA PROKALLIKREIN see **PREKALLIKREIN**

PLASMA PROTEINS see **BLOOD PROTEINS**

PLASMA SUBSTITUTES

see related
BLOOD SUBSTITUTES

Hydroxyethyl starch: safe or not? Warren BB, et al. **Anesth Analg** 1997 Jan;84(1):206-12 (43 ref.)

ADMINISTRATION & DOSAGE

Hypertonic saline dextran (HSD) and intraosseous vascular access for the treatment of haemorrhagic hypotension in the far-forward combat arena. Dubick MA, et al. **Ann Acad Med Singapore** 1997 Jan;26(1):64-9 (48 ref.)

THERAPEUTIC USE

Individual patient cohort analysis of the efficacy of hypertonic saline/dextran in patients with traumatic brain injury and hypotension. Wade CE, et al. **J Trauma** 1997 May;42(5 Suppl):S61-5 (22 ref.)

PLASMA THROMBOPLASTIN ANTECEDENT see **FACTOR XI**

PLASMA THROMBOPLASTIN COMPONENT see **FACTOR IX**

PLASMA TRANSGLUTAMINASE see **PROTEIN-GLUTAMINE GAMMA-GLUTAMYLTRANSFERASE**

PLASMA VOLUME

Clinical aspects of the control of plasma volume at microgravity and during return to one gravity. Convertino VA. **Med Sci Sports Exerc** 1996 Oct;28(10 Suppl):S45-52 (44 ref.)
Dietary sodium and plasma volume levels with exercise. Luetkemeier MJ, et al. **Sports Med** 1997 May;23(5):279-86 (37 ref.)

DRUG EFFECTS

[Indications and role of albumin for vascular loading during postoperative intensive care] Blanloeil Y, et al. **Ann Fr Anesth Reanim** 1996;15(4):497-506 (40 ref.) (Eng. Abstr.) **(Fre)**
[Indications and role of albumin for vascular loading in the operating room] Gérard JL, et al. **Ann Fr Anesth Reanim** 1996;15(4):481-90 (69 ref.) (Eng.

PLASMA VOLUME

Abstr.) **(Fre)**

[Is albumin administration useful in critical care for burnt patients?] Manelli JC. **Ann Fr Anesth Reanim** 1996; 15(4):507–13 (66 ref.) (Eng. Abstr.) **(Fre)**

PLASMA VOLUME EXPANDERS see **PLASMA SUBSTITUTES**

PLASMACYTES see **PLASMA CELLS**

PLASMACYTIC LEUKEMIA see **LEUKEMIA, PLASMACYTIC**

PLASMACYTOMA

Extramedullary plasmacytoma of the jejunum. Tsuruda T, et al. **Intern Med** 1996 May;35(5):422–6 (15 ref.)

COMPLICATIONS

Plasmacytoma of the sigmoid colon associated with a diverticular stricture: case report and review of the literature. Holland AJ, et al. **J R Coll Surg Edinb** 1997 Feb;42(1):47–9 (24 ref.)

DIAGNOSIS

The medium cell sIg+, proplasmocytic lymphoma/leukemia. Positive and differential diagnosis with other B-lymphoblastoid neoplasias [editorial] Mathé G, et al. **Biomed Pharmacother** 1996;50(9):425–32 (23 ref.)

Solitary IgA myeloma of the foot. A case report and review of the literature. Khoddami M, et al. **J Am Podiatr Med Assoc** 1997 May;87(5):233–7 (24 ref.)

Magnetic resonance imaging of the spine in plasma cell dyscrasias. A review. Pertuiset E, et al. **Rev Rhum Engl Ed** 1996 Dec;63(11):837–45 (39 ref.)

[Rare intracranial plasmacytoma manifestations. Case reports and review of the literature in diffuse plasmocytoma, in primary solitary extramedullary plasmacytoma in in primary solitary osseous plasmacytoma] Kujat C, et al. **Radiologe** 1996 Nov;36(11):914–20 (42 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

[B cell malignancies and adhesion molecules] Kawano MM. **Rinsho Byori** 1996 Sep;Suppl 102:207–15 (17 ref.) **(Jpn)**

PATHOLOGY

Amyloidoma of bone, a plasma cell/plasmacytoid neoplasm. Report of three cases and review of the literature. Pambuccian SE, et al. **Am J Surg Pathol** 1997 Feb; 21(2):179–86 (55 ref.)

Plasmacytoma of the eye and orbit. Adkins JW, et al. **Int Ophthalmol** 1996–97;20(6):339–43 (11 ref.)

Primary plasmacytoma of the testis. Case report and review of the literature. Fischer C, et al. **Urol Int** 1996;56(4):263–5 (15 ref.)

[A case of extramedullary plasmacytoma of the stomach] Takehara Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Feb;94(2):111–6 (8 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Monoclonal gammopathy of undetermined significance and solitary plasmacytoma. Implications for progression to overt multiple myeloma. Kyle RA. **Hematol Oncol Clin North Am** 1997 Feb;11(1):71–87 (54 ref.)

SURGERY

[Solitary plasmacytoma of sternum—a case report and review of the Japanese literature] Ohtake Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 May;44(5):717–22 (24 ref.) (Eng. Abstr.) **(Jpn)**

VETERINARY

Tumours of the haematopoietic system. Barthold SW. **IARC Sci Publ** 1996;(126):365–83 (74 ref.)

PLASMACYTOMA GROWTH FACTOR see **INTERLEUKIN-6**

PLASMALOGENS

METABOLISM

Characterization of plasmalogen-selective phospholipase A2 from bovine brain. Yang HC, et al. **Adv Exp Med Biol** 1996;416:309–13 (12 ref.)

Is the high propensity of ethanolamine plasmalogens to form non-lamellar lipid structures manifested in the properties of biomembranes? Lohner K. **Chem Phys Lipids** 1996 Jul 15;81(2):167–84 (127 ref.)

Plasmalogen-selective phospholipase A2 and its role in signal transduction. Yang HC, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):9–13 (13 ref.)

Membrane phospholipid alterations in Alzheimer's disease: deficiency of ethanolamine plasmalogens. Farooqui AA, et al. **Neurochem Res** 1997 Apr;22(4):523–7 (48 ref.)

PLASMAPHERESIS

Low density lipoprotein apheresis: a selective plasma separation method [editorial] Bambauer R. **Artif Organs** 1996 Apr;20(4):284–5 (6 ref.)

Heparin-induced extracorporeal low-density lipoprotein precipitation and low-density lipoprotein chemoadsorption onto dextran sulfate: a comparison. Bosch Y. **Artif Organs** 1996 Apr;20(4):328–31 (20 ref.)

The Lupus Plasmapheresis Study Group: rationale and updated interim report. Euler HH, et al. **Artif Organs** 1996 Apr;20(4):356–9 (33 ref.)

Extracorporeal removal of lipids by dextran sulfate cellulose adsorption. Olbricht CJ. **Artif Organs** 1996 Apr;20(4):332–5 (31 ref.)

Plasma therapy at Klinikum Grosshadern: a 15-year retrospective. Samtleben W, et al. **Artif Organs** 1996 May; 20(5):408–13 (29 ref.)

H.E.L.P. apheresis therapy in the treatment of severe hypercholesterolemia: 10 years of clinical experience. Seidel D. **Artif Organs** 1996 Apr;20(4):303–10 (30 ref.)

Management of plasmapheresis in France. Cazenave JP, et al. **Hematol Cell Ther** 1996 May;38 Suppl 1:S25–33 (21 ref.)

A review of the effects of plasmapheresis on drug clearance. Kale-Pradhan PB, et al. **Pharmacotherapy** 1997 Jul–Aug; 17(4):684–95 (90 ref.)

[The usefulness of plasmapheresis in a case of nephrotic syndrome in Berger's disease] Pergolini M, et al. **Clin Ter** 1996 Nov;147(11):543–7 (13 ref.) (Eng. Abstr.) **(Ita)**

[Exchange plasmapheresis in surgical diseases of abdominal cavity organs] Vatazin AV. **Anesteziol Reanimatol** 1997 May–Jun;(3):83–7 (92 ref.) **(Rus)**

[A case of the successful use of plasmapheresis in the combined treatment of a female patient with autoimmune agranulocytosis against a background of Schmidt's syndrome] Vlasenko AN, et al. **Ter Arkh** 1997;69(2):64–5 (10 ref.) **(Rus)**

[Plasmapheresis and pain] Betaneli AM, et al. **Vestn Khir Im I I Grek** 1997;156(2):120–21 (6 ref.) **(Rus)**

METHODS

Low-density lipoprotein apheresis using the Liposorber dextran sulfate cellulose system for patients with hypercholesterolemia refractory to medical therapy. Gordon BR, et al. **J Clin Apheresis** 1996;11(3):128–31 (23 ref.)

STANDARDS

State of the art of lipid apheresis. Bosch T. **Artif Organs** 1996 Apr;20(4):292–5 (22 ref.)

TRENDS

Low-density lipoprotein removal methods by membranes and future perspectives. Matsuda Y, et al. **Artif Organs** 1996 Apr;20(4):346–54 (37 ref.)

VETERINARY

Therapeutic plasmapheresis. Bartges JW. **Semin Vet Med Surg (Small Anim)** 1997 Aug;12(3):170–7 (85 ref.)

PLASMIDS

see related
EXTRACHROMOSOMAL INHERITANCE

Molecular epidemiologic analysis of antibiotic resistant microorganisms. John JF Jr. **Adv Exp Med Biol** 1995; 390:155–68 (56 ref.)

A low-copy number plasmid mediating beta-lactamase production by Xanthomonas maltophilia. Kelly MD, et al. **Adv Exp Med Biol** 1995;390:71–80 (18 ref.)

Mitochondrial fusion promoting plasmid. Takano H, et al. **Cell Struct Funct** 1997 Jun;22(3):299–308 (43 ref.)

Plasmids in Lactobacillus. Wang TT, et al. **Crit Rev Biotechnol** 1997;17(3):227–72 (188 ref.)

The challenges of recombinant adeno-associated virus manufacturing: alternative use of adeno-associated virus plasmid/liposome complexes for gene therapy applications. Lebkowski JS, et al. **Curr Top Microbiol Immunol** 1996; 218:51–9 (11 ref.)

Helper virus-free herpes simplex virus-1 plasmid vectors for gene therapy of Parkinson's disease and other neurological disorders. Geller AI, et al. **Exp Neurol** 1997 Mar; 144(1):98–102 (26 ref.)

Autonomous plasmid replication in Aspergillus nidulans: AMA1 and MATE elements. Aleksenko A, et al. **Fungal Genet Biol** 1997 Jun;21(3):373–87 (83 ref.)

Plasmids and bacterial resistance to biocides. Russell AD. **J Appl Microbiol** 1997 Aug;83(2):155–65 (120 ref.)

Use of antisense-generating plasmids to probe the function of signal transduction proteins in primary neurons. Abogadie FC, et al. **Methods Mol Biol** 1997;83:217–25 (7 ref.)

Bacteria gone native vs. bacteria gone awry?: plasmidic transfer and bacterial evolution. Souza V, et al. **Proc Natl Acad Sci U S A** 1997 May 27;94(11):5501–3 (23 ref.)

Replication control of plasmid P1 and its host chromosome: the common ground. Chattoraj DK, et al. **Prog Nucleic Acid Res Mol Biol** 1997;57:145–86 (239 ref.)

[Yersinia outer membrane proteins coded for by the virulence plasmid] Mikerov AN, et al. **Mol Gen Mikrobiol Virusol** 1997;(3):3–10 (131 ref.) (Eng. Abstr.) **(Rus)**

[Manipulation of genes causing diseases] Monckeberg F. **Rev Med Chil** 1996 Mar;124(3):371–6 (28 ref.) (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

A little VEGF goes a long way. Therapeutic angiogenesis by direct injection of vascular endothelial growth factor-encoding plasmid DNA [editorial; comment] Majesky MW. **Circulation** 1996 Dec 15;94(12):3062–4 (17 ref.) Comment on: Circulation 1996 Dec 15;94(12):3281–90.

ANALYSIS

Determination of plasmid copy number in yeast. Jordan BE, et al. **Methods Mol Biol** 1996;53:193–203 (5 ref.)

GENETICS

New drug effects on bacteria, the antiplasmid effect. Molnár J. **Acta Microbiol Immunol Hung** 1997;44(1):21–6 (40 ref.)

Evolutionary relationship between plasmids and phages: phasmid P4 as a model. Lagos R, et al. **Arch Biol Med Exp (Santiago)** 1987;20(3–4):325–32 (44 ref.)

Molecular determinants of Yersinia pathogenesis. Iriarte M, et al. **Microbiologia** 1996 Jun;12(2):267–80 (97 ref.)

Broad-host-range plasmid replication: an open question. del Solar G, et al. **Mol Microbiol** 1996 Aug;21(4):661–6 (29 ref.)

[The role of plasmid gef-like genes in eliminating from bacterial populations the specimens that have lost these plasmids] Lishchenko NN, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Jan–Feb;(1):90–4 (24 ref.) **(Rus)**

METABOLISM

Plasmid replication and partition in Escherichia coli: is the cell membrane the key? Firshein W, et al. **Mol Microbiol** 1997 Jan;23(1):1–10 (66 ref.)

PHARMACOKINETICS

[Cancer gene therapy by direct intratumoral injection: gene expression and intratumoral pharmacokinetics of plasmid DNA] Nomura T, et al. **Gan To Kagaku Ryoho** 1997 Feb; 24(4):483–8 (6 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Chemical signals in gram-positive bacteria: the sex-pheromone system in Enterococcus faecalis. Maqueda M, et al. **Microbiologia** 1997 Mar;13(1):23–36 (64 ref.)

PLASMIN

ANALYSIS

[Clinical usefulness of the measurements of plasmin-alpha 2-plasmin inhibitor complex and plasma tissue factor activity in patients with disseminated intravascular coagulation] Fukuda C, et al. **Rinsho Byori** 1996 Aug; 44(8):750–6 (12 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Genetic analysis of the plasminogen and coagulation system in mice. Carmeliet P, et al. **Haemostasis** 1996 Oct;26 Suppl 4:132–53 (106 ref.)

METABOLISM

Annexin II: a novel mediator of cell surface plasmin generation. Hajjar KA, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:337–49 (30 ref.)

Cooperation between matrix metalloproteinases and the plasminogen activator-plasmin system in tumor progression. DeClerck YA, et al. **Enzyme Protein** 1996; 49(1–3):72–84 (95 ref.)

Plasminogen activation by invasive human pathogens. Boyle MD, et al. **Thromb Haemost** 1997 Jan;77(1):1–10 (135 ref.)

PHYSIOLOGY

Pathophysiology of the plasminogen/plasmin system [editorial] Lijnen HR. **Int J Clin Lab Res** 1996;26(1):1–6 (29 ref.)

PLASMINOGEN

GENETICS

Genetic analysis of the plasminogen and coagulation system in mice. Carmeliet P, et al. **Haemostasis** 1996 Oct;26 Suppl 4:132–53 (106 ref.)

Gene manipulation and transfer of the plasminogen and coagulation system in mice. Carmeliet P, et al. **Semin Thromb Hemost** 1996;22(6):525–42 (131 ref.)

METABOLISM

Plasminogen activation by invasive human pathogens. Boyle MD, et al. **Thromb Haemost** 1997 Jan;77(1):1–10 (135 ref.)
Contact activation proteins and the bacterial surface. Lottenberg R. **Trends Microbiol** 1996 Nov;4(11):413–4; discussion 414–5 (12 ref.)

PHARMACOLOGY

Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. O'Reilly MS. **EXS** 1997;79:273–94 (62 ref.)
Molecular and functional properties of fetal plasminogen and its possible influence on clot lysis in the neonatal period. Ries M. **Semin Thromb Hemost** 1997;23(3):247–52 (60 ref.)

PHYSIOLOGY

Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system. Carmeliet P, et al.
Ann N Y Acad Sci 1997 Apr 15;811:191–206 (58 ref.)
Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. O'Reilly MS. **EXS** 1997;79:273–94 (62 ref.)
Pathophysiology of the plasminogen/plasmin system [editorial] Lijnen HR. **Int J Clin Lab Res** 1996;26(1):1–6 (29 ref.)
Molecular and functional properties of fetal plasminogen and its possible influence on clot lysis in the neonatal period. Ries M. **Semin Thromb Hemost** 1997;23(3):247–52 (60 ref.)

PLASMINOGEN ACTIVATOR INHIBITOR 1

BLOOD

PAI-1, obesity, insulin resistance and risk of cardiovascular events. Juhan-Vague I, et al. **Thromb Haemost** 1997 Jul; 78(1):656–60 (56 ref.)
The fat mouse: a powerful genetic model to study elevated plasminogen activator inhibitor 1 in obesity/NIDDM. Samad F, et al. **Thromb Haemost** 1997 Jul;78(1):652–5 (44 ref.)

GENETICS

Expression of fibrinolytic genes in tissues from human atherosclerotic aneurysms and from obese mice. Samad F, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:350–8; discussion 358–60 (68 ref.)

METABOLISM

Haemostatic parameters and vascular risk. Juhan-Vage I. **Atherosclerosis** 1996 Jul;124 Suppl:S49–55 (63 ref.)
Leg ulcers in Klinefelter's syndrome--further evidence for an involvement of plasminogen activator inhibitor-1. Zollner TM, et al. **Br J Dermatol** 1997 Mar;136(3):341–4 (23 ref.)

PHYSIOLOGY

uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Blasi F. **Immunol Today** 1997 Sep;18(9):415–7 (24 ref.)

PLASMINOGEN ACTIVATOR INHIBITOR 3 see **PROTEIN C INHIBITOR**

PLASMINOGEN ACTIVATOR, TISSUE-TYPE see **ALTEPLASE**

PLASMINOGEN ACTIVATOR, UROKINASE-TYPE see **UROKINASE**

PLASMINOGEN ACTIVATORS

Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Schmitt M, et al. **Thromb Haemost** 1997 Jul; 78(1):285–96 (128 ref.)

ADMINISTRATION & DOSAGE

Intra-aneurysmal GDC embolization followed by intrathecal tPA administration for poor-grade basilar tip aneurysm. Ezura M, et al. **Surg Neurol** 1997 Feb;47(2):144–7; discussion 147–8 (20 ref.)
[Local intra-arterial thrombolysis in acute ischemia of an extremity] Enevoldsen MT, et al. **Ugeskr Laeger** 1996 Sep 2;158(36):5011–4 (29 ref.) (Eng. Abstr.) **(Dan)**
[Coronary thrombolysis--current aspects] Legrand V. **Rev Med Liege** 1996 Sep;51(9):571–5 (28 ref.) **(Fre)**
[Regimens for administering plasminogen activators] Maksimenko AV. **Eksp Klin Farmakol** 1996 Jul-Aug; 59(4):58–64 (50 ref.) (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

[Side effects of thrombolytic therapy in patients with myocardial infarction] Agostoni A, et al. **Cardiologia** 1995 Dec;40(12):899–908 (103 ref.) **(Ita)**

CHEMISTRY

Molecular biology of plasminogen activators: what are the clinical implications of drug design? Smalling RW. **Am J Cardiol** 1996 Dec 19;78(12A):2–7 (38 ref.)

METABOLISM

What structure and function of avian plasminogen activator and matrix metalloproteinase-2 reveal about their counterpart mammalian enzymes, their regulation and their role in tumor invasion. Alexander DS, et al.
Enzyme Protein 1996;49(1-3):38–58 (98 ref.)
Cooperation between matrix metalloproteinases and the plasminogen activator-plasmin system in tumor progression. DeClerck YA, et al. **Enzyme Protein** 1996; 49(1-3):72–84 (95 ref.)
The role of the pericellular fibrinolytic system in angiogenesis. Fukao H, et al. **Jpn J Physiol** 1997 Apr; 47(2):161–71 (123 ref.)
Plasminogen activation by invasive human pathogens. Boyle MD, et al. **Thromb Haemost** 1997 Jan;77(1):1–10 (135 ref.)

PHYSIOLOGY

Plasminogen activators in abdominal aortic aneurysmal disease. Reilly JM. **Ann N Y Acad Sci** 1996 Nov 18; 800:151–6 (29 ref.)
Regulation and role of urokinase plasminogen activator in vascular remodelling. Tkachuk V, et al.
Clin Exp Pharmacol Physiol 1996 Sep;23(9):759–65 (75 ref.)
Plasminogen activators and matrix metalloproteinases in angiogenesis. Mignatti P, et al. **Enzyme Protein** 1996; 49(1-3):117–37 (216 ref.)
Fibroblast growth factors as angiogenesis factors: new insights into their mechanism of action. Klein S, et al. **EXS** 1997;79:159–92 (259 ref.)
Role of fibrin and plasminogen activators in repair-associated angiogenesis: in vitro studies with human endothelial cells. van Hinsbergh VW, et al. **EXS** 1997;79:391–411 (119 ref.)
Plasminogen activator system: implications for mammary cell growth and involution. Politis I. **J Dairy Sci** 1996 Jun; 79(6):1097–107 (55 ref.)
The plasminogen activation system in melanoma cell lines and in melanocytic lesions. de Vries TJ, et al.
Melanoma Res 1996 Apr;6(2):79–88 (93 ref.)

THERAPEUTIC USE

Hyperacute stroke therapy with tissue plasminogen activator. Alberts MJ. **Am J Cardiol** 1997 Aug 28;80(4C):29D–34D; discussion 35D–39D (14 ref.)
Patency trials with reteplase (r-PA): what do they tell us? Bode C, et al. **Am J Cardiol** 1996 Dec 19;78(12A):16–9 (26 ref.)
New approaches in plasminogen activator therapy. Bode C, et al. **Ann Hematol** 1996;73 Suppl 1:S1–7 (44 ref.)
Thrombolytic agents--an overview. Gulba DC, et al.
Ann Hematol 1996;73 Suppl 1:S9–27 (227 ref.)
Thrombolytic therapy in acute myocardial infarction. Hampton JR. **Cardiovasc Drugs Ther** 1997 May;11 Suppl 1:241–6 (25 ref.)
Use of urokinase in unstable angina. Duvvuri S, et al.
Coron Artery Dis 1996 Sep;7(9):630–6 (51 ref.)
Urokinase recanalization of chronically occluded aortocoronary vein grafts. Hartmann JR.
Coron Artery Dis 1996 Sep;7(9):641–8 (32 ref.)
Intracoronary recombinant tissue-type plasminogen activator (rt-PA). Tiefenbrunn AJ. **Coron Artery Dis** 1996 Sep; 7(9):637–40 (27 ref.)
New interventions in cerebrovascular disease: the role of thrombolytic therapy and balloon angioplasty. Balousek PA, et al. **Curr Opin Cardiol** 1996 Sep;11(5):550–7 (67 ref.)
Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction. Noble S, et al. **Drugs** 1996 Oct;52(4):589–605 (55 ref.)
Thrombolytic therapy in the elderly. Pharmacoeconomic considerations. Ramanathan K, et al. **Drugs Aging** 1996 Apr;8(4):237–44 (52 ref.)
The role of thrombolytic drugs in the management of myocardial infarction. Comparative clinical trials. Weaver WD. **Eur Heart J** 1996 Dec;17 Suppl F:9–15 (36 ref.)
Antithrombotic treatment in stable coronary syndromes: long-term intermittent urokinase therapy in end-stage coronary artery disease and refractory angina pectoris. Schoebel FC, et al. **Heart** 1997 Jan;77(1):13–7 (53 ref.)
Left atrial thrombus in a 10-month-old boy--successful thrombolysis with recombinant tissue-type plasminogen activator after open-heart surgery: review of the literature. Kehl HG, et al. **Intensive Care Med** 1996 Sep;22(9):968–71 (11 ref.)
Treatment of acute ischemic stroke, Part 1. Fullerton T. **J Am Pharm Assoc (Wash)** 1996 Oct;NS36(10):571–2 (6 ref.)
Comparison of streptokinase and urokinase in local thrombolysis of peripheral arterial occlusions for lower limb salvage. Dubé M, et al. **J Vasc Interv Radiol** 1996 Jul-Aug;7(4):587–93 (25 ref.)
Thrombolytic therapy in acute ischaemic stroke: the jury needs more evidence. Hankey GJ. **Med J Aust** 1997 Apr 21;166(8):419–22 (27 ref.)
Thrombolysis in acute stroke. del Zoppo GJ. **Neurologia** 1995 Dec;10 Suppl 2:37–47 (105 ref.)
Local thrombolytic therapy in deep cerebral venous thrombosis. Smith AG, et al. **Neurology** 1997 Jun; 48(6):1613–9 (37 ref.)
New peptide and protein drugs. Vermeij P, et al.
Pharm World Sci 1996 Jun;18(3):87–93 (81 ref.)
Controlled trials comparing reteplase with alteplase and streptokinase in patients with acute myocardial infarction. Amsterdam EA. **Pharmacotherapy** 1996 Sep-Oct;16(5 Pt 2):137S–140S (9 ref.)
[Ilio-femoral vein thrombosis treated with tissue plasminogen activator in a pregnant woman] Grand A, et al.
Ann Cardiol Angeiol (Paris) 1996 Nov;45(9):517–22 (14 ref.) (Eng. Abstr.) **(Fre)**
[Bolus thrombolysis in pulmonary embolism. Review of experimental and clinical data] Zonzin P, et al.
Ann Ital Med Int 1996 Apr-Jun;11(2):132–7 (35 ref.) (Eng. Abstr.) **(Ita)**

PLASMODIUM

see related
ANTIMALARIALS

Role of geographic information system in malaria control. Sharma VP, et al. **Indian J Med Res** 1997 Aug;106:198–204 (5 ref.)

CYTOLOGY

The biology of malarial parasite in the mosquito--a review. Simonetti AB. **Mem Inst Oswaldo Cruz** 1996 Sep-Oct; 91(5):519–41 (277 ref.)

DRUG EFFECTS

Is haemozoin a target for antimalarial drugs? Meshnick SR. **Ann Trop Med Parasitol** 1996 Aug;90(4):367–72 (40 ref.)
Quinoline antimalarials: mechanisms of action and resistance. Foley M, et al. **Int J Parasitol** 1997 Feb;27(2):231–40 (60 ref.)
Latency of Plasmodium merozoites and drug-resistance. A review. Landau I, et al. **Parasite** 1994 Jun;1(2):105–14 (18 ref.)

ENZYMOLOGY

Aspartic proteinases from parasites. Kay J, et al.
Adv Exp Med Biol 1996;389:247–50 (13 ref.)

GENETICS

Transformation of malaria parasites: the barriers come down. Hyde JE. **Trends Microbiol** 1996 Feb;4(2):43–5 (15 ref.)

GROWTH & DEVELOPMENT

Cell invasion by the vertebrate stages of Plasmodium. Sinnis P, et al. **Trends Microbiol** 1997 Feb;5(2):52–8 (77 ref.)

IMMUNOLOGY

Class I HLA-restricted cytotoxic T lymphocyte responses against malaria--elucidation on the basis of HLA peptide binding motifs. Doolan DL, et al. **Immunol Res** 1996; 15(4):280–305 (180 ref.)
T cell immunity in malaria. Kabilan L.
Indian J Med Res 1997 Aug;106:130–48 (96 ref.)
Transmission-blocking vaccines: uses and current status of development. Kaslow DC. **Int J Parasitol** 1997 Feb; 27(2):183–9 (45 ref.)

ISOLATION & PURIFICATION

Malarial parasites of lizards: diversity and ecology. Schall JJ. **Adv Parasitol** 1996;37:255–333 (125 ref.)

METABOLISM

Biochemical changes induced by malarial parasites. Ganguly NK, et al. **Indian J Med Res** 1997 Aug;106:70–8 (32 ref.)
Hemoglobin catabolism and iron utilization by malaria parasites. Rosenthal PJ, et al. **Mol Biochem Parasitol** 1996 Dec 20;83(2):131–9 (77 ref.)

PARASITOLOGY

Biological control of malaria vectors. Das PK, et al.
Indian J Med Res 1997 Aug;106:174–97 (225 ref.)
Urban malaria vector biology. Hati AK.
Indian J Med Res 1997 Aug;106:149–63 (111 ref.)
Current trends in research on tissue stage of malaria. Kamboj KK. **Indian J Med Res** 1997 Aug;106:120–9 (99 ref.)
Anopheline species complexes & malaria control. Subbarao SK, et al. **Indian J Med Res** 1997 Aug;106:164–73 (41 ref.)

PATHOGENICITY

Cell invasion by the vertebrate stages of Plasmodium. Sinnis P, et al. **Trends Microbiol** 1997 Feb;5(2):52–8 (77 ref.)

PHYSIOLOGY

From malaria to chemokine receptor: the emerging physiologic role of the Duffy blood group antigen. Hadley TJ, et al. **Blood** 1997 May 1;89(9):3077–91 (129 ref.)
The redox status of malaria-infected erythrocytes: an overview with an emphasis on unresolved problems. Ginsburg H, et al. **Parasite** 1994 Mar;1(1):5–13 (65 ref.)
Latency of Plasmodium merozoites and drug-resistance. A review. Landau I, et al. **Parasite** 1994 Jun;1(2):105–14 (18 ref.)

PLASMODIUM BERGHEI

PLASMODIUM BERGHEI

PATHOGENICITY

The malaria sporozoite's journey into the liver. Sinnis P. **Infect Agents Dis** 1996 Jun;5(3):182–9 (54 ref.)

PLASMODIUM FALCIPARUM

Infectivity of malarial parasites to mosquitoes: 'the interdependent roles of parasite, vector and host'. Lensen AH. **Ann Trop Med Parasitol** 1996 Aug;90(4):359–65 (18 ref.)

Erythrocyte membrane alterations in Plasmodium falciparum malaria sequestration. Oh SS, et al. **Curr Opin Hematol** 1997 Mar;4(2):148–54 (67 ref.)

Malaria as a reemerging disease. Krogstad DJ. **Epidemiol Rev** 1996;18(1):77–89 (143 ref.)

DNA vaccines for malaria: the past, the present, & the future. Doolan DL, et al. **Indian J Med Res** 1997 Aug;106:109–19 (77 ref.)

Field trials of malaria vaccines. Kitua AY. **Indian J Med Res** 1997 Aug;106:95–108 (51 ref.)

Knob proteins in falciparum malaria. Sharma YD. **Indian J Med Res** 1997 Aug;106:53–62 (55 ref.)

GENETICS

Molecular approaches to the spreading problem of drug resistant malaria. Plowe CV, et al. **Adv Exp Med Biol** 1995; 390:197–209 (48 ref.)

Current status of the Plasmodium falciparum genome project. Dame JB, et al. **Mol Biochem Parasitol** 1996 Jul;79(1):1–12 (74 ref.)

IMMUNOLOGY

Malaria vaccine trials: the missing qualitative data. Ferreira M. **Immunol Cell Biol** 1996 Aug;74(4):301–5 (20 ref.)

Antigenic variation and immune evasion in Plasmodium falciparum malaria. Reeder JC, et al. **Immunol Cell Biol** 1996 Dec;74(6):546–54 (103 ref.)

Novel putative protective antigens of Plasmodium falciparum. Sharma S, et al. **Indian J Med Res** 1997 Aug; 106:63–9 (42 ref.)

METABOLISM

Metabolic enzymes as potential drug targets in Plasmodium falciparum. Subbayya IN, et al. **Indian J Med Res** 1997 Aug;106:79–94 (127 ref.)

The molecular basis of pathogenesis of cerebral malaria. Fujioka H, et al. **Microb Pathog** 1996 Feb;20(2):63–72 (50 ref.)

PATHOGENICITY

Membrane modifications in erythrocytes parasitized by Plasmodium falciparum. Deitsch KW, et al. **Mol Biochem Parasitol** 1996 Feb–Mar;76(1–2):1–10 (87 ref.)

PHYSIOLOGY

[Genetic susceptibility to malaria in man: contribution of genetic epidemiology (editorial)] Abel L. **Pathol Biol (Paris)** 1995 Nov;43(9):745–8 (19 ref.) **(Fre)**

PLASMODIUM FALCIPARUM MALARIA see **MALARIA, FALCIPARUM**

PLASMODIUM INFECTIONS see **MALARIA**

PLASMODIUM MALARIAE

Mixed-species Plasmodium infections of humans. McKenzie FE, et al. **J Parasitol** 1997 Aug;83(4):593–600 (85 ref.)

PLASMODIUM VIVAX

DRUG EFFECTS

Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Baird JK, et al. **Am J Trop Med Hyg** 1997 Jun;56(6):621–6 (34 ref.)

Primaquine resistance in Plasmodium vivax. Collins WE, et al. **Am J Trop Med Hyg** 1996 Sep;55(3):243–9 (65 ref.)

PLASMODIUM VIVAX MALARIA see **MALARIA, VIVAX**

PLASMODIUM YOELII

PATHOGENICITY

The malaria sporozoite's journey into the liver. Sinnis P. **Infect Agents Dis** 1996 Jun;5(3):182–9 (54 ref.)

PLASMOSOME see **CELL NUCLEOLUS**

PLASTER CASTS see **CASTS, SURGICAL**

PLASTIC CASTS see **CASTS, SURGICAL**

PLASTIC SURGERY see **SURGERY, PLASTIC**

PLASTICITY, NEURONAL see **NEURONAL PLASTICITY**

PLASTICIZERS

ADVERSE EFFECTS

para-Aramid fibrils. **IARC Monogr Eval Carcinog Risks Hum** 1997;68:409–39 (68 ref.)

PLASTICS

Effects of fabrication, finishing, and polishing procedures on preload in prostheses using conventional "gold" and plastic cylinders. Carr AB, et al. **Int J Oral Maxillofac Implants** 1996 Sep–Oct;11(5):589–98 (20 ref.)

ADVERSE EFFECTS

Plastics/acrylics: material safety data sheets need to be improved. Kanerva L, et al. **Clin Dermatol** 1997 Jul–Aug; 15(4):533–46 (67 ref.)

CHEMISTRY

Drug interactions with medicinal plastics. D'Arcy PF. **Adverse Drug React Toxicol Rev** 1996 Nov;15(4):207–19 (80 ref.)

PLASTIDS

The growing importance of the plastid-like DNAs of the Apicomplexa. Jeffries AC, et al. **Int J Parasitol** 1996 Nov; 26(11):1139–50 (77 ref.)

PLATANNA see **XENOPUS LAEVIS**

PLATELET ACTIVATING FACTOR

Platelet-activating factor. Kingsnorth AN. **Scand J Gastroenterol Suppl** 1996;219:28–31 (21 ref.)

[Platelet activating factor (PAF) and Lyme disease] Isogai E, et al. **Nippon Saikingaku Zasshi** 1996 Aug;51(3):863–9 (15 ref.) **(Jpn)**

ANALOGS & DERIVATIVES

Cigarettes and the wages of sn-2: oxidized species of PAF in smoking hamsters [editorial; comment] FitzGerald GA. **J Clin Invest** 1997 May 15;99(10):2300–1 (10 ref.) Comment on: J Clin Invest 1997 May 15;99(10):2358–64.

ANTAGONISTS & INHIBITORS

Lexipafant (BB-882), a potent PAF antagonist in acute pancreatitis. Curtis LD. **Adv Exp Med Biol** 1996;416:361–3 (16 ref.)

The use of lexipafant in the treatment of acute pancreatitis. McKay C, et al. **Adv Exp Med Biol** 1996;416:365–70 (34 ref.)

[PAF receptor antagonist in asthma therapy] Sagara H, et al. **Nippon Rinsho** 1996 Nov;54(11):3056–61 (24 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Platelet-activating factor synthesis and its role in salivary glands. Dohi T, et al. **Adv Exp Med Biol** 1996;416:41–4 (35 ref.)

PAF-synthesizing enzymes in neural cells during differentiation and in gerbil brain during ischemia. Francescangeli E, et al. **Adv Exp Med Biol** 1996;416:21–7 (48 ref.)

PAF response to inflammatory and non-inflammatory stimuli. Saito K. **Adv Exp Med Biol** 1996;416:213–6 (11 ref.)

Production of platelet-activating factor by brain microvascular endothelial cells. Satoh K, et al. **Adv Exp Med Biol** 1996;416:17–20 (7 ref.)

Biosynthesis of platelet-activating factor and enzyme inhibitors. Snyder F, et al. **Adv Exp Med Biol** 1996;416:5–10 (18 ref.)

The role of peroxisomes in ether lipid synthesis. Back to the roots of PAF. van den Bosch H, et al. **Adv Exp Med Biol** 1996;416:33–40 (27 ref.)

METABOLISM

PAF released by preimplantation embryos binds to albumin. Ammit AJ, et al. **Adv Exp Med Biol** 1996;416:263–7 (46 ref.)

Platelet-activating factor receptor. Gene structure and tissue-specific regulation. Shimizu T, et al. **Adv Exp Med Biol** 1996;416:79–84 (25 ref.)

Platelet-activating factor and cardiac diseases: therapeutic potential for PAF inhibitors. Feuerstein G, et al. **J Lipid Mediat Cell Signal** 1997 Mar;15(3):255–84 (193 ref.)

PAF and PAF acetylhydrolase in the nervous system. Hattori M, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):99–102 (9 ref.)

Platelet-activating factor and somatostatin activate mitogen-activated protein kinase (MAP kinase) and arachidonate release. Shimizu T, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):103–8 (22 ref.)

Platelet-activating factor in the CNS. Maclennan KM, et al. **Prog Neurobiol** 1996 Dec;50(5–6):585–96 (120 ref.)

PHARMACOLOGY

Tyrosine kinase activation by PAF leads to downstream gene expression. Shukla SD. **Adv Exp Med Biol** 1996;416:153–5 (11 ref.)

Stimulation of NF-kappa B activation and gene expression by platelet-activating factor. Ye RD, et al. **Adv Exp Med Biol** 1996;416:143–51 (18 ref.)

Effect of histone-H2A (H-H2A), platelet activating factor (PAF) and pregnancy specific protein B (PSPB) on secretion of prostaglandins E and F2 alpha (PGE; PGF2 alpha) by bovine endometrium and H-H2A on basal secretion of luteinizing hormone (LH) by bovine pituitary cells in vitro. Weems CW, et al. **Chin J Physiol** 1996; 39(3):147–54 (53 ref.)

Cigarettes and the wages of sn-2: oxidized species of PAF in smoking hamsters [editorial; comment] FitzGerald GA. **J Clin Invest** 1997 May 15;99(10):2300–1 (10 ref.) Comment on: J Clin Invest 1997 May 15;99(10):2358–64.

Effects of lipidic mediators on the growth of human myeloid and erythroid marrow progenitors. Dupuis F, et al. **J Lipid Mediat Cell Signal** 1997 Jul;16(3):117–25 (33 ref.)

PAF and the digestive tract. A review. Izzo AA. **J Pharm Pharmacol** 1996 Nov;48(11):1103–11 (118 ref.)

PHYSIOLOGY

The role of platelet-activating factor and its receptor in endometrial receptivity. Ahmed A, et al. **Adv Exp Med Biol** 1996;416:277–90 (84 ref.)

A discovery trip to compounds with PAF-like activity. Demopoulos CA, et al. **Adv Exp Med Biol** 1996;416:59–63 (9 ref.)

Physiological action of PAF in yeast Saccharomyces cerevisiae. Nakayama R, et al. **Adv Exp Med Biol** 1996; 416:45–50 (15 ref.)

Role of platelet-activating factor in parturition. Narahara H, et al. **Adv Exp Med Biol** 1996;416:269–75 (41 ref.)

PAF promotes the development of the preimplantation embryo. O'Neill C. **Adv Exp Med Biol** 1996;416:255–61 (20 ref.)

The role of platelet-activating factor in the biocompatibility of hemodialysis membranes. Tetta C, et al. **Adv Exp Med Biol** 1996;416:243–8 (40 ref.)

Platelet-activating factor (PAF): signalling and adhesion in cell-cell interactions. Zimmerman GA, et al. **Adv Exp Med Biol** 1996;416:297–304 (34 ref.)

Platelet activating factor and conception. Minhas BS, et al. **Am J Reprod Immunol** 1996 Mar;35(3):267–71 (52 ref.)

PAF and asthma--time for an appraisal? Kuitert L, et al. **Clin Exp Allergy** 1995 Dec;25(12):1159–62 (35 ref.)

Platelet-activating factor in the modulation of excitatory amino acid neurotransmitter release and of gene expression. Bazan NG, et al. **J Lipid Mediat Cell Signal** 1996 Sep; 14(1–3):321–30 (49 ref.)

Platelet-activating factor: a case for its role in CNS function and brain injury. Feuerstein GZ. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):109–14 (10 ref.)

Inflammation as an early component of atherosclerosis and vascular damage--a role for P-selectin and platelet-activating factor. Prescott SM, et al. **Jpn Circ J** 1996 Mar;60(3):137–41 (26 ref.)

Bioactive lipids in excitatory neurotransmission and neuronal plasticity. Bazan NG, et al. **Neurochem Int** 1997 Feb; 30(2):225–31 (59 ref.)

Platelet activating factor and its role in trauma, shock, and sepsis. Ayala A, et al. **New Horiz** 1996 May;4(2):265–75 (91 ref.)

The biochemical role of platelet-activating factor in reproduction. Frenkel RA, et al. **Prog Lipid Res** 1996; 35(2):155–68 (101 ref.)

The role of platelet-activating factor and the effect of PAF blocking receptors on the outcome of ARF. López-Novoa JM, et al. **Ren Fail** 1996 May;18(3):489–99 (83 ref.)

Platelet-activating factor (PAF) in experimental and clinical sepsis. Mathiak G, et al. **Shock** 1997 Jun;7(6):391–404 (147 ref.)

[Platelet activating factor--role in regulating the functional activity of the mononuclear phagocyte system] Shebzukhov IuV, et al. **Vopr Med Khim** 1996 Oct–Dec;42(4):278–83 (67 ref.) (Eng. Abstr.) **(Rus)**

PLATELET ACTIVATION

Platelet activation and inhibition in unstable coronary syndromes. Patrono C, et al. **Am J Cardiol** 1997 Sep 4; 80(5A):17E–20E (36 ref.)

Hypothesis: is soluble P-selectin a new marker of platelet activation? Blann AD, et al. **Atherosclerosis** 1997 Feb 10; 128(2):135–8 (33 ref.)

Immunoelectron microscopic changes of the platelet plasma membrane after activation. Cramer E, et al. **Blood Coagul Fibrinolysis** 1996 Mar;7(2):172–7 (21 ref.)

Role of lipoproteins in platelet activation. Zhao B. **Blood Coagul Fibrinolysis** 1996 Mar;7(2):270–3 (12 ref.)

Reactive oxygen species and platelet activation in reperfusion injury [editorial; comment] Forde RC, et al. **Circulation** 1997 Feb 18;95(4):787–9 (26 ref.) Comment on: Circulation 1997 Feb 18;95(4):885–91.

Oxidative stress and platelet activation in diabetes mellitus. Catella-Lawson F, et al. **Diabetes Res Clin Pract** 1996 Feb;

30 Suppl:13–8 (40 ref.)
Oxygen free radicals and platelet activation. Iuliano L, et al. **Free Radic Biol Med** 1997;22(6):999–1006 (76 ref.)
Platelet activation: new aspects. Fox JE. **Haemostasis** 1996 Oct;26 Suppl 4:102–31 (171 ref.)
Association of fibrinogen-bound glycoprotein IIb-IIIa complexes on the activated platelet surface [editorial; comment] [see comments] Nurden AT. **J Lab Clin Med** 1996 Jul;128(1):7–8 (14 ref.) Comment on: J Lab Clin Med 1996 Jul;128(1):39–50. Comment in: J Lab Clin Med 1997 Jun;129(6):653–5.
Platelet-associated factor XIII in platelet activation, adhesion, and clot stabilization. Devine DV, et al. **Semin Thromb Hemost** 1996;22(5):409–13 (42 ref.)
Thrombin interaction with platelet membrane glycoprotein Ib. Jandrot-Perrus M, et al. **Semin Thromb Hemost** 1996; 22(2):151–6 (61 ref.)
Platelet internalization in early thrombogenesis. Leistikow EA. **Semin Thromb Hemost** 1996;22(3):289–94 (44 ref.)
Thrombin receptor antagonists. Seiler SM. **Semin Thromb Hemost** 1996;22(3):223–32 (118 ref.)
Signaling through G proteins in platelets: to the integrins and beyond. Brass LF, et al. **Thromb Haemost** 1997 Jul; 78(1):581–9 (98 ref.)
Markers of platelet activation and oxidant stress in atherothrombotic disease. FitzGerald GA, et al. **Thromb Haemost** 1997 Jul;78(1):280–4 (68 ref.)
Pathophysiology of platelet thrombin receptors. Jamieson GA. **Thromb Haemost** 1997 Jul;78(1):242–6 (49 ref.)
Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Warkentin TE. **Transfus Med Rev** 1996 Oct;10(4):249–58 (41 ref.)
[Adherent reaction among activated platelets, polymorphonuclear cells and vascular endothelial cells under thrombin stimulation or shear stress] Kageoka T, et al. **Rinsho Byori** 1996 Aug;44(8):757–63 (9 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Activation of ADP receptors and platelet function. Gachet C, et al. **Thromb Haemost** 1997 Jul;78(1):271–5 (58 ref.)
[Antithrombocytic effectiveness of magnesium] Gawaz M. **Fortschr Med** 1996 Sep 20;114(26):329–32 (16 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Cyclic phenomena in early myocardial infarction. Gasser R, et al. **Acta Med Austriaca** 1995;22(4):69–72 (22 ref.)
Platelet activation via trimeric GTP-binding proteins. Akkerman JW, et al. **Haemostasis** 1996 Oct;26 Suppl 4:199–209 (35 ref.)
Molecular mechanisms of platelet adhesion and activation. Andrews RK, et al. **Int J Biochem Cell Biol** 1997 Jan; 29(1):91–105 (88 ref.)
Platelet activation and interactions with the microvasculature. Body SC. **J Cardiovasc Pharmacol** 1996; 27 Suppl 1:S13–25 (77 ref.)
Amplification of the inflammatory response: adhesion molecules associated with platelet/white cell responses. Rinder C, et al. **J Cardiovasc Pharmacol** 1996;27 Suppl 1:S6–12 (41 ref.)
Platelet activation during myocardial ischaemia: a contributory arrhythmogenic mechanism. Flores NA. **Pharmacol Ther** 1996;72(2):83–108 (237 ref.)
Immunocytochemical aspects of platelet membrane glycoproteins and adhesive proteins during activation. Suzuki H, et al. **Prog Histochem Cytochem** 1996;30(1):1–106 (495 ref.)
Integrin alpha IIb beta 3 and platelet function. Du X, et al. **Thromb Haemost** 1997 Jul;78(1):96–100 (70 ref.)
Passive smoking, platelet function and atherosclerosis. Kritz H, et al. **Wien Klin Wochenschr** 1996;108(18):582–8 (50 ref.)

PLATELET ADHESIVENESS

see related
PLATELET MEMBRANE GLYCOPROTEINS

Platelet-polymorphonuclear leukocyte functional interactions: role of adhesive molecules. Cerletti C, et al. **Haemostasis** 1996 Oct;26 Suppl 4:20–7 (44 ref.)
[Platelet retention test] Ikeda Y. **Nippon Rinsho** 1997 Mar; 55 Suppl 1:102–3 (1 ref.) **(Jpn)**

PHYSIOLOGY

Molecular mechanisms of platelet adhesion and activation. Andrews RK, et al. **Int J Biochem Cell Biol** 1997 Jan; 29(1):91–105 (88 ref.)
Immunocytochemical aspects of platelet membrane glycoproteins and adhesive proteins during activation. Suzuki H, et al. **Prog Histochem Cytochem** 1996;30(1):1–106 (495 ref.)
Integrin alpha IIb beta 3 and platelet function. Du X, et al. **Thromb Haemost** 1997 Jul;78(1):96–100 (70 ref.)
Mechanisms initiating platelet thrombus formation. Ruggeri ZM. **Thromb Haemost** 1997 Jul;78(1):611–6 (25 ref.)
Platelet adhesion to collagen: an update. Sixma JJ, et al. **Thromb Haemost** 1997 Jul;78(1):434–8 (49 ref.)

PLATELET AGGREGATION

see related
PLATELET MEMBRANE GLYCOPROTEINS

Von Willebrand factor-dependent shear-induced platelet aggregation: basic mechanisms and clinical implications. Ikeda Y, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:325–36 (29 ref.)
Purinoceptors and platelet aggregation. Hourani SM. **J Auton Pharmacol** 1996 Dec;16(6):349–52 (31 ref.)
Effects of haemodialysis on coagulation and platelets: are we measuring membrane biocompatibility? Ward RA. **Nephrol Dial Transplant** 1995;10 Suppl 10:12–17 (46 ref.)
Effects of exercise on blood coagulation, fibrinolysis and platelet aggregation. el-Sayed MS. **Sports Med** 1996 Nov; 22(5):282–98 (121 ref.)
[Selenium, glutathione peroxidase, peroxides and platelet functions] Vitoux D, et al. **Ann Biol Clin (Paris)** 1996; 54(5):181–7 (35 ref.) (Eng. Abstr.) **(Fre)**
[Platelet retention test] Ikeda Y. **Nippon Rinsho** 1997 Mar; 55 Suppl 1:102–3 (1 ref.) **(Jpn)**
[Platelet aggregation test] Ikeda Y. **Nippon Rinsho** 1997 Mar; 55 Suppl 1:104–8 (3 ref.) **(Jpn)**

DRUG EFFECTS

Remnant-like particles stimulate platelet aggregation in whole blood. Nakano T, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:480–7 (19 ref.)
Nutritional supplements and surgical patients. Petry JJ. **AORN J** 1997 Jun;65(6):1117–21 (20 ref.)
SJAMP-induced platelet aggregation defect. Shen D. **Chin Med J (Engl)** 1996 Jan;109(1):46–8 (10 ref.)
Polyunsaturated fatty acids and platelet aggregation. Mutanen M, et al. **Curr Opin Lipidol** 1996 Feb;7(1):14–9 (44 ref.)
The anti-GPIIb-IIIa agents: fundamental and clinical aspects. Coller BS, et al. **Haemostasis** 1996 Oct;26 Suppl 4:285–93 (36 ref.)
Inhibition of platelet aggregation as a surrogate marker. Narjes H, et al. **J Clin Pharmacol** 1997 Jan;37(1 Suppl):59S–64S (12 ref.)
[Antithrombocytic effectiveness of magnesium] Gawaz M. **Fortschr Med** 1996 Sep 20;114(26):329–32 (16 ref.) (Eng. Abstr.) **(Ger)**
[Analysis of manganese-induced platelet aggregation] Yabusaki K. **Rinsho Byori** 1997 Feb;Suppl 104:89–98 (21 ref.) **(Jpn)**
[Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple angonists] Miyakawa Y, et al. **Rinsho Ketsueki** 1996 Sep;37(9):785–9 (7 ref.) **(Jpn)**

PHYSIOLOGY

[Isoprostanes, a new substance group in angiology—of future significance?] Aghajanian AA, et al. **Vasa** 1997 May; 26(2):65–9 (24 ref.) (Eng. Abstr.) **(Ger)**

PLATELET AGGREGATION INHIBITORS

Thrombin receptor: a novel target for antiplatelet drug development. Ray A, et al. **Thromb Res** 1997 Jul 1; 87(1):37–50 (55 ref.)

ADMINISTRATION & DOSAGE

Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Kleiman NS. **Am J Cardiol** 1997 Aug 18; 80(4A):29B–33B (17 ref.)
Ticlopidine and aspirin therapy following implantation of coronary artery stents. Hobson AG, et al. **Ann Pharmacother** 1997 Jun;31(6):770–2 (16 ref.)
Treating the non-electrical risks of atrial fibrillation. Gershlick AH. **Eur Heart J** 1997 May;18 Suppl C:C19–26 (39 ref.)
How to prevent stroke recurrence in patients with patent foramen ovale: anticoagulants, antiaggregants, foramen closure, or nothing? [see comments] Nendaz M, et al. **Eur Neurol** 1997;37(4):199–204 (45 ref.) Comment in: Eur Neurol 1997 ;37(4):205–6.
Investigation in the use of topical solutions for management or prevention of thrombosis in traumatized vessels. Cooley BC, et al. **Int Angiol** 1995 Sep;14(3):297–302 (87 ref.)
[Anticoagulation after vascular surgery interventions] Breuer P, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996; 113:870–4 (13 ref.) (Eng. Abstr.) **(Ger)**
[Antiplatelet drugs as a preventive measure of stroke—treatment strategies by subtypes of ischemic stroke] Yamaguchi T. **Rinsho Ketsueki** 1996 Sep;37(9):808–12 (14 ref.) **(Jpn)**

ADVERSE EFFECTS

Bone and tissue changes following prostaglandin therapy in neonates. Kaufman MB, et al. **Ann Pharmacother** 1996 Mar; 30(3):269–74, 277 (29 ref.)
Cardiac tamponade following stent implantation with adjuvant platelet IIb/IIIa receptor inhibitor administration. Bottner RK, et al. **Cathet Cardiovasc Diagn** 1997 Apr; 40(4):380–2 (4 ref.)
Which prophylactic aspirin? **Drug Ther Bull** 1997 Jan; 35(1):7–8 (19 ref.)
Gastric toxicity of antiplatelet therapy with low-dose aspirin. Guslandi M. **Drugs** 1997 Jan;53(1):1–5 (40 ref.)
Pharmacological prophylaxis of bleeding in surgical patients treated with aspirin. Flordal PA. **Eur J Anaesthesiol Suppl** 1997 Mar;14:38–41 (29 ref.)
Precipitous fall in platelet count with anagrelide: case report and critique of dosing recommendations. McCune JS, et al. **Pharmacotherapy** 1997 Jul-Aug;17(4):822–6 (9 ref.)
Ticlopidine induced cholestatic jaundice. Yim HB, et al. **Singapore Med J** 1997 Mar;38(3):132–3 (7 ref.)
Oral anticoagulation alone or in combination with aspirin: risks and benefits. Hafner J, et al. **Vasa** 1996;25(1):1–12 (75 ref.)
[Acetylsalicylic acid and gastrointestinal hemorrhages: preferably a lower dosage] Tytgat GN, et al. **Ned Tijdschr Geneeskd** 1996 Nov 9;140(45):2219–23 (32 ref.) **(Dut)**
[Biological monitoring and prevention of complications from antithrombotic agents] Samama MM, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1569–77 (28 ref.) (Eng. Abstr.) **(Fre)**
[Bone marrow aplasia related to ticlopidine] de Jaureguiberry JP, et al. **Rev Med Interne** 1996;17(12):1032–6 (30 ref.) (Eng. Abstr.) **(Fre)**
[Pulmonary hemorrhage after thrombolysis in acute myocardial infarct (letter) (corrected and republished letter originally printed in An Med Interna 1996 Oct;13(10):514–5)] Rodriguez Blanco VM, et al. **An Med Interna** 1997 Apr;14(4):209 (7 ref.) **(Spa)**

CLASSIFICATION

[Inhibitors of platelet receptors GP IIB/IIIA: a new therapeutic class and its promise in the treatment of acute coronary syndromes] Yerna M, et al. **Rev Med Liege** 1997 May;52(5):329–35 (26 ref.) **(Fre)**

ECONOMICS

Potential economic impact of glycoprotein IIb-IIIa inhibitors in improving outcomes of patients with acute ischemic coronary syndromes. McElwee NE, et al. **Am J Cardiol** 1997 Aug 18;80(4A):39B–43B (16 ref.)

METABOLISM

Endothelial prostaglandin and nitric oxide synthesis in atherogenesis and thrombosis. Wu KK. **J Formos Med Assoc** 1996 Sep;95(9):661–6 (41 ref.)

PHARMACOLOGY

Clinical pharmacology of eptifibatide. Phillips DR, et al. **Am J Cardiol** 1997 Aug 18;80(4A):11B–20B (70 ref.)
Anti-platelet drugs: do they affect megakaryocytes? Cazenave JP, et al. **Baillieres Clin Haematol** 1997 Feb; 10(1):163–80 (93 ref.)
New thoughts on strategies for modulating platelet function through the inhibition of surface receptors. Nurden AT. **Haemostasis** 1996 Oct;26 Suppl 4:78–88 (36 ref.)
Leu271-Glu292 in kininogens blocks thrombin-induced aggregation. Colman RW, et al. **Immunopharmacology** 1996 May;32(1-3):80–1 (3 ref.)
Inhibition of platelet aggregation as a surrogate marker. Narjes H, et al. **J Clin Pharmacol** 1997 Jan;37(1 Suppl):59S–64S (12 ref.)
[Antiplatelet properties of nitrogen monoxide] Adrie C. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1527–32 (55 ref.) (Eng. Abstr.) **(Fre)**
[Glycoprotein IIb/IIIa receptor inhibitors] Bornkessel B. **Med Monatsschr Pharm** 1996 Dec;19(12):356–8 (3 ref.) **(Ger)**

THERAPEUTIC USE

Restenosis: is there a pharmacologic fix in the pipeline? Keiser JA, et al. **Adv Pharmacol** 1997;39:313–51 (250 ref.)
Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. Harrington RA. **Am J Cardiol** 1997 Aug 18; 80(4A):34B–38B (27 ref.)
Reactivation of the coagulation system: rationale for long-term antithrombotic treatment. Kontny F. **Am J Cardiol** 1997 Sep 4;80(5A):55E–60E (63 ref.)
Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Tcheng JE. **Am J Cardiol** 1997 Aug 18;80(4A):21B–28B (15 ref.)
Use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Parmar R, et al. **Am J Med Sci** 1997 Jul; 314(1):31–6 (22 ref.)
ABCIXIMAB: a new antiaggregant used in angioplasty. Genetta TB, et al. **Ann Pharmacother** 1996 Mar;30(3):251–7 (28 ref.)
Aspirin in the treatment and prevention of cardiovascular disease. Hennekens CH. **Annu Rev Public Health** 1997; 18:37–49 (30 ref.)
Tufted angioma associated with platelet trapping syndrome: response to aspirin. Léauté-Labrèze C, et al. **Arch Dermatol** 1997 Sep;133(9):1077–9 (12 ref.)
Heparin as an adjuvant to thrombolytic therapy in acute

myocardial infarction. Metz BK, et al. **Biomed Pharmacother** 1996;50(6-7):243-53 (33 ref.)

Who needs antiplatelet therapy? [see comments] Moher M, et al. **Br J Gen Pract** 1996 Jun;46(407):367-70 (24 ref.) Comment in: Br J Gen Pract 1996 Aug;46(409):494-5.

The case of low-dose aspirin for the prevention of myocardial infarction: but how low is low? Förster W, et al. **Cardiovasc Drugs Ther** 1997 Jan;10(6):727-34 (51 ref.)

Stent thrombosis. Closing in on the best preventive treatment [editorial; comment] Baim DS, et al. **Circulation** 1997 Mar 4;95(5):1098-100 (14 ref.) Comment on: Circulation 1997 Mar 4;95(5):1145-56.

Antiplatelet and antithrombin therapies in the acute coronary syndromes. Alexander JH, et al. **Curr Opin Cardiol** 1997 Jul;12(4):427-37 (44 ref.)

Anticoagulant and antiplatelet therapy in heart failure. Cleland JG. **Curr Opin Cardiol** 1997 May;12(3):276-87 (79 ref.)

Inhibitors of the platelet GP IIb-IIIa function in the treatment of acute coronary syndromes. Kugelmass AD. **Curr Opin Hematol** 1997 Sep;4(5):301-5 (16 ref.)

Diabetes mellitus and peripheral vascular disease: is aspirin effective in preventing vascular events? [see comments] Cimminiello C, et al. **Diabetologia** 1996 Nov;39(11):1402-4 (26 ref.) Comment in: Diabetologia 1996 Nov;39(11):1405-6. Comment in: Diabetologia 1996 Nov;39(11):1407-8.

Recognition and treatment of unstable angina. Brunelli C, et al. **Drugs** 1996 Aug;52(2):196-208 (80 ref.)

Prevention and management of thrombotic complications during coronary interventions. Combination therapy with antithrombins, antiplatelets, and/or thrombolytics: risks and benefits. Neuhaus KL, et al. **Eur Heart J** 1995 Nov;16 Suppl L:63-7 (41 ref.)

New developments in antiplatelet and antithrombotic therapy. Verstraete M. **Eur Heart J** 1995 Nov;16 Suppl L:16-23 (76 ref.)

Ticlopidine or clopidogrel as alternatives to aspirin in prevention of ischemic stroke. Bendixen BH, et al. **Eur Neurol** 1996;36(5):256-7 (11 ref.)

The role of dipyridamole in stroke prevention. Sivenius J, et al. **Eur Neurol** 1996;36(5):253-6 (20 ref.)

The anti-GPIIb-IIIa agents: fundamental and clinical aspects. Coller BS, et al. **Haemostasis** 1996 Oct;26 Suppl 4:285-93 (36 ref.)

IIb/IIIa platelet inhibitors in the management of coronary artery disease. Talley JD. **J Ark Med Soc** 1996 Oct; 93(5):237-9 (8 ref.)

Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives. Landolfi R, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:83-6 (22 ref.)

Fifty years of experience with antithrombotic therapy in cardiac disease. A 1996 approach based on pathogenesis and risk. Freudenrerger RS, et al. **Mt Sinai J Med** 1996 Oct-Nov;63(5-6):342-58 (69 ref.)

Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. Collins R, et al. **N Engl J Med** 1997 Mar 20;336(12):847-60 (97 ref.)

Brain attack. Acute therapeutic intervention. Antithrombotic and antiplatelet-aggregating drugs. Adams Jr HP, et al. **Neurosurg Clin N Am** 1997 Apr;8(2):207-17 (95 ref.)

Aspirin and heart disease. **Nurse Pract** 1996 Nov;21(11):111-2 (14 ref.)

Clinical trials update [news] Kayser SR. **Prog Cardiovasc Nurs** 1997 Spring;12(2):30-3, 44 (10 ref.)

The role of platelet-activating factor antagonists in the prophylaxis of posttransplant acute tubular necrosis. Grinyó JM, et al. **Ren Fail** 1996 May;18(3):445-51 (45 ref.)

The role of platelet-activating factor and the effect of PAF blocking receptors on the outcome of ARF. López-Novoa JM, et al. **Ren Fail** 1996 May;18(3):489-99 (83 ref.)

Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents. Schafer AI. **Tex Heart Inst J** 1997;24(2):90-6 (9 ref.)

[Antiplatelet therapy during coronary endoprosthesis placement] Barragan P, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1515-20 (42 ref.) (Eng. Abstr.) **(Fre)**

[Antithrombotic therapy of atrial fibrillation] Chalon S, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1533-42 (47 ref.) (Eng. Abstr.) **(Fre)**

[Antiplatelet agents (inhibitors of platelet function) orally administered. Bases for their practical use in coronary artery disease] Lecompte T, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1507-13 (26 ref.) (Eng. Abstr.) **(Fre)**

[Antithrombotic therapy in patients with mechanical valve prostheses] Roudaut R, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1543-50 (30 ref.) (Eng. Abstr.) **(Fre)**

[Modern "antiplatelet agents" in unstable angina] Vahanian A, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1521-6 (27 ref.) (Eng. Abstr.) **(Fre)**

[Use of antithrombotic agents in peripheral arterial diseases] Wütschert R, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1551-5 (23 ref.) (Eng. Abstr.) **(Fre)**

[Anticoagulants and platelet aggregation inhibitors in urology] Verdy E. **Prog Urol** 1997 Apr;7(2):326-32 (4 ref.) (Eng. Abstr.) **(Fre)**

[Inhibitors of platelet receptors GP IIB/IIIA: a new therapeutic class and its promise in the treatment of acute coronary syndromes] Yerna M, et al. **Rev Med Liege** 1997 May;52(5):329-35 (26 ref.) **(Fre)**

[Antithrombocytic effectiveness of magnesium] Gawaz M. **Fortschr Med** 1996 Sep 20;114(26):329-32 (16 ref.) (Eng. Abstr.) **(Ger)**

[New antithrombotic drugs. What developments can be expected?] Greinacher A. **Internist (Berl)** 1997 Jul; 38(7):680-7 (41 ref.) **(Ger)**

[Current approach in antithrombotic treatment during coronary interventions: specific thrombocyte aggregation inhibitors and direct thrombin antagonists in high-risk patients] Meyer BJ. **Schweiz Med Wochenschr** 1996 Nov 16;126(46):1961-9 (43 ref.) (Eng. Abstr.) **(Ger)**

[Anti-thrombosis therapy following coronary stent implantation] Schuiki E, et al. **Schweiz Rundsch Med Prax** 1996 Oct 15;85(42):1316-9 (28 ref.) (Eng. Abstr.) **(Ger)**

[Restenosis after percutaneous transluminal angioplasty: II. Possibilities for pharmacologic intervention] Böger RH, et al. **Vasa** 1996;25(1):21-31 (105 ref.) (Eng. Abstr.) **(Ger)**

[Clinical studies of the effectiveness of aspirin in the prevention of major cardio-cerebrovascular occurrences] Mariani M, et al. **Cardiologia** 1995 Dec;40(12 Suppl 1):423-8 (43 ref.) **(Ita)**

[Anticoagulant or antiaggregant therapy in the secondary prevention of myocardial infarct?] De Caterina R, et al. **G Ital Cardiol** 1996 Nov;26(11):1309-21 (42 ref.) (Eng. Abstr.) **(Ita)**

[Medical treatment of arteriosclerosis obliterans (ASO)] Matsuo H. **Nippon Geka Gakkai Zasshi** 1996 Jul;97(7):520-5 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Aggregation inhibitors for treatment of the acute phase of cerebral ischemia] Szczepańska-Szerej A. **Ann Univ Mariae Curie Sklodowska [Med]** 1995;50:131-6 (13 ref.) (Eng. Abstr.) **(Pol)**

[The use of acetylsalicylic acid in IHD] Lenkovsky F, et al. **Ter Arkh** 1996;68(8):79-83 (66 ref.) **(Rus)**

[Antithrombotic treatment in acute ischemia stroke] Díez-Tejedor E, et al. **Neurologia** 1995 Dec;10 Suppl 2:48-54 (42 ref.) (Eng. Abstr.) **(Spa)**

[Treatment protocol of cerebral vascular accident] Biller J. **Rev Neurol** 1997 Jan;25(137):114 (10 ref.) **(Spa)**

PLATELET ALLOANTIGENS see **ANTIGENS, HUMAN PLATELET**

PLATELET ALPHA-GRANULE MEMBRANE PROTEIN see **P-SELECTIN**

PLATELET ANTAGONISTS see **PLATELET AGGREGATION INHIBITORS**

PLATELET ANTIAGGREGEANTS see **PLATELET AGGREGATION INHIBITORS**

PLATELET COUNT

[Pseudothrombocytopenia: case reports and review of the literature] Huss B, et al. **Infusionsther Transfusionsmed** 1995 Oct;22(5):303-9 (66 ref.) (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Influence of antibiotics on posttransfusion platelet increment. Böck M, et al. **Transfusion** 1996 Nov-Dec;36(11-12):952-4 (12 ref.)

[Predictive value of the hemogram for myelotoxicity induced by the association of carboplatin-fluorouracil on the 4th day of the therapeutic regimen] Cappelaere P, et al. **Bull Cancer** 1996 Jul;83(7):559-65 (36 ref.) (Eng. Abstr.) **(Fre)**

PLATELET-DERIVED GROWTH FACTOR

see related
RECEPTORS, PLATELET-DERIVED GROWTH FACTOR

GENETICS

Signals controlling the expression of PDGF. Dirks RP, et al. **Mol Biol Rep** 1995-96;22(1):1-24 (374 ref.)

[Role of TGF-beta and PDGF on the pathogenesis of pulmonary fibrosis--analysis by in vivo gene transfer] Yoshida M, et al. **Nippon Rinsho** 1996 Feb;54(2):418-22 (13 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Retinal development: communication helps you see the light. Wechsler-Reya RJ, et al. **Curr Biol** 1997 Jul 1;7(7):R433-6 (16 ref.)

Simultaneous induction of stimulatory and inhibitory signals by PDGF. Heldin CH. **FEBS Lett** 1997 Jun 23;410(1):17-21 (47 ref.)

Distribution and functions of platelet-derived growth factors and their receptors during embryogenesis. Ataliotis P, et al. **Int Rev Cytol** 1997;172:95-127 (155 ref.)

PHARMACOLOGY

Signal transduction for PDGF-induced chemotaxis of vascular smooth muscle cells. Shimokado K, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:130-3 (14 ref.)

Mechanism of action of platelet-derived growth factor. Claesson-Welsh L. **Int J Biochem Cell Biol** 1996 Apr; 28(4):373-85 (78 ref.)

PHYSIOLOGY

Roles of platelet-derived growth factor in the developing and mature nervous systems. Valenzuela CF, et al. **Brain Res Brain Res Rev** 1997 Jun;24(1):77-89 (116 ref.)

Occupational lung disease and the role of peptide growth factors. Brody AR. **Curr Opin Pulm Med** 1997 May; 3(3):203-8 (37 ref.)

Platelet-derived growth factor (PDGF): actions and mechanisms in vascular smooth muscle. Hughes AD, et al. **Gen Pharmacol** 1996 Oct;27(7):1079-89 (190 ref.)

Platelets and inflammation: role of platelet-derived growth factor, adhesion molecules and histamine. Mannaioni PF, et al. **Inflamm Res** 1997 Jan;46(1):4-18 (119 ref.)

Platelet-derived growth factor: a key regulator of connective tissue cells in embryogenesis and pathogenesis. Betsholtz C, et al. **Kidney Int** 1997 May;51(5):1361-9 (44 ref.)

[Role of TGF-beta and PDGF on the pathogenesis of pulmonary fibrosis--analysis by in vivo gene transfer] Yoshida M, et al. **Nippon Rinsho** 1996 Feb;54(2):418-22 (13 ref.) (Eng. Abstr.) **(Jpn)**

PLATELET-DERIVED GROWTH FACTOR RECEPTORS see **RECEPTORS, PLATELET-DERIVED GROWTH FACTOR**

PLATELET ENDOTHELIAL CELL ADHESION MOLECULE-1 see **ANTIGENS, CD31**

PLATELET FACTOR 4

IMMUNOLOGY

[Platelet factor 4, target of anti-heparin antibodies: application to biological diagnosis of heparin-induced thrombopenia] Amiral J. **Ann Med Interne (Paris)** 1997; 148(2):142-9 (32 ref.) (Eng. Abstr.) **(Fre)**

PLATELET FUNCTION TESTS

[Evaluation and problems on platelet function tests] Kume S. **Nippon Rinsho** 1997 Mar;55 Suppl 1:94-101 (30 ref.) **(Jpn)**

METHODS

Design criteria: tests used to assess platelet function. Schoene NW. **Am J Clin Nutr** 1997 May;65(5 Suppl):1665S-1668S (47 ref.)

[Hemostasis and tests used to investigate it] Verdy E. **Prog Urol** 1997 Apr;7(2):320-5 (3 ref.) (Eng. Abstr.) **(Fre)**

[Platelet retention test] Ikeda Y. **Nippon Rinsho** 1997 Mar; 55 Suppl 1:102-3 (1 ref.) **(Jpn)**

[Platelet aggregation test] Ikeda Y. **Nippon Rinsho** 1997 Mar; 55 Suppl 1:104-8 (3 ref.) **(Jpn)**

[Release of intracellular granule contents in platelets] Ozaki Y. **Nippon Rinsho** 1997 Mar;55 Suppl 1:109-12 (5 ref.) **(Jpn)**

[The measurement of platelet life span] Yatomi Y, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:113-6 (5 ref.) **(Jpn)**

PLATELET GLYCOPROTEIN GPIB-IX COMPLEX

[Cell adhesion molecules on platelet] Ono M, et al. **Rinsho Byori** 1996 Dec;44(12):1132-7 (28 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Structure and function of the glycoprotein Ib-IX-V complex. López JA, et al. **Curr Opin Hematol** 1997 Sep;4(5):323-9 (67 ref.)

DRUG EFFECTS

Snake venom proteins modulating the interaction between von Willebrand factor and platelet glycoprotein Ib. Fujimura Y, et al. **Thromb Haemost** 1996 Nov;76(5):633-9 (62 ref.)

GENETICS

Molecular defects in the Bernard-Soulier syndrome: assessment of receptor genes, transcripts and proteins. Roth GJ. **C R Acad Sci III** 1996 Sep;319(9):819-26 (61 ref.)

Recurrent mutation Asn45-->Ser of glycoprotein IX in Bernard-Soulier syndrome [letter] Donnér M, et al. **Eur J Haematol** 1996 Aug;57(2):178-9 (8 ref.)

METABOLISM

Structure and function of the glycoprotein Ib-IX-V complex. López JA, et al. **Curr Opin Hematol** 1997 Sep;4(5):323-9 (67 ref.)

Thrombin interaction with platelet membrane glycoprotein Ib. Jandrot-Perrus M, et al. **Semin Thromb Hemost** 1996; 22(2):151-6 (61 ref.)

PHYSIOLOGY

Platelet GPIb-V-IX complex. Clemetson KJ. **Thromb Haemost** 1997 Jul;78(1):266-70 (37 ref.)

Pathophysiology of platelet thrombin receptors. Jamieson GA. **Thromb Haemost** 1997 Jul;78(1):242–6 (49 ref.)
[Platelet adhesion receptors and thrombus formation] Tomiyama Y. **Rinsho Byori** 1996 Sep;Suppl 102:153–63 (19 ref.) **(Jpn)**

PLATELET GLYCOPROTEIN GPIIB–IIIA COMPLEX

[Cell adhesion molecules on platelet] Ono M, et al. **Rinsho Byori** 1996 Dec;44(12):1132–7 (28 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

Blood platelet fibrinogen receptors in migraine and related headaches. Kozubski W, et al. **Neurol Neurochir Pol** 1996; 30 Suppl 2:25–33 (40 ref.)
[Analytical procedure of the adhesion molecules: especially for the platelet] Honda S, et al. **Rinsho Byori** 1996 Sep; Suppl 102:97–106 (14 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Kleiman NS. **Am J Cardiol** 1997 Aug 18; 80(4A):29B–33B (17 ref.)
Use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Parmar R, et al. **Am J Med Sci** 1997 Jul; 314(1):31–6 (22 ref.)
Inhibitors of the platelet GP IIb–IIIa function in the treatment of acute coronary syndromes. Kugelmass AD. **Curr Opin Hematol** 1997 Sep;4(5):301–5 (16 ref.)
Bleeding risks, risk factors and management of bleeding complications after treatment with anticoagulants, specific antithrombins, thrombolytics IIb–IIIa receptor blockers. Armstrong PW, et al. **Eur Heart J** 1995 Nov;16 Suppl L:75–80 (28 ref.)
The role of platelets in arterial thrombosis and the rationale for blockade of platelet GPIIb/IIIa receptors as antithrombotic therapy. Coller BS. **Eur Heart J** 1995 Nov; 16 Suppl L:11–5 (29 ref.)
Clinical management of unstable angina: the place of antithrombins and platelet GP IIb/IIIa receptor blockers. Knudtson ML. **Eur Heart J** 1995 Nov;16 Suppl L:68–74 (105 ref.)
Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor. Ohman EM, et al. **Eur Heart J** 1995 Nov;16 Suppl L:50–5 (35 ref.)
The anti-GPIIb–IIIa agents: fundamental and clinical aspects. Coller BS, et al. **Haemostasis** 1996 Oct;26 Suppl 4:285–93 (36 ref.)
New thoughts on strategies for modulating platelet function through the inhibition of surface receptors. Nurden AT. **Haemostasis** 1996 Oct;26 Suppl 4:78–88 (36 ref.)
IIb/IIIa platelet inhibitors in the management of coronary artery disease. Talley JD. **J Ark Med Soc** 1996 Oct; 93(5):237–9 (8 ref.)
Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. Coller BS. **J Clin Invest** 1997 Apr 1;99(7):1467–71 (34 ref.)
Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents. Schafer AI. **Tex Heart Inst J** 1997;24(2):90–6 (9 ref.)
GPIIb/IIIa antagonists: pathophysiologic and therapeutic insights from studies of c7E3 Fab. Coller BS. **Thromb Haemost** 1997 Jul;78(1):730–5 (42 ref.)
Conjunctive use of platelet glycoprotein IIb/IIIa antagonists and thrombolytic therapy for acute myocardial infarction. Moliterno DJ, et al. **Thromb Haemost** 1997 Jul;78(1):214–9 (41 ref.)
Platelet glycoprotein IIb/IIIa integrin blockade: recent clinical trials in interventional cardiology. Tcheng JE. **Thromb Haemost** 1997 Jul;78(1):205–9 (27 ref.)
Clinical trials with glycoprotein IIb/IIIa receptor antagonists in acute coronary syndromes. Van de Werf F. **Thromb Haemost** 1997 Jul;78(1):210–3 (22 ref.)
[Modern "antiplatelet agents" in unstable angina] Vahanian A, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1521–6 (27 ref.) (Eng. Abstr.) **(Fre)**
[Inhibitors of platelet receptors GP IIB/IIIA: a new therapeutic class and its promise in the treatment of acute coronary syndromes] Yerna M, et al. **Rev Med Liege** 1997 May;52(5):329–35 (26 ref.) **(Fre)**
[Glycoprotein IIb/IIIa receptor inhibitors] Bornkessel B. **Med Monatsschr Pharm** 1996 Dec;19(12):356–8 (3 ref.) **(Ger)**

CHEMISTRY

Structure and function of platelet alpha IIb beta 3. Naik UP, et al. **Curr Opin Hematol** 1997 Sep;4(5):317–22 (48 ref.)
[Structure and function of platelet alpha IIb beta 3 integrin] Suzuki H. **Rinsho Byori** 1997 Feb;Suppl 104:60–72 (31 ref.) **(Jpn)**

DRUG EFFECTS

[Analysis of manganese-induced platelet aggregation] Yabusaki K. **Rinsho Byori** 1997 Feb;Suppl 104:89–98 (21 ref.) **(Jpn)**

GENETICS

[Structure and function of CD 36] Tomiyama Y, et al. **Rinsho Byori** 1997 Feb;Suppl 104:73–9 (16 ref.) **(Jpn)**

METABOLISM

Association of fibrinogen-bound glycoprotein IIb–IIIa complexes on the activated platelet surface [editorial; comment] [see comments] Nurden AT. **J Lab Clin Med** 1996 Jul;128(1):7–8 (14 ref.) Comment on: J Lab Clin Med 1996 Jul;128(1):39–50. Comment in: J Lab Clin Med 1997 Jun;129(6):653–5.

PHYSIOLOGY

The biologic and clinical spectrum of Glanzmann's thrombasthenia: implications of integrin alpha IIb beta 3 for its pathogenesis. Kato A. **Crit Rev Oncol Hematol** 1997 May;26(1):1–23 (210 ref.)
Integrin alpha IIb beta 3 and platelet function. Du X, et al. **Thromb Haemost** 1997 Jul;78(1):96–100 (70 ref.)
Not just another pretty face: regulation of platelet function at the cytoplasmic face of integrin alpha IIb beta 3. Shattil SJ, et al. **Thromb Haemost** 1997 Jul;78(1):220–5 (61 ref.)
[RGD-dependent and -independent binding domains of fibronectin to GPIIb/IIIa] Mohri H. **Rinsho Byori** 1997 Feb;Suppl 104:80–8 (35 ref.) **(Jpn)**
[Structure and function of platelet alpha IIb beta 3 integrin] Suzuki H. **Rinsho Byori** 1997 Feb;Suppl 104:60–72 (31 ref.) **(Jpn)**
[Structure and function of CD 36] Tomiyama Y, et al. **Rinsho Byori** 1997 Feb;Suppl 104:73–9 (16 ref.) **(Jpn)**
[Platelet adhesion receptors and thrombus formation] Tomiyama Y. **Rinsho Byori** 1996 Sep;Suppl 102:153–63 (19 ref.) **(Jpn)**

PLATELET GLYCOPROTEIN IV see **ANTIGENS, CD36**

PLATELET MEMBRANE GLYCOPROTEIN IB see **PLATELET GLYCOPROTEIN GPIB–IX COMPLEX**

PLATELET MEMBRANE GLYCOPROTEIN IIB see **PLATELET GLYCOPROTEIN GPIIB–IIIA COMPLEX**

PLATELET MEMBRANE GLYCOPROTEIN IIIA see **PLATELET GLYCOPROTEIN GPIIB–IIIA COMPLEX**

PLATELET MEMBRANE GLYCOPROTEIN IIIB see **ANTIGENS, CD36**

PLATELET MEMBRANE GLYCOPROTEIN V see **PLATELET GLYCOPROTEIN GPIB–IX COMPLEX**

PLATELET MEMBRANE GLYCOPROTEIN IX see **PLATELET GLYCOPROTEIN GPIB–IX COMPLEX**

PLATELET MEMBRANE GLYCOPROTEINS

ANTAGONISTS & INHIBITORS

Platelet-activating factor and cardiac diseases: therapeutic potential for PAF inhibitors. Feuerstein G, et al. **J Lipid Mediat Cell Signal** 1997 Mar;15(3):255–84 (193 ref.)

BIOSYNTHESIS

Platelet-activating factor receptor. Gene structure and tissue-specific regulation. Shimizu T, et al. **Adv Exp Med Biol** 1996;416:79–84 (25 ref.)

GENETICS

Platelet-activating factor receptor. Gene structure and tissue-specific regulation. Shimizu T, et al. **Adv Exp Med Biol** 1996;416:79–84 (25 ref.)
Biochemical and molecular basis of Bernard-Soulier syndrome: a review. de la Salle C, et al. **Nouv Rev Fr Hematol** 1995;37(4):215–22 (58 ref.)

METABOLISM

Platelet receptors for collagen. Moroi M, et al. **Thromb Haemost** 1997 Jul;78(1):439–44 (48 ref.)

PHYSIOLOGY

The role of platelet-activating factor and its receptor in endometrial receptivity. Ahmed A, et al. **Adv Exp Med Biol** 1996;416:277–90 (84 ref.)
PAf receptor anchors Streptococcus pneumoniae to activated human endothelial cells. Cundell DR, et al. **Adv Exp Med Biol** 1996;416:89–94 (15 ref.)
Functional role of platelet-activating factor receptor in secretory response in adrenal chromaffin cells. Dohi T, et al. **Adv Exp Med Biol** 1996;416:101–5 (28 ref.)
Immunocytochemical aspects of platelet membrane glycoproteins and adhesive proteins during activation. Suzuki H, et al. **Prog Histochem Cytochem** 1996;30(1):1–106 (495 ref.)

PLATELET NUMBER see **PLATELET COUNT**

PLATELET-SPECIFIC ANTIGENS see **ANTIGENS, HUMAN PLATELET**

PLATELET TRANSFORMING GROWTH FACTOR see **TRANSFORMING GROWTH FACTOR BETA**

PLATELET TRANSFUSION

Platelet transfusion therapy. AuBuchon JP. **Clin Lab Med** 1996 Dec;16(4):797–816 (107 ref.)
Red cells and platelets. Modifications for special patients. Lehman CM, et al. **Clin Lab Med** 1996 Dec;16(4):781–95 (75 ref.)
Clinical and laboratory factors underlying refractoriness to platelet transfusions. Friedberg RC. **J Clin Apheresis** 1996; 11(3):143–8 (23 ref.)
Algorithm for managing the platelet refractory patient. Slichter SJ. **J Clin Apheresis** 1997;12(1):4–9 (40 ref.)
Transfusion support in acute leukemias. Webb IJ, et al. **Semin Oncol** 1997 Feb;24(1):141–6 (72 ref.)
Influence of antibiotics on posttransfusion platelet increment. Böck M, et al. **Transfusion** 1996 Nov–Dec;36(11–12):952–4 (12 ref.)
[Reality and clinical application of platelet transfusion] Shinada S. **Nippon Naika Gakkai Zasshi** 1996 Jun 10; 85(6):806–10 (4 ref.) **(Jpn)**

ADVERSE EFFECTS

Alloimmunization and platelet transfusion. McFarland JG. **Semin Hematol** 1996 Oct;33(4):315–28 (132 ref.)
Hypotensive reactions: a previously uncharacterized complication of platelet transfusion? [see comments] Hume HA, et al. **Transfusion** 1996 Oct;36(10):904–9 (26 ref.) Comment in: Transfusion 1996 Oct;36(10):852–3.

PLATELETS see **BLOOD PLATELETS**

PLATINUM

see related
ORGANOPLATINUM COMPOUNDS

[Forum: Clips and coils in aneurysm treatment] Spetzger U, et al. **Wien Med Wochenschr** 1997;147(7–8):172–7 (62 ref.) (Eng. Abstr.) **(Ger)**

ANALYSIS

Analytical methods for the determination of platinum in biological and environmental materials. A review. Balcerzak M. **Analyst** 1997 May;122(5):67R–74R (81 ref.)

PLATINUM BLACK see **PLATINUM**

PLATINUM COMPOUNDS

ADMINISTRATION & DOSAGE

High-dose chemotherapy with autologous stem cell support for the treatment of advanced ovarian cancer—initial experience in Uppsala and Turku. Grenman S, et al. **Acta Obstet Gynecol Scand** 1997 Apr;76(4):363–8 (31 ref.)

CHEMISTRY

Structural studies of interactions between anticancer platinum drugs and DNA. Yang D, et al. **Prog Biophys Mol Biol** 1996;66(1):81–111 (65 ref.)

THERAPEUTIC USE

Platinum-based cytotoxic therapy in basal cell carcinoma—a review of the literature. Moeholt K, et al. **Acta Oncol** 1996; 35(6):677–82 (33 ref.)

PLATINUM COMPOUNDS, INORGANIC see **PLATINUM COMPOUNDS**

PLATINUM DIAMMINODICHLORIDE see **CISPLATIN**

PLATYBASIA

see related
ARNOLD-CHIARI DEFORMITY

PLATYFISH see **CYPRINODONTIFORMES**

PLATYHELMINTHS

ANATOMY & HISTOLOGY

Origin of the epidermis in parasitic platyhelminths. Tyler S, et al. **Int J Parasitol** 1997 Jun;27(6):715–38 (78 ref.)

GROWTH & DEVELOPMENT

Neuronal signal substances in asexual multiplication and development in flatworms. Reuter M, et al. **Cell Mol Neurobiol** 1996 Oct;16(5):591–616 (75 ref.)

PHYSIOLOGY

Nutritional adaptations to parasitism within the platyhelminthes. Halton DW. **Int J Parasitol** 1997 Jun; 27(6):693–704 (50 ref.)
The origins of parasitism in the platyhelminthes: a summary interpreted on the basis of recent literature. Rohde K. **Int J Parasitol** 1997 Jun;27(6):739–46 (36 ref.)
Reproduction and host-location among the parasitic

PLATYHELMINTHS

platyhelminthes. Whittington ID. **Int J Parasitol** 1997 Jun; 27(6):705–14 (62 ref.)

PLATYRRHINA see **CEBIDAE**

PLAY AND PLAYTHINGS

The value of studying occupation: an example with primate play [published erratum appears in Am J Occup Ther 1996 Sep;50(8):638] Wood W. **Am J Occup Ther** 1996 May; 50(5):327–37 (60 ref.)

The relationship between joint attention and pretend play in autism. Charman T. **Dev Psychopathol** 1997 Winter; 9(1):1–16 (110 ref.)

Play and game as metaphor for technique. Cohen MC. **J Am Acad Psychoanal** 1996 Spring;24(1):61–73 (25 ref.)

The power of humor and play as nursing interventions for a child with cancer: a case report. Frankenfield PK. **J Pediatr Oncol Nurs** 1996 Jan;13(1):15–20 (21 ref.)

[The analysis of frequency, causes and consequences of accidents on children's playgrounds] Kosmala M. **Pediatr Pol** 1996 Feb;71(2):143–52 (44 ref.) (Eng. Abstr.) **(Pol)**

PSYCHOLOGY

Symbolic play of children with language impairment: a critical review. Casby MW. **J Speech Lang Hear Res** 1997 Jun;40(3):468–79 (73 ref.)

Multiple differences in the play fighting of male and female rats. Implications for the causes and functions of play. Pellis SM, et al. **Neurosci Biobehav Rev** 1997 Jan;21(1):105–20 (92 ref.)

PLETHYSMOGRAPHY

Measurement of lung volumes by plethysmography [see comments] Coates AL, et al. **Eur Respir J** 1997 Jun; 10(6):1415–27 (43 ref.) Comment in: Eur Respir J 1997 Jun;10(6):1205–6.

[Indirect measurement of arterial blood pressure by plethysmography] Tase C. **Nippon Rinsho** 1997 Mar;55 Suppl 1:519–22 (10 ref.) **(Jpn)**

METHODS

Oculopneumoplethysmography. Meissner I. **Neurosurg Clin N Am** 1996 Oct;7(4):571–6 (12 ref.)

PLETHYSMOGRAPHY, IMPEDANCE, TRANSTHORACIC see **CARDIOGRAPHY, IMPEDANCE**

PLETHYSMOGRAPHY, WHOLE BODY

[Plethysmographic measurement of thoracic gas volume] Kimura T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:8–11 (10 ref.) **(Jpn)**

PLEURA

Distribution of intraperitoneal chemotherapy into the pleural cavity. Vaccarello L, et al. **Obstet Gynecol** 1994 Oct;84(4 Pt 2):714–7 (14 ref.)

Oesophagopleural fistula—a rare sequel of pneumonectomy. Lauwers P, et al. **Thorac Cardiovasc Surg** 1996 Oct; 44(5):266–70 (44 ref.)

BLOOD SUPPLY

[Two clinical case of spontaneous hemopneumothorax caused by aberrant vessel] Muraoka M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jul;45(7):1028–33 (16 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Physiology and pathophysiology of pleural fluid turnover [see comments] Miserocchi G. **Eur Respir J** 1997 Jan; 10(1):219–25 (39 ref.) Comment in: Eur Respir J 1997 Jan;10(1):2–3.

PATHOLOGY

Pleuroscopy: therapeutic applications. Weissberg D, et al. **Scand J Thorac Cardiovasc Surg** 1996;30(1):1–10 (55 ref.)

SURGERY

Internalization of pleuroamniotic shunt causing neonatal demise. Blanch G, et al. **Fetal Diagn Ther** 1996 Jan–Feb; 11(1):32–6 (17 ref.)

[Complete Pleuropneumonectomy] Morita T, et al. **Kyobu Geka** 1996 Jul;49(8 Suppl):697–705 (90 ref.) **(Jpn)**

PLEURAL DISEASES

Diseases of the pleura. Light RW. **Curr Opin Pulm Med** 1997 Jul;3(4):303–4 (19 ref.)

Pleuropulmonary amebiasis. Lyche KD, et al. **Semin Respir Infect** 1997 Jun;12(2):106–12 (37 ref.)

CHEMICALLY INDUCED

Pleuropulmonary changes induced by ergoline drugs. Pfitzenmeyer P, et al. **Eur Respir J** 1996 May;9(5):1013–9 (46 ref.)

COMPLICATIONS

Rounded atelectasis. Batra P, et al. **J Thorac Imaging** 1996 Summer;11(3):187–97 (34 ref.)

DIAGNOSIS

Errors and pitfalls in lung and pleural cytology. Linder J. **Monogr Pathol** 1997;(39):40–59 (78 ref.)

ETIOLOGY

Peritoneal and pleural infection following placement of an internal biliary stent for a large bile leak. Weiss K, et al. **Am J Gastroenterol** 1997 Feb;92(2):347–8 (9 ref.)

Traumatic subarachnoid-pleural fistula [see comments] Sarwal V, et al. **Ann Thorac Surg** 1996 Dec;62(6):1622–6 (26 ref.) Comment in: Ann Thorac Surg 1997 May;63(5):1511.

Oesophagopleural fistula—a rare sequel of pneumonectomy. Lauwers P, et al. **Thorac Cardiovasc Surg** 1996 Oct; 44(5):266–70 (44 ref.)

RADIOGRAPHY

Imaging the pleura. Robertson RJ. **Br J Hosp Med** 1996 Jul 10–Aug 20;56(2–3):83–5 (10 ref.)

Radiographic and computed tomography (CT) imaging of complex pleural disease. Knisely BL, et al. **Crit Rev Diagn Imaging** 1997;38(1):1–58 (122 ref.)

SURGERY

Management of microfistula following pulmonary resection. Gall SA Jr, et al. **Chest Surg Clin N Am** 1996 Aug; 6(3):543–65 (53 ref.)

Pleuropericardial cysts: treatment by videothoracoscopy. Mouroux J, et al. **Surg Laparosc Endosc** 1996 Oct;6(5):403–4 (5 ref.)

THERAPY

Fibrin sealant in thoracic surgery. Pulmonary applications, including management of bronchopleural fistula. Bayfield MS, et al. **Chest Surg Clin N Am** 1996 Aug;6(3):567–83 (60 ref.)

Management of postpneumonectomy empyema and bronchopleural fistula. Deschamps C, et al. **Chest Surg Clin N Am** 1996 Aug;6(3):519–27 (34 ref.)

Management of late postpneumonectomy empyema and bronchopleural fistula. Wain JC. **Chest Surg Clin N Am** 1996 Aug;6(3):529–41 (32 ref.)

Pleuroscopy: therapeutic applications. Weissberg D, et al. **Scand J Thorac Cardiovasc Surg** 1996;30(1):1–10 (55 ref.)

ULTRASONOGRAPHY

Imaging the pleura. Robertson RJ. **Br J Hosp Med** 1996 Jul 10–Aug 20;56(2–3):83–5 (10 ref.)

PLEURAL EFFUSION

Pleural infection in children. Alkrinawi S, et al. **Semin Respir Infect** 1996 Sep;11(3):148–54 (27 ref.)

CHEMICALLY INDUCED

[Pleural effusion and severe edema of the lower limbs induced by bromocriptine] Messiaen T, et al. **Rev Med Interne** 1996; 17(8):680–3 (14 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Pleural disease in patients with AIDS. Hamm H, et al. **Curr Opin Pulm Med** 1997 Jul;3(4):315–8 (22 ref.)

DIAGNOSIS

Parapneumonic effusion and empyema. Hamm H, et al. **Eur Respir J** 1997 May;10(5):1150–6 (51 ref.)

[Thoracoscopic surgery for diagnosis and treatment of pleural and mediastinal disease] Ando A. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:155–8 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical application of thoracoscopy] Kitamura S. **Nippon Naika Gakkai Zasshi** 1996 Dec 10;85(12):2091–5 (7 ref.) **(Jpn)**

[Tumor and inflammation markers in diagnosis of serous pleural exudate] Trubnikov GA, et al. **Klin Med (Mosk)** 1997;75(6):15–20 (53 ref.) **(Rus)**

[Pleural effusion: criteria for distinguishing between transudates and exudates (see comments)] Garcia Pachon E, et al. **An Med Interna** 1996 Feb;13(2):91–4 (32 ref.) (Eng. Abstr.) Comment in: An Med Interna 1996 Sep;13(9):460–1. **(Spa)**

[The etiological diagnosis of pleural effusion (editorial)] Villena Garrido V. **Rev Clin Esp** 1997 Jun;197(6):387–8 (29 ref.) **(Spa)**

ENZYMOLOGY

Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Drent M, et al. **Eur Respir J** 1996 Aug;9(8):1736–42 (60 ref.)

ETIOLOGY

Hepatic hydrothorax: possible etiology of recurring pleural effusion. Hahn MH, et al. **Am Fam Physician** 1997 Aug; 56(2):523–7 (09 ref.)

Mechanisms of pleural liquid formation in pleural inflammation. Marchi E, et al. **Curr Opin Pulm Med** 1997 Jul;3(4):305–9 (22 ref.)

Transudative effusions. Kinasewitz GT. **Eur Respir J** 1997 Mar;10(3):714–8 (47 ref.)

Pleural diseases related to metastatic malignancies [see comments] Sahn SA. **Eur Respir J** 1997 Aug;10(8):1907–13 (50 ref.) Comment in: Eur Respir J 1997 Aug;10(8):1701–2.

[Pleural effusion] Reithineier A, et al. **Internist (Berl)** 1996 Sep;37(9):959–68; quiz 968 (10 ref.) **(Ger)**

[Febrile syndrome and isolated pleural effusion as manifestation of Q fever (letter)] Mateos-Colino A, et al. **Rev Clin Esp** 1996 Nov;196(11):800–1 (9 ref.) **(Spa)**

[The etiological diagnosis of pleural effusion (editorial)] Villena Garrido V. **Rev Clin Esp** 1997 Jun;197(6):387–8 (29 ref.) **(Spa)**

METABOLISM

Physiology and pathophysiology of pleural fluid turnover [see comments] Miserocchi G. **Eur Respir J** 1997 Jan; 10(1):219–25 (39 ref.) Comment in: Eur Respir J 1997 Jan;10(1):2–3.

PATHOLOGY

Cytology of pleural, peritoneal and pericardial fluids in children. A 40-year summary. Wong JW, et al. **Acta Cytol** 1997 Mar–Apr;41(2):467–73 (13 ref.)

RADIOGRAPHY

The radiology of melioidosis. Chong VF, et al. **Australas Radiol** 1996 Aug;40(3):244–9 (14 ref.)

SURGERY

Before the horse is out of the barn: fetal surgery for hydrops. Bullard KM, et al. **Semin Perinatol** 1995 Dec;19(6):462–73 (84 ref.)

THERAPY

Parapneumonic effusion and empyema. Hamm H, et al. **Eur Respir J** 1997 May;10(5):1150–6 (51 ref.)

Successful thoracoamniotic shunting and review of the literature in unilateral pleural effusion with hydrops. Wilkins-Haug LE, et al. **J Ultrasound Med** 1997 Feb; 16(2):153–60 (20 ref.)

Pleural sclerosis for the treatment of pneumothorax and pleural effusion. Light RW, et al. **Lung** 1997;175(4):213–23 (55 ref.)

ULTRASONOGRAPHY

Successful thoracoamniotic shunting and review of the literature in unilateral pleural effusion with hydrops. Wilkins-Haug LE, et al. **J Ultrasound Med** 1997 Feb; 16(2):153–60 (20 ref.)

Spontaneous resolution of an isolated unilateral fetal pleural effusion: a case report. Cordero DR, et al. **W V Med J** 1996 Jul–Aug;92(4):194–6 (14 ref.)

PLEURAL EFFUSION, MALIGNANT

The management of malignant pleural and pericardial effusions. Fiocco M, et al. **Hematol Oncol Clin North Am** 1997 Apr;11(2):253–65 (50 ref.)

PATHOLOGY

Brain metastasis in malignant pleural mesothelioma. Kawai A, et al. **Intern Med** 1997 Aug;36(8):591–4 (20 ref.)

THERAPY

Current trends in pleurodesis. Rodriguez-Panadero F. **Curr Opin Pulm Med** 1997 Jul;3(4):319–25 (65 ref.)

Pleurodesis: state of the art. Rodriguez-Panadero F, et al. **Eur Respir J** 1997 Jul;10(7):1648–54 (63 ref.)

[Treatment strategies for malignant pleural effusion] Medalion B, et al. **Harefuah** 1996 May 1;130(9):622–6 (38 ref.) **(Heb)**

PLEURAL NEOPLASMS

[Solitary fibrous tumor of the pleura. Clinical case] Trombetta F, et al. **Minerva Chir** 1996 Jun;51(6):485–8 (13 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

Endobronchial inflammatory pseudotumour in a patient with B-cell chronic lymphocytic leukemia and malignant pleural mesothelioma. Stappaerts I, et al. **Acta Clin Belg** 1996; 51(4):261–4 (8 ref.)

Pyothorax-associated lymphoma. Aozasa K. **Int J Hematol** 1996 Dec;65(1):9–16 (23 ref.)

[Two cases of recurrent hydropneumothorax caused by malignant pleural mesothelioma] Tanaka H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Oct; 44(10):1877–81 (16 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Bilateral pleural masses and shortness of breath associated with multiple myeloma. Cabrera A, et al. **Chest** 1997 Jun; 111(6):1750–3 (11 ref.)

Desmoplastic small round cell tumor. Leuschner I, et al. **Semin Diagn Pathol** 1996 Aug;13(3):204–12 (46 ref.)

[Problems in diagnosis and therapy of malignant pleural mesothelioma] Türler A, et al. **Med Klin** 1997 Feb 15; 92(2):101–5 (40 ref.) (Eng. Abstr.) **(Ger)**

[Localized fibroma: a rare tumor of pleural origin] D'Elia G, et al. **G Chir** 1996 Nov–Dec;17(11–12):597–601 (41 ref.) (Eng. Abstr.) **(Ita)**

[Thoracoscopic surgery for diagnosis and treatment of pleural and mediastinal disease] Ando A. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:155–8 (6 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Occupational and geographical factors in the epidemiology of malignant mesothelioma. Ross D, et al. **Monaldi Arch Chest Dis** 1995 Dec;50(6):459–63 (47 ref.)

ETIOLOGY

Pathology of malignant mesothelioma. Attanoos RL, et al. **Histopathology** 1997 May;30(5):403–18 (120 ref.)

Pleural epidermoid carcinoma from displaced skin following extrapleural pneumothorax in a patient exposed to asbestos. Sapino A, et al. **Virchows Arch** 1996 Oct;429(2–3):173–6 (10 ref.)

[Malignant mesothelioma of the pleura following radiotherapy of Hodgkin disease] Falchero L, et al. **Bull Cancer** 1996 Nov;83(11):964–8 (32 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Non-pyothorax-associated primary pleural lymphoma with complex karyotypic abnormalities. Keung YK, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):621–4 (16 ref.)

PATHOLOGY

Cytology of pleural, peritoneal and pericardial fluids in children. A 40-year summary. Wong JW, et al. **Acta Cytol** 1997 Mar–Apr;41(2):467–73 (13 ref.)

Primary pleural thymoma. Shih DF, et al. **Arch Pathol Lab Med** 1997 Jan;121(1):79–82 (10 ref.)

Malignant pleural mesothelioma. Hoogsteden HC, et al. **Crit Rev Oncol Hematol** 1997 Feb;25(2):97–126 (342 ref.)

Fine-needle aspiration cytology of pleuropulmonary blastoma: case report and review of the literature. Gelven PL, et al. **Diagn Cytopathol** 1997 Apr;16(4):336–40 (29 ref.)

Pathology of malignant mesothelioma. Attanoos RL, et al. **Histopathology** 1997 May;30(5):403–18 (120 ref.)

In vitro and in vivo studies of mesothelioma. Pass HI, et al. **J Cell Biochem Suppl** 1996;24:142–51 (73 ref.)

Small cell carcinoma of lung simulating pleural mesothelioma. Report of 4 cases with autopsy confirmation. Falconieri G, et al. **Pathol Res Pract** 1995 Nov; 191(11):1147–52 (17 ref.)

Immunopathology of malignant mesothelioma. Sheibani K, et al. **Pathology (Phila)** 1996;4(1):191–212 (89 ref.)

From the archives of the AFIP. Malignant pleural mesothelioma: radiologic-pathologic correlation. Miller BH, et al. **Radiographics** 1996 May;16(3):613–44 (72 ref.)

Desmoplastic small round cell tumor. Leuschner I, et al. **Semin Diagn Pathol** 1996 Aug;13(3):204–12 (46 ref.)

[Mesothelioma. Pathology/pathogenesis/mesothelioma register] Müller KM. **Pneumologie** 1997 Apr;51(4):335–44 (18 ref.) **(Ger)**

PHYSIOPATHOLOGY

Diffuse malignant pleural mesotheslioma at CAMC: a retrospective study of 50 patients. Jubelirer SJ, et al. **W V Med J** 1997 May–Jun;93(3):120–5 (10 ref.)

RADIOGRAPHY

From the archives of the AFIP. Malignant pleural mesothelioma: radiologic-pathologic correlation. Miller BH, et al. **Radiographics** 1996 May;16(3):613–44 (72 ref.)

SECONDARY

Spontaneous regression of metastatic renal cancer. Case report and literature review. Lokich J. **Am J Clin Oncol** 1997 Aug;20(4):416–8 (34 ref.)

SURGERY

[Fibrous tumors localized in the pleura] Biancari F, et al. **G Chir** 1996 Aug–Sep;17(8–9):437–43 (57 ref.) (Eng. Abstr.) **(Ita)**

[Complete Pleuropneumonectomy] Morita T, et al. **Kyobu Geka** 1996 Jul;49(8 Suppl):697–705 (90 ref.) **(Jpn)**

VIROLOGY

Evidence for and implications of SV40-like sequences in human mesotheliomas. Pass HI, et al. **Important Adv Oncol** 1996;:89–108 (129 ref.)

PLEURAL RUB see **RESPIRATORY SOUNDS**

PLEURISY

CHEMICALLY INDUCED

[Four cases of similar Hexheimer's reaction during the initial chemotherapy for tuberculosis bacillus] Lu H, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Dec; 18(6):348–50, 382–3 (10 ref.) (Eng. Abstr.) **(Chi)**

DIAGNOSIS

[Diagnosis of exudative pleurisy] Trubnikov GA, et al. **Klin Med (Mosk)** 1997;75(8):62–7 (8 ref.) **(Rus)**

ETIOLOGY

[Uremic pleuritis] Gonda H, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):48–50 (17 ref.) **(Jpn)**

SURGERY

[The potentials for the surgical treatment of intrathoracic sarcoidosis complicated by chronic pleurisy] Duzhil ID, et al. **Lik Sprava** 1996 Jul–Sep;(7–9):168–70 (12 ref.) (Eng. Abstr.) **(Rus)**

PLEURISY, TUBERCULOUS see **TUBERCULOSIS, PLEURAL**

PLEURODELES

EMBRYOLOGY

What mechanisms drive cell migration and cell interactions in Pleurodeles? Boucaut JC, et al. **Int J Dev Biol** 1996 Aug; 40(4):675–83 (55 ref.)

GENETICS

What role might lampbrush chromosomes play in maternal gene expression? Angelier N, et al. **Int J Dev Biol** 1996 Aug;40(4):645–52 (40 ref.)

PLEURODESIS

Current trends in pleurodesis. Rodriguez-Panadero F. **Curr Opin Pulm Med** 1997 Jul;3(4):319–25 (65 ref.)

Pleurodesis: state of the art. Rodriguez-Panadero F, et al. **Eur Respir J** 1997 Jul;10(7):1648–54 (63 ref.)

Pleural sclerosis for the treatment of pneumothorax and pleural effusion. Light RW, et al. **Lung** 1997;175(4):213–23 (55 ref.)

Pleuroscopy: therapeutic applications. Weissberg D, et al. **Scand J Thorac Cardiovasc Surg** 1996;30(1):1–10 (55 ref.)

PLEURODYNIA VIRUS see **COXSACKIEVIRUSES B**

PLEUROPNEUMONIA

DIAGNOSIS

Severe pleuropneumonia without a cough and myocarditis with mixed mycoplasma infection [letter] Chang AB, et al. **J Paediatr Child Health** 1996 Dec;32(6):546–7 (5 ref.)

VETERINARY

Virulence factors of the swine pathogen Actinobacillus pleuropneumoniae. Tascón RI, et al. **Microbiologia** 1996 Jun;12(2):171–84 (101 ref.)

PLEUROPNEUMONIA-LIKE ORGANISMS see **MYCOPLASMA**

PLEXUS COELIACUS see **CELIAC PLEXUS**

PLOIDIES

Megakaryocytes and platelets in vascular disease. van der Loo B, et al. **Baillieres Clin Haematol** 1997 Feb; 10(1):109–23 (102 ref.)

Use of fluorescence in situ hybridization and comparative genomic hybridization in the cytogenetic analysis of testicular germ cell tumors and uveal melanomas. Becher R, et al. **Cancer Genet Cytogenet** 1997 Jan;93(1):22–8 (70 ref.)

Dichotomy of hyperdiploid acute lymphoblastic leukemia on the basis of the distribution of gained chromosomes. Mertens F, et al. **Cancer Genet Cytogenet** 1996 Nov; 92(1):8–10 (10 ref.)

Endometrial neoplasia: prognostic significance of ploidy status. Evans MP, et al. **Clin Obstet Gynecol** 1996 Sep; 39(3):696–706 (31 ref.)

Determination of chromosome ploidy in yeast. Hadfield C, et al. **Methods Mol Biol** 1996;53:205–16 (10 ref.)

DNA ploidy and cell cycle analysis in cancer diagnosis and prognosis. Ross JS. **Oncology (Huntingt)** 1996 Jun; 10(6):867–82, 887; discussion 887–90 (164 ref.)

[The DNA ploidy in squamous cell carcinomas of the head and neck with particular reference to prognosis] Boiocchi M, et al. **Acta Otorhinolaryngol Ital** 1996 Jun;16(3 Suppl 54):27–30 (17 ref.) **(Ita)**

PLURALISM see **CULTURAL DIVERSITY**

PLUTONIUM

ADVERSE EFFECTS

An evaluation of the use of bronchopulmonary lavage in the treatment of plutonium oxide inhalation. Dean MR. **J R Nav Med Serv** 1997;82(3):188–96 (27 ref.)

The radiological hazards of plutonium. Barnaby F. **Med Confl Surviv** 1997 Jul–Sep;13(3):195–206; discussion 207–8 (18 ref.)

PMN ELASTASE see **LEUKOCYTE ELASTASE**

PNEUMATOSIS CYSTOIDES INTESTINALIS

DIAGNOSIS

Gastroduodenal pneumatosis: endoscopic and histological findings. Cordum NR, et al. **Am J Gastroenterol** 1997 Apr; 92(4):692–5 (22 ref.)

Pneumatosis intestinalis. Two case reports and a retrospective review of the literature from 1985 to 1995. Boerner RM, et al. **Dig Dis Sci** 1996 Nov;41(11):2272–85 (131 ref.)

ETIOLOGY

Pneumatosis coli: a proposed pathogenesis based on study of 25 cases and review of the literature. Gagliardi G, et al. **Int J Colorectal Dis** 1996;11(3):111–8 (61 ref.)

[Systemic sclerosis with various gastrointestinal problems including pneumoperitoneum, pneumatosis cystoides intestinalis and malabsorption syndrome] Satoh A, et al. **Ryumachi** 1995 Dec;35(6):927–33 (29 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

[Rare differential diagnosis of free intra-abdominal air. Pneumatosis cystoides intestinalis] Scheulen B, et al. **Internist (Berl)** 1996 Dec;37(12):1260–4 (14 ref.) **(Ger)**

PNEUMOCEPHALUS

ETIOLOGY

Idiopathic spontaneous cerebrospinal fluid rhinorrhoea and pneumocephalus: case report and literature review. Roberts GA, et al. **Br J Neurosurg** 1996 Oct;10(5):513–7 (27 ref.)

Pneumocephalus associated with fracture of thoracic spine: case report. Uemura K, et al. **Br J Neurosurg** 1997 Jun; 11(3):253–6 (16 ref.)

PNEUMOCOCCAL INFECTIONS

[Pneumococcal endocarditis of the tricuspid valve. A case report with review of the literature] Holm M, et al. **Tidsskr Nor Laegeforen** 1997 Feb 28;117(6):815–7 (8 ref.) (Eng. Abstr.) **(Nor)**

COMPLICATIONS

Thrombotic microangiopathy related to infection in an HIV-positive patient [letter] Mayo J, et al. **Eur J Clin Microbiol Infect Dis** 1996 Mar;15(3):254–6 (14 ref.)

DIAGNOSIS

Pneumococcal pericarditis--out of sight, out of mind? McMechan SR, et al. **Clin Cardiol** 1996 Oct;19(10):829–30 (5 ref.)

Pneumococcal sacroiliitis. Pinson AG, et al. **South Med J** 1997 Jun;90(6):649–52 (36 ref.)

DRUG THERAPY

Antibiotic-resistance in Streptococcus pneumoniae. Krisher K. **Adv Exp Med Biol** 1995;390:123–40 (102 ref.)

Antibiotic resistance in Streptococcus pneumoniae. Tomasz A. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S85–8 (22 ref.)

Epidemiology, control and treatment of multiresistant pneumococci. Klugman KP. **Drugs** 1996;52 Suppl 2:42–6 (25 ref.)

New prospects for antibacterial agents against multidrug-resistant pneumococci. Appelbaum PC. **Microb Drug Resist** 1995 Spring;1(1):43–8 (42 ref.)

Penicillin-resistant pneumococci in adult disease with special reference to AIDS patients. Bouza E, et al. **Microb Drug Resist** 1995 Spring;1(1):9–28 (241 ref.)

Antibiotic-resistant pneumococci in pediatric disease. Klugman KP, et al. **Microb Drug Resist** 1995 Spring; 1(1):5–8 (31 ref.)

Epidemiology and in vitro susceptibility of drug-resistant Streptococcus pneumoniae. Appelbaum PC. **Pediatr Infect Dis J** 1996 Oct;15(10):932–4 (65 ref.)

[Increasing antibiotic resistance of pneumococcus. Management of respiratory tract infections and meningitis (see comments)] Kalin M, et al. **Lakartidningen** 1997 Mar 19;94(12):1061–4, 1067–8 (41 ref.) Comment in: Lakartidningen 1997 May 14;94(20):1867–8. **(Swe)**

EPIDEMIOLOGY

Epidemiology and prevention of pneumococcal infections. McIntyre P. **Curr Opin Pediatr** 1997 Feb;9(1):9–13 (35 ref.)

PNEUMOCOCCAL INFECTIONS

Pneumococcal resistance to beta-lactam antibiotics: a global geographic overview. Baquero F. **Microb Drug Resist** 1995 Summer;1(2):115-20 (16 ref.)
Epidemiology of pneumococcal serotypes and conjugate vaccine formulations. Butler JC. **Microb Drug Resist** 1997 Summer;3(2):125-9 (44 ref.)
Pan American Health Organization epidemiological surveillance network for Streptococcus pneumoniae. di Fabio JL, et al. **Microb Drug Resist** 1997 Summer; 3(2):131-3 (4 ref.)
Epidemiology of penicillin resistant pneumococci in Iceland. Kristinsson KG. **Microb Drug Resist** 1995 Summer; 1(2):121-5 (21 ref.)
[Retrospective and comparative study of pneumococcal bacteremia in patients with chronic hepatopathy] Ramos Rincón JM, et al. **An Med Interna** 1996 Jul;13(7):313-6 (21 ref.) (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Public health implications of pneumococcal disease in indigenous Australians [editorial; comment] Torzillo PJ. **Aust N Z J Public Health** 1997 Jun;21(3):243-4 (13 ref.) Comment on: Aust N Z J Public Health 1997 Jun;21(3):281-5.

ETIOLOGY

Invasive soft tissue infections with Streptococcus pneumoniae in patients with systemic lupus erythematosus: case report and review of the literature. Hill MD, et al. **Arthritis Rheum** 1997 Sep;40(9):1716-9 (16 ref.)

IMMUNOLOGY

Systemic and mucosal protective immunity to pneumococcal surface protein A. Briles DE, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:118-26 (42 ref.)
New vaccines for the prevention of pneumococcal infections. Käyhty H, et al. **Emerg Infect Dis** 1996 Oct-Dec; 2(4):289-98 (74 ref.)
Invasive pneumococcal disease in the immunocompromised host. Janoff EN, et al. **Microb Drug Resist** 1997 Fall; 3(3):215-32 (192 ref.)

MICROBIOLOGY

Pneumococcal psoas abscess: report of a case and review of the world literature. Giladi M, et al. **Isr J Med Sci** 1996 Sep;32(9):771-4 (15 ref.)
Epidemiology of penicillin resistant pneumococci in Iceland. Kristinsson KG. **Microb Drug Resist** 1995 Summer; 1(2):121-5 (21 ref.)

PATHOLOGY

[Spontaneous bacterial peritonitis and primary hepatic lymphoma in a female patient with human immunodeficiency virus infection (letter)] Sancho JM, et al. **Med Clin (Barc)** 1997 Feb 15;108(6):238 (7 ref.) **(Spa)**

PREVENTION & CONTROL

Public health implications of pneumococcal disease in indigenous Australians [editorial; comment] Torzillo PJ. **Aust N Z J Public Health** 1997 Jun;21(3):243-4 (13 ref.) Comment on: Aust N Z J Public Health 1997 Jun;21(3):281-5.
Pneumococcal vaccination: four issues for western Europe. Fedson DS. **Biologicals** 1997 Jun;25(2):215-9 (15 ref.)
Epidemiology and prevention of pneumococcal infections. McIntyre P. **Curr Opin Pediatr** 1997 Feb;9(1):9-13 (35 ref.)
New vaccines for the prevention of pneumococcal infections. Käyhty H, et al. **Emerg Infect Dis** 1996 Oct-Dec; 2(4):289-98 (74 ref.)
Adult immunizations: how are we doing? Eickhoff TC. **Hosp Pract (Off Ed)** 1996 Nov 15;31(11):107-8, 111-2, 115-7, passim (12 ref.)
Prevention of pneumococcal disease in sickle cell anemia [editorial; comment] Pearson HA. **J Pediatr** 1996 Dec; 129(6):788-9 (12 ref.) Comment on: J Pediatr 1996 Dec;129(6):821-7. Comment on: J Pediatr 1996 Dec;129(6):828-35.
Pneumococcal conjugate vaccines: review and update. Klein DL. **Microb Drug Resist** 1995 Spring;1(1):49-58 (66 ref.)
Pneumococcal vaccine [published erratum appears in Pediatr Rev 1996 Dec;17(12):425] Peter G, et al. **Pediatr Rev** 1996 Oct;17(10):335-41; quiz 342 (12 ref.)
[Anti-pneumococcal vaccine: justifications and results] Bacle A, et al. **Rev Pneumol Clin** 1997;53(3):128-37 (82 ref.) (Eng. Abstr.) **(Fre)**

PNEUMOCOCCUS see **STREPTOCOCCUS PNEUMONIAE**

PNEUMOCONIOSIS

DIAGNOSIS

Atypical mycobacteriosis as a complication of talc pneumoconiosis. De Coster C, et al. **Eur Respir J** 1996 Aug;9(8):1757-9 (12 ref.)

EPIDEMIOLOGY

Pneumoconiosis in carbon black workers [published erratum appears in Sangyo Ika Daigaku Zasshi 1996 Dec 1;18(4):307] Szozda R. **Sangyo Ika Daigaku Zasshi** 1996 Sep 1;18(3):223-8 (29 ref.)

ETIOLOGY

Clinical perspective of inorganic dusts, metals, and fumes exposures. Skarote SJ, et al. **Curr Opin Pulm Med** 1997 May;3(3):209-14 (53 ref.)

PNEUMOCYSTIS CARINII

Molecular biology and epidemiology of Pneumocystis carinii infection in AIDS [editorial] Stringer JR, et al. **AIDS** 1996 Jun;10(6):561-71 (120 ref.)
Pneumocystis carinii. Levine SJ. **Clin Chest Med** 1996 Dec; 17(4):665-95 (342 ref.)
Molecular epidemiology of Pneumocystis carinii pneumonia. Beard CB, et al. **Emerg Infect Dis** 1996 Apr-Jun; 2(2):147-50 (34 ref.)

CLASSIFICATION

Pneumocystis carinii: what is it, exactly? Stringer JR. **Clin Microbiol Rev** 1996 Oct;9(4):489-98 (122 ref.)

IMMUNOLOGY

Host defense against Pneumocystis carinii: more than the CD4+ lymphocyte [editorial] Shellito JE. **J Lab Clin Med** 1996 Nov;128(5):448-9 (11 ref.)

ISOLATION & PURIFICATION

Hypertrophic osteoarthropathy associated with Pneumocystis carinii pneumonia and human immunodeficiency virus infection. Gunnarsson G, et al. **Clin Infect Dis** 1996 Mar;22(3):590-1 (9 ref.)

METABOLISM

Interactions of parasite and host epithelial cell cycle regulation during Pneumocystis carinii pneumonia. Limper AH, et al. **J Lab Clin Med** 1997 Aug;130(2):132-8 (30 ref.)

PATHOGENICITY

Extrapulmonary pneumocystosis. Ng VL, et al. **Clin Microbiol Rev** 1997 Jul;10(3):401-18 (143 ref.)

PHYSIOLOGY

Pneumocystis carinii: an atypical fungal micro-organism. Cailliez JC, et al. **J Med Vet Mycol** 1996 Jul-Aug; 34(4):227-39 (159 ref.)

PNEUMOCYSTIS CARINII INFECTIONS

Molecular biology and epidemiology of Pneumocystis carinii infection in AIDS [editorial] Stringer JR, et al. **AIDS** 1996 Jun;10(6):561-71 (120 ref.)
Extrapulmonary pneumocystosis. Ng VL, et al. **Clin Microbiol Rev** 1997 Jul;10(3):401-18 (143 ref.)
Co-infection of Toxoplasma gondii with other pathogens: pathogenicity and chemotherapy in animal models. Lacroix C, et al. **Curr Top Microbiol Immunol** 1996;219:223-33 (33 ref.)

ETIOLOGY

[Extrapulmonary and disseminated pneumocystosis in AIDS. A review of the literature] Grasland A, et al. **Ann Med Interne (Paris)** 1997;148(2):177-83 (54 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Central nervous system pneumocystosis in a patient with AIDS. Bartlett JA, et al. **Clin Infect Dis** 1997 Jul;25(1):82-5 (27 ref.)

PREVENTION & CONTROL

Skin involvement with Pneumocystis despite dapsone prophylaxis: a rare cause of skin nodules in a patient with AIDS. Bundow DL, et al. **Am J Med Sci** 1997 Mar; 313(3):182-6 (25 ref.)
Pneumocystis carinii infection: current treatment and prevention. Miller RF, et al. **J Antimicrob Chemother** 1996 May;37 Suppl B:33-53 (90 ref.)

THERAPY

Pneumocystis carinii infection: current treatment and prevention. Miller RF, et al. **J Antimicrob Chemother** 1996 May;37 Suppl B:33-53 (90 ref.)

PNEUMOCYSTIS CARINII PNEUMONIA see **PNEUMONIA, PNEUMOCYSTIS CARINII**

PNEUMOGASTRIC NERVE see **VAGUS NERVE**

PNEUMOLOGY see **PULMONARY DISEASE (SPECIALTY)**

PNEUMOMEDIASTINUM see **MEDIASTINAL EMPHYSEMA**

PNEUMONECTOMY

Postpneumonectomy interatrial right-to-left shunt: successful percutaneous treatment. Godart F, et al. **Ann Thorac Surg** 1997 Sep;64(3):834-6 (7 ref.)
Is there a place for surgery in central small cell lung cancer? Kohman LJ. **Chest Surg Clin N Am** 1997 Feb;7(1):105-12 (36 ref.)
Perioperative management of lung volume reduction patients. Keller CA, et al. **Clin Chest Med** 1997 Jun;18(2):285-300 (39 ref.)
Pulmonary rehabilitation and surgery for end-stage lung disease. Kesten S. **Clin Chest Med** 1997 Jun;18(2):173-81 (55 ref.)
Early and long-term functional outcomes following lung volume reduction surgery. Sciurba FC. **Clin Chest Med** 1997 Jun;18(2):259-76 (109 ref.)
Evaluation and preoperative management of lung volume reduction surgery candidates. Yusen RD, et al. **Clin Chest Med** 1997 Jun;18(2):199-224 (154 ref.)
Lung volume reduction surgery for emphysema. Russi EW, et al. **Eur Respir J** 1997 Jan;10(1):208-18 (46 ref.)
Physiological outcomes of lung volume reduction surgery. Russi EW. **Monaldi Arch Chest Dis** 1997 Apr;52(2):155-8 (35 ref.)
Lung volume reduction surgery in chronic obstructive pulmonary disease. Davies L, et al. **Thorax** 1996 Aug;51 Suppl 2:S29-34 (45 ref.)
[Tumor embolism with fatal cerebral infarct in pneumonectomy. Case report and review of the literature] Zürcher M, et al. **Chirurg** 1996 Sep;67(9):959-62 (37 ref.) (Eng. Abstr.) **(Ger)**
[Radical surgery and lymph node dissection in bronchial carcinoma] Schirren J, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:790-7 (8 ref.) (Eng. Abstr.) **(Ger)**
[Left pneumonectomy in a child with congenital bronchiectasis] Tucciarone L, et al. **Pediatr Med Chir** 1996 May-Jun;18(3):323-5 (11 ref.) (Eng. Abstr.) **(Ita)**
[A case of contralateral pneumothorax after right pneumonectomy] Nishiuchi S, et al. **Kyobu Geka** 1996 Aug; 49(9):725-8 (12 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Natural history of residual air spaces after pulmonary resection. Barker WL. **Chest Surg Clin N Am** 1996 Aug; 6(3):585-613 (61 ref.)
Management of postpneumonectomy empyema and bronchopleural fistula. Deschamps C, et al. **Chest Surg Clin N Am** 1996 Aug;6(3):519-27 (34 ref.)
Acute and delayed space problems following pulmonary resection. Miller JI Jr. **Chest Surg Clin N Am** 1996 Aug; 6(3):615-21 (3 ref.)
Management of late postpneumonectomy empyema and bronchopleural fistula. Wain JC. **Chest Surg Clin N Am** 1996 Aug;6(3):529-41 (32 ref.)
The complications of lung resection in adults: acute respiratory distress syndrome (ARDS). Williams E, et al. **Monaldi Arch Chest Dis** 1996 Aug;51(4):310-5 (27 ref.)
Oesophagopleural fistula--a rare sequel of pneumonectomy. Lauwers P, et al. **Thorac Cardiovasc Surg** 1996 Oct; 44(5):266-70 (44 ref.)
[Postpneumonectomy pulmonary edema. Review of the literature. Apropos of 2 new cases] Faisy C, et al. **Rev Pneumol Clin** 1996;52(4):253-60 (19 ref.) (Eng. Abstr.) **(Fre)**

INSTRUMENTATION

Lobectomy by video-assisted thoracic surgery for a hilar bronchial carcinoid tumor. Watanabe M, et al. **Surg Laparosc Endosc** 1996 Dec;6(6):476-9 (6 ref.)

METHODS

The present status of surgery for lung cancer. Lacquet LK. **Acta Chir Belg** 1996 Nov-Dec;96(6):245-51 (15 ref.)
Recent advances in surgery for emphysema. Lefrak SS, et al. **Annu Rev Med** 1997;48:387-98 (34 ref.)
[Principles of lung volume reduction] Stamatis G, et al. **Chirurg** 1996 Dec;67(12):1204-14 (41 ref.) (Eng. Abstr.) **(Ger)**
[Video-assisted thoracic surgery for lung cancer] Shirakusa T, et al. **Gan To Kagaku Ryoho** 1997 Mar;24(5):520-4 (7 ref.) (Eng. Abstr.) **(Jpn)**
[Lung volume reduction surgery in patients with pulmonary emphysema] Kohno T, et al. **Kyobu Geka** 1997 Jul;50(8 Suppl):722-9 (10 ref.) **(Jpn)**
[Complete Pleuropneumonectomy] Morita T, et al. **Kyobu Geka** 1996 Jul;49(8 Suppl):697-705 (90 ref.) **(Jpn)**
[Video-assisted thoracoscopic surgery for a 89-year-old patient with primary lung cancer--report of a case] Kamiyoshihara M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):628-31 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Relief of dyspnea after lung volume reduction in patients with pulmonary emphysema] Hida W, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:169-71 (8 ref.) (Eng. Abstr.) **(Jpn)**

NURSING

Surgical treatment of emphysema using bovine pericardium strips. Allen GM. **AORN J** 1996 Feb;63(2):373, 376–80, 383–4, passim 388 (14 ref.)
Bilateral lung volume reduction surgery for treatment of emphysema. Dickey DM. **AORN J** 1996 Feb;63(2):355–64, 367, 372; quiz 406, 409–14 (26 ref.)
Bilateral lung volume reduction surgery. Graling PR, et al. **AORN J** 1996 Feb;63(2):389–90, 392, 394 passim (10 ref.)
Lung volume reduction surgery: an overview. McGraw LR. **Heart Lung** 1997 Mar–Apr;26(2):131–7; quiz 138–9 (33 ref.)

PNEUMONIA

Severe community-acquired pneumonia. So HY. **Anaesth Intensive Care** 1997 Jun;25(3):222–34 (99 ref.)
Severe community-acquired pneumonia. Feldman C. **Curr Opin Pulm Med** 1997 Mar;3(2):98–104 (60 ref.)
Pneumonia. Schidlow DV, et al. **Pediatr Rev** 1996 Sep; 17(9):300–9; quiz 310 (12 ref.)
Neonatal pneumonia. Campbell JR. **Semin Respir Infect** 1996 Sep;11(3):155–62 (47 ref.)
Human immunodeficiency-virus-related pulmonary infections in children. McSherry GD. **Semin Respir Infect** 1996 Sep;11(3):173–83 (42 ref.)
Cryptococcal pneumonia. Sarosi GA. **Semin Respir Infect** 1997 Mar;12(1):50–3 (26 ref.)
Community-acquired pneumonia. Ong KC, et al. **Singapore Med J** 1995 Oct;36(5):539–44 (30 ref.)
[Explanatory factors of length of stay at the diagnosis-related group 129: common pneumonia and pleurisy, aged over 69 and/or associated co-morbidities] Vergnenegre A, et al. **Rev Pneumol Clin** 1996;52(4):245–52 (28 ref.) (Eng. Abstr.) **(Fre)**
[Pneumonia after esophagectomy] Matsubara T. **Nippon Geka Gakkai Zasshi** 1996 Jun;97(6):437–41 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Pneumonia in the elderly—recent topics and treatment] Saito A, et al. **Nippon Ronen Igakkai Zasshi** 1996 Oct; 33(10):739–43 (21 ref.) **(Jpn)**

CHEMICALLY INDUCED

Alpha-interferon induced severe pneumonitis [letter] Wolf Y, et al. **J Toxicol Clin Toxicol** 1997;35(1):113–4 (5 ref.)
[Drug-induced pneumonitis and related diseases] Matsushima T. **Nippon Naika Gakkai Zasshi** 1997 Mar 10;86(3):457–62 (6 ref.) **(Jpn)**

COMPLICATIONS

The pediatric clinical evaluation and pneumonia [editorial] McCarthy PL. **Curr Opin Pediatr** 1996 Oct;8(5):427–9 (18 ref.)
[Acute pneumonia in alcoholics: onset and course] Tkachikhin VS, et al. **Klin Med (Mosk)** 1997;75(6):36–8 (26 ref.) (Eng. Abstr.) **(Rus)**
[Chronic eosinophilic pneumonia in AIDS (letter)] Fernández Rodríguez R, et al. **Med Clin (Barc)** 1996 Nov 2;107(15):599 (8 ref.) **(Spa)**

DIAGNOSIS

Can we predict which patients with community-acquired pneumonia we can keep out of hospital? Frank J, et al. **Can Fam Physician** 1997 Jul;43:1230–2 (4 ref.)
Disseminated mucormycosis presenting with lower extremity weakness. von Pohle WR. **Eur Respir J** 1996 Aug; 9(8):1751–3 (10 ref.)
Nosocomial pneumonia. Diagnosis and prevention. Mayhall CG. **Infect Dis Clin North Am** 1997 Jun;11(2):427–57 (103 ref.)
Lower respiratory tract infection. Clarke CW. **Med J Aust** 1997 Jul 7;167(1):42–7 (32 ref.)
The diagnosis of nosocomial pneumonia in ventilated patients. Nardini S. **Monaldi Arch Chest Dis** 1996 Aug; 51(4):342–4 (6 ref.)
Could invasive diagnostic techniques for ventilator-associated pneumonia be associated with reduced antibiotic usage in the ICU? Brun-Buisson C. **New Horiz** 1996 Aug;4(3):345–52 (58 ref.)
Afebrile pneumonia in infants. DeMuri GP. **Prim Care** 1996 Dec;23(4):849–60 (38 ref.)
[Nosocomial pneumonia in intensive care units] Fagon JY, et al. **Presse Med** 1996 Oct 19;25(31):1441–6 (29 ref.) (Eng. Abstr.) **(Fre)**
[German Society of Pneumology: Recommendations for diagnosis of community-acquired pneumonia. "Diagnosis of Community-Acquired Pneumonia" Working Group] Schaberg T, et al. **Pneumologie** 1997 Feb;51(2):69–77 (50 ref.) **(Ger)**

DRUG THERAPY

Community-acquired pneumonia in adults: initial antibiotic therapy. King DE, et al. **Am Fam Physician** 1997 Aug; 56(2):544–50 (27 ref.)
Pneumonia and tuberculosis in pregnancy. Riley L. **Infect Dis Clin North Am** 1997 Mar;11(1):119–33 (64 ref.)
Prognosis factors in severe community-acquired pneumonia: a step forward [editorial; comment] Torres A, et al. **Intensive Care Med** 1996 Dec;22(12):1288–90 (19 ref.) Comment on: Intensive Care Med 1996 Dec;22(12):1307–14.
Lower respiratory tract infection. Clarke CW. **Med J Aust** 1997 Jul 7;167(1):42–7 (32 ref.)

EPIDEMIOLOGY

Acute lower respiratory tract infections in children in China. Zhaori G. **Chin Med J (Engl)** 1996 Jul;109(7):510–3 (16 ref.)

ETIOLOGY

Inflammatory mediators, cytokines, and adhesion molecules in pulmonary inflammation and injury. Lukacs NW, et al. **Adv Immunol** 1996;62:257–304 (227 ref.)
Pneumonia in the surgical patient. Polk HC Jr, et al. **Curr Probl Surg** 1997 Feb;34(2):117–200 (226 ref.)
Contribution of endotracheal tubes to the pathogenesis of ventilator-associated pneumonia. Koerner RJ. **J Hosp Infect** 1997 Feb;35(2):83–9 (24 ref.)
The diagnosis of nosocomial pneumonia in ventilated patients. Nardini S. **Monaldi Arch Chest Dis** 1996 Aug; 51(4):342–4 (6 ref.)
Could invasive diagnostic techniques for ventilator-associated pneumonia be associated with reduced antibiotic usage in the ICU? Brun-Buisson C. **New Horiz** 1996 Aug;4(3):345–52 (58 ref.)
Surgery with cardiopulmonary bypass and pulmonary inflammatory responses. Royston D. **Perfusion** 1996 May; 11(3):213–9 (53 ref.)
[Prevention of acquired pneumonia during artificial ventilation (excluding the use of anti-infectious agents)] Fagon JY, et al. **Rev Mal Respir** 1997 Jan;14(1):13–9 (43 ref.) (Eng. Abstr.) **(Fre)**
[Invasive pneumonia diagnosis in community-acquired pneumonia (see comments)] Dalhoff K, et al. **Pneumologie** 1996 Oct;50(10):687–92 (46 ref.) Comment in: Pneumologie 1997 Feb;51(2):90–2. **(Ger)**
[Pneumonia] Lode H, et al. **Pneumologie** 1996 Sep;50 Suppl 2:592–4 (17 ref.) **(Ger)**

IMMUNOLOGY

Cytokines in host defense against pneumonia. Standiford TJ, et al. **J Investig Med** 1997 Aug;45(6):335–45 (79 ref.)
Lymphocyte subsets in experimental bronchopulmonary inflammation and hyperresponsiveness. Coyle AJ, et al. **Res Immunol** 1997 Jan;148(1):13–8 (44 ref.)
[Diseases of the lung and respiratory tract in disorders of immunodeficiency in childhood and adolescence] Roesler J, et al. **Pneumologie** 1996 Nov;50(11):745–51 (37 ref.) **(Ger)**

METABOLISM

Cytokines and production of surfactant components. Bry K, et al. **Semin Perinatol** 1996 Jun;20(3):194–205 (137 ref.)

MICROBIOLOGY

Incidence, etiologic pathogens, and diagnostic testing of community-acquired pneumonia. File TM Jr, et al. **Curr Opin Pulm Med** 1997 Mar;3(2):89–97 (76 ref.)
Atypical pathogen pneumonia. Lieberman D, et al. **Curr Opin Pulm Med** 1997 Mar;3(2):111–5 (35 ref.)
Severe community-acquired pneumonia: what do we need to know to effectively manage patients? [editorial; comment] Niederman MS. **Intensive Care Med** 1996 Dec; 22(12):1285–7 (10 ref.) Comment on: Intensive Care Med 1996 Dec;22(12):1294–300.
Prognosis factors in severe community-acquired pneumonia: a step forward [editorial; comment] Torres A, et al. **Intensive Care Med** 1996 Dec;22(12):1288–90 (19 ref.) Comment on: Intensive Care Med 1996 Dec;22(12):1307–14.
Respiratory infections: community-acquired pneumonia and newer microbes. Reynolds HY. **Lung** 1996;174(4):207–24 (103 ref.)
Afebrile pneumonia in infants. DeMuri GP. **Prim Care** 1996 Dec;23(4):849–60 (38 ref.)
[Pneumonia due to Haemophilus influenzae type b in children: presentation of 24 cases] Otero Reigada MC, et al. **An Esp Pediatr** 1996 Oct;45(4):380–5 (62 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Role of complement, chemokines, and regulatory cytokines in acute lung injury. Ward PA. **Ann N Y Acad Sci** 1996 Oct 31;796:104–12 (28 ref.)
Update '96 on pulmonary gas exchange pathophysiology in pneumonia. Rodriguez-Roisin R, et al. **Semin Respir Infect** 1996 Mar;11(1):3–12 (37 ref.)
[Non-nosocomial pneumonias in the elderly: clinical findings, etiology, therapeutic approach] Janssens JP, et al. **Schweiz Med Wochenschr** 1996 Sep 7;126(36):1515–23 (64 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Potential interventions for the prevention of childhood pneumonia in developing countries: a systematic review. Kirkwood BR, et al. **Bull World Health Organ** 1995; 73(6):793–8 (9 ref.)
How to use an article on therapy or prevention: pneumonia prevention using subglottic secretion drainage [see comments] Cook DJ, et al. **Crit Care Med** 1997 Sep; 25(9):1502–13 (78 ref.) Comment in: Crit Care Med 1997 Sep;25(9):1448–9.
The science of turning [editorial; comment] deBoisblanc BP. **Crit Care Med** 1997 Sep;25(9):1456–7 (13 ref.) Comment on: Crit Care Med 1997 Sep;25(9):1560–4.
Nosocomial pneumonia. Diagnosis and prevention. Mayhall CG. **Infect Dis Clin North Am** 1997 Jun;11(2):427–57 (103 ref.)
Nursing home-acquired pneumonia: avoiding the hospital [editorial; comment] Zimmer JG, et al. **J Am Geriatr Soc** 1997 Mar;45(3):380–1 (14 ref.) Comment on: J Am Geriatr Soc 1997 Mar;45(3):302–6.
[Prevention of acquired pneumonia during artificial ventilation (excluding the use of anti-infectious agents)] Fagon JY, et al. **Rev Mal Respir** 1997 Jan;14(1):13–9 (43 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

[Pneumonia due to Haemophilus influenzae type b in children: presentation of 24 cases] Otero Reigada MC, et al. **An Esp Pediatr** 1996 Oct;45(4):380–5 (62 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Nursing home-acquired pneumonia. Treatment options. Marrie TJ, et al. **Drugs Aging** 1996 May;8(5):338–48 (64 ref.)
Severe community-acquired pneumonia: what do we need to know to effectively manage patients? [editorial; comment] Niederman MS. **Intensive Care Med** 1996 Dec; 22(12):1285–7 (10 ref.) Comment on: Intensive Care Med 1996 Dec;22(12):1294–300.

VETERINARY

An overview of techniques for dealing with large numbers of independent variables in epidemiologic studies. Dohoo IR, et al. **Prev Vet Med** 1997 Jan;29(3):221–39 (24 ref.)

PNEUMONIA, ASPIRATION

Pulmonary aspiration. Lee-Chiong TL Jr. **Compr Ther** 1997 Jun;23(6):371–7 (54 ref.)

DIAGNOSIS

Bedside methods for detecting aspiration in tube-fed patients. Metheny NA, et al. **Chest** 1997 Mar;111(3):724–31 (35 ref.)
Aspiration pneumonia. Strategies for early recognition and prevention. Lomotan JR, et al. **Postgrad Med** 1997 Aug; 102(2):225–6, 229–31 (21 ref.)
[Pneumonia of the aged] Sasaki H. **Nippon Naika Gakkai Zasshi** 1997 Mar 10;86(3):452–6 (11 ref.) **(Jpn)**

ETIOLOGY

Stomach as a source of colonization of the respiratory tract during mechanical ventilation: association with ventilator-associated pneumonia. Torres A, et al. **Eur Respir J** 1996 Aug;9(8):1729–35 (55 ref.)
Enteral feeding associated gastroesophageal reflux and aspiration pneumonia: a review. Kazi N, et al. **Nutr Rev** 1996 Oct;54(10):324–8 (59 ref.)
Microbial causes of ventilator-associated pneumonia. Rello J, et al. **Semin Respir Infect** 1996 Mar;11(1):24–31 (37 ref.)

PREVENTION & CONTROL

Use of tube feeding to prevent aspiration pneumonia [see comments] Finucane TE, et al. **Lancet** 1996 Nov 23; 348(9039):1421–4 (28 ref.) Comment in: Lancet 1997 Feb 8;349(9049):433.
Acute gastric aspiration: prevention and treatment. Rowe TF. **Semin Perinatol** 1997 Aug;21(4):313–9 (45 ref.)

RADIOGRAPHY

Neonatal radiology casebook. Retropharyngeal abscess in the neonate. Gaglani MJ, et al. **J Perinatol** 1996 May–Jun;16(3 Pt 1):231–3 (12 ref.)

RADIOTHERAPY

[Prophylaxis and treatment of aspiration syndrome and complications of artificial lung ventilation with endotracheal laser therapy] Chesnov VS, et al. **Anesteziol Reanimatol** 1996 Jul–Aug;(4):78–9 (3 ref.) **(Rus)**

THERAPY

Pulmonary aspiration complicating intraoperative small-bowel decompression: a case report and literature review. Phillips I, et al. **Can J Surg** 1996 Dec;39(6):495–8 (32 ref.)
Acute gastric aspiration: prevention and treatment. Rowe TF. **Semin Perinatol** 1997 Aug;21(4):313–9 (45 ref.)

PNEUMONIA, BACTERIAL

Thoracic infection after trauma. Richardson JD, et al. **Chest Surg Clin N Am** 1997 May;7(2):401–27 (64 ref.)
Bacterial pneumonia associated with HIV-1 infection. Noskin GA, et al. **Clin Chest Med** 1996 Dec;17(4):713–23 (57 ref.)

Pneumonia in pregnancy. Goodrum LA. **Semin Perinatol** 1997 Aug;21(4):276–83 (47 ref.)
Q fever pneumonia. Antony SJ, et al. **Semin Respir Infect** 1997 Mar;12(1):2–6 (22 ref.)
Plague pneumonia disease caused by Yersinia pestis. Cleri DJ, et al. **Semin Respir Infect** 1997 Mar;12(1):12–23 (65 ref.)
Nosocomial pneumonia in mechanically ventilated adult patients: epidemiology and prevention in 1996. Craven DE, et al. **Semin Respir Infect** 1996 Mar;11(1):32–53 (188 ref.)
Tularemia pneumonia. Gill V, et al. **Semin Respir Infect** 1997 Mar;12(1):61–7 (22 ref.)
Psittacosis. Gregory DW, et al. **Semin Respir Infect** 1997 Mar;12(1):7–11 (10 ref.)
Leptospiral pneumonia. Hill MK, et al. **Semin Respir Infect** 1997 Mar;12(1):44–9 (42 ref.)
Rhodococcus equi pneumonia. Johnson DH, et al. **Semin Respir Infect** 1997 Mar;12(1):57–60 (23 ref.)
Pasteurella multocida pneumonia. Klein NC, et al. **Semin Respir Infect** 1997 Mar;12(1):54–6 (19 ref.)

COMPLICATIONS

Cutaneous and muscular abscesses secondary to Actinomyces meyeri pneumonia. Liaudet L, et al. **Clin Infect Dis** 1996 Jan;22(1):185–6 (9 ref.)
Relationships between periodontal disease and bacterial pneumonia. Scannapieco FA, et al. **J Periodontol** 1996 Oct; 67(10 Suppl):1114–22 (87 ref.)

DIAGNOSIS

Neonatal pleural empyema with group A Streptococcus. Thaarup J, et al. **Acta Paediatr** 1997 Jul;86(7):769–71 (17 ref.)
New perspectives in the diagnosis of nosocomial pneumonia. Gallego M, et al. **Curr Opin Pulm Med** 1997 Mar;3(2):116–9 (25 ref.)
Lactobacillus casei infection in an AIDS patient [letter] Abgrall S, et al. **Eur J Clin Microbiol Infect Dis** 1997 Feb; 16(2):180–2 (7 ref.)
M. Kansasii pulmonary disease in idiopathic CD4+ T-lymphocytopenia. Anzalone G, et al. **Eur Respir J** 1996 Aug;9(8):1754–6 (14 ref.)
The diagnosis and management of bacterial pneumonias in infants and children. Churgay CA. **Prim Care** 1996 Dec; 23(4):821–35 (31 ref.)
Viral and atypical pneumonias. Latham-Sadler BA, et al. **Prim Care** 1996 Dec;23(4):837–48 (18 ref.)
Diagnostic approach to pneumonia in children. Correa AG. **Semin Respir Infect** 1996 Sep;11(3):131–8 (38 ref.)
[Diagnostic procedures in artificially ventilated patients with pneumonia] Clementsen PS, et al. **Ugeskr Laeger** 1996 Sep 30;158(40):5595–9 (33 ref.) (Eng. Abstr.) **(Dan)**
[Bacillus cereus pneumonia after thoracic trauma. Case report and review of the literature] Bastian L, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Feb; 32(2):124–9 (28 ref.) (Eng. Abstr.) **(Ger)**
[Risks and side effects of diagnostic bronchoalveolar lavage in ventilated patients] Zimmermann P, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Mar; 32(3):169–74 (62 ref.) (Eng. Abstr.) **(Ger)**
[The diagnosis of nosocomial pneumonia] Schaberg T, et al. **Dtsch Med Wochenschr** 1997 Jan 17;122(3):61–4 (20 ref.) **(Ger)**
[New pneumonia pathogens, especially Chlamydia pneumoniae and Hantaviruses] Lode H, et al. **Internist (Berl)** 1996 Sep;37(9):882–9 (45 ref.) **(Ger)**
[Diagnosis of pneumonia in artificial ventilation: principles, techniques, results, preliminary recommendations] Ewig S, et al. **Pneumologie** 1996 Oct;50(10):718–31 (87 ref.) **(Ger)**
[Slowly-evolving pneumonia in a 14-year-old boy] Villuendas C, et al. **Enferm Infecc Microbiol Clin** 1995 Dec; 13(10):629–30 (6 ref.) **(Spa)**

DRUG THERAPY

Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease. Brown BA, et al. **Clin Infect Dis** 1997 May;24(5):958–64 (25 ref.)
Therapy for nosocomial pneumonia. Wunderink RG. **Curr Opin Pulm Med** 1997 Mar;3(2):120–4 (27 ref.)
Pneumonia: the impact of antibiotic resistance on its management. Finch RG. **Microb Drug Resist** 1995 Summer; 1(2):149–58 (47 ref.)
Future indications for macrolides. Tarlow MJ, et al. **Pediatr Infect Dis J** 1997 Apr;16(4):457–62 (27 ref.)
The diagnosis and management of bacterial pneumonias in infants and children. Churgay CA. **Prim Care** 1996 Dec; 23(4):821–35 (31 ref.)
[The therapy of nosocomial pneumonia] Lode H, et al. **Dtsch Med Wochenschr** 1997 Jan 24;122(4):93–6 (18 ref.) **(Ger)**

ETIOLOGY

Sinusitis in mechanically ventilated patients and its role in the pathogenesis of nosocomial pneumonia. Bert F., et al. **Eur J Clin Microbiol Infect Dis** 1996 Jul;15(7):533–44 (84 ref.)
Ventilator-associated pneumonia. Dottorini M. **Monaldi Arch Chest Dis** 1996 Aug;51(4):331–4 (47 ref.)
New etiopathogenic concepts of ventilator-associated pneumonia. Cassiere HA, et al. **Semin Respir Infect** 1996 Mar;11(1):13–23 (55 ref.)

MICROBIOLOGY

Role of colonization of the upper intestinal tract in the pathogenesis of ventilator-associated pneumonia [see comments] Bonten MJ, et al. **Clin Infect Dis** 1997 Mar; 24(3):309–19 (80 ref.) Comment in: Clin Infect Dis 1997 Mar;24(3):320–3.
Leclercia adecarboxylata infections: case report and review. Temesgen Z, et al. **Clin Infect Dis** 1997 Jul;25(1):79–81 (11 ref.)
Pulmonary infection with Nocardia species: a report of 10 cases and review. Menéndez R, et al. **Eur Respir J** 1997 Jul;10(7):1542–6 (28 ref.)
Burkholderia cepacia: medical, taxonomic and ecological issues. Govan JR, et al. **J Med Microbiol** 1996 Dec; 45(6):395–407 (129 ref.)
Pneumonia: the impact of antibiotic resistance on its management. Finch RG. **Microb Drug Resist** 1995 Summer; 1(2):149–58 (47 ref.)
Acute otitis media. Maxson S, et al. **Pediatr Rev** 1996 Jun; 17(6):191–5; quiz 196 (18 ref.)
[Cystic fibrosis and chronic Pseudomonas aeruginosa infection. Possibilities for immunologic prophylaxis and therapy] Bisgaard AT, et al. **Ugeskr Laeger** 1997 Sep 22; 159(39):5786–90 (33 ref.) (Eng. Abstr.) **(Dan)**
[Neisseria meningitidis: isolation from low respiratory tract secretions of adult patients] Ferrer Marcellés A, et al. **Rev Clin Esp** 1996 Nov;196(11):741–6 (36 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Nosocomial infections and nosocomial pneumonia. Hong J, et al. **Am J Surg** 1996 Dec;172(6A):33S–37S (43 ref.)

THERAPY

Viral and atypical pneumonias. Latham-Sadler BA, et al. **Prim Care** 1996 Dec;23(4):837–48 (18 ref.)

TRANSMISSION

A household cluster of fulminant group A streptococcus pneumonia associated with toxic shock syndrome–Quebec. **Can Commun Dis Rep** 1996 Mar 15;22(6):41–3 (6 ref.)

PNEUMONIA, EOSINOPHILIC see **PULMONARY EOSINOPHILIA**

PNEUMONIA, INTERSTITIAL see **LUNG DISEASES, INTERSTITIAL**

PNEUMONIA, INTERSTITIAL PLASMA CELL see **PNEUMONIA, PNEUMOCYSTIS CARINII**

PNEUMONIA, LOBAR

[Pneumococcal infections in patients with HIV infections] Lesprit P, et al. **Presse Med** 1997 Feb 22;26(5):243–7 (37 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Antibiotic resistant Streptococcus pneumoniae. Minton EJ, et al. **Thorax** 1996 Aug;51 Suppl 2:S45–50 (57 ref.)

EPIDEMIOLOGY

Issues and challenges: pneumococcal vaccination in pediatrics. Black S, et al. **Pediatr Ann** 1997 Jun;26(6):355–60 (16 ref.)

IMMUNOLOGY

New vaccines for the prevention of pneumococcal infections. Käyhty H, et al. **Emerg Infect Dis** 1996 Oct-Dec; 2(4):289–98 (74 ref.)

PREVENTION & CONTROL

New vaccines for the prevention of pneumococcal infections. Käyhty H, et al. **Emerg Infect Dis** 1996 Oct-Dec; 2(4):289–98 (74 ref.)
Pneumococcus (including childhood immunization) immunization/prophylaxis: recommendations for adults/older adults. **Nurse Pract** 1997 Feb;22(2):110–3 (15 ref.)
Issues and challenges: pneumococcal vaccination in pediatrics. Black S, et al. **Pediatr Ann** 1997 Jun;26(6):355–60 (16 ref.)
[Pneumococcal vaccination--why so rare?] Persili SA, et al. **Schweiz Rundsch Med Prax** 1997 Jul 2;86(27–28):1097–100 (34 ref.) (Eng. Abstr.) **(Ger)**

PNEUMONIA, MYCOPLASMA

COMPLICATIONS

Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra). Tay YK, et al. **J Am Acad Dermatol** 1996 Nov; 35(5 Pt 1):757–60 (48 ref.)
Bronchitis obliterans due to Mycoplasma pneumonia. Leong MA, et al. **Pediatr Pulmonol** 1997 May;23(5):375–81 (19 ref.)

DIAGNOSIS

Severe pleuropneumonia without a cough and myocarditis with mixed mycoplasma infection [letter] Chang AB, et al. **J Paediatr Child Health** 1996 Dec;32(6):546–7 (5 ref.)
Acute bilateral striatal necrosis associated with Mycoplasma pneumoniae infection. Larsen PD, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1124–6 (16 ref.)
Hopkins syndrome associated with Mycoplasma infection. Acharya AB, et al. **Pediatr Neurol** 1997 Jan;16(1):54–5 (15 ref.)
Viral and atypical pneumonias. Latham-Sadler BA, et al. **Prim Care** 1996 Dec;23(4):837–48 (18 ref.)
Mycoplasma infections of the human respiratory tract. Jacobs E. **Wien Klin Wochenschr** 1997 Aug 8;109(14–15):574–7 (12 ref.)

IMMUNOLOGY

Restricted B-cell responses to microbial challenge of the respiratory tract. Walker J, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):197–204 (28 ref.)

MICROBIOLOGY

Interplay between mycoplasma surface proteins, airway cells, and the protean manifestations of mycoplasma-mediated human infections. Baseman JB, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 2):S137–44 (45 ref.)

THERAPY

Viral and atypical pneumonias. Latham-Sadler BA, et al. **Prim Care** 1996 Dec;23(4):837–48 (18 ref.)

VETERINARY

Enzootic pneumonia in pigs. Maes D, et al. **Vet Q** 1996 Sep; 18(3):104–9 (52 ref.)

PNEUMONIA, PNEUMOCOCCAL see **PNEUMONIA, LOBAR**

PNEUMONIA, PNEUMOCYSTIS CARINII

Pneumocystis carinii. Levine SJ. **Clin Chest Med** 1996 Dec; 17(4):665–95 (342 ref.)
Pneumocystis carinii pneumonia. Santamauro JT, et al. **Med Clin North Am** 1997 Mar;81(2):299–318 (102 ref.)

CHEMICALLY INDUCED

Pneumocystis carinii pneumonia in rheumatoid arthritis patients treated with methotrexate. A report of two cases. Roux N, et al. **Rev Rhum Engl Ed** 1996 Jun;63(6):453–6 (30 ref.)
[Pancytopenia and Pneumocystis carinii pneumonia associated with low dose methotrexate pulse therapy for rheumatoid arthritis--case report and review of literature] Kitsuwa S, et al. **Ryumachi** 1996 Jun;36(3):551–8 (43 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Recent advances. HIV infection-II. Beiser C. **BMJ** 1997 Feb 22;314(7080):579–83 (56 ref.)

DIAGNOSIS

A 31-year-old man with a thick-walled cyst. Lando Y, et al. **Chest** 1997 Jun;111(6):1754–6 (9 ref.)
Neutrophilic eccrine hidradenitis in an HIV-infected patient. Sevila A, et al. **Int J Dermatol** 1996 Sep;35(9):651–2 (4 ref.)
Diagnostic strategies for Pneumocystis carinii pneumonia. Kroe DM, et al. **Semin Respir Infect** 1997 Jun;12(2):70–8 (97 ref.)
[Pneumocystis infection in a non-immunocompromised patient] Yassine N, et al. **Rev Mal Respir** 1996 Dec; 13(6):603–6 (10 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Tremors associated with trimethoprim-sulfamethoxazole therapy in a patient with AIDS: case report and review. Aboulafia DM. **Clin Infect Dis** 1996 Mar;22(3):598–600 (10 ref.)
Treatment of Pneumocystis carinii pneumonia in adults with AIDS. Deresinski SC. **Semin Respir Infect** 1997 Jun; 12(2):79–97 (142 ref.)

EPIDEMIOLOGY

Molecular epidemiology of Pneumocystis carinii pneumonia. Beard CB, et al. **Emerg Infect Dis** 1996 Apr-Jun; 2(2):147–50 (34 ref.)

ETIOLOGY

[Pneumocystis pneumonia in patients with steroid-dependent asthma] Dziedziczko A, et al. **Pneumonol Alergol Pol** 1997; 65(5–6):399–405 (24 ref.) **(Pol)**

[Pneumocystis carinii pneumonia in patients with a solid organ transplant (editorial; comment)] Muñoz P. **Rev Clin Esp** 1997 Jan;197(1):1-3 (14 ref.) Comment on: Rev Clin Esp 1997 Jan;197(1):31-4. **(Spa)**

[Pneumocystis carinii pneumonia in patients with a solid organ transplant: a report of 5 cases (see comments)] Ruiz Ruiz J, et al. **Rev Clin Esp** 1997 Jan;197(1):31-4 (59 ref.) (Eng. Abstr.) Comment in: Rev Clin Esp 1997 Jan;197(1):1-3. **(Spa)**

MICROBIOLOGY

Hypertrophic osteoarthropathy associated with Pneumocystis carinii pneumonia and human immunodeficiency virus infection. Gunnarsson G, et al. **Clin Infect Dis** 1996 Mar;22(3):590-1 (9 ref.)

Interactions of parasite and host epithelial cell cycle regulation during Pneumocystis carinii pneumonia. Limper AH, et al. **J Lab Clin Med** 1997 Aug;130(2):132-8 (30 ref.)

PHYSIOPATHOLOGY

Pneumocystis carinii: an atypical fungal micro-organism. Cailliez JC, et al. **J Med Vet Mycol** 1996 Jul-Aug; 34(4):227-39 (159 ref.)

PREVENTION & CONTROL

Primary and secondary prophylaxis for Pneumocystis carinii related complications in HIV patients [editorial] Held M, et al. **Eur Respir J** 1996 May;9(5):868-71 (47 ref.)

Preventing Pneumocystis carinii pneumonia in human immunodeficiency virus-infected children: new guidelines for prophylaxis. CDC, US Public Health Service, and the Infectious Disease Society of America. Grubman S, et al. **Pediatr Infect Dis J** 1996 Feb;15(2):165-8 (19 ref.)

VETERINARY

Pneumocystis carinii in the miniature dachshund: case report and literature review. Lobetti RG, et al. **J Small Anim Pract** 1996 Jun;37(6):280-5 (19 ref.)

PNEUMONIA, PROGRESSIVE INTERSTITIAL, OF SHEEP

Maedi-Visna and ovine progressive pneumonia. de la Concha-Bermejillo A. **Vet Clin North Am Food Anim Pract** 1997 Mar;13(1):13-33 (125 ref.)

IMMUNOLOGY

Lentivirus replication in lymphoid tissue: use of lymphatic cannulation to study the initial stages of infection and immunity. McConnell I, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):417-20 (18 ref.)

PATHOLOGY

Histogenesis of the pulmonary lesions in the course of visna maedi virus-induced pneumonia. Cadoré JL, et al. **Vet Res** 1996;27(4-5):419-26 (46 ref.)

PHYSIOPATHOLOGY

Histogenesis of the pulmonary lesions in the course of visna maedi virus-induced pneumonia. Cadoré JL, et al. **Vet Res** 1996;27(4-5):419-26 (46 ref.)

PNEUMONIA, RADIATION see **RADIATION PNEUMONITIS**

PNEUMONIA, VIRAL

Viruses and other miscellaneous organisms. Wallace JM. **Clin Chest Med** 1996 Dec;17(4):745-54 (101 ref.)

Pneumonia in pregnancy. Goodrum LA. **Semin Perinatol** 1997 Aug;21(4):276-83 (47 ref.)

DIAGNOSIS

Detecting "occult" viral infection after marrow transplantation [editorial; comment] Crawford SW. **Eur Respir J** 1996 Jun;9(6):1115-7 (27 ref.) Comment on: Eur Respir J 1996 Jun;9(6):1195-1200.

Viral and atypical pneumonias. Latham-Sadler BA, et al. **Prim Care** 1996 Dec;23(4):837-48 (18 ref.)

Diagnostic approach to pneumonia in children. Correa AG. **Semin Respir Infect** 1996 Sep;11(3):131-8 (38 ref.)

[New pneumonia pathogens, especially Chlamydia pneumoniae and Hantaviruses] Lode H, et al. **Internist (Berl)** 1996 Sep;37(9):882-9 (45 ref.) **(Ger)**

THERAPY

Respiratory syncytial virus immune globulin intravenous. Wandstrat TL. **Ann Pharmacother** 1997 Jan;31(1):83-8 (36 ref.)

Viral and atypical pneumonias. Latham-Sadler BA, et al. **Prim Care** 1996 Dec;23(4):837-48 (18 ref.)

PNEUMONITIS, HYPERSENSITIVITY see **ALVEOLITIS, EXTRINSIC ALLERGIC**

PNEUMONITIS, INTERSTITIAL see **LUNG DISEASES, INTERSTITIAL**

PNEUMONITIS, RADIATION see **RADIATION PNEUMONITIS**

PNEUMONOLOGY see **PULMONARY DISEASE (SPECIALTY)**

PNEUMOPERICARDIUM

[Pneumopericardium] Sasaki H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):556-8 (7 ref.) **(Jpn)**

MICROBIOLOGY

Afebrile spontaneous pneumopyopericardium. Tsai WC, et al. **Int J Cardiol** 1996 Apr 19;54(1):69-72 (6 ref.)

ULTRASONOGRAPHY

Direct demonstration of an air-fluid interface by two-dimensional echocardiography: a new diagnostic sign of hydropneumopericardium. Antonini-Canterin F, et al. **J Am Soc Echocardiogr** 1996 Mar-Apr;9(2):187-9 (7 ref.)

PNEUMOPERITONEUM

CHEMICALLY INDUCED

Spontaneous pneumothoraces, pneumomediastinum, and pneumoperitoneum: consequences of smoking crack cocaine. Uva JL. **Pediatr Emerg Care** 1997 Feb;13(1):24-6 (29 ref.)

[Disseminated pneumoperitoneum during the therapy of lymphoma with methotrexate and cytosine arabinoside] Kirchner J, et al. **Dtsch Med Wochenschr** 1996 Oct 18; 121(42):1288-91 (15 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Spontaneous perforated pyometra presenting as pneumoperitoneum. Ikematsu Y, et al. **Gynecol Obstet Invest** 1996;42(4):274-6 (11 ref.)

ETIOLOGY

Ruptured splenic abscess as cause of pneumoperitoneum. Puhakka KB, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Mar;166(3):273-4 (6 ref.)

Tension pneumoperitoneum. Chan SY, et al. **West J Med** 1996 Jul-Aug;165(1-2):61-4 (33 ref.)

[Rare differential diagnosis of free intra-abdominal air. Pneumatosis cystoides intestinalis] Scheulen B, et al. **Internist (Berl)** 1996 Dec;37(12):1260-4 (14 ref.) **(Ger)**

[Systemic sclerosis with various gastrointestinal problems including pneumoperitoneum, pneumatosis cystoides intestinalis and malabsorption syndrome] Satoh A, et al. **Ryumachi** 1995 Dec;35(6):927-33 (29 ref.) (Eng. Abstr.) **(Jpn)**

[Pneumoperitoneum in bladder rupture] Félix M, et al. **Acta Med Port** 1997 Feb-Mar;10(2-3):217-9 (10 ref.) (Eng. Abstr.) **(Por)**

RADIOGRAPHY

Radiological confirmation of intraperitoneal free gas. Williams N, et al. **Ann R Coll Surg Engl** 1997 Jan;79(1):8-12 (33 ref.)

[Pneumoperitoneum and pneumoretroperitoneum without perforation] Kirchner J, et al. **Zentralbl Chir** 1996; 121(10):861-5 (12 ref.) (Eng. Abstr.) **(Ger)**

PNEUMOPERITONEUM, ARTIFICIAL

[Laparoscopic surgery without insufflation in gynecology] d'Ercole C, et al. **Contracept Fertil Sex** 1996 Oct; 24(10):723-6 (22 ref.) **(Fre)**

[Are high risk patients candidates for minimally invasive surgery with CO2 pneumoperitoneum? Viewpoint from anesthesiology] Schulte-Steinberg H, et al. **Chirurg** 1996 Jan;67(1):72-6 (33 ref.) (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

[Pathogenesis of puncture-site metastases after laparoscopy] Reymond MA, et al. **Zentralbl Chir** 1997;122(5):387-94 (75 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Open versus closed establishment of pneumoperitoneum in laparoscopic surgery. Bonjer HJ, et al. **Br J Surg** 1997 May; 84(5):599-602 (27 ref.)

[Video-laparoscopic colorectal surgery: critical review of our experience with mixed gasless pneumo-peritoneal method (editorial)] Tenchini P, et al. **G Chir** 1997 Jun-Jul; 18(6-7):325-30 (12 ref.) **(Ita)**

PNEUMORETROPERITONEUM see **RETROPNEUMOPERITONEUM**

PNEUMOTHORAX

see related
HEMOPNEUMOTHORAX
HYDROPNEUMOTHORAX

Diseases of the pleura. Light RW. **Curr Opin Pulm Med** 1997 Jul;3(4):303-4 (19 ref.)

Current aspects of spontaneous pneumothorax. Schramel FM, et al. **Eur Respir J** 1997 Jun;10(6):1372-9 (99 ref.)

CHEMICALLY INDUCED

Chemotherapy-induced spontaneous pneumothorax in a patient with bulky mediastinal lymphoma: a rare oncologic emergency. Stein ME, et al. **Oncology** 1997 Jan-Feb; 54(1):15-8 (18 ref.)

Spontaneous pneumothoraces, pneumomediastinum, and pneumoperitoneum: consequences of smoking crack cocaine. Uva JL. **Pediatr Emerg Care** 1997 Feb;13(1):24-6 (29 ref.)

COMPLICATIONS

Pleural disease in patients with AIDS. Hamm H, et al. **Curr Opin Pulm Med** 1997 Jul;3(4):315-8 (22 ref.)

DIAGNOSIS

[Clinical application of thoracoscopy] Kitamura S. **Nippon Naika Gakkai Zasshi** 1996 Dec 10;85(12):2091-5 (7 ref.) **(Jpn)**

ETIOLOGY

Pneumothorax in pregnancy associated with cocaine use. Chan L, et al. **Am J Perinatol** 1997 Aug;14(7):385-8 (22 ref.)

[A case of bilateral pneumothorax in the patient with Marfan syndrome] Nishida M, et al. **Kyobu Geka** 1996 Jul; 49(7):591-4 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Contralateral pneumothorax occurring during cardiopulmonary resuscitation] Duzhii ID. **Lik Sprava** 1997 Jan-Feb;(1):106-8 (6 ref.) (Eng. Abstr.) **(Rus)**

SURGERY

Video-assisted thoracoscopic management of primary spontaneous pneumothorax. Yim AP. **Ann Acad Med Singapore** 1996 Sep;25(5):668-72 (28 ref.)

Thoracoscopy in the management of spontaneous pneumothorax. Janssen JP. **Int Surg** 1996 Oct-Dec; 81(4):339-42 (63 ref.)

Video assisted thoracic surgery for spontaneous pneumothorax. Berrisford RG, et al. **Thorax** 1996 Aug;51 Suppl 2:S23-8 (42 ref.)

Spontaneous pneumothorax in a patient with an azygos lobe. Sadikot RT, et al. **Thorax** 1997 Jun;52(6):579-80; discussion 575-6 (9 ref.)

[A case of bilateral pneumothorax in the patient with Marfan syndrome] Nishida M, et al. **Kyobu Geka** 1996 Jul; 49(7):591-4 (18 ref.) (Eng. Abstr.) **(Jpn)**

[A case of contralateral pneumothorax after right pneumonectomy] Nishiuchi S, et al. **Kyobu Geka** 1996 Aug; 49(9):725-8 (12 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Pneumothorax in pregnancy associated with cocaine use. Chan L, et al. **Am J Perinatol** 1997 Aug;14(7):385-8 (22 ref.)

Treatment of spontaneous pneumothorax: a more aggressive approach? Baumann MH, et al. **Chest** 1997 Sep; 112(3):789-804 (132 ref.)

Current trends in pleurodesis. Rodriguez-Panadero F. **Curr Opin Pulm Med** 1997 Jul;3(4):319-25 (65 ref.)

Pleurodesis: state of the art. Rodriguez-Panadero F, et al. **Eur Respir J** 1997 Jul;10(7):1648-54 (63 ref.)

Pleural sclerosis for the treatment of pneumothorax and pleural effusion. Light RW, et al. **Lung** 1997;175(4):213-23 (55 ref.)

PNEUMOTHORAX, ARTIFICIAL

[A case of T-cell malignant lymphoma developing in the chest wall of chronic pyothorax after artificial pneumothorax] Kamiya I. **Nippon Kyobu Geka Gakkai Zasshi** 1996 May;44(5):709-13 (11 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Pyothorax-associated lymphoma. Aozasa K. **Int J Hematol** 1996 Dec;65(1):9-16 (23 ref.)

Pleural epidermoid carcinoma from displaced skin following extrapleural pneumothorax in a patient exposed to asbestos. Sapino A, et al. **Virchows Arch** 1996 Oct;429(2-3):173-6 (10 ref.)

PODIATRY

see related
FOOT DISEASES

Usefulness of preoperative testing in pediatric podiatric surgery. Does it influence clinical decisions? Harris EJ. **Clin Podiatr Med Surg** 1997 Jan;14(1):149-78 (15 ref.)

PODOPHYLLOTOXIN

ADVERSE EFFECTS

The molecular pathogenesis of treatment-induced (secondary) leukemias: foundations for treatment and prevention. Karp JE, et al. **Semin Oncol** 1997 Feb; 24(1):103-13 (89 ref.)

THERAPEUTIC USE

Sarah Cannon Cancer Center Consensus Conference on Novel Developments with Podophyllotoxin Therapy. **Semin Oncol** 1996 Dec;23(6 Suppl 13):1-60 (0 ref.)

PODOPHYLLUM

Mandrake toxicity. A case of mistaken identity. Frasca T, et al. **Arch Intern Med** 1997 Sep 22;157(17):2007-9 (21 ref.)

POECILIA

PHYSIOLOGY

Life history evolution in guppies (Poecilia reticulata): guppies as a model for studying the evolutionary biology of aging [editorial] Reznick DN. **Exp Gerontol** 1997 May-Jun; 32(3):245-58 (49 ref.)

POEMS SYNDROME

[POEMS syndrome] Rose C, et al. **Rev Med Interne** 1997 Jul;18(7):553-62 (85 ref.) (Eng. Abstr.) **(Fre)**

[The POEMS syndrome, apropos of 2 cases and review of the literature] de la Peña A, et al. **An Med Interna** 1996 Jun;13(6):291-4 (28 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Pulmonary hypertension associated with POEMS syndrome. Ribadeau-Dumas S, et al. **Eur Respir J** 1996 Aug; 9(8):1760-2 (17 ref.)

Rheumatic manifestations of dysproteinemias and lymphoproliferative disorders. Duna GF, et al. **Rheum Dis Clin North Am** 1996 Feb;22(1):39-51 (107 ref.)

[Multiple myeloma and Takatsuki syndrome] Matsuzaki H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):143-6 (15 ref.) **(Jpn)**

DIAGNOSIS

Massive haemobilia after percutaneous liver biopsy in a patient with POEMS syndrome successfully treated by arterial embolization. Grieco A, et al. **Eur J Gastroenterol Hepatol** 1996 Jun;8(6):595-8 (20 ref.)

ETIOLOGY

Osteosclerotic myeloma and 'POEMS' syndrome. Schey S. **Blood Rev** 1996 Jun;10(2):75-80 (50 ref.)

POETRY

Toward a conceptual alliance about therapeutic alliance: a voyage through the Inferno. Szajnberg NM. **J Am Acad Psychoanal** 1996 Spring;24(1):95-113 (33 ref.)

POIKILODERMA CONGENITALE

COMPLICATIONS

Osteosarcomatosis with Rothmund-Thomson syndrome. el-Khoury JM, et al. **Br J Radiol** 1997 Feb;70:215-8 (11 ref.)

DIAGNOSIS

Hereditary bullous acrokeratotic poikiloderma of Weary-Kindler associated with pseudoainhum and sclerotic bands. Krunic AL, et al. **Int J Dermatol** 1997 Jul; 36(7):529-33 (18 ref.)

METABOLISM

Immunohistochemical, ultrastructural, and molecular features of Kindler syndrome distinguish it from dystrophic epidermolysis bullosa. Shimizu H, et al. **Arch Dermatol** 1997 Sep;133(9):1111-7 (47 ref.)

PATHOLOGY

Immunohistochemical, ultrastructural, and molecular features of Kindler syndrome distinguish it from dystrophic epidermolysis bullosa. Shimizu H, et al. **Arch Dermatol** 1997 Sep;133(9):1111-7 (47 ref.)

Kindler syndrome: report of a case with ultrastructural study and review of the literature. Patrizi A, et al. **Pediatr Dermatol** 1996 Sep-Oct;13(5):397-402 (21 ref.)

POINT MUTATION

Severe mental retardation and macroorchidism without mutation in the FMR1 gene. Reyniers E, et al. **Am J Med Genet** 1996 Aug 9;64(2):408-12 (26 ref.)

A point mutation associated with a severe phenotype of neurofibromatosis 2. MacCollin M, et al. **Ann Neurol** 1996 Sep;40(3):440-5 (29 ref.)

Sodium channel defects in myotonia and periodic paralysis. Cannon SC. **Annu Rev Neurosci** 1996;19:141-64 (78 ref.)

Phenotypic diversity in siblings with partial androgen insensitivity syndrome. Evans BA, et al. **Arch Dis Child** 1997 Jun;76(6):529-31 (27 ref.)

Recent advances in capillary electrophoresis of DNA fragments and PCR products. Righetti PG, et al. **Biochem Soc Trans** 1997 Feb;25(1):267-73 (46 ref.)

Peripheral nerve amyloidosis. Reilly MM, et al. **Brain Pathol** 1996 Apr;6(2):163-77 (118 ref.)

Methods for detection of point mutations: performance and quality assessment. IFCC Scientific Division, Committee on Molecular Biology Techniques. Nollau P, et al. **Clin Chem** 1997 Jul;43(7):1114-28 (99 ref.)

Somatic hypermutability. Wabl M, et al. **Curr Top Microbiol Immunol** 1996;217:203-19 (90 ref.)

Recurrent mutation Asn45-->Ser of glycoprotein IX in Bernard-Soulier syndrome [letter] Donnér M, et al. **Eur J Haematol** 1996 Aug;57(2):178-9 (8 ref.)

Maternally inherited diabetes and deafness: a diabetic subtype associated with a mutation in mitochondrial DNA. Maassen JA, et al. **Horm Metab Res** 1997 Feb;29(2):50-5 (41 ref.)

Phenotype variation and newcomers in ion channel disorders. Bulman DE. **Hum Mol Genet** 1997;6(10):1679-85 (84 ref.)

Genetics of Parkinson's disease. Nussbaum RL, et al. **Hum Mol Genet** 1997;6(10):1687-91 (69 ref.)

GTP cyclohydrolase I gene, dystonia, juvenile parkinsonism, and Parkinson's disease. Nagatsu T, et al. **J Neural Transm Suppl** 1997;49:203-9 (30 ref.)

De novo mutation (Arg98-->Cys) of the myelin P0 gene and uncompaction of the major dense line of the myelin sheath in a severe variant of Charcot-Marie-Tooth disease type 1B. Komiyama A, et al. **J Neurol Sci** 1997 Jul; 149(1):103-9 (31 ref.)

Oxidative stress, mutant SOD1, and neurofilament pathology in transgenic mouse models of human motor neuron disease. Tu PH, et al. **Lab Invest** 1997 Apr;76(4):441-56 (144 ref.)

c-kit Point mutation in patients with myeloproliferative disorders. Kimura A, et al. **Leuk Lymphoma** 1997 Apr; 25(3-4):281-7 (32 ref.)

The non-random distribution of point mutations in leukaemia and myelodysplasia--a possible pointer to their aetiology. Parry TE. **Leuk Res** 1997 Jun;21(6):559-74 (81 ref.)

Severe congenital neutropenia terminating in acute myeloid leukemia: disease progression associated with mutations in the granulocyte-colony stimulating factor receptor gene. Touw IP, et al. **Leuk Res** 1996 Aug;20(8):629-31 (20 ref.)

Analysis of point mutations by use of amber stop codon suppression. Lesley SA. **Methods Mol Biol** 1996;57:65-73 (6 ref.)

PCR-mediated chemical mutagenesis. Roufa DJ. **Methods Mol Biol** 1996;57:357-67 (16 ref.)

Hypomyelinated pt mutant rabbit as a new model of Pelizeaus-Merzbacher disease. Sypecka J, et al. **Neurol Neurochir Pol** 1996;30 Suppl 2:43-7 (24 ref.)

From mutation to myotonia in sodium channel disorders. Cannon SC. **Neuromuscul Disord** 1997 Jun;7(4):241-9 (44 ref.)

Exploring the role of oxygen in Fanconi's anemia. Liebetrau W, et al. **Recent Results Cancer Res** 1997;143:353-67 (31 ref.)

[Hereditary progressive dystonia with marked diurnal fluctuation--clinical features and GTP cyclohydrolase I gene mutations] Tamaru Y, et al. **Nippon Rinsho** 1997 Jan; 55(1):135-8 (21 ref.) (Eng. Abstr.) **(Jpn)**

[The introduction to molecular biology and its application go pediatrics (4): study of mutations in DNA amplified by PCR] Castaño L, et al. **An Esp Pediatr** 1997 Mar; 46(3):305-10 (7 ref.) **(Spa)**

GENETICS

Resistance to activated protein C and a novel factor V gene mutation. Voelkerding KV. **Clin Lab Med** 1996 Mar; 16(1):169-86 (53 ref.)

Genetic aspects of human infertility. Vogt PH. **Int J Androl** 1995 Dec;18 Suppl 2:3-6 (12 ref.)

[Factor V Leiden and activated protein C resistance] Cauchie P, et al. **Rev Med Brux** 1997 Jun;18(3):97-102 (26 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

beta-Galactosidase gene mutations in patients with slowly progressive GM1 gangliosidosis. Kaye EM, et al. **J Child Neurol** 1997 Jun;12(4):242-7 (19 ref.)

POINT-OF-CARE SYSTEMS

The current status of point-of-care monitoring. Gilbert HC, et al. **Int Anesthesiol Clin** 1996 Summer;34(3):243-61 (33 ref.)

Bedside measurement of pulmonary capillary permeability in patients with acute lung injury. What have we learned? [editorial] Rocker GM. **Intensive Care Med** 1996 Jul; 22(7):619-21 (19 ref.)

ORGANIZATION & ADMINISTRATION

Nurses at the bedside. Influencing outcomes. Lamb-Havard J. **Nurs Clin North Am** 1997 Sep;32(3):579-87 (7 ref.)

POINT OF CARE TECHNOLOGY see **POINT-OF-CARE SYSTEMS**

POISON CONTROL CENTERS

ECONOMICS

State of the national's poison centers: 1995 American Association of Poison Control Centers Survey of US Poison Centers. Felberg L, et al. **Vet Hum Toxicol** 1996 Dec;38(6):445-53 (2 ref.)

HISTORY

The nation's first poison control center: taking a stand against accidental childhood poisoning in Chicago. Burda AM, et al. **Vet Hum Toxicol** 1997 Apr;39(2):115-9 (16 ref.)

ORGANIZATION & ADMINISTRATION

The National Poison Information Center in Poland. Jaraczewska W, et al. **J Toxicol Clin Toxicol** 1996; 34(6):669-72 (4 ref.)

Information technologies for clinical toxicology in Russia. Litvinov NN, et al. **J Toxicol Clin Toxicol** 1996;34(6):665-8 (6 ref.)

STANDARDS

Quality management for poison centers. McGuigan MA. **J Toxicol Clin Toxicol** 1997;35(3):283-93 (17 ref.)

The difficulty in handling poisonings associated with Chinese traditional medicine: a poison control center experience for 1991-1993. Deng JF, et al. **Vet Hum Toxicol** 1997 Apr; 39(2):106-14 (37 ref.)

STATISTICS & NUMERICAL DATA

Characterization of fatal beta blocker ingestion: a review of the American Association of Poison Control Centers data from 1985 to 1995. Love JN, et al. **J Toxicol Clin Toxicol** 1997;35(4):353-9 (25 ref.)

POISON IVY DERMATITIS see **DERMATITIS, TOXICODENDRON**

POISONING

see related

ANTIDOTES

Approach to the poisoned patient. Krenzelok EP, et al. **Dis Mon** 1996 Sep;42(9):509-607 (150 ref.)

Poison prevention for the elderly. McGoodwin L. **J Okla State Med Assoc** 1996 May;89(5):173-6 (35 ref.)

Poisoning and overdose. Giorgi DF, et al. **Mt Sinai J Med** 1997 Sep-Oct;64(4-5):283-91 (32 ref.)

COMPLICATIONS

Hemolysis after acetaminophen overdose in a patient with glucose-6-phosphate dehydrogenase deficiency. Wright RO, et al. **J Toxicol Clin Toxicol** 1996;34(6):731-4 (16 ref.)

DIAGNOSIS

Pearls, pitfalls, and updates in toxicology. Kirk M, et al. **Emerg Med Clin North Am** 1997 May;15(2):427-49 (109 ref.)

General principles of acute poisonings. Seifert CF. **S D J Med** 1996 Dec;49(12):465-6 (1 ref.)

DRUG THERAPY

Pharmacological effects of oximes: how relevant are they? van Helden HP, et al. **Arch Toxicol** 1996;70(12):779-86 (44 ref.)

Clinical applications of commonly used contemporary antidotes. A US perspective. Bowden CA, et al. **Drug Saf** 1997 Jan;16(1):9-47 (186 ref.)

Granulocyte-colony stimulating factor in the treatment of colchicine poisoning. Critchley JA, et al. **Hum Exp Toxicol** 1997 Apr;16(4):229-32 (19 ref.)

Are we ready to replace dimercaprol (BAL) as an arsenic antidote? Mückter H, et al. **Hum Exp Toxicol** 1997 Aug; 16(8):460-5 (22 ref.)

Antidotes for methanol and ethylene glycol poisoning [see comments] Jacobsen D, et al. **J Toxicol Clin Toxicol** 1997; 35(2):127-43 (80 ref.) Comment in: J Toxicol Clin Toxicol 1997 ;35(2):145-6. Comment in: J Toxicol Clin Toxicol 1997 ;35(2):147-8. Comment in: J Toxicol Clin Toxicol 1997 ;35(2):149-50.

[Recommendations for treatment of paracetamol poisoning. Danish Medical Society, Study of the Liver] Clemmesen JO, et al. **Ugeskr Laeger** 1996 Nov 25;158(48):6892-5 (20 ref.) (Eng. Abstr.) **(Dan)**

EPIDEMIOLOGY

The eosinophilia-myalgia syndrome and the toxic oil syndrome. Pursuing parallels. Hertzman PA. **Adv Exp Med Biol** 1996;398:339-42 (8 ref.)

ETIOLOGY

Central and peripheral neurotoxic effects of chronic methyl bromide intoxication. De Haro L, et al. **J Toxicol Clin Toxicol** 1997;35(1):29-34 (13 ref.)

[Neurotransmitter transporters--a role of the molecular mechanism in nervous system diseases and drug poisoning] Nakamura S, et al. **Nippon Yakurigaku Zasshi** 1996 Sep;

108(3):99–100 (0 ref.) **(Jpn)**

HISTORY

The nation's first poison control center: taking a stand against accidental childhood poisoning in Chicago. Burda AM, et al. **Vet Hum Toxicol** 1997 Apr;39(2):115–9 (16 ref.)

METABOLISM

Urinary porphyrins and heme biosynthetic enzyme activities measured by HPLC in arsenic toxicity. García-Vargas GG, et al. **Biomed Chromatogr** 1996 Nov–Dec;10(6):278–84 (40 ref.)

MORTALITY

Fatal human poisonings in northern Greece: 1990–1995. Tsoukali H, et al. **Vet Hum Toxicol** 1996 Oct;38(5):366–7 (5 ref.)

PHYSIOPATHOLOGY

Habitual, toxic, and lethal concentrations of 103 drugs of abuse in humans. Repetto MR, et al.
J Toxicol Clin Toxicol 1997;35(1):1–9 (20 ref.)

PREVENTION & CONTROL

Effectiveness of child-resistant packaging on toxin procurement in young poisoning victims. Lembersky RB, et al. **Vet Hum Toxicol** 1996 Oct;38(5):380–3 (9 ref.)

THERAPY

Poisoning and drug overdose. Vernon DD, et al.
Crit Care Clin 1997 Jul;13(3):647–67 (136 ref.)
Pearls, pitfalls, and updates in toxicology. Kirk M, et al.
Emerg Med Clin North Am 1997 May;15(2):427–49 (109 ref.)
Advanced life support for acute toxic injury (TOXALS). Baker DJ. **Eur J Emerg Med** 1996 Dec;3(4):256–62 (12 ref.)
Pemoline induced acute choreoathetosis: case report and review of the literature. Stork CM, et al.
J Toxicol Clin Toxicol 1997;35(1):105–8 (22 ref.)
General principles of acute poisonings. Seifert CF.
S D J Med 1996 Dec;49(12):465–6 (1 ref.)

VETERINARY

Diagnostic and forensic toxicology. Galey FD.
Vet Clin North Am Equine Pract 1995 Dec;11(3):443–54 (8 ref.)

POISONS

ANALYSIS

Nitrotyrosine as biomarker for reactive nitrogen species. van der Vliet A, et al. **Methods Enzymol** 1996;269:175–84 (50 ref.)

POL GENE PRODUCTS see **GENE PRODUCTS, POL**

POL GENES see **GENES, POL**

POL POLYPROTEINS see **GENE PRODUCTS, POL**

POL PROTEIN see **GENE PRODUCTS, POL**

POL I see **DNA POLYMERASE I**

POL II see **DNA POLYMERASE II**

POLAND SYNDROME

[Poland syndrome] Ogino T.
Ryoikibetsu Shokogun Shirizu 1996;(15):291–2 (10 ref.) **(Jpn)**

POLAR RECOMBINATION see **GENE CONVERSION**

POLAR REGIONS see **COLD CLIMATE**

POLARCARDIOGRAPHY see **VECTORCARDIOGRAPHY**

POLARITY OF DEVELOPMENT see **BODY PATTERNING**

POLARITY OF TRANSCRIPTION see **POLARITY OF TRANSLATION**

POLARITY OF TRANSLATION

Vectors with bidirectional reporter genes for studying divergent promoters. Jain VK. **Methods Enzymol** 1996; 273:319–31 (25 ref.)

POLARIZATION, FLUORESCENCE see **FLUORESCENCE POLARIZATION**

POLARON see **GENE CONVERSION**

POLICE

Law enforcement K-9 dog bites: injuries, complications, and trends. Hutson HR, et al. **Ann Emerg Med** 1997 May; 29(5):637–42 (33 ref.)
Distinguishing passive contamination from active cocaine consumption: assessing the occupational exposure of narcotics officers to cocaine. Mieczkowski T.
Forensic Sci Int 1997 Jan 17;84(1–3):87–111 (47 ref.)

STANDARDS

Vision standards in the Royal Canadian Mounted Police: are they reasonable and fair? [see comments] Easterbrook M, et al. **Can J Ophthalmol** 1997 Apr;32(3):153–7 (23 ref.)
Comment in: Can J Ophthalmol 1997 Apr;32(3):145–7.

POLICY MAKING

see related
HEALTH POLICY
PUBLIC POLICY

Reason and protest in the new urban public health movement: an observation on the sociological analysis of political discourse in the 'healthy city'. Milewa T, et al.
Br J Sociol 1996 Dec;47(4):657–70 (40 ref.)
An evaluation of precaution-based approaches as EMF policy tools in community environments. Sahl J, et al.
Environ Health Perspect 1996 Sep;104(9):908–11 (25 ref.)
Choosing among alternative programs for poor children. Currie JM. **Future Child** 1997 Summer–Fall;7(2):113–31 (43 ref.)
Mental health reform and inclusion of the mentally ill: dilemmas of U.S. policy-making. Rochefort DA.
Int J Law Psychiatry 1996 Summer–Fall;19(3–4):223–37 (40 ref.)
Policy matters: critical policy analysis and nursing. Cheek J, et al. **J Adv Nurs** 1997 Apr;25(4):668–72 (23 ref.)
Managing policy research in nursing. Meerabeau L.
J Adv Nurs 1996 Sep;24(3):633–9 (40 ref.)
Strategies for the development of contemporary nursing policy. Jossens MO. **J Prof Nurs** 1997 Jul–Aug;13(4):222–7 (27 ref.)
Fighting tuberculosis in the 1990s: how effective is planning in policy making? Dievler A. **J Public Health Policy** 1997; 18(2):167–87 (90 ref.)
Policy development for compensating workers exposed to crystalline silica in Ontario, Canada. Elinson L, et al.
Scand J Work Environ Health 1995;21 Suppl 2:111–4 (14 ref.)
Practice policies for surgical red blood cell transfusion: surgical transfusion policies. Spence RK.
Semin Hematol 1996 Jan;33(1 Suppl 1):19–22 (42 ref.)
Translating research findings into health policy. Davis P, et al. **Soc Sci Med** 1996 Sep;43(5):865–72 (40 ref.)

POLIODYSTROPHIA CEREBRI see **CEREBRAL SCLEROSIS, DIFFUSE**

POLIOMYELITIS

see related
POSTPOLIOMYELITIS SYNDROME

Poliomyelitis. Kidd D, et al. **Postgrad Med J** 1996 Nov; 72(853):641–7 (57 ref.)
[Neurologic diseases of enterovirus infections: polioviruses, coxsackieviruses, echoviruses, and enteroviruses type 68–72] Manki A, et al. **Nippon Rinsho** 1997 Apr; 55(4):849–54 (19 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Migration: public health issues (polio, hepatitis A, hepatitis B, tuberculosis, diphtheria). Schwanig M. **Biologicals** 1997 Jun;25(2):187–93 (16 ref.)
Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. Alexander JP Jr, et al. **J Infect Dis** 1997 Feb;175 Suppl 1:S176–82 (35 ref.)
The eradication of poliomyelitis in Egypt: critical factors affecting progress to date. Aylward RB, et al.
J Infect Dis 1997 Feb;175 Suppl 1:S56–61 (18 ref.)
Eradication of wild poliovirus from the Americas: acute flaccid paralysis surveillance, 1988–1995. de Quadros CA, et al. **J Infect Dis** 1997 Feb;175 Suppl 1:S37–42 (22 ref.)
Outbreaks of paralytic poliomyelitis, 1976–1995. Patriarca PA, et al. **J Infect Dis** 1997 Feb;175 Suppl 1:S165–72 (114 ref.)
Epidemiology and control of poliomyelitis. Fatusi AO, et al. **J R Soc Health** 1997 Feb;117(1):7–12 (26 ref.)
Epidemiological considerations on age distribution of paralytic poliomyelitis. Singh J, et al. **J Trop Pediatr** 1996 Aug;42(4):237–41 (36 ref.)

IMMUNOLOGY

Vaccination in pulses: a strategy for global eradication of measles and polio? Nokes DJ, et al. **Trends Microbiol** 1997 Jan;5(1):14–9 (37 ref.)

PREVENTION & CONTROL

The eradication of poliomyelitis in Egypt: critical factors affecting progress to date. Aylward RB, et al.
J Infect Dis 1997 Feb;175 Suppl 1:S56–61 (18 ref.)
National immunization days: state of the art. Birmingham ME, et al. **J Infect Dis** 1997 Feb;175 Suppl 1:S183–8 (39 ref.)
Eradication of wild poliovirus from the Americas: acute flaccid paralysis surveillance, 1988–1995. de Quadros CA, et al. **J Infect Dis** 1997 Feb;175 Suppl 1:S37–42 (22 ref.)
The biologic principles of poliovirus eradication. Dowdle WR, et al. **J Infect Dis** 1997 Feb;175 Suppl 1:S286–92 (74 ref.)
Progress toward global polio eradication. Hull HF, et al.
J Infect Dis 1997 Feb;175 Suppl 1:S4–9 (37 ref.)
Overview of poliomyelitis in the African Region and current regional plan of action. Okwo-Bele JM, et al.
J Infect Dis 1997 Feb;175 Suppl 1:S10–5 (20 ref.)
National immunization days: experience in Latin America. Olivé JM, et al. **J Infect Dis** 1997 Feb;175 Suppl 1:S189–93 (21 ref.)
The effect of diarrhea on oral poliovirus vaccine failure in Brazil. Posey DL, et al. **J Infect Dis** 1997 Feb;175 Suppl 1:S258–63 (57 ref.)
Poliomyelitis prevention in the United States: new recommendations for routine childhood vaccination place greater reliance on inactivated poliovirus vaccine. Prevots DR, et al. **Pediatr Ann** 1997 Jun;26(6):378–83 (13 ref.)
Vaccination in pulses: a strategy for global eradication of measles and polio? Nokes DJ, et al. **Trends Microbiol** 1997 Jan;5(1):14–9 (37 ref.)

TRANSMISSION

The biologic principles of poliovirus eradication. Dowdle WR, et al. **J Infect Dis** 1997 Feb;175 Suppl 1:S286–92 (74 ref.)

VIROLOGY

Comments on some new viruses associated with old diseases in China. Zhu J. **Chin Med J (Engl)** 1996 Jan;109(1):5–10 (31 ref.)
Current status of poliovirus infections. Melnick JL.
Clin Microbiol Rev 1996 Jul;9(3):293–300 (40 ref.)
Molecular determinants of Theiler's murine encephalomyelitis-induced disease. Jakob J, et al.
J Neurovirol 1996 Apr;2(2):70–7 (25 ref.)

POLIOVIRUS VACCINE

Overview of poliomyelitis in the African Region and current regional plan of action. Okwo-Bele JM, et al.
J Infect Dis 1997 Feb;175 Suppl 1:S10–5 (20 ref.)
Poliomyelitis prevention in the United States: new recommendations for routine childhood vaccination place greater reliance on inactivated poliovirus vaccine. Prevots DR, et al. **Pediatr Ann** 1997 Jun;26(6):378–83 (13 ref.)
Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. Vidor E, et al.
Pediatr Infect Dis J 1997 Mar;16(3):312–22 (116 ref.)
Inactivated poliovirus vaccine: past and present experience. Murdin AD, et al. **Vaccine** 1996 Jun;14(8):735–46 (118 ref.)

ADVERSE EFFECTS

The African polio vaccine-acquired immune deficiency syndrome connection. Reinhardt V, et al.
Med Hypotheses 1997 May;48(5):367–74 (131 ref.)

POLIOVIRUS VACCINE, ORAL

Stabilising oral poliovaccine at high ambient temperatures. Newman JF, et al. **Dev Biol Stand** 1996;87:103–11 (15 ref.)
Problems encountered in the delivery and storage of OPV in an African country. Schoub BD, et al.
Dev Biol Stand 1996;87:27–32 (13 ref.)
The eradication of poliomyelitis in Egypt: critical factors affecting progress to date. Aylward RB, et al.
J Infect Dis 1997 Feb;175 Suppl 1:S56–61 (18 ref.)
National immunization days: state of the art. Birmingham ME, et al. **J Infect Dis** 1997 Feb;175 Suppl 1:S183–8 (39 ref.)
Progress toward global polio eradication. Hull HF, et al.
J Infect Dis 1997 Feb;175 Suppl 1:S4–9 (37 ref.)
Development of a more thermostable poliovirus vaccine. Milstien JB, et al. **J Infect Dis** 1997 Feb;175 Suppl 1:S247–53 (24 ref.)
The effect of diarrhea on oral poliovirus vaccine failure in Brazil. Posey DL, et al. **J Infect Dis** 1997 Feb;175 Suppl 1:S258–63 (57 ref.)

ANALYSIS

Laboratory tests for live attenuated poliovirus vaccines. Wood DJ, et al. **Biologicals** 1997 Mar;25(1):3–15 (75 ref.)

CHEMISTRY

Thermostability of poliovirus and measles vaccines. Melnick JL. **Dev Biol Stand** 1996;87:155–60 (20 ref.)

GENETICS

Genomic modifications in Sabin vaccine strains isolated from vaccination-associated cases, healthy contacts and healthy vaccinees. Friedrich F. **Acta Virol** 1996 Jun;40(3):157–70 (142 ref.)

TOXICITY

Development of a neurovirulent testing system for oral

POLIOVIRUS VACCINE, ORAL

poliovirus vaccine with transgenic mice. Levenbook I, et al. **Lab Anim Sci** 1997 Apr;47(2):118–20 (28 ref.)

POLIOVIRUSES

CHEMISTRY

Poliovirus: new insights from an old paradigm. Wien MW, et al. **Structure** 1996 Jul 15;4(7):763–7 (23 ref.)

DRUG EFFECTS

Thermostability of poliovirus and measles vaccines. Melnick JL. **Dev Biol Stand** 1996;87:155–60 (20 ref.)

ISOLATION & PURIFICATION

Laboratory tests for live attenuated poliovirus vaccines. Wood DJ, et al. **Biologicals** 1997 Mar;25(1):3–15 (75 ref.)

Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. Alexander JP Jr, et al. **J Infect Dis** 1997 Feb;175 Suppl 1:S176–82 (35 ref.)

Eradication of wild poliovirus from the Americas: acute flaccid paralysis surveillance, 1988–1995. de Quadros CA, et al. **J Infect Dis** 1997 Feb;175 Suppl 1:S37–42 (22 ref.)

PATHOGENICITY

Current status of poliovirus infections. Melnick JL. **Clin Microbiol Rev** 1996 Jul;9(3):293–300 (40 ref.)

Development of a neurovirulent testing system for oral poliovirus vaccine with transgenic mice. Levenbook I, et al. **Lab Anim Sci** 1997 Apr;47(2):118–20 (28 ref.)

PHYSIOLOGY

Poliovirus assembly and encapsidation of genomic RNA. Ansardi DC, et al. **Adv Virus Res** 1996;46:1–68 (232 ref.)

Stabilising oral poliovaccine at high ambient temperatures. Newman JF, et al. **Dev Biol Stand** 1996;87:103–11 (15 ref.)

Early events in poliovirus infection: virus–receptor interactions. Racaniello VR. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11378–81 (29 ref.)

Poliovirus biology. Minor PD. **Structure** 1996 Jul 15; 4(7):775–8 (12 ref.)

POLIOVIRUSES, HUMAN 1–3

GENETICS

Genomic modifications in Sabin vaccine strains isolated from vaccination–associated cases, healthy contacts and healthy vaccinees. Friedrich F. **Acta Virol** 1996 Jun;40(3):157–70 (142 ref.)

IMMUNOLOGY

The effect of diarrhea on oral poliovirus vaccine failure in Brazil. Posey DL, et al. **J Infect Dis** 1997 Feb;175 Suppl 1:S258–63 (57 ref.)

PATHOGENICITY

The biologic principles of poliovirus eradication. Dowdle WR, et al. **J Infect Dis** 1997 Feb;175 Suppl 1:S286–92 (74 ref.)

POLIOVIRUSES, MURINE see **THEILER'S MURINE ENCEPHALOMYELITIS VIRUS**

POLISHES see **INDUSTRIAL OILS**

POLITEF see **POLYTETRAFLUOROETHYLENE**

POLITICAL ACTIVITY see **POLITICS**

POLITICAL SYSTEMS

Social contract and deterring famine: first thoughts. de Waal A. **Disasters** 1996 Sep;20(3):194–205 (25 ref.)

Rethinking the western construction of the welfare state. Walker A, et al. **Int J Health Serv** 1996;26(1):67–92 (69 ref.)

The politics of phenomenological concepts in nursing. Holmes CA. **J Adv Nurs** 1996 Sep;24(3):579–87 (69 ref.)

POLITICS

Adolescence and senescence: new challenges for the Formerly Socialist Economies of Europe (FSE). Balogh A. **Adv Contracept** 1996 Dec;12(4):315–8 (13 ref.)

Persistence is not always a virtue: tort reform, civil liability for health care, and the lack of empirical evidence. Daniels S, et al. **Behav Sci Law** 1997 Winter;15(1):3–19 (104 ref.)

Politics and South African mental health: hope, truth, and reconciliation. Comas–Díaz L, et al. **Cult Divers Ment Health** 1996;2(2):133–8 (14 ref.)

The political economy of inequality in the "age of extremes" [see comments] Hout M, et al. **Demography** 1996 Nov; 33(4):421–5; discussion 427–8 (22 ref.) Comment in: Demography 1996 Nov;33(4):395–412; discussion 413–6.

The symphony of the damned: racial discourse, complex political emergencies and humanitarian aid. Duffield M. **Disasters** 1996 Sep;20(3):173–93 (45 ref.)

The market is a strange creature: family medicine meeting the challenges of the changing political and socioeconomic structure. Westin S. **Fam Pract** 1995 Dec;12(4):394–401 (37 ref.)

Gender, the state, and constructing the old as dependent: lessons from the economic transition in Poland. Calasanti TM, et al. **Gerontologist** 1997 Aug;37(4):452–61 (34 ref.)

Well–healed: inside lobbying for health care reform, Part III. **Int J Health Serv** 1996;26(1):19–46 (30 ref.)

Renewing the National Health Service: Labour's agenda for a healthier Britain. **Int J Health Serv** 1996;26(2):269–308 (0 ref.)

The politics of women's health: setting a global agenda. Doyal L. **Int J Health Serv** 1996;26(1):47–65 (73 ref.)

Policy and ideology: the politics of post–reform health policy in the United Kingdom. Fierlbeck K. **Int J Health Serv** 1996;26(3):529–46 (43 ref.)

The corporate assault on the Food and Drug Administration. Nixon R. **Int J Health Serv** 1996;26(3):561–8 (18 ref.)

Health as an irreversible part of the welfare state: Canadian government policy under the Tories. O'Neill MA. **Int J Health Serv** 1996;26(3):547–59 (41 ref.)

Injury, death, and the deregulation fetish: the politics of occupational safety regulation in U.K. manufacturing industries. Tombs S. **Int J Health Serv** 1996;26(2):309–29 (73 ref.)

Science, politics, and AIDS prevention policy. Bayer R. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 2:S22–9 (20 ref.)

An analysis of nursing in context: the effects of current health policy. Antrobus S. **J Adv Nurs** 1997 Mar;25(3):447–53 (36 ref.)

The technocratic wish: making sense and finding power in the "managed" medical marketplace. Belkin GS. **J Health Polit Policy Law** 1997 Apr;22(2):509–32 (63 ref.)

Going for the gold: the redistributive agenda behind market–based health care reform [see comments] Evans RG. **J Health Polit Policy Law** 1997 Apr;22(2):427–65 (46 ref.) Comment in: J Health Polit Policy Law 1997 Apr;22(2):467–73. Comment in: J Health Polit Policy Law 1997 Apr;22(2):475–96.

The new politics of U.S. health policy. Hacker JS, et al. **J Health Polit Policy Law** 1997 Apr;22(2):315–38 (43 ref.)

Medicaid and the politics of groups: recipients, providers, and policy making [see comments] Kronebusch K. **J Health Polit Policy Law** 1997 Jun;22(3):839–78 (54 ref.) Comment in: J Health Polit Policy Law 1997 Jun;22(3):879–96. Comment in: J Health Polit Policy Law 1997 Jun;22(3):897–906.

The doctor as businessman: the changing politics of a cultural icon. Stone DA. **J Health Polit Policy Law** 1997 Apr; 22(2):533–56 (43 ref.)

Drawing the line: issues of boundary and the homosexual law reform bill campaign in New Zealand (Aotearoa), 1985–86. Atmore C. **J Homosex** 1995;30(1):23–52 (47 ref.)

Organized labor and health reform: union interests and the Clinton plan. Weil LA. **J Public Health Policy** 1997; 18(1):30–48 (81 ref.)

Bringing political ecology into critical medical anthropology: a challenge to biocultural approaches. Baer HA. **Med Anthropol** 1996 Dec;17(2):129–41 (59 ref.)

Toward a political ecology of health in medical anthropology [comment] Baer HA. **Med Anthropol Q** 1996 Dec; 10(4):451–4 (15 ref.) Comment on: Med Anthropol Q 1996 Dec;10(4):455–75. Comment on: Med Anthropol Q 1996 Dec;10(4):476–95. Comment on: Med Anthropol Q 1996 Dec;10(4):496–515.

Politics, practical logic, and primary health care in rural Haiti. Brodwin PE. **Med Anthropol Q** 1997 Mar;11(1):69–88 (58 ref.)

Farewell to adaptationism: unnatural selection and the politics of biology [see comments] Singer M. **Med Anthropol Q** 1996 Dec;10(4):496–515 (74 ref.) Comment in: Med Anthropol Q 1996 Dec;10(4):451–4. Comment in: Med Anthropol Q 1996 Dec;10(4):516–9. Comment in: Med Anthropol Q 1996 Dec;10(4):519–22.

The social, cultural and political dimensions of contemporary war. Summerfield D. **Med Confl Surviv** 1997 Jan–Mar; 13(1):3–25 (39 ref.)

The politics of "Drive–through deliveries": putting early postpartum discharge on the legislative agenda. Declercq E, et al. **Milbank Q** 1997;75(2):175–202 (69 ref.)

Incorporating political socialization theory into baccalaureate nursing education. Brown SG. **Nurs Outlook** 1996 May–Jun;44(3):120–3 (29 ref.)

Stages of nursing's political development: where we've been and where we ought to go. Cohen SS, et al. **Nurs Outlook** 1996 Nov–Dec;44(6):259–66 (64 ref.)

Considerations for research on consumer empowerment and psychosocial interventions. Corrigan PW, et al. **Psychiatr Serv** 1997 Mar;48(3):347–52 (59 ref.)

Lessons from Chernobyl: the event, the aftermath fallout: radioactive, political, social. Robbins J. **Thyroid** 1997 Apr; 7(2):189–92 (30 ref.)

[Epidemiology of HIV infection, demographic consequences and impact on the politics of health in Sub–Saharan Africa] Gentilini M, et al. **Bull Acad Natl Med** 1996 Jun–Jul; 180(6):1475–89 (20 ref.) **(Fre)**

POLLEN

see related
ALLERGENS
HAY FEVER

Pollen allergy in South Africa. Potter PC, et al. **Clin Exp Allergy** 1996 Dec;26(12):1347–54 (28 ref.)

Oleaceae pollinosis: a review. Liccardi G, et al. **Int Arch Allergy Immunol** 1996 Nov;111(3):210–7 (67 ref.)

[Association between air pollen concentrations and seasonal allergies: synthesis of epidemiological studies published between 1978 and 1995] Quénel P, et al. **Rev Epidemiol Sante Publique** 1997 Jun;45(3):224–36 (41 ref.) (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

Proteinases from pollen and pests. Travis J, et al. **Acta Biochim Pol** 1996;43(3):411–7 (23 ref.)

IMMUNOLOGY

The function of allergens may determine allergenicity. Bufe A, et al. **Adv Exp Med Biol** 1996;409:399–402 (18 ref.)

Air pollution and allergy: experimental studies on modulation of allergen release from pollen by air pollutants. Behrendt H, et al. **Int Arch Allergy Immunol** 1997 May–Jul; 113(1–3):69–74 (26 ref.)

Identification of allergens in apple, pear, celery, carrot and potato: cross–reactivity with pollen allergens. Ebner C, et al. **Monogr Allergy** 1996;32:73–7 (21 ref.)

How flowering plants discriminate between self and non–self pollen to prevent inbreeding. Kao TH, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12059–65 (32 ref.)

[Molecular immunology of Japanese cedar pollen allergens: analysis of T cell epitopes] Hashiguchi S, et al. **Nippon Rinsho** 1996 Aug;54(8):2233–42 (24 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Gametes and fertilization in flowering plants. Southworth D. **Curr Top Dev Biol** 1996;34:259–79 (76 ref.)

Pollen embryogenesis. Reynolds TL. **Plant Mol Biol** 1997 Jan;33(1):1–10 (56 ref.)

Creeping walls, softening fruit, and penetrating pollen tubes: the growing roles of expansins [comment] Cosgrove DJ. **Proc Natl Acad Sci U S A** 1997 May 27;94(11):5504–5 (18 ref.) Comment on: Proc Natl Acad Sci U S A 1997 May 27;94(11):5955–60.

POLVIDONE see **POVIDONE**

POLY A

METABOLISM

Polyadenylation of mRNA in prokaryotes. Sarkar N. **Annu Rev Biochem** 1997;66:173–97 (117 ref.)

A comparison of mammalian and yeast pre–mRNA 3'–end processing. Keller W, et al. **Curr Opin Cell Biol** 1997 Jun; 9(3):329–36 (52 ref.)

Polyadenylation of mRNA in bacteria. Sarkar N. **Microbiology** 1996 Nov;142 (Pt 11):3125–33 (80 ref.)

Alternative poly(A) site selection in complex transcription units: means to an end? Edwalds–Gilbert G, et al. **Nucleic Acids Res** 1997 Jul 1;25(13):2547–61 (287 ref.)

Translational control by polyadenylation during early development. Osborne HB, et al. **Prog Mol Subcell Biol** 1997;18:173–98 (100 ref.)

Function and characterization of poly(A)–specific 3' exoribonucleases. Virtanen A, et al. **Prog Mol Subcell Biol** 1997;18:199–220 (120 ref.)

POLY(A)+ MRNA see **RNA, MESSENGER**

POLY(A)+ RNA see **RNA, MESSENGER**

POLY(A) TAIL see **RNA, MESSENGER**

POLY ADENOSINE DIPHOSPHATE RIBOSE

METABOLISM

Poly(ADP–ribosyl)ation and nuclear matrix/intermediate filament proteins in renal carcinogenesis. Vamvakas S, et al. **Recent Results Cancer Res** 1997;143:195–208 (60 ref.)

The role of poly(ADP–ribosyl)ation. Oei SL, et al. **Rev Physiol Biochem Pharmacol** 1997;131:127–73 (340 ref.)

POLY ADP RIBOSE see **POLY ADENOSINE DIPHOSPHATE RIBOSE**

POLY ADP RIBOSE POLYMERASE see **NAD+ ADP–RIBOSYLTRANSFERASE**

POLY(ADP–RIBOSE) SYNTHASE see **NAD+ ADP–RIBOSYLTRANSFERASE**

POLY(LACTIDE–CO–GLYCOSIDE) see **POLYGLACTIN 910**

POLYACRYLAMIDE GEL ELECTROPHORESIS, TWO–DIMENSIONAL see **ELECTROPHORESIS, GEL, TWO–DIMENSIONAL**

POLYADENYLIC ACIDS see **POLY A**

POLYALKENOATE CEMENTS see **GLASS IONOMER CEMENTS**

POLYAMINES

Modulation and block of ion channels: a new biology of polyamines. Williams K. **Cell Signal** 1997 Jan;9(1):1–13 (148 ref.)

The importance of L-arginine metabolism in melanoma: an hypothesis for the role of nitric oxide and polyamines in tumor angiogenesis. Joshi M. **Free Radic Biol Med** 1997; 22(3):573–8 (63 ref.)

Polyamine transport in mammalian cells. An update. Seiler N, et al. **Int J Biochem Cell Biol** 1996 Aug;28(8):843–61 (184 ref.)

[Creation of new supramolecular science with macrocyclic polyamines] Kimura E. **Yakugaku Zasshi** 1996 Aug; 116(8):587–605 (52 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Antioxidative and metal-chelating effects of polyamines. Løvaas E. **Adv Pharmacol** 1997;38:119–49 (174 ref.)

Interactions of polyamines with ion channels. Williams K. **Biochem J** 1997 Jul 15;325 (Pt 2):289–97 (104 ref.)

New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline. Gerlach M, et al. **J Neural Transm Suppl** 1996;48:7–21 (63 ref.)

Pharmacological implications of inward rectifier K+ channels regulation by cytoplasmic polyamines. Taglialatela M, et al. **Pharmacol Res** 1995 Dec;32(6):335–44 (72 ref.)

Polyamines: small molecules triggering pathways in plant growth and development. Walden R, et al. **Plant Physiol** 1997 Apr;113(4):1009–13 (29 ref.)

Polyamines in human health. Wallace HM. **Proc Nutr Soc** 1996 Mar;55(1B):419–31 (69 ref.)

[The catabolism of polyamines] Pavlov V, et al. **Mol Med (Sofia)** 1996;1(2):16–21 (29 ref.) (Eng. Abstr.) **(Bul)**

PHARMACOLOGY

Neuromodulation by Mg2+ and polyamines of excitatory amino acid currents in rodent neurones in culture. Kumamoto E. **Magnes Res** 1996 Dec;9(4):317–27 (50 ref.)

THERAPEUTIC USE

[Gene transfer with amino lipids and amino polymers] Behr JP. **C R Seances Soc Biol Fil** 1996;190(1):33–8 (11 ref.) (Eng. Abstr.) **(Fre)**

POLYANGIACEAE see **MYXOCOCCALES**

POLYANGIUM see **MYXOCOCCALES**

POLYARTERITIS NODOSA

[Systemic necrotizing angitis, hypersensitivity vasculitis] Aizawa O, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (15):179–84 (10 ref.) **(Jpn)**

COMPLICATIONS

Orchitis due to vasculitis in autoimmune diseases. Pannek J, et al. **Scand J Rheumatol** 1997;26(3):151–4 (40 ref.)

Peripheral neuropathy in polyarteritis nodosa. Said G. **Springer Semin Immunopathol** 1996;18(1):75–84 (44 ref.)

[Acute cholecystitis in periarteritis nodosa. 8 cases] Blidi M, et al. **Ann Med Interne (Paris)** 1996;147(5):304–12 (33 ref.) (Eng. Abstr.) **(Fre)**

[Digestive manifestations of periarteritis nodosa] Généreau T, et al. **Gastroenterol Clin Biol** 1997;21(6–7):503–10 (92 ref.) **(Fre)**

[Clinical symptomatology and prognosis of periarteritis nodosa in the elderly. Retrospective study of 25 periarteritis nodosa cases in young adults and 22 cases in aged patients] Puisieux F, et al. **Rev Med Interne** 1997;18(3):195–200 (22 ref.) (Eng. Abstr.) **(Fre)**

[Coping with pathological changes in nerves and blood vessels in collagen disease--vasculitis syndrome and polyneuritis] Nagasawa T, et al. **Nippon Naika Gakkai Zasshi** 1996 Nov 10;85(11):1822–7 (5 ref.) **(Jpn)**

[Pericarditis in collagen vascular diseases] Matsumoto Y. **Ryoikibetsu Shokogun Shirizu** 1996;(13):511–4 (15 ref.) **(Jpn)**

[Pulmonary fibrosis and polyarteritis nodosa (letter)] Sánchez-Angulo JI, et al. **Med Clin (Barc)** 1996 Nov 23; 107(18):719 (7 ref.) **(Spa)**

DIAGNOSIS

Polyarteritis nodosa presenting as ischaemic colitis [letter] Ruiz-Irastorza G, et al. **Br J Rheumatol** 1996 Dec; 35(12):1333–4 (10 ref.)

ETIOLOGY

[A case of Sjögren's syndrome and systemic lupus erythematosus complicated with necrotizing angiitis of the gallbladder] Suwa A, et al. **Ryumachi** 1995 Dec;35(6):904–9 (19 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

[Microscopic polyarteritis] de Ancos Aracil C, et al. **An Med Interna** 1995 Sep;12(9):456–60 (36 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

New developments in the treatment of Wegener's granulomatosis, polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome. Langford CA, et al. **Curr Opin Rheumatol** 1997 Jan;9(1):26–30 (35 ref.)

POLYARTHRALGIA see **ARTHRALGIA**

POLYARTHRITIS see **ARTHRITIS**

POLYAZIRIDINE see **POLYETHYLENEIMINE**

POLYCHEMOTHERAPY see **DRUG THERAPY, COMBINATION**

POLYCHLORINATED BIPHENYLS

ADVERSE EFFECTS

The human health effects of DDT (dichlorodiphenyltrichloroethane) and PCBS (polychlorinated biphenyls) and an overview of organochlorines in public health. Longnecker MP, et al. **Annu Rev Public Health** 1997;18:211–44 (127 ref.)

Epidemiologic perspective of the developmental neurotoxicity of PCBs in humans. Buck GM. **Neurotoxicol Teratol** 1996 May–Jun;18(3):239–41; discussion 271–6 (11 ref.)

Taking a lead from wildlife. Colborn T, et al. **Neurotoxicol Teratol** 1996 May–Jun;18(3):235–7; discussion 271–6 (21 ref.)

Comments on "developmental neurotoxicity of PCBs in humans: what do we know and where do we go from here"? Gray LE Jr. **Neurotoxicol Teratol** 1996 May–Jun; 18(3):243–5; discussion 271–6 (9 ref.)

Different congeners of PCBs/PCDFs may have contributed to different health outcomes in the Yucheng cohort. Guo YL, et al. **Neurotoxicol Teratol** 1996 May–Jun;18(3):255–6; discussion 271–6 (4 ref.)

Sources and implications of interstudy and interindividual variability in the developmental neurotoxicity of PCBs. Jacobson JL, et al. **Neurotoxicol Teratol** 1996 May–Jun; 18(3):257–64; discussion 271–6 (63 ref.)

Adopting a public health approach to developmental neurotoxicity. Paneth N. **Neurotoxicol Teratol** 1996 May–Jun;18(3):233–4; discussion 271–6 (6 ref.)

PCBs and behavioral impairment: are there lessons we can learn from lead? Rice DC. **Neurotoxicol Teratol** 1996 May–Jun;18(3):229–32; discussion 271–6 (28 ref.)

Developmental neurotoxicity of PCBs in humans: what do we know and where do we go from here? [see comments] Schantz SL. **Neurotoxicol Teratol** 1996 May–Jun; 18(3):217–27; discussion 229–76 (73 ref.) Comment in: Neurotoxicol Teratol 1997 Jan–Feb;19(1):1–5.

Can epidemiological studies discern subtle neurological effects due to perinatal exposure to PCBs? Seegal RF. **Neurotoxicol Teratol** 1996 May–Jun;18(3):251–4; discussion 271–6 (32 ref.)

An overview of some reproductive toxicology studies conducted at Health Canada. Foster WG, et al. **Toxicol Ind Health** 1996 May–Aug;12(3–4):447–59 (77 ref.)

[Organic chlorinated pollutants and the thyroid gland] Langer P, et al. **Vnitr Lek** 1996 Sep;42(9):615–9 (53 ref.) (Eng. Abstr.) **(Slo)**

ANALYSIS

[Polychlorinated biphenyls indoors: attempt at an assessment] Sagunski H, et al. **Gesundheitswesen** 1997 Jun;59(6):391–9 (45 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOKINETICS

Using structural information to create physiologically based pharmacokinetic models for all polychlorinated biphenyls. Parham FM, et al. **Toxicol Appl Pharmacol** 1997 Jun; 144(2):340–7 (27 ref.)

POISONING

Comparison of clinical picture between Yusho/Yucheng cases and occupational PCB poisoning cases. Ikeda M. **Chemosphere** 1996 Feb;32(3):559–66 (53 ref.)

TOXICITY

Epidemiological and laboratory evidence of PCB-induced neurotoxicity. Seegal RF. **Crit Rev Toxicol** 1996 Nov; 26(6):709–37 (146 ref.)

The need for cellular, biochemical, and mechanistic studies. Hanneman WH, et al. **Neurotoxicol Teratol** 1996 May–Jun; 18(3):247–50; discussion 271–6 (34 ref.)

Evidence for PCBs as neurodevelopmental toxicants in humans. Jacobson JL, et al. **Neurotoxicology** 1997; 18(2):415–24 (35 ref.)

Structure-activity relationships of potentially neurotoxic PCB congeners in the rat. Kodavanti PR, et al. **Neurotoxicology** 1997;18(2):425–41 (110 ref.)

Teratogen update: polychlorinated biphenyls. Jacobson JL, et al. **Teratology** 1997 May;55(5):338–47 (91 ref.)

POLYCHLOROBIPHENYL COMPOUNDS see **POLYCHLORINATED BIPHENYLS**

POLYCHONDRITIS, CHRONIC ATROPHIC see **POLYCHONDRITIS, RELAPSING**

POLYCHONDRITIS, RELAPSING

[Relapsing polychondritis] Omori H. **Ryoikibetsu Shokogun Shirizu** 1996;(15):357–9 (17 ref.) **(Jpn)**

COMPLICATIONS

Orchitis due to vasculitis in autoimmune diseases. Pannek J, et al. **Scand J Rheumatol** 1997;26(3):151–4 (40 ref.)

Cardiovascular involvement in relapsing polychondritis. Del Rosso A, et al. **Semin Arthritis Rheum** 1997 Jun;26(6):840–4 (26 ref.)

[Relapsing polychondritis with mental disorders: a case report] Watanabe T, et al. **Rinsho Shinkeigaku** 1997 Mar; 37(3):243–8 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Recurrent polychondritis and meningoencephalitis (letter)] Taborcias D, et al. **Med Clin (Barc)** 1996 Nov 2; 107(15):597–8 (10 ref.) **(Spa)**

DIAGNOSIS

Relapsing polychondritis in association with Crohn's disease. Touma DJ, et al. **Am J Otolaryngol** 1996 Nov–Dec; 17(6):424–6 (14 ref.)

[Atrophic polychondritis with multiple arterial occlusions] Skaria AM, et al. **Hautarzt** 1997 Jun;48(6):420–3 (21 ref.) (Eng. Abstr.) **(Ger)**

POLYCYCLIC COMPOUNDS see **POLYCYCLIC HYDROCARBONS**

POLYCYCLIC HYDROCARBONS

ANALYSIS

[Analysis of aromatic DNA adducts in inhabitants of Upper Silesia] Grzybowska E. **Postepy Hig Med Dosw** 1997; 51(2):185–203 (58 ref.) (Eng. Abstr.) **(Pol)**

CHEMICAL SYNTHESIS

[Developments of highly stereoselective domino reactions and application to medicinal chemistry] Fukumoto K. **Yakugaku Zasshi** 1996 Sep;116(9):671–709 (50 ref.) (Eng. Abstr.) **(Jpn)**

TOXICITY

Risk assessment of complex mixtures: some considerations on polycyclic aromatic hydrocarbons in urban areas. Zapponi GA, et al. **J Environ Pathol Toxicol Oncol** 1997; 16(2–3):209–14 (29 ref.)

POLYCYCLIC HYDROCARBONS, AROMATIC

Interactive effects of polycyclic aromatic hydrocarbons and iron oxides particles. Epidemiological and fundamental aspects. Haguenoer JM, et al. **Cent Eur J Public Health** 1996;4 Suppl:41–5 (42 ref.)

Tropospheric air pollution: ozone, airborne toxics, polycyclic aromatic hydrocarbons, and particles. Finlayson-Pitts BJ, et al. **Science** 1997 May 16;276(5315):1045–52 (193 ref.)

ADVERSE EFFECTS

Dose response relationship between occupational PAH exposure and lung cancer--an overview. Bolm-Audorff U. **Cent Eur J Public Health** 1996;4 Suppl:40 (42 ref.)

Polycyclic aromatic hydrocarbons and cancer in man. Mastrangelo G, et al. **Environ Health Perspect** 1996 Nov; 104(11):1166–70 (33 ref.)

ATSDR evaluation of health effects of chemicals. IV. Polycyclic aromatic hydrocarbons (PAHs): understanding a complex problem. Mumtaz MM, et al. **Toxicol Ind Health** 1996 Nov–Dec;12(6):742–971 (1200 ref.)

BLOOD

Methods for routine biological monitoring of carcinogenic PAH-mixtures. Jongeneelen FJ. **Sci Total Environ** 1997 Jun 20;199(1–2):141–9 (57 ref.)

CHEMISTRY

NMR solution structures of stereoisomeric covalent polycyclic aromatic carcinogen-DNA adduct: principles, patterns, and diversity. Geacintov NE, et al. **Chem Res Toxicol** 1997 Feb;10(2):111–46 (165 ref.)

METABOLISM

Polycyclic aromatic hydrocarbon bioremediation design. Harayama S. **Curr Opin Biotechnol** 1997 Jun;8(3):268–73 (45 ref.)

Polycyclic aromatic hydrocarbon metabolites in urine as

biomarkers of exposure and effect. Strickland P, et al. **Environ Health Perspect** 1996 Oct;104 Suppl 5:927–32 (52 ref.)

TOXICITY

The role of diesel exhaust particles and their associated polyaromatic hydrocarbons in the induction of allergic airway disease. Diaz-Sanchez D. **Allergy** 1997;52(38 Suppl):52–6; discussion 57–8 (16 ref.)

Environmental quality objectives for 10 polycyclic aromatic hydrocarbons (PAHs). Kalf DF, et al. **Ecotoxicol Environ Saf** 1997 Feb;36(1):89–97 (46 ref.)

POLYCYSTIC KIDNEY see **KIDNEY, POLYCYSTIC**

POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT see **KIDNEY, POLYCYSTIC, AUTOSOMAL DOMINANT**

POLYCYSTIC KIDNEY, AUTOSOMAL RECESSIVE see **KIDNEY, POLYCYSTIC, AUTOSOMAL RECESSIVE**

POLYCYSTIC OVARY SYNDROME

see related
HYPERANDROGENISM

The polycystic ovary syndrome. Pathogenesis, metabolic implications, and therapeutic approach. Diamanti-Kandarakis E. **Ann N Y Acad Sci** 1997 Jun 17; 816:177–93 (89 ref.)

Adolescent polycystic ovary syndrome. Dramusic V, et al. **Ann N Y Acad Sci** 1997 Jun 17;816:194–208 (22 ref.)

Polycystic ovary syndrome: the present position. Jacobs HS. **Gynecol Endocrinol** 1996 Dec;10(6):427–33 (35 ref.)

COMPLICATIONS

Polycystic ovary syndrome: clinical aspects. Conway GS. **Baillieres Clin Endocrinol Metab** 1996 Apr;10(2):263–79 (55 ref.)

Surgical ovulation induction: the role of ovarian diathermy in polycystic ovary syndrome. Donesky BW, et al. **Baillieres Clin Endocrinol Metab** 1996 Apr;10(2):293–309 (83 ref.)

Polycystic ovary syndrome: induction of ovulation. Homburg R. **Baillieres Clin Endocrinol Metab** 1996 Apr;10(2):281–92 (50 ref.)

Cardiovascular disease and diabetes in women with polycystic ovary syndrome. McKeigue P. **Baillieres Clin Endocrinol Metab** 1996 Apr;10(2):311–8 (35 ref.)

Obesity and female reproductive function. Pettigrew R, et al. **Br Med Bull** 1997;53(2):341–58 (47 ref.)

Insulin resistance in polycystic ovary syndrome. Prelevic GM. **Curr Opin Obstet Gynecol** 1997 Jun;9(3):193–201 (99 ref.)

Laparoscopic procedures for treatment of infertility related to polycystic ovarian syndrome. Cohen J. **Hum Reprod Update** 1996 Jul-Aug;2(4):337–44 (55 ref.)

Ovarian drilling in infertile women with polycystic ovary syndrome. Rose BI. **J Am Assoc Gynecol Laparosc** 1996 May;3(3):461–8 (44 ref.)

Cardiovascular risk in women with polycystic ovarian syndrome. Guzick DS. **Semin Reprod Endocrinol** 1996 Feb; 14(1):45–9 (38 ref.)

Idiopathic intracranial hypertension, empty sella turcica and polycystic ovary syndrome—a case report. Au Eong KG, et al. **Singapore Med J** 1997 Mar;38(3):129–30 (8 ref.)

[Role of surgery in the treatment of infertility due to polycystic ovaries] Pauthier S, et al. **Contracept Fertil Sex** 1996 Nov;24(11):825–9 (31 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Clinical utility of adjuvant growth hormone in the treatment of patients with polycystic ovaries undergoing in vitro fertilization. Artini PG, et al. **J Assist Reprod Genet** 1997 Jan;14(1):4–7 (24 ref.)

ETIOLOGY

Polycystic ovary syndrome: aetiology and management [see comments] Harrington DJ, et al. **Br J Hosp Med** 1996 Jun 19–Jul 9;56(1):17–20 (19 ref.) Comment in: Br J Hosp Med 1997 Feb 19–Mar 4;57(4):172.

Genetic and non-genetic theories on the etiology of polycystic ovary syndrome. Jahanfar S, et al. **Gynecol Endocrinol** 1996 Oct;10(5):357–64 (67 ref.)

GENETICS

Hypersecretion of androgens by polycystic ovaries: the role of genetic factors in the regulation of cytochrome P450c17 alpha. Franks S, et al. **Baillieres Clin Endocrinol Metab** 1996 Apr;10(2):193–203 (33 ref.)

Genetic and non-genetic theories on the etiology of polycystic ovary syndrome. Jahanfar S, et al. **Gynecol Endocrinol** 1996 Oct;10(5):357–64 (67 ref.)

METABOLISM

Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome. Holte J. **Baillieres Clin Endocrinol Metab** 1996 Apr;10(2):221–47 (145 ref.)

Neuroendocrinology of the polycystic ovary syndrome. Soule SG. **Baillieres Clin Endocrinol Metab** 1996 Apr; 10(2):205–19 (59 ref.)

Clinical utility of adjuvant growth hormone in the treatment of patients with polycystic ovaries undergoing in vitro fertilization. Artini PG, et al. **J Assist Reprod Genet** 1997 Jan;14(1):4–7 (24 ref.)

The treatment of patients with polycystic ovaries undergoing IVF. Franks S. **J Assist Reprod Genet** 1997 Jan;14(1):12–4 (12 ref.)

The significance of high follicular-phase luteinizing hormone levels in the treatment of women with polycystic ovarian syndrome by in vitro fertilization. Tarlatzis BC, et al. **J Assist Reprod Genet** 1997 Jan;14(1):1–4 (22 ref.)

Metabolic aspects of polycystic ovary syndrome. Wild RA. **Semin Reprod Endocrinol** 1997 May;15(2):105–10 (26 ref.)

PHYSIOPATHOLOGY

The insulin resistance syndrome. Smolar EN. **Compr Ther** 1997 Apr;23(4):237–43 (45 ref.)

Circulating and ovarian IGF binding proteins: potential roles in normo-ovulatory cycles and in polycystic ovarian syndrome. Giudice LC, et al. **Prog Growth Factor Res** 1995; 6(2–4):397–408 (48 ref.)

Pathophysiology of ovarian steroid secretion in polycystic ovary syndrome. Barnes RB. **Semin Reprod Endocrinol** 1997 May;15(2):159–68 (61 ref.)

Can polycystic ovary syndrome exist without concomitant hypothalamic dysfunction? Berga SL, et al. **Semin Reprod Endocrinol** 1997 May;15(2):169–75 (40 ref.)

Insulin-like growth factor binding proteins: do they play a role in polycystic ovary syndrome? Cataldo NA. **Semin Reprod Endocrinol** 1997 May;15(2):123–36 (143 ref.)

Growth factors and polycystic ovarian syndrome. Giudice LC, et al. **Semin Reprod Endocrinol** 1996 Aug;14(3):203–8 (42 ref.)

Adrenal involvement in polycystic ovary syndrome. Gonzalez F. **Semin Reprod Endocrinol** 1997 May; 15(2):137–57 (129 ref.)

Role of growth hormone in polycystic ovarian syndrome. Morales AJ. **Semin Reprod Endocrinol** 1997 May; 15(2):177–82 (50 ref.)

Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Nestler JE. **Semin Reprod Endocrinol** 1997 May; 15(2):111–22 (91 ref.)

SURGERY

Ovarian drilling in infertile women with polycystic ovary syndrome. Rose BI. **J Am Assoc Gynecol Laparosc** 1996 May;3(3):461–8 (44 ref.)

Surgical approaches to ovulation induction. Shanti A, et al. **Semin Reprod Endocrinol** 1997 May;15(2):183–91 (64 ref.)

[Role of surgery in the treatment of infertility due to polycystic ovaries] Pauthier S, et al. **Contracept Fertil Sex** 1996 Nov;24(11):825–9 (31 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Polycystic ovary syndrome: aetiology and management [see comments] Harrington DJ, et al. **Br J Hosp Med** 1996 Jun 19–Jul 9;56(1):17–20 (19 ref.) Comment in: Br J Hosp Med 1997 Feb 19–Mar 4;57(4):172.

Polycystic ovarian disease. Barnes RB. **Curr Ther Endocrinol Metab** 1997;6:256–9 (7 ref.)

Treatment of polycystic ovary patients undergoing IVF. Barri PN, et al. **J Assist Reprod Genet** 1997 Jan;14(1):10–2 (17 ref.)

In vitro fertilization treatment in patients with polycystic ovaries. Shulman A, et al. **J Assist Reprod Genet** 1997 Jan; 14(1):7–10 (19 ref.)

The significance of high follicular-phase luteinizing hormone levels in the treatment of women with polycystic ovarian syndrome by in vitro fertilization. Tarlatzis BC, et al. **J Assist Reprod Genet** 1997 Jan;14(1):1–4 (22 ref.)

ULTRASONOGRAPHY

Ultrasound diagnosis of polycystic ovary syndrome. Kyei-Mensah A, et al. **Baillieres Clin Endocrinol Metab** 1996 Apr;10(2):249–62 (50 ref.)

POLYCYTHEMIA

ABC of clinical haematology. Polycythaemia, primary (essential) thrombocythaemia and myelofibrosis. Messinezy M, et al. **BMJ** 1997 Feb 22;314(7080):587–90 (0 ref.)

[Clinical implications of high blood viscosity and its reduction bu photo-hemotherapy] Karandashov VI, et al. **Klin Med (Mosk)** 1997;75(8):19–23 (37 ref.) (Eng. Abstr.) **(Rus)**

COMPLICATIONS

Wilms tumor associated with polycythemia: case report and review of the literature. Lal A, et al. **J Pediatr Hematol Oncol** 1997 May-Jun;19(3):263–5 (19 ref.)

DIAGNOSIS

Diagnostic applications of haemopoietic progenitor culture techniques in polycythaemias and thrombocythaemias. Westwood NB, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:95–103 (91 ref.)

Investigation of patients with polycythaemia. Pearson TC, et al. **Postgrad Med J** 1996 Sep;72(851):519–24 (22 ref.)

[Polycythemia] Takeyama H. **Ryoikibetsu Shokogun Shirizu** 1996;(15):139–42 (12 ref.) **(Jpn)**

DRUG THERAPY

Posttransplant erythrocytosis: a model for the investigation of the pharmacological control of renal erythropoietin production? Gleiter CH. **Int J Clin Pharmacol Ther** 1996 Nov;34(11):489–92 (32 ref.)

Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Petitt RM, et al. **Semin Hematol** 1997 Jan;34(1):51–4 (5 ref.)

ETIOLOGY

Giant uterine fibromyoma producing secondary polycythemia. Clark CL, et al. **Obstet Gynecol** 1994 Oct; 84(4 Pt 2):722–4 (10 ref.)

GENETICS

"Benign erythrocytosis" and other familial and congenital polycythemias. Prchal JT, et al. **Eur J Haematol** 1996 Oct; 57(4):263–8 (35 ref.)

Erythropoietin receptor mutations and human disease. Gregg XT, et al. **Semin Hematol** 1997 Jan;34(1):70–6 (46 ref.)

[Erythropoietin receptor] Komatsu N. **Nippon Rinsho** 1997 Apr;55 Suppl 2:508–11 (9 ref.) **(Jpn)**

METABOLISM

Posttransplant erythrocytosis: a model for the investigation of the pharmacological control of renal erythropoietin production? Gleiter CH. **Int J Clin Pharmacol Ther** 1996 Nov;34(11):489–92 (32 ref.)

POLYCYTHEMIA VERA

Epilogue: broader lessons from the study of polycythemia vera. Berk PD. **Semin Hematol** 1997 Jan;34(1):77–80 (8 ref.)

Prologue: polycythemia vera. The closing of the Wasserman-Polycythemia Vera Study Group era. Berlin NI. **Semin Hematol** 1997 Jan;34(1):1–5 (43 ref.)

The very long-term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981. Najean Y, et al. **Semin Hematol** 1997 Jan;34(1):6–16 (45 ref.)

COMPLICATIONS

[Surgical treatment of aortic stenosis with polycythemia vera: a case report] Matsuyama N, et al. **Kyobu Geka** 1996 Dec; 49(13):1097–9 (15 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

The diagnostic criteria of polycythaemia rubra vera. Pearson TC, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:87–93 (45 ref.)

[Polycythemia] Takeyama H. **Ryoikibetsu Shokogun Shirizu** 1996;(15):139–42 (12 ref.) **(Jpn)**

DRUG THERAPY

New drugs in essential thrombocythemia and polycythemia vera. Tefferi A, et al. **Blood Rev** 1997 Mar;11(1):1–7 (87 ref.)

Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives. Landolfi R, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:83–6 (22 ref.)

From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Fruchtman SM, et al. **Semin Hematol** 1997 Jan;34(1):17–23 (21 ref.)

PATHOLOGY

Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias". Najean Y, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:111–9 (42 ref.)

Diagnostic criteria of the myeloproliferative disorders (MPD): essential thrombocythaemia, polycythaemia vera and chronic megakaryocytic granulocytic metaplasia. Michiels JJ. **Neth J Med** 1997 Aug;51(2):57–64 (45 ref.)

In vitro erythropoiesis in polycythemia vera and other myeloproliferative disorders. Weinberg RS. **Semin Hematol** 1997 Jan;34(1):64–9 (55 ref.)

[Polycythemia vera progressing to acute lymphoblastic leukemia after 13 years] Arai Y, et al. **Rinsho Ketsueki** 1996 Dec;37(12):1405–9 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Polycythemia vera as a multiphasic clonal panmyelopathy: diagnostic profile, chronic pathological progression and effect of therapy on the survival of 74 cases] Sánchez Fayos J, et al. **Sangre (Barc)** 1996 Dec;41(6):447–57 (55 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

The present state of pathophysiology and therapeutic trials in polycythemia vera [published erratum appears in Int J Hematol 1997 Feb;65(2):191] Heimpel H. **Int J Hematol** 1996 Oct;64(3–4):153–65 (82 ref.)
Feasibility of randomised clinical trials in rare diseases: the case of polycythemia vera. Marchioli R, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:121–7 (18 ref.)
Interferon treatment in polycythaemia vera. Reilly JT, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:143–8 (64 ref.)

POLYDACTYLY

Femoral hypoplasia–unusual facies syndrome with bifid hallux, absent tibia, and macrophallus: a report of a Bedouin baby. Sabry MA, et al. **J Med Genet** 1996 Feb;33(2):165–7 (9 ref.)
[Meckel syndrome] Yoshida K, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):406–9 (3 ref.) **(Jpn)**

DIAGNOSIS

Bardet–Biedl syndrome: delayed diagnosis in a child with Hirschsprung disease [letter] Işlek I, et al. **Clin Dysmorphol** 1996 Jul;5(3):271–3 (7 ref.)
Prenatal diagnosis of the split hand anomaly: how early is early? Haratz–Rubinstein N, et al. **Ultrasound Obstet Gynecol** 1996 Jul;8(1):57–61 (28 ref.)
[The McKusick–Kaufman syndrome: a report of 5 new cases, including a male] Paredes Esteban RM, et al. **An Esp Pediatr** 1996 May;44(5):493–5 (17 ref.) **(Spa)**

GENETICS

Genetic aspects of polydactyly. Zguricas J, et al. **Handchir Mikrochir Plast Chir** 1996 Jul;28(4):171–5 (15 ref.)

ULTRASONOGRAPHY

[Meckel syndrome. Update on a recurrent case] Calmelet P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997; 26(4):435–41 (35 ref.) (Eng. Abstr.) **(Fre)**

POLYDEOXYRIBONUCLEOTIDE LIGASES see **POLYDEOXYRIBONUCLEOTIDE SYNTHETASES**

POLYDEOXYRIBONUCLEOTIDE SYNTHETASES

CHEMISTRY

Closing the gap on DNA ligase. Shuman S. **Structure** 1996 Jun 15;4(6):653–6 (10 ref.)

METABOLISM

Ligase chain reaction for site-directed in vitro mutagenesis. Rouwendal GJ, et al. **Methods Mol Biol** 1996;57:149–56 (14 ref.)

POLYDEOXYRIBONUCLEOTIDES

An integrated view of the activities of defibrotide. Pescador R, et al. **Semin Thromb Hemost** 1996;22 Suppl 1:71–5 (70 ref.)

PHARMACOLOGY

Modulation of venous endothelial activity and transcellular calcium transport by defibrotide: the adenosine hypothesis. Pasini FL, et al. **Semin Thromb Hemost** 1996;22 Suppl 1:15–20 (43 ref.)
Effect of defibrotide on platelet function. Ulutin ON, et al. **Semin Thromb Hemost** 1996;22 Suppl 1:21–4 (32 ref.)

THERAPEUTIC USE

Clinical trials with defibrotide in vascular disorders. Cimminiello C. **Semin Thromb Hemost** 1996;22 Suppl 1:29–34 (42 ref.)
Defibrotide as a possible anti-ischemic drug. Coccheri S, et al. **Semin Thromb Hemost** 1996;22 Suppl 1:9–14 (42 ref.)

POLYENDOCRINOPATHIES, AUTOIMMUNE

Type 2 polyglandular autoimmune disease (Schmidt's syndrome). Betterle C, et al. **J Pediatr Endocrinol Metab** 1996 Mar;9 Suppl 1:113–23 (51 ref.)

COMPLICATIONS

Liver disease in polyglandular autoimmune disease type one: clinicopathologic study of three patients and review of the literature. Goldstein NS, et al. **Pediatr Pathol Lab Med** 1996 Jul–Aug;16(4):625–36 (38 ref.)

DIAGNOSIS

Cutaneous hyperpigmentation and polyglandular autoimmune syndrome type II. Chung AD, et al. **Cutis** 1997 Feb;59(2):77–80 (18 ref.)

IMMUNOLOGY

Autoimmune polyendocrinopathy—candidiasis—ectodermal dystrophy (APECED). Perheentupa J. **Horm Metab Res** 1996 Jul;28(7):353–6 (13 ref.)

PATHOLOGY

Liver disease in polyglandular autoimmune disease type one: clinicopathologic study of three patients and review of the literature. Goldstein NS, et al. **Pediatr Pathol Lab Med** 1996 Jul–Aug;16(4):625–36 (38 ref.)

THERAPY

[A case of the successful use of plasmapheresis in the combined treatment of a female patient with autoimmune agranulocytosis against a background of Schmidt's syndrome] Vlasenko AN, et al. **Ter Arkh** 1997;69(2):64–5 (10 ref.) **(Rus)**

POLYENES

ADVERSE EFFECTS

Clinically significant drug interactions with new immunosuppressive agents. Mignat C. **Drug Saf** 1997 Apr; 16(4):267–78 (62 ref.)

IMMUNOLOGY

Immunopharmacology of rapamycin. Abraham RT, et al. **Annu Rev Immunol** 1996;14:483–510 (135 ref.)

METABOLISM

Polyenes and vision. Rando RR. **Chem Biol** 1996 Apr; 3(4):255–62 (20 ref.)

PHARMACOLOGY

Immunopharmacology of rapamycin. Abraham RT, et al. **Annu Rev Immunol** 1996;14:483–510 (135 ref.)
[Growth inhibition of human pancreatic cancer by farnesyl transferase inhibitor] Kainuma O, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1657–9 (6 ref.) (Eng. Abstr.) **(Jpn)**
[Antifungal resistance in opportunistic pathogenic fungi (I). Polyenes and fluorocytosine] Martínez–Suárez JV, et al. **Enferm Infecc Microbiol Clin** 1996 Jun–Jul;14(6):384–9 (43 ref.) **(Spa)**

THERAPEUTIC USE

Sirolimus: a new agent for clinical renal transplantation. Kahan BD. **Transplant Proc** 1997 Feb–Mar;29(1–2):48–50 (23 ref.)
[Effect of orally administered polyene antimycotics on the intestinal colonization with yeasts: possibilities and limitations] Blaschke–Hellmessen R, et al. **Mycoses** 1996; 39 Suppl 1:33–9 (17 ref.) (Eng. Abstr.) **(Ger)**

POLYERGIN see **TRANSFORMING GROWTH FACTOR BETA**

POLYESTERS

Current concepts of absorbable fixation in first ray surgery. Cicchinelli LD, et al. **Clin Podiatr Med Surg** 1996 Jul; 13(3):533–47 (45 ref.)

ADMINISTRATION & DOSAGE

Protein delivery from biodegradable microspheres. Cleland JL. **Pharm Biotechnol** 1997;10:1–43 (120 ref.)

METABOLISM

Biodegradable polyesters. Sasikala C, et al. **Adv Appl Microbiol** 1996;42:97–218 (630 ref.)

POLYETHYLENE GLYCOLS

Hydrogels as mucoadhesive and bioadhesive materials: a review. Peppas NA, et al. **Biomaterials** 1996 Aug; 17(16):1553–61 (109 ref.)
[Chemical modification of proteins by polyethylene glycol] Uemura T, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep; 41(11):1607–13 (26 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Polyethylene glycol–liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS–related Kaposi's sarcoma. Coukell AJ, et al. **Drugs** 1997 Mar; 53(3):520–38 (68 ref.)
Poly(ethylene glycol)–coated nanospheres: potential carriers for intravenous drug administration. Gref R, et al. **Pharm Biotechnol** 1997;10:167–98 (100 ref.)
[A case of rectal varices treated with endoscopic injection sclerotherapy] Zeniya A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Jan;94(1):38–43 (19 ref.) **(Jpn)**

PHARMACOLOGY

Dual effects of allergen–mPEG conjugates. Induction of immunological suppression and inactivation of sensitized mast cells. Sehon AH, et al. **Adv Exp Med Biol** 1996; 409:177–84 (17 ref.)

THERAPEUTIC USE

Polyethylene glycol modification: relevance of improved methodology to tumour targeting. Francis GE, et al. **J Drug Target** 1996;3(5):321–40 (84 ref.)

POLYETHYLENE TEREPHTHALATES

Late disruption of Dacron aortic grafts. Wilson SE, et al. **Ann Vasc Surg** 1997 Jul;11(4):383–6 (19 ref.)

POLYETHYLENEIMINE

THERAPEUTIC USE

[Gene transfer with amino lipids and amino polymers] Behr JP. **C R Seances Soc Biol Fil** 1996;190(1):33–8 (11 ref.) (Eng. Abstr.) **(Fre)**

POLYETHYLENES

Polyethylene wear in total hip and knee arthroplasties. Lewis G. **J Biomed Mater Res** 1997 Spring;38(1):55–75 (118 ref.)

ADVERSE EFFECTS

Osteolysis due to particle wear debris following total hip arthroplasty: the role of high-density polyethylene. Wroblewski BM. **Instr Course Lect** 1994;43:289–94 (12 ref.)

POLYGALACTOSES see **GALACTANS**

POLYGLACTIN 910

METABOLISM

Injectable microcapsules prepared with biodegradable poly(alpha-hydroxy) acids for prolonged release of drugs. Ogawa Y. **J Biomater Sci Polym Ed** 1997;8(5):391–409 (85 ref.)

POLYGLANDULAR TYPE I AUTOIMMUNE SYNDROME see **POLYENDOCRINOPATHIES, AUTOIMMUNE**

POLYGLANDULAR TYPE II AUTOIMMUNE SYNDROME see **POLYENDOCRINOPATHIES, AUTOIMMUNE**

POLYGLUCOSES see **GLUCANS**

POLYGLUTAMATE FOLATES see **PTEROYLPOLYGLUTAMIC ACIDS**

POLYGLUTAMIC ACID

Methotrexate: an effective agent for treating cancer and building careers. The polyglutamate era. Schilsky RL. **Stem Cells** 1996 Jan;14(1):29–32 (10 ref.)

POLYGLYCOLIC ACID

ADVERSE EFFECTS

Complications of hydroxyapatite orbital implants. A review of 100 consecutive cases and a comparison of Dexon mesh (polyglycolic acid) with scleral wrapping. Oestreicher JH, et al. **Ophthalmology** 1997 Feb;104(2):324–9 (20 ref.)

PHARMACOKINETICS

Absorbable polyglycolide devices in trauma and bone surgery. Ashammakhi N, et al. **Biomaterials** 1997 Jan; 18(1):3–9 (101 ref.)

POLYGLYCOLIDE see **POLYGLYCOLIC ACID**

POLYGONUM see **PLANTS, MEDICINAL**

POLYHYDRAMNIOS

Polyhydramnios. Moise KJ Jr. **Clin Obstet Gynecol** 1997 Jun; 40(2):266–79 (65 ref.)
Antenatal–onset infantile cortical hyperostosis and nonimmune hydrops. Herman TE. **J Perinatol** 1996 Mar–Apr;16(2 Pt 1):137–9 (13 ref.)

DIAGNOSIS

Clinical assessment of amniotic fluid. Moore TR. **Clin Obstet Gynecol** 1997 Jun;40(2):303–13 (52 ref.)

ETIOLOGY

[Changes in the amniotic fluid volume in fetal structural anomalies] Khaidar A, et al. **Akush Ginekol (Sofiia)** 1997; 36(1):18–21 (20 ref.) **(Bul)**
[A rare cause of polyhydramnios: Steinert's syndrome. A clinical case report] Palmerio G, et al. **Minerva Ginecol** 1997 Jan–Feb;49(1–2):49–52 (10 ref.) (Eng. Abstr.) **(Ita)**

POLYISOCYANATES see **POLYURETHANES**

POLYISOPRENYL PHOSPHATE SUGARS

METABOLISM

Prospects for the bioengineering of isoprenoid biosynthesis. McCaskill D, et al. **Adv Biochem Eng Biotechnol** 1997; 55:107–46 (225 ref.)

POLYISOPRENYL PHOSPHATES

Novel lipids and cancer. Isoprenoids and other phytochemicals. Elson CE. **Adv Exp Med Biol** 1996; 399:71–86 (131 ref.)

Phosprenyl: a novel drug with antiviral and immunomodulatory activity. Danilov LL, et al. **Arch Immunol Ther Exp (Warsz)** 1996;44(5–6):395–400 (13 ref.)

BIOSYNTHESIS

Organization of isoprenoid biosynthesis. Parmryd I, et al. **Biochem Soc Trans** 1996 Aug;24(3):677–82 (30 ref.)

METABOLISM

Prospects for the bioengineering of isoprenoid biosynthesis. McCaskill D, et al. **Adv Biochem Eng Biotechnol** 1997; 55:107–46 (225 ref.)

POLYKARYOCYTES see **GIANT CELLS**

POLYLYSINE

GENETICS

[Selective transfection of animal cells by non viral vectors: polylysine carrying recognition signals] Monsigny M, et al. **C R Seances Soc Biol Fil** 1996;190(1):39–43 (14 ref.) (Eng. Abstr.) **(Fre)**

POLYMENORRHEA see **MENSTRUATION DISORDERS**

POLYMERASE CHAIN REACTION

see related

SEQUENCE TAGGED SITES

Polymerase chain reaction and its application for the diagnosis and management of skin diseases. Feldman SR, et al. **Adv Dermatol** 1997;12:115–36; discussion 137 (128 ref.)

DNA-based methods in the detection of Leishmania parasites: field applications and practicalities. Wilson SM. **Ann Trop Med Parasitol** 1995 Dec;89 Suppl 1:95–100 (25 ref.)

The role of nucleic acid amplification and detection in the clinical microbiology laboratory. Whelen AC, et al. **Annu Rev Microbiol** 1996;50:349–73 (210 ref.)

PCR and sero-diagnosis of chronic Chagas' disease. Biotechnological advances. Gomes YM. **Appl Biochem Biotechnol** 1997 May;66(2):107–19 (44 ref.)

Applications of molecular biology to analyses of forensic evidence. Baechtel FS, et al. **Biologicals** 1996 Sep; 24(3):201–5 (54 ref.)

Diagnostic polymerase chain reaction. Reizenstein E. **Dev Biol Stand** 1997;89:247–54 (26 ref.)

Application of PCR for fetal cell detection. Lo YM. **Early Hum Dev** 1996 Dec 30;47 Suppl:S73–7 (26 ref.)

Cytomegalovirus enteritis in a nonimmunocompromised host: usefulness of polymerase chain reaction by using paraffin-embedded biopsy specimen for the diagnosis. Yoshida M, et al. **Gastrointest Endosc** 1996 Oct;44(4):482–5 (19 ref.)

Role of polymerase chain reaction in the diagnosis of gastric syphilis [editorial; comment] Norris SJ, et al. **Hum Pathol** 1996 Aug;27(8):749–50 (11 ref.) Comment on: Hum Pathol 1996 Aug;27(8):761–5.

Riboprinting: a tool for the study of genetic diversity in microorganisms. Clark CG. **J Eukaryot Microbiol** 1997 Jul–Aug;44(4):277–83 (52 ref.)

Advances in the genetics of movement disorders: implications for molecular diagnosis. Gasser T. **J Neurol** 1997 Jun; 244(6):341–8 (72 ref.)

Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. Gomella LG, et al. **J Urol** 1997 Aug;158(2):326–37 (87 ref.)

DNA typing in forensic medicine and in criminal investigations: a current survey. Benecke M. **Naturwissenschaften** 1997 May;84(5):181–8 (100 ref.)

Functional and molecular analysis of glutamate-gated channels by patch-clamp and RT-PCR at the single cell level. Audinat E, et al. **Neurochem Int** 1996 Feb; 28(2):119–36 (49 ref.)

Fetal RhD typing by polymerase chain reaction in pregnancies complicated by rhesus alloimmunization. Van den Veyver IB, et al. **Obstet Gynecol** 1996 Dec; 88(6):1061–7 (34 ref.)

Strategies for direct sequencing of PCR-amplified DNA. Rao VB. **PCR Methods Appl** 1994 Aug;4(1):S15–23 (19 ref.)

Applications of the polymerase chain reaction (PCR) to the diagnosis of pediatric pulmonary disease. Buck GE, et al. **Pediatr Pulmonol** 1995 Nov;20(5):309–22 (149 ref.)

Polymerase chain reaction. Chesters JK. **Proc Nutr Soc** 1996 Mar;55(1B):599–604 (23 ref.)

Polymerase chain reaction and in situ hybridization: applications in toxicological pathology. Malarkey DE, et al. **Toxicol Pathol** 1996 Jan–Feb;24(1):13–23 (109 ref.)

The role of the reverse-transcriptase polymerase chain reaction assay for prostate-specific antigen in the selection of patients for radical prostatectomy. Katz AE, et al. **Urol Clin North Am** 1996 Nov;23(4):541–9 (40 ref.)

Reverse transcriptase-polymerase chain reaction assays for prostate cancer. Olsson CA, et al. **Urol Clin North Am** 1997 May;24(2):367–78 (80 ref.)

[Should hepatitis C be screened? Hepatitis C: screening tools] Lunel F. **Gastroenterol Clin Biol** 1997;21(1 Pt 2):S11–24 (86 ref.) **(Fre)**

[Hepatitis C: screening tools] Pham BN, et al. **Gastroenterol Clin Biol** 1997;21(1 Pt 2):S130–9 (70 ref.) **(Fre)**

[Whipple's disease: molecular biology--clinical aspects--therapy] Blum HE. **Schweiz Rundsch Med Prax** 1997 Jul 16;86(29–30):1143–6 (13 ref.) (Eng. Abstr.) **(Ger)**

[Clonality analysis of B-cell lymphoproliferative disorders by means of immunoglobulin heavy chain polymerase reaction] László T, et al. **Orv Hetil** 1996 Sep 8; 137(36):1963–7 (25 ref.) (Eng. Abstr.) **(Hun)**

[Diagnosis of nervous system infections using polymerase chain reaction] Nakamura S, et al. **Nippon Naika Gakkai Zasshi** 1996 May 10;85(5):687–92 (5 ref.) **(Jpn)**

[Genetic diagnosis of viral diseases in nervous system] Nakamura S, et al. **Nippon Rinsho** 1997 Apr;55(4):833–8 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Diagnosis of obstetrical-gynecological infectious diseases using PCR] Fujita Y, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Aug; 48(8):769–80 (29 ref.) **(Jpn)**

[The introduction to molecular biology and its application go pediatrics (4): study of mutations in DNA amplified by PCR] Castaño L, et al. **An Esp Pediatr** 1997 Mar; 46(3):305–10 (7 ref.) **(Spa)**

[Clinical usefulness of the detection and classification of human papilloma viruses using polymerase chain reaction (PCR)] **Gac Med Mex** 1994 Jul–Aug;130(4):273–5 (0 ref.) **(Spa)**

METHODS

Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction [editorial] Cinque P, et al. **AIDS** 1997 Jan;11(1):1–17 (192 ref.)

Single cell PCR for the analysis of Hodgkin's disease: four years later. Küpper M, et al. **Ann Oncol** 1996;7 Suppl 4:35–9 (24 ref.)

Genetic and antigenic diversity of human caliciviruses (HuCVs) using RT-PCR and new EIAs. Jiang X, et al. **Arch Virol Suppl** 1996;12:251–62 (36 ref.)

PCR diagnosis of viral pneumonitis from fixed-lung tissue in children. Akhtar N, et al. **Biochem Mol Med** 1996 Jun; 58(1):66–76 (35 ref.)

Recent advances in capillary electrophoresis of DNA fragments and PCR products. Righetti PG, et al. **Biochem Soc Trans** 1997 Feb;25(1):267–73 (46 ref.)

Technical aspects of quantitative competitive PCR. Zimmermann K, et al. **Biotechniques** 1996 Aug; 21(2):268–72, 274–9 (110 ref.)

Polymerase chain reaction. Day IN. **Br J Hosp Med** 1997 Feb 19–Mar 4;57(4):170–1 (4 ref.)

Detection of melanoma cells in peripheral blood using reverse transcription polymerase chain reaction assay for tyrosinase mRNA. Jung FA, et al. **Cancer Surv** 1996;26:251–65 (38 ref.)

PCR monitoring of response in patients treated with high-dose chemotherapy for low-grade lymphoma. Gribben JG. **Cancer Treat Res** 1996;85:141–60 (58 ref.)

Reverse transcriptase- polymerase chain reaction (RT-PCR) to detect prostate cancer micrometastasis in the blood. Yao KL, et al. **Cancer Treat Res** 1996;88:77–91 (35 ref.)

Molecular diagnosis of genetic diseases. Ferrari M, et al. **Clin Biochem** 1996 Jun;29(3):201–8 (52 ref.)

Multiplex polymerase chain reaction for the diagnosis of sexually transmitted diseases. Mahony JB. **Clin Lab Med** 1996 Mar;16(1):61–71 (32 ref.)

Polymerase chain reaction and other amplification techniques in mycobacteriology. Sandin RL. **Clin Lab Med** 1996 Sep; 16(3):617–39 (40 ref.)

PCR in laboratory diagnosis of human Borrelia burgdorferi infections. Schmidt BL. **Clin Microbiol Rev** 1997 Jan; 10(1):185–201 (195 ref.)

In situ amplification in cytological preparations. O'Leary JJ, et al. **Cytopathology** 1997 Jun;8(3):148–60 (24 ref.)

PCR-based alternative for diagnosis of immunoglobulin heavy chain gene rearrangement: principles, practice, and polemics. Diaz-Cano S. **Diagn Mol Pathol** 1996 Mar; 5(1):3–9 (34 ref.)

Sequencing 5-methylcytosine residues by the bisulphite method. Grigg GW. **DNA Seq** 1996;6(4):189–98 (21 ref.)

Quality management and influential factors for the detection of single metastatic cancer cells by reverse transcriptase polymerase chain reaction. Jung R, et al. **Eur J Clin Chem Clin Biochem** 1997 Jan;35(1):3–10 (53 ref.)

PCR- and RT-PCR-based methods of tumor detection: potential applications and clinical implications. Seiden M, et al. **Important Adv Oncol** 1996;:191–204 (59 ref.)

PCR with arbitrary primers: approach with care. Black WC 4th. **Insect Mol Biol** 1993;2(1):1–6 (23 ref.)

Experience with quantitative PCR for the management of HCMV disease. Schäfer P, et al. **Intervirology** 1996; 39(3):204–12 (95 ref.)

Urine-based diagnosis of sexually transmitted infections using amplified DNA techniques: a shift in paradigms? Orr DP. **J Adolesc Health** 1997 Jan;20(1):3–5 (7 ref.)

Molecular dissection of corticosteroid action in the rat hippocampus. Application of the differential display techniques. Vreugdenhil E, et al. **J Mol Neurosci** 1996 Summer;7(2):135–46 (40 ref.)

Detection of minimal residual disease in multiple myeloma and acute leukaemia. Bakkus MH, et al. **Med Oncol** 1996 Jun;13(2):121–31 (88 ref.)

Site-directed mutagenesis using overlap extension PCR. Aiyar A, et al. **Methods Mol Biol** 1996;57:177–91 (12 ref.)

Site-directed mutagenesis in vitro by megaprimer PCR. Barik S. **Methods Mol Biol** 1996;57:203–15 (14 ref.)

Multiple site-directed mutagenesis. Bhat KS. **Methods Mol Biol** 1996;57:269–77 (6 ref.)

In situ PCR amplification of intracellular mRNA. Chen RH, et al. **Methods Mol Biol** 1997;71:123–32 (20 ref.)

Saturation mutagenesis by mutagenic oligonucleotide-directed PCR amplification (Mod-PCR). Chiang LW. **Methods Mol Biol** 1996;57:311–21 (7 ref.)

Site-directed mutagenesis using a rapid PCR-based method. Costa GL, et al. **Methods Mol Biol** 1996;57:239–48 (15 ref.)

Flow cytometry analysis of an in situ PCR for the detection of human immunodeficiency virus type-1 (HIV-1) proviral DNA. Gibellini DE, et al. **Methods Mol Biol** 1997; 71:113–22 (23 ref.)

Construction of linker-scanning mutations using PCR. Harlow PP, et al. **Methods Mol Biol** 1996;57:287–95 (19 ref.)

Reverse transcriptase PCR in situ on cryopreserved tissue sections. Hendler FJ, et al. **Methods Mol Biol** 1997; 71:99–111 (9 ref.)

Random mutagenesis of short target DNA sequences via PCR with degenerate oligonucleotides. Kirchhoff F, et al. **Methods Mol Biol** 1996;57:323–33 (11 ref.)

Random mutagenesis by using mixtures of dNTP and dITP in PCR. Kuipers OP. **Methods Mol Biol** 1996;57:351–6 (9 ref.)

In situ PCR. An overview. Long AA, et al. **Methods Mol Biol** 1997;71:141–61 (82 ref.)

Modification of the overlap extension method for extensive mutagenesis on the same template. Mikaelian I, et al. **Methods Mol Biol** 1996;57:193–202 (9 ref.)

In situ PCR to cells and to wax sections. An alternative to in situ hybridization for the detection of low copies of human papillomavirus and cytomegalovirus DNA. Mougin C, et al. **Methods Mol Biol** 1997;71:77–97 (44 ref.)

In vitro recombination and mutagenesis by overlap extension PCR. Pogulis RJ, et al. **Methods Mol Biol** 1996;57:167–76 (19 ref.)

PCR-mediated chemical mutagenesis. Roufa DJ. **Methods Mol Biol** 1996;57:357–67 (16 ref.)

PCR-based site-directed mutagenesis. Shimada A. **Methods Mol Biol** 1996;57:157–65 (5 ref.)

PCR-assisted mutagenesis for site-directed insertion/deletion of large DNA segments. Tessier DC, et al. **Methods Mol Biol** 1996;57:229–37 (17 ref.)

A simple method for site-specific mutagenesis that leaves the rest of the template unaltered. Tomic-Canic M, et al. **Methods Mol Biol** 1996;57:259–67 (6 ref.)

Direct in situ single-copy (DISC)-PCR. Troyer DL, et al. **Methods Mol Biol** 1997;71:71–6 (17 ref.)

Localized in situ amplification (LISA). PCR amplification of nucleic acid sequences in tissue sections. Tsongalis GJ. **Methods Mol Biol** 1997;71:133–9 (15 ref.)

Using PCR for rapid site-specific mutagenesis in large plasmids. Watkins BA, et al. **Methods Mol Biol** 1996; 57:217–27 (16 ref.)

Digoxigenin labeling. McCreery T. **Mol Biotechnol** 1997 Apr; 7(2):121–4 (15 ref.)

Differential display PCR: a new age in nutrition investigation. Harris ED. **Nutr Rev** 1996 Sep;54(9):287–9 (11 ref.)

On beyond classic RACE (rapid amplification of cDNA ends). Frohman MA. **PCR Methods Appl** 1994 Aug; 4(1):S40–58 (39 ref.)

Advanced methods in PCR product detection. Lazar JG. **PCR Methods Appl** 1994 Aug;4(1):S1–14 (34 ref.)

DNA fingerprinting by arbitrarily primed PCR. McClelland M, et al. **PCR Methods Appl** 1994 Aug;4(1):S59–65 (24 ref.)

RNA fingerprinting by arbitrarily primed PCR. McClelland M, et al. **PCR Methods Appl** 1994 Aug;4(1):S66–81 (33 ref.)

The application of molecular techniques to the diagnosis and epidemiology of mycobacterial diseases. Butcher PD, et al. **Soc Appl Bacteriol Symp Ser** 1996;25:53S–71S (140 ref.)

The polymerase chain reaction (PCR) in the routine genetic characterization of retinoblastoma: a tool for the clinical laboratory. Mastrangelo D, et al. **Surv Ophthalmol** 1997 Jan–Feb;41(4):331–40 (47 ref.)

Role of PCR in the diagnosis and management of CMV in solid organ recipients: what is the predictive value for the development of disease and should PCR be used to guide antiviral therapy? Abecassis MM, et al. **Transplant Proc** 1996 Dec;28(6 Suppl 2):2–4 (18 ref.)

mRNA differential display: application in the discovery of novel pharmacological targets. Wang X, et al.

Trends Pharmacol Sci 1996 Aug;17(8):276–9 (21 ref.)
[The detection of circulating prostatic cells using RT-PCR] Eschwege P. **Prog Urol** 1997 Feb;7(1):92–6 (10 ref.) **(Fre)**
[Possibilities and limits of molecular genetic detection methods in medical microbiology. Wishful thinking and reality] Göbel UB. **Internist (Berl)** 1996 Sep;37(9):919–25 (24 ref.) **(Ger)**
[Polymerase chain reaction] Suttorp M, et al. **Med Klin** 1997 Jan 15;92(1):37–40 (4 ref.) **(Ger)**
[Clinical use of polymerase chain reaction in diagnosis and monitoring of malignant diseases] Jäger U, et al. **Wien Klin Wochenschr** 1996;108(20):634–9 (35 ref.) (Eng. Abstr.) **(Ger)**
[Long and accurate PCR (LA PCR)] Mukai H, et al. **Nippon Rinsho** 1996 Apr;54(4):917–22 (6 ref.) (Eng. Abstr.) **(Jpn)**
[Application of in situ PCR to clinical pathology--detection of viral infection] Aoyagi K. **Rinsho Byori** 1997 Mar; 45(3):229–33 (23 ref.) (Eng. Abstr.) **(Jpn)**
[A novel quantitative PCR with fluorogenic probe] Isono K. **Rinsho Byori** 1997 Mar;45(3):218–23 (12 ref.) (Eng. Abstr.) **(Jpn)**
[PCR--a new era in clinical microbiologic diagnosis and epidemiologic studies? (Part II)] Kur J, et al. **Przegl Epidemiol** 1996;50(3):227–37 (124 ref.) (Eng. Abstr.) **(Pol)**
[Use of indirect immunofluorescence and polymerase chain reaction (PCR) for detection of Borrelia burgdorferi in ticks] Tylewska-Wierzbanowska S, et al. **Przegl Epidemiol** 1996;50(3):239–44 (11 ref.) (Eng. Abstr.) **(Pol)**
[Molecular biology in medicine. V. Polymerase chain reaction] Bobadilla NA, et al. **Rev Invest Clin** 1996 Sep–Oct;48(5):401–6 (6 ref.) **(Spa)**
[Molecular biology in malignant blood diseases. Methodological aspects: Southern blotting techniques and the polymerase chain reaction] González M, et al. **Sangre (Barc)** 1996 Aug;41(4):311–9 (29 ref.) **(Spa)**

STANDARDS

Problematic controls for reverse transcription polymerase chain reactions (RT-PCR): an issue revisited [see comments] Kidd VJ. **Leukemia** 1996 Nov;10(11):1841–2 (10 ref.) Comment in: Leukemia 1997 Jun;11(6):871–81.
Appropriate controls for RT-PCR. Lion T. **Leukemia** 1996 Nov;10(11):1843 (3 ref.)

TRENDS

DNA amplification. Farrell RE Jr. **Immunol Invest** 1997 Jan–Feb;26(1–2):3–7 (4 ref.)

VETERINARY

Detection of animal pathogens by using the polymerase chain reaction (PCR). Rodriguez JM. **Vet J** 1997 May; 153(3):287–305 (232 ref.)
[Diagnostic PCR in veterinary parasitology: tritrichomonosis, neosporosis/toxoplasmosis echinococcosis/cysticercosis] Felleisen R, et al. **Schweiz Arch Tierheilkd** 1996; 138(3):144–51 (18 ref.) (Eng. Abstr.) **(Ger)**
["Arbitrarily primed PCR". Or: chance in the service of science] Felleisen R, et al. **Schweiz Arch Tierheilkd** 1996; 138(3):139–43 (14 ref.) (Eng. Abstr.) **(Ger)**

POLYMERIC IMMUNOGLOBULIN RECEPTORS see **RECEPTORS, POLYMERIC IMMUNOGLOBULIN**

POLYMERS

see related
MACROMOLECULAR SYSTEMS

Design of nonthrombogenic polymer surfaces for blood-contacting medical devices. Kim SW, et al. **Blood Purif** 1996;14(5):357–72 (24 ref.)
Novel systems for controlled delivery of macromolecules. Kuo PY, et al. **Crit Rev Eukaryot Gene Expr** 1996; 6(1):59–73 (149 ref.)
Applications of polymeric smart materials to environmental problems. Gray HN, et al. **Environ Health Perspect** 1997 Feb;105 Suppl 1:55–63 (46 ref.)
in vivo targeting of colloidal carriers by novel graft copolymers. Arshady R. **J Mol Recognit** 1996 Sep–Dec; 9(5–6):536–42 (30 ref.)
The engineering of biomaterials exhibiting recognition and specificity. Ratner BD. **J Mol Recognit** 1996 Sep–Dec; 9(5–6):617–25 (74 ref.)
New formats of polymeric stationary phases for HPLC separations: molded macroporous disks and rods. Svec F, et al. **J Mol Recognit** 1996 Sep–Dec;9(5–6):326–34 (58 ref.)
[Polymer biomaterials (polyphosphazenes) in the repair of peripheral nervous system] Nicoli Aldini N, et al. **Ann Ital Chir** 1996 Nov–Dec;67(6):843–8 (35 ref.) (Eng. Abstr.) **(Ita)**
[Synthetic vectors for gene transfection] Emi N, et al. **Nippon Rinsho** 1996 Jul;54(7):1997–2002 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Current problems and future trends of polymeric biomaterials for orthopaedic surgery] Ikada Y. **Nippon Seikeigeka Gakkai Zasshi** 1996 Jan;70(1):28–39 (28 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Responsive polymeric drug delivery systems. Meeting the patient's needs. D'Emanuele A. **Clin Pharmacokinet** 1996 Oct;31(4):241–5 (31 ref.)
Degradable controlled release systems useful for protein delivery. Roskos KV, et al. **Pharm Biotechnol** 1997; 10:45–92 (180 ref.)
Protein delivery from nondegradable polymer matrices. Wyatt TL, et al. **Pharm Biotechnol** 1997;10:119–37 (50 ref.)
Delivery of proteins from a controlled release injectable implant. Yewey GL, et al. **Pharm Biotechnol** 1997; 10:93–117 (30 ref.)

ADVERSE EFFECTS

para-Aramid fibrils.
IARC Monogr Eval Carcinog Risks Hum 1997;68:409–39 (68 ref.)

ANALYSIS

Bioactive ingredients: antioxidants and polyphenols in tea. Dreosti IE. **Nutr Rev** 1996 Nov;54(11 Pt 2):S51–8 (62 ref.)

CHEMISTRY

Chiral micelle polymers for chiral separations in capillary electrophoresis. Williams CC, et al. **Adv Chromatogr** 1997; 37:363–423 (94 ref.)
Mechanical properties of hydrogels and their experimental determination. Anseth KS, et al. **Biomaterials** 1996 Sep; 17(17):1647–57 (51 ref.)
Replaceable polymers in DNA sequencing by capillary electrophoresis. Quesada MA. **Curr Opin Biotechnol** 1997 Feb;8(1):82–93 (65 ref.)
Monomeric and polymeric chiral surfactants as pseudo-stationary phases for chiral separations. Shamsi SA, et al. **Electrophoresis** 1997 Jun;18(6):853–72 (76 ref.)
Capillary electrophoresis with polymeric separation media: considerations for theory. Smisek DL. **Electrophoresis** 1995 Nov;16(11):2094–9 (89 ref.)
A review of material properties of biodegradable and bioresorbable polymers and devices for GTR and GBR applications. Hutmacher D, et al. **Int J Oral Maxillofac Implants** 1996 Sep–Oct;11(5):667–78 (73 ref.)
Theory of phase formation in aqueous two-phase systems. Cabezas H Jr. **J Chromatogr B Biomed Appl** 1996 May 17;680(1–2):3–30 (98 ref.)
Polymer materials for the prevention of catheter-related infections. Kohnen W, et al. **Zentralbl Bakteriol** 1995 Dec; 283(2):175–86 (58 ref.)

METABOLISM

Organization of glycosaminoglycan sulfation in the biosynthesis of proteochondroitin sulfate and proteodermatan sulfate. Silbert JE. **Glycoconj J** 1996 Dec; 13(6):907–12 (65 ref.)
Injectable microcapsules prepared with biodegradable poly(alpha-hydroxy) acids for prolonged release of drugs. Ogawa Y. **J Biomater Sci Polym Ed** 1997;8(5):391–409 (85 ref.)

PHARMACOLOGY

Polyphenols as inhibitors of carcinogenesis. Yang CS, et al. **Environ Health Perspect** 1997 Jun;105 Suppl 4:971–6 (72 ref.)
[Cardio-protective effect of red wine as reflected in the literature] Lugasi A, et al. **Orv Hetil** 1997 Mar 16; 138(11):673–8 (50 ref.) (Eng. Abstr.) **(Hun)**

THERAPEUTIC USE

Cancer chemoprevention by polyphenols in green tea and artichoke. Agarwal R, et al. **Adv Exp Med Biol** 1996; 401:35–50 (107 ref.)
Effects of tea on carcinogenesis in animal models and humans. Yang CS, et al. **Adv Exp Med Biol** 1996;401:51–61 (82 ref.)

TOXICITY

Aquatic risk assessment of a polycarboxylate dispersant polymer used in laundry detergents. Hamilton JD, et al. **J Toxicol Environ Health** 1996 Sep;49(1):67–82 (36 ref.)

POLYMETHYLMETHACRYLATE see **METHYLMETHACRYLATES**

POLYMORPHIC EPITHELIAL MUCIN see **CA-15-3 ANTIGEN**

POLYMORPHISM (GENETICS)

Polymorphisms of the D2 dopamine receptor gene and alcoholism and other substance use disorders. Noble EP. **Alcohol Alcohol Suppl** 1994;2:35–43 (61 ref.)
Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? [editorial; comment] Nebert DW. **Am J Hum Genet** 1997 Feb; 60(2):265–71 (35 ref.) Comment on: Am J Hum Genet 1997 Feb;60(2):284–95.
Genetic predictors of common disease: apolipoprotein E genotype as a paradigm. Jarvik GP. **Ann Epidemiol** 1997 Jul;7(5):357–62 (39 ref.)
Clinical relevance of Fc gamma receptor polymorphisms. Rascu A, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:282–95 (76 ref.)
Molecular mechanisms of genetic polymorphisms of drug metabolism. Meyer UA, et al. **Annu Rev Pharmacol Toxicol** 1997;37:269–96 (144 ref.)
Applications of molecular biology to analyses of forensic evidence. Baechtel FS, et al. **Biologicals** 1996 Sep; 24(3):201–5 (54 ref.)
Angiotensin-converting enzyme gene polymorphism. What to do about all the confusion [editorial] [see comments] Singer DR, et al. **Circulation** 1996 Aug 1;94(3):236–9 (43 ref.) Comment in: Circulation 1997 Aug 5;96(3):1050–2.
Biological and clinical significance of haptoglobin polymorphism in humans. Langlois MR, et al. **Clin Chem** 1996 Oct;42(10):1589–600 (160 ref.)
Response to dietary fat and cholesterol and genetic polymorphisms. Clifton P, et al. **Clin Exp Pharmacol Physiol** 1997 May;24(5):A21–5 (59 ref.)
Influence of pharmacogenetics on drug disposition and response. Eichelbaum M, et al. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov;23(10–11):983–5 (21 ref.)
The underlying molecular mechanism of apolipoprotein E polymorphism: relationships to lipid disorders, cardiovascular disease, and Alzheimer's disease. Contois JH, et al. **Clin Lab Med** 1996 Mar;16(1):105–23 (109 ref.)
Use of DNA polymorphisms to monitor engraftment after allogeneic bone marrow transplantation. Rothberg PG, et al. **Clin Lab Med** 1997 Mar;17(1):109–18 (50 ref.)
B27 polymorphism and peptide repertoire. Parham P. **Clin Rheumatol** 1996 Jan;15 Suppl 1:72–3 (20 ref.)
Genetic polymorphism of cytochrome P450 as a biomarker of susceptibility to environmental toxicity. Hong JY, et al. **Environ Health Perspect** 1997 Jun;105 Suppl 4:759–62 (32 ref.)
Cytogenetic markers of susceptibility: influence of polymorphic carcinogen-metabolizing enzymes. Norppa H. **Environ Health Perspect** 1997 Jun;105 Suppl 4:829–35 (53 ref.)
Angiotensin I converting enzyme gene polymorphism and coronary heart disease. Cambien F, et al. **Eur Heart J** 1995 Nov;16 Suppl K:13–22 (84 ref.)
Glycosylation is the structural basis for changes in polymorphism and immunoreactivity of pituitary glycoprotein hormones. Zerfaoui M, et al. **Eur J Clin Chem Clin Biochem** 1996 Sep;34(9):749–53 (12 ref.)
HLA-A2 polymorphism and immune functions. Krausa P, et al. **Eur J Immunogenet** 1996 Aug;23(4):261–74 (41 ref.)
Apolipoprotein E polymorphism: another player in the genetics of colon cancer susceptibility? [editorial; comment] Davidson NO. **Gastroenterology** 1996 Jun;110(6):2006–9 (21 ref.) Comment on: Gastroenterology 1996 Jun;110(6):1785–90.
Impact of migration and fitness on the stability of lethal t-haplotype polymorphism in Mus musculus: a computer study. Durand D, et al. **Genetics** 1997 Apr;145(4):1093–108 (38 ref.)
Genetic variation in India. Papiha SS. **Hum Biol** 1996 Oct; 68(5):607–28 (65 ref.)
Polymorphism in the beta subunit and Na+ transport [editorial] Warnock DG. **J Am Soc Nephrol** 1996 Dec; 7(12):2490–4 (62 ref.)
Interpatient variability: genetic predisposition and other genetic factors. West WL, et al. **J Clin Pharmacol** 1997 Jul;37(7):635–48 (76 ref.)
Diabetic nephropathy: the ACE hypothesis. Marre M. **J Diabetes Complications** 1996 May–Jun;10(3):126–8 (28 ref.)
Molecular basis of polymorphic drug metabolism. Daly AK. **J Mol Med** 1995 Nov;73(11):539–53 (210 ref.)
DNA diagnosis of human genetic individuality. Pena SD, et al. **J Mol Med** 1995 Nov;73(11):555–64 (100 ref.)
Polymorphisms of the renin-angiotensin system genes in progressive renal diseases [editorial] Yoshida H, et al. **Kidney Int** 1996 Sep;50(3):732–44 (137 ref.)
Clinical importance of genetic polymorphism of drug oxidation. Edeki T. **Mt Sinai J Med** 1996 Oct–Nov; 63(5–6):291–300 (134 ref.)
The potential role of the cytochrome P-450 2D6 pharmacogenetic polymorphism in drug abuse. Sellers EM, et al. **NIDA Res Monogr** 1997;173:6–26 (58 ref.)
Genomic drift of Toxoplasma gondii. Frenkel JK, et al. **Parasitol Res** 1997;83(1):1–5 (30 ref.)
Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Krynetski EY, et al. **Pharmacogenetics** 1996 Aug;6(4):279–90 (60 ref.)
Mechanisms leading to the expression of recessive alleles: the use of polymorphic microsatellites and whole-chromosome painting probes to analyze mouse tumors, mutants, and micronuclei. Caspary WJ, et al. **Recent Results Cancer Res** 1997;143:161–82 (82 ref.)
Genetic markers of bone metabolism and bone disease. Ralston SH. **Scand J Clin Lab Invest Suppl** 1997;227:114–21 (46 ref.)
Erythrocyte blood group antigens: polymorphisms of functionally important molecules. Telen MJ. **Semin Hematol** 1996 Oct;33(4):302–14 (98 ref.)
Clinical relevance of polymorphic markers of arterial thrombosis. Di Minno G, et al. **Thromb Haemost** 1997 Jul; 78(1):462–6 (65 ref.)

POLYMORPHISM (GENETICS)

Functional significance of polymorphism among MHC class II gene promoters. Guardiola J, et al. **Tissue Antigens** 1996 Dec;48(6):615–25 (114 ref.)

Ecogenetics: from ecology to health. Nebert DW, et al. **Toxicol Ind Health** 1997 Mar–Jun;13(2–3):163–92 (59 ref.)

Parasite genome analysis. Genome research in Trypanosoma brucei: chromosome size polymorphism and its relevance to genome mapping and analysis. Melville SE. **Trans R Soc Trop Med Hyg** 1997 Mar–Apr;91(2):116–20 (27 ref.)

Blood group polymorphisms: molecular approach and biological significance. Daniels G. **Transfus Clin Biol** 1997 Jul;4(4):383–90 (25 ref.)

Strand asymmetries in DNA evolution. Francino MP, et al. **Trends Genet** 1997 Jun;13(6):240–5 (47 ref.)

Apolipoprotein E polymorphism and plasma cholesterol response to dietary change. Tikkanen MJ. **World Rev Nutr Diet** 1997;80:15–21 (53 ref.)

[Glutathione S–transferase mu 1 (GSTM1): susceptibility gene of breast cancer] Fontana X, et al. **Bull Cancer** 1997 Jan;84(1):35–40 (56 ref.) (Eng. Abstr.) **(Fre)**

[A molecular approach to the structure, polymorphism and function of blood groups] Cartron JP. **Transfus Clin Biol** 1996;3(3):181–210 (80 ref.) (Eng. Abstr.) **(Fre)**

[The strategic use of genetic polymorphisms in carcinogen metabolizing enzyme for prevention of cancer] Ikawa S. **Gan To Kagaku Ryoho** 1997 Feb;24(4):454–9 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Genetic and phenotypic polymorphisms in carcinogen–metabolizing enzymes and cancer susceptibility] Watanabe M. **Nippon Rinsho** 1996 Aug; 54(8):2261–75 (60 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular genetics of apolipoprotein E and its receptors, implications for genetic risk factors of Alzheimer's disease] Okuizumi K, et al. **Tanpakushitsu Kakusan Koso** 1996 Aug; 41(10):1460–4 (20 ref.) **(Jpn)**

[HLA polymorphism: the origin of individual response in immunity] Takata H, et al. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(15 Suppl):2355–68 (49 ref.) **(Jpn)**

[The role of DNA polymorphism in the renin–angiotensin system and the pathogenesis of cardiovascular diseases] Stajszczyk M, et al. **Postepy Hig Med Dosw** 1997; 51(2):171–83 (56 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Genetic polymorphisms in human drug–metabolizing enzymes: potential uses of reverse genetics to identify genes of toxicological relevance. Puga A, et al. **Crit Rev Toxicol** 1997 Mar;27(2):199–222 (243 ref.)

Ataxia–telangiectasia: a multifaceted genetic disorder associated with defective signal transduction. Lavin MF, et al. **Curr Opin Immunol** 1996 Aug;8(4):459–64 (47 ref.)

The role of angiotensin I–converting enzyme gene polymorphism in renal disease. Schmidt S, et al. **Curr Opin Nephrol Hypertens** 1996 Nov;5(6):552–5 (26 ref.)

Genomic instability in head and neck cancer. Scholes AG, et al. **Curr Top Pathol** 1996;90:201–22 (115 ref.)

Mutational and susceptibility genetics are different clinical paradigms [editorial] Roses AD. **Int Psychogeriatr** 1997 Mar;9(1):7–10 (11 ref.)

Angiotensin I–converting enzyme insertion/deletion polymorphism: potential significance in nephrology. Kitamura H, et al. **Kidney Int Suppl** 1996 Jun;55:S101–3 (21 ref.)

Genetic polymorphism of S–mephenytoin 4'–hydroxylation. Daniel HI, et al. **Psychopharmacol Bull** 1996;32(2):219–30 (115 ref.)

[Genetic polymorphism of the renin–angiotensin system and cardiovascular diseases] Castellano M, et al. **Cardiologia** 1997 Aug;42(8):803–13 (127 ref.) **(Ita)**

[Pathogenetic importance of gene polymorphisms in the renin–angiotensin system] Chudek J, et al. **Pol Arch Med Wewn** 1996 Oct;96(4):369–77 (79 ref.) **(Pol)**

[The polymorphism of the angiotensin I–converting enzyme gene and its association with ischemic cardiopathy] Calviño Santos R, et al. **Rev Esp Cardiol** 1996 Dec;49(12):863–8 (36 ref.) (Eng. Abstr.) **(Spa)**

[Chromosomal polymorphism: the biological and medical aspects] Kuznietsova SM, et al. **Tsitol Genet** 1996 Mar–Apr; 30(2):67–74 (75 ref.) (Eng. Abstr.) **(Ukr)**

IMMUNOLOGY

The nature of selection on the major histocompatibility complex. Apanius V, et al. **Crit Rev Immunol** 1997; 17(2):179–224 (388 ref.)

Events in the adaptation of natural killer cell receptors to MHC class I polymorphisms. Parham P. **Res Immunol** 1997 Mar–Apr;148(3):190–4 (19 ref.)

PHYSIOLOGY

The nature of selection on the major histocompatibility complex. Apanius V, et al. **Crit Rev Immunol** 1997; 17(2):179–224 (388 ref.)

POLYMORPHISM, RESTRICTION FRAGMENT LENGTH

Applications of molecular biology to analyses of forensic evidence. Baechtel FS, et al. **Biologicals** 1996 Sep; 24(3):201–5 (54 ref.)

Analysis of human specificity in AFLP systems APOB, PAH, and D1S80. Latorra D, et al. **Forensic Sci Int** 1996 Nov 11;83(1):15–25 (22 ref.)

Sequence polymorphisms of potential functional relevance in the beta–globin gene locus. Labie D, et al. **Hemoglobin** 1996 May;20(2):85–101 (53 ref.)

Rice molecular genetic map using RFLPs and its applications. Nagamura Y, et al. **Plant Mol Biol** 1997 Sep; 35(1–2):79–87 (98 ref.)

Linkage map of phenotype and RFLP markers in rice. Yoshimura A, et al. **Plant Mol Biol** 1997 Sep;35(1–2):49–60 (36 ref.)

POLYMORPHISM, SINGLE–STRANDED CONFORMATIONAL

Single–strand conformation polymorphism analysis with high throughput modifications, and its use in mutation detection in familial hypercholesterolemia. International Federation of Clinical Chemistry Scientific Division: Committee on Molecular Biology Techniques. Humphries SE, et al. **Clin Chem** 1997 Mar;43(3):427–35 (47 ref.)

POLYMORPHONUCLEAR LEUKOCYTE ELASTASE see **LEUKOCYTE ELASTASE**

POLYMORPHONUCLEAR LEUKOCYTES see **NEUTROPHILS**

POLYMYALGIA RHEUMATICA

see related

TEMPORAL ARTERITIS

Polymyalgia rheumatica and temporal arteritis: diagnosis and management. Swannell AJ. **BMJ** 1997 May 3; 314(7090):1329–32 (33 ref.)

Polymyalgia rheumatica. Salvarani C, et al. **Lancet** 1997 Jul 5;350(9070):43–7 (60 ref.)

Polymyalgia rheumatica and giant cell arteritis. Zilko PJ. **Med J Aust** 1996 Oct 21;165(8):438–42 (20 ref.)

CLASSIFICATION

Temporal arteritis and polymyalgia rheumatica: nosographic and nosologic considerations. Turnbull J. **Neurology** 1996 Apr;46(4):901–6 (54 ref.)

COMPLICATIONS

Giant cell arteritis and polymyalgia rheumatica. Hunder GG. **Med Clin North Am** 1997 Jan;81(1):195–219 (93 ref.)

DIAGNOSIS

Diagnostic dilemmas in polymyalgia rheumatica. Brooks RC, et al. **Arch Intern Med** 1997 Jan 27;157(2):162–8 (78 ref.)

Peripheral joint involvement in polymyalgia rheumatica. Chaouat D. **Rev Rhum Engl Ed** 1997 Mar;64(3):184–8 (57 ref.)

ETIOLOGY

Joint manifestations in myelodysplastic syndromes. A report of three cases presenting as polymyalgia rheumatica. Berthelot JM, et al. **Rev Rhum Engl Ed** 1997 Feb; 64(2):95–100 (35 ref.)

POLYMYOSITIS

[Recent topics on inflammatory myositis] Hase A, et al. **Nippon Naika Gakkai Zasshi** 1996 Jan 10;85(1):123–8 (14 ref.) **(Jpn)**

[Eosinophilic polymyositis] Kawano M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):428–31 (17 ref.) **(Jpn)**

COMPLICATIONS

Polymyositis in a patient with thymoma and T cell lymphocytosis. Cranney A, et al. **J Rheumatol** 1997 Jul; 24(7):1413–6 (19 ref.)

Relapse of colon cancer followed by polymyositis: report of a case and review of the literature. Nyui S, et al. **Surg Today** 1997;27(6):559–62 (11 ref.)

[Coping with pathological changes in heart and lung in collagen diseases—dermatomyositis and interstitial pneumonia] Nawata Y. **Nippon Naika Gakkai Zasshi** 1996 Nov 10;85(11):1850–4 (8 ref.) **(Jpn)**

[A male case of polymyositis associated with asymptomatic primary biliary cirrhosis] Nakasho K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Sep;93(9):666–70 (16 ref.) **(Jpn)**

[Non–Hodgkin's lymphoma associated with polymyositis] Onishi S, et al. **Rinsho Ketsueki** 1997 Jul;38(7):582–6 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Polymyositis–dermatomyositis] Kitamoto K. **Ryoikibetsu Shokogun Shirizu** 1996;(15):189–91 (5 ref.) **(Jpn)**

[Structural and functional changes in the heart in dermatomyositis and polymyositis] Makolkin VI, et al. **Klin Med (Mosk)** 1997;75(8):13–5 (38 ref.) **(Rus)**

DIAGNOSIS

Polymyositis as a manifestation of chronic graft–versus–host disease. Parker P, et al. **Medicine (Baltimore)** 1996 Sep; 75(5):279–85 (14 ref.)

DRUG THERAPY

Update on therapy for refractory dermatomyositis and polymyositis. Villalba L, et al. **Curr Opin Rheumatol** 1996 Nov;8(6):544–51 (61 ref.)

[Treating polymyositis: methotrexate or azathioprine?] Mader R. **Harefuah** 1997 Jan 1;132(1):56–8 (20 ref.) **(Heb)**

ETIOLOGY

Relapse of polymyositis after prolonged remission. Lee W, et al. **J Rheumatol** 1997 Aug;24(8):1641–4 (21 ref.)

Idiopathic inflammatory myopathies. Amato AA, et al. **Neurol Clin** 1997 Aug;15(3):615–48 (191 ref.)

[Inflammatory myopathies] Espinosa E. **Rev Neurol** 1996 Nov;24(135):1376–81 (33 ref.) **(Spa)**

IMMUNOLOGY

Clinical significance of antinuclear antibodies in systemic rheumatic diseases. Hietarinta M, et al. **Ann Med** 1996 Aug; 28(4):283–91 (84 ref.)

[Polymyositis/dermatomyositis and autoantibodies] Hirakata M, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Dec; 19(6):588–93 (17 ref.) **(Jpn)**

METABOLISM

The immunopathologic and inflammatory differences between dermatomyositis, polymyositis and sporadic inclusion body myositis. Dalakas MC, et al. **Curr Opin Neurol** 1996 Jun;9(3):235–9 (34 ref.)

MICROBIOLOGY

Musculoskeletal infections in patients with human immunodeficiency virus infection. Vassilopoulos D, et al. **Medicine (Baltimore)** 1997 Jul;76(4):284–94 (129 ref.)

THERAPY

Treatment of inflammatory myopathies. Mastaglia FL, et al. **Muscle Nerve** 1997 Jun;20(6):651–64 (106 ref.)

[Established and new therapeutic approaches in dermatomyositis, polymyositis and overlapping syndromes] Göttfried I, et al. **Wien Klin Wochenschr** 1996 Nov 29; 108(22):705–16 (94 ref.) (Eng. Abstr.) **(Ger)**

POLYMYXIN E see **COLISTIN**

POLYNEURITIS

DIAGNOSIS

Chronic inflammatory demyelinating polyneuropathy. Briani C, et al. **Neuromuscul Disord** 1996 Oct;6(5):311–25 (166 ref.)

[Inflammatory facial paralysis in MRI. An overview] Sartoretti–Schefer S, et al. **Radiologe** 1996 Nov; 36(11):890–6 (52 ref.) (Eng. Abstr.) **(Ger)**

[Critical illness polyneuropathy] Grau JM, et al. **Neurologia** 1996 Oct;11(8):287–93 (45 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Systemic lupus erythematosus with ischemic peripheral neuropathy and lupus anticoagulant: response to intravenous prostaglandin E1. Yoshikawa Y, et al. **Cutis** 1996 Dec;58(6):393–6 (8 ref.)

Inflammatory neuromuscular disorders associated with chronic lymphoid leukemia: evidence for clonal B cells within muscle and nerve. Creange A, et al. **J Neurol Sci** 1996 Apr;137(1):35–41 (25 ref.)

Acute peripheral neuropathy in adults. Guillain–Barré syndrome and related disorders. Pascuzzi RM, et al. **Neurol Clin** 1997 Aug;15(3):529–47 (71 ref.)

[Hepatitis C–associated vasculitic mononeuritis multiplex] Heckmann JG, et al. **Dtsch Med Wochenschr** 1997 Feb 28; 122(9):259–62 (22 ref.) (Eng. Abstr.) **(Ger)**

[Coping with pathological changes in nerves and blood vessels in collagen disease—vasculitis syndrome and polyneuritis] Nagasawa T, et al. **Nippon Naika Gakkai Zasshi** 1996 Nov 10;85(11):1822–7 (5 ref.) **(Jpn)**

IMMUNOLOGY

Guillain–Barré syndrome and chronic inflammatory demyelinating polyneuropathy: immune mechanisms and update on current therapies. van der Meché FG, et al. **Ann Neurol** 1995 May;37 Suppl 1:S14–31 (167 ref.)

Inflammatory neuromuscular disorders associated with chronic lymphoid leukemia: evidence for clonal B cells within muscle and nerve. Creange A, et al. **J Neurol Sci** 1996 Apr;137(1):35–41 (25 ref.)

PHYSIOPATHOLOGY

[Electrodiagnostic features in inflammatory demyelinating polyneuropathy] Baba M, et al. **Rinsho Shinkeigaku** 1995 Dec;35(12):1365–7 (10 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Chronic inflammatory polyneuritis and neuropathies. Toyka KV, et al. **Curr Opin Neurol** 1996 Jun;9(3):240–50 (126 ref.)
Chronic inflammatory demyelinating polyneuropathy. Smith H, et al. **J R Army Med Corps** 1994 Jun;140(2):90–2 (18 ref.)
Chronic inflammatory demyelinating polyneuropathy. Briani C, et al. **Neuromuscul Disord** 1996 Oct;6(5):311–25 (166 ref.)

POLYNUCLEAR AROMATIC HYDROCARBONS see **POLYCYCLIC HYDROCARBONS, AROMATIC**

POLYNUCLEOTIDE VACCINES see **VACCINES, DNA**

POLYNUCLEOTIDES

GENETICS

Polynucleotidyl transfer reactions in site-specific DNA recombination. Mizuuchi K. **Genes Cells** 1997 Jan;2(1):1–12 (79 ref.)

PHARMACOKINETICS

Oligonucleotides and polynucleotides as biologically active compounds. Vlassov VV, et al.
Prog Nucleic Acid Res Mol Biol 1997;57:95–143 (336 ref.)

PHARMACOLOGY

Oligonucleotides and polynucleotides as biologically active compounds. Vlassov VV, et al.
Prog Nucleic Acid Res Mol Biol 1997;57:95–143 (336 ref.)
[The selectivity of the mutagenic action of DNA and other polynucleotides] Gershenzon SM. **Zh Obshch Biol** 1996 Nov–Dec;57(6):661–83 (80 ref.) (Eng. Abstr.) **(Rus)**

POLYOMAVIRUS

Polyomavirus-induced interstitial nephritis in two renal transplant recipients: case reports and review of the literature. Mathur VS, et al. **Am J Kidney Dis** 1997 May; 29(5):754–8 (9 ref.)

GENETICS

Role of mouse polyomavirus late region in the control of viral DNA replication: a review. Iacoangeli A, et al.
Biochimie 1995;77(10):780–6 (50 ref.)

PATHOGENICITY

Evidence for and implications of SV40-like sequences in human mesotheliomas. Pass HI, et al.
Important Adv Oncol 1996;:89–108 (129 ref.)

POLYOMAVIRUS HOMINIS 1

[Human JC and BK polyomavirus infection] Pérez Gracia MT, et al. **Med Clin (Barc)** 1996 Jan 20;106(2):69–75 (123 ref.) **(Spa)**

GENETICS

New aspects in the pathogenesis of polyomavirus-induced disease. Dörries K. **Adv Virus Res** 1997;48:205–61 (204 ref.)

ISOLATION & PURIFICATION

Virus-host interactions and diagnosis of human polyomavirus-associated disease. Dörries K.
Intervirology 1996;39(3):165–75 (75 ref.)

POLYOMAVIRUS HOMINIS 2

[Human JC and BK polyomavirus infection] Pérez Gracia MT, et al. **Med Clin (Barc)** 1996 Jan 20;106(2):69–75 (123 ref.) **(Spa)**

GENETICS

New aspects in the pathogenesis of polyomavirus-induced disease. Dörries K. **Adv Virus Res** 1997;48:205–61 (204 ref.)

ISOLATION & PURIFICATION

Virus-host interactions and diagnosis of human polyomavirus-associated disease. Dörries K.
Intervirology 1996;39(3):165–75 (75 ref.)
Considerations on a possible viral etiology for B-precursor acute lymphoblastic leukemia of childhood. Smith M.
J Immunother 1997 Mar;20(2):89–100 (122 ref.)

POLYOMAVIRUS MACACAE

GENETICS

Evidence for and implications of SV40-like sequences in human mesotheliomas. Pass HI, et al.
Important Adv Oncol 1996;:89–108 (129 ref.)

IMMUNOLOGY

Multiple stages of virus-receptor interactions as shown by simian virus 40. Norkin LC, et al. **Adv Exp Med Biol** 1996; 408:159–67 (26 ref.)

ISOLATION & PURIFICATION

SV40 and human brain tumors. Butel JS, et al.
J Neurovirol 1997 May;3 Suppl 1:S78–9 (5 ref.)

POLYOXYETHYLENES see **POLYETHYLENE GLYCOLS**

POLYPENTOSE SULFATE see **PENTOSAN SULFURIC POLYESTER**

POLYPEPTIDES see **PEPTIDES**

POLYPHARMACY

see related
DRUG ANTAGONISM
DRUG COMBINATIONS
DRUG THERAPY, COMBINATION
Drug interactions among the elderly [news] Liaw ST.
Aust Fam Physician 1997 Apr;26(4):355–7 (29 ref.)

POLYPHOSPHATES

METABOLISM

Metabolism of micro-organisms responsible for enhanced biological phosphorus removal from wastewater. Use of dynamic enrichment cultures. van Loosdrecht MC, et al.
Antonie Van Leeuwenhoek 1997 Feb;71(1–2):109–16 (34 ref.)
Intracellular diadenosine polyphosphates: a novel family of inhibitory ligands of the ATP-sensitive K+ channel. Jovanovic A, et al. **Biochem Pharmacol** 1997 Jul 15; 54(2):219–25 (52 ref.)

POLYPHOSPHOINOSITIDES see **PHOSPHATIDYLINOSITOL PHOSPHATES**

POLYPLOIDY

The tetraploidy of Purkinje cells in the cerebellum in reference to the problem of polyploidy. Kowalska E, et al. **Folia Histochem Cytobiol** 1997;35(2):127 (12 ref.)

POLYPORACEAE

Functional properties of edible mushrooms. Chang R.
Nutr Rev 1996 Nov;54(11 Pt 2):S91–3 (22 ref.)

POLYPOSIS COLI, FAMILIAL see **ADENOMATOUS POLYPOSIS COLI**

POLYPOSIS SYNDROME, FAMILIAL see **ADENOMATOUS POLYPOSIS COLI**

POLYPROTEINS see **PROTEINS**

POLYPS

COMPLICATIONS

[Polypoid cystitis, isolated lesion with a unique presentation] Raventos Busquets CX, et al. **Arch Esp Urol** 1996 Nov; 49(9):988–91 (21 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Diagnosis and management of gastroduodenal polyps. Burke CA, et al. **Surg Oncol Clin N Am** 1996 Jul;5(3):589–607 (69 ref.)
[A fibroepithelial polyp of the ureter. A report of 2 new cases] Tato Rodríguez J, et al. **Actas Urol Esp** 1997 Apr; 21(4):420–5 (23 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Epidemiology of gastrointestinal polyps. Jacobson JS, et al.
Surg Oncol Clin N Am 1996 Jul;5(3):531–44 (115 ref.)

PATHOLOGY

Gastric polyps as precancerous lesions. Schmitz JM, et al.
Gastrointest Endosc Clin N Am 1997 Jan;7(1):29–46 (32 ref.)
Giant cervical polyp. A case report. Khalil AM, et al.
J Reprod Med 1996 Aug;41(8):619–21 (6 ref.)
Pathology neoplastic and non-neoplastic. Graeme-Cook F.
Surg Oncol Clin N Am 1996 Jul;5(3):487–512 (31 ref.)
Fibroepithelial polyp in the renal pelvis. Nakamoto T, et al.
Urol Int 1996;56(1):48–51 (17 ref.)
[A case of synchronous triple early cancer occurring in the stomach, colon and gallbladder] Yazawa K, et al.
Nippon Shokakibyo Gakkai Zasshi 1997 Jun;94(6):440–4 (12 ref.) **(Jpn)**

SURGERY

Endoscopic polypectomy under laparotomy throughout the alimentary tract for a patient with blue rubber bleb nevus syndrome. Shimada S, et al. **Gastrointest Endosc** 1997 May; 45(5):423–7 (25 ref.)
The management of aural polyps. Tay HL, et al.
J Laryngol Otol 1997 Mar;111(3):212–4 (19 ref.)
Management of gallbladder polyps. Mangel AW.
South Med J 1997 May;90(5):481–3 (14 ref.)
Fibroepithelial polyp of the renal pelvis: nephron-sparing surgery after false-positive biopsy for transitional cell carcinoma. Brady JD, et al. **Urology** 1997 Mar;49(3):460–4 (32 ref.)

POLYRADICULITIS

DRUG THERAPY

Cytomegalovirus polyradiculopathy treated successfully with foscarnet [letter] Corral I, et al.
Eur J Clin Microbiol Infect Dis 1996 May;15(5):428–9 (10 ref.)

ETIOLOGY

Diffuse arthralgia and myalgia as the first manifestation of benign myeloradiculopathy due to cytomegalovirus infection in an immunocompetent patient. Etaouil N, et al. **Rev Rhum Engl Ed** 1997 Jan;64(1):57–8 (7 ref.)

POLYRADICULONEURITIS

Guillain-Barr'e syndrome. Baloch R, et al.
JPMA J Pak Med Assoc 1997 May;47(5):145–7 (11 ref.)
Current concepts in Guillain-Barré syndrome. Franco DA, et al. **Nebr Med J** 1996 Dec;81(12):406–11 (53 ref.)
Guillain-Barré syndrome. A severe case calling for intensive treatment. Kankam CG, et al. **Postgrad Med** 1997 Mar; 101(3):279–80, 285–90 (19 ref.)
The Guillain-Barré syndrome; pathogenesis and treatment. Van Der Meché FG. **Rev Neurol (Paris)** 1996 May; 152(5):355–8 (24 ref.)
Guillain-Barre syndrome. Walk D. **Surg Neurol** 1997 Mar; 47(3):305–7 (24 ref.)
[Chronic idiopathic polyradiculoneuritis. Clinical, electrophysiological and histopathological aspects] Bouche P, et al. **Rev Neurol (Paris)** 1996 May;152(5):365–9 (22 ref.) (Eng. Abstr.) **(Fre)**
[Guillain-Barré syndrome: development of concepts] Serratrice G. **Rev Neurol (Paris)** 1996 May;152(5):333–8 (34 ref.) (Eng. Abstr.) **(Fre)**
[Guillain-Barré syndrome and Fisher syndrome] Kusunoki S, et al. **Nippon Rinsho** 1997 Apr;55(4):940–4 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Guillain-Barré syndrome and acute disseminated encephalomyelitis (ADEM)] Hamaguchi K.
Rinsho Shinkeigaku 1996 Dec;36(12):1301–7 (10 ref.) (Eng. Abstr.) **(Jpn)**

CHEMICALLY INDUCED

Drug-associated Guillain-Barré syndrome: a literature review [see comments] Awong IE, et al.
Ann Pharmacother 1996 Feb;30(2):173–80 (43 ref.)
Comment in: Ann Pharmacother 1997 Apr;31(4):500.

COMPLICATIONS

Pulmonary embolism from axillosubclavian thrombosis on a rehabilitation unit: case report. Kissel DJ.
Arch Phys Med Rehabil 1997 Mar;78(3):319–23 (44 ref.)
Guillain-Barré syndrome in immunocompromised patients: a report of three patients and review of the literature. Qureshi AI, et al. **Muscle Nerve** 1997 Aug;20(8):1002–7 (44 ref.)

DIAGNOSIS

Myasthenia gravis and the Miller-Fisher variant of Guillain-Barré syndrome. Newsom-Davis J.
Curr Opin Neurol 1997 Feb;10(1):18–21 (23 ref.)
Guillain-Barré syndrome in children. Jones HR Jr.
Curr Opin Pediatr 1995 Dec;7(6):663–8 (47 ref.)
Landry Guillain-Barre-Strohl syndrome in pregnancy: case report. Amoah GB. **East Afr Med J** 1996 Sep;73(9):623–4 (7 ref.)
Guillain-Barré syndrome. Review and presentation of a case with pedal manifestations. Viegas GV.
J Am Podiatr Med Assoc 1997 May;87(5):209–18 (89 ref.)
Presurgical identification of extradural nerve root anomalies by coronal fat-suppressed magnetic resonance imaging: a report of six cases and a review of the literature. Aota Y, et al. **J Spinal Disord** 1997 Apr;10(2):167–75 (19 ref.)
Guillain-Barré syndrome. Evans OB, et al. **Pediatr Rev** 1997 Jan;18(1):10–6 (21 ref.)
[The Guillain-Barré syndrome in herpes zoster patients] Shishov AS, et al.
Zh Nevropatol Psikhiatr Im S S Korsakova 1996;96(2):26–9 (21 ref.) (Eng. Abstr.) **(Rus)**

ETIOLOGY

Guillain-Barré syndrome and ethylene diamine tetraacetic acid-dependent pseudothrombocytopenia associated with mumps. Sawazaki A, et al. **Intern Med** 1996 Dec; 35(12):996–9 (34 ref.)
Acute peripheral neuropathy in adults. Guillain-Barré syndrome and related disorders. Pascuzzi RM, et al.
Neurol Clin 1997 Aug;15(3):529–47 (71 ref.)
[The pathogenesis of postinfectious encephalomyelitis and polyradiculoneuritis] Ohara Y. **Nippon Rinsho** 1997 Apr; 55(4):800–4 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Sjögren's syndrome with presenting as aseptic meningoencephaloradiculopathy in an elderly woman]

POLYRADICULONEURITIS

Miyachi T, et al. **Nippon Ronen Igakkai Zasshi** 1997 May; 34(5):415–20 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Antiglycolipid antibody in inflammatory neuropathy] Kusunoki S. **Rinsho Shinkeigaku** 1995 Dec;35(12):1370–2 (6 ref.) (Eng. Abstr.) **(Jpn)**

[A case of relapsing Guillain–Barré syndrome following Miller Fisher syndrome] Mochizuki A, et al. **Rinsho Shinkeigaku** 1996 May;36(5):675–9 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Guillain–Barré syndrome and infection] Saida T, et al. **Rinsho Shinkeigaku** 1995 Dec;35(12):1378–9 (10 ref.) **(Jpn)**

[Pathogenesis of Guillain–Barré syndrome and Fisher's syndrome: molecular mimicry between antecedent infectious agents and components of nerve tissues] Yuki N. **Rinsho Shinkeigaku** 1995 Dec;35(12):1373–5 (10 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Guillain–Barré syndrome and chronic inflammatory demyelinating polyneuropathy: immune mechanisms and update on current therapies. van der Meché FG, et al. **Ann Neurol** 1995 May;37 Suppl 1:S14–31 (167 ref.)

The immunopathogenesis of multiple sclerosis and Guillain–Barré syndrome. Giovannoni G, et al. **Curr Opin Neurol** 1996 Jun;9(3):165–77 (134 ref.)

The immunopathology of Guillain–Barré syndrome. Saida K. **Curr Opin Neurol** 1996 Oct;9(5):329–33 (37 ref.)

[Antiganglioside antibodies in neuropathies and motor neuronopathies] Gallardo E, et al. **Neurologia** 1996 Dec;11 Suppl 5:75–80 (44 ref.) (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

[Guillain–Barré syndrome of axonal type, Campylobacter jejuni infection and anti-ganglioside GM1 antibodies] Attarian S, et al. **Rev Neurol (Paris)** 1997 Apr;153(3):205–8 (12 ref.) (Eng. Abstr.) **(Fre)**

[A case of neuroborreliosis with unilateral radiculoneuropathy and elevated serum antibodies for Borrelia garinii and Borrelia afzelii] Miyazaki K, et al. **Rinsho Shinkeigaku** 1996 Oct;36(10):1155–60 (29 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

[Guillain–Barré syndrome: morphological lesions and their relations with clinical manifestations] Said G. **Rev Neurol (Paris)** 1996 May;152(5):344–8 (27 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Guillain–Barré syndrome. Fulgham JR, et al. **Crit Care Clin** 1997 Jan;13(1):1–15 (60 ref.)

Guillain–Barré syndrome: clinical neurophysiologic studies. Cros D, et al. **Rev Neurol (Paris)** 1996 May;152(5):339–43 (54 ref.)

[Electrodiagnostic features in inflammatory demyelinating polyneuropathy] Baba M, et al. **Rinsho Shinkeigaku** 1995 Dec;35(12):1365–7 (10 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Management of Guillain–Barré syndrome (GBS). Hahn AF. **Baillieres Clin Neurol** 1996 Oct;5(3):627–44 (99 ref.)

Guillain–Barré syndrome. Fulgham JR, et al. **Crit Care Clin** 1997 Jan;13(1):1–15 (60 ref.)

Treatment of inflammatory neuropathy. Hughes RA, et al. **Mult Scler** 1997 Apr;3(2):88–92 (51 ref.)

Treatment of patients with chronic inflammatory demyelinating polyneuropathy. Van Doorn PA. **Rev Neurol (Paris)** 1996 May;152(5):383–6 (20 ref.)

[Respective indications of plasma exchange and high-dose immunoglobulins in polyradiculoneuritis and myasthenia gravis] Raphaël JC, et al. **Presse Med** 1996 Oct 19; 25(31):1516–22 (31 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of Guillain–Barré syndrome by plasma exchange: proposal of a therapeutic strategy] Raphael JC, et al. **Rev Neurol (Paris)** 1996 May;152(5):359–64 (42 ref.) (Eng. Abstr.) **(Fre)**

POLYRIBONUCLEOTIDE SYNTHETASE

GENETICS

Mixed mechanisms in yeast pre-mRNA splicing? [comment] Rosbash M. **Cell** 1996 Nov 1;87(3):357–9 (15 ref.) Comment on: Cell 1996 Nov 1;87(3):391–404. Comment on: Cell 1996 Nov 1;87(3):405–13.

POLYRIBONUCLEOTIDE SYNTHETASES see **POLYRIBONUCLEOTIDE SYNTHETASE**

POLYRIBOSOMES

Polysome analysis. Sagliocco FA, et al. **Methods Mol Biol** 1996;53:297–311 (13 ref.)

PHYSIOLOGY

Ultrastructural basis for gene expression at the synapse: synapse-associated polyribosome complexes. Steward O, et al. **J Neurocytol** 1996 Dec;25(12):717–34 (51 ref.)

ULTRASTRUCTURE

Ultrastructural basis for gene expression at the synapse: synapse-associated polyribosome complexes. Steward O, et al. **J Neurocytol** 1996 Dec;25(12):717–34 (51 ref.)

POLYSACCHARIDES

[Neural proteoglycans: neuroglycan C (NGC), neurocan, and phosphacan] Tokita Y, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):567–70 (17 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Current applications of polysaccharides in colon targeting. Hovgaard L, et al. **Crit Rev Ther Drug Carrier Syst** 1996; 13(3–4):185–223 (104 ref.)

ANALYSIS

Glycopinion: biological significance and methods for the analysis of complex carbohydrates of recombinant glycoproteins. Raju TS, et al. **Biotechnol Appl Biochem** 1996 Dec;24 (Pt 3):191–4 (23 ref.)

Post-translational modifications of meningococcal pili. Identification of common substituents: glycans and alpha-glycerophosphate--a review. Virji M. **Gene** 1997 Jun 11;192(1):141–7 (42 ref.)

[Serological diagnosis for cryptococcosis by the detection of beta-glucan and capsular polysaccharide] Kohno S. **Rinsho Byori** 1996 Jun;44(6):524–7 (6 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Molecular architecture of polysaccharide helices in oriented fibers. Chandrasekaran R. **Adv Carbohydr Chem Biochem** 1997;52:311–439 (114 ref.)

The use of electrospray ionization MS to determine the structure of glycans in intact glycoproteins. Oliver RW, et al. **Biochem Soc Trans** 1996 Aug;24(3):917–27 (20 ref.)

Biotechnology of protein and polysaccharide gels. Tombs MP. **Biotechnol Genet Eng Rev** 1997;14:337–63 (62 ref.)

High-field NMR as a technique for the determination of polysaccharide structures. Mulloy B. **Mol Biotechnol** 1996 Dec;6(3):241–65 (164 ref.)

DIAGNOSTIC USE

Clinical experience with echo-enhanced transcranial Doppler and duplex imaging. Ries F. **J Neuroimaging** 1997 Apr;7 Suppl 1:S15–21 (17 ref.)

IMMUNOLOGY

Poly-N-acetyllactosaminyl saccharide chains of band 3 as determinants for anti-band 3 autoantibody binding to senescent and oxidized erythrocytes. Beppu M, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 Nov;42(7):1007–24 (95 ref.)

The use of antibodies to study the architecture and developmental regulation of plant cell walls. Knox JP. **Int Rev Cytol** 1997;171:79–120 (203 ref.)

ISOLATION & PURIFICATION

CHO cells provide access to novel N-glycans and developmentally regulated glycosyltransferases. Stanley P, et al. **Glycobiology** 1996 Oct;6(7):695–9 (70 ref.)

METABOLISM

Microbial hydrolysis of polysaccharides. Warren RA. **Annu Rev Microbiol** 1996;50:183–212 (175 ref.)

Digestive fates of soluble polysaccharides from marine macroalgae: involvement of the colonic microflora and physiological consequences for the host. Michel C, et al. **J Appl Bacteriol** 1996 Apr;80(4):349–69 (170 ref.)

Relaxation in a high-stress environment: the molecular bases of extensible cell walls and cell enlargement. Cosgrove DJ. **Plant Cell** 1997 Jul;9(7):1031–41 (110 ref.)

Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model [published erratum appears in Vaccine 1996 Sep;14(13):1298] Devi SJ. **Vaccine** 1996 Jun;14(9):841–4 (29 ref.)

PHARMACOLOGY

A physico-chemical perspective of plant polysaccharides in relation to glucose absorption, insulin secretion and the entero-insular axis. Ellis PR, et al. **Proc Nutr Soc** 1996 Nov;55(3):881–98 (76 ref.)

PHYSIOLOGY

Cell signalling by inositol phosphoglycans from different species. Varela-Nieto I, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Oct; 115(2):223–41 (204 ref.)

HB-GAM (heparin-binding growth-associated molecule) and heparin-type glycans in the development and plasticity of neuron-target contacts. Rauvala H, et al. **Prog Neurobiol** 1997 Jun;52(2):127–44 (112 ref.)

THERAPEUTIC USE

Glycosaminoglycans and semisynthetic sulfated polysaccharides: an overview of their potential application in treatment of patients with urolithiasis. Cao LC, et al. **Urology** 1997 Aug;50(2):173–83 (111 ref.)

POLYSACCHARIDES, BACTERIAL

ANALYSIS

Macroamphiphilic cell envelope components of Rhodococcus equi and closely related bacteria. Sutcliffe IC. **Vet Microbiol** 1997 Jun 16;56(3–4):287–99 (43 ref.)

BIOSYNTHESIS

Bacterial cell surface carbohydrates: structure and assembly. Hancock IC. **Biochem Soc Trans** 1997 Feb;25(1):183–7 (40 ref.)

Identification of structural genes involved in bacterial exopolysaccharide production. Griffin AM, et al. **Biotechnol Genet Eng Rev** 1996;13:1–18 (111 ref.)

Rhizobium meliloti exopolysaccharides: synthesis and symbiotic function. González JE, et al. **Gene** 1996 Nov 7;179(1):141–6 (50 ref.)

A functional analysis of the Streptococcus pneumoniae genes involved in the synthesis of type 1 and type 3 capsular polysaccharides. García E, et al. **Microb Drug Resist** 1997 Spring;3(1):73–88 (112 ref.)

Characterization of the capsular polysaccharide biosynthesis locus of Streptococcus pneumoniae type 19F. Paton JC, et al. **Microb Drug Resist** 1997 Spring;3(1):89–99 (40 ref.)

Coating the surface: a model for expression of capsular polysialic acid in Escherichia coli K1. Bliss JM, et al. **Mol Microbiol** 1996 Jul;21(2):221–31 (68 ref.)

Bacterial polysaccharide synthesis and gene nomenclature. Reeves PR, et al. **Trends Microbiol** 1996 Dec;4(12):495–503 (33 ref.)

CHEMISTRY

The immune response to the capsular polysaccharide of Neisseria meningitidis group B. Romero JD, et al. **Zentralbl Bakteriol** 1997 Feb;285(3):331–40 (62 ref.)

GENETICS

Identification of structural genes involved in bacterial exopolysaccharide production. Griffin AM, et al. **Biotechnol Genet Eng Rev** 1996;13:1–18 (111 ref.)

A functional analysis of the Streptococcus pneumoniae genes involved in the synthesis of type 1 and type 3 capsular polysaccharides. García E, et al. **Microb Drug Resist** 1997 Spring;3(1):73–88 (112 ref.)

Characterization of the capsular polysaccharide biosynthesis locus of Streptococcus pneumoniae type 19F. Paton JC, et al. **Microb Drug Resist** 1997 Spring;3(1):89–99 (40 ref.)

Bacterial polysaccharide synthesis and gene nomenclature. Reeves PR, et al. **Trends Microbiol** 1996 Dec;4(12):495–503 (33 ref.)

IMMUNOLOGY

A model for induction of T cell-independent humoral immunity in response to polysaccharide antigens. Snapper CM, et al. **J Immunol** 1996 Sep 15;157(6):2229–33 (72 ref.)

The immune response to the capsular polysaccharide of Neisseria meningitidis group B. Romero JD, et al. **Zentralbl Bakteriol** 1997 Feb;285(3):331–40 (62 ref.)

ISOLATION & PURIFICATION

Bioemulsans: microbial polymeric emulsifiers. Rosenberg E, et al. **Curr Opin Biotechnol** 1997 Jun;8(3):313–6 (26 ref.)

METABOLISM

[Role of bacterial lipopolysaccharides in human diseases: evolution of outlook] Malov VA, et al. **Vestn Ross Akad Med Nauk** 1997;(8):33–8 (36 ref.) (Eng. Abstr.) **(Rus)**

POLYSOMES see **POLYRIBOSOMES**

POLYSOMNOGRAPHY

The relationship between sleep and epilepsy in children. Bourgeois B. **Semin Pediatr Neurol** 1996 Mar;3(1):29–35 (40 ref.)

Narcolepsy in children. Kotagal S. **Semin Pediatr Neurol** 1996 Mar;3(1):36–43 (64 ref.)

Obstructive sleep apnea in children. Marcus CL, et al. **Semin Pediatr Neurol** 1996 Mar;3(1):23–8 (21 ref.)

[Sleep--respiration--hemodynamics] Grote L. **Internist (Berl)** 1996 May;37(5):470–82 (76 ref.) **(Ger)**

[Differential diagnostic concepts in sleep medicine and their particular significance for the internist] Peter JH. **Internist (Berl)** 1996 May;37(5):454–62 (33 ref.) **(Ger)**

[Sleep and depression] Voderholzer U, et al. **Internist (Berl)** 1996 May;37(5):483–9 (26 ref.) **(Ger)**

[Polysomnography (PSG)] Hayakawa T, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:383–5 (5 ref.) **(Jpn)**

DRUG EFFECTS

Polysomnography in drug development. Dietrich B.

J Clin Pharmacol 1997 Jan;37(1 Suppl):70S–78S (81 ref.)
The link between sleep and depression: the effects of antidepressants on EEG sleep. van Bemmel AL. **J Psychosom Res** 1997 Jun;42(6):555–64 (77 ref.)
Polysomnographic effects of hypnotic drugs. A review. Parrino L, et al. **Psychopharmacology (Berl)** 1996 Jul; 126(1):1–16 (131 ref.)

INSTRUMENTATION

Home assessment of sleep disorders by portable monitoring. Broughton R, et al. **J Clin Neurophysiol** 1996 Jul; 13(4):272–84 (75 ref.)
Past and future of computer-assisted sleep analysis and drowsiness assessment. Hasan J. **J Clin Neurophysiol** 1996 Jul;13(4):295–313 (190 ref.)
The future of computer-assisted investigation of the polysomnogram: sleep microstructure. Kubicki S, et al. **J Clin Neurophysiol** 1996 Jul;13(4):285–94 (70 ref.)
Effect of nocturnal blood pressure measurement on sleep and blood pressure during sleep. Middeke M. **Z Kardiol** 1996; 85 Suppl 3:99–105 (14 ref.)
[Diagnostic methods and standards in sleep medicine] Penzel T, et al. **Internist (Berl)** 1996 May;37(5):442–53 (45 ref.) **(Ger)**

STANDARDS

Standards for polysomnography in Canada. The Standards Committees of the Canadian Sleep Society and the Canadian Thoracic Society [see comments] George CF. **Can Med Assoc J** 1996 Dec 15;155(12):1673–8 (10 ref.) Comment in: Can Med Assoc J 1996 Dec 15;155(12):1693–4. Comment in: Can Med Assoc J 1997 May 15;156(10):1379.

POLYSORBATE 20 see **POLYSORBATES**

POLYSORBATE 80 see **POLYSORBATES**

POLYSORBATES

PHARMACOLOGY

Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. O'Hagan DT, et al. **Mol Med Today** 1997 Feb;3(2):69–75 (47 ref.)

POLYTEF see **POLYTETRAFLUOROETHYLENE**

POLYTETRAFLUOROETHYLENE

Bone regeneration by a combination of osteopromotive membranes with different BMP preparations: a review. Zellin G, et al. **Connect Tissue Res** 1996;35(1–4):279–84 (20 ref.)
Percutaneous intervention for permanent hemodialysis access: a review. Gray RJ. **J Vasc Interv Radiol** 1997 May–Jun;8(3):313–27 (105 ref.)
[Endoscopic treatment of vesico-renal reflux with teflon: personal experience among adults and neurologic patients] Giannotti P, et al. **Arch Ital Urol Androl** 1997 Feb;69 Suppl 1:47–53 (46 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

Polytetrafluoroethylene giant granuloma and adenopathy: long-term complications following subureteral polytetrafluoroethylene injection for the treatment of vesicoureteral reflux in children. Aragona F, et al. **J Urol** 1997 Oct;158(4):1539–42 (41 ref.)

THERAPEUTIC USE

The use of mesh in gynecologic surgery. Iglesia CB, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1997;8(2):105–15 (76 ref.)
[Peri-ureteral injections for stress urinary incontinence] Haab F. **Prog Urol** 1997 Apr;7(2):293–6 (15 ref.) **(Fre)**

POLYURETHANES

Small caliber vascular grafts. Part II: Polyurethanes revisited. Zdrahala RJ. **J Biomater Appl** 1996 Jul;11(1):37–61 (90 ref.)

POLYURIA

DIAGNOSIS

[Carter-Robbins test] Kimura T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:291–4 (5 ref.) **(Jpn)**
[Water deprivation and water load test] Ota K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:295–8 (4 ref.) **(Jpn)**
[Clinical studies in antidiuretic hormone secretion] Shoji M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:299–302 (3 ref.) **(Jpn)**

ETIOLOGY

The polyuria of solute diuresis. Oster JR, et al. **Arch Intern Med** 1997 Apr 14;157(7):721–9 (42 ref.)

PHYSIOPATHOLOGY

The polyuria of solute diuresis. Oster JR, et al. **Arch Intern Med** 1997 Apr 14;157(7):721–9 (42 ref.)

POLYVIDON see **POVIDONE**

POLYVINYLPYRROLIDONE see **POVIDONE**

POLYVINYLPYRROLIDONE IODINE see **POVIDONE-IODINE**

POMC see **PRO-OPIOMELANOCORTIN**

POMPE'S DISEASE see **GLYCOGEN STORAGE DISEASE TYPE II**

PONGIDAE

[Acquisition of human bipedal gait from the viewpoint of the aquatic ape theory] Bender R, et al. **Anthropol Anz** 1997 Mar;55(1):1–14 (25 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Conflict resolution and distress alleviation in monkeys and apes. de Waal FB, et al. **Ann N Y Acad Sci** 1997 Jan 15; 807:317–28 (57 ref.)

PONGIDAE DISEASES see **APE DISEASES**

PONS

Strategies in the treatment of diffuse pontine gliomas: the therapeutic role of hyperfractionated radiotherapy and chemotherapy. Jennings MT, et al. **J Neurooncol** 1996 May–Jun;28(2–3):207–22 (122 ref.)
Pontine glioma with osteoblastic skeletal metastases in a child. Yanagawa Y, et al. **Surg Neurol** 1996 Nov; 46(5):481–4 (15 ref.)
Intracranial metastases as the first manifestation of prostate cancer. Sutton MA, et al. **Urology** 1996 Nov;48(5):789–93 (28 ref.)

ANATOMY & HISTOLOGY

Anatomic organization of the basilar pontine projections from prefrontal cortices in rhesus monkey. Schmahmann JD, et al. **J Neurosci** 1997 Jan 1;17(1):438–58 (96 ref.)
Salient anatomic features of the cortico-ponto-cerebellar pathway. Brodal P, et al. **Prog Brain Res** 1997;114:227–49 (120 ref.)

BLOOD SUPPLY

[Pure sensory syndrome due to a lacunar infarct in the protuberance (letter)] Marcos Toledano MM, et al. **Med Clin (Barc)** 1997 Feb 15;108(6):236 (9 ref.) **(Spa)**

DRUG EFFECTS

Iatrogenic [corrected] extrapontine myelinolysis in central diabetes insipidus: are cyclosporine and 1-desamino-8-D-arginine vasopressin harmful in association? [published erratum appears in J Clin Endocrinol Metab 1997 Jul;82(7):2282] Maghnie M, et al. **J Clin Endocrinol Metab** 1997 Jun;82(6):1749–51 (18 ref.)

PATHOLOGY

Brain stem involvement in children with neurofibromatosis type 1: role of magnetic resonance imaging and spectroscopy in the distinction from diffuse pontine glioma. Broniscer A, et al. **Neurosurgery** 1997 Feb;40(2):331–7; discussion 337–8 (29 ref.)

PHYSIOLOGY

Cellular basis of pontine ponto-geniculo-occipital wave generation and modulation. Datta S. **Cell Mol Neurobiol** 1997 Jun;17(3):341–65 (172 ref.)
The role of cerebro-ponto-cerebellar pathways in the control of vergence eye movements. Gamlin PD, et al. **Eye** 1996; 10 (Pt 2):167–71 (48 ref.)
Anatomic organization of the basilar pontine projections from prefrontal cortices in rhesus monkey. Schmahmann JD, et al. **J Neurosci** 1997 Jan 1;17(1):438–58 (96 ref.)
Salient anatomic features of the cortico-ponto-cerebellar pathway. Brodal P, et al. **Prog Brain Res** 1997;114:227–49 (120 ref.)
Physiological functions of pontomedullary raphe and medial reticular neurons. Mason P, et al. **Prog Brain Res** 1996; 107:269–82 (130 ref.)

SURGERY

Microsurgical excision of a pontomedullary epidermoid cyst with prepontine extension: case report. Malcolm GP, et al. **Neurosurgery** 1996 Mar;38(3):579–83; discussion 582–3 (21 ref.)

PONTINE MYELINOLYSIS, CENTRAL see **MYELINOLYSIS, CENTRAL PONTINE**

POPLITEAL ARTERY

Atherosclerotic popliteal aneurysm. Dawson I, et al. **Br J Surg** 1997 Mar;84(3):293–9 (82 ref.)
Campylobacter fetus-associated aneurysms: report of a case involving the popliteal artery and review of the literature. Montero A, et al. **Clin Infect Dis** 1997 May;24(5):1019–21 (9 ref.)
Rupture as the exceptional complication of popliteal aneurysm. Gawenda M, et al. **Eur J Surg** 1997 Jan; 163(1):69–71 (17 ref.)
Rupture of a popliteal artery pseudo-aneurysm secondary to a fibular osteochondroma. Ballaro A, et al. **Eur J Vasc Endovasc Surg** 1997 Aug;14(2):151–2 (5 ref.)
Paradoxical embolism and aortic occlusion: a case report. Paes EH, et al. **Int Angiol** 1997 Mar;16(1):72–5 (16 ref.)
Traumatic popliteal artery thrombosis and compartment syndrome of the leg following blunt trauma to the knee: a discussion of treatment and complications. Seybold EA, et al. **J Orthop Trauma** 1996;10(2):138–41 (21 ref.)
Popliteal artery pseudoaneurysm caused by an osteochondroma--a traditional medicine massage sequelae. Kalinga MJ, et al. **Singapore Med J** 1996 Aug;37(4):443–5 (8 ref.)
[Popliteal artery entrapment syndrome] Ishimaru S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):494–6 (9 ref.) **(Jpn)**
[Adventitial cystic disease of the popliteal artery] Ishimaru S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):491–3 (11 ref.) **(Jpn)**

INJURIES

Proximal arterial dilatation developing after surgical closure of long-standing posttraumatic arteriovenous fistula. Mellière D, et al. **Ann Vasc Surg** 1997 Jul;11(4):391–6 (21 ref.)
Radiation-induced arterial disease of the lower limb. Saliou C, et al. **Ann Vasc Surg** 1997 Mar;11(2):173–7 (35 ref.)
Blunt popliteal artery injury: is physical examination alone enough for evaluation? Gable DR, et al. **J Trauma** 1997 Sep;43(3):541–4 (21 ref.)

PATHOLOGY

Ruptured popliteal artery aneurysm. An insidious complication. Sie RB, et al. **Eur J Vasc Endovasc Surg** 1997 May;13(5):432–8 (51 ref.)
MR imaging of cystic adventitial disease of the popliteal artery: 2 cases. Decleir P, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Feb;166(2):167–9 (8 ref.)

SURGERY

[Distal popliteal bypass in the diabetic patient. Clinical case] Cavallini M, et al. **Minerva Chir** 1996 Jul–Aug; 51(7–8):589–95 (23 ref.) (Eng. Abstr.) **(Ita)**
[Femoropopliteal bypass for patients with arteriosclerosis obliterans] Sasajima T. **Nippon Geka Gakkai Zasshi** 1996 Jul;97(7):551–6 (10 ref.) (Eng. Abstr.) **(Jpn)**

POPULATION

Aging and heterogeneity: genetics, social structure, and personality [see comments] Light JM, et al. **Gerontologist** 1996 Apr;36(2):165–73 (52 ref.) Comment in: Gerontologist 1996 Apr;36(2):145–6. Comment in: Gerontologist 1996 Apr;36(2):174–7.
Population characteristics and the modulation of the renin-angiotensin system in the treatment of hypertension. Weir MR. **J Hum Hypertens** 1997 Jan;11(1):17–21 (29 ref.)
Food variety of adult Melbourne Chinese: a case study of a population in transition. Hsu-Hage BH, et al. **World Rev Nutr Diet** 1996;79:53–69 (54 ref.)

POPULATION-BASED PLANNING see **COMMUNITY HEALTH PLANNING**

POPULATION CONTROL

see related
ABORTION, LEGAL
CONTRACEPTION
FAMILY PLANNING
STERILIZATION, SEXUAL

POPULATION DENSITY

see related
CROWDING
SOCIAL ISOLATION

Refugee density and dependence: practical implications of camp size. Cosgrave J. **Disasters** 1996 Sep;20(3):261–70 (11 ref.)

POPULATION DISTRIBUTION see **DEMOGRAPHY**

POPULATION DYNAMICS

The dynamics of childhood poverty. Corcoran ME, et al. **Future Child** 1997 Summer–Fall;7(2):40–54 (41 ref.)
Trends, issues, perspectives, and values for the aging of the baby boom cohorts. Cornman JM, et al. **Gerontologist** 1996 Feb;36(1):15–26 (70 ref.)

POPULATION EXPLOSION see **POPULATION GROWTH**

POPULATION GROWTH

Fertility: past, present, and future. Evans VJ.
Am J Reprod Immunol 1996 Mar;35(3):131–9 (9 ref.)
A theory of technophysio evolution, with some implications for forecasting population, health care costs, and pension costs [published erratum appears in Demography 1997 May;34(2):170] Fogel RW, et al. **Demography** 1997 Feb; 34(1):49–66 (119 ref.)
Understanding U.S. fertility: continuity and change in the National Survey of Family Growth, 1988–1995. Mosher WD, et al. **Fam Plann Perspect** 1996 Jan–Feb;28(1):4–12 (82 ref.)
The consumption bomb. Butler CD. **Med Confl Surviv** 1997 Jul–Sep;13(3):209–18 (50 ref.)
Population review: (9). Summary of issues. Craig J.
Popul Trends 1997 Summer;(88):5–12 (0 ref.)
Population growth, poverty and health. Kibirige JS.
Soc Sci Med 1997 Jul;45(2):247–59 (70 ref.)

POPULATION SIZE see **POPULATION DENSITY**

POPULATION SURVEILLANCE

Implementing the concepts of William Farr: the contributions of Alexander D. Langmuir to Public Health Surveillance and Communications. Thacker SB, et al.
Am J Epidemiol 1996 Oct 15;144(8 Suppl):S23–8 (42 ref.)
Whither studies on the socioeconomic foundations of population health? [editorial; comment] Kaplan GA, et al.
Am J Public Health 1997 Sep;87(9):1409–11 (18 ref.)
Comment on: Am J Public Health 1997 Sep;87(9):1476–83.
Comment on: Am J Public Health 1997 Sep;87(9):1491–8.
Comment on: Am J Public Health 1997 Sep;87(9):1499–503. Comment on: Am J Public Health 1997 Sep;87(9):1504–6.
Approaches to limiting emergence of antimicrobial resistance in bacteria in human populations. Hughes JM, et al.
Clin Infect Dis 1997 Jan;24 Suppl 1:S131–5 (43 ref.)
Communicable diseases surveillance. **Commun Dis Intell** 1997 Mar 6;21(5):63–9 (0 ref.)
Communicable diseases surveillance. **Commun Dis Intell** 1997 Mar 20;21(6):80–7 (0 ref.)
Population health research wins "reprieve" in Europe. Soskolne CL. **Epidemiology** 1996 Jul;7(4):451–2 (17 ref.)
Colon cancer surveillance. Choi PM, et al.
Gastroenterol Clin North Am 1995 Sep;24(3):671–87 (147 ref.)
Screening and surveillance of ulcerative colitis. Axon ATR.
Gastrointest Endosc Clin N Am 1997 Jan;7(1):129–45 (66 ref.)
Screening of patients with a positive family history of colorectal cancer. Burt RW.
Gastrointest Endosc Clin N Am 1997 Jan;7(1):65–79 (71 ref.)
Contributions of the molecular biologist in gastrointestinal cancer and precancer screening: current possibilities and future prospects. Craanen ME, et al.
Gastrointest Endosc Clin N Am 1997 Jan;7(1):147–64 (142 ref.)
Surveillance of familial adenomatous polyposis patients after ileorectal anastomosis or ileoanal pouch anastomosis. Tytgat GNJ. **Gastrointest Endosc Clin N Am** 1997 Jan; 7(1):111–27 (55 ref.)
Population-based care of depression: effective disease management strategies to decrease prevalence. Katon W, et al. **Gen Hosp Psychiatry** 1997 May;19(3):169–78 (39 ref.)
The role of epidemiology and surveillance systems in the control of sexually transmitted diseases. Catchpole MA.
Genitourin Med 1996 Oct;72(5):321–9 (97 ref.)
Basics of surveillance—an overview. Pottinger JM, et al.
Infect Control Hosp Epidemiol 1997 Jul;18(7):513–27 (27 ref.)
Liver regeneration: methods for monitoring and their applications. Assy N, et al. **J Hepatol** 1997 Apr; 26(4):945–52 (81 ref.)
Diabetes and syndrome X in hypertension—population aspects. Nilsson P. **J Hum Hypertens** 1996 Feb;10 Suppl 1:S81–4 (32 ref.)
Eradication of wild poliovirus from the Americas: acute flaccid paralysis surveillance, 1988–1995. de Quadros CA, et al. **J Infect Dis** 1997 Feb;175 Suppl 1:S37–42 (22 ref.)
Pan American Health Organization epidemiological surveillance network for Streptococcus pneumoniae. di Fabio JL, et al. **Microb Drug Resist** 1997 Summer; 3(2):131–3 (4 ref.)
Serum cholesterol and coronary heart disease—a public health perspective [see comments] Verschuren WM.
Neth J Med 1997 Jul;51(1):1–9 (26 ref.) Comment in: Neth J Med 1997 Jul;51(1):v–vii.
Statistical power and design of focused clustering studies. Waller LA. **Stat Med** 1996 Apr 15–May 15;15(7–9):765–82 (39 ref.)
Case-fatality rates and functional outcome after subarachnoid hemorrhage: a systematic review. Hop JW, et al.
Stroke 1997 Mar;28(3):660–4 (44 ref.)
[Use of registries for specific evaluation studies: example of ischemic cardiopathies] Amouyel P.
Rev Epidemiol Sante Publique 1996;44 Suppl 1:S62–9 (9 ref.) (Eng. Abstr.) **(Fre)**
[Value of cancer registries in the evaluation of colorectal cancer treatment] Launoy G, et al.
Rev Epidemiol Sante Publique 1996;44 Suppl 1:S22–32 (10 ref.) (Eng. Abstr.) **(Fre)**
[Temporal trends in the etiology of blindness] Krumpaszky HG. **Klin Monatsbl Augenheilkd** 1997 Feb;210(2):aA9–16 (16 ref.) (Eng. Abstr.) **(Ger)**
[Health information systems: the network of epidemiological surveillance and primary care. The current situation] Mirón Canelo JA, et al. **Aten Primaria** 1997 Apr 15;19(6):323–7 (26 ref.) **(Spa)**

METHODS

Process surveillance: an epidemiologic challenge for all health care organizations. Baker OG.
Am J Infect Control 1997 Apr;25(2):96–101 (34 ref.)
Surveillance of surgical site infections in alternative settings: exploring the current options. Manian FA.
Am J Infect Control 1997 Apr;25(2):102–5 (20 ref.)
The analysis of registry data in relation to various different types of hypothesis regarding the geographical distribution of disease. Draper GJ. **Cent Eur J Public Health** 1997 Jun; 5(2):90–2 (14 ref.)
Communicable diseases surveillance. **Commun Dis Intell** 1997 Aug 7;21(16):222–30 (0 ref.)
Data management issues for emerging diseases and new tools for managing surveillance and laboratory data. Martin SM, et al. **Emerg Infect Dis** 1995 Oct–Dec;1(4):124–8 (5 ref.)
Hospital-acquired infections in the United States. The importance of interhospital comparisons. Archibald LK, et al. **Infect Dis Clin North Am** 1997 Jun;11(2):245–55 (37 ref.)
Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. Alexander JP Jr, et al. **J Infect Dis** 1997 Feb;175 Suppl 1:S176–82 (35 ref.)
Gathering epidemiologic information on inhalant abuse: some methodological issues. Frank B. **NIDA Res Monogr** 1995; 148:260–73 (12 ref.)
Surveillance and intervention studies on respiratory cancers in asbestos-exposed workers. Merler E, et al.
Scand J Work Environ Health 1997 Apr;23(2):83–92 (86 ref.)
Monitoring and assessment of dietary exposure to chemical contaminants. Baht RV, et al. **World Health Stat Q** 1997; 50(1–2):132–49 (82 ref.)
Surveillance of foodborne diseases: what are the options? Borgdorff MW, et al. **World Health Stat Q** 1997; 50(1–2):12–23 (120 ref.)
Global estimation of foodborne diseases. Motarjemi Y, et al. **World Health Stat Q** 1997;50(1–2):5–11 (7 ref.)
Epidemiology of foodborne diseases: tools and applications. Potter ME, et al. **World Health Stat Q** 1997;50(1–2):24–9 (19 ref.)
Epidemiology of foodborne diseases: a worldwide review. Todd EC. **World Health Stat Q** 1997;50(1–2):30–50 (133 ref.)

PORCELAIN see **DENTAL PORCELAIN**

PORCELAIN-METAL ALLOYS see **METAL CERAMIC ALLOYS**

PORCINE CIRCOVIRUS see **CIRCOVIRUS**

PORCINE ENTEROVIRUSES see **ENTEROVIRUSES, PORCINE**

PORCINE EPIDEMIC ABORTION AND RESPIRATORY SYNDROME see **PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME**

PORCINE GASTROENTERITIS, TRANSMISSIBLE see **GASTROENTERITIS, TRANSMISSIBLE, OF SWINE**

PORCINE HEMAGGLUTINATING ENCEPHALOMYELITIS VIRUS see **CORONAVIRUS**

PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME

DIAGNOSIS

Diagnosis of PRRS. Bøtner A. **Vet Microbiol** 1997 Apr; 55(1–4):295–301 (25 ref.)

EPIDEMIOLOGY

Epidemiology of porcine reproductive and respiratory syndrome (PRRS): an overview. Albina E.
Vet Microbiol 1997 Apr;55(1–4):309–16 (42 ref.)
General overview of PRRSV: a perspective from the United States. Zimmerman JJ, et al. **Vet Microbiol** 1997 Apr; 55(1–4):187–96 (43 ref.)

IMMUNOLOGY

Immunity to PRRSV: double-edged sword. Molitor TW, et al. **Vet Microbiol** 1997 Apr;55(1–4):265–76 (33 ref.)

PHYSIOPATHOLOGY

Pathogenesis and clinical aspects of a respiratory porcine reproductive and respiratory syndrome virus infection. Van Reeth K. **Vet Microbiol** 1997 Apr;55(1–4):223–30 (29 ref.)
[Porcine reproductivé and respiratory syndrome: ten years of experience (1986–1996) with this undesirable viral infection] Albina E. **Vet Res** 1997 Jul–Aug;28(4):305–52 (241 ref.) (Eng. Abstr.) **(Fre)**

PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS see **SWINE INFERTILITY AND RESPIRATORY SYNDROME VIRUS**

PORCINE TRANSMISSIBLE GASTROENTERITIS VIRUS see **GASTROENTERITIS VIRUS, PORCINE TRANSMISSIBLE**

PORCINE XENOGRAFT BIOPROSTHESIS see **BIOPROSTHESIS**

PORCINE XENOGRAFT DRESSINGS see **BIOLOGICAL DRESSINGS**

PORCUPINES see **RODENTIA**

PORE PROTEINS see **PORINS**

PORIFERA

CHEMISTRY

Origin of metazoan adhesion molecules and adhesion receptors as deduced from cDNA analyses in the marine sponge Geodia cydonium: a review. M-uller WE.
Cell Tissue Res 1997 Sep;289(3):383–95 (85 ref.)
Intracrystalline macromolecules are involved in the morphogenesis of calcitic sponge spicules. Aizenberg J, et al. **Connect Tissue Res** 1996;34(4):255–61 (21 ref.)

PORINS

CHEMISTRY

Structure and functional mechanism of porins. Jap BK, et al. **Physiol Rev** 1996 Oct;76(4):1073–88 (85 ref.)

METABOLISM

A specific porin is involved in the malate shuttle of leaf peroxisomes. Reumann S, et al. **Biochem Soc Trans** 1996 Aug;24(3):754–7 (17 ref.)
Aquaporins and water transfer across epithelial barriers. Parisi M, et al. **Braz J Med Biol Res** 1996 Aug;29(8):933–9 (63 ref.)
On the targeting and membrane assembly of the Escherichia coli outer membrane porin, PhoE. Phoenix DA.
FEMS Immunol Med Microbiol 1996 Dec 1;16(2):77–82 (35 ref.)
Function and modulation of bacterial porins: insights from electrophysiology. Delcour AH. **FEMS Microbiol Lett** 1997 Jun 15;151(2):115–23 (41 ref.)
Pore-forming proteins in pathogenic protozoan parasites. Horta MF. **Trends Microbiol** 1997 Sep;5(9):363–6 (33 ref.)
[Protective features of pore-forming proteins of pathogenic bacteria] Supotnitskiĭ MB. **Vestn Ross Akad Med Nauk** 1996;(8):18–22 (34 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Structure and functional mechanism of porins. Jap BK, et al. **Physiol Rev** 1996 Oct;76(4):1073–88 (85 ref.)

POROKERATOSIS

Porokeratosis of Mibelli. Overview and review of the literature. Schamroth JM, et al. **Acta Derm Venereol** 1997 May;77(3):207–13 (109 ref.)
Porokeratosis. Sehgal VN, et al. **J Dermatol** 1996 Aug; 23(8):517–25 (96 ref.)

COMPLICATIONS

Disseminated superficial porokeratosis in a patient with chronic liver disease. Park BS, et al. **J Dermatol** 1997 Jul; 24(7):485–7 (13 ref.)

ETIOLOGY

High incidence of porokeratosis in renal transplant recipients. Herranz P, et al. **Br J Dermatol** 1997 Feb;136(2):176–9 (28 ref.)
A case of disseminated superficial actinic porokeratosis subsequent to renal transplantation. Matsushita S, et al.
J Dermatol 1997 Feb;24(2):110–2 (12 ref.)

GENETICS

Cancer proneness of linear porokeratosis may be explained by allelic loss. Happle R. **Dermatology** 1997;195(1):20–5 (73 ref.)

PATHOLOGY

Porokeratotic palmoplantar keratoderma discreta—a new entity or a variant of porokeratosis plantaris discreta? Korstanje MJ, et al. **Clin Exp Dermatol** 1996 Nov; 21(6):451–3 (14 ref.)
The hyperkeratotic variant of porokeratosis Mibelli is a distinct entity: clinical and ultrastructural evidence. Schaller M, et al. **Dermatology** 1996;192(3):255–8 (18 ref.)
Porokeratotic eccrine ostial and dermal duct nevus of late

onset: more frequent than previously suggested? Valks R, et al. **Dermatology** 1996;193(2):138–40 (17 ref.)

POROKERATOSIS PALMARIS ET PLANTARIS DISSEMINATA see **POROKERATOSIS**

PORP see **OSSICULAR REPLACEMENT PROSTHESIS**

PORPHYRIA

The acute porphyrias. Elder GH, et al. **Lancet** 1997 May 31;349(9065):1613–7 (53 ref.)

CHEMICALLY INDUCED

The porphyrias [corrected]: characteristics and laboratory tests [published erratum appears in Regul Toxicol Pharmacol 1996 Dec;24(3):286] Ellefson RD, et al. **Regul Toxicol Pharmacol** 1996 Aug;24(1 Pt 2):S119–25 (33 ref.)

COMPLICATIONS

Psoriasis, ichthyosis, and porphyria. Steiner G, et al. **Int Ophthalmol Clin** 1997 Spring;37(2):41–61 (71 ref.)

The little imitator—porphyria: a neuropsychiatric disorder. Crimlisk HL. **J Neurol Neurosurg Psychiatry** 1997 Apr; 62(4):319–28 (87 ref.)

[Hepatic changes in porphyria] Enríquez de Salamanca R. **Med Clin (Barc)** 1997 May 10;108(18):709–15 (89 ref.) **(Spa)**

DIAGNOSIS

Porphyria: a new perspective. Downey D. **Med Hypotheses** 1996 Apr;46(4):378–82 (20 ref.)

ENZYMOLOGY

The porphyrias. Lim HW, et al. **Clin Dermatol** 1996 Jul–Aug; 14(4):375–87 (114 ref.)

ETIOLOGY

Environmental chemical exposures and disturbances of heme synthesis. Daniell WE, et al. **Environ Health Perspect** 1997 Feb;105 Suppl 1:37–53 (196 ref.)

GENETICS

A molecular view of the neurologic porphyrias. Schreiber WE. **Clin Lab Med** 1997 Mar;17(1):73–83 (42 ref.)

[Heme synthesis and its abnormality] Sassa S. **Rinsho Ketsueki** 1997 Apr;38(4):249–52 (9 ref.) **(Jpn)**

METABOLISM

Cytochrome P450 and its interactions with the heme biosynthetic pathway. De Matteis F, et al. **Can J Physiol Pharmacol** 1996 Jan;74(1):1–8 (59 ref.)

SURGERY

Anaesthesia for porphyria. Ashley EM. **Br J Hosp Med** 1996 Jun 19–Jul 9;56(1):37–42 (22 ref.)

PORPHYRIA, ACUTE INTERMITTENT

Diagnosis and therapy of acute intermittent porphyria. Sassa S. **Blood Rev** 1996 Mar;10(1):53–8 (24 ref.)

Acute intermittent porphyria: clinicopathologic correlation. Report of a case and review of the literature. Suarez JI, et al. **Neurology** 1997 Jun;48(6):1678–83 (78 ref.)

DIAGNOSIS

Acute intermittent porphyria: laboratory diagnosis by molecular methods. Schreiber WE. **Clin Lab Med** 1995 Dec;15(4):943–56 (56 ref.)

DRUG THERAPY

Cimetidine in the treatment of acute intermittent porphyria. Rogers PD. **Ann Pharmacother** 1997 Mar;31(3):365–7 (14 ref.)

GENETICS

Review: molecular pathogenesis of hepatic acute porphyrias. Grandchamp B, et al. **J Gastroenterol Hepatol** 1996 Nov; 11(11):1046–52 (41 ref.)

METABOLISM

Oxidative stress in acute intermittent porphyria and lead poisoning may be triggered by 5-aminolevulinic acid. Bechara EJ. **Braz J Med Biol Res** 1996 Jul;29(7):841–51 (78 ref.)

PORPHYRIA CUTANEA TARDA

COMPLICATIONS

[Porphyria cutanea tarda and hepatitis B and C virus infection] Roux M, et al. **Presse Med** 1996 Nov 2; 25(33):1589–91 (9 ref.) (Eng. Abstr.) **(Fre)**

[Infection with hepatitis C virus in porphyria cutanea tarda] Lima J, et al. **Acta Med Port** 1996 Jul–Sep;9(7–9):283–6 (24 ref.) (Eng. Abstr.) **(Por)**

[A case of myocardial infarct in latent porphyria cutanea tarda] Krivosheev AB. **Ter Arkh** 1997;69(4):80–1 (10 ref.) **(Rus)**

DIAGNOSIS

Porphyria cutanea tarda and pregnancy. Loret de Mola JR, et al. **Obstet Gynecol Surv** 1996 Aug;51(8):493–7 (24 ref.)

ETIOLOGY

Hepatitis C and porphyria cutanea tarda. English JC 3rd, et al. **Cutis** 1996 Jun;57(6):404–8 (35 ref.)

[Extrahepatic diseases certainly related to hepatitis C virus] Durand JM. **Presse Med** 1997 Jun 21;26(21):1014–22 (126 ref.) **(Fre)**

GENETICS

Hepatoerythropoietic porphyria: relationship with familial porphyria cutanea tarda. Castaño Suárez E, et al. **Dermatology** 1996;193(4):332–5 (22 ref.)

[Familial porphyria cutanea tarda disclosed by chronic hepatitis C. Apropos of a case] About I, et al. **Rev Med Interne** 1996;17(12):1020–4 (26 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Porphyria cutanea tarda and pregnancy. Loret de Mola JR, et al. **Obstet Gynecol Surv** 1996 Aug;51(8):493–7 (24 ref.)

VIROLOGY

[Porphyria cutanea tarda: relations to the hepatitis C virus] Cribier B. **Presse Med** 1997 Apr 12;26(12):572–6 (27 ref.) **(Fre)**

PORPHYRIA, ERYTHROHEPATIC

Erythropoietic protoporphyria. Cox TM. **J Inherit Metab Dis** 1997 Jun;20(2):258–69 (70 ref.)

DIAGNOSIS

Hepatoerythropoietic porphyria: relationship with familial porphyria cutanea tarda. Castaño Suárez E, et al. **Dermatology** 1996;193(4):332–5 (22 ref.)

GENETICS

Hepatoerythropoietic porphyria: relationship with familial porphyria cutanea tarda. Castaño Suárez E, et al. **Dermatology** 1996;193(4):332–5 (22 ref.)

PORPHYRIA, ERYTHROPOIETIC

Congenital erythropoietic porphyria. Fritsch C, et al. **J Am Acad Dermatol** 1997 Apr;36(4):594–610 (202 ref.)

PORPHYRIA, ERYTHROPOIETIC, CONGENITAL see **PORPHYRIA, ERYTHROPOIETIC**

PORPHYRIA, HEPATIC

Hepatic porphyrias in children. Elder GH. **J Inherit Metab Dis** 1997 Jun;20(2):237–46 (40 ref.)

Variegate porphyria in South Africa, 1688–1996—new developments in an old disease. Hift RJ, et al. **S Afr Med J** 1997 Jun;87(6):722–31 (51 ref.)

COMPLICATIONS

Multiple chemical sensitivity syndrome and porphyria. A note of caution and concern. Hahn M, et al. **Arch Intern Med** 1997 Feb 10;157(3):281–5 (35 ref.)

GENETICS

The molecular basis of South African genetic porphyria established at last! Jenkins T. **S Afr Med J** 1997 Jun; 87(6):733–5 (25 ref.)

THERAPY

Acute hepatic porphyrias. Detection, prophylaxis and treatment. Kostrzewska E, et al. **Mater Med Pol** 1996 Jan–Mar;28(1):5–7 (18 ref.)

PORPHYRIA, VARIEGATE see **PORPHYRIA, HEPATIC**

PORPHYRINS

BIOSYNTHESIS

Urinary porphyrins and heme biosynthetic enzyme activities measured by HPLC in arsenic toxicity. García-Vargas GG, et al. **Biomed Chromatogr** 1996 Nov–Dec;10(6):278–84 (40 ref.)

Hormones and the control of porphyrin biosynthesis and structure in the hamster harderian gland. Payne AP, et al. **Microsc Res Tech** 1996 Jun 1;34(2):123–32 (84 ref.)

CHEMISTRY

Hormones and the control of porphyrin biosynthesis and structure in the hamster harderian gland. Payne AP, et al. **Microsc Res Tech** 1996 Jun 1;34(2):123–32 (84 ref.)

Complex formation of heterocyclic amines with porphyrins: its use in detection and prevention. Hayatsu H. **Princess Takamatsu Symp** 1995;23:172–80 (14 ref.)

[Model systems based on the lipid-porphyrin assemblies and lipoproteins in biochemical studies] Pikuz SS, et al. **Bioorg Khim** 1996 Oct–Nov;22(10–11):725–36 (69 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Sexual dimorphism in the harderian gland of the Syrian hamster is controlled and maintained by hormones, despite seasonal fluctuations in hormone levels: functional implications. Buzzell GR. **Microsc Res Tech** 1996 Jun 1; 34(2):133–8 (30 ref.)

PHARMACOLOGY

Antimutagenicity of the porphyrins and non-enzyme porphyrin-containing proteins. Odin AP. **Mutat Res** 1997 Aug;387(1):55–68 (100 ref.)

THERAPEUTIC USE

Purpurins and benzochlorins as sensitizers for photodynamic therapy. Garbo GM. **J Photochem Photobiol B** 1996 Jul; 34(2–3):109–16 (64 ref.)

URINE

Alcohol-induced changes in urinary aminolevulinic acid and porphyrins: unrelated to liver disease. Schoenfeld N, et al. **Alcohol** 1996 Jan–Feb;13(1):59–63 (18 ref.)

PORPHYROMONAS GINGIVALIS

[Chemical structure and biological activities of Porphyromonas gingivalis lipid A] Umemoto T, et al. **Nippon Saikingaku Zasshi** 1997 Apr;52(2):475–83 (15 ref.) **(Jpn)**

ENZYMOLOGY

Structure and function of a novel arginine-specific cysteine proteinase (argingipain) as a major periodontal pathogenic factor from porphyromonas gingivalis. Yamamoto K, et al. **Adv Exp Med Biol** 1996;389:33–42 (38 ref.)

Porphyromonas gingivalis proteinases as virulence factors in the development of periodontitis. Travis J, et al. **J Periodontal Res** 1997 Jan;32(1 Pt 2):120–5 (37 ref.)

[The role of Porphyromonas gingivalis proteinases in periodontitis] Polanowska J, et al. **Postepy Hig Med Dosw** 1997;51(2):149–69 (68 ref.) (Eng. Abstr.) **(Pol)**

PATHOGENICITY

[Porphyromonas gingivalis fimbriae function as one of virulence factors] Hanazawa S, et al. **Nippon Saikingaku Zasshi** 1996 Aug;51(3):803–11 (13 ref.) **(Jpn)**

PHYSIOLOGY

Can one acquire periodontal bacteria and periodontitis from a family member? Asikainen S, et al. **J Am Dent Assoc** 1997 Sep;128(9):1263–71 (37 ref.)

PORPOISES see **DOLPHINS**

PORT-WINE STAIN

SURGERY

Laser treatment of port-wine stains and hemangiomas. Garden JM, et al. **Dermatol Clin** 1997 Jul;15(3):373–83 (47 ref.)

The medical necessity for treatment of port-wine stains. McClean K, et al. **Dermatol Surg** 1997 Aug;23(8):663–7 (22 ref.)

THERAPY

Non-invasive determination of port wine stain anatomy and physiology for optimal laser treatment strategies. van Gemert MJ, et al. **Phys Med Biol** 1997 May;42(5):937–50 (35 ref.)

PORTAL PRESSURE

Variceal and portal pressure measurement: techniques and applications. Armonis A, et al. **Ital J Gastroenterol** 1996 Jun;28(5):272–9 (62 ref.)

PORTAL SYSTEM

see related
LIVER CIRCULATION
PORTOGRAPHY

ABNORMALITIES

Feline portosystemic shunts. Schunk CM. **Semin Vet Med Surg (Small Anim)** 1997 Feb;12(1):45–50 (12 ref.)

PHYSIOLOGY

Neural monitoring system for circulating somatostatin in the

PORTAL SYSTEM

hepatoportal area. Nakabayashi H. **Nutrition** 1997 Mar; 13(3):225–9 (17 ref.)

PHYSIOPATHOLOGY

Porto–hepatic venous shunt via portal vein aneurysm with splenomegaly. Hanatate F, et al. **J Gastroenterol** 1995 Dec; 30(6):786–9 (21 ref.)

[Hepatoportal hemodynamics in liver cirrhosis with the portal hypertension syndrome] Bulanov KI. **Lik Sprava** 1996 Jan–Feb;(1–2):32–5 (40 ref.) **(Rus)**

PORTAL VEIN

see related

PORTOGRAPHY

Portal vein aneurysm: report of six cases and review of the literature. Ohnami Y, et al. **Abdom Imaging** 1997 May–Jun; 22(3):281–6 (38 ref.)

Seizure: a rare and transient cause of portal venous gas. Chen KW, et al. **Am J Gastroenterol** 1997 Feb;92(2):351–2 (10 ref.)

Case report: successful treatment of bleeding jejunal varices using mesoportal recanalization and stent placement: report of a case and review of the literature. Stafford Johnson DB, et al. **Clin Radiol** 1997 Jul;52(7):562–5 (17 ref.)

Portal tumor thrombi due to gastric cancer. Sugawara Y, et al. **Hepatogastroenterology** 1996 Jul–Aug;43(10):1000–5 (25 ref.)

The management of extrahepatic portal vein aneurysms: observe or treat? Feliciano PD, et al. **HPB Surg** 1996; 10(2):113–6 (22 ref.)

Porto–hepatic venous shunt via portal vein aneurysm with splenomegaly. Hanatate F, et al. **J Gastroenterol** 1995 Dec; 30(6):786–9 (21 ref.)

Intrahepatic arterioportal fistula after hepatic gunshot wound: a case report and review of the literature. Eastridge BJ, et al. **J Trauma** 1997 Sep;43(3):523–6 (29 ref.)

Appendicitis in an eleven–year–old boy complicated by thrombosis of the portal and superior mesenteric veins. van Spronsen FJ, et al. **Pediatr Infect Dis J** 1996 Oct; 15(10):910–2 (10 ref.)

[Abdominal arteriovenous and arterio–portal fistulas: etiology, diagnosis, therapeutic possibilities] Tomczak R, et al. **Z Gastroenterol** 1997 Jul;35(7):555–62 (57 ref.) (Eng. Abstr.) **(Ger)**

ABNORMALITIES

Congenital mesenteric aneurysm and mesenteric arterioportal fistula. Paşaoğlu E, et al. **Abdom Imaging** 1996 Sep–Oct; 21(5):451–2 (10 ref.)

A rare intrahepatic portacaval tubular shunt in a patient with spastic paraparesis. Ardic S, et al. **Australas Radiol** 1997 May;41(2):181–4 (17 ref.)

Left–sided gallbladder with anomalies of the intrahepatic portal vein and anomalous junction of the pancreaticobiliary ductal system: a case report. Ogawa T, et al. **Hepatogastroenterology** 1995 Sep–Oct;42(5):645–9 (13 ref.)

New issues concerning the etiology of an old problem [editorial; comment] Ryckman FC. **J Am Coll Surg** 1996 Dec;183(6):637–9 (11 ref.) Comment on: J Am Coll Surg 1996 Dec;183(6):543–7.

Congenital extrahepatic portocaval shunts––the Abernethy malformation. Howard ER, et al. **J Pediatr Surg** 1997 Mar; 32(3):494–7 (24 ref.)

[Focal nodular hyperplasia and spontaneous intrahepatic porto–portal communication] Mignon F, et al. **J Radiol** 1996 Dec;77(12):1233–6 (22 ref.) (Eng. Abstr.) **(Fre)**

[A case of preduodenal portal vein diagnosed concomitantly with malrotation of the intestine] Kito Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Aug;94(8):538–42 (10 ref.) **(Jpn)**

PHYSIOLOGY

[Estimation of portal flow by MR angiography] Machida K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:173–6 (9 ref.) **(Jpn)**

RADIOGRAPHY

Technical aspects of accessing the portal vein during the TIPS procedure. Saxon RR, et al. **J Vasc Interv Radiol** 1997 Sep–Oct;8(5):733–44 (43 ref.)

Case records of the LeBonheur Children's Medical Center: a 17–month–old girl with abdominal distension and portal vein gas [clinical conference] Herman MI, et al. **Pediatr Emerg Care** 1997 Jun;13(3):237–42 (45 ref.)

MR angiography of the portal venous system. Nghiem HV, et al. **Semin Ultrasound CT MR** 1996 Aug;17(4):360–73 (44 ref.)

SURGERY

Failure patterns of cryopreserved vein grafts in liver transplantation. Kuang AA, et al. **Transplantation** 1996 Sep 27;62(6):742–7 (21 ref.)

Portal vein thrombosis and stenosis in pediatric liver transplantation. Millis JM, et al. **Transplantation** 1996 Sep 27;62(6):748–54 (24 ref.)

[TIPSS in the Budd–Chiari syndrome with portal vein thrombosis] Nolte W, et al. **Dtsch Med Wochenschr** 1997 Jan 31;122(5):116–21 (25 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

[Ultrasound guided puncture of the portal vein in transjugular intrahepatic portasystemic stent shunt (TIPSS)] Roeren T, et al. **Radiologe** 1996 Sep;36(9):677–82 (22 ref.) (Eng. Abstr.) **(Ger)**

PORTASYSTEMIC SHUNT, SURGICAL

Review article: update on the role of transjugular intrahepatic portosystemic stent–shunt (TIPSS) in the management of complications of portal hypertension. Stanley AJ, et al. **Aliment Pharmacol Ther** 1997 Apr;11(2):261–72 (103 ref.)

Should the distal splenorenal shunt be combined with gastric disconnection and transection? Henderson JM. **HPB Surg** 1997;10(3):184–5 (10 ref.)

[Selective shunt surgery for the treatment of portal hypertension] Kato H, et al. **Nippon Geka Gakkai Zasshi** 1996 Jan;97(1):64–9 (17 ref.) **(Jpn)**

[Endovascular interventions in decompensated liver cirrhosis] Bulanov KI. **Klin Khir** 1996;(4):46–9 (42 ref.) **(Rus)**

METHODS

Current status of transjugular intrahepatic portosystemic shunt (TIPS). Anand BS. **Indian J Gastroenterol** 1996 Apr; 15(2):55–62 (46 ref.)

PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC

TIPS for refractory ascites: neither hemlock nor panacea. The Montreal experience and review of the literature. Martinet JP, et al. **Acta Gastroenterol Belg** 1996 Jul–Sep; 59(3):202–6 (68 ref.)

Transjugular intrahepatic portosystemic shunting (TIPS): a shunt is a shunt is a shunt! [comment] Saksena S, et al. **Eur J Gastroenterol Hepatol** 1997 Jan;9(1):3–5 (27 ref.) Comment on: Eur J Gastroenterol Hepatol 1997 Jan;9(1):15–20.

Transvenous intrahepatic portosystemic shunts. Kamath PS, et al. **Gastroenterology** 1996 Dec;111(6):1700–5 (15 ref.)

Recent position of transjugular intrahepatic portosystemic shunt in the treatment of portal hypertension. Svoboda P, et al. **Hepatogastroenterology** 1997 May–Jun;44(15):647–55 (58 ref.)

Can anticoagulation enhance TIPS patency? [editorial; comment] Shiffman ML. **Hepatology** 1996 Dec; 24(6):1533–5 (31 ref.) Comment on: Hepatology 1996 Dec;24(6):1433–6.

TIPS and refractory ascites. Lessons from the recent history of ascites therapy [editorial] Arroyo V, et al. **J Hepatol** 1996 Aug;25(2):221–3 (24 ref.)

The transjugular intrahepatic portosystemic shunt. Rössle M. **J Hepatol** 1996 Aug;25(2):224–31 (62 ref.)

TIPS and hepatic encephalopathy. Pomier–Layrargues G. **Semin Liver Dis** 1996 Aug;16(3):315–20 (41 ref.)

Hemodynamic and metabolic effects of transjugular intrahepatic portosystemic shunt (TIPS) during anesthesia for orthotopic liver transplantation. Antonini M, et al. **Transpl Int** 1996;9(4):403–7 (9 ref.)

[Intra–hepatic portasystemic shunt and treatment of portal hypertension] Barange K, et al. **Gastroenterol Clin Biol** 1996;20(8–9):674–88 (146 ref.) **(Fre)**

[Intrahepatic porto–systemic shunt in the treatment of hemorrhage in portal hypertension] Barange K, et al. **Presse Med** 1997 Jul 12;26(24):1162–7 (55 ref.) (Eng. Abstr.) **(Fre)**

[TIPSS in the Budd–Chiari syndrome with portal vein thrombosis] Nolte W, et al. **Dtsch Med Wochenschr** 1997 Jan 31;122(5):116–21 (25 ref.) (Eng. Abstr.) **(Ger)**

[Transjugular intrahepatic portasystemic shunt (TIPS)––indications and outcome] Rössle M. **Z Gastroenterol** 1997 Jun;35(6):505–15 (78 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Fatal fungemia resulting from an infected transjugular intrahepatic portosystemic shunt stent. Schiano TD, et al. **Am J Gastroenterol** 1997 Apr;92(4):709–10 (9 ref.)

Transjugular intrahepatic portosystemic shunt and hepatic encephalopathy. Rössle M, et al. **Dig Dis** 1996;14 Suppl 1:12–9 (35 ref.)

INSTRUMENTATION

[Ultrasound guided puncture of the portal vein in transjugular intrahepatic portasystemic stent shunt (TIPSS)] Roeren T, et al. **Radiologe** 1996 Sep;36(9):677–82 (22 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Transjugular intrahepatic portacaval shunt (TIPS). Shankaran K, et al. **J Assoc Physicians India** 1995 Feb; 43(2):119–21 (29 ref.)

Technical aspects of accessing the portal vein during the TIPS procedure. Saxon RR, et al. **J Vasc Interv Radiol** 1997 Sep–Oct;8(5):733–44 (43 ref.)

STANDARDS

Transjugular intrahepatic portosystemic shunt as a form of treatment for portal hypertension: indications and contraindications. Brown RS Jr, et al. **Adv Intern Med** 1997; 42:485–504 (17 ref.)

PORTOGRAPHY

METHODS

CT arterial portography: technique, indications and applications. Redvanly RD, et al. **Clin Radiol** 1997 Apr; 52(4):256–68 (67 ref.)

PORTOSYSTEMIC ENCEPHALOPATHY see **HEPATIC ENCEPHALOPATHY**

PORTOSYSTEMIC SHUNT, SURGICAL see **PORTASYSTEMIC SHUNT, SURGICAL**

PORTOSYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC see **PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC**

POSITION DESCRIPTION see **JOB DESCRIPTION**

POSITIVE END–EXPIRATORY PRESSURE see **POSITIVE–PRESSURE RESPIRATION**

POSITIVE–PRESSURE RESPIRATION

Health effects of obstructive sleep apnoea and the effectiveness of continuous positive airways pressure: a systematic review of the research evidence [see comments] Wright J, et al. **BMJ** 1997 Mar 22;314(7084):851–60 (144 ref.) Comment in: BMJ 1997 Mar 22;314(7084):839–40. Comment in: BMJ 1997 Aug 9;315(7104):367; discussion 369. Comment in: BMJ 1997 Aug 9;315(7104):367–8. Comment in: BMJ 1997 Aug 9;315(7104):368; discussion 369. Comment in: BMJ 1997 Aug 9;315(7104):368–9. Comment in: BMJ 1997 Aug 9;315(7104):369. Comment in: ACP J Club 1997 Sep–Oct;127(2):45.

Nocturnal noninvasive positive pressure ventilatory assistance [see comments] Claman DM, et al. **Chest** 1996 Dec;110(6):1581–8 (71 ref.) Comment in: Chest 1997 May;111(5):1471–2.

The pharyngeal critical pressure. The whys and hows of using nasal continuous positive airway pressure diagnostically. Gold AR, et al. **Chest** 1996 Oct; 110(4):1077–88 (48 ref.)

Noninvasive positive pressure ventilation: a positive view in need of supportive evidence [editorial; comment] Rosenberg JI. **Chest** 1997 Jun;111(6):1479–82 (32 ref.) Comment on: Chest 1997 Jun;111(6):1672–8.

Auto–positive end–expiratory pressure and dynamic hyperinflation. Ranieri VM, et al. **Clin Chest Med** 1996 Sep;17(3):379–94 (50 ref.)

Hemodynamics and positive end–expiratory pressure in critically ill patients. Klinger JR. **Crit Care Clin** 1996 Oct; 12(4):841–64 (68 ref.)

Initial treatment of preterm infants––continuous positive airway pressure or ventilation? Lundstrøm KE. **Eur J Pediatr** 1996 Aug;155 Suppl 2:S25–9 (34 ref.)

Therapy for sleep apnea: who should be treated with CPAP? Chaudhary BA, et al. **J Med Assoc Ga** 1997 Sep;86(3):230–2 (26 ref.)

Hyperventilation and head injury: controversies and concerns. Geraci EB, et al. **J Neurosci Nurs** 1996 Dec; 28(6):381–7 (85 ref.)

Noninvasive positive pressure ventilation in acute respiratory failure of chronic obstructive pulmonary disease. Clark HE, et al. **Lung** 1997;175(3):143–54 (59 ref.)

Physiological and clinical consequences of positive end–expiratory pressure. Ganassini A, et al. **Monaldi Arch Chest Dis** 1997 Feb;52(1):68–70 (17 ref.)

Hemodynamic and sympathoinhibitory effects of nasal CPAP in congestive heart failure. Bradley TD. **Sleep** 1996 Dec; 19(10 Suppl):S232–5 (26 ref.)

Nasal CPAP in cardiac failure: case not proven. Calverley PM. **Sleep** 1996 Dec;19(10 Suppl):S236–9 (26 ref.)

[Positive end–expiratory pressure (PEEP) in respirator therapy of restrictive and obstructive lung diseases] Wagner TO, et al. **Pneumologie** 1996 Mar;50(3):225–30 (33 ref.) **(Ger)**

ADVERSE EFFECTS

High–inflation pressure and positive end–expiratory pressure. Injurious to the lung? No. Nelson LD. **Crit Care Clin** 1996 Jul;12(3):603–25 (110 ref.)

High–inflation pressure and positive end–expiratory pressure. Injurious to the lung? Yes. Papadakos PJ, et al. **Crit Care Clin** 1996 Jul;12(3):627–34 (29 ref.)

[Complications of nasal CPAP therapy. Consequences for general practice] Fietze I, et al. **Med Klin** 1996 Dec 15; 91(12):758–65 (67 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Noninvasive positive–pressure ventilation in patients with acute respiratory failure. Meduri GU. **Clin Chest Med** 1996 Sep;17(3):513–53 (265 ref.)

High–inflation pressure and positive end–expiratory pressure.

Injurious to the lung? No. Nelson LD. **Crit Care Clin** 1996 Jul;12(3):603–25 (110 ref.)
High–inflation pressure and positive end–expiratory pressure. Injurious to the lung? Yes. Papadakos PJ, et al. **Crit Care Clin** 1996 Jul;12(3):627–34 (29 ref.)
Noninvasive mechanical ventilation in acute respiratory failure. Ambrosino N. **Monaldi Arch Chest Dis** 1996 Dec; 51(6):514–8 (34 ref.)
Can the treatment of sleep apnea syndrome prevent the cardiovascular consequences? Fletcher EC. **Sleep** 1996 Nov;19(9 Suppl):S67–70 (9 ref.)
[Noninvasive ventilation at 2 pressure levels (VNI–2P or Bi–PAP)] Sottiaux T, et al. **Rev Med Liege** 1996 Oct; 51(10):635–8 (18 ref.) **(Fre)**

STANDARDS

The unacceptable face of evidence–based medicine [editorial] Stradling JR, et al. **J Eval Clin Pract** 1997 Apr;3(2):99–103 (39 ref.)

UTILIZATION

Noninvasive positive pressure ventilation for acute respiratory failure: underutilized or overrated? [see comments] Jasmer RM, et al. **Chest** 1997 Jun;111(6):1672–8 (44 ref.) Comment in: Chest 1997 Jun;111(6):1479–82.

POSITIVE–PRESSURE RESPIRATION, INTRINSIC

Intrinsic PEEP and cardiopulmonary interaction in patients with COPD and acute ventilatory failure. Ranieri VM, et al. **Eur Respir J** 1996 Jun;9(6):1283–92 (64 ref.)

PHYSIOPATHOLOGY

Auto–positive end–expiratory pressure and dynamic hyperinflation. Ranieri VM, et al. **Clin Chest Med** 1996 Sep;17(3):379–94 (50 ref.)

THERAPY

Auto–positive end–expiratory pressure and dynamic hyperinflation. Ranieri VM, et al. **Clin Chest Med** 1996 Sep;17(3):379–94 (50 ref.)

POSITIVE–PRESSURE RESPIRATION, OCCULT see **POSITIVE–PRESSURE RESPIRATION, INTRINSIC**

POSITIVE REINFORCEMENT see **REINFORCEMENT (PSYCHOLOGY)**

POSITRON–EMISSION TOMOGRAPHY see **TOMOGRAPHY, EMISSION–COMPUTED**

POSITRONS see **ELECTRONS**

POSTANESTHESIA NURSING

METHODS

Emergence and recovery from anesthesia for pediatrics patients in the post–anesthesia care unit. Lee B, et al. **Pediatr Ann** 1997 Aug;26(8):461–9 (19 ref.)

POST–ANESTHESIA NURSING see **POSTANESTHESIA NURSING**

POSTCHOLECYSTECTOMY SYNDROME

ETIOLOGY

[Sequelae of cholecystectomy] Schoenemann J, et al. **Z Gastroenterol** 1997 Feb;35(2):139–45 (69 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

[The "sump syndrome": a case treated by surgical endoscopy. A discussion about biliodigestive diversions and endoscopic sphincterotomies] De Monti M, et al. **Minerva Gastroenterol Dietol** 1996 Jun;42(2):93–7 (22 ref.) (Eng. Abstr.) **(Ita)**

POSTCIBAL PERIOD see **POSTPRANDIAL PERIOD**

POSTCOITAL CONTRACEPTIVES see **CONTRACEPTIVES, POSTCOITAL**

POSTCOMMISSUROTOMY SYNDROME see **POSTPERICARDIOTOMY SYNDROME**

POSTERIOR CERVICAL SYMPATHETIC SYNDROME see **SPINAL OSTEOPHYTOSIS**

POSTERIOR CRUCIATE LIGAMENT

see related
ANTERIOR CRUCIATE LIGAMENT
MEDIAL COLLATERAL LIGAMENT, KNEE

ANATOMY & HISTOLOGY

Posterior cruciate ligament anatomy and length–tension behavior of PCL surface fibers [see comments] Saddler SC, et al. **Am J Knee Surg** 1996 Fall;9(4):194–9 (48 ref.) Comment in: Am J Knee Surg 1996 Fall;9(4):171.

INJURIES

The posterior cruciate ligament: a review. Duri ZA, et al. **Am J Knee Surg** 1997 Summer;10(3):149–64; discussion 164–5 (91 ref.)
Treatment of acute and chronic posterior cruciate ligament deficiency. New approaches [see comments] L'Insalata JC, et al. **Am J Knee Surg** 1996 Fall;9(4):185–93 (46 ref.) Comment in: Am J Knee Surg 1996 Fall;9(4):171.
Treatment of complex injuries involving the posterior cruciate and posterolateral ligaments of the knee [see comments] Noyes FR, et al. **Am J Knee Surg** 1996 Fall; 9(4):200–14 (74 ref.) Comment in: Am J Knee Surg 1996 Fall;9(4):171.
Management of acute and chronic posterior cruciate ligament injuries. New approaches [see comments] Peterson CA 2nd, et al. **Am J Knee Surg** 1996 Fall;9(4):172–84 (48 ref.) Comment in: Am J Knee Surg 1996 Fall;9(4):171.
Arthroscopic posterior cruciate ligament reconstruction. Schulte KR, et al. **Clin Sports Med** 1997 Jan;16(1):145–56 (22 ref.)

PHYSIOLOGY

Posterior cruciate ligament anatomy and length–tension behavior of PCL surface fibers [see comments] Saddler SC, et al. **Am J Knee Surg** 1996 Fall;9(4):194–9 (48 ref.) Comment in: Am J Knee Surg 1996 Fall;9(4):171.

SURGERY

Arthroscopic posterior cruciate ligament reconstruction. Schulte KR, et al. **Clin Sports Med** 1997 Jan;16(1):145–56 (22 ref.)

POSTERIOR INFERIOR CEREBELLAR ARTERY SYNDROME see **WALLENBERG'S SYNDROME**

POSTGASTRECTOMY SYNDROMES

ETIOLOGY

[Motility deficits in Roux–loop gastrojejunal reconstruction after the surgical treatment of reflux diseases (the Roux stasis syndrome)] Mateş IN, et al. **Chirurgia (Bucur)** 1997 May–Jun;92(3):187–98 (50 ref.) (Eng. Abstr.) **(Rum)**

POSTIMPLANTATION PHASE

DRUG EFFECTS

Exposure of embryonic cells to alcohol: contrasting effects during preimplantation and postimplantation development. Armant DR, et al. **Semin Perinatol** 1996 Apr;20(2):127–39 (115 ref.)

PHYSIOLOGY

Bone morphogenetic proteins in development. Hogan BL. **Curr Opin Genet Dev** 1996 Aug;6(4):432–8 (57 ref.)

POST–INFARCTION HEART RUPTURE see **HEART RUPTURE, POST–INFARCTION**

POSTMARKETING PRODUCT SURVEILLANCE see **PRODUCT SURVEILLANCE, POSTMARKETING**

POSTMENOPAUSAL BONE LOSS see **OSTEOPOROSIS, POSTMENOPAUSAL**

POSTMENOPAUSAL HORMONE REPLACEMENT THERAPY see **ESTROGEN REPLACEMENT THERAPY**

POSTMENOPAUSAL OSTEOPOROSIS see **OSTEOPOROSIS, POSTMENOPAUSAL**

POSTMENOPAUSE

Estrogens––pharmacokinetics and pharmacodynamics with special reference to vaginal administration and the new estradiol formulation––Estring. Johnston A. **Acta Obstet Gynecol Scand Suppl** 1996;163:16–25 (41 ref.)
How to provide better care for the postmenopausal woman [see comments] Scura KW, et al. **Am J Nurs** 1997 Apr; 97(4):36–43 (9 ref.) Comment in: Am J Nurs 1997 May;97(5):16.
Postmenopausal adnexal cysts: how clinical management has evolved. Goldstein SR. **Am J Obstet Gynecol** 1996 Dec; 175(6):1498–501 (17 ref.)
Treatments for menopausal and post–menopausal problems: present and future. Whitehead M. **Baillieres Clin Obstet Gynaecol** 1996 Sep;10(3):515–30 (74 ref.)
Serum ferritin and heart disease: the effect of moderate exercise on stored iron levels in postmenopausal women. Naimark BJ, et al. **Can J Cardiol** 1996 Dec;12(12):1253–7 (30 ref.)
Cancer screening in the postmenopausal woman. Seltzer V. **Clin Obstet Gynecol** 1996 Dec;39(4):889–92 (5 ref.)
Hormone replacement therapy and cardiovascular risk in post–menopausal women with NIDDM. Sattar N, et al. **Diabet Med** 1996 Sep;13(9):782–8 (88 ref.)
The role of estrogen replacement therapy in the management of urinary incontinence and urinary tract infection in postmenopausal women. Griebling TL, et al. **Endocrinol Metab Clin North Am** 1997 Jun;26(2):347–60 (76 ref.)
Hormone replacement therapy: a useful tool in the prevention of coronary artery disease in postmenopausal women? Working Group on Women and Cardiovascular Disease of The Netherlands Heart Foundation. Moerman CJ, et al. **Eur Heart J** 1996 May;17(5):658–66 (54 ref.)
Practical aspects of preventing and managing atherosclerotic disease in post–menopausal women. Sullivan JM. **Eur Heart J** 1996 Aug;17 Suppl D:32–7 (53 ref.)
Clinical decision–making with the woman after menopause. Bidikov I, et al. **Geriatrics** 1997 Mar;52(3):28–35; quiz 36 (22 ref.)
Managing postmenopausal cystitis. Hextall A, et al. **Hosp Pract (Off Ed)** 1997 Jun 15;32(6):191–8 (6 ref.)
Estrogen–androgen for hormone replacement. A review. Rosenberg MJ, et al. **J Reprod Med** 1997 Jul;42(7):394–404 (95 ref.)
Diagnostic options for assessment of postmenopausal bleeding. Good AE. **Mayo Clin Proc** 1997 Apr;72(4):345–9 (13 ref.)
Role of estrogen in postmenopausal depression. Halbreich U. **Neurology** 1997 May;48(5 Suppl 7):S16–9 (58 ref.)
Role of new selective aromatase inhibitor in therapy for metastatic breast cancer in postmenopausal women [news] Hannaford M. **Nurse Pract** 1997 Mar;22(3):195–6, 201–2 (21 ref.)
The progestogen challenge test in postmenopausal women: clinical and morphologic aspects. Bortoletto C de C, et al. **Rev Paul Med** 1996 May–Jun;114(3):1166–72 (28 ref.)
Postmenopausal hormone replacement therapy and cardiovascular disease. Chae CU, et al. **Thromb Haemost** 1997 Jul;78(1):770–80 (181 ref.)
[The ultrasonic diagnosis of endometrial pathological processes in the postmenopause] Georgiev DB, et al. **Akush Ginekol (Sofiia)** 1997;36(1):21–3 (29 ref.) (Eng. Abstr.) **(Bul)**
[Menopause and postmenopause. Prognostic criteria in insurance medicine] Schiefeling M. **Versicherungsmedizin** 1996 Aug 1;48(4):116–25 (62 ref.) (Eng. Abstr.) **(Ger)**
[Risk factors for arteriosclerosis in postmenopausal women] De Carvalho ET, et al. **Arq Bras Cardiol** 1996 Jan; 66(1):37–48 (167 ref.) **(Por)**
[Benefits and risks in hormone substitute therapy in postmenopause] Baljić T. **Srp Arh Celok Lek** 1996 May–Jun;124(5–6):143–6 (20 ref.) (Eng. Abstr.) **(Scc)**

BLOOD

Hormone replacement therapy and coronary artery disease. Morris D. **Curr Opin Obstet Gynecol** 1996 Jun;8(3):184–7 (26 ref.)

DRUG EFFECTS

Hormone replacement therapy in the elderly. Miller KL. **Clin Obstet Gynecol** 1996 Dec;39(4):912–32 (66 ref.)
Use of androgens in postmenopausal women. Davis SR, et al. **Curr Opin Obstet Gynecol** 1997 Jun;9(3):177–80 (37 ref.)
New developments in postmenopausal hormone replacement therapy. Prelevic GM, et al. **Curr Opin Obstet Gynecol** 1997 Jun;9(3):207–12 (47 ref.)
Hormone replacement therapy for women after breast carcinoma. Sands R, et al. **Curr Opin Obstet Gynecol** 1996 Jun;8(3):216–20 (41 ref.)
Tamoxifen: from breast cancer therapy to the design of a postmenopausal prevention maintenance therapy. Jordan VC, et al. **Osteoporos Int** 1997;7 Suppl 1:S52–7 (36 ref.)
Gonadal hormone substitutes. Purdie DW. **Osteoporos Int** 1997;7 Suppl 1:S61–3 (5 ref.)
[Evaluation of the cardiovascular impact of hormonal replacement therapy in menopausal women] Gaspard UJ. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(7):671–6 (15 ref.) (Eng. Abstr.) **(Fre)**
[Comparative evaluation of oral versus non–oral hormonal treatments in menopause] Sitruk–Ware R. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(7):688–93 (48 ref.) (Eng. Abstr.) **(Fre)**
[Cardiovascular impact of postmenopausal hormone therapy: new data] Gaspard U. **Rev Med Liege** 1997 Apr;52(4):224–9 (21 ref.) **(Fre)**

METABOLISM

Low endogenous estrogen levels––analytical problems and tissue sensitivity. Carlström K. **Acta Obstet Gynecol Scand Suppl** 1996;163:11–5 (33 ref.)
Estrogens––pharmacokinetics and pharmacodynamics with special reference to vaginal administration and the new estradiol formulation––Estring. Johnston A. **Acta Obstet Gynecol Scand Suppl** 1996;163:16–25 (41 ref.)
Use of transdermal oestradiol (Estraderm TTS) in hypertensive postmenopausal women. Foidart JM. **Br J Clin Pract Symp Suppl** 1996 Sep;86:14–6 (32 ref.)
Postmenopausal hormone replacement therapy and insulin metabolism: effects of route of administration and

POSTMENOPAUSE

implications for heart disease and diabetes risk. Godsland IF, et al. **Br J Clin Pract Symp Suppl** 1996 Sep;86:1–5 (43 ref.)

Smoking and postmenopausal hormone replacement therapy. Jensen J. **Br J Clin Pract Symp Suppl** 1996 Sep;86:6–8 (25 ref.)

PHYSIOLOGY

Menopausal hormonal status and vaginal microbiology. Tolino A, et al. **Acta Eur Fertil** 1994 Nov–Dec;25(6):339–41 (10 ref.)

Sexual function in menopause and postmenopause. Nachtigall LE. **Curr Ther Endocrinol Metab** 1997;6:632–6 (15 ref.)

Body composition and fat distribution by dual energy X-ray absorptiometry in overweight postmenopausal women. Effect of energy-restriction and exercise. Svendsen OL. **Dan Med Bull** 1996 Jun;43(3):249–62 (161 ref.)

Rational prescribing for postmenopausal urogenital complaints. Milsom I. **Drugs Aging** 1996 Aug;9(2):78–86 (59 ref.)

The menopause transition. Greendale GA, et al. **Endocrinol Metab Clin North Am** 1997 Jun;26(2):261–77 (121 ref.)

Clinical review 82: Androgens and the postmenopausal woman. Davis SR, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):2759–63 (59 ref.)

Ultrastructural aspects of the remodeling process of the Corpus albicans in the recent postmenopausal period. Focchi GR, et al. **Rev Paul Med** 1996 May–Jun; 114(3):1173–6 (12 ref.)

POSTMORTEM CHANGES

[Collecting insects, spiders and crustaceans for criminal forensic study] Benecke M. **Arch Kriminol** 1997 May–Jun; 199(5–6):167–76 (40 ref.) (Eng. Abstr.) **(Ger)**

POSTNATAL CARE

[Fetal diaphragmatic hernia. Its prenatal and postnatal management] Ruseva R, et al. **Akush Ginekol (Sofiia)** 1996; 35(3):42–3 (8 ref.) **(Bul)**

[Pre- and postgestational vaccination] Figueroa-Damián R. **Ginecol Obstet Mex** 1996 Jul;64:310–5 (27 ref.) (Eng. Abstr.) **(Spa)**

LEGISLATION & JURISPRUDENCE

The politics of "Drive-through deliveries": putting early postpartum discharge on the legislative agenda. Declercq E, et al. **Milbank Q** 1997;75(2):175–202 (69 ref.)

METHODS

Perinatal social work and the high risk obstetrics patient. Bachman DH, et al. **Soc Work Health Care** 1997; 24(3–4):3–19 (36 ref.)

POSTNATAL DEPRESSION see **DEPRESSION, POSTPARTUM**

POSTNIDATION PHASE see **POSTIMPLANTATION PHASE**

POSTOPERATIVE CARE

Preoperative and postoperative care of the elderly woman. Barber HR. **Clin Obstet Gynecol** 1996 Dec;39(4):902–5 (7 ref.)

Endoscopic evaluation of the postoperative stomach. Mellinger JD, et al. **Gastrointest Endosc Clin N Am** 1996 Jul;6(3):621–39 (59 ref.)

Immediate postoperative care of cardiac surgical patients. Higgins TL, et al. **J Cardiothorac Vasc Anesth** 1996 Aug; 10(5):643–58 (142 ref.)

Medical management and complications in the lung transplant recipient. Midthun DE, et al. **Mayo Clin Proc** 1997 Feb;72(2):175–84 (45 ref.)

Operative and postoperative evaluation and management in the elderly. Abyad A. **Middle East J Anesthesiol** 1995 Oct; 13(3):291–306 (33 ref.)

Therapeutic approach to organ transplantation. Strom TB, et al. **Nephrol Dial Transplant** 1996 Jun;11(6):1176–81 (44 ref.)

Is it possible to prevent recurrent Crohn's disease with medical or surgical interventions? Mcleod RS. **Neth J Med** 1996 Feb;48(2):68–70 (15 ref.)

Postsurgical management of differentiated thyroid carcinoma. Mazzaferri EL, et al. **Otolaryngol Clin North Am** 1996 Aug;29(4):637–62 (115 ref.)

Organizing postoperative accelerated recovery programs. Kehlet H. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):149–51 (20 ref.)

[Ethical-judicial aspects of postoperative patient support] Ulsenheimer K. **Anaesthesist** 1997 Apr;46(4):343–7 (35 ref.) **(Ger)**

[Perioperative nutritional therapy and its relevance for postoperative outcome] Müller JM, et al. **Chirurg** 1997 Jun; 68(6):574–82 (44 ref.) (Eng. Abstr.) **(Ger)**

[Perioperative care of patients with heart dysfunction] Soto S. **Masui** 1996 Dec;45 Suppl:S128–33 (12 ref.) **(Jpn)**

[The postoperative care and treatment in esophageal cancer (4). Postoperative follow up-(recurrence, nutritional management and after-care of IC)] Ide H, et al. **Nippon Geka Gakkai Zasshi** 1996 Jun;97(6):455–9 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Pneumonia after esophagectomy] Matsubara T. **Nippon Geka Gakkai Zasshi** 1996 Jun;97(6):437–41 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Parenteral nutrition in the perioperative period] Pawłowski W. **Pol Tyg Lek** 1996 Apr;51(14–18):246–8 (44 ref.) **(Pol)**

[Safety rules for patients with artificial cardiac pacemaker] Costa R, et al. **Rev Assoc Med Bras** 1996 Jul–Sep; 42(3):185–96 (39 ref.) (Eng. Abstr.) **(Por)**

[Is radioiodine ablation of residual thyroid tissue indicated after an operation for differentiated thyroid cancer?] Chebotareva ED, et al. **Lik Sprava** 1997 Jan–Feb;(1):118–22 (18 ref.) **(Rus)**

METHODS

Follow-up after cardiac transplantation. Parameshwar J. **Br J Hosp Med** 1996 Oct 2–15;56(7):350–4 (15 ref.)

Prophylaxis post-transplant. The role of monitoring surveillance bronchoscopy and antimicrobials. Corris PA. **Clin Chest Med** 1997 Jun;18(2):311–8 (38 ref.)

Perioperative management of lung volume reduction patients. Keller CA, et al. **Clin Chest Med** 1997 Jun;18(2):285–300 (39 ref.)

Perioperative management in lung transplantation. Simpson KP, et al. **Clin Chest Med** 1997 Jun;18(2):277–84 (38 ref.)

Management of cystic fibrosis before and after lung transplantation. Egan JJ, et al. **J R Soc Med** 1997;90 Suppl 31:47–58 (54 ref.)

Prognosis and rehabilitation after hip fracture. Obrant K. **Osteoporos Int** 1996;6 Suppl 3:52–5 (39 ref.)

Preoperative versus postoperative extracorporeal life support in neonatal cardiac patients. McKay VJ, et al. **Perfusion** 1997 May;12(3):179–86 (16 ref.)

Preoperative anesthesia and postoperative considerations in laser resurfacing. Fitzpatrick RE, et al. **Semin Cutan Med Surg** 1996 Sep;15(3):170–6 (11 ref.)

Postoperative care and complications of damage control surgery. Martin RR, et al. **Surg Clin North Am** 1997 Aug; 77(4):929–42 (16 ref.)

[Indications and role of albumin for vascular loading during postoperative intensive care] Blanloeil Y, et al. **Ann Fr Anesth Reanim** 1996;15(4):497–506 (40 ref.) (Eng. Abstr.) **(Fre)**

[The preparation of patients with diabetes mellitus for operations and the management of the postoperative period] Henyk SM, et al. **Klin Khir** 1996;(7):37–40 (50 ref.) **(Ukr)**

VETERINARY

Medical care of the neurosurgical patient. Longshore RC, et al. **Semin Vet Med Surg (Small Anim)** 1996 Nov; 11(4):208–17 (36 ref.)

POSTOPERATIVE COMPLICATIONS

Delayed gastric emptying and postoperative ileus after nongastric abdominal surgery: part II. Resnick J, et al. **Am J Gastroenterol** 1997 Jun;92(6):934–40 (69 ref.)

Spinal cord surgery and galactorrhea: a case report. Faubion WA, et al. **Am J Obstet Gynecol** 1997 Aug;177(2):465–6 (2 ref.)

Complications associated with harvesting autogenous iliac bone graft. Fowler BL, et al. **Am J Orthop** 1995 Dec; 24(12):895–903 (39 ref.)

Late patellar tendon ruptures after removal of the central third for anterior cruciate ligament reconstruction. A report of two cases. Marumoto JM, et al. **Am J Sports Med** 1996 Sep–Oct;24(5):698–701 (31 ref.)

Exaggerated lithotomy position-related rhabdomyolysis. Biswas S, et al. **Am Surg** 1997 Apr;63(4):361–4 (23 ref.)

Compartment syndrome as a complication of the prolonged use of the Lloyd-Davies position. Goldsmith AL, et al. **Anaesthesia** 1996 Nov;51(11):1048–52 (26 ref.)

Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response. Boyle EM Jr, et al. **Ann Thorac Surg** 1997 Jan;63(1):277–84 (62 ref.)

Postpneumonectomy interatrial right-to-left shunt: successful percutaneous treatment. Godart F, et al. **Ann Thorac Surg** 1997 Sep;64(3):834–6 (7 ref.)

Successful management of secondary aortoesophageal fistula. Luketich JD, et al. **Ann Thorac Surg** 1996 Dec;62(6):1852–4 (11 ref.)

Sudden sensorineural hearing loss following nonotologic, noncardiopulmonary bypass surgery. Cox AJ 3rd, et al. **Arch Otolaryngol Head Neck Surg** 1997 Sep;123(9):994–8 (21 ref.)

Giant pseudoaneurysm of the extracranial vertebral artery: case report. Gallo P, et al. **Arq Neuropsiquiatr** 1996 Jun; 54(2):297–303 (53 ref.)

'Trash foot' following operations involving the abdominal aorta. Kuhan G, et al. **Aust N Z J Surg** 1997 Jan;67(1):21–4 (14 ref.)

Complications of hysterectomy. Hill DJ. **Baillieres Clin Obstet Gynaecol** 1997 Mar;11(1):181–97 (70 ref.)

High incidence of porokeratosis in renal transplant recipients. Herranz P, et al. **Br J Dermatol** 1997 Feb;136(2):176–9 (28 ref.)

Recurrent angina after coronary artery bypass surgery. Ramsdale DR. **Br J Hosp Med** 1996 Oct 2–15;56(7):331–7 (15 ref.)

Liver transplantation: review of the literature. Part 2: Vascular and biliary complications. Patenaude YG, et al. **Can Assoc Radiol J** 1997 Aug;48(4):231–42 (63 ref.)

Duodenal obstruction following elective abdominal aortic aneurysm repair. Campagnol M, et al. **Cardiovasc Surg** 1996 Dec;4(6):843–5 (8 ref.)

Cardiopulmonary complications of esophageal surgery. Amar D. **Chest Surg Clin N Am** 1997 Aug;7(3):449–56 (23 ref.)

Secondary craniofacial problems following skull base surgery. Beals SP, et al. **Clin Plast Surg** 1997 Jul; 24(3):565–81 (45 ref.)

Avoiding pitfalls and managing complications of aesthetic contouring of the craniofacial skeleton. Bucky LP, et al. **Clin Plast Surg** 1997 Jul;24(3):613–22 (18 ref.)

Problems following genioplasty. Diagnosis and treatment. Guyuron B, et al. **Clin Plast Surg** 1997 Jul;24(3):507–14 (4 ref.)

Secondary deformities following mandibular reconstruction. Miller MJ, et al. **Clin Plast Surg** 1997 Jul;24(3):551–63 (14 ref.)

Iatrogenic deformities of the first ray. Yu GV, et al. **Clin Podiatr Med Surg** 1996 Jul;13(3):367–422 (69 ref.)

Complications of arthroscopic meniscal repair. Austin KS. **Clin Sports Med** 1996 Jul;15(3):613–9 (45 ref.)

Pneumonia in the surgical patient. Polk HC Jr, et al. **Curr Probl Surg** 1997 Feb;34(2):117–200 (226 ref.)

Management of extrahepatic biliary disease after orthotopic liver transplantation: review of the literature and results of a multicenter survey. Sossenheimer M, et al. **Endoscopy** 1996 Sep;28(7):565–71 (58 ref.)

The role of growth factors in peritoneal healing: transforming growth factor beta (TGF-beta). Chegini N. **Eur J Surg Suppl** 1997;(577):17–23 (41 ref.)

The clinical significance of adhesions: focus on intestinal obstruction. Ellis H. **Eur J Surg Suppl** 1997;(577):5–9 (29 ref.)

Adhesions: pathogenesis and prevention-panel discussion and summary. Holmdahl L, et al. **Eur J Surg Suppl** 1997; (577):56–62 (57 ref.)

Lymphoproliferative disorders in organ transplant recipients. Vanrenterghem Y. **Eur Radiol** 1997;7(5):665–7 (14 ref.)

Hepatitis C after orthotopic liver transplantation. Araya V, et al. **Gastroenterology** 1997 Feb;112(2):575–82 (47 ref.)

Nerve paralysis after surgery in the submandibular triangle: review of University of Tokyo Hospital experience. Ichimura K, et al. **Head Neck** 1997 Jan;19(1):48–53 (19 ref.)

Complications of photorefractive keratectomy. Edmison DR. **Int Ophthalmol Clin** 1997 Winter;37(1):83–94 (24 ref.)

Selected complications of radial keratotomy, photorefractive keratectomy, and laser in situ keratomileusis. Filatov V, et al. **Int Ophthalmol Clin** 1997 Winter;37(1):123–48 (96 ref.)

Management of complications of blepharoplasty. Lyon DB, et al. **Int Ophthalmol Clin** 1997 Summer;37(3):205–16 (20 ref.)

Evisceration after enterocele repair: a rare complication of vaginal surgery. Virtanen HS, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1996;7(6):344–7 (27 ref.)

Widespread cutaneous necrosis and antiphospholipid antibodies: two episodes related to surgical manipulation and urinary tract infection. Del Castillo LF, et al. **J Am Acad Dermatol** 1997 May;36(5 Pt 2):872–5 (15 ref.)

CMV infection of transplant recipients. Mutimer D. **J Hepatol** 1996 Aug;25(2):259–69 (77 ref.)

De novo formation of a central nervous system cavernous malformation: implications for predicting risk of hemorrhage. Case report and review of the literature. Detwiler PW, et al. **J Neurosurg** 1997 Oct;87(4):629–32 (29 ref.)

Acute renal failure in general surgery. Slapak M. **J R Soc Med** 1996;89 Suppl 29:13–5 (8 ref.)

Eye infections after refractive keratotomy. Jain S, et al. **J Refract Surg** 1996 Jan–Feb;12(1):148–55 (49 ref.)

Morbidity and mortality of recurrent hepatitis C infection after orthotopic liver transplantation. Vierling JM, et al. **J Viral Hepat** 1997;4 Suppl 1:117–24 (53 ref.)

Hyperparathyroidism and bone loss in renal graft recipients. Ittel TH, et al. **Kidney Blood Press Res** 1997;20(3):157–62 (72 ref.)

Sudden sensorineural hearing loss after general anesthesia for nonotologic surgery. Evan KE, et al. **Laryngoscope** 1997 Jun;107(6):747–52 (40 ref.)

Fungal infections in lung and heart-lung transplant recipients. Report of 9 cases and review of the literature. Kanj SS, et al. **Medicine (Baltimore)** 1996 May;75(3):142–56 (127 ref.)

Neuropsychiatric complications after temporal lobe limbic system surgery. Gabriel EM, et al. **Neuroimaging Clin N Am** 1997 Feb;7(1):155–64 (62 ref.)

Electrophysiology of "incisional" reentrant atrial tachycardia complicating surgery for congenital heart disease. Lesh MD, et al. **Pacing Clin Electrophysiol** 1997 Aug;20(8 Pt 2):2107–11 (10 ref.)

Radiofrequency ablation of intraatrial reentrant tachycardia after surgery for congenital heart disease. Saul JP, et al. **Pacing Clin Electrophysiol** 1997 Aug;20(8 Pt 2):2112–7 (35 ref.)

Postoperative nausea and vomiting in children. Baines D.

Paediatr Anaesth 1996;6(1):7–14 (52 ref.)

Post-sympathectomy neuralgia: hypotheses on peripheral and central neuronal mechanisms [see comments] Kramis RC, et al. **Pain** 1996 Jan;64(1):1–9 (66 ref.) Comment in: Pain 1996 Sep;67(1):218–20. Comment in: Pain 1997 Apr;70(2–3):290–1.

Long-term survivors of childhood cancer. The medical consequences of cure. Marina N.
Pediatr Clin North Am 1997 Aug;44(4):1021–42 (143 ref.)

A theory of postoperative fatigue: an interaction of biological, psychological, and social processes. Salmon P, et al. **Pharmacol Biochem Behav** 1997 Apr;56(4):623–8 (80 ref.)

Complications in colon and rectal surgery. Early diagnosis and management. Kollmorgen CF, et al.
Rev Gastroenterol Mex 1996 Apr–Jun;61(2):93–9 (48 ref.)

Special problems in limb-salvage surgery. Frassica FJ, et al. **Semin Surg Oncol** 1997 Jan–Feb;13(1):55–63 (44 ref.)

Surgical complications of lung transplantation in children. Huddleston CB. **Semin Thorac Cardiovasc Surg** 1996 Jul; 8(3):296–304 (41 ref.)

Postoperative nausea and vomiting: review and clinical approaches. Haynes GR, et al. **South Med J** 1996 Oct; 89(10):940–9 (118 ref.)

Management of iatrogenic spinal stenosis complicating placement of a fusion cage. A case report. Glassman SD, et al. **Spine** 1996 Oct 15;21(20):2383–6 (16 ref.)

The difficult perineal wound. Del Pino A, et al.
Surg Clin North Am 1997 Feb;77(1):155–74 (110 ref.)

Pelvic abscess following laparoscopic appendectomy [letter] Frizelle FA, et al. **Surg Endosc** 1996 Sep;10(9):947–8 (30 ref.)

Post discharge clinically overt venous thromboembolism in orthopaedic surgery patients with negative venography--an overview analysis. Ricotta S, et al.
Thromb Haemost 1996 Dec;76(6):887–92 (56 ref.)

Hematologic problems and organ transplantation. Dmitrewski J, et al. **World J Surg** 1996 Nov–Dec; 20(9):1160–5 (43 ref.)

Hyperfiltration nephropathy as a cause of late graft loss in renal transplantation. Modlin C, et al. **World J Urol** 1996; 14(4):256–64 (86 ref.)

[Prevention of respiratory complications after abdominal surgery] Rezaiguia S, et al. **Ann Fr Anesth Reanim** 1996; 15(5):623–46 (119 ref.) (Eng. Abstr.) **(Fre)**

[Vascular complications during surgery of lumbar disk herniation. Apropos of 3 personal cases and 37 cases from a national investigation] Mercier P, et al. **Neurochirurgie** 1996;42(4–5):202–8 (16 ref.) (Eng. Abstr.) **(Fre)**

[Postoperative amyotrophic cubital neuralgia: 4 cases] Seror P, et al. **Rev Neurol (Paris)** 1997 Apr;153(3):201–4 (25 ref.) (Eng. Abstr.) **(Fre)**

[Iatrogenic biliary lesions and stenosis] Latteri S, et al.
G Chir 1997 Jan–Feb;18(1–2):61–4 (20 ref.) (Eng. Abstr.) **(Ita)**

[Massive swelling of the tongue in two patients following the repair of cleft palate] Abe Y, et al. **Masui** 1996 Sep; 45(9):1145–8 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Perioperative care of patients with heart dysfunction--influence of epidural anesthesia] Shibata K, et al. **Masui** 1996 Dec;45 Suppl:S122–7 (18 ref.) **(Jpn)**

[Indications of rethoracotomy after esophagectomy for esophageal cancer] Koide Y, et al.
Nippon Geka Gakkai Zasshi 1996 Jun;97(6):442–8 (27 ref.) (Eng. Abstr.) **(Jpn)**

[Pneumonia after esophagectomy] Matsubara T.
Nippon Geka Gakkai Zasshi 1996 Jun;97(6):437–41 (10 ref.) (Eng. Abstr.) **(Jpn)**

[A case of adenocarcinoma of the reconstructed bladder following ileocystoplasty] Ishida T, et al.
Nippon Hinyokika Gakkai Zasshi 1997 Mar;88(3):439–42 (8 ref.) (Eng. Abstr.) **(Jpn)**

[A case of T-cell malignant lymphoma developing in the chest wall of chronic pyothorax after artificial pneumothorax] Kamiya I.
Nippon Kyobu Geka Gakkai Zasshi 1996 May;44(5):709–13 (11 ref.) (Eng. Abstr.) **(Jpn)**

[A case report of postcoarctation mycotic aneurysm after surgical treatment for cerebral arterial aneurysms] Kido M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jul; 45(7):1006–10 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Dysrhythmias following cardiac surgery] Yamashiro T.
Nippon Rinsho 1996 Aug;54(8):2227–32 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Hypertension after renal transplantation] Kokado Y, et al.
Ryoikibetsu Shokogun Shirizu 1996;(12):78–82 (11 ref.) **(Jpn)**

[Complications after cardiac transplantation] Suzuki J, et al.
Ryoikibetsu Shokogun Shirizu 1996;(15):557–9 (18 ref.) **(Jpn)**

[Postoperative cardiac arrhythmias] Yokoyama M.
Ryoikibetsu Shokogun Shirizu 1996;(12):334–6 (5 ref.) **(Jpn)**

[Complications after surgery of the anterior cervical spine] Sinkiewicz A, et al. **Neurol Neurochir Pol** 1997 Jan–Feb; 31(1):135–44 (30 ref.) (Eng. Abstr.) **(Pol)**

[Xanthogranulomatous pyelonephritis in renal allograft. Report of a case and review of the literature] Cozar JM, et al. **Actas Urol Esp** 1996 Jul–Aug;20(7):664–8 (14 ref.) (Eng. Abstr.) **(Spa)**

[Tuberculosis and protozoan infections in patients undergoing transplantation] Aguado JM, et al.
Enferm Infecc Microbiol Clin 1997 May;15 Suppl 2:57–68 (171 ref.) **(Spa)**

[Infections in kidney and pancreas transplantation] Casanova D, et al. **Enferm Infecc Microbiol Clin** 1997 May;15 Suppl 2:104–11 (44 ref.) **(Spa)**

[Bacterial infection in solid organ transplantation] Gavilán F, et al. **Enferm Infecc Microbiol Clin** 1997 May;15 Suppl 2:12–21 (61 ref.) **(Spa)**

[Viral infections in solid organ transplant recipients] Moreno MA. **Enferm Infecc Microbiol Clin** 1997 May;15 Suppl 2:22–33 (260 ref.) **(Spa)**

[Fungal infections in patients undergoing solid organ transplantation] Muñoz P, et al.
Enferm Infecc Microbiol Clin 1997 May;15 Suppl 2:34–50 (241 ref.) **(Spa)**

BLOOD

Biochemical aberrations in a dialysis patient following parathyroidectomy. Cruz DN, et al. **Am J Kidney Dis** 1997 May;29(5):759–62 (6 ref.)

Thromboelastography for the assessment of hypercoagulability during general surgery. Arcelus JI, et al. **Semin Thromb Hemost** 1995;21 Suppl 4:21–6 (62 ref.)

[Pseudothrombocytopenia: case reports and review of the literature] Huss B, et al. **Infusionsther Transfusionsmed** 1995 Oct;22(5):303–9 (66 ref.) (Eng. Abstr.) **(Ger)**

CHEMICALLY INDUCED

Cortical blindness secondary to cyclosporine after orthotopic heart transplantation: a case report and review of the literature. Drachman BM, et al.
J Heart Lung Transplant 1996 Nov;15(11):1158–64 (38 ref.)

[Postoperative nausea and vomiting (see comments)] Jensen LB, et al. **Ugeskr Laeger** 1997 Jan 13;159(3):269–74 (40 ref.) (Eng. Abstr.) Comment in: Ugeskr Laeger 1997 May 19;159(21):3191–2. **(Dan)**

[Surgery in patients treated with anticoagulation during emergency and elective interventions] Encke A. **Chirurg** 1997 Jul;68(7):670–4 (11 ref.) (Eng. Abstr.) **(Ger)**

[Spontaneous liver rupture after thrombolytic therapy with streptokinase] Hinterthaner M, et al. **Zentralbl Chir** 1997; 122(1):49–51 (20 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Asymptomatic large coronary artery saphenous vein bypass graft aneurysm: a case report and review of the literature. Wight JN Jr, et al. **Am Heart J** 1997 Apr;133(4):454–60 (37 ref.)

Biochemical markers of myocardial injury during cardiac operations. Birdi I, et al. **Ann Thorac Surg** 1997 Mar; 63(3):879–84 (59 ref.)

Prognostic value of dobutamine-atropine stress echocardiography for peri-operative and late cardiac events in patients scheduled for vascular surgery. Poldermans D, et al. **Eur Heart J** 1997 Jun;18 Suppl D:D86–96 (56 ref.)

Postsurgical endophthalmitis: diagnosis and management. Das T, et al. **Indian J Ophthalmol** 1995 Sep;43(3):103–16 (80 ref.)

Magnetic resonance imaging of the postoperative spine. Genant HK. **Instr Course Lect** 1994;43:471–3 (12 ref.)

Deep venous thrombosis. The dilemma of diagnosis. Servatjoo P. **J Am Podiatr Med Assoc** 1997 May; 87(5):224–32 (24 ref.)

Electroencephalographic abnormalities in liver transplant recipients: practical considerations and review. Steg RE, et al. **J Clin Neurophysiol** 1996 Jan;13(1):60–8 (30 ref.)

Idiopathic normal-pressure hydrocephalus in adults: result of shunting correlated with clinical findings in 18 patients and review of the literature. Caruso R, et al.
Neurosurg Rev 1997;20(2):104–7 (30 ref.)

Operative treatment of spontaneous spinal epidural hematomas: a study of the factors determining postoperative outcome. Groen RJ, et al. **Neurosurgery** 1996 Sep;39(3):494–508; discussion 508–9 (22 ref.)

Arachnoid cysts associated with subdural hematomas and hygromas: analysis of 16 cases, long-term follow-up, and review of the literature. Parsch CS, et al. **Neurosurgery** 1997 Mar;40(3):483–90 (66 ref.)

Intracerebral depth electrode monitoring in partial epilepsy: the morbidity and efficacy of placement using magnetic resonance image-guided stereotactic surgery. Ross DA, et al. **Neurosurgery** 1996 Aug;39(2):327–33; discussion 333–4 (39 ref.)

Neuropsycholcgical course after surgery for intracranial aneurysms. A prospective study and a critical review. Stabell KE, et al. **Scand J Psychol** 1997 Jun;38(2):127–37 (49 ref.)

Prediction of postoperative deep-vein thrombosis. Lowe GD. **Thromb Haemost** 1997 Jul;78(1):47–52 (41 ref.)

[Modification of axial length and astigmatism by scleral buckling surgery] Grimm G, et al.
Klin Monatsbl Augenheilkd 1997 Mar;210(3):144–6 (16 ref.) (Eng. Abstr.) **(Ger)**

[The diagnosis and surgical treatment of postoperative peritonitis] Shugaev AI, et al. **Vestn Khir Im I I Grek** 1996; 155(2):114–6 (42 ref.) **(Rus)**

[Intracranial hypertension in postoperative hypoparathyroidism (letter)] López JA, et al.
Med Clin (Barc) 1997 Mar 8;108(9):358–9 (10 ref.) **(Spa)**

DRUG THERAPY

Successful management of acute aortic dissection in a heart transplant recipient. Defraigne JO, et al. **Acta Chir Belg** 1997 Jun;97(3):141–4 (15 ref.)

Management of atrial fibrillation after coronary artery bypass graft. Olshansky B. **Am J Cardiol** 1996 Oct 17;78(8A):27–34 (57 ref.)

Risks and benefits of drugs used in the management of postoperative nausea and vomiting. Sung YF. **Drug Saf** 1996 Mar;14(3):181–97 (140 ref.)

Treating the non-electrical risks of atrial fibrillation. Gershlick AH. **Eur Heart J** 1997 May;18 Suppl C:C19–26 (39 ref.)

Thrombolytic therapy for treatment of pulmonary embolism in the postoperative period: case report and review of the literature. Hartmannsgruber MW, et al. **J Clin Anesth** 1996 Dec;8(8):669–74 (41 ref.)

Postoperative nausea and vomiting--its pathophysiology and management. Dabbous A. **Middle East J Anesthesiol** 1996 Jun;13(5):495–512 (5 ref.)

Atrial arrhythmias after cardiothoracic surgery [published erratum appears in N Engl J Med 1997 Jul 17;337(3):209] Ommen SR, et al. **N Engl J Med** 1997 May 15; 336(20):1429–34 (58 ref.)

Respiratory benefits of regional anesthesia. Clergue F, et al. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):18–23 (39 ref.)

Benefits of regional anesthesia on thromboembolic complications following surgery. Rosenfeld BA.
Reg Anesth 1996 Nov–Dec;21(6 Suppl):9–12 (40 ref.)

[Clinical use of antiemetic drugs for prevention and therapy of postoperative nausea and vomiting] Saur P, et al.
Anaesthesiol Reanim 1996;21(6):153–8 (67 ref.) (Eng. Abstr.) **(Ger)**

[Post-implant antithrombotic treatment after intracoronary stents. Thrombotic occlusion] Alonso Martín JJ, et al.
Rev Esp Cardiol 1997;50 Suppl 2:31–43 (97 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Laparoscopic appendicectomy: pros & cons--literature review of 4190 cases. Hermans BP, et al.
Acta Chir Belg 1997 Jun;97(3):110–7 (29 ref.)

Proximal arterial dilatation developing after surgical closure of long-standing posttraumatic arteriovenous fistula. Mellière D, et al. **Ann Vasc Surg** 1997 Jul;11(4):391–6 (21 ref.)

Predicting outcome after cardiac transplantations: lessons from the Cardiac Transplant Research Database. Bourge RC, et al. **Curr Opin Cardiol** 1997 Mar;12(2):136–45 (13 ref.)

Complications of major operative laparoscopy. A review of 452 cases. Saidi MH, et al. **J Reprod Med** 1996 Jul; 41(7):471–6 (29 ref.)

Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Ciric I, et al. **Neurosurgery** 1997 Feb; 40(2):225–36; discussion 236–7 (101 ref.)

Early complications of laparoscopic hysterectomy. Harris WJ, et al. **Obstet Gynecol Surv** 1996 Sep;51(9):559–67 (62 ref.)

Incidence of thromboembolic complications after laparoscopic cholecystectomy: review of the literature. Lindberg F, et al. **Surg Laparosc Endosc** 1997 Aug; 7(4):324–31 (79 ref.)

Blood transfusion and infection after colorectal cancer surgery. Vamvakas EC, et al. **Transfusion** 1996 Nov–Dec; 36(11–12):1000–8 (50 ref.)

Carcinoma of the lung after heart transplantation. Goldstein DJ, et al. **Transplantation** 1996 Sep 27;62(6):772–5 (18 ref.)

[Risk factors and chronology of infection in solid organ transplantation] Gavaldà J, et al.
Enferm Infecc Microbiol Clin 1997 May;15 Suppl 2:3–11 (123 ref.) **(Spa)**

[Complications at the first month following various types of intracoronary stents, implanted with high pressure without intracoronary ultrasonography or anticoagulation] Valdés M, et al. **Rev Esp Cardiol** 1996 Jun;49(6):432–8 (35 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Bleeding causing biliary obstruction after endoscopic sphincterotomy. Mosenkis BN, et al.
Am J Gastroenterol 1997 Apr;92(4):708–9 (5 ref.)

Pulmonary mucormycosis in diabetic renal allograft recipients. Latif S, et al. **Am J Kidney Dis** 1997 Mar; 29(3):461–4 (26 ref.)

Polyomavirus-induced interstitial nephritis in two renal transplant recipients: case reports and review of the literature. Mathur VS, et al. **Am J Kidney Dis** 1997 May; 29(5):754–8 (9 ref.)

Sclerosing lipogranuloma of the scrotum following a laparoscopic herniorraphy and varicocelectomy--a case report. Baladas HG, et al. **Ann Acad Med Singapore** 1997 Mar;26(2):238–40 (4 ref.)

Intestinal perforation after suction lipoplasty: a case report and review of the literature. Talmor M, et al.
Ann Plast Surg 1997 Feb;38(2):169–72 (20 ref.)

Delayed articular cartilage slough: two cases resulting from holmium:YAG laser damage to normal articular cartilage and a review of the literature. Thal R, et al.
Arthroscopy 1996 Feb;12(1):92–4 (8 ref.)

POSTOPERATIVE COMPLICATIONS

Cerebellar mutism following posterior fossa tumour surgery. Jones S, et al. **Br J Neurosurg** 1996 Apr;10(2):221–4 (18 ref.)

Surgical aspects of Clostridium difficile colitis. Bradbury AW, et al. **Br J Surg** 1997 Feb;84(2):150–9 (108 ref.)

Cerebellar mutism: report of two unusual cases and review of the literature. Erşahin Y, et al. **Clin Neurol Neurosurg** 1997 May;99(2):130–4 (27 ref.)

Gastrointestinal endoscopy in high–risk patients. Cappell MS. **Dig Dis** 1996 Jul–Aug;14(4):228–44 (115 ref.)

Graft vascular disease after heart transplantation. Schmid C, et al. **Eur Heart J** 1997 Apr;18(4):554–9 (59 ref.)

Factors influencing the long–term results of abdominal aortic aneurysm repair. Geroulakos G, et al. **Eur J Vasc Endovasc Surg** 1997 Jan;13(1):3–8 (49 ref.)

An impacted metallic clip at the ampulla causing ascending cholangitis. Venu RP, et al. **Gastrointest Endosc** 1997 May; 45(5):435–6 (12 ref.)

Reflex sympathetic dystrophy, patella infera contracture syndrome, and loss of motion following anterior cruciate ligament surgery. Bach BR Jr, et al. **Instr Course Lect** 1997; 46:251–60 (25 ref.)

Cholesterol embolisation. A lethal complication of instrumentation of an aneurysmal aorta: a case report. Geroulakos G, et al. **Int Angiol** 1997 Mar;16(1):69–71 (17 ref.)

Problems of refraction after photorefractive keratectomy. Siow KL, et al. **J Am Optom Assoc** 1996 Dec;67(12):755–61 (7 ref.)

Surgical glove lubricants: from toxicity to opportunity. Woods JA, et al. **J Emerg Med** 1997 Mar–Apr;15(2):209–20 (59 ref.)

Ventricular dysfunction in the pediatric population: evaluation and intervention. Hanna BD. **J Heart Lung Transplant** 1997 Jun;16(6):S16–8 (22 ref.)

Nephrogenic adenoma after urethral reconstruction using bladder mucosa: report of 6 cases and review of the literature. Weingärtner K, et al. **J Urol** 1997 Sep;158(3 Pt 2):1175–7 (20 ref.)

Chronic arm edema following breast cancer treatment. Stanton AW, et al. **Kidney Int Suppl** 1997 Jun;59:S76–81 (34 ref.)

Cholelithoptysis: a rare complication of laparoscopic cholecystectomy [see comments] Breslin AB, et al. **Med J Aust** 1996 Oct 7;165(7):373–4 (6 ref.) Comment in: Med J Aust 1997 Feb 17;166(4):222.

Acoustic neuromas: results of current surgical management. Gormley WB, et al. **Neurosurgery** 1997 Jul;41(1):50–8; discussion 58–60 (45 ref.)

Hemorrhagic complications in association with silastic dural substitute: pediatric and adult case reports with a review of the literature. Robertson SC, et al. **Neurosurgery** 1997 Jan;40(1):201–5; discussion 205–6 (28 ref.)

Management of 1000 vestibular schwannomas (acoustic neuromas): hearing function in 1000 tumor resections. Samii M, et al. **Neurosurgery** 1997 Feb;40(2):248–60; discussion 260–2 (99 ref.)

The influence of biomaterials on inflammatory responses to cardiopulmonary bypass. Courtney JM, et al. **Perfusion** 1996 May;11(3):220–8 (93 ref.)

Review on the multifactorial aspects of bioincompatibility in CPB. Daniel S. **Perfusion** 1996 May;11(3):246–55 (32 ref.)

Systemic inflammatory response and the splanchnic bed in cardiopulmonary bypass. Ohri SK. **Perfusion** 1996 May; 11(3):200–12 (68 ref.)

Surgery with cardiopulmonary bypass and pulmonary inflammatory responses. Royston D. **Perfusion** 1996 May; 11(3):213–9 (53 ref.)

Systemic inflammatory responses to surgery with cardiopulmonary bypass. Royston D. **Perfusion** 1996 May; 11(3):177–89 (81 ref.)

The systemic inflammatory response to cardiopulmonary bypass and the brain. Smith PL. **Perfusion** 1996 May; 11(3):196–9 (15 ref.)

The history of the concept of inflammatory responses to cardiopulmonary bypass. Utley JR. **Perfusion** 1996 May; 11(3):190–5 (46 ref.)

Arteriovenous fistula of the scalp secondary to punch autograft hair transplantation: angioarchitecture, histopathology, and endovascular and surgical therapy. Davis AJ, et al. **Plast Reconstr Surg** 1997 Jul;100(1):242–9 (35 ref.)

Causes of failed back surgery syndrome [editorial] Goupille P. **Rev Rhum Engl Ed** 1996 Apr;63(4):235–9 (40 ref.)

Seizures after orthotopic liver transplantation. Wszolek ZK, et al. **Seizure** 1997 Feb;6(1):31–9 (33 ref.)

Complications of resurfacing. Ragland HP, et al. **Semin Cutan Med Surg** 1996 Sep;15(3):200–7 (23 ref.)

Urinary reconstruction (rather than diversion) for continence in difficult pediatric urologic disorders. Sheldon CA. **Semin Pediatr Surg** 1996 Feb;5(1):8–15 (21 ref.)

Complications in the recovery room [editorial; comment] Dhara SS. **Singapore Med J** 1997 May;38(5):190–1 (5 ref.) Comment on: Singapore Med J 1997 May;38(5):200–4.

Extradural tethering effect as one mechanism of radiculopathy complicating posterior decompression of the cervical spinal cord [see comments] Tsuzuki N, et al. **Spine** 1996 Jan 15;21(2):203–11 (14 ref.) Comment in: Spine 1996 Aug 1;21(15):1839–40.

Postsurgical hypotony: relationship to fistulization, inflammation, chorioretinal lesions, and the vitreous. Schubert HD. **Surv Ophthalmol** 1996 Sep–Oct;41(2):97–125 (331 ref.)

Acute diverticulitis in heart transplant recipients. Detry O, et al. **Transpl Int** 1996;9(4):376–9 (22 ref.)

Failure patterns of cryopreserved vein grafts in liver transplantation. Kuang AA, et al. **Transplantation** 1996 Sep 27;62(6):742–7 (21 ref.)

Portal vein thrombosis and stenosis in pediatric liver transplantation. Millis JM, et al. **Transplantation** 1996 Sep 27;62(6):748–54 (24 ref.)

Laparoscopic complications in markedly obese urologic patients (a multi–institutional review). Mendoza D, et al. **Urology** 1996 Oct;48(4):562–7 (30 ref.)

[Incarcerated hernia following laparoscopic surgery. A complication to be avoided. Case presentation and literature review] Esteve C, et al. **Rev Med Suisse Romande** 1997 Jan;117(1):25–8 (23 ref.) (Eng. Abstr.) **(Fre)**

[Damage due to patient positioning in anesthesia and surgical medicine (1)] Ullrich W, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jan; 32(1):4–20 (0 ref.) (Eng. Abstr.) **(Ger)**

[Development and pathophysiology of abdominal wall defects] Klinge U, et al. **Chirurg** 1997 Apr;68(4):293–303 (26 ref.) (Eng. Abstr.) **(Ger)**

[Errors and risks in oncologic laparoscopic surgery] Köckerling F, et al. **Chirurg** 1997 Mar;68(3):215–24 (39 ref.) (Eng. Abstr.) **(Ger)**

[Hypertension after kidney transplantation] Lenz T, et al. **Dtsch Med Wochenschr** 1996 Nov 15;121(46):1440–5 (45 ref.) **(Ger)**

[Pathogenesis of post–transplantation osteopathy] Hofbauer LC, et al. **Wien Med Wochenschr** 1996;146(12):253–7 (46 ref.) (Eng. Abstr.) **(Ger)**

[High frequency rotational angioplasty] Haude M, et al. **Z Kardiol** 1996;85 Suppl 1:17–23 (41 ref.) (Eng. Abstr.) **(Ger)**

[Quality assurance in surgery––more than documentation of postoperative complications] Grundmann RT. **Zentralbl Chir** 1996;121(3):157–66 (65 ref.) (Eng. Abstr.) **(Ger)**

[Ileostomy––cecal fistula––colostomy––which is the most suitable fecal diversion method with reference to technique, function, complications and reversal?] Köckerling F, et al. **Zentralbl Chir** 1997;122(1):34–8 (23 ref.) (Eng. Abstr.) **(Ger)**

[Postoperative chylous ascites: its etiology and treatment] Carones S, et al. **G Chir** 1996 Nov–Dec;17(11–12):586–8 (15 ref.) (Eng. Abstr.) **(Ita)**

[Laparocele after laparoscopic surgery] Di Vita G, et al. **Minerva Chir** 1997 May;52(5):523–6 (28 ref.) (Eng. Abstr.) **(Ita)**

[Surgical risk factors: lung diseases] Kuznetsov NA. **Khirurgiia (Mosk)** 1997;(5):72–8 (64 ref.) **(Rus)**

[Malignant stomach tumors in patients who have had a vagotomy for duodenal ulcers] Zuev VK, et al. **Vestn Khir Im I I Grek** 1996;155(4):97–100 (48 ref.) **(Rus)**

[The Korsakoff syndrome in a female patient operated on for an aneurysm of the anterior cerebral–anterior communicating arteries (a case report)] Dzhebrailbekov ESh, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1996 Oct–Dec;(4):37–9 (17 ref.) **(Rus)**

[Pulmonary torsion of the right superior lobe: an unusual complication secondary to surgery] Galant J, et al. **Arch Bronconeumol** 1997 May;33(5):254–6 (14 ref.) (Eng. Abstr.) **(Spa)**

[Pneumocystis carinii pneumonia in patients with a solid organ transplant (editorial; comment)] Muñoz P. **Rev Clin Esp** 1997 Jan;197(1):1–3 (14 ref.) Comment on: Rev Clin Esp 1997 Jan;197(1):31–4. **(Spa)**

[Pneumocystis carinii pneumonia in patients with a solid organ transplant: a report of 5 cases (see comments)] Ruiz Ruiz J, et al. **Rev Clin Esp** 1997 Jan;197(1):31–4 (59 ref.) (Eng. Abstr.) Comment in: Rev Clin Esp 1997 Jan;197(1):1–3. **(Spa)**

[A retroperitoneal abscess after endoscopic sphincterotomy: a severe and infrequent complication] Fernández Pérez FJ, et al. **Rev Esp Enferm Dig** 1997 Feb;89(2):139–41 (11 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Cytokine responses to cardiopulmonary bypass: lessons learned from cardiac transplantation. Wan S, et al. **Ann Thorac Surg** 1997 Jan;63(1):269–76 (71 ref.)

Effect of blood transfusion on postoperative immunocompetence [editorial] Wheatley T, et al. **Br J Anaesth** 1997 May;78(5):489–92 (64 ref.)

Opportunistic infections in the cardiac transplant patient. Thaler SJ, et al. **Curr Opin Cardiol** 1996 Mar;11(2):191–203 (95 ref.)

Immunomodulation and epidural anesthesia and analgesia. de Leon–Casasola OA. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):24–5 (16 ref.)

[Surgery in immunosuppressed patients with emergency or elective indications] Lang H, et al. **Chirurg** 1997 Jul; 68(7):675–80 (26 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Metabolic consequences of total colectomy. Christl SU, et al. **Scand J Gastroenterol Suppl** 1997;222:20–4 (80 ref.)

MICROBIOLOGY

Bacterial translocation in surgical patients. MacFie J. **Ann R Coll Surg Engl** 1997 May;79(3):183–9 (19 ref.)

Late infections associated with glaucoma surgery. Braun C. **Int Ophthalmol Clin** 1996 Summer;36(3):73–85 (56 ref.)

Postoperative infection following current cataract extraction surgery. Kanellopoulos AJ, et al. **Int Ophthalmol Clin** 1996 Summer;36(3):97–107 (47 ref.)

[Clinically isolated bacterii seen in complicated infections] Iwai S. **Nippon Geka Gakkai Zasshi** 1996 Dec;97(12):1091–6 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Severe surgical infection with no information in terms of bacteria] Tanimura H, et al. **Nippon Geka Gakkai Zasshi** 1996 Dec;97(12):1066–71 (8 ref.) (Eng. Abstr.) **(Jpn)**

MORTALITY

Importance of patient evaluation for long–term survival in medulloblastoma recurrence. La Marca F, et al. **Childs Nerv Syst** 1997 Jan;13(1):30–4 (30 ref.)

Surgical resection of pulmonary metastases from colorectal carcinoma. Five–year survival and main prognostic factors. Baron O, et al. **Eur J Cardiothorac Surg** 1996;10(5):347–51 (28 ref.)

Prognosis determination in patients with advanced heart failure. Kao W, et al. **J Heart Lung Transplant** 1997 Jun; 16(6):S2–6 (29 ref.)

[Risk assessment] Bartels H, et al. **Chirurg** 1997 Jul; 68(7):654–61 (56 ref.) (Eng. Abstr.) **(Ger)**

[What is the cause of death of the intensive care patient?] Frey L, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:283–8 (19 ref.) **(Ger)**

PATHOLOGY

The relationship between cortical injury and brain tumour. Report of two cases and review of the literature. Stendel R, et al. **Acta Neurochir (Wien)** 1997;139(3):208–14 (52 ref.)

The pathogenesis of cardiac allograft vasculopathy. Dong C, et al. **Curr Opin Cardiol** 1996 Mar;11(2):183–90 (54 ref.)

The clinical and pathologic manifestations of iatrogenically produced mesothelium–rich fragments of operative debris. Walley VM, et al. **Eur J Cardiothorac Surg** 1997 Feb; 11(2):328–32 (8 ref.)

Masked mischief. Bromage PR. **Reg Anesth** 1996 Nov–Dec; 21(6 Suppl):62–3 (6 ref.)

Molecular pathology of posttransplantation lymphoproliferative disorders. Chadburn A, et al. **Semin Diagn Pathol** 1997 Feb;14(1):15–26 (62 ref.)

Classification of the posttransplant lymphoproliferative disorders: from the past to the present. Swerdlow SH. **Semin Diagn Pathol** 1997 Feb;14(1):2–7 (21 ref.)

[Tumor embolism with fatal cerebral infarct in pneumonectomy. Case report and review of the literature] Zürcher M, et al. **Chirurg** 1996 Sep;67(9):959–62 (37 ref.) (Eng. Abstr.) **(Ger)**

[Interstitial changes in kidney transplants] Schindler R, et al. **Internist (Berl)** 1996 Nov;37(11):1152–8 (61 ref.) **(Ger)**

PHYSIOPATHOLOGY

Delayed gastric emptying and postoperative ileus after nongastric abdominal surgery: part I. Resnick J, et al. **Am J Gastroenterol** 1997 May;92(5):751–62 (130 ref.)

Sebaceous carcinoma of the eyelids: a review of six cases. Chee SP, et al. **Ann Acad Med Singapore** 1996 Mar; 25(2):273–8 (18 ref.)

Laparoscopic hernia repair––what are the results? Misra MC, et al. **Ann Acad Med Singapore** 1996 Sep;25(5):737–41 (26 ref.)

Arthroscopy of the knee. Satku K, et al. **Ann Acad Med Singapore** 1996 Sep;25(5):703–7 (29 ref.)

Video–assisted thoracoscopic management of primary spontaneous pneumothorax. Yim AP. **Ann Acad Med Singapore** 1996 Sep;25(5):668–72 (28 ref.)

Massive proximal femoral osteoarticular allograft. Bohm P, et al. **Arch Orthop Trauma Surg** 1996;115(2):100–3 (23 ref.)

Indications for fusion in the lumbar spine. Hanley EN Jr. **Bull Hosp Jt Dis** 1996;55(3):154–7 (38 ref.)

An unusual appearance of velopharyngeal closure in a post–uvulopalatopharyngoplasty patient. Yanagisawa E, et al. **Ear Nose Throat J** 1997 Jan;76(1):14–5 (5 ref.)

Emphysematous cholecystitis after endoscopic wallstent placement complicated by distal migration of the stent. Takasaki M, et al. **Endoscopy** 1995 Nov;27(9):704–6 (10 ref.)

Biochemical events in peritoneal tissue repair. diZerega GS. **Eur J Surg Suppl** 1997;(577):10–6 (44 ref.)

The role of fibrinolysis in adhesion formation. Holmdahl L. **Eur J Surg Suppl** 1997;(577):24–31 (44 ref.)

Use of expandable metal stents for benign biliary strictures: need for balanced multidisciplinary approach. Rossi RL, et al. **Gastrointest Endosc** 1996 Jan;43(1):73–5 (20 ref.)

Therapy of sphincter of Oddi dysfunction. Kalloo AN, et al. **Gastrointest Endosc Clin N Am** 1996 Jan;6(1):117–25 (53 ref.)

Endoscopy in the management of malignant obstructive jaundice. Kozarek RA. **Gastrointest Endosc Clin N Am** 1996 Jan;6(1):153–76 (65 ref.)

Benign biliary strictures and sclerosing cholangitis. Meenan J, et al. **Gastrointest Endosc Clin N Am** 1996 Jan;6(1):127–38 (59 ref.)

Sphincterotomy techniques and risks. Shields SJ, et al. **Gastrointest Endosc Clin N Am** 1996 Jan;6(1):17–42 (80 ref.)

Laparoscopic surgery of the bile ducts. Strasberg SM, et al. **Gastrointest Endosc Clin N Am** 1996 Jan;6(1):81–105 (72 ref.)

Experimental models of accelerated atherosclerosis syndromes. Mehta D, et al. **Int J Cardiol** 1996 Oct 25; 56(3):235–57 (182 ref.)

The role of cytokines in cardiac surgery. Tønnesen E, et al. **Int J Cardiol** 1996 Apr 26;53 Suppl:S1–10 (77 ref.)

Autoimmune haemolytic anaemia associated with ulcerative colitis. Murphy PT, et al. **Ir Med J** 1996 Sep–Oct; 89(5):172–3 (15 ref.)

Nonunion of distal radial fractures associated with distal ulnar shaft fractures: a report of four cases. McKee MD, et al. **J Orthop Trauma** 1997 Jan;11(1):49–53 (16 ref.)

Open total talus dislocation: case report and review of the literature. Palomo–Traver JM, et al. **J Orthop Trauma** 1997 Jan;11(1):45–9 (19 ref.)

Role of osteotomy in the treatment of slipped capital femoral epiphysis. Crawford AH. **J Pediatr Orthop B** 1996 Spring; 5(2):102–9 (55 ref.)

Postoperative nausea and vomiting—its pathophysiology and management. Dabbous A. **Middle East J Anesthesiol** 1996 Jun;13(5):495–512 (5 ref.)

Smoking and the human vertebral column: a review of the impact of cigarette use on vertebral bone metabolism and spinal fusion. Hadley MN, et al. **Neurosurgery** 1997 Jul; 41(1):116–24 (138 ref.)

Multidisciplinary management of resectable rectal cancer. Minsky BD. **Oncology (Huntingt)** 1996 Nov;10(11):1701–8, 1713–4; discussion 1714–18 (77 ref.)

Distal radius fractures: concepts and complications. Glowacki KA, et al. **Orthopedics** 1996 Jul;19(7):601–8 (49 ref.)

Persistent serratus anterior paralysis after fracture of an anterior cervical bone graft. Smith MD, et al. **Orthopedics** 1996 Jul;19(7):611–3 (16 ref.)

Fibrous dysplasia. Stanton RP, et al. **Orthopedics** 1996 Aug; 19(8):679–85 (45 ref.)

Primary sclerosing cholangitis and liver transplantation. Klompmaker IJ, et al. **Scand J Gastroenterol Suppl** 1996; 218:98–102 (42 ref.)

Management of renal artery stenosis in conjunction with aortic aneurysm. Ballard JL. **Semin Vasc Surg** 1996 Sep; 9(3):221–30 (57 ref.)

[The significance of nutrition for muscular function after surgery] Jensen MB. **Ugeskr Laeger** 1997 Feb 10; 159(7):923–6 (40 ref.) (Eng. Abstr.) **(Dan)**

[Diagnosis and follow-up of post-transplantation osteopathies] Seibel MJ. **Acta Med Austriaca** 1997;24(1):1–4 (44 ref.) (Eng. Abstr.) **(Ger)**

[Surgical metabolism] Jauch KW. **Chirurg** 1997 Jun; 68(6):551–8 (27 ref.) (Eng. Abstr.) **(Ger)**

[Infection and sepsis in resuscitation] Rodrigo–Casanova P, et al. **Rev Esp Anestesiol Reanim** 1997 Jun–Jul;44(6):230–43 (101 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

The complications of thoracic surgery: prophylaxis and treatment of arrhythmias. Van Mieghem W. **Acta Cardiol** 1995;50(5):381–6 (11 ref.)

Prophylaxis of venous thromboembolism in surgery. Verhaeghe R, et al. **Acta Chir Belg** 1997 Jun;97(3):106–9 (20 ref.)

Comparison of stress nuclear and stress echocardiography studies in predicting cardiac events in noncardiac surgery [editorial; comment] Talano JV. **Am J Card Imaging** 1996 Apr;10(2):117–9 (21 ref.) Comment on: Am J Card Imaging 1996 Apr;10(2):120–7. Comment on: Am J Card Imaging 1996 Apr;10(2):128–32. Comment on: Am J Card Imaging 1996 Apr;10(2):133–42.

The prevention of complications with the Gamma Locking Nail [see comments] Lyddon DW Jr. **Am J Orthop** 1996 May;25(5):357–63 (23 ref.) Comment in: Am J Orthop 1996 Oct;25(10):729.

Low molecular weight heparin: biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for regional anesthetic management. Horlocker TT, et al. **Anesth Analg** 1997 Oct;85(4):874–85 (78 ref.)

Danaparoid in the prevention of thromboembolic complications. Skoutakis VA. **Ann Pharmacother** 1997 Jul–Aug;31(7–8):876–87 (81 ref.)

Oesophagogastrectomy with an anastomosis using linear staplers. Bird P, et al. **Aust N Z J Surg** 1996 Nov; 66(11):757–63 (17 ref.)

Multimodal approach to control postoperative pathophysiology and rehabilitation. Kehlet H. **Br J Anaesth** 1997 May;78(5):606–17 (117 ref.)

Current views on the prevention of postoperative infectious endophthalmitis. Staudenmaier C. **Can J Ophthalmol** 1997 Aug;32(5):297–302 (54 ref.)

Effects of postoperative intraperitoneal chemotherapy on peritoneal wound healing and adhesion formation. Jacquet P, et al. **Cancer Treat Res** 1996;82:327–35 (39 ref.)

Complications of tracheal surgery. Mathisen DJ. **Chest Surg Clin N Am** 1996 Nov;6(4):853–64 (9 ref.)

Use of adhesion prevention barriers in ovarian surgery, tubalplasty, ectopic pregnancy, endometriosis, adhesiolysis, and myomectomy. diZerega GS. **Curr Opin Obstet Gynecol** 1996 Jun;8(3):230–7 (32 ref.)

Ischemic conditioning of the stomach may reduce the incidence of esophagogastric anastomotic leaks complicating esophagectomy: a hypothesis. Urschel JD. **Dis Esophagus** 1997 Jul;10(3):217–9 (23 ref.)

Unresolved issues in the prevention of venous thromboembolism. Baglin T. **Drugs** 1996;52 Suppl 7:1–6; discussion 6–7 (30 ref.)

The postdischarge risk of venous thromboembolism after hip replacement. The role of prolonged prophylaxis. Bergqvist D. **Drugs** 1996;52 Suppl 7:55–9 (47 ref.)

The risk of thromboembolism in patients undergoing colorectal surgery. McLeod RS. **Drugs** 1996;52 Suppl 7:38–41 (25 ref.)

Prevention and treatment of venous thromboembolism. Pineo GF, et al. **Drugs** 1996 Jul;52(1):71–92 (163 ref.)

Adhesions: preventive strategies. Risberg B. **Eur J Surg Suppl** 1997;(577):32–9 (32 ref.)

Avoiding complications of radical retropubic prostatectomy. Thiel R, et al. **Eur Urol** 1997;31 Suppl 3:9–15 (49 ref.)

Prolonged prophylaxis against postoperative venous thromboembolism. Bergqvist D. **Haemostasis** 1996 Oct;26 Suppl 4:379–87 (57 ref.)

Can anticoagulation enhance TIPS patency? [editorial; comment] Shiffman ML. **Hepatology** 1996 Dec; 24(6):1533–5 (31 ref.) Comment on: Hepatology 1996 Dec;24(6):1433–6.

Is there a role for perioperative nutritional support in liver resection? Bothe A Jr, et al. **HPB Surg** 1997;10(3):177–9 (8 ref.)

Postoperative endophthalmitis: risk factors and prophylaxis. Ng EW, et al. **Int Ophthalmol Clin** 1996 Summer; 36(3):109–30 (114 ref.)

The causes of failure of lumbar transpedicular spinal instrumentation and fusion: a prospective study. Hadjipavlou A, et al. **Int Orthop** 1996;20(1):35–42 (53 ref.)

Use of hypothermic circulatory arrest for cerebral protection during aortic surgery. Griepp RB, et al. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):312–21 (9 ref.)

Brain protection. Svensson LG. **J Card Surg** 1997 Mar–Apr; 12(2 Suppl):326–9; discussion 329–30 (30 ref.)

Inhibition of posterior capsule opacification by an intraocular-lens-bound sustained drug delivery system: an experimental animal study and literature review. Tetz MR, et al. **J Cataract Refract Surg** 1996 Oct;22(8):1070–8 (49 ref.)

Complications of endopyelotomy. Bellman GC. **J Endourol** 1996 Apr;10(2):177–81 (18 ref.)

Efficacy of Interceed in adhesion prevention in gynecologic surgery: a review of 13 clinical studies. Larsson B. **J Reprod Med** 1996 Jan;41(1):27–34 (40 ref.)

Timing of surgery in anterior cruciate ligament-injured knees. Shelbourne KD, et al. **Knee Surg Sports Traumatol Arthrosc** 1995;3(3):148–56 (22 ref.)

Management of vestibular schwannomas (acoustic neuromas): the value of neurophysiology for evaluation and prediction of auditory function in 420 cases. Matthies C, et al. **Neurosurgery** 1997 May;40(5):919–29; discussion 929–30 (44 ref.)

Establishing a universal protocol for deep vein thrombosis following orthopedic surgery: total knee arthroplasty. Sculco TP. **Orthopedics** 1996 Aug;19 Suppl:6–8 (22 ref.)

Low-molecular-weight heparin: from the bench to the orthopedic patient. Turpie AG. **Orthopedics** 1997 Feb;20 Suppl:10–3 (12 ref.)

Leucocyte depletion in cardiothoracic surgery. Allen SM. **Perfusion** 1996 May;11(3):270–7 (59 ref.)

Preoperative pulmonary evaluation. Identifying patients at increased risk for complications. Mohr DN, et al. **Postgrad Med** 1996 Nov;100(5):241–4, 247–8, 251–2 passim (28 ref.)

The value of peri-operative nutrition in the sick patient. Heys SD, et al. **Proc Nutr Soc** 1997 Mar;56(1B):443–57 (69 ref.)

Perioperative anti-endotoxin strategies. Houdijk AP, et al. **Scand J Gastroenterol Suppl** 1997;222:93–7 (57 ref.)

Prophylaxis against postoperative complications in gastroenterology. Kehlet H, et al. **Scand J Gastroenterol Suppl** 1996;216:218–24 (74 ref.)

New and future approaches for spinal cord protection. Svensson LG. **Semin Thorac Cardiovasc Surg** 1997 Jul; 9(3):206–21 (104 ref.)

Complications in the recovery room [editorial; comment] Dhara SS. **Singapore Med J** 1997 May;38(5):190–1 (5 ref.) Comment on: Singapore Med J 1997 May;38(5):200–4.

Laparoscopic anatomy of the region of the esophageal hiatus. Kuster GG, et al. **Surg Endosc** 1997 Sep;11(9):883–93 (54 ref.)

Prevention of post-operative deep leg vein thrombosis in patients with cancer. Gallus AS. **Thromb Haemost** 1997 Jul;78(1):126–32 (67 ref.)

[Prospects of prevention of restenosis after coronary angioplasty] Le Feuvre C, et al. **Ann Cardiol Angeiol (Paris)** 1996 Jul–Sep;45(7):383–8 (36 ref.) (Eng. Abstr.) **(Fre)**

[Perforating injuries: management of the repair of scleral and corneal injuries] Comhaire–Poutchinian Y. **Bull Soc Belge Ophtalmol** 1996;260:81–8 (12 ref.) (Eng. Abstr.) **(Fre)**

[Prevention of postoperative nausea and vomiting with single and repeat administration of ondansetron—review of the literature on different administration forms] Saur P, et al. **Anaesthesiol Reanim** 1996;21(5):131–5 (30 ref.) (Eng. Abstr.) **(Ger)**

[Technique and indications for sphincter-saving transanal resection in rectal carcinoma] Buess G, et al. **Chirurg** 1996 Feb;67(2):121–8 (22 ref.) (Eng. Abstr.) **(Ger)**

[Are high risk patients candidates for minimally invasive surgery with CO2 pneumoperitoneum? Viewpoint from anesthesiology] Schulte–Steinberg H, et al. **Chirurg** 1996 Jan;67(1):72–6 (33 ref.) (Eng. Abstr.) **(Ger)**

[The patient with respiratory problems] Senninger N, et al. **Chirurg** 1997 Jul;68(7):662–9 (58 ref.) (Eng. Abstr.) **(Ger)**

[Vital preoperative function diagnosis in deep anterior rectum resection] Stern J, et al. **Chirurg** 1996 Feb;67(2):129–32 (20 ref.) (Eng. Abstr.) **(Ger)**

[Current approach in antithrombotic treatment during coronary interventions: specific thrombocyte aggregation inhibitors and direct thrombin antagonists in high-risk patients] Meyer BJ. **Schweiz Med Wochenschr** 1996 Nov 16;126(46):1961–9 (43 ref.) (Eng. Abstr.) **(Ger)**

[Preserving continence in treatment of inflammatory bowel disease associated anal fistulas] Farthmann EH, et al. **Schweiz Rundsch Med Prax** 1997 Jun 18;86(25–26):1068–70 (11 ref.) (Eng. Abstr.) **(Ger)**

[Thrombosis in trauma and orthopedic surgery. Prevention, diagnosis, therapy] Haas S. **Unfallchirurg** 1997 Apr; 100(4):307–19 (10 ref.) **(Ger)**

[Preoperative evaluation of aged patients] Meguro K, et al. **Masui** 1996 Dec;45 Suppl:S143–6 (5 ref.) **(Jpn)**

[Surgical procedures and intra-operative management to prevent postoperative complications following resection of esophageal cancer] Fujita H. **Nippon Geka Gakkai Zasshi** 1996 Jun;97(6):421–6 (0 ref.) (Eng. Abstr.) **(Jpn)**

[Prevention and treatment of postoperative septic MOF and DIC and efficacy of blood purification] Hirasawa H, et al. **Nippon Geka Gakkai Zasshi** 1996 Dec;97(12):1079–84 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Perioperative managements for postoperative severe infections in compromised host] Yokoyama T, et al. **Nippon Geka Gakkai Zasshi** 1996 Dec;97(12):1060–5 (14 ref.) (Eng. Abstr.) **(Jpn)**

[The use of the laser in the surgical treatment of acute intestinal obstruction and the prevention of adhesive disease] Kalish IuI, et al. **Khirurgiia (Mosk)** 1996;(6):103–8 (123 ref.) **(Rus)**

[Choice of the method of restoration of intestinal continuity after removal of the ileocecal region] Poida AI, et al. **Klin Khir** 1996;(10):45–7 (29 ref.) **(Rus)**

[The prevention and treatment of postoperative thrombosis of the deep veins of the lower extremities (I. Prevention)] Baeshko AA, et al. **Vestn Khir Im I I Grek** 1997; 156(1):116–21 (108 ref.) **(Rus)**

[Pre-transplant evaluation of the donor and recipient. Recommendations for surveillance and control of infection after transplantation] Cisneros JM, et al. **Enferm Infecc Microbiol Clin** 1997 May;15 Suppl 2:98–103 (68 ref.) **(Spa)**

[Prevention of infection in recipients of solid organ transplants] Lumbreras C, et al. **Enferm Infecc Microbiol Clin** 1997 May;15 Suppl 2:77–89 (155 ref.) **(Spa)**

[Low molecular weight heparins. Implications in anesthesia and resuscitation] Llau JV, et al. **Rev Esp Anestesiol Reanim** 1997 Feb;44(2):70–8 (142 ref.) (Eng. Abstr.) **(Spa)**

[Enteral jejunostomy prevents malnutrition. The method is safe and practical even for home care] Elgadi A, et al. **Lakartidningen** 1997 Jan 29;94(5):324–6 (20 ref.) **(Swe)**

PSYCHOLOGY

Prediction of quality of life after coronary artery bypass graft surgery: a review and evaluation of multiple, recent studies. Duits AA, et al. **Psychosom Med** 1997 May–Jun; 59(3):257–68 (74 ref.)

[Psychosocial aspects of ENT tumor surgery (excluding laryngectomy). 2: Analysis of empirical studies (see comments)] Kollbrunner J, et al. **HNO** 1997 Jun; 45(6):433–41 (0 ref.) (Eng. Abstr.) Comment in: HNO 1997 Jun;45(6):424. **(Ger)**

[Postoperative cognitive dysfunction] Muñoz–Corsini L, et al. **Rev Esp Anestesiol Reanim** 1997 May;44(5):191–200 (71 ref.) (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

Radiologic issues in lung transplantation for end-stage pulmonary disease. Erasmus JJ, et al. **AJR Am J Roentgenol** 1997 Jul;169(1):69–78 (81 ref.)

Case report. Aortic pseudoaneurysm with aortobronchial fistula: diagnosis with CT angiography. Ferretti GR, et al. **J Comput Assist Tomogr** 1996 Nov–Dec;20(6):975–8 (8 ref.)

Epidural lipomatosis: case report and literature review. Hierholzer J, et al. **Neuroradiology** 1996 May;38(4):343–8 (25 ref.)

Incisional herniation of the bladder: CT findings. Catalano O. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Nov;165(5):508–9 (8 ref.)

[Metastatic pulmonary calcification as a rare complication of terminal kidney failure: the x-ray and CT findings] Reuter M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996

Nov;165(5):493–5 (13 ref.) **(Ger)**
[Late results of joint-preserving femur head necrosis surgery] Peters KM, et al. **Zentralbl Chir** 1997;122(3):171–6 (23 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

Sports after total joint replacement. Cirincione RJ. **Md Med J** 1996 Aug;45(8):644–7 (12 ref.)
[Sequelae of total laryngectomy with special reference to rehabilitation of the voice and lower airways] Ackerstaff AH, et al. **HNO** 1997 Feb;45(2):97–104 (26 ref.) **(Ger)**

SURGERY

Ureteric injury at Burch colposuspension. 4 case reports and literature review. Rosen DM, et al. **Aust N Z J Obstet Gynaecol** 1996 Aug;36(3):354–8 (15 ref.)
Debate: 'post-operative urinary fistulae should be managed by gynaecologists in specialist centres'. Hilton P. **Br J Urol** 1997 Jul;80 Suppl 1:35–42 (9 ref.)
Reoperations on the spine--outcome studies. Fraser RD. **Bull Hosp Jt Dis** 1996;55(4):217–20 (54 ref.)
Secondary cleft deformities. Folk SN, et al. **Clin Plast Surg** 1997 Jul;24(3):599–611 (32 ref.)
Endoscopic retrograde cholangiopancreatography and laparoscopic cholecystectomy. Brady PG, et al. **Dig Dis** 1996 Nov-Dec;14(6):371–81 (47 ref.)
Stapedius tendon reconstruction during stapedotomy: technique and results. Causse JB, et al. **Ear Nose Throat J** 1997 Apr;76(4):256–8, 260–9 (29 ref.)
Surgical management of carcinoma of the cervical stump. A case report. Maseela T, et al. **Eur J Gynaecol Oncol** 1996;17(5):381–3 (9 ref.)
Diaphragmatic rupture after plication: etiopathogenesis with review of the literature. Ciftci AO, et al. **Eur J Pediatr Surg** 1996 Jun;6(3):177–9 (17 ref.)
Postsurgical biliary tract complications. Ghahremani GG. **Gastroenterologist** 1997 Mar;5(1):46–57 (64 ref.)
Experience with cardiac tamponade following open heart surgery. Ball JB, et al. **Heart Vessels** 1996;11(1):39–43 (41 ref.)
Stricturoplasty for benign biliary stricture. Bose SM, et al. **Indian J Gastroenterol** 1997 Jul;16(3):107–8 (5 ref.)
Subdural hemorrhage caused by de novo aneurysm complicating extracranial-intracranial bypass surgery: case report. Kohno K, et al. **Neurosurgery** 1996 May; 38(5):1051–5 (17 ref.)
Contralateral cerebellar hemorrhagic infarction after pterional craniotomy: report of five cases and review of the literature. Papanastassiou V, et al. **Neurosurgery** 1996 Oct;39(4):841–51; discussion 851–2 (38 ref.)
Successful treatment of a rectal anastomotic stenosis by transanal endoscopic microsurgery (TEM) using the contact Nd:YAG laser. Kato K, et al. **Surg Endosc** 1997 May;11(5):485–7 (11 ref.)
Vascular injury during lumbar disc surgery. Report of two cases; a review of the literature. Sağdiç K, et al. **Vasa** 1996; 25(4):378–81 (21 ref.)
[Incisional hernias] Eisner L, et al. **Chirurg** 1997 Apr; 68(4):304–9 (43 ref.) (Eng. Abstr.) **(Ger)**
[Tension-free suture of incisional hernia] Farthmann EH, et al. **Chirurg** 1997 Apr;68(4):310–6 (28 ref.) (Eng. Abstr.) **(Ger)**
[Plastic surgery defect coverage in the area of the pelvis and trunk] Germann G, et al. **Chirurg** 1997 May; 68(5):469–76 (26 ref.) (Eng. Abstr.) **(Ger)**
[Late results of Childs-Phillips mesenteric plication for therapy and prevention of small intestine ileus] Sclabas G, et al. **Chirurg** 1997 Jul;68(7):693–9 (32 ref.) (Eng. Abstr.) **(Ger)**
[Endonasal surgery of the paranasal sinuses--concepts, techniques, results, complications and revision interventions] Hosemann W. **Eur Arch Otorhinolaryngol Suppl** 1996;1:155–269 (894 ref.) **(Ger)**
[A case of contralateral pneumothorax after right pneumonectomy] Nishiuchi S, et al. **Kyobu Geka** 1996 Aug; 49(9):725–8 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Current principles of the surgical treatment of postoperative peritonitis] Saenko VF, et al. **Klin Khir** 1996;(6):4–9 (12 ref.) **(Rus)**
[Revision endoprosthesis (the complications of primary endoprosthesis)] Neverov VA, et al. **Vestn Khir Im I I Grek** 1996;155(4):94–6 (14 ref.) **(Rus)**
[The diagnosis and surgical treatment of postoperative peritonitis] Shugaev AI, et al. **Vestn Khir Im I I Grek** 1996; 155(2):114–6 (42 ref.) **(Rus)**

THERAPY

Trabeculectomy with intraoperative sponge 5-fluorouracil in Afro-Caribbeans. Lachkar Y, et al. **Br J Ophthalmol** 1997 Jul;81(7):555–8 (28 ref.)
Malignant glaucoma and its management. Ruben S, et al. **Br J Ophthalmol** 1997 Feb;81(2):163–7 (36 ref.)
Management of azygos vein "steal" following hemi-Fontan by transcatheter coil embolization. Vance MS, et al. **Cathet Cardiovasc Diagn** 1996 Dec;39(4):403–6 (7 ref.)
Fibrin sealant in thoracic surgery. Pulmonary applications, including management of bronchopleural fistula. Bayfield MS, et al. **Chest Surg Clin N Am** 1996 Aug;6(3):567–83 (60 ref.)
Management of postpneumonectomy empyema and bronchopleural fistula. Deschamps C, et al. **Chest Surg Clin N Am** 1996 Aug;6(3):519–27 (34 ref.)
Management of late postpneumonectomy empyema and bronchopleural fistula. Wain JC. **Chest Surg Clin N Am** 1996 Aug;6(3):529–41 (32 ref.)
Diagnosis and management of prosthetic valve dysfunction. Binder T, et al. **Curr Opin Cardiol** 1996 Mar;11(2):131–8 (60 ref.)
Postsurgical endophthalmitis: diagnosis and management. Das T, et al. **Indian J Ophthalmol** 1995 Sep;43(3):103–16 (80 ref.)
Management of subacute stent closure. Hasdai D, et al. **Int J Cardiol** 1996 Jul 26;55(2):115–6 (10 ref.)
Trauma management in solid organ transplant recipients. Barone GW, et al. **J Emerg Med** 1997 Mar-Apr; 15(2):169–76 (12 ref.)
Transrectal and transvaginal abscess drainage. Hovsepian DM. **J Vasc Interv Radiol** 1997 Jul-Aug;8(4):501–15 (39 ref.)
Use of intravascular stents for superior vena caval obstruction after the Mustard operation. MacLellan-Tobert SG, et al. **Mayo Clin Proc** 1996 Nov;71(11):1071–6 (23 ref.)
Management of the failing glaucoma filter. Shingleton BJ. **Ophthalmic Surg Lasers** 1996 Jun;27(6):445–51 (39 ref.)
Infected total knee arthroplasty: review. Berman AT, et al. **Orthopedics** 1997 Jun;20(6):563–6 (17 ref.)
Management of complications resulting from laryngeal cancer treatment. Weissler MC. **Otolaryngol Clin North Am** 1997 Apr;30(2):269–78 (16 ref.)
Gastrointestinal benefits of regional anesthesia/analgesia. Carpenter RL. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):13–7 (29 ref.)
Effect of pain relief on the surgical stress response. Kehlet H. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):35–7 (3 ref.)
Prosthetic loosening after total hip arthroplasty diagnosis and management. Langlais F. **Rev Rhum Engl Ed** 1996 Nov; 63(10):659–69 (36 ref.)
[Value of score systems in heart surgery] Falk V, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:303–6 (18 ref.) (Eng. Abstr.) **(Ger)**
[Risk of infection and wound healing disorders in dialysis patients] Zimmermann J, et al. **Zentralbl Chir** 1996;121 Suppl:58–60 (14 ref.) **(Ger)**
[Treatment and follow-up by primary care physicians of patients after coronary bypass surgery] Nesher N, et al. **Harefuah** 1996 Nov 15;131(10):431–5 (26 ref.) **(Heb)**
[Gastrointestinal tract paralysis in surgery and methods for its treatment] Smirnova VI, et al. **Anesteziol Reanimatol** 1995 Nov-Dec;(6):71–3 (39 ref.) **(Rus)**
[The prevention and treatment of postoperative thrombosis of the deep veins of the lower extremities (II. Treatment)] Baeshko AA, et al. **Vestn Khir Im I I Grek** 1997; 156(2):132–6 (87 ref.) **(Rus)**

ULTRASONOGRAPHY

Direct demonstration of an air-fluid interface by two-dimensional echocardiography: a new diagnostic sign of hydropneumopericardium. Antonini-Canterin F, et al. **J Am Soc Echocardiogr** 1996 Mar-Apr;9(2):187–9 (7 ref.)
Transesophageal echocardiographic features and management of retained intracardiac air in two patients after surgery. Wellford AL, et al. **J Am Soc Echocardiogr** 1996 Mar-Apr;9(2):182–6 (8 ref.)
[2D and Doppler echocardiography after atrial switch operation for transposition of great arteries; a review] Kaulitz R, et al. **Z Kardiol** 1996 Jan;85(1):35–44 (46 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Instrumentation and techniques for treating orthopedic infections in horses. Baxter GM. **Vet Clin North Am Equine Pract** 1996 Aug;12(2):303–35 (70 ref.)
Feline perineal urethrostomy: a potential cause of feline lower urinary tract disease. Osborne CA, et al. **Vet Clin North Am Small Anim Pract** 1996 May; 26(3):535–49 (23 ref.)

VIROLOGY

Cytomegalovirus in transplantation: new developments. Lam KM, et al. **Coron Artery Dis** 1997 May;8(5):305–16 (134 ref.)

POSTOPERATIVE HEMORRHAGE

Endoleak as a complication of endoluminal grafting of abdominal aortic aneurysms: classification, incidence, diagnosis, and management. White GH, et al. **J Endovasc Surg** 1997 May;4(2):152–68 (20 ref.)

BLOOD

Thromboelastography and liver transplantation. Gillies BS. **Semin Thromb Hemost** 1995;21 Suppl 4:45–9 (15 ref.)
Thromboelastography and cardiopulmonary bypass. Spiess BD. **Semin Thromb Hemost** 1995;21 Suppl 4:27–33 (31 ref.)

CHEMICALLY INDUCED

Peri-operative use of nonsteroidal anti-inflammatory drugs in children: analgesic efficacy and bleeding. Rømsing J, et al. **Anaesthesia** 1997 Jul;52(7):673–83 (40 ref.)

DRUG THERAPY

Reduction in requirements for allogeneic blood products: pharmacologic methods. Janssens M, et al. **Ann Thorac Surg** 1996 Dec;62(6):1944–50 (61 ref.)
Controlled clinical studies of fibrin sealant in cardiothoracic surgery--a review. Kjaergard HK, et al. **Eur J Cardiothorac Surg** 1996;10(9):727–33 (30 ref.)

ETIOLOGY

Endothelial cell injury in cardiovascular surgery: the procoagulant response. Boyle EM Jr, et al. **Ann Thorac Surg** 1996 Nov;62(5):1549–57 (54 ref.)
Blood contact activation: pathophysiological effects and therapeutic approaches. Hornick P, et al. **Perfusion** 1996 Jan;11(1):3–19 (143 ref.)

PREVENTION & CONTROL

Intraoperative autologous blood donation preserves red cell mass but does not decrease postoperative bleeding. Helm RE, et al. **Ann Thorac Surg** 1996 Nov;62(5):1431–41 (25 ref.)
[Cataract operation during therapy with anticoagulants. Principles, perioperative procedure, complications and recommendations] Dick B, et al. **Ophthalmologe** 1997 May; 94(5):372–84 (28 ref.) **(Ger)**

SURGERY

[Surgical therapy of hemorrhage after endoscopic sphincterotomy. Indications and technique] Sulkowski U, et al. **Chirurg** 1996 Jan;67(1):26–31 (19 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Hemorrhage and the use of blood products after adult cardiac operations: myths and realities. Bélisle S, et al. **Ann Thorac Surg** 1996 Dec;62(6):1908–17 (63 ref.)
Mediastinal bleeding after cardiopulmonary bypass in pediatric patients. Guay J, et al. **Ann Thorac Surg** 1996 Dec;62(6):1955–60 (30 ref.)

POSTOPERATIVE WOUND INFECTION see **SURGICAL WOUND INFECTION**

POSTOVULATORY PHASE see **LUTEAL PHASE**

POSTPARTUM DEPRESSION see **DEPRESSION, POSTPARTUM**

POSTPARTUM HEMORRHAGE

PREVENTION & CONTROL

The role of oral (methyl)ergometrine in the prevention of postpartum haemorrhage [see comments] de Groot AN. **Eur J Obstet Gynecol Reprod Biol** 1996 Oct;69(1):31–6 (19 ref.) Comment in: Eur J Obstet Gynecol Reprod Biol 1996 Oct;69(1):3–4.
The prevention of post partum haemorrhage: optimising routine management of the third stage of labour. Prendiville WJ. **Eur J Obstet Gynecol Reprod Biol** 1996 Oct; 69(1):19–24 (22 ref.)

THERAPY

Management of postpartum hemorrhage. Norris TC. **Am Fam Physician** 1997 Feb 1;55(2):635–40 (13 ref.)
[Angiographic control of postpartum obstetrical hemorrhage. A clinical case and review of the literature] Guasch-Arévalo E, et al. **Rev Esp Anestesiol Reanim** 1997 Mar;44(3):117–9 (19 ref.) **(Spa)**

POSTPARTUM PERIOD see **PUERPERIUM**

POSTPERICARDIOTOMY SYNDROME

[Postpericardiotomy syndrome] Yanase O, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):572–5 (17 ref.) **(Jpn)**

POSTPHLEBITIC DISEASE see **POSTPHLEBITIC SYNDROME**

POSTPHLEBITIC SYNDROME

[Postphlebitic syndrome] Kusaba A. **Ryoikibetsu Shokogun Shirizu** 1996;(14):502–5 (16 ref.) **(Jpn)**

POSTPHLEBITIC ULCER see **POSTPHLEBITIC SYNDROME**

POSTPOLIOMYELITIS MUSCULAR ATROPHY see **POSTPOLIOMYELITIS SYNDROME**

POSTPOLIOMYELITIS SYNDROME

Post polio syndrome: an update for the primary health care provider. LeCompte CM. **Nurse Pract** 1997 Jun; 22(6):133–6, 139, 142–6 passim (46 ref.)
[Post-polio syndrome--an update] Gadoth N, et al.

Harefuah 1997 Jan 15;132(2):124–7 (53 ref.) **(Heb)**

COMPLICATIONS

Rationale for treatment of new fatigue. Agre JC. **Disabil Rehabil** 1996 Jun;18(6):307–10 (35 ref.)

Dysphagia and post-polio syndrome: past, present, and future. Sonies BC. **Semin Neurol** 1996 Dec;16(4):365–70 (53 ref.)

ETIOLOGY

Faecal incontinence following childhood poliomyelitis. Stiff GJ, et al. **Int J Colorectal Dis** 1996;11(5):259–60 (4 ref.)

PHYSIOPATHOLOGY

Management of postpolio syndrome. Thorsteinsson G. **Mayo Clin Proc** 1997 Jul;72(7):627–38 (67 ref.)

REHABILITATION

Rationale for treatment of new fatigue. Agre JC. **Disabil Rehabil** 1996 Jun;18(6):307–10 (35 ref.)

Management of postpolio syndrome. Thorsteinsson G. **Mayo Clin Proc** 1997 Jul;72(7):627–38 (67 ref.)

POSTPRANDIAL PERIOD

Oestrogens and postprandial lipid metabolism. Westerveld HT, et al. **Biochem Soc Trans** 1997 Feb;25(1):45–9 (48 ref.)

Is atherosclerosis exclusively a postprandial phenomenon? Mamo JC, et al. **Clin Exp Pharmacol Physiol** 1997 Mar–Apr;24(3–4):288–93 (48 ref.)

Assessment of postprandial lipemia: nutritional influences. Bergeron N, et al. **Curr Opin Lipidol** 1997 Feb;8(1):43–52 (59 ref.)

Postprandial lipoprotein metabolism in diabetes mellitus and obesity. Lewis GF. **J Atheroscler Thromb** 1995;2 Suppl 1:S34–5 (4 ref.)

Disposition of lipids in the postprandial state. Williams CM. **Proc Nutr Soc** 1996 Mar;55(1B):79–91 (61 ref.)

[Postprandial angina] Kishida H. **Ryoikibetsu Shokogun Shirizu** 1996;(12):688–91 (15 ref.) **(Jpn)**

[Postprandial hypotension] Watanabe Y. **Ryoikibetsu Shokogun Shirizu** 1996;(12):63–6 (18 ref.) **(Jpn)**

DRUG EFFECTS

The influence of dietary fat on postprandial lipaemia and factor VII coagulant activity in human subjects. Yahia N, et al. **Proc Nutr Soc** 1997 Mar;56(1B):489–96 (41 ref.)

PHYSIOLOGY

Post-prandial protein metabolism. Millward DJ, et al. **Baillieres Clin Endocrinol Metab** 1996 Oct;10(4):533–49 (61 ref.)

Apolipoprotein B-48 as a marker for chylomicrons and their remnants: studies in the postprandial state. Isherwood SG, et al. **Proc Nutr Soc** 1997 Mar;56(1B):497–505 (53 ref.)

POST-SURGICAL NURSING see **POSTANESTHESIA NURSING**

POST-TRANSCRIPTIONAL RNA MODIFICATION see **RNA PROCESSING, POST-TRANSCRIPTIONAL**

POST-TRANSLATIONAL ISOPRENYLATION see **PROTEIN ISOPRENYLATION**

POST-TRANSLATIONAL PROTEIN MODIFICATION see **PROTEIN PROCESSING, POST-TRANSLATIONAL**

POST-TRAUMATIC STRESS DISORDERS see **STRESS DISORDERS, POST-TRAUMATIC**

POSTURE

see related
HYPOTENSION, ORTHOSTATIC

Exaggerated lithotomy position-related rhabdomyolysis. Biswas S, et al. **Am Surg** 1997 Apr;63(4):361–4 (23 ref.)

A review of management of benign paroxysmal positional vertigo by exercise therapy and by repositioning manoeuvres. Beynon GJ. **Br J Audiol** 1997 Feb;31(1):11–26 (56 ref.)

Using technology-based techniques to assess postural control and gait in older adults. Alexander NB. **Clin Geriatr Med** 1996 Nov;12(4):725–44 (135 ref.)

Disorders of posture, balance, and gait in Parkinson's disease. Rogers MW. **Clin Geriatr Med** 1996 Nov;12(4):825–45 (85 ref.)

Cardiac output and blood pressure during active and passive standing. Tanaka H, et al. **Clin Physiol** 1996 Mar; 16(2):157–70 (31 ref.)

The science of turning [editorial; comment] deBoisblanc BP. **Crit Care Med** 1997 Sep;25(9):1456–7 (13 ref.) Comment on: Crit Care Med 1997 Sep;25(9):1560–4.

Repositioning maneuver for benign paroxysmal positional vertigo (BPPV). Brooks JG, et al. **J Am Osteopath Assoc** 1997 May;97(5):277–9 (10 ref.)

Repetitive use and static postures: a source of nerve compression and pain. Novak CB, et al. **J Hand Ther** 1997 Apr–Jun;10(2):151–9 (73 ref.)

Evaluation of postural stability in children: current theories and assessment tools. Westcott SL, et al. **Phys Ther** 1997 Jun;77(6):629–45 (117 ref.)

Mechanical stress reduction during seated jolt/vibration exposure. Wilder DG, et al. **Semin Perinatol** 1996 Feb; 20(1):54–60 (85 ref.)

[Sleeping position, prevention of sudden death syndrome and gastroesophageal reflux] Faure C, et al. **Arch Pediatr** 1996 Jun;3(6):598–601 (16 ref.) (Eng. Abstr.) **(Fre)**

[Damage due to patient positioning in anesthesia and surgical medicine (1)] Ullrich W, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jan; 32(1):4–20 (0 ref.) (Eng. Abstr.) **(Ger)**

[The use of prisms in postural equilibrium] Preoteasa D. **Oftalmologia** 1996 Oct–Dec;40(4):331–9 (12 ref.) (Eng. Abstr.) **(Rum)**

PHYSIOLOGY

Postural orientation, equilibrium, and the spinal cord. Macpherson JM, et al. **Adv Neurol** 1997;72:227–32 (21 ref.)

Visuo-vestibular integration in the development of posture and gait. Amblard B. **Arch Ital Biol** 1996 Jul;134(3):249–77 (104 ref.)

Posture and movement: coordination and control. Lacquaniti F, et al. **Arch Ital Biol** 1997 Sep;135(4):353–67 (80 ref.)

Postural syncope and autoregulation of cerebral blood flow. Mathew RJ. **Biol Psychiatry** 1996 Nov 1;40(9):923–6 (34 ref.)

Postural control in the older adult. Maki BE, et al. **Clin Geriatr Med** 1996 Nov;12(4):635–58 (78 ref.)

Special considerations in orofacial pain and headache. Austin DG. **Dent Clin North Am** 1997 Apr;41(2):325–39 (82 ref.)

Time-varying characteristics of visually induced postural sway. Loughlin PJ, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):416–24 (36 ref.)

Effect of forward lean on postural ankle dynamics. Sinha T, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):348–59 (45 ref.)

Management of intracranial hemodynamics in the adult: a research analysis of head positioning and recommendations for clinical practice and future research. Simmons BJ. **J Neurosci Nurs** 1997 Feb;29(1):44–9 (31 ref.)

Investigation of the validity and reliability of four objective techniques for measuring forward shoulder posture. Peterson DE, et al. **J Orthop Sports Phys Ther** 1997 Jan; 25(1):34–42 (28 ref.)

Beta innervation and recurrent inhibition: a hypothesis for manipulatory and postural control. Illert M, et al. **Pflugers Arch** 1996;432(3 Suppl):R61–7 (62 ref.)

Aging and the mechanisms underlying head and postural control during voluntary motion. Di Fabio RP, et al. **Phys Ther** 1997 May;77(5):458–75 (96 ref.)

Postural perturbations: new insights for treatment of balance disorders. Horak FB, et al. **Phys Ther** 1997 May; 77(5):517–33 (84 ref.)

The role of limb movements in maintaining upright stance: the "change-in-support" strategy. Maki BE, et al. **Phys Ther** 1997 May;77(5):488–507 (70 ref.)

The role of vision and spatial orientation in the maintenance of posture. Wade MG, et al. **Phys Ther** 1997 Jun; 77(6):619–28 (58 ref.)

A concept for the final common pathway of vocalization and lordosis behavior in the cat. VanderHorst VG, et al. **Prog Brain Res** 1996;107:327–42 (83 ref.)

[Positioning trauma in anesthesia and surgical intensive care medicine (2)] Kienzle F, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Feb; 32(2):72–86 (204 ref.) (Eng. Abstr.) **(Ger)**

[Asymmetry of posture and truncal musculature following unilateral arm amputation—a clinical, electromyographic, posture analytical and photogrammetric study] Greitemann B, et al. **Z Orthop Ihre Grenzgeb** 1996 Nov-Dec; 134(6):498–510 (39 ref.) (Eng. Abstr.) **(Ger)**

[Pharmacological test] Hirayama M, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:491–3 (8 ref.) **(Jpn)**

[Furosemide: upright test] Niimura S, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:325–8 (2 ref.) **(Jpn)**

[Posturography: efficacy and prospects in Otorhinolaryngology] Luchikhin LA. **Vestn Otorinolaringol** 1997;(1):19–23 (34 ref.) (Eng. Abstr.) **(Rus)**

POSTVIRAL FATIGUE SYNDROME see **FATIGUE SYNDROME, CHRONIC**

POTASSIUM

see related
HYPERKALEMIA
HYPOKALEMIA

ADMINISTRATION & DOSAGE

The effects of potassium depletion and supplementation on blood pressure: a clinical review. Barri YM, et al. **Am J Med Sci** 1997 Jul;314(1):37–40 (48 ref.)

Is potassium needed in sports drinks for fluid replacement during exercise? Cunningham JJ. **Int J Sport Nutr** 1997 Jun;7(2):154–9 (17 ref.)

[Medicamentous anti-arrhythmia therapy. Is oral adjuvant therapy with electrolytes of value?] Haberl R. **Herz** 1997 Jun;22 Suppl 1:77–80 (20 ref.) (Eng. Abstr.) **(Ger)**

[Value of K+ and Mg2+ in treatment of acute myocardial infarct] Kunert M, et al. **Herz** 1997 Jun;22 Suppl 1:63–72 (24 ref.) (Eng. Abstr.) **(Ger)**

ANALYSIS

International consensus on the standardization of sodium and potassium measurements by ion-selective electrodes in undiluted samples. Külpmann WR, et al. **Scand J Clin Lab Invest Suppl** 1996;224:145–60 (6 ref.)

BLOOD

Diuretics, potassium, and ventricular ectopy. Materson BJ. **Am J Hypertens** 1997 May;10(5 Pt 2):68S–72S (37 ref.)

[Comments on the kinetics and extracellular effects of potassium and magnesium] Vierling W. **Herz** 1997 Jun;22 Suppl 1:3–10 (8 ref.) (Eng. Abstr.) **(Ger)**

[A case of potassium-sensitive periodic paralysis with cardiac dysrhythmia] Nakamagoe K, et al. **Rinsho Shinkeigaku** 1997 Mar;37(3):239–42 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Blood plasma potassium (literature review)] Titov VN. **Klin Lab Diagn** 1996 May–Jun;(3):3–7 (34 ref.) **(Rus)**

METABOLISM

Relevance of Na,K-ATPase to local extracellular potassium homeostasis and modulation of synaptic transmission. Gloor SM. **FEBS Lett** 1997 Jul 21;412(1):1–4 (46 ref.)

Potassium homeostasis and glial energy metabolism. Amédée T, et al. **Glia** 1997 Sep;21(1):46–55 (85 ref.)

Comparison of ion transport mechanisms between vestibular dark cells and strial marginal cells. Wangemann P. **Hear Res** 1995 Oct;90(1–2):149–57 (50 ref.)

Do potassium deficient diets and K+ removal by dialysis contribute to the cardiovascular morbidity and mortality of patients with end stage renal disease? [editorial] Dolson GM. **Int J Artif Organs** 1997 Mar;20(3):134–5 (15 ref.)

Potassium, sodium, and cancer: a review. Jansson B. **J Environ Pathol Toxicol Oncol** 1996;15(2–4):65–73 (12 ref.)

Non-potassium-sparing diuretics and risk of sudden cardiac death. Grobbee DE, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1539–45 (68 ref.)

Potassium transport and potassium channels in the kidney tubules. Kawahara K, et al. **Jpn J Physiol** 1997 Feb; 47(1):1–10 (99 ref.)

Potassium transport: from clearance to channels and pumps. Giebisch G, et al. **Kidney Int** 1996 Jun;49(6):1624–31 (30 ref.)

Some sodium, potassium and water changes in the elderly and their treatment. Andreucci VE, et al. **Nephrol Dial Transplant** 1996;11 Suppl 9:9–17 (113 ref.)

Cell culture studies of the role of elevated extracellular glutamate and K+ in neuronal cell death during and after anoxia/ischemia. Huang R, et al. **Neurosci Biobehav Rev** 1997 Mar;21(2):129–34 (26 ref.)

Potassium and magnesium retaining triamterene derivatives. Priewer H, et al. **Pharmazie** 1997 Mar;52(3):179–81 (56 ref.)

Structure and function of the low conductance KATP channel, ROMK. Hebert SC, et al. **Wien Klin Wochenschr** 1997 Jun 27;109(12–13):471–6 (46 ref.)

[Potassium ion secretion and generation of the endocochlear potential in the stria vascularis] Wangemann P. **HNO** 1997 Apr;45(4):205–9 (31 ref.) (Eng. Abstr.) **(Ger)**

[Na+/K+/2Cl- cotransport protein, Na+/Cl- cotransport protein] Inoue T, et al. **Nippon Rinsho** 1996 Mar; 54(3):625–31 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Potassium-losing nephropathy] Noguchi Y, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):641–5 (9 ref.) **(Jpn)**

PHARMACOLOGY

Sodium, potassium, and blood pressure. Weinberger MH. **Am J Hypertens** 1997 May;10(5 Pt 2):46S–48S (19 ref.)

PHYSIOLOGY

Control of M-current. Marrion NV. **Annu Rev Physiol** 1997; 59:483–504 (81 ref.)

Aldosterone and potassium homeostasis. Rabinowitz L. **Kidney Int** 1996 Jun;49(6):1738–42 (47 ref.)

The enigma of potassium ion in the management of dentine hypersensitivity: is nitric oxide the elusive second messenger? McCormack K, et al. **Pain** 1996 Nov;68(1):5–11 (89 ref.)

Potassium homoeostasis in the elderly. Biswas K, et al. **QJM** 1997 Jul;90(7):487–92 (58 ref.)

Potassium and breathing in exercise. Paterson DJ. **Sports Med** 1997 Mar;23(3):149–63 (80 ref.)

URINE

Leaky urothelium and/or vesical ischemia enable urinary potassium to cause idiopathic urgency/frequency syndrome and urge incontinence. Hohlbrugger G. **Int Urogynecol J Pelvic Floor Dysfunct** 1996;7(5):242–55 (94 ref.)

POTASSIUM CHANNELS

see related
NA(+)-K(+)-EXCHANGING ATPASE

POTASSIUM CHANNELS

[Molecular and biophysical aspects of potassium channels] Isomoto S, et al. **Nippon Rinsho** 1996 Mar;54(3):660–6 (29 ref.) (Eng. Abstr.) **(Jpn)**

[Sulfonylurea receptor] Yamada Y, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:590–3 (6 ref.) **(Jpn)**

[Ligand-sensitive K+ channel--the physiopathological role and possibility as new active site of various drugs] Nakatani H, et al. **Nippon Yakurigaku Zasshi** 1996 Sep;108(3):116–8 (10 ref.) **(Jpn)**

ANALYSIS

Potassium channels in vascular smooth muscle. Brayden JE. **Clin Exp Pharmacol Physiol** 1996 Dec;23(12):1069–76 (74 ref.)

Potassium channels and the coronary circulation. Dellsperger KC. **Clin Exp Pharmacol Physiol** 1996 Dec;23(12):1096–101 (42 ref.)

ANTAGONISTS & INHIBITORS

Intracellular diadenosine polyphosphates: a novel family of inhibitory ligands of the ATP-sensitive K+ channel. Jovanovic A, et al. **Biochem Pharmacol** 1997 Jul 15; 54(2):219–25 (52 ref.)

Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration. Engler RL, et al. **Circulation** 1996 Nov 1;94(9):2297–301 (66 ref.)

Recent studies on dendrotoxins and potassium ion channels. Harvey AL. **Gen Pharmacol** 1997 Jan;28(1):7–12 (93 ref.)

BIOSYNTHESIS

Assembly of potassium channels. Li M, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:51–9 (21 ref.)

CHEMISTRY

The potassium pore and its regulation. Brown AM, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:74–80 (23 ref.)

Assembly of potassium channels. Li M, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:51–9 (21 ref.)

Renal K+ channels: structure and function. Wang W, et al. **Annu Rev Physiol** 1997;59:413–36 (139 ref.)

Inward rectifier potassium channels. Cloning, expression and structure-function studies. Lagrutta AA, et al. **Jpn Heart J** 1996 Sep;37(5):651–60 (19 ref.)

DRUG EFFECTS

Pharmacology of potassium channels. Garcia ML, et al. **Adv Pharmacol** 1997;39:425–71 (225 ref.)

The pharmacology and molecular biology of large-conductance calcium-activated (BK) potassium channels. Gribkoff VK, et al. **Adv Pharmacol** 1997; 37:319–48 (140 ref.)

Toxins affecting K+ channels. Rowan EG, et al. **Braz J Med Biol Res** 1996 Dec;29(12):1765–80 (186 ref.)

Insulin secretion and its modulation by antiarrhythmic and sulfonylurea drugs. Horie M, et al. **Cardiovasc Res** 1997 Apr;34(1):69–72 (42 ref.)

Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients. Schotborgh CE, et al. **Cardiovasc Res** 1997 Apr;34(1):73–80 (88 ref.)

Is there a therapeutic future for "potassium channel openers"? [editorial] Lawson K. **Clin Sci (Colch)** 1996 Dec; 91(6):651–63 (111 ref.)

Cardiovascular effects of sulphonylurea derivatives. Smits P, et al. **Diabetes Res Clin Pract** 1996 Jul;31 Suppl:S55–9 (24 ref.)

Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels? [see comments] Pickkers P, et al. **Diabetologia** 1996 Jul;39(7):861–4 (43 ref.) Comment in: Diabetologia 1996 Jul;39(7):865–7.

Adverse effects of class I antiarrhythmic drugs. Caron J, et al. **Drug Saf** 1997 Jul;17(1):8–36 (366 ref.)

The pulmonary vasodilator properties of potassium channel opening drugs. Wanstall JC. **Gen Pharmacol** 1996 Jun; 27(4):599–605 (91 ref.)

K+ channel opening: a new drug principle in cardiovascular medicine [see comments] Nielsen-Kudsk JE, et al. **Heart** 1996 Aug;76(2):109–16 (51 ref.) Comment in: Heart 1997 May;77(5):487.

Ion channel effects of antidiabetic sulfonylureas. Lazdunski M. **Horm Metab Res** 1996 Sep;28(9):488–95 (95 ref.)

Sodium and potassium channel modulators: their role in neuroprotection. Obrenovitch TP. **Int Rev Neurobiol** 1997; 40:109–35 (159 ref.)

Application of physiologically active substances isolated from natural resources to pharmacological studies. Ohizumi Y. **Jpn J Pharmacol** 1997 Apr;73(4):263–89 (142 ref.)

Molecular aspects of ATP-sensitive K+ channels in the cardiovascular system. Isomoto S, et al. **Jpn J Physiol** 1997; 47 Suppl 1:S5–6 (7 ref.)

Molecular basis of functional diversity of ATP-sensitive K+ channels. Seino S, et al. **Jpn J Physiol** 1997;47 Suppl 1:S3–4 (12 ref.)

Actions of neurotransmitters and other messengers on Ca2+ channels and K+ channels in smooth muscle cells. Beech DJ. **Pharmacol Ther** 1997;73(2):91–119 (353 ref.)

Potassium channel activation: a potential therapeutic approach? Lawson K. **Pharmacol Ther** 1996;70(1):39–63 (301 ref.)

Which cardiac potassium channel subtype is the preferable target for suppression of ventricular arrhythmias? Rees S, et al. **Pharmacol Ther** 1996;69(3):199–217 (272 ref.)

GENETICS

Structure and function of cardiac sodium and potassium channels. Roden DM, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):H511–25 (166 ref.)

Cloned potassium channels from eukaryotes and prokaryotes. Jan LY, et al. **Annu Rev Neurosci** 1997;20:91–123 (281 ref.)

Hypothesis for a serine proteinase-like domain at the COOH terminus of Slowpoke calcium-activated potassium channels. Moss GW, et al. **J Gen Physiol** 1996 Dec; 108(6):473–84 (82 ref.)

Molecular aspects of ATP-sensitive K+ channels in the cardiovascular system. Isomoto S, et al. **Jpn J Physiol** 1997; 47 Suppl 1:S5–6 (7 ref.)

Inwardly rectifying potassium channels: their molecular heterogeneity and function. Isomoto S, et al. **Jpn J Physiol** 1997 Feb;47(1):11–39 (242 ref.)

Molecular basis of functional diversity of ATP-sensitive K+ channels. Seino S, et al. **Jpn J Physiol** 1997;47 Suppl 1:S3–4 (12 ref.)

Potassium channelopathies. Sanguinetti MC, et al. **Neuropharmacology** 1997 Jun;36(6):755–62 (54 ref.)

Properties and regulation of the minK potassium channel protein. Kaczmarek LK, et al. **Physiol Rev** 1997 Jul; 77(3):627–41 (89 ref.)

[Long QT syndrome] Nakajima T, et al. **Nippon Rinsho** 1996 Mar;54(3):776–81 (10 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

The ATP-regulated K+ channel in mitochondria: five years after its discovery. Szewczyk A. **Acta Biochim Pol** 1996; 43(4):713–9 (38 ref.)

Comparison of the three mouse G-protein-activated K+ (GIRK) channels and functional couplings of the opioid receptors with the GIRK1 channel. Ikeda K, et al. **Ann N Y Acad Sci** 1996 Oct 31;801:95–109 (26 ref.)

Cytoplasmic domains of voltage-sensitive K+ channels involved in mediating protein-protein interactions. Scannevin RH, et al. **Biochem Biophys Res Commun** 1997 Mar 27;232(3):585–9 (54 ref.)

Regulation of 4-aminopyridine-sensitive, delayed rectifier K+ channels in vascular smooth muscle by phosphorylation. Cole WC, et al. **Biochem Cell Biol** 1996; 74(4):439–47 (52 ref.)

Pharmacology of ATP-sensitive potassium channel (KATP) openers in models of myocardial ischemia and reperfusion. Grover GJ. **Can J Physiol Pharmacol** 1997 Apr; 75(4):309–15 (49 ref.)

Potassium channels and the cerebral circulation. Faraci FM, et al. **Clin Exp Pharmacol Physiol** 1996 Dec;23(12):1091–5 (76 ref.)

Presynaptic potassium channels. Roeper J, et al. **Curr Opin Neurobiol** 1996 Jun;6(3):338–41 (41 ref.)

The role of ATP-sensitive potassium channels in myocardial ischemia: pharmacology and implications for the future. Grover GJ. **EXS** 1996;76:313–24 (31 ref.)

Brownian dynamics simulation of pH-effects on conductance through potassium channels. Veresov VG. **Gen Physiol Biophys** 1996 Oct;15(5):389–402 (55 ref.)

ATP-regulated K+ channel in mitochondria: pharmacology and function. Szewczyk A, et al. **J Bioenerg Biomembr** 1996 Apr;28(2):147–52 (41 ref.)

Potassium channels, proliferation and G1 progression. Wonderlin WF, et al. **J Membr Biol** 1996 Nov; 154(2):91–107 (105 ref.)

Pharmacological implications of inward rectifier K+ channels regulation by cytoplasmic polyamines. Taglialatela M, et al. **Pharmacol Res** 1995 Dec;32(6):335–44 (72 ref.)

G protein interaction with K+ and Ca2+ channels. Schneider T, et al. **Trends Pharmacol Sci** 1997 Jan; 18(1):8–11 (41 ref.)

[Regulation of muscarinic potassium channels] Thiebot H, et al. **C R Seances Soc Biol Fil** 1996;190(2-3):237–41 (13 ref.) (Eng. Abstr.) **(Fre)**

[Modulation of inwardly rectifying K+ channels by G-protein] Nukada T. **Seikagaku** 1996 Sep;68(9):1554–9 (18 ref.) **(Jpn)**

PHARMACOLOGY

The arterial wall: a new pharmacological and therapeutic target. Laurent S, et al. **Fundam Clin Pharmacol** 1996; 10(3):243–57 (95 ref.)

PHYSIOLOGY

Structure and function of cardiac sodium and potassium channels. Roden DM, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):H511–25 (166 ref.)

The potassium pore and its regulation. Brown AM, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:74–80 (23 ref.)

Inhibition of the cystic fibrosis transmembrane conductance regulator by ATP-sensitive K+ channel regulators. Sheppard DN, et al. **Ann N Y Acad Sci** 1993 Dec 20; 707:275–84 (41 ref.)

Inward rectifier potassium channels. Nichols CG, et al. **Annu Rev Physiol** 1997;59:171–91 (177 ref.)

Renal K+ channels: structure and function. Wang W, et al. **Annu Rev Physiol** 1997;59:413–36 (139 ref.)

Plant K+ channels: structure, activity and function. Chérel I, et al. **Biochem Soc Trans** 1996 Nov;24(4):964–71 (50 ref.)

Toxins affecting K+ channels. Rowan EG, et al. **Braz J Med Biol Res** 1996 Dec;29(12):1765–80 (186 ref.)

Spontaneous transient outward currents in smooth muscle cells. Bolton TB, et al. **Cell Calcium** 1996 Aug;20(2):141–52 (109 ref.)

Recent insights into the regulation of cerebral circulation. Brian JE Jr, et al. **Clin Exp Pharmacol Physiol** 1996 Jun-Jul; 23(6-7):449–57 (111 ref.)

Mechanisms for regulation of arterial tone by Ca2+-dependent K+ channels in hypertension. Rusch NJ, et al. **Clin Exp Pharmacol Physiol** 1996 Dec;23(12):1077–81 (30 ref.)

The ABCs of ATP-sensitive potassium channels: more pieces of the puzzle. Bryan J, et al. **Curr Opin Cell Biol** 1997 Aug;9(4):553–9 (44 ref.)

Regulation of potassium channels by protein kinases. Jonas EA, et al. **Curr Opin Neurobiol** 1996 Jun;6(3):318–23 (45 ref.)

Haemodynamic and other effects of sulphonylurea drugs on the heart. Végh A, et al. **Diabetes Res Clin Pract** 1996 Jul;31 Suppl:S43–53 (75 ref.)

Role of potassium channels in the modulation of insulin release [comment] Smits P. **Diabetologia** 1996 Jul; 39(7):865–7 (17 ref.) Comment on: Diabetologia 1996 Jul;39(7):861–4.

Calcium-activated potassium channels in adrenal chromaffin cells. Lingle CJ, et al. **Ion Channels** 1996;4:261–301 (104 ref.)

Molecular properties of voltage-gated K+ channels. Dolly JO, et al. **J Bioenerg Biomembr** 1996 Jun;28(3):231–53 (149 ref.)

High-conductance calcium-activated potassium channels; structure, pharmacology, and function. Kaczorowski GJ, et al. **J Bioenerg Biomembr** 1996 Jun;28(3):255–67 (84 ref.)

Pathophysiological functions of ATP-sensitive K+ channels in myocardial ischemia. Hiraoka M. **Jpn Heart J** 1997 May; 38(3):297–315 (116 ref.)

Two aspects of the inward rectification mechanism. Effects of cytoplasmic blockers and extracellular K+ on the inward rectifier K+ channel. Kubo Y. **Jpn Heart J** 1996 Sep;37(5):631–41 (25 ref.)

Inward rectifier potassium channels. Cloning, expression and structure-function studies. Lagrutta AA, et al. **Jpn Heart J** 1996 Sep;37(5):651–60 (19 ref.)

Inwardly rectifying potassium channels: their molecular heterogeneity and function. Isomoto S, et al. **Jpn J Physiol** 1997 Feb;47(1):11–39 (242 ref.)

Potassium transport: from clearance to channels and pumps. Giebisch G, et al. **Kidney Int** 1996 Jun;49(6):1624–31 (30 ref.)

Muscarinic mechanisms in nerve cells. Brown DA, et al. **Life Sci** 1997;60(13-14):1137–44 (104 ref.)

Inhibitory glutamate receptor channels. Cleland TA. **Mol Neurobiol** 1996 Oct;13(2):97–136 (114 ref.)

ATP-sensitive K+ channels in the kidney. Quast U. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Aug-Sep; 354(3):213–25 (136 ref.)

The membrane transporters regulating epithelial NaCl secretion. Greger R. **Pflugers Arch** 1996 Aug;432(4):579–88 (97 ref.)

Plasticity of renal epithelial cells: the way a potassium channel supports migration. Schwab A, et al. **Pflugers Arch** 1996;432(3 Suppl):R87–93 (42 ref.)

Properties and regulation of the minK potassium channel protein. Kaczmarek LK, et al. **Physiol Rev** 1997 Jul; 77(3):627–41 (89 ref.)

Roles of higher plant K+ channels. Maathuis FJ, et al. **Plant Physiol** 1997 Aug;114(4):1141–9 (70 ref.)

Is EAG the answer to the M-current? Mathie A, et al. **Trends Neurosci** 1997 Jan;20(1):14 (5 ref.)

A physiological role for ether-à-go-go K+ channels? [see comments] Stansfeld C, et al. **Trends Neurosci** 1997 Jan; 20(1):13–4 (13 ref.) Comment in: Trends Neurosci 1997 Jun;20(6):243–4.

Role of the ISK protein in the IminK channel complex. Busch AE, et al. **Trends Pharmacol Sci** 1997 Jan;18(1):26–9 (48 ref.)

Structure and function of the low conductance KATP channel, ROMK. Hebert SC, et al. **Wien Klin Wochenschr** 1997 Jun 27;109(12–13):471–6 (46 ref.)

[Potassium ion secretion and generation of the endocochlear potential in the stria vascularis] Wangemann P. **HNO** 1997 Apr;45(4):205–9 (31 ref.) (Eng. Abstr.) **(Ger)**

[Myocardial protection from ischemic damage: effects of preconditioning and pharmacologic activation of KATP channels] Galiè N, et al. **Cardiologia** 1995 Dec;40(12 Suppl 1):77–82 (23 ref.) **(Ita)**

[Potassium channels in glial cells] Horio Y, et al. **Nippon Yakurigaku Zasshi** 1997 Mar;109(3):103–10 (48 ref.) (Eng. Abstr.) **(Jpn)**

[Potassium channel dysfunction at the lesion site in multifocal motor neuropathy as revealed by threshold electrotonus] Kaji R, et al. **Rinsho Shinkeigaku** 1995 Dec;35(12):1368–9 (0 ref.) (Eng. Abstr.) **(Jpn)**

[K+ channel] Yokoyama S, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):213–8 (65 ref.) **(Jpn)**

POTASSIUM CITRATE

THERAPEUTIC USE

[Cost-effectiveness analysis of preventive treatment of urinary lithiasis recurrence using potassium citrate] Gisbert Gelonch R, et al. **Arch Esp Urol** 1997 May;50(4):373–80 (14 ref.) (Eng. Abstr.) **(Spa)**

POTASSIUM DEFICIENCY

see related
HYPOKALEMIA

CHEMICALLY INDUCED

[Potassium-sparing diuretics (spironolactone, triamterene, amylorid)] Haris A, et al. **Orv Hetil** 1996 Sep 1; 137(35):1907–14 (72 ref.) (Eng. Abstr.) **(Hun)**

COMPLICATIONS

Do potassium deficient diets and K+ removal by dialysis contribute to the cardiovascular morbidity and mortality of patients with end stage renal disease? [editorial] Dolson GM. **Int J Artif Organs** 1997 Mar;20(3):134–5 (15 ref.)

DRUG THERAPY

The effects of potassium depletion and supplementation on blood pressure: a clinical review. Barri YM, et al. **Am J Med Sci** 1997 Jul;314(1):37–40 (48 ref.)

PHYSIOPATHOLOGY

The effects of potassium depletion and supplementation on blood pressure: a clinical review. Barri YM, et al. **Am J Med Sci** 1997 Jul;314(1):37–40 (48 ref.)

POTASSIUM, DIETARY

PHARMACOLOGY

Dietary sodium chloride and potassium have effects on the pathophysiology of hypertension in humans and animals. Tobian L. **Am J Clin Nutr** 1997 Feb;65(2 Suppl):606S–611S (21 ref.)

POTASSIUM GLUTAMATE see **GLUTAMATES**

POTASSIUM IODIDE

THERAPEUTIC USE

Potassium iodide for thyroid blockade in a reactor accident: administrative policies that govern its use. Becker DV, et al. **Thyroid** 1997 Apr;7(2):193–7 (15 ref.)

POTASSIUM PERMANGANATE

Analysis of open complex formation during RNA polymerase II transcription initiation using heteroduplex templates and potassium permanganate probing. Holstege FC, et al. **Methods** 1997 Jul;12(3):203–11 (46 ref.)

POTASSIUM PUMP see **NA(+)-K(+)-EXCHANGING ATPASE**

POTATO VIRUS Y see **POTYVIRUS**

POTATOES

CHEMISTRY

Steroidal glycoalkaloids in Andean potatoes. Kubo I, et al. **Adv Exp Med Biol** 1996;405:405–17 (30 ref.)

METABOLISM

Free radicals and other paramagnetic ions in interactions between fungal pathogens and potato tubers. Snijder AJ, et al. **Biochem Soc Trans** 1996 May;24(2):442–6 (13 ref.)

MICROBIOLOGY

Free radicals and other paramagnetic ions in interactions between fungal pathogens and potato tubers. Snijder AJ, et al. **Biochem Soc Trans** 1996 May;24(2):442–6 (13 ref.)

The oxidative burst protects plants against pathogen attack: mechanism and role as an emergency signal for plant bio-defence--a review. Doke N, et al. **Gene** 1996 Nov 7; 179(1):45–51 (40 ref.)

POTT'S DISEASE see **TUBERCULOSIS, SPINAL**

POTYVIRUS

GENETICS

Chimeric potyvirus-like particles as vaccine carriers. Jagadish MN, et al. **Intervirology** 1996;39(1-2):85–92 (27 ref.)

POUCHITIS

Ileal pouches: adaptation and inflammation. Merrett MN. **Baillieres Clin Gastroenterol** 1997 Mar;11(1):175–93 (93 ref.)

Pouchitis: pathogenesis, diagnosis, and management. Rubinstein MC, et al. **Gastroenterologist** 1996 Jun; 4(2):129–33 (27 ref.)

[Pouchitis after ileal pouch-anal anastomosis] Abitbol V, et al. **Gastroenterol Clin Biol** 1997;21(4):299–304 (64 ref.) **(Fre)**

COMPLICATIONS

Ileal pouch arthritis: a case report. ter Borg EJ, et al. **Eur J Gastroenterol Hepatol** 1996 Oct;8(10):957–9 (7 ref.)

DRUG THERAPY

Review article: the management of pouchitis. Keighiey MR. **Aliment Pharmacol Ther** 1996 Aug;10(4):449–57 (67 ref.)

GENETICS

Pouchitis--predictable by immunological or genetic markers? Binder V. **Eur J Gastroenterol Hepatol** 1996 Oct; 8(10):943–5 (21 ref.)

IMMUNOLOGY

Pouchitis--predictable by immunological or genetic markers? Binder V. **Eur J Gastroenterol Hepatol** 1996 Oct; 8(10):943–5 (21 ref.)

POULTRY

Soil and solid poultry waste nutrient management and water quality. Chapman SL. **Poult Sci** 1996 Jul;75(7):862–6 (26 ref.)

Impacts of water and air quality legislation on the poultry industry. Morse D. **Poult Sci** 1996 Jul;75(7):857–61 (6 ref.)

25-hydroxycholecalciferol in poultry nutrition. Soares JH Jr, et al. **Poult Sci** 1995 Dec;74(12):1919–34 (102 ref.)

GENETICS

Symposium: the effects of long-term selection on growth of poultry. Introduction. Reddy RP. **Poult Sci** 1996 Oct; 75(10):1164–7 (11 ref.)

GROWTH & DEVELOPMENT

Natural sex steroids and their xenobiotic analogs in animal production: growth, carcass quality, pharmacokinetics, metabolism, mode of action, residues, methods, and epidemiology. Lone KP. **Crit Rev Food Sci Nutr** 1997 Mar; 37(2):93–209 (1177 ref.)

Water quality and poultry production. King AJ. **Poult Sci** 1996 Jul;75(7):852–3 (16 ref.)

Symposium: the effects of long-term selection on growth of poultry. Introduction. Reddy RP. **Poult Sci** 1996 Oct; 75(10):1164–7 (11 ref.)

PHYSIOLOGY

Insulin-like growth factors in poultry. McMurtry JP, et al. **Domest Anim Endocrinol** 1997 Jul;14(4):199–229 (242 ref.)

POULTRY DISEASES

History of infectious bursal disease in the U.S.A.--the first two decades. Lasher HN, et al. **Avian Dis** 1997 Jan-Mar; 41(1):11–9 (54 ref.)

Gordon Memorial Lecture. Chicken anaemia virus--a glimpse of the future? McNulty MS. **Br Poult Sci** 1997 Mar;38(1):7–13 (31 ref.)

DIAGNOSIS

Towards the routine application of nucleic acid technology for avian disease diagnosis. Cavanagh D, et al. **Acta Vet Hung** 1997;45(3):281–98 (37 ref.)

DNA amplification methods for diagnosis and epidemiological investigations of avian mycoplasmosis. Kempf I. **Acta Vet Hung** 1997;45(3):373–86 (65 ref.)

Eimeria spp. from the chicken: occurrence, identification and genetics. Shirley MW. **Acta Vet Hung** 1997;45(3):331–47 (39 ref.)

EPIDEMIOLOGY

Epidemiology of avian diseases. Kaleta EF. **Acta Vet Hung** 1997;45(3):267–80 (11 ref.)

DNA amplification methods for diagnosis and epidemiological investigations of avian mycoplasmosis. Kempf I. **Acta Vet Hung** 1997;45(3):373–86 (65 ref.)

IMMUNOLOGY

Poultry vaccine laboratories in the United States: a historical perspective. Hitchner SB. **Avian Dis** 1996 Apr-Jun; 40(2):255–65 (10 ref.)

PHYSIOPATHOLOGY

Nutritional metabolic diseases of poultry and disorders of the biological antioxidant defence system. Mézes M, et al. **Acta Vet Hung** 1997;45(3):349–60 (55 ref.)

PREVENTION & CONTROL

Novel approaches to control of bacterial infections in animals. Barrow PA. **Acta Vet Hung** 1997;45(3):317–29 (33 ref.)

Changing expectations in the control of Mycoplasma gallisepticum. Kleven SH. **Acta Vet Hung** 1997; 45(3):299–305 (38 ref.)

Viral diseases of the immune system and strategies to control infectious bursal disease by vaccination. Lütticken D. **Acta Vet Hung** 1997;45(3):239–49 (37 ref.)

Poultry vaccine laboratories in the United States: a historical perspective. Hitchner SB. **Avian Dis** 1996 Apr-Jun; 40(2):255–65 (10 ref.)

Nonrecombinant and recombinant avirulent Salmonella vaccines for poultry. Curtiss R 3rd, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1-4):365–72 (40 ref.)

VIROLOGY

Avian tumor viruses: persistent and evolving pathogens. Witter RL. **Acta Vet Hung** 1997;45(3):251–66 (37 ref.)

Injury models of the vascular endothelium: apoptosis and loss of thromboresistance induced by a viral protein. Eldor A, et al. **Haemostasis** 1996 Oct;26 Suppl 4:37–45 (46 ref.)

Avian retroviruses. Fadly AM. **Vet Clin North Am Food Anim Pract** 1997 Mar;13(1):71–85 (65 ref.)

POULTRY PRODUCTS

see related
EGGS

STANDARDS

Biosecurity in poultry production: where are we and where do we go? te Winkel GP. **Acta Vet Hung** 1997;45(3):361–72 (8 ref.)

Pulsed light and pulsed electric field for foods and eggs. Dunn J. **Poult Sci** 1996 Sep;75(9):1133–6 (0 ref.)

Innovative methods of energy transfer. McBee LE. **Poult Sci** 1996 Sep;75(9):1137–40 (24 ref.)

POVERTY

see related
CULTURAL DEPRIVATION

Is AIDS a disease of poverty? Gillies P, et al. **AIDS Care** 1996 Jun;8(3):351–63 (40 ref.)

The effects of poverty on child health and development. Aber JL, et al. **Annu Rev Public Health** 1997;18:463–83 (94 ref.)

Poverty and the health of children and adolescents. Reading R. **Arch Dis Child** 1997 May;76(5):463–7 (108 ref.)

An out-of-home care system in crisis: implications for African American children in the child welfare system. Brown AW, et al. **Child Welfare** 1997 Jan-Feb;76(1):65–83 (49 ref.)

The age of extremes: a revisionist perspective [comment] Farley R. **Demography** 1996 Nov;33(4):417–20; discussion 427–8 (17 ref.) Comment on: Demography 1996 Nov;33(4):395–412; discussion 413–6.

The political economy of inequality in the "age of extremes" [see comments] Hout M, et al. **Demography** 1996 Nov; 33(4):421–5; discussion 427–8 (22 ref.) Comment in: Demography 1996 Nov;33(4):395–412; discussion 413–6.

The age of extremes: concentrated affluence and poverty in the twenty-first century [see comments] Massey DS. **Demography** 1996 Nov;33(4):395–412; discussion 413–6 (100 ref.) Comment in: Demography 1996 Nov;33(4):417–20; discussion 427–8. Comment in: Demography 1996 Nov;33(4):421–5; discussion 427–8.

The effects of poverty on children. Brooks-Gunn J, et al. **Future Child** 1997 Summer-Fall;7(2):55–71 (63 ref.)

Childhood hunger. Lewit EM, et al. **Future Child** 1997 Spring;7(1):128–44 (23 ref.)

Effects of low-wage employment on family well-being [comment] Parcel TL, et al. **Future Child** 1997 Spring; 7(1):116–21 (16 ref.) Comment on: Future Child 1997 Spring;7(1):110–5.

When low-income mothers go to work: implications for children [see comments] Zaslow MJ, et al. **Future Child** 1997 Spring;7(1):110–5 (30 ref.) Comment in: Future Child 1997 Spring;7(1):116–21. Comment in: Future Child 1997 Spring;7(1):122–7.

Severity of childhood asthma by socioeconomic status. Mielck A, et al. **Int J Epidemiol** 1996 Apr;25(2):388–93 (33 ref.)

The class analysis of poverty: a response to Tony Novak [comment] Wright EO. **Int J Health Serv** 1996;26(2):371–9 (6 ref.) Comment on: Int J Health Serv 1995;25(1):85–100. Comment on: Int J Health Serv 1996;26(1):187–95.

Prenatal care for low-income women and the health belief model: a new beginning. Stout AE. **J Community Health Nurs** 1997;14(3):169–80 (21 ref.)

Markets and public programs: insights from Oregon and Tennessee. Gold M. **J Health Polit Policy Law** 1997 Apr; 22(2):633–66 (26 ref.)

Trajectories of poverty and children's mental health. Mcleod JD, et al. **J Health Soc Behav** 1996 Sep;37(3):207–20 (46 ref.)

Biosocial consequences of poverty: associated visual problems. Solan HA, et al. **Optom Vis Sci** 1997 Apr; 74(4):185–9 (44 ref.)

Nutrition and poverty in Europe: an overview. Dowler EA, et al. **Proc Nutr Soc** 1997 Mar;56(1A):51–62 (55 ref.)

Developments in the UK: work of the Low Income Project

POVERTY

Team. Nelson M. **Proc Nutr Soc** 1997 Mar;56(1A):91–100 (13 ref.)
Hunger, food security and welfare policies: issues and debates in First World societies. Riches G. **Proc Nutr Soc** 1997 Mar;56(1A):63–74 (26 ref.)
Socio-economic differentials in health: the role of nutrition. Smith GD, et al. **Proc Nutr Soc** 1997 Mar;56(1A):75–90 (75 ref.)
Empowering patients: issues and strategies. Anderson JM. **Soc Sci Med** 1996 Sep;43(5):697–705 (42 ref.)
Small wars and invisible genocides. Scheper-Hughes N. **Soc Sci Med** 1996 Sep;43(5):889–900 (29 ref.)
Poverty among single elderly women under different systems of old-age security: a comparative review. Siegenthaler JK. **Soc Secur Bull** 1996 Fall;59(3):31–44 (59 ref.)

PREVENTION & CONTROL

Choosing among alternative programs for poor children. Currie JM. **Future Child** 1997 Summer-Fall;7(2):113–31 (43 ref.)
Programs that mitigate the effects of poverty on children. Devaney BL, et al. **Future Child** 1997 Summer-Fall; 7(2):88–112 (76 ref.)
Children and poverty: analysis and recommendations. Lewit EM, et al. **Future Child** 1997 Summer-Fall;7(2):4–24 (44 ref.)
Child poverty can be reduced. Plotnick RD. **Future Child** 1997 Summer-Fall;7(2):72–87 (46 ref.)

PSYCHOLOGY

Gender, race and poverty: bringing the sociopolitical into psychotherapy. Krawitz R, et al.
Aust N Z J Psychiatry 1997 Aug;31(4):474–9 (30 ref.)
Poverty and mental illness. Saraceno B, et al.
Can J Psychiatry 1997 Apr;42(3):285–90 (42 ref.)

STATISTICS & NUMERICAL DATA

Why so many children are poor. Betson DM, et al.
Future Child 1997 Summer-Fall;7(2):25–39 (14 ref.)
The dynamics of childhood poverty. Corcoran ME, et al.
Future Child 1997 Summer-Fall;7(2):40–54 (41 ref.)
Population growth, poverty and health. Kibirige JS.
Soc Sci Med 1997 Jul;45(2):247–59 (70 ref.)

POVERTY AREAS

Planning for a community-based hypertension control program in the inner city. Kotchen JM, et al.
J Hum Hypertens 1996 Sep;10 Suppl 3:S9–13 (22 ref.)

POVIDONE

DIAGNOSTIC USE

[Gordon test] Sato T. **Nippon Rinsho** 1997 Apr;55 Suppl 2:117–9 (4 ref.) **(Jpn)**

POVIDONE-IODINE

ADVERSE EFFECTS

Sclerosing encapsulating peritonitis after intraperitoneal use of povidone iodine. Keating JP, et al.
Aust N Z J Surg 1997 Oct;67(10):742–4 (19 ref.)

POWASSAN VIRUS see **ENCEPHALITIS VIRUSES, TICK-BORNE**

POWER (PSYCHOLOGY)

Consumer empowerment in mental health organizations: concept, benefits, and impediments. Salzer MS.
Adm Policy Ment Health 1997 May;24(5):425–34 (28 ref.)
Empowerment theory, research, and application. Perkins DD, et al. **Am J Community Psychol** 1995 Oct;23(5):569–79 (14 ref.)
Psychological empowerment: issues and illustrations. Zimmerman MA. **Am J Community Psychol** 1995 Oct; 23(5):581–99 (51 ref.)
Controlling ourselves, controlling our world. Psychology's role in understanding positive and negative consequences of seeking and gaining control. Shapiro DH Jr, et al.
Am Psychol 1996 Dec;51(12):1213–30 (330 ref.)
Power and caring: a dialectic in nursing. Rafael AR.
ANS Adv Nurs Sci 1996 Sep;19(1):3–17 (50 ref.)
A personality disorder of excessive power strivings. Charny IW. **Isr J Psychiatry Relat Sci** 1997;34(1):3–15; discussion 16–7 (38 ref.)
Adherence: a matter of self-efficacy and power. Buchmann WF. **J Adv Nurs** 1997 Jul;26(1):132–7 (11 ref.)
Power and vested interests--tacit influences on the construction of nursing curricula? Trnobranski PH.
J Adv Nurs 1997 May;25(5):1084–8 (28 ref.)
The technocratic wish: making sense and finding power in the "managed" medical marketplace. Belkin GS.
J Health Polit Policy Law 1997 Apr;22(2):509–32 (63 ref.)
The normative constitution of professional power [see comments] Frankford DM. **J Health Polit Policy Law** 1997 Feb;22(1):185–221 (95 ref.) Comment in: J Health Polit Policy Law 1997 Feb;22(1):223–30. Comment in: J Health Polit Policy Law 1997 Feb;22(1):231–43.
Awareness, action, and collaboration: how the self-advocacy movement is empowering for persons with developmental disabilities. Miller AB, et al. **Ment Retard** 1996 Oct; 34(5):312–9 (45 ref.)
Stages of nursing's political development: where we've been and where we ought to go. Cohen SS, et al.
Nurs Outlook 1996 Nov-Dec;44(6):259–66 (64 ref.)
Considerations for research on consumer empowerment and psychosocial interventions. Corrigan PW, et al.
Psychiatr Serv 1997 Mar;48(3):347–52 (59 ref.)
Overcoming feelings of powerlessness in "aging" researchers: a primer on statistical power in analysis of variance designs. Levin JR. **Psychol Aging** 1997 Mar;12(1):84–106 (45 ref.)
The social construction of drug debates. Dingelstad D, et al. **Soc Sci Med** 1996 Dec;43(12):1829–38 (65 ref.)
Psychosocial work environment in human service organizations: a conceptual analysis and development of the demand-control model. Söderfeldt B, et al.
Soc Sci Med 1996 May;42(9):1217–26 (50 ref.)
Empowering battered women transnationally: the case for postmodern interventions. Mills L. **Soc Work** 1996 May; 41(3):261–8 (38 ref.)
The strengths perspective in social work practice: extensions and cautions. Saleebey D. **Soc Work** 1996 May; 41(3):296–305 (55 ref.)

POWER, PERSONAL see **POWER (PSYCHOLOGY)**

POWER PLANTS

Nuclear energy facilities and cancers. Wakeford R, et al.
Ann Acad Med Singapore 1996 May;25(3):468–76 (75 ref.)
The consequences of the Chernobyl accident one decade after the disaster. Jankowski J.
Int J Occup Med Environ Health 1996;9(4):365–74 (18 ref.)
The International Chernobyl Project Technical Report: assessment of radiological consequences and evaluation of protective measures. Report by an International Advisory Committee. Mann WB. **Nucl Med Biol** 1994 Jan;21(1):3–7 (7 ref.)
[Protection of the thyroid in children and fetuses in case of nuclear accident] Vernis M, et al. **Arch Pediatr** 1997 May; 4(5):473–9 (29 ref.) (Eng. Abstr.) **(Fre)**
[A decade after Chernobyl: the results of research on radioecology] Aleksakhin RM. **Radiats Biol Radioecol** 1996 Jul-Aug;36(4):451–9 (54 ref.) (Eng. Abstr.) **(Rus)**
[Changes in the immune system of the victims of the action of the factors in the accident at the Chernobyl Atomic Electric Power Station. Their manifestations, nature and the possible sequelae] Iarilin AA, et al.
Radiats Biol Radioecol 1996 Jul-Aug;36(4):587–600 (60 ref.) (Eng. Abstr.) **(Rus)**

POWER, PROFESSIONAL see **POWER (PSYCHOLOGY)**

POWER, SOCIAL see **POWER (PSYCHOLOGY)**

POWER SOURCES

How energy policies affect public health. Romm JJ, et al.
Public Health Rep 1996 Sep-Oct;111(5):390–9 (44 ref.)

ADVERSE EFFECTS

Miniature disc battery in the nose: a dangerous foreign body. Alvi A, et al. **Clin Pediatr (Phila)** 1997 Jul;36(7):427–9 (5 ref.)

POWER SUPPLIES see **POWER SOURCES**

POXVIRIDAE

Applications of pox virus vectors to vaccination: an update. Paoletti E. **Proc Natl Acad Sci U S A** 1996 Oct 15; 93(21):11349–53 (34 ref.)

GENETICS

Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Moss B.
Proc Natl Acad Sci U S A 1996 Oct 15;93(21):11341–8 (180 ref.)
Receptors for gamma-interferon encoded by poxviruses: implications for the unknown origin of vaccinia virus. Alcamí A, et al. **Trends Microbiol** 1996 Aug;4(8):321–6 (38 ref.)

IMMUNOLOGY

Attenuated poxvirus vectors as carriers in vaccines against human T cell leukemia-lymphoma virus type I. Franchini G, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20; 12(5):407–8 (21 ref.)
Evasion of apoptosis by DNA viruses. Cuff S, et al.
Immunol Cell Biol 1996 Dec;74(6):527–37 (137 ref.)
M-T2: a poxvirus TNF receptor homologue with dual activities. Sedger L, et al. **Immunol Cell Biol** 1996 Dec; 74(6):538–45 (77 ref.)

METABOLISM

M-T2: a poxvirus TNF receptor homologue with dual activities. Sedger L, et al. **Immunol Cell Biol** 1996 Dec; 74(6):538–45 (77 ref.)

POXVIRIDAE INFECTIONS

IMMUNOLOGY

Evasion of apoptosis by DNA viruses. Cuff S, et al.
Immunol Cell Biol 1996 Dec;74(6):527–37 (137 ref.)

PREVENTION & CONTROL

Controlling orthopoxvirus infections--200 years after Jenner's revolutionary immunization. Niemialtowski MG, et al. **Arch Immunol Ther Exp (Warsz)** 1996;44(5–6):373–8 (36 ref.)

TRANSMISSION

Poxvirus zoonoses. Baxby D, et al. **J Med Microbiol** 1997 Jan;46(1):17–20, 28–33 (228 ref.)

VIROLOGY

Evasion of apoptosis by DNA viruses. Cuff S, et al.
Immunol Cell Biol 1996 Dec;74(6):527–37 (137 ref.)

POXVIRUS INFECTIONS see **POXVIRIDAE INFECTIONS**

POXVIRUS MYXOMATIS see **MYXOMA VIRUS**

POXVIRUS OFFICINALE see **VACCINIA VIRUS**

PP39(C-MOS) see **PROTO-ONCOGENE PROTEINS C-MOS**

PP60(C-SRC) see **PROTO-ONCOGENE PROTEIN PP60(C-SRC)**

PP60(V-SRC) see **ONCOGENE PROTEIN PP60(V-SRC)**

PPLO see **MYCOPLASMA**

PRACTICE (PSYCHOLOGY)

The neurophysiological basis of motor imagery. Decety J.
Behav Brain Res 1996 May;77(1–2):45–52 (60 ref.)

PRACTICE GUIDELINES

American College of Cardiology/American Heart Association guidelines for pacemaker implantation after acute myocardial infarction. What is persistent advanced block at the atrioventricular node? [editorial] Barold SS.
Am J Cardiol 1997 Sep 15;80(6):770–4 (41 ref.)
Suggested guidelines for determining the trough-to-peak ratio of antihypertensive drugs. Myers MG.
Am J Hypertens 1996 Oct;9(10 Pt 2):76S–82S; discussion 87S–90S (19 ref.)
Clinical practice guidelines. Hoyt DB. **Am J Surg** 1997 Jan; 173(1):32–4; discussion 35–6 (20 ref.)
General surgical clinical pathways: an introduction. Gadacz TR, et al. **Am Surg** 1997 Jan;63(1):107–10 (06 ref.)
The relation between systematic reviews and practice guidelines. Cook DJ, et al. **Ann Intern Med** 1997 Aug 1; 127(3):210–6 (58 ref.)
Management of otitis media with effusion in young children. Paap CM. **Ann Pharmacother** 1996 Nov;30(11):1291–7 (19 ref.)
Clinical practice guidelines in complementary and alternative medicine. An analysis of opportunities and obstacles. Practice and Policy Guidelines Panel, National Institutes of Health Office of Alternative Medicine [see comments] **Arch Fam Med** 1997 Mar-Apr;6(2):149–54 (70 ref.) Comment in: Arch Fam Med 1997 Mar-Apr;6(2):155–6.
Guidelines for treatment of decompression illness. Moon RE, et al. **Aviat Space Environ Med** 1997 Mar;68(3):234–43 (88 ref.)
Use of haemopoietic growth factors: commentary on the ASCO/ECOG guidelines. American Society of Clinical Oncology/Eastern Co-operative Oncology Group. Byrne JL, et al. **Blood Rev** 1997 Mar;11(1):16–27 (83 ref.)
The primary care of patients with schizophrenia: a search for good practice. Burns T, et al. **Br J Gen Pract** 1997 Aug;47(421):515–20 (92 ref.)
Update on vaccination guidelines. Nye FJ, et al.
Br J Hosp Med 1997 Apr 2–15;57(7):313–8 (19 ref.)
Clinical practice guidelines: renal cell carcinoma. Bukowski RM, et al. **Cleve Clin J Med** 1997;64 Suppl 1:SI1–44; quiz SI45–7 (291 ref.)
Strategies for preventing pressure ulcers. Bergstrom NI.
Clin Geriatr Med 1997 Aug;13(3):437–54 (55 ref.)
Why guidelines are required for the treatment of Helicobacter pylori infection in children. Sherman PM, et al.
Clin Invest Med 1996 Oct;19(5):362–7 (25 ref.)
Standards of care and ethical concerns in genetic testing and screening. Parker LS, et al. **Clin Obstet Gynecol** 1996 Dec; 39(4):873–84 (41 ref.)
Management guidelines for participation in collision activities with congenital, developmental, or post-injury lesions involving the cervical spine. Torg JS, et al.
Clin Sports Med 1997 Jul;16(3):501–30 (18 ref.)
Osteoporosis: the need for comprehensive treatment guidelines. Abbott TA 3d, et al. **Clin Ther** 1996 Jan-Feb; 18(1):127–49; discussion 126 (106 ref.)
Translating guidelines into practice. A systematic review of

theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines [see comments] Davis DA, et al. **CMAJ** 1997 Aug 15; 157(4):408–16 (61 ref.) Comment in: CMAJ 1997 Aug 15;157(4):403–4.

Audit in obstetrics. Maresh MM, et al. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):296–9 (19 ref.)

Pediatric guidelines: help or hindrance? Homer CJ, et al. **Curr Opin Pediatr** 1996 Oct;8(5):430–5 (41 ref.)

A strategy for arterial risk assessment and management in type 2 (non-insulin-dependent) diabetes mellitus. European Arterial Risk Policy Group on behalf of the International Diabetes Federation European Region. **Diabet Med** 1997 Jul;14(7):611–21 (73 ref.)

Translation of the diabetes nutrition recommendations for health care institutions. American Diabetes Association. **Diabetes Care** 1997 Jan;20(1):106–8 (5 ref.)

Translation of the diabetes nutrition recommendations for health care institutions. Schafer RG, et al. **Diabetes Care** 1997 Jan;20(1):96–105 (63 ref.)

Consensus or confusion: a review of existing national guidelines on Helicobacter pylori-related disease. Lee J, et al. **Eur J Gastroenterol Hepatol** 1997 May;9(5):527–31 (37 ref.)

Multiple chemical sensitivity. A view from under the grassroots. von Mühlendahl KE. **Eur J Pediatr** 1997 Jun; 156(6):499–500 (6 ref.)

Clinical esophageal pH recording: a technical review for practice guideline development. Kahrilas PJ, et al. **Gastroenterology** 1996 Jun;110(6):1982–96 (107 ref.)

The European convention on bioethics. de Wachter MA. **Hastings Cent Rep** 1997 Jan–Feb;27(1):13–23 (53 ref.)

Practice parameters for anesthesiology. Arens JF. **Int Anesthesiol Clin** 1995 Fall;33(4):103–17 (12 ref.)

From clinical guidelines to quality assurance: the experience of Assistance Publique–Hôpitaux de Paris. Durieux P, et al. **Int J Qual Health Care** 1997 Jun;9(3):215–9 (20 ref.)

The use of clinical guidelines to improve medical practice: main issues in the United States. Huttin C. **Int J Qual Health Care** 1997 Jun;9(3):207–14 (61 ref.)

Guidelines for adolescent health research: issues of race and class. Jenkins RR, et al. **J Adolesc Health** 1995 Nov; 17(5):314–22 (43 ref.)

Implications of the Patient Self-Determination Act: guidelines for involving adolescents in medical decision making. Mccabe MA, et al. **J Adolesc Health** 1996 Nov; 19(5):319–24 (33 ref.)

Developmental issues influencing guidelines for adolescent health research: a review. Petersen AC, et al. **J Adolesc Health** 1995 Nov;17(5):298–305 (72 ref.)

The nurse's role as patient advocate: obligation or imposition? Willard C. **J Adv Nurs** 1996 Jul;24(1):60–6 (30 ref.)

Toward the development of guidelines for the conduct of forensic psychiatric examinations. Simon RI, et al. **J Am Acad Psychiatry Law** 1997;25(1):17–30 (37 ref.)

28th Bethesda Conference. Task Force 3: Guidelines for credentialling practicing physicians. Beller GA, et al. **J Am Coll Cardiol** 1997 May;29(6):1148–62 (57 ref.)

28th Bethesda Conference. Task Force 2: Guideline implementation. Eagle KA, et al. **J Am Coll Cardiol** 1997 May;29(6):1141–8 (39 ref.)

28th Bethesda Conference. Task Force 4: Referral guidelines and the collaborative care of patients with cardiovascular disease. Fye WB, et al. **J Am Coll Cardiol** 1997 May; 29(6):1162–70 (73 ref.)

ACC/AHA Guidelines for Exercise Testing. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). Gibbons RJ, et al. **J Am Coll Cardiol** 1997 Jul;30(1):260–311 (343 ref.)

28th Bethesda Conference. Task Force 1: Clinical practice guideline development, dissemination and computerization. Jones RH, et al. **J Am Coll Cardiol** 1997 May;29(6):1133–41 (25 ref.)

Translation of the diabetes nutrition recommendations for health care institutions: technical review [see comments] Schafer RG, et al. **J Am Diet Assoc** 1997 Jan;97(1):43–51 (63 ref.) Comment in: J Am Diet Assoc 1997 Jan;97(1):22. Comment in: J Am Diet Assoc 1997 Jan;97(1):52–3.

Nursing home-acquired pneumonia: avoiding the hospital [editorial; comment] Zimmer JG, et al. **J Am Geriatr Soc** 1997 Mar;45(3):380–1 (14 ref.) Comment on: J Am Geriatr Soc 1997 Mar;45(3):302–6.

Focus on research utilization. Fitzsimmons L, et al. **J Cardiovasc Nurs** 1995 Jan;9(2):87–94 (30 ref.)

The role of health economics in clinical evaluation. Drummond M. **J Eval Clin Pract** 1995 Sep;1(1):71–5 (15 ref.)

Effective practice. Hunter DJ. **J Eval Clin Pract** 1995 Nov; 1(2):131–4 (12 ref.)

Central dimensions of clinical practice evaluation: efficiency, appropriateness and effectiveness—II. Miles A, et al. **J Eval Clin Pract** 1996 May;2(2):131–52 (153 ref.)

Evidence-based medicine: reference? Dogma? Neologism? New orthodoxy? [editorial] Polychronis A, et al. **J Eval Clin Pract** 1996 Feb;2(1):1–3 (12 ref.)

Clinical practice guidelines in practice and education. Berg AO, et al. **J Gen Intern Med** 1997 Apr;12 Suppl 2:S25–33 (42 ref.)

Impact and interpretation of multiple guidelines and consensus documents. Frohlich ED. **J Hum Hypertens** 1996 Feb;10 Suppl 1:S63–7 (20 ref.)

The future impact of clinical practice guidelines. Meeker WC. **J Manipulative Physiol Ther** 1995 Nov–Dec;18(9):606–10 (11 ref.)

The nursing management of women experiencing preterm labor: clinical guidelines and why they are needed. Jones DP, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Sep; 25(7):569–92 (56 ref.)

Education for the nursing of children and their families: standards and guidelines for prelicensure and early professional education [published erratum appears in J Pediatr Nurs 1997 Apr;12(2):132] Pridham KF, et al. **J Pediatr Nurs** 1996 Oct;11(5):273–80 (29 ref.)

The impact of recent changes in the epidemiology of dental caries on guidelines for the use of dental sealants [see comments] Brown LJ, et al. **J Public Health Dent** 1995; 55(5 Spec No):274–91 (102 ref.) Comment in: J Public Health Dent 1995;55(5 Spec No):292–301. Comment in: J Public Health Dent 1995;55(5 Spec No):302–11.

The impact of recent changes in the epidemiology of dental caries on guidelines for the use of dental sealants: epidemiologic perspectives [comment] Rozier RG. **J Public Health Dent** 1995;55(5 Spec No):292–301 (85 ref.) Comment on: J Public Health Dent 1995;55(5 Spec No):274–91.

The impact of recent changes in the epidemiology of dental caries on guidelines for the use of dental sealants: clinical perspectives [comment] Söderholm KJ. **J Public Health Dent** 1995;55(5 Spec No):302–11 (84 ref.) Comment on: J Public Health Dent 1995;55(5 Spec No):274–91.

Guidelines for the management of severe head injury: what we know and what we think we know. Chesnut RM. **J Trauma** 1997 May;42(5 Suppl):S19–22 (4 ref.)

Clinical practice guidelines in nutrition support: can they be based on randomized clinical trials? Wolfe BM, et al. **JPEN J Parenter Enteral Nutr** 1997 Jan–Feb;21(1):1–6 (35 ref.)

Standards of care for acutely ill children with asthma. Andersen CL, et al. **MCN Am J Matern Child Nurs** 1996 Nov–Dec;21(6):280–7 (18 ref.)

Can clinical practice guidelines increase the cost–effectiveness of geriatric rehabilitation? Stason WB. **Med Care** 1997 Jun;35(6 Suppl):JS68–77; discussion JS78–83 (2 ref.)

The use of oral opioids in patients with chronic non-cancer pain. Management strategies [see comments] Graziotti PJ, et al. **Med J Aust** 1997 Jul 7;167(1):30–4 (20 ref.) Comment in: Med J Aust 1997 Jul 7;167(1):9–10.

Role of opioids in chronic non-cancer pain [editorial; comment] Molloy AR, et al. **Med J Aust** 1997 Jul 7; 167(1):9–10 (14 ref.) Comment on: Med J Aust 1997 Jul 7;167(1):26–9. Comment on: Med J Aust 1997 Jul 7;167(1):30–4.

Women's health and women's health care: recommendations of the 1996 AAN Expert Panel on Women's Health. **Nurs Outlook** 1997 Jan–Feb;45(1):7–15 (27 ref.)

Tetanus and diphtheria immunization/prophylaxis adults and older adults. **Nurse Pract** 1997 Mar;22(3):116, 119–20 (11 ref.)

Hepatitis B immunization/prophylaxis: recommendations for adults/older adults. **Nurse Pract** 1996 Dec;21(12 Pt 1):64, 67–70 (8 ref.)

Update on recommendations for HIV postexposure prophylaxis. Grodesky MJ. **Nurse Pract** 1996 Dec;21(12 Pt 1):74, 77–8 (6 ref.)

Legal and practical impact of clinical practice guidelines on nursing and medical practice. Murphy RN. **Nurse Pract** 1997 Mar;22(3):138, 147–8 (3 ref.)

The legal ramifications of the NCCN practice guidelines. Miller FH. **Oncology (Huntingt)** 1996 Nov;10(11 Suppl):35–9 (20 ref.)

Current status of practice guidelines in oncology. Winn RJ. **Oncology (Huntingt)** 1995 Jul;9(7):601–5, 609 DISC 609–10, 615 (34 ref.)

Management of the young febrile child: a commentary on recent practice guidelines. Kramer MS, et al. **Pediatrics** 1997 Jul;100(1):128–34 (62 ref.)

Refusing to pay for health care—Part III (of III): Avoiding third-party payer liability. Ross EJ. **Prog Cardiovasc Nurs** 1996 Summer;11(3):41–5 (35 ref.)

Strategies to evaluate quality clinical outcomes. Shinn JA. **Prog Cardiovasc Nurs** 1997 Winter;12(1):44–6 (2 ref.)

Age and interval for screening mammography: whom do you believe? Venta LA, et al. **Semin Surg Oncol** 1996 Sep–Oct; 12(5):281–9 (39 ref.)

1995 American College of Chest Physicians (ACCP) consensus guidelines on antithrombotic therapy. Davidson B. **Semin Thromb Hemost** 1996;22 Suppl 2:1–5; discussion 29–30 (34 ref.)

[Medical consensus practice guidelines in gynecology–obstetrics] Lansac J. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(2):124–30 (3 ref.) **(Fre)**

[Medical guidelines. Definitions, goals, implementation] Ollenschläger G, et al. **Z Arztl Fortbild (Jena)** 1996 Jun; 90(4):355–61 (14 ref.) (Eng. Abstr.) **(Ger)**

[Guidelines in cardiology: how much and how are they transferable to the reality in health care?] Specchia G, et al. **Cardiologia** 1996 Oct;41(10):929–36 (26 ref.) **(Ita)**

[Levels of scientific evidence and strength of clinical recommendations. From trials to guidelines. The Italian Group on Medicine Based on Evidence—IGMBE] Cartabellotta A, et al. **Recenti Prog Med** 1997 Jul–Aug; 88(7–8):342–7 (26 ref.) (Eng. Abstr.) **(Ita)**

[International guidelines for the clinical evaluation of anti-infective drugs] Sagawa K. **Jpn J Antibiot** 1997 Jan; 50(1):87–106 (7 ref.) **(Jpn)**

[Guidelines for the diagnosis and management of bronchial asthma—a comparison of the Japanese guidelines for the adult asthma with GINA and ICR] Kabe J. **Nippon Rinsho** 1996 Nov;54(11):2886–92 (4 ref.) (Eng. Abstr.) **(Jpn)**

STANDARDS

Nutritional factors in Dutch family medicine: an inventory. van Binsbergen JJ. **Am J Clin Nutr** 1997 Jun;65(6 Suppl):1967S–1973S (90 ref.)

Guidelines for experts reviewing Papanicolaou smear litigation cases. Frable WJ. **Arch Pathol Lab Med** 1997 Mar; 121(3):331–4 (12 ref.)

Development of clinical practice guidelines for prevention and treatment of osteoporosis. Johnston CC Jr. **Calcif Tissue Int** 1996;59 Suppl 1:S30–3 (13 ref.)

Practice guidelines for the treatment of osteoporosis. Prince RL. **Calcif Tissue Int** 1996;59 Suppl 1:S20–3 (7 ref.)

Harmonization of clinical practice guidelines for the prevention and treatment of osteoporosis and osteopenia in Europe: a difficult challenge. Reginster JL. **Calcif Tissue Int** 1996;59 Suppl 1:S24–9 (17 ref.)

Mantoux (tuberculosis) testing. Evaluation of guidelines for testing in Canadian institutions. Thomas RE. **Can Fam Physician** 1997 May;43:933–8 (40 ref.)

National and international guidelines for the diagnosis and treatment of asthma. Nicklas RA. **Curr Opin Pulm Med** 1997 Jan;3(1):51–5 (28 ref.)

A critical appraisal of current management practices for infant regurgitation—recommendations of a working party. Vandenplas Y, et al. **Eur J Pediatr** 1997 May;156(5):343–57 (142 ref.)

OBRA regulations and the use of psychotropic drugs in long-term care facilities: impact and implications for geropsychiatric care. Stoudemire A, et al. **Gen Hosp Psychiatry** 1996 Mar;18(2):77–94 (138 ref.)

Developing treatment guidelines for Alzheimer's disease and other dementias. Rabins PV. **J Clin Psychiatry** 1996;57 Suppl 14:37–8 (11 ref.)

Reporting guidelines: another perspective. Bray A. **J Endovasc Surg** 1995 Nov;2(4):334–40 (8 ref.)

Revising the reporting guidelines: how far do we need to go? Rutherford RB. **J Endovasc Surg** 1995 Nov;2(4):329–31 (3 ref.)

Can there really be "uniform" reporting guidelines? Veith FJ, et al. **J Endovasc Surg** 1995 Nov;2(4):332–3 (1 ref.)

Developing clinically valid practice guidelines. Grimshaw J, et al. **J Eval Clin Pract** 1995 Sep;1(1):37–48 (59 ref.)

Clinical guidelines and the law: advice, guidance or regulation? Hurwitz B. **J Eval Clin Pract** 1995 Sep; 1(1):49–60 (80 ref.)

PRACTICE MANAGEMENT, MEDICAL

Negotiating managed care contracts. Beckman PA, et al. **Compr Ther** 1997 Aug;23(8):554–9 (8 ref.)

ECONOMICS

Office laboratory procedures, office economics, patient and parent education, and urinary tract infection. Ey JL, et al. **Curr Opin Pediatr** 1996 Dec;8(6):639–49 (78 ref.)

The valuation of health care intangible assets. Reilly RF, et al. **Health Care Manage Rev** 1997 Spring;22(2):55–64 (0 ref.)

[Clinical economics—a guideline for economic management in the clinic and general practice] Porzsolt F. **Med Klin** 1996 Aug 15;91(8):531–5 (27 ref.) **(Ger)**

TRENDS

Informatics: a physician's view. Welsh F. **J Health Care Finance** 1997 Spring;23(3):37–43 (17 ref.)

PRACTICE PATTERNS, DENTAL see **DENTIST'S PRACTICE PATTERNS**

PRACTICE PATTERNS, PROFESSIONAL see **PHYSICIAN'S PRACTICE PATTERNS**

PRADER-WILLI SYNDROME

[Prader-Willi syndrome, Angelman syndrome] Narahara K. **Ryoikibetsu Shokogun Shirizu** 1996;(15):220–3 (22 ref.) **(Jpn)**

GENETICS

Multiple imprinted genes associated with Prader-Willi syndrome and location of an imprinting control element. Nicholls RD, et al. **Acta Genet Med Gemellol (Roma)** 1996; 45(1–2):87–9 (10 ref.)

Why is there no diploid overdose effect in Prader-Willi syndrome due to uniparental disomy? Smith A. **Acta Genet Med Gemellol (Roma)** 1996;45(1–2):179–89 (72 ref.)

Imprint switch mechanism indicated by mutations in Prader-Willi and Angelman syndromes. Kelsey G, et al. **Bioessays** 1997 May;19(5):361–5 (29 ref.)

PRADER-WILLI SYNDROME

Genetic and clinical advances in Prader-Willi syndrome. Wharton RH, et al. **Curr Opin Pediatr** 1996 Dec;8(6):618-24 (54 ref.)

Genomic imprinting: significance in development and diseases and the molecular mechanisms. Nakao M, et al. **J Biochem (Tokyo)** 1996 Sep;120(3):467-73 (50 ref.)

Genomic imprinting and its relevance to genetic diseases. Niikawa N. **Jpn J Hum Genet** 1996 Dec;41(4):351-61 (32 ref.)

Genomic imprinting: potential function and mechanisms revealed by the Prader-Willi and Angelman syndromes. Glenn CC, et al. **Mol Hum Reprod** 1997 Apr;3(4):321-32 (110 ref.)

[Genomic imprinting and its role in Prader-Willi and Angelman syndromes] Mglinets VA, et al. **Genetika** 1996 Dec;32(12):1605-15 (91 ref.) (Eng. Abstr.) **(Rus)**

[Genetic diagnosis of the hypotonic newborn] Bauer MS. **Rev Neurol** 1997 May;25(141):703-6 (21 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Ethical issues in emerging new treatments such as growth hormone therapy for children with Down syndrome and Prader-Willi syndrome. Kodish E, et al. **Curr Opin Pediatr** 1996 Aug;8(4):401-5 (28 ref.)

PRAIRIE DOGS see **SCIURIDAE**

PRAOMYS see **MURIDAE**

PRASTERONE

DHEA: a hormone with multiple effects. Khorram O. **Curr Opin Obstet Gynecol** 1996 Oct;8(5):351-4 (59 ref.)

BLOOD

The relationship of natural androgens to coronary heart disease in males: a review. Alexandersen P, et al. **Atherosclerosis** 1996 Aug 23;125(1):1-13 (85 ref.)

Dehydroepiandrosterone, dehydroepiandrosterone sulphate and cardiovascular disease. Khaw KT. **J Endocrinol** 1996 Sep;150 Suppl:S149-53 (23 ref.)

METABOLISM

Dehydroepiandrosterone and diseases of aging. Watson RR, et al. **Drugs Aging** 1996 Oct;9(4):274-91 (141 ref.)

Dehydroepiandrosterone and dehydroepiandrosterone sulfate as neuroactive neurosteroids. Baulieu EE, et al. **J Endocrinol** 1996 Sep;150 Suppl:S221-39 (75 ref.)

Dehydroepiandrosterone-fatty acid esters in human plasma: formation, transport and delivery to steroid target tissues. Lavallée B, et al. **J Endocrinol** 1996 Sep;150 Suppl:S119-24 (29 ref.)

Dehydroepiandrosterone metabolism. Longcope C. **J Endocrinol** 1996 Sep;150 Suppl:S125-7 (27 ref.)

Obesity and metabolic complications: contribution of dehydroepiandrosterone and other steroid hormones. Tchernof A, et al. **J Endocrinol** 1996 Sep;150 Suppl:S155-64 (97 ref.)

Role of metabolism in the activation of dehydroepiandrosterone as a peroxisome proliferator. Waxman DJ. **J Endocrinol** 1996 Sep;150 Suppl:S129-47 (140 ref.)

PHYSIOLOGY

Hormones and lupus: defective dehydroepiandrosterone activity induces impaired interleukin-2 activity of T lymphocytes in patients with systemic lupus erythematosus. Suzuki N, et al. **Ann Med Interne (Paris)** 1996;147(4):248-52 (37 ref.)

[Actions of dehydroepiandrosterone: possible links with aging] Barrou Z, et al. **Presse Med** 1996 Dec 7; 25(38):1885-9 (25 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Studies of dehydroepiandrosterone (DHEA) as a therapeutic agent in systemic lupus erythematosus. Van Vollenhoven RF, et al. **Ann Med Interne (Paris)** 1996;147(4):290-6 (22 ref.)

Dehydroepiandrosterone (DHEA) for diabetic patients? Assan R, et al. **Eur J Endocrinol** 1996 Jul;135(1):37-8 (20 ref.)

Dehydroepiandrosterone (DHEA) and lupus erythematosus: an update [editorial] Lahita RG. **Lupus** 1997;6(6):491-3 (18 ref.)

The use of anti-aging hormones. Melatonin, growth hormone, testosterone, and dehydroepiandrosterone: consumer enthusiasm for unproven therapies. Shomali ME. **Md Med J** 1997 Apr;46(4):181-6 (45 ref.)

PRAVASTATIN

ECONOMICS

[Economic aspects of drug therapy exemplified by pravastatin. A socioeconomic analysis of cholesterol synthase enzyme inhibition in coronary heart disease patients] Berger K, et al. **Med Klin** 1997 Jun 15;92(6):363-9 (40 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Haria M, et al. **Drugs** 1997 Feb;53(2):299-336 (267 ref.)

THERAPEUTIC USE

Therapy and clinical trials [editorial] Game F. **Curr Opin Lipidol** 1996 Jun;7(3):U105-7 (4 ref.)

Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal [see comments] Pedersen TR, et al. **Drug Saf** 1996 Jan; 14(1):11-24 (94 ref.) Comment in: Drug Saf 1996 Jan;14(1):8-10.

Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Haria M, et al. **Drugs** 1997 Feb;53(2):299-336 (267 ref.)

Statins do more than just lower cholesterol [see comments] [published erratum appears in Lancet 1997 Jan 18;349(9046):214] Vaughan CJ, et al. **Lancet** 1996 Oct 19; 348(9034):1079-82 (29 ref.) Comment in: Lancet 1996 Dec 7;348(9041):1582. Comment in: Lancet 1996 Dec 7;348(9041):1582-3. Comment in: Lancet 1996 Dec 7;348(9041):1583.

PRAWNS see **SHRIMP**

PRAYER HEALING see **MENTAL HEALING**

PRAYING MANTIS see **ORTHOPTERA**

PRAZEPAM

Prazepam. **IARC Monogr Eval Carcinog Risks Hum** 1996; 66:143-55 (44 ref.)

PRAZOSIN

ANALOGS & DERIVATIVES

Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective. Eri LM, et al. **Drugs Aging** 1997 Feb;10(2):107-18 (84 ref.)

Measures of Proscar, Hytrin, and Cardura side effects. Frankel S. **Neurourol Urodyn** 1997;16(1):63-6 (0 ref.)

Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia. McKiernan JM, et al. **South Med J** 1997 May;90(5):509-13 (20 ref.)

PRE-B-CELL LEUKEMIA see **LEUKEMIA, PRE-B-CELL**

PREALBUMIN

CHEMISTRY

Amyloid fibril formation and protein misassembly: a structural quest for insights into amyloid and prion diseases. Kelly JW. **Structure** 1997 May 15;5(5):595-600 (73 ref.)

GENETICS

The evolution of gene expression, structure and function of transthyretin. Schreiber G, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 Feb; 116(2):137-60 (250 ref.)

Clinical aspects and diagnosis of thyroid hormone transport protein anomalies. Langsteger W. **Curr Top Pathol** 1997; 91:129-61 (197 ref.)

[Protein and DNA sequencing analyses of transthyretin in familial amyloidotic polyneuropathy] Nakazato M. **Rinsho Shinkeigaku** 1995 Dec;35(12):1436-7 (2 ref.) (Eng. Abstr.) **(Jpn)**

PREANESTHETIC MEDICATION

Preanaesthetic management of the obstetric patient. Alahuhta S. **Acta Anaesthesiol Scand** 1996 Sep;40(8 Pt 2):991-5 (39 ref.)

Pharmacological premedication for anaesthesia. Kanto J, et al. **Acta Anaesthesiol Scand** 1996 Sep;40(8 Pt 2):982-90 (48 ref.)

Sedation in children: adequacy of two-hour fasting [see comments] Ingebo KR, et al. **J Pediatr** 1997 Jul;131(1 Pt 1):155-8 (26 ref.) Comment in: J Pediatr 1997 Jul;131(1 Pt 1):12-3.

[Mivacurium in pediatric anesthesia] Hofmockel VR, et al. **Anaesthesiol Reanim** 1996;21(1):11-3 (25 ref.) (Eng. Abstr.) **(Ger)**

[New muscle relaxants] Diefenbach C, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Feb; 31(1):2-8 (57 ref.) (Eng. Abstr.) **(Ger)**

[Anesthetic management in pheochromocytoma] Strecker U, et al. **Zentralbl Chir** 1997;122(6):460-6 (44 ref.) (Eng. Abstr.) **(Ger)**

[Usefulness of alpha 2-adrenoceptor agonists and practical problems associated with their use in clinical anesthesia--1. Premedication, anesthetic adjuvants, and hemodynamic effects] Nishikawa T, et al. **Masui** 1996 Dec; 45(12):1490-502 (113 ref.) (Eng. Abstr.) **(Jpn)**

[Preoperative evaluation of patients with heart dysfunction and preanesthetic medication] Nishikawa T. **Masui** 1996 Dec;45 Suppl:S108-13 (21 ref.) **(Jpn)**

[Preanesthetic medication. The current concept] Ferreira AA. **Rev Bras Anestesiol** 1968 Oct-Dec;18(4):417-23 (15 ref.) (Eng. Abstr.) **(Por)**

METHODS

[Premedication] Madler C, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Oct; 31(8):509-24 (19 ref.) **(Ger)**

PREBETA-LIPOPROTEINS see **LIPOPROTEINS, VLDL**

PRECANCEROUS CONDITIONS

Malignant & premalignant tumors. Scheinberg RS. **Compr Ther** 1997 Mar;23(3):190-6 (10 ref.)

Could aplastic anaemia be considered a pre-pre-leukaemic disorder? Socié G. **Eur J Haematol Suppl** 1996;60:60-3 (39 ref.)

DIAGNOSIS

Oncogenes and growth factor receptors as diagnostic and prognostic markers in precancers and cancers of the oral mucosa. Burkhardt A. **Curr Top Pathol** 1996;90:223-39 (136 ref.)

Glandular abnormalities: dilemmas in cytological prediction and clinical management [comment] Waddell CA. **Cytopathology** 1997 Feb;8(1):27-30 (20 ref.) Comment on: Cytopathology 1997 Feb;8(1):20-6.

Role of surveillance endoscopy, biopsy and biomarkers in early detection of Barrett's adenocarcinoma. Ellis FH Jr, et al. **Dis Esophagus** 1997 Jul;10(3):165-71 (85 ref.)

Economic aspects of endoscopic screening for intestinal precancerous conditions. Sonnenberg A, et al. **Gastrointest Endosc Clin N Am** 1997 Jan;7(1):165-84 (19 ref.)

MR imaging of the liver. Cirrhosis and premalignant nodules. Ohtomo K. **Magn Reson Imaging Clin N Am** 1997 May; 5(2):331-46 (38 ref.)

Health care auxiliaries in the detection and prevention of oral cancer. Sankaranarayanan R. **Oral Oncol** 1997 May; 33(3):149-54 (29 ref.)

[Effect of molecular diagnostic procedures on surgical therapy of malignant diseases] von Knebel Doeberitz M, et al. **Chirurg** 1996 Oct;67(10):967-79 (73 ref.) (Eng. Abstr.) **(Ger)**

[Prevention of cancer of the upper gastrointestinal tract] Lersch C, et al. **Dtsch Med Wochenschr** 1997 Feb 7; 122(6):169-73 (38 ref.) **(Ger)**

ECONOMICS

Economic aspects of endoscopic screening for intestinal precancerous conditions. Sonnenberg A, et al. **Gastrointest Endosc Clin N Am** 1997 Jan;7(1):165-84 (19 ref.)

ENZYMOLOGY

Hexokinase expression in liver preneoplasia and neoplasia. Mayer D, et al. **Biochem Soc Trans** 1997 Feb;25(1):122-7 (32 ref.)

ETIOLOGY

Etiology of Barrett's metaplasia and esophageal adenocarcinoma. Kim R, et al. **Cancer Epidemiol Biomarkers Prev** 1997 May;6(5):369-77 (124 ref.)

Preneoplasia in mammary tumorigenesis. Medina D. **Cancer Treat Res** 1996;83:37-69 (145 ref.)

Pathobiology of vulvar squamous neoplasia. Crum CP, et al. **Curr Opin Obstet Gynecol** 1997 Feb;9(1):63-9 (50 ref.)

Short-term animal studies for detecting inflammation, fibrosis and pre-neoplastic changes induced by fibres. Donaldson K. **IARC Sci Publ** 1996;(140):97-106 (54 ref.)

Actinic keratoses. Callen JP, et al. **J Am Acad Dermatol** 1997 Apr;36(4):650-3 (14 ref.)

Is celiac disease (gluten sensitivity) a premalignant disorder? Marsh MN. **J Pediatr Gastroenterol Nutr** 1997 May; 24(5):S25-7 (15 ref.)

[Malignant stomach tumors in patients who have had a vagotomy for duodenal ulcers] Zuev VK, et al. **Vestn Khir Im I I Grek** 1996;155(4):97-100 (48 ref.) **(Rus)**

[Risk factors in stomach diseases] Bézayová T, et al. **Bratisl Lek Listy** 1996 Dec;97(12):705-11 (78 ref.) (Eng. Abstr.) **(Slo)**

GENETICS

p53 alterations in progenitor lesions of the bronchus, esophagus, oral cavity, and colon. Bennett WP. **Cancer Detect Prev** 1995;19(6):503-11 (109 ref.)

Regulation of genomic instability in preneoplastic cells. Tlsty TD. **Cancer Surv** 1996;28:217-24 (14 ref.)

Contributions of the molecular biologist in gastrointestinal cancer and precancer screening: current possibilities and future prospects. Craanen ME, et al. **Gastrointest Endosc Clin N Am** 1997 Jan;7(1):147-64 (142 ref.)

Detection of chromosome instability of tissue fields at risk: in situ hybridization. Hittelman WN, et al.

J Cell Biochem Suppl 1996;25:57–62 (19 ref.)

MICROBIOLOGY

Gastric lymphoma and Helicobacter pylori. Isaacson PG, et al. **Important Adv Oncol** 1996;:111–21 (58 ref.)

PATHOLOGY

High-grade dysplasia in Barrett's oesophagus. Wright TA. **Br J Surg** 1997 Jun;84(6):760–6 (79 ref.)

Models of progression spanning preneoplasia and metastasis: the human MCF10AneoT.TGn series and a panel of mouse mammary tumor subpopulations. Miller FR. **Cancer Treat Res** 1996;83:243–63 (42 ref.)

Recent progress in researches on precancerous lesions of gastric cancer in China. Li C, et al. **Chin Med J (Engl)** 1996 May;109(5):407–10 (14 ref.)

Extent of resection and lymphadenectomy in early Barrett's cancer. Korst RJ, et al. **Dis Esophagus** 1997 Jul;10(3):172–8 (42 ref.)

Biomarkers and histology of premalignant and malignant lesions. Beltrami AC, et al. **Eur J Cancer Prev** 1996 Oct; 5(5):375–6 (18 ref.)

Gastric polyps as precancerous lesions. Schmitz JM, et al. **Gastrointest Endosc Clin N Am** 1997 Jan;7(1):29–46 (32 ref.)

Precursor lesions for cancer of the cardia. Weinstein WM. **Gastrointest Endosc Clin N Am** 1997 Jan;7(1):19–28 (24 ref.)

Gastric epithelial dysplasia and adenoma: historical review and histological criteria for grading. Goldstein NS, et al. **Hum Pathol** 1997 Feb;28(2):127–33 (100 ref.)

Multiple early esophageal cancers arising from Barrett's esophagus, and a review of cases of early adenocarcinoma in Barrett's esophagus in Japan. Itatsu T, et al. **J Gastroenterol** 1997 Jun;32(3):389–95 (40 ref.)

The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues. Häggman MJ, et al. **J Urol** 1997 Jul;158(1):12–22 (159 ref.)

Atypical mole syndrome: a brief overview for the primary care physician. Henneberry JM, et al. **Md Med J** 1997 May–Jun;46(5):243–6 (15 ref.)

Preneoplastic lesions in chronic hepatitis C. Thung SN, et al. **Princess Takamatsu Symp** 1995;25:171–8 (40 ref.)

Hyperplastic polyposis of the large bowel. Three cases and a review of the literature. Jørgensen H, et al. **Scand J Gastroenterol** 1996 Aug;31(8):825–30 (41 ref.)

The role of pathology in premalignancy and as a guide for treatment and prognosis in breast cancer. Simpson JF, et al. **Semin Oncol** 1996 Aug;23(4):428–35 (75 ref.)

Barrett's cancer: indications, extent, and results of surgical resection. Siewert JR, et al. **Semin Surg Oncol** 1997 Jul–Aug;13(4):245–52 (54 ref.)

Management of adenocarcinoma arising in Barrett's esophagus. DeMeester TR. **Semin Thorac Cardiovasc Surg** 1997 Jul;9(3):290–301 (38 ref.)

Intestinal metaplasia is not a strong risk factor for bladder cancer: study of 53 cases with long-term follow-up. Corica FA, et al. **Urology** 1997 Sep;50(3):427–31 (29 ref.)

[Ductal hyperplasia and ductal carcinoma in situ. Definition--classification--differential diagnosis] Böcker W, et al. **Pathologe** 1997 Jan;18(1):3–18 (98 ref.) (Eng. Abstr.) **(Ger)**

[Problems on morphological perception of carcinomas in initial or early phase and precancerous lesion] Nakamura K. **Nippon Rinsho** 1996 May;54(5):1207–16 (24 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Does chronic essential fatty acid deficiency constitute a pro-tumorigenic condition? Eynard AR. **Med Hypotheses** 1997 Jan;48(1):55–62 (67 ref.)

[Cyclins in the G1 phase of the cell cycle, their function and participation in oncogenesis] Grzelakowska-Sztabert B. **Postepy Biochem** 1996;42(2):99–107 (155 ref.) **(Pol)**

PREVENTION & CONTROL

Control of precancer cell transformation into cancer cells: its relevance to cancer prevention. Lupulescu AP. **Cancer Detect Prev** 1996;20(6):634–7 (85 ref.)

Interferons in precancer and cancer prevention: where are we? Tanneberger S, et al. **J Interferon Cytokine Res** 1996 May;16(5):339–46 (113 ref.)

SURGERY

Squamous cell carcinomatous change in a posterior fossa epidermoid: case report with a review of the literature. Mohanty A, et al. **Br J Neurosurg** 1996 Oct;10(5):493–5 (20 ref.)

[Diffuse bile duct papillomatosis: high rate of recurrence and risk of malignant transformation] Brönnimann S, et al. **Chirurg** 1996 Jan;67(1):93–7 (28 ref.) (Eng. Abstr.) **(Ger)**

[Intestinal schistosomiasis, a facultative precancerous condition? Review of the literature with reference to Schistosoma japonicum associated rectum carcinoma] Jatzko G, et al. **Chirurg** 1997 Jul;68(7):727–31 (24 ref.) (Eng. Abstr.) **(Ger)**

[Conventional operation for therapy of incidentaloma] Simon D, et al. **Zentralbl Chir** 1997;122(6):473–6 (29 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Recent management of colo-rectal tumours and precancerous conditions. Köves I. **Acta Chir Hung** 1995–96; 35(3–4):239–55 (114 ref.)

Glandular abnormalities: dilemmas in cytological prediction and clinical management [comment] Waddell CA. **Cytopathology** 1997 Feb;8(1):27–30 (20 ref.) Comment on: Cytopathology 1997 Feb;8(1):20–6.

Actinic cheilitis. A treatment review. Dufresne RG Jr, et al. **Dermatol Surg** 1997 Jan;23(1):15–21 (38 ref.)

[Prevention of cancer with the endoscope] Lersch C, et al. **Internist (Berl)** 1996 Aug;37(8):823–9 (102 ref.) **(Ger)**

ULTRASONOGRAPHY

[Calcifications visible in mammographic examination as a diagnostic problem] Urbanowicz Z, et al. **Ginekol Pol** 1996 Jul;67(7):366–9 (17 ref.) (Eng. Abstr.) **(Pol)**

VIROLOGY

Anogenital premalignant and malignant tumors (including Buschke–Löwenstein tumors). Grussendorf-Conen EI. **Clin Dermatol** 1997 May–Jun;15(3):377–88 (95 ref.)

Role of HPV in cutaneous premalignant and malignant tumors. Pfister H, et al. **Clin Dermatol** 1997 May–Jun; 15(3):335–47 (101 ref.)

PRECEPTORSHIP

ORGANIZATION & ADMINISTRATION

Preceptorship: a review of the literature. Bain L. **J Adv Nurs** 1996 Jul;24(1):104–7 (24 ref.)

PRECIPITATION

Affinity precipitation: a novel approach to protein purification. Irwin JA, et al. **Essays Biochem** 1995; 29:137–56 (41 ref.)

PRECONCEPTION CARE

see related

PRENATAL CARE

Preconception genetic counseling. Hogge JS, et al. **Clin Obstet Gynecol** 1996 Dec;39(4):751–62 (23 ref.)

Preconception health care for the primary care practitioner. Cheng D. **Md Med J** 1996 Apr;45(4):297–304 (41 ref.)

Preconception care: a health promotion opportunity [see comments] Perry LE. **Nurse Pract** 1996 Nov;21(11):24–6, 32, 34 passim (27 ref.) Comment in: Nurse Pract 1997 Mar;22(3):14.

METHODS

Contraception and preconception counseling. Heath CC, et al. **Prim Care** 1997 Mar;24(1):123–33 (30 ref.)

PRECURSOR RNA see **RNA PRECURSORS**

PREDATORY BEHAVIOR

Fertility control of mammal pests and the conservation of endangered marsupials. Sinclair AR. **Reprod Fertil Dev** 1997;9(1):1–16 (59 ref.)

PREDIABETIC STATE

Cardiovascular risk factors and the prediabetic syndrome. Haffner SM. **Ann Med** 1996 Aug;28(4):363–70 (121 ref.)

The prediabetic problem: development of non-insulin-dependent diabetes mellitus and related abnormalities. Haffner SM. **J Diabetes Complications** 1997 Mar–Apr;11(2):69–76 (106 ref.)

Strategies for preventing type I diabetes mellitus [see comments] Verge CF, et al. **West J Med** 1996 Mar; 164(3):249–55 (99 ref.) Comment in: West J Med 1996 Mar;164(3):277–8.

[Pre-diabetes type 1. Evaluation of current clinical trials] Thivolet C. **Journ Annu Diabetol Hotel Dieu** 1997;:201–5 (19 ref.) **(Fre)**

DIAGNOSIS

[Detection of pre-diabetes in France. French Diabetes Detection Group] Bach JF. **Journ Annu Diabetol Hotel Dieu** 1997;:207–15 (28 ref.) **(Fre)**

DRUG THERAPY

Treatment of prediabetic patients with insulin: experience and future. European Prediabetes Study Group. Carel JC, et al. **Horm Res** 1996;45 Suppl 1:44–7 (19 ref.)

EPIDEMIOLOGY

Impaired glucose tolerance in Pima Indians. Lillioja S. **Diabet Med** 1996 Sep;13(9 Suppl 6):S127–32 (15 ref.)

GENETICS

In vivo glucose metabolism, insulin secretion and, insulin action in Europids with non-insulin-dependent diabetes mellitus (NIDDM) and their first-degree relatives. Beck-Nielsen H, et al. **Diabet Med** 1996 Sep;13(9 Suppl 6):S78–84 (17 ref.)

Toward an integrated phenotype in pre-NIDDM. Bergman RN, et al. **Diabet Med** 1996 Sep;13(9 Suppl 6):S67–77 (37 ref.)

IMMUNOLOGY

New strategies in oral immunotherapy for diabetes prevention. Muir A, et al. **Diabetes Metab Rev** 1996 Apr; 12(1):1–14 (109 ref.)

PHYSIOPATHOLOGY

In vivo glucose metabolism, insulin secretion and, insulin action in Europids with non-insulin-dependent diabetes mellitus (NIDDM) and their first-degree relatives. Beck-Nielsen H, et al. **Diabet Med** 1996 Sep;13(9 Suppl 6):S78–84 (17 ref.)

THERAPY

New strategies in oral immunotherapy for diabetes prevention. Muir A, et al. **Diabetes Metab Rev** 1996 Apr; 12(1):1–14 (109 ref.)

[Current therapeutic strategy in type 1 diabetes and its preclinical stages] Martin S, et al. **Internist (Berl)** 1996 Dec; 37(12):1289–304 (6 ref.) **(Ger)**

[Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations] Flórez H. **Invest Clin** 1997 Mar;38(1):39–52 (27 ref.) (Eng. Abstr.) **(Spa)**

PREDICTIVE VALUE OF TESTS

see related

FALSE POSITIVE REACTIONS

Mathematical tools for demonstrating the clinical usefulness of biochemical markers. Boyd JC. **Scand J Clin Lab Invest Suppl** 1997;227:46–63 (42 ref.)

[Lymph node biopsy] Brousse N. **Ann Pathol** 1996; 16(3):219–24 (16 ref.) (Eng. Abstr.) **(Fre)**

[Ethical aspect of predictive gene diagnosis] Furukawa T. **Rinsho Shinkeigaku** 1995 Dec;35(12):1535–6 (9 ref.) (Eng. Abstr.) **(Jpn)**

PREDISPOSING FACTORS see **CAUSALITY**

PREDNISOLONE

ADMINISTRATION & DOSAGE

[Bolus of corticoids: side-effects and precautions of use] Bonnotte B, et al. **Presse Med** 1997 Jun 28;26(22):1070–3 (25 ref.) **(Fre)**

[Classification of bronchial asthma according to steroid and immunosuppressive treatment] Nagasaka Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Dec;33 Suppl:134–9 (22 ref.) (Eng. Abstr.) **(Jpn)**

[A case report of pregnancy complicated with adult Still's disease] Yunohara N, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Jun;48(6):431–4 (15 ref.) **(Jpn)**

ADVERSE EFFECTS

Cutaneous alternariosis: role of corticosteroid-induced cutaneous fragility. Machet L, et al. **Dermatology** 1996; 193(4):342–4 (17 ref.)

THERAPEUTIC USE

Subglottic stenosis in Wegener's granulomatosis limited to the head and neck region. Yumoto E, et al. **Ear Nose Throat J** 1997 Aug;76(8):571–4 (15 ref.)

ANCA-associated vasculitis: diagnosis and treatment in the elderly. Parry R, et al. **Postgrad Med J** 1996 Jul; 72(849):423–6 (16 ref.)

[A high CEA level in a case of Cronkhite-Canada syndrome, showing decrease by prednisolone treatment] Fukazawa M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Aug; 94(8):543–8 (18 ref.) **(Jpn)**

PREDNISONE

ADMINISTRATION & DOSAGE

[A case of the "shrinking lung syndrome" in SLE--improvement with corticosteroid therapy] Kitamura Y, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Jun; 19(3):217–22 (11 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

[Lipomatosis induced by corticosteroid therapy] Humblot S, et al. **Rev Med Interne** 1997;18(5):396–401 (25 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Keys to managing systemic lupus erythematosus. Roberts WN. **Hosp Pract (Off Ed)** 1997 Feb 15;32(2):113–6, 119–22, 125–6 (5 ref.)

A pituitary mass and hypopituitarism: improvement after corticosteroid therapy. Shimon I, et al. **Isr J Med Sci** 1997 Jan;33(1):58–62 (28 ref.)

PREDNISONE

Kimura's disease. A typical case of a rare disorder. Jani A, et al. **West J Med** 1997 Feb;166(2):142–4 (7 ref.)

PRE-ECLAMPSIA

Critical care management of severe pre-eclampsia. Linton DM, et al. **Intensive Care Med** 1997 Mar;23(3):248–55 (43 ref.)

[Progresses in prenatal medicine in China, 1996] Zhou Z. **Chung Hua I Hsueh Tsa Chih** 1996 Dec;76(12):917–8 (0 ref.) **(Chi)**

[Recent advances in the pathophysiology of preeclampsia] Nakabayashi M. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Aug;48(8):733–41 (39 ref.) **(Jpn)**

[Hypertension in preeclamptic pregnant women] Satoh K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):144–7 (4 ref.) **(Jpn)**

BLOOD

Elevated levels of serum lipoprotein(a) and apolipoprotein(a) phenotype are not related to pre-eclampsia. Leerink CB, et al. **Acta Obstet Gynecol Scand** 1997 Aug;76(7):625–8 (20 ref.)

[Uric acid and pre-eclampsia] Garrone C, et al. **Minerva Ginecol** 1997 May;49(5):213–6 (19 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

Spontaneous liver hematoma in pregnancy not clearly associated with preeclampsia: a case presentation and literature review. Schwartz ML, et al. **Am J Obstet Gynecol** 1997 Jun;176(6):1328–32; discussion 1332–3 (19 ref.)

[Subcapsular hematoma of the liver. Six cases and review of the literature] Matar N, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(1):89–93 (21 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Use of the pulmonary artery catheter in severe preeclampsia: a review. Fox DB, et al. **Obstet Gynecol Surv** 1996 Nov; 51(11):684–95 (80 ref.)

DRUG THERAPY

Hypertension in pregnancy: current concepts of preeclampsia. Witlin AG, et al. **Annu Rev Med** 1997; 48:115–27 (47 ref.)

Phenytoin as an alternative treatment for preeclampsia. Lucas LS, et al. **J Obstet Gynecol Neonatal Nurs** 1997 May–Jun; 26(3):263–9 (9 ref.)

Endothelial dysfunction in preeclampsia. Part II: Reducing the adverse consequences of endothelial cell dysfunction in preeclampsia; therapeutic perspectives. Dekker GA, et al. **J Perinat Med** 1996;24(2):119–39 (138 ref.)

[Severe preeclampsia: management. Is conservative treatment justified?] Merviel P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(3):238–49 (61 ref.) (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

Effects of placental proteases on maternal and fetal blood pressure in normal pregnancy and preeclampsia. Mizutani S, et al. **Am J Hypertens** 1996 Jun;9(6):591–7 (39 ref.)

ETIOLOGY

Markers of intravascular coagulation and fibrinolysis in preeclampsia: association with intrauterine growth retardation. Schjetlein R, et al. **Acta Obstet Gynecol Scand** 1997 Jul;76(6):541–6 (36 ref.)

Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications [see comments] Ness RB, et al. **Am J Obstet Gynecol** 1996 Nov; 175(5):1365–70 (51 ref.) Comment in: Am J Obstet Gynecol 1997 Jul;177(1):243; discussion 244. Comment in: Am J Obstet Gynecol 1997 Jul;177(1):243–4.

Placental cytokines and the pathogenesis of preeclampsia. Conrad KP, et al. **Am J Reprod Immunol** 1997 Mar; 37(3):240–9 (129 ref.)

Further observations on the etiology of pre-eclampsia: mobilization of toxic cadmium–metallothionein into the serum during pregnancy. Chisolm JC, et al. **Med Hypotheses** 1996 Aug;47(2):123–8 (93 ref.)

[Preeclampsia resulting from placental defects: biology to clinical considerations] Maquoi E, et al. **Rev Med Liege** 1997,52(7):478–84 (20 ref.) **(Fre)**

[Observations on pe-eclampsia–eclampsia and the advances in the evolution of some laboratory tests] Noguera Sánchez MF, et al. **Ginecol Obstet Mex** 1997 Jul;65:300–4 (39 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

[Severe pre-eclampsia in 3 generations. Case report on heritability of pre-eclampsia] Watermann D, et al. **Zentralbl Gynakol** 1996;118(8):471–4 (26 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Placental cytokines and the pathogenesis of preeclampsia. Conrad KP, et al. **Am J Reprod Immunol** 1997 Mar; 37(3):240–9 (129 ref.)

Review: immunobiology of preeclampsia. Taylor RN. **Am J Reprod Immunol** 1997 Jan;37(1):79–86 (99 ref.)

PATHOLOGY

[Glomerular capillary endotheliosis] Monma N, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):144–6 (13 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Effect of nitric oxide, prostacyclin, and thromboxane on the vasospastic action of hydrogen peroxide on human umbilical artery. Okatani Y, et al. **Acta Obstet Gynecol Scand** 1997 Jul;76(6):515–20 (24 ref.)

Effects of placental proteases on maternal and fetal blood pressure in normal pregnancy and preeclampsia. Mizutani S, et al. **Am J Hypertens** 1996 Jun;9(6):591–7 (39 ref.)

Cerebral hemodynamics in preeclampsia and eclampsia. Qureshi AI, et al. **Arch Neurol** 1996 Dec;53(12):1226–31 (47 ref.)

The renin-angiotensin-aldosterone system in pre-eclampsia. Brown MA, et al. **Clin Exp Hypertens** 1997 Jul–Aug; 19(5–6):713–26 (46 ref.)

The pathophysiology of pre-eclampsia. Williams DJ, et al. **Intensive Care Med** 1997 Jun;23(6):620–9 (109 ref.)

Endothelial dysfunction in preeclampsia. Part II: Reducing the adverse consequences of endothelial cell dysfunction in preeclampsia; therapeutic perspectives. Dekker GA, et al. **J Perinat Med** 1996;24(2):119–39 (138 ref.)

Endothelial dysfunction in preeclampsia. Part I: Primary prevention. Therapeutic perspectives. Dekker GA, et al. **J Perinat Med** 1996;24(2):99–117 (145 ref.)

Pregnancy induced hypertension—anaesthetic considerations. Zubair NA. **JPMA J Pak Med Assoc** 1996 Sep;46(9):206–13 (70 ref.)

[Role of nitric oxic in pregnancy and pre-eclampsia] Boulanger H, et al. **Nephrologie** 1997;18(3):81–90 (117 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Prevention of preeclampsia with calcium supplementation and its relation with the L-arginine:nitric oxide pathway. López-Jaramillo P. **Braz J Med Biol Res** 1996 Jun; 29(6):731–41 (99 ref.)

Pre-eclampsia–eclampsia 1996: preventable? Have disputes on its treatment been resolved? Lindheimer MD. **Curr Opin Nephrol Hypertens** 1996 Sep;5(5):452–8 (46 ref.)

Recent advances in the management of preeclampsia. Lewis R, et al. **J Matern Fetal Med** 1997 Jan–Feb;6(1):6–15 (49 ref.)

THERAPY

Pre-eclampsia and hypertension in pregnancy. Hsueh WA. **Curr Ther Endocrinol Metab** 1997;6:324–7 (18 ref.)

Recent advances in the management of preeclampsia. Lewis R, et al. **J Matern Fetal Med** 1997 Jan–Feb;6(1):6–15 (49 ref.)

Hypertension in pregnancy [clinical conference] Bernheim J. **Nephron** 1997;76(3):254–63 (54 ref.)

ULTRASONOGRAPHY

Pregnancy hypertension and uterine artery Doppler ultrasound. Aquilina J, et al. **Curr Opin Obstet Gynecol** 1996 Dec;8(6):435–40 (31 ref.)

[Value of the systematic uterine Doppler in the primiparous woman. A series of 315 cases] Soutif C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(8):819–23 (17 ref.) (Eng. Abstr.) **(Fre)**

PRE-EXCITATION SYNDROMES

[Enhanced atrioventricular nodal conduction] Enjoji Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):496–9 (16 ref.) **(Jpn)**

[Preexcitation syndrome] Hirao K. **Ryoikibetsu Shokogun Shirizu** 1996;(12):364–9 (11 ref.) **(Jpn)**

PATHOLOGY

Anatomy of the atrioventricular junctions with regard to ventricular preexcitation. Anderson RH, et al. **Pacing Clin Electrophysiol** 1997 Aug;20(8 Pt 2):2072–6 (26 ref.)

PHYSIOPATHOLOGY

Recognizing and managing permanent junctional reciprocating tachycardia in the catheter ablation era. Critelli G. **J Cardiovasc Electrophysiol** 1997 Feb; 8(2):226–36 (27 ref.)

[Ventricular preexcitation] Hirao K. **Ryoikibetsu Shokogun Shirizu** 1996;(12):321–4 (17 ref.) **(Jpn)**

PREFERRED PROVIDER ORGANIZATIONS

LEGISLATION & JURISPRUDENCE

Narrowing provider choice: any willing provider laws after New York Blue Cross v. Travelers. McCarthy D. **Am J Law Med** 1997;23(1):97–113 (166 ref.)

ORGANIZATION & ADMINISTRATION

Development of provider networks for specific diseases. Pristave RJ, et al. **J Health Care Finance** 1995 Winter; 22(2):27–41 (17 ref.)

PREFRONTAL CORTEX

ABNORMALITIES

Familial and developmental abnormalities of front lobe function and neurochemistry in schizophrenia. Deakin FW, et al. **J Psychopharmacol (Oxf)** 1997;11(2):133–42 (110 ref.)

ANATOMY & HISTOLOGY

The anatomical relationships of the prefrontal cortex with limbic structures and the basal ganglia. Groenewegen HJ, et al. **J Psychopharmacol (Oxf)** 1997;11(2):99–106 (100 ref.)

The prefrontal landscape: implications of functional architecture for understanding human mentation and the central executive. Goldman-Rakic PS. **Philos Trans R Soc Lond B Biol Sci** 1996 Oct 29; 351(1346):1445–53 (72 ref.)

DRUG EFFECTS

Noradrenergic mechanisms in the prefrontal cortex. Nutt DJ, et al. **J Psychopharmacol (Oxf)** 1997;11(2):163–8 (45 ref.)

GROWTH & DEVELOPMENT

Development of the prefrontal cortex during adolescence: insights into vulnerable neural circuits in schizophrenia. Lewis DA. **Neuropsychopharmacology** 1997 Jun; 16(6):385–98 (132 ref.)

METABOLISM

31P magnetic resonance spectroscopy studies in schizophrenia. Williamson PC, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Aug; 55(1–2):115–8 (19 ref.)

PATHOLOGY

Anatomy and function of the orbital frontal cortex, II: Function and relevance to obsessive-compulsive disorder. Zald DH, et al. **J Neuropsychiatry Clin Neurosci** 1996 Summer;8(3):249–61 (115 ref.)

PHYSIOLOGY

Modulation of the A10 dopamine system: electrophysiological studies of the role of 5-HT3-like receptors. Wang RY, et al. **Behav Brain Res** 1996; 73(1–2):7–10 (34 ref.)

Mesoprefrontal dopaminergic neurons: can tyrosine availability influence their functions? Tam SY, et al. **Biochem Pharmacol** 1997 Feb 21;53(4):441–53 (60 ref.)

Which brain regions are critically involved in the retrieval of old episodic memory? Markowitsch HJ. **Brain Res Brain Res Rev** 1995 Sep;21(2):117–27 (124 ref.)

The role of the prefrontal cortex in higher cognitive functions. Frith C, et al. **Brain Res Cogn Brain Res** 1996 Dec;5(1–2):175–81 (37 ref.)

Functional modular organization of the primate prefrontal cortex for representing working memory process. Sawaguchi T. **Brain Res Cogn Brain Res** 1996 Dec; 5(1–2):157–63 (31 ref.)

The role of mesoprefrontal dopamine neurons in stress. Horger BA, et al. **Crit Rev Neurobiol** 1996;10(3–4):395–418 (232 ref.)

The role of cerebro-ponto-cerebellar pathways in the control of vergence eye movements. Gamlin PD, et al. **Eye** 1996; 10 (Pt 2):167–71 (48 ref.)

Anatomic organization of the basilar pontine projections from prefrontal cortices in rhesus monkey. Schmahmann JD, et al. **J Neurosci** 1997 Jan 1;17(1):438–58 (96 ref.)

Plasticity of the hippocampal-prefrontal cortex synapses. Jay TM, et al. **J Physiol Paris** 1996;90(5–6):361–6 (19 ref.)

Frontal-subcortical circuits: the anatomic basis of executive, social and motivated behaviors. Masterman DL, et al. **J Psychopharmacol (Oxf)** 1997;11(2):107–14 (60 ref.)

The nature of interactions involving prefrontal and striatal dopamine systems. Wilkinson LS. **J Psychopharmacol (Oxf)** 1997;11(2):143–50 (75 ref.)

A computational approach to prefrontal cortex, cognitive control and schizophrenia: recent developments and current challenges. Cohen JD, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Oct 29; 351(1346):1515–27 (80 ref.)

The somatic marker hypothesis and the possible functions of the prefrontal cortex. Damasio AR. **Philos Trans R Soc Lond B Biol Sci** 1996 Oct 29; 351(1346):1413–20 (43 ref.)

Evidence for the importance of dopamine for prefrontal cortex functions early in life. Diamond A. **Philos Trans R Soc Lond B Biol Sci** 1996 Oct 29; 351(1346):1483–93; discussion 1494 (109 ref.)

The role of the prefrontal cortex in self-consciousness: the case of auditory hallucinations. Frith C. **Philos Trans R Soc Lond B Biol Sci** 1996 Oct 29;

351(1346):1505–12 (52 ref.)
The prefrontal landscape: implications of functional architecture for understanding human mentation and the central executive. Goldman-Rakic PS.
Philos Trans R Soc Lond B Biol Sci 1996 Oct 29; 351(1346):1445–53 (72 ref.)
Dissociating executive functions of the prefrontal cortex. Robbins TW. **Philos Trans R Soc Lond B Biol Sci** 1996 Oct 29;351(1346):1463–70; discussion 1470–1 (37 ref.)
The orbitofrontal cortex. Rolls ET.
Philos Trans R Soc Lond B Biol Sci 1996 Oct 29; 351(1346):1433–43; discussion 1443–4 (103 ref.)
The domain of supervisory processes and temporal organization of behaviour. Shallice T, et al.
Philos Trans R Soc Lond B Biol Sci 1996 Oct 29; 351(1346):1405–11; discussion 1411–2 (45 ref.)
On the role of the cerebellum and basal ganglia in cognitive signal processing. Houk JC. **Prog Brain Res** 1997; 114:543–52 (50 ref.)
Networks related to the orbital and medial prefrontal cortex; a substrate for emotional behavior? Price JL, et al.
Prog Brain Res 1996;107:523–36 (30 ref.)
An application of prefrontal cortex function theory to cognitive aging. West RL. **Psychol Bull** 1996 Sep; 120(2):272–92 (130 ref.)

PHYSIOPATHOLOGY

Rehabilitation of frontal/executive impairments in schizophrenia. Delahunty A, et al.
Aust N Z J Psychiatry 1996 Dec;30(6):760–7 (61 ref.)
A prefrontal dysfunction model of early-treated phenylketonuria. Welsh MC. **Eur J Pediatr** 1996 Jul;155 Suppl 1:S87–9 (33 ref.)
Issues concerning relative speed of processing hypotheses, schizophrenic performance deficits, and prefrontal function: comment on Schooler et al. (1997) [comment] [see comments] Cohen JD, et al. **J Exp Psychol Gen** 1997 Mar;126(1):37–41 (21 ref.) Comment on: J Exp Psychol Gen 1997 Mar;126(1):19–36. Comment in: J Exp Psychol Gen 1997 Mar;126(1):42–4.
Stroop theory, memory, and prefrontal cortical functioning: reply to Cohen et al. (1997) [comment] Schooler C, et al. **J Exp Psychol Gen** 1997 Mar;126(1):42–4 (18 ref.) Comment on: J Exp Psychol Gen 1997 Mar;126(1):37–41.
Anatomy and function of the orbital frontal cortex, II: Function and relevance to obsessive-compulsive disorder. Zald DH, et al. **J Neuropsychiatry Clin Neurosci** 1996 Summer;8(3):249–61 (115 ref.)
Catecholamine regulation of the prefrontal cortex. Arnsten AF. **J Psychopharmacol (Oxf)** 1997;11(2):151–62 (170 ref.)
Neuropsychological and neuroimaging evidence for the involvement of the frontal lobes in depression. Goodwin GM. **J Psychopharmacol (Oxf)** 1997;11(2):115–22 (85 ref.)
Dopamine, the prefrontal cortex and schizophrenia. Knable MB, et al. **J Psychopharmacol (Oxf)** 1997;11(2):123–31 (180 ref.)
Evidence for the importance of dopamine for prefrontal cortex functions early in life. Diamond A.
Philos Trans R Soc Lond B Biol Sci 1996 Oct 29; 351(1346):1483–93; discussion 1494 (109 ref.)
Prefrontal function in schizophrenia: confounds and controversies. Weinberger DR, et al.
Philos Trans R Soc Lond B Biol Sci 1996 Oct 29; 351(1346):1495–503 (73 ref.)

SURGERY

The frontal lobes and neurosurgery for psychiatric disorders. Malizia AL. **J Psychopharmacol (Oxf)** 1997;11(2):179–87 (100 ref.)

PREGNADIENEDIOLS

THERAPEUTIC USE

Once-daily mometasone furoate nasal spray: efficacy and safety of a new intranasal glucocorticoid for allergic rhinitis. Davies RJ, et al. **Clin Ther** 1997 Jan-Feb; 19(1):27–38; discussion 2–3 (24 ref.)
Topical corticosteroids: experience with mometasone furoate. Peets EA. **Curr Probl Dermatol** 1995;23:207–23 (38 ref.)

PREGNANCY

see related
PRENATAL CARE
PSEUDOPREGNANCY

Gestational weight gain as a predictor of birth and placenta weight according to pre-pregnancy body mass index. Zhou W, et al. **Acta Obstet Gynecol Scand** 1997 Apr;76(4):300–7 (36 ref.)
Nutrition during pregnancy. Kolasa KM, et al.
Am Fam Physician 1997 Jul;56(1):205–12, 216–8 (33 ref.)
Can low molecular weight heparin be used in pregnant women? Borg JY. **Ann Med Interne (Paris)** 1996 Sep;147 Suppl 1:45–7 (20 ref.)
Dermatologic drugs, pregnancy, and lactation. A conservative guide. Reed BR. **Arch Dermatol** 1997 Jul; 133(7):894–8 (38 ref.)
ABC of work related disorders. Women at work. Kapadia LH. **BMJ** 1996 Oct 26;313(7064):1073–6 (0 ref.)
Pregnancy and renal transplantation. Davison JM, et al.
Br J Urol 1997 Jul;80 Suppl 1:29–32 (25 ref.)
Childbearing issues in breast carcinoma survivors. Surbone A, et al. **Cancer** 1997 Apr 1;79(7):1271–8 (62 ref.)
Gynecologic issues in pediatric oncology. Jones KP.
Clin Obstet Gynecol 1997 Mar;40(1):200–9 (21 ref.)
Infertility and subsequent pregnancy. Hoxsey R, et al.
Clin Perinatol 1997 Jun;24(2):321–42 (95 ref.)
Bias against the null hypothesis in maternal-fetal pharmacology and toxicology. Koren G.
Clin Pharmacol Ther 1997 Jul;62(1):1–5 (21 ref.)
Pregnancy and travel. Rose SR.
Emerg Med Clin North Am 1997 Feb;15(1):93–111 (45 ref.)
Estimating the risk of breast cancer in relation to the interval since last term pregnancy [see comments] Cummings P, et al. **Epidemiology** 1997 Sep;8(5):488–94 (18 ref.) Comment in: Epidemiology 1997 Sep;8(5):471–3.
Age at and time since: modeling temporal aspects of exposure [editorial; comment] Thompson WD. **Epidemiology** 1997 Sep;8(5):471–3 (11 ref.) Comment on: Epidemiology 1997 Sep;8(5):488–94.
Current status of surgical and nonsurgical management of ectopic pregnancy. Yao M, et al. **Fertil Steril** 1997 Mar; 67(3):421–33 (101 ref.)
Heterotopic pregnancy and assisted reproduction—an update. Rojansky N, et al. **J Assist Reprod Genet** 1996 Aug; 13(7):594–601 (58 ref.)
Vitamin and mineral supplement prior to and during pregnancy. Menard MK.
Obstet Gynecol Clin North Am 1997 Sep;24(3):479–98 (21 ref.)
Off-label prescribing during pregnancy. Rayburn WF, et al.
Obstet Gynecol Clin North Am 1997 Sep;24(3):471–8 (9 ref.)
Cervical pregnancy: past and future. Ushakov FB, et al.
Obstet Gynecol Surv 1997 Jan;52(1):45–59 (105 ref.)
Sociodemographic perspectives on pregnant women at work. Shehan CL. **Semin Perinatol** 1996 Feb;20(1):3–10 (15 ref.)
Immunosuppressive drugs and pregnancy: experimental and clinical data. Albengres E, et al. **Transplant Proc** 1997 Aug; 29(5):2461–6 (14 ref.)
[Nutritional requirements for pregnant women] Putet G.
Arch Pediatr 1997;4(2 Suppl 2):131s–134s (79 ref.) **(Fre)**
[Pregnancy in women over forty years old] Dufour P, et al. **Contracept Fertil Sex** 1997 Jun;25(6):415–22 (49 ref.) **(Fre)**
[Pregnancy after organ transplantation] Many A, et al.
Harefuah 1996 Sep;131(5–6):173–6 (28 ref.) **(Heb)**

BLOOD

Maternal serum screening for fetal Down syndrome: clinical aspects. Saller DN Jr, et al. **Clin Obstet Gynecol** 1996 Dec; 39(4):783–92 (11 ref.)
Maternal serum screening for fetal Down syndrome: the detection of other pathologies. Saller DN Jr, et al.
Clin Obstet Gynecol 1996 Dec;39(4):793–800 (12 ref.)
Prenatal diagnosis using fetal cells isolated from maternal peripheral blood: a review. Steele CD, et al.
Clin Obstet Gynecol 1996 Dec;39(4):801–13 (41 ref.)
Progress in the genetic analysis of fetal cells circulating in maternal blood. Bianchi DW.
Curr Opin Obstet Gynecol 1997 Apr;9(2):121–5 (33 ref.)
Hemostasis during pregnancy and puerperium. Hellgren M. **Haemostasis** 1996 Oct;26 Suppl 4:244–7 (11 ref.)
The serum growth hormone binding protein: pregnant with possibilities. Barnard R, et al. **J Endocrinol** 1997 Apr; 153(1):1–14 (151 ref.)
Maternal serum screening for fetal genetic disorders. Ross HL, et al. **Obstet Gynecol Clin North Am** 1997 Mar; 24(1):33–47 (51 ref.)
[Hyperlipidemia in pregnancy] Dejager S, et al.
Presse Med 1996 Nov 30;25(37):1839–45 (34 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Medications in pregnancy. Colie CF.
Curr Opin Obstet Gynecol 1996 Dec;8(6):398–402 (49 ref.)
Drugs during pregnancy: an issue of risk classification and information to prescribers. Sannerstedt R, et al.
Drug Saf 1996 Feb;14(2):69–77 (7 ref.)
The effect of caffeine on pregnancy outcome variables. Hinds TS, et al. **Nutr Rev** 1996 Jul;54(7):203–7 (32 ref.)
Oxytocin and its receptor in pregnancy and parturition: current concepts and clinical implications. Zeeman GG, et al. **Obstet Gynecol** 1997 May;89(5 Pt 2):873–83 (107 ref.)
[Toxic effects of fluorine compounds on the the fetus and their effect on the course of pregnancy] Chlubek D, et al. **Ginekol Pol** 1996 Aug;67(8):414–8 (21 ref.) (Eng. Abstr.) **(Pol)**

ETHNOLOGY

Cultural differences in beliefs and practices about pregnancy and childbearing. Garcia Coll C, et al. **Med Health R I** 1996 Jul;79(7):257–60 (36 ref.)
Childbearing research: a transcultural review. Steinberg S. **Soc Sci Med** 1996 Dec;43(12):1765–84 (38 ref.)

GENETICS

Altercation of generations: genetic conflicts of pregnancy. Haig D. **Am J Reprod Immunol** 1996 Mar;35(3):226–32 (31 ref.)

IMMUNOLOGY

Immune suppression and Th1/Th2 balance in pregnancy revisited: a (very) personal tribute to Tom Wegmann. Chaouat G, et al. **Am J Reprod Immunol** 1997 Jun; 37(6):427–34 (23 ref.)
Maternal anti-placental cell-mediated reactivity and spontaneous abortions. Raghupathy R.
Am J Reprod Immunol 1997 Jun;37(6):478–84 (62 ref.)
Cytokine-leukocyte networks and the establishment of pregnancy. Robertson SA, et al. **Am J Reprod Immunol** 1997 Jun;37(6):438–42 (37 ref.)
The great balancing acts. The pregnant woman, placenta, fetus, and infectious agents. Nahmias AJ, et al.
Clin Perinatol 1997 Jun;24(2):497–521 (104 ref.)
Maternal T cell reactivity in pregnancy? Chaouat G, et al.
Curr Top Microbiol Immunol 1997;222:103–26 (198 ref.)
Suppressive cellular and molecular activities in maternofetal immune interactions; suppressor cell activity, prostaglandins, and alpha-fetoproteins. Olding LB, et al.
Curr Top Microbiol Immunol 1997;222:159–87 (218 ref.)
Traffic of leukocytes through the maternofetal placental interface and its possible consequences. Papadogiannakis N. **Curr Top Microbiol Immunol** 1997;222:141–57 (137 ref.)
Immunobiology of the trophoblast: mechanisms by which placental tissues evade maternal recognition and rejection. Torry DS, et al. **Curr Top Microbiol Immunol** 1997; 222:127–40 (78 ref.)
ACOG educational bulletin. Management of isoimmunization in pregnancy. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1996 Nov; 55(2):183–90 (35 ref.)
Immunologic adaptations during pregnancy. Priddy KD.
J Obstet Gynecol Neonatal Nurs 1997 Jul-Aug;26(4):388–94 (18 ref.)
There is a bias against type 1 (inflammatory) cytokine expression and function in pregnancy. Guilbert LJ.
J Reprod Immunol 1996 Dec;32(2):105–10 (27 ref.)
Uterine macrophages and environmental programming for pregnancy success. Hunt JS, et al. **J Reprod Immunol** 1996 Nov;32(1):1–25 (120 ref.)
Is there a Th2 bias in human pregnancy? Vince GS, et al.
J Reprod Immunol 1996 Dec;32(2):101–4 (22 ref.)
Placental isoferritin-associated p43 in pregnancy and breast cancer. Minireview. Rosen HR. **Neoplasma** 1996; 43(6):357–62 (21 ref.)
Granulated lymphocytes of pregnancy. Whitelaw PF, et al.
Placenta 1996 Nov;17(8):533–43 (112 ref.)
Antiphospholipid antibodies in healthy pregnant women. Lynch A, et al. **Rheum Dis Clin North Am** 1997 Feb; 23(1):55–70 (106 ref.)
The transfusion immunomodulation theory: the Th1/Th2 paradigm and an analogy with pregnancy as a unifying mechanism. Blumberg N, et al. **Semin Hematol** 1996 Oct; 33(4):329–40 (66 ref.)
[Immunology of early pregnancy. I. Immunologically competent cells in the endometrium and decidua] Krzysiek J, et al. **Ginekol Pol** 1996 Sep;67(9):467–71 (54 ref.) (Eng. Abstr.) **(Pol)**
[Immunology of early pregnancy. II. Decidua and trophoblast relationship] Krzysiek J, et al. **Ginekol Pol** 1996 Sep;67(9):472–7 (55 ref.) (Eng. Abstr.) **(Pol)**
[Immunology of the fetal-maternal relationship] González NC, et al. **Rev Alerg Mex** 1996 Jan-Feb;43(1):18–22 (49 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Protein metabolism in pregnancy. Robinson S, et al.
Baillieres Clin Endocrinol Metab 1996 Oct;10(4):571–87 (56 ref.)
Maternal thyroid function: interpretation of thyroid function tests in pregnancy. Brent GA. **Clin Obstet Gynecol** 1997 Mar;40(1):3–15 (20 ref.)
Maternal nutrition and the outcome of pregnancy. A renaissance in research. Brown JE, et al. **Clin Perinatol** 1997 Jun;24(2):433–49 (101 ref.)
Clinical biochemistry of pregnancy. Lockitch G.
Crit Rev Clin Lab Sci 1997;34(1):67–139 (118 ref.)
Stable isotope methods for studying nutrient mineral metabolism in humans. Mellon FA, et al. **Endeavour** 1997; 21(1):12–8 (22 ref.)
Serum ferritin in Danes: studies of iron status from infancy to old age, during blood donation and pregnancy. Milman N. **Int J Hematol** 1996 Feb;63(2):103–35 (151 ref.)
Neuromuscular transmission and its pharmacological blockade. Part 4: Use of relaxants in paediatric and elderly patients, in obstetrics, and in the intensive care unit. Booij LH. **Pharm World Sci** 1997 Feb;19(1):45–52 (11 ref.)
[The mineral requirements and mineral status in pregnancy] Ivanova L. **Akush Ginekol (Sofiia)** 1996;35(1–2):40–2 (23 ref.) (Eng. Abstr.) **(Bul)**
[Uses of nitric oxide in obstetrics and gynecology] He W, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Feb; 31(2):119–21 (23 ref.) **(Chi)**
[Fatty acids, fetal growth and pregnancy] Ghisolfi J.
Arch Pediatr 1997;4(2 Suppl 2):135s–137s (6 ref.) **(Fre)**
[Normal phosphorus and calcium metabolism during pregnancy and breast feeding] Koeger AC, et al.
Rev Med Interne 1997 Jul;18(7):533–45 (30 ref.) (Eng. Abstr.) **(Fre)**
[Some aspects of prenatal fluoride metabolism in human studies performed during the perinatal period] Chlubek D.

Ann Acad Med Stetin 1996;Suppl 31:1–99 (126 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Effects of placental proteases on maternal and fetal blood pressure in normal pregnancy and preeclampsia. Mizutani S, et al. **Am J Hypertens** 1996 Jun;9(6):591–7 (39 ref.)

Nitric oxide and pregnancy. Sladek SM, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):R441–63 (256 ref.)

Hormone-mediated changes in nutrient metabolism in pregnancy: a physiological basis for normal fetal development. Knopp RH. **Ann N Y Acad Sci** 1997 May 28;817:251–71 (46 ref.)

GnRH in pregnancy. Gohar J, et al. **Arch Gynecol Obstet** 1996;259(1):1–6 (45 ref.)

Nutritional studies on pregnant women in Umbria (Italy). Alberti-Fidanza A, et al. **Bibl Nutr Dieta** 1996;(53):11–22 (14 ref.)

Reproductive stresses in undernourished and well-nourished women. Prentice AM, et al. **Bibl Nutr Dieta** 1996;(53):1–10 (22 ref.)

Tumor necrosis factors: pivotal components of pregnancy? Hunt JS, et al. **Biol Reprod** 1996 Mar;54(3):554–62 (79 ref.)

Physiological changes in the skin during pregnancy. Elling SV, et al. **Clin Dermatol** 1997 Jan–Feb;15(1):35–43 (39 ref.)

The role of vasoactive molecules of endothelial origin in the pathophysiology of normal pregnancy and pregnancy-induced hypertension [editorial] Noris M, et al. **Curr Opin Nephrol Hypertens** 1996 Jul;5(4):347–52 (38 ref.)

Current progress in early pregnancy investigation [editorial] Polliotti BM. **Early Pregnancy** 1997 Mar;3(1):38–51 (50 ref.)

Potential novel roles of luteinizing hormone and human chorionic gonadotropin during early pregnancy in women. Rao CV. **Early Pregnancy** 1997 Mar;3(1):1–9 (88 ref.)

The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. Glinoer D. **Endocr Rev** 1997 Jun;18(3):404–33 (276 ref.)

Parathyroid hormone-related protein and its role in pregnancy, lactation, and neonatal growth and development [comment] Cooper CW. **Eur J Endocrinol** 1997 May;136(5):465–6 (13 ref.) Comment on: Eur J Endocrinol 1997 May;136(5):546–51.

Sonographic assessment of cervical changes during pregnancy and delivery: current concepts. Maymon R, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Aug; 67(2):149–55 (46 ref.)

Vibration effects on setting pregnant women—subjects of various masses. Qassem W, et al. **J Biomech** 1996 Apr; 29(4):493–501 (28 ref.)

Pregnancy and lactation as risk factors for subsequent bone loss and osteoporosis. Sowers M. **J Bone Miner Res** 1996 Aug;11(8):1052–60 (90 ref.)

Maternal vascular function in pregnancy. Poston L. **J Hum Hypertens** 1996 Jun;10(6):391–4 (37 ref.)

Breast cancer risk: protective effect of an early first full-term pregnancy versus increased risk of induced abortion. Canty L. **Oncol Nurs Forum** 1997 Jul;24(6):1025–31 (60 ref.)

Diving and pregnancy. Camporesi EM. **Semin Perinatol** 1996 Aug;20(4):292–302 (32 ref.)

The elite athlete and exercise in pregnancy. Hale RW, et al. **Semin Perinatol** 1996 Aug;20(4):277–84 (43 ref.)

Physical activity at altitude in pregnancy. Huch R. **Semin Perinatol** 1996 Aug;20(4):303–14 (59 ref.)

Body composition in pregnancy. Jaque-Fortunato SV, et al. **Semin Perinatol** 1996 Aug;20(4):340–2 (5 ref.)

Water exercise in pregnancy. Katz VL. **Semin Perinatol** 1996 Aug;20(4):285–91 (47 ref.)

Cardio-respiratory physiological adaptation of pregnancy. O'Day MP. **Semin Perinatol** 1997 Aug;21(4):268–75 (68 ref.)

Cardiovascular responses to aerobic exercise during pregnancy and postpartum. Pivarnik JM. **Semin Perinatol** 1996 Aug;20(4):242–9 (51 ref.)

Maternal and fetal cardiovascular response to exercise during pregnancy. Veille JC. **Semin Perinatol** 1996 Aug; 20(4):250–62 (33 ref.)

Applications of methods and techniques in the study of aerobic fitness during pregnancy. Wiswell RA. **Semin Perinatol** 1996 Aug;20(4):213–21 (54 ref.)

[Role of nitric oxic in pregnancy and pre-eclampsia] Boulanger H, et al. **Nephrologie** 1997;18(3):81–90 (117 ref.) (Eng. Abstr.) **(Fre)**

[Pregnancy in women undergoing a kidney transplant. Our experience and a review of the literature] Tommasi GV, et al. **Minerva Ginecol** 1996 Dec;48(12):553–6 (10 ref.) (Eng. Abstr.) **(Ita)**

[A review of pregnancy-induced analgesia] Iwasaki H, et al. **Masui** 1997 May;46(5):598–606 (62 ref.) (Eng. Abstr.) **(Jpn)**

[Physical exertion at work and the course and outcome of pregnancy] Makowiec-Dąbrowska T, et al. **Med Pr** 1996; 47(6):629–49 (51 ref.) (Eng. Abstr.) **(Pol)**

[Gastrointestinal hormones in the normal state and in pregnancy] Varlamova TM. **Ter Arkh** 1996;68(2):72–5 (52 ref.) **(Rus)**

[New endometrial modulators in early pregnancy] Diaz-Flores M, et al. **Gac Med Mex** 1996 Sep–Oct; 132(5):519–28 (35 ref.) (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

The smoking addiction of pregnant women and the consequences on their offspring's intellectual development. Frydman M. **J Environ Pathol Toxicol Oncol** 1996; 15(2–4):169–72 (11 ref.)

Developmental care of the pregnant couple. Malnory ME. **J Obstet Gynecol Neonatal Nurs** 1996 Jul–Aug;25(6):525–32 (23 ref.)

Defining and measuring unintended pregnancy: issues and concerns. Petersen R, et al. **Womens Health Issues** 1997 Jul–Aug;7(4):234–40 (18 ref.)

Genetic accountability and pregnant women. Rothenberg KH. **Womens Health Issues** 1997 Jul–Aug;7(4):215–9 (12 ref.)

STATISTICS & NUMERICAL DATA

Defining and measuring unintended pregnancy: issues and concerns. Petersen R, et al. **Womens Health Issues** 1997 Jul–Aug;7(4):234–40 (18 ref.)

PREGNANCY, ABDOMINAL

PATHOLOGY

Does primary omental pregnancy exist? Berghella V, et al. **Gynecol Obstet Invest** 1996;42(2):133–6 (18 ref.)

PREGNANCY, ADOLESCENT see **PREGNANCY IN ADOLESCENCE**

PREGNANCY, ANIMAL

see related
ANIMALS, NEWBORN

Control of bilirubin production by synthetic heme analogs: pharmacologic and toxicologic considerations. Drummond GS, et al. **J Perinatol** 1996 May–Jun;16(3 Pt 2):S72–9 (36 ref.)

GENETICS

Altercation of generations: genetic conflicts of pregnancy. Haig D. **Am J Reprod Immunol** 1996 Mar;35(3):226–32 (31 ref.)

IMMUNOLOGY

Uterine macrophages and environmental programming for pregnancy success. Hunt JS, et al. **J Reprod Immunol** 1996 Nov;32(1):1–25 (120 ref.)

Uterine natural killer cells in species with epitheliochorial placentation. Engelhardt H, et al. **Nat Immun** 1996–97; 15(1):53–69 (95 ref.)

Recent developments and potentialities for reducing embryo mortality in ruminants: the role of IFN-tau and other cytokines in early pregnancy. Martal J, et al. **Reprod Fertil Dev** 1997;9(3):355–80 (250 ref.)

METABOLISM

[Metabolic host-tumor relationships during perinatal phase] Argilés JM, et al. **Med Clin (Barc)** 1997 Jun 28; 109(5):186–94 (52 ref.) **(Spa)**

PHYSIOLOGY

Interferon tau: a novel pregnancy recognition signal. Bazer FW, et al. **Am J Reprod Immunol** 1997 Jun;37(6):412–20 (53 ref.)

Nutrition of grazing brood mares and growing horses. McMeniman NP. **Aust Vet J** 1996 Jul;74(1):64–70 (75 ref.)

Placentas and foetal health. Collins MH. **Equine Vet J Suppl** 1993 Apr;(14):8–11 (24 ref.)

Parathyroid hormone-related protein and its role in pregnancy, lactation, and neonatal growth and development [comment] Cooper CW. **Eur J Endocrinol** 1997 May;136(5):465–6 (13 ref.) Comment on: Eur J Endocrinol 1997 May;136(5):546–51.

Relative role of CSF-1, MCP-1/JE, and RANTES in macrophage recruitment during successful pregnancy. Wood GW, et al. **Mol Reprod Dev** 1997 Jan;46(1):62–9; discussion 69–70 (24 ref.)

The uterine environment in early pregnancy in the tammar wallaby. Shaw G. **Reprod Fertil Dev** 1996;8(4):811–8 (66 ref.)

[An olfactory memory formed in the vomeronasal system] Kaba H. **Tanpakushitsu Kakusan Koso** 1996 Nov; 41(14):2077–83 (29 ref.) **(Jpn)**

PREGNANCY COMPLICATIONS

see related
PREGNANCY, PROLONGED

Folic acid: new dimensions of an old friendship. Johnston RB Jr. **Adv Pediatr** 1997;44:231–61 (134 ref.)

Accidental electric shock in pregnancy: a prospective cohort study. Einarson A, et al. **Am J Obstet Gynecol** 1997 Mar; 176(3):678–81 (13 ref.)

Hyperreactio luteinalis complicating a normal singleton pregnancy. Lambers DS, et al. **Am J Perinatol** 1996 Nov; 13(8):491–4 (15 ref.)

Acute myocardial infarction associated with pregnancy. Roth A, et al. **Ann Intern Med** 1996 Nov 1;125(9):751–62 (194 ref.)

Antenatal care. Which tests and when. Comerford JA. **Aust Fam Physician** 1997 Mar;26(3):229–35, 237 (7 ref.)

Contraception, pregnancy and lactation in women with epilepsy. Yerby MS. **Baillieres Clin Neurol** 1996 Dec; 5(4):887–908 (125 ref.)

Thyroid disease and pregnancy [published erratum appears in Br J Hosp Med 1997 Feb 19–Mar 4;57(4):172] Girling JC. **Br J Hosp Med** 1996 Oct 2–15;56(7):316–20 (20 ref.)

Renal calculi in pregnancy. Gorton E, et al. **Br J Urol** 1997 Jul;80 Suppl 1:4–9 (39 ref.)

Smoking cessation in pregnancy. Brown DC. **Can Fam Physician** 1996 Jan;42:102–5 (18 ref.)

Physiological changes in the skin during pregnancy. Elling SV, et al. **Clin Dermatol** 1997 Jan–Feb;15(1):35–43 (39 ref.)

Spontaneous ovarian hyperstimulation syndrome in four consecutive pregnancies. Olatunbosun OA, et al. **Clin Exp Obstet Gynecol** 1996;23(3):127–32 (10 ref.)

Cirrhosis and pregnancy. A case report and review of the literature. Restaino A, et al. **Clin Exp Obstet Gynecol** 1996; 23(4):240–7 (24 ref.)

Maternal and fetal impact of chronic iodine deficiency. Glinoer D. **Clin Obstet Gynecol** 1997 Mar;40(1):102–16 (23 ref.)

Hyperthyroidism in pregnancy. Mestman JH. **Clin Obstet Gynecol** 1997 Mar;40(1):45–64 (56 ref.)

Management of hypothyroidism during pregnancy. Montoro MN. **Clin Obstet Gynecol** 1997 Mar;40(1):65–80 (55 ref.)

Maternal genetic disease and pregnancy. Blum K, et al. **Clin Perinatol** 1997 Jun;24(2):451–65 (61 ref.)

Pregnancy complicated by chronic renal disease. Jones DC. **Clin Perinatol** 1997 Jun;24(2):483–96 (38 ref.)

Asthma and allergy in pregnancy. Schatz M, et al. **Clin Perinatol** 1997 Jun;24(2):407–32 (82 ref.)

Autoimmune disease in pregnancy. Systemic lupus erythematosus and antiphospholipid syndrome. Silver RM, et al. **Clin Perinatol** 1997 Jun;24(2):291–320 (240 ref.)

Management of the pregnant woman who sustains severe brain damage. Webb GW, et al. **Clin Perinatol** 1996 Sep; 23(3):453–64 (50 ref.)

Pregnancy in systemic lupus erythematosus. Khamashta MA, et al. **Curr Opin Rheumatol** 1996 Sep;8(5):424–9 (74 ref.)

Lymphocytic adenohypophysitis and lymphocytic infundibuloneurohypophysitis. Hashimoto K, et al. **Endocr J** 1997 Feb;44(1):1–10 (107 ref.)

Gaucher's disease and pregnancy. Ayhan A, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 May;66(1):69–70 (8 ref.)

Pregnancy and nursing. Burakoff R, et al. **Gastroenterol Clin North Am** 1995 Sep;24(3):689–98 (48 ref.)

Is pregnancy contraindicated after cardiac transplantation? A case report and literature review. Yuh-Jer Shen A, et al. **Int J Cardiol** 1997 Jul 25;60(2):151–6 (39 ref.)

Review: intrahepatic cholestasis. A puzzling disorder of pregnancy. Reyes H. **J Gastroenterol Hepatol** 1997 Mar; 12(3):211–6 (59 ref.)

Antiphospholipid antibodies: a threat throughout pregnancy. Hewell SW, et al. **J Obstet Gynecol Neonatal Nurs** 1997 Mar–Apr;26(2):162–8 (30 ref.)

Behçet's syndrome associated with intrauterine growth restriction: a case report and review of the literature. Guzelian G, et al. **J Perinatol** 1997 Jul–Aug;17(4):318–20 (15 ref.)

Background and overview of mental health and substance abuse treatment systems: meeting the needs of women who are pregnant or parenting. Grella CE. **J Psychoactive Drugs** 1996 Oct–Dec;28(4):319–43 (236 ref.)

The effects of dual diagnosis on pregnancy and parenting. Mallouh C. **J Psychoactive Drugs** 1996 Oct–Dec; 28(4):367–80 (98 ref.)

Rudimentary uterine horn pregnancy. A case report on surviving twins delivered eight days apart. Nahum GG. **J Reprod Med** 1997 Aug;42(8):525–32 (30 ref.)

Progress and new directions in the investigation of the specific dermatoses of pregnancy. Black MM. **Keio J Med** 1997 Mar;46(1):40–1 (13 ref.)

Pregnancy and iron deficiency: unresolved issues. Allen LH. **Nutr Rev** 1997 Apr;55(4):91–101 (93 ref.)

Crigler-Najjar disease in pregnancy. Smith JF Jr, et al. **Obstet Gynecol** 1994 Oct;84(4 Pt 2):670–2 (12 ref.)

Progression of pulmonary arteriovenous malformation during pregnancy: case report and review of the literature. Esplin MS, et al. **Obstet Gynecol Surv** 1997 Apr;52(4):248–53 (22 ref.)

Gaucher's disease in pregnancy. Rosnes JS, et al. **Obstet Gynecol Surv** 1996 Sep;51(9):549–58 (78 ref.)

Osteoporosis in pregnancy. Khovidhunkit W, et al. **Osteoporos Int** 1996;6(5):345–54 (92 ref.)

Urinary calculi during pregnancy. When are they cause for concern? Houshiar AM, et al. **Postgrad Med** 1996 Oct; 100(4):131–8 (29 ref.)

Substance abuse in pregnancy. A bigger problem than you think. King JC. **Postgrad Med** 1997 Sep;102(3):135–7, 140–5, 149–50 (42 ref.)

Systemic lupus erythematosus flares during pregnancy. Khamashta MA, et al. **Rheum Dis Clin North Am** 1997 Feb;23(1):15–30 (69 ref.)

Pregnancy and rheumatoid arthritis. Nelson JL, et al. **Rheum Dis Clin North Am** 1997 Feb;23(1):195–212 (126 ref.)

Hopkins Lupus Pregnancy Center: 1987 to 1996. Petri M. **Rheum Dis Clin North Am** 1997 Feb;23(1):1–13 (34 ref.)

Scleroderma and pregnancy. Steen VD. **Rheum Dis Clin North Am** 1997 Feb;23(1):133–47 (82 ref.)

Neonatal lupus syndromes. Tseng CE, et al. **Rheum Dis Clin North Am** 1997 Feb;23(1):31–54 (122 ref.)

Antiphospholipid syndrome in pregnancy. Obstetric concerns and treatment. Welsch S, et al. **Rheum Dis Clin North Am** 1997 Feb;23(1):71–84 (106 ref.)

Cystic fibrosis in pregnancy. Olson GL. **Semin Perinatol** 1997 Aug;21(4):307–12 (27 ref.)

Assessment and treatment of low back pain in working pregnant women. Ostgaard HC. **Semin Perinatol** 1996 Feb; 20(1):61–9 (25 ref.)

Acute respiratory distress syndrome in pregnancy. Van Hook JW. **Semin Perinatol** 1997 Aug;21(4):320–7 (42 ref.)

Asthma in pregnancy. Witlin AG. **Semin Perinatol** 1997 Aug; 21(4):284–97 (54 ref.)

Pulmonary edema: etiology and treatment. Zlatnik MG. **Semin Perinatol** 1997 Aug;21(4):298–306 (41 ref.)

The long-term effects of cocaine use during pregnancy—reasons for hope. Kane DJ, et al. **Wis Med J** 1997 Feb;96(2):37–40 (43 ref.)

[Consequences of cocaine addiction during pregnancy on the development in the child] Ferraro F, et al. **Arch Pediatr** 1997 Jul;4(7):677–82 (42 ref.) (Eng. Abstr.) **(Fre)**

[Pregnancy and systemic scleroderma. A case report] Diouf A, et al. **Contracept Fertil Sex** 1996 Dec;24(12):917–22 (21 ref.) (Eng. Abstr.) **(Fre)**

[Acute fatty liver in pregnancy] Bacq Y. **Gastroenterol Clin Biol** 1997;21(2):109–15 (81 ref.) **(Fre)**

[Possible contribution of hyperglycemia in utero to glucose homeostasis disorders in the adult] Ktorza A, et al. **Journ Annu Diabetol Hotel Dieu** 1997;:55–68 (43 ref.) **(Fre)**

[Pregnancy after organ transplantation] Chevalier P, et al. **Presse Med** 1996 Nov 9;25(34):1643–8 (29 ref.) (Eng. Abstr.) **(Fre)**

[Perinatal maternal emergencies] Mantz JM. **Presse Med** 1996 Oct 19;25(31):1492–500 (31 ref.) (Eng. Abstr.) **(Fre)**

[Obstetrical complications of antiphospholipid syndrome] Weber JC. **Rev Med Interne** 1997;18(3):240–9 (88 ref.) (Eng. Abstr.) **(Fre)**

[Sturge-Weber angiomatosis responsible for hemiplegia without cerebral infarction in term pregnancy] Chabriat H, et al. **Rev Neurol (Paris)** 1996 Aug–Sep;152(8–9):536–41 (56 ref.) (Eng. Abstr.) **(Fre)**

[Analgesic and antipyretic drugs in pregnancy] Berkowitch M, et al. **Harefuah** 1997 Mar 2;132(5):354–7 (38 ref.) **(Heb)**

[The holy cows of pregnancy and puerperium mental syndrome] Schoenfeld H. **Harefuah** 1996 Nov 1; 131(9):344–7 (32 ref.) **(Heb)**

[Intrahepatic cholestasis in pregnancy] Bonessio L, et al. **Clin Ter** 1996 Jul–Aug;147(7–8):377–84 (42 ref.) (Eng. Abstr.) **(Ita)**

[Syringomyelia and pregnancy. Report of a clinical case and review of the literature] Castello C, et al. **Minerva Ginecol** 1996 Jun;48(6):253–7 (7 ref.) (Eng. Abstr.) **(Ita)**

[Obstetric anesthesia for cesarean section of patients with bronchial asthma] Ueda K. **Masui** 1996 Dec;45 Suppl:S208–11 (1 ref.) **(Jpn)**

[Substance abuse and pregnancy: alcohol] Wilczyński J, et al. **Ginekol Pol** 1996 Dec;67(12):620–5 (57 ref.) (Eng. Abstr.) **(Pol)**

[Zinc, pregnancy and the fetus] Solé D, et al. **Rev Assoc Med Bras** 1996 Jan–Mar;42(1):31–8 (106 ref.) **(Por)**

[Systemic lupus erythematosus and pregnancy (analysis of 84 cases)] Cabral-Castañeda F, et al. **Ginecol Obstet Mex** 1996 Aug;64:363–7 (65 ref.) (Eng. Abstr.) **(Spa)**

[Epilepsy and pregnancy. Balancing between risks to the mother and child] Tomson T, et al. **Lakartidningen** 1997 Aug 20;94(34):2827–32, 2835 (56 ref.) (Eng. Abstr.) **(Swe)**

BLOOD

Renal tubular acidosis in pregnancy: case report and literature review. Hardardottir H, et al. **J Matern Fetal Med** 1997 Jan–Feb;6(1):16–20 (30 ref.)

Pregnancy complicated by primary aldosteronism. Webb JC, et al. **South Med J** 1997 Feb;90(2):243–5 (18 ref.)

Reproductive effects of maternal metabolic disorders: implications for pediatrics and obstetrics. Levy HL. **Turk J Pediatr** 1996 Jul–Sep;38(3):335–44 (36 ref.)

CHEMICALLY INDUCED

Reproductive risks of cocaine. Rizk B, et al. **Hum Reprod Update** 1996 Jan–Feb;2(1):43–55 (119 ref.)

Alcohol and other drugs: the scope of the problem among pregnant and parenting women in California. Young N. **J Psychoactive Drugs** 1997 Jan–Mar;29(1):3–22 (122 ref.)

Effects of alcohol and other drugs on children. Young NK. **J Psychoactive Drugs** 1997 Jan–Mar;29(1):23–42 (145 ref.)

Nitrofurantoin-induced pulmonary toxicity during pregnancy: a report of a case and review of the literature. Boggess KA, et al. **Obstet Gynecol Surv** 1996 Jun; 51(6):367–70 (19 ref.)

[Clomiphene-exposed pregnancies—analysis of 39 information requests including 25 cases with known outcome] Carlier P, et al. **Therapie** 1996 Sep–Oct; 51(5):532–6 (41 ref.) (Eng. Abstr.) **(Fre)**

[Occupational exposure of medical personnel to chemical factors affecting fertility] Sitarek K, et al. **Med Pr** 1997; 48(2):215–21 (36 ref.) (Eng. Abstr.) **(Pol)**

DIAGNOSIS

Suspected urolithiasis in pregnant women: imaging algorithm and literature review. Boridy IC, et al. **AJR Am J Roentgenol** 1996 Oct;167(4):869–75 (62 ref.)

Bartter's syndrome in pregnancy: a case report and review. O'Sullivan E, et al. **Am J Perinatol** 1997 Jan;14(1):55–7 (19 ref.)

Asthma in pregnancy. Nelson-Piercy C, et al. **Br J Hosp Med** 1996 Feb 7–20;55(3):115–7 (38 ref.)

Urinary tract obstruction during pregnancy: recent developments in imaging. Murthy LN. **Br J Urol** 1997 Jul; 80 Suppl 1:1–3 (25 ref.)

Uterine sacculation: myth, reality or rarity—a case report. Adu SA. **Cent Afr J Med** 1996 Jul;42(7):211–5 (16 ref.)

Maternal thyroid function: interpretation of thyroid function tests in pregnancy. Brent GA. **Clin Obstet Gynecol** 1997 Mar;40(1):3–15 (20 ref.)

Landry Guillain-Barre-Strohl syndrome in pregnancy: case report. Amoah GB. **East Afr Med J** 1996 Sep;73(9):623–4 (7 ref.)

Obstetric and gynecologic emergencies. Nadel E, et al. **Emerg Med Clin North Am** 1997 May;15(2):389–97 (49 ref.)

Ectopic vaginal decidualization. An unusual finding that presents problems of differential diagnosis with carcinoma. Castellví Vives J, et al. **Eur J Gynaecol Oncol** 1997; 18(3):183–4 (23 ref.)

ACOG technical bulletin. Pulmonary disease in pregnancy. Number 224—June 1996. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1996 Aug;54(2):187–96 (19 ref.)

Clinical diagnosis and management of hormonally responsive oral pregnancy tumor (pyogenic granuloma). Sills ES, et al. **J Reprod Med** 1996 Jul;41(7):467–70 (30 ref.)

Clinical implications of antiphospholipid antibodies in obstetrics. Danilenko-Dixon DR, et al. **Mayo Clin Proc** 1996 Nov;71(11):1118–20 (16 ref.)

Obstructive sleep apnea in pregnancy. Lefcourt LA, et al. **Obstet Gynecol Surv** 1996 Aug;51(8):503–6 (14 ref.)

Porphyria cutanea tarda and pregnancy. Loret de Mola JR, et al. **Obstet Gynecol Surv** 1996 Aug;51(8):493–7 (24 ref.)

Hyperparathyroidism in pregnancy: diagnostic dilemma? Murray JA, et al. **Obstet Gynecol Surv** 1997 Mar; 52(3):202–5 (17 ref.)

Women's issues in epilepsy. Menses, childbearing, and more. Liporace JD. **Postgrad Med** 1997 Jul;102(1):123–4, 127–9, 133–5 passim (32 ref.)

The acute abdomen in the pregnant patient. Is there a role for laparoscopy? Gurbuz AT, et al. **Surg Endosc** 1997 Feb; 11(2):98–102 (33 ref.)

[Pregnancy in women over forty years old] Dufour P, et al. **Contracept Fertil Sex** 1997 Jun;25(6):415–22 (49 ref.) **(Fre)**

[The eye and pregnancy] Funk J. **Ophthalmologe** 1997 Jan; 94(1):53–63 (81 ref.) **(Ger)**

[Ovarian torsion in pregnancy with a dermoid] Forstner R, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Jan;166(1):84–6 (9 ref.) **(Ger)**

[Postpartum obturator nerve syndrome: case report and review of the nerve compression syndrome during pregnancy and delivery] Lindner A, et al. **Zentralbl Gynakol** 1997;119(3):93–9 (43 ref.) (Eng. Abstr.) **(Ger)**

[A case of myomectomy for infertility and a following twin pregnancy associated with hyperthyroidism] Berlingieri D, et al. **Minerva Ginecol** 1996 Dec;48(12):545–52 (20 ref.) (Eng. Abstr.) **(Ita)**

[Skene's cyst in pregnancy. A clinical case] Ingrassia I, et al. **Minerva Ginecol** 1997 May;49(5):225–8 (13 ref.) (Eng. Abstr.) **(Ita)**

[Severe hypertriglyceridemia in pregnancy. A clinical case report] Perrone G, et al. **Minerva Ginecol** 1996 Dec; 48(12):573–6 (21 ref.) (Eng. Abstr.) **(Ita)**

[Gaucher's disease in pregnancy] Santana IB, et al. **Acta Med Port** 1997 May;10(5):391–3 (11 ref.) (Eng. Abstr.) **(Por)**

[Acute fatty liver of pregnancy complicated by pancreatitis] Castañón-González JA, et al. **Gac Med Mex** 1997 May–Jun;133(3):253–8 (26 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Wegener's granulomatosis in pregnancy. Luisiri P, et al. **Arthritis Rheum** 1997 Jul;40(7):1354–60 (21 ref.)

Asthma in pregnancy. Nelson-Piercy C, et al. **Br J Hosp Med** 1996 Feb 7–20;55(3):115–7 (38 ref.)

Antirheumatic drug therapy during pregnancy. Soscia PN, et al. **Bull Rheum Dis** 1997 Apr;46(2):2–4 (11 ref.)

How to ensure fetal safety when mothers use isotretinoin (Accutane). Koren G, et al. **Can Fam Physician** 1997 Feb; 43:216–9 (4 ref.)

Medications in pregnancy. Colie CF. **Curr Opin Obstet Gynecol** 1996 Dec;8(6):398–402 (49 ref.)

Asthma treatment during pregnancy. What can be safely taken? Schatz M. **Drug Saf** 1997 May;16(5):342–50 (28 ref.)

Antipsychotic use in pregnancy. What are the best treatment options? Trixler M, et al. **Drug Saf** 1997 Jun;16(6):403–10 (67 ref.)

Pregnancy outcome and neurodevelopment of children exposed in utero to psychoactive drugs: the Motherisk experience. Loebstein R, et al. **J Psychiatry Neurosci** 1997 May;22(3):192–6 (21 ref.)

Exposure to a xenoestrogen before birth: the diethylstilbestrol experience. Palmlund I. **J Psychosom Obstet Gynaecol** 1996 Jun;17(2):71–84 (144 ref.)

Chronic medical disorders during pregnancy. Guidelines for prescribing drugs. Rayburn WF. **J Reprod Med** 1997 Jan; 42(1):1–24 (329 ref.)

Antimalarial drugs in pregnancy—the North American experience. Parke AL, et al. **Lupus** 1996 Jun;5 Suppl 1:S67–9 (21 ref.)

Anxiety and depression. Diagnosis and treatment during pregnancy. Diket AL, et al. **Obstet Gynecol Clin North Am** 1997 Sep;24(3):535–58 (50 ref.)

Pharmacologic therapy of asthma during pregnancy. Dombrowski MP. **Obstet Gynecol Clin North Am** 1997 Sep; 24(3):559–74 (64 ref.)

Treatment of thyroid disease in pregnancy. Ecker JL, et al. **Obstet Gynecol Clin North Am** 1997 Sep;24(3):575–89 (40 ref.)

Maternal and fetal implications of anticonvulsive therapy during pregnancy. Eller DP, et al. **Obstet Gynecol Clin North Am** 1997 Sep;24(3):523–34 (46 ref.)

Immunosuppressive drugs and pregnancy. Esplin MS, et al. **Obstet Gynecol Clin North Am** 1997 Sep;24(3):601–16 (94 ref.)

Immunosuppressive drug use during pregnancy. Ramsey-Goldman R, et al. **Rheum Dis Clin North Am** 1997 Feb;23(1):149–67 (133 ref.)

Psychotropics. Goldaber KG. **Semin Perinatol** 1997 Apr; 21(2):154–9 (44 ref.)

Immunosuppressant therapy during gestation. Little BB. **Semin Perinatol** 1997 Apr;21(2):143–8 (52 ref.)

Drugs in pregnancy: anticonvulsants. Malone FD, et al. **Semin Perinatol** 1997 Apr;21(2):114–23 (41 ref.)

[Ciprofloxacin treatment for pregnant or lactating women and children?] Aizenstein O, et al. **Harefuah** 1997 Feb 16; 132(4):283–8 (41 ref.) **(Heb)**

[Use of erythropoietin in pregnancy: review of the literature in connection with 2 cases] Mátyus J, et al. **Orv Hetil** 1997 Jul 13;138(28):1787–90 (43 ref.) (Eng. Abstr.) **(Hun)**

[Prospective biochemical study of the antioxidant defense capacity in retinopathy of prematurity] Papp A, et al. **Orv Hetil** 1997 Jan 26;138(4):201–5 (47 ref.) (Eng. Abstr.) **(Hun)**

[A case report of pregnancy complicated with adult Still's disease] Yunohara N, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Jun;48(6):431–4 (15 ref.) **(Jpn)**

EPIDEMIOLOGY

Adult respiratory distress syndrome in pregnancy: report of three cases and review of the literature. Catanzarite VA, et al. **Obstet Gynecol Surv** 1997 Jun;52(6):381–92 (69 ref.)

Impact of caesarean section on future pregnancy—a review of cohort studies. Hemminki E. **Paediatr Perinat Epidemiol** 1996 Oct;10(4):366–79 (36 ref.)

Clinical and psychosocial correlates of antenatal depression: a review. Kitamura T, et al. **Psychother Psychosom** 1996; 65(3):117–23 (74 ref.)

ETHNOLOGY

Racism and perinatal addiction. Neuspiel DR. **Ethn Dis** 1996 Winter-Spring;6(1–2):47–55 (45 ref.)

ETIOLOGY

Motor vehicle accident during the second or third trimester of pregnancy. Aitokallio-Tallberg A, et al. **Acta Obstet Gynecol Scand** 1997 Apr;76(4):313–7 (32 ref.)

Nonobstetric conditions causing hypoxia during pregnancy: asthma and epilepsy. Coleman MT, et al. **Am J Obstet Gynecol** 1997 Jul;177(1):1–7 (34 ref.)

Spontaneous liver hematoma in pregnancy not clearly associated with preeclampsia: a case presentation and literature review. Schwartz ML, et al. **Am J Obstet Gynecol** 1997 Jun;176(6):1328–32; discussion 1332–3 (19 ref.)

Pregnancy and intercurrent diseases of the urogenital tract. Tomezsko JE, et al. **Clin Perinatol** 1997 Jun;24(2):343–68 (67 ref.)

Obstetric and perinatal outcome in pregnancies after assisted reproduction. Tanbo T, et al. **Curr Opin Obstet Gynecol** 1996 Jun;8(3):193–8 (43 ref.)

Gastrointestinal endoscopy in high-risk patients. Cappell MS. **Dig Dis** 1996 Jul–Aug;14(4):228–44 (115 ref.)

Motor vehicle crashes, pregnancy loss and preterm labor [see comments] Pearlman MD. **Int J Gynaecol Obstet** 1997 May; 57(2):127–32 (17 ref.) Comment in: Int J Gynaecol Obstet 1997 May;57(2):123.

Acute fatty liver of pregnancy. Usta IM, et al. **J Med Liban** 1995;43(4):186–93 (51 ref.)

Pregnancy in women with cerebrospinal shunts: a literature review and case report. Stevens E. **J Perinatol** 1996 Sep–Oct;16(5):374–80 (29 ref.)

Edema in pregnancy. Davison JM. **Kidney Int Suppl** 1997 Jun;59:S90–6 (44 ref.)

Exercise and pregnancy. Margolis RS. **Md Med J** 1996 Aug;

45(8):637–41 (7 ref.)
Clinical biological features of Ballantyne syndrome and the role of placental hydrops. Carbillon L, et al. **Obstet Gynecol Surv** 1997 May;52(5):310–4 (27 ref.)
Pregnancy outcome: physical activities inside versus outside the workplace. Clapp JF 3rd. **Semin Perinatol** 1996 Feb; 20(1):70–6 (46 ref.)
[Adolescence and pregnancy in Guadeloupe. 184 cases] Gallais A, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(5):523–7 (28 ref.) (Eng. Abstr.) **(Fre)**
[Severe congenital thoracic–lumbar scoliosis in pregnancy. A case report and review of the literature] Restaino A, et al. **Minerva Ginecol** 1996 Dec;48(12):565–71 (29 ref.) (Eng. Abstr.) **(Ita)**
[The significance of endocrine factors and microorganisms in the development of gingivitis in pregnant women] Abraham-Inpijn L, et al. **Stomatologiia (Mosk)** 1996; 75(3):15–8 (53 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Impetigo herpetiformis and RhE isoimmunization: a case report. Trevisan G, et al. **Cutis** 1996 Jul;58(1):87–9 (11 ref.)
Clinical implications of antiphospholipid antibodies in obstetrics. Danilenko–Dixon DR, et al. **Mayo Clin Proc** 1996 Nov;71(11):1118–20 (16 ref.)
Antiphospholipid antibodies in healthy pregnant women. Lynch A, et al. **Rheum Dis Clin North Am** 1997 Feb; 23(1):55–70 (106 ref.)
Neonatal lupus: bedside to bench and back [editorial] Buyon JP. **Scand J Rheumatol** 1996;25(5):271–6 (49 ref.)
[Immunopathology of early abortion: current status] Guzmán Sánchez A, et al. **Ginecol Obstet Mex** 1997 Jun;65:262–5 (30 ref.) (Eng. Abstr.) **(Spa)**
[Management of refractory autoimmune thrombocytopenic purpura during pregnancy, Review of the literature and report of three cases] Yáñez Maldonado E, et al. **Ginecol Obstet Mex** 1997 Jun;65:254–7 (13 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

[Pathological phosphorus and calcium metabolism during pregnancy and breast feeding] Koeger AC, et al. **Rev Med Interne** 1997 Jul;18(7):546–52 (36 ref.) (Eng. Abstr.) **(Fre)**

MORTALITY

Maternal mortality in different Pakistani sites: ratios, clinical causes and determinants. Fikree FF, et al. **Acta Obstet Gynecol Scand** 1997 Aug;76(7):637–45 (19 ref.)
Pregnancy–associated deaths in Finland 1987–1994—definition problems and benefits of record linkage. Gissler M, et al. **Acta Obstet Gynecol Scand** 1997 Aug;76(7):651–7 (32 ref.)

NURSING

Hyperthyroidism during pregnancy: nursing care issues. Caldwell J. **J Obstet Gynecol Neonatal Nurs** 1996 Jun; 25(5):395–400 (9 ref.)

PATHOLOGY

Spontaneous rupture of the uterine vessels in a pregnancy complicated by endometriosis. Mizumoto Y, et al. **Acta Obstet Gynecol Scand** 1996 Oct;75(9):860–2 (7 ref.)
Unilateral naevoid telangiectasia syndrome in pregnancy. Woollons A, et al. **Clin Exp Dermatol** 1996 Nov; 21(6):459–60 (6 ref.)
The umbilical cord: obstetrically important lesions. Heifetz SA. **Clin Obstet Gynecol** 1996 Sep;39(3):571–87 (23 ref.)
Postpartum examination of the placenta. Kaplan CG. **Clin Obstet Gynecol** 1996 Sep;39(3):535–48 (18 ref.)
Impetigo herpetiformis and RhE isoimmunization: a case report. Trevisan G, et al. **Cutis** 1996 Jul;58(1):87–9 (11 ref.)
Pregnancy–related changes: a retrospective review of 278 cervical smears. Michael CW, et al. **Diagn Cytopathol** 1997 Aug;17(2):99–107 (28 ref.)
Liver disease in pregnancy. Assy N, et al. **J Am Coll Surg** 1996 Dec;183(6):643–53 (116 ref.)
Placental pathology in systemic lupus erythematosus and phospholipid antibody syndrome. Salafia CM, et al. **Rheum Dis Clin North Am** 1997 Feb;23(1):85–97 (72 ref.)
[Rheumatoid purpura (or Schoenlein–Henoch syndrome) and pregnancy. Review of the literature and a case report] Ekoukou D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(2):197–201 (17 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Choline: essential for brain development and function. Zeisel SH. **Adv Pediatr** 1997;44:263–95 (174 ref.)
Ehlers–Danlos syndrome type II in pregnancy. Ploeckinger B, et al. **Am J Perinatol** 1997 Feb;14(2):99–101 (12 ref.)
Systemic lupus erythematosus and pregnancy. Druzin ML, et al. **Ann Med Interne (Paris)** 1996;147(4):265–73 (124 ref.)
Wegener's granulomatosis in pregnancy. Luisiri P, et al. **Arthritis Rheum** 1997 Jul;40(7):1354–60 (21 ref.)
Lower urinary tract symptoms in pregnancy. Cardozo L, et al. **Br J Urol** 1997 Jul;80 Suppl 1:14–23 (49 ref.)
Reproductive health in patients with beta–thalassemia. Tolis GJ, et al. **Curr Opin Pediatr** 1996 Aug;8(4):406–10 (31 ref.)
Pseudoxanthoma elasticum and pregnancy. Yoles A, et al. **Cutis** 1996 Aug;58(2):161–4 (15 ref.)
A case of splenic artery aneurysm with Cushing's syndrome. Yoshitomi Y, et al. **Int J Cardiol** 1996 Jun;54(3):263–5 (5 ref.)
Autoimmune thyroid disease and pregnancy. Amino N, et al. **J Endocrinol Invest** 1996 Jan;19(1):59–70 (54 ref.)
Congenital monoblastic leukemia as a cause of third–trimester fetal loss: the role of monoclonal antibody testing. Greenbaum BH, et al. **J Perinatol** 1996 May–Jun;16(3 Pt 1):202–4 (20 ref.)
Back pain and pregnancy: a review. MacEvilly M, et al. **Pain** 1996 Mar;64(3):405–14 (87 ref.)
[Physiopathology of maternal and feto–neonatal thyroid in pregnant women with endemic goiter] Pepe F, et al. **Minerva Ginecol** 1997 Apr;49(4):153–60 (15 ref.) (Eng. Abstr.) **(Ita)**
[Iron deficiency as a risk factor during the perinatal period] Zdziennicki A, et al. **Ginekol Pol** 1996 Jun;67(6):301–3 (14 ref.) (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

Scientific basis for the content of routine antenatal care. II. Power to eliminate or alleviate adverse newborn outcomes; some special conditions and examinations. Bergsjø P, et al. **Acta Obstet Gynecol Scand** 1997 Jan;76(1):15–25 (82 ref.)
Scientific basis for the content of routine antenatal care. I. Philosophy, recent studies, and power to eliminate or alleviate adverse maternal outcomes. Villar J, et al. **Acta Obstet Gynecol Scand** 1997 Jan;76(1):1–14 (130 ref.)
A smoking cessation plan for pregnant women. Kilby JW. **J Obstet Gynecol Neonatal Nurs** 1997 Jul–Aug; 26(4):397–402 (25 ref.)
In harm's way: childbearing women and nicotine. Scheibmeir M, et al. **J Obstet Gynecol Neonatal Nurs** 1997 Jul–Aug; 26(4):477–84 (49 ref.)
Prenatal care. Helton MR. **Prim Care** 1997 Mar;24(1):135–46 (50 ref.)

PSYCHOLOGY

Clinical implications and management strategies when depression occurs during pregnancy. Coverdale JH, et al. **Aust N Z J Obstet Gynaecol** 1996 Nov;36(4):424–9 (65 ref.)
Domestic violence and pregnancy. Mezey GC, et al. **Br J Obstet Gynaecol** 1997 May;104(5):528–31 (52 ref.)
Anxiety disorders in pregnant and postpartum women. Shear MK, et al. **Psychopharmacol Bull** 1995;31(4):693–703 (71 ref.)
Perinatal social work and the high risk obstetrics patient. Bachman DH, et al. **Soc Work Health Care** 1997; 24(3–4):3–19 (36 ref.)
The role of the social worker in perinatal substance–abuse. Cook C. **Soc Work Health Care** 1997;24(3–4):65–83 (46 ref.)
[Management of drug addict pregnant women and their children] Lejeune C, et al. **Arch Pediatr** 1997 Mar; 4(3):263–70 (71 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Radiologic studies in acute fatty liver of pregnancy. A review of the literature and 19 new cases. Castro MA, et al. **J Reprod Med** 1996 Nov;41(11):839–43 (23 ref.)

REHABILITATION

Ethical and legal issues associated with substance abuse by pregnant and parenting women. Garcia S. **J Psychoactive Drugs** 1997 Jan–Mar;29(1):101–11 (37 ref.)
The impact of intensive case–managed intervention on substance–using pregnant and postpartum women. Lanehart RE, et al. **J Subst Abuse** 1996;8(4):487–95 (18 ref.)

SURGERY

Cecal volvulus in pregnancy. Case report and review of literature. John H, et al. **Arch Gynecol Obstet** 1996; 258(3):161–4 (18 ref.)
Laparoscopic cholecystectomy in pregnancy. Reyes–Tineo R. **Bol Asoc Med P R** 1997 Jan–Mar;89(1–3):9–11 (5 ref.)
Surgery of the placenta and umbilical cord. De Lia JE. **Clin Obstet Gynecol** 1996 Sep;39(3):607–25 (64 ref.)
Clinical diagnosis and management of hormonally responsive oral pregnancy tumor (pyogenic granuloma). Sills ES, et al. **J Reprod Med** 1996 Jul;41(7):467–70 (30 ref.)
Damage control for the obstetric patient. Moise KJ Jr, et al. **Surg Clin North Am** 1997 Aug;77(4):835–52 (42 ref.)
The acute abdomen in the pregnant patient. Is there a role for laparoscopy? Gurbuz AT, et al. **Surg Endosc** 1997 Feb; 11(2):98–102 (33 ref.)
Laparoscopic surgery during pregnancy. Lemaire BM, et al. **Surg Endosc** 1997 Jan;11(1):15–8 (20 ref.)

THERAPY

Nutrition during pregnancy. Kolasa KM, et al. **Am Fam Physician** 1997 Jul;56(1):205–12, 216–8 (33 ref.)
Clinical uses of intravenous immunoglobulin in pregnancy. Clark AL, et al. **Am J Obstet Gynecol** 1997 Jan;176(1 Pt 1):241–53 (156 ref.)
Evaluation and management of common thyroid disorders in women. Mazzaferri EL. **Am J Obstet Gynecol** 1997 Mar; 176(3):507–14 (38 ref.)
Pneumothorax in pregnancy associated with cocaine use. Chan L, et al. **Am J Perinatol** 1997 Aug;14(7):385–8 (22 ref.)
Fetal alcohol syndrome. Duerbeck NB. **Compr Ther** 1997 Mar;23(3):179–83 (21 ref.)
Hyperthyroidism in pregnancy. Inzucchi SE, et al. **Curr Ther Endocrinol Metab** 1997;6:312–7 (8 ref.)
Obstetric and gynecologic emergencies. Nadel E, et al. **Emerg Med Clin North Am** 1997 May;15(2):389–97 (49 ref.)
ACOG technical bulletin. Pulmonary disease in pregnancy. Number 224—June 1996. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1996 Aug;54(2):187–96 (19 ref.)
Pregnancy and asthma [see comments] Venkataraman MT, et al. **J Asthma** 1997;34(4):265–71 (31 ref.) Comment in: J Asthma 1997 ;34(4):263–4.
California's approach to perinatal substance abuse: toward a model of comprehensive care. Brindis CD, et al. **J Psychoactive Drugs** 1997 Jan–Mar;29(1):113–22 (52 ref.)
Services for perinatal women with substance abuse and mental health disorders: the unmet need. Grella CE. **J Psychoactive Drugs** 1997 Jan–Mar;29(1):67–78 (53 ref.)
Chorea gravidarum: a case report and review. Dike GL. **Md Med J** 1997 Sep;46(8):436–9 (22 ref.)
Obstructive sleep apnea in pregnancy. Lefcourt LA, et al. **Obstet Gynecol Surv** 1996 Aug;51(8):503–6 (14 ref.)
Porphyria cutanea tarda and pregnancy. Loret de Mola JR, et al. **Obstet Gynecol Surv** 1996 Aug;51(8):493–7 (24 ref.)
Management of snake and spider bite in pregnancy. Pantanowitz L, et al. **Obstet Gynecol Surv** 1996 Oct; 51(10):615–20 (48 ref.)
Obstetric management of the high–risk lupus pregnancy. Mascola MA, et al. **Rheum Dis Clin North Am** 1997 Feb; 23(1):119–32 (67 ref.)
Animal models for antiphospholipid syndrome in pregnancy. Ziporen L, et al. **Rheum Dis Clin North Am** 1997 Feb; 23(1):99–117 (90 ref.)
[Pregnancy in women over forty years old] Dufour P, et al. **Contracept Fertil Sex** 1997 Jun;25(6):415–22 (49 ref.) **(Fre)**
[Obstetrical management of triplets. A series of forty five cases] Charasson T, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(7):737–45 (45 ref.) (Eng. Abstr.) **(Fre)**
[Hereditary angioneurotic edema in gynecology–obstetrics. Management] Khalife H, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(6):559–67 (29 ref.) (Eng. Abstr.) **(Fre)**
[Obstetric perspectives: consensus of the gynecology department of the University of Liège. Document of the 3rd cycle studies, October 96] Biquet G, et al. **Rev Med Liege** 1997 Mar;52(3):142–8 (0 ref.) **(Fre)**
[Extracorporeal membrane oxygenation in adult respiratory distress syndrome. Experience in 2 patients] Alamo M, et al. **Rev Med Chil** 1995 Oct;123(10):1275–83 (29 ref.) (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Prenatal ultrasonographic assessment of the middle cerebral artery: a review. Sherer DM. **Obstet Gynecol Surv** 1997 Jul;52(7):444–55 (70 ref.)
Emergency obstetric and gynecologic ultrasound. Estroff JA. **Radiol Clin North Am** 1997 Jul;35(4):921–57 (148 ref.)
Prenatal findings in chondrodysplasia punctata, tibia–metacarpal type. Argo KM, et al. **Ultrasound Obstet Gynecol** 1996 Nov;8(5):350–4 (14 ref.)
[Ultrasonic screening of neonates] Jójárt G, et al. **Orv Hetil** 1996 Mar 24;137(12):623–7 (50 ref.) (Eng. Abstr.) **(Hun)**

VETERINARY

The pregnancy that doesn't stay—lessons from 25 years of observation [editorial; comment] Allen GP. **Vet J** 1997 May;153(3):239–44 (28 ref.) Comment on: Vet J 1997 May;153(3):253–68.

PREGNANCY COMPLICATIONS, CARDIOVASCULAR

Wegener's granulomatosis complicating pregnancy: presentation of two patients and review of the literature. Habib A, et al. **Clin Nephrol** 1996 Nov;46(5):332–6 (29 ref.)
Congenital cardiac disease and pregnancy. Mendelson MA. **Clin Perinatol** 1997 Jun;24(2):467–82 (70 ref.)
Pregnancy in the chronically hypertensive patient. Neerhof MG. **Clin Perinatol** 1997 Jun;24(2):391–406 (56 ref.)
Venous thromboembolism during pregnancy: a current review of diagnosis and management. Toglia MR, et al. **Obstet Gynecol Surv** 1997 Jan;52(1):60–72 (113 ref.)
The effect of the pregnancy–induced hypertension on fetal growth: a review of the literature. Misra DP. **Paediatr Perinat Epidemiol** 1996 Jul;10(3):244–63 (46 ref.)
Aortic and other arterial dissections associated with pregnancy. Rutherford RB, et al. **Semin Vasc Surg** 1995 Dec;8(4):299–305 (29 ref.)
[Infarction and pregnancy. Review of the literature. A case report] Dufour P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(7):746–51 (24 ref.) (Eng. Abstr.) **(Fre)**
[Cerebrovascular diseases in pregnancy and puerperium] Lamy C, et al. **Rev Neurol (Paris)** 1996 Jun–Jul;

152(6-7):422-40 (136 ref.) (Eng. Abstr.) **(Fre)**
[Pregnancy and labor in cardiac patients] Hara F. **Nippon Ika Daigaku Zasshi** 1997 Apr;64(2):180-3 (6 ref.) **(Jpn)**
[Peripartum cardiomyopathy of multiple pregnancy] Ikeda S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):170-3 (17 ref.) **(Jpn)**
[Myocardial infarction during pregnancy] Sakamoto S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):746-8 (15 ref.) **(Jpn)**
[Hypertension in preeclamptic pregnant women] Satoh K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):144-7 (4 ref.) **(Jpn)**
[Peripartum cardiomyopathy] Tateda K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):104-7 (20 ref.) **(Jpn)**
[Amniotic fluid embolism: review] Guasch E, et al. **Rev Esp Anestesiol Reanim** 1996 May;43(5):180-4 (59 ref.) (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

Cardiovascular effects of cocaine during pregnancy. Chao CR. **Semin Perinatol** 1996 Apr;20(2):107-14 (48 ref.)

DIAGNOSIS

Acute myocardial infarction during pregnancy. Fujito T, et al. **Cardiology** 1996 Jul-Aug;87(4):361-4 (20 ref.)
ACOG educational bulletin. Thromboembolism in pregnancy. Number 234, March 1997. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1997 May;57(2):209-18 (56 ref.)
Chronic hypertension in pregnancy. Frangieh AY, et al. **J Med Liban** 1996;44(2):68-74 (50 ref.)
Migraine and pregnancy. Silberstein SD. **Neurol Clin** 1997 Feb;15(1):209-31 (59 ref.)
[Incessant atrial tachycardia and peripartum cardiomyopathy--a therapeutic challenge] Brito D, et al. **Rev Port Cardiol** 1997 Feb;16(2):157-63, 124 (19 ref.) (Eng. Abstr.) **(Por)**

DRUG THERAPY

Hypertension in pregnancy: use of antihypertensive drugs. Henriksen T. **Acta Obstet Gynecol Scand** 1997 Feb; 76(2):96-106 (87 ref.)
ACOG educational bulletin. Thromboembolism in pregnancy. Number 234, March 1997. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1997 May;57(2):209-18 (56 ref.)
Chronic hypertension in pregnancy. Frangieh AY, et al. **J Med Liban** 1996;44(2):68-74 (50 ref.)
Migraine and pregnancy. Silberstein SD. **Neurol Clin** 1997 Feb;15(1):209-31 (59 ref.)
Current concepts of anticoagulant therapy in pregnancy. Barbour LA. **Obstet Gynecol Clin North Am** 1997 Sep; 24(3):499-521 (113 ref.)
Angiotensin converting enzyme inhibitors in pregnancy. Mastrobattista JM. **Semin Perinatol** 1997 Apr;21(2):124-34 (46 ref.)
[Ilio-femoral vein thrombosis treated with tissue plasminogen activator in a pregnant woman] Grand A, et al. **Ann Cardiol Angeiol (Paris)** 1996 Nov;45(9):517-22 (14 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Arterial ischemic strokes associated with pregnancy and puerperium. Leys D, et al. **Acta Neurol Belg** 1997 Mar; 97(1):5-16 (82 ref.)
Thromboembolism in pregnancy: an overview. Girling JC, et al. **Curr Opin Obstet Gynecol** 1996 Dec;8(6):458-63 (48 ref.)

IMMUNOLOGY

Review and hypothesis: the eosinophil and peripartum heart disease (myocarditis and coronary artery dissection)--coincidence or pathogenetic significance? Borczuk AC, et al. **Cardiovasc Res** 1997 Mar;33(3):527-32 (54 ref.)

PATHOLOGY

Thrombophilia and fetal loss. Brenner B, et al. **Blood Rev** 1997 Jun;11(2):72-9 (82 ref.)

PHYSIOPATHOLOGY

Peripartum cardiomyopathy: four case histories and a commentary on anaesthetic management. George LM, et al. **Anaesth Intensive Care** 1997 Jun;25(3):292-6 (17 ref.)
The role of vasoactive molecules of endothelial origin in the pathophysiology of normal pregnancy and pregnancy-induced hypertension [editorial] Noris M, et al. **Curr Opin Nephrol Hypertens** 1996 Jul;5(4):347-52 (38 ref.)
Pregnancy induced hypertension--anaesthetic considerations. Zubair NA. **JPMA J Pak Med Assoc** 1996 Sep;46(9):206-13 (70 ref.)

PREVENTION & CONTROL

Factor V Leiden: should we screen oral contraceptive users and pregnant women? [see comments] Vandenbroucke JP, et al. **BMJ** 1996 Nov 2;313(7065):1127-30 (34 ref.) Comment in: BMJ 1997 Jul 5;315(7099):60.
Prevention of preeclampsia with calcium supplementation and its relation with the L-arginine:nitric oxide pathway. López-Jaramillo P. **Braz J Med Biol Res** 1996 Jun; 29(6):731-41 (99 ref.)

SURGERY

Management of mitral valve stenosis in pregnancy: case presentation and review of the literature. Yaryura RA, et al. **J Heart Valve Dis** 1996 Jan;5(1):16-9 (32 ref.)
[Extracorporeal circulation in pregnancy: report of a case. Update and review of the literature] Carrascal Hinojal Y, et al. **Rev Esp Cardiol** 1996 Oct;49(10):776-9 (8 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Pregnancy after myocardial infarction and a coronary artery bypass graft. Dufour P, et al. **Arch Gynecol Obstet** 1997; 259(4):209-13 (31 ref.)
Valvular disease in pregnancy. Oakley CM. **Curr Opin Cardiol** 1996 Mar;11(2):155-9 (28 ref.)
Pre-eclampsia and hypertension in pregnancy. Hsueh WA. **Curr Ther Endocrinol Metab** 1997;6:324-7 (18 ref.)
ACOG educational bulletin. Hemorrhagic shock. Number 235, April 1997 (replaces no. 82, December 1984). American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1997 May;57(2):219-26 (15 ref.)

PREGNANCY COMPLICATIONS, HEMATOLOGIC

Isolated persistent fetal bradycardia in complete A-V block: a conservative approach is appropriate. A case report and a review of the literature. Rabinerson D, et al. **Am J Perinatol** 1997 Jul;14(6):317-20 (17 ref.)
Thrombocytopenia in pregnancy: diagnosis, pathogenesis and management. Crowther MA, et al. **Blood Rev** 1996 Mar; 10(1):8-16 (83 ref.)
Anesthesia for the parturient with sickle cell disease. Danzer BI, et al. **J Clin Anesth** 1996 Nov;8(7):598-602 (17 ref.)
Essential thrombocythemia and pregnancy. Griesshammer M, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:57-63 (64 ref.)
Essential thrombocythemia during pregnancy. Eliyahu S, et al. **Obstet Gynecol Surv** 1997 Apr;52(4):243-7 (32 ref.)
Thrombocytopenia in pregnancy. Bell WR, et al. **Rheum Dis Clin North Am** 1997 Feb;23(1):183-94 (77 ref.)
[May-Heggelin anomaly and pregnancy. A case report, review of the literature] Tordjeman N, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(8):836-40 (16 ref.) (Eng. Abstr.) **(Fre)**

BLOOD

[Hyperlipidemia in pregnancy] Dejager S, et al. **Presse Med** 1996 Nov 30;25(37):1839-45 (34 ref.) (Eng. Abstr.) **(Fre)**
[Hemoglobin, iron deficiency and anemia in pregnant women. Diagnostic aspects] Haram K, et al. **Tidsskr Nor Laegeforen** 1997 Mar 10;117(7):962-6 (37 ref.) (Eng. Abstr.) **(Nor)**

DIAGNOSIS

[Autoimmune thrombocytopenia and pregnancy] Anselmi Angeli R, et al. **Minerva Ginecol** 1996 Dec;48(12):557-63 (15 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Case report of acute splenic and superior mesenteric vein thrombosis and its successful medical management. Foo E, et al. **Ann Acad Med Singapore** 1996 Sep;25(5):755-8 (36 ref.)
Heparin-induced osteoporosis in pregnancy. Nelson-Piercy C. **Lupus** 1997;6(6):500-4 (37 ref.)
Anticoagulants and thrombolytics during pregnancy. Ramin SM, et al. **Semin Perinatol** 1997 Apr;21(2):149-53 (35 ref.)
[Use of erythropoietin in pregnancy: review of the literature in connection with 2 cases] Mátyus J, et al. **Orv Hetil** 1997 Jul 13;138(28):1787-90 (43 ref.) (Eng. Abstr.) **(Hun)**

ETIOLOGY

Thrombosis in pregnancy. Bates SM, et al. **Curr Opin Hematol** 1997 Sep;4(5):335-43 (96 ref.)
Right atrial thrombus as a complication of total parenteral nutrition in pregnancy. Turrentine MA, et al. **Obstet Gynecol** 1994 Oct;84(4 Pt 2):675-7 (13 ref.)

IMMUNOLOGY

Autoantibodies reactive with Ro(SSA) and La(SSB) and pregnancy. Buyon JP. **J Rheumatol** 1997 Sep;24 Suppl 50:12-6 (47 ref.)

NURSING

Von Willebrand disease: a nursing perspective. Kleinert D, et al. **J Obstet Gynecol Neonatal Nurs** 1997 May-Jun; 26(3):271-6 (14 ref.)
Caring for the pregnant woman with sickle cell disease. Montgomery KS. **MCN Am J Matern Child Nurs** 1996 Sep-Oct;21(5):224-8 (10 ref.)

PATHOLOGY

Thrombophilia and fetal loss. Brenner B, et al. **Blood Rev** 1997 Jun;11(2):72-9 (82 ref.)

PHYSIOPATHOLOGY

Thrombotic microangiopathy during pregnancy. McCrae KR, et al. **Semin Hematol** 1997 Apr;34(2):148-58 (99 ref.)

PREVENTION & CONTROL

Factor V Leiden: should we screen oral contraceptive users and pregnant women? [see comments] Vandenbroucke JP, et al. **BMJ** 1996 Nov 2;313(7065):1127-30 (34 ref.) Comment in: BMJ 1997 Jul 5;315(7099):60.
Translation of the advice of the special mixed advisory commission concerning folic acid supplementation for the prevention of neural tube defects. **Verh K Acad Geneeskd Belg** 1996;58(6):635-79; discussion 679-81 (135 ref.) **(Eng, Dut, Fre)**
[Thrombophilia and antithrombotic prevention in gynecology and obstetrics] Winkler UH. **Internist (Berl)** 1997 Jul;38(7):650-7 (57 ref.) **(Ger)**

THERAPY

Management of sickling conditions in pregnancy. Howard RJ. **Br J Hosp Med** 1996 Jun 19-Jul 9;56(1):7-10 (20 ref.)

PREGNANCY COMPLICATIONS, INFECTIOUS

Breastfeeding and vertical transmission of HIV-1. Kreiss J. **Acta Paediatr Suppl** 1997 Jun;421:113-7 (10 ref.)
Interaction between timing of perinatal human immunodeficiency virus infection and the design of preventive and therapeutic interventions. Mofenson LM. **Acta Paediatr Suppl** 1997 Jun;421:1-9 (86 ref.)
Pregnancy and HIV infection in Europe. Newell ML, et al. **Acta Paediatr Suppl** 1997 Jun;421:10-4 (47 ref.)
HIV and pregnancy. Johnstone FD. **Br J Obstet Gynaecol** 1996 Dec;103(12):1184-90 (10 ref.)
Urinary tract infection in pregnancy. MacLean AB. **Br J Urol** 1997 Jul;80 Suppl 1:10-3 (28 ref.)
Group B streptococcal infections. Baker CJ. **Clin Perinatol** 1997 Mar;24(1):59-70 (47 ref.)
Sexually transmitted diseases and adverse outcomes of pregnancy. Goldenberg RL, et al. **Clin Perinatol** 1997 Mar; 24(1):23-41 (123 ref.)
Hepatitis viruses and the neonate. Kane MA. **Clin Perinatol** 1997 Mar;24(1):181-91 (50 ref.)
Other viral agents of perinatal importance. Varicella, parvovirus, respiratory syncytial virus, and enterovirus. Keyserling HL. **Clin Perinatol** 1997 Mar;24(1):193-211 (91 ref.)
Neonatal herpes simplex virus infection. Kohl S. **Clin Perinatol** 1997 Mar;24(1):129-50 (115 ref.)
Human immunodeficiency virus infection in pregnant women and their newborns. Lindsay MK, et al. **Clin Perinatol** 1997 Mar;24(1):161-80 (150 ref.)
Cytomegalovirus infection in the pregnant mother, fetus, and newborn infant. Nelson CT, et al. **Clin Perinatol** 1997 Mar; 24(1):151-60 (61 ref.)
Syphilis in pregnancy. Sánchez PJ, et al. **Clin Perinatol** 1997 Mar;24(1):71-90 (112 ref.)
Tuberculosis. An old disease but a new threat to the mother, fetus, and neonate. Starke JR. **Clin Perinatol** 1997 Mar; 24(1):107-27 (101 ref.)
Ureaplasma urealyticum infections in the perinatal period. Wang EE, et al. **Clin Perinatol** 1997 Mar;24(1):91-105 (97 ref.)
Infection and prematurity: evidence-based approaches. McGregor JA, et al. **Curr Opin Obstet Gynecol** 1996 Dec; 8(6):428-32 (42 ref.)
Lack of serologic evidence for an association between Cache Valley Virus infection and anencephaly and other neural tube defects in Texas. Edwards JF, et al. **Emerg Infect Dis** 1997 Apr-Jun;3(2):195-7 (19 ref.)
Mother-to-child transmission of human immunodeficiency virus type 1. John GC, et al. **Epidemiol Rev** 1996; 18(2):149-57 (93 ref.)
Counselling HIV patients pursuing infertility investigation and treatment [comment] Rizk B, et al. **Hum Reprod** 1997 Mar;12(3):415-6 (6 ref.) Comment on: Hum Reprod 1996 Dec;11(12):2793-6.
Perinatally transmitted neonatal bacterial infections. Eichenwald EC. **Infect Dis Clin North Am** 1997 Mar; 11(1):223-39 (68 ref.)
Nutrition in pediatric HIV infection: setting the research agenda. Nutrition and immune function II: maternal factors influencing transmission. Landers DV. **J Nutr** 1996 Oct; 126(10 Suppl):2637S-2640S (23 ref.)
Newborn factors in maternal-infant transmission of pediatric HIV infection. Stiehm ER. **J Nutr** 1996 Oct;126(10 Suppl):2632S-2636S (44 ref.)
Acyclovir for the prevention and treatment of varicella zoster in children, adolescents and pregnancy. Kesson AM, et al. **J Paediatr Child Health** 1996 Jun;32(3):211-7 (73 ref.)
Hepatitis C in pregnancy. Hunt CM, et al. **Obstet Gynecol** 1997 May;89(5 Pt 2):883-90 (85 ref.)
Infection by parvovirus B 19 during pregnancy: a review. Levy R, et al. **Obstet Gynecol Surv** 1997 Apr;52(4):254-9 (55 ref.)

Group B streptococcus and pregnancy. Mercer BM, et al. **Pediatr Ann** 1996 Apr;25(4):206–14 (93 ref.)
Women and HIV. A review of current epidemiology, gynecologic manifestations, and perinatal transmission. Khalsa AM, et al. **Prim Care** 1997 Sep;24(3):617–41 (201 ref.)
Tuberculosis in pregnancy. Anderson GD. **Semin Perinatol** 1997 Aug;21(4):328–35 (28 ref.)
Pneumonia in pregnancy. Goodrum LA. **Semin Perinatol** 1997 Aug;21(4):276–83 (47 ref.)
Human immunodeficiency virus (HIV)–related pulmonary complications in pregnancy. Saade GR. **Semin Perinatol** 1997 Aug;21(4):336–50 (126 ref.)
[AIDS and pregnancy] Benos P, et al. **Contracept Fertil Sex** 1997 Mar;25(3):XXV–XXX (0 ref.) **(Fre)**
[Varicella and pregnancy. Current literature] Lostie R, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(7):719–22 (5 ref.) (Eng. Abstr.) **(Fre)**
[Bacterial vaginosis and preterm labor] Bar-David J, et al. **Harefuah** 1997 Jun 15;132(12):871–5 (50 ref.) **(Heb)**
[Campylobacter infection in pregnancy--maternal and perinatal complications] Bar-David J, et al. **Harefuah** 1996 May 1;130(9):609–12 (40 ref.) **(Heb)**

DIAGNOSIS

Legionnaire's disease during pregnancy: a case presentation and review of the literature. Eisenberg VH, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Mar;72(1):15–8 (25 ref.)
ACOG educational bulletin. Human immunodeficiency virus infections in pregnancy. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1997 Apr; 57(1):73–80 (32 ref.)
Sexually transmitted diseases in pregnancy: diagnosis, impact, and intervention. Ament LA, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Oct;25(8):657–66 (29 ref.)
Group C streptococcal infection in a term newborn infant. Faix RG, et al. **J Perinatol** 1997 Jan–Feb;17(1):79–82 (35 ref.)
Management of Salmonella infections during pregnancy and puerperium. van der Klooster JM, et al. **Neth J Med** 1997 Aug;51(2):83–6 (24 ref.)
Gestational herpes simplex virus hepatitis. Yaziji H, et al. **South Med J** 1997 Mar;90(3):347–51 (34 ref.)
[Obstetric aspects of maternal hepatitis C infection] Herzog S, et al. **Z Geburtshilfe Neonatol** 1996 Nov–Dec; 200(6):227–31 (22 ref.) (Eng. Abstr.) **(Ger)**
[Whooping cough in pregnant patients and newborn infants] Hoppe JE. **Z Geburtshilfe Neonatol** 1996 Nov–Dec; 200(6):241–4 (29 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Preventing perinatal HIV transmission: zidovudine use during pregnancy. Carmichael C. **Am Fam Physician** 1997 Jan;55(1):171–4, 177–8 (16 ref.)
Antiretroviral therapy for pregnant women. Minkoff H, et al. **Am J Obstet Gynecol** 1997 Feb;176(2):478–89 (83 ref.)
Management guidelines for M. tuberculosis in pregnancy. Casper GR, et al. **Aust N Z J Obstet Gynaecol** 1995 Nov; 35(4):401–5 (22 ref.)
Prevention of perinatal transmission of human immunodeficiency virus: a progress report 2 years after completion of AIDS Clinical Trials Group trial 076. Wilfert CM. **Clin Infect Dis** 1996 Sep;23(3):438–41 (19 ref.)
Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. Steele RW. **Clin Pediatr (Phila)** 1996 Jul;35(7):378–9 (0 ref.)
Antibacterial therapy in pregnancy and neonates. Edwards MS. **Clin Perinatol** 1997 Mar;24(1):251–66 (78 ref.)
Treatment of viral infections during pregnancy and the neonatal period. Whitley RJ, et al. **Clin Perinatol** 1997 Mar; 24(1):267–83 (51 ref.)
Toxoplasmosis and parvovirus B19. Alger LS. **Infect Dis Clin North Am** 1997 Mar;11(1):55–75 (96 ref.)
Hepatitis in the obstetric patient. Dinsmoor MJ. **Infect Dis Clin North Am** 1997 Mar;11(1):77–91 (56 ref.)
Antibiotic selection in obstetric patients. Duff P. **Infect Dis Clin North Am** 1997 Mar;11(1):1–12 (42 ref.)
Urinary tract infections complicating pregnancy. Millar LK, et al. **Infect Dis Clin North Am** 1997 Mar;11(1):13–26 (61 ref.)
Pneumonia and tuberculosis in pregnancy. Riley L. **Infect Dis Clin North Am** 1997 Mar;11(1):119–33 (64 ref.)
Perinatal herpesvirus infections. Herpes simplex, varicella, and cytomegalovirus. Scott LL, et al. **Infect Dis Clin North Am** 1997 Mar;11(1):27–53 (146 ref.)
The maternal and fetal effects of tuberculosis therapy. Brost BC, et al. **Obstet Gynecol Clin North Am** 1997 Sep; 24(3):659–73 (80 ref.)
Antibiotic use in pregnancy. Dashe JS, et al. **Obstet Gynecol Clin North Am** 1997 Sep;24(3):617–29 (57 ref.)
Antiretroviral therapy during pregnancy. Beyond AZT (ZDV). Dattel BJ. **Obstet Gynecol Clin North Am** 1997 Sep;24(3):645–57 (24 ref.)
Sexually transmitted diseases in pregnancy. Jackson SL, et al. **Obstet Gynecol Clin North Am** 1997 Sep;24(3):631–44 (41 ref.)
[Antibiotics in obstetrics] Fernandez H, et al. **Contracept Fertil Sex** 1997 Jun;25(6):429–33 (13 ref.) **(Fre)**
[HIV and pregnancy: risks of transmission and therapeutic possibilities] Ibe M, et al. **Gynakol Geburtshilfliche Rundsch** 1996;36(4):188–93 (36 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Lyme disease during pregnancy. Silver HM. **Infect Dis Clin North Am** 1997 Mar;11(1):93–7 (11 ref.)
Risk factors for HIV in pregnant women [editorial] Smith NH, et al. **Int J STD AIDS** 1996 Oct;7(6):388–95 (38 ref.)
Overview of perinatal HIV infection. Fowler MG, et al. **J Nutr** 1996 Oct;126(10 Suppl):2602S–2607S (51 ref.)
Prevalence of human immunodeficiency virus infection and drug use in pregnant women: a critical review of the literature. Abercrombie PD, et al. **J Womens Health** 1997 Apr;6(2):163–87 (108 ref.)

ETIOLOGY

Human immunodeficiency virus and pregnancy. Wales NM, et al. **Curr Opin Obstet Gynecol** 1996 Dec;8(6):454–7 (20 ref.)
Chorioamnionitis and endometritis. Casey BM, et al. **Infect Dis Clin North Am** 1997 Mar;11(1):203–22 (90 ref.)
Human immunodeficiency virus infection in women. Anastos K, et al. **Med Clin North Am** 1997 Mar;81(2):533–53 (100 ref.)
Reproductive health hazards in the pharmaceutical industry. Clement JD. **Occup Med** 1997 Jan–Mar;12(1):131–43 (61 ref.)
[Premature labor and intrauterine infection] Egarter C, et al. **Geburtshilfe Frauenheilkd** 1996 Sep;56(9):M138–40 (15 ref.) **(Ger)**

IMMUNOLOGY

Role of immunity in maternal-infant HIV-1 transmission. Jansson M, et al. **Acta Paediatr Suppl** 1997 Jun;421:39–45 (42 ref.)
Early spontaneous abortions and fetal thymic abnormalities in maternal-to-fetal HIV infection. Shearer WT, et al. **Acta Paediatr Suppl** 1997 Jun;421:60–4 (25 ref.)
Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. Dammann O, et al. **Pediatr Res** 1997 Jul;42(1):1–8 (138 ref.)

MICROBIOLOGY

AAP issues revised guidelines for the prevention of early-onset group B streptococcal infection. Rose VL. **Am Fam Physician** 1997 Sep 1;56(3):961, 965 (02 ref.)
Management of neonates born to mothers with group B streptococcus colonization [published erratum appears in J Perinatol 1997 Mar–Apr;17(2):106] Alkalay AL, et al. **J Perinatol** 1996 Nov–Dec;16(6):470–7 (54 ref.)

NURSING

Pregnant and HIV-positive: a case study. Harkey AV. **MCN Am J Matern Child Nurs** 1997 Mar–Apr;22(2):85–8 (18 ref.)

PATHOLOGY

Gestational psittacosis: case report and literature review. Hyde SR, et al. **Mod Pathol** 1997 Jun;10(6):602–7 (16 ref.)

PHYSIOPATHOLOGY

Role of placental cytokines and inflammation in vertical transmission of HIV infection. Shearer WT, et al. **Acta Paediatr Suppl** 1997 Jun;421:33–8 (30 ref.)

PREVENTION & CONTROL

The future of prenatal HIV testing. Minkoff H, et al. **Acta Paediatr Suppl** 1997 Jun;421:72–7 (36 ref.)
Reducing the risk of perinatal HIV-1 transmission with zidovudine: results and implications of AIDS Clinical Trials Group protocol 076. Mofenson LM. **Acta Paediatr Suppl** 1997 Jun;421:89–96 (44 ref.)
Overview of the potential role of vitamin A in mother-to-child transmission of HIV-1. Semba RD. **Acta Paediatr Suppl** 1997 Jun;421:107–12 (29 ref.)
AAP issues revised guidelines for the prevention of early-onset group B streptococcal infection. Rose VL. **Am Fam Physician** 1997 Sep 1;56(3):961, 965 (02 ref.)
Prospects for vaccines during pregnancy and in the newborn period. Fischer GW, et al. **Clin Perinatol** 1997 Mar; 24(1):231–49 (81 ref.)
Human immunodeficiency virus and pregnancy. Wales NM, et al. **Curr Opin Obstet Gynecol** 1996 Dec;8(6):454–7 (20 ref.)
ACOG committee opinion. Prevention of early-onset group B streptococcal disease in newborns. Number 173--June 1996. Committee on Obstetric Practice. American College of Obstetrics and Gynecologists. **Int J Gynaecol Obstet** 1996 Aug;54(2):197–205 (47 ref.)
Group B streptococcus and pregnancy: update and recommendations. Mitchell A, et al. **MCN Am J Matern Child Nurs** 1997 Sep–Oct;22(5):242–8 (16 ref.)
[Urinary infections in pregnant women] Mauroy B, et al. **Prog Urol** 1996 Aug–Sep;6(4):607–22 (38 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

[Prophylactic cesarean section and HIV seropositive patients] Cohen M, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(8):846–50 (21 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Pregnancy in patients with Hansen disease. Lyde CB. **Arch Dermatol** 1997 May;133(5):623–7 (13 ref.)
ACOG educational bulletin. Human immunodeficiency virus infections in pregnancy. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1997 Apr; 57(1):73–80 (32 ref.)
[Management of infections during pregnancy] Hohlfeld P. **Arch Gynecol Obstet** 1996;259 Suppl 1:S97–110 (46 ref.) **(Fre)**

VIROLOGY

Disseminated herpesvirus infection during pregnancy. Young EJ, et al. **Clin Infect Dis** 1996 Jan;22(1):51–8 (71 ref.)
Prevention of mother-to-infant transmission of HIV-1. Melvin AJ, et al. **Mol Med Today** 1997 Jun;3(6):242–5 (27 ref.)
Perinatal exposure to measles virus and the risk of inflammatory bowel disease. Lione A, et al. **Reprod Toxicol** 1997 Sep–Oct;11(5):647–52 (55 ref.)
Congenital papillomas and papillomatoses associated with the human papilloma virus (HPV)–report on 5 cases. Dias EP, et al. **Rev Paul Med** 1995 Jul–Aug;113(4):957–63 (63 ref.)

PREGNANCY COMPLICATIONS, NEOPLASTIC

Central epithelial odontogenic ghost cell tumour. A case report. Junquera LM, et al. **Ann Otolaryngol Chir Cervicofac** 1997;114(3):76–9 (24 ref.)
Management of urological tumours in pregnancy. Hendry WF. **Br J Urol** 1997 Jul;80 Suppl 1:24–8 (40 ref.)
Pancreatic adenocarcinoma in the pregnant patient: case report and review of the literature. Blackbourne LH, et al. **Cancer** 1997 May 1;79(9):1776–9 (21 ref.)
Thyroid nodular disease in pregnancy: current diagnosis and management. Rosen IB, et al. **Clin Obstet Gynecol** 1997 Mar;40(1):81–9 (23 ref.)
Preinvasive and invasive breast and cervical cancer prior to or during pregnancy. Shivvers SA, et al. **Clin Perinatol** 1997 Jun;24(2):369–89 (109 ref.)
Pre leukemic granulocytic sarcoma of vagina. A case report with review of literature. Lakshminarasimhan S, et al. **Indian J Cancer** 1996 Sep;33(3):145–8 (13 ref.)
Primary adenocarcinoma of the bladder presenting during pregnancy. An unusual case report. Rajan N, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1996;7(5):267–9 (18 ref.)
[Thyroid nodule and cancer in pregnant women] Glinoer D. **Ann Endocrinol (Paris)** 1997;58(3):263–7 (11 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Retrorectal tumors complicating pregnancy. Report of two cases. Sobrado CW, et al. **Dis Colon Rectum** 1996 Oct; 39(10):1176–9 (13 ref.)
Thyroid cancer in children, pregnant women, and patients with Graves' disease. McClellan DR, et al. **Endocrinol Metab Clin North Am** 1996 Mar;25(1):27–48 (111 ref.)
Spinal meningiomas in pregnancy: report of two cases and review of the literature. Cioffi F, et al. **Eur J Gynaecol Oncol** 1996;17(5):384–8 (40 ref.)
Pregnancy and breast cancer. Merkel DE. **Semin Surg Oncol** 1996 Sep–Oct;12(5):370–5 (43 ref.)
[Vertebral hemangioma symptomatic during pregnancy. A case report and review of the literature] Abi-Fadel W, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(1):90–4 (20 ref.) (Eng. Abstr.) **(Fre)**
[Bilateral primary lymphoma of the breasts detected in pregnancy] Illés A, et al. **Orv Hetil** 1996 Jun 16; 137(24):1315–7 (22 ref.) (Eng. Abstr.) **(Hun)**

DRUG THERAPY

Platinum based chemotherapy to treat recurrent Sertoli-Leydig cell ovarian carcinoma during pregnancy. Tomlinson MW, et al. **Eur J Gynaecol Oncol** 1997; 18(1):44–6 (18 ref.)
Chemotherapy for metastatic melanoma during pregnancy. Dipaola RS, et al. **Gynecol Oncol** 1997 Sep;66(3):526–30 (21 ref.)
Management of chemotherapy in a pregnancy complicated by a large neuroblastoma. Arango HA, et al. **Obstet Gynecol** 1994 Oct;84(4 Pt 2):665–8 (10 ref.)
The use of chemotherapeutic agents during pregnancy. Sorosky JI, et al. **Obstet Gynecol Clin North Am** 1997 Sep; 24(3):591–9 (27 ref.)
[Quinagolide and macroprolactinomas a progress?] Jaquet P. **Ann Endocrinol (Paris)** 1997;58(2):83–5 (35 ref.) **(Fre)**
[Management of hematologic malignancies during pregnancy] Maloisel F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(6):602–7 (49 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Maternal melanoma metastatic to the placenta: a case report and review of the literature. Baergen RN, et al. **Arch Pathol Lab Med** 1997 May;121(5):508–11 (26 ref.)
Gastric stromal tumor with peritoneal nodules in pregnancy: tumor spread or rare variant of diffuse leiomyomatosis. Valente PT, et al. **Gynecol Oncol** 1996 Dec;63(3):392–7 (29 ref.)
Placental teratoma. A case report and review of the literature. Wang L, et al. **Pathol Res Pract** 1995 Dec;191(12):1267–70; discussion 1270 (21 ref.)
Malignancy metastatic to the products of conception: a case report with literature review. Ackerman J, et al. **Pediatr Pathol Lab Med** 1997 Jul–Aug;17(4):577–86 (71 ref.)
Pregnancy and the prognosis of malignant melanoma. Grin CM, et al. **Semin Oncol** 1996 Dec;23(6):734–6 (20 ref.)

PHYSIOPATHOLOGY

Endocrinology of melanoma. Neifeld JP. **Semin Surg Oncol** 1996 Nov–Dec;12(6):402–6 (37 ref.)
[Pregnancy and cancer of the breast] Herman P, et al. **Rev Med Liege** 1997 Jun;52(6):392–7 (14 ref.) **(Fre)**

SURGERY

Successful outcome of a 9 week pregnancy managed by bilateral salpingo–oophorectomy for ovarian cancer: case report. Colavita M, et al. **Eur J Gynaecol Oncol** 1996; 17(6):522–3 (7 ref.)
Primary surgery for stage IB–IIA cervical cancer, including short–term and long–term morbidity and treatment in pregnancy. Magrina JF. **J Natl Cancer Inst Monogr** 1996; (21):53–9 (67 ref.)

THERAPY

Hodgkin's disease in the pregnant patient. Fisher PM, et al. **Br J Hosp Med** 1996 Nov 20–Dec 10;56(10):529–32 (14 ref.)
Pregnancy and breast cancer. Merkel DE. **Semin Surg Oncol** 1996 Sep–Oct;12(5):370–5 (43 ref.)
[Treatment of breast cancer during pregnancy] Espié M, et al. **Contracept Fertil Sex** 1996 Nov;24(11):805–10 (49 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Clinical and perinatal sonographic features of congenital adrenal cystic neuroblastoma: a case report with review of the literature. Chen CP, et al. **Ultrasound Obstet Gynecol** 1997 Jul;10(1):68–73 (31 ref.)
[Ovarian granulosa cell tumor of juvenile type associated with pregnancy. Clinical case and review of the literature] Bognoni V, et al. **Minerva Ginecol** 1997 Jun;49(6):283–7 (34 ref.) (Eng. Abstr.) **(Ita)**

PREGNANCY COMPLICATIONS, PARASITIC

DIAGNOSIS

Screening for toxoplasmosis in pregnancy: what is the evidence of reducing a health problem? Eskild A, et al. **J Med Screen** 1996;3(4):188–94 (76 ref.)
A recent case of congenital malaria in Singapore. Lee WW, et al. **Singapore Med J** 1996 Oct;37(5):541–3 (18 ref.)
[Value and limits of complementary investigations in cases of toxoplasmosis seroconversion during pregnancy. A case report and review of the literature] Therby D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(5):505–9 (14 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

The safety of antimalarial drugs in pregnancy. Phillips–Howard PA, et al. **Drug Saf** 1996 Mar;14(3):131–45 (101 ref.)
Toxoplasmosis and parvovirus B19. Alger LS. **Infect Dis Clin North Am** 1997 Mar;11(1):55–75 (96 ref.)
Malarial infection during pregnancy. Silver HM. **Infect Dis Clin North Am** 1997 Mar;11(1):99–107 (35 ref.)
Sexually transmitted diseases in pregnancy. Jackson SL, et al. **Obstet Gynecol Clin North Am** 1997 Sep;24(3):631–44 (41 ref.)

IMMUNOLOGY

Role of nitric oxide–induced immune suppression in toxoplasmosis during pregnancy and in infection by a virulent strain of Toxoplasma gondii. Candolfi E, et al. **Curr Top Microbiol Immunol** 1996;219:141–54 (61 ref.)

PREGNANCY, ECTOPIC

Oestrogens and progesterone concentrations and risk of ectopic pregnancy: an epidemiological point of view [comment] Parazzini F. **Hum Reprod** 1996 Feb;11(2):236–8 (20 ref.) Comment on: Hum Reprod 1996 Feb;11(2):235–6.
CME approved article. Ectopic pregnancy. Jain A, et al. **J Am Assoc Gynecol Laparosc** 1997 Aug;4(4):513–32 (80 ref.)
Heterotopic pregnancy and assisted reproduction—an update. Rojansky N, et al. **J Assist Reprod Genet** 1996 Aug; 13(7):594–601 (58 ref.)
Congenital dislocation of the hip in extrauterine pregnancy [see comments] Uglow MG, et al. **J Bone Joint Surg Br** 1996 Sep;78(5):751–3 (17 ref.) Comment in: J Bone Joint Surg Br 1997 Mar;79(2):343.
Cervical pregnancy: past and future. Ushakov FB, et al. **Obstet Gynecol Surv** 1997 Jan;52(1):45–59 (105 ref.)
[Extrauterine pregnancy: diagnosis and treatment] Vejtorp M. **Ugeskr Laeger** 1996 Nov 4;158(45):6424–31 (40 ref.) (Eng. Abstr.) **(Dan)**

DIAGNOSIS

Modern management of ectopic pregnancy. Gazvani MR. **Br J Hosp Med** 1996 Dec 11–1997 Jan 14;56(11):597–9 (12 ref.)
The managed care of early pregnancy problems. Draycott T, et al. **Curr Opin Obstet Gynecol** 1997 Aug;9(4):262–6 (32 ref.)
Laparoscopic management of ovarian ectopic pregnancy. Hage PS, et al. **J Am Assoc Gynecol Laparosc** 1994 May; 1(3):283–5 (10 ref.)
Current treatment options for ectopic pregnancy. Minnick–Smith K, et al. **MCN Am J Matern Child Nurs** 1997 Jan–Feb;22(1):21–5 (25 ref.)
[Cervical pregnancy: case report and review of the literature] Pretzsch G, et al. **Zentralbl Gynakol** 1997;119(1):25–34 (54 ref.) (Eng. Abstr.) **(Ger)**
[Interstitial ectopic pregnancy: early diagnosis and management] Groutz A, et al. **Harefuah** 1997 Apr 15; 132(8):578–81 (38 ref.) **(Heb)**

DRUG THERAPY

Subsequent reproduction and obstetric outcome after methotrexate treatment of cervical pregnancy: a review of original literature and international collaborative follow–up. Kung FT, et al. **Hum Reprod** 1997 Mar; 12(3):591–5 (27 ref.)
Medical management of ectopic pregnancy—the role of methotrexate. Ander DS, et al. **J Emerg Med** 1997 Mar–Apr;15(2):177–82 (33 ref.)

EPIDEMIOLOGY

Heterotopic pregnancy after ovulation induction and assisted reproductive technologies: a literature review from 1971 to 1993. Tal J, et al. **Fertil Steril** 1996 Jul;66(1):1–12 (77 ref.)
Is the rising incidence of ectopic pregnancy unexplained? [comment] Ankum WM. **Hum Reprod** 1996 Feb;11(2):238–9 (15 ref.) Comment on: Hum Reprod 1996 Feb;11(2):235–6.
Women's hormone concentrations and the increasing rates of ectopic pregnancy [see comments] James WH. **Hum Reprod** 1996 Feb;11(2):233–5 (34 ref.) Comment in: Hum Reprod 1996 Feb;11(2):235–6.

ETIOLOGY

Is the rising incidence of ectopic pregnancy unexplained? [comment] Ankum WM. **Hum Reprod** 1996 Feb;11(2):238–9 (15 ref.) Comment on: Hum Reprod 1996 Feb;11(2):235–6.
The hidden side of ectopic pregnancy: the hormonal factor. Fernandez H, et al. **Hum Reprod** 1996 Feb;11(2):243–4 (15 ref.)
Pregnancy after failed tubal sterilization. Napolitano PG, et al. **J Reprod Med** 1996 Aug;41(8):609–13 (30 ref.)
[Extra–uterine pregnancies after in vitro fertilization. Six case reports] Forveille C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(4):374–8 (34 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Chromosomal abnormalities and ectopic pregnancy? New directions for aetiological research [see comments] Job–Spira N, et al. **Hum Reprod** 1996 Feb;11(2):239–42 (22 ref.) Comment in: Hum Reprod 1996 Oct;11(10):2337.

PATHOLOGY

Ectopic pregnancy. A recent five–year study and review of the last 50 years' literature. Ramirez NC, et al. **J Reprod Med** 1996 Oct;41(10):733–40 (26 ref.)

SURGERY

Laparoscopic surgical treatment of ectopic pregnancy: salpingectomy or salpingostomy? Parker J, et al. **Aust N Z J Obstet Gynaecol** 1997 Feb;37(1):115–7 (21 ref.)
Use of adhesion prevention barriers in ovarian surgery, tubalplasty, ectopic pregnancy, endometriosis, adhesiolysis, and myomectomy. diZerega GS. **Curr Opin Obstet Gynecol** 1996 Jun;8(3):230–7 (32 ref.)
Laparoscopic management of ovarian ectopic pregnancy. Hage PS, et al. **J Am Assoc Gynecol Laparosc** 1994 May; 1(3):283–5 (10 ref.)
[Incisional hernia after surgical laparoscopy: a case of hepatic ligament incarceration and review of the literature] Deval B, et al. **Contracept Fertil Sex** 1997 Jan;25(1):66–8 (14 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Modern lines of management of ectopic pregnancy. Dimitry ES, et al. **Br J Clin Pract** 1996 Oct–Nov;50(7):376–80 (117 ref.)
Modern management of ectopic pregnancy. Gazvani MR. **Br J Hosp Med** 1996 Dec 11–1997 Jan 14;56(11):597–9 (12 ref.)
The managed care of early pregnancy problems. Draycott T, et al. **Curr Opin Obstet Gynecol** 1997 Aug;9(4):262–6 (32 ref.)
Current status of surgical and nonsurgical management of ectopic pregnancy. Yao M, et al. **Fertil Steril** 1997 Mar; 67(3):421–33 (101 ref.)
Current treatment options for ectopic pregnancy. Minnick–Smith K, et al. **MCN Am J Matern Child Nurs** 1997 Jan–Feb;22(1):21–5 (25 ref.)
Strategies for conservative treatment of cervical ectopic pregnancy [comment] Benson CB, et al. **Ultrasound Obstet Gynecol** 1996 Dec;8(6):371–2 (13 ref.) Comment on: Ultrasound Obstet Gynecol 1996 Dec;8(6):373–80.
[Is the treatment of ectopic pregnancy still exclusively surgical?] Fernandez H, et al. **Ann Chir** 1997;51(4):343–51 (43 ref.) (Eng. Abstr.) **(Fre)**
[Ectopic pregnancy. A transformed therapeutic strategy] Fernandez H, et al. **Presse Med** 1997 Feb 1;26(2):84–90 (41 ref.) **(Fre)**
[Interstitial ectopic pregnancy: early diagnosis and management] Groutz A, et al. **Harefuah** 1997 Apr 15; 132(8):578–81 (38 ref.) **(Heb)**

ULTRASONOGRAPHY

Cervical pregnancy—a forgotten entity in family practice. Acosta DA. **J Am Board Fam Pract** 1997 Jul–Aug; 10(4):290–5 (33 ref.)
Role of endovaginal sonography in the diagnosis and management of ectopic pregnancy. Atri M, et al. **Radiographics** 1996 Jul;16(4):755–74; discussion 775 (52 ref.)

PREGNANCY, FIRST TRIMESTER see **PREGNANCY TRIMESTER, FIRST**

PREGNANCY, HIGH–RISK

see related
PREGNANCY COMPLICATIONS

Doppler ultrasound in obstetric practice: 2. Beattie RB. **Br J Hosp Med** 1994 Jan 19–Feb 1;51(1–2):34–9 (27 ref.)
Prenatal care for low–income women and the health belief model: a new beginning. Stout AE. **J Community Health Nurs** 1997;14(3):169–80 (21 ref.)
Pregnancy in women with cerebrospinal shunts: a literature review and case report. Stevens E. **J Perinatol** 1996 Sep–Oct;16(5):374–80 (29 ref.)
Maternal and fetal implications of anticonvulsive therapy during pregnancy. Eller DP, et al. **Obstet Gynecol Clin North Am** 1997 Sep;24(3):523–34 (46 ref.)
[Pregnancy after organ transplantation] Chevalier P, et al. **Presse Med** 1996 Nov 9;25(34):1643–8 (29 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Perinatal social work and the high risk obstetrics patient. Bachman DH, et al. **Soc Work Health Care** 1997; 24(3–4):3–19 (36 ref.)

PREGNANCY IN ADOLESCENCE

The implications of teenage pregnancy and motherhood for primary health care: unresolved issues. Irvine H, et al. **Br J Gen Pract** 1997 May;47(418):323–6 (50 ref.)
Adolescent obstetrics and gynecology: children having children—can it be controlled? Plouffe L Jr, et al. **Curr Opin Obstet Gynecol** 1996 Oct;8(5):335–8 (21 ref.)
Primary care management of adolescent sexual behavior. Ellen JM, et al. **Curr Opin Pediatr** 1996 Oct;8(5):442–8 (47 ref.)
Emergency contraception: a second chance at preventing adolescent unintended pregnancy. Gold MA. **Curr Opin Pediatr** 1997 Aug;9(4):300–9 (37 ref.)
Teenage pregnancy prevention programs. Pierre N, et al. **Curr Opin Pediatr** 1997 Aug;9(4):310–6 (23 ref.)
Can statutory rape laws be effective in preventing adolescent pregnancy? Donovan P. **Fam Plann Perspect** 1997 Jan–Feb; 29(1):30–4, 40 (52 ref.)
Understanding the impact of effective teenage pregnancy prevention programs. Frost JJ, et al. **Fam Plann Perspect** 1995 Sep–Oct;27(5):188–95 (13 ref.)
The relationship of partner support to outcomes for teenage mothers and their children: a review. Roye CF, et al. **J Adolesc Health** 1996 Aug;19(2):86–93 (45 ref.)
Mississippi selected facts about teenage pregnancy. Mississippi State Department of Health. **J Miss State Med Assoc** 1997 Feb;38(2):45–50 (11 ref.)
Adolescent medicine. Muram D. **J Pediatr Adolesc Gynecol** 1996 Nov;9(4):203–5 (21 ref.)
Severe eclampsia in an adolescent: a case report and review of the literature. Scribano PV, et al. **Pediatr Emerg Care** 1996 Dec;12(6):425–7 (6 ref.)
Perinatal social work with childbearing adolescents. Adams D, et al. **Soc Work Health Care** 1997;24(3–4):85–97 (37 ref.)

PREGNANCY IN ADOLESCENCE

PHYSIOLOGY

Reduction of birth weight among infants born to adolescents: maternal-fetal growth competition. Frisancho AR. **Ann N Y Acad Sci** 1997 May 28;817:272-80 (11 ref.)

Implications of the Camden Study of adolescent pregnancy: interactions among maternal growth, nutritional status, and body composition. Hediger ML, et al. **Ann N Y Acad Sci** 1997 May 28;817:281-91 (43 ref.)

Nutritional support for the pregnant adolescent. Lederman SA. **Ann N Y Acad Sci** 1997 May 28;817:304-12 (24 ref.)

Overview: nutrition for pregnant and childbearing adolescents. Rees JM. **Ann N Y Acad Sci** 1997 May 28; 817:241-5 (2 ref.)

Nutrition for pregnant and childbearing adolescents: demographics, developmental needs, behavior, and outcome. Rees JM. **Ann N Y Acad Sci** 1997 May 28; 817:246-50 (17 ref.)

Maternal growth and fetal growth: pregnancy course and outcome in the Camden Study. Scholl TO, et al. **Ann N Y Acad Sci** 1997 May 28;817:292-301 (37 ref.)

Promoting healthy eating and ensuring adequate weight gain in pregnant adolescents: issues and strategies. Story M. **Ann N Y Acad Sci** 1997 May 28;817:321-33 (56 ref.)

PSYCHOLOGY

Addressing developmental needs of pregnant adolescents. Drake P. **J Obstet Gynecol Neonatal Nurs** 1996 Jul-Aug; 25(6):518-24 (18 ref.)

Predictors of depression symptoms in pregnant adolescents. Koniak-Griffin D, et al. **J Perinatol** 1996 Jan-Feb; 16(1):69-76 (59 ref.)

STATISTICS & NUMERICAL DATA

Adolescent sexuality. Goldfarb AF. **Ann N Y Acad Sci** 1997 Jun 17;816:395-403 (08 ref.)

[Adolescence and pregnancy in Guadeloupe. 184 cases] Gallais A, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(5):523-7 (28 ref.) (Eng. Abstr.) **(Fre)**

PREGNANCY IN DIABETES

see related

DIABETES, GESTATIONAL

Management of diabetes in pregnancy. Pasui K, et al. **Am Fam Physician** 1997 Jun;55(8):2731-8, 2742-4 (28 ref.)

Successful pregnancy after combined renal-pancreas transplantation: a case report and literature review. Skannal DG, et al. **Am J Perinatol** 1996 Aug;13(6):383-7 (21 ref.)

Diabetic retinopathy in pregnancy. Best RM, et al. **Br J Ophthalmol** 1997 Mar;81(3):249-51 (35 ref.)

Fetal surveillance in diabetic pregnancy. Harman CR, et al. **Curr Opin Obstet Gynecol** 1997 Apr;9(2):83-90 (41 ref.)

Guidelines for the management of insulin-dependent diabetes mellitus in pregnancy. Steel JM, et al. **Drugs** 1996 Jul; 52(1):60-70 (61 ref.)

Mouse embryos in culture: models for understanding diabetes-induced embryopathies and gene function. Sadler TW. **Int J Dev Biol** 1997 Apr;41(2):291-7 (65 ref.)

Femoral hypoplasia-unusual facies syndrome with bifid hallux, absent tibia, and macrophallus: a report of a Bedouin baby. Sabry MA, et al. **J Med Genet** 1996 Feb;33(2):165-7 (9 ref.)

Common clinical manifestations of maternal diabetes in newborn infants: implications for the practicing pediatrician. Rosenn B, et al. **Pediatr Ann** 1996 Apr; 25(4):215-22 (46 ref.)

Multifactorial basis of the syndrome of diabetic embryopathy. Reece EA, et al. **Teratology** 1996 Oct;54(4):171-82 (62 ref.)

[Perinatal issues of diabetes in pregnancy] Menato G, et al. **Minerva Pediatr** 1997 Mar;49(3):61-9 (35 ref.) **(Ita)**

[Pregnancy in diabetes (see comments)] Haram K, et al. **Tidsskr Nor Laegeforen** 1996 Nov 30;116(29):3459-64 (68 ref.) (Eng. Abstr.) Comment in: Tidsskr Nor Laegeforen 1997 Jun 20;117(16):2360-1. **(Nor)**

[Diabetes mellitus in pregnancy] Haram K, et al. **Tidsskr Nor Laegeforen** 1996 Nov 30;116(29):3452-8 (61 ref.) (Eng. Abstr.) **(Nor)**

COMPLICATIONS

Infant of diabetic mother: a continuing challenge for perinatal-neonatal medicine. Wu PY. **Acta Paediatr Sin** 1996 Sep-Oct;37(5):312-9 (57 ref.)

Neonatal hypoglycemia. Baker L, et al. **Curr Ther Endocrinol Metab** 1997;6:409-13 (4 ref.)

Infant of the diabetic mother. Sperling MA, et al. **Curr Ther Endocrinol Metab** 1997;6:405-9 (10 ref.)

Short- and long-range complications in offspring of diabetic mothers. Weintrob N, et al. **J Diabetes Complications** 1996 Sep-Oct;10(5):294-301 (72 ref.)

Coronary artery disease in insulin-dependent diabetes mellitus of pregnancy (class H): a review of the literature. Gordon MC, et al. **Obstet Gynecol Surv** 1996 Jul; 51(7):437-44 (36 ref.)

DIAGNOSIS

[Diabetic nephropathy and pregnancy] Schröder W, et al. **Z Geburtshilfe Neonatol** 1997 May-Jun;201(3):75-81 (88 ref.) (Eng. Abstr.) **(Ger)**

[Gestational diabetes--perinatal hyperinsulinism and postnatal developmental disorders] Briese V, et al. **Zentralbl Gynakol** 1997;119(7):324-30 (55 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

[Insulin therapy during pregnancy: how far and how intensified?] Bringer J, et al. **Journ Annu Diabetol Hotel Dieu** 1997;:81-93 (37 ref.) **(Fre)**

EPIDEMIOLOGY

[Diabetic retinopathy during pregnancy] Rakhab MA, et al. **Akush Ginekol (Sofiia)** 1996;35(3):31-2 (6 ref.) (Eng. Abstr.) **(Bul)**

ETIOLOGY

Reproductive toxicology in animals with induced and spontaneous diabetes. Kalter H. **Reprod Toxicol** 1996 Nov-Dec;10(6):417-38 (144 ref.)

THERAPY

Diabetes during pregnancy. Metzger BE, et al. **Curr Ther Endocrinol Metab** 1997;6:318-24 (6 ref.)

Report of the Pregnancy and Neonatal Care Group. Brown CJ, et al. **Diabet Med** 1996 Sep;13(9 Suppl 4):S43-53 (31 ref.)

The management of diabetes in pregnancy. Hadden DR. **Postgrad Med J** 1996 Sep;72(851):525-31 (23 ref.)

[The clinical management of pregnant women with diabetes] Rkhab MA. **Akush Ginekol (Sofiia)** 1996;35(1-2):45-8 (12 ref.) (Eng. Abstr.) **(Bul)**

[Alternative to insulin therapy: diet and physical exercise] Jovanovic-Peterson L. **Journ Annu Diabetol Hotel Dieu** 1997;:95-124 (135 ref.) **(Fre)**

PREGNANCY MAINTENANCE

Attempt to continue pregnancy of remaining fetuses after delivery of preceding fetus in multiple pregnancies before 24 weeks gestation: report of three cases. Ishikawa K, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Dec; 48(12):1161-4 (18 ref.)

PREGNANCY, MULTIPLE

see related

PREGNANCY REDUCTION, MULTIFETAL

Hyperthyroidism due to inappropriate production of human chorionic gonadotropin. Goodwin TM, et al. **Clin Obstet Gynecol** 1997 Mar;40(1):32-44 (41 ref.)

First trimester fetal reduction: its role in the management of twin and higher order multiple pregnancies. Brambati B, et al. **Hum Reprod Update** 1995 Jul;1(4):397-408 (47 ref.)

Antenatal diagnosis of Grebe syndrome in a twin pregnancy by ultrasound. Kulkarni ML, et al. **Indian Pediatr** 1995 Sep; 32(9):1007-11 (7 ref.)

Neonatal herpes simplex virus infection after cesarean section with intact amniotic membranes. Peng J, et al. **J Perinatol** 1996 Sep-Oct;16(5):397-9 (17 ref.)

Rudimentary uterine horn pregnancy. A case report on surviving twins delivered eight days apart. Nahum GG. **J Reprod Med** 1997 Aug;42(8):525-32 (30 ref.)

Attempt to continue pregnancy of remaining fetuses after delivery of preceding fetus in multiple pregnancies before 24 weeks gestation: report of three cases. Ishikawa K, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Dec; 48(12):1161-4 (18 ref.)

Complete hydatidiform mole and surviving coexistent twin. Bristow RE, et al. **Obstet Gynecol Surv** 1996 Dec; 51(12):705-9 (33 ref.)

Antenatal assessment of twin gestation. Devoe LD, et al. **Semin Perinatol** 1995 Oct;19(5):413-23 (54 ref.)

Ultrasound in twin pregnancy. Divon MY, et al. **Semin Perinatol** 1995 Oct;19(5):404-12 (57 ref.)

Antepartum management of the multiple gestation: the case for specialized care. Newman RB, et al. **Semin Perinatol** 1995 Oct;19(5):387-403 (81 ref.)

Intrapartum management of multiple gestation. Udom-Rice I, et al. **Semin Perinatol** 1995 Oct;19(5):424-34 (94 ref.)

Monochorionic twin pregnancies: 'les liaisons dangereuses' [comment] Ville Y. **Ultrasound Obstet Gynecol** 1997 Aug; 10(2):82-5 (45 ref.) Comment on: Ultrasound Obstet Gynecol 1997 Aug;10(2):86-9.

Use of transvaginal ultrasound-guided puncture for elimination of equine pregnancies. Squires EL. **Vet Clin North Am Equine Pract** 1996 Apr;12(1):161-8 (19 ref.)

[Vaginal delivery in multiple pregnancy--a plea for spontaneous delivery] Hohlfeld P, et al. **Arch Gynecol Obstet** 1996;259 Suppl 1:S137-46 (58 ref.) **(Fre)**

[Multiple pregnancies prevention in in vitro fertilization: limiting the number of transferred embryos to two maximum?] Antonine JM, et al. **Contracept Fertil Sex** 1996 Jan;24(1):52-5 (45 ref.) (Eng. Abstr.) **(Fre)**

[Obstetrical management of triplets. A series of forty five cases] Charasson T, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(7):737-45 (45 ref.) (Eng. Abstr.) **(Fre)**

[Maternal complications from tocolytic treatment with beta-mimetics. Three cases of pulmonary edema] Hourdequin P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(5):528-32 (21 ref.) (Eng. Abstr.) **(Fre)**

[In utero fetal death in multiple pregnancies during the second and third trimesters. A series of 21 cases] Tordjeman N, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(6):594-601 (44 ref.) (Eng. Abstr.) **(Fre)**

[Successful twin delivery following reduction of quadruplet pregnancy] Patkós P, et al. **Orv Hetil** 1996 Nov 3; 137(44):2458-63 (37 ref.) (Eng. Abstr.) **(Hun)**

[A case of myomectomy for infertility and a following twin pregnancy associated with hyperthyroidism] Berlingieri D, et al. **Minerva Ginecol** 1996 Dec;48(12):545-52 (20 ref.) (Eng. Abstr.) **(Ita)**

[Emergency cerclage and twin pregnancy] Bognoni V, et al. **Minerva Ginecol** 1997 May;49(5):229-34 (21 ref.) (Eng. Abstr.) **(Ita)**

[Prevention of multiple pregnancy by induction of single ovulation] Aono T. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Aug; 48(8):666-71 (10 ref.) **(Jpn)**

[Peripartum cardiomyopathy of multiple pregnancy] Ikeda S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):170-3 (17 ref.) **(Jpn)**

GENETICS

Genetic diagnosis in multiple pregnancies. Wapner RJ. **Semin Perinatol** 1995 Oct;19(5):351-62 (61 ref.)

PHYSIOLOGY

[Production of monozygotic multiple offspring in agricultural domestic animals] Reichelt B, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Aug-Sep; 103(8-9):340-8 (72 ref.) (Eng. Abstr.) **(Ger)**

[Surviving mono-amniotic twins. Case report and review of the literature] Golaszewski T, et al. **Z Geburtshilfe Neonatol** 1997 Mar-Apr;201(2):62-4 (11 ref.) (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

The outcome of multiple pregnancy. Doyle P. **Hum Reprod** 1996 Dec;11 Suppl 4:110-7; discussion 118-20 (32 ref.)

PREGNANCY OUTCOME

Scientific basis for the content of routine antenatal care. II. Power to eliminate or alleviate adverse newborn outcomes; some special conditions and examinations. Bergsjø P, et al. **Acta Obstet Gynecol Scand** 1997 Jan;76(1):15-25 (82 ref.)

Pregnancy outcome in natural family planning users: cohort and case-control studies evaluating safety. Simpson JL, et al. **Adv Contracept** 1997 Jun-Sep;13(2-3):201-14 (30 ref.)

Accidental electric shock in pregnancy: a prospective cohort study. Einarson A, et al. **Am J Obstet Gynecol** 1997 Mar; 176(3):678-81 (13 ref.)

Reproductive hazards of the American lifestyle: work during pregnancy. Gabbe SG, et al. **Am J Obstet Gynecol** 1997 Apr;176(4):826-32 (40 ref.)

In utero management of hydrops fetalis caused by critical aortic stenosis. Bitar FF, et al. **Am J Perinatol** 1997 Aug; 14(7):389-91 (7 ref.)

Pneumothorax in pregnancy associated with cocaine use. Chan L, et al. **Am J Perinatol** 1997 Aug;14(7):385-8 (22 ref.)

Isolated persistent fetal bradycardia in complete A-V block: a conservative approach is appropriate. A case report and a review of the literature. Rabinerson D, et al. **Am J Perinatol** 1997 Jul;14(6):317-20 (17 ref.)

Successful pregnancy after combined renal-pancreas transplantation: a case report and literature review. Skannal DG, et al. **Am J Perinatol** 1996 Aug;13(6):383-7 (21 ref.)

Case report of acute splenic and superior mesenteric vein thrombosis and its successful medical management. Foo E, et al. **Ann Acad Med Singapore** 1996 Sep;25(5):755-8 (36 ref.)

Monitoring technology and the clinical perspective. Gardosi J. **Baillieres Clin Obstet Gynaecol** 1996 Jun;10(2):325-39 (52 ref.)

Cirrhosis and pregnancy. A case report and review of the literature. Restaino A, et al. **Clin Exp Obstet Gynecol** 1996; 23(4):240-7 (24 ref.)

Clinical assessment of amniotic fluid. Moore TR. **Clin Obstet Gynecol** 1997 Jun;40(2):303-13 (52 ref.)

Intra-amniotic infection and premature rupture of the membranes. Belady PH, et al. **Clin Perinatol** 1997 Mar; 24(1):43-57 (104 ref.)

Maternal nutrition and the outcome of pregnancy. A renaissance in research. Brown JE, et al. **Clin Perinatol** 1997 Jun;24(2):433-49 (101 ref.)

Sexually transmitted diseases and adverse outcomes of pregnancy. Goldenberg RL, et al. **Clin Perinatol** 1997 Mar; 24(1):23-41 (123 ref.)

Syphilis in pregnancy. Sánchez PJ, et al. **Clin Perinatol** 1997 Mar;24(1):71-90 (112 ref.)

Obstetric and perinatal outcome in pregnancies after assisted reproduction. Tanbo T, et al. **Curr Opin Obstet Gynecol** 1996 Jun;8(3):193-8 (43 ref.)

Pseudoxanthoma elasticum and pregnancy. Yoles A, et al. **Cutis** 1996 Aug;58(2):161-4 (15 ref.)

Managing post-term pregnancy. **Drug Ther Bull** 1997 Mar;

35(3):17–8 (19 ref.)
The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and fetal outcome. Morrell MJ. **Epilepsia** 1996;37 Suppl 6:S34–44 (107 ref.)
Ectopic vaginal decidualization. An unusual finding that presents problems of differential diagnosis with carcinoma. Castellví Vives J, et al. **Eur J Gynaecol Oncol** 1997; 18(3):183–4 (23 ref.)
Successful outcome of a 9 week pregnancy managed by bilateral salpingo–oophorectomy for ovarian cancer: case report. Colavita M, et al. **Eur J Gynaecol Oncol** 1996; 17(6):522–3 (7 ref.)
The outcome of multiple pregnancy. Doyle P. **Hum Reprod** 1996 Dec;11 Suppl 4:110–7; discussion 118–20 (32 ref.)
Subsequent reproduction and obstetric outcome after methotrexate treatment of cervical pregnancy: a review of original literature and international collaborative follow-up. Kung FT, et al. **Hum Reprod** 1997 Mar; 12(3):591–5 (27 ref.)
Development, pharmacology and clinical experience with clomiphene citrate. Dickey RP, et al. **Hum Reprod Update** 1996 Nov–Dec;2(6):483–506 (108 ref.)
ACOG educational bulletin. Human immunodeficiency virus infections in pregnancy. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1997 Apr; 57(1):73–80 (32 ref.)
Delivery after bone marrow transplantation with total lymphoid irradiation for severe aplastic anemia. Ashida T, et al. **Int J Hematol** 1996 Oct;64(3–4):279–81 (14 ref.)
Exploring cost and quality: community-based versus traditional hospital delivery systems. Walker PH, et al. **J Health Care Finance** 1996 Fall;23(1):23–47 (53 ref.)
Chronic hypertension in pregnancy. Frangieh AY, et al. **J Med Liban** 1996;44(2):68–74 (50 ref.)
Antenatal hormone therapy for improving the outcome of the preterm infant. Ballard RA, et al. **J Perinatol** 1996 Sep–Oct;16(5):390–6 (47 ref.)
Group C streptococcal infection in a term newborn infant. Faix RG, et al. **J Perinatol** 1997 Jan–Feb;17(1):79–82 (35 ref.)
Should intravenous hydration be the first line of defense with threatened preterm labor? A critical review of the literature. Freda MC, et al. **J Perinatol** 1996 Sep–Oct; 16(5):385–9 (15 ref.)
Prenatally diagnosed ureterocele presenting as fetal bladder outlet obstruction. Gloor JM, et al. **J Perinatol** 1996 Jul–Aug;16(4):285–7 (18 ref.)
Congenital monoblastic leukemia as a cause of third-trimester fetal loss: the role of monoclonal antibody testing. Greenbaum BH, et al. **J Perinatol** 1996 May–Jun;16(3 Pt 1):202–4 (20 ref.)
Fetal ovarian torsion appearing as a solid abdominal mass. Katz VL, et al. **J Perinatol** 1996 Jul–Aug;16(4):302–4 (37 ref.)
Pregnancy in women with cerebrospinal shunts: a literature review and case report. Stevens E. **J Perinatol** 1996 Sep–Oct;16(5):374–80 (29 ref.)
Pregnancy after failed tubal sterilization. Napolitano PG, et al. **J Reprod Med** 1996 Aug;41(8):609–13 (30 ref.)
Continuous electronic fetal monitoring: does it belong in low-risk births? Supplee RB, et al. **MCN Am J Matern Child Nurs** 1996 Nov–Dec;21(6):301–6 (30 ref.)
Management of Salmonella infections during pregnancy and puerperium. van der Klooster JM, et al. **Neth J Med** 1997 Aug;51(2):83–6 (24 ref.)
The effect of caffeine on pregnancy outcome variables. Hinds TS, et al. **Nutr Rev** 1996 Jul;54(7):203–7 (32 ref.)
Intrapartum rupture of the unscarred uterus. Miller DA, et al. **Obstet Gynecol** 1997 May;89(5 Pt 1):671–3 (18 ref.)
Stress, social support and pregnancy outcome: a reassessment based on recent research. Hoffman S, et al. **Paediatr Perinat Epidemiol** 1996 Oct;10(4):380–405 (144 ref.)
Hopkins Lupus Pregnancy Center: 1987 to 1996. Petri M. **Rheum Dis Clin North Am** 1997 Feb;23(1):1–13 (34 ref.)
Antiphospholipid syndrome in pregnancy. Obstetric concerns and treatment. Welsch S, et al. **Rheum Dis Clin North Am** 1997 Feb;23(1):71–84 (106 ref.)
Clinical course of premature rupture of the membranes. Alexander JM, et al. **Semin Perinatol** 1996 Oct;20(5):369–74 (31 ref.)
Pregnancy outcome: physical activities inside versus outside the workplace. Clapp JF 3rd. **Semin Perinatol** 1996 Feb; 20(1):70–6 (46 ref.)
Drugs in pregnancy: anticonvulsants. Malone FD, et al. **Semin Perinatol** 1997 Apr;21(2):114–23 (41 ref.)
Premature rupture of the membranes: neonatal consequences. Merenstein GB, et al. **Semin Perinatol** 1996 Oct; 20(5):375–80 (71 ref.)
Midtrimester premature rupture of the membranes. Schucker JL, et al. **Semin Perinatol** 1996 Oct;20(5):389–400 (67 ref.)
Holoprosencephaly and chromosomal anomalies. Chow BH, et al. **Singapore Med J** 1996 Aug;37(4):394–7 (19 ref.)
Physical activity and pregnancy outcome. Review and recommendations. Sternfeld B. **Sports Med** 1997 Jan; 23(1):33–47 (124 ref.)
The acute abdomen in the pregnant patient. Is there a role for laparoscopy? Gurbuz AT, et al. **Surg Endosc** 1997 Feb; 11(2):98–102 (33 ref.)
Laparoscopic surgery during pregnancy. Lemaire BM, et al. **Surg Endosc** 1997 Jan;11(1):15–8 (20 ref.)
Prenatal findings in chondrodysplasia punctata, tibia–metacarpal type. Argo KM, et al. **Ultrasound Obstet Gynecol** 1996 Nov;8(5):350–4 (14 ref.)
Neuroectodermal cyst may be a rare differential diagnosis of fetal sacrococcygeal teratoma: first case report of a prenatally observed neuroectodermal cyst. Bloechle M, et al. **Ultrasound Obstet Gynecol** 1996 Jan;7(1):64–7 (11 ref.)
Prenatal diagnosis of the split hand anomaly: how early is early? Haratz–Rubinstein N, et al. **Ultrasound Obstet Gynecol** 1996 Jul;8(1):57–61 (28 ref.)
Prenatal diagnosis of ectrodactyly: the 'lobster claw' anomaly. Leung KY, et al. **Ultrasound Obstet Gynecol** 1995 Dec;6(6):443–6 (16 ref.)
Abnormalities of the intra-abdominal fetal umbilical vein: reports of four cases and a review of the literature. Moore L, et al. **Ultrasound Obstet Gynecol** 1996 Jan;7(1):21–5 (16 ref.)
The prenatal sonographic appearance of enteric duplication cysts. Richards DS, et al. **Ultrasound Obstet Gynecol** 1996 Jan;7(1):17–20 (18 ref.)
Prenatal diagnosis of persistent right umbilical vein. Shen O, et al. **Ultrasound Obstet Gynecol** 1996 Jul;8(1):31–3 (20 ref.)
["Active" and "passive" smoking of pregnant women and risks to the child] Kaminski M. **Bull Acad Natl Med** 1997 Apr; 181(4):754–63 (52 ref.) **(Fre)**
[Home visits during pregnancy. Review of randomized studies and further questions] Blondel B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(5):515–22 (26 ref.) (Eng. Abstr.) **(Fre)**
[Adolescence and pregnancy in Guadeloupe. 184 cases] Gallais A, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(5):523–7 (28 ref.) (Eng. Abstr.) **(Fre)**
[The influence of chemical and physical factors in the work environment on the amount of risk for abnormal pregnancy outcome] Makowiec-Dąbrowska T, et al. **Med Pr** 1997; 48(3):239–59 (84 ref.) (Eng. Abstr.) **(Pol)**

EPIDEMIOLOGY

Environmental epidemiology at the Medical Birth Registry of Norway; strengths and limitations. Lie RT. **Cent Eur J Public Health** 1997 Jun;5(2):57–9 (6 ref.)
[Physical exertion at work and the course and outcome of pregnancy] Makowiec-Dąbrowska T, et al. **Med Pr** 1996; 47(6):629–49 (51 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

A review of the genetics of recurrent pregnancy loss. Trott EA, et al. **Del Med J** 1996 Oct;68(10):495–8 (22 ref.)

PREGNANCY, PROLONGED

Stillbirths and rate of neonatal deaths in 76,761 postterm pregnancies in Sweden, 1982–1991: a register study. Ingemarsson I, et al. **Acta Obstet Gynecol Scand** 1997 Aug; 76(7):658–62 (23 ref.)
Fetal testing in postdates. Bobby PD, et al. **Curr Opin Obstet Gynecol** 1997 Apr;9(2):79–82 (31 ref.)
Managing post-term pregnancy. **Drug Ther Bull** 1997 Mar; 35(3):17–8 (19 ref.)

PREGNANCY PROTEINS

CHEMISTRY

TJ6: the pregnancy-associated cytokine. Beaman K, et al. **Am J Reprod Immunol** 1996 Apr;35(4):338–41 (21 ref.)

IMMUNOLOGY

Placental interferons. Bazer FW, et al. **Am J Reprod Immunol** 1996 Apr;35(4):297–308 (109 ref.)
Human placental Fc gamma-binding proteins in the maternofetal transfer of IgG. Kristoffersen EK. **APMIS Suppl** 1996;64:5–36 (375 ref.)

METABOLISM

Human placental Fc gamma-binding proteins in the maternofetal transfer of IgG. Kristoffersen EK. **APMIS Suppl** 1996;64:5–36 (375 ref.)

PHARMACOLOGY

Effect of histone-H2A (H-H2A), platelet activating factor (PAF) and pregnancy specific protein B (PSPB) on secretion of prostaglandins E and F2 alpha (PGE; PGF2 alpha) by bovine endometrium and H-H2A on basal secretion of luteinizing hormone (LH) by bovine pituitary cells in vitro. Weems CW, et al. **Chin J Physiol** 1996; 39(3):147–54 (53 ref.)

PHYSIOLOGY

Interferon tau: a novel pregnancy recognition signal. Bazer FW, et al. **Am J Reprod Immunol** 1997 Jun;37(6):412–20 (53 ref.)
TJ6: the pregnancy-associated cytokine. Beaman K, et al. **Am J Reprod Immunol** 1996 Apr;35(4):338–41 (21 ref.)
Placental cytokines and the pathogenesis of preeclampsia. Conrad KP, et al. **Am J Reprod Immunol** 1997 Mar; 37(3):240–9 (129 ref.)
Glycodelins as regulators of early events of reproduction. Seppälä M, et al. **Clin Endocrinol (Oxf)** 1997 Apr; 46(4):381–6 (46 ref.)
tau-Interferon: pregnancy recognition signal in ruminants. Spencer TE, et al. **Proc Soc Exp Biol Med** 1996 Dec; 213(3):215–29 (110 ref.)
Recent developments and potentialities for reducing embryo mortality in ruminants: the role of IFN-tau and other cytokines in early pregnancy. Martal J, et al. **Reprod Fertil Dev** 1997;9(3):355–80 (250 ref.)

PREGNANCY RATE

Women's hormone concentrations and the increasing rates of ectopic pregnancy [see comments] James WH. **Hum Reprod** 1996 Feb;11(2):233–5 (34 ref.) Comment in: Hum Reprod 1996 Feb;11(2):235–6.
Increasing the efficiency of suckled calf production using embryo transfer technology. Sinclair KD, et al. **Vet Rec** 1996 Oct 26;139(17):409–12 (25 ref.)

PREGNANCY REDUCTION, MULTIFETAL

Ethical issues surrounding multifetal pregnancy reduction and selective termination. Evans MI, et al. **Clin Perinatol** 1996 Sep;23(3):437–51 (42 ref.)
Congenital abnormalities in twins: selective termination. Stewart KS, et al. **Curr Opin Obstet Gynecol** 1997 Apr; 9(2):136–9 (13 ref.)
First trimester fetal reduction: its role in the management of twin and higher order multiple pregnancies. Brambati B, et al. **Hum Reprod Update** 1995 Jul;1(4):397–408 (47 ref.)
[Should fetal reduction be used in triplet pregnancies?] Nisand I. **Contracept Fertil Sex** 1997 Jun;25(6):423–8 (41 ref.) **(Fre)**

METHODS

Attempt to continue pregnancy of remaining fetuses after delivery of preceding fetus in multiple pregnancies before 24 weeks gestation: report of three cases. Ishikawa K, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Dec; 48(12):1161–4 (18 ref.)
Multifetal pregnancy reduction and selective termination. Stone J, et al. **Semin Perinatol** 1995 Oct;19(5):363–74 (66 ref.)
[Multiple pregnancies prevention in in vitro fertilization: limiting the number of transferred embryos to two maximum?] Antonine JM, et al. **Contracept Fertil Sex** 1996 Jan;24(1):52–5 (45 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Use of transvaginal ultrasound-guided puncture for elimination of equine pregnancies. Squires EL. **Vet Clin North Am Equine Pract** 1996 Apr;12(1):161–8 (19 ref.)

PREGNANCY, SECOND TRIMESTER see **PREGNANCY TRIMESTER, SECOND**

PREGNANCY, TEENAGE see **PREGNANCY IN ADOLESCENCE**

PREGNANCY TESTS

Is this patient pregnant? Can you reliably rule in or rule out early pregnancy by clinical examination? Bastian LA, et al. **JAMA** 1997 Aug 20;278(7):586–91 (21 ref.)

PREGNANCY TRIMESTER, FIRST

PHYSIOLOGY

Maternal circulation in the first-trimester human placenta--myth or reality? Jaffe R, et al. **Am J Obstet Gynecol** 1997 Mar;176(3):695–705 (53 ref.)
Intervillous circulation in the first trimester: the phantom of the color Doppler obstetric opera [editorial] Jauniaux E. **Ultrasound Obstet Gynecol** 1996 Aug;8(2):73–6 (21 ref.)

PREGNANCY TRIMESTER, SECOND

Recurrent second trimester miscarriage. Flint S, et al. **Curr Opin Obstet Gynecol** 1996 Dec;8(6):449–53 (45 ref.)

PREGNANCY, TUBAL

DIAGNOSIS

Bilateral tubal ectopic pregnancy: diagnostic pitfalls. De Graaf FL, et al. **Br J Clin Pract** 1997 Jan–Feb;51(1):56–8 (32 ref.)

SURGERY

[Laparoscopic management of extrauterine pregnancy] Borsellino G, et al. **Minerva Ginecol** 1995 Nov;47(11):471–6 (23 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Controversies and problems in the current management of tubal pregnancy. Maymon R, et al. **Hum Reprod Update** 1996 Nov–Dec;2(6):541–51 (82 ref.)

PREGNANCY, TUBAL

[Diagnosis and therapy of extrauterine pregnancy] Korell M, et al. **Gynakol Geburtshilfliche Rundsch** 1996;36(3):138–42 (14 ref.) (Eng. Abstr.) **(Ger)**

PREGNANCY, UNWANTED

Emergency contraception: a second chance at preventing adolescent unintended pregnancy. Gold MA. **Curr Opin Pediatr** 1997 Aug;9(4):300–9 (37 ref.)

Sexually transmitted diseases and unwanted pregnancies in chronically ill psychiatric patients [editorial] [see comments] Coverdale JH, et al. **Med J Aust** 1997 Mar 3; 166(5):231–2 (10 ref.) Comment in: Med J Aust 1997 Jun 16;166(12):665–6. Comment in: Med J Aust 1997 Jun 16;166(12):666. Comment in: Med J Aust 1997 Jun 16;166(12):666–7.

PSYCHOLOGY

Defining and measuring unintended pregnancy: issues and concerns. Petersen R, et al. **Womens Health Issues** 1997 Jul–Aug;7(4):234–40 (18 ref.)

STATISTICS & NUMERICAL DATA

Meeting unmet need: new strategies. Robey B, et al. **Popul Rep J** 1996 Sep;(43):1–35 (247 ref.)

Defining and measuring unintended pregnancy: issues and concerns. Petersen R, et al. **Womens Health Issues** 1997 Jul–Aug;7(4):234–40 (18 ref.)

PREGNANES

Pregnane glycosides. Deepak D, et al. **Fortschr Chem Org Naturst** 1997;71:169–325 (311 ref.)

PREGNANOLONE

[New intravenous anesthetics. Remifentanil, S(+)-ketamine, eltanolone and target controlled infusion] Albrecht S, et al. **Anaesthesist** 1996 Dec;45(12):1129–41 (85 ref.) (Eng. Abstr.) **(Ger)**

PREGNATRIENES

PHARMACOLOGY

Neuroprotective efficacy of microvascularly-localized versus brain-penetrating antioxidants. Hall ED, et al. **Acta Neurochir Suppl (Wien)** 1996;66:107–13 (23 ref.)

[Tirilazad mesylate (Freedox)—an effective inhibitor of lipid membrane peroxidation] Sániová B. **Bratisl Lek Listy** 1997 Jun;98(6):339–42 (20 ref.) (Eng. Abstr.) **(Slo)**

THERAPEUTIC USE

Efficacy and mechanisms of action of the cytoprotective lipid peroxidation inhibitor tirilazad mesylate in subarachnoid haemorrhage. Hall ED. **Eur J Anaesthesiol** 1996 May; 13(3):279–89 (55 ref.)

PREGNENEDIONES

ADMINISTRATION & DOSAGE

Controlled-release budesonide in Crohn's disease. **Drug Ther Bull** 1997 Apr;35(4):30–1 (13 ref.)

[A new trend of inhaled corticosteroid therapy in Japan] Sano Y. **Nippon Rinsho** 1996 Nov;54(11):3004–10 (16 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Budesonide in the management of patients with Crohn's disease. Thomson AB, et al. **Can J Gastroenterol** 1997 Apr; 11(3):255–60 (30 ref.)

Inhaled budesonide and adrenaline for croup. **Drug Ther Bull** 1996 Mar;34(3):23–4 (19 ref.)

Budesonide in inflammatory bowel disease. Lamers CB, et al. **Neth J Med** 1996 Feb;48(2):60–3 (16 ref.)

PREHOSPITAL EMERGENCY CARE see **EMERGENCY MEDICAL SERVICES**

PREIMPLANTATION PHASE

Preimplantation diagnosis in older patients—but of course! [see comments] Munné S, et al. **Hum Reprod** 1997 Mar; 12(3):413–4 (11 ref.) Comment in: Hum Reprod 1997 Apr;12(4):870–1. Comment in: Hum Reprod 1997 Apr;12(4):871.

Preimplantation diagnosis in older patients, To biopsy or not to biopsy? Reubinoff B, et al. **Hum Reprod** 1996 Oct; 11(10):2071–5 (52 ref.)

Preimplantation genetic diagnosis of inherited disease. Ao A. **Indian J Exp Biol** 1996 Dec;34(12):1177–82 (35 ref.)

Moisaicism in the human preimplantation embryo. Handyside AH. **Reprod Nutr Dev** 1996;36(6):643–9 (29 ref.)

Chromatin structure and gene expression in the preimplantation mammalian embryo. Thompson EM. **Reprod Nutr Dev** 1996;36(6):619–35 (91 ref.)

[The preimplantation diagnosis of genetic defects] Delimitreva SM, et al. **Akush Ginekol (Sofiia)** 1996; 35(4):25–7 (41 ref.) **(Bul)**

[Preimplantation genetic diagnosis. Technical and ethical aspects and international experiences] Laursen SB, et al. **Ugeskr Laeger** 1996 Oct 28;158(44):6248–52 (27 ref.) (Eng. Abstr.) **(Dan)**

GENETICS

Genetic and molecular studies on Om, a locus controlling mouse preimplantation development. Cohen-Tannoudj M, et al. **Acta Genet Med Gemellol (Roma)** 1996;45(1–2):3–14 (23 ref.)

Developmental control of heat shock and chaperone gene expression. Hsp 70 genes and heat shock factors during preimplantation phase of mouse development. Christians E, et al. **Cell Mol Life Sci** 1997 Feb;53(2):168–78 (62 ref.)

PHYSIOLOGY

Preimplantation development of the mammalian embryo and its regulation by growth factors. Stewart CL, et al. **Dev Genet** 1997;21(1):91–101 (125 ref.)

Peptide growth factors and preimplantation development. Kane MT, et al. **Hum Reprod Update** 1997 Mar–Apr; 3(2):137–57 (363 ref.)

Metabolic control during preimplantation mammalian development. Leese HJ. **Hum Reprod Update** 1995 Jan; 1(1):63–72 (106 ref.)

Oviductal-derived growth factors and cytokines: implication in preimplantation. Chegini N. **Semin Reprod Endocrinol** 1996 Aug;14(3):219–29 (93 ref.)

PREJUDICE

Stigma and socio-economic reintegration of leprosy sufferers in Nigeria. Awofeso N. **Acta Leprol** 1996;10(2):89–91 (12 ref.)

Hate crime violence and its emergency department management. Hutson HR, et al. **Ann Emerg Med** 1997 Jun; 29(6):786–91 (34 ref.)

Genetic discrimination and the employment provisions of the Americans with Disabilities Act: emerging legal, empirical, and policy implications. Blanck PD, et al. **Behav Sci Law** 1996 Autumn;14(4):411–32 (0 ref.)

Dissecting people and ignoring social structure: an analysis of individualism, public policy, and genetic labeling. Miringoff ML. **Behav Sci Law** 1996 Autumn;14(4):433–42 (36 ref.)

Understanding and countering racism with first nations children in out-of-home care. Palmer S, et al. **Child Welfare** 1996 Nov–Dec;75(6):709–25 (20 ref.)

Either a paradigm shift or no mental measurement: the nonscience and the nonsense of The Bell Curve. Hilliard AG 3rd. **Cult Divers Ment Health** 1996;2(1):1–20 (37 ref.)

Rethinking the relationships between disability, rehabilitation, and society. Imrie R. **Disabil Rehabil** 1997 Jul;19(7):263–71 (37 ref.)

The symphony of the damned: racial discourse, complex political emergencies and humanitarian aid. Duffield M. **Disasters** 1996 Sep;20(3):173–93 (45 ref.)

Toward a conceptualization of race in epidemiologic research. Herman AA. **Ethn Dis** 1996 Winter–Spring; 6(1–2):7–20 (64 ref.)

Institutional racism and the medical/health complex: a conceptual analysis. King G. **Ethn Dis** 1996 Winter–Spring; 6(1–2):30–46 (99 ref.)

Why we should continue to study race...but do a better job: an essay on race, racism and health. La Veist TA. **Ethn Dis** 1996 Winter–Spring;6(1–2):21–9 (85 ref.)

Are black Americans entitled to equal health care? a new research paradigm. Menefee LT. **Ethn Dis** 1996 Winter–Spring;6(1–2):56–68 (47 ref.)

Racism and the mental health of African Americans: the role of self and system blame. Neighbors HW, et al. **Ethn Dis** 1996 Winter–Spring;6(1–2):167–75 (53 ref.)

Racism and perinatal addiction. Neuspiel DR. **Ethn Dis** 1996 Winter–Spring;6(1–2):47–55 (45 ref.)

Segregation, discrimination and mortality in U.S. blacks. Polednak AP. **Ethn Dis** 1996 Winter–Spring;6(1–2):99–108 (67 ref.)

Racism and children's health: issues in development. Williams-Morris RS. **Ethn Dis** 1996 Winter–Spring; 6(1–2):69–82 (49 ref.)

Working with lesbians, gays, and bisexuals: addressing heterosexism in supervision [see comments] Long JK. **Fam Process** 1996 Sep;35(3):377–88 (69 ref.) Comment in: Fam Process 1996 Sep;35(3):389–400.

Psychosocial assessment of organ transplant candidates and the Americans with Disabilities Act. Orentlicher D. **Gen Hosp Psychiatry** 1996 Nov;18(6 Suppl):5S–12S (24 ref.)

America's most cruel xenophobia. Keigher SM. **Health Soc Work** 1997 Aug;22(3):232–7 (15 ref.)

Men in nursing: issues of gender segregation and hidden advantage. Evans J. **J Adv Nurs** 1997 Aug;26(2):226–31 (30 ref.)

Is non-judgemental care possible in the context of nurses' attitudes to patients' sexuality? Hayter M. **J Adv Nurs** 1996 Oct;24(4):662–6 (39 ref.)

Genetic discrimination and health insurance: a call for legislative action. Rothenberg KH. **J Am Med Womens Assoc** 1997 Winter;52(1):43–4 (16 ref.)

A two way view of gender bias in medicine [editorial] Ruiz MT, et al. **J Epidemiol Community Health** 1997 Apr; 51(2):106–9 (45 ref.)

The protagonists of 'evidence-based medicine': arrogant, seductive and controversial. Polychronis A, et al. **J Eval Clin Pract** 1996 Feb;2(1):9–12 (30 ref.)

Activism and marginalization in the AIDS crisis. Hallett MA. **J Homosex** 1997;32(3–4):1–16 (40 ref.)

Gatekeeping through media format: strategies of voice for the HIV-positive via human interest news formats and organizations. Hallett MA, et al. **J Homosex** 1997; 32(3–4):17–36 (25 ref.)

The undertreatment of anxiety: overcoming the confusion and stigma. Blair DT, et al. **J Psychosoc Nurs Ment Health Serv** 1996 Jun;34(6):9–18 (72 ref.)

Occupational health issues under employment discrimination law. Stillman NG, et al. **Occup Med** 1996 Jan–Mar; 11(1):41–55 (93 ref.)

Intra-household allocation of food and health care: current findings and understandings--introduction. Messer E. **Soc Sci Med** 1997 Jun;44(11):1675–84 (46 ref.)

Gender perspectives and quality of care in underdeveloped countries: disease, gender and contextuality. Zaidi SA. **Soc Sci Med** 1996 Sep;43(5):721–30 (52 ref.)

PREKALLIKREIN

see related
COAGULANTS

PHYSIOLOGY

Contact activation: a revision. Schmaier AH. **Thromb Haemost** 1997 Jul;78(1):101–7 (65 ref.)

PRELEUKEMIA

GENETICS

c-myc amplification in a preleukemia patient with trisomy 4 and double minutes: review of the unique coexistence of these two chromosome abnormalities in acute myelogenous leukemia. Reddy KS, et al. **Cancer Genet Cytogenet** 1997 Jun;95(2):206–9 (10 ref.)

PREMARIN see **ESTROGENS, CONJUGATED**

PREMATURE BEATS see **CARDIAC COMPLEXES, PREMATURE**

PREMATURE CARDIAC COMPLEXES see **CARDIAC COMPLEXES, PREMATURE**

PREMATURE VENTRICULAR BEATS see **VENTRICULAR PREMATURE COMPLEXES**

PREMATURE VENTRICULAR CONTRACTIONS see **VENTRICULAR PREMATURE COMPLEXES**

PREMEDICATION

see related
ANTIBIOTIC PROPHYLAXIS
PREANESTHETIC MEDICATION

Quinolone prophylaxis in transurethral surgery. Gasser TC. **Chemotherapy** 1996 Mar;42 Suppl 1:28–32 (30 ref.)

The pilocarpine paradox [editorial; comment] Ritch R. **J Glaucoma** 1996 Aug;5(4):225–7 (33 ref.) Comment on: J Glaucoma 1996 Aug;5(4):228–32.

Combined androgen blockade in the treatment of advanced prostate cancer—an overview. The Scandinavian Prostatic Cancer Group. Iversen P. **Scand J Urol Nephrol** 1997 Jun; 31(3):249–54 (33 ref.)

[Premedication in pheochromocytoma] Förster G, et al. **Zentralbl Chir** 1997;122(6):454–9 (29 ref.) (Eng. Abstr.) **(Ger)**

METHODS

[Pharmacological preparation of the endometrium in surgical hysteroscopy] Primiero FM, et al. **Clin Ter** 1996 May; 147(5):245–51 (43 ref.) (Eng. Abstr.) **(Ita)**

PREMENOPAUSE

Evidence-guided prescribing of combined oral contraceptives: consensus statement. An International Workshop at Mottram Hall, Wilmslow, U.K., March, 1996. Hannaford PC, et al. **Contraception** 1996 Sep;54(3):125–9 (2 ref.)

Perimenopausal obesity. Milewicz A, et al. **Gynecol Endocrinol** 1996 Aug;10(4):285–91 (68 ref.)

Unraveling bleeding problems in midlife women. Dean CL. **Hosp Pract (Off Ed)** 1996 Sep 15;31(9):155–60 (7 ref.)

Is it time to develop an optimal endocrine therapy for premenopausal patients with axillary node positive and negative breast cancer? Bilimoria MM, et al. **Semin Surg Oncol** 1996 Sep–Oct;12(5):339–45 (44 ref.)

PHYSIOLOGY

The menopause transition. Greendale GA, et al. **Endocrinol Metab Clin North Am** 1997 Jun;26(2):261–77 (121 ref.)

Gonadotropins and ovarian gonadotropin receptors during the perimenopausal transition period. Vihko KK. **Maturitas** 1996 May;23 Suppl:S19–22 (26 ref.)

PREMENSTRUAL SYNDROME

Premenstrual syndrome: current perspectives on treatment and etiology. Freeman EW. **Curr Opin Obstet Gynecol** 1997 Jun;9(3):147–53 (83 ref.)
Premenstrual dysphoric disorder. An update. Steiner M. **Gen Hosp Psychiatry** 1996 Jul;18(4):244–50 (75 ref.)

COMPLICATIONS

Menstrual migraines: etiology, treatment, and relationship to premenstrual syndrome. Kornstein SG, et al. **Curr Opin Obstet Gynecol** 1997 Jun;9(3):154–9 (67 ref.)

DIAGNOSIS

Premenstrual syndromes. Steiner M. **Annu Rev Med** 1997; 48:447–55 (67 ref.)
Anxiety symptoms and anxiety disorders: how are they related to premenstrual disorders? Yonkers KA. **J Clin Psychiatry** 1997;58 Suppl 3:62–7; discussion 68–9 (50 ref.)

ETIOLOGY

The female brain hypoestrogenic continuum from the premenstrual syndrome to menopause. A hypothesis and review of supporting data. Arpels JC. **J Reprod Med** 1996 Sep;41(9):633–9 (87 ref.)
[The etiology and pathogenesis of the premenstrual syndrome] Kolarov G, et al. **Akush Ginekol (Sofiia)** 1997; 36(1):24–5 (38 ref.) **(Bul)**
[Menstrual complaints. Etiology and therapy] Bosse-Bringewatt K. **Med Monatsschr Pharm** 1997 Jan; 20(1):9–16 (15 ref.) **(Ger)**

PHYSIOPATHOLOGY

Premenstrual exacerbation of symptoms in multiple sclerosis is attenuated by treatment with weak electromagnetic fields. Sandyk R. **Int J Neurosci** 1995 Dec;83(3–4):187–98 (139 ref.)

PSYCHOLOGY

The modal study on premenstrual syndrome or tension: a content analysis of 315 recent abstracts along global dimensions. Whissell C. **Psychol Rep** 1996 Dec;79(3 Pt 2):1360–2 (2 ref.)

THERAPY

Premenstrual syndrome. Mortola JF. **Curr Ther Endocrinol Metab** 1997;6:251–6 (8 ref.)
Premenstrual exacerbation of symptoms in multiple sclerosis is attenuated by treatment with weak electromagnetic fields. Sandyk R. **Int J Neurosci** 1995 Dec;83(3–4):187–98 (139 ref.)

PREMENSTRUAL TENSION see **PREMENSTRUAL SYNDROME**

PREMOLAR see **BICUSPID**

PRENATAL CARE

Scientific basis for the content of routine antenatal care. II. Power to eliminate or alleviate adverse newborn outcomes; some special conditions and examinations. Bergsjø P, et al. **Acta Obstet Gynecol Scand** 1997 Jan;76(1):15–25 (82 ref.)
Scientific basis for the content of routine antenatal care. I. Philosophy, recent studies, and power to eliminate or alleviate adverse maternal outcomes. Villar J, et al. **Acta Obstet Gynecol Scand** 1997 Jan;76(1):1–14 (130 ref.)
The future of prenatal HIV testing. Minkoff H, et al. **Acta Paediatr Suppl** 1997 Jun;421:72–7 (36 ref.)
Antenatal care. Which tests and when. Comerford JA. **Aust Fam Physician** 1997 Mar;26(3):229–35, 237 (7 ref.)
In utero haematopoietic stem cell transplantation: current perspectives and future potential. Jones DR, et al. **Bone Marrow Transplant** 1996 Nov;18(5):831–7 (62 ref.)
Prenatal care for low-income women and the health belief model: a new beginning. Stout AE. **J Community Health Nurs** 1997;14(3):169–80 (21 ref.)
Developmental care of the pregnant couple. Malnory ME. **J Obstet Gynecol Neonatal Nurs** 1996 Jul–Aug;25(6):525–32 (23 ref.)
Preterm birth, cerebral palsy and magnesium [news] Goldenberg RL, et al. **Nat Med** 1997 Feb;3(2):146–7 (10 ref.)
Preventing neural tube defects. Buehler JW, et al. **Pediatr Ann** 1997 Sep;26(9):535–9 (17 ref.)
Prevention of prematurity. Hobel CJ. **Pediatr Ann** 1996 Apr; 25(4):188; 191–8 (72 ref.)
Prenatal care. Helton MR. **Prim Care** 1997 Mar;24(1):135–46 (50 ref.)
[Fetal diaphragmatic hernia. Its prenatal and postnatal management] Ruseva R, et al. **Akush Ginekol (Sofiia)** 1996; 35(3):42–3 (8 ref.) **(Bul)**
[Periconceptional multivitamin administration result in reduction of congenital abnormalities: adequate evidence for formulating national recommendations for Germany?] Hort A, et al. **Gesundheitswesen** 1997 Apr;59(4):248–51 (20 ref.) (Eng. Abstr.) **(Ger)**
[Pre- and postgestational vaccination] Figueroa-Damián R. **Ginecol Obstet Mex** 1996 Jul;64:310–5 (27 ref.) (Eng. Abstr.) **(Spa)**

LEGISLATION & JURISPRUDENCE

Legislating to preserve women's autonomy during pregnancy. Feitshans IL. **Med Law** 1995;14(5–6):397–412 (40 ref.)

METHODS

Folic acid to prevent neural tube defects: scientific advances and public health issues. Mills JL, et al. **Curr Opin Obstet Gynecol** 1996 Dec;8(6):394–7 (18 ref.)
Group B streptococcus and pregnancy: update and recommendations. Mitchell A, et al. **MCN Am J Matern Child Nurs** 1997 Sep–Oct;22(5):242–8 (16 ref.)
Management of fetal cardiac arrhythmias. Copel JA, et al. **Obstet Gynecol Clin North Am** 1997 Mar;24(1):201–11 (34 ref.)
Cellular therapy. Flake AW, et al. **Obstet Gynecol Clin North Am** 1997 Mar;24(1):159–77 (20 ref.)
Fetal surgery. Quinn TM, et al. **Obstet Gynecol Clin North Am** 1997 Mar;24(1):143–57 (21 ref.)
Outcomes of enhanced prenatal services for Medicaid-eligible women in public and private settings. Simpson L, et al. **Public Health Rep** 1997 Mar–Apr; 112(2):122–32; discussion 133–4 (42 ref.)
Antepartum management of the multiple gestation: the case for specialized care. Newman RB, et al. **Semin Perinatol** 1995 Oct;19(5):387–403 (81 ref.)
Perinatal social work and the high risk obstetrics patient. Bachman DH, et al. **Soc Work Health Care** 1997; 24(3–4):3–19 (36 ref.)
Royal College of Physicians of Edinburgh/Royal College of Obstetricians and Gynaecologists consensus conference on anti-D prophylaxis 7 & 8 April 1997. Urbaniak SJ. **Transfus Med** 1997 Jun;7(2):143–4 (0 ref.)

ORGANIZATION & ADMINISTRATION

[Home visits during pregnancy. Review of randomized studies and further questions] Blondel B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(5):515–22 (26 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

[Obstetric perspectives: consensus of the gynecology department of the University of Liège. Document of the 3rd cycle studies, October 96] Biquet G, et al. **Rev Med Liege** 1997 Mar;52(3):142–8 (0 ref.) **(Fre)**

PRENATAL DIAGNOSIS

see related
GENETIC COUNSELING

Prenatal diagnosis of haemophilia. Ljung RC. **Baillieres Clin Haematol** 1996 Jun;9(2):243–57 (23 ref.)
Prenatally diagnosed neuroblastoma. Acharya S, et al. **Cancer** 1997 Jul 15;80(2):304–10 (46 ref.)
Control of beta-thalassaemia by carrier screening, genetic counselling and prenatal diagnosis: the Sardinian experience. Cao A, et al. **Ciba Found Symp** 1996; 197:137–51; discussion 151–5 (32 ref.)
Prenatal diagnosis of a de novo trisomy 6q22.2-->6qter and monosomy 1pter-->1p36.3. Case report with a 2-year follow-up and a brief review of other prenatal cases of partial trisomy 6q. Kulharya AS, et al. **Clin Genet** 1997 Feb;51(2):115–7 (2 ref.)
Should all pregnant women be offered carrier testing for fragile X syndrome? Finucane B. **Clin Obstet Gynecol** 1996 Dec;39(4):772–82 (21 ref.)
Maternal serum screening for fetal Down syndrome: clinical aspects. Saller DN Jr, et al. **Clin Obstet Gynecol** 1996 Dec; 39(4):783–92 (11 ref.)
Maternal serum screening for fetal Down syndrome: the detection of other pathologies. Saller DN Jr, et al. **Clin Obstet Gynecol** 1996 Dec;39(4):793–800 (12 ref.)
Detection of beta-core fragment in second trimester Down's syndrome pregnancies. Cole L, et al. **Early Hum Dev** 1996 Dec 30;47 Suppl:S47–8 (4 ref.)
Established markers in second trimester maternal serum. Cuckle H. **Early Hum Dev** 1996 Dec 30;47 Suppl:S27–9 (18 ref.)
Quality assessment of a prenatal screening program. Knight GJ. **Early Hum Dev** 1996 Dec 30;47 Suppl:S49–53 (6 ref.)
Risk communication; the patient's view. Thornton JG, et al. **Early Hum Dev** 1996 Dec 30;47 Suppl:S13–7 (17 ref.)
The moral aspects of prenatal diagnosis. Eisenberg VH, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Mar;72(1):35–45 (79 ref.)
Review: preimplantation diagnosis of inherited disease. Lissens W, et al. **J Inherit Metab Dis** 1996;19(6):709–23 (80 ref.)
Genetic counselling and prenatal diagnosis in disorders of the mitochondrial energy metabolism. Ruitenbeek W, et al. **J Inherit Metab Dis** 1996;19(4):581–7 (33 ref.)
Ethical dimensions in genetic screening: a look into the future. Penticuff JH. **J Obstet Gynecol Neonatal Nurs** 1996 Nov-Dec;25(9):785–9 (8 ref.)
Chorionic villus sampling and amniocentesis for prenatal diagnosis [see comments] Stranc LC, et al. **Lancet** 1997 Mar 8;349(9053):711–4 (50 ref.) Comment in: Lancet 1997 May 10;349(9062):1395–6; discussion 1396–7. Comment in: Lancet 1997 May 10;349(9062):1396; discussion 1396–7.
Legislating to preserve women's autonomy during pregnancy. Feitshans IL. **Med Law** 1995;14(5–6):397–412 (40 ref.)
Prenatal diagnosis of Duchenne and Becker muscular dystrophy. Abbs S. **Prenat Diagn** 1996 Dec;16(13):1187–98 (44 ref.)
Microdeletion and microduplication syndromes. Malcolm S. **Prenat Diagn** 1996 Dec;16(13):1213–9 (57 ref.)
Haemoglobinopathies. Old J. **Prenat Diagn** 1996 Dec; 16(13):1181–6 (46 ref.)
Prospects for DNA-based prenatal diagnosis of mitochondrial disorders. Poulton J, et al. **Prenat Diagn** 1996 Dec;16(13):1247–56 (41 ref.)
Genetic testing for familial hypercholesterolaemia: practical and ethical issues. Humphries SE, et al. **QJM** 1997 Mar; 90(3):169–81 (76 ref.)
Impact of the detection and prevention of developmental abnormalities in human studies. Holmes LB. **Reprod Toxicol** 1997 Mar–Jun;11(2–3):267–9 (19 ref.)
Prenatal diagnosis and management of neonatal alloimmune thrombocytopenia. Johnson JA, et al. **Semin Perinatol** 1997 Feb;21(1):45–52 (32 ref.)
Maternal serum markers for Down's syndrome pregnancies. Chew S, et al. **Singapore Med J** 1995 Aug;36(4):417–23 (85 ref.)
[The value and drawbacks of evaluation of the risk of fetal trisomy 21] Taieb J, et al. **Contracept Fertil Sex** 1997 Apr; 25(4):269–76 (53 ref.) **(Fre)**
[Varicella and pregnancy. Current literature] Lostie R, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(7):719–22 (5 ref.) (Eng. Abstr.) **(Fre)**
[Prenatal diagnosis of orthopedic anomalies] Ganel A, et al. **Harefuah** 1997 May 1;132(9):649–52 (29 ref.) **(Heb)**
[Fetal heart rhythm disorders. Detection and prenatal management] Zielinsky P. **Arq Bras Cardiol** 1996 Feb; 66(2):83–6 (25 ref.) **(Por)**

ADVERSE EFFECTS

Risk of fetal infection from invasive procedures. Workman MR, et al. **J Hosp Infect** 1997 Mar;35(3):169–74 (20 ref.)

METHODS

Uniparental disomy (UPD). Genomic imprinting and a case for new genetics (prenatal and clinical implications: the "Likon" concept). Engel E. **Ann Genet** 1997;40(1):24–34 (74 ref.)
Preimplantation polar body diagnosis. Verlinsky Y, et al. **Biochem Mol Med** 1996 Jun;58(1):13–7 (20 ref.)
First trimester pregnancy: ultrasound and biochemical evaluation. Daly S, et al. **Br J Hosp Med** 1996 Sep 4–17; 56(5):225–7 (20 ref.)
MRCOG. Screening for fetal abnormalities. Smith NC. **Br J Hosp Med** 1996 Jun 5–18;55(11):679–82 (15 ref.)
Customised fetal growth assessment. Leeson S, et al. **Br J Obstet Gynaecol** 1997 Jun;104(6):648–51 (38 ref.)
Noninvasive screening for prenatal genetic diagnosis. Simpson JL. **Bull World Health Organ** 1995;73(6):799–804 (36 ref.)
Prenatal diagnosis using fetal cells isolated from maternal peripheral blood: a review. Steele CD, et al. **Clin Obstet Gynecol** 1996 Dec;39(4):801–13 (41 ref.)
Prenatal diagnosis of congenital diaphragmatic hernia with predictors of mortality. Wilcox DT, et al. **Clin Perinatol** 1996 Dec;23(4):701–9 (41 ref.)
Epidemiology of antepartum fetal testing. Ananth CV, et al. **Curr Opin Obstet Gynecol** 1997 Apr;9(2):101–6 (12 ref.)
Fetal testing in postdates. Bobby PD, et al. **Curr Opin Obstet Gynecol** 1997 Apr;9(2):79–82 (31 ref.)
Fetal testing in intra-uterine growth retardation. Snijders R, et al. **Curr Opin Obstet Gynecol** 1997 Apr;9(2):91–5 (51 ref.)
Congenital abnormalities in twins: selective termination. Stewart KS, et al. **Curr Opin Obstet Gynecol** 1997 Apr; 9(2):136–9 (13 ref.)
Overview of screening techniques. Recent advances in prenatal diagnosis for aneuploidy. Chard T. **Early Hum Dev** 1996 Dec 30;47 Suppl:S3–4 (0 ref.)
Urinary analysis for Down's syndrome: is the measurement of urinary beta-core the future of biochemical screening for Down's syndrome. Iles RK. **Early Hum Dev** 1996 Dec 30;47 Suppl:S41–5 (18 ref.)
Application of PCR for fetal cell detection. Lo YM. **Early Hum Dev** 1996 Dec 30;47 Suppl:S73–7 (26 ref.)
Markers for Down's syndrome in early pregnancy. Van Lith JM. **Early Hum Dev** 1996 Dec 30;47 Suppl:S105–9 (24 ref.)
Preimplantation genetic diagnosis of inherited disease. Ao A. **Indian J Exp Biol** 1996 Dec;34(12):1177–82 (35 ref.)
Screening for Down's syndrome. Chard T, et al. **J Perinat Med** 1995;23(6):421–36 (170 ref.)
Prenatal diagnosis of inherited skin diseases. Shimizu H. **Keio J Med** 1996 Mar;45(1):28–36 (55 ref.)
Management of fetal cardiac arrhythmias. Copel JA, et al. **Obstet Gynecol Clin North Am** 1997 Mar;24(1):201–11 (34 ref.)
DNA diagnosis for the practicing obstetrician. Gupta GK, et al. **Obstet Gynecol Clin North Am** 1997 Mar;24(1):123–42 (74 ref.)

PRENATAL DIAGNOSIS

Maternal serum screening for fetal genetic disorders. Ross HL, et al. **Obstet Gynecol Clin North Am** 1997 Mar; 24(1):33–47 (51 ref.)

The elusive search for fetal infection. Changing the gold standards. Weiner CP. **Obstet Gynecol Clin North Am** 1997 Mar;24(1):19–32 (67 ref.)

Hydrops fetalis: recent advances. Forouzan I. **Obstet Gynecol Surv** 1997 Feb;52(2):130–8 (99 ref.)

Prenatal diagnosis using fetal cells from the maternal circulation. Lamvu G, et al. **Obstet Gynecol Surv** 1997 Jul; 52(7):433–7 (21 ref.)

Strategies for the prenatal diagnosis of primary hyperoxaluria type 1. Danpure CJ, et al. **Prenat Diagn** 1996 Jul; 16(7):587–98 (36 ref.)

Syndromes in twins. D'Alton ME, et al. **Semin Perinatol** 1995 Oct;19(5):375–86 (103 ref.)

Antenatal assessment of twin gestation. Devoe LD, et al. **Semin Perinatol** 1995 Oct;19(5):413–23 (54 ref.)

Genetic diagnosis in multiple pregnancies. Wapner RJ. **Semin Perinatol** 1995 Oct;19(5):351–62 (61 ref.)

Preimplantation genetic diagnosis: strategies and surprises. Handyside AH, et al. **Trends Genet** 1997 Jul;13(7):270–5 (37 ref.)

[The preimplantation diagnosis of genetic defects] Delimitreva SM, et al. **Akush Ginekol (Sofiia)** 1996; 35(4):25–7 (41 ref.) **(Bul)**

[Genetic diagnosis of the embryo before implantation] David G. **Bull Acad Natl Med** 1997 Feb;181(2):261–72; discussion 272–4 (24 ref.) (Eng. Abstr.) **(Fre)**

[Prognosis of prenatal uropathies: should fetal urine tests be continued?] Bensman A. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(5):510–4 (28 ref.) (Eng. Abstr.) **(Fre)**

[Value and limits of complementary investigations in cases of toxoplasmosis seroconversion during pregnancy. A case report and review of the literature] Therby D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(5):505–9 (14 ref.) (Eng. Abstr.) **(Fre)**

[Prenatal diagnosis: methods—indications—risks] Kienholz–Only C. **Fortschr Med** 1997 Jul 10;115(19):24–7 (12 ref.) (Eng. Abstr.) **(Ger)**

[Index of fetal maturity] Klimek R. **Ginekol Pol** 1996 Dec; 67(12):615–9 (5 ref.) (Eng. Abstr.) **(Pol)**

[Control of hereditary thrombophilia through detection of carriage and prenatal diagnosis] Seligson U. **Vestn Ross Akad Med Nauk** 1997;(1):27–9 (25 ref.) **(Rus)**

[Preimplantation genetic diagnosis. An alternative to traditional prenatal diagnosis] Iwarsson E, et al. **Lakartidningen** 1997 Aug 27;94(35):2919–22 (15 ref.) **(Swe)**

NURSING

Fetal surveillance: issues and implications. Raines DA. **J Obstet Gynecol Neonatal Nurs** 1996 Sep;25(7):559–64 (21 ref.)

PSYCHOLOGY

Counseling prenatal diagnosis patients: the role of the social worker. Fertel PE, et al. **Soc Work Health Care** 1997; 24(3–4):47–63 (28 ref.)

STATISTICS & NUMERICAL DATA

Detection rates and false positive rates for Down syndrome screening: how precisely can they be estimated? Gray JC, et al. **Early Hum Dev** 1996 Dec 30;47 Suppl:S59–61 (2 ref.)

TRENDS

Ethical problems in prenatal diagnosis: pediatric considerations. Lenard G. **Brain Dev** 1995;17 Suppl:44–7 (14 ref.)

Progress in the genetic analysis of fetal cells circulating in maternal blood. Bianchi DW. **Curr Opin Obstet Gynecol** 1997 Apr;9(2):121–5 (33 ref.)

[Changes in prenatal diagnosis. Hope for many couples—ethical problems unavoidable] Strobel E. **Fortschr Med** 1997 Jul 10;115(19):23 (12 ref.) **(Ger)**

UTILIZATION

Prenatal diagnosis in France. Aymé S, et al. **Eur J Hum Genet** 1997;5 Suppl 1:26–31 (12 ref.)

Prenatal diagnosis in the Netherlands. Dutch Working Party of Prenatal Diagnosis. Leschot NJ, et al. **Eur J Hum Genet** 1997;5 Suppl 1:51–6 (34 ref.)

Prenatal diagnosis in the United Kingdom—an overview. Lowther GW, et al. **Eur J Hum Genet** 1997;5 Suppl 1:84–9 (17 ref.)

Prenatal diagnosis in Denmark. Lundsteen C, et al. **Eur J Hum Genet** 1997;5 Suppl 1:14–21 (38 ref.)

Prenatal diagnosis in Finland. Salonen R, et al. **Eur J Hum Genet** 1997;5 Suppl 1:22–5 (24 ref.)

Prenatal diagnosis in Germany. Wegner RD, et al. **Eur J Hum Genet** 1997;5 Suppl 1:32–8 (5 ref.)

PRENATAL DIAGNOSIS, ULTRASONIC see **ULTRASONOGRAPHY, PRENATAL**

PRENATAL EXPOSURE DELAYED EFFECTS

see related
MATERNAL EXPOSURE
PATERNAL EXPOSURE

Prenatal determinants of motor disorders. Stanley FJ. **Acta Paediatr Suppl** 1997 Jul;422:92–102 (65 ref.)

Prenatal cocaine exposure and mother–infant interaction: implications for occupational therapy intervention. Miller H. **Am J Occup Ther** 1997 Feb;51(2):119–31 (100 ref.)

Risk of childhood cancer from fetal irradiation [see comments] Doll R, et al. **Br J Radiol** 1997 Feb;70:130–9 (59 ref.) Comment in: Br J Radiol 1997 Jul;70(835):769–70; discussion 771. Comment in: Br J Radiol 1997 Jul;70(835):770–1.

Fetal nutrition and cardiovascular disease in later life. Barker DJ. **Br Med Bull** 1997 Jan;53(1):96–108 (54 ref.)

Infections in childhood and pregnancy as a cause of adult disease—methods and examples. Hall AJ, et al. **Br Med Bull** 1997 Jan;53(1):10–23 (33 ref.)

Nutrition and cognitive development. Morley R, et al. **Br Med Bull** 1997 Jan;53(1):123–34 (45 ref.)

Effects of the intrauterine environment on childhood growth. Strauss RS. **Br Med Bull** 1997 Jan;53(1):81–95 (59 ref.)

Environmental epidemiology at the Medical Birth Registry of Norway; strengths and limitations. Lie RT. **Cent Eur J Public Health** 1997 Jun;5(2):57–9 (6 ref.)

Nutritional influences in early life upon obesity and body proportions. Jackson AA, et al. **Ciba Found Symp** 1996; 201:118–29; discussion 129–37, 188–93 (54 ref.)

Maternal risk factors in asthma. Martinez FD. **Ciba Found Symp** 1997;206:233–9; discussion 239–43 (40 ref.)

Prenatal origins of asthma and allergy. Warner JA, et al. **Ciba Found Symp** 1997;206:220–8; discussion 228–32 (48 ref.)

Adverse consequences of prenatal illicit drug exposure. Woods JR Jr. **Curr Opin Obstet Gynecol** 1996 Dec; 8(6):403–11 (71 ref.)

Maternal cocaine use: impact on child health and development. Frank DA, et al. **Curr Probl Pediatr** 1996 Feb;26(2):57–70 (159 ref.)

Long–term effects of internally deposited alpha–particle emitting radionuclides. Epidemiological, pathological and molecular–biological studies of Danish Thorotrast–administered patients and their offspring. Andersson M. **Dan Med Bull** 1997 Apr;44(2):169–90 (140 ref.)

Evolution of our understanding of methylmercury as a health threat. Watanabe C, et al. **Environ Health Perspect** 1996 Apr;104 Suppl 2:367–79 (69 ref.)

Prenatal factors influencing long–term outcome. Dennison E, et al. **Horm Res** 1997;48 Suppl 1:25–9 (27 ref.)

Puberty in children with intrauterine growth retardation. Preece MA. **Horm Res** 1997;48 Suppl 1:30–2 (11 ref.)

Reproductive risks of cocaine. Rizk B, et al. **Hum Reprod Update** 1996 Jan–Feb;2(1):43–55 (119 ref.)

In utero medroxyprogesterone exposure after contraceptive failure [see comments] Brady JE, et al. **J Am Board Fam Pract** 1996 Jul–Aug;9(4):285–8 (38 ref.) Comment in: J Am Board Fam Pract 1996 Nov–Dec;9(6):467.

Stillbirth after occupational exposure to N–methyl–2–pyrrolidone. A case report and review of the literature [see comments] Solomon GM, et al. **J Occup Environ Med** 1996 Jul;38(7):705–13 (58 ref.) Comment in: J Occup Environ Med 1997 May;39(5):393–4.

Pregnancy outcome and neurodevelopment of children exposed in utero to psychoactive drugs: the Motherisk experience. Loebstein R, et al. **J Psychiatry Neurosci** 1997 May;22(3):192–6 (21 ref.)

Exposure to a xenoestrogen before birth: the diethylstilbestrol experience. Palmlund I. **J Psychosom Obstet Gynaecol** 1996 Jun;17(2):71–84 (144 ref.)

Intrauterine programming of hypertension by glucocorticoids. Langley–Evans SC. **Life Sci** 1997; 60(15):1213–21 (96 ref.)

Epidemiologic perspective of the developmental neurotoxicity of PCBs in humans. Buck GM. **Neurotoxicol Teratol** 1996 May–Jun;18(3):239–41; discussion 271–6 (11 ref.)

Comments on "developmental neurotoxicity of PCBs in humans: what do we know and where do we go from here"? Gray LE Jr. **Neurotoxicol Teratol** 1996 May–Jun; 18(3):243–5; discussion 271–6 (9 ref.)

Sources and implications of interstudy and interindividual variability in the developmental neurotoxicity of PCBs. Jacobson JL, et al. **Neurotoxicol Teratol** 1996 May–Jun; 18(3):257–64; discussion 271–6 (63 ref.)

Adopting a public health approach to developmental neurotoxicity. Paneth N. **Neurotoxicol Teratol** 1996 May–Jun;18(3):233–4; discussion 271–6 (6 ref.)

PCBs and behavioral impairment: are there lessons we can learn from lead? Rice DC. **Neurotoxicol Teratol** 1996 May–Jun;18(3):229–32; discussion 271–6 (28 ref.)

Developmental neurotoxicity of PCBs in humans: what do we know and where do we go from here? [see comments] Schantz SL. **Neurotoxicol Teratol** 1996 May–Jun; 18(3):217–27; discussion 229–76 (73 ref.) Comment in: Neurotoxicol Teratol 1997 Jan–Feb;19(1):1–5.

Can epidemiological studies discern subtle neurological effects due to perinatal exposure to PCBs? Seegal RF. **Neurotoxicol Teratol** 1996 May–Jun;18(3):251–4; discussion 271–6 (32 ref.)

Sensory and cognitive effects of developmental methylmercury exposure in monkeys, and a comparison to effects in rodents. Rice DC. **Neurotoxicology** 1996 Spring;17(1):139–54 (58 ref.)

Comparability of human and animal studies of developmental cocaine exposure. Dow–Edwards D. **NIDA Res Monogr** 1996;164:146–74 (97 ref.)

Behavioral outcomes in preschool and school–age children exposed prenatally to marijuana: a review and speculative interpretation. Fried PA. **NIDA Res Monogr** 1996; 164:242–60 (50 ref.)

Prenatal drug exposure: behavioral functioning in late childhood and adolescence. Hans SL. **NIDA Res Monogr** 1996;164:261–76 (30 ref.)

Exposure to opiates: behavioral outcomes in preschool and school–age children. Kaltenbach KA. **NIDA Res Monogr** 1996;164:230–41 (30 ref.)

Prenatal exposure to drugs of abuse: methodological considerations and effects on sexual differentiation. McGivern RF, et al. **NIDA Res Monogr** 1996;164:78–124 (219 ref.)

Exposure to cocaine: behavioral outcomes in preschool and school–age children. Mayes LC. **NIDA Res Monogr** 1996; 164:211–29 (55 ref.)

The effects of prenatal cocaine exposure on subsequent learning in the rat. Riley EP, et al. **NIDA Res Monogr** 1996;164:53–77 (13 ref.)

Assessment of the effects of developmental toxicants: pharmacological and stress vulnerability of offspring. Spear LP. **NIDA Res Monogr** 1996;164:125–45 (42 ref.)

Long–term effects of developmental exposure to cocaine on learned and unlearned behaviors. Vorhees CV. **NIDA Res Monogr** 1996;164:3–52 (61 ref.)

Drug effects: a search for outcomes. Zuckerman B. **NIDA Res Monogr** 1996;164:277–87 (29 ref.)

Intrauterine programming of hypertension: nutrient–hormone interactions. Langley–Evans S, et al. **Nutr Rev** 1996 Jun; 54(6):163–9 (59 ref.)

Sudden infant death syndrome and parental smoking—a literature review. Golding J. **Paediatr Perinat Epidemiol** 1997 Jan;11(1):67–77 (29 ref.)

New approaches for assessing the etiology and risks of developmental abnormalities from chemical exposure. Goldman LR. **Reprod Toxicol** 1997 Mar–Jun; 11(2–3):443–51 (62 ref.)

Reproductive toxicology in animals with induced and spontaneous diabetes. Kalter H. **Reprod Toxicol** 1996 Nov–Dec;10(6):417–38 (144 ref.)

The impact of prenatal cocaine exposure: studies of the developing infant. Landry SH, et al. **Semin Perinatol** 1996 Apr;20(2):99–106 (39 ref.)

[A child at all costs? At what price? Consequences for the child: experimental data] Auroux M. **Contracept Fertil Sex** 1997 Apr;25(4):277–9 (19 ref.) **(Fre)**

[Possible contribution of hyperglycemia in utero to glucose homeostasis disorders in the adult] Ktorza A, et al. **Journ Annu Diabetol Hotel Dieu** 1997;:55–68 (43 ref.) **(Fre)**

[Atenolol: its cardiorespiratory effects at birth in a premature infant] Zanardo V, et al. **Pediatr Med Chir** 1997 May–Jun; 19(3):149–51 (8 ref.) **(Ita)**

[Toxic effects of fluorine compounds on the the fetus and their effect on the course of pregnancy] Chlubek D, et al. **Ginekol Pol** 1996 Aug;67(8):414–8 (21 ref.) (Eng. Abstr.) **(Pol)**

[The influence of lead on fetal development] Nowak–Węgrzyn A, et al. **Przegl Lek** 1996;53(10):744–9 (29 ref.) (Eng. Abstr.) **(Pol)**

[Intrauterine exposure to drugs] Legido A. **Rev Neurol** 1997 May;25(141):691–702 (120 ref.) (Eng. Abstr.) **(Spa)**

PRENEOPLASTIC CONDITIONS see **PRECANCEROUS CONDITIONS**

PRENIDATION PHASE see **PREIMPLANTATION PHASE**

PRENYLTRANSFERASE see **DIMETHYLALLYLTRANSTRANSFERASE**

PREOPERATIVE CARE

Preparation of adult patients for anaesthesia and surgery. Arvidsson S. **Acta Anaesthesiol Scand** 1996 Sep;40(8 Pt 2):962–70 (40 ref.)

Excretory urography before prostatectomy. Ntia IO, et al. **Afr J Med Med Sci** 1996 Mar;25(1):75–9 (11 ref.)

Preoperative transcatheter arterial embolization for giant cavernous hemangioma of the liver with consumption coagulopathy. Suzuki H, et al. **Am J Gastroenterol** 1997 Apr;92(4):688–91 (29 ref.)

Preoperative and postoperative care of the elderly woman. Barber HR. **Clin Obstet Gynecol** 1996 Dec;39(4):902–5 (7 ref.)

Sedation in children: adequacy of two–hour fasting [see comments] Ingebo KR, et al. **J Pediatr** 1997 Jul;131(1 Pt 1):155–8 (26 ref.) Comment in: J Pediatr 1997 Jul;131(1 Pt 1):12–3.

Anesthesiology. First of two parts. Wiklund RA, et al. **N Engl J Med** 1997 Oct 16;337(16):1132–41 (100 ref.)
Therapeutic approach to organ transplantation. Strom TB, et al. **Nephrol Dial Transplant** 1996 Jun;11(6):1176–81 (44 ref.)
Care of the pediatric patient in ambulatory surgery. Lancaster KA. **Nurs Clin North Am** 1997 Jun;32(2):441–55 (19 ref.)
Preoperative pulmonary evaluation. Identifying patients at increased risk for complications. Mohr DN, et al. **Postgrad Med** 1996 Nov;100(5):241–4, 247–8, 251–2 passim (28 ref.)
The value of peri–operative nutrition in the sick patient. Heys SD, et al. **Proc Nutr Soc** 1997 Mar;56(1B):443–57 (69 ref.)
Importance of preincisional analgesia. Abram SE. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):117–21 (31 ref.)
[Beautifying the breast] Le Gouès G. **Contracept Fertil Sex** 1997 Jun;25(6):475–81 (31 ref.) (Eng. Abstr.) **(Fre)**
[Specificity of the anesthetic consultation for ambulatory surgery] Forster A, et al. **Rev Med Suisse Romande** 1997 May;117(5):371–3 (1 ref.) **(Fre)**
[Preoperative evaluation for anesthesia] Wilhelm W, et al. **Anaesthesist** 1997 Jul;46(7):629–39 (10 ref.) **(Ger)**
[Perioperative nutritional therapy and its relevance for postoperative outcome] Müller JM, et al. **Chirurg** 1997 Jun; 68(6):574–82 (44 ref.) (Eng. Abstr.) **(Ger)**
[Vital preoperative function diagnosis in deep anterior rectum resection] Stern J, et al. **Chirurg** 1996 Feb;67(2):129–32 (20 ref.) (Eng. Abstr.) **(Ger)**
[Preoperative evaluation of aged patients] Meguro K, et al. **Masui** 1996 Dec;45 Suppl:S143–6 (5 ref.) **(Jpn)**
[Preoperative management–cardiac, pulmonary, and renal dysfunction] Murata A, et al. **Nippon Geka Gakkai Zasshi** 1996 Jun;97(6):398–403 (4 ref.) (Eng. Abstr.) **(Jpn)**
[Care of esophageal cancer patients with diabetes mellitus—preoperative management and treatment] Shimada Y, et al. **Nippon Geka Gakkai Zasshi** 1996 Jun; 97(6):404–8 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Parenteral nutrition in the perioperative period] Pawłowski W. **Pol Tyg Lek** 1996 Apr;51(14–18):246–8 (44 ref.) **(Pol)**
[Preoperative parenteral nutrition] Sloventantor VIu, et al. **Vestn Ross Akad Med Nauk** 1996;(5):31–5 (47 ref.) (Eng. Abstr.) **(Rus)**
[Pre–transplant evaluation of the donor and recipient. Recommendations for surveillance and control of infection after transplantation] Cisneros JM, et al. **Enferm Infecc Microbiol Clin** 1997 May;15 Suppl 2:98–103 (68 ref.) **(Spa)**
[New discoveries on metabolic preparation prior to surgery: carbohydrate loading is better than fasting] Ljungqvist O, et al. **Lakartidningen** 1997 Apr 9;94(15):1372–6 (37 ref.) **(Swe)**

METHODS

Pharmacological stress testing with technetium–99m single–photon emission computerized tomography imaging in the preoperative assessment of patients undergoing noncardiac surgery [see comments] Heller GV, et al. **Am J Card Imaging** 1996 Apr;10(2):120–7 (45 ref.) Comment in: Am J Card Imaging 1996 Apr;10(2):117–9.
Use of dobutamine stress echocardiography for risk assessment before noncardiac surgery [see comments] Tawam MN, et al. **Am J Card Imaging** 1996 Apr; 10(2):128–32 (49 ref.) Comment in: Am J Card Imaging 1996 Apr;10(2):117–9.
Preoperative evaluation before noncardiac vascular surgery. Eagle KA, et al. **Cleve Clin J Med** 1996 Oct;63(6):325–30 (15 ref.)
Perioperative management of lung volume reduction patients. Keller CA, et al. **Clin Chest Med** 1997 Jun;18(2):285–300 (39 ref.)
Perioperative management in lung transplantation. Simpson KP, et al. **Clin Chest Med** 1997 Jun;18(2):277–84 (38 ref.)
Patient selection, evaluation, and preoperative management for lung transplant candidates. Smith CM. **Clin Chest Med** 1997 Jun;18(2):183–97 (123 ref.)
Evaluation and preoperative management of lung volume reduction surgery candidates. Yusen RD, et al. **Clin Chest Med** 1997 Jun;18(2):199–224 (154 ref.)
Usefulness of preoperative testing in pediatric podiatric surgery. Does it influence clinical decisions? Harris EJ. **Clin Podiatr Med Surg** 1997 Jan;14(1):149–78 (15 ref.)
Transesophageal echocardiography and the perioperative management of valvular heart disease. Kraker PK, et al. **Curr Opin Cardiol** 1997 Mar;12(2):108–13 (22 ref.)
Preoperative chemotherapy for stage IIIa non–small cell lung cancer. Fossella FV, et al. **Curr Opin Oncol** 1996 Mar; 8(2):106–11 (41 ref.)
Is there a role for induction androgen deprivation prior to radical prostatectomy? Watson R, et al. **Hematol Oncol Clin North Am** 1996 Jun;10(3):627–41 (62 ref.)
Perioperative psychosocial interventions for autistic children undergoing ENT surgery. Seid M, et al. **Int J Pediatr Otorhinolaryngol** 1997 Jun 20;40(2–3):107–13 (11 ref.)
Management of cystic fibrosis before and after lung transplantation. Egan JJ, et al. **J R Soc Med** 1997;90 Suppl 31:47–58 (54 ref.)
Preparation and intraoperative management of the pediatric patient. Hata T. **Pediatr Ann** 1997 Aug;26(8):471–81; quiz 501–3 (28 ref.)
The preoperative evaluation of the pediatric patient. Rasmussen GE. **Pediatr Ann** 1997 Aug;26(8):455–60 (15 ref.)
Preoperative versus postoperative extracorporeal life support in neonatal cardiac patients. McKay VJ, et al. **Perfusion** 1997 May;12(3):179–86 (16 ref.)
Preoperative anesthesia and postoperative considerations in laser resurfacing. Fitzpatrick RE, et al. **Semin Cutan Med Surg** 1996 Sep;15(3):170–6 (11 ref.)
Autologous blood donation and epoetin alfa in cancer surgery. Jeekel J. **Semin Hematol** 1997 Apr;33(2 Suppl 2):43–6; discussion 47 (13 ref.)
Preoperative evaluation and intraoperative management of patients with chronic renal failure undergoing vascular procedures. Morrison DE. **Semin Vasc Surg** 1996 Sep; 9(3):166–71 (16 ref.)
[Indications and role of albumin for vascular loading in trauma patients and during preoperative period] Sztark F. **Ann Fr Anesth Reanim** 1996;15(4):473–80 (34 ref.) (Eng. Abstr.) **(Fre)**
[Preoperative examinations: the essential and the superfluous] Zafiropulo M, et al. **Contracept Fertil Sex** 1997 Jun; 25(6):434–7 (5 ref.) **(Fre)**
[Autotransfusion: reflections on the preparation prior to donation] Zysset F, et al. **Rev Med Suisse Romande** 1997 Jun;117(6):501–7 (19 ref.) **(Fre)**
[Pharmacological preparation of the endometrium in surgical hysteroscopy] Primiero FM, et al. **Clin Ter** 1996 May; 147(5):245–51 (43 ref.) (Eng. Abstr.) **(Ita)**
[The preparation of patients with diabetes mellitus for operations and the management of the postoperative period] Henyk SM, et al. **Klin Khir** 1996;(7):37–40 (50 ref.) **(Ukr)**

STANDARDS

Practical aspects of preoperative autologous transfusion. Yomtovian R. **Am J Clin Pathol** 1997 Apr;107(4 Suppl 1):S28–35 (63 ref.)

VETERINARY

Medical care of the neurosurgical patient. Longshore RC, et al. **Semin Vet Med Surg (Small Anim)** 1996 Nov; 11(4):208–17 (36 ref.)
Instrument sterilization, skin preparation, and wound management. Southwood LL, et al. **Vet Clin North Am Equine Pract** 1996 Aug;12(2):173–94 (79 ref.)

PREOPTIC AREA

GROWTH & DEVELOPMENT

Estrogenic control of preoptic area development in a carnivore, the ferret. Baum MJ, et al. **Cell Mol Neurobiol** 1996 Apr;16(2):117–28 (75 ref.)

PHYSIOLOGY

Determinants of hypothalamic neuronal thermosensitivity. Boulant JA, et al. **Ann N Y Acad Sci** 1997 Mar 15;813:133–8 (17 ref.)
Neuroanatomical circuitry for mammalian maternal behavior. Numan M, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:101–25 (71 ref.)
Estrogenic control of preoptic area development in a carnivore, the ferret. Baum MJ, et al. **Cell Mol Neurobiol** 1996 Apr;16(2):117–28 (75 ref.)

PREOVULATORY PHASE see **FOLLICULAR PHASE**

PREPAID GROUP HEALTH ORGANIZATIONS see **HEALTH MAINTENANCE ORGANIZATIONS**

PRESBYCUSIS

DIAGNOSIS

[Presbycusis] Lefebvre PP. **Rev Med Liege** 1997 Apr; 52(4):304–8 (14 ref.) **(Fre)**

THERAPY

[Presbycusis] Lefebvre PP. **Rev Med Liege** 1997 Apr; 52(4):304–8 (14 ref.) **(Fre)**

PRESCRIPTION FEES

TRENDS

Reference–based pricing in British Columbia: implications for cardiologists—an analysis [see comments] Boulet AP, et al. **Can J Cardiol** 1997 Jan;13(1):46–51 (23 ref.) Comment in: Can J Cardiol 1997 Jan;13(1):31–2. Comment in: Can J Cardiol 1997 Jul;13(7):640, 689.

PRESCRIPTIONS, DRUG

Principles of antibiotic prescribing in the elderly. Borrego F, et al. **Drugs Aging** 1997 Jul;11(1):7–18 (47 ref.)
Misuse of prescription drugs. Finlayson RE. **Int J Addict** 1995 Nov–Dec;30(13–14):1871–901 (88 ref.)
Automated medication dispensing devices. Glover DG. **J Am Pharm Assoc (Wash)** 1997 May–Jun;NS37(3):353–8; quiz 358–60 (4 ref.)
Prescription drug abuse. A question of balance. Parran T Jr. **Med Clin North Am** 1997 Jul;81(4):967–78 (16 ref.)
Prescribing for children: issues in pediatric pharmacology. Niederhauser VP. **Nurse Pract** 1997 Mar;22(3):16–8, 23, 26–8 passim (21 ref.)
Off–label prescribing during pregnancy. Rayburn WF, et al. **Obstet Gynecol Clin North Am** 1997 Sep;24(3):471–8 (9 ref.)
A ten–year review of the effect of OBRA–87 on psychotropic prescribing practices in an academic nursing home. Lantz MS, et al. **Psychiatr Serv** 1996 Sep;47(9):951–5 (34 ref.)
Toward a theory of social pharmacology: the actor–spectator paradox applied to the psychotropic prescribing process. Lilja J, et al. **Subst Use Misuse** 1997 Jul;32(9):1175–215 (38 ref.)
Medication use in seniors: challenges and solutions. Tamblyn R. **Therapie** 1996 May–Jun;51(3):269–82 (186 ref.)
[Cost savings by right choice of drugs. Decision making models for "good prescription" are presented] Hoffmann M. **Lakartidningen** 1997 Feb 26;94(9):733–6, 739 (39 ref.) **(Swe)**

ECONOMICS

Pharmacoeconomics: basic concepts and terminology. Walley T, et al. **Br J Clin Pharmacol** 1997 Apr;43(4):343–8 (38 ref.)

STANDARDS

Implementation of multiple outpatient formularies: undesirable effects. Stein CM, et al. **Clin Pharmacol Ther** 1997 Jan;61(1):1–7 (32 ref.)
Bioequivalence and generic prescribing: a pharmacy view. Calvert RT. **J Pharm Pharmacol** 1996 Jan;48(1):9–10 (9 ref.)
Bioequivalence and generic prescribing: an industrial view. Pidgen A. **J Pharm Pharmacol** 1996 Jan;48(1):11–6 (12 ref.)

STATISTICS & NUMERICAL DATA

The assessment of refill compliance using pharmacy records: methods, validity, and applications. Steiner JF, et al. **J Clin Epidemiol** 1997 Jan;50(1):105–16 (61 ref.)
Appropriateness in health care: application to prescribing. Buetow SA, et al. **Soc Sci Med** 1997 Jul;45(2):261–71 (115 ref.)

PRESCRIPTIONS, NON–DRUG

Use of intraperitoneal pressure, ultrafiltration and purification dwell times for individual peritoneal dialysis prescription in children. Fischbach M, et al. **Clin Nephrol** 1996 Jul; 46(1):14–6 (11 ref.)
Release of contact lens prescriptions: an update. Classé JG. **J Am Optom Assoc** 1997 Feb;68(2):125–9 (4 ref.)
Release of spectacle prescriptions: an update. Classé JG. **J Am Optom Assoc** 1996 Oct;67(10):631–7 (11 ref.)
Exercise prescription: lessening the risk of physical activity. O'Brien CP. **J Cardiovasc Risk** 1996 Apr;3(2):141–7 (81 ref.)

PRESENTATION, BREECH see **BREECH PRESENTATION**

PRESERVATION, BIOLOGICAL

see related
CRYOPROTECTIVE AGENTS
FIXATIVES

PRESERVATION, FOOD see **FOOD PRESERVATION**

PRESERVATIVES, PHARMACEUTICAL

see related
ANTIOXIDANTS

ADVERSE EFFECTS

Contact allergens—what's new? Preservatives. Gruvberger B, et al. **Clin Dermatol** 1997 Jul–Aug;15(4):493–7 (41 ref.)
Compound allergy. An overview. Bashir SJ, et al. **Contact Dermatitis** 1997 Apr;36(4):179–83 (21 ref.)
1,2–Benzisothiazolin–3–one (Proxel): irritant or allergen? A clinical study and literature review. Chew AL, et al. **Contact Dermatitis** 1997 Mar;36(3):131–6 (26 ref.)
Mechanisms of failure in glaucoma filtering surgery: a consequence of antiglaucomatous drugs? Baudouin C. **Int J Clin Pharmacol Res** 1996;16(1):29–41 (39 ref.)
Methyldibromoglutaronitrile (Euxyl K 400): an important "new" allergen in cosmetics. De Groot AC, et al. **J Am Acad Dermatol** 1996 Nov;35(5 Pt 1):743–7 (35 ref.)
[Allergy and preservatives. Apropos of 3 cases of allergy to benzalkonium chloride] Chiambaretta F, et al. **J Fr Ophtalmol** 1997;20(1):8–16 (41 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Stabilization of rinderpest vaccine by modification of the lyophilization process. House JA, et al. **Dev Biol Stand**

1996;87:235–44 (23 ref.)
Thermostability of poliovirus and measles vaccines. Melnick JL. **Dev Biol Stand** 1996;87:155–60 (20 ref.)

PRESSORECEPTORS

see related
BAROREFLEX

PHYSIOLOGY

Blood pressure regulation in baroreceptor–denervated rats. Sved AF, et al. **Clin Exp Pharmacol Physiol** 1997 Jan; 24(1):77–82 (55 ref.)

PHYSIOPATHOLOGY

[Bilateral glomus tumors with a blood pressure regulation disorder due to baroreceptor dysfunction] Hausmann ON, et al. **Dtsch Med Wochenschr** 1997 Feb 28;122(9):253–8 (21 ref.) (Eng. Abstr.) **(Ger)**
[Hypertension and alcohol: central and peripheral mechanisms] Rupp H, et al. **Herz** 1996 Aug;21(4):258–64 (41 ref.) (Eng. Abstr.) **(Ger)**

PRESSURE

see related
ATMOSPHERIC PRESSURE
BLOOD PRESSURE
MANOMETRY
Urethral pressure measurement. Lose G.
Acta Obstet Gynecol Scand Suppl 1997;166:39–42 (31 ref.)
Pressure effects on enzyme activity and stability at high temperatures. Michels PC, et al. **Adv Protein Chem** 1996; 48:341–76 (120 ref.)
The lateral pressure profile in membranes: a physical mechanism of general anesthesia. Cantor RS.
Biochemistry 1997 Mar 4;36(9):2339–44 (33 ref.)
Lateral pressure in membranes. Marsh D.
Biochim Biophys Acta 1996 Oct 29;1286(3):183–223 (139 ref.)
Pressure–relieving strategies for preventing and treating pressure sores. Remsburg RE, et al. **Clin Geriatr Med** 1997 Aug;13(3):513–41 (95 ref.)
Multinuclear MR frequency shifts of hydrated ions as a function of applied pressure and temperature. Sarkar SN, et al. **J Magn Reson B** 1996 Aug;112(2):197–9 (12 ref.)
Oculopneumoplethysmography. Meissner I.
Neurosurg Clin N Am 1996 Oct;7(4):571–6 (12 ref.)

PRESSURE SORE see **DECUBITUS ULCER**

PRESSURE ULCER see **DECUBITUS ULCER**

PRESYNAPTIC RECEPTORS see **RECEPTORS, PRESYNAPTIC**

PRESYNAPTIC TERMINALS

CHEMISTRY

Calcium–channel subtypes in the somata and axon terminals of magnocellular neurosecretory cells. Fisher TE, et al. **Trends Neurosci** 1996 Oct;19(10):440–4 (54 ref.)
The postsynaptic density at glutamatergic synapses. Kennedy MB. **Trends Neurosci** 1997 Jun;20(6):264–8 (60 ref.)

IMMUNOLOGY

Lambert–Eaton myasthenic syndrome: clinical diagnosis, immune–mediated mechanisms, and update on therapies. Sanders DB. **Ann Neurol** 1995 May;37 Suppl 1:S63–73 (58 ref.)

METABOLISM

Presynaptic ionotropic receptors. McGehee DS, et al.
Curr Opin Neurobiol 1996 Jun;6(3):342–9 (96 ref.)
Diversity and function of presynaptic calcium channels in the brain. Reuter H. **Curr Opin Neurobiol** 1996 Jun; 6(3):331–7 (48 ref.)
Presynaptic potassium channels. Roeper J, et al.
Curr Opin Neurobiol 1996 Jun;6(3):338–41 (41 ref.)
Altered glutamatergic transmission in neurological disorders: from high extracellular glutamate to excessive synaptic efficacy. Obrenovitch TP, et al. **Prog Neurobiol** 1997 Jan; 51(1):39–87 (651 ref.)
Presynaptic nicotinic ACh receptors. Wonnacott S.
Trends Neurosci 1997 Feb;20(2):92–8 (76 ref.)
Presynaptic inhibition of elicited neurotransmitter release. Wu LG, et al. **Trends Neurosci** 1997 May;20(5):204–12 (73 ref.)

PHYSIOLOGY

Presynaptic mechanisms in central synaptic transmission: 'biochemistry' of an intact glutamatergic synapse. Shupliakov O, et al. **Acta Physiol Scand** 1996 Jul; 157(3):369–79 (60 ref.)
Molecular genetic analysis of synaptic plasticity, activity–dependent neural development, learning, and memory in the mammalian brain. Chen C, et al.
Annu Rev Neurosci 1997;20:157–84 (149 ref.)
Invertebrate presynaptic inhibition and motor control. Clarac F, et al. **Exp Brain Res** 1996 Nov;112(2):163–80 (112 ref.)
Can deterministic penalty terms model the effects of synaptic weight noise on network fault–tolerance? Edwards PJ, et al. **Int J Neural Syst** 1995 Dec;6(4):401–16 (41 ref.)
Hebb's dream: the resurgence of cell assemblies. Nicolelis MA, et al. **Neuron** 1997 Aug;19(2):219–21 (18 ref.)
Presynaptic interactions between acetylcholine and glycine in the human brain. Marchi M, et al. **Prog Brain Res** 1996; 109:225–9 (35 ref.)
Neural cell adhesion molecules in activity–dependent development and synaptic plasticity. Fields RD, et al.
Trends Neurosci 1996 Nov;19(11):473–80 (95 ref.)
Multiple overlapping processes underlying short–term synaptic enhancement. Fisher SA, et al.
Trends Neurosci 1997 Apr;20(4):170–7 (124 ref.)
Cerebellar circuits and synaptic mechanisms involved in classical eyeblink conditioning. Kim JJ, et al.
Trends Neurosci 1997 Apr;20(4):177–81 (62 ref.)

ULTRASTRUCTURE

Presynaptic bodies ("ribbons"): from ultrastructural observations to molecular perspectives. Wagner HJ.
Cell Tissue Res 1997 Mar;287(3):435–46 (110 ref.)
The Merkel cell as a possible mechanoreceptor cell. Ogawa H. **Prog Neurobiol** 1996 Jul;49(4):317–34 (79 ref.)

PREVALENCE

Statistical methodology: I. Incorporating the prevalence of disease into the sample size calculation for sensitivity and specificity [see comments] Buderer NM.
Acad Emerg Med 1996 Sep;3(9):895–900 (5 ref.) Comment in: Acad Emerg Med 1996 Sep;3(9):824.
Variations in HIV prevalence between urban areas in sub–Saharan Africa: do we understand them? Buvé A, et al. **AIDS** 1995;9 Suppl A:S103–9 (70 ref.)
Modelling prevalence of a condition: chronic graft–versus–host disease after bone marrow transplantation. Couper D, et al. **Stat Med** 1997 Jul 30; 16(14):1551–71 (11 ref.)
[Prevalence and incidence. These (almost) unknowns] De Amici D. **Minerva Anestesiol** 1996 Oct;62(10):343–8 (11 ref.) (Eng. Abstr.) **(Ita)**

PREVENTION, PRIMARY see **PRIMARY PREVENTION**

PREVENTIVE DENTISTRY

[What does a dentist do and why?] Murtomaa H.
Duodecim 1995;111(14):1330–7 (26 ref.) **(Fin)**

PREVENTIVE HEALTH SERVICES

see related
HEALTH PROMOTION
IMMUNIZATION
Challenges to prevention in Dutch general practice. Drenthen T. **Am J Clin Nutr** 1997 Jun;65(6 Suppl):1943S–1945S (12 ref.)
Weighing the evidence: the Canadian experience. Goldbloom RB. **Am J Clin Nutr** 1997 Feb;65(2 Suppl):584S–586S (6 ref.)
Employing prevention in practice. Landis BJ, et al.
Am J Nurs 1997 Aug;97(8):40–6; quiz 47 (10 ref.)
Do we really mean preventive medicine for all? O'Hanlan KA. **Am J Prev Med** 1996 Sep–Oct;12(5):411–4 (57 ref.)
Prevention of IDDM: a public health perspective. Marrero DG, et al. **Diabetes Res Clin Pract** 1996 Oct;34 Suppl:S181–4 (18 ref.)
Clinical decision–making with the woman after menopause. Bidikov I, et al. **Geriatrics** 1997 Mar;52(3):28–35; quiz 36 (22 ref.)
Preventive medicine and screening in older adults. Goldberg TH, et al. **J Am Geriatr Soc** 1997 Mar;45(3):344–54 (150 ref.)
What have HMOs learned about clinical prevention services? An examination of the experience at Group Health Cooperative of Puget Sound. Thompson RS.
Milbank Q 1996;74(4):469–509 (142 ref.)
[Preventive and health promotion work in family practice. Dilemmas and proposals on general guidelines] Hafting M. **Tidsskr Nor Laegeforen** 1997 May 20;117(13):1933–6 (35 ref.) **(Nor)**

ECONOMICS

Economic issues in coronary heart disease prevention. Reckless JP. **Curr Opin Lipidol** 1996 Dec;7(6):356–62 (42 ref.)
[The need for preventive measures. Need for preventive measures at any price? Attempt at an argument in favor of the need for prevention not only for economic reasons (published erratum appears in Gesundheitswesen 1996 Dec;58(12):702)] Nadolski H, et al. **Gesundheitswesen** 1996 Aug–Sep;58(8–9):432–41 (160 ref.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Obstetrician/gynecologist as primary care physician in managed health care. Pritzker J. **Clin Obstet Gynecol** 1997 Jun;40(2):402–13 (21 ref.)
Preventive care. Steps toward implementation. Sifri R, et al. **Prim Care** 1996 Mar;23(1):127–40 (28 ref.)

STATISTICS & NUMERICAL DATA

[The preventive home visit—possibilities for geriatric preventive care] Gerber–Glur E, et al. **Ther Umsch** 1997 Jun;54(6):303–8 (13 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

Behavioral science activities at the Centers for Disease Control and Prevention. A selected overview of exemplary programs. Galavotti C, et al. **Am Psychol** 1997 Feb; 52(2):154–66 (100 ref.)
Prevention in managed care: obstacles and opportunities. Bailey JE, et al. **J Tenn Med Assoc** 1996 Apr;89(4):122–5 (29 ref.)

PREVENTIVE MEDICINE

see related
HEALTH PROMOTION
Therapeutic vaccines. A pandoric prospect. Spier RE.
Adv Exp Med Biol 1996;397:183–9 (7 ref.)
Nutrition screening in old people: its place in a coherent practice of preventive health care. Rush D.
Annu Rev Nutr 1997;17:101–25 (126 ref.)
Salpingectomy improves in–vitro fertilization outcome in patients with a hydrosalpinx: blind victimization of the fallopian tube? Puttemans PJ, et al. **Hum Reprod** 1996 Oct; 11(10):2079–81 (37 ref.)
The role of preventive medicine in sickle cell disease. The Watson Smith lecture. Serjeant GR.
J R Coll Physicians Lond 1996 Jan–Feb;30(1):37–41 (10 ref.)
Efforts of pharmacy to reduce antibiotic resistance. Klem C, et al. **New Horiz** 1996 Aug;4(3):377–84 (66 ref.)
Beta–carotene, vitamin C, and vitamin E: the protective micronutrients. Charleux JL. **Nutr Rev** 1996 Nov;54(11 Pt 2):S109–14 (28 ref.)
Beneficial effects of tempeh in disease prevention and treatment. Karyadi D, et al. **Nutr Rev** 1996 Nov;54(11 Pt 2):S94–8 (19 ref.)
Ascorbic acid and chronic diseases. How strong is the evidence? Boeing H, et al. **Subcell Biochem** 1996;25:117–36 (106 ref.)
[Risk as a concept and a challenge in health care] Graff–Iversen S. **Tidsskr Nor Laegeforen** 1996 Sep 20; 116(22):2669–72 (32 ref.) (Eng. Abstr.) **(Nor)**
[Risk as a concept and challenge in health care] Skolbekken JA. **Tidsskr Nor Laegeforen** 1996 Sep 20;116(22):2673–6 (30 ref.) (Eng. Abstr.) **(Nor)**

EDUCATION

[Challenges in the educational objectives of preventive medicine and community health curriculum in undergraduate medical education] Kahyo H.
Nippon Koshu Eisei Zasshi 1996 Mar;43(3):175–82 (25 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Advances in preventive cardiology. Schieken RM.
Curr Opin Pediatr 1996 Oct;8(5):527–30 (17 ref.)

TRENDS

Current concepts in the role of intravesical instillations in the therapy and prophylaxis of superficial transitional–cell cancer of the bladder. The Finnbladder Research Group. Alfthan O, et al. **World J Urol** 1997;15(2):89–95 (64 ref.)
[Universalism as a concept of medicine in the XXI century] Moszczyński P. **Przegl Lek** 1996;53(3):116–8 (0 ref.) **(Pol)**

PREVENTIVE PSYCHIATRY

METHODS

Early detection and intervention in schizophrenia: research. McGlashan TH. **Schizophr Bull** 1996;22(2):327–45 (34 ref.)
EPPIC: an evolving system of early detection and optimal management. McGorry PD, et al. **Schizophr Bull** 1996; 22(2):305–26 (75 ref.)
Monitoring and care of young people at incipient risk of psychosis. Yung AR, et al. **Schizophr Bull** 1996; 22(2):283–303 (83 ref.)

PREVOTELLA

ISOLATION & PURIFICATION

[Polymicrobial endocarditis in an intravenous drug addict with isolation of Eikenella corrodens (letter)] Saavedra J, et al. **Enferm Infecc Microbiol Clin** 1996 Aug–Sep; 14(7):454–6 (10 ref.) **(Spa)**

PRIAPISM

Priapism: etiology and management. Mulhall JP, et al.
Acad Emerg Med 1996 Aug;3(8):810–6 (70 ref.)
Priapism: diagnosis and management. Harmon WJ, et al.
Mayo Clin Proc 1997 Apr;72(4):350–5 (29 ref.)
[Priapism. Etiology, diagnosis and treatment] Wessel N, et al. **Tidsskr Nor Laegeforen** 1996 Nov 10;116(27):3233–5 (21 ref.) (Eng. Abstr.) **(Nor)**

ETIOLOGY

Priapism. Powars DR, et al.
Hematol Oncol Clin North Am 1996 Dec;10(6):1363–72 (55 ref.)

High-flow priapism associated with Fabry's disease in a child: a case report and review of the literature. Foda MM, et al. **Urology** 1996 Dec;48(6):949–52 (16 ref.)

RADIOGRAPHY

High-flow priapism--recurrence after initially successful selective coil embolization: case report. Millward SF, et al. **Can Assoc Radiol J** 1997 Apr;48(2):105–7 (11 ref.)

THERAPY

Priapism. Powars DR, et al.
Hematol Oncol Clin North Am 1996 Dec;10(6):1363–72 (55 ref.)

Post-traumatic priapism treated with selective cavernosal artery ligation. Shapiro RH, et al. **Urology** 1997 Apr; 49(4):638–43 (15 ref.)

[Prevention and treatment of erectile disorders in sickle cell disease] Bachir D, et al. **Rev Med Interne** 1997;18 Suppl 1:46s–51s (17 ref.) (Eng. Abstr.) **(Fre)**

[Percutaneous superselective bilateral embolization for the therapy of traumatic juvenile arterial priapism] Rilinger N, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1997 Mar;166(3):263–5 (10 ref.) **(Ger)**

ULTRASONOGRAPHY

[Post-traumatic priapism in a 10-year-old boy] Sperling H, et al. **Urologe A** 1997 Mar;36(2):162–4 (11 ref.) (Eng. Abstr.) **(Ger)**

PRILOCAINE

[Topical anesthesia with the EMLA cream: application in pediatric urology] Xavier B, et al. **Actas Urol Esp** 1996 Nov-Dec;20(10):883–5 (15 ref.) (Eng. Abstr.) **(Spa)**

PRIMAQUINE

PHARMACOLOGY

Primaquine resistance in Plasmodium vivax. Collins WE, et al. **Am J Trop Med Hyg** 1996 Sep;55(3):243–9 (65 ref.)

THERAPEUTIC USE

A general review on the prevention and treatment of Theileria annulata in China. Zhang ZH. **Vet Parasitol** 1997 Jun;70(1–3):77–81 (0 ref.)

PRIMARY CARE see **PRIMARY HEALTH CARE**

PRIMARY CARE PHYSICIANS see **PHYSICIANS, FAMILY**

PRIMARY HEALTH CARE

Diagnosis of dementia at the primary care level. Olafsdottir M, et al. **Acta Neurol Scand Suppl** 1996;165:58–62 (7 ref.)

Treating binge eating problems in primary care. Carter JC, et al. **Addict Behav** 1995 Nov-Dec;20(6):765–72 (36 ref.)

Primary care physicians and clinical nutrition: can good medical nutrition care be offered without well-trained physicians in the area? Dutra-de-Oliveira JE, et al.
Am J Clin Nutr 1997 Jun;65(6 Suppl):2010S–2012S (6 ref.)

Review of nutritional attitudes and counseling practices of primary care physicians. Glanz K. **Am J Clin Nutr** 1997 Jun;65(6 Suppl):2016S–2019S (31 ref.)

Major depression in the primary care setting. Boswell EB, et al. **Am J Med** 1996 Dec 30;101(6A):3S–9S (59 ref.)

Reimbursement issues in the treatment of depression. Canterbury RJ. **Am J Med** 1996 Dec 30;101(6A):53S–56S (07 ref.)

Making the diagnosis of depression in the primary care setting. Cole S, et al. **Am J Med** 1996 Dec 30; 101(6A):10S–17S (34 ref.)

Office psychotherapy for depression in the primary care setting. Green SA. **Am J Med** 1996 Dec 30; 101(6A):37S–44S (35 ref.)

Management options for refractory depression. Nierenberg AA, et al. **Am J Med** 1996 Dec 30;101(6A):45S–52S (81 ref.)

Management strategies for depression in primary care. Peden JG Jr, et al. **Am J Med** 1996 Dec 30;101(6A):18S–25S (24 ref.)

Primary care for persons with disabilities. An overview of the problem. DeJong G. **Am J Phys Med Rehabil** 1997 May-Jun;76(3 Suppl):S2–8 (18 ref.)

A preventive ethics approach to counseling patients about clinical futility in the primary care setting. Doukas DJ, et al. **Arch Fam Med** 1996 Nov-Dec;5(10):589–92 (35 ref.)

Developing a strategy for managing behavioral health care within the context of primary care. Fisher L, et al.
Arch Fam Med 1997 Jul-Aug;6(4):324–33 (97 ref.)

Acupuncture in the 1990s. A review for the primary care physician. Peterson JR. **Arch Fam Med** 1996 Apr; 5(4):237–40; discussion 241 (28 ref.)

ABC of mental health. Common mental health problems in primary care. Craig TK, et al. **BMJ** 1997 May 31; 314(7094):1609–12 (8 ref.)

The implications of teenage pregnancy and motherhood for primary health care: unresolved issues. Irvine H, et al.
Br J Gen Pract 1997 May;47(418):323–6 (50 ref.)

Patient educational material in the management of low back pain in primary care. Burton AK, et al.
Bull Hosp Jt Dis 1996;55(3):138–41 (24 ref.)

Characteristics of information resources preferred by primary care physicians. Thompson ML. **Bull Med Libr Assoc** 1997 Apr;85(2):187–92 (80 ref.)

Primary care issues for the breast cancer survivor. Bines J, et al. **Compr Ther** 1997 Sep;23(9):605–11 (48 ref.)

School-based health services. Ryan S, et al.
Curr Opin Pediatr 1996 Oct;8(5):453–8 (30 ref.)

Major depression in primary medical care practice. Research trends and future priorities. Schulberg HC, et al.
Gen Hosp Psychiatry 1996 Nov;18(6):395–406 (90 ref.)

Assessment tools for general health care settings: PRIME-MD, OARS, and SF-36. Primary Care Evaluation of Mental Health Disorders. Older Americans Resources and Services Questionnaire; Short Form-36. Van Hook MP, et al. **Health Soc Work** 1996 Aug;21(3):230–4 (23 ref.)

Recognizing depression in primary care patients. Lieberman JA 3rd. **Hosp Pract (Off Ed)** 1997 Jul 15;32(7):145–8 (12 ref.)

HIV and the primary care physician in Japan. Asai A.
J Acquir Immune Defic Syndr Hum Retrovirol 1997;14 Suppl 2:S30–4 (21 ref.)

Panic disorder in the medical setting. Ballenger JC.
J Clin Psychiatry 1997;58 Suppl 2:13–7; discussion 18–9 (47 ref.)

Barriers to the diagnosis of depression in primary care. Docherty JP. **J Clin Psychiatry** 1997;58 Suppl 1:5–10 (83 ref.)

A treatment algorithm for the management of anxiety in primary care practice. Hales RE, et al.
J Clin Psychiatry 1997;58 Suppl 3:76–80 (24 ref.)

Strategies for treatment of generalized anxiety in the primary care setting. Schweizer E, et al. **J Clin Psychiatry** 1997; 58 Suppl 3:27–31; discussion 32–3 (14 ref.)

Caring for depression in primary care: defining and illustrating the policy context. Wells KB.
J Clin Psychiatry 1997;58 Suppl 1:24–7 (12 ref.)

Rehabilitation of neck/shoulder patients in primary health care clinics. Jordan A, et al.
J Manipulative Physiol Ther 1996 Jan;19(1):32–5 (43 ref.)

Implementation of neck/shoulder rehabilitation in primary health care clinics. Jordan A, et al.
J Manipulative Physiol Ther 1996 Jan;19(1):36–40 (25 ref.)

An overview of rural health [editorial] Lawrence DJ.
J Manipulative Physiol Ther 1996 Feb;19(2):75–81 (61 ref.)

Primary care management of common dermatologic disorders in women. Pharmacologic considerations. Emmons L, et al. **J Nurse Midwifery** 1997 May-Jun; 42(3):228–53 (54 ref.)

Primary care: who leads? Orton P, et al. **Lancet** 1996 Dec 21-28;348 Suppl 2:sII20 (5 ref.)

The physician and the Internet. Wang KK, et al.
Mayo Clin Proc 1997 Jan;72(1):66–71 (05 ref.)

Preconception health care for the primary care practitioner. Cheng D. **Md Med J** 1996 Apr;45(4):297–304 (41 ref.)

Politics, practical logic, and primary health care in rural Haiti. Brodwin PE. **Med Anthropol Q** 1997 Mar;11(1):69–88 (58 ref.)

The role of the generalist in the care of the substance-abusing patient. Lewis DC. **Med Clin North Am** 1997 Jul; 81(4):831–43 (71 ref.)

The role of the general practitioner in the treatment of schizophrenia: specific issues [see comments] Carr VJ.
Med J Aust 1997 Feb 3;166(3):143–6 (25 ref.) Comment in: Med J Aust 1997 Feb 3;166(3):117–8.

Domestic violence: the new standard of care. Holtz HA.
N J Med 1996 Aug;93(8):33–6 (10 ref.)

Overdrugging and undertreatment in primary health care. Huebscher R. **Nurs Outlook** 1997 Jul-Aug;45(4):161–6 (40 ref.)

Multiple sclerosis. Primary health care implications. Swain SE. **Nurse Pract** 1996 Jul;21(7):40, 43, 47–50 passim (23 ref.)

The importance of advance directives in primary care. Arenson CA, et al. **Prim Care** 1996 Mar;23(1):67–82 (69 ref.)

Mind-body medicine in primary care. Implications and applications. Lazar JS. **Prim Care** 1996 Mar;23(1):169–82 (71 ref.)

Prevention of HIV transmission. Reyes EM, et al.
Prim Care 1997 Sep;24(3):469–77 (34 ref.)

The telephone in primary care. Studdiford JS III, et al.
Prim Care 1996 Mar;23(1):83–102 (76 ref.)

Humor in medicine. Wender RC. **Prim Care** 1996 Mar; 23(1):141–54 (23 ref.)

Evaluation of screens for mental disorders in primary care: methodological issues. Leon AC, et al.
Psychopharmacol Bull 1996;32(3):353–61 (21 ref.)

An agenda for primary care research on low back pain. Borkan JM, et al. **Spine** 1996 Dec 15;21(24):2880–4 (6 ref.)

Low back pain. A primary care challenge. Deyo RA, et al.
Spine 1996 Dec 15;21(24):2826–32 (20 ref.)

Educational and behavioral interventions for back pain in primary care. Turner JA. **Spine** 1996 Dec 15;21(24):2851–7; discussion 2858–9 (48 ref.)

The course of back pain in primary care. Von Korff M, et al. **Spine** 1996 Dec 15;21(24):2833–7; discussion 2838–9 (29 ref.)

Alcohol and primary health care. Anderson P.
WHO Reg Publ Eur Ser 1996;64:1–90 (72 ref.)

[Screening for microalbuminuria in diabetic patients in the primary health care system] Farkas K, et al. **Orv Hetil** 1997 Feb 23;138(8):459–65 (46 ref.) (Eng. Abstr.) **(Hun)**

CLASSIFICATION

The International Classification of Primary Care (ICPC): new applications in research and computer-based patient records in family practice. Hofmans-Okkes IM, et al.
Fam Pract 1996 Jun;13(3):294–302 (36 ref.)

ECONOMICS

Economic evaluation and the shifting balance towards primary care: definitions, evidence and methodological issues. Godber E, et al. **Health Econ** 1997 May-Jun; 6(3):275–94 (45 ref.)

Cost-effectiveness and cost containment. A physician's primer. Bishof RO, et al. **Prim Care** 1996 Mar;23(1):115–26 (22 ref.)

MANPOWER

Psychiatry at a crossroad: our role in primary care [see comments] Shore JH. **Am J Psychiatry** 1996 Nov; 153(11):1398–403 (20 ref.) Comment in: Am J Psychiatry 1997 Sep;154(9):1325. Comment in: Am J Psychiatry 1997 Sep;154(9):1325–6. Comment in: Am J Psychiatry 1997 Sep;154(9):1326.

The need for more primary care physicians to contain costs and improve access: myths versus realities. Stimmel B.
Mt Sinai J Med 1996 Jan;63(1):49–59 (44 ref.)

Medical students' specialty choice and the need for primary care. Our future. Rosenthal MP, et al. **Prim Care** 1996 Mar; 23(1):155–67 (79 ref.)

Determining the effect that consultation-liaison psychiatry in primary care has on family physicians' psychiatric knowledge and practice. Carr VJ, et al. **Psychosomatics** 1997 May-Jun;38(3):217–29 (51 ref.)

METHODS

Identification and treatment of children's mental health problems by primary care providers: a critical review of research. Richardson LA, et al. **Arch Psychiatr Nurs** 1996 Oct;10(5):293–303 (30 ref.)

Drug interactions among the elderly [news] Liaw ST.
Aust Fam Physician 1997 Apr;26(4):355–7 (29 ref.)

Primary care of foot and ankle injuries in the athlete. Clanton TO, et al. **Clin Sports Med** 1997 Jul;16(3):435–66 (71 ref.)

Primary care management of adolescent sexual behavior. Ellen JM, et al. **Curr Opin Pediatr** 1996 Oct;8(5):442–8 (47 ref.)

Selections from current literature: clinical detection of abuse. Kelso EB, et al. **Fam Pract** 1996 Aug;13(4):408–13 (21 ref.)

The DSM-IV-PC: a manual for diagnosing mental disorders in the primary care setting. deGruy FV 3rd, et al.
J Am Board Fam Pract 1996 Jul-Aug;9(4):274–81 (14 ref.)

Strategies for managing depression complicated by bipolar disorder, suicidal ideation, or psychotic features. Hartmann PM. **J Am Board Fam Pract** 1996 Jul-Aug;9(4):261–9 (69 ref.)

'Bridge' between knowledge and practice in diagnosing depression [see comments] Bost RH.
J Am Osteopath Assoc 1997 Jan;97(1):49–52 (16 ref.) Comment in: J Am Osteopath Assoc 1997 Apr;97(4):191.

The sequelae of childhood sexual abuse: a primary care focus for adult female survivors. Roberts SJ. **Nurse Pract** 1996 Dec;21(12 Pt 1):42, 45, 49–52 (26 ref.)

Primary care diagnosis of acute abdominal pain. Stone R.
Nurse Pract 1996 Dec;21(12 Pt 1):19–20, 23–30, 35–9; quiz 40–1 (18 ref.)

Pediatric primary care vision examination. Ryan JB.
Optom Clin 1996;5(2):1–34 (64 ref.)

Biosocial consequences of poverty: associated visual problems. Solan HA, et al. **Optom Vis Sci** 1997 Apr; 74(4):185–9 (44 ref.)

Management of acute ischemic stroke. An update for primary care physicians. Albers GW. **West J Med** 1997 Apr; 166(4):253–62 (40 ref.)

ORGANIZATION & ADMINISTRATION

Obstetrician/gynecologist as primary care physician in managed health care. Pritzker J. **Clin Obstet Gynecol** 1997 Jun;40(2):402–13 (21 ref.)

School health centers and primary care for adolescents: a review of the literature. Santelli J, et al.
J Adolesc Health 1996 May;18(5):357–66 (56 ref.)

The management of the client with a leg ulcer: precarious nursing practice. Husband LL. **J Adv Nurs** 1996 Jul; 24(1):53–9 (32 ref.)

Primary health care in Swaziland: is it working? Sukati NA.
J Adv Nurs 1997 Apr;25(4):760–6 (19 ref.)

Managed care and community-oriented care: conflict or complement? Lairson DR, et al.
J Health Care Poor Underserved 1997 Feb;8(1):36–55 (34 ref.)

Family health care delivery for the 21st century. Cox RP.
J Obstet Gynecol Neonatal Nurs 1997 Jan-Feb;26(1):109–18

(35 ref.)
Chronic illness in adolescents: transfer or transition to adult services? Sawyer SM, et al. **J Paediatr Child Health** 1997 Apr;33(2):88–90 (22 ref.)
Expanding the physician–substitute concept to oral health care practitioners. Nielsen–Thompson N, et al. **J Public Health Policy** 1997;18(1):80–97 (63 ref.)
Medicaid and primary care. Rushton FE. **J S C Med Assoc** 1997 Feb;93(2):63–7 (12 ref.)
Developing tomorrow's integrated community health systems: a leadership challenge for public health and primary care. Welton WE, et al. **Milbank Q** 1997; 75(2):261–88 (15 ref.)
Looking beyond primary care to primary health care: an approach to community–based action. Shoultz J, et al. **Nurs Outlook** 1997 Jan–Feb;45(1):23–6 (27 ref.)
Community–based nursing versus community health nursing: what does it all mean? Zotti ME, et al. **Nurs Outlook** 1996 Sep–Oct;44(5):211–7 (25 ref.)
Gay, lesbian, and bisexual adolescents: providing esteem–enhancing care to a battered population. Nelson JA. **Nurse Pract** 1997 Feb;22(2):94, 99, 103 passim (45 ref.)
Collaborative care between nurse practitioners and primary care physicians. Arcangelo V, et al. **Prim Care** 1996 Mar; 23(1):103–13 (15 ref.)
Comprehensive care of lesbian and gay patients and families. Harrison AE, et al. **Prim Care** 1996 Mar;23(1):31–46 (74 ref.)
Community–oriented primary care. Nevin JE, et al. **Prim Care** 1996 Mar;23(1):1–15 (23 ref.)
Preventive care. Steps toward implementation. Sifri R, et al. **Prim Care** 1996 Mar;23(1):127–40 (28 ref.)
Clinical assessment in primary care: professional cooperation. Reid V. **Proc Nutr Soc** 1996 Jul;55(2):679–88 (17 ref.)
The role of nursing in primary health care. Campbell S. **WHO Reg Publ Eur Ser** 1997;74:209–39 (59 ref.)
Women's access to appropriate providers within managed care: implications for the quality of primary care. Bartman BA. **Womens Health Issues** 1996 Jan–Feb;6(1):45–50 (21 ref.)

STANDARDS

Testing the viability of collaborative interdisciplinary practice in community–focused primary health care: a case study in change. Lundeen SP, et al. **Wis Med J** 1997 Jun; 96(6):30–6 (0 ref.)

STATISTICS & NUMERICAL DATA

Performance of gastrointestinal tract endoscopy by primary care physicians. Lessons from the US Medicare database. Ackermann RJ. **Arch Fam Med** 1997 Jan–Feb;6(1):52–8 (67 ref.)
Generalized anxiety disorder in primary care: the precursor/modifier pathway to increased health care utilization. Roy–Byrne PP, et al. **J Clin Psychiatry** 1997; 58 Suppl 3:34–8; discussion 39–40 (37 ref.)

TRENDS

Public health and primary care: a framework for proposed linkages. Starfield B. **Am J Public Health** 1996 Oct; 86(10):1365–9 (28 ref.)
Psychiatry in medical practice. Implications for the education of primary care physicians in the era of managed care: Part 2. Stoudemire A. **Psychosomatics** 1997 Jan–Feb; 38(1):1–9 (74 ref.)
[Health information systems: the network of epidemiological surveillance and primary care. The current situation] Mirón Canelo JA, et al. **Aten Primaria** 1997 Apr 15;19(6):323–7 (26 ref.) **(Spa)**

PRIMARY PREVENTION

An emergency medicine approach to violence throughout the life cycle. SAEM Public Health and Education Committee [see comments] Muelleman RL, et al. **Acad Emerg Med** 1996 Jul;3(7):708–15 (74 ref.) Comment in: Acad Emerg Med 1996 Jul;3(7):651–2.
Employing prevention in practice. Landis BJ, et al. **Am J Nurs** 1997 Aug;97(8):40–6; quiz 47 (10 ref.)
The role of emergency medical services in primary injury prevention. Consensus workshop. Arlington, Virginia, August 25–26, 1995. Garrison HG, et al. **Ann Emerg Med** 1997 Jul;30(1):84–91 (11 ref.)
Prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer. Church JM. **Ann Med** 1996 Dec;28(6):479–82 (15 ref.)
Dissemination and utilization of health promotion and disease prevention knowledge: theory, research and experience. Green LW, et al. **Can J Public Health** 1996 Nov–Dec;87 Suppl 2:S11–7 (80 ref.)
Pediatric preventive cardiology: healthy habits now, healthy hearts later [see comments] Feinstein JA, et al. **Curr Opin Cardiol** 1997 Jan;12(1):70–7 (70 ref.) Comment in: Curr Opin Cardiol 1997 Jan;12(1):41–3.
Primary prevention of NIDDM: a practical reality. Bennett PH. **Diabetes Metab Rev** 1997 Jun;13(2):105–11 (23 ref.)
Diabetes prevention in American Indians and Alaska Natives: where are we in 1994? Gohdes D, et al. **Diabetes Res Clin Pract** 1996 Oct;34 Suppl:S95–100 (38 ref.)
Primary prevention of leprosy. Fine PE. **Int J Lepr Other Mycobact Dis** 1996 Dec;64(4 Suppl):S44–9 (22 ref.)
Cancer prevention. Osborne M, et al. **Lancet** 1997 May;349 Suppl 2:SII27–30 (36 ref.)
How much physical activity do we need to maintain health and prevent disease? Different diseases––different mechanisms. Slattery ML. **Res Q Exerc Sport** 1996 Jun; 67(2):209–12 (19 ref.)
[Cancer prevention by general practitioners in the Rhône area: a declarative survey] Garcia–Giannoli H, et al. **Bull Cancer** 1996 Oct;83(10):853–63 (39 ref.) (Eng. Abstr.) **(Fre)**
[Practical clinical implications of megastudies for primary prevention (editorial)] Brotons Cuixart C. **Rev Esp Cardiol** 1997 May;50(5):295–9 (20 ref.) (Eng. Abstr.) **(Spa)**

METHODS

Prevention and nonpharmacologic treatment of mite allergy. Wickman M. **Allergy** 1997 Apr;52(4):369–73 (43 ref.)
Preventing lead poisoning in children. Silbergeld EK. **Annu Rev Public Health** 1997;18:187–210 (78 ref.)
Prevention of diarrhoea in young children in developing countries. Huttly SR, et al. **Bull World Health Organ** 1997; 75(2):163–74 (111 ref.)
Potential interventions for the prevention of childhood pneumonia in developing countries: a systematic review. Kirkwood BR, et al. **Bull World Health Organ** 1995; 73(6):793–8 (9 ref.)
Single motherhood and mental health: implications for primary prevention [editorial; comment] Avison WR. **Can Med Assoc J** 1997 Mar 1;156(5):661–3 (9 ref.) Comment on: Can Med Assoc J 1997 Mar 1;156(5):639–45.
Role of the environment in falls prevention. Connell BR. **Clin Geriatr Med** 1996 Nov;12(4):859–80 (47 ref.)
The role of antioxidants in preventive cardiology. Rimm EB, et al. **Curr Opin Cardiol** 1997 Mar;12(2):188–94 (31 ref.)
Preventive cardiology in the elderly. Wenger NK. **Curr Opin Cardiol** 1997 Mar;12(2):195–201 (39 ref.)
Direct drug control of the vascular wall. Paoletti R, et al. **J Med Liban** 1995;43(3):122–5 (44 ref.)
Preventing violence, preventing war. Ashford MW. **Med Confl Surviv** 1997 Jan–Mar;13(1):57–62 (7 ref.)
Prevention of primary event. Ischemic stroke risk detection and reduction. Orencia AJ, et al. **Neurosurg Clin N Am** 1997 Apr;8(2):165–78 (218 ref.)
Genetic susceptibility for breast cancer: testing and primary prevention options. Baron RH, et al. **Oncol Nurs Forum** 1997 Apr;24(3):461–8 (55 ref.)
Preventive nutrition in childhood: a rationale. Deckelbaum RJ. **Public Health Rev** 1996;24(2):105–11 (5 ref.)
[Health in the third age. Preventing handicaps related to aging] Svanborg A, et al. **J Med Liban** 1995;43(2):102–6 (13 ref.) **(Fre)**

ORGANIZATION & ADMINISTRATION

Reducing corporal punishment of children: a call for a regional effort. Levav I, et al. **Bull Pan Am Health Organ** 1996 Mar;30(1):70–9 (54 ref.)
Teenage pregnancy prevention programs. Pierre N, et al. **Curr Opin Pediatr** 1997 Aug;9(4):310–6 (23 ref.)
Understanding the impact of effective teenage pregnancy prevention programs. Frost JJ, et al. **Fam Plann Perspect** 1995 Sep–Oct;27(5):188–95 (13 ref.)
School–based programs for preventing eating disturbances. Neumark–Sztainer D. **J Sch Health** 1996 Feb;66(2):64–71 (55 ref.)
Health care auxiliaries in the detection and prevention of oral cancer. Sankaranarayanan R. **Oral Oncol** 1997 May; 33(3):149–54 (29 ref.)
The Sonda Project: prevention, prediction, and psychological disorder. Buscema M. **Subst Use Misuse** 1997 Jul; 32(9):1053–153 (315 ref.)
[Update on the dracunculosis eradication program] Ranque P, et al. **Med Trop (Mars)** 1996;56(3):289–96 (20 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

Drug–abuse prevention efforts for young children: a review and critique of existing programs. Hall NW, et al. **Am J Orthopsychiatry** 1997 Jan;67(1):134–43 (62 ref.)

TRENDS

Primary prevention of NIDDM: a future dream. Assal JP. **Diabetes Metab Rev** 1997 Jun;13(2):113–7 (12 ref.)

PRIMARY TOOTH see TOOTH, DECIDUOUS

PRIMATES

The value of studying occupation: an example with primate play [published erratum appears in Am J Occup Ther 1996 Sep;50(8):638] Wood W. **Am J Occup Ther** 1996 May; 50(5):327–37 (60 ref.)
Evolutionary perspectives on primate mating systems and behavior. Dixson AF. **Ann N Y Acad Sci** 1997 Jan 15; 807:42–61 (102 ref.)
Wasatchian–Bridgerian (Eocene) paleoecology of the western interior of North America: changing paleoenvironments and taxonomic composition of omomyid (Tarsiiformes) primates. Gunnell GF. **J Hum Evol** 1997 Feb–Mar;32(2–3):105–32 (55 ref.)
Beyond hyperacute rejection: strategies for development of pig––>primate xenotransplantation. Hancock WW. **Kidney Int Suppl** 1997 Mar;58:S36–40 (31 ref.)
Strategies for using nonhuman primates in genetic research on multifactorial diseases. VandeBerg JL, et al. **Lab Anim Sci** 1996 Apr;46(2):146–51 (48 ref.)
Stress and behaviorally induced reproductive dysfunction in primates. Cameron JL. **Semin Reprod Endocrinol** 1997 Feb; 15(1):37–45 (56 ref.)
[Results and prospects of medico–biological research in primates] Lapin BA. **Biull Eksp Biol Med** 1996 Sep; 122(9):245–52 (41 ref.) **(Rus)**

ANATOMY & HISTOLOGY

New pedal remains of Megaladapis and their functional significance. Wunderlich RE, et al. **Am J Phys Anthropol** 1996 May;100(1):115–39 (62 ref.)
The primate motor thalamus. Percheron G, et al. **Brain Res Brain Res Rev** 1996 Aug;22(2):93–181 (388 ref.)
Mandibular form and function in North American and European Adapidae and Omomyidae. Ravosa MJ. **J Morphol** 1996 Aug;229(2):171–90 (91 ref.)

EMBRYOLOGY

Development of photoreceptor mosaics in the primate retina. Wikler KC, et al. **Perspect Dev Neurobiol** 1996;3(3):161–75 (80 ref.)

GENETICS

Current knowledge on the major histocompatibility complex class II region in non–human primates. Slierendregt BL, et al. **Eur J Immunogenet** 1994 Oct;21(5):391–402 (75 ref.)
Primate Mhc–E and –G alleles. Arnaiz–Villena A, et al. **Immunogenetics** 1997;46(4):251–66 (24 ref.)
[Molecular paleogenetics of primates] Tëtushkin EIa. **Genetika** 1997 Mar;33(3):293–307 (154 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Nonhuman primate models to evaluate vaccine safety and immunogenicity. Kennedy RC, et al. **Vaccine** 1997 Jun; 15(8):903–8 (42 ref.)

PHYSIOLOGY

New pedal remains of Megaladapis and their functional significance. Wunderlich RE, et al. **Am J Phys Anthropol** 1996 May;100(1):115–39 (62 ref.)
The connections of the primate subthalamic nucleus: indirect pathways and the open–interconnected scheme of basal ganglia–thalamocortical circuitry. Joel D, et al. **Brain Res Brain Res Rev** 1997 Feb;23(1–2):62–78 (115 ref.)
The frontal cortex–basal ganglia system in primates. Wise SP, et al. **Crit Rev Neurobiol** 1996;10(3–4):317–56 (443 ref.)
Developmental and functional biology of the primate fetal adrenal cortex. Mesiano S, et al. **Endocr Rev** 1997 Jun; 18(3):378–403 (252 ref.)
The neural architecture of binocular vision. Casagrande VA, et al. **Eye** 1996;10 (Pt 2):153–60 (64 ref.)
Basic neurophysiology of primate locomotion. Mori S, et al. **Folia Primatol (Basel)** 1996;66(1–4):192–203 (51 ref.)
Size influences on primate locomotion and body shape, with special emphasis on the locomotion of 'small mammals'. Preuschoft H, et al. **Folia Primatol (Basel)** 1996; 66(1–4):93–112 (64 ref.)
Mandibular form and function in North American and European Adapidae and Omomyidae. Ravosa MJ. **J Morphol** 1996 Aug;229(2):171–90 (91 ref.)
Neurochemical modulation of the hippocampus in learning, remembering and forgetting in primates. Ridley RM, et al. **Neurodegeneration** 1996 Dec;5(4):467–71 (27 ref.)
Neural mechanisms of visual motion perception in primates. Andersen RA. **Neuron** 1997 Jun;18(6):865–72 (41 ref.)
Reversal of parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission: potential mechanisms of action. Mitchell IJ, et al. **Neurosci Biobehav Rev** 1997 Jul;21(4):469–75 (63 ref.)
Specialized systems for the processing of mnemonic information within the primate frontal cortex. Petrides M. **Philos Trans R Soc Lond B Biol Sci** 1996 Oct 29; 351(1346):1455–61; discussion 1461–2 (30 ref.)

PSYCHOLOGY

On the rise and fall of self–conception in primates. Gallup GG Jr. **Ann N Y Acad Sci** 1997 Jun 18;818:72–82 (26 ref.)
What is mirror self–recognition in nonhuman primates, and what is it not? Swartz KB. **Ann N Y Acad Sci** 1997 Jun 18;818:64–71 (30 ref.)
The serial organisation of behaviour by non–human primates; an evaluation of experimental paradigms. De Lillio C. **Behav Brain Res** 1996 Nov;81(1–2):1–17 (65 ref.)
Primate cognition and the bared–teeth display: a reevaluation of the concept of formal dominance. Maestripieri D. **J Comp Psychol** 1996 Dec;110(4):402–5 (26 ref.)

VIROLOGY

Baboon endogenous virus evolution and ecology [see

comments] van der Kuyl AC, et al. **Trends Microbiol** 1996 Nov;4(11):455–9 (23 ref.) Comment in: Trends Microbiol 1996 Dec;4(12):478.

PRIMIPARITY see **PARITY**

PRIMITIVE GUT see **GASTRULA**

PRIMITIVE STREAK see **GASTRULA**

PRINDOLOL see **PINDOLOL**

PRINTING

Printing processes and printing inks.
IARC Monogr Eval Carcinog Risks Hum 1996;65:33–147 (272 ref.)

PRINZMETAL'S ANGINA see **ANGINA PECTORIS, VARIANT**

PRION DISEASES

see related
SLOW VIRUS DISEASES

Human prion diseases (spongiform encephalopathies). Kretzschmar HA. **Arch Virol Suppl** 1993;7:261–93 (178 ref.)
Prion disease [editorial] Hart CA. **Br J Hosp Med** 1996 Jul 10–Aug 20;56(2–3):64–5 (7 ref.)
Heat shock proteins, molecular chaperones and the prion encephalopathies. Kenward N, et al.
Cell Stress Chaperones 1996 Apr;1(1):18–22 (34 ref.)
Prion diseases. Shetty AK, et al. **Clin Pediatr (Phila)** 1997 Jan;36(1):1–7 (88 ref.)
Prion diseases. Korczyn AD. **Curr Opin Neurol** 1997 Jun; 10(3):273–81 (86 ref.)
Prion; the unconventional slow infectious agent. Kim YS. **J Korean Med Sci** 1997 Feb;12(1):1–8 (59 ref.)
Prion diseases and the BSE crisis. Prusiner SB. **Science** 1997 Oct 10;278(5336):245–51 (110 ref.)
What a wrong fold can do: transmissible spongiform encephalopathies. Kolchinsky A. **Surg Neurol** 1996 Dec; 46(6):587–90 (02 ref.)
[The prion diseases] Kondo K. **Hokkaido Igaku Zasshi** 1997 Jan;72(1):27–36 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Prion diseases] Tateishi J. **Nippon Naika Gakkai Zasshi** 1996 Sep 10;85(9):1605–7 (4 ref.) **(Jpn)**
[Prion diseases—general aspect] Kuroda Y, et al.
Nippon Rinsho 1997 Apr;55(4):967–71 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Prion infections: most important medical and veterinary aspects] Vorob'ev AA, et al.
Vestn Ross Akad Med Nauk 1997;(6):3–11 (15 ref.) (Eng. Abstr.) **(Rus)**
[Transmissible spongiform encephalopathies] Vujošević M. **Srp Arh Celok Lek** 1997 Jul–Aug;125(7–8):234–43 (45 ref.) (Eng. Abstr.) **(Scc)**
[Human diseases caused by prions] Lepeš T. **Med Pregl** 1997 Jan–Feb;50(1–2):19–22 (10 ref.) (Eng. Abstr.) **(Scr)**
[Dementias by prions: a new pathogenic paradigm] López de Munain A. **Rev Neurol** 1997 Jul;25 Suppl 1:S55–62 (136 ref.) **(Spa)**

COMPLICATIONS

Bovine spongiform encephalopathy: "mad cow disease".
Nutr Rev 1996 Jul;54(7):208–10 (10 ref.)

DIAGNOSIS

[Expanded illness spectrum of human spongiform encephalopathies or prion diseases] Weber T, et al.
Nervenarzt 1997 Apr;68(4):309–23 (167 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

[Epidemiology of human prion diseases] Kondo K.
Nippon Rinsho 1997 Apr;55(4):978–86 (10 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Deadly conformations—protein misfolding in prion disease. Horwich AL, et al. **Cell** 1997 May 16;89(4):499–510 (116 ref.)
Loss of functional prion protein: a role in prion disorders? Borchelt DR, et al. **Chem Biol** 1996 Aug;3(8):619–21 (20 ref.)
Prion biology and diseases—laughing cannibals, mad cows, and scientific heresy. Prusiner SB. **Med Res Rev** 1996 Sep; 16(5):487–505 (131 ref.)
Prion-induced neuro-psychiatric syndromes. Nigro N, et al. **Panminerva Med** 1996 Sep;38(3):173–4 (10 ref.)
Amyloid fibril formation and protein misassembly: a structural quest for insights into amyloid and prion diseases. Kelly JW. **Structure** 1997 May 15;5(5):595–600 (73 ref.)
Molecular biology and pathogenesis of prion diseases [see comments] Prusiner SB. **Trends Biochem Sci** 1996 Dec; 21(12):482–7 (79 ref.) Comment in: Trends Biochem Sci 1997 Jul;22(7):241–2.
Probing the dynamics of prion diseases with amphotericin B. Adjou KT, et al. **Trends Microbiol** 1997 Jan;5(1):27–31 (31 ref.)

GENETICS

Sleep, genes and death: fatal familial insomnia. Fiorino AS. **Brain Res Brain Res Rev** 1996 Oct;22(3):258–64 (51 ref.)
Molecular biology and genetics of prion diseases. Prusiner SB. **Cold Spring Harb Symp Quant Biol** 1996;61:473–93 (290 ref.)
Neurotoxicity of beta-amyloid and prion peptides. Forloni G. **Curr Opin Neurol** 1996 Dec;9(6):492–500 (111 ref.)
Molecular pathology of prion diseases. Smith C, et al.
Essays Biochem 1995;29:157–74 (34 ref.)
Human prion diseases and bovine spongiform encephalopathy (BSE). Collinge J. **Hum Mol Genet** 1997;6(10):1699–705 (80 ref.)
The use of transgenic mice in the investigation of transmissible spongiform encephalopathies. Weissmann C, et al. **Int J Exp Pathol** 1996 Dec;77(6):283–93 (73 ref.)
Human prion diseases. Ironside JW.
J Neural Transm Suppl 1996;47:231–46 (57 ref.)
Transgenic analysis of prion diseases. Moore RC, et al.
Mol Hum Reprod 1997 Jun;3(6):529–44 (170 ref.)
To what extent is strain variation evidence for an independent genome in the agent of the transmissible spongiform encephalopathies? Ridley RM, et al. **Neurodegeneration** 1996 Sep;5(3):219–31 (89 ref.)
Of mice and (mad) cows—transgenic mice help to understand prions. Gabizon R, et al. **Trends Genet** 1997 Jul;13(7):264–9 (54 ref.)

HISTORY

The mysterious prion diseases—a historical perspective. Urich H. **Mater Med Pol** 1996 Apr–Jun;28(2):39–41 (24 ref.)

METABOLISM

Tracking prions: the neurografting approach. Aguzzi A, et al. **Cell Mol Life Sci** 1997 Jun;53(6):485–95 (87 ref.)
Molecular biology and genetics of prion diseases. Prusiner SB. **Cold Spring Harb Symp Quant Biol** 1996;61:473–93 (290 ref.)
Amyloid in Alzheimer's disease and prion-related encephalopathies: studies with synthetic peptides. Forloni G, et al. **Prog Neurobiol** 1996 Jul;49(4):287–315 (273 ref.)
Probing the dynamics of prion diseases with amphotericin B. Adjou KT, et al. **Trends Microbiol** 1997 Jan;5(1):27–31 (31 ref.)
Protein conformation and disease. Nandi PK. **Vet Res** 1996; 27(4–5):373–82 (61 ref.)

MICROBIOLOGY

Spiroplasmas: infectious agents of plants, arthropods and vertebrates. Bové JM. **Wien Klin Wochenschr** 1997 Aug 8;109(14–15):604–12 (70 ref.)

MORTALITY

Sleep, genes and death: fatal familial insomnia. Fiorino AS. **Brain Res Brain Res Rev** 1996 Oct;22(3):258–64 (51 ref.)

PATHOLOGY

Prion protein amyloidosis. Ghetti B, et al. **Brain Pathol** 1996 Apr;6(2):127–45 (90 ref.)
Abnormal plasma membrane properties and functions in prion-infected cell lines. DeArmond SJ, et al.
Cold Spring Harb Symp Quant Biol 1996;61:531–40 (58 ref.)
Microglia and prion disease: a review. Brown DR, et al.
Histol Histopathol 1997 Jul;12(3):883–92 (74 ref.)
Molecular clues to pathogenesis in prion diseases. Laurent M, et al. **Histol Histopathol** 1997 Apr;12(2):583–94 (93 ref.)
Human prion diseases. Ironside JW.
J Neural Transm Suppl 1996;47:231–46 (57 ref.)
Cell death in prion disease. Kretzschmar HA, et al.
J Neural Transm Suppl 1997;50:191–210 (72 ref.)
How do neurons degenerate in transmissible spongiform encephalopathies? Liberski PP. **Mol Chem Neuropathol** 1996 May–Aug;28(1–3):245–9 (10 ref.)
Molecular biology and pathogenesis of prion diseases [see comments] Prusiner SB. **Trends Biochem Sci** 1996 Dec; 21(12):482–7 (79 ref.) Comment in: Trends Biochem Sci 1997 Jul;22(7):241–2.
[Prion disease in animals and experimental prion disease] Ikeda S. **No To Shinkei** 1997 Aug;49(8):689–95 (21 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Prionics or the kinetic basis of prion diseases. Eigen M.
Biophys Chem 1996 Dec 10;63(1):A1–18 (58 ref.)
Sleep, genes and death: fatal familial insomnia. Fiorino AS.
Brain Res Brain Res Rev 1996 Oct;22(3):258–64 (51 ref.)
Transgenic models of neurodegenerative diseases. Lee MK, et al. **Curr Opin Neurobiol** 1996 Oct;6(5):651–60 (115 ref.)
Microglia and prion disease: a review. Brown DR, et al.
Histol Histopathol 1997 Jul;12(3):883–92 (74 ref.)
From prion diseases to Alzheimer's disease. Hsiao KK.
J Neural Transm Suppl 1997;49:135–44 (43 ref.)
Multiple roles for PrP in the prion diseases. Estibeiro JP.
Trends Neurosci 1996 Jul;19(7):257–8 (10 ref.)

PREVENTION & CONTROL

[Clinical management of prion disease] Itoyama Y.
No To Shinkei 1997 Aug;49(8):707–11 (11 ref.) **(Jpn)**

TRANSMISSION

Human prion diseases. McCardle L. **Br J Biomed Sci** 1997 Mar;54(1):2–4 (24 ref.)
Transmissible encephalopathies and biopharmaceutical production. Robinson MM. **Dev Biol Stand** 1996;88:237–41 (15 ref.)
Analysis of risk to biomedical products developed from animal sources (with special emphasis on the spongiform encephalopathy agents, scrapie and BSE). Rohwer RG.
Dev Biol Stand 1996;88:247–56 (24 ref.)
[Unconventional transmissible agents or prions] Dormont D.
Presse Med 1997 Mar 22;26(9):425–30 (52 ref.) (Eng. Abstr.) **(Fre)**
[Transmissible spongiform encephalopathies] Moennig V, et al. **DTW Dtsch Tierarztl Wochenschr** 1997 Jul;104(7):251–3 (38 ref.) (Eng. Abstr.) **(Ger)**
[Interspecies transmissibility of spongiform encephalopathies] Pastoret PP, et al. **Rev Med Liege** 1996 Nov;51(11):705–13 (39 ref.) **(Mul)**
[Transmissible cerebral amyloidoses or prion diseases: is the structure of the infectious agent really understood?] Liberski PP, et al. **Postepy Biochem** 1996;42(4):320–30 (129 ref.) **(Pol)**

PRION PROTEINS see **PRIONS**

PRIONS

The biology and molecular biology of scrapie-like diseases. Hope J. **Arch Virol Suppl** 1993;7:201–14 (55 ref.)
Human prion diseases (spongiform encephalopathies). Kretzschmar HA. **Arch Virol Suppl** 1993;7:261–93 (178 ref.)
Microglia and prion disease: a review. Brown DR, et al.
Histol Histopathol 1997 Jul;12(3):883–92 (74 ref.)
Prion; the unconventional slow infectious agent. Kim YS.
J Korean Med Sci 1997 Feb;12(1):1–8 (59 ref.)
Prion-induced neuro-psychiatric syndromes. Nigro N, et al.
Panminerva Med 1996 Sep;38(3):173–4 (10 ref.)
Of mice and (mad) cows—transgenic mice help to understand prions. Gabizon R, et al. **Trends Genet** 1997 Jul;13(7):264–9 (54 ref.)
[I. The biology of unconventional, transmissible agents or prions (editorial)] Dormont D. **C R Acad Sci III** 1996 Jul; 319(7):549–53 (72 ref.) **(Fre)**
[Unconventional transmissible agents or prions] Dormont D.
Presse Med 1997 Mar 22;26(9):425–30 (52 ref.) (Eng. Abstr.) **(Fre)**
[Dementias by prions: a new pathogenic paradigm] López de Munain A. **Rev Neurol** 1997 Jul;25 Suppl 1:S55–62 (136 ref.) **(Spa)**

ANALYSIS

[Transmissible cerebral amyloidoses or prion diseases: is the structure of the infectious agent really understood?] Liberski PP, et al. **Postepy Biochem** 1996;42(4):320–30 (129 ref.) **(Pol)**

CHEMISTRY

Prions and molecular chaperones. Liautard JP.
Arch Virol Suppl 1993;7:227–43 (45 ref.)
Prion protein amyloidosis. Ghetti B, et al. **Brain Pathol** 1996 Apr;6(2):127–45 (90 ref.)
Deadly conformations—protein misfolding in prion disease. Horwich AL, et al. **Cell** 1997 May 16;89(4):499–510 (116 ref.)
Prion protein structure and scrapie replication: theoretical, spectroscopic, and genetic investigations. Bamborough P, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:495–509 (99 ref.)
The prion folding problem. Harrison PM, et al.
Curr Opin Struct Biol 1997 Feb;7(1):53–9 (51 ref.)
Molecular biology and pathogenesis of prion diseases [see comments] Prusiner SB. **Trends Biochem Sci** 1996 Dec; 21(12):482–7 (79 ref.) Comment in: Trends Biochem Sci 1997 Jul;22(7):241–2.

DRUG EFFECTS

Probing the dynamics of prion diseases with amphotericin B. Adjou KT, et al. **Trends Microbiol** 1997 Jan;5(1):27–31 (31 ref.)

GENETICS

Prions and RNA viruses of Saccharomyces cerevisiae. Wickner RB. **Annu Rev Genet** 1996;30:109–39 (141 ref.)
Prion protein amyloidosis. Ghetti B, et al. **Brain Pathol** 1996 Apr;6(2):127–45 (90 ref.)
Prion protein structure and scrapie replication: theoretical, spectroscopic, and genetic investigations. Bamborough P, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:495–509 (99 ref.)
Prions of yeast, [PSI] and [URE3], as models for neurodegenerative diseases. Wickner RB, et al.
Cold Spring Harb Symp Quant Biol 1996;61:541–50 (57 ref.)
Neurotoxicity of beta-amyloid and prion peptides. Forloni G. **Curr Opin Neurol** 1996 Dec;9(6):492–500 (111 ref.)
Human prion diseases and bovine spongiform encephalopathy (BSE). Collinge J. **Hum Mol Genet** 1997;6(10):1699–705 (80 ref.)
To what extent is strain variation evidence for an independent genome in the agent of the transmissible spongiform

encephalopathies? Ridley RM, et al. **Neurodegeneration** 1996 Sep;5(3):219–31 (89 ref.)
Mad cow disease and Creutzfeldt–Jakob disease—is there a link? Rist CE, et al. **Scand J Infect Dis** 1996;28(3):231–4 (22 ref.)
Maintenance and inheritance of yeast prions. Tuite MF, et al. **Trends Genet** 1996 Nov;12(11):467–71 (41 ref.)
PrP genetics in sheep and the applications for scrapie and BSE. Hunter N. **Trends Microbiol** 1997 Aug;5(8):331–4 (36 ref.)
[Gene mutation and pathology in human prion disease] Tashiro H, et al. **No To Shinkei** 1997 Aug;49(8):681–7 (30 ref.) **(Jpn)**

ISOLATION & PURIFICATION

Transmissible encephalopathies and biopharmaceutical production. Robinson MM. **Dev Biol Stand** 1996;88:237–41 (15 ref.)

METABOLISM

Mad cows meet psi-chotic yeast: the expansion of the prion hypothesis. Lindquist S. **Cell** 1997 May 16;89(4):495–8 (21 ref.)
Tracking prions: the neurografting approach. Aguzzi A, et al. **Cell Mol Life Sci** 1997 Jun;53(6):485–95 (87 ref.)
The role of PrP in pathogenesis of experimental scrapie. Weissmann C, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:511–22 (76 ref.)
Mad cows meet mad yeast: the prion hypothesis [see comments] Lindquist S. **Mol Psychiatry** 1996 Nov; 1(5):376–9 (29 ref.) Comment in: Mol Psychiatry 1996 Nov;1(5):347–8.
A new prion controls fungal cell fusion incompatibility. Wickner RB. **Proc Natl Acad Sci U S A** 1997 Sep 16; 94(19):10012–4 (21 ref.)
Amyloid in Alzheimer's disease and prion-related encephalopathies: studies with synthetic peptides. Forloni G, et al. **Prog Neurobiol** 1996 Jul;49(4):287–315 (273 ref.)
What a wrong fold can do: transmissible spongiform encephalopathies. Kolchinsky A. **Surg Neurol** 1996 Dec; 46(6):587–90 (02 ref.)
Molecular biology and pathogenesis of prion diseases [see comments] Prusiner SB. **Trends Biochem Sci** 1996 Dec; 21(12):482–7 (79 ref.) Comment in: Trends Biochem Sci 1997 Jul;22(7):241–2.

PATHOGENICITY

Deadly conformations—protein misfolding in prion disease. Horwich AL, et al. **Cell** 1997 May 16;89(4):499–510 (116 ref.)
Loss of functional prion protein: a role in prion disorders? Borchelt DR, et al. **Chem Biol** 1996 Aug;3(8):619–21 (20 ref.)
How to limit the spread of Creutzfeldt–Jakob disease. Dormont D. **Infect Control Hosp Epidemiol** 1996 Aug; 17(8):521–8 (71 ref.)
Probing the dynamics of prion diseases with amphotericin B. Adjou KT, et al. **Trends Microbiol** 1997 Jan;5(1):27–31 (31 ref.)
PrP genetics in sheep and the applications for scrapie and BSE. Hunter N. **Trends Microbiol** 1997 Aug;5(8):331–4 (36 ref.)
[Prions and infantile pathology] Nigro N, et al. **Minerva Pediatr** 1996 May;48(5):221–3 (8 ref.) (Eng. Abstr.) **(Ita)**
[Prions—still an enigma of molecular biology? (II)] Israil A. **Bacteriol Virusol Parazitol Epidemiol** 1996 Jul–Dec; 41(3–4):87–98 (30 ref.) **(Rum)**
[Prions—still an enigma of molecular biology? (I)] Israil A. **Bacteriol Virusol Parazitol Epidemiol** 1996 Jan–Jun; 41(1–2):3–13 (63 ref.) **(Rum)**

PRIORITIES, HEALTH see **HEALTH PRIORITIES**

PRISONERS

HIV risk reduction and service delivery strategies in criminal justice settings. Inciardi JA. **J Subst Abuse Treat** 1996 Sep–Oct;13(5):421–8; discussion 439 (52 ref.)

LEGISLATION & JURISPRUDENCE

Forensic conditional release programs and outcomes in three states. Wiederanders MR, et al. **Int J Law Psychiatry** 1997 Spring;20(2):249–57 (19 ref.)

PSYCHOLOGY

Trauma and its sequelae in male prisoners: effects of confinement, overcrowding, and diminished services. Kupers TA. **Am J Orthopsychiatry** 1996 Apr;66(2):189–96 (65 ref.)
The cultural and social consequences and effect on families of women's involvement in drug trafficking in Cameroon: crime and imprisonment. Nouthe-Djubgang J, et al. **Bull Narc** 1995;47(1–2):31–7 (5 ref.)
[Sleep disorders in prison] Bourgeois D. **Encephale** 1997 May–Jun;23(3):180–3 (11 ref.) (Eng. Abstr.) **(Fre)**

STATISTICS & NUMERICAL DATA

Problems among youths entering the juvenile justice system, their service needs and innovative approaches to address them. Dembo R. **Subst Use Misuse** 1996 Jan;31(1):81–94 (100 ref.)

PRISONER'S DILEMMA see **GAME THEORY**

PRISONS

Trauma and its sequelae in male prisoners: effects of confinement, overcrowding, and diminished services. Kupers TA. **Am J Orthopsychiatry** 1996 Apr;66(2):189–96 (65 ref.)
Burns in prisoners: an assessment of problems in handling prisoners in a burns unit. Lee CT, et al. **Burns** 1996 Nov; 22(7):546–8 (5 ref.)
[The health of prisoners] Gentilini M, et al. **Bull Acad Natl Med** 1997 Mar 18;181(3):569–99; discussion 599–601 (48 ref.) (Eng. Abstr.) **(Fre)**
[Sleep disorders in prison] Bourgeois D. **Encephale** 1997 May–Jun;23(3):180–3 (11 ref.) (Eng. Abstr.) **(Fre)**

PRISTINAMYCIN see **VIRGINIAMYCIN**

PRIVACY

see related
CONFIDENTIALITY
PERSONAL SPACE
SELF DISCLOSURE

The erosion of medical privacy today. Katze J. **Md Med J** 1997 Aug;46(7):345–9 (0 ref.)

LEGISLATION & JURISPRUDENCE

Conferring a federal property right in genetic material: stepping into the future with the Genetic Privacy Act. Lin MM. **Am J Law Med** 1996;22(1):109–34 (242 ref.)

PRIVACY ACT see **PRIVACY**

PRIVACY OF PATIENT DATA see **CONFIDENTIALITY**

PRIVACY OF SPACE see **PERSONAL SPACE**

PRIVATE ENTERPRISE see **PRIVATE SECTOR**

PRIVATE PRACTICE

ORGANIZATION & ADMINISTRATION

Obstetrics/gynecology network development. Krieg KA. **Clin Obstet Gynecol** 1997 Jun;40(2):446–52 (5 ref.)

TRENDS

Staying single in the 1990s: single-handed practitioners in the new National Health Service. Lunt N, et al. **Soc Sci Med** 1997 Aug;45(3):341–9 (47 ref.)
Community partnerships work. Selden ST, et al. **Va Med Q** 1997 Summer;124(3):147–8 (2 ref.)

PRIVATE ROOMS see **PATIENTS' ROOMS**

PRIVATE SECTOR

Community care: the independent sector. Barodawala S. **BMJ** 1996 Sep 21;313(7059):740–3 (2 ref.)
Policy issues in the private health sector: examples from long-term care in the U.K. Bartlett HP, et al. **Soc Sci Med** 1996 Sep;43(5):731–7 (37 ref.)

LEGISLATION & JURISPRUDENCE

Managed care and the next generation of mental health law. Appelbaum PS. **New Dir Ment Health Serv** 1996 Winter; (72):65–9 (8 ref.)

ORGANIZATION & ADMINISTRATION

Creating incentives for the delivery of services. Hyde PS. **New Dir Ment Health Serv** 1996 Winter;(72):25–34 (19 ref.)
Advocacy and managed behavioral health care. Shore MF. **New Dir Ment Health Serv** 1996 Winter;(72):59–64 (2 ref.)
The public sector–private sector interface: current issues, future trends. Surles RC, et al. **New Dir Ment Health Serv** 1996 Winter;(72):71–9 (8 ref.)

PRIVATIZATION

Dirty hands: the underside of marketplace health care. Mohr WK, et al. **ANS Adv Nurs Sci** 1996 Sep;19(1):28–37 (24 ref.)
Market commodities and poor relief: the world bank proposal for health. Laurell AC, et al. **Int J Health Serv** 1996; 26(1):1–18 (42 ref.)
Health care reforms in Bulgaria: an initial appraisal. Borissov V, et al. **Soc Sci Med** 1996 Jun;42(11):1501–10 (42 ref.)

ECONOMICS

The welfare state, pensions, privatization: the case of Social Security in the United States. Du Boff RB. **Int J Health Serv** 1997;27(1):1–23 (23 ref.)
From managed competition to managed cooperation: theory and lessons from the British experience. Light DW. **Milbank Q** 1997;75(3):297–341 (131 ref.)

ORGANIZATION & ADMINISTRATION

Privatizing Social Security: the Chilean experience. Kritzer BE. **Soc Secur Bull** 1996 Fall;59(3):45–55 (53 ref.)

PRIVILEGED COMMUNICATION see **CONFIDENTIALITY**

PRL-SECRETING PITUITARY ADENOMA see **PROLACTINOMA**

PRO PROFESSIONAL REVIEW ORGANIZATIONS see **PROFESSIONAL REVIEW ORGANIZATIONS**

PROACCELERIN see **FACTOR V**

PROACTIVATOR CONVERTASE see **PROPERDIN FACTOR D**

PROACTIVE INHIBITION

A stitch in time: self-regulation and proactive coping. Aspinwall LG, et al. **Psychol Bull** 1997 May;121(3):417–36 (175 ref.)

PROALBUMIN see **PREALBUMIN**

PROBABILISTIC MODELS see **MODELS, STATISTICAL**

PROBABILITY

Can quantum processes control synaptic emission? Beck F. **Int J Neural Syst** 1996 Sep;7(4):343–53 (24 ref.)
Adaptive sampling in behavioral surveys. Thompson SK. **NIDA Res Monogr** 1997;167:296–319 (76 ref.)
An introduction to finite mixture distributions [comment] Everitt BS. **Stat Methods Med Res** 1996 Jun;5(2):107–27 (68 ref.) Comment on: Stat Methods Med Res 1996 Jun;5(2):129–53. Comment on: Stat Methods Med Res 1996 Jun;5(2):179–211.
On the value of clinical information. Is there a bridge between quantum theory and medical diagnosis? de Dombal FT. **Technol Health Care** 1996 Aug;4(2):129–36 (13 ref.)

PROBABILITY LEARNING

Constructive training methods for feedforward neural networks with binary weights. Mayoraz E, et al. **Int J Neural Syst** 1996 May;7(2):149–66 (42 ref.)
An adaptive Boolean automation to model circadian cycles. Perazzo RP, et al. **Int J Neural Syst** 1996 Mar;7(1):83–99 (10 ref.)

PROBLEM-BASED LEARNING

An analysis of the scope and value of problem-based learning in the education of health care professionals. Frost M. **J Adv Nurs** 1996 Nov;24(5):1047–53 (32 ref.)
The clinical reasoning case study: a powerful teaching tool. Ryan-Wenger NA, et al. **Nurse Pract** 1997 May;22(5):66–7, 70, 76–9 passim (36 ref.)

PROBLEM-ORIENTED MEDICAL RECORDS see **MEDICAL RECORDS, PROBLEM-ORIENTED**

PROBLEM SOLVING

see related
DECISION MAKING

Issues in cognitive psychology: implications for professional education. Regehr G, et al. **Acad Med** 1996 Sep; 71(9):988–1001 (72 ref.)
Analogical reasoning and cognitive development. Goswami U. **Adv Child Dev Behav** 1996;26:91–138 (85 ref.)
Reasoning and learning by analogy. Gentner D, et al. **Am Psychol** 1997 Jan;52(1):32–4 (23 ref.)
Expert-novice knowledge of computer programming at different levels of abstraction. Ye N, et al. **Ergonomics** 1996 Mar;39(3):461–81 (28 ref.)
Role of chaos in trial-and-error problem solving by an artificial neural network. Obana I, et al. **Int J Neural Syst** 1996 Mar;7(1):101–8 (20 ref.)
Information-seeking strategies and data utilisation: theory and practice. Roberts J, et al. **Int J Nurs Stud** 1995 Dec; 32(6):601–11 (73 ref.)
The interactional context of problem-, emotion-, and relationship-focused coping: the role of the big five personality factors. O'Brien TB, et al. **J Pers** 1996 Dec; 64(4):775–813 (100 ref.)
Counterfactual thinking. Roese NJ. **Psychol Bull** 1997 Jan; 121(1):133–48 (165 ref.)
[Organization and representation of action in schizophrenia] Georgieff N. **Encephale** 1996 Oct;22 Spec No 3:108–15 (46 ref.) **(Fre)**

PROCAINAMIDE

ADVERSE EFFECTS

[Drug-induced pericarditis] Ohnishi A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):612–4 (22 ref.) **(Jpn)**

PROCAINE

ADVERSE EFFECTS

[Side effects of mesotherapy] Doutre MS, et al. **Therapie** 1997 Mar–Apr;52(2):93–6 (15 ref.) **(Fre)**

PROCAINE AMIDE see **PROCAINAMIDE**

PROCARBAZINE

THERAPEUTIC USE

Chemotherapy for malignant gliomas. Forsyth PA, et al. **Baillieres Clin Neurol** 1996 Jun;5(2):371–93 (112 ref.)

PROCATEROL

ADMINISTRATION & DOSAGE

[Long-term effects of inhaled beta 2-agonists on bronchial hyperresponsiveness in asthmatics] Ogawa C, et al. **Nippon Rinsho** 1996 Nov;54(11):3081–6 (14 ref.) (Eng. Abstr.) **(Jpn)**

[The clinical usefulness of the combined use of inhaled beta 2-agonist and inhaled steroid in asthma] Yamamoto C, et al. **Nippon Rinsho** 1996 Nov;54(11):3087–92 (16 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

[Anti-allergic effects of beta-adrenoceptor agonists in the clinical pharmacological studies] Horikoshi S, et al. **Nippon Rinsho** 1996 Nov;54(11):3068–72 (21 ref.) (Eng. Abstr.) **(Jpn)**

PROCESS ASSESSMENT (HEALTH CARE)

ORGANIZATION & ADMINISTRATION

Process surveillance: an epidemiologic challenge for all health care organizations. Baker OG. **Am J Infect Control** 1997 Apr;25(2):96–101 (34 ref.)

PROCETOFEN

THERAPEUTIC USE

Statins and fibrates in the management of diabetic dyslipidemia [editorial; comment] Durrington P. **Diabet Med** 1997 Jul;14(7):513–6 (26 ref.) Comment on: Diabet Med 1997 Jul;14(7):564–70.

PROCOLLAGEN

ANALYSIS

Assays of type I procollagen domains and collagen fragments: problems to be solved and future trends. Risteli J, et al. **Scand J Clin Lab Invest Suppl** 1997;227:105–13 (26 ref.)

[N-terminal peptide of type III procollagen in serum and bronchoalveolar fluid as a marker of collagen metabolism in chronic interstitial lung diseases] Siemińska A. **Przegl Lek** 1996;53(7):574–8 (45 ref.) (Eng. Abstr.) **(Pol)**

BLOOD

New developments in biochemical markers for osteoporosis. Garnero P, et al. **Calcif Tissue Int** 1996;59 Suppl 1:S2–9 (79 ref.)

Collagen: scaffold for repair or execution. Jensen LT, et al. **Cardiovasc Res** 1997 Mar;33(3):535–9 (35 ref.)

CHEMISTRY

Assays of type I procollagen domains and collagen fragments: problems to be solved and future trends. Risteli J, et al. **Scand J Clin Lab Invest Suppl** 1997;227:105–13 (26 ref.)

METABOLISM

Morphogenesis: collagen it takes and bone it makes. Olsen BR. **Curr Biol** 1996 Jun 1;6(6):645–7 (11 ref.)

Biochemical markers of bone turnover. Crofton PM, et al. **Horm Res** 1996;45 Suppl 1:55–8 (10 ref.)

PHYSIOLOGY

The aminoterminal propeptide of type III procollagen. Studies on physiology and pathophysiology. Jensen LT. **Dan Med Bull** 1997 Feb;44(1):70–8 (109 ref.)

PROCONVERTIN see **FACTOR VII**

PROCTITIS

PHYSIOPATHOLOGY

Resolution of anorectal incontinence in herpes proctitis confirmed by anorectal manometry. Joseph D, et al. **Gastrointest Endosc** 1997 May;45(5):429–32 (14 ref.)

PROCTOCOLECTOMY, RESTORATIVE

see related
POUCHITIS

Ileal pouches: adaptation and inflammation. Merrett MN. **Baillieres Clin Gastroenterol** 1997 Mar;11(1):175–93 (93 ref.)

Exenterative surgery. Vergote IB. **Curr Opin Obstet Gynecol** 1997 Feb;9(1):25–8 (34 ref.)

Ileo-anal pouch function and dysfunction. Sagar PM, et al. **Dig Dis** 1997 May–Jun;15(3):172–88 (88 ref.)

Laser photoablation of ileal reservoir adenomas. Geller A, et al. **Gastrointest Endosc** 1996 Oct;44(4):473–7 (57 ref.)

Update on ileal pouch–anal anastomosis. Moreno EF, et al. **Rev Gastroenterol Mex** 1996 Oct–Dec;61(4):387–93 (48 ref.)

[Proctocolectomy with ileal W pouch anal anastomosis for ulcerative colitis] Sakai Y, et al. **Nippon Geka Gakkai Zasshi** 1997 Apr;98(4):449–56 (40 ref.) (Eng. Abstr.) **(Jpn)**

[Development of ileal J-pouch anal anastomosis] Utsunomiya J. **Nippon Geka Gakkai Zasshi** 1997 Apr;98(4):443–8 (5 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

[Pouchitis after ileal pouch–anal anastomosis] Abitbol V, et al. **Gastroenterol Clin Biol** 1997;21(4):299–304 (64 ref.) **(Fre)**

[Proctocolectomy with ileoanal anastomosis: morbidity and functional results in patients with and without colorectal cancer] Luna-Pérez P, et al. **Rev Gastroenterol Mex** 1996 Jul–Sep;61(3):184–92 (45 ref.) (Eng. Abstr.) **(Spa)**

METHODS

Anal transitional zone and columnar cuff in restorative proctocolectomy. Thompson-Fawcett MW, et al. **Br J Surg** 1996 Aug;83(8):1047–55 (104 ref.)

Stapled anastomoses in colorectal surgery: a prospective study. Memon AA, et al. **Eur J Surg** 1996 Oct; 162(10):805–10 (40 ref.)

Ileoanal anastomosis with pelvic pouch: short review. Gullberg K, et al. **Neth J Med** 1996 Feb;48(2):77–9 (24 ref.)

Surgical options in ulcerative colitis. Farouk R, et al. **Surg Clin North Am** 1997 Feb;77(1):85–94 (40 ref.)

[Preservation of anal transitional zone in restorative proctocolectomy] Fukushima T, et al. **Nippon Geka Gakkai Zasshi** 1997 Apr;98(4):457–61 (15 ref.) (Eng. Abstr.) **(Jpn)**

PROCTOCOLITIS

DRUG THERAPY

The topical treatment of distal ulcerative colitis. Ardizzone S, et al. **Eur J Gastroenterol Hepatol** 1996 Jun;8(6):599–602 (14 ref.)

Combination therapy in active distal colitis--more studies are warranted. Löfberg R. **Eur J Gastroenterol Hepatol** 1996 Jun;8(6):541–2 (17 ref.)

PROCTOCOLITIS, HEMORRHAGIC see **COLITIS, ULCERATIVE**

PROCTOCOLITIS, ULCERATIVE see **COLITIS, ULCERATIVE**

PROCTOLOGY see **COLON AND RECTAL SURGERY (SPECIALTY)**

PROCTOSIGMOIDITIS see **PROCTOCOLITIS**

PROCTOSIGMOIDOSCOPY see **SIGMOIDOSCOPY**

PRODRUGS

Safety of fosphenytoin sodium [see comments] Fierro LS, et al. **Am J Health Syst Pharm** 1996 Nov 15;53(22):2707–12 (53 ref.) Comment in: Am J Health Syst Pharm 1996 Nov 15;53(22):2702. Comment in: Am J Health Syst Pharm 1997 Feb 15;54(4):441–2. Comment in: Am J Health Syst Pharm 1997 Feb 15;54(4):442. Comment in: Am J Health Syst Pharm 1997 Feb 15;54(4):442, 445.

Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Perry CM, et al. **Drugs** 1996 Jul;52(1):125–58 (178 ref.)

[(New antimicrobial agent series L): cefcapene pivoxil] Saito A. **Jpn J Antibiot** 1997 Jun;50(6):485–506 (32 ref.) **(Jpn)**

[Development of drug delivery systems for macromolecular drugs] Takakura Y. **Yakugaku Zasshi** 1996 Jul; 116(7):519–32 (59 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations. Rensen PC, et al. **Clin Pharmacokinet** 1996 Aug;31(2):131–55 (190 ref.)

Current applications of polysaccharides in colon targeting. Hovgaard L, et al. **Crit Rev Ther Drug Carrier Syst** 1996; 13(3–4):185–223 (104 ref.)

The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Connors TA. **Gene Ther** 1995 Dec; 2(10):702–9 (64 ref.)

Tazarotene gel: efficacy and safety in plaque psoriasis. Weinstein GD. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 3):S33–8 (19 ref.)

ADVERSE EFFECTS

Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Simmons WD, et al. **Drug Saf** 1997 Aug;17(2):75–92 (68 ref.)

Clinical safety of tazarotene in the treatment of plaque psoriasis. Marks R. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 3):S25–32 (50 ref.)

CHEMICAL SYNTHESIS

New insights regarding the potential of the pronucleotide approach in antiviral chemotherapy. Gosselin G, et al. **Acta Biochim Pol** 1996;43(1):196–208 (31 ref.)

Prodrug strategies based on intramolecular cyclization reactions. Shan D, et al. **J Pharm Sci** 1997 Jul;86(7):765–7 (39 ref.)

CHEMISTRY

[Modified nucleoside phosphates as precursors of antineoplastic and antiviral compounds in a cell] Arzumanov AA, et al. **Bioorg Khim** 1996 Oct–Nov; 22(10–11):777–94 (127 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

The role of beta-glucuronidase in drug disposition and drug targeting in humans. Sperker B, et al. **Clin Pharmacokinet** 1997 Jul;33(1):18–31 (123 ref.)

PHARMACOKINETICS

Famciclovir for treatment of herpesvirus infections. Luber AD, et al. **Ann Pharmacother** 1996 Sep;30(9):978–85 (42 ref.)

Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten. Schatz BS, et al. **Ann Pharmacother** 1996 Mar;30(3):258–68 (122 ref.)

The clinical pharmacokinetics of famciclovir. Gill KS, et al. **Clin Pharmacokinet** 1996 Jul;31(1):1–8 (25 ref.)

Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic–pharmacodynamic relationships. Hoetelmans RM, et al. **Clin Pharmacokinet** 1996 Apr;30(4):314–27 (98 ref.)

Clinical pharmacokinetics of bambuterol. Sitar DS. **Clin Pharmacokinet** 1996 Oct;31(4):246–56 (48 ref.)

Pharmacology of new antiherpes agents: famciclovir and valacyclovir. Stein GE. **J Am Pharm Assoc (Wash)** 1997 Mar–Apr;NS37(2):157–63 (39 ref.)

Fosphenytoin: a novel phenytoin prodrug. Boucher BA. **Pharmacotherapy** 1996 Sep–Oct;16(5):777–91 (60 ref.)

PHARMACOLOGY

Amifostine for protection from antineoplastic drug toxicity. Foster-Nora JA, et al. **Am J Health Syst Pharm** 1997 Apr 1;54(7):787–800 (101 ref.)

Valacyclovir. Acosta EP, et al. **Ann Pharmacother** 1997 Feb; 31(2):185–91 (36 ref.)

Lansoprazole: a proton pump inhibitor. Garnett WR. **Ann Pharmacother** 1996 Dec;30(12):1425–36 (108 ref.)

Famciclovir for treatment of herpesvirus infections. Luber AD, et al. **Ann Pharmacother** 1996 Sep;30(9):978–85 (42 ref.)

Fosphenytoin (Cerebyx). Browne TR. **Clin Neuropharmacol** 1997 Feb;20(1):1–12 (51 ref.)

Molecular mechanisms of tazarotene action in psoriasis. Duvic M, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 3):S18–24 (33 ref.)

An approach to the assessment of therapeutic drug interactions with fixed combination drug products. Rockhold FW, et al. **J Biopharm Stat** 1996 Jul;6(3):231–40 (7 ref.)

Etoposide phosphate, the water soluble prodrug of etoposide. Witterland AH, et al. **Pharm World Sci** 1996 Oct; 18(5):163–70 (38 ref.)

THERAPEUTIC USE

Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten. Schatz BS, et al. **Ann Pharmacother** 1996 Mar;30(3):258–68 (122 ref.)

Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Simmons WD, et al. **Drug Saf** 1997 Aug;17(2):75–92 (68 ref.)

New antiherpesvirus agents. Their targets and therapeutic potential. Alrabiah FA, et al. **Drugs** 1996 Jul;52(1):17–32 (131 ref.)

Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis. Chandraratna RA. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 3):S12–7 (34 ref.)

The use of Mycophenolate Mofetil (Cellcept) in renal transplantation [clinical conference] Vanrenterghem Y. **Nephron** 1997;76(4):392–9 (31 ref.)

Etoposide phosphate, the water solubie prodrug of etoposide. Witterland AH, et al. **Pharm World Sci** 1996 Oct; 18(5):163–70 (38 ref.)

Fosphenytoin: a novel phenytoin prodrug. Boucher BA. **Pharmacotherapy** 1996 Sep–Oct;16(5):777–91 (60 ref.)

Prodrugs in site-selective delivery of radiopharmaceuticals. Baranowska-Kortylewicz J, et al. **Q J Nucl Med** 1997 Jun;

PRODRUGS

41(2):127–39 (47 ref.)
Antiviral drugs in development for herpes zoster. Fiddian AP. **Scand J Infect Dis Suppl** 1996;100:51–4 (17 ref.)
Sarah Cannon Cancer Center Consensus Conference on Novel Developments with Podophyllotoxin Therapy. **Semin Oncol** 1996 Dec;23(6 Suppl 13):1–60 (0 ref.)
Early studies of etoposide phosphate, a water-soluble prodrug. Budman DR. **Semin Oncol** 1996 Dec;23(6 Suppl 13):8–14 (40 ref.)
[New therapy concepts in fibrosing lung diseases] Behr J. **Pneumologie** 1996 Sep;50(9):657–64 (87 ref.) **(Ger)**

TOXICITY

Preclinical toxicology studies with the angiotensin-converting enzyme inhibitor quinapril hydrochloride (Accupril). McGuire EJ, et al. **J Toxicol Sci** 1996 Nov;21(4):207–14 (21 ref.)

PRODUCT CONTAINERS see **PRODUCT PACKAGING**

PRODUCT LABELING

STANDARDS

Health hazard labeling for hazard communication in the pharmaceutical industry. Sussman RG, et al. **Occup Med** 1997 Jan–Mar;12(1):107–17 (12 ref.)

PRODUCT LABELING, DRUG see **DRUG LABELING**

PRODUCT LABELING, FOOD see **FOOD LABELING**

PRODUCT LINE MANAGEMENT

ORGANIZATION & ADMINISTRATION

The role of production control in the development of burnout. Houben GJ, et al. **Int J Health Serv** 1996; 26(2):331–53 (97 ref.)
From health services to medical markets: the commodity transformation of medical production and the nonprofit sector. Imershein AW, et al. **Int J Health Serv** 1996; 26(2):221–38 (44 ref.)

PRODUCT PACKAGING

STANDARDS

Effectiveness of child-resistant packaging on toxin procurement in young poisoning victims. Lembersky RB, et al. **Vet Hum Toxicol** 1996 Oct;38(5):380–3 (9 ref.)

PRODUCT RECYCLING see **EQUIPMENT REUSE**

PRODUCT SURVEILLANCE, POSTMARKETING

Two UK Government proposals bearing on drug safety [editorial] Griffin JP. **Adverse Drug React Toxicol Rev** 1997 Mar;16(1):1–7 (10 ref.)
Cutaneous reactions to alimentary tract medications: results of a seven-year surveillance program and review of the literature. Gruppo Italiano Studi Epidemiologici in Dermatologia (GISED). **Dermatology** 1996;193(1):11–6 (62 ref.)
Ergotamine tartrate and dihydroergotamine mesylate: safety profiles. Lipton RB. **Headache** 1997;37 Suppl 1:S33–41 (33 ref.)
Strategic proposals for avoiding toxic interactions with drugs for clinical use during development and after marketing of a new drug—proposals for designing non-clinical and clinical studies—is the non-clinical study useful? Ozawa N. **J Toxicol Sci** 1996 Dec;21(5):323–9 (3 ref.)
Post-approval drug research: objectives and methods. Schäfer H. **Pharmacopsychiatry** 1997 Jan;30(1 Suppl):4–8 (20 ref.)
[Tolerance and safety of tramadol use. Results of international studies and data from drug surveillance] Cossmann M, et al. **Drugs** 1997;53 Suppl 2:50–62 (68 ref.) (Eng. Abstr.) **(Fre)**
[Pharmacovigilance off the beaten track: herbal surveillance or pharmacovigilance of medicinal plants] Castot A, et al. **Therapie** 1997 Mar–Apr;52(2):97–103 (41 ref.) (Eng. Abstr.) **(Fre)**
[Pharmacovigilance of self-medication] Montastruc JL, et al. **Therapie** 1997 Mar–Apr;52(2):105–10 (26 ref.) (Eng. Abstr.) **(Fre)**
[Planning, realization and evaluation of post-marketing surveillance studies. Recommendations of the Society for Phytotherapy] Kraft K, et al. **Arzneimittelforschung** 1997 Aug;47(8):990–4 (16 ref.) (Eng. Abstr.) **(Ger)**
[Drug surveillance and adverse reactions to drugs. The literature and importance of historical data] Mariani L, et al. **Clin Ter** 1996 Dec;147(12):653–72 (35 ref.) (Eng. Abstr.) **(Ita)**

METHODS

Good practice in the postmarketing surveillance of medicines. Meyboom RH. **Pharm World Sci** 1997 Aug;19(4):186–90 (48 ref.)

PRODUCTIVITY see **EFFICIENCY**

PRODUCTIVITY, ORGANIZATIONAL see **EFFICIENCY, ORGANIZATIONAL**

PROENZYMES see **ENZYME PRECURSORS**

PROERYTHROBLASTS see **ERYTHROBLASTS**

PROESTRUS

PHYSIOLOGY

Oxytocin and the control of LH. Evans JJ. **J Endocrinol** 1996 Nov;151(2):169–74 (75 ref.)

PROFESSIONAL AUTONOMY

A deviant comes of age. Ford LC. **Heart Lung** 1997 Mar–Apr;26(2):87–91 (20 ref.)
Technology and nursing: an anatomy of definition. Barnard A. **Int J Nurs Stud** 1996 Aug;33(4):433–41 (60 ref.)
Social epistemology, gender and nursing theory. Cash K. **Int J Nurs Stud** 1997 Apr;34(2):137–43 (27 ref.)
The postmodernist hoax and its effects on nursing. Kermode S, et al. **Int J Nurs Stud** 1996 Aug;33(4):375–84 (36 ref.)
Emerging licensing issues in Canada and the US. **Int Nurs Rev** 1996 Jul–Aug;43(4):113–20, 126 (37 ref.)
Towards a critical theory of mental health nursing. Hopton J. **J Adv Nurs** 1997 Mar;25(3):492–500 (72 ref.)
The management of the client with a leg ulcer: precarious nursing practice. Husband LL. **J Adv Nurs** 1996 Jul; 24(1):53–9 (32 ref.)
The concept of the specialist community nurse. Kelly A. **J Adv Nurs** 1996 Jul;24(1):42–52 (51 ref.)
The emergency nurse practitioner role in major accident and emergency departments: professional issues and the research agenda. Tye CC. **J Adv Nurs** 1997 Aug; 26(2):364–70 (54 ref.)
The nurse's role as patient advocate: obligation or imposition? Willard C. **J Adv Nurs** 1996 Jul;24(1):60–6 (30 ref.)
Capitation: the legal implications of using capitation to affect physician decision-making processes. Ruskin A. **J Contemp Health Law Policy** 1997 Spring;13(2):391–421 (169 ref.)
The normative constitution of professional power [see comments] Frankford DM. **J Health Polit Policy Law** 1997 Feb;22(1):185–221 (95 ref.) Comment in: J Health Polit Policy Law 1997 Feb;22(1):223–30. Comment in: J Health Polit Policy Law 1997 Feb;22(1):231–43.
Academic freedom amidst competing demands. Larson E. **J Prof Nurs** 1997 Jul–Aug;13(4):211–6 (8 ref.)
Stages of nursing's political development: where we've been and where we ought to go. Cohen SS, et al. **Nurs Outlook** 1996 Nov–Dec;44(6):259–66 (64 ref.)
Freedom and democracy in health care ethics: is the cart before the horse? Meaney ME. **Theor Med** 1996 Dec; 17(4):399–414 (21 ref.)
Reproductive health and blurred professional boundaries. Chavkin W, et al. **Womens Health Issues** 1996 Mar–Apr; 6(2):89–96 (46 ref.)

PROFESSIONAL COMPETENCE

Professional responsibility in elder law: a synthesis of preventive law and therapeutic jurisprudence. Stolle DP. **Behav Sci Law** 1996 Autumn;14(4):459–78 (0 ref.)
Emerging licensing issues in Canada and the US. **Int Nurs Rev** 1996 Jul–Aug;43(4):113–20, 126 (37 ref.)
Intuition and rational decision-making in professional thinking: a false dichotomy? Easen P, et al. **J Adv Nurs** 1996 Oct;24(4):667–73 (28 ref.)
Scientific knowledge in medicine: a new clinical epistemology? Marshall T. **J Eval Clin Pract** 1997 Apr; 3(2):133–8 (16 ref.)
Selection and use of content experts for instrument development. Grant JS, et al. **Res Nurs Health** 1997 Jun; 20(3):269–74 (25 ref.)

PROFESSIONAL-FAMILY RELATIONS

Reconciling the patient's right to confidentiality and the family's need to know [see comments] Furlong M, et al. **Aust N Z J Psychiatry** 1996 Oct;30(5):614–22 (27 ref.) Comment in: Aust N Z J Psychiatry 1997 Jun;31(3):429–31.
The experiences of families with a relative in the intensive care unit. Jamerson PA, et al. **Heart Lung** 1996 Nov–Dec; 25(6):467–74 (36 ref.)
Hope facilitating strategies for the family of the head injury patient. Johnson LH, et al. **J Neurosci Nurs** 1996 Aug; 28(4):259–66 (35 ref.)
Understanding the caring relationship during marrow transplantation: family caregivers and healthcare professionals. Compton K, et al. **Oncol Nurs Forum** 1996 Oct;23(9):1428–32 (16 ref.)

PROFESSIONAL LIABILITY see **LIABILITY, LEGAL**

PROFESSIONAL-PATIENT RELATIONS

see related
TRUTH DISCLOSURE

Lessons from medicine and nursing for pharmacist-patient communication. Landis NT. **Am J Health Syst Pharm** 1996 Jun 1;53(11):1306–14 (66 ref.)
Should we trade person-centered service for a consumer-based model? Peloquin SM. **Am J Occup Ther** 1997 Jul–Aug;51(7):612–5 (26 ref.)
A Copernican revolution in clinical ethics: engagement versus disengagement. Van Amburg R. **Am J Occup Ther** 1997 Mar;51(3):186–90 (20 ref.)
Suicide: how to survive as a survivor? Grad OT. **Crisis** 1996; 17(3):136–42 (38 ref.)
Sexuality in the mental health system. Patients and practitioners. Gutheil TG, et al. **Int J Law Psychiatry** 1996 Spring;19(2):183–90 (15 ref.)
Communication through interpreters in healthcare: ethical dilemmas arising from differences in class, culture, language, and power [see comments] Kaufert JM, et al. **J Clin Ethics** 1997 Spring;8(1):71–87 (47 ref.) Comment in: J Clin Ethics 1997 Spring;8(1):88–93.
From what's neutral to what's meaningful: reflections on a study of medical interpreters [see comments] Solomon MZ. **J Clin Ethics** 1997 Spring;8(1):88–93 (11 ref.) Comment in: J Clin Ethics 1997 Spring;8(1):71–87.
Exploring a fourth dimension: spirituality as a resource for the couple therapist. Anderson DA, et al. **J Marital Fam Ther** 1997 Jan;23(1):3–12 (32 ref.)
Respect for the patient's integrity and self-determination—an ethical imperative called upon in the Swedish Health and Medical Care Act. Margareta A. **Med Law** 1996; 15(2):189–93 (9 ref.)
Establishing a therapeutic alliance with substance abusers. Luborsky L, et al. **NIDA Res Monogr** 1997;165:233–44 (37 ref.)
Establishing and maintaining a therapeutic alliance with substance abuse patients: a cognitive therapy approach. Newman CF. **NIDA Res Monogr** 1997;165:181–206 (38 ref.)
Psychoanalytic observations on the "gift" technique in the treatment of the dying patient: a case report. Garcia EE. **Psychoanal Rev** 1996 Jun;83(3):395–418 (39 ref.)
The psychoanalytic relationship: past and present. Panken S. **Psychoanal Rev** 1996 Apr;83(2):157–79 (76 ref.)
Defining the components of street outreach for HIV prevention: the contact and the encounter. Valentine J, et al. **Public Health Rep** 1996;111 Suppl 1:69–74 (27 ref.)
Imaging patients with chronic disabilities. Davidhizar R, et al. **Radiol Technol** 1997 Jul–Aug;68(6):520–2 (9 ref.)
Interaction, language and the "narrative turn" in psychotherapy and psychiatry. Brown B, et al. **Soc Sci Med** 1996 Dec;43(11):1569–78 (83 ref.)
"Things were different then": countertransference issues for younger female therapists working with older female clients. Levine L. **Soc Work Health Care** 1996;22(4):73–88 (20 ref.)
Listening or telling? Thoughts on responsibility in clinical ethics consultation. Zaner RM. **Theor Med** 1996 Sep; 17(3):255–77 (74 ref.)

PROFESSIONAL PRACTICE

see related
PRACTICE MANAGEMENT, MEDICAL

Therapeutic occupation: a definition. Nelson DL. **Am J Occup Ther** 1996 Nov–Dec;50(10):775–82 (21 ref.)
Advances in computer technology: impact on the practice of medicine. Groth-Vasselli B, et al. **J Med** 1995; 26(5–6):323–31 (18 ref.)
Conceptualization, measurement, and use of gestational age. I. Clinical and public health practice. Alexander GR, et al. **J Perinatol** 1996 Jan–Feb;16(1):53–9 (57 ref.)
Elements of a nursing professional practice model. Hoffart N, et al. **J Prof Nurs** 1996 Nov–Dec;12(6):354–64 (62 ref.)
Expanding the role of the nurse in the Accident and Emergency department. Neades BL. **Postgrad Med J** 1997 Jan;73(855):17–22 (67 ref.)
Towards effective professional practice. Grimshaw JM. **Therapie** 1996 May–Jun;51(3):233–6 (29 ref.)
On the need for evidence-based medicine. Rosenberg WM, et al. **Therapie** 1996 May–Jun;51(3):212–7 (22 ref.)
Studies of ethical conflicts by nursing practice settings or roles. Redman BK, et al. **West J Nurs Res** 1997 Apr; 19(2):243–60 (38 ref.)

ORGANIZATION & ADMINISTRATION

Faculty practice in an age of entrepreneurship: can occupational therapy educators add yet another role? Hanson C, et al. **Am J Occup Ther** 1997 May;51(5):388–92 (22 ref.)
Career satisfaction and clinician-educators. The rewards and challenges of teaching. The Society of General Internal Medicine Career Satisfaction Study Group. Gerrity MS, et al. **J Gen Intern Med** 1997 Apr;12 Suppl 2:S90–7 (55 ref.)
Community-oriented primary care. Nevin JE, et al. **Prim Care** 1996 Mar;23(1):1–15 (23 ref.)

STANDARDS

The performance of doctors. I: Professionalism and self regulation in a changing world. Irvine D. **BMJ** 1997 May 24;314(7093):1540–2 (21 ref.)
The performance of doctors. II: Maintaining good practice, protecting patients from poor performance [see comments] Irvine D. **BMJ** 1997 May 31;314(7094):1613–5 (11 ref.) Comment in: BMJ 1997 May 31;314(7094):1568.

TRENDS

The meaning of professionalism in medicine. Benatar SR. **S Afr Med J** 1997 Apr;87(4):427–31 (45 ref.)

PROFESSIONAL REVIEW ORGANIZATIONS

STANDARDS

HCFA's health care quality improvement program: the medical informatics challenge. Grant JB, et al. **J Am Med Inform Assoc** 1996 Jan–Feb;3(1):15–26 (47 ref.)

PROFESSIONAL STAFF COMMITTEES

see related
UTILIZATION REVIEW

Data monitoring committees and problems of lower–than–expected accrual or events rates. Korn EL, et al. **Control Clin Trials** 1996 Dec;17(6):526–35 (38 ref.)
The Pew Commission's crystal ball. Tilson E, et al. **Radiol Technol** 1996 Nov–Dec;68(2):167–9 (3 ref.)

LEGISLATION & JURISPRUDENCE

Conflict of interest and institutional review boards. Cho MK, et al. **J Investig Med** 1997 Apr;45(4):154–9 (44 ref.)

PROFESSIONAL STANDARDS REVIEW ORGANIZATIONS see **PROFESSIONAL REVIEW ORGANIZATIONS**

PROFIBRINOLYSIN see **PLASMINOGEN**

PROGENITOR CELLS see **STEM CELLS**

PROGENITOR CELLS, ERYTHROPOIETIC see **ERYTHROID PROGENITOR CELLS**

PROGENITOR CELLS, HEMATOPOIETIC see **HEMATOPOIETIC STEM CELLS**

PROGERIA

[Progeria] Kondoh F, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):326–7 (12 ref.) **(Jpn)**

DIAGNOSIS

A probable case of Wiedemann–Rautenstrauch syndrome or neonatal progeroid syndrome and review of the literature. Courtens W, et al. **Clin Dysmorphol** 1997 Jul;6(3):219–27 (26 ref.)

PROGERIA, ADULT see **WERNER'S SYNDROME**

PROGESTATIONAL HORMONE ANALOGS see **PROGESTATIONAL HORMONES, SYNTHETIC**

PROGESTATIONAL HORMONES

Long–acting progestogen–only contraception. **Drug Ther Bull** 1996 Dec;34(12):93–6 (23 ref.)

ADMINISTRATION & DOSAGE

Estrogen–progestin replacement therapy and atherosclerosis. Punnonen R, et al. **Maturitas** 1996 May;23 Suppl:S61–4 (15 ref.)
Estrogens, progestins and lipid metabolism. Tikkanen MJ. **Maturitas** 1996 May;23 Suppl:S51–5 (24 ref.)

ADVERSE EFFECTS

Estrogen and progestin components of oral contraceptives: relationship to vascular disease. Carr BR, et al. **Contraception** 1997 May;55(5):267–72 (36 ref.)
The pharmacology and effectiveness of specific lipid–active drugs: estrogen/sex steroids. LaRosa JC. **Coron Artery Dis** 1996 Sep;7(9):683–8 (37 ref.)
Progestogen intolerance and compliance with hormone replacement therapy in menopausal women. Panay N, et al. **Hum Reprod Update** 1997 Mar–Apr;3(2):159–71 (73 ref.)
Cancer risk in women receiving estrogen–progestin replacement therapy. Persson I. **Maturitas** 1996 May;23 Suppl:S37–45 (42 ref.)
Effect of oral contraceptives on haemostasis variables. Kluft C, et al. **Thromb Haemost** 1997 Jul;78(1):315–26 (141 ref.)
[Do progestins have drawbacks?] Sitruk–Ware R. **Contracept Fertil Sex** 1997 May;25(5):352–7 (44 ref.) **(Fre)**

ANALYSIS

Classification and comparison of oral contraceptives containing new generation progestogens. Newton JR. **Hum Reprod Update** 1995 May;1(3):231–63 (322 ref.)

ANTAGONISTS & INHIBITORS

Clinical uses of antiprogestogens. Van Look PF, et al. **Hum Reprod Update** 1995 Jan;1(1):19–34 (113 ref.)

PHARMACOLOGY

Progestin and estrogen regulation of pulsatile LH release and development of persistent ovarian follicles in cattle. Kinder JE, et al. **J Anim Sci** 1996 Jun;74(6):1424–40 (66 ref.)
Effects of progestogens on haemostasis. Kuhl H. **Maturitas** 1996 May;24(1–2):1–19 (141 ref.)

PHYSIOLOGY

A speculative review of parturition in the mare. Thorburn GD. **Equine Vet J Suppl** 1993 Apr;(14):41–9 (72 ref.)
Ovarian steroids and the brain: implications for cognition and aging. McEwen BS, et al. **Neurology** 1997 May;48(5 Suppl 7):S8–15 (90 ref.)

THERAPEUTIC USE

Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 3. Effects of ovarian hormone therapy on skeletal and extraskeletal tissues in women [see comments] Josse RG. **Can Med Assoc J** 1996 Oct 1;155(7):929–34 (28 ref.) Comment in: Can Med Assoc J 1997 Jun 1;156(11):1530, 1532.
The role of androgens in menopausal hormonal replacement. Kaunitz AM. **Endocrinol Metab Clin North Am** 1997 Jun; 26(2):391–7 (19 ref.)
Endometrial cancer and hormone replacement therapy. Appropriate use of progestins to oppose endogenous and exogenous estrogen. Sulak PJ. **Endocrinol Metab Clin North Am** 1997 Jun;26(2):399–412 (41 ref.)
Hormonal treatment in advanced non–small cell lung cancer: fact or fiction? Vansteenkiste JF, et al. **Eur Respir J** 1996 Aug;9(8):1707–12 (48 ref.)
Medical treatment of symptomatic endometriosis. Cirkel U. **Hum Reprod** 1996 Nov;11 Suppl 3:89–101 (40 ref.)
Progestin–androgen combination regimens for male contraception. Meriggiola MC, et al. **J Androl** 1997 May–Jun;18(3):240–4 (41 ref.)
Progestins. Hirvonen E. **Maturitas** 1996 May;23 Suppl:S13–8 (13 ref.)
Effects of estrogens and progestogens on the renin–aldosterone system and blood pressure. Oelkers WK. **Steroids** 1996 Apr;61(4):166–71 (50 ref.)

PROGESTATIONAL HORMONES, SYNTHETIC

see related
ANTINEOPLASTIC AGENTS, HORMONAL
CONTRACEPTIVE AGENTS, FEMALE
CONTRACEPTIVES, ORAL, SYNTHETIC

ADMINISTRATION & DOSAGE

Management of abnormal bleeding in women receiving hormone replacement therapy. Spencer CP, et al. **BMJ** 1997 Jul 5;315(7099):37–42 (39 ref.)
Progestin–releasing intrauterine devices. Toivonen J, et al. **Curr Ther Endocrinol Metab** 1997;6:281–5 (7 ref.)

ADVERSE EFFECTS

Comments on desogestrel and gestoden (3rd generation progestogens) and the incidence of thromboembolism. Lauritzen C. **Horm Metab Res** 1996 May;28(5):245–7 (11 ref.)
A comparison of mechanisms underlying disturbances of bleeding caused by spontaneous dysfunctional uterine bleeding or hormonal contraception. Fraser IS, et al. **Hum Reprod** 1996 Oct;11 Suppl 2:165–78 (82 ref.)
Progestogen–only pills and bleeding disturbances. Kovacs G. **Hum Reprod** 1996 Oct;11 Suppl 2:20–3 (22 ref.)
Increased risk from third–generation progestogens: fuzzy logic or fuzzy science? [editorial] Corson SL. **J Reprod Med** 1996 Sep;41(9):711–2 (10 ref.)
[Effect of progestins on the breast—protective or proliferative?] Schindler AE. **Zentralbl Gynakol** 1997; 119(8):359–65 (51 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSTIC USE

The progestogen challenge test in postmenopausal women: clinical and morphologic aspects. Bortoletto C de C, et al. **Rev Paul Med** 1996 May–Jun;114(3):1166–72 (28 ref.)

PHARMACOKINETICS

Pharmacokinetics of the new progestogens and influence of gestodene and desogestrel on ethinylestradiol metabolism. Stanczyk FZ. **Contraception** 1997 May;55(5):273–82 (38 ref.)

PHARMACOLOGY

Implantable hormonal and emergency contraception. Cullins VE, et al. **Curr Opin Obstet Gynecol** 1997 Jun;9(3):169–74 (44 ref.)

PROGESTERONE

see related
RECEPTORS, PROGESTERONE

ADMINISTRATION & DOSAGE

Postmenopausal hormone replacement therapy and insulin metabolism: effects of route of administration and implications for heart disease and diabetes risk. Godsland IF, et al. **Br J Clin Pract Symp Suppl** 1996 Sep;86:1–5 (43 ref.)

ADVERSE EFFECTS

[Effect of progestins on the breast—protective or proliferative?] Schindler AE. **Zentralbl Gynakol** 1997; 119(8):359–65 (51 ref.) (Eng. Abstr.) **(Ger)**

ANTAGONISTS & INHIBITORS

Antiprogestin–progesterone interactions. Michna H, et al. **Cancer Treat Res** 1996;83:191–212 (99 ref.)
Hormonal requirement for blastocyst implantation and a new approach for anti–implantation strategy. Ghosh D, et al. **Indian J Physiol Pharmacol** 1997 Apr;41(2):101–8 (54 ref.)

BLOOD

Oestrogens and progesterone concentrations and risk of ectopic pregnancy: an epidemiological point of view [comment] Parazzini F. **Hum Reprod** 1996 Feb;11(2):236–8 (20 ref.) Comment on: Hum Reprod 1996 Feb;11(2):235–6.

DIAGNOSTIC USE

[LH–RH test, clomiphene test, Premarin test, and Kaufmann test] Shimizu Y, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:397–408 (11 ref.) **(Jpn)**

METABOLISM

Testosterone and progesterone metabolism in the central nervous system: cellular localization and mechanism of control of the enzymes involved. Martini L, et al. **Cell Mol Neurobiol** 1996 Jun;16(3):271–82 (60 ref.)

PHARMACOLOGY

Endometrial preparation: lessons from oocyte donation. Younis JS, et al. **Fertil Steril** 1996 Dec;66(6):873–84 (89 ref.)
Progesterone: does it affect response to drug? Kroboth PD, et al. **Psychopharmacol Bull** 1997;33(2):297–301 (18 ref.)

PHYSIOLOGY

The corpus luteum revisited: are the paradoxical effects of RU486 a clue to how progesterone stimulates its own secretion? Rothchild I. **Biol Reprod** 1996 Jul;55(1):1–4 (34 ref.)
Progesterone as a neurosteroid: actions within the nervous system. Baulieu EE, et al. **Cell Mol Neurobiol** 1996 Apr; 16(2):143–54 (50 ref.)
Physiological action of progesterone in target tissues. Graham JD, et al. **Endocr Rev** 1997 Aug;18(4):502–19 (231 ref.)
Ovarian steroidal control of connectivity in the female hippocampus: an overview of recent experimental findings and speculations on its functional consequences. Desmond NL, et al. **Hippocampus** 1997;7(2):239–45 (85 ref.)
The human sperm acrosome reaction: physiology and regulatory mechanisms. An update. Brucker C, et al. **Hum Reprod Update** 1995 Jan;1(1):51–62 (103 ref.)
Hormonal regulation of the normal breast. von Schoultz B, et al. **Maturitas** 1996 May;23 Suppl:S23–5 (13 ref.)
Neurosteroids, with special reference to the effect of progesterone on myelination in peripheral nerves. Baulieu EE, et al. **Mult Scler** 1997 Apr;3(2):105–12 (51 ref.)

THERAPEUTIC USE

Hormone replacement therapy. **Drug Ther Bull** 1996 Nov; 34(11):81–4 (32 ref.)
Medicinal drugs with hormonal activity as chemopreventive agents. Cuzick J. **IARC Sci Publ** 1996;(139):99–114 (116 ref.)
Endocrinology of melanoma. Neifeld JP. **Semin Surg Oncol** 1996 Nov–Dec;12(6):402–6 (37 ref.)

PROGESTERONE RECEPTORS see **RECEPTORS, PROGESTERONE**

PROGESTIN ANALOGS see **PROGESTATIONAL HORMONES, SYNTHETIC**

PROGESTIN RECEPTORS see **RECEPTORS, PROGESTERONE**

PROGESTINS see **PROGESTATIONAL HORMONES**

PROGESTINS, SYNTHETIC see **PROGESTATIONAL**

PROGESTINS, SYNTHETIC

HORMONES, SYNTHETIC

PROGESTOGENS see **PROGESTATIONAL HORMONES**

PROGESTOGENS, SYNTHETIC see **PROGESTATIONAL HORMONES, SYNTHETIC**

PROGLUMIDE RECEPTORS see **RECEPTORS, CHOLECYSTOKININ**

PROGNATHISM

GENETICS

A history of miscarriages and mild prognathism as possible mode of presentation of mosaic trisomy 18 in women. Satge D, et al. **Clin Genet** 1996 Dec;50(6):470–3 (22 ref.)

SURGERY

Peripheral facial palsy after sagittal split ramus osteotomy for setback of the mandible. A case report. Sakashita H, et al. **Int J Oral Maxillofac Surg** 1996 Jun;25(3):182–3 (11 ref.)

PROGNOSIS

[Prognostic scores in intensive care] Unertl K, et al. **Anaesthesist** 1997 Jun;46(6):471–80 (64 ref.) (Eng. Abstr.) **(Ger)**

PROGNOSTIC NUTRITIONAL INDEX (PNI) see **NUTRITION ASSESSMENT**

PROGONOMA, MELANOTIC see **NEUROECTODERMAL TUMOR, MELANOTIC**

PROGRAM DEVELOPMENT

Specimen banking—a planning in advance. Olsson M, et al. **Chemosphere** 1997 May;34(9–10):1961–74 (23 ref.)

Memory enhancement program for community-based older adults: development and evaluation. Caprio-Prevette MD, et al. **Exp Aging Res** 1996 Jul-Sep;22(3):281–303 (41 ref.)

The prevention and treatment of thromboembolic disease in children: a need for Thrombophilia Programs. Andrew M, et al. **J Pediatr Hematol Oncol** 1997 Jan–Feb;19(1):7–22 (192 ref.)

Success on the road to adulthood. Issues and hurdles for adolescents with disabilities. White PH. **Rheum Dis Clin North Am** 1997 Aug;23(3):697–707 (44 ref.)

The design of veterinary vaccination programmes [see comments] Woolhouse ME, et al. **Vet J** 1997 Jan; 153(1):41–7 (18 ref.) Comment in: Vet J 1997 Jan;153(1):7–8.

[The practical theory of occupational health planning: Part Two—The theoretical background from the priority setting procedure to the post project appraisal making procedure (OPST research report 3)] Jahng DJ, et al. **Sangyo Ika Daigaku Zasshi** 1996 Sep 1;18(3):203–11 (17 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Conducting a descriptive survey: 1. Planning the survey. Macfarlane SB. **Trop Doct** 1996 Oct;26(4):161–4 (9 ref.)

PROGRAM EFFICIENCY see **EFFICIENCY, ORGANIZATIONAL**

PROGRAM EVALUATION

The National 5 A Day for Better Health Program. Heimendinger J, et al. **Adv Exp Med Biol** 1996;401:199–206 (29 ref.)

Training in laparoscopic surgery—have we got it right yet? Ooi LL. **Ann Acad Med Singapore** 1996 Sep;25(5):732–6 (34 ref.)

Evaluating healthcare policies: the case of clinical audit. Lord J, et al. **BMJ** 1997 Sep 13;315(7109):668–71 (30 ref.)

The Fort Bragg continuum of care Demonstration Project: the population served was unique and the outcomes are questionable. Mordock JB. **Child Psychiatry Hum Dev** 1997 Summer;27(4):241–54 (63 ref.)

Memory enhancement program for community-based older adults: development and evaluation. Caprio-Prevette MD, et al. **Exp Aging Res** 1996 Jul-Sep;22(3):281–303 (41 ref.)

Occupational stress management programmes: a practical overview of published effect studies. van der Hek H, et al. **Occup Med (Oxf)** 1997 Apr;47(3):133–41 (53 ref.)

[The practical theory of occupational health planning: Part Two—The theoretical background from the priority setting procedure to the post project appraisal making procedure (OPST research report 3)] Jahng DJ, et al. **Sangyo Ika Daigaku Zasshi** 1996 Sep 1;18(3):203–11 (17 ref.) (Eng. Abstr.) **(Jpn)**

ECONOMICS

Economic evaluation of mental health care interventions. A review. Evers SM, et al. **Health Econ** 1997 Mar–Apr; 6(2):161–77 (161 ref.)

METHODS

Alcohol misuse prevention for young people: a systematic review reveals methodological concerns and lack of reliable evidence of effectiveness. Foxcroft DR, et al. **Addiction** 1997 May;92(5):531–7 (45 ref.)

Design and conduct of occupational injury intervention studies: a review of evaluation strategies. Zwerling C, et al. **Am J Ind Med** 1997 Aug;32(2):164–79 (105 ref.)

Choosing among alternative programs for poor children. Currie JM. **Future Child** 1997 Summer–Fall;7(2):113–31 (43 ref.)

Continuing pain education in nursing: a literature review. Francke AL, et al. **Int J Nurs Stud** 1996 Oct;33(5):567–78 (37 ref.)

Evaluating the performance of the APN. Nugent KE, et al. **Nurse Pract** 1997 Apr;22(4):190, 193–4, 197–8 (17 ref.)

The challenge of evaluating a child bereavement programme. Stokes J, et al. **Palliat Med** 1997 May;11(3):179–90 (32 ref.)

Pseudoissues in practice evaluation: impediments to responsible practice. Staudt M. **Soc Work** 1997 Jan; 42(1):99–106 (36 ref.)

PROGRAM EVALUATION, NURSING see **NURSING EVALUATION RESEARCH**

PROGRAMMABLE IMPLANTABLE INSULIN PUMP see **INSULIN INFUSION SYSTEMS**

PROGRAMMABLE IMPLANTABLE MEDICATION SYSTEMS see **INFUSION PUMPS, IMPLANTABLE**

PROGRAMMED INSTRUCTION, COMPUTERIZED see **COMPUTER-ASSISTED INSTRUCTION**

PROGRANULOCYTIC LEUKEMIA see **LEUKEMIA, PROMYELOCYTIC, ACUTE**

PROGRESSIVE INTERSTITIAL PNEUMONIA OF SHEEP see **PNEUMONIA, PROGRESSIVE INTERSTITIAL, OF SHEEP**

PROGRESSIVE LENTICULAR DEGENERATION see **HEPATOLENTICULAR DEGENERATION**

PROGRESSIVE MUSCULAR ATROPHY see **MUSCULAR ATROPHY, SPINAL**

PROGRESSIVE PATIENT CARE

ORGANIZATION & ADMINISTRATION

High dependency units: role and need [editorial] Bodenham AR, et al. **Br J Hosp Med** 1996 Sep 4–17;56(5):192–3 (8 ref.)

PROJECTION

Critical bits and the Rorschach response process. Exner JE Jr. **J Pers Assess** 1996 Dec;67(3):464–77 (15 ref.)

PROJECTIONS AND PREDICTIONS see **FORECASTING**

PROJECTIVE TECHNIQUES

The use of projective techniques in pediatric nursing research from 1984 to 1993. Bellack JP, et al. **J Pediatr Nurs** 1996 Feb;11(1):10–28 (36 ref.)

PROKARYOTIC CELLS

CYTOLOGY

What size should a bacterium be? A question of scale. Koch AL. **Annu Rev Microbiol** 1996;50:317–48 (111 ref.)

METABOLISM

Cloned potassium channels from eukaryotes and prokaryotes. Jan LY, et al. **Annu Rev Neurosci** 1997;20:91–123 (281 ref.)

High temperature ecosystems and their chemical interactions with their environment. Pentecost A. **Ciba Found Symp** 1996;202:99–108; discussion 108–11 (40 ref.)

PHYSIOLOGY

Circadian clocks in prokaryotes. Johnson CH, et al. **Mol Microbiol** 1996 Jul;21(1):5–11 (40 ref.)

PROLACTIN

see related
HYPERPROLACTINEMIA
RECEPTORS, PROLACTIN

Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Ben-Jonathan N, et al. **Endocr Rev** 1996 Dec;17(6):639–69 (368 ref.)

Immunoregulatory properties of growth hormone and prolactin. Weigent DA. **Pharmacol Ther** 1996;69(3):237–57 (258 ref.)

ANALYSIS

Prolactin, growth hormone, and insulin-like growth factor-I in the immune system. Kooijman R, et al. **Adv Immunol** 1996;63:377–454 (364 ref.)

BIOSYNTHESIS

Role of Pit-1 in the gene expression of growth hormone, prolactin, and thyrotropin. Cohen LE, et al. **Endocrinol Metab Clin North Am** 1996 Sep;25(3):523–40 (94 ref.)

BLOOD

Epilepsy and prolactin in adults: a clinical review. Bauer J. **Epilepsy Res** 1996 May;24(1):1–7 (52 ref.)

Lack of association between prolactin levels and clinical activity in patients with systemic lupus erythematosus [letter; comment] Mok CC, et al. **J Rheumatol** 1996 Dec; 23(12):2185–6 (3 ref.) Comment on: J Rheumatol 1996 Apr;23(4):629–32.

Heterogeneity of human prolactin. Influence on immunoassays (RIA and IRMA). Claustrat B, et al. **Nucl Med Biol** 1994 Apr;21(3):331–5 (30 ref.)

[Prolactin and autoimmune diseases] Yang X, et al. **Chung Hua Nei Ko Tsa Chih** 1996 Jan;35(1):60–2 (20 ref.) **(Chi)**

CHEMISTRY

Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen, and related proteins in mammals. Goffin V, et al. **Endocr Rev** 1996 Aug;17(4):385–410 (244 ref.)

DEFICIENCY

Isolated prolactin deficiency. Kauppila A. **Curr Ther Endocrinol Metab** 1997;6:31–3 (4 ref.)

DRUG EFFECTS

Cocaine's effects on neuroendocrine systems: clinical and preclinical studies. Mello NK, et al. **Pharmacol Biochem Behav** 1997 Jul;57(3):571–99 (255 ref.)

IMMUNOLOGY

Prolactin as an immunoreactive agent. Draca S. **Immunol Cell Biol** 1995 Dec;73(6):481–3 (35 ref.)

METABOLISM

Effects of melatonin infused into the III ventricle on prolactin, beta-endorphin and luteotropin secretion in ewes during the different stages of the reproductive cycle. Misztal T, et al. **Acta Neurobiol Exp (Warsz)** 1996; 56(3):769–78 (32 ref.)

Prolactin disorders. Yazigi RA, et al. **Fertil Steril** 1997 Feb; 67(2):215–25 (100 ref.)

Prolactin signaling in mammary gland development. Hennighausen L, et al. **J Biol Chem** 1997 Mar 21; 272(12):7567–9 (40 ref.)

Protein sorting and secretory granule formation in prolactin-producing cells in the anterior pituitary. Ozawa H. **Kaibogaku Zasshi** 1997 Feb;72(1):13–24 (62 ref.)

Molecular actions of prolactin in the immune system. Yu-Lee LY. **Proc Soc Exp Biol Med** 1997 May;215(1):35–52 (292 ref.)

PHARMACOLOGY

Molecular actions of prolactin in the immune system. Yu-Lee LY. **Proc Soc Exp Biol Med** 1997 May;215(1):35–52 (292 ref.)

PHYSIOLOGY

Prolactin and systemic lupus erythematosus. McMurray RW. **Ann Med Interne (Paris)** 1996;147(4):253–8 (37 ref.)

Integrative functions of lactational hormones in social behavior and stress management. Carter CS, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:164–74 (78 ref.)

Adaptation of islets of Langerhans to pregnancy: beta-cell growth, enhanced insulin secretion and the role of lactogenic hormones. Sorenson RL, et al. **Horm Metab Res** 1997 Jun;29(6):301–7 (59 ref.)

[Hormones and male sexual behavior: physiological and physiopathological data] Buvat J. **Contracept Fertil Sex** 1996 Oct;24(10):767–78 (93 ref.) (Eng. Abstr.) **(Fre)**

[Prolactin and male infertility—unsolved enigma] Bar-On E, et al. **Harefuah** 1996 May 1;130(9):617–21 (46 ref.) **(Heb)**

[The transcendence of prolactin and its relation to the immune response] Sandoval C, et al. **Ginecol Obstet Mex** 1997 Apr;65:148–51 (26 ref.) (Eng. Abstr.) **(Spa)**

[Endocrine regulation of the immune response. Prolactin and its function] Durán Chávez C, et al. **Rev Alerg** 1993 Mar-Apr;40(2):27–32 (57 ref.) (Eng. Abstr.) **(Spa)**

SECRETION

Serotonergic regulation of renin and prolactin secretion. Van de Kar LD, et al. **Behav Brain Res** 1996;73(1–2):203–8 (44 ref.)

PROLACTIN-PRODUCING PITUITARY ADENOMA see **PROLACTINOMA**

PROLACTIN RECEPTORS see **RECEPTORS,**

PROLACTIN

PROLACTINOMA

see related
HYPERPROLACTINEMIA

Nerve growth factor suppresses the tumoral phenotype of human prolactinomas. Missale C, et al. **Horm Res** 1997; 47(4–6):240–4 (29 ref.)

DRUG THERAPY

[Quinagolide and macroprolactinomas a progress?] Jaquet P. **Ann Endocrinol (Paris)** 1997;58(2):83–5 (35 ref.) **(Fre)**

[Treatment of macroprolactinomas with quinagolide (Norprolac)] Tabarin A, et al. **Ann Endocrinol (Paris)** 1997; 58(2):87–94 (30 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Two case reports of breast carcinoma associated with prolactinoma. Strungs I, et al. **Pathology** 1997 Aug; 29(3):320–3 (29 ref.)

SECRETION

Prolactinomas. Katznelson L, et al. **Cancer Treat Res** 1997; 89:41–55 (40 ref.)

THERAPY

Prolactinoma. Schlechte JA. **Curr Ther Endocrinol Metab** 1997;6:45–7 (5 ref.)

Recent management of pituitary adenomas. Teramoto A. **Nippon Ika Daigaku Zasshi** 1996 Aug;63(4):255–8 (8 ref.)

PROLAPSED DISK see **INTERVERTEBRAL DISK DISPLACEMENT**

PROLIFERATING CELL NUCLEAR ANTIGEN

[Structure and function of proliferating cell nuclear antigen (PCNA)] Morioka H. **Seikagaku** 1996 Sep;68(9):1543–8 (23 ref.) **(Jpn)**

ANALYSIS

Visualization of cell replication using antibody to proliferating cell nuclear antigen. Hyde-Dunn J, et al. **Methods Mol Biol** 1997;75:341–7 (6 ref.)

BIOSYNTHESIS

Analysis of the capillary architecture in the precursors of prostate cancer: recent findings and new concepts. Montironi R, et al. **Eur Urol** 1996;30(2):191–200 (43 ref.)

p53, proliferating cell nuclear antigen, and Ki-67 expression in extrauterine leiomyosarcomas. O'Reilly PE, et al. **Mod Pathol** 1997 Feb;10(2):91–7 (28 ref.)

IMMUNOLOGY

[Proliferating cell nuclear antigen (PCNA)] Ghnassia JP. **Ann Pathol** 1996 Sep;16(4):241–6 (57 ref.) **(Fre)**

PROLIFERATIVE PHASE see **MENSTRUAL CYCLE**

PROLINE

PEST sequences and regulation by proteolysis. Rechsteiner M, et al. **Trends Biochem Sci** 1996 Jul;21(7):267–71 (48 ref.)

[Function of proline-rich regions in proteins and proline specific peptidases] Maruyama S. **Tanpakushitsu Kakusan Koso** 1997 May;42(6):857–64 (56 ref.) **(Jpn)**

ANALOGS & DERIVATIVES

Naturally occurring proline analogues. Mauger AB. **J Nat Prod** 1996 Dec;59(12):1205–11 (193 ref.)

ANALYSIS

PR-39, a proline-rich peptide antibiotic from pig, and FALL-39, a tentative human counterpart. Agerberth B, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):127–31 (19 ref.)

BIOSYNTHESIS

[Proline biosynthesis and water stress tolerance in plants] Yoshiba Y, et al. **Tanpakushitsu Kakusan Koso** 1997 May; 42(6):842–55 (63 ref.) **(Jpn)**

CHEMISTRY

Naturally occurring proline analogues. Mauger AB. **J Nat Prod** 1996 Dec;59(12):1205–11 (193 ref.)

PROLONGED-ACTION PREPARATIONS see **DELAYED-ACTION PREPARATIONS**

PROLYMPHOCYTIC LEUKEMIA see **LEUKEMIA, PROLYMPHOCYTIC**

PROM (PREGNANCY) see **FETAL MEMBRANES, PREMATURE RUPTURE**

PROMOTER (GENETICS) see **PROMOTER REGIONS (GENETICS)**

PROMOTER REGIONS (GENETICS)

see related
GENES, REPORTER

The polymeric immunoglobulin receptor: structure and synthesis. Kaetzel CS, et al. **Biochem Soc Trans** 1997 May; 25(2):475–80 (50 ref.)

Hexokinase II gene: structure, regulation and promoter organization. Printz RL, et al. **Biochem Soc Trans** 1997 Feb;25(1):107–12 (44 ref.)

Regulation of gene expression by ambient pH in Aspergillus: genes expressed at acid pH. Sarkar S, et al. **Biochem Soc Trans** 1996 May;24(2):360–3 (17 ref.)

Regulation of promoters by two transcription activators: evidence for a 'simultaneous touching' model. Savery N, et al. **Biochem Soc Trans** 1996 May;24(2):351–3 (9 ref.)

Transcription initiation from TATA-less promoters within eukaryotic protein-coding genes. Smale ST. **Biochim Biophys Acta** 1997 Mar 20;1351(1–2):73–88 (105 ref.)

Transcription: building an initiation machine. Travers A. **Curr Biol** 1996 Apr 1;6(4):401–3 (22 ref.)

Activation and repression of E. coli promoters. Gralla JD. **Curr Opin Genet Dev** 1996 Oct;6(5):526–30 (41 ref.)

Regulatory mutations in human lipoprotein disorders and atherosclerosis. Kontula K, et al. **Curr Opin Lipidol** 1996 Apr;7(2):64–8 (28 ref.)

Expression of the mouse ACTH receptor gene and characterisation of its promoter. Clark AJ, et al. **Endocr Res** 1996 Nov;22(4):333–5 (3 ref.)

Targets for gene therapy of Parkinson's disease: growth factors, signal transduction, and promoters. During MJ, et al. **Exp Neurol** 1997 Mar;144(1):74–81 (65 ref.)

The novel estrogen receptor-beta subtype: potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens. Kuiper GG, et al. **FEBS Lett** 1997 Jun 23; 410(1):87–90 (32 ref.)

Gene and other biological therapies for vascular diseases. Stephan D, et al. **Fundam Clin Pharmacol** 1997;11(2):97–110 (85 ref.)

Involvement of host factors in transcription from baculovirus very late promoters — a review. Hasnain SE, et al. **Gene** 1997 Apr 29;190(1):113–8 (45 ref.)

Genetics of atopy and asthma: promoter-based candidate gene studies for IL-4. Rosenwasser LJ. **Int Arch Allergy Immunol** 1997 May-Jul;113(1–3):61–4 (19 ref.)

Tyrosines 113, 128, and 145 of SLP-76 are required for optimal augmentation of NFAT promoter activity. Fang N, et al. **J Immunol** 1996 Nov 1;157(9):3769–73 (16 ref.)

Promoters and basal transcription machinery in eubacteria and eukaryotes: concepts, definitions, and analogies. Fassler JS, et al. **Methods Enzymol** 1996;273:3–29 (248 ref.)

Escherichia coli promoter sequences: analysis and prediction. Hertz GZ, et al. **Methods Enzymol** 1996;273:30–42 (37 ref.)

Quantitative parameters for promoter clearance. Hsu LM. **Methods Enzymol** 1996;273:59–71 (30 ref.)

Vectors with bidirectional reporter genes for studying divergent promoters. Jain VK. **Methods Enzymol** 1996; 273:319–31 (25 ref.)

Regulation of transcription of the testis-specific histone H1t gene by multiple promoter elements. Grimes SR Jr, et al. **Mol Biol Rep** 1997 Aug;24(3):175–84 (70 ref.)

Transcription activation at class II CAP-dependent promoters. Busby S, et al. **Mol Microbiol** 1997 Mar; 23(5):853–9 (31 ref.)

Promoter- and cell-specific responses to sex steroids. Milgrom E, et al. **Osteoporos Int** 1997;7 Suppl 1:S23–8 (40 ref.)

Protein-protein interactions during transcription activation: the case of the Escherichia coli cyclic AMP receptor protein. Savery N, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Apr 29; 351(1339):543–50 (33 ref.)

Dexamethasone stimulation of rat insulin-like growth factor binding protein-1 (IGFBP-1) promoter activity involves the interaction of multiple transcription factors. Suh DS, et al. **Prog Growth Factor Res** 1995;6(2–4):131–40 (18 ref.)

A novel DNA/protein complex interacts with the insulin-like growth factor binding protein-1 (IGFBP-1) insulin response sequence and is required for maximal effects of insulin and glucocorticoids on promoter function. Unterman T, et al. **Prog Growth Factor Res** 1995; 6(2–4):119–29 (26 ref.)

Regulation of the tissue factor gene. Mackman N. **Thromb Haemost** 1997 Jul;78(1):747–54 (49 ref.)

Functional significance of polymorphism among MHC class II gene promoters. Guardiola J, et al. **Tissue Antigens** 1996 Dec;48(6):615–25 (114 ref.)

TAFs mediate transcriptional activation and promoter selectivity [see comments] Verrijzer CP, et al. **Trends Biochem Sci** 1996 Sep;21(9):338–42 (50 ref.) Comment in: Trends Biochem Sci 1996 Sep;21(9):325–6.

Core promoters and transcriptional control. Novina CD, et al. **Trends Genet** 1996 Sep;12(9):351–5 (49 ref.)

[Transcriptional regulation of factor IX promoter by HNF 4, ARP 1 and COUP] Naka H. **Rinsho Byori** 1997 Feb; Suppl 104:107–16 (13 ref.) **(Jpn)**

[Description of eukaryotic promoters in the EPD database] Bucher P. **Mol Biol (Mosk)** 1997 Jul-Aug;31(4):616–25 (8 ref.) **(Rus)**

GENETICS

Modified steroid receptors and steroid-inducible promoters as genetic switches for gene therapy. White JH. **Adv Pharmacol** 1997;40:339–67 (155 ref.)

Cytochromes P450 11: expression of the CYP19 (aromatase) gene: an unusual case of alternative promoter usage. Simpson ER, et al. **FASEB J** 1997 Jan;11(1):29–36 (67 ref.)

Chromatin structure and the regulation of gene expression: remodeling at the MMTV promoter. Beato M. **J Mol Med** 1996 Dec;74(12):711–24 (154 ref.)

Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting. Walther W, et al. **J Mol Med** 1996 Jul;74(7):379–92 (82 ref.)

IMMUNOLOGY

Accessibility control of antigen-receptor variable-region gene assembly: role of cis-acting elements. Sleckman BP, et al. **Annu Rev Immunol** 1996;14:459–81 (116 ref.)

Signals for activation of the GM-CSF promoter and enhancer in T cells. Shannon MF, et al. **Crit Rev Immunol** 1997;17(3–4):301–23 (161 ref.)

PHYSIOLOGY

Accessibility control of antigen-receptor variable-region gene assembly: role of cis-acting elements. Sleckman BP, et al. **Annu Rev Immunol** 1996;14:459–81 (116 ref.)

Chromatin structure of the MMTV promoter and its changes during hormonal induction. Truss M, et al. **Cell Mol Neurobiol** 1996 Apr;16(2):85–101 (110 ref.)

CD11c integrin gene promoter activity during myeloid differentiation. Corbi AL, et al. **Leuk Lymphoma** 1997 May; 25(5–6):415–25 (67 ref.)

PROMOTION OF HEALTH see **HEALTH PROMOTION**

PROMYELOCYTES see **GRANULOCYTES**

PROMYELOCYTIC LEUKEMIA, ACUTE see **LEUKEMIA, PROMYELOCYTIC, ACUTE**

PRONASE

ULTRASTRUCTURE

Scanning force microscopy of biological samples. Lekka M, et al. **Pol J Pathol** 1996;47(2):51–5 (17 ref.)

PRONE POSITION

The prone position in acute respiratory distress syndrome: where we are, and where do we go from here [editorial; comment] Albert RK. **Crit Care Med** 1997 Sep;25(9):1453–4 (36 ref.) Comment on: Crit Care Med 1997 Sep;25(9):1539–44.

Thermal stress, sleeping position, and the sudden infant death syndrome. Sawczenko A, et al. **Sleep** 1996 Dec;19(10 Suppl):S267–70 (36 ref.)

PRONORMOBLASTS see **ERYTHROBLASTS**

PRO-OPIOCORTIN see **PRO-OPIOMELANOCORTIN**

PRO-OPIOMELANOCORTIN

GENETICS

[Structure ond regulation of gene expression of tyrosine aminotransferase and proopiomelanocortin in mammals] Mertvetsov NP. **Vestn Ross Akad Med Nauk** 1997;(8):10–5 (50 ref.) **(Rus)**

IMMUNOLOGY

Pro-opiomelanocortin-derived peptides, cytokines, and nitric oxide in immune responses and stress: an evolutionary approach. Ottaviani E, et al. **Int Rev Cytol** 1997;170:79–141 (400 ref.)

METABOLISM

Post-translational processing of proopiomelanocortin in the pituitary and in the brain. Castro MG, et al. **Crit Rev Neurobiol** 1997;11(1):35–57 (175 ref.)

Obesity, diabetes and functions for proopiomelanocortin-derived peptides. Mountjoy KG, et al. **Mol Cell Endocrinol** 1997 Apr 4;128(1–2):171–7 (51 ref.)

PROPAFENONE

PHARMACOLOGY

The differentiation of propafenone from other class Ic agents, focusing on the effect on ventricular response rate attributable to its beta-blocking action. Faber TS, et al. **Eur J Clin Pharmacol** 1996;51(3–4):199–208 (103 ref.)

POISONING

Lethal suicidal intoxication with propafenone, after a history of self-inflicted injuries. Maxeiner H, et al.

PROPAFENONE

Forensic Sci Int 1997 Sep 19;89(1–2):27–32 (12 ref.)

THERAPEUTIC USE

[Propafenone and flecainide in the therapy of ventricular arrhythmias] Paperini L, et al. **Minerva Cardioangiol** 1995 Oct;43(10):449–57 (32 ref.) (Eng. Abstr.) **(Ita)**

PROPANE

ANALOGS & DERIVATIVES

1,2,3–Trichloropropane.
IARC Monogr Eval Carcinog Risks Hum 1995;63:223–44 (68 ref.)

BLOOD

Liquefied petroleum gas (LPG) poisoning: report of two cases and review of the literature. Fukunaga T, et al. **Forensic Sci Int** 1996 Oct 25;82(3):193–200 (16 ref.)

PROPANEDIOLS

ADVERSE EFFECTS

Propylene glycol–induced proximal renal tubular cell injury. Yorgin PD, et al. **Am J Kidney Dis** 1997 Jul;30(1):134–9 (57 ref.)

PHARMACOLOGY

Felbamate pharmacology and use in epilepsy. Burdette DE, et al. **Clin Neuropharmacol** 1994 Oct;17(5):389–402 (47 ref.)

THERAPEUTIC USE

Felbamate pharmacology and use in epilepsy. Burdette DE, et al. **Clin Neuropharmacol** 1994 Oct;17(5):389–402 (47 ref.)
A review of the newer antiepileptic drugs and the ketogenic diet. Barron TF, et al. **Clin Pediatr (Phila)** 1997 Sep; 36(9):513–21 (61 ref.)
Felbamate. Bourgeois BF. **Semin Pediatr Neurol** 1997 Mar; 4(1):3–8 (27 ref.)
[New antiepileptic drugs] Padró L, et al. **Rev Neurol** 1997 Feb;25(138):291–4 (26 ref.) **(Spa)**

PROPANOL see **ALCOHOL, PROPYL**

PROPANOLAMINES

ADVERSE EFFECTS

Cardiac arrest after esmolol administration: a review of acute beta–blocker toxicity. Litman RS, et al.
J Am Osteopath Assoc 1996 Oct;96(10):616–8 (27 ref.)

PHARMACOLOGY

Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. Ruffolo RR Jr, et al. **Cardiovasc Drugs Ther** 1997 May;11 Suppl 1:247–56 (77 ref.)
Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Dunn CJ, et al. **Drugs** 1997 Jul;54(1):161–85 (179 ref.)

THERAPEUTIC USE

Carvedilol [Coreg]. Kukin M. **Compr Ther** 1997 Sep; 23(9):617–20 (13 ref.)
Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Dunn CJ, et al. **Drugs** 1997 Jul;54(1):161–85 (179 ref.)
Coronary artery disease and antioxidants––is there a role for carvedilol? Landray MJ, et al. **J Clin Pharm Ther** 1997 Feb;22(1):3–5 (26 ref.)
[Therapy with beta blockers in heart failure. Recent studies of carvedilol] Böhm M, et al. **Fortschr Med** 1996 May 10; 114(13):167–8 (0 ref.) **(Ger)**
[Value of beta–blocker therapy in treatment of coronary heart disease and sudden cardiac death with special reference to carvedilol] Zehender M, et al. **Z Kardiol** 1996;85 Suppl 7:23–9 (36 ref.) (Eng. Abstr.) **(Ger)**

TOXICITY

Environmental assessment of the alkanolamines. Davis JW, et al. **Rev Environ Contam Toxicol** 1997;149:87–137 (94 ref.)

PROPERDIN FACTOR D

PHYSIOLOGY

[Adipsin system––acylation–stimulation protein (ASP) and hyperapo–B] Rato Q, et al. **Rev Port Cardiol** 1996 May; 15(5):433–8, 366 (39 ref.) (Eng. Abstr.) **(Por)**

PROPERDIN PATHWAY see **COMPLEMENT PATHWAY, ALTERNATIVE**

PROPHAGE EXCISION see **VIRUS ACTIVATION**

PROPHAGE INDUCTION see **VIRUS ACTIVATION**

PROPHAGE INTEGRATION see **LYSOGENY**

PROPHASE

GENETICS

[Cytogenetic patterns in synapsis of meiotic chromosomes in animals and plants] Bogdanov IuF, et al. **Genetika** 1996 Nov;32(11):1474–93 (95 ref.) (Eng. Abstr.) **(Rus)**

PROPIONATES

THERAPEUTIC USE

[Peptidoleukotriene receptor antagonists in asthma therapy] Sakakibara H, et al. **Nippon Rinsho** 1996 Nov; 54(11):3049–55 (36 ref.) (Eng. Abstr.) **(Jpn)**

PROPIONIBACTERIUM ACNES

ISOLATION & PURIFICATION

Propionebacterium acnes in cultures from ventriculo–peritoneal shunts: infection or contamination? Westergren H, et al. **Acta Neurochir (Wien)** 1997; 139(1):33–6 (24 ref.)

PROPIONIC ACIDS

ADMINISTRATION & DOSAGE

Systemic, but not intraparenchymal, administration of 3–nitropropionic acid mimics the neuropathology of Huntington's disease: a speculative explanation. Borlongan CV, et al. **Neurosci Res** 1997 Jul;28(3):185–9 (27 ref.)

ADVERSE EFFECTS

Bilateral ureteric obstruction secondary to the prolonged use of tiaprofenic acid. Crew JP, et al. **Br J Clin Pract** 1997 Jan–Feb;51(1):59–60 (9 ref.)

BLOOD

Magnetic resonance imaging and spectroscopy of the brain in propionic acidemia: clinical and biochemical considerations. Bergman AJ, et al. **Pediatr Res** 1996 Sep; 40(3):404–9 (30 ref.)

METABOLISM

Short–chain carboxylic–acid–stimulated, PMN–mediated gingival inflammation. Niederman R, et al.
Crit Rev Oral Biol Med 1997;8(3):269–90 (144 ref.)
Stable isotope studies in propionic and methylmalonic acidaemia. Leonard JV. **Eur J Pediatr** 1997 Aug;156 Suppl 1:S67–9 (19 ref.)

PHARMACOKINETICS

Clinical pharmacokinetics of tiaprofenic acid and its enantiomers. Davies NM. **Clin Pharmacokinet** 1996 Nov; 31(5):331–47 (96 ref.)

PHARMACOLOGY

3–Nitropropionic acid animal model and Huntington's disease. Borlongan CV, et al. **Neurosci Biobehav Rev** 1997 May;21(3):289–93 (33 ref.)

THERAPEUTIC USE

Development of a thyroid hormone analogue for the treatment of congestive heart failure. Morkin E, et al. **Thyroid** 1996 Oct;6(5):521–6 (18 ref.)

TOXICITY

L–2–chloropropionic acid–induced neurotoxicity in the rat: a valuable model for studying selective neuronal cell death in vivo. Widdowson PS, et al. **Gen Pharmacol** 1997 Aug; 29(2):113–9 (34 ref.)
Systemic, but not intraparenchymal, administration of 3–nitropropionic acid mimics the neuropathology of Huntington's disease: a speculative explanation. Borlongan CV, et al. **Neurosci Res** 1997 Jul;28(3):185–9 (27 ref.)

PROPITOCAINE see **PRILOCAINE**

PROPOFOL

Propofol: pro– or anticonvulsant? Borgeat A.
Eur J Anaesthesiol Suppl 1997 May;15:17–20 (32 ref.)
[Protective effect of intravenous anesthesia using propofol from surgical stress] Kazama T. **Masui** 1996 Dec;45 Suppl:S68–72 (4 ref.) **(Jpn)**
[Propofol (diprivan): clinical and pharmacological characteristics and use in pediatric anesthesiology] Voskerchian AE. **Anesteziol Reanimatol** 1996 Nov–Dec; (6):72–5 (8 ref.) **(Rus)**

ADVERSE EFFECTS

Infectious risks associated with the use of propofol. Bach A, et al. **Acta Anaesthesiol Scand** 1996 Nov;40(10):1189–96 (67 ref.)
Propofol and bradycardia: causation, frequency and severity. Tramèr MR, et al. **Br J Anaesth** 1997 Jun;78(6):642–51 (103 ref.)

PHARMACOKINETICS

Pharmacokinetic and pharmacodynamic interactions between opioids and propofol. Vuyk J. **J Clin Anesth** 1997 Sep;9(6 Suppl):23S–26S (13 ref.)

THERAPEUTIC USE

Propofol in chemotherapy–associated nausea and vomiting. Phelps KC, et al. **Ann Pharmacother** 1996 Mar;30(3):290–2 (22 ref.)

PROPORTIONAL HAZARDS MODELS

How frailty models can be used for evaluating longevity limits: taking advantage of an interdisciplinary approach. Yashin AI, et al. **Demography** 1997 Feb;34(1):31–48 (105 ref.)

PROPRANOLOL

CONTRAINDICATIONS

[The systemic problems in the dental treatment of the elderly patients] Matsuura H. **Nippon Ronen Igakkai Zasshi** 1996 Jul;33(7):505–7 (0 ref.) **(Jpn)**

DIAGNOSTIC USE

[Glucagon–propranolol provocative test] Takeda S, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:225–8 (9 ref.) **(Jpn)**

THERAPEUTIC USE

Panic attack syndrome [see comments] Prabhu SS, et al. **Indian Pediatr** 1996 May;33(5):409–11 (9 ref.) Comment in: Indian Pediatr 1996 Oct;33(10):869–70.
Pharmacologic prophylaxis of supraventricular tachyarrhythmias after coronary artery bypass. Dorovenis SA, et al. **Pharmacotherapy** 1996 Jul–Aug;16(4):615–8 (24 ref.)

PROPRIOCEPTION

Impaired limb position sense after stroke: a quantitative test for clinical use. Carey LM, et al.
Arch Phys Med Rehabil 1996 Dec;77(12):1271–8 (70 ref.)
Impaired proprioception and osteoarthritis. Sharma L, et al. **Curr Opin Rheumatol** 1997 May;9(3):253–8 (64 ref.)

GENETICS

Touch at the molecular level. Mechanosensation. García–Añoveros J, et al. **Curr Biol** 1996 May 1;6(5):541–3 (16 ref.)

PHYSIOLOGY

Propriospinal myoclonus. Chokroverty S. **Clin Neurosci** 1995–96;3(4):219–22 (19 ref.)
Proprioception and joint stability. Jerosch J, et al.
Knee Surg Sports Traumatol Arthrosc 1996;4(3):171–9 (106 ref.)
Aging and the mechanisms underlying head and postural control during voluntary motion. Di Fabio RP, et al.
Phys Ther 1997 May;77(5):458–75 (96 ref.)
Transmission of the cortical command for human voluntary movement through cervical propriospinal premotoneurons. Pierrot–Deseilligny E. **Prog Neurobiol** 1996 Mar–Apr; 48(4–5):489–517 (60 ref.)
[A physiological study on instability in Parkinson's disease] Mitoma H. **Nippon Rinsho** 1997 Jan;55(1):168–72 (12 ref.) (Eng. Abstr.) **(Jpn)**
[The interoceptive properties of the vestibular apparatus (a systems analysis of vestibular–oculomotor interaction)] Ianov IuK, et al. **Usp Fiziol Nauk** 1996 Oct–Dec; 27(4):63–72 (22 ref.) (Eng. Abstr.) **(Rus)**

PROPTOSIS see **EXOPHTHALMOS**

PROPYLBENZILYLCHOLINE MUSTARD

PHARMACOLOGY

Drug receptor mechanisms in smooth muscle: beta–chloroethylamine–sensitive and –resistant receptor mechanisms. Takayanagi I, et al. **Jpn J Pharmacol** 1997 Jan;73(1):1–22 (89 ref.)

PROPYLENE GLYCOLS see **PROPANEDIOLS**

PROPYLTHIOURACIL

ADVERSE EFFECTS

Case of propylthiouracil–induced vasculitis associated with anti–neutrophil cytoplasmic antibody (ANCA); review of literature. Kitahara T, et al. **Clin Nephrol** 1997 May; 47(5):336–40 (20 ref.)
Propylthiouracil–induced diffuse proliferative lupus nephritis: review of immunological complications. Prasad GV, et al. **J Am Soc Nephrol** 1997 Jul;8(7):1205–10 (18 ref.)
Fifty years of experience with propylthiouracil–associated hepatotoxicity: what have we learned? Williams KV, et al. **J Clin Endocrinol Metab** 1997 Jun;82(6):1727–33 (70 ref.)

[A case of Grave's disease with MPO-ANCA-associated glomerulonephritis during propylthiouracil (PTU) therapy following interstitial pneumonitis] Saeki T, et al. **Nippon Jinzo Gakkai Shi** 1997 Mar;39(2):167-71 (15 ref.) (Eng. Abstr.) **(Jpn)**

TOXICITY

Propylthiouracil-induced fulminant hepatitis: case report and review of the literature. Deidiker R, et al. **Pediatr Pathol Lab Med** 1996 Sep-Oct;16(5):845-52 (25 ref.)

PROSENCEPHALON

ABNORMALITIES

Aprosencephaly and cerebellar dysgenesis in sibs. Florell SR, et al. **Am J Med Genet** 1996 Jun 28;63(4):542-8 (17 ref.)

ANATOMY & HISTOLOGY

Functional anatomy of forebrain vocal control pathways in the budgerigar (Melopsittacus undulatus). Brauth SE, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:368-85 (32 ref.)

The ascending basal forebrain cholinergic system. Page KJ, et al. **Prog Brain Res** 1996;107:513-22 (73 ref.)

BLOOD SUPPLY

Molecular mechanisms of acidosis-mediated damage. Siesjö BK, et al. **Acta Neurochir Suppl (Wien)** 1996;66:8-14 (66 ref.)

CYTOLOGY

Factors regulating the differentiation of neural precursors in the forebrain. Bartlett PF, et al. **Ciba Found Symp** 1995; 193:85-99; discussion 117-26 (22 ref.)

The subependymal zone: "brain marrow". Steindler DA, et al. **Prog Brain Res** 1996;108:349-63 (73 ref.)

Responses of basal forebrain cholinergic neurons to damage in the adult brain. Henderson Z. **Prog Neurobiol** 1996 Feb; 48(3):219-54 (400 ref.)

Is there a neural stem cell in the mammalian forebrain? [see comments] Weiss S, et al. **Trends Neurosci** 1996 Sep; 19(9):387-93 (68 ref.) Comment in: Trends Neurosci 1997 May;20(5):203-4.

EMBRYOLOGY

Patterns of gene expression in the neural plate and neural tube subdivide the embryonic forebrain into transverse and longitudinal domains. Shimamura K, et al. **Dev Neurosci** 1997;19(1):88-96 (64 ref.)

GROWTH & DEVELOPMENT

Early environmental regulation of forebrain glucocorticoid receptor gene expression: implications for adrenocortical responses to stress. Meaney MJ, et al. **Dev Neurosci** 1996; 18(1-2):49-72 (138 ref.)

INJURIES

Responses of basal forebrain cholinergic neurons to damage in the adult brain. Henderson Z. **Prog Neurobiol** 1996 Feb; 48(3):219-54 (400 ref.)

METABOLISM

Early environmental regulation of forebrain glucocorticoid receptor gene expression: implications for adrenocortical responses to stress. Meaney MJ, et al. **Dev Neurosci** 1996; 18(1-2):49-72 (138 ref.)

PHYSIOLOGY

Functional anatomy of forebrain vocal control pathways in the budgerigar (Melopsittacus undulatus). Brauth SE, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:368-85 (32 ref.)

Modulation of cognitive processes by transsynaptic activation of the basal forebrain. Givens B, et al. **Behav Brain Res** 1997 Mar;84(1-2):1-22 (217 ref.)

Cell adhesion molecules and the transition from short- to long-term memory. Rose SP. **J Physiol Paris** 1996; 90(5-6):387-91 (37 ref.)

Theories of basal forebrain organization and the "emotional motor system". Alheid GF, et al. **Prog Brain Res** 1996; 107:461-84 (250 ref.)

Olfaction and brainstem circuits of reproductive behavior in the rat. Shipley MT, et al. **Prog Brain Res** 1996; 107:355-77 (188 ref.)

PHYSIOPATHOLOGY

Immunolesion by 192IgG-saporin of rat basal forebrain cholinergic system: a useful tool to produce cortical cholinergic dysfunction. Schliebs R, et al. **Prog Brain Res** 1996;109:253-64 (57 ref.)

PROSIMII see **STREPSIRHINI**

PROSPECTIVE PAYMENT SYSTEM

LEGISLATION & JURISPRUDENCE

Capitation: the legal implications of using capitation to affect physician decision-making processes. Ruskin A. **J Contemp Health Law Policy** 1997 Spring;13(2):391-421 (169 ref.)

UTILIZATION

The home health visit: an appropriate unit for Medicare payment? [see comments] Bishop CE, et al. **Health Aff (Millwood)** 1996 Winter;15(4):145-55 (19 ref.) Comment in: Health Aff (Millwood) 1997 Mar-Apr;16(2):261-3.

PROSPECTIVE PRICING see **PROSPECTIVE PAYMENT SYSTEM**

PROSPECTIVE REIMBURSEMENT see **PROSPECTIVE PAYMENT SYSTEM**

PROSPECTIVE STUDIES

Systematic reviews of randomized controlled trials: the need for complete data. Clarke MJ, et al. **J Eval Clin Pract** 1995 Nov;1(2):119-26 (23 ref.)

PROSTACYCLIN see **EPOPROSTENOL**

PROSTAGLANDIN ANTAGONISTS

see related
CYCLOOXYGENASE INHIBITORS

PHARMACOLOGY

Tissue selective inhibition of prostaglandin biosynthesis by etodolac. Dvornik DM. **J Rheumatol Suppl** 1997 Feb; 47:40-7 (54 ref.)

PROSTAGLANDIN D2

PHYSIOLOGY

Molecular mechanism of sleep regulation by prostaglandin D2. Urade Y, et al. **J Lipid Mediat Cell Signal** 1996 Sep; 14(1-3):71-82 (47 ref.)

PROSTAGLANDIN E RECEPTORS see **RECEPTORS, PROSTAGLANDIN E**

PROSTAGLANDIN E1 see **ALPROSTADIL**

PROSTAGLANDIN E2 see **DINOPROSTONE**

PROSTAGLANDIN E2ALPHA see **DINOPROSTONE**

PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE

Selective inhibitors of cyclooxygenase-2. Potential in elderly patients. Davies NM, et al. **Drugs Aging** 1996 Dec; 9(6):406-17 (124 ref.)

Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. Smith WL, et al. **J Biol Chem** 1996 Dec 27;271(52):33157-60 (75 ref.)

BIOSYNTHESIS

COX-1 and COX-2 tissue expression: implications and predictions. Crofford LJ. **J Rheumatol** 1997 Jul;24 Suppl 49:15-9 (40 ref.)

Antiphospholipid antibodies, eicosanoids and expression of endothelial cyclooxygenase-2. Carreras LO, et al. **Lupus** 1996 Oct;5(5):494-7 (46 ref.)

CHEMISTRY

Prostaglandin endoperoxide H synthases-1 and -2. Smith WL, et al. **Adv Immunol** 1996;62:167-215 (221 ref.)

DRUG EFFECTS

Review article: COX-II inhibitors--a new generation of safer NSAIDs? Donnelly MT, et al. **Aliment Pharmacol Ther** 1997 Apr;11(2):227-36 (92 ref.)

Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. Levy GN. **FASEB J** 1997 Mar; 11(4):234-47 (109 ref.)

Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract. Masferrer JL, et al. **Gastroenterol Clin North Am** 1996 Jun;25(2):363-72 (35 ref.)

Cyclooxygenase, NSAIDs, and colorectal cancer. DuBois RN, et al. **J Gastroenterol** 1996 Dec;31(6):898-906 (85 ref.)

Pain management in osteoarthritis: the role of COX-2 inhibitors. Lane NE. **J Rheumatol** 1997 Jul;24 Suppl 49:20-4 (30 ref.)

Outcome of specific COX-2 inhibition in rheumatoid arthritis. Lipsky PE, et al. **J Rheumatol** 1997 Jul;24 Suppl 49:9-14 (21 ref.)

Differentiating among nonsteroidal antiinflammatory drugs by pharmacokinetic and pharmacodynamic profiles. Fenner H. **Semin Arthritis Rheum** 1997 Jun;26(6 Suppl 1):28-33 (14 ref.)

Meloxicam: selective COX-2 inhibition in clinical practice. Furst DE. **Semin Arthritis Rheum** 1997 Jun;26(6 Suppl 1):21-7 (24 ref.)

Cyclooxygenase-2 inhibitors: a new approach to the therapy of ocular inflammation. Masferrer JL, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S35-40 (43 ref.)

GENETICS

Prostacyclin and nitric oxide-related gene transfer in preventing arterial thrombosis and restenosis. Wu KK. **Agents Actions Suppl** 1997;48:107-23 (35 ref.)

Self-promotion? Intimate connections between APC and prostaglandin H synthase-2. Prescott SM, et al. **Cell** 1996 Nov 29;87(5):783-6 (15 ref.)

Disruption of cyclooxygenase genes in mice. Mahler JF, et al. **Toxicol Pathol** 1996 Nov-Dec;24(6):717-9 (6 ref.)

METABOLISM

Cyclo-oxygenase and colon cancer: clues to the aspirin effect? Gustafson-Svärd C, et al. **Ann Med** 1997 Jun; 29(3):247-52 (68 ref.)

Regulation of cyclooxygenase enzymes by nitric oxide. Salvemini D. **Cell Mol Life Sci** 1997 Jul;53(7):576-82 (60 ref.)

Isoprostanes--prostaglandin-like compounds formed in vivo independently of cyclooxygenase: use as clinical indicators of oxidant damage. Awad JA, et al. **Gastroenterol Clin North Am** 1996 Jun;25(2):409-27 (76 ref.)

Interactions of nitric oxide with cyclooxygenase: in vitro, ex vivo, and in vivo studies. Salvemini D, et al. **Methods Enzymol** 1996;269:12-25 (40 ref.)

Acute mechanical hyperalgesia in the rat can be produced by coactivation of spinal ionotropic AMPA and metabotropic glutamate receptors, activation of phospholipase A2 and generation of cyclooxygenase products. Meller ST, et al. **Prog Brain Res** 1996;110:177-92 (69 ref.)

Interaction between nitric oxide and cyclooxygenase pathways. Di Rosa M, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Apr; 54(4):229-38 (127 ref.)

Independent prostanoid biosynthetic systems associated with prostaglandin endoperoxide synthases-1 and -2. Smith WL, et al. **Thromb Haemost** 1997 Jul;78(1):627-30 (63 ref.)

PHYSIOLOGY

Coronary and systemic hemodynamic effects of sustained inhibition of nitric oxide synthesis in conscious dogs. Evidence for cross talk between nitric oxide and cyclooxygenase in coronary vessels. Puybasset L, et al. **Circ Res** 1996 Aug;79(2):343-57 (51 ref.)

Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications. Pairet M, et al. **Fundam Clin Pharmacol** 1996;10(1):1-17 (165 ref.)

Cyclooxygenase 2 and wound healing in the stomach [editorial; comment] Stenson WF. **Gastroenterology** 1997 Feb;112(2):645-8 (32 ref.) Comment on: Gastroenterology 1997 Feb;112(2):387-97.

New directions in cyclooxygenase research and their implications for NSAID-gastropathy. Flower RJ. **Ital J Gastroenterol** 1996 Dec;28 Suppl 4:23-7 (26 ref.)

The discovery and function of COX-2. Needleman P, et al. **J Rheumatol** 1997 Jul;24 Suppl 49:6-8 (23 ref.)

Cyclooxygenase 1 and 2 in rheumatic disease: implications for nonsteroidal anti-inflammatory drug therapy. Spangler RS. **Semin Arthritis Rheum** 1996 Aug;26(1):435-46 (79 ref.)

[Selective cyclooxygenase-2 (COX-2) inhibitor. Progress in rheumatoid therapy?] Reuss-Borst M. **Internist (Berl)** 1997 Mar;38(3):266-71 (35 ref.) **(Ger)**

[Cyclooxygenase-1 and cyclooxygenase-2] Yamamoto K, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Dec; 19(6):564-7 (14 ref.) **(Jpn)**

[Multiple roles of inducible cyclooxygenase-2 and its selective inhibitors] Katori M, et al. **Nippon Yakurigaku Zasshi** 1997 Jun;109(6):247-58 (43 ref.) (Eng. Abstr.) **(Jpn)**

PROSTAGLANDIN ENDOPEROXIDE SYNTHASE INHIBITORS see **CYCLOOXYGENASE INHIBITORS**

PROSTAGLANDIN ENDOPEROXIDE SYNTHETASE see **PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE**

PROSTAGLANDIN F ANALOGS see **PROSTAGLANDINS F, SYNTHETIC**

PROSTAGLANDIN F2 see **DINOPROST**

PROSTAGLANDIN F2ALPHA see **DINOPROST**

PROSTAGLANDIN H SYNTHASE see **PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE**

PROSTAGLANDIN I2 see **EPOPROSTENOL**

PROSTAGLANDIN INHIBITORS see **PROSTAGLANDIN ANTAGONISTS**

PROSTAGLANDIN RECEPTORS see **RECEPTORS, PROSTAGLANDIN**

PROSTAGLANDIN SYNTHASE see **PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE**

PROSTAGLANDIN SYNTHASE INHIBITORS

PROSTAGLANDIN SYNTHASE INHIBITORS see **CYCLOOXYGENASE INHIBITORS**

PROSTAGLANDIN SYNTHESIS ANTAGONISTS see **CYCLOOXYGENASE INHIBITORS**

PROSTAGLANDIN X see **EPOPROSTENOL**

PROSTAGLANDINS

see related
PROSTAGLANDIN ANTAGONISTS
RECEPTORS, PROSTAGLANDIN

Medical abortion in early pregnancy: a review of the evidence. Grimes DA. **Obstet Gynecol** 1997 May;89(5 Pt 1):790–6 (55 ref.)

BIOSYNTHESIS

Molecular mechanisms involved in the regulation of prostaglandin biosynthesis by glucocorticoids. Goppelt-Struebe M. **Biochem Pharmacol** 1997 May 15; 53(10):1389–95 (74 ref.)

The clinical implications of inhibition of the inducible form of cyclo-oxygenase. Richardson C, et al. **Drug Saf** 1996 Oct;15(4):249–60 (61 ref.)

Tissue selective inhibition of prostaglandin biosynthesis by etodolac. Dvornik DM. **J Rheumatol Suppl** 1997 Feb; 47:40–7 (54 ref.)

Regulation of prostaglandin synthesis by antiinflammatory drugs. Robinson DR. **J Rheumatol Suppl** 1997 Feb;47:32–9 (33 ref.)

Ascorbic acid and prostaglandin synthesis. Horrobin DF. **Subcell Biochem** 1996;25:109–15 (29 ref.)

Independent prostanoid biosynthetic systems associated with prostaglandin endoperoxide synthases-1 and -2. Smith WL, et al. **Thromb Haemost** 1997 Jul;78(1):627–30 (63 ref.)

CHEMICAL SYNTHESIS

[Development of a silicon-mediated [3 + 2] annulation and its application to the synthesis of natural products] Takeda K. **Yakugaku Zasshi** 1997 Jun;117(6):368–77 (27 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Prostaglandins and their receptors: implications for ovarian physiology. Olofsson JI, et al. **Biol Signals** 1996 Mar-Apr; 5(2):90–100 (103 ref.)

Arachidonic acid cascade and gastric mucosal injury, protection, and healing: topics of this decade. Kobayashi K, et al. **J Clin Gastroenterol** 1995;21 Suppl 1:S12–7 (35 ref.)

The molecular biology and ocular distribution of prostanoid receptors. Woodward DF, et al. **Surv Ophthalmol** 1997 Feb; 41 Suppl 2:S15–21 (58 ref.)

PHARMACOLOGY

Prostaglandins and cholinomimetics [editorial; comment] Kaufman PL. **Arch Ophthalmol** 1997 Jul;115(7):911–3 (41 ref.) Comment on: Arch Ophthalmol 1997 Jul;115(7):857–61.

Prostaglandins in liver disease and liver transplantation. Ruwart MJ, et al. **Gastroenterol Clin North Am** 1996 Jun; 25(2):397–407 (66 ref.)

Regulation of gene transcription by fatty acids, fibrates and prostaglandins: the phosphoenolpyruvate carboxykinase gene as a model. Forest C, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Jul; 57(1):47–56 (66 ref.)

Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: implications for uveoscleral outflow. Lindsey JD, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S53–9 (53 ref.)

Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function. Toris CB, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S69–75 (49 ref.)

Antiviral activity of cyclopentenone prostanoids. Santoro MG. **Trends Microbiol** 1997 Jul;5(7):276–81 (41 ref.)

PHYSIOLOGY

Cooperative modulation of gastrointestinal mucosal defence by prostaglandins and nitric oxide. Wallace JL. **Clin Invest Med** 1996 Oct;19(5):346–51 (52 ref.)

Prostaglandins and menstruation. Baird DT, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Dec;70(1):15–7 (25 ref.)

The role of astroglial cell-derived nitric oxide and prostanoids in neurodegenerative disorders. Mollace V, et al. **Funct Neurol** 1997 May-Aug;12(3-4):199–203 (24 ref.)

Role of prostaglandins in the stimulation of the hypothalamic-pituitary-adrenal axis by adrenergic and neurohormone systems. Bugajski J. **J Physiol Pharmacol** 1996 Dec;47(4):559–75 (78 ref.)

A T-helper-2 bias in decidua: the prostaglandin contribution of the macrophage and trophoblast. Kelly RW, et al. **J Reprod Immunol** 1997 Jul;33(3):181–7 (48 ref.)

Adipocyte differentiation is regulated by a prostaglandin liganded to the nuclear peroxisome proliferator-activated receptor. Wolf G. **Nutr Rev** 1996 Sep;54(9):290–2 (9 ref.)

Prostaglandins in primate semen: biasing the immune system to benefit spermatozoa and virus? Kelly RW. **Prostaglandins Leukot Essent Fatty Acids** 1997 Aug; 57(2):113–8 (71 ref.)

Signal transduction and gene expression in the eye: a contemporary view of the pro-inflammatory, anti-inflammatory and modulatory roles of prostaglandins and other bioactive lipids. Bazan NG, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S23–34 (100 ref.)

[The role of prostaglandins in the defense of the gastric mucosal barrier] Jiménez Molinos P, et al. **Gastroenterol Hepatol** 1997 May;20 Suppl 2:16–21 (37 ref.) **(Spa)**

SECRETION

Effect of histone-H2A (H-H2A), platelet activating factor (PAF) and pregnancy specific protein B (PSPB) on secretion of prostaglandins E and F2 alpha (PGE; PGF2 alpha) by bovine endometrium and H-H2A on basal secretion of luteinizing hormone (LH) by bovine pituitary cells in vitro. Weems CW, et al. **Chin J Physiol** 1996; 39(3):147–54 (53 ref.)

THERAPEUTIC USE

NSAIDs and the gastrointestinal mucosa. Wolfe MM. **Hosp Pract (Off Ed)** 1996 Dec 15;31(12):37–44, 47–8 (6 ref.)

Oral treatments for erectile dysfunction. Riley A. **Int J STD AIDS** 1996;7 Suppl 3:16–8 (12 ref.)

Topical prostaglandins for glaucoma therapy. Wyse TB, et al. **J Glaucoma** 1997 Jun;6(3):180–7 (77 ref.)

PROSTAGLANDINS F, SYNTHETIC

ADMINISTRATION & DOSAGE

Clinical dose-regimen studies with latanoprost, a new ocular hypotensive PGF2 alpha analogue. Diestelhorst M, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S77–81 (28 ref.)

Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow. Mishima HK, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S139–44 (26 ref.)

ADVERSE EFFECTS

Prostaglandins: a new approach to glaucoma management with a new, intriguing side effect. Bito LZ. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S1–14 (74 ref.)

THERAPEUTIC USE

Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension. Patel SS, et al. **Drugs Aging** 1996 Nov;9(5):363–78 (83 ref.)

New medical therapies for glaucoma. Drake MV. **Int Ophthalmol Clin** 1996 Spring;36(2):53–60 (29 ref.)

Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Alm A, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S105–10 (23 ref.)

Reduced intraocular pressure and increased ocular perfusion pressure in normal tension glaucoma: a review of short-term studies with three dose regimens of latanoprost treatment. Greve EL, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S89–92 (18 ref.)

Fluorescein angiographic evaluation of the effect of latanoprost treatment on blood-retinal barrier integrity: a review of studies conducted on pseudophakic glaucoma patients and on phakic and aphakic monkeys. Hoyng PF, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S83–8 (33 ref.)

The additive intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents. Hoyng PF, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S93–8 (43 ref.)

PROSTATE

see related
PROSTATECTOMY

The Pre and Post Massage Test (PPMT): a simple screen for prostatitis. Nickel JC. **Tech Urol** 1997 Spring;3(1):38–43 (23 ref.)

CHEMISTRY

Prostatic alpha 1-adrenoceptors and uroselectivity. Andersson KE, et al. **Prostate** 1997 Feb 15;30(3):202–15 (132 ref.)

Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications Part 2. Tumorigenic cell lines. Webber MM, et al. **Prostate** 1997 Jan 1;30(1):58–64 (46 ref.)

[Androgen receptor] Shimazaki J, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:553–7 (10 ref.) **(Jpn)**

CYTOLOGY

Smooth muscle-epithelial interactions in normal and neoplastic prostatic development. Cunha GR, et al. **Acta Anat (Basel)** 1996;155(1):63–72 (57 ref.)

The canine prostate is a spontaneous model of intraepithelial neoplasia and prostate cancer progression. Waters DJ, et al. **Anticancer Res** 1997 May-Jun;17(3A):1467–70 (22 ref.)

Prostate epithelial differentiation is dictated by its surrounding stroma. Chung LW, et al. **Mol Biol Rep** 1996; 23(1):13–9 (66 ref.)

Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. Part I. Cell markers and immortalized nontumorigenic cell lines. Webber MM, et al. **Prostate** 1996 Dec;29(6):386–94 (151 ref.)

Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications Part 2. Tumorigenic cell lines. Webber MM, et al. **Prostate** 1997 Jan 1;30(1):58–64 (46 ref.)

DRUG EFFECTS

Benign prostatic hyperplasia. Practical treatment guidelines. Tammela T. **Drugs Aging** 1997 May;10(5):349–66 (141 ref.)

Pharmacological options in the treatment of benign prostatic hyperplasia. Kenny B, et al. **J Med Chem** 1997 Apr 25; 40(9):1293–315 (146 ref.)

INJURIES

Animal models for the preneoplastic lesions of the prostate. Pylkkänen L, et al. **Eur Urol** 1996;30(2):243–8 (33 ref.)

METABOLISM

TGF beta in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Barrack ER. **Prostate** 1997 Apr 1;31(1):61–70 (100 ref.)

Citrate metabolism of normal and malignant prostate epithelial cells. Costello LC, et al. **Urology** 1997 Jul; 50(1):3–12 (46 ref.)

PATHOLOGY

The canine prostate is a spontaneous model of intraepithelial neoplasia and prostate cancer progression. Waters DJ, et al. **Anticancer Res** 1997 May-Jun;17(3A):1467–70 (22 ref.)

Evaluating prostate needle biopsy: therapeutic and prognostic importance. Bostwick DG. **CA Cancer J Clin** 1997 Sep-Oct;47(5):297–319 (135 ref.)

Automated reasoning system in histopathologic diagnosis and prognosis of prostate cancer and its precursors. Bartels PH, et al. **Eur Urol** 1996;30(2):222–33 (20 ref.)

Neuroendocrine differentiation in the precursors of prostate cancer. di Sant' Agnese PA. **Eur Urol** 1996;30(2):185–90 (42 ref.)

Age and racial distribution of prostatic intraepithelial neoplasia. Sakr WA, et al. **Eur Urol** 1996;30(2):138–44 (26 ref.)

Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials. Bostwick DG, et al. **J Cell Biochem Suppl** 1996;25:156–64 (59 ref.)

Role of transrectal ultrasound and prostate biopsy. Melchior SW, et al. **J Clin Ultrasound** 1996 Oct;24(8):463–71 (53 ref.)

Antibiotic prophylaxis in ultrasound guided transrectal prostate biopsy. Sieber PR, et al. **J Urol** 1997 Jun; 157(6):2199–200 (13 ref.)

MR imaging of the prostate and seminal vesicles. David V. **Magn Reson Imaging Clin N Am** 1996 Aug;4(3):497–518 (67 ref.)

Does an inability to eradicate normal stem cells preclude the cure of some cancers? Anderson KM, et al. **Med Hypotheses** 1996 Jul;47(1):31–4 (24 ref.)

Evaluating radical prostatectomy specimens: therapeutic and prognostic importance. Bostwick DG, et al. **Virchows Arch** 1997 Jan;430(1):1–16 (92 ref.)

[Diagnostic problems in prostatic pathology: microglandular lesions and intraductal epithelial proliferations] Berger N, et al. **Arch Anat Cytol Pathol** 1996;44(4):141–59 (78 ref.) (Eng. Abstr.) **(Fre)**

[Morbidity of transperineal echo-guided prostatic biopsy, our experience] Zambolin T, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):217–9 (6 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

The role of insulin-like growth factors in prostate biology. Peehl DM, et al. **J Androl** 1996 Jan-Feb;17(1):2–4 (14 ref.)

RADIATION EFFECTS

Neoadjuvant therapy prior to radiotherapy for clinically localized prostate cancer. Roach M 3rd. **Eur Urol** 1997;32 Suppl 3:48–54 (34 ref.)

ULTRASONOGRAPHY

Clinical relevance of scrotal and transrectal ultrasonography in andrological patients. Behre HM, et al. **Int J Androl** 1995 Dec;18 Suppl 2:27–31 (19 ref.)

[Morbidity of transperineal echo-guided prostatic biopsy, our experience] Zambolin T, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):217–9 (6 ref.) (Eng. Abstr.) **(Ita)**

PROSTATE CANCER see **PROSTATIC NEOPLASMS**

PROSTATE-SPECIFIC ANTIGEN

Prostate-specific antigen: molecular forms and the human kallikrein gene family. Lilja H. **Br J Urol** 1997 Mar;79 Suppl 1:44–8 (41 ref.)

Prostate-specific antigen. Its discovery and biochemical characteristics. Sokoll LJ, et al. **Urol Clin North Am** 1997

May;24(2):253–9 (67 ref.)

ANALYSIS

PSA as a marker for prostate cancer: a critical review. Duffy MJ. **Ann Clin Biochem** 1996 Nov;33 (Pt 6):511–9 (62 ref.)

Successful separation between benign prostatic hyperplasia and prostate cancer by measurement of free and complexed PSA. Lilja H, et al. **Cancer Treat Res** 1996;88:93–101 (50 ref.)

Prostate-specific antigen expression in a case of intracystic carcinoma of the breast: characterization of immunoreactive protein and literature surveys. Mannello F, et al. **Clin Chem** 1997 Aug;43(8 Pt 1):1448–54 (72 ref.)

The role of prostate-specific antigen in the chemoprevention of prostate cancer. Crawford ED, et al. **J Cell Biochem Suppl** 1996;25:149–55 (59 ref.)

Prostate cancer: to screen or not to screen? **Oncology (Huntingt)** 1997 Mar;11(3):325–6, 329–30 (11 ref.)

Prostate-specific antigen: what's new in 1997. Pannek J, et al. **Oncology (Huntingt)** 1997 Sep;11(9):1273–8; discussion 1279–82 (59 ref.)

Signet-ring carcinoma of the prostate. Leong FJ, et al. **Pathol Res Pract** 1996 Dec;192(12):1232–8; discussion 1239–41 (30 ref.)

Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values. Semjonow A, et al. **Prostate Suppl** 1996;7:3–16 (112 ref.)

Review on the simultaneous determination of total prostate-specific antigen and free prostate-specific antigen. van Iersel MP, et al. **Prostate Suppl** 1996;7:48–57 (66 ref.)

[What can the clinician expect today from PSA determination?] Teillac P. **Nucl Med Biol** 1994 Apr; 21(3):455–69 (43 ref.) (Eng. Abstr.) **(Fre)**

[The prostate-specific antigen in the early recognition of prostate carcinoma] Wolff JM, et al. **Dtsch Med Wochenschr** 1996 Nov 29;121(48):1508–14 (63 ref.) **(Ger)**

[Usefulness of prostate-specific antigen in the screening of cancer of the prostate] Buitrago F, et al. **Aten Primaria** 1996 Sep 30;18(5):265–70 (67 ref.) **(Spa)**

BIOSYNTHESIS

Prostate-specific antigen-producing cells in the bone marrow of a patient with early-stage prostate cancer. D'Amico AV, et al. **Urology** 1997 Feb;49(2):279–82 (17 ref.)

BLOOD

Prostate specific antigen in the diagnosis and staging of prostate cancer. Jung P, et al. **Acta Urol Belg** 1996 Sep; 64(3):1–6 (41 ref.)

Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians. Coley CM, et al. **Ann Intern Med** 1997 Mar 1;126(5):394–406 (181 ref.)

New diagnostic applications of prostate-specific antigen. Diamandis EP. **Br J Urol** 1997 Mar;79 Suppl 1:87–91 (53 ref.)

Enhancing the specificity of prostate-specific antigen (PSA): an overview of PSA density, velocity and age-specific reference ranges. Nixon RG, et al. **Br J Urol** 1997 Mar; 79 Suppl 1:61–7 (43 ref.)

Some comments on progress in the standardization of immunoassays for prostate-specific antigen. Stamey TA. **Br J Urol** 1997 Mar;79 Suppl 1:49–52 (17 ref.)

Prostate-specific antigen, clinical use and staging: an overview. Stenman UH. **Br J Urol** 1997 Mar;79 Suppl 1:53–60 (53 ref.)

PSA and early prostate cancer detection: the importance of age-specific reference ranges. Oesterling JE. **Can J Oncol** 1994 Nov;4 Suppl 1:52–6 (22 ref.)

Individual prostate-specific antigen (PSA) forms as prostate tumor markers. Becker C, et al. **Clin Chim Acta** 1997 Jan 3;257(1):117–32 (87 ref.)

Problems in the determination of prostate specific antigen. Stenman UH, et al. **Eur J Clin Chem Clin Biochem** 1996 Sep;34(9):735–40 (39 ref.)

Free/total prostate-specific antigen ratio--hope and controversies. Ravery V, et al. **Eur Urol** 1997;31(4):385–8 (19 ref.)

Evaluation of prostate specific antigen density and transrectal ultrasonography-guided biopsies in 100 consecutive patients with a negative digital rectal examination and intermediate serum prostate specific antigen levels. Tarcan T, et al. **Int J Urol** 1997 Jul;4(4):362–7 (30 ref.)

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. Small EJ, et al. **J Clin Oncol** 1997 Jan;15(1):382–8 (39 ref.)

Prospective evaluation of prostate specific antigen density and systematic biopsy for detecting prostate cancer in Japanese patients with normal rectal examinations and intermediate prostate specific antigen levels. Arai Y, et al. **J Urol** 1997 Sep;158(3 Pt 1):861–4 (18 ref.)

Significance of serum free prostate specific antigen in the screening of prostate cancer. Higashihara E, et al. **J Urol** 1996 Dec;156(6):1964–8 (22 ref.)

Statistical review and analysis of the relationship between serum prostate specific antigen and age. Kirollos MM. **J Urol** 1997 Jul;158(1):143–5 (13 ref.)

Biological variation of prostate specific antigen levels in serum: an evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients [see comments] Nixon RG, et al. **J Urol** 1997 Jun; 157(6):2183–90 (33 ref.) Comment in: J Urol 1997 Jun;157(6):2197–8.

Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate. Presti JC Jr, et al. **J Urol** 1996 Nov;156(5):1685–90 (10 ref.)

The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. Schild SE, et al. **J Urol** 1996 Nov; 156(5):1725–9 (22 ref.)

Treatment options for localized prostate cancer based on pretreatment serum prostate specific antigen levels. Vicini FA, et al. **J Urol** 1997 Aug;158(2):319–25 (79 ref.)

Percent free prostate-specific antigen: entering a new era in the detection of prostate cancer. Vashi AR, et al. **Mayo Clin Proc** 1997 Apr;72(4):337–44 (52 ref.)

Screening for prostate cancer: the role of prostate-specific antigen. Ferrer RL. **Md Med J** 1996 Nov;45(11):938–40 (7 ref.)

The role of PSA in the radiotherapy of prostate cancer. Roach M 3rd. **Oncology (Huntingt)** 1996 Aug; 10(8):1143–53; discussion 1154–61 (55 ref.)

Management of asymptomatic rising PSA after prostatectomy or radiation therapy. Waxman S, et al. **Oncology (Huntingt)** 1997 Apr;11(4):457–60, 465; discussion 465–6, 469 (48 ref.)

Pathological definitions and characteristics of stage T1 prostate cancer. Bhargava V. **Semin Urol Oncol** 1996 Aug; 14(3):145–8 (20 ref.)

Metastatic prostate cancer: assessment of response to systemic therapy. Dreicer R. **Semin Urol Oncol** 1997 Feb;15(1):28–32 (36 ref.)

Use of prostate-specific antigen (PSA) and PSA density in the detection of stage T1 carcinoma of the prostate. Presti JC Jr, et al. **Semin Urol Oncol** 1996 Aug;14(3):134–8 (10 ref.)

Prostate-specific antigen and early detection of prostate cancer. Chu TM. **Tumour Biol** 1997;18(2):123–34 (53 ref.)

Molecular forms of serum prostate-specific antigen. The clinical value of percent free prostate-specific antigen. Abrahamsson PA, et al. **Urol Clin North Am** 1997 May; 24(2):353–65 (90 ref.)

Prostate-specific antigen as a screening test for prostate cancer. The United States experience. Arcangeli CG, et al. **Urol Clin North Am** 1997 May;24(2):299–306 (82 ref.)

The socioeconomic implications of prostate-specific antigen screening. Benoit RM, et al. **Urol Clin North Am** 1997 May; 24(2):451–8 (28 ref.)

The role of the reverse-transcriptase polymerase chain reaction assay for prostate-specific antigen in the selection of patients for radical prostatectomy. Katz AE, et al. **Urol Clin North Am** 1996 Nov;23(4):541–9 (40 ref.)

Serum prostate-specific antigen elevation in the post-radical prostatectomy patient. Malkowicz SB. **Urol Clin North Am** 1996 Nov;23(4):665–75 (64 ref.)

Reverse transcriptase-polymerase chain reaction assays for prostate cancer. Olsson CA, et al. **Urol Clin North Am** 1997 May;24(2):367–78 (80 ref.)

The use of prostate-specific antigen and free/total prostate-specific antigen in the diagnosis of localized prostate cancer. Partin AW, et al. **Urol Clin North Am** 1996 Nov;23(4):531–40 (63 ref.)

Use of prostate-specific antigen, Gleason score, and digital rectal examination in staging patients with newly diagnosed prostate cancer. Rees MA, et al. **Urol Clin North Am** 1997 May;24(2):379–88 (68 ref.)

Quality of life in patients with prostatic carcinoma: a review and results of a study in N+ disease. Prostate-specific antigen as predictor of quality of life. van Andel G, et al. **Urol Res** 1997;25 Suppl 2:S79–88 (36 ref.)

[Prostate specific antigen] Koutani A, et al. **Ann Urol (Paris)** 1996;30(5):257–61 (30 ref.) (Eng. Abstr.) **(Fre)**

[Prostate specific antigen (PSA): impact of a seric marker on the diagnosis and therapeutic management of cancers of the prostate] Chauvet B, et al. **Bull Cancer Radiother** 1996;83(4):334–44 (108 ref.) **(Fre)**

[The incidence of the variability of the free PSA/total PSA ratio on the early diagnosis of prostate cancer] de La Taille A, et al. **Prog Urol** 1997 Jun;7(3):455–63 (35 ref.) (Eng. Abstr.) **(Fre)**

[Post-treatment PSA, indicator of radical treatment effectiveness of localized cancer of the prostate] Ravery V, et al. **Prog Urol** 1996 Dec;6(6):981–6 (35 ref.) (Eng. Abstr.) **(Fre)**

[Free prostate-specific antigen] Ravery V. **Prog Urol** 1997 Feb;7(1):88–91 (19 ref.) **(Fre)**

[Prostate-specific antigen in the diagnosis of organ-confined treatable prostate carcinoma] Recker F. **Schweiz Med Wochenschr** 1996 Nov 2;126(44):1881–90 (58 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSTIC USE

Prostate cancer: to screen or not to screen? **Oncology (Huntingt)** 1997 Apr;11(4):447–8, 451–2 (9 ref.)

Age-specific reference ranges for PSA in the detection of prostate cancer. DeAntoni EP. **Oncology (Huntingt)** 1997 Apr;11(4):475–82, 485; discussion 485–6, 489 (57 ref.)

DRUG EFFECTS

Evaluation of men on finasteride. Gormley GJ. **Semin Urol Oncol** 1996 Aug;14(3):139–44 (40 ref.)

GENETICS

Development of gene therapy for prostate cancer using a novel promoter of prostate-specific antigen. Dannull J, et al. **Br J Urol** 1997 Mar;79 Suppl 1:97–103 (49 ref.)

Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. Gomella LG, et al. **J Urol** 1997 Aug;158(2):326–37 (87 ref.)

METABOLISM

Clinical use of posttherapy prostate-specific antigen changes in advanced prostate cancer. Kelly WK, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 14):8–14 (36 ref.)

PROSTATECTOMY

Excretory urography before prostatectomy. Ntia IO, et al. **Afr J Med Med Sci** 1996 Mar;25(1):75–9 (11 ref.)

The National Prostatectomy Audit. Neal DE. **Br J Urol** 1997 Apr;79 Suppl 2:69–75 (29 ref.)

Quinolone prophylaxis in transurethral surgery. Gasser TC. **Chemotherapy** 1996 Mar;42 Suppl 1:28–32 (30 ref.)

Adjuvant therapy for prostate cancer patients at high risk of recurrence following radical prostatectomy. Andriole GL. **Eur Urol** 1997;32 Suppl 3:65–9 (59 ref.)

Who is best benefited by radical prostatectomy? Nadler RB, et al. **Hematol Oncol Clin North Am** 1996 Jun;10(3):581–93 (39 ref.)

Is there a role for induction androgen deprivation prior to radical prostatectomy? Watson R, et al. **Hematol Oncol Clin North Am** 1996 Jun;10(3):627–41 (62 ref.)

The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. Schild SE, et al. **J Urol** 1996 Nov; 156(5):1725–9 (22 ref.)

Does transurethral resection of the prostate compromise the radical treatment of prostate cancer? Mansfield JT, et al. **Semin Urol Oncol** 1996 Aug;14(3):174–7 (26 ref.)

Neoadjuvant hormonal therapy in the management of prostate cancer: a surgical and radiation therapy review. Soderdahl DW, et al. **Tech Urol** 1996 Winter;2(4):194–206 (73 ref.)

Adjuvant hormone therapy after radical prostatectomy: indications and results. Ditonno P, et al. **Tumori** 1997 Mar–Apr;83(2):567–75 (64 ref.)

Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary. Abbas F, et al. **Urol Clin North Am** 1996 Nov;23(4):587–604 (121 ref.)

Incidence and significance of positive margins in radical prostatectomy specimens. Epstein JI. **Urol Clin North Am** 1996 Nov;23(4):651–63 (29 ref.)

The role of neoadjuvant androgen deprivation prior to radical prostatectomy. Fradet Y. **Urol Clin North Am** 1996 Nov;23(4):575–85 (47 ref.)

The role of the reverse-transcriptase polymerase chain reaction assay for prostate-specific antigen in the selection of patients for radical prostatectomy. Katz AE, et al. **Urol Clin North Am** 1996 Nov;23(4):541–9 (40 ref.)

Serum prostate-specific antigen elevation in the post-radical prostatectomy patient. Malkowicz SB. **Urol Clin North Am** 1996 Nov;23(4):665–75 (64 ref.)

New approaches to adjuvant therapy for patients with adverse histopathologic findings following radical prostatectomy. Nelson WG, et al. **Urol Clin North Am** 1996 Nov;23(4):685–96 (117 ref.)

Localized prostate cancer: overview of surgical management. Richie JP. **Urology** 1997 Mar;49(3A Suppl):35–7 (11 ref.)

[Adjuvant radiotherapy after radical prostatectomy. Apropos of a series of 73 patients in Lyons (France)] Fric D, et al. **Cancer Radiother** 1997;1(1):52–9 (35 ref.) (Eng. Abstr.) **(Fre)**

[Neoadjuvant hormone therapy before prostatectomy for cancer localized to the prostate] Boccon-Gibod L. **Prog Urol** 1997 Feb;7(1):97–8 (14 ref.) **(Fre)**

[Radiotherapy after radical prostatectomy: indications, results and side effects] Wiegel T, et al. **Strahlenther Onkol** 1997 Jun;173(6):309–15 (53 ref.) (Eng. Abstr.) **(Ger)**

[Echographic follow-up after radical prostatectomy] Rosi P, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):43–8 (7 ref.) (Eng. Abstr.) **(Ita)**

[A case of prostate cancer diagnosed one and half year after retropubic prostatectomy for benign prostatic hypertrophy] Kato Y, et al. **Hinyokika Kiyo** 1996 Nov;42(11):907–9 (8 ref.) (Eng. Abstr.) **(Jpn)**

[A transurethral endoscopic incision in the treatment of patients with benign prostatic hyperplasia and bladder neck sclerosis] Gorilovskii ML, et al. **Urol Nefrol (Mosk)** 1996 May–Jun;(3):47–51 (79 ref.) **(Rus)**

ADVERSE EFFECTS

Transurethral resection of the prostate (TURP) syndrome: a review of the pathophysiology and management. Gravenstein D. **Anesth Analg** 1997 Feb;84(2):438–46 (97 ref.)

Risk factors for urinary incontinence after radical prostatectomy [see comments] Eastham JA, et al.

PROSTATECTOMY

J Urol 1996 Nov;156(5):1707–13 (32 ref.) Comment in: J Urol 1996 Nov;156(5):1724.

Post–prostatectomy incontinence and the artificial urinary sphincter: a long–term study of patient satisfaction and criteria for success. Litwiller SE, et al. **J Urol** 1996 Dec; 156(6):1975–80 (21 ref.)

Transurethral collagen injection for treatment of postprostatectomy urinary incontinence in men. Griebling TL, et al. **Urology** 1997 Jun;49(6):907–12 (25 ref.)

ECONOMICS

Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective. Eri LM, et al. **Drugs Aging** 1997 Feb;10(2):107–18 (84 ref.)

METHODS

Radical prostatectomy: consideration of the risk factors. Schulman CC. **Br J Urol** 1997 Apr;79 Suppl 2:53–6 (30 ref.)

Beyond the nerve–sparing radical prostatectomy. Smith RC, et al. **Cancer Treat Res** 1996;88:129–45 (145 ref.)

Neoadjuvant hormonal treatment prior to radical prostatectomy: facts and open questions. Schulman CC, et al. **Eur Urol** 1997;32 Suppl 3:41–7 (62 ref.)

Avoiding complications of radical retropubic prostatectomy. Thiel R, et al. **Eur Urol** 1997;31 Suppl 3:9–15 (49 ref.)

Cryoablation for carcinoma of the prostate. Patel BG, et al. **J Surg Oncol** 1996 Dec;63(4):256–64 (42 ref.)

Risk factors for urinary incontinence after radical prostatectomy [see comments] Eastham JA, et al. **J Urol** 1996 Nov;156(5):1707–13 (32 ref.) Comment in: J Urol 1996 Nov;156(5):1724.

The use of ethanol as a marker to detect and quantify the absorption of irrigation fluid during transurethral resection of the prostate. Hjertberg H. **Scand J Urol Nephrol Suppl** 1996;178:1–64 (180 ref.)

Techniques of coagulation laser prostatectomy for narrow divergence angle fibers. Milam DF. **Tech Urol** 1996 Spring; 2(1):34–9 (20 ref.)

Laser prostatectomy is a safer, better operation than electrovaporization of the prostate [editorial] Kabalin JN. **Urology** 1997 Feb;49(2):160–5 (70 ref.)

Comparison of the modified vest and the direct anastomosis for radical retropubic prostatectomy. Novicki DE, et al. **Urology** 1997 May;49(5):732–6 (9 ref.)

Evaluating radical prostatectomy specimens: therapeutic and prognostic importance. Bostwick DG, et al. **Virchows Arch** 1997 Jan;430(1):1–16 (92 ref.)

[Prostatic electrovaporization] Conquy S, et al. **Prog Urol** 1997 Feb;7(1):99–101 (9 ref.) **(Fre)**

[Laser treatment of benign prostatic hyperplasia] Ogreid P, et al. **Nord Med** 1997 Mar;112(3):89–92 (15 ref.) (Eng. Abstr.) **(Nor)**

STANDARDS

Evaluating radical prostatectomy specimens: therapeutic and prognostic importance. Bostwick DG, et al. **Virchows Arch** 1997 Jan;430(1):1–16 (92 ref.)

TRENDS

Lasers in the treatment of benign prostatic obstruction: past, present, and future. te Slaa E, et al. **Eur Urol** 1996; 30(1):1–10 (51 ref.)

PROSTATECTOMY, TRANSURETHRAL see **PROSTATECTOMY**

PROSTATIC ADENOMA see **PROSTATIC HYPERPLASIA**

PROSTATIC DISEASES

DIAGNOSIS

New diagnostic applications of prostate–specific antigen. Diamandis EP. **Br J Urol** 1997 Mar;79 Suppl 1:87–91 (53 ref.)

Tuberculosis of the prostate: MR appearance. Wang JH, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):639–40 (6 ref.)

MR imaging of the prostate and seminal vesicles. David V. **Magn Reson Imaging Clin N Am** 1996 Aug;4(3):497–518 (67 ref.)

Malakoplakia of the prostate gland––report of two cases and review of the literature. Sarma HN, et al. **Scand J Urol Nephrol** 1996 Apr;30(2):155–7 (20 ref.)

[Modern radiologic diagnosis of prostatic diseases] Stojanović S, et al. **Med Pregl** 1996;49(11–12):459–63 (20 ref.) (Eng. Abstr.) **(Scr)**

SURGERY

Cryosurgery. Onik G. **Crit Rev Oncol Hematol** 1996 May; 23(1):1–24 (58 ref.)

PROSTATIC HYPERPLASIA

Benign prostatic hyperplasia: natural history, endocrine pathogenesis, and medical treatment with finasteride. Sherwood LM. **Mt Sinai J Med** 1996 Jan;63(1):1–9 (25 ref.)

Is screening for prostate cancer necessary in men with symptoms of benign prostatic hyperplasia? Hall MC, et al. **Semin Urol Oncol** 1996 Aug;14(3):122–33 (72 ref.)

[Natural history of the benign prostatic hyperplasia] Akimoto S, et al. **Nippon Hinyokika Gakkai Zasshi** 1997 Apr; 88(4):451–62 (106 ref.) **(Jpn)**

BLOOD

Biological variation of prostate specific antigen levels in serum: an evaluation of day–to–day physiological fluctuations in a well–defined cohort of 24 patients [see comments] Nixon RG, et al. **J Urol** 1997 Jun; 157(6):2183–90 (33 ref.) Comment in: J Urol 1997 Jun;157(6):2197–8.

DIAGNOSIS

Benign prostatic hyperplasia [see comments] Simpson RJ. **Br J Gen Pract** 1997 Apr;47(417):235–40 (114 ref.) Comment in: Br J Gen Pract 1997 Jun;47(419):401.

Successful separation between benign prostatic hyperplasia and prostate cancer by measurement of free and complexed PSA. Lilja H, et al. **Cancer Treat Res** 1996;88:93–101 (50 ref.)

Assessment of the patient with benign prostatic hyperplasia. Carlin BI, et al. **Compr Ther** 1996 Sep;22(9):586–91 (25 ref.)

Making the diagnosis of benign prostatic hyperplasia. A critical review. el Din KE, et al. **Eur Urol** 1997; 31(3):257–62 (48 ref.)

Symptom scores in benign prostatic hyperplasia. Riehmann M, et al. **Urology** 1997 Jan;49(1):10–8 (91 ref.)

DRUG THERAPY

Benign prostatic hyperplasia: diagnosis and treatment guideline. Lee M, et al. **Ann Pharmacother** 1997 Apr; 31(4):481–6 (30 ref.)

Medical approaches in the management of prostatic disease. Droller MJ. **Br J Urol** 1997 Apr;79 Suppl 2:42–52 (49 ref.)

Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia. Wilde MI, et al. **Drugs** 1996 Dec;52(6):883–98 (73 ref.)

Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective. Eri LM, et al. **Drugs Aging** 1997 Feb;10(2):107–18 (84 ref.)

Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Plosker GL, et al. **Drugs Aging** 1996 Nov;9(5):379–95 (86 ref.)

Medical management of benign prostatic hyperplasia: a review. Magoha GA. **East Afr Med J** 1996 Jul;73(7):453–6 (43 ref.)

Clinical relevance of growth factor antagonists in the treatment of benign prostatic hyperplasia. Desgrandchamps F. **Eur Urol** 1997;32 Suppl 1:28–31 (16 ref.)

Pharmacological options in the treatment of benign prostatic hyperplasia. Kenny B, et al. **J Med Chem** 1997 Apr 25; 40(9):1293–315 (146 ref.)

Measures of Proscar, Hytrin, and Cardura side effects. Frankel S. **Neurourol Urodyn** 1997;16(1):63–6 (0 ref.)

The use of alpha–adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy: an overview. Hieble JP, et al. **Pharmacol Res** 1996 Mar;33(3):145–60 (158 ref.)

Pharmacological treatment of benign prostatic hyperplasia, current options and future perspectives. Hansen BJ. **Scand J Urol Nephrol Suppl** 1996;180:1–55 (186 ref.)

Evaluation of men on finasteride. Gormley GJ. **Semin Urol Oncol** 1996 Aug;14(3):139–44 (40 ref.)

Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia. McKiernan JM, et al. **South Med J** 1997 May;90(5):509–13 (20 ref.)

Conservative non–instrumental treatment of benign prostatic hyperplasia. Ruud Bosch JL. **Urol Res** 1997;25 Suppl 2:S107–14 (43 ref.)

Alpha–blockade: monotherapy for hypertension and benign prostatic hyperplasia. Kaplan SA, et al. **Urology** 1996 Oct; 48(4):541–50 (58 ref.)

Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Reuter VE. **Urology** 1997 Mar;49(3A Suppl):16–22 (31 ref.)

[Drug therapy of benign prostatic hyperplasia] Vahlensieck W Jr, et al. **Fortschr Med** 1996 Nov 10;114(31):407–11 (0 ref.) (Eng. Abstr.) **(Ger)**

[Treatment of benign prostatic hyperplasia with alpha 1–adrenoreceptor antagonists] Heimbach D, et al. **Urologe A** 1997 Jan;36(1):18–34 (157 ref.) (Eng. Abstr.) **(Ger)**

[Significance of 5–alpha–reductase inhibitors in therapy of benign prostatic hyperplasia with mild to modern symptoms] Wirth MP, et al. **Urologe A** 1997 Jan;36(1):35–9 (20 ref.) (Eng. Abstr.) **(Ger)**

[Alpha blockers in the treatment of benign hyperplasia of the prostate] Gómez Sancha F, et al. **Rev Clin Esp** 1997 May;197(5):358–62 (46 ref.) **(Spa)**

ECONOMICS

The economics of benign prostatic hyperplasia treatment: a literature review. Kortt MA, et al. **Clin Ther** 1996 Nov–Dec;18(6):1227–41 (32 ref.)

Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective. Eri LM, et al. **Drugs Aging** 1997 Feb;10(2):107–18 (84 ref.)

EPIDEMIOLOGY

Prostate disease: epidemiology, natural history and demographic shifts. Garraway WM, et al. **Br J Urol** 1997 Apr;79 Suppl 2:3–8 (42 ref.)

ETIOLOGY

Role of growth factors in benign prostatic hyperplasia. Lawson RK. **Eur Urol** 1997;32 Suppl 1:22–7 (38 ref.)

Intrinsic and extrinsic factors controlling benign prostatic growth. Lee C, et al. **Prostate** 1997 May 1;31(2):131–8 (83 ref.)

GENETICS

Atypical adenomatous hyperplasia of the prostate: a critical review. Grignon DJ, et al. **Eur Urol** 1996;30(2):206–11 (57 ref.)

PATHOLOGY

Diagnostic limits in precursor lesions of prostatic cancer. Algaba F, et al. **Eur Urol** 1996;30(2):212–21 (27 ref.)

Comparative pathology of benign prostatic hyperplasia and prostate cancer. Maini A, et al. **In Vivo** 1997 Jul–Aug; 11(4):293–9 (57 ref.)

Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Reuter VE. **Urology** 1997 Mar;49(3A Suppl):16–22 (31 ref.)

[Diagnostic problems in prostatic pathology: microglandular lesions and intraductal epithelial proliferations] Berger N, et al. **Arch Anat Cytol Pathol** 1996;44(4):141–59 (78 ref.) (Eng. Abstr.) **(Fre)**

[Proposal of a new transurethral method for repeated prostatic biopsy] Marzano D, et al. **Arch Ital Urol Androl** 1997 Feb;69 Suppl 1:87–91 (16 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Animal models for the preneoplastic lesions of the prostate. Pylkkänen L, et al. **Eur Urol** 1996;30(2):243–8 (33 ref.)

The role of urodynamic study in the evaluation and management of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Gerber GS. **Urology** 1996 Nov;48(5):668–75 (88 ref.)

[Benign prostatic hyperplasia––the outcome of age–induced alteration of androgen–estrogen balance?] Weisser H, et al. **Urologe A** 1997 Jan;36(1):3–9 (28 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Excretory urography before prostatectomy. Ntia IO, et al. **Afr J Med Med Sci** 1996 Mar;25(1):75–9 (11 ref.)

SURGERY

Electrovaporization of the prostate. Tewari A, et al. **Br J Urol** 1996 Nov;78(5):667–76 (31 ref.)

Lasers in the treatment of benign prostatic obstruction: past, present, and future. te Slaa E, et al. **Eur Urol** 1996; 30(1):1–10 (51 ref.)

Techniques of coagulation laser prostatectomy for narrow divergence angle fibers. Milam DF. **Tech Urol** 1996 Spring; 2(1):34–9 (20 ref.)

Laser prostatectomy is a safer, better operation than electrovaporization of the prostate [editorial] Kabalin JN. **Urology** 1997 Feb;49(2):160–5 (70 ref.)

Transurethral needle ablation of the prostate [editorial] Naslund MJ. **Urology** 1997 Aug;50(2):167–72 (13 ref.)

[Progresses in urology in China, 1996] Guo Y. **Chung Hua I Hsueh Tsa Chih** 1996 Dec;76(12):907–8 (0 ref.) **(Chi)**

[Laser thermocoagulation of adenoma of the prostate using an interstitial approach] Muschter R, et al. **Ann Urol (Paris)** 1997;31(1):27–37 (56 ref.) (Eng. Abstr.) **(Fre)**

[Alternative treatment of benign prostatic hypertrophy] Fiorelli C, et al. **Minerva Urol Nefrol** 1996 Dec; 48(4):177–82 (19 ref.) (Eng. Abstr.) **(Ita)**

[A case of prostate cancer diagnosed one and half year after retropubic prostatectomy for benign prostatic hypertrophy] Kato Y, et al. **Hinyokika Kiyo** 1996 Nov;42(11):907–9 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Laser treatment of benign prostatic hyperplasia] Ogreid P, et al. **Nord Med** 1997 Mar;112(3):89–92 (15 ref.) (Eng. Abstr.) **(Nor)**

[A transurethral endoscopic incision in the treatment of patients with benign prostatic hyperplasia and bladder neck sclerosis] Gorilovskiĭ ML, et al. **Urol Nefrol (Mosk)** 1996 May–Jun;(3):47–51 (79 ref.) **(Rus)**

[Treatment of prostate benign hyperplasia (BPH) with visually controlled laser, assessment at 2 years, and anatomopathologic findings] Laguna MP, et al. **Actas Urol Esp** 1996 Sep;20(8):681–8 (23 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Management of benign prostatic hyperplasia. Barry M, et al. **Annu Rev Med** 1997;48:177–89 (40 ref.)

Treatment options for benign prostatic hyperplasia. Portis

AJ, et al. **Can Fam Physician** 1997 Aug;43:1395–404 (50 ref.)
Treatment of benign prostatic hyperplasia: surgery, medical therapy, or watchful waiting. Sall M, et al. **Compr Ther** 1996 Sep;22(9):554–8 (14 ref.)
Benign prostatic hypertrophy. Geller J. **Curr Ther Endocrinol Metab** 1997;6:586–93 (23 ref.)
Benign prostatic hyperplasia. Practical treatment guidelines. Tammela T. **Drugs Aging** 1997 May;10(5):349–66 (141 ref.)
Prostate disease in older men: 1. Benign hyperplasia. Albertsen PC. **Hosp Pract (Off Ed)** 1997 May 15;32(5):61–4, 67–8, 77 passim (6 ref.)
Recent advances in the treatment of benign prostatic hyperplasia. Lai MK. **J Formos Med Assoc** 1996 Nov; 95(11):822–7 (59 ref.)
Current status of thermotherapy of the prostate. de la Rosette JJ, et al. **J Urol** 1997 Feb;157(2):430–8 (75 ref.)
Benign prostatic hyperplasia in elderly men. What are the special issues in treatment? Guthrie R. **Postgrad Med** 1997 May;101(5):141–3, 148, 151–4 passim (21 ref.)
[Phytotherapy of benign prostatic hyperplasia] Bracher F. **Urologe A** 1997 Jan;36(1):10–7 (27 ref.) (Eng. Abstr.) **(Ger)**
[Nonendoscopic thermal treatment methods in benign prostatic hyperplasia: hyperthermia, thermotherapy, thermoablation] Apolikhin OI, et al. **Urol Nefrol (Mosk)** 1996 Jul–Aug;(4):48–56 (70 ref.) **(Rus)**
[New technologies in the treatment of benign prostatic hyperplasia] Trapeznikova MF, et al. **Urol Nefrol (Mosk)** 1996 Jul–Aug;(4):41–7 (73 ref.) **(Rus)**
[Retrospective study of the treatment of 329 patients with prostatism syndrome and review of the literature] Fernández Gómez JM, et al. **Arch Esp Urol** 1996 Nov; 49(9):929–43 (36 ref.) (Eng. Abstr.) **(Spa)**

PROSTATIC HYPERTROPHY see **PROSTATIC HYPERPLASIA**

PROSTATIC HYPERTROPHY, BENIGN see **PROSTATIC HYPERPLASIA**

PROSTATIC INTRAEPITHELIAL NEOPLASIA

Prostatic intraepithelial neoplasia: significance and management. Lipski BA, et al. **Semin Urol Oncol** 1996 Aug; 14(3):149–55 (29 ref.)

DIAGNOSIS

Follow-up of prostatic intraepithelial neoplasia. Berner A, et al. **Eur Urol** 1996;30(2):256–60 (49 ref.)

DRUG THERAPY

Influence of irradiation and androgen ablation on prostatic intraepithelial neoplasia. Wheeler TM. **Eur Urol** 1996; 30(2):261–4 (20 ref.)

EPIDEMIOLOGY

Age and racial distribution of prostatic intraepithelial neoplasia. Sakr WA, et al. **Eur Urol** 1996;30(2):138–44 (26 ref.)

GENETICS

Potential markers of aggressiveness in prostatic intraepithelial neoplasia detected by fluorescence in situ hybridization. Qian J, et al. **Eur Urol** 1996;30(2):177–84 (49 ref.)

METABOLISM

Neuroendocrine differentiation in the precursors of prostate cancer. di Sant' Agnese PA. **Eur Urol** 1996;30(2):185–90 (42 ref.)
Molecular events in the early phases of prostate carcinogenesis. Magi-Galluzzi C, et al. **Eur Urol** 1996; 30(2):167–76 (72 ref.)
Biomarker expression in prostatic intraepithelial neoplasia. Myers RB, et al. **Eur Urol** 1996;30(2):153–66 (126 ref.)

PATHOLOGY

The canine prostate is a spontaneous model of intraepithelial neoplasia and prostate cancer progression. Waters DJ, et al. **Anticancer Res** 1997 May-Jun;17(3A):1467–70 (22 ref.)
Diagnostic limits in precursor lesions of prostatic cancer. Algaba F, et al. **Eur Urol** 1996;30(2):212–21 (27 ref.)
Knowledge-based image analysis in the precursors of prostatic adenocarcinoma. Bartels PH, et al. **Eur Urol** 1996; 30(2):234–42 (17 ref.)
Analysis of the capillary architecture in the precursors of prostate cancer: recent findings and new concepts. Montironi R, et al. **Eur Urol** 1996;30(2):191–200 (43 ref.)
Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials. Bostwick DG, et al. **J Cell Biochem Suppl** 1996;25:156–64 (59 ref.)
The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues. Häggman MJ, et al. **J Urol** 1997 Jul;158(1):12–22 (159 ref.)
[Proposal of a new transurethral method for repeated prostatic biopsy] Marzano D, et al. **Arch Ital Urol Androl** 1997 Feb;69 Suppl 1:87–91 (16 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Progression of prostatic intraepithelial neoplasia to early invasive adenocarcinoma. Bostwick DG. **Eur Urol** 1996; 30(2):145–52 (38 ref.)
Precursors of prostatic cancer: progression, regression and chemoprevention [editorial] Montironi R, et al. **Eur Urol** 1996;30(2):133–7 (24 ref.)
Animal models for the preneoplastic lesions of the prostate. Pylkkänen L, et al. **Eur Urol** 1996;30(2):243–8 (33 ref.)
Clinical prognostic criteria for later diagnosis of prostate carcinoma in patients with initial isolated prostatic intraepithelial neoplasia. Zlotta AR, et al. **Eur Urol** 1996; 30(2):249–55 (30 ref.)

PREVENTION & CONTROL

Chemoprevention for prostatic intraepithelial neoplasia. Nelson PS, et al. **Eur Urol** 1996;30(2):269–78 (97 ref.)

VETERINARY

The canine prostate is a spontaneous model of intraepithelial neoplasia and prostate cancer progression. Waters DJ, et al. **Anticancer Res** 1997 May-Jun;17(3A):1467–70 (22 ref.)

PROSTATIC NEOPLASMS

Primary extramedullary leukemia of the prostate: case report and review of the literature. Quien ET, et al. **Am J Hematol** 1996 Dec;53(4):267–71 (18 ref.)
Report prepared for the Health Technology Assessment panel of the NHS Executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales. Chamberlain J, et al. **Br J Urol** 1997 May;79 Suppl 3:1–32 (145 ref.)
Prostate cancer: where are we and where are we going? Denmeade SR, et al. **Br J Urol** 1997 Mar;79 Suppl 1:2–7 (42 ref.)
The natural history of clinical prostate carcinoma [editorial; comment] Abbas F, et al. **Cancer** 1997 Sep 1;80(5):827–33 (61 ref.) Comment on: Cancer 1997 Sep 1;80(5):917–28.
Prostate cancer. Balducci L, et al. **Clin Geriatr Med** 1997 May;13(2):283–306 (82 ref.)
Prostate cancer and smoking: a review of case-control and cohort studies [published erratum appears in Prostate 1996 Dec;29(6):402] Lumey LH. **Prostate** 1996 Oct;29(4):249–60 (71 ref.)
Southwest Oncology Group studies in hormone-refractory prostate cancer. Hussain MH, et al. **Semin Oncol** 1996 Dec; 23(6 Suppl 14):24–7 (13 ref.)
Preclinical models of prostate cancer. Royai R, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 14):35–40 (18 ref.)
Prostatic intraepithelial neoplasia: significance and management. Lipski BA, et al. **Semin Urol Oncol** 1996 Aug; 14(3):149–55 (29 ref.)
[Diagnosis and treatment of bladder and prostate cancer in early stages] Watanabe H, et al. **Nippon Rinsho** 1996 May; 54(5):1405–9 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Cystic adenoid carcinoma of the prostate. Report of a case] Osorio Acosta V, et al. **Arch Esp Urol** 1997 Jan–Feb; 50(1):67–71 (17 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

Some comments on progress in the standardization of immunoassays for prostate-specific antigen. Stamey TA. **Br J Urol** 1997 Mar;79 Suppl 1:49–52 (17 ref.)
Prospective evaluation of prostate specific antigen density and systematic biopsy for detecting prostate cancer in Japanese patients with normal rectal examinations and intermediate prostate specific antigen levels. Arai Y, et al. **J Urol** 1997 Sep;158(3 Pt 1):861–4 (18 ref.)
Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. Gomella LG, et al. **J Urol** 1997 Aug;158(2):326–37 (87 ref.)
Biological variation of prostate specific antigen levels in serum: an evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients [see comments] Nixon RG, et al. **J Urol** 1997 Jun; 157(6):2183–90 (33 ref.) Comment in: J Urol 1997 Jun;157(6):2197–8.
The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. Schild SE, et al. **J Urol** 1996 Nov; 156(5):1725–9 (22 ref.)
Treatment options for localized prostate cancer based on pretreatment serum prostate specific antigen levels. Vicini FA, et al. **J Urol** 1997 Aug;158(2):319–25 (79 ref.)
Screening for prostate cancer: the role of prostate-specific antigen. Ferrer RL. **Md Med J** 1996 Nov;45(11):938–40 (7 ref.)
The role of PSA in the radiotherapy of prostate cancer. Roach M 3rd. **Oncology (Huntingt)** 1996 Aug; 10(8):1143–53; discussion 1154–61 (55 ref.)
Metastatic prostate cancer: assessment of response to systemic therapy. Dreicer R. **Semin Urol Oncol** 1997 Feb;15(1):28–32 (36 ref.)
[Prostate specific antigen] Koutani A, et al. **Ann Urol (Paris)** 1996;30(5):257–61 (30 ref.) (Eng. Abstr.) **(Fre)**
[Post-treatment PSA, indicator of radical treatment effectiveness of localized cancer of the prostate] Ravery V, et al. **Prog Urol** 1996 Dec;6(6):981–6 (35 ref.) (Eng. Abstr.) **(Fre)**

CEREBROSPINAL FLUID

Metastasizing extraneural tumors along the CSF pathway. Lee JY, et al. **Clin Neuropathol** 1997 May-Jun;16(3):117–21 (15 ref.)

CHEMISTRY

Changes in biomarker expression in the development of prostatic adenocarcinoma. Myers RB, et al. **Biotech Histochem** 1997 Mar;72(2):86–95 (73 ref.)
Signet-ring carcinoma of the prostate. Leong FJ, et al. **Pathol Res Pract** 1996 Dec;192(12):1232–8; discussion 1239–41 (30 ref.)
The androgen receptor in prostate cancer. Trapman J, et al. **Pathol Res Pract** 1996 Jul;192(7):752–60 (79 ref.)
Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications Part 2. Tumorigenic cell lines. Webber MM, et al. **Prostate** 1997 Jan 1;30(1):58–64 (46 ref.)

COMPLICATIONS

Influence of urological complications on the prognosis of prostate cancer. Colombel M, et al. **Eur Urol** 1997;31 Suppl 3:21–4 (12 ref.)
Atypical metastasis from prostatic carcinoma. Report of a case of renal metastasis and literature review. Galindo Gallego M, et al. **Minerva Urol Nefrol** 1996 Dec; 48(4):183–7 (27 ref.)
Ketoconazole-induced adrenal crisis in a patient with metastatic prostatic adenocarcinoma: case report and review of the literature. Sarver RG, et al. **Urology** 1997 May;49(5):781–5 (27 ref.)
[The effective therapy of the hot flashes during hormone withdrawal treatment in patients with advanced prostatic carcinoma] Kliesch S, et al. **Dtsch Med Wochenschr** 1997 Jul 25;122(30):940–5 (64 ref.) **(Ger)**

DIAGNOSIS

Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer. Isaacs JT. **Am J Pathol** 1997 May;150(5):1511–21 (92 ref.)
PSA as a marker for prostate cancer: a critical review. Duffy MJ. **Ann Clin Biochem** 1996 Nov;33 (Pt 6):511–9 (62 ref.)
Screening for prostate cancer. American College of Physicians [see comments] **Ann Intern Med** 1997 Mar 15; 126(6):480–4 (52 ref.) Comment in: Ann Intern Med 1997 Mar 15;126(6):465–7.
Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians. Coley CM, et al. **Ann Intern Med** 1997 Mar 1;126(5):394–406 (181 ref.)
Diagnosis and treatment of urological malignancy: the prostate. Doherty AP, et al. **Br J Hosp Med** 1996 Feb 7–20;55(3):104–6, 123–4 (13 ref.)
Prostatic cancer: future prospects for diagnosis and screening. Franks LM. **Br J Urol** 1997 Mar;79 Suppl 1:107–8 (6 ref.)
Enhancing the specificity of prostate-specific antigen (PSA): an overview of PSA density, velocity and age-specific reference ranges. Nixon RG, et al. **Br J Urol** 1997 Mar; 79 Suppl 1:61–7 (43 ref.)
Prostate-specific antigen, clinical use and staging: an overview. Stenman UH. **Br J Urol** 1997 Mar;79 Suppl 1:53–60 (53 ref.)
Evaluating prostate needle biopsy: therapeutic and prognostic importance. Bostwick DG. **CA Cancer J Clin** 1997 Sep-Oct;47(5):297–319 (135 ref.)
PSA and early prostate cancer detection: the importance of age-specific reference ranges. Oesterling JE. **Can J Oncol** 1994 Nov;4 Suppl 1:52–6 (22 ref.)
Successful separation between benign prostatic hyperplasia and prostate cancer by measurement of free and complexed PSA. Lilja H, et al. **Cancer Treat Res** 1996;88:93–101 (50 ref.)
Prostate cancer screening: current issues. Prorok PC, et al. **Cancer Treat Res** 1996;86:93–112 (85 ref.)
Individual prostate-specific antigen (PSA) forms as prostate tumor markers. Becker C, et al. **Clin Chim Acta** 1997 Jan 3;257(1):117–32 (87 ref.)
Diagnostic limits in precursor lesions of prostatic cancer. Algaba F, et al. **Eur Urol** 1996;30(2):212–21 (27 ref.)
Automated reasoning system in histopathologic diagnosis and prognosis of prostate cancer and its precursors. Bartels PH, et al. **Eur Urol** 1996;30(2):222–33 (20 ref.)
Follow-up of prostatic intraepithelial neoplasia. Berner A, et al. **Eur Urol** 1996;30(2):256–60 (49 ref.)
Prostate cancer: to screen or not to screen? Bouffioux C. **Eur Urol** 1997;31 Suppl 1:2–4 (17 ref.)
Clinical assessment and management of stage T3 prostate cancer. Newling DW. **Eur Urol** 1997;32 Suppl 3:55–9 (15 ref.)
Free/total prostate-specific antigen ratio--hope and controversies. Ravery V, et al. **Eur Urol** 1997;31(4):385–8 (19 ref.)
Can screening for early-stage prostate cancer be rationalized? Jacobson JO. **Hematol Oncol Clin North Am** 1996 Jun;

10(3):549–64 (72 ref.)

Significance of serum free prostate specific antigen in the screening of prostate cancer. Higashihara E, et al. **J Urol** 1996 Dec;156(6):1964–8 (22 ref.)

Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate. Presti JC Jr, et al. **J Urol** 1996 Nov;156(5):1685–90 (10 ref.)

Prostate cancer diagnosis and management [see comments] Frydenberg M, et al. **Lancet** 1997 Jun 7;349(9066):1681–7 (85 ref.) Comment in: Lancet 1997 Aug 23;350(9077):592.

Benefits and costs of MR imaging of prostate cancer. Langlotz CP. **Magn Reson Imaging Clin N Am** 1996 Aug; 4(3):533–44 (32 ref.)

Percent free prostate-specific antigen: entering a new era in the detection of prostate cancer. Vashi AR, et al. **Mayo Clin Proc** 1997 Apr;72(4):337–44 (52 ref.)

Small cell carcinoma of the prostate: a case report and review of the literature. Aygun C. **Md Med J** 1997 Aug;46(7):353–6 (28 ref.)

Prostate cancer: diagnosis, treatment, and experience at one tertiary-care military medical center, 1989 and 1994. Bauer JJ, et al. **Mil Med** 1996 Nov;161(11):646–53 (47 ref.)

Age-specific reference ranges for PSA in the detection of prostate cancer. DeAntoni EP. **Oncology (Huntingt)** 1997 Apr;11(4):475–82, 485; discussion 485–6, 489 (57 ref.)

Prostate-specific antigen: what's new in 1997. Pannek J, et al. **Oncology (Huntingt)** 1997 Sep;11(9):1273–8; discussion 1279–82 (59 ref.)

Current status of enhancing the detection of prostate cancer [editorial] Babaian RJ. **Prostate** 1997 May 15;31(3):204–5 (10 ref.)

Diagnostic and prognostic markers for human prostate cancer. Gao X, et al. **Prostate** 1997 Jun 1;31(4):264–81 (185 ref.)

Clinical utility of measurements of free and total prostate-specific antigen (PSA): a review. Catalona WJ. **Prostate Suppl** 1996;7:64–9 (48 ref.)

Prostate-specific human kallikrein (hK2) as a novel marker for prostate cancer. Young CY, et al. **Prostate Suppl** 1996; 7:17–24 (41 ref.)

Epidemiology, diagnosis and treatment of prostate cancer [see comments] Newman J. **Radiol Technol** 1996 Sep–Oct; 68(1):39–64; quiz 65–8 (113 ref.) Comment in: Radiol Technol 1997 Jan–Feb;68(3):194–5.

Prostate-specific antigen and early detection of prostate cancer. Chu TM. **Tumour Biol** 1997;18(2):123–34 (53 ref.)

Prostate-specific antigen as a screening test for prostate cancer. The United States experience. Arcangeli CG, et al. **Urol Clin North Am** 1997 May;24(2):299–306 (82 ref.)

The socioeconomic implications of prostate-specific antigen screening. Benoit RM, et al. **Urol Clin North Am** 1997 May; 24(2):451–8 (28 ref.)

Prostate-specific membrane antigen and other prostatic tumor markers on the horizon. Israeli RS, et al. **Urol Clin North Am** 1997 May;24(2):439–50 (79 ref.)

The role of the reverse-transcriptase polymerase chain reaction assay for prostate-specific antigen in the selection of patients for radical prostatectomy. Katz AE, et al. **Urol Clin North Am** 1996 Nov;23(4):541–9 (40 ref.)

Reverse transcriptase-polymerase chain reaction assays for prostate cancer. Olsson CA, et al. **Urol Clin North Am** 1997 May;24(2):367–78 (80 ref.)

The use of prostate-specific antigen and free/total prostate-specific antigen in the diagnosis of localized prostate cancer. Partin AW, et al. **Urol Clin North Am** 1996 Nov;23(4):531–40 (63 ref.)

Issues on early diagnosis and treatment of localized prostate cancer. Pontes JE. **Urol Int** 1996;56 Suppl 1:1–5 (35 ref.)

Recommendations of the first Michigan conference on prostate cancer. Porter AT, et al. **Urology** 1996 Oct; 48(4):519–33; discussion 533–4 (0 ref.)

[Prostate specific antigen (PSA): impact of a seric marker on the diagnosis and therapeutic management of cancers of the prostate] Chauvet B, et al. **Bull Cancer Radiother** 1996;83(4):334–44 (108 ref.) **(Fre)**

[What can the clinician expect today from PSA determination?] Teillac P. **Nucl Med Biol** 1994 Apr; 21(3):455–69 (43 ref.) (Eng. Abstr.) **(Fre)**

[The incidence of the variability of the free PSA/total PSA ratio on the early diagnosis of prostate cancer] de La Taille A, et al. **Prog Urol** 1997 Jun;7(3):455–63 (35 ref.) (Eng. Abstr.) **(Fre)**

[The prostate-specific antigen in the early recognition of prostate carcinoma] Wolff JM, et al. **Dtsch Med Wochenschr** 1996 Nov 29;121(48):1508–14 (63 ref.) **(Ger)**

[Determination of cellular DNA content in the diagnosis and prognosis of mesenchymal tumors] Tóth E, et al. **Orv Hetil** 1996 Nov 10;137(45):2511–5 (27 ref.) (Eng. Abstr.) **(Hun)**

[A case of prostate cancer diagnosed one and half year after retropubic prostatectomy for benign prostatic hypertrophy] Kato Y, et al. **Hinyokika Kiyo** 1996 Nov;42(11):907–9 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Prostatic cancer with cystic formation: a case report] Takayama H, et al. **Hinyokika Kiyo** 1996 Dec;42(12):977–80 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Usefulness of prostate-specific antigen in the screening of cancer of the prostate] Buitrago F, et al. **Aten Primaria** 1996 Sep 30;18(5):265–70 (67 ref.) **(Spa)**

DRUG THERAPY

Apoptosis in hormone-responsive malignancies. Denmeade SR, et al. **Adv Pharmacol** 1997;41:553–83 (126 ref.)

Nilutamide: an antiandrogen for the treatment of prostate cancer. Dole EJ, et al. **Ann Pharmacother** 1997 Jan; 31(1):65–75 (64 ref.)

Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer. Blackledge G, et al. **Anticancer Drugs** 1996 Jan;7(1):27–34 (38 ref.)

Interferon and hormone sensitivity of endocrine-related tumors. Sica G, et al. **Anticancer Drugs** 1996 Feb; 7(2):150–60 (80 ref.)

Medical approaches in the management of prostatic disease. Droller MJ. **Br J Urol** 1997 Apr;79 Suppl 2:42–52 (49 ref.)

Therapy for hormone-resistant prostate cancer: no longer a myth. Petrylak DP, et al. **Cancer Treat Res** 1996;88:211–8 (41 ref.)

Androgen deprivation and antagonism in the treatment of advanced prostatic carcinoma. Gibbs SJ, et al. **Clin Oncol (R Coll Radiol)** 1996;8(6):346–52 (44 ref.)

Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. Wiseman LR, et al. **Drugs Aging** 1997 Jun; 10(6):473–85 (52 ref.)

Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. Raghavan D, et al. **Eur J Cancer** 1997 Apr;33(4):566–74 (101 ref.)

Adjuvant therapy for prostate cancer patients at high risk of recurrence following radical prostatectomy. Andriole GL. **Eur Urol** 1997;32 Suppl 3:65–9 (59 ref.)

Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer. Blackledge GR, et al. **Eur Urol** 1997;31 Suppl 2:30–9 (44 ref.)

Maximum androgen blockade in 1996. Boccon-Gibod L. **Eur Urol** 1996;30 Suppl 1:15–8; discussion 19–21 (10 ref.)

Androgens, androgen receptors, antiandrogens and the treatment of prostate cancer. Griffiths K, et al. **Eur Urol** 1997;32 Suppl 3:24–40 (82 ref.)

Combined androgen blockade: the gold standard for metastatic prostate cancer. McLeod DG, et al. **Eur Urol** 1997;32 Suppl 3:70–7 (43 ref.)

Neoadjuvant therapy prior to radiotherapy for clinically localized prostate cancer. Roach M 3rd. **Eur Urol** 1997;32 Suppl 3:48–54 (34 ref.)

Neoadjuvant hormonal treatment prior to radical prostatectomy: facts and open questions. Schulman CC, et al. **Eur Urol** 1997;32 Suppl 3:41–7 (62 ref.)

Innovative approaches to the hormonal treatment of advanced prostate cancer. Trachtenberg J. **Eur Urol** 1997; 32 Suppl 3:78–80 (5 ref.)

Influence of irradiation and androgen ablation on prostatic intraepithelial neoplasia. Wheeler TM. **Eur Urol** 1996; 30(2):261–4 (20 ref.)

Is "off-protocol" chemotherapy for androgen-independent carcinoma of prostate warranted? Mani S, et al. **Hematol Oncol Clin North Am** 1996 Jun;10(3):749–68 (106 ref.)

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. Small EJ, et al. **J Clin Oncol** 1997 Jan;15(1):382–8 (39 ref.)

Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer. Koivisto P, et al. **Scand J Clin Lab Invest Suppl** 1996;226:57–63 (19 ref.)

Combined androgen blockade in the treatment of advanced prostate cancer--an overview. The Scandinavian Prostatic Cancer Group. Iversen P. **Scand J Urol Nephrol** 1997 Jun; 31(3):249–54 (33 ref.)

Overview of Canadian trials in hormonally resistant prostate cancer. Moore MJ, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 14):15–9 (7 ref.)

New therapeutic agents for hormone-refractory prostate cancer. Roth BJ. **Semin Oncol** 1996 Dec;23(6 Suppl 14):49–55 (56 ref.)

Cancer and Leukemia Group B trials for advanced prostate cancer. Small EJ, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 14):28–31 (13 ref.)

Estramustine-based chemotherapy. Hudes G. **Semin Urol Oncol** 1997 Feb;15(1):13–9 (47 ref.)

Other chemotherapy regimens including mitoxantrone and suramin. Siu LL, et al. **Semin Urol Oncol** 1997 Feb; 15(1):20–7 (38 ref.)

Current treatment of advanced prostate cancer. Ismail M, et al. **Tech Urol** 1997 Spring;3(1):16–24 (55 ref.)

Neoadjuvant hormonal therapy in the management of prostate cancer: a surgical and radiation therapy review. Soderdahl DW, et al. **Tech Urol** 1996 Winter;2(4):194–206 (73 ref.)

Adjuvant hormone therapy after radical prostatectomy: indications and results. Ditonno P, et al. **Tumori** 1997 Mar–Apr;83(2):567–75 (64 ref.)

Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary. Abbas F, et al. **Urol Clin North Am** 1996 Nov;23(4):587–604 (121 ref.)

The role of neoadjuvant androgen deprivation prior to radical prostatectomy. Fradet Y. **Urol Clin North Am** 1996 Nov;23(4):575–85 (47 ref.)

Intermittent androgen deprivation in advanced prostate cancer. de Reijke TM. **Urol Res** 1997;25 Suppl 2:S63–6 (35 ref.)

The antiandrogen withdrawal syndrome. Wirth MP, et al. **Urol Res** 1997;25 Suppl 2:S67–71 (28 ref.)

First International Conference on Neoadjuvant Hormonal Therapy of Prostate Cancer: overview consensus statement. Garnick MB, et al. **Urology** 1997 Mar;49(3A Suppl):1–4 (0 ref.)

Hormonal therapy in the management of prostate cancer: from Huggins to the present. Garnick MB. **Urology** 1997 Mar;49(3A Suppl):5–15 (35 ref.)

Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Reuter VE. **Urology** 1997 Mar;49(3A Suppl):16–22 (31 ref.)

Evaluating neoadjuvant therapy effectiveness on systemic disease: use of a prostatic-specific membrane reverse transcription polymerase chain reaction. Su SL, et al. **Urology** 1997 Mar;49(3A Suppl):95–101 (37 ref.)

Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: experimental and clinical results. Zietman AL, et al. **Urology** 1997 Mar;49(3A Suppl):74–83 (43 ref.)

[Hepatic encephalopathy induced by flutamide administered for the treatment of prostatic cancer] Patel H, et al. **J Urol (Paris)** 1996;102(3):123–5 (12 ref.) (Eng. Abstr.) **(Fre)**

[The role of etoposide therapy in urogenital cancer] Kawai K, et al. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1929–35 (36 ref.) (Eng. Abstr.) **(Jpn)**

[Combined hormone/chemotherapy for advanced prostatic cancer] Komatsu H. **Nippon Hinyokika Gakkai Zasshi** 1997 Mar;88(3):375–85 (86 ref.) **(Jpn)**

[Zoladex (ICI) in the therapy of prostatic cancer patients] Popko AS, et al. **Urol Nefrol (Mosk)** 1996 Nov–Dec; (6):53–5 (40 ref.) **(Rus)**

[The use of Casodex (bicalutamide) in the treatment of disseminated prostatic cancer] Sivko AV, et al. **Urol Nefrol (Mosk)** 1997 May–Jun;(3):49–52 (83 ref.) **(Rus)**

[Current hormone therapy of prostate cancer] Perevodchikova NI, et al. **Vopr Onkol** 1996;42(4):7–11 (11 ref.) **(Rus)**

EPIDEMIOLOGY

Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians. Coley CM, et al. **Ann Intern Med** 1997 Mar 1;126(5):394–406 (181 ref.)

Prostate disease: epidemiology, natural history and demographic shifts. Garraway WM, et al. **Br J Urol** 1997 Apr;79 Suppl 2:3–8 (42 ref.)

Epidemiology of prostate cancer. Haas GP, et al. **CA Cancer J Clin** 1997 Sep–Oct;47(5):273–87 (111 ref.)

Consensus conference: smoking and prostate cancer. Colditz G. **Cancer Causes Control** 1996 Sep;7(5):560–2 (7 ref.)

Nutrition and prostate cancer. Kolonel LN. **Cancer Causes Control** 1996 Jan;7(1):83–44 (91 ref.)

Epidemiology of prostate cancer and bladder cancer: an overview. Ross RK. **Cancer Treat Res** 1996;88:1–11 (51 ref.)

Prostate cancer. Small EJ. **Curr Opin Oncol** 1997 May; 9(3):277–86 (88 ref.)

Recent developments in the epidemiology of prostate cancer. Mettlin C. **Eur J Cancer** 1997 Mar;33(3):340–7 (58 ref.)

Epidemiology of prostate cancer. Dijkman GA, et al. **Eur Urol** 1996;30(3):281–95 (134 ref.)

Age and racial distribution of prostatic intraepithelial neoplasia. Sakr WA, et al. **Eur Urol** 1996;30(2):138–44 (26 ref.)

How is individual risk for prostate cancer assessed? Giovannucci E. **Hematol Oncol Clin North Am** 1996 Jun; 10(3):537–48 (121 ref.)

Prostate cancer, race, and socioeconomic status: inadequate adjustment for social factors in assessing racial differences. Dale W, et al. **Prostate** 1996 Nov;29(5):271–81 (53 ref.)

Changes in patterns of prostate cancer care in the United States: results of American College of Surgeons Commission on Cancer studies, 1974–1993. Mettlin C. **Prostate** 1997 Aug 1;32(3):221–6 (21 ref.)

Metal workers and repairmen at risk for prostate cancer: a review. van der Gulden JW. **Prostate** 1997 Feb 1; 30(2):107–16 (93 ref.)

Epidemiology of prostate cancer: molecular and environmental clues. Pienta KJ, et al. **Urology** 1996 Nov; 48(5):676–83 (76 ref.)

ETHNOLOGY

The management of prostate cancer in blacks: the physician's dilemma intensified. Haynes MA. **Compr Ther** 1996 Jul; 22(7):449–53 (11 ref.)

Prostate cancer and African-American men. Powell IJ. **Oncology (Huntingt)** 1997 May;11(5):599–605; discussion 606–15 passim (35 ref.)

Genetic predisposition to prostate cancer: possible explanations for ethnic differences in risk. Shibata A, et al. **Prostate** 1997 Jun 15;32(1):65–72 (50 ref.)

ETIOLOGY

Environmental and genetic factors: a possible link with prostate cancer. Ekman P, et al. **Br J Urol** 1997 Apr;79 Suppl 2:35–41 (67 ref.)

Molecular and cellular biology of the prostate: is it clinically relevant? Habib FK, et al. **Br J Urol** 1996 Oct;78(4):546–51 (55 ref.)

Epidemiology of prostate cancer. Haas GP, et al. **CA Cancer J Clin** 1997 Sep–Oct;47(5):273–87 (111 ref.)

Precursors of prostatic cancer: progression, regression and chemoprevention [editorial] Montironi R, et al. **Eur Urol** 1996;30(2):133–7 (24 ref.)

GENETICS

Tumour–suppressor genes in prostatic oncogenesis: a positional approach. Bookstein R, et al. **Br J Urol** 1997 Mar;79 Suppl 1:28–36 (73 ref.)

Familial prostate cancer: the evidence and the Cancer Research Campaign/British Prostate Group (CRC/BPG) UK Familial Prostate Cancer Study. Eeles RA, et al. **Br J Urol** 1997 Mar;79 Suppl 1:8–14 (51 ref.)

The concept of evolution in the pathogenesis and treatment of prostate cancer. Garcia–Schurmann M, et al. **Br J Urol** 1997 Apr;79 Suppl 2:9–17 (10 ref.)

Molecular and cellular biology of prostate cancer. Lalani el–N, et al. **Cancer Metastasis Rev** 1997 Jun;16(1–2):29–66 (403 ref.)

Androgen receptor mutations in prostate cancer. Gelmann EP. **Cancer Treat Res** 1996;87:285–302 (84 ref.)

Reverse transcriptase– polymerase chain reaction (RT–PCR) to detect prostate cancer micrometastasis in the blood. Yao KL, et al. **Cancer Treat Res** 1996;88:77–91 (35 ref.)

Molecular cytogenetics of prostate cancer. Koivisto PA. **Crit Rev Oncog** 1996;7(3–4):143–50 (67 ref.)

Molecular advances in prostate cancer. Dong JT, et al. **Curr Opin Oncol** 1997 Jan;9(1):101–7 (99 ref.)

Androgen receptor gene mutations in prostate cancer. Implications for disease progression and therapy. Culig Z, et al. **Drugs Aging** 1997 Jan;10(1):50–8 (69 ref.)

Atypical adenomatous hyperplasia of the prostate: a critical review. Grignon DJ, et al. **Eur Urol** 1996;30(2):206–11 (57 ref.)

Potential markers of aggressiveness in prostatic intraepithelial neoplasia detected by fluorescence in situ hybridization. Qian J, et al. **Eur Urol** 1996;30(2):177–84 (49 ref.)

Genetic susceptibility to cancer from exogenous and endogenous exposures. Feigelson HS, et al. **J Cell Biochem Suppl** 1996;25:15–22 (48 ref.)

Androgen receptor mutations in prostate cancer. Barrack ER. **Mt Sinai J Med** 1996 Oct–Nov;63(5–6):403–12 (61 ref.)

Genetic predisposition to prostate cancer: possible explanations for ethnic differences in risk. Shibata A, et al. **Prostate** 1997 Jun 15;32(1):65–72 (50 ref.)

Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. Part 3. Oncogenes, suppressor genes, and applications. Webber MM, et al. **Prostate** 1997 Feb 1;30(2):136–42 (70 ref.)

Molecular carcinogenesis of prostate cancer: potential clinical relevance and nursing implications. Weber CE. **Semin Oncol Nurs** 1997 May;13(2):99–107 (54 ref.)

The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker? Heidenberg HB, et al. **Urology** 1996 Dec;48(6):971–9 (66 ref.)

Review of allelic loss and gain in prostate cancer. Bova GS, et al. **World J Urol** 1996;14(5):338–46 (78 ref.)

Androgen–receptor gene structure and function in prostate cancer. Hakimi JM, et al. **World J Urol** 1996;14(5):329–37 (46 ref.)

Molecular biology of prostate cancer. Shi XB, et al. **World J Urol** 1996;14(5):318–28 (137 ref.)

[Mutations of the androgen receptor gene a possible role in prostate cancer] Mowszowicz I, et al. **Bull Cancer** 1997 Feb;84(2):183–8 (37 ref.) (Eng. Abstr.) **(Fre)**

[Genetic aspects in cancers of the prostate] Cussenot O, et al. **Pathol Biol (Paris)** 1996 Oct;44(8):737–43 (59 ref.) (Eng. Abstr.) **(Fre)**

[Significance of prostate–specific membrane antigen (PSMA). A neurocarboxypeptidase and membrane folate hydrolase] Heston WD. **Urologe A** 1996 Sep;35(5):400–7 (17 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

A case of lymphocutaneous nocardiosis with a review of lymphocutaneous nocardiosis reported in Japan [see comments] Ye Z, et al. **J Dermatol** 1996 Feb;23(2):120–4 (29 ref.) Comment in: J Dermatol 1997 Jan;24(1):68.

Percent free prostate–specific antigen: entering a new era in the detection of prostate cancer. Vashi AR, et al. **Mayo Clin Proc** 1997 Apr;72(4):337–44 (52 ref.)

Quality of life in patients with prostatic carcinoma: a review and results of a study in N+ disease. Prostate–specific antigen as predictor of quality of life. van Andel G, et al. **Urol Res** 1997;25 Suppl 2:S79–88 (36 ref.)

[Prostate–specific antigen in the diagnosis of organ–confined treatable prostate carcinoma] Recker F. **Schweiz Med Wochenschr** 1996 Nov 2;126(44):1881–90 (58 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Androgens and prostate cancer: biology, pathology and hormonal therapy. Galbraith SM, et al. **Eur J Cancer** 1997 Apr;33(4):545–54 (78 ref.)

Neuroendocrine differentiation in the precursors of prostate cancer. di Sant' Agnese PA. **Eur Urol** 1996;30(2):185–90 (42 ref.)

Molecular events in the early phases of prostate carcinogenesis. Magi–Galluzzi C, et al. **Eur Urol** 1996; 30(2):167–76 (72 ref.)

Biomarker expression in prostatic intraepithelial neoplasia. Myers RB, et al. **Eur Urol** 1996;30(2):153–66 (126 ref.)

Hyperactive androgen receptor in prostate cancer: what does it mean for new therapy concepts? Culig Z, et al. **Histol Histopathol** 1997 Jul;12(3):781–6 (55 ref.)

Androgen receptors in prostate cancer. Bentel JM, et al. **J Endocrinol** 1996 Oct;151(1):1–11 (91 ref.)

TGF beta in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Barrack ER. **Prostate** 1997 Apr 1;31(1):61–70 (100 ref.)

Clinical use of posttherapy prostate–specific antigen changes in advanced prostate cancer. Kelly WK, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 14):8–14 (36 ref.)

Citrate metabolism of normal and malignant prostate epithelial cells. Costello LC, et al. **Urology** 1997 Jul; 50(1):3–12 (46 ref.)

Prostate–specific antigen–producing cells in the bone marrow of a patient with early–stage prostate cancer. D'Amico AV, et al. **Urology** 1997 Feb;49(2):279–82 (17 ref.)

MORTALITY

Natural course of localized prostate cancer. a personal view with a review of published papers. Hugosson J, et al. **Anticancer Res** 1997 May–Jun;17(3A):1441–8 (44 ref.)

PATHOLOGY

Smooth muscle–epithelial interactions in normal and neoplastic prostatic development. Cunha GR, et al. **Acta Anat (Basel)** 1996;155(1):63–72 (57 ref.)

The treatment of osseous metastases of hormone–refractory prostate cancer with external beam radiotherapy and Strontium–89. De Ruysscher D, et al. **Acta Urol Belg** 1996 Sep;64(3):13–9 (44 ref.)

Prostate specific antigen in the diagnosis and staging of prostate cancer. Jung P, et al. **Acta Urol Belg** 1996 Sep; 64(3):1–6 (41 ref.)

Activation of programmed (apoptotic) cell death for the treatment of prostate cancer. Denmeade SR, et al. **Adv Pharmacol** 1996;35:281–306 (78 ref.)

Small cell anaplastic carcinoma of the prostate: seven new cases, review of the literature, and discussion of a therapeutic strategy. Rubenstein JH, et al. **Am J Clin Oncol** 1997 Aug;20(4):376–80 (27 ref.)

Prostate cancer. The problem of prognostic factors. Murphy WM. **Am J Clin Pathol** 1996 Oct;106(4 Suppl 1):S45–9 (45 ref.)

Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer. Isaacs JT. **Am J Pathol** 1997 May;150(5):1511–21 (92 ref.)

Models for cancer skeletal metastasis: a reappraisal of Batson's plexus. Geldof AA. **Anticancer Res** 1997 May–Jun; 17(3A):1535–9 (45 ref.)

Growth factors mediate glucocorticoid receptor function and dexamethasone–induced regression of osteoblastic lesions in hormone refractory prostate cancer. Koutsilieris M, et al. **Anticancer Res** 1997 May–Jun;17(3A):1461–5 (29 ref.)

The canine prostate is a spontaneous model of intraepithelial neoplasia and prostate cancer progression. Waters DJ, et al. **Anticancer Res** 1997 May–Jun;17(3A):1467–70 (22 ref.)

Stromal–epithelial interactions in the normal and neoplastic prostate. Hayward SW, et al. **Br J Urol** 1997 Apr;79 Suppl 2:18–26 (48 ref.)

Cellular interactions in prostate cancer. Lee C. **Br J Urol** 1997 Mar;79 Suppl 1:21–7 (47 ref.)

The cadherin cell–cell adhesion pathway in prostate cancer progression. Paul R, et al. **Br J Urol** 1997 Mar;79 Suppl 1:37–43 (48 ref.)

Apoptosis, tumour invasion and prostate cancer. Tenniswood M. **Br J Urol** 1997 Apr;79 Suppl 2:27–34 (82 ref.)

Molecular and cellular biology of prostate cancer. Lalani el–N, et al. **Cancer Metastasis Rev** 1997 Jun;16(1–2):29–66 (403 ref.)

Knowledge–based image analysis in the precursors of prostatic adenocarcinoma. Bartels PH, et al. **Eur Urol** 1996; 30(2):234–42 (17 ref.)

Staging prostate cancer—1997: current methods and limitations. Bostwick DG. **Eur Urol** 1997;32 Suppl 3:2–14 (86 ref.)

Predicting pelvic lymph node involvement in patients with localized prostate cancer. Ekman P. **Eur Urol** 1997;32 Suppl 3:60–4 (19 ref.)

Application of self–expanding stents in prostate cancer with rectal involvement. Report of two cases and review of the literature. Lujan M, et al. **Eur Urol** 1997;31(2):251–3 (13 ref.)

Analysis of the capillary architecture in the precursors of prostate cancer: recent findings and new concepts. Montironi R, et al. **Eur Urol** 1996;30(2):191–200 (43 ref.)

Prostate cancer: indicators of aggressiveness. Sakr WA, et al. **Eur Urol** 1997;32 Suppl 3:15–23 (91 ref.)

Early–stage prostate cancer. When is observation appropriate? Albertsen PC. **Hematol Oncol Clin North Am** 1996 Jun;10(3):611–25 (40 ref.)

Metastatic carcinoma of the prostate presenting as parotid tumour. Simpson RH, et al. **Histopathology** 1997 Jan; 30(1):70–4 (14 ref.)

Comparative pathology of benign prostatic hyperplasia and prostate cancer. Maini A, et al. **In Vivo** 1997 Jul–Aug; 11(4):293–9 (57 ref.)

Evaluation of prostate specific antigen density and transrectal ultrasonography–guided biopsies in 100 consecutive patients with a negative digital rectal examination and intermediate serum prostate specific antigen levels. Tarcan T, et al. **Int J Urol** 1997 Jul;4(4):362–7 (30 ref.)

A case of testicular metastasis from carcinoma of the prostate. D'Amico A, et al. **Int Urol Nephrol** 1995;27(5):593–6 (23 ref.)

Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials. Bostwick DG, et al. **J Cell Biochem Suppl** 1996;25:156–64 (59 ref.)

Role of transrectal ultrasound and prostate biopsy. Melchior SW, et al. **J Clin Ultrasound** 1996 Oct;24(8):463–71 (53 ref.)

Quintuple cancers: report of a case with triple cancers in the head and neck. Martin–Granizo R, et al. **J Craniomaxillofac Surg** 1997 Jun;25(3):153–7 (34 ref.)

Clinical trials in relapsed prostate cancer: defining the target. Scher HI, et al. **J Natl Cancer Inst** 1996 Nov 20; 88(22):1623–34 (90 ref.)

Prospective evaluation of prostate specific antigen density and systematic biopsy for detecting prostate cancer in Japanese patients with normal rectal examinations and intermediate prostate specific antigen levels. Arai Y, et al. **J Urol** 1997 Sep;158(3 Pt 1):861–4 (18 ref.)

Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. Carter HB, et al. **J Urol** 1997 Jun;157(6):2206–9 (10 ref.)

Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. Gomella LG, et al. **J Urol** 1997 Aug;158(2):326–37 (87 ref.)

Metastatic adenocarcinoma of the prostate to the orbit as a presenting symptom. Gonzalez CM, et al. **J Urol** 1997 Feb;157(2):625 (4 ref.)

The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues. Häggman MJ, et al. **J Urol** 1997 Jul;158(1):12–22 (159 ref.)

Update on the appropriate staging evaluation for newly diagnosed prostate cancer. O'Dowd GJ, et al. **J Urol** 1997 Sep;158(3 Pt 1):687–98 (140 ref.)

Prostatic carcinoma. Diagnostic pathology and prognosis. Renshaw AA. **Magn Reson Imaging Clin N Am** 1996 Aug; 4(3):439–48 (108 ref.)

MR staging of prostate cancer. How we can improve our accuracy with decisions aids and optimal techniques. Tempany CM. **Magn Reson Imaging Clin N Am** 1996 Aug; 4(3):519–32 (20 ref.)

Does an inability to eradicate normal stem cells preclude the cure of some cancers? Anderson KM, et al. **Med Hypotheses** 1996 Jul;47(1):31–4 (24 ref.)

Atypical metastasis from prostatic carcinoma. Report of a case of renal metastasis and literature review. Galindo Gallego M, et al. **Minerva Urol Nefrol** 1996 Dec; 48(4):183–7 (27 ref.)

Histologic variants of adenocarcinoma and other carcinomas of prostate: pathologic criteria and clinical significance. Randolph TL, et al. **Mod Pathol** 1997 Jun;10(6):612–29 (133 ref.)

Prostate–specific membrane antigen. Fair WR, et al. **Prostate** 1997 Jul 1;32(2):140–8 (52 ref.)

Target to apoptosis: a hopeful weapon for prostate cancer. Tang DG, et al. **Prostate** 1997 Sep 1;32(4):284–93 (115 ref.)

Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. Part 3. Oncogenes, suppressor genes, and applications. Webber MM, et al. **Prostate** 1997 Feb 1;30(2):136–42 (70 ref.)

Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. Part I. Cell markers and immortalized nontumorigenic cell lines. Webber MM, et al. **Prostate** 1996 Dec;29(6):386–94 (151 ref.)

Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications Part 2. Tumorigenic cell lines. Webber MM, et al. **Prostate** 1997 Jan 1;30(1):58–64 (46 ref.)

Heel pain as the inaugural manifestation of metastatic prostate cancer [letter] Gisserot O, et al. **Rev Rhum Engl Ed** 1996 Dec;63(11):870–1 (8 ref.)

Squamous cell carcinoma of the prostate. Uchibayashi T, et al. **Scand J Urol Nephrol** 1997 Apr;31(2):223–4 (6 ref.)

Pathological definitions and characteristics of stage T1 prostate cancer. Bhargava V. **Semin Urol Oncol** 1996 Aug; 14(3):145–8 (20 ref.)

Can insignificant prostate cancer be predicted preoperatively in men with stage T1 disease? Epstein JI. **Semin Urol Oncol** 1996 Aug;14(3):165–73 (40 ref.)

Staging of incidentally detected prostate cancer: role of repeat resection, prostate–specific antigen, needle biopsy, and imaging. Griebling TL, et al. **Semin Urol Oncol** 1996 Aug;14(3):156–64 (54 ref.)

Use of prostate–specific antigen, Gleason score, and digital rectal examination in staging patients with newly diagnosed prostate cancer. Rees MA, et al. **Urol Clin North Am** 1997 May;24(2):379–88 (68 ref.)

The role of color Doppler and staging biopsies in prostate cancer detection. Bree RL. **Urology** 1997 Mar;49(3A Suppl):31–4 (28 ref.)

Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure. D'Amico AV, et al. **Urology** 1997 Mar;49(3A Suppl):23–30 (24 ref.)

Pathological changes in benign and malignant prostatic tissue

following androgen deprivation therapy. Reuter VE. **Urology** 1997 Mar;49(3A Suppl):16–22 (31 ref.)

Complications of transrectal ultrasound–guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population–based screening program. Rietbergen JB, et al. **Urology** 1997 Jun; 49(6):875–80 (26 ref.)

Evaluating neoadjuvant therapy effectiveness on systemic disease: use of a prostatic–specific membrane reverse transcription polymerase chain reaction. Su SL, et al. **Urology** 1997 Mar;49(3A Suppl):95–101 (37 ref.)

Intracranial metastases as the first manifestation of prostate cancer. Sutton MA, et al. **Urology** 1996 Nov;48(5):789–93 (28 ref.)

[Diagnostic problems in prostatic pathology: microglandular lesions and intraductal epithelial proliferations] Berger N, et al. **Arch Anat Cytol Pathol** 1996;44(4):141–59 (78 ref.) (Eng. Abstr.) **(Fre)**

[In vitro and in vivo models developed from human prostatic cancer] Bladou F, et al. **Prog Urol** 1997 Jun;7(3):384–96 (96 ref.) (Eng. Abstr.) **(Fre)**

[Prostatic urothelial location of a tumor of the bladder] Coulange C, et al. **Prog Urol** 1997 Feb;7(1):128–31 (14 ref.) (Eng. Abstr.) **(Fre)**

[The detection of circulating prostatic cells using RT–PCR] Eschwege P. **Prog Urol** 1997 Feb;7(1):92–6 (10 ref.) **(Fre)**

[Apoptosis––principles and importance of programmed cell death for prostatic carcinoma] Gschwend JE. **Urologe A** 1996 Sep;35(5):390–9 (71 ref.) (Eng. Abstr.) **(Ger)**

[Proposal of a new transurethral method for repeated prostatic biopsy] Marzano D, et al. **Arch Ital Urol Androl** 1997 Feb;69 Suppl 1:87–91 (16 ref.) (Eng. Abstr.) **(Ita)**

[Mechanism on androgen–independent progression of prostate cancer] Shimazaki J, et al. **Nippon Rinsho** 1997 May;55(5):1143–8 (23 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Gene therapy of prostate cancer: p53, suicidal genes, and other targets. Boulikas T. **Anticancer Res** 1997 May–Jun; 17(3A):1471–505 (236 ref.)

Natural course of localized prostate cancer. a personal view with a review of published papers. Hugosson J, et al. **Anticancer Res** 1997 May–Jun;17(3A):1441–8 (44 ref.)

Steroid hormones and cancer: IV. Prostate cancer. Habib FK. **Eur J Surg Oncol** 1997 Jun;23(3):264–8 (36 ref.)

Progression of prostatic intraepithelial neoplasia to early invasive adenocarcinoma. Bostwick DG. **Eur Urol** 1996; 30(2):145–52 (38 ref.)

Animal models for the preneoplastic lesions of the prostate. Pylkkänen L, et al. **Eur Urol** 1996;30(2):243–8 (33 ref.)

Clinical prognostic criteria for later diagnosis of prostate carcinoma in patients with initial isolated prostatic intraepithelial neoplasia. Zlotta AR, et al. **Eur Urol** 1996; 30(2):249–55 (30 ref.)

Prostate cancer: a clinical and basic science review. Long RJ, et al. **J Androl** 1997 Jan–Feb;18(1):15–20 (61 ref.)

The role of motility proteins and metastasis–suppressor genes in prostate cancer progression. Rinker–Schaeffer CW, et al. **Stem Cells** 1996 Sep;14(5):508–16 (50 ref.)

Transforming growth factor–beta and prostate cancer. Steiner MS. **World J Urol** 1995;13(6):329–36 (77 ref.)

PREVENTION & CONTROL

Nutritional approaches to the prevention of prostate cancer progression. Yip I, et al. **Adv Exp Med Biol** 1996;399:173–81 (75 ref.)

Prostate cancer screening: what general practitioners and patients need to know. Boyden A. **Aust Fam Physician** 1996 Sep;25(9 Suppl 2):S86–90 (28 ref.)

Prostate cancer prevention: investigational approaches and opportunities. Karp JE, et al. **Cancer Res** 1996 Dec 15; 56(24):5547–56 (120 ref.)

Is screening for prostate cancer the current gold standard?—"no". Kramer BS, et al. **Eur J Cancer** 1997 Mar; 33(3):348–53 (50 ref.)

Is screening for prostate cancer the current gold standard?—"yes". Lange PH. **Eur J Cancer** 1997 Mar; 33(3):354–6 (23 ref.)

Chemoprevention for prostatic intraepithelial neoplasia. Nelson PS, et al. **Eur Urol** 1996;30(2):269–78 (97 ref.)

The role of prostate–specific antigen in the chemoprevention of prostate cancer. Crawford ED, et al. **J Cell Biochem Suppl** 1996;25:149–55 (59 ref.)

Discussion of the controversies associated with prostate cancer screening. Wolfe ES, et al. **J R Soc Health** 1997 Jun;117(3):151–5 (20 ref.)

Controversies in prostate cancer screening. Analogies to the early lung cancer screening debate [see comments] Collins MM, et al. **JAMA** 1996 Dec 25;276(24):1976–9 (73 ref.) Comment in: JAMA 1997 Apr 9;277(14):1120; discussion 1121–2. Comment in: JAMA 1997 Apr 9;277(14):1120–1; discussion 1121–2. Comment in: JAMA 1997 Apr 9;277(14):1121; discussion 1121–2.

Screening for prostate cancer: the role of prostate–specific antigen. Ferrer RL. **Md Med J** 1996 Nov;45(11):938–40 (7 ref.)

Prostate cancer screening and management. Freid RM, et al. **Med Clin North Am** 1997 May;81(3):801–22 (84 ref.)

Prostate cancer: to screen or not to screen? **Oncology (Huntingt)** 1997 Mar;11(3):325–6, 329–30 (11 ref.)

Prostate cancer: to screen or not to screen? **Oncology (Huntingt)** 1997 Apr;11(4):447–8, 451–2 (9 ref.)

Is screening for prostate cancer necessary in men with symptoms of benign prostatic hyperplasia? Hall MC, et al. **Semin Urol Oncol** 1996 Aug;14(3):122–33 (72 ref.)

Use of prostate–specific antigen (PSA) and PSA density in the detection of stage T1 carcinoma of the prostate. Presti JC Jr, et al. **Semin Urol Oncol** 1996 Aug;14(3):134–8 (10 ref.)

Is exercise beneficial in the prevention of prostate cancer? Oliveria SA, et al. **Sports Med** 1997 May;23(5):271–8 (42 ref.)

Screening for prostate cancer is neither appropriate nor cost–effective. Albertsen PC. **Urol Clin North Am** 1996 Nov;23(4):521–30 (58 ref.)

Screening for prostate cancer. Kirkels WJ, et al. **Urol Res** 1997;25 Suppl 2:S53–6 (17 ref.)

[Mass screening for prostate cancer in Japan] Akimoto S, et al. **Nippon Rinsho** 1996 May;54(5):1447–51 (17 ref.) (Eng. Abstr.) **(Jpn)**

PSYCHOLOGY

Quality of life in patients with prostatic carcinoma: a review and results of a study in N+ disease. Prostate–specific antigen as predictor of quality of life. van Andel G, et al. **Urol Res** 1997;25 Suppl 2:S79–88 (36 ref.)

RADIONUCLIDE IMAGING

Possible role of FDG–PET in the evaluation of urologic malignancies. Bender H, et al. **Anticancer Res** 1997 May–Jun;17(3B):1655–60 (28 ref.)

Malignant paraganglioma of the prostate: case report, depiction by meta–iodobenzylguanidine scintigraphy and review of the literature. Shapiro B, et al. **Q J Nucl Med** 1997 Mar;41(1):36–41 (37 ref.)

RADIOTHERAPY

Clinical strategies for improving the radiotherapeutic management of prostate cancer. Chuba PJ, et al. **Anticancer Res** 1997 May–Jun;17(3A):1449–54 (43 ref.)

Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re–186–HEDP. De Klerk JM, et al. **Anticancer Res** 1997 May–Jun;17(3B):1773–7 (21 ref.)

Three–dimensional conformal therapy (3D–CRT) for prostate cancer. Chuba PJ, et al. **Cancer Treat Res** 1996; 88:147–65 (48 ref.)

Progress in the management of T3–4 adenocarcinoma of the prostate. Zietman AL, et al. **Eur J Cancer** 1997 Apr; 33(4):555–9 (33 ref.)

Neoadjuvant therapy prior to radiotherapy for clinically localized prostate cancer. Roach M 3rd. **Eur Urol** 1997;32 Suppl 3:48–54 (34 ref.)

Does brachytherapy have a role in the treatment of prostate cancer? Grimm PD, et al. **Hematol Oncol Clin North Am** 1996 Jun;10(3):653–73 (66 ref.)

Prostate cancer. Who is best benefited by external beam radiation therapy? Hartford AC, et al. **Hematol Oncol Clin North Am** 1996 Jun;10(3):595–610 (65 ref.)

Interstitial implantation techniques in prostate cancer. Sylvester J, et al. **J Surg Oncol** 1997 Sep;66(1):65–75 (65 ref.)

The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. Schild SE, et al. **J Urol** 1996 Nov; 156(5):1725–9 (22 ref.)

The role of PSA in the radiotherapy of prostate cancer. Roach M 3rd. **Oncology (Huntingt)** 1996 Aug; 10(8):1143–53; discussion 1154–61 (55 ref.)

Palliative radiotherapy in prostate cancer. Catton CN, et al. **Semin Urol Oncol** 1997 Feb;15(1):65–72 (70 ref.)

Should brachytherapy be considered a therapeutic option in localized prostate cancer? Blasko JC, et al. **Urol Clin North Am** 1996 Nov;23(4):633–50 (85 ref.)

Treatment options for localized recurrence of prostate cancer following radiation therapy. Corral DA, et al. **Urol Clin North Am** 1996 Nov;23(4):677–84 (41 ref.)

External beam radiation therapy does not offer long–term control of prostate cancer. Goluboff ET, et al. **Urol Clin North Am** 1996 Nov;23(4):617–21 (31 ref.)

Long–term control of prostate cancer with radiation. Past, present, and future. Hanks GE. **Urol Clin North Am** 1996 Nov;23(4):605–16 (33 ref.)

Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: experimental and clinical results. Zietman AL, et al. **Urology** 1997 Mar;49(3A Suppl):74–83 (43 ref.)

[Radiotherapy after radical prostatectomy: indications, results and side effects] Wiegel T, et al. **Strahlenther Onkol** 1997 Jun;173(6):309–15 (53 ref.) (Eng. Abstr.) **(Ger)**

SECONDARY

Second–line treatment of metastatic prostatic carcinoma. Newling DW. **Urol Res** 1997;25 Suppl 2:S73–8 (34 ref.)

Prostate cancer––biology of metastasis and its clinical implications. Dong JT, et al. **World J Urol** 1996;14(3):182–9 (63 ref.)

[Maximal androgen blockade in metastatic prostatic carcinoma (see comments)] Jørgensen T, et al. **Tidsskr Nor Laegeforen** 1997 Jan 30;117(3):381–3 (17 ref.) (Eng. Abstr.) Comment in: Tidsskr Nor Laegeforen 1997 Mar 20;117(8):1187. **(Nor)**

SURGERY

Surgery for the urinary tract cancer. Lukkarinen O. **Ann Chir Gynaecol** 1996;85(3):202–6 (47 ref.)

The National Prostatectomy Audit. Neal DE. **Br J Urol** 1997 Apr;79 Suppl 2:69–75 (29 ref.)

Radical prostatectomy: consideration of the risk factors. Schulman CC. **Br J Urol** 1997 Apr;79 Suppl 2:53–6 (30 ref.)

Beyond the nerve–sparing radical prostatectomy. Smith RC, et al. **Cancer Treat Res** 1996;88:129–45 (145 ref.)

Application of self–expanding stents in prostate cancer with rectal involvement. Report of two cases and review of the literature. Lujan M, et al. **Eur Urol** 1997;31(2):251–3 (13 ref.)

Avoiding complications of radical retropubic prostatectomy. Thiel R, et al. **Eur Urol** 1997;31 Suppl 3:9–15 (49 ref.)

Is there a role for cryoablation of the prostate in the management of localized prostate carcinoma? Long JP. **Hematol Oncol Clin North Am** 1996 Jun;10(3):675–90 (55 ref.)

Who is best benefited by radical prostatectomy? Nadler RB, et al. **Hematol Oncol Clin North Am** 1996 Jun;10(3):581–93 (39 ref.)

Cryoablation for carcinoma of the prostate. Patel BG, et al. **J Surg Oncol** 1996 Dec;63(4):256–64 (42 ref.)

The role of MR imaging in the selection of therapy for prostate cancer. D'Amico AV. **Magn Reson Imaging Clin N Am** 1996 Aug;4(3):471–9 (26 ref.)

Surgical perspective on prostate cancer. Detection, staging, and treatment. Loughlin KR. **Magn Reson Imaging Clin N Am** 1996 Aug;4(3):449–69 (64 ref.)

Does transurethral resection of the prostate compromise the radical treatment of prostate cancer? Mansfield JT, et al. **Semin Urol Oncol** 1996 Aug;14(3):174–7 (26 ref.)

Adjuvant hormone therapy after radical prostatectomy: indications and results. Ditonno P, et al. **Tumori** 1997 Mar–Apr;83(2):567–75 (64 ref.)

Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary. Abbas F, et al. **Urol Clin North Am** 1996 Nov;23(4):587–604 (121 ref.)

Should cryosurgery be considered a therapeutic option in localized prostate cancer? Connolly JA, et al. **Urol Clin North Am** 1996 Nov;23(4):623–31 (25 ref.)

Incidence and significance of positive margins in radical prostatectomy specimens. Epstein JI. **Urol Clin North Am** 1996 Nov;23(4):651–63 (29 ref.)

The role of neoadjuvant androgen deprivation prior to radical prostatectomy. Fradet Y. **Urol Clin North Am** 1996 Nov;23(4):575–85 (47 ref.)

The role of the reverse–transcriptase polymerase chain reaction assay for prostate–specific antigen in the selection of patients for radical prostatectomy. Katz AE, et al. **Urol Clin North Am** 1996 Nov;23(4):541–9 (40 ref.)

Serum prostate–specific antigen elevation in the post–radical prostatectomy patient. Malkowicz SB. **Urol Clin North Am** 1996 Nov;23(4):665–75 (64 ref.)

New approaches to adjuvant therapy for patients with adverse histopathologic findings following radical prostatectomy. Nelson WG, et al. **Urol Clin North Am** 1996 Nov;23(4):685–96 (117 ref.)

Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure. D'Amico AV, et al. **Urology** 1997 Mar;49(3A Suppl):23–30 (24 ref.)

Localized prostate cancer: overview of surgical management. Richie JP. **Urology** 1997 Mar;49(3A Suppl):35–7 (11 ref.)

[Neoadjuvant hormone therapy before prostatectomy for cancer localized to the prostate] Boccon–Gibod L. **Prog Urol** 1997 Feb;7(1):97–8 (14 ref.) **(Fre)**

[Small–cell sarcoma of the esophagus as a fourth malignancy. Its palliative therapy with argon gas coagulation] Glaser J, et al. **Dtsch Med Wochenschr** 1997 Aug 22; 122(34–35):1037–40 (8 ref.) (Eng. Abstr.) **(Ger)**

[Echographic follow–up after radical prostatectomy] Rosi P, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):43–8 (7 ref.) (Eng. Abstr.) **(Ita)**

[The surgical therapy of prostatic tumors] Caruso U, et al. **Minerva Chir** 1997 May;52(5):625–8 (5 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Treatment of metastatic carcinoma of the prostate. Goethuys H, et al. **Am J Clin Oncol** 1997 Feb;20(1):40–5 (47 ref.)

Adenocarcinoma of the prostate: innovations in management. Petrovich Z, et al. **Am J Clin Oncol** 1997 Apr;20(2):111–9 (62 ref.)

Gene therapy of prostate cancer: p53, suicidal genes, and other targets. Boulikas T. **Anticancer Res** 1997 May–Jun; 17(3A):1471–505 (236 ref.)

Recent advances in the medical management of prostate cancer [see comments] Kirby RS. **Br J Clin Pract** 1996 Mar;50(2):88–93 (57 ref.) Comment in: Br J Clin Pract 1996 Jul–Aug;50(5):287.

Diagnosis and treatment of urological malignancy: the prostate. Doherty AP, et al. **Br J Hosp Med** 1996 Feb 7-20;55(3):104-6, 123-4 (13 ref.)
Phytotherapy for the prostate. Buck AC. **Br J Urol** 1996 Sep;78(3):325-36 (59 ref.)
Development of gene therapy for prostate cancer using a novel promoter of prostate-specific antigen. Dannull J, et al. **Br J Urol** 1997 Mar;79 Suppl 1:97-103 (49 ref.)
The palliative therapy of advanced prostate cancer, with particular reference to the results of recent European clinical trials. Newling DW. **Br J Urol** 1997 Mar;79 Suppl 1:72-81 (63 ref.)
Gene therapy for prostate cancer. Sikora K, et al. **Br J Urol** 1997 Apr;79 Suppl 2:64-8 (20 ref.)
Renal, bladder, and prostate cancers: gene therapy. Carducci MA, et al. **Cancer Treat Res** 1996;88:219-34 (66 ref.)
Total androgen blockade for prostate cancer: the end does not justify the means. Javle M, et al. **Cancer Treat Res** 1996;88:201-10 (61 ref.)
The management of prostate cancer in blacks: the physician's dilemma intensified. Haynes MA. **Compr Ther** 1996 Jul; 22(7):449-53 (11 ref.)
Prostate cancer. Garzotto M, et al. **Curr Ther Endocrinol Metab** 1997;6:582-6 (5 ref.)
The assessment of treatment outcomes in metastatic prostate cancer: changing endpoints. Dawson NA, et al. **Eur J Cancer** 1997 Apr;33(4):560-5 (46 ref.)
Treatment of hormone-refractory prostate carcinoma. Fournier G. **Eur Urol** 1996;30 Suppl 1:32-7 (46 ref.)
Early versus delayed hormonal therapy in advanced prostate cancer. Mazeman E, et al. **Eur Urol** 1996;30 Suppl 1:40-3; discussion 49 (24 ref.)
Facing progressive localized prostatic cancer. Newling DW. **Eur Urol** 1997;31 Suppl 3:16-20 (28 ref.)
Clinical assessment and management of stage T3 prostate cancer. Newling DW. **Eur Urol** 1997;32 Suppl 3:55-9 (15 ref.)
Gene therapy for prostate cancer. Hrouda D, et al. **Gene Ther** 1996 Oct;3(10):845-52 (87 ref.)
Treatment of metastatic prostate cancer. Lessons from the androgen receptor. Bubley GJ, et al. **Hematol Oncol Clin North Am** 1996 Jun;10(3):713-25 (57 ref.)
Evaluating early-stage prostate cancer. What pretreatment criteria best guide therapeutic decision making? Corless CL. **Hematol Oncol Clin North Am** 1996 Jun;10(3):565-79 (113 ref.)
What is the optimal patient selection for combined androgen ablative and radiation therapy? The role of combined modality staging. D'Amico AV. **Hematol Oncol Clin North Am** 1996 Jun;10(3):643-51 (13 ref.)
Should asymptomatic progression following definitive local treatment for prostate cancer be treated? Lillis P, et al. **Hematol Oncol Clin North Am** 1996 Jun;10(3):703-12 (68 ref.)
How is androgen-dependent metastatic prostate cancer best treated? Robson M, et al. **Hematol Oncol Clin North Am** 1996 Jun;10(3):727-47 (149 ref.)
Quality of life in early prostate cancer. Do we know enough to treat? Talcott JA. **Hematol Oncol Clin North Am** 1996 Jun;10(3):691-701 (32 ref.)
Is there a role for induction androgen deprivation prior to radical prostatectomy? Watson R, et al. **Hematol Oncol Clin North Am** 1996 Jun;10(3):627-41 (62 ref.)
Clinical trials in relapsed prostate cancer: defining the target. Scher HI, et al. **J Natl Cancer Inst** 1996 Nov 20; 88(22):1623-34 (90 ref.)
Treatment options for localized prostate cancer based on pretreatment serum prostate specific antigen levels. Vicini FA, et al. **J Urol** 1997 Aug;158(2):319-25 (79 ref.)
Prostate cancer diagnosis and management [see comments] Frydenberg M, et al. **Lancet** 1997 Jun 7;349(9066):1681-7 (85 ref.) Comment in: Lancet 1997 Aug 23;350(9077):592.
Does an inability to eradicate normal stem cells preclude the cure of some cancers? Anderson KM, et al. **Med Hypotheses** 1996 Jul;47(1):31-4 (24 ref.)
Prostate cancer: diagnosis, treatment, and experience at one tertiary-care military medical center, 1989 and 1994. Bauer JJ, et al. **Mil Med** 1996 Nov;161(11):646-53 (47 ref.)
Prostate cancer clinical trials of the Southwest Oncology Group. Crawford ED, et al. **Oncology (Huntingt)** 1997 Aug; 11(8):1154-63; discussion 1163-70 (54 ref.)
Combinations of hormones and local therapies in locally advanced prostate carcinoma. Eulau SM, et al. **Oncology (Huntingt)** 1996 Aug;10(8):1193-202; discussion 1207-14 (60 ref.)
Current challenges of gene therapy for prostate cancer. Harrison GS, et al. **Oncology (Huntingt)** 1997 Jun; 11(6):845-50, 856; discussion 856-8, 861 (40 ref.)
Management of locally advanced prostate cancer. Mordkin RM, et al. **Oncology (Huntingt)** 1996 Sep;10(9):1289, 1299-300; discussion 1300-6 (80 ref.)
Management of hot flushes due to endocrine therapy for prostate carcinoma. Smith JA Jr. **Oncology (Huntingt)** 1996 Sep;10(9):1319-22; discussion 1324 (22 ref.)
Will current clinical trials answer the most important questions about prostate adenocarcinoma? Thompson IM, et al. **Oncology (Huntingt)** 1997 Aug;11(8):1109-17; discussion 1117-8, 1121 (27 ref.)
Management of asymptomatic rising PSA after prostatectomy or radiation therapy. Waxman S, et al. **Oncology (Huntingt)** 1997 Apr;11(4):457-60, 465; discussion 465-6, 469 (48 ref.)
The Prostate Cancer Intervention Versus Observation Trial (PIVOT). Wilt TJ, et al. **Oncology (Huntingt)** 1997 Aug; 11(8):1133-9; discussion 1139-40, 1143 (27 ref.)
Changes in patterns of prostate cancer care in the United States: results of American College of Surgeons Commission on Cancer studies, 1974-1993. Mettlin C. **Prostate** 1997 Aug 1;32(3):221-6 (21 ref.)
Target to apoptosis: a hopeful weapon for prostate cancer. Tang DG, et al. **Prostate** 1997 Sep 1;32(4):284-93 (115 ref.)
Prostate cancer treatment strategies based on tumor-specific biological principles: future directions. Carducci MA, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 14):56-62 (41 ref.)
Quality of life in advanced prostate cancer. Fosså SD. **Semin Oncol** 1996 Dec;23(6 Suppl 14):32-4 (15 ref.)
Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach. Slovin SF, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 14):41-8 (61 ref.)
Supportive care in the patient with hormone refractory prostate cancer. Esper PS, et al. **Semin Urol Oncol** 1997 Feb;15(1):56-64 (35 ref.)
Novel therapies for advanced prostate cancer. Konety BR, et al. **Semin Urol Oncol** 1997 Feb;15(1):33-42 (80 ref.)
Management of stage T1b (A2) and stage T1c adenocarcinoma of the prostate. Konety BR, et al. **Semin Urol Oncol** 1996 Aug;14(3):183-94 (110 ref.)
Management of stage T1a prostate cancer. Lowe BA. **Semin Urol Oncol** 1996 Aug;14(3):178-82 (24 ref.)
Biological principles and clinical development of prostate cancer gene therapy. Sanda MG. **Semin Urol Oncol** 1997 Feb;15(1):43-55 (77 ref.)
Secondary hormonal therapy. Smith DC. **Semin Urol Oncol** 1997 Feb;15(1):3-12 (95 ref.)
Surveillance is not a viable and appropriate treatment option in the management of localized prostate cancer. Hugosson J, et al. **Urol Clin North Am** 1996 Nov;23(4):557-73 (58 ref.)
Defining the role of surveillance in the management of localized prostate cancer. Palmer JS, et al. **Urol Clin North Am** 1996 Nov;23(4):551-6 (25 ref.)
Issues on early diagnosis and treatment of localized prostate cancer. Pontes JE. **Urol Int** 1996;56 Suppl 1:1-5 (35 ref.)
Second-line treatment of metastatic prostatic carcinoma. Newling DW. **Urol Res** 1997;25 Suppl 2:S73-8 (34 ref.)
Proceedings of the 1st International Conference on Neoadjuvant Hormonal Therapy for Prostate Cancer. Boston, Massachusetts, March 29-30, 1996. **Urology** 1997 Mar;49(3A Suppl):1-118; quiz 121-3 (0 ref.)
Focal therapy for prostate cancer 1996: maximizing outcome. Carroll PR, et al. **Urology** 1997 Mar;49(3A Suppl):84-94 (64 ref.)
Recommendations of the first Michigan conference on prostate cancer. Porter AT, et al. **Urology** 1996 Oct; 48(4):519-33; discussion 533-4 (0 ref.)
[Adjuvant radiotherapy after radical prostatectomy. Apropos of a series of 73 patients in Lyons (France)] Fric D, et al. **Cancer Radiother** 1997;1(1):52-9 (35 ref.) (Eng. Abstr.) **(Fre)**
[Post-treatment PSA, indicator of radical treatment effectiveness of localized cancer of the prostate] Ravery V, et al. **Prog Urol** 1996 Dec;6(6):981-6 (35 ref.) (Eng. Abstr.) **(Fre)**
[The natural course of prostate carcinoma] Abrahamsson PA. **Urologe A** 1996 Nov;35(6):438-42 (17 ref.) **(Ger)**
[Current status and problems associated with endocrine therapy of prostatic cancer] Naito S. **Fukuoka Igaku Zasshi** 1996 Feb;87(2):41-4 (5 ref.) **(Jpn)**

ULTRASONOGRAPHY

The changing role of transrectal ultrasound in the diagnosis of prostate cancer [see comments] Clements R. **Clin Radiol** 1996 Oct;51(10):671-6 (43 ref.) Comment in: Clin Radiol 1997 May;52(5):402-3.
Has ultrasonography a role in screening for prostatic cancer? Clements R. **Eur Radiol** 1997;7(2):217-23 (43 ref.)
Evaluation of prostate specific antigen density and transrectal ultrasonography-guided biopsies in 100 consecutive patients with a negative digital rectal examination and intermediate serum prostate specific antigen levels. Tarcan T, et al. **Int J Urol** 1997 Jul;4(4):362-7 (30 ref.)
Transrectal ultrasonography for the detection and staging of carcinoma of the prostate. Smith JA Jr. **J Clin Ultrasound** 1996 Oct;24(8):455-61 (24 ref.)
Use of transrectal ultrasound and biopsy in the detection of prostate cancer. Selzman AA, et al. **Tech Urol** 1995 Winter; 1(4):209-16 (56 ref.)
The role of color Doppler and staging biopsies in prostate cancer detection. Bree RL. **Urology** 1997 Mar;49(3A Suppl):31-4 (28 ref.)
Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program. Rietbergen JB, et al. **Urology** 1997 Jun; 49(6):875-80 (26 ref.)
[Echography and follow-up of prostate carcinoma: "follow up echography in the course of drug therapy"] Martino P, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):37-42 (10 ref.) (Eng. Abstr.) **(Ita)**
[Echographic follow-up after radical prostatectomy] Rosi P, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):43-8 (7 ref.) (Eng. Abstr.) **(Ita)**

ULTRASTRUCTURE

Intermediate filament expression in prostate cancer. Nagle RB. **Cancer Metastasis Rev** 1996 Dec;15(4):473-82 (88 ref.)

VETERINARY

The canine prostate is a spontaneous model of intraepithelial neoplasia and prostate cancer progression. Waters DJ, et al. **Anticancer Res** 1997 May-Jun;17(3A):1467-70 (22 ref.)

PROSTATITIS

The prostatitis syndromes. Luzzi G. **Int J STD AIDS** 1996 Nov-Dec;7(7):471-8 (84 ref.)
Prostatitis: especially concerning studies of leukocytosis in prostatic fluid and bacterial culture, and daily practice. Nishimura T. **Nippon Ika Daigaku Zasshi** 1997 Feb; 64(1):2-8 (28 ref.)
Prostatitis: diagnosis and treatment in primary care. Donovan DA, et al. **Nurse Pract** 1997 Apr;22(4):144-6, 149-56 (13 ref.)
A review of clinical and pathological prostatitis syndromes. Roberts RO, et al. **Urology** 1997 Jun;49(6):809-21 (127 ref.)
[Granulomatous prostatitis. Analysis of 15 cases and review of the literature] Madrid García FJ, et al. **Arch Esp Urol** 1996 Oct;49(8):789-95 (13 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Diagnosis of chronic prostatitis: overview and update [editorial] Thin RN. **Int J STD AIDS** 1997 Aug;8(8):475-81 (32 ref.)
The Pre and Post Massage Test (PPMT): a simple screen for prostatitis. Nickel JC. **Tech Urol** 1997 Spring;3(1):38-43 (23 ref.)
Chronic pelvic pains represent the most prominent urogenital symptoms of "chronic prostatitis". Krieger JN, et al. **Urology** 1996 Nov;48(5):715-21; discussion 721-2 (39 ref.)
[Prostatitis and bladder neck obstruction (editorial)] Jiménez Cruz JF. **Actas Urol Esp** 1997 Apr;21(4):315-8 (13 ref.) **(Spa)**

MICROBIOLOGY

Chronic abacterial prostatitis--a urological chronic pain syndrome? Egan KJ, et al. **Pain** 1997 Feb;69(3):213-8 (35 ref.)

PATHOLOGY

[Advanced tubercular disease of urogenital tract] Pereira Arias JG, et al. **Arch Esp Urol** 1997 May;50(4):396-9 (11 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Transurethral microwave hyperthermia in the treatment of chronic nonbacterial prostatitis [see comments] Mené MP, et al. **J Am Osteopath Assoc** 1997 Jan;97(1):25-30 (14 ref.) Comment in: J Am Osteopath Assoc 1997 Jan;97(1):24.
Practical approach to the management of prostatitis. Nickel JC. **Tech Urol** 1995 Fall;1(3):162-7 (29 ref.)

PROSTHESIS

see related
PROSTHODONTICS

The artificial disc: theory, design and materials. Bao QB, et al. **Biomaterials** 1996 Jun;17(12):1157-67 (107 ref.)
Input-output nonlinearities and time delays increase tracking errors in hand grasp neuroprostheses. Adamczyk MM, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):271-9 (18 ref.)
Tri-state myoelectric control of bilateral upper extremity neuroprostheses for tetraplegic individuals. Scott TR, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):251-63 (25 ref.)
Massive prostheses for malignant bone tumours of the limbs. Cannon SR. **J Bone Joint Surg Br** 1997 May;79(3):497-506 (20 ref.)
New control strategies for neuroprosthetic systems. Crago PE, et al. **J Rehabil Res Dev** 1996 Apr;33(2):158-72 (40 ref.)
Technology transfer of neuroprosthetic devices. Peckham PH, et al. **J Rehabil Res Dev** 1996 Apr;33(2):173-83 (13 ref.)
Challenges to clinical deployment of upper limb neuroprostheses. Triolo R, et al. **J Rehabil Res Dev** 1996 Apr;33(2):111-22 (19 ref.)
Titanium-anchored prostheses in otology. Burton MJ, et al. **Otolaryngol Clin North Am** 1996 Apr;29(2):301-10 (32 ref.)
Prosthetic-surgical collaborations in the rehabilitation of patients with head and neck defects. Davis BK, et al. **Otolaryngol Clin North Am** 1997 Aug;30(4):631-45 (16 ref.)
Endoprosthetic replacement following limb-sparing resection for bone sarcoma. Damron TA. **Semin Surg Oncol** 1997 Jan-Feb;13(1):3-10 (35 ref.)
[Percutaneous biliary prostheses. Type of material and indications] L'Hermine C, et al. **J Radiol** 1996 Dec; 77(12):1175-82 (39 ref.) (Eng. Abstr.) **(Fre)**
[Implants in urology] Huschke T, et al. **Z Arztl Fortbild (Jena)** 1997 Jan;90(8):725-31 (0 ref.) (Eng. Abstr.) **(Ger)**

PROSTHESIS

ADVERSE EFFECTS

Pitfalls and complications of esophageal prosthesis, laser therapy, and dilation. Reed CE. **Chest Surg Clin N Am** 1997 Aug;7(3):623–36 (63 ref.)

STANDARDS

Using titanium plate or meshplate for chest wall reconstruction: report of 6 cases and literature review. Luh SP, et al. **Artif Organs** 1996 Dec;20(12):1295–8 (13 ref.)

Different approaches and cultural considerations in third world prosthetics. Meanley S. **Prosthet Orthot Int** 1995 Dec;19(3):176–80 (35 ref.)

PROSTHESIS COLORING

[White esthetics] Lüthy H, et al.
Schweiz Monatsschr Zahnmed 1996;106(10):896–908 (30 ref.) **(Ger, Fre)**

PROSTHESIS, DENTAL see **DENTAL PROSTHESIS**

PROSTHESIS DESIGN

see related
DENTURE DESIGN

Prosthetic selection in total knee arthroplasty. Vince KG. **Am J Knee Surg** 1996 Spring;9(2):76–82 (54 ref.)

Small caliber vascular grafts. Part II: Polyurethanes revisited. Zdrahala RJ. **J Biomater Appl** 1996 Jul;11(1):37–61 (90 ref.)

The CarboMedics prosthetic heart valve: a second generation bileaflet prosthesis. Copeland JG.
Semin Thorac Cardiovasc Surg 1996 Jul;8(3):237–41 (17 ref.)

Carpentier pericardial valve. Cosgrove DM.
Semin Thorac Cardiovasc Surg 1996 Jul;8(3):269–75 (36 ref.)

Porcine valves: Hancock and Carpentier–Edwards aortic prostheses. Fann JI, et al.
Semin Thorac Cardiovasc Surg 1996 Jul;8(3):259–68 (39 ref.)

PROSTHESIS FAILURE

see related
DENTAL RESTORATION FAILURE

Late disruption of Dacron aortic grafts. Wilson SE, et al. **Ann Vasc Surg** 1997 Jul;11(4):383–6 (19 ref.)

Wear of the epiphysis–acetabulum in total hip arthroplasty: a review of the literature. Affatato S, et al.
Chir Organi Mov 1996 Apr–Jun;81(2):119–28 (22 ref.) **(Eng, Ita)**

Polyethylene wear and osteolysis following total knee replacement. Ayers DC. **Instr Course Lect** 1997;46:205–13 (31 ref.)

The generation of wear debris from cementless hip prostheses. Collier JP, et al. **Instr Course Lect** 1994; 43:257–62 (11 ref.)

Extensor mechanism problems in total knee arthroplasty. Dennis DA. **Instr Course Lect** 1997;46:171–80 (119 ref.)

Osteolysis caused by polymethylmethacrylate (PMMA). Eftekhar NS. **Instr Course Lect** 1994;43:263–75 (53 ref.)

The management of bone defects in revision total knee arthroplasty. Engh GA, et al. **Instr Course Lect** 1997; 46:227–36 (26 ref.)

Fixing the cup. Petrera P, et al. **Instr Course Lect** 1994; 43:393–407 (64 ref.)

Surgical exposure in revision total knee arthroplasty. Whiteside LA. **Instr Course Lect** 1997;46:221–5 (8 ref.)

Osteolysis due to particle wear debris following total hip arthroplasty: the role of high-density polyethylene. Wroblewski BM. **Instr Course Lect** 1994;43:289–94 (12 ref.)

Fatigue failure of cancellous bone: a possible cause of implant migration and loosening. Taylor M, et al.
J Bone Joint Surg Br 1997 Mar;79(2):181–2 (18 ref.)

In vivo and in vitro models of calcification in porcine aortic valve cusps. Mako WJ, et al. **J Heart Valve Dis** 1997 May; 6(3):316–23 (37 ref.)

Structural failure of pyrolytic carbon heart valves. Richard G, et al. **J Heart Valve Dis** 1996 Jun;5 Suppl 1:S79–85 (11 ref.)

Stem loosening and thigh pain in THA: are they related to prosthesis stiffness? Mishra AK, et al. **Orthopedics** 1997 Jan;20(1):58–61; quiz 62–3 (36 ref.)

Biological reaction to debris in relation to joint prostheses. Revell PA, et al. **Proc Inst Mech Eng [H]** 1997; 211(2):187–97 (90 ref.)

Prosthetic loosening after total hip arthroplasty diagnosis and management. Langlais F. **Rev Rhum Engl Ed** 1996 Nov; 63(10):659–69 (36 ref.)

[Prosthetic valve thrombosis in the aortic position] Morita K. **Ryoikibetsu Shokogun Shirizu** 1996;(13):411–4 (18 ref.) **(Jpn)**

PROSTHESIS FITTING

METHODS

A finite element analysis of the load transfer between an above-knee residual limb and its prosthetic socket—roles of interface friction and distal-end boundary conditions. Zhang M, et al. **IEEE Trans Rehabil Eng** 1996 Dec; 4(4):337–46 (45 ref.)

PROSTHESIS LOOSENING see **PROSTHESIS FAILURE**

PROSTHESIS-RELATED INFECTIONS

see related
BIOFILMS

Diagnosis and management of the infected total knee arthroplasty. Simmons TD, et al. **Am J Knee Surg** 1996 Spring;9(2):99–106 (77 ref.)

Candida prosthetic valve endocarditis: prospective study of six cases and review of the literature. Nguyen MH, et al. **Clin Infect Dis** 1996 Feb;22(2):262–7 (21 ref.)

Infections following implant arthroplasties of the forefoot. Shapiro SE, et al. **Clin Podiatr Med Surg** 1996 Oct; 13(4):767–91 (73 ref.)

Host–bacteria interactions in foreign body infections. François P, et al. **Infect Control Hosp Epidemiol** 1996 Aug; 17(8):514–20 (63 ref.)

Candida albicans infection of prosthetic joints. Cardinal E, et al. **Orthopedics** 1996 Mar;19(3):247–51 (34 ref.)

[Graft infections] Miyamoto T.
Ryoikibetsu Shokogun Shirizu 1996;(15):551–3 (7 ref.) **(Jpn)**

[Prosthetic valve endocarditis] Yamada S, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):464–6 (9 ref.) **(Jpn)**

COMPLICATIONS

Spontaneous obliteration of a pseudo–aneurysm complicating an aortic homograft. Federmann M, et al.
Eur J Cardiothorac Surg 1996;10(8):705–6 (5 ref.)

Unilateral lower limb hypertrophic osteoarthropathy due to aortic graft infection and aortoenteric fistula. Martínez JI, et al. **Eur J Vasc Endovasc Surg** 1996 Nov;12(4):497–500 (23 ref.)

DIAGNOSIS

Prosthetic valve endocarditis due to Streptococcus pneumoniae [letter] Collazos J, et al. **Arch Intern Med** 1996 Oct 14;156(18):2141, 2146, 2148 (10 ref.)

Metallosis mimicking infection in a cemented total knee replacement. Huo MH, et al. **Orthopedics** 1997 May; 20(5):466–70 (18 ref.)

DRUG THERAPY

Listeria endocarditis: current management and patient outcome—world literature review. Spyrou N, et al.
Heart 1997 Apr;77(4):380–3 (51 ref.)

Management of port infections. Simpson KR.
J Vasc Interv Radiol 1997 Jul–Aug;8(4):591–3 (8 ref.)

ETIOLOGY

The influence of the chemical composition and surface of the implant on infection. Cordero J, et al. **Injury** 1996;27 Suppl 3:SC34–7 (28 ref.)

Implantable materials and infection. Williams DF. **Injury** 1996;27 Suppl 3:SC1–4 (9 ref.)

Oerskovia xanthineolytica infection of a prosthetic joint: case report and review. Harrington RD, et al.
J Clin Microbiol 1996 Jul;34(7):1821–4 (18 ref.)

[Infectious complications of cardioverter/defibrillators—case report and review of the literature] Hollenstein U, et al. **Acta Med Austriaca** 1996;23(5):164–7 (20 ref.) (Eng. Abstr.) **(Ger)**

[Vesico-acetabular fistula occurring 10 years after total hip replacement] Hamano S, et al. **Hinyokika Kiyo** 1996 Oct; 42(10):743–5 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Mitral prosthetic valve endocarditis (M-PVE)] Abe T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):393–5 (17 ref.) **(Jpn)**

MICROBIOLOGY

Infective endocarditis and occult splenic abscess caused by Brucella melitensis infection: a case report and review of the literature. Saadeh AM, et al. **Acta Cardiol** 1996; 51(3):279–85 (32 ref.)

Infection of a total knee arthroplasty by Candida parapsilosis. A case report of successful treatment by joint reimplantation with a literature review. Hennessy MJ.
Am J Knee Surg 1996 Summer;9(3):133–6 (15 ref.)

PREVENTION & CONTROL

Prevention of deep periprosthetic joint infection. Hanssen AD, et al. **Instr Course Lect** 1997;46:555–67 (132 ref.)

Prevention of sepsis in total joint arthroplasty. An YH, et al. **J Hosp Infect** 1996 Jun;33(2):93–108 (135 ref.)

Use of prophylactic antibiotics in the prevention of infective endocarditis and prosthesis infection. Lam MS, et al.
Singapore Med J 1995 Aug;36(4):424–7 (22 ref.)

SURGERY

Conservative surgery for aortic graft infection. Earnshaw JJ. **Cardiovasc Surg** 1996 Oct;4(5):570–2 (32 ref.)

THERAPY

Infection of a total knee arthroplasty by Candida parapsilosis. A case report of successful treatment by joint reimplantation with a literature review. Hennessy MJ.
Am J Knee Surg 1996 Summer;9(3):133–6 (15 ref.)

Successful treatment of fungal prosthetic valve endocarditis: case report and review [see comments] Gilbert HM, et al. **Clin Infect Dis** 1996 Feb;22(2):348–54 (52 ref.) Comment in: Clin Infect Dis 1996 Dec;23(6):1338–40.

Management of the patient with an infected knee arthroplasty. Pellegrini VD Jr. **Instr Course Lect** 1997; 46:215–9 (29 ref.)

[A case of successful treatment of mediastinitis and prosthetic graft infection after aortic arch and thoracoabdominal aortic reconstruction] Kawashima T, et al.
Nippon Kyobu Geka Gakkai Zasshi 1997 Feb;45(2):220–4 (12 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

The impact of transesophageal echocardiography on the management of prosthetic valve endocarditis: experience of 31 cases and review of the literature. Lengyel M.
J Heart Valve Dis 1997 Mar;6(2):204–11 (48 ref.)

[The potentials of echocardiography in the diagnosis of infectious endocarditis of a valve prosthesis] Shevchenko IuL, et al. **Vestn Khir Im I I Grek** 1997;156(3):97–100 (64 ref.) **(Rus)**

PROSTHODONTICS

A review of pharmacotherapeutics for prosthetic dentistry: Part I. Felpel LP. **J Prosthet Dent** 1997 Mar;77(3):285–92 (29 ref.)

A review of pharmacotherapeutics for prosthetic dentistry: Part II. Felpel LP. **J Prosthet Dent** 1997 Mar;77(3):293–305 (41 ref.)

PROSTITUTION

The 100% condom program in Thailand. Rojanapithayakorn W, et al. **AIDS** 1996 Jan;10(1):1–7 (21 ref.)

PROTAMINE SULFATE see **PROTAMINES**

PROTAMINES

THERAPEUTIC USE

Intraoperative heparin anticoagulation and its reversal. Wakefield TW, et al. **Semin Vasc Surg** 1996 Dec; 9(4):296–302 (86 ref.)

PROTEASE ANTAGONISTS see **PROTEASE INHIBITORS**

PROTEASE INHIBITORS

Neutral proteinases and their inhibitors in the loosening of total hip prostheses. Takagi M.
Acta Orthop Scand Suppl 1996 Oct;271:3–29 (198 ref.)

Changing views of the role of matrix metalloproteinases in metastasis. Chambers AF, et al. **J Natl Cancer Inst** 1997 Sep 3;89(17):1260–70 (127 ref.)

Growth factors, proteases and protease inhibitors in the maternal–fetal dialogue. Lala PK, et al. **Placenta** 1996 Nov; 17(8):545–55 (135 ref.)

[New function of proteases and protease inhibitors—aiming for development of new drug design] Yamamoto K, et al. **Nippon Yakurigaku Zasshi** 1996 Sep;108(3):135–7 (0 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

[Microcirculation and hemostasis in inflammatory processes. Modulation by administration of physiologic protease inhibitors as a therapeutic approach] Leithäuser B, et al. **Med Klin** 1997 Jul 15;92(7):426–31 (40 ref.) (Eng. Abstr.) **(Ger)**

CHEMISTRY

Discovery of a new type of proteinase inhibitor family whose members have an anchoring sequence. Hirose S, et al.
Adv Exp Med Biol 1996;389:43–9 (24 ref.)

ISOLATION & PURIFICATION

Protein proteinase inhibitors from avian egg whites. Saxena I, et al. **Cell Mol Life Sci** 1997 Jan;53(1):13–23 (97 ref.)

[Structural analysis of defense molecules found in large and small granules in hemocytes of horseshoe crab] Kawabata S. **Seikagaku** 1996 Sep;68(9):1523–36 (63 ref.) **(Jpn)**

METABOLISM

Protein proteinase inhibitors in legume seeds—overview. Birk Y. **Arch Latinoam Nutr** 1996 Dec;44(4 Suppl 1):26S–30S (47 ref.)

The interdependence of lung antioxidants and antiprotease defense in ARDS. Gadek JE, et al. **Chest** 1996 Dec;110(6 Suppl):273S–277S (13 ref.)

The role of metalloproteinases and their inhibitors in hematological disorders. Guedez L, et al.
Crit Rev Oncog 1996;7(3–4):205–25 (177 ref.)

Tissue inhibitors of metalloproteinases in liver fibrosis. Iredale JP. **Int J Biochem Cell Biol** 1997 Jan;29(1):43–54 (108 ref.)

[Proteinase/antiproteinase balance in patients with cystic fibrosis] Welte T. **Pneumologie** 1996 Dec;50 Suppl 3:838–40 (16 ref.) **(Ger)**

PHARMACOKINETICS

Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Barry M, et al. **Clin Pharmacokinet** 1997 Mar;32(3):194–209 (124 ref.)

PHARMACOLOGY

Involvement of tissue inhibitors of metalloproteinases (TIMPS) during matrix metalloproteinase activation. Nagase H, et al. **Adv Exp Med Biol** 1996;389:23–31 (37 ref.)

Protease inhibitors and carcinogenesis: a review. Clawson GA. **Cancer Invest** 1996;14(6):597–608 (114 ref.)

Preventing the inflammatory response to open-heart surgery: the role of aprotinin and other protease inhibitors. Royston D. **Int J Cardiol** 1996 Apr 26;53 Suppl:S11–37 (137 ref.)

Characterization of neuropeptidases using inhibitors. Hooper NM. **Methods Mol Biol** 1997;73:369–81 (14 ref.)

[Inhibitory effect of FOY-305 on liver metastasis of the pancreatic cancer] Ohta T, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1669–72 (10 ref.) (Eng. Abstr.) **(Jpn)**

[CDK and MMP inhibitors] Okuyama A, et al. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1547–62 (62 ref.) (Eng. Abstr.) **(Jpn)**

[Vascular smooth muscle cell and extrinsic coagulation pathway] Nakahara Y, et al. **Rinsho Byori** 1997 Feb;Suppl 104:205–15 (39 ref.) **(Jpn)**

THERAPEUTIC USE

Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Barry M, et al. **Clin Pharmacokinet** 1997 Mar;32(3):194–209 (124 ref.)

Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus. Lewis JS 2nd, et al. **Clin Ther** 1997 Mar–Apr;19(2):187–214 (89 ref.)

Decelerating gastric emptying: therapeutic possibilities in type 2 diabetes. Phillips WT, et al. **Diabet Med** 1996 Sep; 13(9 Suppl 5):S44–8 (13 ref.)

Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Talbot DC, et al. **Eur J Cancer** 1996 Dec;32A(14):2528–33 (42 ref.)

Matrix metalloproteinase inhibitors. Wojtowicz-Praga SM, et al. **Invest New Drugs** 1997;15(1):61–75 (94 ref.)

HIV/AIDS management in office practice. Antiretroviral therapy. Hartman AF. **Prim Care** 1997 Sep;24(3):531–60 (46 ref.)

Protease-antiprotease interactions and the rationale for therapeutic protease inhibitors. Schmid S, et al. **Scand J Gastroenterol Suppl** 1996;219:47–50 (29 ref.)

PROTECTIVE CLOTHING

Educating workers on the need for a firm, safe footing. Johnson LF. **Occup Health Saf** 1997 Jul;66(7):20–7, 36 (0 ref.)

Effects of wetsuit use in swimming events. Practical recommendations. Chatard JC, et al. **Sports Med** 1996 Aug; 22(2):70–5 (26 ref.)

[Does a physician's apron protect against nosocomial infection?] Grys E, et al. **Ginekol Pol** 1996 Jun;67(6):309–12 (12 ref.) (Eng. Abstr.) **(Pol)**

PROTECTIVE DEVICES

Poison ivy/oak dermatitis. Part I: Prevention--soap and water, topical barriers, hyposensitization. Fisher AA. **Cutis** 1996 Jun;57(6):384–6 (13 ref.)

[Prevention with hip protectors. Biomechanical aspects in falls and hip fractures] Lauritzen JB. **Nord Med** 1996 Dec; 111(10):340–3 (15 ref.) (Eng. Abstr.) **(Dan)**

PROTECTIVE GLOVES see **GLOVES, PROTECTIVE**

PROTEIN A see **STAPHYLOCOCCAL PROTEIN A**

PROTEIN BINDING

see related
BINDING SITES
CARRIER PROTEINS
METALLOPROTEINS
RADIOLIGAND ASSAY
THYROXINE-BINDING PROTEINS

The fascinating complexities of steroid-binding enzymes. Duax WL, et al. **Curr Opin Struct Biol** 1996 Dec; 6(6):813–23 (52 ref.)

Computational methods for biomolecular docking. Lengauer T, et al. **Curr Opin Struct Biol** 1996 Jun;6(3):402–6 (46 ref.)

Protein-biotin interactions. Lindqvist Y, et al. **Curr Opin Struct Biol** 1996 Dec;6(6):798–803 (46 ref.)

The multiple origins of cooperativity in binding to multi-site lattices. Sackett DL, et al. **FEBS Lett** 1996 Nov 11; 397(1):1–6 (19 ref.)

Drug-protein binding sites. New trends in analytical and experimental methodology. Oravcová J, et al. **J Chromatogr B Biomed Appl** 1996 Feb 23;677(1):1–28 (241 ref.)

Protein binding versus protein folding: the role of hydrophilic bridges in protein associations. Xu D, et al. **J Mol Biol** 1997 Jan 10;265(1):68–84 (92 ref.)

Gene identification using the yeast two-hybrid system. Bai C, et al. **Methods Enzymol** 1996;273:331–47 (17 ref.)

IMMUNOLOGY

Appreciating the complexity of MHC class II peptide binding: lysozyme peptide and I-Ak. Nelson CA, et al. **Immunol Rev** 1996 Jun;151:81–105 (57 ref.)

Measuring bonds between surface-associated molecules. Pierres A, et al. **J Immunol Methods** 1996 Sep 27; 196(2):105–20 (72 ref.)

PROTEIN-BINDING RADIOASSAY see **RADIOLIGAND ASSAY**

PROTEIN-BOUND IODINE TEST see **THYROID FUNCTION TESTS**

PROTEIN C

Activated protein C resistance as a basis for venous thrombosis. Hillarp A, et al. **Am J Med** 1996 Nov; 101(5):534–40 (12 ref.)

Inherited defects of the protein C anticoagulant system in childhood thrombo-embolism. Nowak-Göttl U, et al. **Eur J Pediatr** 1996 Nov;155(11):921–7 (83 ref.)

[Activated protein C resistance in the Japanese] Ozawa T. **Rinsho Ketsueki** 1996 Sep;37(9):790–3 (9 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

[Early stent-induced thrombosis in the pelvic circulation: a complication in APC resistance] Lenglinger FX, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Mar;166(3):260–2 (11 ref.) **(Ger)**

CHEMISTRY

Effect of Ca2+ on the structure of vitamin K-dependent coagulation factors. Sunnerhagen M, et al. **Haemostasis** 1996;26 Suppl 1:45–53 (44 ref.)

Comparative analysis of haemostatic proteinases: structural aspects of thrombin, factor Xa, factor IXa and protein C. Bode W, et al. **Thromb Haemost** 1997 Jul;78(1):501–11 (97 ref.)

DEFICIENCY

Inherited thrombophilia: memorandum from a joint WHO/International Society on Thrombosis and Haemostasis meeting. **Bull World Health Organ** 1997; 75(3):177–89 (69 ref.)

Molecular basis for protein C hereditary deficiency. Aiach M, et al. **Haemostasis** 1996 Oct;26 Suppl 4:9–19 (61 ref.)

Protein C and protein S deficiencies. Aiach M, et al. **Semin Hematol** 1997 Jul;34(3):205–16 (89 ref.)

Thrombophilia and complex acquired deficiencies of antithrombin, protein C, and protein S. Humphries JE. **Semin Hematol** 1995 Oct;32(4 Suppl 2):8–16; discussion 17–8 (16 ref.)

Protein C deficiency: from gene defects to disease. Reitsma PH. **Thromb Haemost** 1997 Jul;78(1):344–50 (69 ref.)

The Leiden Thrombophilia Study (LETS). van der Meer FJ, et al. **Thromb Haemost** 1997 Jul;78(1):631–5 (18 ref.)

[Inherited thrombophilia] Jia X, et al. **Chung Hua Nei Ko Tsa Chih** 1996 Feb;35(2):133–6 (18 ref.) **(Chi)**

[Protein C deficiency] Negoro N, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):483–6 (10 ref.) **(Jpn)**

GENETICS

Inherited thrombotic disorders: an update. Florell SR, et al. **Am J Hematol** 1997 Jan;54(1):53–60 (53 ref.)

Resistance to activated protein C and factor V Leiden. Perry DJ, et al. **QJM** 1997 Jun;90(6):379–85 (44 ref.)

Protein C and protein S deficiencies. Aiach M, et al. **Semin Hematol** 1997 Jul;34(3):205–16 (89 ref.)

[Resistance to activated protein C. The most common cause of familial thrombophilia] Larsen TB, et al. **Ugeskr Laeger** 1996 Nov 11;158(46):6584–8 (40 ref.) (Eng. Abstr.) **(Dan)**

[Activated protein C resistance--an evaluation of current status (see comments)] Hopmeier P. **Wien Klin Wochenschr** 1996;108(19):599–606 (93 ref.) (Eng. Abstr.) Comment in: Wien Klin Wochenschr 1996;108(19):595–8. **(Ger)**

METABOLISM

Resistance to activated protein C: role in venous and arterial thrombosis. Emmerich J, et al. **Biomed Pharmacother** 1996; 50(6-7):254–60 (64 ref.)

Activated protein C resistance--a major risk factor for thrombosis. Rosén SB, et al. **Eur J Clin Chem Clin Biochem** 1997 Jul;35(7):501–16 (177 ref.)

Anterior ischemic optic neuropathy and activated protein C resistance. A case report and review of the literature. Worrall BB, et al. **J Neuroophthalmol** 1997 Sep;17(3):162–5 (52 ref.)

APC resistance in childhood thromboembolism: diagnosis and clinical aspects. Nowak-Göttl U, et al. **Semin Thromb Hemost** 1997;23(3):253–8 (35 ref.)

Laboratory diagnosis of resistance to activated protein C (APC-resistance). Bertina RM. **Thromb Haemost** 1997 Jul; 78(1):478–82 (71 ref.)

Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis. Dahlbäck B. **Thromb Haemost** 1997 Jul; 78(1):483–8 (69 ref.)

[The significance of APC resistance (activated protein C) for clinical practice] Lämmle B, et al. **Schweiz Rundsch Med Prax** 1997 Jan 28;86(5):154–61 (51 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Activated protein C resistance: from phenotype to genotype and clinical practice. Hillarp A, et al. **Blood Rev** 1995 Dec; 9(4):201–12 (156 ref.)

Resistance to activated protein C and a novel factor V gene mutation. Voelkerding KV. **Clin Lab Med** 1996 Mar; 16(1):169–86 (53 ref.)

PHYSIOLOGY

Resistance to activated protein C as pathogenic factor of venous thromboembolism. Chrobák L, et al. **Acta Medica (Hradec Kralove)** 1996;39(2):55–62 (104 ref.)

Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis. Zöller B, et al. **Annu Rev Med** 1997;48:45–58 (102 ref.)

Factor VLeiden and thrombophilia. Kalafatis M, et al. **Arterioscler Thromb Vasc Biol** 1997 Apr;17(4):620–7 (88 ref.)

Factor V and protein S as cofactors to activated protein C. Dahlbäck B. **Haematologica** 1997 Jan–Feb;82(1):91–5 (46 ref.)

Inherited resistance to activated protein C caused by presence of the FV:Q506 allele as a basis of venous thrombosis. Dahlbäck B, et al. **Haemostasis** 1996 Oct;26 Suppl 4:301–14 (101 ref.)

Diagnosis and clinical characteristics of inherited activated protein C resistance. Samama MM, et al. **Haemostasis** 1996 Oct;26 Suppl 4:315–30 (55 ref.)

Inherited activated protein C resistance in a patient with familial primary antiphospholipid syndrome. Alarcón-Segovia D, et al. **J Rheumatol** 1996 Dec; 23(12):2162–5 (42 ref.)

Protein C and other cofactors involved in the binding of antiphospholipid antibodies: relation to the pathogenesis of thrombosis. de Groot PG, et al. **Lupus** 1996 Oct; 5(5):488–93 (52 ref.)

Combination of activated protein C resistance and antibodies to phospholipids in the development of thrombosis. Bokarewa MI, et al. **Semin Hematol** 1997 Jul;34(3):235–43 (74 ref.)

Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management. Dahlbäck B. **Semin Hematol** 1997 Jul;34(3):217–34 (107 ref.)

Regulation of thrombin formation by activated protein C: effect of the factor V Leiden mutation. Tans G, et al. **Semin Hematol** 1997 Jul;34(3):244–55 (92 ref.)

Coagulation factor V: an old star shines again. Rosing J, et al. **Thromb Haemost** 1997 Jul;78(1):427–33 (89 ref.)

[Physiologie and cellular regulation of the protein C system] Vincenot A, et al. **Ann Biol Clin (Paris)** 1997 Jan–Feb; 55(1):17–24 (31 ref.) (Eng. Abstr.) **(Fre)**

[Factor V Leiden and activated protein C resistance] Cauchie P, et al. **Rev Med Brux** 1997 Jun;18(3):97–102 (26 ref.) (Eng. Abstr.) **(Fre)**

[Activated protein C resistance as a cause of thrombophilia] Ruiz-Argüelles GJ. **Rev Invest Clin** 1996 May-Jun; 48(3):223–9 (48 ref.) (Eng. Abstr.) **(Spa)**

PROTEIN C INHIBITOR

METABOLISM

Protein C inhibitor (PCI). Geiger M, et al. **Immunopharmacology** 1996 May;32(1–3):53–6 (18 ref.)

PHYSIOLOGY

Protein C inhibitor (PCI). Geiger M, et al. **Immunopharmacology** 1996 May;32(1–3):53–6 (18 ref.)

[Protein C inhibitor: its properties, function and significance in equilibrium of hemostasis] Fijałkowska I. **Postepy Biochem** 1997;43(1):51–7 (53 ref.) **(Pol)**

PROTEIN-CALORIE MALNUTRITION see **PROTEIN-ENERGY MALNUTRITION**

PROTEIN CONFORMATION

Synthesis, physicochemical and biological properties of poly-alpha-amino acids--the simplest of protein models. Katchalski-Katzir E. **Acta Biochim Pol** 1996;43(1):217–26 (35 ref.)

Criticality found in a model for orientational ordering of protein arrays. Hogyoku M. **Adv Biophys** 1997;34:55–68 (25 ref.)

Protein arrays: concepts and subjects. Nagayama K. **Adv Biophys** 1997;34:3–23 (192 ref.)

Protein structures in receptor classification. Barnard EA. **Ann N Y Acad Sci** 1997 May 30;812:14–28 (69 ref.)

PROTEIN CONFORMATION

Studies of the pharmacology, localization, and structure of muscarinic acetylcholine receptors. Brann MR, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:225–36 (59 ref.)

Visualizing protein–nucleic acid interactions on a large scale with the scanning force microscope. Bustamante C, et al. **Annu Rev Biophys Biomol Struct** 1996;25:395–429 (93 ref.)

Antibodies as tools to study the structure of membrane proteins: the case of the nicotinic acetylcholine receptor. Conti-Fine BM, et al. **Annu Rev Biophys Biomol Struct** 1996;25:197–229 (112 ref.)

Use of 19F NMR to probe protein structure and conformational changes. Danielson MA, et al. **Annu Rev Biophys Biomol Struct** 1996;25:163–95 (98 ref.)

Computational studies of protein folding. Friesner RA, et al. **Annu Rev Biophys Biomol Struct** 1996;25:315–42 (73 ref.)

Lipoxygenases: structural principles and spectroscopy. Gaffney BJ. **Annu Rev Biophys Biomol Struct** 1996; 25:431–59 (91 ref.)

The sugar kinase/heat shock protein 70/actin superfamily: implications of conserved structure for mechanism. Hurley JH. **Annu Rev Biophys Biomol Struct** 1996;25:137–62 (75 ref.)

Protein function in the crystal. Mozzarelli A, et al. **Annu Rev Biophys Biomol Struct** 1996;25:343–65 (145 ref.)

Bridging the protein sequence–structure gap by structure predictions. Rost B, et al. **Annu Rev Biophys Biomol Struct** 1996;25:113–36 (99 ref.)

Theory and practice of nuclear spin relaxation in proteins. Dayie KT, et al. **Annu Rev Phys Chem** 1996;47:243–82 (147 ref.)

Protein crystallization. Durbin SD, et al. **Annu Rev Phys Chem** 1996;47:171–204 (217 ref.)

Insights into protein folding from NMR. Dyson HJ, et al. **Annu Rev Phys Chem** 1996;47:369–95 (144 ref.)

Evolution and the structural domains of proteins. Babul J. **Arch Biol Med Exp (Santiago)** 1987;20(3–4):333–41 (70 ref.)

Protein phosphatases: structures and implications. Jia Z. **Biochem Cell Biol** 1997;75(1):17–26 (57 ref.)

NMR methods for the study of protein structure and dynamics. Kay LE. **Biochem Cell Biol** 1997;75(1):1–15 (41 ref.)

Merck Frosst award lecture 1995. La conference Merck Frosst 1995. Structural studies of lipoproteins and their apolipoprotein components. Ryan RO. **Biochem Cell Biol** 1996;74(2):155–64 (48 ref.)

Progress towards understanding beta-sheet structure. Nesloney CL, et al. **Bioorg Med Chem** 1996 Jun;4(6):739–66 (237 ref.)

New approaches in molecular structure prediction. Böhm G. **Biophys Chem** 1996 Mar 7;59(1–2):1–32 (364 ref.)

Biotechnology of protein and polysaccharide gels. Tombs MP. **Biotechnol Genet Eng Rev** 1997;14:337–63 (62 ref.)

Form and function in protein dephosphorylation [comment] Denu JM, et al. **Cell** 1996 Nov 1;87(3):361–4 (20 ref.) Comment on: Cell 1996 Nov 1;87(3):365–8.

Structure of the band 3 transmembrane domain. Vince JW, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 Nov; 42(7):1041–51 (56 ref.)

Insights into acylphosphatase structure and catalytic mechanism. Stefani M, et al. **Cell Mol Life Sci** 1997 Feb; 53(2):141–51 (88 ref.)

Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Souness JE, et al. **Cell Signal** 1997 May–Jun;9(3–4):227–36 (66 ref.)

Predicting the structure of protein complexes: a step in the right direction. Shoichet BK, et al. **Chem Biol** 1996 Mar; 3(3):151–6 (49 ref.)

Chemical engineering at the antibody hinge. Stevenson GT. **Chem Immunol** 1997;65:57–72 (25 ref.)

Alpha 1-antitrypsin deficiency. A conformational disease. Carrell RW, et al. **Chest** 1996 Dec;110(6 Suppl):243S–247S (31 ref.)

Glycosylation: heterogeneity and the 3D structure of proteins. Rudd PM, et al. **Crit Rev Biochem Mol Biol** 1997; 32(1):1–100 (215 ref.)

Motile systems: Tubulin-based motility races ahead. Egelman EH. **Curr Biol** 1995 Dec 1;5(12):1354–6 (19 ref.)

Protein folding and intermediates. Clarke AR, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):400–10 (74 ref.)

Engineering novel proteins by transfer of active sites to natural scaffolds. Vita C. **Curr Opin Biotechnol** 1997 Aug; 8(4):429–34 (56 ref.)

The RING finger domain: a recent example of a sequence–structure family. Borden KL, et al. **Curr Opin Struct Biol** 1996 Jun;6(3):395–401 (46 ref.)

Protein sequence motifs. Bork P, et al. **Curr Opin Struct Biol** 1996 Jun;6(3):366–76 (78 ref.)

Entropy in protein folding and in protein–protein interactions. Brady GP, et al. **Curr Opin Struct Biol** 1997 Apr;7(2):215–21 (42 ref.)

Protein structure: what is it possible to predict now? Finkelstein AV. **Curr Opin Struct Biol** 1997 Feb;7(1):60–71 (113 ref.)

Surprising similarities in structure comparison. Gibrat JF, et al. **Curr Opin Struct Biol** 1996 Jun;6(3):377–85 (65 ref.)

Progress in protein structure prediction. Jones DT. **Curr Opin Struct Biol** 1997 Jun;7(3):377–87 (89 ref.)

Structural classification of proteins: new superfamilies. Murzin AG. **Curr Opin Struct Biol** 1996 Jun;6(3):386–94 (49 ref.)

Theory and simulation. Old problems, new paradigms [editorial] Novotny J, et al. **Curr Opin Struct Biol** 1997 Apr;7(2):179–80 (11 ref.)

Advances in comparative protein-structure modelling. Sánchez R, et al. **Curr Opin Struct Biol** 1997 Apr; 7(2):206–14 (105 ref.)

Perspectives in protein-fold recognition. Torda AE. **Curr Opin Struct Biol** 1997 Apr;7(2):200–5 (46 ref.)

Empirical potentials and functions for protein folding and binding. Vajda S, et al. **Curr Opin Struct Biol** 1997 Apr; 7(2):222–8 (71 ref.)

Human fibrinogen: anticipating a 3-dimensional structure. Doolittle RF, et al. **FASEB J** 1996 Nov;10(13):1464–70 (56 ref.)

Ambiguous distance data in the calculation of NMR structures. Nilges M. **Fold Des** 1997;2(4):S53–7 (49 ref.)

Developing three-dimensional models of ion channel proteins. Guy HR, et al. **Ion Channels** 1996;4:1–40 (135 ref.)

From electron density and sequence to structure: integrating protein image analysis and threading for structure determination. Baxter K, et al. **Ismb** 1996;4:25–33 (10 ref.)

Discovering patterns and subfamilies in biosequences. Brazma A, et al. **Ismb** 1996;4:34–43 (26 ref.)

Structural modifications of proteins during aging. Gafni A. **J Am Geriatr Soc** 1997 Jul;45(7):871–80 (133 ref.)

Phylogenetic relationships of Bacillus thuringiensis delta-endotoxin family proteins and their functional domains. Bravo A. **J Bacteriol** 1997 May;179(9):2793–801 (54 ref.)

Conformational transmission in ATP synthase during catalysis: search for large structural changes. Futai M, et al. **J Bioenerg Biomembr** 1996 Oct;28(5):409–14 (41 ref.)

The coupling of the relative movement of the a and c subunits of the F0 to the conformational changes in the F1-ATPase. Howitt SM, et al. **J Bioenerg Biomembr** 1996 Oct; 28(5):415–20 (55 ref.)

Assisted protein folding. Ruddon RW, et al. **J Biol Chem** 1997 Feb 7;272(6):3125–8 (60 ref.)

Protofilaments and rings, two conformations of the tubulin family conserved from bacterial FtsZ to alpha/beta and gamma tubulin. Erickson HP, et al. **J Cell Biol** 1996 Oct; 135(1):5–8 (25 ref.)

Switches, latches, and amplifiers: common themes of G proteins and molecular motors. Vale RD. **J Cell Biol** 1996 Oct;135(2):291–302 (92 ref.)

Current limitations to protein threading approaches. Smith TF, et al. **J Comput Biol** 1997 Fall;4(3):217–25 (23 ref.)

Coupling H+ transport and ATP synthesis in F1F0-ATP synthases: glimpses of interacting parts in a dynamic molecular machine. Fillingame RH. **J Exp Biol** 1997 Jan; 200 (Pt 2):217–24 (68 ref.)

Low-pH induced conformational changes in viral fusion proteins: implications for the fusion mechanism. Gaudin Y, et al. **J Gen Virol** 1995 Jul;76 (Pt 7):1541–56 (128 ref.)

Elucidation of the basic three-dimensional structure of type I interferons and its functional and evolutionary implications. Mitsui Y, et al. **J Interferon Cytokine Res** 1997 Jun;17(6):319–26 (40 ref.)

Membrane topology motifs in the SGLT cotransporter family. Turk E, et al. **J Membr Biol** 1997 Sep 1;159(1):1–20 (75 ref.)

Conformational disease. Carrell RW, et al. **Lancet** 1997 Jul 12;350(9071):134–8 (40 ref.)

Conformational heterogeneity in crystalline proteins: time-resolved fluorescence studies. Dahms TE, et al. **Methods Enzymol** 1997;278:202–21 (40 ref.)

Reconstitution of RNA polymerase. Fujita N, et al. **Methods Enzymol** 1996;273:121–30 (21 ref.)

Mutational analysis of structure-function relationship of RNA polymerase in Escherichia coli. Jin DJ, et al. **Methods Enzymol** 1996;273:300–19 (71 ref.)

Intramolecular pyrene excimer fluorescence: a probe of proximity and protein conformational change. Lehrer SS. **Methods Enzymol** 1997;278:286–95 (18 ref.)

Trace structural analysis of proteins. Swiderek KM, et al. **Methods Enzymol** 1996;271:68–86 (9 ref.)

Escherichia coli RNA polymerase holoenzyme: rapid reconstitution from recombinant alpha, beta, beta', and sigma subunits. Tang H, et al. **Methods Enzymol** 1996; 273:130–4 (19 ref.)

Protein structure analysis by mass spectrometry. Yates JR. **Methods Enzymol** 1996;271:351–77 (40 ref.)

Calculating protein structures from NMR data. Güntert P. **Methods Mol Biol** 1997;60:157–94 (101 ref.)

Introduction to the NMR of proteins. Reid DG, et al. **Methods Mol Biol** 1997;60:1–28 (55 ref.)

Penicillin and beyond: evolution, protein fold, multimodular polypeptides, and multiprotein complexes. Ghuysen JM, et al. **Microb Drug Resist** 1996 Summer;2(2):163–75 (42 ref.)

Through a magnet, clearly [editorial; comment] **Nat Struct Biol** 1997 Mar;4(3):159–60 (12 ref.) Comment on: Nat Struct Biol 1997 Mar;4(3):167–9.

Penetrating insights into pore formation [news] Hughson FM. **Nat Struct Biol** 1997 Feb;4(2):89–92 (28 ref.)

GAGA over the nucleosome [news; comment] Read CM, et al. **Nat Struct Biol** 1997 Feb;4(2):87–9 (27 ref.) Comment on: Nat Struct Biol 1997 Feb;4(2):122–32.

Interaction of Hsp70 chaperones with substrates. Rüdiger S, et al. **Nat Struct Biol** 1997 May;4(5):342–9 (75 ref.)

Histone acetylation in chromatin structure and transcription. Grunstein M. **Nature** 1997 Sep 25;389(6649):349–52 (75 ref.)

How do proteins acquire their three-dimensional structure and stability? Jaenicke R. **Naturwissenschaften** 1996 Dec; 83(12):544–54 (42 ref.)

Equilibrium, kinetics, diffusion and self-association of proteins at membrane surfaces: measurement by total internal reflection fluorescence microscopy. Thompson NL, et al. **Photochem Photobiol** 1997 Jan;65(1):39–46 (43 ref.)

Symmetry, stability, and dynamics of multidomain and multicomponent protein systems. Blundell TL, et al. **Proc Natl Acad Sci U S A** 1996 Dec 10;93(25):14243–8 (69 ref.)

Minimized protein structures: a little goes a long way. Nedwidek MN, et al. **Proc Natl Acad Sci U S A** 1997 Sep 16;94(19):10010–1 (18 ref.)

Protein dynamics and conformational transitions in allosteric proteins. Jardetzky O. **Prog Biophys Mol Biol** 1996; 65(3):171–219 (220 ref.)

Protein conformational substates from X-ray crystallography. Rejto PA, et al. **Prog Biophys Mol Biol** 1996;66(2):167–96 (175 ref.)

Conformation and design of peptides with alpha,beta-dehydro-amino acid residues. Singh TP, et al. **Prog Biophys Mol Biol** 1996;66(2):141–65 (96 ref.)

High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. Bustin M, et al. **Prog Nucleic Acid Res Mol Biol** 1996;54:35–100 (287 ref.)

Milestones in the molecular structure of the major histocompatibility complex. Chelvanayagam G, et al. **Protein Eng** 1997 May;10(5):471–4 (58 ref.)

Association of complementary fragments and the elucidation of protein folding pathways. de Prat-Gay G. **Protein Eng** 1996 Oct;9(10):843–7 (75 ref.)

Protein folding for realists: a timeless phenomenon. Shortle D, et al. **Protein Sci** 1996 Jun;5(6):991–1000 (25 ref.)

Structure and distribution of modules in extracellular proteins. Bork P, et al. **Q Rev Biophys** 1996 May; 29(2):119–67 (95 ref.)

Roles of electrostatic interaction in proteins. Nakamura H. **Q Rev Biophys** 1996 Feb;29(1):1–90 (211 ref.)

The cis-trans paradox of integrase [see comments] Jayaram M. **Science** 1997 Apr 4;276(5309):49–51 (22 ref.) Comment in: Science 1997 Apr 4;276(5309):126–31.

Making a fitting choice: common aspects of sugar-binding sites in plant and animal lectins. Drickamer K. **Structure** 1997 Apr 15;5(4):465–8 (30 ref.)

Now we're cooking: new successes for shake-and-bake. Ealick SE. **Structure** 1997 Apr 15;5(4):469–72 (30 ref.)

Pieces of the puzzle: assembling the preinitiation complex of Pol II. Ghosh G, et al. **Structure** 1996 Aug 15;4(8):891–5 (19 ref.)

Knowledge-based potentials for protein folding: what can we learn from known protein structures? Godzik A. **Structure** 1996 Apr 15;4(4):363–6 (14 ref.)

The long and short of colicin action: the molecular basis for the biological activity of channel-forming colicins. Gouaux E. **Structure** 1997 Mar 15;5(3):313–7 (21 ref.)

New structure--novel fold? Holm L, et al. **Structure** 1997 Feb 15;5(2):165–71 (24 ref.)

Angströms and calories. Janin J. **Structure** 1997 Apr 15; 5(4):473–9 (41 ref.)

Not just another Fab: the crystal structure of a TcR-MHC-peptide complex. Jardetzky T. **Structure** 1997 Feb 15;5(2):159–63 (17 ref.)

Structures of a hemoglobin-based blood substitute: insights into the function of allosteric proteins. Kroeger KS, et al. **Structure** 1997 Feb 15;5(2):227–37 (57 ref.)

Stopping death cold. Werner MH. **Structure** 1996 Aug 15; 4(8):879–83 (23 ref.)

Hydrogen exchange at equilibrium: a short cut for analysing protein-folding pathways? Clarke J, et al. **Trends Biochem Sci** 1997 Aug;22(8):284–7 (32 ref.)

How important is the molten globule for correct protein folding? Creighton TE. **Trends Biochem Sci** 1997 Jan; 22(1):6–10 (30 ref.)

Coiled coils: new structures and new functions. Lupas A. **Trends Biochem Sci** 1996 Oct;21(10):375–82 (50 ref.)

Protein architecture, dynamics and allostery in tryptophan synthase channeling. Pan P, et al. **Trends Biochem Sci** 1997 Jan;22(1):22–7 (25 ref.)

[Molecular organization and the realization of what is possible.] Debru C. **Arch Physiol Biochem** 1996 Oct; 104(6):775–81 (14 ref.) (Eng. Abstr.) **(Fre)**

[Distribution of amino acid residue conformation in three-dimensional protein structures. Analysis of the non-glycine residues in "positive" conformations] Basharov MA. **Biofizika** 1997 May–Jun;42(3):753–64 (25 ref.) (Eng. Abstr.) **(Rus)**

PROTEIN CONFORMATION, ALPHA-HELICAL see **PROTEIN STRUCTURE, SECONDARY**

PROTEIN CONFORMATION, BETA-SHEET see **PROTEIN STRUCTURE, SECONDARY**

PROTEIN DENATURATION

The application of circular dichroism to studies of protein folding and unfolding. Kelly SM, et al. **Biochim Biophys Acta** 1997 Apr 4;1338(2):161–85 (118 ref.)

IMMUNOLOGY

Destruction of proteins as a creative force. Ploegh HL. **Immunol Today** 1997 Jun;18(6):269–71 (15 ref.)

PROTEIN-ENERGY MALNUTRITION

Overview and consensus statement on diabetes in tropical areas. Tripathy BB, et al. **Diabetes Metab Rev** 1997 Mar; 13(1):63–76 (76 ref.)

COMPLICATIONS

Protein-calorie malnutrition and the etiology of cirrhosis [editorial; comment] McCullough AJ, et al. **Am J Gastroenterol** 1997 May;92(5):734–8 (77 ref.) Comment on: Am J Gastroenterol 1997 May;92(5):777–83.

The role of nutrition in prevention and healing of pressure ulcers. Thomas DR. **Clin Geriatr Med** 1997 Aug; 13(3):497–511 (75 ref.)

Nutrition in pediatric HIV infection: setting the research agenda. Nutrition and immune function: overview. Beisel WR. **J Nutr** 1996 Oct;126(10 Suppl):2611S–2615S (32 ref.)

DIAGNOSIS

[Malnutrition in the elderly: the Mini Nutritional Assessment (MNA)] Guigoz Y, et al. **Ther Umsch** 1997 Jun;54(6):345–50 (27 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

McCollum Award Lecture, 1996: protein-energy malnutrition in maintenance dialysis patients. Kopple JD. **Am J Clin Nutr** 1997 May;65(5):1544–57 (134 ref.)

Protein metabolism and liver disease. Charlton MR. **Baillieres Clin Endocrinol Metab** 1996 Oct;10(4):617–35 (110 ref.)

Metabolic acidosis and nutrition in dialysis patients. Bergström J. **Blood Purif** 1995 Nov-Dec;13(6):361–7 (26 ref.)

Dementia is not necessarily a cause of undernutrition [editorial; comment] Morley JE. **J Am Geriatr Soc** 1996 Nov;44(11):1403–4 (34 ref.) Comment on: J Am Geriatr Soc 1996 Nov;44(11):1366–70.

IMMUNOLOGY

Trace elements and vitamins in immunomodulation in infancy and childhood. Zuin G, et al. **Eur J Cancer Prev** 1997 Mar; 6 Suppl 1:S69–77 (50 ref.)

Nutrition in pediatric HIV infection: setting the research agenda. Nutrition and immune function: overview. Beisel WR. **J Nutr** 1996 Oct;126(10 Suppl):2611S–2615S (32 ref.)

METABOLISM

Energy and protein requirements of patients with chronic liver disease. Kondrup J, et al. **J Hepatol** 1997 Jul; 27(1):239–47 (74 ref.)

PATHOLOGY

Reduction of liver mass due to malnutrition in rats. Correlation with emaciation of animals and size of organs not inserted in the portal system. Miguel Parra O, et al. **Rev Paul Med** 1995 May-Jun;113(3):903–9 (53 ref.)

THERAPY

Is there a role for parenteral feeding in clinical medicine? Phinney SD, et al. **West J Med** 1996 Feb;164(2):130–6 (46 ref.)

[Prevention and therapy of complications of liver cirrhosis: ascites, encephalopathy and malnutrition] Köllinger M, et al. **Med Klin** 1996 Feb 15;91(2):89–102 (143 ref.) **(Ger)**

PROTEIN ENGINEERING

Structure and function of subtilisin BPN' as studied through crystallographic studies on a series of its complexes with genetically engineered proteinaceous inhibitor SSI. Nonaka T, et al. **Adv Exp Med Biol** 1996;379:21–7 (24 ref.)

Propeptide-mediated folding in subtilisin: the intramolecular chaperone concept. Shinde U, et al. **Adv Exp Med Biol** 1996;379:147–54 (35 ref.)

Crystallographic study of eglin-C binding to thermitase. Teplyakov A, et al. **Adv Exp Med Biol** 1996;379:5–9 (20 ref.)

Molecular design of soybean glycinins with enhanced food qualities and development of crops producing such glycinins. Utsumi S, et al. **Adv Exp Med Biol** 1997;415:1–15 (54 ref.)

Engineering the gramicidin channel. Koeppe RE 2nd, et al. **Annu Rev Biophys Biomol Struct** 1996;25:231–58 (126 ref.)

Protein engineering of lantibiotics. Kuipers OP, et al. **Antonie Van Leeuwenhoek** 1996 Feb;69(2):161–69 (28 ref.)

Selectively infective phages (SIP). Spada S, et al. **Biol Chem** 1997 Jun;378(6):445–56 (58 ref.)

Engineering nutritious proteins. Hefford MA. **Biotechnol Genet Eng Rev** 1997;14:191–210 (108 ref.)

Strategies for in vitro and in vivo translation with non-natural amino acids. Ibba M. **Biotechnol Genet Eng Rev** 1996;13:197–216 (116 ref.)

Chimeric receptors as gene switches. Allgood VE, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):474–9 (24 ref.)

Design of peptide and polypeptide vaccines. Ben-Yedidia T, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):442–8 (66 ref.)

Production of human antibody repertoires in transgenic mice. Brüggemann M, et al. **Curr Opin Biotechnol** 1997 Aug; 8(4):455–8 (24 ref.)

Engineering antibodies for imaging and therapy. Carter P, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):449–54 (54 ref.)

Therapeutic peptides and peptidomimetics. Kieber-Emmons T, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):435–41 (56 ref.)

Stabilization of protein structures. Lee B, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):423–8 (65 ref.)

The state of antibody catalysis. Smithrud DB, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):459–66 (46 ref.)

Engineering novel proteins by transfer of active sites to natural scaffolds. Vita C. **Curr Opin Biotechnol** 1997 Aug; 8(4):429–34 (56 ref.)

Incorporating anomalous scattering centres into macromolecules. Pappa HS, et al. **Curr Opin Struct Biol** 1996 Oct;6(5):611–6 (53 ref.)

A decade of protein engineering on ribonuclease T1—atomic dissection of the enzyme-substrate interactions. Steyaert J. **Eur J Biochem** 1997 Jul 1;247(1):1–11 (91 ref.)

Intrabodies: turning the humoral immune system outside in for intracellular immunization. Marasco WA. **Gene Ther** 1997 Jan;4(1):11–5 (61 ref.)

New protein engineering approaches to multivalent and bispecific antibody fragments. Plückthun A, et al. **Immunotechnology** 1997 Jun;3(2):83–105 (174 ref.)

When protein engineering confronts the tRNA world. Schimmel P, et al. **Proc Natl Acad Sci U S A** 1997 Sep 16;94(19):10007–9 (24 ref.)

Glutathione-independent prostaglandin D synthase as a lead molecule for designing new functional proteins. Toh H, et al. **Protein Eng** 1996 Dec;9(12):1067–82 (51 ref.)

[Protein engineering of artificial proteins] Dolgikh DA, et al. **Mol Biol (Mosk)** 1996 Mar-Apr;30(2):261–72 (73 ref.) **(Rus)**

METHODS

Protein engineering strategies for designing more stable hemoglobin-based blood substitutes. Olson JS, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1997 Jan-Mar; 25(1-2):227–41 (29 ref.)

3D structural information as a guide to protein engineering using genetic selection. Kast P, et al. **Curr Opin Struct Biol** 1997 Aug;7(4):470–9 (80 ref.)

Engineering metal-binding sites in proteins. Lu Y, et al. **Curr Opin Struct Biol** 1997 Aug;7(4):495–500 (61 ref.)

Scaffolds for engineering novel binding sites in proteins. Nygren PA, et al. **Curr Opin Struct Biol** 1997 Aug; 7(4):463–9 (42 ref.)

Combinatorial protein design: strategies for screening protein libraries. Zhao H, et al. **Curr Opin Struct Biol** 1997 Aug; 7(4):480–5 (49 ref.)

Strategies for expressing human antibody repertoires in transgenic mice. Brüggemann M, et al. **Immunol Today** 1996 Aug;17(8):391–7 (47 ref.)

Random sequence mutagenesis for the generation of active enzymes. Black ME, et al. **Methods Mol Biol** 1996; 57:335–49 (13 ref.)

Display of heterologous proteins on the surface of microorganisms: from the screening of combinatorial libraries to live recombinant vaccines. Georgiou G, et al. **Nat Biotechnol** 1997 Jan;15(1):29–34 (90 ref.)

TRENDS

Recombinant proteins for therapy. Buckel P. **Trends Pharmacol Sci** 1996 Dec;17(12):450–6 (31 ref.)

PROTEIN FOLDING

see related
PROTEIN CONFORMATION

Propeptide-mediated folding in subtilisin: the intramolecular chaperone concept. Shinde U, et al. **Adv Exp Med Biol** 1996;379:147–54 (35 ref.)

The roles of tryptophan residues in the structure, function, and folding of the gramicidin transmembrane ion channel. Wallace BA. **Adv Exp Med Biol** 1996;398:607–14 (29 ref.)

The final stage of gene expression: chaperones and the regulation of protein fate. Ashkenas J, et al. **Am J Hum Genet** 1997 Aug;61(2):267–72 (39 ref.)

Protein folding: the endgame. Levitt M, et al. **Annu Rev Biochem** 1997;66:549–79 (251 ref.)

Protein folds in the all-beta and all-alpha classes. Chothia C, et al. **Annu Rev Biophys Biomol Struct** 1997;26:597–627 (103 ref.)

Computational studies of protein folding. Friesner RA, et al. **Annu Rev Biophys Biomol Struct** 1996;25:315–42 (73 ref.)

Bridging the protein sequence-structure gap by structure predictions. Rost B, et al. **Annu Rev Biophys Biomol Struct** 1996;25:113–36 (99 ref.)

Theory and practice of nuclear spin relaxation in proteins. Dayie KT, et al. **Annu Rev Phys Chem** 1996;47:243–82 (147 ref.)

Insights into protein folding from NMR. Dyson HJ, et al. **Annu Rev Phys Chem** 1996;47:369–95 (144 ref.)

Molecular chaperones, folding catalysts, and the recovery of active recombinant proteins from E. coli. To fold or to refold. Thomas JG, et al. **Appl Biochem Biotechnol** 1997 Jun;66(3):197–238 (214 ref.)

Cotranslational folding of nascent proteins on Escherichia coli ribosomes. Hardesty B, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11–12):1199–207 (22 ref.)

Cotranslational folding of proteins. Kolb VA, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11–12):1217–20 (38 ref.)

The application of circular dichroism to studies of protein folding and unfolding. Kelly SM, et al. **Biochim Biophys Acta** 1997 Apr 4;1338(2):161–85 (118 ref.)

The ternary complex of aminoacylated tRNA and EF-Tu-GTP. Recognition of a bond and a fold. Nissen P, et al. **Biochimie** 1996;78(11–12):921–33 (62 ref.)

Enzymology and folding of natural and engineered bacterial beta-glucanases studied by X-ray crystallography. Heinemann U, et al. **Biol Chem** 1996 Jul-Aug; 377(7–8):447–54 (42 ref.)

Catalyzed and assisted protein folding of ribonuclease T1. Schmid FX, et al. **Biol Chem** 1996 Jul-Aug;377(7–8):417–24 (65 ref.)

The effect of molecular chaperones on in vivo and in vitro folding processes. Schwarz E, et al. **Biol Chem** 1996 Jul-Aug;377(7–8):411–6 (77 ref.)

Protein folding in vivo: unraveling complex pathways. Johnson JL, et al. **Cell** 1997 Jul 25;90(2):201–4 (19 ref.)

Protein folding: concepts and perspectives. Yon JM. **Cell Mol Life Sci** 1997 Jul;53(7):557–67 (150 ref.)

Fit for life? Evolution of chaperones and folding catalysts parallels the development of complex organisms. Pahl A, et al. **Cell Stress Chaperones** 1997 Jun;2(2):78–86 (41 ref.)

Influence of molecular and chemical chaperones on protein folding [published erratum appears in Cell Stress Chaperones 1996 Sep;1(3):207] Welch WJ, et al. **Cell Stress Chaperones** 1996 Jun;1(2):109–15 (34 ref.)

Putting a lid on protein folding: structure and function of the co-chaperonin, GroES. Fenton WA, et al. **Chem Biol** 1996 Mar;3(3):157–61 (37 ref.)

Fast-folding experiments and the topography of protein folding energy landscapes. Wolynes P, et al. **Chem Biol** 1996 Jun;3(6):425–32 (39 ref.)

Mechanisms and pathways of chaperone-mediated protein folding. Hartle FU. **Cold Spring Harb Symp Quant Biol** 1995;60:429–34 (56 ref.)

Kinesis of polypeptide during GroEL-mediated folding. Horwich AL, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:435–40 (35 ref.)

Thermal unfolding of beta-lactoglobulin, alpha-lactalbumin, and bovine serum albumin. A thermodynamic approach. Relkin P. **Crit Rev Food Sci Nutr** 1996 Jul;36(6):565–601 (180 ref.)

Splicing together the unfolded-protein response. Shamu CE. **Curr Biol** 1997 Feb 1;7(2):R67–70 (15 ref.)

Chaperones get Hip. Protein folding. Ziegelhoffer T, et al. **Curr Biol** 1996 Mar 1;6(3):272–5 (20 ref.)

Protein folding and intermediates. Clarke AR, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):400–10 (74 ref.)

Submillisecond kinetics of protein folding. Eaton WA, et al. **Curr Opin Struct Biol** 1997 Feb;7(1):10–4 (49 ref.)

Nucleation mechanisms in protein folding. Fersht AR. **Curr Opin Struct Biol** 1997 Feb;7(1):3–9 (73 ref.)

The prion folding problem. Harrison PM, et al. **Curr Opin Struct Biol** 1997 Feb;7(1):53–9 (51 ref.)

Chaperone-assisted protein folding. Martin J, et al. **Curr Opin Struct Biol** 1997 Feb;7(1):41–52 (99 ref.)

Engineering peptides and proteins that undergo alpha-to-beta transitions. Mihara H, et al. **Curr Opin Struct Biol** 1997 Aug;7(4):501–8 (56 ref.)

Time-resolved biophysical methods in the study of protein folding. Plaxco KW, et al. **Curr Opin Struct Biol** 1996 Oct; 6(5):630–6 (49 ref.)

Kinetic role of early intermediates in protein folding. Roder H, et al. **Curr Opin Struct Biol** 1997 Feb;7(1):15–28 (116 ref.)

Theoretical studies of protein-folding thermodynamics and kinetics. Shakhnovich EI. **Curr Opin Struct Biol** 1997 Feb; 7(1):29–40 (102 ref.)

Normal protein folding machinery. Hartman D, et al. **EXS** 1996;77:3–24 (104 ref.)

Protein folding and assembly in the endoplasmic reticulum. Wei J, et al. **EXS** 1996;77:41–55 (52 ref.)

On-pathway versus off-pathway folding intermediates. Baldwin RL. **Fold Des** 1996;1(1):R1–8 (36 ref.)

Real-time NMR investigations of triple-helix folding and collagen folding diseases. Baum J, et al. **Fold Des** 1997; 2(4):R53–60 (51 ref.)

Revisiting the Anfinsen cage. Ellis RJ. **Fold Des** 1996; 1(1):R9–15 (45 ref.)

Experimental investigation of sidechain interactions in early folding intermediates. Engelhard M, et al. **Fold Des** 1996; 1(2):R31–7 (32 ref.)

Probing the partly folded states of proteins by limited proteolysis. Fontana A, et al. **Fold Des** 1997;2(2):R17–26 (105 ref.)

Adding backbone to protein folding: why proteins are polypeptides. Honig B, et al. **Fold Des** 1996;1(1):R17–20 (35 ref.)

The Levinthal paradox: yesterday and today. Karplus M. **Fold Des** 1997;2(4):S69–75 (75 ref.)

X-ray solution scattering studies of protein folding. Kataoka M, et al. **Fold Des** 1996;1(5):R107–14 (45 ref.)

Local versus nonlocal interactions in protein folding and

stability--an experimentalist's point of view. Muñoz V, et al. **Fold Des** 1996;1(4):R71-7 (80 ref.)
Folding studies on ribonuclease A, a model protein. Neira JL, et al. **Fold Des** 1997;2(1):R1-11 (70 ref.)
Protein folding from a combinatorial perspective. Sauer RT. **Fold Des** 1996;1(2):R27-30 (31 ref.)
Modeling protein folding: the beauty and power of simplicity. Shakhnovich EI. **Fold Des** 1996;1(3):R50-4 (41 ref.)
The concept of a random coil. Residual structure in peptides and denatured proteins. Smith LJ, et al. **Fold Des** 1996; 1(5):R95-106 (76 ref.)
Protein quality control: triage by chaperones and proteases. Gottesman S, et al. **Genes Dev** 1997 Apr 1;11(7):815-23 (70 ref.)
Protein folding in the bacterial periplasm. Missiakas D, et al. **J Bacteriol** 1997 Apr;179(8):2465-71 (88 ref.)
Local interactions in protein folding: lessons from the alpha-helix. Aurora R, et al. **J Biol Chem** 1997 Jan 17; 272(3):1413-6 (82 ref.)
Protein binding versus protein folding: the role of hydrophilic bridges in protein associations. Xu D, et al. **J Mol Biol** 1997 Jan 10;265(1):68-84 (92 ref.)
Picosecond fluorescence decay curves collected on millisecond time scale: direct measurement of hydrodynamic radii, local/global mobility, and intramolecular distances during protein-folding reactions. Beechem JM. **Methods Enzymol** 1997;278:24-49 (13 ref.)
Fluorescence methods for studying kinetics of protein-folding reactions. Eftink MR, et al. **Methods Enzymol** 1997;278:258-86 (68 ref.)
Protein folding in vivo and renaturation of recombinant proteins from inclusion bodies. Guise AD, et al. **Mol Biotechnol** 1996 Aug;6(1):53-64 (67 ref.)
From Levinthal to pathways to funnels. Dill KA, et al. **Nat Struct Biol** 1997 Jan;4(1):10-9 (109 ref.)
Common fold, common function, common origin? [news] Suck D. **Nat Struct Biol** 1997 Mar;4(3):161-5 (39 ref.)
Molecular chaperones and protein folding in plants. Boston RS, et al. **Plant Mol Biol** 1996 Oct;32(1-2):191-222 (344 ref.)
A speed limit for protein folding. McCammon JA. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11426-7 (19 ref.)
Contacting the protein folding funnel with NMR. Onuchic JN. **Proc Natl Acad Sci U S A** 1997 Jul 8;94(14):7129-31 (28 ref.)
Design of alpha-helical peptides: their role in protein folding and molecular biology. Parthasarathy R, et al. **Prog Biophys Mol Biol** 1995;64(1):1-54 (205 ref.)
Association of complementary fragments and the elucidation of protein folding pathways. de Prat-Gay G. **Protein Eng** 1996 Oct;9(10):843-7 (75 ref.)
Hydrogen exchange: the modern legacy of Linderstrøm-Lang. Englander SW, et al. **Protein Sci** 1997 May;6(5):1101-9 (88 ref.)
GroEL-mediated protein folding. Fenton WA, et al. **Protein Sci** 1997 Apr;6(4):743-60 (121 ref.)
Protein folding in the endoplasmic reticulum: lessons from the human chorionic gonadotropin beta subunit. Ruddon RW, et al. **Protein Sci** 1996 Aug;5(8):1443-52 (72 ref.)
Protein folding for realists: a timeless phenomenon. Shortle D, et al. **Protein Sci** 1996 Jun;5(6):991-1000 (25 ref.)
Future directions in folding: the multi-state nature of protein structure. Bai Y, et al. **Proteins** 1996 Feb;24(2):145-51 (28 ref.)
Protein folding, nucleation phenomena and delayed neurodegeneration in Alzheimer's disease. Fox N, et al. **Rev Neurosci** 1996 Jan-Mar;7(1):21-8 (61 ref.)
Chaperone-assisted protein expression. Cole PA. **Structure** 1996 Mar 15;4(3):239-42 (29 ref.)
Fast events in protein folding. Eaton WA, et al. **Structure** 1996 Oct 15;4(10):1133-9 (53 ref.)
Knowledge-based potentials for protein folding: what can we learn from known protein structures? Godzik A. **Structure** 1996 Apr 15;4(4):363-6 (14 ref.)
New structure--novel fold? Holm L, et al. **Structure** 1997 Feb 15;5(2):165-71 (24 ref.)
Threading thrills and threats. Sippl MJ, et al. **Structure** 1996 Jan 15;4(1):15-9 (14 ref.)
Hydrogen exchange at equilibrium: a short cut for analysing protein-folding pathways? Clarke J, et al. **Trends Biochem Sci** 1997 Aug;22(8):284-7 (32 ref.)
How important is the molten globule for correct protein folding? Creighton TE. **Trends Biochem Sci** 1997 Jan; 22(1):6-10 (30 ref.)
A measure of success in fold recognition. Marchler-Bauer A, et al. **Trends Biochem Sci** 1997 Jul;22(7):236-40 (35 ref.)
[Chaperonin: structure and function] Taguchi H, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(7):849-59 (53 ref.) **(Jpn)**
[Fibrillary proteins from bacteriophage T4 as a model for studying folding] Mesianzhinov VV. **Mol Biol (Mosk)** 1997 May-Jun;31(3):389-97 (53 ref.) **(Rus)**

PROTEIN FOLDING, GLOBULAR see **PROTEIN FOLDING**

PROTEIN-GLUTAMINE GAMMA-GLUTAMYLTRANSFERASE

ANALYSIS

Transglutaminases: purification and activity assays. Wilhelm B, et al. **J Chromatogr B Biomed Appl** 1996 Sep 20; 684(1-2):163-77 (79 ref.)

ISOLATION & PURIFICATION

Transglutaminases: purification and activity assays. Wilhelm B, et al. **J Chromatogr B Biomed Appl** 1996 Sep 20; 684(1-2):163-77 (79 ref.)

METABOLISM

Transglutaminase induction by various cell death and apoptosis pathways. Fesus L, et al. **Experientia** 1996 Oct 31;52(10-11):942-9 (84 ref.)
Determinants of substrate specificity for factor XIII. McDonagh J, et al. **Semin Thromb Hemost** 1996; 22(5):369-76 (47 ref.)

PHYSIOLOGY

Is transglutaminase the mediator between antimalarial drugs and psoriasis? Wolf R, et al. **Int J Dermatol** 1997 Jan; 36(1):10-3 (36 ref.)
Tissue transglutaminase and factor XIII in cartilage and bone remodeling. Aeschlimann D, et al. **Semin Thromb Hemost** 1996;22(5):437-43 (45 ref.)
Platelet-associated factor XIII in platelet activation, adhesion, and clot stabilization. Devine DV, et al. **Semin Thromb Hemost** 1996;22(5):409-13 (42 ref.)
[Various physiological functions suggested for protein cross-linking enzyme, transglutaminase] Ikura K. **Seikagaku** 1997 Jun;69(6):416-20 (23 ref.) **(Jpn)**

PROTEIN GLYCOSYLATION see **GLYCOSYLATION**

PROTEIN ISOPRENYLATION

Protein prenylation: molecular mechanisms and functional consequences. Zhang FL, et al. **Annu Rev Biochem** 1996; 65:241-69 (207 ref.)
Novel salvage pathway utilizing farnesol and geranylgeraniol for protein isoprenylation. Crick DC, et al. **Biochem Biophys Res Commun** 1997 Aug 28;237(3):483-7 (47 ref.)
Geranylgeranylation of Rab proteins. Desnoyers L, et al. **Biochem Soc Trans** 1996 Aug;24(3):699-703 (27 ref.)
Prenylation-dependent interaction of Rab proteins with GDP dissociation inhibitors. Maltese WA, et al. **Biochem Soc Trans** 1996 Aug;24(3):703-8 (50 ref.)
Chemical biology of isoprenylation/methylation. Rando RR. **Biochem Soc Trans** 1996 Aug;24(3):682-87 (48 ref.)
Inhibitors of farnesyl:protein transferase--a possible cancer chemotherapeutic. Scholten JD, et al. **Bioorg Med Chem** 1996 Sep;4(9):1537-43 (26 ref.)
Synthesis of prenylated peptides and peptide esters. Naider FR, et al. **Biopolymers** 1997;43(1):3-14 (60 ref.)
Ras farnesyltransferase: a new therapeutic target. Leonard DM. **J Med Chem** 1997 Sep 12;40(19):2971-90 (187 ref.)
[Inhibitors of Ras farnesylation: tomorrow's anticancer agents?] Perrin D, et al. **Bull Cancer** 1997 Jun;84(6):635-42 (56 ref.) (Eng. Abstr.) **(Fre)**
[Inhibitors of isoprenylation of ras p21] Yoshimatsu K. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1495-502 (30 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design. Lerner EC, et al. **Anticancer Drug Des** 1997 Jun;12(4):229-38 (55 ref.)

PHYSIOLOGY

The role of prenylation in G-protein assembly and function. Higgins JB, et al. **Cell Signal** 1996 Sep;8(6):433-7 (50 ref.)

PROTEIN KINASE A see **CYCLIC AMP-DEPENDENT PROTEIN KINASES**

PROTEIN KINASE C

Annexins and protein kinases C. Dubois T, et al. **Biochim Biophys Acta** 1996 Oct 11;1313(3):290-4 (32 ref.)
Protein kinase C isoenzymes: regulation and function. Blobe GC, et al. **Cancer Surv** 1996;27:213-48 (190 ref.)
[An aspect of the research on protein kinase C] Ohno S. **Seikagaku** 1996 May;68(5):345-61 (59 ref.) **(Jpn)**

ANALYSIS

Retinal protein kinase C. Wood JP, et al. **Neurochem Int** 1997 Feb;30(2):119-36 (146 ref.)

ANTAGONISTS & INHIBITORS

Protein kinase C inhibition by ET-18-OCH3 and related analogs. A target for cancer chemotherapy. Pauig SB, et al. **Adv Exp Med Biol** 1996;416:173-80 (49 ref.)
Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase. Henry SP, et al. **Anticancer Drug Des** 1997 Jul;12(5):409-20 (38 ref.)
Antisense oligonucleotide inhibitors of isozymes of protein kinase C: in vitro and in vivo activity, and clinical development as anti-cancer therapeutics. McGraw K, et al. **Anticancer Drug Des** 1997 Jul;12(5):315-26 (42 ref.)
Protein kinase C: a worthwhile target for anticancer drugs? Caponigro F, et al. **Anticancer Drugs** 1997 Jan;8(1):26-33 (70 ref.)

BIOSYNTHESIS

Is PKC activation required for leukemia cell differentiation? [comment] Woloschak GE. **Leuk Res** 1997 May;21(5):411-4 (42 ref.) Comment on: Leuk Res 1997 May;21(5):403-10.

BLOOD

Posttranslational effects of protein kinase C and insulin on red cell membrane phosphorylation and cation heteroexchange in hypertension. Semplicini A, et al. **Blood Press Suppl** 1996;1:55-8 (25 ref.)

CHEMISTRY

Protein kinase C and phospholipase C: bilayer interactions and regulation. Hurley JH, et al. **Curr Opin Struct Biol** 1997 Aug;7(4):557-65 (69 ref.)
Protein kinase C: an example of a calcium-regulated protein binding to membranes (review). Mosior M, et al. **Mol Membr Biol** 1997 Apr-Jun;14(2):65-70 (43 ref.)
The C2 domain calcium-binding motif: structural and functional diversity. Nalefski EA, et al. **Protein Sci** 1996 Dec;5(12):2375-90 (139 ref.)

GENETICS

The potential for isoenzyme-selective modulation of protein kinase C. Hofmann J. **FASEB J** 1997 Jul;11(8):649-69 (256 ref.)

METABOLISM

Intracellular signal transduction in the postischemic brain. Wieloch T, et al. **Adv Neurol** 1996;71:371-87; discussion 387-8 (147 ref.)
Protein kinase C mediation of Ca(2+)-independent contractions of vascular smooth muscle. Walsh MP, et al. **Biochem Cell Biol** 1996;74(4):485-502 (214 ref.)
Hijacking host cell signal transduction mechanisms during infection with enteropathogenic Escherichia coli. Baldwin TJ, et al. **Biochem Soc Trans** 1996 May;24(2):552-8 (56 ref.)
Protein kinase C: ports of anchor in the cell. Newton AC. **Curr Biol** 1996 Jul 1;6(7):806-9 (20 ref.)
Regulation of protein kinase C. Newton AC. **Curr Opin Cell Biol** 1997 Apr;9(2):161-7 (58 ref.)
Regulation of protein kinase C: a tale of lipids and proteins. Quest AF. **Enzyme Protein** 1996;49(5-6):231-61 (242 ref.)
Regulation of p53 by protein kinase C during multi-stage carcinogenesis [editorial] Magnelli L, et al. **J Cancer Res Clin Oncol** 1997;123(7):365-9 (48 ref.)
Phosphatidylcholine hydrolysis and protein kinase C activation for intracellular signaling network. Nakamura S. **J Lipid Mediat Cell Signal** 1996 Sep;14(1-3):197-202 (16 ref.)
Effects of hyperammonemia on brain protein kinase C substrates. Grau E, et al. **Metab Brain Dis** 1996 Sep; 11(3):205-16 (48 ref.)
Protein kinase C and its substrates. Liu JP. **Mol Cell Endocrinol** 1996 Jan 15;116(1):1-29 (505 ref.)
Protein kinase C: an example of a calcium-regulated protein binding to membranes (review). Mosior M, et al. **Mol Membr Biol** 1997 Apr-Jun;14(2):65-70 (43 ref.)
Influence of cell differentiation and protein kinase C activation on sub-cellular distribution of beta-N-acetylhexosaminidases of HL 60 cells. Emiliani C, et al. **Physiol Chem Phys Med NMR** 1995;27(4):369-76 (26 ref.)
Phospholipase D: regulation by GTPases and protein kinase C and physiological relevance. Cockcroft S. **Prog Lipid Res** 1996 Dec;35(4):345-70 (270 ref.)
Receptor-mediated activation of protein kinase C in hippocampal long-term potentiation: facts, problems and implications [see comments] Angenstein F, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Apr; 21(3):427-54 (113 ref.) Comment in: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):373-8.
Intracellular signal modulation: a pivotal role for protein kinase C [see comments] Casabona G. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Apr; 21(3):407-25 (75 ref.) Comment in: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):373-8.
Protein kinase C, learning and memory: a circular determinism between physiology and behaviour [see comments] Nogués X. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Apr; 21(3):507-29 (68 ref.) Comment in: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):373-8.
Protein kinase C in synaptic plasticity: changes in the in situ phosphorylation state of identified pre- and postsynaptic substrates [see comments] Ramakers GM, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Apr;

21(3):455–86 (193 ref.) Comment in: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):373–8.
Protein kinase C: a memory kinase? [comment] Riedel G. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Apr; 21(3):373–8 (21 ref.) Comment on: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):379–406. Comment on: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):407–25. Comment on: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):427–54. Comment on: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):455–86. Comment on: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):487–505. Comment on: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):507–29. Comment on: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):531–72.
Historical review of research on protein kinase C in learning and memory [see comments] Van der Zee EA, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Apr; 21(3):379–406 (117 ref.) Comment in: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):373–8.
Learning-induced alterations in hippocampal PKC-immunoreactivity: a review and hypothesis of its functional significance [see comments] Van der Zee EA, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Apr;21(3):531–72 (144 ref.) Comment in: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):373–8.
More on target with protein phosphorylation: conferring specificity by location. Faux MC, et al. **Trends Biochem Sci** 1996 Aug;21(8):312–5 (48 ref.)
The role of anchoring protein RACK1 in PKC activation in the ageing rat brain. Battaini F, et al. **Trends Neurosci** 1997 Sep;20(9):410–5 (72 ref.)
Amyotrophic lateral sclerosis: the involvement of intracellular Ca2+ and protein kinase C. Krieger C, et al. **Trends Pharmacol Sci** 1996 Mar;17(3):114–20 (70 ref.)

PHARMACOLOGY

Protection of the myocardium by ischaemic preconditioning: mechanisms and therapeutic implications. Millar CG, et al. **Pharmacol Ther** 1996;69(2):143–51 (89 ref.)

PHYSIOLOGY

Exploration of the possible roles of phospholipase D and protein kinase C in the mechanism of ischemic preconditioning in the myocardium. Eskildsen-Helmond YE, et al. **Ann N Y Acad Sci** 1996 Sep 30;793:210–25 (79 ref.)
The role of protein kinase C in ischemic preconditioning. Goto M, et al. **Ann N Y Acad Sci** 1996 Sep 30;793:177–90 (59 ref.)
Mechanism of formation of post Golgi vesicles from TGN membranes: Arf-dependent coat assembly and PKC-regulated vesicle scission. Sabatini DD, et al. **Biocell** 1996 Dec;20(3):287–300 (104 ref.)
PKC--a pivotal regulator of early development. Gallicano GI, et al. **Bioessays** 1997 Jan;19(1):29–36 (69 ref.)
Protein kinase C and breast cancer. Davidson NE, et al. **Cancer Treat Res** 1996;83:91–105 (57 ref.)
Does protein kinase C play a pivotal role in the mechanisms of ischemic preconditioning? Gho BC, et al. **Cardiovasc Drugs Ther** 1997 Jan;10(6):775–86 (83 ref.)
Protein kinase C and transmitter release. Majewski H, et al. **Clin Exp Pharmacol Physiol** 1997 Aug;24(8):619–23 (56 ref.)
Protein kinase C signalling in pancreatic beta-cells: cellular and molecular approaches. Persaud SJ. **Digestion** 1997;58 Suppl 2:86–92 (32 ref.)
Mitogenic actions of peroxidase proliferators: involvement of protein kinase C and tumor necrosis factor alpha. Bojes HK, et al. **Drug Metab Rev** 1997 Feb-May;29(1-2):235–60 (71 ref.)
Linking protein kinase C to cell-cycle control. Livneh E, et al. **Eur J Biochem** 1997 Aug 15;248(1):1–9 (136 ref.)
GnRH receptor signaling: cross-talk of Ca2+ and protein kinase C. Naor Z. **Eur J Endocrinol** 1997 Feb;136(2):123–7 (39 ref.)
Role of protein kinase activity in apoptosis. Lavin MF, et al. **Experientia** 1996 Oct 31;52(10–11):979–94 (246 ref.)
Regulation of vascular smooth muscle contraction. The roles of Ca2+, protein kinase C and myosin light chain phosphatase. Takuwa Y. **Jpn Heart J** 1996 Nov; 37(6):793–813 (116 ref.)
Isoenzymes of protein kinase C: differential involvement in apoptosis and pathogenesis. Deacon EM, et al. **Mol Pathol** 1997 Jun;50(3):124–31 (140 ref.)
Involvement of glutamatergic neurotransmission and protein kinase C in spinal plasticity and the development of chronic pain. Tölle TR, et al. **Prog Brain Res** 1996;110:193–206 (54 ref.)
P-glycoprotein, multidrug resistance and protein kinase C. Fine RL, et al. **Stem Cells** 1996 Jan;14(1):47–55 (50 ref.)
[Protein kinase C in neuronal signaling] Suzuki A, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):411–7 (35 ref.) **(Jpn)**

PROTEIN KINASES

The giant protein titin. Emerging roles in physiology and pathophysiology [see comments] Labeit S, et al. **Circ Res** 1997 Feb;80(2):290–4 (40 ref.) Comment in: Circ Res 1997 Feb;80(2):295–6.
Phosphatidylinositol 3-kinase related kinases. Abraham RT. **Curr Opin Immunol** 1996 Jun;8(3):412–8 (69 ref.)
Anchoring and scaffold proteins for kinases and phosphatases. Lester LB, et al. **Recent Prog Horm Res** 1997; 52:409–29; discussion 429–30 (98 ref.)

ANTAGONISTS & INHIBITORS

Protein kinase inhibitors--potential chemotherapeutic agents. Shugar D. **Acta Biochim Pol** 1995;42(4):405–18 (50 ref.)
Protein kinase inhibitors: induction of apoptosis and drug-resistance modulation in neoplastic cell lines. Chorváth B, et al. **Neoplasma** 1996;43(1):3–9 (71 ref.)
[Cdk inhibiting proteins] Tomoda K, et al. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1407–13 (25 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Development of connectin/titin and nebulin in striated muscles of chicken. Shimada Y, et al. **Adv Biophys** 1996; 33:223–33 (37 ref.)

CHEMISTRY

The super-repeats of titin/connectin and their interactions: glimpses at sarcomeric assembly. Gautel M. **Adv Biophys** 1996;33:27–37 (61 ref.)
cDNA sequence of rabbit cardiac titin/connectin. Greaser ML, et al. **Adv Biophys** 1996;33:13–25 (27 ref.)
Proteolytic cleavage of connectin/titin. Suzuki A, et al. **Adv Biophys** 1996;33:53–64 (48 ref.)
Myomesin, M-protein and the structure of the sarcomeric M-band. Van Der Ven PF, et al. **Adv Biophys** 1996;33:91–9 (37 ref.)
The phytochromes: a biochemical mechanism of signaling in sight? Quail PH. **Bioessays** 1997 Jul;19(7):571–9 (56 ref.)
Assaying CTD kinases in vitro and phosphorylation-modulated properties of RNA polymerase II in vivo. Morris DP, et al. **Methods** 1997 Jul;12(3):264–75 (41 ref.)
Tripping the switch fantastic: how a protein kinase cascade can convert graded inputs into switch-like outputs [see comments] Ferrell JE Jr. **Trends Biochem Sci** 1996 Dec; 21(12):460–6 (32 ref.) Comment in: Trends Biochem Sci 1997 Aug;22(8):288.

GENETICS

cDNA sequence of rabbit cardiac titin/connectin. Greaser ML, et al. **Adv Biophys** 1996;33:13–25 (27 ref.)
Mutator specificity and disease: looking over the FENce [comment] Kunkel TA, et al. **Cell** 1997 Jan 24;88(2):155–8 (20 ref.) Comment on: Cell 1997 Jan 24;88(2):253–63.
Human genetics: dissecting Williams syndrome. Monaco AP. **Curr Biol** 1996 Nov 1;6(11):1396–8 (14 ref.)
Translational regulation of yeast GCN4. A window on factors that control initiator-trna binding to the ribosome. Hinnebusch AG. **J Biol Chem** 1997 Aug 29;272(35):21661–4 (61 ref.)
The protein kinases of budding yeast: six score and more. Hunter T, et al. **Trends Biochem Sci** 1997 Jan;22(1):18–22 (39 ref.)
[Myotonin protein kinase] Ishiura S, et al. **Rinsho Shinkeigaku** 1995 Dec;35(12):1482–3 (3 ref.) (Eng. Abstr.) **(Jpn)**
[Molecular mechanisms of self-incompatibility in Brassica] Takayama S, et al. **Tanpakushitsu Kakusan Koso** 1997 Jul; 42(9):1386–95 (41 ref.) **(Jpn)**

METABOLISM

The NTP phosphate donor in kinase reactions: is ATP a monopolist? Shugar D. **Acta Biochim Pol** 1996;43(1):9–23 (68 ref.)
The super-repeats of titin/connectin and their interactions: glimpses at sarcomeric assembly. Gautel M. **Adv Biophys** 1996;33:27–37 (61 ref.)
Proteolytic cleavage of connectin/titin. Suzuki A, et al. **Adv Biophys** 1996;33:53–64 (48 ref.)
Regulation of rat ALDH-3 by hepatic protein kinases and glucocorticoids. Prough RA, et al. **Adv Exp Med Biol** 1997; 414:29–36 (18 ref.)
Dissection of protein kinase cascades that mediate cellular response to cytokines and cellular stress. Cohen P. **Adv Pharmacol** 1996;36:15–27 (29 ref.)
Novel components of mammalian stress-activated protein kinase cascades. Kiefer F, et al. **Biochem Soc Trans** 1997 May;25(2):491–8 (68 ref.)
Multi-site phosphorylation of p53 by protein kinases inducible by p53 and DNA damage. Meek DW, et al. **Biochem Soc Trans** 1997 May;25(2):416–9 (21 ref.)
How do protein kinases recognize their substrates? Pinna LA, et al. **Biochim Biophys Acta** 1996 Dec 12;1314(3):191–225 (205 ref.)
Protein kinase cascades activated by stress and inflammatory cytokines. Kyriakis JM, et al. **Bioessays** 1996 Jul; 18(7):567–77 (70 ref.)
The stress activated protein kinase pathway. Woodgett JR, et al. **Cancer Surv** 1996;27:127–38 (41 ref.)
Protein kinase modulation of mu opioid receptor signalling. Yu L. **Cell Signal** 1996 Aug;8(5):371–4 (36 ref.)
Drosophila morphogenesis: follow-my-leader in epithelia. Knust E. **Curr Biol** 1996 Apr 1;6(4):379–81 (18 ref.)
Kinase connections on the cellular intranet. Signalling pathways. Pelech SL. **Curr Biol** 1996 May 1;6(5):551–4 (19 ref.)
The AMP-activated protein kinase--fuel gauge of the mammalian cell? Hardie DG, et al. **Eur J Biochem** 1997 Jun 1;246(2):259–73 (138 ref.)
Regulation of phosphorylation pathways by p21 GTPases. The p21 Ras-related Rho subfamily and its role in phosphorylation signalling pathways. Lim L, et al. **Eur J Biochem** 1996 Dec 1;242(2):171–85 (123 ref.)
Sounding the alarm: protein kinase cascades activated by stress and inflammation. Kyriakis JM, et al. **J Biol Chem** 1996 Oct 4;271(40):24313–6 (78 ref.)
Nuclear import of protein kinases and cyclins. Boulikas T. **J Cell Biochem** 1996 Jan;60(1):61–82 (109 ref.)
Histidine kinases in signal transduction pathways of eukaryotes. Loomis WF, et al. **J Cell Sci** 1997 May;110 (Pt 10):1141–5 (26 ref.)
Protein kinase mediators of integrin signal transduction. Hannigan GE, et al. **J Mol Med** 1997 Jan;75(1):35–44 (116 ref.)
Assay of G protein-coupled receptor kinase activity by rhodopsin phosphorylation. Gagnon AW, et al. **Methods Mol Biol** 1997;83:235–42 (14 ref.)
Kinase cascades regulating entry into apoptosis. Anderson P. **Microbiol Mol Biol Rev** 1997 Mar;61(1):33–46 (189 ref.)
Bacterial signalling involving eukaryotic-type protein kinases. Zhang CC. **Mol Microbiol** 1996 Apr;20(1):9–15 (32 ref.)
Signal transduction and protein kinases: the long way from the plasma membrane into the nucleus. Hucho F, et al. **Naturwissenschaften** 1997 Jul;84(7):281–90 (88 ref.)
Visualization of protein kinase activities in single cells by antibodies against phosphorylated vimentin and GFAP. Inagaki N, et al. **Neurochem Res** 1996 Jul;21(7):795–800 (30 ref.)
The contribution of protein kinases to plastic events in the superior colliculus [see comments] McCrossan D, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Apr; 21(3):487–505 (49 ref.) Comment in: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):373–8.
Stimulation of kinase cascades by growth hormone: a paradigm for cytokine signaling. Wood TJ, et al. **Prog Nucleic Acid Res Mol Biol** 1997;57:73–94 (107 ref.)
The role of workhorse protein kinases in coordinating DNA metabolism and cell growth. Christenson E, et al. **Recent Results Cancer Res** 1997;143:263–74 (32 ref.)
Dissection of protein kinase and phosphatase targeting interactions. Scott JD. **Soc Gen Physiol Ser** 1997;52:227–39 (36 ref.)
Tripping the switch fantastic: how a protein kinase cascade can convert graded inputs into switch-like outputs [see comments] Ferrell JE Jr. **Trends Biochem Sci** 1996 Dec; 21(12):460–6 (32 ref.) Comment in: Trends Biochem Sci 1997 Aug;22(8):288.
[Coupling of seven transmembrane domains receptors cytosolic PLA2: role of G proteins and protein kinases] Masliah J, et al. **C R Seances Soc Biol Fil** 1996; 190(4):417–23 (28 ref.) (Eng. Abstr.) **(Fre)**
[Biochemical mechanisms of NCS-chromophore-induced DNA cleavage and inhibition of protein kinase activity] Ohtsuki K, et al. **Gan To Kagaku Ryoho** 1997 Feb; 24(4):443–53 (35 ref.) (Eng. Abstr.) **(Jpn)**
[Tobacco PMSAP kinase is transiently activated by wounding] Usami S, et al. **Tanpakushitsu Kakusan Koso** 1997 Apr;42(5):717–26 (28 ref.) **(Jpn)**
[Ca(2+)-phospholipid-dependent protein kinases and their role in regulating metabolic processes] Ostapchenko LI. **Ukr Biokhim Zh** 1995 Nov-Dec;67(6):3–11 (84 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Viscoelasticity and function of connectin/titin filaments in skinned muscle fibers. Higuchi H. **Adv Biophys** 1996; 33:159–71 (26 ref.)
Comparative aspects of muscle elastic proteins. Kawamura Y, et al. **Adv Biophys** 1996;33:175–81 (29 ref.)
Structure and physiological functions of ubiquitous and tissue-specific calpain species. Muscle-specific calpain, p94, interacts with connectin/titin. Sorimachi H, et al. **Adv Biophys** 1996;33:101–22 (89 ref.)
Physiological significance of viscoelastic structures in myoplasm. Takemori S, et al. **Adv Biophys** 1996;33:151–7 (16 ref.)
Titin/connectin and nebulin: giant protein rulers of muscle structure and function. Wang K. **Adv Biophys** 1996; 33:123–34 (84 ref.)
Role of protein kinases in nerve terminal maturation and function. Valtorta E, et al. **Biochem Soc Trans** 1996 Aug; 24(3):645–53 (60 ref.)
Rho: theme and variations. Ridley AJ. **Curr Biol** 1996 Oct 1;6(10):1256–64 (73 ref.)
Titin as a scaffold and spring. Cytoskeleton. Trinick J. **Curr Biol** 1996 Mar 1;6(3):258–60 (15 ref.)
Regulation of potassium channels by protein kinases. Jonas EA, et al. **Curr Opin Neurobiol** 1996 Jun;6(3):318–23 (45

PROTEIN KINASES

ref.)
Regulation of excitatory and inhibitory neurotransmitter-gated ion channels by protein phosphorylation. Smart TG. **Curr Opin Neurobiol** 1997 Jun; 7(3):358–67 (72 ref.)
Long-term enhancement of excitability and the regulation of glutamate receptors by protein kinases. MacDonald JF, et al. **Epilepsy Res Suppl** 1996;12:275–82 (38 ref.)
Connectin/titin, giant elastic protein of muscle. Maruyama K. **FASEB J** 1997 Apr;11(5):341–5 (43 ref.)
Angiotensin II signal transduction in vascular smooth muscle cells: role of tyrosine kinases. Ishida M, et al. **Keio J Med** 1997 Jun;46(2):61–8 (86 ref.)
Analysis of two-component signal transduction systems involved in transcriptional regulation. Hakenbeck R, et al. **Methods Enzymol** 1996;273:281–300 (96 ref.)
Integrin signals and tumor growth control. Juliano RL. **Princess Takamatsu Symp** 1994;24:118–24 (33 ref.)
Regulation of lipid biosynthesis by the AMP-activated protein kinase and its role in the hepatocellular response to stress. Corton JM, et al. **Prog Liver Dis** 1996;14:69–99 (133 ref.)
[Postsynaptic density proteins related to the expression and modulation of synaptic plasticity] Suzuki T. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Apr; 16(2):53–8 (21 ref.) (Eng. Abstr.) **(Jpn)**
[Signal transduction pathways mediated by small GTPases and protein kinases] Kuroda S, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1258–64 (44 ref.) **(Jpn)**
[Roles of polo homologous kinases in cell division—diversity and conservation] Ohkura H. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1863–8 (16 ref.) **(Jpn)**
[MAP kinases and their role in regulation of protein level, subunit composition and degree of phosphorylation of transcription factor AP-1] Biedermann IW. **Postepy Biochem** 1996;42(3):244–52 (57 ref.) **(Pol)**

SECRETION

Stimulus-secretion coupling of pancreatic digestive enzyme secretion. Williams JA, et al. **Digestion** 1997;58 Suppl 1:42–5 (16 ref.)

ULTRASTRUCTURE

Microscopic analysis of the elastic properties of connectin/titin and nebulin in myofibrils. Ishiwata S, et al. **Adv Biophys** 1996;33:135–42 (23 ref.)

PROTEIN-LOSING ENTEROPATHIES

[Protein-losing gastroenteropathy] Fukuda S, et al. **Nippon Naika Gakkai Zasshi** 1996 Jul 10;85(7):1098–103 (4 ref.) **(Jpn)**

DIAGNOSIS

[Protein-losing gastroenteropathy (Ménétrier's disease) in childhood: a report of 3 cases] Ricci S, et al. **Pediatr Med Chir** 1996 May-Jun;18(3):269–73 (17 ref.) (Eng. Abstr.) **(Ita)**
[Absorption and leakage test for diagnosis of malabsorption syndrome or protein-losing enteropathy] Masamune O. **Nippon Naika Gakkai Zasshi** 1996 Jul 10;85(7):1048–53 (5 ref.) **(Jpn)**
[Image diagnosis of malabsorption syndrome or protein-losing enteropathy] Yao T. **Nippon Naika Gakkai Zasshi** 1996 Jul 10;85(7):1054–60 (5 ref.) **(Jpn)**
[Alpha 1-antitrypsin clearance] Nagayama R, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:120–2 (9 ref.) **(Jpn)**
[Gordon test] Sato T. **Nippon Rinsho** 1997 Apr;55 Suppl 2:117–9 (4 ref.) **(Jpn)**

ETIOLOGY

[Case of systemic lupus erythematosus with protein-losing gastroenteropathy] Matsumura M, et al. **Nippon Naika Gakkai Zasshi** 1996 Jul 10;85(7):1150–3 (8 ref.) **(Jpn)**

THERAPY

[Enteral nutrition therapy of malabsorption syndrome or protein-losing enteropathy] Matsueda K. **Nippon Naika Gakkai Zasshi** 1996 Jul 10;85(7):1085–97 (7 ref.) **(Jpn)**

PROTEIN-LYSINE 6-OXIDASE

METABOLISM

Newer findings on a unified perspective of copper restriction and cardiomyopathy. Medeiros DM, et al. **Proc Soc Exp Biol Med** 1997 Sep;215(4):299–313 (156 ref.)

PROTEIN P34CDC2

GENETICS

A quantitative model for the cdc2 control of S phase and mitosis in fission yeast. Stern B, et al. **Trends Genet** 1996 Sep;12(9):345–50 (36 ref.)

PROTEIN P53

The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Bristow RG, et al. **Radiother Oncol** 1996 Sep;40(3):197–223 (297 ref.)

ANALYSIS

Suppressor protein p53 and its occurrence in oral tumours. Slootweg PJ. **Curr Top Pathol** 1996;90:179–200 (119 ref.)

BIOSYNTHESIS

Time for integration of predictive factors for selection of breast cancer patients who need postoperative radiation therapy? [editorial; comment] Bergh J. **J Natl Cancer Inst** 1997 May 7;89(9):605–7 (31 ref.) Comment on: J Natl Cancer Inst 1997 May 7;89(9):639–45.
p53, proliferating cell nuclear antigen, and Ki-67 expression in extrauterine leiomyosarcomas. O'Reilly PE, et al. **Mod Pathol** 1997 Feb;10(2):91–7 (28 ref.)

BLOOD

Biomarkers of gene expression: growth factors and oncoproteins. Brandt-Rauf PW. **Environ Health Perspect** 1997 Jun;105 Suppl 4:807–16 (125 ref.)

CHEMISTRY

[p53] Takahashi R. **Gan To Kagaku Ryoho** 1997 Sep; 24(11):1381–5 (23 ref.) (Eng. Abstr.) **(Jpn)**

DEFICIENCY

The role of p53 loss in genomic instability and tumor progression in a murine mammary cancer model. Donehower LA, et al. **Prog Clin Biol Res** 1996;395:1–11 (19 ref.)

GENETICS

Role of p53 in apoptosis. Canman CE, et al. **Adv Pharmacol** 1997;41:429–60 (241 ref.)
Wild-type p53 gene transfer: a novel therapeutic strategy for neointimal hyperplasia after arterial injury. Yonemitsu Y, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:395–400 (13 ref.)
Looking at p53: theoretical implications and methodological aspects. Opalka B, et al. **Arch Toxicol Suppl** 1997;19:17–28 (35 ref.)
Li-Fraumeni syndrome—a molecular and clinical review. Varley JM, et al. **Br J Cancer** 1997;76(1):1–14 (160 ref.)
p53, the cellular gatekeeper for growth and division. Levine AJ. **Cell** 1997 Feb 7;88(3):323–31 (55 ref.)
Lonely no more: p53 finds its kin in a tumor suppressor haven. Oren M. **Cell** 1997 Sep 5;90(5):829–32 (13 ref.)
Double indemnity: p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in Brca1 and Brca2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair [news] Brugarolas J, et al. **Nat Med** 1997 Jul;3(7):721–2 (24 ref.)
The role of p53 in cell cycle regulation. Shaw PH. **Pathol Res Pract** 1996 Jul;192(7):669–75 (75 ref.)
p16: at last a tumor suppressor gene involved in childhood acute lymphoblastic leukemias! [editorial] Leblanc T. **Pediatr Hematol Oncol** 1997 Mar-Apr;14(2):iii–viii (15 ref.)
The molecular epidemiology of p53 gene mutations in human breast cancer. Hartmann A, et al. **Trends Genet** 1997 Jan; 13(1):27–33 (79 ref.)
[Tumor suppressor gene p53—function and significance in gastroenterology] Schoppmeyer K, et al. **Z Gastroenterol** 1997 Jun;35(6):491–509 (153 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Oncogene products represent potential targets of tumor vaccines. Tuttle TM. **Cancer Immunol Immunother** 1996 Nov;43(3):135–41 (62 ref.)
p53 as a target for anti-cancer immunotherapy. Chen HL, et al. **Mol Med Today** 1997 Apr;3(4):160–7 (48 ref.)
[P53 antibodies: a new method for the analysis of alterations of the p53 gene: application to breast cancer (editorial)] Soussi T, et al. **Pathol Biol (Paris)** 1996 Apr;44(4):232–4 (13 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

The role of p53 as a transcription factor in the induction of apoptosis. Yonish-Rouach E, et al. **Behring Inst Mitt** 1996 Oct;(97):60–71 (104 ref.)
Multi-site phosphorylation of p53 by protein kinases inducible by p53 and DNA damage. Meek DW, et al. **Biochem Soc Trans** 1997 May;25(2):416–9 (21 ref.)
Mechanisms of carcinogenesis and the mutant mouse. Williams BO, et al. **Curr Opin Genet Dev** 1996 Feb; 6(1):65–70 (71 ref.)
p53 and CD44 as clinical markers of tumour progression in colorectal carcinogenesis. Mulder JW, et al. **Histochem J** 1997 Jun;29(6):439–52 (163 ref.)
Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Manne U, et al. **Int J Cancer** 1997 Jun 20;74(3):346–58 (75 ref.)
Regulation of p53 by protein kinase C during multi-stage carcinogenesis [editorial] Magnelli L, et al. **J Cancer Res Clin Oncol** 1997;123(7):365–9 (48 ref.)
Binding of MAR-DNA elements by mutant p53: possible implications for its oncogenic functions. Deppert W. **J Cell Biochem** 1996 Aug;62(2):172–80 (42 ref.)
p53 Phosphorylation: biochemical and functional consequences. Milczarek GJ, et al. **Life Sci** 1997;60(1):1–11 (76 ref.)
[p53 mutation does not determine prognosis in non-Hodgkin's lymphoma] Osada M, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(4):471–5 (25 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

The role of p53 in cell cycle regulation. Shaw PH. **Pathol Res Pract** 1996 Jul;192(7):669–75 (75 ref.)

PHYSIOLOGY

p53 and ATM: cell cycle, cell death, and cancer. Morgan SE, et al. **Adv Cancer Res** 1997;71:1–25 (190 ref.)
The dual role of mutant p53 protein in chemosensitivity of human cancers. Mueller H, et al. **Anticancer Res** 1996 Nov-Dec;16(6B):3845–8 (25 ref.)
Involvement of p53 in cell differentiation and development. Almog N, et al. **Biochim Biophys Acta** 1997 Aug 8; 1333(1):F1–27 (203 ref.)
TP53 tumour suppressor gene: clues to molecular carcinogenesis and cancer therapy. Wang XW, et al. **Cancer Surv** 1996;28:169–96 (231 ref.)
Tumor suppressors: a developing role for p53? Hall PA, et al. **Curr Biol** 1997 Mar 1;7(3):R144–7 (23 ref.)
A new twist to the tale? Apoptosis. Warbrick E. **Curr Biol** 1996 Sep 1;6(9):1057–9 (10 ref.)
p53; from inductive signal to cellular effect. Hansen R, et al. **Curr Opin Genet Dev** 1997 Feb;7(1):46–51 (72 ref.)
Proliferative lifespan checkpoints: cell-type specificity and influence on tumour biology. Wynford-Thomas D. **Eur J Cancer** 1997 Apr;33(5):716–26 (87 ref.)
The p53 tumour suppressor gene: a mediator of a G1 growth arrest and of apoptosis. Yonish-Rouach E. **Experientia** 1996 Oct 31;52(10–11):1001–7 (116 ref.)
Strange bedfellows in even stranger places: the role of ATM in meiotic cells, lymphocytes, tumors, and its functional links to p53 [comment] Hawley RS, et al. **Genes Dev** 1996 Oct 1;10(19):2383–8 (49 ref.) Comment on: Genes Dev 1996 Oct 1;10(19):2423–37. Comment on: Genes Dev 1996 Oct 1;10(19):2401–10. Comment on: Genes Dev 1996 Oct 1;10(19):2411–22.
p53-dependent repression of cdk4 synthesis in transforming growth factor-beta-induced G1 cell cycle arrest. Ewen ME. **J Lab Clin Med** 1996 Oct;128(4):355–60 (13 ref.)
How phosphorylation regulates the activity of p53. Steegenga WT, et al. **J Mol Biol** 1996 Oct 25;263(2):103–13 (97 ref.)
p53: guardian of cellular senescence. Wynford-Thomas D. **J Pathol** 1996 Oct;180(2):118–21 (40 ref.)
Mdm2: keeping p53 under control. Piette J, et al. **Oncogene** 1997 Aug 28;15(9):1001–10 (111 ref.)
Telomeres, p53 and cellular senescence. Wynford-Thomas D. **Oncol Res** 1996;8(10–11):387–98 (95 ref.)
p53 and tumour viruses: catching the guardian off-guard. Neil JC, et al. **Trends Microbiol** 1997 Mar;5(3):115–20 (69 ref.)
Pathways of p53-dependent apoptosis. Grasso L, et al. **Vitam Horm** 1997;53:139–73 (210 ref.)
[p53] Takahashi R. **Gan To Kagaku Ryoho** 1997 Sep; 24(11):1381–5 (23 ref.) (Eng. Abstr.) **(Jpn)**

PROTEIN PHOSPHATASES see **PHOSPHOPROTEIN PHOSPHATASE**

PROTEIN PRECURSORS

see related
ENZYME PRECURSORS

[Precursor targeting to mitochondria] Mihara K. **Seikagaku** 1996 Oct;68(10):1605–14 (22 ref.) **(Jpn)**

ANALYSIS

Distribution of GLP-1 and PACAP receptors in human tissues. Wei Y, et al. **Acta Physiol Scand** 1996 Jul; 157(3):355–7 (7 ref.)

BIOSYNTHESIS

Synthesis and biochemical characterization of proglucagon-related peptides. Yanaihara N, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:20–9; discussion 29–30 (31 ref.)
Regulation of preproenkephalin expression in astrocytes: is there a role for glia-derived opioid peptides in reactive gliosis? McMillian MK, et al. **Crit Rev Neurobiol** 1994; 9(1):91–103 (109 ref.)

BLOOD

Plasma cholecystokinin and its precursors in hepatic cirrhosis. Paloheimo LI, et al. **J Hepatol** 1997 Aug;27(2):299–305 (36 ref.)

CHEMISTRY

Propeptide-mediated folding in subtilisin: the intramolecular chaperone concept. Shinde U, et al. **Adv Exp Med Biol**

1996;379:147–54 (35 ref.)
Synthesis and biochemical characterization of proglucagon-related peptides. Yanaihara N, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:20–9; discussion 29–30 (31 ref.)

GENETICS

Glucagon and GLP-1 receptors: lessons from chimeric ligands and receptors. Hjorth SA, et al. **Acta Physiol Scand** 1996 Jul;157(3):343–5 (12 ref.)
The molecular biology of preprotachykinin-A gene expression. Fiskerstrand C, et al. **Neuropeptides** 1996 Dec; 30(6):602–10 (59 ref.)
Mechanisms regulating proenkephalin gene expression: contributions of transgenic models. Hyman SE, et al. **NIDA Res Monogr** 1996;161:59–71 (40 ref.)

IMMUNOLOGY

Paneth cell defensins: endogenous peptide components of intestinal host defense. Ouellette AJ, et al. **FASEB J** 1996 Sep;10(11):1280–9 (58 ref.)
Safety and immunogenicity of recombinant human immunodeficiency virus-like particles in rodents and rhesus macaques. Wagner R, et al. **Intervirology** 1996; 39(1–2):93–103 (76 ref.)

METABOLISM

Glucagon and GLP-1 receptors: lessons from chimeric ligands and receptors. Hjorth SA, et al. **Acta Physiol Scand** 1996 Jul;157(3):343–5 (12 ref.)
On the road to translocase. Wickner W, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:285–90 (59 ref.)
The Tom and Tim machine. Pfanner N, et al. **Curr Biol** 1997 Feb 1;7(2):R100–3 (23 ref.)
Intracellular trafficking of prohormones and proneuropeptides: cell type-specific sorting and targeting. Perone MJ, et al. **Exp Physiol** 1997 Jul;82(4):609–28 (137 ref.)
The major pathways of protein translocation across membranes. Ito K. **Genes Cells** 1996 Apr;1(4):337–46 (64 ref.)
The mitochondrial protein import pathway: are precursors imported through membrane channels? Jensen RE, et al. **J Bioenerg Biomembr** 1997 Feb;29(1):3–10 (77 ref.)
Recognition and binding of mitochondrial presequences during the import of proteins into mitochondria. Roise D. **J Bioenerg Biomembr** 1997 Feb;29(1):19–27 (98 ref.)
Bidirectional feedback regulation on 17 kD tumor necrosis factor (TNF) production by 26 kD membrane-bound TNF precursor. Soma IG, et al. **J Inflamm** 1995–96;47(1–2):52–60 (9 ref.)
Protein import into plant mitochondria. Whelan J, et al. **Plant Mol Biol** 1997 Mar;33(5):771–89 (195 ref.)
Activation of human granulocyte type 1-prophospholipase A2. Rae D, et al. **Scand J Gastroenterol Suppl** 1996;219:24–7 (20 ref.)

PHARMACOLOGY

On the effects of glucagon-like peptide-1 on blood glucose regulation in normal and diabetic subjects. Holst JJ, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:729–36 (54 ref.)

PHYSIOLOGY

Molecular mechanism underlying glucagon-like peptide 1 induced calcium mobilization from internal stores in insulin-secreting beta TC3 cells. Gromada J, et al. **Acta Physiol Scand** 1996 Jul;157(3):349–51 (7 ref.)
Glucagon, glucagon-like peptide-1 and their receptors: an introduction. Holst JJ. **Acta Physiol Scand** 1996 Jul; 157(3):309–15 (65 ref.)
In vitro insulinomimetic [corrected] effects of GLP-1 in liver, muscle and fat [published erratum appears in Acta Physiol Scand 1996 Nov;158(3):297] Valverde I, et al. **Acta Physiol Scand** 1996 Jul;157(3):359–60 (11 ref.)
Central glucagon-like peptide-I in the control of feeding. Gunn I, et al. **Biochem Soc Trans** 1996 May;24(2):581–4 (22 ref.)
Human studies with glucagon-like-peptide-1: potential of the gut hormone for clinical use. Byrne MM, et al. **Diabet Med** 1996 Oct;13(10):854–60 (70 ref.)
GLP-1 in NIDDM. Holst JJ. **Diabet Med** 1996 Sep;13(9 Suppl 6):S156–60 (48 ref.)
Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes. Nauck M. **Diabet Med** 1996 Sep;13(9 Suppl 5):S39–43 (33 ref.)
Defined amino acids in the gag proteins of human immunodeficiency virus type 1 are functionally active during virus assembly. Kattenbeck B, et al. **Intervirology** 1996;39(1–2):32–9 (55 ref.)
Enterostatin—a peptide regulating fat intake. Erlanson-Albertsson C, et al. **Obes Res** 1997 Jul; 5(4):360–72 (95 ref.)
The renal paracrine peptide system—possible urologic implications of urodilatin. Meyer M, et al. **World J Urol** 1996;14(6):375–9 (49 ref.)

THERAPEUTIC USE

Human studies with glucagon-like-peptide-1: potential of the gut hormone for clinical use. Byrne MM, et al. **Diabet Med** 1996 Oct;13(10):854–60 (70 ref.)
Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes. Nauck M. **Diabet Med** 1996 Sep;13(9 Suppl 5):S39–43 (33 ref.)

PROTEIN PRENYLATION see **PROTEIN ISOPRENYLATION**

PROTEIN PROCESSING, POST-TRANSLATIONAL

The final stage of gene expression: chaperones and the regulation of protein fate. Ashkenas J, et al. **Am J Hum Genet** 1997 Aug;61(2):267–72 (39 ref.)
Endoprotease regulation of miniglucagon production. Bataille D, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:1–8; discussion 8–9 (12 ref.)
The biosynthetic processing and secretion of endogenous carboxypeptidase H in mouse pituitary cells. Mains RE, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:10–8; discussion 18–9 (51 ref.)
Do posttranslational modifications of CuZnSOD lead to sporadic amyotrophic lateral sclerosis? Bredesen DE, et al. **Ann Neurol** 1997 Aug;42(2):135–7 (25 ref.)
Post-translational modifications of lantibiotics. Kupke T, et al. **Antonie Van Leeuwenhoek** 1996 Feb;69(2):139–50 (72 ref.)
Palmitoylation: a post-translational modification that regulates signalling from G-protein coupled receptors. Morello JP, et al. **Biochem Cell Biol** 1996;74(4):449–57 (70 ref.)
Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Billingsley ML, et al. **Biochem J** 1997 May 1;323 (Pt 3):577–91 (216 ref.)
Targeting proteins to mitochondria: is there a role for mRNA localization? Lightowlers RN, et al. **Biochem Soc Trans** 1996 May;24(2):527–31 (41 ref.)
Intracellular targeting of secretory proteins in neuroendocrine cells. Shennan KI. **Biochem Soc Trans** 1996 May;24(2):535–9 (36 ref.)
Posttranslational effects of protein kinase C and insulin on red cell membrane phosphorylation and cation heteroexchange in hypertension. Semplicini A, et al. **Blood Press Suppl** 1996;1:55–8 (25 ref.)
Form and function in protein dephosphorylation [comment] Denu JM, et al. **Cell** 1996 Nov 1;87(3):361–4 (20 ref.) Comment on: Cell 1996 Nov 1;87(3):365–8.
From form to function: signaling by protein tyrosine phosphatases [see comments] Tonks NK, et al. **Cell** 1996 Nov 1;87(3):365–8 (21 ref.) Comment in: Cell 1996 Nov 1;87(3):361–4.
Post-translational processing of proopiomelanocortin in the pituitary and in the brain. Castro MG, et al. **Crit Rev Neurobiol** 1997;11(1):35–57 (175 ref.)
Sorting sweet sorting. Protein secretion. Ponnambalam S, et al. **Curr Biol** 1996 Sep 1;6(9):1076–8 (23 ref.)
Two-dimensional gel analysis of glandular keratin intermediate filament phosphorylation. Liao J, et al. **Electrophoresis** 1996 Nov;17(11):1671–6 (67 ref.)
Current challenges and future applications for protein maps and post-translational vector maps in proteome projects. Wilkins MR, et al. **Electrophoresis** 1996 May;17(5):830–8 (74 ref.)
Intracellular trafficking of prohormones and proneuropeptides: cell type-specific sorting and targeting. Perone MJ, et al. **Exp Physiol** 1997 Jul;82(4):609–28 (137 ref.)
Post-translational modifications of meningococcal pili. Identification of common substituents: glycans and alpha-glycerophosphate—a review. Virji M. **Gene** 1997 Jun 11;192(1):141–7 (42 ref.)
The major pathways of protein translocation across membranes. Ito K. **Genes Cells** 1996 Apr;1(4):337–46 (64 ref.)
Complexity in O-linked oligosaccharide biosynthesis engendered by multiple polypeptide N-acetylgalactosaminyltransferases. Marth JD. **Glycobiology** 1996 Oct;6(7):701–5 (60 ref.)
RNA polymerase II dependent genes that do not code for protein. Lakhotia SC. **Indian J Biochem Biophys** 1996 Apr; 33(2):93–102 (132 ref.)
Tyrosines 113, 128, and 145 of SLP-76 are required for optimal augmentation of NFAT promoter activity. Fang N, et al. **J Immunol** 1996 Nov 1;157(9):3769–73 (16 ref.)
The roles of the thiol:protein disulfide oxidoreductases in membrane and secretory protein synthesis within the lumen of the endoplasmic reticulum. Holtzman JL. **J Investig Med** 1997 Feb;45(2):28–34 (52 ref.)
Cell adhesion molecules and the transition from short- to long-term memory. Rose SP. **J Physiol Paris** 1996; 90(5–6):387–91 (37 ref.)
Nitric oxide-induced covalent modification of glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase. Brüne B, et al. **Methods Enzymol** 1996;269:400–7 (18 ref.)
Phosphorylation of mammalian RNA polymerase II. Dahmus ME. **Methods Enzymol** 1996;273:185–93 (19 ref.)
Biosynthesis of lipoic acid and posttranslational modification with lipoic acid in Escherichia coli. Jordan SW, et al. **Methods Enzymol** 1997;279:176–83 (19 ref.)
Protein tyrosine phosphorylation modulates microvessel permeability in frog mesentery. Adamson RH. **Microcirculation** 1996 Jun;3(2):245–7 (13 ref.)
Where does amidation take place? Martinez A, et al. **Mol Cell Endocrinol** 1996 Oct 30;123(2):113–7 (33 ref.)
Oxidative posttranslational modifications in Alzheimer disease. A possible pathogenic role in the formation of senile plaques and neurofibrillary tangles. Smith MA, et al. **Mol Chem Neuropathol** 1996 May-Aug;28(1–3):41–8 (41 ref.)
Can cysteine direct tyrosine in signal transduction for environment-oriented gene control? Nakashima I. **Nagoya J Med Sci** 1996 Mar;59(1–2):1–10 (72 ref.)
Posttranslational arginylation of brain proteins. Hallak ME, et al. **Neurochem Res** 1997 Apr;22(4):467–73 (32 ref.)
Heterogeneity of circulating growth hormone. Baumann G, et al. **Nucl Med Biol** 1994 Apr;21(3):369–79 (36 ref.)
Tyrosine kinase signalling pathways. Pawson T. **Princess Takamatsu Symp** 1994;24:303–22 (120 ref.)
Possible involvement of VEGF-FLT tyrosine kinase receptor system in normal and tumor angiogenesis. Shibuya M, et al. **Princess Takamatsu Symp** 1994;24:162–70 (23 ref.)
The chemistry and enzymology of the type I signal peptidases. Dalbey RE, et al. **Protein Sci** 1997 Jun; 6(6):1129–38 (100 ref.)
Creating conditional mutations in mammals. Spencer DM. **Trends Genet** 1996 May;12(5):181–7 (31 ref.)
[Vg1, a possible natural mesoderm inducer derived from the study of the localized maternal mRNA in the Xenopus egg cytoplasm] Shiokawa K, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(11):1594–9 (18 ref.) **(Jpn)**

GENETICS

Protein processing: a role in the pathophysiology of genetic disease. Brooks DA. **FEBS Lett** 1997 Jun 9;409(2):115–20 (50 ref.)
The mechanism and functional roles of protein palmitoylation in the nervous system. Bizzozero OA. **Neuropediatrics** 1997 Feb;28(1):23–6 (47 ref.)

PHYSIOLOGY

Regulation of cellular signalling by fatty acid acylation and prenylation of signal transduction proteins. Resh MD. **Cell Signal** 1996 Sep;8(6):403–12 (134 ref.)
Protein splicing: occurrence, mechanisms and related phenomena. Shao Y, et al. **Chem Biol** 1997 Mar;4(3):187–94 (47 ref.)

PROTEIN-RESTRICTED DIET see **DIET, PROTEIN-RESTRICTED**

PROTEIN S

GENETICS

Inherited thrombotic disorders: an update. Florell SR, et al. **Am J Hematol** 1997 Jan;54(1):53–60 (53 ref.)

PHYSIOLOGY

Factor V and protein S as cofactors to activated protein C. Dahlbäck B. **Haematologica** 1997 Jan–Feb;82(1):91–5 (46 ref.)
Protein S deficiency. Borgel D, et al. **Thromb Haemost** 1997 Jul;78(1):351–6 (93 ref.)

PROTEIN S DEFICIENCY

[Physiologie and cellular regulation of the protein C system] Vincenot A, et al. **Ann Biol Clin (Paris)** 1997 Jan–Feb; 55(1):17–24 (31 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Thrombophilia and complex acquired deficiencies of antithrombin, protein C, and protein S. Humphries JE. **Semin Hematol** 1995 Oct;32(4 Suppl 2):8–16; discussion 17–8 (16 ref.)
[Cerebral thrombophlebitis, sural phlebitis, pulmonary embolisms and protein S deficiencies] Bostroem H, et al. **Rev Neurol (Paris)** 1996 Dec;152(12):755–8 (26 ref.) (Eng. Abstr.) **(Fre)**
[Cerebral sinus thrombosis in a patient with protein S deficiency: a case report] Fujita A, et al. **No Shinkei Geka** 1997 May;25(5):467–72 (22 ref.) (Eng. Abstr.) **(Jpn)**

CONGENITAL

[Inherited thrombophilia] Jia X, et al. **Chung Hua Nei Ko Tsa Chih** 1996 Feb;35(2):133–6 (18 ref.) **(Chi)**

DIAGNOSIS

[Idiopathic portal hypertension, multiple focal nodular hepatic hyperplasia, the CREST syndrome and protein S deficiency] Sánchez Manuel J, et al. **Rev Esp Enferm Dig** 1997 Jan;89(1):55–9 (30 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Inherited thrombophilia: memorandum from a joint WHO/International Society on Thrombosis and

PROTEIN S DEFICIENCY

Haemostasis meeting. **Bull World Health Organ** 1997; 75(3):177–89 (69 ref.)
Protein C and protein S deficiencies. Aiach M, et al. **Semin Hematol** 1997 Jul;34(3):205–16 (89 ref.)

PHYSIOPATHOLOGY

Protein S deficiency. Borgel D, et al. **Thromb Haemost** 1997 Jul;78(1):351–6 (93 ref.)

PROTEIN-SERINE-THREONINE KINASES

[Interferon] Tanaka H. **Gan To Kagaku Ryoho** 1997 Sep; 24(11):1471–6 (51 ref.) (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase. Henry SP, et al. **Anticancer Drug Des** 1997 Jul;12(5):409–20 (38 ref.)
First- and second-generation antisense inhibitors targeted to human c-raf kinase: in vitro and in vivo studies. Monia BP. **Anticancer Drug Des** 1997 Jul;12(5):327–39 (46 ref.)

GENETICS

Is myotonic dystrophy a single-gene disorder? Johnson KJ, et al. **Biochem Soc Trans** 1996 May;24(2):510–3 (28 ref.)
Cyclin-dependent kinase 7: at the cross-roads of transcription, DNA repair and cell cycle control? Nigg EA. **Curr Opin Cell Biol** 1996 Jun;8(3):312–7 (50 ref.)
Identification of the catalytic subunit of DNA dependent protein kinase as the product of the mouse scid gene. Jeggo PA, et al. **Curr Top Microbiol Immunol** 1996;217:79–89 (60 ref.)
Myotonic dystrophy, knockouts, warts and all. Hamshere MG, et al. **Trends Genet** 1996 Sep;12(9):332–4 (31 ref.)

METABOLISM

Genetic dissection of signal transduction mechanisms underlying PACAP-like neuropeptide transmission in Drosophila: synergy of cAMP and Ras/Raf pathways. Zhong Y. **Ann N Y Acad Sci** 1996 Dec 26;805:67–79; discussion 79–80 (36 ref.)
The DNA-dependent protein kinase, DNA-PK: 10 years and no ends in sight. Lees-Miller SP. **Biochem Cell Biol** 1996; 74(4):503–12 (108 ref.)
Neuronal Cdc2-like kinase: from cell cycle to neuronal function. Tang D, et al. **Biochem Cell Biol** 1996; 74(4):419–29 (56 ref.)
Regulation of Raf-1 kinase by interaction with the lipid second messenger, phosphatidic acid. Ghosh S, et al. **Biochem Soc Trans** 1997 May;25(2):561–5 (19 ref.)
Protein kinase D: a novel target for diacylglycerol and phorbol esters. Rozengurt E, et al. **Biochem Soc Trans** 1997 May;25(2):565–71 (49 ref.)
Role of the double-stranded RNA-activated protein kinase (PKR) in cell regulation. Williams BR. **Biochem Soc Trans** 1997 May;25(2):509–13 (28 ref.)
The regulation of the protein kinase PKR by RNA. Robertson HD, et al. **Biochimie** 1996;78(11–12):909–14 (27 ref.)
Participation of annexins in protein phosphorylation. Rothhut B. **Cell Mol Life Sci** 1997 Jun;53(6):522–6 (51 ref.)
The Raf/MAP kinase cascade in cell cycle regulation and differentiation in Drosophila. Nishida Y, et al. **Cell Struct Funct** 1996 Oct;21(5):437–44 (40 ref.)
Nef and PAK: virulence factor and cellular accomplice. Trono D, et al. **Chem Biol** 1997 Jan;4(1):13–5 (23 ref.)
HIV-1: is Nef a PAK animal? Cullen BR. **Curr Biol** 1996 Dec 1;6(12):1557–9 (15 ref.)
The complexity of Raf-1 regulation. Morrison DK, et al. **Curr Opin Cell Biol** 1997 Apr;9(2):174–9 (62 ref.)
Cyclin dependent kinase activating kinases. Sclafani RA. **Curr Opin Cell Biol** 1996 Dec;8(6):788–94 (35 ref.)
The recognition of DNA damage. Jackson SP. **Curr Opin Genet Dev** 1996 Feb;6(1):19–25 (66 ref.)
Mitogen-activated protein kinase cascades and regulation of gene expression. Su B, et al. **Curr Opin Immunol** 1996 Jun; 8(3):402–11 (95 ref.)
The eIF-2alpha kinases and the control of protein synthesis. de Haro C, et al. **FASEB J** 1996 Oct;10(12):1378–87 (64 ref.)
PDK1, one of the missing links in insulin signal transduction? Cohen P, et al. **FEBS Lett** 1997 Jun 23;410(1):3–10 (71 ref.)
The modular phosphorylation and activation of p70s6k. Pullen N, et al. **FEBS Lett** 1997 Jun 23;410(1):78–82 (51 ref.)
Nuclear matrix as an anchor for protein kinase CK2 nuclear signalling. Tawfic S, et al. **J Cell Biochem** 1996 Aug; 62(2):165–71 (36 ref.)
Howard Temin memorial lectureship. Molecular biology of HTLV-1: deregulation of host cell gene expression and cell cycle. Yoshida M. **Leukemia** 1997 Jan;11(1):14–5 (10 ref.)
Phosphorylation of acidic peptides by protein kinase CKII. Cardellini E, et al. **Physiol Chem Phys Med NMR** 1995; 27(4):363–8 (6 ref.)
The role of Raf kinases in development and growth of tumors. Naumann U, et al. **Recent Results Cancer Res** 1997; 143:237–44 (24 ref.)
Apoptosis regulation by Raf, Bcl-2, and R-Ras. Troppmair J, et al. **Recent Results Cancer Res** 1997;143:245–9 (16 ref.)
Nef and the Nef-associated kinase. Sawai ET, et al. **Res Virol** 1997 Jan-Feb;148(1):47–52 (59 ref.)
p70 S6 kinase: an enigma with variations. Proud CG. **Trends Biochem Sci** 1996 May;21(5):181–5 (49 ref.)
[Cdc2 activation by phosphorylation] Yamashita K. **Seikagaku** 1996 May;68(5):367–71 (15 ref.) **(Jpn)**
[Regulation of cyclin E and Cdk2 expression at G1/S transition: post-transcriptional reguration mediated by delta FosB] Oda S, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1725–31 (43 ref.) **(Jpn)**

PHYSIOLOGY

Activin receptors: cellular signalling by receptor serine kinases. Zimmerman CM, et al. **Biochem Soc Symp** 1996; 62:25–38 (47 ref.)
The p70S6K signalling pathway: a novel signalling system involved in growth regulation. Grammer TC, et al. **Cancer Surv** 1996;27:271–92 (97 ref.)
DNA damage detection by DNA dependent protein kinase and related enzymes. Jackson SP. **Cancer Surv** 1996; 28:261–79 (99 ref.)
Control of the ERK MAP kinase cascade by Ras and Raf. Marais R, et al. **Cancer Surv** 1996;27:101–25 (125 ref.)
The DNA-dependent protein kinase: a matter of life and (cell) death. McConnell K, et al. **Curr Opin Cell Biol** 1996 Jun;8(3):325–30 (54 ref.)
MEKKs, GCKs, MLKs, PAKs, TAKs, and tpls: upstream regulators of the c-Jun amino-terminal kinases? Fanger GR, et al. **Curr Opin Genet Dev** 1997 Feb;7(1):67–74 (58 ref.)
Serine/threonine kinase receptors and ligands. Josso N, et al. **Curr Opin Genet Dev** 1997 Jun;7(3):371–7 (68 ref.)
Tying loose ends: roles of Ku and DNA-dependent protein kinase in the repair of double-strand breaks. Lieber MR, et al. **Curr Opin Genet Dev** 1997 Feb;7(1):99–104 (68 ref.)
The role of serine/threonine phosphorylation in hematopoietic cytokine receptor signal transduction. Mufson RA. **FASEB J** 1997 Jan;11(1):37–44 (56 ref.)
Rho effectors and reorganization of actin cytoskeleton. Narumiya S, et al. **FEBS Lett** 1997 Jun 23;410(1):68–72 (41 ref.)
The PKR protein kinase--an interferon-inducible regulator of cell growth and differentiation. Samuel CE, et al. **Int J Hematol** 1997 Apr;65(3):227–37 (89 ref.)
Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. Imahori K, et al. **J Biochem (Tokyo)** 1997 Feb;121(2):179–88 (63 ref.)
Polo kinase: the choreographer of the mitotic stage? Glover DM, et al. **J Cell Biol** 1996 Dec;135(6 Pt 2):1681–4 (28 ref.)
DNA-PK: at the cross-roads of biochemistry and genetics. Jeggo PA. **Mutat Res** 1997 Jun 9;384(1):1–14 (119 ref.)
Signaling molecules that mediate the actions of FGF. Demo SD, et al. **Princess Takamatsu Symp** 1994;24:243–9 (23 ref.)
Activins and activin receptors in cell growth. Ying SY, et al. **Proc Soc Exp Biol Med** 1997 Feb;214(2):114–22 (114 ref.)
[Execution of M-phase by Cdc2 kinase] Kishimoto T. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1839–46 (32 ref.) **(Jpn)**
[Roles of protein Ser/Thr phosphatases in regulation of neural cell functions] Kobayashi T, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):439–45 (40 ref.) **(Jpn)**
[G2 phase cell cycle control and checkpoint] Nagata A. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1833–8 (32 ref.) **(Jpn)**
[How different is the meiotic cell cycle control from the mitotic one?] Shimoda C. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1856–62 (49 ref.) **(Jpn)**

PROTEIN SPLICING

Protein splicing: occurrence, mechanisms and related phenomena. Shao Y, et al. **Chem Biol** 1997 Mar;4(3):187–94 (47 ref.)
Protein splicing: its chemistry and biology. Anraku Y. **Genes Cells** 1997 Jun;2(6):359–67 (47 ref.)

PROTEIN STRUCTURE, PRIMARY see **AMINO ACID SEQUENCE**

PROTEIN STRUCTURE, QUATERNARY see **PROTEIN CONFORMATION**

PROTEIN STRUCTURE, SECONDARY

Nucleotide probes of DNA polymerases. Wright GE. **Acta Biochim Pol** 1996;43(1):115–24 (30 ref.)
Supramolecular assembly using helical peptides. Fujita K, et al. **Adv Biophys** 1997;34:127–37 (20 ref.)
The roles of tryptophan residues in the structure, function, and folding of the gramicidin transmembrane ion channel. Wallace BA. **Adv Exp Med Biol** 1996;398:607–14 (29 ref.)
The potassium pore and its regulation. Brown AM, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:74–80 (23 ref.)
Structure and modulation of Na+ and Ca2+ channels. Catterall WA. **Ann N Y Acad Sci** 1993 Dec 20;707:1–19 (79 ref.)
Structural perspectives of phospholamban, a helical transmembrane pentamer. Arkin IT, et al. **Annu Rev Biophys Biomol Struct** 1997;26:157–79 (76 ref.)
Protein folds in the all-beta and all-alpha classes. Chothia C, et al. **Annu Rev Biophys Biomol Struct** 1997;26:597–627 (103 ref.)
G protein beta gamma subunits. Clapham DE, et al. **Annu Rev Pharmacol Toxicol** 1997;37:167–203 (231 ref.)
Insights into protein folding from NMR. Dyson HJ, et al. **Annu Rev Phys Chem** 1996;47:369–95 (144 ref.)
Interferons alpha/beta and their receptors: place in the hierarchy of cytokines. Zav'Yalov VP, et al. **APMIS** 1997 Mar;105(3):161–86 (220 ref.)
Boehringer Mannheim award lecture 1995. La conference Boehringer Mannheim 1995. De novo design of alpha-helical proteins: basic research to medical applications. Hodges RS. **Biochem Cell Biol** 1996; 74(2):133–54 (127 ref.)
DNA glycosylases in the base excision repair of DNA. Krokan HE, et al. **Biochem J** 1997 Jul 1;325 (Pt 1):1–16 (232 ref.)
Structure-based design of peptides that inhibit IgE binding to its high-affinity receptor Fc epsilon RI. McDonnell JM, et al. **Biochem Soc Trans** 1997 May;25(2):387–92 (34 ref.)
Perspectives on the synthesis and application of triple-helical, collagen-model peptides. Fields GB, et al. **Biopolymers** 1996;40(4):345–57 (70 ref.)
Signal transduction: clamping down on Src activity. Mayer BJ. **Curr Biol** 1997 May 1;7(5):R295–8 (13 ref.)
DNA-protein interactions: IHF--the master bender. Travers A. **Curr Biol** 1997 Apr 1;7(4):R252–4 (27 ref.)
Structural aspects of heterotrimeric G-protein signaling. Bohm A, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):480–7 (52 ref.)
Therapeutic peptides and peptidomimetics. Kieber-Emmons T, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):435–41 (56 ref.)
Peptide secondary structure mimetics: applications to vaccines and pharmaceuticals. Qabar M, et al. **Farmaco** 1996 Feb;51(2):87–96 (77 ref.)
DNA recognition and structural specificities. Roy KB. **Indian J Biochem Biophys** 1996 Apr;33(2):83–7 (26 ref.)
Alpha-helical protein assembly motifs. Kohn WD, et al. **J Biol Chem** 1997 Jan 31;272(5):2583–6 (121 ref.)
Kinesin and NCD, two structural cousins of myosin. Sellers JR. **J Muscle Res Cell Motil** 1996 Apr;17(2):173–5 (23 ref.)
The collagen triple-helix structure. Brodsky B, et al. **Matrix Biol** 1997 Mar;15(8–9):545–54 (53 ref.)
Alpha-helical coiled-coil oligomerization domains in extracellular proteins. Kammerer RA. **Matrix Biol** 1997 Mar;15(8–9):555–65; discussion 567–8 (67 ref.)
Structural and functional aspects of calcium binding in extracellular matrix proteins. Maurer P, et al. **Matrix Biol** 1997 Mar;15(8–9):569–80; discussion 581 (93 ref.)
Structure and function of fibronectin modules. Potts JR, et al. **Matrix Biol** 1996 Nov;15(5):313–20; discussion 321 (50 ref.)
A case history. NMR studies of the structure of a small protein, omega-conotoxin MVIIA. MacLachlan LK, et al. **Methods Mol Biol** 1997;60:337–62 (38 ref.)
Protein chemical shifts. Williamson MP, et al. **Methods Mol Biol** 1997;60:53–69 (25 ref.)
Adenylyl cyclases: structure, regulation and function in an enzyme superfamily. Hanoune J, et al. **Mol Cell Endocrinol** 1997 Apr 4;128(1–2):179–94 (113 ref.)
Common fold, common function, common origin? [news] Suck D. **Nat Struct Biol** 1997 Mar;4(3):161–5 (39 ref.)
Structure and function of Escherichia coli met repressor: similarities and contrasts with trp repressor. Phillips SE, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Apr 29; 351(1339):527–35 (42 ref.)
Allosteric regulation of muscarinic receptors. Birdsall NJ, et al. **Prog Brain Res** 1996;109:147–51 (17 ref.)
Molecular aspects of muscarinic receptor assembly and function. Wess J, et al. **Prog Brain Res** 1996;109:153–62 (45 ref.)
Hydrogen exchange: the modern legacy of Linderstrøm-Lang. Englander SW, et al. **Protein Sci** 1997 May;6(5):1101–9 (88 ref.)
Interleukin-6: structure-function relationships. Simpson RJ, et al. **Protein Sci** 1997 May;6(5):929–55 (338 ref.)
Protein conformation and disease. Nandi PK. **Vet Res** 1996; 27(4–5):373–82 (61 ref.)

PROTEIN STRUCTURE, TERTIARY

Novel members of mammalian kexin family proteases, pace 4C, pace 4D, PC 7A and PC 7B. Matsuda Y, et al. **Adv Exp Med Biol** 1996;389:63–71 (15 ref.)
Structure-function relationships of the PEA3 group of Ets-related transcription factors. de Launoit Y, et al. **Biochem Mol Med** 1997 Aug;61(2):127–35 (47 ref.)
Influence of tertiary structure on nucleophilic substitution reactions of proteins. Skipper PL. **Chem Res Toxicol** 1996 Sep;9(6):918–23 (45 ref.)
On the potential significance of the enzymatic activity of mite allergens to immunogenicity. Clues to structure and function revealed by molecular characterization. Robinson C, et al. **Clin Exp Allergy** 1997 Jan;27(1):10–21 (58 ref.)
Folding studies on ribonuclease A, a model protein. Neira JL, et al. **Fold Des** 1997;2(1):R1–11 (70 ref.)

Factor VIIa-tissue factor interactions: an evaluation using factor VII-factor IX chimeras. Chang JY. **Haemostasis** 1996;26 Suppl 1:35-9 (22 ref.)
Domain organization and sequence relationship of killer cell inhibitory receptors. Salter RD, et al. **Immunol Rev** 1997 Feb;155:175-82 (39 ref.)
Mechanism of action of platelet-derived growth factor. Claesson-Welsh L. **Int J Biochem Cell Biol** 1996 Apr; 28(4):373-85 (78 ref.)
Domains of laminin. Engvall E, et al. **J Cell Biochem** 1996 Jun 15;61(4):493-501 (51 ref.)
Conservation of structural features reveals the existence of a large family of inhibitory cell surface receptors and noninhibitory/activatory counterparts. Vély F, et al. **J Immunol** 1997 Sep 1;159(5):2075-7 (27 ref.)
Ectodomain interactions of leukocyte integrins and pro-inflammatory GPI-linked membrane proteins. Petty HR, et al. **J Pharm Biomed Anal** 1997 Jun;15(9-10):1405-16 (94 ref.)
A case history. NMR studies of the structure of a small protein, omega-conotoxin MVIIA. MacLachlan LK, et al. **Methods Mol Biol** 1997;60:337-62 (38 ref.)
Protein chemical shifts. Williamson MP, et al. **Methods Mol Biol** 1997;60:53-69 (25 ref.)
Activating mechanism of CNTF and related cytokines. Inoue M, et al. **Mol Neurobiol** 1996 Jun;12(3):195-209 (128 ref.)
Discrete structural domains and cell-specific expression determine functional selectivity of the dopamine and norepinephrine transporters. Buck KJ, et al. **NIDA Res Monogr** 1996;161:154-75 (30 ref.)
Second generation, B-domain deleted recombinant factor VIII. Berntorp E. **Thromb Haemost** 1997 Jul;78(1):256-60 (33 ref.)
Factor VIIa-tissue factor: functional importance of protein-membrane interactions. Morrissey JH, et al. **Thromb Haemost** 1997 Jul;78(1):112-6 (47 ref.)
The aconitase family: three structural variations on a common theme. Gruer MJ, et al. **Trends Biochem Sci** 1997 Jan; 22(1):3-6 (20 ref.)
Cn3D: a new generation of three-dimensional molecular structure viewer. Hogue CW. **Trends Biochem Sci** 1997 Aug;22(8):314-6 (9 ref.)
Structural and mechanistic relationships between nucleic acid polymerases. Sousa R. **Trends Biochem Sci** 1996 May; 21(5):186-90 (51 ref.)
[Androgen receptor gene structure and protein function. Gene structural defects that promote androgen resistance in men] Pino AM. **Rev Med Chil** 1996 Sep;124(9):1127-36 (32 ref.) (Eng. Abstr.) **(Spa)**

PROTEIN SYNTHESIS ANTAGONISTS see **PROTEIN SYNTHESIS INHIBITORS**

PROTEIN SYNTHESIS INHIBITORS

PHARMACOLOGY

A hypothesis to explain why translation inhibitors stabilize mRNAs in mammalian cells: mRNA stability and mitosis. Ross J. **Bioessays** 1997 Jun;19(6):527-9 (18 ref.)
Brefeldin A effects in plant and fungal cells: something new about vesicle trafficking? Satiat-Jeunemaitre B, et al. **J Microsc** 1996 Feb;181 (Pt 2):162-77 (75 ref.)
[Protein synthesis inhibitor--antitumor activity and mode of action of KRN 5500] Kawai H. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1571-7 (20 ref.) (Eng. Abstr.) **(Jpn)**

PROTEIN TP53 see **PROTEIN P53**

PROTEIN-TYROSINE KINASE

see related
ONCOGENE PROTEIN PP60(V-SRC)
SRC HOMOLOGY DOMAINS

Coupling of the IL2 receptor complex with non-receptor protein tyrosine kinases. Miyazaki T, et al. **Cancer Surv** 1996;27:25-40 (72 ref.)
Cytoplasmic signalling domains: the next generation. Bork P, et al. **Trends Biochem Sci** 1997 Aug;22(8):296-8 (20 ref.)

ANALYSIS

Tyrosine protein kinase assays. Boutin JA. **J Chromatogr B Biomed Appl** 1996 Sep 20;684(1-2):179-99 (160 ref.)

ANTAGONISTS & INHIBITORS

Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Kelloff GJ, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Aug;5(8):657-66 (108 ref.)
Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R. Traxler P, et al. **J Pharm Belg** 1997 Mar-Apr; 52(2):88-96 (26 ref.)
[Recent advances in development of antitumor tyrosine kinase inhibitors] Uehara Y. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1536-40 (12 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

Non-receptor protein tyrosine kinases and phosphatases in human platelets. Jackson SP, et al. **Thromb Haemost** 1996 Nov;76(5):640-50 (151 ref.)

CHEMISTRY

Modular peptide recognition domains in eukaryotic signaling. Kuriyan J, et al. **Annu Rev Biophys Biomol Struct** 1997; 26:259-88 (102 ref.)
Much more than the sum of the parts: structures of the dual SH2 domains of ZAP-70 and Syp. Cowburn D. **Chem Biol** 1996 Feb;3(2):79-82 (18 ref.)

DEFICIENCY

Immunodeficiencies caused by genetic defects in protein kinases. Notarangelo LD. **Curr Opin Immunol** 1996 Aug; 8(4):448-53 (56 ref.)

GENETICS

Genetic analysis of tyrosine kinase function in B cell development. Satterthwaite A, et al. **Annu Rev Immunol** 1996;14:131-54 (167 ref.)
X-linked agammaglobulinemia (XLA): a genetic tyrosine kinase (Btk) disease. Mattsson PT, et al. **Bioessays** 1996 Oct;18(10):825-34 (84 ref.)
Xid and Xid-like immunodeficiencies from a signaling point of view. Tarakhovsky A. **Curr Opin Immunol** 1997 Jun; 9(3):319-23 (50 ref.)
The JAK-STAT pathway in Drosophila. Hou XS, et al. **Trends Genet** 1997 Mar;13(3):105-10 (34 ref.)

IMMUNOLOGY

ITIMs and ITAMs. The Yin and Yang of antigen and Fc receptor-linked signaling machinery. Isakov N. **Immunol Res** 1997 Feb;16(1):85-100 (112 ref.)

METABOLISM

Tyrosine kinase activation by PAF leads to downstream gene expression. Shukla SD. **Adv Exp Med Biol** 1996;416:153-5 (11 ref.)
Sphingolipid-dependent protein kinases. Hakomori S. **Adv Pharmacol** 1996;36:155-71 (33 ref.)
Leukocyte protein tyrosine kinases: potential targets for drug discovery. Bolen JB, et al. **Annu Rev Immunol** 1997; 15:371-404 (222 ref.)
The identification of Bruton's tyrosine kinase and Wiskott-Aldrich syndrome protein associated proteins and signalling pathways. Kinnon C, et al. **Biochem Soc Trans** 1997 May;25(2):648-50 (27 ref.)
Inhibition of protein tyrosine phosphorylation in endothelial cells: relationship to antiproliferative action of genistein. Koroma BM, et al. **Biochem Soc Trans** 1997 Feb; 25(1):35-40 (37 ref.)
Participation of annexins in protein phosphorylation. Rothhut B. **Cell Mol Life Sci** 1997 Jun;53(6):522-6 (51 ref.)
Signal transduction from the extracellular matrix--a role for the focal adhesion protein-tyrosine kinase FAK. Schlaepfer DD, et al. **Cell Struct Funct** 1996 Oct;21(5):445-50 (90 ref.)
Intracellular signalling: putting JAKs on the kinase MAP. Winston LA, et al. **Curr Biol** 1996 Jun 1;6(6):668-71 (25 ref.)
Roles of the JAK-STAT system in signal transduction via cytokine receptors. Watanabe S, et al. **Curr Opin Genet Dev** 1996 Oct;6(5):587-96 (54 ref.)
Redox modulation of tyrosine phosphorylation-dependent signal transduction pathways. Monteiro HP, et al. **Free Radic Biol Med** 1996;21(3):323-33 (106 ref.)
A coiled-coil tetramerization domain of BCR-ABL is essential for the interactions of SH2-containing signal transduction molecules. Tauchi T, et al. **Hum Cell** 1996 Dec;9(4):333-6 (18 ref.)
Non-receptor protein tyrosine kinases as immune targets of viruses. Collette Y, et al. **Immunol Today** 1997 Aug; 18(8):393-400 (86 ref.)
Focal adhesion kinase: at the crossroads of signal transduction. Ilić D, et al. **J Cell Sci** 1997 Feb;110 (Pt 4):401-7 (72 ref.)
Tyrosines 113, 128, and 145 of SLP-76 are required for optimal augmentation of NFAT promoter activity. Fang N, et al. **J Immunol** 1996 Nov 1;157(9):3769-73 (16 ref.)
The role of tyrosine phosphorylation in angiotensin II mediated intracellular signaling and cell growth. Schieffer B, et al. **J Mol Med** 1996 Feb;74(2):85-91 (57 ref.)
Protein tyrosine phosphorylation in smooth muscle: a potential coupling mechanism between receptor activation and intracellular calcium. Di Salvo J, et al. **Proc Soc Exp Biol Med** 1997 Apr;214(4):285-301 (97 ref.)
The JAK-STAT pathway in Drosophila. Hou XS, et al. **Trends Genet** 1997 Mar;13(3):105-10 (34 ref.)

PHARMACOLOGY

Role of Bcr-Abl kinase in resistance to apoptosis. Samali A, et al. **Adv Pharmacol** 1997;41:533-52 (124 ref.)
Regulation of antigen receptor signal transduction by protein tyrosine kinases. Chan AC, et al. **Curr Opin Immunol** 1996 Jun;8(3):394-401 (61 ref.)

PHYSIOLOGY

The role of Ets transcription factors in the development and function of the mammalian immune system. Bassuk AG, et al. **Adv Immunol** 1997;64:65-104 (273 ref.)
Genetic analysis of tyrosine kinase function in B cell development. Satterthwaite A, et al. **Annu Rev Immunol** 1996;14:131-54 (167 ref.)
Cytokine receptor signal transduction through Jak tyrosine kinases and Stat transcription factors. Silvennoinen O, et al. **APMIS** 1997 Jul;105(7):497-509 (67 ref.)
Signaling through focal adhesion kinase. Hanks SK, et al. **Bioessays** 1997 Feb;19(2):137-45 (70 ref.)
The JAK/STAT pathway. Wilks AF, et al. **Cancer Surv** 1996;27:139-63 (113 ref.)
Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases. Berk BC, et al. **Circ Res** 1997 May; 80(5):607-16 (19 ref.)
Eph receptor tyrosine kinases and their ligands in neural development. Friedman GC, et al. **Curr Opin Neurobiol** 1996 Feb;6(1):127-33 (72 ref.)
Role of protein kinase activity in apoptosis. Lavin MF, et al. **Experientia** 1996 Oct 31;52(10-11):979-94 (246 ref.)
Vertebrate non-receptor protein-tyrosine kinase families. Neet K, et al. **Genes Cells** 1996 Feb;1(2):147-69 (130 ref.)
Growth hormone signalling mechanisms: involvement of the tyrosine kinase JAK2. Argetsinger LS, et al. **Horm Res** 1996;45 Suppl 1:22-4 (19 ref.)
Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet? O'Shea JJ. **Immunity** 1997 Jul;7(1):1-11 (126 ref.)
Roles of JAK kinases in human GM-CSF receptor signal transduction. Watanabe S, et al. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 2):S183-91 (26 ref.)
Regulation of connexin43 function by activated tyrosine protein kinases. Lau AF, et al. **J Bioenerg Biomembr** 1996 Aug;28(4):359-68 (47 ref.)
Disruption of cytokine signaling in lymphoid development: unique contributions of the common cytokine gamma chain and the Jak3 kinase. Eynon EE, et al. **J Interferon Cytokine Res** 1996 Sep;16(9):677-84 (32 ref.)
Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency. Johnston JA, et al. **J Leukoc Biol** 1996 Oct;60(4):441-52 (153 ref.)
Selective neural cell adhesion molecule signaling by Src family tyrosine kinases and tyrosine phosphatases. Maness PF, et al. **Perspect Dev Neurobiol** 1996;4(2-3):169-81 (169 ref.)
Non-receptor tyrosine kinases in mammalian neurogenesis. Aizawa S, et al. **Princess Takamatsu Symp** 1994;24:323-37 (67 ref.)
Tyrosine kinase signalling pathways. Pawson T. **Princess Takamatsu Symp** 1994;24:303-22 (120 ref.)
Signaling through the focal adhesion kinase. Schaller MD. **Soc Gen Physiol Ser** 1997;52:241-55 (106 ref.)
[Roles of protein tyrosine kinases in activation, proliferation and apoptosis of immuno-hematopoietic cells] Minami Y, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1666-72 (25 ref.) **(Jpn)**
[The functions of tyrosine kinases in the neuronal tissues] Takayama Y, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb; 42(3 Suppl):431-8 (44 ref.) **(Jpn)**

PROTEIN-TYROSINE-PHOSPHATASE

Protein tyrosine phosphatase-like proteins: link with IDDM. Pietropaolo M, et al. **Diabetes Care** 1997 Feb;20(2):208-14 (42 ref.)
Structural, catalytic, and functional properties of low M(r), phosphotyrosine protein phosphatases. Evidence of a long evolutionary history. Ramponi G, et al. **Int J Biochem Cell Biol** 1997 Feb;29(2):279-92 (90 ref.)
[Protein tyrosine phosphatases in the neural system] Mizuno K, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):446-52 (35 ref.) **(Jpn)**

CHEMISTRY

Much more than the sum of the parts: structures of the dual SH2 domains of ZAP-70 and Syp. Cowburn D. **Chem Biol** 1996 Feb;3(2):79-82 (18 ref.)
Protein phosphatases. Barford D. **Curr Opin Struct Biol** 1995 Dec;5(6):728-34 (64 ref.)
Structure, mechanism, and specificity of protein-tyrosine phosphatases. Zhang ZY. **Curr Top Cell Regul** 1997; 35:21-68 (157 ref.)
Structure and function of the protein tyrosine phosphatases. Fauman EB, et al. **Trends Biochem Sci** 1996 Nov; 21(11):413-7 (48 ref.)

IMMUNOLOGY

Role of phosphatases in lymphocyte activation. Neel BG. **Curr Opin Immunol** 1997 Jun;9(3):405-20 (124 ref.)
Inhibitory receptors, ITIM sequences and phosphatases. Unkeless JC, et al. **Curr Opin Immunol** 1997 Jun;9(3):338-43 (42 ref.)
Regulation of cell signaling by the protein tyrosine phosphatases, CD45 and SHP-1. Ulyanova T, et al. **Immunol Res** 1997 Feb;16(1):101-13 (117 ref.)
Protein tyrosine phosphatases in T-cell development, apoptosis and signalling. Frearson JA, et al. **Immunol Today** 1996 Aug;17(8):385-91 (57 ref.)

METABOLISM

Tyrosine phosphatases in T-cell development and signalling. Conroy LA, et al. **Biochem Soc Trans** 1997 May;

25(2):445-51 (41 ref.)
The role of phosphotyrosine phosphatases in haematopoietic cell signal transduction. Frearson JA, et al. **Bioessays** 1997 May;19(5):417-27 (85 ref.)
Suppression of insulin receptor activation by overexpression of the protein-tyrosine phosphatase LAR in hepatoma cells. Li PM, et al. **Cell Signal** 1996 Nov;8(7):467-73 (35 ref.)
Protein tyrosine phosphatases in the nervous system. Naegele JR, et al. **Crit Rev Neurobiol** 1994;9(1):105-14 (97 ref.)
Cell-cell signaling: The ins and outs of receptor tyrosine phosphatases. Fashena SJ, et al. **Curr Biol** 1995 Dec 1; 5(12):1367-9 (21 ref.)
Axon guidance: motor-way madness. Stoker AW. **Curr Biol** 1996 Jul 1;6(7):794-7 (17 ref.)
Structure, mechanism, and specificity of protein-tyrosine phosphatases. Zhang ZY. **Curr Top Cell Regul** 1997; 35:21-68 (157 ref.)
Role of PI 3-kinase and SH-PTP2 in insulin action. Kasuga M. **Diabet Med** 1996 Sep;13(9 Suppl 6):S87-9 (23 ref.)
Redox modulation of tyrosine phosphorylation-dependent signal transduction pathways. Monteiro HP, et al. **Free Radic Biol Med** 1996;21(3):323-33 (106 ref.)
Modulation of insulin action by vanadate: evidence of a role for phosphotyrosine phosphatase activity to alter cellular signaling. Fantus IG, et al. **Mol Cell Biochem** 1995 Dec 6-20;153(1-2):103-12 (76 ref.)
Structure and function of the protein tyrosine phosphatases. Fauman EB, et al. **Trends Biochem Sci** 1996 Nov; 21(11):413-7 (48 ref.)
[Development of anti cancer drugs targeted on Fas-mediated apoptosis signal] Takahashi M, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(2):222-8 (13 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Protein tyrosine phosphatases and the control of cellular signaling responses. Tonks NK. **Adv Pharmacol** 1996; 36:91-119 (104 ref.)
Form and function in protein dephosphorylation [comment] Denu JM, et al. **Cell** 1996 Nov 1;87(3):361-4 (20 ref.) Comment on: Cell 1996 Nov 1;87(3):365-8.
The emerging field of receptor-mediated inhibitory signaling: SHP or SHIP? Scharenberg AM, et al. **Cell** 1996 Dec 13; 87(6):961-4 (16 ref.)
From form to function: signaling by protein tyrosine phosphatases [see comments] Tonks NK, et al. **Cell** 1996 Nov 1;87(3):365-8 (21 ref.) Comment in: Cell 1996 Nov 1;87(3):361-4.
Protein tyrosine phosphatase roles in the regulation of lymphocyte signaling. Pani G, et al. **Clin Immunol Immunopathol** 1997 Jul;84(1):1-16 (110 ref.)
Regulation of cell signaling by the protein tyrosine phosphatases, CD45 and SHP-1. Ulyanova T, et al. **Immunol Res** 1997 Feb;16(1):101-13 (117 ref.)
Protein tyrosine phosphatases in T-cell development, apoptosis and signalling. Frearson JA, et al. **Immunol Today** 1996 Aug;17(8):385-91 (57 ref.)
Molecular mechanisms of antiproliferative effect of somatostatin: involvement of a tyrosine phosphatase. Lopez F, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):14-6 (24 ref.)
Selective neural cell adhesion molecule signaling by Src family tyrosine kinases and tyrosine phosphatases. Maness PF, et al. **Perspect Dev Neurobiol** 1996;4(2-3):169-81 (169 ref.)
Regulation of growth factor-induced signaling by protein-tyrosine-phosphatases. Byon JC, et al. **Proc Soc Exp Biol Med** 1997 Oct;216(1):1-20 (152 ref.)
Yeast protein serine/threonine phosphatases: multiple roles and diverse regulation. Stark MJ. **Yeast** 1996 Dec; 12(16):1647-75 (200 ref.)

PROTEINASE INHIBITORS see **PROTEASE INHIBITORS**

PROTEINASES see **PEPTIDE PEPTIDOHYDROLASES**

PROTEINS

see related
AMINO ACID SEQUENCE
BLOOD PROTEINS
PROTEIN CONFORMATION

The search for molecular defects in genetic disease. Galjaard H. **Acta Genet Med Gemellol (Roma)** 1996;45(1-2):43-52 (33 ref.)
Diagnostic and therapeutic aspects of calciotropic hormones. Cormier C, et al. **Curr Opin Rheumatol** 1997 Jul;9(4):370-6 (40 ref.)
Human 2-D PAGE databases for proteome analysis in health and disease: http://biobase.dk/cgi-bin/celis. Celis JE, et al. **FEBS Lett** 1996 Dec 2;398(2-3):129-34 (39 ref.)
Leptin: genes, concepts and clinical perspective. Considine RV, et al. **Horm Res** 1996;46(6):249-56 (70 ref.)
A unified nomenclature for peroxisome biogenesis factors. Distel B, et al. **J Cell Biol** 1996 Oct;135(1):1-3 (48 ref.)
The molecular basis of von Hippel-Lindau disease. Iliopoulos O, et al. **Mol Med** 1997 May;3(5):289-93 (43 ref.)
C-type natriuretic peptide. Barr CS, et al. **Peptides** 1996; 17(7):1243-51 (116 ref.)
Molecular linguistics: extracting information from gene and protein sequences [comment] Botstein D, et al. **Proc Natl Acad Sci U S A** 1997 May 27;94(11):5506-7 (13 ref.) Comment on: Proc Natl Acad Sci U S A 1997 May 27;94(11):5831-6.
The deiodinase family of selenoproteins. St Germain DL, et al. **Thyroid** 1997 Aug;7(4):655-68 (178 ref.)
[NF1 (neurofibromatosis type 1)] Maruta H, et al. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1422-6 (30 ref.) (Eng. Abstr.) **(Jpn)**
[Protein- and peptide-derived radiopharmaceuticals] Arano Y. **Kaku Igaku** 1996 Oct;33(10):1111-8 (27 ref.) (Eng. Abstr.) **(Jpn)**
[Parathyroid hormone-related peptide (PTHrP) and PTH/PTHrP receptor in the gastrointestinal tract] Ito M, et al. **Nippon Rinsho** 1996 Apr;54(4):1104-8 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Structural analysis of proteins by mass spectrometry] Nakayama H, et al. **Seikagaku** 1996 Oct;68(10):1615-36 (132 ref.) **(Jpn)**
[Hard protein and soft protein: structural flexibility as revealed by compressibility] Gekko K. **Tanpakushitsu Kakusan Koso** 1996 Oct;41(13):2025-36 (48 ref.) **(Jpn)**
[Fluorescent nucleotides: their applications for studies on the structure and function of proteins] Hiratsuka T. **Tanpakushitsu Kakusan Koso** 1997 Jan;42(1):64-72 (195 ref.) **(Jpn)**
[The protein data bank: recent trends and developments] Kusunoki M. **Tanpakushitsu Kakusan Koso** 1997 Jun; 42(8):1315-9 (22 ref.) **(Jpn)**
[Spider silk: protein science] Osaki S. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(14):2108-16 (7 ref.) **(Jpn)**
[Protein immobilization in lipid bilayer membrane films on electrodes and their electron transfer reactions] Tominaga M, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep; 41(11):1600-6 (8 ref.) **(Jpn)**
[Control of cell cycle by the p27 Cdk-inhibitor] Toyoshima H. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1732-6 (11 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Targeted delivery of peptides, proteins, and genes by receptor-mediated endocytosis. Kato Y, et al. **Crit Rev Ther Drug Carrier Syst** 1997;14(3):287-331 (156 ref.)
Advances and opportunities in delivery of therapeutic proteins and peptides. Banakar UV. **J Biomater Appl** 1997 Apr;11(4):377-429 (128 ref.)
Oral protein drug delivery. Wang W. **J Drug Target** 1996; 4(4):195-232 (202 ref.)
Controlled release of proteins to tissue transplants for the treatment of neurodegenerative disorders. Mahoney MJ, et al. **J Pharm Sci** 1996 Dec;85(12):1276-81 (46 ref.)
Diffusion-controlled delivery of proteins from hydrogels and other hydrophilic systems. am Ende MT, et al. **Pharm Biotechnol** 1997;10:139-65 (60 ref.)
Protein delivery with infusion pumps. Bremer U, et al. **Pharm Biotechnol** 1997;10:239-54 (12 ref.)
Protein delivery from biodegradable microspheres. Cleland JL. **Pharm Biotechnol** 1997;10:1-43 (120 ref.)
Oral delivery of microencapsulated proteins. DiBiase MD, et al. **Pharm Biotechnol** 1997;10:255-88 (210 ref.)
Degradable controlled release systems useful for protein delivery. Roskos KV, et al. **Pharm Biotechnol** 1997; 10:45-92 (180 ref.)
Multiple emulsions for the delivery of proteins. Shively ML. **Pharm Biotechnol** 1997;10:199-211 (40 ref.)
Protein delivery from nondegradable polymer matrices. Wyatt TL, et al. **Pharm Biotechnol** 1997;10:119-37 (50 ref.)
Delivery of proteins from a controlled release injectable implant. Yewey GL, et al. **Pharm Biotechnol** 1997; 10:93-117 (30 ref.)

ANALYSIS

Capillary electrophoresis of proteins. Wehr T, et al. **Adv Chromatogr** 1997;37:237-361 (271 ref.)
Parathyroid hormone-related protein in an esophageal squamous cell carcinoma with tumor-induced hypercalcemia. Jaïs P, et al. **Am J Gastroenterol** 1997 Feb; 92(2):343-6 (19 ref.)
Theoretical analysis of protein concentration determination using biosensor technology under conditions of partial mass transport limitation. Christensen LL. **Anal Biochem** 1997 Jul 1;249(2):153-64 (20 ref.)
Separation and analysis of peptides and proteins. Hühmer AF, et al. **Anal Chem** 1997 Jun 15;69(12):29R-57R (512 ref.)
Optical detection of single molecules. Nie S, et al. **Annu Rev Biophys Biomol Struct** 1997;26:567-96 (151 ref.)
Cell-specific protein and gene expression in the juxtaglomerular apparatus. Barajas L. **Clin Exp Pharmacol Physiol** 1997 Jul;24(7):520-6 (74 ref.)
Resolution power of two-dimensional electrophoresis and identification of proteins from gels. Jungblut P, et al. **Electrophoresis** 1996 May;17(5):839-47 (76 ref.)
Protein and peptide analysis by capillary zone electrophoresis and micellar electrokinetic chromatography. Szökö E. **Electrophoresis** 1997 Jan;18(1):74-81 (99 ref.)
From gel filtration to adsorptive size exclusion. Porath J. **J Protein Chem** 1997 Jul;16(5):463-8 (47 ref.)
Clinical and biological significance of serum tumor markers in adult T-cell leukemia. Sadamori N. **Leuk Lymphoma** 1996 Aug;22(5-6):415-9 (59 ref.)
Leptin: an annotated addendum. Remesar X, et al. **Med Res Rev** 1997 Sep;17(5):499-504 (167 ref.)
Detection and quantitation of nitrotyrosine residues in proteins: in vivo marker of peroxynitrite. Crow JP, et al. **Methods Enzymol** 1996;269:185-94 (26 ref.)
Time-resolved room temperature tryptophan phosphorescence in proteins. Schauerte JA, et al. **Methods Enzymol** 1997;278:49-71 (89 ref.)
Affinophoresis: selective electrophoretic separation of proteins using specific carriers. Shimura K, et al. **Methods Enzymol** 1996;271:203-18 (18 ref.)
Fluorescence line narrowing spectroscopy: a tool for studying proteins. Vanderkooi JM, et al. **Methods Enzymol** 1997;278:71-94 (76 ref.)
Competitive binding assays for biotin-binding proteins. White HB 3rd. **Methods Enzymol** 1997;279:464-6 (6 ref.)
Mass spectrometry in the analysis of peptides and proteins, past and present. Roepstorff P. **Methods Mol Biol** 1996; 61:1-7 (16 ref.)
Mechanisms of signal-mediated protein sorting in the endocytic and secretory pathways. Bonifacino JS, et al. **Proc Assoc Am Physicians** 1996 Jul;108(4):285-95 (76 ref.)
Ly-6-domain proteins--new insights and new members: a C-terminal Ly-6 domain in sperm acrosomal protein SP-10. Palfree RG. **Tissue Antigens** 1996 Aug;48(2):71-9 (77 ref.)

ANTAGONISTS & INHIBITORS

A discussion of mechanisms of NO genotoxicity: implication of inhibition of DNA repair proteins. Laval F, et al. **Rev Physiol Biochem Pharmacol** 1997;131:175-91 (64 ref.)

BIOSYNTHESIS

Regulation of selenoprotein gene expression and thyroid hormone metabolism. Arthur JR, et al. **Biochem Soc Trans** 1996 May;24(2):384-8 (50 ref.)
Targeting proteins to mitochondria: is there a role for mRNA localization? Lightowlers RN, et al. **Biochem Soc Trans** 1996 May;24(2):527-31 (41 ref.)
Intracellular protein synthesis, modifications and aging. Rattan SI, et al. **Biochem Soc Trans** 1996 Nov;24(4):1043-9 (58 ref.)
Deregulation of protein synthesis as a mechanism of neoplastic transformation. Rosenwald IB. **Bioessays** 1996 Mar;18(3):243-50 (83 ref.)
Imprinting through molecular mimicry. Protein synthesis. Liljas A. **Curr Biol** 1996 Mar 1;6(3):247-9 (12 ref.)
Ribosomes: protein synthesis in slow motion. Moore PB. **Curr Biol** 1997 Mar 1;7(3):R179-81 (10 ref.)
The ternary complex of EF-Tu and its role in protein biosynthesis. Clark BF, et al. **Curr Opin Struct Biol** 1997 Feb;7(1):110-6 (48 ref.)
Biosynthesis, processing and sorting of neutrophil proteins: insight into neutrophil granule development. Gullberg U, et al. **Eur J Haematol** 1997 Mar;58(3):137-53 (134 ref.)
The eIF-2alpha kinases and the control of protein synthesis. de Haro C, et al. **FASEB J** 1996 Oct;10(12):1378-87 (64 ref.)
RNA processing and clinical variability in neurofibromatosis type I (NF1). Skuse GR, et al. **Hum Mol Genet** 1997; 6(10):1707-12 (53 ref.)
The compartmentalization of protein synthesis: importance of cytoskeleton and role in mRNA targeting. Hovland R, et al. **Int J Biochem Cell Biol** 1996 Oct;28(10):1089-105 (161 ref.)
Cytokines secreted by glial cells infected with HTLV-I modulate the expression of matrix metalloproteinases (MMPs) and their natural inhibitor (TIMPs): possible involvement in neurodegenerative processes. Giraudon P, et al. **Mol Psychiatry** 1997 Mar;2(2):107-10, 84 (23 ref.)
Microorganisms as an alternative source of protein. Kuhad RC, et al. **Nutr Rev** 1997 Mar;55(3):65-75 (60 ref.)
The elongation phase of protein synthesis. Czworkowski J, et al. **Prog Nucleic Acid Res Mol Biol** 1996;54:293-332 (232 ref.)
Role of translation initiation factor eIF-2B in the regulation of protein synthesis in mammalian cells. Kimball SR, et al. **Prog Nucleic Acid Res Mol Biol** 1996;54:165-96 (106 ref.)
Exploring the role of oxygen in Fanconi's anemia. Liebetrau W, et al. **Recent Results Cancer Res** 1997;143:353-67 (31 ref.)
Cell death induction by TNF: a matter of self control. Wallach D. **Trends Biochem Sci** 1997 Apr;22(4):107-9 (29 ref.)
[Historical aspects of early stages of studies on cell-free protein biosynthesis] Ogata K. **Tanpakushitsu Kakusan Koso** 1997 Apr;42(5):770-6 (6 ref.) **(Jpn)**
[MAP kinases and their role in regulation of protein level, subunit composition and degree of phosphorylation of transcription factor AP-1] Biedermann IW. **Postepy Biochem** 1996;42(3):244-52 (57 ref.) **(Pol)**

CHEMICAL SYNTHESIS

Protein design: the choice of de novo sequences. Beasley JR, et al. **J Biol Chem** 1997 Jan 24;272(4):2031-4 (57 ref.)
Protein design as a challenge for peptide chemists. Tuchscherer G, et al. **J Pept Sci** 1995 Jan-Feb;1(1):3-10

(37 ref.)

CHEMISTRY

Assembly process of 2D protein arrays in wetting films. Adachi E, et al. **Adv Biophys** 1997;34:81–92 (46 ref.)

Electron crystallography of macromolecular periodic arrays on phospholipid monolayers. Chiu W, et al. **Adv Biophys** 1997;34:161–72 (59 ref.)

Criticality found in a model for orientational ordering of protein arrays. Hogyoku M. **Adv Biophys** 1997;34:55–68 (25 ref.)

Lateral forces acting between particles in liquid films or lipid membranes. Kralchevsky PA. **Adv Biophys** 1997;34:25–39 (74 ref.)

The influence of protein and interfacial structure on the self-assembly of oriented protein arrays. Leckband DE. **Adv Biophys** 1997;34:173–90 (36 ref.)

Protein arrays: concepts and subjects. Nagayama K. **Adv Biophys** 1997;34:3–23 (192 ref.)

Significant role of electrostatic interactions for stabilization of protein assemblies. Takahashi T. **Adv Biophys** 1997; 34:41–54 (28 ref.)

Advances in tryptophan analysis in peptides and proteins. Molnár-Perl I. **Adv Exp Med Biol** 1996;398:635–48 (88 ref.)

Methods to estimate the conformation of proteins and polypeptides from circular dichroism data. Greenfield NJ. **Anal Biochem** 1996 Mar 1;235(1):1–10 (44 ref.)

Size-exclusion chromatography with on-line light-scattering, absorbance, and refractive index detectors for studying proteins and their interactions. Wen J, et al. **Anal Biochem** 1996 Sep 5;240(2):155–66 (52 ref.)

Electron transfer in proteins. Gray HB, et al. **Annu Rev Biochem** 1996;65:537–61 (111 ref.)

Nanosecond time-resolved spectroscopy of biomolecular processes. Chen E, et al. **Annu Rev Biophys Biomol Struct** 1997;26:327–55 (79 ref.)

Using self-assembled monolayers to understand the interactions of man-made surfaces with proteins and cells. Mrksich M, et al. **Annu Rev Biophys Biomol Struct** 1996; 25:55–78 (87 ref.)

Biomolecular dynamics at long timesteps: bridging the timescale gap between simulation and experimentation. Schlick T, et al. **Annu Rev Biophys Biomol Struct** 1997; 26:181–222 (122 ref.)

Theory and practice of nuclear spin relaxation in proteins. Dayie KT, et al. **Annu Rev Phys Chem** 1996;47:243–82 (147 ref.)

Protein crystallization. Durbin SD, et al. **Annu Rev Phys Chem** 1996;47:171–204 (217 ref.)

Insights into protein folding from NMR. Dyson HJ, et al. **Annu Rev Phys Chem** 1996;47:369–95 (144 ref.)

Of genomes and proteomes. James P. **Biochem Biophys Res Commun** 1997 Feb 3;231(1):1–6 (41 ref.)

Biochemistry and pathology of radical-mediated protein oxidation. Dean RT, et al. **Biochem J** 1997 May 15;324 (Pt 1):1–18 (312 ref.)

Analysis of hydrophobic proteins and peptides by electrospray ionization MS. Fearnley IM, et al. **Biochem Soc Trans** 1996 Aug;24(3):912–7 (16 ref.)

Chemical biology of isoprenylation/methylation. Rando RR. **Biochem Soc Trans** 1996 Aug;24(3):682–87 (48 ref.)

Intracellular targeting of secretory proteins in neuroendocrine cells. Shennan KI. **Biochem Soc Trans** 1996 May;24(2):535–9 (36 ref.)

Structure and function of proteins in G-protein-coupled signal transfer. Helmreich EJ, et al. **Biochim Biophys Acta** 1996 Oct 29;1286(3):285–322 (525 ref.)

The application of circular dichroism to studies of protein folding and unfolding. Kelly SM, et al. **Biochim Biophys Acta** 1997 Apr 4;1338(2):161–85 (118 ref.)

Chalcogen-analogs of amino acids. Their use in X-ray crystallographic and folding studies of peptides and proteins. Besse D, et al. **Biol Chem** 1997 Mar-Apr; 378(3-4):211–8 (40 ref.)

The suitability of Ta6Br12(2+) for phasing in protein crystallography. Neuefeind T, et al. **Biol Chem** 1997 Mar-Apr;378(3-4):219–21 (21 ref.)

Protein analogues in artificial surfactants. Johansson J. **Biol Neonate** 1997;71 Suppl 1:49–52 (12 ref.)

Definite answers from random events [comment] Briehl RW. **Biophys J** 1997 Jan;72(1):3–4 (12 ref.) Comment on: Biophys J 1997 Jan;72(1):343–52.

Proteins as invited guests of reverse micelles: conformational effects, significance, applications. Nicot C, et al. **Biotechnol Genet Eng Rev** 1996;13:267–314 (157 ref.)

Biotechnology of protein and polysaccharide gels. Tombs MP. **Biotechnol Genet Eng Rev** 1997;14:337–63 (62 ref.)

Structurally related receptors and antagonists compete for secreted Wnt ligands. Moon RT, et al. **Cell** 1997 Mar 21; 88(6):725–8 (16 ref.)

Stabilization of protein. Imoto T. **Cell Mol Life Sci** 1997 Mar; 53(3):215–23 (124 ref.)

RNA surfaces as functional mimetics of proteins. Keene JD. **Chem Biol** 1996 Jul;3(7):505–13 (39 ref.)

Sensing the heat: the application of isothermal titration calorimetry to thermodynamic studies of biomolecular interactions. Ladbury JE, et al. **Chem Biol** 1996 Oct; 3(10):791–801 (38 ref.)

Accommodating structurally diverse peptides in proteins. Wilkinson AJ. **Chem Biol** 1996 Jul;3(7):519–24 (23 ref.)

Influence of tertiary structure on nucleophilic substitution reactions of proteins. Skipper PL. **Chem Res Toxicol** 1996 Sep;9(6):918–23 (45 ref.)

The N-end rule. Varshavsky A. **Cold Spring Harb Symp Quant Biol** 1995;60:461–78 (90 ref.)

Sisyphus and prediction of protein structure. Rost B, et al. **Comput Appl Biosci** 1997 Aug;13(4):345–56 (183 ref.)

Vertebrate mineralized matrix proteins: structure and function. Robey PG. **Connect Tissue Res** 1996; 35(1-4):131–6 (6 ref.)

Glycosylation: heterogeneity and the 3D structure of proteins. Rudd PM, et al. **Crit Rev Biochem Mol Biol** 1997; 32(1):1–100 (215 ref.)

Protein-protein interactions: PDZ domain networks. Fanning AS, et al. **Curr Biol** 1996 Nov 1;6(11):1385–8 (16 ref.)

Protein folding and intermediates. Clarke AR, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):400–10 (74 ref.)

Stabilization of protein structures. Lee B, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):423–8 (65 ref.)

Mass spectrometry in protein studies from genome to function. Roepstorff P. **Curr Opin Biotechnol** 1997 Feb; 8(1):6–13 (96 ref.)

Reliable determination of binding affinity and kinetics using surface plasmon resonance biosensors. Schuck P. **Curr Opin Biotechnol** 1997 Aug;8(4):498–502 (43 ref.)

Population statistics of protein structures: lessons from structural classifications. Brenner SE, et al. **Curr Opin Struct Biol** 1997 Jun;7(3):369–76 (54 ref.)

Prediction of N-terminal protein sorting signals. Claros MG, et al. **Curr Opin Struct Biol** 1997 Jun;7(3):394–8 (41 ref.)

Proteins at atomic resolution. Dauter Z, et al. **Curr Opin Struct Biol** 1995 Dec;5(6):784–90 (38 ref.)

Sometimes a great motion: the application of transient electric birefringence to the study of macromolecular structure. Hagerman PJ. **Curr Opin Struct Biol** 1996 Oct;6(5):643–9 (56 ref.)

Three-dimensional domain duplication, swapping and stealing. Heringa J, et al. **Curr Opin Struct Biol** 1997 Jun; 7(3):416–21 (55 ref.)

Progress in protein structure prediction. Jones DT. **Curr Opin Struct Biol** 1997 Jun;7(3):377–87 (89 ref.)

3D structural information as a guide to protein engineering using genetic selection. Kast P, et al. **Curr Opin Struct Biol** 1997 Aug;7(4):470–9 (80 ref.)

How nature deals with stereoisomers. Lamzin VS, et al. **Curr Opin Struct Biol** 1995 Dec;5(6):830–6 (45 ref.)

Circular permutations of natural protein sequences: structural evidence. Lindqvist Y, et al. **Curr Opin Struct Biol** 1997 Jun;7(3):422–7 (40 ref.)

Engineering metal-binding sites in proteins. Lu Y, et al. **Curr Opin Struct Biol** 1997 Aug;7(4):495–500 (61 ref.)

Predicting coiled-coil regions in proteins. Lupas A. **Curr Opin Struct Biol** 1997 Jun;7(3):388–93 (53 ref.)

High-resolution NMR of biological solids. McDowell LM, et al. **Curr Opin Struct Biol** 1996 Oct;6(5):624–9 (59 ref.)

New structures of allosteric proteins revealing remarkable conformational changes. Mattevi A, et al. **Curr Opin Struct Biol** 1996 Dec;6(6):824–9 (35 ref.)

Engineering peptides and proteins that undergo alpha-to-beta transitions. Mihara H, et al. **Curr Opin Struct Biol** 1997 Aug;7(4):501–8 (56 ref.)

Scaffolds for engineering novel binding sites in proteins. Nygren PA, et al. **Curr Opin Struct Biol** 1997 Aug; 7(4):463–9 (42 ref.)

Incorporating anomalous scattering centres into macromolecules. Pappa HS, et al. **Curr Opin Struct Biol** 1996 Oct;6(5):611–6 (53 ref.)

Time-resolved biophysical methods in the study of protein folding. Plaxco KW, et al. **Curr Opin Struct Biol** 1996 Oct; 6(5):630–6 (49 ref.)

What makes a binding site a binding site? Ringe D. **Curr Opin Struct Biol** 1995 Dec;5(6):825–9 (22 ref.)

Modern developments in molecular replacement. Turkenburg JP, et al. **Curr Opin Struct Biol** 1996 Oct;6(5):604–10 (53 ref.)

Solubilization of proteins for electrophoretic analyses. Rabilloud T. **Electrophoresis** 1996 May;17(5):813–29 (147 ref.)

Interest of epitopic dissection in immunoanalysis of proteins and peptides: review of theoretical and practical aspects. Niccoli P, et al. **Eur J Clin Chem Clin Biochem** 1996 Sep; 34(9):741–8 (19 ref.)

On-pathway versus off-pathway folding intermediates. Baldwin RL. **Fold Des** 1996;1(1):R1–8 (36 ref.)

Experimental investigation of sidechain interactions in early folding intermediates. Engelhard M, et al. **Fold Des** 1996; 1(2):R31–7 (32 ref.)

Probing the partly folded states of proteins by limited proteolysis. Fontana A, et al. **Fold Des** 1997;2(2):R17–26 (105 ref.)

Adding backbone to protein folding: why proteins are polypeptides. Honig B, et al. **Fold Des** 1996;1(1):R17–20 (35 ref.)

X-ray solution scattering studies of protein folding. Kataoka M, et al. **Fold Des** 1996;1(5):R107–14 (45 ref.)

Local versus nonlocal interactions in protein folding and stability--an experimentalist's point of view. Muñoz V, et al. **Fold Des** 1996;1(4):R71–7 (80 ref.)

Protein folding from a combinatorial perspective. Sauer RT. **Fold Des** 1996;1(2):R27–30 (31 ref.)

Modeling protein folding: the beauty and power of simplicity. Shakhnovich EI. **Fold Des** 1996;1(3):R50–4 (41 ref.)

The concept of a random coil. Residual structure in peptides and denatured proteins. Smith LJ, et al. **Fold Des** 1996; 1(5):R95–106 (76 ref.)

SH2 and SH3-containing adaptor proteins: redundant or independent mediators of intracellular signal transduction. Birge RB, et al. **Genes Cells** 1996 Jul;1(7):595–613 (198 ref.)

Acylation of proteins: recent advances. Joseph M, et al. **Indian J Biochem Biophys** 1996 Oct;33(5):343–8 (44 ref.)

Future potential of targeted component analysis by multidimensional liquid chromatography-mass spectrometry. Regnier F, et al. **J Chromatogr A** 1996 Oct 25;750(1-2):3–10 (26 ref.)

Characterising non-covalent interactions with the Cambridge Structural Database. Lommerse JP, et al. **J Enzyme Inhib** 1997 Feb;11(4):223–43 (49 ref.)

Molecular structure of the apical junction complex and its contribution to the paracellular barrier. Lutz KL, et al. **J Pharm Sci** 1997 Sep;86(9):977–84 (127 ref.)

A multidimensional approach to protein characterization. Anderegg RJ, et al. **J Protein Chem** 1997 Jul;16(5):523–6 (25 ref.)

Mercury-responsive gene regulation and mercury-199 as a probe of protein structure. Huffman DL, et al. **Met Ions Biol Syst** 1997;34:503–26 (61 ref.)

Picosecond fluorescence decay curves collected on millisecond time scale: direct measurement of hydrodynamic radii, local/global mobility, and intramolecular distances during protein-folding reactions. Beechem JM. **Methods Enzymol** 1997;278:24–49 (13 ref.)

1La and 1Lb transitions of tryptophan: applications of theory and experimental observations to fluorescence of proteins. Callis PR. **Methods Enzymol** 1997;278:113–50 (86 ref.)

Conformational heterogeneity in crystalline proteins: time-resolved fluorescence studies. Dahms TE, et al. **Methods Enzymol** 1997;278:202–21 (40 ref.)

Fluorescence methods for studying equilibrium macromolecule-ligand interactions. Eftink MR. **Methods Enzymol** 1997;278:221–57 (67 ref.)

Fluorescence methods for studying kinetics of protein-folding reactions. Eftink MR, et al. **Methods Enzymol** 1997;278:258–86 (68 ref.)

Fluorescence studies of zinc finger peptides and proteins. Eis PS. **Methods Enzymol** 1997;278:330–43 (32 ref.)

Fluorescence approaches to study of protein-nucleic acid complexation. Hill JJ, et al. **Methods Enzymol** 1997; 278:390–416 (67 ref.)

Protein liquid chromatographic analysis in biotechnology. Janis LJ, et al. **Methods Enzymol** 1996;271:86–113 (42 ref.)

Intramolecular pyrene excimer fluorescence: a probe of proximity and protein conformational change. Lehrer SS. **Methods Enzymol** 1997;278:286–95 (18 ref.)

Time-resolved fluorescence of constrained tryptophan derivatives: implications for protein fluorescence. McLaughlin ML, et al. **Methods Enzymol** 1997;278:190–202 (22 ref.)

Enhancement of protein spectra with tryptophan analogs: fluorescence spectroscopy of protein-protein and protein-nucleic acid interactions. Ross JB, et al. **Methods Enzymol** 1997;278:151–90 (110 ref.)

N-terminal modification of proteins for fluorescence measurements. Wu P, et al. **Methods Enzymol** 1997; 278:321–30 (17 ref.)

Spectrometer calibration and experimental setup. Basic principles and procedures. Brereton IM. **Methods Mol Biol** 1997;60:363–410 (65 ref.)

Studies of protein-ligand interactions by NMR. Craik DJ, et al. **Methods Mol Biol** 1997;60:195–232 (61 ref.)

Calculating protein structures from NMR data. Güntert P. **Methods Mol Biol** 1997;60:157–94 (101 ref.)

NMR of paramagnetic proteins. Osborne MJ, et al. **Methods Mol Biol** 1997;60:233–69 (101 ref.)

Data processing in multidimensional NMR. Pelczer I, et al. **Methods Mol Biol** 1997;60:71–155 (388 ref.) .

Introduction to the NMR of proteins. Reid DG, et al. **Methods Mol Biol** 1997;60:1–28 (55 ref.)

Double and triple resonance NMR methods for protein assignment. Whitehead B, et al. **Methods Mol Biol** 1997; 60:29–52 (60 ref.)

Protein chemical shifts. Williamson MP, et al. **Methods Mol Biol** 1997;60:53–69 (25 ref.)

NMR spectroscopy of peptides and proteins. Practical considerations. Hinds MG, et al. **Mol Biotechnol** 1997 Jun; 7(3):315–31 (87 ref.)

Protein:protein interactions in the lipid bilayer (review). Harrison PT. **Mol Membr Biol** 1996 Apr-Jun;13(2):67–79 (69 ref.)

Phage presentation. Hill HR, et al. **Mol Microbiol** 1996 May; 20(4):685–92 (51 ref.)

Through a magnet, clearly [editorial; comment] **Nat Struct Biol** 1997 Mar;4(3):159–60 (12 ref.) Comment on: Nat Struct Biol 1997 Mar;4(3):167–9.

How do proteins acquire their three-dimensional structure and stability? Jaenicke R. **Naturwissenschaften** 1996 Dec; 83(12):544–54 (42 ref.)

Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Altschul SF, et al. **Nucleic Acids Res** 1997 Sep 1;25(17):3389–402 (90 ref.)

Rational design of stable lyophilized protein formulations: some practical advice. Carpenter JF, et al. **Pharm Res** 1997 Aug;14(8):969–75 (36 ref.)

Medical applications of synchrotron radiation x-rays. Lewis R. **Phys Med Biol** 1997 Jul;42(7):1213–43 (89 ref.)

PROTEINS

Symmetry, stability, and dynamics of multidomain and multicomponent protein systems. Blundell TL, et al. **Proc Natl Acad Sci U S A** 1996 Dec 10;93(25):14243–8 (69 ref.)

Rational protein design: combining theory and experiment. Hellinga HW. **Proc Natl Acad Sci U S A** 1997 Sep 16; 94(19):10015–7 (30 ref.)

Contacting the protein folding funnel with NMR. Onuchic JN. **Proc Natl Acad Sci U S A** 1997 Jul 8;94(14):7129–31 (28 ref.)

Structural and functional diversity in the leucine-rich repeat family of proteins. Buchanan SG, et al. **Prog Biophys Mol Biol** 1996;65(1–2):1–44 (196 ref.)

Protein–protein recognition. Janin J. **Prog Biophys Mol Biol** 1995;64(2–3):145–66 (100 ref.)

Hydration in protein crystallography. Schoenborn BP, et al. **Prog Biophys Mol Biol** 1995;64(2–3):105–19 (97 ref.)

Structure and function of the WW domain. Sudol M. **Prog Biophys Mol Biol** 1996;65(1–2):113–32 (128 ref.)

Hydrogen exchange: the modern legacy of Linderstrøm–Lang. Englander SW, et al. **Protein Sci** 1997 May;6(5):1101–9 (88 ref.)

Protein folding for realists: a timeless phenomenon. Shortle D, et al. **Protein Sci** 1996 Jun;5(6):991–1000 (25 ref.)

Heptad breaks in alpha-helical coiled coils: stutters and stammers. Brown JH, et al. **Proteins** 1996 Oct;26(2):134–45 (57 ref.)

Structural trees for protein superfamilies. Efimov AV. **Proteins** 1997 Jun;28(2):241–60 (254 ref.)

Structure and distribution of modules in extracellular proteins. Bork P, et al. **Q Rev Biophys** 1996 May; 29(2):119–67 (95 ref.)

Trends and challenges in experimental macromolecular crystallography. Chayen NE, et al. **Q Rev Biophys** 1996 Aug;29(3):227–78 (215 ref.)

Optical evanescent wave methods for the study of biomolecular interactions. Garland PB. **Q Rev Biophys** 1996 Feb;29(1):91–117 (80 ref.)

Roles of electrostatic interaction in proteins. Nakamura H. **Q Rev Biophys** 1996 Feb;29(1):1–90 (211 ref.)

Mass spectrometry in the study of non-enzymatic glyco-oxidation of proteins. Traldi P, et al. **Rapid Commun Mass Spectrom** 1997;11(6):673–8 (21 ref.)

Finding a basis for flipping bases. Cheng X, et al. **Structure** 1996 Jun 15;4(6):639–45 (24 ref.)

A structural explanation for the twilight zone of protein sequence homology. Chung SY, et al. **Structure** 1996 Oct 15;4(10):1123–7 (26 ref.)

Adaptors and integrators. Cowburn D. **Structure** 1996 Sep 15;4(9):1005–8 (20 ref.)

Now we're cooking: new successes for shake-and-bake. Ealick SE. **Structure** 1997 Apr 15;5(4):469–72 (30 ref.)

Knowledge-based potentials for protein folding: what can we learn from known protein structures? Godzik A. **Structure** 1996 Apr 15;4(4):363–6 (14 ref.)

Defining the structure and stability of macromolecular assemblies in solution: the re-emergence of analytical ultracentrifugation as a practical tool. Hensley P. **Structure** 1996 Apr 15;4(4):367–73 (59 ref.)

Angströms and calories. Janin J. **Structure** 1997 Apr 15; 5(4):473–9 (41 ref.)

A biopolymer by any other name would bind as well: a comparison of the ligand-binding pockets of nucleic acids and proteins. Marshall KA, et al. **Structure** 1997 Jun 15; 5(6):729–34 (29 ref.)

Electrostatic interaction of myristoylated proteins with membranes: simple physics, complicated biology. Murray D, et al. **Structure** 1997 Aug 15;5(8):985–9 (45 ref.)

As MAD as can be. Read RJ. **Structure** 1996 Jan 15;4(1):11–4 (19 ref.)

Use of deuterium labeling in NMR: overcoming a sizeable problem. Sattler M, et al. **Structure** 1996 Nov 15; 4(11):1245–9 (32 ref.)

WW domains. Staub O, et al. **Structure** 1996 May 15; 4(5):495–9 (38 ref.)

Hydrogen exchange at equilibrium: a short cut for analysing protein-folding pathways? Clarke J, et al. **Trends Biochem Sci** 1997 Aug;22(8):284–7 (32 ref.)

Cn3D: a new generation of three-dimensional molecular structure viewer. Hogue CW. **Trends Biochem Sci** 1997 Aug;22(8):314–6 (9 ref.)

Coiled coils: new structures and new functions. Lupas A. **Trends Biochem Sci** 1996 Oct;21(10):375–82 (50 ref.)

PDZ domains bind carboxy-terminal sequences of target proteins. Saras J, et al. **Trends Biochem Sci** 1996 Dec; 21(12):455–8 (25 ref.)

Proteins and DNA in systematic biology. Sibley CG. **Trends Biochem Sci** 1997 Sep;22(9):364–7 (33 ref.)

C-H...O hydrogen bonding in biology. Wahl MC, et al. **Trends Biochem Sci** 1997 Mar;22(3):97–102 (35 ref.)

[VHL gene and TSC 2 gene] Hino O. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1386–91 (27 ref.) (Eng. Abstr.) **(Jpn)**

[3D-reconstruction of proteins by electron microscopy] Hayase T. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1008–14 (22 ref.) **(Jpn)**

[Conformational ensembles of biopolymers] Suzuki E. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):989–95 (9 ref.) **(Jpn)**

[Getting the coordinates of proteins and displaying the spatial structures] Suzuki R, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):963–70 (7 ref.) **(Jpn)**

[Molecular structure and function of proteins] Tanokura M, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):961–2 (0 ref.) **(Jpn)**

[Distribution of amino acid residue conformation in three-dimensional protein structures. Analysis of the non-glycine residues in "positive" conformations] Basharov MA. **Biofizika** 1997 May-Jun;42(3):753–64 (25 ref.) (Eng. Abstr.) **(Rus)**

[Biologically active peptide fragments of functional proteins produced by proteolysis in vitro] Filippova MM, et al. **Bioorg Khim** 1997 May;23(5):388–409 (168 ref.) (Eng. Abstr.) **(Rus)**

[Protein engineering of artificial proteins] Dolgikh DA, et al. **Mol Biol (Mosk)** 1996 Mar-Apr;30(2):261–72 (73 ref.) **(Rus)**

CLASSIFICATION

Protein sequence motifs. Bork P, et al. **Curr Opin Struct Biol** 1996 Jun;6(3):366–76 (78 ref.)

Population statistics of protein structures: lessons from structural classifications. Brenner SE, et al. **Curr Opin Struct Biol** 1997 Jun;7(3):369–76 (54 ref.)

Structural classification of proteins: new superfamilies. Murzin AG. **Curr Opin Struct Biol** 1996 Jun;6(3):386–94 (49 ref.)

On the classification and evolution of protein modules. Hegyi H, et al. **J Protein Chem** 1997 Jul;16(5):545–51 (32 ref.)

DRUG EFFECTS

Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification--a role in pathogenesis and antiproliferative chemotherapy. Thornalley PJ. **Gen Pharmacol** 1996 Jun;27(4):565–73 (77 ref.)

Lipofuscin fluorophore inhibits lysosomal protein degradation and may cause early stages of macular degeneration. Eldred GE. **Gerontology** 1995;41 Suppl 2:15–28 (72 ref.)

GENETICS

Lessons from the discovery of leptin: is obesity an endocrine disease? [editorial] Scheen AJ. **Acta Clin Belg** 1996; 51(6):371–6 (51 ref.)

Analysis of gene function in lymphocytes by RAG-2-deficient blastocyst complementation. Chen J. **Adv Immunol** 1996;62:31–59 (104 ref.)

Epithelial cell polarity and disease. Wilson PD. **Am J Physiol** 1997 Apr;272(4 Pt 2):F434–42 (47 ref.)

Homologous recombination proteins in prokaryotes and eukaryotes. Camerini-Otero RD, et al. **Annu Rev Genet** 1995;29:509–52 (261 ref.)

The Polycomb and trithorax group proteins of Drosophila: trans-regulators of homeotic gene function. Kennison JA. **Annu Rev Genet** 1995;29:289–303 (83 ref.)

Of genomes and proteomes. James P. **Biochem Biophys Res Commun** 1997 Feb 3;231(1):1–6 (41 ref.)

The FHIT gene, a multiple tumor suppressor gene encompassing the carcinogen sensitive chromosome fragile site, FRA3B. Huebner K, et al. **Biochim Biophys Acta** 1997 Jun 7;1332(3):M65–70 (25 ref.)

Transcription initiation from TATA-less promoters within eukaryotic protein-coding genes. Smale ST. **Biochim Biophys Acta** 1997 Mar 20;1351(1–2):73–88 (105 ref.)

Protein targeting and translocation; a comparative survey. Baker A, et al. **Biol Rev Camb Philos Soc** 1996 Nov; 71(4):637–702 (318 ref.)

Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. Wilkins MR, et al. **Biotechnol Genet Eng Rev** 1996;13:19–50 (153 ref.)

Identifying distantly related protein sequences. Pearson WR. **Comput Appl Biosci** 1997 Aug;13(4):325–32 (14 ref.)

Defusing the Cambrian 'explosion'? Morris SC. **Curr Biol** 1997 Feb 1;7(2):R71–4 (13 ref.)

Searching for regulatory elements in human noncoding sequences. Duret L, et al. **Curr Opin Struct Biol** 1997 Jun; 7(3):399–406 (48 ref.)

Circular permutations of natural protein sequences: structural evidence. Lindqvist Y, et al. **Curr Opin Struct Biol** 1997 Jun;7(3):422–7 (40 ref.)

Leptin: the tale of an obesity gene. Caro JF, et al. **Diabetes** 1996 Nov;45(11):1455–62 (61 ref.)

Proteome research: complementarity and limitations with respect to the RNA and DNA worlds. Humphery-Smith I, et al. **Electrophoresis** 1997 Aug;18(8):1217–42 (321 ref.)

Role of the beta3-adrenoceptor in the control of leptin expression. Giacobino JP. **Horm Metab Res** 1996 Dec; 28(12):633–7 (58 ref.)

Regulation of ob gene expression in rodents and humans. Saladin R, et al. **Horm Metab Res** 1996 Dec;28(12):638–41 (41 ref.)

RNA processing and clinical variability in neurofibromatosis type I (NF1). Skuse GR, et al. **Hum Mol Genet** 1997; 6(10):1707–12 (53 ref.)

Diversity of ATM gene mutations detected in patients with ataxia-telangiectasia. Concannon P, et al. **Hum Mutat** 1997; 10(2):100–7 (40 ref.)

Partitioning of genetic variation between regulatory and coding gene segments: the predominance of software variation in genes encoding introvert proteins. Mitchison A. **Immunogenetics** 1997;46(1):46–52 (48 ref.)

RNA polymerase II dependent genes that do not code for protein. Lakhotia SC. **Indian J Biochem Biophys** 1996 Apr; 33(2):93–102 (132 ref.)

Functional roles of immediate early proteins encoded by the human cytomegalovirus UL36–38, UL115–119, TRS1/IRS1 and US3 loci. Colberg-Poley AM. **Intervirology** 1996;39(5–6):350–60 (78 ref.)

The new biology of body weight regulation. Schwartz MW, et al. **J Am Diet Assoc** 1997 Jan;97(1):54–8; quiz 59–60 (41 ref.)

Leptin, its receptor and obesity. Misra A, et al. **J Investig Med** 1996 Dec;44(9):540–8 (83 ref.)

The role of the agouti gene in the yellow obese syndrome. Miltenberger RJ, et al. **J Nutr** 1997 Sep;127(9):1902S–1907S (81 ref.)

Proteome analysis: genomics via the output rather than the input code. Humphery-Smith I, et al. **J Protein Chem** 1997 Jul;16(5):537–44 (18 ref.)

Renal disease. II. The polycystic kidney disease 1 (PKD-1) gene: an important clue in the study of renal cyst formation. Ong AC. **J R Coll Physicians Lond** 1997 Mar-Apr; 31(2):141–6 (16 ref.)

Mutation watch: PEX PLUS? Gene(s) for X-linked hypophosphatemia and deafness. Meisler M. **Mamm Genome** 1997 Aug;8(8):543–4 (8 ref.)

Exon shuffling and other ways of module exchange. Patthy L. **Matrix Biol** 1996 Nov;15(5):301–10; discussion 311–2 (61 ref.)

Production of heterologous proteins using the baculovirus/insect expression system. Griffiths CM, et al. **Methods Mol Biol** 1997;75:427–40 (18 ref.)

Expression of subunits of the 19S complex and of the PA28 activator in rat skeletal muscle. Attaix D, et al. **Mol Biol Rep** 1997 Mar;24(1–2):95–8 (30 ref.)

Advances in polycystic kidney disease. Schneider MC. **Mol Med Today** 1996 Feb;2(2):70–5 (32 ref.)

Transcription activation at class II CAP-dependent promoters. Busby S, et al. **Mol Microbiol** 1997 Mar; 23(5):853–9 (31 ref.)

Structural motifs of the PKD1 protein. Löhning C, et al. **Nephrol Dial Transplant** 1996;11 Suppl 6:2–4 (26 ref.)

Leptin: the weight-reducing plasma protein encoded by the obese gene. **Nutr Rev** 1996 Mar;54(3):91–3 (12 ref.)

New insights into the development of obesity: obese genes and the leptin system. Trayhurn P. **Proc Nutr Soc** 1996 Nov;55(3):783–91 (53 ref.)

Proteins and DNA in systematic biology. Sibley CG. **Trends Biochem Sci** 1997 Sep;22(9):364–7 (33 ref.)

[Leptin and genetics of obesity] Clément K, et al. **Journ Annu Diabetol Hotel Dieu** 1997;:161–71 (31 ref.) **(Fre)**

[DAN gene] Sakiyama S, et al. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1465–70 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Regulation of secretory leukoprotease inhibitor gene expression] Kikuchi T, et al. **Nippon Rinsho** 1996 Feb; 54(2):405–10 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Origin and evolution of the proteasome subunit genes, LMP2 and LMP7] Nonaka M, et al. **Seikagaku** 1996 Sep; 68(9):1559–63 (13 ref.) **(Jpn)**

[ob protein--product of expressing an obesity gene and some aspects of modern-day endocrinology] Pankov IuA. **Biokhimiia** 1996 Jun;61(6):984–92 (13 ref.) (Eng. Abstr.) **(Rus)**

[Obesity gene and the product of expressing its hormone, leptin] Pankov IuA. **Mol Biol (Mosk)** 1996 Jul-Aug; 30(4):743–7 (13 ref.) **(Rus)**

IMMUNOLOGY

Hemidesmosomes: roles in adhesion, signaling and human diseases. Borradori L, et al. **Curr Opin Cell Biol** 1996 Oct; 8(5):647–56 (74 ref.)

Antigen presentation by MHC class II molecules: invariant chain function, protein trafficking, and the molecular basis of diverse determinant capture. Castellino F, et al. **Hum Immunol** 1997 May;54(2):159–69 (88 ref.)

Processing and presentation of endocytically acquired protein antigens by MHC class II and class I molecules. German RN, et al. **Immunol Rev** 1996 Jun;151:5–30 (122 ref.)

The role of Grb2-associated proteins in T-cell activation. Koretzky GA. **Immunol Today** 1997 Aug;18(8):401–6 (48 ref.)

Mouse NK1.1+ T cells: a new family of T cells. Vicari AP, et al. **Immunol Today** 1996 Feb;17(2):71–6 (76 ref.)

The prophenoloxidase activating system and associated proteins in invertebrates. Johansson MW, et al. **Prog Mol Subcell Biol** 1996;15:46–66 (142 ref.)

Ly-6-domain proteins--new insights and new members: a C-terminal Ly-6 domain in sperm acrosomal protein SP-10. Palfree RG. **Tissue Antigens** 1996 Aug;48(2):71–9 (77 ref.)

ISOLATION & PURIFICATION

Fluidized bed adsorption as a primary recovery step in protein purification. Thömmes J. **Adv Biochem Eng Biotechnol** 1997;58:185–230 (87 ref.)

Quantitative two-dimensional gel electrophoresis: from proteins to proteomes. Dunn MJ. **Biochem Soc Trans** 1997 Feb;25(1):248–54 (41 ref.)

Progress with proteome projects: why all proteins expressed

by a genome should be identified and how to do it. Wilkins MR, et al. **Biotechnol Genet Eng Rev** 1996;13:19–50 (153 ref.)

Marine adhesive proteins and some biotechnological applications. Yamamoto H. **Biotechnol Genet Eng Rev** 1996; 13:133–65 (96 ref.)

Environmental bioadhesion: themes and applications. Burzio LO, et al. **Curr Opin Biotechnol** 1997 Jun;8(3):309–12 (32 ref.)

Identification of cytokine-regulated proteins in normal and malignant cells by the combination of two-dimensional polyacrylamide gel electrophoresis, mass spectrometry, Edman degradation and immunoblotting and approaches to the analysis of their functional roles. Epstein LB, et al. **Electrophoresis** 1996 Nov;17(11):1655–70 (75 ref.)

Capillary sodium dodecyl sulfate-gel electrophoresis of proteins. Guttman A. **Electrophoresis** 1996 Aug; 17(8):1333–41 (51 ref.)

Capillary isoelectric focusing of proteins. Pritchett TJ. **Electrophoresis** 1996 Jul;17(7):1195–201 (51 ref.)

Affinity precipitation: a novel approach to protein purification. Irwin JA, et al. **Essays Biochem** 1995; 29:137–56 (41 ref.)

Dye-affinity techniques for bioprocessing: recent developments. Garg N, et al. **J Mol Recognit** 1996 Jul–Aug; 9(4):259–74 (109 ref.)

Affinity precipitation of proteins. Gupta MN, et al. **J Mol Recognit** 1996 Sep–Dec;9(5–6):356–9 (12 ref.)

Screening for protein purification: is there an optimum adsorbent for every protein? Scopes RK. **J Mol Recognit** 1996 Sep–Dec;9(5–6):305–8 (17 ref.)

Capillary electrophoresis with polymer matrices: DNA and protein separation and analysis. Karger BL, et al. **Methods Enzymol** 1996;271:293–319 (83 ref.)

Trends and challenges in experimental macromolecular crystallography. Chayen NE, et al. **Q Rev Biophys** 1996 Aug;29(3):227–78 (215 ref.)

Mixed self-assembled monolayers in chemical separations. Wirth MJ, et al. **Science** 1997 Jan 3;275(5296):44–7 (32 ref.)

METABOLISM

Rapid non-empirical approaches for estimating relative binding free energies. Mark AE, et al. **Acta Biochim Pol** 1995;42(4):525–35 (29 ref.)

Modulatory role of GTP-binding proteins in the endogenous ADP-ribosylation of cytosolic proteins. Di Girolamo M, et al. **Adv Exp Med Biol** 1997;419:343–7 (18 ref.)

Structure and experimental uses of arthropod venom proteins. Jones D. **Adv Exp Med Biol** 1996;391:379–86 (45 ref.)

The neuronal ceroid lipofuscinoses (Batten disease): a group of lysosomal proteinoses. Palmer DN, et al. **Adv Exp Med Biol** 1996;389:129–36 (55 ref.)

Binding proteins on synaptic membranes for certain phospholipases A2 with presynaptic toxicity. Tzeng MC, et al. **Adv Exp Med Biol** 1996;391:271–8 (46 ref.)

Signal transductions of SH2/SH3: Ash/Grb–2 downstream signaling. Takenawa T, et al. **Adv Pharmacol** 1996; 36:139–53 (24 ref.)

Compartmentalization of protein traffic in insulin-sensitive cells. Kandror KV, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):E1–14 (134 ref.)

Theoretical analysis of protein concentration determination using biosensor technology under conditions of partial mass transport limitation. Christensen LL. **Anal Biochem** 1997 Jul 1;249(2):153–64 (20 ref.)

Protein import into peroxisomes: new developments. Rehling P, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:34–46 (81 ref.)

Signals, receptors, and cytosolic factors involved in peroxisomal protein import. Terlecky SR, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:11–20 (71 ref.)

Protein import into mitochondria. Neupert W. **Annu Rev Biochem** 1997;66:863–917 (501 ref.)

Protein transport across the eukaryotic endoplasmic reticulum and bacterial inner membranes. Rapoport TA, et al. **Annu Rev Biochem** 1996;65:271–303 (234 ref.)

The dynamics of water–protein interactions. Bryant RG. **Annu Rev Biophys Biomol Struct** 1996;25:29–53 (129 ref.)

Ubiquitin-dependent protein degradation. Hochstrasser M. **Annu Rev Genet** 1996;30:405–39 (115 ref.)

Protein targets of xenobiotic reactive intermediates. Pumford NR, et al. **Annu Rev Pharmacol Toxicol** 1997;37:91–117 (168 ref.)

The proteolytic systems of lactic acid bacteria. Kunji ER, et al. **Antonie Van Leeuwenhoek** 1996 Oct;70(2–4):187–221 (186 ref.)

Protein tyrosine phosphorylation and signal transduction during capacitation–acrosome reaction and zona pellucida binding in human sperm. Naz RK. **Arch Androl** 1996 Jul–Aug;37(1):47–55 (48 ref.)

Participation of oxygen-free radicals in the oxido-reduction of proteins. Vilar-Rojas C, et al. **Arch Med Res** 1996 Spring;27(1):1–6 (42 ref.)

Contributions to senescence: non-enzymatic glycosylation of proteins. Sullivan R. **Arch Physiol Biochem** 1996 Dec; 104(7):797–806 (76 ref.)

Protein metabolism in diabetes mellitus. Abu-Lebdeh HS, et al. **Baillieres Clin Endocrinol Metab** 1996 Oct; 10(4):589–601 (59 ref.)

Metabolic actions of growth hormone: direct and indirect. Berneis K, et al. **Baillieres Clin Endocrinol Metab** 1996 Jul; 10(3):337–52 (78 ref.)

Protein metabolism and liver disease. Charlton MR. **Baillieres Clin Endocrinol Metab** 1996 Oct;10(4):617–35 (110 ref.)

Post-prandial protein metabolism. Millward DJ, et al. **Baillieres Clin Endocrinol Metab** 1996 Oct;10(4):533–49 (61 ref.)

Protein metabolism in pregnancy. Robinson S, et al. **Baillieres Clin Endocrinol Metab** 1996 Oct;10(4):571–87 (56 ref.)

The measurement of tissue protein turnover. Smith K, et al. **Baillieres Clin Endocrinol Metab** 1996 Oct;10(4):469–95 (145 ref.)

The role of substrates in the regulation of protein metabolism. Tessari P, et al. **Baillieres Clin Endocrinol Metab** 1996 Oct; 10(4):511–32 (125 ref.)

The hormonal control of protein metabolism. Umpleby AM, et al. **Baillieres Clin Endocrinol Metab** 1996 Oct; 10(4):551–70 (110 ref.)

Protein metabolism in critical illness. Wernerman J, et al. **Baillieres Clin Endocrinol Metab** 1996 Oct;10(4):603–15 (80 ref.)

Cell volume and the metabolic actions of insulin. Zhande R, et al. **Biochem Cell Biol** 1996;74(4):513–22 (79 ref.)

Biochemistry and pathology of radical-mediated protein oxidation. Dean RT, et al. **Biochem J** 1997 May 15;324 (Pt 1):1–18 (312 ref.)

Binding and translocation of glucokinase in hepatocytes. Agius L, et al. **Biochem Soc Trans** 1997 Feb;25(1):145–50 (28 ref.)

Retinoylation of proteins in mammalian cells. Breitman TR, et al. **Biochem Soc Trans** 1996 Aug;24(3):723–7 (48 ref.)

Free radicals, proteins and DNA: oxidative damage versus redox regulation. Halliwell B. **Biochem Soc Trans** 1996 Nov;24(4):1023–7 (62 ref.)

The identification of Bruton's tyrosine kinase and Wiskott–Aldrich syndrome protein associated proteins and signalling pathways. Kinnon C, et al. **Biochem Soc Trans** 1997 May;25(2):648–50 (27 ref.)

Chemical biology of isoprenylation/methylation. Rando RR. **Biochem Soc Trans** 1996 Aug;24(3):682–87 (48 ref.)

Intracellular targeting of secretory proteins in neuroendocrine cells. Shennan KI. **Biochem Soc Trans** 1996 May;24(2):535–9 (36 ref.)

The regulatory protein of glucokinase. van Schaftingen E, et al. **Biochem Soc Trans** 1997 Feb;25(1):136–40 (41 ref.)

Accumulating evidence suggests that several AB-toxins subvert the endoplasmic reticulum–associated protein degradation pathway to enter target cells. Hazes B, et al. **Biochemistry** 1997 Sep 16;36(37):11051–4 (48 ref.)

What is the driving force for protein import into mitochondria? Horst M, et al. **Biochim Biophys Acta** 1997 Jan 16;1318(1–2):71–8 (72 ref.)

RNAs mediating cotranslational insertion of selenocysteine in eukaryotic selenoproteins. Hubert N, et al. **Biochimie** 1996;78(7):590–6 (40 ref.)

Cellular regulation by protein phosphorylation: a historical overview. Fischer EH. **Biofactors** 1997;6(3):367–74 (42 ref.)

Breakdown of oxidized proteins as a part of secondary antioxidant defenses in mammalian cells. Grune T, et al. **Biofactors** 1997;6(2):165–72 (36 ref.)

Surface hydrophobicity and intracellular degradation of proteins. Bohley P. **Biol Chem** 1996 Jul–Aug; 377(7–8):425–35 (129 ref.)

New insights into the mechanisms and importance of the proteasome in intracellular protein degradation. Goldberg AL, et al. **Biol Chem** 1997 Mar–Apr;378(3–4):131–40 (51 ref.)

Protein targeting and translocation; a comparative survey. Baker A, et al. **Biol Rev Camb Philos Soc** 1996 Nov; 71(4):637–702 (318 ref.)

Derangements of protein metabolism in chronic renal failure. Kaysen GA, et al. **Blood Purif** 1996;14(5):373–81 (68 ref.)

Assessment of the nutritional state of dialysis patients. Kerr PG, et al. **Blood Purif** 1996;14(5):382–7 (25 ref.)

Switching the model: a concerted mechanism for GTPases in protein targeting [comment] Millman JS, et al. **Cell** 1997 May 30;89(5):673–6 (14 ref.) Comment on: Cell 1997 May 30;89(5):703–13.

Regulation of cellular signalling by fatty acid acylation and prenylation of signal transduction proteins. Resh MD. **Cell Signal** 1996 Sep;8(6):403–12 (134 ref.)

Ras–GTPase activating protein (GAP): a putative effector for Ras. Tocque B, et al. **Cell Signal** 1997 Feb;9(2):153–8 (72 ref.)

The granin family—its role in sorting and secretory granule formation. Ozawa H, et al. **Cell Struct Funct** 1995 Dec; 20(6):415–20 (47 ref.)

Mechanisms of protein import into mitochondria. Stuart RA, et al. **Cell Struct Funct** 1996 Oct;21(5):403–6 (37 ref.)

Sonic hedgehog: making the gradient. Bumcrot DA, et al. **Chem Biol** 1996 Jan;3(1):13–6 (23 ref.)

Protein templates for the biosynthesis of peptide antibiotics. Marahiel MA. **Chem Biol** 1997 Aug;4(8):561–7 (31 ref.)

Protein splicing: occurrence, mechanisms and related phenomena. Shao Y, et al. **Chem Biol** 1997 Mar;4(3):187–94 (47 ref.)

Reactive oxygen-mediated protein oxidation in aging and disease. Stadtman ER, et al. **Chem Res Toxicol** 1997 May; 10(5):485–94 (154 ref.)

International Federation of Clinical Chemistry. Laboratory assessment of protein-energy status. Shenkin A, et al. **Clin Chim Acta** 1996 Sep 30;253(1–2):S5–59 (163 ref.)

Protein phosphorylation events in exocytosis and endocytosis. Liu JP. **Clin Exp Pharmacol Physiol** 1997 Aug; 24(8):611–8 (76 ref.)

Obesity research continues to spring leaks. Harper ME. **Clin Invest Med** 1997 Aug;20(4):239–44 (32 ref.)

Unidirectional and bidirectional protein traffic across membranes. Blobel G. **Cold Spring Harb Symp Quant Biol** 1995;60:1–10 (59 ref.)

Targeting pathways to the endoplasmic reticulum membrane. Brown JD, et al. **Cold Spring Harb Symp Quant Biol** 1995; 60:23–30 (45 ref.)

Dissection of protein translocation across the mitochondrial outer and inner membranes. Brunner M, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:619–27 (46 ref.)

Protein import into peroxisomes: an exception to the rule? Huhse B, et al. **Cold Spring Harb Symp Quant Biol** 1995; 60:657–62 (62 ref.)

Generation of epithelial cell polarity: roles for protein trafficking, membrane–cytoskeleton, and E–cadherin–mediated cell adhesion. Mays RW, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:763–73 (84 ref.)

Regulation of protein traffic in polarized epithelial cells: the polymeric immunoglobulin receptor model. Mostov KE, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:775–81 (25 ref.)

Protein kinesis: the dynamics of protein trafficking and stability. Summary. Palade GE. **Cold Spring Harb Symp Quant Biol** 1995;60:821–31 (10 ref.)

Posttranslational protein transport into the endoplasmic reticulum. Panzner S, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:31–40 (38 ref.)

Transport of proteins and metabolites across the impermeable membrane of peroxisomes. Tabak HF, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:649–55 (37 ref.)

The N–end rule. Varshavsky A. **Cold Spring Harb Symp Quant Biol** 1995;60:461–78 (90 ref.)

Regulation of calcite crystal morphology by intracrystalline acidic proteins and glycoproteins. Albeck S, et al. **Connect Tissue Res** 1996;35(1–4):365–70 (19 ref.)

Glycosylation: heterogeneity and the 3D structure of proteins. Rudd PM, et al. **Crit Rev Biochem Mol Biol** 1997; 32(1):1–100 (215 ref.)

Protein transports: the nonclassical ins and outs. Cleves AE. **Curr Biol** 1997 May 1;7(5):R318–20 (10 ref.)

Rehearsing the ABCs. Protein translocation. Cleves AE, et al. **Curr Biol** 1996 Mar 1;6(3):276–8 (28 ref.)

Protein–protein interactions: PDZ domain networks. Fanning AS, et al. **Curr Biol** 1996 Nov 1;6(11):1385–8 (16 ref.)

Disease mechanism: unravelling Wiskott–Aldrich syndrome. Kirchhausen T, et al. **Curr Biol** 1996 Jun 1;6(6):676–8 (19 ref.)

Neural patterning: A forward role for hedgehog. Lumsden A, et al. **Curr Biol** 1995 Dec 1;5(12):1347–50 (25 ref.)

Appetite control: Does leptin lighten the problem of obesity? McGarry JD. **Curr Biol** 1995 Dec 1;5(12):1342–4 (23 ref.)

Protein kinase C: ports of anchor in the cell. Newton AC. **Curr Biol** 1996 Jul 1;6(7):806–9 (20 ref.)

Bone growth: coordinating chondrocyte differentiation. Wallis GA. **Curr Biol** 1996 Dec 1;6(12):1577–80 (10 ref.)

The role of protein degradation in mitochondrial function and biogenesis. Rep M, et al. **Curr Genet** 1996 Nov; 30(5):367–80 (170 ref.)

Protein folding and intermediates. Clarke AR, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):400–10 (74 ref.)

Genetic and biochemical probes for protein–protein interactions. McNabb DS, et al. **Curr Opin Biotechnol** 1996 Oct;7(5):554–9 (51 ref.)

Coatomer (COPI)–coated vesicles: role in intracellular transport and protein sorting. Cosson P, et al. **Curr Opin Cell Biol** 1997 Aug;9(4):484–7 (29 ref.)

A new family of G–protein regulators – the RGS proteins. Koelle MR. **Curr Opin Cell Biol** 1997 Apr;9(2):143–7 (35 ref.)

The trans–Golgi network: a late secretory sorting station. Traub LM, et al. **Curr Opin Cell Biol** 1997 Aug;9(4):527–33 (50 ref.)

Responses to DNA damage and regulation of cell cycle checkpoints by the ATM protein kinase family. Hoekstra MF. **Curr Opin Genet Dev** 1997 Apr;7(2):170–5 (48 ref.)

Parathyroid hormone–related peptide and the parathyroid hormone/parathyroid hormone–related peptide receptor in skeletal development. Karaplis AC, et al. **Curr Opin Nephrol Hypertens** 1997 Jul;6(4):308–13 (52 ref.)

The natriuretic peptide family. Nakao K, et al. **Curr Opin Nephrol Hypertens** 1996 Jan;5(1):4–11 (73 ref.)

Prediction of N–terminal protein sorting signals. Claros MG, et al. **Curr Opin Struct Biol** 1997 Jun;7(3):394–8 (41 ref.)

Three–dimensional domain duplication, swapping and stealing. Heringa J, et al. **Curr Opin Struct Biol** 1997 Jun; 7(3):416–21 (55 ref.)

Recent solution structures of RNA and its complexes with drugs, peptides and proteins. Ramos A, et al. **Curr Opin Struct Biol** 1997 Jun;7(3):317–23 (59 ref.)

Design and synthesis of carbohydrate–based inhibitors of protein–carbohydrate interactions. von Itzstein M, et al. **Curr Opin Struct Biol** 1996 Oct;6(5):703–9 (44 ref.)

Protein–facilitated RNA folding. Weeks KM. **Curr Opin Struct Biol** 1997 Jun;7(3):336–42 (58 ref.)

The cell cycle and V(D)J recombination. Desiderio S, et al. **Curr Top Microbiol Immunol** 1996;217:45–59 (60 ref.)

rag–1 and rag–2: biochemistry and protein interactions. Schatz DG, et al. **Curr Top Microbiol Immunol** 1996;

217:11–29 (27 ref.)
Initiation of V(D)J recombinations in a cell–free system by RAG1 and RAG2 proteins. van Gent DC, et al. **Curr Top Microbiol Immunol** 1996;217:1–10 (22 ref.)
Selective protein arylation and acetaminophen–induced hepatotoxicity. Cohen SD, et al. **Drug Metab Rev** 1997 Feb–May;29(1–2):59–77 (111 ref.)
Covalent binding of xenobiotics to specific proteins in the liver. Pumford NR, et al. **Drug Metab Rev** 1997 Feb–May; 29(1–2):39–57 (67 ref.)
Protein adduct biomarkers: state of the art. Meyer MJ, et al. **Environ Health Perspect** 1996 Oct;104 Suppl 5:879–82 (26 ref.)
Hormonal regulation of human protein metabolism. De Feo P. **Eur J Endocrinol** 1996 Jul;135(1):7–18 (126 ref.)
Protein anabolic action of insulin, growth hormone and insulin–like growth factor I. Russell–Jones DL, et al. **Eur J Endocrinol** 1996 Dec;135(6):631–42 (144 ref.)
Protein turnover in critically ill children. Bodamer OA, et al. **Eur J Pediatr** 1997 Aug;156 Suppl 1:S59–61 (16 ref.)
Regulation of energy balance by leptin. Hamann A, et al. **Exp Clin Endocrinol Diabetes** 1996;104(4):293–300 (46 ref.)
Involvement of molecular chaperones in intracellular protein breakdown. Sherman MY, et al. **EXS** 1996;77:57–78 (100 ref.)
The nicotinamide dinucleotide binding motif: a comparison of nucleotide binding proteins. Bellamacina CR. **FASEB J** 1996 Sep;10(11):1257–69 (47 ref.)
Degradation of oxidized proteins in mammalian cells. Grune T, et al. **FASEB J** 1997 Jun;11(7):526–34 (60 ref.)
Is leptin an insulin counter–regulatory hormone? Remesar X, et al. **FEBS Lett** 1997 Jan 27;402(1):9–11 (46 ref.)
The interaction of Ras with GTPase–activating proteins. Wittinghofer A, et al. **FEBS Lett** 1997 Jun 23;410(1):63–7 (60 ref.)
The cleavage of host cell proteins by HIV–1 protease. Snášel J, et al. **Folia Biol (Praha)** 1996;42(5):227–30 (35 ref.)
Electron movement through proteins and DNA. Symons MC. **Free Radic Biol Med** 1997;22(7):1271–6 (35 ref.)
SH2 and SH3–containing adaptor proteins: redundant or independent mediators of intracellular signal transduction. Birge RB, et al. **Genes Cells** 1996 Jul;1(7):595–613 (198 ref.)
The N–end rule pathway of protein degradation. Varshavsky A. **Genes Cells** 1997 Jan;2(1):13–28 (75 ref.)
Blood group antigens: molecules seeking a function? Greenwell P. **Glycoconj J** 1997 Feb;14(2):159–73 (223 ref.)
Protein glycosylation in the endoplasmic reticulum and the Golgi apparatus and cell type–specificity of cell surface glycoconjugate expression: analysis by the protein A–gold and lectin–gold techniques. Roth J. **Histochem Cell Biol** 1996 Jul;106(1):79–92 (130 ref.)
Autophagic proteolysis: control and specificity. Blommaart EF, et al. **Histochem J** 1997 May;29(5):365–85 (187 ref.)
Antigen presentation by MHC class II molecules: invariant chain function, protein trafficking, and the molecular basis of diverse determinant capture. Castellino F, et al. **Hum Immunol** 1997 May;54(2):159–69 (88 ref.)
Destruction of proteins as a creative force. Ploegh HL. **Immunol Today** 1997 Jun;18(6):269–71 (15 ref.)
Regulating protein degradation by ubiquitination. Weissman AM. **Immunol Today** 1997 Apr;18(4):189–98 (119 ref.)
Acylation of proteins: recent advances. Joseph M, et al. **Indian J Biochem Biophys** 1996 Oct;33(5):343–8 (44 ref.)
Nucleocytoplasmic transport of proteins and control of cellular function. Parnaik VK. **Indian J Biochem Biophys** 1996 Jun;33(3):164–7 (22 ref.)
Aging and the acute phase response to exercise: implications for the role of systemic factors on skeletal muscle protein turnover. Fielding RA, et al. **Int J Sports Med** 1997 Mar; 18 Suppl 1:S22–7 (59 ref.)
Distribution and functions of parathyroid hormone–related protein in vertebrate cells. Ingleton PM, et al. **Int Rev Cytol** 1996;166:231–80 (212 ref.)
The role of molecular chaperones in mitochondrial protein import and folding. Ryan MT, et al. **Int Rev Cytol** 1997; 174:127–93 (382 ref.)
Alveolar epithelial clearance of protein. Folkesson HG, et al. **J Appl Physiol** 1996 May;80(5):1431–45 (166 ref.)
Coupling chemical energy by the hsp70/tim44 complex to drive protein translocation into mitochondria. Cyr DM. **J Bioenerg Biomembr** 1997 Feb;29(1):29–34 (32 ref.)
The first steps of protein import into mitochondria. Haucke V, et al. **J Bioenerg Biomembr** 1997 Feb;29(1):11–7 (56 ref.)
Recognition and binding of mitochondrial presequences during the import of proteins into mitochondria. Roise D. **J Bioenerg Biomembr** 1997 Feb;29(1):19–27 (98 ref.)
Protein oxidation in aging, disease, and oxidative stress. Berlett BS, et al. **J Biol Chem** 1997 Aug 15;272(33):20313–6 (49 ref.)
Mechanism of polypeptide translocation into the endoplasmic reticulum. Corsi AK, et al. **J Biol Chem** 1996 Nov 29; 271(48):30299–302 (63 ref.)
RGS proteins and signaling by heterotrimeric G proteins. Dohlman HG, et al. **J Biol Chem** 1997 Feb 14;272(7):3871–4 (63 ref.)
The protein import system of mitochondria. Schatz G. **J Biol Chem** 1996 Dec 13;271(50):31763–6 (42 ref.)
Protein translocation into peroxisomes. Subramani S. **J Biol Chem** 1996 Dec 20;271(51):32483–6 (50 ref.)
Carcinogen–DNA and protein adducts: biomarkers for cohort selection and modifiable endpoints in chemoprevention trials. Kensler TW, et al. **J Cell Biochem Suppl** 1996;25:85–91 (30 ref.)
Variations on the intracellular transport theme: maturing cisternae and trafficking tubules. Mironov AA, et al. **J Cell Biol** 1997 Aug 11;138(3):481–4 (39 ref.)
Epidermal structural proteins in skin disorders. Manabe M, et al. **J Dermatol Sci** 1997 Sep;15(3):143–65 (167 ref.)
Identification of p55 tumor necrosis factor receptor–associated proteins that couple to signaling pathways not initiated by the death domain. Adam D, et al. **J Inflamm** 1995–96;47(1–2):61–6 (35 ref.)
Detection of pathological changes of proteins by peptide mapping after protein digestion by use of oriented immobilized proteinases. Turková J, et al. **J Mol Recognit** 1996 Sep–Dec;9(5–6):360–3 (15 ref.)
Obesity as a pleiotropic effect of gene action. Wolff GL. **J Nutr** 1997 Sep;127(9):1897S–1901S (31 ref.)
Energetic and entropic factors determining binding affinity in protein–ligand complexes. Klebe G, et al. **J Recept Signal Transduct Res** 1997 Jan–May; 17(1–3):459–73 (58 ref.)
Protein sorting and secretory granule formation in prolactin–producing cells in the anterior pituitary. Ozawa H. **Kaibogaku Zasshi** 1997 Feb;72(1):13–24 (62 ref.)
Protein glycation in the kidney: role in diabetes and aging. Vlassara H. **Kidney Int** 1996 Jun;49(6):1795–804 (69 ref.)
Regulation of the cyclin–dependent kinase inhibitor p27 by degradation and phosphorylation. Alessandrini A, et al. **Leukemia** 1997 Mar;11(3):342–5 (63 ref.)
Detection of nitric oxide interaction with zinc finger proteins. Kröncke KD, et al. **Methods Enzymol** 1996;269:279–84 (26 ref.)
Studies of protein–ligand interactions by NMR. Craik DJ, et al. **Methods Mol Biol** 1997;60:195–232 (61 ref.)
Nucleocytoplasmic transport of macromolecules. Corbett AH, et al. **Microbiol Mol Biol Rev** 1997 Jun;61(2):193–211 (282 ref.)
Proteins in unexpected locations. Smalheiser NR. **Mol Biol Cell** 1996 Jul;7(7):1003–14 (141 ref.)
Protein degradation by the proteasome and dissection of its in vivo importance with synthetic inhibitors. Goldberg AL, et al. **Mol Biol Rep** 1997 Mar;24(1–2):69–75 (32 ref.)
Structural and functional properties of proteasome activator PA28. Kuehn L, et al. **Mol Biol Rep** 1997 Mar; 24(1–2):89–93 (39 ref.)
Nuclear targeting of secretory proteins. Henderson JE. **Mol Cell Endocrinol** 1997 Apr 25;129(1):1–5 (23 ref.)
Fluorescence polarization analysis of protein–DNA and protein–protein interactions. Lundblad JR, et al. **Mol Endocrinol** 1996 Jun;10(6):607–12 (12 ref.)
Protein:protein interactions in the lipid bilayer (review). Harrison PT. **Mol Membr Biol** 1996 Apr–Jun;13(2):67–79 (69 ref.)
Antimutagenicity of the porphyrins and non–enzyme porphyrin–containing proteins. Odin AP. **Mutat Res** 1997 Aug;387(1):55–68 (100 ref.)
Obesity research springs a proton leak [news; comment] Flier JS, et al. **Nat Genet** 1997 Mar;15(3):223–4 (17 ref.) Comment on: Nat Genet 1997 Mar;15(3):269–72.
How do proteins acquire their three–dimensional structure and stability? Jaenicke R. **Naturwissenschaften** 1996 Dec; 83(12):544–54 (42 ref.)
Protein catabolism in maintenance haemodialysis: the influence of the dialysis membrane. Gutierrez A. **Nephrol Dial Transplant** 1996;11 Suppl 2:108–11 (40 ref.)
Protein degradation by proteasomes: molecular mechanisms of muscle catabolism [editorial] Mitch WE, et al. **Nephrol Dial Transplant** 1997 Jan;12(1):13–5 (15 ref.)
Lipoxidation products as biomarkers of oxidative damage to proteins during lipid peroxidation reactions. Requena JR, et al. **Nephrol Dial Transplant** 1996;11 Suppl 5:48–53 (28 ref.)
New biomarkers of Maillard reaction damage to proteins. Wells–Knecht KJ, et al. **Nephrol Dial Transplant** 1996;11 Suppl 5:41–7 (53 ref.)
Leptin. Meinders AE, et al. **Neth J Med** 1996 Dec; 49(6):247–52 (24 ref.)
Low–protein intakes and protein turnover in elderly women. de Groot LC, et al. **Nutr Rev** 1996 Feb;54(2 Pt 1):58–60 (12 ref.)
Metabolic response to injury and sepsis: changes in protein metabolism. Biolo G, et al. **Nutrition** 1997 Sep;13(9 Suppl):52S–57S (52 ref.)
Models for investigation of peptide and protein transport across cultured mammalian respiratory epithelial barriers. Kim KJ, et al. **Pharm Biotechnol** 1996;8:325–46 (155 ref.)
Equilibrium, kinetics, diffusion and self–association of proteins at membrane surfaces: measurement by total internal reflection fluorescence microscopy. Thompson NL, et al. **Photochem Photobiol** 1997 Jan;65(1):39–46 (43 ref.)
The interaction of agouti signal protein and melanocyte stimulating hormone to regulate melanin formation in mammals. Furumura M, et al. **Pigment Cell Res** 1996 Aug; 9(4):191–203 (135 ref.)
The N–end rule: functions, mysteries, uses. Varshavsky A. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12142–9 (79 ref.)
Modelling post–absorptive protein and amino acid metabolism in the ruminant. Hanigan MD, et al. **Proc Nutr Soc** 1997 Jul;56(2):631–43 (49 ref.)
Liver protein and glutamine metabolism during cachexia. Hulsewé KW, et al. **Proc Nutr Soc** 1997 Jul;56(2):801–6 (23 ref.)
Protein–protein recognition. Janin J. **Prog Biophys Mol Biol** 1995;64(2–3):145–66 (100 ref.)
Growth hormone therapy for protein catabolism. Jenkins RC, et al. **QJM** 1996 Nov;89(11):813–9 (47 ref.)
Anchoring and scaffold proteins for kinases and phosphatases. Lester LB, et al. **Recent Prog Horm Res** 1997; 52:409–29; discussion 429–30 (98 ref.)
Mechanisms causing loss of muscle in acute uremia. Mitch WE. **Ren Fail** 1996 May;18(3):389–94 (36 ref.)
Can hemodialysis technique modify the hypercatabolic state? Sunder–Plassmann G, et al. **Ren Fail** 1996 May; 18(3):395–404 (70 ref.)
How proteolysis drives the cell cycle. King RW, et al. **Science** 1996 Dec 6;274(5293):1652–9 (120 ref.)
Pass the butter... [comment] Martin G. **Science** 1996 Oct 11; 274(5285):203–4 (22 ref.) Comment on: Science 1996 Oct 11;274(5285):255–9.
Journey across the osteoclast [comment] Mostov K, et al. **Science** 1997 Apr 11;276(5310):219–20 (17 ref.) Comment on: Science 1997 Apr 11;276(5310):266–9. Comment on: Science 1997 Apr 11;276(5310):270–3.
A biopolymer by any other name would bind as well: a comparison of the ligand–binding pockets of nucleic acids and proteins. Marshall KA, et al. **Structure** 1997 Jun 15; 5(6):729–34 (29 ref.)
Lysosomal metabolism of proteins. Mason RW. **Subcell Biochem** 1996;27:159–90 (120 ref.)
Intracellular protein transport to the thyrocyte plasma membrane: potential implications for thyroid physiology. Arvan P, et al. **Thyroid** 1997 Feb;7(1):89–105 (293 ref.)
Selective protein covalent binding and target organ toxicity. Cohen SD, et al. **Toxicol Appl Pharmacol** 1997 Mar; 143(1):1–12 (99 ref.)
Not all Shc's roads lead to Ras. Bonfini L, et al. **Trends Biochem Sci** 1996 Jul;21(7):257–61 (51 ref.)
Proteasomes: destruction as a programme. Hilt W, et al. **Trends Biochem Sci** 1996 Mar;21(3):96–102 (48 ref.)
Highways for protein delivery to the mitochondria [see comments] Lithgow T, et al. **Trends Biochem Sci** 1997 Apr; 22(4):110–3 (30 ref.) Comment in: Trends Biochem Sci 1997 Aug;22(8):290.
PEST sequences and regulation by proteolysis. Rechsteiner M, et al. **Trends Biochem Sci** 1996 Jul;21(7):267–71 (48 ref.)
PDZ domains bind carboxy–terminal sequences of target proteins. Saras J, et al. **Trends Biochem Sci** 1996 Dec; 21(12):455–8 (25 ref.)
ATP–dependent proteases that also chaperone protein biogenesis. Suzuki CK, et al. **Trends Biochem Sci** 1997 Apr; 22(4):118–23 (48 ref.)
A senescent pattern of pituitary function during critical illness and dopamine treatment. Van den Berghe GH, et al. **Verh K Acad Geneeskd Belg** 1996;58(4):383–411 (178 ref.)
[Leptin—a new weight–loss agent?] Holst JJ. **Nord Med** 1996 Nov;111(9):300–3 (13 ref.) (Eng. Abstr.) **(Dan)**
[Protein requirements of healthy infants and children. Comité de nutrition de la Société française de Pediatrie] **Arch Pediatr** 1997 Apr;4(4):373–82 (48 ref.) (Eng. Abstr.) **(Fre)**
[OB protein and its receptor: signal transduction between adipose tissue and central nervous system] Campfield LA, et al. **Journ Annu Diabetol Hotel Dieu** 1997;:131–48 (63 ref.) **(Fre)**
[Nephrotic syndrome and protein metabolism] Fouque D. **Nephrologie** 1996;17(5):279–82 (24 ref.) (Eng. Abstr.) **(Fre)**
[Glutamine: effects on the immune system, protein balance and intestinal functions (see comments)] Roth E, et al. **Wien Klin Wochenschr** 1996;108(21):669–76 (59 ref.) (Eng. Abstr.) Comment in: Wien Klin Wochenschr 1996 ;108(21):667–8. **(Ger)**
[Characterization of the MCC gene product] Matsumine A. **Nippon Rinsho** 1996 Apr;54(4):981–5 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Protein turnover] Tashiro T, et al. **Nippon Rinsho** 1997 Mar; 55 Suppl 1:256–61 (16 ref.) **(Jpn)**
[Spatial resolution of proteolytic reactions in brain ischemia and Alzheimer's disease] Saido TC. **Seikagaku** 1996 Sep; 68(9):1507–22 (73 ref.) **(Jpn)**
[ERM (ezrin/radixin/moesin) as crosslinkers between actin filaments and plasma membranes] Tsukita S. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1899–905 (44 ref.) **(Jpn)**
[Insulin–like growth factors (IGFs) and their binding proteins (IGFBPs)in physiologic and pathologic states] Marek B, et al. **Pol Arch Med Wewn** 1996 Sep;96(3):290–6 (82 ref.) **(Pol)**
[Cell polarity, polar proteins and cytokinesis] Kaczanowska J, et al. **Postepy Biochem** 1996;42(3):227–37 (46 ref.) **(Pol)**
[Biologically active peptide fragments of functional proteins produced by proteolysis in vitro] Filippova MM, et al. **Bioorg Khim** 1997 May;23(5):388–409 (168 ref.) (Eng. Abstr.) **(Rus)**
[Signal reception, protein kinesis and aging] García de Jalón P. **An R Acad Nac Med (Madr)** 1996;113(3):593–610; discussion 610–3 (41 ref.) **(Spa)**
[Stable isotopes in nutrition research] de Santiago S, et al. **Arch Latinoam Nutr** 1995 Mar;45(1):6–11 (28 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOKINETICS

Some approaches to improve bioavailability of peptides and proteins through oral and other mucosal routes. Vyas SP, et al. **Pharmazie** 1997 May;52(5):339–45 (67 ref.)

[Digestion and absorption mechanism of carbohydrates and proteins in intestines] Takeda E, et al. **Nippon Naika Gakkai Zasshi** 1996 Jul 10;85(7):1029–33 (5 ref.) **(Jpn)**

PHARMACOLOGY

C-type natriuretic protein inhibits intimal thickening after vascular injury. Matsuo H, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:45–7 (10 ref.)

Sympathetic and cardiorenal actions of leptin. Haynes WG, et al. **Hypertension** 1997 Sep;30(3 Pt 2):619–23 (45 ref.)

A new uncoupling protein: a potential component of the human body weight regulation system. Wolf G. **Nutr Rev** 1997 May;55(5):178–9 (8 ref.)

Proteins and bone health. Bonjour JP, et al. **Pathol Biol (Paris)** 1997 Jan;45(1):57–9 (31 ref.)

[Uronic-acid-rich protein: a new glycoprotein inhibiting the crystallization of calcium oxalate in vitro] Atmani F, et al. **Nephrologie** 1996;17(3):157–62 (57 ref.) (Eng. Abstr.) **(Fre)**

[The clinical pharmacology and efficacy of statins] Sidorenko BA, et al. **Ter Arkh** 1996;68(9):80–4 (30 ref.) **(Rus)**

PHYSIOLOGY

p53 and ATM: cell cycle, cell death, and cancer. Morgan SE, et al. **Adv Cancer Res** 1997;71:1–25 (190 ref.)

A proposed role for protein. Protein complexes in the regulation of the reversible ADP-ribosylation of dinitrogenase reductase. Grunwald SK, et al. **Adv Exp Med Biol** 1997;419:61–9 (30 ref.)

Role of host proteins in gene expression of nonsegmented negative strand RNA viruses. De BP, et al. **Adv Virus Res** 1997;48:169–204 (141 ref.)

Parathyroid hormone-related protein: from hypercalcemia of malignancy to developmental regulatory molecule. Dunbar ME, et al. **Am J Med Sci** 1996 Dec;312(6):287–94 (42 ref.)

Parathyroid-hormone-related peptides. A new class of multifunctional proteins. Roskams T, et al. **Am J Pathol** 1997 Mar;150(3):779–85 (91 ref.)

Leptin and other secretory products of adipocytes modulate multiple physiological functions. Weigle DS. **Ann Endocrinol (Paris)** 1997;58(2):132–6 (34 ref.)

Endogenous vertebrate antibiotics. Defensins, protegrins, and other cysteine-rich antimicrobial peptides. Lehrer RI, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:228–39 (55 ref.)

A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth. Anand-Apte B, et al. **Biochem Cell Biol** 1996;74(6):853–62 (75 ref.)

Of mice and women: the beta 3-adrenergic receptor leptin and obesity. Bégin-Heick N. **Biochem Cell Biol** 1996; 74(5):615–22 (67 ref.)

Molecular regulation of cellular invasion--role of gelatinase A and TIMP-2. Yu AE, et al. **Biochem Cell Biol** 1996; 74(6):823–31 (74 ref.)

Properties of A-kinase anchoring proteins. Hausken ZE, et al. **Biochem Soc Trans** 1996 Nov;24(4):986–91 (50 ref.)

Hormones and the ob gene product (leptin) in the control of energy balance. Trayhurn P, et al. **Biochem Soc Trans** 1996 May;24(2):565–70 (36 ref.)

Proteins involved in peroxisome biogenesis and functioning. Elgersma Y, et al. **Biochim Biophys Acta** 1996 Oct 29; 1286(3):269–83 (129 ref.)

Structure and function of proteins in G-protein-coupled signal transfer. Helmreich EJ, et al. **Biochim Biophys Acta** 1996 Oct 29;1286(3):285–322 (525 ref.)

Wnt signalling goes nuclear. Kühl M, et al. **Bioessays** 1997 Feb;19(2):101–4 (29 ref.)

Obesity genes and the regulation of body fat content. Weigle DS, et al. **Bioessays** 1996 Nov;18(11):867–74 (79 ref.)

Computational genomic analysis of hemorrhagic fever viruses. Viral selenoproteins as a potential factor in pathogenesis. Ramanathan CS, et al. **Biol Trace Elem Res** 1997 Jan;56(1):93–106 (46 ref.)

Parathyroid hormone-related peptide and hypercalcemia of malignancy. Goltzman D, et al. **Cancer Treat Res** 1997; 89:193–215 (96 ref.)

Blood vessel formation: what is its molecular basis? [comment] Folkman J, et al. **Cell** 1996 Dec 27;87(7):1153–5 (20 ref.) Comment on: Cell 1996 Dec 27;87(7):1161–9. Comment on: Cell 1996 Dec 27;87(7):1171–80. Comment on: Cell 1996 Dec 27;87(7):1181–90.

Adipogenesis and obesity: rounding out the big picture. Spiegelman BM, et al. **Cell** 1996 Nov 1;87(3):377–89 (110 ref.)

CED-4--the third horseman of apoptosis [comment] Vaux DL. **Cell** 1997 Aug 8;90(3):389–90 (17 ref.) Comment on: Cell 1997 Aug 8;90(3):405–13.

Roles of cartilage matrix proteins, chondromodulin-I and -II, in endochondral bone formation: a review. Suzuki F. **Connect Tissue Res** 1996;35(1–4):303–7 (21 ref.)

Actin cytoskeleton: are FH proteins local organizers? Frazier JA, et al. **Curr Biol** 1997 Jul 1;7(7):R414–7 (22 ref.)

A new twist to the tale? Apoptosis. Warbrick E. **Curr Biol** 1996 Sep 1;6(9):1057–9 (10 ref.)

Cell-cell signalling: frog frizbees. Zorn AM. **Curr Biol** 1997 Aug 1;7(8):R501–4 (18 ref.)

ERM (ezrin/radixin/moesin) family: from cytoskeleton to signal transduction. Tsukita S, et al. **Curr Opin Cell Biol** 1997 Feb;9(1):70–5 (42 ref.)

Physiological and pathological roles of parathyroid hormone-related peptide. Guise TA, et al. **Curr Opin Nephrol Hypertens** 1996 Jul;5(4):307–15 (126 ref.)

The Eph family in retinal axon guidance. Drescher U, et al. **Curr Opin Neurobiol** 1997 Feb;7(1):75–80 (54 ref.)

Role of Tiam 1 in Rac-mediated signal transduction pathways. Collard JG, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 2):253–65 (73 ref.)

Leptin and OB-R: body weight regulation by a cytokine receptor. White DW, et al. **Cytokine Growth Factor Rev** 1996 Dec;7(4):303–9 (61 ref.)

Parathyroid hormone-related protein as a cardiovascular regulatory peptide [editorial; comment] Massfelder T, et al. **Endocrinology** 1996 Aug;137(8):3151–3 (31 ref.) Comment on: Endocrinology 1996 Aug;137(8):3154–62.

Lords and ladies leapin 'on leptin [editorial; comment] Steiner RA. **Endocrinology** 1996 Nov;137(11):4533–5 (29 ref.) Comment on: Endocrinology 1996 Nov;137(11):5182–5.

Parathyroid hormone-related protein and its role in pregnancy, lactation, and neonatal growth and development [comment] Cooper CW. **Eur J Endocrinol** 1997 May;136(5):465–6 (13 ref.) Comment on: Eur J Endocrinol 1997 May;136(5):546–51.

Human leptin: the hormone of adipose tissue. Sinha MK. **Eur J Endocrinol** 1997 May;136(5):461–4 (33 ref.)

Leptin, leptin receptors and the control of body weight. Friedman JM. **Eur J Med Res** 1997 Jan;2(1):7–13 (46 ref.)

Strange bedfellows in even stranger places: the role of ATM in meiotic cells, lymphocytes, tumors, and its functional links to p53 [comment] Hawley RS, et al. **Genes Dev** 1996 Oct 1;10(19):2383–8 (49 ref.) Comment on: Genes Dev 1996 Oct 1;10(19):2423–37. Comment on: Genes Dev 1996 Oct 1;10(19):2401–10. Comment on: Genes Dev 1996 Oct 1;10(19):2411–22.

The OB protein (leptin) pathway--a link between adipose tissue mass and central neural networks. Campfield LA, et al. **Horm Metab Res** 1996 Dec;28(12):619–32 (96 ref.)

The loop system between neuropeptide Y and leptin in normal and obese rodents. Rohner-Jeanrenaud F, et al. **Horm Metab Res** 1996 Dec;28(12):642–8 (61 ref.)

Obesity results as a consequence of glucocorticoid induced leptin resistance. Ur E, et al. **Horm Metab Res** 1996 Dec; 28(12):744–7 (38 ref.)

The endothelin-parathyroid hormone-related protein vasoactive peptide system in human endometrium: modulation by transforming growth factor-beta. Casey ML, et al. **Hum Reprod** 1996 Oct;11 Suppl 2:62–82 (116 ref.)

The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application. Bramhall SR. **Int J Pancreatol** 1997 Feb; 21(1):1–12 (100 ref.)

Cellular and molecular analysis of lymphoid development using Rag-deficient mice. Spanopoulou E. **Int Rev Immunol** 1996;13(4):257–88 (216 ref.)

Interaction of HTLV-I Tax with the human proteasome: implications for NF-kappa B induction. Béraud C, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S76–84 (88 ref.)

The leptin receptor. Tartaglia LA. **J Biol Chem** 1997 Mar 7;272(10):6093–6 (59 ref.)

Clinical review 90: Leptin and clinical medicine: a new piece in the puzzle of obesity. Bray GA, et al. **J Clin Endocrinol Metab** 1997 Sep;82(9):2771–6 (77 ref.)

Guanine nucleotide exchange factors for the Rho GTPases: a role in human disease? Olson MF. **J Mol Med** 1996 Oct; 74(10):563–71 (85 ref.)

On the classification and evolution of protein modules. Hegyi H, et al. **J Protein Chem** 1997 Jul;16(5):545–51 (32 ref.)

Leptin. Remesar X, et al. **Med Res Rev** 1997 May; 17(3):225–34 (124 ref.)

Leptin in anorexia nervosa and amenorrhea [editorial; comment] Licinio J. **Mol Psychiatry** 1997 Jul;2(4):267–9 (23 ref.) Comment on: Mol Psychiatry 1997 Jul;2(4):330–4. Comment on: Mol Psychiatry 1997 Jul;2(4):335–40.

Leptin: the weight-reducing plasma protein encoded by the obese gene. **Nutr Rev** 1996 Mar;54(3):91–3 (12 ref.)

Neuropeptides responding to leptin. Wolf G. **Nutr Rev** 1997 Mar;55(3):85–8 (20 ref.)

An update on the discovery, pathophysiological actions, clinical manifestations and possible physiology of parathyroid related peptide. Alcantara A, et al. **P R Health Sci J** 1997 Mar;16(1):15–22 (19 ref.)

The role of ras GTPase activating protein in human tumorigenesis. Friedman E. **Pathobiology** 1995;63(6):348–50 (21 ref.)

Glycosaminoglycans, proteins, and stone formation: adult themes and child's play. Ryall RL. **Pediatr Nephrol** 1996 Oct;10(5):656–66 (134 ref.)

Biological role of tyrosinase related protein and its biosynthesis and transport from TGN to stage I melanosome, late endosome, through gene transfection study. Jimbow K, et al. **Pigment Cell Res** 1997 Aug; 10(4):206–13 (34 ref.)

Signaling molecules that mediate the actions of FGF. Demo SD, et al. **Princess Takamatsu Symp** 1994;24:243–9 (23 ref.)

Rho small G protein and cytoskeletal control. Takai Y, et al. **Princess Takamatsu Symp** 1994;24:338–50 (64 ref.)

Evidence for a central mechanism of obesity in the Zucker rat: role of neuropeptide Y and leptin. White BD, et al. **Proc Soc Exp Biol Med** 1997 Mar;214(3):222–32 (135 ref.)

Structural and functional diversity in the leucine-rich repeat family of proteins. Buchanan SG, et al. **Prog Biophys Mol Biol** 1996;65(1–2):1–44 (196 ref.)

Structure and function of the WW domain. Sudol M. **Prog Biophys Mol Biol** 1996;65(1–2):113–32 (128 ref.)

Role of translation initiation factor eIF-2B in the regulation of protein synthesis in mammalian cells. Kimball SR, et al. **Prog Nucleic Acid Res Mol Biol** 1996;54:165–96 (106 ref.)

Role of parathyroid hormone-related peptide in hypercalcemia of malignancy and the development of osteolytic metastases. de Vernejoul MC. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):119S–123S (36 ref.)

The world according to hedgehog. Hammerschmidt M, et al. **Trends Genet** 1997 Jan;13(1):14–21 (93 ref.)

Physiological roles for parathyroid hormone-related protein: lessons from gene knockout mice. Karaplis AC, et al. **Vitam Horm** 1996;52:177–93 (24 ref.)

The roles of 14-3-3 proteins in signal transduction. Reuther GW, et al. **Vitam Horm** 1996;52:149–75 (97 ref.)

[The molecular pathogenesis of obesity. The physiological and pathophysiological role of leptin] Spitzweg C, et al. **Dtsch Med Wochenschr** 1996 Sep 13;121(37):1134–8 (33 ref.) **(Ger)**

[APC, beta-catenin, DLG] Akiyama T. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1432–5 (9 ref.) (Eng. Abstr.) **(Jpn)**

[VHL gene and TSC 2 gene] Hino O. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1386–91 (27 ref.) (Eng. Abstr.) **(Jpn)**

[Cdk inhibiting proteins] Tomoda K, et al. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1407–13 (25 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular structure and function of proteins] Tanokura M, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):961–2 (0 ref.) **(Jpn)**

[Visualized biomolecules as tools to explore cell function] Yuba S, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):915–9 (10 ref.) **(Jpn)**

[Leptin and its biological and clinical significance. Is leptin and insulin resistance in the X-5H hormonal metabolic syndrome a parallel or causally-linked phenomenon?] Hrnčiar J. **Vnitr Lek** 1997 Feb;43(2):120–4 (21 ref.) (Eng. Abstr.) **(Slo)**

SECRETION

Leptin and other secretory products of adipocytes modulate multiple physiological functions. Weigle DS. **Ann Endocrinol (Paris)** 1997;58(2):132–6 (34 ref.)

The dynamic organisation of the secretory pathway. Pelham HR. **Cell Struct Funct** 1996 Oct;21(5):413–9 (48 ref.)

Sorting sweet sorting. Protein secretion. Ponnambalam S, et al. **Curr Biol** 1996 Sep 1;6(9):1076–8 (23 ref.)

Protein secretion: puzzling receptors. Thiele C, et al. **Curr Biol** 1997 Aug 1;7(8):R496–500 (25 ref.)

Regulation of membrane traffic in the secretory pathway. Schekman RW. **Harvey Lect** 1994–95;90:41–57 (58 ref.)

The osmotic and intrinsic mechanisms of the pharmacological laxative action of oral high doses of magnesium sulphate. Importance of the release of digestive polypeptides and nitric oxide. Izzo AA, et al. **Magnes Res** 1996 Jun; 9(2):133–8 (35 ref.)

Nuclear targeting of secretory proteins. Henderson JE. **Mol Cell Endocrinol** 1997 Apr 25;129(1):1–5 (23 ref.)

THERAPEUTIC USE

PTHrP(1–36) as a skeletal anabolic agent for the treatment of osteoporosis. Stewart AF. **Bone** 1996 Oct;19(4):303–6 (41 ref.)

Use of secretory leukoprotease inhibitor to augment lung antineutrophil elastase activity. Vogelmeier C, et al. **Chest** 1996 Dec;110(6 Suppl):261S–266S (58 ref.)

Statins and fibrates in the management of diabetic dyslipidemia [editorial; comment] Durrington P. **Diabet Med** 1997 Jul;14(7):513–6 (26 ref.) Comment on: Diabet Med 1997 Jul;14(7):564–70.

Secretory leukoprotease inhibitor: partnering alpha 1-proteinase inhibitor to combat pulmonary inflammation. Bingle L, et al. **Thorax** 1996 Dec;51(12):1273–4 (13 ref.)

[The clinical pharmacology and efficacy of statins] Sidorenko BA, et al. **Ter Arkh** 1996;68(9):80–4 (30 ref.) **(Rus)**

ULTRASTRUCTURE

The physical chemical basis for preserving cell structure for electron microscopy at the molecular level and available preparatory methods. Sjöstrand FS. **J Submicrosc Cytol Pathol** 1997 Apr;29(2):157–72 (27 ref.)

[Visualization of protein molecules using fluorescence-labeled bioactive compounds] Hiratsuka T. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1069–74 (15 ref.) **(Jpn)**

PROTEINS, ACUTE-PHASE see **ACUTE-PHASE PROTEINS**

PROTEINS, DIETARY

PROTEINS, DIETARY see **DIETARY PROTEINS**

PROTEINS, IMMEDIATE-EARLY see **IMMEDIATE-EARLY PROTEINS**

PROTEINS, RIBOSOMAL see **RIBOSOMAL PROTEINS**

PROTEINURIA

Proteinuria as a consequence of altered glomerular permselectivity--clinical implications. Oberbauer R, et al. **Clin Nephrol** 1996 Dec;46(6):357-61 (29 ref.)

Proteinuria and progression of renal disease: therapeutic implications. Gansevoort RT, et al.
Curr Opin Nephrol Hypertens 1997 Mar;6(2):133-40 (55 ref.)

Proteinuria. Roy S 3rd. **Pediatr Ann** 1996 May;25(5):277-8, 281-2 (13 ref.)

DIAGNOSIS

Proteinuria. How much evaluation is appropriate? Ali H. **Postgrad Med** 1997 Apr;101(4):173-5, 179-80 (5 ref.)

[Approach to proteinuria] Ishida M.
Nippon Naika Gakkai Zasshi 1996 Sep 10;85(9):1534-9 (12 ref.) **(Jpn)**

DRUG THERAPY

Effect of antiproteinuric treatment on the lipid profile in nondiabetic renal disease. Navis G, et al.
Contrib Nephrol 1997;120:88-96 (50 ref.)

Prognostic value of the short-term antiproteinuric response to ACE inhibition for prediction of GFR decline in patients with nondiabetic renal disease. Wapstra FH, et al.
Exp Nephrol 1996;4 Suppl 1:47-52 (48 ref.)

ACE inhibitors and proteinuria. Gansevoort RT, et al.
Pharm World Sci 1996 Dec;18(6):204-10 (81 ref.)

ETIOLOGY

[Approach to proteinuria] Ishida M.
Nippon Naika Gakkai Zasshi 1996 Sep 10;85(9):1534-9 (12 ref.) **(Jpn)**

[Idiopathic tubular proteinuria (Dent's disease)] Igarashi T.
Ryoikibetsu Shokogun Shirizu 1997;(16 Pt 1):670-3 (17 ref.) **(Jpn)**

GENETICS

Expression of genes that promote renal interstitial fibrosis in rats with proteinuria. Eddy AA. **Kidney Int Suppl** 1996 May;54:S49-54 (24 ref.)

PHYSIOPATHOLOGY

Prognostic value of the short-term antiproteinuric response to ACE inhibition for prediction of GFR decline in patients with nondiabetic renal disease. Wapstra FH, et al.
Exp Nephrol 1996;4 Suppl 1:47-52 (48 ref.)

Progression of proteinuric diabetic and nondiabetic renal diseases: a possible role for renal endothelin. Remuzzi G, et al. **Kidney Int Suppl** 1997 Mar;58:S66-8 (40 ref.)

Proteinuria and albumin homeostasis in the nephrotic syndrome: effect of dietary protein intake. Rodrigo R, et al. **Nutr Rev** 1996 Nov;54(11 Pt 1):337-47 (107 ref.)

PREVENTION & CONTROL

Titrating for antiproteinuric effect: the clue to renoprotection? Navis G, et al. **J Hum Hypertens** 1996 Oct; 10(10):669-73 (47 ref.)

THERAPY

Focal segmental glomerulosclerosis: to treat or not to treat? 2. Focal and segmental glomerulosclerosis is not a disease, but an untreatable lesion of unknown pathophysiology. Its treatment must not be uselessly hazardous. Meyrier A.
Nephrol Dial Transplant 1995 Dec;10(12):2355-9 (31 ref.)

URINE

Salt intake and reductions in arterial pressure and proteinuria. Is there a direct link? Bakris GL, et al.
Am J Hypertens 1996 Dec;9(12 Pt 2):200S-206S (75 ref.)

PROTEINURIA-EDEMA-HYPERTENSION GESTOSIS see **GESTOSIS, EPH**

PROTEOCHONDROITIN SULFATES

Versican. Lebaron RG. **Perspect Dev Neurobiol** 1996; 3(4):261-71 (98 ref.)

[Neural proteoglycans: neuroglycan C (NGC), neurocan, and phosphacan] Tokita Y, et al.
Tanpakushitsu Kakusan Koso 1997 Feb;42(3 Suppl):567-70 (17 ref.) **(Jpn)**

BIOSYNTHESIS

Organization of glycosaminoglycan sulfation in the biosynthesis of proteochondroitin sulfate and proteodermatan sulfate. Silbert JE. **Glycoconj J** 1996 Dec; 13(6):907-12 (65 ref.)

METABOLISM

beta-Catenin is a target for extracellular signals controlling cadherin function: the neurocan-GalNAcPTase connection. Lilien J, et al. **Curr Top Dev Biol** 1997; 35:161-89 (137 ref.)

Neurocan and phosphacan: two major nervous tissue-specific chondroitin sulfate proteoglycans. Margolis RK, et al. **Perspect Dev Neurobiol** 1996;3(4):273-90 (91 ref.)

Brevican: a major proteoglycan in adult brain. Yamaguchi Y. **Perspect Dev Neurobiol** 1996;3(4):307-17 (54 ref.)

PHYSIOLOGY

Characterization of appican, the chondroitin sulfate proteoglycan form of the Alzheimer amyloid precursor protein. Pangalos MN, et al. **Neurodegeneration** 1996 Dec; 5(4):445-51 (57 ref.)

Functions of brain chondroitin sulfate proteoglycans during developments: interactions with adhesion molecules. Grumet M, et al. **Perspect Dev Neurobiol** 1996;3(4):319-30 (67 ref.)

PROTEOGLYCANS

The family of the small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth. Iozzo RV. **Crit Rev Biochem Mol Biol** 1997;32(2):141-74 (162 ref.)

[Neural proteoglycans: neuroglycan C (NGC), neurocan, and phosphacan] Tokita Y, et al.
Tanpakushitsu Kakusan Koso 1997 Feb;42(3 Suppl):567-70 (17 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Pre- and/or post-operative immunochemotherapy for advanced digestive cancer. Saji S, et al.
Gan To Kagaku Ryoho 1997 May;24 Suppl 1:239-49 (14 ref.)

ANALYSIS

Biochemical markers of skeletal growth in children. Branca F. **Bibl Nutr Dieta** 1996;(53):90-102 (39 ref.)

BIOSYNTHESIS

Organization of glycosaminoglycan sulfation in the biosynthesis of proteochondroitin sulfate and proteodermatan sulfate. Silbert JE. **Glycoconj J** 1996 Dec; 13(6):907-12 (65 ref.)

Glucosamine may retard atherogenesis by promoting endothelial production of heparan sulfate proteoglycans. McCarty MF. **Med Hypotheses** 1997 Mar;48(3):245-51 (94 ref.)

Inherited disorders of glycoprotein synthesis: cell biological insights. McDowell G, et al. **Proc Soc Exp Biol Med** 1997 Jun;215(2):145-57 (89 ref.)

CHEMISTRY

Glycoconjugate cross-talk in metastatic cancer cells, leucocytes, parasites and bacteria. Leroy A, et al.
Biochem Soc Trans 1997 Feb;25(1):228-34 (48 ref.)

Arabinogalactan proteins: a family of cell-surface and extracellular matrix plant proteoglycans. Bacic A, et al. **Essays Biochem** 1996;31:91-101 (29 ref.)

N-syndecan: structure and function of a transmembrane heparan sulfate proteoglycan. Carey DJ.
Perspect Dev Neurobiol 1996;3(4):331-46 (77 ref.)

GENETICS

[Cloning of testican/SPOCK in man and mouse. Neuromuscular expression perspectives in pathology] Charbonnier F, et al. **C R Seances Soc Biol Fil** 1997; 191(1):127-33 (20 ref.) (Eng. Abstr.) **(Fre)**

[Proteoglycans and pathology--new aspects] Kolset SO, et al. **Tidsskr Nor Laegeforen** 1997 Mar 10;117(7):951-4 (11 ref.) (Eng. Abstr.) **(Nor)**

METABOLISM

Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis. Hurt-Camejo E, et al. **Arterioscler Thromb Vasc Biol** 1997 Jun;17(6):1011-7 (101 ref.)

Arabinogalactan proteins: a family of cell-surface and extracellular matrix plant proteoglycans. Bacic A, et al. **Essays Biochem** 1996;31:91-101 (29 ref.)

Heparan sulphate proteoglycans and diabetic nephropathy. van der Woude FJ, et al. **Exp Nephrol** 1997 May-Jun; 5(3):180-8 (77 ref.)

Articular cartilage destruction in experimental inflammatory arthritis: insulin-like growth factor-1 regulation of proteoglycan metabolism in chondrocytes. Verschure PJ, et al. **Histochem J** 1996 Dec;28(12):835-57 (263 ref.)

Microbial adherence to and invasion through proteoglycans. Rostand KS, et al. **Infect Immun** 1997 Jan;65(1):1-8 (114 ref.)

Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans. Biological implications in neovascularization. Rusnati M, et al.
Int J Clin Lab Res 1996;26(1):15-23 (91 ref.)

Proteoglycans and related components in plant cells. Nothnagel EA. **Int Rev Cytol** 1997;174:195-291 (296 ref.)

The glypican family of heparan sulfate proteoglycans: major cell-surface proteoglycans of the developing nervous system. Lander AD, et al. **Perspect Dev Neurobiol** 1996; 3(4):347-58 (69 ref.)

Brain aggrecan. Schwartz NB, et al.
Perspect Dev Neurobiol 1996;3(4):291-306 (87 ref.)

Brevican: a major proteoglycan in adult brain. Yamaguchi Y. **Perspect Dev Neurobiol** 1996;3(4):307-17 (54 ref.)

[Proteoglycans and breast cancer] Delehedde M, et al. **Pathol Biol (Paris)** 1997 Apr;45(4):305-11 (57 ref.) (Eng. Abstr.) **(Fre)**

[The role of syndecan and tenascine during tooth development. Review o the literature] Bucci P, et al. **Minerva Stomatol** 1996 Jun;45(6):259-66 (15 ref.) (Eng. Abstr.) **(Ita)**

PHARMACOKINETICS

Matrigel: a useful tool to study endothelial differentiation. Baatout S, et al. **Rom J Intern Med** 1996 Jul-Dec; 34(3-4):263-9 (51 ref.)

PHARMACOLOGY

Inhibition of neointimal formation by natural heparan sulfate proteoglycans of the arterial wall. Bingley JA, et al.
Ann N Y Acad Sci 1997 Apr 15;811:238-42; 242-4 (19 ref.)

PHYSIOLOGY

The role of syndecan-1 in malignancies. Inki P, et al.
Ann Med 1996 Feb;28(1):63-7 (32 ref.)

Heparan sulfate in immune responses. Selvan RS, et al.
Ann N Y Acad Sci 1996 Oct 25;797:127-39 (106 ref.)

Endothelial differentiation using Matrigel (review). Baatout S. **Anticancer Res** 1997 Jan-Feb;17(1A):451-5 (65 ref.)

Heparan sulfate proteoglycans. Essential co-factors in receptor-mediated processes with relevance to the biology of the vascular wall. David G, et al. **Atherosclerosis** 1995 Dec;118 Suppl:S57-67 (75 ref.)

Human leucocyte heparan sulphate proteoglycans and their roles in inflammation. Jackson DG. **Biochem Soc Trans** 1997 Feb;25(1):220-4 (23 ref.)

Glycoconjugate cross-talk in metastatic cancer cells, leucocytes, parasites and bacteria. Leroy A, et al.
Biochem Soc Trans 1997 Feb;25(1):228-34 (48 ref.)

Syndecans, signaling, and cell adhesion. Couchman JR, et al. **J Cell Biochem** 1996 Jun 15;61(4):578-84 (34 ref.)

Proteoglycans: their possible role in renal fibrosis. Davies M, et al. **Kidney Int Suppl** 1996 May;54:S55-60 (46 ref.)

Signaling from the matrix to the cytoskeleton: role of cell surface proteoglycans in matrix assembly. Woods A, et al.
Kidney Int Suppl 1996 May;54:S64-7 (33 ref.)

Characterization of appican, the chondroitin sulfate proteoglycan form of the Alzheimer amyloid precursor protein. Pangalos MN, et al. **Neurodegeneration** 1996 Dec; 5(4):445-51 (57 ref.)

N-syndecan: structure and function of a transmembrane heparan sulfate proteoglycan. Carey DJ.
Perspect Dev Neurobiol 1996;3(4):331-46 (77 ref.)

Agrin: an extracellular matrix heparan sulfate proteoglycan involved in cell interactions and synaptogenesis. Cole GJ, et al. **Perspect Dev Neurobiol** 1996;3(4):359-71 (86 ref.)

The NG2 chondroitin sulfate proteoglycan: a multifunctional proteoglycan associated with immature cells. Levine JM, et al. **Perspect Dev Neurobiol** 1996;3(4):245-59 (80 ref.)

Proteoglycans and other repulsive molecules in glial boundaries during development and regeneration of the nervous system. Höke A, et al. **Prog Brain Res** 1996; 108:149-63 (123 ref.)

Unilateral containment of retinal axons by tectal glia: a possible role for sulfated proteoglycans. Jhaveri S, et al. **Prog Brain Res** 1996;108:135-48 (104 ref.)

[Function of proteoglycans in the extracellular matrix] Yanagishita M. **Kokubyo Gakkai Zasshi** 1997 Jun; 64(2):193-204 (72 ref.) **(Jpn)**

[Proteoglycans and cells] Bychkov SM, et al.
Biull Eksp Biol Med 1996 Feb;121(2):124-7 (20 ref.) **(Rus)**

[The role of glycosaminoglycans and proteoglycans in hemopoiesis and the physiological functions of the blood cells] Kharchenko MF, et al.
Fiziol Zh Im I M Sechenova 1996 May-Jun;82(5-6):18-25 (40 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Pathogenesis of diabetic vascular disease: evidence for the role of reduced heparan sulfate proteoglycan. Jensen T. **Diabetes** 1997 Sep;46 Suppl 2:S98-100 (23 ref.)

PROTEOLIPID PROTEIN, MYELIN see **MYELIN PROTEOLIPID PROTEIN**

PROTEOLIPIDS

see related
LIPOPROTEINS

ANALYSIS

NK-lysin, structure and function of a novel effector molecule of porcine T and NK cells. Andersson M, et al.
Vet Immunol Immunopathol 1996 Nov;54(1-4):123-6 (11 ref.)

CHEMISTRY

Synthetic protein analogues in artificial surfactants [see comments] Johansson J, et al. **Acta Paediatr** 1996 Jun; 85(6):642–6 (28 ref.) Comment in: Acta Paediatr 1996 Jun;85(6):641.

The structure and function of surfactant protein–A. McCormack F. **Chest** 1997 Jun;111(6 Suppl):114S–119S (57 ref.)

GENETICS

Transcriptional regulation of the surfactant protein–A gene in fetal lung. Mendelson CR, et al. **Chest** 1997 Jun;111(6 Suppl):96S–104S (32 ref.)

METABOLISM

Inherited surfactant protein–B deficiency. Hamvas A. **Adv Pediatr** 1997;44:369–88 (65 ref.)

Membrane proteins which exhibit multiple topological orientations. Levy D. **Essays Biochem** 1996;31:49–60 (21 ref.)

Surfactant protein A and lamellar bodies: a homologous secretory function of peritoneum, synovium, and lung. Dobbie JW. **Perit Dial Int** 1996 Nov–Dec;16(6):574–81 (43 ref.)

PHYSIOLOGY

The structure and function of surfactant protein–A. McCormack F. **Chest** 1997 Jun;111(6 Suppl):114S–119S (57 ref.)

Surfactant protein–B deficiency. Nogee LM. **Chest** 1997 Jun; 111(6 Suppl):129S–135S (43 ref.)

Granulysin, a new human cytolytic granule–associated protein with possible involvement in cell–mediated cytotoxicity. Peña SV, et al. **Semin Immunol** 1997 Apr; 9(2):117–25 (50 ref.)

PROTEOLYTIC ENZYMES see **PEPTIDE HYDROLASES**

PROTESTANTISM see **CHRISTIANITY**

PROTEUS

IMMUNOLOGY

[Proteus lipopolysaccharides] Sidorczyk Z. **Postepy Hig Med Dosw** 1996;50(5):401–17 (51 ref.) (Eng. Abstr.) **(Pol)**

PATHOGENICITY

Potential virulence factors of Proteus bacilli. Różalski A, et al. **Microbiol Mol Biol Rev** 1997 Mar;61(1):65–89 (317 ref.)

PHYSIOLOGY

Potential virulence factors of Proteus bacilli. Różalski A, et al. **Microbiol Mol Biol Rev** 1997 Mar;61(1):65–89 (317 ref.)

PROTEUS INFECTIONS

ETIOLOGY

[The role of Pseudomonas aeruginosa and Proteus in the etiology of suppurative surgical infection] Nazarchuk LV. **Lik Sprava** 1996 Oct–Dec;(10–12):31–5 (22 ref.) **(Rus)**

PHYSIOPATHOLOGY

Potential virulence factors of Proteus bacilli. Różalski A, et al. **Microbiol Mol Biol Rev** 1997 Mar;61(1):65–89 (317 ref.)

PROTEUS SYNDROME

COMPLICATIONS

Spinal canal compromise in Proteus syndrome: case report and review of the literature. Ring D, et al. **Am J Orthop** 1997 Apr;26(4):275–8 (14 ref.)

DIAGNOSIS

[A case for diagnosis: Proteus syndrome] Bensa–Didier AF, et al. **Ann Dermatol Venereol** 1996;123(8):495–7 (12 ref.) **(Fre)**

RADIOGRAPHY

[Proteus syndrome: a case report] Reize P, et al. **Z Orthop Ihre Grenzgeb** 1997 Mar–Apr;135(2):174–8 (27 ref.) (Eng. Abstr.) **(Ger)**

PROTHROMBIN

see related
COAGULANTS

IMMUNOLOGY

Non beta 2–glycoprotein I cofactors for antiphospholipid antibodies. Galli M. **Lupus** 1996 Oct;5(5):388–92 (42 ref.)

[New targets of antiphospholipid antibodies] Arvieux J, et al. **Rev Med Interne** 1997;18(4):292–302 (69 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Phospholipid binding plasma proteins required for antiphospholipid antibody detection—an overview. McIntyre JA, et al. **Am J Reprod Immunol** 1997 Jan; 37(1):101–10 (86 ref.)

Coagulation factor V: an old star shines again. Rosing J, et al. **Thromb Haemost** 1997 Jul;78(1):427–33 (89 ref.)

PROTHROMBIN TIME

The PT and the pendulum [editorial; comment] Florell SR, et al. **Am J Clin Pathol** 1996 Dec;106(6):699–700 (12 ref.) Comment on: Am J Clin Pathol 1996 Dec;106(6):786–94.

Precision and accuracy of the international normalized ratio in oral anticoagulant control. van den Besselaar AM. **Haemostasis** 1996 Oct;26 Suppl 4:248–65 (44 ref.)

[Tests for the extrinsic clotting pathways] Fukue H, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:132–4 (5 ref.) **(Jpn)**

PROTIRELIN

DIAGNOSTIC USE

[TRH test] Azuma K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:245–8 (8 ref.) **(Jpn)**

[TRH loading test] Bando H. **Nippon Rinsho** 1997 Apr;55 Suppl 2:283–7 (11 ref.) **(Jpn)**

[TRH test] Ochi Y, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:313–6 (9 ref.) **(Jpn)**

[TRH provocative test] Takeda S, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:241–4 (11 ref.) **(Jpn)**

METABOLISM

A gut reaction: lymphoepithelial communication in the intestine [comment] [see comments] Shanahan F. **Science** 1997 Mar 28;275(5308):1897–8 (11 ref.) Comment on: Science 1997 Mar 28;275(5308):1937–9. Comment in: Science 1997 Mar 28;275(5308):1897–8.

THERAPEUTIC USE

Thyrotropin–releasing hormone: basis and potential for its therapeutic use. Kelly JA. **Essays Biochem** 1995;30:133–49 (35 ref.)

[The clinical use of rifathyroin] Kolotilov NN, et al. **Lik Sprava** 1997 Jan–Feb;(1):24–8 (30 ref.) **(Rus)**

PROTO-ONCOGENE PROTEIN FMS see **RECEPTORS, MACROPHAGE COLONY-STIMULATING FACTOR**

PROTO-ONCOGENE PROTEIN P21(RAS)

ANTAGONISTS & INHIBITORS

Farnesyl protein transferase inhibitors as potential cancer chemopreventives. Kelloff GJ, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Apr;6(4):267–82 (187 ref.)

GENETICS

p21ras in carcinogenesis. de Vries JE, et al. **Pathol Res Pract** 1996 Jul;192(7):658–68 (138 ref.)

METABOLISM

Control of ras activation. Downward J. **Cancer Surv** 1996; 27:87–100 (80 ref.)

Regulation of phosphorylation pathways by p21 GTPases. The p21 Ras–related Rho subfamily and its role in phosphorylation signalling pathways. Lim L, et al. **Eur J Biochem** 1996 Dec 1;242(2):171–85 (123 ref.)

PHARMACOLOGY

p21ras in carcinogenesis. de Vries JE, et al. **Pathol Res Pract** 1996 Jul;192(7):658–68 (138 ref.)

PHYSIOLOGY

Functional aspects of apoptosis in hematopoiesis and consequences of failure. McKenna SL, et al. **Adv Cancer Res** 1997;71:121–64 (284 ref.)

PROTO-ONCOGENE PROTEIN P185(NEU) see **PROTO-ONCOGENE PROTEINS C-ERBB-2**

PROTO-ONCOGENE PROTEIN PP60(C-SRC)

GENETICS

[Cell biology of osteoclasts and molecular mechanisms of bone resorption] Amling M, et al. **Pathologe** 1996 Sep; 17(5):358–67 (76 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Activation of human pp60c–src. Bjorge JD, et al. **Biochem Cell Biol** 1996;74(4):477–84 (88 ref.)

DNA tumor viruses and Src family tyrosine kinases, an intimate relationship. Messerschmitt AS, et al. **Virology** 1997 Jan 20;227(2):271–80 (100 ref.)

PHYSIOLOGY

Role of c–Src in cellular events associated with colony–stimulating factor–1–induced spreading in osteoclasts. Insogna K, et al. **Mol Reprod Dev** 1997 Jan; 46(1):104–8 (22 ref.)

PROTO-ONCOGENE PROTEINS

[Apoptosis related gene, Pim–1] Ariga H, et al. **Nippon Rinsho** 1996 Jul;54(7):1903–6 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Expression of Bcl–2 and Bax in human gastric cancer tissue] Komatsu K, et al. **Nippon Rinsho** 1996 Jul;54(7):1929–34 (20 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

Oncogene– and tumor–suppressor gene–related proteins in plants and fungi. Loidl A, et al. **Crit Rev Oncog** 1996; 7(1–2):49–64 (93 ref.)

ANTAGONISTS & INHIBITORS

Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC–alpha and C–raf kinase. Henry SP, et al. **Anticancer Drug Des** 1997 Jul;12(5):409–20 (38 ref.)

First– and second–generation antisense inhibitors targeted to human c–raf kinase: in vitro and in vivo studies. Monia BP. **Anticancer Drug Des** 1997 Jul;12(5):327–39 (46 ref.)

BIOSYNTHESIS

Bcl–6 protein expression in normal and neoplastic lymphoid tissues. Falini B, et al. **Ann Oncol** 1997;8 Suppl 2:101–4 (28 ref.)

[Control of growth and expression of protooncogenes in regenerating liver] Zou Y, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan;27(1):7–12 (17 ref.) (Eng. Abstr.) **(Chi)**

CHEMISTRY

Structurally related receptors and antagonists compete for secreted Wnt ligands. Moon RT, et al. **Cell** 1997 Mar 21; 88(6):725–8 (16 ref.)

Structure and function of vav. Romero F, et al. **Cell Signal** 1996 Dec;8(8):545–53 (88 ref.)

Stopping death cold. Werner MH. **Structure** 1996 Aug 15; 4(8):879–83 (23 ref.)

DIAGNOSTIC USE

Laboratory probing of oncogenes from human liquid and solid specimens as markers of exposure to toxicants. Nelson E. **Crit Rev Toxicol** 1996 Sep;26(5):483–549 (397 ref.)

GENETICS

Are ABL and BCR imprinted? Fink M, et al. **Acta Genet Med Gemellol (Roma)** 1996;45(1–2):233–7 (24 ref.)

Genetic screening for RET mutations in families with multiple endocrine neoplasia 2 syndromes. Alevizaki M, et al. **Ann N Y Acad Sci** 1997 Jun 17;816:383–8 (23 ref.)

A versatile transcriptional effector of Wingless signaling. Nusse R. **Cell** 1997 May 2;89(3):321–3 (21 ref.)

Myb–induced transformation. Wolff L. **Crit Rev Oncog** 1996; 7(3–4):245–60 (126 ref.)

RET oncogene. Mak YF, et al. **Curr Opin Genet Dev** 1996 Feb;6(1):82–6 (45 ref.)

Familial neuroendocrine tumors as a model of hereditary cancer. Anderson RJ, et al. **Curr Opin Oncol** 1997 Jan; 9(1):45–54 (85 ref.)

RET mutations in multiple endocrine neoplasia type 2 and Hirschsprung disease. Reynolds LF, et al. **Curr Opin Pediatr** 1995 Dec;7(6):702–9 (63 ref.)

RET receptor tyrosine kinase gene mutations: molecular biological, physiological and clinical aspects. Höppener JW, et al. **Eur J Clin Invest** 1996 Aug;26(8):613–24 (88 ref.)

BCL3 rearrangements and t(14;19) in chronic lymphocytic leukemia and other B–cell malignancies: a molecular and cytogenetic study. McKeithan TW, et al. **Genes Chromosomes Cancer** 1997 Sep;20(1):64–72 (38 ref.)

The regulation of p53–mediated transcription and the roles of hTAFII31 and mdm–2. Lu H, et al. **Harvey Lect** 1994–95;90:81–93 (32 ref.)

RET proto–oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. Marsh DJ, et al. **Horm Res** 1997;47(4–6):168–78 (105 ref.)

Mutations of the RET proto–oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease. Eng C, et al. **Hum Mutat** 1997;9(2):97–109 (105 ref.)

p21WAF1 mutations and human malignancies. Shiohara M, et al. **Leuk Lymphoma** 1997 Jun;26(1–2):35–41 (75 ref.)

Overexpression of the MDM2 oncogene in leukemia and lymphoma. Watanabe T, et al. **Leuk Lymphoma** 1996 May; 21(5–6):391–7, color plates XVI following 5 (49 ref.)

RET protooncogene mutational analysis in multiple endocrine neoplasia syndrome type 2B: case report and review of the literature. Kahn MA, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Sep;82(3):288–94 (21 ref.)

PROTO-ONCOGENE PROTEINS

The RET proto-oncogene: a challenge to our understanding of disease pathogenesis. Kusafuka T, et al. **Pediatr Surg Int** 1997;12(1):11–8 (99 ref.)
Hirschsprung's disease as a neurochristopathy. Martucciello G. **Pediatr Surg Int** 1997;12(1):2–10 (74 ref.)
Genetic control of cellular suicide. Yuan J. **Reprod Toxicol** 1997 Mar-Jun;11(2–3):377–84 (73 ref.)
The role of the Bcl-2 family of apoptosis regulatory proteins in the immune system. Hawkins CJ, et al. **Semin Immunol** 1997 Feb;9(1):25–33 (93 ref.)
Has the quest for a Wnt receptor finally frizzled out? Ingham PW. **Trends Genet** 1996 Oct;12(10):382–4 (18 ref.)
Engrailed, Wnt and Pax genes regulate midbrain—hindbrain development. Joyner AL. **Trends Genet** 1996 Jan; 12(1):15–20 (50 ref.)
Extra specificity from extradenticle: the partnership between HOX and PBX/EXD homeodomain proteins [published erratum appears in Trends Genet 1996 Aug;12(8):328] Mann RS, et al. **Trends Genet** 1996 Jul;12(7):258–62 (52 ref.)
RET mutations in human disease. Pasini B, et al. **Trends Genet** 1996 Apr;12(4):138–44 (60 ref.)
The GDNF-RET signalling partnership. Robertson K, et al. **Trends Genet** 1997 Jan;13(1):1–3 (36 ref.)
The coming of age of the GDNF family and its receptors: gene delivery in a rat Parkinson model may have clinical implications. Olson L. **Trends Neurosci** 1997 Jul;20(7):277–9 (22 ref.)
The RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications. Komminoth P. **Virchows Arch** 1997 Jul;431(1):1–9 (109 ref.)
Participation of nerve growth factor in the regulation of ovarian function. Dissen GA, et al. **Zygote** 1996 Nov; 4(4):309–12 (38 ref.)
[Genetic alterations associated with pathologic differentiation of Wilms' tumors] Chevalier G, et al. **Bull Cancer** 1997 Mar;84(3):289–303 (127 ref.) (Eng. Abstr.) **(Fre)**
[Thrombopoietin signal transduction via its receptor encoded by c-mpl: its association with hematological diseases] Takatoku M, et al. **Rinsho Ketsueki** 1997 Mar;38(3):203–8 (13 ref.) **(Jpn)**

IMMUNOLOGY

Regulation of lymphoid apoptosis by Bcl-2 and Bcl-XL. Nuñez G, et al. **Adv Exp Med Biol** 1996;406:75–82 (36 ref.)

METABOLISM

Genetic dissection of signal transduction mechanisms underlying PACAP-like neuropeptide transmission in Drosophila: synergy of cAMP and Ras/Raf pathways. Zhong Y. **Ann N Y Acad Sci** 1996 Dec 26;805:67–79; discussion 79–80 (36 ref.)
Regulation of Raf-1 kinase by interaction with the lipid second messenger, phosphatidic acid. Ghosh S, et al. **Biochem Soc Trans** 1997 May;25(2):561–5 (19 ref.)
Involvement of the neuregulins and their receptors in cardiac and neural development. Carraway KL 3rd. **Bioessays** 1996 Apr;18(4):263–6 (27 ref.)
The Raf/MAP kinase cascade in cell cycle regulation and differentiation in Drosophila. Nishida Y, et al. **Cell Struct Funct** 1996 Oct;21(5):437–44 (40 ref.)
The VAV family of signal transduction molecules. Bustelo XR. **Crit Rev Oncog** 1996;7(1–2):65–88 (114 ref.)
Vav: Captain Hook for signal transduction? Katzav S. **Crit Rev Oncog** 1995;6(2):87–97 (82 ref.)
Myb-induced transformation. Wolff L. **Crit Rev Oncog** 1996; 7(3–4):245–60 (126 ref.)
Cell-cell signalling: Wingless lands at last. Orsulic S, et al. **Curr Biol** 1996 Nov 1;6(11):1363–7 (28 ref.)
The complexity of Raf-1 regulation. Morrison DK, et al. **Curr Opin Cell Biol** 1997 Apr;9(2):174–9 (62 ref.)
New members of the Bcl-2 family and their protein partners. Farrow SN, et al. **Curr Opin Genet Dev** 1996 Feb;6(1):45–9 (34 ref.)
Molecular analysis of the fyn-complex: cloning of SKAP55 and SLAP-130, two novel adaptor proteins which associate with fyn and may participate in the regulation of T cell receptor-mediated signaling. Schraven B, et al. **Immunol Lett** 1997 Jun 1;57(1–3):165–9 (26 ref.)
The role of Raf kinases in development and growth of tumors. Naumann U, et al. **Recent Results Cancer Res** 1997; 143:237–44 (24 ref.)
Apoptosis regulation by Raf, Bcl-2, and R-Ras. Troppmair J, et al. **Recent Results Cancer Res** 1997;143:245–9 (16 ref.)
Akt signaling: linking membrane events to life and death decisions [comment] Hemmings BA. **Science** 1997 Jan 31; 275(5300):628–30 (25 ref.) Comment on: Science 1997 Jan 31;275(5300):661–5. Comment on: Science 1997 Jan 31;275(5300):665–8.
PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Marte BM, et al. **Trends Biochem Sci** 1997 Sep;22(9):355–8 (41 ref.)
Has the quest for a Wnt receptor finally frizzled out? Ingham PW. **Trends Genet** 1996 Oct;12(10):382–4 (18 ref.)
The GDNF-RET signalling partnership. Robertson K, et al. **Trends Genet** 1997 Jan;13(1):1–3 (36 ref.)

PHYSIOLOGY

The role of Ets transcription factors in the development and function of the mammalian immune system. Bassuk AG, et al. **Adv Immunol** 1997;64:65–104 (273 ref.)
Dbl family proteins. Whitehead IP, et al. **Biochim Biophys Acta** 1997 Feb 22;1332(1):F1–23 (138 ref.)
The c-erbB3/HER3 receptor in human cancer. Gullick WJ. **Cancer Surv** 1996;27:339–49 (59 ref.)
Control of the ERK MAP kinase cascade by Ras and Raf. Marais R, et al. **Cancer Surv** 1996;27:101–25 (125 ref.)
The c-myb proto-oncogene: a novel target for human gene therapy. Gewirtz AM. **Cancer Treat Res** 1996;84:93–112 (58 ref.)
PI3K: downstream AKTion blocks apoptosis. Franke TF, et al. **Cell** 1997 Feb 21;88(4):435–7 (20 ref.)
Structure and function of vav. Romero F, et al. **Cell Signal** 1996 Dec;8(8):545–53 (88 ref.)
MutS homologs in mammalian cells. Fishel R, et al. **Curr Opin Genet Dev** 1997 Feb;7(1):105–13 (84 ref.)
E2A–Pbx1 induces growth, blocks differentiation, and interacts with other homeodomain proteins regulating normal differentiation. Kamps MP. **Curr Top Microbiol Immunol** 1997;220:25–43 (68 ref.)
The HGF receptor family: unconventional signal transducers for invasive cell growth. Comoglio PM, et al. **Genes Cells** 1996 Apr;1(4):347–54 (70 ref.)
Views on Vav. Collins TL, et al. **Immunol Today** 1997 May; 18(5):221–5 (42 ref.)
BCL-6 in diffuse large-cell lymphomas. Dalla-Favera R, et al. **Important Adv Oncol** 1996;:139–48 (49 ref.)
Mdm-2: "big brother" of p53. Momand J, et al. **J Cell Biochem** 1997 Mar 1;64(3):343–52 (98 ref.)
The GDNF receptor: recent progress and unanswered questions. Mason I. **Mol Cell Neurosci** 1996;8(2–3):112–9 (46 ref.)
Double identity for proteins of the Bcl-2 family. Reed JC. **Nature** 1997 Jun 19;387(6635):773–6 (40 ref.)
GDNF in a bind with known orphan: accessory implicated in new twist. Lindsay RM, et al. **Neuron** 1996 Oct; 17(4):571–4 (28 ref.)
Rel/NF-kappaB/IkappaB proteins and cancer. Gilmore TD, et al. **Oncogene** 1996 Oct 3;13(7):1367–78 (171 ref.)
Mdm2: keeping p53 under control. Piette J, et al. **Oncogene** 1997 Aug 28;15(9):1001–10 (111 ref.)
Signaling molecules that mediate the actions of FGF. Demo SD, et al. **Princess Takamatsu Symp** 1994;24:243–9 (23 ref.)
Possible involvement of VEGF-FLT tyrosine kinase receptor system in normal and tumor angiogenesis. Shibuya M, et al. **Princess Takamatsu Symp** 1994;24:162–70 (23 ref.)
Invasive carcinomas dismantle surrounding stroma induced to express the nuclear factor c-ets-1. Stehelin D. **Princess Takamatsu Symp** 1994;24:171–86 (48 ref.)
Vav: function and regulation in hematopoietic cell signaling. Bonnefoy-Bérard N, et al. **Stem Cells** 1996 May; 14(3):250–68 (125 ref.)
Regulatory roles of the ligand for Flk2/Flt3 tyrosine kinase receptor on human hematopoiesis. Namikawa R, et al. **Stem Cells** 1996 Jul;14(4):388–95 (69 ref.)
Role of c-Fes in normal and neoplastic hematopoiesis. Yates KE, et al. **Stem Cells** 1996 Jan;14(1):117–23 (66 ref.)
Extra specificity from extradenticle: the partnership between HOX and PBX/EXD homeodomain proteins [published erratum appears in Trends Genet 1996 Aug;12(8):328] Mann RS, et al. **Trends Genet** 1996 Jul;12(7):258–62 (52 ref.)
MYB transcription factors in plants. Martin C, et al. **Trends Genet** 1997 Feb;13(2):67–73 (55 ref.)
WNTs modulate cell fate and behavior during vertebrate development. Moon RT, et al. **Trends Genet** 1997 Apr; 13(4):157–62 (57 ref.)
p75NTR and apoptosis: Trk-dependent and Trk-independent effects. Bredesen DE, et al. **Trends Neurosci** 1997 Jul; 20(7):287–90 (36 ref.)
[Postsynaptic density proteins related to the expression and modulation of synaptic plasticity] Suzuki T. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Apr; 16(2):53–8 (21 ref.) (Eng. Abstr.) **(Jpn)**
[Thrombopoietin signal transduction via its receptor encoded by c-mpl: its association with hematological diseases] Takatoku M, et al. **Rinsho Ketsueki** 1997 Mar;38(3):203–8 (13 ref.) **(Jpn)**

THERAPEUTIC USE

In vivo effects of Mpl ligand administration and emerging clinical applications for the Mpl ligands. Kuter DJ. **Curr Opin Hematol** 1997 May;4(3):163–70 (53 ref.)

PROTO-ONCOGENE PROTEINS C-ABL

see related
FUSION PROTEINS, BCR-ABL

GENETICS

Are ABL and BCR imprinted? Fink M, et al. **Acta Genet Med Gemellol (Roma)** 1996;45(1–2):233–7 (24 ref.)

PHYSIOLOGY

Functional aspects of apoptosis in hematopoiesis and consequences of failure. McKenna SL, et al. **Adv Cancer Res** 1997;71:121–64 (284 ref.)
Pathogenesis and progression of chronic myeloid leukemia. Santucci MA, et al. **Haematologica** 1996 Jan-Feb; 81(1):63–76 (64 ref.)

PROTO-ONCOGENE PROTEINS C-BCL-2

[Expression of Bcl-2 and Bax in human gastric cancer tissue] Komatsu K, et al. **Nippon Rinsho** 1996 Jul;54(7):1929–34 (20 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Retinal ganglion cell anatomy and physiology after section of the optic nerve in mice overexpressing bcl-2. Ratto GM, et al. **Adv Neurol** 1997;72:87–94 (20 ref.)
Bcl-2 expression in acute myeloblastic leukaemia: relationship with autonomous growth and CD34 antigen expression. Bradbury DA, et al. **Leuk Lymphoma** 1997 Jan; 24(3–4):221–8 (48 ref.)
Interferon-alpha, Bcl-2 expression and apoptosis in B-cell chronic lymphocytic leukemia. Jewell AP. **Leuk Lymphoma** 1996 Mar;21(1–2):43–7 (48 ref.)
The human immunodeficiency virus type-1 (HIV-1) Tat protein and Bcl-2 gene expression. Zauli G, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):551–60 (93 ref.)

CHEMISTRY

Structure-function analysis of Bcl-2 family proteins. Regulators of programmed cell death. Reed JC, et al. **Adv Exp Med Biol** 1996;406:99–112 (86 ref.)

GENETICS

BCL-2, a novel regulator of apoptosis. Park JR, et al. **J Cell Biochem** 1996 Jan;60(1):12–7 (35 ref.)
BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. Reed JC, et al. **J Cell Biochem** 1996 Jan;60(1):23–32 (55 ref.)
The role of the Bcl-2 family of apoptosis regulatory proteins in the immune system. Hawkins CJ, et al. **Semin Immunol** 1997 Feb;9(1):25–33 (93 ref.)
Bcl-2 related proteins, apoptosis and disease. Anderson GP. **Trends Pharmacol Sci** 1997 Feb;18(2):51 (2 ref.)
[Overexpression of bcl-2 suppresses apoptotic cell death of the human leukemic cell line TF-1] Ito T, et al. **Nippon Rinsho** 1996 Jul;54(7):1815–21 (23 ref.) (Eng. Abstr.) **(Jpn)**
[Prevention of cell death by Bcl-2 family genes] Tsujimoto Y. **Nippon Rinsho** 1996 Jul;54(7):1895–902 (19 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Apoptotic cell death in the chicken bursa of Fabricius. Jacobsen KA, et al. **Adv Exp Med Biol** 1996;406:155–65 (22 ref.)
Regulation of lymphoid apoptosis by Bcl-2 and Bcl-XL. Nuñez G, et al. **Adv Exp Med Biol** 1996;406:75–82 (36 ref.)

METABOLISM

Structure-function analysis of Bcl-2 family proteins. Regulators of programmed cell death. Reed JC, et al. **Adv Exp Med Biol** 1996;406:99–112 (86 ref.)
New members of the Bcl-2 family and their protein partners. Farrow SN, et al. **Curr Opin Genet Dev** 1996 Feb;6(1):45–9 (34 ref.)
Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Manne U, et al. **Int J Cancer** 1997 Jun 20;74(3):346–58 (75 ref.)
Apoptosis regulation by Raf, Bcl-2, and R-Ras. Troppmair J, et al. **Recent Results Cancer Res** 1997;143:245–9 (16 ref.)

PHARMACOLOGY

Bcl-2 family proteins: strategies for overcoming chemoresistance in cancer. Reed JC. **Adv Pharmacol** 1997; 41:501–32 (190 ref.)

PHYSIOLOGY

Functional aspects of apoptosis in hematopoiesis and consequences of failure. McKenna SL, et al. **Adv Cancer Res** 1997;71:121–64 (284 ref.)
Mechanisms of Bcl-2 family protein function and dysfunction in health and disease. Reed JC. **Behring Inst Mitt** 1996 Oct;(97):72–100 (193 ref.)
Lessons from bcl-2 transgenic mice for immunology, cancer biology and cell death research. Strasser A, et al. **Behring Inst Mitt** 1996 Oct;(97):101–17 (120 ref.)
Bcl-2 family proteins and the regulation of programmed cell death in leukemia and lymphoma. Reed JC, et al. **Cancer Treat Res** 1996;84:31–72 (231 ref.)
Apoptosis: Bcl-2-related proteins get connected. Jacobson MD. **Curr Biol** 1997 May 1;7(5):R277–81 (26 ref.)
Bcl-2 and the ICE family of apoptotic regulators: making a connection. Rao L, et al. **Curr Opin Genet Dev** 1997 Feb; 7(1):52–8 (60 ref.)
Importance of the Bcl-2 family in cell death regulation. McDonnell TJ, et al. **Experientia** 1996 Oct 31; 52(10–11):1008–17 (110 ref.)
Bcl-x and the regulation of survival in the immune system. Behrens TW, et al. **Immunol Res** 1997;16(2):149–60 (72 ref.)
Promise and problems of Bcl-2 antisense therapy [editorial; comment] Reed JC. **J Natl Cancer Inst** 1997 Jul 16;

89(14):988–90 (36 ref.) Comment on: J Natl Cancer Inst 1997 Jul 16;89(14):1027–36.
The proto-oncogene Bcl-2 and its role in regulating apoptosis [published erratum appears in Nat Med 1997 Aug;3(8):934] Kroemer G. **Nat Med** 1997 Jun;3(6):614–20 (64 ref.)
Double identity for proteins of the Bcl-2 family. Reed JC. **Nature** 1997 Jun 19;387(6635):773–6 (40 ref.)
Bcl-2 family proteins and the hormonal control of cell life and death in normalcy and neoplasia. Reed JC. **Vitam Horm** 1997;53:99–138 (161 ref.)
[Apoptosis and anti-apoptosis genes in the Bcl-2 family] Dietrich JB. **Arch Physiol Biochem** 1997 Apr;105(2):125–35 (73 ref.) (Eng. Abstr.) **(Fre)**

PROTO-ONCOGENE PROTEINS C-ERBA see **RECEPTORS, THYROID HORMONE**

PROTO-ONCOGENE PROTEINS C-ERBB-1 see **RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE**

PROTO-ONCOGENE PROTEINS C-ERBB-2

ANTAGONISTS & INHIBITORS

Inhibition of signaling from Type 1 receptor tyrosine kinases via intracellular expression of single-chain antibodies. Beerli RR, et al. **Breast Cancer Res Treat** 1996;38(1):11–7 (32 ref.)
Preclinical testing of an anti-erbB-2 recombinant toxin. King CR, et al. **Breast Cancer Res Treat** 1996;38(1):19–25 (17 ref.)

GENETICS

Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor. Meden H, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Feb;71(2):173–9 (36 ref.)

IMMUNOLOGY

HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Disis ML, et al. **Adv Cancer Res** 1997;71:343–71 (105 ref.)
Oncogene products represent potential targets of tumor vaccines. Tuttle TM. **Cancer Immunol Immunother** 1996 Nov;43(3):135–41 (62 ref.)

METABOLISM

The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. Alroy I, et al. **FEBS Lett** 1997 Jun 23;410(1):83–6 (47 ref.)
HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Baselga J, et al. **Oncology (Huntingt)** 1997 Mar;11(3 Suppl 2):43–8 (47 ref.)

PHYSIOLOGY

HER-2/neu signal transduction in human breast and ovarian cancer. Reese DM, et al. **Stem Cells** 1997;15(1):1–8 (85 ref.)

PROTO-ONCOGENE PROTEINS C-FOS

see related
TRANSCRIPTION FACTOR AP-1

ANALYSIS

c-Fos expression during wakefulness and sleep. Pompeiano M, et al. **Neurophysiol Clin** 1995;25(6):329–41 (56 ref.)

BIOSYNTHESIS

Mating-induced c-fos expression patterns complement and supplement observations after lesions in the male Syrian hamster brain. Newman SW, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:239–59 (44 ref.)
Activation of c-fos in the brain. Herrera DG, et al. **Prog Neurobiol** 1996 Oct;50(2–3):83–107 (265 ref.)

GENETICS

Involvement of a pertussis-toxin sensitive G protein in the induction of gene expression by insulin. Butler AP, et al. **Cell Signal** 1996 Nov;8(7):475–80 (47 ref.)
[Cell biology of osteoclasts and molecular mechanisms of bone resorption] Amling M, et al. **Pathologe** 1996 Sep; 17(5):358–67 (76 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Relationship between the drinking response to angiotensin II and induction of Fos in the brain. Rowland NE, et al. **Adv Exp Med Biol** 1996;396:113–9 (35 ref.)
Complex mechanisms for c-fos and c-jun degradation. Jariel-Encontre I, et al. **Mol Biol Rep** 1997 Mar; 24(1–2):51–6 (39 ref.)

PHYSIOLOGY

Bone morphogenetic proteins and C-FOS: early signals in endochondral bone formation. Kaplan FS, et al. **Bone** 1996 Jul;19(1 Suppl):13S–21S (69 ref.)
Putative roles for the inducible transcription factor c-fos in the central nervous system: studies with antisense oligonucleotides. Chiasson BJ, et al. **Neurochem Int** 1997 Sep;31(3):459–75 (136 ref.)
On the role of c-fos expression in striatal transmission. The antisense oligonucleotide approach. Sommer W, et al. **Neurochem Int** 1997 Sep;31(3):425–36 (50 ref.)
[Overexpression of c-Fos induces apoptosis of CD43+ pro-B cells] Hu L, et al. **Nippon Rinsho** 1996 Jul; 54(7):1876–80 (16 ref.) (Eng. Abstr.) **(Jpn)**

PROTO-ONCOGENE PROTEINS C-JUN

see related
TRANSCRIPTION FACTOR AP-1

GENETICS

Involvement of a pertussis-toxin sensitive G protein in the induction of gene expression by insulin. Butler AP, et al. **Cell Signal** 1996 Nov;8(7):475–80 (47 ref.)

METABOLISM

Jun: transcription factor and oncoprotein. Rahmsdorf HJ. **J Mol Med** 1996 Dec;74(12):725–47 (276 ref.)
Complex mechanisms for c-fos and c-jun degradation. Jariel-Encontre I, et al. **Mol Biol Rep** 1997 Mar; 24(1–2):51–6 (39 ref.)

PHYSIOLOGY

The c-Jun transcription factor—bipotential mediator of neuronal death, survival and regeneration. Herdegen T, et al. **Trends Neurosci** 1997 May;20(5):227–31 (72 ref.)

PROTO-ONCOGENE PROTEINS C-KIT

GENETICS

C-kit mutations and mast cell disorders. A model of activating mutations of growth factor receptors. Pignon JM. **Hematol Cell Ther** 1997 Apr;39(2):114–6 (14 ref.)
c-kit Point mutation in patients with myeloproliferative disorders. Kimura A, et al. **Leuk Lymphoma** 1997 Apr; 25(3–4):281–7 (32 ref.)
Perturbing gene expression with oligodeoxynucleotides: research and potential therapeutic applications. Gewirtz AM. **Mt Sinai J Med** 1996 Oct-Nov;63(5–6):372–80 (14 ref.)
Role of c-kit receptor tyrosine kinase in the development, survival and neoplastic transformation of mast cells. Tsujimura T. **Pathol Int** 1996 Dec;46(12):933–8 (35 ref.)
[Mutations of c-kit receptor tyrosine kinase in hematologic disease] Ikeda H, et al. **Rinsho Ketsueki** 1997 Mar; 38(3):177–80 (10 ref.) **(Jpn)**

METABOLISM

Deficiency of c-kit+ cells in patients with a myopathic form of chronic idiopathic intestinal pseudo-obstruction. Isozaki K, et al. **Am J Gastroenterol** 1997 Feb;92(2):332–4 (18 ref.)

PHYSIOLOGY

Stem cell factor and c-kit in the mammalian testis: lessons originating from Mother Nature's gene knockouts. Loveland KL, et al. **J Endocrinol** 1997 Jun;153(3):337–44 (71 ref.)
C-kit receptors in childhood malignant lymphoblastic cells. Sykora KW, et al. **Leuk Lymphoma** 1997 Apr; 25(3–4):201–16 (94 ref.)

PROTO-ONCOGENE PROTEINS C-MOS

see related
PROTEIN-SERINE-THREONINE KINASES

METABOLISM

[The roles of the Mos-MAPK pathway in oocyte meiosis and cellular transformation] Sagata N. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1847–55 (62 ref.) **(Jpn)**

PHYSIOLOGY

Synthesis and function of Mos: the control switch of vertebrate oocyte meiosis. Gebauer F, et al. **Bioessays** 1997 Jan;19(1):23–8 (61 ref.)
What does Mos do in oocytes and somatic cells? Sagata N. **Bioessays** 1997 Jan;19(1):13–21 (70 ref.)

PROTO-ONCOGENE PROTEINS C-MYC

GENETICS

Cell cycle: on target with Myc. Zörnig M, et al. **Curr Biol** 1996 Dec 1;6(12):1553–6 (22 ref.)

PHYSIOLOGY

c-Myc in the control of cell proliferation and embryonic development. Lemaitre JM, et al. **Adv Cancer Res** 1996; 70:95–144 (348 ref.)
Defining a role for c-Myc in breast tumorigenesis. Nass SJ, et al. **Breast Cancer Res Treat** 1997 May;44(1):1–22 (177 ref.)
Influence of c-myc on the progression of human breast cancer. Watson PH, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 2):267–83 (146 ref.)

PROTO-ONCOGENE PROTEINS HER-2 see **PROTO-ONCOGENE PROTEINS C-ERBB-2**

PROTO-ONCOGENES

The MEN II syndromes and the role of the ret proto-oncogene. Ponder BA, et al. **Adv Cancer Res** 1996; 70:179–222 (194 ref.)
Genetic testing and early thyroidectomy for inherited medullary thyroid carcinoma. Lairmore TC, et al. **Ann Med** 1996 Oct;28(5):401–6 (39 ref.)
RET in human development and oncogenesis. Edery P, et al. **Bioessays** 1997 May;19(5):389–95 (77 ref.)
Molecular approaches to diagnosis and management of ovarian cancer. Katso RM, et al. **Cancer Metastasis Rev** 1997 Jun;16(1–2):81–107 (268 ref.)
Nuclear oncogenes in breast cancer. Dubik D, et al. **Cancer Treat Res** 1996;83:171–89 (123 ref.)
Structure and function of vav. Romero F, et al. **Cell Signal** 1996 Dec;8(8):545–53 (88 ref.)
The molecular biology of endometrial adenocarcinoma. Baker VV. **Clin Obstet Gynecol** 1996 Sep;39(3):707–15 (55 ref.)
Vav: Captain Hook for signal transduction? Katzav S. **Crit Rev Oncog** 1995;6(2):87–97 (82 ref.)
Familial neuroendocrine tumors as a model of hereditary cancer. Anderson RJ, et al. **Curr Opin Oncol** 1997 Jan; 9(1):45–54 (85 ref.)
The BRCA1 and BRCA2 breast cancer genes. Casey G. **Curr Opin Oncol** 1997 Jan;9(1):88–93 (84 ref.)
BCL-6 in diffuse large-cell lymphomas. Dalla-Favera R, et al. **Important Adv Oncol** 1996;:139–48 (49 ref.)
The role of the ret proto-oncogene in human disease. Takahashi M. **Nagoya J Med Sci** 1997 Mar;60(1–2):23–30 (49 ref.)
Hirschsprung's disease as a neurochristopathy. Martucciello G. **Pediatr Surg Int** 1997;12(1):2–10 (74 ref.)
Complex activation of inducible transcription factors in the brain of normotensive and spontaneously hypertensive rats following central angiotensin II administration. Lebrun CJ, et al. **Regul Pept** 1996 Oct 8;66(1–2):19–23 (33 ref.)
[Apoptosis and leukemia] Ma D, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Oct;34(10):709–11 (22 ref.) **(Chi)**
[The bcl-2 gene family, an important regulator of apoptosis] Bao FK. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan;27(1):67–9 (10 ref.) **(Chi)**
[Control of growth and expression of protooncogenes in regenerating liver] Zou Y, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan;27(1):7–12 (17 ref.) (Eng. Abstr.) **(Chi)**
[Cellular oncogenes and antioncogenes in thyroid tumors] Abrosimov AIu. **Arkh Patol** 1997 Jan-Feb;59(1):64–9 (41 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Genetic screening for RET mutations in families with multiple endocrine neoplasia 2 syndromes. Alevizaki M, et al. **Ann N Y Acad Sci** 1997 Jun 17;816:383–8 (23 ref.)
t(14;19)/BCL3 rearrangements in lymphoproliferative disorders: a review of 23 cases. Michaux L, et al. **Cancer Genet Cytogenet** 1997 Mar;94(1):36–43 (49 ref.)
BCL-2 gene rearrangements in lymphoid malignancies. Crisan D. **Clin Lab Med** 1996 Mar;16(1):23–47 (107 ref.)
The involvement of the candidate proto-oncogene NFKB2/lyt-10 in lymphoid malignancies. Neri A, et al. **Leuk Lymphoma** 1996 Sep;23(1–2):43–8 (38 ref.)
Perturbing gene expression with oligodeoxynucleotides: research and potential therapeutic applications. Gewirtz AM. **Mt Sinai J Med** 1996 Oct-Nov;63(5–6):372–80 (14 ref.)
The RET proto-oncogene: a challenge to our understanding of disease pathogenesis. Kusafuka T, et al. **Pediatr Surg Int** 1997;12(1):11–8 (99 ref.)
Genetic studies and molecular markers of bladder cancer. Cordon-Cardo C, et al. **Semin Surg Oncol** 1997 Sep-Oct; 13(5):319–27 (73 ref.)
The RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications. Komminoth P. **Virchows Arch** 1997 Jul;431(1):1–9 (109 ref.)
[Somatic genetics of breast cancer] Bièche I, et al.

PROTO-ONCOGENES

Bull Cancer 1997 Jan;84(1):83–96 (85 ref.) (Eng. Abstr.) **(Fre)**
[Molecular genetics of human tumors] Imianitov EN, et al. **Vopr Onkol** 1997;43(1):95–101 (46 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Role of extracellular matrix, growth factors and proto-oncogenes in metanephric development. Kanwar YS, et al. **Kidney Int** 1997 Sep;52(3):589–606 (240 ref.)
[Molecular mechanisms of cancer metastasis—ets-related nuclear transcription factor play an important role in cancer metastasis] Kaya M, et al. **Gan To Kagaku Ryoho** 1996 Sep; 23(10):1225–34 (52 ref.) (Eng. Abstr.) **(Jpn)**

PROTOCOL-DIRECTED THERAPY, COMPUTER-ASSISTED see **THERAPY, COMPUTER-ASSISTED**

PROTOCOL DRUG THERAPY, COMPUTER-ASSISTED see **DRUG THERAPY, COMPUTER-ASSISTED**

PROTOCOLLAGEN see **PROCOLLAGEN**

PROTOCOLS, CLINICAL see **CLINICAL PROTOCOLS**

PROTOHEME see **HEME**

PROTON-INDUCED X-RAY EMISSION SPECTROMETRY see **SPECTROMETRY, X-RAY EMISSION**

PROTON-MOTIVE FORCE

see related
PROTON PUMP

The key role of the H+ V-ATPase in acid-base balance and Na+ transport processes in frog skin. Ehrenfeld J, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):247–56 (78 ref.)
Coupling H+ transport and ATP synthesis in F1F0-ATP synthases: glimpses of interacting parts in a dynamic molecular machine. Fillingame RH. **J Exp Biol** 1997 Jan; 200 (Pt 2):217–24 (68 ref.)
Animal plasma membrane energization by chemiosmotic H+ V-ATPases. Harvey WR, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):203–16 (92 ref.)
Regulation of proton-translocating V-ATPases. Merzendorfer H, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):225–35 (82 ref.)
Proton-dependent multidrug efflux systems. Paulsen IT, et al. **Microbiol Rev** 1996 Dec;60(4):575–608 (326 ref.)

PROTON PUMP

see related
H(+)-TRANSPORTING ATP SYNTHASE

[Gastric proton pump: genes and their expression] Futai M. **Nippon Rinsho** 1996 Apr;54(4):1138–43 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Regulation of cation pump activity in nervous system] Inoue N. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):235–43 (49 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Review article: controversy in the therapy of gastro-oesophageal reflux disease—long-term proton pump inhibition or laparoscopic anti-reflux surgery? Walker SJ, et al. **Aliment Pharmacol Ther** 1997 Apr; 11(2):249–60 (133 ref.)
Long-term acid control and proton pump inhibitors: interactions and safety issues in perspective. Freston JW. **Am J Gastroenterol** 1997 Apr;92(4 Suppl):51S–55S; discussion 55S–57S (28 ref.)
Pathogenesis and treatment of acid peptic disorders: comparison of proton pump inhibitors with other antiulcer agents. Sanders SW. **Clin Ther** 1996 Jan–Feb;18(1):2–34; discussion 1 (178 ref.)
Medical Therapy of GERD: current state of the art. Johnson DA. **Hosp Pract (Off Ed)** 1996 Oct 15;31(10):135–9, 143–4, 147–8 (0 ref.)
Lack of pantoprazole drug interactions in man: an updated review. Steinijans VW, et al. **Int J Clin Pharmacol Ther** 1996 Jun;34(6):243–62 (125 ref.)
Proton pump inhibitors and acid-related diseases. Sachs G. **Pharmacotherapy** 1997 Jan–Feb;17(1):22–37 (112 ref.)
Lansoprazole: a comprehensive review. Zimmermann AE, et al. **Pharmacotherapy** 1997 Mar–Apr;17(2):308–26 (184 ref.)
Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. Meyer UA. **Yale J Biol Med** 1996 May–Jun;69(3):203–9 (38 ref.)
Acid, protons and Helicobacter pylori. Sachs G, et al. **Yale J Biol Med** 1996 May–Jun;69(3):301–16 (47 ref.)
Proton pump inhibitory therapy: then and now. Schepp W. **Yale J Biol Med** 1996 Mar–Apr;69(2):175–86 (99 ref.)
Pharmacotherapy for acid/peptic disorders. Schubert ML. **Yale J Biol Med** 1996 Mar–Apr;69(2):197–201 (23 ref.)
[A new strategy for the therapy of pancreatic cancer by proton pump inhibitor] Ohta T, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1660–4 (11 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

Regulation of Na+/H+ antiporter in trout red blood cells. Malapert M, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):353–60 (48 ref.)

CHEMISTRY

Protein structure: proton-pumping oxidases. Gennis RB, et al. **Curr Biol** 1996 Jan 1;6(1):36–8 (10 ref.)

GENETICS

Molecular genetic analysis of V-ATPase function in Drosophila melanogaster. Dow JA, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):237–45 (69 ref.)
[Genes for gastric proton pump and their transcriptional regulation] Maeda M. **Yakugaku Zasshi** 1996 Feb; 116(2):91–105 (45 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

The F0F1-type ATP synthases of bacteria: structure and function of the F0 complex. Deckers-Hebestreit G, et al. **Annu Rev Microbiol** 1996;50:791–824 (174 ref.)
Coupling H+ transport and ATP synthesis in F1F0-ATP synthases: glimpses of interacting parts in a dynamic molecular machine. Fillingame RH. **J Exp Biol** 1997 Jan; 200 (Pt 2):217–24 (68 ref.)
Animal plasma membrane energization by chemiosmotic H+ V-ATPases. Harvey WR, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):203–16 (92 ref.)
Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. Meyer UA. **Yale J Biol Med** 1996 May–Jun;69(3):203–9 (38 ref.)

PHYSIOLOGY

Role of V-ATPase-rich cells in acidification of the male reproductive tract. Brown D, et al. **J Exp Biol** 1997 Jan; 200 (Pt 2):257–62 (63 ref.)
The key role of the H+ V-ATPase in acid-base balance and Na+ transport processes in frog skin. Ehrenfeld J, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):247–56 (78 ref.)
Mitochondrial ammonia metabolism and the proton-neutral theory of hepatic ammonia detoxication. Campbell JW. **J Exp Zool** 1997 Aug 1;278(5):308–21 (121 ref.)

PROTON-TRANSLOCATING ATPASE COMPLEX see **H(+)-TRANSPORTING ATP SYNTHASE**

PROTONS

A possible role of slips in cytochrome C oxidase in the antioxygen defense system of the cell. Papa S, et al. **Biosci Rep** 1997 Feb;17(1):23–31 (33 ref.)
The physiological significance of mitochondrial proton leak in animal cells and tissues. Rolfe DF, et al. **Biosci Rep** 1997 Feb;17(1):9–16 (36 ref.)
[Proton and neutron radiation in cancer treatment: clinical and economic outcomes] Fleurette F, et al. **Bull Cancer Radiother** 1996;83 Suppl:223s–7s (29 ref.)
Subunit rotation in F0F1-ATP synthases as a means of coupling proton transport through F0 to the binding changes in F1. Cross RL, et al. **J Bioenerg Biomembr** 1996 Oct;28(5):403–8 (38 ref.)
Mitochondria-rich, proton-secreting epithelial cells. Brown D, et al. **J Exp Biol** 1996 Nov;199 (Pt 11):2345–58 (156 ref.)
The manipulation of water relaxation and water suppression in biological systems using the water-PRESS pulse sequence. Price WS, et al. **J Magn Reson B** 1996 Aug; 112(2):190–2 (20 ref.)
Proton transfer reactivity of large multiply charged ions. Williams ER. **J Mass Spectrom** 1996 Aug;31(8):831–42 (132 ref.)
Function and molecular structure of brush border membrane peptide/H+ symporters. Daniel H. **J Membr Biol** 1996 Dec;154(3):197–203 (68 ref.)
[Protontherapy. Clinical features] Habrand JL, et al. **Bull Cancer Radiother** 1996;83(4):247–53 (26 ref.) **(Fre)**
[Protontherapy: physical and technical basis] Mazal A, et al. **Bull Cancer Radiother** 1996;83(4):230–46 (60 ref.) **(Fre)**

THERAPEUTIC USE

Proton beams. Kacperek A, et al. **Br J Radiol** 1996;Suppl 25:131–7 (13 ref.)

PROTOPLASTS

DRUG EFFECTS

Killer plaque technique for selecting hybrids and cybrids obtained by induced protoplast fusion. Palková Z, et al. **Methods Mol Biol** 1996;53:339–42 (2 ref.)
Application of killer toxins in stepwise selection of hybrids and cybrids obtained by induced protoplast fusion. Vondrejs V, et al. **Methods Mol Biol** 1996;53:331–8 (15 ref.)

PHYSIOLOGY

Protoplast fusion in Saccharomyces cerevisiae. Curran BP, et al. **Methods Mol Biol** 1996;53:45–9 (6 ref.)

PROTOPORPHYRIA, ERYTHROPOIETIC see **PORPHYRIA, ERYTHROHEPATIC**

PROTOPORPHYRINS

PHARMACOLOGY

Pitfalls using metalloporphyrins in carbon monoxide research. Grundemar L, et al. **Trends Pharmacol Sci** 1997 Jun;18(6):193–5 (35 ref.)

PROTOZOA

see related
ANTIPROTOZOAL AGENTS

Protistan communities in aquifers: a review. Novarino G, et al. **FEMS Microbiol Rev** 1997 Jul;20(3–4):261–75 (95 ref.)

CLASSIFICATION

Riboprinting: a tool for the study of genetic diversity in microorganisms. Clark CG. **J Eukaryot Microbiol** 1997 Jul–Aug;44(4):277–83 (52 ref.)
Zooflagellate phylogeny and classification. Cavalier-Smith T. **Tsitologiia** 1995;37(11):1010–29 (95 ref.)
The position of flagellated protists in the system of lower eukaryotes. Starobogatov YI. **Tsitologiia** 1995; 37(11):1030–7 (18 ref.)

CYTOLOGY

Protozoan cell cycle control. Wong JT. **Biol Signals** 1996 Nov–Dec;5(6):301–8 (69 ref.)
The secretory pathway of protists: spatial and functional organization and evolution. Becker B, et al. **Microbiol Rev** 1996 Dec;60(4):697–721 (337 ref.)

DRUG EFFECTS

Antioxidant defense mechanisms in parasitic protozoa. Mehlotra RK. **Crit Rev Microbiol** 1996;22(4):295–314 (144 ref.)

GENETICS

Genetic transformation of parasitic protozoa. Kelly JM. **Adv Parasitol** 1997;39:227–70 (110 ref.)
Towards a unified evolutionary genetics of microorganisms. Tibayrenc M. **Annu Rev Microbiol** 1996;50:401–29 (75 ref.)
Good things in small packages: the tiny genomes of chlorarachniophyte endosymbionts. Gilson PR, et al. **Bioessays** 1997 Feb;19(2):167–73 (31 ref.)
Whither microbiology? Phylogenetic trees. Woese CR. **Curr Biol** 1996 Sep 1;6(9):1060–3 (10 ref.)
RNA editing in kinetoplastid protozoa. Stuart K, et al. **Microbiol Mol Biol Rev** 1997 Mar;61(1):105–20 (114 ref.)
RNA editing in kinetoplastid parasites: what to do with U. Sloof P, et al. **Trends Microbiol** 1997 May;5(5):189–95 (54 ref.)

GROWTH & DEVELOPMENT

Literature review and analysis of biological complexity in model stream ecosystems: influence of size and experimental design. Belanger SE. **Ecotoxicol Environ Saf** 1997 Feb;36(1):1–16 (187 ref.)

IMMUNOLOGY

Regulation of host cell function by glycosylphosphatidylinositols of the parasitic protozoa. Schofield L, et al. **Immunol Cell Biol** 1996 Dec;74(6):555–63 (103 ref.)

ISOLATION & PURIFICATION

Using molecular tools for diagnosis in veterinary parasitology. Comes AM, et al. **Vet Res** 1996; 27(4–5):333–42 (52 ref.)

METABOLISM

Antioxidant defense mechanisms in parasitic protozoa. Mehlotra RK. **Crit Rev Microbiol** 1996;22(4):295–314 (144 ref.)
Parasite sulphur amino acid metabolism. Walker J, et al. **Int J Parasitol** 1997 Aug;27(8):883–97 (90 ref.)
RNA editing in kinetoplastid protozoa. Stuart K, et al. **Microbiol Mol Biol Rev** 1997 Mar;61(1):105–20 (114 ref.)
RNA editing in kinetoplastid parasites: what to do with U. Sloof P, et al. **Trends Microbiol** 1997 May;5(5):189–95 (54 ref.)

MICROBIOLOGY

Endosymbiotic interactions in anaerobic protozoa. Hackstein JH, et al. **Antonie Van Leeuwenhoek** 1997 Feb;71(1–2):151–8 (52 ref.)
The molecular ecology of legionellae. Fields BS. **Trends Microbiol** 1996 Jul;4(7):286–90 (62 ref.)

PATHOGENICITY

The evolution and maintenance of virulence in microparasites. Levin BR. **Emerg Infect Dis** 1996 Apr–Jun; 2(2):93–102 (62 ref.)
Regulation of host cell function by glycosylphosphatidylinositols of the parasitic protozoa.

Schofield L, et al. **Immunol Cell Biol** 1996 Dec;74(6):555–63 (103 ref.)
Microbial adherence to and invasion through proteoglycans. Rostand KS, et al. **Infect Immun** 1997 Jan;65(1):1–8 (114 ref.)
Pore-forming proteins in pathogenic protozoan parasites. Horta MF. **Trends Microbiol** 1997 Sep;5(9):363–6 (33 ref.)

PHYSIOLOGY

The secretory pathway of protists: spatial and functional organization and evolution. Becker B, et al. **Microbiol Rev** 1996 Dec;60(4):697–721 (337 ref.)
Southern hemisphere mollusc diseases and an overview of associated risk assessment problems. Hine PM. **Rev Sci Tech** 1996 Jun;15(2):563–77 (77 ref.)
Appearance and spread of diseases among bivalve molluscs in the northern hemisphere in relation to international trade. Renault T. **Rev Sci Tech** 1996 Jun;15(2):551–61 (40 ref.)
[New details of the life cycle of Myxobolus cerebralis according to the literature] Prost M. **Wiad Parazytol** 1996; 42(3):283–90 (8 ref.) (Eng. Abstr.) **(Pol)**

ULTRASTRUCTURE

The cytoskeleton of protozoan parasites. Tilney LG, et al. **Curr Opin Cell Biol** 1996 Feb;8(1):43–8 (25 ref.)
Epibiotic microorganisms on copepods and other marine crustaceans. Carman KR, et al. **Microsc Res Tech** 1997 Apr 15;37(2):116–35 (137 ref.)

PROTOZOAN ANTIBODIES see **ANTIBODIES, PROTOZOAN**

PROTOZOAN ANTIGENS see **ANTIGENS, PROTOZOAN**

PROTOZOAN DNA see **DNA, PROTOZOAN**

PROTOZOAN GENES see **GENES, PROTOZOAN**

PROTOZOAN GENOME see **GENOME, PROTOZOAN**

PROTOZOAN INFECTIONS

see related
ANTIPROTOZOAL AGENTS

Pulmonary disease in selected protozoal infections. Kemper CA. **Semin Respir Infect** 1997 Jun;12(2):113–21 (60 ref.)
[Protozoal myocarditis] Kimura K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):79–82 (21 ref.) **(Jpn)**

COMPLICATIONS

[Myositis caused by Pleistophora in a patient with AIDS] Grau A, et al. **Med Clin (Barc)** 1996 Dec 7;107(20):779–81 (23 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Waterborne protozoan pathogens. Marshall MM, et al. **Clin Microbiol Rev** 1997 Jan;10(1):67–85 (206 ref.)
The uncommon gastrointestinal Protozoa: Microsporidia, Blastocystis, Isospora, Dientamoeba, and Balantidium. Weiss LM, et al. **Curr Clin Top Infect Dis** 1997;17:147–87 (261 ref.)

DRUG THERAPY

Chelators in biomedical research: a review. Mbati PA. **East Afr Med J** 1996 Jun;73(6):350–6 (51 ref.)

EPIDEMIOLOGY

Waterborne protozoan pathogens. Marshall MM, et al. **Clin Microbiol Rev** 1997 Jan;10(1):67–85 (206 ref.)
Communicable diseases surveillance. **Commun Dis Intell** 1997 Aug 7;21(16):222–30 (0 ref.)
The uncommon gastrointestinal Protozoa: Microsporidia, Blastocystis, Isospora, Dientamoeba, and Balantidium. Weiss LM, et al. **Curr Clin Top Infect Dis** 1997;17:147–87 (261 ref.)
Sensitive populations: who is at the greatest risk? Gerba CP, et al. **Int J Food Microbiol** 1996 Jun;30(1–2):113–23 (59 ref.)

ETIOLOGY

[Tuberculosis and protozoan infections in patients undergoing transplantation] Aguado JM, et al. **Enferm Infecc Microbiol Clin** 1997 May;15 Suppl 2:57–68 (171 ref.) **(Spa)**

IMMUNOLOGY

Role of natural killer cells in innate resistance to protozoan infections. Scharton-Kersten TM, et al. **Curr Opin Immunol** 1997 Feb;9(1):44–51 (86 ref.)
Shared themes of antigenic variation and virulence in bacterial, protozoal, and fungal infections. Deitsch KW, et al. **Microbiol Mol Biol Rev** 1997 Sep;61(3):281–93 (192 ref.)

METABOLISM

Pore-forming proteins in pathogenic protozoan parasites. Horta MF. **Trends Microbiol** 1997 Sep;5(9):363–6 (33 ref.)

PARASITOLOGY

[The heart and parasitic diseases] Mafart B, et al. **Med Trop (Mars)** 1996;56(3 Suppl):40–4 (41 ref.) **(Fre)**

PHYSIOPATHOLOGY

[Physiopathology of protozoan infections] Hommel M. **C R Seances Soc Biol Fil** 1996;190(4):341–55 (53 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Vaccines against protozoal diseases of veterinary importance. Cornelissen AW, et al. **FEMS Immunol Med Microbiol** 1996 Sep;15(2–3):61–72 (84 ref.)
Biological control. Aspects of biological control--with special reference to arthropods, protozoans and helminths of domesticated animals. Grønvold J, et al. **Vet Parasitol** 1996 Aug;64(1–2):47–64 (61 ref.)
Parasitic zoonoses in wildlife. van Knapen F. **Vet Q** 1996; 18 Suppl 3:S141–2 (0 ref.)
[Diagnostic PCR in veterinary parasitology: tritrichomonosis, neosporosis/toxoplasmosis echinococcosis/cysticercosis] Felleisen R, et al. **Schweiz Arch Tierheilkd** 1996; 138(3):144–51 (18 ref.) (Eng. Abstr.) **(Ger)**
[New details of the life cycle of Myxobolus cerebralis according to the literature] Prost M. **Wiad Parazytol** 1996; 42(3):283–90 (8 ref.) (Eng. Abstr.) **(Pol)**

PROTOZOAN PROTEINS

Transmission-blocking vaccines: uses and current status of development. Kaslow DC. **Int J Parasitol** 1997 Feb; 27(2):183–9 (45 ref.)

ANTAGONISTS & INHIBITORS

Energy production in Entamoeba histolytica: new perspectives in rational drug design. Saavedra-Lira E, et al. **Arch Med Res** 1996 Autumn;27(3):257–64 (62 ref.)

BIOSYNTHESIS

Toxoplasma gondii: kinetics of stage-specific protein expression during tachyzoite-bradyzoite conversion in vitro. Soête M, et al. **Curr Top Microbiol Immunol** 1996; 219:76–80 (16 ref.)

CHEMISTRY

Structural studies on myosin II: communication between distant protein domains. Gulick AM, et al. **Bioessays** 1997 Jul;19(7):561–9 (62 ref.)

GENETICS

Physiology and molecular biology of multidrug resistance in Entamoeba histolytica. Gómez MD, et al. **Arch Med Res** 1996 Autumn;27(3):421–5 (24 ref.)
A telomerase mutant defective in sister chromatid separation at mitosis. Nakaseko Y, et al. **Bioessays** 1997 Jul;19(7):557–9 (22 ref.)
Toxoplasma gondii microneme proteins: gene cloning and possible function. Fourmaux MN, et al. **Curr Top Microbiol Immunol** 1996;219:55–8 (16 ref.)

IMMUNOLOGY

Detection of IgA anti-P30 (SAG1) antibodies in acquired and congenital toxoplasmosis. Decoster A. **Curr Top Microbiol Immunol** 1996;219:199–207 (54 ref.)
Malaria vaccine trials: the missing qualitative data. Ferreira M. **Immunol Cell Biol** 1996 Aug;74(4):301–5 (20 ref.)

METABOLISM

Trichomonas vaginalis adhesin proteins display molecular mimicry to metabolic enzymes. Engbring JA, et al. **Adv Exp Med Biol** 1996;408:207–23 (86 ref.)
Role of secretory dense granule organelles in the pathogenesis of toxoplasmosis. Cesbron-Delauw MF, et al. **Curr Top Microbiol Immunol** 1996;219:59–65 (31 ref.)
The major surface proteins of Toxoplasma gondii: structures and functions. Tomavo S. **Curr Top Microbiol Immunol** 1996;219:45–54 (38 ref.)
Metabolic enzymes as potential drug targets in Plasmodium falciparum. Subbayya IN, et al. **Indian J Med Res** 1997 Aug;106:79–94 (127 ref.)
Pore-forming proteins in pathogenic protozoan parasites. Horta MF. **Trends Microbiol** 1997 Sep;5(9):363–6 (33 ref.)

PHYSIOLOGY

Members of the Tc-85 protein family from Trypanosoma cruzi are adhesion proteins. Alves MJ. **Braz J Med Biol Res** 1996 Jul;29(7):831–3 (32 ref.)

PROTOZOAN RNA see **RNA, PROTOZOAN**

PROTOZOAN STRUCTURAL GENES see **GENES, STRUCTURAL, PROTOZOAN**

PROTOZOAN VACCINES

Experimental models for leishmaniasis and for testing anti-leishmanial vaccines. Hommel M, et al. **Ann Trop Med Parasitol** 1995 Dec;89 Suppl 1:55–73 (142 ref.)
Prospects for subunit vaccines against tick-borne diseases [see comments] Musoke AJ, et al. **Br Vet J** 1996 Nov; 152(6):621–39 (125 ref.) Comment in: Br Vet J 1996 Nov;152(6):617–9.
Leishmaniasis: Immunological and clinical aspects and vaccines in Venezuela. Convit J. **Clin Dermatol** 1996 Sep-Oct;14(5):479–87 (15 ref.)
Vaccine for prophylaxis and immunotherapy, Brazil. Genaro O, et al. **Clin Dermatol** 1996 Sep-Oct;14(5):503–12 (43 ref.)
Vaccines against protozoal diseases of veterinary importance. Cornelissen AW, et al. **FEMS Immunol Med Microbiol** 1996 Sep;15(2–3):61–72 (84 ref.)
Reverse immunogenetics: from HLA-disease associations to vaccine candidates. Davenport MP, et al. **Mol Med Today** 1996 Jan;2(1):38–45 (25 ref.)
A general review on the prevention and treatment of Theileria annulata in China. Zhang ZH. **Vet Parasitol** 1997 Jun;70(1–3):77–81 (0 ref.)
[Vaccines against parasitic diseases of domestic animals] Eckert J, et al. **Tierarztl Prax** 1996 Aug;24(4):322–9 (50 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Immunological control of Toxoplasma gondii and appropriate vaccine design. Alexander J, et al. **Curr Top Microbiol Immunol** 1996;219:183–95 (81 ref.)

THERAPEUTIC USE

Vaccines against leishmaniasis. Modabber F. **Ann Trop Med Parasitol** 1995 Dec;89 Suppl 1:83–8 (24 ref.)

PROVIRUS INTEGRATION see **VIRUS INTEGRATION**

PROVIRUSES

see related
MUTAGENESIS, INSERTIONAL

GENETICS

Genetic variability and molecular epidemiology of human and simian T cell leukemia/lymphoma virus type I. Gessain A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S132–45 (106 ref.)
Human immunodeficiency virus-1 proviral gene disruption by targeted gene therapy: a hypothetical technique for the elimination of provirus from the infected cells. Batchu RB, et al. **Med Hypotheses** 1997 Jul;49(1):35–9 (32 ref.)

PROVOCATION TESTS, BRONCHIAL see **BRONCHIAL PROVOCATION TESTS**

PROVOCATION TESTS, NASAL see **NASAL PROVOCATION TESTS**

PROXEMICS see **SPATIAL BEHAVIOR**

PROXIMAL RENAL TUBULAR DYSFUNCTION see **FANCONI SYNDROME**

PRP PROTEINS see **PRIONS**

PRPC PROTEINS

Heat shock proteins, molecular chaperones and the prion encephalopathies. Kenward N, et al. **Cell Stress Chaperones** 1996 Apr;1(1):18–22 (34 ref.)
Microglia and prion disease: a review. Brown DR, et al. **Histol Histopathol** 1997 Jul;12(3):883–92 (74 ref.)
Prion diseases and the BSE crisis. Prusiner SB. **Science** 1997 Oct 10;278(5336):245–51 (110 ref.)

METABOLISM

Multiple roles for PrP in the prion diseases. Estibeiro JP. **Trends Neurosci** 1996 Jul;19(7):257–8 (10 ref.)

PRPP SYNTHETASE see **RIBOSE-PHOSPHATE PYROPHOSPHOKINASE**

PRPSC PROTEINS

Heat shock proteins, molecular chaperones and the prion encephalopathies. Kenward N, et al. **Cell Stress Chaperones** 1996 Apr;1(1):18–22 (34 ref.)
Prion diseases and the BSE crisis. Prusiner SB. **Science** 1997 Oct 10;278(5336):245–51 (110 ref.)

GENETICS

Molecular biology and pathogenesis of prion diseases [see comments] Prusiner SB. **Trends Biochem Sci** 1996 Dec; 21(12):482–7 (79 ref.) Comment in: Trends Biochem Sci 1997 Jul;22(7):241–2.

PRRS see **PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME**

PRRSV see **SWINE INFERTILITY AND RESPIRATORY SYNDROME VIRUS**

PRUNE BELLY SYNDROME

EMBRYOLOGY

Prune-belly syndrome: ongoing controversies regarding pathogenesis and management. Wheatley JM, et al. **Semin Pediatr Surg** 1996 May;5(2):95–106 (59 ref.)

SURGERY

Prune-belly syndrome: ongoing controversies regarding pathogenesis and management. Wheatley JM, et al. **Semin Pediatr Surg** 1996 May;5(2):95–106 (59 ref.)

PRURIGO

COMPLICATIONS

Progress and new directions in the investigation of the specific dermatoses of pregnancy. Black MM. **Keio J Med** 1997 Mar;46(1):40–1 (13 ref.)

ETIOLOGY

Prurigo pigmentosa, ketonemia and diabetes mellitus. Kobayashi T, et al. **Dermatology** 1996;192(1):78–80 (16 ref.)

THERAPY

Managing PLE and actinic prurigo. Grabczyska SA, et al. **Practitioner** 1997 Feb;241(1571):74, 77, 79 (6 ref.)

PRURITUS

ETIOLOGY

Uremic pruritus [published erratum appears in Am J Health Syst Pharm 1996 Oct 15;53(20):2523] Robertson KE, et al. **Am J Health Syst Pharm** 1996 Sep 15;53(18):2159–70; quiz 2215–6 (127 ref.)

Pruritus—itching for a cause and relief? Kam PC, et al. **Anaesthesia** 1996 Dec;51(12):1133–8 (54 ref.)

Uremic pruritus [editorial] Hiroshige K, et al. **Int J Artif Organs** 1996 May;19(5):265–7 (13 ref.)

PHYSIOPATHOLOGY

Pathophysiology of itching [see comments] Greaves MW, et al. **Lancet** 1996 Oct 5;348(9032):938–40 (30 ref.) Comment in: Lancet 1996 Nov 30;348(9040):1513. Comment in: Lancet 1996 Nov 30;348(9040):1513–4.

THERAPY

Pruritus—itching for a cause and relief? Kam PC, et al. **Anaesthesia** 1996 Dec;51(12):1133–8 (54 ref.)

[Symptomatic treatment of pruritus in cholestasis] Sapey T, et al. **Gastroenterol Clin Biol** 1997;21(6–7):472–80 (97 ref.) **(Fre)**

PSEUDARTHROSIS

CONGENITAL

Congenital pseudarthrosis of the tibia. Delgado-Martínez AD, et al. **Int Orthop** 1996;20(3):192–9 (61 ref.)

ETIOLOGY

[Spinal pseudarthroses] Räber D, et al. **Orthopade** 1996 Sep; 25(5):435–40 (53 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Familial congenital pseudoarthrosis of the clavicle: case report and literature review. Price BD, et al. **Iowa Orthop J** 1996;16:153–6 (21 ref.)

SURGERY

[Perspectives in callus distraction] Baumgart R, et al. **Unfallchirurg** 1996 Feb;99(2):84–91 (26 ref.) (Eng. Abstr.) **(Ger)**

[Infected pseudarthrosis] Ekkernkamp A, et al. **Unfallchirurg** 1996 Dec;99(12):914–24 (61 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Use of extracorporeal shock waves in the treatment of pseudarthrosis, tendinopathy and other orthopedic diseases. Haupt G. **J Urol** 1997 Jul;158(1):4–11 (151 ref.)

[High-energy extracorporeal shock-wave therapy (ESWT) in the treatment of pseudarthrosis] Vogel J, et al. **Z Orthop Ihre Grenzgeb** 1997 Mar–Apr;135(2):145–9 (42 ref.) (Eng. Abstr.) **(Ger)**

PSEUDO-HURLER POLYDYSTROPHY see **MUCOLIPIDOSIS**

PSEUDO-OBSTRUCTION, COLONIC see **COLONIC PSEUDO-OBSTRUCTION**

PSEUDO-OBSTRUCTION, INTESTINAL see **INTESTINAL PSEUDO-OBSTRUCTION**

PSEUDOANEURYSM see **ANEURYSM, FALSE**

PSEUDOBULBAR PARALYSIS see **PARALYSIS**

PSEUDOCHOLINESTERASE

BLOOD

[Pseudocholinesterase: biochemical, genetic and clinical aspects] Sela BA, et al. **Harefuah** 1996 Aug;131(3–4):112–5 (21 ref.) **(Heb)**

GENETICS

[Pseudocholinesterase: biochemical, genetic and clinical aspects] Sela BA, et al. **Harefuah** 1996 Aug;131(3–4):112–5 (21 ref.) **(Heb)**

PSEUDOCYESIS see **PSEUDOPREGNANCY**

PSEUDODEMENTIA see **FACTITIOUS DISORDERS**

PSEUDOEPHEDRINE see **EPHEDRINE**

PSEUDOEXFOLIATION SYNDROME see **EXFOLIATION SYNDROME**

PSEUDOGLOBULINS see **SERUM GLOBULINS**

PSEUDOGOUT see **CHONDROCALCINOSIS**

PSEUDOHERMAPHRODITISM

DIAGNOSIS

Ambiguous genitalia. Anhalt H, et al. **Pediatr Rev** 1996 Jun; 17(6):213–20 (6 ref.)

ENZYMOLOGY

5 alpha-reductase-2 deficiency. Imperato-McGinley J. **Curr Ther Endocrinol Metab** 1997;6:384–7 (5 ref.)

METABOLISM

Physiology and molecular genetics of 17 beta-hydroxysteroid dehydrogenases. Andersson S, et al. **Steroids** 1997 Jan; 62(1):143–7 (36 ref.)

SURGERY

5 alpha-reductase-2 deficiency. Imperato-McGinley J. **Curr Ther Endocrinol Metab** 1997;6:384–7 (5 ref.)

THERAPY

5 alpha-reductase-2 deficiency. Imperato-McGinley J. **Curr Ther Endocrinol Metab** 1997;6:384–7 (5 ref.)

PSEUDOHYPOALDOSTERONISM

[Pseudohypoaldosteronism] Arai K, et al. **Nippon Rinsho** 1996 Mar;54(3):812–8 (15 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[Pseudohypoaldosteronism in a premature newborn infant] González González MJ, et al. **An Esp Pediatr** 1996 May; 44(5):517–9 (10 ref.) **(Spa)**

ETIOLOGY

[Pseudohypoaldosteronism (type I)] Ogino Y, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):650–2 (13 ref.) **(Jpn)**

GENETICS

Abnormalities of aldosterone synthesis and action in children [see comments] White PC. **Curr Opin Pediatr** 1997 Aug; 9(4):424–30 (47 ref.) Comment in: Curr Opin Pediatr 1997 Aug;9(4):407–12.

The ENaC channel as the primary determinant of two human diseases: Liddle syndrome and pseudohypoaldosteronism. Schild L. **Nephrologie** 1996;17(7):395–400 (27 ref.)

METABOLISM

[Pseudohypoaldosteronism (type II)] Ogino Y, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):653–5 (13 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Mineralocorticoid resistance. Zennaro MC. **Steroids** 1996 Apr;61(4):189–92 (26 ref.)

PSEUDOHYPOPARATHYROIDISM

DIAGNOSIS

[Pseudohypoparathyroidism: new diagnostic and therapeutic approaches] Carel JC, et al. **Arch Pediatr** 1997;4(2 Suppl 2):86s–90s (35 ref.) **(Fre)**

[PTH infusion test] Yamamoto M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:307–9 (4 ref.) **(Jpn)**

THERAPY

Pseudohypoparathyroidism. Mallette LE. **Curr Ther Endocrinol Metab** 1997;6:577–81 (10 ref.)

[Pseudohypoparathyroidism: new diagnostic and therapeutic approaches] Carel JC, et al. **Arch Pediatr** 1997;4(2 Suppl 2):86s–90s (35 ref.) **(Fre)**

PSEUDOLYMPHOMA

CHEMICALLY INDUCED

Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Bocquet H, et al. **Semin Cutan Med Surg** 1996 Dec;15(4):250–7 (70 ref.)

COMPLICATIONS

A case of pseudolymphoma of the liver with chronic hepatitis C. Kim SR, et al. **J Hepatol** 1997 Jan;26(1):209–14 (30 ref.)

DIAGNOSIS

Current aspects of Lyme disease and other Borrelia burgdorferi infections. Berger BW. **Dermatol Clin** 1997 Apr;15(2):247–55 (58 ref.)

PSEUDOMONAS

DRUG EFFECTS

[Metal resistance systems in Pseudomonas] Cervantes C, et al. **Rev Latinoam Microbiol** 1996 Jan–Mar;38(1):45–64 (138 ref.) (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

Microbial dehalogenation of halogenated alkanoic acids, alcohols and alkanes. Slater JH, et al. **Adv Microb Physiol** 1997;38:133–76 (170 ref.)

METABOLISM

Microbial dehalogenation of halogenated alkanoic acids, alcohols and alkanes. Slater JH, et al. **Adv Microb Physiol** 1997;38:133–76 (170 ref.)

PATHOGENICITY

The type III (Hrp) secretion pathway of plant pathogenic bacteria: trafficking harpins, Avr proteins, and death. Alfano JR, et al. **J Bacteriol** 1997 Sep;179(18):5655–62 (89 ref.)

PSEUDOMONAS AERUGINOSA

[An improved phagocytic plaque method using gram-negative bacilli] Tomiya Y, et al. **Nippon Saikingaku Zasshi** 1996 Oct;51(4):1049–53 (6 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

The type-4 pilus is the major virulence-associated adhesin of Pseudomonas aeruginosa—a review. Hahn HP. **Gene** 1997 Jun 11;192(1):99–108 (64 ref.)

Pseudomonas aeruginosa lipopolysaccharides and pathogenesis. Goldberg JB, et al. **Trends Microbiol** 1996 Dec;4(12):490–4 (50 ref.)

DRUG EFFECTS

Fluoroquinolone therapy in pediatrics: where we stand [editorial; comment] Sabella C, et al. **Clin Pediatr (Phila)** 1997 Aug;36(8):445–8 (36 ref.) Comment on: Clin Pediatr (Phila) 1997 Aug;36(8):435–44.

Aminoglycoside adaptive resistance. Karlowsky JA, et al. **Pharmacotherapy** 1997 May–Jun;17(3):549–55 (37 ref.)

[Mechanisms of bacterial resistance to quinolones] Yoshida H. **Nippon Saikingaku Zasshi** 1996 Oct;51(4):973–92 (126 ref.) **(Jpn)**

ENZYMOLOGY

Structure-function relationship of type-IV prepilin peptidase of Pseudomonas aeruginosa—a review. Lory S, et al. **Gene** 1997 Jun 11;192(1):117–21 (26 ref.)

GENETICS

Recognition of mucin by the adhesin-flagellar system of Pseudomonas aeruginosa. Ramphal R, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 2):S170–4 (32 ref.)

Molecular genetic analysis of type-4 pilus biogenesis and twitching motility using Pseudomonas aeruginosa as a model system—a review. Darzins A, et al. **Gene** 1997 Jun 11;192(1):109–15 (56 ref.)

The molecular genetics of type-4 fimbriae in Pseudomonas aeruginosa—a review. Mattick JS, et al. **Gene** 1996 Nov 7;179(1):147–55 (70 ref.)

IMMUNOLOGY

Towards anti-Pseudomonas aeruginosa adhesion therapy. Gilboa-Garber N. **Adv Exp Med Biol** 1996;408:39–50 (63 ref.)

IgG subclasses and chronic bacterial infection. Subclass antibodies and the clinical course of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. Pressler T. **APMIS Suppl** 1996;66:1–41 (192 ref.)

ISOLATION & PURIFICATION

Microbiology and management of sinusitis. Brook I. **J Otolaryngol** 1996 Aug;25(4):249–56 (44 ref.)

METABOLISM

Interactions between glycoconjugates from human respiratory airways and Pseudomonas aeruginosa. Scharfman A, et al. **Am J Respir Crit Care Med** 1996 Oct; 154(4 Pt 2):S163–9 (59 ref.)

The effects of bacterial products on airway cells and their function. Wilson R, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 2):S197–201 (50 ref.)

Catabolite repression control in the Pseudomonads. Collier DN, et al. **Res Microbiol** 1996 Jul–Sep;147(6–7):551–61 (41 ref.)

The chain of command in Pseudomonas quorum sensing. Pesci EC, et al. **Trends Microbiol** 1997 Apr;5(4):132–4; discussion 134–5 (18 ref.)

[Antibiotic extrusion and multidrug resistance] Nakae T. **Nippon Rinsho** 1997 May;55(5):1173–8 (20 ref.) (Eng. Abstr.) **(Jpn)**

PATHOGENICITY

The type–4 pilus is the major virulence–associated adhesin of Pseudomonas aeruginosa—a review. Hahn HP. **Gene** 1997 Jun 11;192(1):99–108 (64 ref.)

Pseudomonas aeruginosa lipopolysaccharides and pathogenesis. Goldberg JB, et al. **Trends Microbiol** 1996 Dec;4(12):490–4 (50 ref.)

PHYSIOLOGY

Receptors in the Pseudomonas aeruginosa adherence to injured and repairing airway epithelium. de Bentzmann S, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 2):S155–62 (54 ref.)

Pseudomonas aeruginosa adherence to remodelling respiratory epithelium. de Bentzmann S, et al. **Eur Respir J** 1996 Oct;9(10):2145–50 (47 ref.)

ULTRASTRUCTURE

Periplasm, periplasmic spaces, and their relation to bacterial wall structure: novel secretion of selected periplasmic proteins from Pseudomonas aeruginosa. Beveridge TJ, et al. **Microb Drug Resist** 1996 Spring;2(1):1–8 (43 ref.)

PSEUDOMONAS CEPACIA see **BURKHOLDERIA CEPACIA**

PSEUDOMONAS INFECTIONS

[Cystic fibrosis and chronic Pseudomonas aeruginosa infection. Possibilities for immunologic prophylaxis and therapy] Bisgaard AT, et al. **Ugeskr Laeger** 1997 Sep 22; 159(39):5786–90 (33 ref.) (Eng. Abstr.) **(Dan)**

COMPLICATIONS

Malignant otitis externa in HIV and AIDS. Hern JD, et al. **J Laryngol Otol** 1996 Aug;110(8):770–5 (37 ref.)

DIAGNOSIS

Mycobacterium smegmatis infection in a healthy woman following a facelift: case report and review of the literature. Pennekamp A, et al. **Ann Plast Surg** 1997 Jul;39(1):80–3 (12 ref.)

Pseudomonas pericarditis and tamponade in an infant with human immunodeficency virus infection. Tumaliuan JA, et al. **Arch Pediatr Adolesc Med** 1997 Feb;151(2):207–8 (9 ref.)

Cost effectiveness of magnetic resonance imaging in diagnosing Pseudomonas aeruginosa infection after puncture wound. Lau LS, et al. **J Foot Ankle Surg** 1997 Jan–Feb;36(1):36–43 (23 ref.)

DRUG THERAPY

Towards anti–Pseudomonas aeruginosa adhesion therapy. Gilboa–Garber N. **Adv Exp Med Biol** 1996;408:39–50 (63 ref.)

Inhaled antibiotics in cystic fibrosis: a review. Toso C, et al. **Ann Pharmacother** 1996 Jul–Aug;30(7–8):840–50 (61 ref.)

Combination intravenous ceftazidime and aminoglycosides in the treatment of pseudomonal scleritis. Hehm CJ, et al. **Ophthalmology** 1997 May;104(5):838–43 (30 ref.)

Use of carbapenems and other antibiotics for pulmonary infections in patients with cystic fibrosis. Høiby N, et al. **Pediatr Infect Dis J** 1996 Aug;15(8):738–43 (80 ref.)

[Inhalational antibiotic therapy in patients with cystic fibrosis and Pseudomonas infection] Mordasini C, et al. **Schweiz Med Wochenschr** 1997 May 24;127(21):905–10 (46 ref.) (Eng. Abstr.) **(Ger)**

[The therapeutic and diagnostic contribution of ceftazidime (Fortum) in Pseudomonas aeruginosa superinfection in a patient with chronic bronchopathy] Mihăiţan F, et al. **Pneumoftiziologia** 1997 Jan–Mar;46(1):53–7 (12 ref.) (Eng. Abstr.) **(Rum)**

ETIOLOGY

Fatal infection of coronary stent implantation. Leroy O, et al. **Cathet Cardiovasc Diagn** 1996 Oct;39(2):168–70; discussion 171 (6 ref.)

Pseudomonas aeruginosa: assessment of risk from drinking water. Hardalo C, et al. **Crit Rev Microbiol** 1997; 23(1):47–75 (179 ref.)

Mycotic aortic aneurysms after orthotopic heart transplantation: a three–case report and review of the literature. Knosalla C, et al. **J Heart Lung Transplant** 1996 Aug;15(8):827–39 (27 ref.)

Outbreaks of infection in neonatal intensive care units (NICU) [letter; comment] Damjanovic V, et al. **J Hosp Infect** 1997 Mar;35(3):237–44 (19 ref.) Comment on: J Hosp Infect 1996 Jun;33(2):145–51.

Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Govan JR, et al. **Microbiol Rev** 1996 Sep;60(3):539–74 (492 ref.)

[The role of Pseudomonas aeruginosa and Proteus in the etiology of suppurative surgical infection] Nazarchuk LV. **Lik Sprava** 1996 Oct–Dec;(10–12):31–5 (22 ref.) **(Rus)**

IMMUNOLOGY

IgG subclasses and chronic bacterial infection. Subclass antibodies and the clinical course of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. Pressler T. **APMIS Suppl** 1996;66:1–41 (192 ref.)

MICROBIOLOGY

Potential of preventing Pseudomonas aeruginosa lung infections in cystic fibrosis patients: experimental studies in animals. Johansen HK. **APMIS Suppl** 1996;63:5–42 (311 ref.)

Pseudomonas aeruginosa lipopolysaccharides and pathogenesis. Goldberg JB, et al. **Trends Microbiol** 1996 Dec;4(12):490–4 (50 ref.)

PREVENTION & CONTROL

Potential of preventing Pseudomonas aeruginosa lung infections in cystic fibrosis patients: experimental studies in animals. Johansen HK. **APMIS Suppl** 1996;63:5–42 (311 ref.)

The preservation of function: treatment of new acquisition of a pathogen [editorial; comment] Rabin HR, et al. **Pediatr Pulmonol** 1997 May;23(5):323–4 (3 ref.) Comment on: Pediatr Pulmonol 1997 May;23(5):330–5.

Something is (not) rotten in Denmark [Hamlet (not) W. Shakespeare] [editorial; comment] Schidlow DV. **Pediatr Pulmonol** 1997 May;23(5):325–6 (4 ref.) Comment on: Pediatr Pulmonol 1997 May;23(5):330–5.

PSEUDOMONIC ACID see **MUPIROCIN**

PSEUDOMYXOMA PERITONEI

COMPLICATIONS

[Mucocele of the appendix with pseudomyxoma peritonei—a rare cause of a paraneoplastic syndrome] Pollack T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Mar;166(3):266–8 (13 ref.) **(Ger)**

DIAGNOSIS

Unusual tumors of the appendix and pseudomyxoma peritonei. Carr NJ, et al. **Semin Diagn Pathol** 1996 Nov; 13(4):314–25 (83 ref.)

PATHOLOGY

Columnar cells in smears from pseudomyxoma peritonei [letter] Gu M, et al. **Diagn Cytopathol** 1997 Feb;16(2):182–3 (13 ref.)

Unusual tumors of the appendix and pseudomyxoma peritonei. Carr NJ, et al. **Semin Diagn Pathol** 1996 Nov; 13(4):314–25 (83 ref.)

THERAPY

Pseudomyxoma peritonei syndrome. Sugarbaker PH, et al. **Adv Surg** 1996;30:233–80 (35 ref.)

Clinical determinants of treatment failure in patients with pseudomyxoma peritonei. Sugarbaker PH, et al. **Cancer Treat Res** 1996;81:121–32 (20 ref.)

Pseudomyxoma peritonei. Sugarbaker PH. **Cancer Treat Res** 1996;81:105–19 (79 ref.)

PSEUDONEUROTIC SCHIZOPHRENIA see **SCHIZOTYPAL PERSONALITY DISORDER**

PSEUDOPELADE see **ALOPECIA**

PSEUDOPOLYARTHRITIS, RHIZOMELIC see **POLYMYALGIA RHEUMATICA**

PSEUDOPREGNANCY

PSYCHOLOGY

Delusions of pregnancy in the elderly. Harland RF, et al. **Int J Geriatr Psychiatry** 1997 Jan;12(1):115–7 (6 ref.)

PSEUDOPROMOTER (GENETICS) see **PROMOTER REGIONS (GENETICS)**

PSEUDOPSYCHOPATHIC SCHIZOPHRENIA see **SCHIZOTYPAL PERSONALITY DISORDER**

PSEUDOPSYCHOSIS see **FACTITIOUS DISORDERS**

PSEUDORABIES

EPIDEMIOLOGY

Agricultural policy and social returns to eradication programs: the case of Aujeszky's disease in Sweden. Andersson H, et al. **Prev Vet Med** 1997 Feb;29(4):311–28 (30 ref.)

IMMUNOLOGY

The role of biotechnologically engineered vaccines and diagnostics in pseudorabies (Aujeszky's disease) eradication strategies. Mengeling WL, et al. **Vet Microbiol** 1997 Apr; 55(1–4):49–60 (70 ref.)

Vaccination strategies for improving the efficacy of programs to eradicate Aujeszky's disease virus. Visser N. **Vet Microbiol** 1997 Apr;55(1–4):61–74 (38 ref.)

PHYSIOPATHOLOGY

Recent developments in latency and recombination of Aujeszky's disease (pseudorabies) virus. Maes RK, et al. **Vet Microbiol** 1997 Apr;55(1–4):13–27 (48 ref.)

Functional aspects of Aujeszky's disease (pseudorabies) viral proteins with relation to invasion, virulence and immunogenicity. Nauwynck HJ. **Vet Microbiol** 1997 Apr; 55(1–4):3–11 (48 ref.)

PREVENTION & CONTROL

Agricultural policy and social returns to eradication programs: the case of Aujeszky's disease in Sweden. Andersson H, et al. **Prev Vet Med** 1997 Feb;29(4):311–28 (30 ref.)

The role of biotechnologically engineered vaccines and diagnostics in pseudorabies (Aujeszky's disease) eradication strategies. Mengeling WL, et al. **Vet Microbiol** 1997 Apr; 55(1–4):49–60 (70 ref.)

Vaccination strategies for improving the efficacy of programs to eradicate Aujeszky's disease virus. Visser N. **Vet Microbiol** 1997 Apr;55(1–4):61–74 (38 ref.)

VIROLOGY

Pseudorabies virus infections in pigs. Role of viral proteins in virulence, pathogenesis and transmission. Mulder WA, et al. **Vet Res** 1997;28(1):1–17 (142 ref.)

PSEUDORABIES VIRUS see **HERPESVIRUS 1, SUID**

PSEUDOSCLEROSIS see **HEPATOLENTICULAR DEGENERATION**

PSEUDOTUBERCULOSIS, PASTEURELLA see **YERSINIA PSEUDOTUBERCULOSIS INFECTIONS**

PSEUDOTUMOR CEREBRI

Intracranial hypertension. Kabat AG. **Optom Clin** 1996; 5(3–4):153–79 (51 ref.)

CHEMICALLY INDUCED

All–trans–retinoic acid and pseudotumor cerebri. Visani G, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):437–42 (96 ref.)

[Benign intracranial hypertension as a secondary effect of treatment with a biosynthetic growth hormone] Bermúdez de la Vega JA, et al. **An Esp Pediatr** 1996 May;44(5):507–8 (6 ref.) **(Spa)**

COMPLICATIONS

Idiopathic intracranial hypertension and seventh nerve palsy. Capobianco DJ, et al. **Headache** 1997 May;37(5):286–8 (20 ref.)

Idiopathic intracranial hypertension, empty sella turcica and polycystic ovary syndrome—a case report. Au Eong KG, et al. **Singapore Med J** 1997 Mar;38(3):129–30 (8 ref.)

DIAGNOSIS

Hydrocephalus and chronically increased intracranial pressure in achondroplasia. Erdinçler P, et al. **Childs Nerv Syst** 1997 Jun;13(6):345–8 (15 ref.)

Primary diffuse leptomeningeal gliomatosis with signs of increased intracranial pressure and progressive meningeal enhancement on MRI. Park JS, et al. **J Neuroimaging** 1996 Oct;6(4):250–4 (16 ref.)

[Benign intracranial hypertension in children] Maletskaia EV, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1997; 97(1):52–6 (66 ref.) **(Rus)**

[Intracranial hypertension in postoperative hypoparathyroidism (letter)] López JA, et al. **Med Clin (Barc)** 1997 Mar 8;108(9):358–9 (10 ref.) **(Spa)**

ETIOLOGY

Cranial hemophilic pseudotumor: case report. Sim KB, et al. **Neurosurgery** 1996 Dec;39(6):1239–42 (21 ref.)

PSEUDOTUMOR CEREBRI

NURSING

Management of intracranial hemodynamics in the adult: a research analysis of head positioning and recommendations for clinical practice and future research. Simmons BJ. **J Neurosci Nurs** 1997 Feb;29(1):44–9 (31 ref.)

PHYSIOPATHOLOGY

[Monitoring cerebral oxygenation in increased intracranial pressure] Unterberg A. **Zentralbl Neurochir** 1997;58(1):47–9 (24 ref.) **(Ger)**

PREVENTION & CONTROL

The use of barbiturates in the control of intracranial hypertension. Brain Trauma Foundation. **J Neurotrauma** 1996 Nov;13(11):711–4 (15 ref.)

The role of glucocorticoids in the treatment of severe head injury. Brain Trauma Foundation. **J Neurotrauma** 1996 Nov;13(11):715–8 (19 ref.)

The use of mannitol in severe head injury. Brain Trauma Foundation. **J Neurotrauma** 1996 Nov;13(11):705–9 (43 ref.)

THERAPY

[Intensive care in increased intracranial pressure. II: General intensive care treatment of patients with increased intracranial pressure. Ventilation. Intensive Care Committee of the German Society of Anesthesia and Intensive care] Burchardi H, et al. **Zentralbl Neurochir** 1997;58(2):76–82 (37 ref.) **(Ger)**

ULTRASONOGRAPHY

[Value of transcranial Doppler ultrasound in increased intracranial pressure] Schregel W. **Zentralbl Neurochir** 1997;58(1):43–6 (28 ref.) **(Ger)**

PSEUDOTUMOR, INFLAMMATORY see **GRANULOMA, PLASMA CELL**

PSEUDOTUMOR, INFLAMMATORY, ORBITAL see **GRANULOMA, PLASMA CELL, ORBITAL**

PSEUDOTUMOR, INFLAMMATORY, PULMONARY see **GRANULOMA, PLASMA CELL, PULMONARY**

PSEUDOURIDINE

CHEMISTRY

The pseudouridine residues of ribosomal RNA. Ofengand J, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):915–24 (39 ref.)

PSEUDOXANTHOMA ELASTICUM

[Pseudoxanthoma elasticum] Sakamoto K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):118–20 (19 ref.) **(Jpn)**

COMPLICATIONS

A case of actinic granuloma associated with periumbilical perforating pseudoxanthoma elasticum. Lee HW, et al. **Acta Derm Venereol** 1996 Mar;76(2):133–5 (12 ref.)

New report of severe coronary artery disease in an eighteen-year-old girl with pseudoxanthoma elasticum. Case report and review of the literature. Kévorkian JP, et al. **Angiology** 1997 Aug;48(8):735–41 (21 ref.)

GENETICS

Pseudoxanthoma elasticum and pregnancy. Yoles A, et al. **Cutis** 1996 Aug;58(2):161–4 (15 ref.)

PATHOLOGY

Pseudoxanthoma elasticum-like papillary dermal elastolysis. A report of two cases and review of the literature. Vargas-Diez E, et al. **Acta Derm Venereol** 1997 Jan; 77(1):43–5 (19 ref.)

Pseudoxanthoma elasticum and pregnancy. Yoles A, et al. **Cutis** 1996 Aug;58(2):161–4 (15 ref.)

PSITTACINES

PHYSIOLOGY

[Anesthesia in domestic animals (small mammals, psittacines and reptiles)] Kuntze A. **Tierarztl Prax** 1996 Dec; 24(6):600–3 (24 ref.) (Eng. Abstr.) **(Ger)**

PSITTACOSIS see **ORNITHOSIS**

PSITTACOSIS-LYMPHOGRANULOMA GROUP see **CHLAMYDIA**

PSOAS ABSCESS

COMPLICATIONS

Infected abdominal aortic aneurysm associated with a psoas abscess, aorto-duodenal and sigmoid fistulas. Case report and review of the literature. Louagie YA, et al. **Acta Chir Belg** 1997 Jan–Feb;97(1):39–43 (22 ref.)

MICROBIOLOGY

Pneumococcal psoas abscess: report of a case and review of the world literature. Giladi M, et al. **Isr J Med Sci** 1996 Sep;32(9):771–4 (15 ref.)

PSORALEN see **FICUSIN**

PSORALEN ULTRAVIOLET A THERAPY see **PUVA THERAPY**

PSORALENS

see related
COUMARINS

PHARMACOLOGY

Psoralen photosensitization: damages to nucleic acid and membrane lipid components. Caffieri S, et al. **Acta Biochim Pol** 1996;43(1):241–6 (31 ref.)

THERAPEUTIC USE

Vitiligo, psoralen, and melanogenesis: some observations and understanding. Chakraborty DP, et al. **Pigment Cell Res** 1996 Jun;9(3):107–16 (90 ref.)

TOXICITY

Psoralen photobiology: the relationship between DNA damage, chromatin structure, transcription, and immunogenic effects. Gasparro FP, et al. **Recent Results Cancer Res** 1997;143:101–27 (77 ref.)

PSORIASIS

Psoriasis and elective foot surgery [see comments] Cheleuitte E, et al. **J Foot Ankle Surg** 1996 Jul–Aug;35(4):297–302; discussion 371 (25 ref.) Comment in: J Foot Ankle Surg 1997 Jan–Feb;36(1):77–8.

[Psoriasis today] Guilhou JJ. **Presse Med** 1997 Jul 12; 26(24):1168–72 (31 ref.) (Eng. Abstr.) **(Fre)**

CHEMICALLY INDUCED

Is transglutaminase the mediator between antimalarial drugs and psoriasis? Wolf R, et al. **Int J Dermatol** 1997 Jan; 36(1):10–3 (36 ref.)

Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: four case reports and a review of drug-induced psoriasis. Gupta AK, et al. **J Am Acad Dermatol** 1997 May;36(5 Pt 2):858–62 (97 ref.)

[Psoriasis induced by interferon-alpha. Apropos of a case (letter)] Nguyen C, et al. **Ann Med Interne (Paris)** 1996; 147(7):519–21 (15 ref.) **(Fre)**

COMPLICATIONS

HIV and psoriasis. Badger J, et al. **Clin Rev Allergy Immunol** 1996–97 Winter;14(4):417–31 (39 ref.)

Psoriasis and HIV infection. Montazeri A, et al. **Int J Dermatol** 1996 Jul;35(7):475–9 (51 ref.)

Psoriasis, ichthyosis, and porphyria. Steiner G, et al. **Int Ophthalmol Clin** 1997 Spring;37(2):41–61 (71 ref.)

Erosion of psoriatic plaques: an early sign of methotrexate toxicity. Pearce HP, et al. **J Am Acad Dermatol** 1996 Nov; 35(5 Pt 2):835–8 (44 ref.)

DIAGNOSIS

Juvenile generalized pustular psoriasis. Kalla G, et al. **Pediatr Dermatol** 1996 Jan–Feb;13(1):45–6 (5 ref.)

DRUG THERAPY

Advances in psoriasis therapy. Koo J, et al. **Adv Dermatol** 1997;12:47–72; discussion 73 (102 ref.)

New horizons in the treatment of psoriasis and cutaneous fungal infections. Cowen P. **Aust Fam Physician** 1996 Mar; 25(3):317–22 (7 ref.)

Antipsoriatic and proinflammatory action of anthralin. Implications for the role of oxygen radicals. Müller K. **Biochem Pharmacol** 1997 May 9;53(9):1215–21 (69 ref.)

Efficacy of calcipotriol in psoriasis. **Br J Clin Pract Symp Suppl** 1996 Feb;83:8–25 (0 ref.)

Consensus conference on cyclosporin A microemulsion for psoriasis, June 1996. Berth-Jones J, et al. **Br J Dermatol** 1996 Nov;135(5):775–7 (2 ref.)

Vitamin D analogues in psoriasis: effects on systemic calcium homeostasis. Bourke JF, et al. **Br J Dermatol** 1996 Sep; 135(3):347–54 (47 ref.)

Individualized short-course cyclosporin therapy in psoriasis. Finzi AF. **Br J Dermatol** 1996 Sep;135 Suppl 48:31–4 (17 ref.)

Oral retinoids—efficacy and toxicity in psoriasis. Gollnick HP. **Br J Dermatol** 1996 Oct;135 Suppl 49:6–17 (80 ref.)

Methotrexate for psoriasis. Boffa MJ, et al. **Clin Exp Dermatol** 1996 Nov;21(6):399–408 (113 ref.)

Failure of combination therapy with acitretin and cyclosporin A in 3 patients with erythrodermic psoriasis [letter] Kuijpers AL, et al. **Dermatology** 1997;194(1):88–90 (11 ref.)

Coal tar, pine tar and sulfonated shale oil preparations: comparative activity, efficacy and safety. Schmid MH, et al. **Dermatology** 1996;193(1):1–5 (29 ref.)

Vitiligo following the resolution of psoriatic plaques during PUVA therapy. Halcin C, et al. **Int J Dermatol** 1997 Jul; 36(7):534–6 (11 ref.)

Psoriasis and calcipotriol: an overview. Jain S, et al. **Int J Dermatol** 1997 Apr;36(4):255–8 (46 ref.)

Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis. Chandraratna RA. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 3):S12–7 (34 ref.)

Molecular mechanisms of tazarotene action in psoriasis. Duvic M, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 3):S18–24 (33 ref.)

Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. Kitchin JE, et al. **J Am Acad Dermatol** 1997 Sep;37(3 Pt 1):445–9 (25 ref.)

Clinical safety of tazarotene in the treatment of plaque psoriasis. Marks R. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 3):S25–32 (50 ref.)

Erosion of psoriatic plaques: an early sign of methotrexate toxicity. Pearce HP, et al. **J Am Acad Dermatol** 1996 Nov; 35(5 Pt 2):835–8 (44 ref.)

Tazarotene gel: efficacy and safety in plaque psoriasis. Weinstein GD. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 3):S33–8 (19 ref.)

Vitamin D analogues and psoriasis. Stewart DG, et al. **J Clin Pharm Ther** 1996 Jun;21(3):143–8 (53 ref.)

Glucosamine for psoriasis? McCarty MF. **Med Hypotheses** 1997 May;48(5):437–41 (57 ref.)

Current thinking on psoriasis [published erratum appears in Practitioner 1997 Mar;241(1572):112] Donaldson L, et al. **Practitioner** 1997 Feb;241(1571):66–8, 70, 72 (10 ref.)

ETIOLOGY

Aetiology and pathogenesis of psoriasis. Ortonne JP. **Br J Dermatol** 1996 Oct;135 Suppl 49:1–5 (35 ref.)

Is psoriasis induced by streptococcal superantigens and maintained by M-protein-specific T cells that cross-react with keratin? Valdimarsson H, et al. **Clin Exp Immunol** 1997 Jan;107 Suppl 1:21–4 (28 ref.)

Langerhans cells may trigger the psoriatic disease process via production of nitric oxide. Morhenn VB. **Immunol Today** 1997 Sep;18(9):433–6 (53 ref.)

The role of epidermal proliferation in the pathogenesis of psoriasis. Van de Kerkhof PC, et al. **Skin Pharmacol** 1996; 9(6):343–54 (90 ref.)

Psoriasis and bacterial superantigens—formal or causal correlation? Boehncke WH. **Trends Microbiol** 1996 Dec; 4(12):485–9 (39 ref.)

GENETICS

The genetics of psoriasis. Henseler T. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 3):S1–11 (80 ref.)

IMMUNOLOGY

Psoriasis vulgaris, streptococci and the immune system: a riddle to be solved soon? Prinz JC. **Scand J Immunol** 1997 Jun;45(6):583–6 (30 ref.)

MICROBIOLOGY

Psoriasis vulgaris, streptococci and the immune system: a riddle to be solved soon? Prinz JC. **Scand J Immunol** 1997 Jun;45(6):583–6 (30 ref.)

PATHOLOGY

Chronic diffuse sclerosing osteomyelitis of the mandible or mandibular location of S.A.P.H.O. syndrome. García-Marín F, et al. **Acta Stomatol Belg** 1996 Jun; 93(2):65–71 (31 ref.)

Transition from symptomless to lesional psoriatic skin. Van de Kerkhof PC, et al. **Clin Exp Dermatol** 1996 Sep; 21(5):325–9 (49 ref.)

Oral mucositis with features of psoriasis: report of a case and review of the literature. Younai FS, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jul;84(1):61–7 (58 ref.)

THERAPY

The influence of mineral water solutions in phototherapy. Boer J. **Clin Dermatol** 1996 Nov–Dec;14(6):665–73 (48 ref.)

The Blue Lagoon in Iceland and psoriasis. Olafsson JH. **Clin Dermatol** 1996 Nov–Dec;14(6):647–51 (16 ref.)

Recent advances in the treatment of psoriasis. Guzzo C. **Dermatol Clin** 1997 Jan;15(1):59–68 (76 ref.)

The management of psoriasis. **Drug Ther Bull** 1996 Mar; 34(3):17–9 (31 ref.)

Psoriasis. Barker J. **J R Coll Physicians Lond** 1997 May–Jun; 31(3):238–40 (14 ref.)

[Systemic therapy of psoriasis] Altmeyer P, et al. **Dtsch Med Wochenschr** 1996 Dec 20;121(51–52):1605–7 (14 ref.) **(Ger)**

PSORIASIS, ARTHRITIC see **ARTHRITIS, PSORIATIC**

PSORIASIS ARTHROPATHICA see **ARTHRITIS, PSORIATIC**

PSRO see **PROFESSIONAL REVIEW ORGANIZATIONS**

PSYCHEDELIC AGENTS see **HALLUCINOGENS**

PSYCHIATRIC DEPARTMENT, HOSPITAL

A substance abuse consultation service. Enhancing the care of hospitalized substance abusers and providing training in addiction psychiatry. McDuff DR, et al. **Am J Addict** 1997 Summer;6(3):256–65 (43 ref.)

[Comprehensive psychiatry and the graduate education at Kitasato University] Nakajima S, et al. **Seishin Shinkeigaku Zasshi** 1997;99(5):271–8 (10 ref.) **(Jpn)**

ORGANIZATION & ADMINISTRATION

The problems of researching mixed sex wards. Batcup D. **J Adv Nurs** 1997 May;25(5):1018–24 (71 ref.)

Can psychiatric and chemical dependency treatment units be smoke free? Patten CA, et al. **J Subst Abuse Treat** 1996 Mar–Apr;13(2):107–18 (77 ref.)

PSYCHIATRIC NURSING

No more mother blaming: a feminist nursing perspective on the mother's role in father–daughter incest. Ehrmin JT. **Arch Psychiatr Nurs** 1996 Aug;10(4):252–60 (53 ref.)

Single subject experimentation for psychiatric nursing. Elder JH. **Arch Psychiatr Nurs** 1997 Jun;11(3):133–8 (17 ref.)

Delayed recall of childhood sexual abuse: psychiatric nursing's responsibilities to clients [comment] Hall JM. **Arch Psychiatr Nurs** 1996 Dec;10(6):342–6 (14 ref.) Comment on: Arch Psychiatr Nurs 1996 Apr;10(2):110–5.

Informal family caregiving to older people with dementia: research priorities for community psychiatric nursing. Adams T. **J Adv Nurs** 1996 Oct;24(4):703–10 (97 ref.)

The human science basis of psychiatric nursing: theory and practice. Barker PJ, et al. **J Adv Nurs** 1997 Apr;25(4):660–7 (44 ref.)

Liaison mental health nursing: origins, definition and prospects. Roberts D. **J Adv Nurs** 1997 Jan;25(1):101–8 (60 ref.)

Forensic nursing in Pakistan. Bridging the gap between victimized women and health care delivery systems. Carbonu DM, et al. **J Psychosoc Nurs Ment Health Serv** 1997 Jun;35(6):19–27 (41 ref.)

ECONOMICS

Psychiatric rehabilitation: a breath of fresh air in a turbulent health–care environment. Palmer–Erbs V. **J Psychosoc Nurs Ment Health Serv** 1996 Sep;34(9):16–21 (38 ref.)

METHODS

Towards a rhetoric of spirituality in mental health care. Nolan P, et al. **J Adv Nurs** 1997 Aug;26(2):289–94 (27 ref.)

Integration of therapeutic approaches: a new direction for mental health nurses? Wilshaw G. **J Adv Nurs** 1997 Jul; 26(1):15–9 (17 ref.)

Writing as a therapeutic modality. McGihon NN. **J Psychosoc Nurs Ment Health Serv** 1996 Jun;34(6):31–5 (8 ref.)

Managing threatening behavior. The role of talk down and talk up. Maier GJ. **J Psychosoc Nurs Ment Health Serv** 1996 Jun;34(6):25–30 (17 ref.)

STANDARDS

Patient outcomes used by advanced practice psychiatric nurses to evaluate effectiveness of practice. Barrell LM, et al. **Arch Psychiatr Nurs** 1997 Aug;11(4):184–97 (13 ref.)

TRENDS

Towards a critical theory of mental health nursing. Hopton J. **J Adv Nurs** 1997 Mar;25(3):492–500 (72 ref.)

The placebogenic phenomenon: art in psychiatric nursing. Blair DT. **J Psychosoc Nurs Ment Health Serv** 1996 Aug; 34(8):11–5 (24 ref.)

The impact of biological psychiatry on psychiatric nursing. Dawson PJ. **J Psychosoc Nurs Ment Health Serv** 1996 Aug; 34(8):28–33; discussion 33–35 (15 ref.)

PSYCHIATRIC SOCIAL WORK see **SOCIAL WORK, PSYCHIATRIC**

PSYCHIATRIC STATUS RATING SCALES

Schizotypal disorder: at the crossroads of genetics and nosology. Battaglia M, et al. **Acta Psychiatr Scand** 1996 Nov;94(5):303–10 (94 ref.)

The nature and assessment of catastrophic thoughts in panic disorder. Cox BJ. **Behav Res Ther** 1996 Apr;34(4):363–74 (55 ref.)

Early detection of autism. Diagnostic instruments for clinicians. Gillberg C, et al. **Eur Child Adolesc Psychiatry** 1996 Jun;5(2):67–74 (66 ref.)

Assessment tools for general health care settings: PRIME–MD, OARS, and SF–36. Primary Care Evaluation of Mental Health Disorders. Older Americans Resources and Services Questionnaire; Short Form–36. Van Hook MP, et al. **Health Soc Work** 1996 Aug;21(3):230–4 (23 ref.)

Diagnostic classification of neuropsychiatric signs and symptoms in patients with dementia. Caine ED. **Int Psychogeriatr** 1996;8 Suppl 3:273–9; discussion 289–91 (12 ref.)

Theories behind existing scales for rating behavior in dementia. Cummings JL. **Int Psychogeriatr** 1996;8 Suppl 3:293–300 (34 ref.)

More theory–driven and less diagnosis–based behavior therapy. Eifert GH. **J Behav Ther Exp Psychiatry** 1996 Jun;27(2):75–86 (50 ref.)

Models of scientific progress and the role of theory in taxonomy development: a case study of the DSM. Follette WC, et al. **J Consult Clin Psychol** 1996 Dec;64(6):1120–32 (59 ref.)

Symptom dimensions of schizophrenia: a selective integration of neurophysiological and neuropsychological correlates. Aderibigbe YA, et al. **Neuropsychobiology** 1996; 34(4):192–200 (89 ref.)

Late–life psychiatric diagnosis in DSM–IV. Martin RL. **Psychiatr Clin North Am** 1997 Mar;20(1):1–14 (18 ref.)

Evaluation of screens for mental disorders in primary care: methodological issues. Leon AC, et al. **Psychopharmacol Bull** 1996;32(3):353–61 (21 ref.)

Computer–administered clinical rating scales. A review. Kobak KA, et al. **Psychopharmacology (Berl)** 1996 Oct; 127(4):291–301 (70 ref.)

[Significance of primary negative symptoms in schizophrenic and other psychiatric patients] Gerbaldo H, et al. **Fortschr Neurol Psychiatr** 1996 Jun;64(6):221–7 (50 ref.) (Eng. Abstr.) **(Ger)**

[Dementia rating scale] Yamada M, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:310–4 (5 ref.) **(Jpn)**

STANDARDS

The assessment of panic using self–report: a comprehensive survey of validated instruments. Bouchard S, et al. **J Anxiety Disord** 1997 Jan–Feb;11(1):89–111 (73 ref.)

Use and abuse of the Children's Depression Inventory. Fristad MA, et al. **J Consult Clin Psychol** 1997 Aug; 65(4):699–702 (21 ref.)

International experiences with the Hospital Anxiety and Depression Scale—a review of validation data and clinical results. Herrmann C. **J Psychosom Res** 1997 Jan;42(1):17–41 (211 ref.)

Assessing clinical outcomes: the community functioning of persons with serious mental illness. Dickerson FB. **Psychiatr Serv** 1997 Jul;48(7):897–902 (51 ref.)

STATISTICS & NUMERICAL DATA

Cultures in psychiatric nosology: the CCMD–2–R and international classification of mental disorders. Lee S. **Cult Med Psychiatry** 1996 Dec;20(4):421–72 (115 ref.)

The book of names: DSM–IV in context. Jensen PS, et al. **Dev Psychopathol** 1997 Spring;9(2):231–49 (100 ref.)

Behavioral disturbances of dementia in DSM–IV and ICD–10: fact or fiction? Zaudig M. **Int Psychogeriatr** 1996; 8 Suppl 3:285–8 (10 ref.)

Framing research on culture in psychiatric diagnosis: the case of the DSM–IV. Rogler LH. **Psychiatry** 1996 Summer; 59(2):145–55 (35 ref.)

Psychiatric assessment instruments developed by the World Health Organization. Sartorius N, et al. **Soc Psychiatry Psychiatr Epidemiol** 1996 Mar;31(2):55–69 (59 ref.)

SCAN and the PSE tradition. Wing J. **Soc Psychiatry Psychiatr Epidemiol** 1996 Mar;31(2):50–4 (42 ref.)

[Indications for new antidepressants with reference to ICD–10: a waggish question or the future of psychiatry?] De Smet Y. **Encephale** 1997 Mar–Apr;23(2):77–82 (31 ref.) (Eng. Abstr.) **(Fre)**

[The PANSS (Positive And Negative Symptom) Scale] Guelfi JD. **Encephale** 1997 Apr;23 Spec No 2:35–8 (19 ref.) (Eng. Abstr.) **(Fre)**

PSYCHIATRY

Intellectual handicap in contemporary psychiatry. Einfeld SL. **Aust N Z J Psychiatry** 1997 Aug;31(4):452–6 (14 ref.)

Religion, spirituality and psychiatry: conceptual, cultural and personal challenges. Turbott J. **Aust N Z J Psychiatry** 1996 Dec;30(6):720–7; discussion 728–30 (65 ref.)

Risk assessment in psychiatry. Maden A. **Br J Hosp Med** 1996 Jul 10–Aug 20;56(2–3):78–82 (16 ref.)

Psychosocial rehabilitation and psychiatry: what are the boundaries? Bachrach LL. **Can J Psychiatry** 1996 Feb; 41(1):28–35 (55 ref.)

From evidence to conclusions in psychiatric research. Bilsker D. **Can J Psychiatry** 1996 May;41(4):227–32 (19 ref.)

Why psychiatrists in India prescribe so many drugs. Nunley M. **Cult Med Psychiatry** 1996 Jun;20(2):165–97 (91 ref.)

Chronic gynecologic pain. Stewart DE. **Gen Hosp Psychiatry** 1996 Jul;18(4):230–7 (30 ref.)

Conceptions and misconceptions. Decisions about pregnancy. Stotland NL. **Gen Hosp Psychiatry** 1996 Jul;18(4):238–43 (11 ref.)

Cognitive screening instruments in neuropsychiatry: a report of the Committee on Research of the American Neuropsychiatric Association. Malloy PF, et al. **J Neuropsychiatry Clin Neurosci** 1997 Spring;9(2):189–97 (73 ref.)

Complexity measures in molecular psychiatry. Rapp PE, et al. **Mol Psychiatry** 1996 Nov;1(5):408–16 (83 ref.)

A selective overview of occupational psychiatry. Greenfield DP, et al. **N J Med** 1996 Jan;93(1):28–30 (17 ref.)

Psychiatry and physician–assisted suicide. Zaubler TS, et al. **Psychiatr Clin North Am** 1996 Sep;19(3):413–27 (59 ref.)

The fate of the ego in contemporary psychiatry with particular reference to etiologic theories of schizophrenia. Diamond DB. **Psychiatry** 1997 Spring;60(1):67–88 (78 ref.)

Determining the effect that consultation–liaison psychiatry in primary care has on family physicians' psychiatric knowledge and practice. Carr VJ, et al. **Psychosomatics** 1997 May–Jun;38(3):217–29 (51 ref.)

An agenda for primary care psychiatry. Wulsin LR. **Psychosomatics** 1996 Mar–Apr;37(2):93–9 (21 ref.)

Interaction, language and the "narrative turn" in psychotherapy and psychiatry. Brown B, et al. **Soc Sci Med** 1996 Dec;43(11):1569–78 (83 ref.)

Roles of mental health professionals in multidisciplinary medically supervised treatment programs for obesity. Hunter SM, et al. **South Med J** 1997 Jun;90(6):578–86 (76 ref.)

[Psychiatry between neurosciences and psychoanalysis] Dongier M. **Rev Med Liege** 1996 Dec;51(12):763–70 (26 ref.) **(Fre)**

[The pitfalls of liaison psychiatry] Dongier M, et al. **Rev Med Liege** 1996 Sep;51(9):590–8 (45 ref.) **(Fre)**

[Literature and psychiatry] Borgna E. **Recenti Prog Med** 1996 Dec;87(12):628–34 (26 ref.) (Eng. Abstr.) **(Ita)**

[Psychiatrists and their identity] Kasahara Y. **Seishin Shinkeigaku Zasshi** 1996;98(9):597–602 (4 ref.) **(Jpn)**

[Problems in establishment of psychiatry specialty certification—viewed from an experience at Musashi National Hospital in Japan] Uno S. **Seishin Shinkeigaku Zasshi** 1997;99(5):278–81 (0 ref.) **(Jpn)**

CLASSIFICATION

[Classification in actual psychiatry] Martínez DR. **Acta Psiquiatr Psicol Am Lat** 1995 Dec;41(4):275–81 (34 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

"While you're up, get me a grant": a guide to grant writing. Streiner DL. **Can J Psychiatry** 1996 Apr;41(3):137–43 (2 ref.)

EDUCATION

Psychiatry at a crossroad: our role in primary care [see comments] Shore JH. **Am J Psychiatry** 1996 Nov; 153(11):1398–403 (20 ref.) Comment in: Am J Psychiatry 1997 Sep;154(9):1325. Comment in: Am J Psychiatry 1997 Sep;154(9):1325–6. Comment in: Am J Psychiatry 1997 Sep;154(9):1326.

Ethnocultural factors in the development of an Asian American psychiatrist. Chung H, et al. **Cult Divers Ment Health** 1996;2(2):99–106 (12 ref.)

Psychiatry in medical practice. Implications for the education of primary care physicians in the era of managed care: Part 2. Stoudemire A. **Psychosomatics** 1997 Jan–Feb; 38(1):1–9 (74 ref.)

[What is psychiatry? Psychiatry in German language textbooks—I] Hoffmann–Richter U. **Psychiatr Prax** 1997 Mar;24(2):99–105 (0 ref.) **(Ger)**

[Psychotherapeutic responsibilities in psychiatry—and the cooperation of fields (editorial)] Müller P. **Psychiatr Prax** 1997 May;24(3):107–9 (20 ref.) (Eng. Abstr.) **(Ger)**

[Reality and task of psychiatry education at Matsuzawa Hospital in Tokyo] Ehata K. **Seishin Shinkeigaku Zasshi** 1997;99(5):266–71 (4 ref.) **(Jpn)**

[Comprehensive psychiatry and the graduate education at Kitasato University] Nakajima S, et al. **Seishin Shinkeigaku Zasshi** 1997;99(5):271–8 (10 ref.) **(Jpn)**

[Problems in establishment of psychiatry specialty certification—viewed from an experience at Musashi National Hospital in Japan] Uno S. **Seishin Shinkeigaku Zasshi** 1997;99(5):278–81 (0 ref.) **(Jpn)**

HISTORY

Sandor Rado and Adolf Meyer: a nodal point in American psychiatry and psychoanalysis. Tomlinson C. **Int J Psychoanal** 1996 Oct;77 (Pt 5):963–82 (131 ref.)

The psychiatric unit comes to the general hospital: a history of the movement. Walkup J. **New Dir Ment Health Serv** 1997 Spring;(73):11–23 (62 ref.)

[History of mental disease therapy—concept of the diseases and method of the therapy] Yagi K, et al. **Seishin Shinkeigaku Zasshi** 1996;98(9):603–11 (0 ref.) **(Jpn)**

LEGISLATION & JURISPRUDENCE

Physician–assisted suicide in psychiatry: developments in The Netherlands. Legemaate J, et al. **Camb Q Healthc Ethics** 1997 Spring;6(2):175–88 (45 ref.)

[The practice of placing under psychiatric observation] Boxho P. **Rev Med Liege** 1997 May;52(5):345–51 (24 ref.)

PSYCHIATRY

(Fre)

MANPOWER

Consultation–liaison psychiatry and the practice of medicine. The Thomas P. Hackett Award lecture given at the 42nd annual meeting of the Academy of Psychosomatic Medicine, 1995. Kornfeld DS. **Psychosomatics** 1996 May–Jun;37(3):236–48 (66 ref.)

METHODS

A role for near infrared spectroscopy in psychiatry? Hock C, et al. **Adv Exp Med Biol** 1997;413:105–23 (25 ref.)

Suicide and violence assessment in psychiatry. Hughes DH. **Gen Hosp Psychiatry** 1996 Nov;18(6):416–21 (37 ref.)

[The importance of hypnosis in psychiatry] Schäfer ML. **Fortschr Neurol Psychiatr** 1997 Jul;65(7):304–12 (69 ref.) (Eng. Abstr.) (Ger)

ORGANIZATION & ADMINISTRATION

Consultation–liaison psychiatry and the practice of medicine. The Thomas P. Hackett Award lecture given at the 42nd annual meeting of the Academy of Psychosomatic Medicine, 1995. Kornfeld DS. **Psychosomatics** 1996 May–Jun;37(3):236–48 (66 ref.)

STANDARDS

Psychosocial intervention following suicide attempt: a systematic review of treatment interventions. van der Sande R, et al. **Acta Psychiatr Scand** 1997 Jul;96(1):43–50 (33 ref.)

The code of professional ethics of the Russian Society of Psychiatrists. Text and commentary. Polubinskaya SV, et al. **Int J Law Psychiatry** 1996 Spring;19(2):143–72 (52 ref.)

TRENDS

Redefining the role of psychiatry in medicine [see comments] Lieberman JA, et al. **Am J Psychiatry** 1996 Nov; 153(11):1388–97 (95 ref.) Comment in: Am J Psychiatry 1997 Sep;154(9):1325.

Unity and diversity in psychiatry: some philosophical issues. Dewhurst D, et al. **Aust N Z J Psychiatry** 1996 Jun; 30(3):382–8; discussion 388–91 (20 ref.)

Clinical practice issues in consultation–liaison psychiatry. Wright M, et al. **Aust N Z J Psychiatry** 1996 Apr; 30(2):238–45 (66 ref.)

Personal hopefulness: a conceptual review of the relevance of the perceived future to psychiatry. Nunn KP. **Br J Med Psychol** 1996 Sep;69 (Pt 3):227–45 (122 ref.)

The history and future of cross–cultural psychiatric services. Moffic HS, et al. **Community Ment Health J** 1996 Dec; 32(6):581–92 (32 ref.)

Psychiatry's culture. Littlewood R. **Int J Soc Psychiatry** 1996 Winter;42(4):245–68 (95 ref.)

Elucidating mental disorder in liaison psychiatry: the Johns Hopkins "perspectives" [editorial] Lobo A. **J Psychosom Res** 1996 Jul;41(1):7–11 (29 ref.)

Psychiatry. The brain hallucinates and gets caught in the web. Friedman L, et al. **Lancet** 1996 Dec 21–28;348 Suppl 2:sII21 (5 ref.)

Consultation–liaison psychiatry in the managed care arena. Gonzales JJ, et al. **Psychiatr Clin North Am** 1996 Sep; 19(3):449–66 (53 ref.)

Psychiatric interventions in the medically ill. Outcome and effectiveness research. Saravay SM. **Psychiatr Clin North Am** 1996 Sep;19(3):467–80 (66 ref.)

PSYCHIATRY, BIOLOGICAL see **BIOLOGICAL PSYCHIATRY**

PSYCHIATRY, COMMUNITY see **COMMUNITY PSYCHIATRY**

PSYCHIATRY, GERIATRIC see **GERIATRIC PSYCHIATRY**

PSYCHIATRY, MILITARY see **MILITARY PSYCHIATRY**

PSYCHICAL RESEARCH see **PARAPSYCHOLOGY**

PSYCHOACTIVE AGENTS see **PSYCHOTROPIC DRUGS**

PSYCHOANALYSIS

Play and game as metaphor for technique. Cohen MC. **J Am Acad Psychoanal** 1996 Spring;24(1):61–73 (25 ref.)

"Reality" and countertransference in the treatment of sexual abuse patients: the false memory controversy. Perlman SD. **J Am Acad Psychoanal** 1996 Spring;24(1):115–35 (32 ref.)

Toward a conceptual alliance about therapeutic alliance: a voyage through the Inferno. Szajnberg NM. **J Am Acad Psychoanal** 1996 Spring;24(1):95–113 (33 ref.)

External reality: the elusive dimension of psychoanalysis. Oliner MM. **Psychoanal Q** 1996 Apr;65(2):267–300 (49 ref.)

[Psychiatry between neurosciences and psychoanalysis] Dongier M. **Rev Med Liege** 1996 Dec;51(12):763–70 (26 ref.) (Fre)

[Review of the research on "theory of mind"] Koyasu M, et al. **Shinrigaku Kenkyu** 1997 Apr;68(1):51–67 (76 ref.) (Eng. Abstr.) (Jpn)

[Death and burial of psychoanalysis] García–Albea E. **Rev Neurol** 1997 Jan;25(137):89–90 (11 ref.) (Spa)

EDUCATION

How useful is selection? Kappelle W. **Int J Psychoanal** 1996 Dec;77 (Pt 6):1213–32 (34 ref.)

Dialogue with other sciences: opportunities for mutual gain [editorial] Olds D, et al. **Int J Psychoanal** 1997 Apr;78 (Pt 2):219–25 (48 ref.)

The multiple functions of the supervisor: a summary of the seventh IPA conference of training analysis. Vollmer Filho G, et al. **Int J Psychoanal** 1996 Aug;77 (Pt 4):813–8 (0 ref.)

Supervision as an analytic experience. Pegeron JP. **Psychoanal Q** 1996 Oct;65(4):693–710 (26 ref.)

HISTORY

Sandor Rado and Adolf Meyer: a nodal point in American psychiatry and psychoanalysis. Tomlinson C. **Int J Psychoanal** 1996 Oct;77 (Pt 5):963–82 (131 ref.)

TRENDS

What postmodernism can do for psychoanalysis: a guide to the postmodern vision. Shawver L. **Am J Psychoanal** 1996 Dec;56(4):371–94 (67 ref.)

PSYCHOANALYTIC INTERPRETATION

"Fearing our mothers": an overview of the psychoanalytic theories concerning the vagina dentata motif F547.1.1. Otero S. **Am J Psychoanal** 1996 Sep;56(3):269–88 (81 ref.)

PSYCHOANALYTIC THEORY

The psychology of self: an update. Meares R. **Aust N Z J Psychiatry** 1996 Jun;30(3):312–6 (15 ref.)

Why scientific hypnosis needs psychoanalysis (or something like it). Nash MR. **Int J Clin Exp Hypn** 1997 Jul; 45(3):291–300 (32 ref.)

Mourning: a review and reconsideration. Hagman G. **Int J Psychoanal** 1995 Oct;76 (Pt 5):909–25 (87 ref.)

Problems in the concept of repression and proposals for their resolution. Maze JR, et al. **Int J Psychoanal** 1996 Dec;77 (Pt 6):1085–100 (36 ref.)

How brain development is shaped by genetic and environmental factors. Pally R. **Int J Psychoanal** 1997 Jun; 78 (Pt 3):587–93 (21 ref.)

The aim of psychoanalysis in theory and in practice [see comments] Steiner J. **Int J Psychoanal** 1996 Dec;77 (Pt 6):1073–83 (29 ref.) Comment in: Int J Psychoanal 1997 Jun;78 (Pt 3):580–3.

The application of postmodern thought to the clinical practice of psychoanalytic psychotherapy. Chessick RD. **J Am Acad Psychoanal** 1996 Fall;24(3):385–407 (46 ref.)

Archaic sadism. Chessick RD. **J Am Acad Psychoanal** 1996 Winter;24(4):605–18 (37 ref.)

Mind, brain, machine: language. Forrest DV. **J Am Acad Psychoanal** 1996 Fall;24(3):409–30 (51 ref.)

Radical constructivism and narrative. Gomez EA. **J Am Acad Psychoanal** 1996 Spring;24(1):1–14 (21 ref.)

Psychoanalysis is self–centered. Rubin JB. **J Am Acad Psychoanal** 1996 Winter;24(4):633–48 (50 ref.)

Reflections on the authority of the past in psychoanalytic thinking. Chodorow NJ. **Psychoanal Q** 1996 Jan; 65(1):32–51 (33 ref.)

External reality: the elusive dimension of psychoanalysis. Oliner MM. **Psychoanal Q** 1996 Apr;65(2):267–300 (49 ref.)

A review of psychoanalytic theory and treatment of childhood autism. Roser K. **Psychoanal Rev** 1996 Jun; 83(3):325–41 (37 ref.)

Polarities and amalgams: analytic dyads and the individuals within them. Silverman DK. **Psychoanal Rev** 1996 Apr; 83(2):247–71 (107 ref.)

Beauty and the beast: a myth of sadness, madness, and hope in anaclitic depression. Wu J. **Psychoanal Rev** 1997 Jun; 84(3):365–80 (16 ref.)

[New approaches for understanding borderline personality disorder] Frommer J, et al. **Fortschr Neurol Psychiatr** 1997 Jan;65(1):34–40 (70 ref.) (Eng. Abstr.) (Ger)

[Differentiation and therapy of delinquent behavior in borderline disorders. Psychodynamic approach] Dulz B. **Nervenarzt** 1997 May;68(5):395–400 (31 ref.) (Eng. Abstr.) (Ger)

[Anxiety as an existential phenomenon. An existential analytic approach to understanding and therapy of anxieties] Längle A. **Psychother Psychosom Med Psychol** 1997 Jul; 47(7):227–33 (18 ref.) (Eng. Abstr.) (Ger)

[Review of the research on "theory of mind"] Koyasu M, et al. **Shinrigaku Kenkyu** 1997 Apr;68(1):51–67 (76 ref.) (Eng. Abstr.) (Jpn)

PSYCHOANALYTIC THERAPY

Values in psychotherapy. Holmes J. **Am J Psychother** 1996 Summer;50(3):259–73 (31 ref.)

A clinical and interactionist perspective on the bully–victim–bystander relationship. Twemlow SW, et al. **Bull Menninger Clin** 1996 Summer;60(3):296–313 (40 ref.)

Psychic reality and unconscious belief: a reconsideration. Gerard HB. **Int J Psychoanal** 1997 Apr;78 (Pt 2):327–33; discussion 335–40 (30 ref.)

Problems in the concept of repression and proposals for their resolution. Maze JR, et al. **Int J Psychoanal** 1996 Dec;77 (Pt 6):1085–100 (36 ref.)

The aim of psychoanalysis in theory and in practice [see comments] Steiner J. **Int J Psychoanal** 1996 Dec;77 (Pt 6):1073–83 (29 ref.) Comment in: Int J Psychoanal 1997 Jun;78 (Pt 3):580–3.

Mind, brain, machine: language. Forrest DV. **J Am Acad Psychoanal** 1996 Fall;24(3):409–30 (51 ref.)

Bereavement and neurosis. Hagman G. **J Am Acad Psychoanal** 1995 Winter;23(4):635–53 (33 ref.)

Assessing outcome in psychoanalysis and long–term dynamic psychotherapy. Marshall RD, et al. **J Am Acad Psychoanal** 1996 Winter;24(4):575–604 (150 ref.)

Psychoanalysis is self–centered. Rubin JB. **J Am Acad Psychoanal** 1996 Winter;24(4):633–48 (50 ref.)

A third individuation: immigration, identity, and the psychoanalytic process. Akhtar S. **J Am Psychoanal Assoc** 1995;43(4):1051–84 (145 ref.)

The primal scene: variations on a theme. Knafo D, et al. **J Am Psychoanal Assoc** 1996;44(2):549–69 (41 ref.)

Feminist psychodynamic psychotherapy of eating disorders. Theoretic integration informing clinical practice. Zerbe KJ. **Psychiatr Clin North Am** 1996 Dec;19(4):811–27 (83 ref.)

Reflections on the authority of the past in psychoanalytic thinking. Chodorow NJ. **Psychoanal Q** 1996 Jan; 65(1):32–51 (33 ref.)

How can we study the efficacy of psychoanalysis? Waldron S Jr. **Psychoanal Q** 1997 Apr;66(2):283–322 (144 ref.)

Anna Freud's contributions to our knowledge of child development. An overview. Yorke C. **Psychoanal Study Child** 1996;51:7–24 (46 ref.)

[Beautifying the breast] Le Gouès G. **Contracept Fertil Sex** 1997 Jun;25(6):475–81 (31 ref.) (Eng. Abstr.) (Fre)

[Burning mouth syndromes and depression. A psychoanalytic approach] Demange C, et al. **Rev Stomatol Chir Maxillofac** 1996;97(4):244–52 (19 ref.) (Eng. Abstr.) (Fre)

[Differentiation and therapy of delinquent behavior in borderline disorders. Psychodynamic approach] Dulz B. **Nervenarzt** 1997 May;68(5):395–400 (31 ref.) (Eng. Abstr.) (Ger)

[Self–reflection, interpersonal behavior and psychoanalytic ethics] Bürgy M. **Psychother Psychosom Med Psychol** 1997 May;47(5):181–6 (32 ref.) (Eng. Abstr.) (Ger)

[Insight into the illness by schizophrenic patients: a psychoanalytic perspective] Rittmannsberger H. **Psychother Psychosom Med Psychol** 1996 Jul;46(7):269–75 (55 ref.) (Eng. Abstr.) (Ger)

METHODS

Techniques to accelerate dynamic psychotherapy. Fosha D, et al. **Am J Psychother** 1997 Spring;51(2):229–51 (59 ref.)

Hypnosis and psychoanalytic therapy (hypnoanalysis). Wolberg LR. **Am J Psychother** 1996 Fall;50(4):393–413; discussion 414–5 (25 ref.)

Meaning and development in the interpersonal treatment of severe psychopathology. Kline J, et al. **Bull Menninger Clin** 1996 Summer;60(3):314–30 (39 ref.)

The application of postmodern thought to the clinical practice of psychoanalytic psychotherapy. Chessick RD. **J Am Acad Psychoanal** 1996 Fall;24(3):385–407 (46 ref.)

The analytic initiation: the effect of the archetype of initiation on the personal unconscious. Sullivan M. **J Anal Psychol** 1996 Oct;41(4):509–27 (13 ref.)

Psychoanalytic observations on the "gift" technique in the treatment of the dying patient: a case report. Garcia EE. **Psychoanal Rev** 1996 Jun;83(3):395–418 (39 ref.)

The psychoanalytic relationship: past and present. Panken S. **Psychoanal Rev** 1996 Apr;83(2):157–79 (76 ref.)

Polarities and amalgams: analytic dyads and the individuals within them. Silverman DK. **Psychoanal Rev** 1996 Apr; 83(2):247–71 (107 ref.)

[Treatment failures and analysis of resistance in behavior therapy exemplified by a parent–child program for the treatment of hyperkinetic and oppositional children] Dopfner M, et al. **Prax Kinderpsychol Kinderpsychiatr** 1996 Jan;45(1):10–19 (0 ref.) (Eng. Abstr.) (Ger)

PSYCHODIDAE

CLASSIFICATION

Preliminary taxonomy of Costa Rican Psychodidae (Diptera), exclusive of Phlebotominae. Quate LW. **Rev Biol Trop** 1996 Aug;44 Suppl 1:1–81 (44 ref.)

PSYCHOGENETICS see **GENETICS, BEHAVIORAL**

PSYCHOGERIATRICS see **GERIATRIC PSYCHIATRY**

PSYCHOIMMUNOLOGY see **PSYCHONEUROIMMUNOLOGY**

PSYCHOLINGUISTICS

see related
LANGUAGE DEVELOPMENT

PSYCHOLOGICAL TESTS

Cognitive and psychomotor performance tests and experiment design in multiple chemical sensitivity.

Wetherell A. **Environ Health Perspect** 1997 Mar;105 Suppl 2:495–503 (45 ref.)

Psychological measures: practical issues in observational studies and clinical monitoring. Lassere M, et al. **J Rheumatol** 1997 May;24(5):1004–7 (10 ref.)

Psychosocial measures in musculoskeletal trials. Newman SP. **J Rheumatol** 1997 May;24(5):979–84 (60 ref.)

Practical issues in psychosocial measures. Wolfe F. **J Rheumatol** 1997 May;24(5):990–3 (35 ref.)

Practical guidelines in the use of symptom validity and other psychological tests to measure malingering and symptom exaggeration in traumatic brain injury cases. Etcoff LM, et al. **Neuropsychol Rev** 1996 Dec;6(4):171–201 (91 ref.)

The NEECHAM Confusion Scale: construction, validation, and clinical testing. Neelon VJ, et al. **Nurs Res** 1996 Nov–Dec;45(6):324–30 (49 ref.)

Psychological assessment and intervention: future prospects for women with breast cancer. Walker LG, et al. **Semin Surg Oncol** 1996 Jan–Feb;12(1):76–83 (45 ref.)

PSYCHOLOGICAL THEORY

Behavioural feedback to risk variation ensues from unsatisfied appetency. Dussault C. **Accid Anal Prev** 1996 Jul; 28(4):477–86 (20 ref.)

A critique of social bonding and control theory of delinquency using the principles of Psychology of Mind. Kelley TM. **Adolescence** 1996 Summer;31(122):321–37 (31 ref.)

Dyssynchrony, conflict, and resolution: positive contributions to infant development. Biringen Z, et al. **Am J Orthopsychiatry** 1997 Jan;67(1):4–19 (69 ref.)

Cognitive theory applied to the treatment of delusions of schizophrenia. Jensen LH, et al. **Arch Psychiatr Nurs** 1996 Dec;10(6):335–41 (23 ref.)

In search of a metatheory for cognitive development (or, Piaget is dead and I don't feel so good myself). Bjorklund DF. **Child Dev** 1997 Feb;68(1):144–8 (36 ref.)

Sibling rivalry in the 1990s. Renshaw DC. **Compr Ther** 1996 Jul;22(7):415–9 (11 ref.)

Mental imagery as the adaptationist views it. Pani JR. **Conscious Cogn** 1996 Sep;5(3):288–326 (235 ref.)

Incorporating diversity: meaning, levels of research, and implications for theory [see comments] Calasanti TM. **Gerontologist** 1996 Apr;36(2):147–56 (60 ref.) Comment in: Gerontologist 1996 Apr;36(2):145–6. Comment in: Gerontologist 1996 Apr;36(2):174–7.

Theoretical developments in the psychology of aging. Schroots JJ. **Gerontologist** 1996 Dec;36(6):742–8 (51 ref.)

Attachment disruption in anorexia nervosa and bulimia nervosa: a review of theory and empirical research. O'Kearney R. **Int J Eat Disord** 1996 Sep;20(2):115–27 (74 ref.)

Culture, needs and nursing: a critical theory approach. Holmes CA, et al. **J Adv Nurs** 1997 Mar;25(3):463–70 (66 ref.)

Exploring the nursing role in pain management from a post-structuralist perspective. Price K, et al. **J Adv Nurs** 1996 Nov;24(5):899–904 (35 ref.)

Hypnosis and phenomenological-perceptual psychology [published erratum appears in J Clin Psychol 1996 May;52(3):373] Woodard FJ. **J Clin Psychol** 1996 Mar; 52(2):209–18 (28 ref.)

Bandura's theory of self-efficacy: applications to oncology. Lev EL. **Sch Inq Nurs Pract** 1997 Spring;11(1):21–37; discussion 39–43 (62 ref.)

[Clinical dimensions of contemporary cultural psychiatry] Alarcón RD. **Acta Psiquiatr Psicol Am Lat** 1995 Dec; 41(4):265–74 (73 ref.) (Eng. Abstr.) **(Spa)**

PSYCHOLOGICAL WARFARE

see related
PERSUASIVE COMMUNICATION

PSYCHOLOGY

Contributions of inhibitory mechanisms to unified theory in neuroscience and psychology. Clark JM. **Brain Cogn** 1996 Feb;30(1):127–52 (104 ref.)

The psychosocial impact of skin disease. An overview. Ginsburg IH. **Dermatol Clin** 1996 Jul;14(3):473–84 (69 ref.)

[A survey of virtual reality research: From technology to psychology] Sakurai K. **Shinrigaku Kenkyu** 1995 Oct; 66(4):296–309 (106 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Psychological medicine, pain, and musculoskeletal disorders. Merskey H. **Rheum Dis Clin North Am** 1996 Aug; 22(3):623–37 (48 ref.)

TRENDS

Annotation: computers for learning: psychological perspectives. Light P. **J Child Psychol Psychiatry** 1997 Jul; 38(5):497–504 (69 ref.)

PSYCHOLOGY, CLINICAL

Stress in clinical psychologists. Cushway D, et al. **Int J Soc Psychiatry** 1996 Summer;42(2):141–9 (39 ref.)

STANDARDS

Anger and hostility in maritally violent men: conceptual distinctions, measurement issues, and literature review. Eckhardt CI, et al. **Clin Psychol Rev** 1997;17(4):333–58 (111 ref.)

PSYCHOLOGY, CRIMINAL see **CRIMINAL PSYCHOLOGY**

PSYCHOLOGY, EXPERIMENTAL

METHODS

The serial organisation of behaviour by non-human primates: an evaluation of experimental paradigms. De Lillio C. **Behav Brain Res** 1996 Nov;81(1–2):1–17 (65 ref.)

PSYCHOLOGY, HEALTH see **BEHAVIORAL MEDICINE**

PSYCHOLOGY, INDUSTRIAL

see related
HUMAN ENGINEERING

The role of production control in the development of burnout. Houben GJ, et al. **Int J Health Serv** 1996; 26(2):331–53 (97 ref.)

PSYCHOLOGY, PASTORAL see **PASTORAL CARE**

PSYCHOLOGY, PHYSIOLOGICAL see **PSYCHOPHYSIOLOGY**

PSYCHOLOGY, SCHIZOPHRENIC see **SCHIZOPHRENIC PSYCHOLOGY**

PSYCHOLOGY, SELF see **SELF PSYCHOLOGY**

PSYCHOLOGY, SOCIAL

see related
RACE RELATIONS

The social, cultural and political dimensions of contemporary war. Summerfield D. **Med Confl Surviv** 1997 Jan–Mar; 13(1):3–25 (39 ref.)

Militarism: a psychosocial disease. Coulter NA. **Med War** 1992 Jan–Mar;8(1):7–17 (15 ref.)

PSYCHOMETRICS

Quality of life assessment and HIV infection: a review. Vanhems P, et al. **Eur J Epidemiol** 1996 Jun;12(3):221–8 (33 ref.)

The geometric structure, construction, and interpretation of path-following (trail-making) tests. Vickers D, et al. **J Clin Psychol** 1996 Nov;52(6):651–61 (50 ref.)

Changing conceptions of measurement validity [see comments] Goodwin LD. **J Nurs Educ** 1997 Mar; 36(3):102–7 (44 ref.) Comment in: J Nurs Educ 1997 Mar;36(3):99–101.

Assessing clinical outcomes: the community functioning of persons with serious mental illness. Dickerson FB. **Psychiatr Serv** 1997 Jul;48(7):897–902 (51 ref.)

Assessing quality of life in chronic non-specific lung disease—a review of empirical studies published between 1980 and 1994. Maillé AR, et al. **Qual Life Res** 1996 Apr; 5(2):287–301 (116 ref.)

Neuropsychological course after surgery for intracranial aneurysms. A prospective study and a critical review. Stabell KE, et al. **Scand J Psychol** 1997 Jun;38(2):127–37 (49 ref.)

INSTRUMENTATION

Computerized methods of neuropsychological assessment. Curtis-Prior PB. **Br J Hosp Med** 1996 Nov 6–19; 56(9):445–9 (30 ref.)

METHODS

Functional assessment and binge eating. A review of the literature and suggestions for future research. Lee MI, et al. **Behav Modif** 1997 Apr;21(2):159–71 (38 ref.)

Assessment of health-related quality of life in children and adolescents: an integrative review. Spieth LE, et al. **J Pediatr Psychol** 1996 Apr;21(2):175–93 (64 ref.)

Structural equation modeling: basic concepts and applications in personality assessment research. Crowley SL, et al. **J Pers Assess** 1997 Jun;68(3):508–31 (44 ref.)

Measurement of aggression in psychiatric patients. Gothelf D, et al. **Psychiatry Res** 1997 Jul 4;71(2):83–95 (90 ref.)

STANDARDS

Studying the quality of life after organ transplantation: research problems and solutions. Joralemon D, et al. **Soc Sci Med** 1997 May;44(9):1259–69 (100 ref.)

PSYCHOMOTOR AGITATION

DIAGNOSIS

Conceptualization of agitation: results based on the Cohen-Mansfield Agitation Inventory and the Agitation Behavior Mapping Instrument. Cohen-Mansfield J. **Int Psychogeriatr** 1996;8 Suppl 3:309–15; discussion 351–4 (45 ref.)

Assessment of agitation. Cohen-Mansfield J. **Int Psychogeriatr** 1996 Summer;8(2):233–45 (26 ref.)

Agitation, wandering, pacing, restlessness, and repetitive mannerisms. Neistein S, et al. **Int Psychogeriatr** 1996;8 Suppl 3:399–402 (13 ref.)

[Agitation in the elderly person. Diagnostic and therapeutic approach] Roberge RF. **Can Fam Physician** 1996 Dec; 42:2392–8 (39 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Management of agitation in nursing home patients. Billig N. **Drugs Aging** 1996 Aug;9(2):93–100 (51 ref.)

Optimal management of behavioural disorders associated with dementia. Class CA, et al. **Drugs Aging** 1997 Feb; 10(2):95–106 (70 ref.)

Treatment strategies for agitation and psychosis in dementia. Tariot PN. **J Clin Psychiatry** 1996;57 Suppl 14:21–9 (97 ref.)

Pharmacologic treatment of agitation in dementia: a comprehensive review. Lantz MS, et al. **J Geriatr Psychiatry Neurol** 1996 Jul;9(3):107–19 (130 ref.)

Palliative care: an update on "terminal restlessness". Burke AL. **Med J Aust** 1997 Jan 6;166(1):39–42 (37 ref.)

Sedation in acute and chronic agitation. Levy RH. **Pharmacotherapy** 1996 Nov–Dec;16(6 Pt 2):152S–159S; discussion 166S–168S (33 ref.)

NURSING

Interventions for cognitive impairment and neurobehavioral disturbances of older adults. Cronin-Stubbs D. **Annu Rev Nurs Res** 1997;15:35–56 (98 ref.)

PHYSIOPATHOLOGY

Restlessness: the anatomy of a neuropsychiatric symptom. Sachdev P, et al. **Aust N Z J Psychiatry** 1996 Feb; 30(1):38–53 (100 ref.)

PSYCHOLOGY

The agitated brain injured patient. Part 1: Definitions, differential diagnosis, and assessment. Sandel ME, et al. **Arch Phys Med Rehabil** 1996 Jun;77(6):617–23 (64 ref.)

THERAPY

The treatment of sundowning. A selective review of pharmacological and nonpharmacological studies. McGaffigan S, et al. **Drugs Aging** 1997 Jan;10(1):10–7 (52 ref.)

[Agitation in the elderly person. Diagnostic and therapeutic approach] Roberge RF. **Can Fam Physician** 1996 Dec; 42:2392–8 (39 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOMOTOR DISORDERS

COMPLICATIONS

De novo interstitial tandem duplication of chromosome 4(q21–q28). Navarro EG, et al. **Am J Med Genet** 1996 Mar 29;62(3):297–9 (12 ref.)

[Cognitive organization in the motor pathology] Masi G, et al. **Minerva Psichiatr** 1996 Jun;37(2):69–81 (59 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Psychomotor symptoms of depression. Sobin C, et al. **Am J Psychiatry** 1997 Jan;154(1):4–17 (146 ref.)

Developmental dyspraxia and developmental coordination disorder. Miyahara M, et al. **Neuropsychol Rev** 1995 Dec; 5(4):245–68 (112 ref.)

ETIOLOGY

Persistence of neurological damage induced by dietary vitamin B-12 deficiency in infancy. von Schenck U, et al. **Arch Dis Child** 1997 Aug;77(2):137–9 (20 ref.)

The hand and the eye. Filan SL, et al. **J Hand Surg [Br]** 1997 Jun;22(3):293–8 (48 ref.)

Psychomotor development and behavior in iron-deficient anemic infants. de Andraca I, et al. **Nutr Rev** 1997 Apr; 55(4):125–32 (46 ref.)

[Left hand clumsiness due to disturbance of kinesthesia after damage to the dorsal column of the high cervical cord] Hashimoto R, et al. **Rinsho Shinkeigaku** 1997 Apr; 37(4):319–25 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Drug-related motor disorders in aged people] Martí-Massó JF. **Rev Neurol** 1997 Jul;25 Suppl 1:S37–43 (35 ref.) **(Spa)**

[Motor disorders of vascular origin in aged people] Zarranz JJ. **Rev Neurol** 1997 Jul;25 Suppl 1:S33–6 (25 ref.) **(Spa)**

PSYCHOLOGY

[Is periodic psychosis in adolescence a disease of its own? The differential diagnosis of psychomotor psychoses in childhood and adolescence] Neumärker KJ, et al. **Fortschr Neurol Psychiatr** 1996 Feb;64(2):66–80 (89 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOMOTOR PERFORMANCE

Neurobehavioral aspects of lead neurotoxicity in children. Winneke G, et al. **Cent Eur J Public Health** 1997 Jun; 5(2):65–9 (41 ref.)

Cognitive and psychomotor performance tests and experiment design in multiple chemical sensitivity. Wetherell A. **Environ Health Perspect** 1997 Mar;105 Suppl 2:495–503 (45 ref.)

Procedural skills in medicine: linking theory to practice. Kovacs G. **J Emerg Med** 1997 May–Jun;15(3):387–91 (22 ref.)

Simple reaction time and perception of temporal order: dissociations and hypotheses. Jaśkowski P. **Percept Mot Skills** 1996 Jun;82(3 Pt 1):707–30 (110 ref.)

A computational theory of executive cognitive processes and multiple-task performance: Part 1. Basic mechanisms. Meyer DE, et al. **Psychol Rev** 1997 Jan;104(1):3–65 (280 ref.)

[Examination of eye–head coordination] Arai Y. **Nippon Rinsho** 1997 Mar;55 Suppl 1:432–4 (8 ref.) **(Jpn)**

DRUG EFFECTS

Sedation and performance issues in the treatment of allergic conditions [see comments] Adelsberg BR. **Arch Intern Med** 1997 Mar 10;157(5):494–500 (42 ref.) Comment in: ACP J Club 1997 Jul–Aug;127(1):10.

Performance tests. Wetherell A. **Environ Health Perspect** 1996 Apr;104 Suppl 2:247–73 (418 ref.)

Management of motor fluctuations in Parkinson's disease. Koller WC. **Eur Neurol** 1996;36 Suppl 1:43–8 (48 ref.)

Motor fluctuations in levodopa treatment: clinical pharmacology. Stocchi F, et al. **Eur Neurol** 1996;36 Suppl 1:38–42 (38 ref.)

The effects of antidepressants on psychomotor function with particular reference to reboxetine. Hindmarch I. **Eur Neuropsychopharmacol** 1997 Apr;7 Suppl 1:S17–21; discussion S71–3 (31 ref.)

In search of dose–response relationships of solvent mixtures to neurobehavioural effects in paint manufacturing and painters. Seeber A, et al. **Food Chem Toxicol** 1996 Nov–Dec;34(11–12):1113–20 (22 ref.)

A review of the psychomotor effects of paroxetine. Hawley CJ, et al. **Int Clin Psychopharmacol** 1997 Jan;12(1):13–8 (24 ref.)

Psychomotor and electroencephalographic sequelae of cocaine dependence. Bauer LO. **NIDA Res Monogr** 1996; 163:66–93 (83 ref.)

Battery of neurobehavioral tests recommended to ATSDR: solvent-induced deficits in microelectronic workers. Hudnell HK, et al. **Toxicol Ind Health** 1996 Mar–Apr; 12(2):235–43 (6 ref.)

PHYSIOLOGY

Visuo–vestibular integration in the development of posture and gait. Amblard B. **Arch Ital Biol** 1996 Jul;134(3):249–77 (104 ref.)

Posture and movement: coordination and control. Lacquaniti F, et al. **Arch Ital Biol** 1997 Sep;135(4):353–67 (80 ref.)

Attention control: explorations of the work of an executive controller. Gopher D. **Brain Res Cogn Brain Res** 1996 Dec; 5(1–2):23–38 (51 ref.)

The acquisition of perceptual and motor skills: a memory system in the adult human cortex. Karni A. **Brain Res Cogn Brain Res** 1996 Dec;5(1–2):39–48 (50 ref.)

Representation of object-centered space in the primate frontal lobe. Olson CR, et al. **Brain Res Cogn Brain Res** 1996 Dec;5(1–2):147–56 (32 ref.)

Mental transformations in the motor cortex. Pellizzer G. **Brain Res Cogn Brain Res** 1996 Dec;5(1–2):123–30 (23 ref.)

Functional modular organization of the primate prefrontal cortex for representing working memory process. Sawaguchi T. **Brain Res Cogn Brain Res** 1996 Dec; 5(1–2):157–63 (31 ref.)

Role of the cerebellum and motor cortex in the regulation of visually controlled locomotion. Armstrong DM, et al. **Can J Physiol Pharmacol** 1996 Apr;74(4):443–55 (55 ref.)

Visuomotor modules in the vertebrate brain. Goodale MA. **Can J Physiol Pharmacol** 1996 Apr;74(4):390–400 (37 ref.)

Parietal cortex area 5 and visuomotor behavior. Kalaska JF. **Can J Physiol Pharmacol** 1996 Apr;74(4):483–98 (69 ref.)

Cooperative structures for visually guided reach. MacKay WA. **Can J Physiol Pharmacol** 1996 Apr;74(4):463–8 (46 ref.)

Fast and slow feedback loops for the visual correction of spatial errors in a pointing task: a reappraisal. Paillard J. **Can J Physiol Pharmacol** 1996 Apr;74(4):401–17 (136 ref.)

The fuzzy logic of visuomotor control. Prochazka A. **Can J Physiol Pharmacol** 1996 Apr;74(4):456–62 (30 ref.)

Visuomotor regulation of locomotion. Rossignol S. **Can J Physiol Pharmacol** 1996 Apr;74(4):418–25 (94 ref.)

The premotor cortex and nonstandard sensorimotor mapping. Wise SP, et al. **Can J Physiol Pharmacol** 1996 Apr; 74(4):469–82 (92 ref.)

Separate channels for visuomotor transformations in the pigeon. Jäger R. **Eur J Morphol** 1997 Oct;35(4):277–89 (70 ref.)

Visual sensation during pecking in pigeons. Ostheim J. **Eur J Morphol** 1997 Oct;35(4):269–76 (36 ref.)

Behavioral morphology of the pigeon's peck: ingestion, prehension and cognition. Zeigler HP. **Eur J Morphol** 1997 Oct;35(4):255–68 (31 ref.)

Pathophysiology of cerebellar dysmetria: the imbalance between the agonist and the antagonist electromyographic activities. Manto M. **Eur Neurol** 1996;36(6):333–7 (51 ref.)

Event-related synchronization (ERS) in the alpha band—an electrophysiological correlate of cortical idling: a review. Pfurtscheller G, et al. **Int J Psychophysiol** 1996 Nov; 24(1–2):39–46 (47 ref.)

Arm movements in monkeys: behavior and neurophysiology. Georgopoulos AP. **J Comp Physiol [A]** 1996 Nov; 179(5):603–12 (46 ref.)

The hand and the eye. Filan SL, et al. **J Hand Surg [Br]** 1997 Jun;22(3):293–8 (48 ref.)

What features of visually guided arm movements are encoded in the simple spike discharge of cerebellar Purkinje cells? Ebner TJ, et al. **Prog Brain Res** 1997;114:431–47 (80 ref.)

Neural mechanisms of visual orienting responses. Sprague JM. **Prog Brain Res** 1996;112:1–15 (110 ref.)

The neuroscience of spatial navigation: focus on behavior yields advances. Cain DP, et al. **Rev Neurosci** 1996 Jul–Sep; 7(3):215–31 (140 ref.)

Nutrition for improved sports performance. Current issues on ergogenic aids. Clarkson PM. **Sports Med** 1996 Jun; 21(6):393–401 (89 ref.)

Biomechanical factors critical for performance in the men's javelin throw. Morriss C, et al. **Sports Med** 1996 Jun; 21(6):438–46 (22 ref.)

The TINS Lecture. The parietal association cortex in depth perception and visual control of hand action. Sakata H, et al. **Trends Neurosci** 1997 Aug;20(8):350–7 (75 ref.)

[Technical aspects of studying motor asymmetry] Reiss M. **Wien Med Wochenschr** 1997;147(11):275–8 (22 ref.) (Eng. Abstr.) **(Ger)**

[The cholinergic system of the striatum: its participation in the motor and sensory components of motor behavior] Shapovalova KB. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 Mar–Apr;47(2):393–411 (50 ref.) (Eng. Abstr.) **(Rus)**

PSYCHONEUROIMMUNOLOGY

see related
NEUROIMMUNOMODULATION

The immune system and major depression. Anderson JL. **Adv Neuroimmunol** 1996;6(2):119–29 (61 ref.)

Psychoneuroimmunology and cancer: historical perspectives and current research. Fife A, et al. **Adv Neuroimmunol** 1996; 6(2):179–90 (73 ref.)

Psychoneuroimmunology of autoimmune disorders. Rogers MP, et al. **Adv Neuroimmunol** 1996;6(2):169–77 (73 ref.)

Psychoneuroimmunology: searching for the main deteriorating psychobehavioral factor. Rotenberg VS, et al. **Genet Soc Gen Psychol Monogr** 1996 Aug;122(3):329–46 (72 ref.)

Psychoneuroendoimmunology: the biological basis of the placebo phenomenon? [see comments] Jamison JR. **J Manipulative Physiol Ther** 1996 Sep;19(7):484–7 (47 ref.) Comment in: J Manipulative Physiol Ther 1997 Mar–Apr;20(3):224.

Methodological issues in psychoneuroimmunology research. Zeller JM, et al. **Nurs Res** 1996 Sep–Oct;45(5):314–8 (39 ref.)

Mind–body medicine in primary care. Implications and applications. Lazar JS. **Prim Care** 1996 Mar;23(1):169–82 (71 ref.)

TRENDS

Psycho–neuro–cytokine/endocrine pathways in immunoregulation during pregnancy. Clark DA, et al **Am J Reprod Immunol** 1996 Apr;35(4):330–7 (71 ref.)

PSYCHONEUROSES see **NEUROTIC DISORDERS**

PSYCHOPATHIC PERSONALITY see **ANTISOCIAL PERSONALITY DISORDER**

PSYCHOPATHOLOGY

Era-related changes in the Japanese cultural and social structure and conformist personality pathology—with a particular emphasis on borderline personality disorder. Tamai K. **Fukuoka Igaku Zasshi** 1997 Apr;88(4):84–9 (2 ref.)

Psychopathological concepts. Scharfetter C, et al. **Psychopathology** 1995;28 Suppl 1:8–12 (22 ref.)

Linking mind and brain in the study of mental illnesses: a project for a scientific psychopathology. Andreasen NC. **Science** 1997 Mar 14;275(5306):1586–93 (55 ref.)

METHODS

Assessment and documentation of psychopathology. Baumann U. **Psychopathology** 1995;28 Suppl 1:13–20 (48 ref.)

PSYCHOPHARMACEUTICALS see **PSYCHOTROPIC DRUGS**

PSYCHOPHARMACOLOGY

see related
PSYCHOTROPIC DRUGS

Plant hallucinogens: springboards for psychotherapeutic drug discovery. McKenna DJ. **Behav Brain Res** 1996; 73(1–2):109–16 (45 ref.)

The importance of presystemic extraction in clinical psychopharmacology [editorial] Greenblatt DJ, et al. **J Clin Psychopharmacol** 1996 Dec;16(6):417–9 (33 ref.)

The psychopharmacology of hallucinogens. Abraham HD, et al. **Neuropsychopharmacology** 1996 Apr;14(4):285–98 (78 ref.)

Neuropsychopharmacology: are we ready for a paradigm shift? Meyer RE. **Neuropsychopharmacology** 1996 Mar; 14(3):169–79 (62 ref.)

INSTRUMENTATION

Instrumental measures in geriatric psychopharmacology. Lebowitz BD, et al. **Psychopharmacol Bull** 1995;31(4):641–9 (55 ref.)

METHODS

Psychopharmacology—in vivo neurochemistry and pharmacology. Grasby P, et al. **Br Med Bull** 1996 Jul; 52(3):513–26 (41 ref.)

Randomized trials in single subjects: the N of 1 study. Cook DJ. **Psychopharmacol Bull** 1996;32(3):363–7 (4 ref.)

Socioecological and sociocultural variables in psychopharmacological research: methodological considerations. Turner SM, et al. **Psychopharmacol Bull** 1996;32(2):183–92 (56 ref.)

TRENDS

Clinical relevance of response and improvement in psychopharmacology: European College of Neuropsychopharmacology. **Eur Neuropsychopharmacol** 1995 Dec;5(4):531–3 (0 ref.)

PSYCHOPHYSICS

Misconceptions about classical psychophysics and the measurement of response bias. Gardner RM. **Percept Mot Skills** 1997 Apr;84(2):587–94 (19 ref.)

METHODS

Improvement in Vernier acuity in adults with amblyopia. Practice makes better. Levi DM, et al. **Invest Ophthalmol Vis Sci** 1997 Jul;38(8):1493–510 (58 ref.)

Quantitative sensory testing. Yarnitsky D. **Muscle Nerve** 1997 Feb;20(2):198–204 (66 ref.)

Conventions of measurement in psychophysics: von Kries on the so-called psychophysical law. Niall KK. **Spat Vis** 1995;9(3):275–305 (38 ref.)

PSYCHOPHYSIOLOGIC DISORDERS

Adolescents with psychosomatic problems. Brown RT. **Compr Ther** 1996 Dec;22(12):810–6 (30 ref.)

Psychiatric dizziness. Furman JM, et al. **Neurology** 1997 May; 48(5):1161–6 (75 ref.)

Blaming the victim. The psychologizing of endometriosis. Ballweg ML. **Obstet Gynecol Clin North Am** 1997 Jun; 24(2):441–53 (27 ref.)

Breath-holding spells. Evans OB. **Pediatr Ann** 1997 Jul; 26(7):410–4 (15 ref.)

Animal models provide insight into psychosomatic factors in diabetes. Surwit RS, et al. **Psychosom Med** 1996 Nov–Dec;58(6):582–9 (65 ref.)

[A lot of irrelevance on psychoses. A more streamlined approach is needed] Jonsson H. **Lakartidningen** 1997 Jul 9;94(28–29):2567–71 (49 ref.) **(Swe)**

COMPLICATIONS

How are alexithymia and physical illness linked? A review and critique of pathways. Lumley MA, et al. **J Psychosom Res** 1996 Dec;41(6):505–18 (101 ref.)

Acute tibial compartment syndrome secondary to psychosomatic disorder. Eskander MB, et al. **J R Army Med Corps** 1994 Jun;140(2):97–8 (5 ref.)

[Chronic pelvic pain: searching for the "psychological factor".] Dellenbach P, et al. **Contracept Fertil Sex** 1996 Nov;24(11):791–9 (59 ref.) **(Fre)**

[Burning mouth syndromes and depression. A psychoanalytic approach] Demange C, et al. **Rev Stomatol Chir Maxillofac** 1996;97(4):244–52 (19 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Psychodermatology of women. Koblenzer CS. **Clin Dermatol** 1997 Jan–Feb;15(1):127–41 (127 ref.)

Factitious fever: a modern update. Sarwari AR, et al. **Curr Clin Top Infect Dis** 1997;17:88–94 (15 ref.)

Psychoneuroimmunology and its relationship to the differential diagnosis of temporomandibular disorders. Auvenshine RC. **Dent Clin North Am** 1997 Apr; 41(2):279–96 (21 ref.)

Dermatologic nondisease. Cotterill JA. **Dermatol Clin** 1996 Jul;14(3):439–45 (68 ref.)

Chronic fatigue syndrome. A practical guide to assessment and management. Sharpe M, et al. **Gen Hosp Psychiatry** 1997 May;19(3):185–99 (128 ref.)

[Somatoform disorders in urology] Csef H. **Urologe A** 1997 Jan;36(1):87–99; quiz 97–8 (9 ref.) **(Ger)**

["Soma" and "psyche". Six of one, half a dozen of the other? (editorial; comment)] Cirera E. **Med Clin (Barc)** 1997 Mar 8;108(9):341–3 (27 ref.) Comment on: Med Clin (Barc) 1997 Mar 8;108(9):321–4. **(Spa)**

EPIDEMIOLOGY

The contribution of epidemiology to psychosomatic medicine. Lobo A, et al. **Epidemiol Psichiatr Soc** 1997 Jan–Apr;6(1):40–7 (83 ref.)

ETIOLOGY

The sequelae of childhood sexual abuse: a primary care focus for adult female survivors. Roberts SJ. **Nurse Pract** 1996 Dec;21(12 Pt 1):42, 45, 49–52 (26 ref.)

[Psychosomatic consequences of sexual abuse: a case of Bartter pseudo-syndrome in an anorexic patient] Martin-Du Pan RC, et al. **Rev Med Suisse Romande** 1997 Jun;117(6):495–500 (43 ref.) **(Fre)**

IMMUNOLOGY

Psychological stress, neuroimmunomodulation, and susceptibility to infectious diseases in animals and man: a review. Biondi M, et al. **Psychother Psychosom** 1997; 66(1):3–26 (271 ref.)

PATHOLOGY

Pathology of cortical development and neuropsychiatric disorders. Roberts GW, et al. **Ciba Found Symp** 1995; 193:296–321 (40 ref.)

PHYSIOPATHOLOGY

Neural regulation of viscera elicited by individual interpretations of life experiences. Wolf S. **Integr Physiol Behav Sci** 1997 Apr–Jun;32(2):109–12 (14 ref.)

Plasma neurotransmitters and functional illness. Lechin F, et al. **Psychother Psychosom** 1996;65(6):293–318 (203 ref.)

[Stress research between molecular and supra-molecular observations] Oehme P, et al. **Med Monatsschr Pharm** 1996 Sep;19(9):270–4 (7 ref.) **(Ger)**

PREVENTION & CONTROL

[Prevention and therapy of post-traumatic disorders from a biopsychosocial viewpoint] Schnyder U. **Schweiz Rundsch Med Prax** 1996 Dec 10;85(50):1603–8 (43 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Health psychology: what is an unhealthy environment and how does it get under the skin? Taylor SE, et al. **Annu Rev Psychol** 1997;48:411–47 (215 ref.)

Psychosocial factors: role in cardiac risk and treatment strategies. Williams RB, et al. **Cardiol Clin** 1996 Feb; 14(1):97–104 (58 ref.)

Factitious fever: a modern update. Sarwari AR, et al. **Curr Clin Top Infect Dis** 1997;17:88–94 (15 ref.)

Multiple chemical sensitivities or idiopathic environmental intolerances: psychophysiologic foundation of knowledge for a psychogenic explanation [editorial; comment] Staudenmayer H. **J Allergy Clin Immunol** 1997 Apr; 99(4):434–7 (23 ref.) Comment on: J Allergy Clin Immunol 1997 Apr;99(4):438–42. Comment on: J Allergy Clin Immunol 1997 Apr;99(4):570–4.

Pain in the family [editorial] Bebbington P, et al. **J Psychosom Res** 1996 May;40(5):451–6 (45 ref.)

Eating disorders associated with hyperemesis gravidarum [editorial] Lingam R, et al. **J Psychosom Res** 1996 Mar; 40(3):231–4 (21 ref.)

The postconcussional syndrome: a rose by any other name [editorial] McClelland RJ. **J Psychosom Res** 1996 Jun; 40(6):563–8 (41 ref.)

Whiplash neck injury. Mayou R, et al. **J Psychosom Res** 1996 May;40(5):461–74 (60 ref.)

Hypertension and objective and self-reported stressor exposure: a review. Nyklíček I, et al. **J Psychosom Res** 1996 Jun;40(6):585–601 (76 ref.)

Psychosocial factors and physical illness in primary care: promoting the biopsychosocial model in medical practice [editorial] Zimmermann C, et al. **J Psychosom Res** 1996 Apr;40(4):351–8 (60 ref.)

From the lesson of Harvey Cushing to current knowledge: psychosocial aspects of endocrine disease [editorial] Sonino N. **Psychother Psychosom** 1997;66(3):113–6 (32 ref.)

[Somatic gain, somatic transfer and somatic neurosis] Chemouni J. **Ann Med Psychol (Paris)** 1996 Jun; 154(3):174–83 (18 ref.) (Eng. Abstr.) **(Fre)**

[Stress theories and the somatization process] Dantzer R. **Encephale** 1995 Dec;21 Spec No 7:3–9 (21 ref.) (Eng. Abstr.) **(Fre)**

["Doctor shopping" in fertility medicine] Strauss B. **Arch Gynecol Obstet** 1996;259 Suppl 1:S24–32 (25 ref.) **(Ger)**

[Psychophysiologic and psychoneuroimmunologic studies in neurodermatitis. Overview and critical evaluation] Buhk H, et al. **Hautarzt** 1997 Jan;48(1):5–11 (24 ref.) (Eng. Abstr.) **(Ger)**

[Psychosomatic aspects of chronic pain] Doering S, et al. **Orthopade** 1997 Jun;26(6):521–7 (19 ref.) (Eng. Abstr.) **(Ger)**

[Cardiovascular diseases caused by unemployment? An analysis from the viewpoint of social medicine (see comments)] Weber A, et al. **Wien Klin Wochenschr** 1997 Mar 28;109(6):202–10 (50 ref.) (Eng. Abstr.) Comment in: Wien Klin Wochenschr 1997 Mar 28;109(6):177–9. **(Ger)**

[Psychosocial factors in Crohn disease--an overview] Enck P, et al. **Z Gastroenterol** 1996 Oct;34(10):708–13 (62 ref.) (Eng. Abstr.) **(Ger)**

[Psychological approach to headaches in children and adolescents] Pedreira Massa JL. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 Sep–Oct;24(5):293–9 (19 ref.) (Eng. Abstr.) **(Spa)**

REHABILITATION

[Psychosomatic rehabilitation] Lamprecht F. **Z Arztl Fortbild (Jena)** 1996 Oct;90(6):511–7 (13 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Reappraising reassurance--the role of investigations [editorial] Howard LM, et al. **J Psychosom Res** 1996 Oct; 41(4):307–11 (26 ref.)

Psychosomatic medicine and evidence-based treatment [editorial] Sharpe M, et al. **J Psychosom Res** 1996 Aug; 41(2):101–7 (35 ref.)

[Critical review of the various treatments of temporomandibular joint pain-dysfunction syndrome. What will be the psychosomatic approach to these patients?] Fleury JE, et al. **Rev Stomatol Chir Maxillofac** 1997 Jan;98(1):50–4 (13 ref.) (Eng. Abstr.) **(Fre)**

[What is supportive psychotherapy?] Wöller W, et al. **Nervenarzt** 1996 Mar;67(3):249–52 (17 ref.) (Eng. Abstr.) **(Ger)**

[Psychotherapeutic responsibilities in psychiatry--and the cooperation of fields (editorial)] Müller P. **Psychiatr Prax** 1997 May;24(3):107–9 (20 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOPHYSIOLOGY

see related
PSYCHOSOMATIC MEDICINE

Can artificial intelligence be of help to psychoanalysis ... or ... vice versa? Rodado J, et al. **Am J Psychoanal** 1996 Dec; 56(4):395–413 (59 ref.)

The contribution of epidemiology to psychosomatic medicine. Lobo A, et al. **Epidemiol Psichiatr Soc** 1997 Jan–Apr;6(1):40–7 (83 ref.)

The North American polygraph and psychophysiology: disinterested, uninterested, and interested perspectives. Furedy JJ. **Int J Psychophysiol** 1996 Feb–Mar; 21(2–3):97–105 (13 ref.)

Gastrointestinal illness and the biopsychosocial model [editorial] Drossman DA. **J Clin Gastroenterol** 1996 Jun; 22(4):252–4 (11 ref.)

Attitude and disposition: do they make a difference in cancer survival? Creagan ET. **Mayo Clin Proc** 1997 Feb; 72(2):160–4 (24 ref.)

Lucid dreaming and the mind–body relationship: a model for the cognitive and physiological variations in rapid eye movement sleep. Lequerica A. **Percept Mot Skills** 1996 Aug;83(1):331–6 (17 ref.)

Impact of social environment characteristics on neuroendocrine regulation. Seeman TE, et al. **Psychosom Med** 1996 Sep–Oct;58(5):459–71 (159 ref.)

The irreducible perspectives of consciousness. Feinberg TE. **Semin Neurol** 1997 Jun;17(2):85–93 (63 ref.)

PSYCHOSES see **PSYCHOTIC DISORDERS**

PSYCHOSES, AFFECTIVE see **AFFECTIVE DISORDERS, PSYCHOTIC**

PSYCHOSES, ALCOHOLIC

Psychiatric disorders in alcoholics. Mueller TI. **Med Health R I** 1997 Mar;80(3):87–90 (16 ref.)

PHYSIOPATHOLOGY

[Alcohol-induced hallucinosis. Clinical aspects, pathophysiology and therapy] Soyka M. **Nervenarzt** 1996 Nov;67(11):891–5 (52 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOSES, DRUG see **PSYCHOSES, SUBSTANCE-INDUCED**

PSYCHOSES, ORGANIC see **ORGANIC MENTAL DISORDERS, PSYCHOTIC**

PSYCHOSES, PRESENILE see **DEMENTIA, PRESENILE**

PSYCHOSES, SENILE see **DEMENTIA, SENILE**

PSYCHOSES, SUBSTANCE-INDUCED

Glucocorticoid medication, memory and steroid psychosis in medical illness. Wolkowitz OM, et al. **Ann N Y Acad Sci** 1997 Aug 14;823:81–96 (99 ref.)

Anticonvulsant-induced psychiatric disorders. The role of forced normalisation. Trimble MR. **Drug Saf** 1996 Sep; 15(3):159–66 (47 ref.)

DIAGNOSIS

Drug induced psychosis [editorial] [see comments] Poole R, et al. **Br J Psychiatry** 1996 Feb;168(2):135–8 (34 ref.) Comment in: Br J Psychiatry 1996 May;168(5):651. Comment in: Br J Psychiatry 1996 May;168(5):651–2. Comment in: Br J Psychiatry 1996 Jul;169(1):114–5.

Differentiating behavioral disturbances of dementia from drug side effects. Eastham JH, et al. **Int Psychogeriatr** 1996; 8 Suppl 3:429–34; discussion 447–8 (57 ref.)

Psychiatric illnesses in the elderly: a review. Jenike MA. **J Geriatr Psychiatry Neurol** 1996 Apr;9(2):57–82 (125 ref.)

[MDMA ("Ecstasy") use--an overview of psychiatric and medical sequelae] Thomasius R, et al. **Fortschr Neurol Psychiatr** 1997 Feb;65(2):49–61 (125 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Clozapine for the treatment of psychosis in Parkinson's disease: a review. Auzou P, et al. **Acta Neurol Scand** 1996 Nov;94(5):329–36 (76 ref.)

ETIOLOGY

Psychotic and severe behavioural reactions with vigabatrin: a review [see comments] Ferrie CD, et al. **Acta Neurol Scand** 1996 Jan;93(1):1–8 (73 ref.) Comment in: Acta Neurol Scand 1997 Mar;95(3):189–90.

Clozapine withdrawal resulting in delirium with psychosis: a report of three cases. Stanilla JK, et al. **J Clin Psychiatry** 1997 Jun;58(6):252–5 (26 ref.)

Psychiatric presentations of medical illness. Marsh CM. **Psychiatr Clin North Am** 1997 Mar;20(1):181–204 (54 ref.)

[Adverse psychological drug effects. Methodological problems in detection and examples from clinical practice] Hollweg M, et al. **Med Monatsschr Pharm** 1997 Feb; 20(2):36–43 (57 ref.) **(Ger)**

PATHOLOGY

The neurotoxic effects of continuous cocaine and amphetamine in Habenula: implications for the substrates of psychosis. Ellison G, et al. **NIDA Res Monogr** 1996; 163:117–45 (72 ref.)

PSYCHOLOGY

The behavioral and neurochemical effects of phencyclidine in humans and animals: some implications for modeling psychosis. Steinpresis RE. **Behav Brain Res** 1996 Jan; 74(1–2):45–55 (195 ref.)

Chronic substance-induced psychotic disorders: state of the literature. Boutros NN, et al. **J Neuropsychiatry Clin Neurosci** 1996 Summer;8(3):262–9 (65 ref.)

PSYCHOSES, TOXIC see **PSYCHOSES, SUBSTANCE-INDUCED**

PSYCHOSES, TRAUMATIC see **ORGANIC MENTAL DISORDERS, PSYCHOTIC**

PSYCHOSEXUAL DEVELOPMENT

Gender identity disorder: a review of the past 10 years. Bradley SJ, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Jul;36(7):872–80 (70 ref.)

The primal scene: variations on a theme. Knafo D, et al. **J Am Psychoanal Assoc** 1996;44(2):549–69 (41 ref.)

Sibling sex ratio of boys with gender identity disorder. Zucker KJ, et al. **J Child Psychol Psychiatry** 1997 Jul; 38(5):543–51 (131 ref.)

An additional facet of the incest taboo: a protection of the mating-strategy template. Immerman RS, et al. **J Genet Psychol** 1997 Jun;158(2):151–64 (100 ref.)

Female adolescent sexuality. Sugar M. **J Pediatr Adolesc Gynecol** 1996 Nov;9(4):175–83 (73 ref.)

DRUG EFFECTS

Appropriate end points for the characterization of behavioral changes in developmental toxicology. Cuomo V, et al. **Environ Health Perspect** 1996 Apr;104 Suppl 2:307–15 (133 ref.)

PHYSIOLOGY

Hormones and psychosexual differentiation. Giordano G, et al. **Minerva Endocrinol** 1995 Sep;20(3):165–93 (228 ref.)

PSYCHOSEXUAL DISORDERS

ABC of mental health. Psychosexual problems. Watson JP, et al. **BMJ** 1997 Jul 26;315(7102):239–42 (4 ref.)

CHEMICALLY INDUCED

A critical review of selective serotonin reuptake inhibitor-related sexual dysfunction; incidence, possible aetiology and implications for management. Lane RM. **J Psychopharmacol (Oxf)** 1997;11(1):72–82 (126 ref.)

PSYCHOSEXUAL DISORDERS

DIAGNOSIS

Gender identity disorder: a review of the past 10 years. Bradley SJ, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Jul;36(7):872–80 (70 ref.)

ETIOLOGY

[Role of hormones in sexual dysfunctions, homosexuality, transsexualism and deviant sexual behavior: diagnostic and therapeutic consequences] Buvat J, et al. **Contracept Fertil Sex** 1996 Nov;24(11):834–46 (80 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Sibling sex ratio of boys with gender identity disorder. Zucker KJ, et al. **J Child Psychol Psychiatry** 1997 Jul; 38(5):543–51 (131 ref.)

THERAPY

Psychotherapy for female sexual dysfunction: a review. O'Donohue W, et al. **Clin Psychol Rev** 1997;17(5):537–66 (60 ref.)

[Sexual problems--possible counseling by the general physician] Loewit K. **Fortschr Med** 1996 Oct 30; 114(30):387–92 (9 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOSEXUAL DYSFUNCTIONS

DRUG THERAPY

Antidepressants in the treatment of premature ejaculation. Balon R. **J Sex Marital Ther** 1996 Summer;22(2):85–96 (51 ref.)

ETIOLOGY

Hysterectomy: social and psychosexual aspects. Ryan MM. **Baillieres Clin Obstet Gynaecol** 1997 Mar;11(1):23–36 (56 ref.)

Subject review on head injury and sexual dysfunction [letter; comment] Zasler ND. **Brain Inj** 1997 May;11(5):389–90 (4 ref.) Comment on: Brain Inj 1996 Oct;10(10):703–17.

Psychological and psychosexual implications of herpes simplex virus infections. Mindel A. **Scand J Infect Dis Suppl** 1996;100:27–32 (53 ref.)

PHYSIOPATHOLOGY

Diabetic sexual dysfunction. Hakim LS, et al. **Endocrinol Metab Clin North Am** 1996 Jun;25(2):379–400 (133 ref.)

THERAPY

Psychotherapy for female sexual dysfunction: a review. O'Donohue W, et al. **Clin Psychol Rev** 1997;17(5):537–66 (60 ref.)

[Sexual problems--possible counseling by the general physician] Loewit K. **Fortschr Med** 1996 Oct 30; 114(30):387–92 (9 ref.) (Eng. Abstr.) **(Ger)**

[Psychological aspects of erectile dysfunction] Seikowski K. **Wien Med Wochenschr** 1997;147(4–5):105–8 (24 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOSIS, BRIEF REACTIVE see **PSYCHOTIC DISORDERS**

PSYCHOSIS, MANIC-DEPRESSIVE see **BIPOLAR DISORDER**

PSYCHOSOCIAL DEPRIVATION

Psychological and neuroendocrinological sequelae of early social deprivation in institutionalized children in Romania. Carlson M, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:419–28 (34 ref.)

The concept of resilience. Wolff S. **Aust N Z J Psychiatry** 1995 Dec;29(4):565–74 (61 ref.)

Burn management. Psychosocial interventions: pharmacologic and psychologic modalities. Davis ST, et al. **Nurs Clin North Am** 1997 Jun;32(2):331–42 (56 ref.)

[Schizophrenia and exclusion. Current and future perspectives] Furtos J, et al. **Encephale** 1996 Oct;22 Spec No 3:39–48 (50 ref.) **(Fre)**

PSYCHOSOCIAL SUPPORT SYSTEMS see **SOCIAL SUPPORT**

PSYCHOSOMATIC DISORDERS see **PSYCHOPHYSIOLOGIC DISORDERS**

PSYCHOSOMATIC MEDICINE

see related
PSYCHOPHYSIOLOGIC DISORDERS
PSYCHOPHYSIOLOGY

The contribution of epidemiology to psychosomatic medicine. Lobo A, et al. **Epidemiol Psichiatr Soc** 1997 Jan–Apr;6(1):40–7 (83 ref.)

METHODS

Transgenic and null mutant animals for psychosomatic research. Crnic LS. **Psychosom Med** 1996 Nov–Dec; 58(6):622–32 (57 ref.)

TRENDS

Psychosomatic medicine and evidence-based treatment [editorial] Sharpe M, et al. **J Psychosom Res** 1996 Aug; 41(2):101–7 (35 ref.)

PSYCHOSURGERY

Treatment of temporal lobe epilepsy. Ojemann GA. **Annu Rev Med** 1997;48:317–28 (71 ref.)

METHODS

The frontal lobes and neurosurgery for psychiatric disorders. Malizia AL. **J Psychopharmacol (Oxf)** 1997;11(2):179–87 (100 ref.)

TRENDS

Sixty years of psychosurgery: its present status and its future. Sachdev P, et al. **Aust N Z J Psychiatry** 1997 Aug; 31(4):457–64 (54 ref.)

PSYCHOTHERAPY

Integrating psychotherapy and pharmacotherapy to improve drug abuse outcomes. Carroll KM. **Addict Behav** 1997 Mar–Apr;22(2):233–45 (70 ref.)

Psychotherapeutic considerations in pharmacological trials. O'Malley SS, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7 Suppl):17A–22A (49 ref.)

Office psychotherapy for depression in the primary care setting. Green SA. **Am J Med** 1996 Dec 30; 101(6A):37S–44S (35 ref.)

Values in psychotherapy. Holmes J. **Am J Psychother** 1996 Summer;50(3):259–73 (31 ref.)

Treatment failure in acute PTSD. Lessons learned about the complexity of the disorder. Shalev AY. **Ann N Y Acad Sci** 1997 Jun 21;821:372–87 (52 ref.)

Computer aids to treatment in psychiatry. Kirkby KC, et al. **Aust N Z J Psychiatry** 1996 Feb;30(1):142–5 (20 ref.)

Manual-based treatments: the clinical application of research findings. Wilson GT. **Behav Res Ther** 1996 Apr; 34(4):295–314 (120 ref.)

Cross-cultural competencies in the psychiatric assessment. Bhui K, et al. **Br J Hosp Med** 1997 May 21–Jun 3; 57(10):492–6 (24 ref.)

Victims and perpetrators of child sexual abuse. Hilton MR, et al. **Br J Psychiatry** 1996 Oct;169(4):408–15 (63 ref.)

Severe personality disorders. Treatment issues and selection for in-patient psychotherapy [see comments] Norton K, et al. **Br J Psychiatry** 1996 Jun;168(6):723–31 (29 ref.) Comment in: Br J Psychiatry 1996 Oct;169(4):524. Comment in: Br J Psychiatry 1996 Dec;169(6):792–3. Comment in: Br J Psychiatry 1997 Jan;170:90–1.

Evaluating the effectiveness of interventions in child psychiatry. Fonagy P. **Can J Psychiatry** 1997 Aug; 42(6):584–94 (165 ref.)

A critical review of recovered memories in psychotherapy: Part II--Trauma and therapy. Paris J. **Can J Psychiatry** 1996 May;41(4):206–10 (35 ref.)

A critical review of recovered memories in psychotherapy: Part I--Trauma and memory. Paris J. **Can J Psychiatry** 1996 May;41(4):201–5 (52 ref.)

Psychotherapy outcome research in child psychiatric disorders. Pearsall DF. **Can J Psychiatry** 1997 Aug; 42(6):595–601 (62 ref.)

Psychotherapy for female sexual dysfunction: a review. O'Donohue W, et al. **Clin Psychol Rev** 1997;17(5):537–66 (60 ref.)

Anorexia nervosa and bulimia: psychiatric approach. Walsh BT. **Curr Ther Endocrinol Metab** 1997;6:18–21 (3 ref.)

Physical abuse of children: an update. Sirotnak AP, et al. **Del Med J** 1997 Jul;69(7):335–43 (20 ref.)

Psychotherapeutic intervention in dementia. Haupt M. **Dementia** 1996 Jul–Aug;7(4):207–9 (23 ref.)

Believing in make-believe: looking at theater as a metaphor for psychotherapy. MacCormack T. **Fam Process** 1997 Jun; 36(2):151–69 (81 ref.)

Late-life depression: treatment strategies for primary care practice. Butler RN, et al. **Geriatrics** 1997 Apr;52(4):51–2, 58–60, 63–4 (10 ref.)

Tangled in the web: countertransference in the therapy of factitious disorders. Feldman MD, et al. **Int J Psychiatry Med** 1995;25(4):389–99 (45 ref.)

The patient as moral agent in psychotherapy. Chazan R. **Isr J Psychiatry Relat Sci** 1997;34(1):26–36 (27 ref.)

Annotation: communication strategies for deaf children. Gregory S, et al. **J Child Psychol Psychiatry** 1996 Nov; 37(8):895–905 (95 ref.)

A model for developing effective treatments: progression and interplay of theory, research, and practice. Kazdin AE. **J Clin Child Psychol** 1997 Jun;26(2):114–29 (66 ref.)

Issues in the assessment of treatment response in panic disorder with special reference to fluvoxamine. Ninan PT. **J Clin Psychiatry** 1997;58 Suppl 5:24–31 (39 ref.)

Demystifying the concept of ethnicity for psychotherapy researchers. Alvidrez J, et al. **J Consult Clin Psychol** 1996 Oct;64(5):903–8 (50 ref.)

Evidence that therapy works in clinically representative conditions. Shadish WR, et al. **J Consult Clin Psychol** 1997 Jun;65(3):355–65 (120 ref.)

Set, setting, and matrix. Eisner B. **J Psychoactive Drugs** 1997 Apr–Jun;29(2):213–6 (6 ref.)

Miscarriage as a traumatic event: a review of the literature and new implications for intervention. Lee C, et al. **J Psychosom Res** 1996 Mar;40(3):235–44 (60 ref.)

Therapeutic and iatrogenic interventions with adults who were sexually abused as children. McCarthy BW. **J Sex Marital Ther** 1997 Summer;23(2):118–25 (14 ref.)

Counseling Latino alcohol and other substance users/abusers. Cultural considerations for counselors. Gloria AM, et al. **J Subst Abuse Treat** 1996 Mar–Apr;13(2):119–26 (80 ref.)

Attachment transition, addiction and therapeutic bonding--an integrative approach. Höfler DZ, et al. **J Subst Abuse Treat** 1996 Nov–Dec;13(6):511–9 (56 ref.)

Establishing a therapeutic alliance with substance abusers. Luborsky L, et al. **NIDA Res Monogr** 1997;165:233–44 (37 ref.)

Psychotherapeutic approaches to aggressive and violent patients. Alpert JE, et al. **Psychiatr Clin North Am** 1997 Jun;20(2):453–72 (122 ref.)

Working with difficult-to-treat eating disorders using an integration of twelve-step and traditional psychotherapies. Johnson CL, et al. **Psychiatr Clin North Am** 1996 Dec; 19(4):829–41 (28 ref.)

Treatment of major depression in later life: a life cycle perspective. Reynolds CF 3rd. **Psychiatr Q** 1997 Fall; 68(3):221–46 (66 ref.)

Is psychotherapy ever medically necessary? Bennett MJ. **Psychiatr Serv** 1996 Sep;47(9):966–70 (23 ref.)

Does managed care permit appropriate use of psychotherapy? Borenstein DB. **Psychiatr Serv** 1996 Sep;47(9):971–4 (41 ref.)

The concept of recovery in affective disorders [editorial] Fava GA. **Psychother Psychosom** 1996;65(1):2–13 (160 ref.)

Psychological well-being: meaning, measurement, and implications for psychotherapy research. Ryff CD, et al. **Psychother Psychosom** 1996;65(1):14–23 (56 ref.)

Interaction, language and the "narrative turn" in psychotherapy and psychiatry. Brown B, et al. **Soc Sci Med** 1996 Dec;43(11):1569–78 (83 ref.)

[Psychological, psychotherapeutic and other non-pharmacologic forms of therapy in treatment of insomnia. Position of the "Insomnia" Study Group of the German Society of Sleep Research and Sleep Medicine] Hajak G, et al. **Fortschr Neurol Psychiatr** 1997 Mar; 65(3):133–44 (144 ref.) (Eng. Abstr.) **(Ger)**

[Panic disorder and its psychological treatment] Margraf J, et al. **Naturwissenschaften** 1996 Sep;83(9):401–13 (137 ref.) (Eng. Abstr.) **(Ger)**

[A psychological therapy methods in chronic non-radicular backache] Söllner W, et al. **Orthopade** 1997 Jun; 26(6):535–43 (62 ref.) (Eng. Abstr.) **(Ger)**

[The physically ill patient needs psychotherapy] Barolin GS. **Wien Med Wochenschr** 1996;146(12):245–52 (19 ref.) (Eng. Abstr.) **(Ger)**

[Is psychotherapy in depression efficient? Physician-patient relations are significant for therapeutic results] Cullberg J. **Lakartidningen** 1996 Nov 27;93(48):4405–6 (6 ref.) **(Swe)**

ECONOMICS

The economic impact of psychotherapy: a review. Gabbard GO, et al. **Am J Psychiatry** 1997 Feb;154(2):147–55 (47 ref.)

EDUCATION

[Psychotherapeutic responsibilities in psychiatry--and the cooperation of fields (editorial)] Müller P. **Psychiatr Prax** 1997 May;24(3):107–9 (20 ref.) (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

Informed consent by children and adolescents to psychiatric treatment. Batten DA. **Aust N Z J Psychiatry** 1996 Oct; 30(5):623–9; discussion 630–2 (24 ref.)

Reconciling the patient's right to confidentiality and the family's need to know [see comments] Furlong M, et al. **Aust N Z J Psychiatry** 1996 Oct;30(5):614–22 (27 ref.) Comment in: Aust N Z J Psychiatry 1997 Jun;31(3):429–31.

Memory, repression, and child sexual abuse: forensic implications for the mental health professional. Corelli TB, et al. **J Am Acad Psychiatry Law** 1997;25(1):31–47 (62 ref.)

Survivors of sexual abuse allege therapist negligence. Regehr C, et al. **J Am Acad Psychiatry Law** 1997;25(1):49–58 (70 ref.)

METHODS

Controlling ourselves, controlling our world. Psychology's role in understanding positive and negative consequences of seeking and gaining control. Shapiro DH Jr, et al. **Am Psychol** 1996 Dec;51(12):1213–30 (330 ref.)

Long-term psychotherapy in borderline and narcissistic disorders: when is it necessary? Beatson JA. **Aust N Z J Psychiatry** 1995 Dec;29(4):591–7 (37 ref.)

Gender, race and poverty: bringing the sociopolitical into psychotherapy. Krawitz R, et al. **Aust N Z J Psychiatry** 1997 Aug;31(4):474–9 (30 ref.)

ABC of mental health. Psychological treatments. Richardson P. **BMJ** 1997 Sep 20;315(7110):733–5 (0 ref.)

Psychotherapy integration: its implications for psychiatry.

Albeniz A, et al. **Br J Psychiatry** 1996 Nov;169(5):563–70 (20 ref.)

The management of difficult to treat patients with schizophrenia, using non-drug therapies. Kuipers E. **Br J Psychiatry Suppl** 1996 Dec;(31):41–51 (100 ref.)

Psychological approaches to the management of pain in patients with advanced cancer. Loscalzo M. **Hematol Oncol Clin North Am** 1996 Feb;10(1):139–55 (59 ref.)

Personal construct psychotherapy of addictions. Klion RE, et al. **J Subst Abuse Treat** 1997 Jan–Feb;14(1):37–43 (26 ref.)

Nonpharmacologic approaches to substance abuse treatment. Carroll KM, et al. **Med Clin North Am** 1997 Jul; 81(4):927–44 (88 ref.)

New directions in the prevention and treatment of schizophrenia: a biological perspective. Wyatt RJ, et al. **Psychiatry** 1996 Winter;59(4):357–70 (90 ref.)

Mental retardation and domestic violence: an ecological approach to intervention. Carlson BE. **Soc Work** 1997 Jan; 42(1):79–89 (30 ref.)

[Kangaroo method and care] Vaivre-Douret L, et al. **Arch Pediatr** 1996 Dec;3(12):1262–9 (35 ref.) (Eng. Abstr.) **(Fre)**

[The role of psychotherapy in managing panic disorder] Cottraux J. **Encephale** 1996 Dec;22 Spec No 5:54–60 (53 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of post-traumatic stress disorder] Ebbinghaus R, et al. **Fortschr Neurol Psychiatr** 1996 Nov;64(11):433–43 (140 ref.) (Eng. Abstr.) **(Ger)**

[Psychotherapy of delusions] Mundt C. **Nervenarzt** 1996 Jul; 67(7):515–23 (54 ref.) (Eng. Abstr.) **(Ger)**

[Psychotherapy of depressive disorders: on theoretical background and practice relevance] Mundt C. **Nervenarzt** 1996 Mar;67(3):183–97 (91 ref.) (Eng. Abstr.) **(Ger)**

[What is supportive psychotherapy?] Wöller W, et al. **Nervenarzt** 1996 Mar;67(3):249–52 (17 ref.) (Eng. Abstr.) **(Ger)**

[Mother-child treatment in psychiatry. I: Overview of experiences up to now] Hartmann HP. **Psychiatr Prax** 1997 Mar;24(2):56–60 (56 ref.) (Eng. Abstr.) **(Ger)**

[Combination of methods and integration of methods as standard in psychotherapy?] Senf W, et al. **Psychother Psychosom Med Psychol** 1997 Mar–Apr; 47(3–4):92–6 (17 ref.) (Eng. Abstr.) **(Ger)**

[Psychological contributions to rehabilitation in ambulatory health care] Vogel H. **Z Arztl Fortbild (Jena)** 1996 Oct; 90(6):519–25 (23 ref.) (Eng. Abstr.) **(Ger)**

[Body-related psychotherapy for anorexia nervosa—treatment at the psychosomatic hospital in Germany] Noma S. **Seishin Shinkeigaku Zasshi** 1997; 99(2):68–78 (22 ref.) **(Jpn)**

STANDARDS

Management of post traumatic stress disorder using combat stress treatment principles—a case report. Lee JT. **Ann Acad Med Singapore** 1997 Jan;26(1):113–7 (24 ref.)

Post-traumatic stress counselling: benefit or indulgence? [editorial] [see comments] Cramer D. **Br J Hosp Med** 1996 Dec 11–1997 Jan 14;56(11):567–8 (9 ref.) Comment in: Br J Hosp Med 1997 Feb 5–18;57(3):111–2. Comment in: Br J Hosp Med 1997 Feb 5–18;57(3):112.

What meta-analyses have and have not taught us about psychotherapy effects: a review and future directions. Matt GE, et al. **Clin Psychol Rev** 1997;17(1):1–32 (114 ref.)

Is psychotherapy helpful for adolescent suicide attempters? Spirito A. **Crisis** 1997;18(1):3–4 (4 ref.)

Sexuality in the mental health system. Patients and practitioners. Gutheil TG, et al. **Int J Law Psychiatry** 1996 Spring;19(2):183–90 (15 ref.)

STATISTICS & NUMERICAL DATA

The dilemma of factitious demographic distinctions in psychological research. Beutler LE, et al. **J Consult Clin Psychol** 1996 Oct;64(5):892–902 (50 ref.)

TRENDS

The placebogenic phenomenon: art in psychiatric nursing. Blair DT. **J Psychosoc Nurs Ment Health Serv** 1996 Aug; 34(8):11–5 (24 ref.)

Morita therapy: 1919 to 1995. Kitanishi K, et al. **Psychiatry Clin Neurosci** 1995 Dec;49(5–6):245–54 (142 ref.)

[Research on emotions is advancing. Psychotherapists are leaving the trenches] Törneke N. **Lakartidningen** 1997 Apr 23;94(17):1628, 1631–3 (13 ref.) **(Swe)**

PSYCHOTHERAPY, BRIEF

The public health and brief interventions for excessive alcohol consumption: the British experience. Heather N. **Addict Behav** 1996 Nov–Dec;21(6):857–68 (41 ref.)

Alcohol interventions: do the best things come in small packages? Drummond DC. **Addiction** 1997 Apr;92(4):375–9 (20 ref.)

METHODS

Techniques to accelerate dynamic psychotherapy. Fosha D, et al. **Am J Psychother** 1997 Spring;51(2):229–51 (59 ref.)

PSYCHOTHERAPY, COGNITIVE see **COGNITIVE THERAPY**

PSYCHOTHERAPY, GROUP

EDUCATION

The supervisor as gender analyst: feminist perspectives on group supervision and training. Schoenholtz-Read J. **Int J Group Psychother** 1996 Oct;46(4):479–500 (33 ref.)

METHODS

Treatment of substance abusers: single or mixed gender programs? Hodgins DC, et al. **Addiction** 1997 Jul; 92(7):805–12 (60 ref.)

Factors influencing the outcome of group psychotherapy for bulimia nervosa. McKisack C, et al. **Int J Eat Disord** 1997 Jul;22(1):1–13 (60 ref.)

Dreams in group therapy: a review of models. Derr DB, et al. **Int J Group Psychother** 1996 Oct;46(4):501–15 (28 ref.)

[Results of research on therapeutic factors and treatment effectiveness of group therapy with adolescent patients] Tschuschke V. **Prax Kinderpsychol Kinderpsychiatr** 1996 Feb;45(2):38–47 (85 ref.) (Eng. Abstr.) **(Ger)**

[Family group in schizophrenic diseases. Overview, personal concept and report of experiences] Pott W. **Psychiatr Prax** 1996 Sep;23(5):219–25 (36 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOTIC DISORDERS

Psychopharmacology for dermatologic patients. Koo J, et al. **Dermatol Clin** 1996 Jul;14(3):509–23 (53 ref.)

CLASSIFICATION

A treatment-relevant classification of psychotic disorders. McGorry P. **Aust N Z J Psychiatry** 1995 Dec;29(4):555–8 (27 ref.)

Acute psychoses: a proposed diagnosis for ICD-11 and DSM-V. Susser E, et al. **Psychiatr Q** 1996 Fall; 67(3):165–76 (38 ref.)

DIAGNOSIS

Psychological disorders in Singaporean national servicemen. Ang YG. **Ann Acad Med Singapore** 1997 Jan;26(1):70–5 (3 ref.)

Aspects of perinatal psychiatric illness. Pritchard DB, et al. **Br J Psychiatry** 1996 Nov;169(5):555–62 (65 ref.)

Functional imaging, affective disorder and dementia. Goodwin GM. **Br Med Bull** 1996 Jul;52(3):495–512 (93 ref.)

Severe mental illness and HIV-related medical and neuropsychiatric sequelae. McDaniel JS, et al. **Clin Psychol Rev** 1997;17(3):311–25 (85 ref.)

Geriatric psychosis. Lacro JP, et al. **Psychiatr Q** 1997 Fall; 68(3):247–60 (45 ref.)

Acute psychoses: a proposed diagnosis for ICD-11 and DSM-V. Susser E, et al. **Psychiatr Q** 1996 Fall; 67(3):165–76 (38 ref.)

First-episode schizophrenia: I. Early course parameters. Larsen TK, et al. **Schizophr Bull** 1996;22(2):241–56 (36 ref.)

The prodromal phase of first-episode psychosis: past and current conceptualizations. Yung AR, et al. **Schizophr Bull** 1996;22(2):353–70 (76 ref.)

[Chronic hallucinatory psychosis and late onset schizophrenia: the same entity?] Dubertret C, et al. **Encephale** 1997 May–Jun;23(3):157–67 (38 ref.) (Eng. Abstr.) **(Fre)**

[Psychiatric disorders and illnesses after childbirth] Riecher-Rössler A. **Fortschr Neurol Psychiatr** 1997 Mar; 65(3):97–107 (83 ref.) (Eng. Abstr.) **(Ger)**

[A prospective study of patient with schizophreniform disorder: a nosological dilemma?] Chinchilla Moreno A, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 Sep–Oct;24(5):245–51 (27 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Risperidone-induced neuroleptic malignant syndrome: a case report and review. Meterissian GB. **Can J Psychiatry** 1996 Feb;41(1):52–4 (9 ref.)

Pharmacotherapy of affective disorders in old age. Tourigny-Rivard MF. **Can J Psychiatry** 1997 Jun;42 Suppl 1:10S–18S (107 ref.)

Antipsychotic use in pregnancy. What are the best treatment options? Trixler M, et al. **Drug Saf** 1997 Jun;16(6):403–10 (67 ref.)

Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Fulton B, et al. **Drugs** 1997 Feb; 53(2):281–98 (71 ref.)

Chelators in biomedical research: a review. Mbati PA. **East Afr Med J** 1996 Jun;73(6):350–6 (51 ref.)

The D3 receptor and its relevance in psychiatry. Schwartz JC, et al. **Int Clin Psychopharmacol** 1995 Sep;10 Suppl 3:15–20 (43 ref.)

New dimensions in the pharmacologic treatment of schizophrenia and related psychoses. Buckley PF. **J Clin Pharmacol** 1997 May;37(5):363–78 (121 ref.)

Side effect profiles of new antipsychotic agents. Casey DE. **J Clin Psychiatry** 1996;57 Suppl 11:40–5; discussion 46–52 (30 ref.)

Olanzapine and the new generation of antipsychotic agents: patterns of use. Glazer WM. **J Clin Psychiatry** 1997;58 Suppl 10:18–21 (30 ref.)

Evaluating outcomes of treatments for persons with psychotic disorders. Lehman AF. **J Clin Psychiatry** 1996; 57 Suppl 11:61–7 (18 ref.)

Treatment strategies for agitation and psychosis in dementia. Tariot PN. **J Clin Psychiatry** 1996;57 Suppl 14:21–9 (97 ref.)

Olanzapine: a new typical antipsychotic drug. Meltzer HY, et al. **Neuropsychopharmacology** 1996 Feb;14(2):83–5 (21 ref.)

New antipsychotic medications: what advantages do they offer? Citrome L. **Postgrad Med** 1997 Feb;101(2):207–10, 213–4 (19 ref.)

Treating older adults with psychotic symptoms. Kim KY, et al. **Psychiatr Serv** 1997 Sep;48(9):1123–6 (34 ref.)

Current topics in tardive dyskinesia in Japan. Inada T, et al. **Psychiatry Clin Neurosci** 1995 Dec;49(5–6):239–44 (142 ref.)

Lack of gender differences in neuroleptic response in patients with schizophrenia. Pinals DA, et al. **Schizophr Res** 1996 Dec 15;22(3):215–22 (38 ref.)

[New chemotherapy approaches to psychoses] Olié JP, et al. **Encephale** 1997 Apr;23 Spec No 2:2–9 (53 ref.) (Eng. Abstr.) **(Fre)**

[Neuroleptic malignant syndrome] Bryois C, et al. **Rev Med Suisse Romande** 1996 Sep;116(9):713–7 (17 ref.) **(Fre)**

[Neuroleptic malignant syndrome and acute life-threatening catatonia—two contrasting disease entities?] Heils A, et al. **Fortschr Neurol Psychiatr** 1997 Jan;65(1):8–15 (75 ref.) (Eng. Abstr.) **(Ger)**

[Pharmacological treatment of delusional depression] Amore M, et al. **Minerva Psichiatr** 1996 Mar;37(1):29–33 (28 ref.) (Eng. Abstr.) **(Ita)**

[Brighter prospects for patients with psychoses? New neuroleptics may improve the long-term prognosis] Lindström L. **Lakartidningen** 1996 Nov 6;93(45):3989–90 (11 ref.) **(Swe)**

EPIDEMIOLOGY

Risk for human immunodeficiency virus (HIV) infection among persons with severe mental illnesses. Carey MP, et al. **Clin Psychol Rev** 1997;17(3):271–91 (80 ref.)

HIV seroprevalence among people with severe mental illness in the United States: a critical review. Cournos F, et al. **Clin Psychol Rev** 1997;17(3):259–69 (17 ref.)

ETHNOLOGY

A Malay crosscultural worldview and forensic review of amok. Hatta SM. **Aust N Z J Psychiatry** 1996 Aug; 30(4):505–10 (30 ref.)

ETIOLOGY

The phenomenology of psychosis associated with complex partial seizure disorder. Brewerton TD. **Ann Clin Psychiatry** 1997 Mar;9(1):31–51 (278 ref.)

GENETICS

Molecular biology and the major psychoses. Lloyd A, et al. **Aust N Z J Psychiatry** 1997 Feb;31(1):12–6 (13 ref.)

HISTORY

Historical perspectives in epileptic psychosis in Japan. Onuma T. **Psychiatry Clin Neurosci** 1995 Aug;49(4):179–83 (23 ref.)

METABOLISM

Phosphoinositide signaling in human brain. Pacheco MA, et al. **Prog Neurobiol** 1996 Oct;50(2–3):255–73 (65 ref.)

PHYSIOPATHOLOGY

The case for a psychological perspective on late-onset psychosis. Hassett A. **Aust N Z J Psychiatry** 1997 Feb; 31(1):68–75 (76 ref.)

The placebo effect on mood and behavior: the role of the endogenous opioid system. Sher L. **Med Hypotheses** 1997 Apr;48(4):347–9 (32 ref.)

Serotonin, sex, and psychiatric illness [see comments] Heninger GR. **Proc Natl Acad Sci U S A** 1997 May 13; 94(10):4823–4 (26 ref.) Comment in: Proc Natl Acad Sci U S A 1997 May 13;94(10):5308–13.

PREVENTION & CONTROL

Early intervention in psychosis: opportunities for secondary prevention. Jackson C, et al. **Br J Clin Psychol** 1996 Nov; 35 (Pt 4):487–502 (82 ref.)

EPPIC: an evolving system of early detection and optimal management. McGorry PD, et al. **Schizophr Bull** 1996; 22(2):305–26 (75 ref.)

PSYCHOLOGY

Neuropsychology—dementia and affective disorders. Robbins TW, et al. **Br Med Bull** 1996 Jul;52(3):627–43 (47 ref.)

Overview of severe mental illness. Johnson DL. **Clin Psychol Rev** 1997;17(3):247–57 (27 ref.)

Requiem for "Schizophrenia". Howard JS 3rd.

PSYCHOTIC DISORDERS

Integr Physiol Behav Sci 1996 Apr-Jun;31(2):148-54; discussion 147 (37 ref.)

Assessment of insight in psychotic disorders. Fennig S, et al. **Isr J Psychiatry Relat Sci** 1996;33(3):175-87 (42 ref.)

For an anthropology of vulnerability. Stanghellini G. **Psychopathology** 1997;30(1):1-11 (71 ref.)

[Mental disorders in (Laurence Moon)-Bardet-Biedl syndrome] Biéder J, et al. **Ann Med Psychol (Paris)** 1996 Jun;154(4):264-5 (22 ref.) **(Fre)**

REHABILITATION

Early intervention in psychosis: opportunities for secondary prevention. Jackson C, et al. **Br J Clin Psychol** 1996 Nov; 35 (Pt 4):487-502 (82 ref.)

Meaning and development in the interpersonal treatment of severe psychopathology. Kline J, et al. **Bull Menninger Clin** 1996 Summer;60(3):314-30 (39 ref.)

HIV risk reduction interventions for persons with severe mental illness. Kelly JA. **Clin Psychol Rev** 1997; 17(3):293-309 (50 ref.)

Integrating substance abuse treatment for the seriously mentally ill into inpatient psychiatric treatment. Bradizza CM, et al. **J Subst Abuse Treat** 1997 Mar-Apr;14(2):103-11 (34 ref.)

Engaging significant others: the Tom Sawyer approach to case management. Kanter J. **Psychiatr Serv** 1996 Aug; 47(8):799-801 (20 ref.)

Moving from psychoeducation to family education for families of adults with serious mental illness. Solomon P. **Psychiatr Serv** 1996 Dec;47(12):1364-70 (47 ref.)

THERAPY

Psychological disorders in Singaporean national servicemen. Ang YG. **Ann Acad Med Singapore** 1997 Jan;26(1):70-5 (3 ref.)

A review of continuation and maintenance electroconvulsive therapy. Rabheru K, et al. **Can J Psychiatry** 1997 Jun; 42(5):476-84 (90 ref.)

Management of behavioral dysfunction: a corporate physician's perspective. Farid I. **Occup Med** 1996 Oct-Dec; 11(4):599-615 (27 ref.)

Geriatric psychosis. Lacro JP, et al. **Psychiatr Q** 1997 Fall; 68(3):247-60 (45 ref.)

First-episode schizophrenia: I. Early course parameters. Larsen TK, et al. **Schizophr Bull** 1996;22(2):241-56 (36 ref.)

EPPIC: an evolving system of early detection and optimal management. McGorry PD, et al. **Schizophr Bull** 1996; 22(2):305-26 (75 ref.)

[Indications for electroconvulsive therapy] Boiteux J, et al. **Encephale** 1997 Jun;23 Spec No 3:21-6 (27 ref.) (Eng. Abstr.) **(Fre)**

[Are convulsions necessary for the antidepressive effect of electroconvulsive therapy: outcome of repeated transcranial magnetic stimulation] Post RM, et al. **Encephale** 1997 Jun;23 Spec No 3:27-35 (42 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOTOMIMETIC AGENTS see **HALLUCINOGENS**

PSYCHOTROPIC DRUGS

Alcohol and drug abuse in patients with physical disabilities. Hubbard JR, et al. **Am J Drug Alcohol Abuse** 1996 May; 22(2):215-31 (41 ref.)

Familial factors in illicit drug abuse: an interdisciplinary perspective. Ripple CH, et al. **Am J Drug Alcohol Abuse** 1996 May;22(2):147-72 (54 ref.)

What is the psychiatrist's role in drugs and alcohol? Pols RG, et al. **Aust N Z J Psychiatry** 1996 Aug;30(4):540-8; discussion 548-9 (99 ref.)

Psychobiology of novelty seeking and drug seeking behavior. Bardo MT, et al. **Behav Brain Res** 1996 May;77(1-2):23-43 (205 ref.)

The costs of drug abuse consequences: a summary of research findings. French MT, et al. **J Subst Abuse Treat** 1996 Nov-Dec;13(6):453-66 (56 ref.)

Role of oxytocin in the neuroadaptation to drugs of abuse. Sarnyai Z, et al. **Psychoneuroendocrinology** 1994; 19(1):85-117 (100 ref.)

The role of ethnic versus nonethnic sociocultural factors in substance use and misuse. Collins RL. **Subst Use Misuse** 1996 Jan;31(1):95-101 (27 ref.)

Southeast Asians: Asian-Pacific Americans at risk for substance misuse. D'Avanzo CE. **Subst Use Misuse** 1997 Jun;32(7-8):829-48 (65 ref.)

Problems among youths entering the juvenile justice system, their service needs and innovative approaches to address them. Dembo R. **Subst Use Misuse** 1996 Jan;31(1):81-94 (100 ref.)

Drug problems among immigrants and refugees in The Netherlands and the Dutch health care and treatment system. van de Wijngaart GF. **Subst Use Misuse** 1997 Jun; 32(7-8):909-38 (60 ref.)

[Ambulatory medical treatment of drug dependent patients] Gölz J. **Z Arztl Fortbild (Jena)** 1996 Jun;90(4):271-8 (5 ref.) (Eng. Abstr.) **(Ger)**

[Substance dependence. Information, diagnosis and therapy--encouragement for pragmatic treatment] Salloch-Vogel RR, et al. **Z Arztl Fortbild (Jena)** 1996 Jun; 90(4):279-94 (0 ref.) (Eng. Abstr.) **(Ger)**

[Drug dependence among physicians] Schifferdecker M, et al. **Z Arztl Fortbild (Jena)** 1996 Jun;90(4):295-300 (39 ref.) (Eng. Abstr.) **(Ger)**

[Are there new methods in therapy of drug dependence?] Täschner KL. **Z Arztl Fortbild (Jena)** 1996 Jun; 90(4):315-20 (18 ref.) (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

The psychiatric advanced practice nurse with prescriptive authority: role development, practice issues, and outcomes measurement. Cornwell C, et al. **Arch Psychiatr Nurs** 1997 Apr;11(2):57-65 (36 ref.)

Limitations of controlled augmentation trials in schizophrenia. Stern RG, et al. **Biol Psychiatry** 1997 Jul 15;42(2):138-43 (28 ref.)

Practical use of rectal medications in palliative care [see comments] Warren DE. **J Pain Symptom Manage** 1996 Jun; 11(6):378-87 (37 ref.) Comment in: J Pain Symptom Manage 1997 May;13(5):250. Comment in: J Pain Symptom Manage 1997 May;13(5):250-1. Comment in: J Pain Symptom Manage 1997 Jun;13(6):313-4. Comment in: J Pain Symptom Manage 1997 Jun;13(6):314-5.

The placebogenic phenomenon: art in psychiatric nursing. Blair DT. **J Psychosoc Nurs Ment Health Serv** 1996 Aug; 34(8):11-5 (24 ref.)

Pharmacodynamic and pharmacokinetic considerations in geriatric psychopharmacology. Catterson ML, et al. **Psychiatr Clin North Am** 1997 Mar;20(1):205-18 (73 ref.)

ADVERSE EFFECTS

Drug induced psychosis [editorial] [see comments] Poole R, et al. **Br J Psychiatry** 1996 Feb;168(2):135-8 (34 ref.) Comment in: Br J Psychiatry 1996 May;168(5):651. Comment in: Br J Psychiatry 1996 May;168(5):651-2. Comment in: Br J Psychiatry 1996 Jul;169(1):114-5.

Are psychotropic drugs at therapeutic levels a concern for cardiologists? Burggraf GW. **Can J Cardiol** 1997 Jan; 13(1):75-80 (55 ref.)

Clinically significant interactions of psychotropic agents with antipsychotic drugs. Meyer MC, et al. **Drug Saf** 1996 Nov; 15(5):333-46 (200 ref.)

Hepatotoxicity of anesthetics and other central nervous system drugs. Holt C, et al. **Gastroenterol Clin North Am** 1995 Dec;24(4):853-74 (165 ref.)

Misuse of prescription drugs. Finlayson RE. **Int J Addict** 1995 Nov-Dec;30(13-14):1871-901 (88 ref.)

Pregnancy outcome and neurodevelopment of children exposed in utero to psychoactive drugs: the Motherisk experience. Loebstein R, et al. **J Psychiatry Neurosci** 1997 May;22(3):192-6 (21 ref.)

Catastrophic consequences secondary to psychotropic drugs, Part 1. Keltner NL. **J Psychosoc Nurs Ment Health Serv** 1997 Apr;35(4):41-5 (35 ref.)

Psychotropics. Goldaber KG. **Semin Perinatol** 1997 Apr; 21(2):154-9 (44 ref.)

[Body weight changes under psychotropic treatment] Bernard D, et al. **Presse Med** 1996 Sep 28;25(28):1292-6 (38 ref.) (Eng. Abstr.) **(Fre)**

[Nephropathy induced by stimulants and narcotics (heroin, amphetamine, etc)] Hashimoto K, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):526-8 (9 ref.) **(Jpn)**

ECONOMICS

The importance of considering non-monetary costs and benefits in selecting pharmacologic interventions in mental health. Pleil AM. **Psychopharmacol Bull** 1995;31(4):727-34 (30 ref.)

METABOLISM

Metabolism of psychotropic drugs: pharmacological and clinical relevance. Daniel W. **Pol J Pharmacol** 1995 Sep-Oct;47(5):367-79 (132 ref.)

Gender differences in psychotropic drug metabolism. Pollock BG. **Psychopharmacol Bull** 1997;33(2):235-41 (80 ref.)

PHARMACOKINETICS

The metabolism of psychoactive drugs: a review of enzymatic biotransformation and inhibition. Shen WW. **Biol Psychiatry** 1997 Apr 1;41(7):814-26 (201 ref.)

Psychotropic medications and cytochrome P450 2D6: pharmacokinetic considerations in the elderly. Shulman RW, et al. **Can J Psychiatry** 1997 Jun;42 Suppl 1:4S-9S (83 ref.)

The importance of presystemic extraction in clinical psychopharmacology [editorial] Greenblatt DJ, et al. **J Clin Psychopharmacol** 1996 Dec;16(6):417-9 (33 ref.)

Slow accumulation of psychotropic substances in the human brain. Relationship to therapeutic latency of neuroleptic and antidepressant drugs? Kornhuber J, et al. **J Neural Transm Suppl** 1995;46:315-23 (34 ref.)

Drug metabolism as a confounding factor in PK/PD population approaches. Balant LP, et al. **Therapie** 1996 Jul-Aug;51(4):390-8 (69 ref.)

[Involvement of cytochrome P450 in psychopharmacology] Hendler T, et al. **Harefuah** 1996 Oct;131(7-8):264-9 (28 ref.) **(Heb)**

PHARMACOLOGY

Pharmacokinetics and pharmacodynamics of mood-altering drugs in patients with cancer. Lovejoy NC, et al. **Cancer Nurs** 1996 Dec;19(6):407-18 (75 ref.)

Oscillation follows drug sensitization: implications. Antelman SM, et al. **Crit Rev Neurobiol** 1996;10(1):101-17 (80 ref.)

Influence of common drugs and related factors on stroke outcome. Goldstein LB. **Curr Opin Neurol** 1997 Feb; 10(1):52-7 (79 ref.)

Clinically significant interactions of psychotropic agents with antipsychotic drugs. Meyer MC, et al. **Drug Saf** 1996 Nov; 15(5):333-46 (200 ref.)

Ethnicity and psychopharmacology in latin America. Ramirez LF. **Mt Sinai J Med** 1996 Oct-Nov;63(5-6):330-1 (8 ref.)

Ethnicity and pharmacogenetics. Smith MW, et al. **Mt Sinai J Med** 1996 Oct-Nov;63(5-6):285-90 (75 ref.)

Malnutrition and reactivity to drugs acting in the central nervous system. Almeida SS, et al. **Neurosci Biobehav Rev** 1996 Autumn;20(3):389-402 (168 ref.)

Microdialysis-coupled place cell detection in the hippocampus: a new strategy for the search for cognition enhancer drugs. Ludvig N. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Feb; 21(2):249-71 (91 ref.)

Hormonal interventions with psychopharmacological potential: an overview. Halbreich U. **Psychopharmacol Bull** 1997;33(2):281-6 (69 ref.)

Drug metabolism as a confounding factor in PK/PD population approaches. Balant LP, et al. **Therapie** 1996 Jul-Aug;51(4):390-8 (69 ref.)

Pharmacologic treatments for behavior problems. Overall KL. **Vet Clin North Am Small Anim Pract** 1997 May; 27(3):637-65 (59 ref.)

POISONING

[Suicide and psychotropic drugs] Lejoyeux M, et al. **Encephale** 1996 Dec;22 Spec No 4:40-5 (34 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Treatment of non-cognitive symptoms in dementia. Karlsson I. **Acta Neurol Scand Suppl** 1996;168:93-5 (20 ref.)

Integrating psychotherapy and pharmacotherapy to improve drug abuse outcomes. Carroll KM. **Addict Behav** 1997 Mar-Apr;22(2):233-45 (70 ref.)

Neurobehavioural basis for the pharmacotherapy of alcoholism: current and future directions. Anton RF. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:43-53 (70 ref.)

Review of neurotransmitters and their role in alcoholism treatment. Erickson CK. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:5-11 (35 ref.)

Alcohol reinforcement and neuropharmacological therapeutics. Lewis MJ. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:17-25 (36 ref.)

The pharmacological treatment of alcohol dependence: needs and possibilities. Mann K. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:55-8 (30 ref.)

Pharmacotherapies for alcohol problems: a review of research with focus on developments since 1991 [see comments] Litten RZ, et al. **Alcohol Clin Exp Res** 1996 Aug;20(5):859-76 (247 ref.) Comment in: Alcohol Clin Exp Res 1997 Apr;21(2):380.

Medication development and testing in children and adolescents. Current problems, future directions [see comments] Vitiello B, et al. **Arch Gen Psychiatry** 1997 Sep; 54(9):871-6 (45 ref.) Comment in: Arch Gen Psychiatry 1997 Sep;54(9):785-9.

A review of cognitive behavioral and pharmacological treatment of body dysmorphic disorder. Neziroglu F, et al. **Behav Modif** 1997 Jul;21(3):324-40 (50 ref.)

ABC of mental health. Psychotropic drug treatment. Pathare SR, et al. **BMJ** 1997 Sep 13;315(7109):661-4 (0 ref.)

From transmitters to treatment: the pharmacotherapy of behavioural disturbances in dementia. Herrmann N, et al. **Can J Psychiatry** 1997 Jun;42 Suppl 1:51S-64S (193 ref.)

Role of dopamine mesolimbic system in opioid action of psychotropic analgesic nitrous oxide in alcohol and drug withdrawal. Lichtigfeld FJ, et al. **Clin Neuropharmacol** 1996 Jun;19(3):246-51 (43 ref.)

Pharmacotherapy of late life mood disorders. Herrmann N, et al. **Clin Neurosci** 1997;4(1):41-7 (81 ref.)

Pharmacological treatment of psychiatric disorders in children and adolescents: focus on guidelines for the primary care practitioner. Carrey NJ, et al. **Drugs** 1996 May;51(5):750-9 (69 ref.)

Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes. Fleischhacker WW, et al. **Drugs** 1997 Jun;53(6):915-29 (151 ref.)

Clinical relevance of response and improvement in psychopharmacology: European College of Neuropsychopharmacology. **Eur Neuropsychopharmacol** 1995 Dec;5(4):531-3 (0 ref.)

OBRA regulations and the use of psychotropic drugs in long-term care facilities: impact and implications for geropsychiatric care. Stoudemire A, et al. **Gen Hosp Psychiatry** 1996 Mar;18(2):77-94 (138 ref.)

A research agenda for disruptive behaviors in Alzheimer's disease: a combined biomedical and behavioral approach.

Raskind M. **Int Psychogeriatr** 1996;8 Suppl 1:53–8 (29 ref.)
Developments in the drug treatment of panic disorder: what is the place of the selective serotonin reuptake inhibitors? Westenberg HG. **J Affect Disord** 1996 Sep 9;40(1–2):85–93 (56 ref.)
Traditional and alternative research designs and methods in clinical pediatric psychopharmacology. Fava M. **J Am Acad Child Adolesc Psychiatry** 1996 Oct; 35(10):1292–303 (20 ref.)
Regulatory issues in pediatric psychopharmacology. Laughren TP. **J Am Acad Child Adolesc Psychiatry** 1996 Oct;35(10):1276–82 (19 ref.)
Integrating use of psychotropic drugs with environmental management and behavioral modification for treatment of problem behavior in animals [see comments] Hart BL, et al. **J Am Vet Med Assoc** 1996 Nov 1;209(9):1549–51 (6 ref.) Comment in: J Am Vet Med Assoc 1997 Jan 1;210(1):18–9.
Interpreting published results of extra-label drug use with special reference to reports of drugs used to correct problem behavior in animals. Hart BL, et al. **J Am Vet Med Assoc** 1996 Oct 15;209(8):1382–5 (32 ref.)
Biological therapies for posttraumatic stress disorder: an overview. Davidson JR. **J Clin Psychiatry** 1997;58 Suppl 9:29–32 (20 ref.)
Issues in the assessment of treatment response in panic disorder with special reference to fluvoxamine. Ninan PT. **J Clin Psychiatry** 1997;58 Suppl 5:24–31 (39 ref.)
Cognitive-behavior therapy versus pharmacotherapy: Now that the jury's returned its verdict, it's time to present the rest of the evidence [see comments] Jacobson NS, et al. **J Consult Clin Psychol** 1996 Feb;64(1):74–80 (45 ref.) Comment in: J Consult Clin Psychol 1996 Feb;64(1):81–7.
Pharmacologic treatment of agitation in dementia: a comprehensive review. Lantz MS, et al. **J Geriatr Psychiatry Neurol** 1996 Jul;9(3):107–19 (130 ref.)
Psychopharmacologic management of women with common mental health problems. Clarke C, et al. **J Nurse Midwifery** 1997 May–Jun;42(3):254–74 (97 ref.)
New developments in the management of violent children and adolescents. Smith CA. **J Paediatr Child Health** 1996 Dec;32(6):480–3 (28 ref.)
Practical use of rectal medications in palliative care [see comments] Warren DE. **J Pain Symptom Manage** 1996 Jun; 11(6):378–87 (37 ref.) Comment in: J Pain Symptom Manage 1997 May;13(5):250. Comment in: J Pain Symptom Manage 1997 May;13(5):250–1. Comment in: J Pain Symptom Manage 1997 Jun;13(6):313–4. Comment in: J Pain Symptom Manage 1997 Jun;13(6):314–5.
Psychotropic drug use by women: could violence account for the gender difference? Mazza D, et al. **J Psychosom Obstet Gynaecol** 1996 Dec;17(4):229–34 (43 ref.)
The art and science of the psychopharmacotherapy of African Americans. Lawson WB. **Mt Sinai J Med** 1996 Oct–Nov;63(5–6):301–5 (52 ref.)
A ten-year review of the effect of OBRA-87 on psychotropic prescribing practices in an academic nursing home. Lantz MS, et al. **Psychiatr Serv** 1996 Sep;47(9):951–5 (34 ref.)
NCDEU update. Natural product formulations available in europe for psychotropic indications. Cott J. **Psychopharmacol Bull** 1995;31(4):745–51 (45 ref.)
The importance of considering non-monetary costs and benefits in selecting pharmacologic interventions in mental health. Pleil AM. **Psychopharmacol Bull** 1995;31(4):727–34 (30 ref.)
A behavioral diagnostic paradigm for integrating behavior-analytic and psychopharmacological interventions for people with a dual diagnosis. Pyles DA, et al. **Res Dev Disabil** 1997 May–Jun;18(3):185–214 (60 ref.)
Toward a theory of social pharmacology: the actor–spectator paradox applied to the psychotropic prescribing process. Lilja J, et al. **Subst Use Misuse** 1997 Jul;32(9):1175–215 (38 ref.)
[Pharmacotherapy of panic disorder] Bougerol T, et al. **Encephale** 1996 Dec;22 Spec No 5:46–53 (53 ref.) (Eng. Abstr.) **(Fre)**
[New drug therapies] Olié JP, et al. **Encephale** 1996 Oct;22 Spec No 3:63–71; discussion 76 (33 ref.) **(Fre)**
[Special characteristics of psychopharmacotherapy of elderly patients] Bauer J. **Fortschr Med** 1996 Sep 10; 114(25):297–302 (0 ref.) (Eng. Abstr.) **(Ger)**
[Panic disorder] Heinzl S. **Med Monatsschr Pharm** 1996 Mar; 19(3):79–80 (2 ref.) **(Ger)**
[Pharmacotherapy of alcoholism] Soyka M, et al. **Med Monatsschr Pharm** 1996 Dec;19(12):359–64 (21 ref.) **(Ger)**
[Pharmacopsychiatric guidelines for treatment of alcohol withdrawal syndrome] Schröder-Rosenstock K, et al. **Z Arztl Fortbild (Jena)** 1996 Jun;90(4):301–6 (29 ref.) (Eng. Abstr.) **(Ger)**
[Clinical significance of the pharmacogenetics in psychiatric and neurological syndromes] Milejski P, et al. **Neurol Neurochir Pol** 1996 Nov–Dec;30(6):997–1007 (28 ref.) (Eng. Abstr.) **(Pol)**

PTA DEFICIENCY see **FACTOR XI DEFICIENCY**

PTC see **FACTOR IX**

PTCA see **ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY**

PTDINS see **PHOSPHATIDYLINOSITOLS**

PTERIDINES

[Xanthine oxidase deficiency (hereditary xanthinuria), molybdenum cofactor deficiency] Sumi S, et al. **Nippon Rinsho** 1996 Dec;54(12):3333–6 (11 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Molybdenum-cofactor-containing enzymes: structure and mechanism. Kisker C, et al. **Annu Rev Biochem** 1997; 66:233–67 (74 ref.)

METABOLISM

Molybdenum-cofactor-containing enzymes: structure and mechanism. Kisker C, et al. **Annu Rev Biochem** 1997; 66:233–67 (74 ref.)

PTEROYLGLUTAMIC ACID see **FOLIC ACID**

PTEROYLPOLYGLUTAMIC ACIDS

METABOLISM

Exploitation of folate and antifolate polyglutamylation to achieve selective anticancer chemotherapy. McGuire JJ, et al. **Invest New Drugs** 1996;14(3):317–23 (28 ref.)

PTERYGOID MUSCLES

[Myositis ossificans of the pterygoid and temporal muscles with metachronous contralateral involvement] Salgarelli A, et al. **Minerva Stomatol** 1997 May;46(5):259–65 (23 ref.) (Eng. Abstr.) **(Ita)**

PTINS 4,5-P2 see **PHOSPHATIDYLINOSITOL 4,5-DIPHOSPHATE**

PTOSIS, EYELID see **BLEPHAROPTOSIS**

PTPASE see **PROTEIN-TYROSINE-PHOSPHATASE**

PTSD see **STRESS DISORDERS, POST-TRAUMATIC**

PUBERTY

Female genital tract malignancies during puberty. Uterine and cervical malignancies. Tscherne G. **Ann N Y Acad Sci** 1997 Jun 17;816:331–7 (09 ref.)
Gynecologic issues in pediatric oncology. Jones KP. **Clin Obstet Gynecol** 1997 Mar;40(1):200–9 (21 ref.)
Management of puberty in growth hormone deficient children. Rogol AD. **Endocr J** 1996 Oct;43 Suppl:S5–11 (28 ref.)
Puberty in children with intrauterine growth retardation. Preece MA. **Horm Res** 1997;48 Suppl 1:30–2 (11 ref.)
Does puberty interfere with asthma? Zannolli R, et al. **Med Hypotheses** 1997 Jan;48(1):27–32 (38 ref.)
[Pubertal development in males] Zurlo de Mirotti SM, et al. **Rev Fac Cien Med Univ Nac Cordoba** 1995;53 Suppl:31–6 (23 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

The influence of estrogen on growth. Lee PA, et al. **Curr Opin Pediatr** 1997 Aug;9(4):431–6 (22 ref.)

PHYSIOLOGY

Puberal hormonal status and vaginal microbiology. Tolino A, et al. **Acta Eur Fertil** 1994 Nov–Dec;25(6):343–6 (10 ref.)
Environmental factors and human puberty. Bourguignon JP. **Acta Paediatr Suppl** 1996 Oct;417:92–4 (24 ref.)
Development of the hypothalamic-pituitary-ovarian axis. Apter D. **Ann N Y Acad Sci** 1997 Jun 17;816:9–21 (57 ref.)
Neuromodulatory role of opioidergic system on hypothalamus-pituitary-gonadal axis during puberty. Genazzani AD, et al. **Ann N Y Acad Sci** 1997 Jun 17; 816:76–82 (29 ref.)
Modifications of growth hormone secretion during female puberty. Toublanc JE. **Ann N Y Acad Sci** 1997 Jun 17; 816:60–75 (73 ref.)
The GH/IGF-I axis in puberty. Loche S, et al. **Br J Clin Pract Symp Suppl** 1996 Aug;85:1–4 (22 ref.)
Sexual development of the fetus and pubertal child. Malasanos TH. **Clin Obstet Gynecol** 1997 Mar;40(1):153–67 (17 ref.)
Growth hormones and sex steroid interactions at puberty. Clark PA, et al. **Endocrinol Metab Clin North Am** 1996 Sep;25(3):665–81 (94 ref.)
Does recombinant human insulin-like growth factor I have a role in the treatment of type I (insulin dependent) diabetes during puberty? Dunger DB, et al. **J Pediatr Endocrinol Metab** 1995 Oct–Dec;8(4):237–42 (51 ref.)
Role of growth hormone in ovarian physiology and onset of puberty. Sharara FI, et al. **J Soc Gynecol Investig** 1997 Jan–Feb;4(1):2–7 (82 ref.)
Hirsutism [see comments] Rittmaster RS. **Lancet** 1997 Jan 18;349(9046):191–5 (30 ref.) Comment in: Lancet 1997 Mar 1;349(9052):650; discussion 651. Comment in: Lancet 1997 Mar 1;349(9052):651.
Neuroendocrine mechanisms mediating awakening of the human gonadotropic axis in puberty. Veldhuis JD. **Pediatr Nephrol** 1996 Jun;10(3):304–17 (131 ref.)
[Andrology in adolescence: objectives and preventive measures (editorial)] Jacquin P. **Arch Pediatr** 1996 Oct; 3(10):947–50 (21 ref.) **(Fre)**
[The role of the pineal body in the endocrine control of puberty] Aleandri V, et al. **Minerva Ginecol** 1997 Jan–Feb; 49(1–2):43–8 (51 ref.) (Eng. Abstr.) **(Ita)**
[Endocrino-gynecologic problems of the female adolescent] Sirpresi S, et al. **Pediatr Med Chir** 1996 Sep–Oct;18(5 Suppl):1–7 (6 ref.) (Eng. Abstr.) **(Ita)**

PSYCHOLOGY

[Disappearance of shame and puberty in girls] Kämmerer A, et al. **Prax Kinderpsychol Kinderpsychiatr** 1997 Feb; 46(2):113–21 (35 ref.) (Eng. Abstr.) **(Ger)**

PUBERTY, DELAYED

Delayed puberty. Kulin HE. **J Clin Endocrinol Metab** 1996 Oct;81(10):3460–4 (17 ref.)

DIAGNOSIS

Sexual development of the fetus and pubertal child. Malasanos TH. **Clin Obstet Gynecol** 1997 Mar;40(1):153–67 (17 ref.)
New aspects in the diagnosis and treatment of pubertal disorders. Styne DM. **Pediatr Clin North Am** 1997 Apr; 44(2):505–29 (197 ref.)

ETIOLOGY

[Benign delayed puberty in boys] Bernasconi S, et al. **Minerva Pediatr** 1996 Sep;48(9):349–52 (22 ref.) **(Ita)**
[Endocrinologic problems of the male adolescent] Reina C, et al. **Pediatr Med Chir** 1996 Sep–Oct;18(5 Suppl):9–13 (11 ref.) (Eng. Abstr.) **(Ita)**
[Endocrino-gynecologic problems of the female adolescent] Sirpresi S, et al. **Pediatr Med Chir** 1996 Sep–Oct;18(5 Suppl):1–7 (6 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

Disorders of puberty: inactivating and activating molecular mutations. DiMeglio LA, et al. **J Pediatr** 1997 Jul;131(1 Pt 2):S8–12 (22 ref.)

PREVENTION & CONTROL

How do we treat patients with inflammatory bowel disease in adolescence? Taminiau JA, et al. **Neth J Med** 1996 Feb; 48(2):57–9 (6 ref.)

THERAPY

Delayed puberty in boys. Kulin HE. **Curr Ther Endocrinol Metab** 1997;6:346–9 (8 ref.)
Delayed puberty in girls and primary amenorrhea. Thomas MA, et al. **Curr Ther Endocrinol Metab** 1997;6:223–6 (7 ref.)
New aspects in the diagnosis and treatment of pubertal disorders. Styne DM. **Pediatr Clin North Am** 1997 Apr; 44(2):505–29 (197 ref.)

PUBERTY, PRECOCIOUS

Female sexual precocity. Dacou-Voutetakis C. **Ann N Y Acad Sci** 1997 Jun 17;816:209–18 (21 ref.)

DIAGNOSIS

Evaluation and management of precocious puberty. Merke DP, et al. **Arch Dis Child** 1996 Oct;75(4):269–71 (21 ref.)
Sexual development of the fetus and pubertal child. Malasanos TH. **Clin Obstet Gynecol** 1997 Mar;40(1):153–67 (17 ref.)
New aspects in the diagnosis and treatment of pubertal disorders. Styne DM. **Pediatr Clin North Am** 1997 Apr; 44(2):505–29 (197 ref.)

ETIOLOGY

Primary intrasellar mixed germ-cell tumor with precocious puberty and diabetes insipidus. Cho DY, et al. **Childs Nerv Syst** 1997 Jan;13(1):42–6 (14 ref.)
Endocrinologic disorders and optic pathway gliomas in children with neurofibromatosis type 1. Cnossen MH, et al. **Pediatrics** 1997 Oct;100(4):667–70 (24 ref.)

GENETICS

Clinical manifestations of genetic defects affecting gonadotrophins and their receptors. Conway GS. **Clin Endocrinol (Oxf)** 1996 Dec;45(6):657–63 (41 ref.)
Familial male precocious puberty. Leschek EW, et al. **Curr Ther Endocrinol Metab** 1997;6:343–5 (6 ref.)
Gonadotropin receptor mutations. Themmen AP, et al. **J Endocrinol** 1997 May;153(2):179–83 (33 ref.)
Disorders of puberty: inactivating and activating molecular mutations. DiMeglio LA, et al. **J Pediatr** 1997 Jul;131(1 Pt 2):S8–12 (22 ref.)

PUBERTY, PRECOCIOUS

THERAPY

Familial male precocious puberty. Leschek EW, et al. **Curr Ther Endocrinol Metab** 1997;6:343–5 (6 ref.)

Premature thelarche and precocious puberty. Quigley CA, et al. **Curr Ther Endocrinol Metab** 1997;6:7–13 (21 ref.)

New aspects in the diagnosis and treatment of pubertal disorders. Styne DM. **Pediatr Clin North Am** 1997 Apr; 44(2):505–29 (197 ref.)

PUBIC BONE

INJURIES

Insufficiency fractures of the pubic ramus. Schapira D, et al. **Semin Arthritis Rheum** 1996 Jun;25(6):373–82 (62 ref.)

PUBIC SYMPHYSIS

[Brucellosis of the pubic symphysis. Apropos of a case. Review of the literature] Mansoori D, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(8):753–6 (30 ref.) (Eng. Abstr.) **(Fre)**

INJURIES

Peripartum pubic symphysis separation: a case series and review of the literature. Snow RE, et al. **Obstet Gynecol Surv** 1997 Jul;52(7):438–43 (21 ref.)

SURGERY

Chronic postpartum pelvic pain treated by surgical stabilization. Shuler TE, et al. **Orthopedics** 1996 Aug; 19(8):687–9 (16 ref.)

PUBLIC ADVOCACY see **CONSUMER ADVOCACY**

PUBLIC ASSISTANCE

see related
SOCIAL WELFARE

LEGISLATION & JURISPRUDENCE

Children and poverty: analysis and recommendations. Lewit EM, et al. **Future Child** 1997 Summer–Fall;7(2):4–24 (44 ref.)

ORGANIZATION & ADMINISTRATION

Choosing among alternative programs for poor children. Currie JM. **Future Child** 1997 Summer–Fall;7(2):113–31 (43 ref.)

Programs that mitigate the effects of poverty on children. Devaney BL, et al. **Future Child** 1997 Summer–Fall; 7(2):88–112 (76 ref.)

PUBLIC DOMAIN see **PUBLIC SECTOR**

PUBLIC ENTERPRISE see **PUBLIC SECTOR**

PUBLIC HEALTH

see related
SOCIAL MEDICINE
ZOONOSES

The public health and brief interventions for excessive alcohol consumption: the British experience. Heather N. **Addict Behav** 1996 Nov–Dec;21(6):857–68 (41 ref.)

Wheat bran, colon cancer, and breast cancer. What do we have? What do we need? Black RM. **Adv Exp Med Biol** 1996;401:221–9 (37 ref.)

Summary of track C: epidemiology and public health. Coutinho RA, et al. **AIDS** 1996 Dec;10 Suppl 3:S115–21 (48 ref.)

An overview of HIV prevention in central and eastern Europe. Danziger R. **AIDS Care** 1996 Dec;8(6):701–7 (10 ref.)

The failure of academic epidemiology: witness for the prosecution. Shy CM. **Am J Epidemiol** 1997 Mar 15; 145(6):479–84; discussion 485–7 (29 ref.)

From genes to public health: the applications of genetic technology in disease prevention. Genetics Working Group [see comments] Khoury MJ. **Am J Public Health** 1996 Dec; 86(12):1717–22 (58 ref.) Comment in: Am J Public Health 1996 Dec;86(12):1701–4.

CDC's first 50 years: lessons learned and relearned. Satcher D. **Am J Public Health** 1996 Dec;86(12):1705–8 (08 ref.)

Environmental tobacco smoke: health effects and policies to reduce exposure. Brownson RC, et al. **Annu Rev Public Health** 1997;18:163–85 (117 ref.)

Perspectives on the place of environmental health and protection in public health and public health agencies. Kotchian S. **Annu Rev Public Health** 1997;18:245–59 (36 ref.)

Measuring social class in US public health research: concepts, methodologies, and guidelines. Krieger N, et al. **Annu Rev Public Health** 1997;18:341–78 (202 ref.)

Survival analysis in public health research. Lee ET, et al. **Annu Rev Public Health** 1997;18:105–34 (62 ref.)

Reinventing public health. Lee P, et al. **Annu Rev Public Health** 1997;18:1–35 (121 ref.)

Censoring issues in survival analysis. Leung KM, et al. **Annu Rev Public Health** 1997;18:83–104 (36 ref.)

The human health effects of DDT (dichlorodiphenyltrichloroethane) and PCBS (polychlorinated biphenyls) and an overview of organochlorines in public health. Longnecker MP, et al. **Annu Rev Public Health** 1997;18:211–44 (127 ref.)

Categorical data analysis in public health. Preisser JS, et al. **Annu Rev Public Health** 1997;18:51–82 (94 ref.)

Environmental ecology of Cryptosporidium and public health implications. Rose JB. **Annu Rev Public Health** 1997; 18:135–61 (109 ref.)

Preventing lead poisoning in children. Silbergeld EK. **Annu Rev Public Health** 1997;18:187–210 (78 ref.)

On the tension between individual health rights and public health responsibilities [editorial] Short S. **Aust N Z J Public Health** 1997 Jun;21(3):246–7 (12 ref.)

Public health implications of pneumococcal disease in indigenous Australians [editorial; comment] Torzillo PJ. **Aust N Z J Public Health** 1997 Jun;21(3):243–4 (13 ref.) Comment on: Aust N Z J Public Health 1997 Jun;21(3):281–5.

Malaria in the 1990s: plus ça change, plus ça même chose [editorial] Walker J. **Aust N Z J Public Health** 1997 Jun; 21(3):244–6 (11 ref.)

Reducing cervical cancer by two-thirds: a public health target within our reach [editorial; comment] Ward J. **Aust N Z J Public Health** 1997 Jun;21(3):248–9 (14 ref.) Comment on: Aust N Z J Public Health 1997 Jun;21(3):265–7.

Migration: public health issues (polio, hepatitis A, hepatitis B, tuberculosis, diphtheria). Schwanig M. **Biologicals** 1997 Jun;25(2):187–93 (16 ref.)

Trace elements in health and diseases. Xiu YM. **Biomed Environ Sci** 1996 Sep;9(2–3):130–6 (22 ref.)

Key issues in the prevention of obesity. Gill TP. **Br Med Bull** 1997;53(2):359–88 (107 ref.)

What went wrong in BSE? From prion disease to public disaster. Baker HF, et al. **Brain Res Bull** 1996;40(4):237–44 (73 ref.)

The public health basis of cancer screening: principles and ethical aspects. Miller AB. **Cancer Treat Res** 1996;86:1–7 (19 ref.)

Universal directly observed therapy. A treatment strategy for tuberculosis. Weis SE. **Clin Chest Med** 1997 Mar; 18(1):155–63 (11 ref.)

Leishmaniasis. Public health aspects and control. Desjeux P. **Clin Dermatol** 1996 Sep–Oct;14(5):417–23 (21 ref.)

Public health and nonpasteurized fruit juices. Parish ME. **Crit Rev Microbiol** 1997;23(2):109–19 (61 ref.)

Public health application of acellular pertussis vaccines. Hadler SC, et al. **Dev Biol Stand** 1997;89:355–61 (8 ref.)

Building community capacity to promote social and public health: challenges for universities [editorial] Poole DL. **Health Soc Work** 1997 Aug;22(3):163–70 (48 ref.)

Public health in a managed care environment. Walker B Jr. **J Health Care Poor Underserved** 1997 Aug;8(3):345–50; discussion 350–1 (9 ref.)

The World Health Organization's global initiative on neurology and public health. Janca A, et al. **J Neurol Sci** 1997 Jan;145(1):1–2 (4 ref.)

The public health threat of emerging viral disease. Morse SS. **J Nutr** 1997 May;127(5 Suppl):951S–957S (60 ref.)

Conceptualization, measurement, and use of gestational age. I. Clinical and public health practice. Alexander GR, et al. **J Perinatol** 1996 Jan–Feb;16(1):53–9 (57 ref.)

Drugs, communities, and "harm reduction" in Germany: the new relevance of "public health" principles in local responses. Fischer B. **J Public Health Policy** 1995; 16(4):389–411 (54 ref.)

Working towards social justice in health. Whitehead M. **J R Soc Health** 1996 Aug;116(4):256–63 (55 ref.)

Violence and public health. Golding A. **J R Soc Med** 1996 Sep;89(9):501–5 (35 ref.)

Tuberculosis—the global challenge [editorial] Ebrahim GJ. **J Trop Pediatr** 1996 Aug;42(4):190–1 (17 ref.)

Creating knowledge relevant for public health applications in immunology and aging. Dean K. **Mech Ageing Dev** 1997 Mar;94(1–3):251–62 (64 ref.)

Public mental health. III: Hatred and reconciliation. Curle A. **Med Confl Surviv** 1997 Jan–Mar;13(1):37–47 (2 ref.)

Public mental health. II: The psychological dimension. Curle A. **Med Confl Surviv** 1997 Jan–Mar;13(1):26–36 (3 ref.)

Salt intake, cardiovascular disease and public health [editorial; comment] Beilin LJ. **Med J Aust** 1997 Apr 21; 166(8):396–7 (12 ref.) Comment on: Med J Aust 1997 Apr 21;166(8):404–7.

Heart failure: the Cinderella of cardiology? McKinnon ME, et al. **Public Health** 1996 Nov;110(6):351–5 (64 ref.)

How energy policies affect public health. Romm JJ, et al. **Public Health Rep** 1996 Sep–Oct;111(5):390–9 (44 ref.)

Public health benefits of using algae for simultaneous multiple metal extraction from waters. Pascucci PR, et al. **Rev Environ Health** 1996 Oct–Dec;11(4):205–11 (16 ref.)

Human health and environmental hazards arising from the use of chemicals in developing countries. Plestina R, et al. **Sci Total Environ** 1996 Sep;188 Suppl 1:S135–40 (15 ref.)

Environmental contaminants and reproductive abnormalities in wildlife: implications for public health? Guillette LJ Jr, et al. **Toxicol Ind Health** 1996 May–Aug;12(3–4):537–50 (64 ref.)

Food animal and poultry retroviruses and human health. DiGiacomo RF, et al. **Vet Clin North Am Food Anim Pract** 1997 Mar;13(1):177–90 (81 ref.)

An emerging public health perspective on domestic violence: implications for Wisconsin physicians and health care organizations. Dunham NC, et al. **Wis Med J** 1997 Jan; 96(1):46–50 (21 ref.)

Epidemiology of foodborne diseases: tools and applications. Potter ME, et al. **World Health Stat Q** 1997;50(1–2):24–9 (19 ref.)

Is there an increase of health risks due to the impact of environmental pollution on outdoor microfungal growth? [editorial] Marfenina OE. **Zentralbl Bakteriol** 1996 Sep; 285(1):5–10 (15 ref.)

[Urban atmospheric pollution and public health: epidemiologic data] Aubier M. **Bull Acad Natl Med** 1997 Mar 18;181(3):489–97 (21 ref.) (Eng. Abstr.) **(Fre)**

[Epidemiology of HIV infection, demographic consequences and impact on the politics of health in Sub-Saharan Africa] Gentilini M, et al. **Bull Acad Natl Med** 1996 Jun–Jul; 180(6):1475–89 (20 ref.) **(Fre)**

[Degradation of soil quality: health and environmental risks] Robert M. **Bull Acad Natl Med** 1997 Jan;181(1):21–40; discussion 40–2 (29 ref.) (Eng. Abstr.) **(Fre)**

[Control of mosquitos in Martinique. A collective public health action and improvement of the quality of life] Yebakima A. **Bull Soc Pathol Exot** 1996;89(2):145–7 (4 ref.) (Eng. Abstr.) **(Fre)**

[Colombia 1996: social and health situation] Botero D. **Med Trop (Mars)** 1996;56(2):123–8 (12 ref.) **(Fre)**

[Epidemiology and public health—useful tool or a problem?] Nordhagen R, et al. **Tidsskr Nor Laegeforen** 1997 May 10; 117(12):1799–803 (52 ref.) (Eng. Abstr.) **(Nor)**

[Amebiasis and amebic liver abscess in Mexico: a present-day public health problem] Escandón Romero C, et al. **Rev Gastroenterol Mex** 1996 Oct–Dec;61(4):378–86 (18 ref.) (Eng. Abstr.) **(Spa)**

[Contribution of health services to public health. Longer life, quality of life and functional capacity] Rosén M. **Lakartidningen** 1997 Sep 3;94(36):3065–71 (32 ref.) **(Swe)**

ECONOMICS

[Depressive disorders and public health: a review of the economic impact] Martin P. **Encephale** 1996 Sep–Oct; 22(5):321–30 (47 ref.) (Eng. Abstr.) **(Fre)**

EDUCATION

Continuing education for public health medicine—is it just another paper exercise? Young Y, et al. **J Public Health Med** 1996 Sep;18(3):357–63 (67 ref.)

[Analysis of education processes in areas of public health and occupational medicine. Introductory premises and hypotheses] Boczkowski A, et al. **Med Pr** 1997;48(1):61–7 (9 ref.) (Eng. Abstr.) **(Pol)**

[The Masters of Public Health in Cuba. An experience in advanced health education] Rojo Pérez N, et al. **Educ Med Salud** 1995 Jul–Dec;29(3–4):321–30 (11 ref.) **(Spa)**

LEGISLATION & JURISPRUDENCE

The merchants, not the customers: resisting the alcohol and tobacco industries' strategy to blame young people for illegal alcohol and tobacco sales. Mosher JF. **J Public Health Policy** 1995;16(4):412–32 (47 ref.)

METHODS

How are nations trying to prevent suicide? An analysis of national suicide prevention strategies. Taylor SJ, et al. **Acta Psychiatr Scand** 1997 Jun;95(6):457–63 (29 ref.)

Diabetic retinopathy: a public health challenge [editorial] Taylor HR. **Am J Ophthalmol** 1997 Apr;123(4):543–5 (11 ref.)

Data management issues for emerging diseases and new tools for managing surveillance and laboratory data. Martin SM, et al. **Emerg Infect Dis** 1995 Oct–Dec;1(4):124–8 (5 ref.)

Adaptation of behavioral theory to CDC's HIV prevention research: experience at the Centers for Disease Control and Prevention [editorial] Leviton LC, et al. **Public Health Rep** 1996;111 Suppl 1:11–7 (45 ref.)

STANDARDS

Nutritional factors in Dutch family medicine: an inventory. van Binsbergen JJ. **Am J Clin Nutr** 1997 Jun;65(6 Suppl):1967S–1973S (90 ref.)

Prevention of IDDM: a public health perspective. Marrero DG, et al. **Diabetes Res Clin Pract** 1996 Oct;34 Suppl:S181–4 (18 ref.)

The application of GIS in environmental health sciences: opportunities and limitations. Tim US. **Environ Res** 1995 Nov;71(2):75–88 (57 ref.)

Public health implications of hazardous waste sites: findings, assessment and research. De Rosa CT, et al. **Food Chem Toxicol** 1996 Nov–Dec;34(11–12):1131–8 (18 ref.)

Exposure to mixtures of chemical substances: is there a need for regulations? Van Zorge JA. **Food Chem Toxicol** 1996 Nov–Dec;34(11–12):1033–6 (5 ref.)

Public confidence in public health research ethics [comment] [see comments] Mariner WK. **Public Health Rep** 1997 Jan–Feb;112(1):33–6 (17 ref.) Comment on: Public Health Rep 1997 Jan–Feb;112(1):29–32. Comment in: Public

Health Rep 1997 Jul-Aug;112(4):266.
Defining research when it comes to public health [see comments] Snider DE Jr, et al. **Public Health Rep** 1997 Jan-Feb;112(1):29-32 (19 ref.) Comment in: Public Health Rep 1997 Jan-Feb;112(1):33-6. Comment in: Public Health Rep 1997 Jul-Aug;112(4):266.
Product safety, risk assessment, and responsible care in the biocide chemical industry. Weiler ED, et al. **Regul Toxicol Pharmacol** 1996 Aug;24(1 Pt 1):1-5 (23 ref.)
Public health consequences of hazardous substance releases. Hall HI, et al. **Toxicol Ind Health** 1996 Mar-Apr; 12(2):289-93 (4 ref.)
Assessment of reproductive health effects of hazardous waste. Kipen HM. **Toxicol Ind Health** 1996 Mar-Apr;12(2):211-24 (43 ref.)
Review of extant community-based epidemiologic studies on health effects of hazardous wastes. Miller AB. **Toxicol Ind Health** 1996 Mar-Apr;12(2):225-33 (25 ref.)
Health effects from hazardous waste incineration facilities: five case studies. Pleus RC, et al. **Toxicol Ind Health** 1996 Mar-Apr;12(2):277-87 (23 ref.)
Breast-feeding exposure of infants to environmental contaminants--a public health risk assessment viewpoint: chlorinated dibenzodioxins and chlorinated dibenzofurans. Pohl HR, et al. **Toxicol Ind Health** 1996 Sep-Oct; 12(5):593-611 (98 ref.)

STATISTICS & NUMERICAL DATA

Socioeconomic determinants of health. The contribution of nutrition to inequalities in health. James WP, et al. **BMJ** 1997 May 24;314(7093):1545-9 (31 ref.)
Physical activity among persons with disabilities--a public health perspective. Heath GW, et al. **Exerc Sport Sci Rev** 1997;25:195-234 (233 ref.)

TRENDS

Public health and primary care: a framework for proposed linkages. Starfield B. **Am J Public Health** 1996 Oct; 86(10):1365-9 (28 ref.)
Diagnosing ecosystem health. Schaeffer DJ. **Ecotoxicol Environ Saf** 1996 Jun;34(1):18-34 (63 ref.)
An osteopathic prescription for medical education reform: Part 2. Specialty mix and community integration. Ross-Lee B, et al. **J Am Osteopath Assoc** 1997 Aug;97(8):463-8 (18 ref.)

PUBLIC HEALTH ADMINISTRATION

see related
COMMUNITY HEALTH SERVICES

Occupational and environmental health in Turkmenistan and Uzbekistan. Reynolds SJ. **Am Ind Hyg Assoc J** 1996 Dec; 57(12):1096-102 (16 ref.)
A national strategy for research and development: lessons from England. Black N. **Annu Rev Public Health** 1997; 18:485-505 (48 ref.)
Perspectives on the place of environmental health and protection in public health and public health agencies. Kotchian S. **Annu Rev Public Health** 1997;18:245-59 (36 ref.)
Reinventing public health. Lee P, et al. **Annu Rev Public Health** 1997;18:1-35 (121 ref.)
The public health aspects of complex emergencies and refugee situations. Toole MJ, et al. **Annu Rev Public Health** 1997;18:283-312 (61 ref.)
Reason and protest in the new urban public health movement: an observation on the sociological analysis of political discourse in the 'healthy city'. Milewa T, et al. **Br J Sociol** 1996 Dec;47(4):657-70 (40 ref.)
Reorienting intensive family preservation services in relation to public child welfare practice. Wells K, et al. **Child Welfare** 1996 Nov-Dec;75(6):667-92 (75 ref.)
The use of mapping in public health and planning health services. Gordon A, et al. **J Public Health Med** 1997 Jun; 19(2):139-47 (8 ref.)
The National Women's Tobacco Control Plan. McLellan DL, et al. **J Public Health Policy** 1996;17(1):47-58 (02 ref.)
Setting the stage for health impact assessment. Ratner PA, et al. **J Public Health Policy** 1997;18(1):67-79 (26 ref.)
A ten year review of the iodine deficiency disorders program of the People's Republic of China. Wang J, et al. **J Public Health Policy** 1997;18(2):219-41 (57 ref.)
Developing tomorrow's integrated community health systems: a leadership challenge for public health and primary care. Welton WE, et al. **Milbank Q** 1997; 75(2):261-88 (15 ref.)
Public managed care: the role of the consultant. Cohen MD. **New Dir Ment Health Serv** 1996 Winter;(72):35-44 (5 ref.)
Managing the whole system of care. Hogan MF. **New Dir Ment Health Serv** 1996 Winter;(72):13-24 (14 ref.)
Creating incentives for the delivery of services. Hyde PS. **New Dir Ment Health Serv** 1996 Winter;(72):25-34 (19 ref.)
Managed care and the public health challenge of TB. Halverson PK, et al. **Public Health Rep** 1997 Jan-Feb; 112(1):22-8 (14 ref.)

EDUCATION

The Dutch experience with regard to the training for public health. Doeleman F. **Public Health** 1997 May;111(3):125-7 (0 ref.)

LEGISLATION & JURISPRUDENCE

Washington State reorganization: more of the story. Gebbie KM. **J Public Health Policy** 1997;18(2):188-218 (12 ref.)

STANDARDS

From measuring to improving public health practice. Turnock BJ, et al. **Annu Rev Public Health** 1997;18:261-82 (59 ref.)
Evidence-based medicine and public health. Aveyard P. **J Eval Clin Pract** 1997 Apr;3(2):139-44 (24 ref.)
QALYS and ethics: a health economist's perspective. Williams A. **Soc Sci Med** 1996 Dec;43(12):1795-804 (42 ref.)
Modernizing food control systems: the experience of Thailand. Pothisiri P. **World Health Stat Q** 1997; 50(1-2):150-4 (6 ref.)

PUBLIC HEALTH NURSING

ORGANIZATION & ADMINISTRATION

Managing policy research in nursing. Meerabeau L. **J Adv Nurs** 1996 Sep;24(3):633-9 (40 ref.)

STANDARDS

A typology of the potential outcomes of maternal-child home visits: a literature analysis. Byrd ME. **Public Health Nurs** 1997 Feb;14(1):3-11 (34 ref.)

PUBLIC HEALTH SCHOOLS see **SCHOOLS, PUBLIC HEALTH**

PUBLIC HEALTH SURVEILLANCE see **POPULATION SURVEILLANCE**

PUBLIC OPINION

see related
ATTITUDE TO HEALTH

Normatology: a review and commentary with reference to abortion and physician-assisted suicide. Brodie HK, et al. **Am J Psychiatry** 1997 Jun;154(6 Suppl):13-9 (42 ref.)
Disasters, the media and social structures: a typology of credibility hierarchy persistence based on a newspaper coverage of the Love Canal and six other disasters. Ploughman P. **Disasters** 1997 Jun;21(2):118-37 (79 ref.)
Books on health policy and health reform: how is nursing represented? Mundt MH. **J Prof Nurs** 1997 Jan-Feb; 13(1):19-27 (47 ref.)
A taxonomy for lay risk perceptions of dentistry. Deahl ST 2nd, et al. **J Public Health Dent** 1996 Summer;56(4):213-8 (28 ref.)

PUBLIC POLICY

Using qualitative data to inform public policy: evaluating "choose to de-fuse". Levine IS, et al. **Am J Orthopsychiatry** 1996 Jul;66(3):363-77 (34 ref.)
Media violence, gun control, and public policy. Zuckerman DM. **Am J Orthopsychiatry** 1996 Jul;66(3):378-89 (32 ref.)
Homelessness: care, prevention, and public policy. Plumb JD. **Ann Intern Med** 1997 Jun 15;126(12):973-5 (26 ref.)
Dissecting people and ignoring social structure: an analysis of individualism, public policy, and genetic labeling. Miringoff ML. **Behav Sci Law** 1996 Autumn;14(4):433-42 (36 ref.)
Financing child care: analysis and recommendations. Gomby DS, et al. **Future Child** 1996 Summer-Fall;6(2):5-25 (88 ref.)
Child poverty can be reduced. Plotnick RD. **Future Child** 1997 Summer-Fall;7(2):72-87 (46 ref.)
Gender, the state, and constructing the old as dependent: lessons from the economic transition in Poland. Calasanti TM, et al. **Gerontologist** 1997 Aug;37(4):452-61 (34 ref.)
Physician-assisted suicide: a tragic view. Arras JD. **J Contemp Health Law Policy** 1997 Spring;13(2):361-89 (94 ref.)
Academic research: policies and practice. Bertha SL. **J Ethnopharmacol** 1996 Apr;51(1-3):59-73 (7 ref.)
Drugs, communities, and "harm reduction" in Germany: the new relevance of "public health" principles in local responses. Fischer B. **J Public Health Policy** 1995; 16(4):389-411 (54 ref.)
The merchants, not the customers: resisting the alcohol and tobacco industries' strategy to blame young people for illegal alcohol and tobacco sales. Mosher JF. **J Public Health Policy** 1995;16(4):412-32 (47 ref.)
Lead poisoning: the implications of current biomedical knowledge for public policy. Silbergeld EK. **Md Med J** 1996 Mar;45(3):209-17 (38 ref.)
Deterrence of biological and chemical warfare: a review of policy options. Lebeda FJ. **Mil Med** 1997 Mar; 162(3):156-61 (61 ref.)
How energy policies affect public health. Romm JJ, et al. **Public Health Rep** 1996 Sep-Oct;111(5):390-9 (44 ref.)
Alcohol--less is better. **WHO Reg Publ Eur Ser** 1996;70:1-39 (39 ref.)

PUBLIC RELATIONS

Research responses to outbreaks of concern about local environments [see comments] Cole DC, et al. **Arch Environ Health** 1996 Sep-Oct;51(5):352-8 (47 ref.) Comment in: Arch Environ Health 1996 Sep-Oct;51(5):351.

PUBLIC SECTOR

ORGANIZATION & ADMINISTRATION

The public sector-private sector interface: current issues, future trends. Surles RC, et al. **New Dir Ment Health Serv** 1996 Winter;(72):71-9 (8 ref.)

PUBLICATION BIAS

How important is publication bias? A synthesis of available data. Dickersin K. **AIDS Educ Prev** 1997 Feb;9(1 Suppl):15-21 (22 ref.)
Invited commentary: confounding, measurement error, and publication bias in studies of passive smoking. Kawachi I, et al. **Am J Epidemiol** 1996 Nov 15;144(10):909-15 (57 ref.)
The cult of the double-blind placebo-controlled trial. Ellis SJ, et al. **Br J Clin Pract** 1997 Jan-Feb;51(1):36-9 (13 ref.)

PUBLISHING

see related
PERIODICALS

How to read a paper. Papers that report drug trials. Greenhalgh T. **BMJ** 1997 Aug 23;315(7106):480-3 (29 ref.)
Dissemination of research findings in family medicine. Renger R, et al. **Can Fam Physician** 1996 Sep;42:1783-6, 1788-9 (16 ref.)
Peer review, authorship, ethics, and conflict of interest. King CR, et al. **Image J Nurs Sch** 1997;29(2):163-7 (47 ref.)
Preparing manuscripts for publication in The Journal of Bone and Joint Surgery: a view from the former editor of the British volume. Apley AG. **Instr Course Lect** 1994;43:573-7 (3 ref.)
Popular press diagnoses and psychiatric diagnoses. Elks ML. **Med Hypotheses** 1996 Apr;46(4):331-6 (37 ref.)
Guidelines for reporting results of quality of life assessments in clinical trials. Staquet M, et al. **Qual Life Res** 1996 Oct; 5(5):496-502 (13 ref.)
[Economics of health systems in developing countries: what is the contribution of work published in french?] Flori YA, et al. **Sante** 1996 Nov-Dec;6(6):360-5 (38 ref.) (Eng. Abstr.) **(Fre)**
[Medical publishing--dissemination of knowledge or personal promotion?] Nylenna M. **Tidsskr Nor Laegeforen** 1996 Dec 10;116(30):3652-5 (29 ref.) (Eng. Abstr.) **(Nor)**
[Evaluation of statistical procedures in the original articles of "Anales Espanõles de Pediatria": comparison of two different periods (1989-90 and 1994-95)] González de Dios J, et al. **An Esp Pediatr** 1996 Oct;45(4):351-60 (35 ref.) **(Spa)**

STANDARDS

Assessing the methodological quality of published papers. Greenhalgh T. **BMJ** 1997 Aug 2;315(7103):305-8 (15 ref.)
Reporting guidelines: another perspective. Bray A. **J Endovasc Surg** 1995 Nov;2(4):334-40 (8 ref.)
Revising the reporting guidelines: how far do we need to go? Rutherford RB. **J Endovasc Surg** 1995 Nov;2(4):329-31 (3 ref.)
Can there really be "uniform" reporting guidelines? Veith FJ, et al. **J Endovasc Surg** 1995 Nov;2(4):332-3 (1 ref.)

STATISTICS & NUMERICAL DATA

Impact of using weighted versus unweighted measures to assess optometry faculty productivity in research. Doughty MJ, et al. **J Am Optom Assoc** 1996 Jul;67(7):410-20 (28 ref.)

PUERICULTURE see **CHILD CARE**

PUERPERAL DISORDERS

Acute myocardial infarction associated with pregnancy. Roth A, et al. **Ann Intern Med** 1996 Nov 1;125(9):751-62 (194 ref.)
Postpartum thyroid dysfunction. Browne-Martin K, et al. **Clin Obstet Gynecol** 1997 Mar;40(1):90-101 (51 ref.)
Postpartum thyroiditis. Sharma S, et al. **J Indian Med Assoc** 1995 May;93(5):175, 172 (10 ref.)
[Postpartum cardiomyopathy] Bertrand E. **Med Trop (Mars)** 1996;56(3 Suppl):45-6 (0 ref.) **(Fre)**
[Perinatal maternal emergencies] Mantz JM. **Presse Med** 1996 Oct 19;25(31):1492-500 (31 ref.) (Eng. Abstr.) **(Fre)**
[Cerebrovascular diseases in pregnancy and puerperium] Lamy C, et al. **Rev Neurol (Paris)** 1996 Jun-Jul; 152(6-7):422-40 (136 ref.) (Eng. Abstr.) **(Fre)**
[The holy cows of pregnancy and puerperium mental syndrome] Schoenfeld H. **Harefuah** 1996 Nov 1; 131(9):344-7 (32 ref.) **(Heb)**
[A case of primary biliary cirrhosis associated with fatty liver following delivery] Nakamura T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Aug;94(8):558-63 (20 ref.) **(Jpn)**
[Peripartum cardiomyopathy of multiple pregnancy] Ikeda S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):170-3 (17

PUERPERAL DISORDERS

ref.) **(Jpn)**

[Peripartum cardiomyopathy] Tateda K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):104–7 (20 ref.) **(Jpn)**

[Kidney involvement in trophoblastic disease (chorionepithelioma)] Timoshenko NI, et al. **Ter Arkh** 1995; 67(12):59–61 (6 ref.) (Eng. Abstr.) **(Rus)**

CHEMICALLY INDUCED

Do epidurals cause back pain? Buggy D, et al. **Br J Hosp Med** 1996 Jul 10–Aug 20;56(2–3):99–101 (18 ref.)

[Benign angiopathy of the puerperium: a clinicoradiological case associated with ingestion of bromocriptine] Lucas C, et al. **Rev Med Interne** 1996;17(10):839–41 (12 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

"Dural tail" adjacent to a giant posterior cerebral artery aneurysm: case report and review of the literature. Good CD, et al. **Neuroradiology** 1997 Aug;39(8):577–80 (25 ref.)

[Postpartum obturator nerve syndrome: case report and review of the nerve compression syndrome during pregnancy and delivery] Lindner A, et al. **Zentralbl Gynakol** 1997;119(3):93–9 (43 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Puerperal inversion of the uterus in Nepal: case reports and review of literature. Dali SM, et al. **J Obstet Gynaecol Res** 1997 Jun;23(3):319–25 (44 ref.)

ETIOLOGY

Arterial ischemic strokes associated with pregnancy and puerperium. Leys D, et al. **Acta Neurol Belg** 1997 Mar; 97(1):5–16 (82 ref.)

The female brain hypoestrogenic continuum from the premenstrual syndrome to menopause. A hypothesis and review of supporting data. Arpels JC. **J Reprod Med** 1996 Sep;41(9):633–9 (87 ref.)

Post–partum dilated cardiomyopathy in anti–phospholipid positive woman. Airoldi ML, et al. **Lupus** 1996 Jun; 5(3):247–50 (14 ref.)

[Unilateral spontaneous adrenal hematoma during the postpartum period. Apropos of a case] Badaoui R, et al. **Cah Anesthesiol** 1996;44(4):369–71 (17 ref.) (Eng. Abstr.) **(Fre)**

NURSING

Postpartum fatigue: clarifying a concept. Milligan R, et al. **Sch Inq Nurs Pract** 1996 Fall;10(3):279–91 (42 ref.)

REHABILITATION

The impact of intensive case–managed intervention on substance–using pregnant and postpartum women. Lanehart RE, et al. **J Subst Abuse** 1996;8(4):487–95 (18 ref.)

PUERPERAL INFECTION

DIAGNOSIS

Management of Salmonella infections during pregnancy and puerperium. van der Klooster JM, et al. **Neth J Med** 1997 Aug;51(2):83–6 (24 ref.)

MICROBIOLOGY

Streptococcus B meningitis in post–partum. Guerin JM, et al. **J Infect** 1997 Mar;34(2):151–3 (14 ref.)

[Puerperal infection. Analysis of 618 cases] del Valle–Padilla MA, et al. **Ginecol Obstet Mex** 1997 Feb;65:33–8 (30 ref.) (Eng. Abstr.) **(Spa)**

PUERPERIUM

Post–partum contraception. Kennedy KI. **Baillieres Clin Obstet Gynaecol** 1996 Apr;10(1):25–41 (64 ref.)

Postpartum thyroid disease. Amino N, et al. **Curr Ther Endocrinol Metab** 1997;6:327–30 (2 ref.)

The postpartum period: the key to maternal mortality. Li XF, et al. **Int J Gynaecol Obstet** 1996 Jul;54(1):1–10 (20 ref.)

Uterine health and disorders. Lewis GS. **J Dairy Sci** 1997 May;80(5):984–94 (67 ref.)

Post–partum anoestrus in dairy cows: a review. Opsomer G, et al. **Vet Q** 1996 Jun;18(2):68–75 (133 ref.)

BLOOD

Hemostasis during pregnancy and puerperium. Hellgren M. **Haemostasis** 1996 Oct;26 Suppl 4:244–7 (11 ref.)

PHYSIOLOGY

Cardiovascular responses to aerobic exercise during pregnancy and postpartum. Pivarnik JM. **Semin Perinatol** 1996 Aug;20(4):242–9 (51 ref.)

PUERTO RICANS see **HISPANIC AMERICANS**

PULMONARY ADENOMATOSIS, OVINE

VIROLOGY

Retrovirus–associated neoplasms of the respiratory system of sheep and goats. Ovine pulmonary carcinoma and enzootic nasal tumor. DeMartini JC, et al. **Vet Clin North Am Food Anim Pract** 1997 Mar;13(1):55–70 (73 ref.)

PULMONARY ALVEOLAR PROTEINOSIS

DIAGNOSIS

Diagnosing pulmonary alveolar proteinosis. A review and an update. Wang BM, et al. **Chest** 1997 Feb;111(2):460–6 (42 ref.)

ETIOLOGY

Secondary alveolar proteinosis in cancer patients. Ladeb S, et al. **Support Care Cancer** 1996 Nov;4(6):420–6 (47 ref.)

[Scavenger receptor gene––regulation of scavenger receptor gene expression in alveolar macrophages and the pathogenesis of pulmonary alveolar proteinosis] Mori T, et al. **Nippon Rinsho** 1996 Feb;54(2):353–7 (13 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

[Pulmonary alveolar proteinosis: ultrastructural study of 4 cases] Garrido L, et al. **Invest Clin** 1997 Mar;38(1):25–37 (33 ref.) (Eng. Abstr.) **(Spa)**

PULMONARY ALVEOLI

Pulmonary alveolar microlithiasis: review of Italian reports. Mariotta S, et al. **Eur J Epidemiol** 1997 Jul;13(5):587–90 (40 ref.)

Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome. Zamora MR, et al. **Medicine (Baltimore)** 1997 May;76(3):192–202 (58 ref.)

[Coping with pathological changes in heart and lung in collagen diseases––pulmonary alveolar hemorrhage] Yamakido M, et al. **Nippon Naika Gakkai Zasshi** 1996 Nov 10;85(11):1845–9 (5 ref.) **(Jpn)**

ANATOMY & HISTOLOGY

Intraalveolar bubbles and bubble films: II. Formation in vivo through adulthood. Scarpelli EM, et al. **Anat Rec** 1996 Oct; 246(2):245–70 (81 ref.)

CHEMISTRY

Repairing the cables of the lung [see comments] Kuhn C 3rd. **Am J Respir Cell Mol Biol** 1997 Sep;17(3):287–8 (12 ref.) Comment in: Am J Respir Cell Mol Biol 1997 Sep;17(3):289–301.

CYTOLOGY

Cell cycle kinetics in the alveolar epithelium. Uhal BD. **Am J Physiol** 1997 Jun;272(6 Pt 1):L1031–45 (120 ref.)

The pulmonary lipofibroblast (lipid interstitial cell) and its contributions to alveolar development. McGowan SE, et al. **Annu Rev Physiol** 1997;59:43–62 (87 ref.)

IMMUNOLOGY

[Scavenger receptor gene––regulation of scavenger receptor gene expression in alveolar macrophages and the pathogenesis of pulmonary alveolar proteinosis] Mori T, et al. **Nippon Rinsho** 1996 Feb;54(2):353–7 (13 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Carbon monoxide excretion, not oxygen secretion? Torrance RW. **Adv Exp Med Biol** 1996;410:335–9 (11 ref.)

Biophysical and molecular properties of amiloride–inhibitable Na+ channels in alveolar epithelial cells. Matalon S, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):L1–22 (152 ref.)

Salt and water transport across alveolar and distal airway epithelia in the adult lung. Matthay MA, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):L487–503 (145 ref.)

Intraalveolar bubbles and bubble films: II. Formation in vivo through adulthood. Scarpelli EM, et al. **Anat Rec** 1996 Oct; 246(2):245–70 (81 ref.)

The pulmonary lipofibroblast (lipid interstitial cell) and its contributions to alveolar development. McGowan SE, et al. **Annu Rev Physiol** 1997;59:43–62 (87 ref.)

G protein regulation of alveolar ion channels: implications for lung fluid transport. Kemp PJ, et al. **Exp Physiol** 1996 May;81(3):493–504 (35 ref.)

Alveolar epithelial clearance of protein. Folkesson HG, et al. **J Appl Physiol** 1996 May;80(5):1431–45 (166 ref.)

Airway and alveolar permeability and surface liquid thickness: theory. Widdicombe J. **J Appl Physiol** 1997 Jan; 82(1):3–12 (116 ref.)

Drug transport across Xenopus alveolar epithelium in vitro. Wall D, et al. **Pharm Biotechnol** 1996;8:347–59 (25 ref.)

[Simple, practical closed–circuit anesthesia] Lin CY. **Masui** 1997 Apr;46(4):498–505 (19 ref.) (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

Interactions of parasite and host epithelial cell cycle regulation during Pneumocystis carinii pneumonia. Limper AH, et al. **J Lab Clin Med** 1997 Aug;130(2):132–8 (30 ref.)

PATHOLOGY

Alveolar type II cells at the crossroad of inflammation, fibrogenesis, and neoplasia [comment] Saffiotti U. **Am J Pathol** 1996 Nov;149(5):1423–6 (29 ref.) Comment on: Am J Pathol 1996 Nov;149(5):1627–38.

Pulmonary capillaritis and alveolar hemorrhage. Update on diagnosis and management [published erratum appears in Chest 1997 Jul;112(1):300] Green RJ, et al. **Chest** 1996 Nov; 110(5):1305–16 (69 ref.)

Alterations in the alveolar epithelium after injury leading to pulmonary fibrosis. Kasper M, et al. **Histol Histopathol** 1996 Apr;11(2):463–83 (190 ref.)

Clinical and subclinical alveolitis in connective tissue diseases assessed by bronchoalveolar lavage. Manganelli P, et al. **Semin Arthritis Rheum** 1997 Apr;26(5):740–54 (94 ref.)

Pulmonary nodule caused by an alveolar adenoma of the lung. Böhm J, et al. **Virchows Arch** 1997 Feb;430(2):181–4 (9 ref.)

[Cell types of respiratory epithelium: morphology, molecular biology and clinical significance] Bals R. **Pneumologie** 1997 Feb;51(2):142–9 (79 ref.) (Eng. Abstr.) **(Ger)**

[Pulmonary structural remodeling in interstitial lung disease] Fukuda Y. **Nippon Ika Daigaku Zasshi** 1996 Oct; 63(5):379–83 (13 ref.) **(Jpn)**

[Proliferation of alveolar epithelial cells and gene expression of surfactant proteins in adult respiratory distress syndrome (ARDS)] Sugahara K. **Nippon Rinsho** 1996 Feb;54(2):341–5 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Pulmonary alveolar microlithiasis] Konovalov EP, et al. **Klin Khir** 1994;(12):31–3 (5 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Expanding the frontiers of lung biology through the creative use of alveolar epithelial cells in culture [see comments] Paine R 3rd, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):L484–6 (32 ref.) Comment in: Am J Physiol 1996 Apr;270(4 Pt 1):L483.

PHYSIOPATHOLOGY

Repairing the cables of the lung [see comments] Kuhn C 3rd. **Am J Respir Cell Mol Biol** 1997 Sep;17(3):287–8 (12 ref.) Comment in: Am J Respir Cell Mol Biol 1997 Sep;17(3):289–301.

ULTRASTRUCTURE

[Cellular and subcellular morphology of the repair process in pulmonary tuberculosis] Erokhin VV. **Probl Tuberk** 1996;(6):10–4 (10 ref.) (Eng. Abstr.) **(Rus)**

[Pulmonary alveolar proteinosis: ultrastructural study of 4 cases] Garrido L, et al. **Invest Clin** 1997 Mar;38(1):25–37 (33 ref.) (Eng. Abstr.) **(Spa)**

PULMONARY ARTERY

Death due to a leiomyosarcoma of the pulmonary artery. Marchetti D, et al. **Am J Forensic Med Pathol** 1996 Dec; 17(4):315–8 (21 ref.)

Nonneoplastic diseases of aorta and pulmonary trunk––Part II. Waller BF, et al. **Clin Cardiol** 1997 Sep;20(9):798–804 (15 ref.)

Nonneoplastic diseases of aorta and pulmonary trunk––Part I. Waller BF, et al. **Clin Cardiol** 1997 Aug;20(8):730–4 (21 ref.)

Multiple pulmonary artery pseudoaneurysms: intrasaccular embolization. Ghaye B, et al. **Eur Radiol** 1997;7(2):176–9 (18 ref.)

Primary sarcoma of pulmonary artery and valve: multimodality treatment by chemotherapy and homograft replacement. Zerkowski HR, et al. **J Thorac Cardiovasc Surg** 1996 Oct;112(4):1122–4 (12 ref.)

Fatal rupture of an acquired aneurysm of the pulmonary artery: rare complication after surgical palliation of tricuspid atresia. Boubaker A, et al. **Pediatr Cardiol** 1997 Sep–Oct;18(5):392–5 (9 ref.)

[Rare etiology of multiple pulmonary lacunae] Nourdine K, et al. **Rev Pneumol Clin** 1996;52(6):391–7 (32 ref.) (Eng. Abstr.) **(Fre)**

[Aneurysms of the pulmonary artery in Behçet disease. Apropos of 5 new cases] Yassine N, et al. **Rev Pneumol Clin** 1997;53(1):42–8 (24 ref.) (Eng. Abstr.) **(Fre)**

[Arteriovenous lung fistula as a pulmonary complication of biliary cirrhosis] Kramann B, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Nov;165(5):502–4 (17 ref.) **(Ger)**

[Pulmonary arteritis] Ito Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):606–10 (15 ref.) **(Jpn)**

[Primary pulmonary artery sarcoma (e.g. spindle cell sarcoma of the pulmonary artery, pulmonary artery leiomyosarcoma)] Miyahara Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):598–600 (16 ref.)

(Jpn)
[Pulmonary artery atherosclerosis] Noguchi T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):611–3 (17 ref.) (Jpn)

ABNORMALITIES

Management of the anomalous origin of the left coronary artery from the pulmonary artery. Ardehali A, et al. **Adv Card Surg** 1996;7:137–46 (32 ref.)

Isolated anomalous origin of left pulmonary artery from the ascending aorta. Tagliente MR, et al. **Am Heart J** 1996 Dec;132(6):1289–92 (6 ref.)

Surgical treatment of a fistula between the right pulmonary artery and the left atrium: presentation of two cases and review of literature. Zeebregts CJ, et al. **Eur J Cardiothorac Surg** 1997 Jun;11(6):1056–61 (58 ref.)

Multiple coronary–pulmonary fistulae involving all three coronary arteries: a case report. Abhyankar AD, et al. **Int J Cardiol** 1996 Dec 6;57(2):181–3 (9 ref.)

Pulmonary arteriovenous malformations: diagnosis and transcatheter embolotherapy. White RI Jr, et al. **J Vasc Interv Radiol** 1996 Nov–Dec;7(6):787–804 (56 ref.)

Progression of pulmonary arteriovenous malformation during pregnancy: case report and review of the literature. Esplin MS, et al. **Obstet Gynecol Surv** 1997 Apr;52(4):248–53 (22 ref.)

Supravalvular aortic stenosis, pulmonary artery stenosis, and coronary artery stenosis in twins. Nakanishi T, et al. **Pediatr Cardiol** 1996 Mar–Apr;17(2):125–8 (12 ref.)

Diffuse pulmonary arteriovenous malformations (angiodysplasia) with unusual histologic features: case report and review of the literature. Shapiro JL, et al. **Pediatr Pulmonol** 1996 Apr;21(4):255–61 (26 ref.)

Tracheoesophageal compression due to congenital vascular anomalies (vascular rings). Valletta EA, et al. **Pediatr Pulmonol** 1997 Aug;24(2):93–105 (82 ref.)

Endovascular stents in congenital heart disease. Benson LN, et al. **Prog Cardiovasc Dis** 1996 Sep–Oct;39(2):165–86 (76 ref.)

[Coronary artery–cardiac fistulas. Review of the literature. Two accidentally discovered cases] Jazra C, et al. **J Med Liban** 1995;43(3):162–5 (25 ref.) (Eng. Abstr.) (Fre)

[Pulmonary artery branch stenosis] Fukabori T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):317–20 (21 ref.) (Jpn)

[Unilateral absence of the pulmonary artery] Ganaha H. **Ryoikibetsu Shokogun Shirizu** 1996;(13):337–9 (10 ref.) (Jpn)

[Systemic arterial supply to the basal segments of the lung] Hamada T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):308–10 (19 ref.) (Jpn)

[Pulmonary vascular sling] Hayano T. **Ryoikibetsu Shokogun Shirizu** 1996;(13):22–4 (8 ref.) (Jpn)

[Anomalous origin of the left coronary artery from the pulmonary artery (ALCAPA) (Bland–White–Garland syndrome)] Hiraishi T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):825–8 (20 ref.) (Jpn)

[Origin of the right or left pulmonary artery from the ascending aorta] Hoshino S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):314–6 (8 ref.) (Jpn)

[Anomalous origin of the right coronary artery from the pulmonary artery] Kobayashi T. **Ryoikibetsu Shokogun Shirizu** 1996;(12):790–2 (17 ref.) (Jpn)

[Anomalous communication between the coronary and pulmonary arteries] Kobayashi T. **Ryoikibetsu Shokogun Shirizu** 1996;(12):810–2 (15 ref.) (Jpn)

[Pulmonary arteriovenous fistula] Yamashita M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):311–3 (14 ref.) (Jpn)

CYTOLOGY

Smooth muscle cell heterogeneity in pulmonary and systemic vessels. Importance in vascular disease. Frid MG, et al. **Arterioscler Thromb Vasc Biol** 1997 Jul;17(7):1203–9 (40 ref.)

DRUG EFFECTS

[Effect of cyclosporin A on the reactivity of the pulmonary vascular network in dogs] Mathieu P, et al. **Ann Chir** 1996;50(8):682–8 (25 ref.) (Eng. Abstr.) (Fre)

ENZYMOLOGY

Nitric oxide and the pulmonary artery smooth muscle cell. Degnim AC, et al. **Semin Pediatr Surg** 1996 Aug;5(3):160–4 (42 ref.)

PATHOLOGY

Clinicopathologic findings in congenital aneurysms of the great vessels. Adès LC, et al. **Am J Med Genet** 1996 Dec 18;66(3):289–99 (37 ref.)

Three–dimensional contrast–enhanced magnetic resonance angiography of the thoracic vasculature. Leung DA, et al. **Eur Radiol** 1997;7(7):981–9 (28 ref.)

Magnetic resonance imaging of thoracic vascular disease (congenital diseases excluded). Croisille P, et al. **J Belge Radiol** 1997 Jun;80(3):136–8 (8 ref.)

Pulmonary artery sarcomas: a review of clinical and radiologic features. Cox JE, et al. **J Comput Assist Tomogr** 1997 Sep–Oct;21(5):750–5 (30 ref.)

Dynamic breath–hold 3D gadolinium–enhanced MRI of intraarterial masses: findings in two patients. Krinsky G, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):631–4 (9 ref.)

Pulmonary MR angiography. Gefter WB, et al. **Semin Ultrasound CT MR** 1996 Aug;17(4):316–23 (67 ref.)

[Peripheral pulmonic stenosis] Arakaki Y. **Ryoikibetsu Shokogun Shirizu** 1996;(15):618–21 (6 ref.) (Jpn)

[Peripheral pulmonary artery stenosis] Yokota M. **Ryoikibetsu Shokogun Shirizu** 1996;(13):340–3 (11 ref.) (Jpn)

PHYSIOLOGY

[Measurement of vascular resistance] Itoh Y, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:511–3 (5 ref.) (Jpn)

[Pressure measurement systems in cardiac chambers and pulmonary artery] Shigematsu Y, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:501–3 (2 ref.) (Jpn)

PHYSIOPATHOLOGY

Reversal of flow in the left pulmonary artery after cavopulmonary connection. Minich LL, et al. **J Am Soc Echocardiogr** 1996 Mar–Apr;9(2):202–5 (5 ref.)

RADIOGRAPHY

Aneurysms of proximal pulmonary arteries: CT diagnosis and preoperative assessment. Iula G, et al. **Eur Radiol** 1996;6(5):730–3 (16 ref.)

Swyer–James syndrome documented by spiral CT angiography and high resolution inspiratory and expiratory CT: an accurate single modality exploration. Ghossain MA, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):616–8 (9 ref.)

Pulmonary arteries must be seen before they can be assessed [editorial; comment] Woodard PK. **Radiology** 1997 Jul;204(1):11–2 (21 ref.) Comment on: Radiology 1997 Jul;204(1):157–63.

[The rupture and intravascular migration of the distal fragment of a central venous access catheter (letter)] Maroto P, et al. **Rev Clin Esp** 1997 Jan;197(1):68–9 (10 ref.) (Spa)

SURGERY

[Treatment of congenital heart diseases with pulmonary artery cerclage.Immediate and medium term results in 51 patients] Neville P, et al. **Arch Mal Coeur Vaiss** 1997 Mar;90(3):371–7 (30 ref.) (Eng. Abstr.) (Fre)

[An operative case of bilateral peripheral pulmonary arterial aneurysms] Inaba H, et al. **Kyobu Geka** 1997 Apr;50(4):331–4 (5 ref.) (Eng. Abstr.) (Jpn)

PULMONARY ATRESIA

[Pulmonary atresia with intact ventricular septum] Yokota M. **Ryoikibetsu Shokogun Shirizu** 1996;(13):136–9 (15 ref.) (Jpn)

[Morphological aspects, evolution and prognostic factors in pulmonary atresia with intact ventricular septum. Review of the literature and update] Maia MM, et al. **Arq Bras Cardiol** 1996 May;66(5):299–303 (89 ref.) (Por)

PATHOLOGY

Case report: bronchial atresia associated with pectus excavatum. Scholl RJ 3rd, et al. **Conn Med** 1997 May;61(5):263–7 (15 ref.)

PULMONARY BLASTOMA

DIAGNOSIS

[Pneumoblastoma in children. A clinical case and review of the literature] Bongo S, et al. **Bull Cancer** 1996 Oct;83(10):877–81 (33 ref.) (Eng. Abstr.) (Fre)

PATHOLOGY

Fine–needle aspiration cytology of pleuropulmonary blastoma: case report and review of the literature. Gelven PL, et al. **Diagn Cytopathol** 1997 Apr;16(4):336–40 (29 ref.)

THERAPY

Pulmonary blastoma: a review with special emphasis on prognosis and treatment. Larsen H, et al. **Cancer Treat Rev** 1996 May;22(3):145–60 (120 ref.)

PULMONARY CIRCULATION

see related
VENTILATION–PERFUSION RATIO

Pulmonary tumor embolism. Bassiri AG, et al. **Am J Respir Crit Care Med** 1997 Jun;155(6):2089–95 (61 ref.)

Cellular and molecular mechanisms of pulmonary vascular remodeling. Stenmark KR, et al. **Annu Rev Physiol** 1997;59:89–144 (282 ref.)

The regulation of pulmonary vascular tone. Wilkins MR, et al. **Br J Clin Pharmacol** 1996 Jul;42(1):127–31 (39 ref.)

Disorders of pulmonary circulation [editorial; comment] Pineo GF, et al. **Curr Opin Pulm Med** 1997 Jul;3(4):265–7 (20 ref.) Comment on: Curr Opin Pulm Med 1997 Jul;3(4):268–74. Comment on: Curr Opin Pulm Med 1997 Jul;3(4):275–9. Comment on: Curr Opin Pulm Med 1997 Jul;3(4):280–5. Comment on: Curr Opin Pulm Med 1997 Jul;3(4):286–90. Comment on: Curr Opin Pulm Med 1997 Jul;3(4):291–302.

Acute and chronic influences of obstructive sleep apnoea on the pulmonary circulation. Marrone O, et al. **Monaldi Arch Chest Dis** 1997 Jun;52(3):263–7 (42 ref.)

Rare variant of total anomalous pulmonary venous connection: intrapulmonary drainage of one lung by the other--a case report and review of the literature. Chung JH, et al. **Pediatr Pathol Lab Med** 1997 Jan–Feb;17(1):133–40 (15 ref.)

Endothelin in the pulmonary circulation with special reference to hypoxic pulmonary vasoconstriction. Holm P. **Scand Cardiovasc J Suppl** 1997;46:1–40 (231 ref.)

Cell–extracellular matrix interactions in the ductus arteriosus and perinatal pulmonary circulation. Rabinovitch M. **Semin Perinatol** 1996 Dec;20(6):531–41 (45 ref.)

[Pulmonary MR angiography] Honda N. **Nippon Rinsho** 1997 Apr;55 Suppl 2:48–50 (10 ref.) (Jpn)

[Pulmonary perfusion scintigraphy and ventilation perfusion scintigraphy] Kawakami K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:39–41 (3 ref.) (Jpn)

DRUG EFFECTS

The pulmonary vasodilator properties of potassium channel opening drugs. Wanstall JC. **Gen Pharmacol** 1996 Jun;27(4):599–605 (91 ref.)

PHYSIOLOGY

Exercise physiology. Irvin CG. **Allergy Asthma Proc** 1996 Nov–Dec;17(6):327–30 (15 ref.)

Pulmonary capillary pressure. Clinical implications. Levy MM. **Crit Care Clin** 1996 Oct;12(4):819–39 (47 ref.)

Neutral endopeptidase inhibitors and the pulmonary circulation. Thompson JS, et al. **Gen Pharmacol** 1996 Jun;27(4):581–5 (50 ref.)

Hemostatic–endothelial interactions: a potential anticoagulant role of the endothelium in the pulmonary circulation during cardiac surgery. Cardigan RA, et al. **J Cardiothorac Vasc Anesth** 1997 May;11(3):329–36 (59 ref.)

The role of the pulmonary circulation in the regulation of coagulation and fibrinolysis in relation to major surgery. Dahl OE. **J Cardiothorac Vasc Anesth** 1997 May;11(3):322–8 (42 ref.)

Acute hypoxic pulmonary vasoconstriction: a model of oxygen sensing. Michelakis ED, et al. **Physiol Res** 1995;44(6):361–7 (45 ref.)

PULMONARY COIN LESION see **COIN LESION, PULMONARY**

PULMONARY DIFFUSING CAPACITY

Alveolar–capillary membrane diffusing capacity and its role in the functional capacity of chronic heart failure patients. Chua TP, et al. **Cardiologia** 1997 Mar;42(3):265–8 (23 ref.)

[The measurement of pulmonary diffusing capacity for carbon monoxide] Ishibashi M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:27–30 (6 ref.) (Jpn)

PULMONARY DISEASE, CHRONIC OBSTRUCTIVE see **LUNG DISEASES, OBSTRUCTIVE**

PULMONARY DISEASE (SPECIALTY)

Allergy testing in respiratory medicine. Varney VA, et al. **Br J Hosp Med** 1996 Oct 16–Nov 5;56(8):406–8 (16 ref.)

[The role of the pulmonologist in pulmonary infection (editorial)] Dorca J. **Arch Bronconeumol** 1997 May;33(5):210–2 (21 ref.) (Spa)

EDUCATION

[Psychological and moral aspects of physician's training at the phthisiopulmonological clinic of medical university] Khudzik LB, et al. **Probl Tuberk** 1997;(2):58–9 (0 ref.) (Rus)

METHODS

Sedation and anesthesia for pediatric bronchoscopy. Tobias JD. **Curr Opin Pediatr** 1997 Jun;9(3):198–206 (23 ref.)

TRENDS

Recent advances in pulmonary medicine. Passero MA. **Med Health R I** 1996 Mar;79(3):106–9 (30 ref.)

PULMONARY DISEASES see **LUNG DISEASES**

PULMONARY EDEMA

CHEMICALLY INDUCED

An international registry for toxic inhalation and pulmonary

PULMONARY EDEMA

edema: notes from work in progress. Guidotti TL. **Int Arch Occup Environ Health** 1996;68(6):380–6 (28 ref.)

Adult respiratory distress syndrome induced by a Chinese medicine, Kamisyoyo–san [see comments] Shiota Y, et al. **Intern Med** 1996 Jun;35(6):494–6 (10 ref.) Comment in: Intern Med 1996 Jun;35(6):433.

Acute lung injury after phosgene inhalation. Lim SC, et al. **Korean J Intern Med** 1996 Jan;11(1):87–92 (18 ref.)

[Maternal complications from tocolytic treatment with beta–mimetics. Three cases of pulmonary edema] Hourdequin P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(5):528–32 (21 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Acute pulmonary oedema complicating laryngospasm. Ingrams D, et al. **J Laryngol Otol** 1997 May;111(5):482–4 (13 ref.)

Negative–pressure pulmonary edema in the otolaryngology patient. Goldenberg JD, et al. **Otolaryngol Head Neck Surg** 1997 Jul;117(1):62–6 (21 ref.)

Pulmonary edema: etiology and treatment. Zlatnik MG. **Semin Perinatol** 1997 Aug;21(4):298–306 (41 ref.)

[Acute altitude pulmonary edema] Savoy J, et al. **Rev Med Suisse Romande** 1997 Jun;117(6):471–4 (22 ref.) **(Fre)**

[Postpneumonectomy pulmonary edema. Review of the literature. Apropos of 2 new cases] Faisy C, et al. **Rev Pneumol Clin** 1996;52(4):253–60 (19 ref.) (Eng. Abstr.) **(Fre)**

[The pulmonary interstitium in the transition from a physiological state to the development of edema] Miserocchi G. **Cardiologia** 1997 Feb;42(2):163–9 (25 ref.) **(Ita)**

[Cardiogenic pulmonary edema] Gotoh K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):95–8 (19 ref.) **(Jpn)**

[Cardiovascular abnormalities in subarachnoidal hemorrhage] Kubo S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):422–4 (14 ref.) **(Jpn)**

[Severe neurogenic pulmonary edema as a result of rupture of a giant intracranial arterial aneurysm] Lubnin AIu. **Anesteziol Reanimatol** 1995 Nov–Dec;(6):57–60 (23 ref.) **(Rus)**

PHYSIOPATHOLOGY

High–altitude pulmonary edema. Mechanisms and management. Sartori C, et al. **Cardiologia** 1997 Jun; 42(6):559–67 (92 ref.)

High altitude pulmonary edema: hemodynamic aspects. Hultgren HN. **Int J Sports Med** 1997 Jan;18(1):20–5 (59 ref.)

[Experimental changes in the alveolo–capillary barrier induced by artificial ventilation] Dreyfuss D, et al. **Schweiz Med Wochenschr** 1997 Jun 14;127(24):1023–9 (30 ref.) (Eng. Abstr.) **(Fre)**

[High–altitude pulmonary edema in Japan] Kobayashi T. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Dec;33 Suppl:1–6 (17 ref.) (Eng. Abstr.) **(Jpn)**

[New prospects in the clearance of pulmonary edema (editorial)] Sznajder JI, et al. **Arch Bronconeumol** 1997 May; 33(5):207–9 (29 ref.) **(Spa)**

RADIOGRAPHY

Reexpansion pulmonary edema. Tarver RD, et al. **J Thorac Imaging** 1996 Summer;11(3):198–209 (38 ref.)

RADIONUCLIDE IMAGING

Radionuclide assessment of pulmonary microvascular permeability. Groeneveld AB. **Eur J Nucl Med** 1997 Apr; 24(4):449–61 (103 ref.)

THERAPY

Pulmonary edema: etiology and treatment. Zlatnik MG. **Semin Perinatol** 1997 Aug;21(4):298–306 (41 ref.)

[The treatment of postinfarct pulmonary edema: the reserves and potentials] Sirenko IuN, et al. **Lik Sprava** 1996 Jan–Feb; (1–2):26–32 (55 ref.) **(Rus)**

PULMONARY EMBOLISM

Advances in acute pulmonary embolism and chronic pulmonary hypertension. Fedullo PF, et al. **Adv Intern Med** 1997;42:67–104 (115 ref.)

Pulmonary embolism. Fedullo PF. **Compr Ther** 1996 Oct; 22(10):654–60 (26 ref.)

Diagnosis and management of pulmonary embolism. Stein PD. **Curr Opin Cardiol** 1996 Sep;11(5):543–9 (32 ref.)

Disorders of pulmonary circulation [editorial; comment] Pineo GF, et al. **Curr Opin Pulm Med** 1997 Jul;3(4):265–7 (20 ref.) Comment on: Curr Opin Pulm Med 1997 Jul;3(4):268–74. Comment on: Curr Opin Pulm Med 1997 Jul;3(4):275–9. Comment on: Curr Opin Pulm Med 1997 Jul;3(4):280–5. Comment on: Curr Opin Pulm Med 1997 Jul;3(4):286–90. Comment on: Curr Opin Pulm Med 1997 Jul;3(4):291–302.

Venous thromboembolism during pregnancy: a current review of diagnosis and management. Toglia MR, et al. **Obstet Gynecol Surv** 1997 Jan;52(1):60–72 (113 ref.)

[Update on deep thrombophlebitis and pulmonary thromboembolism] Fiori E, et al. **Minerva Chir** 1996 Jun; 51(6):461–9 (76 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

[Chronic cor pulmonale caused by hydatid embolism complicating hepatic hydatid cyst] Kammoun S, et al. **Ann Cardiol Angeiol (Paris)** 1997 May–Jun;46(5–6):317–20 (12 ref.) (Eng. Abstr.) **(Fre)**

[Chronic cor pulmonale after embolism, antiphospholipid syndrome, Horton disease: therapeutic approach apropos of a case] Beynel P, et al. **Rev Pneumol Clin** 1997; 53(3):162–6 (22 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Pseudopulmonary embolism: acute respiratory distress in the syndrome of heparin–induced thrombocytopenia. Popov D, et al. **Am J Kidney Dis** 1997 Mar;29(3):449–52 (12 ref.)

The diagnosis of pulmonary embolism [see comments] Fennerty T. **BMJ** 1997 Feb 8;314(7078):425–9 (23 ref.) Comment in: BMJ 1997 May 24;314(7093):1550. Comment in: BMJ 1997 May 24;314(7093):1551.

Prolonged survival after massive pulmonary embolism in a patient with atrial septal defect and mass in the right ventricle. Tak T, et al. **Can J Cardiol** 1997 Feb; 13(2):199–202 (4 ref.)

Diagnosing pulmonary embolism: noninvasive strategies. Miniati M. **Cardiologia** 1997 Jun;42(6):569–77 (44 ref.)

New imaging techniques for the diagnosis of pulmonary embolism [see comments] Layish DT, et al. **Curr Opin Pulm Med** 1997 Jul;3(4):280–5 (47 ref.) Comment in: Curr Opin Pulm Med 1997 Jul;3(4):265–7.

The role of D–dimer in the diagnosis of venous thromboembolism [see comments] Lee AY, et al. **Curr Opin Pulm Med** 1997 Jul;3(4):275–9 (42 ref.) Comment in: Curr Opin Pulm Med 1997 Jul;3(4):265–7.

Noninvasive diagnosis of pulmonary embolism. Perrier A. **Haematologica** 1997 May–Jun;82(3):328–31 (17 ref.)

Diagnosis of pulmonary embolism. Georgopoulos DC. **Monaldi Arch Chest Dis** 1996 Aug;51(4):306–9 (25 ref.)

Pulmonary embolism: the role of computed tomography and magnetic resonance imaging. Bonomo L, et al. **Rays** 1996 Jul–Sep;21(3):378–96 (73 ref.) **(Eng, Ita)**

Clinical and instrumental diagnosis of pulmonary embolism. Cina G, et al. **Rays** 1996 Jul–Sep;21(3):340–51 (81 ref.) **(Eng, Ita)**

Pulmonary embolism presenting as acute abdominal pain. von Pohle WR. **Respiration** 1996;63(5):318–20 (11 ref.)

[The algorithm of imaging diagnostics of pulmonary embolism: is it time for a new definition?] Roberts HC, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Jun;166(6):463–74 (84 ref.) (Eng. Abstr.) **(Ger)**

[How to "adjectivize" acute pulmonary embolism? (editorial)] Morpurgo M, et al. **Cardiologia** 1996 Nov;41(11):1029–31 (21 ref.) **(Ita)**

DRUG THERAPY

Pharmacologic hemodynamic support in massive pulmonary embolism. Layish DT, et al. **Chest** 1997 Jan;111(1):218–24 (55 ref.)

Promising applications of thrombolytic agents from results in studies in laboratory animals. Prewitt RM. **Coron Artery Dis** 1996 Sep;7(9):625–9 (24 ref.)

Current status on new anticoagulant and antithrombotic drugs and devices [see comments] Walenga JM, et al. **Curr Opin Pulm Med** 1997 Jul;3(4):291–302 (96 ref.) Comment in: Curr Opin Pulm Med 1997 Jul;3(4):265–7.

Management of venous thromboembolism: optimization by clinical trials. Turpie AG. **Haemostasis** 1996 Oct;26 Suppl 4:220–6 (20 ref.)

Thrombolytic therapy for treatment of pulmonary embolism in the postoperative period: case report and review of the literature. Hartmannsgruber MW, et al. **J Clin Anesth** 1996 Dec;8(8):669–74 (41 ref.)

The clinical significance of pulmonary embolism: uncertainties and implications for treatment--a debate [published erratum appears in J Intern Med 1997 Apr;241(4):341] Egermayer P, et al. **J Intern Med** 1997 Jan;241(1):5–10 (42 ref.)

Management of venous thromboembolism [see comments] Ginsberg JS. **N Engl J Med** 1996 Dec 12;335(24):1816–28 (106 ref.) Comment in: N Engl J Med 1997 May 22;336(21):1528; discussion 1529. Comment in: N Engl J Med 1997 May 22;336(21):1528–9; discussion 1529.

Medical treatment of pulmonary embolism. Marra R. **Rays** 1996 Jul–Sep;21(3):425–31 (13 ref.) **(Eng, Ita)**

[Bolus thrombolysis in pulmonary embolism. Review of experimental and clinical data] Zonzin P, et al. **Ann Ital Med Int** 1996 Apr–Jun;11(2):132–7 (35 ref.) (Eng. Abstr.) **(Ita)**

[Acute pulmonary thromboembolism. Physiopathogenesis and use of thrombolytic agents] Baruzzi AC, et al. **Arq Bras Cardiol** 1996 Sep;67(3):201–7 (56 ref.) **(Por)**

[Use of heparin and oral anticoagulants to prevent and treat deep venous thrombosis and pulmonary embolism] Hamerschlak N, et al. **Arq Bras Cardiol** 1996 Sep; 67(3):209–13 (20 ref.) **(Por)**

EPIDEMIOLOGY

Epidemiology, pathophysiology and natural history of venous thromboembolism. Cina G, et al. **Rays** 1996 Jul–Sep;21(3):315–27 (95 ref.) **(Eng, Ita)**

ETIOLOGY

Wilms' tumour presenting as a pulmonary embolism. Ceelen W, et al. **Acta Chir Belg** 1997 Jun;97(3):148–50 (12 ref.)

Missile emboli to the pulmonary artery [letter] Gupta AK, et al. **Am J Emerg Med** 1997 Mar;15(2):213–4 (12 ref.)

Pulmonary embolism from axillosubclavian thrombosis on a rehabilitation unit: case report. Kissel DJ. **Arch Phys Med Rehabil** 1997 Mar;78(3):319–23 (44 ref.)

The venous thrombotic risk in nonsurgical patients. Bouthier J. **Drugs** 1996;52 Suppl 7:16–28; discussion 28–9 (42 ref.)

Diffuse microvascular pulmonary thrombosis associated with primary antiphospholipid antibody syndrome [see comments] Maggiorini M, et al. **Eur Respir J** 1997 Mar; 10(3):727–30 (19 ref.) Comment in: Eur Respir J 1997 Mar;10(3):511–2.

Diagnosis and clinical characteristics of inherited activated protein C resistance. Samama MM, et al. **Haemostasis** 1996 Oct;26 Suppl 4:315–30 (55 ref.)

Deep venous thrombosis and pulmonary embolism following cast immobilization of the lower extremity. Nesheiwat F, et al. **J Foot Ankle Surg** 1996 Nov–Dec;35(6):590–4; discussion 602 (24 ref.)

[Pulmonary problems related to aging] Weber T, et al. **Rev Med Liege** 1997 Apr;52(4):245–50 (13 ref.) **(Fre)**

[Cerebral thrombophlebitis, sural phlebitis, pulmonary embolisms and protein S deficiencies] Bostroem H, et al. **Rev Neurol (Paris)** 1996 Dec;152(12):755–8 (26 ref.) (Eng. Abstr.) **(Fre)**

[Venous thromboembolism: epidemiology and risk factors] Siragusa S, et al. **Minerva Cardioangiol** 1996 Nov; 44(11):581–9 (58 ref.) (Eng. Abstr.) **(Ita)**

[Embolism of the small branches of the pulmonary artery in x–ray endovascular occlusion of the renal vessels in cancer] Iurin AG. **Arkh Patol** 1996 Nov–Dec;58(6):62–4 (9 ref.) (Eng. Abstr.) **(Rus)**

[Bilateral pulmonary thromboembolism secondary to a double malformation of the iliac veins (letter)] Mata J, et al. **Med Clin (Barc)** 1997 Feb 1;108(4):159 (8 ref.) **(Spa)**

MORTALITY

The changing pattern of venous thromboembolic disease. Cohen AT, et al. **Haemostasis** 1996 Mar–Apr;26(2):65–71 (14 ref.)

PATHOLOGY

Embolism of fetal brain tissue to the lungs and the placenta. Baergen RN, et al. **Pediatr Pathol Lab Med** 1997 Jan–Feb; 17(1):159–67 (25 ref.)

[Fat embolism--a too infrequently determined pathoanatomic diagnosis] Behn C, et al. **Versicherungsmedizin** 1997 Jun 1;49(3):89–93 (30 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Pharmacologic hemodynamic support in massive pulmonary embolism. Layish DT, et al. **Chest** 1997 Jan;111(1):218–24 (55 ref.)

Early electrocardiographic signs in acute massive pulmonary embolism. Hubloue I, et al. **Eur J Emerg Med** 1996 Sep; 3(3):199–204 (17 ref.)

Lung mechanics and gas exchange in pulmonary embolism. D'Angelo E. **Haematologica** 1997 May–Jun;82(3):371–4 (34 ref.)

Epidemiology, pathophysiology and natural history of venous thromboembolism. Cina G, et al. **Rays** 1996 Jul–Sep;21(3):315–27 (95 ref.) **(Eng, Ita)**

[Acute pulmonary thromboembolism. Physiopathogenesis and use of thrombolytic agents] Baruzzi AC, et al. **Arq Bras Cardiol** 1996 Sep;67(3):201–7 (56 ref.) **(Por)**

PREVENTION & CONTROL

Thromboprophylaxis, coagulation disorders, and regional anaesthesia. Haljamäe H. **Acta Anaesthesiol Scand** 1996 Sep; 40(8 Pt 2):1024–40 (94 ref.)

Clinical results of Greenfield filter use in patients with cancer. Greenfield LJ, et al. **Cardiovasc Surg** 1997 Apr;5(2):145–9 (21 ref.)

Prolonged prophylaxis against postoperative venous thromboembolism. Bergqvist D. **Haemostasis** 1996 Oct;26 Suppl 4:379–87 (57 ref.)

New antithrombotic agents for the prevention and treatment of deep vein thrombosis. Boneu B. **Haemostasis** 1996 Oct; 26 Suppl 4:368–78 (30 ref.)

Risk factors and prevention of venous thromboembolism. Storti S, et al. **Rays** 1996 Jul–Sep;21(3):439–60 (137 ref.) **(Eng, Ita)**

[Ultrahigh–dosage urokinase lysis during pulmonary embolism prophylaxis by means of an extractable caval filter] Neuerburg J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Nov;165(5):510–3 (16 ref.) **(Ger)**

[Treatment and prevention of acute embolic venous thrombosis] Genyk SN, et al. **Khirurgiia (Mosk)** 1996; (2):138–40 (31 ref.) **(Rus)**

RADIOGRAPHY

Spiral computed tomography and pulmonary embolism:

current state. Hansell DM. **Clin Radiol** 1997 Aug; 52(8):575–81 (36 ref.)

Ventilation–perfusion lung scanning and spiral computed tomography of the lungs: competing or complementary modalities? Robinson PJ. **Eur J Nucl Med** 1996 Nov; 23(11):1547–53 (55 ref.)

Spiral CT of pulmonary embolism: technical considerations and interpretive pitfalls. Remy-Jardin M, et al. **J Thorac Imaging** 1997 Apr;12(2):103–17 (41 ref.)

Spiral CT of pulmonary hypertension and chronic thromboembolism. Roberts HC, et al. **J Thorac Imaging** 1997 Apr;12(2):118–27 (69 ref.)

Pulmonary arteries must be seen before they can be assessed [editorial; comment] Woodard PK. **Radiology** 1997 Jul; 204(1):11–2 (21 ref.) Comment on: Radiology 1997 Jul;204(1):157–63.

Chest radiograph in pulmonary embolism. Pirronti T, et al. **Rays** 1996 Jul-Sep;21(3):352–62 (14 ref.) **(Eng, Ita)**

Fast CT for pulmonary embolus. Sheedy PF 2nd, et al. **Semin Ultrasound CT MR** 1996 Aug;17(4):324–38 (16 ref.)

[Spiral-CT in diagnosis of lung embolism] Kauczor HU, et al. **Rontgenpraxis** 1996 Aug;49(8):195–200 (25 ref.) **(Ger)**

[Interventional radiology in thoracic emergencies] Florio FP, et al. **Minerva Med** 1997 Jan-Feb;88(1-2):31–8 (16 ref.) (Eng. Abstr.) **(Ita)**

RADIONUCLIDE IMAGING

Ventilation–perfusion lung scanning and spiral computed tomography of the lungs: competing or complementary modalities? Robinson PJ. **Eur J Nucl Med** 1996 Nov; 23(11):1547–53 (55 ref.)

The role of nuclear medicine in pulmonary embolism. Galli G, et al. **Rays** 1996 Jul-Sep;21(3):363–77 (62 ref.) **(Eng, Ita)**

SURGERY

Pulmonary resection for treatment of cavitary pulmonary infarction. Butler MD, et al. **Ann Thorac Surg** 1997 Mar; 63(3):849–50 (8 ref.)

Thromboendarterectomy: some unanswered questions [editorial; comment] Shure D. **Ann Thorac Surg** 1996 Nov; 62(5):1253–4 (9 ref.) Comment on: Ann Thorac Surg 1996 Nov;62(5):1255–59; discussion 1259–60.

Surgical treatment of massive pulmonary embolism. Luciani N, et al. **Rays** 1996 Jul-Sep;21(3):432–8 (21 ref.) **(Eng, Ita)**

[Pulmonary thromboendarterectomy in a patient with primary antiphospholipid syndrome] Cucurull E, et al. **Med Clin (Barc)** 1996 Apr 6;106(13):498–500 (27 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Right heart pulmonary embolism in transit: a review of therapeutic considerations. Pandey AS, et al. **Can J Cardiol** 1997 Apr;13(4):397–402 (39 ref.)

Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Hirsh J, et al. **Circulation** 1996 Jun 15; 93(12):2212–45 (451 ref.)

Practical management of venous thromboembolism following pelvic fractures. Montgomery KD, et al. **Orthop Clin North Am** 1997 Jul;28(3):397–404 (56 ref.)

Interventional radiology in the treatment of pulmonary embolism. Cotroneo AR, et al. **Rays** 1996 Jul-Sep; 21(3):417–24 (16 ref.) **(Eng, Ita)**

The treatment of deep vein thrombosis and pulmonary embolism. Turkstra F, et al. **Thromb Haemost** 1997 Jul; 78(1):489–96 (76 ref.)

[Pulmonary embolism treatment] Meyer G, et al. **Rev Mal Respir** 1997 Jan;14(1):67–8 (9 ref.) **(Fre)**

ULTRASONOGRAPHY

Echocardiographic detection of reversible right ventricular strain in patients with acute pulmonary embolism: report of 2 cases. Fang BR, et al. **Cardiology** 1996 Jul-Aug; 87(4):279–82 (12 ref.)

Impending paradoxical embolism and dynamic left ventricular outflow obstruction in a patient with recurrent pulmonary embolism and secondary pulmonary hypertension [letter] Kruzer J, et al. **Eur Heart J** 1996 Sep; 17(9):1448–9 (5 ref.)

[Transthoracic echocardiography and diagnosis of acute pulmonary embolism. Change in the diagnostic valve with respect to thresholds of classification] Nazeyrollas P, et al. **Arch Mal Coeur Vaiss** 1997 Apr;90(4):463–9 (21 ref.) (Eng. Abstr.) **(Fre)**

PULMONARY EMPHYSEMA

COMPLICATIONS

[Arrhythmias in patients with chronic pulmonary emphysema] Makino M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):436–9 (15 ref.) **(Jpn)**

DIAGNOSIS

[Radiology and geriatrics: limits between normal values and pathology exemplified by conventional thoracic roentgen image, cerebral CT and MRI and pelvic-leg angiography] Osterheider MA. **Z Gerontol Geriatr** 1997 May-Jun; 30(3):226–34 (17 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Intravenous alpha-1-antitrypsin replacement therapy: case report after one year of treatment. Ward AC, et al. **Ir J Med Sci** 1997 Jan-Mar;166(1):7–9 (10 ref.)

ETIOLOGY

Alpha-1-antitrypsin deficiency: biochemistry and clinical manifestations. Perlmutter DH. **Ann Med** 1996 Oct; 28(5):385–94 (70 ref.)

Antiproteinase deficiency, emphysema and replacement therapy. Burdon JG, et al. **Aust N Z J Med** 1996 Dec; 26(6):769–71 (28 ref.)

[Pulmonary emphysema] Konietzko N. **Pneumologie** 1996 Sep;50 Suppl 2:585–7 (18 ref.) **(Ger)**

GENETICS

Clinical features and natural history of severe alpha 1-antitrypsin deficiency. Roger S. Mitchell Lecture. Stoller JK. **Chest** 1997 Jun;111(6 Suppl):123S–128S (30 ref.)

PATHOLOGY

New air–fluid levels in bullous lung disease: a reevaluation. Richardson MS, et al. **J Natl Med Assoc** 1996 Mar; 88(3):185–7 (19 ref.)

PHYSIOPATHOLOGY

Hyperinflation and respiratory muscle interaction. Decramer M. **Eur Respir J** 1997 Apr;10(4):934–41 (53 ref.)

Effect of hyperinflation on the diaphragm. De Troyer A. **Eur Respir J** 1997 Mar;10(3):708–13 (56 ref.)

Physiological outcomes of lung volume reduction surgery. Russi EW. **Monaldi Arch Chest Dis** 1997 Apr;52(2):155–8 (35 ref.)

RADIOGRAPHY

CT appearance of interstitial pulmonary emphysema. Satoh K, et al. **J Thorac Imaging** 1996 Spring;11(2):153–4 (8 ref.)

Assessment of the severity of pulmonary emphysema by computed tomography. Zompatori M, et al. **Monaldi Arch Chest Dis** 1997 Apr;52(2):147–54 (56 ref.)

[Radiological diagnosis of emphysema prior to volume-reduction surgery] Kontrus M, et al. **Wien Med Wochenschr** 1996;146(23):587–91 (22 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Surgical treatment of emphysema. Little AG. **Adv Surg** 1996; 30:189–207 (29 ref.)

Recent advances in surgery for emphysema. Lefrak SS, et al. **Annu Rev Med** 1997;48:387–98 (34 ref.)

Surgical treatment of emphysema using bovine pericardium strips. Allen GM. **AORN J** 1996 Feb;63(2):373, 376–80, 383–4, passim 388 (14 ref.)

Bilateral lung volume reduction surgery for treatment of emphysema. Dickey DM. **AORN J** 1996 Feb;63(2):355–64, 367, 372; quiz 406, 409–14 (26 ref.)

Bilateral lung volume reduction surgery. Graling PR, et al. **AORN J** 1996 Feb;63(2):389–90, 392, 394 passim (10 ref.)

Management of a giant fluid-filled bulla by closed-chest thoracostomy tube drainage. Kirschner LS, et al. **Chest** 1997 Jun;111(6):1772–4 (7 ref.)

Lung transplantation for alpha 1-antitrypsin deficiency emphysema. Trulock EP. **Chest** 1996 Dec;110(6 Suppl):284S–294S (37 ref.)

Perioperative management of lung volume reduction patients. Keller CA, et al. **Clin Chest Med** 1997 Jun;18(2):285–300 (39 ref.)

Early and long-term functional outcomes following lung volume reduction surgery. Sciurba FC. **Clin Chest Med** 1997 Jun;18(2):259–76 (109 ref.)

Surgical treatment for advanced emphysema. Nepomuceno DJ, et al. **Compr Ther** 1996 Oct;22(10):631–40 (42 ref.)

Lung volume reduction surgery for emphysema. Russi EW, et al. **Eur Respir J** 1997 Jan;10(1):208–18 (46 ref.)

[Thoracoscopic methods in treatment of pulmonary emphysema] Klepetko W, et al. **Chirurg** 1996 Dec; 67(12):1215–21 (26 ref.) (Eng. Abstr.) **(Ger)**

[Principles of lung volume reduction] Stamatis G, et al. **Chirurg** 1996 Dec;67(12):1204–14 (41 ref.) (Eng. Abstr.) **(Ger)**

[Radiological diagnosis of emphysema prior to volume-reduction surgery] Kontrus M, et al. **Wien Med Wochenschr** 1996;146(23):587–91 (22 ref.) (Eng. Abstr.) **(Ger)**

[Selection of patients with pulmonary emphysema for surgical volume reduction] Russi EW. **Wien Med Wochenschr** 1996;146(23):582–5 (11 ref.) (Eng. Abstr.) **(Ger)**

[Lung volume reduction for treatment of pulmonary emphysema] Azuri Y, et al. **Harefuah** 1997 Jan 15; 132(2):104–6 (39 ref.) **(Heb)**

[Lung volume reduction surgery in patients with pulmonary emphysema] Kohno T, et al. **Kyobu Geka** 1997 Jul;50(8 Suppl):722–9 (10 ref.) **(Jpn)**

[Relief of dyspnea after lung volume reduction in patients with pulmonary emphysema] Hida W, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:169–71 (8 ref.) (Eng. Abstr.) **(Jpn)**

PULMONARY EOSINOPHILIA

Extrinsic allergic alveolitis and eosinophilic lung disease. Screaton NJ, et al. **Br J Hosp Med** 1996 Jul 10-Aug 20; 56(2-3):90–3 (14 ref.)

Tropical pulmonary eosinophilia. Vijayan VK. **Indian J Chest Dis Allied Sci** 1996 Jul-Sep;38(3):169–80 (101 ref.)

Acute eosinophilic pneumonia. A summary of 15 cases and review of the literature. Pope-Harman AL, et al. **Medicine (Baltimore)** 1996 Nov;75(6):334–42 (60 ref.)

Dirofilaria, visceral larva migrans, and tropical pulmonary eosinophilia. Chitkara RK, et al. **Semin Respir Infect** 1997 Jun;12(2):138–48 (78 ref.)

CHEMICALLY INDUCED

A case of eosinophilic pneumonia and vasculitis induced by diflunisal. Rich MW, et al. **Chest** 1997 Jun;111(6):1767–9 (7 ref.)

Adult respiratory distress syndrome induced by a Chinese medicine, Kamisyoyo-san [see comments] Shiota Y, et al. **Intern Med** 1996 Jun;35(6):494–6 (10 ref.) Comment in: Intern Med 1996 Jun;35(6):433.

COMPLICATIONS

Rapid diagnosis of acute eosinophilic pneumonia (AEP) in a patient with respiratory failure using bronchoalveolar lavage (BAL) with calcofluor white (CW) staining. Hogan TF, et al. **J Clin Lab Anal** 1997;11(4):202–7 (65 ref.)

DIAGNOSIS

Rapid diagnosis of acute eosinophilic pneumonia (AEP) in a patient with respiratory failure using bronchoalveolar lavage (BAL) with calcofluor white (CW) staining. Hogan TF, et al. **J Clin Lab Anal** 1997;11(4):202–7 (65 ref.)

RADIOGRAPHY

Pulmonary eosinophilia. Bain GA, et al. **Eur J Radiol** 1996 Aug;23(1):3–8 (20 ref.)

Clinics in diagnostic imaging (17). Chronic eosinophilic pneumonia (CEP). Khoo JB, et al. **Singapore Med J** 1996 Oct;37(5):532–4 (7 ref.)

PULMONARY FIBROSIS

Cryptogenic fibrosing alveolitis. Chan-Yeung M, et al. **Lancet** 1997 Aug 30;350(9078):651–6 (37 ref.)

CHEMICALLY INDUCED

C-C chemokines: novel mediators of the profibrotic inflammatory response to bleomycin challenge. Smith RE, et al. **Am J Respir Cell Mol Biol** 1996 Dec;15(6):693–702 (122 ref.)

COMPLICATIONS

[Pulmonary fibrosis and polyarteritis nodosa (letter)] Sánchez-Angulo JI, et al. **Med Clin (Barc)** 1996 Nov 23; 107(18):719 (7 ref.) **(Spa)**

DIAGNOSIS

[Interstitial lung diseases in children] Lindemann H. **Pneumologie** 1996 Mar;50(3):245–8 (11 ref.) **(Ger)**

[N-terminal peptide of type III procollagen in serum and bronchoalveolar fluid as a marker of collagen metabolism in chronic interstitial lung diseases] Siemińska A. **Przegl Lek** 1996;53(7):574–8 (45 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future. Mapel DW, et al. **Chest** 1996 Oct;110(4):1058–67 (67 ref.)

[Glucocorticoids in pneumology] Criée CP, et al. **Internist (Berl)** 1997 May;38(5):490–3 (10 ref.) **(Ger)**

[New therapy concepts in fibrosing lung diseases] Behr J. **Pneumologie** 1996 Sep;50(9):657–64 (87 ref.) **(Ger)**

ETIOLOGY

Pulmonary radiation injury. Movsas B, et al. **Chest** 1997 Apr; 111(4):1061–76 (98 ref.)

Transient gene transfer and expression in the lung. Sime PJ, et al. **Chest** 1997 Jun;111(6 Suppl):89S–94S (33 ref.)

The pathogenesis of pulmonary fibrosis: is there a fibrosis gene? Marshall RP, et al. **Int J Biochem Cell Biol** 1997 Jan;29(1):107–20 (129 ref.)

Noncancer inhalation toxicology of crystalline silica: exposure-response assessment. Gift JS, et al. **J Expo Anal Environ Epidemiol** 1997 Jul-Sep;7(3):345–58 (42 ref.)

Laboratory studies on silica induced toxicity and relationship to carcinogenicity. Rabovsky J. **J Expo Anal Environ Epidemiol** 1997 Jul-Sep;7(3):267–78 (51 ref.)

[Interstitial lung diseases] Costabel U. **Pneumologie** 1996 Sep;

50 Suppl 2:611–4 (20 ref.) **(Ger)**

[The role of cytokines in pulmonary fibrosis] Ogushi F. **Nippon Ika Daigaku Zasshi** 1996 Oct;63(5):391–4 (7 ref.) **(Jpn)**

[Role of TGF-beta and PDGF on the pathogenesis of pulmonary fibrosis--analysis by in vivo gene transfer] Yoshida M, et al. **Nippon Rinsho** 1996 Feb;54(2):418–22 (13 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

The pathogenesis of pulmonary fibrosis: is there a fibrosis gene? Marshall RP, et al. **Int J Biochem Cell Biol** 1997 Jan;29(1):107–20 (129 ref.)

[Progressive course of idiopathic pulmonary fibrosis in 2 monozygotic twin sisters] Thomas H, et al. **Pneumologie** 1996 Sep;50(9):679–82 (28 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Cytokines and pulmonary fibrosis. Zhang K, et al. **Biol Signals** 1996 Jul–Aug;5(4):232–9 (57 ref.)

PATHOLOGY

Pathogenic mechanisms in the development of diffuse pulmonary fibrosis. Selman M, et al. **Braz J Med Biol Res** 1996 Sep;29(9):1117–26 (60 ref.)

Alterations in the alveolar epithelium after injury leading to pulmonary fibrosis. Kasper M, et al. **Histol Histopathol** 1996 Apr;11(2):463–83 (190 ref.)

Role of the myofibroblast in pulmonary fibrosis. Phan SH. **Kidney Int Suppl** 1996 May;54:S46–8 (30 ref.)

[Effects of in vivo instillation of genes coding for cytokines on pulmonary fibrosis] Hayashi S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:190–4 (19 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

CT evaluation of fibrosing alveolitis--applications and insights. Hansell DM, et al. **J Thorac Imaging** 1996 Fall; 11(4):231–49 (129 ref.)

SURGERY

Indications. Unilateral, bilateral, heart–lung, and lobar transplant procedures. Patterson GA. **Clin Chest Med** 1997 Jun;18(2):225–30 (18 ref.)

Pediatric lung transplantation. Stillwell PC, et al. **Clin Chest Med** 1997 Jun;18(2):405–14 (46 ref.)

VIROLOGY

Viruses and idiopathic pulmonary fibrosis [editorial; comment] Egan JJ, et al. **Eur Respir J** 1997 Jul;10(7):1433–7 (47 ref.) Comment on: Eur Respir J 1997 Jul;10(7):1445–9.

PULMONARY FUNCTION TESTS see **RESPIRATORY FUNCTION TESTS**

PULMONARY GAS EXCHANGE

Acute severe asthma: pathophysiology and pathobiology of gas exchange abnormalities. Rodriguez-Roisin R. **Eur Respir J** 1997 Jun;10(6):1359–71 (82 ref.)

Gas exchange, expiratory flow obstruction and the clinical spectrum of asthma. Wagner PD, et al. **Eur Respir J** 1996 Jun;9(6):1278–82 (17 ref.)

Lung mechanics and gas exchange in pulmonary embolism. D'Angelo E. **Haematologica** 1997 May–Jun;82(3):371–4 (34 ref.)

The theory of and experimentation into respiratory gas exchange--Carl Ludwig and his school. Schubert E. **Pflugers Arch** 1996;432(3 Suppl):R111–9 (34 ref.)

The role of gas analysis in stress testing. Higginbotham MB. **Prim Care** 1994 Sep;21(3):557–67 (44 ref.)

Update '96 on pulmonary gas exchange pathophysiology in pneumonia. Rodriguez-Roisin R, et al. **Semin Respir Infect** 1996 Mar;11(1):3–12 (37 ref.)

[Reproducibility of measurements of blood gas exchange during exercise in mild cardiac failure: need for a preliminary test?] Valy Y, et al. **Arch Mal Coeur Vaiss** 1997 Apr;90(4):477–82 (31 ref.) (Eng. Abstr.) **(Fre)**

[Expired gas analysis] Omiya K. **Nippon Rinsho** 1997 Apr; 55 Suppl 2:74–9 (14 ref.) **(Jpn)**

DRUG EFFECTS

Nitric oxide in chronic obstructive pulmonary disease. Barberà JA. **Monaldi Arch Chest Dis** 1996 Dec;51(6):528–32 (28 ref.)

PHYSIOLOGY

Clinical strategies in intravascular gas exchange. Sim KM, et al. **Artif Organs** 1996 Jul;20(7):807–10 (11 ref.)

Advances in the management of respiratory failure. Intracorporeal membrane gas exchange: will it still prevail? Zwischenberger JB, et al. **ASAIO J** 1996 May–Jun; 42(3):207–8 (11 ref.)

[Liquid ventilation with perfluorocarbons (see comments)] Quintel M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Oct; 31(8):461–9 (72 ref.) (Eng. Abstr.) Comment in: Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Oct;31(8):459–60. **(Ger)**

PULMONARY HEART DISEASE

[Cor pulmonale] Handa S. **Ryoikibetsu Shokogun Shirizu** 1996;(12):148–50 (12 ref.) **(Jpn)**

DIAGNOSIS

[Pulmonary hypertension and cor pulmonale] Henk CB, et al. **Radiologe** 1997 May;37(5):388–401 (60 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

[Chronic cor pulmonale caused by hydatid embolism complicating hepatic hydatid cyst] Kammoun S, et al. **Ann Cardiol Angeiol (Paris)** 1997 May–Jun;46(5–6):317–20 (12 ref.) (Eng. Abstr.) **(Fre)**

[Chronic cor pulmonale after embolism, antiphospholipid syndrome, Horton disease: therapeutic approach apropos of a case] Beynel P, et al. **Rev Pneumol Clin** 1997; 53(3):162–6 (22 ref.) (Eng. Abstr.) **(Fre)**

PARASITOLOGY

[Cardiopulmonary involvement in schistosomiasis] Barbosa MM, et al. **Arq Bras Cardiol** 1995 Oct;65(4):343–8 (59 ref.) **(Por)**

THERAPY

[Decompensated pulmonary heart: topical aspects of management] Kazanbiev NK. **Klin Med (Mosk)** 1996; 74(4):11–4 (22 ref.) **(Rus)**

ULTRASONOGRAPHY

Echocardiographic pattern of acute cor pulmonale. Jardin F, et al. **Chest** 1997 Jan;111(1):209–17 (33 ref.)

Hemodynamic estimation of chronic cor pulmonale by Doppler echocardiography. Clinical value and comparison with other noninvasive imaging techniques. Zompatori M, et al. **Rays** 1997 Jan–Mar;22(1):73–93 (50 ref.) **(Eng, Ita)**

PULMONARY INCOMPETENCE see **PULMONARY VALVE INSUFFICIENCY**

PULMONARY MACROPHAGES see **MACROPHAGES, ALVEOLAR**

PULMONARY MEDICINE see **PULMONARY DISEASE (SPECIALTY)**

PULMONARY NEOPLASMS see **LUNG NEOPLASMS**

PULMONARY NODULE, SOLITARY see **COIN LESION, PULMONARY**

PULMONARY REGURGITATION see **PULMONARY VALVE INSUFFICIENCY**

PULMONARY SARCOIDOSIS see **SARCOIDOSIS, PULMONARY**

PULMONARY SEQUESTRATION see **BRONCHOPULMONARY SEQUESTRATION**

PULMONARY STENOSIS see **PULMONARY VALVE STENOSIS**

PULMONARY STRETCH RECEPTORS

PHYSIOLOGY

Sensory mechanisms. Widdicombe J. **Pulm Pharmacol** 1996 Oct–Dec;9(5–6):383–7 (77 ref.)

PULMONARY SURFACTANTS

Synthetic or natural surfactants. Halliday HL. **Acta Paediatr** 1997 Mar;86(3):233–7 (55 ref.)

Free oxygen radicals and surfactant. Bracci R. **Biol Neonate** 1997;71 Suppl 1:23–7 (35 ref.)

[Recent advances in molecular biology with respect to pulmonary surfactant apoproteins] Kuroki Y, et al. **Nippon Rinsho** 1996 Feb;54(2):334–40 (30 ref.) (Eng. Abstr.) **(Jpn)**

[Pulmonary surfactant] Javorka K. **Cesk Fysiol** 1996 Dec; 45(4):179–89 (74 ref.) (Eng. Abstr.) **(Slo)**

ADMINISTRATION & DOSAGE

Surfactant replacement therapy for adult respiratory distress syndrome in children. Evans DA, et al. **Pediatr Pulmonol** 1996 May;21(5):328–36 (100 ref.)

ADVERSE EFFECTS

Circulatory effects of surfactant therapy. Moen A. **Biol Neonate** 1997;71 Suppl 1:18–22 (30 ref.)

ANALYSIS

Current status of amniotic fluid tests of fetal maturity. Field NT, et al. **Clin Obstet Gynecol** 1997 Jun;40(2):366–86 (51 ref.)

NK-lysin, structure and function of a novel effector molecule of porcine T and NK cells. Andersson M, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):123–6 (11 ref.)

BIOSYNTHESIS

Cytokines and production of surfactant components. Bry K, et al. **Semin Perinatol** 1996 Jun;20(3):194–205 (137 ref.)

[Humoral and metabolic regulation of pulmonary surfactant production] Serebrovskaia IA, et al. **Fiziol Cheloveka** 1997 Jul–Aug;23(4):83–9 (88 ref.) **(Rus)**

CHEMISTRY

Synthetic protein analogues in artificial surfactants [see comments] Johansson J, et al. **Acta Paediatr** 1996 Jun; 85(6):642–6 (28 ref.) Comment in: Acta Paediatr 1996 Jun;85(6):641.

Protein analogues in artificial surfactants. Johansson J. **Biol Neonate** 1997;71 Suppl 1:49–52 (12 ref.)

The structure and function of surfactant protein-A. McCormack F. **Chest** 1997 Jun;111(6 Suppl):114S–119S (57 ref.)

Molecular structures and interactions of pulmonary surfactant components. Johansson J, et al. **Eur J Biochem** 1997 Mar 15;244(3):675–93 (206 ref.)

[Molecular aspects of pulmonary surfactant in neonatal respiratory distress syndrome and surfactant replacement therapy] Chida S, et al. **Nippon Rinsho** 1996 Feb; 54(2):346–52 (20 ref.) (Eng. Abstr.) **(Jpn)**

DEFICIENCY

Surfactant protein-B deficiency. Nogee LM. **Chest** 1997 Jun; 111(6 Suppl):129S–135S (43 ref.)

DRUG EFFECTS

Toxic oxidant species and their impact on the pulmonary surfactant system. Putman E, et al. **Lung** 1997;175(2):75–103 (156 ref.)

Nitric oxide and lung surfactant. Hallman M, et al. **Semin Perinatol** 1996 Jun;20(3):173–85 (101 ref.)

GENETICS

Transcriptional regulation of the surfactant protein-A gene in fetal lung. Mendelson CR, et al. **Chest** 1997 Jun;111(6 Suppl):96S–104S (32 ref.)

[Proliferation of alveolar epithelial cells and gene expression of surfactant proteins in adult respiratory distress syndrome (ARDS)] Sugahara K. **Nippon Rinsho** 1996 Feb;54(2):341–5 (12 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Inherited surfactant protein-B deficiency. Hamvas A. **Adv Pediatr** 1997;44:369–88 (65 ref.)

Molecular structures and interactions of pulmonary surfactant components. Johansson J, et al. **Eur J Biochem** 1997 Mar 15;244(3):675–93 (206 ref.)

Surfactant protein A and lamellar bodies: a homologous secretory function of peritoneum, synovium, and lung. Dobbie JW. **Perit Dial Int** 1996 Nov–Dec;16(6):574–81 (43 ref.)

PHARMACOLOGY

[Surfactants of the airways. Critical review and personal research] Mira E, et al. **Acta Otorhinolaryngol Ital** 1997 Feb;17(1 Suppl 56):3–16 (77 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

From bubbles to babies: the evolution of surfactant replacement therapy. Enhorning G. **Biol Neonate** 1997;71 Suppl 1:28–31 (12 ref.)

Molecular interactions between nitric oxide and lung surfactant. Hallman M. **Biol Neonate** 1997;71 Suppl 1:44–8 (21 ref.)

Ventilation patterns, surfactant and lung injury. Jonson B. **Biol Neonate** 1997;71 Suppl 1:13–7 (24 ref.)

Pulmonary surfactant dysfunction in congenital diaphragmatic hernia: experimental and clinical findings. Valls-i-Soler A, et al. **Biol Neonate** 1996;69(5):318–26 (62 ref.)

The structure and function of surfactant protein-A. McCormack F. **Chest** 1997 Jun;111(6 Suppl):114S–119S (57 ref.)

Surfactant protein-B deficiency. Nogee LM. **Chest** 1997 Jun; 111(6 Suppl):129S–135S (43 ref.)

Maturation of the cardiopulmonary system. Cottrill CM. **Equine Vet J Suppl** 1993 Apr;(14):26–30 (74 ref.)

The role of pulmonary surfactant in obstructive airways disease. Hohlfeld J, et al. **Eur Respir J** 1997 Feb; 10(2):482–91 (119 ref.)

The pulmonary surfactant system: biochemical and clinical aspects. Creuwels LA, et al. **Lung** 1997;175(1):1–39 (358 ref.)

Role for granulocyte/macrophage colony-stimulating factor in pulmonary surfactant homeostasis. Luisetti M. **Monaldi Arch Chest Dis** 1997 Apr;52(2):176–7 (5 ref.)

Granulysin, a new human cytolytic granule-associated protein with possible involvement in cell-mediated cytotoxicity. Peña SV, et al. **Semin Immunol** 1997 Apr; 9(2):117–25 (50 ref.)

[The exogenous surfactant and its effect on the respiratory distress syndrome (RDS)] Brabec R, et al. **Cesk Fysiol** 1996

Sep;45(3):139–45 (40 ref.) (Eng. Abstr.) **(Cze)**
[Composition, secretion and function of pulmonary surfactant] Helewski K, et al. **Pneumonol Alergol Pol** 1996; 64(7–8):527–31 (30 ref.) **(Pol)**

THERAPEUTIC USE

Surfactant therapy. Clinical implications [editorial; comment] Zetterström R. **Acta Paediatr** 1996 Jun;85(6):641 (2 ref.) Comment on: Acta Paediatr 1996 Jun;85(6):642–6. Comment on: Acta Paediatr 1996 Jun;85(6):713–8. Comment on: Acta Paediatr 1996 Jun;85(6):719–23.
From bubbles to babies: the evolution of surfactant replacement therapy. Enhorning G. **Biol Neonate** 1997;71 Suppl 1:28–31 (12 ref.)
Clinical aspects of nitric oxide and surfactant replacement. Frostell CG. **Biol Neonate** 1997;71 Suppl 1:39–43 (37 ref.)
Clinical trials of surfactant replacement in Europe. Halliday HL. **Biol Neonate** 1997;71 Suppl 1:8–12 (31 ref.)
Surfactant therapy in the USA: trials and current routines. Soll RF. **Biol Neonate** 1997;71 Suppl 1:1–7 (39 ref.)
Resuscitation strategy and surfactant therapy. Werner O, et al. **Biol Neonate** 1997;71 Suppl 1:32–4 (10 ref.)
Controversies: synthetic or natural surfactant. The case for natural surfactant. Halliday HL. **J Perinat Med** 1996; 24(5):417–26 (54 ref.)
Controversies: synthetic or natural surfactant treatment for respiratory distress syndrome? The case for synthetic surfactant. Whitelaw A. **J Perinat Med** 1996;24(5):427–35 (17 ref.)
Surfactant replacement therapy. Kresch MJ, et al. **Thorax** 1996 Nov;51(11):1137–54 (213 ref.)
Exogenous surfactant therapy in non-respiratory distress syndrome. Greenough A. **Turk J Pediatr** 1996 Jan–Mar; 38(1):45–50 (13 ref.)
Surfactant and respiratory distress syndrome. Milner AD. **Turk J Pediatr** 1996 Jan–Mar;38(1):37–43 (27 ref.)
[The exogenous surfactant and its effect on the respiratory distress syndrome (RDS)] Brabec R, et al. **Cesk Fysiol** 1996 Sep;45(3):139–45 (40 ref.) (Eng. Abstr.) **(Cze)**
[Molecular aspects of pulmonary surfactant in neonatal respiratory distress syndrome and surfactant replacement therapy] Chida S, et al. **Nippon Rinsho** 1996 Feb; 54(2):346–52 (20 ref.) (Eng. Abstr.) **(Jpn)**

PULMONARY VALVE

Primary sarcoma of pulmonary artery and valve: multimodality treatment by chemotherapy and homograft replacement. Zerkowski HR, et al.
J Thorac Cardiovasc Surg 1996 Oct;112(4):1122–4 (12 ref.)
[Pulmonary valve vegetation] Minagawa T, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):441–3 (22 ref.) **(Jpn)**

ABNORMALITIES

Tetralogy of Fallot, absent pulmonary valve and coarctation of the aorta [letter; comment] Momma K. **Int J Cardiol** 1996 Jun;54(3):287 (5 ref.) Comment on: Int J Cardiol 1995 Dec;52(3):203–6.
[Pulmonary regurgitation, pulmonary valve absence] Matsuda H, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (13):321–2 (9 ref.) **(Jpn)**

PATHOLOGY

Blood cyst of the pulmonary valve in an adult: report of a case and review of the literature. Minato H, et al.
Hum Pathol 1997 Feb;28(2):252–5 (21 ref.)

SURGERY

Successful tricuspid valve replacement and pulmonary valvulotomy for carcinoid heart disease. Defraigne JO, et al. **Acta Chir Belg** 1996 Jul–Aug;96(4):170–6 (46 ref.)

TRANSPLANTATION

Anatomic and physiologic bases for the Ross procedure. Gonzalez-Lavin L, et al. **J Heart Valve Dis** 1996 Jul; 5(4):383–90; discussion 401–3 (87 ref.)
Aortic valve replacement with homograft and autograft. Doty DB. **Semin Thorac Cardiovasc Surg** 1996 Jul; 8(3):249–58 (27 ref.)
Clinical aspects of the Ross procedure: indications and contraindications. Oury JH.
Semin Thorac Cardiovasc Surg 1996 Oct;8(4):328–35 (25 ref.)

PULMONARY VALVE ATRESIA see **PULMONARY ATRESIA**

PULMONARY VALVE INCOMPETENCE see **PULMONARY VALVE INSUFFICIENCY**

PULMONARY VALVE INSUFFICIENCY

[Pulmonary valve disease] Awano K.
Ryoikibetsu Shokogun Shirizu 1996;(13):438–40 (15 ref.) **(Jpn)**
[Pulmonary regurgitation, pulmonary valve absence] Matsuda H, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (13):321–2 (9 ref.) **(Jpn)**

ETIOLOGY

[Clinical, echocardiographic and Doppler outcome in ischemic right ventricular dysfunction associated with inferior wall infarction] Logeart D, et al.
Arch Mal Coeur Vaiss 1997 Mar;90(3):363–9 (22 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

[Pulmonary valve replacement in children] Saro-Servando E, et al. **Ann Chir** 1996;50(8):703–6 (27 ref.) (Eng. Abstr.) **(Fre)**

PULMONARY VALVE STENOSIS

Cardio-facio-cutaneous (CFC) syndrome--a distinct entity? Report of three patients demonstrating the diagnostic difficulties in delineation of CFC syndrome. Wieczorek D, et al. **Clin Genet** 1997 Jul;52(1):37–46 (57 ref.)
[Pulmonary valve disease] Awano K.
Ryoikibetsu Shokogun Shirizu 1996;(13):438–40 (15 ref.) **(Jpn)**
[Pulmonary artery branch stenosis] Fukabori T, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):317–20 (21 ref.) **(Jpn)**
[Isolated pulmonary stenosis] Matsuda H, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):91–3 (14 ref.) **(Jpn)**

COMPLICATIONS

Pulmonary valve stenosis in a patient with ataxia telangiectasia [letter] Ruggieri M, et al. **Eur Heart J** 1996 Jun;17(6):968 (5 ref.)

DIAGNOSIS

[Aortico-left ventricular tunnel associated with pulmonary valve stenosis] Martín Jiménez J, et al. **Rev Esp Cardiol** 1996 Dec;49(12):921–4 (9 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

[A case of congenital tricuspid regurgitation associated with atrial septal defect and peripheral pulmonary stenosis] Tanji M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Dec; 44(12):2146–50 (16 ref.) (Eng. Abstr.) **(Jpn)**

PULMONARY VEINS

[Arteriovenous lung fistula as a pulmonary complication of biliary cirrhosis] Kramann B, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996 Nov;165(5):502–4 (17 ref.) **(Ger)**
[Communication between intercostal artery and pulmonary vein--report of a case] Oura S, et al.
Nippon Kyobu Geka Gakkai Zasshi 1996 May;44(5):691–6 (32 ref.) (Eng. Abstr.) **(Jpn)**
[Prophylaxis of venous thromboembolic disease. SEPAR's Pulmonary Thromboembolism Group] Ruiz Manzano J, et al. **Arch Bronconeumol** 1996 Aug–Sep;32(7):348–56 (60 ref.) **(Spa)**

ABNORMALITIES

Intraatrial baffle repair of isolated ventricular inversion with left atrial isomerism. McElhinney DB, et al.
Ann Thorac Surg 1996 Nov;62(5):1529–32 (12 ref.)
Pulmonary arteriovenous malformations: diagnosis and transcatheter embolotherapy. White RI Jr, et al.
J Vasc Interv Radiol 1996 Nov–Dec;7(6):787–804 (56 ref.)
Progression of pulmonary arteriovenous malformation during pregnancy: case report and review of the literature. Esplin MS, et al. **Obstet Gynecol Surv** 1997 Apr;52(4):248–53 (22 ref.)
Rare variant of total anomalous pulmonary venous connection: intrapulmonary drainage of one lung by the other--a case report and review of the literature. Chung JH, et al. **Pediatr Pathol Lab Med** 1997 Jan–Feb; 17(1):133–40 (15 ref.)
Diffuse pulmonary arteriovenous malformations (angiodysplasia) with unusual histologic features: case report and review of the literature. Shapiro JL, et al.
Pediatr Pulmonol 1996 Apr;21(4):255–61 (26 ref.)
[Techniques of correction of partial right abnormal pulmonary venous return associated with atrial septal defect] Dervanian P, et al. **Arch Mal Coeur Vaiss** 1996 Jul;89(7):857–63 (29 ref.) (Eng. Abstr.) **(Fre)**
[Partial anomalous pulmonary venous return (connection)] Miyake T, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (13):330–3 (22 ref.) **(Jpn)**
[Meandering pulmonary veins] Saitoh H, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):305–7 (20 ref.) **(Jpn)**
[Pulmonary arteriovenous fistula] Yamashita M, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):311–3 (14 ref.) **(Jpn)**
[Pulmonary vein stenosis, common pulmonary vein atresia] Yokota M. **Ryoikibetsu Shokogun Shirizu** 1996;(13):301–4 (9 ref.) **(Jpn)**
[Total anomalous pulmonary venous return] Yokoyama T.
Ryoikibetsu Shokogun Shirizu 1996;(13):215–6 (3 ref.) **(Jpn)**

ANATOMY & HISTOLOGY

Pericardial reflection around the venous aspect of the heart. Chaffanjon P, et al. **Surg Radiol Anat** 1997;19(1):17–21 (19 ref.)

PHYSIOLOGY

[Flow in pulmonary veins] Veselka J. **Cesk Fysiol** 1996 Sep; 45(3):154–7 (27 ref.) (Eng. Abstr.) **(Cze)**

PULMONARY VENO-OCCLUSIVE DISEASE

CONGENITAL

[Pulmonary vein stenosis, common pulmonary vein atresia] Yokota M. **Ryoikibetsu Shokogun Shirizu** 1996;(13):301–4 (9 ref.) **(Jpn)**

DIAGNOSIS

Pulmonary veno-occlusive disease. Kothari SS, et al.
Indian Pediatr 1996 May;33(5):406–9 (10 ref.)

ETIOLOGY

Malignancy-associated pulmonary veno-occlusive disease: report of a case following autologous bone marrow transplantation and review. Salzman D, et al.
Bone Marrow Transplant 1996 Oct;18(4):755–60 (40 ref.)

PATHOLOGY

[Pulmonary veno-occlusive disease] Takahashi T, et al.
Ryoikibetsu Shokogun Shirizu 1996;(15):601–5 (14 ref.) **(Jpn)**

PULMONARY VENTILATION

Recent advances in airway management in anesthesiology: an update for otolaryngologists. American Society of Anesthesiologists. Gonzalez RM, et al.
Am J Otolaryngol 1996 May–Jun;17(3):145–60 (74 ref.)
Magnetic resonance imaging of the cardiovascular system and airway. Berlin SC. **Pediatr Clin North Am** 1997 Jun; 44(3):659–79 (71 ref.)
The efficacy of surgical modifications of the upper airway in adults with obstructive sleep apnea syndrome. Sher AE, et al. **Sleep** 1996 Feb;19(2):156–77 (97 ref.)
[Regional evaluation of ventilation by RI] Kawakami K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:42–4 (3 ref.) **(Jpn)**
[Ventilatory response to hypoxia and hypercapnia] Saito H, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:65–9 (12 ref.) **(Jpn)**

PHYSIOLOGY

Role of exercise ventilation in the limitation of functional capacity in patients with congestive heart failure. Metra M, et al. **Basic Res Cardiol** 1996;91 Suppl 1:31–6 (66 ref.)
Respiratory muscles and ventilatory failure. Vassilakopoulos T, et al. **Monaldi Arch Chest Dis** 1996 Dec;51(6):489–98 (42 ref.)
Effect of ventilatory drive on upper airway patency in humans during NREM sleep. Badr MS. **Respir Physiol** 1996 Jan;103(1):1–10 (33 ref.)
Properties of tissues surrounding the upper airway. Schwab RJ. **Sleep** 1996 Dec;19(10 Suppl):S170–4 (25 ref.)
[Liquid ventilation: a new mode of ventilation in neonatology?] Hamon I. **Arch Pediatr** 1997 Feb;4(2):176–80 (20 ref.) (Eng. Abstr.) **(Fre)**
[Pneumologic diagnosis with model aerosols--1: Intrapulmonary morphometry. Principles and initial results of clinical research] Kohlhäufl M, et al. **Pneumologie** 1997 Jan;51(1):40–6 (41 ref.) **(Ger)**

PULMONOLOGY see **PULMONARY DISEASE (SPECIALTY)**

PULP CANAL see **DENTAL PULP CAVITY**

PULP CHAMBER see **DENTAL PULP CAVITY**

PULP GANGRENE see **DENTAL PULP NECROSIS**

PULP NECROSIS see **DENTAL PULP NECROSIS**

PULPITIS

COMPLICATIONS

Correlation of clinical pain symptoms with histopathological changes of the dental pulp: a review. Ngassapa D.
East Afr Med J 1996 Dec;73(12):779–81 (28 ref.)

PATHOLOGY

Correlation of clinical pain symptoms with histopathological changes of the dental pulp: a review. Ngassapa D.
East Afr Med J 1996 Dec;73(12):779–81 (28 ref.)

PULSATILE FLOW

Intermittent antegrade/selective cerebral perfusion during

PULSATILE FLOW

circulatory arrest for repair of the aortic arch. Maas C, et al. **Perfusion** 1997 Mar;12(2):127–32 (12 ref.)
Doppler ultrasound simulation model for pulsatile flow with nonaxial components. Oung H, et al. **Ultrason Imaging** 1996 Jul;18(3):157–72 (31 ref.)

DRUG EFFECTS

Antihypertensive therapy and wave reflections. Safar ME, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Jan; 54(1):71–6 (27 ref.)

PHYSIOLOGY

Representativeness of peripheral blood pressure values: the pulsatile component of blood pressure in hypertension. Safar M. **Z Kardiol** 1996;85 Suppl 3:51–9 (26 ref.)

PULSE

Obtaining arterial access in trauma patients. Sclafani SJ. **J Vasc Interv Radiol** 1997 Jul–Aug;8(4):593–4 (0 ref.)
[Cardiac tamponade with the absence of a paradoxical pulse. The practical utility of echocardiography] Zamorano J, et al. **Rev Esp Cardiol** 1995 Jun;48(6):443–5 (6 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Pulse wave analysis. O'Rourke MF, et al. **J Hypertens Suppl** 1996 Dec;14(5):S147–57 (60 ref.)
[Analysis of the pulse harmonic frequency spectrum. A new method of pulse study of traditional Chinese medicine] Zhang XC, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Dec; 15(12):743–5 (13 ref.) **(Chi)**
[Evaluation of the degree of atherosclerosis by pulse wave velocity (PWV)] Hasegawa M. **Nippon Rinsho** 1997 Mar; 55 Suppl 1:688–90 (8 ref.) **(Jpn)**

PULSE OXIMETRY see **OXIMETRY**

PULSED DYE LASER LITHOTRIPSY see **LITHOTRIPSY, LASER**

PULSELESS DISEASE see **TAKAYASU'S ARTERITIS**

PUMPING, INTRA-AORTIC BALLOON see **INTRA-AORTIC BALLOON PUMPING**

PUMPS, HEART-ASSIST see **HEART-ASSIST DEVICES**

PUMPS, INFUSION see **INFUSION PUMPS**

PUNCTURE BIOPSY see **BIOPSY, NEEDLE**

PUNCTURES

see related
PARACENTESIS

ADVERSE EFFECTS

[Forensic medical implications of vascular punctures and catheterization and radiologic procedures with diagnostic or therapeutic purpose] Natali J, et al. **J Mal Vasc** 1996 Nov;21(4):238–47 (9 ref.) (Eng. Abstr.) **(Fre)**

INSTRUMENTATION

Synovial fluid cell analysis. Dougados M. **Baillieres Clin Rheumatol** 1996 Aug;10(3):519–34 (29 ref.)
Percutaneous needle biopsy and synovial histology. Saaibi DL, et al. **Baillieres Clin Rheumatol** 1996 Aug;10(3):535–54 (118 ref.)
[CT-guided puncture] Nöldge G, et al. **Radiologe** 1996 Sep; 36(9):683–91 (34 ref.) (Eng. Abstr.) **(Ger)**
[Ultrasound guided puncture of the portal vein in transjugular intrahepatic portasystemic stent shunt (TIPSS)] Roeren T, et al. **Radiologe** 1996 Sep;36(9):677–82 (22 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Procedures in the evaluation of the febrile pediatric patient [see comments] Sanchez JL, et al. **Pediatr Ann** 1996 Dec; 25(12):686–92 (19 ref.) Comment in: Pediatr Ann 1997 May;26(5):278.
Sonographic evaluation of ovarian masses and its therapeutical implications [editorial] Osmers R. **Ultrasound Obstet Gynecol** 1996 Oct;8(4):217–22 (60 ref.)

PUNISHMENT

Reducing corporal punishment of children: a call for a regional effort. Levav I, et al. **Bull Pan Am Health Organ** 1996 Mar;30(1):70–9 (54 ref.)
Crossing the line from physical discipline to child abuse: how much is too much? Whipple EE, et al. **Child Abuse Negl** 1997 May;21(5):431–44 (75 ref.)
Disciplining children with disabilities under the Individuals with Disabilities Education Act. Ramsingh OM. **J Contemp Health Law Policy** 1995 Fall;12(1):155–81 (211 ref.)
A review of the outcomes of parental use of nonabusive or customary physical punishment [see comments] Larzelere RE. **Pediatrics** 1996 Oct;98(4 Pt 2):824–8 (37 ref.) Comment in: Pediatrics 1996 Oct;98(4 Pt 2):828–31.

PUPIL

see related
MIOTICS
REFLEX, PUPILLARY

PHYSIOLOGY

Eye-centering: the basic ocular motor reflex--literature review, observations and hypotheses. Jampel RS, et al. **Curr Eye Res** 1996 Aug;15(8):890–8 (41 ref.)
Graether pupil expander for managing the small pupil during surgery. Graether JM. **J Cataract Refract Surg** 1996 Jun; 22(5):530–5 (19 ref.)

PUPILLARY FUNCTIONS, ABNORMAL

DIAGNOSIS

Afferent pupillary defects and the swinging flashlight test. What you thought you already knew. Modica PA. **Optom Clin** 1996;5(3–4):1–15 (24 ref.)

ETIOLOGY

[Pupillary abnormalities in a patient with clinically diagnosed corticobasal degeneration] Hirabayashi H, et al. **Rinsho Shinkeigaku** 1997 Apr;37(4):344–6 (10 ref.) (Eng. Abstr.) **(Jpn)**

PUPPET CHILDREN see **ANGELMAN SYNDROME**

PUPPETS see **PLAY AND PLAYTHINGS**

PURE RED-CELL APLASIA see **RED-CELL APLASIA, PURE**

PURGATIVES see **CATHARTICS**

PURINE-NUCLEOSIDE PHOSPHORYLASE

[Purine nucleoside phosphorylase (PNP)] Sakiyama T. **Nippon Rinsho** 1996 Dec;54(12):3220–5 (13 ref.) (Eng. Abstr.) **(Jpn)**

DEFICIENCY

[Purine nucleoside phosphorylase (PNP) deficiency] Sakiyama T. **Nippon Rinsho** 1996 Dec;54(12):3328–32 (10 ref.) (Eng. Abstr.) **(Jpn)**

PURINE NUCLEOSIDES

CHEMISTRY

Adverse and beneficial immunological effects of purine nucleoside analogues. Dighiero G. **Hematol Cell Ther** 1996 Dec;38 Suppl 2:S75–81 (98 ref.)

METABOLISM

Ectonucleotidases, purine nucleoside transporter, and function of the bile canalicular plasma membrane of the hepatocyte. Che M, et al. **FASEB J** 1997 Feb;11(2):101–8 (86 ref.)

THERAPEUTIC USE

Purine analogs in marginal-zone lymphomas. Horning SJ. **Ann Oncol** 1996;7 Suppl 6:S21–6 (34 ref.)
Purine analogs in chronic lymphocytic leukemia and Waldenström's macroglobulinemia. O'Brien S, et al. **Ann Oncol** 1996;7 Suppl 6:S27–33 (53 ref.)
Purine nucleoside therapy of low-grade follicular lymphoma. Piro LD. **Ann Oncol** 1996;7 Suppl 6:S41–7 (50 ref.)

PURINE NUCLEOTIDES

CHEMISTRY

Sheared purine x purine pairing in biology. Chou SH, et al. **J Mol Biol** 1997 Apr 18;267(5):1055–67 (75 ref.)

METABOLISM

[Metabolic disorder of purine nucleotide in patients with renal disease] Hosoya T, et al. **Nippon Rinsho** 1996 Dec; 54(12):3354–9 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Metabolism of purine nucleotides and the production of uric acid] Yamaoka T, et al. **Nippon Rinsho** 1996 Dec; 54(12):3188–94 (11 ref.) (Eng. Abstr.) **(Jpn)**

PURINE-PYRIMIDINE METABOLISM, INBORN ERRORS

Inborn errors of pyrimidine degradation: clinical, biochemical and molecular aspects. van Gennip AH, et al. **J Inherit Metab Dis** 1997 Jun;20(2):203–13 (46 ref.)
[Abnormalities in nucleic acid metabolism and gout] Kamatani N. **Nippon Naika Gakkai Zasshi** 1997 Mar 10; 86(3):374–9 (8 ref.) **(Jpn)**
[PRPP synthetase superactivity] Fujimori S. **Nippon Rinsho** 1996 Dec;54(12):3309–14 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Renal hypouricemia] Hisatome I, et al. **Nippon Rinsho** 1996 Dec;54(12):3337–42 (21 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Inherited defects of purine and pyrimidine metabolism: laboratory methods for diagnosis. Duran M, et al. **J Inherit Metab Dis** 1997 Jun;20(2):227–36 (23 ref.)
When to investigate for purine and pyrimidine disorders. Introduction and review of clinical and laboratory indications. Simmonds HA, et al. **J Inherit Metab Dis** 1997 Jun;20(2):214–26 (29 ref.)
[Inherited disorders of uric acid metabolism--classification, enzymatic- and DNA-diagnosis] Iwahana H, et al. **Nippon Rinsho** 1996 Dec;54(12):3303–8 (17 ref.) (Eng. Abstr.) **(Jpn)**
[The genetic diagnosis of hypoxanthine-guanine phosphoribosyltransferase (HGPRT) deficiency. A study of 12 cases] Torres Jiménez R, et al. **Med Clin (Barc)** 1997 Mar 8;108(9):344–8 (24 ref.) (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

Inborn errors of the purine nucleotide cycle: adenylosuccinase deficiency. Van den Berghe G, et al. **J Inherit Metab Dis** 1997 Jun;20(2):193–202 (34 ref.)

GENETICS

The recognition of Lesch-Nyhan syndrome as an inborn error of purine metabolism. Nyhan WL. **J Inherit Metab Dis** 1997 Jun;20(2):171–8 (16 ref.)
[Xanthine oxidase deficiency (hereditary xanthinuria), molybdenum cofactor deficiency] Sumi S, et al. **Nippon Rinsho** 1996 Dec;54(12):3333–6 (11 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

[Gene therapy for genetic disorders of purine metabolism] Hidaka Y. **Nippon Rinsho** 1996 Dec;54(12):3374–8 (18 ref.) (Eng. Abstr.) **(Jpn)**

PURINE RECEPTORS see **RECEPTORS, PURINERGIC**

PURINERGIC P1 RECEPTORS see **RECEPTORS, PURINERGIC P1**

PURINERGIC P2 RECEPTORS see **RECEPTORS, PURINERGIC P2**

PURINERGIC RECEPTORS see **RECEPTORS, PURINERGIC**

PURINES

Purines as targets for DNA photodamage. Davies RJ. **Biochem Soc Trans** 1997 Feb;25(1):323–6 (25 ref.)
[Pyrimidine/purine-biased sequences: potential to form DNA triplex and its physiological effects] Kato M. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(15 Suppl):2259–66 (37 ref.) **(Jpn)**

BIOSYNTHESIS

Enzymes of nucleotide synthesis. Smith JL. **Curr Opin Struct Biol** 1995 Dec;5(6):752–7 (37 ref.)

CHEMICAL SYNTHESIS

[Highlights from 43 years of chemistry of naturally occurring nitrogen-containing heterocycles. (2). Syntheses and reactions of purines and of their nucleosides (published erratum appears in Yakugaku Zasshi 1996 Dec;116(12):961)] Fujii T, et al. **Yakugaku Zasshi** 1996 May;116(5):355–73 (89 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Peroxisomal purine metabolism. Yeldandi AV, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:165–75 (25 ref.)
A purinergic hypothesis for immunomodulation. Di Virgilio F, et al. **Ital J Biochem** 1996 Dec;45(4):195–203 (42 ref.)
When to investigate for purine and pyrimidine disorders. Introduction and review of clinical and laboratory indications. Simmonds HA, et al. **J Inherit Metab Dis** 1997 Jun;20(2):214–26 (29 ref.)

THERAPEUTIC USE

Mantle-cell lymphoma: classification and therapeutic implications. Fisher RI. **Ann Oncol** 1996;7 Suppl 6:S35–9 (38 ref.)
Perspectives on purine analogues. Cheson BD. **Hematol Cell Ther** 1996 Dec;38 Suppl 2:S109–16 (104 ref.)

PURINOCEPTORS see **RECEPTORS, PURINERGIC**

PURKINJE CELLS

CYTOLOGY

Localized calcium signalling and neuronal integration in

cerebellar Purkinje neurones. Eilers J, et al. **Cell Calcium** 1996 Aug;20(2):215–26 (65 ref.)

The tetraploidy of Purkinje cells in the cerebellum in reference to the problem of polyploidy. Kowalska E, et al. **Folia Histochem Cytobiol** 1997;35(2):127 (12 ref.)

METABOLISM

Intracellular Ca2+ release by InsP3 in cerebellar Purkinje neurones. Ogden D, et al. **Acta Physiol Scand** 1996 Jul; 157(3):381–94 (40 ref.)

PHYSIOLOGY

Dendritic signal integration. Eilers J, et al. **Curr Opin Neurobiol** 1997 Jun;7(3):385–90 (55 ref.)

Aspects of cerebellar function in relation to locomotor movements. Armstrong DM, et al. **Prog Brain Res** 1997; 114:401–21 (84 ref.)

A new functional role for cerebellar long-term depression. De Schutter E. **Prog Brain Res** 1997;114:529–42 (107 ref.)

What features of visually guided arm movements are encoded in the simple spike discharge of cerebellar Purkinje cells? Ebner TJ, et al. **Prog Brain Res** 1997;114:431–47 (80 ref.)

Reciprocal trophic interactions between climbing fibres and Purkinje cells in the rat cerebellum. Strata P, et al. **Prog Brain Res** 1997;114:263–82 (91 ref.)

Control of the three-dimensional dynamic characteristics of the angular vestibulo-ocular reflex by the nodulus and uvula. Wearne S, et al. **Prog Brain Res** 1997;114:321–34 (104 ref.)

Reciprocal trophic interactions in the adult climbing fibre-Purkinje cell system. Rossi F, et al. **Prog Neurobiol** 1995 Nov-Dec;47(4–5):341–69 (188 ref.)

Synapse elimination in the central nervous system: functional significance and cellular mechanisms. Lohof AM, et al. **Rev Neurosci** 1996 Apr-Jun;7(2):85–101 (138 ref.)

PURPLE MEMBRANE

see related
BACTERIORHODOPSIN

PURPURA

ETIOLOGY

Posttransfusion purpura: two unusual cases and a literature review. McCrae KR, et al. **Am J Hematol** 1996 Jul; 52(3):205–11 (45 ref.)

[Purpura as the leading symptom in internal medicine] Steins M, et al. **Internist (Berl)** 1997 Jun;38(6):634–42 (6 ref.) **(Ger)**

[A case with petechiae due to human parvovirus B19] Shimada Y, et al. **Kansenshogaku Zasshi** 1996 Sep; 70(9):976–80 (21 ref.) (Eng. Abstr.) **(Jpn)**

PURPURA FULMINANS see **PURPURA, SCHOENLEIN-HENOCH**

PURPURA HEMORRHAGICA see **PURPURA, SCHOENLEIN-HENOCH**

PURPURA, NONTHROMBOCYTOPENIC see **PURPURA, SCHOENLEIN-HENOCH**

PURPURA, SCHOENLEIN-HENOCH

What is Schönlein-Henoch purpura, and why should we care? [editorial; comment] Piette WW. **Arch Dermatol** 1997 Apr;133(4):515–8 (59 ref.) Comment on: Arch Dermatol 1997 Apr;133(4):438–42.

COMPLICATIONS

Pulmonary hemorrhage: an often fatal complication of Henoch-Schoenlein purpura. Paller AS, et al. **Pediatr Dermatol** 1997 Jul-Aug;14(4):299–302 (10 ref.)

[Acute pancreatitis in rheumatoid purpura. Apropos of 2 cases] Lévy-Weil FE, et al. **Rev Med Interne** 1997; 18(1):54–8 (14 ref.) (Eng. Abstr.) **(Fre)**

[The role of endoscopy in the diagnosis of Schönlein-Henoch purpura] Novák J. **Orv Hetil** 1997 Aug 31;138(35):2169–73 (38 ref.) (Eng. Abstr.) **(Hun)**

[Acute scrotum: unusual presentation of Schönlein-Henoch purpura] Suarez González JA, et al. **Actas Urol Esp** 1997 Jan;21(1):78–81 (22 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Henoch-Schönlein purpura: a diagnosis not to be forgotten. Trujillo H, et al. **J Fam Pract** 1996 Nov;43(5):495–8 (17 ref.)

[The first manifestations of Schönlein-Henoch purpura in a 74-year-old female patient with hyperthyroidism] Kamm M, et al. **Dtsch Med Wochenschr** 1997 Jan 17;122(3):54–8 (19 ref.) (Eng. Abstr.) **(Ger)**

[Cutaneous reactions in Crohn disease. Vasculitis in various skin segments] Schlehaider UK, et al. **Hautarzt** 1997 May; 48(5):328–31 (17 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Origin and structure of pathogenic IgA in IgA nephropathy. Allen A, et al. **Biochem Soc Trans** 1997 May;25(2):486–90 (34 ref.)

PATHOLOGY

[Rheumatoid purpura (or Schoenlein-Henoch syndrome) and pregnancy. Review of the literature and a case report] Ekoukou D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(2):197–201 (17 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Henoch-Schönlein purpura: when and how to treat. Szer IS. **J Rheumatol** 1996 Sep;23(9):1661–5 (23 ref.)

PURPURA, THROMBOCYTOPENIC

COMPLICATIONS

Rapid progression of acquired amegakaryocytic thrombocytopenia to aplastic anemia. King JA, et al. **South Med J** 1997 Jan;90(1):91–4 (18 ref.)

DRUG THERAPY

Therapy for adults with refractory chronic immune thrombocytopenic purpura. McMillan R. **Ann Intern Med** 1997 Feb 15;126(4):307–14 (98 ref.)

ETIOLOGY

Post transfusion purpura in a thalassemic child. Kashyap R, et al. **Indian Pediatr** 1997 Mar;34(3):246–7 (6 ref.)

PURPURA, THROMBOCYTOPENIC, AUTOIMMUNE see **PURPURA, THROMBOCYTOPENIC, IDIOPATHIC**

PURPURA, THROMBOCYTOPENIC, IDIOPATHIC

Autoimmune (idiopathic) thrombocytopenic purpura [see comments] Karpatkin S. **Lancet** 1997 May 24; 349(9064):1531–6 (48 ref.) Comment in: Lancet 1997 Aug 2;350(9074):368.

[Pathophysiology and treatment of idiopathic thrombocytopenic purpura] Dan K. **Nippon Ika Daigaku Zasshi** 1996 Oct;63(5):319–26 (31 ref.) **(Jpn)**

[Essential thrombocythemia, thrombocytopenia] Nomura S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):125–8 (15 ref.) **(Jpn)**

COMPLICATIONS

Evans' syndrome associated with Graves' disease. Yashiro M, et al. **Intern Med** 1996 Dec;35(12):987–90 (13 ref.)

Autoimmune thrombocytopenic purpura associated with hyperthyroidism in a single individual. Aggarwal A, et al. **South Med J** 1997 Sep;90(9):933–6 (43 ref.)

[A case of chronic subdural hematoma associated with idiopathic thrombocytopenic purpura (ITP)] Miyamoto T, et al. **No Shinkei Geka** 1997 Feb;25(2):157–61 (15 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Diagnosis and treatment of idiopathic thrombocytopenic purpura. American Society of Hematology ITP Practice Guideline Panel. **Am Fam Physician** 1996 Dec; 54(8):2437–47, 2451–2 (30 ref.)

Clinical decisions in idiopathic thrombocytopenic purpura. George JN, et al. **Hosp Pract (Off Ed)** 1997 Sep 15; 32(9):159–60, 163–6, 169–70, passim (9 ref.)

Idiopathic thrombocytopenic purpura in children: recognition and management. Sadowitz D, et al. **Pediatr Emerg Care** 1996 Jun;12(3):222–7 (37 ref.)

[Autoimmune thrombopenic purpura. Clinical practices during diagnosis. A French survey and recommendations. French College of Hemotologists Evaluation Commission] Marie JP, et al. **Presse Med** 1997 Mar 22;26(9):433–8 (18 ref.) (Eng. Abstr.) **(Fre)**

[Autoimmune thrombocytopenia and pregnancy] Anselmi Angeli R, et al. **Minerva Ginecol** 1996 Dec;48(12):557–63 (15 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

[Effective cyclosporine therapy to resistant-Evans syndrome] Tsudo M, et al. **Rinsho Ketsueki** 1996 Nov;37(11):1289–92 (13 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Megakaryocytes and platelets in immune thrombocytopenic purpura. Wang ZY, et al. **Baillieres Clin Haematol** 1997 Feb;10(1):89–107 (80 ref.)

Immunologic aspects in the pathogenesis and treatment of immune thrombocytopenic purpura in children [published erratum appears in Curr Opin Pediatr 1997 Jun;9(3):298] Imbach PA, et al. **Curr Opin Pediatr** 1997 Feb;9(1):35–40 (63 ref.)

[Management of refractory autoimmune thrombocytopenic purpura during pregnancy, Review of the literature and report of three cases] Yáñez Maldonado E, et al. **Ginecol Obstet Mex** 1997 Jun;65:254–7 (13 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Laparoscopic accessory splenectomy for recurrent idiopathic thrombocytopenic purpura. Amaral JF, et al. **Surg Laparosc Endosc** 1997 Aug;7(4):340–4 (15 ref.)

THERAPY

Diagnosis and treatment of idiopathic thrombocytopenic purpura. American Society of Hematology ITP Practice Guideline Panel. **Am Fam Physician** 1996 Dec; 54(8):2437–47, 2451–2 (30 ref.)

Immunologic aspects in the pathogenesis and treatment of immune thrombocytopenic purpura in children [published erratum appears in Curr Opin Pediatr 1997 Jun;9(3):298] Imbach PA, et al. **Curr Opin Pediatr** 1997 Feb;9(1):35–40 (63 ref.)

Clinical decisions in idiopathic thrombocytopenic purpura. George JN, et al. **Hosp Pract (Off Ed)** 1997 Sep 15; 32(9):159–60, 163–6, 169–70, passim (9 ref.)

Idiopathic thrombocytopenic purpura in children: recognition and management. Sadowitz D, et al. **Pediatr Emerg Care** 1996 Jun;12(3):222–7 (37 ref.)

Intravenous immunoglobulin in rheumatic disease. Klassen LW, et al. **Rheum Dis Clin North Am** 1996 Feb;22(1):155–73 (95 ref.)

[Autoimmune thrombopenic purpura. Therapeutic modalities] Macro M, et al. **Presse Med** 1997 Mar 22; 26(9):439–43 (24 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of autoimmune thrombopenic purpura in adults] Godeau B, et al. **Rev Med Interne** 1996;17(8):661–9 (86 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Canine idiopathic thrombocytopenic purpura. Lewis DC, et al. **J Vet Intern Med** 1996 Jul-Aug;10(4):207–18 (178 ref.)

PURPURA, THROMBOPENIC see **PURPURA, THROMBOCYTOPENIC**

PURPURA, THROMBOTIC THROMBOCYTOPENIC

Thrombotic thrombocytopenic purpura: evolution across 15 years. Elkins SL, et al. **J Clin Apheresis** 1996;11(4):173–5 (14 ref.)

BLOOD

Interactions of platelets and endothelial cells with erythrocytes and leukocytes in thrombotic thrombocytopenic purpura. Smith BR, et al. **Semin Hematol** 1997 Apr;34(2):90–7 (79 ref.)

COMPLICATIONS

Disparate prognosis of thrombotic microangiopathy in HIV-infected patients with and without AIDS. Gadallah MF, et al. **Am J Nephrol** 1996;16(5):446–50 (33 ref.)

Thrombotic microangiopathy during pregnancy. McCrae KR, et al. **Semin Hematol** 1997 Apr;34(2):148–58 (99 ref.)

ETIOLOGY

Thrombotic microangiopathy related to infection in an HIV-positive patient [letter] Mayo J, et al. **Eur J Clin Microbiol Infect Dis** 1996 Mar;15(3):254–6 (14 ref.)

Pathogenesis and treatment of thrombotic microangiopathy. Ruggenenti P, et al. **Kidney Int Suppl** 1997 Mar;58:S97–101 (38 ref.)

Cancer- and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Gordon LI, et al. **Semin Hematol** 1997 Apr;34(2):140–7 (80 ref.)

Human immunodeficiency virus infection and thrombotic microangiopathy. Hymes KB, et al. **Semin Hematol** 1997 Apr;34(2):117–25 (80 ref.)

Transplantation-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Schriber JR, et al. **Semin Hematol** 1997 Apr;34(2):126–33 (76 ref.)

[Renal thrombotic microangiopathy] Sakakibara K. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):316–9 (18 ref.) **(Jpn)**

[Nephropathy by food poisoning] Yoshikawa Y, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):560–2 (8 ref.) **(Jpn)**

IMMUNOLOGY

Chronic relapsing thrombotic thrombocytopenic purpura and antiphospholipid antibodies: a report of two cases. Trent K, et al. **Am J Hematol** 1997 Feb;54(2):155–9 (31 ref.)

Thrombotic thrombocytopenic purpura associated with Shiga toxins. Keusch GT, et al. **Semin Hematol** 1997 Apr; 34(2):106–16 (80 ref.)

PHYSIOPATHOLOGY

Haemolytic uraemic syndrome and thrombocytopenic thrombotic purpura [editorial] Zijlstra JG, et al. **Int J Artif Organs** 1997 Apr;20(4):191–4 (18 ref.)

Apoptosis of microvascular endothelial cells in the pathophysiology of thrombotic thrombocytopenic purpura/sporadic hemolytic uremic syndrome. Laurence J, et al. **Semin Hematol** 1997 Apr;34(2):98–105 (34 ref.)

PURPURA, THROMBOTIC THROMBOCYTOPENIC

Studies on the pathophysiology of thrombotic thrombocytopenic purpura. Moake JL. **Semin Hematol** 1997 Apr;34(2):83–9 (70 ref.)
[Pathogenesis of hemolytic uremic syndrome and thrombotic thrombocytopenia purpura] Gruenbaum G, et al. **Harefuah** 1997 May 1;132(9):665–9 (34 ref.) **(Heb)**

THERAPY

Thrombotic thrombocytopenic purpura: a treatable cause of childhood encephalopathy. Lawlor ER, et al. **J Pediatr** 1997 Feb;130(2):313–6 (14 ref.)
Pathogenesis and treatment of thrombotic microangiopathy. Ruggenenti P, et al. **Kidney Int Suppl** 1997 Mar;58:S97–101 (38 ref.)
Management of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Kwaan HC, et al. **Semin Hematol** 1997 Apr;34(2):159–66 (64 ref.)
[Treatment of thrombocytopenic thrombotic purpura] Corte Buelga JR, et al. **Sangre (Barc)** 1997 Feb;42(1):53–61 (85 ref.) **(Spa)**

PURPURA, THROMBOTIC THROMBOPENIC see **PURPURA, THROMBOTIC THROMBOCYTOPENIC**

PURSUIT, SACCADIC see **SACCADES**

PURSUIT, SMOOTH

Periodic vestibulocerebellar ataxia, an autosomal dominant ataxia with defective smooth pursuit, is genetically distinct from other autosomal dominant ataxias. Damji KF, et al. **Arch Neurol** 1996 Apr;53(4):338–44 (42 ref.)

PUSTULANTS see **IRRITANTS**

PUSTULAR DERMATOSIS, SUBCORNEAL see **SKIN DISEASES, VESICULOBULLOUS**

PUSTULAR PSORIASIS OF PALMS AND SOLES see **PSORIASIS**

PUSTULOSIS OF PALMS AND SOLES see **PSORIASIS**

PUSTULOSIS PALMARIS ET PLANTARIS see **PSORIASIS**

PUTAMEN

[Adrenal transplantation and Parkinson's disease] Luquin MR, et al. **Rev Med Univ Navarra** 1994 Oct–Dec; 38(4):174–80 (38 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

[Methanol poisoning with bilateral necrosis of the putamen and additional involvement of the globus pallidus] Penndorf–Wehner F, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Jul;167(1):99–100 (10 ref.) **(Ger)**

PUTRESCINE

METABOLISM

Ethanol and polyamine metabolism: physiologic and pathologic implications: a review. Sessa A, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):318–25 (121 ref.)

PUUMALA VIRUS see **HANTAVIRUS**

PUVA THERAPY

Photochemotherapy for mycosis fungoides: current status. Watson A. **Australas J Dermatol** 1997 Feb;38(1):9–11 (20 ref.)
Sclerodermatous changes of chronic graft–versus–host–disease treated with puva. Woscoff A, et al. **Int J Dermatol** 1996 Sep;35(9):656–8 (26 ref.)
Ultraviolet phototherapy. Farr PM. **J R Coll Physicians Lond** 1997 May–Jun;31(3):250–3 (25 ref.)

ADVERSE EFFECTS

Vitiligo following the resolution of psoriatic plaques during PUVA therapy. Halcin C, et al. **Int J Dermatol** 1997 Jul; 36(7):534–6 (11 ref.)
Therapy with orally administered methoxsalen and ultraviolet A radiation during childhood increases the risk of basal cell carcinoma. The PUVA Follow–up Study. Stern RS, et al. **J Pediatr** 1996 Dec;129(6):915–7 (8 ref.)

PVP–IODINE see **POVIDONE–IODINE**

PX GENES see **GENES, PX**

PYELITIS

DIAGNOSIS

Imaging and radiologic management of upper urinary tract infections. Baumgarten DA, et al. **Urol Clin North Am** 1997 Aug;24(3):545–69 (74 ref.)

PATHOLOGY

[Pyelitis glandularis] Hishiki T, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):252–3 (10 ref.) **(Jpn)**

PYELOCYSTITIS see **PYELITIS**

PYELOGRAPHY see **UROGRAPHY**

PYELONEPHRITIS

see related
KIDNEY FAILURE, CHRONIC

[Atrophic pyelonephritis] Orikasa S, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):229–34 (19 ref.) **(Jpn)**
[Emphysematous pyelonephritis] Yuri T, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):239–41 (19 ref.) **(Jpn)**

COMPLICATIONS

[Tubulointerstitial kidney diseases in urinary tract infection, reflux and obstruction] Krautzig S, et al. **Internist (Berl)** 1996 Nov;37(11):1096–110 (61 ref.) **(Ger)**
[Emphysematous pyelonephritis] Valbuena Alvarez RJ, et al. **Actas Urol Esp** 1997 Feb;21(2):154–7 (11 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

[Mycoplasma hominis. A rare causative agent of acute pyelonephritis] Küchle C, et al. **Dtsch Med Wochenschr** 1997 Apr 25;122(17):542–4 (15 ref.) (Eng. Abstr.) **(Ger)**
[Progress in diagnosis and treatment of kidney diseases. III. Hereditary kidney diseases and others. 4. Chronic pyelonephritis] Yoshida M. **Nippon Naika Gakkai Zasshi** 1996 Oct 10;85(10):1694–8 (4 ref.) **(Jpn)**
[Pyelonephritis] Kaneko S, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):248–51 (9 ref.) **(Jpn)**

DRUG THERAPY

[Progress in diagnosis and treatment of kidney diseases. III. Hereditary kidney diseases and others. 4. Chronic pyelonephritis] Yoshida M. **Nippon Naika Gakkai Zasshi** 1996 Oct 10;85(10):1694–8 (4 ref.) **(Jpn)**

ETIOLOGY

[Obstructive pyelonephritis] Orikasa S, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):272–4 (17 ref.) **(Jpn)**

PATHOLOGY

[Advanced tubercular disease of urogenital tract] Pereira Arias JG, et al. **Arch Esp Urol** 1997 May;50(4):396–9 (11 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Successful conservative management of emphysematous pyelonephritis, bilateral or in a solitary kidney. Angulo JC, et al. **Scand J Urol Nephrol** 1997 Apr;31(2):193–7 (32 ref.)
[The potential pathogenetic therapy of pyelonephritis] Maldannik VG. **Lik Sprava** 1996 Mar–Apr;(3–4):13–8 (40 ref.) **(Rus)**

PYELONEPHRITIS, ACUTE NECROTIZING see **KIDNEY PAPILLARY NECROSIS**

PYELONEPHRITIS, XANTHOGRANULOMATOUS

[Xanthogranulomatous pyelonephritis] Eguchi M, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):235–8 (24 ref.) **(Jpn)**
[Xanthogranulomatous pyelonephritis in renal allograft. Report of a case and review of the literature] Cozar JM, et al. **Actas Urol Esp** 1996 Jul–Aug;20(7):664–8 (14 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

A middle–aged woman with back and flank pain. Cruz DN, et al. **Hosp Pract (Off Ed)** 1996 Sep 15;31(9):193–4, 199–200, 203, passim (12 ref.)
Renocolic fistula as a complication to xanthogranulomatous pyelonephritis. Majeed HA, et al. **Singapore Med J** 1997 Mar;38(3):116–9 (17 ref.)
Xanthogranulomatous pyelonephritis associated with transitional cell carcinoma of the renal pelvis. Val–Bernal JF, et al. **Urol Int** 1996;57(4):240–5 (34 ref.)

DIAGNOSIS

A middle–aged woman with back and flank pain. Cruz DN, et al. **Hosp Pract (Off Ed)** 1996 Sep 15;31(9):193–4, 199–200, 203, passim (12 ref.)
Focal xanthogranulomatous pyelonephritis presenting as renal tumour in children. Case report with a review of the literature. Marteinsson VT, et al. **Scand J Urol Nephrol** 1996 Jun;30(3):235–9 (32 ref.)

DRUG THERAPY

Xanthogranulomatous pyelonephritis: report of nonsurgical management of a case and review of the literature. Brown PS Jr, et al. **Clin Infect Dis** 1996 Feb;22(2):308–14 (24 ref.)

PYKNOLEPSY see **EPILEPSY, ABSENCE**

PYLORIC ANTRUM

BLOOD SUPPLY

Watermelon stomach. Abedi M, et al. **Gastroenterologist** 1997 Sep;5(3):179–84 (32 ref.)
Gastric antral vascular ectasia: a case report and review of the literature. Herman BE, et al. **J Nucl Med** 1996 May; 37(5):854–6 (40 ref.)

PATHOLOGY

Helicobacter pylori and acid secretion: where are we now? [comment] McColl KE. **Eur J Gastroenterol Hepatol** 1997 Apr;9(4):333–5 (20 ref.) Comment on: Eur J Gastroenterol Hepatol 1997 Apr;9(4):361–5.

PHYSIOLOGY

Antroduodenal manometry: an evaluation of an emerging methodology. Byrne KG, et al. **Dig Dis** 1997;15 Suppl 1:53–63 (39 ref.)

PYLORIC STENOSIS

COMPLICATIONS

Gastric outlet obstruction. Khullar SK, et al. **Gastrointest Endosc Clin N Am** 1996 Jul;6(3):585–603 (82 ref.)

ETIOLOGY

The enigma of pyloric stenosis. Some thoughts on the aetiology. Rogers IM. **Acta Paediatr** 1997 Jan;86(1):6–9 (30 ref.)

PYLORUS

see related
GASTRIC EMPTYING

Gastric Crohn's disease complicated by adenocarcinoma of the stomach: case report and review of the literature. Patel M, et al. **Am J Gastroenterol** 1997 Aug;92(8):1368–71 (19 ref.)

ABNORMALITIES

Pyloric atresia associated with intestinal atresia [letter] Al–Salem AH, et al. **J Pediatr Surg** 1997 Aug;32(8):1262–3 (5 ref.)

SURGERY

[Preservation of the pylorus in duodenopancreatectomy] Partensky C, et al. **Ann Chir** 1996;50(7):517–23 (53 ref.) (Eng. Abstr.) **(Fre)**

PYODERMA

DIAGNOSIS

Distinguishing vesicular and pustular disorders in the neonate. Wagner A. **Curr Opin Pediatr** 1997 Aug; 9(4):396–405 (86 ref.)

ETIOLOGY

Distinguishing vesicular and pustular disorders in the neonate. Wagner A. **Curr Opin Pediatr** 1997 Aug; 9(4):396–405 (86 ref.)

PYODERMA GANGRENOSUM

Pyoderma gangrenosum in childhood. Dourmishev AL, et al. **Cutis** 1996 Oct;58(4):257–62 (89 ref.)
Neutrophilic dermatoses: pyoderma gangrenosum and Sweet's syndrome. Lear JT, et al. **Postgrad Med J** 1997 Feb;73(856):65–8 (27 ref.)

PYONEPHROSIS see **PYELONEPHRITIS**

PYORRHEA ALVEOLARIS see **PERIODONTAL DISEASES**

PYOTHORAX see **EMPYEMA, PLEURAL**

PYRAMIDAL CELLS

DRUG EFFECTS

(–)Deprenyl reduces delayed neuronal death of hippocampal pyramidal cells. Paterson IA, et al. **Neurosci Biobehav Rev** 1997 Mar;21(2):181–6 (27 ref.)

PATHOLOGY

Pyramidal nerve cell loss in Alzheimer's disease. Mann DM. **Neurodegeneration** 1996 Dec;5(4):423–7 (58 ref.)

PHYSIOLOGY

Active properties of neuronal dendrites. Johnston D, et al. **Annu Rev Neurosci** 1996;19:165–86 (150 ref.)
A network of tufted layer 5 pyramidal neurons. Markram H. **Cereb Cortex** 1997 Sep;7(6):523–33 (97 ref.)
Synaptic interactions in neocortical local circuits: dual intracellular recordings in vitro. Thomson AM, et al. **Cereb Cortex** 1997 Sep;7(6):510–22 (114 ref.)
Induction of heterosynaptic and homosynaptic LTD in hippocampal sub-regions in vivo. Abraham WC. **J Physiol Paris** 1996;90(5–6):305–6 (13 ref.)
Expression mechanisms of long-term potentiation in the hippocampus. Isaac JT, et al. **J Physiol Paris** 1996; 90(5–6):299–303 (12 ref.)
Plasticity of the hippocampal-prefrontal cortex synapses. Jay TM, et al. **J Physiol Paris** 1996;90(5–6):361–6 (19 ref.)
Pyramidal neurone modulation: a therapeutic target for Alzheimer's disease. Francis PT. **Neurodegeneration** 1996 Dec;5(4):461–5 (31 ref.)
A quarter of a century of place cells. Muller R. **Neuron** 1996 Nov;17(5):813–22 (50 ref.)

PYRAMIDAL TRACTS

Ectasia of the vertebral artery as a cause of isolated pyramidal tract signs: case report and a review of the literature. Moss MS, et al. **Br J Neurosurg** 1996 Oct;10(5):497–9 (13 ref.)

PATHOLOGY

Neuropathology of amyotrophic lateral sclerosis: new perspectives on an old disease. Chou SM. **J Formos Med Assoc** 1997 Jul;96(7):488–98 (74 ref.)

PYRAZINAMIDE

ADVERSE EFFECTS

[Fulminant hepatitis during the therapy for tuberculous meningitis] Garavelli PL. **Recenti Prog Med** 1996 Dec; 87(12):597 (8 ref.) **(Ita)**

PYRAZINES

CHEMICAL SYNTHESIS

[Reactions and syntheses of pyrazines] Ohta A, et al. **Yakugaku Zasshi** 1997 Jan;117(1):1–17 (60 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

[Reactions and syntheses of pyrazines] Ohta A, et al. **Yakugaku Zasshi** 1997 Jan;117(1):1–17 (60 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Chemoprevention by inducers of carcinogen detoxication enzymes. Kensler TW. **Environ Health Perspect** 1997 Jun; 105 Suppl 4:965–70 (55 ref.)

PYRAZINOPYRIMIDINES see **PTERIDINES**

PYRAZOLES

PHARMACOLOGY

[Inhibition of RAS-transformation by SCH51344] Kumar CC. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1503–11 (35 ref.) (Eng. Abstr.) **(Jpn)**

PYRENES

Intramolecular pyrene excimer fluorescence: a probe of proximity and protein conformational change. Lehrer SS. **Methods Enzymol** 1997;278:286–95 (18 ref.)

PYRETHRINS

Application of deltamethrin-impregnated bednets for mosquito and malaria control in Yunnan, China. Zhang Z, et al. **Southeast Asian J Trop Med Public Health** 1996 Jun;27(2):367–71 (14 ref.)

ANALYSIS

Chromatographic methods for the determination of pyrethrin and pyrethroid pesticide residues in crops, foods and environmental samples. Chen ZM, et al. **J Chromatogr A** 1996 Nov 22;754(1–2):367–95 (226 ref.)

CHEMISTRY

Interaction of synthetic pyrethroids with micro-organisms: a review. Johri AK, et al. **Microbios** 1997; 89(360–361):151–6 (35 ref.)

PHARMACOLOGY

Review: mosquito nets and insecticides for net treatment: a discussion of existing and potential distribution systems in Africa. Lines J. **Trop Med Int Health** 1996 Oct; 1(5):616–32 (54 ref.)

TOXICITY

Interaction of synthetic pyrethroids with micro-organisms: a review. Johri AK, et al. **Microbios** 1997; 89(360–361):151–6 (35 ref.)

PYREXIA see **FEVER**

PYRIDAZINES

THERAPEUTIC USE

Effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Kubo SH. **Cardiology** 1997;88 Suppl 2:21–7 (24 ref.)

PYRIDINES

ANALYSIS

Identification of new mutagenic heterocyclic amines and quantification of known heterocyclic amines. Wakabayashi K, et al. **Princess Takamatsu Symp** 1995;23:39–49 (31 ref.)

METABOLISM

Microbial metabolism of pyridine, quinoline, acridine, and their derivatives under aerobic and anaerobic conditions. Kaiser JP, et al. **Microbiol Rev** 1996 Sep;60(3):483–98 (146 ref.)

PHARMACOLOGY

Pharmacology of the neurotransmitter release enhancer linopirdine (DuP 996), and insights into its mechanism of action. Aiken SP, et al. **Adv Pharmacol** 1996;35:349–84 (84 ref.)
Electropharmacology of Ro 22-9194, a new antiarrhythmic agent. Kodama I, et al. **Gen Pharmacol** 1996 Jul; 27(5):755–60 (19 ref.)
[Recent progress in development of psychotropic drugs (5)—Hypnotics] Ohta T. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Oct; 16(5):161–70 (40 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Zolpidem: distinct from triazolam? Lobo BL, et al. **Ann Pharmacother** 1997 May;31(5):625–32 (52 ref.)
Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist. Bristow LJ, et al. **Trends Pharmacol Sci** 1997 Jun;18(6):186–8 (11 ref.)

PYRIDINIUM COMPOUNDS

CHEMISTRY

The measurement of pyridinium crosslinks: a methodological overview. James IT, et al. **Ann Clin Biochem** 1996 Sep;33 (Pt 5):397–420 (146 ref.)

URINE

Standardization of HPLC measurements of pyridinium crosslinks. Bjellerup P. **Scand J Clin Lab Invest Suppl** 1997; 227:80–3 (10 ref.)

PYRIDINONES see **PYRIDONES**

PYRIDONES

THERAPEUTIC USE

Oral iron chelation with deferiprone. Diav-Citrin O, et al. **Pediatr Clin North Am** 1997 Feb;44(1):235–47 (75 ref.)

TOXICITY

Adverse effects of aluminium-chelating compounds for clinical use. Domingo JL. **Adverse Drug React Toxicol Rev** 1996 Aug;15(3):145–65 (159 ref.)

PYRIDOXAL PHOSPHATE

ANALOGS & DERIVATIVES

Overview of MnDPDP as a pancreas-specific contrast agent for MR imaging [see comments] Ahlström H, et al. **Acta Radiol** 1997 Jul;38(4 Pt 2):660–4 (18 ref.) Comment in: Acta Radiol 1997 Jul;38(4 Pt 2):623–5.
Cardiovascular safety of MnDPDP and MnCl2. Jynge P, et al. **Acta Radiol** 1997 Jul;38(4 Pt 2):740–9 (49 ref.)
General toxicology of MnDPDP. Larsen LE, et al. **Acta Radiol** 1997 Jul;38(4 Pt 2):770–9 (70 ref.)
Clinical implications of studies with MnDPDP in animal models of hepatic abnormalities [see comments] Ni Y, et al. **Acta Radiol** 1997 Jul;38(4 Pt 2):724–31 (42 ref.) Comment in: Acta Radiol 1997 Jul;38(4 Pt 2):623–5.
Contrast agents for MR imaging of the liver. Low RN. **J Magn Reson Imaging** 1997 Jan–Feb;7(1):56–67 (76 ref.)
Clinical development of human polymerized hemoglobin as a blood substitute. Gould SA, et al. **World J Surg** 1996 Nov–Dec;20(9):1200–7 (36 ref.)

METABOLISM

Interrelationships between metabolism of glycogen phosphorylase and pyridoxal phosphate—implications in McArdle's disease. Beynon RJ, et al. **Adv Food Nutr Res** 1996;40:135–47 (23 ref.)

PYRIDOXINE

METABOLISM

Modeling vitamin B6 metabolism. Coburn SP. **Adv Food Nutr Res** 1996;40:107–32 (87 ref.)

PHARMACOKINETICS

Bioavailability of vitamin B-6. Gregory JF 3rd. **Eur J Clin Nutr** 1997 Jan;51 Suppl 1:S43–8 (63 ref.)

PHYSIOLOGY

[The importance of vitamin B 6 for development of the infant. Human medical and animal experiment studies] Gerster H. **Z Ernahrungswiss** 1996 Dec;35(4):309–17 (50 ref.) (Eng. Abstr.) **(Ger)**

PYRIDOXINE DEFICIENCY

see related
ANEMIA, SIDEROBLASTIC

COMPLICATIONS

Pyridoxine dependency: an update. Gordon N. **Dev Med Child Neurol** 1997 Jan;39(1):63–5 (20 ref.)

EMBRYOLOGY

[The importance of vitamin B 6 for development of the infant. Human medical and animal experiment studies] Gerster H. **Z Ernahrungswiss** 1996 Dec;35(4):309–17 (50 ref.) (Eng. Abstr.) **(Ger)**

PYRIMETHAMINE

ANALOGS & DERIVATIVES

Oxygen-radical-scavenging activity of DDMP-conjugated saponins and physiological role in leguminous plant. Okubo K, et al. **Adv Exp Med Biol** 1996;405:141–54 (27 ref.)
Chemiluminescence of oxygen radical scavengers such as DDMP saponins in the presence of radicals and aldehyde. Yoshiki Y, et al. **Adv Exp Med Biol** 1996;405:231–9 (16 ref.)

POISONING

[A case of acute pyrimethamine poisoning] Aguemon AR, et al. **Bull Soc Pathol Exot** 1997;90(2):117–9 (7 ref.) (Eng. Abstr.) **(Fre)**

PYRIMIDINE DIMERS

ANALYSIS

Ultraviolet-induced photolesions: repair and mutagenesis. Mullenders LH, et al. **Recent Results Cancer Res** 1997; 143:89–99 (33 ref.)

RADIATION EFFECTS

Mutagenic lesions in photocarcinogenesis: the fate of pyrimidine photoproducts in repair-deficient disorders. Cleaver JE. **Photochem Photobiol** 1996 Apr;63(4):377–9 (17 ref.)
Mutagenic lesions in carcinogenesis: induction and repair of pyrimidine dimers. Sutherland BM. **Photochem Photobiol** 1996 Apr;63(4):375–7 (27 ref.)

PYRIMIDINE 5'-NUCLEOTIDASE see **5'-NUCLEOTIDASE**

PYRIMIDINE PHOSPHORYLASE see **THYMIDINE PHOSPHORYLASE**

PYRIMIDINES

[Pyrimidine/purine-biased sequences: potential to form DNA triplex and its physiological effects] Kato M. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(15 Suppl):2259–66 (37 ref.) **(Jpn)**

BIOSYNTHESIS

Enzymes of nucleotide synthesis. Smith JL. **Curr Opin Struct Biol** 1995 Dec;5(6):752–7 (37 ref.)
Isotopically labeled precursors and mass spectrometry in elucidating biosynthesis of pyrimidine moiety of thiamin in Saccharomyces cerevisiae. Tazuya K, et al. **Methods Enzymol** 1997;279:97–108 (9 ref.)

METABOLISM

P2 purinoceptors and pyrimidinoceptors of catecholamine-producing cells and immunocytes. Illes P, et al. **Ciba Found Symp** 1996;198:110–25; discussion 125–9 (59 ref.)
When to investigate for purine and pyrimidine disorders.

PYRIMIDINES

Introduction and review of clinical and laboratory indications. Simmonds HA, et al. **J Inherit Metab Dis** 1997 Jun;20(2):214–26 (29 ref.)

Inborn errors of pyrimidine degradation: clinical, biochemical and molecular aspects. van Gennip AH, et al. **J Inherit Metab Dis** 1997 Jun;20(2):203–13 (46 ref.)

PHARMACOLOGY

Non-genotoxic hepatocarcinogenesis: suppression of apoptosis by peroxisome proliferators. Roberts RA. **Ann N Y Acad Sci** 1996 Dec 27;804:588–611 (97 ref.)

The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs). Staels B, et al. **Biochimie** 1997 Feb-Mar;79(2-3):95–9 (39 ref.)

[Recent progress in development of psychotropic drugs (5)—Hypnotics] Ohta T. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Oct; 16(5):161–70 (40 ref.) (Eng. Abstr.) **(Jpn)**

[A new approach to innovating selective anxiolytics: pharmacological profile of a novel 5-HT1A agonist (tandospirone)] Sasa M. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1997 Apr; 17(2):53–9 (33 ref.) (Eng. Abstr.) **(Jpn)**

PYROGENS

ANALYSIS

New indicators to evaluate bacteriological quality of the dialysis fluid and the associated inflammatory response in ESRD patients. Krautzig S, et al. **Nephrol Dial Transplant** 1996;11 Suppl 2:87–91 (29 ref.)

CHEMISTRY

The staphylococcal and streptococcal pyrogenic toxin family. Bohach GA, et al. **Adv Exp Med Biol** 1996;391:131–54 (116 ref.)

PHYSIOLOGY

The toxins of group A streptococcus, the flesh eating bacteria. Stevens DL. **Immunol Invest** 1997 Jan-Feb; 26(1-2):129–50 (74 ref.)

PYROGLUTAMIC ACID see **PYRROLIDONECARBOXYLIC ACID**

PYROMANIA see **FIRESETTING BEHAVIOR**

PYROPHOSPHATASES

CHEMISTRY

Precluding uracil from DNA. Vassylyev DG, et al. **Structure** 1996 Dec 15;4(12):1381–5 (18 ref.)

METABOLISM

Glycobiotechnology: enzymes for the synthesis of nucleotide sugars. Elling L. **Adv Biochem Eng Biotechnol** 1997; 58:89–144 (363 ref.)

PYROPHOSPHATES see **DIPHOSPHATES**

PYRROLES

THERAPEUTIC USE

A brief review paper of the efficacy and safety of atorvastatin in early clinical trials. Bakker-Arkema RG, et al. **Atherosclerosis** 1997 May;131(1):17–23 (31 ref.)

Is there a therapeutic future for "potassium channel openers"? [editorial] Lawson K. **Clin Sci (Colch)** 1996 Dec; 91(6):651–63 (111 ref.)

Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Lea AP, et al. **Drugs** 1997 May;53(5):828–47 (133 ref.)

Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist. Bristow LJ, et al. **Trends Pharmacol Sci** 1997 Jun;18(6):186–8 (11 ref.)

PYRROLIDINES

DIAGNOSTIC USE

IBZM- and CIT-SPECT of the dopaminergic system in parkinsonism. Tissingh G, et al. **J Neural Transm Suppl** 1997;50:31–7 (38 ref.)

THERAPEUTIC USE

Discovery & development of selective M3 antagonists for clinical use. Alabaster VA. **Life Sci** 1997;60(13-14):1053–60 (24 ref.)

PYRROLIDINONES

ADVERSE EFFECTS

Stillbirth after occupational exposure to N-methyl-2-pyrrolidone. A case report and review of the literature [see comments] Solomon GM, et al. **J Occup Environ Med** 1996 Jul;38(7):705–13 (58 ref.) Comment in: J Occup Environ Med 1997 May;39(5):393–4.

PHARMACOLOGY

Intracellular targeting, interaction with Src homology 3 (SH3) domains and rolipram-detected conformational switches in cAMP-specific PDE4A phosphodiesterase. Houslay MD, et al. **Biochem Soc Trans** 1997 May; 25(2):374–81 (50 ref.)

PYRROLIDONECARBOXYLIC ACID

METABOLISM

Biologically active pyroglutamyl N-terminal oligopeptides: parts of larger molecules? Elgjo K, et al. **Physiol Chem Phys Med NMR** 1995;27(4):351–3 (17 ref.)

PYRROLIDONES see **PYRROLIDINONES**

PYRROLIZIDINE ALKALOIDS

METABOLISM

A simple procedure for determining the aqueous half-lives of pyrrolic metabolites of pyrrolizidine alkaloids. Cooper RA, et al. **Toxicon** 1996 May;34(5):604–7 (15 ref.)

PHARMACOKINETICS

Metabolic bioactivation reactions potentially related to drug toxicities. Castagnoli N Jr, et al. **NIDA Res Monogr** 1997; 173:85–105 (81 ref.)

PYRUVALDEHYDE

PHARMACOLOGY

Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification—a role in pathogenesis and antiproliferative chemotherapy. Thornalley PJ. **Gen Pharmacol** 1996 Jun;27(4):565–73 (77 ref.)

PYRUVATE see **PYRUVIC ACID**

PYRUVATE CARBOXYLASE

GENETICS

Disorders of pyruvate carboxylase and the pyruvate dehydrogenase complex. Robinson BH, et al. **J Inherit Metab Dis** 1996;19(4):452–62 (35 ref.)

PYRUVATE DECARBOXYLASE

CHEMISTRY

Protein design on pyruvate decarboxylase (PDC) by site-directed mutagenesis. Application to mechanistical investigations, and tailoring PDC for the use in organic synthesis. Pohl M. **Adv Biochem Eng Biotechnol** 1997; 58:15–43 (182 ref.)

[Pyruvate decarboxylase: mechanistic model of paracatalytic interactions] Vovk AI. **Ukr Biokhim Zh** 1996 May-Jun; 68(3):13–26 (91 ref.) (Eng. Abstr.) **(Rus)**

PYRUVATE DEHYDROGENASE COMPLEX

GENETICS

Disorders of pyruvate carboxylase and the pyruvate dehydrogenase complex. Robinson BH, et al. **J Inherit Metab Dis** 1996;19(4):452–62 (35 ref.)

METABOLISM

Role of NAD(+)-dependent 'malic' enzyme and pyruvate dehydrogenase complex in leaf metabolism. Hill S, et al. **Biochem Soc Trans** 1996 Aug;24(3):743–6 (15 ref.)

PYRUVATE KINASE

see related
ANEMIA, HEMOLYTIC

BIOSYNTHESIS

Metabolic regulation of hepatic gene expression. Towle HC, et al. **Biochem Soc Trans** 1996 May;24(2):364–8 (31 ref.)

DEFICIENCY

[Molecular basis and pathophysiology of red cell enzymopathies] Kanno H. **Nippon Rinsho** 1996 Sep; 54(9):2382–9 (27 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

[Erythrocyte pyruvate kinase—an enzyme that may have an influence on oxygen transport to tissues] Dąbrowska A. **Postepy Hig Med Dosw** 1997;51(3):305–18 (69 ref.) (Eng. Abstr.) **(Pol)**

PYRUVIC ACID

METABOLISM

Physiology of pyruvate metabolism in Lactococcus lactis. Cocaign-Bousquet M, et al. **Antonie Van Leeuwenhoek** 1996 Oct;70(2-4):253–67 (87 ref.)

Metabolic fuel utilization and pyruvate oxidation during the postnatal period. Medina JM, et al. **J Inherit Metab Dis** 1996;19(4):432–42 (33 ref.)

Buffers: bicarbonate, lactate and pyruvate. Feriani M. **Kidney Int Suppl** 1996 Nov;56:S75–80 (61 ref.)

Pyruvate metabolism in Saccharomyces cerevisiae. Pronk JT, et al. **Yeast** 1996 Dec;12(16):1607–33 (162 ref.)

PYRUVIC DECARBOXYLASE see **PYRUVATE DECARBOXYLASE**

Q BETA REPLICASE

GENETICS

[Cell-free system for RNA replication, expression and cloning] Chetverin AB. **Mol Biol (Mosk)** 1996 Sep-Oct; 30(5):981–90 (41 ref.) **(Rus)**

Q FEVER

Q fever pneumonia. Antony SJ, et al. **Semin Respir Infect** 1997 Mar;12(1):2–6 (22 ref.)

COMPLICATIONS

[Febrile syndrome and isolated pleural effusion as manifestation of Q fever (letter)] Mateos-Colino A, et al. **Rev Clin Esp** 1996 Nov;196(11):800–1 (9 ref.) **(Spa)**

[A fatal case of chronic Q fever with cardiovascular involvement] Kushnir ZH, et al. **Lik Sprava** 1995 Sep-Dec; (9-12):170–3 (10 ref.) (Eng. Abstr.) **(Ukr)**

EPIDEMIOLOGY

Q fever endocarditis in Israel and a worldwide review. Siegman-Igra Y, et al. **Scand J Infect Dis** 1997;29(1):41–9 (110 ref.)

[A review of Q fever in the Canary Islands (letter)] Pascual Velasco F. **Rev Clin Esp** 1997 Jan;197(1):69 (10 ref.) **(Spa)**

IMMUNOLOGY

Coxiella burnetii: the 'query' fever bacterium. A model of immune subversion by a strictly intracellular microorganism. Mege JL, et al. **FEMS Microbiol Rev** 1997 Apr;19(4):209–17 (67 ref.)

[Thrombophlebitis in a patient with acute Q fever and anticardiolipin antibodies (letter)] Gálvez J, et al. **Med Clin (Barc)** 1997 Mar 15;108(10):396–7 (6 ref.) **(Spa)**

QALY see **QUALITY-ADJUSTED LIFE YEARS**

QUADRIGEMINAL PLATE see **CORPORA QUADRIGEMINA**

QUADRIPLEGIA

Measurement of isometric elbow and shoulder moments: position-dependent strength of posterior deltoid-to-triceps muscle tendon transfer in tetraplegia. Kirsch RF, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):403–9 (10 ref.)

COMPLICATIONS

Electrical stimulation to restore respiration. Creasey G, et al. **J Rehabil Res Dev** 1996 Apr;33(2):123–32 (40 ref.)

DIAGNOSIS

Factitious quadriplegia. A rare new case and literature review. Feldman MD, et al. **Psychosomatics** 1997 Jan-Feb; 38(1):76–80 (18 ref.)

[Acute tetraplegia in a patient with Sjögren's syndrome (letter)] Sánchez-Chaparro MA, et al. **Med Clin (Barc)** 1997 Mar 8;108(9):356–7 (10 ref.) **(Spa)**

ETIOLOGY

[Symptomatic arteriovenous fistula in a patient with neurofibromatosis type I] Anegawa S, et al. **No Shinkei Geka** 1997 Apr;25(4):373–8 (25 ref.) (Eng. Abstr.) **(Jpn)**

REHABILITATION

Input-output nonlinearities and time delays increase tracking errors in hand grasp neuroprostheses. Adamczyk MM, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):271–9 (18 ref.)

Tri-state myoelectric control of bilateral upper extremity neuroprostheses for tetraplegic individuals. Scott TR, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):251–63 (25 ref.)

Development of an upper extremity FES system for individuals with C4 tetraplegia. Smith BT, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):264–70 (26 ref.)

Challenges to clinical deployment of upper limb neuroprostheses. Triolo R, et al. **J Rehabil Res Dev** 1996 Apr;33(2):111–22 (19 ref.)

QUADRUPLETS

[Successful twin delivery following reduction of quadruplet pregnancy] Patkós P, et al. **Orv Hetil** 1996 Nov 3; 137(44):2458–63 (37 ref.) (Eng. Abstr.) **(Hun)**

QUAIL

PHYSIOLOGY

The behavior of the Japanese or domestic quail Coturnix japonica. Mills AD, et al. **Neurosci Biobehav Rev** 1997 May; 21(3):261–81 (367 ref.)

QUALITY-ADJUSTED LIFE YEARS

An assessment of the use of costs and quality of life as outcomes in endoscopic research. Sahai AV, et al. **Gastrointest Endosc** 1997 Aug;46(2):113–8 (75 ref.)

The impact of age on cost–effectiveness ratios and its control in decision making. Baltussen R, et al. **Health Econ** 1996 May–Jun;5(3):227–39 (40 ref.)

Outcome measurement in economic evaluation [see comments] Johannesson M, et al. **Health Econ** 1996 Jul–Aug;5(4):279–96 (73 ref.) Comment in: Health Econ 1997 Jan–Feb;6(1):91–3.

Intergenerational equity: an exploration of the 'fair innings' argument. Williams A. **Health Econ** 1997 Mar–Apr; 6(2):117–32 (28 ref.)

Preferences, needs and QALYs. Cohen J. **J Med Ethics** 1996 Oct;22(5):267–72 (35 ref.)

The role of cost–effectiveness analysis in health and medicine. Panel on Cost–Effectiveness in Health and Medicine [see comments] Russell LB, et al. **JAMA** 1996 Oct 9; 276(14):1172–7 (51 ref.) Comment in: JAMA 1996 Oct 9;276(14):1180.

Recommendations of the Panel on Cost–effectiveness in Health and Medicine. Weinstein MC, et al. **JAMA** 1996 Oct 16;276(15):1253–8 (23 ref.)

The relationship between descriptive and valuational quality–of–life measures in patients with intermittent claudication. Bosch JL, et al. **Med Decis Making** 1996 Jul–Sep;16(3):217–25 (29 ref.)

Assigning values to intermediate health states for cost–utility analysis: theory and practice. Cohen BJ. **Med Decis Making** 1996 Oct–Dec;16(4):376–85 (56 ref.)

A criticism of healthy–years equivalents [see comments] Wakker P. **Med Decis Making** 1996 Jul–Sep;16(3):207–14 (30 ref.) Comment in: Med Decis Making 1996 Jul–Sep;16(3):215–6.

QALYs and mental health care. Chisholm D, et al. **Soc Psychiatry Psychiatr Epidemiol** 1997 Feb;32(2):68–75 (44 ref.)

Measuring the quality of life of severely mentally ill people using the Lancashire Quality of Life Profile. Oliver JP, et al. **Soc Psychiatry Psychiatr Epidemiol** 1997 Feb; 32(2):76–83 (24 ref.)

QALYS and ethics: a health economist's perspective. Williams A. **Soc Sci Med** 1996 Dec;43(12):1795–804 (42 ref.)

QUALITY ASSESSMENT, HEALTH CARE see **QUALITY ASSURANCE, HEALTH CARE**

QUALITY ASSURANCE, HEALTH CARE

Practical approaches to improve laboratory performance and transfusion safety. Galel SA, et al. **Am J Clin Pathol** 1997 Apr;107(4 Suppl 1):S43–9 (19 ref.)

Practical aspects of the self–assessment of the issue and administration of blood: a review of two hospitals' experiences. Shulman IA, et al. **Am J Clin Pathol** 1997 Apr;107(4 Suppl 1):S17–22 (13 ref.)

Quality assessment in anatomic pathology in the cost–conscious era. Zarbo RJ. **Am J Clin Pathol** 1996 Oct; 106(4 Suppl 1):S3–10 (58 ref.)

College of American Pathologists Conference XXX on quality and liability issues with the Papanicolaou smear: summation. Austin RM. **Arch Pathol Lab Med** 1997 Mar; 121(3):341–2 (21 ref.)

Pediatric guidelines: help or hindrance? Homer CJ, et al. **Curr Opin Pediatr** 1996 Oct;8(5):430–5 (41 ref.)

Quality assurance in cervical cytopathology––time for a more evidence–based approach [editorial; comment] Slater DN. **Cytopathology** 1997 Apr;8(2):75–8 (12 ref.) Comment on: Cytopathology 1997 Apr;8(2):96–102. Comment on: Cytopathology 1997 Apr;8(2):79–84. Comment on: Cytopathology 1997 Apr;8(2):85–95. Comment on: Cytopathology 1997 Apr;8(2):103–7.

Requirements for quality assessment in coronary angiograph and angioplasty. Brennecke R, et al. **Eur Heart J** 1995 Nov; 16(11):1578–88 (94 ref.)

Methods for quality assessment in general practice. Rethans JJ, et al. **Fam Pract** 1996 Oct;13(5):468–76 (64 ref.)

Who is holding whom accountable for quality? [see comments] Gosfield AG. **Health Aff (Millwood)** 1997 May–Jun;16(3):26–40 (21 ref.) Comment in: Health Aff (Millwood) 1997 May–Jun;16(3):41–3.

Accountability for health care: a white paper on leadership and management for the U.S. health care system. Schneller ES. **Health Care Manage Rev** 1997 Winter;22(1):38–48; discussion 49–57 (27 ref.)

Emerging model of quality. Larrabee JH. **Image J Nurs Sch** 1996 Winter;28(4):353–8 (44 ref.)

The effectiveness of quality assurance. Donabedian A. **Int J Qual Health Care** 1996 Aug;8(4):401–7 (16 ref.)

Policy matters: critical policy analysis and nursing. Cheek J, et al. **J Adv Nurs** 1997 Apr;25(4):668–72 (23 ref.)

Quality indicators in clinical nursing: a review of the literature. Idvall E, et al. **J Adv Nurs** 1997 Jan;25(1):6–17 (110 ref.)

Myocardial single–photon emission computed tomographic quality assurance. Baron JM, et al. **J Nucl Cardiol** 1996 Mar–Apr;3(2):157–66 (33 ref.)

Ethics committees and quality improvement: a necessary link. Anderson CA. **J Nurs Care Qual** 1996 Oct;11(1):22–8 (10 ref.)

Professional shopping of hospital services: an analysis of sub rosa investigative methods in determination of quality. Komarek AG. **J Nurs Care Qual** 1996 Oct;11(1):44–55 (18 ref.)

The synergistic relationship between ethics and quality improvement: thriving in managed care. Mitchell K, et al. **J Nurs Care Qual** 1996 Oct;11(1):9–21 (27 ref.)

Nurse–sensitive health care outcomes in acute care settings: an integrative analysis of the literature. Pierce SF. **J Nurs Care Qual** 1997 Apr;11(4):60–72 (56 ref.)

Using automated continual performance assessment to improve health care. Wulff KR, et al. **MD Comput** 1997 Jan–Feb;14(1):24–30, 32–5 (51 ref.)

Outcomes research methods in nutritional support. August DA. **Nutrition** 1996 Oct;12(10):724–5 (9 ref.)

Quality assurance in clinical trials. Feigenbaum SL. **Semin Reprod Endocrinol** 1996 May;14(2):93–100 (26 ref.)

Quality of mental health service care: the forgotten pathway from process to outcome. Brugha TS, et al. **Soc Psychiatry Psychiatr Epidemiol** 1996 Mar;31(2):89–98 (72 ref.)

Citation analysis for measuring the value of scientific publications: quality assessment tool or comedy of errors? [see comments] Schoonbaert D, et al. **Trop Med Int Health** 1996 Dec;1(6):739–52 (71 ref.) Comment in: Trop Med Int Health 1996 Dec;1(6):737.

[Traumatology. Scoring systems and their use] Printzlau A, et al. **Ugeskr Laeger** 1996 Oct 21;158(43):6074–80 (35 ref.) (Eng. Abstr.) **(Dan)**

[European recommendations for quality assurance in the setting of mammographic screening for breast cancer. Report of pathologists of the working group "Breast Cancer Screening" of the European Union] **Ann Pathol** 1996 Nov; 16(5):315–33 (25 ref.) **(Fre)**

[Improvement of transfusion safety in a health care service through the implementation of a quality program] Hergon E, et al. **Transfus Clin Biol** 1996;3(5):305–14 (12 ref.) (Eng. Abstr.) **(Fre)**

[Intensive fetal monitoring sub partu or the quality of clinical research (see comments)] Schneider H. **Geburtshilfe Frauenheilkd** 1996 Aug;56(8):397–400 (7 ref.) (Eng. Abstr.) Comment in: Geburtshilfe Frauenheilkd 1996 Aug;56(8):M126–9. **(Ger)**

[Quality evaluation in endoscopy] Riemann JF, et al. **Internist (Berl)** 1996 Aug;37(8):830–8 (27 ref.) **(Ger)**

[Quality management in diagnosis and therapy of colorectal carcinoma] Hermanek P. **Leber Magen Darm** 1996 Jan; 26(1):20–4 (14 ref.) (Eng. Abstr.) **(Ger)**

[Patient satisfaction––artefact or social reality?] Leimkühler AM, et al. **Nervenarzt** 1996 Sep;67(9):765–73 (54 ref.) (Eng. Abstr.) **(Ger)**

[Inpatient pneumologic rehabilitation of adults: goals––diagnostic and therapeutic standards––research needs] Bergmann KC, et al. **Pneumologie** 1997 May; 51(5):523–32 (87 ref.) **(Ger)**

[Combination of methods and integration of methods as standard in psychotherapy?] Senf W, et al. **Psychother Psychosom Med Psychol** 1997 Mar–Apr; 47(3–4):92–6 (17 ref.) (Eng. Abstr.) **(Ger)**

[Medical performance: ethical and conceptual issues] Widder J. **Wien Klin Wochenschr** 1996;108(19):621–6 (30 ref.) (Eng. Abstr.) **(Ger)**

[Quality assurance in radiology] Mohr W. **Z Arztl Fortbild Qualitatssich** 1997 Jul;91(4):361–8 (9 ref.) (Eng. Abstr.) **(Ger)**

[Value of clinical scoring systems for evaluation of injury severity and as an instrument for quality management of severely injured patients] Bouillon B, et al. **Zentralbl Chir** 1996;121(11):914–23 (45 ref.) (Eng. Abstr.) **(Ger)**

[Quality assurance in surgery––more than documentation of postoperative complications] Grundmann RT. **Zentralbl Chir** 1996;121(3):157–66 (65 ref.) (Eng. Abstr.) **(Ger)**

[Measuring quality of life as an integral component of quality management in surgical medicine] Lorenz W, et al. **Zentralbl Chir** 1996;121(7):545–51 (26 ref.) (Eng. Abstr.) **(Ger)**

[Unacceptable quality in certain sectors of medical research] Høiseth A. **Tidsskr Nor Laegeforen** 1997 Feb 10; 117(4):531–5 (14 ref.) (Eng. Abstr.) **(Nor)**

[Hospital quality assurance programs] Burmester H. **Rev Panam Salud Publica** 1997 Feb;1(2):149–54 (17 ref.) **(Spa)**

ECONOMICS

Functional outcomes in spinal cord injury (SCI): quality care versus cost containment. Ditunno JF Jr. **J Spinal Cord Med** 1997 Jan;20(1):1–7 (36 ref.)

Clinicoeconomics in geropsychiatry. Burke MJ. **Psychiatr Clin North Am** 1997 Mar;20(1):219–40 (65 ref.)

Quality of care and cost–containment in managed mental health: policy, education, research, advocacy. Dana RH, et al. **Psychol Rep** 1996 Dec;79(3 Pt 2):1395–422 (125 ref.)

[Documentation and therapeutic standards in anesthesia and intensive care medicine––means for quality assurance and cost control] Bach A, et al. **Zentralbl Chir** 1996; 121(7):521–8 (35 ref.) (Eng. Abstr.) **(Ger)**

[The limits of intensive care medicine] Kox WJ, et al. **Zentralbl Chir** 1996;121(7):515–20 (15 ref.) (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

Papanicolaou smear 5–year retrospective review: what is required by the Clinical Laboratory Improvement Amendments of 1988? Davey DD. **Arch Pathol Lab Med** 1997 Mar;121(3):296–8 (11 ref.)

Quality and liability issues with the Papanicolaou smear: lessons from the science of error prevention. Derman H. **Arch Pathol Lab Med** 1997 Mar;121(3):287–91 (16 ref.)

Liability issues with the Papanicolaou smear: general legal background. Kline TJ. **Arch Pathol Lab Med** 1997 Mar; 121(3):250–2 (14 ref.)

ORGANIZATION & ADMINISTRATION

Tools for improving quality in the transfusion service. Berte LM. **Am J Clin Pathol** 1997 Apr;107(4 Suppl 1):S36–42 (30 ref.)

Practical use of computerized hospital information systems to improve blood transfusion. Butch SH. **Am J Clin Pathol** 1997 Apr;107(4 Suppl 1):S50–6 (7 ref.)

From measuring to improving public health practice. Turnock BJ, et al. **Annu Rev Public Health** 1997;18:261–82 (59 ref.)

Quality of care initiatives in the French context. de Pouvourville G. **Int J Qual Health Care** 1997 Jun; 9(3):163–70 (12 ref.)

From clinical guidelines to quality assurance: the experience of Assistance Publique–Hôpitaux de Paris. Durieux P, et al. **Int J Qual Health Care** 1997 Jun;9(3):215–9 (20 ref.)

The use of clinical guidelines to improve medical practice: main issues in the United States. Huttin C. **Int J Qual Health Care** 1997 Jun;9(3):207–14 (61 ref.)

The contribution of epidemiology to CQI: a commentary. Kazandjian VA. **Int J Qual Health Care** 1996 Aug; 8(4):351–7 (14 ref.)

Managed care and melting moments [editorial] Palmer RH. **Int J Qual Health Care** 1996 Aug;8(4):317–9 (15 ref.)

Management tools and organization as key factors towards quality care: reflections from experience. Tonneau D. **Int J Qual Health Care** 1997 Jun;9(3):201–5 (12 ref.)

Purchasing quality in clinical practice: what on Earth do we mean? Miles A, et al. **J Eval Clin Pract** 1995 Nov; 1(2):87–95 (57 ref.)

Improving outcomes in rehabilitation. A call to arms (and legs). Kane RL. **Med Care** 1997 Jun;35(6 Suppl):JS21–7 (8 ref.)

The next medical revolution should be quality. Friedenberg RM. **Radiology** 1997 Jul;204(1):31A–34A (14 ref.)

STANDARDS

Quality and liability issues with the Papanicolaou smear: the problem of definition of errors and false–negative smears. Davey DD. **Arch Pathol Lab Med** 1997 Mar;121(3):267–9 (26 ref.)

The gynecologist's perspective of liability and quality issues with the Papanicolaou smear. Greer BE. **Arch Pathol Lab Med** 1997 Mar;121(3):246–9 (30 ref.)

American Society of Cytopathology Laboratory Accreditation Program. Gupta PK, et al. **Arch Pathol Lab Med** 1997 Mar;121(3):260–3 (25 ref.)

The challenge of quality improvement with the Papanicolaou smear. Kline TS. **Arch Pathol Lab Med** 1997 Mar; 121(3):253–5 (20 ref.)

Strategies for reducing Papanicolaou smear screening errors: principles derived from data and experience with quality control. Krieger PA. **Arch Pathol Lab Med** 1997 Mar; 121(3):277–81 (5 ref.)

Cytopathology laboratory improvement programs of the College of American Pathologists: Laboratory Accreditation Program (CAP LAP) and Performance Improvement Program in Cervicovaginal Cytology (CAP PAP). Nielsen ML. **Arch Pathol Lab Med** 1997 Mar; 121(3):256–9 (26 ref.)

Quality and liability issues with the Papanicolaou smear: the role of professional organizations in reform initiatives. Stanley MW. **Arch Pathol Lab Med** 1997 Mar;121(3):321–6 (10 ref.)

False negatives in focused rescreening of Papanicolaou smears: how frequently are 'abnormal' cells detected in retrospective review of smears preceding cancer or high–grade intraepithelial neoplasia? Wilbur DC. **Arch Pathol Lab Med** 1997 Mar;121(3):273–6 (12 ref.)

[Development of standards for quality management in interventional cardiology] Brennecke R. **Herz** 1996 Oct;

21(5):304–13 (45 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

The role of program quality in producing early childhood program benefits. Frede EC. **Future Child** 1995 Winter; 5(3):115–32 (61 ref.)

Quality control in the United States. Margolis JR. **Herz** 1996 Dec;21(6):359–63 (11 ref.)

Quality in health care: traditions, influences and future directions. Harvey G. **Int J Qual Health Care** 1996 Aug; 8(4):341–50 (85 ref.)

[Cervical smears and evaluation of quality] Marsan C. **Ann Pathol** 1996 Nov;16(5):344–9 (41 ref.) **(Fre)**

[Quality assurance in medicine. Current status, future requirements] Künzel U. **Herz** 1996 Dec;21(6):341–6 (41 ref.) (Eng. Abstr.) **(Ger)**

[Quality assurance in phoniatrics. Recommendation for standardization of clinical voice evaluation (see comments)] Friedrich G. **HNO** 1996 Jul;44(7):401–16 (65 ref.) Comment in: HNO 1996 Aug;44(8):423. **(Ger)**

[Quality assurance in audiology and pediatric audiology (see comments] Welzl-Müller K. **HNO** 1996 Jul;44(7):385–92 (26 ref.) (Eng. Abstr.) Comment in: HNO 1996 Jul;44(7):357. **(Ger)**

[Minimal invasive surgery—impact on conventional surgery] Schumpelick V, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:528–32 (8 ref.) (Eng. Abstr.) **(Ger)**

[Medical guidelines. Definitions, goals, implementation] Ollenschläger G, et al. **Z Arztl Fortbild (Jena)** 1996 Jun; 90(4):355–61 (14 ref.) (Eng. Abstr.) **(Ger)**

[Status and perspectives of quality assurance in socialized medical services] Ollenschläger G, et al. **Z Arztl Fortbild Qualitatssich** 1997 Feb;91(1):59–67 (34 ref.) (Eng. Abstr.) **(Ger)**

[Current personnel status and qualification requirements in nursing care] Kühnert S, et al. **Z Gerontol Geriatr** 1996 Nov–Dec;29(6):411–7 (7 ref.) (Eng. Abstr.) **(Ger)**

[Perspectives of polytrauma management] Mutschler W, et al. **Zentralbl Chir** 1996;121(11):979–84 (39 ref.) (Eng. Abstr.) **(Ger)**

QUALITY CONTROL

see related
REFERENCE STANDARDS
TOTAL QUALITY MANAGEMENT

The calibration of an artificial stream system used to investigate the tolerances of South African riverine invertebrates to selected water quality variables. Palmer CG, et al. **Arch Environ Contam Toxicol** 1997 Jan; 32(1):22–31 (25 ref.)

How many mistakes, how to find them. Blase AB. **Clin Chem** 1997 May;43(5):897–902 (14 ref.)

Decision-making laboratory computer systems as essential tools for achievement of total quality. Blick KE. **Clin Chem** 1997 May;43(5):908–12 (8 ref.)

Thoughts on quality-control systems: a laboratorian's perspective. Cembrowski GS. **Clin Chem** 1997 May; 43(5):886–92 (33 ref.)

Defining the best quality-control systems by design and inspection. Hinckley CM. **Clin Chem** 1997 May;43(5):873–9 (19 ref.)

Quality: the next six months. Laessig RH, et al. **Clin Chem** 1997 May;43(5):903–7 (13 ref.)

Designing in quality through design control: a manufacturer's perspective. Lasky FD, et al. **Clin Chem** 1997 May; 43(5):866–72 (16 ref.)

Quality systems for unit-use testing devices. Phillips DL. **Clin Chem** 1997 May;43(5):893–6 (9 ref.)

Automated selection of statistical quality-control procedures to assure meeting clinical or analytical quality requirements. Westgard JO, et al. **Clin Chem** 1997 Feb;43(2):400–3 (32 ref.)

Quality assurance in the mycobacteriology laboratory. Quality control, quality improvement, and proficiency testing. Woods GL, et al. **Clin Lab Med** 1996 Sep; 16(3):657–75 (45 ref.)

Review on tropical root and tuber crops. I. Storage methods and quality changes. Ravi V, et al. **Crit Rev Food Sci Nutr** 1996 Oct;36(7):661–709 (374 ref.)

Conceptual frameworks for setting environmental standards. Philipp R. **Int J Occup Med Environ Health** 1996; 9(3):201–10 (40 ref.)

Statistical process control methods for expert system performance monitoring. Kahn MG, et al. **J Am Med Inform Assoc** 1996 Jul–Aug;3(4):258–69 (22 ref.)

Toxicological considerations in environmental audit studies. Jaffery FN, et al. **Qual Assur** 1997 Jan–Mar;5(1):19–26 (7 ref.)

A procedure for assessing a contract testing facility: one sponsor's perspective. Twitty MM, et al. **Qual Assur** 1997 Jan–Mar;5(1):61–8 (4 ref.)

Integrating quality, safety, and environment management systems. Winder C. **Qual Assur** 1997 Jan–Mar;5(1):27–48 (11 ref.)

The need for protein containing quality control materials for blood pH and electrolyte analyzers. Maas B, et al. **Scand J Clin Lab Invest Suppl** 1996;224:179–86 (8 ref.)

End-stage renal disease: a proving ground for quality improvement in health care. Rutherford WE, et al. **Semin Nephrol** 1997 May;17(3):218–25 (28 ref.)

Clinical hematology. In-clinic analysis, quality control, reference values, and system selection. Knoll JS, et al. **Vet Clin North Am Small Anim Pract** 1996 Sep; 26(5):981–1002 (21 ref.)

[Clinical and methodological aspects of quality assurance in external radiotherapy: optimization of radiotherapy in early cancer of the breast] Valdagni R, et al. **Radiol Med (Torino)** 1996 Oct;92(4):462–9 (68 ref.) (Eng. Abstr.) **(Ita)**

QUALITY OF HEALTH CARE

see related
PROFESSIONAL STAFF COMMITTEES

Some priorities in maximizing access to and quality of contraceptive services. Shelton JD, et al. **Adv Contracept** 1996 Sep;12(3):233–7 (10 ref.)

Should we trade person-centered service for a consumer-based model? Peloquin SM. **Am J Occup Ther** 1997 Jul–Aug;51(7):612–5 (26 ref.)

A district stroke service. Pollock S. **Br J Hosp Med** 1997 Mar 5–18;57(5):224–8 (21 ref.)

Clearing 'the fog on the Tyne': can the quality of therapeutics be assessed? Bateman DN. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov;23(10–11):1005–9 (8 ref.)

Standards of care and ethical concerns in genetic testing and screening. Parker LS, et al. **Clin Obstet Gynecol** 1996 Dec; 39(4):873–84 (41 ref.)

Treatment of acute gastroenteritis: too much and too little care. Merrick N, et al. **Clin Pediatr (Phila)** 1996 Sep; 35(9):429–35 (38 ref.)

Can organised dental care for children be both good and cheap? Riordan PJ. **Community Dent Oral Epidemiol** 1997 Feb;25(1):119–25 (49 ref.)

Does a full-time, 24-hour intensivist improve care and efficiency? Carlson RW, et al. **Crit Care Clin** 1996 Jul; 12(3):525–51 (63 ref.)

Managed care in obstetrics. Devoe LD. **Curr Opin Obstet Gynecol** 1997 Aug;9(4):258–61 (17 ref.)

Setting standards and implementing quality improvement in trauma care. Dick WF. **Eur J Emerg Med** 1996 Dec; 3(4):270–3 (7 ref.)

Methods of measuring patient satisfaction in health care organizations. Ford RC, et al. **Health Care Manage Rev** 1997 Spring;22(2):74–89 (41 ref.)

Health care quality management: a status report. Vorhaus CB, et al. **Int Anesthesiol Clin** 1995 Fall;33(4):1–14 (17 ref.)

The ghost of health services past: comparing British health policy of the 1930s with the 1980s and 1990s. Powell MA. **Int J Health Serv** 1996;26(2):253–68 (80 ref.)

Supporting consumer involvement in decision making: what constitutes quality in consumer health information? Entwistle VA, et al. **Int J Qual Health Care** 1996 Oct; 8(5):425–37 (48 ref.)

Cultural safety in nursing: the New Zealand experience. Papps E, et al. **Int J Qual Health Care** 1996 Oct;8(5):491–7 (23 ref.)

Incorporating outpatient perceptions into definitions of quality. Hart M. **J Adv Nurs** 1996 Dec;24(6):1234–40 (36 ref.)

28th Bethesda Conference. Task Force 3: Guidelines for credentialling practicing physicians. Beller GA, et al. **J Am Coll Cardiol** 1997 May;29(6):1148–62 (57 ref.)

28th Bethesda Conference. Task Force 2: Guideline implementation. Eagle KA, et al. **J Am Coll Cardiol** 1997 May;29(6):1141–8 (39 ref.)

28th Bethesda Conference. Task Force 4: Referral guidelines and the collaborative care of patients with cardiovascular disease. Fye WB, et al. **J Am Coll Cardiol** 1997 May; 29(6):1162–70 (73 ref.)

28th Bethesda Conference. Task Force 1: Clinical practice guideline development, dissemination and computerization. Jones RH, et al. **J Am Coll Cardiol** 1997 May;29(6):1133–41 (25 ref.)

Evidence-based medicine and public health. Aveyard P. **J Eval Clin Pract** 1997 Apr;3(2):139–44 (24 ref.)

Is clinical practice improved by risk management? Bowden D. **J Eval Clin Pract** 1995 Sep;1(1):77–9 (3 ref.)

Autonomy: the need for limits. Jiwa M. **J Med Ethics** 1996 Dec;22(6):340–3 (18 ref.)

Dimensions and indicators of patients' perceived nursing care quality in the hospital setting. Chang K. **J Nurs Care Qual** 1997 Aug;11(6):26–37 (35 ref.)

Patient satisfaction and quality of care. Jackson JL, et al. **Mil Med** 1997 Apr;162(4):273–7 (79 ref.)

Informing consumer decisions in health care: implications from decision-making research. Hibbard JH, et al. **Milbank Q** 1997;75(3):395–414 (31 ref.)

Using outcomes measurement to improve quality and value. Nelson EC. **New Dir Ment Health Serv** 1996 Fall; (71):111–24 (25 ref.)

Economic implications of the timing of do-not-resuscitate orders for ICU patients. Bock KR, et al. **New Horiz** 1997 Feb;5(1):51–5 (29 ref.)

Environments that support ethical practice. Rushton CH, et al. **New Horiz** 1997 Feb;5(1):20–9 (55 ref.)

Outcomes research. Clues to quality and organizational effectiveness? Mark BA, et al. **Nurs Clin North Am** 1997 Sep;32(3):589–601 (24 ref.)

The effect of managed care on breast cancer detection, treatment, and research. Haas BK. **Nurs Outlook** 1997 Jul–Aug;45(4):167–72 (36 ref.)

Justifying nurse practitioner existence: hard facts to hard figures [see comments] Buppert CK. **Nurse Pract** 1995 Aug; 20(8):43–4, 46–8 (12 ref.) Comment in: Nurse Pract 1996 Jan;21(1):6. Comment in: Nurse Pract 1996 Jan;21(1):6, 9.

Legal and practical impact of clinical practice guidelines on nursing and medical practice. Murphy RN. **Nurse Pract** 1997 Mar;22(3):138, 147–8 (3 ref.)

The impact of clinical pharmacists on psychiatric patients. Jenkins MH, et al. **Pharmacotherapy** 1996 Jul–Aug; 16(4):708–14 (40 ref.)

Outcomes of enhanced prenatal services for Medicaid-eligible women in public and private settings. Simpson L, et al. **Public Health Rep** 1997 Mar–Apr; 112(2):122–32; discussion 133–4 (42 ref.)

The next medical revolution should be quality. Friedenberg RM. **Radiology** 1997 Jul;204(1):31A–34A (14 ref.)

A conceptual framework for the study of early readmission as an indicator of quality of care. Ashton CM, et al. **Soc Sci Med** 1996 Dec;43(11):1533–41 (39 ref.)

Policy issues in the private health sector: examples from long-term care in the U.K. Bartlett HP, et al. **Soc Sci Med** 1996 Sep;43(5):731–7 (37 ref.)

Gender perspectives and quality of care: towards appropriate and adequate health care for women. Gijsbers van Wijk CM, et al. **Soc Sci Med** 1996 Sep;43(5):707–20 (75 ref.)

Gender perspectives and quality of care in underdeveloped countries: disease, gender and contextuality. Zaidi SA. **Soc Sci Med** 1996 Sep;43(5):721–30 (52 ref.)

CLASSIFICATION

Case mix adjustment in comparative audit. Hayes C, et al. **J Eval Clin Pract** 1995 Nov;1(2):105–11 (37 ref.)

Consumer satisfaction: a key to financial success in the managed care environment. Jones KC. **J Health Care Finance** 1997 Summer;23(4):21–32 (10 ref.)

ECONOMICS

Hypertension can be treated effectively without increasing the cost of care. Moser M. **J Hum Hypertens** 1996 Feb; 10 Suppl 2:533–8 (42 ref.)

Economic reform and health sector policy: lessons from structural adjustment programs. Peabody JW. **Soc Sci Med** 1996 Sep;43(5):823–35 (58 ref.)

LEGISLATION & JURISPRUDENCE

Determining the standard of care in medical negligence litigation in Australia. Collins A, et al. **Med Law** 1997; 16(2):201–7 (0 ref.)

What's happened to the healing process? Goldberg RM. **W V Med J** 1997 Jul–Aug;93(4):172–3 (0 ref.)

ORGANIZATION & ADMINISTRATION

Disease management: definitions and exploration of issues. Coons SJ. **Clin Ther** 1996 Nov–Dec;18(6):1321–6 (4 ref.)

STANDARDS

Physician assistants (PAs) provide quality care. Falligant L. **Wis Med J** 1997 Jun;96(6):13–4 (9 ref.)

TRENDS

What is driving health system change? [see comments] Etheredge L, et al. **Health Aff (Millwood)** 1996 Winter; 15(4):93–104 (8 ref.) Comment in: Health Aff (Millwood) 1996 Winter;15(4):111–13. Comment in: Health Aff (Millwood) 1996 Winter;15(4):114–5.

[Science priority, medical paternalism or participation in medical practice] Gibiński K. **Pol Merkuriusz Lek** 1996 Sep;1(3):213–5 (39 ref.) (Eng. Abstr.) **(Pol)**

QUALITY OF LIFE

see related
LIFE STYLE
SICKNESS IMPACT PROFILE

The effects and uses of heparin in the care of burns that improves treatment and enhances the quality of life. Saliba MJ Jr. **Acta Chir Plast** 1997;39(1):13–6 (34 ref.)

Patient history in the diagnosis of urinary incontinence and determining the quality of life. Kujansuu E. **Acta Obstet Gynecol Scand Suppl** 1997;166:15–8 (14 ref.)

Quality of life in head and neck cancer patients. Borghgraef K, et al. **Acta Otorhinolaryngol Belg** 1997;51(2):69–72 (7 ref.)

Learning impairment and allergic rhinitis. Simons FE. **Allergy Asthma Proc** 1996 Jul–Aug;17(4):185–9. (35 ref.)

Quality of life for critical care patients: a concept analysis. Bond AE. **Am J Crit Care** 1996 Jul;5(4):309–13 (54 ref.)

The impact of the implantable cardioverter defibrillator on quality of life. Gallagher RD, et al. **Am J Crit Care** 1997 Jan;6(1):16–24 (57 ref.)

Assessing health and quality of life outcomes in dialysis: a report on an Institute of Medicine workshop. Rettig RA, et al. **Am J Kidney Dis** 1997 Jul;30(1):140–55 (85 ref.)

The crippling consequences of fractures and their impact on quality of life. Cooper C. **Am J Med** 1997 Aug 18; 103(2A):12S–17S; discussion 17S–19S (34 ref.)

Tolerability, safety, and quality of life and hypertensive therapy: the case for low-dose diuretics. Weir MR, et al.

Am J Med 1996 Sep 30;101(3A):83S–92S (59 ref.)
Work and leisure: transcending the dichotomy. Primeau LA. **Am J Occup Ther** 1996 Jul–Aug;50(7):569–77 (61 ref.)
Venous disease: from pathophysiology to quality of life. Vanhoutte PM, et al. **Angiology** 1997 Jul;48(7):559–67 (29 ref.)
Measurement of quality of life in pediatric asthma clinical trials. Bender BG. **Ann Allergy Asthma Immunol** 1996 Dec; 77(6):438–45; quiz 446–7 (23 ref.)
Lessons from psychosocial studies of chronic renal failure. Postlethwaite RJ, et al. **Arch Dis Child** 1996 Nov; 75(5):455–9 (26 ref.)
Quality of life assessment in peripheral arterial disease. Hiatt WR. **Atherosclerosis** 1997 Jun;131 Suppl:S35–6 (7 ref.)
Approaches to measuring quality of life and their relevance to mental health. Stedman T. **Aust N Z J Psychiatry** 1996 Dec;30(6):731–40 (65 ref.)
Hodgkin's disease. Treatment sequelae and quality of life. Henry-Amar M. **Baillieres Clin Haematol** 1996 Sep; 9(3):595–618 (114 ref.)
Quality of life and neurobehavioural functioning in patients with malignant gliomas. Weitzner MA, et al. **Baillieres Clin Neurol** 1996 Jun;5(2):425–39 (64 ref.)
Quality of life measurement in dermatology: a practical guide. Finlay AY. **Br J Dermatol** 1997 Mar;136(3):305–14 (98 ref.)
Quality of life and its assessment in urology. Macdonagh R. **Br J Urol** 1996 Oct;78(4):485–96 (87 ref.)
Evaluation of quality of life for diverse patient populations. Yabroff KR, et al. **Breast Cancer Res Treat** 1996; 40(1):87–104 (196 ref.)
Impact of medical interventions on quality of life in cardiovascular disease: a consensus viewpoint. Arnold JM, et al. **Can J Cardiol** 1997 Mar;13(3):235–6 (08 ref.)
Health-related quality of life as a treatment endpoint in metastatic breast cancer. Osoba D. **Can J Oncol** 1995 Dec; 5 Suppl 1:47–53 (52 ref.)
Symptom distress in adult patients with cancer. McClement SE, et al. **Cancer Nurs** 1997 Aug;20(4):236–43 (44 ref.)
Assessing health-related quality of life in patients with genitourinary malignancies. Litwin MS. **Cancer Treat Res** 1996;88:249–64 (94 ref.)
Post-treatment limb function in soft tissue sarcomas. Robinson MH. **Cancer Treat Res** 1997;91:77–93 (38 ref.)
Quality of life in patients with atrial fibrillation. Jenkins LS, et al. **Cardiol Clin** 1996 Nov;14(4):597–606 (35 ref.)
Effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Kubo SH. **Cardiology** 1997;88 Suppl 2:21–7 (24 ref.)
The cost of lung transplantation and the quality of life post-transplant. Gross CR, et al. **Clin Chest Med** 1997 Jun; 18(2):391–403 (58 ref.)
Life expectancy, comorbidity, and quality of life. A framework of reference for medical decisions. Bennahum DA, et al. **Clin Geriatr Med** 1997 Feb;13(1):33–53 (94 ref.)
Symptomatic management of the older person with cancer. Sheehan DC, et al. **Clin Geriatr Med** 1997 Feb;13(1):203–19 (66 ref.)
A review of health-related quality-of-life measures used in end-stage renal disease. Edgell ET, et al. **Clin Ther** 1996 Sep–Oct;18(5):887–938 (129 ref.)
Physician and patient-oriented outcomes in progressive neurological disease: which to measure? Hobart JC, et al. **Curr Opin Neurol** 1996 Dec;9(6):441–4 (34 ref.)
The role of supportive care in quality of life. Warr D, et al. **Curr Opin Oncol** 1996 Jul;8(4):279–83 (24 ref.)
Impact of pancreas transplantation on diabetic secondary complications and quality of life. Landgraf R. **Diabetologia** 1996 Dec;39(12):1415–24 (112 ref.)
The role of leisure in stroke rehabilitation. Parker CJ, et al. **Disabil Rehabil** 1997 Jan;19(1):1–5 (40 ref.)
Outcome assessment in epilepsy: available rating scales for adults and methodological issues pertaining to the development of scales for childhood epilepsy. Carpay HA, et al. **Epilepsy Res** 1996 Jul;24(3):127–36 (78 ref.)
Do oncologists have an increasing interest in the quality of life of their patients? A literature review of the last 15 years. Batel-Copel LM, et al. **Eur J Cancer** 1997 Jan;33(1):29–32 (23 ref.)
Improving quality of life in patients with non-small cell lung cancer: research experience with gemcitabine. Thatcher N, et al. **Eur J Cancer** 1997 Jan;33 Suppl 1:S8–13 (33 ref.)
Widening perspectives: quality of life as a measure of outcome in the treatment of patients with cancers of the head and neck. Morris J. **Eur J Cancer B Oral Oncol** 1994 Jan;30B(1):29–31 (19 ref.)
Quality of life assessment and HIV infection: a review. Vanhems P, et al. **Eur J Epidemiol** 1996 Jun;12(3):221–8 (33 ref.)
Quality of life assessment in vascular disease: towards a consensus. Beattie DK, et al. **Eur J Vasc Endovasc Surg** 1997 Jan;13(1):9–13 (49 ref.)
Quality of life as an outcome measure in cancer clinical trials. Kiebert GM. **Eur Urol** 1997;31 Suppl 1:56–64 (21 ref.)
Conservative surgery and quality of life in a young patient with synchronous bilateral embryonal carcinoma. Mearini E, et al. **Eur Urol** 1996;29(1):119–21 (16 ref.)
Effect of angiotensin converting enzyme inhibitors on quality of life in hypertensive patients. Pharmacodynamic basis. Govantes C, et al. **Fundam Clin Pharmacol** 1996;10(4):400–5 (61 ref.)
When low-income mothers go to work: implications for children [see comments] Zaslow MJ, et al. **Future Child** 1997 Spring;7(1):110–5 (30 ref.) Comment in: Future Child 1997 Spring;7(1):116–21. Comment in: Future Child 1997 Spring;7(1):122–7.
Assessment tools for general health care settings: PRIME-MD, OARS, and SF-36. Primary Care Evaluation of Mental Health Disorders. Older Americans Resources and Services Questionnaire; Short Form-36. Van Hook MP, et al. **Health Soc Work** 1996 Aug;21(3):230–4 (23 ref.)
Quality of life in early prostate cancer. Do we know enough to treat? Talcott JA. **Hematol Oncol Clin North Am** 1996 Jun;10(3):691–701 (32 ref.)
Quality of life in anxiety and social phobia. Bech P, et al. **Int Clin Psychopharmacol** 1996 Jun;11 Suppl 3:97–100 (28 ref.)
Definition of life quality from a patient versus health care professional perspective. Woodend AK, et al. **Int J Rehabil Res** 1997 Mar;20(1):71–80 (35 ref.)
Assessment of quality of life: preservation of the self. Ronch JL. **Int Psychogeriatr** 1996 Summer;8(2):267–75 (35 ref.)
Women's experiences of non-invasive breast cancer: literature review and study report. Webb C, et al. **J Adv Nurs** 1997 Mar;25(3):514–25 (62 ref.)
Quality of life consequences of sleep-disordered breathing. Flemons WW, et al. **J Allergy Clin Immunol** 1997 Feb; 99(2):S750–6 (76 ref.)
Measuring health-related quality of life in rhinitis. Juniper EF. **J Allergy Clin Immunol** 1997 Feb;99(2):S742–9 (31 ref.)
Passion and heretics: meaning in life and quality of life of persons with dementia [editorial; comment] Russell K. **J Am Geriatr Soc** 1996 Nov;44(11):1400–2 (25 ref.) Comment on: J Am Geriatr Soc 1996 Nov;44(11):1342–7.
Outcome assessment in cardiac rehabilitation. Health-related quality of life and economic evaluation. Oldridge NB. **J Cardiopulm Rehabil** 1997 May–Jun;17(3):179–94 (169 ref.)
Can the measurement of quality of life contribute to evaluation in cardiac rehabilitation services? McGee HM. **J Cardiovasc Risk** 1996 Apr;3(2):148–53 (55 ref.)
Outcome measures, pooled index and quality of life instruments in rheumatoid arthritis. Cheah SY, et al. **J Clin Pharm Ther** 1996 Oct;21(5):297–316 (119 ref.)
Quality of life assessment in children: a review of conceptual and methodological issues in multidimensional health status measures. Pal DK. **J Epidemiol Community Health** 1996 Aug;50(4):391–6 (35 ref.)
Health outcomes research on Hispanics/Latinos. Giachello AL. **J Med Syst** 1996 Oct;20(5):235–54 (41 ref.)
Health outcome and quality-of-life measurements in amyotrophic lateral sclerosis. Swash M. **J Neurol** 1997 May;244 Suppl 2:S26–9 (22 ref.)
Assessment of health-related quality of life in children and adolescents: an integrative review. Spieth LE, et al. **J Pediatr Psychol** 1996 Apr;21(2):175–93 (64 ref.)
Quality of life measurement during antipsychotic drug therapy of schizophrenia. Voruganti LN, et al. **J Psychiatry Neurosci** 1997 Jul;22(4):267–74 (37 ref.)
Quality of life in cystic fibrosis. Abbott J, et al. **J R Soc Med** 1997;90 Suppl 31:37–42 (29 ref.)
Systemic Lupus International Collaborating Clinics conference on assessment of lupus flare and quality of life measures in SLE. Systemic Lupus International Collaborating Clinics Group. Gladman D, et al. **J Rheumatol** 1996 Nov;23(11):1953–5 (14 ref.)
Rheumatic and musculoskeletal diseases and impaired quality of life: a challenge for rheumatologists [editorial] [see comments] Morales-Torres J, et al. **J Rheumatol** 1996 Jan; 23(1):1–3 (30 ref.) Comment in: J Rheumatol 1997 Feb;24(2):411.
WHO/ILAR Taskforce on quality of life. Strand CV, et al. **J Rheumatol** 1997 Aug;24(8):1630–3 (1 ref.)
Longterm followup and quality of life after hematopoietic stem cell transplantation. Sullivan KM. **J Rheumatol Suppl** 1997 May;48:46–52 (50 ref.)
Proper preference-based outcome measures in economic evaluations of pharmaceutical interventions. Gafni A. **Med Care** 1996 Dec;34(12 Suppl):DS48–58 (59 ref.)
Variation among quality-of-life surveys. Theory and practice. Hornberger J, et al. **Med Care** 1996 Dec;34(12 Suppl):DS23–33 (81 ref.)
The consequence of production loss or increased costs of production. Koopmanschap MA, et al. **Med Care** 1996 Dec; 34(12 Suppl):DS59–68 (22 ref.)
Evaluation of quality of life in coronary heart disease. Wiklund I. **Methods Find Exp Clin Pharmacol** 1996;18 Suppl C:37–8 (13 ref.)
Sexual abuse during childhood and adolescence and its effects on the physical and emotional quality of life of the survivor: a review of the literature. Wood DP. **Mil Med** 1996 Oct; 161(10):582–7 (38 ref.)
Development of measurement techniques. Munsat TL. **Neurology** 1996 Oct;47(4 Suppl 2):S83–5 (11 ref.)
Evolution of the measurement of quality of life in migraine. Solomon GD. **Neurology** 1997 Mar;48(3 Suppl 3):S10–5 (33 ref.)
The rural elderly: living the good life? Jensen GL. **Nutr Rev** 1996 Jan;54(1 Pt 2):S17–21 (16 ref.)
Quality of life and the cancer experience: the state-of-the-knowledge. King CR, et al. **Oncol Nurs Forum** 1997 Jan–Feb;24(1):27–41 (138 ref.)
Physical exercise as an oncology nursing intervention to enhance quality of life. Smith SL. **Oncol Nurs Forum** 1996 Jun;23(5):771–8 (51 ref.)
Quality of life among long-term cancer survivors. Ferrell BR, et al. **Oncology (Huntingt)** 1997 Apr;11(4):565–8, 571; discussion 572, 575–6 (32 ref.)
Quality of life after radiation therapy for base of tongue cancer. Moore GJ. **Oncology (Huntingt)** 1996 Nov; 10(11):1643–8; discussion 1649–50, 1655 (20 ref.)
Interaction of tamoxifen's impact on overall net mortality and quality of life. Ragaz J. **Oncology (Huntingt)** 1997 Feb; 11(2 Suppl 1):45–8 (22 ref.)
Assessing pharmacotherapy outcomes: a model for clinicians. Gleason PP, et al. **Pharmacotherapy** 1996 Nov–Dec; 16(6):1142–53 (102 ref.)
Overview of health-related quality-of-life measures for pediatric patients: application in the assessment of pharmacotherapeutic and pharmacoeconomic outcomes. Marra CA, et al. **Pharmacotherapy** 1996 Sep–Oct; 16(5):879–88 (81 ref.)
Management of epilepsy: pharmacologic therapy and quality-of-life issues. Schachter SC, et al. **Postgrad Med** 1997 Feb;101(2):133–8, 141–4, 150–3 (21 ref.)
Patients' quality of life: a continuing concern in the literature. Bachrach LI. **Psychiatr Serv** 1996 Dec;47(12):1305–6, 1330 (15 ref.)
Prediction of quality of life after coronary artery bypass graft surgery: a review and evaluation of multiple, recent studies. Duits AA, et al. **Psychosom Med** 1997 May–Jun; 59(3):257–68 (74 ref.)
Psychological well-being: meaning, measurement, and implications for psychotherapy research. Ryff CD, et al. **Psychother Psychosom** 1996;65(1):14–23 (56 ref.)
'Equivalence' and the translation and adaptation of health-related quality of life questionnaires. Herdman M, et al. **Qual Life Res** 1997 Apr;6(3):237–47 (42 ref.)
The problem of quality of life [editorial] Hunt SM. **Qual Life Res** 1997 Apr;6(3):205–12 (54 ref.)
Quality of life claims in trials of anti-hypertensive therapy. Hunt SM. **Qual Life Res** 1997 Mar;6(2):185–91 (49 ref.)
The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. King MT. **Qual Life Res** 1996 Dec;5(6):555–67 (35 ref.)
Assessing quality of life in chronic non-specific lung disease—a review of empirical studies published between 1980 and 1994. Maillé AR, et al. **Qual Life Res** 1996 Apr; 5(2):287–301 (116 ref.)
Guidelines for reporting results of quality of life assessments in clinical trials. Staquet M, et al. **Qual Life Res** 1996 Oct; 5(5):496–502 (13 ref.)
Quality of life: a reflection of symptoms and concerns. Glise H, et al. **Scand J Gastroenterol Suppl** 1996;221:14–7 (20 ref.)
Measuring quality of life: a review. Irvine EJ. **Scand J Gastroenterol Suppl** 1996;221:5–7 (10 ref.)
Quality of life in HIV infection. O'Keefe EA, et al. **Scand J Gastroenterol Suppl** 1996;221:30–2 (15 ref.)
Quality of life in functional dyspepsia. Talley NJ. **Scand J Gastroenterol Suppl** 1996;221:21–2 (18 ref.)
Psychological and psychosexual implications of herpes simplex virus infections. Mindel A. **Scand J Infect Dis Suppl** 1996;100:27–32 (53 ref.)
Roles of diet and physical activity in the prevention of osteoporosis. Anderson JJ, et al. **Scand J Rheumatol Suppl** 1996;103:65–74 (43 ref.)
What is an acceptable treatment outcome? Djurhuus JC, et al. **Scand J Urol Nephrol Suppl** 1997;183:75–7 (9 ref.)
Development of a conceptual model of quality of life. Ferrans CE. **Sch Inq Nurs Pract** 1996 Fall;10(3):293–304 (71 ref.)
Health-related quality of life after total hip replacement. Towheed TE, et al. **Semin Arthritis Rheum** 1996 Aug; 26(1):483–91 (42 ref.)
Quality of life in advanced prostate cancer. Fosså SD. **Semin Oncol** 1996 Dec;23(6 Suppl 14):32–4 (15 ref.)
Quality of life assessment in chemotherapy trials for non-small cell lung cancer: are theory and practice significantly different? Hopwood P. **Semin Oncol** 1996 Oct; 23(5 Suppl 10):60–4 (24 ref.)
Psychosocial issues and lung cancer: a behavioral approach. Ryan LS. **Semin Oncol Nurs** 1996 Nov;12(4):318–23 (80 ref.)
Quality of life assessment. Morales AJ, et al. **Semin Reprod Endocrinol** 1996 May;14(2):155–9 (33 ref.)
Quality of life as an outcome measure in evaluating mental health services: a review of the empirical evidence. Barry MM, et al. **Soc Psychiatry Psychiatr Epidemiol** 1997 Jan; 32(1):38–47 (32 ref.)
Measures of quality of life among persons with severe and persistent mental disorders. Lehman AF. **Soc Psychiatry Psychiatr Epidemiol** 1996 Mar;31(2):78–88 (26 ref.)
Quality of life: a dynamic construct. Allison PJ, et al. **Soc Sci Med** 1997 Jul;45(2):221–30 (60 ref.)
Studying the quality of life after organ transplantation: research problems and solutions. Joralemon D, et al. **Soc Sci Med** 1997 May;44(9):1259–69 (100 ref.)
Quality of life in patients with prostatic carcinoma: a review and results of a study in N+ disease. Prostate-specific antigen as predictor of quality of life. van Andel G, et al. **Urol Res** 1997;25 Suppl 2:S79–88 (36 ref.)
[Evaluation of the quality of life in patients with gynecologic cancer and its intervention] Sun X, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Jun;31(6):378–80 (16 ref.) **(Chi)**
[Importance of early detection of metastases? Impact on survival and quality of life] Pujol H. **Nucl Med Biol** 1994

Apr;21(3):303–15 (16 ref.) (Eng. Abstr.) **(Fre)**
[Quality of life after orthopedic surgery of the lower limbs. A new approach] Guillemin F, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(6):549–56 (27 ref.) (Eng. Abstr.) **(Fre)**
[Non-motor symptoms of Parkinson disease. Significant impact on quality of life—using possible treatments] Müller T, et al. **Fortschr Med** 1997 May 20;115(14):45–8 (0 ref.) (Eng. Abstr.) **(Ger)**
[The need for preventive measures. Need for preventive measures at any price? Attempt at an argument in favor of the need for prevention not only for economic reasons (published erratum appears in Gesundheitswesen 1996 Dec;58(12):702)] Nadolski H, et al. **Gesundheitswesen** 1996 Aug–Sep;58(8–9):432–41 (160 ref.) **(Ger)**
[Indications and performance of a 6 minute treadmill test in pneumology] Kirsten D, et al. **Pneumologie** 1997 Jan; 51(1):33–5 (17 ref.) (Eng. Abstr.) **(Ger)**
[Health related quality of life and subjective health. Overview of the status of research for new evaluation criteria in medicine] Bullinger M. **Psychother Psychosom Med Psychol** 1997 Mar–Apr; 47(3–4):76–91 (165 ref.) (Eng. Abstr.) **(Ger)**
[HIV infection and long-term health: therapeutically attainable?] Baumgarten R. **Z Arztl Fortbild Qualitatssich** 1997 Mar;91(2):149–53 (13 ref.) (Eng. Abstr.) **(Ger)**
[Quality of life in advanced coronary heart disease] Siegrist J, et al. **Z Kardiol** 1997;86 Suppl 1:1–7 (22 ref.) (Eng. Abstr.) **(Ger)**
[Measuring quality of life as an integral component of quality management in surgical medicine] Lorenz W, et al. **Zentralbl Chir** 1996;121(7):545–51 (26 ref.) (Eng. Abstr.) **(Ger)**
[The concept of quality of life in cardiac failure] Cafagna D, et al. **Minerva Med** 1997 Apr;88(4):151–62 (55 ref.) (Eng. Abstr.) **(Ita)**
[Quality of life. Assessment and application] Okuda M. **Nippon Ika Daigaku Zasshi** 1996 Feb;63(1):2–8 (13 ref.) **(Jpn)**
[The quality of life for the elderly in long-term care—view point of social welfare] Ohkuni M. **Nippon Ronen Igakkai Zasshi** 1996 Jul;33(7):508–11 (0 ref.) **(Jpn)**
[Evaluation of quality of life in oncology] Radosavljević D, et al. **Srp Arh Celok Lek** 1997 Sep–Oct;125(9–10):303–10 (36 ref.) (Eng. Abstr.) **(Scc)**
[Quality of life in epilepsy] Oliveros Juste A. **Neurologia** 1996 Dec;11 Suppl 4:100–7 (11 ref.) (Eng. Abstr.) **(Spa)**
[Investigation methods in clinical cardiology. VI. Evaluation of results (outcomes) and its clinical relevance in cardiology: with a special reference to the quality of life] Brotons Cuixart C, et al. **Rev Esp Cardiol** 1997 Mar; 50(3):192–200 (44 ref.) (Eng. Abstr.) **(Spa)**
[Multiple sclerosis and quality of life] Hernández MA. **Rev Neurol** 1996 Oct;24(134):1221–3 (11 ref.) **(Spa)**

QUANTUM THEORY

Strategic leadership: a view from quantum and chaos theories. McDaniel RR Jr. **Health Care Manage Rev** 1997 Winter;22(1):21–37 (74 ref.)
Can quantum processes control synaptic emission? Beck F. **Int J Neural Syst** 1996 Sep;7(4):343–53 (24 ref.)
Consciousness and biological order: toward a quantum theory of life and its evolution [see comments] Goswami A. **Integr Physiol Behav Sci** 1997 Jan–Mar;32(1):86–100 (46 ref.) Comment in: Integr Physiol Behav Sci 1997 Apr–Jun;32(2):132–42.
On the value of clinical information. Is there a bridge between quantum theory and medical diagnosis? de Dombal FT. **Technol Health Care** 1996 Aug;4(2):129–36 (13 ref.)

QUARANTINE

see related
PATIENT ISOLATION
Involuntary confinement for tuberculosis control: the Jewish view. Rosner F. **Mt Sinai J Med** 1996 Jan;63(1):44–8 (27 ref.)
Quarantine of aquatic animals in Australia. Doyle KA, et al. **Rev Sci Tech** 1996 Jun;15(2):659–73 (25 ref.)

VETERINARY
Quarantine protocols and preventive medicine procedures for reptiles, birds and mammals in zoos. Miller RE. **Rev Sci Tech** 1996 Mar;15(1):183–9 (1 ref.)

QUERCETIN

THERAPEUTIC USE
Quercetin and the growth of leukemic progenitors. Larocca LM, et al. **Leuk Lymphoma** 1996 Sep;23(1–2):49–53 (51 ref.)

QUESTIONNAIRES

Assessments of food-frequency questionnaires in minority populations. Coates RJ, et al. **Am J Clin Nutr** 1997 Apr; 65(4 Suppl):1108S–1115S (46 ref.)
Biochemical markers as additional measurements in studies of the accuracy of dietary questionnaire measurements: conceptual issues. Kaaks RJ. **Am J Clin Nutr** 1997 Apr; 65(4 Suppl):1232S–1239S (29 ref.)
Development of culturally competent food-frequency questionnaires. Teufel NI. **Am J Clin Nutr** 1997 Apr;65(4 Suppl):1173S–1178S (31 ref.)
Dietary and exercise assessment in general practice. Little P, et al. **Fam Pract** 1996 Oct;13(5):477–82 (47 ref.)
Assessment tools for general health care settings: PRIME-MD, OARS, and SF-36. Primary Care Evaluation of Mental Health Disorders. Older Americans Resources and Services Questionnaire; Short Form-36. Van Hook MP, et al. **Health Soc Work** 1996 Aug;21(3):230–4 (23 ref.)
Practical issues in psychosocial measures. Wolfe F. **J Rheumatol** 1997 May;24(5):990–3 (35 ref.)
Quality of life claims in trials of anti-hypertensive therapy. Hunt SM. **Qual Life Res** 1997 Mar;6(2):185–91 (49 ref.)
The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. King MT. **Qual Life Res** 1996 Dec;5(6):555–67 (35 ref.)
Assessing quality of life in chronic non-specific lung disease—a review of empirical studies published between 1980 and 1994. Maillé AR, et al. **Qual Life Res** 1996 Apr; 5(2):287–301 (116 ref.)
The role of personal interviews by direct questioning on blood donors with particular reference to prevention of transfusion-related infections: a Scottish perspective. Galea G. **Transfus Med** 1997 Mar;7(1):13–7 (20 ref.)
[Questionnaires on preoperative evaluation of patients] Irita K, et al. **Masui** 1996 Dec;45 Suppl:S147–54 (9 ref.) **(Jpn)**

CLASSIFICATION
Measuring health-related quality of life in rhinitis. Juniper EF. **J Allergy Clin Immunol** 1997 Feb;99(2):S742–9 (31 ref.)

STANDARDS
Impact of medical interventions on quality of life in cardiovascular disease: a consensus viewpoint. Arnold JM, et al. **Can J Cardiol** 1997 Mar;13(3):235–6 (08 ref.)
Measuring and monitoring general health status in elderly persons: practical and methodological issues in using the SF-36 Health Survey. McHorney CA. **Gerontologist** 1996 Oct;36(5):571–83 (74 ref.)
The assessment of panic using self-report: a comprehensive survey of validated instruments. Bouchard S, et al. **J Anxiety Disord** 1997 Jan–Feb;11(1):89–111 (73 ref.)
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers [see comments] Hayes DF, et al. **J Natl Cancer Inst** 1996 Oct 16; 88(20):1456–66 (65 ref.) Comment in: J Natl Cancer Inst 1996 Oct 16;88(20):1419–20.
Health status measures: strategies and analytic methods for assessing change scores. Stratford PW, et al. **Phys Ther** 1996 Oct;76(10):1109–23 (33 ref.)
'Equivalence' and the translation and adaptation of health-related quality of life questionnaires. Herdman M, et al. **Qual Life Res** 1997 Apr;6(3):237–47 (42 ref.)
Selection and use of content experts for instrument development. Grant JS, et al. **Res Nurs Health** 1997 Jun; 20(3):269–74 (25 ref.)

QUETELET'S INDEX see **BODY MASS INDEX**

QUEUING THEORY see **SYSTEMS THEORY**

QUICK TEST see **PROTHROMBIN TIME**

QUINACRINE

100,000 quinacrine sterilizations. Kessel E. **Adv Contracept** 1996 Jun;12(2):69–76 (37 ref.)
Quinacrine revised. Zipper J, et al. **Hum Reprod Update** 1995 Jul;1(4):324–42 (133 ref.)

THERAPEUTIC USE
Transcervical quinacrine sterilization: clinical experience. Sokal DC, et al. **Int J Gynaecol Obstet** 1995 Dec;51 Suppl 1:S57–69 (50 ref.)
Quinacrine: sclerosing agent of the utero-tubal junction in women, with anticarcinogenic actions in transplanted tumors in mice. Zipper J, et al. **Int J Gynaecol Obstet** 1995 Dec;51 Suppl 1:S47–55 (73 ref.)

QUINAZOLINES

ADVERSE EFFECTS
Precipitous fall in platelet count with anagrelide: case report and critique of dosing recommendations. McCune JS, et al. **Pharmacotherapy** 1997 Jul–Aug;17(4):822–6 (9 ref.)

CHEMISTRY
Quinoline, quinazoline and acridone alkaloids. Michael JP. **Nat Prod Rep** 1997 Feb;14(1):11–20 (61 ref.)

PHARMACOKINETICS
Pharmacokinetic and pharmacodynamic properties and therapeutic use of bunazosin in hypertension. A review. Weidinger G. **Arzneimittelforschung** 1995 Nov; 45(11):1166–71 (66 ref.)

PHARMACOLOGY
Pharmacokinetic and pharmacodynamic properties and therapeutic use of bunazosin in hypertension. A review. Weidinger G. **Arzneimittelforschung** 1995 Nov; 45(11):1166–71 (66 ref.)
Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Wakeling AE, et al. **Breast Cancer Res Treat** 1996;38(1):67–73 (25 ref.)
Efficacy and tolerability of a new inhibitor of thymidylate synthase: 'Tomudex' (raltitrexed). Cunningham D. **Tumori** 1997 Jan–Feb;83(1 Suppl):S70–1 (08 ref.)

THERAPEUTIC USE
New drugs in essential thrombocythemia and polycythemia vera. Tefferi A, et al. **Blood Rev** 1997 Mar;11(1):1–7 (87 ref.)
Raltitrexed in colorectal cancer. **Drug Ther Bull** 1996 Oct; 34(10):78–80 (11 ref.)
Tomudex (ZD1694): from concept to care, a programme in rational drug discovery. Jackman AL, et al. **Invest New Drugs** 1996;14(3):305–16 (83 ref.)
Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Petitt RM, et al. **Semin Hematol** 1997 Jan;34(1):51–4 (5 ref.)
The potential role of Tomudex in the treatment of advanced colorectal cancer. Sobrero AF. **Tumori** 1997 Mar–Apr; 83(2):576–80 (42 ref.)

QUINCKE'S EDEMA see **ANGIONEUROTIC EDEMA**

QUINIDINE

PHARMACOKINETICS
Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Krishna S, et al. **Clin Pharmacokinet** 1996 Apr;30(4):263–99 (267 ref.)

PHARMACOLOGY
Dofetilide versus quinidine for atrial flutter: viva la difference!? [editorial; comment] Olshansky B. **J Cardiovasc Electrophysiol** 1996 Sep;7(9):828–32 (18 ref.) Comment on: J Cardiovasc Electrophysiol 1996 Sep;7(9):809–27.
[Quinidine and high-amplification ECG] Brembilla-Perrot B, et al. **Ann Cardiol Angeiol (Paris)** 1997 Jan;46(1):15–20 (20 ref.) (Eng. Abstr.) **(Fre)**

QUININE

ADVERSE EFFECTS
Quinine-induced hemolytic uremic syndrome. McDonald SP, et al. **Clin Nephrol** 1997 Jun;47(6):397–400 (21 ref.)

PHARMACOKINETICS
Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Krishna S, et al. **Clin Pharmacokinet** 1996 Apr;30(4):263–99 (267 ref.)

PHARMACOLOGY
[Effect of quinine on the multiple drug resistance and intracellular distribution of pirarubicin in LR73 tumor cells: a comparative study with verapamil and S9788 by confocal laser microspectrofluorometry] Belhoussine R, et al. **Bull Cancer** 1997 Apr;84(4):343–9 (39 ref.) (Eng. Abstr.) **(Fre)**

QUINOLINATE see **QUINOLINIC ACID**

QUINOLINES

CHEMISTRY
Quinoline, quinazoline and acridone alkaloids. Michael JP. **Nat Prod Rep** 1997 Feb;14(1):11–20 (61 ref.)
New developments in the molecular pharmacology of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate and kainate receptors. Fletcher EJ, et al. **Pharmacol Ther** 1996;70(1):65–89 (251 ref.)

METABOLISM
Microbial metabolism of pyridine, quinoline, acridine, and their derivatives under aerobic and anaerobic conditions. Kaiser JP, et al. **Microbiol Rev** 1996 Sep;60(3):483–98 (146 ref.)
Metabolism of heterocyclic aromatic amines and strategies of human biomonitoring. Turesky RJ, et al. **Princess Takamatsu Symp** 1995;23:59–68 (30 ref.)

PHARMACOKINETICS
Exposure to and activation of dietary heterocyclic amines in humans. Lynch AM, et al. **Crit Rev Oncol Hematol** 1995 Nov;21(1–3):19–31 (124 ref.)

PHARMACOLOGY
Quinoline antimalarials: mechanisms of action and resistance. Foley M, et al. **Int J Parasitol** 1997 Feb;27(2):231–40 (60 ref.)

Vesnarinone: a potential cytokine inhibitor. Sasayama S, et al. **J Card Fail** 1996 Sep;2(3):251–8 (52 ref.)
[Overcoming of multidrug resistance by a newly synthesized quinoline compound, MS-209] Naito M, et al. **Nippon Rinsho** 1997 May;55(5):1122–7 (12 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

[Peptidoleukotriene receptor antagonists in asthma therapy] Sakakibara H, et al. **Nippon Rinsho** 1996 Nov; 54(11):3049–55 (36 ref.) (Eng. Abstr.) **(Jpn)**

TOXICITY

Genetic changes induced by heterocyclic amines. Nagao M, et al. **Mutat Res** 1997 May 12;376(1–2):161–7 (43 ref.)

QUINOLINIC ACID

CEREBROSPINAL FLUID

[Biochemical changes in cerebrospinal fluid associated with the neurotoxic action of HIV-1] Gómez Alcalde MS, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 Jul–Aug;24(4):209–18 (65 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

The kynurenine pathway and neurologic disease. Therapeutic strategies. Heyes MP. **Adv Exp Med Biol** 1996;398:125–9 (23 ref.)
Kynurenine pathway enzymes in brain. Properties of enzymes and regulation of quinolinic acid synthesis. Saito K, et al. **Adv Exp Med Biol** 1996;398:485–92 (42 ref.)

QUINOLINOLS see **HYDROXYQUINOLINES**

QUINOLINONES see **QUINOLONES**

QUINOLIZINES

Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. Balfour JA, et al. **Drugs** 1997 Aug;54(2):273–98 (86 ref.)

CHEMICAL SYNTHESIS

[Highlights from 43 years of chemistry of naturally occurring nitrogen-containing heterocycles. (1). Syntheses and structure determinations of benzo[a]quinolizidine-type and indolo[2,3-a]quinolizidine-type alkaloids isolated from several plants] Fujii T. **Yakugaku Zasshi** 1996 May; 116(5):335–54 (76 ref.) (Eng. Abstr.) **(Jpn)**

QUINOLONE ANTI-INFECTIVE AGENTS see **ANTI-INFECTIVE AGENTS, QUINOLONE**

QUINOLONES

see related
ANTI-INFECTIVE AGENTS, QUINOLONE

METABOLISM

New quinocofactors in eukaryotes. Klinman JP. **J Biol Chem** 1996 Nov 1;271(44):27189–92 (39 ref.)

PHARMACOKINETICS

Disposition of single-dose oral enrofloxacin in the horse. Langston VC, et al. **J Vet Pharmacol Ther** 1996 Aug; 19(4):316–9 (11 ref.)

PHARMACOLOGY

Sparfloxacin worldwide in vitro literature: isolate data available through 1994. Cohen MA, et al. **Diagn Microbiol Infect Dis** 1996 Jun;25(2):53–64 (114 ref.)
Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections. Goa KL, et al. **Drugs** 1997 Apr;53(4):700–25 (150 ref.)
DNA gyrase, topoisomerase IV, and the 4-quinolones. Drlica K, et al. **Microbiol Mol Biol Rev** 1997 Sep;61(3):377–92 (214 ref.)

POISONING

An unlikely childhood overdose: temafloxacin. Muñiz AE. **Pediatr Emerg Care** 1996 Jun;12(3):215–6 (13 ref.)

THERAPEUTIC USE

New generations of quinolones: with particular attention to levofloxacin. Ambrose PG, et al. **Conn Med** 1997 May; 61(5):269–72 (11 ref.)
Grepafloxacin. Wagstaff AJ, et al. **Drugs** 1997 May; 53(5):817–24; discussion 825–7 (39 ref.)
Sequential antimicrobial therapy—the role of quinolones. Nathwani D, et al. **J Antimicrob Chemother** 1997 Apr; 39(4):441–6 (54 ref.)

QUINONE REDUCTASE see **NAD(P)H DEHYDROGENASE (QUINONE)**

QUINONE REDUCTASES

[NADH-quinone oxidoreductase: the hugest and most complicated membrane-bound enzyme complex] Yano T. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(2):154–63 (46 ref.) **(Jpn)**

GENETICS

Hormonal regulation of hepatic enzymes involved in foreign compound metabolism. Prough RA, et al. **FASEB J** 1996 Oct;10(12):1369–77 (39 ref.)

QUINONES

CHEMICAL SYNTHESIS

[Weitz' aminium salt initiated electron transfer reactions and application to the synthesis of natural products] Takeya T, et al. **Yakugaku Zasshi** 1997 Jun;117(6):353–67 (21 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Quinoprotein-catalysed reactions. Anthony C. **Biochem J** 1996 Dec 15;320 (Pt 3):697–711 (142 ref.)

METABOLISM

Quinoprotein-catalysed reactions. Anthony C. **Biochem J** 1996 Dec 15;320 (Pt 3):697–711 (142 ref.)
New quinocofactors in eukaryotes. Klinman JP. **J Biol Chem** 1996 Nov 1;271(44):27189–92 (39 ref.)

QUINOXALINES

Overview of carcinogenic heterocyclic amines. Sugimura T. **Mutat Res** 1997 May 12;376(1–2):211–9 (62 ref.)
Factors affecting the formation and yield of heterocyclic amines. Skog K, et al. **Princess Takamatsu Symp** 1995; 23:9–19 (23 ref.)

ADMINISTRATION & DOSAGE

Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Walters TR. **Surv Ophthalmol** 1996 Nov;41 Suppl 1:S19–26 (26 ref.)

ANALYSIS

Identification of new mutagenic heterocyclic amines and quantification of known heterocyclic amines. Wakabayashi K, et al. **Princess Takamatsu Symp** 1995;23:39–49 (31 ref.)

CHEMICAL SYNTHESIS

Synthetic routes to the food carcinogen 2 amino-3,8-dimethylimidazo[4,5-f]quinoxaline (8-MeIQx) and related compounds. Grivas S. **Princess Takamatsu Symp** 1995;23:1–8 (27 ref.)

METABOLISM

Enzymatic studies of the activation of heterocyclic food mutagens in man. Boobis AR, et al. **Princess Takamatsu Symp** 1995;23:134–44 (38 ref.)
Systemic exposure to dietary heterocyclic amines in man. Davies DS, et al. **Princess Takamatsu Symp** 1995;23:190–6 (30 ref.)
Metabolism of heterocyclic aromatic amines and strategies of human biomonitoring. Turesky RJ, et al. **Princess Takamatsu Symp** 1995;23:59–68 (30 ref.)
Assessment of the DNA adduction and pharmacokinetics of PhIP and MeIOx in rodents at doses approximating human exposure using the technique of accelerator mass spectrometry (AMS) and 32P-postlabeling. Turteltaub KW, et al. **Princess Takamatsu Symp** 1995;23:93–102 (30 ref.)

PHARMACOKINETICS

Exposure to and activation of dietary heterocyclic amines in humans. Lynch AM, et al. **Crit Rev Oncol Hematol** 1995 Nov;21(1–3):19–31 (124 ref.)

PHARMACOLOGY

Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment. Greenfield DS, et al. **J Glaucoma** 1997 Aug;6(4):250–8 (52 ref.)
Preclinical evaluation of brimonidine. Burke J, et al. **Surv Ophthalmol** 1996 Nov;41 Suppl 1:S9–18 (62 ref.)

THERAPEUTIC USE

The role of brimonidine in the treatment of open-angle glaucoma. Wilensky JT. **Surv Ophthalmol** 1996 Nov;41 Suppl 1:S3–7 (24 ref.)

TOXICITY

Heterocyclic amines: evaluation of their role in diet associated human cancer. Gooderham NJ, et al. **Br J Clin Pharmacol** 1996 Jul;42(1):91–8 (56 ref.)

QUINUCLIDINES

THERAPEUTIC USE

Discovery & development of selective M3 antagonists for clinical use. Alabaster VA. **Life Sci** 1997;60(13–14):1053–60 (24 ref.)

QUISQUALATE RECEPTORS see **RECEPTORS, AMPA**

QUOKKAS see **KANGAROOS**

R FACTORS

Resistance mechanisms to arsenicals and antimonials. Rosen BP. **J Basic Clin Physiol Pharmacol** 1995;6(3–4):251–63 (50 ref.)

R GENE PRODUCTS see **GENE PRODUCTS, VPR**

R PLASMIDS see **R FACTORS**

R REPETITIVE SEQUENCE see **REPETITIVE SEQUENCES, NUCLEIC ACID**

RABBIT AORTA CONTRACTING SUBSTANCE see **THROMBOXANE A2**

RABBITPOX VIRUS see **VACCINIA VIRUS**

RABBITS

Rabbit haemorrhagic disease: the new scourge of Oryctolagus cuniculus. Chasey D. **Lab Anim** 1997 Jan;31(1):33–44 (138 ref.)
Progress towards using recombinant myxoma virus as a vector for fertility control in rabbits. Robinson AJ, et al. **Reprod Fertil Dev** 1997;9(1):77–83 (43 ref.)

IMMUNOLOGY

B lymphocyte development in the rabbit. Knight KL, et al. **Int Rev Immunol** 1997;15(3–4):129–63 (108 ref.)

PHYSIOLOGY

Coital and estrogen signals: a contrast in the preovulatory neuroendocrine networks of rabbits and rhesus monkeys. Spies HG, et al. **Biol Reprod** 1997 Feb;56(2):310–9 (157 ref.)

PSYCHOLOGY

Hippocampal electrical activity and behavior in the rabbit. Fontani G, et al. **Arch Ital Biol** 1997 Jan;135(1):49–71 (130 ref.)

RABIES

New aspects of rabies with emphasis on epidemiology, diagnosis, and prevention of the disease in the United States. Smith JS. **Clin Microbiol Rev** 1996 Apr;9(2):166–76 (73 ref.)
Rabies. Hemachudha T, et al. **Curr Opin Neurol** 1997 Jun; 10(3):260–7 (83 ref.)
Rabies and rabies research: past, present and future. Fu ZF. **Vaccine** 1997 Spring;15 Suppl:S20–4 (21 ref.)
[Rabies virus] Fukaya K. **Nippon Rinsho** 1997 Apr; 55(4):891–6 (11 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[Diagnosis and therapy of rabies] Thraenhart O, et al. **Dtsch Med Wochenschr** 1997 Feb 21;122(8):231–4 (13 ref.) **(Ger)**

EPIDEMIOLOGY

Rabies in New Hampshire and Vermont: an update. Brown CI, et al. **Ann Clin Lab Sci** 1997 May–Jun;27(3):216–23 (17 ref.)
The ascension of wildlife rabies: a cause for public health concern or intervention? Rupprecht CE, et al. **Emerg Infect Dis** 1995 Oct–Dec;1(4):107–14 (46 ref.)

HISTORY

Rabies: interactions between neurons and viruses. A review of the history of Negri inclusion bodies. Kristensson K, et al. **Neuropathol Appl Neurobiol** 1996 Jun;22(3):179–87 (30 ref.)

IMMUNOLOGY

Superantigen related to rabies. Lafon M, et al. **Springer Semin Immunopathol** 1996;17(4):307–18 (60 ref.)

PATHOLOGY

Rabies: interactions between neurons and viruses. A review of the history of Negri inclusion bodies. Kristensson K, et al. **Neuropathol Appl Neurobiol** 1996 Jun;22(3):179–87 (30 ref.)

PREVENTION & CONTROL

Rabies prophylaxis. Vanhoof R, et al. **Acta Clin Belg** 1996; 51(5):328–39 (38 ref.)

RABIES

RADIOGRAPHY

Imaging findings in rabies. Sing TM, et al. **Australas Radiol** 1996 Aug;40(3):338–41 (14 ref.)

THERAPY

[Diagnosis and therapy of rabies] Thraenhart O, et al. **Dtsch Med Wochenschr** 1997 Feb 21;122(8):231–4 (13 ref.) **(Ger)**

VETERINARY

Rabies in New Hampshire and Vermont: an update. Brown CI, et al. **Ann Clin Lab Sci** 1997 May–Jun;27(3):216–23 (17 ref.)

The ascension of wildlife rabies: a cause for public health concern or intervention? Rupprecht CE, et al. **Emerg Infect Dis** 1995 Oct–Dec;1(4):107–14 (46 ref.)

Rabies. Green SL. **Vet Clin North Am Equine Pract** 1997 Apr;13(1):1–11 (39 ref.)

RABIES VACCINE

A global review of rabies vaccines for human use. Dreesen DW. **Vaccine** 1997 Spring;15 Suppl:S2–6 (25 ref.)

ADMINISTRATION & DOSAGE

[Pre- and postgestational vaccination] Figueroa-Damián R. **Ginecol Obstet Mex** 1996 Jul;64:310–5 (27 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Rabies prophylaxis. Vanhoof R, et al. **Acta Clin Belg** 1996; 51(5):328–39 (38 ref.)

RABIES VIRUS

New aspects of rabies with emphasis on epidemiology, diagnosis, and prevention of the disease in the United States. Smith JS. **Clin Microbiol Rev** 1996 Apr;9(2):166–76 (73 ref.)

Rabies: interactions between neurons and viruses. A review of the history of Negri inclusion bodies. Kristensson K, et al. **Neuropathol Appl Neurobiol** 1996 Jun;22(3):179–87 (30 ref.)

IMMUNOLOGY

Superantigen related to rabies. Lafon M, et al. **Springer Semin Immunopathol** 1996;17(4):307–18 (60 ref.)

RACCOON DOGS see **CARNIVORA**

RACCOONS

Rabies in New Hampshire and Vermont: an update. Brown CI, et al. **Ann Clin Lab Sci** 1997 May–Jun;27(3):216–23 (17 ref.)

RACE see **RACIAL STOCKS**

RACE RELATIONS

see related
CIVIL RIGHTS

Politics and South African mental health: hope, truth, and reconciliation. Comas-Díaz L, et al. **Cult Divers Ment Health** 1996;2(2):133–8 (14 ref.)

RACHITIS see **RICKETS**

RACIAL STOCKS

Gender, ethnicity and transmission category variation in HIV disease progression. Hessol NA, et al. **AIDS** 1996;10 Suppl A:S69–74 (53 ref.)

Race and health: basic questions, emerging directions [see comments] Williams DR. **Ann Epidemiol** 1997 Jul; 7(5):322–33 (120 ref.) Comment in: Ann Epidemiol 1997 Jul;7(5):320–1.

Relationship of cardiovascular risk factors to racial differences in femoral bypass surgery and abdominal aortic aneurysmectomy in Massachusetts. LaMorte WW, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:25–35 (27 ref.)

Either a paradigm shift or no mental measurement: the nonscience and the nonsense of The Bell Curve. Hilliard AG 3rd. **Cult Divers Ment Health** 1996;2(1):1–20 (37 ref.)

Looking beyond age and race: the structure of networks, functions of support, and chronic stress [editorial; comment] Berkman LF. **Epidemiology** 1997 Sep;8(5):469–70 (9 ref.) Comment on: Epidemiology 1997 Sep;8(5):475–81. Comment on: Epidemiology 1997 Sep;8(5):482–7.

Institutional racism and the medical/health complex: a conceptual analysis. King G. **Ethn Dis** 1996 Winter–Spring; 6(1–2):30–46 (99 ref.)

Why we should continue to study race...but do a better job: an essay on race, racism and health. La Veist TA. **Ethn Dis** 1996 Winter–Spring;6(1–2):21–9 (85 ref.)

Ultraviolet light may contribute to geographic and racial blood pressure differences. Rostand SG. **Hypertension** 1997 Aug;30(2 Pt 1):150–6 (110 ref.)

Race/ethnicity and socioeconomic status: measurement and methodological issues. Williams DR. **Int J Health Serv** 1996;26(3):483–505 (81 ref.)

Guidelines for adolescent health research: issues of race and class. Jenkins RR, et al. **J Adolesc Health** 1995 Nov; 17(5):314–22 (43 ref.)

Prostate cancer, race, and socioeconomic status: inadequate adjustment for social factors in assessing racial differences. Dale W, et al. **Prostate** 1996 Nov;29(5):271–81 (53 ref.)

Race/ethnicity, the social environment, and health. Lillie-Blanton M, et al. **Soc Sci Med** 1996 Jul;43(1):83–91 (41 ref.)

RACISM see **PREJUDICE**

RACQUET SPORTS

The biomechanics of fast bowling in men's cricket: a review. Bartlett RM, et al. **J Sports Sci** 1996 Oct;14(5):403–24 (80 ref.)

PHYSIOLOGY

Squash racquets. A review of physiology and medicine. Locke S, et al. **Sports Med** 1997 Feb;23(2):130–8 (25 ref.)

RACQUETBALL see **RACQUET SPORTS**

RADAR

Radiation hazard assessment of pulsed microwave radars. Puranen L, et al. **J Microw Power Electromagn Energy** 1996;31(3):165–77 (32 ref.)

RADIAL ARTERY

Radial access for primary PTCA in patients with acute myocardial infarction and contraindication or impossible femoral access. Steg G, et al. **Cathet Cardiovasc Diagn** 1996 Dec;39(4):424–6 (9 ref.)

How good is the radial artery as a bypass graft? Buxton B, et al. **Coron Artery Dis** 1997 Mar–Apr;8(3–4):225–33 (33 ref.)

Spontaneous arterial thrombosis with an advanced ovarian malignancy. Minjarez DA, et al. **Gynecol Oncol** 1997 Jan; 64(1):176–9 (18 ref.)

INJURIES

Pseudoaneurysms of the radial artery. Importance of microsurgery. Apropos of a case. Moufarrège R, et al. **Ann Chir Main** 1982;1(1):40–4 (13 ref.) **(Eng, Fre)**

SURGERY

Multiple idiopathic arterial aneurysms in children: a case report and review of the literature. Halpern V, et al. **J Vasc Surg** 1997 May;25(5):949–56 (22 ref.)

TRANSPLANTATION

Arterial autologous graft-stent for treatment of coronary artery disease: a new technique. Stefanadis C, et al. **Cathet Cardiovasc Diagn** 1997 Mar;40(3):302–7 (23 ref.)

The radial artery as a bypass graft. Buxton B, et al. **Curr Opin Cardiol** 1996 Nov;11(6):591–8 (35 ref.)

Total arterial myocardial revascularization [editorial] Calafiore AM. **Thorac Cardiovasc Surg** 1997 Jun; 45(3):105–8 (17 ref.)

RADIAL KERATOTOMY see **KERATOTOMY, RADIAL**

RADIAL NERVE

Radial tunnel syndrome. Barnum M, et al. **Hand Clin** 1996 Nov;12(4):679–89 (45 ref.)

Pediatric radial mononeuropathies: a clinical and electromyographic study of sixteen children with review of the literature. Escolar DM, et al. **Muscle Nerve** 1996 Jul;19(7):876–83 (38 ref.)

PATHOLOGY

Inflammatory pseudotumor of nerve. Weiland TL, et al. **Am J Surg Pathol** 1996 Oct;20(10):1212–8 (17 ref.)

PHYSIOLOGY

Effect of long-term implanted nerve cuff electrodes on the electrophysiological properties of human sensory nerves. Slot PJ, et al. **Artif Organs** 1997 Mar;21(3):207–9 (7 ref.)

RADIATION

see related
NUCLEAR WARFARE

[Methods of bioimaging and their principles] Arai T. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):911–4 (0 ref.) **(Jpn)**

CLASSIFICATION

Conversion coefficients for use in radiological protection against external radiation. Adopted by the ICRP and ICRU in September 1995. **Ann ICRP** 1996;26(3–4):1–205 (176 ref.)

RADIATION ACCIDENTS see **ACCIDENTS, RADIATION**

RADIATION BIOLOGY see **RADIOBIOLOGY**

RADIATION CHIMERA

[Mixed chimerism and immune tolerance induction by low-stress pretreatment before kidney transplantation in monkeys] Kawai T, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):670–4 (6 ref.) **(Jpn)**

RADIATION DOSAGE

see related
DOSE-RESPONSE RELATIONSHIP, RADIATION
RADIOTHERAPY DOSAGE

Conversion coefficients for use in radiological protection against external radiation. Adopted by the ICRP and ICRU in September 1995. **Ann ICRP** 1996;26(3–4):1–205 (176 ref.)

Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Maxon HR, et al. **Thyroid** 1997 Apr; 7(2):183–7 (26 ref.)

Percent 131I uptake and post-therapy 131I scans: their role in the management of thyroid cancer. Reynolds JC. **Thyroid** 1997 Apr;7(2):281–4 (13 ref.)

Radiation dose to patients and relatives incident to 131I therapy. Zanzonico PB. **Thyroid** 1997 Apr;7(2):199–204 (20 ref.)

RADIATION EFFECTS

Radiation therapy toxicities. Harris D, et al. **Vet Clin North Am Small Anim Pract** 1997 Jan;27(1):37–46 (27 ref.)

[The current concepts of the effect of ionizing radiation exposure on the human body (a review of the literature)] Liubarets TF. **Lik Sprava** 1995 Mar–Apr;(3–4):15–22 (54 ref.) **(Rus)**

[A decade after Chernobyl: the results of research on radioecology] Aleksakhin RM. **Radiats Biol Radioecol** 1996 Jul–Aug;36(4):451–9 (54 ref.) (Eng. Abstr.) **(Rus)**

[A single mechanism for the initiation of different effects of low doses of ionizing radiation] Eĭdus LKh. **Radiats Biol Radioecol** 1996 Nov–Dec;36(6):874–82 (57 ref.) (Eng. Abstr.) **(Rus)**

[The biological role of Vavilov-Cerenkov emission] Morozov II. **Radiats Biol Radioecol** 1996 Nov–Dec; 36(6):921–5 (32 ref.) (Eng. Abstr.) **(Rus)**

[Natural ultraviolet radiation: the nature of its behavior and human health] Strzhizhovskiĭ AD. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Jul–Aug; (4):49–53 (75 ref.) **(Rus)**

RADIATION GENETICS

[131 iodine: medical use. Carcinogenic and genetic effects] Schlumberger M, et al. **Ann Endocrinol (Paris)** 1996; 57(3):166–76 (48 ref.) (Eng. Abstr.) **(Fre)**

METHODS

[The latest achievements of radiation cytogenetics in connection with the discovery of the method for the fluorescence hybridization in situ of the metaphase chromosomes of man and experimental animals using DNA probes (FISH)] Pilinskaia MA. **Tsitol Genet** 1996 Jul–Aug; 30(4):70–85 (74 ref.) (Eng. Abstr.) **(Rus)**

RADIATION-INDUCED DERMATITIS see **RADIODERMATITIS**

RADIATION INJURIES

see related
ACCIDENTS, RADIATION

Radiation-induced arterial disease of the lower limb. Saliou C, et al. **Ann Vasc Surg** 1997 Mar;11(2):173–7 (35 ref.)

Pulmonary radiation injury. Movsas B, et al. **Chest** 1997 Apr; 111(4):1061–76 (98 ref.)

Endocrine sequelae of cancer therapy. Shalet SM. **Eur J Endocrinol** 1996 Aug;135(2):135–43 (46 ref.)

Radiation injuries of the gastrointestinal tract. Saclarides TJ. **Surg Clin North Am** 1997 Feb;77(1):261–8 (31 ref.)

Radiation injury. Mathes SJ, et al. **Surg Oncol Clin N Am** 1996 Oct;5(4):809–24 (54 ref.)

[Ultraviolet irradiation devices. Risks related to their use] Doré JF, et al. **Presse Med** 1997 Jun 14;26(20):966–71 (39 ref.) **(Fre)**

[Radiation-induced heart disease (RIHD)] Takao N, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):614–7 (8 ref.) **(Jpn)**

COMPLICATIONS

[Obliteration of the large arteries as a late sequela of radiation-induced vasculopathies] Knaack L, et al. **Dtsch Med Wochenschr** 1997 May 16;122(20):655–8 (10 ref.) **(Ger)**

[Radiation-induced pericarditis] Horimoto M. **Ryoikibetsu Shokogun Shirizu** 1996;(13):597–9 (26 ref.) **(Jpn)**

[Radiation induced cardiomyopathy] Inoue K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):206–10 (20 ref.) **(Jpn)**

DIAGNOSIS

Laryngeal radionecrosis versus recurrent cancer. McGuirt WF. **Otolaryngol Clin North Am** 1997 Apr;30(2):243–50 (19 ref.)

Radiation-induced changes in the central nervous system and head and neck. Rabin BM, et al. **Radiographics** 1996 Sep; 16(5):1055–72 (24 ref.)

EPIDEMIOLOGY

The consequences of the Chernobyl accident one decade after the disaster. Jankowski J. **Int J Occup Med Environ Health** 1996;9(4):365–74 (18 ref.)

What are the risks of low-level exposure to alpha radiation from radon? [see comments] Little JB. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):5996–7 (21 ref.) Comment in: Proc Natl Acad Sci U S A 1997 Apr 15;94(8):3765–70.

ETIOLOGY

Intracranial aneurysm following radiation therapy for medulloblastoma. A case report and review of the literature. Jensen FK, et al. **Acta Radiol** 1997 Jan; 38(1):37–42 (29 ref.)

Radiotherapy-associated neutropenia and thrombocytopenia: analysis of risk factors and development of a predictive model. Mac Manus M, et al. **Blood** 1997 Apr 1; 89(7):2303–10 (36 ref.)

Case report: severe fibrosis in a patient with scleroderma and previous radiotherapy—a case report and literature review. Aref I, et al. **Br J Radiol** 1996 Nov;69(827):1055–6 (9 ref.)

Status of accelerated fractionation radiotherapy in head and neck squamous cell carcinomas. Bourhis J, et al. **Curr Opin Oncol** 1997 May;9(3):262–6 (50 ref.)

Late complications of radiotherapy. **Drug Ther Bull** 1997 Feb; 35(2):13–6 (38 ref.)

Acute and late side effects of radiotherapy for ocular disease: an overview. Alberti W. **Front Radiat Ther Oncol** 1997; 30:281–6 (23 ref.)

Late onset bone marrow transplant nephropathy. Oyama Y, et al. **Intern Med** 1996 Jun;35(6):489–93 (23 ref.)

Manifestations and treatment of xerostomia and associated oral effects secondary to head and neck radiation therapy. Garg AK, et al. **J Am Dent Assoc** 1997 Aug;128(8):1128–33 (40 ref.)

Cytotoxic endocrinopathy: a legacy of insults. Shalet SM. **J R Soc Med** 1997 Apr;90(4):192–9 (36 ref.)

Response of the normal eye to high dose radiotherapy [see comments] Parsons JT, et al. **Oncology (Huntingt)** 1996 Jun; 10(6):837–47; discussion 847–8, 851–2 (39 ref.) Comment in: Oncology (Huntingt) 1996 Jul;10(7):981–2, 984.

Effects of pediatric cancer therapy on the musculoskeletal system. Fletcher BD. **Pediatr Radiol** 1997 Aug;27(8):623–36 (102 ref.)

Radiation-induced xerostomia: pathophysiology, clinical course and supportive treatment [see comments] Guchelaar HJ, et al. **Support Care Cancer** 1997 Jul;5(4):281–8 (57 ref.) Comment in: Support Care Cancer 1997 Jul;5(4):261–2.

[Inoperable cancers of the cervix: therapeutic perspectives] Resbeut M. **Bull Cancer Radiother** 1996;83(4):385–7 (16 ref.) **(Fre)**

GENETICS

[The use of an automated micronucleus test for the biological dosimetry of radiation lesions] Romanova EP, et al. **Tsitol Genet** 1997 Mar-Apr;31(2):61–9 (67 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

[The role of natural growth stimulators in regulation of regeneration processes in small intestinal epithelium after irradiation] Dziekiewicz M. **Przegl Lek** 1996;53(8):610–3 (21 ref.) (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

Mucosal protectants and their application for head and neck chemoirradiation. Marks JE. **Curr Opin Oncol** 1997 May; 9(3):267–73 (35 ref.)

Managing radiation risks. Clarke RH. **J R Soc Med** 1997 Feb;90(2):88–92 (5 ref.)

Radio- and chemoprotection of bone marrow cells by opposite cell cycle-acting cytokines [editorial] Dalmau SR, et al. **Leuk Res** 1997 Feb;21(2):93–9 (67 ref.)

[The therapeutic management of radiogenic oral mucositis] Dörr W, et al. **Strahlenther Onkol** 1997 Apr;173(4):183–92 (81 ref.) (Eng. Abstr.) **(Ger)**

[Clinical use of Amifostine (WR-2721) as a preparation protecting healthy tissues from the cytotoxic effects of chemotherapy and radiation therapy] Wrembel-Wargocka J, et al. **Przegl Lek** 1996;53(11):820–5 (15 ref.) (Eng. Abstr.) **(Pol)**

RADIOGRAPHY

[Imaging of digestive involvements after irradiation] Chopier J, et al. **J Radiol** 1996 Aug;77(8):543–53 (64 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Free gastro-omental flap reconstruction of the complex, irradiated pharyngeal wound. Carlson GW, et al. **Head Neck** 1997 Jan;19(1):68–71 (11 ref.)

[Plastic surgery defect coverage in the area of the pelvis and trunk] Germann G, et al. **Chirurg** 1997 May; 68(5):469–76 (26 ref.) (Eng. Abstr.) **(Ger)**

[Reconstructive plastic surgery of thoracic wall defects] Steinau HU, et al. **Chirurg** 1997 May;68(5):461–8 (23 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Oral health care for the cancer patient. Scully C, et al. **Eur J Cancer B Oral Oncol** 1996 Sep;32B(5):281–92 (282 ref.)

An evaluation of the use of bronchopulmonary lavage in the treatment of plutonium oxide inhalation. Dean MR. **J R Nav Med Serv** 1997;82(3):188–96 (27 ref.)

[Hyperbaric oxygenation (HBO) in the treatment of radiogenic side effects] Hartmann A, et al. **Strahlenther Onkol** 1996 Dec;172(12):641–8 (51 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Radiation therapy toxicities. Harris D, et al. **Vet Clin North Am Small Anim Pract** 1997 Jan;27(1):37–46 (27 ref.)

RADIATION INJURIES, EXPERIMENTAL

GENETICS

Radiation-induced genomic instability in haemopoietic cells: implications for radiation pathology. Wright EG. **Radiat Oncol Investig** 1997;5(3):115–8 (20 ref.)

[The use of an automated micronucleus test for the biological dosimetry of radiation lesions] Romanova EP, et al. **Tsitol Genet** 1997 Mar-Apr;31(2):61–9 (67 ref.) (Eng. Abstr.) **(Rus)**

RADIATION, IONIZING

Telomeres, senescence and cellular radiation response. Crompton NE. **Cell Mol Life Sci** 1997 Jul;53(7):568–75 (104 ref.)

Modulating the radiation response. Coleman CN. **Stem Cells** 1996 Jan;14(1):10–5 (35 ref.)

[Problems evaluating the risk of occupational neoplasms in persons exposed to ionizing radiation] Jankowski J. **Med Pr** 1996;47(6):615–27 (62 ref.) (Eng. Abstr.) **(Pol)**

RADIATION MONITORING

Radiation safety considerations for PET centers. Brown TF, et al. **J Nucl Med Technol** 1997 Jun;25(2):98–102; quiz 104–5 (16 ref.)

METHODS

Radiation safety review for 511-keV emitters in nuclear medicine. Dell MA. **J Nucl Med Technol** 1997 Mar; 25(1):12–7; quiz 33 (6 ref.)

PDT light dosimetry revisited. Grossweiner LI. **J Photochem Photobiol B** 1997 Apr;38(2-3):258–68 (35 ref.)

RADIATION ONCOLOGY

Palliative radiation therapy in the United States. Coia LR. **Can J Oncol** 1996 Feb;6 Suppl 1:62–8; discussion 84 (14 ref.)

Biologic basis for radiation oncology. Coleman CN, et al. **Oncology (Huntingt)** 1996 Mar;10(3):399–411; discussion: 411–5 (60 ref.)

[The use of sucralfate in radiation oncology] Belka C, et al. **Strahlenther Onkol** 1997 May;173(5):247–52 (25 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Neuroradiation oncology. Burk RL. **Vet Clin North Am Small Anim Pract** 1997 Jan;27(1):95–100 (38 ref.)

A selected review of the physics of radiation therapy. Burk RL, et al. **Vet Clin North Am Small Anim Pract** 1997 Jan; 27(1):7–20 (5 ref.)

Radiation oncology of head and neck tumors. King GK, et al. **Vet Clin North Am Small Anim Pract** 1997 Jan; 27(1):101–13 (79 ref.)

Radiation therapy: a radiation oncologist's point of view. Mauldin GN. **Vet Clin North Am Small Anim Pract** 1996 Jan;26(1):17–27 (22 ref.)

[Application of three-dimensional computer graphics in oncology] Joyeux H, et al. **Bull Acad Natl Med** 1996 Jun-Jul;180(6):1455–65; discussion 1465–6 (25 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

Palliative radiotherapy in Canada. Dixon P. **Can J Oncol** 1996 Feb;6 Suppl 1:74–83; discussion 84 (7 ref.)

Palliative radiotherapy in the UK. Priestman TJ. **Can J Oncol** 1996 Feb;6 Suppl 1:69–73; discussion 84 (14 ref.)

Advances in radiation oncology. Vijayakumar S, et al. **Lancet** 1997 May;349 Suppl 2:SII1–3 (24 ref.)

Future of veterinary radiation oncology. Gavin PR. **Vet Clin North Am Small Anim Pract** 1997 Jan;27(1):157–65 (24 ref.)

RADIATION PNEUMONITIS

Pulmonary radiation injury. Movsas B, et al. **Chest** 1997 Apr; 111(4):1061–76 (98 ref.)

RADIATION PROTECTION

Managing radiation risks. Clarke RH. **J R Soc Med** 1997 Feb;90(2):88–92 (5 ref.)

The International Chernobyl Project Technical Report: assessment of radiological consequences and evaluation of protective measures. Report by an International Advisory Committee. Mann WB. **Nucl Med Biol** 1994 Jan;21(1):3–7 (7 ref.)

METHODS

[The problem of chemical protection from the chronic action of ionizing radiation] Goncharenko EN, et al. **Radiats Biol Radioecol** 1996 Jul-Aug;36(4):573–86 (60 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

Conversion coefficients for use in radiological protection against external radiation. Adopted by the ICRP and ICRU in September 1995. **Ann ICRP** 1996;26(3–4):1–205 (176 ref.)

Setting standards for radiation protection: the process appraised [see comments] Patterson HW. **Health Phys** 1997 Mar;72(3):450–7 (80 ref.) Comment in: Health Phys 1997 Jul;73(1):270.

RADIATION-PROTECTIVE AGENTS

ADMINISTRATION & DOSAGE

[Clinical use of Amifostine (WR-2721) as a preparation protecting healthy tissues from the cytotoxic effects of chemotherapy and radiation therapy] Wrembel-Wargocka J, et al. **Przegl Lek** 1996;53(11):820–5 (15 ref.) (Eng. Abstr.) **(Pol)**

PHARMACOLOGY

Amifostine for protection from antineoplastic drug toxicity. Foster-Nora JA, et al. **Am J Health Syst Pharm** 1997 Apr 1;54(7):787–800 (101 ref.)

[The problem of chemical protection from the chronic action of ionizing radiation] Goncharenko EN, et al. **Radiats Biol Radioecol** 1996 Jul-Aug;36(4):573–86 (60 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Radio- and chemoprotection of bone marrow cells by opposite cell cycle-acting cytokines [editorial] Dalmau SR, et al. **Leuk Res** 1997 Feb;21(2):93–9 (67 ref.)

[Protection of the thyroid in children and fetuses in case of nuclear accident] Vernis M, et al. **Arch Pediatr** 1997 May; 4(5):473–9 (29 ref.) (Eng. Abstr.) **(Fre)**

[Amifostine: current and future applications in cytoprotection] Lenoble M. **Bull Cancer** 1996 Sep; 83(9):773–87 (48 ref.) (Eng. Abstr.) **(Fre)**

[The use of sucralfate in radiation oncology] Belka C, et al. **Strahlenther Onkol** 1997 May;173(5):247–52 (25 ref.) (Eng. Abstr.) **(Ger)**

[The cytoprotective agent amifostine (WR-2721): current clinical use and trends in its development] Dragojević-Simić V, et al. **Vojnosanit Pregl** 1996 Jul-Aug; 53(4):305–10 (54 ref.) **(Scr)**

RADIATION SENSITIVITY see **RADIATION TOLERANCE**

RADIATION-SENSITIZING AGENTS

[Topoisomerase I inhibitor with potential radiosensitizing effect] Sauer R, et al. **Strahlenther Onkol** 1997 Mar; 173(3):125–30 (39 ref.) (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

Role of delivery vehicles for photosensitizers in the photodynamic therapy of tumours. Reddi E. **J Photochem Photobiol B** 1997 Feb;37(3):189–95 (50 ref.)

ADVERSE EFFECTS

Paclitaxel-induced radiation recall dermatitis [letter] Bokemeyer C, et al. **Ann Oncol** 1996 Sep;7(7):755–6 (7 ref.)

ISOLATION & PURIFICATION

Withania somnifera Dunal (Ashwagandha): potential plant source of a promising drug for cancer chemotherapy and radiosensitization. Devi PU. **Indian J Exp Biol** 1996 Oct; 34(10):927–32 (41 ref.)

PHARMACOLOGY

Gemcitabine-mediated radiosensitization. Lawrence TS, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 7):S7-24–S7-28 (22

ref.)

THERAPEUTIC USE

ARCON--current status: summary of a workshop on preclinical and clinical studies. Denekamp J, et al. **Acta Oncol** 1997;36(5):517-25 (0 ref.)

Hypoxic sensitizer and cytotoxin for head and neck cancer. Lee DJ, et al. **Ann Acad Med Singapore** 1996 May; 25(3):397-404 (42 ref.)

Gemcitabine and radiosensitization in human tumor cells. Shewach DS, et al. **Invest New Drugs** 1996;14(3):257-63 (52 ref.)

The Fox Chase Cancer Center and Free University Hospital Investigators' Workshop and Consensus Conference on Paclitaxel. Part 1: Lung Cancer. Puerto Rico, March 12-16, 1997. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12-1-S12-162; quiz S12-163-S12-173 (0 ref.)

The Fox Chase Cancer Center and Free University Hospital Investigators' Workshop and Consensus Conference on Paclitaxel. Part 3: Gynecologic malignancies, head and neck cancer, and other tumor types. Marrakech, Morocco, January 18-20, 1996 and St Croix, Virgin Islands, March 13-16, 1996. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2-1-S2-120; quiz S2-121-S2-123 (0 ref.)

Paclitaxel in head and neck and other cancers: future prospects. Aisner J, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2-113-S2-115 (21 ref.)

Defining the role of paclitaxel in lung cancer: summary of recent studies and implications for future directions. Bunn PA Jr. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12-153-S12-162 (63 ref.)

Radiosensitization of human solid tumor cell lines with gemcitabine. Shewach DS, et al. **Semin Oncol** 1996 Oct; 23(5 Suppl 10):65-71 (42 ref.)

Simultaneous paclitaxel and radiotherapy: initial clinical experience in lung cancer and other malignancies. Vogt HG, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12-101-S12-105 (15 ref.)

[Effect of etoposide on a human pancreatic cancer cell line exposed to high dose X-ray irradiation] Mizumoto K, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1673-5 (3 ref.) (Eng. Abstr.) **(Jpn)**

RADIATION SICKNESS see **RADIATION INJURIES**

RADIATION SYNDROME see **RADIATION INJURIES**

RADIATION TOLERANCE

see related
RADIATION-PROTECTIVE AGENTS
RADIATION-SENSITIZING AGENTS

Radiation therapy for skin neoplasms. Parker RG. **Clin Dermatol** 1995 Nov-Dec;13(6):579-88 (51 ref.)

Current topics: radiosensitive human cells at the crossroads, high split-dose recovery and diminished inducible response. Alsbeih G, et al. **Int J Radiat Biol** 1997 Aug; 72(2):135-7 (13 ref.)

Adaptation: a new concept in radiation biology and oncology and its clinical relevance. Lin HS. **J Formos Med Assoc** 1996 Nov;95(11):817-21 (37 ref.)

Is there a radiobiologic basis for improving the treatment of advanced stage cervical cancer? Lindegaard JC, et al. **J Natl Cancer Inst Monogr** 1996;(21):105-12 (91 ref.)

Potential clinical impact of normal-tissue intrinsic radiosensitivity testing. Bentzen SM. **Radiother Oncol** 1997 May;43(2):121-31 (43 ref.)

Modulating the radiation response. Coleman CN. **Stem Cells** 1996 Jan;14(1):10-5 (35 ref.)

Molecular processes and radiosensitivity. Zdzienicka MZ. **Strahlenther Onkol** 1997 Sep;173(9):457-61 (48 ref.)

Radioresistance, chemoresistance, and apoptosis resistance. The past, present, and future. Bergman PJ, et al. **Vet Clin North Am Small Anim Pract** 1997 Jan;27(1):47-57 (42 ref.)

[Predictive biological factors of response to radiotherapy and chemotherapy in carcinoma of the upper respiratory and digestive tracts] Bourhis J, et al. **Bull Cancer Radiother** 1996;83(4):308-13 (55 ref.) **(Fre)**

[Genetic predisposition and radiation sensitivity of tumors] Budach W. **Strahlenther Onkol** 1997 Sep;173(9):469-79 (52 ref.) (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Radiation lethality enhancement with 9-aminocamptothecin: comparison to other topoisomerase I inhibitors. Lamond JP, et al. **Int J Radiat Oncol Biol Phys** 1996 Sep 1; 36(2):369-76 (38 ref.)

GENETICS

Identification of the XRCC4 gene: complementation of the DSBR and V(D)J recombination defects of XR-1 cells. Li Z, et al. **Curr Top Microbiol Immunol** 1996;217:143-50 (25 ref.)

PHYSIOLOGY

Programmed cell death and radioresistance. Meyn RE, et al. **Cancer Metastasis Rev** 1996 Mar;15(1):119-31 (78 ref.)

Melatonin in mast cells and tumor radiosensitivity. Kvetnoy IM, et al. **J Pineal Res** 1997 Apr;22(3):169-70 (16 ref.)

Hypersensitivity to very-low single radiation doses: its relationship to the adaptive response and induced radioresistance. Joiner MC, et al. **Mutat Res** 1996 Nov 4; 358(2):171-83 (71 ref.)

Mutants of Arabidopsis as tools to understand the regulation of phenylpropanoid pathway and UVB protection mechanisms. Bharti AK, et al. **Photochem Photobiol** 1997 May;65(5):765-76 (104 ref.)

RADIATION, VISIBLE see **LIGHT**

RADIATION, WHOLE-BODY see **WHOLE-BODY IRRADIATION**

RADICAL NECK DISSECTION

Current concepts in surgical management of neck metastases from head and neck cancer. Stringer SP. **Oncology (Huntingt)** 1995 Jun;9(6):547-54; discussion 554, 557-8 (47 ref.)

Primary leiomyosarcoma of the thyroid gland. Ozaki O, et al. **Surg Today** 1997;27(2):177-80 (13 ref.)

[Laryngeal cancer treatment concept in metastases (see comments)] Hagen R. **HNO** 1997 Jul;45(7):512-8 (8 ref.) (Eng. Abstr.) Comment in: HNO 1997 Jul;45(7):493-4. **(Ger)**

ADVERSE EFFECTS

Anterior ischemic optic neuropathy following neck dissection. Strome SE, et al. **Head Neck** 1997 Mar; 19(2):148-52 (12 ref.)

METHODS

Surgical management of cervical lymph node metastases. Eicher SA, et al. **Curr Opin Oncol** 1996 May;8(3):215-20 (30 ref.)

RADICULITIS

DIAGNOSIS

[Inflammatory diseases of the spinal cord and spinal nerve roots in the MRI] Sartoretti-Schefer S, et al. **Radiologe** 1996 Nov;36(11):897-913 (159 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Giant intrasacral schwannoma forming a presacral mass: a report of an unusual cause of lumbosacral radiculopathy. Turgut M, et al. **Zentralbl Neurochir** 1996;57(4):201-5 (19 ref.)

RADIO WAVES

see related
RADAR

Radio frequency electromagnetic exposure: tutorial review on experimental dosimetry. Chou CK, et al. **Bioelectromagnetics** 1996;17(3):195-208 (78 ref.)

ADVERSE EFFECTS

Assessment of cellular telephone and other radio frequency exposure for epidemiologic research [see comments] Rothman KJ, et al. **Epidemiology** 1996 May;7(3):291-8 (43 ref.) Comment in: Epidemiology 1996 May;7(3):219. Comment in: Epidemiology 1997 Jul;8(4):466-7.

Exposure to extremely-low-frequency electromagnetic fields and radiofrequency radiation: cardiovascular effects in humans. Jauchem JR. **Int Arch Occup Environ Health** 1997; 70(1):9-21 (160 ref.)

RADIOACTIVE AIR POLLUTANTS see **AIR POLLUTANTS, RADIOACTIVE**

RADIOACTIVE FALLOUT

Long-term effective decrease of cesium concentration in foodstuffs after nuclear fallout. Mück K. **Health Phys** 1997 May;72(5):659-73 (52 ref.)

Lessons from Chernobyl: the event, the aftermath fallout: radioactive, political, social. Robbins J. **Thyroid** 1997 Apr; 7(2):189-92 (30 ref.)

Profiles of non-cancer diseases in atomic bomb survivors. Kodama K, et al. **World Health Stat Q** 1996;49(1):7-16 (79 ref.)

RADIOACTIVE POLLUTANTS

Technical basis for EPA's proposed regulation on the cleanup of sites contaminated with radioactivity. Wolbarst AB, et al. **Health Phys** 1996 Nov;71(5):644-60 (56 ref.)

ADVERSE EFFECTS

The radiological hazards of plutonium. Barnaby F. **Med Confl Surviv** 1997 Jul-Sep;13(3):195-206; discussion 207-8 (18 ref.)

Reproductive health hazards in the pharmaceutical industry. Clement JD. **Occup Med** 1997 Jan-Mar;12(1):131-43 (61 ref.)

Radioepidemiology in the aftermath of the nuclear program of the former Soviet Union: unique lessons to be learnt. Burkart W. **Radiat Environ Biophys** 1996 May;35(2):65-73 (19 ref.)

ANALYSIS

Radioecology and and the health of the indigenous inhabitants in Chukotka. Doudarev AA, et al. **Arctic Med Res** 1996;55 Suppl 1:32-4 (1 ref.)

PARATI--a dynamic model for radiological assessments in urban areas. Part I. Modelling of urban areas, their contamination and radiation fields. Rochedo ER, et al. **Radiat Environ Biophys** 1996 Nov;35(4):243-61 (87 ref.)

RADIOACTIVE TRACERS

Noncompartmental models of whole-body clearance of tracers: a review. Norwich KH. **Ann Biomed Eng** 1997 May-Jun;25(3):421-39 (72 ref.)

Some new methods for the synthesis of cardiac neurotransmission PET radiotracers. Någren K, et al. **Nucl Med Biol** 1995 Nov;22(8):1037-43 (21 ref.)

Radioligands for PET studies of central 5-HT receptors and re-uptake sites--current status. Pike VW. **Nucl Med Biol** 1995 Nov;22(8):1011-8 (38 ref.)

Relevance of PET/SPET tracers for cardiac neurotransmission. Voipio-Pulkki LM. **Nucl Med Biol** 1995 Nov;22(8):1027-35 (68 ref.)

RADIOACTIVE WASTE

Microbial studies in the Canadian nuclear fuel waste management program. Stroes-Gascoyne S, et al. **FEMS Microbiol Rev** 1997 Jul;20(3-4):573-90 (74 ref.)

RADIOALLERGOSORBENT TEST

Might laboratory tests other than RAST help in diagnosing food allergy? Ventura A, et al. **Pediatr Allergy Immunol** 1995;6 Suppl 8:44-8 (70 ref.)

RADIOAUTOGRAPHY see **AUTORADIOGRAPHY**

RADIOBIOLOGY

see related
NUCLEAR MEDICINE

Perspectives of tumour radiotherapy in the Czech Republic and "Oncology 2000" Foundation. Prokeš K, et al. **Cent Eur J Public Health** 1996 Sep;4(3):208-12 (19 ref.)

Comparison of internal emitter radiobiology in animals and humans. Lloyd RD, et al. **Health Phys** 1997 Jan; 72(1):100-10 (98 ref.)

Radiation biology in brachytherapy. Brenner DJ. **J Surg Oncol** 1997 May;65(1):66-70 (22 ref.)

Biologic basis for radiation oncology. Coleman CN, et al. **Oncology (Huntingt)** 1996 Mar;10(3):399-411; discussion: 411-5 (60 ref.)

METHODS

Biologic basis of radiation therapy. Thrall DE. **Vet Clin North Am Small Anim Pract** 1997 Jan;27(1):21-35 (40 ref.)

RADIODERMATITIS

ETIOLOGY

Paclitaxel-induced radiation recall dermatitis [letter] Bokemeyer C, et al. **Ann Oncol** 1996 Sep;7(7):755-6 (7 ref.)

Mixed connective tissue disease and radiation toxicity. A case report. Mayr NA, et al. **Cancer** 1997 Feb 1;79(3):612-8 (12 ref.)

RADIOGRAPHIC FILM see **X-RAY FILM**

RADIOGRAPHIC IMAGE ENHANCEMENT

see related
X-RAY INTENSIFYING SCREENS

Update in digital mammography. Hogge JP, et al. **Crit Rev Diagn Imaging** 1997;38(1):89-113 (51 ref.)

Digital radiography. Results of a survey (part A) and a consensus conference (part B). Braunschweig R, et al. **Eur Radiol** 1997;7 Suppl 3:S94-101 (88 ref.)

Computed tomographic colography and virtual colonoscopy. Ahlquist DA, et al. **Gastrointest Endosc Clin N Am** 1997 Jul;7(3):439-52 (47 ref.)

Efficacy of digital intra-oral radiography in clinical dentistry. Versteeg CH, et al. **J Dent** 1997 May-Jul;25(3-4):215-24 (63 ref.)

Pediatric musculoskeletal computed radiography. Kottamasu SR, et al. **Pediatr Radiol** 1997 Jul;27(7):563-75 (25 ref.)

Computed radiography: its impact on radiographers. Cesar LJ. **Radiol Technol** 1997 Jan-Feb;68(3):225-32 (7 ref.)

Current status of digital mammography. Feig SA, et al. **Semin Ultrasound CT MR** 1996 Oct;17(5):424-43 (28 ref.)

[Parameters influencing hepatic parenchyma enhancement in x-ray computed tomography after intravenous injection of iodinated contrast medium] Bonaldi VM, et al. **J Radiol** 1997 Apr;78(4):265-70 (39 ref.) (Eng. Abstr.) **(Fre)**

[Digital radiography--results of a user survey (A) and

consensus conference (B)] Busch HP, et al. **Aktuelle Radiol** 1997 Jan;7(1):56–63 (0 ref.) (Eng. Abstr.) **(Ger)**

[Diagnostic value of digital projection radiography in comparison with conventional roentgen technique] Krug B, et al. **Aktuelle Radiol** 1997 Mar;7(2):65–8 (33 ref.) (Eng. Abstr.) **(Ger)**

[Diagnostic imaging in bronchiectases. Value of CT and HRCT] Diederich S, et al. **Radiologe** 1996 Jul;36(7):550–9 (39 ref.) (Eng. Abstr.) **(Ger)**

[HRCT of the lung in collagenoses] Diederich S, et al. **Radiologe** 1996 Jul;36(7):567–78 (37 ref.) (Eng. Abstr.) **(Ger)**

[Phenomenology of pulmonary HRCT. Definitions, differential diagnosis and clinical relevance] Roos N, et al. **Radiologe** 1996 Jul;36(7):521–33 (46 ref.) (Eng. Abstr.) **(Ger)**

[Cardiac function using ultrafast computed tomography] Aizawa N, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:623–6 (4 ref.) **(Jpn)**

[Evaluation of pulmonary function by expiratory CT using helical CT] Eda S, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:45–7 (6 ref.) **(Jpn)**

[Drip infusion cholangiography combined helical computed tomography] Ishihara K, et al. **Nippon Rinsho** 1997 Apr; 55 Suppl 2:180–2 (8 ref.) **(Jpn)**

[Estimation of cardiac function by helical CT] Itani Y, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:627–9 (7 ref.) **(Jpn)**

[Contrast enhanced CT] Kohno A, et al. **Nippon Rinsho** 1996 May;54(5):1249–54 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Gastric emptying test using helical CT] Matsumoto K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:146–9 (7 ref.) **(Jpn)**

[An evaluation of the heart by enhanced CT] Watanabe S, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:619–22 (3 ref.) **(Jpn)**

INSTRUMENTATION

Digital radiography for clinical applications. Busch HP. **Eur Radiol** 1997;7 Suppl 3:S66–72 (11 ref.)

Digital image processing. Prokop M, et al. **Eur Radiol** 1997; 7 Suppl 3:S73–82 (11 ref.)

Storage phosphor radiography. Schaefer-Prokop CM, et al. **Eur Radiol** 1997;7 Suppl 3:S58–65 (35 ref.)

Stimulable phosphor plates in chest radiology. Tylén U. **Eur Radiol** 1997;7 Suppl 3:S83–6 (16 ref.)

X-ray detectors for digital radiography. Yaffe MJ, et al. **Phys Med Biol** 1997 Jan;42(1):1–39 (98 ref.)

[Digital radiology] Pärtan G, et al. **Z Arztl Fortbild Qualitatssich** 1997 Jul;91(4):301–8 (28 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Stress echocardiography: new techniques. Leischik R, et al. **Eur Heart J** 1997 Jun;18 Suppl D:D49–56 (53 ref.)

Direct digital mammography image acquisition. Cowen AR, et al. **Eur Radiol** 1997;7(6):918–30 (59 ref.)

MR first pass imaging: quantitative assessment of transmural perfusion and collateral flow. Jerosch-Herold M, et al. **Int J Card Imaging** 1997 Jun;13(3):205–18 (53 ref.)

Urologic applications of multiplanar and three-dimensional computed tomography. Olson MC, et al. **Tech Urol** 1995 Fall;1(3):141–9 (8 ref.)

[Digital radiography of the thorax] Frija J, et al. **J Radiol** 1997 Mar;78(3):193–207 (81 ref.) (Eng. Abstr.) **(Fre)**

[Current methods for processing of radiographic medical films] Koveshnikov AI. **Vestn Rentgenol Radiol** 1997 Jul-Aug;(4):44–9 (3 ref.) **(Rus)**

TRENDS

Technical trends in functional radiology of the lung. Meduri A, et al. **Rays** 1997 Jan-Mar;22(1):14–37 (8 ref.) **(Eng, Ita)**

RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED

Update in digital mammography. Hogge JP, et al. **Crit Rev Diagn Imaging** 1997;38(1):89–113 (51 ref.)

Digital radiography. Results of a survey (part A) and a consensus conference (part B). Braunschweig R, et al. **Eur Radiol** 1997;7 Suppl 3:S94–101 (88 ref.)

[Computer-assisted diagnosis in screening mammography] Bick U. **Radiologe** 1996 Jan;36(1):72–80 (53 ref.) (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

Digital image processing. Prokop M, et al. **Eur Radiol** 1997; 7 Suppl 3:S73–82 (11 ref.)

RADIOGRAPHIC INTENSIFYING SCREENS see **X-RAY INTENSIFYING SCREENS**

RADIOGRAPHIC PHANTOMS see **PHANTOMS, IMAGING**

RADIOGRAPHY

see related
CONTRAST MEDIA
EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS
TECHNOLOGY, RADIOLOGIC

Pediatric sedation in radiology: the practice of safe sleep. Frush DP, et al. **AJR Am J Roentgenol** 1996 Dec; 167(6):1381–7 (48 ref.)

Gallery of medical devices. Hunter TB, et al. **Curr Probl Diagn Radiol** 1997 May-Jun;26(3):109–52 (166 ref.)

Radiological sciences, past and present. Lentle B, et al. **Lancet** 1997 Jul 26;350(9073):280–5 (30 ref.)

[Endoscopy, ultrasound and roentgen as a rational complementary system. Exemplified by diseases of the upper gastrointestinal tract] Keim V, et al. **Internist (Berl)** 1996 Aug;37(8):785–92 (50 ref.) **(Ger)**

[Diagnostic radiology development, medical ranking, socioeconomic significance. At the threshold of the second century of radiology] Wolf KJ. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Dec;165(6):515–9 (18 ref.) **(Ger)**

METHODS

Medical applications of synchrotron radiation x-rays. Lewis R. **Phys Med Biol** 1997 Jul;42(7):1213–43 (89 ref.)

[Clinical application of optical flow method in esophageal wall movement] Shimada M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:156–61 (5 ref.) **(Jpn)**

STANDARDS

Unified measurement of observer performance in detecting and localizing target objects on images. Swensson RG. **Med Phys** 1996 Oct;23(10):1709–25 (62 ref.)

TRENDS

The future of radiology in west Africa. Makanjuola RO. **West Afr J Med** 1996 Jul-Sep;15(3):132–8 (30 ref.)

VETERINARY

Imaging of adrenal gland disorders. Tidwell AS, et al. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):237–54 (47 ref.)

RADIOGRAPHY, DENTAL

Efficacy of digital intra-oral radiography in clinical dentistry. Versteeg CH, et al. **J Dent** 1997 May-Jul;25(3-4):215–24 (63 ref.)

INSTRUMENTATION

Base and fog densities of fresh Ektaspeed Plus dental X-ray films. Sewerin IP. **Acta Odontol Scand** 1997 Apr; 55(2):79–83 (20 ref.)

METHODS

Imaging of the temporomandibular joint: a position paper of the American Academy of Oral and Maxillofacial Radiology. Brooks SL, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 May;83(5):609–18 (92 ref.)

[The role of the traditional radiological methods in conservative therapy and endodontics] Bianchi SD, et al. **Minerva Stomatol** 1996 Dec;45(12):575–87 (27 ref.) (Eng. Abstr.) **(Ita)**

STANDARDS

The use of dental radiographs to estimate the probability of cavitation of carious interproximal lesions. Part I: Evidence from the literature. Woodward GL, et al. **J Can Dent Assoc** 1996 Sep;62(9):731–6 (30 ref.)

STATISTICS & NUMERICAL DATA

The use of dental radiographs to estimate the probability of cavitation of carious interproximal lesions. Part I: Evidence from the literature. Woodward GL, et al. **J Can Dent Assoc** 1996 Sep;62(9):731–6 (30 ref.)

RADIOGRAPHY, INTERVENTIONAL

Spiral CT angiography of the abdomen and pelvis: interventional applications. Brink JA. **Abdom Imaging** 1997 Jul-Aug;22(4):365–72 (26 ref.)

Antibiotic prophylaxis in vascular and interventional radiology. McDermott VG, et al. **AJR Am J Roentgenol** 1997 Jul;169(1):31–8 (66 ref.)

Interventional radiology for hepatic arterial infusion chemotherapy. Arai Y. **Gan To Kagaku Ryoho** 1996 Sep; 23(11):1385–9 (8 ref.)

Fine-needle aspiration of the liver and pancreas: a cytology primer for radiologists. Dodd LG, et al. **Radiology** 1997 Apr;203(1):1–9 (58 ref.)

Interventional radiology in the treatment of pulmonary embolism. Cotroneo AR, et al. **Rays** 1996 Jul-Sep; 21(3):417–24 (16 ref.) **(Eng, Ita)**

Percutaneous interventions in the biliary tree. Wu SM, et al. **Semin Roentgenol** 1997 Jul;32(3):228–45 (109 ref.)

Update on interventional uroradiology. Dyer RB, et al. **Urol Clin North Am** 1997 Aug;24(3):623–52 (128 ref.)

[Progresses in radiology in China, 1996] Zhang X. **Chung Hua I Hsueh Tsa Chih** 1996 Dec;76(12):938–9 (0 ref.) **(Chi)**

[Conservative treatment of postoperative pancreatic fistula. Role of interventional radiology] Aldrighetti L, et al. **Minerva Chir** 1996 Oct;51(10):839–48 (30 ref.) (Eng. Abstr.) **(Ita)**

INSTRUMENTATION

Endovascular stents in the arterial system—current status. Dyet JF. **Clin Radiol** 1997 Feb;52(2):83–108 (80 ref.)

[Invasive or noninvasive angiography? The role of "classical" catheter angiography] Hagen B. **Radiologe** 1997 Jul; 37(7):493–500 (50 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Minimally invasive therapy for advanced oesophageal malignancy. Tan BS, et al. **Clin Radiol** 1996 Dec; 51(12):828–36 (76 ref.)

Interventional radiology in the acute pediatric abdomen. Hoffer FA. **Radiol Clin North Am** 1997 Jul;35(4):977–87 (35 ref.)

[Therapeutic angiography] Pisco JM. **Acta Med Port** 1996 Oct-Dec;9(10-12):361–6 (14 ref.) (Eng. Abstr.) **(Por)**

RADIOGRAPHY, PANORAMIC

Panoramic radiography in dental diagnostics. Molander B. **Swed Dent J Suppl** 1996;119:1–26 (169 ref.)

[Survey on oral health of university students: examination on tooth conditions using panoramic X-ray films] Susami T, et al. **Kokubyo Gakkai Zasshi** 1996 Sep;63(3):459–67 (31 ref.) (Eng. Abstr.) **(Jpn)**

RADIOIMMUNOASSAY

Detection of misreported drug use in forensic populations: an overview of hair analysis. Kelly KS, et al. **Bull Am Acad Psychiatry Law** 1996;24(1):85–94 (45 ref.)

Heterogeneity of human prolactin. Influence on immunoassays (RIA and IRMA). Claustrat B, et al. **Nucl Med Biol** 1994 Apr;21(3):331–5 (30 ref.)

RADIOIMMUNOCONJUGATES see **IMMUNOCONJUGATES**

RADIOIMMUNODETECTION

The role of immunoscintigraphy in the staging and management of colorectal cancer. Doerr RJ, et al. **Am Surg** 1996 Nov;62(11):956–60 (29 ref.)

Nuclear medicine techniques for the study of breast cancer. Bombardieri E, et al. **Eur J Nucl Med** 1997 Jul;24(7):809–24 (142 ref.)

Diagnostic use of radiolabeled antibodies for cancer. Harrison KA, et al. **Oncology (Huntingt)** 1995 Jul;9(7):625–31 DISC 634, 636, 641 (45 ref.)

Radiolabelled monoclonal antibodies in clinical and surgical oncology: a review. Biassoni L, et al. **Panminerva Med** 1997 Mar;39(1):46–52 (17 ref.)

Single-chain Fv radioimmunotargeting. Huston JS, et al. **Q J Nucl Med** 1996 Sep;40(3):320–33 (61 ref.)

Two-step immunological approaches for imaging and therapy. Rosebrough SF. **Q J Nucl Med** 1996 Sep; 40(3):234–51 (110 ref.)

The clinical role of immunoscintigraphy for the detection of ocular melanoma. Schaling DF, et al. **Q J Nucl Med** 1996 Dec;40(4):335–40 (50 ref.)

Antibody imaging in breast cancer. Nabi HA. **Semin Nucl Med** 1997 Jan;27(1):30–9 (56 ref.)

Trials and tribulations: oncological antibody imaging comes to the fore. Zuckier LS, et al. **Semin Nucl Med** 1997 Jan; 27(1):10–29 (180 ref.)

New methods for the staging of colorectal cancer using noninvasive techniques. Blend MJ, et al. **Semin Surg Oncol** 1996 Jul-Aug;12(4):253–63 (57 ref.)

Use of monoclonal antibodies in colorectal cancer: a review. Schulte WJ. **World J Surg** 1996 Feb;20(2):238–40 (6 ref.)

METHODS

Pretargeting strategies for radio-immunoguided tumour localisation and therapy. Stoldt HS, et al. **Eur J Cancer** 1997 Feb;33(2):186–92 (49 ref.)

Cancer imaging with radiolabeled antibodies: new advances with technetium-99m-labeled monoclonal antibody Fab' fragments, especially CEA-Scan and prospects for therapy. Goldenberg DM, et al. **J Nucl Med Technol** 1997 Mar; 25(1):18–23; quiz 34 (46 ref.)

Exploration of novel strategies to enhance monoclonal antibodies targeting. Khawli LA, et al. **Q J Nucl Med** 1997 Mar;41(1):25–35 (80 ref.)

RADIOIMMUNOIMAGING see **RADIOIMMUNODETECTION**

RADIOIMMUNOSCINTIGRAPHY see **RADIOIMMUNODETECTION**

RADIOIMMUNOSORBENT ASSAY OF ALLERGENS see **RADIOALLERGOSORBENT TEST**

RADIOIMMUNOSORBENT TEST

see related
RADIOALLERGOSORBENT TEST

RADIOIMMUNOTHERAPY

Radioimmunotherapy of ovarian cancer with radiolabelled monoclonal antibodies: biological basis, present status and future perspectives. Bombardieri E, et al. **Anticancer Res** 1997 May-Jun;17(3B):1719-29 (90 ref.)

Vehicles, chelators, and radionuclides: choosing the "building blocks" of an effective therapeutic radioimmunoconjugate. Schubiger PA, et al. **Bioconjug Chem** 1996 Mar-Apr; 7(2):165-79 (98 ref.)

Radioimmunotherapy of solid tumors: a review "of mice and men". Behr TM, et al. **Hybridoma** 1997 Feb;16(1):101-7 (27 ref.)

Triumph over mischance: a role for nuclear medicine in gene therapy [editorial; comment] Larson SM, et al. **J Nucl Med** 1997 Aug;38(8):1230-3 (28 ref.) Comment on: J Nucl Med 1997 Aug;38(8):1221-9.

Two-step immunological approaches for imaging and therapy. Rosebrough SF. **Q J Nucl Med** 1996 Sep; 40(3):234-51 (110 ref.)

Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach. Slovin SF, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 14):41-8 (61 ref.)

[New therapeutic approach to pancreatic cancer by monoclonal antibodies] Sawada T, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1654-6 (10 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Radioimmunotherapy strategies for non-Hodgkin's lymphomas. Corcoran MC, et al. **Ann Oncol** 1997;8 Suppl 1:133-8 (49 ref.)

Pretargeting strategies for radio-immunoguided tumour localisation and therapy. Stoldt HS, et al. **Eur J Cancer** 1997 Feb;33(2):186-92 (49 ref.)

The current status of targeted radiotherapy in clinical practice. Gaze MN. **Phys Med Biol** 1996 Oct; 41(10):1895-903 (49 ref.)

Exploration of novel strategies to enhance monoclonal antibodies targeting. Khawli LA, et al. **Q J Nucl Med** 1997 Mar;41(1):25-35 (80 ref.)

TRENDS

Recent progress in radioimmunotherapy for cancer. Meredith RF, et al. **Oncology (Huntingt)** 1997 Jul;11(7):979-84, 987; discussion 987-8 (50 ref.)

RADIOISOTOPE ANGIOGRAPHY see **RADIONUCLIDE ANGIOGRAPHY**

RADIOISOTOPE BRACHYTHERAPY see **BRACHYTHERAPY**

RADIOISOTOPE RENOGRAPHY

Clinical renography: 25 years on. Britton KE, et al. **Eur J Nucl Med** 1996 Nov;23(11):1541-6 (33 ref.)

The true clinical significance of renography in nephro-urology. Woolfson RG, et al. **Eur J Nucl Med** 1997 May;24(5):557-70 (199 ref.)

[Quantitative analysis in nuclear nephrourology: clearance, uptake and transit time] Itoh K. **Kaku Igaku** 1997 Jan; 34(1):53-8 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Quantitative divided renal function studies with radionuclides--renoscintigraphy] Kawamura J. **Nippon Rinsho** 1997 Apr;55 Suppl 2:624-30 (26 ref.) **(Jpn)**

RADIOISOTOPE SCANNING see **RADIONUCLIDE IMAGING**

RADIOISOTOPE TELETHERAPY

The treatment of osseous metastases of hormone-refractory prostate cancer with external beam radiotherapy and Strontium-89. De Ruysscher D, et al. **Acta Urol Belg** 1996 Sep;64(3):13-9 (44 ref.)

Basal cell carcinoma in a girl after cobalt irradiation to the cranium for acute lymphoblastic leukemia: case report and literature review. Garcia-Silva J, et al. **Pediatr Dermatol** 1996 Jan-Feb;13(1):54-7 (13 ref.)

METHODS

Teletherapy in the management of patients with age-related macular degeneration complicated by subfoveal neovascularisation: an overview. Hart PM, et al. **Front Radiat Ther Oncol** 1997;30:229-37 (26 ref.)

STANDARDS

Caesium-137 gamma-ray beams. Burns JE. **Br J Radiol** 1996; Suppl 25:39-45 (9 ref.)

Cobalt-60 gamma-ray beams. McKenzie AL. **Br J Radiol** 1996;Suppl 25:46-61 (22 ref.)

RADIOISOTOPES

see related
ISOTOPE LABELING

Preparation of radiolabeled gangliosides. Sonnino S, et al. **Glycobiology** 1996 Jul;6(5):479-87 (45 ref.)

Comparison of internal emitter radiobiology in animals and humans. Lloyd RD, et al. **Health Phys** 1997 Jan; 72(1):100-10 (98 ref.)

Radiation safety review for 511-keV emitters in nuclear medicine. Dell MA. **J Nucl Med Technol** 1997 Mar; 25(1):12-7; quiz 33 (6 ref.)

Imaging technologies for radionuclide dosimetry. Ott RJ. **Phys Med Biol** 1996 Oct;41(10):1885-94 (34 ref.)

Radionuclides and carrier molecules for therapy. Zweit J. **Phys Med Biol** 1996 Oct;41(10):1905-14 (40 ref.)

ADMINISTRATION & DOSAGE

Age-dependent doses to members of the public from intake of radionuclides: Part 5. Compilation of ingestion and inhalation dose coefficients. **Ann ICRP** 1996;26(1):1-91 (17 ref.)

ADVERSE EFFECTS

Radionuclides in the body: meeting the challenge. Lauriston S. Taylor Lecture. Blair WJ. **Health Phys** 1997 Sep; 73(3):423-32 (52 ref.)

Complications and difficulties in radiolabelling blood cells: a review. Sampson CB. **Nucl Med Commun** 1996 Aug; 17(8):648-58 (66 ref.)

Cancer risk in relation to radioactivity in tobacco. Kilthau GF. **Radiol Technol** 1996 Jan-Feb;67(3):217-22 (53 ref.)

CHEMISTRY

Targeted radiotherapy using Auger electron emitters. O'Donoghue JA, et al. **Phys Med Biol** 1996 Oct; 41(10):1973-92 (81 ref.)

DIAGNOSTIC USE

Quantitative evaluation of myocardial blood flow with [13N]ammonia. Hutchins GD. **Cardiology** 1997 Jan-Feb; 88(1):106-15 (50 ref.)

Stable isotope methods for studying nutrient mineral metabolism in humans. Mellon FA, et al. **Endeavour** 1997; 21(1):12-8 (22 ref.)

Radiolabeled peptides and other ligands for receptors overexpressed in tumor cells for imaging neoplasms. McAfee JG, et al. **Nucl Med Biol** 1996 Aug;23(6):673-6 (36 ref.)

Complications and difficulties in radiolabelling blood cells: a review. Sampson CB. **Nucl Med Commun** 1996 Aug; 17(8):648-58 (66 ref.)

Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Reubi JC. **Q J Nucl Med** 1997 Jun; 41(2):63-70 (18 ref.)

[A role of radionuclide studies for gastrointestinal and hepatobiliary diseases] Koizumi K. **Kaku Igaku** 1996 Jul; 33(7):785-9 (12 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOKINETICS

Influence of microorganisms on the environmental fate of radionuclides. Gadd GM. **Endeavour** 1996;20(4):150-6 (50 ref.)

The assessment of doses and effects from intakes of radioactive particles. Harrison JD, et al. **J Anat** 1996 Dec; 189 (Pt 3):521-30 (23 ref.)

Cancer therapy using bone-seeking isotopes. Lewington VJ. **Phys Med Biol** 1996 Oct;41(10):2027-42 (78 ref.)

THERAPEUTIC USE

Radioisotopes in the treatment of bone metastases. Ben-Josef E, et al. **Ann Med** 1997 Feb;29(1):31-5 (41 ref.)

Clinical aspects of local and regional tumor therapy with 188Re-RC-160. Bender H, et al. **Anticancer Res** 1997 May-Jun;17(3B):1705-12 (31 ref.)

Pre-clinical experience with Re-188-RC-160, a radiolabeled somatostatin analog for use in peptide-targeted radiotherapy. Zamora PO, et al. **Anticancer Res** 1997 May-Jun;17(3B):1803-8 (33 ref.)

Vehicles, chelators, and radionuclides: choosing the "building blocks" of an effective therapeutic radioimmunoconjugate. Schubiger PA, et al. **Bioconjug Chem** 1996 Mar-Apr; 7(2):165-79 (98 ref.)

Targeted therapy using alpha emitters. Vaidyanathan G, et al. **Phys Med Biol** 1996 Oct;41(10):1915-31 (76 ref.)

[Radiotherapy of bone metastases. A review of the literature] Simon JM. **Bull Cancer Radiother** 1996;83(4):290-8 (67 ref.) **(Fre)**

RADIOLIGAND ASSAY

Receptor assays in the clinical laboratory. Soldin SJ. **Clin Biochem** 1996 Oct;29(5):439-44 (42 ref.)

Two-point kinetic experiments to quantify allosteric effects on radioligand dissociation [comment] Kostenis E, et al. **Trends Pharmacol Sci** 1996 Aug;17(8):280-3 (22 ref.) Comment on: Trends Pharmacol Sci 1996 Dec;17(12):443-4.

METHODS

Competitive binding assays for biotin-binding proteins. White HB 3rd. **Methods Enzymol** 1997;279:464-6 (6 ref.)

Radioligand-binding methods for membrane preparations and intact cells. Keen M. **Methods Mol Biol** 1997;83:1-24 (15 ref.)

Receptor imaging: competitive or complementary to antibody imaging? Goldsmith SJ. **Semin Nucl Med** 1997 Apr;27(2):85-93 (20 ref.)

RADIOLOGIC PHANTOMS see **PHANTOMS, IMAGING**

RADIOLOGIC PHYSICS see **HEALTH PHYSICS**

RADIOLOGY

Ethics and research. Carriero A, et al. **Eur Radiol** 1996;6 Suppl 1:S11-5 (21 ref.)

Research project design in diagnostic radiology. Debatin JF. **Eur Radiol** 1996;6 Suppl 1:S5-10 (35 ref.)

Physics in medicine: a potential unfolding in the radiological sciences. Jacobson JI. **Panminerva Med** 1997 Jun; 39(2):111-27 (15 ref.)

[Internet and radiology] Frouge C, et al. **J Radiol** 1997 Jan; 78(1):21-6 (26 ref.) **(Fre)**

[Quality assurance in radiology] Mohr W. **Z Arztl Fortbild Qualitatssich** 1997 Jul;91(4):361-8 (9 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

Outcomes research and cost-effectiveness analysis in radiology. Hunink MG. **Eur Radiol** 1996;6(5):615-20 (37 ref.)

EDUCATION

Teaching radiology on the internet. Downie AC. **Clin Radiol** 1997 Jan;52(1):4-7 (5 ref.)

MANPOWER

Unrelieved job stress can lead to burnout. Clarke S, et al. **Radiol Technol** 1996 Nov-Dec;68(2):159-60 (9 ref.)

The Pew Commission's crystal ball. Tilson E, et al. **Radiol Technol** 1996 Nov-Dec;68(2):167-9 (3 ref.)

METHODS

Radiology and spondylarthritis. Calin A. **Baillieres Clin Rheumatol** 1996 Aug;10(3):455-76 (16 ref.)

STANDARDS

Quality control in diagnostic radiology--a United States perspective. Thiele DL. **Australas Phys Eng Sci Med** 1996 Jun;19(2):97-105 (60 ref.)

Evidence-based diagnostic radiology. Dixon AK. **Lancet** 1997 Aug 16;350(9076):509-12 (31 ref.)

TRENDS

Problems of the Polish radiology in light of anticipated changes in the system of financing and organisation of the health care. Pruszyński B. **Eur Radiol** 1997;7(1):135-7 (5 ref.)

Radiology. From electron to spin doctor. Hawnaur J, et al. **Lancet** 1996 Dec 21-28;348 Suppl 2:sII22 (5 ref.)

Future directions in interventional pediatric radiology. Chait P. **Pediatr Clin North Am** 1997 Jun;44(3):763-82 (88 ref.)

The future of radiology in west Africa. Makanjuola RO. **West Afr J Med** 1996 Jul-Sep;15(3):132-8 (30 ref.)

RADIOLOGY, DIAGNOSTIC X-RAY see **RADIOGRAPHY**

RADIOLOGY INFORMATION SYSTEMS

Teaching radiology on the internet. Downie AC. **Clin Radiol** 1997 Jan;52(1):4-7 (5 ref.)

Digital radiography. Results of a survey (part A) and a consensus conference (part B). Braunschweig R, et al. **Eur Radiol** 1997;7 Suppl 3:S94-101 (88 ref.)

[The digital image archive--its clinical applications and importance in cardiology consulting by telemedicine] Fiuza M, et al. **Rev Port Cardiol** 1997 Feb;16(2):127-39, 123 (44 ref.) (Eng. Abstr.) **(Por)**

ECONOMICS

Review article: some cost-benefit considerations for PACS: a radiological perspective. Strickland NH. **Br J Radiol** 1996 Dec;69(828):1089-98 (28 ref.)

INSTRUMENTATION

Digital radiography for clinical applications. Busch HP. **Eur Radiol** 1997;7 Suppl 3:S66-72 (11 ref.)

Digital image processing. Prokop M, et al. **Eur Radiol** 1997; 7 Suppl 3:S73-82 (11 ref.)

Storage phosphor radiography. Schaefer-Prokop CM, et al. **Eur Radiol** 1997;7 Suppl 3:S58-65 (35 ref.)

RADIOLOGY, INTERVENTIONAL

Interventional radiology techniques in musculoskeletal disease. Gibbon WW. **Baillieres Clin Rheumatol** 1996 Nov; 10(4):711–27 (22 ref.)

Approach to the patient with diabetes undergoing a vascular or interventional procedure. Hirsch IB. **J Vasc Interv Radiol** 1997 May–Jun;8(3):329–36 (43 ref.)

The use of ultrasound as an adjunct to the performance of vascular procedures. Nemcek AA Jr. **J Vasc Interv Radiol** 1996 Nov–Dec;7(6):869–75 (23 ref.)

Image guidance with laser applications. Fried MP, et al. **Otolaryngol Clin North Am** 1996 Dec;29(6):1063–78 (45 ref.)

Imaging and interventional radiology in laparoscopic injuries to the gallbladder and biliary system. Slanetz PJ, et al. **Radiology** 1996 Dec;201(3):595–603 (40 ref.)

Doppler US in interventional neuroradiology. Rollo M, et al. **Rays** 1995 Oct–Dec;20(4):454–66 (18 ref.)

Carcinoid tumors: imaging procedures and interventional radiology. Wallace S, et al. **World J Surg** 1996 Feb; 20(2):147–56 (73 ref.)

[Interventional radiology in thoracic emergencies] Florio FP, et al. **Minerva Med** 1997 Jan–Feb;88(1–2):31–8 (16 ref.) (Eng. Abstr.) **(Ita)**

INSTRUMENTATION

General principles for evaluation of new interventional technologies and devices. Technology Assessment Committee. Sacks D, et al. **J Vasc Interv Radiol** 1997 Jan–Feb;8(1 Pt 1):133–6 (21 ref.)

[Interventional pneumology: procedures for pulmonary hemorrhage and tumor-induced superior vena cava syndrome] Witt C, et al. **Pneumologie** 1996 Feb;50(2):202–8 (51 ref.) (Eng. Abstr.) **(Ger)**

[Interventional radiology—current status and future importance] Stösslein F. **Z Arztl Fortbild Qualitatssich** 1997 Jul;91(4):323–34 (0 ref.) (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

[Forensic medical implications of vascular punctures and catheterization and radiologic procedures with diagnostic or therapeutic purpose] Natali J, et al. **J Mal Vasc** 1996 Nov;21(4):238–47 (9 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Interventional radiology in palliative medicine. Morgan RA, et al. **Br J Hosp Med** 1997 Feb 5–18;57(3):69–75 (9 ref.)

Technical aspects of accessing the portal vein during the TIPS procedure. Saxon RR, et al. **J Vasc Interv Radiol** 1997 Sep–Oct;8(5):733–44 (43 ref.)

TRENDS

[Interventional radiology. A therapeutic alternative rapidly developing] Cwikiel W. **Lakartidningen** 1997 Feb 19; 94(8):640, 643–5 (7 ref.) **(Swe)**

RADIOLOGY, THERAPEUTIC see **RADIATION ONCOLOGY**

RADIOMETRY

Definition of tissue–air ratio. Burns JE. **Br J Radiol** 1996; Suppl 25:177–82 (12 ref.)

METHODS

Current status of the EPR method to detect irradiated food. Desrosiers MF. **Appl Radiat Isot** 1996 Nov–Dec; 47(11–12):1621–8 (80 ref.)

Aspects of retrospective ESR dosimetry (invited paper). Romanyukha AA, et al. **Appl Radiat Isot** 1996 Nov–Dec; 47(11–12):1293–7 (22 ref.)

Radio frequency electromagnetic exposure: tutorial review on experimental dosimetry. Chou CK, et al. **Bioelectromagnetics** 1996;17(3):195–208 (78 ref.)

The equivalent field method for dose determinations in rectangular fields. Day MJ, et al. **Br J Radiol** 1996;Suppl 25:138–51 (64 ref.)

[Three-dimensional dosimetry: realities and perspectives] Bridier A, et al. **Bull Cancer Radiother** 1996;83(4):345–54 (50 ref.) **(Fre)**

RADIONUCLIDE ANGIOGRAPHY

Assessment of the right ventricle with radionuclide techniques. Schulman DS. **J Nucl Cardiol** 1996 May–Jun; 3(3):253–64 (75 ref.)

Determination of ventricular ejection fraction: a comparison of available imaging methods. The Cardiovascular Imaging Working Group. Rumberger JA, et al. **Mayo Clin Proc** 1997 Sep;72(9):860–70 (54 ref.)

METHODS

New imaging techniques for assessing cardiac function. Johnson LL, et al. **Crit Care Clin** 1996 Oct;12(4):919–37 (24 ref.)

RADIONUCLIDE ANGIOGRAPHY, FIRST-PASS see **VENTRICULOGRAPHY, FIRST-PASS**

RADIONUCLIDE ANGIOGRAPHY, GATED see **GATED BLOOD-POOL IMAGING**

RADIONUCLIDE IMAGING

see related
GAMMA CAMERAS

Radionuclide imaging of infection in the immunocompromised host. Rubin RH, et al. **Clin Infect Dis** 1996 Mar;22(3):414–23 (38 ref.)

Imaging the child with a limp. Myers MT, et al. **Pediatr Clin North Am** 1997 Jun;44(3):637–58 (30 ref.)

Imaging of child abuse. Nimkin K, et al. **Pediatr Clin North Am** 1997 Jun;44(3):615–35 (47 ref.)

Technical pitfalls in image acquisition, processing, and display. Forstrom LA, et al. **Semin Nucl Med** 1996 Oct; 26(4):278–94 (44 ref.)

Patient-related pitfalls and artifacts in nuclear medicine imaging. Howarth DM, et al. **Semin Nucl Med** 1996 Oct; 26(4):295–307 (32 ref.)

Radiopharmaceutical-related pitfalls and artifacts. Hung JC, et al. **Semin Nucl Med** 1996 Oct;26(4):208–55 (465 ref.)

Instrument- and computer-related problems and artifacts in nuclear medicine. O'Connor MK. **Semin Nucl Med** 1996 Oct;26(4):256–77 (21 ref.)

INSTRUMENTATION

The use of monoclonal antibodies (MAbs) and the development of an intraoperative hand-held probe for cancer detection [see comments] Martin EW Jr, et al. **Cancer Invest** 1996;14(6):560–71 (21 ref.) Comment in: Cancer Invest 1996;14(6):637–9.

[Nuclear medicine diagnosis—principles and indications] Schicha H. **Z Arztl Fortbild Qualitatssich** 1997 Jul; 91(4):335–40 (6 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Noninvasive evaluation of patients with peripheral vascular disease scheduled to undergo surgery: dobutamine stress echocardiography versus myocardial perfusion imaging [see comments] Kovács A, et al. **Am J Card Imaging** 1996 Apr;10(2):133–42 (58 ref.) Comment in: Am J Card Imaging 1996 Apr;10(2):117–9.

Radionuclide imaging of infection in soft tissue and bone. Strauss HW, et al. **Curr Clin Top Infect Dis** 1997;17:95–109 (64 ref.)

Computational methods in radionuclide dosimetry. Bardiès M, et al. **Phys Med Biol** 1996 Oct;41(10):1941–55 (130 ref.)

[Prerequisites for diagnostic use of antisense oligonucleotides in nuclear medicine] Hildebrandt M, et al. **Nuklearmedizin** 1996 Aug;35(4):126–31 (39 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Imaging of adrenal gland disorders. Tidwell AS, et al. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):237–54 (47 ref.)

Application of the pin-hole collimator in small animal nuclear scintigraphy: a review. Young K, et al. **Vet Radiol Ultrasound** 1997 Mar–Apr;38(2):83–93 (5 ref.)

RADIONUCLIDE TOMOGRAPHY, COMPUTED see **TOMOGRAPHY, EMISSION-COMPUTED**

RADIONUCLIDE TOMOGRAPHY, SINGLE-PHOTON EMISSION-COMPUTED see **TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON**

RADIONUCLIDE VENTRICULOGRAPHY

The role of imaging techniques in stress testing. Manoucheri M, et al. **Prim Care** 1994 Sep;21(3):535–55 (66 ref.)

[A study of 36 cases of mitral valve prolapse by isotopic ventricular tomography] Delhomme C, et al. **Arch Mal Coeur Vaiss** 1996 Sep;89(9):1127–35 (30 ref.) (Eng. Abstr.) **(Fre)**

RADIONUCLIDE VENTRICULOGRAPHY, FIRST-PASS see **VENTRICULOGRAPHY, FIRST-PASS**

RADIONUCLIDE VENTRICULOGRAPHY, GATED see **GATED BLOOD-POOL IMAGING**

RADIONUCLIDES see **RADIOISOTOPES**

RADIOPAQUE MEDIA see **CONTRAST MEDIA**

RADIOPHARMACEUTICALS

Two ways to establish potential At-211 radiopharmaceuticals. Wunderlich G, et al. **Anticancer Res** 1997 May–Jun;17(3B):1809–13 (28 ref.)

Radiation safety review for 511-keV emitters in nuclear medicine. Dell MA. **J Nucl Med Technol** 1997 Mar; 25(1):12–7; quiz 33 (6 ref.)

Radiolabeled bone-seeking radiopharmaceuticals. Atkins HL, et al. **Q J Nucl Med** 1996 Sep;40(3):285–9 (17 ref.)

The role of radiopharmacological imaging in streamlining the drug development process. Campbell DB. **Q J Nucl Med** 1997 Jun;41(2):163–9 (32 ref.)

Small peptides radiolabeled with 99mTc. Lister-James J, et al. **Q J Nucl Med** 1996 Sep;40(3):221–33 (34 ref.)

Radiolabelled cytokines. Mather SJ, et al. **Q J Nucl Med** 1996 Sep;40(3):290–300 (51 ref.)

Radiopharmaceuticals to monitor gene transfer. Wiebe LI, et al. **Q J Nucl Med** 1997 Jun;41(2):79–89 (66 ref.)

Radiopharmaceutical-related pitfalls and artifacts. Hung JC, et al. **Semin Nucl Med** 1996 Oct;26(4):208–55 (465 ref.)

Radioiodine dispensing and usage in a centralized hospital nuclear pharmacy. Hung JC. **Thyroid** 1997 Apr;7(2):289–94 (31 ref.)

[Protein- and peptide-derived radiopharmaceuticals] Arano Y. **Kaku Igaku** 1996 Oct;33(10):1111–8 (27 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Pharmacokinetic considerations in the development of labeled liposomes and micelles for diagnostic imaging. Torchilin VP. **Q J Nucl Med** 1997 Jun;41(2):141–53 (64 ref.)

Drug administration practices in medical imaging: a survey. Tortorici M, et al. **Radiol Technol** 1997 May–Jun; 68(5):379–85 (11 ref.)

ADVERSE EFFECTS

Risk assessment of the nuclear medicine patient. Mountford PJ. **Br J Radiol** 1997 Jul;70(835):671–84 (83 ref.)

CHEMISTRY

Copper radionuclides and radiopharmaceuticals in nuclear medicine. Blower PJ, et al. **Nucl Med Biol** 1996 Nov; 23(8):957–80 (210 ref.)

DIAGNOSTIC USE

Pharmacological stress testing with technetium-99m single-photon emission computerized tomography imaging in the preoperative assessment of patients undergoing noncardiac surgery [see comments] Heller GV, et al. **Am J Card Imaging** 1996 Apr;10(2):120–7 (45 ref.) Comment in: Am J Card Imaging 1996 Apr;10(2):117–9.

Role of nuclear cardiology in the evaluation of acute coronary syndromes. Kim SC, et al. **Ann Emerg Med** 1997 Aug;30(2):210–8 (38 ref.)

False-positive radioiodine uptake in the abdomen and the pelvis: radioiodine retention in the kidneys and review of the literature. Bakheet SM, et al. **Clin Nucl Med** 1996 Dec; 21(12):932–7 (25 ref.)

FDG SPECT in the assessment of myocardial viability. Comparison with dobutamine echo. Bax JJ, et al. **Eur Heart J** 1997 Jun;18 Suppl D:D124–9 (39 ref.)

Nuclear medicine techniques for the study of breast cancer. Bombardieri E, et al. **Eur J Nucl Med** 1997 Jul;24(7):809–24 (142 ref.)

Iodine-123 labelled radiopharmaceuticals and single-photon emission tomography: a natural liaison. Bourguignon MH, et al. **Eur J Nucl Med** 1997 Mar;24(3):331–44 (106 ref.)

Radiolabeled somatostatin analog scintigraphy in oncology and immune diseases: an overview. Kwekkeboom DJ, et al. **Eur Radiol** 1997;7(7):1103–9 (37 ref.)

Occult sepsis: fate or challenge? [editorial] Locher JT. **Intensive Care Med** 1996 Sep;22(9):844–6 (10 ref.)

Tracer selection with different stress modalities based on tracer kinetics. Heller GV. **J Nucl Cardiol** 1996 Nov–Dec; 3(6 Pt 2):S15–21 (20 ref.)

The rim sign in hepatic abscess: case report and review of the literature. McDonald KL, et al. **J Nucl Med** 1997 Aug; 38(8):1282–3 (7 ref.)

Cancer imaging with radiolabeled antibodies: new advances with technetium-99m-labeled monoclonal antibody Fab' fragments, especially CEA-Scan and prospects for therapy. Goldenberg DM, et al. **J Nucl Med Technol** 1997 Mar; 25(1):18–23; quiz 34 (46 ref.)

Copper radionuclides and radiopharmaceuticals in nuclear medicine. Blower PJ, et al. **Nucl Med Biol** 1996 Nov; 23(8):957–80 (210 ref.)

Radiopharmaceuticals for the study of inflammatory processes: a review. Chianelli M, et al. **Nucl Med Commun** 1997 May;18(5):437–55 (136 ref.)

Detection of hibernated myocardium using intracoronary technetium-99m-sestamibi. Giordano A, et al. **Q J Nucl Med** 1997 Mar;41(1):46–50 (30 ref.)

Scintimammography: the new role of technetium-99m Sestamibi imaging for the diagnosis of breast carcinoma. Khalkhali I, et al. **Q J Nucl Med** 1997 Sep;41(3):231–8 (42 ref.)

Breast cancer seeking agents: basic approach. Maffioli L, et al. **Q J Nucl Med** 1997 Sep;41(3):211–24 (121 ref.)

Diagnostic and prognostic role of 99mTc-Tetrofosmin in breast cancer. Mansi L, et al. **Q J Nucl Med** 1997 Sep; 41(3):239–50 (70 ref.)

Clinical use of metaiodobenzylguanidine imaging in cardiology. Merlet P, et al. **Q J Nucl Med** 1995 Dec;39(4 Suppl 1):29–39 (79 ref.)

The current status of meta-iodobenzylguanidine and related agents for the diagnosis of neuro-endocrine tumors. Shapiro B, et al. **Q J Nucl Med** 1995 Dec;39(4 Suppl 1):3–8 (60 ref.)

Advances in pulmonary nuclear medicine. Salvatori M. **Rays** 1997 Jan–Mar;22(1):51–72 (47 ref.) **(Eng, Ita)**

[Ulcerative colitis and colonic angiodysplasia associated with

a lower digestive hemorrhage. Their diagnosis by 99-technetium-labelled red blood cells]
Martínez-Caballero A, et al. **Rev Esp Enferm Dig** 1997 Jan;89(1):51-4 (16 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

The application of receptor theory to receptor-binding and enzyme-binding oncologic radiopharmaceuticals.
Eckelman WC. **Nucl Med Biol** 1994 Jul;21(5):759-69 (81 ref.)

PHARMACOKINETICS

Pharmacokinetic considerations in the development of oligomers as radiopharmaceuticals. Hnatowich DJ.
Q J Nucl Med 1997 Jun;41(2):91-100 (47 ref.)
Pharmacokinetic considerations in the development of peptide-based imaging agents. Lister-James J, et al.
Q J Nucl Med 1997 Jun;41(2):111-8 (17 ref.)
Receptor ligands. Signore A. **Q J Nucl Med** 1995 Dec;39(4 Suppl 1):83-5 (8 ref.)
Pharmacokinetics of SPECT radiopharmaceuticals for imaging hypoxic tissues. Wiebe LI, et al.
Q J Nucl Med 1996 Sep;40(3):270-84 (43 ref.)

THERAPEUTIC USE

Treatment of metastatic carcinoma of the prostate. Goethuys H, et al. **Am J Clin Oncol** 1997 Feb;20(1):40-5 (47 ref.)
Prodrugs in site-selective delivery of radiopharmaceuticals. Baranowska-Kortylewicz J, et al. **Q J Nucl Med** 1997 Jun; 41(2):127-39 (47 ref.)

RADIOPROTECTIVE AGENTS see **RADIATION-PROTECTIVE AGENTS**

RADIORECEPTOR ASSAY see **RADIOLIGAND ASSAY**

RADIOSENSITIVITY see **RADIATION TOLERANCE**

RADIOSENSITIZING AGENTS see **RADIATION-SENSITIZING AGENTS**

RADIOSURGERY

Radiosurgery for brain metastases: relationship of dose and pattern of enhancement to local control. Shiau CY, et al. **Int J Radiat Oncol Biol Phys** 1997 Jan 15;37(2):375-83 (21 ref.)
Stereotactic radiosurgery of pituitary adenomas. Motti ED, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):111-4 (11 ref.)
Radiosurgery: its role in brain metastasis management. Flickinger JC, et al. **Neurosurg Clin N Am** 1996 Jul; 7(3):497-504 (25 ref.)
Gamma knife radiosurgery for trigeminal neuralgia. Kondziolka D, et al. **Neurosurg Clin N Am** 1997 Jan; 8(1):79-85 (17 ref.)
Eosinophilic granuloma of the clivus: case report, follow-up of two previously reported cases, and review of the literature on cranial base eosinophilic granuloma. Brisman JL, et al. **Neurosurgery** 1997 Jul;41(1):273-8; discussion 278-9 (43 ref.)
Radiosurgery for pineal tumors: is biopsy indicated? Chasan CB, et al. **Stereotact Funct Neurosurg** 1996;66 Suppl 1:157-63 (12 ref.)
[Stereotaxic radiotherapy of cerebral arteriovenous malformations: the role of neuroradiology] Meder JF, et al. **J Neuroradiol** 1997 Aug;24(2):126-33 (57 ref.) (Eng. Abstr.) **(Fre)**
[Radiosurgery] Philippon J, et al. **Rev Neurol (Paris)** 1997 May;153(4):235-8 (13 ref.) (Eng. Abstr.) **(Fre)**
[Gamma knife radiosurgery for acoustic neurinoma: history and present situation] Jokura H, et al. **No To Shinkei** 1996 Feb;48(2):103-11 (39 ref.) **(Jpn)**
[Radiosurgery of cerebral arteriovenous malformations: an update] Kawamoto S. **No To Shinkei** 1996 Feb;48(2):129-41 (107 ref.) **(Jpn)**
[Gamma radiosurgery for malignant tumors] Kobayashi T, et al. **No To Shinkei** 1996 Feb;48(2):121-8 (15 ref.) **(Jpn)**

ADVERSE EFFECTS

Post gamma knife headache: a new headache syndrome? Rozen TD, et al. **Headache** 1997 Mar;37(3):180-3 (10 ref.)

INSTRUMENTATION

[Gamma knife radiosurgery for metastatic brain tumors: neuropathological report of two autopsy cases and review of literatures] Tago M, et al.
Nippon Igaku Hoshasen Gakkai Zasshi 1997 Feb; 57(3):119-26 (30 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Fractionated stereotactic radiotherapy. Shrieve DC, et al. **Important Adv Oncol** 1996;:205-24 (67 ref.)
[Stereotactic multiple arc radiotherapy] Nomura K, et al. **No To Shinkei** 1996 Feb;48(2):143-8 (15 ref.) **(Jpn)**

RADIOTHERAPY

Radiotherapy in Sweden--a study of present use in relation to the literature and an estimate of future trends. Frödin JE, et al. **Acta Oncol** 1996;35(8):967-79 (09 ref.)
Palliative use of ionizing radiations. Parker RG.
Acta Oncol 1996;35(8):981-7 (69 ref.)
p53 and response to chemotherapy and radiotherapy. Ruley HE. **Important Adv Oncol** 1996;:37-56 (269 ref.)
Molecular aspects of cellular responses to radiotherapy. Yarnold J. **Radiother Oncol** 1997 Jul;44(1):1-7 (15 ref.)
Theory and practice of predictive assays in radiation therapy. Crompton NE, et al. **Strahlenther Onkol** 1997 Feb; 173(2):58-67 (42 ref.)
[Recent progress in radiotherapy] Bey P, et al.
Rev Med Interne 1996;17(9):761-8 (22 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Octreotide in the management of treatment-related diarrhoea. Baillie-Johnson HR. **Anticancer Drugs** 1996 Jan; 7 Suppl 1:11-5 (43 ref.)
Radiotherapy-associated neutropenia and thrombocytopenia: analysis of risk factors and development of a predictive model. Mac Manus M, et al. **Blood** 1997 Apr 1; 89(7):2303-10 (36 ref.)
Pelvic surgery after radiotherapy. Mundy AR. **Br J Urol** 1997 Jul;80 Suppl 1:66-8 (0 ref.)
Programmed instruction: cancer therapy. Associated late effects (III). Rodriguez CS, et al. **Cancer Nurs** 1996 Oct; 19(5):392-400; quiz 401-2 (26 ref.)
Late complications of radiotherapy. **Drug Ther Bull** 1997 Feb; 35(2):13-6 (38 ref.)
Radiotherapy and second primary tumour. Cartei F.
Eur J Cancer Prev 1996 Oct;5(5):388-90 (9 ref.)
Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature. Martino R, et al. **Haematologica** 1997 May-Jun;82(3):297-304 (38 ref.)
Laryngeal necrosis after combined chemotherapy and radiation therapy. Miyaguchi M, et al. **J Laryngol Otol** 1997 Aug;111(8):763-5 (13 ref.)
Development of primary hypothyroidism with antithyroglobulin, antiperoxidase, and blocking-type thyrotropin receptor antibodies after radiation therapy for neuroblastoma. Kikawa Y, et al. **J Pediatr** 1996 Dec; 129(6):909-12 (19 ref.)
Protective effects of glutamine enriched diets on acute actinic enteritis. Campos FG, et al. **Nutr Hosp** 1996 May-Jun; 11(3):167-77 (140 ref.)
Oral complications from cancer therapy: Part 1--Pathophysiology and secondary complications. Madeya ML. **Oncol Nurs Forum** 1996 Jun;23(5):801-7 (28 ref.)
Oral complications from cancer therapy: Part 2--Nursing implications for assessment and treatment. Madeya ML. **Oncol Nurs Forum** 1996 Jun;23(5):808-19 (63 ref.)
Laryngeal radionecrosis versus recurrent cancer. McGuirt WF. **Otolaryngol Clin North Am** 1997 Apr;30(2):243-50 (19 ref.)
Management of complications resulting from laryngeal cancer treatment. Weissler MC.
Otolaryngol Clin North Am 1997 Apr;30(2):269-78 (16 ref.)
Estimates of numbers of civilians treated with nasopharyngeal radium irradiation in the United States. Mellinger-Birdsong AK. **Otolaryngol Head Neck Surg** 1996 Nov;115(5):429-32 (29 ref.)
Head and neck radiation carcinogenesis: epidemiologic evidence. Ron E, et al. **Otolaryngol Head Neck Surg** 1996 Nov;115(5):403-8 (38 ref.)
Nasopharyngeal radium irradiation: fundamental considerations. Royal HD. **Otolaryngol Head Neck Surg** 1996 Nov;115(5):399-402 (26 ref.)
Epidemiologic issues related to nasopharyngeal radium exposures. Shore RE. **Otolaryngol Head Neck Surg** 1996 Nov;115(5):422-8 (13 ref.)
Radiation injury. Mathes SJ, et al.
Surg Oncol Clin N Am 1996 Oct;5(4):809-24 (54 ref.)
Linear basal cell carcinomas: report of multiple sequential tumors localized to a radiotherapy port and review of the literature. Chopra KF, et al. **Tex Med** 1997 Jul;93(7):57-9 (10 ref.)
[Amifostine: current and future applications in cytoprotection] Lenoble M. **Bull Cancer** 1996 Sep; 83(9):773-87 (48 ref.) (Eng. Abstr.) **(Fre)**
[Imaging of digestive involvements after irradiation] Chopier J, et al. **J Radiol** 1996 Aug;77(8):543-53 (64 ref.) (Eng. Abstr.) **(Fre)**
[Hyperbaric oxygenation (HBO) in the treatment of radiogenic side effects] Hartmann A, et al.
Strahlenther Onkol 1996 Dec;172(12):641-8 (51 ref.) (Eng. Abstr.) **(Ger)**
[Dental changes induced by radiotherapy: a study of subjects with retinoblastoma. I] Mascagni EE, et al.
Minerva Stomatol 1997 Apr;46(4):191-200 (66 ref.) (Eng. Abstr.) **(Ita)**
[Skeletal changes induced by radiotherapy. A study of subjects with retinoblastoma. II] Mascagni EE, et al.
Minerva Stomatol 1997 May;46(5):233-46 (67 ref.) (Eng. Abstr.) **(Ita)**
[Oral candidiasis following radiotherapy for neoplasms of the oromaxillofacial area] Tartaro GP, et al.
Minerva Stomatol 1996 Oct;45(10):451-4 (9 ref.) (Eng. Abstr.) **(Ita)**
[Cellular mechanisms of functional disorders of the lymphatic system in high-dose radiotherapy] Chukhlovin AB, et al.
Vopr Onkol 1997;43(2):231-7 (58 ref.) **(Rus)**

METHODS

Current status of conformal radiotherapy. Dahl O, et al.
Acta Oncol 1996;35 Suppl 8:41-57 (235 ref.)
Clinical strategies for improving the radiotherapeutic management of prostate cancer. Chuba PJ, et al.
Anticancer Res 1997 May-Jun;17(3A):1449-54 (43 ref.)
Review article: effects of radiation on the cell proliferation kinetics of epithelial tissues--therapeutic implications. Morris GM. **Br J Radiol** 1996 Sep;69(825):795-803 (72 ref.)
Biological rationale and clinical experience with hyperthermia. Engin K. **Control Clin Trials** 1996 Aug; 17(4):316-42 (183 ref.)
Current status of larynx preservation trials. Lefebvre JL, et al. **Curr Opin Oncol** 1996 May;8(3):209-14 (55 ref.)
Computational methods in radionuclide dosimetry. Bardiès M, et al. **Phys Med Biol** 1996 Oct;41(10):1941-55 (130 ref.)
Dose-rate effects in targeted radiotherapy. Dale RG.
Phys Med Biol 1996 Oct;41(10):1871-84 (46 ref.)
The current status of targeted radiotherapy in clinical practice. Gaze MN. **Phys Med Biol** 1996 Oct; 41(10):1895-903 (49 ref.)
Perturbation effects in dosimetry: Part I. Kilovoltage x-rays and electrons. Nahum AE. **Phys Med Biol** 1996 Sep; 41(9):1531-80 (148 ref.)
Targeted radiotherapy using Auger electron emitters. O'Donoghue JA, et al. **Phys Med Biol** 1996 Oct; 41(10):1973-92 (81 ref.)
Targeted therapy using alpha emitters. Vaidyanathan G, et al. **Phys Med Biol** 1996 Oct;41(10):1915-31 (76 ref.)
Radionuclides and carrier molecules for therapy. Zweit J. **Phys Med Biol** 1996 Oct;41(10):1905-14 (40 ref.)
Hyperfractionation: where do we stand? Beck-Bornholdt HP, et al. **Radiother Oncol** 1997 Apr;43(1):1-21 (170 ref.)
[Laryngeal cancer and conservative treatment. Place of combined radiotherapy chemotherapy and modified fractionation radiotherapy] Brunin F, et al. **Bull Cancer** 1997 Feb;84(2):191-8 (43 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

[Present state and future of radiation therapy for pancreatic cancer] Kato H, et al. **Gan To Kagaku Ryoho** 1996 Oct; 23(12):1642-6 (11 ref.) (Eng. Abstr.) **(Jpn)**

VETERINARY

Radioresistance, chemoresistance, and apoptosis resistance. The past, present, and future. Bergman PJ, et al.
Vet Clin North Am Small Anim Pract 1997 Jan;27(1):47-57 (42 ref.)
A selected review of the physics of radiation therapy. Burk RL, et al. **Vet Clin North Am Small Anim Pract** 1997 Jan; 27(1):7-20 (5 ref.)
Radiation therapy in the treatment of oral neoplasia. Burk RL. **Vet Clin North Am Small Anim Pract** 1996 Jan; 26(1):155-63 (56 ref.)
Radiation therapy toxicities. Harris D, et al.
Vet Clin North Am Small Anim Pract 1997 Jan;27(1):37-46 (27 ref.)
Radiation therapy in the management of bone tumors. McEntee MC. **Vet Clin North Am Small Anim Pract** 1997 Jan;27(1):131-8 (32 ref.)
The role of radiotherapy in the treatment of lymphoma and thymoma. Meleo KA.
Vet Clin North Am Small Anim Pract 1997 Jan;27(1):115-29 (36 ref.)
Palliative radiotherapy. Siegel S, et al.
Vet Clin North Am Small Anim Pract 1997 Jan;27(1):149-55 (25 ref.)
Biologic basis of radiation therapy. Thrall DE.
Vet Clin North Am Small Anim Pract 1997 Jan;27(1):21-35 (40 ref.)

RADIOTHERAPY, ADJUVANT

Management of esophageal cancer. Ilson DH, et al.
Oncology (Huntingt) 1996 Sep;10(9):1385-96, 1401-2; discussion 1402-8 (79 ref.)
[Adjuvant and neoadjuvant methods: what is their value--do they change surgical procedure?] Meyer HJ, et al.
Langenbecks Arch Chir Suppl Kongressbd 1996;113:70-5 (25 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Fractures in children treated with radiotherapy for soft tissue sarcoma. Wall JE, et al. **Orthopedics** 1996 Aug;19(8):657-64 (24 ref.)
[Role of radiotherapy in the management of adenocarcinoma of the breast accessible to conservative surgery] Romestaing P, et al. **Cancer Radiother** 1997;1(1):14-28 (134 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Adjuvant therapy for colorectal cancer: past accomplishments, future directions. Vaughn DJ, et al.
Cancer Invest 1997;15(5):435-47 (88 ref.)
New approaches to treating advanced melanoma: adjuvant treatment of high-risk primary melanoma and boron neutron capture therapy. Rogers GS, et al.
Semin Cutan Med Surg 1997 Jun;16(2):165-73 (40 ref.)

RADIOTHERAPY DOSAGE

see related
DOSE-RESPONSE RELATIONSHIP, RADIATION

Altered fractionated radiation therapy for head and neck carcinomas--A Massachusetts General Hospital experience. Wang CC. **Ann Acad Med Singapore** 1996 May; 25(3):335-40 (21 ref.)
Definition of tissue-air ratio. Burns JE. **Br J Radiol** 1996; Suppl 25:177-82 (12 ref.)
Conversion of PDD for photon beams from one SSD to another and calculation of TAR, TMR and TPR. Burns JE. **Br J Radiol** 1996;Suppl 25:153-7 (12 ref.)
The normalized peak scatter factor and normalized scatter functions for high energy photon beams. Day MJ, et al. **Br J Radiol** 1996;Suppl 25:168-76 (18 ref.)
Three-dimensional conformal therapy (3D-CRT) for prostate cancer. Chuba PJ, et al. **Cancer Treat Res** 1996; 88:147-65 (48 ref.)
Fractionated stereotactic radiotherapy. Shrieve DC, et al. **Important Adv Oncol** 1996;:205-24 (67 ref.)
Computational methods in radionuclide dosimetry. Bardiès M, et al. **Phys Med Biol** 1996 Oct;41(10):1941-55 (130 ref.)
Dose-rate effects in targeted radiotherapy. Dale RG. **Phys Med Biol** 1996 Oct;41(10):1871-84 (46 ref.)
Perturbation effects in dosimetry: Part I. Kilovoltage x-rays and electrons. Nahum AE. **Phys Med Biol** 1996 Sep; 41(9):1531-80 (148 ref.)
Imaging technologies for radionuclide dosimetry. Ott RJ. **Phys Med Biol** 1996 Oct;41(10):1885-94 (34 ref.)

STANDARDS

Equivalent half-value layers. Burns JE. **Br J Radiol** 1996; Suppl 25:158-61 (7 ref.)
Caesium-137 gamma-ray beams. Burns JE. **Br J Radiol** 1996; Suppl 25:39-45 (9 ref.)
The equivalent field method for dose determinations in rectangular fields. Day MJ, et al. **Br J Radiol** 1996;Suppl 25:138-51 (64 ref.)
X-rays: half-value layers 0.01-8.0 mm Al (approx. 6-150 kV peak potential difference). Harrison RM. **Br J Radiol** 1996; Suppl 25:1-23 (47 ref.)
Megavoltage X-ray beams: 2-50 MV. Jordan TJ. **Br J Radiol** 1996;Suppl 25:62-109 (92 ref.)
Proton beams. Kacperek A, et al. **Br J Radiol** 1996;Suppl 25:131-7 (13 ref.)
Electron beams. Lillicrap SC. **Br J Radiol** 1996;Suppl 25:110-9 (28 ref.)
Cobalt-60 gamma-ray beams. McKenzie AL. **Br J Radiol** 1996;Suppl 25:46-61 (22 ref.)
The variation of percentage depth dose and scatter factor with beam quality. Pitchford WG. **Br J Radiol** 1996;Suppl 25:162-7 (3 ref.)
Fast neutron beams. Shaw JE, et al. **Br J Radiol** 1996;Suppl 25:120-30 (8 ref.)
Orthovoltage X-ray beams (0.5 mm-4.0 mm Cu HVL). Smith CW. **Br J Radiol** 1996;Suppl 25:24-38 (21 ref.)

RADIOTHERAPY, HIGH-ENERGY

[Proton and neutron radiation in cancer treatment: clinical and economic outcomes] Fleurette F, et al. **Bull Cancer Radiother** 1996;83 Suppl:223s-7s (29 ref.)
Present status, trends and needs in fast neutron therapy. Wambersie A, et al. **Bull Cancer Radiother** 1996;83 Suppl:68s-77s (28 ref.)

ADVERSE EFFECTS

The pitfalls and complications of radiation therapy for esophageal carcinoma. Moni J, et al. **Chest Surg Clin N Am** 1997 Aug;7(3):565-84; discussion 585 (48 ref.)
Postirradiation laryngeal osteosarcoma: case report and literature review. Sheen TS, et al. **Head Neck** 1997 Jan; 19(1):57-62 (36 ref.)
Response of the normal eye to high dose radiotherapy [see comments] Parsons JT, et al. **Oncology (Huntingt)** 1996 Jun; 10(6):837-47; discussion 847-8, 851-2 (39 ref.) Comment in: Oncology (Huntingt) 1996 Jul;10(7):981-2, 984.

METHODS

Mycosis fungoides and total skin electron beam radiation [letter; comment] Jones GW, et al. **Blood** 1997 Apr 15; 89(8):3062-4 (12 ref.) Comment on: Blood 1996 Oct 1;88(7):2385-409.
Fast neutrons in the treatment of grade IV astrocytomas. Breteau N, et al. **Bull Cancer Radiother** 1996;83 Suppl:135s-41s (42 ref.)
Fast neutron therapy for inoperable or recurrent sacrococcygeal chordomas. Breteau N, et al. **Bull Cancer Radiother** 1996;83 Suppl:142s-5s (19 ref.)
European results in neutron therapy of malignant salivary gland tumors. Krüll A, et al. **Bull Cancer Radiother** 1996; 83 Suppl:125-9s (44 ref.)
Ten years of fast neutron therapy in Münster. Prott FJ, et al. **Bull Cancer Radiother** 1996;83 Suppl:115s-21s (23 ref.)
Present status, trends and needs in fast neutron therapy. Wambersie A, et al. **Bull Cancer Radiother** 1996;83 Suppl:68s-77s (28 ref.)
[Protontherapy. Clinical features] Habrand JL, et al. **Bull Cancer Radiother** 1996;83(4):247-53 (26 ref.) **(Fre)**
[Protontherapy: physical and technical basis] Mazal A, et al. **Bull Cancer Radiother** 1996;83(4):230-46 (60 ref.) **(Fre)**

STANDARDS

Megavoltage X-ray beams: 2-50 MV. Jordan TJ. **Br J Radiol** 1996;Suppl 25:62-109 (92 ref.)

RADIOTHERAPY, INTERSTITIAL see **BRACHYTHERAPY**

RADIOTHERAPY, INTRACAVITY see **BRACHYTHERAPY**

RADIOTHERAPY, LYMPHATIC see **LYMPHATIC IRRADIATION**

RADIOTHERAPY PLANNING, COMPUTER-ASSISTED

Clinical implementation of electronic portal imaging: correction strategies and set-up errors. De Neve W, et al. **Bull Cancer Radiother** 1996;83(4):401-5 (33 ref.)
Three-dimensional conformal therapy (3D-CRT) for prostate cancer. Chuba PJ, et al. **Cancer Treat Res** 1996; 88:147-65 (48 ref.)
Three-dimensional planning and conformal radiotherapy. Harmer C, et al. **Cancer Treat Res** 1997;91:129-41 (24 ref.)
The use of medical images in planning and delivery of radiation therapy. Kalet IJ, et al. **J Am Med Inform Assoc** 1997 Sep-Oct;4(5):327-39 (38 ref.)
Microdosimetry and radiocurability: modelling targeted therapy with beta-emitters. Nahum AE. **Phys Med Biol** 1996 Oct;41(10):1957-72 (34 ref.)
Imaging technologies for radionuclide dosimetry. Ott RJ. **Phys Med Biol** 1996 Oct;41(10):1885-94 (34 ref.)
Magnetic resonance imaging (MRI): considerations and applications in radiotherapy treatment planning. Khoo VS, et al. **Radiother Oncol** 1997 Jan;42(1):1-15 (100 ref.)
[Three-dimensional dosimetry: realities and perspectives] Bridier A, et al. **Bull Cancer Radiother** 1996;83(4):345-54 (50 ref.) **(Fre)**
[Overview of the development of clinical and dosimetric methods for radiotherapy planning for cancer patients in Hungary (see comments)] Treer T, et al. **Orv Hetil** 1996 Aug 18;137(33):1805-9 (33 ref.) (Eng. Abstr.) Comment in: Orv Hetil 1997 Jun 15;138(24):1604. **(Hun)**

METHODS

A review of electron beam dose calculation algorithms. Keall PJ, et al. **Australas Phys Eng Sci Med** 1996 Sep; 19(3):111-30 (120 ref.)
A CT-aided PC-based physical treatment planning of TBI: a method for dose calculation. Sánchez-Nieto B, et al. **Radiother Oncol** 1997 Jan;42(1):77-85 (27 ref.)

TRENDS

Recent developments in radiation therapy planning and treatment optimization. Brahme A. **Australas Phys Eng Sci Med** 1996 Jun;19(2):53-66 (76 ref.)

RADIOTHERAPY, SURFACE see **BRACHYTHERAPY**

RADIOTHERAPY, TARGETED see **RADIOTHERAPY**

RADIOVISIOGRAPHY, DENTAL

Efficacy of digital intra-oral radiography in clinical dentistry. Versteeg CH, et al. **J Dent** 1997 May-Jul;25(3-4):215-24 (63 ref.)

RADIUM

ADVERSE EFFECTS

Epidemiologic issues related to nasopharyngeal radium exposures. Shore RE. **Otolaryngol Head Neck Surg** 1996 Nov;115(5):422-8 (13 ref.)

THERAPEUTIC USE

Nasopharyngeal radium irradiation: fundamental considerations. Royal HD. **Otolaryngol Head Neck Surg** 1996 Nov;115(5):399-402 (26 ref.)
Epidemiologic issues related to nasopharyngeal radium exposures. Shore RE. **Otolaryngol Head Neck Surg** 1996 Nov;115(5):422-8 (13 ref.)

RADIUS

The distal radioulnar joint: anatomy and management of disorders. Jaffe R, et al. **J Hand Ther** 1996 Apr-Jun; 9(2):129-38 (65 ref.)

ABNORMALITIES

Longitudinal failure of upper-limb formation. Manske PR. **Instr Course Lect** 1997;46:83-110 (95 ref.)

INJURIES

Disorders of the distal radioulnar joint. Glowacki K, et al. **Am J Orthop** 1997 Mar;26(3):193-200 (51 ref.)
Isolated palmar radiocarpal dislocation and ulnar translocation: a case report and review of the literature. Howard RF, et al. **J Hand Surg [Am]** 1997 Jan;22(1):78-82 (10 ref.)

RADIUS FRACTURES

Management of radial head fracture. Gutierrez G. **Am Fam Physician** 1997 May 1;55(6):2213-6 (07 ref.)
Distal radius fractures: concepts and complications. Glowacki KA, et al. **Orthopedics** 1996 Jul;19(7):601-8 (49 ref.)

CLASSIFICATION

Comparative classification for fractures of the distal end of the radius. Jupiter JB, et al. **J Hand Surg [Am]** 1997 Jul; 22(4):563-71 (29 ref.)

COMPLICATIONS

Cortical bone cyst following a greenstick radial fracture. Wass AR, et al. **J Accid Emerg Med** 1996 Jan;13(1):63-4 (6 ref.)
Nonunion of distal radial fractures associated with distal ulnar shaft fractures: a report of four cases. McKee MD, et al. **J Orthop Trauma** 1997 Jan;11(1):49-53 (16 ref.)
Ulnar nerve laceration in a closed both bone forearm fracture. Torpey BM, et al. **J Orthop Trauma** 1996;10(2):131-4 (12 ref.)

PHYSIOPATHOLOGY

Premature closure of the distal radial physics after fracture of the distal radial metaphysis [letter; comment] Peterson HA. **J Pediatr Orthop** 1997 Jan-Feb;17(1):126-7 (8 ref.) Comment on: J Pediatr Orthop 1995 Jul-Aug;15(4):495-8.

SURGERY

External fixation for distal radius fractures: adverse effects of excess distraction. Kaempffe FA. **Am J Orthop** 1996 Mar;25(3):205-9 (25 ref.)
The Galeazzi-equivalent lesion in children revisited. Imatani J, et al. **J Hand Surg [Br]** 1996 Aug;21(4):455-7 (11 ref.)
Fractures of the distal radius in adults. Amadio PC. **J South Orthop Assoc** 1994 Winter;3(4):312-22 (42 ref.)

RADON

see related
AIR POLLUTANTS, RADIOACTIVE

What are the risks of low-level exposure to alpha radiation from radon? [see comments] Little JB. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):5996-7 (21 ref.) Comment in: Proc Natl Acad Sci U S A 1997 Apr 15;94(8):3765-70.

ADVERSE EFFECTS

Radon and cancer. Bochicchio F. **Eur J Cancer Prev** 1996 Oct;5(5):383-4 (12 ref.)
[Carcinogenic effects of radon in humans (literature review)] Averkina NA. **Med Tr Prom Ekol** 1996;(9):32-6 (20 ref.) (Eng. Abstr.) **(Rus)**

RAILLIETINA see **CESTODA**

RAILLIETINIASIS see **CESTODE INFECTIONS**

RAJA see **SKATES (FISH)**

RALES see **RESPIRATORY SOUNDS**

RAMAN SPECTROSCOPY see **SPECTRUM ANALYSIS, RAMAN**

RAMPS see **ARCHITECTURAL ACCESSIBILITY**

RAMSAY HUNT AURICULAR SYNDROME see **HERPES ZOSTER OTICUS**

RAMSAY HUNT PARALYSIS SYNDROME see **PARKINSON DISEASE**

RANDOM ALLOCATION

Random versus nonrandom assignment in controlled experiments: do you get the same answer? Shadish WR, et al. **J Consult Clin Psychol** 1996 Dec;64(6):1290-305 (169 ref.)

RANDOM AMPLIFIED POLYMORPHIC DNA TECHNIQUE

see related
DNA FINGERPRINTING
GENETIC MARKERS

Molecular epidemiology: applications of nucleic acid amplification and sequence analysis. McDade JE, et al. **Epidemiol Rev** 1996;18(1):90-7 (46 ref.)
RAPD typing in microbiology--a technical review. Power EG. **J Hosp Infect** 1996 Dec;34(4):247-65 (55 ref.)

RANDOM PEPTIDE LIBRARY see **PEPTIDE LIBRARY**

RANDOMIZATION

RANDOMIZATION see **RANDOM ALLOCATION**

RANDOMIZED CONTROLLED TRIALS

Randomized controlled trials and systematic reviews: a foundation for evidence-based perinatal medicine. Ohlsson A. **Acta Paediatr** 1996 Jun;85(6):647-55 (100 ref.)

Retracing the steps of Marco Polo: from clinical trials to diffusion of interventions for smokers. Richmond RL. **Addict Behav** 1996 Nov-Dec;21(6):683-97 (65 ref.)

Review article: critical review of meta-analyses of randomized clinical trials in hepatogastroenterology. Auperin A, et al. **Aliment Pharmacol Ther** 1997 Apr; 11(2):215-25 (97 ref.)

Digitalis Investigation Group (DIG) trial: a stimulus for further research. Gheorghiade M, et al. **Am Heart J** 1997 Jul;134(1):3-12 (136 ref.)

Patency trials with reteplase (r-PA): what do they tell us? Bode C, et al. **Am J Cardiol** 1996 Dec 19;78(12A):16-9 (26 ref.)

Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. Harrington RA. **Am J Cardiol** 1997 Aug 18; 80(4A):34B-38B (27 ref.)

Clinical trials in thrombolytic therapy: what do they tell us? INJECT 6-month outcomes data. Wilcox RG. **Am J Cardiol** 1996 Dec 19;78(12A):20-3 (8 ref.)

Ambulatory blood pressure monitoring in clinical trials. Bieniaszewski L, et al. **Ann N Y Acad Sci** 1996 Aug 15; 783:295-303 (75 ref.)

Efficacy of non-steroidal anti-inflammatory drugs for low back pain: a systematic review of randomised clinical trials. Koes BW, et al. **Ann Rheum Dis** 1997 Apr;56(4):214-23 (53 ref.)

Physiotherapy for patients with soft tissue shoulder disorders: a systematic review of randomised clinical trials. van der Heijden GJ, et al. **BMJ** 1997 Jul 5;315(7099):25-30 (45 ref.)

Analysis of randomized controlled trials in laparoscopic surgery. Slim K, et al. **Br J Surg** 1997 May;84(5):610-4 (36 ref.)

The role of percutaneous revascularization in the treatment of ischemic heart disease: insights from published reports and randomized clinical trials. Levine GN, et al. **Chest** 1997 Sep;112(3):805-21 (95 ref.)

Major clinical trials assessing the prophylactic use of amiodarone in patients with ventricular tachyarrhythmias. Fogoros RN. **Control Clin Trials** 1996 Jun;17(3 Suppl):37S-46S (18 ref.)

Clinical trials with implications regarding heart failure therapy. Young JB. **Curr Opin Cardiol** 1997 Jul; 12(4):407-17 (20 ref.)

Cohort studies and randomized controlled studies in endocrinology. Salamone LM, et al. **Endocrinol Metab Clin North Am** 1997 Mar;26(1):17-29 (49 ref.)

Clinical trials in patients with epithelial ovarian cancer: past, present and future. Vermorken JB, et al. **Eur J Surg Oncol** 1996 Oct;22(5):455-66 (87 ref.)

Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS. PROGRESS Management Committee. Perindopril Protection Against Recurrent Stroke Study. **J Hypertens Suppl** 1996 Sep; 14(2):S41-5; discussion S45-6 (20 ref.)

Interpretation of data from multiple trials: a critical review. Conn HO. **J Intern Med** 1997 Mar;241(3):177-83 (48 ref.)

Feasibility of randomised clinical trials in rare diseases: the case of polycythemia vera. Marchioli R, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:121-7 (18 ref.)

Antioxidants in cardiovascular disease: randomized trials. Gaziano JM. **Nutr Rev** 1996 Jun;54(6):175-7 (6 ref.)

Antioxidants in cardiovascular disease: randomized trials. Gaziano JM. **Nutrition** 1996 Sep;12(9):583-8 (59 ref.)

Implications and results of the Diabetes Control and Complications Trial. Tamborlane WV, et al. **Pediatr Clin North Am** 1997 Apr;44(2):285-300 (37 ref.)

Clinical trials. Blichert-Toft M, et al. **Semin Surg Oncol** 1996 Jan-Feb;12(1):32-8 (24 ref.)

Esophageal cancer surgery: the value of controlled clinical trials. Law SY, et al. **Semin Surg Oncol** 1997 Jul-Aug; 13(4):281-7 (75 ref.)

The role of meta-analysis in monitoring clinical trials. Begg CB. **Stat Med** 1996 Jun 30;15(12):1299-306; discussion 1307-11 (25 ref.)

Meta-analysis and meta-analytic monitoring of clinical trials. Feinstein AR. **Stat Med** 1996 Jun 30;15(12):1273-80; discussion 1281-3 (12 ref.)

The role of external evidence in data monitoring of a clinical trial. Pocock SJ. **Stat Med** 1996 Jun 30;15(12):1285-93; discussion 1295-7 (18 ref.)

[Role of diuretics in the treatment of hypertension: from large controlled trials to international guidelines] Chalmers J. **Arch Mal Coeur Vaiss** 1996 Sep;89 Spec No 4:39-43 (41 ref.) (Eng. Abstr.) **(Fre)**

[Therapeutic indications: on the concept and applications] Koch A, et al. **Med Klin** 1996 Feb 15;91(2):103-5 (7 ref.) **(Ger)**

[Levels of scientific evidence and strength of clinical recommendations. From trials to guidelines. The Italian Group on Medicine Based on Evidence--IGMBE] Cartabellotta A, et al. **Recenti Prog Med** 1997 Jul-Aug; 88(7-8):342-7 (26 ref.) (Eng. Abstr.) **(Ita)**

CLASSIFICATION

Clinical practice guidelines in nutrition support: can they be based on randomized clinical trials? Wolfe BM, et al. **JPEN J Parenter Enteral Nutr** 1997 Jan-Feb;21(1):1-6 (35 ref.)

ECONOMICS

Pharmacoeconomics: integrating economic evaluation into clinical trials. Haycox A, et al. **Br J Clin Pharmacol** 1997 Jun;43(6):559-62 (13 ref.)

The risk and cost-effective individual patient management: the challenge of a new generation of clinical trials. Maseri A, et al. **Cardiovasc Drugs Ther** 1997 Jan;10(6):751-8 (30 ref.)

The use of claims databases for outcomes research: rationale, challenges, and strategies. Motheral BR, et al. **Clin Ther** 1997 Mar-Apr;19(2):346-66 (74 ref.)

METHODS

Statistics notes. Trials randomised in clusters. Bland JM, et al. **BMJ** 1997 Sep 6;315(7108):600 (8 ref.)

Megatrials are based on a methodological mistake [see comments] Charlton BG. **Br J Gen Pract** 1996 Jul; 46(408):429-31 (20 ref.) Comment in: Br J Gen Pract 1996 Nov;46(412):688.

Limitations of the randomized trial for the early detection of cancer: a clinical perspective. Smart CR. **Cancer** 1997 May 1;79(9):1740-6 (20 ref.)

Data monitoring committees and problems of lower-than-expected accrual or events rates. Korn EL, et al. **Control Clin Trials** 1996 Dec;17(6):526-35 (38 ref.)

Implications of different study designs for the evaluation of acellular pertussis vaccines. Fine PE. **Dev Biol Stand** 1997; 89:123-33 (5 ref.)

A plea for improved use of the tools available for the evaluation of anticancer drugs. MacRae K. **Eur J Cancer** 1997 Jan;33 Suppl 2:S14-6 (10 ref.)

Methodological issues in the design of primary prevention trials. Gaziano JM, et al. **IARC Sci Publ** 1996;(136):7-12 (13 ref.)

Evaluation of human trial findings. Huttunen JK. **IARC Sci Publ** 1996;(139):271-6 (15 ref.)

Traditional and alternative research designs and methods in clinical pediatric psychopharmacology. Fava M. **J Am Acad Child Adolesc Psychiatry** 1996 Oct; 35(10):1292-303 (20 ref.)

Methodological issues of randomized controlled trials for the evaluation of reproductive health interventions. Villar J, et al. **Prev Med** 1996 May-Jun;25(3):365-75 (53 ref.)

Randomized trials in single subjects: the N of 1 study. Cook DJ. **Psychopharmacol Bull** 1996;32(3):363-7 (4 ref.)

Placebo washout in trials of antipsychotic drugs. Volavka J, et al. **Schizophr Bull** 1996;22(4):567-76 (40 ref.)

[The principles, planning and realization of a clinical trial] Uhari M. **Duodecim** 1995;111(19):1844-50 (14 ref.) **(Fin)**

[Contemporary opinion on placebo] Bogdanik T. **Przegl Lek** 1996;53(6):481-5 (20 ref.) (Eng. Abstr.) **(Pol)**

STANDARDS

A review of problems in clinical acupuncture research. Ernst E, et al. **Am J Chin Med** 1997;25(1):3-11 (31 ref.)

The need for large-scale randomized evidence. Baigent C. **Br J Clin Pharmacol** 1997 Apr;43(4):349-53 (24 ref.)

Ethical concerns about relapse studies [see comments] Shamoo AE, et al. **Camb Q Healthc Ethics** 1996 Summer; 5(3):373-86 (51 ref.) Comment in: Camb Q Healthc Ethics 1997 Spring;6(2):233-4.

Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: some explanations and suggestions for future studies. Pincus T, et al. **Clin Exp Rheumatol** 1997 May-Jun;15 Suppl 17:S27-38 (59 ref.)

Systematic reviews of randomized controlled trials: the need for complete data. Clarke MJ, et al. **J Eval Clin Pract** 1995 Nov;1(2):119-26 (23 ref.)

Logical limits of randomized controlled trials. Sleigh JW. **J Eval Clin Pract** 1997 Apr;3(2):145-8 (5 ref.)

Placebos in clinical practice and research. De Deyn PP, et al. **J Med Ethics** 1996 Jun;22(3):140-6 (40 ref.)

Importance of clinical trials in evaluating therapy of renal diseases. Polzin DJ. **Vet Clin North Am Small Anim Pract** 1996 Nov; 26(6):1519-25 (8 ref.)

STATISTICS & NUMERICAL DATA

Assessing social work effectiveness in child care practice: the contribution of randomized controlled trials [see comments] Newman T, et al. **Child Care Health Dev** 1997 Jul;23(4):287-96 (25 ref.) Comment in: Child Care Health Dev 1997 Jul;23(4):283-5.

Forty years of randomised trials in the New Zealand Medical Journal. Neal B, et al. **N Z Med J** 1996 Oct 11; 109(1031):372-3 (6 ref.)

[Randomization in clinical studies. Empirically founded or only a dogma?] Abel U, et al. **Internist (Berl)** 1997 Apr; 38(4):318-24 (30 ref.) **(Ger)**

TRENDS

Trends in randomized controlled trials in ENT: a 30-year review. Ah-See KW, et al. **J Laryngol Otol** 1997 Jul; 111(7):611-3 (9 ref.)

RANGE OF MOTION, ARTICULAR

Ankle joint dorsiflexion measurement studies. A review of the literature. Rome K. **J Am Podiatr Med Assoc** 1996 May; 86(5):205-11 (28 ref.)

The influence of the mobility in the cervicothoracic spine and the upper ribs (shoulder girdle) on the mobility of the scapulohumeral joint. Sobel JS, et al. **J Manipulative Physiol Ther** 1996 Sep;19(7):469-74 (16 ref.)

PHYSIOLOGY

Extensor mechanism problems in total knee arthroplasty. Dennis DA. **Instr Course Lect** 1997;46:171-80 (119 ref.)

The stiff total knee replacement: causes, treatment, and prevention. Johanson NA. **Instr Course Lect** 1997;46:191-5 (28 ref.)

Reflex sympathetic dystrophy and pain dysfunction in the lower extremity. Lindenfeld TN, et al. **Instr Course Lect** 1997;46:261-8 (51 ref.)

The physical examination of the glenohumeral joint: emphasis on the stabilizing structures. Wilk KE, et al. **J Orthop Sports Phys Ther** 1997 Jun;25(6):380-9 (42 ref.)

Quantification of the uncertainties in resultant joint moments computed in a dynamic activity. Challis JH, et al. **J Sports Sci** 1996 Jun;14(3):219-31 (32 ref.)

RANITIDINE

ADVERSE EFFECTS

The safety of ranitidine in over a decade of use. Mills JG, et al. **Aliment Pharmacol Ther** 1997 Feb;11(1):129-37 (58 ref.)

ANALOGS & DERIVATIVES

The actions of bismuth in the treatment of Helicobacter pylori infection. Lambert JR, et al. **Aliment Pharmacol Ther** 1997 Apr;11 Suppl 1:27-33 (62 ref.)

THERAPEUTIC USE

[Intravenous omeprazole versus ranitidine in the treatment of hemorrhagic duodenal ulcer: a prospective randomized study] Cardi M, et al. **Ann Chir** 1997;51(2):136-9 (32 ref.) (Eng. Abstr.) **(Fre)**

RANK-SUM TESTS see **STATISTICS, NONPARAMETRIC**

RANTES

PHYSIOLOGY

Relative role of CSF-1, MCP-1/JE, and RANTES in macrophage recruitment during successful pregnancy. Wood GW, et al. **Mol Reprod Dev** 1997 Jan;46(1):62-9; discussion 69-70 (24 ref.)

[The roles of adhesion molecules, cytokines and chemokines in relation to eosinophil activation in allergic inflammation] Chihara J. **Rinsho Byori** 1996 Dec;44(12):1147-51 (11 ref.) (Eng. Abstr.) **(Jpn)**

RANVIER'S NODES

CHEMISTRY

Molecular specializations at nodes and paranodes in peripheral nerve. Scherer SS. **Microsc Res Tech** 1996 Aug 1;34(5):452-61 (102 ref.)

Molecular architecture of the specialized axonal membrane at the node of Ranvier. Bennett V, et al. **Soc Gen Physiol Ser** 1997;52:107-20 (75 ref.)

IMMUNOLOGY

Antibodies to GM1 and Gal(beta 1-3)GalNAc at the nodes of Ranvier in human and experimental autoimmune neuropathy. Thomas FP. **Microsc Res Tech** 1996 Aug 15; 34(6):536-43 (124 ref.)

METABOLISM

Immunocytochemical investigations of sodium channels along nodal and internodal portions of demyelinated axons. England JD, et al. **Microsc Res Tech** 1996 Aug 1; 34(5):445-51 (51 ref.)

PATHOLOGY

Morphological changes at paranodes in IgM paraproteinaemic neuropathy. Jacobs JM. **Microsc Res Tech** 1996 Aug 15;34(6):544-53 (59 ref.)

ULTRASTRUCTURE

Development of nodes of Ranvier in feline nerves: an ultrastructural presentation. Berthold CH. **Microsc Res Tech** 1996 Aug 1;34(5):399-421 (95 ref.)

Node-paranode regions as local degradative centres in alpha-motor axons. Gatzinsky KP. **Microsc Res Tech** 1996 Aug 15;34(6):492–506 (117 ref.)
Accumulation of synaptic vesicle proteins and cytoskeletal specializations at the peripheral node of Ranvier. Zimmermann H. **Microsc Res Tech** 1996 Aug 1; 34(5):462–73 (70 ref.)
Clustering sodium channels at the node of Ranvier: close encounters of the axon-glia kind. Salzer JL. **Neuron** 1997 Jun;18(6):843–6 (24 ref.)

RAP GENE PRODUCTS see **GENE PRODUCTS, VPR**

RAPD-PCR see **RANDOM AMPLIFIED POLYMORPHIC DNA TECHNIQUE**

RAPD TECHNIQUE see **RANDOM AMPLIFIED POLYMORPHIC DNA TECHNIQUE**

RAPE

Rape and rapists: theory and treatment. Polaschek DL, et al. **Clin Psychol Rev** 1997;17(2):117–44 (208 ref.)
Sequelae of abuse. Health effects of childhood sexual abuse, domestic battering, and rape. Bohn DK, et al. **J Nurse Midwifery** 1996 Nov-Dec;41(6):442–56 (106 ref.)

LEGISLATION & JURISPRUDENCE

Can statutory rape laws be effective in preventing adolescent pregnancy? Donovan P. **Fam Plann Perspect** 1997 Jan–Feb; 29(1):30–4, 40 (52 ref.)

PREVENTION & CONTROL

Can statutory rape laws be effective in preventing adolescent pregnancy? Donovan P. **Fam Plann Perspect** 1997 Jan–Feb; 29(1):30–4, 40 (52 ref.)

REHABILITATION

Helping elderly women survive rape using a crisis framework. Tyra PA. **J Psychosoc Nurs Ment Health Serv** 1996 Dec;34(12):20–5 (28 ref.)

RAPESEED see **BRASSICA**

RAPHE NUCLEI

PHYSIOLOGY

The medullary raphe nuclei: a system for integration and gain control in autonomic and somatomotor responsiveness? Lovick TA. **Exp Physiol** 1997 Jan; 82(1):31–41 (32 ref.)
Physiological functions of pontomedullary raphe and medial reticular neurons. Mason P, et al. **Prog Brain Res** 1996; 107:269–82 (130 ref.)

RAPID EYE MOVEMENTS see **SLEEP, REM**

RARE EARTH METALS see **METALS, RARE EARTH**

RAS GENES see **GENES, RAS**

RAS ONCOGENE PROTEIN P21 see **ONCOGENE PROTEIN P21(RAS)**

RAS PROTEINS

Interplay between Ras-related and heterotrimeric GTP binding proteins: lifestyles of the BIG and little. Bokoch GM. **FASEB J** 1996 Sep;10(11):1290–5 (71 ref.)

ANTAGONISTS & INHIBITORS

Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Cox AD, et al. **Biochim Biophys Acta** 1997 Aug 8;1333(1):F51–71 (139 ref.)
Farnesyltransferase inhibitors and anti-Ras therapy. Gibbs JB, et al. **Breast Cancer Res Treat** 1996;38(1):75–83 (29 ref.)
[Activation of Rap1, antagonist to ras, by Crk-C3G] Hattori S, et al. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1414–21 (25 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

C-terminal motifs found in Ras-superfamily G-proteins: CAAX and C-seven motifs. Del Villar K, et al. **Biochem Soc Trans** 1996 Aug;24(3):709–13 (29 ref.)
Regulatory GTPases. Hilgenfeld R. **Curr Opin Struct Biol** 1995 Dec;5(6):810–7 (80 ref.)
How Ras-related proteins talk to their effectors. Wittinghofer A, et al. **Trends Biochem Sci** 1996 Dec;21(12):488–91 (36 ref.)

DRUG EFFECTS

Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design. Lerner EC, et al. **Anticancer Drug Des** 1997 Jun;12(4):229–38 (55 ref.)
Bacterial toxins that target Rho proteins. Aktories K. **J Clin Invest** 1997 Mar 1;99(5):827–9 (10 ref.)

GENETICS

Expression of ras proto-oncogenes: regulation and implications in the development of human tumors. Zachos G, et al. **Crit Rev Oncol Hematol** 1997 Jul;26(2):65–75 (92 ref.)
[Isoprenylated proteins and cell proliferation: regulators and effectors of Ras proteins] de Gunzburg J. **C R Seances Soc Biol Fil** 1997;191(2):195–210 (106 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Genetic dissection of signal transduction mechanisms underlying PACAP-like neuropeptide transmission in Drosophila: synergy of cAMP and Ras/Raf pathways. Zhong Y. **Ann N Y Acad Sci** 1996 Dec 26;805:67–79; discussion 79–80 (36 ref.)
Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling. Denhardt DT. **Biochem J** 1996 Sep 15;318 (Pt 3):729–47 (228 ref.)
Rational design of Ras prenyltransferase inhibitors as potential anticancer drugs. Sebti SM, et al. **Biochem Soc Trans** 1996 Aug;24(3):692–9 (45 ref.)
Ras-GTPase activating protein (GAP): a putative effector for Ras. Tocque B, et al. **Cell Signal** 1997 Feb;9(2):153–8 (72 ref.)
Isoprenoids, Ras and proliferative glomerular disease. O'Donnell MP, et al. **Contrib Nephrol** 1997;120:219–27 (35 ref.)
Signal transduction from multiple Ras effectors. Katz ME, et al. **Curr Opin Genet Dev** 1997 Feb;7(1):75–9 (50 ref.)
Regulation of proliferation and apoptosis by Ras and Rho GTPases through specific phospholipid-dependent signaling. Lacal JC. **FEBS Lett** 1997 Jun 23;410(1):73–7 (59 ref.)
The interaction of Ras with GTPase-activating proteins. Wittinghofer A, et al. **FEBS Lett** 1997 Jun 23;410(1):63–7 (60 ref.)
Ras farnesyltransferase: a new therapeutic target. Leonard DM. **J Med Chem** 1997 Sep 12;40(19):2971–90 (187 ref.)
Apoptosis regulation by Raf, Bcl-2, and R-Ras. Troppmair J, et al. **Recent Results Cancer Res** 1997;143:245–9 (16 ref.)
Not all Shc's roads lead to Ras. Bonfini L, et al. **Trends Biochem Sci** 1996 Jul;21(7):257–61 (51 ref.)
Evidence for a Ras/Ral signaling cascade. Feig LA, et al. **Trends Biochem Sci** 1996 Nov;21(11):438–41 (49 ref.)
How Ras-related proteins talk to their effectors. Wittinghofer A, et al. **Trends Biochem Sci** 1996 Dec;21(12):488–91 (36 ref.)
Large clostridial cytotoxins--a family of glycosyltransferases modifying small GTP-binding proteins. von Eichel-Streiber C, et al. **Trends Microbiol** 1996 Oct; 4(10):375–82 (55 ref.)
[Ras proteins in Saccharomyces cerevisiae, their partners and their activation] Jacquet M. **C R Seances Soc Biol Fil** 1997; 191(2):221–35 (63 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

[Isoprenylated proteins and cell proliferation: regulators and effectors of Ras proteins] de Gunzburg J. **C R Seances Soc Biol Fil** 1997;191(2):195–210 (106 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Monoterpenes as regulators of malignant cell proliferation. Hohl RJ. **Adv Exp Med Biol** 1996;401:137–46 (43 ref.)
Dbl family proteins. Whitehead IP, et al. **Biochim Biophys Acta** 1997 Feb 22;1332(1):F1–23 (138 ref.)
Control of the ERK MAP kinase cascade by Ras and Raf. Marais R, et al. **Cancer Surv** 1996;27:101–25 (125 ref.)
Cell cycle: routine role for Ras. Downward J. **Curr Biol** 1997 Apr 1;7(4):R258–60 (26 ref.)
Rho GTPases and signaling networks. Van Aelst L, et al. **Genes Dev** 1997 Sep 15;11(18):2295–322 (295 ref.)
Inhibitors of the Ras signal transduction pathway as potential antitumour agents. Perrin D, et al. **J Enzyme Inhib** 1996 Oct;11(2):77–95 (103 ref.)
Signaling molecules that mediate the actions of FGF. Demo SD, et al. **Princess Takamatsu Symp** 1994;24:243–9 (23 ref.)
Rho small G protein and cytoskeletal control. Takai Y, et al. **Princess Takamatsu Symp** 1994;24:338–50 (64 ref.)
Ras and its effectors. Herrmann C, et al. **Prog Biophys Mol Biol** 1996;66(1):1–41 (177 ref.)
[Activation of Rap1, antagonist to ras, by Crk-C3G] Hattori S, et al. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1414–21 (25 ref.) (Eng. Abstr.) **(Jpn)**
[RalGDS mediates an intracellular signal-transduction system from a proto-oncogene product Ras] Koyama S, et al. **Seikagaku** 1996 Oct;68(10):1646–50 (20 ref.) **(Jpn)**

RAS PROTO-ONCOGENE PROTEIN P21 see **PROTO-ONCOGENE PROTEIN P21(RAS)**

RAT CORONAVIRUS see **CORONAVIRUS, RAT**

RAT VIRUS see **PARVOVIRUS**

RATE SETTING AND REVIEW

see related **RELATIVE VALUE SCALES**

TRENDS

Tracking the demise of state hospital rate setting. McDonough JE. **Health Aff (Millwood)** 1997 Jan–Feb; 16(1):142–9 (17 ref.)

RATIONING, HEALTH CARE see **HEALTH CARE RATIONING**

RATS

Rodent models of experimental allergic encephalomyelitis applied to the study of multiple sclerosis. Goverman J, et al. **Lab Anim Sci** 1996 Oct;46(5):482–92 (167 ref.)
Study of immune response to tumors in the rat. Frey AB. **Methods** 1997 Jun;12(2):173–88 (43 ref.)
The brown Norway rats and the kinin system. Damas J. **Peptides** 1996;17(5):859–72 (183 ref.)

ANATOMY & HISTOLOGY

Survival, regeneration and sprouting of central neurons: the rat septohippocampal projection as a model. Frotscher M, et al. **Anat Anz** 1996 Aug;178(4):311–5 (33 ref.)
High endothelial venules of the rat lymph node. A review and a question: is their activity antigen specific? Sainte-Marie G, et al. **Anat Rec** 1996 Aug;245(4):593–620 (144 ref.)

GENETICS

The rat: an experimental animal in search of a genetic map. Szpirer C, et al. **Folia Biol (Praha)** 1996;42(4):175–226 (40 ref.)

GROWTH & DEVELOPMENT

Excitation-contraction coupling of the developing rat heart. Vornanen M. **Mol Cell Biochem** 1996 Oct-Nov; 163–164:5–11 (51 ref.)

IMMUNOLOGY

Current status of the genetic and physical maps of the major histocompatibility complex in the rat. Gill TJ 3rd, et al. **Transplant Proc** 1997 May;29(3):1657–9 (67 ref.)

PHYSIOLOGY

High endothelial venules of the rat lymph node. A review and a question: is their activity antigen specific? Sainte-Marie G, et al. **Anat Rec** 1996 Aug;245(4):593–620 (144 ref.)
Oscillations and gaseous oxides in invertebrate olfaction. Gelperin A, et al. **J Neurobiol** 1996 May;30(1):110–22 (119 ref.)

RATS, BANDICOOT see **MURIDAE**

RATS, COTTON see **HESPEROMYINAE**

RATS, HOLTZMAN see **RATS, SPRAGUE-DAWLEY**

RATS, INBRED BB

The biobreeding Worcester rat--a model of organ-specific autoimmunity. Allen EM, et al. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 3:7–10 (51 ref.)
The BB rat as a model for autoimmune thyroiditis: relevance for the pathogenesis of human disease. Delemarre FG, et al. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 3:10–2 (26 ref.)

IMMUNOLOGY

The BB/Wor rat and the balance hypothesis of autoimmunity. Mordes JP, et al. **Diabetes Metab Rev** 1996 Jul;12(2):103–9 (55 ref.)

RATS, INBRED SHR

PHYSIOLOGY

The transition to failure in the spontaneously hypertensive rat. Mitchell GF, et al. **Am J Hypertens** 1997 May;10(5 Pt 2):120S–126S (13 ref.)
[Clinical implications derived from arterial hypertension models] Lanzani C, et al. **Cardiologia** 1997 Mar; 42(3):269–80 (126 ref.) **(Ita)**

RATS, INBRED STRAINS

GENETICS

The implication of renin-angiotensin system on renal injury seen in Dahl salt-sensitive rats. Hirawa N, et al. **Am J Hypertens** 1997 May;10(5 Pt 2):102S–106S (19 ref.)
Renal P450 metabolites of arachidonic acid and the development of hypertension in Dahl salt-sensitive rats. Roman RJ, et al. **Am J Hypertens** 1997 May;10(5 Pt 2):63S–67S (33 ref.)

RATS, INBRED STRAINS

Mouse and rat genotype choices. Sprott RL. **Exp Gerontol** 1997 Jan-Apr;32(1-2):79-86 (15 ref.)

PHYSIOLOGY

The implication of renin-angiotensin system on renal injury seen in Dahl salt-sensitive rats. Hirawa N, et al. **Am J Hypertens** 1997 May;10(5 Pt 2):102S-106S (19 ref.)

[Clinical implications derived from arterial hypertension models] Lanzani C, et al. **Cardiologia** 1997 Mar; 42(3):269-80 (126 ref.) **(Ita)**

RATS, LABORATORY see **RATS**

RATS, NORWAY see **RATS**

RATS, RICE see **HESPEROMYINAE**

RATS, SPONTANEOUSLY HYPERTENSIVE see **RATS, INBRED SHR**

RATS, SPRAGUE-DAWLEY

PHYSIOLOGY

The effects of diet, overfeeding and moderate dietary restriction on Sprague-Dawley rat survival, disease and toxicology. Keenan KP, et al. **J Nutr** 1997 May;127(5 Suppl):851S-856S (43 ref.)

RATS, ZUCKER

Zucker rat (fa/fa), a model for the study of immune function in type-II diabetes mellitus: effect of exercise and caloric restriction on the phagocytic activity of macrophages. Plotkin BJ, et al. **Lab Anim Sci** 1996 Dec;46(6):682-4 (17 ref.)

METABOLISM

Evidence for a central mechanism of obesity in the Zucker rat: role of neuropeptide Y and leptin. White BD, et al. **Proc Soc Exp Biol Med** 1997 Mar;214(3):222-32 (135 ref.)

RATTLESNAKE see **CROTALUS**

RATTLESNAKE VENOMS see **CROTALID VENOMS**

RATTUS see **MURIDAE**

RATTUS NORVEGICUS see **RATS**

RAYNAUD'S DISEASE

[Raynaud's syndrome, Raynaud's disease] Kuramochi M. **Ryoikibetsu Shokogun Shirizu** 1996;(14):432-3 (1 ref.) **(Jpn)**

COMPLICATIONS

Digital ischemia and occult malignancy. Paw P, et al. **Int J Colorectal Dis** 1996;11(4):196-7 (12 ref.)

DIAGNOSIS

Raynaud's phenomenon. Belch J. **Cardiovasc Res** 1997 Jan; 33(1):25-30 (41 ref.)

[Development of instrumental and technical measurement aspects for clinical capillary microscopy] Gasser P, et al. **Z Rheumatol** 1996 Jul-Aug;55(4):260-6 (30 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Pharmacotherapy of Raynaud's phenomenon. Belch JJ, et al. **Drugs** 1996 Nov;52(5):682-95 (73 ref.)

ETIOLOGY

Raynaud's phenomenon and systemic sclerosis. Generini S, et al. **Ann Ital Med Int** 1996 Apr-Jun;11(2):125-31 (78 ref.)

Pulvis de sclerotium and the mummified finger. Weber KT. **Cardiovasc Res** 1997 Jan;33(1):23-4 (41 ref.)

Raynaud's phenomenon and other features of scleroderma, including pulmonary hypertension. Wigley FM. **Curr Opin Rheumatol** 1996 Nov;8(6):561-8 (92 ref.)

[Raynaud syndrome] Schnabel A, et al. **Internist (Berl)** 1996 Aug;37(8):867-79 (13 ref.) **(Ger)**

[Mixed connective tissue disease: progress in diagnosis and treatment. III. Treatment. 3. Clinical aspects and treatment of specific conditions. 5) Peripheral circulatory dysfunction] Yoshida S, et al. **Nippon Naika Gakkai Zasshi** 1996 Aug 10;85(8):1259-64 (5 ref.) **(Jpn)**

IMMUNOLOGY

[Raynaud's phenomenon. Practical considerations on the forms secondary to immunomediated systemic diseases] Marcolongo R, et al. **Minerva Med** 1997 Jul-Aug; 88(7-8):307-10 (7 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Raynaud's phenomenon. Wigley FM, et al. **Rheum Dis Clin North Am** 1996 Nov;22(4):765-81 (121 ref.)

Raynaud's syndrome in women. Landry GJ, et al. **Semin Vasc Surg** 1995 Dec;8(4):327-34 (63 ref.)

THERAPY

Current management of Raynaud's syndrome. Landry GJ, et al. **Adv Surg** 1996;30:333-47 (73 ref.)

Comprehensive management of Raynaud's syndrome. Merritt WH. **Clin Plast Surg** 1997 Jan;24(1):133-59 (184 ref.)

RAZOXANE

THERAPEUTIC USE

Dexrazoxane (ICRF-187): a cardioprotective agent during anthracycline chemotherapy. O'Marcaigh AS, et al. **J Pediatr Oncol Nurs** 1997 Apr;14(2):96-8 (11 ref.)

ICRF-187 as a cardioprotectant in children treated with anthracyclines [editorial; comment] Blatt J. **Pediatr Hematol Oncol** 1997 May-Jun;14(3):iii-vi (13 ref.) Comment on: Pediatr Hematol Oncol 1997 May-Jun;14(3):213-22.

Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): progress in supportive care. Hellmann K. **Support Care Cancer** 1996 Jul;4(4):305-7 (5 ref.)

RB GENES see **GENES, RETINOBLASTOMA**

RB PROTEIN see **RETINOBLASTOMA PROTEIN**

REACTANTS, ACUTE-PHASE see **ACUTE-PHASE PROTEINS**

REACTION, ACUTE-PHASE see **ACUTE-PHASE REACTION**

REACTION CENTER PROTEIN, BACTERIAL see **PHOTOSYNTHETIC REACTION CENTER, BACTERIAL**

REACTION CENTER PROTEIN, PLANT see **PHOTOSYNTHETIC REACTION CENTER, PLANT**

REACTION TIME

Visual attention: control, representation, and time course. Egeth HE, et al. **Annu Rev Psychol** 1997;48:269-97 (110 ref.)

Simple reaction time and perception of temporal order: dissociations and hypotheses. Jaśkowski P. **Percept Mot Skills** 1996 Jun;82(3 Pt 1):707-30 (110 ref.)

Raster-scan cathode-ray tubes for vision research--limits of resolution in space, time and intensity, and some solutions. Bach M, et al. **Spat Vis** 1997;10(4):403-14 (48 ref.)

PHYSIOLOGY

Multiple cortical motor areas and temporal sequencing of movements. Tanji J, et al. **Brain Res Cogn Brain Res** 1996 Dec;5(1-2):117-22 (66 ref.)

Pathophysiology of cerebellar dysmetria: the imbalance between the agonist and the antagonist electromyographic activities. Manto M. **Eur Neurol** 1996;36(6):333-7 (51 ref.)

Parametric changes in response equilibrium during an intra-cranial self stimulation (ICSS) task: can reward value be assessed independently of absolute threshold? Easterling KW, et al. **Neurosci Biobehav Rev** 1997 Jan;21(1):55-65 (32 ref.)

On the utility of P3 latency as an index of mental chronometry. Verleger R. **Psychophysiology** 1997 Mar; 34(2):131-56 (172 ref.)

Neuroscience and human intelligence differences. Deary IJ, et al. **Trends Neurosci** 1997 Aug;20(8):365-71 (82 ref.)

REACTIVE DISORDERS see **ADJUSTMENT DISORDERS**

REACTIVE OXYGEN SPECIES

see related
FREE RADICALS
OXIDATIVE STRESS

Reactive oxygen species and their contribution to pathology in Down syndrome. de Haan JB, et al. **Adv Pharmacol** 1997; 38:379-402 (73 ref.)

Disruption of brain cell ion homeostasis in Alzheimer's disease by oxy radicals, and signaling pathways that protect therefrom. Mattson MP, et al. **Chem Res Toxicol** 1997 May; 10(5):507-17 (85 ref.)

Reactive oxygen species and platelet activation in reperfusion injury [editorial; comment] Forde RC, et al. **Circulation** 1997 Feb 18;95(4):787-9 (26 ref.) Comment on: Circulation 1997 Feb 18;95(4):885-91.

Metal-independent putative superoxide dismutase mimics in chemistry, biology, and medicine. Ahmad N, et al. **Ecotoxicol Environ Saf** 1996 Jul;34(2):141-4 (37 ref.)

Oxygen toxicity, free radicals and antioxidants in human disease: biochemical implications in atherosclerosis and the problems of premature neonates. Rice-Evans CA, et al. **Essays Biochem** 1995;29:39-63 (25 ref.)

Reactive oxygen species and human spermatozoa: physiology and pathology. Griveau JF, et al. **Int J Androl** 1997 Apr; 20(2):61-9 (79 ref.)

Chemical toxicity and reactive oxygen species. Parke DV, et al. **Int J Occup Med Environ Health** 1996;9(4):331-40 (45 ref.)

Cancer risk and oxidative DNA damage in man [published erratum appears in J Mol Med 1997 Jan;75(1):67-8] Loft S, et al. **J Mol Med** 1996 Jun;74(6):297-312 (167 ref.)

Reactive oxygen species and glomerular injury. Rohrmoser MM, et al. **Kidney Blood Press Res** 1996;19(5):263-9 (82 ref.)

Influence of oxygen radical injury on DNA methylation [see comments] Cerda S, et al. **Mutat Res** 1997 Apr; 386(2):141-52 (136 ref.) Comment in: Mutat Res 1997 Apr;386(2):103-5.

Iron-induced tissue damage and cancer: the role of reactive oxygen species-free radicals. Okada S. **Pathol Int** 1996 May;46(5):311-32 (109 ref.)

Blood radicals: reactive nitrogen species, reactive oxygen species, transition metal ions, and the vascular system. Darley-Usmar V, et al. **Pharm Res** 1996 May;13(5):649-62 (192 ref.)

Oxidative stress in malaria; implications for prevention and therapy. Postma NS, et al. **Pharm World Sci** 1996 Aug; 18(4):121-9 (124 ref.)

Free radical pathology in schizophrenia: a review. Reddy RD, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Aug;55(1-2):33-43 (137 ref.)

Antioxidant treatment of tardive dyskinesia. Rotrosen J, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Aug; 55(1-2):77-81 (63 ref.)

Therapeutic modulation of free radical-mediated reperfusion injury of the liver and its surgical implications. Marubayashi S, et al. **Surg Today** 1996;26(8):573-80 (97 ref.)

Reactive oxygen species and programmed cell death. Jacobson MD. **Trends Biochem Sci** 1996 Mar;21(3):83-6 (47 ref.)

[Measurement of reactive oxygen species in a biological system and its perspectives] Todoki K, et al. **Nippon Yakurigaku Zasshi** 1996 Dec;108(6):295-306 (32 ref.) (Eng. Abstr.) **(Jpn)**

[Role of oxidative stress in health and disease] Inoue M. **Rinsho Byori** 1996 Oct;44(10):911-4 (0 ref.) (Eng. Abstr.) **(Jpn)**

[Active forms of oxygen and pathogenesis of rheumatoid arthritis and systemic lupus erythematosus] Lisitsyna TA, et al. **Vestn Ross Akad Med Nauk** 1996;(12):15-20 (51 ref.) (Eng. Abstr.) **(Rus)**

[Free radicals. Benefits and problems] Piña-Garza E, et al. **Gac Med Mex** 1996 Mar-Apr;132(2):183-203 (39 ref.) **(Spa)**

METABOLISM

Mechanisms of tissue injury by oxygen radicals: implications for neonatal disease. Saugstad OD. **Acta Paediatr** 1996 Jan; 85(1):1-4 (32 ref.)

PO2 affinities, heme proteins, and reactive oxygen intermediates involved in intracellular signal cascades for sensing oxygen. Acker H. **Adv Exp Med Biol** 1996; 410:59-64 (36 ref.)

Ethylene oxide as a biological reactive intermediate of endogenous origin. Törnqvist M. **Adv Exp Med Biol** 1996; 387:275-83 (42 ref.)

Novel indices of oxidant stress in cardiovascular disease: specific analysis of F2-isoprostanes. Praticò D, et al. **Agents Actions Suppl** 1997;48:25-41 (61 ref.)

Exercise, free radical generation, and aging. Fielding RA, et al. **Aging (Milano)** 1997 Feb-Apr;9(1-2):12-8 (64 ref.)

Oxygen radical detoxification processes during aging: the functional importance of melatonin. Reiter RJ. **Aging (Milano)** 1995 Oct;7(5):340-51 (98 ref.)

Ethanol-induced apoptosis and oxidative stress in hepatocytes. Higuchi H, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9 Suppl):340A-346A (65 ref.)

Reactive oxygen species and the neurodegenerative disorders. Knight JA. **Ann Clin Lab Sci** 1997 Jan-Feb; 27(1):11-25 (93 ref.)

Mammalian peroxisomes: metabolism of oxygen and reactive oxygen species. Singh I. **Ann N Y Acad Sci** 1996 Dec 27; 804:612-27 (50 ref.)

Participation of oxygen-free radicals in the oxido-reduction of proteins. Vilar-Rojas C, et al. **Arch Med Res** 1996 Spring;27(1):1-6 (42 ref.)

Oxidative burst: an early plant response to pathogen infection. Wojtaszek P. **Biochem J** 1997 Mar 15;322 (Pt 3):681-92 (144 ref.)

The intracellular reducing environment modulates cytoregulation and cytotoxicity by reactive oxygen species. Chiu DT, et al. **Biochem Soc Trans** 1996 Aug;24(3):884-7 (26 ref.)

Manipulation of glutathione metabolism in transgenic plants. Creissen G, et al. **Biochem Soc Trans** 1996 May;24(2):465-9 (28 ref.)

Reactive oxygen species and nitric oxide in viral diseases. Peterhans E. **Biol Trace Elem Res** 1997 Jan;56(1):107-16 (75 ref.)

The role of reactive oxygen species in mitochondrial permeability transition. Vercesi AE, et al. **Biosci Rep** 1997 Feb;17(1):43-52 (74 ref.)

Oxidative stress in acute intermittent porphyria and lead poisoning may be triggered by 5-aminolevulinic acid. Bechara EJ. **Braz J Med Biol Res** 1996 Jul;29(7):841-51 (78 ref.)

Behçet's disease associated with myelodysplastic syndromes. A case report and a review of the literature. Ohno E, et

al. **Cancer** 1997 Jan 15;79(2):262–8 (31 ref.)
Reactive oxygen metabolites and arterial thrombosis. Ambrosio G, et al. **Cardiovasc Res** 1997 Jun;34(3):445–52 (58 ref.)
Superoxide dismutase and oxygen radical neurotoxicity. Hosler BA, et al. **Curr Opin Neurol** 1996 Dec;9(6):486–91 (49 ref.)
Oxidative stress and mitochondrial dysfunction in neurodegeneration. Schapira AH. **Curr Opin Neurol** 1996 Aug;9(4):260–4 (49 ref.)
Gene regulation by reactive oxygen species. Cimino F, et al. **Curr Top Cell Regul** 1997;35:123–48 (135 ref.)
The role of oxygen free radicals in occupational and environmental lung diseases. Vallyathan V, et al. **Environ Health Perspect** 1997 Feb;105 Suppl 1:165–77 (147 ref.)
Reactive oxygen species and antioxidants in inflammatory diseases. Chapple IL. **J Clin Periodontol** 1997 May; 24(5):287–96 (103 ref.)
Leukocyte responsiveness to substances that activate the respiratory burst is not altered in borderline and essential hypertension. Kopprasch S, et al. **J Hum Hypertens** 1996 Feb;10(2):69–76 (56 ref.)
Enzymatic repair mechanisms for base modifications induced by oxygen radicals. Yamamoto K, et al. **J Radiat Res (Tokyo)** 1997 Mar;38(1):1–4 (17 ref.)
In vivo ESR measurements of free radical reactions in living mice. Utsumi H, et al. **J Toxicol Sci** 1996 Dec;21(5):293–5 (0 ref.)
Oxidant-regulation of gene expression in the chronically inflamed intestine. Jourd'heuil D, et al. **Keio J Med** 1997 Mar;46(1):10–5 (58 ref.)
Pharmacological actions of melatonin in oxygen radical pathophysiology. Reiter R, et al. **Life Sci** 1997; 60(25):2255–71 (103 ref.)
Regulation of gene expression in the nervous system by reactive oxygen and nitrogen species. Merrill JE, et al. **Metab Brain Dis** 1997 Jun;12(2):97–112 (135 ref.)
Study of gene regulation by NF-kappa B and AP-1 in response to reactive oxygen intermediates. Müller JM, et al. **Methods** 1997 Mar;11(3):301–12 (90 ref.)
Species differences in the generation of reactive oxygen species by microglia. Colton C, et al. **Mol Chem Neuropathol** 1996 May–Aug;28(1–3):15–20 (18 ref.)
Response of glial cells to ischemia: roles of reactive oxygen species and glutathione. Juurlink BH. **Neurosci Biobehav Rev** 1997 Mar;21(2):151–66 (176 ref.)
Role of DNA repair enzymes in the cellular resistance to oxidative stress. Laval J. **Pathol Biol (Paris)** 1996 Jan; 44(1):14–24 (92 ref.)
Oxidative injury and potential use of antioxidants in schizophrenia. Mahadik SP, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Aug; 55(1–2):45–54 (117 ref.)
Role of reactive oxygen species in male infertility. Sharma RK, et al. **Urology** 1996 Dec;48(6):835–50 (154 ref.)
[Alcohol and free radicals: from basic research to clinical prospects] Nordmann R, et al. **Ann Gastroenterol Hepatol (Paris)** 1996 May–Jun; 32(3):128–33; discussion 133–4 (41 ref.) (Eng. Abstr.) **(Fre)**
[Coronary heart disease—a free radical associated disease? What is the value of antioxidant substances?] Döll M. **Med Monatsschr Pharm** 1997 Mar;20(3):66–70 (35 ref.) **(Ger)**
[The significance of antioxidants] Kuhl H. **Zentralbl Gynakol** 1997;119(1):1–5 (11 ref.) **(Ger)**
[Selenium and oral cancer. Review of the literature] Carinci F, et al. **Minerva Stomatol** 1996 Jul–Aug;45(7–8):345–8 (12 ref.) (Eng. Abstr.) **(Ita)**
[Measurement of reactive oxygen species generated from neutrophils] Yoshikawa T, et al. **Nippon Rinsho** 1997 Mar; 55 Suppl 1:210–5 (5 ref.) **(Jpn)**
[Does the oxygen--radical metabolic--cycle exist in the organism?] Gondko R. **Postepy Biochem** 1995;41(4):243–7 (36 ref.) **(Pol)**
[Oxidative damage of mitochondrial DNA associated with degenerative diseases and aging] Jurgowiak M, et al. **Postepy Biochem** 1997;43(1):30–40 (97 ref.) **(Pol)**

PHYSIOLOGY

Control of cell proliferation by reactive oxygen species. Burdon RH. **Biochem Soc Trans** 1996 Nov;24(4):1028–32 (26 ref.)
Free radicals, proteins and DNA: oxidative damage versus redox regulation. Halliwell B. **Biochem Soc Trans** 1996 Nov;24(4):1023–7 (62 ref.)
Reactive oxygen and nitrogen species regulate mitochondrial Ca2+ homeostasis and respiration. Richter C. **Biosci Rep** 1997 Feb;17(1):53–66 (106 ref.)
The role of cyclic AMP and oxygen intermediates in the inhibition of cellular immunity in cancer. Uotila P. **Cancer Immunol Immunother** 1996 Sep;43(1):1–9 (118 ref.)
Reactive oxygen-mediated protein oxidation in aging and disease. Stadtman ER, et al. **Chem Res Toxicol** 1997 May; 10(5):485–94 (154 ref.)
Role of reactive oxygen species in dermatologic diseases. Boh EE. **Clin Dermatol** 1996 Jul–Aug;14(4):343–52 (53 ref.)
Free radicals, oxidative damage and degenerative diseases [editorial] Giacosa A, et al. **Eur J Cancer Prev** 1996 Oct; 5(5):307–12 (35 ref.)
An essential role for free radicals and derived species in signal transduction. Lander HM. **FASEB J** 1997 Feb;11(2):118–24 (90 ref.)
Oxidants as stimulators of signal transduction. Suzuki YJ, et al. **Free Radic Biol Med** 1997;22(1–2):269–85 (184 ref.)
Are the reactive oxygen-derived species (ROS) interactive properties of the many therapeutic drugs from various categories pertinent to their beneficial effects? Cash CD. **Gen Pharmacol** 1997 Feb;28(2):169–75 (113 ref.)
The molecular defences against reactive oxygen species in yeast. Moradas-Ferreira P, et al. **Mol Microbiol** 1996 Feb; 19(4):651–8 (50 ref.)
Calcium and Free Radicals: Mediators of neurotrophic factor and excitatory transmitter-regulated developmental plasticity and cell death. Mattson MP. **Perspect Dev Neurobiol** 1996;3(2):79–91 (101 ref.)
Oxidative stress in malaria; implications for prevention and therapy. Postma NS, et al. **Pharm World Sci** 1996 Aug; 18(4):121–9 (124 ref.)
Oxidative reactions and schizophrenia: a review-discussion. Smythies JR. **Schizophr Res** 1997 Apr 11;24(3):357–64 (88 ref.)
[Reactive oxygen forms in pathogenesis of selected eye diseases] Kałuzny JJ, et al. **Klin Oczna** 1996 Feb;98(2):145–9 (28 ref.) (Eng. Abstr.) **(Pol)**
[Free oxygen radicals and their role in the etiopathogenesis of cardiovascular diseases] Komosińska K, et al. **Postepy Hig Med Dosw** 1996;50(6):597–612 (82 ref.) (Eng. Abstr.) **(Pol)**
[Cytotoxic action of active forms of oxygen and mechanisms of development of a chronic process in the liver in liver disease] Loginov AS, et al. **Patol Fiziol Eksp Ter** 1996 Oct–Dec;(4):3–5 (20 ref.) (Eng. Abstr.) **(Rus)**

REACTIVE SITE see **BINDING SITES**

READINESS POTENTIAL see **CONTINGENT NEGATIVE VARIATION**

READING

see related
DYSLEXIA, ACQUIRED

Preparing to read: the foundations of literacy. Bialystok E. **Adv Child Dev Behav** 1996;26:1–34 (140 ref.)
Essential practices as adults read to meet the needs of deaf or hard of hearing students. Luetke-Stahlman B, et al. **Am Ann Deaf** 1996 Oct;141(4):309–20 (176 ref.)
Reading with magnifiers. Den Brinker BP, et al. **Ergonomics** 1996 Oct;39(10):1231–48 (90 ref.)
Effect of oculomotor and other visual skills on reading performance: a literature review. Kulp MT, et al. **Optom Vis Sci** 1996 Apr;73(4):283–92 (122 ref.)
Visual predictors of reading performance in kindergarten and first grade children. Kulp MT, et al. **Optom Vis Sci** 1996 Apr;73(4):255–62 (99 ref.)
Mr. Chips: an ideal-observer model of reading. Legge GE, et al. **Psychol Rev** 1997 Jul;104(3):524–53 (130 ref.)

READING DISABILITY, ACQUIRED see **DYSLEXIA, ACQUIRED**

READING DISABILITY, DEVELOPMENTAL see **DYSLEXIA**

READING FRAMES

Translational bypassing: a new reading alternative of the genetic code. Groisman I, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1055–9 (21 ref.)
Molecular mechanisms governing reading frame choice of immunoglobulin diversity genes. Raaphorst FM, et al. **Immunol Today** 1997 Jan;18(1):37–43 (58 ref.)

REAGENT KITS, DIAGNOSTIC

Helicobacter pylori testing kits. **Drug Ther Bull** 1997 Mar; 35(3):23–4 (19 ref.)
False-positive hepatitis B surface antigen screening test results in patients receiving granulocyte-colony-stimulating factor. Mair DC, et al. **Transfusion** 1996 Nov–Dec;36(11–12):948–51 (11 ref.)
Methods and reagents. Chemiluminescent detection methods. Hengen PN. **Trends Biochem Sci** 1997 Aug;22(8):313–4 (9 ref.)
[Hepatitis C: screening tools] Pham BN, et al. **Gastroenterol Clin Biol** 1997;21(1 Pt 2):S130–9 (70 ref.) **(Fre)**
[Immunodiagnosis and blood biochemical diagnosis of visceral candidiasis and the cutoff limits of positive] Kume H, et al. **Rinsho Byori** 1996 Jun;44(6):505–11 (21 ref.) (Eng. Abstr.) **(Jpn)**

STANDARDS

Consensus of a group of professional societies and diagnostic companies on guidelines for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC/BCR/CAP Reference Material (CRM 470). International Federation of Clinical Chemistry. Community Bureau of Reference of the Commission of the European Communities. College of American Pathologists. Dati F, et al. **Eur J Clin Chem Clin Biochem** 1996 Jun;34(6):517–20 (8 ref.)

REAGENT STRIPS

Monitoring reproductive hormones to detect the fertile period: development of Persona--the first home use system. May K. **Adv Contracept** 1997 Jun–Sep;13(2–3):139–41 (0 ref.)
[Laboratory diagnosis of acute pancreatitis. Amylase analysis is still the leading one, but a "urinary strip" is on its way to be marketed] Andrén-Sandberg A, et al. **Lakartidningen** 1997 Jun 25;94(26–27):2451–3 (17 ref.) **(Swe)**

REAGENTS see **INDICATORS AND REAGENTS**

REAL-TIME SYSTEMS see **COMPUTER SYSTEMS**

REALITY TESTING

The experience of effortlessness in hypnosis: perceived or real? Ruehle BL, et al. **Int J Clin Exp Hypn** 1997 Apr; 45(2):144–57 (33 ref.)
Psychic reality and unconscious belief: a reconsideration. Gerard HB. **Int J Psychoanal** 1997 Apr;78 (Pt 2):327–33; discussion 335–40 (30 ref.)
[Structural affinities of the incomprehensible in schizophrenic delusion] Feldmann H, et al. **Nervenarzt** 1997 Mar; 68(3):226–30 (31 ref.) (Eng. Abstr.) **(Ger)**

REALITY THERAPY

External reality: the elusive dimension of psychoanalysis. Oliner MM. **Psychoanal Q** 1996 Apr;65(2):267–300 (49 ref.)

REASSORTANT VIRUSES

IMMUNOLOGY

Chimeric rhinoviruses as tools for vaccine development and characterization of protein epitopes. Arnold GF, et al. **Intervirology** 1996;39(1–2):72–8 (38 ref.)
Chimaera and its modern virus-like descendants. Ulrich R, et al. **Intervirology** 1996;39(1–2):126–32 (107 ref.)

REC A PROTEIN

CHEMISTRY

Locations of functional domains in the RecA protein. Overlap of domains and regulation of activities. Takahashi M, et al. **Eur J Biochem** 1996 Nov 15;242(1):20–8 (84 ref.)
RecA protein: structure, function, and role in recombinational DNA repair. Roca AI, et al. **Prog Nucleic Acid Res Mol Biol** 1997;56:129–223 (428 ref.)

GENETICS

recA mutants of E. coli K12: a personal turning point. Clark AJ. **Bioessays** 1996 Sep;18(9):767–72 (31 ref.)

METABOLISM

RecA-mediated Achilles' heel cleavage. Szybalski W. **Curr Opin Biotechnol** 1997 Feb;8(1):75–81 (64 ref.)
Homologous recognition by RecA protein using non-equivalent three DNA-strand-binding sites. Kurumizaka H, et al. **J Biochem (Tokyo)** 1996 Feb; 119(2):216–23 (91 ref.)
recA-independent DNA recombination between repetitive sequences: mechanisms and implications. Bi X, et al. **Prog Nucleic Acid Res Mol Biol** 1996;54:253–92 (86 ref.)
RecA protein: structure, function, and role in recombinational DNA repair. Roca AI, et al. **Prog Nucleic Acid Res Mol Biol** 1997;56:129–223 (428 ref.)

RECA PROTEIN see **REC A PROTEIN**

RECALL

The interaction of knowledge, aptitude, and strategies in children's memory performance. Bjorklund DF, et al. **Adv Child Dev Behav** 1996;26:59–89 (98 ref.)
The role of schemata in children's memory. Davidson D. **Adv Child Dev Behav** 1996;26:35–58 (70 ref.)
Self-reports of diet: how children remember what they have eaten. Domel SB. **Am J Clin Nutr** 1997 Apr;65(4 Suppl):1148S–1152S (30 ref.)
Insights into dietary recall from a longitudinal study: accuracy over four decades. Dwyer JT, et al. **Am J Clin Nutr** 1997 Apr;65(4 Suppl):1153S–1158S (27 ref.)
Delayed recall of childhood sexual abuse: psychiatric nursing's responsibilities to clients [comment] Hall JM. **Arch Psychiatr Nurs** 1996 Dec;10(6):342–6 (14 ref.) Comment on: Arch Psychiatr Nurs 1996 Apr;10(2):110–5.
Traumatic intrusive imagery as an emotional memory phenomenon: a review of research and explanatory information processing theories. vanOyen Witvliet C. **Clin Psychol Rev** 1997;17(5):509–36 (150 ref.)
Mental time travel and the evolution of the human mind. Suddendorf T, et al. **Genet Soc Gen Psychol Monogr** 1997 May;123(2):133–67 (190 ref.)
Admissibility and per se exclusion of hypnotically elicited recall in American courts of law. Perry C.

RECALL

Int J Clin Exp Hypn 1997 Jul;45(3):266–79 (27 ref.)
Implicit memory performance of patients with Alzheimer's disease: a brief review. Jelicic M, et al.
Int Psychogeriatr 1995 Fall;7(3):385–92 (36 ref.)
Memory, repression, and child sexual abuse: forensic implications for the mental health professional. Corelli TB, et al. **J Am Acad Psychiatry Law** 1997;25(1):31–47 (62 ref.)
"Reality" and countertransference in the treatment of sexual abuse patients: the false memory controversy. Perlman SD.
J Am Acad Psychoanal 1996 Spring;24(1):115–35 (32 ref.)
Memory deficits in schizophrenia: inadequate assimilation or true amnesia? Findings from the Wechsler Memory Scale—revised. Hawkins KA, et al.
J Psychiatry Neurosci 1997 May;22(3):169–79 (24 ref.)
The recall of physical activity: using a cognitive model of the question–answering process. Durante R, et al.
Med Sci Sports Exerc 1996 Oct;28(10):1282–91 (61 ref.)
A dual representation theory of posttraumatic stress disorder. Brewin CR, et al. **Psychol Rev** 1996 Oct;103(4):670–86 (190 ref.)
The emergence and early development of autobiographical memory. Howe ML, et al. **Psychol Rev** 1997 Jul; 104(3):499–523 (290 ref.)
Dissociations in infant memory: rethinking the development of implicit and explicit memory. Rovee–Collier C.
Psychol Rev 1997 Jul;104(3):467–98 (360 ref.)
[Disorders of early information processing and vigilance as vulnerability markers for schizophrenia] Suslow T, et al. **Fortschr Neurol Psychiatr** 1996 Mar;64(3):90–104 (81 ref.) (Eng. Abstr.) **(Ger)**
[Trauma diagnosis: difficulty in differentiating between recall and fantasy] Person ES, et al.
Psychother Psychosom Med Psychol 1997 Mar–Apr; 47(3–4):97–107 (31 ref.) (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Recall in the sedated ICU patient. Cheng EY.
J Clin Anesth 1996 Dec;8(8):675–8 (30 ref.)

PHYSIOLOGY

The primate temporal pole: its putative role in object recognition and memory. Nakamura K, et al.
Behav Brain Res 1996 May;77(1–2):53–77 (290 ref.)
Neural mechanisms of behavioral plasticity: metamorphosis and learning in Manduca sexta. Weeks JC, et al.
Brain Behav Evol 1997;50 Suppl 1:69–80 (60 ref.)
Which brain regions are critically involved in the retrieval of old episodic memory? Markowitsch HJ.
Brain Res Brain Res Rev 1995 Sep;21(2):117–27 (124 ref.)
Mental transformations in the motor cortex. Pellizzer G.
Brain Res Cogn Brain Res 1996 Dec;5(1–2):123–30 (23 ref.)
Functional anatomy of object recognition in humans: evidence from positron emission tomography and functional magnetic resonance imaging. Bly BM, et al.
Curr Opin Neurol 1997 Feb;10(1):5–9 (27 ref.)
Role of GABA in memory and anxiety. Kalueff A, et al.
Depress Anxiety 1996–97;4(3):100–10 (86 ref.)
Encoding and retrieval of episodic memories: role of cholinergic and GABAergic modulation in the hippocampus. Hasselmo ME, et al. **Hippocampus** 1996; 6(6):693–708 (107 ref.)
Toward a theory of episodic memory: the frontal lobes and autonoetic consciousness. Wheeler MA, et al.
Psychol Bull 1997 May;121(3):331–54 (155 ref.)

RECEPTOR AGGREGATION

Immunons revisited: binding of multivalent antigens to B cells. Sulzer B, et al. **Mol Immunol** 1997 Jan;34(1):63–74 (24 ref.)

RECEPTOR–CD3 COMPLEX, ANTIGEN, T-CELL

see related
SIGNAL TRANSDUCTION
[TCR CDR3 motif expression in PLP specific T cell from patients with multiple sclerosis] Kondo T, et al.
Nihon Rinsho Meneki Gakkai Kaishi 1995 Dec;18(6):666–9 (8 ref.). **(Jpn)**
[Programmed thymic T cell death and negative selection via Fas and TCR/CD3 complex] Kishi S. **Nippon Rinsho** 1996 Jul;54(7):1760–7 (17 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Felty's syndrome, pseudo–felty's syndrome, monoclonal or polyclonal CD3 lymphocytosis of undetermined significance. Masson C, et al. **Rev Rhum Engl Ed** 1996 Jan; 63(1):5–8 (32 ref.)

GENETICS

Functions of TCR and pre–TCR subunits: lessons from gene ablation. Malissen B, et al. **Curr Opin Immunol** 1996 Jun; 8(3):383–93 (69 ref.)

IMMUNOLOGY

Cell cycle control of T cell apoptosis induced by activation through the T cell antigen receptor. Chalupny NJ, et al.
Adv Exp Med Biol 1996;406:57–67 (31 ref.)
T cell receptors and T cell development. Chen CH, et al.
Curr Top Microbiol Immunol 1996;212:37–53 (88 ref.)
Early T-cell development in CD3-deficient mice. Tanaka Y, et al. **Immunol Rev** 1995 Dec;148:171–99 (89 ref.)

PHYSIOLOGY

Functions of TCR and pre–TCR subunits: lessons from gene ablation. Malissen B, et al. **Curr Opin Immunol** 1996 Jun; 8(3):383–93 (69 ref.)

RECEPTOR, COMPLEMENT 3 see **MACROPHAGE–1 ANTIGEN**

RECEPTOR–MEDIATED SIGNAL TRANSDUCTION see **SIGNAL TRANSDUCTION**

RECEPTOR PROTEIN–TYROSINE KINASE

see related
PROTO–ONCOGENE PROTEINS C–KIT
[Receptors for factors of the VEGF (Vascular Endothelial Growth Family)] Fournier E, et al. **Bull Cancer** 1997 Apr; 84(4):397–405 (61 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Lipid modifications of G–protein–coupled receptor kinases. Inglese J, et al. **Biochem Soc Trans** 1996 Aug;24(3):714–7 (33 ref.)
The biology of vascular endothelial growth factor. Ferrara N, et al. **Endocr Rev** 1997 Feb;18(1):4–25 (250 ref.)

GENETICS

Anti–angiogenic gene therapy of malignant glioma. Stratmann A, et al. **Acta Neurochir Suppl (Wien)** 1997; 68:105–10 (30 ref.)
Genetic screening for RET mutations in families with multiple endocrine neoplasia 2 syndromes. Alevizaki M, et al. **Ann N Y Acad Sci** 1997 Jun 17;816:383–8 (23 ref.)
The receptor tyrosine kinase MuSK is required for neuromuscular junction formation and is a functional receptor for agrin. Glass DJ, et al.
Cold Spring Harb Symp Quant Biol 1996;61:435–44 (65 ref.)
RET oncogene. Mak YF, et al. **Curr Opin Genet Dev** 1996 Feb;6(1):82–6 (45 ref.)
Novel gene families involved in neural pathfinding. Müller BK, et al. **Curr Opin Genet Dev** 1996 Aug;6(4):469–74 (61 ref.)
Familial neuroendocrine tumors as a model of hereditary cancer. Anderson RJ, et al. **Curr Opin Oncol** 1997 Jan; 9(1):45–54 (85 ref.)
RET mutations in multiple endocrine neoplasia type 2 and Hirschsprung disease. Reynolds LF, et al.
Curr Opin Pediatr 1995 Dec;7(6):702–9 (63 ref.)
RET receptor tyrosine kinase gene mutations: molecular biological, physiological and clinical aspects. Höppener JW, et al. **Eur J Clin Invest** 1996 Aug;26(8):613–24 (88 ref.)
RET proto–oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. Marsh DJ, et al. **Horm Res** 1997;47(4–6):168–78 (105 ref.)
Mutations of the RET proto–oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease. Eng C, et al.
Hum Mutat 1997;9(2):97–109 (105 ref.)
The role of the ret proto–oncogene in human disease. Takahashi M. **Nagoya J Med Sci** 1997 Mar;60(1–2):23–30 (49 ref.)
RET protooncogene mutational analysis in multiple endocrine neoplasia syndrome type 2B: case report and review of the literature. Kahn MA, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Sep;82(3):288–94 (21 ref.)
Role of c–kit receptor tyrosine kinase in the development, survival and neoplastic transformation of mast cells. Tsujimura T. **Pathol Int** 1996 Dec;46(12):933–8 (35 ref.)
The RET proto–oncogene: a challenge to our understanding of disease pathogenesis. Kusafuka T, et al.
Pediatr Surg Int 1997;12(1):11–8 (99 ref.)
Hirschsprung's disease as a neurochristopathy. Martucciello G. **Pediatr Surg Int** 1997;12(1):2–10 (74 ref.)
RET mutations in human disease. Pasini B, et al.
Trends Genet 1996 Apr;12(4):138–44 (60 ref.)
The GDNF–RET signalling partnership. Robertson K, et al. **Trends Genet** 1997 Jan;13(1):1–3 (36 ref.)
The coming of age of the GDNF family and its receptors: gene delivery in a rat Parkinson model may have clinical implications. Olson L. **Trends Neurosci** 1997 Jul;20(7):277–9 (22 ref.)
The RET proto–oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications. Komminoth P. **Virchows Arch** 1997 Jul;431(1):1–9 (109 ref.)
Participation of nerve growth factor in the regulation of ovarian function. Dissen GA, et al. **Zygote** 1996 Nov; 4(4):309–12 (38 ref.)
[Correlation of neovascularization and vascular endothelial growth factor in human renal cell carcinoma] Sato K, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(4):389–94 (17 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Endosomes, receptor tyrosine kinase internalization and signal transduction. Bergeron JJ, et al. **Biosci Rep** 1995 Dec;15(6):411–8 (41 ref.)
G–protein–coupled receptor regulation: role of G–protein–coupled receptor kinases and arrestins. Ferguson SS, et al. **Can J Physiol Pharmacol** 1996 Oct; 74(10):1095–110 (137 ref.)
Biological properties of VEGF/VPF receptors. Terman BI, et al. **Cancer Metastasis Rev** 1996 Jun;15(2):159–63 (42 ref.)
Protein tyrosine kinase receptors. Héldin CH.
Cancer Surv 1996;27:7–24 (82 ref.)
Receptor signalling: to sevenless, a daughter. MacDougall LK, et al. **Curr Biol** 1996 Oct 1;6(10):1250–3 (12 ref.)
The path less traveled by [editorial; comment] Baserga R. **Endocrinology** 1997 Jun;138(6):2217–8 (9 ref.) Comment on: Endocrinology 1997 Jun;138(6):2219–26.
Telling axons where to grow: a role for Eph receptor tyrosine kinases in guidance. Brambilla R, et al.
Mol Cell Neurosci 1995 Dec;6(6):487–95 (65 ref.)
Signal transduction by the oncogenic receptor tyrosine kinase Xmrk in melanoma formation of Xiphophorus. Wellbrock C, et al. **Pigment Cell Res** 1997 Feb–Apr;10(1–2):34–40 (60 ref.)
Inhibitory receptors abound? [comment] Cambier JC.
Proc Natl Acad Sci U S A 1997 Jun 10;94(12):5993–5 (24 ref.) Comment on: Proc Natl Acad Sci U S A 1997 May 13;94(10):5261–6.
Not all Shc's roads lead to Ras. Bonfini L, et al.
Trends Biochem Sci 1996 Jul;21(7):257–61 (51 ref.)
The GDNF–RET signalling partnership. Robertson K, et al. **Trends Genet** 1997 Jan;13(1):1–3 (36 ref.)
[The molecular determinants of receptors and GTP–binding proteins that define the specificity of the interactions between them] Shpakov AO. **Zh Evol Biokhim Fiziol** 1996 Jul–Aug;32(4):488–510 (127 ref.) **(Rus)**

PHYSIOLOGY

Retrograde transport of acidic fibroblast growth factor as a part of the growth factor signaling. Więdłocha A.
Arch Immunol Ther Exp (Warsz) 1996;44(4):201–7 (64 ref.)
G–protein–coupled receptor kinases and arrestins: regulators of G–protein–coupled receptor sequestration. Ferguson SS, et al. **Biochem Soc Trans** 1996 Nov;24(4):953–9 (49 ref.)
Receptor tyrosine kinase–dependent neural crest migration in response to differentially localized growth factors. Wehrle–Haller B, et al. **Bioessays** 1997 Apr;19(4):337–45 (73 ref.)
Receptor tyrosine kinase signaling in vascular development. Merenmies J, et al. **Cell Growth Differ** 1997 Jan;8(1):3–10 (93 ref.)
Novel mechanisms of RTK signal generation. Weiss FU, et al. **Curr Opin Genet Dev** 1997 Feb;7(1):80–6 (50 ref.)
Signalling through the neurotrophin receptor p75NTR. Dechant G, et al. **Curr Opin Neurobiol** 1997 Jun;7(3):413–8 (58 ref.)
Vascular endothelial growth factor and its receptors. Klagsbrun M, et al. **Cytokine Growth Factor Rev** 1996 Oct; 7(3):259–70 (136 ref.)
Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. Brown LF, et al. **EXS** 1997;79:233–69 (133 ref.)
Vascular endothelial growth factor: basic biology and clinical implications. Ferrara N, et al. **EXS** 1997;79:209–32 (142 ref.)
The HGF receptor family: unconventional signal transducers for invasive cell growth. Comoglio PM, et al.
Genes Cells 1996 Apr;1(4):347–54 (70 ref.)
Targeting G protein–coupled receptor kinases to their receptor substrates. Stoffel RH 3rd, et al.
J Membr Biol 1997 May 1;157(1):1–8 (49 ref.)
Recent progress on the role of Axl, a receptor tyrosine kinase, in malignant transformation of myeloid leukemias. Neubauer A, et al. **Leuk Lymphoma** 1997 Mar;25(1–2):91–6 (23 ref.)
The GDNF receptor: recent progress and unanswered questions. Mason I. **Mol Cell Neurosci** 1996;8(2–3):112–9 (46 ref.)
Neurotrophin–3 knocks heart off Trk. Srivastava D, et al.
Nat Med 1996 Oct;2(10):1069–71 (17 ref.)
Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis. Burden S, et al.
Neuron 1997 Jun;18(6):847–55 (48 ref.)
GDNF in a bind with known orphan: accessory implicated in new twist. Lindsay RM, et al. **Neuron** 1996 Oct; 17(4):571–4 (28 ref.)
New insights into the control of cell growth; the role of the Axl family. Crosier KE, et al. **Pathology** 1997 May; 29(2):131–5 (43 ref.)
Possible involvement of VEGF–FLT tyrosine kinase receptor system in normal and tumor angiogenesis. Shibuya M, et al. **Princess Takamatsu Symp** 1994;24:162–70 (23 ref.)
Cancer–stromal interaction through growth factor/cytokine networks implicated in growth of stomach cancer. Tahara E. **Princess Takamatsu Symp** 1994;24:187–94 (19 ref.)
Regulatory roles of the ligand for Flk2/Flt3 tyrosine kinase receptor on human hematopoiesis. Namikawa R, et al.
Stem Cells 1996 Jul;14(4):388–95 (69 ref.)
Angiogenesis in embryos and ischemic diseases. Breier G, et al. **Thromb Haemost** 1997 Jul;78(1):678–83 (70 ref.)
The Eph receptor family: axonal guidance by contact

repulsion. Orioli D, et al. **Trends Genet** 1997 Sep; 13(9):354–9 (49 ref.)
p75NTR and apoptosis: Trk–dependent and Trk–independent effects. Bredesen DE, et al. **Trends Neurosci** 1997 Jul; 20(7):287–90 (36 ref.)

RECEPTOR TYROSINE KINASE see **RECEPTOR PROTEIN–TYROSINE KINASE**

RECEPTORS, ACETYLCHOLINE see **RECEPTORS, CHOLINERGIC**

RECEPTORS, ACTH see **RECEPTORS, CORTICOTROPIN**

RECEPTORS, ADENOSINE see **RECEPTORS, PURINERGIC P1**

RECEPTORS, ADP see **RECEPTORS, PURINERGIC P2**

RECEPTORS, ADRENERGIC

Protection of the myocardium by ischaemic preconditioning: mechanisms and therapeutic implications. Millar CG, et al. **Pharmacol Ther** 1996;69(2):143–51 (89 ref.)
[Adrenaline receptor and dopamine receptor] Kurose H. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):316–26 (42 ref.) **(Jpn)**

CHEMISTRY

[Adrenergic receptors and alpha 2 agonists—1) Molecular biological study of adrenoceptors] Mizobe T. **Masui** 1997 May;46(5):650–7 (18 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Venlafaxine: a novel antidepressant that has a dual mechanism of action. Andrews JM, et al. **Depression** 1996; 4(2):48–56 (40 ref.)
The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission [published erratum appears in Int Clin Psychopharmacol 1996 Jun;11(2):153] de Boer T. **Int Clin Psychopharmacol** 1995 Dec;10 Suppl 4:19–23 (33 ref.)
Noradrenergic modulation of central serotonergic neurotransmission: acute and long–term actions of mirtazapine [published erratum appears in Int Clin Psychopharmacol 1996 Jun;11(2):153] Haddjeri N, et al. **Int Clin Psychopharmacol** 1995 Dec;10 Suppl 4:11–7 (30 ref.)
Adrenergic mechanisms in the control of gastrointestinal motility: from basic science to clinical applications. De Ponti F, et al. **Pharmacol Ther** 1996;69(1):59–78 (378 ref.)

METABOLISM

Noradrenaline in basic models of depression. Leonard BE. **Eur Neuropsychopharmacol** 1997 Apr;7 Suppl 1:S11–6; discussion S71–3 (17 ref.)

PHYSIOLOGY

Cardiac function in genetically engineered mice with altered adrenergic receptor signaling. Rockman HA, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):H1553–9 (46 ref.)
Noradrenergic alterations in posttraumatic stress disorder. Southwick SM, et al. **Ann N Y Acad Sci** 1997 Jun 21; 821:125–41 (115 ref.)
Adrenergic regulation of brown adipocyte differentiation. Cannon B, et al. **Biochem Soc Trans** 1996 May;24(2):407–12 (29 ref.)
Adrenergic modulation of hepatotoxicity. Roberts SM, et al. **Drug Metab Rev** 1997 Feb–May;29(1–2):329–53 (56 ref.)
Cell surface adrenergic receptor stimulation modifies the endothelial response to SIRS. Systemic Inflammatory Response Syndrome. Tighe D, et al. **New Horiz** 1996 Nov; 4(4):426–42 (104 ref.)
Emptying against outflow obstruction—pharmacological aspects. Andersson KE. **Scand J Urol Nephrol Suppl** 1997; 184:77–84 (83 ref.)
[The molecular physiology of the adrenergic receptors] Shishkina GT, et al. **Usp Fiziol Nauk** 1997 Jan–Mar; 28(1):61–74 (121 ref.) (Eng. Abstr.) **(Rus)**
[The role of the interaction of serotonin– and noradrenergic systems in regulating behavior] Semenova TP. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 Mar–Apr; 47(2):358–61 (21 ref.) (Eng. Abstr.) **(Rus)**

RECEPTORS, ADRENERGIC, ALPHA

[Molecular function of subtype and subunit drug receptors] Kimura M, et al. **Nippon Yakurigaku Zasshi** 1996 Sep; 108(3):155–6 (0 ref.) **(Jpn)**

DRUG EFFECTS

The alpha–adrenoceptor–mediated actions of chloroethylclonidine. Docherty JR, et al. **Gen Pharmacol** 1997 Feb;28(2):197–201 (36 ref.)

METABOLISM

Pharmacological options in the treatment of benign prostatic hyperplasia. Kenny B, et al. **J Med Chem** 1997 Apr 25; 40(9):1293–315 (146 ref.)
The distribution and significance of CNS adrenoceptors examined with in situ hybridization. Nicholas AP, et al. **Trends Pharmacol Sci** 1996 Jul;17(7):245–55 (64 ref.)

PHYSIOLOGY

alpha–Adrenergic regulation of human renal function. Michel MC, et al. **Fundam Clin Pharmacol** 1996;10(6):493–503 (108 ref.)
From alpha and beta to I1: an overview of sympathetic receptors involved in blood pressure control targets for drug treatment. van Zwieten PA. **J Cardiovasc Pharmacol** 1996;27 Suppl 3:S5–10 (36 ref.)

RECEPTORS, ADRENERGIC, ALPHA–1

Recent advances in the molecular pharmacology of the alpha 1–adrenergic receptors. Guarino RD, et al. **Cell Signal** 1996 Aug;8(5):323–33 (136 ref.)
Prostatic alpha 1–adrenoceptors and uroselectivity. Andersson KE, et al. **Prostate** 1997 Feb 15;30(3):202–15 (132 ref.)

ANTAGONISTS & INHIBITORS

[Treatment of benign prostatic hyperplasia with alpha 1–adrenoreceptor antagonists] Heimbach D, et al. **Urologe A** 1997 Jan;36(1):18–34 (157 ref.) (Eng. Abstr.) **(Ger)**

CLASSIFICATION

Subclassification and nomenclature of alpha 1– and alpha 2–adrenoceptors. Hieble JP, et al. **Prog Drug Res** 1996; 47:81–130 (207 ref.)

DRUG EFFECTS

Drug receptor mechanisms in smooth muscle: beta–chloroethylamine–sensitive and –resistant receptor mechanisms. Takayanagi I, et al. **Jpn J Pharmacol** 1997 Jan;73(1):1–22 (89 ref.)

PHYSIOLOGY

Molecular mechanisms underlying the activation and regulation of the alpha 1B–adrenergic receptor. Cotecchia S, et al. **Biochem Soc Trans** 1996 Nov;24(4):959–63 (21 ref.)
Myocardial alpha1–adrenoceptor: inotropic effect and physiologic and pathologic implications. Li K, et al. **Life Sci** 1997;60(16):1305–18 (127 ref.)
Cardiac alpha(1)–adrenoceptors that regulate contractile function: subtypes and subcellular signal transduction mechanisms. Endoh M. **Neurochem Res** 1996 Feb; 21(2):217–29 (100 ref.)

RECEPTORS, ADRENERGIC, ALPHA–2

AGONISTS

Alpha 2 adrenoceptor agonists in the horse—a review. England GC, et al. **Br Vet J** 1996 Nov;152(6):641–57 (105 ref.)
Alpha–2 adrenergic agonists. Kamibayashi T, et al. **Can J Anaesth** 1997 May;44(5 Pt 2):R13–22 (50 ref.) **(Eng, Fre)**
[Usefulness of alpha 2–adrenoceptor agonists and practical problems associated with their use in clinical anesthesia—1. Premedication, anesthetic adjuvants, and hemodynamic effects] Nishikawa T, et al. **Masui** 1996 Dec; 45(12):1490–502 (113 ref.) (Eng. Abstr.) **(Jpn)**
[Usefulness of alpha 2–adrenoceptor agonists and practical problems associated with their use in clinical anesthesia—II. Effects in regional anesthesia and analgesic effects for pain relief] Nishikawa T, et al. **Masui** 1997 Jan;46(1):64–72 (209 ref.) (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission [published erratum appears in Int Clin Psychopharmacol 1996 Jun;11(2):153] de Boer T. **Int Clin Psychopharmacol** 1995 Dec;10 Suppl 4:19–23 (33 ref.)

CHEMISTRY

[Adrenergic receptor and alpha 2 agonist—2: Structure–function relationship of adrenoceptors] Mizobe T. **Masui** 1997 Jun;46(6):770–6 (14 ref.) (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

Subclassification and nomenclature of alpha 1– and alpha 2–adrenoceptors. Hieble JP, et al. **Prog Drug Res** 1996; 47:81–130 (207 ref.)

DRUG EFFECTS

Psychopharmacology of imidazoline and alpha 2–adrenergic receptors: implications for depression. Piletz JE, et al. **Crit Rev Neurobiol** 1994;9(1):29–66 (300 ref.)
Four cases of amitraz poisoning in humans. Kennel O, et al. **Vet Hum Toxicol** 1996 Feb;38(1):28–30 (26 ref.)

GENETICS

Gene targeting—homing in on alpha 2–adrenoceptor–subtype function. MacDonald E, et al. **Trends Pharmacol Sci** 1997 Jun;18(6):211–9 (48 ref.)

PHYSIOLOGY

Neurons and receptors in the rostroventrolateral medulla mediating the antihypertensive actions of drugs acting at imidazoline receptors. Reis DJ. **J Cardiovasc Pharmacol** 1996;27 Suppl 3:S11–18 (65 ref.)
Differential targeting and retention of G protein–coupled receptors in polarized epithelial cells. Wozniak M, et al. **J Recept Signal Transduct Res** 1997 Jan–May; 17(1–3):373–83 (15 ref.)
A view on noradrenergic, hypothalamic–pituitary–adrenal axis and extrahypothalamic corticotrophin–releasing factor function in anxiety and affective disorders: the reduced growth hormone response to clonidine. Coplan JD, et al. **Psychopharmacol Bull** 1997;33(2):193–204 (93 ref.)

RECEPTORS, ADRENERGIC, BETA

[Molecular function of subtype and subunit drug receptors] Kimura M, et al. **Nippon Yakurigaku Zasshi** 1996 Sep; 108(3):155–6 (0 ref.) **(Jpn)**

ANALYSIS

Changes in beta–adrenoceptors and G–proteins during the transition from cardiac hypertrophy to heart failure. Flesch M, et al. **J Card Fail** 1996 Dec;2(4 Suppl):S35–43 (64 ref.)

BIOSYNTHESIS

Beta 1–adrenoceptor autoimmunity in cardiomyopathy. Magnusson Y, et al. **Int J Cardiol** 1996 May;54(2):137–41 (23 ref.)

CHEMISTRY

Structure and function of the beta 3–adrenergic receptor. Strosberg AD. **Annu Rev Pharmacol Toxicol** 1997; 37:421–50 (76 ref.)

DRUG EFFECTS

Review article: beta 3–adrenoceptor agonists—future anti–inflammatory drugs for the gastrointestinal tract? Anthony A. **Aliment Pharmacol Ther** 1996 Dec; 10(6):859–63 (45 ref.)
Clinical pharmacology of beta 3–adrenoceptors. Lipworth BJ. **Br J Clin Pharmacol** 1996 Sep;42(3):291–300 (70 ref.)
Pharmacological criteria for the detection of beta 3–adrenoceptors [letter; comment] De Ponti F. **Trends Pharmacol Sci** 1997 Feb;18(2):52–3 (14 ref.)
Comment on: Trends Pharmacol Sci 1996 Oct;17(10):373–81.
Four beta–adrenoceptor subtypes in the mammalian heart. Kaumann AJ. **Trends Pharmacol Sci** 1997 Mar;18(3):70–6 (61 ref.)
Pharmacological properties of beta 3–adrenoceptors [letter] Nisoli E, et al. **Trends Pharmacol Sci** 1997 Jul;18(7):257–8 (9 ref.)
[Beta receptors and beta blockers in heart failure] Heinzl S. **Med Monatsschr Pharm** 1997 Jun;20(6):146–8 (4 ref.) **(Ger)**

GENETICS

Obesity genes. Beales PL, et al. **Clin Endocrinol (Oxf)** 1996 Oct;45(4):373–8 (50 ref.)
[Genetic analysis of bronchial asthma in Japanese population—Fc epsilon RI beta gene and beta 2 adrenergic receptor gene] Hizawa N, et al. **Nippon Rinsho** 1996 Feb; 54(2):539–43 (23 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Role of G–proteins in altered beta–adrenergic responsiveness in the failing and hypertrophied myocardium. Böhm M, et al. **Basic Res Cardiol** 1996;91 Suppl 2:47–51 (30 ref.)
Beta–adrenergic receptors in failing human myocardium. Brodde OE. **Basic Res Cardiol** 1996;91 Suppl 2:35–40 (39 ref.)
Mechanisms of beta–adrenergic receptor desensitization: from molecular biology to heart failure. Lohse MJ, et al. **Basic Res Cardiol** 1996;91 Suppl 2:29–34 (62 ref.)
cAMP–dependent phosphorylation of the cardiac L–type Ca channel: a missing link? Charnet P, et al. **Biochimie** 1995; 77(12):957–62 (46 ref.)
Antiadrenergic and muscarinic receptor antibodies in Chagas' cardiomyopathy. Borda ES, et al. **Int J Cardiol** 1996 May; 54(2):149–56 (38 ref.)
Myocardial beta–adrenergic receptor signaling in vivo: insights from transgenic mice. Rockman HA, et al. **J Mol Med** 1996 Sep;74(9):489–95 (32 ref.)
Potentiation of beta–adrenergic signaling by gene transfer. Drazner MH, et al. **Proc Assoc Am Physicians** 1997 May; 109(3):220–7 (54 ref.)
The distribution and significance of CNS adrenoceptors examined with in situ hybridization. Nicholas AP, et al. **Trends Pharmacol Sci** 1996 Jul;17(7):245–55 (64 ref.)
[Beta adrenergic signal transduction and heart adenyl cyclase] Mercadier JJ, et al. **C R Seances Soc Biol Fil** 1996; 190(2–3):207–18 (23 ref.) (Eng. Abstr.) **(Fre)**

RECEPTORS, ADRENERGIC, BETA

PHYSIOLOGY

Brown adipose tissue, beta 3-adrenergic receptors, and obesity. Lowell BB, et al. **Annu Rev Med** 1997;48:307-16 (67 ref.)

Of mice and women: the beta 3-adrenergic receptor leptin and obesity. Bégin-Heick N. **Biochem Cell Biol** 1996; 74(5):615-22 (67 ref.)

Beta 3-adrenoceptors and the regulation of metabolism in adipose tissues. Arch JR, et al. **Biochem Soc Trans** 1996 May;24(2):412-8 (51 ref.)

Role of the beta3-adrenoceptor in the control of leptin expression. Giacobino JP. **Horm Metab Res** 1996 Dec; 28(12):633-7 (58 ref.)

The cardiac beta-adrenoceptor-mediated signaling pathway and its alterations in hypertensive heart disease. Castellano M, et al. **Hypertension** 1997 Mar;29(3):715-22 (52 ref.)

Cardiac contractility: modulation of myofibrillar calcium sensitivity by beta-adrenergic stimulation. Kögler H, et al. **Isr J Med Sci** 1997 Jan;33(1):1-7 (32 ref.)

From alpha and beta to I1: an overview of sympathetic receptors involved in blood pressure control targets for drug treatment. van Zwieten PA. **J Cardiovasc Pharmacol** 1996;27 Suppl 3:S5-10 (36 ref.)

Modulation of human cardiac function through 4 beta-adrenoceptor populations. Kaumann AJ, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Jun; 355(6):667-81 (114 ref.)

Do beta-adrenoceptors and serotonin 5-HT1A receptors have similar functions in the control of intraocular pressure in the rabbit? Osborne NN, et al. **Ophthalmologica** 1996; 210(5):308-14 (40 ref.)

Function and regulation of the beta 3-adrenoceptor [see comments] Strosberg AD, et al. **Trends Pharmacol Sci** 1996 Oct;17(10):373-81 (64 ref.) Comment in: Trends Pharmacol Sci 1997 Feb;18(2):52-3.

RECEPTORS, ADRENERGIC, BETA-1

PHYSIOLOGY

[Mechanisms of the regulation of adrenergic beta-receptors] Lohse MJ. **Z Kardiol** 1996;85 Suppl 7:1-3 (12 ref.) (Eng. Abstr.) **(Ger)**

RECEPTORS, ADRENERGIC, BETA-2

AGONISTS

Interactions of glucocorticoids and beta 2-agonists. Adcock IM, et al. **Eur Respir J** 1996 Jan;9(1):160-8 (82 ref.)

Bioanalysis of beta 2-agonists by hyphenated chromatographic and mass spectrometric techniques. Polettini A. **J Chromatogr B Biomed Appl** 1996 Dec 6; 687(1):27-42 (58 ref.)

Exosites: their current status, and their relevance to the duration of action of long-acting beta 2-adrenoceptor agonists [see comments] Coleman RA, et al. **Trends Pharmacol Sci** 1996 Sep;17(9):324-30 (52 ref.) Comment in: Trends Pharmacol Sci 1997 May;18(5):149-51.

Phosphodiesterase 4 and tolerance to beta 2-adrenoceptor agonists in asthma. Giembycz MA. **Trends Pharmacol Sci** 1996 Sep;17(9):331-6 (62 ref.)

CHEMISTRY

[Adrenergic receptor and alpha 2 agonist—2: Structure-function relationship of adrenoceptors] Mizobe T. **Masui** 1997 Jun;46(6):770-6 (14 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Airway subsensitivity with long-acting beta 2-agonists. Is there cause for concern? Lipworth BJ. **Drug Saf** 1997 May; 16(5):295-308 (60 ref.)

GENETICS

Beta 2-adrenoceptor polymorphisms and asthma. Hall IP. **Monogr Allergy** 1996;33:153-67 (42 ref.)

PHYSIOLOGY

[Mechanisms of the regulation of adrenergic beta-receptors] Lohse MJ. **Z Kardiol** 1996;85 Suppl 7:1-3 (12 ref.) (Eng. Abstr.) **(Ger)**

RECEPTORS, ADRENOCORTICOTROPIC HORMONE see **RECEPTORS, CORTICOTROPIN**

RECEPTORS, AH see **RECEPTORS, ARYL HYDROCARBON**

RECEPTORS, ALPHA-ADRENERGIC see **RECEPTORS, ADRENERGIC, ALPHA**

RECEPTORS, ALPHA-1 ADRENERGIC see **RECEPTORS, ADRENERGIC, ALPHA-1**

RECEPTORS, ALPHA-2 ADRENERGIC see **RECEPTORS, ADRENERGIC, ALPHA-2**

RECEPTORS, AMINO ACID

CHEMISTRY

The structural basis of negative cooperativity: receptors and enzymes. Koshland DE Jr. **Curr Opin Struct Biol** 1996 Dec; 6(6):757-61 (24 ref.)

METABOLISM

Immunoreceptor tyrosine-based activation motif (ITAM), a unique module linking antigen and Fc receptors to their signaling cascades. Isakov N. **J Leukoc Biol** 1997 Jan; 61(1):6-16 (123 ref.)

PHYSIOLOGY

Role of Ca+2 and other second messengers in excitatory amino acid receptor mediated neurodegeneration: clinical perspectives. Schousboe A, et al. **Clin Neurosci** 1997; 4(4):194-8 (87 ref.)

RECEPTORS, AMPA

ANTAGONISTS & INHIBITORS

New developments in the molecular pharmacology of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate and kainate receptors. Fletcher EJ, et al. **Pharmacol Ther** 1996;70(1):65-89 (251 ref.)

IMMUNOLOGY

[Autoantibodies to glutamate receptor subtypes--markers of functional brain damage: their diagnostic significance for detecting paroxysmal activity and ischemia] Dambinova SA, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 Mar-Apr;47(2):439-46 (48 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Acute mechanical hyperalgesia in the rat can be produced by coactivation of spinal ionotropic AMPA and metabotropic glutamate receptors, activation of phospholipase A2 and generation of cyclooxygenase products. Meller ST, et al. **Prog Brain Res** 1996;110:177-92 (69 ref.)

PHYSIOLOGY

The GluR2 hypothesis: Ca(++)-permeable AMPA receptors in delayed neurodegeneration. Bennett MV, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:373-84 (29 ref.)

RECEPTORS, ANDROGEN

The androgen receptor in prostate cancer. Trapman J, et al. **Pathol Res Pract** 1996 Jul;192(7):752-60 (79 ref.)

[Androgen receptor] Shimazaki J, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:553-7 (10 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

The challenge posed by endocrine-disrupting chemicals. Ashby J, et al. **Environ Health Perspect** 1997 Feb; 105(2):164-9 (44 ref.)

Combined androgen blockade: the gold standard for metastatic prostate cancer. McLeod DG, et al. **Eur Urol** 1997;32 Suppl 3:70-7 (43 ref.)

DRUG EFFECTS

Neoadjuvant therapy prior to radiotherapy for clinically localized prostate cancer. Roach M 3rd. **Eur Urol** 1997;32 Suppl 3:48-54 (34 ref.)

GENETICS

Phenotypic diversity in siblings with partial androgen insensitivity syndrome. Evans BA, et al. **Arch Dis Child** 1997 Jun;76(6):529-31 (27 ref.)

Role of transcription factors in the age-dependent regulation of the androgen receptor gene in rat liver. Supakar PC, et al. **Biol Signals** 1996 May-Jun;5(3):170-9 (37 ref.)

Androgen receptor mutations in prostate cancer. Gelmann EP. **Cancer Treat Res** 1996;87:285-302 (84 ref.)

Molecular cytogenetics of prostate cancer. Koivisto PA. **Crit Rev Oncog** 1996;7(3-4):143-50 (67 ref.)

Androgen receptor gene mutations in prostate cancer. Implications for disease progression and therapy. Culig Z, et al. **Drugs Aging** 1997 Jan;10(1):50-8 (69 ref.)

Molecular analysis of the androgen receptor gene in Kennedy's disease. Report of two families and review of the literature. Lumbroso S, et al. **Horm Res** 1997;47(1):23-9 (44 ref.)

Occurrence of androgen and estrogen receptor mRNAs in the harderian gland: a comparative survey. Varriale B. **Microsc Res Tech** 1996 Jun 1;34(2):97-103 (33 ref.)

Androgen receptor mutations in prostate cancer. Barrack ER. **Mt Sinai J Med** 1996 Oct-Nov;63(5-6):403-12 (61 ref.)

Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer. Koivisto P, et al. **Scand J Clin Lab Invest Suppl** 1996;226:57-63 (19 ref.)

A clinician looks at androgen resistance. Balducci R, et al. **Steroids** 1996 Apr;61(4):205-11 (66 ref.)

Molecular basis of androgen insensitivity. Brinkmann A, et al. **Steroids** 1996 Apr;61(4):172-5 (30 ref.)

Androgen-receptor gene structure and function in prostate cancer. Hakimi JM, et al. **World J Urol** 1996;14(5):329-37 (46 ref.)

[Mutations of the androgen receptor gene a possible role in prostate cancer] Mowszowicz I, et al. **Bull Cancer** 1997 Feb;84(2):183-8 (37 ref.) (Eng. Abstr.) **(Fre)**

[Androgen receptor gene structure and protein function. Gene structural defects that promote androgen resistance in men] Pino AM. **Rev Med Chil** 1996 Sep;124(9):1127-36 (32 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Molecular and cellular biology of the prostate: is it clinically relevant? Habib FK, et al. **Br J Urol** 1996 Oct;78(4):546-51 (55 ref.)

Androgen receptor phosphorylation. Blok LJ, et al. **Endocr Res** 1996 Aug;22(3):197-219 (37 ref.)

Hyperactive androgen receptor in prostate cancer: what does it mean for new therapy concepts? Culig Z, et al. **Histol Histopathol** 1997 Jul;12(3):781-6 (55 ref.)

Androgen receptors in prostate cancer. Bentel JM, et al. **J Endocrinol** 1996 Oct;151(1):1-11 (91 ref.)

An overview of animal toxicology studies with bicalutamide (ICI 176,334). Iswaran TJ, et al. **J Toxicol Sci** 1997 May; 22(2):75-88 (38 ref.)

PHYSIOLOGY

Androgens, androgen receptors, antiandrogens and the treatment of prostate cancer. Griffiths K, et al. **Eur Urol** 1997;32 Suppl 3:24-40 (82 ref.)

Treatment of metastatic prostate cancer. Lessons from the androgen receptor. Bubley GJ, et al. **Hematol Oncol Clin North Am** 1996 Jun;10(3):713-25 (57 ref.)

Molecular biology and function of the androgen receptor in genital development. Wiener JS, et al. **J Urol** 1997 Apr; 157(4):1377-86 (121 ref.)

Androgen-receptor gene structure and function in prostate cancer. Hakimi JM, et al. **World J Urol** 1996;14(5):329-37 (46 ref.)

RECEPTORS, ANF see **RECEPTORS, ATRIAL NATRIURETIC FACTOR**

RECEPTORS, ANGIOTENSIN

Physiologic and pharmacologic implications of AT1 versus AT2 receptors. Chung O, et al. **Blood Press Suppl** 1996; 2:47-52 (48 ref.)

[Significance of the angiotensin-II receptor AT1 in the pathogenesis of arterial hypertension and arteriosclerosis] Nickenig G, et al. **Dtsch Med Wochenschr** 1997 Aug 15; 122(33):1009-13 (21 ref.) **(Ger)**

[Molecular biology of angiotensin II receptor and clinical application of the antagonist] Hiwada K. **Nippon Naika Gakkai Zasshi** 1994 Jan 10;83(1):143-8 (15 ref.) **(Jpn)**

[Angiotensin receptor] Nakahashi T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:546-8 (12 ref.) **(Jpn)**

AGONISTS

Molecular determinants of peptide and non-peptide binding to the AT1 receptor. Karnik SS, et al. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S58-66 (35 ref.)

ANTAGONISTS & INHIBITORS

Effects of angiotensin-converting enzyme inhibition and angiotensin II AT1 receptor antagonism on cardiac parameters in left ventricular hypertrophy. Zhu YC, et al. **Am J Cardiol** 1997 Aug 4;80(3A):110A-117A (65 ref.)

Angiotensin II receptor antagonists: the prototype losartan. Schaefer KL, et al. **Ann Pharmacother** 1996 Jun; 30(6):625-36 (81 ref.)

Angiotensin II receptor inhibition. A new therapeutic principle. Messerli FH, et al. **Arch Intern Med** 1996 Sep 23;156(17):1957-65 (100 ref.)

Angiotensin II antagonism: a new avenue of hypertension management. Gavras H. **Blood Press Suppl** 1997;1:42-6 (24 ref.)

Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension. Mallion JM, et al. **Blood Press Suppl** 1996; 2:82-6 (14 ref.)

The clinical efficacy and tolerability of the angiotensin II-receptor antagonist losartan in Japanese patients with hypertension. Ogihara T, et al. **Blood Press Suppl** 1996; 2:78-81 (9 ref.)

Angiotensin II-receptor (AT1) blockade in the human forearm. Ritter JM, et al. **Blood Press Suppl** 1996;2:67-70 (31 ref.)

The diversified pharmacology of angiotensin II-receptor blockade. Timmermans PB, et al. **Blood Press Suppl** 1996; 2:53-61 (112 ref.)

Historical development of losartan (DuP 753) and angiotensin II receptor subtypes. Wong PC, et al. **Blood Press Suppl** 1996;3:11-4 (29 ref.)

Pathologic consequences of increased angiotensin II activity. Ferrario CM, et al. **Cardiovasc Drugs Ther** 1996 Nov;

10(5):511–8 (100 ref.)
Renin inhibitors: cardiovascular drugs of the future? Wood JM, et al. **Cardiovasc Drugs Ther** 1996 Jul;10(3):309–12 (31 ref.)
Angiotensin–II–receptors: new targets for antihypertensive therapy. Oliverio MI, et al. **Clin Cardiol** 1997 Jan;20(1):3–6 (19 ref.)
Angiotensin receptors and development: the kidney. Alcorn D, et al. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S88–92 (55 ref.)
Transgenic rats: tools to study the function of the renin–angiotensin system. Bader M, et al.
Clin Exp Pharmacol Physiol Suppl 1996;3:S81–7 (80 ref.)
Endogenous angiotensin II levels and the mechanism of action of angiotensin–converting enzyme inhibitors and angiotensin receptor type 1 antagonists. Campbell DJ.
Clin Exp Pharmacol Physiol Suppl 1996;3:S125–31 (68 ref.)
Human type–1 angiotensin II (AT1) receptor gene structure and function. Curnow KM.
Clin Exp Pharmacol Physiol Suppl 1996;3:S67–73 (40 ref.)
Functions of angiotensin peptides in the rostral ventrolateral medulla. Dampney RA, et al.
Clin Exp Pharmacol Physiol Suppl 1996;3:S105–11 (65 ref.)
Angiotensin II and the adrenal. Giacchetti G, et al.
Clin Exp Pharmacol Physiol Suppl 1996;3:S119–24 (49 ref.)
Physiological actions of angiotensin II mediated by AT1 and AT2 receptors in the brain. McKinley MJ, et al.
Clin Exp Pharmacol Physiol Suppl 1996;3:S99–104 (69 ref.)
Molecular mechanisms of angiotensin II (AT1A) receptor endocytosis. Thomas WG, et al.
Clin Exp Pharmacol Physiol Suppl 1996;3:S74–80 (60 ref.)
The angiotensin II type 1 receptor blocker losartan in clinical practice: a review. Gavras HP, et al. **Clin Ther** 1996 Nov–Dec;18(6):1058–67; discussion 1057 (10 ref.)
A risk–benefit assessment of losartan potassium in the treatment of hypertension. Burrell LM. **Drug Saf** 1997 Jan; 16(1):56–65 (33 ref.)
Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease. Burrell LM, et al.
Drugs Aging 1997 Jun;10(6):421–34 (65 ref.)
Renal effects of angiotensin II receptor blockade and angiotensin–converting enzyme inhibition in healthy subjects. Burnier M, et al. **Exp Nephrol** 1996;4 Suppl 1:41–6 (41 ref.)
From converting enzyme inhibition to angiotensin II receptor blockade: new insight on angiotensin II receptor subtypes in the kidney. Wolf G, et al. **Exp Nephrol** 1996;4 Suppl 1:8–19 (133 ref.)
Angiotensin–converting enzyme inhibitors, angiotensin II receptor antagonists and calcium channel blocking agents: a review of potential benefits and possible adverse reactions. Moser M. **J Am Coll Cardiol** 1997 Jun; 29(7):1414–21 (46 ref.)
Angiotensin receptor antagonists—a new class of antihypertensive drug. Gibbs CR, et al.
J Clin Pharm Ther 1996 Jun;21(3):127–30 (25 ref.)
Losartan: first of a new class of angiotensin antagonists for the management of hypertension. Carr AA, et al.
J Clin Pharmacol 1996 Jan;36(1):3–12 (34 ref.)
Commentary: do angiotensin II receptor antagonists regress left ventricular hypertrophy? Lip GY.
J Hum Hypertens 1996 Nov;10(11):725–7 (28 ref.)
Long–term inhibition of the renin–angiotensin system in genetic hypertension: analysis of the impact on blood pressure and cardiovascular structural changes. Lundie MJ, et al. **J Hypertens** 1997 Apr;15(4):339–48 (104 ref.)
Renal effects of angiotensin II receptor blockade in normotensive subjects. Burnier M, et al. **Kidney Int** 1996 Jun;49(6):1787–90 (32 ref.)
Will angiotensin II receptor antagonists be renoprotective in humans? Ichikawa I. **Kidney Int** 1996 Aug;50(2):684–92 (53 ref.)
Pharmacokinetic–pharmacodynamic relationships of three angiotensin II receptor antagonists in normal volunteers. Burnier M, et al. **Kidney Int Suppl** 1996 Jun;55:S24–9 (20 ref.)
Are angiotensin II receptor blockers superior to angiotensin converting enzyme inhibitors with regard to their renoprotective effect? [editorial] Geiger H.
Nephrol Dial Transplant 1997 Apr;12(4):640–2 (15 ref.)
A new class of antihypertensive therapy: angiotensin II receptor antagonists. Ellis ML, et al. **Pharmacotherapy** 1996 Sep–Oct;16(5):849–60 (55 ref.)
The development of nonpeptide angiotensin II receptor antagonists: a success story. Höltje HD, et al.
Pharmazie 1997 Feb;52(2):83–6 (22 ref.)
The medicine of the month. Losartan (Cozaar)] Scheen AJ.
Rev Med Liege 1997 May;52(5):367–9 (8 ref.) **(Fre)**
[Angiotensin II receptor antagonists] Chung O, et al.
Internist (Berl) 1996 May;37(5):534–8; discussion 538 (34 ref.) **(Ger)**
[Angiotensin II—receptor antagonists: a new action group for an established active principle] Pfaffendorf M.
Pharm Unserer Zeit 1996 Jan;25(1):10–6 (15 ref.) **(Ger)**
[Inhibition of the renin–angiotensin system: ACE inhibitors and angiotensin II receptor blockers] Pichler M, et al.
Wien Med Wochenschr 1996;146(11):228–31 (35 ref.) (Eng. Abstr.) **(Ger)**
[Pathophysiological mechanisms of the renin–angiotensin system and its pharmacologic modification by ACE inhibitors or angiotensin II (type 1) receptor blockers in cardiovascular diseases] Huber K, et al. **Z Kardiol** 1997 Apr;86(4):239–50 (124 ref.) (Eng. Abstr.) **(Ger)**
[Angiotensin–2 receptor blockade—new therapeutic approach to treatment of hypertension] Zimlichman R.
Harefuah 1996 Jul;131(1–2):43–5 (27 ref.) **(Heb)**
[History of the pharmacologic therapy of arterial hypertension: from diuretics to angiotensin II receptor antagonists] Salvetti A, et al. **Cardiologia** 1995 Dec;40(12 Suppl 1):181–6 (30 ref.) **(Ita)**
[The therapy of arterial hypertension: a comparison between ACE inhibitors and angiotensin–II–receptor antagonists] Rossi F, et al. **Clin Ter** 1996 Oct;147(10):475–88 (54 ref.) (Eng. Abstr.) **(Ita)**
[Molecular biology of angiotensin II receptor and clinical application of the antagonist] Hiwada K.
Nippon Naika Gakkai Zasshi 1994 Jan 10;83(1):143–8 (15 ref.) **(Jpn)**
[Losartan, an angiotensin II receptor blocker: a new trend in cardiovascular chemotherapy] Krasnikova TL.
Klin Med (Mosk) 1996;74(3):17–21 (38 ref.) **(Rus)**

BIOSYNTHESIS

Downregulation of angiotensin II receptor type 1 in heart failure. A process of adaptation or deterioration? [editorial; comment] Kurabayashi M, et al. **Circulation** 1997 Mar 4; 95(5):1104–7 (30 ref.) Comment on: Circulation 1997 Mar 4;95(5):1193–200.

CHEMISTRY

A review of mutagenesis studies of angiotensin II type 1 receptor, the three–dimensional receptor model in search of the agonist and antagonist binding site and the hypothesis of a receptor activation mechanism. Inoue Y, et al.
J Hypertens 1997 Jul;15(7):703–14 (91 ref.)

CLASSIFICATION

From converting enzyme inhibition to angiotensin II receptor blockade: new insight on angiotensin II receptor subtypes in the kidney. Wolf G, et al. **Exp Nephrol** 1996;4 Suppl 1:8–19 (133 ref.)

GENETICS

Heterogeneity of rat angiotensin II AT2 receptor. Ciuffo GM, et al. **Adv Exp Med Biol** 1996;396:189–97 (31 ref.)
Molecular cloning and expression of angiotensin II type 2 receptor gene. Ichiki T, et al. **Adv Exp Med Biol** 1996; 396:145–52 (53 ref.)
Molecular cloning of the human AT2 receptor. Martin MM, et al. **Adv Exp Med Biol** 1996;396:153–65 (58 ref.)
Antisense oligonucleotides for in vivo studies of angiotensin receptors. Phillips MI, et al. **Adv Exp Med Biol** 1996; 396:79–92 (42 ref.)
Heterogeneity of angiotensin type 2 (AT2) receptors. Reagan LP, et al. **Adv Exp Med Biol** 1996;396:199–208 (25 ref.)
Human AT1 receptor gene regulation. Su B, et al.
Adv Exp Med Biol 1996;396:11–21 (43 ref.)
Genetics of the renin–angiotensin system and renal disease: a progress report. Schmidt S, et al.
Curr Opin Nephrol Hypertens 1997 Mar;6(2):146–51 (57 ref.)
The role of genetic variants in angiotensin I converting enzyme, angiotensinogen and the angiotensin II type–1 receptor in the pathophysiology of heart muscle disease. Raynolds MV, et al. **Eur Heart J** 1995 Nov;16 Suppl K:23–30 (85 ref.)
A review of mutagenesis studies of angiotensin II type 1 receptor, the three–dimensional receptor model in search of the agonist and antagonist binding site and the hypothesis of a receptor activation mechanism. Inoue Y, et al.
J Hypertens 1997 Jul;15(7):703–14 (91 ref.)
Regulation of the gene–encoding angiotensin II receptor in vascular tissue. Wang DH, et al. **Microcirculation** 1996 Jun; 3(2):237–9 (22 ref.)

METABOLISM

Regulation of the hypothalmic–pituitary–adrenal axis and vasopressin secretion. Role of angiotensin II. Aguilera G, et al. **Adv Exp Med Biol** 1996;396:105–12 (29 ref.)
Angiotensin receptor heterogeneity in the dorsal medulla oblongata as defined by angiotensin–(1–7). Diz DI, et al.
Adv Exp Med Biol 1996;396:225–35 (65 ref.)
Functional aspects of angiotensin type 2 receptor. Horiuchi M. **Adv Exp Med Biol** 1996;396:217–24 (39 ref.)
Angiotensin II stimulates protein phosphatase 2A activity in cultured neuronal cells via type 2 receptors in a pertussis toxin sensitive fashion. Huang XC, et al.
Adv Exp Med Biol 1996;396:209–15 (25 ref.)
Molecular and functional characterization of angiotensin II AT2 receptor in neuroblastoma N1E–115 cells. Nahmias C, et al. **Adv Exp Med Biol** 1996;396:167–73 (42 ref.)
AT2 receptor expression in ovaries: a review. Nielsen AH, et al. **Adv Exp Med Biol** 1996;396:183–7 (26 ref.)
Brain angiotensin II and related receptors: new developments. Saavedra JM, et al. **Adv Exp Med Biol** 1996; 396:247–52 (24 ref.)
Atypical (non–AT1, non–AT2) angiotensin receptors. Smith RD. **Adv Exp Med Biol** 1996;396:237–45 (80 ref.)
Identification of AT1 receptors on cultured astrocytes. Tallant EA, et al. **Adv Exp Med Biol** 1996;396:121–9 (42 ref.)
Characterization of the AT2 receptor on rat ovarian granulosa cells. Tanaka M, et al. **Adv Exp Med Biol** 1996; 396:175–82 (27 ref.)
Subtype 2 and atypical angiotensin receptors in the human heart. Regitz–Zagrosek V, et al. **Basic Res Cardiol** 1996; 91 Suppl 2:73–7 (18 ref.)
Angiotensin II type 1 receptor induced signal–transduction pathways as new targets for pharmacological treatment of the renin–angiotensin system. Schorb W, et al.
Basic Res Cardiol 1996;91 Suppl 2:91–6 (35 ref.)
Modulation of membrane potential and ionic currents by the AT1 and AT2 receptors of angiotensin II. Chorvatova A, et al. **Cell Signal** 1996 Dec;8(8):525–32 (90 ref.)
Acute and chronic mechanisms for regulating proximal tubule angiotensin II receptor expression. Harris RC, et al. **J Am Soc Nephrol** 1997 Feb;8(2):306–13 (86 ref.)
The ligand binding site of the angiotensin AT1 receptor. Hunyady L, et al. **Trends Pharmacol Sci** 1996 Apr; 17(4):135–40 (52 ref.)

PHYSIOLOGY

Cardiac effects of AII. AT1A receptor signaling, desensitization, and internalization. Thomas WG, et al.
Adv Exp Med Biol 1996;396:59–69 (60 ref.)
The role of angiotensin receptors in cardiovascular diseases. Helin K, et al. **Ann Med** 1997 Feb;29(1):23–9 (67 ref.)
Biological functions of angiotensin and its receptors. Matsusaka T, et al. **Annu Rev Physiol** 1997;59:395–412 (99 ref.)
The potential role of nitric oxide in angiotensin II–receptor blockade. Cachofeiro V, et al. **Blood Press Suppl** 1996; 2:29–35 (49 ref.)
Distribution and signal transduction of angiotensin II AT1 and AT2 receptors. Capponi AM. **Blood Press Suppl** 1996; 2:41–6 (55 ref.)
Angiotensin II receptors and renal hemodynamics and function. Ichikawa I. **Blood Press Suppl** 1996;2:19–21 (7 ref.)
Aortic collagen, aortic stiffness, and AT1 receptors in experimental and human hypertension. Benetos A, et al.
Can J Physiol Pharmacol 1996 Jul;74(7):862–6 (30 ref.)
The arterial wall: a new pharmacological and therapeutic target. Laurent S, et al. **Fundam Clin Pharmacol** 1996; 10(3):243–57 (95 ref.)
Angiotensin receptors. Unger T, et al. **J Hypertens Suppl** 1996 Dec;14(5):S95–103 (86 ref.)

RECEPTORS, ANTIGEN

DRUG EFFECTS

Regulation of antigen receptor signal transduction by protein tyrosine kinases. Chan AC, et al. **Curr Opin Immunol** 1996 Jun;8(3):394–401 (61 ref.)

GENETICS

Role of the Ku autoantigen in V(D)J recombination and double–strand break repair. Chu G.
Curr Top Microbiol Immunol 1996;217:113–32 (60 ref.)
The cell cycle and V(D)J recombination. Desiderio S, et al. **Curr Top Microbiol Immunol** 1996;217:45–59 (60 ref.)
Identification of the XRCC4 gene: complementation of the DSBR and V(D)J recombination defects of XR–1 cells. Li Z, et al. **Curr Top Microbiol Immunol** 1996;217:143–50 (25 ref.)
A new view of V(D)J recombination. Gellert M.
Genes Cells 1996 Mar;1(3):269–75 (40 ref.)
Essential and perilous: V(D)J recombination and DNA damage checkpoints in lymphocyte precursors. Danska JS, et al. **Semin Immunol** 1997 Jun;9(3):199–206 (81 ref.)
V(D)J recombination moves in vitro. Schatz DG.
Semin Immunol 1997 Jun;9(3):149–59 (67 ref.)
Accessibility and the developmental regulation of V(D)J recombination. Schlissel MS, et al. **Semin Immunol** 1997 Jun;9(3):161–70 (65 ref.)
The end–joining reaction in V(D)J recombination. Smider V, et al. **Semin Immunol** 1997 Jun;9(3):189–97 (76 ref.)
[Developmental regulation of V(D)J type recombination in the antigen receptor genes in lymphocytes] Sakano H.
Seikagaku 1996 Aug;68(8):1470–4 (18 ref.) **(Jpn)**

PHYSIOLOGY

Protein tyrosine phosphatase roles in the regulation of lymphocyte signaling. Pani G, et al.
Clin Immunol Immunopathol 1997 Jul;84(1):1–16 (110 ref.)

RECEPTORS, ANTIGEN, B–CELL

[Function of HS1 protein in B–cell antigen–receptor signaling and induction of apoptosis] Kitamura D. **Nippon Rinsho** 1996 Jul;54(7):1773–8 (23 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

Antigen receptor function in chronic lymphocytic leukemia B cells. Lankester AC, et al. **Leuk Lymphoma** 1996 Dec; 24(1–2):27–33 (22 ref.)

CHEMISTRY

Biochemistry of antigen receptor signaling in mature and developing B lymphocytes. Bireland ML, et al.
Crit Rev Immunol 1997;17(3–4):353–85 (228 ref.)

RECEPTORS, ANTIGEN, B-CELL

Structural aspects of signal transduction in B-cells. Vihinen M, et al. **Crit Rev Immunol** 1996;16(3):251-75 (254 ref.)
Composition and function of T-cell receptor and B-cell receptor complexes on precursor lymphocytes. Borst J, et al. **Curr Opin Immunol** 1996 Apr;8(2):181-90 (64 ref.)
Compartmentalization of B-cell antigen receptor functions. Lankester AC, et al. **Mol Immunol** 1996 Jun;33(9):769-75 (94 ref.)

GENETICS

Recent advances in understanding V(D)J recombination. Gellert M. **Adv Immunol** 1997;64:39-64 (108 ref.)
The origins of V(D)J recombination. Lewis SM, et al. **Cell** 1997 Jan 24;88(2):159-62 (20 ref.)
Initiation of V(D)J recombinations in a cell-free system by RAG1 and RAG2 proteins. van Gent DC, et al. **Curr Top Microbiol Immunol** 1996;217:1-10 (22 ref.)
Can receptor editing play an important role in normal B-cell development? Nemazee D. **J Autoimmun** 1996 Apr; 9(2):259-61 (26 ref.)

IMMUNOLOGY

B-cell epitopes: fact and fiction. Benjamin DC. **Adv Exp Med Biol** 1995;386:95-108 (30 ref.)
Structural aspects of signal transduction in B-cells. Vihinen M, et al. **Crit Rev Immunol** 1996;16(3):251-75 (254 ref.)
The two-headed antigen. B-cell co-receptors. DeFranco AL. **Curr Biol** 1996 May 1;6(5):548-50 (12 ref.)
Molecular mechanisms in B cell antigen receptor signaling. Kurosaki T. **Curr Opin Immunol** 1997 Jun;9(3):309-18 (84 ref.)
Receptor editing, immune diversification, and self-tolerance. Radic MZ, et al. **Immunity** 1996 Dec;5(6):505-11 (50 ref.)
B-cell development and differentiation. Duchosal MA. **Semin Hematol** 1997 Jan;34(1 Suppl 1):2-12 (146 ref.)
Key differentiation steps in normal B cells and in myeloma cells. Zubler RH. **Semin Hematol** 1997 Jan;34(1 Suppl 1):13-22 (52 ref.)

METABOLISM

Initiation and processing of signals from the B cell antigen receptor. Reth M, et al. **Annu Rev Immunol** 1997;15:453-79 (138 ref.)
CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Tedder TF, et al. **Annu Rev Immunol** 1997;15:481-504 (98 ref.)
Regulation of signalling through B-lymphocyte antigen receptors by cell-cell interaction molecules. Law CL, et al. **Immunol Rev** 1996 Oct;153:123-54 (200 ref.)
Immunons revisited: binding of multivalent antigens to B cells. Sulzer B, et al. **Mol Immunol** 1997 Jan;34(1):63-74 (24 ref.)

PHYSIOLOGY

Positive and negative signal co-operativity in the immune system: the BCR, Fc gamma RIIB, CR2 paradigm. Cambier JC. **Biochem Soc Trans** 1997 May;25(2):441-5 (21 ref.)
Antigen receptor signaling gives lymphocytes a long life [comment] Neuberger MS. **Cell** 1997 Sep 19;90(6):971-3 (8 ref.) Comment on: Cell 1997 Sep 19;90(6):1073-83.
Biochemistry of antigen receptor signaling in mature and developing B lymphocytes. Bireland ML, et al. **Crit Rev Immunol** 1997;17(3-4):353-85 (228 ref.)
Composition and function of T-cell receptor and B-cell receptor complexes on precursor lymphocytes. Borst J, et al. **Curr Opin Immunol** 1996 Apr;8(2):181-90 (64 ref.)
The complexity of signaling pathways activated by the BCR. DeFranco AL. **Curr Opin Immunol** 1997 Jun;9(3):296-308 (120 ref.)
Tuning antigen receptor signaling by CD22: integrating cues from antigens and the microenvironment. Cyster JG, et al. **Immunity** 1997 May;6(5):509-17 (72 ref.)
Immunoreceptor tyrosine-based activation motif (ITAM), a unique module linking antigen and Fc receptors to their signaling cascades. Isakov N. **J Leukoc Biol** 1997 Jan; 61(1):6-16 (123 ref.)
Compartmentalization of B-cell antigen receptor functions. Lankester AC, et al. **Mol Immunol** 1996 Jun;33(9):769-75 (94 ref.)

RECEPTORS, ANTIGEN, T-CELL

see related
ANTIGENS, CD3
GENE REARRANGEMENT, T-LYMPHOCYTE

Chimeric T-cell receptors: highly specific tools to target cytotoxic T-lymphocytes to tumour cells. Abken H, et al. **Cancer Treat Rev** 1997 Mar;23(2):97-112 (42 ref.)
The T cell receptor (TCR) in HLA-B27-restricted T cell responses--an introduction. Märker-Hermann E, et al. **Clin Rheumatol** 1996 Jan;15 Suppl 1:86-90 (28 ref.)
Soluble T-lymphocyte antigen-specific immunoproteins: a progress report. Cone RE. **Proc Soc Exp Biol Med** 1997 Mar;214(3):204-9 (39 ref.)
Study of the T cell receptor repertoire in viral immunodeficiency disease. Ciurli C, et al. **Springer Semin Immunopathol** 1996;17(4):319-32 (87 ref.)
[T cell receptor V beta repertoire in Crohn's disease] Matsumoto T, et al. **Nippon Rinsho** 1996 Apr;54(4):1182-7 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Molecular biological characterization of intestinal intraepithelial lymphocytes and their receptors] Nagura H, et al. **Nippon Rinsho** 1996 Apr;54(4):1162-9 (23 ref.) (Eng. Abstr.) **(Jpn)**
[Molecular mechanisms of allergy] Totsuka M, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1055-62 (33 ref.) **(Jpn)**

ANALYSIS

[TCR repertoire of autoreactive T cells in autoimmune disorders] Sumida T, et al. **Nippon Rinsho** 1997 Jun; 55(6):1410-8 (13 ref.) (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Antigen analogs as therapeutic agents. Alexander J, et al. **Adv Exp Med Biol** 1995;386:109-18 (24 ref.)
Opposing functions of activatory T-cell receptors and inhibitory NK-cell receptors on cytotoxic T cells. Ciccone E, et al. **Immunol Today** 1996 Oct;17(10):450-3 (9 ref.)
Antigen analogs as tools to study T-cell activation function and activation. Sette A, et al. **Semin Immunol** 1996 Apr; 8(2):103-8 (29 ref.)

BIOSYNTHESIS

Age-related changes in CD4 T cells of T cell receptor transgenic mice. Haynes L, et al. **Mech Ageing Dev** 1997 Feb;93(1-3):95-105 (44 ref.)

CHEMISTRY

Computational biochemistry of antibodies and T-cell receptors. Novotny J, et al. **Adv Protein Chem** 1996; 49:149-260 (492 ref.)
The structure of the T cell antigen receptor. Bentley GA, et al. **Annu Rev Immunol** 1996;14:563-90 (110 ref.)
MHC restriction in three dimensions: a view of T cell receptor/ligand interactions. Bjorkman PJ. **Cell** 1997 Apr 18;89(2):167-70 (14 ref.)
T cell receptor biochemistry, repertoire selection and general features of TCR and Ig structure. Davis MM, et al. **Ciba Found Symp** 1997;204:94-100; discussion 100-4 (21 ref.)
Composition and function of T-cell receptor and B-cell receptor complexes on precursor lymphocytes. Borst J, et al. **Curr Opin Immunol** 1996 Apr;8(2):181-90 (64 ref.)
Studying interactions involving the T-cell antigen receptor by surface plasmon resonance. Margulies DH, et al. **Curr Opin Immunol** 1996 Apr;8(2):262-70 (56 ref.)
T-cell epitope determination. Walden P. **Curr Opin Immunol** 1996 Feb;8(1):68-74 (60 ref.)
Structure and function of the T-cell receptor: insights from X-ray crystallography. Fields BA, et al. **Immunol Today** 1996 Jul;17(7):330-6 (50 ref.)
Superantigens as immunomodulators: recent structural insights. Papageorgiou AC, et al. **Structure** 1997 Aug 15; 5(8):991-6 (37 ref.)
[The T-cell receptor] Bozhkov B. **Mol Med (Sofia)** 1996; 1(1):8-13 (9 ref.) **(Bul)**

GENETICS

Recent advances in understanding V(D)J recombination. Gellert M. **Adv Immunol** 1997;64:39-64 (108 ref.)
Accessibility control of antigen-receptor variable-region gene assembly: role of cis-acting elements. Sleckman BP, et al. **Annu Rev Immunol** 1996;14:459-81 (116 ref.)
Transrearrangements as biomarkers for risk of lymphoid malignancy. Kirsch IR, et al. **Cancer Surv** 1996;28:311-27 (81 ref.)
Mechanism of V(D)J recombination. Zhu C, et al. **Cancer Surv** 1996;28:295-309 (69 ref.)
The origins of V(D)J recombination. Lewis SM, et al. **Cell** 1997 Jan 24;88(2):159-62 (20 ref.)
Mechanism of V(D)J recombination. Bogue M, et al. **Curr Opin Immunol** 1996 Apr;8(2):175-80 (51 ref.)
Functions of TCR and pre-TCR subunits: lessons from gene ablation. Malissen B, et al. **Curr Opin Immunol** 1996 Jun; 8(3):383-93 (69 ref.)
Double-strand breaks, DNA hairpins, and the mechanism of V(D)J recombination. Steen SB, et al. **Curr Top Microbiol Immunol** 1996;217:61-77 (60 ref.)
Oligoclonality of CD8+ T cells in health and disease: aging, infection, or immune regulation? Batliwalla F, et al. **Hum Immunol** 1996 Jun-Jul;48(1-2):68-76 (37 ref.)
IL-7 receptor and VDJ recombination: trophic versus mechanistic actions. Candéias S, et al. **Immunity** 1997 May; 6(5):501-8 (104 ref.)
The evolutionary origins of immunoglobulins and T-cell receptors: possibilities and probabilities. Langman RE. **Res Immunol** 1996 May;147(4):214-7 (2 ref.)
The organization and structure of immunoglobulin and T-cell receptor genes in the most phylogenetically distant jawed vertebrates: evolutionary implications. Litman GW, et al. **Res Immunol** 1996 May;147(4):226-33 (36 ref.)
Occam's Razor, invertebrate allorecognition and Ig superfamily evolution. Mokady O. **Res Immunol** 1996 May; 147(4):241-6 (20 ref.)
The origin of immunoglobulins and T-cell receptors is likely to be the cell death sensor of macrophages. Ohno S. **Res Immunol** 1996 May;147(4):247-52 (12 ref.)
[TCR CDR3 motif expression in PLP specific T cell from patients with multiple sclerosis] Kondo T, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):666-9 (8 ref.) **(Jpn)**
[Intra-hepatic infiltrating T cell clonality analysis in patients with autoimmune hepatitis and the clinical significance] Takahashi H, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):708-12 (9 ref.) **(Jpn)**

IMMUNOLOGY

Antigen receptor signalling. Monteseirín J, et al. **Allergol Immunopathol (Madr)** 1996 Sep-Oct;24(5):185-92 (9 ref.)
Fine specificity of myelin basic protein reactive T-cells: implications for T-cell receptor antagonism. Anderton SM, et al. **Biochem Soc Trans** 1997 May;25(2):659-61 (14 ref.)
T-cell receptor in Sjögren's syndrome. Sumida T, et al. **Br J Rheumatol** 1997 Jun;36(6):622-9 (52 ref.)
Immunotherapy II: Antigens, receptors and costimulation. Searle PF, et al. **Cancer Metastasis Rev** 1996 Sep; 15(3):329-49 (103 ref.)
Accessory molecule and costimulation requirements for CD4 T cell response. Croft M, et al. **Crit Rev Immunol** 1997; 17(1):89-118 (159 ref.)
T-cell receptors: is the repertoire inherently MHC-specific? Janeway CA, et al. **Curr Biol** 1997 May 1;7(5):R299-300 (11 ref.)
T-cell repertoire: political correctness in the immune system. Lucas B, et al. **Curr Biol** 1996 Jul 1;6(7):783-7 (12 ref.)
Immunology: why the baby isn't thrown out.... Simpson E. **Curr Biol** 1996 Jan 1;6(1):43-4 (6 ref.)
Interactions of TCRs with MHC-peptide complexes: a quantitative basis for mechanistic models. Margulies DH. **Curr Opin Immunol** 1997 Jun;9(3):390-5 (56 ref.)
T cell clonal anergy. Schwartz RH. **Curr Opin Immunol** 1997 Jun;9(3):351-7 (44 ref.)
TCR zeta chain in T cell development and selection. Shores EW, et al. **Curr Opin Immunol** 1997 Jun;9(3):380-9 (96 ref.)
Altered peptide ligands: prospects for immune intervention in autoimmune disease. Fairchild PJ. **Eur J Immunogenet** 1997 Apr;24(2):155-67 (65 ref.)
The diversity of antigen-specific TCR repertoires reflects the relative complexity of epitopes recognized. Maryanski JL, et al. **Hum Immunol** 1997 May;54(2):117-28 (50 ref.)
In thymic selection, peptide diversity gives and takes away. Bevan MJ. **Immunity** 1997 Aug;7(2):175-8 (16 ref.)
Mice lacking terminal deoxynucleotidyl transferase: adult mice with a fetal antigen receptor repertoire. Gilfillan S, et al. **Immunol Rev** 1995 Dec;148:201-19 (85 ref.)
Alloreactivity, antigen recognition and T-cell selection: three diverse T-cell recognition problems with a common solution. Joyce S, et al. **Immunol Rev** 1996 Dec;154:59-103 (251 ref.)
Use of adoptive transfer of T-cell-antigen-receptor-transgenic T cell for the study of T-cell activation in vivo. Pape KA, et al. **Immunol Rev** 1997 Apr;156:67-78 (59 ref.)
Opposing functions of activatory T-cell receptors and inhibitory NK-cell receptors on cytotoxic T cells. Ciccone E, et al. **Immunol Today** 1996 Oct;17(10):450-3 (9 ref.)
Inhibitory receptors for HLA class I molecules on cytolytic T lymphocytes. Functional relevance and implications for anti-tumor immune responses. Mingari MC, et al. **Int J Clin Lab Res** 1997;27(2):87-94 (57 ref.)
T cell receptor (TCR) repertoire in alloimmune responses. Finn OJ, et al. **Int Rev Immunol** 1996;13(3):187-207 (131 ref.)
Significance of antigen-specific T cell clones in collagen diseases: analyses with a novel T cell clonality evaluation system. Yamamoto K. **Intern Med** 1997 Apr;36(4):242-7 (29 ref.)
Key differentiation steps in normal B cells and in myeloma cells. Zubler RH. **Semin Hematol** 1997 Jan;34(1 Suppl 1):13-22 (52 ref.)
Introduction: T-cell recognition of variant ligands. Allen PM. **Semin Immunol** 1996 Apr;8(2):61 (7 ref.)
Responses of T cells to ligands for the T-cell receptor. Janeway CA Jr, et al. **Semin Immunol** 1996 Apr; 8(2):108-115 (28 ref.)
Variant TCR ligands: new insights into the molecular basis of antigen-dependent signal transduction and T-cell activation. Madrenas J, et al. **Semin Immunol** 1996 Apr; 8(2):83-101 (99 ref.)
Cross-talk between the T cell antigen receptor and the glucocorticoid receptor regulates thymocyte development. Ashwell JD, et al. **Stem Cells** 1996 Sep;14(5):490-500 (58 ref.)
[The T-cell receptor--its participation in the pathological immune response] Bozhkov B. **Mol Med (Sofia)** 1996; 1(2):9-15 (20 ref.) (Eng. Abstr.) **(Bul)**
[T cell vaccination--induction of anti-idiotypic immune response against TCR and shift of Th1/Th2 balance] Kakimoto K, et al. **Nippon Rinsho** 1997 Jun;55(6):1512-8 (18 ref.) (Eng. Abstr.) **(Jpn)**
[TCR peptide vaccination for autoimmune diseases: involvement of T-T interaction between autoimmune T cells presenting TCR peptide and CD4-CD8- regulatory T cells] Yamamura T. **Nippon Rinsho** 1997 Jun; 55(6):1519-24 (14 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Antigen-specific T-cell receptors and their reactions with

complexes formed by peptides with major histocompatibility complex proteins. Eisen HN, et al. **Adv Protein Chem** 1996;49:1–56 (227 ref.)
T cell antigen receptor signal transduction. Qian D, et al. **Curr Opin Cell Biol** 1997 Apr;9(2):205–12 (71 ref.)
Studying interactions involving the T-cell antigen receptor by surface plasmon resonance. Margulies DH, et al. **Curr Opin Immunol** 1996 Apr;8(2):262–70 (56 ref.)
A high affinity T cell receptor? Alberti S. **Immunol Cell Biol** 1996 Jun;74(3):292–7 (38 ref.)
Molecular analysis of the fyn-complex: cloning of SKAP55 and SLAP–130, two novel adaptor proteins which associate with fyn and may participate in the regulation of T cell receptor-mediated signaling. Schraven B, et al. **Immunol Lett** 1997 Jun 1;57(1–3):165–9 (26 ref.)
Regulation of signal transduction through the T cell antigen receptor. Zhao H, et al. **J Lab Clin Med** 1997 Aug; 130(2):126–31 (56 ref.)
Introduction: T-cell recognition of variant ligands. Allen PM. **Semin Immunol** 1996 Apr;8(2):61 (7 ref.)
Variant TCR ligands: new insights into the molecular basis of antigen-dependent signal transduction and T-cell activation. Madrenas J, et al. **Semin Immunol** 1996 Apr; 8(2):83–101 (99 ref.)
Identifying the molecular control of T-cell death; on the hunt for killer genes. Wong B, et al. **Semin Immunol** 1997 Feb;9(1):7–16 (53 ref.)

PHYSIOLOGY

Differential signaling by lymphocyte antigen receptors. Alberola-Ila J, et al. **Annu Rev Immunol** 1997;15:125–54 (203 ref.)
T cell antigen receptor signal transduction pathways. Cantrell D. **Annu Rev Immunol** 1996;14:259–74 (91 ref.)
CD28 co-receptor signal transduction in T-cell activation. Blair PJ, et al. **Biochem Soc Trans** 1997 May;25(2):651–7 (57 ref.)
Tyrosine phosphatases in T-cell development and signalling. Conroy LA, et al. **Biochem Soc Trans** 1997 May; 25(2):445–51 (41 ref.)
T cell antigen receptor signal transduction pathways. Cantrell DA. **Cancer Surv** 1996;27:165–75 (165 ref.)
T lymphocyte migration: the influence of interactions via adhesion molecules, the T cell receptor, and cytokines. Hauzenberger D, et al. **Crit Rev Immunol** 1995; 15(3–4):285–316 (310 ref.)
Composition and function of T-cell receptor and B-cell receptor complexes on precursor lymphocytes. Borst J, et al. **Curr Opin Immunol** 1996 Apr;8(2):181–90 (64 ref.)
Functions of TCR and pre-TCR subunits: lessons from gene ablation. Malissen B, et al. **Curr Opin Immunol** 1996 Jun; 8(3):383–93 (69 ref.)
Making the T cell receptor go the distance: a topological view of T cell activation. Shaw AS, et al. **Immunity** 1997 Apr;6(4):361–9 (58 ref.)
Thymic stromal cell specialization and the T-cell receptor repertoire. Lo D, et al. **Immunol Res** 1997 Feb;16(1):3–14 (46 ref.)
Structure and function of the T-cell receptor: insights from X-ray crystallography. Fields BA, et al. **Immunol Today** 1996 Jul;17(7):330–6 (50 ref.)
TCR signaling regulates thymic organization: lessons from TCR-transgenic mice. Goverman J, et al. **Immunol Today** 1997 May;18(5):204–8 (22 ref.)
Serial triggering of TCRs: a basis for the sensitivity and specificity of antigen recognition. Valitutti S, et al. **Immunol Today** 1997 Jun;18(6):299–304 (38 ref.)
Insights into T cell development and signal transduction provided by TCR-zeta chain deficient mice. Shores EW, et al. **Int Rev Immunol** 1996;13(4):301–15 (97 ref.)
Tyrosines 113, 128, and 145 of SLP-76 are required for optimal augmentation of NFAT promoter activity. Fang N, et al. **J Immunol** 1996 Nov 1;157(9):3769–73 (16 ref.)
Immunoreceptor tyrosine-based activation motif (ITAM), a unique module linking antigen and Fc receptors to their signaling cascades. Isakov N. **J Leukoc Biol** 1997 Jan; 61(1):6–16 (123 ref.)
Regulation of T cell apoptosis via T cell receptors and steroid receptors. Iwata M, et al. **Stem Cells** 1996 Nov;14(6):632–41 (66 ref.)

RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA

ANALYSIS

T-cell receptor alpha beta and gamma delta T cells in rat and human skin--are they equivalent? Elbe A, et al. **Semin Immunol** 1996 Dec;8(6):341–9 (82 ref.)

BIOSYNTHESIS

Bias toward use of T-cell receptor variable regions in the lung: research tool or clinically useful technique? [editorial; comment] Semenzato G. **Eur Respir J** 1997 Apr;10(4):767–9 (33 ref.) Comment on: Eur Respir J 1997 Apr;10(4):772–9.

CHEMISTRY

Structure and function of the pre-T cell receptor. von Boehmer H, et al. **Annu Rev Immunol** 1997;15:433–52 (53 ref.)
Biophysical studies of T-cell receptors and their ligands. Fremont DH, et al. **Curr Opin Immunol** 1996 Feb; 8(1):93–100 (80 ref.)
Biophysical and structural studies of TCRs and ligands: implications for T cell signaling. Ward ES, et al. **Curr Opin Immunol** 1997 Feb;9(1):97–106 (59 ref.)
Not just another Fab: the crystal structure of a TcR-MHC-peptide complex. Jardetzky T. **Structure** 1997 Feb 15;5(2):159–63 (17 ref.)

GENETICS

T-cell receptors in immune responses. Robinson MA. **Adv Exp Med Biol** 1995;386:121–32 (37 ref.)
TCR usage in human and experimental demyelinating disease. Hafler DA, et al. **Immunol Today** 1996 Apr;17(4):152–9 (71 ref.)
Indictment of the microglia as the villain in multiple sclerosis. Sriram S, et al. **Neurology** 1997 Feb;48(2):464–70 (69 ref.)
[Analysis of infiltrating T-cell receptor in multiple organ lesions of patients with Sjogren's syndrome] Sumida T, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec; 18(6):653–9 (20 ref.) **(Jpn)**
[Intra-hepatic infiltrating T cell clonality analysis in patients with autoimmune hepatitis and the clinical significance] Takahashi H, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):708–12 (9 ref.) **(Jpn)**

IMMUNOLOGY

T-cells with two T-cell receptors: are they important in autoimmunity? Stockinger B, et al. **Biochem Soc Trans** 1997 May;25(2):617–20 (22 ref.)
T cell receptors and T cell development. Chen CH, et al. **Curr Top Microbiol Immunol** 1996;212:37–53 (88 ref.)
T cell migration during ontogeny and T cell repertoire generation. Dunon D, et al. **Curr Top Microbiol Immunol** 1996;212:79–93 (45 ref.)
Diversity in the human T cell receptor beta chain. LaRocque R, et al. **Hum Immunol** 1996 Jun-Jul;48(1–2):3–11 (51 ref.)
Role of the T cell receptor alpha-chain in superantigen recognition. Blackman MA, et al. **Immunol Res** 1996; 15(2):98–113 (84 ref.)
Aspects of cytotoxic T cell memory. Müllbacher A, et al. **Immunol Rev** 1996 Apr;150:113–27 (70 ref.)

METABOLISM

Structure and function of the pre-T cell receptor. von Boehmer H, et al. **Annu Rev Immunol** 1997;15:433–52 (53 ref.)
Treatment of malignancy by direct gene transfer of a foreign MHC class I molecule. DeBruyne L. **Cancer Immunol Immunother** 1996 Nov;43(3):180–9 (107 ref.)
Events that regulate differentiation of alpha beta TCR+ and gamma delta TCR+ T cells from a common precursor. Kang J, et al. **Semin Immunol** 1997 Jun;9(3):171–9 (60 ref.)

PHYSIOLOGY

Biophysical and structural studies of TCRs and ligands: implications for T cell signaling. Ward ES, et al. **Curr Opin Immunol** 1997 Feb;9(1):97–106 (59 ref.)
[Role of TCR V alpha 24 J alpha Q+ T cells in autoimmune diseases] Oishi Y, et al. **Nippon Rinsho** 1997 Jun; 55(6):1425–30 (20 ref.) (Eng. Abstr.) **(Jpn)**

RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA

see related
GENE REARRANGEMENT, GAMMA-CHAIN T-CELL ANTIGEN RECEPTOR

Clinical and pathological heterogeneity in cutaneous gamma-delta T-cell lymphoma: a report of three cases and a review of the literature. Munn SE, et al. **Br J Dermatol** 1996 Dec;135(6):976–81 (17 ref.)

ANALYSIS

An innate view of gamma delta T cells. Boismenu R, et al. **Curr Opin Immunol** 1997 Feb;9(1):57–63 (73 ref.)
Sentinel function of broadly reactive human gamma delta T cells. De Libero G. **Immunol Today** 1997 Jan;18(1):22–6 (37 ref.)
T-cell receptor alpha beta and gamma delta T cells in rat and human skin--are they equivalent? Elbe A, et al. **Semin Immunol** 1996 Dec;8(6):341–9 (82 ref.)
Thymic development of V gamma 3 cells. Leclercq G, et al. **Semin Immunol** 1996 Dec;8(6):315–21 (63 ref.)

BIOSYNTHESIS

Origin and development of the gamma delta T-cell system in sheep: a critical role for the thymus in the generation of TcR diversity and tissue tropism. Cahill RN, et al. **Semin Immunol** 1996 Dec;8(6):351–60 (61 ref.)

IMMUNOLOGY

Recognition by gamma/delta T cells. Chien YH, et al. **Annu Rev Immunol** 1996;14:511–32 (75 ref.)
T cell subsets and the activation of gamma delta T cells. Arstila TP. **Curr Top Microbiol Immunol** 1996;212:71–7 (36 ref.)
T cell receptors and T cell development. Chen CH, et al. **Curr Top Microbiol Immunol** 1996;212:37–53 (88 ref.)
T cell migration during ontogeny and T cell repertoire generation. Dunon D, et al. **Curr Top Microbiol Immunol** 1996;212:79–93 (45 ref.)
Chicken gamma delta T cells. Sanchez-Garcia FJ, et al. **Curr Top Microbiol Immunol** 1996;212:55–69 (79 ref.)
Contribution of 65-kDa heat shock protein induced by gamma and delta T cells to protection against Toxoplasma gondii infection. Himeno K, et al. **Immunol Res** 1996; 15(3):258–64 (25 ref.)
Gamma delta T cells: their immunobiology and role in malaria infections. Rzepczyk CM, et al. **Int J Parasitol** 1997 Feb;27(2):191–200 (74 ref.)
Stimulation of gamma delta T cells by phosphoantigens. Fournié JJ, et al. **Res Immunol** 1996 Jun;147(5):338–47 (60 ref.)
Direct presentation of non-peptide prenyl pyrophosphate antigens to human gamma delta T cells. Morita CT, et al. **Res Immunol** 1996 Jun;147(5):347–53 (44 ref.)
[Cellular immunity in tuberculosis particularly the role of gamma delta T lymphocytes] Mróz RM, et al. **Pneumonol Alergol Pol** 1996;64(11–12):815–20 (33 ref.) **(Pol)**

METABOLISM

Events that regulate differentiation of alpha beta TCR+ and gamma delta TCR+ T cells from a common precursor. Kang J, et al. **Semin Immunol** 1997 Jun;9(3):171–9 (60 ref.)

PHYSIOLOGY

Gamma delta T cells in bacterial infections. Ferrick DA, et al. **Res Immunol** 1996 Oct-Dec;147(8–9):532–41 (74 ref.)
Human gamma delta T cells in tuberculosis. Poquet Y, et al. **Res Immunol** 1996 Oct-Dec;147(8–9):542–9 (52 ref.)
Origin and development of the gamma delta T-cell system in sheep: a critical role for the thymus in the generation of TcR diversity and tissue tropism. Cahill RN, et al. **Semin Immunol** 1996 Dec;8(6):351–60 (61 ref.)

RECEPTORS, ARYL HYDROCARBON

[Structure and function of PAS proteins: Ah receptor, Arnt, and others] Sogawa K, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1288–96 (47 ref.) **(Jpn)**

DRUG EFFECTS

Dioxins and the Ah receptor: probes to uncover processes in neuroendocrine development. Gasiewicz TA. **Neurotoxicology** 1997;18(2):393–413 (162 ref.)

GENETICS

[The strategic use of genetic polymorphisms in carcinogen metabolizing enzyme for prevention of cancer] Ikawa S. **Gan To Kagaku Ryoho** 1997 Feb;24(4):454–9 (15 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Interactions of procarcinogenic heterocyclic amines and indolocarbazoles with the dioxin receptor. Kleman M, et al. **Biol Chem** 1996 Nov;377(11):741–62 (270 ref.)
[The Anders Jahres Prize. Intracellular signal transmission via dioxin receptors] Poellinger L. **Nord Med** 1996 Feb; 111(2):45–8 (15 ref.) (Eng. Abstr.) **(Swe)**

PHYSIOLOGY

Ah receptor signaling pathways. Schmidt JV, et al. **Ann Rev Cell Dev Biol** 1996;12:55–89 (142 ref.)
How knockout mouse lines will be used to study the role of drug-metabolizing enzymes and their receptors during reproduction and development, and in environmental toxicity, cancer, and oxidative stress. Nebert DW, et al. **Biochem Pharmacol** 1997 Feb 7;53(3):249–54 (44 ref.)
Aryl hydrocarbon receptor-mediated signal transduction. Rowlands JC, et al. **Crit Rev Toxicol** 1997 Mar;27(2):109–34 (223 ref.)
The role of the aryl hydrocarbon receptor in animal development, physiological homeostasis and toxicity of TCDD. Gonzalez FJ, et al. **J Toxicol Sci** 1996 Dec; 21(5):273–7 (9 ref.)

RECEPTORS, ATP see **RECEPTORS, PURINERGIC P2**

RECEPTORS, ATRIAL NATRIURETIC FACTOR

[Pathophysiological significance of natriuretic peptide receptor] Naruse M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:549–52 (10 ref.) **(Jpn)**

METABOLISM

Atrial natriuretic peptide-C receptor and membrane signalling in hypertension. Anand-Srivastava MB. **J Hypertens** 1997 Aug;15(8):815–26 (134 ref.)

RECEPTORS, ATRIAL NATRIURETIC FACTOR

PHYSIOLOGY

Regulation of the atrial natriuretic peptide receptor guanylyl cyclase. Chinkers M. **Proc Soc Exp Biol Med** 1996 Nov; 213(2):105–8 (25 ref.)

Functional properties and dynamics of natriuretic peptide receptors. Maack T, et al. **Proc Soc Exp Biol Med** 1996 Nov;213(2):109–16 (32 ref.)

RECEPTORS, ATRIOPEPTIN see **RECEPTORS, ATRIAL NATRIURETIC FACTOR**

RECEPTORS, BENZODIAZEPINE see **RECEPTORS, GABA-A**

RECEPTORS, BENZODIAZEPINE-GABA see **RECEPTORS, GABA-A**

RECEPTORS, BETA-ADRENERGIC see **RECEPTORS, ADRENERGIC, BETA**

RECEPTORS, BETA-1 ADRENERGIC see **RECEPTORS, ADRENERGIC, BETA-1**

RECEPTORS, BETA-2 ADRENERGIC see **RECEPTORS, ADRENERGIC, BETA-2**

RECEPTORS, BIOGENIC AMINE

DRUG EFFECTS

Neurobiological correlates of acute neuroleptic treatment. Sedvall GC. **Int Clin Psychopharmacol** 1996 May;11 Suppl 2:41–6 (20 ref.)

RECEPTORS, BOMBESIN

ANTAGONISTS & INHIBITORS

Bombesin receptor antagonists. de Castiglione R, et al. **Crit Rev Oncol Hematol** 1996 Oct;24(2):117–51 (215 ref.)

RECEPTORS, BRADYKININ

ANTAGONISTS & INHIBITORS

Beneficial effects of bradykinin on myocardial energy metabolism and infarct size. Linz W, et al. **Am J Cardiol** 1997 Aug 4;80(3A):118A–123A (111 ref.)

Bradykinin receptors. Hall JM. **Gen Pharmacol** 1997 Jan; 28(1):1–6 (32 ref.)

METABOLISM

Inositol trisphosphate/Ca2+ as messengers of bradykinin B2 and muscarinic acetylcholine m1–m4 receptors in neuroblastoma–derived hybrid cells. Noda M, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):175–85 (44 ref.)

Acute regulation of the receptor–mediated phosphoinositide signal transduction pathway. Willars GB, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):157–68 (35 ref.)

PHYSIOLOGY

Bradykinin B2 receptors and signal transduction analyzed in NG108–15 neuroblastoma x glioma hybrid cells, B2 receptor–transformed CHO cells and ras–transformed NIH/3T3 fibroblasts. Higashida H, et al. **Prog Brain Res** 1996;113:215–30 (82 ref.)

Bradykinin receptors and receptor ligands (with special emphasis on vascular receptors). Regoli D, et al. **Regul Pept** 1996 Aug 27;65(1):83–9 (51 ref.)

RECEPTORS, C3D see **RECEPTORS, COMPLEMENT 3D**

RECEPTORS, CAERULEIN see **RECEPTORS, CHOLECYSTOKININ**

RECEPTORS, CALCITONIN

GENETICS

Receptors of calciotropic hormones. Findlay DM, et al. **Horm Metab Res** 1997 Mar;29(3):128–34 (77 ref.)

RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE

Calcitonin gene–related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Wimalawansa SJ. **Endocr Rev** 1996 Oct; 17(5):533–85 (655 ref.)

METABOLISM

Calcitonin gene–related peptide in the cardiovascular system: characterization of receptor populations and their (patho)physiological significance. Bell D, et al. **Pharmacol Rev** 1996 Jun;48(2):253–88 (302 ref.)

RECEPTORS, CALCITRIOL

[Vitamin D receptor] Wei S, et al. **Nippon Rinsho** 1997 Apr; 55 Suppl 2:512–5 (9 ref.) **(Jpn)**

ANALYSIS

Abnormalities of the vitamin D receptor in uraemia. Kumar R. **Nephrol Dial Transplant** 1996;11 Suppl 3:6–10 (77 ref.)

CHEMISTRY

The vitamin D receptor—structure and transcriptional activation. Strugnell SA, et al. **Proc Soc Exp Biol Med** 1997 Jul;215(3):223–8 (56 ref.)

GENETICS

Vitamin D receptor gene variants: implications for therapy. Eisman JA. **Curr Opin Genet Dev** 1996 Jun;6(3):361–5 (53 ref.)

The vitamin D receptor—structure and transcriptional activation. Strugnell SA, et al. **Proc Soc Exp Biol Med** 1997 Jul;215(3):223–8 (56 ref.)

Genetic markers of bone metabolism and bone disease. Ralston SH. **Scand J Clin Lab Invest Suppl** 1997;227:114–21 (46 ref.)

Vitamin D receptor gene polymorphisms and osteoporosis. van Leeuwen JP, et al. **Steroids** 1996 Apr;61(4):154–6 (28 ref.)

RECEPTORS, CALCIUM CHANNEL BLOCKER see **CALCIUM CHANNELS**

RECEPTORS, CATECHOLAMINE

METABOLISM

The energetics of ligand binding at catecholamine receptors. Strange PG. **Trends Pharmacol Sci** 1996 Jul;17(7):238–44 (51 ref.)

RECEPTORS, CCK see **RECEPTORS, CHOLECYSTOKININ**

RECEPTORS, CD4 see **ANTIGENS, CD4**

RECEPTORS, CELL-ADHESION PROTEIN see **INTEGRINS**

RECEPTORS, CELL SURFACE

Tools for the study of receptor immunity. Hoebeke J. **Blood Press Suppl** 1996;3:56–8 (18 ref.)

G protein coupled R7G receptors. Strosberg AD. **Cancer Surv** 1996;27:65–83 (44 ref.)

Scavenger receptors in innate immunity. Pearson AM. **Curr Opin Immunol** 1996 Feb;8(1):20–8 (92 ref.)

Mitogenic signaling via G protein–coupled receptors. van Biesen T, et al. **Endocr Rev** 1996 Dec;17(6):698–714 (272 ref.)

[Signalling by Notch family receptors] Schweisguth F, et al. **C R Seances Soc Biol Fil** 1997;191(1):55–75 (71 ref.) (Eng. Abstr.) **(Fre)**

[Physiological roles of Fas, an apoptosis inductor cell surface receptor molecule] Yonehara N. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):581–2 (0 ref.) **(Jpn)**

[Receptor diseases and their evaluation methods] Miyachi Y, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:435–43 (7 ref.) **(Jpn)**

[Diphtheria toxin receptor complex] Mekada E, et al. **Nippon Saikingaku Zasshi** 1996 Aug;51(3):853–62 (15 ref.) **(Jpn)**

ANALYSIS

Autoradiographical and immunohistochemical analysis of receptor localization in the central nervous system. Chabot JG, et al. **Histochem J** 1996 Nov;28(11):729–45 (110 ref.)

Immunocytochemical methods for investigating receptor localization. Fonseca MI, et al. **Methods Mol Biol** 1997; 83:91–106 (16 ref.)

In situ hybridization. Mak JC, et al. **Methods Mol Biol** 1997; 83:81–9 (17 ref.)

Radiolabeled peptides and other ligands for receptors overexpressed in tumor cells for imaging neoplasms. McAfee JG, et al. **Nucl Med Biol** 1996 Aug;23(6):673–6 (36 ref.)

Can receptors be imaged with MRI agents? Nunn AD, et al. **Q J Nucl Med** 1997 Jun;41(2):155–62 (33 ref.)

Fluorescent ligands for the study of receptors. McGrath JC, et al. **Trends Pharmacol Sci** 1996 Nov;17(11):393–9 (42 ref.)

ANTAGONISTS & INHIBITORS

AR4–2J cells: a model to study polypeptide hormone receptors. Dietrich JB. **Biosci Rep** 1996 Aug;16(4):273–88 (88 ref.)

New thoughts on strategies for modulating platelet function through the inhibition of surface receptors. Nurden AT. **Haemostasis** 1996 Oct;26 Suppl 4:78–88 (36 ref.)

Conjunctive use of platelet glycoprotein IIb/IIIa antagonists and thrombolytic therapy for acute myocardial infarction. Moliterno DJ, et al. **Thromb Haemost** 1997 Jul;78(1):214–9 (41 ref.)

Clinical trials with glycoprotein IIb/IIIa receptor antagonists in acute coronary syndromes. Van de Werf F. **Thromb Haemost** 1997 Jul;78(1):210–3 (22 ref.)

BIOSYNTHESIS

Regulating expression and function of G–protein–linked receptors. Karoor V, et al. **Prog Neurobiol** 1996 Apr; 48(6):555–68 (155 ref.)

CHEMISTRY

Metal–ion sites as structural and functional probes of helix–helix interactions in 7TM receptors. Elling CE, et al. **Ann N Y Acad Sci** 1997 Apr 24;814:142–51 (57 ref.)

Receptors for VIP, PACAP, secretin, GRF, glucagon, GLP–1, and other members of their new family of G protein–linked receptors: structure–function relationship with special reference to the human VIP–1 receptor. Laburthe M, et al. **Ann N Y Acad Sci** 1996 Dec 26; 805:94–109; discussion 110–1 (64 ref.)

Speculations on the mechanism of hormone–receptor interactions of the secretin/glucagon family of polypeptide hormones derived from computational structural studies. Momany FA, et al. **Ann N Y Acad Sci** 1996 Dec 26; 805:172–81; discussion 181–3 (18 ref.)

Receptor signaling: dimerization and beyond. Stock J. **Curr Biol** 1996 Jul 1;6(7):825–7 (18 ref.)

Natural killer cell receptors specific for MHC class I molecules [published erratum appears in Curr Opin Immunol 1996 Jun;8(3):419] Colonna M. **Curr Opin Immunol** 1996 Feb;8(1):101–7 (60 ref.)

Bacterial chemotaxis: a field in motion. Stock AM, et al. **Curr Opin Struct Biol** 1995 Dec;5(6):744–51 (56 ref.)

Recognition at the cell surface: recent structural insights. Stuart DI, et al. **Curr Opin Struct Biol** 1995 Dec;5(6):735–43 (50 ref.)

Animal lectins. Gabius HJ. **Eur J Biochem** 1997 Feb 1; 243(3):543–76 (500 ref.)

Engineering of metal–ion sites as distance constraints in structural and functional analysis of 7TM receptors. Elling CE, et al. **Fold Des** 1997;2(4):S76–80 (41 ref.)

Evolution of a family of receptors containing multiple C–type carbohydrate–recognition domains [letter] Taylor ME. **Glycobiology** 1997 Apr;7(3):v–viii (14 ref.)

Aglycone modulation of glycolipid receptor function. Lingwood CA. **Glycoconj J** 1996 Aug;13(4):495–503 (114 ref.)

Conservation of structural features reveals the existence of a large family of inhibitory cell surface receptors and noninhibitory/activatory counterparts. Vély F, et al. **J Immunol** 1997 Sep 1;159(5):2075–7 (27 ref.)

Inhibitory receptors abound? [comment] Cambier JC. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):5993–5 (24 ref.) Comment on: Proc Natl Acad Sci U S A 1997 May 13;94(10):5261–6.

Dynamic receptor superstructures at the plasma membrane. Damjanovich S, et al. **Q Rev Biophys** 1997 Feb; 30(1):67–106 (165 ref.)

Automated modelling of the transmembrane region of G–protein coupled receptor by Swiss–model. Peitsch MC, et al. **Receptors Channels** 1996;4(3):161–4 (12 ref.)

[7TM receptors—from the olfactory system and new hormones against HIV infection] Schwartz TW. **Ugeskr Laeger** 1997 Feb 24;159(9):1239–45 (34 ref.) (Eng. Abstr.) **(Dan)**

CLASSIFICATION

Protein structures in receptor classification. Barnard EA. **Ann N Y Acad Sci** 1997 May 30;812:14–28 (69 ref.)

Criteria for the classification of hormone receptors with implications for nomenclature. An impossible task? Lomasney J. **Ann N Y Acad Sci** 1997 May 30;812:48–54 (5 ref.)

Is promiscuity of G protein interaction an issue in the classification of receptors? Milligan G. **Ann N Y Acad Sci** 1997 May 30;812:126–32 (31 ref.)

The alpha and omega of G protein–coupled receptors. A novel method for classification. Moereels H, et al. **Ann N Y Acad Sci** 1997 May 30;812:147–8 (3 ref.)

The classification of bioamine receptors. How helpful are molecular phylogenies? Vernier P, et al. **Ann N Y Acad Sci** 1997 May 30;812:141–3 (1 ref.)

Factors to consider in the naming of a G protein–coupled receptor subtype. Watson SP. **J Recept Signal Transduct Res** 1995 Jan–Mar;15(1–4):5–17, discussion 19–21 (14 ref.)

The classification of seven transmembrane receptors in recombinant expression systems. Kenakin T. **Pharmacol Rev** 1996 Sep;48(3):413–63 (569 ref.)

DRUG EFFECTS

Challenges of high throughput screening against cell surface receptors. Major JS. **J Recept Signal Transduct Res** 1995 Jan–Mar;15(1–4):595–607 (5 ref.)

GENETICS

A genome–based receptor nomenclature. Hartig PR. **Ann N Y Acad Sci** 1997 May 30;812:85–91 (30 ref.)

How receptor mutagenesis may confirm or confuse receptor classification. Schwartz TW, et al. **Ann N Y Acad Sci** 1997 May 30;812:71–84 (41 ref.)

Calcium–receptor–regulated parathyroid and renal function. Brown EM, et al. **Bone** 1997 Apr;20(4):303–9 (50 ref.)

Molecular defects in the Bernard–Soulier syndrome: assessment of receptor genes, transcripts and proteins. Roth

GJ. **C R Acad Sci III** 1996 Sep;319(9):819–26 (61 ref.)
Inborn errors of signal transduction: mutations in G proteins and G protein–coupled receptors as a cause of disease. Spiegel AM. **J Inherit Metab Dis** 1997 Jun;20(2):113–21 (20 ref.)
Mutations and diseases of G protein coupled receptors. Birnbaumer M. **J Recept Signal Transduct Res** 1995 Jan–Mar;15(1–4):131–60 (74 ref.)
Heterologous expression of receptors and signaling proteins in adult mammalian sympathetic neurons by microinjection. Ikeda SR. **Methods Mol Biol** 1997;83:191–202 (15 ref.)
Regulation of receptor expression. Analysis of receptor mRNA and gene transcription. Iredale PA, et al. **Methods Mol Biol** 1997;83:251–72 (15 ref.)
[Signalling by Notch family receptors] Schweisguth F, et al. **C R Seances Soc Biol Fil** 1997;191(1):55–75 (71 ref.) (Eng. Abstr.) **(Fre)**
[Activated protein C resistance—an evaluation of current status (see comments)] Hopmeier P. **Wien Klin Wochenschr** 1996;108(19):599–606 (93 ref.) (Eng. Abstr.) Comment in: Wien Klin Wochenschr 1996;108(19):595–8. **(Ger)**
[Detection of functional abnormalities of hormone receptors by gene diagnosis] Amino N, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:450–6 (7 ref.) **(Jpn)**

IMMUNOLOGY

Tools for the study of receptor immunity. Hoebeke J. **Blood Press Suppl** 1996;3:56–8 (18 ref.)
Antibodies targeting the calcium sensing receptor: acquired hypoparathyroidism—an autoimmune disease at last? Hofbauer LC, et al. **Eur J Endocrinol** 1996 Aug; 135(2):172–3 (8 ref.)
Comparative structural and antigenic properties of zona pellucida glycoproteins. Hedrick JL. **J Reprod Fertil Suppl** 1996;50:9–17 (32 ref.)
The generation of receptor–selective antibodies. Mackrill JJ. **Methods Mol Biol** 1997;83:65–79 (14 ref.)

ISOLATION & PURIFICATION

Natural killer cell receptors specific for MHC class I molecules [published erratum appears in Curr Opin Immunol 1996 Jun;8(3):419] Colonna M. **Curr Opin Immunol** 1996 Feb;8(1):101–7 (60 ref.)

METABOLISM

Structure and function of phospholipase A2 receptor. Hanasaki K, et al. **Adv Exp Med Biol** 1996;416:315–9 (29 ref.)
Receptors in the Pseudomonas aeruginosa adherence to injured and repairing airway epithelium. de Bentzmann S, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 2):S155–62 (54 ref.)
To what extent can binding studies allow the quantification of affinity and efficacy? Birdsall NJ, et al. **Ann N Y Acad Sci** 1997 May 30;812:41–7 (33 ref.)
Do recombinant receptor assays provide affinity and potency estimates? Bockaert J, et al. **Ann N Y Acad Sci** 1997 May 30;812:55–70 (27 ref.)
Metal–ion sites as structural and functional probes of helix–helix interactions in 7TM receptors. Elling CE, et al. **Ann N Y Acad Sci** 1997 Apr 24;814:142–51 (57 ref.)
Hematopoietic receptor complexes. Wells JA, et al. **Annu Rev Biochem** 1996;65:609–34 (103 ref.)
Response of Neisseria meningitidis to iron limitation. Pettersson A, et al. **Antonie Van Leeuwenhoek** 1997 Feb; 71(1–2):129–36 (34 ref.)
Elastin receptor and cell–matrix interactions in heart transplant–associated arteriosclerosis. Hinek A. **Arch Immunol Ther Exp (Warsz)** 1997;45(1):15–29 (114 ref.)
Heparan sulfate proteoglycans. Essential co–factors in receptor–mediated processes with relevance to the biology of the vascular wall. David G, et al. **Atherosclerosis** 1995 Dec;118 Suppl:S57–67 (75 ref.)
Melatonin receptors in the mammalian suprachiasmatic nucleus. Dubocovich ML, et al. **Behav Brain Res** 1996; 73(1–2):141–7 (79 ref.)
Palmitoylation: a post–translational modification that regulates signalling from G–protein coupled receptors. Morello JP, et al. **Biochem Cell Biol** 1996;74(4):449–57 (70 ref.)
Localization signals in proteins internalized from the cell surface. Banting G. **Biochem Soc Trans** 1996 May; 24(2):531–4 (29 ref.)
Determinants of steroid hormone bioavailability. Hammond GL. **Biochem Soc Trans** 1997 May;25(2):577–82 (51 ref.)
Specificity of interaction between receptor and G protein: use of antisense techniques to relate G–protein subunits to function. Kalkbrenner F, et al. **Biochim Biophys Acta** 1996 Nov 8;1314(1–2):125–39 (78 ref.)
Mechanistic hypotheses for the activation of G–protein–coupled receptors. Fong TM. **Cell Signal** 1996 Mar;8(3):217–24 (74 ref.)
A new class of models for computing receptor–ligand binding affinities. Gilson MK, et al. **Chem Biol** 1997 Feb;4(2):87–92 (78 ref.)
Nuclear hormone receptors: ligand–activated regulators of transcription and diverse cell responses. Katzenellenbogen JA, et al. **Chem Biol** 1996 Jul;3(7):529–36 (52 ref.)
Getting it together: signal transduction in G–protein coupled receptors by association of receptor domains. Underwood DJ, et al. **Chem Biol** 1997 Apr;4(4):239–48 (81 ref.)
P2 purinoceptors and pyrimidinoceptors of catecholamine–producing cells and immunocytes. Illes P, et al. **Ciba Found Symp** 1996;198:110–25; discussion 125–9 (59 ref.)
Structures, assays and receptors for locust adipokinetic hormones. Goldsworthy GJ, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 Aug; 117(4):483–96 (136 ref.)
Animal membrane receptors and adhesive molecules. Kubrycht J, et al. **Crit Rev Biotechnol** 1997;17(2):123–47 (160 ref.)
Targeting of drugs to cell surface receptors. Říhová B. **Crit Rev Biotechnol** 1997;17(2):149–69 (147 ref.)
Cell–cell signalling: Wingless lands at last. Orsulic S, et al. **Curr Biol** 1996 Nov 1;6(11):1363–7 (28 ref.)
Receptor signaling: dimerization and beyond. Stock J. **Curr Biol** 1996 Jul 1;6(7):825–7 (18 ref.)
How receptors talk to trimeric G proteins. Bourne HR. **Curr Opin Cell Biol** 1997 Apr;9(2):134–42 (66 ref.)
Receptor–regulated ion channels. Jan LY, et al. **Curr Opin Cell Biol** 1997 Apr;9(2):155–60 (60 ref.)
Presynaptic ionotropic receptors. McGehee DS, et al. **Curr Opin Neurobiol** 1996 Jun;6(3):342–9 (96 ref.)
G–protein–coupled receptors: molecular mechanisms involved in receptor activation and selectivity of G–protein recognition. Wess J. **FASEB J** 1997 Apr;11(5):346–54 (87 ref.)
Sex steroid–binding protein and its membrane receptor in estrogen–dependent breast cancer: biological and pathophysiological impact. Fortunati N, et al. **Horm Res** 1996;45(3–5):202–6 (16 ref.)
Growth hormone– and prolactin–binding proteins: soluble forms of receptors. Postel–Vinay MC. **Horm Res** 1996; 45(3–5):178–81 (33 ref.)
Hormone receptors in breast carcinomas. Mandal AK. **Indian J Pathol Microbiol** 1995 Jan;38(1):109–18 (17 ref.)
Microbial adherence to and invasion through proteoglycans. Rostand KS, et al. **Infect Immun** 1997 Jan;65(1):1–8 (114 ref.)
Insect storage proteins: gene families and receptors. Haunerland NH. **Insect Biochem Mol Biol** 1996 Sep–Oct; 26(8–9):755–65 (60 ref.)
Vitellogenin receptors: oocyte–specific members of the low–density lipoprotein receptor supergene family. Schneider WJ. **Int Rev Cytol** 1996;166:103–37 (119 ref.)
Selectin ligands: will the real ones please stand up? Varki A. **J Clin Invest** 1997 Jan 15;99(2):158–62 (74 ref.)
Urokinase–type plasminogen activator and its receptor in bladder cancer [editorial; comment] Hasui Y, et al. **J Natl Cancer Inst** 1997 May 21;89(10):678–9 (19 ref.) Comment on: J Natl Cancer Inst 1997 May 21;89(10):709–17.
Comparison of binding mechanisms at cholinergic, serotonergic, glycinergic and GABAergic receptors. Aprison MH, et al. **J Neurosci Res** 1996 Jan 15;43(2):127–36 (39 ref.)
Challenges of high throughput screening against cell surface receptors. Major JS. **J Recept Signal Transduct Res** 1995 Jan–Mar;15(1–4):595–607 (5 ref.)
Biochemical approaches to examine the specificity of interactions between receptors and guanine nuclotide binding proteins. Milligan G, et al. **J Recept Signal Transduct Res** 1995 Jan–Mar; 15(1–4):253–65 (35 ref.)
Multiple receptor populations: binding isotherms and their numerical analysis. Pliska V. **J Recept Signal Transduct Res** 1995 Jan–Mar; 15(1–4):651–75 (36 ref.)
Thermodynamic parameters of ligand–receptor interactions: computation and error margins [published erratum appears in J Recept Signal Transduct Res 1997 Jul;17(4):667] Pliška V. **J Recept Signal Transduct Res** 1997 Jan–May; 17(1–3):495–510 (22 ref.)
Constitutively active G protein–coupled receptors: potential mechanisms of receptor activation. Scheer A, et al. **J Recept Signal Transduct Res** 1997 Jan–May;17(1–3):57–73 (46 ref.)
Structure and function of the N–linked carbohydrate chains of pig zona pellucida glycoproteins. Nakano M, et al. **J Reprod Fertil Suppl** 1996;50:25–34 (40 ref.)
What is the role of the gamma–hydroxybutyrate receptor? Cash CD. **Med Hypotheses** 1996 Dec;47(6):455–9 (41 ref.)
Protein–glycosaminoglycan interactions: infectiological aspects. Sawitzky D. **Med Microbiol Immunol (Berl)** 1996 Feb;184(4):155–61 (78 ref.)
Assay of G protein–coupled receptor kinase activity by rhodopsin phosphorylation. Gagnon AW, et al. **Methods Mol Biol** 1997;83:235–42 (14 ref.)
Agonist–induced high–affinity GTP hydrolysis as an index of receptor–mediated G protein activation in mammalian brain membranes. Odagaki Y, et al. **Methods Mol Biol** 1997; 83:133–41 (15 ref.)
Axons turn as netrins find their receptor. Keynes R, et al. **Neuron** 1996 Dec;17(6):1031–4 (25 ref.)
The application of receptor theory to receptor–binding and enzyme–binding oncologic radiopharmaceuticals. Eckelman WC. **Nucl Med Biol** 1994 Jul;21(5):759–69 (81 ref.)
Peptides and growth factors in non–small cell lung cancer. Moody TW. **Peptides** 1996;17(3):545–55 (151 ref.)
SV2proteoglycan: a potential synaptic vesicle transporter and nerve terminal extracellular matrix receptor. Carlson SS. **Perspect Dev Neurobiol** 1996;3(4):373–86 (79 ref.)
Receptor ligands. Signore A. **Q J Nucl Med** 1995 Dec;39(4 Suppl 1):83–5 (8 ref.)
Signaling across membranes: a one and a two and a... [comment] Stock J. **Science** 1996 Oct 18;274(5286):370–1 (10 ref.) Comment on: Science 1996 Oct 18;274(5286):423–5. Comment on: Science 1996 Oct 18;274(5286):425–6.
Protease–activated G protein–coupled receptors on human platelets and endothelial cells. Brass LF, et al. **Thromb Haemost** 1997 Jul;78(1):234–41 (89 ref.)
G protein–coupled receptors: heterologous regulation of homologous desensitization and its implications. Chuang TT, et al. **Trends Pharmacol Sci** 1996 Nov;17(11):416–21 (51 ref.)
G16 as a universal G protein adapter: implications for agonist screening strategies. Milligan G, et al. **Trends Pharmacol Sci** 1996 Jul;17(7):235–7 (26 ref.)
Melatonin receptors step into the light: cloning and classification of subtypes. Reppert SM, et al. **Trends Pharmacol Sci** 1996 Mar;17(3):100–2 (20 ref.)
Solving inconsistencies in the analysis of receptor–ligand interactions. Tuk B, et al. **Trends Pharmacol Sci** 1996 Nov; 17(11):403–9 (22 ref.)
[A family of receptors for secretory phospholipases A2] Lambeau G, et al. **C R Seances Soc Biol Fil** 1996; 190(4):425–35 (42 ref.) (Eng. Abstr.) **(Fre)**
[Receptor diseases and their evaluation methods] Miyachi Y, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:435–43 (7 ref.) **(Jpn)**
[Analysis and characterization of ligand–receptor binding systems] Ogawa N. **Nippon Rinsho** 1997 Apr;55 Suppl 2:444–9 (14 ref.) **(Jpn)**
[Quantitative evaluation of pharmacological effects and adverse effects based on receptor occupancy theory] Sawada Y, et al. **Yakugaku Zasshi** 1997 Feb;117(2):65–90 (47 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Structure and function of leukocyte chemoattractant receptors. Ye RD, et al. **Adv Pharmacol** 1997;39:221–89 (360 ref.)
Eosinophil receptors. Monteseirín J, et al. **Allergol Immunopathol (Madr)** 1996 Sep–Oct;24(5):226–34 (82 ref.)
Turning off the signal: mechanisms that attenuate signaling by G protein–coupled receptors. Grady EF, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):G586–601 (132 ref.)
Do recent operational studies indicate that a single state model is no longer applicable to G protein–coupled receptors? Bond RA. **Ann N Y Acad Sci** 1997 May 30; 812:92–7 (24 ref.)
Receptors for VIP, PACAP, secretin, GRF, glucagon, GLP–1, and other members of their new family of G protein–linked receptors: structure–function relationship with special reference to the human VIP–1 receptor. Laburthe M, et al. **Ann N Y Acad Sci** 1996 Dec 26; 805:94–109; discussion 110–1 (64 ref.)
Transduction is a major factor influencing receptor characterization. Spedding M, et al. **Ann N Y Acad Sci** 1997 May 30;812:29–40 (49 ref.)
Virus–host interactions in African swine fever: the attachment to cellular receptors. Angulo A, et al. **Arch Virol Suppl** 1993;7:169–83 (48 ref.)
Aging of the vascular wall and atherogenesis: role of the elastin–laminin receptor [published erratum appears in Atherosclerosis 1996 Sep 27;126(1):173] Robert L. **Atherosclerosis** 1996 Jun;123(1–2):169–79 (56 ref.)
Regulatory mechanisms that modulate signalling by G–protein–coupled receptors. Böhm SK, et al. **Biochem J** 1997 Feb 15;322 (Pt 1):1–18 (237 ref.)
Nuclear hormone receptors and the Drosophila ecdysone response. Russell SR. **Biochem Soc Symp** 1996;62:111–21 (56 ref.)
cAMP and 'death signals' in a myeloid leukaemia cell: from membrane receptors to nuclear responses: a review. Ruchaud S, et al. **Biochem Soc Trans** 1997 May;25(2):410–5 (56 ref.)
Biological roles of the non–integrin elastin/laminin receptor. Hinek A. **Biol Chem** 1996 Jul–Aug;377(7–8):471–80 (76 ref.)
From malaria to chemokine receptor: the emerging physiologic role of the Duffy blood group antigen. Hadley TJ, et al. **Blood** 1997 May 1;89(9):3077–91 (129 ref.)
Bone morphogenetic protein receptors. Yamashita H, et al. **Bone** 1996 Dec;19(6):569–74 (52 ref.)
Receptor localization in the mammalian dorsal horn and primary afferent neurons. Coggeshall RE, et al. **Brain Res Brain Res Rev** 1997 Jun;24(1):28–66 (341 ref.)
Metalloprotease–disintegrins: links to cell adhesion and cleavage of TNF alpha and Notch. Blobel CP. **Cell** 1997 Aug 22;90(4):589–92 (17 ref.)
The emerging field of receptor–mediated inhibitory signaling: SHP or SHIP? Scharenberg AM, et al. **Cell** 1996 Dec 13; 87(6):961–4 (16 ref.)
Regulation and role of urokinase plasminogen activator in vascular remodelling. Tkachuk V, et al. **Clin Exp Pharmacol Physiol** 1996 Sep;23(9):759–65 (75 ref.)
Visualizing signal transduction: receptors, G–proteins, and adenylate cyclases [published erratum appears in Clin Sci (Colch) 1997 Feb;92(2):223] Dessauer CW, et al. **Clin Sci (Colch)** 1996 Nov;91(5):527–37 (56 ref.)

RECEPTORS, CELL SURFACE

Targeted delivery of peptides, proteins, and genes by receptor-mediated endocytosis. Kato Y, et al. **Crit Rev Ther Drug Carrier Syst** 1997;14(3):287–331 (156 ref.)

Axon guidance: netrin receptors are revealed. Guthrie S. **Curr Biol** 1997 Jan 1;7(1):R6–9 (19 ref.)

Receptor function at the junction. Cell–cell communication. Lambie EJ. **Curr Biol** 1996 Sep 1;6(9):1089–91 (16 ref.)

Linking cargo to vesicle formation: receptor tail interactions with coat proteins. Kirchhausen T, et al. **Curr Opin Cell Biol** 1997 Aug;9(4):488–95 (59 ref.)

New insights on the functions of the guanylyl cyclase receptors. Wedel BJ, et al. **FEBS Lett** 1997 Jun 23; 410(1):29–33 (32 ref.)

Membrane sex-steroid receptors in the brain. Ramirez VD, et al. **Front Neuroendocrinol** 1996 Oct;17(4):402–39 (200 ref.)

The HGF receptor family: unconventional signal transducers for invasive cell growth. Comoglio PM, et al. **Genes Cells** 1996 Apr;1(4):347–54 (70 ref.)

uPA, uPAR, PAI–1: key intersection of proteolytic, adhesive and chemotactic highways? Blasi F. **Immunol Today** 1997 Sep;18(9):415–7 (24 ref.)

The receptor mosaic hypothesis of the engram: possible relevance of Boolean network modeling. Zoli M, et al. **Int J Neural Syst** 1996 Sep;7(4):363–8 (40 ref.)

Ion channels and membrane receptors in follicle-enclosed Xenopus oocytes. Arellano RO, et al. **Ion Channels** 1996; 4:203–59 (130 ref.)

Role of the Ca(2+)-sensing receptor in divalent mineral ion homeostasis. Hebert SC, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):295–302 (73 ref.)

Regulation of gene expression by nuclear hormone receptors. Meier CA. **J Recept Signal Transduct Res** 1997 Jan–May; 17(1–3):319–35 (45 ref.)

Extracellular calcium-sensing receptor: implications for calcium and magnesium handling in the kidney. Hebert SC. **Kidney Int** 1996 Dec;50(6):2129–39 (97 ref.)

Mechanisms of action of sex steroid hormones: basic concepts and clinical correlations. Tuohimaa P, et al. **Maturitas** 1996 May;23 Suppl:S3–12 (75 ref.)

The role of Notch in lateral inhibition and cell fate specification [corrected and republished with original paging, article originally printed in Mol Cell Neurosci 1995 Aug;6(4):311–21] Chitnis AB. **Mol Cell Neurosci** 1995 Dec; 6(6):311–21 (73 ref.)

PDZs and receptor/channel clustering: rounding up the latest suspects [comment] Sheng M. **Neuron** 1996 Oct;17(4):575–8 (19 ref.) Comment on: Neuron 1996 Oct;17(4):759–67.

Cell surface adrenergic receptor stimulation modifies the endothelial response to SIRS. Systemic Inflammatory Response Syndrome. Tighe D, et al. **New Horiz** 1996 Nov; 4(4):426–42 (104 ref.)

Integrin receptors, the cytoskeleton, and glomerular cell function. Schnaper HW. **Pediatr Nephrol** 1996 Aug; 10(4):523–8 (11 ref.)

Notch signaling in development. Simpson P. **Perspect Dev Neurobiol** 1997;4(4):297–304 (67 ref.)

Diverse roles for the Notch receptor in the development of D. melanogaster. Young MW, et al. **Perspect Dev Neurobiol** 1997;4(4):345–55 (77 ref.)

Inhibitory receptors abound? [comment] Cambier JC. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):5993–5 (24 ref.) Comment on: Proc Natl Acad Sci U S A 1997 May 13;94(10):5261–6.

Cell-surface receptors for retroviruses and implications for gene transfer. Miller AD. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11407–13 (52 ref.)

The role of G-protein coupled receptor kinases in the regulation of muscarinic cholinergic receptors. Hosey MM, et al. **Prog Brain Res** 1996;109:169–79 (64 ref.)

Evolutionary significance of the hormone recognition capacity in unicellular organisms. Development of hormone receptors. Csaba G. **Prog Mol Subcell Biol** 1996; 17:1–28 (106 ref.)

Animal lectins as cell surface receptors: current status for invertebrate species. Vasta GR, et al. **Prog Mol Subcell Biol** 1996;17:158–82 (137 ref.)

Membrane receptors and hormones. Barbarino A, et al. **Q J Nucl Med** 1995 Dec;39(4 Suppl 1):78–82 (25 ref.)

The urokinase receptor and cell migration. Blasi F. **Semin Thromb Hemost** 1996;22(6):513–6 (36 ref.)

Pathophysiology of platelet thrombin receptors. Jamieson GA. **Thromb Haemost** 1997 Jul;78(1):242–6 (49 ref.)

Signaling through chemoattractant receptors in Dictyostelium. Chen MY, et al. **Trends Genet** 1996 Feb; 12(2):52–7 (43 ref.)

The role of anchoring protein RACK1 in PKC activation in the ageing rat brain. Battaini F, et al. **Trends Neurosci** 1997 Sep;20(9):410–5 (72 ref.)

Endocytosis and recycling of G protein–coupled receptors. Koenig JA, et al. **Trends Pharmacol Sci** 1997 Aug; 18(8):276–87 (59 ref.)

[Endocytosis and receptors: molecular and physiological aspects] Verroust PJ, et al. **Nephrologie** 1996;17(7):359–64 (49 ref.) (Eng. Abstr.) **(Fre)**

[Role of the Notch receptors in intercellular communication] Seugnet L, et al. **Pathol Biol (Paris)** 1996 Apr;44(4):282–6 (43 ref.) (Eng. Abstr.) **(Fre)**

[Cell membrane receptors and intracellular signalling. Characterization in cultivated, contractile and endothelial cells] Briner V. **Fortschr Med** 1996 Oct 20;114(29):384–6 (18 ref.) (Eng. Abstr.) **(Ger)**

[Development and experimental use of receptor-specific MR contrast media] Reimer P, et al. **Radiologe** 1996 Feb; 36(2):153–63 (77 ref.) (Eng. Abstr.) **(Ger)**

[An "orphan" receptor looks for its function] Enmark E, et al. **Lakartidningen** 1996 Oct 9;93(41):3585–9 (14 ref.) **(Swe)**

RECEPTORS, CGRP see **RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE**

RECEPTORS, CHOLECYSTOKININ

[Gastrin and gastrin receptor] Chiba T. **Nippon Rinsho** 1996 Apr;54(4):1083–6 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Cholecystokinin and cholecystokinin receptor] Funakoshi A. **Nippon Rinsho** 1996 Apr;54(4):1097–1103 (20 ref.) (Eng. Abstr.) **(Jpn)**

AGONISTS

Use of the chemical structure of peptides as the starting point to design nonpeptide agonists and antagonists at peptide receptors: examples with cholecystokinin and tachykinins. Horwell DC. **Bioorg Med Chem** 1996 Oct;4(10):1573–6 (24 ref.)

ANTAGONISTS & INHIBITORS

Use of the chemical structure of peptides as the starting point to design nonpeptide agonists and antagonists at peptide receptors: examples with cholecystokinin and tachykinins. Horwell DC. **Bioorg Med Chem** 1996 Oct;4(10):1573–6 (24 ref.)

'Targeted' molecular diversity: design and development of non-peptide antagonists for cholecystokinin and tachykinin receptors. Horwell D, et al. **Immunopharmacology** 1996 Jun; 33(1–3):68–72 (14 ref.)

Association of enkephalin catabolism inhibitors and CCK-B antagonists: a potential use in the management of pain and opioid addiction. Roques BP, et al. **Neurochem Res** 1996 Nov;21(11):1397–410 (116 ref.)

CCKB/gastrin receptor antagonists: recent advances and potential uses in gastric secretory disorders. Jensen RT. **Yale J Biol Med** 1996 May–Jun;69(3):245–59 (106 ref.)

DRUG EFFECTS

CCKB/gastrin receptor antagonists: recent advances and potential uses in gastric secretory disorders. Jensen RT. **Yale J Biol Med** 1996 May–Jun;69(3):245–59 (106 ref.)

GENETICS

[Cholecystokinin-B/gastrin receptor is a novel molecular probe for human small cell lung cancer] Matsumori Y, et al. **Nippon Rinsho** 1996 Feb;54(2):507–12 (14 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Biology of gut cholecystokinin and gastrin receptors. Shulkes A, et al. **Clin Exp Pharmacol Physiol** 1997 Mar–Apr; 24(3–4):209–16 (98 ref.)

Phosphorylation and desensitization of the pancreatic cholecystokinin-A receptor. Willems PH, et al. **Digestion** 1997;58 Suppl 2:75–80 (33 ref.)

PHYSIOLOGY

Gastrin and colon cancer: a unifying hypothesis. Joshi SN, et al. **Dig Dis** 1996 Nov–Dec;14(6):334–44 (78 ref.)

RECEPTORS, CHOLINERGIC

[Acetylcholine receptor] Ebihara T, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):275–84 (70 ref.) **(Jpn)**

GENETICS

Genetic manipulations of cholinergic communication reveal trans-acting control mechanisms over acetylcholine receptors. Broide RS, et al. **J Recept Signal Transduct Res** 1997 Jan–May; 17(1–3):279–91 (27 ref.)

IMMUNOLOGY

Heterogeneity and immunotherapy of specific T-cells in myasthenia gravis. Bond A, et al. **Biochem Soc Trans** 1997 May;25(2):665–70 (44 ref.)

Myasthenia gravis. Somnier FE. **Dan Med Bull** 1996 Feb; 43(1):1–10 (126 ref.)

[Receptor function and monoclonal antibody] Ueno S. **Nippon Rinsho** 1997 Apr;55 Suppl 2:457–62 (15 ref.) **(Jpn)**

METABOLISM

Nuclear magnetic resonance (NMR) analysis of ligand receptor interactions: the cholinergic system--a model. Fraenkel Y, et al. **Crit Rev Biochem Mol Biol** 1996; 31(4):273–301 (149 ref.)

The hair cell acetylcholine receptors: a synthesis. Guth PS, et al. **Hear Res** 1996 Sep 1;98(1–2):1–8 (68 ref.)

Antiadrenergic and muscarinic receptor antibodies in Chagas' cardiomyopathy. Borda ES, et al. **Int J Cardiol** 1996 May; 54(2):149–56 (38 ref.)

Phospholipid metabolism in Alzheimer's disease and in a human cholinergic cell. Kanfer JN, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):361–3 (7 ref.)

Neuromuscular blockade: offset anomalies. Are they simply potency-related receptor bonding effects? Midgley JM, et al. **J Pharm Pharmacol** 1997 Apr;49(4):416–20 (42 ref.)

PHYSIOLOGY

The pharmacology of (–)-nicotine and novel cholinergic channel modulators. Brioni JD, et al. **Adv Pharmacol** 1997; 37:153–214 (298 ref.)

Human placental cholinergic system. Sastry BV. **Biochem Pharmacol** 1997 Jun 1;53(11):1577–86 (116 ref.)

Manipulation of the cholinergic system. Geroldi C, et al. **Funct Neurol** 1997 May–Aug;12(3–4):187–91 (23 ref.)

Intercellular communication that mediates formation of the neuromuscular junction. Daniels MP. **Mol Neurobiol** 1997 Jun;14(3):143–70 (225 ref.)

The acetylcholine receptor ligand-gated channel as a molecular target of disease and therapeutic agents. Barrantes FJ. **Neurochem Res** 1997 Apr;22(4):391–400 (68 ref.)

The Otto Loewi Lecture. Loewi's discovery and the XXI century. Karczmar AG. **Prog Brain Res** 1996;109:1–27, xvii (108 ref.)

Immunolesion by 192IgG-saporin of rat basal forebrain cholinergic system: a useful tool to produce cortical cholinergic dysfunction. Schliebs R, et al. **Prog Brain Res** 1996;109:253–64 (57 ref.)

[The cholinergic system of the striatum: its participation in the motor and sensory components of motor behavior] Shapovalova KB. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 Mar–Apr;47(2):393–411 (50 ref.) (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

[Current concepts of the neuromorphology and neurochemistry of the striatal cholinergic system and its role in regulating movement] Shapovalova KB. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jul–Aug; 46(4):656–73 (145 ref.) (Eng. Abstr.) **(Rus)**

RECEPTORS, CHORIONIC GONADOTROPIN see **RECEPTORS, LH**

RECEPTORS, COLONY-STIMULATING FACTOR

ANTAGONISTS & INHIBITORS

Suppression or overexpression of genes encoding myeloid growth factors or their receptors. Metcalf D. **Hematol Cell Ther** 1997 Apr;39(2):98–101 (26 ref.)

BLOOD

Differential expression of receptors for hemopoietic growth factors on subsets of CD34+ hemopoietic cells. Wognum AW, et al. **Leuk Lymphoma** 1996 Dec;24(1–2):11–25 (92 ref.)

GENETICS

Suppression or overexpression of genes encoding myeloid growth factors or their receptors. Metcalf D. **Hematol Cell Ther** 1997 Apr;39(2):98–101 (26 ref.)

Transcriptional control of the expression of the c-fms gene encoding the receptor for macrophage colony-stimulating factor (CSF-1). Yue X, et al. **Immunobiology** 1996 Oct; 195(4–5):461–76 (59 ref.)

Molecular understanding of hematopoietin/cytokine receptor signaling defects in hematopoietic disorders. Soede-Bobok AA, et al. **J Mol Med** 1997 Jul;75(7):470–7 (80 ref.)

PHYSIOLOGY

Receptors for hematopoietic regulatory cytokines: overview of structure and function. Gullberg U, et al. **Cancer Treat Res** 1995;80:1–24 (118 ref.)

Selection versus instruction? **Ciba Found Symp** 1997;204:33–9 (4 ref.)

Test tube data and in vivo realities. **Ciba Found Symp** 1997; 204:88–93 (5 ref.)

RECEPTORS, COMPLEMENT

PHYSIOLOGY

Positive and negative signal co-operativity in the immune system: the BCR, Fc gamma RIIB, CR2 paradigm. Cambier JC. **Biochem Soc Trans** 1997 May;25(2):441–5 (21 ref.)

RECEPTORS, COMPLEMENT 3D

IMMUNOLOGY

Pairs of surface molecules involved in human IgE regulation: CD23–CD21 and CD40–CD40L. Bonnefoy JY, et al. **Eur Respir J Suppl** 1996 Aug;22:63s–66s (48 ref.)

The CD19–CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity.

Tedder TF, et al. **Immunity** 1997 Feb;6(2):107–18 (94 ref.)
Membrane and soluble forms of CD21 (the C3dg/EBV receptor). Frémeaux-Bacchi V, et al. **Immunol Lett** 1996 Dec;54(2–3):201–4 (25 ref.)

PHYSIOLOGY

Complement: instructing the acquired immune system through the CD21/CD19 complex. Dempsey PW, et al. **Res Immunol** 1996 Feb;147(2):71–5; discussion 119–20 (34 ref.)

RECEPTORS, CORTICOSTEROID see **RECEPTORS, STEROID**

RECEPTORS, CORTICOTROPIN

Melanocortin receptors: identification and characterization by melanotropic peptide agonists and antagonists. Hadley ME, et al. **Pigment Cell Res** 1996 Oct;9(5):213–34 (117 ref.)
[ACTH receptor] Hiroi N, et al. **Nippon Rinsho** 1997 Apr; 55 Suppl 2:476–9 (17 ref.) **(Jpn)**

GENETICS

Expression of the mouse ACTH receptor gene and characterisation of its promoter. Clark AJ, et al. **Endocr Res** 1996 Nov;22(4):333–5 (3 ref.)
Adrenocorticotropin receptor and adrenal disorders. Allolio B, et al. **Horm Res** 1997;47(4–6):273–8 (42 ref.)
Homologous pigmentation mutations in human, mouse and other model organisms. Jackson IJ. **Hum Mol Genet** 1997; 6(10):1613–24 (122 ref.)
Familial glucocorticoid deficiency: one syndrome, but more than one gene. Clark AJ, et al. **J Mol Med** 1997 Jun; 75(6):394–9 (17 ref.)

PHYSIOLOGY

Obesity, diabetes and functions for proopiomelanocortin-derived peptides. Mountjoy KG, et al. **Mol Cell Endocrinol** 1997 Apr 4;128(1–2):171–7 (51 ref.)
Receptor biology of the melanocortins, a family of neuroimmunomodulatory peptides. Tatro JB. **Neuroimmunomodulation** 1996 Sep–Oct;3(5):259–84 (224 ref.)

RECEPTORS, CORTICOTROPIN-RELEASING HORMONE

[CRH receptor: evaluation of the receptor functions] Horiba N, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:472–5 (10 ref.) **(Jpn)**

DRUG EFFECTS

Corticotrophin-releasing factor receptors: from molecular biology to drug design. Chalmers DT, et al. **Trends Pharmacol Sci** 1996 Apr;17(4):166–72 (46 ref.)

METABOLISM

Corticotropin-releasing factor (CRF) and endocrine responses to stress: CRF receptors, binding protein, and related peptides. Turnbull AV, et al. **Proc Soc Exp Biol Med** 1997 May;215(1):1–10 (114 ref.)
Corticotrophin-releasing factor receptors: from molecular biology to drug design. Chalmers DT, et al. **Trends Pharmacol Sci** 1996 Apr;17(4):166–72 (46 ref.)

PHYSIOLOGY

Corticotropin-releasing factor receptors: an overview. Dieterich KD, et al. **Exp Clin Endocrinol Diabetes** 1997; 105(2):65–82 (210 ref.)
Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein: implications for the treatment of CNS disorders [see comments] Behan DP, et al. **Mol Psychiatry** 1996 Sep;1(4):265–77 (113 ref.) Comment in: Mol Psychiatry 1996 Sep;1(4):300–1.
Corticotropin-releasing factor receptors: physiology, pharmacology, biochemistry and role in central nervous system and immune disorders. De Souza EB. **Psychoneuroendocrinology** 1995;20(8):789–819 (144 ref.)

RECEPTORS, CR2 see **RECEPTORS, COMPLEMENT 3D**

RECEPTORS, CRH see **RECEPTORS, CORTICOTROPIN-RELEASING HORMONE**

RECEPTORS, CYCLIC AMP

see related
CYCLIC AMP-DEPENDENT PROTEIN KINASES
CYCLIC AMP RECEPTOR PROTEIN

RECEPTORS, CYTOKINE

Chemokines and HIV–1 second receptors. Confluence of two fields generates optimism in AIDS research. D'Souza MP, et al. **Nat Med** 1996 Dec;2(12):1293–300 (79 ref.)
[Chemokines and HIV–1 second receptors] Murakami T, et al. **Tanpakushitsu Kakusan Koso** 1997 Jul;42(9):1427–34 (35 ref.) **(Jpn)**

BIOSYNTHESIS

Regulation of cytokine and cytokine receptor expression by glucocorticoids. Almawi WY, et al. **J Leukoc Biol** 1996 Nov;60(5):563–72 (166 ref.)
MCP-1 and CCR2 in HIV infection: regulation of agonist and receptor expression. Sozzani S, et al. **J Leukoc Biol** 1997 Jul;62(1):30–3 (23 ref.)

CHEMISTRY

Chemokine receptors: structure, function and role in microbial pathogenesis. Murphy PM. **Cytokine Growth Factor Rev** 1996 Jun;7(1):47–64 (174 ref.)

GENETICS

Activating mutations in cytokine receptors: implications for receptor function and role in disease. Gonda TJ, et al. **Blood** 1997 Jan 15;89(2):355–69 (138 ref.)
Regulation of autocrine motility factor receptor expression in tumor cell locomotion and metastasis. Silletti S, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 2):137–69 (153 ref.)
Host genes and HIV: the role of the chemokine receptor gene CCR5 and its allele. McNicholl JM, et al. **Emerg Infect Dis** 1997 Jul–Sep;3(3):261–71 (62 ref.)
Molecular understanding of hematopoietin/cytokine receptor signaling defects in hematopoietic disorders. Soede-Bobok AA, et al. **J Mol Med** 1997 Jul;75(7):470–7 (80 ref.)
[Effects of in vivo instillation of genes coding for cytokines on pulmonary fibrosis] Hayashi S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:190–4 (19 ref.) (Eng. Abstr.) **(Jpn)**
[Analysis of self-renewal mechanism of hematopoietic stem cells using transgenic mice expressing cytokine receptors] Takagi M, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1297–305 (27 ref.) **(Jpn)**

IMMUNOLOGY

Common cytokine receptor gamma chain (gamma c)-dependent cytokines: understanding in vivo functions by gene targeting. Di Santo JP, et al. **Immunol Rev** 1995 Dec;148:19–34 (60 ref.)
Role of the common cytokine receptor gamma chain in cytokine signaling and lymphoid development. Leonard WJ, et al. **Immunol Rev** 1995 Dec;148:97–114 (77 ref.)
Chemokine receptors: gateways to inflammation and infection. Premack BA, et al. **Nat Med** 1996 Nov; 2(11):1174–8 (39 ref.)

METABOLISM

Hematopoietic receptor complexes. Wells JA, et al. **Annu Rev Biochem** 1996;65:609–34 (103 ref.)
The structural and functional basis of cytokine receptor activation: lessons from the common beta subunit of the granulocyte–macrophage colony-stimulating factor, interleukin-3 (IL-3), and IL-5 receptors. Bagley CJ, et al. **Blood** 1997 Mar 1;89(5):1471–82 (87 ref.)
The role of serine/threonine phosphorylation in hematopoietic cytokine receptor signal transduction. Mufson RA. **FASEB J** 1997 Jan;11(1):37–44 (56 ref.)
Leptin: genes, concepts and clinical perspective. Considine RV, et al. **Horm Res** 1996;46(6):249–56 (70 ref.)
Soluble receptors for cytokines and growth factors. Müller-Newen G, et al. **Int Arch Allergy Immunol** 1996 Oct;111(2):99–106 (58 ref.)
Characteristic distribution of circulating autoantibodies against G-protein coupled cardiovascular receptors in patients with idiopathic dilated and hypertrophic cardiomyopathy. Matsui S, et al. **Int J Cardiol** 1996 May; 54(2):143–7 (28 ref.)
Coreceptors: implications for HIV pathogenesis and therapy. Moore JP. **Science** 1997 Apr 4;276(5309):51–2 (19 ref.)
Chemokines and HIV: a remarkable synergism. Moser B. **Trends Microbiol** 1997 Mar;5(3):88–90 (33 ref.)

PHYSIOLOGY

Soluble cytokine receptors: their roles in immunoregulation, disease, and therapy. Fernandez-Botran R, et al. **Adv Immunol** 1996;63:269–336 (325 ref.)
HIV type 1 coreceptors, neutralization serotypes, and vaccine development. Moore J, et al. **AIDS Res Hum Retroviruses** 1997 Jun 10;13(9):733–6 (35 ref.)
Cytokine receptor signal transduction and the control of hematopoietic cell development. Watowich SS, et al. **Ann Rev Cell Dev Biol** 1996;12:91–128 (280 ref.)
The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. Sugamura K, et al. **Annu Rev Immunol** 1996;14:179–205 (120 ref.)
Cytokine receptor signal transduction through Jak tyrosine kinases and Stat transcription factors. Silvennoinen O, et al. **APMIS** 1997 Jul;105(7):497–509 (67 ref.)
Chemokine receptors – the new frontier for AIDS research. Wells TN, et al. **Chem Biol** 1996 Aug;3(8):603–9 (35 ref.)
Roles of the JAK–STAT system in signal transduction via cytokine receptors. Watanabe S, et al. **Curr Opin Genet Dev** 1996 Oct;6(5):587–96 (54 ref.)
Trans-signaling by cytokine and growth factor receptors. Castellino AM, et al. **Cytokine Growth Factor Rev** 1996 Dec;7(4):297–302 (56 ref.)
Cardiotrophin-1: a multifunctional cytokine that signals via LIF receptor-gp 130 dependent pathways. Pennica D, et al. **Cytokine Growth Factor Rev** 1996 Jun;7(1):81–91 (63 ref.)
Chemokine–leukocyte interactions. The voodoo that they do so well. Taub DD. **Cytokine Growth Factor Rev** 1996 Dec; 7(4):355–76 (162 ref.)
Chemokine receptors as fusion cofactors for human immunodeficiency virus type 1 (HIV–1). Doranz BJ, et al. **Immunol Res** 1997 Feb;16(1):15–28 (79 ref.)
Soluble receptors for cytokines and growth factors. Müller-Newen G, et al. **Int Arch Allergy Immunol** 1996 Oct;111(2):99–106 (58 ref.)
The leptin receptor. Tartaglia LA. **J Biol Chem** 1997 Mar 7;272(10):6093–6 (59 ref.)
Roles of gp130 signaling pathways in cardiac myocytes: recent advances and implications for cardiovascular disease. Yamauchi-Takihara K, et al. **J Card Fail** 1996 Dec; 2(4 Suppl):S63–8 (44 ref.)
Disruption of cytokine signaling in lymphoid development: unique contributions of the common cytokine gamma chain and the Jak3 kinase. Eynon EE, et al. **J Interferon Cytokine Res** 1996 Sep;16(9):677–84 (32 ref.)
Chemokine receptors and HIV. Broder CC, et al. **J Leukoc Biol** 1997 Jul;62(1):20–9 (84 ref.)
Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency. Johnston JA, et al. **J Leukoc Biol** 1996 Oct;60(4):441–52 (153 ref.)
Cytokine regulation: an overview. Miyajima A. **Leukemia** 1997 Apr;11 Suppl 3:413–5 (5 ref.)
Host factors and the pathogenesis of HIV-induced disease. Fauci AS. **Nature** 1996 Dec 12;384(6609):529–34 (113 ref.)
Neuropsychiatric aspects of cytokines research: an overview. Malek-Ahmadi P. **Neurosci Biobehav Rev** 1996 Autumn; 20(3):359–65 (89 ref.)
Cytokines which signal through the LIF receptor and their actions in the nervous system. Murphy M, et al. **Prog Neurobiol** 1997 Aug;52(5):355–78 (196 ref.)
Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry. Doms RW, et al. **Virology** 1997 Sep 1;235(2):179–90 (108 ref.)
[Cytokine network in the brain] Sawada M. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):504–11 (49 ref.) **(Jpn)**
[Biology of thrombopoietin and its receptors] Robak T. **Postepy Hig Med Dosw** 1996;50(6):649–63 (57 ref.) (Eng. Abstr.) **(Pol)**

RECEPTORS, CYTOPLASMIC AND NUCLEAR

see related
TRANSCRIPTION FACTORS

Structure and function of inositol 1,4,5–trisphosphate receptor. Yoshida Y, et al. **Jpn J Pharmacol** 1997 Jun; 74(2):125–37 (119 ref.)
Nuclear receptor coactivators and corepressors. Horwitz KB, et al. **Mol Endocrinol** 1996 Oct;10(10):1167–77 (87 ref.)
[Adipocyte differentiation and nuclear receptor] Hirose T, et al. **Nippon Rinsho** 1997 Jun;55(6):1596–604 (30 ref.) (Eng. Abstr.) **(Jpn)**
[Inositol 1,4,5–trisphosphate receptor (IP3 receptor)] Mikoshiba K. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):224–9 (33 ref.) **(Jpn)**
[Signal transduction of steroids and vitamins mediated by nuclear receptor proteins] Umesono K. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1265–72 (37 ref.) **(Jpn)**

CHEMISTRY

Structure and function of inositol 1,4,5–trisphosphate receptor. Mikoshiba K, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:178–97 (65 ref.)
Transcriptional control: how nuclear receptors get turned on. Schwabe JW. **Curr Biol** 1996 Apr 1;6(4):372–4 (13 ref.)

CLASSIFICATION

Orphan nuclear receptors—the first eight years. Enmark E, et al. **Mol Endocrinol** 1996 Nov;10(11):1293–307 (155 ref.)

DRUG EFFECTS

Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects. Auwerx J, et al. **J Atheroscler Thromb** 1996;3(2):81–9 (71 ref.)

GENETICS

Role of the peroxisome proliferator-activated receptor in cytochrome P450 4A gene regulation. Johnson EF, et al. **FASEB J** 1996 Sep;10(11):1241–8 (67 ref.)

METABOLISM

The role of the hsp90-based chaperone system in signal transduction by nuclear receptors and receptors signaling via MAP kinase. Pratt WB. **Annu Rev Pharmacol Toxicol** 1997;37:297–326 (183 ref.)
Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C–III genes by activating the nuclear receptor PPAR.

Auwerx J, et al. **Atherosclerosis** 1996 Jul;124 Suppl:S29–37 (59 ref.)
Melatonin receptors in the mammalian suprachiasmatic nucleus. Dubocovich ML, et al. **Behav Brain Res** 1996; 73(1–2):141–7 (79 ref.)
Binding and translocation of glucokinase in hepatocytes. Agius L, et al. **Biochem Soc Trans** 1997 Feb;25(1):145–50 (28 ref.)
TIF1 alpha: a chromatin-specific mediator for the ligand-dependent activation function AF-2 of nuclear receptors? Le Douarin B, et al. **Biochem Soc Trans** 1997 May;25(2):605–12 (39 ref.)
Type 3 inositol 1,4,5-trisphosphate receptor and capacitative calcium entry. Putney JW Jr. **Cell Calcium** 1997 Mar; 21(3):257–61 (41 ref.)
Nuclear hormone receptors: ligand-activated regulators of transcription and diverse cell responses. Katzenellenbogen JA, et al. **Chem Biol** 1996 Jul;3(7):529–36 (52 ref.)
Interrelationships between nuclear structure and ligand-activated intracellular receptors. Ruh MF, et al. **Crit Rev Eukaryot Gene Expr** 1996;6(2–3):271–83 (105 ref.)
Inositol 1,4,5-trisphosphate receptors and calcium signaling. Michikawa T, et al. **Crit Rev Neurobiol** 1996;10(1):39–55 (117 ref.)
Transcriptional control: how nuclear receptors get turned on. Schwabe JW. **Curr Biol** 1996 Apr 1;6(4):372–4 (13 ref.)
Nuclear receptor coactivators. Glass CK, et al. **Curr Opin Cell Biol** 1997 Apr;9(2):222–32 (50 ref.)
Peroxisome proliferator-activated receptor gamma and the control of adipogenesis. Brun RP, et al. **Curr Opin Lipidol** 1997 Aug;8(4):212–8 (55 ref.)
Control of the differentiation commitment by nuclear hormone receptors in chicken erythrocytic progenitor cells. Samarut J. **Curr Top Microbiol Immunol** 1996;212:163–73 (35 ref.)
Ligand-dependent interaction of nuclear receptors with potential transcriptional intermediary factors (mediators). Le Douarin B, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Apr 29; 351(1339):569–78 (45 ref.)
Melatonin receptors step into the light: cloning and classification of subtypes. Reppert SM, et al. **Trends Pharmacol Sci** 1996 Mar;17(3):100–2 (20 ref.)

PHYSIOLOGY

Effects of tryptophan related compounds on nuclear regulatory control. Possible role in the eosinophilia-myalgia syndrome. Sidransky H, et al. **Adv Exp Med Biol** 1996;398:343–50 (47 ref.)
The peroxisome proliferator-activated receptors: ligands and activators. Forman BM, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:266–75 (42 ref.)
Structure and function of inositol 1,4,5-trisphosphate receptor. Mikoshiba K, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:178–97 (65 ref.)
Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Lemberger T, et al. **Ann Rev Cell Dev Biol** 1996;12:335–63 (116 ref.)
Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators of lipid metabolism. Latruffe N, et al. **Biochimie** 1997 Feb-Mar; 79(2–3):81–94 (162 ref.)
PPAR gamma and the control of adipogenesis. Spiegelman BM, et al. **Biochimie** 1997 Feb-Mar;79(2–3):111–2 (4 ref.)
The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs). Staels B, et al. **Biochimie** 1997 Feb-Mar;79(2–3):95–9 (39 ref.)
The function of inositol high polyphosphate binding proteins. Fukuda M, et al. **Bioessays** 1997 Jul;19(7):593–603 (85 ref.)
Dueling orphans--interacting nuclear receptors coordinate Drosophila metamorphosis. Thummel CS. **Bioessays** 1997 Aug;19(8):669–72 (26 ref.)
Nuclear receptors in Sicily: all in the famiglia. Perlmann T, et al. **Cell** 1997 Aug 8;90(3):391–7 (31 ref.)
Protein secretion: puzzling receptors. Thiele C, et al. **Curr Biol** 1997 Aug 1;7(8):R496–500 (25 ref.)
Lipid metabolism [editorial] Poisson JP. **Curr Opin Lipidol** 1997 Apr;8(2):U20–1 (5 ref.)
Peroxisome proliferator-activated receptors, orphans with ligands and functions. Schoonjans K, et al. **Curr Opin Lipidol** 1997 Jun;8(3):159–66 (101 ref.)
Nuclear hormone receptors inhibit matrix metalloproteinase (MMP) gene expression through diverse mechanisms. Schroen DJ, et al. **Gene Expr** 1996;6(4):197–207 (95 ref.)
Multilayered control of intracellular receptor function. Yamamoto KR. **Harvey Lect** 1995–96;91:1–19 (63 ref.)
Regulating adipogenesis. Mandrup S, et al. **J Biol Chem** 1997 Feb 28;272(9):5367–70 (56 ref.)
Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. Schoonjans K, et al. **J Lipid Res** 1996 May;37(5):907–25 (193 ref.)
Orphan nuclear receptors--the first eight years. Enmark E, et al. **Mol Endocrinol** 1996 Nov;10(11):1293–307 (155 ref.)
Adipocyte differentiation is regulated by a prostaglandin liganded to the nuclear peroxisome proliferator-activated receptor. Wolf G. **Nutr Rev** 1996 Sep;54(9):290–2 (9 ref.)

RECEPTORS, DELTA see **RECEPTORS, OPIOID, DELTA**

RECEPTORS, DELTA OPIOID see **RECEPTORS, OPIOID, DELTA**

RECEPTORS, DIAZEPAM see **RECEPTORS, GABA-A**

RECEPTORS, DIIODOTYROSINE see **RECEPTORS, THYROID HORMONE**

RECEPTORS, DIOXIN see **RECEPTORS, ARYL HYDROCARBON**

RECEPTORS, DOPAMINE

Molecular attributes of dopamine receptors: new potential for antipsychotic drug development. Hartman DS, et al. **Ann Med** 1996 Jun;28(3):211–9 (77 ref.)
[Adrenaline receptor and dopamine receptor] Kurose H. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):316–26 (42 ref.) **(Jpn)**

CHEMISTRY

Dopamine and serotonin receptors: amino acid sequences, and clinical role in neuroleptic parkinsonism. Seeman P, et al. **Jpn J Pharmacol** 1996 Jul;71(3):187–204 (140 ref.)

CLASSIFICATION

Current concepts in the molecular diversity and pharmacology of dopamine receptors. Kulkarni SK, et al. **Methods Find Exp Clin Pharmacol** 1996 Nov;18(9):599–613 (116 ref.)

DRUG EFFECTS

Ibogaine and cocaine abuse: pharmacological interactions at dopamine and serotonin receptors. Sershen H, et al. **Brain Res Bull** 1997;42(3):161–8 (77 ref.)
Antisense strategies in dopamine receptor pharmacology. Weiss B, et al. **Life Sci** 1997;60(7):433–55 (110 ref.)
Dopamine receptor diversity: molecular and pharmacological perspectives. Hartman DS, et al. **Prog Drug Res** 1997; 48:173–94 (126 ref.)
Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Kinon BJ, et al. **Psychopharmacology (Berl)** 1996 Mar;124(1–2):2–34 (517 ref.)

GENETICS

Utilising molecular biological and histopathological techniques to study the dopaminergic system in patients with melancholia. Hickie I, et al. **Aust N Z J Psychiatry** 1997 Feb;31(1):27–35 (36 ref.)

METABOLISM

Renal dopamine receptors: mechanisms of action and developmental aspects. Cheung PY, et al. **Cardiovasc Res** 1996 Jan;31(1):2–6 (54 ref.)
Light microscope autoradiography of peripheral dopamine receptor subtypes. Amenta F. **Clin Exp Hypertens** 1997 Jan-Feb;19(1–2):27–41 (30 ref.)
Comparative hypertensionology-renal dopaminergic activity in experimental hypertensive rats. Iimura O, et al. **Clin Exp Hypertens** 1997 Jan-Feb;19(1–2):117–30 (26 ref.)
Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease. Elsworth JD, et al. **Exp Neurol** 1997 Mar;144(1):4–9 (44 ref.)
The D3 receptor and its relevance in psychiatry. Schwartz JC, et al. **Int Clin Psychopharmacol** 1995 Sep;10 Suppl 3:15–20 (43 ref.)
Stress, depression and the mesolimbic dopamine system. Cabib S, et al. **Psychopharmacology (Berl)** 1996 Dec; 128(4):331–42 (100 ref.)

PHYSIOLOGY

Complexity of dopaminergic function in the retinal dark-light switch. Morgan IG, et al. **Aust N Z J Ophthalmol** 1996 May;24(2 Suppl):56–8 (13 ref.)
Transgenic mice to study the role of dopamine receptors in cardiovascular function. Jose PA, et al. **Clin Exp Hypertens** 1997 Jan-Feb;19(1–2):15–25 (61 ref.)
Renal and intestinal autocrine monoaminergic systems: dopamine versus 5-hydroxytryptamine. Vieira-Coelho MA, et al. **Clin Exp Hypertens** 1997 Jan-Feb;19(1–2):43–58 (22 ref.)
The use of dopamine in acute renal failure [letter] Harper L, et al. **Clin Nephrol** 1997 May;47(5):347–9 (29 ref.)
What we can learn from the selective manipulation of dopaminergic receptors about the pathogenesis and treatment of hypertension? Jose PA, et al. **Curr Opin Nephrol Hypertens** 1996 Sep;5(5):447–51 (62 ref.)
Ultrastructural view of central catecholaminergic transmission: immunocytochemical localization of synthesizing enzymes, transporters and receptors. Pickel VM, et al. **J Neurocytol** 1996 Dec;25(12):843–56 (141 ref.)
Limbic circuits and monoamine receptors: dissecting the effects of antipsychotics from disease processes. Joyce JN, et al. **J Psychiatr Res** 1997 Mar-Apr;31(2):197–217 (70 ref.)
Dopamine and serotonin receptors: amino acid sequences, and clinical role in neuroleptic parkinsonism. Seeman P, et al. **Jpn J Pharmacol** 1996 Jul;71(3):187–204 (140 ref.)
Current concepts in the molecular diversity and pharmacology of dopamine receptors. Kulkarni SK, et al. **Methods Find Exp Clin Pharmacol** 1996 Nov;18(9):599–613 (116 ref.)
Dopamine receptors and brain function. Jaber M, et al. **Neuropharmacology** 1996;35(11):1503–19 (205 ref.)
Functional and molecular differentiation of the dopamine system induced by neonatal denervation. Joyce JN, et al. **Neurosci Biobehav Rev** 1996 Autumn;20(3):453–86 (285 ref.)
[The central dopaminergic system and depression] Ebert D, et al. **Nervenarzt** 1997 Jul;68(7):545–55 (89 ref.) (Eng. Abstr.) **(Ger)**
[The renal dopaminergic system and arterial hypertension] Pestana M, et al. **Rev Port Cardiol** 1996 Dec;15(12):893–902 (66 ref.) **(Por)**
[The brain dopaminergic systems: receptor heterogeneity, functional role and pharmacological regulation] Raevskii KS, et al. **Usp Fiziol Nauk** 1996 Oct-Dec;27(4):3–29 (144 ref.) (Eng. Abstr.) **(Rus)**
[Dopamine receptor subtypes] Janković SM, et al. **Med Pregl** 1996;49(7–8):281–5 (40 ref.) (Eng. Abstr.) **(Scr)**

RECEPTORS, DOPAMINE D1

METABOLISM

Dopamine-1 receptor G-protein coupling and the involvement of phospholipase A2 in dopamine-1 receptor mediated cellular signaling mechanisms in the proximal tubules of SHR. Hussain T, et al. **Clin Exp Hypertens** 1997 Jan-Feb;19(1–2):131–40 (31 ref.)
The energetics of ligand binding at catecholamine receptors. Strange PG. **Trends Pharmacol Sci** 1996 Jul;17(7):238–44 (51 ref.)

PHYSIOLOGY

A phosphorylation cascade in the basal ganglia of the mammalian brain: regulation by the D-1 dopamine receptor. A mathematical model of known biochemical reactions. Kebabian JW. **J Neural Transm Suppl** 1997; 49:145–53 (14 ref.)
Role of dopamine receptors in the short- and long-term regulation of corticostriatal transmission. Calabresi P, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1997 Apr; 17(2):101–4 (25 ref.)
DA D2 receptors in the ventral striatum: multiple effects or receptor subtypes? White FJ, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1997 Apr; 17(2):91–5 (29 ref.)

RECEPTORS, DOPAMINE D2

AGONISTS

Electrophysiological pharmacology of the autoreceptor-mediated responses of dopaminergic cells to antiparkinsonian drugs. Mercuri NB, et al. **Trends Pharmacol Sci** 1997 Jul;18(7):232–5 (34 ref.)

ANALYSIS

[Striatal dopamine D2 receptor in Parkinson disease and its related disorders assessed by C-11 NMSP and PET] Momose T, et al. **Nippon Rinsho** 1997 Jan;55(1):227–32 (4 ref.) (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Domperidone as a tool to assess the role of dopamine within carotid body chemoreception. Zapata P, et al. **Adv Exp Med Biol** 1996;410:291–7 (36 ref.)
D4 receptors and their antagonists. Hadley MS. **Med Res Rev** 1996 Nov;16(6):507–26 (82 ref.)
Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist. Bristow LJ, et al. **Trends Pharmacol Sci** 1997 Jun;18(6):186–8 (11 ref.)

BIOSYNTHESIS

Dopamine in schizophrenia. Hietala J, et al. **Ann Med** 1996 Dec;28(6):557–61 (43 ref.)

DRUG EFFECTS

The importance of dopamine D4 receptors in the action and development of antipsychotic agents [published erratum appears in Drugs 1996 Mar;51(3):505] Reynolds GP. **Drugs** 1996 Jan;51(1):7–11 (35 ref.)
Amisulpride: from animal pharmacology to therapeutic action. Scatton B, et al. **Int Clin Psychopharmacol** 1997 May;12 Suppl 2:S29–36 (45 ref.)
Review the role of dopamine D4 receptors in schizophrenia and antipsychotic action. Sanyal S, et al. **J Psychiatr Res** 1997 Mar-Apr;31(2):219–32 (85 ref.)
Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Seeman P, et al. **Neuropsychopharmacology** 1997 Feb;16(2):93–110; discussion 111–35 (136 ref.)

GENETICS

Polymorphisms of the D2 dopamine receptor gene and alcoholism and other substance use disorders. Noble EP. **Alcohol Alcohol Suppl** 1994;2:35–43 (61 ref.)
Association study between bipolar disorder and candidate genes involved in dopamine-serotonin metabolism and

GABAergic neurotransmission: a preliminary report [letter] Oruč L, et al. **Psychiatr Genet** 1996 Winter;6(4):213–7 (40 ref.)

METABOLISM

The energetics of ligand binding at catecholamine receptors. Strange PG. **Trends Pharmacol Sci** 1996 Jul;17(7):238–44 (51 ref.)

[PET study of dopamine metabolism and dopamine D2 receptor in juvenile parkinsonism] Tanji H, et al. **Nippon Rinsho** 1997 Jan;55(1):89–94 (25 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Signal transduction pathways modulated by the D2 subfamily of dopamine receptors. Huff RM. **Cell Signal** 1996 Sep; 8(6):453–9 (91 ref.)

Dopamine D2 receptors in signal transduction and behavior. Picetti R, et al. **Crit Rev Neurobiol** 1997;11(2–3):121–42 (130 ref.)

Linking the family of D2 receptors to neuronal circuits in human brain: insights into schizophrenia. Joyce JN, et al. **Neuropsychopharmacology** 1997 Jun;16(6):375–84 (78 ref.)

The dopamine D4 receptor. Van Tol HH. **NIDA Res Monogr** 1996;161:20–38 (50 ref.)

Role of dopamine receptors in the short- and long-term regulation of corticostriatal transmission. Calabresi P, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1997 Apr; 17(2):101–4 (25 ref.)

Do D2-like dopamine receptors mediate neuronal excitation or inhibition: some functional-behavioural implications. Waddington JL. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1997 Apr; 17(2):111–2 (16 ref.)

DA D2 receptors in the ventral striatum: multiple effects or receptor subtypes? White FJ, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1997 Apr; 17(2):91–5 (29 ref.)

[Dopamine D2 and serotonin 5HT2 receptors: functions, interactions and clinical consequences in schizophrenia] Guise S, et al. **Encephale** 1997 Apr;23 Spec No 2:10–6 (20 ref.) (Eng. Abstr.) **(Fre)**

RECEPTORS, DRUG

Endogenous cannabinoid ligands—chemical and biological studies. Mechoulam R, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):45–9 (23 ref.)

Imidazoline receptors. Bousquet P. **Neurochem Int** 1997 Jan; 30(1):3–7 (68 ref.)

[Sulfonylurea receptor] Yamada Y, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:590–3 (6 ref.) **(Jpn)**

[Pharmacological studies on drug receptor mechanisms] Takayanagi I. **Yakugaku Zasshi** 1996 Jun;116(6):417–40 (77 ref.) (Eng. Abstr.) **(Jpn)**

AGONISTS

Pharmacology of moxonidine, an I1-imidazoline receptor agonist. Ziegler D, et al. **J Cardiovasc Pharmacol** 1996;27 Suppl 3:S26–37 (52 ref.)

Imidazoline receptor agonist drugs: a new approach to the treatment of systemic hypertension. Yu A, et al. **J Clin Pharmacol** 1996 Feb;36(2):98–111 (100 ref.)

Considerations in the treatment of insulin resistance and related disorders with a new sympatholytic agent. Lithell HO. **J Hypertens Suppl** 1997 Jan;15(1):S39–42 (30 ref.)

The use of moxonidine in the treatment of hypertension. Prichard BN, et al. **J Hypertens Suppl** 1997 Jan; 15(1):S47–55 (50 ref.)

The two-state model of agonist action: challenges to pharmacological receptor theory. Leff P. **Proc West Pharmacol Soc** 1996;39:67–8 (17 ref.)

ANTAGONISTS & INHIBITORS

Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration. Engler RL, et al. **Circulation** 1996 Nov 1;94(9):2297–301 (66 ref.)

BIOSYNTHESIS

Bioreactor cultivation of the nematode Caenorhabditis elegans: large scale production of biologically active drug receptors for pharmaceutical research. Gbewonyo K, et al. **Biotechnol Genet Eng Rev** 1997;14:37–49 (35 ref.)

CHEMISTRY

[Can drugs be designed on a computer?] Holzgrabe U. **Pharm Unserer Zeit** 1996 Nov;25(6):322–5 (17 ref.) **(Ger)**

DRUG EFFECTS

Current status of putative imidazoline (I1) receptors and renal mechanisms in relation to their antihypertensive therapeutic potential. Evans RG. **Clin Exp Pharmacol Physiol** 1996 Oct-Nov;23(10–11):845–54 (90 ref.)

Neurons and receptors in the rostroventrolateral medulla mediating the antihypertensive actions of drugs acting at imidazoline receptors. Reis DJ. **J Cardiovasc Pharmacol** 1996;27 Suppl 3:S11–18 (65 ref.)

Vanilloid receptors: new insights enhance potential as a therapeutic target. Szallasi A, et al. **Pain** 1996 Dec; 68(2–3):195–208 (172 ref.)

GENETICS

Cannabinoid receptor genes. Onaivi ES, et al. **Prog Neurobiol** 1996 Mar-Apr;48(4–5):275–305 (117 ref.)

METABOLISM

Current status of putative imidazoline (I1) receptors and renal mechanisms in relation to their antihypertensive therapeutic potential. Evans RG. **Clin Exp Pharmacol Physiol** 1996 Oct-Nov;23(10–11):845–54 (90 ref.)

N-arachidonoylethanolamine (anandamide), an endogenous cannabinoid receptor ligand, and related lipid molecules in the nervous tissues. Sugiura T, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):51–6 (20 ref.)

Euphorbium: modern research on its active principle, resiniferatoxin, revives an ancient medicine. Appendino G, et al. **Life Sci** 1997;60(10):681–96 (87 ref.)

Two-point kinetic experiments to quantify allosteric effects on radioligand dissociation [comment] Kostenis E, et al. **Trends Pharmacol Sci** 1996 Aug;17(8):280–3 (22 ref.) Comment on: Trends Pharmacol Sci 1996 Dec;17(12):443–4.

PHYSIOLOGY

Imidazoline binding sites and signal transduction pathways. Musgrave IF, et al. **Clin Exp Pharmacol Physiol** 1996 Oct-Nov;23(10–11):990–4 (35 ref.)

Molecular aspects of cannabinoid receptors. Matsuda LA. **Crit Rev Neurobiol** 1997;11(2–3):143–66 (154 ref.)

Receptors and medicinal chemistry: new methods and perspectives. Recanatini M. **Farmaco** 1996 Jan;51(1):5–12 (47 ref.)

Molecular neurobiology of the cannabinoid receptor. Abood ME, et al. **Int Rev Neurobiol** 1996;39:197–221 (97 ref.)

From alpha and beta to I1: an overview of sympathetic receptors involved in blood pressure control targets for drug treatment. van Zwieten PA. **J Cardiovasc Pharmacol** 1996;27 Suppl 3:S5–10 (36 ref.)

The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease. Ernsberger P, et al. **J Hypertens Suppl** 1997 Jan;15(1):S9–23 (102 ref.)

Inducible receptors. Donaldson LF, et al. **Trends Pharmacol Sci** 1997 May;18(5):171–81 (36 ref.)

[Development and experimental use of receptor-specific MR contrast media] Reimer P, et al. **Radiologe** 1996 Feb; 36(2):153–63 (77 ref.) (Eng. Abstr.) **(Ger)**

RECEPTORS, EICOSANOID

CHEMISTRY

[Molecular structures of eicosanoid receptors] Negishi M, et al. **Nippon Rinsho** 1996 Feb;54(2):423–8 (10 ref.) (Eng. Abstr.) **(Jpn)**

RECEPTORS, ENDOGENOUS SUBSTANCES see **RECEPTORS, CELL SURFACE**

RECEPTORS, ENDORPHIN see **RECEPTORS, OPIOID**

RECEPTORS, ENDOTHELIN

[Endothelin receptor] Tsujino M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:581–5 (10 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

The clinical potential of endothelin receptor antagonists in cardiovascular medicine. Ferro CJ, et al. **Drugs** 1996 Jan; 51(1):12–27 (188 ref.)

Effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist, and an endothelin receptor antagonist on renal afferent arteriolar structure. Skov K, et al. **Hypertension** 1996 Sep;28(3):464–71 (62 ref.)

Endothelin receptors: receptor classification, novel receptor antagonists, and potential therapeutic targets. Ohlstein EH, et al. **Med Res Rev** 1996 Jul;16(4):365–90 (155 ref.)

[Endothelial receptor antagonists] Bornkessel B. **Med Monatsschr Pharm** 1997 Jul;20(7):174–6 (3 ref.) **(Ger)**

CLASSIFICATION

Endothelin receptors: receptor classification, novel receptor antagonists, and potential therapeutic targets. Ohlstein EH, et al. **Med Res Rev** 1996 Jul;16(4):365–90 (155 ref.)

DRUG EFFECTS

[Blockade of endothelin receptors in cardiovascular diseases. A possible therapeutic alternative in the future] Pernow J, et al. **Lakartidningen** 1997 Mar 19;94(12):1069–73 (70 ref.) **(Swe)**

GENETICS

Expression and signal transduction pathways of endothelin receptors in neuroendocrine cells. Stojilkovic SS, et al. **Front Neuroendocrinol** 1996 Jul;17(3):327–69 (224 ref.)

Endothelin receptor-mediated signaling in hirschsprung disease. Chakravarti A. **Hum Mol Genet** 1996 Mar; 5(3):303–7 (36 ref.)

Mutations of the endothelin-B receptor and endothelin-3 genes in Hirschsprung's disease. Kusafuka T, et al. **Pediatr Surg Int** 1997;12(1):19–23 (38 ref.)

METABOLISM

Endothelin peptides. Hirata Y. **Curr Opin Nephrol Hypertens** 1996 Jan;5(1):12–5 (16 ref.)

Endothelin receptor-mediated signaling in hirschsprung disease. Chakravarti A. **Hum Mol Genet** 1996 Mar; 5(3):303–7 (36 ref.)

PHYSIOLOGY

The role of endothelin in the pathogenesis of atherosclerosis. Kowala MC. **Adv Pharmacol** 1997;37:299–318 (159 ref.)

Endothelin, vascular hypertrophy, and hypertension. Rosendorff C. **Cardiovasc Drugs Ther** 1997 Jan; 10(6):795–802 (80 ref.)

Endothelin receptors and gonadal function: an invited commentary [comment] Stojilkovic SS. **Eur J Endocrinol** 1996 Oct;135(4):391–3 (18 ref.) Comment on: Eur J Endocrinol 1996 Oct;135(4):449–54.

Expression and signal transduction pathways of endothelin receptors in neuroendocrine cells. Stojilkovic SS, et al. **Front Neuroendocrinol** 1996 Jul;17(3):327–69 (224 ref.)

The arterial wall: a new pharmacological and therapeutic target. Laurent S, et al. **Fundam Clin Pharmacol** 1996; 10(3):243–57 (95 ref.)

RECEPTORS, ENDOTHELIUM-DERIVED VASOCONSTRICTOR FACTOR see **RECEPTORS, ENDOTHELIN**

RECEPTORS, ENKEPHALIN see **RECEPTORS, OPIOID**

RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE

AGONISTS

Regulation and interactions of transforming growth factor-beta with cardiovascular cells: implications for development and disease. Saltis J, et al. **Clin Exp Pharmacol Physiol** 1996 Mar;23(3):193–200 (94 ref.)

ANTAGONISTS & INHIBITORS

Rational design for the development of epidermal growth factor receptor antagonists. van Zoelen EJ, et al. **Pathol Res Pract** 1996 Jul;192(7):761–7 (25 ref.)

[Recent advances in development of antitumor tyrosine kinase inhibitors] Uehara Y. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1536–40 (12 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R. Traxler P, et al. **J Pharm Belg** 1997 Mar-Apr; 52(2):88–96 (26 ref.)

DRUG EFFECTS

The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Rusch V, et al. **Cytokine Growth Factor Rev** 1996 Aug;7(2):133–41 (64 ref.)

Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R. Traxler P, et al. **J Pharm Belg** 1997 Mar-Apr; 52(2):88–96 (26 ref.)

GENETICS

The EGFR gene family in embryonic cell activities. Adamson ED, et al. **Curr Top Dev Biol** 1997;35:71–120 (321 ref.)

Combined immunocytochemistry and PRINS DNA synthesis for simultaneous detection of phenotypic and genomic parameters in cells. Speel EJ, et al. **Methods Mol Biol** 1997; 71:53–9 (15 ref.)

IMMUNOLOGY

Transforming growth factor-alpha (TGF-alpha) and epidermal growth factor-receptor (EGF-R) immunoreactivity in normal and pathologic brain. Ferrer I, et al. **Prog Neurobiol** 1996 Jun;49(2):99–123 (110 ref.)

METABOLISM

The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Rusch V, et al. **Cytokine Growth Factor Rev** 1996 Aug;7(2):133–41 (64 ref.)

The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. Alroy I, et al. **FEBS Lett** 1997 Jun 23;410(1):83–6 (47 ref.)

Principles of receptor-based inhibition of erbB family receptor kinases: prospects for new therapies for human cancers. O'Rourke DM, et al. **Proc Assoc Am Physicians** 1997 May;109(3):209–19 (78 ref.)

Not all Shc's roads lead to Ras. Bonfini L, et al.

Trends Biochem Sci 1996 Jul;21(7):257–61 (51 ref.)

PHYSIOLOGY

Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Kelloff GJ, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Aug;5(8):657–66 (108 ref.)

There must be 50 ways to rule the signal: the case of the Drosophila EGF receptor. Perrimon N, et al. **Cell** 1997 Apr 4;89(1):13–6 (18 ref.)

Use of transgenic mice to study autocrine–paracrine signaling in lung morphogenesis and differentiation. Whitsett JA, et al. **Clin Perinatol** 1996 Dec;23(4):753–69 (54 ref.)

Epidermal growth factor receptor family and chemosensitization [editorial; comment] Mendelsohn J, et al. **J Natl Cancer Inst** 1997 Mar 5;89(5):341–3 (45 ref.) Comment on: J Natl Cancer Inst 1997 Mar 5;89(5):365–73.

Insights into the physiology of TGF alpha and signaling through the EGF receptor revealed by gene targeting and acts of nature. Dunn AR, et al. **Princess Takamatsu Symp** 1994;24:276–89 (63 ref.)

A thousand and one roles for the Drosophila EGF receptor. Schweitzer R, et al. **Trends Genet** 1997 May;13(5):191–6 (56 ref.)

RECEPTORS, EPINEPHRINE see **RECEPTORS, ADRENERGIC**

RECEPTORS, ERYTHROPOIETIN

[Erythropoietin receptor] Komatsu N. **Nippon Rinsho** 1997 Apr;55 Suppl 2:508–11 (9 ref.) **(Jpn)**

[Role of c-jun in the inhibition of apoptosis through the erythropoietin receptor] Shimizu R, et al. **Rinsho Ketsueki** 1996 Jul;37(7):526–30 (5 ref.) **(Jpn)**

BIOSYNTHESIS

The erythropoietin receptor: biogenesis, dimerization, and intracellular signal transduction. Lodish HF, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:93–104 (59 ref.)

GENETICS

Erythropoietin receptor mutations and human disease. Gregg XT, et al. **Semin Hematol** 1997 Jan;34(1):70–6 (46 ref.)

PHYSIOLOGY

Eph receptor tyrosine kinases and their ligands in neural development. Friedman GC, et al. **Curr Opin Neurobiol** 1996 Feb;6(1):127–33 (72 ref.)

[Physiological and pathological roles of the truncated erythropoietin receptor] Nakamura Y, et al. **Rinsho Ketsueki** 1997 Mar;38(3):200–2 (5 ref.) **(Jpn)**

[Signal transduction of the erythropoietin receptor] Yoshimura A, et al. **Rinsho Ketsueki** 1997 Mar;38(3):196–9 (10 ref.) **(Jpn)**

RECEPTORS, ESTRADIOL

METABOLISM

Estradiol receptors and metastasis in human breast cancer. Görlich M, et al. **Folia Biol (Praha)** 1996;42(1–2):3–10 (65 ref.)

RECEPTORS, ESTROGEN

Estrogen and progesterone receptors in endometrial cancer. Clinicopathological correlations and prognostic significance. Nyholm HC. **APMIS Suppl** 1996;65:5–33 (186 ref.)

A new actor in the estrogen receptor drama—enter ER-beta [editorial] Katzenellenbogen BS, et al. **Endocrinology** 1997 Mar;138(3):861–2 (22 ref.)

[Examination of estrogen receptor and its significance] Onouchi T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:558–61 (10 ref.) **(Jpn)**

AGONISTS

The challenge posed by endocrine-disrupting chemicals. Ashby J, et al. **Environ Health Perspect** 1997 Feb; 105(2):164–9 (44 ref.)

Antagonistic and agonistic effects of tamoxifen: significance in human cancer. Gallo MA, et al. **Semin Oncol** 1997 Feb; 24(1 Suppl 1):S1–71–S1–80 (72 ref.)

ANALYSIS

The pelvic floor muscles: muscle thickness in healthy and urinary-incontinent women measured by perineal ultrasonography with reference to the effect of pelvic floor training. Estrogen receptor studies. Bernstein IT. **Neurourol Urodyn** 1997;16(4):237–75 (145 ref.)

Immunohistological detection of estrogen and progesterone receptors in multiple and well differentiated leiomyomatous lung tumors in women with uterine leiomyomas (so-called benign metastasizing leiomyomas). A report on 5 cases. Jautzke G, et al. **Pathol Res Pract** 1996 Mar;192(3):215–23 (77 ref.)

[A comparative study of hormone receptors in breast cancer with quantitative immunocytochemistry and biochemistry] Marcot I, et al. **Bull Cancer** 1997 Jun;84(6):613–8 (27 ref.) (Eng. Abstr.) **(Fre)**

[Current questions about estrogen receptor determination and hormone dependence (does estrogen receptor positivity equal estrogen dependence?)] Kahán Z. **Orv Hetil** 1996 Oct 20;137(42):2305–8 (35 ref.) (Eng. Abstr.) **(Hun)**

[Tamoxifen: modern drug therapy of estrogen-dependent breast tumors] Jovanović-Mićić D, et al. **Med Pregl** 1996; 49(7–8):287–90 (20 ref.) (Eng. Abstr.) **(Scr)**

ANTAGONISTS & INHIBITORS

Antagonistic and agonistic effects of tamoxifen: significance in human cancer. Gallo MA, et al. **Semin Oncol** 1997 Feb; 24(1 Suppl 1):S1–71–S1–80 (72 ref.)

CHEMISTRY

The estradiol pharmacophore: ligand structure–estrogen receptor binding affinity relationships and a model for the receptor binding site. Anstead GM, et al. **Steroids** 1997 Mar;62(3):268–303 (248 ref.)

DEFICIENCY

Oestrogen receptor deficiency: consequences for growth. Smith EP, et al. **Acta Paediatr Suppl** 1996 Oct;417:39–43; discussion 44 (52 ref.)

DRUG EFFECTS

Antiestrogen–estrogen receptor interactions. Parker MG. **Cancer Treat Res** 1996;83:213–24 (52 ref.)

Environmental endocrinology: hidden, but potent ways of activating the estrogen receptor. Heufelder AE, et al. **Eur J Endocrinol** 1996 Dec;135(6):653–4 (7 ref.)

Interaction of chemopreventive agents with hormone receptors. Wiseman H. **IARC Sci Publ** 1996;(139):159–64 (20 ref.)

The molecular pharmacology of ovarian steroid receptors. Vegeto E, et al. **Vitam Horm** 1996;52:99–128 (129 ref.)

GENETICS

Oestrogen receptor variants and mutations in human breast cancer. Murphy LC, et al. **Ann Med** 1997 Jun;29(3):221–34 (82 ref.)

Dimethyl formamide (DMFA) and ethylene glycol (EG) are estrogenic in rainbow trout. Ren L, et al. **Chem Biol Interact** 1996 Sep 27;102(1):63–7 (6 ref.)

Oestrogen receptor mutants and variants in breast cancer. Dowsett M, et al. **Eur J Cancer** 1997 Jul;33(8):1177–83 (67 ref.)

Estrogen receptor function as revealed by knockout studies: neuroendocrine and behavioral aspects. Rissman EF, et al. **Horm Behav** 1997 Jun;31(3):232–43 (90 ref.)

Occurrence of androgen and estrogen receptor mRNAs in the harderian gland: a comparative survey. Varriale B. **Microsc Res Tech** 1996 Jun 1;34(2):97–103 (33 ref.)

Prognostic factors and variant estrogen receptor RNAs in clinical breast cancer. Auchus RJ, et al. **Nucl Med Biol** 1994 Apr;21(3):449–54 (15 ref.)

METABOLISM

Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer. Lykkesfeldt AE. **Acta Oncol** 1996; 35 Suppl 5:9–14 (60 ref.)

Estrogen and progesterone receptors in the endometrium. Moutsatsou P, et al. **Ann N Y Acad Sci** 1997 Jun 17; 816:99–115 (70 ref.)

Sex hormones and the thymus in relation to thymocyte proliferation and maturation. Seiki K, et al. **Arch Histol Cytol** 1997 Mar;60(1):29–38 (25 ref.)

Cell-specific mechanisms of estrogen receptor in the pituitary gland. Demay F, et al. **Cell Biol Toxicol** 1996 Dec; 12(4–6):317–24 (45 ref.)

The estrogen receptor activity cycle: dependence on multiple protein-protein interactions. Lieberman BA. **Crit Rev Eukaryot Gene Expr** 1997;7(1–2):43–59 (147 ref.)

Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary. Geisler JP, et al. **Gynecol Oncol** 1996 Mar;60(3):424–7 (18 ref.)

Steroid hormone receptors and antineoplastic chemotherapy in human breast cancer. Görlich M, et al. **J Exp Clin Cancer Res** 1997 Mar;16(1):95–103 (59 ref.)

Estrogen receptor status of breast cancer: a marker of different stages of tumor or different entities of the disease? Zhu K, et al. **Med Hypotheses** 1997 Jul;49(1):69–75 (61 ref.)

Reliability of estrogen receptors in predicting response to antiestrogens. Valavaara R. **Oncology (Huntingt)** 1997 May; 11(5 Suppl 4):14–8 (49 ref.)

The estradiol pharmacophore: ligand structure–estrogen receptor binding affinity relationships and a model for the receptor binding site. Anstead GM, et al. **Steroids** 1997 Mar;62(3):268–303 (248 ref.)

PHYSIOLOGY

Oestrogen receptors and cardiovascular disease. Baysal K, et al. **Clin Exp Pharmacol Physiol** 1996 Jun–Jul; 23(6–7):537–48 (82 ref.)

The estrogen/neurotrophin connection during neural development: is co-localization of estrogen receptors with the neurotrophins and their receptors biologically relevant? Toran-Allerand CD. **Dev Neurosci** 1996;18(1–2):36–48 (105 ref.)

The novel estrogen receptor-beta subtype: potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens. Kuiper GG, et al. **FEBS Lett** 1997 Jun 23; 410(1):87–90 (32 ref.)

Synergism in estrogen-regulated gene expression. Arnold SF, et al. **Mol Cell Endocrinol** 1996 Oct 30;123(2):119–22 (14 ref.)

Analysis of the molecular pharmacology of estrogen receptor agonists and antagonists provides insights into the mechanism of action of estrogen in bone. McDonnell DP, et al. **Osteoporos Int** 1997;7 Suppl 1:S29–34 (43 ref.)

Steroid receptor specificity with reference to the estrogen receptor. Williams GH. **Osteoporos Int** 1997;7 Suppl 1:S35–9 (21 ref.)

RECEPTORS, EXCITATORY AMINO ACID see **RECEPTORS, GLUTAMATE**

RECEPTORS, FC

BIOSYNTHESIS

Complement in IgA immune-complex-induced neutrophil activation. Zhang W, et al. **Biochem Soc Trans** 1997 May; 25(2):462–6 (28 ref.)

Expression and function of Fc receptors in the thymus. Leclercq G, et al. **Crit Rev Immunol** 1995;15(3–4):215–33 (151 ref.)

CHEMISTRY

The polymeric immunoglobulin receptor: structure and synthesis. Kaetzel CS, et al. **Biochem Soc Trans** 1997 May; 25(2):475–80 (50 ref.)

Structure and function of human IgA Fc receptors (Fc alpha R). Morton HC, et al. **Crit Rev Immunol** 1996;16(4):423–40 (155 ref.)

GENETICS

The polymeric immunoglobulin receptor: structure and synthesis. Kaetzel CS, et al. **Biochem Soc Trans** 1997 May; 25(2):475–80 (50 ref.)

Fc receptors. Ravetch JV. **Curr Opin Immunol** 1997 Feb; 9(1):121–5 (52 ref.)

IMMUNOLOGY

Fc receptors. Ravetch JV. **Curr Opin Immunol** 1997 Feb; 9(1):121–5 (52 ref.)

Complement and Fc-receptors in regulation of the antibody response. Heyman B. **Immunol Lett** 1996 Dec;54(2–3):195–9 (68 ref.)

Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG [published erratum appears in Immunol Res 1997;16(2):215] Junghans RP. **Immunol Res** 1997 Feb; 16(1):29–57 (108 ref.)

Divergent signal transduction pathways and effects on natural killer cell functions induced by interaction of Fc receptors with physiologic ligands or antireceptor antibodies. Sulica A, et al. **Nat Immun** 1995;14(3):123–33 (58 ref.)

The structure and evolution of FcRn. Simister NE, et al. **Res Immunol** 1996 Jun;147(5):333–7; discussion 353 (38 ref.)

Role of complement and Fc receptors in the pathogenesis of HIV-1 infection. Montefiori DC. **Springer Semin Immunopathol** 1997;18(3):371–90 (176 ref.)

PHYSIOLOGY

Fc receptors and their interactions with immunoglobulins. Raghavan M, et al. **Ann Rev Cell Dev Biol** 1996;12:181–220 (158 ref.)

Fc receptor biology. Daëron M. **Annu Rev Immunol** 1997; 15:203–34 (198 ref.)

New functions of the MHC class I-related Fc receptor, FcRn. Simister NE, et al. **Biochem Soc Trans** 1997 May; 25(2):481–6 (70 ref.)

Immunomodulatory effect of immunoglobulins. Wolf HM, et al. **Clin Exp Rheumatol** 1996 May–Jun;14 Suppl 15:S17–25 (88 ref.)

Expression and function of Fc receptors in the thymus. Leclercq G, et al. **Crit Rev Immunol** 1995;15(3–4):215–33 (151 ref.)

Structure and function of human IgA Fc receptors (Fc alpha R). Morton HC, et al. **Crit Rev Immunol** 1996;16(4):423–40 (155 ref.)

Immunoreceptor tyrosine-based activation motif (ITAM), a unique module linking antigen and Fc receptors to their signaling cascades. Isakov N. **J Leukoc Biol** 1997 Jan; 61(1):6–16 (123 ref.)

[Immunoregulatory functions of Fc receptors] Takai T. **Seikagaku** 1997 Jun;69(6):394–409 (74 ref.) **(Jpn)**

[Subunits gamma and zeta of Fc receptors. Structure and function] Mikulska J. **Postepy Hig Med Dosw** 1996; 50(4):351–61 (50 ref.) (Eng. Abstr.) **(Pol)**

RECEPTORS, FC EPSILON see **RECEPTORS, IGE**

RECEPTORS, FC GAMMA see **RECEPTORS, IGG**

RECEPTORS, FGF see **RECEPTORS, FIBROBLAST GROWTH FACTOR**

RECEPTORS, FIBRINOGEN see **PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX**

RECEPTORS, FIBROBLAST GROWTH FACTOR

CHEMISTRY

Receptors for fibroblast growth factors. Coutts JC, et al. **Immunol Cell Biol** 1995 Dec;73(6):584–9 (64 ref.)

GENETICS

Skeletal disorders associated with fibroblast growth factor receptor mutations. De Moerlooze L, et al. **Curr Opin Genet Dev** 1997 Jun;7(3):378–85 (68 ref.)

Fibroblast growth factor receptor 3 and the human chondrodysplasias. Horton WA. **Curr Opin Pediatr** 1997 Aug;9(4):437–42 (49 ref.)

Short-limb skeletal dysplasias and craniosynostosis: what do they have in common? Cohen MM Jr. **Pediatr Radiol** 1997 May;27(5):442–6 (19 ref.)

Shared cell adhesion molecule (CAM) homology domains point to CAMs signalling via FGF receptors. Doherty P, et al. **Perspect Dev Neurobiol** 1996;4(2–3):157–68 (55 ref.)

Craniosynostosis and skeletal dysplasias: fibroblast growth factor receptor defects. Lewanda AF, et al. **Proc Assoc Am Physicians** 1996 Jan;108(1):19–24 (32 ref.)

FGFR activation in skeletal disorders: too much of a good thing. Webster MK, et al. **Trends Genet** 1997 May; 13(5):178–82 (57 ref.)

[Association of achondroplasia to a mutation in the transmembrane domain of fibroblastic growth factor receptor 3 (FGFR3)] Rousseau F, et al. **Ann Endocrinol (Paris)** 1996;57(3):151–2 (6 ref.) **(Fre)**

METABOLISM

Neural induction: do fibroblast growth factors strike a cord? Mason I. **Curr Biol** 1996 Jun 1;6(6):672–5 (12 ref.)

PHYSIOLOGY

Retrograde transport of acidic fibroblast growth factor as a part of the growth factor signaling. Więdłocha A. **Arch Immunol Ther Exp (Warsz)** 1996;44(4):201–7 (64 ref.)

Review: a role for the FGF receptor in the axonal growth response stimulated by cell adhesion molecules? Hall H, et al. **Cell Adhes Commun** 1996 Apr;3(6):441–50 (97 ref.)

Use of transgenic mice to study autocrine–paracrine signaling in lung morphogenesis and differentiation. Whitsett JA, et al. **Clin Perinatol** 1996 Dec;23(4):753–69 (54 ref.)

Functions of fibroblast growth factors in vertebrate development. Goldfarb M. **Cytokine Growth Factor Rev** 1996 Dec;7(4):311–25 (143 ref.)

Fibroblast growth factors, their receptors and receptor disorders. Gorlin RJ. **J Craniomaxillofac Surg** 1997 Apr; 25(2):69–79 (77 ref.)

CAM–FGF receptor interactions: a model for axonal growth. Doherty P, et al. **Mol Cell Neurosci** 1996;8(2–3):99–111 (77 ref.)

Shared cell adhesion molecule (CAM) homology domains point to CAMs signalling via FGF receptors. Doherty P, et al. **Perspect Dev Neurobiol** 1996;4(2–3):157–68 (55 ref.)

RECEPTORS, FIBRONECTIN

[Induction of apoptosis by fibronectin via its interaction with VLA5] Sugahara H. **Nippon Rinsho** 1996 Jul;54(7):1809–14 (16 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Fibronectin and fibronectin receptors in lung development. Roman J. **Exp Lung Res** 1997 Mar–Apr;23(2):147–59 (50 ref.)

PHYSIOLOGY

[The interaction between beta 1 integrin (VLA–5) and extracellular matrix protein (fibronectin)--activation of cultured monocytes by fibronectin] Nishinarita S, et al. **Rinsho Byori** 1996 Sep;Suppl 102:140–6 (19 ref.) **(Jpn)**

RECEPTORS, FOLLICLE-STIMULATING HORMONE see **RECEPTORS, FSH**

RECEPTORS, FSH

CHEMISTRY

The LH/CG and FSH receptors: different molecular forms and intracellular traffic. Misrahi M, et al. **Mol Cell Endocrinol** 1996 Dec 20;125(1–2):161–7 (33 ref.)

Advances in the molecular understanding of gonadotropins–receptors interactions. el Tayar N. **Mol Cell Endocrinol** 1996 Dec 20;125(1–2):65–70 (33 ref.)

GENETICS

Premature ovarian failure. Conway GS. **Curr Opin Obstet Gynecol** 1997 Jun;9(3):202–6 (51 ref.)

Bioassays of gonadotropins based on cloned receptors. Christin-Maitre S, et al. **Mol Cell Endocrinol** 1996 Dec 20;125(1–2):151–9 (49 ref.)

Functional and clinical consequences of mutations in the FSH receptor. Gromoll J, et al. **Mol Cell Endocrinol** 1996 Dec 20;125(1–2):177–82 (21 ref.)

Expression of follicle stimulating hormone–receptor mRNA during gonadal development. O'Shaughnessy PJ, et al. **Mol Cell Endocrinol** 1996 Dec 20;125(1–2):169–75 (46 ref.)

METABOLISM

Human follitropin heterodimerization and receptor binding structural motifs: identification and analysis by a combination of synthetic peptide and mutagenesis approaches. Dias JA. **Mol Cell Endocrinol** 1996 Dec 20; 125(1–2):45–54 (74 ref.)

PHYSIOLOGY

Functional and clinical consequences of mutations in the FSH receptor. Gromoll J, et al. **Mol Cell Endocrinol** 1996 Dec 20;125(1–2):177–82 (21 ref.)

RECEPTORS, GABA

GABAA receptor pharmacology. Johnston GA. **Pharmacol Ther** 1996;69(3):173–98 (346 ref.)

[GABA receptors] Kuriyama K, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):302–7 (50 ref.) **(Jpn)**

CHEMISTRY

GABAC receptors in the vertebrate retina. Lukasiewicz PD. **Mol Neurobiol** 1996 Jun;12(3):181–94 (73 ref.)

DRUG EFFECTS

GABA and neuroprotection. Lyden PD. **Int Rev Neurobiol** 1997;40:233–58 (80 ref.)

Melatonin effects on behavior: possible mediation by the central GABAergic system. Golombek DA, et al. **Neurosci Biobehav Rev** 1996 Autumn;20(3):403–12 (175 ref.)

GABA and its receptors in the spinal cord. Malcangio M, et al. **Trends Pharmacol Sci** 1996 Dec;17(12):457–62 (59 ref.)

METABOLISM

Cerebral GABA receptors. Kuriyama K. **Alcohol Alcohol Suppl** 1994;2:181–6 (47 ref.)

From kinetics and thermodynamics of GABAA receptor binding to ionophore function. Maksay G. **Neurochem Int** 1996 Oct;29(4):361–70 (65 ref.)

PHYSIOLOGY

Olfaction, GABAergic neurotransmission in the olfactory bulb, and intermale aggression in mice: modulation by steroids. Guillot PV, et al. **Behav Genet** 1996 Sep; 26(5):497–504 (65 ref.)

Role of GABA in cerebral cortex. Krnjević K. **Can J Physiol Pharmacol** 1997 May;75(5):439–51 (95 ref.)

The GABAA receptors. From subunits to diverse functions. Mohler H, et al. **Ion Channels** 1996;4:89–113 (150 ref.)

GABAC receptors in the vertebrate retina. Lukasiewicz PD. **Mol Neurobiol** 1996 Jun;12(3):181–94 (73 ref.)

The pharmacology of amino-acid responses in septal neurons. Kumamoto E. **Prog Neurobiol** 1997 Jun;52(3):197–259 (425 ref.)

GABAc receptors: relatively simple transmitter -gated ion channels? Johnston GA. **Trends Pharmacol Sci** 1996 Sep; 17(9):319–23 (30 ref.)

GABA and its receptors in the spinal cord. Malcangio M, et al. **Trends Pharmacol Sci** 1996 Dec;17(12):457–62 (59 ref.)

RECEPTORS, GABA-A

ANALYSIS

[Evaluation of benzodiazepine receptor in the cerebral cortex of Parkinson's disease using 123I-iomazenil SPECT] Kawabata K, et al. **Nippon Rinsho** 1997 Jan;55(1):244–8 (21 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Multiplicity, structure, and function in GABAA receptors. Barnard EA, et al. **Ann N Y Acad Sci** 1993 Dec 20; 707:116–25 (37 ref.)

Peripheral benzodiazepine receptor in cholesterol transport and steroidogenesis. Papadopoulos V, et al. **Steroids** 1997 Jan;62(1):21–8 (66 ref.)

DRUG EFFECTS

Regulation of GABAA receptor structure and function by chronic drug treatments in vivo and with stably transfected cells. Klein RL, et al. **Jpn J Pharmacol** 1996 Jan;70(1):1–15 (124 ref.)

Pharmacology of tolerance to benzodiazepine receptor ligands. Plaźnik A. **Pol J Pharmacol** 1995 Nov–Dec; 47(6):489–99 (67 ref.)

Possible involvement of an endogenous benzodiazepine receptor ligand of the inverse agonist type in the regulation of rapid-eye movement (REM) sleep: an hypothesis. Wichlinski LJ. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Jan; 20(1):1–44 (182 ref.)

Alcohol, GABAA-benzodiazepine receptor complex, and aggression. Miczek KA, et al. **Recent Dev Alcohol** 1997; 13:139–71 (164 ref.)

GENETICS

Genetic approaches to CNS disorders with particular reference to GABAA-receptor mutations. Mohler H. **J Recept Signal Transduct Res** 1997 Jan–May;17(1–3):1–10 (33 ref.)

Methods for transient expression of hetero-oligomeric ligand-gated ion channels. Lüddens H, et al. **Methods Mol Biol** 1997;83:55–63 (25 ref.)

Association study between bipolar disorder and candidate genes involved in dopamine–serotonin metabolism and GABAergic neurotransmission: a preliminary report [letter] Oruč L, et al. **Psychiatr Genet** 1996 Winter;6(4):213–7 (40 ref.)

METABOLISM

Prediction of the therapeutic dose for benzodiazepine anxiolytics based on receptor occupancy theory. Ito K, et al. **Biopharm Drug Dispos** 1997 May;18(4):293–303 (37 ref.)

Neurosteroid modulation of native and recombinant GABAA receptors. Lambert JJ, et al. **Cell Mol Neurobiol** 1996 Apr; 16(2):155–74 (100 ref.)

The autoradiographic perspective of central benzodiazepine receptors; a short review. Fernández-López A, et al. **Gen Pharmacol** 1997 Aug;29(2):173–80 (84 ref.)

Structural and pharmacological aspects of the GABAA receptor: involvement in behavioral pathogenesis. Clément Y. **J Physiol Paris** 1996;90(1):1–13 (144 ref.)

Functional modulation of ligand-gated GABAA and NMDA receptor channels by phosphorylation. Sigel E. **J Recept Signal Transduct Res** 1995 Jan–Mar; 15(1–4):325–32 (21 ref.)

Overview--flavonoids: a new family of benzodiazepine receptor ligands. Medina JH, et al. **Neurochem Res** 1997 Apr;22(4):419–25 (58 ref.)

GABA and epilepsy in the photosensitive baboon Papio papio. Brailowsky S. **Proc West Pharmacol Soc** 1996; 39:71–5 (37 ref.)

PHYSIOLOGY

Alcohol dependence: a commentary on mechanisms. Hoffman PL, et al. **Alcohol Alcohol** 1996 Jul;31(4):333–40 (60 ref.)

Multiplicity, structure, and function in GABAA receptors. Barnard EA, et al. **Ann N Y Acad Sci** 1993 Dec 20; 707:116–25 (37 ref.)

Multiple forms and locations for the peripheral-type benzodiazepine receptor. Woods MJ, et al. **Biochem Pharmacol** 1996 Dec 24;52(12):1805–14 (94 ref.)

Functional and pharmacological properties of GABA-mediated inhibition in the human neocortex. Avoli M, et al. **Can J Physiol Pharmacol** 1997 May;75(5):526–34 (46 ref.)

Do GABAA and GABAB inhibitory postsynaptic responses originate from distinct interneurons in the hippocampus? Nurse S, et al. **Can J Physiol Pharmacol** 1997 May; 75(5):520–5 (59 ref.)

Peripheral benzodiazepine receptors: molecular pharmacology to possible physiological significance in stress-induced hypertension. Drugan RC. **Clin Neuropharmacol** 1996 Dec;19(6):475–96 (157 ref.)

Is the mitochondrial benzodiazepine receptor involved in the control of airway smooth muscle tone? Pelaia G, et al. **Gen Pharmacol** 1997 Apr;28(4):495–8 (18 ref.)

Use-dependent regulation of GABAA receptors. Barnes EM Jr. **Int Rev Neurobiol** 1996;39:53–76 (112 ref.)

Contrasting strategies for anoxic brain survival--glycolysis up or down. Lutz PL, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):411–9 (59 ref.)

The cerebellum: a model system for studying GABAA receptor diversity. Wisden W, et al. **Neuropharmacology** 1996;35(9–10):1139–60 (130 ref.)

Eubacterial signal transduction by ligands of the mammalian peripheral benzodiazepine receptor complex [see comments] Donohue TJ. **Proc Natl Acad Sci U S A** 1997 May 13;94(10):4821–2 (18 ref.) Comment in: Proc Natl Acad Sci U S A 1997 May 13;94(10):5101–6.

Compartmentalised distribution of GABAA and glutamate receptors in relation to transmitter release sites on the surface of cerebellar neurones. Nusser Z, et al. **Prog Brain Res** 1997;114:109–27 (91 ref.)

Progesterone: does it affect response to drug? Kroboth PD, et al. **Psychopharmacol Bull** 1997;33(2):297–301 (18 ref.)

Peripheral benzodiazepine receptor in cholesterol transport and steroidogenesis. Papadopoulos V, et al. **Steroids** 1997 Jan;62(1):21–8 (66 ref.)

[Mitochondrial transport of nucleic acids. Participation of the benzodiazepine receptor] Zorov DB. **Biokhimiia** 1996 Jul;61(7):1320–32 (88 ref.) (Eng. Abstr.) **(Rus)**

RECEPTORS, GABA-B

GENETICS

Metabotropic GABA(B) receptors cloned at last. Bowery NG. **Trends Pharmacol Sci** 1997 Apr;18(4):103 (6 ref.)

PHYSIOLOGY

Functional and pharmacological properties of GABA-mediated inhibition in the human neocortex. Avoli M, et al. **Can J Physiol Pharmacol** 1997 May;75(5):526–34 (46 ref.)

Do GABAA and GABAB inhibitory postsynaptic responses originate from distinct interneurons in the hippocampus? Nurse S, et al. **Can J Physiol Pharmacol** 1997 May; 75(5):520–5 (59 ref.)

The role of GABAB mechanisms in animal models of absence seizures. Caddick SJ, et al. **Mol Neurobiol** 1996 Aug; 13(1):23–32 (62 ref.)

RECEPTORS, GABA-BENZODIAZEPINE see **RECEPTORS, GABA-A**

RECEPTORS, GAMMA-AMINOBUTYRIC ACID see **RECEPTORS, GABA**

RECEPTORS, GASTRIN see **RECEPTORS, CHOLECYSTOKININ**

RECEPTORS, GASTRIN-RELEASING PEPTIDE see **RECEPTORS, BOMBESIN**

RECEPTORS, GASTROINTESTINAL HORMONE

[Motilin and motilin receptor] Satoh M, et al. **Nippon Rinsho** 1996 Apr;54(4):1092–6 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Gastric inhibitory polypeptide (GIP) and GIP receptor (GIPR)] Yasuda K, et al. **Nippon Rinsho** 1996 Apr; 54(4):1078–82 (14 ref.) (Eng. Abstr.) **(Jpn)**

AGONISTS

[Acute reversible pan-dysautonomia: effect of erythromycin on gastrointestinal involvement] Lagasse JP, et al. **Gastroenterol Clin Biol** 1997;21(4):331–4 (12 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Speculations on the mechanism of hormone-receptor interactions of the secretin/glucagon family of polypeptide hormones derived from computational structural studies. Momany FA, et al. **Ann N Y Acad Sci** 1996 Dec 26; 805:172–81; discussion 181–3 (18 ref.)

Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide. Larhammar D. **Regul Pept** 1996 Sep 16;65(3):165–74 (64 ref.)

PHYSIOLOGY

GIP receptors and signal-transduction mechanisms. McIntosh CH, et al. **Acta Physiol Scand** 1996 Jul; 157(3):361–5 (30 ref.)

Receptors for VIP, PACAP, secretin, GRF, glucagon, GLP-1, and other members of their new family of G protein-linked receptors: structure-function relationship with special reference to the human VIP-1 receptor. Laburthe M, et al. **Ann N Y Acad Sci** 1996 Dec 26; 805:94–109; discussion 110–1 (64 ref.)

Galanin receptors: involvement in feeding, pain, depression and Alzheimer's disease. Kask K, et al. **Life Sci** 1997; 60(18):1523–33 (110 ref.)

RECEPTORS, GASTROINTESTINAL PEPTIDES see **RECEPTORS, GASTROINTESTINAL HORMONE**

RECEPTORS, GLUCAGON

CHEMISTRY

Speculations on the mechanism of hormone-receptor interactions of the secretin/glucagon family of polypeptide hormones derived from computational structural studies. Momany FA, et al. **Ann N Y Acad Sci** 1996 Dec 26; 805:172–81; discussion 181–3 (18 ref.)

GENETICS

Glucagon and GLP-1 receptors: lessons from chimeric ligands and receptors. Hjorth SA, et al. **Acta Physiol Scand** 1996 Jul;157(3):343–5 (12 ref.)

Regulation of glucagon receptor expression. Nishimura E, et al. **Acta Physiol Scand** 1996 Jul;157(3):329–32 (26 ref.)

METABOLISM

Glucagon and GLP-1 receptors: lessons from chimeric ligands and receptors. Hjorth SA, et al. **Acta Physiol Scand** 1996 Jul;157(3):343–5 (12 ref.)

Glucagon and its receptor in various tissues. Christophe J. **Ann N Y Acad Sci** 1996 Dec 26;805:31–42; discussion 42–3 (69 ref.)

PHYSIOLOGY

Glucagon, glucagon-like peptide-1 and their receptors: an introduction. Holst JJ. **Acta Physiol Scand** 1996 Jul; 157(3):309–15 (65 ref.)

Receptors for VIP, PACAP, secretin, GRF, glucagon, GLP-1, and other members of their new family of G protein-linked receptors: structure-function relationship with special reference to the human VIP-1 receptor. Laburthe M, et al. **Ann N Y Acad Sci** 1996 Dec 26; 805:94–109; discussion 110–1 (64 ref.)

Pancreatic beta-cell receptors and G proteins coupled to adenylyl cyclase. Marie JC, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:122–31; discussion 132 (61 ref.)

Molecular and cellular aspects of the glucagon receptor: role in diabetes and metabolism. Burcelin R, et al. **Diabetes Metab** 1996 Dec;22(6):373–96 (267 ref.)

RECEPTORS, GLUCOCORTICOID

Steroid receptor number. Individual variation and downregulation by treatment. Brönnegård M. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 2):S28–32; discussion S32–3 (49 ref.)

[Glucocorticoid receptor] Ashida K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:562–5 (5 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

The antiglucocorticoid action of mifepristone. Agarwai MK. **Pharmacol Ther** 1996;70(3):183–213 (552 ref.)

BIOSYNTHESIS

Early environmental regulation of forebrain glucocorticoid receptor gene expression: implications for adrenocortical responses to stress. Meaney MJ, et al. **Dev Neurosci** 1996; 18(1–2):49–72 (138 ref.)

DRUG EFFECTS

[Mechanisms of action of glucocorticoids] Bamberger CM, et al. **Internist (Berl)** 1997 Apr;38(4):366–70 (41 ref.) **(Ger)**

GENETICS

Glucocorticoid and mineralocorticoid receptors: biology and clinical relevance. Funder JW. **Annu Rev Med** 1997; 48:231–40 (53 ref.)

Early environmental regulation of forebrain glucocorticoid receptor gene expression: implications for adrenocortical responses to stress. Meaney MJ, et al. **Dev Neurosci** 1996; 18(1–2):49–72 (138 ref.)

Glucocorticoid resistant syndromes—molecular basis and clinical presentations. Brönnegård M, et al. **J Neuroendocrinol** 1996 Jun;8(6):405–15 (105 ref.)

Clinical aspects of glucocorticoid sensitivity. Lamberts SW, et al. **Steroids** 1996 Apr;61(4):157–60 (37 ref.)

Molecular basis of glucocorticoid-resistant syndromes. Werner S, et al. **Steroids** 1996 Apr;61(4):216–21 (42 ref.)

IMMUNOLOGY

Cross-talk between the T cell antigen receptor and the glucocorticoid receptor regulates thymocyte development. Ashwell JD, et al. **Stem Cells** 1996 Sep;14(5):490–500 (58 ref.)

METABOLISM

Mineralocorticoid receptors and glucocorticoid receptors. Funder JW. **Clin Endocrinol (Oxf)** 1996 Dec;45(6):651–6 (43 ref.)

Macrophage migration inhibitory factor: a counter-regulator of glucocorticoid action and critical mediator of septic shock. Calandra T, et al. **J Inflamm** 1995–96;47(1–2):39–51 (52 ref.)

Hypercortisolemia, hippocampal glucocorticoid receptors, and fast feedback. Young EA, et al. **Mol Psychiatry** 1996 May;1(2):149–59 (87 ref.)

Molecular basis of glucocorticoid-resistant syndromes. Werner S, et al. **Steroids** 1996 Apr;61(4):216–21 (42 ref.)

Heterodimerization between mineralocorticoid and glucocorticoid receptors increases the functional diversity of corticosteroid action. Trapp T, et al. **Trends Pharmacol Sci** 1996 Apr;17(4):145–9 (49 ref.)

PHYSIOLOGY

Glucocorticoid receptors: ATP and cell cycle dependence, phosphorylation, and hormone resistance. Bodwell JE, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 2):S2–6 (35 ref.)

Growth factors mediate glucocorticoid receptor function and dexamethasone-induced regression of osteoblastic lesions in hormone refractory prostate cancer. Koutsilieris M, et al. **Anticancer Res** 1997 May-Jun;17(3A):1461–5 (29 ref.)

Mechanism of gene expression by the glucocorticoid receptor: role of protein-protein interactions. McEwan IJ, et al. **Bioessays** 1997 Feb;19(2):153–60 (70 ref.)

Brain–corticosteroid hormone dialogue: slow and persistent. de Kloet ER, et al. **Cell Mol Neurobiol** 1996 Jun; 16(3):345–56 (52 ref.)

Corticosteroids in essential hypertension: multiple candidate loci and phenotypic variation. Connell JM, et al. **Clin Exp Pharmacol Physiol** 1996 May;23(5):369–74 (46 ref.)

Glucocorticoid resistance. de Castro M, et al. **Curr Ther Endocrinol Metab** 1997;6:188–9 (7 ref.)

Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Bamberger CM, et al. **Endocr Rev** 1996 Jun;17(3):245–61 (216 ref.)

The glucocorticoid insensitivity syndrome. Lamberts SW. **Horm Res** 1996;45 Suppl 1:2–4 (10 ref.)

[Receptor mechanisms of glucocorticoid and antiglucocorticoid effects] Golikov PP. **Vopr Med Khim** 1996 Jul-Sep;42(3):184–92 (76 ref.) (Eng. Abstr.) **(Rus)**

RECEPTORS, GLUTAMATE

[Molecular diversity and physiological roles of the glutamate receptor channel] Mishina M. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):285–94 (36 ref.) **(Jpn)**

DRUG EFFECTS

The pharmacology of antimyoclonic drugs. Pranzatelli MR. **Clin Neurosci** 1995–96;3(4):246–52 (60 ref.)

The L-AP4 receptor. Thomsen C. **Gen Pharmacol** 1997 Aug; 29(2):151–8 (80 ref.)

GENETICS

High affinity glutamate transporters: regulation of expression and activity. Gegelashvili G, et al. **Mol Pharmacol** 1997 Jul;52(1):6–15 (98 ref.)

IMMUNOLOGY

The role of autoimmunity to glutamate receptors in neurological disease. Rogers SW, et al. **Mol Med Today** 1996 Feb;2(2):76–81 (27 ref.)

METABOLISM

Glutamate receptor autoimmunity in Rasmussen's encephalitis. McNamara JO, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:327–32 (46 ref.)

Etiology of (CAG)n triplet repeat neurodegenerative diseases such as Huntington's disease is connected to stimulation of glutamate receptors. Fischer KM. **Med Hypotheses** 1997 May;48(5):393–8 (66 ref.)

The neurotransmitter candidature of sulphur-containing excitatory amino acids in the mammalian central nervous system. Thompson GA, et al. **Pharmacol Ther** 1996; 72(1):25–36 (109 ref.)

Cytoskeletal interactions with glutamate receptors at central synapses. Westbrook GL, et al. **Soc Gen Physiol Ser** 1997; 52:163–75 (76 ref.)

News on glutamate receptors in glial cells. Steinhäuser C, et al. **Trends Neurosci** 1996 Aug;19(8):339–45 (99 ref.)

Ionotropic glutamate receptors: new types and new concepts. Barnard EA. **Trends Pharmacol Sci** 1997 May;18(5):141–8 (47 ref.)

PHYSIOLOGY

Glutamate receptors in the central nervous system. Jonas P. **Ann N Y Acad Sci** 1993 Dec 20;707:126–35 (29 ref.)

Glutamatergic transmission in the nucleus tractus solitarii: from server to peripherals in the cardiovascular information superhighway. Talman WT. **Braz J Med Biol Res** 1997 Jan;30(1):1–7 (66 ref.)

Glutamate receptors and gene induction: signalling from receptor to nucleus. Lerea LS. **Cell Signal** 1997 May-Jun; 9(3–4):219–26 (72 ref.)

The GluR2 hypothesis: Ca(++)-permeable AMPA receptors in delayed neurodegeneration. Bennett MV, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:373–84 (29 ref.)

Functions and roles of glutamate receptors in synaptic transmission and plasticity. Nakanishi S, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:67–75 (39 ref.)

Interaction of ion channels and receptors with PDZ domain proteins. Kornau HC, et al. **Curr Opin Neurobiol** 1997 Jun; 7(3):368–73 (35 ref.)

Long-term enhancement of excitability and the regulation of glutamate receptors by protein kinases. MacDonald JF, et al. **Epilepsy Res Suppl** 1996;12:275–82 (38 ref.)

Effects of nitric oxide on glutamate-gated channels and other ionic channels. Fagni L, et al. **J Chem Neuroanat** 1996 Jun; 10(3–4):231–40 (55 ref.)

Inhibitory glutamate receptor channels. Cleland TA. **Mol Neurobiol** 1996 Oct;13(2):97–136 (114 ref.)

Modulation of glutamate receptors by calcium/calmodulin-dependent protein kinase II. Soderling TR. **Neurochem Int** 1996 Apr;28(4):359–61 (27 ref.)

Modulation of dopamine neuronal activity by glutamate receptor subtypes. Meltzer LT, et al. **Neurosci Biobehav Rev** 1997 Jul;21(4):511–8 (96 ref.)

Behavioural pharmacology of glutamate receptors in the basal ganglia. Schmidt WJ, et al. **Neurosci Biobehav Rev** 1997 Jul;21(4):381–92 (142 ref.)

Glutamate receptors in cortical plasticity: molecular and cellular biology. Kaczmarek L, et al. **Physiol Rev** 1997 Jan; 77(1):217–55 (392 ref.)

Compartmentalised distribution of GABAA and glutamate receptors in relation to transmitter release sites on the surface of cerebellar neurones. Nusser Z, et al. **Prog Brain Res** 1997;114:109–27 (91 ref.)

Involvement of glutamatergic neurotransmission and protein kinase C in spinal plasticity and the development of chronic pain. Tölle TR, et al. **Prog Brain Res** 1996;110:193–206 (54 ref.)
The role of glutamate in the photic regulation of the suprachiasmatic nucleus. Ebling FJ. **Prog Neurobiol** 1996 Oct;50(2–3):109–32 (209 ref.)
The pharmacology of amino–acid responses in septal neurons. Kumamoto E. **Prog Neurobiol** 1997 Jun;52(3):197–259 (425 ref.)

RECEPTORS, GLUTAMATE, METABOTROPIC see **RECEPTORS, METABOTROPIC GLUTAMATE**

RECEPTORS, GLYCINE

The glycine receptor. Rajendra S, et al. **Pharmacol Ther** 1997; 73(2):121–46 (222 ref.)
[Molecular function of subtype and subunit drug receptors] Kimura M, et al. **Nippon Yakurigaku Zasshi** 1996 Sep; 108(3):155–6 (0 ref.) **(Jpn)**

AGONISTS

Chronic administration of a partial agonist at strychnine–insensitive glycine receptors: a novel experimental approach to the treatment of ischemias. Fossom LH, et al. **J Neural Transm Suppl** 1997;49:235–44 (38 ref.)

CHEMISTRY

Structure and biology of inhibitory glycine receptors. Betz H, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:109–15 (40 ref.)

DRUG EFFECTS

The pharmacology of antimyoclonic drugs. Pranzatelli MR. **Clin Neurosci** 1995–96;3(4):246–52 (60 ref.)

GENETICS

Hyperekplexia: abnormal startle response due to glycine receptor mutations. Andrew M, et al. **Br J Psychiatry** 1997 Feb;170:106–8 (30 ref.)

PHYSIOLOGY

Structure and biology of inhibitory glycine receptors. Betz H, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:109–15 (40 ref.)
Molecular biology of glycinergic neurotransmission. Zafra F, et al. **Mol Neurobiol** 1997 Jun;14(3):117–42 (187 ref.)
The pharmacology of amino–acid responses in septal neurons. Kumamoto E. **Prog Neurobiol** 1997 Jun;52(3):197–259 (425 ref.)
[Strychnine/glycine cytoprotective receptor] Li TC, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan;27(1):61–3 (10 ref.) **(Chi)**

RECEPTORS, GNRH see **RECEPTORS, LHRH**

RECEPTORS, GONADOLIBERIN see **RECEPTORS, LHRH**

RECEPTORS, GONADORELIN see **RECEPTORS, LHRH**

RECEPTORS, GONADOTROPIN

GENETICS

Clinical manifestations of genetic defects affecting gonadotrophins and their receptors. Conway GS. **Clin Endocrinol (Oxf)** 1996 Dec;45(6):657–63 (41 ref.)
Gonadotropin receptor mutations. Themmen AP, et al. **J Endocrinol** 1997 May;153(2):179–83 (33 ref.)

METABOLISM

Functional consequences of the phosphorylation of the gonadotropin receptors. Ascoli M. **Biochem Pharmacol** 1996 Dec 13;52(11):1647–55 (65 ref.)

PHYSIOLOGY

Polymorphism of gonadotropin action; molecular mechanisms and clinical implications. Huhtaniemi IT. **Acta Neurobiol Exp (Warsz)** 1996;56(3):743–51 (37 ref.)
Gonadotropins and ovarian gonadotropin receptors during the perimenopausal transition period. Vihko KK. **Maturitas** 1996 May;23 Suppl:S19–22 (26 ref.)

RECEPTORS, GRANULOCYTE COLONY–STIMULATING FACTOR

GENETICS

Pathophysiology of Kostmann syndrome: the G–CSF receptor issue. Donadieu J. **Hematol Cell Ther** 1997 Apr; 39(2):102–4 (16 ref.)
Severe congenital neutropenia terminating in acute myeloid leukemia: disease progression associated with mutations in the granulocyte–colony stimulating factor receptor gene. Touw IP, et al. **Leuk Res** 1996 Aug;20(8):629–31 (20 ref.)

METABOLISM

The structural and functional basis of cytokine receptor activation: lessons from the common beta subunit of the granulocyte–macrophage colony–stimulating factor, interleukin–3 (IL–3), and IL–5 receptors. Bagley CJ, et al. **Blood** 1997 Mar 1;89(5):1471–82 (87 ref.)
Granulocyte colony–stimulating factor receptor at various differentiation stages of normal and leukemic hematopoietic cells. Shinjo K, et al. **Leuk Lymphoma** 1997 Mar; 25(1–2):37–46 (49 ref.)

PHYSIOLOGY

Advances in understanding postreceptor signaling in response to granulocyte colony–stimulating factor. Tidow N, et al. **Curr Opin Hematol** 1997 May;4(3):171–5 (27 ref.)
[Signal transduction through G–CSF receptors] Shimoda K, et al. **Rinsho Ketsueki** 1997 Mar;38(3):193–5 (10 ref.) **(Jpn)**

RECEPTORS, GRANULOCYTE–MACROPHAGE COLONY–STIMULATING FACTOR

[Granulocyte–macrophage colony–stimulating factor receptor] Kurata H. **Nippon Rinsho** 1997 Apr;55 Suppl 2:542–5 (14 ref.) **(Jpn)**

CHEMISTRY

The structural basis of the biological actions of the GM–CSF receptor. Nicola NA, et al. **Ciba Found Symp** 1997; 204:19–27; discussion 27–32 (23 ref.)

DEFICIENCY

[Mice deficient for the IL–3/GM–CSF/IL–5 beta receptors] Nishinakamura R. **Rinsho Ketsueki** 1997 Mar;38(3):181–5 (8 ref.) **(Jpn)**

PHYSIOLOGY

Roles of JAK kinases in human GM–CSF receptor signal transduction. Watanabe S, et al. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 2):S183–91 (26 ref.)
GM–CSF and its effects on replication of HIV–1 in cells of macrophage lineage. Crowe SM, et al. **J Leukoc Biol** 1997 Jul;62(1):41–8 (100 ref.)
Signal transduction by the GM–CSF, IL–3 and IL–5 receptors. Miyajima A, et al. **Leukemia** 1997 Apr;11 Suppl 3:418–22 (16 ref.)

RECEPTORS, GROWTH FACTOR

Serine/threonine kinase receptors: mediators of transforming growth factor beta family signals. Massagué J, et al. **Cancer Surv** 1996;27:41–64 (128 ref.)
[Receptors for factors of the VEGF (Vascular Endothelial Growth Family)] Fournier E, et al. **Bull Cancer** 1997 Apr; 84(4):397–405 (61 ref.) (Eng. Abstr.) **(Fre)**

ANALYSIS

Oncogenes and growth factor receptors as diagnostic and prognostic markers in precancers and cancers of the oral mucosa. Burkhardt A. **Curr Top Pathol** 1996;90:223–39 (136 ref.)

BIOSYNTHESIS

Growth factor receptors and medulloblastoma. Goumnerova LC. **J Neurooncol** 1996 Jul;29(1):85–9 (17 ref.)

BLOOD

Biomarkers of gene expression: growth factors and oncoproteins. Brandt–Rauf PW. **Environ Health Perspect** 1997 Jun;105 Suppl 4:807–16 (125 ref.)

CHEMISTRY

Ligand–induced dimerization of growth factor receptors: variations on the theme. Heldin CH, et al. **Cytokine Growth Factor Rev** 1996 Jun;7(1):3–10 (59 ref.)
The biology of vascular endothelial growth factor. Ferrara N, et al. **Endocr Rev** 1997 Feb;18(1):4–25 (250 ref.)

DRUG EFFECTS

Targeted therapy for prostate cancer: the Memorial Sloan–Kettering Cancer Center approach. Slovin SF, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 14):41–8 (61 ref.)

GENETICS

Anti–angiogenic gene therapy of malignant glioma. Stratmann A, et al. **Acta Neurochir Suppl (Wien)** 1997; 68:105–10 (30 ref.)
C–kit mutations and mast cell disorders. A model of activating mutations of growth factor receptors. Pignon JM. **Hematol Cell Ther** 1997 Apr;39(2):114–6 (14 ref.)
[Correlation of neovascularization and vascular endothelial growth factor in human renal cell carcinoma] Sato K, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(4):389–94 (17 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Virocrine transformation. Drummond–Barbosa D, et al. **Biochim Biophys Acta** 1997 Feb 22;1332(1):M1–17 (148 ref.)
Biological properties of VEGF/VPF receptors. Terman BI, et al. **Cancer Metastasis Rev** 1996 Jun;15(2):159–63 (42 ref.)
Soluble receptors for cytokines and growth factors. Müller–Newen G, et al. **Int Arch Allergy Immunol** 1996 Oct;111(2):99–106 (58 ref.)
Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors. Friess H, et al. **J Mol Med** 1996 Jan;74(1):35–42 (120 ref.)
Signal transduction by the oncogenic receptor tyrosine kinase Xmrk in melanoma formation of Xiphophorus. Wellbrock C, et al. **Pigment Cell Res** 1997 Feb–Apr;10(1–2):34–40 (60 ref.)

PHYSIOLOGY

Activin receptors: cellular signalling by receptor. serine kinases. Zimmerman CM, et al. **Biochem Soc Symp** 1996; 62:25–38 (47 ref.)
Competition by second messenger systems for receptor interaction and activation: implications for tissue–specific responses and disease therapy. Crouch MF, et al. **Clin Exp Pharmacol Physiol** 1997 Aug;24(8):632–8 (22 ref.)
Use of transgenic mice to study autocrine–paracrine signaling in lung morphogenesis and differentiation. Whitsett JA, et al. **Clin Perinatol** 1996 Dec;23(4):753–69 (54 ref.)
Serine/threonine kinase receptors and ligands. Josso N, et al. **Curr Opin Genet Dev** 1997 Jun;7(3):371–7 (68 ref.)
Trans–signaling by cytokine and growth factor receptors. Castellino AM, et al. **Cytokine Growth Factor Rev** 1996 Dec;7(4):297–302 (56 ref.)
Vascular endothelial growth factor and its receptors. Klagsbrun M, et al. **Cytokine Growth Factor Rev** 1996 Oct; 7(3):259–70 (136 ref.)
Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. Brown LF, et al. **EXS** 1997;79:233–69 (133 ref.)
Vascular endothelial growth factor: basic biology and clinical implications. Ferrara N, et al. **EXS** 1997;79:209–32 (142 ref.)
Soluble receptors for cytokines and growth factors. Müller–Newen G, et al. **Int Arch Allergy Immunol** 1996 Oct;111(2):99–106 (58 ref.)
The role of exogenous growth–promoting factors and their receptors in organogenesis. Pratten MK. **Int J Dev Biol** 1997 Apr;41(2):319–28 (108 ref.)
Transforming growth factor beta s and fibroblast growth factors and their receptors: role in sutural biology and craniosynostosis [editorial; comment] Cohen MM Jr. **J Bone Miner Res** 1997 Mar;12(3):322–31 (76 ref.)
Comment on: J Bone Miner Res 1997 Mar;12(3):301–10.
Comment on: J Bone Miner Res 1997 Mar;12(3):311–21.
Treatment strategies for neurodegenerative diseases based on trophic factors and cell transplantation techniques. Hoffer B, et al. **J Neural Transm Suppl** 1997;49:1–10 (31 ref.)
Possible involvement of VEGF–FLT tyrosine kinase receptor system in normal and tumor angiogenesis. Shibuya M, et al. **Princess Takamatsu Symp** 1994;24:162–70 (23 ref.)
Activins and activin receptors in cell growth. Ying SY, et al. **Proc Soc Exp Biol Med** 1997 Feb;214(2):114–22 (114 ref.)
Angiogenesis in embryos and ischemic diseases. Breier G, et al. **Thromb Haemost** 1997 Jul;78(1):678–83 (70 ref.)

RECEPTORS, GROWTH HORMONE see **RECEPTORS, SOMATOTROPIN**

RECEPTORS, HEMATOPOIETIC GROWTH FACTORS see **RECEPTORS, COLONY–STIMULATING FACTOR**

RECEPTORS, HISTAMINE

DRUG EFFECTS

Ebastine in context. Introduction. Buendia E. **Drugs** 1996;52 Suppl 1:1–7 (24 ref.)

METABOLISM

Histamine: the quintessential mediator. Greaves MW, et al. **J Dermatol** 1996 Nov;23(11):735–40 (43 ref.)

RECEPTORS, HISTAMINE H1

[Histamine receptors] Watanabe T, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):327–34 (28 ref.) **(Jpn)**

DRUG EFFECTS

[Can one adjust the distribution of a drug in an organism to its target sites? The example of antihistaminics (anti–H1) and cetirizine] Tillement JP, et al. **Allerg Immunol (Paris)** 1996 Dec;28(10):330–2 (6 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

[Structure of the histamine H1 receptor gene and transcriptional up–regulation of the H1 receptor] Fukui H. **Nippon Rinsho** 1996 Feb;54(2):389–95 (15 ref.) (Eng. Abstr.) **(Jpn)**

RECEPTORS, HISTAMINE H1

METABOLISM

Dietary induced anorexia: a review of involvement of the histaminergic system. Mercer LP, et al. **J Am Coll Nutr** 1996 Jun;15(3):223–30 (78 ref.)

PHYSIOLOGY

A role for histamine receptors in rheumatoid arthritis. Tanaka S, et al. **Semin Arthritis Rheum** 1997 Jun;26(6):824–33 (25 ref.)

RECEPTORS, HISTAMINE H2

[Structural analysis of the histamine H2 receptor] Fukushima Y, et al. **Nippon Rinsho** 1996 Apr;54(4):1144–8 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Histamine receptors] Watanabe T, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):327–34 (28 ref.) **(Jpn)**

PHYSIOLOGY

A role for histamine receptors in rheumatoid arthritis. Tanaka S, et al. **Semin Arthritis Rheum** 1997 Jun;26(6):824–33 (25 ref.)

RECEPTORS, HISTAMINE H3

PHYSIOLOGY

Physiopathology of H3-receptors and pharmacology of betahistine. Van Cauwenberge PB, et al. **Acta Otolaryngol Suppl (Stockh)** 1997;526:43–6 (23 ref.)

A role for histamine receptors in rheumatoid arthritis. Tanaka S, et al. **Semin Arthritis Rheum** 1997 Jun;26(6):824–33 (25 ref.)

RECEPTORS, HIV

see related
HIV ENVELOPE PROTEIN GP120

Chemokines and HIV-1 second receptors. Confluence of two fields generates optimism in AIDS research. D'Souza MP, et al. **Nat Med** 1996 Dec;2(12):1293–300 (79 ref.)

[Chemokines and HIV-1 second receptors] Murakami T, et al. **Tanpakushitsu Kakusan Koso** 1997 Jul;42(9):1427–34 (35 ref.) **(Jpn)**

CHEMISTRY

HIV and the 7-transmembrane domain receptors. Broder CC, et al. **Pathobiology** 1996;64(4):171–9 (108 ref.)

GENETICS

Host genes and HIV: the role of the chemokine receptor gene CCR5 and its allele. McNicholl JM, et al. **Emerg Infect Dis** 1997 Jul–Sep;3(3):261–71 (62 ref.)

METABOLISM

Coreceptors: implications for HIV pathogenesis and therapy. Moore JP. **Science** 1997 Apr 4;276(5309):51–2 (19 ref.)

PHYSIOLOGY

HIV type 1 coreceptors, neutralization serotypes, and vaccine development. Moore J, et al. **AIDS Res Hum Retroviruses** 1997 Jun 10;13(9):733–6 (35 ref.)

Chemokine receptors as fusion cofactors for human immunodeficiency virus type 1 (HIV-1). Doranz BJ, et al. **Immunol Res** 1997 Feb;16(1):15–28 (79 ref.)

Chemokine receptors and HIV. Broder CC, et al. **J Leukoc Biol** 1997 Jul;62(1):20–9 (84 ref.)

Host factors and the pathogenesis of HIV-induced disease. Fauci AS. **Nature** 1996 Dec 12;384(6609):529–34 (113 ref.)

HIV and the 7-transmembrane domain receptors. Broder CC, et al. **Pathobiology** 1996;64(4):171–9 (108 ref.)

Control of HIV co-receptor expression: implications for pathogenesis and treatment. Rowland-Jones S, et al. **Trends Microbiol** 1997 Aug;5(8):300–2; discussion 302–3 (28 ref.)

Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry. Doms RW, et al. **Virology** 1997 Sep 1;235(2):179–90 (108 ref.)

RECEPTORS, HUMAN CHORIONIC GONADOTROPIN see **RECEPTORS, LH**

RECEPTORS, HYALURONAN see **ANTIGENS, CD44**

RECEPTORS, HYPOTHALAMIC RELEASE-INHIBITING HORMONES see **RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE**

RECEPTORS, HYPOTHALAMIC RELEASING HORMONES see **RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE**

RECEPTORS, IGE

ANALYSIS

Fc epsilon RI on antigen-presenting cells. Bieber T. **Curr Opin Immunol** 1996 Dec;8(6):773–7 (26 ref.)

ANTAGONISTS & INHIBITORS

Structure-based design of peptides that inhibit IgE binding to its high-affinity receptor Fc epsilon RI. McDonnell JM, et al. **Biochem Soc Trans** 1997 May;25(2):387–92 (34 ref.)

BIOSYNTHESIS

Fc epsilon RI-expressing antigen-presenting cells: new players in the atopic game. Bieber T. **Immunol Today** 1997 Jul;18(7):311–3 (17 ref.)

CHEMISTRY

[Low affinity Fc receptor for IgE (Fc epsilon R II/CD23)] Gon Y, et al. **Nippon Rinsho** 1996 Feb;54(2):456–60 (20 ref.) (Eng. Abstr.) **(Jpn)**

[High affinity receptor for immunoglobulin E (Fc epsilon R I)] Ra C. **Nippon Rinsho** 1996 Feb;54(2):446–55 (39 ref.) (Eng. Abstr.) **(Jpn)**

[Receptor CD23 and sCD23—structure and biological function] Gina AR, et al. **Pol Arch Med Wewn** 1995 Nov; 94(5):436–41 (20 ref.) **(Pol)**

GENETICS

Molecular genetics of the high-affinity IgE receptor. Hopkin JM. **Monogr Allergy** 1996;33:97–108 (72 ref.)

[Isolation of atopic genes] Yamaguchi E, et al. **Nippon Naika Gakkai Zasshi** 1996 Jun 10;85(6):942–7 (11 ref.) **(Jpn)**

[Genetic analysis of bronchial asthma in Japanese population—Fc epsilon RI beta gene and beta 2 adrenergic receptor gene] Hizawa N, et al. **Nippon Rinsho** 1996 Feb; 54(2):539–43 (23 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

The roles of CD40 and CD23 in IgE regulation. Yasui T, et al. **Adv Exp Med Biol** 1996;409:349–54 (28 ref.)

Antigen-mediated IGE receptor aggregation and signaling: a window on cell surface structure and dynamics. Holowka D, et al. **Annu Rev Biophys Biomol Struct** 1996;25:79–112 (149 ref.)

The low-affinity receptor for IgE (Fc epsilon RII or CD23) as a therapeutic target. Conrad DH, et al. **Biochem Soc Trans** 1997 May;25(2):393–7 (28 ref.)

Anti-IgE and anti-Fc epsilon RI autoantibodies in clinical allergy. Fiebiger E, et al. **Curr Opin Immunol** 1996 Dec; 8(6):784–9 (40 ref.)

Pairs of surface molecules involved in human IgE regulation: CD23-CD21 and CD40-CD40L. Bonnefoy JY, et al. **Eur Respir J Suppl** 1996 Aug;22:63s–66s (48 ref.)

Regulation of IgE synthesis. Lessons from the study of IgE transgenic and CD23-deficient mice. Lamers MC, et al. **Immunol Rev** 1995 Dec;148:71–95 (74 ref.)

[Pathogenetic significance of IgE-binding epitopes allergens (published erratum appears in Pneumologie 1996 Dec;50(12):938)] Bufe A, et al. **Pneumologie** 1996 Sep; 50(9):625–31 (55 ref.) **(Ger)**

[Low affinity Fc receptor for IgE (Fc epsilon R II/CD23)] Gon Y, et al. **Nippon Rinsho** 1996 Feb;54(2):456–60 (20 ref.) (Eng. Abstr.) **(Jpn)**

[High affinity receptor for immunoglobulin E (Fc epsilon R I)] Ra C. **Nippon Rinsho** 1996 Feb;54(2):446–55 (39 ref.) (Eng. Abstr.) **(Jpn)**

[Receptor CD23 and sCD23—structure and biological function] Gina AR, et al. **Pol Arch Med Wewn** 1995 Nov; 94(5):436–41 (20 ref.) **(Pol)**

PHYSIOLOGY

Downstream signals initiated in mast cells by Fc epsilon RI and other receptors. Beaven MA, et al. **Curr Opin Immunol** 1996 Dec;8(6):766–72 (66 ref.)

IgE receptor (Fc epsilon RI) and signal transduction. Kinet JP, et al. **Eur Respir J Suppl** 1996 Aug;22:116s–118s (31 ref.)

Fc epsilon RI on human epidermal Langerhans cells: an old receptor with new structure and functions. Bieber T. **Int Arch Allergy Immunol** 1997 May-Jul;113(1-3):30–4 (28 ref.)

Fc epsilon RI and the FcR-beta amplifier. Scharenberg AM, et al. **Int Arch Allergy Immunol** 1997 May-Jul; 113(1–3):42–4 (18 ref.)

IgE-mediated allergen presentation via Fc epsilon RI on antigen-presenting cells. Stingl G, et al. **Int Arch Allergy Immunol** 1997 May-Jul;113(1-3):24–9 (46 ref.)

Role of CD23 in NO production by human monocytic cells. Kolb JP, et al. **Res Immunol** 1995 Nov-Dec;146(9):684–9 (52 ref.)

RECEPTORS, IGF-I see **RECEPTORS, INSULIN-LIKE-GROWTH FACTOR I**

RECEPTORS, IGF-II see **RECEPTORS, INSULIN-LIKE-GROWTH-FACTOR II**

RECEPTORS, IGG

Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies. Deo YM, et al. **Immunol Today** 1997 Mar;18(3):127–35 (57 ref.)

DEFICIENCY

Multiple loss of effector cell functions in FcR gamma-deficient mice. Takai T. **Int Rev Immunol** 1996; 13(4):369–81 (48 ref.)

GENETICS

Clinical relevance of Fc gamma receptor polymorphisms. Rascu A, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:282–95 (76 ref.)

IMMUNOLOGY

Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG [published erratum appears in Immunol Res 1997;16(2):215] Junghans RP. **Immunol Res** 1997 Feb; 16(1):29–57 (108 ref.)

METABOLISM

Human placental Fc gamma-binding proteins in the maternofetal transfer of IgG. Kristoffersen EK. **APMIS Suppl** 1996;64:5–36 (375 ref.)

Tyrosine phosphorylation and Fcgamma receptor-mediated phagocytosis. Strzelecka A, et al. **FEBS Lett** 1997 Jan 2; 400(1):11–4 (51 ref.)

PHYSIOLOGY

Positive and negative signal co-operativity in the immune system: the BCR, Fc gamma RIIB, CR2 paradigm. Cambier JC. **Biochem Soc Trans** 1997 May;25(2):441–5 (21 ref.)

New functions of the MHC class I-related Fc receptor, FcRn. Simister NE, et al. **Biochem Soc Trans** 1997 May; 25(2):481–6 (70 ref.)

Activation of B lymphocytes: integrating signals from CD19, CD22 and Fc gamma RIIb1. Doody GM, et al. **Curr Opin Immunol** 1996 Jun;8(3):378–82 (47 ref.)

ITIMs and ITAMs. The Yin and Yang of antigen and Fc receptor-linked signaling machinery. Isakov N. **Immunol Res** 1997 Feb;16(1):85–100 (112 ref.)

Negative regulation of mast cell activation by receptors for IgG. Daëron M. **Int Arch Allergy Immunol** 1997 May-Jul; 113(1-3):138–41 (29 ref.)

Protein tyrosine phosphorylation in leukocyte activation through receptors for IgG. Santana C, et al. **J Leukoc Biol** 1996 Oct;60(4):433–40 (74 ref.)

RECEPTORS, IL-1 see **RECEPTORS, INTERLEUKIN-1**

RECEPTORS, IL-2 see **RECEPTORS, INTERLEUKIN-2**

RECEPTORS, IL-3 see **RECEPTORS, INTERLEUKIN-3**

RECEPTORS, IMMUNOLOGIC

Scavenger receptors in atherosclerosis. Freeman MW. **Curr Opin Hematol** 1997 Jan;4(1):41–7 (52 ref.)

Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes. Moretta A, et al. **Immunol Rev** 1997 Feb;155:105–17 (92 ref.)

[Scavenger receptor] Kodama T. **Nippon Rinsho** 1997 Apr; 55 Suppl 2:574–6 (6 ref.) **(Jpn)**

[Diversity of scavenger receptor molecules] Fukasawa M. **Seikagaku** 1996 May;68(5):372–7 (16 ref.) **(Jpn)**

[LRP (alpha 2-macroglobulin receptor) and Alzheimer lesions] Akiyama H, et al. **Tanpakushitsu Kakusan Koso** 1996 Aug;41(10):1470–5 (11 ref.) **(Jpn)**

ANALYSIS

Why is CTX all the RAGE? Du Pasquier L, et al. **Res Immunol** 1996 May;147(4):261–6 (15 ref.)

ANTAGONISTS & INHIBITORS

Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment [editorial; comment] Zeni F, et al. **Crit Care Med** 1997 Jul;25(7):1095–100 (38 ref.) Comment on: Crit Care Med 1997 Jul;25(7):1115–24.

Opposing functions of activatory T-cell receptors and inhibitory NK-cell receptors on cytotoxic T cells. Ciccone E, et al. **Immunol Today** 1996 Oct;17(10):450–3 (9 ref.)

CHEMISTRY

Molecular structures of HLA-specific human NK cell receptors. Cantoni C, et al. **Chem Immunol** 1996;64:88–103 (70 ref.)

Killer cell inhibitory receptors: diversity, specificity, and function. Long EO, et al. **Immunol Rev** 1997 Feb; 155:135–44 (51 ref.)

Structure and function of the CD94 C-type lectin receptor complex involved in recognition of HLA class I molecules. López-Botet M, et al. **Immunol Rev** 1997 Feb;155:165–74 (74 ref.)

Domain organization and sequence relationship of killer cell inhibitory receptors. Salter RD, et al. **Immunol Rev** 1997 Feb;155:175–82 (39 ref.)

Polymorphism and domain variability of human killer cell inhibitory receptors. Selvakumar A, et al. **Immunol Rev** 1997 Feb;155:183–96 (57 ref.)
Immunoreceptor tyrosine–based inhibition motifs. Vivier E, et al. **Immunol Today** 1997 Jun;18(6):286–91 (52 ref.)
Inhibitory and activatory receptors for MHC class I molecules. Cambiaggi A, et al. **Res Immunol** 1997 Mar–Apr;148(3):172–9 (53 ref.)
HLA class–I–specific NK receptors belong to two distinct molecular families and display inhibitory or activating function. Cantoni C, et al. **Res Immunol** 1997 Mar–Apr; 148(3):146–50 (28 ref.)

CLASSIFICATION

Inhibitory and activatory receptors for HLA class I molecules in human natural killer cells. Moretta A, et al. **Chem Immunol** 1996;64:77–87 (50 ref.)

GENETICS

NKB1: a killer cell inhibitory receptor for class I HLA–B allotypes. D'Andrea A, et al. **Chem Immunol** 1996; 64:104–15 (44 ref.)
Role of murine NK cells and their receptors in hybrid resistance. Kumar V, et al. **Curr Opin Immunol** 1997 Feb; 9(1):52–6 (39 ref.)
Inhibitory receptors, ITIM sequences and phosphatases. Unkeless JC, et al. **Curr Opin Immunol** 1997 Jun;9(3):338–43 (42 ref.)
Multiple function of macrophage scavenger receptors mediated by fibrous coiled coil domains. Liao HS, et al. **Gerontology** 1996;42 Suppl 1:37–47 (32 ref.)
Polymorphism and domain variability of human killer cell inhibitory receptors. Selvakumar A, et al. **Immunol Rev** 1997 Feb;155:183–96 (57 ref.)
CTX, a new lymphocyte receptor in Xenopus, and the early evolution of Ig domains. DuPasquier L, et al. **Res Immunol** 1996 May;147(4):218–26 (28 ref.)
Events in the adaptation of natural killer cell receptors to MHC class I polymorphisms. Parham P. **Res Immunol** 1997 Mar–Apr;148(3):190–4 (19 ref.)
The killer cell inhibitory receptor genomic region on human chromosome 19q13.4. Dupont B, et al. **Tissue Antigens** 1997 Jun;49(6):557–63 (43 ref.)
[Scavenger receptor gene—regulation of scavenger receptor gene expression in alveolar macrophages and the pathogenesis of pulmonary alveolar proteinosis] Mori T, et al. **Nippon Rinsho** 1996 Feb;54(2):353–7 (13 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Nonfimbrial adhesins of Escherichia coli. Goldhar J. **Adv Exp Med Biol** 1996;408:63–72 (29 ref.)
HLA–class I–specific inhibitory receptors of NK type on a subset of human T cells. Mingari MC, et al. **Chem Immunol** 1996;64:135–45 (51 ref.)
Recognition and signaling by mouse Ly–49 receptors. Seaman WE, et al. **Chem Immunol** 1996;64:19–27 (31 ref.)
Role of murine NK cells and their receptors in hybrid resistance. Kumar V, et al. **Curr Opin Immunol** 1997 Feb; 9(1):52–6 (39 ref.)
Natural killer cell receptors. Long EO, et al. **Curr Opin Immunol** 1997 Jun;9(3):344–50 (69 ref.)
Co–receptors of B lymphocytes. O'Rourke L, et al. **Curr Opin Immunol** 1997 Jun;9(3):324–9 (65 ref.)
Specificity, tolerance and developmental regulation of natural killer cells defined by expression of class I–specific Ly49 receptors. Raulet DH, et al. **Immunol Rev** 1997 Feb; 155:41–52 (46 ref.)
Opposing functions of activatory T–cell receptors and inhibitory NK–cell receptors on cytotoxic T cells. Ciccone E, et al. **Immunol Today** 1996 Oct;17(10):450–3 (9 ref.)
Inhibitory MHC class I receptors on NK cells and T cells [see comments] Lanier LL, et al. **Immunol Today** 1996 Feb; 17(2):86–91 (52 ref.) Comment in: Immunol Today 1997 Mar;18(3):146.
Receptors that turn on and turn off natural killer cells. Chong AS. **J Heart Lung Transplant** 1996 Jul;15(7):675–83 (71 ref.)
A newly recognized pathway for the negative regulation of mast cell–dependent hypersensitivity and inflammation mediated by an endogenous cell surface receptor of the gp49 family. Katz HR, et al. **J Immunol** 1997 Jun 1; 158(11):5065–70 (32 ref.)
Intracellular signaling in neutrophil priming and activation. Downey GP, et al. **Semin Cell Biol** 1995 Dec;6(6):345–56 (61 ref.)

METABOLISM

Natural killer cell receptors and MHC class I interactions. Lanier LL. **Curr Opin Immunol** 1997 Feb;9(1):126–31 (63 ref.)
Collagenous macrophage scavenger receptors. Kodama T, et al. **Curr Opin Lipidol** 1996 Oct;7(5):287–91 (37 ref.)
What's the RAGE? The receptor for advanced glycation end products (RAGE) and the dark side of glucose. Yan SD, et al. **Eur J Clin Invest** 1997 Mar;27(3):179–81 (20 ref.)
Multiple function of macrophage scavenger receptors mediated by fibrous coiled coil domains. Liao HS, et al. **Gerontology** 1996;42 Suppl 1:37–47 (32 ref.)
The Sialoadhesins—a family of sialic acid–dependent cellular recognition molecules within the immunoglobulin superfamily. Kelm S, et al. **Glycoconj J** 1996 Dec; 13(6):913–26 (114 ref.)
Killer cell inhibitory receptor interactions with HLA class I molecules: implications for alloreactivity and transplantation. Young NT, et al. **Hum Immunol** 1997 Jan; 52(1):1–11 (109 ref.)
Intracellular signaling and endosomal trafficking of immunoreceptors. Shared effectors underlying MHC class II–restricted antigen presentation. Bonnerot C, et al. **Immunol Lett** 1997 Jun 1;57(1–3):1–4 (35 ref.)
Signal transduction by human NK cell MHC–recognizing receptors. Binstadt BA, et al. **Immunol Rev** 1997 Feb; 155:197–203 (70 ref.)
Why is it so hard to dissociate multivalent antigens from cell–surface antibodies? [see comments] Goldstein B, et al. **Immunol Today** 1996 Feb;17(2):77–80 (22 ref.) Comment in: Immunol Today 1997 Jun;18(6):305–6.
Endocytic uptake of lysophosphatidylcholine mediated by macrophage scavenger receptor plays a major role in oxidized low density lipoprotein–induced macrophage growth. Sakai M, et al. **J Atheroscler Thromb** 1996; 2(2):81–6 (19 ref.)
Expression of receptors for advanced glycation end–products in occlusive vascular and renal disease. Bierhaus A, et al. **Nephrol Dial Transplant** 1996;11 Suppl 5:87–90 (32 ref.)
The receptor for advanced glycation end–products has a central role in mediating the effects of advanced glycation end–products on the development of vascular disease in diabetes mellitus. Hori O, et al. **Nephrol Dial Transplant** 1996;11 Suppl 5:13–6 (26 ref.)

PHYSIOLOGY

Receptors for HLA class–I molecules in human natural killer cells. Moretta A, et al. **Annu Rev Immunol** 1996;14:619–48 (127 ref.)
Functional resemblance between the Ig–related NK cell receptors specific for HLA class I molecules and the CD94 C–type lectin. López–Botet M, et al. **Chem Immunol** 1996; 64:116–34 (60 ref.)
Inhibitory and activatory receptors for HLA class I molecules in human natural killer cells. Moretta A, et al. **Chem Immunol** 1996;64:77–87 (50 ref.)
Downstream signals initiated in mast cells by Fc epsilon RI and other receptors. Beaven MA, et al. **Curr Opin Immunol** 1996 Dec;8(6):766–72 (66 ref.)
Atherosclerosis: cell biology and lipoproteins [editorial] Tabas I. **Curr Opin Lipidol** 1997 Apr;8(2):U25–7 (16 ref.)
Natural killer cells: from no receptors to too many. Lanier LL. **Immunity** 1997 Apr;6(4):371–8 (109 ref.)
Signal transduction during natural killer cell activation: inside the mind of a killer. Leibson PJ. **Immunity** 1997 Jun; 6(6):655–61 (117 ref.)
Specificity and function of immunoglobulin superfamily NK cell inhibitory and stimulatory receptors. Colonna M. **Immunol Rev** 1997 Feb;155:127–33 (55 ref.)
Arousal and inhibition of human NK cells. Lanier LL, et al. **Immunol Rev** 1997 Feb;155:145–54 (98 ref.)
Killer cell inhibitory receptors: diversity, specificity, and function. Long EO, et al. **Immunol Rev** 1997 Feb; 155:135–44 (51 ref.)
Structure and function of the CD94 C–type lectin receptor complex involved in recognition of HLA class I molecules. López–Botet M, et al. **Immunol Rev** 1997 Feb;155:165–74 (74 ref.)
Transduction of cytotoxic signals in natural killer cells: a general model of fine tuning between activatory and inhibitory pathways in lymphocytes. Renard V, et al. **Immunol Rev** 1997 Feb;155:205–21 (153 ref.)
Human NK cells: their ligands, receptors and functions. Reyburn H, et al. **Immunol Rev** 1997 Feb;155:119–25 (70 ref.)
Divergent functions of lectin–like receptors on NK cells. Ryan JC, et al. **Immunol Rev** 1997 Feb;155:79–89 (70 ref.)
Killer cell receptors: keeping pace with MHC class I evolution. Valiante NM, et al. **Immunol Rev** 1997 Feb; 155:155–64 (51 ref.)
NK–cell receptors and recognition of MHC class I molecules. López–Botet M, et al. **Immunol Today** 1996 May; 17(5):212–4 (4 ref.)
Immunoreceptor tyrosine–based inhibition motifs. Vivier E, et al. **Immunol Today** 1997 Jun;18(6):286–91 (52 ref.)
B–cell activation versus tolerance—the central role of immunoglobulin receptor engagement and T–cell help. Fulcher DA, et al. **Int Rev Immunol** 1997;15(1–2):33–52 (22 ref.)
Immunoglobulin superfamily inhibitory receptors: from natural killer cells to antigen–presenting cells. Colonna M. **Res Immunol** 1997 Mar–Apr;148(3):169–71 (33 ref.)
HLA class–I–specific inhibitory receptor in human T lymphocytes: interference with T–cell functions. Mingari MC, et al. **Res Immunol** 1997 Mar–Apr;148(3):150–5 (32 ref.)
NK receptors and signalling. Palmieri G, et al. **Res Immunol** 1997 Mar–Apr;148(3):184–90 (55 ref.)

RECEPTORS, INSULIN

[Insulin receptor] Matsuba H, et al. **Nippon Rinsho** 1997 Apr; 55 Suppl 2:499–502 (9 ref.) **(Jpn)**

ANALYSIS

Location of insulin receptors in the placenta and its progenitor tissues. Desoye G, et al. **Microsc Res Tech** 1997 Jul 1–15;38(1–2):63–75 (80 ref.)

GENETICS

Insulin receptor gene in hypertension. Morris BJ. **Clin Exp Hypertens** 1997 Jul–Aug;19(5–6):551–65 (78 ref.)
Leprechaunism/Donohue syndrome/insulin receptor gene mutations: a syndrome delineation story from clinicopathological description to molecular understanding. Kosztolányi G. **Eur J Pediatr** 1997 Apr;156(4):253–5 (17 ref.)

METABOLISM

Logical analysis of timing–dependent receptor signalling specificity: application to the insulin receptor metabolic and mitogenic signalling pathways. Shymko RM, et al. **Biochem J** 1997 Sep 1;326 (Pt 2):463–9 (51 ref.)
Suppression of insulin receptor activation by overexpression of the protein–tyrosine phosphatase LAR in hepatoma cells. Li PM, et al. **Cell Signal** 1996 Nov;8(7):467–73 (35 ref.)
Signaling via the insulin–like growth factor–I receptor: does it differ from insulin receptor signaling? Blakesley VA, et al. **Cytokine Growth Factor Rev** 1996 Aug;7(2):153–9 (52 ref.)
Inhibition of insulin receptor signaling by TNF: potential role in obesity and non–insulin–dependent diabetes mellitus. Skolnik EY, et al. **Cytokine Growth Factor Rev** 1996 Aug; 7(2):161–73 (111 ref.)
[Effects of hyperglycemia in the transmission of the insulin message] Hauguel–de Mouzon S, et al. **Journ Annu Diabetol Hotel Dieu** 1996;:145–56 (85 ref.) **(Fre)**

PHYSIOLOGY

Insulin receptor/IRS–1/PI 3–kinase signaling system in corticosteroid–induced insulin resistance. Folli F, et al. **Acta Diabetol** 1996 Sep;33(3):185–92 (82 ref.)
Logical analysis of timing–dependent receptor signalling specificity: application to the insulin receptor metabolic and mitogenic signalling pathways. Shymko RM, et al. **Biochem J** 1997 Sep 1;326 (Pt 2):463–9 (51 ref.)
Insulin second messengers. Strålfors P. **Bioessays** 1997 Apr; 19(4):327–35 (79 ref.)
Role of PI 3–kinase and SH–PTP2 in insulin action. Kasuga M. **Diabet Med** 1996 Sep;13(9 Suppl 6):S87–9 (23 ref.)
Insulin receptors in breast cancer: biological and clinical role. Papa V, et al. **J Endocrinol Invest** 1996 May;19(5):324–33 (54 ref.)
The early intracellular signaling pathway for the insulin/insulin–like growth factor receptor family in the mammalian central nervous system. Folli F, et al. **Mol Neurobiol** 1996 Oct;13(2):155–83 (162 ref.)

RECEPTORS, INSULIN–LIKE–GROWTH FACTOR I

GENETICS

Control of insulin–like growth factor (IGF) action by regulation of IGF–I receptor expression. Roberts CT Jr. **Endocr J** 1996 Oct;43 Suppl:S49–55 (50 ref.)

METABOLISM

Signaling via the insulin–like growth factor–I receptor: does it differ from insulin receptor signaling? Blakesley VA, et al. **Cytokine Growth Factor Rev** 1996 Aug;7(2):153–9 (52 ref.)
The contribution of quantitative confocal laser scanning microscopy in cartilage research: chondrocyte insulin–like growth factor–1 receptors in health and pathology. Verschure PJ, et al. **Microsc Res Tech** 1997 May 15; 37(4):285–98 (65 ref.)

PHYSIOLOGY

The path less traveled by [editorial; comment] Baserga R. **Endocrinology** 1997 Jun;138(6):2217–8 (9 ref.) Comment on: Endocrinology 1997 Jun;138(6):2219–26.
Role of the IGF–I receptor in mutagenesis and tumor promotion. Blakesley VA, et al. **J Endocrinol** 1997 Mar; 152(3):339–44 (51 ref.)
The role of the IGF–I receptor in apoptosis. Baserga R, et al. **Vitam Horm** 1997;53:65–98 (124 ref.)

RECEPTORS, INSULIN–LIKE–GROWTH–FACTOR II

PHYSIOLOGY

[Intracellular transport of lysosomal enzyme—role of mannose–6–phosphate receptors] Czartoryska B. **Postepy Biochem** 1996;42(4):350–7 (75 ref.) **(Pol)**

RECEPTORS, INSULIN–LIKE GROWTH FACTORS see **RECEPTORS, SOMATOMEDIN**

RECEPTORS, INTERFERON

CHEMISTRY

Interferons alpha/beta and their receptors: place in the hierarchy of cytokines. Zav'Yalov VP, et al. **APMIS** 1997 Mar;105(3):161–86 (220 ref.)

The type–I interferon receptor. The long and short of it. Domanski P, et al. **Cytokine Growth Factor Rev** 1996 Aug; 7(2):143–51 (68 ref.)

DEFICIENCY

Immune defence in mice lacking type I and/or type II interferon receptors. van den Broek MF, et al. **Immunol Rev** 1995 Dec;148:5–18 (61 ref.)

GENETICS

Interferon receptors. Langer J, et al. **Biotherapy** 1996; 8(3–4):163–74 (112 ref.)

Receptors for gamma–interferon encoded by poxviruses: implications for the unknown origin of vaccinia virus. Alcamí A, et al. **Trends Microbiol** 1996 Aug;4(8):321–6 (38 ref.)

IMMUNOLOGY

Immune defence in mice lacking type I and/or type II interferon receptors. van den Broek MF, et al. **Immunol Rev** 1995 Dec;148:5–18 (61 ref.)

METABOLISM

The type–I interferon receptor. The long and short of it. Domanski P, et al. **Cytokine Growth Factor Rev** 1996 Aug; 7(2):143–51 (68 ref.)

Immune defence in mice lacking type I and/or type II interferon receptors. van den Broek MF, et al. **Immunol Rev** 1995 Dec;148:5–18 (61 ref.)

PHYSIOLOGY

The IFN gamma receptor: a paradigm for cytokine receptor signaling. Bach EA, et al. **Annu Rev Immunol** 1997; 15:563–91 (107 ref.)

Interferons alpha/beta and their receptors: place in the hierarchy of cytokines. Zav'Yalov VP, et al. **APMIS** 1997 Mar;105(3):161–86 (220 ref.)

The interferon receptors. Pestka S. **Semin Oncol** 1997 Jun; 24(3 Suppl 9):S9–18–S9–40 (122 ref.)

RECEPTORS, INTERLEUKIN

[Interleukin–5 receptor] Ogata N, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:534–7 (9 ref.) **(Jpn)**

[Interleukin 4 receptor (IL–4R)] Saito S. **Nippon Rinsho** 1997 Apr;55 Suppl 2:531–3 (3 ref.) **(Jpn)**

[Interleukin–6 (IL–6) receptor] Sakamoto K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:538–41 (10 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

IL12 receptors and receptor antagonists. Presky DH, et al. **Res Immunol** 1995 Sep–Oct;146(7–8):439–45 (21 ref.)

CHEMISTRY

Interleukin–6: structure–function relationships. Simpson RJ, et al. **Protein Sci** 1997 May;6(5):929–55 (338 ref.)

DEFICIENCY

[Mice deficient for the IL–3/GM–CSF/IL–5 beta receptors] Nishinakamura R. **Rinsho Ketsueki** 1997 Mar;38(3):181–5 (8 ref.) **(Jpn)**

GENETICS

IL–7 receptor and VDJ recombination: trophic versus mechanistic actions. Candéias S, et al. **Immunity** 1997 May; 6(5):501–8 (104 ref.)

IMMUNOLOGY

[Clinical application of interleukin–6 receptor antibody] Nishimoto N, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1997 Apr;20(2):87–94 (18 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

The structural and functional basis of cytokine receptor activation: lessons from the common beta subunit of the granulocyte–macrophage colony–stimulating factor, interleukin–3 (IL–3), and IL–5 receptors. Bagley CJ, et al. **Blood** 1997 Mar 1;89(5):1471–82 (87 ref.)

Diphtheria toxin–based receptor–specific chimaeric toxins as targeted therapies. Sweeney EB, et al. **Essays Biochem** 1995;30:119–31 (23 ref.)

Interleukin 5 interactions with soluble and cell surface forms of its receptor. Li J, et al. **J Mol Recognit** 1996 Sep–Dec; 9(5–6):347–55 (60 ref.)

PHYSIOLOGY

Interleukin 4 and interleukin 13: same response, different receptors. Callard RE, et al. **Biochem Soc Trans** 1997 May; 25(2):451–5 (44 ref.)

Structure and function of interleukin–4 and its receptor. Puri RK. **Cancer Treat Res** 1995;80:143–85 (318 ref.)

Interleukin 4: signalling mechanisms and control of T cell differentiation. Paul WE. **Ciba Found Symp** 1997; 204:208–16; discussion 216–9 (40 ref.)

IL–4 and IL–13 receptors: are they one and the same? Callard RE, et al. **Immunol Today** 1996 Mar;17(3):108–10 (33 ref.)

Interleukin–4 and its receptor: essential mediators of the allergic response. Ryan JJ. **J Allergy Clin Immunol** 1997 Jan;99(1 Pt 1):1–5 (8 ref.)

In vivo, in vitro, and molecular aspects of interleukin–8 and the interleukin–8 receptors. Hoch RC, et al. **J Lab Clin Med** 1996 Aug;128(2):134–45 (97 ref.)

Signal transduction by the GM–CSF, IL–3 and IL–5 receptors. Miyajima A, et al. **Leukemia** 1997 Apr;11 Suppl 3:418–22 (16 ref.)

Interleukin–6: structure–function relationships. Simpson RJ, et al. **Protein Sci** 1997 May;6(5):929–55 (338 ref.)

RECEPTORS, INTERLEUKIN–1

[Interleukin–1 receptor] Kasahara T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:516–9 (8 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Negative regulators of the interleukin–1 system: receptor antagonists and a decoy receptor. Mantovani A, et al. **Int J Clin Lab Res** 1996;26(1):7–14 (78 ref.)

The promise of a new clinical trial—intra–articular IL–1 receptor antagonist. Evans CH, et al. **Proc Assoc Am Physicians** 1996 Jan;108(1):1–5 (34 ref.)

Interleukin–1 receptor antagonism. Nikolic–Paterson DJ, et al. **Semin Nephrol** 1996 Nov;16(6):583–90 (38 ref.)

METABOLISM

Interleukin–1 and interleukin–1 receptor antagonist in inflammatory bowel disease. Cominelli F, et al. **Aliment Pharmacol Ther** 1996;10 Suppl 2:49–53; discussion 54 (39 ref.)

Dual expression of p80 type I and p68 type II interleukin–I receptors on anterior pituitary cells synthesizing growth hormone. French RA, et al. **Endocrinology** 1996 Sep; 137(9):4027–36 (84 ref.)

The interleukin–1 receptor complex and interleukin–1 signal transduction. Martin MU, et al. **Eur Cytokine Netw** 1997 Mar;8(1):5–17 (65 ref.)

PHYSIOLOGY

Central interleukin–1 receptors as mediators of sickness. Kelley KW, et al. **Ann N Y Acad Sci** 1997 Aug 14; 823:234–46 (91 ref.)

RECEPTORS, INTERLEUKIN–2

Coupling of the IL2 receptor complex with non–receptor protein tyrosine kinases. Miyazaki T, et al. **Cancer Surv** 1996;27:25–40 (72 ref.)

[Interleukin–2 receptor] Takakura K. **Nippon Rinsho** 1997 Apr;55 Suppl 2:520–5 (6 ref.) **(Jpn)**

ANALYSIS

[Common gamma chains for cytokine receptors] Nakamura M. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Dec; 19(6):623–8 (30 ref.) **(Jpn)**

BLOOD

Clinical significance of soluble interleukin–2 receptor. Chrobák L. **Acta Medica (Hradec Kralove)** 1996;39(1):3–6 (42 ref.)

Circulating interleukin 2 receptor (IL2R) in nephrotic syndrome. Hulton SA, et al. **Kidney Int Suppl** 1997 Mar; 58:S83–4 (15 ref.)

CHEMISTRY

Characterization of interleukin–15 (IL–15) and the IL–15 receptor complex. Kennedy MK, et al. **J Clin Immunol** 1996 May;16(3):134–43 (56 ref.)

DRUG EFFECTS

The promiscuous IL–2/IL–15 receptor: a target for immunotherapy of HTLV–I–associated disorders. Waldmann TA. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S179–85 (43 ref.)

IMMUNOLOGY

Interleukin–2 receptor signaling mechanisms. Karnitz LM, et al. **Adv Immunol** 1996;61:147–99 (255 ref.)

Interleukin 2 and its receptors: recent advances and new immunological functions [see comments] Thèze J, et al. **Immunol Today** 1996 Oct;17(10):481–6 (39 ref.) Comment in: Immunol Today 1997 May;18(5):254.

METABOLISM

Interleukin–2 fusion protein: an investigational therapy for interleukin–2 receptor expressing malignancies. Nichols J, et al. **Eur J Cancer** 1997 Jan;33 Suppl 1:S34–6 (27 ref.)

[The expression of IL–2 receptor alpha subunit in T cells] Liu CB, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:183–8 (17 ref.) **(Jpn)**

PHYSIOLOGY

The interleukin–2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. Sugamura K, et al. **Annu Rev Immunol** 1996;14:179–205 (120 ref.)

Interleukin 15. Cosman D, et al. **Biochem Soc Trans** 1997 May;25(2):371–4 (30 ref.)

Promotion of interleukin–2 activity as a strategy for 'rejuvenating' geriatric immune function. McCarty MF. **Med Hypotheses** 1997 Jan;48(1):47–54 (120 ref.)

RECEPTORS, INTERLEUKIN–3

[Interleukin–3 receptor] Liu CB, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:526–30 (14 ref.) **(Jpn)**

BIOSYNTHESIS

IL–3 receptor expression, regulation and function in cells of the vasculature. Korpelainen EI, et al. **Immunol Cell Biol** 1996 Feb;74(1):1–7 (63 ref.)

DEFICIENCY

[Mice deficient for the IL–3/GM–CSF/IL–5 beta receptors] Nishinakamura R. **Rinsho Ketsueki** 1997 Mar;38(3):181–5 (8 ref.) **(Jpn)**

METABOLISM

The structural and functional basis of cytokine receptor activation: lessons from the common beta subunit of the granulocyte–macrophage colony–stimulating factor, interleukin–3 (IL–3), and IL–5 receptors. Bagley CJ, et al. **Blood** 1997 Mar 1;89(5):1471–82 (87 ref.)

PHYSIOLOGY

Interleukin–3 and its receptor. Lindemann A, et al. **Cancer Treat Res** 1995;80:107–42 (283 ref.)

IL–3 receptor expression, regulation and function in cells of the vasculature. Korpelainen EI, et al. **Immunol Cell Biol** 1996 Feb;74(1):1–7 (63 ref.)

Signal transduction by the GM–CSF, IL–3 and IL–5 receptors. Miyajima A, et al. **Leukemia** 1997 Apr;11 Suppl 3:418–22 (16 ref.)

Function and signal transduction mediated by the interleukin 3 receptor system in hematopoiesis. Hara T, et al. **Stem Cells** 1996 Nov;14(6):605–18 (99 ref.)

RECEPTORS, INTERSTITIAL CELL–STIMULATING HORMONE see **RECEPTORS, LH**

RECEPTORS, KAINATE see **RECEPTORS, KAINIC ACID**

RECEPTORS, KAINIC ACID

METABOLISM

New developments in the molecular pharmacology of alpha–amino–3–hydroxy–5–methyl–4–isoxazole propionate and kainate receptors. Fletcher EJ, et al. **Pharmacol Ther** 1996;70(1):65–89 (251 ref.)

PHYSIOLOGY

Glutamate receptors of the kainate type and synaptic transmission. Lerma J, et al. **Trends Neurosci** 1997 Jan; 20(1):9–12 (45 ref.)

RECEPTORS, KAPPA see **RECEPTORS, OPIOID, KAPPA**

RECEPTORS, KAPPA OPIOID see **RECEPTORS, OPIOID, KAPPA**

RECEPTORS, LAMININ

METABOLISM

Receptors for laminins during epithelial morphogenesis. Ekblom P. **Curr Opin Cell Biol** 1996 Oct;8(5):700–6 (58 ref.)

Dystroglycan: an extracellular matrix receptor linked to the cytoskeleton. Henry MD, et al. **Curr Opin Cell Biol** 1996 Oct;8(5):625–31 (69 ref.)

PHYSIOLOGY

Aging of the vascular wall and atherogenesis: role of the elastin–laminin receptor [published erratum appears in Atherosclerosis 1996 Sep 27;126(1):173] Robert L. **Atherosclerosis** 1996 Jun;123(1–2):169–79 (56 ref.)

Biological roles of the non–integrin elastin/laminin receptor. Hinek A. **Biol Chem** 1996 Jul–Aug;377(7–8):471–80 (76 ref.)

Neuronal laminins and their cellular receptors. Powell SK, et al. **Int J Biochem Cell Biol** 1997 Mar;29(3):401–14 (133 ref.)

RECEPTORS, LDL

[LDL receptor] Ishibashi S. **Nippon Rinsho** 1997 Apr;55 Suppl 2:577–80 (11 ref.) **(Jpn)**

ANALYSIS

[Study of low density lipoprotein (LDL) receptor mutations, using restriction endonucleases, in familial hypercholesterolemia] Kerepesi M, et al. **Orv Hetil** 1997 Jan 5;138(1):15–8 (17 ref.) (Eng. Abstr.) **(Hun)**

DEFICIENCY

The emergence of mouse models of atherosclerosis and their relevance to clinical research. Smith JD, et al. **J Intern Med** 1997 Aug;242(2):99–109 (99 ref.)

GENETICS

A new member with eleven binding repeats: novel insights into the LDL receptor gene family. Bujo H, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:185–90 (19 ref.)

Single-strand conformation polymorphism analysis with high throughput modifications, and its use in mutation detection in familial hypercholesterolemia. International Federation of Clinical Chemistry Scientific Division: Committee on Molecular Biology Techniques. Humphries SE, et al. **Clin Chem** 1997 Mar;43(3):427–35 (47 ref.)

VLDL receptor in health and disease: interview with a receptor in avian oocytes and mammalian muscle and fat cells. Bujo H, et al. **J Atheroscler Thromb** 1996;2(2):71–5 (33 ref.)

Low density lipoprotein receptor gene family members mediate yolk deposition. Bujo H, et al. **J Nutr** 1997 May; 127(5 Suppl):801S–804S (29 ref.)

[The family of lipoprotein receptors is growing] Heliö T, et al. **Duodecim** 1995;111(16):1534–41 (38 ref.) **(Fin)**

[Molecular genetics of apolipoprotein E and its receptors, implications for genetic risk factors of Alzheimer's disease] Okuizumi K, et al. **Tanpakushitsu Kakusan Koso** 1996 Aug; 41(10):1460–4 (20 ref.) **(Jpn)**

METABOLISM

LDL receptor-independent and -dependent uptake of lipoproteins. van Berkel TJ, et al. **Atherosclerosis** 1995 Dec; 118 Suppl:S43–50 (59 ref.)

Intracellular transport of the low-density lipoprotein receptor. Soutar AK. **Biochem Soc Trans** 1996 May; 24(2):547–52 (41 ref.)

Vitellogenin receptors: oocyte-specific members of the low-density lipoprotein receptor supergene family. Schneider WJ. **Int Rev Cytol** 1996;166:103–37 (119 ref.)

Cellular binding and degradation of lipoprotein (a). Fless GM. **J Atheroscler Thromb** 1995;2 Suppl 1:S1–4 (20 ref.)

[Intracellular signal transmission of low density lipoprotein receptors in human monocytes] Balogh Z, et al. **Orv Hetil** 1997 Sep 7;138(36 Suppl 2):2318–21 (30 ref.) (Eng. Abstr.) **(Hun)**

RECEPTORS, LECTIN see **RECEPTORS, MITOGEN**

RECEPTORS, LEUKOCYTE-ADHESION

see related
LEUKOCYTE-ADHESION DEFICIENCY SYNDROME

METABOLISM

Beta 2 (CD11/CD18) integrins can serve as signaling partners for other leukocyte receptors. Todd RF 3rd, et al. **J Lab Clin Med** 1997 May;129(5):492–8 (64 ref.)

RECEPTORS, LEUKOTRIENE

ANTAGONISTS & INHIBITORS

Leukotrienes and their antagonists in allergic disorders. Negro JM, et al. **Allergol Immunopathol (Madr)** 1997 Mar-Apr;25(2):104–12 (69 ref.)

Zafirlukast: the first leukotriene-receptor antagonist approved for the treatment of asthma [see comments] Kelloway JS. **Ann Pharmacother** 1997 Sep;31(9):1012–21 (43 ref.) Comment in: Ann Pharmacother 1997 Sep;31(9):1084–6.

Leukotrienes in asthma. The potential therapeutic role of antileukotriene agents. Smith LJ. **Arch Intern Med** 1996 Oct 28;156(19):2181–9 (95 ref.)

Worldwide clinical experience with the first marketed leukotriene receptor antagonist. Barnes NC, et al. **Chest** 1997 Feb;111(2 Suppl):52S–60S (20 ref.)

Pharmacology of leukotriene receptor antagonists. More than inhibitors of bronchoconstriction. Hay DW. **Chest** 1997 Feb;111(2 Suppl):35S–45S (131 ref.)

Challenge studies of a leukotriene receptor antagonist. Okudaira H. **Chest** 1997 Feb;111(2 Suppl):46S–51S (22 ref.)

Antileukotriene agents. Tan RA, et al. **Curr Opin Pulm Med** 1997 May;3(3):215–20 (46 ref.)

Management of asthma with zafirlukast. Clinical experience and tolerability profile. Spector SL. **Drugs** 1996;52 Suppl 6:36–46 (46 ref.)

Leukotriene receptor antagonists: clinical effects. Barnes N. **J R Soc Med** 1997 Apr;90(4):200–4 (63 ref.)

Pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in the management of asthma. Drazen JM. **Pharmacotherapy** 1997 Jan-Feb;17(1 Pt 2):22S–30S (58 ref.)

The use of 5-lipoxygenase inhibitors and leukotriene receptor antagonists in the treatment of chronic asthma. Sorkness CA. **Pharmacotherapy** 1997 Jan-Feb;17(1 Pt 2):50S–54S (14 ref.)

Anti-leukotriene intervention: is there adequate information for clinical use in asthma? Ind PW. **Respir Med** 1996 Nov; 90(10):575–86 (70 ref.)

[Leukotrienes and antagonists of leukotriene receptors] **J Pharm Belg** 1997 May-Jun;52(3):131–2 (0 ref.) **(Fre)**

[Leukotriene antagonists. A new therapeutic approach in asthma] Chanez P, et al. **Presse Med** 1997 Feb 22; 26(5):234–9 (70 ref.) (Eng. Abstr.) **(Fre)**

[Leukotriene receptor antagonists] Bornkessel B. **Med Monatsschr Pharm** 1996 Oct;19(10):284–6 (3 ref.) **(Ger)**

[Clinical pharmacology of leucotriene inhibitors] Paggiaro PL, et al. **Ann Ital Med Int** 1996 Oct;11 Suppl 2:85S–89S (39 ref.) (Eng. Abstr.) **(Ita)**

[Peptidoleukotriene receptor antagonists in asthma therapy] Sakakibara H, et al. **Nippon Rinsho** 1996 Nov; 54(11):3049–55 (36 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

[Leukotrienes and asthma. Clinical and experimental experiences with leukotriene receptor antagonists and leukotriene synthesis inhibitors] Henriksen AH, et al. **Tidsskr Nor Laegeforen** 1997 Feb 20;117(5):647–51 (27 ref.) (Eng. Abstr.) **(Nor)**

METABOLISM

Cysteinyl leukotriene receptors in the human lung: what's new? [see comments] Gorenne I, et al. **Trends Pharmacol Sci** 1996 Oct;17(10):342–5 (27 ref.) Comment in: Trends Pharmacol Sci 1997 May;18(5):148–9.

RECEPTORS, LH

TSH receptor and LH receptor, 1996. Kosugi S, et al. **Endocr J** 1996 Dec;43(6):595–604 (37 ref.)

[The functional analysis of LH receptor] Yano K. **Nippon Rinsho** 1997 Apr;55 Suppl 2:487–90 (6 ref.) **(Jpn)**

CHEMISTRY

The LH/CG and FSH receptors: different molecular forms and intracellular traffic. Misrahi M, et al. **Mol Cell Endocrinol** 1996 Dec 20;125(1-2):161–7 (33 ref.)

hCG-receptor binding and transmembrane signaling. Puett D, et al. **Mol Cell Endocrinol** 1996 Dec 20;125(1-2):55–64 (61 ref.)

Structure and functional significance of the carbohydrates of the LH/CG receptor. Rajaniemi HJ, et al. **Mol Cell Endocrinol** 1996 Dec 20;125(1-2):101–5 (35 ref.)

Mapping of HCG-receptor complexes. Remy JJ, et al. **Mol Cell Endocrinol** 1996 Dec 20;125(1-2):79–91 (51 ref.)

Molecular mechanism of LH/CG receptor activation. Ryu KS, et al. **Mol Cell Endocrinol** 1996 Dec 20;125(1-2):93–100 (34 ref.)

Advances in the molecular understanding of gonadotropins-receptors interactions. el Tayar N. **Mol Cell Endocrinol** 1996 Dec 20;125(1-2):65–70 (33 ref.)

GENETICS

Bioassays of gonadotropins based on cloned receptors. Christin-Maitre S, et al. **Mol Cell Endocrinol** 1996 Dec 20;125(1-2):151–9 (49 ref.)

METABOLISM

hCG-receptor binding and transmembrane signaling. Puett D, et al. **Mol Cell Endocrinol** 1996 Dec 20;125(1-2):55–64 (61 ref.)

Molecular mechanism of LH/CG receptor activation. Ryu KS, et al. **Mol Cell Endocrinol** 1996 Dec 20;125(1-2):93–100 (34 ref.)

Interaction, signal generation, signal divergence, and signal transduction of LH/CG and the receptor. Ji TH, et al. **Recent Prog Horm Res** 1997;52:431–53; discussion 454 (78 ref.)

PHYSIOLOGY

Potential novel roles of luteinizing hormone and human chorionic gonadotropin during early pregnancy in women. Rao CV. **Early Pregnancy** 1997 Mar;3(1):1–9 (88 ref.)

Structure and functional significance of the carbohydrates of the LH/CG receptor. Rajaniemi HJ, et al. **Mol Cell Endocrinol** 1996 Dec 20;125(1-2):101–5 (35 ref.)

RECEPTORS, LHRH

see related
INHIBIN

[Pathophysiology of Gn-RH receptor] Imai A, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:463–7 (14 ref.) **(Jpn)**

AGONISTS

Is there a role for induction androgen deprivation prior to radical prostatectomy? Watson R, et al. **Hematol Oncol Clin North Am** 1996 Jun;10(3):627–41 (62 ref.)

ANALYSIS

Studies of gonadotropin-releasing hormone (GnRH) action using GnRH receptor-expressing pituitary cell lines. Kaiser UB, et al. **Endocr Rev** 1997 Feb;18(1):46–70 (191 ref.)

Brain gonadotropin releasing hormone receptors: localization and regulation. Jennes L, et al. **Recent Prog Horm Res** 1997;52:475–90; discussion 490–1 (73 ref.)

BIOSYNTHESIS

Gonadotropin-releasing hormone receptor: gene structure, expression and regulation. Leung PC, et al. **Biol Signals** 1996 Mar-Apr;5(2):63–9 (54 ref.)

CHEMISTRY

Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Sealfon SC, et al. **Endocr Rev** 1997 Apr;18(2):180–205 (237 ref.)

The gonadotrophin-releasing hormone receptor: structural determinants and regulatory control. Sealfon SC, et al. **Hum Reprod Update** 1995 May;1(3):216–30 (156 ref.)

GENETICS

Gonadotropin-releasing hormone receptor: gene structure, expression and regulation. Leung PC, et al. **Biol Signals** 1996 Mar-Apr;5(2):63–9 (54 ref.)

Brain gonadotropin releasing hormone receptors: localization and regulation. Jennes L, et al. **Recent Prog Horm Res** 1997;52:475–90; discussion 490–1 (73 ref.)

METABOLISM

Signal transduction of GnRH receptor in the reproductive tract tumor. Imai A, et al. **Endocr J** 1996 Jun;43(3):249–60 (139 ref.)

PHYSIOLOGY

Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Sealfon SC, et al. **Endocr Rev** 1997 Apr;18(2):180–205 (237 ref.)

GnRH receptor signaling: cross-talk of Ca2+ and protein kinase C. Naor Z. **Eur J Endocrinol** 1997 Feb;136(2):123–7 (39 ref.)

The gonadotrophin-releasing hormone receptor: structural determinants and regulatory control. Sealfon SC, et al. **Hum Reprod Update** 1995 May;1(3):216–30 (156 ref.)

RECEPTORS, LIPOPOLYSACCHARIDE see **ANTIGENS, CD14**

RECEPTORS, LIPOPROTEIN

[Apolipoprotein E and its receptors in Alzheimer's disease] Ikeda K. **Tanpakushitsu Kakusan Koso** 1996 Aug; 41(10):1465–9 (29 ref.) **(Jpn)**

GENETICS

[The family of lipoprotein receptors is growing] Heliö T, et al. **Duodecim** 1995;111(16):1534–41 (38 ref.) **(Fin)**

METABOLISM

Close encounters with apolipoprotein E receptors. Yamamoto T, et al. **Curr Opin Lipidol** 1996 Oct; 7(5):298–302 (31 ref.)

Expression of lipoprotein receptors and related molecules in atherosclerotic lesions. Ylä-Herttuala S. **Curr Opin Lipidol** 1996 Oct;7(5):292–7 (73 ref.)

Lipoprotein trafficking in vascular cells. Molecular Trojan horses and cellular saboteurs. Hajjar DP, et al. **J Biol Chem** 1997 Sep 12;272(37):22975–8 (64 ref.)

Lipoprotein lipase (EC 3.1.1.34) targeting of lipoproteins to receptors. Beisiegel U, et al. **Proc Nutr Soc** 1997 Jul; 56(2):731–7 (37 ref.)

PHYSIOLOGY

Gene transfer and disruption strategies to elucidate hepatic lipoprotein receptor functions. Herz J, et al. **Atherosclerosis** 1995 Dec;118 Suppl:S37–41 (15 ref.)

[High density lipoproteins: physiological importance] Kurashvili LV. **Patol Fiziol Eksp Ter** 1997 Jul-Sep;(3):40–3 (52 ref.) **(Rus)**

RECEPTORS, LOW DENSITY LIPOPROTEIN see **RECEPTORS, LDL**

RECEPTORS, LULIBERIN see **RECEPTORS, LHRH**

RECEPTORS, LUTEINIZING HORMONE see **RECEPTORS, LH**

RECEPTORS, LYMPHOCYTE HOMING

IMMUNOLOGY

T cell migration during ontogeny and T cell repertoire generation. Dunon D, et al. **Curr Top Microbiol Immunol** 1996;212:79–93 (45 ref.)

RECEPTORS, LYMPHOCYTE HOMING

METABOLISM

The role of alpha 4 integrins in lung pathophysiology. Lobb RR, et al. **Eur Respir J Suppl** 1996 Aug;22:104s–108s (34 ref.)

PHYSIOLOGY

The role of adhesion molecules in multiple myeloma. Cook G, et al. **Acta Haematol** 1997;97(1–2):81–9 (65 ref.)

Regulation and function of adhesion molecules in B-cell chronic lymphocytic leukaemia. Jewell AP, et al. **Acta Haematol** 1997;97(1–2):67–72 (25 ref.)

Adhesion molecules in the dissemination of non-Hodgkin's lymphomas. Pals ST, et al. **Acta Haematol** 1997; 97(1–2):73–80 (84 ref.)

Homing and trafficking of hemopoietic progenitor cells. Papayannopoulou T, et al. **Acta Haematol** 1997; 97(1–2):97–104 (73 ref.)

The role of adhesion and costimulation molecules in graft-versus-host disease. Schlegel PG. **Acta Haematol** 1997;97(1–2):105–17 (191 ref.)

Pathophysiologic role of alpha 4 integrins in the lung. Lobb RR, et al. **Ann N Y Acad Sci** 1996 Oct 31;796:113–23 (47 ref.)

High-endothelial-venule ligands for L-selectin: identification and functions. Rosen SD, et al. **Biochem Soc Trans** 1997 May;25(2):428–33 (45 ref.)

Lymphocyte homing: the scent of a follicle. Goodnow CC, et al. **Curr Biol** 1997 Apr 1;7(4):R219–22 (26 ref.)

The role of alpha 4 integrins in lung pathophysiology. Lobb RR, et al. **Eur Respir J Suppl** 1996 Aug;22:104s–108s (34 ref.)

VLA-4-mediated interactions between normal human hematopoietic progenitors and stromal cells. Oostendorp RA, et al. **Leuk Lymphoma** 1997 Feb;24(5–6):423–35 (94 ref.)

RECEPTORS, MACROPHAGE COLONY-STIMULATING FACTOR

BIOSYNTHESIS

Regulation of CSF-1 receptor expression. Hume DA, et al. **Mol Reprod Dev** 1997 Jan;46(1):46–52; discussion 52–3 (20 ref.)

CHEMISTRY

Macrophage colony-stimulating-factor (M-CSF or CSF-1) and its receptor: structure-function relationships. Fixe P, et al. **Eur Cytokine Netw** 1997 Jun;8(2):125–36 (140 ref.)

GENETICS

[Cell biology of osteoclasts and molecular mechanisms of bone resorption] Amling M, et al. **Pathologe** 1996 Sep; 17(5):358–67 (76 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Macrophage colony-stimulating-factor (M-CSF or CSF-1) and its receptor: structure-function relationships. Fixe P, et al. **Eur Cytokine Netw** 1997 Jun;8(2):125–36 (140 ref.)

CSF-1 signal transduction. Hamilton JA. **J Leukoc Biol** 1997 Aug;62(2):145–55 (121 ref.)

CSF-1 and its receptor in breast carcinomas and neoplasms of the female reproductive tract. Kacinski BM. **Mol Reprod Dev** 1997 Jan;46(1):71–4 (17 ref.)

Growth and differentiation signals regulated by the M-CSF receptor. Rohrschneider LR, et al. **Mol Reprod Dev** 1997 Jan;46(1):96–103 (11 ref.)

[Signaling pathway of macrophage colony-stimulating factor receptor] Kimura F, et al. **Rinsho Ketsueki** 1997 Mar; 38(3):189–92 (10 ref.) **(Jpn)**

RECEPTORS, MANNOSE-6-PHOSPHATE see **RECEPTORS, INSULIN-LIKE-GROWTH-FACTOR II**

RECEPTORS, MENOTROPIN see **RECEPTORS, GONADOTROPIN**

RECEPTORS, METABOTROPIC GLUTAMATE

[Metabotropic glutamate receptors] Minakami R, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):295–301 (43 ref.) **(Jpn)**

CHEMISTRY

Molecular characterization of NMDA and metabotropic glutamate receptors. Masu M, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:153–64 (36 ref.)

DRUG EFFECTS

Metabotropic glutamate receptors and neuronal degeneration in culture. Bruno V, et al. **Adv Neurol** 1996;71:47–51, discussion 51–2 (23 ref.)

Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Nicoletti F, et al. **Trends Neurosci** 1996 Jul;19(7):267–71 (74 ref.)

METABOLISM

Acute mechanical hyperalgesia in the rat can be produced by coactivation of spinal ionotropic AMPA and metabotropic glutamate receptors, activation of phospholipase A2 and generation of cyclooxygenase products. Meller ST, et al. **Prog Brain Res** 1996;110:177–92 (69 ref.)

PHYSIOLOGY

Metabotropic glutamate receptors in hippocampal long-term potentiation and learning and memory. Riedel G, et al. **Acta Physiol Scand** 1996 May;157(1):1–19 (125 ref.)

Molecular characterization of NMDA and metabotropic glutamate receptors. Masu M, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:153–64 (36 ref.)

Pharmacology and functions of metabotropic glutamate receptors. Conn PJ, et al. **Annu Rev Pharmacol Toxicol** 1997;37:205–37 (198 ref.)

Synaptic transmission: well-placed modulators. Forsythe ID, et al. **Curr Biol** 1997 Jun 1;7(6):R362–5 (21 ref.)

Roles of metabotropic glutamate receptors in glial function and glial-neuronal communication. Winder DG, et al. **J Neurosci Res** 1996 Oct 15;46(2):131–7 (63 ref.)

The modulation of calcium currents by the activation of mGluRs. Functional implications. Stefani A, et al. **Mol Neurobiol** 1996 Aug;13(1):81–95 (81 ref.)

Receptor-mediated activation of protein kinase C in hippocampal long-term potentiation: facts, problems and implications [see comments] Angenstein F, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Apr; 21(3):427–54 (113 ref.) Comment in: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):373–8.

Comparing the role of metabotropic glutamate receptors in long-term potentiation and in learning and memory. Riedel G, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Jul;20(5):761–89 (118 ref.)

Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Nicoletti F, et al. **Trends Neurosci** 1996 Jul;19(7):267–71 (74 ref.)

RECEPTORS, N-METHYL-D-ASPARTATE

[Molecular function of subtype and subunit drug receptors] Kimura M, et al. **Nippon Yakurigaku Zasshi** 1996 Sep; 108(3):155–6 (0 ref.) **(Jpn)**

[Molecular diversity and physiological roles of the NMDA-receptor channel] Mori H, et al. **Nippon Yakurigaku Zasshi** 1996 Jul;108(1):1–12 (50 ref.) (Eng. Abstr.) **(Jpn)**

AGONISTS

Developmental spectrum of the excitotoxic cascade induced by ibotenate: a model of hypoxic insults in fetuses and neonates. Gressens P, et al. **Neuropathol Appl Neurobiol** 1996 Dec;22(6):498–502 (22 ref.)

ANALYSIS

Neuronal and glial localization of NMDA receptors in the cerebral cortex. Conti F, et al. **Mol Neurobiol** 1997 Feb-Apr;14(1–2):1–18 (85 ref.)

ANTAGONISTS & INHIBITORS

Ethanol inhibition of NMDA receptor function in primary cultures of rat cerebellar granule cells and cerebral cortical cells. Hoffman PL, et al. **Alcohol Alcohol Suppl** 1994; 2:199–204 (34 ref.)

Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Kornhuber J, et al. **Biol Psychiatry** 1997 Jan 15;41(2):135–44 (85 ref.)

Similarity of neuronal cell injury and death in AIDS dementia and focal cerebral ischemia: potential treatment with NMDA open-channel blockers and nitric oxide-related species. Lipton SA. **Brain Pathol** 1996 Oct;6(4):507–17 (117 ref.)

Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease. Blanchet PJ, et al. **Neurosci Biobehav Rev** 1997 Jul;21(4):447–53 (80 ref.)

Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents—preclinical studies. Danysz W, et al. **Neurosci Biobehav Rev** 1997 Jul;21(4):455–68 (151 ref.)

Innovations in pharmacologic therapies. Miaskowski C. **Semin Oncol Nurs** 1997 Feb;13(1):30–5 (44 ref.)

BIOSYNTHESIS

Functional consequences of changes in NMDA receptor subunit expression during development. Feldmeyer D, et al. **J Neurocytol** 1996 Dec;25(12):857–67 (80 ref.)

CHEMISTRY

Molecular characterization of NMDA and metabotropic glutamate receptors. Masu M, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:153–64 (36 ref.)

Molecular and functional diversity of the NMDA receptor channel. Mishina M, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:136–52 (43 ref.)

DRUG EFFECTS

N-methyl-D-aspartate receptors, nitric oxide, and ethanol tolerance. Morato GS, et al. **Braz J Med Biol Res** 1996 Nov;29(11):1415–26 (138 ref.)

NMDA antagonists: their role in neuroprotection. Small DL, et al. **Int Rev Neurobiol** 1997;40:137–71 (229 ref.)

New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline. Gerlach M, et al. **J Neural Transm Suppl** 1996;48:7–21 (63 ref.)

GENETICS

Molecular biological investigations into the role of the NMDA receptor in the pathophysiology of schizophrenia. Catts SV, et al. **Aust N Z J Psychiatry** 1997 Feb;31(1):17–26 (110 ref.)

NMDA receptors: from genes to channels. Sucher NJ, et al. **Trends Pharmacol Sci** 1996 Oct;17(10):348–55 (67 ref.)

IMMUNOLOGY

[Autoantibodies to glutamate receptor subtypes--markers of functional brain damage: their diagnostic significance for detecting paroxysmal activity and ischemia] Dambinova SA, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 Mar-Apr;47(2):439–46 (48 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Functional modulation of ligand-gated GABAA and NMDA receptor channels by phosphorylation. Sigel E. **J Recept Signal Transduct Res** 1995 Jan-Mar; 15(1–4):325–32 (21 ref.)

NMDA receptor-mediated calcium fluxes in the hippocampus: relevance to ischemic brain pathology. Salińska E, et al. **Neurol Neurochir Pol** 1996;30 Suppl 2:35–42 (34 ref.)

A pivotal role for glutamate in the pathogenesis of schizophrenia, and its cognitive dysfunction. Hirsch SR, et al. **Pharmacol Biochem Behav** 1997 Apr;56(4):797–802 (51 ref.)

Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Skolnick P, et al. **Pharmacopsychiatry** 1996 Jan;29(1):23–6 (28 ref.)

NMDA receptors: from genes to channels. Sucher NJ, et al. **Trends Pharmacol Sci** 1996 Oct;17(10):348–55 (67 ref.)

PHYSIOLOGY

Alcohol dependence: a commentary on mechanisms. Hoffman PL, et al. **Alcohol Alcohol** 1996 Jul;31(4):333–40 (60 ref.)

Molecular characterization of NMDA and metabotropic glutamate receptors. Masu M, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:153–64 (36 ref.)

Molecular and functional diversity of the NMDA receptor channel. Mishina M, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:136–52 (43 ref.)

Gonadal and adrenal steroids regulate neurochemical and structural plasticity of the hippocampus via cellular mechanisms involving NMDA receptors. McEwen BS. **Cell Mol Neurobiol** 1996 Apr;16(2):103–16 (75 ref.)

The role of glutamate in the pathophysiology of Parkinson's disease. Blandini F, et al. **Funct Neurol** 1996 Jan-Feb; 11(1):3–15 (95 ref.)

NMDA receptor-dependent LTD in different subfields of hippocampus in vivo and in vitro. Thiels E, et al. **Hippocampus** 1996;6(1):43–51 (64 ref.)

Progress in understanding NMDA-receptor-dependent synaptic plasticity in the visual cortex. Bear MF. **J Physiol Paris** 1996;90(3–4):223–7 (39 ref.)

Cascade of gene expression induced by Ca2+ signals in neurons. Tsuda M. **Neurochem Int** 1996 Nov;29(5):443–51 (49 ref.)

A synaptic basis for memory storage in the cerebral cortex. Bear MF. **Proc Natl Acad Sci U S A** 1996 Nov 26; 93(24):13453–9 (59 ref.)

NMDA-receptor-dependent synaptic plasticity in the visual cortex. Bear MF. **Prog Brain Res** 1996;108:205–18 (78 ref.)

The role of NMDA receptors and nitric oxide in retinogeniculate development. Cramer KS, et al. **Prog Brain Res** 1996;108:235–44 (84 ref.)

Is there a nociceptive carousel? Urban L, et al. **Trends Pharmacol Sci** 1997 Jul;18(7):223–4 (7 ref.)

[Dynamic regulation of the NMDA receptor channel subunits in the central nervous system and their involvement in synaptic plasticity and development] Watanabe M. **Kaibogaku Zasshi** 1996 Oct;71(5):517–22 (17 ref.) (Eng. Abstr.) **(Jpn)**

[N-methyl-D-aspartate (NMDA) receptor and pain] Yamamoto T. **Masui** 1996 Nov;45(11):1312–8 (24 ref.) (Eng. Abstr.) **(Jpn)**

RECEPTORS, MINERALOCORTICOID

[Mineralocorticoid receptor] Suzuki Y, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:566–9 (17 ref.) **(Jpn)**

GENETICS

Glucocorticoid and mineralocorticoid receptors: biology and clinical relevance. Funder JW. **Annu Rev Med** 1997;

48:231–40 (53 ref.)

METABOLISM

Mineralocorticoid receptors and glucocorticoid receptors. Funder JW. **Clin Endocrinol (Oxf)** 1996 Dec;45(6):651–6 (43 ref.)

Heterodimerization between mineralocorticoid and glucocorticoid receptors increases the functional diversity of corticosteroid action. Trapp T, et al. **Trends Pharmacol Sci** 1996 Apr;17(4):145–9 (49 ref.)

PHYSIOLOGY

Brain–corticosteroid hormone dialogue: slow and persistent. de Kloet ER, et al. **Cell Mol Neurobiol** 1996 Jun; 16(3):345–56 (52 ref.)

11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. White PC, et al. **Endocr Rev** 1997 Feb;18(1):135–56 (209 ref.)

Corticosteroids enhance convulsion susceptibility via central mineralocorticoid receptors. Roberts AJ, et al. **Psychoneuroendocrinology** 1995;20(8):891–902 (52 ref.)

Mineralocorticoid receptors, salt, and hypertension. Funder JW, et al. **Recent Prog Horm Res** 1997;52:247–60; discussion 261–2 (54 ref.)

RECEPTORS, MITOGEN

The CD94/NKG2 C-type lectin receptor complex: involvement in NK cell–mediated recognition of HLA class I molecules. López-Botet M, et al. **Immunol Res** 1997; 16(2):175–85 (50 ref.)

METABOLISM

The CD94/NKG2C-type lectin receptor complex in recognition of HLA class I molecules. López-Botet M, et al. **Res Immunol** 1997 Mar–Apr;148(3):155–9 (30 ref.)

RECEPTORS, MORPHINE see **RECEPTORS, OPIOID, MU**

RECEPTORS, MU see **RECEPTORS, OPIOID, MU**

RECEPTORS, MU OPIOID see **RECEPTORS, OPIOID, MU**

RECEPTORS, MUSCARINIC

Selective muscarinic receptor agonists and antagonists. Eglen RM, et al. **Pharmacol Toxicol** 1996 Feb;78(2):59–68 (101 ref.)

[Molecular function of subtype and subunit drug receptors] Kimura M, et al. **Nippon Yakurigaku Zasshi** 1996 Sep; 108(3):155–6 (0 ref.) **(Jpn)**

ANALYSIS

Radiolabeled ligands for imaging the muscarinic–cholinergic receptors of the heart and brain. Knapp FF Jr, et al. **Anticancer Res** 1997 May–Jun;17(3B):1559–72 (63 ref.)

Immunocytochemical localization of muscarinic receptors as an autoantigen in heart tissue [published erratum appears in Int J Cardiol 1996 Sep;56(1):103] Schulze W, et al. **Int J Cardiol** 1996 May;54(2):177–82 (39 ref.)

Radioligand binding measurement of receptor sequestration in intact and permeabilized cells. Slowiejko DM, et al. **Methods Mol Biol** 1997;83:243–50 (11 ref.)

Cholinergic innervation and receptors in the cerebellum. Jaarsma D, et al. **Prog Brain Res** 1997;114:67–96 (113 ref.)

[Muscarinic cholinergic receptor imaging of parkinsonian brain using 11C-NMPB and PET] Asahina M, et al. **Nippon Rinsho** 1997 Jan;55(1):233–7 (10 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease. Levey AI. **Proc Natl Acad Sci U S A** 1996 Nov 26; 93(24):13541–6 (64 ref.)

CHEMISTRY

Studies of the pharmacology, localization, and structure of muscarinic acetylcholine receptors. Brann MR, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:225–36 (59 ref.)

Molecular basis of the muscarinic acetylcholine receptor. Kubo T. **Ann N Y Acad Sci** 1993 Dec 20;707:210–24 (44 ref.)

Structural basis of receptor/G protein coupling selectivity studied with muscarinic receptors as model systems. Wess J, et al. **Life Sci** 1997;60(13–14):1007–14 (33 ref.)

Allosteric regulation of muscarinic receptors. Birdsall NJ, et al. **Prog Brain Res** 1996;109:147–51 (17 ref.)

Molecular aspects of muscarinic receptor assembly and function. Wess J, et al. **Prog Brain Res** 1996;109:153–62 (45 ref.)

CLASSIFICATION

The M5 (m5) receptor subtype: fact or fiction? Reever CM, et al. **Life Sci** 1997;60(13–14):1105–12 (20 ref.)

Muscarinic receptor subtypes and smooth muscle function. Eglen RM, et al. **Pharmacol Rev** 1996 Dec;48(4):531–65 (482 ref.)

DRUG EFFECTS

Drug receptor mechanisms in smooth muscle: beta-chloroethylamine-sensitive and -resistant receptor mechanisms. Takayanagi I, et al. **Jpn J Pharmacol** 1997 Jan;73(1):1–22 (89 ref.)

Muscarinic receptor subtype selective toxins. Adem A, et al. **Life Sci** 1997;60(13–14):1069–76 (32 ref.)

Discovery & development of selective M3 antagonists for clinical use. Alabaster VA. **Life Sci** 1997;60(13–14):1053–60 (24 ref.)

Selective allosteric enhancement of the binding and actions of acetylcholine at muscarinic receptor subtypes. Birdsall NJ, et al. **Life Sci** 1997;60(13–14):1047–52 (29 ref.)

IMMUNOLOGY

Characterization of anti-heart M2 muscarinic receptor antibodies—a combined clinical and experimental study. Fu ML. **Mol Cell Biochem** 1996 Oct–Nov;163–164:343–7 (33 ref.)

METABOLISM

Molecular biology of muscarinic acetylcholine receptors. Wess J. **Crit Rev Neurobiol** 1996;10(1):69–99 (196 ref.)

Antiadrenergic and muscarinic receptor antibodies in Chagas' cardiomyopathy. Borda ES, et al. **Int J Cardiol** 1996 May; 54(2):149–56 (38 ref.)

Anti-M2 muscarinic receptor autoantibodies and idiopathic dilated cardiomyopathy. Fu ML. **Int J Cardiol** 1996 May; 54(2):127–35 (57 ref.)

Receptor-mediated phosphoinositide metabolism in peripheral nerve and cultured Schwann cells. Eichberg J, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):187–95 (26 ref.)

Inositol trisphosphate/Ca2+ as messengers of bradykinin B2 and muscarinic acetylcholine m1–m4 receptors in neuroblastoma-derived hybrid cells. Noda M, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):175–85 (44 ref.)

Acute regulation of the receptor-mediated phosphoinositide signal transduction pathway. Willars GB, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):157–68 (35 ref.)

Use of random-saturation mutagenesis to study receptor–G protein coupling. Burstein ES, et al. **Methods Mol Biol** 1997;83:143–57 (18 ref.)

Allosteric regulation of muscarinic receptors. Birdsall NJ, et al. **Prog Brain Res** 1996;109:147–51 (17 ref.)

PHYSIOLOGY

G protein-coupled receptor kinase: phosphorylation of muscarinic receptors and facilitation of receptor sequestration. Haga T, et al. **Adv Pharmacol** 1996;36:173–91 (23 ref.)

Studies of the pharmacology, localization, and structure of muscarinic acetylcholine receptors. Brann MR, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:225–36 (59 ref.)

Molecular basis of the muscarinic acetylcholine receptor. Kubo T. **Ann N Y Acad Sci** 1993 Dec 20;707:210–24 (44 ref.)

Regulation of muscarinic M2 receptors. Barnes PJ, et al. **Life Sci** 1997;60(13–14):1015–21 (29 ref.)

Muscarinic mechanisms in nerve cells. Brown DA, et al. **Life Sci** 1997;60(13–14):1137–44 (104 ref.)

Pathways and roadblocks in muscarinic receptor–mediated growth regulation. Brown JH, et al. **Life Sci** 1997; 60(13–14):1077–84 (49 ref.)

The pathway connecting m2 receptors to the nucleus involves small GTP-binding proteins acting on divergent MAP kinase cascades. Gutkind JS, et al. **Life Sci** 1997; 60(13–14):999–1006 (19 ref.)

Regulation of muscarinic receptor expression and function in cultured cells and in knock-out mice. McKinnon LA, et al. **Life Sci** 1997;60(13–14):1101–4 (17 ref.)

Muscarinic M3 receptor coupling and regulation. Nahorski SR, et al. **Life Sci** 1997;60(13–14):1039–45 (45 ref.)

Muscarinic receptors involved in hippocampal plasticity. Segal M, et al. **Life Sci** 1997;60(13–14):1085–91 (37 ref.)

Muscarinic control of airway function. Zaagsma J, et al. **Life Sci** 1997;60(13–14):1061–8 (40 ref.)

Muscarinic receptor subtypes and smooth muscle function. Eglen RM, et al. **Pharmacol Rev** 1996 Dec;48(4):531–65 (482 ref.)

Muscarinic M2 and M3 receptor function in smooth muscle. Eglen RM. **Proc West Pharmacol Soc** 1996;39:57–60 (48 ref.)

The role of G-protein coupled receptor kinases in the regulation of muscarinic cholinergic receptors. Hosey MM, et al. **Prog Brain Res** 1996;109:169–79 (64 ref.)

Muscarinic activation of phosphatidylcholine hydrolysis. Klein J, et al. **Prog Brain Res** 1996;109:201–8 (57 ref.)

Muscarinic receptors and cell signalling. Löffelholz K. **Prog Brain Res** 1996;109:191–4 (33 ref.)

Activation, cellular redistribution and enhanced degradation of the G proteins Gq and G11 by endogenously expressed and transfected phospholipase C-coupled muscarinic m1 acetylcholine receptors. Mullaney I, et al. **Prog Brain Res** 1996;109:181–7 (44 ref.)

Regulation of muscarinic acetylcholine receptor expression and function. Nathanson NM. **Prog Brain Res** 1996; 109:165–8 (20 ref.)

Participation of small GTP-binding proteins in m3 muscarinic acetylcholine receptor signalling to phospholipase D and C. Rümenapp U, et al. **Prog Brain Res** 1996;109:209–16 (42 ref.)

Molecular aspects of muscarinic receptor assembly and function. Wess J, et al. **Prog Brain Res** 1996;109:153–62 (45 ref.)

Emptying against outflow obstruction—pharmacological aspects. Andersson KE. **Scand J Urol Nephrol Suppl** 1997; 184:77–84 (83 ref.)

RECEPTORS, MUSCIMOL see **RECEPTORS, GABA-A**

RECEPTORS, NARCOTIC see **RECEPTORS, OPIOID**

RECEPTORS, NERVE GROWTH FACTOR

[Neurotrophins and their receptors] Furukawa Y, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):470–80 (55 ref.) **(Jpn)**

ANALYSIS

Cell-surface markers for assessing gene transfer into human hematopoietic cells [see comments] Phillips K, et al. **Nat Med** 1996 Oct;2(10):1154–6 (25 ref.) Comment in: Nat Med 1996 Dec;2(12):1280–1.

BIOSYNTHESIS

Neurotrophin and neurotrophin receptors in islet cells. Scharfmann R. **Horm Metab Res** 1997 Jun;29(6):294–6 (13 ref.)

GENETICS

Participation of nerve growth factor in the regulation of ovarian function. Dissen GA, et al. **Zygote** 1996 Nov; 4(4):309–12 (38 ref.)

METABOLISM

Excitotoxicity and excitoprotection in vitro. Mattson MP, et al. **Adv Neurol** 1996;71:1–30; discussion 30–5 (267 ref.)

Neurotrophin-Trk receptor interactions in neoplasia: a possible role in interstitial and perineural invasion in ductal pancreatic cancer. Miknyoczki SJ, et al. **Crit Rev Oncog** 1996;7(1–2):89–100 (109 ref.)

Signal transduction by the neurotrophin receptors. Kaplan DR, et al. **Curr Opin Cell Biol** 1997 Apr;9(2):213–21 (79 ref.)

Craniosynostosis: novel insights into pathogenesis and treatment. Wilkie AO, et al. **Curr Opin Neurol** 1996 Apr; 9(2):146–52 (84 ref.)

Neurotrophin receptors and selective loss of cholinergic neurons in Alzheimer disease. Boissière F, et al. **Mol Chem Neuropathol** 1996 May–Aug;28(1–3):219–23 (17 ref.)

Activating mechanism of CNTF and related cytokines. Inoue M, et al. **Mol Neurobiol** 1996 Jun;12(3):195–209 (128 ref.)

Nerve growth factors from snake venoms: chemical properties, mode of action and biological significance. Kostiza T, et al. **Toxicon** 1996 Jul;34(7):787–806 (75 ref.)

PHYSIOLOGY

The neurotrophins and CNTF: two families of collaborative neurotrophic factors. Ip NY, et al. **Annu Rev Neurosci** 1996; 19:491–515 (137 ref.)

Physiology of the neurotrophins. Lewin GR, et al. **Annu Rev Neurosci** 1996;19:289–317 (203 ref.)

Exploring cell death mechanisms by analyzing signaling cascades of the TNF/NGF receptor family. Wallach D, et al. **Behring Inst Mitt** 1996 Oct;(97):144–55 (69 ref.)

Signalling through the neurotrophin receptor p75NTR. Dechant G, et al. **Curr Opin Neurobiol** 1997 Jun;7(3):413–8 (58 ref.)

Neuregulins and neuregulin receptors in neural development. Gassmann M, et al. **Curr Opin Neurobiol** 1997 Feb; 7(1):87–92 (48 ref.)

The estrogen/neurotrophin connection during neural development: is co-localization of estrogen receptors with the neurotrophins and their receptors biologically relevant? Toran-Allerand CD. **Dev Neurosci** 1996;18(1–2):36–48 (105 ref.)

Neurotrophin-3 knocks heart off Trk. Srivastava D, et al. **Nat Med** 1996 Oct;2(10):1069–71 (17 ref.)

Neurotrophins and their receptors in nerve injury and repair. Ebadi M, et al. **Neurochem Int** 1997 Apr–May; 30(4–5):347–74 (240 ref.)

Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis. Burden S, et al. **Neuron** 1997 Jun;18(6):847–55 (48 ref.)

Neurotrophins live or let die: does p75NTR decide? Carter BD, et al. **Neuron** 1997 Feb;18(2):187–90 (24 ref.)

p75NTR and apoptosis: Trk-dependent and Trk-independent effects. Bredesen DE, et al. **Trends Neurosci** 1997 Jul; 20(7):287–90 (36 ref.)

RECEPTORS, NEU see **PROTO-ONCOGENE PROTEINS C-ERBB-2**

RECEPTORS, NEURAL see **RECEPTORS, SENSORY**

RECEPTORS, NEUROHUMOR

RECEPTORS, NEUROHUMOR see **RECEPTORS, NEUROTRANSMITTER**

RECEPTORS, NEUROKININ-1

ANTAGONISTS & INHIBITORS

Nonpeptide tachykinin antagonists: medicinal chemistry and molecular biology. Lowe JA 3rd. **Med Res Rev** 1996 Nov; 16(6):527–45 (87 ref.)

Nonpeptide antagonists of the NK1 tachykinin receptor. McLean S. **Med Res Rev** 1996 Jul;16(4):297–317 (175 ref.)

BIOSYNTHESIS

Commentary on magnesium deficiency, substance P receptor up-regulation and NO overproduction. Weglicki WB, et al. **Magnes Res** 1996 Dec;9(4):331–2 (10 ref.)

PHYSIOLOGY

Neurogenic inflammation. A model for studying efferent actions of sensory nerves. McDonald DM, et al. **Adv Exp Med Biol** 1996;410:453–62 (68 ref.)

RECEPTORS, NEUROKININ-2

ANTAGONISTS & INHIBITORS

A review of the design, synthesis and biological activity of the bicyclic hexapeptide tachykinin NK2 antagonist MEN 10627. Quartara L, et al. **Regul Pept** 1996 Aug 27;65(1):55–9 (29 ref.)

RECEPTORS, NEUROMEDIN B see **RECEPTORS, BOMBESIN**

RECEPTORS, NEUROPEPTIDE

[GRH receptor] Sato M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:468–71 (7 ref.) **(Jpn)**

[Motilin and motilin receptor] Satoh M, et al. **Nippon Rinsho** 1996 Apr;54(4):1092–6 (20 ref.) (Eng. Abstr.) **(Jpn)**

AGONISTS

[Acute reversible pan-dysautonomia: effect of erythromycin on gastrointestinal involvement] Lagasse JP, et al. **Gastroenterol Clin Biol** 1997;21(4):331–4 (12 ref.) (Eng. Abstr.) **(Fre)**

ANALYSIS

Peptide receptors in gut endocrine tumours. de Herder WW, et al. **Baillieres Clin Gastroenterol** 1996 Dec;10(4):571–87 (55 ref.)

METABOLISM

The study of membrane- or receptor-bound neuropeptides by NMR. Hicks RP. **Methods Mol Biol** 1997;73:185–207 (50 ref.)

PHYSIOLOGY

The growth-hormone-releasing hormone receptor: signal transduction, gene expression, and physiological function in growth regulation. Mayo KE, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:184–203 (35 ref.)

RECEPTORS, NEUROPEPTIDE Y

ANTAGONISTS & INHIBITORS

BIBP 3226, the first selective neuropeptide Y1 receptor antagonist: a review of its pharmacological properties. Doods HN, et al. **Regul Pept** 1996 Aug 27;65(1):71–7 (48 ref.)

Recent developments with neuropeptide Y receptor antagonists. Lundberg JM, et al. **Trends Pharmacol Sci** 1996 Sep;17(9):301–4 (35 ref.)

CHEMISTRY

Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide. Larhammar D. **Regul Pept** 1996 Sep 16;65(3):165–74 (64 ref.)

CLASSIFICATION

Neuropeptide Y receptor subtypes. Wan CP, et al. **Life Sci** 1995 Feb 17;56(13):1055–64 (79 ref.)

GENETICS

Y-receptor subtypes--how many more? Blomqvist AG, et al. **Trends Neurosci** 1997 Jul;20(7):294–8 (64 ref.)

METABOLISM

Neuropeptide Y family of hormones: receptor subtypes and antagonists. Balasubramaniam AA. **Peptides** 1997; 18(3):445–57 (159 ref.)

PHYSIOLOGY

Neuropeptide Y Y1 receptor mechanisms in sympathetic vascular control. Malmström RE. **Acta Physiol Scand Suppl** 1997;636:1–55 (229 ref.)

RECEPTORS, NEUROTRANSMITTER

Evolution and overview of classical transmitter molecules and their receptors. Walker RJ, et al. **Parasitology** 1996; 113 Suppl:S3–33 (221 ref.)

[In vitro and in vivo techniques for the location of the receptors in human brain: methodological basis and general applications] Pazos A. **Rev Neurol** 1997 Jul;25 Suppl 1:S23–7 (16 ref.) **(Spa)**

[Receptors localization in human brain: contribution to neurochemistry of normal aging and neurodegenerative diseases] Pazos A. **Rev Neurol** 1997 Jul;25 Suppl 1:S28–32 (28 ref.) **(Spa)**

ANALYSIS

Autoradiographic visualization in brain of receptor-G protein coupling using [35S]GTP gamma S binding. Sim LJ, et al. **Methods Mol Biol** 1997;83:117–32 (40 ref.)

CLASSIFICATION

Nomenclature and classification of transmitter receptors: an integrated approach. Hoyer D, et al. **J Recept Signal Transduct Res** 1997 Jan-May; 17(1-3):551–68 (49 ref.)

DRUG EFFECTS

Review of neurotransmitters and their role in alcoholism treatment. Erickson CK. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:5–11 (35 ref.)

Molecular and cellular mechanisms of antidepressant drugs. Owens MJ. **Depress Anxiety** 1996-97;4(4):153–9 (35 ref.)

In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. Bymaster FP, et al. **J Clin Psychiatry** 1997;58 Suppl 10:28–36 (59 ref.)

Synaptic effects of antidepressants. Richelson E. **J Clin Psychopharmacol** 1996 Jun;16(3 Suppl 2):1S–7S; discussion 7S–9S (9 ref.)

Antisense oligonucleotides in psychopharmacology and behaviour: promises and pitfalls. Robinson ES, et al. **J Psychopharmacol (Oxf)** 1997;11(3):259–69 (100 ref.)

[Neuroleptic-induced supersensitivity] Börner I, et al. **Fortschr Neurol Psychiatr** 1997 May;65(5):214–20 (45 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Molecular cloning and in vitro expression of C. elegans and parasitic nematode ionotropic receptors. Fleming JT, et al. **Parasitology** 1996;113 Suppl:S175–90 (73 ref.)

METABOLISM

Clinical applications of neurotransmitter-receptor studies in geriatric neuropharmacology. Gómez-Vargas M, et al. **Acta Med Okayama** 1996 Aug;50(4):173–90 (148 ref.)

Amino acid neurotransmitter receptor/chloride channels of mammalian sperm and the acrosome reaction. Meizel S. **Biol Reprod** 1997 Mar;56(3):569–74 (86 ref.)

Saturation of postsynaptic receptors at central synapses? Frerking M, et al. **Curr Opin Neurobiol** 1996 Jun; 6(3):395–403 (66 ref.)

Antiadrenergic and muscarinic receptor antibodies in Chagas' cardiomyopathy. Borda ES, et al. **Int J Cardiol** 1996 May; 54(2):149–56 (38 ref.)

The cytoskeleton and neurotransmitter receptors. Whatley VJ, et al. **Int Rev Neurobiol** 1996;39:113–43 (79 ref.)

[New drugs in the last year. Part 2. Antipsychotics] Eiden F, et al. **Pharm Unserer Zeit** 1996 Sep;25(5):250–9 (46 ref.) **(Ger)**

[Analysis and characterization of ligand-receptor binding systems] Ogawa N. **Nippon Rinsho** 1997 Apr;55 Suppl 2:444–9 (14 ref.) **(Jpn)**

PHYSIOLOGY

SPECT measurements of brain function in dementia; a review. Ryding E. **Acta Neurol Scand Suppl** 1996;168:54–8 (87 ref.)

The characterization and classification of neurotransmitter receptors. Humphrey PP. **Ann N Y Acad Sci** 1997 May 30;812:1–13 (63 ref.)

Determination of the chemical mechanism of neurotransmitter receptor-mediated reactions by rapid chemical kinetic methods. Hess GP. **Arch Physiol Biochem** 1996 Oct;104(6):752–61 (31 ref.)

Synaptic targeting of ionotropic neurotransmitter receptors. Kirsch J, et al. **Mol Cell Neurosci** 1996;8(2-3):93–8 (50 ref.)

Neurotransmitter receptor/G-protein mediated signal transduction in Alzheimer's disease brain. Cowburn RF, et al. **Neurodegeneration** 1996 Dec;5(4):483–8 (37 ref.)

Receptors controlling transmitter release from sympathetic neurons in vitro. Boehm S, et al. **Prog Neurobiol** 1997 Feb; 51(3):225–42 (94 ref.)

Astrocytic neurotransmitter receptors in situ and in vivo. Porter JT, et al. **Prog Neurobiol** 1997 Mar;51(4):439–55 (150 ref.)

The impact of receptor desensitization on fast synaptic transmission. Jones MV, et al. **Trends Neurosci** 1996 Mar; 19(3):96–101 (84 ref.)

The transmitter-gated channels: a range of receptor types and structures. Barnard EA. **Trends Pharmacol Sci** 1996 Sep;17(9):305–9 (38 ref.)

[Schizophrenia: receptors and clinical aspects] Azorin JM. **Encephale** 1997 Apr;23 Spec No 2:17–9 (9 ref.) (Eng. Abstr.) **(Fre)**

RECEPTORS, NGF see **RECEPTORS, NERVE GROWTH FACTOR**

RECEPTORS, NICOTINIC

[Aspect of patho-receptor in the modern pharmacology for drug design developing from Japanese traditional sino-medicines systems] Kimura M. **Yakugaku Zasshi** 1996 Nov;116(11):831–49 (120 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

Nicotinic acetylcholine receptors on hippocampal neurons: distribution on the neuronal surface and modulation of receptor activity. Albuquerque EX, et al. **J Recept Signal Transduct Res** 1997 Jan-May; 17(1-3):243–66 (50 ref.)

Cholinergic innervation and receptors in the cerebellum. Jaarsma D, et al. **Prog Brain Res** 1997;114:67–96 (113 ref.)

CHEMISTRY

Antigenic structure of the muscle nicotinic acetylcholine receptor. Tzartos SJ, et al. **Ann Med Interne (Paris)** 1996; 147(6):442–6 (28 ref.)

Molecular aspects of ion permeation through channels. Imoto K. **Ann N Y Acad Sci** 1993 Dec 20;707:38–50 (28 ref.)

Antibodies as tools to study the structure of membrane proteins: the case of the nicotinic acetylcholine receptor. Conti-Fine BM, et al. **Annu Rev Biophys Biomol Struct** 1996;25:197–229 (112 ref.)

Structure and function of neuronal nicotinic acetylcholine receptors. Lindstrom J, et al. **Prog Brain Res** 1996; 109:125–37 (65 ref.)

DRUG EFFECTS

Noncompetitive agonism at nicotinic acetylcholine receptors; functional significance for CNS signal transduction. Maelicke A, et al. **J Recept Signal Transduct Res** 1995 Jan-Mar;15(1-4):333–53 (43 ref.)

Luminal and non-luminal non-competitive inhibitor binding sites on the nicotinic acetylcholine receptor. Arias HR. **Mol Membr Biol** 1996 Jan-Mar;13(1):1–17 (150 ref.)

Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Balfour DJ, et al. **Pharmacol Ther** 1996;72(1):51–81 (289 ref.)

METABOLISM

The molecular biology of neuronal nicotinic acetylcholine receptors. Boyd RT. **Crit Rev Toxicol** 1997 May; 27(3):299–318 (164 ref.)

Allosteric proteins after thirty years: the binding and state functions of the neuronal alpha 7 nicotinic acetylcholine receptors. Edelstein SJ, et al. **Experientia** 1996 Dec 15; 52(12):1083–90 (67 ref.)

Noncompetitive agonism at nicotinic acetylcholine receptors; functional significance for CNS signal transduction. Maelicke A, et al. **J Recept Signal Transduct Res** 1995 Jan-Mar;15(1-4):333–53 (43 ref.)

Luminal and non-luminal non-competitive inhibitor binding sites on the nicotinic acetylcholine receptor. Arias HR. **Mol Membr Biol** 1996 Jan-Mar;13(1):1–17 (150 ref.)

A membrane skeleton that clusters nicotinic acetylcholine receptors in muscle. Bloch RJ, et al. **Soc Gen Physiol Ser** 1997;52:177–95 (68 ref.)

Binding of native kappa-neurotoxins and site-directed mutants to nicotinic acetylcholine receptors. Chiappinelli VA, et al. **Toxicon** 1996 Nov-Dec;34(11-12):1243–56 (41 ref.)

Presynaptic nicotinic ACh receptors. Wonnacott S. **Trends Neurosci** 1997 Feb;20(2):92–8 (76 ref.)

PHYSIOLOGY

The pharmacology of (–)-nicotine and novel cholinergic channel modulators. Brioni JD, et al. **Adv Pharmacol** 1997; 37:153–214 (298 ref.)

Pharmacology of neuronal nicotinic acetylcholine receptor subtypes. Colquhoun LM, et al. **Adv Pharmacol** 1997; 39:191–220 (150 ref.)

Molecular aspects of ion permeation through channels. Imoto K. **Ann N Y Acad Sci** 1993 Dec 20;707:38–50 (28 ref.)

Nicotinic receptors and brain plasticity. Changeux JP, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:343–62 (103 ref.)

The nicotinic acetylcholine receptor at the neuromuscular junction: assembly and tyrosine phosphorylation. Wang ZZ, et al. **Cold Spring Harb Symp Quant Biol** 1996; 61:363–71 (51 ref.)

Sequential roles of agrin, MuSK and rapsyn during neuromuscular junction formation. Glass DJ, et al. **Curr Opin Neurobiol** 1997 Jun;7(3):379–84 (45 ref.)

Neuronal nicotinic acetylcholine receptors. Lindstrom J. **Ion Channels** 1996;4:377–450 (270 ref.)

Nicotinic receptors in the brain. Molecular biology, function, and therapeutics. Vidal C. **Mol Chem Neuropathol** 1996 May-Aug;28(1-3):3–11 (48 ref.)

Elevation of intracellular calcium levels in neurons by

nicotinic acetylcholine receptors. Rathouz MM, et al. **Mol Neurobiol** 1996 Apr;12(2):117–31 (113 ref.)
Immunological approaches to nicotine receptors. Patrick JW, et al. **NIDA Res Monogr** 1996;161:3–19 (70 ref.)
Nicotinic acetylcholine receptors on hippocampal neurons: cell compartment-specific expression and modulatory control of channel activity. Albuquerque EX, et al. **Prog Brain Res** 1996;109:111–24 (88 ref.)
Structure and function of neuronal nicotinic acetylcholine receptors. Lindstrom J, et al. **Prog Brain Res** 1996; 109:125–37 (65 ref.)
Nicotinic receptors of the vertebrate CNS: introductory remarks. Maelicke A. **Prog Brain Res** 1996;109:107–10 (25 ref.)
Nicotinic receptor function in schizophrenia. Leonard S, et al. **Schizophr Bull** 1996;22(3):431–45 (101 ref.)

RECEPTORS, NK-2 see **RECEPTORS, NEUROKININ-2**

RECEPTORS, NMDA see **RECEPTORS, N-METHYL-D-ASPARTATE**

RECEPTORS, NOREPINEPHRINE see **RECEPTORS, ADRENERGIC**

RECEPTORS, ODORANT

GENETICS

The molecular biology of olfactory perception. Mombaerts P, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:135–45 (41 ref.)
Genetic approaches to mammalian olfaction. Reed RR. **Cold Spring Harb Symp Quant Biol** 1996;61:165–72 (53 ref.)
Olfaction: scents and sensibility. Firestein S. **Curr Biol** 1996 Jun 1;6(6):666–7 (9 ref.)

PHYSIOLOGY

Information coding in the vertebrate olfactory system. Buck LB. **Annu Rev Neurosci** 1996;19:517–44 (187 ref.)
Olfactory receptors, vomeronasal receptors, and the organization of olfactory information. Bargmann CI. **Cell** 1997 Aug 22;90(4):585–7 (17 ref.)
Molecular basis of signal recognition in olfaction. Breer H. **Pflugers Arch** 1996;431(6 Suppl 2):R311–2 (5 ref.)

RECEPTORS, OPIATE see **RECEPTORS, OPIOID**

RECEPTORS, OPIOID

International Union of Pharmacology. XII. Classification of opioid receptors. Dhawan BN, et al. **Pharmacol Rev** 1996 Dec;48(4):567–92 (350 ref.)
Insights into opioid action in the intestinal tract. De Luca A, et al. **Pharmacol Ther** 1996;69(2):103–15 (164 ref.)
[Molecular biological study on structure and function of the opioid receptor] Fukuda K. **Masui** 1996 Sep;45(9):1060–66 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Opioid receptors] Minami M, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):335–42 (22 ref.) **(Jpn)**

AGONISTS

Orphan receptors and their natural ligands. Civelli O, et al. **J Recept Signal Transduct Res** 1997 Jan–May; 17(1–3):545–50 (49 ref.)
Role of opioidergic and serotonergic mechanisms in cough and antitussives. Kamei J. **Pulm Pharmacol** 1996 Oct–Dec; 9(5–6):349–56 (67 ref.)
[Opioid agonists and antagonists, opioid receptors] Holzgrabe U, et al. **Pharmazie** 1997 Jan;52(1):4–22 (220 ref.) **(Ger)**
[Aquaretic agents] Bosch-Marcé M, et al. **Gastroenterol Hepatol** 1996 Nov;19(9):472–7 (55 ref.) **(Spa)**

ANTAGONISTS & INHIBITORS

Role of opioidergic and serotonergic mechanisms in cough and antitussives. Kamei J. **Pulm Pharmacol** 1996 Oct–Dec; 9(5–6):349–56 (67 ref.)
[Opioid agonists and antagonists, opioid receptors] Holzgrabe U, et al. **Pharmazie** 1997 Jan;52(1):4–22 (220 ref.) **(Ger)**

CHEMISTRY

[The molecular structure of the opioid receptors] Sirakov L. **Mol Med (Sofia)** 1996;1(1):4–7 (18 ref.) **(Bul)**
[Endomorphins in pain relief. New endogenous peptides a sensational discovery] Nyberg F. **Lakartidningen** 1997 Sep 3;94(36):3019–21 (15 ref.) **(Swe)**

DRUG EFFECTS

Peptide and nonpeptide ligands for opioid receptors. Misicka A. **Acta Pol Pharm** 1995 Sep–Oct;52(5):349–63 (128 ref.)
Cocaine, dopamine and the endogenous opioid system. Kreek MJ. **J Addict Dis** 1996;15(4):73–96 (84 ref.)
Pharmacotherapy of opioids: present and future developments. Meert TF. **Pharm World Sci** 1996 Jan; 18(1):1–15 (136 ref.)
Endogenous opioid systems and alcohol addiction. Herz A. **Psychopharmacology (Berl)** 1997 Jan;129(2):99–111 (150 ref.)

GENETICS

Human opioid receptors: chromosomal mapping and mRNA localization. Miotto K, et al. **NIDA Res Monogr** 1996; 161:72–82 (34 ref.)
Molecular biology of opioid receptors. Raynor K, et al. **NIDA Res Monogr** 1996;161:83–103 (42 ref.)

IMMUNOLOGY

The relevance of opioids and opioid receptors on immunocompetence and immune homeostasis. Carr DJ, et al. **Proc Soc Exp Biol Med** 1996 Dec;213(3):248–57 (97 ref.)

METABOLISM

Morphine affects the brain–immune axis by modulating an interleukin–1 beta dependent pathway. Chang SL, et al. **Adv Exp Med Biol** 1996;402:35–42 (34 ref.)
Opiates, glia, and neurotoxicity. Chao CC, et al. **Adv Exp Med Biol** 1996;402:29–33 (20 ref.)
Comparison of the three mouse G-protein-activated K+ (GIRK) channels and functional couplings of the opioid receptors with the GIRK1 channel. Ikeda K, et al. **Ann N Y Acad Sci** 1996 Oct 31;801:95–109 (26 ref.)
Milk protein-derived opioid receptor ligands. Teschemacher H, et al. **Biopolymers** 1997;43(2):99–117 (171 ref.)
G proteins and opioid receptor-mediated signalling. Standifer KM, et al. **Cell Signal** 1997 May–Jun;9(3–4):237–48 (166 ref.)
Structure-function analysis of the cloned opiate receptors: peptide and small molecule interactions. Blake AD, et al. **Chem Biol** 1996 Dec;3(12):967–72 (28 ref.)
Opioid and opiate immunoregulatory processes. Stefano GB, et al. **Crit Rev Immunol** 1996;16(2):109–44 (258 ref.)
Orphan receptors and their natural ligands. Civelli O, et al. **J Recept Signal Transduct Res** 1997 Jan–May; 17(1–3):545–50 (49 ref.)
Regulation of acute and chronic opioid receptor functions by OBCAM, a cell adhesion-like molecule. Loh HH, et al. **NIDA Res Monogr** 1996;161:141–53 (24 ref.)
Regulation and distribution of members of the opioid receptor family. Monteillet-Agius G, et al. **Proc West Pharmacol Soc** 1996;39:69–70 (12 ref.)

PHYSIOLOGY

Opiate receptor-mediated mechanisms in the regulation of cerebral blood flow. Benyó Z, et al. **Cerebrovasc Brain Metab Rev** 1996 Winter;8(4):326–57 (216 ref.)
Nutritional infertility: the role of the interconnected hypothalamic neuropeptide Y-galanin-opioid network. Kalra SP, et al. **Front Neuroendocrinol** 1996 Oct; 17(4):371–401 (219 ref.)
Opioid receptors: some perspectives from early studies of their role in normal physiology, stress responsivity, and in specific addictive diseases. Kreek MJ. **Neurochem Res** 1996 Nov;21(11):1469–88 (139 ref.)
Functional analysis of cloned opioid receptors in transfected cell lines. Piros ET, et al. **Neurochem Res** 1996 Nov; 21(11):1277–85 (86 ref.)
The orphan opioid receptor and its endogenous ligand--nociceptin/orphanin FQ. Henderson G, et al. **Trends Pharmacol Sci** 1997 Aug;18(8):293–300 (67 ref.)
[Opioid receptor types and dependence] Suzuki T, et al. **Nippon Yakurigaku Zasshi** 1997 Apr;109(4):165–74 (49 ref.) (Eng. Abstr.) **(Jpn)**
[The role of the opioid system in body adaptation and protection of the heart in stress] Lishmanov IuB, et al. **Usp Fiziol Nauk** 1997 Jan–Mar;28(1):75–96 (120 ref.) (Eng. Abstr.) **(Rus)**
[Stimulation of the endorphin structures of the brain--a new nondrug treatment method] Aleksandrova VA, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(2):101–4 (65 ref.) **(Rus)**

RECEPTORS, OPIOID, DELTA

GENETICS

Cloning and characterization of multiple opioid receptors. Akil H, et al. **NIDA Res Monogr** 1996;161:127–40 (27 ref.)

PHYSIOLOGY

Modulatory effects of Gs-coupled excitatory opioid receptor functions on opioid analgesia, tolerance, and dependence. Crain SM, et al. **Neurochem Res** 1996 Nov;21(11):1347–51 (59 ref.)

RECEPTORS, OPIOID, KAPPA

AGONISTS

Cyclazocine revisited. Archer S, et al. **Neurochem Res** 1996 Nov;21(11):1369–73 (22 ref.)
Sensitization to the behavioral effects of cocaine: modulation by dynorphin and kappa-opioid receptor agonists. Shippenberg TS, et al. **Pharmacol Biochem Behav** 1997 Jul; 57(3):449–55 (66 ref.)

ANTAGONISTS & INHIBITORS

Role of dopamine mesolimbic system in opioid action of psychotropic analgesic nitrous oxide in alcohol and drug withdrawal. Lichtigfeld FJ, et al. **Clin Neuropharmacol** 1996 Jun;19(3):246–51 (43 ref.)

DRUG EFFECTS

Kappa opioids: therapeutic considerations in epilepsy and CNS injury. Tortella FC, et al. **Clin Neuropharmacol** 1994 Oct;17(5):403–16 (77 ref.)
Discriminative stimulus and subjective effects of opioids with mu and kappa activity: data from laboratory animals and human subjects. Dykstra LA, et al. **Psychopharmacology (Berl)** 1997 Mar;130(1):14–27 (94 ref.)

GENETICS

Cloning and characterization of multiple opioid receptors. Akil H, et al. **NIDA Res Monogr** 1996;161:127–40 (27 ref.)

PHYSIOLOGY

Modulatory effects of Gs-coupled excitatory opioid receptor functions on opioid analgesia, tolerance, and dependence. Crain SM, et al. **Neurochem Res** 1996 Nov;21(11):1347–51 (59 ref.)

RECEPTORS, OPIOID, MU

ANTAGONISTS & INHIBITORS

Role of dopamine mesolimbic system in opioid action of psychotropic analgesic nitrous oxide in alcohol and drug withdrawal. Lichtigfeld FJ, et al. **Clin Neuropharmacol** 1996 Jun;19(3):246–51 (43 ref.)
Cyclazocine revisited. Archer S, et al. **Neurochem Res** 1996 Nov;21(11):1369–73 (22 ref.)

GENETICS

Cloning and characterization of multiple opioid receptors. Akil H, et al. **NIDA Res Monogr** 1996;161:127–40 (27 ref.)

METABOLISM

Protein kinase modulation of mu opioid receptor signalling. Yu L. **Cell Signal** 1996 Aug;8(5):371–4 (36 ref.)
[Specific regulation of gene expression in brain by antisense oligodeoxynucleotides] Yoshikawa M, et al. **Nippon Yakurigaku Zasshi** 1997 Apr;109(4):187–91 (10 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Modulatory effects of Gs-coupled excitatory opioid receptor functions on opioid analgesia, tolerance, and dependence. Crain SM, et al. **Neurochem Res** 1996 Nov;21(11):1347–51 (59 ref.)
Mu opioid receptors: cellular action and tolerance development. Mestek A, et al. **NIDA Res Monogr** 1996; 161:104–26 (87 ref.)

RECEPTORS, OPIOID, SIGMA see **RECEPTORS, SIGMA**

RECEPTORS, OXYTOCIN

GENETICS

Gene targeting approaches to neuroendocrinology: oxytocin, maternal behavior, and affiliation. Young LJ, et al. **Horm Behav** 1997 Jun;31(3):221–31 (34 ref.)

METABOLISM

Vasopressin and oxytocin receptors in the central nervous system. Barberis C, et al. **Crit Rev Neurobiol** 1996; 10(1):119–54 (287 ref.)
Small molecule ligands for oxytocin and vasopressin receptors. Freidinger RM, et al. **Med Res Rev** 1997 Jan; 17(1):1–16 (68 ref.)

PHYSIOLOGY

Molecular aspects of monogamy. Insel TR, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:302–16 (44 ref.)
Analogies between oxytocin systems of the uterus and brain. Caldwell JD, et al. **Horm Metab Res** 1996 Feb;28(2):65–74 (100 ref.)
Oxytocin and its receptor in pregnancy and parturition: current concepts and clinical implications. Zeeman GG, et al. **Obstet Gynecol** 1997 May;89(5 Pt 2):873–83 (107 ref.)

RECEPTORS, PAIN see **NOCICEPTORS**

RECEPTORS, PANCREOZYMIN see **RECEPTORS, CHOLECYSTOKININ**

RECEPTORS, PARATHYROID HORMONE

[PTH/PTHrP receptor] Ito M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:495–8 (10 ref.) **(Jpn)**
[Parathyroid hormone-related peptide (PTHrP) and PTH/PTHrP receptor in the gastrointestinal tract] Ito M, et al. **Nippon Rinsho** 1996 Apr;54(4):1104–8 (17 ref.) (Eng. Abstr.) **(Jpn)**

RECEPTORS, PARATHYROID HORMONE

BIOSYNTHESIS

Abnormal skeletal response to parathyroid hormone and the expression of its receptor in chronic uremia. Drüeke TB. **Pediatr Nephrol** 1996 Jun;10(3):348–50 (23 ref.)

GENETICS

Receptors of calciotropic hormones. Findlay DM, et al. **Horm Metab Res** 1997 Mar;29(3):128–34 (77 ref.)

METABOLISM

Molecular basis for the management of secondary hyperparathyroidism in chronic renal failure. Fukagawa M, et al. **Artif Organs** 1995 Dec;19(12):1210–4 (25 ref.)

Parathyroid hormone–related peptide and the parathyroid hormone/parathyroid hormone–related peptide receptor in skeletal development. Karaplis AC, et al. **Curr Opin Nephrol Hypertens** 1997 Jul;6(4):308–13 (52 ref.)

PHYSIOLOGY

Receptors for parathyroid hormone and parathyroid hormone–related peptide: from molecular cloning to definition of diseases. Jüppner H, et al. **Curr Opin Nephrol Hypertens** 1996 Jul;5(4):300–6 (62 ref.)

[Parathyroid hormone receptors: from cloning to physiological, physiopathological and clinical implications (editorial)] Mannstadt M, et al. **Nephrologie** 1997;18(1):5–10 (45 ref.) (Eng. Abstr.) **(Fre)**

RECEPTORS, PDGF see **RECEPTORS, PLATELET-DERIVED GROWTH FACTOR**

RECEPTORS, PEPTIDE

[Vasoactive intestinal contractor (VIC)/mouse ET-2 and VIC receptor: biological activity, gene expression, and specific receptor] Saida K, et al. **Nippon Rinsho** 1996 Apr; 54(4):1115–21 (14 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Sequence-selective nonmacrocyclic two-armed receptors for peptides. Nestler HP. **Mol Divers** 1996 Oct;2(1–2):35–40 (18 ref.)

DRUG EFFECTS

Use of peptide receptor agonists and antagonists for diagnosis and treatment. Jensen RT. **Digestion** 1997;58 Suppl 1:86–93 (26 ref.)

GENETICS

Molecular biology of MIS and its receptors. Teixeira J, et al. **J Androl** 1996 Jul–Aug;17(4):336–41 (21 ref.)

DNA antisense strategies in the study of receptors for vasoactive peptides, and of growth and wound-healing factors. D'Orléans-Juste P, et al. **Mol Cell Biochem** 1997 Jul;172(1–2):199–211 (77 ref.)

METABOLISM

Receptor imaging of human diseases using radiolabeled peptides. Reubi JC, et al. **J Recept Signal Transduct Res** 1995 Jan–Mar; 15(1–4):379–92 (19 ref.)

Modes of peptide binding in G protein–coupled receptors. Berthold M, et al. **Neurochem Res** 1997 Aug;22(8):1023–31 (57 ref.)

PHYSIOLOGY

Müllerian inhibiting substance as a model for the transforming growth factor–beta family: development of new treatment strategies. Shah PC, et al. **Semin Pediatr Surg** 1996 Aug; 5(3):182–90 (34 ref.)

RECEPTORS, PHEROMONE see **CHEMORECEPTORS**

RECEPTORS, PITUITARY HORMONE

ANALYSIS

Distribution of GLP-1 and PACAP receptors in human tissues. Wei Y, et al. **Acta Physiol Scand** 1996 Jul; 157(3):355–7 (7 ref.)

BIOSYNTHESIS

Ontogeny of PACAP and PACAP receptors in the rat brain: role of PACAP in the cerebellum during development. Gonzalez BJ, et al. **Ann N Y Acad Sci** 1996 Dec 26; 805:302–13; discussion 313–4 (51 ref.)

PHYSIOLOGY

Pituitary adenylate cyclase–activating polypeptides, PACAP-38 and PACAP-27, regulation of sympathetic neuron catecholamine, and neuropeptide Y expression through activation of type I PACAP/VIP receptor isoforms. Braas KM, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:204–16; discussion 217–8 (47 ref.)

PACAP/VIP receptor subtypes, signal transducers, and effectors in pituitary cells. Hezareh M, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:315–27; discussion 327–8 (41 ref.)

PACAP/VIP receptors in pancreatic beta-cells: their roles in insulin secretion. Inagaki N, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:44–51; discussion 52–3 (23 ref.)

Receptors for VIP, PACAP, secretin, GRF, glucagon, GLP-1, and other members of their new family of G protein–linked receptors: structure–function relationship with special reference to the human VIP-1 receptor. Laburthe M, et al. **Ann N Y Acad Sci** 1996 Dec 26; 805:94–109; discussion 110–1 (64 ref.)

VIP and PACAP receptor–mediated actions on cell proliferation and survival. Waschek JA. **Ann N Y Acad Sci** 1996 Dec 26;805:290–300; discussion 300–1 (71 ref.)

RECEPTORS, PITUITARY HORMONE–REGULATING HORMONE

[GRH receptor] Sato M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:468–71 (7 ref.) **(Jpn)**

PHYSIOLOGY

The growth-hormone–releasing hormone receptor: signal transduction, gene expression, and physiological function in growth regulation. Mayo KE, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:184–203 (35 ref.)

RECEPTORS, PITUITARY HORMONE RELEASE INHIBITING HORMONES see **RECEPTORS, PITUITARY HORMONE–REGULATING HORMONE**

RECEPTORS, PITUITARY HORMONE–RELEASING HORMONE see **RECEPTORS, PITUITARY HORMONE–REGULATING HORMONE**

RECEPTORS, PLATELET-DERIVED GROWTH FACTOR

METABOLISM

Mechanism of action of platelet-derived growth factor. Claesson-Welsh L. **Int J Biochem Cell Biol** 1996 Apr; 28(4):373–85 (78 ref.)

Distribution and functions of platelet-derived growth factors and their receptors during embryogenesis. Ataliotis P, et al. **Int Rev Cytol** 1997;172:95–127 (155 ref.)

RECEPTORS, POLYMERIC IMMUNOGLOBULIN

METABOLISM

Regulation of protein traffic in polarized epithelial cells: the polymeric immunoglobulin receptor model. Mostov KE, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:775–81 (25 ref.)

RECEPTORS, PRESYNAPTIC

DRUG EFFECTS

Presynaptic inhibition by serotonin: a possible mechanism for switching motor output of the hypoglossal nucleus. Singer JH, et al. **Sleep** 1996 Dec;19(10 Suppl):S146–9 (28 ref.)

METABOLISM

Binding proteins on synaptic membranes for certain phospholipases A2 with presynaptic toxicity. Tzeng MC, et al. **Adv Exp Med Biol** 1996;391:271–8 (46 ref.)

Presynaptic 5-HT auto- and heteroreceptors in the human central and peripheral nervous system. Göthert M, et al. **Behav Brain Res** 1996;73(1–2):89–92 (24 ref.)

The calcium channel and the organization of the presynaptic transmitter release face. Stanley EF. **Trends Neurosci** 1997 Sep;20(9):404–9 (54 ref.)

PHYSIOLOGY

Purinergic regulation of acetylcholine release. Ribeiro JA, et al. **Prog Brain Res** 1996;109:231–41 (41 ref.)

25 years since the discovery of presynaptic receptors: present knowledge and future perspectives. Langer SZ. **Trends Pharmacol Sci** 1997 Mar;18(3):95–9 (39 ref.)

RECEPTORS, PROGESTERONE

Estrogen and progesterone receptors in endometrial cancer. Clinicopathological correlations and prognostic significance. Nyholm HC. **APMIS Suppl** 1996;65:5–33 (186 ref.)

ANALYSIS

Progesterone receptor in Norplant endometrium. Lau TM, et al. **Hum Reprod** 1996 Oct;11 Suppl 2:90–4 (16 ref.)

Immunohistological detection of estrogen and progesterone receptors in multiple and well differentiated leiomyomatous lung tumors in women with uterine leiomyomas (so–called benign metastasizing leiomyomas). A report on 5 cases. Jautzke G, et al. **Pathol Res Pract** 1996 Mar;192(3):215–23 (77 ref.)

[A comparative study of hormone receptors in breast cancer with quantitative immunocytochemistry and biochemistry] Marcot I, et al. **Bull Cancer** 1997 Jun;84(6):613–8 (27 ref.) (Eng. Abstr.) **(Fre)**

[Current questions about estrogen receptor determination and hormone dependence (does estrogen receptor positivity equal estrogen dependence?)] Kahán Z. **Orv Hetil** 1996 Oct 20;137(42):2305–8 (35 ref.) (Eng. Abstr.) **(Hun)**

ANTAGONISTS & INHIBITORS

Clinical uses of antiprogestogens. Van Look PF, et al. **Hum Reprod Update** 1995 Jan;1(1):19–34 (113 ref.)

DRUG EFFECTS

The molecular pharmacology of ovarian steroid receptors. Vegeto E, et al. **Vitam Horm** 1996;52:99–128 (129 ref.)

METABOLISM

Estrogen and progesterone receptors in the endometrium. Moutsatsou P, et al. **Ann N Y Acad Sci** 1997 Jun 17; 816:99–115 (70 ref.)

Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary. Geisler JP, et al. **Gynecol Oncol** 1996 Mar;60(3):424–7 (18 ref.)

Steroid hormone receptors and antineoplastic chemotherapy in human breast cancer. Görlich M, et al. **J Exp Clin Cancer Res** 1997 Mar;16(1):95–103 (59 ref.)

PHYSIOLOGY

Progesterone receptor function from a behavioral perspective. Mani SK, et al. **Horm Behav** 1997 Jun; 31(3):244–55 (80 ref.)

RECEPTORS, PROGESTIN see **RECEPTORS, PROGESTERONE**

RECEPTORS, PROGLUMIDE see **RECEPTORS, CHOLECYSTOKININ**

RECEPTORS, PROLACTIN

GENETICS

[Expression of brain prolactin receptor mRNA and induction of maternal behavior] Sakaguchi K, et al. **Seikagaku** 1997 Apr;69(4):247–50 (15 ref.) **(Jpn)**

METABOLISM

Prolactin and growth hormone receptors. Goffin V, et al. **Clin Endocrinol (Oxf)** 1996 Sep;45(3):247–55 (120 ref.)

Prolactin signaling in mammary gland development. Hennighausen L, et al. **J Biol Chem** 1997 Mar 21; 272(12):7567–9 (40 ref.)

RECEPTORS, PROSTAGLANDIN

[Prostanoid receptors] Sasaki Y, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:586–9 (6 ref.) **(Jpn)**

ANALYSIS

Radioligand–binding methods for membrane preparations and intact cells. Keen M. **Methods Mol Biol** 1997;83:1–24 (15 ref.)

METABOLISM

Prostaglandins and their receptors: implications for ovarian physiology. Olofsson JI, et al. **Biol Signals** 1996 Mar–Apr; 5(2):90–100 (103 ref.)

Functional and molecular aspects of renal prostaglandin receptors [see comments] Breyer MD, et al. **J Am Soc Nephrol** 1996 Jan;7(1):8–17 (87 ref.) Comment in: J Am Soc Nephrol 1996 Aug;7(8):1245–6.

Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids. Resul B, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S47–52 (16 ref.)

The molecular biology and ocular distribution of prostanoid receptors. Woodward DF, et al. **Surv Ophthalmol** 1997 Feb; 41 Suppl 2:S15–21 (58 ref.)

PHYSIOLOGY

The role of prostaglandin receptors in regulating cerebral blood flow in the perinatal period. Chemtob S, et al. **Acta Paediatr** 1996 May;85(5):517–24 (107 ref.)

Prostanoid receptors and signal transduction. Narumiya S. **Prog Brain Res** 1996;113:231–41 (70 ref.)

RECEPTORS, PROSTAGLANDIN E

PHYSIOLOGY

[Prostanoid receptors] Negishi M. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Dec;19(6):569–71 (0 ref.) **(Jpn)**

RECEPTORS, PULMONARY STRETCH see **PULMONARY STRETCH RECEPTORS**

RECEPTORS, PURINERGIC

Development and perspectives of the purinoceptor concept. Burnstock G. **J Auton Pharmacol** 1996 Dec;16(6):295-302 (90 ref.)

DRUG EFFECTS

Purinergic receptors. Malec D. **Pol J Pharmacol** 1996 Sep-Oct;48(5):457-65 (96 ref.)

PHYSIOLOGY

Purinergic receptors: their role in nociception and primary afferent neurotransmission. Burnstock G, et al. **Curr Opin Neurobiol** 1996 Aug;6(4):526-32 (63 ref.)

Purinoceptors and platelet aggregation. Hourani SM. **J Auton Pharmacol** 1996 Dec;16(6):349-52 (31 ref.)

Purinoceptors: from history to recent progress. A review. Windscheif U. **J Pharm Pharmacol** 1996 Oct; 48(10):993-1011 (227 ref.)

Induction of reactive gliosis by purinoceptor activation: a critical appraisal. Walz W. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1997 Jan; 13(1):30-5 (25 ref.)

RECEPTORS, PURINERGIC P1

AGONISTS

Realizing the potential of adenosine-receptor-based therapeutics. Barrett RJ. **Proc West Pharmacol Soc** 1996; 39:61-6 (42 ref.)

ANTAGONISTS & INHIBITORS

Hypertension due to chronic blockade of P1-purinoceptors. Guimarães S, et al. **J Auton Pharmacol** 1996 Dec; 16(6):367-70 (27 ref.)

Realizing the potential of adenosine-receptor-based therapeutics. Barrett RJ. **Proc West Pharmacol Soc** 1996; 39:61-6 (42 ref.)

Adenosine receptor ligands: differences with acute versus chronic treatment. Jacobson KA, et al. **Trends Pharmacol Sci** 1996 Mar;17(3):108-13 (50 ref.)

DRUG EFFECTS

Adenosine and neuroprotection. Fredholm BB. **Int Rev Neurobiol** 1997;40:259-80 (130 ref.)

Pharmacology of adenosine A2A receptors. Ongini E, et al. **Trends Pharmacol Sci** 1996 Oct;17(10):364-72 (60 ref.)

GENETICS

Approaches to the stable transfection of G protein-coupled receptors. Townsend-Nicholson A. **Methods Mol Biol** 1997;83:45-54 (7 ref.)

METABOLISM

Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Shryock JC, et al. **Am J Cardiol** 1997 Jun 19;79(12A):2-10 (123 ref.)

Nucleotide receptors. North RA, et al. **Curr Opin Neurobiol** 1997 Jun;7(3):346-57 (107 ref.)

Receptor-mediated phosphoinositide metabolism in peripheral nerve and cultured Schwann cells. Eichberg J, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1-3):187-95 (26 ref.)

Binding thermodynamics at A1 and A2A adenosine receptors. Borea PA, et al. **Life Sci** 1996;59(17):1373-88 (52 ref.)

Site-directed mutagenesis and chimeric receptors in the study of receptor-ligand binding. Olah ME, et al. **Methods Mol Biol** 1997;83:25-43 (29 ref.)

PHYSIOLOGY

Role of adenosine as a modulator of synaptic activity in the central nervous system. Brundege JM, et al. **Adv Pharmacol** 1997;39:353-91 (200 ref.)

Nucleotide receptors. North RA, et al. **Curr Opin Neurobiol** 1997 Jun;7(3):346-57 (107 ref.)

Purines and neutrophil leukocytes. Fredholm BB. **Gen Pharmacol** 1997 Mar;28(3):345-50 (100 ref.)

A2 adenosine receptors: their presence and neuromodulatory role in the central nervous system. Latini S, et al. **Gen Pharmacol** 1996 Sep;27(6):925-33 (110 ref.)

Purinoceptor-mediated regulation of the renal microvasculature. Inscho EW. **J Auton Pharmacol** 1996 Dec;16(6):385-8 (20 ref.)

Cellular and molecular biology of chloride secretion in the shark rectal gland: regulation by adenosine receptors. Forrest JN Jr. **Kidney Int** 1996 Jun;49(6):1557-62 (20 ref.)

Adenosine physiology and pharmacology: how about A2 receptors? Daval JL, et al. **Pharmacol Ther** 1996; 71(3):325-35 (117 ref.)

Purinergic regulation of acetylcholine release. Ribeiro JA, et al. **Prog Brain Res** 1996;109:231-41 (41 ref.)

Adenosine A2 receptor-mediated excitatory actions on the nervous system. Sebastião AM, et al. **Prog Neurobiol** 1996 Feb;48(3):167-89 (225 ref.)

RECEPTORS, PURINERGIC P2

The diverse series of recombinant P2Y purinoceptors. Barnard EA, et al. **Ciba Found Symp** 1996;198:166-80; discussion 180-8 (53 ref.)

Involvement of distinct receptors in the actions of extracellular uridine nucleotides. Boeynaems JM, et al. **Ciba Found Symp** 1996;198:266-74; discussion 274-7 (26 ref.)

P2U purinoceptors: cDNA cloning, signal transduction mechanisms and structure-function analysis. Lustig KD, et al. **Ciba Found Symp** 1996;198:193-204; discussion 204-7 (28 ref.)

Challenges in developing P2 purinoceptor-based therapeutics. Williams M. **Ciba Found Symp** 1996; 198:309-21 (53 ref.)

Uridine nucleotide receptors and their ligands: structural, physiological, and pathophysiological aspects, with special emphasis on the nervous system. Heilbronn E, et al. **Neurochem Res** 1997 Aug;22(8):1041-50 (86 ref.)

ADP receptors on platelets. Mills DC. **Thromb Haemost** 1996 Dec;76(6):835-56 (263 ref.)

[ATP receptor and intracellular signaling] Katsuragi T, et al. **Nippon Yakurigaku Zasshi** 1996 Sep;108(3):166-8 (0 ref.) **(Jpn)**

[ATP receptors] Inoue K. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):308-15 (48 ref.) **(Jpn)**

AGONISTS

Activation of ADP receptors and platelet function. Gachet C, et al. **Thromb Haemost** 1997 Jul;78(1):271-5 (58 ref.)

ANTAGONISTS & INHIBITORS

Design and pharmacology of selective P2-purinoceptor antagonists. Lambrecht G. **J Auton Pharmacol** 1996 Dec; 16(6):341-4 (21 ref.)

CHEMISTRY

P2X receptors: an emerging channel family. Buell G, et al. **Eur J Neurosci** 1996 Oct;8(10):2221-8 (47 ref.)

CLASSIFICATION

P2 purinoceptors: historical perspective and classification. Burnstock G. **Ciba Found Symp** 1996;198:1-28; discussion 29-34 (239 ref.)

Endothelial P2-purinoceptors: subtypes and signal transduction. Pirotton S, et al. **J Auton Pharmacol** 1996 Dec;16(6):353-6 (26 ref.)

GENETICS

The molecular biology of P2X receptors. Evans RJ. **J Auton Pharmacol** 1996 Dec;16(6):309-10 (18 ref.)

IMMUNOLOGY

P2 purinoceptors in the immune system. Di Virgilio F, et al. **Ciba Found Symp** 1996;198:290-302; discussion 302-5 (49 ref.)

ISOLATION & PURIFICATION

Receptors responsive to extracellular pyrimidine nucleotides. Communi D, et al. **Trends Pharmacol Sci** 1997 Mar; 18(3):83-6 (30 ref.)

METABOLISM

Trophic roles of P2 purinoceptors in central nervous system astroglial cells. Abbracchio MP, et al. **Ciba Found Symp** 1996;198:142-7; discussion 147-8 (23 ref.)

Features of P2X receptor-mediated synapses in the rat brain: why doesn't ATP kill the postsynaptic cell? Edwards FA. **Ciba Found Symp** 1996;198:278-86; discussion 286-9 (15 ref.)

P2Z purinoceptors. Hickman SE, et al. **Ciba Found Symp** 1996;198:71-83; discussion 83-90 (40 ref.)

P2T purinoceptors: ADP receptors on platelets. Hourani SM, et al. **Ciba Found Symp** 1996;198:53-64; discussion 64-70 (50 ref.)

P2 purinoceptors and pyrimidinoceptors of catecholamine-producing cells and immunocytes. Illes P, et al. **Ciba Found Symp** 1996;198:110-25; discussion 125-9 (59 ref.)

P2X receptors: a third major class of ligand-gated ion channels. North RA. **Ciba Found Symp** 1996;198:91-105; discussion 105-9 (76 ref.)

Transduction mechanisms of P2Z purinoceptors. Wiley JS, et al. **Ciba Found Symp** 1996;198:149-60; discussion 160-5 (52 ref.)

A purinergic hypothesis for immunomodulation. Di Virgilio F, et al. **Ital J Biochem** 1996 Dec;45(4):195-203 (42 ref.)

Release, metabolism and interconversion of adenine and uridine nucleotides: implications for G protein-coupled P2 receptor agonist selectivity. Harden TK, et al. **Trends Pharmacol Sci** 1997 Feb;18(2):43-6 (15 ref.)

[Ecto-ATPases and receptors for ATP] Ziganshin AU, et al. **Eksp Klin Farmakol** 1997 May-Jun;60(3):78-82 (59 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Signaling by extracellular nucleotides. Brake AJ, et al. **Ann Rev Cell Dev Biol** 1996;12:519-41 (111 ref.)

ATP receptors in sickness, pain and death. Brake A, et al. **Chem Biol** 1996 Apr;3(4):229-32 (23 ref.)

Functional properties of native and cloned P2X receptors. Surprenant A. **Ciba Found Symp** 1996;198:208-19; discussion 219-22 (40 ref.)

Purines and neutrophil leukocytes. Fredholm BB. **Gen Pharmacol** 1997 Mar;28(3):345-50 (100 ref.)

Purinoceptor-mediated regulation of the renal microvasculature. Inscho EW. **J Auton Pharmacol** 1996 Dec;16(6):385-8 (20 ref.)

ATP as a cotransmitter in perivascular sympathetic nerves. Kennedy C. **J Auton Pharmacol** 1996 Dec;16(6):337-40 (11 ref.)

P2-purinoceptors on postganglionic sympathetic neurones. von Kügelgen I, et al. **J Auton Pharmacol** 1996 Dec; 16(6):413-6 (28 ref.)

New insights on P2X purinoceptors. Humphrey PP, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Dec; 352(6):585-96 (94 ref.)

Implication of ATP receptors in brain functions. Inoue K, et al. **Prog Neurobiol** 1996 Dec;50(5-6):483-92 (73 ref.)

RECEPTORS, RETINOIC ACID

BIOSYNTHESIS

Retinoic acid receptor expression abnormalities in lung cancer: important clues or major obstacles? [editorial; comment] Minna JD, et al. **J Natl Cancer Inst** 1997 May 7;89(9):602-4 (42 ref.) Comment on: J Natl Cancer Inst 1997 May 7;89(9):624-9.

CHEMISTRY

Structure/function of cytoplasmic vitamin A-binding proteins. Li E, et al. **Annu Rev Nutr** 1996;16:205-34 (159 ref.)

DRUG EFFECTS

Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis. Chandraratna RA. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 3):S12-7 (34 ref.)

A new metabolite of retinol: all-trans-4-oxo-retinol as a receptor activator and differentiation agent. Ross SA, et al. **Nutr Rev** 1996 Nov;54(11 Pt 1):355-6 (10 ref.)

GENETICS

Sex determining gene on the X chromosome short arm: dosage sensitive sex reversal. Ogata T, et al. **Acta Paediatr Jpn** 1996 Aug;38(4):390-8 (40 ref.)

The molecular genetics of retinoic acid receptors: cardiovascular and limb development. Sucov HM, et al. **Biochem Soc Symp** 1996;62:143-56 (47 ref.)

METABOLISM

Mechanisms of transcriptional activation by retinoic acid receptors. Glass CK, et al. **Biochem Soc Trans** 1997 May; 25(2):602-5 (20 ref.)

TIF1 alpha: a chromatin-specific mediator for the ligand-dependent activation function AF-2 of nuclear receptors? Le Douarin B, et al. **Biochem Soc Trans** 1997 May;25(2):605-12 (39 ref.)

Retinoids in patterning: chimeras win by a knockout. Maden M. **Curr Biol** 1996 Jul 1;6(7):790-3 (18 ref.)

Retinoid receptors in transcriptional regulation. Minucci S, et al. **Curr Opin Genet Dev** 1996 Oct;6(5):567-74 (67 ref.)

Retinoic acid receptors and nuclear orphan receptors in the development of Xenopus laevis. Dreyer C, et al. **Int J Dev Biol** 1996 Feb;40(1):255-62 (55 ref.)

Some new twists in the regulation of gene expression by thyroid hormone and retinoic acid receptors. Glass CK. **J Endocrinol** 1996 Sep;150(3):349-57 (64 ref.)

A new metabolite of retinol: all-trans-4-oxo-retinol as a receptor activator and differentiation agent. Ross SA, et al. **Nutr Rev** 1996 Nov;54(11 Pt 1):355-6 (10 ref.)

Retinoids: from hindbrain patterning to Parkinson disease. Eichele G. **Trends Genet** 1997 Sep;13(9):343-5 (25 ref.)

PHYSIOLOGY

Structure/function of cytoplasmic vitamin A-binding proteins. Li E, et al. **Annu Rev Nutr** 1996;16:205-34 (159 ref.)

Regulation of metabolism by retinoic acid and its nuclear receptors. Pfahl M, et al. **Annu Rev Nutr** 1996;16:257-83 (157 ref.)

Retinoid signalling and retinoid receptors in amphibian limb regeneration. Brockes JP. **Biochem Soc Symp** 1996; 62:137-42 (22 ref.)

Retinoid-dependent transcription: the RAR/RXR-TBP-EIA/EIA-LA connection. Meyer M, et al. **Biochem Soc Symp** 1996;62:97-109 (50 ref.)

Roles of retinoids and their nuclear receptors in the development and prevention of upper aerodigestive tract cancers. Lotan R. **Environ Health Perspect** 1997 Jun;105 Suppl 4:985-8 (52 ref.)

Nuclear retinoid receptors: mediators of retinoid effects. van der Saag PT. **Eur J Clin Nutr** 1996 Jul;50 Suppl 3:S24-8 (46 ref.)

Retinoid X receptors. Rowe A. **Int J Biochem Cell Biol** 1997 Feb;29(2):275-8 (11 ref.)

RECEPTORS, SENSORY

ANATOMY & HISTOLOGY

Evolution of gnathostome lateral line ontogenies. Northcutt RG. **Brain Behav Evol** 1997 Jul;50(1):25–37 (70 ref.)

DRUG EFFECTS

Action of cholinesters on sensory nerve endings in skin and muscle. Carr RW, et al. **Clin Exp Pharmacol Physiol** 1996 May;23(5):355–62 (81 ref.)

Capsaicin-sensitive sensory nerve terminals with local and systemic efferent functions: facts and scopes of an unorthodox neuroregulatory mechanism. Szolcsányi J. **Prog Brain Res** 1996;113:343–59 (132 ref.)

METABOLISM

Neurotransmitters and neuroreceptors in the lower urinary tract. Andersson KE. **Curr Opin Obstet Gynecol** 1996 Oct; 8(5):361–5 (49 ref.)

The neuroreceptors: one key for many locks. Civelli O. **J Recept Signal Transduct Res** 1995 Jan–Mar; 15(1–4):161–72 (11 ref.)

PHYSIOLOGY

Injury-stimulated neurogenesis in sensory systems. Farbman AI. **Adv Neurol** 1997;72:157–61 (9 ref.)

Functional and structural complexity of signal transduction via G-protein–coupled receptors. Gudermann T, et al. **Annu Rev Neurosci** 1997;20:399–427 (192 ref.)

Making sense of chemicals. Gilbertson TA, et al. **Chem Biol** 1996 Apr;3(4):233–7 (41 ref.)

Neuropeptides in dural fine sensory nerve endings—involvement in neurogenic inflammation? Hanesch U. **Prog Brain Res** 1996;113:299–317 (89 ref.)

Functional morphology of nociceptive and other fine sensory endings (free nerve endings) in different tissues. Messlinger K. **Prog Brain Res** 1996;113:273–98 (75 ref.)

[Reversible changes of the neural pathways and receptor functions associated with development and regeneration following nerve injuries] Nabekura J. **Fukuoka Igaku Zasshi** 1997 Jul;88(7):267–73 (7 ref.) **(Jpn)**

RECEPTORS, SEROTONIN

BIOSYNTHESIS

Regulation of 5-HT2A receptor mRNA in P11 cells. Ferry RC, et al. **Behav Brain Res** 1996;73(1–2):187–91 (26 ref.)

Transcriptional regulation of the 5-HT2A receptor. Toth M. **Behav Brain Res** 1996;73(1–2):183–6 (17 ref.)

Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Fink G, et al. **Cell Mol Neurobiol** 1996 Jun;16(3):325–44 (87 ref.)

CHEMISTRY

Evolutionary conservation of the 5-HT2B receptors. Colas JF, et al. **Ann N Y Acad Sci** 1997 May 30;812:149–53 (11 ref.)

Dopamine and serotonin receptors: amino acid sequences, and clinical role in neuroleptic parkinsonism. Seeman P, et al. **Jpn J Pharmacol** 1996 Jul;71(3):187–204 (140 ref.)

Structure and function of serotonin 5-HT2 receptors. Shih JC, et al. **NIDA Res Monogr** 1994;146:284–97 (22 ref.)

Hallucinogens acting at 5-HT receptors: toward a mechanistic understanding at atomic resolution. Weinstein H, et al. **NIDA Res Monogr** 1994;146:241–62 (63 ref.)

Molecular modeling of the interaction of LSD and other hallucinogens with 5-HT2 receptors. Westkaemper RB, et al. **NIDA Res Monogr** 1994;146:263–83 (32 ref.)

The 5-HT7 receptor: orphan found. Eglen RM, et al. **Trends Pharmacol Sci** 1997 Apr;18(4):104–7 (52 ref.)

CLASSIFICATION

Classification and nomenclature of 5-HT receptors: a comment on current issues. Hoyer D, et al. **Behav Brain Res** 1996;73(1–2):263–8 (30 ref.)

5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Hoyer D, et al. **Neuropharmacology** 1997 Apr–May;36(4–5):419–28 (65 ref.)

Alignment of receptor nomenclature with the human genome: classification of 5-HT1B and 5-HT1D receptor subtypes. Hartig PR, et al. **Trends Pharmacol Sci** 1996 Mar; 17(3):103–5 (22 ref.)

DRUG EFFECTS

5-HT receptors: implications for the neuropharmacology of alcohol and alcoholism. Overstreet DH, et al. **Alcohol Alcohol Suppl** 1994;2:205–10 (49 ref.)

Novel discriminatory ligands for 5-HT2B receptors. Baxter GS. **Behav Brain Res** 1996;73(1–2):149–52 (19 ref.)

The role of serotonin in the actions of psychostimulants: molecular and pharmacological analyses. Cunningham KA, et al. **Behav Brain Res** 1996;73(1–2):93–102 (66 ref.)

Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent. Nichols DE, et al. **Behav Brain Res** 1996;73(1–2):117–9 (9 ref.)

Development of 5-HT1A receptor antagonists. Routledge C. **Behav Brain Res** 1996;73(1–2):153–6 (31 ref.)

GR127935: a potent and selective 5-HT1D receptor antagonist. Skingle M, et al. **Behav Brain Res** 1996; 73(1–2):157–61 (23 ref.)

The antipsychotic potential of subtype-selective 5-HT receptor ligands based on interactions with mesolimbic dopamine systems. Tricklebank MD. **Behav Brain Res** 1996; 73(1–2):15–7 (25 ref.)

Ibogaine and cocaine abuse: pharmacological interactions at dopamine and serotonin receptors. Sershen H, et al. **Brain Res Bull** 1997;42(3):161–8 (77 ref.)

Venlafaxine: a novel antidepressant that has a dual mechanism of action. Andrews JM, et al. **Depression** 1996; 4(2):48–56 (40 ref.)

Serotonin syndrome and drug combinations: focus on MAOI and RIMA. Hilton SE, et al. **Eur Arch Psychiatry Clin Neurosci** 1997;247(3):113–9 (49 ref.)

The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission [published erratum appears in Int Clin Psychopharmacol 1996 Jun;11(2):153] de Boer T. **Int Clin Psychopharmacol** 1995 Dec;10 Suppl 4:19–23 (33 ref.)

Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine [published erratum appears in Int Clin Psychopharmacol 1996 Jun;11(2):153] Haddjeri N, et al. **Int Clin Psychopharmacol** 1995 Dec;10 Suppl 4:11–7 (30 ref.)

Two actions are better than one: avoiding self-inhibition of serotonergic neurones enhances the effects of serotonin uptake inhibitors. Romero L, et al. **Int Clin Psychopharmacol** 1996 Sep;11 Suppl 4:1–8 (50 ref.)

Mixed depression and anxiety: serotonin1A receptors as a common pharmacologic link. Stahl SM. **J Clin Psychiatry** 1997;58 Suppl 8:20–6 (64 ref.)

Serotonergic receptors as targets for pharmacotherapy. Kirk EE, et al. **J Neurosci Nurs** 1997 Jun;29(3):191–7 (61 ref.)

Serotonin 5-HT3 and 5-HT4 receptor antagonists. Gaster LM, et al. **Med Res Rev** 1997 Mar;17(2):163–214 (311 ref.)

Electrophysiological studies on the actions of hallucinogenic drugs at 5-HT2 receptors in rat brain. Aghajanian GK. **NIDA Res Monogr** 1994;146:183–202 (49 ref.)

Serotonin receptor involvement in an animal model of the acute effects of hallucinogens. Geyer MA, et al. **NIDA Res Monogr** 1994;146:124–56 (59 ref.)

Structure and function of serotonin 5-HT2 receptors. Shih JC, et al. **NIDA Res Monogr** 1994;146:284–97 (22 ref.)

Hallucinogens acting at 5-HT receptors: toward a mechanistic understanding at atomic resolution. Weinstein H, et al. **NIDA Res Monogr** 1994;146:241–62 (63 ref.)

Molecular modeling of the interaction of LSD and other hallucinogens with 5-HT2 receptors. Westkaemper RB, et al. **NIDA Res Monogr** 1994;146:263–83 (32 ref.)

A pharmacological analysis of serotonergic receptors: effects of their activation of blockade in learning. Meneses A, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Feb; 21(2):273–96 (121 ref.)

Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability [see comments] Curzon G, et al. **Trends Pharmacol Sci** 1997 Jan;18(1):21–5 (51 ref.) Comment in: Trends Pharmacol Sci 1997 Jun;18(6):191–2.

Allosteric modulation of 5-HT3 receptors: focus on alcohols and anaesthetic agents. Parker RM, et al. **Trends Pharmacol Sci** 1996 Mar;17(3):95–9 (38 ref.)

[The 5-HT1A receptor: a new effective principle in psychopharmacologic therapy?] Davids E, et al. **Fortschr Neurol Psychiatr** 1996 Nov;64(11):460–72 (135 ref.) (Eng. Abstr.) **(Ger)**

[The role of serotonergic system in the mechanism of action of antidepressant agents] Wielosz M. **Psychiatr Pol** 1996 Nov–Dec;30(6):963–72 (32 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Transcriptional regulation of the 5-HT2A receptor. Toth M. **Behav Brain Res** 1996;73(1–2):183–6 (17 ref.)

RNA editing: rewriting receptors. O'Connell MA. **Curr Biol** 1997 Jul 1;7(7):R437–9 (28 ref.)

5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Hoyer D, et al. **Neuropharmacology** 1997 Apr–May;36(4–5):419–28 (65 ref.)

Association study between bipolar disorder and candidate genes involved in dopamine-serotonin metabolism and GABAergic neurotransmission: a preliminary report [letter] Oruč L, et al. **Psychiatr Genet** 1996 Winter;6(4):213–7 (40 ref.)

Alignment of receptor nomenclature with the human genome: classification of 5-HT1B and 5-HT1D receptor subtypes. Hartig PR, et al. **Trends Pharmacol Sci** 1996 Mar; 17(3):103–5 (22 ref.)

[Molecular genetic approach to schizophrenia: direct analysis of 5-HT receptor genes] Ozaki N. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Oct; 16(5):175–80 (23 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Regulation of central 5-HT2A receptors: a review of in vivo studies. Eison AS, et al. **Behav Brain Res** 1996; 73(1–2):177–81 (54 ref.)

Presynaptic 5-HT auto- and heteroreceptors in the human central and peripheral nervous system. Göthert M, et al. **Behav Brain Res** 1996;73(1–2):89–92 (24 ref.)

Ventral tegmental area 5-HT receptors: mesolimbic dopamine release and behavioural studies. Mylecharane EJ. **Behav Brain Res** 1996;73(1–2):1–5 (37 ref.)

Peripheral 5-HT4 receptors. Hegde SS, et al. **FASEB J** 1996 Oct;10(12):1398–407 (80 ref.)

Radioligands for PET studies of central 5-HT receptors and re-uptake sites—current status. Pike VW. **Nucl Med Biol** 1995 Nov;22(8):1011–8 (38 ref.)

PHYSIOLOGY

Serotonin receptors involved in regulation of pituitary-adrenocortical function in rats. Fuller RW. **Behav Brain Res** 1996;73(1–2):215–9 (33 ref.)

Electrophysiological studies of 5-hydroxytryptamine receptors on enteric neurons. Galligan JJ. **Behav Brain Res** 1996;73(1–2):199–201 (19 ref.)

5-HT3 and 5-HT4 receptors in terminal regions of the mesolimbic system. Kilpatrick GJ, et al. **Behav Brain Res** 1996;73(1–2):11–3 (23 ref.)

Modulation of serotonin2A/2C receptors and these receptor-linked phosphoinositide system by ethanol. Pandey SC, et al. **Behav Brain Res** 1996;73(1–2):235–8 (26 ref.)

Serotonergic regulation of renin and prolactin secretion. Van de Kar LD, et al. **Behav Brain Res** 1996;73(1–2):203–8 (44 ref.)

Modulation of the A10 dopamine system: electrophysiological studies of the role of 5-HT3-like receptors. Wang RY, et al. **Behav Brain Res** 1996; 73(1–2):7–10 (34 ref.)

Renal and intestinal autocrine monoaminergic systems: dopamine versus 5-hydroxytryptamine. Vieira-Coelho MA, et al. **Clin Exp Hypertens** 1997 Jan–Feb;19(1–2):43–58 (22 ref.)

Serotonin receptors in cognitive behaviors. Buhot MC. **Curr Opin Neurobiol** 1997 Apr;7(2):243–54 (67 ref.)

Role of 5-HT1A autoreceptors in the mechanism of action of serotoninergic antidepressant drugs: recent findings from in vivo microdialysis studies. Gardier AM, et al. **Fundam Clin Pharmacol** 1996;10(1):16–27 (88 ref.)

Limbic circuits and monoamine receptors: dissecting the effects of antipsychotics from disease processes. Joyce JN, et al. **J Psychiatr Res** 1997 Mar–Apr;31(2):197–217 (70 ref.)

Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia. Busatto GF, et al. **J Psychopharmacol (Oxf)** 1997;11(1):3–12 (127 ref.)

Functional interaction between serotonin and other neuronal systems: focus on in vivo microdialysis studies. Saito H, et al. **Jpn J Pharmacol** 1996 Mar;70(3):203–5 (221 ref.)

Dopamine and serotonin receptors: amino acid sequences, and clinical role in neuroleptic parkinsonism. Seeman P, et al. **Jpn J Pharmacol** 1996 Jul;71(3):187–204 (140 ref.)

Specific involvement of central 5-HT1A receptors in the mediation of male rat ejaculatory behavior. Ahlenius S, et al. **Neurochem Res** 1997 Aug;22(8):1065–70 (34 ref.)

311C90: increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists. Ferrari MD. **Neurology** 1997 Mar;48(3 Suppl 3):S21–4 (15 ref.)

Behavioral characterization of mice packing the 5-HT1B receptor. Ramboz S, et al. **NIDA Res Monogr** 1996; 161:39–57 (32 ref.)

Do beta-adrenoceptors and serotonin 5-HT1A receptors have similar functions in the control of intraocular pressure in the rabbit? Osborne NN, et al. **Ophthalmologica** 1996; 210(5):308–14 (40 ref.)

5-HT3 receptors and central effects of ethanol. Kostowski W. **Pol J Pharmacol** 1996 May–Jun;48(3):243–54 (108 ref.)

[Dopamine D2 and serotonin 5HT2 receptors: functions, interactions and clinical consequences in schizophrenia] Guise S, et al. **Encephale** 1997 Apr;23 Spec No 2:10–6 (20 ref.) (Eng. Abstr.) **(Fre)**

[Is it feasible to develop a 5-HT basis for the treatment of depression?] Hamon M. **Encephale** 1995 Dec;21 Spec No 4:27–32 (26 ref.) **(Fre)**

[Affective disturbances and serotonin-2 receptor functions] Kuzumi I, et al. **Seishin Shinkeigaku Zasshi** 1996; 98(11):915–9 (22 ref.) **(Jpn)**

[The role of the interaction of serotonin- and noradrenergic systems in regulating behavior] Semenova TP. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 Mar–Apr; 47(2):358–61 (21 ref.) (Eng. Abstr.) **(Rus)**

RECEPTORS, SIGMA

DRUG EFFECTS

Neuroprotective and anti-amnesic potentials of sigma (sigma) receptor ligands. Maurice T, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Jan; 21(1):69–102 (224 ref.)

METABOLISM

[Neuropharmacological effects of sigma receptor ligands: anxiolytic, anti-amnesic and neuroprotective effects] Amano M, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Jun; 16(3):73–84 (103 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

The mysteries of sigma receptors: new family members reveal

a role in cholesterol synthesis. Moebius FF, et al. **Trends Pharmacol Sci** 1997 Mar;18(3):67–70 (30 ref.)

RECEPTORS, SIGMA OPIOID see **RECEPTORS, SIGMA**

RECEPTORS, SINCALIDE see **RECEPTORS, CHOLECYSTOKININ**

RECEPTORS, SOMATOMEDIN

DRUG EFFECTS

Insulin-like growth factors in breast cancer. Helle SI, et al. **Acta Oncol** 1996;35 Suppl 5:19–22 (29 ref.)

PHYSIOLOGY

The early intracellular signaling pathway for the insulin/insulin-like growth factor receptor family in the mammalian central nervous system. Folli F, et al. **Mol Neurobiol** 1996 Oct;13(2):155–83 (162 ref.)

RECEPTORS, SOMATOMEDIN C see **RECEPTORS, INSULIN-LIKE-GROWTH FACTOR I**

RECEPTORS, SOMATOSTATIN

Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Reubi JC. **Q J Nucl Med** 1997 Jun; 41(2):63–70 (18 ref.)

[Somatostatin receptors] Kimura N. **Nippon Rinsho** 1997 Apr; 55 Suppl 2:503–7 (19 ref.) **(Jpn)**

[Somatostatin and its receptors] Yamada Y, et al. **Nippon Rinsho** 1996 Apr;54(4):1109–14 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Somatostatin receptors. A new way to diagnosis and therapy of neuroendocrine tumors] Wängberg B, et al. **Lakartidningen** 1997 Mar 5;94(10):829–30, 835–8 (20 ref.) (Eng. Abstr.) **(Swe)**

ANALYSIS

Enhanced bilateral somatostatin receptor expression in mediastinal lymph nodes ("chimney sign") in occult metastatic medullary thyroid cancer: a typical site of tumour manifestation? Behr TM, et al. **Eur J Nucl Med** 1997 Feb;24(2):184–91 (20 ref.)

Studies on radiolabeled somatostatin analogues in rats and in patients. Breeman WA, et al. **Q J Nucl Med** 1996 Sep; 40(3):209–20 (93 ref.)

Somatostatin receptor scintigraphy in the diagnosis of neuroendocrine gastroenteropancreatic tumors. Bäder M, et al. **Recent Results Cancer Res** 1996;142:137–62 (66 ref.)

[Somatostatin receptor scintigraphy. Methodology, indications, results] Eising EG, et al. **Radiologe** 1996 Jan; 36(1):81–8 (33 ref.) (Eng. Abstr.) **(Ger)**

CHEMISTRY

Molecular and functional properties of somatostain receptor subtypes. Liapakis G, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):12–3 (11 ref.)

GENETICS

Molecular pharmacology of somatostatin receptor subtypes. Patel YC. **J Endocrinol Invest** 1997 Jun;20(6):348–67 (159 ref.)

Molecular biology of somatostatin receptor subtypes. Patel YC, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):31–8 (31 ref.)

Molecular control of peptide hormone and receptor expression. Dimaline R. **Proc Nutr Soc** 1996 Mar; 55(1B):265–77 (77 ref.)

[Molecular biology, pharmacology and signal transduction of 5 cloned human somatostatin receptors] Fehmann HC, et al. **Z Gastroenterol** 1996 Nov;34(11):767–74 (53 ref.) (Eng. Abstr.) **(Ger)**

ISOLATION & PURIFICATION

Somatostatin analogs and receptors. Diagnostic and therapeutic applications. Hofland LJ, et al. **Cancer Treat Res** 1997;89:365–82 (91 ref.)

METABOLISM

Somatostatin receptor manipulation. Visser-Wisselaar HA, et al. **Digestion** 1996;57 Suppl 1:7–10 (32 ref.)

Binding properties of somatostatin receptor subtypes. Bruns C, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):17–20 (15 ref.)

Receptor-specific somatostatin analogs: correlations with biological activity. Coy DH, et al. **Metabolism** 1996 Aug; 45(8 Suppl 1):21–3 (14 ref.)

Molecular and functional properties of somatostain receptor subtypes. Liapakis G, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):12–3 (11 ref.)

Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. Reubi JC, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):39–41 (5 ref.)

Somatostatin receptor subtypes: specific expression and signaling properties. Schonbrunn A, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):8–11 (24 ref.)

Somatostatin receptor expression in clinical immunology. van Hagen PM. **Metabolism** 1996 Aug;45(8 Suppl 1):86–7 (10 ref.)

Neural monitoring system for circulating somatostatin in the hepatoportal area. Nakabayashi H. **Nutrition** 1997 Mar; 13(3):225–9 (17 ref.)

Intracellular transducing mechanisms coupled to brain somatostatin receptors. Florio T, et al. **Pharmacol Res** 1996 Jun;33(6):297–305 (94 ref.)

PHYSIOLOGY

Somatostatin receptor regulation of gastric carcinoid tumours. Tang LH, et al. **Digestion** 1996;57 Suppl 1:11–4 (30 ref.)

Multiple intracellular effectors modulate physiological functions of the cloned somatostatin receptors. Florio T, et al. **J Mol Endocrinol** 1996 Oct;17(2):89–100 (102 ref.)

Mechanism of signaling by growth hormone receptor. Argetsinger LS, et al. **Physiol Rev** 1996 Oct;76(4):1089–107 (240 ref.)

Somatostatin receptors in the central nervous system. Schindler M, et al. **Prog Neurobiol** 1996 Sep;50(1):9–47 (255 ref.)

RECEPTORS, SOMATOTROPIN

Growth hormone receptor signalling. Postel-Vinay MC, et al. **Baillieres Clin Endocrinol Metab** 1996 Jul;10(3):323–36 (79 ref.)

[GH receptor function and its evaluation] Matsuzaki F. **Nippon Rinsho** 1997 Apr;55 Suppl 2:483–6 (12 ref.) **(Jpn)**

AGONISTS

An unusual host-parasite relationship: the growth hormone-like factor from plerocercoids of spirometrid tapeworms. Phares K. **Int J Parasitol** 1996 Jun;26(6):575–88 (80 ref.)

CHEMISTRY

Stimulation of kinase cascades by growth hormone: a paradigm for cytokine signaling. Wood TJ, et al. **Prog Nucleic Acid Res Mol Biol** 1997;57:73–94 (107 ref.)

DEFICIENCY

Partial growth hormone insensitivity in childhood. Carlsson LM. **Baillieres Clin Endocrinol Metab** 1996 Jul; 10(3):389–400 (49 ref.)

Treatment of growth hormone insensitivity syndrome (GHIS) with insulin-like growth factor (IGF-I). Ranke MB. **Baillieres Clin Endocrinol Metab** 1996 Jul;10(3):401–10 (28 ref.)

Laron syndrome: typical and atypical forms. Woods KA, et al. **Baillieres Clin Endocrinol Metab** 1996 Jul; 10(3):371–87 (71 ref.)

Growth hormone insensitivity. Rosenbloom AL, et al. **Pediatr Clin North Am** 1997 Apr;44(2):423–42 (65 ref.)

GENETICS

Molecular basis of inherited growth hormone resistance in childhood. Amselem S, et al. **Baillieres Clin Endocrinol Metab** 1996 Jul;10(3):353–69 (63 ref.)

The spectrum of growth-hormone insensitivity. Parks JS, et al. **J Pediatr** 1997 Jul;131(1 Pt 2):S45–50 (20 ref.)

METABOLISM

Prolactin and growth hormone receptors. Goffin V, et al. **Clin Endocrinol (Oxf)** 1996 Sep;45(3):247–55 (120 ref.)

Growth hormone receptor/binding protein--clinical implications. Postel-Vinay MC. **J Pediatr Endocrinol Metab** 1996 Jun;9 Suppl 3:279–83 (38 ref.)

Growth hormone binding protein and free growth hormone in chronic renal failure. Baumann G. **Pediatr Nephrol** 1996 Jun;10(3):328–30 (32 ref.)

PHYSIOLOGY

The role of growth hormone (GH), GH-receptor and GH-binding protein in reproduction and ovulation induction. Blumenfeld Z, et al. **J Pediatr Endocrinol Metab** 1996 Mar-Apr;9(2):145–62 (82 ref.)

Stimulation of kinase cascades by growth hormone: a paradigm for cytokine signaling. Wood TJ, et al. **Prog Nucleic Acid Res Mol Biol** 1997;57:73–94 (107 ref.)

RECEPTORS, SOMATOTROPIN RELEASE INHIBITING HORMONE see **RECEPTORS, SOMATOSTATIN**

RECEPTORS, SRS-A see **RECEPTORS, LEUKOTRIENE**

RECEPTORS, STEM CELL FACTOR see **PROTO-ONCOGENE PROTEINS C-KIT**

RECEPTORS, STEROID

[NGFI-B/nur77 family involved in T-cell apoptosis] Okabe T, et al. **Nippon Rinsho** 1996 Jul;54(7):1768–72 (11 ref.) (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

Ten years after: reclassification of steroid-responsive genes. Dean DM, et al. **Mol Endocrinol** 1996 Dec;10(12):1489–95 (50 ref.)

DRUG EFFECTS

Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Katzenellenbogen JA, et al. **Mol Endocrinol** 1996 Feb; 10(2):119–31 (129 ref.)

GENETICS

Modified steroid receptors and steroid-inducible promoters as genetic switches for gene therapy. White JH. **Adv Pharmacol** 1997;40:339–67 (155 ref.)

Chick ovalbumin upstream promoter-transcription factors (COUP-TFs): coming of age. Tsai SY, et al. **Endocr Rev** 1997 Apr;18(2):229–40 (94 ref.)

Ten years after: reclassification of steroid-responsive genes. Dean DM, et al. **Mol Endocrinol** 1996 Dec;10(12):1489–95 (50 ref.)

METABOLISM

Steroid hormone receptors and their regulation by phosphorylation. Weigel NL. **Biochem J** 1996 Nov 1;319 (Pt 3):657–67 (156 ref.)

Subnuclear trafficking of steroid receptors. DeFranco DB. **Biochem Soc Trans** 1997 May;25(2):592–7 (50 ref.)

Steroid-independent activation of steroid receptors in mammalian and yeast cells and in breast cancer. Picard D, et al. **Biochem Soc Trans** 1997 May;25(2):597–602 (50 ref.)

Chimeric receptors as gene switches. Allgood VE, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):474–9 (24 ref.)

Interaction of steroid hormone receptors with the transcription initiation complex. Beato M, et al. **Endocr Rev** 1996 Dec;17(6):587–609 (261 ref.)

Steroid receptor interactions with heat shock protein and immunophilin chaperones. Pratt WB, et al. **Endocr Rev** 1997 Jun;18(3):306–60 (698 ref.)

Molecular chaperoning of steroid hormone receptors. Pratt WB, et al. **EXS** 1996;77:79–95 (103 ref.)

Promoter- and cell-specific responses to sex steroids. Milgrom E, et al. **Osteoporos Int** 1997;7 Suppl 1:S23–8 (40 ref.)

Transcriptional regulation by steroid hormones. Beato M, et al. **Steroids** 1996 Apr;61(4):240–51 (176 ref.)

PHYSIOLOGY

Steroid receptors and nervous system metamorphosis in insects. Truman JW. **Dev Neurosci** 1996;18(1-2):87–101 (41 ref.)

Molecular dissection of corticosteroid action in the rat hippocampus. Application of the differential display techniques. Vreugdenhil E, et al. **J Mol Neurosci** 1996 Summer;7(2):135–46 (40 ref.)

Nuclear factor-kappa-B/steroid hormone receptor interactions as a functional basis of anti-inflammatory action of steroids in reproductive organs. van der Burg B, et al. **Mol Hum Reprod** 1996 Jun;2(6):433–8 (57 ref.)

Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Shibata H, et al. **Recent Prog Horm Res** 1997;52:141–64; discussion 164–5 (119 ref.)

Regulation of T cell apoptosis via T cell receptors and steroid receptors. Iwata M, et al. **Stem Cells** 1996 Nov;14(6):632–41 (66 ref.)

RECEPTORS, STRETCH see **MECHANORECEPTORS**

RECEPTORS, STRETCH, ARTERIAL see **PRESSORECEPTORS**

RECEPTORS, STRETCH, MUSCLE see **MUSCLE SPINDLES**

RECEPTORS, STRETCH, PULMONARY see **PULMONARY STRETCH RECEPTORS**

RECEPTORS, STRETCH, VASCULAR see **PRESSORECEPTORS**

RECEPTORS, SUBSTANCE K see **RECEPTORS, NEUROKININ-2**

RECEPTORS, SUBSTANCE P see **RECEPTORS, NEUROKININ-1**

RECEPTORS, SYNAPTIC see **RECEPTORS, NEUROTRANSMITTER**

RECEPTORS, T-CELL GROWTH FACTOR see **RECEPTORS, INTERLEUKIN-2**

RECEPTORS, TACHYKININ

Tachykinins: receptor to effector. Khawaja AM, et al. **Int J Biochem Cell Biol** 1996 Jul;28(7):721–38 (152 ref.)

[Peptide receptors] Yokota Y.

RECEPTORS, TACHYKININ

Tanpakushitsu Kakusan Koso 1997 Feb;42(3 Suppl):343–8 (31 ref.) **(Jpn)**

AGONISTS

Use of the chemical structure of peptides as the starting point to design nonpeptide agonists and antagonists at peptide receptors: examples with cholecystokinin and tachykinins. Horwell DC. **Bioorg Med Chem** 1996 Oct;4(10):1573–6 (24 ref.)

ANTAGONISTS & INHIBITORS

Use of the chemical structure of peptides as the starting point to design nonpeptide agonists and antagonists at peptide receptors: examples with cholecystokinin and tachykinins. Horwell DC. **Bioorg Med Chem** 1996 Oct;4(10):1573–6 (24 ref.)

The role of tachykinin receptor antagonists in the prevention of bronchial hyperresponsiveness, airway inflammation and cough. Advenier C, et al. **Eur Respir J** 1997 Aug; 10(8):1892–906 (196 ref.)

'Targeted' molecular diversity: design and development of non-peptide antagonists for cholecystokinin and tachykinin receptors. Horwell D, et al. **Immunopharmacology** 1996 Jun; 33(1–3):68–72 (14 ref.)

Potential role of tachykinins in inflammatory diseases. Canning BJ. **J Allergy Clin Immunol** 1997 May;99(5):579–82 (30 ref.)

Tachykinin and kinin receptor antagonists: therapeutic perspectives in allergic airway disease. Bertrand C, et al. **Trends Pharmacol Sci** 1996 Jul;17(7):255–9 (58 ref.)

[Antagonists of the tachykinin receptors] Kasheverov IE, et al. **Bioorg Khim** 1997 Jun;23(6):451–68 (180 ref.) (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Upregulation of tachykinin receptors in chronic airway inflammation. McDonald DM. **Pulm Pharmacol** 1995 Aug–Oct;8(4–5):203–5 (15 ref.)

METABOLISM

Neurokinin receptors. Comparison of data from classical pharmacology, binding, and molecular biology. Regoli D, et al. **Ann N Y Acad Sci** 1997 May 30;812:144–6 (12 ref.)

RECEPTORS, TETRAGASTRIN see **RECEPTORS, CHOLECYSTOKININ**

RECEPTORS, TGF-ALPHA see **RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE**

RECEPTORS, TGF-BETA see **RECEPTORS, TRANSFORMING GROWTH FACTOR BETA**

RECEPTORS, THROMBIN

Thrombin receptor: a novel target for antiplatelet drug development. Ray A, et al. **Thromb Res** 1997 Jul 1; 87(1):37–50 (55 ref.)

ANTAGONISTS & INHIBITORS

Thrombin receptor antagonists: a work in progress. Brass LF. **Coron Artery Dis** 1997 Jan;8(1):49–58 (59 ref.)

Thrombin receptor antagonists. Seiler SM. **Semin Thromb Hemost** 1996;22(3):223–32 (118 ref.)

Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation. Harker LA, et al. **Thromb Haemost** 1997 Jul;78(1):736–41 (55 ref.)

METABOLISM

Restenosis following percutaneous revascularization—the potential role of thrombin and the thrombin receptor. Stouffer GA, et al. **Ann Hematol** 1996;73 Suppl 1:S39–41 (14 ref.)

The thrombin receptor in the nervous system. Suidan HS, et al. **Semin Thromb Hemost** 1996;22(2):125–33 (63 ref.)

Protease-activated G protein-coupled receptors on human platelets and endothelial cells. Brass LF, et al. **Thromb Haemost** 1997 Jul;78(1):234–41 (89 ref.)

PHYSIOLOGY

Thrombin, its receptor and protease nexin I, its potent serpin, in the nervous system. Festoff BW, et al. **Semin Thromb Hemost** 1996;22(3):267–71 (47 ref.)

Pathophysiology of platelet thrombin receptors. Jamieson GA. **Thromb Haemost** 1997 Jul;78(1):242–6 (49 ref.)

RECEPTORS, THROMBOSPONDIN see **ANTIGENS, CD36**

RECEPTORS, THROMBOXANE

ANTAGONISTS & INHIBITORS

[Thromboxane A2 receptor antagonist in asthma therapy] Endo S, et al. **Nippon Rinsho** 1996 Nov;54(11):3045–8 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular pharmacology and application to the bronchial asthma of thromboxane A2 antagonists] Kohno S. **Nippon Rinsho** 1996 Feb;54(2):551–8 (25 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Thromboxane A2 and related prostaglandins in airways. Devillier P, et al. **Fundam Clin Pharmacol** 1997;11(1):2–18 (186 ref.)

Prostanoid receptors and signal transduction. Narumiya S. **Prog Brain Res** 1996;113:231–41 (70 ref.)

RECEPTORS, THROMBOXANE A2 see **RECEPTORS, THROMBOXANE**

RECEPTORS, THYROID HORMONE

see related
THYROID HORMONE RESISTANCE SYNDROME

[Thyroid hormone receptors] Nakamura H. **Nippon Rinsho** 1997 Apr;55 Suppl 2:570–3 (9 ref.) **(Jpn)**

BIOSYNTHESIS

Mutations in the c-erbA beta 1 gene: do they underlie euthyroid fibromyalgia? Lowe JC, et al. **Med Hypotheses** 1997 Feb;48(2):125–35 (152 ref.)

GENETICS

SF-1: a key regulator of development and function in the mammalian reproductive system. Ikeda Y. **Acta Paediatr Jpn** 1996 Aug;38(4):412–9 (45 ref.)

Chick ovalbumin upstream promoter-transcription factors (COUP-TFs): coming of age. Tsai SY, et al. **Endocr Rev** 1997 Apr;18(2):229–40 (94 ref.)

Mutations in the c-erbA beta 1 gene: do they underlie euthyroid fibromyalgia? Lowe JC, et al. **Med Hypotheses** 1997 Feb;48(2):125–35 (152 ref.)

METABOLISM

Steroid hormone receptors and their regulation by phosphorylation. Weigel NL. **Biochem J** 1996 Nov 1;319 (Pt 3):657–67 (156 ref.)

Three steps in the regulation of transcription by the thyroid hormone receptor: establishment of a repressive chromatin structure, disruption of chromatin and transcriptional activation. Wolffe AP, et al. **Biochem Soc Trans** 1997 May; 25(2):612–5 (18 ref.)

Cell–cell and cell–ECM interactions in epithelial apoptosis and cell renewal during frog intestinal development. Shi YB. **Cell Biochem Biophys** 1995;27(3):179–202 (85 ref.)

Thyroid carcinoma: interrelationships between local thyroid hormone metabolism by the type I 5'-deiodinase and the expression of thyroid hormone receptors and other thyroid-specific (de-)differentiation markers. Köhrle J. **Curr Top Pathol** 1997;91:83–116 (230 ref.)

When is a thyroid hormone receptor not a thyroid hormone receptor? [editorial; comment] Lazar MA. **Endocrinology** 1996 Oct;137(10):4071–2 (24 ref.) Comment on: Endocrinology 1996 Oct;137(10):4073–81.

Some new twists in the regulation of gene expression by thyroid hormone and retinoic acid receptors. Glass CK. **J Endocrinol** 1996 Sep;150(3):349–57 (64 ref.)

PHYSIOLOGY

Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Shibata H, et al. **Recent Prog Horm Res** 1997;52:141–64; discussion 164–5 (119 ref.)

RECEPTORS, THYROID STIMULATING HORMONE see **RECEPTORS, THYROTROPIN**

RECEPTORS, THYROTROPIN

TSH receptor and LH receptor, 1996. Kosugi S, et al. **Endocr J** 1996 Dec;43(6):595–604 (37 ref.)

[TSH receptor] Kosugi S, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:480–2 (9 ref.) **(Jpn)**

CHEMISTRY

Epitope analysis of the thyrotropin receptor, 1997. Kosugi S, et al. **Mol Cell Endocrinol** 1997 Apr 4;128(1–2):11–8 (58 ref.)

Structure and function of the TSH receptor: its suitability as a target for radiotherapy. Morris JC. **Thyroid** 1997 Apr; 7(2):253–8 (50 ref.)

GENETICS

The gene for the thyrotropin receptor (TSHR) as a candidate gene for congenital hypothyroidism with thyroid dysgenesis. Krude H, et al. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 4:117–20 (11 ref.)

Constitutively activating TSH receptor mutations as the cause of toxic thyroid adenoma, multinodular toxic goiter and autosomal dominant non autoimmune hyperthyroidism. Paschke R. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 4:129–32 (18 ref.)

Clinical consequences of activating germline mutations of TSH receptor, the concept of toxic hyperplasia. Leclère J, et al. **Horm Res** 1997;47(4–6):158–62 (15 ref.)

TSH receptor and Gs-alpha gene mutations in the pathogenesis of toxic thyroid adenomas—a note of caution [editorial] Derwahl M. **J Clin Endocrinol Metab** 1996 Aug; 81(8):2783–5 (27 ref.)

Activating mutations of the thyrotropin receptor—unanswered questions [editorial; comment] Morris JC. **J Clin Endocrinol Metab** 1996 Jun;81(6):2021–2 (17 ref.) Comment on: J Clin Endocrinol Metab 1996 Jun;81(6):2023–6.

Molecular insights into TSH receptor abnormality and thyroid disease. Russo D, et al. **J Endocrinol Invest** 1997 Jan;20(1):36–47 (74 ref.)

IMMUNOLOGY

Autoimmunity to the thyroid stimulating hormone receptor. Patibandla SA, et al. **Adv Neuroimmunol** 1996;6(4):347–57 (57 ref.)

Immunopathogenicity of thyrotropin receptor—ability to induce autoimmune thyroid disease in an experimental animal model. Banga JP. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 3:32–4 (21 ref.)

Thyrotropin-receptor-mediated diseases: a paradigm for receptor autoimmunity. Prabhakar BS, et al. **Immunol Today** 1997 Sep;18(9):437–42 (54 ref.)

Development of primary hypothyroidism with antithyroglobulin, antiperoxidase, and blocking-type thyrotropin receptor antibodies after radiation therapy for neuroblastoma. Kikawa Y, et al. **J Pediatr** 1996 Dec; 129(6):909–12 (19 ref.)

METABOLISM

Epitope analysis of the thyrotropin receptor, 1997. Kosugi S, et al. **Mol Cell Endocrinol** 1997 Apr 4;128(1–2):11–8 (58 ref.)

PHYSIOLOGY

Stimulation of thyroidal and extrathyroidal thyrotropin receptors. Hoermann R. **Exp Clin Endocrinol Diabetes** 1996; 104 Suppl 4:88–91 (13 ref.)

Structure and function of the TSH receptor: its suitability as a target for radiotherapy. Morris JC. **Thyroid** 1997 Apr; 7(2):253–8 (50 ref.)

RECEPTORS, THYROXINE see **RECEPTORS, THYROID HORMONE**

RECEPTORS, TRANSFERRIN

see related
CARRIER PROTEINS

ANALYSIS

Assessment of iron status. Baynes RD. **Clin Biochem** 1996 Jun;29(3):209–15 (35 ref.)

ANTAGONISTS & INHIBITORS

Iron deprivation and cancer: a view beginning with studies of monoclonal antibodies against the transferrin receptor. Kemp JD. **Histol Histopathol** 1997 Jan;12(1):291–6 (52 ref.)

GENETICS

Interaction between iron-regulatory proteins and their RNA target sequences, iron-responsive elements. Henderson BR, et al. **Prog Mol Subcell Biol** 1997;18:117–39 (115 ref.)

Mechanisms for posttranscriptional regulation by iron-responsive elements and iron regulatory proteins. Muckenthaler M, et al. **Prog Mol Subcell Biol** 1997; 18:93–115 (100 ref.)

METABOLISM

Response of Neisseria meningitidis to iron limitation. Pettersson A, et al. **Antonie Van Leeuwenhoek** 1997 Feb; 71(1–2):129–36 (34 ref.)

The paradox of transferrin receptor-mediated drug delivery—intracellular targeting or transcellular transport? Shah D, et al. **J Drug Target** 1995;3(4):243–5 (14 ref.)

RECEPTORS, TRANSFORMING-GROWTH FACTOR ALPHA see **RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE**

RECEPTORS, TRANSFORMING GROWTH FACTOR BETA

AGONISTS

Regulation and interactions of transforming growth factor-beta with cardiovascular cells: implications for development and disease. Saltis J, et al. **Clin Exp Pharmacol Physiol** 1996 Mar;23(3):193–200 (94 ref.)

CLASSIFICATION

An emerging complexity of receptors for transforming growth factor-beta. Derynck R, et al. **Princess Takamatsu Symp** 1994;24:264–75 (54 ref.)

GENETICS

The type II transforming growth factor-beta receptor as a

tumor-suppressor gene. Brattain MG, et al. **Curr Opin Oncol** 1996 Jan;8(1):49-53 (26 ref.)

METABOLISM

From receptor to nucleus: the Smad pathway. Baker JC, et al. **Curr Opin Genet Dev** 1997 Aug;7(4):467-73 (50 ref.)

PHYSIOLOGY

Signal transduction and TGF-beta superfamily receptors. Kolodziejczyk SM, et al. **Biochem Cell Biol** 1996; 74(3):299-314 (133 ref.)

Signal transduction by members of the transforming growth factor-beta superfamily. Attisano L, et al. **Cytokine Growth Factor Rev** 1996 Dec;7(4):327-39 (127 ref.)

TGF-beta receptors and signal transduction. Miyazono K. **Int J Hematol** 1997 Feb;65(2):97-104 (42 ref.)

Müllerian inhibiting substance as a model for the transforming growth factor-beta family: development of new treatment strategies. Shah PC, et al. **Semin Pediatr Surg** 1996 Aug; 5(3):182-90 (34 ref.)

[TGF-beta and its receptors] Yuasa Y. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1460-4 (19 ref.) (Eng. Abstr.) **(Jpn)**

RECEPTORS, TRIIODOTHYRONINE see **RECEPTORS, THYROID HORMONE**

RECEPTORS, TRYPTAMINE see **RECEPTORS, SEROTONIN**

RECEPTORS, TUMOR NECROSIS FACTOR

Tumor necrosis factor receptor superfamily. Naismith JH, et al. **J Inflamm** 1995-96;47(1-2):1-7 (9 ref.)

Myxoma T2 protein as a model for poxvirus TNF receptor homologs. McFadden G, et al. **J Neuroimmunol** 1997 Feb; 72(2):119-26 (47 ref.)

[TNF] Yamauchi N, et al. **Gan To Kagaku Ryoho** 1997 Sep; 24(11):1486-94 (68 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

Mini-review: tumor necrosis factor (TNF) and TNF soluble receptors (TNF-sR) in liver disease and liver transplantation. Majno PE, et al. **Swiss Surg** 1995;(4):182-5 (27 ref.)

CHEMISTRY

Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily. Gruss HJ. **Int J Clin Lab Res** 1996;26(3):143-59 (238 ref.)

GENETICS

[TNF/TNFR gene and apoptosis] Takeda Y, et al. **Nippon Rinsho** 1996 Jul;54(7):1888-94 (15 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Autoimmunity due to defective Nur77, Fas, and TNF-RI apoptosis. Mountz JD, et al. **Adv Exp Med Biol** 1996; 406:241-62 (93 ref.)

Recent advances in tumor necrosis factor and CD40 signaling. Tewari M, et al. **Curr Opin Genet Dev** 1996 Feb; 6(1):39-44 (52 ref.)

Tumour necrosis factor-alpha (TNF-alpha): the good, the bad and potentially very effective. Barbara JA, et al. **Immunol Cell Biol** 1996 Oct;74(5):434-43 (107 ref.)

Lymphotoxin-alpha-deficient and TNF receptor-I-deficient mice define developmental and functional characteristics of germinal centers. Matsumoto M, et al. **Immunol Rev** 1997 Apr;156:137-44 (40 ref.)

Cytokines, viruses and macrophages: an interactive network. An immune dysregulation involving the members of the tumor necrosis factor (TNF) receptor superfamily could be critical in AIDS pathogenesis. Herbein G. **Pathol Biol (Paris)** 1997 Feb;45(2):115-25 (127 ref.)

[The TRAF family protein-mediated B cell proliferation signal and the mechanism of LMP1-induced B cell transformation] Inoue J. **Nippon Rinsho** 1997 Feb; 55(2):299-304 (18 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Transducing signals of life and death. Yuan J. **Curr Opin Cell Biol** 1997 Apr;9(2):247-51 (31 ref.)

Cell death induction by receptors of the TNF family: towards a molecular understanding. Wallach D, et al. **FEBS Lett** 1997 Jun 23;410(1):96-106 (155 ref.)

Identification of p55 tumor necrosis factor receptor-associated proteins that couple to signaling pathways not initiated by the death domain. Adam D, et al. **J Inflamm** 1995-96;47(1-2):61-6 (35 ref.)

The TNF-ligand and receptor superfamilies: controllers of immunity and the Trojan horses of autoimmune disease? Hill CM, et al. **Mol Aspects Med** 1996 Oct;17(5):455-509 (240 ref.)

The CD95 system and the death of a lymphocyte. Matiba B, et al. **Semin Immunol** 1997 Feb;9(1):59-68 (108 ref.)

PHYSIOLOGY

Structural and biological features of the TNF receptor and TNF ligand superfamilies: interactive signals in the pathobiology of Hodgkin's disease. Gruss HJ, et al. **Ann Oncol** 1996;7 Suppl 4:19-26 (66 ref.)

FasL/Fas and TNF/TNFR interactions in the regulation of immune responses and disease. Lynch DH, et al. **Behring Inst Mitt** 1996 Oct;(97):175-84 (36 ref.)

Exploring cell death mechanisms by analyzing signaling cascades of the TNF/NGF receptor family. Wallach D, et al. **Behring Inst Mitt** 1996 Oct;(97):144-55 (69 ref.)

Apoptosis by death factor. Nagata S. **Cell** 1997 Feb 7; 88(3):355-65 (85 ref.)

Bone morphogenesis and modeling: soluble signals sculpt osteosomes in the solid state [comment] Reddi AH. **Cell** 1997 Apr 18;89(2):159-61 (15 ref.) Comment on: Cell 1997 Apr 18;89(2):309-19.

The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Aderka D. **Cytokine Growth Factor Rev** 1996 Oct;7(3):231-40 (106 ref.)

Suicide by order: some open questions about the cell-killing activities of the TNF ligand and receptor families. Wallach D. **Cytokine Growth Factor Rev** 1996 Oct;7(3):211-21 (133 ref.)

M-T2: a poxvirus TNF receptor homologue with dual activities. Sedger L, et al. **Immunol Cell Biol** 1996 Dec; 74(6):538-45 (77 ref.)

Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily. Gruss HJ. **Int J Clin Lab Res** 1996;26(3):143-59 (238 ref.)

How do tumor necrosis factor receptors work? Bazzoni F, et al. **J Inflamm** 1995;45(4):221-38 (139 ref.)

Cellular and molecular mechanisms of TNF protection in septic peritonitis. Echtenacher B, et al. **J Inflamm** 1995-96; 47(1-2):85-9 (24 ref.)

Tumor necrosis factor (TNF) receptors in cellular signaling of soluble and membrane-expressed TNF. Grell M. **J Inflamm** 1995-96;47(1-2):8-17 (28 ref.)

TNF receptors in the microvascular pathology of acute respiratory distress syndrome and cerebral malaria. Lucas R, et al. **J Leukoc Biol** 1997 May;61(5):551-8 (65 ref.)

TNF-alpha receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyelination in Lewis rats: an overview. Klinkert WE, et al. **J Neuroimmunol** 1997 Feb;72(2):163-8 (44 ref.)

RECEPTORS, UROGASTRONE see **RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE**

RECEPTORS, V1 see **RECEPTORS, VASOPRESSIN**

RECEPTORS, V2 see **RECEPTORS, VASOPRESSIN**

RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE

ANALYSIS

Functional and molecular characterization of VIP receptors and signal transduction in human and rodent immune systems. Calvo JR, et al. **Adv Neuroimmunol** 1996; 6(1):39-47 (52 ref.)

CHEMISTRY

Characterization of the VIP receptor from SUP T1 lymphoblasts. Robberecht P, et al. **Adv Neuroimmunol** 1996; 6(1):49-57 (58 ref.)

Receptors for VIP, PACAP, secretin, GRF, glucagon, GLP-1, and other members of their new family of G protein-linked receptors: structure-function relationship with special reference to the human VIP-1 receptor. Laburthe M, et al. **Ann N Y Acad Sci** 1996 Dec 26; 805:94-109; discussion 110-1 (64 ref.)

PHYSIOLOGY

Functional and molecular characterization of VIP receptors and signal transduction in human and rodent immune systems. Calvo JR, et al. **Adv Neuroimmunol** 1996; 6(1):39-47 (52 ref.)

Pituitary adenylate cyclase-activating polypeptides, PACAP-38 and PACAP-27, regulation of sympathetic neuron catecholamine, and neuropeptide Y expression through activation of type I PACAP/VIP receptor isoforms. Braas KM, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:204-16; discussion 217-8 (47 ref.)

Development of VIP agonists and antagonists with tissue and receptor specificity: effects on behavioral maturation, sexual function, and the biologic clock. Gozes I, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:159-69; discussion 169-71 (60 ref.)

PACAP/VIP receptor subtypes, signal transducers, and effectors in pituitary cells. Hezareh M, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:315-27; discussion 327-8 (41 ref.)

VIP regulation of embryonic growth. Hill JM, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:259-68; discussion 268-9 (23 ref.)

PACAP/VIP receptors in pancreatic beta-cells: their roles in insulin secretion. Inagaki N, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:44-51; discussion 52-3 (23 ref.)

Receptors for VIP, PACAP, secretin, GRF, glucagon, GLP-1, and other members of their new family of G protein-linked receptors: structure-function relationship with special reference to the human VIP-1 receptor. Laburthe M, et al. **Ann N Y Acad Sci** 1996 Dec 26; 805:94-109; discussion 110-1 (64 ref.)

VIP and PACAP receptor-mediated actions on cell proliferation and survival. Waschek JA. **Ann N Y Acad Sci** 1996 Dec 26;805:290-300; discussion 300-1 (71 ref.)

RECEPTORS, VASOPRESSIN

ANTAGONISTS & INHIBITORS

A diurnal rhythm of stimulatory input to the hypothalamo-pituitary-adrenal system as revealed by timed intrahypothalamic administration of the vasopressin V1 antagonist. Kalsbeek A, et al. **J Neurosci** 1996 Sep 1; 16(17):5555-65 (80 ref.)

SIADH and other hyponatremic disorders: diagnosis and therapeutic problems. Saito T. **Nippon Jinzo Gakkai Shi** 1996 Oct;38(10):429-34 (22 ref.)

[Aquaretic agents] Bosch-Marcé M, et al. **Gastroenterol Hepatol** 1996 Nov;19(9):472-7 (55 ref.) **(Spa)**

CHEMISTRY

[Structure, function and abnormality of ADH receptors] Okada K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:491-4 (22 ref.) **(Jpn)**

GENETICS

Molecular and cellular defects in nephrogenic diabetes insipidus. Knoers NV, et al. **Curr Opin Nephrol Hypertens** 1996 Jul;5(4):353-8 (43 ref.)

V3 vasopressin receptor and corticotropic phenotype in pituitary and nonpituitary tumors. de Keyzer Y, et al. **Horm Res** 1997;47(4-6):259-62 (18 ref.)

METABOLISM

Vasopressin and oxytocin receptors in the central nervous system. Barberis C, et al. **Crit Rev Neurobiol** 1996; 10(1):119-54 (287 ref.)

Small molecule ligands for oxytocin and vasopressin receptors. Freidinger RM, et al. **Med Res Rev** 1997 Jan; 17(1):1-16 (68 ref.)

PHYSIOLOGY

Vasopressin receptors in health and disease. Bichet DG. **Kidney Int** 1996 Jun;49(6):1706-11 (33 ref.)

[Structure, function and abnormality of ADH receptors] Okada K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:491-4 (22 ref.) **(Jpn)**

RECEPTORS, VERY LATE ANTIGEN

IMMUNOLOGY

Selective immunomodulation: utilization of CD29/VLA molecules. Morimoto C, et al. **Artif Organs** 1996 Aug; 20(8):828-31 (29 ref.)

RECEPTORS, VIP see **RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE**

RECEPTORS, VIRUS

The beta-chemokines, HIV type 1 second receptors, and exposed uninfected persons. Paxton WA, et al. **AIDS Res Hum Retroviruses** 1996 Sep 1;12(13):1203-7 (51 ref.)

[Measles virus receptor CD46] Yanagi Y. **Uirusu** 1995 Dec; 45(2):159-64 (21 ref.) **(Jpn)**

ANALYSIS

Identification and biology of cellular receptors for the coxsackie B viruses group. Kuhn RJ. **Curr Top Microbiol Immunol** 1997;223:209-26 (65 ref.)

IMMUNOLOGY

Multiple stages of virus-receptor interactions as shown by simian virus 40. Norkin LC, et al. **Adv Exp Med Biol** 1996; 408:159-67 (26 ref.)

METABOLISM

Chemokines and HIV: a remarkable synergism. Moser B. **Trends Microbiol** 1997 Mar;5(3):88-90 (33 ref.)

Is CD46 the cellular receptor for measles virus? Buckland R, et al. **Virus Res** 1997 Apr;48(1):1-9 (44 ref.)

PHYSIOLOGY

Virus-receptor interactions in the enteric tract. Virus-receptor interactions. Holmes KV, et al. **Adv Exp Med Biol** 1997;412:125-33 (49 ref.)

CD46, a complement regulatory protein/measles virus receptor, and its relation to hematological disorders. Seya T. **Int J Hematol** 1996 Aug;64(2):101-9 (38 ref.)

RECEPTORS, VIRUS

Molecular and cellular aspects of measles virus persistence in the CNS. ter Meulen V. **J Neurovirol** 1997 May;3 Suppl 1:S3–5 (25 ref.)
Cell–surface receptors for retroviruses and implications for gene transfer. Miller AD. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11407–13 (52 ref.)
Early events in poliovirus infection: virus–receptor interactions. Racaniello VR. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11378–81 (29 ref.)
The poliovirus receptor: a hook, or an unzipper? Racaniello VR. **Structure** 1996 Jul 15;4(7):769–73 (29 ref.)
The attachment receptor for hepatitis A virus. Locarnini S. **Trends Microbiol** 1997 Feb;5(2):45–7; discussion 47–8 (17 ref.)
[ICAM–1 and allergic inflammation] Canonica GW. **Allerg Immunol (Paris)** 1997 Mar;29(3):77–9; discussion 84 (17 ref.) (Eng. Abstr.) **(Fre)**

RECEPTORS, VITAMIN D see **RECEPTORS, CALCITRIOL**

RECEPTORS, VITRONECTIN

PHYSIOLOGY

REVIEW: the integrin alpha V beta 3: angiogenesis and apoptosis. Varner JA, et al. **Cell Adhes Commun** 1995 Nov; 3(4):367–74 (60 ref.)
The role of vascular cell integrins alpha v beta 3 and alpha v beta 5 in angiogenesis. Varner JA. **EXS** 1997;79:361–90 (243 ref.)
Tumor angiogenesis and the role of vascular cell integrin alphavbeta3. Varner JA, et al. **Important Adv Oncol** 1996; :69–87 (259 ref.)
The alpha v beta 3 integrin "vitronectin receptor". Horton MA. **Int J Biochem Cell Biol** 1997 May;29(5):721–5 (14 ref.)

RECEPTORS, VLA see **RECEPTORS, VERY LATE ANTIGEN**

RECEPTORS, VLA–5 see **RECEPTORS, FIBRONECTIN**

RECEPTOSOMES see **ENDOSOMES**

RECKLINGHAUSEN'S DISEASE OF NERVE see **NEUROFIBROMATOSIS 1**

RECOMBINANT DNA see **DNA, RECOMBINANT**

RECOMBINANT DNA VACCINES see **VACCINES, DNA**

RECOMBINANT ERYTHROPOIETIN see **ERYTHROPOIETIN, RECOMBINANT**

RECOMBINANT FUSION PROTEINS

see related
IMMUNOTOXINS

BIOSYNTHESIS

Protein expression using ubiquitin fusion and cleavage. Baker RT. **Curr Opin Biotechnol** 1996 Oct;7(5):541–6 (42 ref.)
Strategies for expressing human antibody repertoires in transgenic mice. Brüggemann M, et al. **Immunol Today** 1996 Aug;17(8):391–7 (47 ref.)
Gene identification using the yeast two–hybrid system. Bai C, et al. **Methods Enzymol** 1996;273:331–47 (17 ref.)

CHEMISTRY

Escherichia coli RNA polymerase holoenzyme: rapid reconstitution from recombinant alpha, beta, beta', and sigma subunits. Tang H, et al. **Methods Enzymol** 1996; 273:130–4 (19 ref.)

GENETICS

Protein expression using ubiquitin fusion and cleavage. Baker RT. **Curr Opin Biotechnol** 1996 Oct;7(5):541–6 (42 ref.)

ISOLATION & PURIFICATION

Purification of overproduced Escherichia coli RNA polymerase sigma factors by solubilizing inclusion bodies and refolding from Sarkosyl. Burgess RR. **Methods Enzymol** 1996;273:145–9 (7 ref.)
Blood proteins from transgenic animal bioreactors. Luboń H, et al. **Transfus Med Rev** 1996 Apr;10(2):131–43 (86 ref.)

METABOLISM

Rotavirus protein expression is important for virus assembly and pathogenesis. Tian P, et al. **Arch Virol Suppl** 1996; 12:69–77 (26 ref.)

THERAPEUTIC USE

Interleukin–2 fusion protein: an investigational therapy for interleukin–2 receptor expressing malignancies. Nichols J, et al. **Eur J Cancer** 1997 Jan;33 Suppl 1:S34–6 (27 ref.)
TNF–alpha receptor fusion protein prevents experimental auto–immune encephalomyelitis and demyelination in Lewis rats: an overview. Klinkert WE, et al. **J Neuroimmunol** 1997 Feb;72(2):163–8 (44 ref.)
Destroying retroviruses from within. Boeke JD, et al. **Trends Microbiol** 1996 Nov;4(11):421–6 (27 ref.)

RECOMBINANT G–CSF see **GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT**

RECOMBINANT GM–CSF see **GRANULOCYTE MACROPHAGE COLONY–STIMULATING FACTORS, RECOMBINANT**

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR see **GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT**

RECOMBINANT GRANULOCYTE–MACROPHAGE COLONY–STIMULATING FACTORS see **GRANULOCYTE MACROPHAGE COLONY–STIMULATING FACTORS, RECOMBINANT**

RECOMBINANT INTERFERON ALFA–2A see **INTERFERON ALFA–2A**

RECOMBINANT INTERFERON ALFA–2B see **INTERFERON ALFA–2B**

RECOMBINANT INTERFERON ALFA–2C see **INTERFERON ALFA, RECOMBINANT**

RECOMBINANT INTERFERON–GAMMA see **INTERFERON–GAMMA, RECOMBINANT**

RECOMBINANT–METHIONYL HUMAN GRANULOCYTE COLONY–STIMULATING F see **FILGRASTIM**

RECOMBINANT PITUITARY GROWTH HORMONES see **SOMATOTROPINS, RECOMBINANT**

RECOMBINANT PROTEINS

Going beyond the native: protecting DNA and protein patents. Chahine KG. **Nat Biotechnol** 1997 Feb;15(2):183–6 (11 ref.)
Special considerations concerning regulatory requirements and drug development for peptides and biotech products in the EU. Braun A, et al. **Pharm Acta Helv** 1996 Dec; 71(6):447–58 (22 ref.)
[Functions of recombination proteins in meiosis] Terasawa M, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep; 41(11):1535–42 (39 ref.) **(Jpn)**

ANALYSIS

Biological assays: their role in the development and quality control of recombinant biological medicinal products. Mire–Sluis AR, et al. **Biologicals** 1996 Dec;24(4):351–62 (76 ref.)
Capillary electrophoresis analysis of recombinant proteins. Teshima G, et al. **Methods Enzymol** 1996;271:264–93 (41 ref.)
Cell–surface markers for assessing gene transfer into human hematopoietic cells [see comments] Phillips K, et al. **Nat Med** 1996 Oct;2(10):1154–6 (25 ref.) Comment in: Nat Med 1996 Dec;2(12):1280–1.

BIOSYNTHESIS

Gene transfer to neurons using herpes simplex virus–based vectors. Fink DJ, et al. **Annu Rev Neurosci** 1996;19:265–87 (111 ref.)
Methylotrophic yeast hansenula polymorpha as production organism for recombinant pharmaceuticals. Gellissen G, et al. **Arzneimittelforschung** 1996 Sep;46(9):943–8 (28 ref.)
Bioreactor cultivation of the nematode Caenorhabditis elegans: large scale production of biologically active drug receptors for pharmaceutical research. Gbewonyo K, et al. **Biotechnol Genet Eng Rev** 1997;14:37–49 (35 ref.)
Engineering nutritious proteins. Hefford MA. **Biotechnol Genet Eng Rev** 1997;14:191–210 (108 ref.)
Subcellular targeting and purification of recombinant proteins in plant production systems. Moloney MM, et al. **Biotechnol Genet Eng Rev** 1997;14:321–36 (63 ref.)
Expression of recombinant glycoproteins in the simple eukaryote Dictyostelium discoideum. Slade MB, et al. **Biotechnol Genet Eng Rev** 1997;14:1–35 (212 ref.)
Commercial production of lactoferrin, a multifunctional iron–binding glycoprotein. Ward PP, et al. **Biotechnol Genet Eng Rev** 1997;14:303–19 (114 ref.)
Engineering novel antibody molecules. Sensel MG, et al. **Chem Immunol** 1997;65:129–58 (80 ref.)
Expression in bacteria other than Escherichia coli. Billman–Jacobe H. **Curr Opin Biotechnol** 1996 Oct; 7(5):500–4 (52 ref.)
Engineering antibodies for imaging and therapy. Carter P, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):449–54 (54 ref.)
Phage display of proteins. Dunn IS. **Curr Opin Biotechnol** 1996 Oct;7(5):547–53 (71 ref.)
Recombinant protein production in transgenic animals. Echelard Y. **Curr Opin Biotechnol** 1996 Oct;7(5):536–40 (60 ref.)
Quality and authenticity of heterologous proteins synthesized in yeast. Eckart MR, et al. **Curr Opin Biotechnol** 1996 Oct; 7(5):525–30 (47 ref.)
The state of antibody catalysis. Smithrud DB, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):459–66 (46 ref.)
Optimization of heterologous protein production in Escherichia coli. Weickert MJ, et al. **Curr Opin Biotechnol** 1996 Oct;7(5):494–9 (39 ref.)
Strategies for achieving high–level expression of genes in Escherichia coli. Makrides SC. **Microbiol Rev** 1996 Sep; 60(3):512–38 (623 ref.)
Bacterial growth inhibition by overproduction of protein. Kurland CG, et al. **Mol Microbiol** 1996 Jul;21(1):1–4 (25 ref.)
Eukaryotic expression systems: a comparison. Geisse S, et al. **Protein Expr Purif** 1996 Nov;8(3):271–82 (111 ref.)

CHEMISTRY

Structure of cellulases and their applications. Ohmiya K, et al. **Biotechnol Genet Eng Rev** 1997;14:365–414 (180 ref.)
Biotechnology of protein and polysaccharide gels. Tombs MP. **Biotechnol Genet Eng Rev** 1997;14:337–63 (62 ref.)
Stabilization of protein structures. Lee B, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):423–8 (65 ref.)
Engineering novel proteins by transfer of active sites to natural scaffolds. Vita C. **Curr Opin Biotechnol** 1997 Aug; 8(4):429–34 (56 ref.)
Analytical peptide mapping of recombinant DNA–derived proteins by reversed–phase high–performance liquid chromatography. Hoff ER, et al. **Methods Enzymol** 1996; 271:51–68 (32 ref.)
Production and characterization of recombinant proteins for NMR structural studies. Mossakowska DE, et al. **Methods Mol Biol** 1997;60:325–35 (24 ref.)
A compendium and hydropathy/flexibility analysis of common reactive sites in proteins: reactivity at Asn, Asp, Gln, and Met motifs in neutral pH solution. Amphlett G, et al. **Pharm Biotechnol** 1996;9:1–140 (165 ref.)

DIAGNOSTIC USE

Recombinant mite allergens. New technologies for the management of patients with asthma. Chapman MD, et al. **Allergy** 1997 Apr;52(4):374–9 (34 ref.)
Use of recombinant proteins in the diagnosis of autoimmune connective tissue diseases. Galperin C, et al. **Int Arch Allergy Immunol** 1996 Dec;111(4):337–47 (103 ref.)

GENETICS

Expression in bacteria other than Escherichia coli. Billman–Jacobe H. **Curr Opin Biotechnol** 1996 Oct; 7(5):500–4 (52 ref.)
Phage display of proteins. Dunn IS. **Curr Opin Biotechnol** 1996 Oct;7(5):547–53 (71 ref.)
Recombinant protein production in transgenic animals. Echelard Y. **Curr Opin Biotechnol** 1996 Oct;7(5):536–40 (60 ref.)
Quality and authenticity of heterologous proteins synthesized in yeast. Eckart MR, et al. **Curr Opin Biotechnol** 1996 Oct; 7(5):525–30 (47 ref.)
Errors of heterologous protein expression. Kurland C, et al. **Curr Opin Biotechnol** 1996 Oct;7(5):489–93 (44 ref.)
The expression of recombinant proteins in yeasts. Sudbery PE. **Curr Opin Biotechnol** 1996 Oct;7(5):517–24 (33 ref.)
Optimization of heterologous protein production in Escherichia coli. Weickert MJ, et al. **Curr Opin Biotechnol** 1996 Oct;7(5):494–9 (39 ref.)
Therapeutic proteins and enzymes from genetically engineered yeasts. Wiseman A. **Endeavour** 1996;20(3):130–2 (15 ref.)
Display of heterologous proteins on the surface of microorganisms: from the screening of combinatorial libraries to live recombinant vaccines. Georgiou G, et al. **Nat Biotechnol** 1997 Jan;15(1):29–34 (90 ref.)
Upstream strategies to minimize proteolytic degradation upon recombinant production in Escherichia coli. Murby M, et al. **Protein Expr Purif** 1996 Mar;7(2):129–36 (76 ref.)

IMMUNOLOGY

Expression of the house dust mite allergen Der p2 and mutants in the baker's yeast Saccharomyces cerevisiae. Hakkaart GA, et al. **Adv Exp Med Biol** 1996;409:395–8 (5 ref.)
Parameters affecting the immunogenicity of recombinant T cell epitopes inserted into hybrid proteins. Lo–Man R, et al. **Hum Immunol** 1997 May;54(2):180–8 (75 ref.)
New perspectives on recombinant human antibodies. de Kruif J, et al. **Immunol Today** 1996 Oct;17(10):453–5 (13 ref.)

ISOLATION & PURIFICATION

Inclusion bodies and purification of proteins in biologically active forms. Mukhopadhyay A. **Adv Biochem Eng Biotechnol** 1997;56:61–109 (160 ref.)
Subcellular targeting and purification of recombinant proteins in plant production systems. Moloney MM, et al. **Biotechnol Genet Eng Rev** 1997;14:321–36 (63 ref.)

METABOLISM

Do recombinant receptor assays provide affinity and potency estimates? Bockaert J, et al. **Ann N Y Acad Sci** 1997 May 30;812:55–70 (27 ref.)

PHARMACOKINETICS

Pharmacology and pharmacokinetics of LEX 032, a bioengineered serpin: the first of a potential new class of drugs. Sands H, et al. **Drug Metab Rev** 1997 Feb–May; 29(1–2):309–28 (68 ref.)

Design of biological equivalence programs for therapeutic biotechnology products in clinical development: a perspective. Mordenti J, et al. **Pharm Res** 1996 Oct; 13(10):1427–37 (29 ref.)

PHARMACOLOGY

Inclusion bodies and purification of proteins in biologically active forms. Mukhopadhyay A. **Adv Biochem Eng Biotechnol** 1997;56:61–109 (160 ref.)

Recombinant allergens. Steps on the way to diagnosis and therapy of type I allergy. Valenta R, et al. **Adv Exp Med Biol** 1996;409:185–96 (31 ref.)

Pharmacology and pharmacokinetics of LEX 032, a bioengineered serpin: the first of a potential new class of drugs. Sands H, et al. **Drug Metab Rev** 1997 Feb–May; 29(1–2):309–28 (68 ref.)

The effect of granulocyte-macrophage colony stimulating factor (rGM-CSF) on macrophage function in microbial disease. Jones TC. **Med Oncol** 1996 Sep;13(3):141–7 (54 ref.)

SECRETION

Secretion of recombinant proteins by Gram-negative bacteria. Sandkvist M, et al. **Curr Opin Biotechnol** 1996 Oct;7(5):505–11 (61 ref.)

Merits of secretion of heterologous proteins from industrial microorganisms. Quax WJ. **Folia Microbiol (Praha)** 1997; 42(2):99–103 (11 ref.)

Secretion of proteins by Escherichia coli and its application in production of recombinant proteins. Fikus MM, et al. **Postepy Biochem** 1995;41(5 Suppl):313–8 (45 ref.)

STANDARDS

Safety considerations of recombinant protein therapy: introductory comments [comment] Hayes TJ, et al. **Clin Immunol Immunopathol** 1997 Apr;83(1):1–4 (11 ref.) Comment on: Clin Immunol Immunopathol 1997 Apr;83(1):5–7. Comment on: Clin Immunol Immunopathol 1997 Apr;83(1):15–7. Comment on: Clin Immunol Immunopathol 1997 Apr;83(1):18–20.

THERAPEUTIC USE

Recombinant mite allergens. New technologies for the management of patients with asthma. Chapman MD, et al. **Allergy** 1997 Apr;52(4):374–9 (34 ref.)

Recombinant secretory IgA for immune intervention against mucosal pathogens. Corthésy B. **Biochem Soc Trans** 1997 May;25(2):471–5 (27 ref.)

Safety of human recombinant proteins. Ryffel B. **Biomed Environ Sci** 1997 Mar;10(1):65–72 (35 ref.)

Administration of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation in children with acute myelogenous leukemia: a note of caution. Calderwood S, et al. **Bone Marrow Transplant** 1996 Jul; 18(1):87–91 (23 ref.)

Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: a retrospective analysis. Peters BG, et al. **Bone Marrow Transplant** 1996 Jul;18(1):93–102 (60 ref.)

Safety considerations of recombinant protein therapy: introductory comments [comment] Hayes TJ, et al. **Clin Immunol Immunopathol** 1997 Apr;83(1):1–4 (11 ref.) Comment on: Clin Immunol Immunopathol 1997 Apr;83(1):5–7. Comment on: Clin Immunol Immunopathol 1997 Apr;83(1):15–7. Comment on: Clin Immunol Immunopathol 1997 Apr;83(1):18–20.

Does recombinant human insulin-like growth factor I have a role in the treatment of type I (insulin dependent) diabetes during puberty? Dunger DB, et al. **J Pediatr Endocrinol Metab** 1995 Oct–Dec;8(4):237–42 (51 ref.)

Recombinant proteins for therapy. Buckel P. **Trends Pharmacol Sci** 1996 Dec;17(12):450–6 (31 ref.)

TOXICITY

Safety assessment of biotechnology-derived pharmaceutical products. General principles and the relevant cases. Maki E. **J Toxicol Sci** 1996 Dec;21(5):531–3 (3 ref.)

RECOMBINANT SOMATOTROPINS see **SOMATOTROPINS, RECOMBINANT**

RECOMBINATION, GENETIC

see related
REASSORTANT VIRUSES

V(D)J recombination pathology. Schwarz K, et al. **Adv Immunol** 1996;61:285–326 (281 ref.)

mtDNA recombination: what do in vitro data mean? [letter] Howell N. **Am J Hum Genet** 1997 Jul;61(1):19–22 (32 ref.)

Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Modrich P, et al. **Annu Rev Biochem** 1996;65:101–33 (225 ref.)

Population genetic perspectives on the evolution of recombination. Feldman MW, et al. **Annu Rev Genet** 1996; 30:261–95 (119 ref.)

Recombinational repair of genetic mutations. Cole-Strauss A, et al. **Antisense Nucleic Acid Drug Dev** 1997 Jun; 7(3):211–6 (20 ref.)

recA mutants of E. coli K12: a personal turning point. Clark AJ. **Bioessays** 1996 Sep;18(9):767–72 (31 ref.)

The origins of V(D)J recombination. Lewis SM, et al. **Cell** 1997 Jan 24;88(2):159–62 (20 ref.)

Role of the Ku autoantigen in V(D)J recombination and double-strand break repair. Chu G. **Curr Top Microbiol Immunol** 1996;217:113–32 (60 ref.)

The cell cycle and V(D)J recombination. Desiderio S, et al. **Curr Top Microbiol Immunol** 1996;217:45–59 (60 ref.)

Regulation of recombination activating gene expression during lymphocyte development. Grawunder U, et al. **Curr Top Microbiol Immunol** 1996;217:31–43 (60 ref.)

Biochemical studies of class switch recombination. Jessberger R, et al. **Curr Top Microbiol Immunol** 1996;217:191–202 (30 ref.)

Identification of the XRCC4 gene: complementation of the DSBR and V(D)J recombination defects of XR-1 cells. Li Z, et al. **Curr Top Microbiol Immunol** 1996;217:143–50 (25 ref.)

Developmental and molecular regulation of immunoglobulin class switch recombination. Lorenz M, et al. **Curr Top Microbiol Immunol** 1996;217:151–69 (80 ref.)

Double-strand breaks, DNA hairpins, and the mechanism of V(D)J recombination. Steen SB, et al. **Curr Top Microbiol Immunol** 1996;217:61–77 (60 ref.)

Initiation of V(D)J recombinations in a cell-free system by RAG1 and RAG2 proteins. van Gent DC, et al. **Curr Top Microbiol Immunol** 1996;217:1–10 (22 ref.)

Recombination in HIV: an important viral evolutionary strategy. Burke DS. **Emerg Infect Dis** 1997 Jul–Sep; 3(3):253–9 (40 ref.)

Meiotic recombination and germ cell aneuploidy. Ferguson LR, et al. **Environ Mol Mutagen** 1996;28(3):192–210 (178 ref.)

Recombinant adenovirus: a gene transfer vector for study and treatment of CNS diseases. Davidson BL, et al. **Exp Neurol** 1997 Mar;144(1):125–30 (66 ref.)

Microevolution and epidemic spread of serogroup A Neisseria meningitidis--a review. Achtman M. **Gene** 1997 Jun 11;192(1):135–40 (23 ref.)

Polynucleotidyl transfer reactions in site-specific DNA recombination. Mizuuchi K. **Genes Cells** 1997 Jan;2(1):1–12 (79 ref.)

Recombination hot spots and human disease. Purandare SM, et al. **Genome Res** 1997 Aug;7(8):773–86 (102 ref.)

Hyper-recombination and Bloom's syndrome: microbes again provide clues about cancer. Rothstein R, et al. **Genome Res** 1995 Dec;5(5):421–6 (30 ref.)

Recombination in a balanced complex translocation of a mother leading to a balanced reciprocal translocation in the child. Review of 60 cases of balanced complex translocations. Madan K, et al. **Hum Genet** 1997 Jun; 99(6):806–15 (72 ref.)

Recombination and nondisjunction in humans and flies. Koehler KE, et al. **Hum Mol Genet** 1996;5 Spec No:1495–504 (54 ref.)

Recognition and manipulation of branched DNA structure by junction-resolving enzymes. White MF, et al. **J Mol Biol** 1997 Jun 27;269(5):647–64 (140 ref.)

Chromosome engineering in yeast with a site-specific recombination system from a heterologous yeast plasmid. Oshima Y, et al. **Methods Mol Biol** 1996;53:217–25 (10 ref.)

In vitro recombination and mutagenesis by overlap extension PCR. Pogulis RJ, et al. **Methods Mol Biol** 1996;57:167–76 (19 ref.)

Control of recombination rate during transformation of Streptococcus pneumoniae: an overview. Mortier-Barriere I, et al. **Microb Drug Resist** 1997 Fall;3(3):233–42 (53 ref.)

Stable DNA replication: interplay between DNA replication, homologous recombination, and transcription. Kogoma T. **Microbiol Mol Biol Rev** 1997 Jun;61(2):212–38 (266 ref.)

Recombination in mycobacteria. McFadden J. **Mol Microbiol** 1996 Jul;21(2):205–11 (36 ref.)

recA-independent DNA recombination between repetitive sequences: mechanisms and implications. Bi X, et al. **Prog Nucleic Acid Res Mol Biol** 1996;54:253–92 (86 ref.)

Homologous genetic recombination in Xenopus: mechanism and implications for gene manipulation. Carroll D. **Prog Nucleic Acid Res Mol Biol** 1996;54:101–25 (79 ref.)

Developmental genome reorganization in ciliated protozoa: the transposon link. Klobutcher LA, et al. **Prog Nucleic Acid Res Mol Biol** 1997;56:1–62 (153 ref.)

Double-strand break-induced recombination in eukaryotes. Osman F, et al. **Prog Nucleic Acid Res Mol Biol** 1998; 58:263–99 (143 ref.)

RecA protein: structure, function, and role in recombinational DNA repair. Roca AI, et al. **Prog Nucleic Acid Res Mol Biol** 1997;56:129–223 (428 ref.)

The cis–trans paradox of integrase [see comments] Jayaram M. **Science** 1997 Apr 4;276(5309):49–51 (22 ref.) Comment in: Science 1997 Apr 4;276(5309):126–31.

Essential and perilous: V(D)J recombination and DNA damage checkpoints in lymphocyte precursors. Danska JS, et al. **Semin Immunol** 1997 Jun;9(3):199–206 (81 ref.)

V(D)J recombination moves in vitro. Schatz DG. **Semin Immunol** 1997 Jun;9(3):149–59 (67 ref.)

Accessibility and the developmental regulation of V(D)J recombination. Schlissel MS, et al. **Semin Immunol** 1997 Jun;9(3):161–70 (65 ref.)

The end-joining reaction in V(D)J recombination. Smider V, et al. **Semin Immunol** 1997 Jun;9(3):189–97 (76 ref.)

Processing the holliday junction in homologous recombination. Shinagawa H, et al. **Trends Biochem Sci** 1996 Mar;21(3):107–11 (49 ref.)

Genetic barriers among bacteria. Matic I, et al. **Trends Microbiol** 1996 Feb;4(2):69–72 (51 ref.)

New insights into the mechanisms of RNA recombination. Nagy PD, et al. **Virology** 1997 Aug 18;235(1):1–9 (80 ref.)

[Effects of in vivo instillation of genes coding for cytokines on pulmonary fibrosis] Hayashi S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:190–4 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Analysis of EBV infection in various cell types with recombinant EBV] Shimizu N. **Nippon Rinsho** 1997 Feb; 55(2):311–5 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Developmental regulation of V(D)J type recombination in the antigen receptor genes in lymphocytes] Sakano H. **Seikagaku** 1996 Aug;68(8):1470–4 (18 ref.) **(Jpn)**

[Recombination of chromosomes] Morita T, et al. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(15 Suppl):2386–92 (33 ref.) **(Jpn)**

DRUG EFFECTS

The molecular mechanism of aflatoxin B1-induced liver cancer: is mitotic recombination involved? Sengstag C. **Mol Carcinog** 1997 Jul;19(3):147–52 (22 ref.)

GENETICS

Meiotic recombination hotspots. Lichten M, et al. **Annu Rev Genet** 1995;29:423–44 (157 ref.)

A super new twist on the initiation of meiotic recombination. Haber JE. **Cell** 1997 Apr 18;89(2):163–6 (21 ref.)

Specificity in V(D)J recombination: new lessons from biochemistry and genetics. Ramsden DA, et al. **Curr Opin Immunol** 1997 Feb;9(1):114–20 (42 ref.)

A new view of V(D)J recombination. Gellert M. **Genes Cells** 1996 Mar;1(3):269–75 (40 ref.)

Deleterious mutations, variable epistatic interactions, and the evolution of recombination. Otto SP, et al. **Theor Popul Biol** 1997 Apr;51(2):134–47 (37 ref.)

Exchanging partners: recombination in E. coli. Eggleston AK, et al. **Trends Genet** 1996 Jan;12(1):20–6 (65 ref.)

[Use of recombinant DNA technique in circulatory system diseases. A short outline of recombinant DNA methods] Buraczyńska M, et al. **Pol Merkuriusz Lek** 1996 Aug; 1(2):139–42 (18 ref.) (Eng. Abstr.) **(Pol)**

[Use of recombinant DNA techniques in circulatory system diseases. Use of DNA analysis for evaluating diseases of circulation] Buraczyńska M, et al. **Pol Merkuriusz Lek** 1996 Aug;1(2):143–6 (31 ref.) **(Pol)**

IMMUNOLOGY

Specificity in V(D)J recombination: new lessons from biochemistry and genetics. Ramsden DA, et al. **Curr Opin Immunol** 1997 Feb;9(1):114–20 (42 ref.)

PHYSIOLOGY

Meiotic recombination in yeast: coronation of the double-strand-break repair model. Stahl F. **Cell** 1996 Dec 13;87(6):965–8 (10 ref.)

Conditional mutagenesis in mice: the Cre/loxP recombination system. Plück A. **Int J Exp Pathol** 1996 Dec;77(6):269–78 (15 ref.)

RECORD LINKAGE, MEDICAL see **MEDICAL RECORD LINKAGE**

RECORDS

STATISTICS & NUMERICAL DATA

The assessment of refill compliance using pharmacy records: methods, validity, and applications. Steiner JF, et al. **J Clin Epidemiol** 1997 Jan;50(1):105–16 (61 ref.)

RECORDS CONTROL see **FORMS AND RECORDS CONTROL**

RECOVERY PERIOD, ANESTHESIA see **ANESTHESIA RECOVERY PERIOD**

RECOVERY ROOM NURSING see **POSTANESTHESIA NURSING**

RECREATION

Recreational exercise in arthritis. Minor MA, et al. **Rheum Dis Clin North Am** 1996 Aug;22(3):563–77 (51 ref.)

RECREATIONAL DRUGS see **STREET DRUGS**

RECTAL DISEASES

Anorectal disease: how to relieve pain and improve other symptoms. Hyman NH. **Geriatrics** 1997 Apr;52(4):75–6, 85–8, 91 (0 ref.)

RECTAL DISEASES

HPV infection and disease in men. Palefsky JM, et al. **Obstet Gynecol Clin North Am** 1996 Dec;23(4):895–916 (43 ref.)

[Perianal glands of Hermann and their pathology. Review of the literature. Apropos of a cyst case] Gullino D, et al. **J Chir (Paris)** 1996;133(9–10):422–6 (31 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

[Anorectal causes of constipation problems in dogs] Neumann S. **DTW Dtsch Tierarztl Wochenschr** 1996 Oct; 103(10):428–30 (7 ref.) (Eng. Abstr.) **(Ger)**

CONGENITAL

Tail-gut cyst. Jain P, et al. **Australas Radiol** 1997 May; 41(2):207–10 (10 ref.)

DIAGNOSIS

Colorectal diseases. Isbister WH. **Aust N Z J Surg** 1997 Jul; 67(7):457–67 (65 ref.)

Imaging of the anorectal region. Hussain SM, et al. **Eur J Radiol** 1996 May;22(2):116–22 (19 ref.)

ETIOLOGY

Rectal stricture caused by actinomycosis of the pelvis. Bertram P, et al. **Eur J Surg** 1996 Oct;162(10):837–9 (8 ref.)

Anorectal diseases. Parè AA, et al. **Gastroenterol Clin North Am** 1997 Jun;26(2):367–76 (68 ref.)

Massive gastrointestinal bleeding from a Dieulafoy-like lesion of the rectum. Eguchi S, et al. **J Clin Gastroenterol** 1997 Jun;24(4):262–3 (6 ref.)

Complicated anorectal sepsis. Gilliland R, et al. **Surg Clin North Am** 1997 Feb;77(1):115–53 (205 ref.)

[Anorectal diseases in patients with human immunodeficiency virus (HIV) infection] Rius J, et al. **Rev Gastroenterol Mex** 1996 Apr–Jun;61(2):139–46 (18 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Physiology and pathophysiology of anal function. Rasmussen OO, et al. **Scand J Gastroenterol Suppl** 1996;216:169–74 (46 ref.)

[Anorectal dynamic disorders] Pigot F, et al. **Gastroenterol Clin Biol** 1997;21(1):17–27 (100 ref.) **(Fre)**

RADIOGRAPHY

Computed tomography of the rectosigmoid region. Dixon AK. **Eur J Radiol** 1996 May;22(2):107–15 (39 ref.)

[The computed tomographic finding of sigmoid-rectal invagination and the radiological-macropathological correlation] Rodekohr S, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Jan;166(1):78–80 (10 ref.) **(Ger)**

SURGERY

Colorectal diseases. Isbister WH. **Aust N Z J Surg** 1997 Jul; 67(7):457–67 (65 ref.)

Current advances and controversies in the surgical therapy for anorectal motility disorders. Nyam DC, et al. **Dig Dis** 1997;15 Suppl 1:93–103 (72 ref.)

Treatment of bowel endometriosis: a report of six cases of colorectal endometriosis and a survey of the literature. Verspyck E, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Jan;71(1):81–4 (24 ref.)

Repair of a long-standing coccygeal hernia and open wound. Zook NL, et al. **Plast Reconstr Surg** 1997 Jul;100(1):96–9 (14 ref.)

Surgical therapy for Crohn's disease of the colon and rectum. Fazio VW, et al. **Surg Clin North Am** 1997 Feb; 77(1):197–210 (89 ref.)

Complicated anorectal sepsis. Gilliland R, et al. **Surg Clin North Am** 1997 Feb;77(1):115–53 (205 ref.)

Transanal endoscopic microsurgery. Saclarides TJ. **Surg Clin North Am** 1997 Feb;77(1):229–39 (10 ref.)

Anorectal stenosis in a neonate: report of a case and review of the Japanese literature. Hamada Y, et al. **Surg Today** 1996;26(10):814–7 (20 ref.)

Retractile mesenteritis of the large bowel: report of a case and review of the literature. Ikoma A, et al. **Surg Today** 1996;26(6):435–8 (21 ref.)

[Bowel endometriosis. Eight cases of colorectal resection] Canis M, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(7):699–709 (63 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of rectovaginal endometriosis] Querleu D. **Presse Med** 1997 May 17;26(16):774–7 (10 ref.) (Eng. Abstr.) **(Fre)**

[Sources of hazards in laparoscopic colon surgery and how to avoid them] Christen D, et al. **Swiss Surg** 1996;2(5):203–7 (11 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

A novel therapeutic approach for rectal varices: a case report of rectal varices treated with double balloon-occluded embolotherapy. Kimura T, et al. **Am J Gastroenterol** 1997 May;92(5):883–6 (14 ref.)

Aggressive giant condyloma acuminatum associated with oncogenic human papilloma virus: a case report. Kibrité A, et al. **Can J Surg** 1997 Apr;40(2):143–5 (10 ref.)

RECTAL DRUG ADMINISTRATION see **ADMINISTRATION, RECTAL**

RECTAL FISTULA

[Complex anal fistulas] Correa Rovelo JM, et al. **Rev Gastroenterol Mex** 1996 Apr–Jun;61(2):147–51 (30 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Basal cell carcinoma arising in a fistula-in-ano. Kulaylat MN, et al. **Am Surg** 1996 Dec;62(12):1000–2 (26 ref.)

SURGERY

Practice parameters for treatment of fistula-in-ano—supporting documentation. The Standards Practice Task Force. The American Society of Colon and Rectal Surgeons. **Dis Colon Rectum** 1996 Dec; 39(12):1363–72 (62 ref.)

Long-term, indwelling setons for low transsphincteric and intersphincteric anal fistulas. Experience with 108 cases. Lentner A, et al. **Dis Colon Rectum** 1996 Oct; 39(10):1097–101 (15 ref.)

[Preserving continence in treatment of inflammatory bowel disease associated anal fistulas] Farthmann EH, et al. **Schweiz Rundsch Med Prax** 1997 Jun 18;86(25–26):1068–70 (11 ref.) (Eng. Abstr.) **(Ger)**

RECTAL GLAND see **SALT GLAND**

RECTAL NEOPLASMS

Perineal and perirectal sarcomas: report of two cases. Kessler KJ, et al. **Dis Colon Rectum** 1996 Apr;39(4):468–72 (27 ref.)

Colorectal polyps and their relationship to cancer. Kim EC, et al. **Gastroenterol Clin North Am** 1997 Mar;26(1):1–17 (56 ref.)

Local and regional recurrence of carcinoma of the colon and rectum: I. Tumour-host factors and adjuvant therapy. Lee YT. **Surg Oncol** 1995;4(6):283–93 (42 ref.)

[Cancer of the rectum: staging and curative surgical treatment] De Calan L, et al. **Gastroenterol Clin Biol** 1996; 20(8–9):645–56 (115 ref.) **(Fre)**

[Malignant melanoma of the esophagus and anorectum] Stremmel C, et al. **Dtsch Med Wochenschr** 1996 Dec 13; 121(50):1573–5 (16 ref.) **(Ger)**

BLOOD SUPPLY

Angiogenesis in colorectal cancer. Saclarides TJ. **Surg Clin North Am** 1997 Feb;77(1):253–60 (56 ref.)

COMPLICATIONS

EBV-associated anorectal lymphomas in patients with acquired immune deficiency syndrome. Ioachim HL, et al. **Am J Surg Pathol** 1997 Sep;21(9):997–1006 (56 ref.)

Papuloerythroderma of Ofuji: a report of 2 cases including the first European case associated with visceral carcinoma. Schepers C, et al. **Dermatology** 1996;193(2):131–5 (22 ref.)

Inflammatory cloacogenic polyp: an unrecognized cause of hematochezia and tenesmus in childhood. Poon KK, et al. **J Pediatr** 1997 Feb;130(2):327–9 (13 ref.)

[Cavernous hemangioma of the rectum: an uncommon cause of pelvic pain. Apropos of 2 cases] Lautard M, et al. **Chirurgie** 1997;122(2):149–52 (18 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Retrorectal tumors complicating pregnancy. Report of two cases. Sobrado CW, et al. **Dis Colon Rectum** 1996 Oct; 39(10):1176–9 (13 ref.)

[Malignant anorectal melanoma: description of a clinical case and review of the literature] Malaguarnera M, et al. **Bull Cancer** 1997 Apr;84(4):423–6 (35 ref.) (Eng. Abstr.) **(Fre)**

[Primary gastrointestinal localization of N-H lymphoma: authors' experience] Versaci A, et al. **G Chir** 1997 Jun–Jul; 18(6–7):340–3 (40 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Multidisciplinary management of resectable rectal cancer. Minsky BD. **Oncology (Huntingt)** 1996 Nov;10(11):1701–8, 1713–4; discussion 1714–18 (77 ref.)

Infusional chemoradiation for operable rectal cancer: post-, pre-, or nonoperative management? Rich TA. **Oncology (Huntingt)** 1997 Mar;11(3):295–300, 305; discussion 306 passim (13 ref.)

[Moderately differentiated adenocarcinoma of the rectum: a case report of remarkable response to preoperative administration of FT suppository] Izumi M, et al. **Gan To Kagaku Ryoho** 1997 Aug;24(10):1321–5 (10 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Nutrition and colorectal cancer. Potter JD. **Cancer Causes Control** 1996 Jan;7(1):127–46 (278 ref.)

GENETICS

[Genetic and environmental factors in colorectal cancer. Mutations in the familial adenomatous polyposis gene] Steffensen IL, et al. **Tidsskr Nor Laegeforen** 1997 May 30; 117(14):2046–51 (25 ref.) (Eng. Abstr.) **(Nor)**

IMMUNOLOGY

[The role of cell adhesion molecules in inflammatory bowel disease and colorectal cancer] Pedersen G, et al. **Ugeskr Laeger** 1997 Aug 18;159(34):5077–84 (40 ref.) (Eng. Abstr.) **(Dan)**

[Carcinoembryonic antigen, CEA, in colorectal cancer. An insensitive marker which may be excluded from follow-ups] Wählby L. **Lakartidningen** 1997 Apr 30; 94(18):1716–8 (34 ref.) **(Swe)**

MICROBIOLOGY

[Intestinal bacterial flora and cancer of the large bowel] Yang FJ, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1996 Feb;17(1):52–3 (20 ref.) **(Chi)**

PATHOLOGY

Large bowel adenomas: markers of risk and endpoints. Baron JA. **J Cell Biochem Suppl** 1996;25:142–8 (34 ref.)

Colorectal cancer and peritoneal carcinomatosis. Cintron JR, et al. **Semin Surg Oncol** 1996 Jul–Aug;12(4):267–78 (17 ref.)

Management of pulmonary metastases from colorectal cancer. Vigneswaran WT. **Semin Surg Oncol** 1996 Jul–Aug; 12(4):264–6 (19 ref.)

Re-resection for colorectal liver metastasis. Bismuth H, et al. **Surg Oncol Clin N Am** 1996 Apr;5(2):353–64 (52 ref.)

Nodal metastases in rectal cancer: the role of surgery in outcome. MacFarlane JK. **Surg Oncol Clin N Am** 1996 Jan;5(1):191–202 (41 ref.)

Carcinoids of the rectum: an evaluation of 1271 reported cases. Soga J. **Surg Today** 1997;27(2):112–9 (16 ref.)

Temporomandibular joint metastasis from rectal carcinoma: CT findings before and after radiotherapy. A case report. Balestreri L, et al. **Tumori** 1997 May–Jun;83(3):718–20 (6 ref.)

[The staging of rectal tumors with endorectal study technics: the demonstration of a possible source of error] Gossmann A, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Jul;167(1):96–8 (7 ref.) **(Ger)**

PREVENTION & CONTROL

Surveillance of familial adenomatous polyposis patients after ileorectal anastomosis or ileoanal pouch anastomosis. Tytgat GNJ. **Gastrointest Endosc Clin N Am** 1997 Jan; 7(1):111–27 (55 ref.)

[Mass screening of colorectal cancer: where are we up to?] Tazi MA, et al. **Bull Cancer** 1996 Sep;83(9):746–9 (21 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Computed tomography of the rectosigmoid region. Dixon AK. **Eur J Radiol** 1996 May;22(2):107–15 (39 ref.)

Ossification of a rectal tumor: CT evaluation. Beauchamp NJ, et al. **J Comput Assist Tomogr** 1997 Jul–Aug; 21(4):671–3 (8 ref.)

RADIONUCLIDE IMAGING

New methods for the staging of colorectal cancer using noninvasive techniques. Blend MJ, et al. **Semin Surg Oncol** 1996 Jul–Aug;12(4):253–63 (57 ref.)

Use of monoclonal antibodies in colorectal cancer: a review. Schulte WJ. **World J Surg** 1996 Feb;20(2):238–40 (6 ref.)

RADIOTHERAPY

Indications for and results of irradiation +/- chemotherapy for rectal cancer. Gunderson LL, et al. **Ann Acad Med Singapore** 1996 May;25(3):448–59 (32 ref.)

The role of radiotherapy in the management of pelvic recurrence of rectal cancer. Wong R, et al. **Can J Oncol** 1996 Feb;6 Suppl 1:39–47 (18 ref.)

Radiotherapy in addition to radical surgery in rectal cancer: evidence for a dose-response effect favoring preoperative treatment. Glimelius B, et al. **Int J Radiat Oncol Biol Phys** 1997 Jan 15;37(2):281–7 (55 ref.)

Treatment planning for adenocarcinoma of the rectum and sigmoid: a patterns of care study. PCS Committee. Kline RW, et al. **Int J Radiat Oncol Biol Phys** 1997 Jan 15; 37(2):305–11 (3 ref.)

Sphincter-preserving operations for rectal cancer. Enker WE. **Oncology (Huntingt)** 1996 Nov;10(11):1673–84, 1689; discussion 1690–2 (32 ref.)

Multidisciplinary management of resectable rectal cancer. Minsky BD. **Oncology (Huntingt)** 1996 Nov;10(11):1701–8, 1713–4; discussion 1714–18 (77 ref.)

Infusional chemoradiation for operable rectal cancer: post-, pre-, or nonoperative management? Rich TA. **Oncology (Huntingt)** 1997 Mar;11(3):295–300, 305; discussion 306 passim (13 ref.)

Preoperative and postoperative radiotherapy in rectal carcinoma. Budach V, et al. **Recent Results Cancer Res** 1996;142:257–79 (79 ref.)

Adjuvant radiation therapy for adenocarcinoma of the rectum. Fleshman JW, et al. **Surg Clin North Am** 1997 Feb; 77(1):15–25 (31 ref.)

[Intraoperative radiotherapy in cancers of the pancreas and

in recurrent colorectal cancers] Houry S, et al. **Ann Chir** 1996;50(6):438–44 (31 ref.) (Eng. Abstr.) **(Fre)**

[Effect radiotherapy on postoperative staging and residual tumor cell density in rectal cancers] Berger C, et al. **Cancer Radiother** 1997;1(3):240–8 (31 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

Application of self–expanding stents in prostate cancer with rectal involvement. Report of two cases and review of the literature. Lujan M, et al. **Eur Urol** 1997;31(2):251–3 (13 ref.)

SURGERY

Total mesorectal excision—the new golden standard of surgery for rectal cancer. Enker WE. **Ann Med** 1997 Apr; 29(2):127–33 (27 ref.)

The anatomical substrate for a difference in surgical approach to rectal cancer in male and female patients. Verschueren RC, et al. **Anticancer Res** 1997 Jan–Feb;17(1B):637–41 (18 ref.)

Total mesorectal excision: evaluating the evidence. McCall JL. **Aust N Z J Surg** 1997 Sep;67(9):599–602 (50 ref.)

Morbidity and mortality after single– and double–stapled colorectal anastomoses in patients with carcinoma of the rectum. Moore JW, et al. **Aust N Z J Surg** 1996 Dec; 66(12):820–3 (22 ref.)

Sphincter preservation therapy for distal rectal carcinoma: a review. Ng AK, et al. **Cancer** 1997 Feb 15;79(4):671–83 (69 ref.)

Surgical strategies in the treatment of colorectal cancer. Bergamaschi R. **Eur J Surg Suppl** 1995;(575):1–22 (317 ref.)

Radiotherapy in addition to radical surgery in rectal cancer: evidence for a dose–response effect favoring preoperative treatment. Glimelius B, et al. **Int J Radiat Oncol Biol Phys** 1997 Jan 15;37(2):281–7 (55 ref.)

Local recurrence after operative treatment of rectal carcinoma: a strategy for change. Søreide O, et al. **J Am Coll Surg** 1997 Jan;184(1):84–92 (77 ref.)

Sphincter–preserving operations for rectal cancer. Enker WE. **Oncology (Huntingt)** 1996 Nov;10(11):1673–84, 1689; discussion 1690–2 (32 ref.)

Current aspects of sphincter preservation in the surgical therapy of rectal cancer. Schlag PM. **Recent Results Cancer Res** 1996;142:249–56 (25 ref.)

Personalized surgery for rectal tumours: the patient's opinion counts. Audisio RA, et al. **Support Care Cancer** 1997 Jan; 5(1):17–21 (77 ref.)

Preservation of the anus in the therapy of distal rectal cancers. Breen E, et al. **Surg Clin North Am** 1997 Feb; 77(1):71–83 (51 ref.)

Local and regional recurrence of carcinoma of the colon and rectum: II. Factors relating to operative technique. Lee YT. **Surg Oncol** 1996 Feb;5(1):1–13 (71 ref.)

Nodal metastases in rectal cancer: the role of surgery in outcome. MacFarlane JK. **Surg Oncol Clin N Am** 1996 Jan;5(1):191–202 (41 ref.)

Surgical excision of large rectal villous adenomas. Whitlow CB, et al. **Surg Oncol Clin N Am** 1996 Jul;5(3):723–34 (56 ref.)

Primary linitis plastica of the rectum: report of four cases and review of the literature. Murayama H, et al. **Surg Today** 1996;26(11):875–81 (22 ref.)

Pelvic exenteration for locally advanced rectal carcinoma: factors predicting improved survival. Meterissian SH, et al. **Surgery** 1997 May;121(5):479–87 (31 ref.)

Surgical management for carcinoid tumors of small bowel, appendix, colon, and rectum. Stinner B, et al. **World J Surg** 1996 Feb;20(2):183–8 (26 ref.)

[Laparoscopic excision of the rectum. An advanced technique or true clinical progress?] Bardram L, et al. **Ugeskr Laeger** 1996 Oct 14;158(42):5911–4 (32 ref.) (Eng. Abstr.) **(Dan)**

[Cancer of the rectum: is it possible to decrease therapeutic sequelae and improve quality of life?] Tiret E. **Gastroenterol Clin Biol** 1996;20(11):946–54 (47 ref.) **(Fre)**

[Technique and indications for sphincter–saving transanal resection in rectal carcinoma] Buess G, et al. **Chirurg** 1996 Feb;67(2):121–8 (22 ref.) (Eng. Abstr.) **(Ger)**

[Intestinal schistosomiasis, a facultative precancerous condition? Review of the literature with reference to Schistosoma japonicum associated rectum carcinoma] Jatzko G, et al. **Chirurg** 1997 Jul;68(7):727–31 (24 ref.) (Eng. Abstr.) **(Ger)**

[Anterior rectum resection] Rosen HR, et al. **Chirurg** 1996 Feb;67(2):99–109 (62 ref.) (Eng. Abstr.) **(Ger)**

[Surgical relevance of preoperative diagnosis of tumors of the gastrointestinal tract—decision making in esophageal, stomach, colon and rectal carcinoma] Siewert JR, et al. **Chirurg** 1997 Apr;68(4):317–24 (29 ref.) (Eng. Abstr.) **(Ger)**

[Vital preoperative function diagnosis in deep anterior rectum resection] Stern J, et al. **Chirurg** 1996 Feb;67(2):129–32 (20 ref.) (Eng. Abstr.) **(Ger)**

[Therapy of rectal carcinoma: oncologically adequate surgery is crucial] Maurer CA, et al. **Ther Umsch** 1996 Nov; 53(11):829–38 (31 ref.) (Eng. Abstr.) **(Ger)**

[The effect of blood transfusion on the late results of the surgical treatment of rectal cancer] Görög D, et al. **Orv Hetil** 1996 Aug 4;137(31):1693–8 (39 ref.) (Eng. Abstr.) **(Hun)**

[Functional results of sphincter–saving techniques in cancer of the low rectum] Santoro GA, et al. **G Chir** 1996 Oct; 17(10):547–50 (25 ref.) (Eng. Abstr.) **(Ita)**

[Sphincter–preserving surgery in rectal cancer] Belmonte Montes C, et al. **Rev Gastroenterol Mex** 1996 Apr–Jun; 61(2):124–33 (80 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Where are we now with adjuvant therapy for rectal cancer? Chapuis P, et al. **Aust N Z J Surg** 1997 Sep;67(9):588–90 (30 ref.)

Aggressive multimodality treatment for locally advanced irresectable rectal cancer. Farouk R, et al. **Br J Surg** 1997 Jun;84(6):741–9 (95 ref.)

Where next in the treatment of rectal cancer? [editorial] James RD. **Clin Oncol (R Coll Radiol)** 1997;9(3):144–7 (17 ref.)

Organ preservation in anal and rectal cancers. Willett CG. **Curr Opin Oncol** 1996 Jul;8(4):329–33 (25 ref.)

Locally advanced rectal cancer with a pelvic kidney complicating adjuvant radiation therapy. Bokhari MB, et al. **J Surg Oncol** 1996 Sep;63(1):57–60 (14 ref.)

Adjuvant treatment of colon and rectal cancer: impact of chemotherapy, radiotherapy, and immunotherapy on routine postsurgical patient management. Forschungsgruppe Onkologie Gastrointestinaler Tumoren (FOGT). Link KH, et al. **Recent Results Cancer Res** 1996; 142:311–52 (185 ref.)

Hyperthermia in the multimodal therapy of advanced rectal carcinomas. Wust P, et al. **Recent Results Cancer Res** 1996; 142:281–309 (136 ref.)

Treatment of colorectal cancer: hepatic metastasis. Fong Y, et al. **Semin Surg Oncol** 1996 Jul–Aug;12(4):219–52 (215 ref.)

Adjuvant medical therapy for colorectal cancer. Diaz–Canton EA, et al. **Surg Clin North Am** 1997 Feb; 77(1):211–28 (67 ref.)

[Treatment of colorectal cancer with monoclonal antibodies (see comments)] Nielsen SE. **Ugeskr Laeger** 1997 May 19; 159(21):3134–9 (40 ref.) (Eng. Abstr.) Comment in: Ugeskr Laeger 1997 Aug 18;159(34):5110–1. **(Dan)**

[Malignant anorectal melanoma: description of a clinical case and review of the literature] Malaguarnera M, et al. **Bull Cancer** 1997 Apr;84(4):423–6 (35 ref.) (Eng. Abstr.) **(Fre)**

[Adjuvant radio–chemotherapy of cancers of the rectum] Piedbois P, et al. **Cancer Radiother** 1997;1(1):42–51 (48 ref.) (Eng. Abstr.) **(Fre)**

[Adjuvant therapy of cancer of the rectum (see comments)] Ducreux M, et al. **Gastroenterol Clin Biol** 1996; 20(10):858–72 (112 ref.) Comment in: Gastroenterol Clin Biol 1997;21(5):430–2. **(Fre)**

[Medical treatment of colorectal cancer] Díaz–Cantón EA, et al. **Medicina (B Aires)** 1996;56(4):414–22 (49 ref.) (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

[Consensus conference 1994 on treatments of cancer of the rectum: what can we expect from endorectal ultrasonography?] Burtin P, et al. **Gastroenterol Clin Biol** 1995 Dec;19(12):1001–3 (30 ref.) **(Fre)**

RECTAL PROLAPSE

Rectocele. Brubaker L. **Curr Opin Obstet Gynecol** 1996 Oct; 8(5):876–9 (14 ref.)

PHYSIOPATHOLOGY

Functional problems in adult rectal prolapse and controversies in surgical treatment. Eu KW, et al. **Br J Surg** 1997 Jul;84(7):904–11 (140 ref.)

SURGERY

Functional problems in adult rectal prolapse and controversies in surgical treatment. Eu KW, et al. **Br J Surg** 1997 Jul;84(7):904–11 (140 ref.)

The best operation for rectal prolapse. Jacobs LK, et al. **Surg Clin North Am** 1997 Feb;77(1):49–70 (51 ref.)

[Surgical therapy of rectal prolapse] Leppert R, et al. **Zentralbl Chir** 1996;121(8):698–703 (42 ref.) (Eng. Abstr.) **(Ger)**

[Rectal prolapse] Medina González S. **Rev Gastroenterol Mex** 1996 Apr–Jun;61(2):119–23 (27 ref.) (Eng. Abstr.) **(Spa)**

RECTAL SURGERY (SPECIALTY) see **COLON AND RECTAL SURGERY (SPECIALTY)**

RECTOCOLITIS see **PROCTOCOLITIS**

RECTOCOLITIS, HEMORRHAGIC see **COLITIS, ULCERATIVE**

RECTOCOLITIS, ULCERATIVE see **COLITIS, ULCERATIVE**

RECTOSIGMOIDITIS see **PROCTOCOLITIS**

RECTOVAGINAL FISTULA

PREVENTION & CONTROL

The problem of post–partum fistulas in developing countries. Steiner AK. **Acta Trop** 1996 Dec 30;62(4):217–23 (10 ref.)

SURGERY

The problem of post–partum fistulas in developing countries. Steiner AK. **Acta Trop** 1996 Dec 30;62(4):217–23 (10 ref.)

Rectovaginal fistulas. Therapeutic options. Tsang CB, et al. **Surg Clin North Am** 1997 Feb;77(1):95–114 (59 ref.)

RECTUM

Digital rectal examination during early acute MI [editorial] Lee JR, et al. **Hosp Pract (Off Ed)** 1997 Sep 15;32(9):15–6 (11 ref.)

ABNORMALITIES

Sacrococcygeal teratoma and anorectal malformation. Ng WT, et al. **Aust N Z J Surg** 1997 Apr;67(4):218–20 (28 ref.)

Accessory scrotum and anorectal malformation associated with "pseudo" prune belly in a neonate. Shoshany G, et al. **J Perinatol** 1996 May–Jun;16(3 Pt 1):224–6 (25 ref.)

BLOOD SUPPLY

Idiopathic non–familial rectal and colonic varices requiring sigmoidorectal resection and coloanal anastomosis. Detry RJ, et al. **Eur J Gastroenterol Hepatol** 1996 Oct; 8(10):1023–6 (32 ref.)

Massive gastrointestinal bleeding from a Dieulafoy–like lesion of the rectum. Eguchi S, et al. **J Clin Gastroenterol** 1997 Jun;24(4):262–3 (6 ref.)

[A case of massive bleeding from rectal varices treated with endoscopic variceal ligation (EVL)] Kojima T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Feb;93(2):114–9 (16 ref.) **(Jpn)**

[A case of rectal varices treated with endoscopic injection sclerotherapy] Zeniya A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Jan;94(1):38–43 (19 ref.) **(Jpn)**

DRUG EFFECTS

Pharmacology of the internal anal sphincter and abnormalities in faecal incontinence. Speakman CT. **Eur J Gastroenterol Hepatol** 1997 May;9(5):442–6 (56 ref.)

INJURIES

Rectal sexual trauma including foreign bodies [editorial] Irizarry E, et al. **Int J STD AIDS** 1996 May–Jun;7(3):166–9 (21 ref.)

PATHOLOGY

[Clinical anatomy of the continence organ] Fritsch H. **Zentralbl Chir** 1996;121(8):613–6 (14 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Current techniques of assessing defecation dynamics. Rao SS, et al. **Dig Dis** 1997;15 Suppl 1:64–77 (62 ref.)

PHYSIOPATHOLOGY

Resolution of anorectal incontinence in herpes proctitis confirmed by anorectal manometry. Joseph D, et al. **Gastrointest Endosc** 1997 May;45(5):429–32 (14 ref.)

RADIOGRAPHY

Defecation disorders and the role of defecography. Newman J. **Radiol Technol** 1997 May–Jun;68(5):399–416; quiz 417–20 (104 ref.)

SURGERY

Total mesorectal excision—the new golden standard of surgery for rectal cancer. Enker WE. **Ann Med** 1997 Apr; 29(2):127–33 (27 ref.)

Morbidity and mortality after single– and double–stapled colorectal anastomoses in patients with carcinoma of the rectum. Moore JW, et al. **Aust N Z J Surg** 1996 Dec; 66(12):820–3 (22 ref.)

Sphincter preservation therapy for distal rectal carcinoma: a review. Ng AK, et al. **Cancer** 1997 Feb 15;79(4):671–83 (69 ref.)

The risk of thromboembolism in patients undergoing colorectal surgery. McLeod RS. **Drugs** 1996;52 Suppl 7:38–41 (25 ref.)

Idiopathic non–familial rectal and colonic varices requiring sigmoidorectal resection and coloanal anastomosis. Detry RJ, et al. **Eur J Gastroenterol Hepatol** 1996 Oct; 8(10):1023–6 (32 ref.)

Stapled anastomoses in colorectal surgery: a prospective study. Memon AA, et al. **Eur J Surg** 1996 Oct; 162(10):805–10 (40 ref.)

Surveillance of familial adenomatous polyposis patients after ileorectal anastomosis or ileoanal pouch anastomosis. Tytgat GNJ. **Gastrointest Endosc Clin N Am** 1997 Jan; 7(1):11–27 (55 ref.)

RECTUM

Sphincter-preserving operations for rectal cancer. Enker WE. **Oncology (Huntingt)** 1996 Nov;10(11):1673-84, 1689; discussion 1690-2 (32 ref.)
Complications in colon and rectal surgery. Early diagnosis and management. Kollmorgen CF, et al. **Rev Gastroenterol Mex** 1996 Apr-Jun;61(2):93-9 (48 ref.)
Current status in laparoscopic colorectal surgery. Milsom JW, et al. **Rev Gastroenterol Mex** 1996 Apr-Jun;61(2):113-8 (51 ref.)
The best operation for rectal prolapse. Jacobs LK, et al. **Surg Clin North Am** 1997 Feb;77(1):49-70 (51 ref.)
Rectovaginal fistulas. Therapeutic options. Tsang CB, et al. **Surg Clin North Am** 1997 Feb;77(1):95-114 (59 ref.)
Successful treatment of a rectal anastomotic stenosis by transanal endoscopic microsurgery (TEM) using the contact Nd:YAG laser. Kato K, et al. **Surg Endosc** 1997 May;11(5):485-7 (11 ref.)
[Progresses in pediatric surgery in China, 1996] Jin B. **Chung Hua I Hsueh Tsa Chih** 1996 Dec;76(12):908-9 (0 ref.) **(Chi)**
[Laparoscopic excision of the rectum. An advanced technique or true clinical progress?] Bardram L, et al. **Ugeskr Laeger** 1996 Oct 14;158(42):5911-4 (32 ref.) (Eng. Abstr.) **(Dan)**
[Subtotal colectomy with ceco-rectal anastomosis (Deloyers) for severe idiopathic constipation: an alternative to total colectomy reducing risks of digestive sequelae] Costalat G, et al. **Ann Chir** 1997;51(3):248-55 (33 ref.) (Eng. Abstr.) **(Fre)**
[Technique and indications for sphincter-saving transanal resection in rectal carcinoma] Buess G, et al. **Chirurg** 1996 Feb;67(2):121-8 (22 ref.) (Eng. Abstr.) **(Ger)**
[Anterior rectum resection] Rosen HR, et al. **Chirurg** 1996 Feb;67(2):99-109 (62 ref.) (Eng. Abstr.) **(Ger)**
[Vital preoperative function diagnosis in deep anterior rectum resection] Stern J, et al. **Chirurg** 1996 Feb;67(2):129-32 (20 ref.) (Eng. Abstr.) **(Ger)**
[Therapy of rectal carcinoma: oncologically adequate surgery is crucial] Maurer CA, et al. **Ther Umsch** 1996 Nov; 53(11):829-38 (31 ref.) (Eng. Abstr.) **(Ger)**
[Laparoscopic colo-rectal surgery] Hayashi K, et al. **Nippon Rinsho** 1996 May;54(5):1312-21 (15 ref.) (Eng. Abstr.) **(Jpn)**

RECTUS ABDOMINIS

Hematoma of the rectus abdominis muscle: case report and review of the literature. Dubinsky IL. **J Emerg Med** 1997 Mar-Apr;15(2):165-7 (07 ref.)

RECURRENCE

see related
NEOPLASM RECURRENCE, LOCAL

RECYCLING see **CONSERVATION OF NATURAL RESOURCES**

RECYCLING, EQUIPMENT see **EQUIPMENT REUSE**

RED BLOOD CELL COUNT see **ERYTHROCYTE COUNT**

RED BLOOD CELL MEMBRANE SIALOGLYCOPROTEIN see **GLYCOPHORIN**

RED BLOOD CELL TRANSFUSION see **ERYTHROCYTE TRANSFUSION**

RED BLOOD CELLS see **ERYTHROCYTES**

RED-CELL APLASIA, PURE

Pure red-cell aplasia: a review. Erslev AJ, et al. **Blood Rev** 1996 Mar;10(1):20-8 (98 ref.)

CHEMICALLY INDUCED

Drug-induced pure red cell aplasia. Thompson DF, et al. **Pharmacotherapy** 1996 Nov-Dec;16(6):1002-8 (74 ref.)
[Bone marrow aplasia and ticlopidine (letter)] Gaspar Alonso-Vega G, et al. **Med Clin (Barc)** 1997 Apr 19; 108(15):596-7 (10 ref.) **(Spa)**

COMPLICATIONS

Severe acute hepatitis A associated with acute pure red cell aplasia. Tomida S, et al. **J Gastroenterol** 1996 Aug; 31(4):612-7 (26 ref.)
[T-cell large granular lymphocytic leukemia associated with pure red cell aplasia, successfully treated with cyclophosphamide] Mátrai Z, et al. **Orv Hetil** 1997 Aug 17;138(33):2075-80 (45 ref.) (Eng. Abstr.) **(Hun)**

PHYSIOPATHOLOGY

Pure red cell aplasia associated with hepatitis C infection. al-Awami Y, et al. **Am J Med Sci** 1997 Aug;314(2):113-7 (48 ref.)

VIROLOGY

Pure red cell aplasia due to parvovirus B19 infection in solid organ transplantation. Ahsan N, et al. **Clin Transplant** 1997 Aug;11(4):265-70 (26 ref.)

RED CELL GHOST see **ERYTHROCYTE MEMBRANE**

RED CELL INDICES see **ERYTHROCYTE INDICES**

RED CELL MASS see **ERYTHROCYTE VOLUME**

RED CELL SUBSTITUTES see **BLOOD SUBSTITUTES**

RED MARROW see **BONE MARROW**

RED NUCLEUS

PATHOLOGY

Huntington's disease and dentatorubral-pallidoluysian atrophy: proteins, pathogenesis and pathology. Ross CA, et al. **Brain Pathol** 1997 Jul;7(3):1003-16 (137 ref.)

PHYSIOPATHOLOGY

Bipolar disorders, dystonia, and compulsion after dysfunction of the cerebellum, dentatorubrothalamic tract, and substantia nigra. Lauterbach EC. **Biol Psychiatry** 1996 Oct 15;40(8):726-30 (65 ref.)

RED TIDE see **DINOFLAGELLIDA**

REDOX see **OXIDATION-REDUCTION**

REDUCED GRAVITY see **HYPOGRAVITY**

REDUCTASES see **OXIDOREDUCTASES**

REDUVIIDAE see **TRIATOMINAE**

REED-STERNBERG CELLS

see related
HODGKIN'S DISEASE

PATHOLOGY

Single cell analysis of H/RS cells. Chan WC, et al. **Ann Oncol** 1996;7 Suppl 4:41-3 (18 ref.)
Single cell PCR for the analysis of Hodgkin's disease: four years later. Küpper M, et al. **Ann Oncol** 1996;7 Suppl 4:35-9 (24 ref.)
Single cell analysis of Hodgkin/Reed-Sternberg cells. Küppers R, et al. **Ann Oncol** 1996;7 Suppl 4:27-30 (27 ref.)
Report on the workshop biology of the Third International Symposium on Hodgkin's Lymphoma in Cologne 1995. Wolf J, et al. **Ann Oncol** 1996;7 Suppl 4:45-7 (8 ref.)
T-cell-rich B-cell lymphoma—a distinct clinicopathologic entity? Schmidt U, et al. **Leuk Lymphoma** 1996 Sep; 23(1-2):17-24 (39 ref.)

PHYSIOLOGY

Ig rearrangements in isolated Reed-Sternberg cells: conclusions from four different studies. Hummel M, et al. **Ann Oncol** 1996;7 Suppl 4:31-3 (13 ref.)
Single cell PCR for the analysis of Hodgkin's disease: four years later. Küpper M, et al. **Ann Oncol** 1996;7 Suppl 4:35-9 (24 ref.)

REELER MICE see **MICE, NEUROLOGIC MUTANTS**

REFERENCE BOOKS

see related
TEXTBOOKS

REFERENCE BOOKS, MEDICAL

[Medical databases, index books and library services] Suutarinen P. **Duodecim** 1995;111(19):1838-43 (6 ref.) **(Fin)**

REFERENCE RANGES see **REFERENCE VALUES**

REFERENCE STANDARDS

The WHO growth chart: historical considerations and current scientific issues. de Onis M, et al. **Bibl Nutr Dieta** 1996;(53):74-89 (39 ref.)
Inferences for likelihood ratios in the absence of a "gold standard". Joseph L, et al. **Med Decis Making** 1996 Oct-Dec;16(4):412-7 (18 ref.)

REFERENCE VALUES

The range of normal. Olive DL. **Semin Reprod Endocrinol** 1996 May;14(2):119-23 (11 ref.)

REFERRAL AND CONSULTATION

A substance abuse consultation service. Enhancing the care of hospitalized substance abusers and providing training in addiction psychiatry. McDuff DR, et al. **Am J Addict** 1997 Summer;6(3):256-65 (43 ref.)
Second opinions in surgical pathology [see comments] Leslie KO, et al. **Am J Clin Pathol** 1996 Oct;106(4 Suppl 1):S58-64 (17 ref.) Comment in: Am J Clin Pathol 1997 Apr;107(4):497-8.
Consultation to residential psychosocial rehabilitation agencies. Kupers TA. **Community Ment Health J** 1996 Aug; 32(4):403-13; discussion 415-8 (32 ref.)
Immunizations and travel. Thanassi WT, et al. **Emerg Med Clin North Am** 1997 Feb;15(1):43-70 (30 ref.)
Improving consultations between health-care professionals and older clients: implications for pharmacists. Morrow D. **Int J Aging Hum Dev** 1997;44(1):47-72 (98 ref.)
Family demographics of clinically referred children: what we know and what we need to know. Phares V, et al. **J Abnorm Child Psychol** 1996 Dec;24(6):787-801 (56 ref.)
28th Bethesda Conference. Task Force 4: Referral guidelines and the collaborative care of patients with cardiovascular disease. Fye WB, et al. **J Am Coll Cardiol** 1997 May; 29(6):1162-70 (73 ref.)
Relationships between primary care physicians and consultants in managed care. Brett AS. **J Clin Ethics** 1997 Spring;8(1):60-5 (13 ref.)
Types of pain treatment facilities referral selection criteria: are they medically and cost effective? Rosomoff HL, et al. **J Fla Med Assoc** 1997 Jan;84(1):41-5 (17 ref.)
Common urologic disorders. When to treat and when to refer. Gottesman J, et al. **Postgrad Med** 1997 Aug; 102(2):235-40, 243, 246 (18 ref.)
The telephone in primary care. Studdiford JS III, et al. **Prim Care** 1996 Mar;23(1):83-102 (76 ref.)
Determining the effect that consultation-liaison psychiatry in primary care has on family physicians' psychiatric knowledge and practice. Carr VJ, et al. **Psychosomatics** 1997 May-Jun;38(3):217-29 (51 ref.)
Current medical treatment and indications for surgical referral for gastroesophageal reflux disease (GERD). Katz PO, et al. **Semin Thorac Cardiovasc Surg** 1997 Apr; 9(2):169-72 (20 ref.)
Listening or telling? Thoughts on responsibility in clinical ethics consultation. Zaner RM. **Theor Med** 1996 Sep; 17(3):255-77 (74 ref.)
[The pitfalls of liaison psychiatry] Dongier M, et al. **Rev Med Liege** 1996 Sep;51(9):590-8 (45 ref.) **(Fre)**
[The pediatric physician and consultation in ophthalmology] Boles Carenini B, et al. **Minerva Pediatr** 1995 Dec; 47(12):493-504 (46 ref.) **(Ita)**
[Problems in preoperative evaluation of patients--differences in viewpoint among physicians] Katayama H, et al. **Masui** 1996 Dec;45 Suppl:S139-42 (0 ref.) **(Jpn)**

LEGISLATION & JURISPRUDENCE

The legal and ethical implications of gag clauses in physician contracts. Martin JA, et al. **Am J Law Med** 1996; 22(4):433-76 (351 ref.)
Ethical and legal implications of managed care. Hall RC. **Gen Hosp Psychiatry** 1997 May;19(3):200-8 (88 ref.)
[Legal implications, patient education responsibilities for referring and treating physicians] Ulsenheimer K. **Z Kardiol** 1996 Aug;85(8):529-36 (29 ref.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Should general practitioners refer patients directly to physical therapists? Robert G, et al. **Br J Gen Pract** 1997 May; 47(418):314-8 (26 ref.)
Meeting the diverse needs of clients in the community: effective use of the referral process. McGuire SL, et al. **Nurs Outlook** 1996 Sep-Oct;44(5):218-22 (11 ref.)

STANDARDS

What are the goals of ethics consultation? A consensus statement. Fletcher JC, et al. **J Clin Ethics** 1996 Summer; 7(2):122-6 (06 ref.)
Evaluating outcomes in ethics consultation research. Fox E, et al. **J Clin Ethics** 1996 Summer;7(2):127-38 (47 ref.)
Physicians' collaboration with chaplains: difficulties and benefits. Thiel MM, et al. **J Clin Ethics** 1997 Spring; 8(1):94-103 (23 ref.)
Evaluating ethics consultation: framing the questions. Tulsky JA, et al. **J Clin Ethics** 1996 Summer;7(2):109-15 (24 ref.)

STATISTICS & NUMERICAL DATA

A comparison of studies from the United States and western Europe on psychiatric hospitalization referrals for youths exhibiting suicidal behavior. Safer DJ. **Ann Clin Psychiatry** 1996 Sep;8(3):161-8 (142 ref.)

TRENDS

Lymphoid lesions. Burke JS. **Pathology (Phila)** 1996; 3(2):503-12 (32 ref.)
Urinary tract and male genital system. Coulson WF. **Pathology (Phila)** 1996;3(2):493-502 (17 ref.)
Liver. Ferrell LD, et al. **Pathology (Phila)** 1996;3(2):367-78 (36 ref.)
Gastrointestinal tract. Goldstein NS, et al. **Pathology (Phila)** 1996;3(2):349-65 (65 ref.)
Soft tissue. Kempson RL. **Pathology (Phila)** 1996;3(2):545-53 (11 ref.)
Lung. Lombard CM. **Pathology (Phila)** 1996;3(2):321-38 (16 ref.)
The female genital tract. Longacre TA, et al. **Pathology (Phila)** 1996;3(2):427-92 (26 ref.)
The mediastinum. Marchevsky A. **Pathology (Phila)** 1996; 3(2):339-48 (19 ref.)
Salivary gland. Ranchod M. **Pathology (Phila)** 1996;

3(2):305–19 (12 ref.)
The pancreas and peripancreatic area. Ranchod M, et al. **Pathology (Phila)** 1996;3(2):379–87 (20 ref.)
Thyroid gland. Ranchod M. **Pathology (Phila)** 1996; 3(2):389–403 (24 ref.)
Parathyroid gland. Ranchod M. **Pathology (Phila)** 1996; 3(2):405–16 (28 ref.)
Bone. Ranchod M, et al. **Pathology (Phila)** 1996;3(2):535–44 (11 ref.)
Intraoperative consultation: introduction and general principles. Ranchod M. **Pathology (Phila)** 1996;3(2):259–71 (7 ref.)
Skin. Smoller BR, et al. **Pathology (Phila)** 1996;3(2):285–98 (15 ref.)
Central nervous system. Vinters HV, et al. **Pathology (Phila)** 1996;3(2):513–34 (39 ref.)
Breast. Weidner N, et al. **Pathology (Phila)** 1996;3(2):417–26 (23 ref.)

REFETOFF SYNDROME see **THYROID HORMONE RESISTANCE SYNDROME**

REFLEX

Blindsight in man and monkey. Stoerig P, et al. **Brain** 1997 Mar;120 (Pt 3):535–59 (173 ref.)
Volume reflex in diabetes. Patel KP. **Cardiovasc Res** 1997 Apr;34(1):81–90 (78 ref.)

IMMUNOLOGY

Autonomic reflexes and non-allergic rhinitis. Jones AS. **Allergy** 1997;52(36 Suppl):14–9 (53 ref.)

PHYSIOLOGY

Peripheral chemoreflex in chronic heart failure: friend and foe [editorial] Chugh SS, et al. **Am Heart J** 1996 Oct; 132(4):900–4 (42 ref.)
Construction of a model demonstrating neural pathways and reflex arcs. Chan V, et al. **Am J Physiol** 1996 Dec;271(6 Pt 3):S14–42 (4 ref.)
Neural reflexes controlling intestinal microcirculation. Vanner S, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):G223–30 (66 ref.)
The pressor reflex evoked by static contraction: neurochemistry at the site of the first synapse. Wilson LB, et al. **Brain Res Brain Res Rev** 1997 Apr;23(3):196–209 (120 ref.)
Spatial orientation perception and reflexive eye movements—a perspective, an overview, and some clinical implications. Guedry FE. **Brain Res Bull** 1996; 40(5–6):505–12 (77 ref.)
Orienting a spatial attention—its reflexive, compensatory, and voluntary mechanisms. Hikosaka O, et al. **Brain Res Cogn Brain Res** 1996 Dec;5(1–2):1–9 (32 ref.)
Dysautonomic and reflex syncope syndromes. Grubb BP, et al. **Cardiol Clin** 1997 May;15(2):257–68 (49 ref.)
Reflexes mediated by cardiac sympathetic afferents during myocardial ischaemia: role of adenosine. Thames MD, et al. **Clin Exp Pharmacol Physiol** 1996 Aug;23(8):709–14 (33 ref.)
Negative myoclonus. Tassinari CA, et al. **Clin Neurosci** 1995–96;3(4):209–13 (19 ref.)
Eye–centering: the basic ocular motor reflex—literature review, observations and hypotheses. Jampel RS, et al. **Curr Eye Res** 1996 Aug;15(8):890–8 (41 ref.)
Neural regulation of coronary vascular resistance: role of nitric oxide in reflex cholinergic coronary vasodilation in normal and pathophysiologic states. Zhao G, et al. **EXS** 1996;76:1–19 (94 ref.)
Sensory neurophysiology of the cough reflex. Widdicombe JG. **J Allergy Clin Immunol** 1996 Nov;98(5 Pt 2):S84–9; discussion S89–90 (40 ref.)
Influence of gravity on cardiovascular reflexes from skeletal muscle receptors. Essfeld D, et al. **Med Sci Sports Exerc** 1996 Oct;28(10 Suppl):S23–8 (26 ref.)
Contemporary state of reflex theory. Batuev AS. **Neurosci Behav Physiol** 1996 Jul–Aug;26(4):324–8 (18 ref.)
Neural control of renal function. DiBona GF, et al. **Physiol Rev** 1997 Jan;77(1):75–197 (1736 ref.)
Cerebellar contributions to the acquisition and execution of learned reflex and volitional movements. Bloedel JR, et al. **Prog Brain Res** 1997;114:499–509 (38 ref.)
Spinal interneurons and preganglionic neurons in sacral autonomic reflex pathways. deGroat WC, et al. **Prog Brain Res** 1996;107:97–111 (90 ref.)
Spinal cord reflex organization of sympathetic systems. Jänig W. **Prog Brain Res** 1996;107:43–77 (131 ref.)
Sensori–sensory afferent conditioning with leg movement: gain control in spinal reflex and ascending paths. Brooke JD, et al. **Prog Neurobiol** 1997 Mar;51(4):393–421 (180 ref.)
[Pulmonary vagal afferents in man] Paleček F. **Cesk Fysiol** 1997 Jun;46(2):57–63 (90 ref.) (Eng. Abstr.) **(Cze)**
[Reflex hypertension—cardiogenic hypertensive chemoreflex] Imamura K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):155–8 (15 ref.) **(Jpn)**
[The neuronal organization of the amygdala–visceral reflex arch] Baklavadzhian OG, et al. **Usp Fiziol Nauk** 1996 Jul–Sep;27(3):51–77 (193 ref.) (Eng. Abstr.) **(Rus)**

REFLEX, ABNORMAL

Autonomic dysreflexia/hyperreflexia. Comarr AE, et al. **J Spinal Cord Med** 1997 Jul;20(3):345–54 (92 ref.)
Autonomic dysreflexia: pharmacological management of hypertensive crises in spinal cord injured patients. Naftchi NE, et al. **J Spinal Cord Med** 1997 Jul;20(3):355–60 (34 ref.)
[A case of atypical Miller–Fisher syndrome treated with intravenous immunoglobulins (letter)] Auzou P, et al. **Ann Med Interne (Paris)** 1996;147(6):458–9 (12 ref.) **(Fre)**
[A case of relapsing Guillain–Barré syndrome following Miller Fisher syndrome] Mochizuki A, et al. **Rinsho Shinkeigaku** 1996 May;36(5):675–9 (18 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Inhalation cough challenge in the investigation of the cough reflex and antitussives. Morice AH. **Pulm Pharmacol** 1996 Oct–Dec;9(5–6):281–4 (25 ref.)

PHYSIOLOGY

Reflex hyperexcitability and muscle contracture in relation to spastic hypertonia. O'Dwyer NJ, et al. **Curr Opin Neurol** 1996 Dec;9(6):451–5 (38 ref.)
A case of reflex anuria and uremia related to a unilateral ureteral stone. Hayashi K, et al. **Nippon Jinzo Gakkai Shi** 1996 Oct;38(10):460–2 (5 ref.)

REFLEX, ACOUSTIC

PHYSIOLOGY

Roles of the amygdala and bed nucleus of the stria terminalis in fear and anxiety measured with the acoustic startle reflex. Possible relevance to PTSD. Davis M, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:305–31 (76 ref.)

REFLEX, BARORECEPTOR see **BAROREFLEX**

REFLEX, BLINK see **BLINKING**

REFLEX, CONDITIONED see **CONDITIONING, CLASSICAL**

REFLEX, CORNEAL see **BLINKING**

REFLEX, ORBICULARIS OCULI see **BLINKING**

REFLEX, PHARYNGEAL see **GAGGING**

REFLEX, PSYCHOGALVANIC see **GALVANIC SKIN RESPONSE**

REFLEX, PUPILLARY

PHYSIOLOGY

Afferent pupillary defects and the swinging flashlight test. What you thought you already knew. Modica PA. **Optom Clin** 1996;5(3–4):1–15 (24 ref.)
[The pupil and retrogeniculate visual pathway. Overview] Wilhelm H. **Ophthalmologe** 1996 Aug;93(4):319–24 (24 ref.) (Eng. Abstr.) **(Ger)**

REFLEX, STRETCH

[A case of relapsing Guillain–Barré syndrome following Miller Fisher syndrome] Mochizuki A, et al. **Rinsho Shinkeigaku** 1996 May;36(5):675–9 (18 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

[A physiological study on instability in Parkinson's disease] Mitoma H. **Nippon Rinsho** 1997 Jan;55(1):168–72 (12 ref.) (Eng. Abstr.) **(Jpn)**

REFLEX SYMPATHETIC DYSTROPHY

Complex regional pain syndromes: including "reflex sympathetic dystrophy" and "causalgia". Walker SM, et al. **Anaesth Intensive Care** 1997 Apr;25(2):113–25 (76 ref.)
Reflex sympathetic dystrophy. The controversy continues. Nath RK, et al. **Clin Plast Surg** 1996 Jul;23(3):435–46 (86 ref.)
Reflex sympathetic dystrophy syndrome: diagnosis and treatment. Borg AA. **Disabil Rehabil** 1996 Apr;18(4):174–80 (56 ref.)
Osteopathic medical considerations of reflex sympathetic dystrophy. Nelson KE. **J Am Osteopath Assoc** 1997 May; 97(5):286–9 (30 ref.)
Complex regional pain syndrome. Colton AM, et al. **J Foot Ankle Surg** 1996 Jul–Aug;35(4):284–96 (42 ref.)
Reflex sympathetic dystrophy. Timely diagnosis and treatment can prevent severe contractures. Lopez RF. **Postgrad Med** 1997 Apr;101(4):185–90 (21 ref.)

COMPLICATIONS

Spontaneous fusion of the midfoot following reflex sympathetic dystrophy. A case report and review of the literature. Stratton NJ, et al. **Am J Orthop** 1996 Jul; 25(7):497–9 (16 ref.)
Anterior knee pain syndromes in the adolescent. Stanitski CL. **Instr Course Lect** 1994;43:211–20 (77 ref.)
Two new case–reports of reflex sympathetic dystrophy syndrome in patients with osteogenesis imperfecta. Review of the literature [letter] Bouvier M, et al. **Rev Rhum Engl Ed** 1997 Mar;64(3):202–4 (14 ref.)

DIAGNOSIS

Reflex sympathetic dystrophy. Gordon N. **Brain Dev** 1996 Jul–Aug;18(4):257–62 (49 ref.)
Reflex sympathetic dystrophy: the clinician's perspective. Hardy MA, et al. **J Hand Ther** 1997 Apr–Jun;10(2):137–50 (153 ref.)
Two new case–reports of reflex sympathetic dystrophy syndrome in patients with osteogenesis imperfecta. Review of the literature [letter] Bouvier M, et al. **Rev Rhum Engl Ed** 1997 Mar;64(3):202–4 (14 ref.)
An X–ray absorptiometry study of reflex sympathetic dystrophy syndrome. Laroche M, et al. **Rev Rhum Engl Ed** 1997 Feb;64(2):106–11 (17 ref.)
[Algodystrophies: diagnosis] Estève M, et al. **Cah Anesthesiol** 1996;44(4):377–82 (15 ref.) **(Fre)**

DRUG THERAPY

The pharmacologic approach to the painful hand. Czop C, et al. **Hand Clin** 1996 Nov;12(4):633–42 (42 ref.)

EPIDEMIOLOGY

Eating disorders and reflex sympathetic dystrophy syndrome: is there a common pathway? Silber TJ. **Med Hypotheses** 1997 Mar;48(3):197–200 (21 ref.)

ETIOLOGY

Reflex sympathetic dystrophy. Gordon N. **Brain Dev** 1996 Jul–Aug;18(4):257–62 (49 ref.)
Reflex sympathetic dystrophy, patella infera contracture syndrome, and loss of motion following anterior cruciate ligament surgery. Bach BR Jr, et al. **Instr Course Lect** 1997; 46:251–60 (25 ref.)
Reflex sympathetic dystrophy and pain dysfunction in the lower extremity. Lindenfeld TN, et al. **Instr Course Lect** 1997;46:261–8 (51 ref.)
[Inflammation theory for etiopathogenesis of algodystrophy] Zyluk A. **Chir Narzadow Ruchu Ortop Pol** 1996;61(5):493–8 (25 ref.) (Eng. Abstr.) **(Pol)**
[Lower limb injury and Sudeck's syndrome] Kotela I. **Przegl Lek** 1996;53(6):501–3 (19 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

Orofacial pain mechanisms and their clinical application. Merrill RL. **Dent Clin North Am** 1997 Apr;41(2):167–88 (71 ref.)
The painful hand. Koman LA, et al. **Hand Clin** 1996 Nov; 12(4):757–64 (34 ref.)
The reflex sympathetic dystrophy syndrome: a review with special reference to chronic pain and motor impairments. Ribbers G, et al. **Int J Rehabil Res** 1995 Dec;18(4):277–95 (78 ref.)
[Sudeck's syndrome. Was Sudeck right?] van der Laan L, et al. **Unfallchirurg** 1997 Feb;100(2):90–9 (70 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

What makes treatment for reflex sympathetic dystrophy successful? Hareau J. **J Hand Ther** 1996 Oct–Dec; 9(4):367–70 (10 ref.)

THERAPY

Treatment of algodystrophy using intravenous guanethidine regional block. Jacquemoud G, et al. **Ann Chir Main** 1982; 1(1):57–64 (16 ref.) **(Eng, Fre)**
Reflex sympathetic dystrophy: the clinician's perspective. Hardy MA, et al. **J Hand Ther** 1997 Apr–Jun;10(2):137–50 (153 ref.)
[Reflex dystrophy] Pohjolainen T. **Duodecim** 1995; 111(18):1783–9 (24 ref.) **(Fin)**

REFLEX, TENDON see **REFLEX, STRETCH**

REFLEX, VESTIBULO-OCULAR

Testing the vestibulo–ocular reflex. Halmagyi GM, et al. **Adv Otorhinolaryngol** 1997;53:132–54 (24 ref.)

DRUG EFFECTS

Recent advances in the pharmacology of the vestibulo–ocular reflex system. Smith PF, et al. **Trends Pharmacol Sci** 1996 Nov;17(11):421–7 (60 ref.)

PHYSIOLOGY

The synaptic organization of the horizontal vestibulo–ocular reflex in the frog. Dieringer N, et al. **Acta Biol Hung** 1996; 47(1–4):61–72 (37 ref.)
Control of the three–dimensional dynamic characteristics of the angular vestibulo–ocular reflex by the nodulus and

uvula. Wearne S, et al. **Prog Brain Res** 1997;114:321–34 (104 ref.)
Recent advances in the pharmacology of the vestibulo-ocular reflex system. Smith PF, et al. **Trends Pharmacol Sci** 1996 Nov;17(11):421–7 (60 ref.)

REFLEXOLOGY see **MASSAGE**

REFRACTION, OCULAR

Nomogram generation for keratomileusis: an introduction to multivariate analysis and neural nets. Sánchez-Thorin JC, et al. **Int Ophthalmol Clin** 1996 Fall;36(4):39–44 (9 ref.)
Reliability of refraction—a literature review. Goss DA, et al. **J Am Optom Assoc** 1996 Oct;67(10):619–30 (31 ref.)
Problems of refraction after photorefractive keratectomy. Siow KL, et al. **J Am Optom Assoc** 1996 Dec;67(12):755–61 (7 ref.)
Photorefractive keratectomy for myopia of −8.00 to −24.00 diopters. Goes FJ. **J Refract Surg** 1996 Jan–Feb;12(1):91–7 (14 ref.)
Prevalence of myopia in adults: implications for refractive surgeons [see comments] McCarty CA, et al.
J Refract Surg 1997 May–Jun;13(3):229–34 (41 ref.)
Comment in: J Refract Surg 1997 May–Jun;13(3):213–5.
The refractive group. Campbell C. **Optom Vis Sci** 1997 Jun; 74(6):381–7 (13 ref.)
Meridional profiles of variance–covariance of symmetric dioptric power: classes of variation that are uniform across the meridians of the eye. Harris WF. **Optom Vis Sci** 1997 Jun;74(6):397–413 (44 ref.)
Clinical refraction in three-dimensional dioptric space revisited [see comments] Raasch T. **Optom Vis Sci** 1997 Jun;74(6):376–80 (28 ref.) Comment in: Optom Vis Sci 1997 Jun;74(6):339–41.
[Modification of axial length and astigmatism by scleral buckling surgery] Grimm G, et al.
Klin Monatsbl Augenheilkd 1997 Mar;210(3):144–6 (16 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Spherical aberration of the reduced schematic eye with elliptical refracting surface. Thibos LN, et al.
Optom Vis Sci 1997 Jul;74(7):548–56 (26 ref.)

REFRACTIVE ERRORS

DIAGNOSIS

Reliability of refraction—a literature review. Goss DA, et al. **J Am Optom Assoc** 1996 Oct;67(10):619–30 (31 ref.)
[Selected problems with ocular accommodation in children and youth] Kubatko-Zielińska A, et al. **Klin Oczna** 1996; 98(6):459–61 (4 ref.) (Eng. Abstr.) **(Pol)**

SURGERY

Photorefractive keratectomy (PRK) in the military aviator: an aeromedical perspective. Ivan DJ, et al.
Aviat Space Environ Med 1996 Aug;67(8):770–6 (44 ref.)
Update in cataract and refractive surgery. MacInnis BJ.
Can J Ophthalmol 1996 Apr;31(3):111–2 (14 ref.)
Surgical technique for laser-assisted in situ keratomileusis. Duplessie M. **Int Ophthalmol Clin** 1996 Fall;36(4):45–51 (7 ref.)
Surgical correction of refractive errors after penetrating keratoplasty. Hardten DR, et al. **Int Ophthalmol Clin** 1997 Winter;37(1):1–35 (118 ref.)
Midinfrared photorefractive surgery: technical standards and clinical aspects. Mrochen M, et al. **Int Ophthalmol Clin** 1996 Fall;36(4):73–7 (12 ref.)
Excimer laser phototherapeutic keratectomy. Rapuano CJ. **Int Ophthalmol Clin** 1996 Fall;36(4):127–36 (11 ref.)
Corneal wound healing in laser in situ keratomileusis. Rocha G, et al. **Int Ophthalmol Clin** 1996 Fall;36(4):9–20 (41 ref.)
A comparison of modern incisional keratotomy and photorefractive keratectomy. Shapiro DR.
Int Ophthalmol Clin 1997 Winter;37(1):65–81 (56 ref.)
Advances in lamellar corneal refractive surgery. Slade SG, et al. **Int Ophthalmol Clin** 1997 Winter;37(1):103–22 (91 ref.)
Considering corneal and lenticular techniques of refractive surgery [editorial; comment] Rosen ES.
J Cataract Refract Surg 1997 Jun;23(5):689–91 (13 ref.)
Comment on: J Cataract Refract Surg 1997 Jun;23(5):731–5.
Refractive surgery, optical aberrations, and visual performance [see comments] Applegate RA, et al.
J Refract Surg 1997 May–Jun;13(3):295–9 (17 ref.)
Comment in: J Refract Surg 1997 May–Jun;13(3):213–5.
Evolving coverage in reporting refractive surgery in the popular press. Shah S, et al. **J Refract Surg** 1996 Jul–Aug; 12(5):638–41 (19 ref.)
20/20—how close must we get? [see comments] Werblin TP.
J Refract Surg 1997 May–Jun;13(3):300–1 (3 ref.) Comment in: J Refract Surg 1997 May–Jun;13(3):213–5.
Refractive surgery. Heffler KF. **Pa Med** 1996 Mar;99 Suppl:57–62 (45 ref.)

THERAPY

Contact lenses for children. Jurkus JM. **Optom Clin** 1996; 5(2):91–104 (29 ref.)
Power vectors: an application of Fourier analysis to the description and statistical analysis of refractive error [see comments] Thibos LN, et al. **Optom Vis Sci** 1997 Jun; 74(6):367–75 (44 ref.) Comment in: Optom Vis Sci 1997 Jun;74(6):339–41.

REFRACTORY ANEMIA see **ANEMIA, REFRACTORY**

REFRIGERATION

see related
HYPOTHERMIA, INDUCED

Experience with veterinary vaccines in warm climates. Tulasne JJ, et al. **Dev Biol Stand** 1996;87:33–42 (20 ref.)
Vaccine transport and storage: environmental challenges. Zaffran M. **Dev Biol Stand** 1996;87:9–17 (14 ref.)

REFSUM DISEASE, INFANTILE see **PEROXISOMAL DISORDERS**

REFUGEES

The public health aspects of complex emergencies and refugee situations. Toole MJ, et al.
Annu Rev Public Health 1997;18:283–312 (61 ref.)
Overseas screening for tuberculosis in immigrants and refugees to the United States: current status. Binkin NJ, et al. **Clin Infect Dis** 1996 Dec;23(6):1226–32 (21 ref.)
Environmental causes and impact of refugee movements: a critique of the current debate. Kibreab G. **Disasters** 1997 Mar;21(1):20–38 (90 ref.)
Cruel wars and safe havens: humanitarian aid in Liberia 1989–1996. Outram Q. **Disasters** 1997 Sep;21(3):189–205 (60 ref.)
Sexually transmitted diseases in mobile populations. Mabey D, et al. **Genitourin Med** 1997 Feb;73(1):18–22 (33 ref.)
Alcohol and drug use among displaced persons: an overview. Johnson TP. **Subst Use Misuse** 1996 Nov;31(13):1853–89 (80 ref.)
Torture and war trauma survivors in primary care practice. Weinstein HM, et al. **West J Med** 1996 Sep;165(3):112–8 (30 ref.)
Refugees: do not forget the basics. Malé S.
World Health Stat Q 1996;49(3–4):221–5 (19 ref.)

PSYCHOLOGY

Psychiatric implications of displacement: contributions from the psychology of place [see comments] Fullilove MT.
Am J Psychiatry 1996 Dec;153(12):1516–23 (84 ref.)
Comment in: Am J Psychiatry 1997 Sep;154(9):1328–9.
Psychological well-being of Cambodian women in resettlement. Catolico O. **ANS Adv Nurs Sci** 1997 Jun; 19(4):75–84 (52 ref.)
Refugee density and dependence: practical implications of camp size. Cosgrave J. **Disasters** 1996 Sep;20(3):261–70 (11 ref.)
The influence of culture on psychiatric assessment: the Vietnamese refugee. Phan T, et al. **Psychiatr Serv** 1997 Jan;48(1):86–90 (59 ref.)
The effects of violence on health and adjustment of Southeast Asian refugee children: an integrative review. Fox PG, et al. **Public Health Nurs** 1994 Jun;11(3):195–201 (28 ref.)

STATISTICS & NUMERICAL DATA

Refugee density and dependence: practical implications of camp size. Cosgrave J. **Disasters** 1996 Sep;20(3):261–70 (11 ref.)
Health problems of refugees. Ackerman LK.
J Am Board Fam Pract 1997 Sep–Oct;10(5):337–48 (72 ref.)
Southeast Asians: Asian-Pacific Americans at risk for substance misuse. D'Avanzo CE. **Subst Use Misuse** 1997 Jun;32(7–8):829–48 (65 ref.)
Drug problems among immigrants and refugees in The Netherlands and the Dutch health care and treatment system. van de Wijngaart GF. **Subst Use Misuse** 1997 Jun; 32(7–8):909–38 (60 ref.)

REFUSAL OF TREATMENT see **TREATMENT REFUSAL**

REFUSAL TO TREAT

Physicians' refusal to provide life-prolonging medical interventions. Paris JJ, et al. **Clin Perinatol** 1996 Sep; 23(3):563–71 (31 ref.)

REFUSE DISPOSAL

METHODS

Composting alternative for animal carcass disposal. Glanville TD, et al. **J Am Vet Med Assoc** 1997 Apr 15;210(8):1116–20 (23 ref.)

REGENERATION

see related
WOUND HEALING

Hair cell regeneration in the avian cochlea. Cotanche DA. **Ann Otol Rhinol Laryngol Suppl** 1997 May;168:9–15 (61 ref.)
Retinoid signalling and retinoid receptors in amphibian limb regeneration. Brockes JP. **Biochem Soc Symp** 1996; 62:137–42 (22 ref.)
Recent advances in tissue synthesis in vivo by use of collagen-glycosaminoglycan copolymers. Ellis DL, et al. **Biomaterials** 1996 Feb;17(3):291–9 (70 ref.)
Growth factors in skeletal muscle regeneration. Husmann I, et al. **Cytokine Growth Factor Rev** 1996 Oct;7(3):249–58 (108 ref.)
Lymphangiogenesis: mechanisms, significance and clinical implications. Witte MH, et al. **EXS** 1997;79:65–112 (172 ref.)
Spinal cord regeneration: a phenomenon unique to urodeles? Chernoff EA. **Int J Dev Biol** 1996 Aug;40(4):823–31 (78 ref.)
Re-examining jaw regeneration in urodeles: what have we learnt? Ferretti P. **Int J Dev Biol** 1996 Aug;40(4):807–11 (30 ref.)
Molecular mechanisms in the control of limb regeneration: the role of homeobox genes. Gardiner DM, et al.
Int J Dev Biol 1996 Aug;40(4):797–805 (76 ref.)
The cellular basis of limb regeneration in urodeles. Mescher AL. **Int J Dev Biol** 1996 Aug;40(4):785–95 (102 ref.)
Mechanisms of retina regeneration in urodeles. Mitashov VI. **Int J Dev Biol** 1996 Aug;40(4):833–44 (140 ref.)
Heart development and regeneration in urodeles. Neff AW, et al. **Int J Dev Biol** 1996 Aug;40(4):719–25 (76 ref.)
A conceptual framework for analyzing axial patterning in regenerating urodele limbs. Stocum DL. **Int J Dev Biol** 1996 Aug;40(4):773–83 (108 ref.)
Can insights into urodele limb regeneration be achieved with cell cultures and retroviruses? Tsonis PA, et al.
Int J Dev Biol 1996 Aug;40(4):813–6 (13 ref.)
Is retinoic acid an endogenous ligand during urodele limb regeneration? Viviano CM, et al. **Int J Dev Biol** 1996 Aug; 40(4):817–22 (42 ref.)
A scientific basis for the biologic regeneration of synovial joints. Luyten FP.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jan;83(1):167–9 (169 ref.)
Amphibian limb regeneration: rebuilding a complex structure. Brockes JP. **Science** 1997 Apr 4;276(5309):81–7 (55 ref.)
Wound healing—aiming for perfect skin regeneration. Martin P. **Science** 1997 Apr 4;276(5309):75–81 (92 ref.)
[Current views on the structural basis of repair regeneration of testis in mammals and humans] Kurnosova TR, et al.
Biull Eksp Biol Med 1994 Apr;117(4):396–9 (50 ref.) **(Rus)**
[Spinal cord trauma: the current concepts of the mechanisms of the damage, regeneration and means for its correction] Grishenkova LN, et al.
Zh Vopr Neirokhir Im N N Burdenko 1997 Apr–Jun; (2):37–44 (173 ref.) **(Rus)**

DRUG EFFECTS

Mineralocorticoids, salt and high blood pressure. Gómez-Sánchez EP, et al. **Steroids** 1996 Apr;61(4):184–8 (51 ref.)

GENETICS

[Molecular mechanism of morphogenesis: a theory of locational DNA] Olovnikov AM. **Biokhimiia** 1996 Nov; 61(11):1948–70 (69 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. Mackall CL, et al. **Immunol Rev** 1997 Jun; 157:61–72 (68 ref.)

PHYSIOLOGY

Target-specific guidance cues for regenerating axons are reexpressed in the lesioned adult mammalian central nervous system. Bähr M. **Adv Neurol** 1997;73:83–90 (49 ref.)
Novel molecular correlates of neuronal death and regeneration. Chen SC, et al. **Adv Neurol** 1996;71:433–49; discussion 449–50 (166 ref.)
Perilesional cortical dysfunction and reorganization. Eysel UT. **Adv Neurol** 1997;73:195–206 (38 ref.)
Restriction of plastic fiber growth after lesions by central nervous system myelin-associated neurite growth inhibitors. Kapfhammer JP. **Adv Neurol** 1997;73:7–27 (180 ref.)
Microimplantation of glial cells to promote regeneration of a lesioned fiber tract in the adult mammalian brain. Müller HW, et al. **Adv Neurol** 1997;73:29–36 (34 ref.)
Lesion-induced neuronal reorganization in the spinal cord: morphological aspects. Nacimiento W, et al.
Adv Neurol 1997;73:37–59 (102 ref.)
Techniques of cartilage growth enhancement: a review of the literature. Wirth CJ, et al. **Arthroscopy** 1996 Jun; 12(3):300–8 (96 ref.)
Experimental skeletal muscle grafts as a model of regeneration. Lawson-Smith MJ, et al.
Aust N Z J Surg 1997 Jan;67(1):35–9 (53 ref.)
Molecular basis of skeletal muscle regeneration. Chambers RL, et al. **Can J Appl Physiol** 1996 Jun;21(3):155–84 (133 ref.)
The potential role of insulin-like growth factors in skeletal muscle regeneration. MacGregor J, et al.
Can J Appl Physiol 1996 Aug;21(4):236–50 (35 ref.)

Biochemistry of periodontal connective tissues and their regeneration: a current perspective. Narayanan AS, et al. **Connect Tissue Res** 1996;34(3):191–201 (91 ref.)

Tissue engineering, morphogenesis, and regeneration of the periodontal tissues by bone morphogenetic proteins. Ripamonti U, et al. **Crit Rev Oral Biol Med** 1997; 8(2):154–63 (86 ref.)

Islet regeneration in IFNgamma transgenic mice. Jones EM, et al. **Horm Metab Res** 1997 Jun;29(6):308–10 (32 ref.)

Tissue regeneration as the basic oncogenic factor. Korystov YN. **Med Hypotheses** 1996 Sep;47(3):183–90 (51 ref.)

Cultured epithelial autografts: diving from surgery into matrix biology. Raghunath M, et al. **Pediatr Surg Int** 1997 Sep;12(7):478–83 (52 ref.)

Hepatocyte growth factor as mitogen, motogen and morphogen, and its roles in organ regeneration. Nakamura T. **Princess Takamatsu Symp** 1994;24:195–213 (76 ref.)

Inflammatory cells in renal regeneration. Ghielli M, et al. **Ren Fail** 1996 May;18(3):355–75 (106 ref.)

Growth cones and the cues that repel them. Kolodkin AL. **Trends Neurosci** 1996 Nov;19(11):507–13 (64 ref.)

[Cell growth factors and tissue repair] Vaillant P. **Rev Mal Respir** 1996 Dec;13(6):555–8 (15 ref.) **(Fre)**

[Nitrogen monoxide: mediator of tissue repair?] Schäffer M, et al. **Dtsch Med Wochenschr** 1997 Mar 14;122(11):339–45 (50 ref.) **(Ger)**

[Limbus stem cells and their significance for regeneration of of the corneal surface] Kruse FE. **Ophthalmologe** 1996 Oct;93(5):633–43 (32 ref.) **(Ger)**

[The role of natural growth stimulators in regulation of regeneration processes in small intestinal epithelium after irradiation] Dziekiewicz M. **Przegl Lek** 1996;53(8):610–3 (21 ref.) (Eng. Abstr.) **(Pol)**

[The problem of regeneration of the gastrointestinal tract mucosa in erosive–ulcerous lesions] Potkhin PP, et al. **Arkh Patol** 1997 Mar–Apr;59(2):68–71 (47 ref.) (Eng. Abstr.) **(Rus)**

[Mediator aspects of the inflammatory process] Shubich MG, et al. **Arkh Patol** 1997 Mar–Apr;59(2):3–8 (50 ref.) (Eng. Abstr.) **(Rus)**

[Chronic inflammation of mucous membranes: integration of immunity and regeneration] Zinov'ev AS, et al. **Arkh Patol** 1997 May–Jun;59(3):18–24 (50 ref.) (Eng. Abstr.) **(Rus)**

[Molecular mechanisms of cell–to–cell interactions during the progress and healing of tuberculosis] Kaminskaia GO, et al. **Probl Tuberk** 1996;(6):19–22 (31 ref.) (Eng. Abstr.) **(Rus)**

REGENERATION, GUIDED TISSUE see **GUIDED TISSUE REGENERATION**

REGIONAL BLOOD FLOW

Regional blood flow and hemorrhage. How far do the protective mechanisms go? [editorial; comment] Hemmer M. **Intensive Care Med** 1996 Oct;22(10):1006–8 (15 ref.) Comment on: Intensive Care Med 1996 Oct;22(10):1026–33.

A model for the coupling between cerebral blood flow and oxygen metabolism during neural stimulation. Buxton RB, et al. **J Cereb Blood Flow Metab** 1997 Jan;17(1):64–72 (53 ref.)

PHYSIOLOGY

Effects of pH on vascular tension: which are the important mechanisms? Aalkjaer C, et al. **J Vasc Res** 1996 Sep–Oct; 33(5):347–59 (109 ref.)

REGIONAL HEALTH PLANNING

Appropriateness in health care: application to prescribing. Buetow SA, et al. **Soc Sci Med** 1997 Jul;45(2):261–71 (115 ref.)

ORGANIZATION & ADMINISTRATION

Managed behavioral health care: a key component of integrated regional delivery systems. Nauert RC. **J Health Care Finance** 1997 Spring;23(3):49–61 (2 ref.)

REGIONAL MEDICAL PROGRAMS

The Baltimore City Health Department program of directly observed therapy for tuberculosis. Chaulk CP, et al. **Clin Chest Med** 1997 Mar;18(1):149–54 (5 ref.)

[The first results of the international project "Tuberculosis in the Tomsk region"] Strelis AK, et al. **Probl Tuberk** 1997; (1):10–2 (0 ref.) **(Rus)**

ORGANIZATION & ADMINISTRATION

Managed care merged with the German model [see comments] Weil TP. **Am J Med Qual** 1997 Spring; 12(1):19–24 (22 ref.) Comment in: Am J Med Qual 1997 Spring;12(1):25–7.

Toward effective regional trauma networks: management auditing initiatives in Ontario. Caro DH. **Health Care Manage Rev** 1997 Spring;22(2):21–32 (46 ref.)

A proposal for the training of regional medical experts. Johnson DE. **Mil Med** 1997 Aug;162(8):533–6 (11 ref.)

[Senegal: regionalization, a spring–board for health] Mane I, et al. **Med Trop (Mars)** 1997;57(2):127–35 (11 ref.) **(Fre)**

STANDARDS

Quality management for health care in the Middle East and north Africa: professional cooperation as part of the peace process. Habib J, et al. **Jt Comm J Qual Improv** 1997 Jan; 23(1):65–8 (0 ref.)

REGIONAL PERFUSION see **PERFUSION, REGIONAL**

REGISTRIES

Earnings and schooling: an overview of economic research based on the Australian Twin Register. Miller P, et al. **Acta Genet Med Gemellol (Roma)** 1996;45(4):417–29 (19 ref.)

CDC and ATSDR electronic information resources for health officers [see comments] Friede A, et al. **Am J Infect Control** 1996 Dec;24(6):440–54 (9 ref.) Comment in: Am J Infect Control 1996 Dec;24(6):417–20.

Connective tissue disease registries. Mayes MD, et al. **Arthritis Rheum** 1997 Sep;40(9):1556–9 (4 ref.)

What are the facts concerning the number of residency positions in Canada? [editorial] [see comments] Dauphinee D, et al. **Can Med Assoc J** 1997 Mar 1;156(5):665–7 (2 ref.) Comment in: CMAJ 1997 Jul 15;157(2):134, 136; discussion 139. Comment in: CMAJ 1997 Jul 15;157(2):136; discussion 139. Comment in: CMAJ 1997 Jul 15;157(2):136, 138; discussion 139. Comment in: CMAJ 1997 Jul 15;157(2):138.

The analysis of registry data in relation to various different types of hypothesis regarding the geographical distribution of disease. Draper GJ. **Cent Eur J Public Health** 1997 Jun; 5(2):90–2 (14 ref.)

Environmental epidemiology at the Medical Birth Registry of Norway; strengths and limitations. Lie RT. **Cent Eur J Public Health** 1997 Jun;5(2):57–9 (6 ref.)

Follow–up of atrial fibrillation: The initial experience of the Canadian Registry of Atrial Fibrillation. Kerr C, et al. **Eur Heart J** 1996 Jul;17 Suppl C:48–51 (12 ref.)

The Italian Registry of Antiphospholipid Antibodies. Finazzi G. **Haematologica** 1997 Jan–Feb;82(1):101–5 (25 ref.)

Registers of in–vitro fertilization and assisted conception. Lancaster PA. **Hum Reprod** 1996 Dec;11 Suppl 4:89–104; discussion 105–9 (49 ref.)

Registration of congenital anomalies in ART populations: pitfalls. Simpson JL. **Hum Reprod** 1996 Dec;11 Suppl 4:81–8 (19 ref.)

An international registry for toxic inhalation and pulmonary edema: notes from work in progress. Guidotti TL. **Int Arch Occup Environ Health** 1996;68(6):380–6 (28 ref.)

Prevalence and impact of chronic childhood conditions in Auckland, New Zealand. Vogel AM, et al. **J Paediatr Child Health** 1996 Dec;32(6):484–90 (50 ref.)

Registers in the study of pediatric rheumatic diseases—limitations and potential [editorial; comment] Gäre BA. **J Rheumatol** 1996 Nov;23(11):1834–7 (32 ref.) Comment on: J Rheumatol 1996 Nov;23(11):1981–7.

Multi–centre glomerulonephritis registry—basis for optimised therapy. Risler T, et al. **Kidney Blood Press Res** 1997; 20(3):184–7 (14 ref.)

Histopathological reporting of breast biopsies and mastectomies for carcinoma of the breast. Looi LM. **Malays J Pathol** 1994 Dec;16(2):173 (0 ref.)

Computer database for melanoma registry. A clinical management and research tool to monitor outcomes and ensure continuous quality improvement. Reintgen D, et al. **Surg Clin North Am** 1996 Dec;76(6):1273–85 (20 ref.)

Validation of large data sets, an essential prerequisite for data analysis: an analytical survey of the Bone Marrow Donors Worldwide. Schipper RF, et al. **Tissue Antigens** 1996 Mar; 47(3):169–78 (10 ref.)

The importance of diabetes registries and clinical biology for the study and treatment of type 1 (insulin–dependent) diabetes mellitus. Gorus FK. **Verh K Acad Geneeskd Belg** 1996;58(5):539–86 (143 ref.)

Induction of immune tolerance, the future of the Registry. Ewing NP. **Vox Sang** 1996;70 Suppl 1:47–51 (43 ref.)

[Use of registries for specific evaluation studies: example of ischemic cardiopathies] Amouyel P. **Rev Epidemiol Sante Publique** 1996;44 Suppl 1:S62–9 (9 ref.) (Eng. Abstr.) **(Fre)**

[Management of stroke. The value of the Dijon Stroke Registry] Giroud M, et al. **Rev Epidemiol Sante Publique** 1996;44 Suppl 1:S70–7 (12 ref.) (Eng. Abstr.) **(Fre)**

[Value of cancer registries in the evaluation of colorectal cancer treatment] Launoy G, et al. **Rev Epidemiol Sante Publique** 1996;44 Suppl 1:S22–32 (10 ref.) (Eng. Abstr.) **(Fre)**

[Mesothelioma. Pathology/pathogenesis/mesothelioma register] Müller KM. **Pneumologie** 1997 Apr;51(4):335–44 (18 ref.) **(Ger)**

STANDARDS

Nordic Medical Birth Registers in epidemiological research. Gissler M, et al. **Eur J Epidemiol** 1997 Feb;13(2):169–75 (28 ref.)

A framework for evaluation of secondary data sources for epidemiological research. Sorensen HT, et al. **Int J Epidemiol** 1996 Apr;25(2):435–42 (66 ref.)

REGRESSION (PSYCHOLOGY)

The analytic initiation: the effect of the archetype of initiation on the personal unconscious. Sullivan M. **J Anal Psychol** 1996 Oct;41(4):509–27 (13 ref.)

REGRESSION ANALYSIS

Regression calibration method for correcting measurement–error bias in nutritional epidemiology. Spiegelman D, et al. **Am J Clin Nutr** 1997 Apr;65(4 Suppl):1179S–1186S (35 ref.)

Regression analysis and multivariate analysis. Duleba AJ, et al. **Semin Reprod Endocrinol** 1996 May;14(2):139–53 (10 ref.)

The use of sampling weights for survey data analysis. Pfeffermann D. **Stat Methods Med Res** 1996 Sep; 5(3):239–61 (42 ref.)

Regression towards the mean, historically considered. Stigler SM. **Stat Methods Med Res** 1997 Jun;6(2):103–14 (22 ref.)

[Update on regression: softening relationships] Sánchez–Cantalejo Ramírez E, et al. **Gac Sanit** 1997 Jan–Feb;11(1):24–32 (25 ref.) (Eng. Abstr.) **(Spa)**

REGRESSION DIAGNOSTICS see **REGRESSION ANALYSIS**

REGULATION OF GENE EXPRESSION see **GENE EXPRESSION REGULATION**

REGULATION OF GENE EXPRESSION, BACTERIAL see **GENE EXPRESSION REGULATION, BACTERIAL**

REGULATION OF GENE EXPRESSION, DEVELOPMENTAL see **GENE EXPRESSION REGULATION, DEVELOPMENTAL**

REGULATION OF GENE EXPRESSION, EMBRYOLOGIC see **GENE EXPRESSION REGULATION, DEVELOPMENTAL**

REGULATION OF GENE EXPRESSION, ENZYMOLOGIC see **GENE EXPRESSION REGULATION, ENZYMOLOGIC**

REGULATION OF GENE EXPRESSION, FUNGAL see **GENE EXPRESSION REGULATION, FUNGAL**

REGULATION OF GENE EXPRESSION, LEUKEMIC see **GENE EXPRESSION REGULATION, LEUKEMIC**

REGULATION OF GENE EXPRESSION, NEOPLASTIC see **GENE EXPRESSION REGULATION, NEOPLASTIC**

REGULATION OF GENE EXPRESSION, PLANT see **GENE EXPRESSION REGULATION, PLANT**

REGULATION OF GENE EXPRESSION, VIRAL see **GENE EXPRESSION REGULATION, VIRAL**

REGULATORY REGIONS, NUCLEIC ACID (GENETICS) see **REGULATORY SEQUENCES, NUCLEIC ACID**

REGULATORY SEQUENCES, NUCLEIC ACID

Common themes in the function of transcription and splicing enhancers. Hertel KJ, et al. **Curr Opin Cell Biol** 1997 Jun; 9(3):350–7 (68 ref.)

The role of insulator elements in defining domains of gene expression. Geyer PK. **Curr Opin Genet Dev** 1997 Apr; 7(2):242–8 (49 ref.)

Regulation of beta–globin gene expression: straightening out the locus. Martin DI, et al. **Curr Opin Genet Dev** 1996 Aug;6(4):488–95 (65 ref.)

Life and death in the cytoplasm: messages from the 3' end. Wickens M, et al. **Curr Opin Genet Dev** 1997 Apr; 7(2):220–32 (105 ref.)

Searching for regulatory elements in human noncoding sequences. Duret L, et al. **Curr Opin Struct Biol** 1997 Jun; 7(3):399–406 (48 ref.)

Retinoic acid response elements as positive and negative regulators of the expression of the homeobox b–1 gene. De Luca LM, et al. **Nutr Rev** 1996 Feb;54(2 Pt 1):61–3 (17 ref.)

Silencers and locus control regions: opposite sides of the same coin. Kamakaka RT. **Trends Biochem Sci** 1997 Apr; 22(4):124–8 (42 ref.)

GENETICS

Small genetic effects in complex diseases: a review of regulatory sequence variants in dyslipoproteinemia and atherosclerosis. Hegele RA. **Clin Biochem** 1997 Apr; 30(3):183–8 (56 ref.)

The hardwiring of development: organization and function of genomic regulatory systems. Arnone MI, et al. **Development** 1997 May;124(10):1851–64 (119 ref.)

IMMUNOLOGY

Inhibitory receptors, ITIM sequences and phosphatases. Unkeless JC, et al. **Curr Opin Immunol** 1997 Jun;9(3):338–43

(42 ref.)
Partitioning of genetic variation between regulatory and coding gene segments: the predominance of software variation in genes encoding introvert proteins. Mitchison A. **Immunogenetics** 1997;46(1):46–52 (48 ref.)

REGULON

Two-stage gene regulation of the superoxide stress response soxRS system in Escherichia coli. Nunoshiba T. **Crit Rev Eukaryot Gene Expr** 1996;6(4):377–89 (92 ref.)
Redox signaling and gene control in the Escherichia coli soxRS oxidative stress regulon—a review. Demple B. **Gene** 1996 Nov 7;179(1):53–7 (25 ref.)
A flexible partnership: the CytR anti-activator and the cAMP-CRP activator protein, comrades in transcription control. Valentin-Hansen P, et al. **Mol Microbiol** 1996 May; 20(3):461–6 (26 ref.)

GENETICS

Antitermination of transcription of catabolic operons. Rutberg B. **Mol Microbiol** 1997 Feb;23(3):413–21 (71 ref.)

REGURGITATION, GASTRIC see **GASTROESOPHAGEAL REFLUX**

REHABILITATION

see related
DISABILITY EVALUATION
EARLY INTERVENTION (EDUCATION)

Team decision-making in rehabilitation: a commentary [see comments] Unsworth C. **Am J Phys Med Rehabil** 1996 Nov-Dec;75(6):483–6 (24 ref.) Comment in: Am J Phys Med Rehabil 1997 Jul-Aug;76(4):348.
Industrial rehabilitation medicine. 1. Why is industrial rehabilitation medicine unique? Robinson JP, et al. **Arch Phys Med Rehabil** 1997 Mar;78(3 Suppl):S3–9 (81 ref.)
Disablement observed, addressed, and experienced: integrating subjective experience into disablement models. Peters DJ. **Disabil Rehabil** 1996 Dec;18(12):593–603 (44 ref.)
[Rehabilitation as interdisciplinary responsibility—the medical specialty "physical and rehabilitative medicine"] Gehrk A. **Z Arztl Fortbild (Jena)** 1996 Oct;90(6):471–8 (7 ref.) (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

Ergonomic data of elderly people and their application in rehabilitation design. Rogers N, et al. **Disabil Rehabil** 1996 Oct;18(10):487–96 (59 ref.)
Measurement of isometric elbow and shoulder moments: position-dependent strength of posterior deltoid-to-triceps muscle tendon transfer in tetraplegia. Kirsch RF, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):403–9 (10 ref.)
Detection of static and dynamic activities using uniaxial accelerometers. Veltink PH, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):375–85 (17 ref.)
[Modern technology and the rehabilitation of the disabled] Azaria M, et al. **Harefuah** 1996 Jul;131(1–2):57–9 (28 ref.) **(Heb)**

METHODS

Improving treatment compliance among adolescent suicide attempters. Spirito A. **Crisis** 1996;17(4):152–4 (18 ref.)
Motor control research in rehabilitation medicine. Latash ML, et al. **Disabil Rehabil** 1996 Jun;18(6):293–9 (40 ref.)
Investigation of spectral content from discrete plantar areas during adult gait: an expansion of rehabilitation technology. Harris GF, et al. **IEEE Trans Rehabil Eng** 1996 Dec; 4(4):360–74 (20 ref.)
Effective teamwork in rehabilitation. Bakheit AM. **Int J Rehabil Res** 1996 Dec;19(4):301–6 (27 ref.)
Relative role of ambulatory and residential rehabilitation. Cobelli F, et al. **J Cardiovasc Risk** 1996 Apr;3(2):172–5 (20 ref.)

ORGANIZATION & ADMINISTRATION

Ethics, values, and world culture: the impact on rehabilitation. Banja JD. **Disabil Rehabil** 1996 Jun; 18(6):279–84 (7 ref.)

PSYCHOLOGY

[Psychological contributions to rehabilitation in ambulatory health care] Vogel H. **Z Arztl Fortbild (Jena)** 1996 Oct; 90(6):519–25 (23 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

Outcome assessment in cardiac rehabilitation. Health-related quality of life and economic evaluation. Oldridge NB. **J Cardiopulm Rehabil** 1997 May-Jun;17(3):179–94 (169 ref.)
Disablement outcomes in geriatric rehabilitation. Jette AM. **Med Care** 1997 Jun;35(6 Suppl):JS28–37; discussion JS38–44 (25 ref.)
Improving outcomes in rehabilitation. A call to arms (and legs). Kane RL. **Med Care** 1997 Jun;35(6 Suppl):JS21–7 (8 ref.)
Rehabilitation care and outcomes from the patient's perspective. Kramer AM. **Med Care** 1997 Jun;35(6 Suppl):JS48–57; discussion JS58–63 (20 ref.)
Can clinical practice guidelines increase the cost-effectiveness of geriatric rehabilitation? Stason WB. **Med Care** 1997 Jun;35(6 Suppl):JS68–77; discussion JS78–83 (2 ref.)

STATISTICS & NUMERICAL DATA

[Goals in rehabilitation: assessment and outcome evaluation] Meier-Baumgartner HP, et al. **Ther Umsch** 1997 Jun; 54(6):337–9 (22 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION CENTERS

ECONOMICS

Head injury rehabilitation in the U.K.: an economic perspective. McGregor K, et al. **Soc Sci Med** 1997 Jul; 45(2):295–303 (65 ref.)

REHABILITATION CENTERS, DRUG see **SUBSTANCE ABUSE TREATMENT CENTERS**

REHABILITATION, VOCATIONAL

see related
EMPLOYMENT

Mental illness and the Americans with Disabilities Act. Understanding the fundamentals. Wasserbauer LI. **J Psychosoc Nurs Ment Health Serv** 1997 Jan;35(1):22–6 (13 ref.)
[Musculoskeletal pain disorders] Klockars M. **Duodecim** 1995; 111(17):1671–4 (10 ref.) **(Fin)**

ECONOMICS

Occupational therapy practice: focusing on occupational performance. Baum CM, et al. **Am J Occup Ther** 1997 Apr; 51(4):277–88 (39 ref.)

PSYCHOLOGY

The biopsychosocial disease consequence model in rehabilitation: model development in the Finnish 'work hardening' programme for chronic pain. Talo S, et al. **Int J Rehabil Res** 1996 Jun;19(2):93–109 (35 ref.)

REHYDRATION see **FLUID THERAPY**

REHYDRATION, ORAL see **FLUID THERAPY**

REHYDRATION SOLUTIONS

Water and electrolyte replenishment in the exercising child. Bar-Or O, et al. **Int J Sport Nutr** 1996 Jun;6(2):93–9 (26 ref.)

REICHEL'S SYNDROME see **CHONDROMATOSIS, SYNOVIAL**

REIMBURSEMENT, FEE-FOR-SERVICE see **FEE-FOR-SERVICE PLANS**

REIMBURSEMENT, HEALTH INSURANCE see **INSURANCE, HEALTH, REIMBURSEMENT**

REIMBURSEMENT MECHANISMS

Global budgets and excess demand for hospital care. Feldman R, et al. **Health Econ** 1997 Mar-Apr;6(2):187–96 (20 ref.)
Comprehensive reimbursement model: an alternative to fee-for-service reimbursement by blood centers. Fuller MJ, et al. **Transfus Med Rev** 1997 Jan;11(1):38–43 (4 ref.)

LEGISLATION & JURISPRUDENCE

The impact of the NHS reforms 1991–1995: a review of research evidence. Robinson R. **J Public Health Med** 1996 Sep;18(3):337–42 (91 ref.)

ORGANIZATION & ADMINISTRATION

Medicaid and primary care. Rushton FE. **J S C Med Assoc** 1997 Feb;93(2):63–7 (12 ref.)

TRENDS

Payment hassles [see comments] BeSaw L. **Tex Med** 1997 Jan;93(1):36–9 (0 ref.) Comment in: Tex Med 1997 Mar;93(3):7–8.

REIMBURSEMENT, PROSPECTIVE see **PROSPECTIVE PAYMENT SYSTEM**

REIMPLANTATION see **REPLANTATION**

REINFORCEMENT (PSYCHOLOGY)

Some potential contributions of reinforcement and consumer-demand theory to reducing cocaine use. Higgins ST. **Addict Behav** 1996 Nov-Dec;21(6):803–16 (50 ref.)
Behavioral momentum. Implications and development from reinforcement theories. Plaud JJ, et al. **Behav Modif** 1996 Apr;20(2):183–201 (38 ref.)
The ascending neuromodulatory systems in learning by reinforcement: comparing computational conjectures with experimental findings. Pennartz CM. **Brain Res Brain Res Rev** 1995 Nov;21(3):219–45 (235 ref.)
Neural basis of utility estimation. Shizgal P. **Curr Opin Neurobiol** 1997 Apr;7(2):198–208 (76 ref.)
Nigrostriatal dopamine system may contribute to behavioral learning through providing reinforcement signals to the striatum. Kimura M, et al. **Eur Neurol** 1997;38 Suppl 1:11–7 (33 ref.)
In pursuit of general behavioral relations. Mace FC. **J Appl Behav Anal** 1996 Winter;29(4):557–63 (37 ref.)
Reinforcement processes in opiate addiction: a homeostatic model. Schulteis G, et al. **Neurochem Res** 1996 Nov; 21(11):1437–54 (133 ref.)
Reinforcement concept in investigations on simple nervous systems. Balaban PM. **Neurosci Behav Physiol** 1997 Jul-Aug;27(4):435–40 (15 ref.)
A systems process of reinforcement. Sudakov KV. **Neurosci Behav Physiol** 1997 Jul-Aug;27(4):370–80 (60 ref.)
Motivation and reinforcement in the systemic mechanisms of behavior: dynamic reinforcement engrams. Sudakov KV. **Neurosci Behav Physiol** 1996 Sep-Dec;26(5):445–53 (40 ref.)
A critique of fixed and progressive ratio schedules used to examine the neural substrates of drug reinforcement. Arnold JM, et al. **Pharmacol Biochem Behav** 1997 Jul; 57(3):441–7 (70 ref.)
Cellular mechanisms underlying reinforcement-related processing in the nucleus accumbens: electrophysiological studies in behaving animals. Carelli RM, et al. **Pharmacol Biochem Behav** 1997 Jul;57(3):495–504 (55 ref.)
The influence of alternative reinforcers on cocaine use and abuse: a brief review. Higgins ST. **Pharmacol Biochem Behav** 1997 Jul;57(3):419–27 (24 ref.)
Serotonergic mechanisms involved in the discriminative stimulus, reinforcing and subjective effects of cocaine. Walsh SL, et al. **Psychopharmacology (Berl)** 1997 Mar; 130(1):41–58 (157 ref.)
[Biochemical mechanism of reinforcement: findings in the studies of self-stimulation] Nakajima S. **Shinrigaku Kenkyu** 1996 Feb;66(6):449–56 (57 ref.) (Eng. Abstr.) **(Jpn)**
[The concept of reinforcement in research on simple nervous systems] Baladan PM. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 Mar-Apr; 47(2):280–5 (13 ref.) (Eng. Abstr.) **(Rus)**
[The systems process of reinforcement] Sudakov KV. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jul-Aug; 46(4):643–55 (60 ref.) (Eng. Abstr.) **(Rus)**

REINFORCING FACTORS see **CAUSALITY**

REITER'S DISEASE

[Reiter's syndrome] Kobayashi S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):376–8 (14 ref.) **(Jpn)**
[Recent concept and clinical manifestations of reactive arthritis] Kobayashi S. **Ryumachi** 1997 Jun;37(3):504–13 (46 ref.) **(Jpn)**

COMPLICATIONS

[Cardiac involvement in Reiter's disease] Dzhus MB, et al. **Lik Sprava** 1995 Sep-Dec;(9-12):168–9 (10 ref.) (Eng. Abstr.) **(Ukr)**

PHYSIOPATHOLOGY

Anatomic predilection of the spondyloarthropathies(-)a case of the nerves? Segal AH. **J Rheumatol** 1996 Mar; 23(3):491–4 (60 ref.)

RADIOGRAPHY

The seronegative spondyloarthropathies. Kettering JM, et al. **Semin Roentgenol** 1996 Jul;31(3):220–8 (18 ref.)

REL GENES see **ONCOGENES**

RELAPSING FEVER

PARASITOLOGY

Ticks and Borrelia: model systems for investigating pathogen-arthropod interactions. Schwan TG. **Infect Agents Dis** 1996 Jun;5(3):167–81 (120 ref.)

RELATIVE RISK see **RISK**

RELATIVE VALUE SCALES

The valuation of health care intangible assets. Reilly RF, et al. **Health Care Manage Rev** 1997 Spring;22(2):55–64 (0 ref.)

RELATIVE-VALUE SCHEDULES see **RELATIVE VALUE SCALES**

RELAXATION

Exercise and relaxation in health promotion. Shephard RJ. **Sports Med** 1997 Apr;23(4):211–7 (51 ref.)

RELAXATION TECHNIQUES

Analysis of recent literature concerning relaxation and imagery interventions for cancer pain. Wallace KG. **Cancer Nurs** 1997 Apr;20(2):79–87 (45 ref.)

The efficacy of relaxation response interventions with adult patients: a review of the literature [see comments] Mandle CL, et al. **J Cardiovasc Nurs** 1996 Apr;10(3):4–26 (88 ref.)
Comment in: J Cardiovasc Nurs 1996 Apr;10(3):v–x.

Psychological influences on pain perception and non-pharmacologic approaches to the treatment of pain. DePalma MT, et al. **J Hand Ther** 1997 Apr–Jun; 10(2):183–91 (68 ref.)

Effectiveness of psychological interventions for people with poorly controlled epilepsy. Goldstein LH. **J Neurol Neurosurg Psychiatry** 1997 Aug;63(2):137–42 (61 ref.)

Biofeedback, relaxation training, and cognitive behaviour modification as treatments for lower functional gastrointestinal disorders. Bassotti G, et al. **QJM** 1997 Aug; 90(8):545–50 (69 ref.)

STANDARDS

Effects of relaxation and music on postoperative pain: a review. Good M. **J Adv Nurs** 1996 Nov;24(5):905–14 (51 ref.)

RELAXATION THERAPY see **RELAXATION TECHNIQUES**

RELAXIN

CHEMISTRY

Stability and characterization of recombinant human relaxin. Nguyen TH, et al. **Pharm Biotechnol** 1996;9:247–74 (63 ref.)

PHYSIOLOGY

A speculative review of parturition in the mare. Thorburn GD. **Equine Vet J Suppl** 1993 Apr;(14):41–9 (72 ref.)

Relaxin: a pleiotropic hormone. Bani D. **Gen Pharmacol** 1997 Jan;28(1):13–22 (136 ref.)

RELIABILITY AND VALIDITY see **REPRODUCIBILITY OF RESULTS**

RELIEF WORK

Doing the right thing: relief agencies, moral dilemmas and responsibility in political emergencies and war. Slim H. **Disasters** 1997 Sep;21(3):244–57 (15 ref.)

Exploring the determinants of support provision: provider characteristics, personal networks, community contexts, and support following life events. Haines VA, et al. **J Health Soc Behav** 1996 Sep;37(3):252–64 (48 ref.)

[Avalanche emergency. New aspects of the pathophysiology and therapy of buried avalanche victims] Brugger H, et al. **Wien Klin Wochenschr** 1997 Mar 14;109(5):145–59 (114 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

The public health aspects of complex emergencies and refugee situations. Toole MJ, et al. **Annu Rev Public Health** 1997;18:283–312 (61 ref.)

Refugee density and dependence: practical implications of camp size. Cosgrave J. **Disasters** 1996 Sep;20(3):261–70 (11 ref.)

Estimating the capacity of warehouses. Cosgrave J. **Disasters** 1997 Jun;21(2):155–65 (31 ref.)

Social contract and deterring famine: first thoughts. de Waal A. **Disasters** 1996 Sep;20(3):194–205 (25 ref.)

The symphony of the damned: racial discourse, complex political emergencies and humanitarian aid. Duffield M. **Disasters** 1996 Sep;20(3):173–93 (45 ref.)

Information exchange in the disaster zone: interaction between aid workers and recipients in south Sudan. Jok JM. **Disasters** 1996 Sep;20(3):206–15 (6 ref.)

Conflict, the continuum and chronic emergencies: a critical analysis of the scope for linking relief, rehabilitation and development planning in Sudan. Macrae J, et al. **Disasters** 1997 Sep;21(3):223–43 (23 ref.)

Cruel wars and safe havens: humanitarian aid in Liberia 1989–1996. Outram Q. **Disasters** 1997 Sep;21(3):189–205 (60 ref.)

Research in the war zones of Eritrea and northern Ethiopia. Silkin T, et al. **Disasters** 1997 Jun;21(2):166–76 (15 ref.)

A research note about military–civilian humanitarianism: more questions than answers. Weiss TG. **Disasters** 1997 Jun;21(2):95–117 (116 ref.)

RELIGION

Practical issues when confronting the patient who refuses blood transfusion therapy. Bennett DR, et al. **Am J Clin Pathol** 1997 Apr;107(4 Suppl 1):S23–7 (17 ref.)

Religious orientation and pain management. Low JF. **Am J Occup Ther** 1997 Mar;51(3):215–9 (22 ref.)

Post-coital sperm retrieval could lead to the wider approval of assisted conception by some religions. Hirsh A. **Hum Reprod** 1996 Feb;11(2):245–7 (26 ref.)

Epidemiology of inflammatory bowel disease in different ethnic and religious groups: limitations and aetiological clues. Probert CS, et al. **Int J Colorectal Dis** 1996;11(1):25–8 (29 ref.)

Religion and subjective health among black and white elders. Musick MA. **J Health Soc Behav** 1996 Sep;37(3):221–37 (60 ref.)

Exploring a fourth dimension: spirituality as a resource for the couple therapist. Anderson DA, et al. **J Marital Fam Ther** 1997 Jan;23(1):3–12 (32 ref.)

Wellness spirituality in the older adult. Assessment and intervention protocol. Leetun MC. **Nurse Pract** 1996 Aug; 21(8):60, 65–70 (36 ref.)

Psychosocial and spiritual issues in terminal care. Kashiwagi T. **Psychiatry Clin Neurosci** 1995 May;49 Suppl 1:S123–7 (4 ref.)

RELIGION AND MEDICINE

Children, medicine, religion, and the law. Swan R. **Adv Pediatr** 1997;44:491–543 (205 ref.)

Spiritual issues and bioethics in the intensive care unit: the role of the chaplain. Wagner JT, et al. **Crit Care Clin** 1996 Jan;12(1):15–27 (09 ref.)

Ramadan fasting—effects on health and disease. Malik GM, et al. **J Assoc Physicians India** 1996 May;44(5):332–4 (15 ref.)

Involuntary confinement for tuberculosis control: the Jewish view. Rosner F. **Mt Sinai J Med** 1996 Jan;63(1):44–8 (27 ref.)

The spiritual dimension of hospice: the secularization of an ideal. Bradshaw A. **Soc Sci Med** 1996 Aug;43(3):409–19 (44 ref.)

How religion influences morbidity and health: reflections on natural history, salutogenesis and host resistance. Levin JS. **Soc Sci Med** 1996 Sep;43(5):849–64 (67 ref.)

Dilemmas and solutions for the pathologist and clinician encountering religious views of the autopsy [see comments] Davis GJ, et al. **South Med J** 1996 Nov;89(11):1041–4 (29 ref.) Comment in: South Med J 1996 Nov;89(11):1125–6.

[Sects, sectarisms and authentic spiritual pathways: can we learn to discern between them in order to counsel?] Wulliemier F. **Rev Med Suisse Romande** 1997 Jun; 117(6):525–33 (24 ref.) **(Fre)**

[Oxygen supply and acid–base status in extreme anemia] Zander R. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Oct; 31(8):492–4 (30 ref.) **(Ger)**

RELIGION AND PSYCHOLOGY

Religion, spirituality and psychiatry: conceptual, cultural and personal challenges. Turbott J. **Aust N Z J Psychiatry** 1996 Dec;30(6):720–7; discussion 728–30 (65 ref.)

Issues in forensic psychiatry in Islamic jurisprudence. Chaleby KS. **Bull Am Acad Psychiatry Law** 1996; 24(1):117–24 (21 ref.)

Towards a rhetoric of spirituality in mental health care. Nolan P, et al. **J Adv Nurs** 1997 Aug;26(2):289–94 (27 ref.)

The neural substrates of religious experience. Saver JL, et al. **J Neuropsychiatry Clin Neurosci** 1997 Summer; 9(3):498–510 (145 ref.)

[Who and why accept new religions?] Inoue M. **Seishin Shinkeigaku Zasshi** 1996;98(9):590–6 (6 ref.) **(Jpn)**

[Religion and psychology—review of the concept] Tsuchiya H. **Seishin Shinkeigaku Zasshi** 1996;98(9):583–90 (14 ref.) **(Jpn)**

RELIGION AND SCIENCE

The fourth state of consciousness: the Thuriya Avastha. Ramamurthi B. **Psychiatry Clin Neurosci** 1995 May; 49(2):107–10 (0 ref.)

RELIGION AND SEX

Female genital mutilation: an overview. Wright J. **J Adv Nurs** 1996 Aug;24(2):251–9 (54 ref.)

RELIGIOUS BELIEFS see **RELIGION**

REMANTADINE see **RIMANTADINE**

REMEDIAL TEACHING

Remediation of children with developmental language disorders. Dunn M. **Semin Pediatr Neurol** 1997 Jun; 4(2):135–42 (22 ref.)

REMISSION, SPONTANEOUS

Connectionist modeling of the recovery of language functions following brain damage. Harley TA. **Brain Lang** 1996 Jan; 52(1):7–24 (71 ref.)

REMISSION, SPONTANEOUS NEOPLASM see **NEOPLASM REGRESSION, SPONTANEOUS**

REMOTE CONSULTATION

[The digital image archive—its clinical applications and importance in cardiology consulting by telemedicine] Fiuza M, et al. **Rev Port Cardiol** 1997 Feb;16(2):127–39, 123 (44 ref.) (Eng. Abstr.) **(Por)**

METHODS

Practising oncology via telemedicine. Doolittle GC, et al. **J Telemed Telecare** 1997;3(2):63–70 (14 ref.)

REMOTE OPERATIONS (ROBOTICS) see **ROBOTICS**

RENAL AGENTS

ADVERSE EFFECTS

Hyponatremia in patients with nocturnal enuresis treated with DDAVP. Robson WL, et al. **Eur J Pediatr** 1996 Nov; 155(11):959–62 (32 ref.)

Intranasal desmopressin-associated hyponatremia: a case report and literature review. Bernstein SA, et al. **J Fam Pract** 1997 Feb;44(2):203–8 (21 ref.)

THERAPEUTIC USE

Cure of nocturnal enuresis: why isn't desmopressin very effective? Koff SA. **Pediatr Nephrol** 1996 Oct;10(5):667–70 (21 ref.)

Genetic factors as predictors for desmopressin treatment success. Hogg RJ. **Scand J Urol Nephrol Suppl** 1997; 183:37–9 (12 ref.)

[Drug therapy of enuresis] von Gontard A, et al. **Z Kinder Jugenpsychiatr** 1996 Mar;24(1):18–33 (65 ref.) **(Ger)**

RENAL ARTERY

Aneurysms of the visceral and renal arteries. Panayiotopoulos YP, et al. **Ann R Coll Surg Engl** 1996 Sep;78(5):412–9 (85 ref.)

Arteriovenous fistula following nephrectomy. Kajbafzadeh AM, et al. **Eur Urol** 1997;31(1):112–4 (12 ref.)

Management of renal artery aneurysms. Cinat M, et al. **Semin Vasc Surg** 1996 Sep;9(3):236–44 (50 ref.)

Aortic reconstruction in patients with horseshoe or ectopic kidneys. de Virgilio C, et al. **Semin Vasc Surg** 1996 Sep; 9(3):245–52 (12 ref.)

Renal artery thrombosis in the newborn infant. Kavaler E, et al. **Urology** 1997 Aug;50(2):282–4 (6 ref.)

[Renal cell carcinoma associated with renal artery aneurysm] Yazawa K, et al. **Hinyokika Kiyo** 1997 May;43(5):343–5 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Renal arteritis] Hiromura K. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):323–5 (8 ref.) **(Jpn)**

[Renovascular fibromuscular hyperplasia (dysplasia)] Kanazawa M, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):334–7 (2 ref.) **(Jpn)**

[Renal artery aneurysm] Kato T, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):338–40 (9 ref.) **(Jpn)**

[Renal thrombotic microangiopathy] Sakakibara K. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):316–9 (18 ref.) **(Jpn)**

[Renal arteriovenous fistula] Taniyama Y, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):320–2 (10 ref.) **(Jpn)**

[Renal arterial thrombosis, renal arterial embolism, renal artery occlusion] Yoshimura M, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):330–3 (8 ref.) **(Jpn)**

[Embolism of the small branches of the pulmonary artery in x-ray endovascular occlusion of the renal vessels in cancer] Iurin AG. **Arkh Patol** 1996 Nov–Dec;58(6):62–4 (9 ref.) (Eng. Abstr.) **(Rus)**

ABNORMALITIES

Spontaneous renal arteriovenous fistula as a cause of haematuria. Fogazzi GB, et al. **Nephrol Dial Transplant** 1997 Feb;12(2):350–6 (67 ref.)

[Multiple renal arteries] Yamada M, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):297–300 (11 ref.) **(Jpn)**

ANATOMY & HISTOLOGY

MR angiography of the renal arteries. King BF Jr. **Semin Ultrasound CT MR** 1996 Aug;17(4):398–403 (15 ref.)

PATHOLOGY

Vasoactive hormones and renal sclerosis. Egido J. **Kidney Int** 1996 Feb;49(2):578–97 (229 ref.)

MR angiography of the renal arteries. King BF Jr. **Semin Ultrasound CT MR** 1996 Aug;17(4):398–403 (15 ref.)

PHYSIOLOGY

Mechanical stress–cell function relationships in renal cells [editorial] Harris RC, et al. **Exp Nephrol** 1997 Jul–Aug; 5(4):263–70 (85 ref.)

RADIOGRAPHY

Proximal ureter obstruction caused by a lower polar renal artery: demonstration with spiral CT angiography. Lee JY, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):641–2 (7 ref.)

RENAL ARTERY

Spiral (helical) CT of the renal vasculature. Rubin GD. **Semin Ultrasound CT MR** 1996 Aug;17(4):374–97 (33 ref.)

SURGERY

Kidney salvage in a case of ruptured renal artery aneurysm: case report and literature review. Schorn B, et al. **Cardiovasc Surg** 1997 Feb;5(1):134–6 (21 ref.)

Surgical methods for renal revascularization. Fujitani RM, et al. **Semin Vasc Surg** 1996 Sep;9(3):198–217 (58 ref.)

Abdominal aortic aneurysm and congenital pelvic kidney. A rare association. Glock Y, et al. **Tex Heart Inst J** 1997; 24(2):131–3 (5 ref.)

ULTRASONOGRAPHY

The use of duplex sonography in the diagnosis of renal artery stenosis. Riehl J, et al. **Eur J Med Res** 1997 Jan;2(1):14–22 (62 ref.)

RENAL ARTERY OBSTRUCTION

see related

HYPERTENSION, RENOVASCULAR

New thoughts and unsolved problems in atheromatous renovascular disease. Missouris CG, et al. **Contrib Nephrol** 1996;119:39–44 (11 ref.)

Management of renal artery stenosis in conjunction with aortic aneurysm. Ballard JL. **Semin Vasc Surg** 1996 Sep; 9(3):221–30 (57 ref.)

[Renal artery stenosis] Kanazawa M, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):326–9 (5 ref.) **(Jpn)**

[Renal arterial thrombosis, renal arterial embolism, renal artery occlusion] Yoshimura M, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):330–3 (8 ref.) **(Jpn)**

COMPLICATIONS

Ischemic renal failure. Zucchelli P, et al. **Contrib Nephrol** 1996;119:59–66 (45 ref.)

Renovascular disease: the fifth frontier. Nicholls A. **J R Soc Med** 1997 Jun;90(6):315–8 (43 ref.)

Renal arterial disease and hypertension. Dustan HP. **Med Clin North Am** 1997 Sep;81(5):1199–212 (65 ref.)

DIAGNOSIS

Radiographic evaluation of the renal vasculature. Textor SC, et al. **Curr Opin Nephrol Hypertens** 1996 Nov;5(6):541–51 (61 ref.)

Renal artery stenosis towards the year 2000. Derkx FH, et al. **J Hypertens Suppl** 1996 Dec;14(5):S167–72 (28 ref.)

Renal MR angiography. Borrello JA. **Magn Reson Imaging Clin N Am** 1997 Feb;5(1):83–93 (49 ref.)

Renal vascular lesions in the elderly: nephrosclerosis or atheromatous renal disease? Meyrier A. **Nephrol Dial Transplant** 1996;11 Suppl 9:45–52 (60 ref.)

Noninvasive assessment of renal artery stenosis. Dawson DL. **Semin Vasc Surg** 1996 Sep;9(3):172–81 (65 ref.)

[Diagnosis and therapy of hypertension with renal artery stenosis (see comments)] Postma CT, et al. **Ned Tijdschr Geneeskd** 1996 Oct 26;140(43):2114–8 (22 ref.) Comment in: Ned Tijdschr Geneeskd 1997 Jan 4;141(1):64–5. **(Dut)**

[Nephrology update—III. Renal artery stenosis—rational diagnosis] Sperschneider H, et al. **Med Klin** 1996 Aug 15; 91(8):517–20 (21 ref.) **(Ger)**

DRUG THERAPY

ACE inhibitors and unilateral renal artery stenosis—what price? Kothari SS. **Int J Cardiol** 1996 Mar;53(3):199–201 (22 ref.)

ETIOLOGY

Atherosclerotic renovascular disease: clinical clues and natural history. Gosset J, et al. **J Endovasc Surg** 1997 Aug; 4(3):316–20 (27 ref.)

Atherosclerosis and the kidney. Scoble JE. **J R Coll Physicians Lond** 1997 Jan–Feb;31(1):19–22 (19 ref.)

PHYSIOPATHOLOGY

Revascularization of the occluded renal artery. Chaikof EL. **Semin Vasc Surg** 1996 Sep;9(3):218–20 (22 ref.)

PREVENTION & CONTROL

Renal artery stenosis in the nineties: screening dilemmas. Salvetti A, et al. **Contrib Nephrol** 1996;119:45–53 (26 ref.)

RADIOGRAPHY

Is there a role for non-invasive screening tests in diagnosing renal artery stenosis? [editorial] Pickering TG, et al. **J Hypertens** 1996 Nov;14(11):1265–6 (9 ref.)

RADIONUCLIDE IMAGING

Nuclear medicine imaging in renovascular disease: the nephrologist's view [editorial] Scoble JE. **Nucl Med Commun** 1997 Jun;18(6):503–4 (13 ref.)

SURGERY

David M. Hume memorial lecture. Surgical treatment of renovascular hypertension. Stanley JC. **Am J Surg** 1997 Aug;174(2):102–10 (75 ref.)

The use of captopril testing in the selection of patients for renal artery repair. Duschek S, et al. **Semin Vasc Surg** 1996 Sep;9(3):182–7 (26 ref.)

Surgical methods for renal revascularization. Fujitani RM, et al. **Semin Vasc Surg** 1996 Sep;9(3):198–217 (58 ref.)

[Therapy of renovascular hypertension in neurofibromatosis: surgical revascularization versus percutaneous transluminal angioplasty] Türler A, et al. **Vasa** 1996;25(4):368–72 (34 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Renal artery stenosis towards the year 2000. Derkx FH, et al. **J Hypertens Suppl** 1996 Dec;14(5):S167–72 (28 ref.)

Management of renal artery stenosis in conjunction with aortic aneurysm. Ballard JL. **Semin Vasc Surg** 1996 Sep; 9(3):221–30 (57 ref.)

Revascularization of the occluded renal artery. Chaikof EL. **Semin Vasc Surg** 1996 Sep;9(3):218–20 (22 ref.)

The indications and results of percutaneous transluminal angioplasty and stenting in renal artery stenosis. Kidney DD, et al. **Semin Vasc Surg** 1996 Sep;9(3):188–97 (54 ref.)

[Diagnosis and therapy of hypertension with renal artery stenosis (see comments)] Postma CT, et al. **Ned Tijdschr Geneeskd** 1996 Oct 26;140(43):2114–8 (22 ref.) Comment in: Ned Tijdschr Geneeskd 1997 Jan 4;141(1):64–5. **(Dut)**

[The successful percutaneous revascularization of a subacute renal artery obstruction] Weishaupt D, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Mar;166(3):269–72 (15 ref.) **(Ger)**

ULTRASONOGRAPHY

The use of duplex sonography in the diagnosis of renal artery stenosis. Riehl J, et al. **Eur J Med Res** 1997 Jan;2(1):14–22 (62 ref.)

Doppler ultrasound of the kidney. Platt JF. **Semin Ultrasound CT MR** 1997 Feb;18(1):22–32 (81 ref.)

Duplex Doppler evaluation of acute renal obstruction. Platt JF. **Semin Ultrasound CT MR** 1997 Apr;18(2):147–53 (36 ref.)

RENAL ARTERY STENOSIS see **RENAL ARTERY OBSTRUCTION**

RENAL BLOOD FLOW see **RENAL CIRCULATION**

RENAL BLOOD FLOW, EFFECTIVE

PHYSIOLOGY

Glomerular hemodynamics in acute renal failure. Boim MA, et al. **Ren Fail** 1997 Mar;19(2):209–12 (17 ref.)

RENAL CALCULI see **KIDNEY CALCULI**

RENAL CIRCULATION

Role of the renal medulla in volume and arterial pressure regulation. Cowley AW Jr. **Am J Physiol** 1997 Jul;273(1 Pt 2):R1–15 (109 ref.)

Vasculitis and the kidney. Rees AJ. **Curr Opin Nephrol Hypertens** 1996 May;5(3):273–81 (122 ref.)

Radiographic evaluation of the renal vasculature. Textor SC, et al. **Curr Opin Nephrol Hypertens** 1996 Nov;5(6):541–51 (61 ref.)

Purinoceptor-mediated regulation of the renal microvasculature. Inscho EW. **J Auton Pharmacol** 1996 Dec;16(6):385–8 (20 ref.)

Vasculitis and the kidney. Kallenberg CG. **Kidney Blood Press Res** 1997;20(3):194–7 (15 ref.)

Methods of renal blood flow measurement. Young LS, et al. **Urol Res** 1996;24(3):149–60 (85 ref.)

DRUG EFFECTS

Insulin resistance and salt sensitivity. A renal hemodynamic abnormality? Weir MR. **Am J Hypertens** 1996 Dec;9(12 Pt 2):193S–199S (74 ref.)

Renal haemodynamic and protective effects of calcium antagonists in hypertension. Zanchi A, et al. **J Hypertens** 1995 Dec;13(12 Pt 1):1363–75 (134 ref.)

Impact of nitric oxide on renal hemodynamics and glomerular function: modulation by atherogenic lipoproteins? Galle J, et al. **Kidney Blood Press Res** 1996;19(1):2–15 (180 ref.)

PHYSIOLOGY

Review article: renal circulatory changes in cirrhosis—pathogenesis and therapeutic prospects. Forrest EH, et al. **Aliment Pharmacol Ther** 1996 Jun;10(3):219–31 (121 ref.)

Renal hemodynamic mechanisms of blood pressure rhythms. Pons M, et al. **Ann N Y Acad Sci** 1996 Aug 15;783:95–112 (66 ref.)

Physiological role of endothelin in cardiovascular and renal hemodynamics: studies in animals. Gellai M. **Curr Opin Nephrol Hypertens** 1997 Jan;6(1):64–8 (50 ref.)

Physiological role of the endothelin system in human cardiovascular and renal haemodynamics. Webb D. **Curr Opin Nephrol Hypertens** 1997 Jan;6(1):69–73 (46 ref.)

Regulation of renal sodium and water excretion in the nephrotic syndrome and cirrhosis of the liver. Jespersen B. **Dan Med Bull** 1997 Apr;44(2):191–207 (230 ref.)

Adrenomedullin: a new peptide involved in cardiorenal homeostasis? Edwards RM, et al. **Exp Nephrol** 1997 Jan–Feb;5(1):18–22 (25 ref.)

Nitric oxide and renal autoregulation. Just A. **Kidney Blood Press Res** 1997;20(3):201–4 (60 ref.)

Pathogenesis of chronic renal failure in the primary glomerulopathies, renal vasculopathies, and chronic interstitial nephritides. Bohle A, et al. **Kidney Int Suppl** 1996 May;54:S2–9 (44 ref.)

Intradialytic renal haemodynamics—potential consequences for the management of the patient with acute renal failure [editorial] Manns M, et al. **Nephrol Dial Transplant** 1997 May;12(5):870–2 (18 ref.)

Neural control of renal function. DiBona GF, et al. **Physiol Rev** 1997 Jan;77(1):75–197 (1736 ref.)

The renal hemodynamic basis of diabetic nephropathy. O'Bryan GT, et al. **Semin Nephrol** 1997 Mar;17(2):93–100 (110 ref.)

RENAL CORTICAL NECROSIS see **KIDNEY CORTEX NECROSIS**

RENAL DIALYSIS UNITS, HOSPITAL see **HEMODIALYSIS UNITS, HOSPITAL**

RENAL DISEASE, END-STAGE see **KIDNEY FAILURE, CHRONIC**

RENAL FAILURE see **KIDNEY FAILURE**

RENAL FAILURE, ACUTE see **KIDNEY FAILURE, ACUTE**

RENAL FAILURE, CHRONIC see **KIDNEY FAILURE, CHRONIC**

RENAL FAILURE, END-STAGE see **KIDNEY FAILURE, CHRONIC**

RENAL INSUFFICIENCY see **KIDNEY FAILURE**

RENAL INSUFFICIENCY, ACUTE see **KIDNEY FAILURE, ACUTE**

RENAL INSUFFICIENCY, CHRONIC see **KIDNEY FAILURE, CHRONIC**

RENAL OSTEODYSTROPHY

Renal osteodystrophy. Hruska KA. **Baillieres Clin Endocrinol Metab** 1997 Apr;11(1):165–94 (86 ref.)

COMPLICATIONS

Slipped capital femoral epiphysis associated with renal failure osteodystrophy. Loder RT, et al. **J Pediatr Orthop** 1997 Mar–Apr;17(2):205–11 (33 ref.)

Is severe renal osteodystrophy a contraindication for recombinant human growth hormone treatment? Watkins SL. **Pediatr Nephrol** 1996 Jun;10(3):351–4 (22 ref.)

[Renal osteomalacia] Eguchi J, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):17–20 (12 ref.) **(Jpn)**

DIAGNOSIS

Bone disease in moderate renal failure: cause, nature and prevention. Bushinsky DA. **Annu Rev Med** 1997;48:167–76 (46 ref.)

Thoracic complications in uremic patients and in patients undergoing dialytic treatment: state of the art. Gavelli G, et al. **Eur Radiol** 1997;7(5):708–17 (76 ref.)

DRUG THERAPY

Vitamin D analogs: from renal bone disease to osteoporosis. Kanis JA. **Calcif Tissue Int** 1997 Jan;60(1):106–10 (42 ref.)

Use of erythropoietin, active vitamin D3 metabolites, and alkali agents in predialysis patients. Ismail N. **Semin Nephrol** 1997 Jul;17(4):270–84 (112 ref.)

[Current treatment of renal osteodystrophy in children] Macher MA, et al. **Arch Pediatr** 1997;4(2 Suppl 2):91s–94s (20 ref.) **(Fre)**

ETIOLOGY

Renal osteodystrophy. Bardin T. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):114S–118S (27 ref.)

GENETICS

[Idiopathic tubular proteinuria (Dent's disease)] Igarashi T. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):670–3 (17 ref.) **(Jpn)**

IMMUNOLOGY

Role of cytokines in renal osteodystrophy. Monier-Faugere MC, et al. **Curr Opin Nephrol Hypertens** 1997 Jul;

6(4):327–32 (87 ref.)

PATHOLOGY

Bone biopsy—beyond light microscopy and histodynamics [editorial] Moore PR, et al. **Nephrol Dial Transplant** 1997 Apr;12(4):659–63 (21 ref.)

THERAPY

Renal osteodystrophy. González EA, et al. **Curr Ther Endocrinol Metab** 1997;6:540–6 (4 ref.)

Renal hypophosphatemic rickets. Hanna JD, et al. **Curr Ther Endocrinol Metab** 1997;6:533–40 (19 ref.)

RENAL PAPILLITIS, NECROTIZING see **KIDNEY PAPILLARY NECROSIS**

RENAL PLASMA FLOW, EFFECTIVE

[The measurement of renal plasma flow] Nagai T. **Nippon Rinsho** 1997 Apr;55 Suppl 2:597–600 (6 ref.) **(Jpn)**

RENAL REPLACEMENT THERAPY

see related
KIDNEY
KIDNEY DISEASES

HIV infection: challenges for dialysis personnel. Bradley-Springer L. **Adv Ren Replace Ther** 1996 Oct; 3(4):293–7 (35 ref.)

Staphylococcus aureus vaccination for dialysis patients—an update. Fattom AI, et al. **Adv Ren Replace Ther** 1996 Oct; 3(4):302–8 (57 ref.)

Hepatitis C in dialysis patients. Natov SN, et al. **Adv Ren Replace Ther** 1996 Oct;3(4):275–83 (83 ref.)

Maintenance of employment on dialysis. Rasgon S, et al. **Adv Ren Replace Ther** 1997 Apr;4(2):152–9 (26 ref.)

Transport characteristics of the slow therapies: implications for achieving adequacy of dialysis in acute renal failure. Sigler MH. **Adv Ren Replace Ther** 1997 Jan;4(1):68–80 (38 ref.)

Renal replacement therapy in acute renal failure. McCarthy JT. **Curr Opin Nephrol Hypertens** 1996 Nov;5(6):480–4 (38 ref.)

De novo diabetes in dialysis patients: when diabetes is not diabetic nephropathy [editorial] Catalano C. **Nephrol Dial Transplant** 1996 Jun;11(6):938–41 (21 ref.)

Will pimagidine improve survival of diabetics on dialysis? Friedman EA. **Nephrol Dial Transplant** 1996 Aug; 11(8):1524–7 (44 ref.)

Renal replacement therapy in the elderly: an old problem with young solutions [editorial] Ismail N. **Nephrol Dial Transplant** 1997 May;12(5):873–6 (31 ref.)

Outcome of renal replacement therapy in autosomal dominant polycystic kidney disease. Pirson Y, et al. **Nephrol Dial Transplant** 1996;11 Suppl 6:24–8 (31 ref.)

Autosomal dominant polycystic kidney disease—the patient on renal replacement therapy. Zeier M, et al. **Nephrol Dial Transplant** 1996;11 Suppl 6:18–20 (17 ref.)

Optimizing end-stage renal disease therapy for the patient with diabetes mellitus. Friedlander MA, et al. **Semin Nephrol** 1997 Jul;17(4):331–45 (107 ref.)

[Uremia: pathophysiologic sequelae and indications for kidney replacement therapy] Jakob SM, et al. **Schweiz Med Wochenschr** 1997 Jun 21;127(25):1077–81 (20 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Can cardiovascular complications be prevented in dialysis patients? Raine AE. **Adv Nephrol Necker Hosp** 1996; 25:317–39 (103 ref.)

Kinetics of intradialytic disequilibria: the problem, the causes, and new methods for the alleviation of patient morbidity. Kelly TD. **Nephrol Dial Transplant** 1996;11 Suppl 8:3–9 (40 ref.)

Should hyperlipidaemia in dialysis patients be treated? [editorial] Wheeler DC. **Nephrol Dial Transplant** 1997 Jan; 12(1):19–21 (10 ref.)

METHODS

Kinetics of intradialytic disequilibria: the problem, the causes, and new methods for the alleviation of patient morbidity. Kelly TD. **Nephrol Dial Transplant** 1996;11 Suppl 8:3–9 (40 ref.)

Urea, sodium, and water changes in profiling dialysis. Mann H, et al. **Nephrol Dial Transplant** 1996;11 Suppl 8:10–5 (12 ref.)

Options for renal replacement therapy: special considerations. Becker BN, et al. **Semin Nephrol** 1997 May;17(3):176–87 (71 ref.)

[Indications for and problems in active therapy of uremic patients (editorial)] Forsström J. **Duodecim** 1995; 111(15):1395–8 (8 ref.) **(Fin)**

[Active treatment of renal disease in Finland] Stenman S, et al. **Duodecim** 1995;111(15):1497–504 (17 ref.) **(Fin)**

[Choice of renal replacement therapy] Favre H. **Schweiz Med Wochenschr** 1997 Jun 21;127(25):1082–7 (19 ref.) (Eng. Abstr.) **(Fre)**

RENAL TRANSPLANTATION see **KIDNEY TRANSPLANTATION**

RENAL VEINS

Arteriovenous fistula following nephrectomy. Kajbafzadeh AM, et al. **Eur Urol** 1997;31(1):112–4 (12 ref.)

Leiomyosarcoma of the renal vein. Brandes SB, et al. **J Surg Oncol** 1996 Nov;63(3):195–200 (26 ref.)

[Intravenous leiomyomatosis of uterine origin with cardiac extension. A case report and review of the literature] Tribondeau P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(2):187–92 (33 ref.) (Eng. Abstr.) **(Fre)**

[Renal vein thrombosis] Matsui N. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):312–5 (15 ref.) **(Jpn)**

[Renal arteriovenous fistula] Taniyama Y, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):320–2 (10 ref.) **(Jpn)**

ABNORMALITIES

Spontaneous renal arteriovenous fistula as a cause of haematuria. Fogazzi GB, et al. **Nephrol Dial Transplant** 1997 Feb;12(2):350–6 (67 ref.)

PATHOLOGY

Venous aneurysms: MR diagnosis with the "layered gadolinium" sign. Krinsky G, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):623–7 (12 ref.)

Renal MR angiography. Borrello JA. **Magn Reson Imaging Clin N Am** 1997 Feb;5(1):83–93 (49 ref.)

[Nutcracker phenomenon] Ubara Y, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):289–92 (20 ref.) **(Jpn)**

ULTRASONOGRAPHY

Renal vein aneurysm: diagnosis with color Doppler sonography. Kabaalioğlu A, et al. **AJR Am J Roentgenol** 1997 Mar;168(3):645–6 (8 ref.)

RENIN

ANTAGONISTS & INHIBITORS

Renin inhibitors: cardiovascular drugs of the future? Wood JM, et al. **Cardiovasc Drugs Ther** 1996 Jul;10(3):309–12 (31 ref.)

Hepatobiliary elimination of certain peptide-mimicking drugs: linear hydrophobic and hydrophilic renin-inhibitors and hydrophobic cyclopeptides. Ziegler K, et al. **J Hepatol** 1996;24 Suppl 1:47–52 (22 ref.)

BIOSYNTHESIS

Regulation of renin synthesis in the juxtaglomerular cells. Della Bruna R, et al. **Curr Opin Nephrol Hypertens** 1996 Jan;5(1):16–9 (33 ref.)

[Juxtaglomerular cell tumor] Tanabe A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):33–5 (9 ref.) **(Jpn)**

DRUG EFFECTS

Effects of estrogens and progestogens on the renin–aldosterone system and blood pressure. Oelkers WK. **Steroids** 1996 Apr;61(4):166–71 (50 ref.)

ISOLATION & PURIFICATION

Purification and assay methods for angiotensin-converting enzyme. Meng QC, et al. **J Chromatogr A** 1996 Aug 30; 743(1):105–22 (113 ref.)

PHYSIOLOGY

Local renin-angiotensin system: especially in coagulating glands of mice. Kon Y. **Arch Histol Cytol** 1996 Dec; 59(5):399–420 (207 ref.)

SECRETION

Serotonergic regulation of renin and prolactin secretion. Van de Kar LD, et al. **Behav Brain Res** 1996;73(1-2):203–8 (44 ref.)

Renin secretion in Lyon hypertensive rats. Julien C, et al. **Clin Exp Hypertens** 1997 Jul–Aug;19(5–6):699–711 (26 ref.)

Comments on different states of secretory autonomy of juxtaglomerular cell tumors of the kidney [editorial] Kihara I. **Intern Med** 1996 Apr;35(4):239–40 (13 ref.)

RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM see **RENIN-ANGIOTENSIN SYSTEM**

RENIN-ANGIOTENSIN SYSTEM

see related
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Renin angiotensin system in development of mice and men [comment] Fogo A, et al. **Am J Pathol** 1996 Dec; 149(6):1797–801 (32 ref.) Comment on: Am J Pathol 1996 Dec;149(6):2067–79.

The role of the renin-angiotensin system in the pathophysiology of cardiac remodeling. Booz GW, et al. **Blood Press Suppl** 1996;2:10–8 (67 ref.)

DRUG EFFECTS

Effects of angiotensin-converting enzyme inhibition and angiotensin II AT1 receptor antagonism on cardiac parameters in left ventricular hypertrophy. Zhu YC, et al. **Am J Cardiol** 1997 Aug 4;80(3A):110A–117A (65 ref.)

Tissue renin-angiotensin system: a site of drug action? Zimmerman BG, et al. **Annu Rev Pharmacol Toxicol** 1997; 37:53–69 (87 ref.)

Angiotensin II type 1 receptor induced signal-transduction pathways as new targets for pharmacological treatment of the renin-angiotensin system. Schorb W, et al. **Basic Res Cardiol** 1996;91 Suppl 2:91–6 (35 ref.)

Renin inhibitors: cardiovascular drugs of the future? Wood JM, et al. **Cardiovasc Drugs Ther** 1996 Jul;10(3):309–12 (31 ref.)

Inhibition of the renin-angiotensin-aldosterone system in heart failure: new insights from basic clinical research. Cleland JG, et al. **Curr Opin Cardiol** 1996 May;11(3):252–62 (101 ref.)

Renal responses to antagonism of the renin-angiotensin system. Braam B, et al. **Curr Opin Nephrol Hypertens** 1996 Jan;5(1):89–96 (69 ref.)

Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease. Burrell LM, et al. **Drugs Aging** 1997 Jun;10(6):421–34 (65 ref.)

Impact of renin-angiotensin system blockade on structure and function of glomerular membrane components in animal models of kidney disease. Remuzzi A, et al. **Exp Nephrol** 1996;4 Suppl 1:27–33 (57 ref.)

Population characteristics and the modulation of the renin-angiotensin system in the treatment of hypertension. Weir MR. **J Hum Hypertens** 1997 Jan;11(1):17–21 (29 ref.)

Inhibitors of the renin-angiotensin system. Krum H. **Med J Aust** 1997 Jul 7;167(1):38–40 (19 ref.)

[Inhibition of the renin-angiotensin system: ACE inhibitors and angiotensin II receptor blockers] Pichler M, et al. **Wien Med Wochenschr** 1996;146(11):228–31 (35 ref.) (Eng. Abstr.) **(Ger)**

[Pathophysiological mechanisms of the renin-angiotensin system and its pharmacologic modification by ACE inhibitors or angiotensin II (type 1) receptor blockers in cardiovascular diseases] Huber K, et al. **Z Kardiol** 1997 Apr;86(4):239–50 (124 ref.) (Eng. Abstr.) **(Ger)**

[The use of angiotensin-converting enzyme inhibitors and the function of the renin-angiotensin-aldosterone system in chronic glomerulonephritis (a review of the literature and the author's own data)] Ospanova TS. **Lik Sprava** 1996 Jul–Sep;(7–9):22–6 (29 ref.) **(Rus)**

GENETICS

Adaptive and genetic alterations of the renin angiotensin system in cardiac hypertrophy and failure. Holmer SR, et al. **Basic Res Cardiol** 1996;91 Suppl 2:65–71 (53 ref.)

Hypertension, thermotolerance, and the "African gene": an hypothesis. Moskowitz DW. **Clin Exp Hypertens** 1996 Jan; 18(1):1–19 (97 ref.)

Transgenic rats: tools to study the function of the renin-angiotensin system. Bader M, et al. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S81–7 (80 ref.)

Genetics of the renin-angiotensin system and renal disease: a progress report. Schmidt S, et al. **Curr Opin Nephrol Hypertens** 1997 Mar;6(2):146–51 (57 ref.)

Genetic approach to diagnostic and therapeutic decisions in human hypertension [see comments] Williams GH, et al. **Curr Opin Nephrol Hypertens** 1997 Mar;6(2):199–204 (64 ref.) Comment in: Curr Opin Nephrol Hypertens 1997 Mar;6(2):167–8.

Gene targeting in nephrology. Matsusaka T, et al. **Exp Nephrol** 1997 Mar–Apr;5(2):168–73 (40 ref.)

Cardiovascular disease and genetics of the renin-angiotensin system. Harrap SB. **Heart** 1996 Nov;76(3 Suppl 3):13–7 (52 ref.)

Polymorphisms of the renin-angiotensin system genes in progressive renal diseases [editorial] Yoshida H, et al. **Kidney Int** 1996 Sep;50(3):732–44 (137 ref.)

Molecular genetics of the renin-angiotensin-aldosterone system in human hypertension. Corvol P, et al. **Pathol Biol (Paris)** 1997 Mar;45(3):229–39 (74 ref.)

[Genetic polymorphism of the renin-angiotensin system and cardiovascular diseases] Castellano M, et al. **Cardiologia** 1997 Aug;42(8):803–13 (127 ref.) **(Ita)**

[Pathogenetic importance of gene polymorphisms in the renin-angiotensin system] Chudek J, et al. **Pol Arch Med Wewn** 1996 Oct;96(4):369–77 (79 ref.) **(Pol)**

[The role of DNA polymorphism in the renin-angiotensin system and the pathogenesis of cardiovascular diseases] Stajszczyk M, et al. **Postepy Hig Med Dosw** 1997; 51(2):171–83 (56 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

The renin-angiotensin system and fibrinolysis. Vaughan DE. **Am J Cardiol** 1997 Mar 6;79(5A):12–6 (29 ref.)

The implication of renin-angiotensin system on renal injury seen in Dahl salt-sensitive rats. Hirawa N, et al. **Am J Hypertens** 1997 May;10(5 Pt 2):102S–106S (19 ref.)

Local renin-angiotensin system: especially in coagulating

glands of mice. Kon Y. **Arch Histol Cytol** 1996 Dec; 59(5):399–420 (207 ref.)

Activated tissue renin–angiotensin systems add to the progression of heart failure. Pinto YM, et al. **Basic Res Cardiol** 1996;91 Suppl 2:85–90 (25 ref.)

Effect of the renin–angiotensin–aldosterone system on the cardiac interstitium in heart failure. Wilke A, et al. **Basic Res Cardiol** 1996;91 Suppl 2:79–84 (33 ref.)

Physiologic and pharmacologic implications of AT1 versus AT2 receptors. Chung O, et al. **Blood Press Suppl** 1996; 2:47–52 (48 ref.)

Blood pressure control by the renin–angiotensin system and its interaction with the sympathetic nervous system in fish. Platzack B. **Braz J Med Biol Res** 1995 Nov–Dec; 28(11–12):1227–31 (31 ref.)

Activation of the neuroendocrine response in heart failure: adaptive or maladaptive process? Ferrari R, et al. **Cardiovasc Drugs Ther** 1996 Nov;10 Suppl 2:623–9 (68 ref.)

Pathologic consequences of increased angiotensin II activity. Ferrario CM, et al. **Cardiovasc Drugs Ther** 1996 Nov; 10(5):511–8 (100 ref.)

Role of the renin–angiotensin system as a risk factor for control of morbidity and mortality in coronary artery disease. Riegger GA. **Cardiovasc Drugs Ther** 1996 Nov;10 Suppl 2:613–5 (19 ref.)

Stretching the evidence in the case of cardiac growth [see comments] Yamazaki T, et al. **Cardiovasc Res** 1996 Apr; 31(4):493–8 (45 ref.) Comment in: Cardiovasc Res 1996 Apr;31(4):492.

The renin–angiotensin–aldosterone system in pre–eclampsia. Brown MA, et al. **Clin Exp Hypertens** 1997 Jul–Aug; 19(5–6):713–26 (46 ref.)

Update on local cardiac renin–angiotensin system. Ruzicka M, et al. **Curr Opin Cardiol** 1997 Jul;12(4):347–53 (30 ref.)

Emerging concepts about the renin angiotensin system: present and future clinical applications. McLigeyo SO. **East Afr Med J** 1996 Sep;73(9):607–10 (39 ref.)

The intrarenal renin–angiotensin system: a paracrine system for the local control of renal function separate from the systemic axis. Harris RC, et al. **Exp Nephrol** 1996;4 Suppl 1:2–7 (66 ref.)

Impact of renin–angiotensin system blockade on structure and function of glomerular membrane components in animal models of kidney disease. Remuzzi A, et al. **Exp Nephrol** 1996;4 Suppl 1:27–33 (57 ref.)

The ovarian renin–angiotensin system in reproductive physiology. Yoshimura Y. **Front Neuroendocrinol** 1997 Jul; 18(3):247–91 (235 ref.)

Is there a link between the circulating renin–angiotensin system and coronary disease? A buoyant view. Alderman MH. **Heart** 1996 Nov;76(3 Suppl 3):18–22 (20 ref.)

Neuroendocrine activation after myocardial infarction: causes and consequences. Cleland JG, et al. **Heart** 1996 Nov;76(3 Suppl 3):53–9 (68 ref.)

Is there an internal cardiac renin–angiotensin system? Danser AH, et al. **Heart** 1996 Nov;76(3 Suppl 3):28–32 (39 ref.)

The renin–angiotensin system and coronary vasomotion. Ertl G, et al. **Heart** 1996 Nov;76(3 Suppl 3):45–52 (106 ref.)

The renin–angiotensin–aldosterone system and cardiac ischaemia. Ikram H. **Heart** 1996 Nov;76(3 Suppl 3):60–7 (99 ref.)

The renin–angiotensin system and cardiac remodelling after acute myocardial infarction. Ikram H. **Heart** 1996 Nov;76(3 Suppl 3):68–72 (33 ref.)

The renin–angiotensin system and the heart: beyond 2000. Morgan T, et al. **Heart** 1996 Nov;76(3 Suppl 3):98–103 (42 ref.)

The renin–angiotensin–aldosterone system and the cardiac natriuretic peptides. Richards AM. **Heart** 1996 Nov;76(3 Suppl 3):36–44 (80 ref.)

Is there a link between the circulating renin–angiotensin system and coronary disease? A sceptical view. Swales JD. **Heart** 1996 Nov;76(3 Suppl 3):23–7 (40 ref.)

The renin–angiotensin system and cardiac hypertrophy. Yamazaki T, et al. **Heart** 1996 Nov;76(3 Suppl 3):33–5 (30 ref.)

Dual role of angiotensin II in the human endometrium. Li XF, et al. **Hum Reprod** 1996 Oct;11 Suppl 2:95–108 (74 ref.)

Tissue renin–angiotensin systems and reproduction. Vinson GP, et al. **Hum Reprod** 1997 Apr;12(4):651–62 (176 ref.)

The renin–angiotensin system and vascular hypertrophy. Rosendorff C. **J Am Coll Cardiol** 1996 Oct;28(4):803–12 (131 ref.)

The role of the cardiac renin–angiotensin system in load–induced cardiac hypertrophy. Sadoshima J, et al. **J Card Fail** 1996 Dec;2(4 Suppl):S1–6 (43 ref.)

Growth or antigrowth: angiotensin and the endothelium. Stoll M, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1529–34 (48 ref.)

Alterations of signal transduction system in heart failure. Kawaguchi H, et al. **Jpn Heart J** 1997 May;38(3):317–32 (48 ref.)

Activated and inactivated renin–angiotensin system in transgenic animals: from genes to blood pressure. Fukamizu A, et al. **Lab Anim Sci** 1997 Apr;47(2):127–31 (36 ref.)

The application of molecular genetic techniques to the study of hypertensive diseases. Re RN. **Med Clin North Am** 1997 Sep;81(5):1099–112 (126 ref.)

Insulin, the renin–angiotensin–aldosterone system and blood pressure. Tait JF, et al. **Perspect Biol Med** 1997 Winter; 40(2):246–59 (64 ref.)

The renin–angiotensin–aldosterone system: focus on its distinct role in arterial hypertension and its various inhibitors as a therapeutic strategy to effectively lower blood pressure. Soldner A, et al. **Pharmazie** 1996 Nov; 51(11):783–99 (239 ref.)

[Ovarian renin–angiotensin system] Wu X, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Jul;31(7):434–6 (17 ref.) **(Chi)**

[Effect of the cardiac renin–angiotensin system on hypertrophy] Ertl G, et al. **Z Kardiol** 1996;85 Suppl 6:233–40 (58 ref.) (Eng. Abstr.) **(Ger)**

[The cardiac renin–angiotensin system and its role in ventricular hypertrophy associated with arterial hypertension] Rubattu S, et al. **Cardiologia** 1997 Jan; 42(1):47–50 (36 ref.) **(Ita)**

[The ovarian renin–angiotensin–aldosterone system] Pizzo A, et al. **Minerva Ginecol** 1996 Dec;48(12):539–44 (33 ref.) (Eng. Abstr.) **(Ita)**

[Role of the renin–angiotensin system in cardiovascular and renal diseases] Kim S. **Nippon Yakurigaku Zasshi** 1997 May; 109(5):223–33 (41 ref.) (Eng. Abstr.) **(Jpn)**

[Genetics of human hypertension: renin–angiotensin–aldosterone system] Markel' AL, et al. **Vestn Ross Akad Med Nauk** 1997;(7):59–66 (60 ref.) **(Rus)**

[Tissue angiotensin II and its impact in the treatment of arterial hypertension] Escobar–Morreale HF, et al. **Med Clin (Barc)** 1997 Jan 25;108(3):105–8 (63 ref.) **(Spa)**

RENIN–SUBSTRATE see **ANGIOTENSINOGEN**

RENOGRAPHY see **RADIOISOTOPE RENOGRAPHY**

REOPERATION

METHODS

Revision of failed prosthetic anterior cruciate ligament reconstruction. Greis PE, et al. **Clin Orthop** 1996 Apr; (325):78–90 (34 ref.)

Graft selection in anterior cruciate ligament revision surgery. Ritchie JR, et al. **Clin Orthop** 1996 Apr;(325):65–77 (58 ref.)

Technical considerations of revision anterior cruciate ligament surgery. Safran MR, et al. **Clin Orthop** 1996 Apr; (325):50–64 (24 ref.)

[Clinical significance and subject of second look operation] Yakushiji M, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Aug;48(8):761–8 (19 ref.) **(Jpn)**

REOVIRIDAE

ISOLATION & PURIFICATION

Reovirus type 1 associated with meningitis. Johansson PJ, et al. **Scand J Infect Dis** 1996;28(2):117–20 (11 ref.)

REOVIRIDAE INFECTIONS

DIAGNOSIS

Reovirus type 1 associated with meningitis. Johansson PJ, et al. **Scand J Infect Dis** 1996;28(2):117–20 (11 ref.)

REOVIRUS INFECTIONS see **REOVIRIDAE INFECTIONS**

REOVIRUSES, AQUATIC see **REOVIRIDAE**

REPEAT CESAREAN SECTION see **CESAREAN SECTION, REPEAT**

REPERFUSION

Volume expansion during cardiopulmonary resuscitation reduces cerebral no–reflow. Fischer M, et al. **Resuscitation** 1996 Oct;32(3):227–40 (66 ref.)

[Intestinal reperfusion: the physiopathological fundamentals of its therapeutic prospects] Rodríguez García JI, et al. **Rev Esp Enferm Dig** 1997 Jan;89(1):39–45 (74 ref.) **(Spa)**

METHODS

[Reduction of amputation incidence and mortality following prolonged ischemia of the lower limbs. Value of a controlled reperfusion?] Defraigne JO, et al. **Rev Med Liege** 1996 Aug;51(8):534–44 (57 ref.) **(Fre)**

REPERFUSION INJURY

Reperfusion of the brain after global ischemia: hemodynamic disturbances. Hossmann KA. **Shock** 1997 Aug;8(2):95–101; discussion 102–3 (129 ref.)

Transplantation–induced injuries of the intestinal muscularis and its innervation: from preservation to chronic rejection. Bauer AJ. **Transplant Proc** 1996 Oct;28(5):2539–41 (11 ref.)

[Progresses in physiopathology in China, 1996] Jin H. **Chung Hua I Hsueh Tsa Chih** 1996 Dec;76(12):945–6 (0 ref.) **(Chi)**

[Pneumatic tourniquets in orthopedics] Estebe JP, et al. **Ann Fr Anesth Reanim** 1996;15(2):162–78 (211 ref.) (Eng. Abstr.) **(Fre)**

[Myonephropathic metabolic syndrome (MNMS)] Shimai S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):469–71 (11 ref.) **(Jpn)**

BLOOD

Ischemia/reperfusion–induced leukocyte–endothelial interactions in postcapillary venules. Eppihimer MJ, et al. **Shock** 1997 Jul;8(1):16–25 (85 ref.)

[Neutrophils and ischemia reperfusion injury] Xing X, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1996 Mar;12(2):138–40 (25 ref.) **(Chi)**

COMPLICATIONS

Reperfusion injury as the mechanism of brain damage after perinatal asphyxia. Fellman V, et al. **Pediatr Res** 1997 May; 41(5):599–606 (138 ref.)

DIET THERAPY

Fatty acid oxidation in the heart. Grynberg A, et al. **J Cardiovasc Pharmacol** 1996;28 Suppl 1:S11–7 (21 ref.)

ETIOLOGY

Reperfusion injury after liver preservation for transplantation. Lemasters JJ, et al. **Annu Rev Pharmacol Toxicol** 1997;37:327–38 (89 ref.)

The role of nitric oxide and cell adhesion molecules on the microcirculation in ischaemia–reperfusion. Lefer AM, et al. **Cardiovasc Res** 1996 Oct;32(4):743–51 (70 ref.)

METABOLISM

Free radicals and heat shock protein in the heart. Kukreja RC, et al. **Ann N Y Acad Sci** 1996 Sep 30;793:108–22 (64 ref.)

Heat shock–induced myocardial protection against ischemic injury: a role for Hsp70? Plumier JC, et al. **Cell Stress Chaperones** 1996 Apr;1(1):13–7 (51 ref.)

Direct measurement of free radicals in ischemic/reperfused diabetic rat retina. Szabo ME, et al. **Clin Neurosci** 1997; 4(5):240–5 (40 ref.)

Metabolic and clonogenic consequences of ischaemia reperfusion insult in solid tumours. Parkins CS, et al. **Exp Physiol** 1997 Mar;82(2):361–8 (22 ref.)

Poly–phosphoinositide–mediated messengers in focal cerebral ischemia and reperfusion. Sun GY, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):137–45 (19 ref.)

Involvement of cytokine production in pathogenesis of transient cerebral ischemic damage. Yamasaki Y, et al. **Keio J Med** 1996 Sep;45(3):225–9 (16 ref.)

Prevention of reperfusion–induced, free radical–mediated acute endothelial injury by superoxide dismutase as an effective tool to delay/prevent chronic renal allograft failure: a review. Land W, et al. **Transplant Proc** 1997 Sep; 29(6):2567–8 (7 ref.)

PATHOLOGY

Endothelial damage caused by ischemia and reperfusion and different ventilatory strategies in the lung. Moore TM, et al. **Chin J Physiol** 1996;39(2):65–81 (132 ref.)

PHYSIOPATHOLOGY

Protection by preconditioning and cardiac pacing against ventricular arrhythmias resulting from ischemia and reperfusion. Parratt JR, et al. **Ann N Y Acad Sci** 1996 Sep 30;793:98–107 (42 ref.)

The role of Na+/H+ exchange in ischemia–reperfusion. Piper HM, et al. **Basic Res Cardiol** 1996 May–Jun; 91(3):191–202 (91 ref.)

Endothelial damage caused by ischemia and reperfusion and different ventilatory strategies in the lung. Moore TM, et al. **Chin J Physiol** 1996;39(2):65–81 (132 ref.)

Ischemic injury of optic nerve axons: the nuts and bolts. Fern R, et al. **Clin Neurosci** 1997;4(5):246–50 (32 ref.)

Reperfusion damage following focal ischemia: pathophysiology and therapeutic windows. Kuroda S, et al. **Clin Neurosci** 1997;4(4):199–212 (211 ref.)

Metabolic and clonogenic consequences of ischaemia reperfusion insult in solid tumours. Parkins CS, et al. **Exp Physiol** 1997 Mar;82(2):361–8 (22 ref.)

Mechanisms of postischemic injury in skeletal muscle: intervention strategies. Rubin BB, et al. **J Appl Physiol** 1996 Feb;80(2):369–87 (220 ref.)

The microvascular cell and ischemia–reperfusion injury. Verrier E. **J Cardiovasc Pharmacol** 1996;27 Suppl 1:S26–30 (20 ref.)

Protection against ischemic–reperfusion injury of skeletal muscle: role of ischemic preconditioning and adenosine pretreatment. Lee HT, et al. **J Reconstr Microsurg** 1996 Aug;12(6):383–8 (39 ref.)

Reperfusion injury. Ar'Rajab A, et al. **New Horiz** 1996 May; 4(2):224–34 (115 ref.)

Shock: ischemia, reperfusion, and inflammation. Waxman K. **New Horiz** 1996 May;4(2):153–60 (69 ref.)

Ischaemia–reperfusion mechanisms in acute pancreatitis. Toyama MT, et al. **Scand J Gastroenterol Suppl** 1996; 219:20–3 (24 ref.)

Remodeling of hepatic microvascular responsiveness after ischemia/reperfusion. Clemens MG, et al. **Shock** 1997 Aug; 8(2):80–5 (66 ref.)

Capillary dysfunction in striated muscle ischemia/reperfusion: on the mechanisms of capillary "no-reflow". Menger MD, et al. **Shock** 1997 Jul;8(1):2-7 (47 ref.)
The pathophysiological role of peroxynitrite in shock, inflammation, and ischemia-reperfusion injury. Szabó C. **Shock** 1996 Aug;6(2):79-88 (162 ref.)
Methods for studying microvascular barrier function in ischemia-reperfusion injury. Tucker VL, et al. **Shock** 1997 Jul;8(1):8-15 (48 ref.)
The role of leukocyte and endothelial adhesion molecules in ischemia-reperfusion injury. Thiagarajan RR, et al. **Thromb Haemost** 1997 Jul;78(1):310-4 (35 ref.)
[Reduction of amputation incidence and mortality following prolonged ischemia of the lower limbs. Value of a controlled reperfusion?] Defraigne JO, et al. **Rev Med Liege** 1996 Aug;51(8):534-44 (57 ref.) **(Fre)**
[The basic patterns of the ischemic and reperfusion changes in the tissues of the ischemic extremity and in the whole body] Tsapenko MV. **Klin Khir** 1996;(9):44-9 (49 ref.) **(Ukr)**

PREVENTION & CONTROL

Neuroprotection by the pyridoindole stobadine: a minireview. Stolc S, et al. **Brain Res Bull** 1997;42(5):335-40 (55 ref.)
Mechanisms of postischemic injury in skeletal muscle: intervention strategies. Rubin BB, et al. **J Appl Physiol** 1996 Feb;80(2):369-87 (220 ref.)
Protection against ischemic-reperfusion injury of skeletal muscle: role of ischemic preconditioning and adenosine pretreatment. Lee HT, et al. **J Reconstr Microsurg** 1996 Aug;12(6):383-8 (39 ref.)
The role of platelet-activating factor antagonists in the prophylaxis of posttransplant acute tubular necrosis. Grinyó JM, et al. **Ren Fail** 1996 May;18(3):445-51 (45 ref.)
Mechanism and protection from ischemic intestinal injury. Banda MA, et al. **Transplant Proc** 1996 Oct;28(5):2595-7 (27 ref.)
Reperfusion injury. Grinyó JM. **Transplant Proc** 1997 Feb-Mar;29(1-2):59-62 (67 ref.)
Rationale for the use of antioxidant vitamins in clinical organ transplantation. Lehr HA, et al. **Transplantation** 1996 Nov 15;62(9):1197-9 (47 ref.)

THERAPY

Anti-adhesion therapy. Cornejo CJ, et al. **Adv Pharmacol** 1997;39:99-142 (200 ref.)
Therapeutic approaches for clinical ischemia and reperfusion injury. Cryer HG. **Shock** 1997 Jul;8(1):26-32 (23 ref.)
Therapeutic modulation of free radical-mediated reperfusion injury of the liver and its surgical implications. Marubayashi S, et al. **Surg Today** 1996;26(8):573-80 (97 ref.)

REPERFUSION INJURY, MYOCARDIAL see **MYOCARDIAL REPERFUSION INJURY**

REPERFUSION, MYOCARDIAL see **MYOCARDIAL REPERFUSION**

REPETITION STRAIN INJURY see **CUMULATIVE TRAUMA DISORDERS**

REPETITIVE REGION see **REPETITIVE SEQUENCES, NUCLEIC ACID**

REPETITIVE SEQUENCES, NUCLEIC ACID

Dynamic mutations pose unique challenges for the molecular diagnostics laboratory [comment] McGlennen RC. **Clin Chem** 1996 Oct;42(10):1582-8 (16 ref.) Comment on: Clin Chem 1996 Oct;42(10):1601-3.
Transposable elements: how non-LTR retrotransposons do it. Finnegan DJ. **Curr Biol** 1997 Apr 1;7(4):R245-8 (16 ref.)
The origin of interspersed repeats in the human genome. Smit AF. **Curr Opin Genet Dev** 1996 Dec;6(6):743-8 (54 ref.)
The DNA structures at the ends of eukaryotic chromosomes. Wellinger RJ, et al. **Eur J Cancer** 1997 Apr;33(5):735-49 (244 ref.)
Repeat offenders: simple repeat sequences and complex genetic problems. Richards RI, et al. **Hum Mutat** 1996; 8(1):1-7 (66 ref.)
Inverted repeats, stem-loops, and cruciforms: significance for initiation of DNA replication. Pearson CE, et al. **J Cell Biochem** 1996 Oct;63(1):1-22 (225 ref.)
Biochemical and molecular basis of Bernard-Soulier syndrome: a review. de la Salle C, et al. **Nouv Rev Fr Hematol** 1995;37(4):215-22 (58 ref.)
Clinicopathology of spinocerebellar degeneration: its correlation to the unstable CAG repeat of the affected gene. Yagishita S, et al. **Pathol Int** 1997 Jan;47(1):1-15 (114 ref.)
Simple sequence repeats as a source of quantitative genetic variation. Kashi Y, et al. **Trends Genet** 1997 Feb;13(2):74-8 (82 ref.)
Epigenetic phenomena in filamentous fungi: useful paradigms or repeat-induced confusion? [see comments] Selker EU. **Trends Genet** 1997 Aug;13(8):296-301 (57 ref.) Comment in: Trends Genet 1997 Aug;13(8):293-5.
Reverse transcriptase: mediator of genomic plasticity. Brosius J, et al. **Virus Genes** 1995;11(2-3):163-79 (259 ref.)

GENETICS

Chromosomal instability and alteration of telomere repeat sequences. Pommier JP, et al. **Biochimie** 1995;77(10):817-25 (75 ref.)
Glutamine repeats and inherited neurodegenerative diseases: molecular aspects. Perutz MF. **Curr Opin Struct Biol** 1996 Dec;6(6):848-58 (62 ref.)
Considerations from the European DNA profiling group (EDNAP) concerning STR nomenclature. Gill P, et al. **Forensic Sci Int** 1997 Jun 23;87(3):185-92 (27 ref.)
DNA recommendations--further report of the DNA Commission of the ISFH regarding the use of short tandem repeat systems. Lincoln PJ. **Forensic Sci Int** 1997 Jun 23; 87(3):181-4 (4 ref.)
The phylogeny and molecular epidemiology of human T-cell lymphotropic virus type II. Heneine W. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S236-41 (17 ref.)
Evolution, expression, and possible function of a master gene for amplification of an interspersed repeated DNA family in rodents. Deininger PL, et al. **Prog Nucleic Acid Res Mol Biol** 1996;52:67-88 (62 ref.)

PHYSIOLOGY

Repeat-induced gene silencing: common mechanisms in plants and fungi. Meyer P. **Biol Chem Hoppe Seyler** 1996 Feb;377(2):87-95 (91 ref.)

REPLACEMENT THERAPY, ESTROGEN see **ESTROGEN REPLACEMENT THERAPY**

REPLANTATION

Thumb reconstruction. Brunelli GA, et al. **Bull Hosp Jt Dis** 1996;54(4):245-8 (21 ref.)
Total ear replantation. Kind GM, et al. **Plast Reconstr Surg** 1997 Jun;99(7):1858-67 (21 ref.)
[Replantation of amputated limb and digit] Tamai S. **Nippon Seikeigeka Gakkai Zasshi** 1996 Jul;70(7):380-90 (8 ref.) **(Jpn)**

ADVERSE EFFECTS

Clinical use of leeches in reconstructive surgery. Daane S, et al. **Am J Orthop** 1997 Aug;26(8):528-32 (36 ref.)

METHODS

Advances in digital replantation. Merle M, et al. **Clin Plast Surg** 1997 Jan;24(1):87-105 (27 ref.)

REPLICATION ORIGIN

Two steps to binding replication origins? DNA-protein interactions. Dean FB, et al. **Curr Biol** 1996 Aug 1; 6(8):931-4 (14 ref.)
Chromatin proteins involved in the initiation of DNA replication. Rowles A, et al. **Curr Opin Genet Dev** 1997 Apr;7(2):152-7 (57 ref.)
[Structure of origin of replication] Ariga H, et al. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(15 Suppl):2254-8 (23 ref.) **(Jpn)**
[Replication of chromosomal DNA: process for its initiation] Matsukage A. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(15 Suppl):2369-77 (35 ref.) **(Jpn)**

GENETICS

Archaea and the origin(s) of DNA replication proteins. Edgell DR, et al. **Cell** 1997 Jun 27;89(7):995-8 (27 ref.)
Common structural features of replication origins in all life forms. Boulikas T. **J Cell Biochem** 1996 Mar 1; 60(3):297-316 (162 ref.)
Sequence and context effects on origin function in mammalian cells. Dijkwel PA, et al. **J Cell Biochem** 1996 Aug;62(2):210-22 (85 ref.)

REPLICATION UNIT see **REPLICON**

REPLICON

Use of viral replicons for the expression of genes in plants. Porta C, et al. **Mol Biotechnol** 1996 Jun;5(3):209-21 (73 ref.)

GENETICS

Organization of DNA into foci during replication. Newport J, et al. **Curr Opin Cell Biol** 1996 Jun;8(3):365-8 (17 ref.)

REPORTER GENES see **GENES, REPORTER**

REPRESSED MEMORY see **REPRESSION**

REPRESSION

Beyond "true" and "false" memories: remembering and recovery in the survival of childhood sexual abuse. Hall JM, et al. **ANS Adv Nurs Sci** 1997 Jun;19(4):37-54 (109 ref.)
Delayed traumatic recall in adults: a synthesis with legal, clinical, and forensic recommendations. Beahrs JO, et al. **Bull Am Acad Psychiatry Law** 1996;24(1):45-55 (63 ref.)
Memory distortion and false memory creation. Loftus EF. **Bull Am Acad Psychiatry Law** 1996;24(3):281-95 (45 ref.)
The repressed memory controversy: is there middle ground? [see comments] Penfold PS. **Can Med Assoc J** 1996 Sep 15;155(6):647-53 (90 ref.) Comment in: Can Med Assoc J 1997 Feb 1;156(3):344; discussion 345. Comment in: Can Med Assoc J 1997 Feb 1;156(3):344-5. Comment in: Can Med Assoc J 1997 May 1;156(9):1265.
Problems in the concept of repression and proposals for their resolution. Maze JR, et al. **Int J Psychoanal** 1996 Dec;77 (Pt 6):1085-100 (36 ref.)
Memory, repression, and child sexual abuse: forensic implications for the mental health professional. Corelli TB, et al. **J Am Acad Psychiatry Law** 1997;25(1):31-47 (62 ref.)

REPRESSION-SENSITIZATION

Kindling versus quenching. Implications for the evolution and treatment of posttraumatic stress disorder. Post RM, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:285-95 (50 ref.)

REPRESSION-SENSITIZATION SCALES see **REPRESSION-SENSITIZATION**

REPRESSOR MOLECULES see **REPRESSOR PROTEINS**

REPRESSOR PROTEINS

BIOSYNTHESIS

Drosophila development. Delimiting patterns by repression. Ip YT, et al. **Curr Biol** 1997 Apr 1;7(4):R216-8 (19 ref.)

CHEMISTRY

Structure and function of Escherichia coli met repressor: similarities and contrasts with trp repressor. Phillips SE, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Apr 29; 351(1339):527-35 (42 ref.)
Lac repressor at last. Sauer RT. **Structure** 1996 Mar 15; 4(3):219-22 (21 ref.)
The SANT domain: a putative DNA-binding domain in the SWI-SNF and ADA complexes, the transcriptional co-repressor N-CoR and TFIIIB. Aasland R, et al. **Trends Biochem Sci** 1996 Mar;21(3):87-8 (16 ref.)
[VHL gene and TSC 2 gene] Hino O. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1386-91 (27 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Tuberous sclerosis: between genetic and physical analysis. Halley DJ. **Acta Genet Med Gemellol (Roma)** 1996; 45(1-2):63-75 (39 ref.)
The Polycomb and trithorax group proteins of Drosophila: trans-regulators of homeotic gene function. Kennison JA. **Annu Rev Genet** 1995;29:289-303 (83 ref.)
The various strategies within the TyrR regulation of Escherichia coli to modulate gene expression. Pittard J. **Genes Cells** 1996 Aug;1(8):717-25 (48 ref.)
Statistical analysis of the lacI transgenic mouse mutagenicity assay. Fung KY, et al. **Mutat Res** 1997 Mar 4;374(1):21-40 (32 ref.)
Lac repressor genetic map in real space. Pace HC, et al. **Trends Biochem Sci** 1997 Sep;22(9):334-9 (19 ref.)
Loss of oxyR in Mycobacterium tuberculosis. Deretic V, et al. **Trends Microbiol** 1997 Sep;5(9):367-72 (49 ref.)

METABOLISM

Drosophila development: homeodomains and translational control. Zamore PD, et al. **Curr Biol** 1996 Jul 1;6(7):773-5 (17 ref.)
Activation and repression of E. coli promoters. Gralla JD. **Curr Opin Genet Dev** 1996 Oct;6(5):526-30 (41 ref.)
Lac repressor-operator complex. Kercher MA, et al. **Curr Opin Struct Biol** 1997 Feb;7(1):76-85 (97 ref.)
DnaA initiator--also a transcription factor. Messer W, et al. **Mol Microbiol** 1997 Apr;24(1):1-6 (68 ref.)
A flexible partnership: the CytR anti-activator and the cAMP-CRP activator protein, comrades in transcription control. Valentin-Hansen P, et al. **Mol Microbiol** 1996 May; 20(3):461-6 (26 ref.)
Structure and function of Escherichia coli met repressor: similarities and contrasts with trp repressor. Phillips SE, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Apr 29; 351(1339):527-35 (42 ref.)
Lactose repressor protein: functional properties and structure. Matthews KS, et al. **Prog Nucleic Acid Res Mol Biol** 1998;58:127-64 (243 ref.)
CcpA and HPr(ser-P): mediators of catabolite repression in Bacillus subtilis. Chauvaux S. **Res Microbiol** 1996 Jul-Sep; 147(6-7):518-22 (20 ref.)
Cra and the control of carbon flux via metabolic pathways. Ramseier TM. **Res Microbiol** 1996 Jul-Sep;147(6-7):489-93 (17 ref.)
Silencers and locus control regions: opposite sides of the same coin. Kamakaka RT. **Trends Biochem Sci** 1997 Apr; 22(4):124-8 (42 ref.)
Active repression mechanisms of eukaryotic transcription repressors. Hanna-Rose W, et al. **Trends Genet** 1996 Jun; 12(6):229-34 (46 ref.)

REPRESSOR PROTEINS

PHYSIOLOGY

Splicing together the unfolded-protein response. Shamu CE. **Curr Biol** 1997 Feb 1;7(2):R67-70 (15 ref.)
Carbon repression in Aspergilli. Ruijter GJ, et al. **FEMS Microbiol Lett** 1997 Jun 15;151(2):103-14 (51 ref.)
Negative regulation of gene expression in eukaryotes. Imagawa M. **Neurochem Int** 1996 Dec;29(6):565-72 (35 ref.)
The world according to Maf. Motohashi H, et al. **Nucleic Acids Res** 1997 Aug 1;25(15):2953-59 (60 ref.)
Role of suppressor of hairless in the delta-activated Notch signaling pathway. Lecourtois M, et al. **Perspect Dev Neurobiol** 1997;4(4):305-11 (50 ref.)
Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Shibata H, et al. **Recent Prog Horm Res** 1997;52:141-64; discussion 164-5 (119 ref.)
[VHL gene and TSC 2 gene] Hino O. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1386-91 (27 ref.) (Eng. Abstr.) **(Jpn)**
[Role of yeast global repressors, Bel2 and Tup1, in chromatin-and nucleosome-mediated transcriptional regulation] Harashima S. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1187-97 (31 ref.) **(Jpn)**

REPRODUCIBILITY OF RESULTS

Reliability and validity of stationary cystometry, stationary cysto-urethrometry and ambulatory cysto-urethro-vaginometry. Kulseng-Hanssen S. **Acta Obstet Gynecol Scand Suppl** 1997;166:33-8 (36 ref.)
Statistical design of calibration studies. Carroll RJ, et al. **Am J Clin Nutr** 1997 Apr;65(4 Suppl):1187S-1189S (9 ref.)
Understanding error grid analysis [editorial; comment] Cox DJ, et al. **Diabetes Care** 1997 Jun;20(6):911-2 (36 ref.) Comment on: Diabetes Care 1997 Jun;20(6):1034-6.
Perspective: validating surrogate markers--are we being naive? De Gruttola V, et al. **J Infect Dis** 1997 Feb; 175(2):237-46 (21 ref.)
Changing conceptions of measurement validity [see comments] Goodwin LD. **J Nurs Educ** 1997 Mar; 36(3):102-7 (44 ref.) Comment in: J Nurs Educ 1997 Mar;36(3):99-101.

REPRODUCTION

Changing behavior: a challenge for reproductive health awareness. Andreasen AR. **Adv Contracept** 1997 Jun-Sep; 13(2-3):351-3 (0 ref.)
Reproductive health before and after the childbearing age: the Japanese scene. Aso T. **Adv Contracept** 1996 Dec; 12(4):305-8 (0 ref.)
Body/self awareness and interpersonal communications: fundamental components of reproductive health awareness. Aumack-Yee K. **Adv Contracept** 1997 Jun-Sep; 13(2-3):319-23 (6 ref.)
Reproductive health as an essential human right. Benagiano G. **Adv Contracept** 1996 Dec;12(4):243-50 (20 ref.)
Reproductive health in the People's Republic of China. Bilian X. **Adv Contracept** 1996 Dec;12(4):257-63 (11 ref.)
Reproductive health: the Thai experience. Boonkasemsanti W. **Adv Contracept** 1996 Dec;12(4):271-4 (0 ref.)
Reproductive health of the young and the elderly in the USA. Brenner PF. **Adv Contracept** 1996 Dec;12(4):297-303 (27 ref.)
The WHO Research and Training Centre in Human Reproduction at the Karolinska Institute between 1970 and 1995. Bygdeman M. **Adv Contracept** 1996 Dec;12(4):319-24 (12 ref.)
Implementing reproductive health awareness: progress to date. Cachan J, et al. **Adv Contracept** 1997 Jun-Sep; 13(2-3):363-71 (3 ref.)
A woman-centered agenda for the twenty-first century. Fathalla MF. **Adv Contracept** 1996 Dec;12(4):331-4 (0 ref.)
STDs, AIDS and reproductive health. Johannisson E. **Adv Contracept** 1996 Dec;12(4):281-4 (0 ref.)
The potential contribution of sexuality and gender awareness. Kopp Z. **Adv Contracept** 1997 Jun-Sep;13(2-3):325-9 (5 ref.)
Reproductive tract malignancies: a neglected aspect of reproductive health. López de la Osa E. **Adv Contracept** 1996 Dec;12(4):293-6 (8 ref.)
Reproductive health awareness: an integrated approach to obtaining a high quality of health. Marshall M, et al. **Adv Contracept** 1997 Jun-Sep;13(2-3):313-8 (0 ref.)
Reproductive health in Mexico and Latin America. Perez-Palacios G. **Adv Contracept** 1996 Dec;12(4):251-6 (0 ref.)
Reproductive health awareness: an important dimension to be integrated into existing sexual and reproductive health programs. Pyper C. **Adv Contracept** 1997 Jun-Sep; 13(2-3):331-8 (5 ref.)
Reproductive health in India. Saxena BN. **Adv Contracept** 1996 Dec;12(4):265-70 (0 ref.)
Breaking the mold: expanding options for reproductive health awareness: the CARE experience. Schubert J, et al. **Adv Contracept** 1997 Jun-Sep;13(2-3):355-61 (0 ref.)
Issues to consider in operationalizing reproductive health. Spicehandler J. **Adv Contracept** 1997 Jun-Sep; 13(2-3):345-50 (12 ref.)
The reproductive health awareness (RHA) model: a qualitative perspective. Wilson A. **Adv Contracept** 1997 Jun-Sep;13(2-3):339-42 (3 ref.)
Specific neuroendocrine mechanisms not involving generalized stress mediate social regulation of female reproduction in cooperatively breeding marmoset monkeys. Abbott DH, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:219-38 (106 ref.)
Toxicology of male reproduction in animals and humans. De Celis R, et al. **Arch Androl** 1996 Nov-Dec;37(3):201-18 (156 ref.)
How knockout mouse lines will be used to study the role of drug-metabolizing enzymes and their receptors during reproduction and development, and in environmental toxicity, cancer, and oxidative stress. Nebert DW, et al. **Biochem Pharmacol** 1997 Feb 7;53(3):249-54 (44 ref.)
Naked mole-rats on the move. Behavioural ecology. Bromham L, et al. **Curr Biol** 1996 Sep 1;6(9):1082-3 (10 ref.)
Environmental effects on reproductive health: the endocrine disruption hypothesis. Hollander D. **Fam Plann Perspect** 1997 Mar-Apr;29(2):82-6, 89 (37 ref.)
Procreation after death or mental incompetence: medical advance or technology gone awry? Ohl DA, et al. **Fertil Steril** 1996 Dec;66(6):889-95 (24 ref.)
Galanin gene expression in hypothalamic GnRH-containing neurons of the rat: a model for autocrine regulation. Rossmanith WG, et al. **Horm Metab Res** 1996 Jun; 28(6):257-66 (64 ref.)
Infertility revisited: the state of the art today and tomorrow. The ESHRE Capri Workshop. European Society for Human Reproduction and Embryology. **Hum Reprod** 1996 Aug;11(8):1779-807 (254 ref.)
Secular trends in monitors of reproductive hazard. James WH. **Hum Reprod** 1997 Mar;12(3):417-21 (53 ref.)
The pineal gland and reproduction. Aleandri V, et al. **Hum Reprod Update** 1996 May-Jun;2(3):225-35 (115 ref.)
Reproductive failure due to spontaneous abortion and recurrent miscarriage. Bulletti C, et al. **Hum Reprod Update** 1996 Mar-Apr;2(2):118-36 (209 ref.)
Assessing individual risk for breast cancer: risky business. McTiernan A, et al. **J Clin Epidemiol** 1997 May; 50(5):547-56 (60 ref.)
Review: dairy cattle reproductive physiology research and management--past progress and future prospects. Foote RH. **J Dairy Sci** 1996 Jun;79(6):980-90 (82 ref.)
Issues in sexuality and gynecologic care of women with developmental disabilities. Sulpizi LK. **J Obstet Gynecol Neonatal Nurs** 1996 Sep;25(7):609-14 (24 ref.)
Cytokines in mammalian reproduction and speculation about their possible involvement in nonmammalian viviparity. Paulesu L. **Microsc Res Tech** 1997 Jul 1-15;38(1-2):188-94 (79 ref.)
Role for glycoconjugates in cellular communication in the human reproductive system. Clark GF, et al. **Mol Hum Reprod** 1996 Jul;2(7):513-7 (35 ref.)
Epidemiology of reproductive hazards in the workplace. Lemasters GK. **Occup Med** 1996 Jul-Sep;11(3):545-60 (80 ref.)
Reproductive hazards and firefighters. McDiarmid MA, et al. **Occup Med** 1995 Oct-Dec;10(4):829-41 (84 ref.)
Nutritional issues for women in developing countries. Walker SP. **Proc Nutr Soc** 1997 Mar;56(1B):345-56 (66 ref.)
The effect of diabetes mellitus on endocrine and reproductive function. Steger RW, et al. **Proc Soc Exp Biol Med** 1997 Jan;214(1):1-11 (164 ref.)
African bats: evolution of reproductive patterns and delays. Bernard RT, et al. **Q Rev Biol** 1997 Sep;72(3):253-74 (137 ref.)
Possum biocontrol: prospects for fertility regulation. Cowan PE. **Reprod Fertil Dev** 1996;8(4):655-60 (38 ref.)
Reproductive health and blurred professional boundaries. Chavkin W, et al. **Womens Health Issues** 1996 Mar-Apr; 6(2):89-96 (46 ref.)
[20 years of research in epidemiology of human reproduction] Spira A. **Rev Epidemiol Sante Publique** 1996 Nov; 44(6):588-95 (19 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Methoxychlor as a model for environmental estrogens. Cummings AM. **Crit Rev Toxicol** 1997 Jul;27(4):367-79 (75 ref.)
Ovarian stimulation for assisted reproduction. Meldrum DR. **Curr Opin Obstet Gynecol** 1996 Jun;8(3):166-70 (33 ref.)
The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and fetal outcome. Morrell MJ. **Epilepsia** 1996;37 Suppl 6:S34-44 (107 ref.)
Endocrine disruptors and reproductive development: a weight-of-evidence overview. Cooper RL, et al. **J Endocrinol** 1997 Feb;152(2):159-66 (71 ref.)
Perspectives on Canadian field studies examining the potential of pulp and paper mill effluent to affect fish reproduction. Kovacs TG, et al. **J Toxicol Environ Health** 1997 Jul;51(4):305-52 (77 ref.)
Biochemical and molecular changes at the cellular level in response to exposure to environmental estrogen-like chemicals. Roy D, et al. **J Toxicol Environ Health** 1997 Jan;50(1):1-29 (180 ref.)
FIFRA Subdivision F testing Guidelines: are these tests adequate to detect potential hormonal activity for crop protection chemicals? Federal Insecticide, Fungicide, and Rodenticide Act. Stevens JT, et al. **J Toxicol Environ Health** 1997 Apr 11;50(5):415-31 (35 ref.)
Reproductive health hazards in the pharmaceutical industry. Clement JD. **Occup Med** 1997 Jan-Mar;12(1):131-43 (61 ref.)
New guidelines for preclinical testing of novel medicines for their effects on reproduction: clarity or confusion? Sutherland MF. **Regul Toxicol Pharmacol** 1996 Jun; 23(3):300-3 (19 ref.)
The effects of antirheumatic drugs on reproductive function. Brent LH, et al. **Reprod Toxicol** 1997 Jul-Aug;11(4):561-77 (324 ref.)
Environmental estrogens and reproductive health: a discussion of the human and environmental data. Daston GP, et al. **Reprod Toxicol** 1997 Jul-Aug;11(4):465-81 (148 ref.)
An assessment of boric acid and borax using the IEHR Evaluative Process for Assessing Human Developmental and Reproductive Toxicity of Agents. Expert Scientific Committee. Moore JA. **Reprod Toxicol** 1997 Jan-Feb; 11(1):123-60 (137 ref.)
Teratogen update: smoking and reproductive outcomes. Werler MM. **Teratology** 1997 Jun;55(6):382-8 (101 ref.)
Environmental contaminants and reproductive abnormalities in wildlife: implications for public health? Guillette LJ Jr, et al. **Toxicol Ind Health** 1996 May-Aug;12(3-4):537-50 (64 ref.)
Assessment of reproductive health effects of hazardous waste. Kipen HM. **Toxicol Ind Health** 1996 Mar-Apr;12(2):211-24 (43 ref.)
Review of reproductive and developmental toxicity of 1,3-butadiene. Christian MS. **Toxicology** 1996 Oct 28; 113(1-3):137-43 (26 ref.)

GENETICS

Immunogenetics of reproduction: an overview. Ober C, et al. **Curr Top Microbiol Immunol** 1997;222:1-23 (124 ref.)
[The problem of breeding for fertility] Jansen S, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Oct;103(10):414-6 (14 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Role of the major histocompatibility complex region in reproduction, cancer, and autoimmunity. Gill TJ 3rd. **Am J Reprod Immunol** 1996 Mar;35(3):211-5 (14 ref.)
Immunoteratology: where we are and where to go. Toder V, et al. **Am J Reprod Immunol** 1996 Feb;35(2):114-7 (33 ref.)
Clinical rheumatologic applications of reproductive immunology. Facts, fiction, and fancy. Wallace DJ, et al. **Arthritis Rheum** 1997 Feb;40(2):209-16 (68 ref.)
Immunogenetics of reproduction: an overview. Ober C, et al. **Curr Top Microbiol Immunol** 1997;222:1-23 (124 ref.)
NK cells and reproduction. King A, et al. **Immunol Today** 1997 Feb;18(2):64-6 (15 ref.)
The importance of mucosal immunology to problems in human reproduction. Anderson DJ. **J Reprod Immunol** 1996 Aug;31(1-2):3-19 (75 ref.)

PHYSIOLOGY

Effects of melatonin infused into the III ventricle on prolactin, beta-endorphin and luteotropin secretion in ewes during the different stages of the reproductive cycle. Misztal T, et al. **Acta Neurobiol Exp (Warsz)** 1996; 56(3):769-78 (32 ref.)
Fertility: past, present, and future. Evans VJ. **Am J Reprod Immunol** 1996 Mar;35(3):131-9 (9 ref.)
The hypothalamic-pituitary-adrenal axis and the female reproductive system. Magiakou MA, et al. **Ann N Y Acad Sci** 1997 Jun 17;816:42-56 (69 ref.)
Ecological constraints and the evolution of hormone-behavior interrelationships. Wingfield JC, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:22-41 (67 ref.)
Reproductive stresses in undernourished and well-nourished women. Prentice AM, et al. **Bibl Nutr Dieta** 1996;(53):1-10 (22 ref.)
Adhesion molecules in reproduction. Klentzeris LD. **Br J Obstet Gynaecol** 1997 Apr;104(4):401-9 (53 ref.)
Effect of altered reproductive function and lowered testosterone levels on bone density in male endurance athletes. Bennell KL, et al. **Br J Sports Med** 1996 Sep; 30(3):205-8 (59 ref.)
Preservation of reproductive function before therapy for cancer: new options involving sperm and ovary cryopreservation [editorial] Opsahl MS, et al. **Cancer J Sci Am** 1997 Jul-Aug;3(4):189-91 (12 ref.)
Glycodelins as regulators of early events of reproduction. Seppälä M, et al. **Clin Endocrinol (Oxf)** 1997 Apr; 46(4):381-6 (46 ref.)
Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Ben-Jonathan N, et al. **Endocr Rev** 1996 Dec;17(6):639-69 (368 ref.)
Transgenic animal models in reproductive endocrine research. Reventós J, et al. **Eur J Endocrinol** 1997 Jun; 136(6):566-80 (128 ref.)
Autoimmunity and reproduction. Geva E, et al. **Fertil Steril** 1997 Apr;67(4):599-611 (100 ref.)
Inhibin, activin, and follistatin in reproductive medicine. Halvorson LM, et al. **Fertil Steril** 1996 Mar;65(3):459-69 (110 ref.)
Integrins and reproductive physiology: expression and modulation in fertilization, embryogenesis, and implantation. Sueoka K, et al. **Fertil Steril** 1997 May; 67(5):799-811 (100 ref.)

Roles of inhibins, activins, and follistatin in the female reproductive system. Knight PG. **Front Neuroendocrinol** 1996 Oct;17(4):476–509 (231 ref.)
The ovarian renin–angiotensin system in reproductive physiology. Yoshimura Y. **Front Neuroendocrinol** 1997 Jul; 18(3):247–91 (235 ref.)
Tissue renin–angiotensin systems and reproduction. Vinson GP, et al. **Hum Reprod** 1997 Apr;12(4):651–62 (176 ref.)
Biotechnological advances in goat reproduction. Amoah EA, et al. **J Anim Sci** 1997 Feb;75(2):578–85 (74 ref.)
Direct regulation of mammalian reproductive organs by serotonin and melatonin. Sirotkin AV, et al. **J Endocrinol** 1997 Jul;154(1):1–5 (60 ref.)
Influence of melatonin and photoperiod on animal and human reproduction. Cagnacci A, et al. **J Endocrinol Invest** 1996 Jun;19(6):382–411 (419 ref.)
Hypothalamic cellular and molecular mechanisms helping to satisfy axiomatic requirements for reproduction. Pfaff DW, et al. **J Neuroendocrinol** 1996 May;8(5):325–36 (114 ref.)
The role of growth hormone (GH), GH–receptor and GH–binding protein in reproduction and ovulation induction. Blumenfeld Z, et al. **J Pediatr Endocrinol Metab** 1996 Mar–Apr;9(2):145–62 (82 ref.)
Mechanisms regulating the reproduction and fertility of some mammalian species in their natural environments. Hearn JP. **Lab Anim Sci** 1996 Apr;46(2):152–8 (31 ref.)
Integrins and human reproduction. Bronson RA, et al. **Mol Hum Reprod** 1996 Mar;2(3):153–68 (160 ref.)
Matrix metalloproteinases as mediators of reproductive function. Hulboy DL, et al. **Mol Hum Reprod** 1997 Jan; 3(1):27–45 (211 ref.)
Role of colony–stimulating factor–1 in reproduction and development. Pollard JW. **Mol Reprod Dev** 1997 Jan; 46(1):54–60; discussion 60–1 (31 ref.)
Time to pregnancy: a measure of reproductive function in either sex. Asclepios Project. Joffe M. **Occup Environ Med** 1997 May;54(5):289–95 (20 ref.)
Circadian control of reproduction in the female rat. van der Beek EM. **Prog Brain Res** 1996;111:295–320 (172 ref.)
The biochemical role of platelet–activating factor in reproduction. Frenkel RA, et al. **Prog Lipid Res** 1996; 35(2):155–68 (101 ref.)
Aging of the female reproductive system: a window into brain aging. Wise PM, et al. **Recent Prog Horm Res** 1997; 52:279–303; discussion 303–5 (104 ref.)
Stress and behaviorally induced reproductive dysfunction in primates. Cameron JL. **Semin Reprod Endocrinol** 1997 Feb; 15(1):37–45 (56 ref.)
The effect of endurance training on reproductive function in male runners. A 'volume threshold' hypothesis. De Souza MJ, et al. **Sports Med** 1997 Jun;23(6):357–74 (79 ref.)
Anatomy and physiology of the bull's reproductive system. Fayrer–Hosken R. **Vet Clin North Am Food Anim Pract** 1997 Jul;13(2):195–202 (7 ref.)
[Reproductive physiology in New World camelids. Review] Gauly M. **Tierarztl Prax** 1997 Jan;25(1):74–9 (41 ref.) (Eng. Abstr.) **(Ger)**
[Apoptosis in the reproductive system] Nakano R, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Aug; 48(8):721–32 (4 ref.) **(Jpn)**
[The functional morphology of the Langerhans cells in the female reproductive tract] Bykov VL. **Morfologiia** 1997; 111(2):7–16 (109 ref.) (Eng. Abstr.) **(Rus)**
[The role of oxytocin and vasopressin in the regulation of mammalian reproduction] Grinevich VV, et al. **Morfologiia** 1997;111(2):17–27 (96 ref.) (Eng. Abstr.) **(Rus)**
[Participation of growth factors in human reproduction] Marín–Cantú VA, et al. **Ginecol Obstet Mex** 1997 Jan; 65:27–32 (68 ref.) (Eng. Abstr.) **(Spa)**

RADIATION EFFECTS

Environmental radiation and male reproduction. Hoyes KP, et al. **Int J Androl** 1996 Aug;19(4):199–204 (75 ref.)
Reproductive health hazards in the pharmaceutical industry. Clement JD. **Occup Med** 1997 Jan–Mar;12(1):131–43 (61 ref.)

REPRODUCTION, ASEXUAL

GENETICS

RNA editing in metazoan mitochondria: staying fit without sex. Börner GV, et al. **FEBS Lett** 1997 Jun 16;409(3):320–4 (34 ref.)

PHYSIOLOGY

Neuronal signal substances in asexual multiplication and development in flatworms. Reuter M, et al. **Cell Mol Neurobiol** 1996 Oct;16(5):591–616 (75 ref.)

REPRODUCTION TECHNIQUES

Use of assisted reproductive techniques for treatment of ejaculatory disorders. Denil J, et al. **Andrologia** 1996;28 Suppl 1:43–51 (62 ref.)
Ovarian stimulation in assisted reproduction. Gips H, et al. **Andrologia** 1996;28 Suppl 1:3–7 (16 ref.)
Prospects for human reproductive medicine—applications of experimental techniques used in farm animal breeding. Michelmann HW, et al. **Andrologia** 1996;28 Suppl 1:93–5 (0 ref.)
Assisted reproductive technology: the state of the ART. Hummel WP, et al. **Ann Med** 1997 Jun;29(3):207–14 (44 ref.)
The case against new reproductive technologies in developing countries [see comments] Okonofua FE. **Br J Obstet Gynaecol** 1996 Oct;103(10):957–62 (37 ref.) Comment in: Br J Obstet Gynaecol 1997 Mar;104(3):385. Comment in: Br J Obstet Gynaecol 1997 Aug;104(8):969; discussion 969–70. Comment in: Br J Obstet Gynaecol 1997 Aug;104(8):970.
Infertility and subsequent pregnancy. Hoxsey R, et al. **Clin Perinatol** 1997 Jun;24(2):321–42 (95 ref.)
In vitro fertilisation. A review of drug therapy and clinical management. Jennings JC, et al. **Drugs** 1996 Sep; 52(3):313–43 (180 ref.)
The history of assisted human conception with especial reference to endocrinology. Edwards RG. **Exp Clin Endocrinol Diabetes** 1996;104(3):183–204 (99 ref.)
Heterotopic pregnancy after ovulation induction and assisted reproductive technologies: a literature review from 1971 to 1993. Tal J, et al. **Fertil Steril** 1996 Jul;66(1):1–12 (77 ref.)
Post–coital sperm retrieval could lead to the wider approval of assisted conception by some religions. Hirsh A. **Hum Reprod** 1996 Feb;11(2):245–7 (26 ref.)
Development, pharmacology and clinical experience with clomiphene citrate. Dickey RP, et al. **Hum Reprod Update** 1996 Nov–Dec;2(6):483–506 (108 ref.)
The role of ultrasonography in the evaluation of endometrial receptivity following assisted reproductive treatments: a critical review. Friedler S, et al. **Hum Reprod Update** 1996 Jul–Aug;2(4):323–35 (64 ref.)
Recent scientific and medical advances in assisted human conception. Edwards RG. **Int J Dev Biol** 1997 Apr; 41(2):255–62 (81 ref.)
Current status of assisted reproductive technology in Asia and Oceania. Chang YS, et al. **J Obstet Gynaecol Res** 1996 Aug;22(4):305–30 (0 ref.)
[Contribution of pathology in procedures for medically assisted reproduction] Ceresa–Manoux A, et al. **Ann Pathol** 1996 Nov;16(5):392–4 (10 ref.) **(Fre)**
[A child at all costs? At what price? Consequences for the child: experimental data] Auroux M. **Contracept Fertil Sex** 1997 Apr;25(4):277–9 (19 ref.) **(Fre)**
[Oocyte maturation. From animal experiments to human reproduction techniques] Lefèvre B. **Contracept Fertil Sex** 1996 Jul–Aug;24(7–8):559–63 (34 ref.) (Eng. Abstr.) **(Fre)**
[Elucidation of the mechanism of fertilization and clinical application of assisted reproductive technology] Hiroi M. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Aug; 48(8):578–90 (18 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Registration of congenital anomalies in ART populations: pitfalls. Simpson JL. **Hum Reprod** 1996 Dec;11 Suppl 4:81–8 (19 ref.)
Heterotopic pregnancy and assisted reproduction—an update. Rojansky N, et al. **J Assist Reprod Genet** 1996 Aug; 13(7):594–601 (58 ref.)
Genomic imprinting abnormalities: a new potential risk of assisted reproduction. Tesarik J, et al. **Mol Hum Reprod** 1996 May;2(5):295–8 (28 ref.)
[A child at all costs? At what price? Consequences for the mother] Belaisch–Allart J, et al. **Contracept Fertil Sex** 1997 Apr;25(4):279–84 (44 ref.) **(Fre)**

ECONOMICS

Sex, lies, and health insurance: employer–provided health insurance coverage of abortion and infertility services and the ADA. Millsap D. **Am J Law Med** 1996;22(1):51–84 (309 ref.)

HISTORY

Legal, ethical and historical aspects of assisted human reproduction. Austin CR. **Int J Dev Biol** 1997 Apr; 41(2):263–5 (4 ref.)

LEGISLATION & JURISPRUDENCE

Approaches responsive to reproductive technologies: a need for critical assessment and directions for further study. Kondratowicz DM. **Camb Q Healthc Ethics** 1997 Spring; 6(2):148–56 (49 ref.)
Registers of in–vitro fertilization and assisted conception. Lancaster PA. **Hum Reprod** 1996 Dec;11 Suppl 4:89–104; discussion 105–9 (49 ref.)
Assisted reproduction practice in Europe: legal and ethical aspects. Schenker JG. **Hum Reprod Update** 1997 Mar–Apr; 3(2):173–84 (34 ref.)
Legal, ethical and historical aspects of assisted human reproduction. Austin CR. **Int J Dev Biol** 1997 Apr; 41(2):263–5 (4 ref.)

PSYCHOLOGY

Infertility and assisted reproductive technology: the role of the perinatal social worker. Greenfeld DA. **Soc Work Health Care** 1997;24(3–4):39–46 (12 ref.)

VETERINARY

Comparison between in vivo–derived and in vitro–produced pre–elongation embryos from domestic ruminants. Thompson JG. **Reprod Fertil Dev** 1997;9(3):341–54 (133 ref.)

REPRODUCTIVE HISTORY

Evaluation of nature–nurture impact on reproductive health using half–siblings [see comments] Olsen J, et al. **Epidemiology** 1997 Jan;8(1):6–11 (22 ref.) Comment in: Epidemiology 1997 Jan;8(1):2–4.
Breast cancer risk: protective effect of an early first full–term pregnancy versus increased risk of induced abortion. Canty L. **Oncol Nurs Forum** 1997 Jul;24(6):1025–31 (60 ref.)

REPRODUCTIVE MEDICINE

see related
REPRODUCTION TECHNIQUES

Management of involuntary childlessness [see comments] Himmel W, et al. **Br J Gen Pract** 1997 Feb;47(415):111–8 (166 ref.) Comment in: Br J Gen Pract 1997 Feb;47(415):69–70. Comment in: Br J Gen Pract 1997 Jun;47(419):404.
Potential health hazards of assisted human reproduction. Possible immunological complications. Narayanan M, et al. **Hum Reprod** 1996 Apr;11(4):701–2 (25 ref.)
Assisted reproductive technologies, ads, and ethics: philosophical, ethical, and clinical perspectives on the use of advertising in reproductive medicine. A conference held by the National Advisory Board on Ethics in Reproduction. Macklin R, et al. **Womens Health Issues** 1997 May–Jun;7(3):127–31 (0 ref.)

LEGISLATION & JURISPRUDENCE

Medically–assisted procreation: a maturing technology or a premature fear? Response to Testart and Sèle. Fiddler M, et al. **Hum Reprod** 1996 Apr;11(4):708–9 (9 ref.)
Health policy and third–generation oral contraceptives. Michaels MA, et al. **Hum Reprod** 1996 Apr;11(4):691–2 (10 ref.)

REPTILES

Infectious and parasitic disease of captive reptiles and amphibians, with special emphasis on husbandry practices which prevent or promote diseases. Ippen R, et al. **Rev Sci Tech** 1996 Mar;15(1):43–54 (1 ref.)
Quarantine protocols and preventive medicine procedures for reptiles, birds and mammals in zoos. Miller RE. **Rev Sci Tech** 1996 Mar;15(1):183–9 (1 ref.)

ANATOMY & HISTOLOGY

Squamate Harderian gland: an overview. Rehorek SJ. **Anat Rec** 1997 Jul;248(3):301–6 (53 ref.)

METABOLISM

The composition and function of reptilian pulmonary surfactant. Daniels CB, et al. **Respir Physiol** 1995 Dec; 102(2–3):121–35 (50 ref.)

MICROBIOLOGY

Review of the literature and investigations on the prevalence and consequences of yeasts in reptiles. Kostka VM, et al. **Vet Rec** 1997 Mar 15;140(11):282–7 (36 ref.)

PHYSIOLOGY

Estivation in South American amphibians and reptiles. Abe AS. **Braz J Med Biol Res** 1995 Nov–Dec;28(11–12):1241–7 (38 ref.)
Cytokines in mammalian reproduction and speculation about their possible involvement in nonmammalian viviparity. Paulesu L. **Microsc Res Tech** 1997 Jul 1–15;38(1–2):188–94 (79 ref.)
[Anesthesia in domestic animals (small mammals, psittacines and reptiles)] Kuntze A. **Tierarztl Prax** 1996 Dec; 24(6):600–3 (24 ref.) (Eng. Abstr.) **(Ger)**
[New data on the characteristics of sleep and the organization of the wakefulness–sleep cycle in cold–blooded vertebrates] Karmanova IG. **Zh Evol Biokhim Fiziol** 1996 Jul–Aug; 32(4):511–35 (10 ref.) **(Rus)**

RESCUE WORK

see related
RELIEF WORK

METHODS

The Kobe earthquake: the system response. A disaster report from Japan. Tanaka K. **Eur J Emerg Med** 1996 Dec; 3(4):263–9 (7 ref.)

RESEARCH

see related
DENTAL RESEARCH
INFORMATION SERVICES
NURSING RESEARCH

RESEARCH

SYSTEMS ANALYSIS

Earnings and schooling: an overview of economic research based on the Australian Twin Register. Miller P, et al. **Acta Genet Med Gemellol (Roma)** 1996;45(4):417–29 (19 ref.)

Review of research on the clinical presentation of acquired childhood aphasia [see comments] Paquier PF, et al. **Acta Neurol Scand** 1996 Jun;93(6):428–36 (101 ref.) Comment in: Acta Neurol Scand 1997 Apr;95(4):253–5.

Manual–based treatments: the clinical application of research findings. Wilson GT. **Behav Res Ther** 1996 Apr; 34(4):295–314 (120 ref.)

Clinical academic medicine: a Socratic dialogue. Grahame–Smith DG. **BMJ** 1997 Sep 6;315(7108):593–5 (21 ref.)

Advances in post mortem molecular neurochemistry and neuropathology: examples from schizophrenia research. Harrison PJ. **Br Med Bull** 1996 Jul;52(3):527–38 (62 ref.)

Clinical and research contributions of the intracarotid amobarbital procedure to neuropsychology. Jones–Gotman M, et al. **Brain Cogn** 1997 Feb;33(1):1–6 (20 ref.)

Health research in the developing world: a gastroenterological view from Bangladesh. Hamilton JR. **Can J Gastroenterol** 1997 Jan–Feb;11(1):94–8 (25 ref.)

The biology of aging: the current research agenda. Ershler WB, et al. **Cancer** 1997 Oct 1;80(7):1284–93 (103 ref.)

Differential electrophysiology of repolarisation from clone to clinic. Coronel R, et al. **Cardiovasc Res** 1997 Mar; 33(3):503–17 (30 ref.)

Maternal nutrition and the outcome of pregnancy. A renaissance in research. Brown JE, et al. **Clin Perinatol** 1997 Jun;24(2):433–49 (101 ref.)

Research priorities for the WHO Global Programme for Vaccines and Immunization. Lambert PH. **Dev Biol Stand** 1996;87:45–9 (0 ref.)

To bridge science and patient care in diabetes [published erratum appears in Diabetologia 1996 Sep;39(9):1130] Berger M. **Diabetologia** 1996 Jul;39(7):749–57 (85 ref.)

Institutional racism and the medical/health complex: a conceptual analysis. King G. **Ethn Dis** 1996 Winter–Spring; 6(1–2):30–46 (99 ref.)

Why we should continue to study race...but do a better job: an essay on race, racism and health. La Veist TA. **Ethn Dis** 1996 Winter–Spring;6(1–2):21–9 (85 ref.)

The role of basic arrhythmia research. The continued need for experiments in the intact heart and organism. Allessie A, et al. **Eur Heart J** 1995 Nov;16(11):1469–75 (81 ref.)

Scientific creativity in biomedical research: some case histories. Holmes FL. **Eur J Clin Chem Clin Biochem** 1996 Dec;34(12):941–8 (26 ref.)

Ethics and research. Carriero A, et al. **Eur Radiol** 1996;6 Suppl 1:S11–5 (21 ref.)

Getting research into practice. Bouchier IA. **Health Bull (Edinb)** 1997 Jan;55(1):62–7 (14 ref.)

Measurement of body composition: applications in hormone research. Pierson RN Jr, et al. **Horm Res** 1997;48 Suppl 1:56–62 (17 ref.)

Risk and cause in medical science. Kumar R, et al. **Indian Pediatr** 1995 Sep;32(9):1031–5 (5 ref.)

Research communication media: creating an outstanding impression with abstracts, poster exhibits, and slides. Russell JA, et al. **Instr Course Lect** 1994;43:625–37 (29 ref.)

Bangkok Workshop on Leprosy Research. Research needs related to disabilities and rehabilitation. Smith WC, et al. **Int J Lepr Other Mycobact Dis** 1996 Dec;64(4 Suppl):S52–4; discussion S54–5 (12 ref.)

Science, politics, and AIDS prevention policy. Bayer R. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 2:S22–9 (20 ref.)

Protein levels in beef cattle finishing diets: industry application, university research, and systems results. Galyean ML. **J Anim Sci** 1996 Nov;74(11):2860–70 (33 ref.)

The clinical investigator: bewitched, bothered, and bewildered—but still beloved [editorial] Goldstein JL, et al. **J Clin Invest** 1997 Jun 15;99(12):2803–12 (38 ref.)

Epilogue: bridging the gap between research on attachment and psychopathology. del Carmen R, et al. **J Consult Clin Psychol** 1996 Apr;64(2):291–4 (33 ref.)

Random versus nonrandom assignment in controlled experiments: do you get the same answer? Shadish WR, et al. **J Consult Clin Psychol** 1996 Dec;64(6):1290–305 (169 ref.)

How can clinicians incorporate research advances into practice? Larson EB. **J Gen Intern Med** 1997 Apr;12 Suppl 2:S20–4 (13 ref.)

Remote operation: a selective review of research into visual depth perception. Reinhardt–Rutland AH. **J Gen Psychol** 1996 Jul;123(3):237–48 (54 ref.)

The ethics of research into the cause(s) of homosexuality. Schüklenk U, et al. **J Homosex** 1996;31(3):5–30 (85 ref.)

Basic science research in chiropractic: the state of the art and recommendations for a research agenda. Brennan PC, et al. **J Manipulative Physiol Ther** 1997 Mar–Apr; 20(3):150–68 (182 ref.)

This I have learned from over 40 years of personality research. Epstein S. **J Pers** 1997 Mar;65(1):3–32 (75 ref.)

The cotton rat in biomedical research. Faith RE, et al. **Lab Anim Sci** 1997 Aug;47(4):337–45 (90 ref.)

Medical informatics, art or science? van Bemmel JH. **Methods Inf Med** 1996 Sep;35(3):157–72; discussion 173–201 (54 ref.)

Research and development on functional foods in Malaysia. Ahmad S. **Nutr Rev** 1996 Nov;54(11 Pt 2):S169–71 (13 ref.)

The ethical boundaries of drug research in pediatrics. Rowell M, et al. **Pediatr Clin North Am** 1997 Feb;44(1):27–40 (47 ref.)

Closing the gap between alcoholism research and practice: the case for pharmacotherapy. Meza E, et al. **Psychiatr Serv** 1996 Sep;47(9):917–20 (49 ref.)

Considerations for toxicology studies of respiratory drug products. DeGeorge JJ, et al. **Regul Toxicol Pharmacol** 1997 Apr;25(2):189–93 (16 ref.)

Future directions for resuscitation research. I. Advanced airway control measures. Benson D, et al. **Resuscitation** 1996 Jul;32(1):51–62 (51 ref.)

Future directions for resuscitation research. II. External cardiopulmonary resuscitation basic life support. Bircher N, et al. **Resuscitation** 1996 Jul;32(1):63–75 (68 ref.)

Cardiac arrest research in humans—insights into failure. Paradis NA. **Resuscitation** 1996 Apr;31(2):93–100 (30 ref.)

Future directions for resuscitation research: introduction. Safar P, et al. **Resuscitation** 1996 Jul;32(1):45–50 (20 ref.)

The International Spinal Research Trust's strategic approach to the development of treatments for the repair of spinal cord injury. Harper GP, et al. **Spinal Cord** 1996 Aug; 34(8):449–59 (57 ref.)

An agenda for primary care research on low back pain. Borkan JM, et al. **Spine** 1996 Dec 15;21(24):2880–4 (6 ref.)

Progress in urodynamic research on the upper urinary tract: implications for practical urology [editorial] Kinn AC. **Urol Res** 1996;24(1):1–7 (39 ref.)

Communications: technology transfer in the developed world. Murrell KD. **Vet Parasitol** 1996 Aug;64(1–2):107–20 (19 ref.)

[The need for humanistic research in medicine] Lunde IM. **Ugeskr Laeger** 1997 Mar 31;159(14):2077–81 (20 ref.) (Eng. Abstr.) **(Dan)**

[The Internet for medical research] Della Mea V, et al. **Pathologica** 1995 Oct;87(5):485–91 (22 ref.) (Eng. Abstr.) **(Ita)**

[Unacceptable quality in certain sectors of medical research] Høiseth A. **Tidsskr Nor Laegeforen** 1997 Feb 10; 117(4):531–5 (14 ref.) (Eng. Abstr.) **(Nor)**

[Experience with integration of research institutes if the Russian Academy of Medical Sciences with the departments if higher educational establishments of the IM Sechenov is an effective type of teaching and research intensification] Paltsev MA, et al. **Vestn Ross Akad Med Nauk** 1997;(3):54–8 (0 ref.) **(Rus)**

[Research on emotions is advancing. Psychotherapists are leaving the trenches] Törneke N. **Lakartidningen** 1997 Apr 23;94(17):1628, 1631–3 (13 ref.) **(Swe)**

ECONOMICS

The role of outcome studies in allergy and clinical immunology. Blaiss MS. **Allergy Asthma Proc** 1996 Nov–Dec;17(6):355–8 (15 ref.)

Impact of exporting dependence on livestock production systems, industry structure, and research. Macmillan KL, et al. **J Anim Sci** 1997 Feb;75(2):522–32 (25 ref.)

EDUCATION

The WHO Research and Training Centre in Human Reproduction at the Karolinska Institute between 1970 and 1995. Bygdeman M. **Adv Contracept** 1996 Dec;12(4):319–24 (12 ref.)

[International research programs and training of researchers] Helander E, et al. **Duodecim** 1995;111(19):1872–6 (0 ref.) **(Fin)**

INSTRUMENTATION

Further developments of the laser scanning confocal microscope in biomedical research. Paddock SW. **Proc Soc Exp Biol Med** 1996 Oct;213(1):24–31 (54 ref.)

LEGISLATION & JURISPRUDENCE

Research on the cognitively impaired: lessons and warnings from the emergency research debate [see comments] Karlawish JH, et al. **J Am Geriatr Soc** 1997 Apr; 45(4):474–81 (65 ref.) Comment in: J Am Geriatr Soc 1997 Apr;45(4):521–3.

Technology transfer at US universities: seeking public benefit from the results of basic research. Goodwin CD. **Technol Health Care** 1996 Sep;4(3):323–30 (6 ref.)

METHODS

Review of research methodology used in clinical trials of magnesium and myocardial infarction—why does controversy persist despite ISIS–4? Woods KL. **Coron Artery Dis** 1996 May;7(5):348–51 (24 ref.)

Impact of knockout mice in toxicology. Ryffel B. **Crit Rev Toxicol** 1997 Mar;27(2):135–54 (120 ref.)

The use of standardized patients in research in general practice. Beullens J, et al. **Fam Pract** 1997 Feb;14(1):58–62 (36 ref.)

In vivo gene transfer and gene modulation in hypertension research. Dzau VJ, et al. **Hypertension** 1996 Dec; 28(6):1132–7 (44 ref.)

Female adolescents and onset of sexual intercourse: a theory–based review of research from 1984 to 1994. Goodson P, et al. **J Adolesc Health** 1997 Sep;21(3):147–56 (75 ref.)

Variability and consistency of electric and magnetic field occupational exposure measurements [published erratum appears in J Expo Anal Environ Epidemiol 1996 Oct–Dec;6(4):527] Bracken TD, et al. **J Expo Anal Environ Epidemiol** 1996 Jul–Sep;6(3):355–74 (27 ref.)

Secular trends in menopause age. Flint MP. **J Psychosom Obstet Gynaecol** 1997 Jun;18(2):65–72 (34 ref.)

Menopause in different cultures. Richters JM. **J Psychosom Obstet Gynaecol** 1997 Jun;18(2):73–80 (34 ref.)

A new biological framework for cancer research. Schipper H, et al. **Lancet** 1996 Oct 26;348(9035):1149–51 (33 ref.)

Statistical principles underlying the applications of laboratory methods to field studies. Guo SS, et al. **Muscle Nerve Suppl** 1997;5:S32–4 (7 ref.)

Confounding variables and comorbidity in sarcopenia research. Miller JP. **Muscle Nerve Suppl** 1997;5:S35–8 (4 ref.)

Human research on cardiopulmonary resuscitation: current constraints on implementation. Cummins RO. **New Horiz** 1997 May;5(2):120–7 (82 ref.)

"To be of use": enhancing the utility of qualitative research. Sandelowski M. **Nurs Outlook** 1997 May–Jun;45(3):125–32 (58 ref.)

Research interviewing. Plant H. **Palliat Med** 1996 Oct; 10(4):339–41 (16 ref.)

ORGANIZATION & ADMINISTRATION

A national strategy for research and development: lessons from England. Black N. **Annu Rev Public Health** 1997; 18:485–505 (48 ref.)

STANDARDS

How to assess a research study [see comments] Rankin M, et al. **Am J Nurs** 1996 Dec;96(12):32–6; quiz 37 (10 ref.) Comment in: Am J Nurs 1997 Mar;97(3):23.

Is research into ethnicity and health racist, unsound, or important science? [see comments] Bhopal R. **BMJ** 1997 Jun 14;314(7096):1751–6 (62 ref.) Comment in: BMJ 1997 Jun 14;314(7096):1703–4.

From evidence to conclusions in psychiatric research. Bilsker D. **Can J Psychiatry** 1996 May;41(4):227–32 (19 ref.)

Health care for research animals is essential and affordable. Jacoby RO, et al. **FASEB J** 1997 Jul;11(8):609–14 (6 ref.)

The challenges of assessing fat intake in cancer research investigations. Wynder EL, et al. **J Am Diet Assoc** 1997 Jul;97(7 Suppl):S5–8 (39 ref.)

Academic research: policies and practice. Bertha SL. **J Ethnopharmacol** 1996 Apr;51(1–3):59–73 (7 ref.)

Health state descriptions. Purposes, issues, a proposal. Llewellyn–Thomas HA. **Med Care** 1996 Dec;34(12 Suppl):DS109–18 (39 ref.)

Public confidence in public health research ethics [comment] [see comments] Mariner WK. **Public Health Rep** 1997 Jan–Feb;112(1):33–6 (17 ref.) Comment on: Public Health Rep 1997 Jan–Feb;112(1):29–32. Comment in: Public Health Rep 1997 Jul–Aug;112(4):266.

Defining research when it comes to public health [see comments] Snider DE Jr, et al. **Public Health Rep** 1997 Jan–Feb;112(1):29–32 (19 ref.) Comment in: Public Health Rep 1997 Jan–Feb;112(1):33–6. Comment in: Public Health Rep 1997 Jul–Aug;112(4):266.

STATISTICS & NUMERICAL DATA

Impact of using weighted versus unweighted measures to assess optometry faculty productivity in research. Doughty MJ, et al. **J Am Optom Assoc** 1996 Jul;67(7):410–20 (28 ref.)

Overcoming feelings of powerlessness in "aging" researchers: a primer on statistical power in analysis of variance designs. Levin JR. **Psychol Aging** 1997 Mar;12(1):84–106 (45 ref.)

TRENDS

Dialyzers and dialysis membranes. Research directions [editorial] Leypoldt JK. **ASAIO J** 1996 May–Jun; 42(3):133–5 (24 ref.)

Tourette's syndrome in the year 2000. Robertson MM, et al. **Aust N Z J Psychiatry** 1996 Dec;30(6):749–59 (136 ref.)

Behavioral and social research in rheumatology [see comments] Callahan LF, et al. **Curr Opin Rheumatol** 1997 Mar;9(2):126–32 (40 ref.) Comment in: Curr Opin Rheumatol 1997 Mar;9(2):87–9.

Future directions for research on endometrial bleeding. Findlay JK. **Hum Reprod** 1996 Oct;11 Suppl 2:179–83 (6 ref.)

Scientific underpinnings for the profession: dietitians in research. Dwyer JT. **J Am Diet Assoc** 1997 Jun;97(6):593–7 (15 ref.)

Review: dairy cattle reproductive physiology research and management—past progress and future prospects. Foote RH. **J Dairy Sci** 1996 Jun;79(6):980–90 (82 ref.)

The Journal of Human Hypertension: looking back over 10 years of research and thinking of the future [editorial] Beevers DG, et al. **J Hum Hypertens** 1997 Jan;11(1):1–5 (36 ref.)

Future direction of research in Tourette syndrome. Kurlan R. **Neurol Clin** 1997 May;15(2):451–6 (49 ref.)

Current topics in complement research. Lachmann PJ. **Res Immunol** 1996 Feb;147(2):69–70 (4 ref.)

Future directions for resuscitation research. III. External

cardiopulmonary resuscitation advanced life support. Ornato JP, et al. **Resuscitation** 1996 Sep;32(2):139–58 (128 ref.)
Future directions for resuscitation research. V. Ultra-advanced life support. Tisherman SA, et al. **Resuscitation** 1997 Jun;34(3):281–93 (93 ref.)
Romanian contribution to stress research. Derevenco P. **Rom J Physiol** 1996 Jan–Dec;33(1–4):101–12 (60 ref.)
[Science needs experimental animals] Kunstyr I. **Tierarztl Prax** 1996 Dec;24(6):532–6 (7 ref.) (Eng. Abstr.) **(Ger)**
[Future trend in research for infectious diseases] Shimizu K. **Kansenshogaku Zasshi** 1997 Apr;71(4):293–8 (0 ref.) **(Jpn)**

RESEARCH, CLINICAL NURSING see **CLINICAL NURSING RESEARCH**

RESEARCH, DENTAL see **DENTAL RESEARCH**

RESEARCH DESIGN

Statistical methodology: I. Incorporating the prevalence of disease into the sample size calculation for sensitivity and specificity [see comments] Buderer NM. **Acad Emerg Med** 1996 Sep;3(9):895–900 (5 ref.) Comment in: Acad Emerg Med 1996 Sep;3(9):824.
Design criteria for studies examining individual fatty acid effects on cardiovascular disease risk factors: human and animal studies. Kris-Etherton PM, et al. **Am J Clin Nutr** 1997 May;65(5 Suppl):1590S–1596S (25 ref.)
The INTERSALT Study: background, methods, findings, and implications. Stamler J. **Am J Clin Nutr** 1997 Feb;65(2 Suppl):626S–642S (153 ref.)
Invited commentary: confounding, measurement error, and publication bias in studies of passive smoking. Kawachi I, et al. **Am J Epidemiol** 1996 Nov 15;144(10):909–15 (57 ref.)
Methodological challenges to the study of occupational injury—an international epidemiology workshop. Courtney TK, et al. **Am J Ind Med** 1997 Aug;32(2):103–5 (15 ref.)
Methodological limitations in the study of video display terminal use and upper extremity musculoskeletal disorders. Gerr F, et al. **Am J Ind Med** 1996 Jun;29(6):649–56 (38 ref.)
Design factors in epidemiologic cohort studies of work-related low back injury or pain. Kraus JF, et al. **Am J Ind Med** 1997 Aug;32(2):153–63 (50 ref.)
Alternative approaches to analytical designs in occupational injury epidemiology. Mittleman MA, et al. **Am J Ind Med** 1997 Aug;32(2):129–41 (58 ref.)
Design and conduct of occupational injury intervention studies: a review of evaluation strategies. Zwerling C, et al. **Am J Ind Med** 1997 Aug;32(2):164–79 (105 ref.)
Some principles in study design for preventing HIV transmission: rigor or reality. Susser M. **Am J Public Health** 1996 Dec;86(12):1713–6 (14 ref.)
Race and health: basic questions, emerging directions [see comments] Williams DR. **Ann Epidemiol** 1997 Jul;7(5):322–33 (120 ref.) Comment in: Ann Epidemiol 1997 Jul;7(5):320–1.
A contemporary research paradigm for the genetic analysis of a common chronic disease. Boerwinkle E. **Ann Med** 1996 Oct;28(5):451–7 (52 ref.)
Design of parenteral synthetic dipeptides for clinical nutrition: in vitro and in vivo utilization. Fürst P, et al. **Ann Nutr Metab** 1997;41(1):10–21 (64 ref.)
Workshop on phase I study design. Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996. Arbuck SG. **Ann Oncol** 1996 Aug;7(6):567–73 (8 ref.)
Measuring social class in US public health research: concepts, methodologies, and guidelines. Krieger N, et al. **Annu Rev Public Health** 1997;18:341–78 (202 ref.)
Pharmacoeconomics: state of the art in 1997. Schulman KA, et al. **Annu Rev Public Health** 1997;18:529–48 (50 ref.)
Explicating middle-range theory through methodological diversity. Acton GJ, et al. **ANS Adv Nurs Sci** 1997 Mar;19(3):78–85 (22 ref.)
Lessons from psychosocial studies of chronic renal failure. Postlethwaite RJ, et al. **Arch Dis Child** 1996 Nov;75(5):455–9 (26 ref.)
Single subject experimentation for psychiatric nursing. Elder JH. **Arch Psychiatr Nurs** 1997 Jun;11(3):133–8 (17 ref.)
Statistics notes. Trials randomised in clusters. Bland JM, et al. **BMJ** 1997 Sep 6;315(7108):600 (8 ref.)
Papers that go beyond numbers (qualitative research). Greenhalgh T, et al. **BMJ** 1997 Sep 20;315(7110):740–3 (21 ref.)
Study design in clinical research: sample size estimation and power analysis [published erratum appears in Can J Anaesth 1996 Aug;43(8):880] Lerman J. **Can J Anaesth** 1996 Feb;43(2):184–91 (11 ref.)
Contributions of risk-factor research to developmental psychopathology. Kazdin AE, et al. **Clin Psychol Rev** 1997;17(4):375–406 (84 ref.)
Data monitoring committees and problems of lower-than-expected accrual or events rates. Korn EL, et al. **Control Clin Trials** 1996 Dec;17(6):526–35 (38 ref.)
The clinical-economic trial: promise, problems, and challenges. Powe NR, et al. **Control Clin Trials** 1995 Dec;16(6):377–94 (56 ref.)
Implications of different study designs for the evaluation of acellular pertussis vaccines. Fine PE. **Dev Biol Stand** 1997;89:123–33 (5 ref.)
Clinical relevance of response and improvement in psychopharmacology: European College of Neuropsychopharmacology. **Eur Neuropsychopharmacol** 1995 Dec;5(4):531–3 (0 ref.)
Research project design in diagnostic radiology. Debatin JF. **Eur Radiol** 1996;6 Suppl 1:S5–10 (35 ref.)
Experimental design and husbandry. Festing MF. **Exp Gerontol** 1997 Jan–Apr;32(1–2):39–47 (19 ref.)
Critical factors in the determination of focus group size. Tang KC, et al. **Fam Pract** 1995 Dec;12(4):474–5 (13 ref.)
A postmodern perspective on feminist gerontology. Ray RE. **Gerontologist** 1996 Oct;36(5):674–80 (64 ref.)
Challenging the validity of conclusions based on P-values alone: a critique of contemporary clinical research design and methods. Ebramzadeh E, et al. **Instr Course Lect** 1994;43:587–600 (26 ref.)
Moving promising research findings to the clinic: methodological issues in the design and conduct of clinical trials of retinoids. Arnold A. **Int J Cancer** 1997 Feb 7;70(4):467–9 (11 ref.)
Research on the psychotherapy of bulimia nervosa: half empty or half full. Mitchell JE, et al. **Int J Eat Disord** 1996 Nov;20(3):219–29 (23 ref.)
Costing methods in the Canadian literature on the economic evaluation of health care. A survey and assessment. Jacobs P, et al. **Int J Technol Assess Health Care** 1996 Fall;12(4):721–34 (59 ref.)
A review of statistical methods in the Journal of Advanced Nursing. Anthony D. **J Adv Nurs** 1996 Nov;24(5):1089–94 (10 ref.)
Finding your way around qualitative methods in nursing research. Bailey PH. **J Adv Nurs** 1997 Jan;25(1):18–22 (21 ref.)
Using triangulation in nursing research. Begley CM. **J Adv Nurs** 1996 Jul;24(1):122–8 (35 ref.)
Mixed messages in nursing research: their contribution to the persisting hiatus between evidence and practice. Hicks C, et al. **J Adv Nurs** 1997 Mar;25(3):595–601 (20 ref.)
Methodological issues conducting sensitive research on lesbian and gay men's experience of nursing care. Platzer H, et al. **J Adv Nurs** 1997 Mar;25(3):626–33 (32 ref.)
Status of research on gender differences. Berg MJ. **J Am Pharm Assoc (Wash)** 1997 Jan–Feb;NS37(1):43–56 (70 ref.)
How should zoster trials be conducted? Wood MJ, et al. **J Antimicrob Chemother** 1995 Dec;36(6):1089–1101 (28 ref.)
Clinical trial designs—made to order. Andersen JS. **J Biopharm Stat** 1996 Nov;6(4):515–22 (10 ref.)
A model for developing effective treatments: progression and interplay of theory, research, and practice. Kazdin AE. **J Clin Child Psychol** 1997 Jun;26(2):114–29 (66 ref.)
Clinical trials in sepsis: where do we stand? [see comments] Vincent JL. **J Crit Care** 1997 Mar;12(1):3–6 (17 ref.) Comment in: J Crit Care 1997 Mar;12(1):1–2.
Error budgets: a system to characterize error source in health care experimentation. Caruso BJ. **J Manipulative Physiol Ther** 1996 Jul–Aug;19(6):385–90 (10 ref.)
Interpreting epidemiologic studies of diet–disease relationships. Tarasuk VS, et al. **J Nutr** 1997 Sep;127(9):1847–52 (68 ref.)
Planning the design phase of a clinical study. Madison M. **J Orthop Trauma** 1997 Jan;11(1):63–7 (19 ref.)
Studying knowledge, culture, and behavior in applied medical anthropology [see comments] Pelto PJ, et al. **Med Anthropol Q** 1997 Jun;11(2):147–63 (29 ref.) Comment in: Med Anthropol Q 1997 Jun;11(2):252–5.
Choosing the best strength measure in frail older persons: importance of task specificity. Chandler J, et al. **Muscle Nerve Suppl** 1997;5:S47–51 (34 ref.)
Noninvasive measures of central and peripheral activation in human muscle fatigue. Kent-Braun JA. **Muscle Nerve Suppl** 1997;5:S98–101 (12 ref.)
Use and misuse of repeated measures designs. Barcikowski RS, et al. **NIDA Res Monogr** 1994;142:302–41 (44 ref.)
Gathering epidemiologic information on inhalant abuse: some methodological issues. Frank B. **NIDA Res Monogr** 1995;148:260–73 (12 ref.)
"To be of use": enhancing the utility of qualitative research. Sandelowski M. **Nurs Outlook** 1997 May–Jun;45(3):125–32 (58 ref.)
Methodological issues in psychoneuroimmunology research. Zeller JM, et al. **Nurs Res** 1996 Sep–Oct;45(5):314–8 (39 ref.)
Research design and methods of quantitative synthesis of medical evidence. Peipert JF, et al. **Obstet Gynecol** 1997 Sep;90(3):473–8 (23 ref.)
Chronic occupational respiratory disease. Attfield MD, et al. **Occup Med** 1996 Jul–Sep;11(3):451–65 (53 ref.)
Occupational epidemiologic study design and application. Blair A, et al. **Occup Med** 1996 Jul–Sep;11(3):403–19 (112 ref.)
Is there a research paradigm for palliative care? Corner J. **Palliat Med** 1996 Jul;10(3):201–8 (26 ref.)
Health status measures: strategies and analytic methods for assessing change scores. Stratford PW, et al. **Phys Ther** 1996 Oct;76(10):1109–23 (33 ref.)
The use and interpretation of the Friedman test in the analysis of ordinal-scale data in repeated measures designs. Sheldon MR, et al. **Physiother Res Int** 1996;1(4):221–8 (28 ref.)
Place cells and place navigation. Bures J, et al. **Proc Natl Acad Sci U S A** 1997 Jan 7;94(1):343–50 (63 ref.)
Concept analysis in nursing research: a critical appraisal. Morse JM, et al. **Sch Inq Nurs Pract** 1996 Fall;10(3):253–77 (104 ref.)
Design of controlled clinical trials for diabetic polyneuropathy. Sima AA, et al. **Semin Neurol** 1996 Jun;16(2):187–91 (22 ref.)
Study design for the evaluation of diagnostic tests. Daya S. **Semin Reprod Endocrinol** 1996 May;14(2):101–9 (10 ref.)
Study design for the evaluation of treatment. Morales AJ. **Semin Reprod Endocrinol** 1996 May;14(2):111–8 (13 ref.)
Human immunodeficiency virus transmission and the role of other sexually transmitted diseases. Measures of association and study design. Boily MC, et al. **Sex Transm Dis** 1996 Jul–Aug;23(4):312–32 (69 ref.)
The role of meta-analysis in monitoring clinical trials. Begg CB. **Stat Med** 1996 Jun 30;15(12):1299–306; discussion 1307–11 (25 ref.)
Meta-analysis and meta-analytic monitoring of clinical trials. Feinstein AR. **Stat Med** 1996 Jun 30;15(12):1273–80; discussion 1281–3 (12 ref.)
The role of external evidence in data monitoring of a clinical trial. Pocock SJ. **Stat Med** 1996 Jun 30;15(12):1285–93; discussion 1295–7 (18 ref.)
Modelling the sampling design in the analysis of health surveys. Graubard BI, et al. **Stat Methods Med Res** 1996 Sep;5(3):263–81 (53 ref.)
Variance estimation for complex surveys using replication techniques. Rust KF, et al. **Stat Methods Med Res** 1996 Sep;5(3):283–310 (52 ref.)
Considerations in the design of clinical trials of neuroprotective therapy in acute stroke. Dorman PJ, et al. **Stroke** 1996 Sep;27(9):1507–15 (85 ref.)
Ethnography: an overview. Agar MH. **Subst Use Misuse** 1997 Jul;32(9):1155–73 (19 ref.)
Composite outcome measures in alcoholism treatment research: problems and potentialities. Zweben A, et al. **Subst Use Misuse** 1996 Nov;31(13):1783–805 (36 ref.)
Methodology of trials with antiemetics. Tonato M, et al. **Support Care Cancer** 1996 Jul;4(4):281–6 (9 ref.)
New research avenues in toxicology: 7-gas N-Gas Model, toxicant suppressants, and genetic toxicology. Levin BC. **Toxicology** 1996 Dec 31;115(1–3):89–106 (41 ref.)
Conducting a descriptive survey: 1. Planning the survey. Macfarlane SB. **Trop Doct** 1996 Oct;26(4):161–4 (9 ref.)
[Manipulation of genes causing diseases] Monckeberg F. **Rev Med Chil** 1996 Mar;124(3):371–6 (28 ref.) (Eng. Abstr.) **(Spa)**

STANDARDS

A review of problems in clinical acupuncture research. Ernst E, et al. **Am J Chin Med** 1997;25(1):3–11 (31 ref.)
Rethinking the conduct of psychiatric research [comment] [see comments] Appelbaum PS. **Arch Gen Psychiatry** 1997 Feb;54(2):117–20 (29 ref.) Comment on: Arch Gen Psychiatry 1997 Feb;54(2):105–11. Comment on: Arch Gen Psychiatry 1997 Feb;54(2):113–6. Comment on: Arch Gen Psychiatry 1997 Feb;54(2):121–3. Comment in: Arch Gen Psychiatry 1997 Feb;54(2):121–3.
The rationale and ethics of medication-free research in schizophrenia [see comments] Carpenter WT Jr, et al. **Arch Gen Psychiatry** 1997 May;54(5):401–7 (58 ref.) Comment in: Arch Gen Psychiatry 1997 May;54(5):412–3. Comment in: Arch Gen Psychiatry 1997 May;54(5):415–6.
Preventable death studies: an inappropriate tool for evaluating trauma systems. Kelly AM, et al. **Aust N Z J Surg** 1997 Sep;67(9):591–2 (25 ref.)
Alternatives to mega-trials in cardiovascular disease. Hampton JR. **Cardiovasc Drugs Ther** 1997 Jan;10(6):759–65 (34 ref.)
The design of clinical trials aimed at assessing the DC-ART properties of new molecules in rheumatoid arthritis. Ortiz Z, et al. **Clin Exp Rheumatol** 1997 May–Jun;15 Suppl 17:S39–44 (33 ref.)
How to use an article on therapy or prevention: pneumonia prevention using subglottic secretion drainage [see comments] Cook DJ, et al. **Crit Care Med** 1997 Sep;25(9):1502–13 (78 ref.) Comment in: Crit Care Med 1997 Sep;25(9):1448–9.
How to use diagnostic test articles in the intensive care unit: diagnosing weanability using f/Vt. Jaeschke RZ, et al. **Crit Care Med** 1997 Sep;25(9):1514–21 (24 ref.)
Either a paradigm shift or no mental measurement: the nonscience and the nonsense of The Bell Curve. Hilliard AG 3rd. **Cult Divers Ment Health** 1996;2(1):1–20 (37 ref.)
Multiparous species present problems (and possibilities) to developmentalists. Zorrilla EP. **Dev Psychobiol** 1997 Mar;30(2):141–50 (49 ref.)
Purpose and guidelines for toxicokinetic studies within the National Toxicology Program. Buchanan JR, et al. **Environ Health Perspect** 1997 May;105(5):468–71 (4 ref.)
Estimating the risk of breast cancer in relation to the interval since last term pregnancy [see comments] Cummings P, et al. **Epidemiology** 1997 Sep;8(5):488–94 (18 ref.) Comment in: Epidemiology 1997 Sep;8(5):471–3.
Empowering research: statistical power in general practice research. Fox N, et al. **Fam Pract** 1997 Aug;14(4):324–9 (7 ref.)

RESEARCH DESIGN

A review of recently published qualitative research in general practice. More methodological questions than answers? Hoddinott P, et al. **Fam Pract** 1997 Aug;14(4):313–9 (33 ref.)

Guidelines for international collaborative research. Rosser WW, et al. **Fam Pract** 1997 Aug;14(4):330–4 (14 ref.)

Economical designs for detecting and characterizing departure from additivity in mixtures of many chemicals. Gennings C. **Food Chem Toxicol** 1996 Nov–Dec; 34(11–12):1053–8 (22 ref.)

Statistical designs in combination toxicology: a matter of choice. Schoen ED. **Food Chem Toxicol** 1996 Nov–Dec; 34(11–12):1059–65 (17 ref.)

Experimental designs, statistics and interpretation. Simmons JE, et al. **Food Chem Toxicol** 1996 Nov–Dec; 34(11–12):1169–71 (3 ref.)

How to do a simple epidemiological study. I. Planning. Bowker TJ. **Int J Cardiol** 1996 Dec 6;57(2):105–17 (23 ref.)

EUR–ASSESS Project Subgroup report on Methodology. Methodological guidance for the conduct of health technology assessment. Liberati A, et al. **Int J Technol Assess Health Care** 1997 Spring;13(2):186–219 (55 ref.)

Design issues addressed in published evaluations of adolescent HIV–risk reduction interventions: a review [see comments] Stanton B, et al. **J Adolesc Health** 1996 Jun; 18(6):387–96 (61 ref.) Comment in: J Adolesc Health 1996 Jun;18(6):379.

A re–examination of the experimental design for nursing research. Poole K, et al. **J Adv Nurs** 1996 Jul;24(1):108–14 (64 ref.)

Use and abuse of the Children's Depression Inventory. Fristad MA, et al. **J Consult Clin Psychol** 1997 Aug; 65(4):699–702 (21 ref.)

Detecting poor design, erroneous analysis and misinterpretation of studies. Appleton DR. **J Eval Clin Pract** 1995 Nov;1(2):113–7 (8 ref.)

On evidence, embellishment and efficacy. Morgan WK. **J Eval Clin Pract** 1997 Apr;3(2):117–22 (12 ref.)

The case for failed meta–analyses. Naylor CD. **J Eval Clin Pract** 1995 Nov;1(2):127–30 (21 ref.)

How convergence of research paradigms can improve research on diagnostic judgment. Hammond KR. **Med Decis Making** 1996 Jul–Sep;16(3):281–7 (30 ref.)

Challenges in measuring patient outcomes. Strickland OL. **Nurs Clin North Am** 1997 Sep;32(3):495–512 (23 ref.)

Prostate cancer, race, and socioeconomic status: inadequate adjustment for social factors in assessing racial differences. Dale W, et al. **Prostate** 1996 Nov;29(5):271–81 (53 ref.)

Early detection and intervention in schizophrenia: research. McGlashan TH. **Schizophr Bull** 1996;22(2):327–45 (34 ref.)

Studying the quality of life after organ transplantation: research problems and solutions. Joralemon D, et al. **Soc Sci Med** 1997 May;44(9):1259–69 (100 ref.)

Olfactory remediation: current evidence and possible applications. Martin GN. **Soc Sci Med** 1996 Jul;43(1):63–70 (75 ref.)

Statistical power and design of focused clustering studies. Waller LA. **Stat Med** 1996 Apr 15–May 15;15(7–9):765–82 (39 ref.)

STATISTICS & NUMERICAL DATA

Comparing methods of measurements. Ludbrook J. **Clin Exp Pharmacol Physiol** 1997 Feb;24(2):193–203 (34 ref.)

Statistical considerations concerning clinical studies designed to assess DC–ARTs. Della Casa–Alberighi O, et al. **Clin Exp Rheumatol** 1997 May–Jun;15 Suppl 17:S45–52 (48 ref.)

Bias against the null hypothesis in maternal–fetal pharmacology and toxicology. Koren G. **Clin Pharmacol Ther** 1997 Jul;62(1):1–5 (21 ref.)

An introduction to the statistical design of phase III cancer clinical trials. Sylvester R. **Eur Urol** 1997;31 Suppl 1:65–71 (8 ref.)

Statistical principles underlying the applications of laboratory methods to field studies. Guo SS, et al. **Muscle Nerve Suppl** 1997;5:S32–4 (7 ref.)

RESEARCH, HEALTH SERVICES see **HEALTH SERVICES RESEARCH**

RESEARCH INSTITUTES see **ACADEMIES AND INSTITUTES**

RESEARCH, NURSING see **NURSING RESEARCH**

RESEARCH, NURSING ADMINISTRATION see **NURSING ADMINISTRATION RESEARCH**

RESEARCH, NURSING EDUCATION see **NURSING EDUCATION RESEARCH**

RESEARCH, NURSING EVALUATION see **NURSING EVALUATION RESEARCH**

RESEARCH, NURSING METHODOLOGY see **NURSING METHODOLOGY RESEARCH**

RESEARCH PERSONNEL

The clinical investigator: bewitched, bothered, and bewildered—but still beloved [editorial] Goldstein JL, et al. **J Clin Invest** 1997 Jun 15;99(12):2803–12 (38 ref.)

The role of the clinical research coordinator in multicenter clinical trials. Pelke S, et al. **J Obstet Gynecol Neonatal Nurs** 1997 May–Jun; 26(3):279–85 (14 ref.)

The consequences of knowing: ethical and legal liabilities in illicit drug research. Fitzgerald J, et al. **Soc Sci Med** 1996 Dec;43(11):1591–600 (35 ref.)

[Laboratory animals as a cause of occupational allergy] Krakowiak A, et al. **Med Pr** 1996;47(5):523–31 (55 ref.) (Eng. Abstr.) **(Pol)**

RESEARCH PRIORITIES see **RESEARCH**

RESEARCH PROTOCOLS, CLINICAL see **CLINICAL PROTOCOLS**

RESEARCH SUBJECT RECRUITMENT see **PATIENT SELECTION**

RESEARCH SUPPORT

Funding nursing informatics activities. Internet access to announcements of government funding. McCormick KA, et al. **Comput Nurs** 1996 Nov–Dec;14(6):315–22 (10 ref.)

Published literature on faculty development programs. Meurer LN, et al. **Fam Med** 1997 Apr;29(4):248–50 (21 ref.)

[Future research for the treatment of intractable diseases] Mizushima Y. **Ryumachi** 1995 Dec;35(6):877–9 (6 ref.) **(Jpn)**

[The practical theory of occupational health planning: Part Two—The theoretical background from the priority setting procedure to the post project appraisal making procedure (OPST research report 3)] Jahng DJ, et al. **Sangyo Ika Daigaku Zasshi** 1996 Sep 1;18(3):203–11 (17 ref.) (Eng. Abstr.) **(Jpn)**

[The development of the occupational physician support system—OPST research report] Jahng DJ. **Sangyo Ika Daigaku Zasshi** 1996 Sep 1;18(3):185–92 (8 ref.) **(Jpn)**

[Increased concentration on research of women's health] Schei B, et al. **Tidsskr Nor Laegeforen** 1997 Apr 30; 117(11):1634–6 (42 ref.) **(Nor)**

ECONOMICS

"While you're up, get me a grant": a guide to grant writing. Streiner DL. **Can J Psychiatry** 1996 Apr;41(3):137–43 (2 ref.)

STANDARDS

Health care for research animals is essential and affordable. Jacoby RO, et al. **FASEB J** 1997 Jul;11(8):609–14 (6 ref.)

RESEARCHERS see **RESEARCH PERSONNEL**

RESERPINE

ADVERSE EFFECTS

Reserpine: a tragic victim of myths, marketing, and fashionable prescribing. Fraser HS. **Clin Pharmacol Ther** 1996 Oct;60(4):368–73 (57 ref.)

RESIDENCE CHARACTERISTICS

Segregation, discrimination and mortality in U.S. blacks. Polednak AP. **Ethn Dis** 1996 Winter–Spring;6(1–2):99–108 (67 ref.)

The epidemiology of atopic diseases in Germany: an east–west comparison. Trepka MJ, et al. **Rev Environ Health** 1996 Jul–Sep;11(3):119–31 (49 ref.)

Magnetic fields and leukemia—risk for adults living close to power lines. Verkasalo PK. **Scand J Work Environ Health** 1996;22 Suppl 2:1–56 (145 ref.)

Disease cluster statistics for imprecise space–time locations. Jacquez GM. **Stat Med** 1996 Apr 15–May 15; 15(7–9):873–85 (29 ref.)

[Illegal drug use by secondary school children in Belgium: north–south differences] Navarro FJ, et al. **Rev Epidemiol Sante Publique** 1996 Oct;44(5):395–406 (41 ref.) (Eng. Abstr.) **(Fre)**

RESIDENCY, DENTAL see **INTERNSHIP AND RESIDENCY**

RESIDENCY, MEDICAL see **INTERNSHIP AND RESIDENCY**

RESIDENTIAL MOBILITY

Psychiatric implications of displacement: contributions from the psychology of place [see comments] Fullilove MT. **Am J Psychiatry** 1996 Dec;153(12):1516–23 (84 ref.) Comment in: Am J Psychiatry 1997 Sep;154(9):1328–9.

Environmental causes and impact of refugee movements: a critique of the current debate. Kibreab G. **Disasters** 1997 Mar;21(1):20–38 (90 ref.)

RESIDENTIAL TREATMENT

LEGISLATION & JURISPRUDENCE

A ten–year review of the effect of OBRA–87 on psychotropic prescribing practices in an academic nursing home. Lantz MS, et al. **Psychiatr Serv** 1996 Sep;47(9):951–5 (34 ref.)

METHODS

Relative role of ambulatory and residential rehabilitation. Cobelli F, et al. **J Cardiovasc Risk** 1996 Apr;3(2):172–5 (20 ref.)

RESIDUAL CANCER see **NEOPLASM, RESIDUAL**

RESIDUAL TUMOR see **NEOPLASM, RESIDUAL**

RESIN-BONDED ACID-ETCHED FIXED PARTIAL DENTURE see **DENTURE, PARTIAL, FIXED, RESIN-BONDED**

RESIN-BONDED BRIDGE see **DENTURE, PARTIAL, FIXED, RESIN-BONDED**

RESIN-BONDED FIXED PARTIAL DENTURE see **DENTURE, PARTIAL, FIXED, RESIN-BONDED**

RESIN CEMENTS

CHEMISTRY

[Characterization of glass ionomer cements containing resin] Gladys S, et al. **Rev Belge Med Dent** 1996;51(1):36–53 (24 ref.) (Eng. Abstr.) **(Fre)**

RESINS

ADVERSE EFFECTS

Adverse effects of colophony. Keira T, et al. **Ind Health** 1997;35(1):1–7 (63 ref.)

RESINS, SYNTHETIC

Summary and recommendations. Stein PD, et al. **J Heart Valve Dis** 1996 Aug;5 Suppl 2:S246–8 (10 ref.)

The Björk–Shiley Delrin tilting disc heart valve: historical perspective, design and need for scientific analyses after 25 years. Wieting DW. **J Heart Valve Dis** 1996 Aug;5 Suppl 2:S157–68 (37 ref.)

CHEMISTRY

Consolidation of particle beds and packing of chromatographic columns. Guiochon G, et al. **J Chromatogr A** 1997 Feb 21;762(1–2):83–8 (38 ref.)

Delrin material characteristics. Clark ES. **J Heart Valve Dis** 1996 Aug;5 Suppl 2:S184–9 (20 ref.)

PHARMACOKINETICS

Bioavailability of components of resin–based materials which are applied to teeth. Hume WR, et al. **Crit Rev Oral Biol Med** 1996;7(2):172–9 (93 ref.)

RESISTANCE FACTORS see **R FACTORS**

RESISTANCE, NATURAL see **IMMUNITY, NATURAL**

RESISTANT OVARY SYNDROME see **OVARIAN FAILURE, PREMATURE**

RESORCINOLS

The proper use of glue: a 20–year experience with the GRF glue in acute aortic dissection. Bachet J, et al. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):243–53; discussion 253–5 (30 ref.)

ADMINISTRATION & DOSAGE

Medium–depth chemical peeling. Otley CC, et al. **Semin Cutan Med Surg** 1996 Sep;15(3):145–54 (23 ref.)

RESORTS see **HEALTH RESORTS**

RESOURCE ALLOCATION see **HEALTH CARE RATIONING**

RESOURCE-BASED RELATIVE VALUE SCALE see **RELATIVE VALUE SCALES**

RESPIRATION

see related
APNEA
BREATH TESTS
DYSPNEA

Respiratory inputs to central cardiovascular neurons. Pilowsky P, et al. **Ann N Y Acad Sci** 1996 Aug 15;783:64–70 (36 ref.)

Airway and respiratory management following non–lethal hanging. Kaki A, et al. **Can J Anaesth** 1997 Apr; 44(4):445–50 (15 ref.)

Pressure-controlled and volume-cycled mechanical ventilation. McKibben AW, et al. **Clin Chest Med** 1996 Sep;17(3):395–410 (78 ref.)
Breathing—what's the "right" answer? [editorial; comment] Givan DC, et al. **J Pediatr** 1996 Dec;129(6):781–2 (18 ref.) Comment on: J Pediatr 1996 Dec;129(6):804–8.
[Animal respiration as a combustion phenomenon. A historical overview] de Micheli A. **Arch Inst Cardiol Mex** 1996 Nov–Dec;66(6):519–24 (20 ref.) **(Spa)**

PHYSIOLOGY

Upper airway influences on breathing. Sant'Ambrogio G. **Adv Exp Med Biol** 1995;381:37–46 (26 ref.)
Carotid chemoreflex. Neural pathways and transmitters. Sapru HN. **Adv Exp Med Biol** 1996;410:357–64 (22 ref.)
Prolegomena. Chemoreception upstream of transmitters. Torrance RW. **Adv Exp Med Biol** 1996;410:13–38 (49 ref.)
Feeding and breathing in lampreys. Rovainen CM. **Brain Behav Evol** 1996;48(5):297–305 (67 ref.)
Interactions between body temperature regulation and blood acid–base status in anuran amphibians. Branco LG. **Braz J Med Biol Res** 1995 Nov–Dec;28(11–12):1191–6 (54 ref.)
The frog brainstem preparation as a model for studying the central control of breathing in tetrapods. Perry SF, et al. **Braz J Med Biol Res** 1995 Nov–Dec;28(11–12):1339–46 (24 ref.)
Functional consequences of acute and chronic hypoxia on respiratory and skeletal muscles in mammals. Jammes Y, et al. **Comp Biochem Physiol A Physiol** 1997 Sep; 118(1):15–22 (54 ref.)
The avian respiratory system: a unique model for studies of respiratory toxicosis and for monitoring air quality. Brown RE, et al. **Environ Health Perspect** 1997 Feb;105(2):188–200 (108 ref.)
Control of breathing in mechanically ventilated patients. Georgopoulos D, et al. **Eur Respir J** 1996 Oct; 9(10):2151–60 (67 ref.)
Behavioural and arousal-related influences on breathing in humans. Shea SA. **Exp Physiol** 1996 Jan;81(1):1–26 (162 ref.)
Monitoring respiratory function. Jacobsohn E, et al. **Int Anesthesiol Clin** 1996 Summer;34(3):1–36 (50 ref.)
Temporal variations in the pattern of breathing. Bruce EN. **J Appl Physiol** 1996 Apr;80(4):1079–87 (94 ref.)
The interaction of pulmonary ventilation and the right–left shunt on arterial oxygen levels. Wang T, et al. **J Exp Biol** 1996 Oct;199 (Pt 10):2121–9 (28 ref.)
Figuring out why we breathe. Farnsworth WE. **Med Hypotheses** 1997 Mar;48(3):229–36 (54 ref.)
Midbrain and medullary regulation of respiration and vocalization. Davis PJ, et al. **Prog Brain Res** 1996; 107:315–25 (61 ref.)
Rostral brain regions contributing to respiratory control. Harper RM, et al. **Prog Brain Res** 1996;107:145–56 (76 ref.)
Regulation of fetal breathing. Rigatto H. **Reprod Fertil Dev** 1996;8(1):23–33 (67 ref.)
The cerebral regulation of cardiovascular and respiratory functions. Harper RM. **Semin Pediatr Neurol** 1996 Mar; 3(1):13–22 (81 ref.)
Excitatory drive to the respiratory system in REM sleep. Orem J. **Sleep** 1996 Dec;19(10 Suppl):S154–6 (18 ref.)
Potassium and breathing in exercise. Paterson DJ. **Sports Med** 1997 Mar;23(3):149–63 (80 ref.)
Primordial respiratory-like rhythm generation in the vertebrate embryo. Champagnat J, et al. **Trends Neurosci** 1997 Mar;20(3):119–24 (40 ref.)
[Role of nitric oxide in respiratory physiology and in the physiopathology of pulmonary diseases] Dinh-Xuan AT. **Rev Mal Respir** 1996;13(4):381–8 (30 ref.) (Eng. Abstr.) **(Fre)**
[Respiratory mechanics in animals. 1. Physiological bases and conventional measurement methods—review] Reinhold P. **Berl Munch Tierarztl Wochenschr** 1997 Jul–Aug; 110(7–8):251–6 (73 ref.) (Eng. Abstr.) **(Ger)**
[Respiratory mechanics in animals. 2. The forced oscillation technique—review] Reinhold P. **Berl Munch Tierarztl Wochenschr** 1997 Jul–Aug; 110(7–8):257–66 (77 ref.) (Eng. Abstr.) **(Ger)**
[Chronobiology of the bronchial system] Marek W. **Pneumologie** 1997 Apr;51 Suppl 2:430–9 (59 ref.) (Eng. Abstr.) **(Ger)**
[Control and development of breathing, pathophysiological aspects] Schläfke ME. **Pneumologie** 1997 Apr;51 Suppl 2:398–402 (10 ref.) (Eng. Abstr.) **(Ger)**
[Deterministic-chaotic and spectral-functional analysis of heart rate and respiratory movements] Zwiener U, et al. **Pneumologie** 1997 Apr;51 Suppl 2:415–22 (48 ref.) (Eng. Abstr.) **(Ger)**
[Respiratory arrhythmia] Hayashi H. **Ryoikibetsu Shokogun Shirizu** 1996;(12):274–6 (20 ref.) **(Jpn)**
[Circadian variation of lung function in health persons] Franczuk M, et al. **Pneumonol Alergol Pol** 1997; 65(1–2):96–103 (26 ref.) **(Pol)**

RESPIRATION, ARTIFICIAL

see related
VENTILATORS, MECHANICAL
Mechanical ventilation in ARDS. Kesecioğlu J. **Adv Exp Med Biol** 1996;388:533–8 (30 ref.)
Inhaled bronchodilator therapy in mechanically ventilated patients. Dhand R, et al. **Am J Respir Crit Care Med** 1997 Jul;156(1):3–10 (78 ref.)
Ventilatory strategies for acute respiratory failure. Moore FA, et al. **Am J Surg** 1997 Jan;173(1):53–6; discussion 57–8 (15 ref.)
Therapeutic aerosol delivery during mechanical ventilation. Coleman DM, et al. **Ann Pharmacother** 1996 Jun; 30(6):644–55 (54 ref.)
Advances in the management of respiratory failure. Advanced strategies for mechanical ventilation in severe acute respiratory failure. Conrad SA. **ASAIO J** 1996 May–Jun;42(3):204–6 (15 ref.)
The respiratory system. Zifko U, et al. **Baillieres Clin Neurol** 1996 Oct;5(3):477–95 (69 ref.)
Resuscitation strategy and surfactant therapy. Werner O, et al. **Biol Neonate** 1997;71 Suppl 1:32–4 (10 ref.)
Patient–ventilator interactions. Dick CR, et al. **Clin Chest Med** 1996 Sep;17(3):423–38 (99 ref.)
Monitoring during mechanical ventilation. Jubran A, et al. **Clin Chest Med** 1996 Sep;17(3):453–73 (117 ref.)
Mechanical ventilation in obstructive lung disease. Leatherman JW. **Clin Chest Med** 1996 Sep;17(3):577–90 (83 ref.)
Mechanical ventilation of the newborn. An overview. Mammel MC, et al. **Clin Chest Med** 1996 Sep;17(3):603–13 (45 ref.)
Evolving concepts in the ventilatory management of acute respiratory distress syndrome. Marini JJ. **Clin Chest Med** 1996 Sep;17(3):555–75 (116 ref.)
Adjuncts to mechanical ventilation. Nahum A, et al. **Clin Chest Med** 1996 Sep;17(3):491–511 (168 ref.)
The use of hyperventilation and its impact on cerebral ischemia in the treatment of traumatic brain injury. Yundt KD, et al. **Crit Care Clin** 1997 Jan;13(1):163–84 (85 ref.)
Initial treatment of preterm infants—continuous positive airway pressure or ventilation? Lundstrøm KE. **Eur J Pediatr** 1996 Aug;155 Suppl 2:S25–9 (34 ref.)
New strategies in mechanical ventilation for acute lung injury. Burchardi H. **Eur Respir J** 1996 May;9(5):1063–72 (80 ref.)
Control of breathing in mechanically ventilated patients. Georgopoulos D, et al. **Eur Respir J** 1996 Oct; 9(10):2151–60 (67 ref.)
Weaning from mechanical ventilation. Mancebo J. **Eur Respir J** 1996 Sep;9(9):1923–31 (71 ref.)
Pulmonary hyperinflation and ventilator-dependent patients. Rossi A, et al. **Eur Respir J** 1997 Jul;10(7):1663–74 (90 ref.)
Mechanical ventilation and adjuncts in acute respiratory distress syndrome. Deb B, et al. **Int Anesthesiol Clin** 1997 Winter;35(1):109–24 (115 ref.)
Extracorporeal support of oxygenation and ventilation. Furukawa S. **Int Anesthesiol Clin** 1997 Winter;35(1):169–76 (34 ref.)
Considerations for mechanical ventilation in patients with obstructive airways disease. Gal TJ. **Int Anesthesiol Clin** 1997 Winter;35(1):125–37 (25 ref.)
Mechanical ventilation for pediatric patients. Hammer GB, et al. **Int Anesthesiol Clin** 1997 Winter;35(1):139–67 (119 ref.)
The monitoring of mechanically ventilated patients. Kirby RR. **Int Anesthesiol Clin** 1997 Winter;35(1):65–86 (61 ref.)
Indications for mechanical ventilation. Tung A. **Int Anesthesiol Clin** 1997 Winter;35(1):1–17 (40 ref.)
Current status of mechanical ventilation decision support systems: a review. Rudowski R, et al. **Int J Clin Monit Comput** 1996 Aug;13(3):157–66 (39 ref.)
Continuous arterial gas monitoring: initial experience with the Paratrend 7 in children. Weiss IK, et al. **Intensive Care Med** 1996 Dec;22(12):1414–7 (13 ref.)
A look at recent hyperventilation studies: outcomes and recommendations for early use in the head-injured patient. Geraci E, et al. **J Neurosci Nurs** 1996 Aug;28(4):222–4, 229–33 (35 ref.)
Respiratory support in refractory ARDS. Keogh BF. **Middle East J Anesthesiol** 1996 Jun;13(5):461–93 (56 ref.)
Effects of mechanical ventilation on control of breathing. Georgopoulos DB, et al. **Monaldi Arch Chest Dis** 1997 Jun; 52(3):253–62 (45 ref.)
Lungs at home. Petty TL. **Monaldi Arch Chest Dis** 1996 Feb; 51(1):60–3 (20 ref.)
Home mechanical ventilation in children: techniques, outcomes and ethics. Shneerson JM. **Monaldi Arch Chest Dis** 1996 Oct;51(5):426–30 (23 ref.)
Respiratory insufficiency and ventilatory support. 39th ENMC International Workshop, Naarden, The Netherlands, 26–28 January 1996. European Consortium on Chronic Respiratory Insufficiency. Rutgers M, et al. **Neuromuscul Disord** 1996 Dec;6(6):431–5 (0 ref.)
Continuous ketamine infusion for the treatment of refractory asthma in a mechanically ventilated infant: case report and review of the pediatric literature. Nehama J, et al. **Pediatr Emerg Care** 1996 Aug;12(4):294–7 (20 ref.)
Strategies of invasive ventilatory support in ARDS. Kirkpatrick AW, et al. **Shock** 1996;6 Suppl 1:S17–22 (64 ref.)
[Diagnostic procedures in artificially ventilated patients with pneumonia] Clementsen PS, et al. **Ugeskr Laeger** 1996 Sep 30;158(40):5595–9 (33 ref.) (Eng. Abstr.) **(Dan)**
[Experimental changes in the alveolo-capillary barrier induced by artificial ventilation] Dreyfuss D, et al. **Schweiz Med Wochenschr** 1997 Jun 14;127(24):1023–9 (30 ref.) (Eng. Abstr.) **(Fre)**
[Augmented spontaneous breathing] Hachenberg T. **Anaesthesist** 1996 Sep;45(9):839–55 (143 ref.) (Eng. Abstr.) **(Ger)**
[Ventilation during cardiopulmonary resuscitation (CPR). A literature study and analysis of ventilation strategies] Wenzel V, et al. **Anaesthesist** 1997 Feb;46(2):133–41 (32 ref.) (Eng. Abstr.) **(Ger)**
[Mucociliary clearance function and medicamentous modification] Konrad F. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Sep; 31(7):404–8 (38 ref.) (Eng. Abstr.) **(Ger)**
[Risks and side effects of diagnostic bronchoalveolar lavage in ventilated patients] Zimmermann P, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Mar; 32(3):169–74 (62 ref.) (Eng. Abstr.) **(Ger)**
[New therapy aspects of chronic respiratory insufficiency] Karg O. **Med Klin** 1997 Apr 28;92 Suppl 1:14–7 (25 ref.) (Eng. Abstr.) **(Ger)**
[Diagnosis of pneumonia in artificial ventilation: principles, techniques, results, preliminary recommendations] Ewig S, et al. **Pneumologie** 1996 Oct;50(10):718–31 (87 ref.) **(Ger)**
[Perspectives in mechanical ventilation in ARDS] Max M, et al. **Schweiz Med Wochenschr** 1997 Jun 14;127(24):1030–8 (68 ref.) (Eng. Abstr.) **(Ger)**
[Intensive care in increased intracranial pressure. II: General intensive care treatment of patients with increased intracranial pressure. Ventilation. Intensive Care Committee of the German Society of Anesthesia and Intensive care] Burchardi H, et al. **Zentralbl Neurochir** 1997;58(2):76–82 (37 ref.) **(Ger)**
[Airway management of the multiple trauma patient] Ben-Abraham R, et al. **Harefuah** 1997 Jun 15; 132(12):897–902 (35 ref.) **(Heb)**
[Cardiopulmonary support in high-risk percutaneous coronary angioplasty] Bartorelli AL. **Cardiologia** 1997 May; 42(5):533–9 (5 ref.) **(Ita)**
[Experience of an intermediate respiratory intensive therapy in the treatment of prolonged weaning from mechanical ventilation] Vitacca M, et al. **Minerva Anestesiol** 1996 Mar; 62(3):57–64 (23 ref.) (Eng. Abstr.) **(Ita)**
[Current systems of ventilation of the lungs and methods of their monitoring] Al'es VF, et al. **Anesteziol Reanimatol** 1996 Nov–Dec;(6):67–71 (80 ref.) **(Rus)**

ADVERSE EFFECTS

Ventilation patterns, surfactant and lung injury. Jonson B. **Biol Neonate** 1997;71 Suppl 1:13–7 (24 ref.)
Complications of mechanical ventilation. A bedside approach. Keith RL, et al. **Clin Chest Med** 1996 Sep; 17(3):439–51 (37 ref.)
How to use an article on therapy or prevention: pneumonia prevention using subglottic secretion drainage [see comments] Cook DJ, et al. **Crit Care Med** 1997 Sep; 25(9):1502–13 (78 ref.) Comment in: Crit Care Med 1997 Sep;25(9):1448–9.
Sinusitis in mechanically ventilated patients and its role in the pathogenesis of nosocomial pneumonia. Bert F., et al. **Eur J Clin Microbiol Infect Dis** 1996 Jul;15(7):533–44 (84 ref.)
Noninvasive mechanical ventilation in acute respiratory failure. Ambrosino N. **Eur Respir J** 1996 Apr;9(4):795–807 (116 ref.)
Stomach as a source of colonization of the respiratory tract during mechanical ventilation: association with ventilator-associated pneumonia. Torres A, et al. **Eur Respir J** 1996 Aug;9(8):1729–35 (55 ref.)
Nosocomial pneumonia. Diagnosis and prevention. Mayhall CG. **Infect Dis Clin North Am** 1997 Jun;11(2):427–57 (103 ref.)
Factors influencing acquired upper airway obstruction in newborn infants receiving assisted ventilation because of respiratory failure: an overview. da Silva OP. **J Perinatol** 1996 Jul–Aug;16(4):272–5 (35 ref.)
Ventilator-associated pneumonia. Dottorini M. **Monaldi Arch Chest Dis** 1996 Aug;51(4):331–4 (47 ref.)
The diagnosis of nosocomial pneumonia in ventilated patients. Nardini S. **Monaldi Arch Chest Dis** 1996 Aug; 51(4):342–4 (6 ref.)
Could invasive diagnostic techniques for ventilator-associated pneumonia be associated with reduced antibiotic usage in the ICU? Brun-Buisson C. **New Horiz** 1996 Aug;4(3):345–52 (58 ref.)
New etiopathogenic concepts of ventilator-associated pneumonia. Cassiere HA, et al. **Semin Respir Infect** 1996 Mar;11(1):13–23 (55 ref.)
Nosocomial pneumonia in mechanically ventilated adult patients: epidemiology and prevention in 1996. Craven DE, et al. **Semin Respir Infect** 1996 Mar;11(1):32–53 (188 ref.)
Microbial causes of ventilator-associated pneumonia. Rello J, et al. **Semin Respir Infect** 1996 Mar;11(1):24–31 (37 ref.)
Histology and microbiology of ventilator-associated pneumonias. Rouby JJ. **Semin Respir Infect** 1996 Mar; 11(1):54–61 (20 ref.)
Neurological complications of severe illness and prolonged mechanical ventilation. Wiles CM. **Thorax** 1996 Aug;51 Suppl 2:S40–4 (27 ref.)
Tension pneumoperitoneum. Chan SY, et al. **West J Med** 1996 Jul–Aug;165(1–2):61–4 (33 ref.)

[Prevention of acquired pneumonia during artificial ventilation (excluding the use of anti-infectious agents)] Fagon JY, et al. **Rev Mal Respir** 1997 Jan;14(1):13–9 (43 ref.) (Eng. Abstr.) **(Fre)**

[Pathophysiology of hypercapnia] Pakulski C, et al. **Przegl Lek** 1997;54(3):185–8 (23 ref.) (Eng. Abstr.) **(Pol)**

[Prophylaxis and treatment of aspiration syndrome and complications of artificial lung ventilation with endotracheal laser therapy] Chesnov VS, et al. **Anesteziol Reanimatol** 1996 Jul–Aug;(4):78–9 (3 ref.) **(Rus)**

INSTRUMENTATION

Anaesthetic machine and breathing system contamination and the efficacy of bacterial/viral filters. Hogarth I. **Anaesth Intensive Care** 1996 Apr;24(2):154–63 (74 ref.)

[Concepts of noninvasive ventilation] Becker HF, et al. **Internist (Berl)** 1996 May;37(5):500–10 (82 ref.) **(Ger)**

[Non-invasive ventilation in acute respiratory insufficiency] Karg O, et al. **Pneumologie** 1996 Nov;50(11):759–63 (31 ref.) (Eng. Abstr.) **(Ger)**

[Proportional assisted ventilation—advantages and limits of a new ventilation concept] Stahl CA, et al. **Pneumologie** 1997 Mar;51(3):264–9 (7 ref.) **(Ger)**

[A diaphragmatic pacemaker in the treatment of ventilatory failure] Ponce P, et al. **Acta Med Port** 1995 Nov; 8(11):639–42 (10 ref.) (Eng. Abstr.) **(Por)**

METHODS

Refractory asthma, Part 2: Airway interventions and management. Jagoda A, et al. **Ann Emerg Med** 1997 Feb; 29(2):275–81 (59 ref.)

Advances in the management of respiratory failure. Liquid ventilation in the setting of respiratory failure. Hirschl RB. **ASAIO J** 1996 May–Jun;42(3):209–10 (22 ref.)

New modes of mechanical ventilation. MacIntyre NR. **Clin Chest Med** 1996 Sep;17(3):411–21 (63 ref.)

Pressure-controlled and volume-cycled mechanical ventilation. McKibben AW, et al. **Clin Chest Med** 1996 Sep;17(3):395–410 (78 ref.)

Independent lung ventilation. Ost D, et al. **Clin Chest Med** 1996 Sep;17(3):591–601 (57 ref.)

Home oxygen and ventilation therapies in pediatric patients. Voter KZ, et al. **Curr Opin Pediatr** 1996 Jun;8(3):221–5 (30 ref.)

Liquid ventilation: an alternative ventilation strategy for management of neonatal respiratory distress. Shaffer TH, et al. **Eur J Pediatr** 1996 Aug;155 Suppl 2:S30–4 (48 ref.)

Noninvasive mechanical ventilation in acute respiratory failure. Ambrosino N. **Eur Respir J** 1996 Apr;9(4):795–807 (116 ref.)

Negative pressure ventilation in the treatment of acute respiratory failure: an old noninvasive technique reconsidered. Corrado A, et al. **Eur Respir J** 1996 Jul; 9(7):1531–44 (113 ref.)

Conventional modes of mechanical ventilation. Botz GH, et al. **Int Anesthesiol Clin** 1997 Winter;35(1):19–27 (25 ref.)

Noninvasive ventilation. Murray MJ, et al. **Int Anesthesiol Clin** 1997 Winter;35(1):45–64 (46 ref.)

The hemodynamic consequences of mechanical ventilation: an evolving story. Pinsky MR. **Intensive Care Med** 1997 May;23(5):493–503 (93 ref.)

Delivery and monitoring of inhaled nitric oxide. Young JD, et al. **Intensive Care Med** 1996 Jan;22(1):77–86 (61 ref.)

Noninvasive mechanical ventilation in acute on chronic respiratory failure: determinants of success and failure. Ambrosino N. **Monaldi Arch Chest Dis** 1997 Feb;52(1):73–5 (26 ref.)

Noninvasive pressure support ventilation: physiological and clinical results in patients with COPD and acute respiratory failure. Brochard L. **Monaldi Arch Chest Dis** 1997 Feb; 52(1):64–7 (20 ref.)

Patient ventilator interfaces: practical aspects in the chronic situation. Clini E. **Monaldi Arch Chest Dis** 1997 Feb; 52(1):76–9 (27 ref.)

Noninvasive mechanical ventilation and acute respiratory failure: indications and limitations. Muir JF, et al. **Monaldi Arch Chest Dis** 1997 Feb;52(1):56–9 (20 ref.)

Update in mechanical ventilation. Tobin MJ. **Monaldi Arch Chest Dis** 1996 Dec;51(6):510–3 (19 ref.)

Where and how must we perform noninvasive mechanical ventilation? Vitacca M. **Monaldi Arch Chest Dis** 1997 Feb; 52(1):80–2 (17 ref.)

Techniques in mechanical ventilation: principles and practice. Shneerson JM. **Thorax** 1996 Jul;51(7):756–61 (23 ref.)

Non-invasive ventilation for exacerbations of respiratory failure in chronic obstructive pulmonary disease. Wedzicha JA. **Thorax** 1996 Aug;51 Suppl 2:S35–9 (25 ref.)

[Artificial ventilation in acute respiratory distress syndrome in adults. Towards an individual optimization] Joly LM, et al. **Presse Med** 1996 Oct 19;25(31):1473–8 (24 ref.) (Eng. Abstr.) **(Fre)**

[Role of non-invasive ventilation in internal medicine] Weber T. **Rev Med Liege** 1996 May;51(5):355–8 (21 ref.) **(Fre)**

[Assisted ventilation in chronic neuromuscular diseases. The Vincre Group] Kohler A, et al. **Rev Med Suisse Romande** 1997 Jun;117(6):479–84 (16 ref.) **(Fre)**

[Ventilation modes and strategies in intensive care medicine] Rathgeber J. **Anaesthesiol Reanim** 1997;22(1):4–14 (63 ref.) (Eng. Abstr.) **(Ger)**

[Current concepts and techniques in home ventilation therapy] Raschke F, et al. **Pneumologie** 1997 Apr;51 Suppl 2:450–5 (18 ref.) (Eng. Abstr.) **(Ger)**

[Noninvasive ventilation in intensive care] Jolliet P, et al. **Schweiz Med Wochenschr** 1997 Jan 25;127(4):107–21 (85 ref.) (Eng. Abstr.) **(Ger)**

[Hyperbaric medicine and anesthesiology] Manubens E, et al. **Rev Esp Anestesiol Reanim** 1996 Nov;43(9):321–6 (14 ref.) **(Spa)**

[Evaluation and management of the difficult airway (see comments)] Rodrigo MP, et al. **Rev Esp Anestesiol Reanim** 1996 Jan;43(1):34–41 (25 ref.) Comment in: Rev Esp Anestesiol Reanim 1997 Apr;44(4):167–9. **(Spa)**

TRENDS

Advances in neonatal conventional ventilation. Sinha SK, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 Sep; 75(2):F135–40 (25 ref.)

RESPIRATION DISORDERS

Respiratory control disorders in infancy and childhood. Silvestri JM, et al. **Curr Opin Pediatr** 1996 Jun;8(3):216–20 (44 ref.)

CHEMICALLY INDUCED

Side effects of opioids in postoperative pain treatment. Camu F. **Acta Anaesthesiol Belg** 1996;47(3):105–9 (28 ref.)

Review of trimellitic anhydride (TMA) induced respiratory response. Grammer LC, et al. **Allergy Asthma Proc** 1997 Jul–Aug;18(4):235–7 (14 ref.)

The airways and anaesthesia II. Pathophysiology. Burwell DR, et al. **Anaesthesia** 1996 Oct;51(10):943–54 (108 ref.)

Some consequences of ozone exposure on health. Paz C. **Arch Med Res** 1997 Summer;28(2):163–70 (96 ref.)

Monitoring opioids. Mulroy MF. **Reg Anesth** 1996 Nov–Dec; 21(6 Suppl):89–93 (27 ref.)

Controlled human studies of ozone exposure. Bylin G. **Scand J Work Environ Health** 1996;22 Suppl 3:52–71 (113 ref.)

[Iatrogenic disorders in the active respiratory systems (respiratory center and its performance] Similowski T, et al. **Rev Mal Respir** 1996;13(4):361–79 (221 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Influences of dysfunctional respiratory mechanics on orofacial pain. Hruska RJ Jr. **Dent Clin North Am** 1997 Apr;41(2):211–27 (71 ref.)

DIAGNOSIS

[Closing volume measurement and its clinical significance] Yoshida K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:22–6 (11 ref.) **(Jpn)**

DRUG THERAPY

Exogenous surfactant therapy in non-respiratory distress syndrome. Greenough A. **Turk J Pediatr** 1996 Jan–Mar; 38(1):45–50 (13 ref.)

ETIOLOGY

Lung development and early origins of childhood respiratory illness. Dezateux C, et al. **Br Med Bull** 1997 Jan;53(1):40–57 (74 ref.)

Respiratory complications of gastroesophageal reflux disease. Siegel PD, et al. **Prim Care** 1996 Sep;23(3):433–41 (42 ref.)

[Obesity and cardiorespiratory disease] Bonsignore G, et al. **Cardiologia** 1996 Jul;41(7):613–9 (32 ref.) **(Ita)**

[Sleep respiratory disorders in fibromyalgia syndrome] Alvarez Lario B, et al. **Arch Bronconeumol** 1997 Mar; 33(3):143–7 (73 ref.) **(Spa)**

[Respiratory disorders during sleep in chronic obstructive lung disease] Togores Solivellas B, et al. **Arch Bronconeumol** 1996 Jan;32(1):32–9 (78 ref.) **(Spa)**

IMMUNOLOGY

Review of trimellitic anhydride (TMA) induced respiratory response. Grammer LC, et al. **Allergy Asthma Proc** 1997 Jul–Aug;18(4):235–7 (14 ref.)

PHYSIOPATHOLOGY

Functional respiratory disorders. Butani L, et al. **Ann Allergy Asthma Immunol** 1997 Aug;79(2):91–9; quiz 99–101 (65 ref.)

Medical perspectives of nitric oxide. Wang Z. **Chin Med J (Engl)** 1996 Jan;109(1):60–2 (0 ref.)

[Respiratory disorders during sleep in children] Kirjavainen T, et al. **Duodecim** 1995;111(12):1154–64 (44 ref.) **(Fin)**

PSYCHOLOGY

Functional respiratory disorders. Butani L, et al. **Ann Allergy Asthma Immunol** 1997 Aug;79(2):91–9; quiz 99–101 (65 ref.)

THERAPY

Home oxygen and ventilation therapies in pediatric patients. Voter KZ, et al. **Curr Opin Pediatr** 1996 Jun;8(3):221–5 (30 ref.)

RESPIRATOR WEANING see **VENTILATOR WEANING**

RESPIRATORS see **VENTILATORS, MECHANICAL**

RESPIRATORS, AIR-PURIFYING see **RESPIRATORY PROTECTIVE DEVICES**

RESPIRATORS, INDUSTRIAL see **RESPIRATORY PROTECTIVE DEVICES**

RESPIRATORS, NEGATIVE-PRESSURE see **VENTILATORS, NEGATIVE-PRESSURE**

RESPIRATORS, PULMONARY, NEGATIVE-PRESSURE see **VENTILATORS, NEGATIVE-PRESSURE**

RESPIRATORY ACIDOSIS see **ACIDOSIS, RESPIRATORY**

RESPIRATORY AIRFLOW see **PULMONARY VENTILATION**

RESPIRATORY BURST

see related
GRANULOMATOUS DISEASE, CHRONIC

The origin of the oxidative burst in plants. Bolwell GP. **Biochem Soc Trans** 1996 May;24(2):438–42 (50 ref.)

The oxidative burst protects plants against pathogen attack: mechanism and role as an emergency signal for plant bio-defence—a review. Doke N, et al. **Gene** 1996 Nov 7; 179(1):45–51 (40 ref.)

DRUG EFFECTS

[Modulation of the oxidative burst of human neutrophils by pro- and anti-inflammatory cytokines] Gougerot-Podicalo MA, et al. **Pathol Biol (Paris)** 1996 Jan;44(1):36–41 (14 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

NADPH oxidase and the respiratory burst. Wientjes FB, et al. **Semin Cell Biol** 1995 Dec;6(6):357–65 (82 ref.)

RESPIRATORY CENTER

DRUG EFFECTS

[Iatrogenic disorders in the active respiratory systems (respiratory center and its performance] Similowski T, et al. **Rev Mal Respir** 1996;13(4):361–79 (221 ref.) (Eng. Abstr.) **(Fre)**

RESPIRATORY CHAIN see **ELECTRON TRANSPORT**

RESPIRATORY DISTRESS SYNDROME

[Current aspects of acute respiratory distress syndrome in children] Durand P, et al. **Arch Pediatr** 1997 Jan;4(1):61–77 (110 ref.) (Eng. Abstr.) **(Fre)**

BLOOD

Antithrombin deficiency in special clinical syndromes—Part I: neonatal and pediatric/physiologic deficiency: extracorporeal membrane oxygenation. Shapiro A. **Semin Hematol** 1995 Oct;32(4 Suppl 2):33–6 (10 ref.)

COMPLICATIONS

Strategies to prevent chronic neonatal lung disease. Schindler MB. **J Paediatr Child Health** 1996 Dec;32(6):477–9 (33 ref.)

DIAGNOSIS

[Mucoviscidosis with respiratory symptomatology in the neonatal period] Lamy S, et al. **Acta Med Port** 1997 Feb–Mar;10(2–3):209–12 (34 ref.) (Eng. Abstr.) **(Por)**

DRUG THERAPY

Surfactant therapy. Clinical implications [editorial; comment] Zetterström R. **Acta Paediatr** 1996 Jun;85(6):641 (2 ref.) Comment on: Acta Paediatr 1996 Jun;85(6):642–6. Comment on: Acta Paediatr 1996 Jun;85(6):713–8. Comment on: Acta Paediatr 1996 Jun;85(6):719–23.

From bubbles to babies: the evolution of surfactant replacement therapy. Enhorning G. **Biol Neonate** 1997;71 Suppl 1:28–31 (12 ref.)

Clinical trials of surfactant replacement in Europe. Halliday HL. **Biol Neonate** 1997;71 Suppl 1:8–12 (31 ref.)

Surfactant therapy in the USA: trials and current routines. Soll RF. **Biol Neonate** 1997;71 Suppl 1:1–7 (39 ref.)

Controversies: synthetic or natural surfactant. The case for natural surfactant. Halliday HL. **J Perinat Med** 1996; 24(5):417–26 (54 ref.)

Controversies: synthetic or natural surfactant treatment for respiratory distress syndrome? The case for synthetic surfactant. Whitelaw A. **J Perinat Med** 1996;24(5):427–35 (17 ref.)

Nitric oxide inhalation therapy in acute respiratory distress

syndrome: intended effects and possible side effects. Rossaint R, et al. **Methods Enzymol** 1996;269:442–53 (55 ref.)

[Nitric oxide via inhalation in the newborn infant and the child with acute hypoxemic respiratory failure] Biban P, et al. **Pediatr Med Chir** 1996 May–Jun;18(3):245–51 (44 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Surfactant protein–B deficiency. Nogee LM. **Chest** 1997 Jun; 111(6 Suppl):129S–135S (43 ref.)

Immature epithelial Na+ channel expression is one of the pathogenetic mechanisms leading to human neonatal respiratory distress syndrome. O'Brodovich HM. **Proc Assoc Am Physicians** 1996 Sep;108(5):345–55 (86 ref.)

METABOLISM

[Molecular aspects of pulmonary surfactant in neonatal respiratory distress syndrome and surfactant replacement therapy] Chida S, et al. **Nippon Rinsho** 1996 Feb; 54(2):346–52 (20 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

TNF receptors in the microvascular pathology of acute respiratory distress syndrome and cerebral malaria. Lucas R, et al. **J Leukoc Biol** 1997 May;61(5):551–8 (65 ref.)

PHYSIOPATHOLOGY

Mechanisms of tissue injury by oxygen radicals: implications for neonatal disease. Saugstad OD. **Acta Paediatr** 1996 Jan; 85(1):1–4 (32 ref.)

[The exogenous surfactant and its effect on the respiratory distress syndrome (RDS)] Brabec R, et al. **Cesk Fysiol** 1996 Sep;45(3):139–45 (40 ref.) (Eng. Abstr.) **(Cze)**

[Animal experiment and clinical studies of the significance of carnitine for energy metabolism in pregnant patients and the fetus during the pre- and perinatal period] Lohninger A, et al. **Wien Klin Wochenschr** 1996;108(2):33–9 (64 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

[Prenatal lung maturation with corticosteroids--an overview] Hildebrand K, et al. **Z Geburtshilfe Neonatol** 1996 Nov–Dec;200(6):207–12 (54 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

High frequency oscillation and exogenous surfactant in the treatment of neonatal respiratory distress syndrome. Claris O, et al. **Acta Paediatr** 1997 Apr;86(4):339–41 (18 ref.)

Is chronic lung disease (CLD) in premature infants preventable? [editorial] Yeh TF. **Acta Paediatr Sin** 1996 Jul–Aug;37(4):241–3 (17 ref.)

Advances in the management of respiratory failure. Liquid ventilation in the setting of respiratory failure. Hirschl RB. **ASAIO J** 1996 May–Jun;42(3):209–10 (22 ref.)

Ventilation patterns, surfactant and lung injury. Jonson B. **Biol Neonate** 1997;71 Suppl 1:13–7 (24 ref.)

High–frequency oscillatory ventilation--a new management for respiratory distress syndrome and intractable respiratory failure. Jeng MJ, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1997 Mar–Apr;38(2):87–97 (70 ref.)

Liquid ventilation: an alternative ventilation strategy for management of neonatal respiratory distress. Shaffer TH, et al. **Eur J Pediatr** 1996 Aug;155 Suppl 2:S30–4 (48 ref.)

High frequency ventilation. Ramsden CA, et al. **J Paediatr Child Health** 1997 Apr;33(2):85–7 (23 ref.)

Factors influencing acquired upper airway obstruction in newborn infants receiving assisted ventilation because of respiratory failure: an overview. da Silva OP. **J Perinatol** 1996 Jul–Aug;16(4):272–5 (35 ref.)

J'accuse!–M. LeComte de LaPlace a Prohibé le Recrutement des Alvéoles du Poumon [Can high–frequency ventilation conscript alveolar recruits and encourage re–enlistment?] [comment] Nelson NM. **Pediatrics** 1996 Dec;98(6 Pt 1):1196–7 (15 ref.) Comment on: Pediatrics 1996 Dec;98(6 Pt 1):1044–57.

Surfactant and respiratory distress syndrome. Milner AD. **Turk J Pediatr** 1996 Jan–Mar;38(1):37–43 (27 ref.)

[Liquid ventilation with perfluorocarbons (see comments)] Quintel M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Oct; 31(8):461–9 (72 ref.) (Eng. Abstr.) Comment in: Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Oct;31(8):459–60. **(Ger)**

[Extracorporeal membrane oxygenation (ECMO) in the newborn infant and the child with intractable respiratory failure] Pettenazzo A, et al. **Pediatr Med Chir** 1996 May–Jun;18(3):235–42 (32 ref.) (Eng. Abstr.) **(Ita)**

[Molecular aspects of pulmonary surfactant in neonatal respiratory distress syndrome and surfactant replacement therapy] Chida S, et al. **Nippon Rinsho** 1996 Feb; 54(2):346–52 (20 ref.) (Eng. Abstr.) **(Jpn)**

RESPIRATORY DISTRESS SYNDROME, ADULT

Adult respiratory distress syndrome: a radical perspective. Louie S, et al. **Adv Pharmacol** 1997;38:457–90 (197 ref.)

Biological markers of acute lung injury: prognostic and pathogenetic significance. Pittet JF, et al. **Am J Respir Crit Care Med** 1997 Apr;155(4):1187–205 (257 ref.)

Computed tomography in adult respiratory distress syndrome: what has it taught us? Pelosi P, et al. **Eur Respir J** 1996 May;9(5):1055–62 (36 ref.)

Adult respiratory distress syndrome: a disorder in need of improved outcome [see comments] Brandstetter RD, et al. **Heart Lung** 1997 Jan–Feb;26(1):3–14 (84 ref.) Comment in: Heart Lung 1997 May–Jun;26(3):252.

Acute respiratory distress syndrome in pregnancy. Van Hook JW. **Semin Perinatol** 1997 Aug;21(4):320–7 (42 ref.)

[Respiratory distress syndrome in adults with trauma or some other diseases] Gembitskiĭ EV, et al. **Klin Med (Mosk)** 1997; 75(6):8–12 (18 ref.) **(Rus)**

[Respiratory distress syndrome in adults] Celikić S. **Vojnosanit Pregl** 1997 May–Jun;54(3):227–32 (23 ref.) **(Scr)**

COMPLICATIONS

Staphylococcal tracheitis, pneumonia, and adult respiratory distress syndrome. Horowitz IN. **Pediatr Emerg Care** 1996 Aug;12(4):288–90 (14 ref.)

DIAGNOSIS

Pseudopulmonary embolism: acute respiratory distress in the syndrome of heparin–induced thrombocytopenia. Popov D, et al. **Am J Kidney Dis** 1997 Mar;29(3):449–52 (12 ref.)

Markers for predicting the development of acute respiratory distress syndrome. Connelly KG, et al. **Annu Rev Med** 1997; 48:429–45 (67 ref.)

[A case of a favorable outcome in a large–focus myocardial infarct with the adult respiratory distress syndrome] Shvyrkova NM, et al. **Ter Arkh** 1996;68(5):80–1 (7 ref.) **(Rus)**

DRUG THERAPY

Surfactant for acute respiratory distress syndrome. Jobe AH, et al. **Adv Intern Med** 1997;42:203–30 (70 ref.)

Phenylephrine and inhaled nitric oxide in adult respiratory distress syndrome. When are two better than one? [editorial; comment] Pearl RG. **Anesthesiology** 1997 Jul;87(1):1–3 (16 ref.) Comment on: Anesthesiology 1997 Jul;87(1):18–25.

The role of the host defence response in the progression and outcome of ARDS: pathophysiological correlations and response to glucocorticoid treatment. Meduri GU. **Eur Respir J** 1996 Dec;9(12):2650–70 (219 ref.)

Nitric oxide in the pulmonary circulation. Adnot S, et al. **Monaldi Arch Chest Dis** 1996 Dec;51(6):519–27 (30 ref.)

[NO and alternative inhalational therapy approaches in pulmonary hypertension] Walmrath D, et al. **Internist (Berl)** 1997 May;38(5):453–60 (55 ref.) **(Ger)**

EPIDEMIOLOGY

Adult respiratory distress syndrome in pregnancy: report of three cases and review of the literature. Catanzarite VA, et al. **Obstet Gynecol Surv** 1997 Jun;52(6):381–92 (69 ref.)

ETIOLOGY

Traumatic adult respiratory distress syndrome. Bass TL, et al. **Chest Surg Clin N Am** 1997 May;7(2):429–42 (71 ref.)

Mechanisms of acute lung injury. Downey GP, et al. **Curr Opin Pulm Med** 1997 May;3(3):234–41 (60 ref.)

Acute respiratory distress syndrome (ARDS) in miliary tuberculosis: a twelve year experience. Mohan A, et al. **Indian J Chest Dis Allied Sci** 1996 Jul–Sep;38(3):157–62 (17 ref.)

Acute lung injury: clinical concept and experimental approaches to pathogenesis. Kanazawa M. **Keio J Med** 1996 Sep;45(3):131–9 (61 ref.)

The complications of lung resection in adults: acute respiratory distress syndrome (ARDS). Williams E, et al. **Monaldi Arch Chest Dis** 1996 Aug;51(4):310–5 (27 ref.)

The expression of adhesion molecule and ARDS. Malik AB, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:29–34 (25 ref.)

[ARDS (adult respiratory distress syndrome)] Seeger W. **Pneumologie** 1996 Sep;50 Suppl 2:615–7 (15 ref.) **(Ger)**

[Surgical stress and acute lung injury] Takezawa J. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):739–44 (33 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Application of differential display to isolate novel genes in interleukin–2–induced adult respiratory distress syndrome. Neville LF, et al. **Ann N Y Acad Sci** 1996 Oct 31;796:257–71 (52 ref.)

[Proliferation of alveolar epithelial cells and gene expression of surfactant proteins in adult respiratory distress syndrome (ARDS)] Sugahara K. **Nippon Rinsho** 1996 Feb;54(2):341–5 (12 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Current concepts of sepsis and acute lung injury. Sessler CN, et al. **Clin Chest Med** 1996 Jun;17(2):213–35 (151 ref.)

MORTALITY

The prognosis of ARDS: appropriate optimism? [editorial] Lemaire F. **Intensive Care Med** 1996 May;22(5):371–3 (18 ref.)

PATHOLOGY

[Proliferation of alveolar epithelial cells and gene expression of surfactant proteins in adult respiratory distress syndrome (ARDS)] Sugahara K. **Nippon Rinsho** 1996 Feb;54(2):341–5 (12 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

The interdependence of lung antioxidants and antiprotease defense in ARDS. Gadek JE, et al. **Chest** 1996 Dec;110(6 Suppl):273S–277S (13 ref.)

Coordination of genetic, epigenetic, and environmental factors in lung development, injury, and repair. Warburton D, et al. **Chest** 1997 Jun;111(6 Suppl):119S–122S (51 ref.)

Adult respiratory distress syndrome (ARDS): current management, future directions. Wiedemann HP, et al. **Cleve Clin J Med** 1997 Jul–Aug;64(7):365–72 (30 ref.)

The prone position in acute respiratory distress syndrome: where we are, and where do we go from here [editorial; comment] Albert RK. **Crit Care Med** 1997 Sep;25(9):1453–4 (36 ref.) Comment on: Crit Care Med 1997 Sep;25(9):1539–44.

The role of the host defence response in the progression and outcome of ARDS: pathophysiological correlations and response to glucocorticoid treatment. Meduri GU. **Eur Respir J** 1996 Dec;9(12):2650–70 (219 ref.)

Endothelial modification of pulmonary vascular tone. Curzen NP, et al. **Intensive Care Med** 1996 Jun;22(6):596–607 (109 ref.)

The role of nitric oxide in sepsis and ARDS: synopsis of a roundtable conference held in Brussels on 18–20 March 1995. Fink MP, et al. **Intensive Care Med** 1996 Feb; 22(2):158–65 (103 ref.)

Role of oxidant stress in the adult respiratory distress syndrome: evaluation of a novel antioxidant strategy in a porcine model of endotoxin–induced acute lung injury. Gonzalez PK, et al. **Shock** 1996;6 Suppl 1:S23–6 (54 ref.)

[Experimental changes in the alveolo–capillary barrier induced by artificial ventilation] Dreyfuss D, et al. **Schweiz Med Wochenschr** 1997 Jun 14;127(24):1023–9 (30 ref.) (Eng. Abstr.) **(Fre)**

[Acute respiratory failure in the adult: pathophysiology, diagnosis and treatment] Lewandowski K, et al. **Pneumologie** 1996 Aug;50(8):505–17 (82 ref.) **(Ger)**

[Adhesion molecules and their role in pathogenesis of ARDS] Skiba–Choińska I, et al. **Przegl Lek** 1996;53(8):627–30 (34 ref.) (Eng. Abstr.) **(Pol)**

RADIOGRAPHY

Lung imaging in the adult respiratory distress syndrome: current practice and new insights. Desai SR, et al. **Intensive Care Med** 1997 Jan;23(1):7–15 (101 ref.)

RADIONUCLIDE IMAGING

Radionuclide assessment of pulmonary microvascular permeability. Groeneveld AB. **Eur J Nucl Med** 1997 Apr; 24(4):449–61 (103 ref.)

Bedside measurement of pulmonary capillary permeability in patients with acute lung injury. What have we learned? [editorial] Rocker GM. **Intensive Care Med** 1996 Jul; 22(7):619–21 (19 ref.)

THERAPY

Extracorporeal lung assist in ARDS: history and state of the art. Lennartz H. **Acta Anaesthesiol Scand Suppl** 1996; 109:114–6 (15 ref.)

Extracorporeal oxygenation. Esen F. **Adv Exp Med Biol** 1996; 388:513–9 (13 ref.)

Mechanical ventilation in ARDS. Kesecioğlu J. **Adv Exp Med Biol** 1996;388:533–8 (30 ref.)

The lung in distress. So KL, et al. **Adv Exp Med Biol** 1996; 388:463–71 (46 ref.)

Ventilatory strategies for acute respiratory failure. Moore FA, et al. **Am J Surg** 1997 Jan;173(1):53–6; discussion 57–8 (15 ref.)

Induced hypothermia in intensive care medicine. Bernard S. **Anaesth Intensive Care** 1996 Jun;24(3):382–8 (104 ref.)

Adult respiratory distress syndrome (ARDS): current management, future directions. Wiedemann HP, et al. **Cleve Clin J Med** 1997 Jul–Aug;64(7):365–72 (30 ref.)

Evolving concepts in the ventilatory management of acute respiratory distress syndrome. Marini JJ. **Clin Chest Med** 1996 Sep;17(3):555–75 (116 ref.)

Adjuncts to mechanical ventilation. Nahum A, et al. **Clin Chest Med** 1996 Sep;17(3):491–511 (168 ref.)

High–inflation pressure and positive end–expiratory pressure. Injurious to the lung? No. Nelson LD. **Crit Care Clin** 1995 Jul;12(3):603–25 (110 ref.)

High–inflation pressure and positive end–expiratory pressure. Injurious to the lung? Yes. Papadakos PJ, et al. **Crit Care Clin** 1996 Jul;12(3):627–34 (29 ref.)

Acute respiratory distress syndrome. Sachdeva RC, et al. **Crit Care Clin** 1997 Jul;13(3):503–21 (75 ref.)

Acute respiratory distress syndrome in children. Beaufils F, et al. **Curr Opin Pediatr** 1997 Jun;9(3):207–12 (47 ref.)

New regimens in the management of posttraumatic respiratory failure. O'Keefe GE, et al. **Curr Opin Pulm Med** 1997 May;3(3):227–33 (47 ref.)

New strategies in mechanical ventilation for acute lung injury. Burchardi H. **Eur Respir J** 1996 May;9(5):1063–72 (80 ref.)
Mechanical ventilation and adjuncts in acute respiratory distress syndrome. Deb B, et al. **Int Anesthesiol Clin** 1997 Winter;35(1):109–24 (115 ref.)
The prognosis of ARDS: appropriate optimism? [editorial] Lemaire F. **Intensive Care Med** 1996 May;22(5):371–3 (18 ref.)
Anti-inflammatory therapies: application of molecular biology techniques in intensive care medicine. Liu M, et al. **Intensive Care Med** 1997 Jul;23(7):718–31 (127 ref.)
Respiratory support in refractory ARDS. Keogh BF. **Middle East J Anesthesiol** 1996 Jun;13(5):461–93 (56 ref.)
Surfactant replacement therapy for adult respiratory distress syndrome in children. Evans DA, et al. **Pediatr Pulmonol** 1996 May;21(5):328–36 (100 ref.)
The changing prognosis of ARDS. Schuster DP. **Schweiz Med Wochenschr** 1997 Jun 14;127(24):1018–22 (11 ref.)
Strategies of invasive ventilatory support in ARDS. Kirkpatrick AW, et al. **Shock** 1996;6 Suppl 1:S17–22 (64 ref.)
[Artificial ventilation in acute respiratory distress syndrome in adults. Towards an individual optimization] Joly LM, et al. **Presse Med** 1996 Oct 19;25(31):1473–8 (24 ref.) (Eng. Abstr.) **(Fre)**
[Liquid ventilation with perfluorocarbons (see comments)] Quintel M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Oct; 31(8):461–9 (72 ref.) (Eng. Abstr.) Comment in: Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Oct;31(8):459–60. **(Ger)**
[Perspectives in mechanical ventilation in ARDS] Max M, et al. **Schweiz Med Wochenschr** 1997 Jun 14;127(24):1030–8 (68 ref.) (Eng. Abstr.) **(Ger)**
[Extracorporeal membrane oxygenation in adult respiratory distress syndrome. Experience in 2 patients] Alamo M, et al. **Rev Med Chil** 1995 Oct;123(10):1275–83 (29 ref.) (Eng. Abstr.) **(Spa)**

RESPIRATORY DRUG ADMINISTRATION see **ADMINISTRATION, INHALATION**

RESPIRATORY ENTERIC ORPHAN VIRUSES see **REOVIRIDAE**

RESPIRATORY FAILURE see **RESPIRATORY INSUFFICIENCY**

RESPIRATORY FUNCTION TESTS

Refractory asthma, Part 2: Airway interventions and management. Jagoda A, et al. **Ann Emerg Med** 1997 Feb; 29(2):275–81 (59 ref.)
Use of lung function tests in sarcoidosis. Brådvik I. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Mar;13(1):59–62 (14 ref.)
[Evaluation methods for respiratory muscle function and their application in respiratory rehabilitation] Delhez L. **J Belge Med Phys Rehabil** 1980;3(1):7–32 (30 ref.) **(Fre)**
[Pulmonary function tests for diagnosis and management of asthma] Miyazawa N, et al. **Nippon Rinsho** 1996 Nov; 54(11):2914–8 (5 ref.) (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

End-tidal carbon dioxide detectors--are they useful in children? Bhende MS. **J Postgrad Med** 1994 Apr–Jun; 40(2):78–82 (51 ref.)
[Comparison of different types of peak flow meter and reference values for peak expiratory flow (PEF) for healthy Japanese subjects] Tsukioka K. **Nippon Rinsho** 1996 Nov; 54(11):2927–32 (20 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Assessing lung function. Mecoy RJ. **Aust Fam Physician** 1996 Feb;25(2):153, 156–9 (1 ref.)
Respiratory muscle testing. Moxham J. **Monaldi Arch Chest Dis** 1996 Dec;51(6):483–8 (19 ref.)
[Evaluation of pulmonary function by expiratory CT using helical CT] Eda S, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:45–7 (6 ref.) **(Jpn)**
[Analytical method of lung sounds] Murata A, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:80–3 (6 ref.) **(Jpn)**
[Differential pulmonary function] Nishio K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:19–21 (11 ref.) **(Jpn)**
[Respiratory muscle functional test] Saito H, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:62–4 (19 ref.) **(Jpn)**
[Pulmonary magnetic field] Sasaki H, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:51–4 (10 ref.) **(Jpn)**
[Medical practice-supporting system in pulmonary function testing] Kino H. **Rinsho Byori** 1997 May;45(5):438–41 (8 ref.) (Eng. Abstr.) **(Jpn)**

STATISTICS & NUMERICAL DATA

Interpretation of longitudinal studies. An overview. Schouten JP, et al. **Am J Respir Crit Care Med** 1996 Dec;154(6 Pt 2):S278–84 (39 ref.)
[Cardiopulmonary normal values in geriatrics] Gassmann KG, et al. **Z Gerontol Geriatr** 1997 May–Jun;30(3):193–9 (55 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

[Respiratory mechanics in animals. 2. The forced oscillation technique--review] Reinhold P. **Berl Munch Tierarztl Wochenschr** 1997 Jul–Aug; 110(7–8):257–66 (77 ref.) (Eng. Abstr.) **(Ger)**
[Respiratory mechanics in animals. 1. Physiological bases and conventional measurement methods--review] Reinhold P. **Berl Munch Tierarztl Wochenschr** 1997 Jul–Aug; 110(7–8):251–6 (73 ref.) (Eng. Abstr.) **(Ger)**

RESPIRATORY HYPERSENSITIVITY

Air pollution and allergic disease. Report of a Working Party of the British Society for Allergy and Clinical Immunology. Wardlaw AJ. **Clin Exp Allergy** 1995 Nov;25 Suppl 3:6–8 (0 ref.)
Sensitization and enhanced allergen responsiveness. Wardlaw AJ, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 3:56–9 (0 ref.)
Pediatric sinusitis: a literature review with emphasis on the role of allergy. Gungor A, et al. **Otolaryngol Head Neck Surg** 1997 Jan;116(1):4–15 (77 ref.)
[Airway hyperreactivity and respiratory allergy in children] **Rev Alerg Mex** 1996;43 Spec No:22–37 (73 ref.) **(Spa)**

CHEMICALLY INDUCED

Allergen-irritant interaction and the role of corticosteroids. Davies RJ, et al. **Allergy** 1997;52(38 Suppl):59–65 (30 ref.)
Mechanisms of pollution-induced airway disease: in vitro studies in the upper and lower airways. Devalia JL, et al. **Allergy** 1997;52(38 Suppl):45–51; discussion 57–8 (37 ref.)
The role of diesel exhaust particles and their associated polyaromatic hydrocarbons in the induction of allergic airway disease. Diaz-Sanchez D. **Allergy** 1997;52(38 Suppl):52–6; discussion 57–8 (16 ref.)
Mechanisms of pollution-induced airway disease: in vivo studies. Peden DB. **Allergy** 1997;52(38 Suppl):37–44; discussion 57–8 (64 ref.)
Ozone, airways and allergic airways disease. Krishna MT, et al. **Clin Exp Allergy** 1995 Dec;25(12):1150–8 (82 ref.)
Impact of the environment on allergic lung diseases. Rusznak C, et al. **Clin Exp Allergy** 1997 May;27 Suppl 1:26–35 (80 ref.)
Toxicology of air pollutants (animal studies). Wardlaw AJ. **Clin Exp Allergy** 1995 Nov;25 Suppl 3:40–3 (0 ref.)

COMPLICATIONS

[Pathogenetic basis of treatment for chronic obstructive pulmonary disease] Kozak-Szkopek E, et al. **Pol Merkuriusz Lek** 1996 Jul;1(1):56–9 (44 ref.) (Eng. Abstr.) **(Pol)**

DIAGNOSIS

[Recombinant allergens and their potential in allergologic diagnosis] Crameri R, et al. **Pneumologie** 1996 Jun; 50(6):387–93 (84 ref.) **(Ger)**
[Not all coughing is asthma--on differential bronchial asthma diagnosis in childhood] Leupold W. **Wien Med Wochenschr** 1996;146(15):419–22 (9 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

[New drugs in the treatment of respiratory allergic diseases] Gani F, et al. **Recenti Prog Med** 1997 Jul–Aug; 88(7–8):333–41 (38 ref.) (Eng. Abstr.) **(Ita)**

EPIDEMIOLOGY

Epidemiology of pollution-induced airway disease in Japan. Miyamoto T. **Allergy** 1997;52(38 Suppl):30–4; discussion 35–6 (13 ref.)
Executive summary and future research. **Clin Exp Allergy** 1995 Nov;25 Suppl 3:9–11 (0 ref.)
Epidemiology of the effects of air pollutants on allergic disease in adults. Ayres JG. **Clin Exp Allergy** 1995 Nov; 25 Suppl 3:47–51 (0 ref.)
Epidemiology of the effects of air pollutants on allergic disease in children. Carswell F. **Clin Exp Allergy** 1995 Nov; 25 Suppl 3:52–5 (0 ref.)

ETIOLOGY

Epidemiology of pollution-induced airway disease in Japan. Miyamoto T. **Allergy** 1997;52(38 Suppl):30–4; discussion 35–6 (13 ref.)
Review on buckwheat allergy. Wieslander G. **Allergy** 1996 Oct;51(10):661–5 (25 ref.)
Global increases in allergic respiratory disease: the possible role of diesel exhaust particles. Peterson B, et al. **Ann Allergy Asthma Immunol** 1996 Oct;77(4):263–8; quiz 269–70 (45 ref.)
Human exposure to air pollutants. Ashmore M. **Clin Exp Allergy** 1995 Nov;25 Suppl 3:12–21 (0 ref.)
Oleaceae pollinosis: a review. Liccardi G, et al. **Int Arch Allergy Immunol** 1996 Nov;111(3):210–7 (67 ref.)
[Room air allergens: clinical significance, detection and prevention] Müsken H. **Pneumologie** 1996 Feb;50(2):168–76 (119 ref.) **(Ger)**
[Bronchial asthma: extrinsic, intrinsic or mixed?] Virchow JC Jr. **Wien Med Wochenschr** 1996;146(15):415–8 (36 ref.) (Eng. Abstr.) **(Ger)**
[Laboratory animals as a cause of occupational allergy] Krakowiak A, et al. **Med Pr** 1996;47(5):523–31 (55 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Immunoregulation of the allergic reaction in the respiratory tract. Holt PG. **Eur Respir J Suppl** 1996 Aug;22:85s–89s (35 ref.)
Immunologic responses following respiratory sensitization to house dust mite allergens in mice. O'Brien R, et al. **Immunol Cell Biol** 1996 Apr;74(2):174–9 (23 ref.)
Asthma as an inflammatory disease: implications for management. Dolen WK. **J Am Board Fam Pract** 1996 May–Jun;9(3):182–90 (75 ref.)
Cellular and molecular mechanisms involved in the regulation of eosinophil trafficking in vivo. Hogan SP, et al. **Med Res Rev** 1996 Sep;16(5):407–32 (205 ref.)
[Specific immunotherapy of respiratory allergies] Michel FB, et al. **Presse Med** 1997 Apr 12;26(12):567–71 (35 ref.) **(Fre)**
[Pathogenetic significance of IgE-binding epitopes allergens (published erratum appears in Pneumologie 1996 Dec;50(12):938)] Bufe A, et al. **Pneumologie** 1996 Sep; 50(9):625–31 (55 ref.) **(Ger)**
[Important cross-reactive allergens] Helbling A. **Schweiz Med Wochenschr** 1997 Mar 8;127(10):382–9 (56 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

The role of alveolar macrophages and dendritic cells in allergic airway sensitization. Jansen HM. **Allergy** 1996 May; 51(5):279–92 (138 ref.)
[Dysregulated apoptosis in chronic eosinophilic diseases--new therapeutic strategies for allergies and bronchial asthma] Simon HU. **Pneumologie** 1996 Nov; 50(11):790–6 (56 ref.) **(Ger)**

PHYSIOPATHOLOGY

The role of alveolar macrophages and dendritic cells in allergic airway sensitization. Jansen HM. **Allergy** 1996 May; 51(5):279–92 (138 ref.)
Enhancement of afferent nerve excitability in the airways by allergic inflammation. Riccio MM, et al. **Pulm Pharmacol** 1995 Aug–Oct;8(4–5):181–5 (16 ref.)
[The role of the autonomic nervous system in airway hyperresponsiveness] Hanzlik J, et al. **Pol Arch Med Wewn** 1996 Aug;96(2):165–9 (23 ref.) **(Pol)**

THERAPY

[Value of selected parameters for monitoring efficacy of specific immunotherapy in allergic disorders] Cichocka-Jarosz E. **Przegl Lek** 1996;53(10):739–43 (35 ref.) (Eng. Abstr.) **(Pol)**

RESPIRATORY INSUFFICIENCY

Intrinsic PEEP and cardiopulmonary interaction in patients with COPD and acute ventilatory failure. Ranieri VM, et al. **Eur Respir J** 1996 Jun;9(6):1283–92 (64 ref.)
The hemodynamic consequences of mechanical ventilation: an evolving story. Pinsky MR. **Intensive Care Med** 1997 May;23(5):493–503 (93 ref.)

BLOOD

Measurement and interpretation of arterial blood gases. Syabbalo N. **Br J Clin Pract** 1997 Apr–May;51(3):173–6 (20 ref.)
Continuous arterial gas monitoring: initial experience with the Paratrend 7 in children. Weiss IK, et al. **Intensive Care Med** 1996 Dec;22(12):1414–7 (13 ref.)

CHEMICALLY INDUCED

Glaucoma therapy may take your breath away. Diggory P, et al. **Age Ageing** 1997 Mar;26(2):63–7 (24 ref.)
[Drug-induced pneumopathies accompanied by acute respiratory insufficiency] Mayaud C, et al. **Rev Mal Respir** 1996 Dec;13(6):559–74 (188 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Management of acute respiratory failure in chronic obstructive pulmonary disease. Zuege DJ, et al. **Curr Opin Pulm Med** 1997 May;3(3):190–7 (58 ref.)
Moebius syndrome and central respiratory dysfunction. Igarashi M, et al. **Pediatr Neurol** 1997 Apr;16(3):237–40 (18 ref.)

DIAGNOSIS

How to use diagnostic test articles in the intensive care unit: diagnosing weanability using f/Vt. Jaeschke RZ, et al. **Crit Care Med** 1997 Sep;25(9):1514–21 (24 ref.)
Scoring of severity in patients admitted to a respiratory intensive care unit. Nava S. **Monaldi Arch Chest Dis** 1997 Feb;52(1):71–2 (15 ref.)
Respiratory failure. Stokes DC. **Pediatr Rev** 1997 Oct; 18(10):361–6 (8 ref.)

Evaluation and treatment of respiratory failure in neuromuscular disease. Teener JW, et al. **Rheum Dis Clin North Am** 1997 May;23(2):277–92 (48 ref.)

[Computer–assisted diagnosis of respiratory failure] Nefedov VB, et al. **Probl Tuberk** 1997;(3):61–2 (11 ref.) **(Rus)**

DRUG THERAPY

Advances in the management of respiratory failure. Nitric oxide. Steinhorn RH. **ASAIO J** 1996 May–Jun; 42(3):199–200 (16 ref.)

Recombinant human growth hormone in chronic and acute respiratory insufficiency. Pichard C, et al. **Horm Res** 1996; 46(4–5):222–9 (72 ref.)

Nitric oxide and acute respiratory failure. Frostell CG. **Monaldi Arch Chest Dis** 1996 Dec;51(6):538–42 (67 ref.)

Acute ventilatory failure in Lambert–Eaton myasthenic syndrome and its response to 3,4–diaminopyridine. Smith AG, et al. **Neurology** 1996 Apr;46(4):1143–5 (15 ref.)

Continuous ketamine infusion for the treatment of refractory asthma in a mechanically ventilated infant: case report and review of the pediatric literature. Nehama J, et al. **Pediatr Emerg Care** 1996 Aug;12(4):294–7 (20 ref.)

[Nitric oxide via inhalation in the newborn infant and the child with acute hypoxemic respiratory failure] Biban P, et al. **Pediatr Med Chir** 1996 May–Jun;18(3):245–51 (44 ref.) (Eng. Abstr.) **(Ita)**

EPIDEMIOLOGY

Current status and research on chronic respiratory failure in Japan. Kawakami Y. **Intern Med** 1996 Jun;35(6):436–42 (12 ref.)

ETIOLOGY

Acute respiratory failure in the HIV–seropositive patient. Cowan MJ, et al. **Crit Care Clin** 1997 Jul;13(3):523–52 (155 ref.)

Diffuse microvascular pulmonary thrombosis associated with primary antiphospholipid antibody syndrome [see comments] Maggiorini M, et al. **Eur Respir J** 1997 Mar; 10(3):727–30 (19 ref.) Comment in: Eur Respir J 1997 Mar;10(3):511–2.

Rapid diagnosis of acute eosinophilic pneumonia (AEP) in a patient with respiratory failure using bronchoalveolar lavage (BAL) with calcofluor white (CW) staining. Hogan TF, et al. **J Clin Lab Anal** 1997;11(4):202–7 (65 ref.)

Nature's high–voltage injuries: sometimes a deadly consequence. Shaw PK, et al. **Neth J Med** 1996 Oct; 49(4):153–9 (20 ref.)

Acute ventilatory failure in Lambert–Eaton myasthenic syndrome and its response to 3,4–diaminopyridine. Smith AG, et al. **Neurology** 1996 Apr;46(4):1143–5 (15 ref.)

Hypotensive reactions: a previously uncharacterized complication of platelet transfusion? [see comments] Hume HA, et al. **Transfusion** 1996 Oct;36(10):904–9 (26 ref.) Comment in: Transfusion 1996 Oct;36(10):852–3.

[Severe pulmonary manifestation in adult–onset Still's disease] Paccalin M, et al. **Rev Med Interne** 1997 Jul; 18(7):575–7 (12 ref.) (Eng. Abstr.) **(Fre)**

[Exertional intolerance in respiratory insufficiency: principal mechanisms] Janssens JP, et al. **Rev Med Suisse Romande** 1997 Jun;117(6):457–64 (22 ref.) **(Fre)**

MORTALITY

Pulmonary failure as a cause of death in COPD. Braghiroli A, et al. **Monaldi Arch Chest Dis** 1997 Apr;52(2):170–5 (55 ref.)

[The patient with respiratory problems] Senninger N, et al. **Chirurg** 1997 Jul;68(7):662–9 (58 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Impact of sleep in respiratory failure. McNicholas WT. **Eur Respir J** 1997 Apr;10(4):920–33 (185 ref.)

Respiratory muscles and ventilatory failure. Vassilakopoulos T, et al. **Monaldi Arch Chest Dis** 1996 Dec;51(6):489–98 (42 ref.)

Brainstem encephalopathy with stimulus–sensitive myoclonus leading to respiratory arrest, but with recovery: a description of two cases and review of the literature. Kullmann DM, et al. **Mov Disord** 1996 Nov;11(6):715–8 (22 ref.)

[Exertional intolerance in respiratory insufficiency: principal mechanisms] Janssens JP, et al. **Rev Med Suisse Romande** 1997 Jun;117(6):457–64 (22 ref.) **(Fre)**

[Pathophysiology and clinical aspects of global respiratory insufficiency] Becker HF. **Med Klin** 1997 Apr 28;92 Suppl 1:10–3 (33 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

[Recommendations of Bavarian Muscle Centers of the German Neuromuscular Disease Society for home ventilation of neuromuscular diseases of adult patients] Winterholler M, et al. **Nervenarzt** 1997 Apr;68(4):351–7 (23 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Advances in the management of respiratory failure. Advanced strategies for mechanical ventilation in severe acute respiratory failure. Conrad SA. **ASAIO J** 1996 May–Jun;42(3):204–6 (15 ref.)

Advances in the management of respiratory failure. Liquid ventilation in the setting of respiratory failure. Hirschl RB. **ASAIO J** 1996 May–Jun;42(3):209–10 (22 ref.)

Advances in the management of respiratory failure. Accelerating lung growth. Wilson JM. **ASAIO J** 1996 May–Jun;42(3):201–3 (12 ref.)

Advances in the management of respiratory failure. Intracorporeal membrane gas exchange: will it still prevail? Zwischenberger JB, et al. **ASAIO J** 1996 May–Jun; 42(3):207–8 (11 ref.)

Nocturnal noninvasive positive pressure ventilatory assistance [see comments] Claman DM, et al. **Chest** 1996 Dec;110(6):1581–8 (71 ref.) Comment in: Chest 1997 May;111(5):1471–2.

Noninvasive positive pressure ventilation for acute respiratory failure: underutilized or overrated? [see comments] Jasmer RM, et al. **Chest** 1997 Jun;111(6):1672–8 (44 ref.) Comment in: Chest 1997 Jun;111(6):1479–82.

High–frequency oscillatory ventilation—a new management for respiratory distress syndrome and intractable respiratory failure. Jeng MJ, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1997 Mar–Apr;38(2):87–97 (70 ref.)

Noninvasive positive–pressure ventilation in patients with acute respiratory failure. Meduri GU. **Clin Chest Med** 1996 Sep;17(3):513–53 (265 ref.)

Management of acute respiratory failure in chronic obstructive pulmonary disease. Zuege DJ, et al. **Curr Opin Pulm Med** 1997 May;3(3):190–7 (58 ref.)

Noninvasive mechanical ventilation in acute respiratory failure. Ambrosino N. **Eur Respir J** 1996 Apr;9(4):795–807 (116 ref.)

Negative pressure ventilation in the treatment of acute respiratory failure: an old noninvasive technique reconsidered. Corrado A, et al. **Eur Respir J** 1996 Jul; 9(7):1531–44 (113 ref.)

Extracorporeal support of oxygenation and ventilation. Furukawa S. **Int Anesthesiol Clin** 1997 Winter;35(1):169–76 (34 ref.)

Mechanical ventilation for pediatric patients. Hammer GB, et al. **Int Anesthesiol Clin** 1997 Winter;35(1):139–67 (119 ref.)

Indications for mechanical ventilation. Tung A. **Int Anesthesiol Clin** 1997 Winter;35(1):1–17 (40 ref.)

Pediatric noninvasive nasal ventilation. Birnkrant DJ, et al. **J Child Neurol** 1997 Jun;12(4):231–6 (31 ref.)

Weaning from mechanical ventilation. Dries DJ. **J Trauma** 1997 Aug;43(2):372–84 (113 ref.)

Noninvasive positive pressure ventilation in acute respiratory failure of chronic obstructive pulmonary disease. Clark HE, et al. **Lung** 1997;175(3):143–54 (59 ref.)

Noninvasive mechanical ventilation in acute respiratory failure. Ambrosino N. **Monaldi Arch Chest Dis** 1996 Dec; 51(6):514–8 (34 ref.)

Noninvasive mechanical ventilation in acute on chronic respiratory failure: determinants of success and failure. Ambrosino N. **Monaldi Arch Chest Dis** 1997 Feb;52(1):73–5 (26 ref.)

Noninvasive pressure support ventilation: physiological and clinical results in patients with COPD and acute respiratory failure. Brochard L. **Monaldi Arch Chest Dis** 1997 Feb; 52(1):64–7 (20 ref.)

Negative pressure ventilation in COPD patients with acute on chronic respiratory failure. Corrado A, et al. **Monaldi Arch Chest Dis** 1997 Feb;52(1):60–3 (44 ref.)

Physiological and clinical consequences of positive end–expiratory pressure. Ganassini A, et al. **Monaldi Arch Chest Dis** 1997 Feb;52(1):68–70 (17 ref.)

Noninvasive mechanical ventilation and acute respiratory failure: indications and limitations. Muir JF, et al. **Monaldi Arch Chest Dis** 1997 Feb;52(1):56–9 (20 ref.)

Home mechanical ventilation in children: techniques, outcomes and ethics. Shneerson JM. **Monaldi Arch Chest Dis** 1996 Oct;51(5):426–30 (23 ref.)

Where and how must we perform noninvasive mechanical ventilation? Vitacca M. **Monaldi Arch Chest Dis** 1997 Feb; 52(1):80–2 (17 ref.)

Respiratory insufficiency and ventilatory support. 39th ENMC International Workshop, Naarden, The Netherlands, 26–28 January 1996. European Consortium on Chronic Respiratory Insufficiency. Rutgers M, et al. **Neuromuscul Disord** 1996 Dec;6(6):431–5 (0 ref.)

Respiratory failure. Stokes DC. **Pediatr Rev** 1997 Oct; 18(10):361–6 (8 ref.)

Evaluation and treatment of respiratory failure in neuromuscular disease. Teener JW, et al. **Rheum Dis Clin North Am** 1997 May;23(2):277–92 (48 ref.)

Non–invasive ventilation for exacerbations of respiratory failure in chronic obstructive pulmonary disease. Wedzicha JA. **Thorax** 1996 Aug;51 Suppl 2:S35–9 (25 ref.)

[Noninvasive ventilation at 2 pressure levels (VNI–2P or Bi–PAP)] Sottiaux T, et al. **Rev Med Liege** 1996 Oct; 51(10):635–8 (18 ref.) **(Fre)**

[Role of non–invasive ventilation in internal medicine] Weber T. **Rev Med Liege** 1996 May;51(5):355–8 (21 ref.) **(Fre)**

[Ventilation modes and strategies in intensive care medicine] Rathgeber J. **Anaesthesiol Reanim** 1997;22(1):4–14 (63 ref.) (Eng. Abstr.) **(Ger)**

[Liquid ventilation with perfluorocarbons (see comments)] Quintel M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Oct; 31(8):461–9 (72 ref.) (Eng. Abstr.) Comment in: Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Oct;31(8):459–60. **(Ger)**

[Concepts of noninvasive ventilation] Becker HF, et al. **Internist (Berl)** 1996 May;37(5):500–10 (82 ref.) **(Ger)**

[New therapy aspects of chronic respiratory insufficiency] Karg O. **Med Klin** 1997 Apr 28;92 Suppl 1:14–7 (25 ref.) (Eng. Abstr.) **(Ger)**

[Non–invasive ventilation in acute respiratory insufficiency] Karg O, et al. **Pneumologie** 1996 Nov;50(11):759–63 (31 ref.) (Eng. Abstr.) **(Ger)**

[Proportional assisted ventilation—advantages and limits of a new ventilation concept] Stahl CA, et al. **Pneumologie** 1997 Mar;51(3):264–9 (7 ref.) **(Ger)**

[Noninvasive ventilation in intensive care] Jolliet P, et al. **Schweiz Med Wochenschr** 1997 Jan 25;127(4):107–21 (85 ref.) (Eng. Abstr.) **(Ger)**

[Experience of an intermediate respiratory intensive therapy in the treatment of prolonged weaning from mechanical ventilation] Vitacca M, et al. **Minerva Anestesiol** 1996 Mar; 62(3):57–64 (23 ref.) (Eng. Abstr.) **(Ita)**

[Extracorporeal membrane oxygenation (ECMO) in the newborn infant and the child with intractable respiratory failure] Pettenazzo A, et al. **Pediatr Med Chir** 1996 May–Jun;18(3):235–42 (32 ref.) (Eng. Abstr.) **(Ita)**

[A diaphragmatic pacemaker in the treatment of ventilatory failure] Ponce P, et al. **Acta Med Port** 1995 Nov; 8(11):639–42 (10 ref.) (Eng. Abstr.) **(Por)**

[The treatment of chronic respiratory insufficiency] Mihăiţan F. **Pneumoftiziologia** 1996 Jul–Dec;45(3–4):173–82 (69 ref.) **(Rum)**

[Home oxygen therapy with transtracheal catheter] Díaz Lobato S, et al. **Rev Clin Esp** 1996 Dec;196(12):846–50 (63 ref.) **(Spa)**

RESPIRATORY MECHANICS

The pharyngeal critical pressure. The whys and hows of using nasal continuous positive airway pressure diagnostically. Gold AR, et al. **Chest** 1996 Oct; 110(4):1077–88 (48 ref.)

Patient–ventilator interactions. Dick CR, et al. **Clin Chest Med** 1996 Sep;17(3):423–38 (99 ref.)

The prone position in acute respiratory distress syndrome: where we are, and where do we go from here [editorial; comment] Albert RK. **Crit Care Med** 1997 Sep;25(9):1453–4 (36 ref.) Comment on: Crit Care Med 1997 Sep;25(9):1539–44.

Lung mechanics and gas exchange in pulmonary embolism. D'Angelo E. **Haematologica** 1997 May–Jun;82(3):371–4 (34 ref.)

PHYSIOLOGY

Some recent advances in studies on J receptors. Paintal AS. **Adv Exp Med Biol** 1995;381:15–25 (40 ref.)

Upper airway influences on breathing. Sant'Ambrogio G. **Adv Exp Med Biol** 1995;381:37–46 (26 ref.)

Central nervous mechanisms responsible for cardio–respiratory homeostasis. Spyer KM. **Adv Exp Med Biol** 1995;381:73–9 (20 ref.)

The multilevel mechanical behaviour of the lung during induced bronchoconstriction. Bates JH. **Australas Phys Eng Sci Med** 1996 Jun;19(2):35–45 (41 ref.)

The role of CO2/pH chemoreceptors in ventilatory control. Milsom WK. **Braz J Med Biol Res** 1995 Nov–Dec; 28(11–12):1147–60 (113 ref.)

Endothelial damage caused by ischemia and reperfusion and different ventilatory strategies in the lung. Moore TM, et al. **Chin J Physiol** 1996;39(2):65–81 (132 ref.)

The neuronal mechanisms of respiratory rhythm generation. Ramirez JM, et al. **Curr Opin Neurobiol** 1996 Dec; 6(6):817–25 (85 ref.)

Influences of dysfunctional respiratory mechanics on orofacial pain. Hruska RJ Jr. **Dent Clin North Am** 1997 Apr;41(2):211–27 (71 ref.)

ACOG technical bulletin. Pulmonary disease in pregnancy. Number 224—June 1996. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1996 Aug;54(2):187–96 (19 ref.)

The hemodynamic consequences of mechanical ventilation: an evolving story. Pinsky MR. **Intensive Care Med** 1997 May;23(5):493–503 (93 ref.)

Interactions among metabolic rate, hypoxia, and control of breathing. Gautier H. **J Appl Physiol** 1996 Aug;81(2):521–7 (67 ref.)

Medullary regions for neurogenesis of gasping: noeud vital or noeuds vitals? St John WM. **J Appl Physiol** 1996 Nov; 81(5):1865–77 (92 ref.)

Biophysics of airflow within the airway: a review. O'Grady K, et al. **J Otolaryngol** 1997 Apr;26(2):123–8 (28 ref.)

Respiratory muscle perfusion and energetics during exercise. Dempsey JA, et al. **Med Sci Sports Exerc** 1996 Sep; 28(9):1123–8 (30 ref.)

Contractility of the ventilatory pump muscles. Farkas GA, et al. **Med Sci Sports Exerc** 1996 Sep;28(9):1106–14 (101 ref.)

Effects of mechanical ventilation on control of breathing. Georgopoulos DB, et al. **Monaldi Arch Chest Dis** 1997 Jun; 52(3):253–62 (45 ref.)

[Proportional assisted ventilation—advantages and limits of

RESPIRATORY MECHANICS

a new ventilation concept] Stahl CA, et al. **Pneumologie** 1997 Mar;51(3):264–9 (7 ref.) **(Ger)**

RESPIRATORY MUSCLES

BLOOD SUPPLY

Regulation of ventilatory muscle blood flow. Hussain SN. **J Appl Physiol** 1996 Oct;81(4):1455–68 (133 ref.)

DRUG EFFECTS

Respiratory muscle pharmacology. Decramer M. **Monaldi Arch Chest Dis** 1996 Dec;51(6):499–503 (47 ref.)

Pharmacotherapy of respiratory muscles in chronic obstructive pulmonary disease. van der Heijden HF, et al. **Respir Med** 1996 Oct;90(9):513–22 (101 ref.)

[Iatrogenic disorders in the active respiratory systems (respiratory center and its performance] Similowski T, et al. **Rev Mal Respir** 1996;13(4):361–79 (221 ref.) (Eng. Abstr.) **(Fre)**

INNERVATION

Brainstem respiratory networks and cough. Shannon R, et al. **Pulm Pharmacol** 1996 Oct–Dec;9(5–6):343–7 (20 ref.)

METABOLISM

Respiratory muscle perfusion and energetics during exercise. Dempsey JA, et al. **Med Sci Sports Exerc** 1996 Sep; 28(9):1123–8 (30 ref.)

PHYSIOLOGY

Hyperinflation and respiratory muscle interaction. Decramer M. **Eur Respir J** 1997 Apr;10(4):934–41 (53 ref.)

Effect of hyperinflation on the diaphragm. De Troyer A. **Eur Respir J** 1997 Mar;10(3):708–13 (56 ref.)

Respiratory muscles and weaning failure. Vassilakopoulos T, et al. **Eur Respir J** 1996 Nov;9(11):2383–400 (114 ref.)

Fatigue of the respiratory muscles. Roussos C, et al. **Intensive Care Med** 1996 Feb;22(2):134–55 (87 ref.)

Contractility of the ventilatory pump muscles. Farkas GA, et al. **Med Sci Sports Exerc** 1996 Sep;28(9):1106–14 (101 ref.)

Respiratory muscle fatigue during exercise: implications for performance. Johnson BD, et al. **Med Sci Sports Exerc** 1996 Sep;28(9):1129–37 (48 ref.)

Adaptive strategies of respiratory muscles in response to endurance exercise. Powers SK, et al. **Med Sci Sports Exerc** 1996 Sep;28(9):1115–22 (54 ref.)

Respiratory muscles: clinical relevance. Gibson GJ. **Monaldi Arch Chest Dis** 1996 Dec;51(6):504–6 (12 ref.)

Respiratory muscle testing. Moxham J. **Monaldi Arch Chest Dis** 1996 Dec;51(6):483–8 (19 ref.)

Exercise training–induced changes in respiratory muscles. Powers SK, et al. **Sports Med** 1997 Aug;24(2):120–31 (20 ref.)

[Augmented spontaneous breathing] Hachenberg T. **Anaesthesist** 1996 Sep;45(9):839–55 (143 ref.) (Eng. Abstr.) **(Ger)**

[Respiratory muscle functional test] Saito H, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:62–4 (19 ref.) **(Jpn)**

[Function of the respiratory muscles] Sliwiński P. **Pneumonol Alergol Pol** 1996;64(9–10):697–709 (61 ref.) **(Pol)**

PHYSIOPATHOLOGY

Influences of dysfunctional respiratory mechanics on orofacial pain. Hruska RJ Jr. **Dent Clin North Am** 1997 Apr;41(2):211–27 (71 ref.)

Peripheral and respiratory muscles in chronic heart failure. Stassijns G, et al. **Eur Respir J** 1996 Oct;9(10):2161–7 (55 ref.)

Respiratory muscles and ventilatory failure. Vassilakopoulos T, et al. **Monaldi Arch Chest Dis** 1996 Dec;51(6):489–98 (42 ref.)

Tension–time index of inspiratory muscles in children [editorial; comment] Gaultier C. **Pediatr Pulmonol** 1997 May;23(5):327–9 (18 ref.) Comment on: Pediatr Pulmonol 1997 May;23(5):336–43.

[Evaluation methods for respiratory muscle function and their application in respiratory rehabilitation] Delhez L. **J Belge Med Phys Rehabil** 1980;3(1):7–32 (30 ref.) **(Fre)**

[Changes in ventilatory mechanics in emphysema] Wanke T. **Wien Med Wochenschr** 1996;146(23):585–7 (14 ref.) (Eng. Abstr.) **(Ger)**

RESPIRATORY PARALYSIS

THERAPY

Electrical stimulation to restore respiration. Creasey G, et al. **J Rehabil Res Dev** 1996 Apr;33(2):123–32 (40 ref.)

RESPIRATORY PROTECTIVE DEVICES

Personal respiratory protection against Mycobacterium tuberculosis. Fennelly KP. **Clin Chest Med** 1997 Mar; 18(1):1–17 (79 ref.)

The management of aircraft passenger survival in fire. Trimble EJ. **Toxicology** 1996 Dec 31;115(1–3):41–61 (25 ref.)

RESPIRATORY SOUNDS

Long–term outcome of early childhood wheezing: population data. Strachan D, et al. **Eur Respir J Suppl** 1996 Apr; 21:42s–47s (59 ref.)

Managing stridor in children. Clough J. **Practitioner** 1995 Dec;239(1557):724–8 (2 ref.)

All that wheezes is not asthma. Goldman J. **Practitioner** 1997 Jan;241(1570):35–8 (6 ref.)

[Diagnostic significance of fine crackles in interstitial pulmonary disease] Murata A. **Nippon Ika Daigaku Zasshi** 1996 Oct;63(5):404–8 (4 ref.) **(Jpn)**

[Analytical method of lung sounds] Murata A, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:80–3 (6 ref.) **(Jpn)**

DIAGNOSIS

A cost–effective approach to the diagnosis and treatment of the wheezing infant. Mamlok R. **Allergy Asthma Proc** 1997 May–Jun;18(3):149–52 (20 ref.)

Inflammatory markers of outcome. Grigg J, et al. **Eur Respir J Suppl** 1996 Apr;21:16s–21s (31 ref.)

Lung function and airway responsiveness in infancy. Landau LI. **Monaldi Arch Chest Dis** 1996 Aug;51(4):303–5 (23 ref.)

Stridor in neonates. Mancuso RF. **Pediatr Clin North Am** 1996 Dec;43(6):1339–56 (40 ref.)

When to treat the child who wheezes. Connett G. **Practitioner** 1997 Jun;241(1575):336–40 (7 ref.)

ETIOLOGY

Stridor in the neonate: laryngomalacia. Thurmond M, et al. **J La State Med Soc** 1996 Sep;148(9):375–8 (15 ref.)

An unusual foreign body in the larynx: a case report. Bhat NA, et al. **J Laryngol Otol** 1996 Dec;110(12):1164–5 (7 ref.)

Stridor in neonates. Mancuso RF. **Pediatr Clin North Am** 1996 Dec;43(6):1339–56 (40 ref.)

Vocal cord dysfunction presenting as acute asthma in a pediatric patient. Poirier MP, et al. **Pediatr Emerg Care** 1996 Jun;12(3):213–4 (14 ref.)

Noisy breathing in children: history and presentation hold many clues to the cause. Pryor MP. **Postgrad Med** 1997 Feb;101(2):103–12 (17 ref.)

[Respiratory inflammation] Holgate ST. **Allerg Immunol (Paris)** 1997 Mar;29(3):75–6; discussion 82 (11 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Partial deletion of 18p and partial duplication of 18q caused by a paternal pericentric inversion. Israëls T, et al. **Clin Genet** 1996 Dec;50(6):520–4 (17 ref.)

PHYSIOPATHOLOGY

Short–term clinical measurement: acute severe episodes. de Blic J, et al. **Eur Respir J Suppl** 1996 Apr;21:4s–7s (32 ref.)

RESPIRATORY STIMULANTS see **RESPIRATORY SYSTEM AGENTS**

RESPIRATORY SYNCYTIAL VIRUS, BOVINE

IMMUNOLOGY

Identification of potential CTL epitopes of bovine RSV using allele–specific peptide motifs from bovine MHC class I molecules. Gaddum RM, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):211–9 (50 ref.)

RESPIRATORY SYNCYTIAL VIRUS, HUMAN

[Nosocomial infections due to syncytial respiratory virus: which hygienic measures] Sizun J, et al. **Arch Pediatr** 1996 Jul;3(7):723–7 (34 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Respiratory syncytial virus immune globulin intravenous. Wandstrat TL. **Ann Pharmacother** 1997 Jan;31(1):83–8 (36 ref.)

Prevention of respiratory syncytial virus infection in high risk infants: consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulin. Meissner HC, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1059–68 (51 ref.)

PATHOGENICITY

Immunological determinants of disease caused by respiratory syncytial virus [see comments] Graham BS. **Trends Microbiol** 1996 Jul;4(7):290–3 (39 ref.) Comment in: Trends Microbiol 1996 Aug;4(8):299–300.

RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

Respiratory syncytial virus bronchiolitis. Jeng MJ, et al. **Am Fam Physician** 1997 Mar;55(4):1139–46, 1149–50 (30 ref.)

COMPLICATIONS

Successful treatment of severe dysrhythmias in infants with respiratory syncytial virus infections: two cases and a literature review. Thomas JA, et al. **Crit Care Med** 1997 May;25(5):880–6 (44 ref.)

A 6–week–old girl with persistent apnea and worsening pulmonary disease. Vernacchio L, et al. **Curr Opin Pediatr** 1996 Oct;8(5):459–66 (67 ref.)

Respiratory syncytial virus bronchiolitis in a girl undergoing chemotherapy for acute lymphoblastic leukemia: an immunologic study of local secretion. Tsutsumi H, et al. **Pediatr Infect Dis J** 1996 Jul;15(7):635–6 (12 ref.)

DIAGNOSIS

Respiratory syncytial virus infection in the elderly. Mlinaric–Galinovic G, et al. **Eur J Clin Microbiol Infect Dis** 1996 Oct;15(10):777–81 (71 ref.)

Respiratory syncytial virus: not just for kids. Murry AR, et al. **Hosp Pract (Off Ed)** 1997 Jul 15;32(7):87–8, 91–4, 98 passim (14 ref.)

Bronchiolitis. Bar–on ME, et al. **Prim Care** 1996 Dec; 23(4):805–19 (64 ref.)

DRUG THERAPY

Respiratory syncytial virus immune globulin intravenous. Wandstrat TL. **Ann Pharmacother** 1997 Jan;31(1):83–8 (36 ref.)

Advances in antiviral therapy. Dwyer DE, et al. **Curr Opin Pediatr** 1997 Feb;9(1):24–30 (36 ref.)

Respiratory syncytial virus: not just for kids. Murry AR, et al. **Hosp Pract (Off Ed)** 1997 Jul 15;32(7):87–8, 91–4, 98 passim (14 ref.)

IMMUNOLOGY

Immunological determinants of disease caused by respiratory syncytial virus [see comments] Graham BS. **Trends Microbiol** 1996 Jul;4(7):290–3 (39 ref.) Comment in: Trends Microbiol 1996 Aug;4(8):299–300.

PREVENTION & CONTROL

Prophylaxis for severe respiratory syncytial virus disease [news] Kupecz D. **Nurse Pract** 1996 Sep;21(9):116–8 (8 ref.)

Prevention of respiratory syncytial virus infection in high risk infants: consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulin. Meissner HC, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1059–68 (51 ref.)

[Nosocomial infections due to syncytial respiratory virus: which hygienic measures] Sizun J, et al. **Arch Pediatr** 1996 Jul;3(7):723–7 (34 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Prevention of respiratory syncytial virus infection in high risk infants: consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulin. Meissner HC, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1059–68 (51 ref.)

Bronchiolitis. Bar–on ME, et al. **Prim Care** 1996 Dec; 23(4):805–19 (64 ref.)

RESPIRATORY SYNCYTIAL VIRUSES

IMMUNOLOGY

The effect of respiratory virus infection on expression of cell surface antigens associated with binding of potentially pathogenic bacteria. Elahmer OR, et al. **Adv Exp Med Biol** 1996;408:169–77 (26 ref.)

Respiratory syncytial virus immunology. Kimpen JL. **Pediatr Allergy Immunol** 1996;7(9 Suppl):86–90 (38 ref.)

PATHOGENICITY

Respiratory syncytial virus infection in the elderly. Mlinaric–Galinovic G, et al. **Eur J Clin Microbiol Infect Dis** 1996 Oct;15(10):777–81 (71 ref.)

RESPIRATORY SYSTEM

Smoke inhalation among firefighters. Bizovi KE, et al. **Occup Med** 1995 Oct–Dec;10(4):721–33 (52 ref.)

ABNORMALITIES

Congenital thoracic masses: imaging features in the adult. Raymond GS, et al. **Crit Rev Diagn Imaging** 1997; 38(2):115–205 (68 ref.)

Foolers: things that look like pneumonia in children. Oermann CM, et al. **Semin Respir Infect** 1996 Sep; 11(3):204–13 (31 ref.)

ANATOMY & HISTOLOGY

The airways and anaesthesia—I. Anatomy, physiology and fluid mechanics. Burwell DR, et al. **Anaesthesia** 1996 Sep; 51(9):849–57 (40 ref.)

CHEMISTRY

[Surfactants of the airways. Critical review and personal research] Mira E, et al. **Acta Otorhinolaryngol Ital** 1997 Feb;17(1 Suppl 56):3–16 (77 ref.) (Eng. Abstr.) **(Ita)**

CYTOLOGY

Airway mucosa: secretory cells, mucus and mucin genes [see comments] Jeffery PK, et al. **Eur Respir J** 1997 Jul; 10(7):1655–62 (63 ref.) Comment in: Eur Respir J 1997 Jul;10(7):1438.

Stem cells of the respiratory epithelium and their in vitro cultivation. Emura M. **In Vitro Cell Dev Biol Anim** 1997 Jan;33(1):3–14 (100 ref.)

DRUG EFFECTS

Mechanisms of pollution–induced airway disease: in vitro studies in the upper and lower airways. Devalia JL, et al. **Allergy** 1997;52(38 Suppl):45–51; discussion 57–8 (37 ref.)

The epithelium as a target of glucocorticoid action in the treatment of asthma. Schwiebert LM, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 2):S16–9; discussion S19–20 (35 ref.)

Clinical studies of effects of nitrogen oxides in healthy and asthmatic subjects. Kjaergaard SK, et al. **Cent Eur J Public Health** 1996;4 Suppl:23–6 (18 ref.)

Noise stress and airway toxicity: a prospect for experimental analysis. Van Raaij MT, et al. **Food Chem Toxicol** 1996 Nov–Dec;34(11–12):1159–61 (15 ref.)

The effects of nedocromil sodium and sodium cromoglycate on airway nerves and neurogenic responses in asthma. Norris AA. **Pulm Pharmacol** 1995 Aug–Oct;8(4–5):227–30 (31 ref.)

Drugs affecting neurotransmitter release in the airways. Spina D. **Pulm Pharmacol** 1995 Aug–Oct;8(4–5):217–25 (117 ref.)

Ozone–induced toxicity in experimental animals and isolated cell systems. Gustafsson LE, et al. **Scand J Work Environ Health** 1996;22 Suppl 3:27–41 (93 ref.)

[Atenolol: its cardiorespiratory effects at birth in a premature infant] Zanardo V, et al. **Pediatr Med Chir** 1997 May–Jun; 19(3):149–51 (8 ref.) **(Ita)**

IMMUNOLOGY

Immune functions and immunopathology of the mucosa of the upper respiratory pathways. Brandtzaeg P, et al. **Acta Otolaryngol (Stockh)** 1996 Mar;116(2):149–59 (72 ref.)

Respiratory problems in the immune–compromised host. Schauer U. **Pediatr Allergy Immunol** 1996;7(9 Suppl):82–5 (33 ref.)

M cells and the pathogenesis of mucosal and systemic infections. Siebers A, et al. **Trends Microbiol** 1996 Jan; 4(1):22–9 (60 ref.)

The respiratory immune system of pigs. Pabst R. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):191–5 (35 ref.)

Restricted B–cell responses to microbial challenge of the respiratory tract. Walker J, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):197–204 (28 ref.)

[The significance of muco–ciliary clearance as a defense mechanism in the respiratory tract] Pietrzyk A, et al. **Pneumonol Alergol Pol** 1996;64(11–12):821–8 (25 ref.) **(Pol)**

INNERVATION

Phosphodiesterase inhibitors and endothelin as modulators of respiratory neurotransmission. Fernandes LB. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov;23(10–11):980–2 (35 ref.)

NANC neural control of airway smooth muscle tone. Lindén A. **Gen Pharmacol** 1996 Oct;27(7):1109–21 (140 ref.)

Mechanisms and modulation of capsaicin activity on airway afferent nerves. Fox AJ. **Pulm Pharmacol** 1995 Aug–Oct; 8(4–5):207–15 (64 ref.)

Plasticity of the afferent innervation of the airways. Kummer W, et al. **Pulm Pharmacol** 1995 Aug–Oct;8(4–5):169–72 (8 ref.)

METABOLISM

Models for investigation of peptide and protein transport across cultured mammalian respiratory epithelial barriers. Kim KJ, et al. **Pharm Biotechnol** 1996;8:325–46 (155 ref.)

Drugs affecting neurotransmitter release in the airways. Spina D. **Pulm Pharmacol** 1995 Aug–Oct;8(4–5):217–25 (117 ref.)

Synthetic functions of airway smooth muscle in asthma. Johnson SR, et al. **Trends Pharmacol Sci** 1997 Aug; 18(8):288–92 (60 ref.)

Pharmacokinetics of antimicrobial agents in the respiratory tract. Cruciani M, et al. **Zentralbl Bakteriol** 1996 Jun; 284(1):1–31 (154 ref.)

[Ion transports across the respiratory epithelium] Charfi MR, et al. **Rev Pneumol Clin** 1997;53(2):71–8 (83 ref.) (Eng. Abstr.) **(Fre)**

[Mucin gene—regulation of the expression of MUC2 and MUC3 mucin gene in the airway] Ohmori H, et al. **Nippon Rinsho** 1996 Feb;54(2):411–7 (24 ref.) (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

Interplay between mycoplasma surface proteins, airway cells, and the protean manifestations of mycoplasma–mediated human infections. Baseman JB, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 2):S137–44 (45 ref.)

Receptors in the Pseudomonas aeruginosa adherence to injured and repairing airway epithelium. de Bentzmann S, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 2):S155–62 (54 ref.)

Molecular determinants of the interaction between Haemophilus influenzae and human cells. Geme JW 3rd. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 2):S192–6 (54 ref.)

Interactions between glycoconjugates from human respiratory airways and Pseudomonas aeruginosa. Scharfman A, et al. **Am J Respir Crit Care Med** 1996 Oct; 154(4 Pt 2):S163–9 (59 ref.)

Genetic regulation of airway colonization by Bordetella species. Yuk MH, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 2):S150–4 (33 ref.)

Pseudomonas aeruginosa adherence to remodelling respiratory epithelium. de Bentzmann S, et al. **Eur Respir J** 1996 Oct;9(10):2145–50 (47 ref.)

Restricted B–cell responses to microbial challenge of the respiratory tract. Walker J, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):197–204 (28 ref.)

[The interrelations of mucosal epithelial cells with microbes—intracellular parasites] Domaradskiĭ IV, et al. **Med Parazitol (Mosk)** 1996 Oct–Dec;(4):3–8 (53 ref.) (Eng. Abstr.) **(Rus)**

PATHOLOGY

Upper aerodigestive tract. Ranchod M. **Pathology (Phila)** 1996;3(2):299–304 (5 ref.)

PHYSIOLOGY

Aging and the respiratory system. Rossi A, et al. **Aging (Milano)** 1996 Jun;8(3):143–61 (136 ref.)

The airways and anaesthesia—I. Anatomy, physiology and fluid mechanics. Burwell DR, et al. **Anaesthesia** 1996 Sep; 51(9):849–57 (40 ref.)

Relationship between the humidity and temperature of inspired gas and the function of the airway mucosa. Williams R, et al. **Crit Care Med** 1996 Nov;24(11):1920–9 (75 ref.)

Cardiorespiratory adaptations in neonatal foals. Rose RJ. **Equine Vet J Suppl** 1988 Sep;(5):11–3 (24 ref.)

NANC neural control of airway smooth muscle tone. Lindén A. **Gen Pharmacol** 1996 Oct;27(7):1109–21 (140 ref.)

Invited editorial on "Airway thermal volume in humans and its relation to body size" [editorial] McFadden ER Jr. **J Appl Physiol** 1997 Aug;83(2):331–2 (18 ref.)

Airway and alveolar permeability and surface liquid thickness: theory. Widdicombe J. **J Appl Physiol** 1997 Jan; 82(1):3–12 (116 ref.)

The physiology behind exercise testing. Myers JN. **Prim Care** 1994 Sep;21(3):415–37 (96 ref.)

The endothelins in the pulmonary system. Goldie RG, et al. **Pulm Pharmacol** 1996 Apr;9(2):69–93 (309 ref.)

Cardio–respiratory physiological adaptation of pregnancy. O'Day MP. **Semin Perinatol** 1997 Aug;21(4):268–75 (68 ref.)

Upper respiratory causes of exercise intolerance. Beard W. **Vet Clin North Am Equine Pract** 1996 Dec;12(3):435–55 (42 ref.)

[Control and development of breathing, pathophysiological aspects] Schläfke ME. **Pneumologie** 1997 Apr;51 Suppl 2:398–402 (10 ref.) (Eng. Abstr.) **(Ger)**

[Intraoperative monitoring of respiratory function] Suwa K. **Masui** 1996 Dec;45 Suppl:S187–91 (2 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Advances in critical care monitoring. Barie PS. **Arch Surg** 1997 Jul;132(7):734–9 (43 ref.)

Bronchial hyperresponsiveness: what causes twitchy airways? Page C. **J Pharm Pharmacol** 1997 May;49 Suppl 3:9–11 (37 ref.)

[Non–nosocomial pneumonias in the elderly: clinical findings, etiology, therapeutic approach] Janssens JP, et al. **Schweiz Med Wochenschr** 1996 Sep 7;126(36):1515–23 (64 ref.) (Eng. Abstr.) **(Fre)**

[Respiratory disorders in movement disorders] Jiménez Jiménez FJ, et al. **Med Clin (Barc)** 1996 Sep 21;107(9):342–6 (69 ref.) **(Spa)**

[Airway hyperreactivity and respiratory allergy in children] **Rev Alerg Mex** 1996;43 Spec No:22–37 (73 ref.) **(Spa)**

SECRETION

Airway mucosa: secretory cells, mucus and mucin genes [see comments] Jeffery PK, et al. **Eur Respir J** 1997 Jul; 10(7):1655–62 (63 ref.) Comment in: Eur Respir J 1997 Jul;10(7):1438.

[Pharmacology of airway inflammation—special reference to hypersecretion of the mucous] Miyata K, et al. **Nippon Yakurigaku Zasshi** 1996 Sep;108(3):144–6 (0 ref.) **(Jpn)**

SURGERY

Upper aerodigestive tract. Ranchod M. **Pathology (Phila)** 1996;3(2):299–304 (5 ref.)

RESPIRATORY SYSTEM AGENTS

THERAPEUTIC USE

[Treatment of chronic rhinosinusitis] Galindo de Jaime G. **Rev Alerg Mex** 1996;43 Spec No:19–21 (11 ref.) (Eng. Abstr.) **(Spa)**

TOXICITY

Considerations for toxicology studies of respiratory drug products. DeGeorge JJ, et al. **Regul Toxicol Pharmacol** 1997 Apr;25(2):189–93 (16 ref.)

RESPIRATORY THERAPY

Airway and respiratory management following non–lethal hanging. Kaki A, et al. **Can J Anaesth** 1997 Apr; 44(4):445–50 (15 ref.)

Home care of children dependent on respiratory technology. Toder DS, et al. **Pediatr Rev** 1997 Aug;18(8):273–80; quiz 281 (2 ref.)

Insufficient control of asthma: increase the dose of inhaled steroids or add long–acting beta 2–agonists? Aubert JD, et al. **Schweiz Med Wochenschr** 1997 Feb 1;127(5):176–81 (28 ref.)

[Inhalation therapy in asthma] Gameros Gardea RA. **Rev Alerg Mex** 1996 Sep–Oct;43(5):109–15 (32 ref.) (Eng. Abstr.) **(Spa)**

METHODS

Refractory asthma, Part 2: Airway interventions and management. Jagoda A, et al. **Ann Emerg Med** 1997 Feb; 29(2):275–81 (59 ref.)

Acute respiratory distress syndrome in children. Beaufils F, et al. **Curr Opin Pediatr** 1997 Jun;9(3):207–12 (47 ref.)

Home care of children dependent on respiratory technology. Toder DS, et al. **Pediatr Rev** 1997 Aug;18(8):273–80; quiz 281 (2 ref.)

Aerosol therapy in patients with cystic fibrosis. Schöni MH, et al. **Schweiz Med Wochenschr** 1997 Feb 1;127(5):158–64 (53 ref.)

[Inhalation therapy in chronic obstructive bronchial diseases (see comments)] Barandun J. **Schweiz Med Wochenschr** 1996 Oct 5;126(40):1693–703 (46 ref.) (Eng. Abstr.) Comment in: Schweiz Med Wochenschr 1997 Mar 8;127(10):411. **(Ger)**

[Methodological aspects and clinicophysiological substantiation of applying the hypoxic therapy] Novikov VS, et al. **Aviakosm Ekolog Med** 1996;30(6):42–6 (34 ref.) (Eng. Abstr.) **(Rus)**

RESPIRATORY TRACT DISEASES

Epidemiological studies of the respiratory effects of air pollution. Lebowitz MD. **Eur Respir J** 1996 May; 9(5):1029–54 (306 ref.)

Respiratory medicine. A breath of fresh air? Morrison D, et al. **Lancet** 1996 Dec 21–28;348 Suppl 2:sII23 (5 ref.)

Respiratory health hazards and lung function in wildland firefighters. Harrison R, et al. **Occup Med** 1995 Oct–Dec; 10(4):857–70 (41 ref.)

[Introduction of molecular biology in respiratory medicine and its perspective] Kira S, et al. **Nippon Rinsho** 1996 Feb; 54(2):287–91 (9 ref.) (Eng. Abstr.) **(Jpn)**

CHEMICALLY INDUCED

Systemic side effects of topical beta–adrenergic blockers. Stewart WC, et al. **Clin Cardiol** 1996 Sep;19(9):691–7 (82 ref.)

Effect of occupational exposure to opiates on the respiratory system. Górski P, et al. **Int J Occup Med Environ Health** 1996;9(3):245–53 (48 ref.)

Chronic inhalation toxicity and carcinogenicity testing of respirable fibrous particles. Workshop report. Vu V, et al. **Regul Toxicol Pharmacol** 1996 Dec;24(3):202–12 (5 ref.)

Epidemiologic studies on ozone. Nyberg F, et al. **Scand J Work Environ Health** 1996;22 Suppl 3:72–98 (144 ref.)

Chemical mixtures in atmospheric aerosols and their correlation to lung diseases and lung cancer occurence in the general population. Spurny KR. **Toxicol Lett** 1996 Nov; 88(1–3):271–7 (34 ref.)

COMPLICATIONS

[Gastroesophageal reflux disease and respiratory disease] Mattioli G, et al. **Ann Ital Chir** 1995 Sep–Oct;66(5):629–35 (19 ref.) (Eng. Abstr.) **(Ita)**

CONGENITAL

Congenital thoracic masses: imaging features in the adult. Raymond GS, et al. **Crit Rev Diagn Imaging** 1997; 38(2):115–205 (68 ref.)

DIAGNOSIS

Evaluation of impairment, disability and handicap caused by

respiratory disease--the Thoracic Society of Australia and New Zealand. Abramson M, et al. **Aust N Z J Med** 1996 Oct;26(5):697-701 (12 ref.)

Congenital thoracic masses: imaging features in the adult. Raymond GS, et al. **Crit Rev Diagn Imaging** 1997; 38(2):115-205 (68 ref.)

Respiratory pearls, pitfalls, and updates [corrected; erratum to be published] Fermann GJ, et al. **Emerg Med Clin North Am** 1997 May;15(2):315-26 (40 ref.)

Nitric oxide in exhaled air. Lundberg JO, et al. **Eur Respir J** 1996 Dec;9(12):2671-80 (71 ref.)

Nitric oxide in exhaled air is a new marker of airway inflammation. Kharitonov SA, et al. **Monaldi Arch Chest Dis** 1996 Dec;51(6):533-7 (50 ref.)

Lung function and airway responsiveness in infancy. Landau LI. **Monaldi Arch Chest Dis** 1996 Aug;51(4):303-5 (23 ref.)

Respiratory symptoms. Burge S. **Occup Med (Oxf)** 1997 Jan; 47(1):55-6 (6 ref.)

[Spiroergometry. Indications, methods, relevance] Breuer HW. **Dtsch Med Wochenschr** 1997 Apr 4;122(14):447-9 (20 ref.) **(Ger)**

[Preoperative evaluation of aged patients] Meguro K, et al. **Masui** 1996 Dec;45 Suppl:S143-6 (5 ref.) **(Jpn)**

DRUG THERAPY

The role of corticosteroids in respiratory diseases of children. de Benedictis FM, et al. **Pediatr Pulmonol** 1996 Jul; 22(1):44-57 (234 ref.)

Respiratory benefits of regional anesthesia. Clergue F, et al. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):18-23 (39 ref.)

EPIDEMIOLOGY

Respiratory morbidity in preschool children born prematurely. Relationship to adverse neonatal events. Greenough A, et al. **Acta Paediatr** 1996 Jul;85(7):772-7 (46 ref.)

Epidemiology of pollution-induced airway disease in Scandinavia and Eastern Europe. Björkstén B. **Allergy** 1997;52(38 Suppl):23-5; discussion 35-6 (11 ref.)

Epidemiology of pollution-induced airway disease: urban/rural differences in East and West Germany. Nicolai T. **Allergy** 1997;52(38 Suppl):26-9; discussion 35-6 (18 ref.)

Epidemiologic studies on ozone. Nyberg F, et al. **Scand J Work Environ Health** 1996;22 Suppl 3:72-98 (144 ref.)

[Epidemiology of health problems caused by passive smoking] Schwarz B, et al. **Wien Klin Wochenschr** 1996; 108(18):565-9 (48 ref.) (Eng. Abstr.) **(Ger)**

[The lung in AIDS] Lo Giudice V, et al. **Minerva Med** 1996 Jul-Aug;87(7-8):347-54 (40 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Epidemiology of pollution-induced airway disease in Scandinavia and Eastern Europe. Björkstén B. **Allergy** 1997;52(38 Suppl):23-5; discussion 35-6 (11 ref.)

Upper gastrointestinal motility disorders and respiratory symptoms. Schiller LR. **Am J Health Syst Pharm** 1996 Nov 15;53(22 Suppl 3):S13-6 (21 ref.)

What to do about softwood? A review of respiratory effects and recommendations regarding exposure limits. Demers PA, et al. **Am J Ind Med** 1997 Apr;31(4):385-98 (72 ref.)

The respiratory system. Zifko U, et al. **Baillieres Clin Neurol** 1996 Oct;5(3):477-95 (69 ref.)

Epithelial shedding--restitution as a causative process in airway inflammation. Persson CG, et al. **Clin Exp Allergy** 1996 Jul;26(7):746-55 (73 ref.)

Evaluation and management of gastroesophageal reflux and pulmonary disease. del Rosario JF, et al. **Curr Opin Pediatr** 1996 Jun;8(3):209-15 (98 ref.)

Health and respirable particulate (PM10) air pollution: a causal or statistical association? Gamble JF, et al. **Environ Health Perspect** 1996 Aug;104(8):838-50 (97 ref.)

Mechanisms of airway inflammation in cystic fibrosis. Döring G. **Pediatr Allergy Immunol** 1996;7(9 Suppl):63-6 (31 ref.)

Respiratory health effects of exposure to environmental tobacco smoke. Jinot J, et al. **Rev Environ Health** 1996 Jul-Sep;11(3):89-100 (63 ref.)

Respiratory manifestations of tick-borne diseases in the Southeastern United States [see comments] Byrd RP Jr, et al. **South Med J** 1997 Jan;90(1):1-4 (33 ref.) Comment in: South Med J 1997 Jun;90(6):663.

[Urban atmospheric pollution and public health: epidemiologic data] Aubier M. **Bull Acad Natl Med** 1997 Mar 18;181(3):489-97 (21 ref.) (Eng. Abstr.) **(Fre)**

[Respiratory disorders in movement disorders] Jiménez Jiménez FJ, et al. **Med Clin (Barc)** 1996 Sep 21;107(9):342-6 (69 ref.) **(Spa)**

GENETICS

[Research trends in molecular genetics of respiratory medicine] Yamaguchi E, et al. **Nippon Rinsho** 1996 Feb; 54(2):292-8 (17 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Eosinophil lysis and free granules: an in vivo paradigm for cell activation and drug development. Persson CG, et al. **Trends Pharmacol Sci** 1997 Apr;18(4):117-23 (70 ref.)

METABOLISM

Nasal lavage biomarkers in air pollution epidemiology. Steerenberg PA, et al. **Arch Toxicol Suppl** 1997;19:207-16 (35 ref.)

Upregulation of tachykinin receptors in chronic airway inflammation. McDonald DM. **Pulm Pharmacol** 1995 Aug-Oct;8(4-5):203-5 (15 ref.)

[Mucin gene--regulation of the expression of MUC2 and MUC3 mucin gene in the airway] Ohmori H, et al. **Nippon Rinsho** 1996 Feb;54(2):411-7 (24 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Neurogenic inflammation. A model for studying efferent actions of sensory nerves. McDonald DM, et al. **Adv Exp Med Biol** 1996;410:453-62 (68 ref.)

Treatment of mucociliary dysfunction [see comments] Salathe M, et al. **Chest** 1996 Oct;110(4):1048-57 (154 ref.) Comment in: Chest 1996 Oct;110(4):876.

Noisy breathing in children: history and presentation hold many clues to the cause. Pryor MP. **Postgrad Med** 1997 Feb;101(2):103-12 (17 ref.)

[Pharmacology of airway inflammation--special reference to hypersecretion of the mucous] Miyata K, et al. **Nippon Yakurigaku Zasshi** 1996 Sep;108(3):144-6 (0 ref.) **(Jpn)**

PREVENTION & CONTROL

The role of tachykinin receptor antagonists in the prevention of bronchial hyperresponsiveness, airway inflammation and cough. Advenier C, et al. **Eur Respir J** 1997 Aug; 10(8):1892-906 (196 ref.)

[Prevention of respiratory complications after abdominal surgery] Rezaiguia S, et al. **Ann Fr Anesth Reanim** 1996; 15(5):623-46 (119 ref.) (Eng. Abstr.) **(Fre)**

[Prospects of using computer expert system in the diagnosis of diseases of the respiratory system] Akhlakov MK, et al. **Klin Med (Mosk)** 1996;74(8):48-9 (4 ref.) (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

Functional imaging of the airways. Goldin JG, et al. **J Thorac Imaging** 1997 Jan;12(1):29-37 (56 ref.)

Volumetric (helical/spiral) CT (VCT) of the airways. Naidich DP, et al. **J Thorac Imaging** 1997 Jan;12(1):11-28 (43 ref.)

REHABILITATION

[Evaluation methods for respiratory muscle function and their application in respiratory rehabilitation] Delhez L. **J Belge Med Phys Rehabil** 1980;3(1):7-32 (30 ref.) **(Fre)**

[Sequelae of total laryngectomy with special reference to rehabilitation of the voice and lower airways] Ackerstaff AH, et al. **HNO** 1997 Feb;45(2):97-104 (26 ref.) **(Ger)**

[Respiratory rehabilitation of the elderly patient: results and prospects] Di Marzo A. **Clin Ter** 1996 Nov;147(11):599-605 (15 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Surgical management and treatment of esophageal fistula. Fernando HC, et al. **Surg Clin North Am** 1996 Oct; 76(5):1123-35 (36 ref.)

THERAPY

Respiratory pearls, pitfalls, and updates [corrected; erratum to be published] Fermann GJ, et al. **Emerg Med Clin North Am** 1997 May;15(2):315-26 (40 ref.)

[Problems of gene transfer to human airway in the patients with respiratory diseases] Ohwada A. **Nippon Rinsho** 1996 Feb;54(2):329-33 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Bronchoscopic cryotherapy] Kozielski J, et al. **Pneumonol Alergol Pol** 1997;65(5-6):411-6 (20 ref.) **(Pol)**

ULTRASONOGRAPHY

Thoracic sonography for diagnosis and intervention. Sistrom CL, et al. **Curr Probl Diagn Radiol** 1997 Jan-Feb;26(1):1-49 (148 ref.)

VETERINARY

Lower respiratory tract disease. Moore BR. **Vet Clin North Am Equine Pract** 1996 Dec;12(3):457-72 (79 ref.)

Instrumentation and techniques in respiratory surgery. Stick JA. **Vet Clin North Am Equine Pract** 1996 Aug;12(2):351-72 (31 ref.)

Instrumentation and techniques in transendoscopic upper respiratory tract laser surgery. Tulleners E. **Vet Clin North Am Equine Pract** 1996 Aug;12(2):373-95 (19 ref.)

VIROLOGY

Mucosal immunity: an overview and studies of enteric and respiratory coronavirus infections in a swine model of enteric disease. Saif LJ. **Vet Immunol Immunopathol** 1996 Nov;54(1-4):163-9 (50 ref.)

RESPIRATORY TRACT INFECTIONS

HIV in illicit drug users. O'Donnell AE. **Clin Chest Med** 1996 Dec;17(4):797-807 (90 ref.)

Overview of pulmonary complications. Rosen MJ. **Clin Chest Med** 1996 Dec;17(4):621-31 (79 ref.)

Atopic disease, rhinitis and conjunctivitis, and upper respiratory infections. Schneider LC, et al. **Curr Opin Pediatr** 1996 Oct;8(5):531-40 (95 ref.)

Pulmonary complications of HIV infection. Schneider RF, et al. **Curr Opin Pulm Med** 1997 Mar;3(2):151-8 (73 ref.)

Respiratory illness in HIV-negative immunocompromised patients. Tietjen PA, et al. **Curr Opin Pulm Med** 1997 Mar; 3(2):125-30 (28 ref.)

Lower respiratory tract infections in the community: towards a more rational approach [editorial; comment] Dorca J, et al. **Eur Respir J** 1996 Aug;9(8):1588-9 (17 ref.) Comment on: Eur Respir J 1996 Aug;9(8):1596-600.

[Infections of the lower respiratory tract in patients with human immunodeficiency virus infection] Arzuaga JA, et al. **Enferm Infecc Microbiol Clin** 1997 Feb;15(2):91-106 (152 ref.) **(Spa)**

COMPLICATIONS

Viruses in asthma. Busse WW, et al. **J Allergy Clin Immunol** 1997 Aug;100(2):147-50 (12 ref.)

Role of exposure to inhalant irritants and infections for the development of allergic diseases. Björkstén B. **Pediatr Allergy Immunol** 1996;7(9 Suppl):111-6 (37 ref.)

Codeine, cough and upper respiratory infection. Eccles R. **Pulm Pharmacol** 1996 Oct-Dec;9(5-6):293-7 (17 ref.)

[Respiratory inflammation] Holgate ST. **Allerg Immunol (Paris)** 1997 Mar;29(3):75-6; discussion 82 (11 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Microbiology and laboratory diagnosis of upper respiratory tract infections [see comments] Carroll K, et al. **Clin Infect Dis** 1996 Sep;23(3):442-8 (79 ref.) Comment in: Clin Infect Dis 1997 May;24(5):1027.

Relevance of nucleic acid amplification techniques for diagnosis of respiratory tract infections in the clinical laboratory. Ieven M, et al. **Clin Microbiol Rev** 1997 Apr; 10(2):242-56 (220 ref.)

Respiratory cryptosporidiosis: case series and review of the literature. Clavel A, et al. **Infection** 1996 Sep-Oct; 24(5):341-6 (47 ref.)

Applications of the polymerase chain reaction (PCR) to the diagnosis of pediatric pulmonary disease. Buck GE, et al. **Pediatr Pulmonol** 1995 Nov;20(5):309-22 (149 ref.)

Pulmonary infections mimicking cancer: a retrospective, three-year review. Rolston KV, et al. **Support Care Cancer** 1997 Mar;5(2):90-3 (29 ref.)

[Advances in genetic diagnostics for respiratory tract infections] Koga H. **Nippon Rinsho** 1996 Feb;54(2):560-9 (25 ref.) (Eng. Abstr.) **(Jpn)**

[The role of the pulmonologist in pulmonary infection (editorial)] Dorca J. **Arch Bronconeumol** 1997 May; 33(5):210-2 (21 ref.) **(Spa)**

DRUG THERAPY

Bacterial resistance to antibiotics in acute respiratory infections (ARIs). López-Antuñano FJ, et al. **Arch Med Res** 1997 Summer;28(2):195-203 (36 ref.)

Streamlining antimicrobial therapy for lower respiratory tract infections. Hitt CM, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S231-7 (58 ref.)

Cefixime in the treatment of patients with lower respiratory tract infections: results of US clinical trials. Quintiliani R. **Clin Ther** 1996 May-Jun;18(3):373-90; discussion 372 (37 ref.)

Antibiotic penetration in the respiratory tract and implications for the selection of antimicrobial therapy. Honeybourne D. **Curr Opin Pulm Med** 1997 Mar;3(2):170-4 (35 ref.)

Can antimicrobial activity be sustained? An appraisal of orally administered drugs used for respiratory tract infections. Jones RN. **Diagn Microbiol Infect Dis** 1997 Jan-Feb; 27(1-2):21-8 (20 ref.)

Role of oral antibiotics in treatment of community-acquired lower respiratory tract infections. Legnani D. **Diagn Microbiol Infect Dis** 1997 Jan-Feb;27(1-2):41-7 (33 ref.)

Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Dunn CJ, et al. **Drugs** 1996 Mar;51(3):483-505 (120 ref.)

Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections. Goa KL, et al. **Drugs** 1997 Apr;53(4):700-25 (150 ref.)

Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients. Langtry HD, et al. **Drugs** 1997 Jun;53(6):973-1004 (205 ref.)

Treating respiratory infections in the elderly: current strategies and considerations. Norman DC, et al. **Geriatrics** 1997 Jan;52 Suppl 1:S1-28 (18 ref.)

Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. Drusano GL, et al. **J Chemother** 1997 May;9 Suppl 3:38-44 (11 ref.)

Empiric therapy in lower respiratory tract infection--an ongoing challenge. Geddes AM. **J Chemother** 1997 May; 9 Suppl 3:5-9 (22 ref.)
Respiratory tract infection: epidemiology and surveillance. Jacobs MR. **J Chemother** 1997 May;9 Suppl 3:10-7 (25 ref.)
Pharmacologic management of common lower respiratory tract disorders in women. Mays M, et al. **J Nurse Midwifery** 1997 May-Jun;42(3):163-75 (57 ref.)
Home intravenous antibiotic therapy: practical aspects in children. Leaver J, et al. **J R Soc Med** 1997;90 Suppl 31:26-33 (5 ref.)
Home intravenous antibiotic therapy: practical aspects in adults. Phillips AM. **J R Soc Med** 1997;90 Suppl 31:34-6 (14 ref.)
Lower respiratory tract infections in the intensive care unit: consequences of antibiotic resistance for choice of antibiotic. Lode H, et al. **Microb Drug Resist** 1995 Summer; 1(2):163-7 (33 ref.)
Empirical antibiotic therapy and lower respiratory tract infections: European guidelines and current practices. Woodhead M. **Monaldi Arch Chest Dis** 1995 Dec; 50(6):472-6 (20 ref.)
Empiric antibiotic selection criteria for respiratory infections in pediatric practice. Pichichero ME. **Pediatr Infect Dis J** 1997 Mar;16(3 Suppl):S60-4 (38 ref.)
[Anti-infective treatment of acute pneumopathies in children] Le Masne A, et al. **Arch Pediatr** 1997;4(2 Suppl 2):69s-71s (33 ref.) **(Fre)**
[When and why are antibiotics indicated in airway infections (except pneumonia)?] Brändli O, et al. **Schweiz Rundsch Med Prax** 1997 Apr 30;86(18):737-40 (14 ref.) (Eng. Abstr.) **(Ger)**
[Azithromycin (sumamed)--in the treatment of respiratory tract infections] Fomina IP, et al. **Antibiot Khimioter** 1996 Feb;41(2):52-61 (36 ref.) **(Rus)**
[Increasing antibiotic resistance of pneumococcus. Management of respiratory tract infections and meningitis (see comments)] Kalin M, et al. **Lakartidningen** 1997 Mar 19;94(12):1061-4, 1067-8 (41 ref.) Comment in: Lakartidningen 1997 May 14;94(20):1867-8. **(Swe)**

ECONOMICS

Streamlining antimicrobial therapy for lower respiratory tract infections. Hitt CM, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S231-7 (58 ref.)

EPIDEMIOLOGY

Vitamin C, neutrophil function, and upper respiratory tract infection risk in distance runners: the missing link. Peters-Futre EM. **Exerc Immunol Rev** 1997;3:32-52 (99 ref.)
Respiratory tract infection: epidemiology and surveillance. Jacobs MR. **J Chemother** 1997 May;9 Suppl 3:10-7 (25 ref.)

ETIOLOGY

Are respiratory infections more frequent in glucocorticoid-dependent asthmatic patients? [editorial; comment] Demoly P, et al. **Allergy** 1997 Feb;52(2):122-3 (17 ref.) Comment on: Allergy 1997 Feb;52(2):144-54.
Evaluation of recurrent respiratory tract infections in children. Hopp R. **Curr Probl Pediatr** 1996 May-Jun; 26(5):148-58 (35 ref.)
Mechanisms of virus induced exacerbations of asthma. Corne JM, et al. **Thorax** 1997 Apr;52(4):380-9 (29 ref.)
[Pulmonary problems related to aging] Weber T, et al. **Rev Med Liege** 1997 Apr;52(4):245-50 (13 ref.) **(Fre)**
[Etiological structure of respiratory virus diseases and modern therapeutic opportunities] Kolomiets AG, et al. **Klin Med (Mosk)** 1997;75(2):6-12 (41 ref.) **(Rus)**

IMMUNOLOGY

Cytokines and pulmonary host defenses. Standiford TJ. **Curr Opin Pulm Med** 1997 Mar;3(2):81-8 (56 ref.)
Immunity in athletes. Mackinnon LT. **Int J Sports Med** 1997 Mar;18 Suppl 1:S62-8 (54 ref.)
Exercise immunology: practical applications. Nieman DC. **Int J Sports Med** 1997 Mar;18 Suppl 1:S91-100 (129 ref.)
Exercise, immunology and upper respiratory tract infections. Peters EM. **Int J Sports Med** 1997 Mar;18 Suppl 1:S69-77 (101 ref.)
Immunology of non-viral respiratory tract infections. Rieger CH, et al. **Pediatr Allergy Immunol** 1996;7(9 Suppl):91-4 (16 ref.)
[Hematopoietic growth factors and anti-infective respiratory defenses] Gagnadoux F, et al. **Rev Mal Respir** 1997 Apr; 14(2):93-9 (40 ref.) (Eng. Abstr.) **(Fre)**
[Diseases of the lung and respiratory tract in disorders of immunodeficiency in childhood and adolescence] Roesler J, et al. **Pneumologie** 1996 Nov;50(11):745-51 (37 ref.) **(Ger)**
[Mechanisms of immune response in acute viral respiratory infections] Zheleznikova GF. **Vopr Virusol** 1997 Jul-Aug; 42(4):153-7 (60 ref.) **(Rus)**

METABOLISM

Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. Drusano GL, et al. **J Chemother** 1997 May;9 Suppl 3:38-44 (11 ref.)

MICROBIOLOGY

Microbiology and laboratory diagnosis of upper respiratory tract infections [see comments] Carroll K, et al. **Clin Infect Dis** 1996 Sep;23(3):442-8 (79 ref.) Comment in: Clin Infect Dis 1997 May;24(5):1027.
The biology of bacterial colonization and invasion of the respiratory mucosa [see comments] Wilson R, et al. **Eur Respir J** 1996 Jul;9(7):1523-30 (90 ref.) Comment in: Eur Respir J 1996 Jul;9(7):1342-3.
Moraxella (Branhamella) catarrhalis--clinical and molecular aspects of a rediscovered pathogen. Enright MC, et al. **J Med Microbiol** 1997 May;46(5):360-71 (129 ref.)
Clinical aspects on antibiotic resistance: upper respiratory tract infections. Prellner K. **Microb Drug Resist** 1995 Summer;1(2):143-7 (34 ref.)
Beta-Lactam antibiotic resistance in gram-positive bacterial pathogens of the upper respiratory tract: a brief overview of mechanisms. Tomasz A, et al. **Microb Drug Resist** 1995 Summer;1(2):103-9 (30 ref.)
Role of nontypeable Haemophilus influenzae in pediatric respiratory tract infections. Klein JO. **Pediatr Infect Dis J** 1997 Feb;16(2 Suppl):S5-8 (27 ref.)
Models of mycoplasma respiratory and genital tract infections. Brunner H. **Wien Klin Wochenschr** 1997 Aug 8;109(14-15):569-73 (30 ref.)
[Causative role of infections with viruses or atypical pathogens in acute exacerbations of chronic bronchitis less frequent than expected (see comments)] Roessingh PH, et al. **Ned Tijdschr Geneeskd** 1996 Nov 30;140(48):2406-10 (28 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1997 Feb 15;141(7):351. **(Dut)**
[Respiratory infections--pathogenesis of acute and chronic infections] Matsumoto K. **Kekkaku** 1996 Aug;71(8):477-94 (42 ref.) (Eng. Abstr.) **(Jpn)**
[Severe surgical infection with no information in terms of bacteria] Tanimura H, et al. **Nippon Geka Gakkai Zasshi** 1996 Dec;97(12):1066-71 (8 ref.) (Eng. Abstr.) **(Jpn)**
[Relationship between virus and bacterial infections--with special reference to respiratory tract infections] Nagatake T, et al. **Nippon Naika Gakkai Zasshi** 1997 Mar 10; 86(3):491-5 (10 ref.) **(Jpn)**

PARASITOLOGY

Respiratory cryptosporidiosis: case series and review of the literature. Clavel A, et al. **Infection** 1996 Sep-Oct; 24(5):341-6 (47 ref.)

PHYSIOPATHOLOGY

The relationship of childhood respiratory infection to growth and decline in lung function. Britton J, et al. **Am J Respir Crit Care Med** 1996 Dec;154(6 Pt 2):S240-5 (57 ref.)

PREVENTION & CONTROL

[Control of Nosocomial infections: prevention of respiratory infections in the elderly] Nagatake T, et al. **Nippon Saikingaku Zasshi** 1996 Aug;51(3):871-6 (14 ref.) **(Jpn)**
[Airway hyperreactivity and respiratory allergy in children] **Rev Alerg Mex** 1996;43 Spec No:22-37 (73 ref.) **(Spa)**

THERAPY

[Hematopoietic growth factors and anti-infective respiratory defenses] Gagnadoux F, et al. **Rev Mal Respir** 1997 Apr; 14(2):93-9 (40 ref.) (Eng. Abstr.) **(Fre)**
[Etiological structure of respiratory virus diseases and modern therapeutic opportunities] Kolomiets AG, et al. **Klin Med (Mosk)** 1997;75(2):6-12 (41 ref.) **(Rus)**

VIROLOGY

The role of respiratory viruses in asthma. Busse WW, et al. **Ciba Found Symp** 1997;206:208-13; discussion 213-9 (27 ref.)
Eosinophils, respiratory viruses and allergic asthma. Handzel ZT. **Isr J Med Sci** 1997 Jan;33(1):66-70 (40 ref.)
Macrophages and respiratory viruses. Van Reeth K, et al. **Pathol Biol (Paris)** 1997 Feb;45(2):184-92 (74 ref.)
Common (but not always considered) viral infections of the lower respiratory tract. Fete TJ, et al. **Pediatr Ann** 1996 Oct;25(10):577-84 (12 ref.)
[Causative role of infections with viruses or atypical pathogens in acute exacerbations of chronic bronchitis less frequent than expected (see comments)] Roessingh PH, et al. **Ned Tijdschr Geneeskd** 1996 Nov 30;140(48):2406-10 (28 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1997 Feb 15;141(7):351. **(Dut)**

RESPIRATORY TRACT NEOPLASMS

CHEMICALLY INDUCED

Epidemiologic evidence on the relationship between mists containing sulfuric acid and respiratory tract cancer. Sathiakumar N, et al. **Crit Rev Toxicol** 1997 May; 27(3):233-51 (36 ref.)

DIAGNOSIS

Recurrent respiratory papillomatosis. Kashima HK, et al. **Obstet Gynecol Clin North Am** 1996 Sep;23(3):699-706 (20 ref.)

ETIOLOGY

Particles, inflammation and respiratory tract carcinogenesis. Borm PJ, et al. **Toxicol Lett** 1996 Nov;88(1-3):109-13 (16 ref.)

PATHOLOGY

[Cell types of respiratory epithelium: morphology, molecular biology and clinical significance] Bals R. **Pneumologie** 1997 Feb;51(2):142-9 (79 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Surveillance and intervention studies on respiratory cancers in asbestos-exposed workers. Merler E, et al. **Scand J Work Environ Health** 1997 Apr;23(2):83-92 (86 ref.)

RADIOTHERAPY

[Accelerated radiotherapy: initial results in a series of locally very advanced carcinomas of the upper respiratory and digestive tracts] Dupuis O, et al. **Ann Otolaryngol Chir Cervicofac** 1996;113(5):251-60 (41 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Video-assisted thoracic surgery (VATS) for cancer. Risk of parietal seeding and of early local recurrence. Collard JM, et al. **Int Surg** 1996 Oct-Dec;81(4):343-6 (70 ref.)

THERAPY

[Molecular-biological aspects of juvenile respiratory papillomatosis and its combined treatment] Gerain V, et al. **Vestn Otorinolaringol** 1996 Jul-Aug;(4):3-8 (44 ref.) (Eng. Abstr.) **(Rus)**

VIROLOGY

Role of human papillomaviruses in cancer of the respiratory and upper digestive tract. Snijders PJ, et al. **Clin Dermatol** 1997 May-Jun;15(3):415-25 (112 ref.)

RESPIRATORY TRANSPORT

The prone position in acute respiratory distress syndrome: where we are, and where do we go from here [editorial; comment] Albert RK. **Crit Care Med** 1997 Sep;25(9):1453-4 (36 ref.) Comment on: Crit Care Med 1997 Sep;25(9):1539-44.

PHYSIOLOGY

[Human hemoglobin structure and respiratory transport] Imamura T. **Nippon Rinsho** 1996 Sep;54(9):2320-5 (6 ref.) (Eng. Abstr.) **(Jpn)**

RESPITE CARE

PSYCHOLOGY

Effects of respite care on patients with dementia and their caregivers. Flint AJ. **Int Psychogeriatr** 1995 Winter; 7(4):505-17 (31 ref.)

RESPONSE, ACUTE-PHASE see **ACUTE-PHASE REACTION**

RESPONSE LATENCY see **REACTION TIME**

RESPONSE TIME see **REACTION TIME**

RESPONSIBILITY, SOCIAL see **SOCIAL RESPONSIBILITY**

REST

see related
BED REST

PHYSIOLOGY

Loss of cardiovascular adaptations after physical inactivity. Ehsani AA, et al. **Cardiol Clin** 1997 Aug;15(3):431-8 (54 ref.)
Thermoregulation at rest and during exercise in healthy older adults. Kenney WL. **Exerc Sport Sci Rev** 1997;25:41-76 (132 ref.)
Assessment of left ventricular dimensions and functions in athletes and sedentary subjects at rest and during exercise using echocardiography, Doppler sonography and radionuclide ventriculography. Huonker M, et al. **Int J Sports Med** 1996 Nov;17 Suppl 3:S173-9 (64 ref.)
The role of lifestyle in health: the epidemiology and consequences of inactivity. Dietz WH. **Proc Nutr Soc** 1996 Nov;55(3):829-40 (75 ref.)

REST VERTICAL DIMENSION see **VERTICAL DIMENSION**

RESTAURANTS

STANDARDS

Improving the safety of street-vended food. Moy G, et al. **World Health Stat Q** 1997;50(1-2):124-31 (8 ref.)

RESTING PHASE see **INTERPHASE**

RESTING POTENTIALS see **MEMBRANE POTENTIALS**

RESTLESS LEGS

Restless legs syndrome. Silber MH. **Mayo Clin Proc** 1997 Mar;72(3):261-4 (16 ref.)

Periodic limb movements and restless legs syndrome. Trenkwalder C, et al. **Neurol Clin** 1996 Aug;14(3):629-50 (138 ref.)

COMPLICATIONS

Periodic limb movements of sleep and the restless legs syndrome. Williams DC. **Va Med Q** 1996 Fall;123(4):260-5 (50 ref.)

PHYSIOPATHOLOGY

Restless legs and periodic leg movements in sleep syndromes. Wetter TC, et al. **J Neurol** 1997 Apr;244(4 Suppl 1):S37-45 (104 ref.)

[Restless legs syndrome--current aspects] Grandjean P. **Schweiz Rundsch Med Prax** 1997 Apr 30;86(18):732-6 (23 ref.) (Eng. Abstr.) **(Ger)**

RESTLESSNESS see **PSYCHOMOTOR AGITATION**

RESTRAINT, PHYSICAL

see related
IMMOBILIZATION
PROTECTIVE DEVICES

Safety and efficacy of physical restraints for the elderly. Review of the evidence. Frank C, et al. **Can Fam Physician** 1996 Dec;42:2402-9 (42 ref.)

Exercising restraint: autonomy, welfare and elderly patients. Dodds S. **J Med Ethics** 1996 Jun;22(3):160-3 (13 ref.)

ADVERSE EFFECTS

A suppressive protein generated in peripheral lymph tissue induced by restraint stress. Fan SG, et al. **Adv Neuroimmunol** 1996;6(3):279-88 (44 ref.)

RESTRICTION ENDONUCLEASES see **DNA RESTRICTION ENZYMES**

RESTRICTION ENDONUCLEASES, TYPE II see **DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC**

RESTRICTION FRAGMENT LENGTH POLYMORPHISM see **POLYMORPHISM, RESTRICTION FRAGMENT LENGTH**

RESTRICTION MAPPING

Riboprinting: a tool for the study of genetic diversity in microorganisms. Clark CG. **J Eukaryot Microbiol** 1997 Jul-Aug;44(4):277-83 (52 ref.)

Linkage map of phenotype and RFLP markers in rice. Yoshimura A, et al. **Plant Mol Biol** 1997 Sep;35(1-2):49-60 (36 ref.)

[Physical mapping of human chromosome] Kudoh J, et al. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(15 Suppl):2414-23 (21 ref.) **(Jpn)**

METHODS

Rice molecular genetic map using RFLPs and its applications. Nagamura Y, et al. **Plant Mol Biol** 1997 Sep; 35(1-2):79-87 (98 ref.)

RESUME, JOB see **JOB APPLICATION**

RESUSCITATION

Ethics of resuscitation. Hook CC, et al. **Crit Care Clin** 1996 Jan;12(1):135-48 (53 ref.)

The integration of brain-specific treatments into the initial resuscitation of the severe head injury patient. Brain Trauma Foundation. **J Neurotrauma** 1996 Nov;13(11):653-9 (19 ref.)

Resuscitation of blood pressure and oxygenation. Brain Trauma Foundation. **J Neurotrauma** 1996 Nov;13(11):661-6 (15 ref.)

Irreversible shock revisited: mechanical support of the cardiovascular system: a case report and review. Lisagor P, et al. **J Trauma** 1997 Jun;42(6):1182-6 (28 ref.)

Accidental hypothermia. Lloyd EL. **Resuscitation** 1996 Sep; 32(2):111-24 (81 ref.)

Paediatric life support. An advisory statement by the Paediatric Life Support Working Group of the International Liaison Committee on Resuscitation. Nadkarni V, et al. **Resuscitation** 1997 Apr;34(2):115-27 (69 ref.)

The delivery room resuscitation of the hydropic neonate. McMahan MJ, et al. **Semin Perinatol** 1995 Dec;19(6):474-82 (33 ref.)

Resuscitation and the limited utility of the present generation of blood substitutes. Hess JR, et al. **Transfus Med Rev** 1996 Oct;10(4):276-85 (68 ref.)

[The pathophysiological and intensive care-resuscitation aspects of septic shock] Vasilev D, et al. **Khirurgiia (Sofiia)** 1996;49(4):9-11 (24 ref.) (Eng. Abstr.) **(Bul)**

[How to detect, correct and prevent tissue hypoxia in patients in intensive care units. 3rd European Consensus Conference on Resuscitation. Versailles, 7-8 December 1995] **Rev Pneumol Clin** 1996;52(4):269-72 (0 ref.) **(Fre)**

[Prehospital fluid resuscitation] Kreimeier U, et al. **Anaesthesist** 1996 Oct;45(10):884-99 (104 ref.) (Eng. Abstr.) **(Ger)**

[Myocardial infarct and rhabdomyolysis after a high-voltage accident with successful resuscitation] Franzius C, et al. **Dtsch Med Wochenschr** 1997 Mar 27;122(13):400-6 (22 ref.) (Eng. Abstr.) **(Ger)**

[Emergency management of polytrauma patients] Ziegenfuss T. **Zentralbl Chir** 1996;121(11):924-42 (91 ref.) (Eng. Abstr.) **(Ger)**

[Brain resuscitation] Arai T. **Masui** 1996 Dec;45 Suppl:S168-72 (15 ref.) **(Jpn)**

[The simplest methods for controlling patient status in resuscitation and intensive therapy units] Zolotokrylina ES, et al. **Anesteziol Reanimatol** 1996 Sep-Oct;(5):81-6 (30 ref.) (Eng. Abstr.) **(Rus)**

[Infection and sepsis in resuscitation] Rodrigo-Casanova P, et al. **Rev Esp Anestesiol Reanim** 1997 Jun-Jul;44(6):230-43 (101 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Preventing harm in resuscitation medicine. Ardagh M. **N Z Med J** 1997 Apr 11;110(1041):113-5 (28 ref.)

EDUCATION

Better to lay it out on the table rather than do it behind the curtain: hospitals need to obtain consent before using newly deceased patients to teach resuscitation procedures. Kerns AF. **J Contemp Health Law Policy** 1997 Spring; 13(2):581-612 (197 ref.)

METHODS

Emergency brain resuscitation. Alberts MJ. **Compr Ther** 1997 Jun;23(6):391-9 (48 ref.)

Use of albumin in neonatal resuscitation. Roberton NR. **Eur J Pediatr** 1997 Jun;156(6):428-31 (38 ref.)

Trauma management on the battlefield: a modern approach. Hawley A. **J R Army Med Corps** 1996 Oct;142(3):120-5 (33 ref.)

Hypertonic saline: A review of the literature and evaluation of its role in resuscitation of traumatic hypovolaemic shock. Heath KJ. **J R Army Med Corps** 1994 Feb;140(1):37-41 (29 ref.)

Therapy of patients with head injuries: key parameters for management. Prough DS, et al. **J Trauma** 1997 May;42(5 Suppl):S10-8 (78 ref.)

Pharmacology of pediatric resuscitation. Ushay HM, et al. **Pediatr Clin North Am** 1997 Feb;44(1):207-33 (129 ref.)

Hypotensive resuscitation [editorial] [see comments] Dries DJ. **Shock** 1996 Nov;6(5):311-6 (41 ref.) Comment in: Shock 1996 Nov;6(5):317-8.

The damage control sequence and underlying logic. Rotondo MF, et al. **Surg Clin North Am** 1997 Aug;77(4):761-77 (80 ref.)

NURSING

How to conquer the fear of codes. Badger JM. **Am J Nurs** 1996 Oct;96(10):26-31; quiz 32 (8 ref.)

PSYCHOLOGY

How to conquer the fear of codes. Badger JM. **Am J Nurs** 1996 Oct;96(10):26-31; quiz 32 (8 ref.)

STANDARDS

Avoidance of hypotension: conditio sine qua non of successful severe head-injury management. Chesnut RM. **J Trauma** 1997 May;42(5 Suppl):S4-9 (31 ref.)

TRENDS

Future directions for resuscitation research. V. Ultra-advanced life support. Tisherman SA, et al. **Resuscitation** 1997 Jun;34(3):281-93 (93 ref.)

[The old and eternally new problems of resuscitation] Negovskiĭ VA. **Anesteziol Reanimatol** 1996 Sep-Oct;(5):4-9 (23 ref.) **(Rus)**

RESUSCITATION DECISIONS see **RESUSCITATION ORDERS**

RESUSCITATION ORDERS

Cardiopulmonary resuscitation and do-not-resuscitate orders in the nursing home. Zweig SC. **Arch Fam Med** 1997 Sep-Oct;6(5):424-9 (83 ref.)

Worldwide similarities and differences in the foregoing of life-sustaining treatments [editorial; comment] Sprung CL, et al. **Intensive Care Med** 1996 Oct;22(10):1003-5 (37 ref.) Comment on: Intensive Care Med 1996 Oct;22(10):1015-9. Comment on: Intensive Care Med 1996 Oct;22(10):1020-5.

Economic implications of the timing of do-not-resuscitate orders for ICU patients. Bock KR, et al. **New Horiz** 1997 Feb;5(1):51-5 (29 ref.)

[Ethical conflicts during anesthesia. "Do not resuscitate" orders in the operating room] Mohr M. **Anaesthesist** 1997 Apr;46(4):267-74 (36 ref.) (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

Do not resuscitate. Jones TL. **Tex Med** 1997 Jan;93(1):33-4 (0 ref.)

RETAINERS, ORTHODONTIC see **ORTHODONTIC RETAINERS**

RETE TESTIS

Adenocarcinoma of the rete testis. Glazier DB, et al. **World J Urol** 1996;14(6):397-400 (25 ref.)

PATHOLOGY

Cystic transformation of the rete testis. Nistal M, et al. **Am J Surg Pathol** 1996 Oct;20(10):1231-9 (27 ref.)

RETENTION (PSYCHOLOGY)

The interaction of knowledge, aptitude, and strategies in children's memory performance. Bjorklund DF, et al. **Adv Child Dev Behav** 1996;26:59-89 (98 ref.)

The role of schemata in children's memory. Davidson D. **Adv Child Dev Behav** 1996;26:35-58 (70 ref.)

Implicit memory performance of patients with Alzheimer's disease: a brief review. Jelicic M, et al. **Int Psychogeriatr** 1995 Fall;7(3):385-92 (36 ref.)

The emergence and early development of autobiographical memory. Howe ML, et al. **Psychol Rev** 1997 Jul; 104(3):499-523 (290 ref.)

Dissociations in infant memory: rethinking the development of implicit and explicit memory. Rovee-Collier C. **Psychol Rev** 1997 Jul;104(3):467-98 (360 ref.)

PHYSIOLOGY

The primate temporal pole: its putative role in object recognition and memory. Nakamura K, et al. **Behav Brain Res** 1996 May;77(1-2):53-77 (290 ref.)

The neuroplastic phenomenon: a physiologic link between chronic pain and learning. Arnstein PM. **J Neurosci Nurs** 1997 Jun;29(3):179-86 (33 ref.)

[Nondeclarative memory--neuropsychological findings and neuroanatomic principles] Daum I, et al. **Fortschr Neurol Psychiatr** 1997 Mar;65(3):122-32 (115 ref.) (Eng. Abstr.) **(Ger)**

RETICULAR FORMATION

PHYSIOLOGY

The acoustic startle reflex: neurons and connections. Yeomans JS, et al. **Brain Res Brain Res Rev** 1995 Nov; 21(3):301-14 (79 ref.)

The medullary subnucleus reticularis dorsalis (SRD) as a key link in both the transmission and modulation of pain signals. Villanueva L, et al. **Pain** 1996 Oct;67(2-3):231-40 (109 ref.)

Inadequate frameworks for understanding bodily homeostasis. Blessing WW. **Trends Neurosci** 1997 Jun; 20(6):235-9 (44 ref.)

[Waking mechanisms: multiple networks in the mesencephalic reticular formation] Jouvet M. **Arch Physiol Biochem** 1996 Oct;104(6):762-9 (26 ref.) (Eng. Abstr.) **(Fre)**

RETICULOCYTE COUNT

METHODS

Reticulocyte counting in thalassaemia. Paterakis GS. **Clin Lab Haematol** 1996 Dec;18 Suppl 1:17-28 (18 ref.)

The reticulocyte count: progress towards the resurrection of a useful clinical test. Rowan RM, et al. **Clin Lab Haematol** 1996 Dec;18 Suppl 1:3-8 (45 ref.)

RETICULOCYTES

CYTOLOGY

The reticulocyte count: progress towards the resurrection of a useful clinical test. Rowan RM, et al. **Clin Lab Haematol** 1996 Dec;18 Suppl 1:3-8 (45 ref.)

METABOLISM

Cellular iron processing. Morgan EH. **J Gastroenterol Hepatol** 1996 Nov;11(11):1027-30 (6 ref.)

RETICULOCYTOSIS see **RETICULOCYTE COUNT**

RETICULOENDOTHELIAL SYSTEM

see related
HISTIOCYTES

KUPFFER CELLS
MACROPHAGES
PHAGOCYTES

RETICULOENDOTHELIOSIS, LEUKEMIC see **LEUKEMIA, HAIRY CELL**

RETICULOENDOTHELIOSIS VIRUS, AVIAN

Avian retroviruses. Fadly AM.
Vet Clin North Am Food Anim Pract 1997 Mar;13(1):71–85 (65 ref.)

RETICULOHISTIOCYTOMA see **HISTIOCYTOSIS, NON-LANGERHANS-CELL**

RETICULOLYMPHOSARCOMA see **LYMPHOMA**

RETICULOSIS, HISTIOCYTIC MEDULLARY see **HISTIOCYTOSIS, MALIGNANT**

RETICULUM-CELL SARCOMA see **LYMPHOMA, LARGE-CELL**

RETINA

see related
ANGIOID STREAKS
ELECTRORETINOGRAPHY

Strategies for approaching retinoblastoma tumor suppressor gene therapy. Xu HJ. **Adv Pharmacol** 1997;40:369–97 (145 ref.)

Lipofuscin fluorophore inhibits lysosomal protein degradation and may cause early stages of macular degeneration. Eldred GE. **Gerontology** 1995;41 Suppl 2:15–28 (72 ref.)

ABNORMALITIES

The albino retina: an abnormality that provides insight into normal retinal development. Jeffery G. **Trends Neurosci** 1997 Apr;20(4):165–9 (37 ref.)

ANATOMY & HISTOLOGY

An appraisal of the accuracy of Littmann's method of determining the real dimension of a retinal object. Barr DB. **Acta Ophthalmol Scand Suppl** 1995;(216):1–12 (38 ref.)

CYTOLOGY

Dopaminergic and GABAergic retinal cell populations in mammals. Nguyen-Legros J, et al. **Microsc Res Tech** 1997 Jan 1;36(1):26–42 (140 ref.)

Distribution of cone photoreceptors in the mammalian retina. Szél A, et al. **Microsc Res Tech** 1996 Dec 15;35(6):445–62 (167 ref.)

Microglia in human retina: a heterogeneous population with distinct ontogenies. Provis JM, et al.
Perspect Dev Neurobiol 1996;3(3):213–22 (40 ref.)

Clonal architecture of the mouse retina. Goldowitz D, et al. **Prog Brain Res** 1996;108:3–15 (52 ref.)

The Müller cell: a functional element of the retina. Newman E, et al. **Trends Neurosci** 1996 Aug;19(8):307–12 (58 ref.)

DRUG EFFECTS

Docosahexaenoic acid and the development and function of the infant retina. Heird WC, et al. **Curr Opin Lipidol** 1997 Feb;8(1):12–6 (31 ref.)

Central serous retinopathy associated with adrenocorticotrophic hormone therapy. A case report and a hypothesis. Zamir E.
Graefes Arch Clin Exp Ophthalmol 1997 Jun;235(6):339–44 (37 ref.)

Effects of Chinese herbal products on mammalian retinal functions. Liu SX, et al. **J Ocul Pharmacol Ther** 1996 Fall; 12(3):377–86 (52 ref.)

EMBRYOLOGY

The patterning and onset of opsin expression in vertebrate retinae. Cepko CL. **Curr Opin Neurobiol** 1996 Aug; 6(4):542–6 (32 ref.)

Synaptic development in macaque monkey retina and its implications for other developmental sequences. Hendrickson AE. **Perspect Dev Neurobiol** 1996; 3(3):195–201 (58 ref.)

Spatiotemporal gradients of cell genesis in the primate retina. Rapaport DH, et al. **Perspect Dev Neurobiol** 1996; 3(3):147–59 (116 ref.)

Prenatal development of axon outgrowth and connectivity. Casagrande VA, et al. **Prog Brain Res** 1996;108:83–93 (71 ref.)

ENZYMOLOGY

Retinal protein kinase C. Wood JP, et al. **Neurochem Int** 1997 Feb;30(2):119–36 (146 ref.)

GROWTH & DEVELOPMENT

Extracellular regulators and pattern formation in the developing Drosophila retina. Tio M, et al.
Biochem Soc Symp 1996;62:61–75 (111 ref.)

Retinal development: communication helps you see the light. Wechsler-Reya RJ, et al. **Curr Biol** 1997 Jul 1;7(7):R433–6 (16 ref.)

The patterning and onset of opsin expression in vertebrate retinae. Cepko CL. **Curr Opin Neurobiol** 1996 Aug; 6(4):542–6 (32 ref.)

The albino retina: an abnormality that provides insight into normal retinal development. Jeffery G. **Trends Neurosci** 1997 Apr;20(4):165–9 (37 ref.)

IMMUNOLOGY

Tolerance and uveitis [editorial; comment] Bach JF.
Am J Ophthalmol 1997 May;123(5):684–7 (22 ref.)
Comment on: Am J Ophthalmol 1997 May;123(5):583–92.

Nonteratoid medulloepithelioma of the retina with electron microscopic and immunohistochemical characterization. Vadmal M, et al. **Pediatr Pathol Lab Med** 1996 Jul–Aug; 16(4):663–72 (17 ref.)

METABOLISM

Signal transduction in the retina and inherited retinopathies. Shastry BS. **Cell Mol Life Sci** 1997 May;53(5):419–29 (160 ref.)

Direct measurement of free radicals in ischemic/reperfused diabetic rat retina. Szabo ME, et al. **Clin Neurosci** 1997; 4(5):240–5 (40 ref.)

Retinal development: communication helps you see the light. Wechsler-Reya RJ, et al. **Curr Biol** 1997 Jul 1;7(7):R433–6 (16 ref.)

Electrophysiological assessment of retinal dopaminergic deficiency. Bodis-Wollner I.
Electroencephalogr Clin Neurophysiol Suppl 1996;46:35–41 (29 ref.)

Dopaminergic and GABAergic retinal cell populations in mammals. Nguyen-Legros J, et al. **Microsc Res Tech** 1997 Jan 1;36(1):26–42 (140 ref.)

PATHOLOGY

Understanding angioid streaks. Gurwood AS, et al.
J Am Optom Assoc 1997 May;68(5):309–24 (95 ref.)

Ophthalmomyiasis interna posterior and pigmentary retinopathy of Guam. Hira NK, et al.
J Am Optom Assoc 1997 Jul;68(7):452–8 (23 ref.)

Epiretinal fibrosis. Ciulla TA, et al.
Ophthalmic Surg Lasers 1997 Aug;28(8):670–9 (72 ref.)

Turned on by Ca2+! The physiology and pathology of Ca(2+)-binding proteins in the retina. Polans A, et al.
Trends Neurosci 1996 Dec;19(12):547–54 (69 ref.)

PHYSIOLOGY

Retinal regeneration: common principles but a diversity of mechanisms. Raymond PA, et al. **Adv Neurol** 1997; 72:171–84 (110 ref.)

A fundamental step-transition in retinal function at low light intensities. Morgan IG, et al. **Aust N Z J Ophthalmol** 1997 May;25 Suppl 1:S70–2 (15 ref.)

Complexity of dopaminergic function in the retinal dark-light switch. Morgan IG, et al. **Aust N Z J Ophthalmol** 1996 May;24(2 Suppl):56–8 (13 ref.)

Stimulus-driven facilitation and inhibition of visual information processing in environmental and retinotopic representations of space. Shimojo S, et al.
Brain Res Cogn Brain Res 1996 Dec;5(1–2):11–21 (14 ref.)

Apoptosis in the retina. Rosenbaum PS, et al.
Clin Neurosci 1997;4(5):224–32 (100 ref.)

Role of nitric oxide in retinal cell death. Roth S.
Clin Neurosci 1997;4(5):216–23 (98 ref.)

Retinal development: on the crest of an exciting wave. Copenhagen DR. **Curr Biol** 1996 Nov 1;6(11):1368–70 (32 ref.)

Binocular rivalry: ambiguities resolved. Sengpiel F.
Curr Biol 1997 Jul 1;7(7):R447–50 (15 ref.)

Retinal physiology: adapting to the changing scene. Shapley R. **Curr Biol** 1997 Jul 1;7(7):R421–3 (14 ref.)

Cortical development: a role for spontaneous activity? Thompson I. **Curr Biol** 1997 May 1;7(5):R324–6 (25 ref.)

The Eph family in retinal axon guidance. Drescher U, et al. **Curr Opin Neurobiol** 1997 Feb;7(1):75–80 (54 ref.)

Processing and encoding of visual information in the retina. Masland RH. **Curr Opin Neurobiol** 1996 Aug;6(4):467–74 (47 ref.)

Electrophysiology of retina and optic nerve: effects of changes in serum glucose and of exogenous adenosine in vitro. Niemeyer G, et al.
Electroencephalogr Clin Neurophysiol Suppl 1996;46:141–6 (22 ref.)

Mechanisms of retina regeneration in urodeles. Mitashov VI. **Int J Dev Biol** 1996 Aug;40(4):833–44 (140 ref.)

Neurotransmitters in the vertebrate retina. Lam DM.
Invest Ophthalmol Vis Sci 1997 Mar;38(3):553–6 (20 ref.)

Effects of Chinese herbal products on mammalian retinal functions. Liu SX, et al. **J Ocul Pharmacol Ther** 1996 Fall; 12(3):377–86 (52 ref.)

GABAC receptors in the vertebrate retina. Lukasiewicz PD. **Mol Neurobiol** 1996 Jun;12(3):181–94 (73 ref.)

Physiological properties of the normal lens. Mathias RT, et al. **Physiol Rev** 1997 Jan;77(1):21–50 (196 ref.)

Circadian rhythm generation, expression and entrainment in a molluscan model system. Block GD, et al.
Prog Brain Res 1996;111:93–102 (37 ref.)

The role of NMDA receptors and nitric oxide in retinogeniculate development. Cramer KS, et al.
Prog Brain Res 1996;108:235–44 (84 ref.)

Light entrainment and activation of signal transduction pathways in the SCN. Kornhauser JM, et al.
Prog Brain Res 1996;111:133–46 (80 ref.)

Entrainment pathways and the functional organization of the circadian system. Moore RY. **Prog Brain Res** 1996; 111:103–19 (65 ref.)

Mr. Chips: an ideal-observer model of reading. Legge GE, et al. **Psychol Rev** 1997 Jul;104(3):524–53 (130 ref.)

The Müller cell: a functional element of the retina. Newman E, et al. **Trends Neurosci** 1996 Aug;19(8):307–12 (58 ref.)

Turned on by Ca2+! The physiology and pathology of Ca(2+)-binding proteins in the retina. Polans A, et al.
Trends Neurosci 1996 Dec;19(12):547–54 (69 ref.)

A retinal dark-light switch: a review of the evidence. Morgan IG, et al. **Vis Neurosci** 1996 May–Jun;13(3):399–409 (134 ref.)

Nitric oxide: a review of its role in retinal function and disease. Goldstein IM, et al. **Vision Res** 1996 Sep; 36(18):2979–94 (173 ref.)

[Retinal calcium-binding proteins--their function and pathology] Witkowska D, et al. **Postepy Hig Med Dosw** 1997;51(1):1–22 (97 ref.) (Eng. Abstr.) **(Pol)**

[The neurophysiological characteristics of the retina and the potentials of clinical electroretinography] Shamshinova AM, et al. **Vestn Oftalmol** 1996 Apr–Jun;112(2):52–5 (50 ref.) **(Rus)**

PHYSIOPATHOLOGY

How useful is anomalous correspondence? Herzau V. **Eye** 1996;10 (Pt 2):266–9 (16 ref.)

Assessing retinal/neural function in the presence of ocular media opacities. McGraw PV, et al.
Graefes Arch Clin Exp Ophthalmol 1996 Apr;234(4):280–3 (24 ref.)

Clinical applications of fundus reflection densitometry. Liem AT, et al. **Surv Ophthalmol** 1996 Jul–Aug;41(1):37–50 (108 ref.)

TRANSPLANTATION

The first decade of continuous progress in retinal transplantation. del Cerro M, et al. **Microsc Res Tech** 1997 Jan 15;36(2):130–41 (135 ref.)

[New techniques for retinal surgery. Cell transplantation, a future therapeutic method?] Nystrand A. **Lakartidningen** 1997 Apr 23;94(17):1617–20, 1623 (10 ref.) **(Swe)**

ULTRASTRUCTURE

Vitamin A, visual pigments, and visual receptors in Drosophila. Lee RD, et al. **Microsc Res Tech** 1996 Dec 15;35(6):418–30 (96 ref.)

Plasticity of retinal ribbon synapses. Vollrath L, et al.
Microsc Res Tech 1996 Dec 15;35(6):472–87 (151 ref.)

Nonteratoid medulloepithelioma of the retina with electron microscopic and immunohistochemical characterization. Vadmal M, et al. **Pediatr Pathol Lab Med** 1996 Jul–Aug; 16(4):663–72 (17 ref.)

Unilateral containment of retinal axons by tectal glia: a possible role for sulfated proteoglycans. Jhaveri S, et al. **Prog Brain Res** 1996;108:135–48 (104 ref.)

Control of retinotectal axon arbor growth by postsynaptic CaMKII. Zou DJ, et al. **Prog Brain Res** 1996;108:303–12 (44 ref.)

RETINAL see **RETINALDEHYDE**

RETINAL ANLAGE TUMOR see **NEUROECTODERMAL TUMOR, MELANOTIC**

RETINAL ARTERY OCCLUSION

COMPLICATIONS

Branch retinal artery occlusion in a child. Sebban AI, et al.
Aust N Z J Ophthalmol 1996 Aug;24(3):283–6 (18 ref.)

RETINAL BREAKS see **RETINAL PERFORATIONS**

RETINAL DEGENERATION

CHEMICALLY INDUCED

Interferon alfa-associated retinopathy. Chambers RB, et al.
J Am Osteopath Assoc 1997 Jan;97(1):43–5 (12 ref.)

COMPLICATIONS

[Renal retinal dysplasia] Tomosugi N, et al.
Ryoikibetsu Shokogun Shirizu 1997;(16 Pt 1):381–4 (20 ref.) **(Jpn)**

DIAGNOSIS

Paraneoplastic ophthalmological syndromes. Constantinescu A. **Oftalmologia** 1996 Jul–Sep;40(3):214–8 (7 ref.)

DRUG THERAPY

Growth factors in the treatment of degenerative retinal disorders. Reh TA, et al. **Ciba Found Symp** 1996; 196:120–31; discussion 131–4 (50 ref.)

RETINAL DEGENERATION

GENETICS

Molecular genetics of central retinal dystrophies. Moore AT, et al. **Aust N Z J Ophthalmol** 1996 Aug;24(3):189–98 (77 ref.)

Inherited retinal degeneration: exceptional genetic and clinical heterogeneity. Sullivan LS, et al. **Mol Med Today** 1996 Sep;2(9):380–6 (35 ref.)

[Hereditary retinal dystrophies. 2: Differential diagnosis] Kellner U. **Ophthalmologe** 1997 Jun;94(6):450–65 (35 ref.) **(Ger)**

PATHOLOGY

The retina. Burdon MA, et al. **Curr Opin Neurol** 1996 Feb; 9(1):16–20 (20 ref.)

THERAPY

Transplantation of retinal pigment epithelial, photoreceptor and other cells as treatment for retinal degeneration. Litchfield TM, et al. **Exp Eye Res** 1997 May;64(5):655–66 (130 ref.)

RETINAL DETACHMENT

see related
SCLERAL BUCKLING

COMPLICATIONS

[Retinal detachment and posterior lens luxation. Value of liquid perfluorocarbons] Nacef L, et al. **J Fr Ophtalmol** 1996;19(6–7):432–4 (10 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

[Vitrectomy–laser–gas for treating optic disk pits complicated by serous macular detachment] Taiel–Sartral M, et al. **J Fr Ophtalmol** 1996;19(10):603–9 (31 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

The Silicone Study. A small piece of the PVR puzzle is put into place [editorial; comment] Campochiaro PA. **Arch Ophthalmol** 1997 Mar;115(3):407–8 (6 ref.) Comment on: Arch Ophthalmol 1997 Mar;115(3):335–44.

Latest developments in treating retinal detachment. Aylward GW. **Br J Hosp Med** 1996 Feb 7–20;55(3):100–3 (14 ref.)

Pneumatic retinopexy: principles and practice. Hilton GF, et al. **Indian J Ophthalmol** 1996 Sep;44(3):131–43 (35 ref.)

Fluid vitreous substitutes in vitreo retinal surgery. Saxena S, et al. **Indian J Ophthalmol** 1996 Dec;44(4):191–206 (142 ref.)

Encirclement of the globe and air in the vitreal cavity––unconsidered aspects. Chawla HB. **Klin Oczna** 1996 Jan;98(1):67–8 (3 ref.)

[Modification of axial length and astigmatism by scleral buckling surgery] Grimm G, et al. **Klin Monatsbl Augenheilkd** 1997 Mar;210(3):144–6 (16 ref.) (Eng. Abstr.) **(Ger)**

RETINAL DIALYSES see **RETINAL PERFORATIONS**

RETINAL DISEASES

Epiretinal membranes. Jacobsen CH. **Optom Clin** 1996; 5(1):77–94 (48 ref.)

CHEMICALLY INDUCED

Ophthalmological monitoring for hydroxychloroquine toxicity: a scientific review of available data [see comments] Silman A, et al. **Br J Rheumatol** 1997 May;36(5):599–601 (15 ref.) Comment in: Br J Rheumatol 1997 May;36(5):514–5.

Central serous retinopathy associated with adrenocorticotrophic hormone therapy. A case report and a hypothesis. Zamir E. **Graefes Arch Clin Exp Ophthalmol** 1997 Jun;235(6):339–44 (37 ref.)

Ophthalmologic considerations in using antimalarials in the United States. Rynes RI. **Lupus** 1996 Jun;5 Suppl 1:S73–4 (14 ref.)

Retinopathy and antimalarial drugs––the British experience. Spalton DJ. **Lupus** 1996 Jun;5 Suppl 1:S70–2 (17 ref.)

[Chloroquine maculopathy and prevention of malaria] Balo KP, et al. **J Fr Ophtalmol** 1996;19(12):770–6 (15 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

Hypertensive retinopathy: a review of existing classification systems and a suggestion for a simplified grading system. Dodson PM, et al. **J Hum Hypertens** 1996 Feb;10(2):93–8 (37 ref.)

COMPLICATIONS

Loss of vision alone may result in seesaw nystagmus. May EF, et al. **J Neuroophthalmol** 1997 Jun;17(2):84–5 (8 ref.)

Optic disk edema with a macular star. Brazis PW, et al. **Mayo Clin Proc** 1996 Dec;71(12):1162–6 (66 ref.)

Central serous chorioretinopathy in patients with systemic lupus erythematosus. Cunningham ET Jr, et al. **Ophthalmology** 1996 Dec;103(12):2081–90 (84 ref.)

Postsurgical hypotony: relationship to fistulization, inflammation, chorioretinal lesions, and the vitreous. Schubert HD. **Surv Ophthalmol** 1996 Sep–Oct;41(2):97–125 (331 ref.)

DIAGNOSIS

Multiple evanescent white dot syndrome––an uncommon cause for an enlarged blind spot. Fong KS, et al. **Ann Acad Med Singapore** 1996 Nov;25(6):866–8 (13 ref.)

Adenocarcinoma of the retinal pigment epithelium: a diagnostic and therapeutic challenge. Finger PT, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Aug;234 Suppl 1:S22–7 (23 ref.)

Retinal vasculitis: pathogenesis and laboratory investigations. Rahi AH, et al. **Int Ophthalmol Clin** 1995 Summer; 35(3):93–105 (62 ref.)

Idiopathic peripheral vitreous membranes. Marren SE. **Optom Vis Sci** 1996 Aug;73(8):562–8 (53 ref.)

DRUG THERAPY

Thalidomide may impede cell migration in primates by down–regulating integrin beta–chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis. McCarty MF. **Med Hypotheses** 1997 Aug; 49(2):123–31 (108 ref.)

ETIOLOGY

Traumatic retinopathy resembling acute macular neuroretinopathy. Gillies M, et al. **Aust N Z J Ophthalmol** 1997 Aug;25(3):207–10 (11 ref.)

Cancer–induced retinal hypersensitivity. Thirkill CE. **Br J Biomed Sci** 1996 Sep;53(3):227–34 (110 ref.)

Retinal vasculitis: pathogenesis and laboratory investigations. Rahi AH, et al. **Int Ophthalmol Clin** 1995 Summer; 35(3):93–105 (62 ref.)

Hypertensive retinopathy: a review of existing classification systems and a suggestion for a simplified grading system. Dodson PM, et al. **J Hum Hypertens** 1996 Feb;10(2):93–8 (37 ref.)

Purtscher's retinopathy. Buckley SA, et al. **Postgrad Med J** 1996 Jul;72(849):409–12 (30 ref.)

[Cancer–associated retinopathy] Ohguro H, et al. **Nippon Ganka Gakkai Zasshi** 1997 Apr;101(4):283–7 (45 ref.) (Eng. Abstr.) **(Jpn)**

[Renal retinopathy] Okisaka S. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):24–6 (6 ref.) **(Jpn)**

GENETICS

The retina: genetic studies of several retinopathies located on the short arm of chromosome 17. Joshi AR, et al. **Curr Opin Neurol** 1997 Feb;10(1):31–5 (39 ref.)

METABOLISM

Vascularised vitreoretinopathy: the role of growth factors [see comments] Boulton ME, et al. **Eye** 1996;10 (Pt 6):691–6 (49 ref.) Comment in: Eye 1996 ;10 (Pt 6):651–2.

PARASITOLOGY

[Toxocara canis infection. 2 cases of peripheral granuloma in adults] Saint–Blancat P, et al. **J Fr Ophtalmol** 1997; 20(4):252–7 (19 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

The retina. Burdon MA, et al. **Curr Opin Neurol** 1996 Feb; 9(1):16–20 (20 ref.)

Torpedo maculopathy. Teitelbaum BA, et al. **J Am Optom Assoc** 1997 Jun;68(6):373–6 (12 ref.)

PHYSIOPATHOLOGY

Resuturing the scleral flap leads to resolution of hypotony maculopathy. Schwartz GF, et al. **J Glaucoma** 1996 Aug; 5(4):246–51 (50 ref.)

Clinical applications of fundus reflection densitometry. Liem AT, et al. **Surv Ophthalmol** 1996 Jul–Aug;41(1):37–50 (108 ref.)

PREVENTION & CONTROL

Medical cardiovascular treatment trials: relevant to medical ophthalmology in 1997? Dodson PM, et al. **Eye** 1997;11 (Pt 1):3–11 (70 ref.)

RADIOTHERAPY

Radiation therapy for choroidal and retinal hemangiomas. Augsburger JJ, et al. **Front Radiat Ther Oncol** 1997; 30:265–80 (19 ref.)

SURGERY

Lasers, optical systems and safety in ophthalmology: a review. Fankhauser F, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Aug;234(8):473–87 (56 ref.)

Resuturing the scleral flap leads to resolution of hypotony maculopathy. Schwartz GF, et al. **J Glaucoma** 1996 Aug; 5(4):246–51 (50 ref.)

Laser treatment of macular disease. Bass SJ, et al. **Optom Clin** 1996;5(1):161–73 (20 ref.)

[New techniques for retinal surgery. Cell transplantation, a future therapeutic method?] Nystrand A. **Lakartidningen** 1997 Apr 23;94(17):1617–20, 1623 (10 ref.) **(Swe)**

THERAPY

[Electrostimulation as a treatment method in partial atrophy of the optic nerve and retinal diseases] Rogatina EV. **Vestn Oftalmol** 1997 Jan–Feb;113(1):41–3 (51 ref.) **(Rus)**

RETINAL DISPARITY see **VISION DISPARITY**

RETINAL DRUSEN

GENETICS

Ultrastructural findings in autosomal dominant drusen. Holz FG, et al. **Arch Ophthalmol** 1997 Jun;115(6):788–92 (29 ref.)

PATHOLOGY

Ultrastructural findings in autosomal dominant drusen. Holz FG, et al. **Arch Ophthalmol** 1997 Jun;115(6):788–92 (29 ref.)

RETINAL GANGLION CELLS

CYTOLOGY

Morphogenesis of retinal ganglion cells: a model of dendritic, mosaic, and foveal development. Kirby MA, et al. **Perspect Dev Neurobiol** 1996;3(3):177–94 (71 ref.)

The chronotopic reordering of optic axons. Reese BE. **Perspect Dev Neurobiol** 1996;3(3):233–42 (70 ref.)

DRUG EFFECTS

Effects of neurotrophins on the survival and regrowth of injured retinal neurons. Aguayo AJ, et al. **Ciba Found Symp** 1996;196:135–44; discussion 144–8 (42 ref.)

METABOLISM

Excitatory mechanisms in retinal ganglion cell death in primary open angle glaucoma (POAG). Dreyer EB, et al. **Clin Neurosci** 1997;4(5):270–3 (24 ref.)

PATHOLOGY

The cellular mechanism underlying neuronal degeneration in glaucoma: parallels with Alzheimer's disease. Vickers JC. **Aust N Z J Ophthalmol** 1997 May;25(2):105–9 (47 ref.)

Retinal ganglion cell death in glaucoma: the how, the why, and the maybe. Nickells RW. **J Glaucoma** 1996 Oct; 5(5):345–56 (83 ref.)

PHYSIOLOGY

Retinal ganglion cell anatomy and physiology after section of the optic nerve in mice overexpressing bcl–2. Ratto GM, et al. **Adv Neurol** 1997;72:87–94 (20 ref.)

Survival of axotomized retinal ganglion cells in adult mammals. Watanabe M, et al. **Clin Neurosci** 1997;4(5):233–9 (87 ref.)

The neural architecture of binocular vision. Casagrande VA, et al. **Eye** 1996;10 (Pt 2):153–60 (64 ref.)

Neuronal coupling in rod–signal pathways of the retina. Vaney DI. **Invest Ophthalmol Vis Sci** 1997 Feb; 38(2):267–73 (24 ref.)

Retinal ganglion cell dendritic development and its control. Filling the gaps. Wingate RJ. **Mol Neurobiol** 1996 Apr; 12(2):133–44 (96 ref.)

Evidence that retinal ganglion cell density affects foveal development. Leventhal AG. **Perspect Dev Neurobiol** 1996; 3(3):203–11 (20 ref.)

Nitric oxide and the developmental remodeling of retinal connections in the brain. Wu HH, et al. **Prog Brain Res** 1996;108:273–86 (81 ref.)

Modelling the spatio–temporal modulation response of ganglion cells with difference–of–Gaussians receptive fields: relation to photoreceptor response kinetics. Donner K, et al. **Vis Neurosci** 1996 Jan–Feb;13(1):173–86 (67 ref.)

ULTRASTRUCTURE

Retinal ganglion cell anatomy and physiology after section of the optic nerve in mice overexpressing bcl–2. Ratto GM, et al. **Adv Neurol** 1997;72:87–94 (20 ref.)

Retinal ganglion cell dendritic development and its control. Filling the gaps. Wingate RJ. **Mol Neurobiol** 1996 Apr; 12(2):133–44 (96 ref.)

Specificity of retinal ganglion cell projections in the embryonic rhesus monkey. Chalupa LM, et al. **Perspect Dev Neurobiol** 1996;3(3):223–31 (82 ref.)

Retinal axon divergence in the optic chiasm: growth cone behaviors and signalling cells. Mason CA, et al. **Prog Brain Res** 1996;108:95–107 (66 ref.)

RETINAL HEMORRHAGE

ETIOLOGY

Hemorrhages in the vitreo–retinal interface: premacular hemorrhages. Tassignon MJ, et al. **Bull Soc Belge Ophtalmol** 1995;258:71–81 (50 ref.)

Macular hemorrhage after excimer laser photorefractive keratectomy. Loewenstein A, et al. **J Cataract Refract Surg** 1997 Jun;23(5):808–10 (8 ref.)
The significance of optic disc hemorrhages in glaucoma. Gordon J, et al. **J Glaucoma** 1997 Feb;6(1):62–4 (15 ref.)

RETINAL HOLES see **RETINAL PERFORATIONS**

RETINAL NECROSIS SYNDROME, ACUTE

Acute retinal necrosis syndrome: findings, management, and differential diagnosis. Freilich JM, et al. **Int Ophthalmol Clin** 1996 Summer;36(3):141–6 (32 ref.)

RETINAL NEOVASCULARIZATION

[Advances in cell biology and research on neovascularization] Inomata H. **Nippon Ganka Gakkai Zasshi** 1996 Aug;100(8):573–4 (14 ref.) **(Jpn)**

PHYSIOPATHOLOGY

[Angiogenesis and inhibition of angiogenesis in the eye] Cursiefen C, et al. **Klin Monatsbl Augenheilkd** 1997 Jun;210(6):341–51 (104 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Vascular endothelial growth factor. 20th–century mechanisms, 21st–century therapies. Aiello LP. **Invest Ophthalmol Vis Sci** 1997 Aug;38(9):1647–52 (19 ref.)

RETINAL PERFORATIONS

Idiopathic macular hole. Mann DF. **Optom Clin** 1996;5(1):95–110 (30 ref.)

ETIOLOGY

Retina update: idiopathic macular holes [see comments] Gonder JR. **Can J Ophthalmol** 1996 Jun;31(4):165–8 (35 ref.) Comment in: Can J Ophthalmol 1996 Jun;31(4):163.
Tumor–associated retinal pigment epithelial tears. Leys AM, et al. **Retina** 1997;17(3):258–60 (5 ref.)

SURGERY

Macular surgery [published erratum appears in Br J Hosp Med 1996 Apr 17–30;55(8):526] Aylward GW. **Br J Hosp Med** 1996 Feb 7–20;55(3):85–8 (14 ref.)
Pneumatic retinopexy: principles and practice. Hilton GF, et al. **Indian J Ophthalmol** 1996 Sep;44(3):131–43 (35 ref.)
Management of idiopathic macular holes. Saxena S, et al. **Ophthalmic Surg Lasers** 1996 Jul;27(7):618–27 (71 ref.)
[Surgical treatment of post–traumatic macular holes] Barreau E, et al. **J Fr Ophtalmol** 1997;20(6):423–9 (24 ref.) (Eng. Abstr.) **(Fre)**
[Surgery of macular holes] Santiago PY, et al. **J Fr Ophtalmol** 1996;19(12):787–813 (171 ref.) **(Fre)**

THERAPY

Surgery for idiopathic full–thickness macular holes. Gregor ZJ. **Eye** 1996;10 (Pt 6):685–90 (37 ref.)

RETINAL PIGMENT EPITHELIUM see **PIGMENT EPITHELIUM OF EYE**

RETINAL PIGMENTS

CHEMISTRY

Synthesis of isotopically labelled retinal. Structural and functional studies at the atomic level of the chromophore in visual pigments. Lugtenburg J. **Eur J Clin Nutr** 1996 Jul;50 Suppl 3:S17–20 (18 ref.)

PHYSIOLOGY

Clinical applications of fundus reflection densitometry. Liem AT, et al. **Surv Ophthalmol** 1996 Jul–Aug;41(1):37–50 (108 ref.)

RETINAL S–ANTIGEN see **ARRESTIN**

RETINAL TEARS see **RETINAL PERFORATIONS**

RETINAL VEIN OCCLUSION

DIAGNOSIS

[Retinal venous occlusion] Piguet B. **Rev Med Suisse Romande** 1996 Jan;116(1):31–5 (35 ref.) **(Fre)**

ETIOLOGY

[Retinal vein occlusion and deep–sea diving] Merle H, et al. **J Fr Ophtalmol** 1997;20(6):456–60 (13 ref.) (Eng. Abstr.) **(Fre)**
[Impaired glucose tolerance and branch retinal vein obstruction] Yoshimoto H, et al. **Nippon Rinsho** 1996 Oct;54(10):2786–9 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Contemporary views on the etiopathogenesis of thrombotic changes in the retinal vein] Góralczyk M, et al. **Klin Oczna** 1996 Feb;98(2):155–8 (24 ref.) (Eng. Abstr.) **(Pol)**

SURGERY

Treatment of central retinal vein occlusion. Baumal CR, et al. **Ophthalmic Surg Lasers** 1997 Jul;28(7):590–600 (81 ref.)

RETINAL VESSELS

see related
FLUORESCEIN ANGIOGRAPHY

Retinal vasculitis in Lyme borreliosis. Leys AM, et al. **Bull Soc Belge Ophtalmol** 1995;259:205–14 (64 ref.)
[The retinochoroidal ischemia syndrome. Its classification, etiopathogenesis and clinical aspects] Munteanu G. **Oftalmologia** 1996 Jul–Sep;40(3):241–8 (24 ref.) (Eng. Abstr.) **(Rum)**

METABOLISM

Direct measurement of free radicals in ischemic/reperfused diabetic rat retina. Szabo ME, et al. **Clin Neurosci** 1997;4(5):240–5 (40 ref.)

PATHOLOGY

[Cellular and molecular biology of ischemic retina] Honda Y. **Nippon Ganka Gakkai Zasshi** 1996 Dec;100(12):937–55 (189 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Endothelium: the main actor in the remodelling of the retinal microvasculature in diabetes [see comments] Porta M. **Diabetologia** 1996 Jun;39(6):739–44 (65 ref.) Comment in: Diabetologia 1996 Jun;39(6):745–6.
[Measurement of retinal circulation] Konno S, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:446–9 (14 ref.) **(Jpn)**

PHYSIOPATHOLOGY

[Measurement of retinal blood flow by laser Doppler method] Ogasawara H, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:454–7 (15 ref.) **(Jpn)**

RETINALDEHYDE

CHEMICAL SYNTHESIS

Synthesis of isotopically labelled retinal. Structural and functional studies at the atomic level of the chromophore in visual pigments. Lugtenburg J. **Eur J Clin Nutr** 1996 Jul;50 Suppl 3:S17–20 (18 ref.)

PHYSIOLOGY

Synthesis of isotopically labelled retinal. Structural and functional studies at the atomic level of the chromophore in visual pigments. Lugtenburg J. **Eur J Clin Nutr** 1996 Jul;50 Suppl 3:S17–20 (18 ref.)
Retinoids and the visual process. Crouch RK, et al. **Photochem Photobiol** 1996 Oct;64(4):613–21 (113 ref.)

RETINENE see **RETINALDEHYDE**

RETINITIS

COMPLICATIONS

[Pathology of the retina in patients with AIDS] Adán–Civera A, et al. **Rev Neurol** 1996 Dec;24(136):1614–8 (17 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Antiendothelial cell antibodies (AECA) in patients with uveoretinitis. Edelsten C, et al. **Clin Rev Allergy Immunol** 1997 Spring;15(1):41–52 (40 ref.)

PHYSIOPATHOLOGY

Progressive zonal outer retinitis. Abe T, et al. **Jpn J Ophthalmol** 1996;40(3):412–8 (4 ref.)

VIROLOGY

Cidofovir [editorial; comment] Jabs DA. **Arch Ophthalmol** 1997 Jun;115(6):785–6 (19 ref.) Comment on: Arch Ophthalmol 1997 Jun;115(6):733–7. Comment on: Arch Ophthalmol 1997 Jun;115(6):801–2.

RETINITIS, CYTOMEGALOVIRUS see **CYTOMEGALOVIRUS RETINITIS**

RETINITIS PIGMENTOSA

[Retinitis pigmentosa] Souied E, et al. **J Fr Ophtalmol** 1997;20(6):461–86 (243 ref.) **(Fre)**

COMPLICATIONS

Retinitis pigmentosa in a young man with Noonan syndrome: further evidence that Noonan syndrome (NS) and the cardio–facio–cutaneous syndrome (CFC) are variable manifestations of the same entity? [see comments] Lorenzetti ME, et al. **Am J Med Genet** 1996 Oct 16;65(2):97–9 (17 ref.) Comment in: Am J Med Genet 1996 Oct 16;65(2):100.

DIAGNOSIS

Bardet–Biedl syndrome: delayed diagnosis in a child with Hirschsprung disease [letter] Işlek I, et al. **Clin Dysmorphol** 1996 Jul;5(3):271–3 (7 ref.)

ETIOLOGY

[Physiological roles of rhodopsin phosphorylation and dephosphorylation and its relationship with retinitis pigmentosa] Oguro H. **Nippon Ganka Gakkai Zasshi** 1996 Aug;100(8):575–81 (49 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Signal transduction in the retina and inherited retinopathies. Shastry BS. **Cell Mol Life Sci** 1997 May;53(5):419–29 (160 ref.)
[Retinitis pigmentosa—clinical, genetic and pathophysiologic aspects] Jurklies B, et al. **Klin Monatsbl Augenheilkd** 1997 Jan;210(1):1–18 (229 ref.) (Eng. Abstr.) **(Ger)**
[Candidate gene approach] Hotta Y, et al. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(15 Suppl):2433–40 (54 ref.) **(Jpn)**

PARASITOLOGY

Ophthalmomyiasis interna posterior and pigmentary retinopathy of Guam. Hira NK, et al. **J Am Optom Assoc** 1997 Jul;68(7):452–8 (23 ref.)

RETINOBLASTOMA

see related
GENES, RETINOBLASTOMA

COMPLICATIONS

[Dental changes induced by radiotherapy: a study of subjects with retinoblastoma. I] Mascagni EE, et al. **Minerva Stomatol** 1997 Apr;46(4):191–200 (66 ref.) (Eng. Abstr.) **(Ita)**
[Skeletal changes induced by radiotherapy. A study of subjects with retinoblastoma. II] Mascagni EE, et al. **Minerva Stomatol** 1997 May;46(5):233–46 (67 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

The genetics of retinoblastoma and current diagnostic testing. Smith BJ, et al. **J Pediatr Ophthalmol Strabismus** 1996 Mar–Apr;33(2):120–3 (20 ref.)

DRUG THERAPY

Chemotherapy in the treatment of retinoblastoma. O'Brien JM, et al. **Int Ophthalmol Clin** 1996 Spring;36(2):11–24 (58 ref.)

EPIDEMIOLOGY

Second primary tumors in patients with retinoblastoma. A review of the literature. Moll AC, et al. **Ophthalmic Genet** 1997 Mar;18(1):27–34 (33 ref.)

GENETICS

The retinoblastoma gene: its role in cell cycle and cancer. Giordano A, et al. **In Vivo** 1996 Mar–Apr;10(2):223–7 (71 ref.)
The genetics of retinoblastoma and current diagnostic testing. Smith BJ, et al. **J Pediatr Ophthalmol Strabismus** 1996 Mar–Apr;33(2):120–3 (20 ref.)
The polymerase chain reaction (PCR) in the routine genetic characterization of retinoblastoma: a tool for the clinical laboratory. Mastrangelo D, et al. **Surv Ophthalmol** 1997 Jan–Feb;41(4):331–40 (47 ref.)
[Molecular genetics and diagnosis of retinoblastoma. Significance for ophthalmologic practice] Lohmann DR, et al. **Ophthalmologe** 1997 Apr;94(4):263–7 (11 ref.) (Eng. Abstr.) **(Ger)**
[Evaluation of cancer risk through genetic analysis?] Luz A. **Strahlenther Onkol** 1997 Sep;173(9):444–56 (178 ref.) (Eng. Abstr.) **(Ger)**

NURSING

The power of humor and play as nursing interventions for a child with cancer: a case report. Frankenfield PK. **J Pediatr Oncol Nurs** 1996 Jan;13(1):15–20 (21 ref.)

PATHOLOGY

Unilateral retinoblastoma in an adult: report of a case and review of the literature [see comments] Mietz H, et al. **Ophthalmology** 1997 Jan;104(1):43–7 (30 ref.) Comment in: Ophthalmology 1997 Aug;104(8):1207.
[Invasion of the optic nerve in undifferentiated retinoblastoma] Florescu M, et al. **Oftalmologia** 1996 Oct–Dec;40(4):354–6 (7 ref.) (Eng. Abstr.) **(Rum)**

RADIOTHERAPY

Radiotherapy for retinoblastoma. Treatment strategies. Sauerwein W, et al. **Front Radiat Ther Oncol** 1997;30:93–6

RETINOBLASTOMA

(6 ref.)
Brachytherapy in primary ocular tumors. Freire JE, et al. **Semin Surg Oncol** 1997 May–Jun;13(3):167–76 (47 ref.)

THERAPY

Strategies for approaching retinoblastoma tumor suppressor gene therapy. Xu HJ. **Adv Pharmacol** 1997;40:369–97 (145 ref.)
Nasopharyngeal osteosarcoma as second malignant neoplasm in a post-treated unilateral retinoblastoma: report of a case and review of literature. Dubey SP, et al. **Int J Pediatr Otorhinolaryngol** 1996 Feb;34(3):265–71 (14 ref.)

RETINOBLASTOMA GENES see **GENES, RETINOBLASTOMA**

RETINOBLASTOMA NUCLEAR PHOSPHOPROTEIN P105-RB see **RETINOBLASTOMA PROTEIN**

RETINOBLASTOMA PROTEIN

CHEMISTRY

[The retinoblastoma gene: from its basic understanding as a signal mediator for growth and differentiation to its use in the treatment of cancer] Lee WH, et al. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1368–80 (87 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Activity of the retinoblastoma family proteins, pRB, p107, and p130, during cellular proliferation and differentiation. Sidle A, et al. **Crit Rev Biochem Mol Biol** 1996 Jun; 31(3):237–71 (197 ref.)
The retinoblastoma gene family and its role in proliferation, differentiation and development. De Luca A, et al. **Histol Histopathol** 1996 Oct;11(4):1029–34 (65 ref.)
RB kinases and RB-binding proteins: new points of view. Taya Y. **Trends Biochem Sci** 1997 Jan;22(1):14–7 (50 ref.)
Regulation of RNA polymerases I and III by the retinoblastoma protein: a mechanism for growth control? White RJ. **Trends Biochem Sci** 1997 Mar;22(3):77–80 (33 ref.)

PHARMACOLOGY

[Control of cell proliferation by the retinoblastoma gene product (editorial)] Trouche D. **Pathol Biol (Paris)** 1997 Jan;45(1):5–8 (18 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Recent insights into the functions of the retinoblastoma susceptibility gene product. Kaelin WG Jr. **Cancer Invest** 1997;15(3):243–54 (183 ref.)
The retinoblastoma protein pathway and the restriction point. Bartek J, et al. **Curr Opin Cell Biol** 1996 Dec;8(6):805–14 (71 ref.)
Retinoblastoma protein in growth suppression and death protection. Wang JY. **Curr Opin Genet Dev** 1997 Feb; 7(1):39–45 (51 ref.)
The retinoblastoma protein: a master regulator of cell cycle, differentiation and apoptosis. Herwig S, et al. **Eur J Biochem** 1997 Jun 15;246(3):581–601 (396 ref.)
Retinoblastoma protein family in cell cycle and cancer: a review. Paggi MG, et al. **J Cell Biochem** 1996 Sep 1; 62(3):418–30 (160 ref.)
The retinoblastoma susceptibility gene RB-1 in multiple myeloma. Juge-Morineau N, et al. **Leuk Lymphoma** 1997 Jan;24(3-4):229–37 (71 ref.)
[The retinoblastoma gene: from its basic understanding as a signal mediator for growth and differentiation to its use in the treatment of cancer] Lee WH, et al. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1368–80 (87 ref.) (Eng. Abstr.) **(Jpn)**
[Study of the cell cycle-dependent phosphorylation of the RB protein to the development of a method to cure cancer] Taya Y. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1737–41 (33 ref.) **(Jpn)**

RETINOIC ACID see **TRETINOIN**

13-CIS-RETINOIC ACID see **ISOTRETINOIN**

RETINOIC ACID-BINDING PROTEINS see **RECEPTORS, RETINOIC ACID**

RETINOIC ACID RECEPTORS see **RECEPTORS, RETINOIC ACID**

RETINOIDS

Retinoid signalling during embryogenesis. Pijnappel WW, et al. **Eur J Clin Nutr** 1996 Jul;50 Suppl 3:S29–31 (20 ref.)
[Retinoids and glial tumors. A new therapeutic approach? (editorial)] Defer G. **Rev Neurol (Paris)** 1996 Nov; 152(11):653–7 (24 ref.) **(Fre)**

ADMINISTRATION & DOSAGE

Oral retinoids—efficacy and toxicity in psoriasis. Gollnick HP. **Br J Dermatol** 1996 Oct;135 Suppl 49:6–17 (80 ref.)
Tazarotene gel: efficacy and safety in plaque psoriasis. Weinstein GD. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 3):S33–8 (19 ref.)

ADVERSE EFFECTS

Clinical safety of tazarotene in the treatment of plaque psoriasis. Marks R. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 3):S25–32 (50 ref.)
Vitamin A and its congeners. Monga M. **Semin Perinatol** 1997 Apr;21(2):135–42 (64 ref.)

ANTAGONISTS & INHIBITORS

[Retinoid antagonists] Umemiya H, et al. **Yakugaku Zasshi** 1996 Dec;116(12):928–41 (31 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

[Accounting for conformational flexibility of molecules in structure-property studies] Mekenian OG, et al. **Vopr Med Khim** 1997 May–Jun;43(3):127–38 (19 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Retinoid signalling and axial patterning during early vertebrate embryogenesis. Durston AJ, et al. **Cell Mol Life Sci** 1997 Apr;53(4):339–49 (136 ref.)
Regulation and regulatory role of the retinoids. Ng KW, et al. **Crit Rev Eukaryot Gene Expr** 1995;5(3–4):219–53 (373 ref.)
Life-and-death decisions influenced by retinoids. Rogers MB. **Curr Top Dev Biol** 1997;35:1–46 (274 ref.)
Retinoid (vitamin A) metabolism. Hendriks HF. **Eur J Clin Nutr** 1996 Jul;50 Suppl 3:S2–6 (46 ref.)
Extra-and intracellular transport of retinoids: a reappraisal. Siegenthaler G. **Horm Res** 1996;45(3–5):122–7 (30 ref.)
Hepatic stellate cells—from the viewpoint of retinoid handling and function of the extracellular matrix. Senoo H, et al. **Kaibogaku Zasshi** 1997 Apr;72(2):79–94 (51 ref.)
Retinoids: from hindbrain patterning to Parkinson disease. Eichele G. **Trends Genet** 1997 Sep;13(9):343–5 (25 ref.)

PHARMACOLOGY

Roles of retinoids and their nuclear receptors in the development and prevention of upper aerodigestive tract cancers. Lotan R. **Environ Health Perspect** 1997 Jun;105 Suppl 4:985–8 (52 ref.)
Nuclear retinoid receptors: mediators of retinoid effects. van der Saag PT. **Eur J Clin Nutr** 1996 Jul;50 Suppl 3:S24–8 (46 ref.)
Molecular mechanisms of tazarotene action in psoriasis. Duvic M, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 3):S18–24 (33 ref.)
Molecular epidemiology and retinoid chemoprevention of head and neck cancer. Khuri FR, et al. **J Natl Cancer Inst** 1997 Feb 5;89(3):199–211 (116 ref.)
Retinoids and the control of growth/death decisions in human neuroblastoma cell lines. Melino G, et al. **J Neurooncol** 1997 Jan;31(1-2):65–83 (133 ref.)

THERAPEUTIC USE

Retinoids in the management of non-melanoma skin cancer and melanoma. Craven NM, et al. **Cancer Surv** 1996; 26:267–88 (145 ref.)
Retinoids in clinical cancer therapy. Muindi JR. **Cancer Treat Res** 1996;87:305–42 (242 ref.)
Retinoids in aging. Torras H. **Clin Dermatol** 1996 Mar–Apr; 14(2):207–15 (53 ref.)
Current use and future potential role of retinoids in dermatology. Orfanos CE, et al. **Drugs** 1997 Mar; 53(3):358–88 (262 ref.)
Chemoprevention of respiratory tract cancer. Khuri FR, et al. **Hematol Oncol Clin North Am** 1997 Jun;11(3):387–408 (72 ref.)
Retinoids as cancer-preventive agents. Sankaranarayanan R, et al. **IARC Sci Publ** 1996;(139):47–59 (94 ref.)
Moving promising research findings to the clinic: methodological issues in the design and conduct of clinical trials of retinoids. Arnold A. **Int J Cancer** 1997 Feb 7; 70(4):467–9 (11 ref.)
Retinoid-interferon therapy of solid tumors. Lippman SM, et al. **Int J Cancer** 1997 Feb 7;70(4):481–3 (27 ref.)
Retinoid actions and implications for prevention and therapy of oral cancer. Girod SC, et al. **Int J Oral Maxillofac Surg** 1996 Feb;25(1):69–73 (79 ref.)
Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis. Chandraratna RA. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 3):S12–7 (34 ref.)
Carotenoids and retinoids: a review of research, clinical, and public health applications. Hinds TS, et al. **J Clin Pharmacol** 1997 Jul;37(7):551–8 (54 ref.)
Current status of retinoids in chemoprevention of oral squamous cell carcinoma: an overview. Conley BA, et al. **J Craniomaxillofac Surg** 1996 Dec;24(6):339–45 (56 ref.)
Topical treatments for photoaged skin. Separating the reality from the hype. Kligman AM. **Postgrad Med** 1997 Aug; 102(2):115–8, 123–6 (11 ref.)
Resurfacing with topical agents. Lewis AB, et al. **Semin Cutan Med Surg** 1996 Sep;15(3):139–44 (26 ref.)
[Prevention and treatment of solid tumors with retinoids] Moriwaki H. **Gan To Kagaku Ryoho** 1996 Oct; 23(12):1625–8 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Chemoprevention in cancer of the head and neck] Sánchez Hernández A, et al. **Acta Otorrinolaringol Esp** 1997 Jan-Feb;48(1):1–4 (30 ref.) (Eng. Abstr.) **(Spa)**

RETINOL see **VITAMIN A**

RETINOL-BINDING PROTEINS

CHEMISTRY

Structure/function of cytoplasmic vitamin A-binding proteins. Li E, et al. **Annu Rev Nutr** 1996;16:205–34 (159 ref.)

PHYSIOLOGY

Structure/function of cytoplasmic vitamin A-binding proteins. Li E, et al. **Annu Rev Nutr** 1996;16:205–34 (159 ref.)

RETINOPATHY OF PREMATURITY

Retinopathy of prematurity. Dobson V, et al. **Optom Clin** 1996;5(2):105–24 (40 ref.)
[Prospective biochemical study of the antioxidant defense capacity in retinopathy of prematurity] Papp A, et al. **Orv Hetil** 1997 Jan 26;138(4):201–5 (47 ref.) (Eng. Abstr.) **(Hun)**

DRUG THERAPY

Control of cerebral and ocular blood flow autoregulation in neonates. Hardy P, et al. **Pediatr Clin North Am** 1997 Feb;44(1):137–52 (129 ref.)

RETIREMENT

[Performance capacity of elderly workers—internal and external influencing factors] Dittmann-Kohli F, et al. **Z Gerontol Geriatr** 1996 Sep–Oct;29(5):323–7 (47 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

Gender, the state, and constructing the old as dependent: lessons from the economic transition in Poland. Calasanti TM, et al. **Gerontologist** 1997 Aug;37(4):452–61 (34 ref.)
Research Grant Summary. **Soc Secur Bull** 1996 Winter; 59(4):71–4 (11 ref.)
The economics of retirement: a nontechnical guide. Leonesio MV. **Soc Secur Bull** 1996 Winter;59(4):29–50 (64 ref.)
Pension benefits among the aged: conflicting measures, unequal distributions. Woods JR. **Soc Secur Bull** 1996 Fall; 59(3):3–30 (30 ref.)

TRENDS

Guidance on ill health retirement. Poole CJ. **Br J Rheumatol** 1997 May;36(5):573–6 (18 ref.)
Human resource policies and older workers in Japan. Clark RL, et al. **Gerontologist** 1996 Oct;36(5):627–36 (26 ref.)

RETIREMENT BENEFITS see **PENSIONS**

RETREATMENT

see related
REOPERATION

RETROBULBAR HEMORRHAGE

COMPLICATIONS

Subperiosteal orbital haematoma presenting as proptosis at birth. Skull SA, et al. **J Paediatr Child Health** 1997 Jun; 33(3):256–8 (18 ref.)

RETROGRADE DEGENERATION

Progressive systemic sclerosis associated with multiple mononeuropathy. Nitta Y, et al. **Dermatology** 1996; 193(1):22–6 (19 ref.)

GENETICS

Principles of neuronal regeneration. Kreutzberg GW. **Acta Neurochir Suppl (Wien)** 1996;66:103–6 (10 ref.)

RETROGRADE OBTURATION

Is there a best retrograde filling material? Jou YT, et al. **Dent Clin North Am** 1997 Jul;41(3):555–61 (24 ref.)

RETROLENTAL FIBROPLASIA see **RETINOPATHY OF PREMATURITY**

RETROPERITONEAL FIBROSIS

DIAGNOSIS

Retroperitoneal fibrosis. Kottra JJ, et al. **Radiol Clin North Am** 1996 Nov;34(6):1259–75 (79 ref.)
[Idiopathic retroperitoneal fibrosis localizing in pelvic cavity: a case report] Touge H, et al. **Hinyokika Kiyo** 1996 Aug;

42(8):577–81 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Ormond's disease—a form of retroperitoneal fibrosis] Madaliński M, et al. **Pol Arch Med Wewn** 1996 Nov; 96(5):490–4 (15 ref.) **(Pol)**

[Idiopathic retroperitoneal fibrosis simulating pelvic tumor with distal ureter infiltration. Report of a case] Luján Galán M, et al. **Arch Esp Urol** 1997 Apr;50(3):299–302 (10 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

New data on diagnosis and medical treatment of retroperitoneal fibrosis. Oosterlinck W, et al. **Acta Urol Belg** 1997 Jun;65(2):3–6 (25 ref.)

ETIOLOGY

[Edema caused by retroperitoneal and tricuspid fibrosis with scleroderma tous cutaneous involvement disclosing carcinoid tumor. Apropos of a case and review of the literature] Morand JJ, et al. **Rev Med Interne** 1997; 18(5):388–95 (61 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Retroperitoneal fibrosis. A true connective tissue disease. Gilkeson GS, et al. **Rheum Dis Clin North Am** 1996 Feb; 22(1):23–38 (81 ref.)

[Idiopathic retroperitoneal fibrosis localizing in pelvic cavity: a case report] Touge H, et al. **Hinyokika Kiyo** 1996 Aug; 42(8):577–81 (13 ref.) (Eng. Abstr.) **(Jpn)**

RETROPERITONEAL NEOPLASMS

Juxta-adrenal malignant schwannoma. Fabbro MA, et al. **Pediatr Surg Int** 1997 Sep;12(7):532–4 (13 ref.)

[Malignant fibrous histiocytoma of the retroperitoneum] Saile N, et al. **Prog Urol** 1996 Dec;6(6):944–7 (11 ref.) (Eng. Abstr.) **(Fre)**

[Retroperitoneal sarcomas: recent advances in nosographic framework, diagnosis and integrated surgical treatment] Capaldi M, et al. **G Chir** 1997 Jan–Feb;18(1–2):55–60 (17 ref.) (Eng. Abstr.) **(Ita)**

[Lymphangioleiomyoma with retroperitoneal and thoracic involvement] Barron Medrano M, et al. **An Med Interna** 1996 Feb;13(2):75–8 (38 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

[Retroperitoneal mucinous cystadenocarcinoma associated with horseshoe kidney: a case report] Takayama H, et al. **Hinyokika Kiyo** 1996 Aug;42(8):573–6 (8 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Malignant retroperitoneal teratoma: case report and literature review. Renato F, et al. **Acta Urol Belg** 1996 Sep; 64(3):49–54 (19 ref.)

Retrorectal tumors complicating pregnancy. Report of two cases. Sobrado CW, et al. **Dis Colon Rectum** 1996 Oct; 39(10):1176–9 (13 ref.)

Retroperitoneal MR imaging. Engelken JD, et al. **Magn Reson Imaging Clin N Am** 1997 Feb;5(1):165–78 (51 ref.)

Retroperitoneal MR imaging in children. Meyer JS. **Magn Reson Imaging Clin N Am** 1996 Nov;4(4):657–78 (70 ref.)

Extrarenal retroperitoneal angiomyolipoma. Fegan JE, et al. **South Med J** 1997 Jan;90(1):59–62 (22 ref.)

[Retroperitoneal schwannoma. Diagnostic and therapeutic outcome] Krid M, et al. **Acta Urol Belg** 1997 Mar; 65(1):69–72 (18 ref.) (Eng. Abstr.) **(Fre)**

[A case of mature retroperitoneal teratoma producing CEA] Iwai T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jul; 93(7):491–5 (16 ref.) **(Jpn)**

[Retrovesical schwannosarcoma] Gonzalvo Pérez V, et al. **Actas Urol Esp** 1997 Apr;21(4):416–9 (8 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Early postoperative intraperitoneal Adriamycin as an adjuvant treatment for visceral and retroperitoneal sarcoma. Sugarbaker PH. **Cancer Treat Res** 1996;81:7–14 (12 ref.)

Combination chemotherapy for malignant paraganglioma. Kimura S, et al. **Intern Med** 1997 Jan;36(1):35–9 (21 ref.)

Residual masses after chemotherapy for metastatic testicular cancer: the clinical implications of the association between retroperitoneal and pulmonary histology. Re-analysis of Histology in Testicular Cancer (ReHiT) Study Group. Steyerberg EW, et al. **J Urol** 1997 Aug;158(2):474–8 (23 ref.)

Management of chemotherapy in a pregnancy complicated by a large neuroblastoma. Arango HA, et al. **Obstet Gynecol** 1994 Oct;84(4 Pt 2):665–8 (10 ref.)

ETIOLOGY

Radiation-induced sarcoma following curative radiotherapy for testicular seminoma: case report and brief review of the literature. Stein ME, et al. **Tumori** 1997 May–Jun; 83(3):721–3 (14 ref.)

METABOLISM

High-molecular weight IGF-2 expression in a haemangiopericytoma associated with hypoglycaemia. Höög A, et al. **APMIS** 1997 Jun;105(6):469–82 (58 ref.)

PATHOLOGY

Primary retroperitoneal mucinous tumor of low malignant potential: histogenetic aspects and review of the literature. Papadogiannakis N, et al. **APMIS** 1997 Jun;105(6):483–6 (32 ref.)

Two cases of primary retroperitoneal mucinous cystadenocarcinoma. Lee IW, et al. **Gynecol Oncol** 1996 Oct;63(1):145–50 (13 ref.)

[A case of giant cavernous hemangioma of the retroperitoneum] Bellini F, et al. **Minerva Chir** 1996 Oct; 51(10):867–70 (14 ref.) (Eng. Abstr.) **(Ita)**

RADIOGRAPHY

[Retroperitoneal leiomyosarcoma: case report and literature review] Baraké H, et al. **Rev Med Brux** 1996 Dec; 17(6):384–8 (19 ref.) (Eng. Abstr.) **(Fre)**

RADIOTHERAPY

Role of radiation therapy in retroperitoneal sarcomas. Clark JA, et al. **Oncology (Huntingt)** 1996 Dec;10(12):1867–72; discussion 1872–4 (27 ref.)

[Organ preservation in the treatment of malignant solid tumors in children] Saeki M, et al. **Gan To Kagaku Ryoho** 1997 Apr;24(6):666–72 (5 ref.) (Eng. Abstr.) **(Jpn)**

SECONDARY

Residual masses after chemotherapy for metastatic testicular cancer: the clinical implications of the association between retroperitoneal and pulmonary histology. Re-analysis of Histology in Testicular Cancer (ReHiT) Study Group. Steyerberg EW, et al. **J Urol** 1997 Aug;158(2):474–8 (23 ref.)

SURGERY

[Retroperitoneal schwannoma. Diagnostic and therapeutic outcome] Krid M, et al. **Acta Urol Belg** 1997 Mar; 65(1):69–72 (18 ref.) (Eng. Abstr.) **(Fre)**

[Retroperitoneal tumors and surgery of the great vessels] Barret A, et al. **Chirurgie** 1997;122(1):25–30 (18 ref.) (Eng. Abstr.) **(Fre)**

[surgical relevance of diagnostic imaging in abdominal tumors—decision making in retroperitoneal tumors] Schildberg FW, et al. **Chirurg** 1997 Apr;68(4):346–55 (33 ref.) (Eng. Abstr.) **(Ger)**

[Retroperitoneal schwannoma: report of a clinical case and review of the literature] Ziparo V, et al. **G Chir** 1996 Aug–Sep;17(8–9):399–404 (33 ref.) (Eng. Abstr.) **(Ita)**

[Retroperitoneal mucinous cystadenocarcinoma associated with horseshoe kidney: a case report] Takayama H, et al. **Hinyokika Kiyo** 1996 Aug;42(8):573–6 (8 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

[Results of surgical and combined treatment of retroperitoneal non-organ neoformations] Chernyĭ VV. **Klin Khir** 1996;(6):41–3 (38 ref.) **(Rus)**

RETROPERITONEAL SPACE

PATHOLOGY

Retroperitoneal MR imaging in children. Meyer JS. **Magn Reson Imaging Clin N Am** 1996 Nov;4(4):657–78 (70 ref.)

[Benign non-organ-related diseases of the retroperitoneal space] Szolar DH, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Aug;167(2):107–21 (101 ref.) (Eng. Abstr.) **(Ger)**

[Retroperitoneal hematoma during heparin therapy. Comments on 3 cases] Di Rosa C, et al. **Minerva Chir** 1997 Apr;52(4):493–7 (30 ref.) (Eng. Abstr.) **(Ita)**

RADIOGRAPHY

CT of pancreatitis with renal and juxtarenal manifestations. Farman J, et al. **Clin Imaging** 1997 May–Jun;21(3):183–8 (9 ref.)

[Benign non-organ-related diseases of the retroperitoneal space] Szolar DH, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Aug;167(2):107–21 (101 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

[Echo-guided drainage of pararenal and pelvic fluid accumulations: technique, indications, and results] Porena M, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):19–26 (8 ref.) (Eng. Abstr.) **(Ita)**

RETROPHARYNGEAL ABSCESS

Supraglottic airway infections. Millan SB, et al. **Prim Care** 1996 Dec;23(4):741–58 (106 ref.)

COMPLICATIONS

Retropharyngeal abscess associated with tuberculosis of the cervical spine. Al Soub H. **Tuber Lung Dis** 1996 Dec; 77(6):563–5 (17 ref.)

DIAGNOSIS

Acute non-tuberculous retropharyngeal abscess in an adult. A case report and review of the literature. Karkanevatos A, et al. **J Laryngol Otol** 1997 Feb;111(2):169–71 (9 ref.)

RADIOGRAPHY

Neonatal radiology casebook. Retropharyngeal abscess in the neonate. Gaglani MJ, et al. **J Perinatol** 1996 May–Jun;16(3 Pt 1):231–3 (12 ref.)

RETROPNEUMOPERITONEUM

RADIOGRAPHY

[Pneumoperitoneum and pneumoretroperitoneum without perforation] Kirchner J, et al. **Zentralbl Chir** 1996; 121(10):861–5 (12 ref.) (Eng. Abstr.) **(Ger)**

RETROPOSONS see **RETROTRANSPOSONS**

RETROTRANSPOSONS

Transposable elements: how non-LTR retrotransposons do it. Finnegan DJ. **Curr Biol** 1997 Apr 1;7(4):R245–8 (16 ref.)

Turned on by stress. Plant retrotransposons. Wessler SR. **Curr Biol** 1996 Aug 1;6(8):959–61 (17 ref.)

Retroviruses and retroelements in diseases and in gene therapy. Svoboda J. **Folia Biol (Praha)** 1996;42(6):283–94 (46 ref.)

Retrotransposons of rice: their regulation and use for genome analysis. Hirochika H. **Plant Mol Biol** 1997 Sep; 35(1–2):231–40 (74 ref.)

Error-prone retrotransposition: rime of the ancient mutators [comment] Preston BD. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):7427–31 (74 ref.) Comment on: Proc Natl Acad Sci U S A 1996 Jul 23;93(15):7767–71.

Retroelements in genome organization [comment] Voytas DF. **Science** 1996 Nov 1;274(5288):737–8 (5 ref.) Comment on: Science 1996 Nov 1;274(5288):765–8.

The adventures of the Ty1-copia group of retrotransposons in plants. Kumar A. **Trends Genet** 1996 Feb;12(2):41–3 (26 ref.)

Reverse transcriptase: mediator of genomic plasticity. Brosius J, et al. **Virus Genes** 1995;11(2–3):163–79 (259 ref.)

Retrotransposition and herpesvirus evolution. Brunovskis P, et al. **Virus Genes** 1995;11(2–3):259–70 (124 ref.)

Retroelements: propagation and adaptation. Hull R, et al. **Virus Genes** 1995;11(2–3):105–18 (91 ref.)

Structure, function, and evolution of bacterial reverse transcriptase. Inouye S, et al. **Virus Genes** 1995; 11(2–3):81–94 (47 ref.)

Evolution and biological significance of human retroelements. Leib-Mösch C, et al. **Virus Genes** 1995; 11(2–3):133–45 (153 ref.)

GENETICS

Structure and functional properties of mouse VL30 retrotransposons. French NS, et al. **Biochim Biophys Acta** 1997 May 2;1352(1):33–47 (99 ref.)

Morphogenesis at the retrotransposon-retrovirus interface: gypsy and copia families in yeast and Drosophila. Sandmeyer SB, et al. **Curr Top Microbiol Immunol** 1996; 214:261–96 (136 ref.)

Tying together integration and chromatin. Curcio MJ, et al. **Trends Genet** 1996 Nov;12(11):436–8 (25 ref.)

The contributions of retroelements to plant genome organization, function and evolution. Bennetzen JL. **Trends Microbiol** 1996 Sep;4(9):347–53 (70 ref.)

PHYSIOLOGY

It's prime time for reverse transcriptase. Levin HL. **Cell** 1997 Jan 10;88(1):5–8 (20 ref.)

RETROVIRIDAE

Control of differentiation, transformation, and apoptosis in granulosa cells by oncogenes, oncoviruses, and tumor suppressor genes. Amsterdam A, et al. **Endocr Rev** 1997 Aug;18(4):435–61 (367 ref.)

Retroviruses and retroelements in diseases and in gene therapy. Svoboda J. **Folia Biol (Praha)** 1996;42(6):283–94 (46 ref.)

Can insights into urodele limb regeneration be achieved with cell cultures and retroviruses? Tsonis PA, et al. **Int J Dev Biol** 1996 Aug;40(4):813–6 (13 ref.)

On viruses, sex, and motherhood. Villareal LP. **J Virol** 1997 Feb;71(2):859–65 (88 ref.)

Retroviral vectors. From laboratory tools to molecular medicine. Vile RG, et al. **Mol Biotechnol** 1996 Apr; 5(2):139–58 (115 ref.)

Strategies for targeted gene therapy. Harris JD, et al. **Trends Genet** 1996 Oct;12(10):400–5 (67 ref.)

Laboratory diagnostic tests for retroviral infections in dairy and beef cattle. Evermann JF, et al. **Vet Clin North Am Food Anim Pract** 1997 Mar;13(1):87–106

(105 ref.)

CHEMISTRY

From the natural evolution to the genetic manipulation of the host-range of retroviruses. Dornburg R. **Biol Chem** 1997 Jun;378(6):457–68 (101 ref.)

CLASSIFICATION

Comparative morphology and structural classification of retroviruses. Nermut MV, et al.
Curr Top Microbiol Immunol 1996;214:1–24 (60 ref.)

Retrovirus classification and cell interactions. Weiss RA.
J Antimicrob Chemother 1996 May;37 Suppl B:1–11 (16 ref.)

ENZYMOLOGY

Retroviral proteases: structure, function and inhibition from a non-anticipated viral enzyme to the target of a most promising HIV therapy. von der Helm K. **Biol Chem** 1996 Dec;377(12):765–74 (97 ref.)

Reverse transcriptase jumps and gaps. Kupiec JJ, et al.
J Gen Virol 1996 Sep;77 (Pt 9):1987–91 (38 ref.)

Analysis of inhibition of retroviral reverse transcriptase. Balzarini J, et al. **Methods Enzymol** 1996;275:472–502 (112 ref.)

GENETICS

Endogenous retroviral sequences in the pathogenesis of systemic autoimmune disease. Walchner M, et al.
Arch Dermatol 1997 Jun;133(6):767–71 (69 ref.)

Dimerization of retroviral genomic RNAs: structural and functional implications. Paillart JC, et al. **Biochimie** 1996; 78(7):639–53 (138 ref.)

From the natural evolution to the genetic manipulation of the host-range of retroviruses. Dornburg R. **Biol Chem** 1997 Jun;378(6):457–68 (101 ref.)

Ex vivo gene therapy for Alzheimer's disease and spinal cord injury. Blesch A, et al. **Clin Neurosci** 1995–96;3(5):268–74 (51 ref.)

Transposable elements: how non-LTR retrotransposons do it. Finnegan DJ. **Curr Biol** 1997 Apr 1;7(4):R245–8 (16 ref.)

Morphogenesis at the retrotransposon-retrovirus interface: gypsy and copia families in yeast and Drosophila. Sandmeyer SB, et al. **Curr Top Microbiol Immunol** 1996; 214:261–96 (136 ref.)

Adenoviral/retroviral vector chimeras: a novel strategy to achieve high-efficiency stable transduction in vivo. Bilbao G, et al. **FASEB J** 1997 Jul;11(8):624–34 (112 ref.)

Targeting retrovirus entry. Cosset FL, et al. **Gene Ther** 1996 Nov;3(11):946–56 (70 ref.)

Retroviral targeted delivery. Schnierle BS, et al.
Gene Ther 1996 Dec;3(12):1069–73 (29 ref.)

The potential roles of endogenous retroviruses in autoimmunity. Nakagawa K, et al. **Immunol Rev** 1996 Aug; 152:193–236 (219 ref.)

Biological significance of human endogenous retroviral sequences. Hohenadl C, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996;13 Suppl 1:S268–73 (59 ref.)

HERV-K: the biologically most active human endogenous retrovirus family. Tönjes RR, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996;13 Suppl 1:S261–7 (56 ref.)

Biosynthetic retrovectoring systems for gene therapy. Hodgson CP, et al. **J Mol Med** 1997 Apr;75(4):249–58 (50 ref.)

New insight on the role of extrachromosomal retroviral DNA. Cara A, et al. **Leukemia** 1997 Sep;11(9):1395–9 (48 ref.)

Use of single-cycle analysis to study rates and mechanisms of retroviral mutation. Yu H, et al. **Methods** 1997 Aug; 12(4):325–36 (62 ref.)

Selection of retrovirally transduced cells to enhance the efficiency of gene therapy. Medin JA, et al.
Proc Assoc Am Physicians 1997 Mar;109(2):111–9 (67 ref.)

Retroviral stem cell gene therapy. Havenga M, et al.
Stem Cells 1997;15(3):162–79 (144 ref.)

Eleven chromosomal integration sites of a human endogenous retrovirus (HERV 4–1) map close to known loci of thirteen hereditary malformation syndromes. Taruscio DA, et al. **Teratology** 1996 Aug;54(2):108–10 (21 ref.)

Viral vector-mediated gene therapy for hemophilia B. Eisensmith RC, et al. **Thromb Haemost** 1997 Jul;78(1):24–30 (81 ref.)

Accessory replication proteins and the accuracy of reverse transcription: implications for retroviral genetic diversity. Mansky LM. **Trends Genet** 1997 Apr;13(4):134–6 (19 ref.)

Our retroviral heritage. Patience C, et al. **Trends Genet** 1997 Mar;13(3):116–20 (62 ref.)

Endogenous retroviruses and the evolution of resistance to retroviral infection. Best S, et al. **Trends Microbiol** 1997 Aug;5(8):313–8 (33 ref.)

Pararetro- and retrovirus RNA: splicing and the control of nuclear export. Kiss-László Z, et al. **Trends Microbiol** 1996 Dec;4(12):480–5 (52 ref.)

Retrovirus variation: a finger on the pulse [comment] Meyerhans A. **Trends Microbiol** 1996 Jun;4(6):218–9 (15 ref.) Comment on: Trends Microbiol 1996 Apr;4(4):135–41.

Mechanisms of retroviral mutation. Preston BD, et al.
Trends Microbiol 1996 Jan;4(1):16–21 (88 ref.)

Baboon endogenous virus evolution and ecology [see comments] van der Kuyl AC, et al. **Trends Microbiol** 1996 Nov;4(11):455–9 (23 ref.) Comment in: Trends Microbiol 1996 Dec;4(12):478.

[Endogenous retroviral sequences as a factor in the pathogenesis of systemic lupus erythematosus] Walchner M, et al. **Hautarzt** 1996 Jul;47(7):502–9 (55 ref.) (Eng. Abstr.) **(Ger)**

[Gene therapy in neurology. State of the art and future prospects] Duarte RG. **Neurologia** 1995 Dec;10 Suppl 1:56–61 (14 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Comparative approach to retroviral vaccines. Burny A.
AIDS Res Hum Retroviruses 1996 Mar 20;12(5):389–92 (6 ref.)

Perspectives on retroviral pathogenesis and vaccines. Weiss RA. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):465–7 (3 ref.)

Retroviruses and systemic lupus erythematosus. Herrmann M, et al. **Immunol Rev** 1996 Aug;152:145–56 (54 ref.)

The potential roles of endogenous retroviruses in autoimmunity. Nakagawa K, et al. **Immunol Rev** 1996 Aug; 152:193–236 (219 ref.)

HERV-K: the biologically most active human endogenous retrovirus family. Tönjes RR, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996;13 Suppl 1:S261–7 (56 ref.)

Retrovirus and filovirus "immunosuppressive motif" and the evolution of virus pathogenicity in HIV-1, HIV-2, and Ebola viruses. Becker Y. **Virus Genes** 1995;11(2–3):191–5 (28 ref.)

[Anti-retrovirus agents in AIDS: therapeutic strategy and prospectives for the future] **Rev Med Interne** 1997; 18(2):100–5 (37 ref.) **(Fre)**

[Endogenous retroviruses in autoimmune diseases] Katsumata K, et al. **Nippon Rinsho** 1997 Jun;55(6):1475–81 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Systemic lupus erythematosus (SLE) and retrovirus] Sekigawa I, et al. **Nippon Rinsho** 1997 Jun;55(6):1492–7 (20 ref.) (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

Retrovirus screening of vaccine cell substrates. Khan AS.
Dev Biol Stand 1996;88:157–62 (24 ref.)

Viruses and oncogenes in brain tumors. Archer GE, et al.
J Neurovirol 1997 May;3 Suppl 1:S76–7 (7 ref.)

Food animal and poultry retroviruses and human health. DiGiacomo RF, et al.
Vet Clin North Am Food Anim Pract 1997 Mar;13(1):177–90 (81 ref.)

PATHOGENICITY

Perspectives on retroviral pathogenesis and vaccines. Weiss RA. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):465–7 (3 ref.)

Oncogenic retroviruses of cattle, chickens and turkeys: potential infectivity and oncogenicity for humans. Johnson ES, et al. **Med Hypotheses** 1996 Apr;46(4):354–6 (19 ref.)

Our retroviral heritage. Patience C, et al. **Trends Genet** 1997 Mar;13(3):116–20 (62 ref.)

Endogenous retroviruses and the evolution of resistance to retroviral infection. Best S, et al. **Trends Microbiol** 1997 Aug;5(8):313–8 (33 ref.)

PHYSIOLOGY

HIV and human endogenous retroviruses: an hypothesis with therapeutic implications. McIntosh EM, et al.
Acta Biochim Pol 1996;43(4):583–92 (42 ref.)

RNA packaging. Berkowitz R, et al.
Curr Top Microbiol Immunol 1996;214:177–218 (218 ref.)

Use of heterologous expression systems to study retroviral morphogenesis. Boulanger P, et al.
Curr Top Microbiol Immunol 1996;214:237–60 (112 ref.)

Role of auxiliary proteins in retroviral morphogenesis. Cohen EA, et al. **Curr Top Microbiol Immunol** 1996;214:219–35 (102 ref.)

Dynamic interactions of the Gag polyprotein. Craven RC, et al. **Curr Top Microbiol Immunol** 1996;214:65–94 (113 ref.)

Maturation and assembly of retroviral glycoproteins. Einfeld D. **Curr Top Microbiol Immunol** 1996;214:133–76 (285 ref.)

Intracellular transport of retroviral capsid components. Kräusslich HG, et al. **Curr Top Microbiol Immunol** 1996; 214:25–63 (179 ref.)

Proteolytic processing and particle maturation. Vogt VM. **Curr Top Microbiol Immunol** 1996;214:95–131 (154 ref.)

The physico-chemical factors that govern retrovirus-mediated gene transfer. Palsson B, et al.
Exp Hematol 1997 Feb;25(2):94–102 (94 ref.)

Cellular and viral protein interactions regulating I kappa B alpha activity during human retrovirus infection. Hiscott J, et al. **J Leukoc Biol** 1997 Jul;62(1):82–92 (80 ref.)

Cell-surface receptors for retroviruses and implications for gene transfer. Miller AD. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11407–13 (52 ref.)

Retrovirus-associated neoplasms of the respiratory system of sheep and goats. Ovine pulmonary carcinoma and enzootic nasal tumor. DeMartini JC, et al.
Vet Clin North Am Food Anim Pract 1997 Mar;13(1):55–70 (73 ref.)

Murine AIDS, a key to understanding retrovirus-induced immunodeficiency. Liang B, et al. **Viral Immunol** 1996; 9(4):225–39 (122 ref.)

RETROVIRIDAE INFECTIONS

CLASSIFICATION

HERV-K: the biologically most active human endogenous retrovirus family. Tönjes RR, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996;13 Suppl 1:S261–7 (56 ref.)

DRUG THERAPY

[Antiretroviral treatment and resistance] Gómez-Cano M, et al. **Rev Clin Esp** 1997 Aug;197(8):574–82 (74 ref.) **(Spa)**

EPIDEMIOLOGY

Baboon endogenous virus evolution and ecology [see comments] van der Kuyl AC, et al. **Trends Microbiol** 1996 Nov;4(11):455–9 (23 ref.) Comment in: Trends Microbiol 1996 Dec;4(12):478.

Food animal and poultry retroviruses and human health. DiGiacomo RF, et al.
Vet Clin North Am Food Anim Pract 1997 Mar;13(1):177–90 (81 ref.)

ETIOLOGY

Immunosuppressive retroviral peptides: immunopathological implications for immunosuppressive influences of retroviral infections. Haraguchi S, et al. **J Leukoc Biol** 1997 Jun; 61(6):654–66 (161 ref.)

Oncogenic retroviruses of cattle, chickens and turkeys: potential infectivity and oncogenicity for humans. Johnson ES, et al. **Med Hypotheses** 1996 Apr;46(4):354–6 (19 ref.)

Mouse mammary tumor virus and mammary tumorigenesis in wild mice. Imai S. **Pathol Int** 1996 Dec;46(12):919–32 (136 ref.)

Leukemogenesis by Moloney murine leukemia virus: a multistep process. Fan H. **Trends Microbiol** 1997 Feb; 5(2):74–82 (48 ref.)

GENETICS

Biological significance of human endogenous retroviral sequences. Hohenadl C, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996;13 Suppl 1:S268–73 (59 ref.)

Molecular biology of the human foamy virus. Saïb A, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996;13 Suppl 1:S254–60 (69 ref.)

HERV-K: the biologically most active human endogenous retrovirus family. Tönjes RR, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996;13 Suppl 1:S261–7 (56 ref.)

Viral genetic variation, AIDS, and the multistep nature of carcinogenesis: the feline leukemia virus model. Rohn JL, et al. **Leukemia** 1996 Dec;10(12):1867–9 (31 ref.)

Establishment of a therapeutic model for retroviral infection using the genetic resistance mechanism of the host. Kitagawa M, et al. **Pathol Int** 1996 Oct;46(10):719–25 (73 ref.)

Endogenous retroviruses and the evolution of resistance to retroviral infection. Best S, et al. **Trends Microbiol** 1997 Aug;5(8):313–8 (33 ref.)

Pararetro- and retrovirus RNA: splicing and the control of nuclear export. Kiss-László Z, et al. **Trends Microbiol** 1996 Dec;4(12):480–5 (52 ref.)

[Gene therapy in neurology. State of the art and future prospects] Duarte RG. **Neurologia** 1995 Dec;10 Suppl 1:56–61 (14 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Mouse mammary tumor virus and the immune system. Ross SR. **Adv Pharmacol** 1997;39:21–46 (95 ref.)

Moloney leukemia virus-induced cell surface antigen mimicry by monoclonal antibodies. Baskin JG, et al.
Immunol Res 1995;14(4):292–316 (96 ref.)

Follicular dendritic cells (FDC) in retroviral infection: host/pathogen perspectives. Burton GF, et al.
Immunol Rev 1997 Apr;156:185–97 (58 ref.)

Immunosuppressive retroviral peptides: immunopathological implications for immunosuppressive influences of retroviral infections. Haraguchi S, et al. **J Leukoc Biol** 1997 Jun; 61(6):654–66 (161 ref.)

The role of the immune response in MULV-induced lymphomagenesis. Marshall DJ, et al. **Leukemia** 1996 Dec; 10(12):1860–6 (79 ref.)

Immunity to retroviral infection: the Friend virus model. Hasenkrug KJ, et al. **Proc Natl Acad Sci U S A** 1997 Jul 22;94(15):7811–6 (95 ref.)

Study of the T cell receptor repertoire in viral immunodeficiency disease. Ciurli C, et al.
Springer Semin Immunopathol 1996;17(4):319–32 (87 ref.)

Endogenous retroviruses and the evolution of resistance to retroviral infection. Best S, et al. **Trends Microbiol** 1997 Aug;5(8):313–8 (33 ref.)

METABOLISM

Nuclear export and its significance in retroviral infection.

Yoneda Y. **Trends Microbiol** 1996 Jan;4(1):1–2 (15 ref.)

PATHOLOGY

Cytopathic feline leukemia viruses cause apoptosis in hemolymphatic cells. Rojko JL, et al.
Prog Mol Subcell Biol 1996;16:13–43 (150 ref.)

PREVENTION & CONTROL

Comparative approach to retroviral vaccines. Burny A.
AIDS Res Hum Retroviruses 1996 Mar 20;12(5):389–92 (6 ref.)

Efficacy of an inactivated feline leukemia virus vaccine. Hoover EA, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):379–83 (53 ref.)

The relevance of feline retroviruses to the development of vaccines against HIV. Jarrett O.
AIDS Res Hum Retroviruses 1996 Mar 20;12(5):385–7 (23 ref.)

Efficacy of recombinant feline leukemia virus vaccines. Jarrett O. **AIDS Res Hum Retroviruses** 1996 Mar 20; 12(5):435–6 (14 ref.)

Correlates of immune protection after vaccination with attenuated live murine leukemia virus. Ruprecht RM, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):375–7 (14 ref.)

Perspectives on retroviral pathogenesis and vaccines. Weiss RA. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):465–7 (3 ref.)

Nucleic acid vaccines. Cernescu C. **Rom J Virol** 1995 Jan–Jun;46(1–2):69–73 (13 ref.)

Destroying retroviruses from within. Boeke JD, et al.
Trends Microbiol 1996 Nov;4(11):421–6 (27 ref.)

THERAPY

Targeted vectors for gene therapy of cancer and retroviral infections. Walther W, et al. **Mol Biotechnol** 1996 Dec; 6(3):267–86 (66 ref.)

Establishment of a therapeutic model for retroviral infection using the genetic resistance mechanism of the host. Kitagawa M, et al. **Pathol Int** 1996 Oct;46(10):719–25 (73 ref.)

[Gene therapy in neurology. State of the art and future prospects] Duarte RG. **Neurologia** 1995 Dec;10 Suppl 1:56–61 (14 ref.) (Eng. Abstr.) **(Spa)**

VETERINARY

Feline leukaemia virus: a review of immunity and vaccination. Sparkes AH. **J Small Anim Pract** 1997 May; 38(5):187–94 (49 ref.)

Cooperating events in lymphomagenesis mediated by feline leukemia virus. Levy LS, et al. **Leukemia** 1997 Apr;11 Suppl 3:239–41 (16 ref.)

Laboratory diagnostic tests for retroviral infections in dairy and beef cattle. Evermann JF, et al.
Vet Clin North Am Food Anim Pract 1997 Mar;13(1):87–106 (105 ref.)

Avian retroviruses. Fadly AM.
Vet Clin North Am Food Anim Pract 1997 Mar;13(1):71–85 (65 ref.)

Laboratory diagnostic tests for retrovirus infections of small ruminants. Knowles DP Jr.
Vet Clin North Am Food Anim Pract 1997 Mar;13(1):1–11 (64 ref.)

VIROLOGY

Possible involvement of endogenous retroviruses in the development of autoimmune disorders, especially multiple sclerosis. Rasmussen HB, et al.
Acta Neurol Scand Suppl 1997;169:32–7 (28 ref.)

Biological significance of human endogenous retroviral sequences. Hohenadl C, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996;13 Suppl 1:S268–73 (59 ref.)

Unexpected replication pathways of foamy viruses. Rethwilm A. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S248–53 (52 ref.)

Molecular biology of the human foamy virus. Saïb A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S254–60 (69 ref.)

The role of the immune response in MULV-induced lymphomagenesis. Marshall DJ, et al. **Leukemia** 1996 Dec; 10(12):1860–6 (79 ref.)

Viral genetic variation, AIDS, and the multistep nature of carcinogenesis: the feline leukemia virus model. Rohn JL, et al. **Leukemia** 1996 Dec;10(12):1867–9 (31 ref.)

Mouse Moloney leukemia virus infects microglia but not neurons even though it induces motor neuron disease. Zachary JF, et al. **Mol Psychiatry** 1997 Mar;2(2):104–6 (19 ref.)

RETROVIRIDAE PROTEINS, ONCOGENIC

DRUG EFFECTS

Biological and biochemical inhibitors of the NF-kappa B/Rel proteins and cytokine synthesis. Beauparlant P, et al.
Cytokine Growth Factor Rev 1996 Aug;7(2):175–90 (141 ref.)

IMMUNOLOGY

Efficacy of recombinant feline leukemia virus vaccines. Jarrett O. **AIDS Res Hum Retroviruses** 1996 Mar 20; 12(5):435–6 (14 ref.)

METABOLISM

Biological and biochemical inhibitors of the NF-kappa B/Rel proteins and cytokine synthesis. Beauparlant P, et al.
Cytokine Growth Factor Rev 1996 Aug;7(2):175–90 (141 ref.)

PHARMACOLOGY

Immunosuppressive retroviral peptides: immunopathological implications for immunosuppressive influences of retroviral infections. Haraguchi S, et al. **J Leukoc Biol** 1997 Jun; 61(6):654–66 (161 ref.)

PHYSIOLOGY

Emerging components of the Crk oncogene product: the first identified adaptor protein. Matsuda M, et al. **Cell Signal** 1996 Aug;8(5):335–40 (68 ref.)

RETROVIRUS D, NEW ENGLAND see **RETROVIRUSES TYPE D, SIMIAN**

RETROVIRUS INFECTIONS see **RETROVIRIDAE INFECTIONS**

RETROVIRUSES see **RETROVIRIDAE**

RETROVIRUSES TYPE D, SIMIAN

IMMUNOLOGY

Simian retrovirus vaccines: simian retrovirus and simian immunodeficiency lentivirus. Gardner MB, et al.
AIDS Res Hum Retroviruses 1996 Mar 20;12(5):399–401 (20 ref.)

RETT SYNDROME

Rett syndrome. Clarke A. **J Med Genet** 1996 Aug;33(8):693–9 (105 ref.)

Review of Rett syndrome. Armstrong DD.
J Neuropathol Exp Neurol 1997 Aug;56(8):843–9 (90 ref.)

PHYSIOPATHOLOGY

Rett syndrome: a disorder affecting early brain growth. Naidu S. **Ann Neurol** 1997 Jul;42(1):3–10 (100 ref.)

Rett syndrome: neurobiological changes underlying specific symptoms. Wenk GL. **Prog Neurobiol** 1997 Mar; 51(4):383–91 (90 ref.)

REV GENE PRODUCTS see **GENE PRODUCTS, REV**

REV GENES see **GENES, REV**

REV PROTEIN see **GENE PRODUCTS, REV**

REV-RESPONSIVE ELEMENT see **GENES, ENV**

REVERSE IMMUNOBLOTTING see **IMMUNOBLOTTING**

REVERSE TRANSCRIPTASE see **RNA-DIRECTED DNA POLYMERASE**

REVERSE TRANSCRIPTASE, HIV-1 see **HIV-1 REVERSE TRANSCRIPTASE**

REVERSE TRANSCRIPTASE INHIBITORS

ADVERSE EFFECTS

Minimising the dosage-limiting toxicities of foscarnet induction therapy. Jayaweera DT. **Drug Saf** 1997 Apr; 16(4):258–66 (40 ref.)

CHEMICAL SYNTHESIS

Development of nonnucleoside HIV reverse transcriptase inhibitors. Tucker TJ, et al. **Methods Enzymol** 1996; 275:440–72 (67 ref.)

CHEMISTRY

Targeting HIV reverse transcriptase for anti-AIDS drug design: structural and biological considerations for chemotherapeutic strategies. Arnold E, et al.
Drug Des Discov 1996 Apr;13(3–4):29–47 (62 ref.)

A check on rational drug design: molecular simulation of the allosteric inhibition of HIV-1 reverse transcriptase. Mager PP. **Med Res Rev** 1997 May;17(3):235–76 (53 ref.)

Analysis of inhibition of retroviral reverse transcriptase. Balzarini J, et al. **Methods Enzymol** 1996;275:472–502 (112 ref.)

PHARMACOLOGY

Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes. Aquaro S, et al.
J Leukoc Biol 1997 Jul;62(1):138–43 (39 ref.)

Anti-human immunodeficiency virus (anti-HIV) natural products with special emphasis on HIV reverse transcriptase inhibitors. Ng TB, et al. **Life Sci** 1997; 61(10):933–49 (67 ref.)

A check on rational drug design: molecular simulation of the allosteric inhibition of HIV-1 reverse transcriptase. Mager PP. **Med Res Rev** 1997 May;17(3):235–76 (53 ref.)

Analysis of inhibition of retroviral reverse transcriptase. Balzarini J, et al. **Methods Enzymol** 1996;275:472–502 (112 ref.)

Analysis of resistance mutants of viral polymerases. Oxford JS, et al. **Methods Enzymol** 1996;275:555–600 (179 ref.)

THERAPEUTIC USE

Perspective: research highlights at the Albert Einstein College of Medicine Center for AIDS research. Approaches to control drug resistance in HIV: the role of increased polymerase fidelity. Prasad VR, et al.
AIDS Res Hum Retroviruses 1996 Jul 20;12(11):959–63 (54 ref.)

New approaches to using antiretroviral therapy for the management of HIV Infection. Doran CM.
Ann Pharmacother 1997 Feb;31(2):228–36 (51 ref.)

Pharmacotherapy of HIV dementia. Melton ST, et al.
Ann Pharmacother 1997 Apr;31(4):457–73 (90 ref.)

Antiretroviral therapy. Threlkeld SC, et al.
Med Clin North Am 1996 Nov;80(6):1263–82 (107 ref.)

Antiretroviral therapy during pregnancy. Beyond AZT (ZDV). Dattel BJ. **Obstet Gynecol Clin North Am** 1997 Sep;24(3):645–57 (24 ref.)

HIV/AIDS management in office practice. Antiretroviral therapy. Hartman AF. **Prim Care** 1997 Sep;24(3):531–60 (46 ref.)

[Nucleoside analogs inhibiting reverse transcriptase: use in adult patient with HIV infection] Aguirrebengoa K, et al. **Enferm Infecc Microbiol Clin** 1996 Oct;14 Suppl 1:3–9 (99 ref.) **(Spa)**

REVERSE TRANSCRIPTION see **TRANSCRIPTION, GENETIC**

REVIEW LITERATURE

see related
META-ANALYSIS

Getting the most from review articles: a guide for readers and writers [see comments] Shaughnessy AF, et al.
Am Fam Physician 1997 May 1;55(6):2155–60 (14 ref.)
Comment in: Am Fam Physician 1997 May 1;55(6):2064, 2069–70, 2072.

The relation between systematic reviews and practice guidelines. Cook DJ, et al. **Ann Intern Med** 1997 Aug 1; 127(3):210–6 (58 ref.)

[Methods of investigation in clinical cardiology. VIII. Meta-analysis and systematic reviews in cardiology] Guallar E, et al. **Rev Esp Cardiol** 1997 May;50(5):345–54 (43 ref.) (Eng. Abstr.) **(Spa)**

REVISION, JOINT see **REOPERATION**

REVISION, SURGICAL see **REOPERATION**

REWARD

Detrimental effects of reward. Reality or myth? Eisenberger R, et al. **Am Psychol** 1996 Nov;51(11):1153–66 (110 ref.)

Addictive drugs and brain stimulation reward. Wise RA.
Annu Rev Neurosci 1996;19:319–40 (202 ref.)

Should we pay the patient? Review of financial incentives to enhance patient compliance. Giuffrida A, et al. **BMJ** 1997 Sep 20;315(7110):703–7 (64 ref.)

Dopamine neurons and their role in reward mechanisms. Schultz W. **Curr Opin Neurobiol** 1997 Apr;7(2):191–7 (83 ref.)

Feeding, drug abuse, and the sensitization of reward by metabolic need. Carr KD. **Neurochem Res** 1996 Nov; 21(11):1455–67 (107 ref.)

A neural substrate of prediction and reward. Schultz W, et al. **Science** 1997 Mar 14;275(5306):1593–9 (37 ref.)

The neural basis of associative reward learning in honeybees. Hammer M. **Trends Neurosci** 1997 Jun;20(6):245–52 (58 ref.)

REWARMING

Accidental hypothermia. Lloyd EL. **Resuscitation** 1996 Sep; 32(2):111–24 (81 ref.)

[Therapy for accidental hypothermia] Antretter H, et al.
Dtsch Med Wochenschr 1997 Mar 21;122(12):373–7 (17 ref.) **(Ger)**

METHODS

Severe accidental hypothermia: pathophysiology and therapeutic options for hospitals without cardiopulmonary bypass equipment. Schrijver G, et al. **Neth J Med** 1996 Oct;49(4):167–76 (36 ref.)

REX GENES see **GENES, PX**

REYE'S SYNDROME

REYE'S SYNDROME

DIAGNOSIS

Reye's syndrome. Larsen SU. **Med Sci Law** 1997 Jul; 37(3):235–41 (46 ref.)

EPIDEMIOLOGY

Reye syndrome: an international perspective. Stumpf DA. **Brain Dev** 1995;17 Suppl:77–8 (15 ref.)

ETIOLOGY

[Neurological outcome associated with influenza viral infection] Kamimura N, et al. **Nippon Rinsho** 1997 Apr; 55(4):880–5 (22 ref.) (Eng. Abstr.) **(Jpn)**

RFLP see POLYMORPHISM, RESTRICTION FRAGMENT LENGTH

RH FACTORS see RH-HR BLOOD-GROUP SYSTEM

RH-HR BLOOD-GROUP SYSTEM

see related
ERYTHROBLASTOSIS, FETAL

Molecular insights into the Rh protein family and associated antigens. Huang CH. **Curr Opin Hematol** 1997 Mar; 4(2):94–103 (94 ref.)

From butterflies to babies. Clarke CA. **J R Nav Med Serv** 1997;82(3):232–8 (8 ref.)

Quantitation and the Rh blood group system. Hughes-Jones NC. **Transfus Med** 1991 Jun;1(2):69–76 (43 ref.)

The Rh antigen D: partial D antigens and associated low incidence antigens. Tippett P, et al. **Vox Sang** 1996; 70(3):123–31 (36 ref.)

[Is it always necessary to give anti-D gamma-globulins in the case of spontaneous miscarriage in Rhesus-negative patients?] Salvat J, et al. **Contracept Fertil Sex** 1997 Apr; 25(4):V–IX (27 ref.) **(Fre)**

BLOOD

Fetal RhD typing by polymerase chain reaction in pregnancies complicated by rhesus alloimmunization. Van den Veyver IB, et al. **Obstet Gynecol** 1996 Dec; 88(6):1061–7 (34 ref.)

Royal College of Physicians of Edinburgh/Royal College of Obstetricians and Gynaecologists consensus conference on anti-D prophylaxis 7 & 8 April 1997. Urbaniak SJ. **Transfus Med** 1997 Jun;7(2):143–4 (0 ref.)

IMMUNOLOGY

The role of the fetal immune system in the pathogenesis of RhD-hemolytic disease of newborns. Gurevich P, et al. **Hum Antibodies** 1997;8(2):76–89 (120 ref.)

RH IMMUNE GLOBULIN see RHO(D) IMMUNE GLOBULIN

RH ISOIMMUNIZATION

see related
ERYTHROBLASTOSIS, FETAL

ACOG educational bulletin. Management of isoimmunization in pregnancy. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1996 Nov; 55(2):183–90 (35 ref.)

BLOOD

Fetal RhD typing by polymerase chain reaction in pregnancies complicated by rhesus alloimmunization. Van den Veyver IB, et al. **Obstet Gynecol** 1996 Dec; 88(6):1061–7 (34 ref.)

COMPLICATIONS

Clinical biological features of Ballantyne syndrome and the role of placental hydrops. Carbillon L, et al. **Obstet Gynecol Surv** 1997 May;52(5):310–4 (27 ref.)

IMMUNOLOGY

The management of hemolytic disease in the fetus and newborn. Bowman J. **Semin Perinatol** 1997 Feb;21(1):39–44 (19 ref.)

PREVENTION & CONTROL

Royal College of Physicians of Edinburgh/Royal College of Obstetricians and Gynaecologists consensus conference on anti-D prophylaxis 7 & 8 April 1997. Urbaniak SJ. **Transfus Med** 1997 Jun;7(2):143–4 (0 ref.)

[Is it always necessary to give anti-D gamma-globulins in the case of spontaneous miscarriage in Rhesus-negative patients?] Salvat J, et al. **Contracept Fertil Sex** 1997 Apr; 25(4):V–IX (27 ref.) **(Fre)**

THERAPY

Intravenous immune globulin in the management of severe Rh D hemolytic disease. Porter TF, et al. **Obstet Gynecol Surv** 1997 Mar;52(3):193–7 (19 ref.)

RHABDITIDA

DRUG EFFECTS

[An analysis of the results of histological and histochemical research on the integumental tissues and the digestive system of nematodes of the suborder Strongylata after the use of anthelmintics] Bogoiavlenskii IuK. **Med Parazitol (Mosk)** 1996 Oct-Dec;(4):54–8 (17 ref.) (Eng. Abstr.) **(Rus)**

RHABDOID TUMOR

Malignant rhabdoid tumor of the uterine corpus [letter; comment] Niemann T. **Gynecol Oncol** 1997 Jan;64(1):181–2 (5 ref.) Comment on: Gynecol Oncol 1996 Apr;61(1):142–6.

DIAGNOSIS

Malignant rhabdoid tumor of the central nervous system. Ruiz ME, et al. **Wis Med J** 1996 Dec;95(12):864–6 (7 ref.)

[Rhabdoid tumor of the central nervous system. Ultrasonographic, computed tomographic and MRI aspects apropos of a case in an infant] Guessoum M, et al. **J Neuroradiol** 1997 Jun;24(1):60–4 (16 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

"Proximal-type" epithelioid sarcoma, a distinctive aggressive neoplasm showing rhabdoid features. Clinicopathologic, immunohistochemical, and ultrastructural study of a series. Guillou L, et al. **Am J Surg Pathol** 1997 Feb;21(2):130–46 (70 ref.)

Rhabdoid tumour of the kidney: a clinicopathological study of 22 patients from the International Society of Paediatric Oncology (SIOP) nephroblastoma file. Vujanić GM, et al. **Histopathology** 1996 Apr;28(4):333–40 (20 ref.)

Malignant rhabdoid tumor in adults—heterogenous tumors with a unique morphological phenotype. Leong FJ, et al. **Pathol Res Pract** 1996 Aug;192(8):796–807 (34 ref.)

Primary malignant rhabdoid tumor of the central nervous system. Bhattacharjee M, et al. **Ultrastruct Pathol** 1997 Jul-Aug;21(4):361–8 (23 ref.)

Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood. Bhattacharjee M, et al. **Ultrastruct Pathol** 1997 Jul-Aug;21(4):369–78 (14 ref.)

RHABDOMYOLYSIS

[Rhabdomyolysis and acute kidney failure] Rosa EC, et al. **Rev Assoc Med Bras** 1996 Jan-Mar;42(1):39–45 (71 ref.) **(Por)**

CHEMICALLY INDUCED

MDMA induced hyperthermia: report of a fatality and review of current therapy. Dar KJ, et al. **Intensive Care Med** 1996 Sep;22(9):995–6 (13 ref.)

Rhabdomyolysis and anesthesia: a report of two cases and review of the literature. Pedrozzi NE, et al. **Pediatr Neurol** 1996 Oct;15(3):254–7 (52 ref.)

Inadvertent intraoperative myelography with Hypaque: case report and discussion. Killeffer JA, et al. **Surg Neurol** 1997 Jul;48(1):70–3 (23 ref.)

[Nontraumatic rhabdomyolysis due to oral poisoning by doxylamine succinate (letter)] Paytubi Garí C, et al. **Med Clin (Barc)** 1997 Mar 8;108(9):356 (5 ref.) **(Spa)**

ETIOLOGY

Exaggerated lithotomy position-related rhabdomyolysis. Biswas S, et al. **Am Surg** 1997 Apr;63(4):361–4 (23 ref.)

Livedo reticularis, rhabdomyolysis, massive intestinal infarction, and death after carbon dioxide arteriography. Rundback JH, et al. **J Vasc Surg** 1997 Aug;26(2):337–40 (13 ref.)

Myoglobinuria, malignant hyperthermia, neuroleptic malignant syndrome and serotonin syndrome. Bertorini TE. **Neurol Clin** 1997 Aug;15(3):649–71 (193 ref.)

[Myocardial infarct and rhabdomyolysis after a high-voltage accident with successful resuscitation] Franzius C, et al. **Dtsch Med Wochenschr** 1997 Mar 27;122(13):400–6 (22 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Inadvertent intraoperative myelography with Hypaque: case report and discussion. Killeffer JA, et al. **Surg Neurol** 1997 Jul;48(1):70–3 (23 ref.)

URINE

Rhabdomyolysis and myohemoglobinuric acute renal failure [editorial] Zager RA. **Kidney Int** 1996 Feb;49(2):314–26 (148 ref.)

VETERINARY

Chronic exertional rhabdomyolysis. Beech J. **Vet Clin North Am Equine Pract** 1997 Apr;13(1):145–68 (84 ref.)

RHABDOMYOMA

Perianal fetal rhabdomyoma: case report. Lapner PC, et al. **Pediatr Surg Int** 1997 Sep;12(7):544–7 (26 ref.)

[Cardiac rhabdomyoma, cardiac rhabdomyosarcoma] Kondo T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):227–9 (21 ref.) **(Jpn)**

DIAGNOSIS

Two cases of benign vaginal rhabdomyoma. Case reports. Iversen UM. **APMIS** 1996 Jul-Aug;104(7–8):575–8 (18 ref.)

[Primary tumors of the cardiac septum] Nakamura N, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):260–2 (19 ref.) **(Jpn)**

RHABDOMYOSARCOMA

Rhabdomyosarcoma and other soft tissue sarcomas in children. Pappo AS. **Curr Opin Oncol** 1996 Jul;8(4):311–6 (20 ref.)

[Cardiac rhabdomyoma, cardiac rhabdomyosarcoma] Kondo T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):227–9 (21 ref.) **(Jpn)**

DIAGNOSIS

Rhabdomyosarcoma presenting as acute hematologic malignancy: case report and review of the literature. Ambrosiani L, et al. **Tumori** 1996 Jul-Aug;82(4):408–12 (23 ref.)

GENETICS

Translocations in solid tumours. Cooper CS. **Curr Opin Genet Dev** 1996 Feb;6(1):71–5 (27 ref.)

MICROBIOLOGY

Two case reports and review of vascular catheter-associated bacteremia caused by nontuberculous Mycobacterium species. Rodgers GL, et al. **Pediatr Infect Dis J** 1996 Mar; 15(3):260–4 (50 ref.)

PATHOLOGY

Dedifferentiated chondrosarcoma with rhabdomyosarcomatous differentiation. Reith JD, et al. **Am J Surg Pathol** 1996 Mar;20(3):293–8 (18 ref.)

SURGERY

Surgical management of rhabdomyosarcoma in children. Corpron CA, et al. **Curr Opin Pediatr** 1996 Jun;8(3):283–6 (26 ref.)

THERAPY

Rhabdomyosarcoma. Biology and treatment. Pappo AS, et al. **Pediatr Clin North Am** 1997 Aug;44(4):953–72 (59 ref.)

Rhabdomyosarcoma. Andrassy RJ. **Semin Pediatr Surg** 1997 Feb;6(1):17–23 (51 ref.)

RHABDOMYOSARCOMA, ALVEOLAR

BLOOD

Pure alveolar rhabdomyosarcoma of the corpus uteri: description of a case with increased serum level of CA-125. Chiarle R, et al. **Gynecol Oncol** 1997 Aug;66(2):320–3 (19 ref.)

GENETICS

Fusions involving paired box and fork head family transcription factors in the pediatric cancer alveolar rhabdomyosarcoma. Barr FG. **Curr Top Microbiol Immunol** 1997;220:113–29 (68 ref.)

PATHOLOGY

Pure alveolar rhabdomyosarcoma of the corpus uteri: description of a case with increased serum level of CA-125. Chiarle R, et al. **Gynecol Oncol** 1997 Aug;66(2):320–3 (19 ref.)

RHABDOMYOSARCOMA, EMBRYONAL

Perineal and perirectal sarcomas: report of two cases. Kessler KJ, et al. **Dis Colon Rectum** 1996 Apr;39(4):468–72 (27 ref.)

PATHOLOGY

Sarcoma botryoides of the uterine endocervix: long-term results of conservative surgery. Balat O, et al. **Eur J Gynaecol Oncol** 1996;17(5):335–7 (13 ref.)

[A rare case of rhabdomyosarcoma of the heart] Kysil'ova VF. **Lik Sprava** 1996 Jan-Feb;(1–2):161–4 (8 ref.) **(Ukr)**

RHABDOVIRIDAE

[Marine fish pathogenic ssRNA viruses] Nishizawa T. **Uirusu** 1996 Jun;46(1):67–72 (32 ref.) **(Jpn)**

ENZYMOLOGY

Role of cellular kinases in the gene expression of nonsegmented negative strand RNA viruses. De BP, et al. **Biol Chem** 1997 Jun;378(6):489–93 (29 ref.)

GENETICS

Role of cellular kinases in the gene expression of nonsegmented negative strand RNA viruses. De BP, et al. **Biol Chem** 1997 Jun;378(6):489–93 (29 ref.)

Harnessing viral devices as pharmaceuticals: fighting HIV–1's fire with fire [comment] Nolan GP. **Cell** 1997 Sep 5;90(5):821–4 (11 ref.) Comment on: Cell 1997 Sep 5;90(5):841–7. Comment on: Cell 1997 Sep 5;90(5):849–57.

IMMUNOLOGY

Immunization with viral antigens: viral haemorrhagic septicaemia. Lorenzen N, et al. **Dev Biol Stand** 1997; 90:201–9 (37 ref.)

Immunization with viral antigens: infectious haematopoietic necrosis. Winton JR. **Dev Biol Stand** 1997;90:211–20 (35 ref.)

RHABDOVIRIDAE INFECTIONS

VETERINARY

Immunization with viral antigens: viral haemorrhagic septicaemia. Lorenzen N, et al. **Dev Biol Stand** 1997; 90:201–9 (37 ref.)

Immunization with viral antigens: infectious haematopoietic necrosis. Winton JR. **Dev Biol Stand** 1997;90:211–20 (35 ref.)

RHENIUM

THERAPEUTIC USE

Clinical aspects of local and regional tumor therapy with 188Re–RC–160. Bender H, et al. **Anticancer Res** 1997 May–Jun;17(3B):1705–12 (31 ref.)

Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re–186–HEDP. De Klerk JM, et al. **Anticancer Res** 1997 May–Jun;17(3B):1773–7 (21 ref.)

Pre–clinical experience with Re–188–RC–160, a radiolabeled somatostatin analog for use in peptide–targeted radiotherapy. Zamora PO, et al. **Anticancer Res** 1997 May–Jun;17(3B):1803–8 (33 ref.)

RHEOLOGY

Rheological properties of selected dairy products. Vélez–Ruiz JF, et al. **Crit Rev Food Sci Nutr** 1997 Jun; 37(4):311–59 (183 ref.)

Modelling nanoscale fluid dynamics and transport in physiological flows. Ciofalo M, et al. **Med Eng Phys** 1996 Sep;18(6):437–51 (88 ref.)

INSTRUMENTATION

Thermal diffusion flowmetry. Carter LP. **Neurosurg Clin N Am** 1996 Oct;7(4):749–54 (17 ref.)

METHODS

Thermal diffusion flowmetry. Carter LP. **Neurosurg Clin N Am** 1996 Oct;7(4):749–54 (17 ref.)

[Ultrasound Doppler blood flowmetry] Chihara K. **Nippon Rinsho** 1997 Mar;55 Suppl 1:59–64 (20 ref.) **(Jpn)**

RHESUS BLOOD–GROUP SYSTEM see **RH–HR BLOOD–GROUP SYSTEM**

RHESUS MONKEY see **MACACA MULATTA**

RHETINIC ACID see **GLYCYRRHETINIC ACID**

RHEUMATIC DISEASES

Liability issues in the treatment of patients with rheumatic diseases. Gibofsky A. **Am J Med** 1997 Jan 27; 102(1A):40S–42S (04 ref.)

Legal rights of children with musculoskeletal disabilities. Cassidy JT, et al. **Bull Rheum Dis** 1996 Nov;45(7):1–5 (24 ref.)

The T cell receptor (TCR) in HLA–B27–restricted T cell responses—an introduction. Märker–Hermann E, et al. **Clin Rheumatol** 1996 Jan;15 Suppl 1:86–90 (28 ref.)

Patient education in rheumatology [see comments] Lorish CD, et al. **Curr Opin Rheumatol** 1997 Mar;9(2):106–11 (21 ref.) Comment in: Curr Opin Rheumatol 1997 Mar;9(2):87–9.

Health services research [see comments] Saag KG. **Curr Opin Rheumatol** 1997 Mar;9(2):118–25 (50 ref.) Comment in: Curr Opin Rheumatol 1997 Mar;9(2):87–9.

Rheumatic and musculoskeletal diseases and impaired quality of life: a challenge for rheumatologists [editorial] [see comments] Morales–Torres J, et al. **J Rheumatol** 1996 Jan; 23(1):1–3 (30 ref.) Comment in: J Rheumatol 1997 Feb;24(2):411.

Obstetric complications and rheumatic disease. Johnson MJ. **Rheum Dis Clin North Am** 1997 Feb;23(1):169–82 (50 ref.)

Inherited deficiencies of complement in rheumatic diseases. Ratnoff WD. **Rheum Dis Clin North Am** 1996 Feb; 22(1):75–94 (73 ref.)

[Rheumatoid aortitis] Nakamura H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):417–20 (11 ref.) **(Jpn)**

BLOOD

Clinical use of the measurement of soluble cell adhesion molecules in patients with autoimmune rheumatic diseases [see comments] Sfikakis PP, et al. **Clin Diagn Lab Immunol** 1997 May;4(3):241–6 (50 ref.) Comment in: Clin Diagn Lab Immunol 1997 Jul;4(4):496–7.

Immunoglobulin A—alpha–1–antitrypsin complex in rheumatic diseases. Łącki JK, et al. **Mater Med Pol** 1996 Oct–Dec;28(4):138–40 (21 ref.)

CHEMICALLY INDUCED

Drug–induced rheumatic disorders. Bannwarth B. **Rev Rhum Engl Ed** 1996 Nov;63(10):639–47 (125 ref.)

CLASSIFICATION

[Teaching evolution of the working classification and nomenclature of rheumatism] Nasonova VA. **Vestn Ross Akad Med Nauk** 1996;(11):10–4 (9 ref.) **(Rus)**

COMPLICATIONS

Skin disorders associated with rheumatic disease. Kaminski MJ. **Clin Podiatr Med Surg** 1996 Jan;13(1):139–53 (46 ref.)

Rheumatic manifestations of infectious diseases in children. Adebajo AO. **Curr Opin Rheumatol** 1997 Jan;9(1):68–74 (36 ref.)

Rheumatic manifestations of neurologic and psychiatric diseases. Aviña–Zubieta JA, et al. **Curr Opin Rheumatol** 1997 Jan;9(1):51–5 (30 ref.)

Hyperlipidemia and the rheumatic diseases. Ilowite NT. **Curr Opin Rheumatol** 1996 Sep;8(5):455–8 (24 ref.)

Rheumatologic manifestations of malignancy. Mody GM, et al. **Curr Opin Rheumatol** 1997 Jan;9(1):75–9 (28 ref.)

Rheumatic features of sarcoidosis. Pettersson T. **Curr Opin Rheumatol** 1997 Jan;9(1):62–7 (42 ref.)

Rheumatic features of gastrointestinal tract, hepatic, and pancreatic diseases. Ramos–Remus C, et al. **Curr Opin Rheumatol** 1997 Jan;9(1):56–61 (68 ref.)

Rheumatic manifestations of inherited diseases. Sholter D, et al. **Curr Opin Rheumatol** 1997 Jan;9(1):80–2 (14 ref.)

WHO/ILAR Taskforce on quality of life. Strand CV, et al. **J Rheumatol** 1997 Aug;24(8):1630–3 (1 ref.)

Hepatitis C virus and rheumatic disease [editorial] Wener MH, et al. **J Rheumatol** 1996 Jun;23(6):953–9 (92 ref.)

Malignant lymphoma in patients with rheumatic diseases other than Sjögren's syndrome: a clinicopathologic study of five cases and a review of the Japanese literature. Kojima M, et al. **Jpn J Clin Oncol** 1997 Apr;27(2):84–90 (43 ref.)

Parvovirus B19 infection and rheumatic diseases. Caramaschi P, et al. **Rev Rhum Engl Ed** 1996 Dec;63(11):846–53 (103 ref.)

Alveolar hemorrhage in patients with rheumatic disease. Dweik RA, et al. **Rheum Dis Clin North Am** 1997 May; 23(2):395–410 (67 ref.)

Emergency and critical care issues in pediatric rheumatology. Fitch JA, et al. **Rheum Dis Clin North Am** 1997 May; 23(2):439–60 (198 ref.)

Cerebrovascular complications of rheumatic disease. Hinchey JA, et al. **Rheum Dis Clin North Am** 1997 May; 23(2):293–316 (98 ref.)

Urticaria, angioedema, and rheumatologic disease. Kulp–Shorten CL, et al. **Rheum Dis Clin North Am** 1996 Feb;22(1):95–115 (74 ref.)

Upper airway obstruction in the rheumatic diseases. Langford CA, et al. **Rheum Dis Clin North Am** 1997 May; 23(2):345–63 (125 ref.)

Prophylactic use of antibiotics and vaccines in patients with rheumatologic disorders. Mounzer KC, et al. **Rheum Dis Clin North Am** 1997 May;23(2):259–75 (83 ref.)

Esophageal manifestations of rheumatic disorders. Fitzgerald RC, et al. **Semin Arthritis Rheum** 1997 Feb;26(4):641–66 (149 ref.)

The association of malignancy with rheumatic and connective tissue diseases. Carsons S. **Semin Oncol** 1997 Jun;24(3):360–72 (102 ref.)

[Cutaneous manifestations in rheumatic diseases] Kaneko F, et al. **Ryumachi** 1996 Aug;36(4):676–87 (33 ref.) **(Jpn)**

[Osteoporosis: the rheumatological perspectives (editorial)] Nasonov EL, et al. **Ter Arkh** 1997;69(5):5–9 (53 ref.) **(Rus)**

DIAGNOSIS

Soft–tissue rheumatism: diagnosis and treatment. Reveille JD. **Am J Med** 1997 Jan 27;102(1A):23S–29S (14 ref.)

Autoantibodies to the A/B proteins of the heterogeneous nuclear ribonucleoprotein complex: novel tools for the diagnosis of rheumatic diseases. Steiner G, et al. **Int Arch Allergy Immunol** 1996 Dec;111(4):314–9 (34 ref.)

Remitting distal extremity swelling with pitting edema: a distinct syndrome or a clinical feature of different inflammatory rheumatic diseases? [editorial; comment] Olivieri I, et al. **J Rheumatol** 1997 Feb;24(2):249–52 (30 ref.) Comment on: J Rheumatol 1997 Feb;24(2):333–6.

Functional and clinical aspects of the myelomonocyte protein calprotectin. Johne B, et al. **Mol Pathol** 1997 Jun; 50(3):113–23 (142 ref.)

[Bone and joint manifestations in the elderly patient] André B, et al. **Rev Med Liege** 1997 Apr;52(4):270–7 (12 ref.) **(Fre)**

[Nosologic criteria in rheumatology] Genth E. **Z Rheumatol** 1996 Sep–Oct;55(5):319–30 (78 ref.) (Eng. Abstr.) **(Ger)**

[The clinical pictures of rheumatological involvement in neoplasms] Dipasquale G. **Riv Med Aeronaut Spaz** 1975 Oct–Dec;38(4):547–60 (27 ref.) (Eng. Abstr.) **(Ita)**

[A case of a combined course of gout and rheumatism] Chukabaev ET, et al. **Ter Arkh** 1996;68(9):86–8 (13 ref.) **(Rus)**

DRUG THERAPY

Auranofin. Kean WF, et al. **Br J Rheumatol** 1997 May; 36(5):560–72 (111 ref.)

Antimalarial drugs in the treatment of rheumatological diseases. Rynes RI. **Br J Rheumatol** 1997 Jul;36(7):799–805 (64 ref.)

Antirheumatic drug therapy during pregnancy. Soscia PN, et al. **Bull Rheum Dis** 1997 Apr;46(2):2–4 (11 ref.)

Biologic agents in the treatment of inflammatory rheumatic diseases. Kalden JR, et al. **Curr Opin Rheumatol** 1996 May; 8(3):195–200 (29 ref.)

Immunosuppressive drug treatment. McCune J, et al. **Curr Opin Rheumatol** 1997 May;9(3):191–9 (45 ref.)

Recent clinical trials in the rheumatic diseases [see comments] Matteson EL. **Curr Opin Rheumatol** 1997 Mar;9(2):95–101 (49 ref.) Comment in: Curr Opin Rheumatol 1997 Mar;9(2):87–9.

Corticosteroids in the treatment of rheumatologic diseases. Morand E. **Curr Opin Rheumatol** 1997 May;9(3):200–5 (46 ref.)

Corticosteroids in the treatment of rheumatologic diseases. Weisman MH. **Curr Opin Rheumatol** 1996 May;8(3):188–94 (15 ref.)

Aceclofenac. A review of its pharmacodynamic properties and therapeutic potential in the treatment of rheumatic disorders and in pain management. Brogden RN, et al. **Drugs** 1996 Jul;52(1):113–24 (52 ref.)

Drug treatment of rheumatic diseases in the 1990s. Achievements and future developments. Choy EH, et al. **Drugs** 1997 Mar;53(3):337–48 (91 ref.)

Antimalarial workshop. **J Rheumatol** 1997 Jul;24(7):1393–5 (13 ref.)

Prescribing nonsteroidal antiinflammatory drugs—what's new? [editorial] Hawker G. **J Rheumatol** 1997 Feb; 24(2):243–5 (15 ref.)

Immunosuppressive drugs and pregnancy. Esplin MS, et al. **Obstet Gynecol Clin North Am** 1997 Sep;24(3):601–16 (94 ref.)

Hematologic complications of rheumatic disease therapies. George CS, et al. **Rheum Dis Clin North Am** 1997 May; 23(2):425–37 (82 ref.)

Immunosuppressive drug use during pregnancy. Ramsey–Goldman R, et al. **Rheum Dis Clin North Am** 1997 Feb;23(1):149–67 (133 ref.)

Infectious complications of immunosuppressive therapy in patients with rheumatic diseases. Segal BH, et al. **Rheum Dis Clin North Am** 1997 May;23(2):219–37 (93 ref.)

Considerations for nonsteroidal anti–inflammatory drug therapy: benefits. Emery P. **Scand J Rheumatol Suppl** 1996; 105:5–9; discussion 10–2 (15 ref.)

Cyclooxygenase 1 and 2 in rheumatic disease: implications for nonsteroidal anti–inflammatory drug therapy. Spangler RS. **Semin Arthritis Rheum** 1996 Aug;26(1):435–46 (79 ref.)

[Antimalarial agents in rheumatic diseases. New therapeutic aspects of an old medication] Barthel HR, et al. **Dtsch Med Wochenschr** 1996 Dec 13;121(50):1576–82 (48 ref.) **(Ger)**

[Cyclosporin A in inflammatory rheumatic diseases] Gross WL, et al. **Internist (Berl)** 1996 Jan;37(1):91–7 (61 ref.) **(Ger)**

[General principles of immunosuppressive therapy of diseases of rheumatic origin] Peter HH. **Internist (Berl)** 1997 Jun; 38(6):514–9 (20 ref.) **(Ger)**

[New aspects of anti–inflammatory therapy of rheumatic diseases: preclinical validation and clinical trial of meloxicam] Nasonov EL, et al. **Klin Med (Mosk)** 1996; 74(4):4–8 (48 ref.) **(Rus)**

[The use of methotrexate in rheumatology: results and prospects] Nasonov EL. **Klin Med (Mosk)** 1996;74(5):10–5 (74 ref.) **(Rus)**

[Sulphasalazine: a promising drug in rheumatology] Nasonov EL. **Klin Med (Mosk)** 1997;75(6):39–44 (71 ref.) **(Rus)**

ECONOMICS

Economic impact of rheumatologic disorders [see comments] Sangha O, et al. **Curr Opin Rheumatol** 1997 Mar;9(2):102–5 (18 ref.) Comment in: Curr Opin Rheumatol 1997 Mar;9(2):87–9.

ENZYMOLOGY

Cyclooxygenase 1 and 2 in rheumatic disease: implications for nonsteroidal anti–inflammatory drug therapy. Spangler RS. **Semin Arthritis Rheum** 1996 Aug;26(1):435–46 (79 ref.)

EPIDEMIOLOGY

Rheumatology in Iceland. Jónsson H, et al. **Br J Rheumatol** 1997 May;36(5):577–9 (14 ref.)

Epidemiology of rheumatic disease in children. Gäre BA. **Curr Opin Rheumatol** 1996 Sep;8(5):449–54 (52 ref.)

Update on the epidemiology of the rheumatic diseases [see comments] Hawker G. **Curr Opin Rheumatol** 1997 Mar;

9(2):90–4 (42 ref.) Comment in: Curr Opin Rheumatol 1997 Mar;9(2):87–9.
Registers in the study of pediatric rheumatic diseases—limitations and potential [editorial; comment] Gäre BA. **J Rheumatol** 1996 Nov;23(11):1834–7 (32 ref.) Comment on: J Rheumatol 1996 Nov;23(11):1981–7.
[Rheumatism in the Russian Federation: statistic and reality] Folomeeva OM, et al. **Vestn Ross Akad Med Nauk** 1996;(11):21–4 (0 ref.) (Eng. Abstr.) **(Rus)**

ETIOLOGY

Occupational medicine and rheumatic diseases [editorial] Harrington JM. **Br J Rheumatol** 1997 Feb;36(2):153–4 (12 ref.)
Rheumatic manifestations of tropical diseases. Adebajo AO. **Curr Opin Rheumatol** 1996 Jan;8(1):85–9 (30 ref.)
Rheumatic manifestations of malignancy. Aviña-Zubieta JA, et al. **Curr Opin Rheumatol** 1996 Jan;8(1):47–51 (45 ref.)
Rheumatologic manifestations of renal disease. Ferrari R. **Curr Opin Rheumatol** 1996 Jan;8(1):71–6 (13 ref.)
Immunodeficient states and associated rheumatic manifestations. Stein CM. **Curr Opin Rheumatol** 1996 Jan; 8(1):52–6 (26 ref.)
Silicone-associated rheumatic disease: an unsupported myth. Blackburn WD Jr, et al. **Plast Reconstr Surg** 1997 Apr; 99(5):1362–7 (45 ref.)
Rheumatic manifestations due to human parvovirus B19. A report of four cases. Golstein MA, et al. **Rev Rhum Engl Ed** 1996 Dec;63(11):854–8 (21 ref.)
Rheumatic manifestations of dysproteinemias and lymphoproliferative disorders. Duna GF, et al. **Rheum Dis Clin North Am** 1996 Feb;22(1):39–51 (107 ref.)
Adult immunodeficiency and rheumatic disease. Itescu S. **Rheum Dis Clin North Am** 1996 Feb;22(1):53–73 (67 ref.)

GENETICS

Rheumatology in Iceland. Jónsson H, et al. **Br J Rheumatol** 1997 May;36(5):577–9 (14 ref.)

IMMUNOLOGY

Lymphocyte adhesion molecules in autoimmune rheumatic diseases: basic issues and clinical expectations. Sfikakis PP, et al. **Clin Exp Rheumatol** 1995 Nov–Dec;13(6):763–77 (108 ref.)
Clinical relevance of autoantibodies in systemic rheumatic diseases. Fritzler MJ. **Mol Biol Rep** 1996;23(3–4):133–45 (204 ref.)
Molecular biology of autoantigens in rheumatic diseases. Galperin C, et al. **Rheum Dis Clin North Am** 1996 Feb; 22(1):175–210 (243 ref.)
Anti-heat-shock protein antibodies in rheumatic and autoimmune diseases. Tishler M, et al. **Semin Arthritis Rheum** 1996 Oct;26(2):558–63 (25 ref.)

METABOLISM

Biological markers in inflammatory rheumatic diseases. Hilliquin P. **Cell Mol Biol (Noisy-le-grand)** 1995 Dec; 41(8):993–1006 (119 ref.)
Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Furst DE. **Lupus** 1996 Jun;5 Suppl 1:S11–5 (48 ref.)

MICROBIOLOGY

Chronic health effects of microbial foodborne disease. Bunning VK, et al. **World Health Stat Q** 1997;50(1–2):51–6 (45 ref.)

PATHOLOGY

The arthropathy of fibroblastic rheumatism. Romas E, et al. **Arthritis Rheum** 1997 Jan;40(1):183–7 (16 ref.)
[Panoramic nailfold capillary microscopy and its application in rheumatic diseases] da Silva LS, et al. **Rev Assoc Med Bras** 1997 Jan–Mar;43(1):69–73 (27 ref.) **(Por)**

PHYSIOPATHOLOGY

Advances in the understanding of neuroendocrine function in rheumatic disease. Morand EF, et al. **Aust N Z J Med** 1996 Aug;26(4):543–51 (91 ref.)
Cytokines in rheumatic diseases. Miller LC. **Biotherapy** 1994; 8(2):99–111 (138 ref.)
Guidance on ill health retirement. Poole CJ. **Br J Rheumatol** 1997 May;36(5):573–6 (18 ref.)
Nerve growth factor and autoimmune rheumatic diseases. Aloe L, et al. **Clin Exp Rheumatol** 1997 Jul–Aug; 15(4):433–8 (70 ref.)
Health assessment in the rheumatic diseases of childhood. Duffy CM, et al. **Curr Opin Rheumatol** 1997 Sep;9(5):440–7 (49 ref.)
Rheumatologic features of hematologic disorders. Mody GM, et al. **Curr Opin Rheumatol** 1996 Jan;8(1):57–61 (27 ref.)
Molecular and cellular interactions in rheumatoid synovium. Müller-Ladner U. **Curr Opin Rheumatol** 1996 May; 8(3):210–20 (105 ref.)
Assessment of sexual function in patients with rheumatic disorders: a critical appraisal. Quarersma MR, et al. **J Rheumatol** 1997 Sep;24(9):1673–6 (19 ref.)

RADIOGRAPHY

Imaging in clinical trials. Bird HA. **Baillieres Clin Rheumatol** 1996 Nov;10(4):699–709 (61 ref.)
DXA scanning. Truscott JG, et al. **Baillieres Clin Rheumatol** 1996 Nov;10(4):679–98 (50 ref.)

RADIONUCLIDE IMAGING

Isotope imaging. Ryan PJ, et al. **Baillieres Clin Rheumatol** 1996 Nov;10(4):589–613 (54 ref.)

REHABILITATION

Rheumatologic aspects of mineral water. Fabiani D, et al. **Clin Dermatol** 1996 Nov–Dec;14(6):571–5 (21 ref.)
Ancillary services in rheumatology. Jones G, et al. **Med J Aust** 1997 Apr 21;166(8):434–9 (34 ref.)
[Care in warm climate is good for patients with rheumatism. Both the functional ability and well-being is improved] Hafström I. **Lakartidningen** 1997 Mar 19;94(12):1094–6 (23 ref.) **(Swe)**

THERAPY

Soft-tissue rheumatism: diagnosis and treatment. Reveille JD. **Am J Med** 1997 Jan 27;102(1A):23S–29S (14 ref.)
Costs, outcomes, and patient satisfaction by provider type for patients with rheumatic and musculoskeletal conditions: a critical review of the literature and proposed methodologic standards [see comments] Solomon DH, et al. **Ann Intern Med** 1997 Jul 1;127(1):52–60 (35 ref.) Comment in: Ann Intern Med 1997 Jul 1;127(1):72–4.
Prospects and advances in hormonal immunomodulatory therapy. Jorgensen C, et al. **Baillieres Clin Rheumatol** 1996 May;10(2):379–92 (84 ref.)
Shoes and insoles for patients with rheumatoid foot disease. Grifka JK. **Clin Orthop** 1997 Jul;(340):18–25 (15 ref.)
Behavioral and social research in rheumatology [see comments] Callahan LF, et al. **Curr Opin Rheumatol** 1997 Mar;9(2):126–32 (40 ref.) Comment in: Curr Opin Rheumatol 1997 Mar;9(2):87–9.
Biologic agents in the treatment of inflammatory rheumatic diseases. Kalden JR, et al. **Curr Opin Rheumatol** 1997 May; 9(3):206–12 (40 ref.)
Indications, contraindications and possible side-effects of climatotherapy at the Dead-Sea. Shani J, et al. **Int J Dermatol** 1997 Jul;36(7):481–92 (47 ref.)
Preclinical investigations that subserve efforts to employ bone marrow transplantation for rheumatoid or autoimmune diseases. Good RA, et al. **J Rheumatol Suppl** 1997 May; 48:5–12 (73 ref.)
Stem cell transplantation for severe autoimmune disorders, with special reference to rheumatic diseases. Marmont AM. **J Rheumatol Suppl** 1997 May;48:13–8 (48 ref.)
Hematopoietic stem cell transplantation in rheumatic diseases other than systemic sclerosis and systemic lupus erythematosus. Tyndall A. **J Rheumatol Suppl** 1997 May; 48:94–7 (25 ref.)
Unorthodox treatment practices in rheumatology [editorial] Kahn MF. **Rev Rhum Engl Ed** 1997 Feb;64(2):75–7 (73 ref.)
Intravenous immunoglobulin in rheumatic disease. Klassen LW, et al. **Rheum Dis Clin North Am** 1996 Feb;22(1):155–73 (95 ref.)
[Bone and joint manifestations in the elderly patient] André B, et al. **Rev Med Liege** 1997 Apr;52(4):270–7 (12 ref.) **(Fre)**

ULTRASONOGRAPHY

Musculoskeletal ultrasound. Gibbon WW. **Baillieres Clin Rheumatol** 1996 Nov;10(4):561–88 (38 ref.)

VIROLOGY

[Autoimmune rheumatic diseases associated with HIV infection and its pathogenesis] Matsumoto Y. **Nippon Rinsho** 1997 Jun;55(6):1486–91 (18 ref.) (Eng. Abstr.) **(Jpn)**

RHEUMATIC FEVER

Rheumatic fever [see comments] Stollerman GH. **Lancet** 1997 Mar 29;349(9056):935–42 (49 ref.) Comment in: Lancet 1997 Jun 7;349(9066):1700.
Acute rheumatic fever. Still a challenge. da Silva NA, et al. **Rheum Dis Clin North Am** 1997 Aug;23(3):545–68 (144 ref.)
[Rheumatic carditis] Kunitomi T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):219–21 (11 ref.) **(Jpn)**
[Rheumatic fever] Miyata K. **Ryoikibetsu Shokogun Shirizu** 1996;(15):195–7 (6 ref.) **(Jpn)**
[New potentialities of diagnosis and any primary prevention of rheumatic fever] Shostak NA. **Vestn Ross Akad Med Nauk** 1996;(11):38–41 (22 ref.) **(Rus)**

DIAGNOSIS

[Adult-onset acute rheumatic fever: 4 cases in Guadeloupe] Cnudde F, et al. **Presse Med** 1996 Nov 30;25(37):1823–6 (21 ref.) (Eng. Abstr.) **(Fre)**
[A resurgence of rheumatic fever. New causes or old attitudes?] Brito MJ, et al. **Acta Med Port** 1996 Oct–Dec; 9(10–12):401–5 (33 ref.) (Eng. Abstr.) **(Por)**

IMMUNOLOGY

Immunologic and clinical correlations in rheumatic fever and rheumatic heart disease. Veasy LG, et al. **Pediatr Infect Dis J** 1997 Apr;16(4):400–7 (82 ref.)
[Activation of cellular immunity in acute rheumatic fever: clinical and pathogenetic significance] Nasonov EL, et al. **Vestn Ross Akad Med Nauk** 1996;(11):41–4 (50 ref.) **(Rus)**

MICROBIOLOGY

Immunologic and clinical correlations in rheumatic fever and rheumatic heart disease. Veasy LG, et al. **Pediatr Infect Dis J** 1997 Apr;16(4):400–7 (82 ref.)

PREVENTION & CONTROL

Changing streptococci and prospects for the global eradication of rheumatic fever. Stollerman GH. **Perspect Biol Med** 1997 Winter;40(2):165–89 (113 ref.)

RHEUMATIC HEART DISEASE

Rheumatic fever [see comments] Stollerman GH. **Lancet** 1997 Mar 29;349(9056):935–42 (49 ref.) Comment in: Lancet 1997 Jun 7;349(9066):1700.
[Rheumatic pericarditis] Fujikawa S. **Ryoikibetsu Shokogun Shirizu** 1996;(13):615–7 (6 ref.) **(Jpn)**
[Rheumatic valvular heart disease] Kitamura F. **Ryoikibetsu Shokogun Shirizu** 1996;(13):444–7 (4 ref.) **(Jpn)**
[Rheumatic carditis] Kunitomi T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):219–21 (11 ref.) **(Jpn)**
[Rheumatic endocarditis] Murata K. **Ryoikibetsu Shokogun Shirizu** 1996;(13):486–8 (12 ref.) **(Jpn)**

DIAGNOSIS

[A diagnostically difficult case of a combination of extrapulmonary tuberculosis with a rheumatic heart defect] Sarkisova ND, et al. **Ter Arkh** 1996;68(4):24–7 (9 ref.) **(Rus)**

IMMUNOLOGY

Immunologic and clinical correlations in rheumatic fever and rheumatic heart disease. Veasy LG, et al. **Pediatr Infect Dis J** 1997 Apr;16(4):400–7 (82 ref.)
[Acute rheumatic fever and rheumatic heart disease: immunological studies] Speranskii AI, et al. **Vestn Ross Akad Med Nauk** 1996;(11):44–50 (17 ref.) (Eng. Abstr.) **(Rus)**

MICROBIOLOGY

Immunologic and clinical correlations in rheumatic fever and rheumatic heart disease. Veasy LG, et al. **Pediatr Infect Dis J** 1997 Apr;16(4):400–7 (82 ref.)

SURGERY

Spontaneous restoration of sinus rhythm after cardiac surgery [letter] Sechi LA, et al. **Eur Heart J** 1996 Dec;17(12):1914 (5 ref.)

THERAPY

Rheumatic heart disease. Feldman T. **Curr Opin Cardiol** 1996 Mar;11(2):126–30 (25 ref.)
The management of patients with rheumatic valvular heart disease in rural communities. Strang JI. **S Afr Med J** 1996 Jun;86 Suppl 3:C160–4 (10 ref.)

ULTRASONOGRAPHY

[Intravascular ultrasound. Initial experience and review of the literature] Ledesma M, et al. **Arch Inst Cardiol Mex** 1996 Jul–Aug;66(4):313–21 (33 ref.) (Eng. Abstr.) **(Spa)**

RHEUMATISM see **RHEUMATIC DISEASES**

RHEUMATISM, ARTICULAR, ACUTE see **RHEUMATIC FEVER**

RHEUMATISM, MUSCULAR see **FIBROMYALGIA**

RHEUMATISM, PERI-EXTRA-ARTICULAR see **POLYMYALGIA RHEUMATICA**

RHEUMATOID FACTOR

ANALYSIS

Rheumatoid factor autoantibodies in health and disease. Mageed RA, et al. **Ann N Y Acad Sci** 1997 Apr 5; 815:296–311 (63 ref.)
[Clinical evaluation of immuno-serological laboratory data] Kasukawa R, et al. **Rinsho Byori** 1996 Dec;44(12):1157–63 (7 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Unique site of IgG2a and rheumatoid factor production in MRL/lpr mice. Jacobson BA, et al. **Immunol Rev** 1997 Apr;156:103–10 (65 ref.)

When do microbes stimulate rheumatoid factor? [comment] Posnett DN, et al. **J Exp Med** 1997 May 19;185(10):1721–3 (26 ref.) Comment on: J Exp Med 1997 May 19;185(10):1785–92.

BLOOD

[The rheumatoid patient as back pain patient. Diagnosis and differential diagnosis of seronegative spondylarthropathies] Lakomek HJ. **Versicherungsmedizin** 1997 Jun 1;49(3):78–81 (8 ref.) (Eng. Abstr.) **(Ger)**

RHEUMATOID NODULE

CHEMICALLY INDUCED

Methotrexate-associated appearance and rapid progression of rheumatoid nodules in systemic-onset juvenile rheumatoid arthritis. Falcini F, et al. **Arthritis Rheum** 1997 Jan;40(1):175–8 (22 ref.)

RHEUMATOID PURPURA see **PURPURA, SCHOENLEIN-HENOCH**

RHEUMATOID SPONDYLITIS see **SPONDYLITIS, ANKYLOSING**

RHEUMATOLOGY

see related
COLLAGEN DISEASES
RHEUMATIC DISEASES

Behavioral and social research in rheumatology [see comments] Callahan LF, et al. **Curr Opin Rheumatol** 1997 Mar;9(2):126–32 (40 ref.) Comment in: Curr Opin Rheumatol 1997 Mar;9(2):87–9.

[Rheumatoid patients in rheumatology (editorial)] Imura S. **Ryumachi** 1996 Dec;36(6):815–8 (5 ref.) **(Jpn)**

ECONOMICS

Health economics in rheumatology. McCabe CJ, et al. **Baillieres Clin Rheumatol** 1997 Feb;11(1):145–56 (23 ref.)

EDUCATION

Rheumatology in Iceland. Jónsson H, et al. **Br J Rheumatol** 1997 May;36(5):577–9 (14 ref.)

Patient education in rheumatology [see comments] Lorish CD, et al. **Curr Opin Rheumatol** 1997 Mar;9(2):106–11 (21 ref.) Comment in: Curr Opin Rheumatol 1997 Mar;9(2):87–9.

HISTORY

The contribution of Sir James Paget (1814–1894) to the study of rheumatic disease. Buchanan W. **Clin Rheumatol** 1996 Sep;15(5):461–72 (205 ref.)

METHODS

Methods for quantitative analysis of trabecular bone structure. Cortet B, et al. **Rev Rhum Engl Ed** 1995 Dec; 62(11):781–93 (78 ref.)

Unorthodox treatment practices in rheumatology [editorial] Kahn MF. **Rev Rhum Engl Ed** 1997 Feb;64(2):75–7 (73 ref.)

ORGANIZATION & ADMINISTRATION

WHO/ILAR Taskforce on quality of life. Strand CV, et al. **J Rheumatol** 1997 Aug;24(8):1630–3 (1 ref.)

Ancillary services in rheumatology. Jones G, et al. **Med J Aust** 1997 Apr 21;166(8):434–9 (34 ref.)

STANDARDS

Clinical guidelines for management. Scott DL. **Baillieres Clin Rheumatol** 1997 Feb;11(1):157–79 (78 ref.)

TRENDS

Early rheumatoid arthritis. Future treatment. Breedveld FC. **Baillieres Clin Rheumatol** 1997 Feb;11(1):83–96 (42 ref.)

Specialist management: needs and benefits. Stucki G. **Baillieres Clin Rheumatol** 1997 Feb;11(1):97–107 (49 ref.)

Thrombomodulin: a new frontier in lupus research? [editorial] Cucurull E, et al. **Clin Exp Rheumatol** 1997 Jan–Feb; 15(1):1–4 (38 ref.)

Rheumatology. Inflammation and HIV infection: a friendly connection. Gómez-Reino JJ, et al. **Lancet** 1996 Dec 21–28; 348 Suppl 2:sII24 (5 ref.)

Role and evolution of therapeutic options. Keen RW, et al. **Osteoporos Int** 1996;6 Suppl 2:16–20 (29 ref.)

What is the future of fibromyalgia? Goldenberg DL. **Rheum Dis Clin North Am** 1996 May;22(2):393–406 (48 ref.)

Recent progress in the prevention of osteoporosis. To screen or not to screen? Sørensen OH, et al. **Scand J Rheumatol Suppl** 1996;103:25–9 (38 ref.)

[Fourty Years' Progress in Rheumatology, and future Perspectives in Japan] Shiokawa Y. **Ryumachi** 1996 Aug; 36(4):662–9 (17 ref.) **(Jpn)**

RHINENCEPHALON see **LIMBIC SYSTEM**

RHINITIS

CHEMICALLY INDUCED

The use of nasal lavage for objective measurement of irritant-induced nasal inflammation. Peden DB. **Regul Toxicol Pharmacol** 1996 Aug;24(1 Pt 2):S76–8 (23 ref.)

COMPLICATIONS

Allergic manifestations in AIDS. Avila PC, et al. **Clin Rev Allergy Immunol** 1996–97 Winter;14(4):433–49 (83 ref.)

DIAGNOSIS

Rhinopharyngoscopy, computed tomography and magnetic resonance imaging. Bonifazi F, et al. **Allergy** 1997;52(33 Suppl):28–31 (32 ref.)

Idiopathic rhinitis: idiopathic or not? Carney AS, et al. **Clin Otolaryngol** 1996 Jun;21(3):198–202 (47 ref.)

[Diagnosis of chronic rhinosinusitis] Canseco Villarreal JI. **Rev Alerg Mex** 1996;43 Spec No:6–7 (10 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Effects of corticosteroid therapy in non-allergic rhinosinusitis. Mygind N. **Acta Otolaryngol (Stockh)** 1996 Mar;116(2):164–6 (25 ref.)

The pharmacological basis for the treatment of perennial allergic rhinitis and non-allergic rhinitis with topical corticosteroids. Meltzer EO. **Allergy** 1997;52(36 Suppl):33–40 (65 ref.)

Adverse effects of medications for rhinitis. Milgrom H, et al. **Ann Allergy Asthma Immunol** 1997 May;78(5):439–44; quiz 445–6 (63 ref.)

Challenge tests in nose and bronchi: pharmacological modulation of rhinitis and asthma. Mygind N, et al. **Clin Exp Allergy** 1996 May;26 Suppl 3:39–43 (35 ref.)

Intranasal fluticasone propionate. A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis. Wiseman LR, et al. **Drugs** 1997 May;53(5):885–907 (114 ref.)

Ipratropium bromide (Atrovent) nasal spray. A new treatment for rhinorrhea [news] Pfister SM. **Nurse Pract** 1996 Jul;21(7):104, 107–8 (8 ref.)

Treating allergic rhinitis with second-generation antihistamines. Nightingale CH. **Pharmacotherapy** 1996 Sep–Oct;16(5):905–14 (95 ref.)

ECONOMICS

Treating allergic rhinitis with second-generation antihistamines. Nightingale CH. **Pharmacotherapy** 1996 Sep–Oct;16(5):905–14 (95 ref.)

EPIDEMIOLOGY

[Prevalence of rhinosinusitis. Statistics: January–December 1993] González Escamilla JA, et al. **Rev Alerg Mex** 1996; 43 Spec No:8–11 (31 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

A new triad: sensitivity to aspirin, allergic rhinitis, and severe allergic reaction to ingested aeroallergens. Sánchez-Borges M, et al. **Cutis** 1997 Jun;59(6):311–4 (11 ref.)

Allergic diagnosis: skin testing and rast. Thurmond M, et al. **J La State Med Soc** 1997 May;149(5):141–3 (9 ref.)

[Respiratory inflammation] Holgate ST. **Allerg Immunol (Paris)** 1997 Mar;29(3):75–6; discussion 82 (11 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Autonomic reflexes and non-allergic rhinitis. Jones AS. **Allergy** 1997;52(36 Suppl):14–9 (53 ref.)

[Significance of vascular endothelium for specific functional behavior of nasal mucosa] Grevers G, et al. **Laryngorhinootologie** 1997 Jul;76(7):398–404 (24 ref.) (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

Effects of viral and bacterial infection on nasal and sinus mucosa. van Cauwenberge P, et al. **Acta Otolaryngol (Stockh)** 1996 Mar;116(2):316–21 (25 ref.)

PATHOLOGY

Pathology of rhinitis and bronchial asthma. Djukanović R, et al. **Clin Exp Allergy** 1996 May;26 Suppl 3:44–51 (68 ref.)

Response of nose and bronchi to exercise in asthma and rhinitis: similarities and differences. Picado C. **Clin Exp Allergy** 1996 May;26 Suppl 3:36–8 (9 ref.)

PHYSIOPATHOLOGY

Pathophysiology and therapy for allergic and nonallergic rhinitis: an updated review. Levenson T, et al. **Allergy Asthma Proc** 1997 Jul–Aug;18(4):213–20 (54 ref.)

[Physiopathology of chronic rhinosinusitis] González Díaz SN. **Rev Alerg Mex** 1996;43 Spec No:12–5 (46 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Pathophysiology and therapy for allergic and nonallergic rhinitis: an updated review. Levenson T, et al. **Allergy Asthma Proc** 1997 Jul–Aug;18(4):213–20 (54 ref.)

[Treatment of chronic rhinosinusitis] Galindo de Jaime G. **Rev Alerg Mex** 1996;43 Spec No:19–21 (11 ref.) (Eng. Abstr.) **(Spa)**

VIROLOGY

Effects of viral and bacterial infection on nasal and sinus mucosa. van Cauwenberge P, et al. **Acta Otolaryngol (Stockh)** 1996 Mar;116(2):316–21 (25 ref.)

RHINITIS, ALLERGIC, NONSEASONAL see **RHINITIS, ALLERGIC, PERENNIAL**

RHINITIS, ALLERGIC, PERENNIAL

Cytokines and allergic rhinitis. Fireman P. **Allergy Asthma Proc** 1996 Jul–Aug;17(4):175–8 (11 ref.)

Diagnosis and management of seasonal and perennial allergic rhinitis. Tan RA, et al. **Compr Ther** 1996 Jun;22(6):363–74 (35 ref.)

Allergic rhinitis in South Africa—diagnosis and management. South African Allergic Rhinitis Working Group. **S Afr Med J** 1996 Oct;86(10 Pt 2):1315–28 (95 ref.)

COMPLICATIONS

Otitis media and its relation to allergic rhinitis. Fireman P. **Allergy Asthma Proc** 1997 May–Jun;18(3):135–43 (46 ref.)

Learning impairment and allergic rhinitis. Simons FE. **Allergy Asthma Proc** 1996 Jul–Aug;17(4):185–9. (35 ref.)

Allergic rhinitis and asthma: how important is the link? Corren J. **J Allergy Clin Immunol** 1997 Feb;99(2):S781–6 (55 ref.)

Otitis media and eustachian tube dysfunction: connection to allergic rhinitis. Fireman P. **J Allergy Clin Immunol** 1997 Feb;99(2):S787–97 (95 ref.)

DIAGNOSIS

The upper airway. Scadding GK. **Br J Hosp Med** 1996 Oct 16–Nov 5;56(8):401–5 (17 ref.)

Allergic diagnosis: skin testing and rast. Thurmond M, et al. **J La State Med Soc** 1997 May;149(5):141–3 (9 ref.)

Allergic rhinitis. Recognizing signs, symptoms, and triggering allergens. Ferguson BJ. **Postgrad Med** 1997 May; 101(5):110–6 (9 ref.)

[Nasal hyperreactivity. Allergic rhinitis and differential diagnoses—consensus report on pathophysiology, classification, diagnosis and therapy] Bachert C, et al. **Laryngorhinootologie** 1997 Feb;76(2):65–76 (57 ref.) **(Ger)**

DRUG THERAPY

Allergic rhinitis and inflammation: the effect of nasal corticosteroid therapy. Fokkens WJ, et al. **Allergy** 1997; 52(36 Suppl):29–32 (23 ref.)

The pharmacological basis for the treatment of perennial allergic rhinitis and non-allergic rhinitis with topical corticosteroids. Meltzer EO. **Allergy** 1997;52(36 Suppl):33–40 (65 ref.)

Treatment of allergic rhinitis: effect on occupation productivity and work force costs. Fireman P. **Allergy Asthma Proc** 1997 Mar–Apr;18(2):63–7 (10 ref.)

Treatment strategies designed to minimize medical complications of allergic rhinitis. Fireman P. **Am J Rhinol** 1997 Mar–Apr;11(2):95–102 (42 ref.)

Changing strategies in the treatment of allergic rhinitis [editorial; comment] Nathan RA. **Ann Allergy Asthma Immunol** 1996 Oct;77(4):255–9 (55 ref.) Comment on: Ann Allergy Asthma Immunol 1996 Oct;77(4):277–81.

The rationale for use of topical corticosteroids in allergic rhinitis. Mygind N, et al. **Clin Exp Allergy** 1996 May;26 Suppl 3:2–10 (42 ref.)

Once-daily mometasone furoate nasal spray: efficacy and safety of a new intranasal glucocorticoid for allergic rhinitis. Davies RJ, et al. **Clin Ther** 1997 Jan–Feb; 19(1):27–38; discussion 2–3 (24 ref.)

Sedative effects of antihistamines: safety, performance, learning, and quality of life. Nolen TM. **Clin Ther** 1997 Jan–Feb;19(1):39–55; discussion 2–3 (63 ref.)

Triamcinolone acetonide. A review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis. Jeal W, et al. **Drugs** 1997 Feb;53(2):257–80 (73 ref.)

Tachykinin and kinin receptor antagonists: therapeutic perspectives in allergic airway disease. Bertrand C, et al. **Trends Pharmacol Sci** 1996 Jul;17(7):255–9 (58 ref.)

[Fluticasone propionate—a new name common in asthma and rhinitis] Ulmeanu R, et al. **Pneumoftiziologia** 1997 Jan–Mar; 46(1):63–4 (8 ref.) **(Rum)**

ECONOMICS

The prevalence and medical and economic impact of allergic rhinitis in the United States. Meltzer EO. **J Allergy Clin Immunol** 1997 Jun;99(6 Pt 2):S805–28 (65 ref.)

RHINITIS, ALLERGIC, PERENNIAL

EPIDEMIOLOGY

One airway, one disease. Grossman J. **Chest** 1997 Feb;111(2 Suppl):11S–16S (55 ref.)

Pollen allergy in South Africa. Potter PC, et al. **Clin Exp Allergy** 1996 Dec;26(12):1347–54 (28 ref.)

The prevalence and medical and economic impact of allergic rhinitis in the United States. Meltzer EO. **J Allergy Clin Immunol** 1997 Jun;99(6 Pt 2):S805–28 (65 ref.)

Epidemiology of allergic rhinitis. Mygind N, et al. **Pediatr Allergy Immunol** 1996;7(9 Suppl):57–62 (55 ref.)

ETIOLOGY

Otitis media and eustachian tube dysfunction: connection to allergic rhinitis. Fireman P. **J Allergy Clin Immunol** 1997 Feb;99(2):S787–97 (95 ref.)

Overview of comorbid associations of allergic rhinitis. Spector SL. **J Allergy Clin Immunol** 1997 Feb; 99(2):S773–80 (95 ref.)

Allergic rhinosinusitis in the pediatric population. Cook PR, et al. **Otolaryngol Clin North Am** 1996 Feb;29(1):39–56 (67 ref.)

Allergic rhinitis. Recognizing signs, symptoms, and triggering allergens. Ferguson BJ. **Postgrad Med** 1997 May; 101(5):110–6 (9 ref.)

[Identify the allergic rhinitis in your patient] Nuutinen J. **Duodecim** 1995;111(16):1609–15 (20 ref.) **(Fin)**

[Clinical aspects of environmental illnesses of the nose and paranasal sinuses--science and clinical practice] Bachert C. **Eur Arch Otorhinolaryngol Suppl** 1996;1:73–153 (651 ref.) **(Ger)**

[Nasal hyperreactivity. Allergic rhinitis and its differential diagnoses. Consensus report of pathophysiology, classification, diagnosis and therapy (see comments)] **HNO** 1997 Apr;45(4):189–201 (57 ref.) Comment in: HNO 1997 Apr;45(4):187–8. **(Ger)**

[Nasal hyperreactivity (comment)] Heppt W. **HNO** 1997 Apr; 45(4):187–8 (3 ref.) Comment on: HNO 1997 Apr;45(4):189–201. **(Ger)**

IMMUNOLOGY

Purine derivatives in the study of allergic inflammation in respiratory diseases. Crimi N, et al. **Allergy** 1997;52(34 Suppl):48–54 (70 ref.)

Pathophysiology of perennial allergic rhinitis. Naclerio RM. **Allergy** 1997;52(36 Suppl):7–13 (23 ref.)

Local nasal immunotherapy: experimental evidences and general considerations. Passalacqua G, et al. **Allergy** 1997; 52(33 Suppl):10–6 (32 ref.)

The link between the nose and lung, perennial rhinitis and asthma—is it the same disease? Rowe-Jones JM. **Allergy** 1997;52(36 Suppl):20–8 (124 ref.)

Nasal sensitization. Van Cauwenberge PB. **Allergy** 1997;52(33 Suppl):7–9 (13 ref.)

The role of leukotrienes in asthma and allergic rhinitis. Busse WW. **Clin Exp Allergy** 1996 Aug;26(8):868–79 (75 ref.)

Pathogenesis of allergic rhinitis. Baraniuk JN. **J Allergy Clin Immunol** 1997 Feb;99(2):S763–72 (69 ref.)

[Clinical and laboratory features of 100 patients with perennial allergic rhinitis] Segura Méndez NH, et al. **Rev Alerg Mex** 1993 Sep–Oct;40(5):110–3 (20 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Purine derivatives in the study of allergic inflammation in respiratory diseases. Crimi N, et al. **Allergy** 1997;52(34 Suppl):48–54 (70 ref.)

PHYSIOPATHOLOGY

Pathophysiology and therapy for allergic and nonallergic rhinitis: an updated review. Levenson T, et al. **Allergy Asthma Proc** 1997 Jul–Aug;18(4):213–20 (54 ref.)

Pathogenesis of allergic rhinitis. Baraniuk JN. **J Allergy Clin Immunol** 1997 Feb;99(2):S763–72 (69 ref.)

PSYCHOLOGY

Measuring health-related quality of life in rhinitis. Juniper EF. **J Allergy Clin Immunol** 1997 Feb;99(2):S742–9 (31 ref.)

SURGERY

[Inferior turbinectomy in asthmatic children] Ducroz V, et al. **Ann Otolaryngol Chir Cervicofac** 1997;114(1–2):36–40 (14 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Modern management of allergic rhinitis. Katelaris CH. **Adv Otorhinolaryngol** 1997;51:68–71 (13 ref.)

Local nasal immunotherapy: experimental evidences and general considerations. Passalacqua G, et al. **Allergy** 1997; 52(33 Suppl):10–6 (32 ref.)

Monitoring methods for local nasal immunotherapy. Passali D, et al. **Allergy** 1997;52(33 Suppl):22–5 (13 ref.)

Pathophysiology and therapy for allergic and nonallergic rhinitis: an updated review. Levenson T, et al. **Allergy Asthma Proc** 1997 Jul–Aug;18(4):213–20 (54 ref.)

Allergic rhinitis. Options for pharmacotherapy and immunotherapy. Ferguson BJ. **Postgrad Med** 1997 May; 101(5):117–20, 123–6, 131 (15 ref.)

RHINITIS, ALLERGIC, SEASONAL see **HAY FEVER**

RHINITIS, ATROPHIC

DIAGNOSIS

Primary atrophic rhinitis: a summary of four cases and review of the literature. Chand MS, et al. **Otolaryngol Head Neck Surg** 1997 Apr;116(4):554–8 (20 ref.)

ETIOLOGY

Atrophic rhinitis. Shehata MA. **Am J Otolaryngol** 1996 Mar–Apr;17(2):81–6 (42 ref.)

RHINITIS, VASOMOTOR

DIAGNOSIS

[Nasal hyperreactivity. Allergic rhinitis and differential diagnoses--consensus report on pathophysiology, classification, diagnosis and therapy] Bachert C, et al. **Laryngorhinootologie** 1997 Feb;76(2):65–76 (57 ref.) **(Ger)**

ETIOLOGY

[Clinical aspects of environmental illnesses of the nose and paranasal sinuses--science and clinical practice] Bachert C. **Eur Arch Otorhinolaryngol Suppl** 1996;1:73–153 (651 ref.) **(Ger)**

RHINOPHARYNX see **NASOPHARYNX**

RHINOPLASTY

Current concepts in plastic surgery of the nose. Fuleihan NS. **J Med Liban** 1996;44(3):150–60 (18 ref.)

[Advances in the research on implanted tissue of rhinoplasty materials and its tissue substitutes] Shang S, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1996 May;12(3):219–21 (29 ref.) **(Chi)**

[The deviated nose. Classification and treatment. Apropos of 100 cases] Tomasi M, et al. **Ann Otolaryngol Chir Cervicofac** 1997;114(1–2):41–50 (26 ref.) (Eng. Abstr.) **(Fre)**

[Modern corrective nasoseptal surgery] Palma P, et al. **Acta Otorhinolaryngol Ital** 1996 Jun;16(3):211–24 (45 ref.) (Eng. Abstr.) **(Ita)**

[Presumed physiopathology of the nasal wall surgery and contemporary techniques of the inferior turbinates surgery] Passàli D, et al. **Acta Otorhinolaryngol Ital** 1996 Jun; 16(3):202–10 (61 ref.) (Eng. Abstr.) **(Ita)**

RHINOSPORIDIOSIS

Infection of the conjunctiva by Rhinosporidium seeberi. Reidy JJ, et al. **Surv Ophthalmol** 1997 Mar–Apr; 41(5):409–13 (32 ref.)

PATHOLOGY

Rhinosporodium: case report. Ashiru JO, et al. **East Afr Med J** 1996 Jun;73(6):414–5 (16 ref.)

RHINOVIRUS

The role of respiratory viruses in asthma. Busse WW, et al. **Ciba Found Symp** 1997;206:208–13; discussion 213–9 (27 ref.)

[Respiratory inflammation] Holgate ST. **Allerg Immunol (Paris)** 1997 Mar;29(3):75–6; discussion 82 (11 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Chimeric rhinoviruses as tools for vaccine development and characterization of protein epitopes. Arnold GF, et al. **Intervirology** 1996;39(1–2):72–8 (38 ref.)

IMMUNOLOGY

Chimeric rhinoviruses as tools for vaccine development and characterization of protein epitopes. Arnold GF, et al. **Intervirology** 1996;39(1–2):72–8 (38 ref.)

The development of cowpea mosaic virus as a potential source of novel vaccines. Porta C, et al. **Intervirology** 1996; 39(1–2):79–84 (24 ref.)

Virus versus antibody. Colman PM. **Structure** 1997 May 15; 5(5):591–3 (19 ref.)

Recent structural solutions for antibody neutralization of viruses. Stewart PL, et al. **Trends Microbiol** 1997 Jun; 5(6):229–33 (36 ref.)

ISOLATION & PURIFICATION

Effects of viral and bacterial infection on nasal and sinus mucosa. van Cauwenberge P, et al. **Acta Otolaryngol (Stockh)** 1996 Mar;116(2):316–21 (25 ref.)

PHYSIOLOGY

[ICAM-1 and allergic inflammation] Canonica GW. **Allerg Immunol (Paris)** 1997 Mar;29(3):77–9; discussion 84 (17 ref.) (Eng. Abstr.) **(Fre)**

RHIZOBIACEAE

GENETICS

The genetic and biochemical basis for nodulation of legumes by rhizobia. Pueppke SG. **Crit Rev Biotechnol** 1996; 16(1):1–51 (435 ref.)

Environmental regulation of rhizobial symbiotic nitrogen fixation genes. Fischer HM. **Trends Microbiol** 1996 Aug; 4(8):317–20 (27 ref.)

METABOLISM

The genetic and biochemical basis for nodulation of legumes by rhizobia. Pueppke SG. **Crit Rev Biotechnol** 1996; 16(1):1–51 (435 ref.)

PHYSIOLOGY

Nodulation: finding the lost common denominator. Peters NK. **Curr Biol** 1997 Apr 1;7(4):R223–6 (22 ref.)

RHIZOBIUM

ENZYMOLOGY

Microbial dehalogenation of halogenated alkanoic acids, alcohols and alkanes. Slater JH, et al. **Adv Microb Physiol** 1997;38:133–76 (170 ref.)

GENETICS

Nodulation genes in the Rhizobium--plant signal exchange. Lorkiewicz Z. **Acta Biochim Pol** 1997;44(1):1–12 (94 ref.)

Rhizobium symbiosis: nod factors in perspective. Long SR. **Plant Cell** 1996 Oct;8(10):1885–98 (140 ref.)

METABOLISM

Microbial dehalogenation of halogenated alkanoic acids, alcohols and alkanes. Slater JH, et al. **Adv Microb Physiol** 1997;38:133–76 (170 ref.)

Rhizobium lipo-chitooligosaccharide nodulation factors: signaling molecules mediating recognition and morphogenesis. Dénarié J, et al. **Annu Rev Biochem** 1996; 65:503–35 (185 ref.)

Signal transduction in Rhizobium-induced nodule formation. Geurts R, et al. **Plant Physiol** 1996 Oct;112(2):447–53 (42 ref.)

PHYSIOLOGY

The role of lipochitooligosaccharides in root nodule organogenesis and plant cell growth. Schultze M, et al. **Curr Opin Genet Dev** 1996 Oct;6(5):631–8 (76 ref.)

Biogenesis of the peribacteroid membrane in root nodules. Verma DP, et al. **Trends Microbiol** 1996 Sep;4(9):364–8 (40 ref.)

RHIZOBIUM MELILOTI

METABOLISM

Rhizobium meliloti exopolysaccharides: synthesis and symbiotic function. González JE, et al. **Gene** 1996 Nov 7;179(1):141–6 (50 ref.)

RHIZOPUS

Pulmonary mucormycosis in diabetic renal allograft recipients. Latif S, et al. **Am J Kidney Dis** 1997 Mar; 29(3):461–4 (26 ref.)

ENZYMOLOGY

Safety evaluation of lipase derived from Rhizopus oryzae: summary of toxicological data. Coenen TM, et al. **Food Chem Toxicol** 1997 Mar–Apr;35(3–4):315–22 (24 ref.)

ISOLATION & PURIFICATION

Pulmonary mucormycosis diagnosed by bronchoalveolar lavage: a case report and review of the literature. al-Abbadi MA, et al. **Pediatr Pulmonol** 1997 Mar;23(3):222–5 (14 ref.)

RHIZOTOMY

Sensory rhizotomy for the treatment of childhood spasticity. Abbott R. **J Child Neurol** 1996 Nov;11 Suppl 1:S36–42 (60 ref.)

METHODS

Treatment of trigeminal neuralgia by percutaneous radiofrequency rhizotomy. Taha JM, et al. **Neurosurg Clin N Am** 1997 Jan;8(1):31–9 (30 ref.)

RHO(D) IMMUNE GLOBULIN

THERAPEUTIC USE

[Is it always necessary to give anti-D gamma-globulins in the case of spontaneous miscarriage in Rhesus-negative patients?] Salvat J, et al. **Contracept Fertil Sex** 1997 Apr; 25(4):V–IX (27 ref.) **(Fre)**

RHODAMINES

Nystatin–rhodamine B assay for estimating activity of killer toxin from Kluyveromyces lactis. Palková Z, et al. **Methods Mol Biol** 1996;53:325–9 (5 ref.)

Rhodamine B assay for estimating activity of killer toxins permeabilizing cytoplasmic membranes. Vondrejs V, et al. **Methods Mol Biol** 1996;53:319–24 (4 ref.)

RHODANATES see **THIOCYANATES**

RHODANESE see **THIOSULFATE SULFURTRANSFERASE**

RHODNIUS

PHYSIOLOGY

Thrombin inhibitors of bloodsucking animals. Dodt J, et al. **Semin Thromb Hemost** 1996;22(2):203–8 (44 ref.)

RHODOBACTER

METABOLISM

Reverse catabolite repression and the regulation of CO2 fixation in Rhodobacter and related bacteria. Inui M, et al. **Res Microbiol** 1996 Jul–Sep;147(6–7):562–6 (32 ref.)

RHODOBACTER SPHAEROIDES

PHYSIOLOGY

Eubacterial signal transduction by ligands of the mammalian peripheral benzodiazepine receptor complex [see comments] Donohue TJ. **Proc Natl Acad Sci U S A** 1997 May 13;94(10):4821–2 (18 ref.) Comment in: Proc Natl Acad Sci U S A 1997 May 13;94(10):5101–6.

RHODOCOCCUS

GENETICS

Molecular aspects of pesticide degradation by microorganisms. Kumar S, et al. **Crit Rev Microbiol** 1996; 22(1):1–26 (129 ref.)

RHODOCOCCUS EQUI

Rhodococcus equi and Arcanobacterium haemolyticum: two "coryneform" bacteria increasingly recognized as agents of human infection. Linder R. **Emerg Infect Dis** 1997 Apr–Jun; 3(2):145–53 (43 ref.)

Rhodococcus equi pneumonia. Johnson DH, et al. **Semin Respir Infect** 1997 Mar;12(1):57–60 (23 ref.)

Spontaneous resolution of rhodococcal pulmonary infection in a liver transplant recipient. Schilz RJ, et al. **South Med J** 1997 Aug;90(8):851–4 (33 ref.)

Rhodococcus equi: an emerging opportunistic pathogen. Mosser DM, et al. **Trends Microbiol** 1996 Jan;4(1):29–33 (50 ref.)

Clinical manifestations, diagnosis, treatment, and prevention of Rhodococcus equi infections in foals. Giguère S, et al. **Vet Microbiol** 1997 Jun 16;56(3–4):313–34 (97 ref.)

Immunity to Rhodococcus equi. Hines SA, et al. **Vet Microbiol** 1997 Jun 16;56(3–4):177–85 (49 ref.)

Pathogenesis and virulence of Rhodococcus equi. Hondalus MK. **Vet Microbiol** 1997 Jun 16;56(3–4):257–68 (77 ref.)

Epidemiology of Rhodococcus equi infections: a review. Takai S. **Vet Microbiol** 1997 Jun 16;56(3–4):167–76 (49 ref.)

[Rhodococcus equi--a newly recognized opportunistic pathogen in man] Votava M, et al. **Epidemiol Mikrobiol Imunol** 1997 May;46(2):58–66 (58 ref.) (Eng. Abstr.) **(Cze)**

[Current concepts and implications for future research on Rhodococcus equi] Takai S. **Nippon Saikingaku Zasshi** 1996 Feb;51(2):485–96 (31 ref.) **(Jpn)**

CHEMISTRY

Macroamphiphilic cell envelope components of Rhodococcus equi and closely related bacteria. Sutcliffe IC. **Vet Microbiol** 1997 Jun 16;56(3–4):287–99 (43 ref.)

ISOLATION & PURIFICATION

[Review of 105 cases of isolation of Rhodococcus equi in humans] Votava M, et al. **Cas Lek Cesk** 1997 Jan 22; 136(2):51–3 (29 ref.) (Eng. Abstr.) **(Cze)**

ULTRASTRUCTURE

Macroamphiphilic cell envelope components of Rhodococcus equi and closely related bacteria. Sutcliffe IC. **Vet Microbiol** 1997 Jun 16;56(3–4):287–99 (43 ref.)

RHODOPSEUDOMONAS SPHAEROIDES see **RHODOBACTER SPHAEROIDES**

RHODOPSIN

[Physiological roles of rhodopsin phosphorylation and dephosphorylation and its relationship with retinitis pigmentosa] Oguro H. **Nippon Ganka Gakkai Zasshi** 1996 Aug;100(8):575–81 (49 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

Vitamin A, visual pigments, and visual receptors in Drosophila. Lee RD, et al. **Microsc Res Tech** 1996 Dec 15;35(6):418–30 (96 ref.)

CHEMISTRY

Intramembrane signaling mediated by hydrogen-bonding of water and carboxyl groups in bacteriorhodopsin and rhodopsin. Maeda A, et al. **J Biochem (Tokyo)** 1997 Mar; 121(3):399–406 (62 ref.)

GENETICS

Activating mutations of rhodopsin and other G protein–coupled receptors. Rao VR, et al. **Annu Rev Biophys Biomol Struct** 1996;25:287–314 (120 ref.)

METABOLISM

Assay of G protein–coupled receptor kinase activity by rhodopsin phosphorylation. Gagnon AW, et al. **Methods Mol Biol** 1997;83:235–42 (14 ref.)

Long-term rod dark adaptation in man. Threshold measurements, rhodopsin regeneration and allosteric sensitivity regulation. An evaluation. Stabell U, et al. **Scand J Psychol** 1996 Sep;37(3):259–68 (30 ref.)

RHOMBENCEPHALIC SLEEP see **SLEEP, REM**

RHOMBENCEPHALON

EMBRYOLOGY

Phenotypic specification of hindbrain rhombomeres and the origins of rhythmic circuits in vertebrates. Bass AH, et al. **Brain Behav Evol** 1997;50 Suppl 1:3–16 (120 ref.)

Prorhombomeric subdivision of the mammalian embryonic hindbrain: is it functionally meaningful? Ruberte E, et al. **Int J Dev Biol** 1997 Apr;41(2):213–22 (40 ref.)

Engrailed, Wnt and Pax genes regulate midbrain–hindbrain development. Joyner AL. **Trends Genet** 1996 Jan; 12(1):15–20 (50 ref.)

[Role of the Krox-20 gene in the development of rhombencephalon] Schneider-Maunoury S, et al. **C R Seances Soc Biol Fil** 1997;191(1):91–4 (15 ref.) (Eng. Abstr.) **(Fre)**

GROWTH & DEVELOPMENT

Cell–cell interactions and segmentation in the developing vertebrate hindbrain. Irving C, et al. **Biochem Soc Symp** 1996;62:85–95 (41 ref.)

Patterning the hindbrain. Guthrie S. **Curr Opin Neurobiol** 1996 Feb;6(1):41–8 (54 ref.)

Retinoids: from hindbrain patterning to Parkinson disease. Eichele G. **Trends Genet** 1997 Sep;13(9):343–5 (25 ref.)

PHYSIOLOGY

Axon decussation and midline glia in the developing ferret auditory hindbrain. Brunso-Bechtold JK, et al. **Prog Brain Res** 1996;108:165–81 (67 ref.)

PHYSIOPATHOLOGY

Somatosensory evoked potentials to median nerve stimulation in meningomyelocele: what is occurring in the hindbrain and its connections during growth? Nishimura T, et al. **Childs Nerv Syst** 1996 Jan;12(1):13–26 (35 ref.)

RHONCHI see **RESPIRATORY SOUNDS**

RHUS DERMATITIS see **DERMATITIS, TOXICODENDRON**

RHYTHM METHOD

Natural family planning effectiveness: evaluating published reports. Lamprecht V, et al. **Adv Contracept** 1997 Jun–Sep; 13(2–3):155–65 (16 ref.)

An overview on the effectiveness of natural family planning. Guida M, et al. **Gynecol Endocrinol** 1997 Jun;11(3):203–19 (81 ref.)

RHYTHMICITY see **PERIODICITY**

RHYTIDECTOMY see **RHYTIDOPLASTY**

RHYTIDOPLASTY

Mycobacterium smegmatis infection in a healthy woman following a facelift: case report and review of the literature. Pennekamp A, et al. **Ann Plast Surg** 1997 Jul;39(1):80–3 (12 ref.)

METHODS

Rejuvenation of the upper face. A logical gamut of surgical options. Michelow BJ, et al. **Clin Plast Surg** 1997 Apr; 24(2):199–212 (20 ref.)

[Current systematic definition and terminology of the face lifting technique] Mayer B. **Laryngorhinootologie** 1996 Aug; 75(8):471–5 (44 ref.) (Eng. Abstr.) **(Ger)**

RIB FRACTURES

The fractured rib in chest wall trauma. Mayberry JC, et al. **Chest Surg Clin N Am** 1997 May;7(2):239–61 (75 ref.)

COMPLICATIONS

Stress fracture of the second rib as a cause of back pain. Nikkola-Sihto A, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Jul;167(1):103–5 (12 ref.)

DIAGNOSIS

Stress fracture of the neck of the seventh and eighth ribs: a case report. Brukner P, et al. **Clin J Sport Med** 1996 Jul;6(3):204–6 (12 ref.)

RADIOGRAPHY

Traumatic first rib fracture: is angiography necessary? A review of 730 cases. Gupta A, et al. **Cardiovasc Surg** 1997 Feb;5(1):48–53 (21 ref.)

RIBAVIRIN

THERAPEUTIC USE

Therapy of hepatitis C: alpha interferon and ribavirin. Reichard O, et al. **Hepatology** 1997 Sep;26(3 Suppl 1):108S–111S (29 ref.)

Treatment of chronic hepatitis C: another therapeutic option. Trepo C, et al. **Nephrol Dial Transplant** 1996;11 Suppl 4:62–4 (9 ref.)

New approaches to treatment of recurrent hepatitis C virus following liver transplantation using ribavirin. Bizollon T, et al. **Transplant Proc** 1996 Oct;28(5):2842–3 (13 ref.)

RIBOFLAVIN

PHARMACOKINETICS

Bioavailability of riboflavin. Bates CJ. **Eur J Clin Nutr** 1997 Jan;51 Suppl 1:S38–42 (56 ref.)

RIBONUCLEASE A see **RIBONUCLEASE, PANCREATIC**

RIBONUCLEASE H see **RIBONUCLEASE H, CALF THYMUS**

RIBONUCLEASE H, CALF THYMUS

METABOLISM

Ribonuclease H–mediated antisense effects in intact human leukaemia cells. Tidd DM. **Biochem Soc Trans** 1996 Aug; 24(3):619–23 (21 ref.)

RIBONUCLEASE N1 see **RIBONUCLEASE T1**

RIBONUCLEASE, PANCREATIC

CHEMISTRY

Folding studies on ribonuclease A, a model protein. Neira JL, et al. **Fold Des** 1997;2(1):R1–11 (70 ref.)

RIBONUCLEASE T1

CHEMISTRY

A decade of protein engineering on ribonuclease T1--atomic dissection of the enzyme–substrate interactions. Steyaert J. **Eur J Biochem** 1997 Jul 1;247(1):1–11 (91 ref.)

METABOLISM

Catalyzed and assisted protein folding of ribonuclease T1. Schmid FX, et al. **Biol Chem** 1996 Jul–Aug;377(7–8):417–24 (65 ref.)

[Inactivation mechanism of carboxymethylated RNase T1] Ishikawa K, et al. **Tanpakushitsu Kakusan Koso** 1997 May; 42(7 Suppl):971–6 (17 ref.) **(Jpn)**

RIBONUCLEASES

CHEMISTRY

A multi-functional enzyme with RNA polymerase and RNase activities: molecular anatomy of influenza virus RNA polymerase. Ishihama A. **Biochimie** 1996; 78(11–12):1097–102 (46 ref.)

Structure–function relationships in human ribonucleases: main distinctive features of the major RNase types. Sorrentino S, et al. **FEBS Lett** 1997 Mar 3;404(1):1–5 (56 ref.)

CLASSIFICATION

Structure–function relationships in human ribonucleases: main distinctive features of the major RNase types. Sorrentino S, et al. **FEBS Lett** 1997 Mar 3;404(1):1–5 (56 ref.)

RIBONUCLEASES

DIAGNOSTIC USE

From housekeeper to microsurgeon: the diagnostic and therapeutic potential of ribonucleases. Schein CH. **Nat Biotechnol** 1997 Jun;15(6):529–36 (115 ref.)

IMMUNOLOGY

The function of allergens may determine allergenicity. Bufe A, et al. **Adv Exp Med Biol** 1996;409:399–402 (18 ref.)

METABOLISM

A multi-functional enzyme with RNA polymerase and RNase activities: molecular anatomy of influenza virus RNA polymerase. Ishihama A. **Biochimie** 1996; 78(11–12):1097–102 (46 ref.)

RNases in ColE1 DNA metabolism. Jung YH, et al. **Mol Biol Rep** 1995–96;22(2–3):195–200 (35 ref.)

THERAPEUTIC USE

From housekeeper to microsurgeon: the diagnostic and therapeutic potential of ribonucleases. Schein CH. **Nat Biotechnol** 1997 Jun;15(6):529–36 (115 ref.)

RIBONUCLEIC ACID see **RNA**

RIBONUCLEOPROTEINS

GENETICS

Embryonic lethal abnormal visual RNA-binding proteins involved in growth, differentiation, and posttranscriptional gene expression. Antic D, et al. **Am J Hum Genet** 1997 Aug;61(2):273–8 (59 ref.)

Calreticulin. Krause KH, et al. **Cell** 1997 Feb 21;88(4):439–43 (25 ref.)

Biology of EWS/FLI and related fusion genes in Ewing's sarcoma and primitive neuroectodermal tumor. May WA, et al. **Curr Top Microbiol Immunol** 1997;220:143–50 (35 ref.)

Chromosome translocation-mediated conversion of a tumor suppressor gene into a dominant oncogene: fusion of EWS1 to WT1 in desmoplastic small round cell tumors. Rauscher FJ 3rd. **Curr Top Microbiol Immunol** 1997;220:151–62 (47 ref.)

Evolution, expression, and possible function of a master gene for amplification of an interspersed repeated DNA family in rodents. Deininger PL, et al. **Prog Nucleic Acid Res Mol Biol** 1996;52:67–88 (62 ref.)

IMMUNOLOGY

Anti-Ro (SSA) and anti-La (SSB) antibodies and complete congenital heart block. Finkelstein Y, et al. **Ann Med Interne (Paris)** 1997;148(3):205–8 (60 ref.)

Autoantibodies to the A/B proteins of the heterogeneous nuclear ribonucleoprotein complex: novel tools for the diagnosis of rheumatic diseases. Steiner G, et al. **Int Arch Allergy Immunol** 1996 Dec;111(4):314–9 (34 ref.)

Autoantibodies reactive with Ro(SSA) and La(SSB) and pregnancy. Buyon JP. **J Rheumatol** 1997 Sep;24 Suppl 50:12–6 (47 ref.)

Cutaneous diseases in adults associated with anti-Ro/SS-A autoantibody production. McCauliffe DP. **Lupus** 1997; 6(2):158–66 (100 ref.)

Clinical and immunological aspects of autoantibodies to RA33/hnRNP-A/B proteins--a link between RA, SLE and MCTD. Steiner G, et al. **Mol Biol Rep** 1996; 23(3–4):167–71 (29 ref.)

Neonatal lupus: bedside to bench and back [editorial] Buyon JP. **Scand J Rheumatol** 1996;25(5):271–6 (49 ref.)

[Sjögren's syndrome and anti-Ro syndrome] Tanaka M. **Ryoikibetsu Shokogun Shirizu** 1996;(15):379–82 (17 ref.) **(Jpn)**

METABOLISM

Preribosomal RNA processing in archaea: characterization of the RNP endonuclease mediated processing of precursor 16S rRNA in the thermoacidophile Sulfolobus acidocaldarius. Potter S, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):813–23 (31 ref.)

The roles of heterogeneous nuclear ribonucleoproteins (hnRNP) in RNA metabolism. Weighardt F, et al. **Bioessays** 1996 Sep;18(9):747–56 (72 ref.)

Calreticulin. Krause KH, et al. **Cell** 1997 Feb 21;88(4):439–43 (25 ref.)

Calnexin, calreticulin, and Bip/Kar2p in protein folding. Hebert DN, et al. **Cold Spring Harb Symp Quant Biol** 1995; 60:405–15 (70 ref.)

Diverse molecular interactions of the hnRNP K protein. Bomsztyk K, et al. **FEBS Lett** 1997 Feb 17;403(2):113–5 (28 ref.)

The spliceosome is a dynamic ribonucleoprotein machine. Guthrie C. **Harvey Lect** 1994–95;90:59–80 (77 ref.)

The signal recognition particle and related small cytoplasmic ribonucleoprotein particles. Bovia F, et al. **J Cell Sci** 1996 Nov;109 (Pt 11):2601–8 (64 ref.)

Structural and functional similarities between MRP and RNase P. Reddy R, et al. **Mol Biol Rep** 1995–96; 22(2–3):81–5 (68 ref.)

PHYSIOLOGY

TLS-CHOP and the role of RNA-binding proteins in oncogenic transformation. Ron D. **Curr Top Microbiol Immunol** 1997;220:131–42 (53 ref.)

RIBONUCLEOPROTEINS, SMALL NUCLEAR

GENETICS

Pre-mRNA splicing: the discovery of a new spliceosome doubles the challenge. Tarn WY, et al. **Trends Biochem Sci** 1997 Apr;22(4):132–7 (40 ref.)

IMMUNOLOGY

Clinical and immunological aspects of autoantibodies to RA33/hnRNP-A/B proteins--a link between RA, SLE and MCTD. Steiner G, et al. **Mol Biol Rep** 1996; 23(3–4):167–71 (29 ref.)

METABOLISM

RNA splicing: unexpected spliceosome diversity. Kreivi JP, et al. **Curr Biol** 1996 Jul 1;6(7):802–5 (9 ref.)

Ribosomal RNA: small nucleolar RNAs make their mark. Peculis BA, et al. **Curr Biol** 1996 Nov 1;6(11):1413–5 (10 ref.)

PHYSIOLOGY

Protein functions in pre-mRNA splicing. Will CL, et al. **Curr Opin Cell Biol** 1997 Jun;9(3):320–8 (92 ref.)

RIBONUCLEOPROTEINS, SMALL, U1

IMMUNOLOGY

[Mixed connective tissue disease: progress in diagnosis and treatment. II. Physiopathology and diagnosis. 1. Etiology and pathogenesis] Mimori T. **Nippon Naika Gakkai Zasshi** 1996 Aug 10;85(8):1196–202 (9 ref.) **(Jpn)**

RIBONUCLEOPROTEINS, SMALL, U3 see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

RIBONUCLEOPROTEINS, SMALL, U7 see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

RIBONUCLEOSIDES

TOXICITY

Clinical cases and problems of delayed (tardive) reactions to drugs--for pharmaceuticals in general. Hama R. **J Toxicol Sci** 1996 Feb;21(1):81–91 (7 ref.)

RIBONUCLEOTIDE REDUCTASES

ANTAGONISTS & INHIBITORS

Modulation of 5-FU/alpha-interferon with high-dose continuous infusion hydroxyurea. Horowitz R, et al. **J Infus Chemother** 1995 Fall;5(4):212–4 (33 ref.)

Efficacy of single-agent gemcitabine in advanced non-small cell lung cancer: a review. Hansen HH, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 7):S7-38–S7-41 (15 ref.)

Preclinical, pharmacologic, and phase I studies of gemcitabine. Storniolo AM, et al. **Semin Oncol** 1997 Apr; 24(2 Suppl 7):S7-2–S7-7 (16 ref.)

Gemcitabine: symptomatic benefit in advanced non-small cell lung cancer. Thatcher N, et al. **Semin Oncol** 1997 Jun;24(3 Suppl 8):S8-6–S8-12 (37 ref.)

Combination chemotherapy studies with gemcitabine. van Moorsel CJ, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 7):S7-17–S7-23 (40 ref.)

CHEMISTRY

Electron paramagnetic resonance and nuclear magnetic resonance studies of class I ribonucleotide reductase. Gräslund A, et al. **Annu Rev Biophys Biomol Struct** 1996; 25:259–86 (64 ref.)

Model complexes of di-iron sites in methane mono-oxygenase and ribonucleotide reductase: structure and reactivity. Fontecave M, et al. **Biochem Soc Trans** 1997 Feb;25(1):65–9 (36 ref.)

Di-iron-carboxylate proteins. Nordlund P, et al. **Curr Opin Struct Biol** 1995 Dec;5(6):758–66 (54 ref.)

The evolution of ribonucleotide reduction. Reichard P. **Trends Biochem Sci** 1997 Mar;22(3):81–5 (31 ref.)

METABOLISM

Ribonucleotide reductase, lipoxygenase and the intracellular low-molecular-weight iron pool. Cooper CE, et al. **Biochem Soc Trans** 1997 Feb;25(1):75–80 (25 ref.)

Model complexes of di-iron sites in methane mono-oxygenase and ribonucleotide reductase: structure and reactivity. Fontecave M, et al. **Biochem Soc Trans** 1997 Feb;25(1):65–9 (36 ref.)

The evolution of ribonucleotide reduction. Reichard P. **Trends Biochem Sci** 1997 Mar;22(3):81–5 (31 ref.)

RIBONUCLEOTIDES

METABOLISM

Switches, latches, and amplifiers: common themes of G proteins and molecular motors. Vale RD. **J Cell Biol** 1996 Oct;135(2):291–302 (92 ref.)

The evolution of ribonucleotide reduction. Reichard P. **Trends Biochem Sci** 1997 Mar;22(3):81–5 (31 ref.)

RIBOSE

METABOLISM

Guiding ribose methylation of rRNA. Bachellerie JP, et al. **Trends Biochem Sci** 1997 Jul;22(7):257–61 (34 ref.)

RIBOSE-PHOSPHATE PYROPHOSPHOKINASE

[Mammalian phosphoribosylpyrophosphate synthetase] Tatibana M. **Nippon Rinsho** 1996 Dec;54(12):3195–201 (24 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

[Structure of family proteins constituting mammalian phosphoribosylpyrophosphate synthetase] Ishijima S, et al. **Seikagaku** 1997 Feb;69(2):122–6 (15 ref.) **(Jpn)**

GENETICS

[PRPP synthetase superactivity] Fujimori S. **Nippon Rinsho** 1996 Dec;54(12):3309–14 (20 ref.) (Eng. Abstr.) **(Jpn)**

RIBOSOMAL DNA see **DNA, RIBOSOMAL**

RIBOSOMAL FRAMESHIFTING see **FRAMESHIFTING, RIBOSOMAL**

RIBOSOMAL PROTEINS

[Expression of monocyte chemotactic activity by cross-linked dimerization of a ribosomal protein] Yamamoto T. **Seikagaku** 1997 May;69(5):324–8 (15 ref.) **(Jpn)**

BIOSYNTHESIS

Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? Yewdell JW, et al. **J Immunol** 1996 Sep 1;157(5):1823–6 (21 ref.)

CHEMISTRY

Histidine 229 in protein L2 is apparently essential for 50S peptidyl transferase activity. Cooperman BS, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1087–94 (43 ref.)

Structures of prokaryotic ribosomal proteins: implications for RNA binding and evolution. Ramakrishnan V, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):979–86 (30 ref.)

Proteins P1, P2, and P0, components of the eukaryotic ribosome stalk. New structural and functional aspects. Remacha M, et al. **Biochem Cell Biol** 1995 Nov–Dec; 73(11–12):959–68 (49 ref.)

Structure and evolution of mammalian ribosomal proteins. Wool IG, et al. **Biochem Cell Biol** 1995 Nov–Dec; 73(11–12):933–47 (55 ref.)

Ribosomal proteins and elongation factors. Liljas A, et al. **Curr Opin Struct Biol** 1995 Dec;5(6):721–7 (59 ref.)

The L7/L12 ribosomal domain of the ribosome: structural and functional studies. Gudkov AT. **FEBS Lett** 1997 May 5;407(3):253–6 (60 ref.)

GENETICS

Structure and expression of ribosomal protein genes in Xenopus laevis. Amaldi F, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):969–77 (60 ref.)

A pseudoknot is required for efficient translational initiation and regulation of the Escherichia coli rpsO gene coding for ribosomal protein S15. Ehresmann C, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1131–40 (34 ref.)

The accuracy center of a eukaryotic ribosome. Liebman SW, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1141–9 (49 ref.)

TOP genes: a translationally controlled class of genes including those coding for ribosomal proteins. Amaldi F, et al. **Prog Mol Subcell Biol** 1997;18:1–17 (70 ref.)

IMMUNOLOGY

Anti-P antibodies and neuropsychiatric lupus erythematosus. Georgescu L, et al. **Ann N Y Acad Sci** 1997 Aug 14; 823:263–9 (28 ref.)

Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? Yewdell JW, et al. **J Immunol** 1996 Sep 1;157(5):1823–6 (21 ref.)

METABOLISM

The L7/L12 ribosomal domain of the ribosome: structural and functional studies. Gudkov AT. **FEBS Lett** 1997 May

5;407(3):253–6 (60 ref.)
New RNA recognition features revealed in ancient ribosomal proteins [news] Yonath A, et al. **Nat Struct Biol** 1997 Jan; 4(1):3–5 (23 ref.)

RIBOSOMAL RNA see **RNA, RIBOSOMAL**

5S RIBOSOMAL RNA see **RNA, RIBOSOMAL, 5S**

16S RIBOSOMAL RNA see **RNA, RIBOSOMAL, 16S**

23S RIBOSOMAL RNA see **RNA, RIBOSOMAL, 23S**

28S RIBOSOMAL RNA see **RNA, RIBOSOMAL, 28S**

RIBOSOMES

see related
DNA, RIBOSOMAL
RIBOSOMAL PROTEINS
RNA, RIBOSOMAL

The accuracy center of a eukaryotic ribosome. Liebman SW, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1141–9 (49 ref.)
Recent advances in the uses and applications of ribosome-inactivating proteins from plants. Girbés T, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 Jun;42(4):461–71 (122 ref.)

CHEMISTRY

Identification of ribosome–ligand interactions using cleavage reagents. Hill WE, et al. **Biochem Cell Biol** 1995 Nov–Dec; 73(11–12):1033–9 (47 ref.)
The elongating ribosome: structural and functional aspects. Nierhaus KH, et al. **Biochem Cell Biol** 1995 Nov–Dec; 73(11–12):1011–21 (24 ref.)
A milestone in ribosomal crystallography: the construction of preliminary electron density maps at intermediate resolution. Schlünzen F, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):739–49 (53 ref.)
The conformation of ribosomes and rRNA. Moore PB. **Curr Opin Struct Biol** 1997 Jun;7(3):343–7 (36 ref.)
[Three-dimensional structure and function of ribosomal elongation factors: new data and new questions] Chirgadze IuN. **Mol Biol (Mosk)** 1996 Jul–Aug;30(4):773–85 (24 ref.) **(Rus)**

DRUG EFFECTS

Fungal ribotoxins: a family of naturally engineered targeted toxins? Kao R, et al. **Biochem Cell Biol** 1995 Nov–Dec; 73(11–12):1151–9 (70 ref.)

GENETICS

Structure and function of 5S rRNA in the ribosome. Bogdanov AA, et al. **Biochem Cell Biol** 1995 Nov–Dec; 73(11–12):869–76 (52 ref.)
An oligonucleotide analog approach to the decoding region of 16S rRNA. Stern S, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):899–905 (19 ref.)
Multiparameter microscopic analysis of nucleolar structure and ribosomal gene transcription. Trendelenburg MF, et al. **Histochem Cell Biol** 1996 Aug;106(2):167–92 (156 ref.)

METABOLISM

rRNA transcription and growth rate-dependent regulation of ribosome synthesis in Escherichia coli. Gourse RL, et al. **Annu Rev Microbiol** 1996;50:645–77 (157 ref.)
Ribosomally synthesized antimicrobial peptides: their function, structure, biogenesis, and mechanism of action. Nissen-Meyer J, et al. **Arch Microbiol** 1997 Feb–Mar; 167(2–3):67–77 (90 ref.)
tRNA–ribosome interactions. Ehrenberg M, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1049–54 (35 ref.)
Global regulators of ribosome biosynthesis in yeast. Planta RJ, et al. **Biochem Cell Biol** 1995 Nov–Dec; 73(11–12):825–34 (70 ref.)
Elongation factor Tu, a GTPase triggered by codon recognition on the ribosome: mechanism and GTP consumption. Rodnina MV, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1221–7 (42 ref.)
Peptidyl transferase and beyond. Wower J, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1041–7 (45 ref.)
Dual functions of ribosome recycling factor in protein biosynthesis: disassembling the termination complex and preventing translational errors. Janosi L, et al. **Biochimie** 1996;78(11–12):959–69 (50 ref.)
Structure and function of 10Sa RNA: trans-translation system. Muto A, et al. **Biochimie** 1996;78(11–12):985–91 (41 ref.)
Recognition of a transmembrane domain: another role for the ribosome? [comment] Siegel V. **Cell** 1997 Jul 11; 90(1):5–8 (19 ref.) Comment on: Cell 1997 Jul 11;90(1):31–41.
Function and synthesis of small nucleolar RNAs. Tollervey D, et al. **Curr Opin Cell Biol** 1997 Jun;9(3):337–42 (49 ref.)
The conformation of ribosomes and rRNA. Moore PB. **Curr Opin Struct Biol** 1997 Jun;7(3):343–7 (36 ref.)
Trans-acting factors in ribosome synthesis. Tollervey D. **Exp Cell Res** 1996 Dec 15;229(2):226–32 (74 ref.)
Divergence towards a dead end? Cleavage of the divergent domains of ribosomal RNA in apoptosis. Houge G, et al. **Experientia** 1996 Oct 31;52(10–11):963–7 (29 ref.)
Movement of the 3'-end of tRNA through the peptidyl transferase centre and its inhibition by antibiotics. Kirillov S, et al. **FEBS Lett** 1997 Apr 14;406(3):223–33 (165 ref.)
eIF4G: a multipurpose ribosome adapter? [published erratum appears in Science 1997 Mar 14;275(5306):1553] Hentze MW. **Science** 1997 Jan 24;275(5299):500–1 (12 ref.)

PHYSIOLOGY

Ribosomes and translation. Green R, et al. **Annu Rev Biochem** 1997;66:679–716 (198 ref.)
Tetracycline resistance mediated by ribosomal protection. Taylor DE, et al. **Antimicrob Agents Chemother** 1996 Jan; 40(1):1–5 (41 ref.)
News and views on the nucleolus in 1996. Report on the 'Colloquium on the nucleolus', a meeting at Paris–Grignon, July 18–20, 1996. Mosgoeller W, et al. **Biol Cell** 1996; 88(1–2):1–4 (12 ref.)
Emerging understanding of translation termination. Nakamura Y, et al. **Cell** 1996 Oct 18;87(2):147–50 (20 ref.)

ULTRASTRUCTURE

Modeling the structure of the ribosome. Easterwood TR, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):751–6 (35 ref.)
A model of the translational apparatus based on a three-dimensional reconstruction of the Escherichia coli ribosome. Frank J, et al. **Biochem Cell Biol** 1995 Nov–Dec; 73(11–12):757–65 (38 ref.)
Cotranslational folding of nascent proteins on Escherichia coli ribosomes. Hardesty B, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1199–207 (22 ref.)
Ribosomes: protein synthesis in slow motion. Moore PB. **Curr Biol** 1997 Mar 1;7(3):R179–81 (10 ref.)
The ribosome at higher resolution—the donut takes shape. Frank J. **Curr Opin Struct Biol** 1997 Apr;7(2):266–72 (61 ref.)

RIBOVIRIN see **RIBAVIRIN**

RIBOZYMES see **RNA, CATALYTIC**

RIBS

see related
TIETZE'S SYNDROME

Primary angiosarcoma of the rib. Batt H, et al. **South Med J** 1997 Apr;90(4):454–6 (8 ref.)

ABNORMALITIES

Cerebro–costo–mandibular syndrome [published erratum appears in Am J Med Genet 1996 Aug 23;64(3):527] Plötz FB, et al. **Am J Med Genet** 1996 Mar 29;62(3):286–92 (20 ref.)
Anomalous articulation of the first rib mimicking supraclavicular neoplasia. Zrada SE, et al. **Otolaryngol Head Neck Surg** 1997 Mar;116(3):389–91 (14 ref.)

SURGERY

Chest wall resection and reconstruction. Sabanathan S, et al. **Br J Hosp Med** 1997 Mar 19–Apr 1;57(6):255–9 (21 ref.)
[Removal of the 1st rib in thoracic outlet syndrome. Is it helpful? Is it safe? (see comments)] Richter HP. **Nervenarzt** 1996 Dec;67(12):1034–7 (26 ref.) (Eng. Abstr.) Comment in: Nervenarzt 1996 Dec;67(12):1038–9. **(Ger)**
[Thoracic outlet syndrome—an interdisciplinary topic. Experience with diagnosis and therapy in a 15-year patient cohort (80 trans-axillary resections of the 1st rib in 67 patients) and a literature review] Wenz W, et al. **Z Orthop Ihre Grenzgeb** 1997 Jan–Feb;135(1):84–90 (32 ref.) (Eng. Abstr.) **(Ger)**

RIBULOSE BIPHOSPHATE CARBOXYLASE-OXYGENASE see **RIBULOSEBIPHOSPHATE CARBOXYLASE**

RIBULOSE DIPHOSPHATE CARBOXYLASE see **RIBULOSEBIPHOSPHATE CARBOXYLASE**

RIBULOSEBIPHOSPHATE CARBOXYLASE

GENETICS

Microbial ribulose 1,5-bisphosphate carboxylase/oxygenase: a molecule for phylogenetic and enzymological investigation. Watson GM, et al. **FEMS Microbiol Lett** 1997 Jan 1;146(1):13–22 (39 ref.)
[Mechanisms of calcification and molecular phylogeny of Rubisco genes in coccolithophorid algae] Fujiwara S. **Seikagaku** 1996 Aug;68(8):1445–8 (8 ref.) **(Jpn)**

METABOLISM

Microbial ribulose 1,5-bisphosphate carboxylase/oxygenase: a molecule for phylogenetic and enzymological investigation. Watson GM, et al. **FEMS Microbiol Lett** 1997 Jan 1;146(1):13–22 (39 ref.)

RICE

Rice bran proteins: properties and food uses. Prakash J. **Crit Rev Food Sci Nutr** 1996 Jul;36(6):537–52 (113 ref.)

GENETICS

Cereal genome analysis using rice as a model. Havukkala IJ. **Curr Opin Genet Dev** 1996 Dec;6(6):711–4 (38 ref.)
The Japanese Rice Genome Research Program. Sasaki T, et al. **Genome Res** 1996 Aug;6(8):661–6 (16 ref.)
Public informatics resources for rice and other grasses. Cartinhour SW. **Plant Mol Biol** 1997 Sep;35(1–2):241–51 (71 ref.)
Rice transformation: bombardment. Christou P. **Plant Mol Biol** 1997 Sep;35(1–2):197–203 (29 ref.)
Transformation of rice mediated by Agrobacterium tumefaciens. Hiei Y, et al. **Plant Mol Biol** 1997 Sep; 35(1–2):205–18 (119 ref.)
Retrotransposons of rice: their regulation and use for genome analysis. Hirochika H. **Plant Mol Biol** 1997 Sep; 35(1–2):231–40 (74 ref.)
Transposon tagging in rice. Izawa T, et al. **Plant Mol Biol** 1997 Sep;35(1–2):219–29 (42 ref.)
Conservation of rice genetic resources: the role of the International Rice Genebank at IRRI. Jackson MT. **Plant Mol Biol** 1997 Sep;35(1–2):61–7 (34 ref.)
Physical mapping of the rice genome with YAC clones. Kurata N, et al. **Plant Mol Biol** 1997 Sep;35(1–2):101–13 (26 ref.)
Microsatellite marker development, mapping and applications in rice genetics and breeding. McCouch SR, et al. **Plant Mol Biol** 1997 Sep;35(1–2):89–99 (76 ref.)
Are rice chromosomes components of a holocentric chromosome ancestor? Moore G, et al. **Plant Mol Biol** 1997 Sep;35(1–2):17–23 (37 ref.)
Rice molecular genetic map using RFLPs and its applications. Nagamura Y, et al. **Plant Mol Biol** 1997 Sep; 35(1–2):79–87 (98 ref.)
Rice genetic resources: history, conservation, investigative characterization and use in Japan. Nakagahra M, et al. **Plant Mol Biol** 1997 Sep;35(1–2):69–77 (45 ref.)
QTL analysis to study the association between leaf size and abscisic acid accumulation in droughted rice leaves and comparisons across cereals. Quarrie SA, et al. **Plant Mol Biol** 1997 Sep;35(1–2):155–65 (45 ref.)
Large-scale EST sequencing in rice. Yamamoto K, et al. **Plant Mol Biol** 1997 Sep;35(1–2):135–44 (39 ref.)
Genetic and molecular dissection of quantitative traits in rice. Yano M, et al. **Plant Mol Biol** 1997 Sep;35(1–2):145–53 (61 ref.)
Linkage map of phenotype and RFLP markers in rice. Yoshimura A, et al. **Plant Mol Biol** 1997 Sep;35(1–2):49–60 (36 ref.)
Physical mapping of the rice genome with BACs. Zhang HB, et al. **Plant Mol Biol** 1997 Sep;35(1–2):115–27 (55 ref.)

HISTORY

Rice genetic resources: history, conservation, investigative characterization and use in Japan. Nakagahra M, et al. **Plant Mol Biol** 1997 Sep;35(1–2):69–77 (45 ref.)

MICROBIOLOGY

Breaking and entering: host penetration by the fungal rice blast pathogen Magnaporthe grisea. Howard RJ, et al. **Annu Rev Microbiol** 1996;50:491–512 (98 ref.)
Alien introgression in rice. Brar DS, et al. **Plant Mol Biol** 1997 Sep;35(1–2):35–47 (45 ref.)
Transformation of rice mediated by Agrobacterium tumefaciens. Hiei Y, et al. **Plant Mol Biol** 1997 Sep; 35(1–2):205–18 (119 ref.)

PARASITOLOGY

Alien introgression in rice. Brar DS, et al. **Plant Mol Biol** 1997 Sep;35(1–2):35–47 (45 ref.)

PHYSIOLOGY

Oxidative stress and responses in Arabidopsis thaliana and Oryza sativa subjected to chilling and salinity stress. Burdon RH, et al. **Biochem Soc Trans** 1996 May; 24(2):469–72 (17 ref.)

POISONING

Comparison of clinical picture between Yusho/Yucheng cases and occupational PCB poisoning cases. Ikeda M. **Chemosphere** 1996 Feb;32(3):559–66 (53 ref.)

STANDARDS

Rice inhibits intestinal secretions. Goldberg ED, et al. **Nutr Rev** 1996 Jan;54(1 Pt 1):36–7 (8 ref.)

RICIN

GENETICS

Cotranslational folding of nascent proteins on Escherichia coli ribosomes. Hardesty B, et al. **Biochem Cell Biol** 1995

RICIN

Nov-Dec;73(11-12):1199-207 (22 ref.)

METABOLISM

Accumulating evidence suggests that several AB-toxins subvert the endoplasmic reticulum-associated protein degradation pathway to enter target cells. Hazes B, et al. **Biochemistry** 1997 Sep 16;36(37):11051-4 (48 ref.)

PHARMACOKINETICS

Endocytosis, intracellular transport, and cytotoxic action of Shiga toxin and ricin. Sandvig K, et al. **Physiol Rev** 1996 Oct;76(4):949-66 (235 ref.)

TOXICITY

Endocytosis, intracellular transport, and cytotoxic action of Shiga toxin and ricin. Sandvig K, et al. **Physiol Rev** 1996 Oct;76(4):949-66 (235 ref.)

RICINUS

see related
RICIN

RICKETS

DRUG THERAPY

Vitamin-D dependent rickets type II. Mishra S, et al. **Indian Pediatr** 1996 Apr;33(4):334-6 (15 ref.)

ETIOLOGY

[Nutritional rickets--an old disease with new relevance] Brunvand L, et al. **Nord Med** 1996 Sep;111(7):219-21 (13 ref.) (Eng. Abstr.) **(Nor)**

GENETICS

Genetic rickets and osteomalacia. Weisman Y, et al. **Curr Ther Endocrinol Metab** 1997;6:527-9 (6 ref.)

Vitamin-D dependent rickets type II. Mishra S, et al. **Indian Pediatr** 1996 Apr;33(4):334-6 (15 ref.)

Craniosynostosis in X-linked hypophosphataemic rickets. Willis FR, et al. **J Paediatr Child Health** 1997 Feb; 33(1):78-9 (12 ref.)

[Molecular mechanisms of familial rachitis] Glorieux FH. **Arch Pediatr** 1997;4(2 Suppl 2):102s-105s (26 ref.) **(Fre)**

METABOLISM

[Molecular mechanisms of familial rachitis] Glorieux FH. **Arch Pediatr** 1997;4(2 Suppl 2):102s-105s (26 ref.) **(Fre)**

THERAPY

Genetic rickets and osteomalacia. Weisman Y, et al. **Curr Ther Endocrinol Metab** 1997;6:527-9 (6 ref.)

VETERINARY

Rickets in a 6-month-old monkey. Liu SK. **Skeletal Radiol** 1996 Jan;25(1):70-2 (13 ref.)

RICKETS, HYPOPHOSPHATEMIC see **HYPOPHOSPHATEMIA, FAMILIAL**

RICKETS, RENAL see **RENAL OSTEODYSTROPHY**

RICKETS, VITAMIN D-RESISTANT see **HYPOPHOSPHATEMIA, FAMILIAL**

RICKETS, X-LINKED HYPOPHOSPHATEMIC see **HYPOPHOSPHATEMIA, FAMILIAL**

RICKETTSIA

The biology of rickettsiae. Hackstadt T. **Infect Agents Dis** 1996 Jun;5(3):127-43 (154 ref.)

CLASSIFICATION

African tick-bite fever. An imported spotless rickettsiosis. Brouqui P, et al. **Arch Intern Med** 1997 Jan 13; 157(1):119-24 (40 ref.)

ISOLATION & PURIFICATION

Ulceroglandular lymphadenopathy due to Rickettsia conorii in Italy [letter] Castagnola E, et al. **Eur J Clin Microbiol Infect Dis** 1996 Sep;15(9):766-7 (5 ref.)

PATHOGENICITY

[Astrakhan fever--a rickettsiosis of the tick-borne spotted fevers caused by a new pathovar of rickettsiae, Rickettsia conorii] Lukin EP, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Sep-Oct;(5):96-9 (37 ref.) **(Rus)**

RICKETTSIA INFECTIONS

[Rickettsial myocarditis] Uemura A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):222-4 (10 ref.) **(Jpn)**

DIAGNOSIS

African tick-bite fever. An imported spotless rickettsiosis. Brouqui P, et al. **Arch Intern Med** 1997 Jan 13; 157(1):119-24 (40 ref.)

EPIDEMIOLOGY

Flea-borne rickettsioses: ecologic considerations. Azad AF, et al. **Emerg Infect Dis** 1997 Jul-Sep;3(3):319-27 (27 ref.)

Japanese spotted fever: report of 31 cases and review of the literature. Mahara F. **Emerg Infect Dis** 1997 Apr-Jun; 3(2):105-11 (42 ref.)

PARASITOLOGY

The biology of rickettsiae. Hackstadt T. **Infect Agents Dis** 1996 Jun;5(3):127-43 (154 ref.)

PATHOLOGY

Viruses and rickettsiae. Esiri MM. **Brain Pathol** 1997 Jan; 7(1):695-709 (107 ref.)

TRANSMISSION

Flea-borne rickettsioses: ecologic considerations. Azad AF, et al. **Emerg Infect Dis** 1997 Jul-Sep;3(3):319-27 (27 ref.)

VETERINARY

The rickettsia: an emerging group of pathogens in fish. Fryer JL, et al. **Emerg Infect Dis** 1997 Apr-Jun;3(2):137-44 (34 ref.)

RICKETTSIA PROWAZEKII

PHYSIOLOGY

[The ecology of Rickettsia prowazekii] Lukin EP. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Jan-Feb; (1):88-91 (50 ref.) **(Rus)**

RICKETTSIA QUINTANA see **BARTONELLA QUINTANA**

RICKETTSIA TSUTSUGAMUSHI

PATHOGENICITY

[Symbiotic relationship between Orientia tsutsugamushi and vector mites] Urakami H, et al. **Nippon Saikingaku Zasshi** 1996 Feb;51(2):497-511 (78 ref.) **(Jpn)**

RICKETTSIACEAE INFECTIONS

DIAGNOSIS

Rickettsialpox. Boyd AS. **Dermatol Clin** 1997 Apr; 15(2):313-8 (26 ref.)

[Microbiological diagnosis of rickettsial infections] Cardeñosa N, et al. **Enferm Infecc Microbiol Clin** 1997 Jan;15(1):32-7 (56 ref.) **(Spa)**

RICKETTSIALES

IMMUNOLOGY

Immunization with bacterial antigens: piscirickettsiosis. Smith PA, et al. **Dev Biol Stand** 1997;90:161-6 (12 ref.)

RICKETTSIALES INFECTIONS

VETERINARY

Immunization with bacterial antigens: piscirickettsiosis. Smith PA, et al. **Dev Biol Stand** 1997;90:161-6 (12 ref.)

RICKETTSIALPOX see **RICKETTSIACEAE INFECTIONS**

RIDA see **SCRAPIE**

RIFABUTIN

ADVERSE EFFECTS

Uveitis associated with rifabutin therapy: a clinical alert. Petrowski JT 3rd. **J Am Optom Assoc** 1996 Nov; 67(11):693-6 (17 ref.)

PHARMACOKINETICS

Inducing properties of rifabutin, and effects on the pharmacokinetics and metabolism of concomitant drugs. Benedetti MS. **Pharmacol Res** 1995 Oct;32(4):177-87 (48 ref.)

THERAPEUTIC USE

Against the proposition: all patients with advanced HIV disease should be offered rifabutin prophylaxis. Pozniak A, et al. **Genitourin Med** 1996 Aug;72(4):269-71 (14 ref.)

Is rifabutin prophylaxis against Mycobacterium avium complex infection in HIV infection worthwhile? The net impact on patients suggests not. Stephenson JM, et al. **Genitourin Med** 1996 Aug;72(4):272-6 (10 ref.)

The use of rifabutin in Europe for the treatment of mycobacterial infection in AIDS patients. Dautzenberg B. **Infection** 1997 Jan-Feb;25(1):63-6 (16 ref.)

Clinical experience with rifabutin in the treatment of mycobacterial infections. De Cian W, et al. **Scand J Infect Dis Suppl** 1995;98:22-6 (28 ref.)

[Rifabutin--a new antituberculous antibiotic] **Antibiot Khimioter** 1997;42(5):47-8 (13 ref.) **(Rus)**

RIFAMPICIN see **RIFAMPIN**

RIFAMPIN

ADVERSE EFFECTS

Delayed onset of pseudomembranous colitis after rifampin therapy. Byrd RP Jr, et al. **South Med J** 1997 Jun; 90(6):644-6 (18 ref.)

[Fulminant hepatitis during the therapy for tuberculous meningitis] Garavelli PL. **Recenti Prog Med** 1996 Dec; 87(12):597 (8 ref.) **(Ita)**

PHARMACOLOGY

Inability to attain oral anticoagulation: warfarin-rifampin interaction revisited. Casner PR. **South Med J** 1996 Dec; 89(12):1200-3 (21 ref.)

THERAPEUTIC USE

Mycobacterium szulgai infection of the lung: case report and review of an unusual pathogen. Benator DA, et al. **Am J Med Sci** 1997 Jun;313(6):346-51 (25 ref.)

The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: current antibiotic therapy in the 1990s. Bradley JS, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S213-21 (58 ref.)

Epidemiology, control and treatment of multidrug-resistant tuberculosis. Chaulet P, et al. **Drugs** 1996;52 Suppl 2:103-7; discussion 107-8 (17 ref.)

RIFLES see **FIREARMS**

RIGHT HEART BYPASS see **HEART BYPASS, RIGHT**

RIGHT TO DIE

see related
SUICIDE, ASSISTED

Constitutional aspects of physician-assisted suicide after Lee v. Oregon. Canick SM. **Am J Law Med** 1997;23(1):69-96 (251 ref.)

Utility and the principle of medical futility: safeguarding autonomy and the prohibition against cruel and unusual punishment [published erratum appears in J Contemp Health Law Policy 1996 Spring;12(2):following table of contents] Smith GP 2nd. **J Contemp Health Law Policy** 1995 Fall;12(1):1-39 (178 ref.)

Death with dignity. End-of-life issues for the HIV/AIDS patient. Evangelisto M. **J Psychosoc Nurs Ment Health Serv** 1996 Jun;34(6):45-7 (4 ref.)

Dignified death: a German perspective. Mundt C. **Psychiatry Clin Neurosci** 1995 May;49 Suppl 1:S149-54 (30 ref.)

Death with dignity in the Japanese culture. Nakagawa Y. **Psychiatry Clin Neurosci** 1995 May;49 Suppl 1:S161-3 (2 ref.)

Ethical orientations and dignified death. Ohi G. **Psychiatry Clin Neurosci** 1995 May;49 Suppl 1:S155-9 (16 ref.)

An ethical analysis of end-of-life decision-making: can the pediatrician's approach to the never-capacitated and the internist's approach to the formerly-capacitated be mutually enhancing? Fleischman AR. **Trans Am Clin Climatol Assoc** 1996;108:222-31; discussion 231-2 (29 ref.)

When patients ask about assisted suicide. A viewpoint from Oregon. Lee MA, et al. **West J Med** 1996 Oct;165(4):205-8 (23 ref.)

LEGISLATION & JURISPRUDENCE

Assisted suicide and euthanasia: what about the clinical issues? [see comments] Kelly BJ, et al. **Aust N Z J Psychiatry** 1996 Feb;30(1):3-8 (34 ref.) Comment in: Aust N Z J Psychiatry 1996 Aug;30(4):557-8.

It's my body and I'll die if I want to: a property-based argument in support of assisted suicide. Friedman RF. **J Contemp Health Law Policy** 1995 Fall;12(1):183-213 (210 ref.)

RIGHT TO TREATMENT see **PATIENT ADVOCACY**

RIGHT VENTRICULAR DYSFUNCTION see **VENTRICULAR DYSFUNCTION, RIGHT**

RIGHT VENTRICULAR FUNCTION see **VENTRICULAR FUNCTION, RIGHT**

RIGHT VENTRICULAR HYPERTROPHY see **HYPERTROPHY, RIGHT VENTRICULAR**

RIGIDITY, DECEREBRATE see **DECEREBRATE STATE**

RIMANTADINE

THERAPEUTIC USE

Use of antivirals in influenza in the elderly: prophylaxis and therapy. Nicholson KG. **Gerontology** 1996;42(5):280–9 (55 ref.)

Influenza, influenza vaccine, and amantadine/rimantadine. Zimmerman RK, et al. **J Fam Pract** 1997 Aug;45(2):107–22; quiz 123–4 (44 ref.)

RINDERPEST VIRUS

IMMUNOLOGY

Stabilization of rinderpest vaccine by modification of the lyophilization process. House JA, et al. **Dev Biol Stand** 1996;87:235–44 (23 ref.)

RING CHROMOSOMES

Familial ring (19) chromosome mosaicism: case report and review. Flejter WL, et al. **Am J Med Genet** 1996 Dec 18; 66(3):276–80 (11 ref.)

Leiomyoma of uterus in a patient with ring chromosome 12: case presentation and literature review. Hajianpour MJ, et al. **Am J Med Genet** 1996 May 17;63(2):335–9 (12 ref.)

Ring chromosome X in a child with manifestations of Kabuki syndrome. McGinniss MJ, et al. **Am J Med Genet** 1997 May 2;70(1):37–42 (34 ref.)

Ring chromosome 20 and nonconvulsive status epilepticus. A new epileptic syndrome. Inoue Y, et al. **Brain** 1997 Jun; 120 (Pt 6):939–53 (38 ref.)

Ring chromosome 22 and mood disorders. Sovner R, et al. **J Intellect Disabil Res** 1996 Feb;40 (Pt 1):82–6 (8 ref.)

Prenatal diagnosis of ring chromosome 6 in a fetus with hydrocephalus. Walker ME, et al. **Prenat Diagn** 1996 Sep; 16(9):857–61 (26 ref.)

RING CONSTRICTIONS, INTRAUTERINE see **AMNIOTIC BAND SYNDROME**

RINGWORM see **TINEA**

RIOTS

see related
VIOLENCE

RISK

Risk communication; the patient's view. Thornton JG, et al. **Early Hum Dev** 1996 Dec 30;47 Suppl:S13–7 (17 ref.)

[Risk as a concept and a challenge in health care] Graff-Iversen S. **Tidsskr Nor Laegeforen** 1996 Sep 20; 116(22):2669–72 (32 ref.) (Eng. Abstr.) **(Nor)**

[Risk as a concept and challenge in health care] Skolbekken JA. **Tidsskr Nor Laegeforen** 1996 Sep 20;116(22):2673–6 (30 ref.) (Eng. Abstr.) **(Nor)**

RISK ASSESSMENT

Human GSH-transferase in risk assessment. Bolt HM. **Adv Exp Med Biol** 1996;387:405–9 (28 ref.)

The use of data on biologically reactive intermediates in risk assessment. Buchanan JR, et al. **Adv Exp Med Biol** 1996; 387:429–37 (19 ref.)

Role of molecular biology in risk assessment. Puga A, et al. **Adv Exp Med Biol** 1996;387:395–404 (46 ref.)

An overview of the risk assessment of hazardous materials and the role of toxicology. Mattie DR. **Ann Clin Lab Sci** 1997 May-Jun;27(3):173–8 (3 ref.)

The correction of risk estimates for measurement error. Bashir SA, et al. **Ann Epidemiol** 1997 Feb;7(2):154–64 (34 ref.)

Ecotoxicology for risk assessment in arid zones: some key issues. Everts JW. **Arch Environ Contam Toxicol** 1997 Jan; 32(1):1–10 (123 ref.)

The environmental experience: ecosystem protection. Bro-Rasmussen F. **Arch Toxicol Suppl** 1997;19:155–66 (17 ref.)

The identification of thresholds of acceptability and danger: the biological route. Tarazona JV. **Arch Toxicol Suppl** 1997; 19:137–46 (17 ref.)

The application of quantitative risk assessment to microbial food safety risks. Jaykus LA. **Crit Rev Microbiol** 1996; 22(4):279–93 (48 ref.)

Risk assessment and exposure control in an occupational setting. Packham CL. **Curr Probl Dermatol** 1996;25:133–44 (0 ref.)

Predictive testing of metalworking fluids and development of contact dermatitis in metalworkers. Wigger-Alberti W, et al. **Curr Probl Dermatol** 1996;25:106–15 (35 ref.)

Switching between cyclosporin formulations. What are the risks? Olyaei AJ, et al. **Drug Saf** 1997 Jun;16(6):366–73 (44 ref.)

Research needs for the risk assessment of health and environmental effects of endocrine disruptors: a report of the U.S. EPA-sponsored workshop. Kavlock RJ, et al. **Environ Health Perspect** 1996 Aug;104 Suppl 4:715–40 (193 ref.)

Acetylation as an indicator of risk. Lang NP. **Environ Health Perspect** 1997 Jun;105 Suppl 4:763–6 (44 ref.)

Reactivity parameters in structure-activity relationship-based risk assessment of chemicals. McKinney JD. **Environ Health Perspect** 1996 Aug;104(8):810–6 (44 ref.)

Supraventricular tachycardia. Occasional nuisance or frequent threat? Campbell RW. **Eur Heart J** 1996 Jul;17 Suppl C:21–5 (33 ref.)

Risk assessment of mixtures and standard setting: working towards practical compromises. Bolt HM, et al. **Food Chem Toxicol** 1996 Nov-Dec;34(11–12):1179–81 (16 ref.)

Surgical risk assessment and management in patients with HIV disease. Harris HW, et al. **Gastroenterol Clin North Am** 1997 Jun;26(2):377–91 (38 ref.)

Risk and cause in medical science. Kumar R, et al. **Indian Pediatr** 1995 Sep;32(9):1031–5 (5 ref.)

Developments in microbiological risk assessment models for drinking water—a short review. Gale P. **J Appl Bacteriol** 1996 Oct;81(4):403–10 (27 ref.)

Risk assessment in dentistry: health risks of dental amalgam revisited. Choi BC. **J Can Dent Assoc** 1996 Apr; 62(4):328–32 (28 ref.)

Anesthesia information-management systems: their role in risk-versus cost assessment and outcomes research. Gibby GL. **J Cardiothorac Vasc Anesth** 1997 Apr;11(2 Suppl 1):2–5; discussion 24–5 (22 ref.)

Risk assessment in patients with stable coronary artery disease: incremental value of nuclear imaging. Berman DS, et al. **J Nucl Cardiol** 1996 Nov-Dec;3(6 Pt 2):S41–9 (11 ref.)

Risk assessment after myocardial infarction: have the rules changed with thrombolytic therapy?. Verani MS. **J Nucl Cardiol** 1996 Nov-Dec;3(6 Pt 2):S50–9 (20 ref.)

Future approaches to genetic toxicology risk assessment. Elespuru RK. **Mutat Res** 1996 Sep;365(1–3):191–204 (100 ref.)

Basic occupational epidemiologic measures. Marsh GM. **Occup Med** 1996 Jul-Sep;11(3):421–31 (34 ref.)

Validation issues for the use of transgenic mouse mutation assays in risk assessment. Gorelick NJ. **Prog Clin Biol Res** 1996;395:81–108 (85 ref.)

Genetic variation in susceptibility as a key parameter in risk assessment and risk communication: policy aspects. Omenn GS. **Prog Clin Biol Res** 1996;395:235–47 (37 ref.)

Risk appraisal and management of violent behavior. Harris GT, et al. **Psychiatr Serv** 1997 Sep;48(9):1168–76 (132 ref.)

Toxicological considerations in environmental audit studies. Jaffery FN, et al. **Qual Assur** 1997 Jan-Mar;5(1):19–26 (7 ref.)

A new approach to risk assessment integrating scientific evaluation and economic assessment of costs and benefits. Barnard RC. **Regul Toxicol Pharmacol** 1996 Oct;24(2 Pt 1):121–5 (7 ref.)

Cancer risk assessment at the crossroads: the need to turn to a biological approach. Clayson DB, et al. **Regul Toxicol Pharmacol** 1996 Aug;24(1 Pt 1):45–59 (112 ref.)

Evolution of science-based uncertainty factors in noncancer risk assessment [see comments] Dourson ML, et al. **Regul Toxicol Pharmacol** 1996 Oct;24(2 Pt 1):108–20 (62 ref.) Comment in: Regul Toxicol Pharmacol 1996 Oct;24(2 Pt 1):107.

Hexavalent chromium-contaminated soils: options for risk assessment and risk management. Felter SP, et al. **Regul Toxicol Pharmacol** 1997 Feb;25(1):43–59 (65 ref.)

Science, imaginable risks, and public policy: anatomy of a mirage. Gori GB. **Regul Toxicol Pharmacol** 1996 Jun; 23(3):304–11 (41 ref.)

Environmental risk harmonization: federal/state approaches to risk assessment and management. Kamrin MA. **Regul Toxicol Pharmacol** 1997 Apr;25(2):158–65 (16 ref.)

Mortality from tobacco in developed countries: are indirect estimates reliable? Lee PN. **Regul Toxicol Pharmacol** 1996 Aug;24(1 Pt 1):60–8 (25 ref.)

Analysis of diesel-exhaust unit-risk estimates derived from animal bioassays. Valberg PA, et al. **Regul Toxicol Pharmacol** 1996 Aug;24(1 Pt 1):30–44 (58 ref.)

A mechanistic interpretation of the oncogenicity of chlorothalonil in rodents and an assessment of human relevance. Wilkinson CF, et al. **Regul Toxicol Pharmacol** 1996 Aug;24(1 Pt 1):69–84 (94 ref.)

Advances in understanding mechanisms of toxicity and implications for risk assessment. Daston GP. **Reprod Toxicol** 1997 Mar-Jun;11(2–3):389–96 (48 ref.)

Recent advances in mathematical modeling of developmental abnormalities using mechanistic information. Kavlock RJ. **Reprod Toxicol** 1997 Mar-Jun;11(2–3):423–34 (86 ref.)

A perspective on the risk assessment process for endocrine-disruptive effects on wildlife and human health. Kavlock RJ, et al. **Risk Anal** 1996 Dec;16(6):731–9 (65 ref.)

Quantification of historical exposures in occupational cohort studies [see comments] Stewart PA, et al. **Scand J Work Environ Health** 1996 Dec;22(6):405–14 (42 ref.) Comment in: Scand J Work Environ Health 1996 Dec;22(6):401–3.

Selected issues in quality improvement and risk management. Chapman AH, et al. **Semin Oncol Nurs** 1996 Aug; 12(3):231–7 (20 ref.)

Combining qualitative and quantitative approaches to assessing impacts of environments on human health and well-being in local community studies. Cole DC, et al. **Toxicol Ind Health** 1997 Mar-Jun;13(2–3):259–65 (25 ref.)

Review of risk assessments on 1,3-butadiene (1985–1991). Cagen SZ, et al. **Toxicology** 1996 Oct 28;113(1–3):215–20 (17 ref.)

A database designed to support dose-response analysis and risk assessment. Guth DJ, et al. **Toxicology** 1996 Nov 15; 114(1):81–90 (26 ref.)

Future research needs for non-cancer and cancer effects among populations exposed to 1,3-butadiene. Koppikar AM. **Toxicology** 1996 Oct 28;113(1–3):203–9 (43 ref.)

Risk formulas in calcium oxalate urolithiasis. Tiselius HG. **World J Urol** 1997;15(3):176–85 (50 ref.)

[Risk as a concept and a challenge in health care] Graff-Iversen S. **Tidsskr Nor Laegeforen** 1996 Sep 20; 116(22):2669–72 (32 ref.) (Eng. Abstr.) **(Nor)**

[Risk as a concept and challenge in health care] Skolbekken JA. **Tidsskr Nor Laegeforen** 1996 Sep 20;116(22):2673–6 (30 ref.) (Eng. Abstr.) **(Nor)**

RISK BEHAVIOR see **RISK-TAKING**

RISK FACTORS

Prediction of fracture risk. II: Other risk factors. Ross PD. **Am J Med Sci** 1996 Dec;312(6):260–9 (172 ref.)

[Fetal megalosomia: clinical and prognostic value of main risk factors] Rech F, et al. **Minerva Ginecol** 1995 Nov; 47(11):487–98 (44 ref.) (Eng. Abstr.) **(Ita)**

RISK MANAGEMENT

Pap smear risk management by process control. Gill GW. **Cancer** 1997 Aug 25;81(4):198–211 (52 ref.)

Nevada's elderly: nutrition screening, risk, and interventions. Wilson D, et al. **Nutr Rev** 1996 Jan;54(1 Pt 2):S45–7 (12 ref.)

Risk management in transfusion medicine. Isbister JP. **Transfus Med Rev** 1996 Jul;10(3):183–202 (42 ref.)

Meat inspection: an overview of present practices and future trends. Edwards DS, et al. **Vet J** 1997 Sep;154(2):135–47 (78 ref.)

LEGISLATION & JURISPRUDENCE

Hazard communication: challenges in the pharmaceutical industry. Hayes EP. **Occup Med** 1997 Jan-Mar; 12(1):95–105 (7 ref.)

Risk management issues in the new managed care environment. Bettman JW, et al. **Surv Ophthalmol** 1996 Nov-Dec;41(3):268–70 (6 ref.)

METHODS

Risk management issues in long-term care. Weinberg AD. **Compr Ther** 1996 May;22(5):311–7 (17 ref.)

The chlorine controversy. Cap AP. **Int Arch Occup Environ Health** 1996;68(6):455–8 (19 ref.)

Risk management in allergen immunotherapy. Greineder DK. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 3):S330–4 (24 ref.)

Suicide risk factors among veterans: risk management in the changing culture of the Department of Veterans Affairs. Lambert MT, et al. **J Ment Health Adm** 1997 Summer; 24(3):350–8 (50 ref.)

Workplace violence: preventive and interventive strategies. Warshaw LJ, et al. **J Occup Environ Med** 1996 Oct; 38(10):993–1006 (53 ref.)

De-escalating verbal aggression in primary care settings. Anderson LN, et al. **Nurse Pract** 1996 Oct;21(10):95, 98, 101–2, passim (30 ref.)

Occupational toxicology: test methods and approaches for the pharmaceutical industry. Sprague G, et al. **Occup Med** 1997 Jan-Mar;12(1):119–29 (13 ref.)

The need for policy and risk analysis—the Department of Energy experience. Henry CJ, et al. **Toxicol Pathol** 1997 Jan-Feb;25(1):27–31 (11 ref.)

Sustainable improvement of animal health care by systematic quality risk management according to the HACCP concept. Noordhuizen JP, et al. **Vet Q** 1996 Dec;18(4):121–6 (32 ref.)

ORGANIZATION & ADMINISTRATION

Is clinical practice improved by risk management? Bowden D. **J Eval Clin Pract** 1995 Sep;1(1):77–9 (3 ref.)

STANDARDS

Raising food hygiene standards—could customer power and the new laws hold the key? Leach JC. **J R Soc Health** 1996 Dec;116(6):351–5 (36 ref.)

RISK-TAKING

Behavioural feedback to risk variation ensues from unsatisfied appetency. Dussault C. **Accid Anal Prev** 1996 Jul; 28(4):477–86 (20 ref.)

The acquisition of life skills through adventure-based activities and programs: a review of the literature. Moote GT Jr, et al. **Adolescence** 1997 Spring;32(125):143–67 (102 ref.)

Role of HIV counseling and testing in changing risk behavior in developing countries. De Zoysa I, et al. **AIDS** 1995;9

RISK-TAKING

Suppl A:S95-101 (47 ref.)
Social and behavioral issues in phase III HIV preventive vaccine trials. Grinstead OA. **AIDS** 1995;9 Suppl A:S245-50 (32 ref.)
Risk-taking behavior in adolescents: the paradigm. Irwin CE Jr, et al. **Ann N Y Acad Sci** 1997 May 28;817:1-35 (139 ref.)
Unhealthy eating and other risk-taking behavior: are they related? Lytle LA, et al. **Ann N Y Acad Sci** 1997 May 28;817:49-65 (31 ref.)
The risk society in an age of anxiety: situating fear of crime. Hollway W, et al. **Br J Sociol** 1997 Jun;48(2):255-66 (15 ref.)
Adolescent alcohol use: social determinants and the case for early family-centered prevention. Family-focused prevention of adolescent drinking. Schor EL. **Bull N Y Acad Med** 1996 Winter;73(2):335-56 (86 ref.)
Rethinking perceived risk and health behavior: a critical review of HIV prevention research. Kowalewski MR, et al. **Health Educ Behav** 1997 Jun;24(3):313-25 (101 ref.)
HIV epidemiology and interventions among injecting drug users. Des Jarlais DC, et al. **Int J STD AIDS** 1996;7 Suppl 2:57-61 (35 ref.)
Interventions for homeless men and women with mental illness: reducing sexual risk behaviours for HIV. Susser E, et al. **Int J STD AIDS** 1996;7 Suppl 2:66-70 (28 ref.)
Relationship of alcohol use and risky sexual behavior: a review and analysis of findings. Halpern-Felsher BL, et al. **J Adolesc Health** 1996 Nov;19(5):331-6 (42 ref.)
Changing concepts of allergic disease: the attempt to keep up with real changes in lifestyles. Platts-Mills TA, et al. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 3):S297-306 (75 ref.)
Personal risk taking and the spread of disease: beyond core groups. Rothenberg RB, et al. **J Infect Dis** 1996 Oct;174 Suppl 2:S144-9 (36 ref.)
Bridging student health risks and academic achievement through comprehensive school health programs. Symons CW, et al. **J Sch Health** 1997 Aug;67(6):220-7 (73 ref.)
Recent developments in an animal model of visual evoked potential augmenting/reducing and sensation seeking behavior. Siegel J, et al. **Neuropsychobiology** 1996; 34(3):130-5 (38 ref.)

RISPERIDONE

ADMINISTRATION & DOSAGE

Use of novel antipsychotic drugs. Raleigh F. **Pharmacotherapy** 1996 Nov-Dec;16(6 Pt 2):160S-165S; discussion 166S-168S (20 ref.)

ADVERSE EFFECTS

Risperidone-induced neuroleptic malignant syndrome: a case report and review. Meterissian GB. **Can J Psychiatry** 1996 Feb;41(1):52-4 (9 ref.)
Side effect profiles of new antipsychotic agents. Casey DE. **J Clin Psychiatry** 1996;57 Suppl 11:40-5; discussion 46-52 (30 ref.)
Development and implementation of drug use evaluation (DUE) criteria for risperidone in an outpatient psychiatric setting. Shepski JC, et al. **Psychopharmacol Bull** 1996; 32(4):705-19 (45 ref.)

THERAPEUTIC USE

Treatment of schizophrenia: advances during the decade of the brain. Buckley PF. **Br J Hosp Med** 1996 Dec 11-1997 Jan 14;56(11):574-80 (31 ref.)
Schizophrenia, violence, clozapine and risperidone: a review. The Special Hospitals Treatment Resistant Schizophrenia Research Group. **Br J Psychiatry Suppl** 1996 Dec; (31):21-30 (60 ref.)
Changing antipsychotic medication: guidelines on the transition to treatment with risperidone. The Consensus Study Group on Risperidone Dosing. Borison RL. **Clin Ther** 1996 Jul-Aug;18(4):592-607; discussion 591 (42 ref.)
New antipsychotic medications: what advantages do they offer? Citrome L. **Postgrad Med** 1997 Feb;101(2):207-10, 213-4 (19 ref.)
Development and implementation of drug use evaluation (DUE) criteria for risperidone in an outpatient psychiatric setting. Shepski JC, et al. **Psychopharmacol Bull** 1996; 32(4):705-19 (45 ref.)
Risperidone: how good is the evidence for efficacy? Mattes JA. **Schizophr Bull** 1997;23(1):155-61 (36 ref.)

RITANSERIN

PHARMACOLOGY

Ritanserin and alcohol abuse and dependence. Meert TF. **Alcohol Alcohol Suppl** 1994;2:523-30 (33 ref.)

RITODRINE

ADVERSE EFFECTS

Ritodrine-induced leukopenia: a case report and literature review. Wu CD, et al. **Chang Keng I Hsueh** 1996 Dec; 19(4):388-91 (7 ref.)
[Maternal complications from tocolytic treatment with beta-mimetics. Three cases of pulmonary edema] Hourdequin P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(5):528-32 (21 ref.) (Eng. Abstr.) **(Fre)**

RITONAVIR

PHARMACOLOGY

HIV protease inhibitors. Carr A, et al. **AIDS** 1996;10 Suppl A:S151-7 (51 ref.)
Ritonavir. Lea AP, et al. **Drugs** 1996 Oct;52(4):541-6; discussion 547-8 (37 ref.)

RITTER DISEASE see **STAPHYLOCOCCAL SCALDED SKIN SYNDROME**

RNA

see related
REPETITIVE SEQUENCES, NUCLEIC ACID

Chromatin structure and function: the heretical path to an RNA transcription factor. Krause MO. **Biochem Cell Biol** 1996;74(5):623-32 (91 ref.)
Processing of human mitochondrial tRNA(Ser(AGY))GCU: a novel pathway in tRNA biosynthesis. Rossmanith W. **J Mol Biol** 1997 Jan 31;265(4):365-71 (26 ref.)
Functional importance of RNA interactions in selection of translation initiation codons. Sprengart ML, et al. **Mol Microbiol** 1997 Apr;24(1):19-28 (57 ref.)

ANALYSIS

Technical aspects of quantitative competitive PCR. Zimmermann K, et al. **Biotechniques** 1996 Aug; 21(2):268-72, 274-9 (110 ref.)
Quantification of nucleic acids. Killeen AA. **Clin Lab Med** 1997 Mar;17(1):1-19 (109 ref.)
RNA molecules lighting up under the microscope. Dirks RW. **Histochem Cell Biol** 1996 Aug;106(2):151-66 (104 ref.)
Cytochemical detection systems for in situ hybridization, and the combination with immunocytochemistry, 'who is still afraid of red, green and blue?' Speel EJ, et al. **Histochem J** 1995 Nov;27(11):833-58 (212 ref.)
Multifunctional compartments in the nucleus: insights from DNA and RNA localization. Clemson CM, et al. **J Cell Biochem** 1996 Aug;62(2):181-90 (68 ref.)

BIOSYNTHESIS

Killing two birds with one stone: a chemically plausible scheme for linked nucleic acid replication and coded peptide synthesis. Sutherland JD, et al. **Chem Biol** 1997 Jul;4(7):481-8 (17 ref.)
Nuclear domains involved in RNA synthesis, RNA processing, and replication. de Jong L, et al. **Crit Rev Eukaryot Gene Expr** 1996;6(2-3):215-46 (208 ref.)

BLOOD

[The role of nucleic homeostasis in different pathological states of the human body] Andriiuk LV. **Lik Sprava** 1996 Mar-Apr;(3-4):3-6 (28 ref.) **(Ukr)**

CHEMISTRY

Hierarchy and dynamics of RNA folding. Brion P, et al. **Annu Rev Biophys Biomol Struct** 1997;26:113-37 (118 ref.)
Flexibility of RNA. Hagerman PJ. **Annu Rev Biophys Biomol Struct** 1997;26:139-56 (64 ref.)
Facilitators of RNA-RNA annealing: implications for the catalytic cycle of hammerhead ribozymes. Nedbal W, et al. **Biochem Soc Trans** 1996 Aug;24(3):615-8 (17 ref.)
Molecular palaeontology: understanding catalytic mechanisms in the RNA world by excavating clues from a ribozyme three-dimensional structure. Scott WG. **Biochem Soc Trans** 1996 Aug;24(3):604-8 (14 ref.)
RNA crystallography. Holbrook SR, et al. **Biopolymers** 1997; 44(1):3-21 (100 ref.)
RNA structure comes of age. Uhlenbeck OC, et al. **Cell** 1997 Sep 5;90(5):833-40 (46 ref.)
Aptamer structures from A to zeta. Feigon J, et al. **Chem Biol** 1996 Aug;3(8):611-7 (36 ref.)
RNA surfaces as functional mimetics of proteins. Keene JD. **Chem Biol** 1996 Jul;3(7):505-13 (39 ref.)
Quantitative nucleic acids footprinting: thermodynamic and kinetic approaches. Petri V, et al. **Curr Opin Biotechnol** 1997 Feb;8(1):36-44 (79 ref.)
RNA structure: crystal clear? Doudna JA, et al. **Curr Opin Struct Biol** 1997 Jun;7(3):310-6 (62 ref.)
Hammering away at RNA global structure. Hagerman PJ, et al. **Curr Opin Struct Biol** 1996 Jun;6(3):317-21 (21 ref.)
Fluorescence studies of DNA and RNA structure and dynamics. Millar DP. **Curr Opin Struct Biol** 1996 Jun; 6(3):322-6 (38 ref.)
Recent solution structures of RNA and its complexes with drugs, peptides and proteins. Ramos A, et al. **Curr Opin Struct Biol** 1997 Jun;7(3):317-23 (59 ref.)
Protein-facilitated RNA folding. Weeks KM. **Curr Opin Struct Biol** 1997 Jun;7(3):336-42 (58 ref.)
Nucleic acids. From self-assembly to induced-fit recognition [editorial] Westhof E, et al. **Curr Opin Struct Biol** 1997 Jun;7(3):305-9 (19 ref.)
RNA tectonics: towards RNA design. Westhof E, et al. **Fold Des** 1996;1(4):R78-88 (97 ref.)
In vitro selection methodologies to probe RNA function and structure. Conrad RC, et al. **Mol Divers** 1995 Sep; 1(1):69-78 (50 ref.)
Through a magnet, clearly [editorial; comment] **Nat Struct Biol** 1997 Mar;4(3):159-60 (12 ref.) Comment on: Nat Struct Biol 1997 Mar;4(3):167-9.
Mirror symmetry breaking at the molecular level. Avetisov V, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15; 93(21):11435-42 (59 ref.)
From oligonucleotide shapes to genomic SELEX: novel biological regulatory loops. Gold L, et al. **Proc Natl Acad Sci U S A** 1997 Jan 7;94(1):59-64 (42 ref.)
Mismatch base pairs in RNA. Limmer S. **Prog Nucleic Acid Res Mol Biol** 1997;57:1-39 (129 ref.)
Optical evanescent wave methods for the study of biomolecular interactions. Garland PB. **Q Rev Biophys** 1996 Feb;29(1):91-117 (80 ref.)
Ribozymes: structure and mechanism in RNA catalysis. Scott WG, et al. **Trends Biochem Sci** 1996 Jun;21(6):220-4 (31 ref.)
RNA seeing double: close-packing of helices in RNA tertiary structure. Strobel SA, et al. **Trends Biochem Sci** 1997 Jul; 22(7):262-6 (49 ref.)

DRUG EFFECTS

Psoralen photosensitization: damages to nucleic acid and membrane lipid components. Caffieri S, et al. **Acta Biochim Pol** 1996;43(1):241-6 (31 ref.)

GENETICS

Anti-oncogene ribozymes for cancer gene therapy. Irie A, et al. **Adv Pharmacol** 1997;40:207-57 (350 ref.)
RNA-RNA interaction and gene splicing. Verma M, et al. **Cancer Biochem Biophys** 1997 Jun;15(4):211-20 (65 ref.)
Proteome research: complementarity and limitations with respect to the RNA and DNA worlds. Humphery-Smith I, et al. **Electrophoresis** 1997 Aug;18(8):1217-42 (321 ref.)
RNA in spermatozoa: implications for the alternative haploid genome. Kramer JA, et al. **Mol Hum Reprod** 1997 Jun; 3(6):473-8 (58 ref.)
RNA fingerprinting by arbitrarily primed PCR. McClelland M, et al. **PCR Methods Appl** 1994 Aug;4(1):S66-81 (33 ref.)

IMMUNOLOGY

RNA recognition by autoantigens and autoantibodies. Keene JD. **Mol Biol Rep** 1996;23(3-4):173-81 (63 ref.)

METABOLISM

Facilitators of RNA-RNA annealing: implications for the catalytic cycle of hammerhead ribozymes. Nedbal W, et al. **Biochem Soc Trans** 1996 Aug;24(3):615-8 (17 ref.)
Molecular palaeontology: understanding catalytic mechanisms in the RNA world by excavating clues from a ribozyme three-dimensional structure. Scott WG. **Biochem Soc Trans** 1996 Aug;24(3):604-8 (14 ref.)
RNAs mediating cotranslational insertion of selenocysteine in eukaryotic selenoproteins. Hubert N, et al. **Biochimie** 1996;78(7):590-6 (40 ref.)
Targeting RNA structures by antisense oligonucleotides. Toulmé JJ, et al. **Biochimie** 1996;78(7):663-73 (85 ref.)
RNA-RNA interaction and gene splicing. Verma M, et al. **Cancer Biochem Biophys** 1997 Jun;15(4):211-20 (65 ref.)
Nuclear domains involved in RNA synthesis, RNA processing, and replication. de Jong L, et al. **Crit Rev Eukaryot Gene Expr** 1996;6(2-3):215-46 (208 ref.)
RNA turnover: the helicase story unwinds. Anderson JS, et al. **Curr Biol** 1996 Jul 1;6(7):780-2 (16 ref.)
Macromolecular complexes: how RNA and protein get together. Woodson SA. **Curr Biol** 1996 Jan 1;6(1):23-5 (9 ref.)
Nuclear export of proteins and RNAs. Nakielny S, et al. **Curr Opin Cell Biol** 1997 Jun;9(3):420-9 (81 ref.)
RNA localization and the development of asymmetry during Drosophila oogenesis. Grünert S, et al. **Curr Opin Genet Dev** 1996 Aug;6(4):395-402 (59 ref.)
Recent solution structures of RNA and its complexes with drugs, peptides and proteins. Ramos A, et al. **Curr Opin Struct Biol** 1997 Jun;7(3):317-23 (59 ref.)
Protein-facilitated RNA folding. Weeks KM. **Curr Opin Struct Biol** 1997 Jun;7(3):336-42 (58 ref.)
Nucleic acids. From self-assembly to induced-fit recognition [editorial] Westhof E, et al. **Curr Opin Struct Biol** 1997 Jun;7(3):305-9 (19 ref.)
Molecular basis for cytoplasmic localization. King ML. **Dev Genet** 1996;19(3):183-9 (85 ref.)
The localization of sites containing nascent RNA and splicing factors. Pombo A, et al. **Exp Cell Res** 1996 Dec 15; 229(2):201-3 (14 ref.)
Nucleocytoplasmic transport of macromolecules. Corbett AH, et al. **Microbiol Mol Biol Rev** 1997 Jun;61(2):193-211 (282 ref.)
In vitro selection methodologies to probe RNA function and structure. Conrad RC, et al. **Mol Divers** 1995 Sep; 1(1):69-78 (50 ref.)
RNA in spermatozoa: implications for the alternative haploid genome. Kramer JA, et al. **Mol Hum Reprod** 1997 Jun; 3(6):473-8 (58 ref.)
Plant pathogenic RNAs and RNA catalysis. Symons RH. **Nucleic Acids Res** 1997 Jul 15;25(14):2683-9 (71 ref.)

RNase L: effector nuclease of an activatable RNA degradation system in mammals. Bisbal C. **Prog Mol Subcell Biol** 1997;18:19–34 (87 ref.)
Interaction between iron–regulatory proteins and their RNA target sequences, iron–responsive elements. Henderson BR, et al. **Prog Mol Subcell Biol** 1997;18:117–39 (115 ref.)
How Tat targets TAR: structure of the BIV peptide–RNA complex. Greenbaum NL. **Structure** 1996 Jan 15;4(1):5–9 (18 ref.)
A biopolymer by any other name would bind as well: a comparison of the ligand–binding pockets of nucleic acids and proteins. Marshall KA, et al. **Structure** 1997 Jun 15; 5(6):729–34 (29 ref.)
RNA turnover and the control of mitochondrial gene expression. Margossian SP, et al. **Trends Biochem Sci** 1996 Oct;21(10):392–6 (36 ref.)
RNA editing in kinetoplastid parasites: what to do with U. Sloof P, et al. **Trends Microbiol** 1997 May;5(5):189–95 (54 ref.)
[Phosphate sites of RNA–ligands interacting with ribosome at different stages of translation. Thiophosphate method of analysis] Dabrowski M, et al. **Biokhimiia** 1996 Nov; 61(11):1971–83 (38 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

RNA structure comes of age. Uhlenbeck OC, et al. **Cell** 1997 Sep 5;90(5):833–40 (46 ref.)
Function and synthesis of small nucleolar RNAs. Tollervey D, et al. **Curr Opin Cell Biol** 1997 Jun;9(3):337–42 (49 ref.)
[Visualized biomolecules as tools to explore cell function] Yuba S, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):915–9 (10 ref.) **(Jpn)**

ULTRASTRUCTURE

RNA structures and folding: from conventional to new issues in structure predictions. Schuster P, et al. **Curr Opin Struct Biol** 1997 Apr;7(2):229–35 (73 ref.)

RNA, ANTISENSE

In vitro and in vivo action of antisense RNA. Nellen W, et al. **Mol Biotechnol** 1996 Aug;6(1):7–15 (48 ref.)

CHEMISTRY

Natural antisense RNA/target RNA interactions: possible models for antisense oligonucleotide drug design. Delihas N, et al. **Nat Biotechnol** 1997 Aug;15(8):751–3 (55 ref.)

PHARMACOLOGY

Regulation of gene expression by natural antisense RNA transcripts. Knee R, et al. **Neurochem Int** 1997 Sep; 31(3):379–92 (122 ref.)

RNA, BACTERIAL

Bacterial reverse transcriptase and msDNA. Rice SA, et al. **Virus Genes** 1995;11(2–3):95–104 (54 ref.)
[Identification of eubacterial SRP RNA as a multifunctional molecule] Nakamura K, et al. **Seikagaku** 1997 Mar; 69(3):192–6 (15 ref.) **(Jpn)**

BIOSYNTHESIS

Mechanisms of primer RNA synthesis and D–loop/R–loop–dependent DNA replication in Escherichia coli. Masai H, et al. **Biochimie** 1996; 78(11–12):1109–17 (55 ref.)
Mutation in resting cells: the role of endogenous DNA damage. Bridges BA. **Cancer Surv** 1996;28:155–67 (47 ref.)

CHEMISTRY

Modeling the structure of the ribosome. Easterwood TR, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):751–6 (35 ref.)
Structure and function of 10Sa RNA: trans–translation system. Muto A, et al. **Biochimie** 1996;78(11–12):985–91 (41 ref.)
Recent approaches to probe functional groups in ribonuclease P RNA by modification interference. Hardt WD, et al. **Mol Biol Rep** 1995–96;22(2–3):161–9 (63 ref.)
Analysis of the tertiary structure of bacterial RNase P RNA. Harris ME, et al. **Mol Biol Rep** 1995–96;22(2–3):115–23 (50 ref.)
Early studies of native ribonuclease P, including discovery of its essential RNA component. Stark BC. **Mol Biol Rep** 1995–96;22(2–3):95–7 (14 ref.)
RNase P RNA of Mycoplasma capricolum. Ushida C, et al. **Mol Biol Rep** 1995–96;22(2–3):125–9 (28 ref.)

GENETICS

Evolution of bacterial genomes. Trevors JT. **Antonie Van Leeuwenhoek** 1997 Mar;71(3):265–70 (28 ref.)
Pleiotropic effects of mutations at positions 13 and 914 in Escherichia coli 16S ribosomal RNA. Brakier–Gingras L, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):907–13 (52 ref.)
Escherichia coli initiator tRNA: structure–function relationships and interactions with the translational machinery. Mangroo D, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1023–31 (51 ref.)
Preribosomal RNA processing in archaea: characterization of the RNP endonuclease mediated processing of precursor 16S rRNA in the thermoacidophile Sulfolobus acidocaldarius. Potter S, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):813–23 (31 ref.)
Comparison of functional peptide encoded in the Escherichia coli 23S rRNA with other peptides involved in cis–regulation of translation. Tenson T, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1061–70 (40 ref.)
Transfer RNA gene organization and RNase P. Green CJ. **Mol Biol Rep** 1995–96;22(2–3):181–5 (67 ref.)
[The 16S–23s rRNA intergenic spacer regions of mycoplasmas] Harasawa R. **Nippon Saikingaku Zasshi** 1996 Feb;51(2):583–8 (15 ref.) **(Jpn)**

METABOLISM

Evolution of bacterial genomes. Trevors JT. **Antonie Van Leeuwenhoek** 1997 Mar;71(3):265–70 (28 ref.)
Recognition determinants for proteins and antibiotics within 23S rRNA. Douthwalte S, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1179–85 (56 ref.)
tRNA–ribosome interactions. Ehrenberg M, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1049–54 (35 ref.)
Peptidyl transferase and beyond. Wower J, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1041–7 (45 ref.)
Structure and function of 10Sa RNA: trans–translation system. Muto A, et al. **Biochimie** 1996;78(11–12):985–91 (41 ref.)
Movement of the 3'–end of tRNA through the peptidyl transferase centre and its inhibition by antibiotics. Kirillov S, et al. **FEBS Lett** 1997 Apr 14;406(3):223–33 (165 ref.)
Polyadenylation of mRNA in bacteria. Sarkar N. **Microbiology** 1996 Nov;142 (Pt 11):3125–33 (80 ref.)
RNases in ColE1 DNA metabolism. Jung YH, et al. **Mol Biol Rep** 1995–96;22(2–3):195–200 (35 ref.)
RNase P RNA of Mycoplasma capricolum. Ushida C, et al. **Mol Biol Rep** 1995–96;22(2–3):125–9 (28 ref.)
The decay of bacterial messenger RNA. Nierlich DP, et al. **Prog Nucleic Acid Res Mol Biol** 1996;52:153–216 (298 ref.)

ULTRASTRUCTURE

Getting closer to an understanding of the three–dimensional structure of ribosomal RNA. Mueller F, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):767–73 (40 ref.)

RNA–BINDING PROTEINS

Iron regulatory proteins 1 and 2. Henderson BR. **Bioessays** 1996 Sep;18(9):739–46 (57 ref.)

CHEMISTRY

Structures of prokaryotic ribosomal proteins: implications for RNA binding and evolution. Ramakrishnan V, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):979–86 (30 ref.)
Getting into the major groove. Protein–RNA interactions. Moras D, et al. **Curr Biol** 1996 May 1;6(5):530–2 (15 ref.)

GENETICS

Fragile X syndrome in humans and mice. Oostra BA. **Acta Genet Med Gemellol (Roma)** 1996;45(1–2):93–108 (79 ref.)
Embryonic lethal abnormal visual RNA–binding proteins involved in growth, differentiation, and posttranscriptional gene expression. Antic D, et al. **Am J Hum Genet** 1997 Aug;61(2):273–8 (59 ref.)
A case of convergent evolution of nucleic acid binding modules. Graumann P, et al. **Bioessays** 1996 Apr; 18(4):309–15 (46 ref.)
RNA–binding proteins as regulators of gene expression. Siomi H, et al. **Curr Opin Genet Dev** 1997 Jun;7(3):345–53 (70 ref.)
Antitermination of transcription of catabolic operons. Rutberg B. **Mol Microbiol** 1997 Feb;23(3):413–21 (71 ref.)
Tudor domains in proteins that interact with RNA. Ponting CP. **Trends Biochem Sci** 1997 Feb;22(2):51–2 (17 ref.)
The SR protein family: pleiotropic functions in pre–mRNA splicing. Valcárcel J, et al. **Trends Biochem Sci** 1996 Aug; 21(8):296–301 (49 ref.)
RNA–binding proteins and human male infertility. Cooke HJ, et al. **Trends Genet** 1997 Mar;13(3):87–9 (30 ref.)

IMMUNOLOGY

Autoantibodies to the A/B proteins of the heterogeneous nuclear ribonucleoprotein complex: novel tools for the diagnosis of rheumatic diseases. Steiner G, et al. **Int Arch Allergy Immunol** 1996 Dec;111(4):314–9 (34 ref.)
Paraneoplastic encephalomyelitis: an update of the effects of the anti–Hu immune response on the nervous system and tumour [editorial] Voltz RD, et al. **J Neurol Neurosurg Psychiatry** 1997 Aug;63(2):133–6 (49 ref.)

METABOLISM

Structure and function of rotavirus NSP1. Taniguchi K, et al. **Arch Virol Suppl** 1996;12:53–8 (22 ref.)
Recognition determinants for proteins and antibiotics within 23S rRNA. Douthwalte S, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1179–85 (56 ref.)
The role of thymidylate synthase as an RNA binding protein. Chu E, et al. **Bioessays** 1996 Mar;18(3):191–8 (66 ref.)
New features in RNA recognition: a Tat–TAR complex. Wemmer DE. **Chem Biol** 1996 Jan;3(1):17–9 (12 ref.)
Macromolecular complexes: how RNA and protein get together. Woodson SA. **Curr Biol** 1996 Jan 1;6(1):23–5 (9 ref.)
Drosophila development: homeodomains and translational control. Zamore PD, et al. **Curr Biol** 1996 Jul 1;6(7):773–5 (17 ref.)
RNA–protein interactions in regulation of picornavirus RNA translation. Belsham GJ, et al. **Microbiol Rev** 1996 Sep; 60(3):499–511 (159 ref.)
New RNA recognition features revealed in ancient ribosomal proteins [news] Yonath A, et al. **Nat Struct Biol** 1997 Jan; 4(1):3–5 (23 ref.)
Interaction between iron–regulatory proteins and their RNA target sequences, iron–responsive elements. Henderson BR, et al. **Prog Mol Subcell Biol** 1997;18:117–39 (115 ref.)
Cytoplasmic fate of eukaryotic mRNA: identification and characterization of AU–binding proteins. Jarzembowski JA, et al. **Prog Mol Subcell Biol** 1997;18:141–72 (123 ref.)
Regulation of eukaryotic messenger RNA turnover. Rajagopalan LE, et al. **Prog Nucleic Acid Res Mol Biol** 1997;56:257–86 (128 ref.)

PHYSIOLOGY

TLS–CHOP and the role of RNA–binding proteins in oncogenic transformation. Ron D. **Curr Top Microbiol Immunol** 1997;220:131–42 (53 ref.)

RNA CAPS

A proposed mechanism of mRNA synthesis and capping by vesicular stomatitis virus. Shuman S. **Virology** 1997 Jan 6;227(1):1–6 (41 ref.)

BIOSYNTHESIS

Viral and cellular enzymes involved in synthesis of mRNA cap structure. Bisaillon M, et al. **Virology** 1997 Sep 15; 236(1):1–7 (65 ref.)

CHEMISTRY

The role of the cap structure in RNA processing and nuclear export. Lewis JD, et al. **Eur J Biochem** 1997 Jul 15; 247(2):461–9 (70 ref.)

METABOLISM

mRNA decapping activities and their biological roles. LaGrandeur TE, et al. **Biochimie** 1996;78(11–12):1049–55 (45 ref.)

RNA, CATALYTIC

Ribozymes. James HA, et al. **Essays Biochem** 1995;29:175–92 (52 ref.)
Ribozymes. James HA, et al. **Methods Mol Biol** 1997;74:1–9 (36 ref.)
Ribozymes. Their functions and strategies for their use. Gibson SA, et al. **Mol Biotechnol** 1997 Apr;7(2):125–37 (57 ref.)
Anti–HIV ribozymes. Sun LQ, et al. **Mol Biotechnol** 1997 Jun;7(3):241–51 (76 ref.)

CHEMISTRY

Hairpin ribozyme: current status and future prospects. Burke JM. **Biochem Soc Trans** 1996 Aug;24(3):608–15 (36 ref.)
The hammerhead ribozyme. Eckstein F. **Biochem Soc Trans** 1996 Aug;24(3):601–4 (39 ref.)
Molecular palaeontology: understanding catalytic mechanisms in the RNA world by excavating clues from a ribozyme three–dimensional structure. Scott WG. **Biochem Soc Trans** 1996 Aug;24(3):604–8 (14 ref.)
Group II introns: elaborate ribozymes. Jacquier A. **Biochimie** 1996;78(6):474–87 (77 ref.)
RNA enzymes: putting together a large ribozyme. Tinoco I Jr. **Curr Biol** 1996 Nov 1;6(11):1374–6 (12 ref.)
RNA structure: crystal clear? Doudna JA, et al. **Curr Opin Struct Biol** 1997 Jun;7(3):310–6 (62 ref.)
The New World of ribozymes. Jaeger L. **Curr Opin Struct Biol** 1997 Jun;7(3):324–35 (79 ref.)
The structure, function and application of the hammerhead ribozyme. Birikh KR, et al. **Eur J Biochem** 1997 Apr 1; 245(1):1–16 (184 ref.)
Ribonuclease P structure and function in Archaea. Brown JW, et al. **Mol Biol Rep** 1995–96;22(2–3):131–4 (16 ref.)
The RNase P of Dictyostelium discoideum. Draimas D. **Mol Biol Rep** 1995–96;22(2–3):135–8 (42 ref.)
Structure–function analysis in nuclear RNase P RNA. Engelke DR, et al. **Mol Biol Rep** 1995–96;22(2–3):157–60 (22 ref.)
Recent approaches to probe functional groups in ribonuclease P RNA by modification interference. Hardt WD, et al. **Mol Biol Rep** 1995–96;22(2–3):161–9 (63 ref.)
Analysis of the tertiary structure of bacterial RNase P RNA. Harris ME, et al. **Mol Biol Rep** 1995–96;22(2–3):115–23 (50 ref.)
RNase P as hyperprocessing enzyme: a model for formation of a biologically functional tRNA fragment. Kikuchi Y. **Mol Biol Rep** 1995–96;22(2–3):171–5 (17 ref.)

RNA, CATALYTIC

RNase P from bacteria. Substrate recognition and function of the protein subunit. Kirsebom LA, et al. **Mol Biol Rep** 1995–96;22(2–3):99–109 (97 ref.)
Enzymatic RNA synthesis and RNase P. Evolutionary aspects. Krupp G. **Mol Biol Rep** 1995–96;22(2–3):177–80 (29 ref.)
Structural and functional similarities between MRP and RNase P. Reddy R, et al. **Mol Biol Rep** 1995–96; 22(2–3):81–5 (68 ref.)
The yeast, Saccharomyces cerevisiae, RNase P/MRP ribonucleoprotein endoribonuclease family. Reilly TH, et al. **Mol Biol Rep** 1995–96;22(2–3):87–93 (63 ref.)
Ribonuclease P from plant nuclei and photosynthetic organelles. Schön A. **Mol Biol Rep** 1995–96;22(2–3):139–45 (41 ref.)
Early studies of native ribonuclease P, including discovery of its essential RNA component. Stark BC. **Mol Biol Rep** 1995–96;22(2–3):95–7 (14 ref.)
RNase P RNA of Mycoplasma capricolum. Ushida C, et al. **Mol Biol Rep** 1995–96;22(2–3):125–9 (28 ref.)
The hairpin ribozyme: discovery, two-dimensional model, and development for gene therapy. Hampel A. **Prog Nucleic Acid Res Mol Biol** 1998;58:1–39 (44 ref.)
Ribozymes: structure and mechanism in RNA catalysis. Scott WG, et al. **Trends Biochem Sci** 1996 Jun;21(6):220–4 (31 ref.)

GENETICS

Anti-oncogene ribozymes for cancer gene therapy. Irie A, et al. **Adv Pharmacol** 1997;40:207–57 (350 ref.)
Ribozymes: red in tooth and claw. Robertson MP, et al. **Curr Biol** 1997 Jun 1;7(6):R376–9 (9 ref.)
Genetic analysis of the structure and function of RNase P from E. coli. Shiraishi H, et al. **Mol Biol Rep** 1995–96; 22(2–3):111–4 (35 ref.)
Antisense and ribozyme constructs in transgenic animals. Sokol DL, et al. **Transgenic Res** 1996 Nov;5(6):363–71 (89 ref.)
[Polyribozymes] Zhenodarova SM. **Mol Biol (Mosk)** 1996 Nov–Dec;30(6):1237–41 (24 ref.) **(Rus)**

METABOLISM

Mechanistic aspects of enzymatic catalysis: lessons from comparison of RNA and protein enzymes. Narlikar GJ, et al. **Annu Rev Biochem** 1997;66:19–59 (240 ref.)
The hammerhead ribozyme. Eckstein F. **Biochem Soc Trans** 1996 Aug;24(3):601–4 (39 ref.)
Facilitators of RNA-RNA annealing: implications for the catalytic cycle of hammerhead ribozymes. Nedbal W, et al. **Biochem Soc Trans** 1996 Aug;24(3):615–8 (17 ref.)
Molecular palaeontology: understanding catalytic mechanisms in the RNA world by excavating clues from a ribozyme three-dimensional structure. Scott WG. **Biochem Soc Trans** 1996 Aug;24(3):604–8 (14 ref.)
Ribozymes: aiming at RNA replication and protein synthesis. Hager AJ, et al. **Chem Biol** 1996 Sep;3(9):717–25 (51 ref.)
Building the RNA world. Ribozymes. Joyce GF. **Curr Biol** 1996 Aug 1;6(8):965–7 (7 ref.)
The New World of ribozymes. Jaeger L. **Curr Opin Struct Biol** 1997 Jun;7(3):324–35 (79 ref.)
Self-cleaving ribozymes of hepatitis delta virus RNA. Been MD, et al. **Eur J Biochem** 1997 Aug 1;247(3):741–53 (87 ref.)
Ribonuclease P structure and function in Archaea. Brown JW, et al. **Mol Biol Rep** 1995–96;22(2–3):131–4 (16 ref.)
The RNase P of Dictyostelium discoideum. Drainas D. **Mol Biol Rep** 1995–96;22(2–3):135–8 (42 ref.)
Structure-function analysis in nuclear RNase P RNA. Engelke DR, et al. **Mol Biol Rep** 1995–96;22(2–3):157–60 (22 ref.)
Structure, mechanism and evolution of chloroplast transfer RNA processing systems. Gegenheimer P. **Mol Biol Rep** 1995–96;22(2–3):147–50 (27 ref.)
Transfer RNA gene organization and RNase P. Green CJ. **Mol Biol Rep** 1995–96;22(2–3):181–5 (67 ref.)
Recent approaches to probe functional groups in ribonuclease P RNA by modification interference. Hardt WD, et al. **Mol Biol Rep** 1995–96;22(2–3):161–9 (63 ref.)
RNase P as hyperprocessing enzyme: a model for formation of a biologically functional tRNA fragment. Kikuchi Y. **Mol Biol Rep** 1995–96;22(2–3):171–5 (17 ref.)
RNase P from bacteria. Substrate recognition and function of the protein subunit. Kirsebom LA, et al. **Mol Biol Rep** 1995–96;22(2–3):99–109 (97 ref.)
Enzymatic RNA synthesis and RNase P. Evolutionary aspects. Krupp G. **Mol Biol Rep** 1995–96;22(2–3):177–80 (29 ref.)
Plant mitochondrial RNase P. Marchfelder A. **Mol Biol Rep** 1995–96;22(2–3):151–6 (29 ref.)
tRNA processing in human mitochondrial disorders. Masucci JP, et al. **Mol Biol Rep** 1995–96;22(2–3):187–93 (78 ref.)
Structural and functional similarities between MRP and RNase P. Reddy R, et al. **Mol Biol Rep** 1995–96; 22(2–3):81–5 (68 ref.)
The yeast, Saccharomyces cerevisiae, RNase P/MRP ribonucleoprotein endoribonuclease family. Reilly TH, et al. **Mol Biol Rep** 1995–96;22(2–3):87–93 (63 ref.)
Ribonuclease P from plant nuclei and photosynthetic organelles. Schön A. **Mol Biol Rep** 1995–96;22(2–3):139–45 (41 ref.)
Genetic analysis of the structure and function of RNase P from E. coli. Shiraishi H, et al. **Mol Biol Rep** 1995–96; 22(2–3):111–4 (35 ref.)
Early studies of native ribonuclease P, including discovery of its essential RNA component. Stark BC. **Mol Biol Rep** 1995–96;22(2–3):95–7 (14 ref.)
RNase P RNA of Mycoplasma capricolum. Ushida C, et al. **Mol Biol Rep** 1995–96;22(2–3):125–9 (28 ref.)
Plant pathogenic RNAs and RNA catalysis. Symons RH. **Nucleic Acids Res** 1997 Jul 15;25(14):2683–9 (71 ref.)
Ribozymes: structure and mechanism in RNA catalysis. Scott WG, et al. **Trends Biochem Sci** 1996 Jun;21(6):220–4 (31 ref.)
[Reversal of drug resistance in human cancer cells by anti-oncogenes] Funato T. **Gan To Kagaku Ryoho** 1997 Feb;24(4):395–400 (6 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Anti-gene therapy: the use of ribozymes to inhibit gene function. Couture LA, et al. **Trends Genet** 1996 Dec; 12(12):510–5 (55 ref.)

PHYSIOLOGY

Ribozymes: structure, function, and potential therapy for dominant genetic disorders. Grassi G, et al. **Ann Med** 1996 Dec;28(6):499–510 (117 ref.)

THERAPEUTIC USE

Ribozymes: structure, function, and potential therapy for dominant genetic disorders. Grassi G, et al. **Ann Med** 1996 Dec;28(6):499–510 (117 ref.)
Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants. von Weizsäcker F, et al. **Hepatology** 1997 Aug;26(2):251–5 (72 ref.)
Ribozyme-mediated cancer gene therapy. Irie A, et al. **Int J Urol** 1997 Jul;4(4):329–37 (90 ref.)
Anti-HIV therapy with antisense oligonucleotides and ribozymes: realistic approaches or expensive myths? Akhtar S, et al. **J Antimicrob Chemother** 1996 Aug;38(2):159–65 (64 ref.)
Multi-unit anti-BCR-ABL ribozyme therapy in chronic myelogenous leukemia. Leopold LH, et al. **Leuk Lymphoma** 1996 Aug;22(5–6):365–73 (56 ref.)
Clinical aspects of ribozymes as therapeutics in gene therapy. Looney D, et al. **Methods Mol Biol** 1997;74:469–86 (71 ref.)
[Circumventing multidrug resistance in human cancer by anti-ribozyme] Funato T. **Nippon Rinsho** 1997 May; 55(5):1116–21 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Specific inhibition of anti-DNA antibody production by an anti-DH ribozyme] Suzuki Y, et al. **Nippon Rinsho** 1997 Jun;55(6):1557–61 (18 ref.) (Eng. Abstr.) **(Jpn)**

RNA-DEPENDENT DNA POLYMERASE see **RNA-DIRECTED DNA POLYMERASE**

RNA-DEPENDENT RNA POLYMERASE see **RNA REPLICASE**

RNA-DIRECTED DNA POLYMERASE

Reverse transcriptase jumps and gaps. Kupiec JJ, et al. **J Gen Virol** 1996 Sep;77 (Pt 9):1987–91 (38 ref.)

GENETICS

Structure, function, and evolution of bacterial reverse transcriptase. Inouye S, et al. **Virus Genes** 1995; 11(2–3):81–94 (47 ref.)
Bacterial reverse transcriptase and msDNA. Rice SA, et al. **Virus Genes** 1995;11(2–3):95–104 (54 ref.)

ISOLATION & PURIFICATION

Purification of viral polymerases: general considerations. Sardana V, et al. **Methods Enzymol** 1996;275:3–16 (47 ref.)

METABOLISM

Human immunodeficiency virus type 1 reverse transcriptase and early events in reverse transcription. Arts EJ, et al. **Adv Virus Res** 1996;46:97–163 (333 ref.)
Perspective: research highlights at the Albert Einstein College of Medicine Center for AIDS research. Approaches to control drug resistance in HIV: the role of increased polymerase fidelity. Prasad VR, et al. **AIDS Res Hum Retroviruses** 1996 Jul 20;12(11):959–63 (54 ref.)
It's prime time for reverse transcriptase. Levin HL. **Cell** 1997 Jan 10;88(1):5–8 (20 ref.)
Analysis of resistance mutants of viral polymerases. Oxford JS, et al. **Methods Enzymol** 1996;275:555–600 (179 ref.)
Reverse transcriptase: mediator of genomic plasticity. Brosius J, et al. **Virus Genes** 1995;11(2–3):163–79 (259 ref.)

RNA, DOUBLE-STRANDED

Structure, reactivity, and biology of double-stranded RNA. Nicholson AW. **Prog Nucleic Acid Res Mol Biol** 1996; 52:1–65 (275 ref.)

GENETICS

Double-stranded RNA viruses of Saccharomyces cerevisiae. Wickner RB. **Microbiol Rev** 1996 Mar;60(1):250–65 (172 ref.)

METABOLISM

The regulation of the protein kinase PKR by RNA. Robertson HD, et al. **Biochimie** 1996;78(11–12):909–14 (27 ref.)

RNA EDITING

Gene regulation by mRNA editing [editorial; comment] Ashkenas J. **Am J Hum Genet** 1997 Feb;60(2):278–83 (43 ref.) Comment on: Am J Hum Genet 1997 Feb;60(2):305–12.
RNA editing. Simpson L, et al. **Annu Rev Neurosci** 1996; 19:27–52 (177 ref.)
Apobec-1 and apolipoprotein B mRNA editing. Chan L, et al. **Biochim Biophys Acta** 1997 Mar 10;1345(1):11–26 (90 ref.)
RNA editing: rewriting receptors. O'Connell MA. **Curr Biol** 1997 Jul 1;7(7):R437–9 (28 ref.)
Mammalian RNA-dependent deaminases and edited mRNAs. Maas S, et al. **Curr Opin Cell Biol** 1997 Jun;9(3):343–9 (49 ref.)
RNA editing in kinetoplastid protozoa. Stuart K, et al. **Microbiol Mol Biol Rev** 1997 Mar;61(1):105–20 (114 ref.)
RNA editing in plant mitochondria and chloroplasts. Maier RM, et al. **Plant Mol Biol** 1996 Oct;32(1–2):343–65 (113 ref.)
RNA editing and hypermutation by adenosine deamination [published erratum appears in Trends Biochem Sci 1997 Jul;22(7):278] Bass BL. **Trends Biochem Sci** 1997 May; 22(5):157–62 (54 ref.)
RNA editing: getting U into RNA. Kable ML, et al. **Trends Biochem Sci** 1997 May;22(5):162–6 (27 ref.)
Cell and genome coevolution: facultative anaerobiosis, glycosomes and kinetoplastan RNA editing. Cavalier-Smith T. **Trends Genet** 1997 Jan;13(1):6–9 (30 ref.)
RNA editing, introns and evolution. Herbert A. **Trends Genet** 1996 Jan;12(1):6–9 (23 ref.)
Base-modification mRNA editing through deamination--the good, the bad and the unregulated. Smith HC, et al. **Trends Genet** 1996 Oct;12(10):418–24 (69 ref.)
[RNA editing] Yamanaka S, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(6):803–11 (48 ref.) **(Jpn)**

GENETICS

Control of gene expression by base deamination: the case of RNA editing in wheat mitochondria. Blanc V, et al. **Biochimie** 1996;78(6):511–7 (50 ref.)

PHYSIOLOGY

RNA editing in metazoan mitochondria: staying fit without sex. Börner GV, et al. **FEBS Lett** 1997 Jun 16;409(3):320–4 (34 ref.)

RNA, FUNGAL

GENETICS

Trans-acting factors in yeast pre-rRNA and pre-snoRNA processing. Lafontaine D, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11–12):803–12 (71 ref.)
The accuracy center of a eukaryotic ribosome. Liebman SW, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11–12):1141–9 (49 ref.)
Mixed mechanisms in yeast pre-mRNA splicing? [comment] Rosbash M. **Cell** 1996 Nov 1;87(3):357–9 (15 ref.) Comment on: Cell 1996 Nov 1;87(3):391–404. Comment on: Cell 1996 Nov 1;87(3):405–13.
The transcriptional apparatus required for mRNA encoding genes in the yeast Saccharomyces cerevisiae emerges from a jigsaw puzzle of transcription factors. Künzler M, et al. **FEMS Microbiol Rev** 1996 Dec;19(2):117–36 (167 ref.)
3'-end-forming signals of yeast mRNA. Guo Z, et al. **Trends Biochem Sci** 1996 Dec;21(12):477–81 (41 ref.)

ISOLATION & PURIFICATION

Preparation of total RNA. Brown AJ. **Methods Mol Biol** 1996;53:269–76 (9 ref.)

METABOLISM

Strategy for RNA recognition by yeast histidyl-tRNA synthetase. Rudinger J, et al. **Bioorg Med Chem** 1997 Jun; 5(6):1001–9 (56 ref.)
Translational regulation of yeast GCN4. A window on factors that control initiator-trna binding to the ribosome. Hinnebusch AG. **J Biol Chem** 1997 Aug 29;272(35):21661–4 (61 ref.)
mRNA abundance and half-life measurements. Brown AJ, et al. **Methods Mol Biol** 1996;53:277–95 (10 ref.)
Mechanisms and control of mRNA turnover in Saccharomyces cerevisiae. Caponigro G, et al. **Microbiol Rev** 1996 Mar;60(1):233–49 (126 ref.)

RNA, GUIDE

see related
RNA EDITING

GENETICS

The genomic organization of guide RNA genes in kinetoplastid protozoa: several conundrums and their solutions. Simpson L. **Mol Biochem Parasitol** 1997 Jun; 86(2):133–41 (39 ref.)

METABOLISM

RNA editing in kinetoplastid protozoa. Stuart K, et al. **Microbiol Mol Biol Rev** 1997 Mar;61(1):105–20 (114 ref.)

RNA, HETEROGENEOUS NUCLEAR

IMMUNOLOGY

Autoantibodies to the A/B proteins of the heterogeneous nuclear ribonucleoprotein complex: novel tools for the diagnosis of rheumatic diseases. Steiner G, et al. **Int Arch Allergy Immunol** 1996 Dec;111(4):314–9 (34 ref.)

METABOLISM

The roles of heterogeneous nuclear ribonucleoproteins (hnRNP) in RNA metabolism. Weighardt F, et al. **Bioessays** 1996 Sep;18(9):747–56 (72 ref.)

RNA LIGASE see **POLYRIBONUCLEOTIDE SYNTHETASE**

RNA, MESSENGER

Translational regulation of maternal mRNAs. Macdonald PM, et al. **Curr Opin Genet Dev** 1996 Aug;6(4):403–7 (46 ref.)

Life and death in the cytoplasm: messages from the 3' end. Wickens M, et al. **Curr Opin Genet Dev** 1997 Apr; 7(2):220–32 (105 ref.)

The compartmentalization of protein synthesis: importance of cytoskeleton and role in mRNA targeting. Hovland R, et al. **Int J Biochem Cell Biol** 1996 Oct;28(10):1089–105 (161 ref.)

Control of messenger RNA stability in higher eukaryotes. Ross J. **Trends Genet** 1996 May;12(5):171–5 (39 ref.)

[Vg1, a possible natural mesoderm inducer derived from the study of the localized maternal mRNA in the Xenopus egg cytoplasm] Shiokawa K, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(11):1594–9 (18 ref.) **(Jpn)**

ANALYSIS

RNA molecules lighting up under the microscope. Dirks RW. **Histochem Cell Biol** 1996 Aug;106(2):151–66 (104 ref.)

Molecular analysis of human glomerular disease. Esposito C, et al. **Kidney Int Suppl** 1996 Jan;53:S21–5 (31 ref.)

In situ PCR amplification of intracellular mRNA. Chen RH, et al. **Methods Mol Biol** 1997;71:123–32 (20 ref.)

Reverse transcriptase PCR in situ on cryopreserved tissue sections. Hendler FJ, et al. **Methods Mol Biol** 1997; 71:99–111 (9 ref.)

mRNA in situ hybridization to in vitro cultured cells. Raap AK, et al. **Methods Mol Biol** 1997;75:367–75 (32 ref.)

mRNA localization in neurons: a multipurpose mechanism? Steward O. **Neuron** 1997 Jan;18(1):9–12 (19 ref.)

Human opioid receptors: chromosomal mapping and mRNA localization. Miotto K, et al. **NIDA Res Monogr** 1996; 161:72–82 (34 ref.)

ANTAGONISTS & INHIBITORS

Antisense-protein kinase A: a single-gene-based therapeutic approach. Cho-Chung YS, et al. **Antisense Nucleic Acid Drug Dev** 1997 Jun;7(3):217–23 (20 ref.)

BIOSYNTHESIS

Regulation of 5-HT2A receptor mRNA in P11 cells. Ferry RC, et al. **Behav Brain Res** 1996;73(1–2):187–91 (26 ref.)

Regulation of neuronal nitric oxide synthase through alternative transcripts. Brenman JE, et al. **Dev Neurosci** 1997;19(3):224–31 (39 ref.)

A proposed mechanism of mRNA synthesis and capping by vesicular stomatitis virus. Shuman S. **Virology** 1997 Jan 6;227(1):1–6 (41 ref.)

[Unique mechanism of coronavirus mRNA transcription] Tsukamoto K. **Uirusu** 1996 Dec;46(2):99–107 (41 ref.) **(Jpn)**

CHEMISTRY

Modeling the structure of the ribosome. Easterwood TR, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):751–6 (35 ref.)

An oligonucleotide analog approach to the decoding region of 16S rRNA. Stern S, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):899–905 (19 ref.)

Nematode spliced leaders—ubiquity, evolution and utility. Blaxter M, et al. **Int J Parasitol** 1996 Oct;26(10):1025–33 (51 ref.)

Antitermination of transcription of catabolic operons. Rutberg B. **Mol Microbiol** 1997 Feb;23(3):413–21 (71 ref.)

The role of mRNA stability in the control of globin gene expression. Russell JE, et al. **Prog Nucleic Acid Res Mol Biol** 1997;57:249–87 (99 ref.)

DRUG EFFECTS

Oligonucleotide analogs might be designed to bind to m-RNA. Crooke ST. **Anticancer Drug Des** 1997 Jul; 12(5):311–3 (13 ref.)

A hypothesis to explain why translation inhibitors stabilize mRNAs in mammalian cells: mRNA stability and mitosis. Ross J. **Bioessays** 1997 Jun;19(6):527–9 (18 ref.)

GENETICS

Recoding: dynamic reprogramming of translation. Gesteland RF, et al. **Annu Rev Biochem** 1996;65:741–68 (181 ref.)

Upstream stimulators for recoding. Larsen B, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1123–9 (45 ref.)

Structure and evolution of mammalian ribosomal proteins. Wool IG, et al. **Biochem Cell Biol** 1995 Nov–Dec; 73(11–12):933–47 (55 ref.)

Apobec-1 and apolipoprotein B mRNA editing. Chan L, et al. **Biochim Biophys Acta** 1997 Mar 10;1345(1):11–26 (90 ref.)

Ending the message is not so simple. Proudfoot N. **Cell** 1996 Nov 29;87(5):779–81 (15 ref.)

Translational control during early development. Stebbins-Boaz B, et al. **Crit Rev Eukaryot Gene Expr** 1997; 7(1–2):73–94 (159 ref.)

A comparison of mammalian and yeast pre-mRNA 3'-end processing. Keller W, et al. **Curr Opin Cell Biol** 1997 [illegible]n; 9(3):329–36 (52 ref.)

The transcriptional apparatus required for mRNA encoding genes in the yeast Saccharomyces cerevisiae emerges from a jigsaw puzzle of transcription factors. Künzler M, et al. **FEMS Microbiol Rev** 1996 Dec;19(2):117–36 (167 ref.)

RNA polymerase II dependent genes that do not code for protein. Lakhotia SC. **Indian J Biochem Biophys** 1996 Apr; 33(2):93–102 (132 ref.)

Abnormal cholecystokinin mRNA levels in entorhinal cortex of schizophrenics. Bachus SE, et al. **J Psychiatr Res** 1997 Mar–Apr;31(2):233–56 (170 ref.)

Regulation of gene expression by natural antisense RNA transcripts. Knee R, et al. **Neurochem Int** 1997 Sep; 31(3):379–92 (122 ref.)

Prognostic factors and variant estrogen receptor RNAs in clinical breast cancer. Auchus RJ, et al. **Nucl Med Biol** 1994 Apr;21(3):449–54 (15 ref.)

Making (anti)sense of non-coding sequence conservation. Lipman DJ. **Nucleic Acids Res** 1997 Sep 15;25(18):3580–3 (54 ref.)

Control of mRNA stability in higher plants. Abler ML, et al. **Plant Mol Biol** 1996 Oct;32(1–2):63–78 (99 ref.)

Translational control of cellular and viral mRNAs. Gallie DR. **Plant Mol Biol** 1996 Oct;32(1–2):145–58 (109 ref.)

Plant mRNA 3'-end formation. Rothnie HM. **Plant Mol Biol** 1996 Oct;32(1–2):43–61 (133 ref.)

Splicing of precursors to mRNA in higher plants: mechanism, regulation and sub-nuclear organisation of the spliceosomal machinery. Simpson GG, et al. **Plant Mol Biol** 1996 Oct; 32(1–2):1–41 (307 ref.)

TOP genes: a translationally controlled class of genes including those coding for ribosomal proteins. Amaldi F, et al. **Prog Mol Subcell Biol** 1997;18:1–17 (70 ref.)

Mechanisms for posttranscriptional regulation by iron-responsive elements and iron regulatory proteins. Muckenthaler M, et al. **Prog Mol Subcell Biol** 1997; 18:93–115 (100 ref.)

3' untranslated regions of c-myc and c-fos mRNAs: multifunctional elements regulating mRNA translation, degradation and subcellular localization. Veyrune JL, et al. **Prog Mol Subcell Biol** 1997;18:35–63 (160 ref.)

Structure and function of the human immunodeficiency virus leader RNA. Berkhout B. **Prog Nucleic Acid Res Mol Biol** 1996;54:1–34 (182 ref.)

3'-end-forming signals of yeast mRNA. Guo Z, et al. **Trends Biochem Sci** 1996 Dec;21(12):477–81 (41 ref.)

PHAS/4E-BPs as regulators of mRNA translation and cell proliferation. Lawrence JC Jr, et al. **Trends Biochem Sci** 1997 Sep;22(9):345–9 (46 ref.)

Pre-mRNA splicing: the discovery of a new spliceosome doubles the challenge. Tarn WY, et al. **Trends Biochem Sci** 1997 Apr;22(4):132–7 (40 ref.)

The SR protein family: pleiotropic functions in pre-mRNA splicing. Valcárcel J, et al. **Trends Biochem Sci** 1996 Aug; 21(8):296–301 (49 ref.)

Base-modification mRNA editing through deamination—the good, the bad and the unregulated. Smith HC, et al. **Trends Genet** 1996 Oct;12(10):418–24 (69 ref.)

mRNA differential display: application in the discovery of novel pharmacological targets. Wang X, et al. **Trends Pharmacol Sci** 1996 Aug;17(8):276–9 (21 ref.)

[Unique mechanism of coronavirus mRNA transcription] Tsukamoto K. **Uirusu** 1996 Dec;46(2):99–107 (41 ref.) **(Jpn)**

ISOLATION & PURIFICATION

Detection of melanoma cells in peripheral blood using reverse transcription polymerase chain reaction assay for tyrosinase mRNA. Jung FA, et al. **Cancer Surv** 1996;26:251–65 (38 ref.)

METABOLISM

Regulation of tyrosine hydroxylase mRNA stability by oxygen in PC12 cells. Czyzyk-Krzeska MF, et al. **Adv Exp Med Biol** 1996;410:143–50 (20 ref.)

Posttranscriptional regulation of lung elastin production [comment] Parks WC. **Am J Respir Cell Mol Biol** 1997 Jul;17(1):1–2 (13 ref.) Comment on: Am J Respir Cell Mol Biol 1997 Jul;17(1):10–6.

Interrelationships of the pathways of mRNA decay and translation in eukaryotic cells. Jacobson A, et al. **Annu Rev Biochem** 1996;65:693–739 (400 ref.)

The structure and function of proteins involved in mammalian pre-mRNA splicing. Krämer A. **Annu Rev Biochem** 1996;65:367–409 (329 ref.)

Polyadenylation of mRNA in prokaryotes. Sarkar N. **Annu Rev Biochem** 1997;66:173–97 (117 ref.)

Basic mechanisms of transcript elongation and its regulation. Uptain SM, et al. **Annu Rev Biochem** 1997;66:117–72 (422 ref.)

RNA transport. Nakielny S, et al. **Annu Rev Neurosci** 1997; 20:269–301 (211 ref.)

Oligonucleotide analogs might be designed to bind to m-RNA. Crooke ST. **Anticancer Drug Des** 1997 Jul; 12(5):311–3 (13 ref.)

Mechanisms of beta-adrenergic receptor desensitization: from molecular biology to heart failure. Lohse MJ, et al. **Basic Res Cardiol** 1996;91 Suppl 2:29–34 (62 ref.)

mRNA targeting: signals in the 3'-untranslated sequences for sorting of some mRNAs. Hesketh JE. **Biochem Soc Trans** 1996 May;24(2):521–7 (55 ref.)

Targeting proteins to mitochondria: is there a role for mRNA localization? Lightowlers RN, et al. **Biochem Soc Trans** 1996 May;24(2):527–31 (41 ref.)

Translational regulation of maternal mRNA. Hake LE, et al. **Biochim Biophys Acta** 1997 Feb 22;1332(1):M31–8 (45 ref.)

A role for Rev in the association of HIV-1 gag mRNA with cytoskeletal beta-actin and viral protein expression. Kimura T, et al. **Biochimie** 1996;78(11–12):1075–80 (48 ref.)

Messenger RNA translation in prokaryotes: GTPase centers associated with translational factors. Laalami S, et al. **Biochimie** 1996;78(7):577–89 (192 ref.)

mRNA decapping activities and their biological roles. LaGrandeur TE, et al. **Biochimie** 1996;78(11–12):1049–55 (45 ref.)

mRNA and cytoskeletal filaments. Bassell G, et al. **Curr Opin Cell Biol** 1997 Feb;9(1):109–15 (58 ref.)

Common themes in the function of transcription and splicing enhancers. Hertel KJ, et al. **Curr Opin Cell Biol** 1997 Jun; 9(3):350–7 (68 ref.)

mRNA abundance and half-life measurements. Brown AJ, et al. **Methods Mol Biol** 1996;53:277–95 (10 ref.)

Mechanisms and control of mRNA turnover in Saccharomyces cerevisiae. Caponigro G, et al. **Microbiol Rev** 1996 Mar;60(1):233–49 (126 ref.)

Polyadenylation of mRNA in bacteria. Sarkar N. **Microbiology** 1996 Nov;142 (Pt 11):3125–33 (80 ref.)

Occurrence of androgen and estrogen receptor mRNAs in the harderian gland: a comparative survey. Varriale B. **Microsc Res Tech** 1996 Jun 1;34(2):97–103 (33 ref.)

Quo vadis: extrasomatic targeting of neuronal mRNAs in mammals. Kindler S, et al. **Mol Cell Endocrinol** 1997 Apr 4;128(1–2):7–10 (22 ref.)

Amyloid precursor protein mRNAs in Alzheimer's disease. Harrison PJ, et al. **Neurodegeneration** 1996 Dec;5(4):409–15 (51 ref.)

Alternative poly(A) site selection in complex transcription units: means to an end? Edwalds-Gilbert G, et al. **Nucleic Acids Res** 1997 Jul 1;25(13):2547–61 (287 ref.)

Cell-free systems for analysis of cytoplasmic mRNA turnover. DeMaria CT, et al. **Prog Mol Subcell Biol** 1997; 18:65–91 (67 ref.)

Cytoplasmic fate of eukaryotic mRNA: identification and characterization of AU-binding proteins. Jarzembowski JA, et al. **Prog Mol Subcell Biol** 1997;18:141–72 (123 ref.)

Cytoplasmic fate of messenger RNA. Introduction. Jeanteur P. **Prog Mol Subcell Biol** 1997;18:V–VIII (0 ref.)

Function and characterization of poly(A)-specific 3' exoribonucleases. Virtanen A, et al. **Prog Mol Subcell Biol** 1997;18:199–220 (120 ref.)

The decay of bacterial messenger RNA. Nierlich DP, et al. **Prog Nucleic Acid Res Mol Biol** 1996;52:153–216 (298 ref.)

Regulation of eukaryotic messenger RNA turnover. Rajagopalan LE, et al. **Prog Nucleic Acid Res Mol Biol** 1997;56:257–86 (128 ref.)

The role of mRNA stability in the control of globin gene expression. Russell JE, et al. **Prog Nucleic Acid Res Mol Biol** 1997;57:249–87 (99 ref.)

The mechanism of 3' cleavage and polyadenylation of eukaryotic pre-mRNA. Wahle E, et al. **Prog Nucleic Acid Res Mol Biol** 1997;57:41–71 (227 ref.)

eIF4G: a multipurpose ribosome adapter? [published erratum appears in Science 1997 Mar 14;275(5306):1553] Hentze MW. **Science** 1997 Jan 24;275(5299):500–1 (12 ref.)

Highways for protein delivery to the mitochondria [see comments] Lithgow T, et al. **Trends Biochem Sci** 1997 Apr; 22(4):110–3 (30 ref.) Comment in: Trends Biochem Sci 1997 Aug;22(8):290.

Making sense of nonsense in yeast. Ruiz-Echevarria MJ, et al. **Trends Biochem Sci** 1996 Nov;21(11):433–8 (31 ref.)

RNA, MESSENGER

Identifying changes in gene expression in the nervous system: mRNA differential display. Livesey FJ, et al. **Trends Neurosci** 1996 Mar;19(3):84–8 (20 ref.)

mRNA differential display: application in the discovery of novel pharmacological targets. Wang X, et al. **Trends Pharmacol Sci** 1996 Aug;17(8):276–9 (21 ref.)

[gamma–Glutamylcysteine synthetase and chemosensitivity] Nishio K, et al. **Gan To Kagaku Ryoho** 1997 Feb; 24(4):418–23 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Specific regulation of gene expression in brain by antisense oligodeoxynucleotides] Yoshikawa M, et al. **Nippon Yakurigaku Zasshi** 1997 Apr;109(4):187–91 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Expression of brain prolactin receptor mRNA and induction of maternal behavior] Sakaguchi K, et al. **Seikagaku** 1997 Apr;69(4):247–50 (15 ref.) **(Jpn)**

[A mechanism of mRNA transport in fission yeast: nucleolar involvement and heat shock inhibition in mRNA transport] Tani T. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1193–200 (23 ref.) **(Jpn)**

PHYSIOLOGY

Starting at the beginning, middle, and end: translation initiation in eukaryotes. Sachs AB, et al. **Cell** 1997 Jun 13; 89(6):831–8 (61 ref.)

Messengers from the synapses to the nucleus (MSNs) that establish late phase of long–term potentiation (LTP) and long–term memory. Suzuki T. **Neurosci Res** 1996 May; 25(1):1–6 (75 ref.)

Translational control by polyadenylation during early development. Osborne HB, et al. **Prog Mol Subcell Biol** 1997;18:173–98 (100 ref.)

RNA, MESSENGER, EDITING see **RNA EDITING**

RNA, MESSENGER, POLYADENYLATED see **RNA, MESSENGER**

RNA, MESSENGER, PRECURSORS see **RNA PRECURSORS**

RNA, MESSENGER, SPLICING see **RNA SPLICING**

RNA METHYLASES see **RNA, TRANSFER, METHYLTRANSFERASES**

RNA, NEOPLASM

ANALYSIS

PCR– and RT–PCR–based methods of tumor detection: potential applications and clinical implications. Seiden M, et al. **Important Adv Oncol** 1996;:191–204 (59 ref.)

GENETICS

Single cell PCR for the analysis of Hodgkin's disease: four years later. Küpper M, et al. **Ann Oncol** 1996;7 Suppl 4:35–9 (24 ref.)

Expression genetics in cancer: shifting the focus from DNA to RNA. Sager R. **Proc Natl Acad Sci U S A** 1997 Feb 4;94(3):952–5 (56 ref.)

[Molecular genetics of human tumors] Imianitov EN, et al. **Vopr Onkol** 1997;43(1):95–101 (46 ref.) (Eng. Abstr.) **(Rus)**

RNA, NON–POLYADENYLATED see **RNA**

RNA NUCLEOTIDYLTRANSFERASES

CHEMISTRY

Homomorphous hexameric helicases: tales from the ring cycle. Egelman EH. **Structure** 1996 Jul 15;4(7):759–62 (35 ref.)

METABOLISM

RNA turnover: the helicase story unwinds. Anderson JS, et al. **Curr Biol** 1996 Jul 1;6(7):780–2 (16 ref.)

Virus–encoded RNA helicases. Kadaré G, et al. **J Virol** 1997 Apr;71(4):2583–90 (65 ref.)

RNA PHAGES

GENETICS

RNA phage Q beta coat protein as a carrier for foreign epitopes. Kozlovska TM, et al. **Intervirology** 1996; 39(1–2):9–15 (19 ref.)

RNA, PLANT

CHEMISTRY

RNA structure and the regulation of gene expression. Klaff P, et al. **Plant Mol Biol** 1996 Oct;32(1–2):89–106 (147 ref.)

GENETICS

Control of mRNA stability in higher plants. Abler ML, et al. **Plant Mol Biol** 1996 Oct;32(1–2):63–78 (99 ref.)

RNA as a target and an initiator of post–transcriptional gene silencing in transgenic plants. Baulcombe DC. **Plant Mol Biol** 1996 Oct;32(1–2):79–88 (56 ref.)

Translational control of cellular and viral mRNAs. Gallie DR. **Plant Mol Biol** 1996 Oct;32(1–2):145–58 (109 ref.)

RNA structure and the regulation of gene expression. Klaff P, et al. **Plant Mol Biol** 1996 Oct;32(1–2):89–106 (147 ref.)

Plant mRNA 3'–end formation. Rothnie HM. **Plant Mol Biol** 1996 Oct;32(1–2):43–61 (133 ref.)

Splicing of precursors to mRNA in higher plants: mechanism, regulation and sub–nuclear organisation of the spliceosomal machinery. Simpson GG, et al. **Plant Mol Biol** 1996 Oct; 32(1–2):1–41 (307 ref.)

METABOLISM

Structure, mechanism and evolution of chloroplast transfer RNA processing systems. Gegenheimer P. **Mol Biol Rep** 1995–96;22(2–3):147–50 (27 ref.)

RNA, POLYADENYLATED see **RNA, MESSENGER**

RNA POLYMERASE I

GENETICS

Regulation of RNA polymerases I and III by the retinoblastoma protein: a mechanism for growth control? White RJ. **Trends Biochem Sci** 1997 Mar;22(3):77–80 (33 ref.)

ISOLATION & PURIFICATION

Purification, assay, and properties of RNA polymerase I and class I–specific transcription factors in mouse. Schnapp A, et al. **Methods Enzymol** 1996;273:233–48 (16 ref.)

METABOLISM

Regulation of RNA polymerases I and III by the retinoblastoma protein: a mechanism for growth control? White RJ. **Trends Biochem Sci** 1997 Mar;22(3):77–80 (33 ref.)

RNA POLYMERASE II

CHEMISTRY

Assaying CTD kinases in vitro and phosphorylation–modulated properties of RNA polymerase II in vivo. Morris DP, et al. **Methods** 1997 Jul;12(3):264–75 (41 ref.)

Yeast RNA polymerase II holoenzyme. Li Y, et al. **Methods Enzymol** 1996;273:172–5 (11 ref.)

Pieces of the puzzle: assembling the preinitiation complex of Pol II. Ghosh G, et al. **Structure** 1996 Aug 15;4(8):891–5 (19 ref.)

GENETICS

Transcription: building an initiation machine. Travers A. **Curr Biol** 1996 Apr 1;6(4):401–3 (22 ref.)

RNA polymerase II dependent genes that do not code for protein. Lakhotia SC. **Indian J Biochem Biophys** 1996 Apr; 33(2):93–102 (132 ref.)

Analysis of open complex formation during RNA polymerase II transcription initiation using heteroduplex templates and potassium permanganate probing. Holstege FC, et al. **Methods** 1997 Jul;12(3):203–11 (46 ref.)

Assays for investigating transcription by RNA polymerase II in vitro. Reines D, et al. **Methods** 1997 Jul;12(3):192–202 (75 ref.)

Mechanisms of transcriptional regulation and neural gene expression. Tamura T, et al. **Neurochem Int** 1996 Dec; 29(6):573–81 (61 ref.)

Mediator of transcriptional regulation [see comments] Björklund S, et al. **Trends Biochem Sci** 1996 Sep;21(9):335–7 (25 ref.) Comment in: Trends Biochem Sci 1996 Sep;21(9):325–6.

The role of general initiation factors in transcription by RNA polymerase II. Roeder RG. **Trends Biochem Sci** 1996 Sep; 21(9):327–35 (65 ref.)

ISOLATION & PURIFICATION

Purification of yeast RNA polymerase II holoenzymes. Koleske AJ, et al. **Methods Enzymol** 1996;273:176–84 (12 ref.)

Purification and analysis of functional preinitiation complexes. Roberts SG, et al. **Methods Enzymol** 1996; 273:110–8 (10 ref.)

METABOLISM

Pre–mRNA processing and the CTD of RNA polymerase II: the tail that wags the dog? Steinmetz EJ. **Cell** 1997 May 16;89(4):491–4 (21 ref.)

The general transcription factors of RNA polymerase II. Orphanides G, et al. **Genes Dev** 1996 Nov 1;10(21):2657–83 (281 ref.)

Assaying CTD kinases in vitro and phosphorylation–modulated properties of RNA polymerase II in vivo. Morris DP, et al. **Methods** 1997 Jul;12(3):264–75 (41 ref.)

Purification of RNA polymerase II general transcription factors from rat liver. Conaway RC, et al. **Methods Enzymol** 1996;273:194–207 (18 ref.)

Phosphorylation of mammalian RNA polymerase II. Dahmus ME. **Methods Enzymol** 1996;273:185–93 (19 ref.)

Basal and activated in vitro transcription in plants by RNA polymerase II and III. Fan H, et al. **Methods Enzymol** 1996; 273:268–77 (12 ref.)

Global steps during initiation by RNA polymerase II. Gralla JD. **Methods Enzymol** 1996;273:99–110 (30 ref.)

Rigorous and quantitative assay of transcription in vitro. Zhang H, et al. **Methods Enzymol** 1996;273:86–99 (39 ref.)

General transcription factors for RNA polymerase II. Conaway RC, et al. **Prog Nucleic Acid Res Mol Biol** 1997; 56:327–46 (170 ref.)

Mediator of transcriptional regulation [see comments] Björklund S, et al. **Trends Biochem Sci** 1996 Sep;21(9):335–7 (25 ref.) Comment in: Trends Biochem Sci 1996 Sep;21(9):325–6.

The RNA polymerase II general elongation factors. Reines D, et al. **Trends Biochem Sci** 1996 Sep;21(9):351–5 (37 ref.)

The role of general initiation factors in transcription by RNA polymerase II. Roeder RG. **Trends Biochem Sci** 1996 Sep; 21(9):327–35 (65 ref.)

Gene expression: increasing evidence for a transcriptosome. Halle JP, et al. **Trends Genet** 1996 May;12(5):161–3 (22 ref.)

PHYSIOLOGY

RNA polymerase II holoenzyme and transcriptional regulation. Greenblatt J. **Curr Opin Cell Biol** 1997 Jun; 9(3):310–9 (78 ref.)

RNA POLYMERASE III

RNA polymerase III and class III transcription factors from Saccharomyces cerevisiae. Huet J, et al. **Methods Enzymol** 1996;273:249–67 (70 ref.)

METABOLISM

Basal and activated in vitro transcription in plants by RNA polymerase II and III. Fan H, et al. **Methods Enzymol** 1996; 273:268–77 (12 ref.)

Regulation of RNA polymerases I and III by the retinoblastoma protein: a mechanism for growth control? White RJ. **Trends Biochem Sci** 1997 Mar;22(3):77–80 (33 ref.)

RNA POLYMERASES

[Molecular evolution of human immunodeficiency virus type 1 and the reverse transcriptase from the virus] Doi H. **Uirusu** 1996 Jun;46(1):7–12 (11 ref.) **(Jpn)**

[Molecular dissection of the influenza virus RNA polymerase] Toyoda T. **Uirusu** 1996 Dec;46(2):131–43 (67 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Stabilising oral poliovaccine at high ambient temperatures. Newman JF, et al. **Dev Biol Stand** 1996;87:103–11 (15 ref.)

CHEMISTRY

A multi–functional enzyme with RNA polymerase and RNase activities: molecular anatomy of influenza virus RNA polymerase. Ishihama A. **Biochimie** 1996; 78(11–12):1097–102 (46 ref.)

RNA polymerase slides home: pause and termination site recognition. Landick R. **Cell** 1997 Mar 21;88(6):741–4 (20 ref.)

Identification of a prime suspect. Buc H. **Curr Biol** 1997 Feb 1;7(2):R97–9 (13 ref.)

Purification of overproduced Escherichia coli RNA polymerase sigma factors by solubilizing inclusion bodies and refolding from Sarkosyl. Burgess RR. **Methods Enzymol** 1996;273:145–9 (7 ref.)

Sigma factors: purification and DNA binding. Dombroski AJ. **Methods Enzymol** 1996;273:134–44 (25 ref.)

Reconstitution of RNA polymerase. Fujita N, et al. **Methods Enzymol** 1996;273:121–30 (21 ref.)

Escherichia coli RNA polymerase holoenzyme: rapid reconstitution from recombinant alpha, beta, beta', and sigma subunits. Tang H, et al. **Methods Enzymol** 1996; 273:130–4 (19 ref.)

RNA polymerase sigma factors of Bacillus subtilis: purification and characterization. Tatti KM, et al. **Methods Enzymol** 1996;273:149–62 (20 ref.)

A structure/function analysis of Escherichia coli RNA polymerase. Gross CA, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Apr 29; 351(1339):475–82 (60 ref.)

Sigma domain structure: one down, one to go. Chan CL, et al. **Structure** 1996 Nov 15;4(11):1235–8 (34 ref.)

Structural and mechanistic relationships between nucleic acid polymerases. Sousa R. **Trends Biochem Sci** 1996 May; 21(5):186–90 (51 ref.)

GENETICS

Transcription factors: regulators of gene expression in normal and pathological states [editorial] Wilson DB. **Ann Med** 1996 Feb;28(1):1–3 (15 ref.)

The molecular anatomy of influenza virus RNA polymerase. Honda A, et al. **Biol Chem** 1997 Jun;378(6):483–8 (54 ref.)

RNA polymerase sigma factors and cell–specific gene transcription in a simple developing organism. Losick R.

Harvey Lect 1994–95;90:1–17 (44 ref.)
Evolution of viral DNA-dependent RNA polymerases. Sonntag KC, et al. **Virus Genes** 1995;11(2–3):271–84 (81 ref.)

METABOLISM

A multi-functional enzyme with RNA polymerase and RNase activities: molecular anatomy of influenza virus RNA polymerase. Ishihama A. **Biochimie** 1996; 78(11–12):1097–102 (46 ref.)
Identification of a prime suspect. Buc H. **Curr Biol** 1997 Feb 1;7(2):R97–9 (13 ref.)
Molecular motors: single-molecule mechanics. Simmons R. **Curr Biol** 1996 Apr 1;6(4):392–4 (17 ref.)
The topology of transcription by immobilized polymerases. Iborra FJ, et al. **Exp Cell Res** 1996 Dec 15;229(2):167–73 (27 ref.)
Kinetic analysis of RNA polymerase-promoter interactions. Gussin GN. **Methods Enzymol** 1996;273:45–59 (44 ref.)
Quantitative parameters for promoter clearance. Hsu LM. **Methods Enzymol** 1996;273:59–71 (30 ref.)
In vitro assay for reiterative transcription during transcriptional initiation by Escherichia coli RNA polymerase. Qi F, et al. **Methods Enzymol** 1996;273:71–85 (18 ref.)
Nuclear RNA polymerases: role of general initiation factors and cofactors in eukaryotic transcription. Roeder RG. **Methods Enzymol** 1996;273:165–71 (30 ref.)
The antiglucocorticoid action of mifepristone. Agarwai MK. **Pharmacol Ther** 1996;70(3):183–213 (552 ref.)
A structure/function analysis of Escherichia coli RNA polymerase. Gross CA, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Apr 29; 351(1339):475–82 (60 ref.)

PHYSIOLOGY

RNA polymerase slides home: pause and termination site recognition. Landick R. **Cell** 1997 Mar 21;88(6):741–4 (20 ref.)
Mutational analysis of structure-function relationship of RNA polymerase in Escherichia coli. Jin DJ, et al. **Methods Enzymol** 1996;273:300–19 (71 ref.)
[Functions of influenza virus RNA polymerase subunits] Nakada S. **Uirusu** 1995 Dec;45(2):125–43 (58 ref.) **(Jpn)**

RNA PRECURSORS

RNA splicing: unexpected spliceosome diversity. Kreivi JP, et al. **Curr Biol** 1996 Jul 1;6(7):802–5 (9 ref.)
RNA editing: rewriting receptors. O'Connell MA. **Curr Biol** 1997 Jul 1;7(7):R437–9 (28 ref.)
Regulation of pre-mRNA splicing in metazoa. Wang J, et al. **Curr Opin Genet Dev** 1997 Apr;7(2):205–11 (53 ref.)

BLOOD

Role of tissue specific alternative pre-mRNA splicing in the differentiation of the erythrocyte membrane. Benz EJ Jr, et al. **Trans Am Clin Climatol Assoc** 1996;108:78–95 (43 ref.)

CHEMISTRY

Biochemistry and regulation of pre-mRNA splicing. Adams MD, et al. **Curr Opin Cell Biol** 1996 Jun;8(3):331–9 (86 ref.)
Structural organization of the pre-mRNA splicing commitment: a hypothesis. Melčák I, et al. **J Struct Biol** 1996 Nov–Dec;117(3):189–94 (64 ref.)
Secrets of RNA folding revealed. Price S, et al. **Structure** 1996 Oct 15;4(10):1129–32 (30 ref.)

GENETICS

Trans-acting factors in yeast pre-rRNA and pre-snoRNA processing. Lafontaine D, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):803–12 (71 ref.)
Preribosomal RNA processing in archaea: characterization of the RNP endonuclease mediated processing of precursor 16S rRNA in the thermoacidophile Sulfolobus acidocaldarius. Potter S, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):813–23 (31 ref.)
Processing of eukaryotic pre-rRNA: the role of the transcribed spacers. van Nues RW, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):789–801 (65 ref.)
U3 snoRNA may recycle through different compartments of the nucleolus. Gerbi SA, et al. **Chromosoma** 1997 Jun; 105(7–8):401–6 (70 ref.)
Biochemistry and regulation of pre-mRNA splicing. Adams MD, et al. **Curr Opin Cell Biol** 1996 Jun;8(3):331–9 (86 ref.)
Splicing of precursors to mRNA in higher plants: mechanism, regulation and sub-nuclear organisation of the spliceosomal machinery. Simpson GG, et al. **Plant Mol Biol** 1996 Oct; 32(1–2):1–41 (307 ref.)
Role of tissue specific alternative pre-mRNA splicing in the differentiation of the erythrocyte membrane. Benz EJ Jr, et al. **Trans Am Clin Climatol Assoc** 1996;108:78–95 (43 ref.)
The SR protein family: pleiotropic functions in pre-mRNA splicing. Valcárcel J, et al. **Trends Biochem Sci** 1996 Aug; 21(8):296–301 (49 ref.)

METABOLISM

The structure and function of proteins involved in mammalian pre-mRNA splicing. Krämer A. **Annu Rev Biochem** 1996;65:367–409 (329 ref.)
Structural features of U6 snRNA and dynamic interactions with other spliceosomal components leading to pre-mRNA splicing. Forné T, et al. **Biochimie** 1996;78(6):436–42 (71 ref.)
Tissue-specific splicing of two mutually exclusive exons of the chicken beta-tropomyosin pre-mRNA: positive and negative regulations. Gallego ME, et al. **Biochimie** 1996; 78(6):457–65 (68 ref.)
A look at messenger RNP moving through the nuclear pore. Daneholt B. **Cell** 1997 Mar 7;88(5):585–8 (20 ref.)
Mixed mechanisms in yeast pre-mRNA splicing? [comment] Rosbash M. **Cell** 1996 Nov 1;87(3):357–9 (15 ref.) Comment on: Cell 1996 Nov 1;87(3):391–404. Comment on: Cell 1996 Nov 1;87(3):405–13.
Pre-mRNA processing and the CTD of RNA polymerase II: the tail that wags the dog? Steinmetz EJ. **Cell** 1997 May 16;89(4):491–4 (21 ref.)
Processing of pre-mRNA in polytene nuclei of Chironomus tentans salivary gland cells. Wieslander L, et al. **Exp Cell Res** 1996 Dec 15;229(2):240–6 (54 ref.)
Dynamic organization of pre-mRNA splicing factors. Huang S, et al. **J Cell Biochem** 1996 Aug;62(2):191–7 (53 ref.)
Structural organization of the pre-mRNA splicing commitment: a hypothesis. Melčák I, et al. **J Struct Biol** 1996 Nov–Dec;117(3):189–94 (64 ref.)
The RNase P of Dictyostelium discoideum. Drainas D. **Mol Biol Rep** 1995–96;22(2–3):135–8 (42 ref.)
Structure, mechanism and evolution of chloroplast transfer RNA processing systems. Gegenheimer P. **Mol Biol Rep** 1995–96;22(2–3):147–50 (27 ref.)
Transfer RNA gene organization and RNase P. Green CJ. **Mol Biol Rep** 1995–96;22(2–3):181–5 (67 ref.)
Enzymatic RNA synthesis and RNase P. Evolutionary aspects. Krupp G. **Mol Biol Rep** 1995–96;22(2–3):177–80 (29 ref.)
RNase MRP and rRNA processing. Lindahl L, et al. **Mol Biol Rep** 1995–96;22(2–3):69–73 (47 ref.)
Arabidopsis intron mutations and pre-mRNA splicing. Brown JW. **Plant J** 1996 Nov;10(5):771–80 (73 ref.)
The mechanism of 3' cleavage and polyadenylation of eukaryotic pre-mRNA. Wahle E, et al. **Prog Nucleic Acid Res Mol Biol** 1997;57:41–71 (227 ref.)

RNA PROCESSING, POST-TRANSCRIPTIONAL

Embryonic lethal abnormal visual RNA-binding proteins involved in growth, differentiation, and posttranscriptional gene expression. Antic D, et al. **Am J Hum Genet** 1997 Aug;61(2):273–8 (59 ref.)
Preribosomal RNA processing in archaea: characterization of the RNP endonuclease mediated processing of precursor 16S rRNA in the thermoacidophile Sulfolobus acidocaldarius. Potter S, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):813–23 (31 ref.)
Processing of eukaryotic pre-rRNA: the role of the transcribed spacers. van Nues RW, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):789–801 (65 ref.)
mRNA targeting: signals in the 3'-untranslated sequences for sorting of some mRNAs. Hesketh JE. **Biochem Soc Trans** 1996 May;24(2):521–7 (55 ref.)
Intron-dependent enzymatic formation of modified nucleosides in eukaryotic tRNAs: a review. Grosjean H, et al. **Biochimie** 1997 May;79(5):293–302 (74 ref.)
Post-transcriptional gene silencing in plants. Depicker A, et al. **Curr Opin Cell Biol** 1997 Jun;9(3):373–82 (57 ref.)
A comparison of mammalian and yeast pre-mRNA 3'-end processing. Keller W, et al. **Curr Opin Cell Biol** 1997 Jun; 9(3):329–36 (52 ref.)
Function and synthesis of small nucleolar RNAs. Tollervey D, et al. **Curr Opin Cell Biol** 1997 Jun;9(3):337–42 (49 ref.)
The role of the cap structure in RNA processing and nuclear export. Lewis JD, et al. **Eur J Biochem** 1997 Jul 15; 247(2):461–9 (70 ref.)
Regulation of gonadotropin-releasing hormone gene expression in vivo and in vitro. Gore AC, et al. **Front Neuroendocrinol** 1997 Apr;18(2):209–45 (192 ref.)
The multifaceted roles of the RNA processing enzyme ribonuclease III. Srivastava RA, et al. **Indian J Biochem Biophys** 1996 Aug;33(4):253–60 (47 ref.)
Processing of human mitochondrial tRNA(Ser(AGY))GCU: a novel pathway in tRNA biosynthesis. Rossmanith W. **J Mol Biol** 1997 Jan 31;265(4):365–71 (26 ref.)
Post-transcriptional control of PARP gene expression. Clayton C, et al. **Mol Biochem Parasitol** 1996 Apr;77(1):1–6 (40 ref.)
Structure, mechanism and evolution of chloroplast transfer RNA processing systems. Gegenheimer P. **Mol Biol Rep** 1995–96;22(2–3):147–50 (27 ref.)
RNase P as hyperprocessing enzyme: a model for formation of a biologically functional tRNA fragment. Kikuchi Y. **Mol Biol Rep** 1995–96;22(2–3):171–5 (17 ref.)
RNase MRP and rRNA processing. Lindahl L, et al. **Mol Biol Rep** 1995–96;22(2–3):69–73 (47 ref.)
Plant mitochondrial RNase P. Marchfelder A. **Mol Biol Rep** 1995–96;22(2–3):151–6 (29 ref.)
RNA as a target and an initiator of post-transcriptional gene silencing in transgenic plants. Baulcombe DC. **Plant Mol Biol** 1996 Oct;32(1–2):79–88 (56 ref.)
Optimizing expression of transgenes with an emphasis on post-transcriptional events. Koziel MG, et al. **Plant Mol Biol** 1996 Oct;32(1–2):393–405 (80 ref.)
Post-transcriptional regulation of chloroplast gene expression in Chlamydomonas reinhardtii. Rochaix JD. **Plant Mol Biol** 1996 Oct;32(1–2):327–41 (94 ref.)
Mechanisms for posttranscriptional regulation by iron-responsive elements and iron regulatory proteins. Muckenthaler M, et al. **Prog Mol Subcell Biol** 1997; 18:93–115 (100 ref.)
Regulation of eukaryotic messenger RNA turnover. Rajagopalan LE, et al. **Prog Nucleic Acid Res Mol Biol** 1997;56:257–86 (128 ref.)
RNA editing in kinetoplastid parasites: what to do with U. Sloof P, et al. **Trends Microbiol** 1997 May;5(5):189–95 (54 ref.)

RNA, PROTOZOAN

GENETICS

The genomic organization of guide RNA genes in kinetoplastid protozoa: several conundrums and their solutions. Simpson L. **Mol Biochem Parasitol** 1997 Jun; 86(2):133–41 (39 ref.)

METABOLISM

RNA editing in kinetoplastid protozoa. Stuart K, et al. **Microbiol Mol Biol Rev** 1997 Mar;61(1):105–20 (114 ref.)

RNA REPLICASE

GENETICS

The molecular anatomy of influenza virus RNA polymerase. Honda A, et al. **Biol Chem** 1997 Jun;378(6):483–8 (54 ref.)

METABOLISM

New insights into the mechanisms of RNA recombination. Nagy PD, et al. **Virology** 1997 Aug 18;235(1):1–9 (80 ref.)

PHYSIOLOGY

Replicase-mediated resistance to plant virus disease. Palukaitis P, et al. **Adv Virus Res** 1997;48:349–77 (93 ref.)

RNA, RIBOSOMAL

BIOSYNTHESIS

rRNA transcription and growth rate-dependent regulation of ribosome synthesis in Escherichia coli. Gourse RL, et al. **Annu Rev Microbiol** 1996;50:645–77 (157 ref.)
RNase MRP and rRNA processing. Lindahl L, et al. **Mol Biol Rep** 1995–96;22(2–3):69–73 (47 ref.)

CHEMISTRY

Identification of ribosome–ligand interactions using cleavage reagents. Hill WE, et al. **Biochem Cell Biol** 1995 Nov–Dec; 73(11–12):1033–9 (47 ref.)
Fragmentation of the ribosome to investigate RNA–ligand interactions. Howard BA, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1161–6 (31 ref.)
Structure and function of ribosomal RNA. Noller HF, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):997–1009 (35 ref.)
The pseudouridine residues of ribosomal RNA. Ofengand J, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):915–24 (39 ref.)
The conformation of ribosomes and rRNA. Moore PB. **Curr Opin Struct Biol** 1997 Jun;7(3):343–7 (36 ref.)
Secrets of RNA folding revealed. Price S, et al. **Structure** 1996 Oct 15;4(10):1129–32 (30 ref.)

GENETICS

Novel intron-encoded small nucleolar RNAs with long sequence complementarities to mature rRNAs involved in ribosome biogenesis. Bachellerie JP, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):835–43 (30 ref.)
Trans-acting factors in yeast pre-rRNA and pre-snoRNA processing. Lafontaine D, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):803–12 (71 ref.)
Upstream stimulators for recoding. Larsen B, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1123–9 (45 ref.)
The accuracy center of a eukaryotic ribosome. Liebman SW, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1141–9 (49 ref.)
Genetic probes of ribosomal RNA function. O'Connor M, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):859–68 (45 ref.)
Processing of eukaryotic pre-rRNA: the role of the transcribed spacers. van Nues RW, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):789–801 (65 ref.)
News and views on the nucleolus in 1996. Report on the 'Colloquium on the nucleolus', a meeting at Paris–Grignon, July 18–20, 1996. Mosgoeller W, et al. **Biol Cell** 1996; 88(1–2):1–4 (12 ref.)

RNA, RIBOSOMAL

U3 snoRNA may recycle through different compartments of the nucleolus. Gerbi SA, et al. **Chromosoma** 1997 Jun; 105(7–8):401–6 (70 ref.)
Eukaryotic ribosomal RNA: the recent excitement in the nucleotide modification problem. Maden BEH, et al. **Chromosoma** 1997 Jun;105(7–8):391–400 (69 ref.)
Multiparameter microscopic analysis of nucleolar structure and ribosomal gene transcription. Trendelenburg MF, et al. **Histochem Cell Biol** 1996 Aug;106(2):167–92 (156 ref.)
Riboprinting: a tool for the study of genetic diversity in microorganisms. Clark CG. **J Eukaryot Microbiol** 1997 Jul–Aug;44(4):277–83 (52 ref.)

METABOLISM

Eukaryotic ribosomal RNA: the recent excitement in the nucleotide modification problem. Maden BEH, et al. **Chromosoma** 1997 Jun;105(7–8):391–400 (69 ref.)
Ribosomal RNA: small nucleolar RNAs make their mark. Peculis BA, et al. **Curr Biol** 1996 Nov 1;6(11):1413–5 (10 ref.)
Function and synthesis of small nucleolar RNAs. Tollervey D, et al. **Curr Opin Cell Biol** 1997 Jun;9(3):337–42 (49 ref.)
The conformation of ribosomes and rRNA. Moore PB. **Curr Opin Struct Biol** 1997 Jun;7(3):343–7 (36 ref.)
Guiding ribose methylation of rRNA. Bachellerie JP, et al. **Trends Biochem Sci** 1997 Jul;22(7):257–61 (34 ref.)

ULTRASTRUCTURE

Getting closer to an understanding of the three-dimensional structure of ribosomal RNA. Mueller F, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):767–73 (40 ref.)

RNA, RIBOSOMAL, PRECURSORS see **RNA PRECURSORS**

RNA, RIBOSOMAL, SELF-SPLICING see **RNA, CATALYTIC**

RNA, RIBOSOMAL, 5S

GENETICS

Structure and function of 5S rRNA in the ribosome. Bogdanov AA, et al. **Biochem Cell Biol** 1995 Nov–Dec; 73(11–12):869–76 (52 ref.)

RNA, RIBOSOMAL, 16S

CHEMISTRY

An oligonucleotide analog approach to the decoding region of 16S rRNA. Stern S, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):899–905 (19 ref.)

GENETICS

Pleiotropic effects of mutations at positions 13 and 914 in Escherichia coli 16S ribosomal RNA. Brakier-Gingras L, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):907–13 (52 ref.)
Preribosomal RNA processing in archaea: characterization of the RNP endonuclease mediated processing of precursor 16S rRNA in the thermoacidophile Sulfolobus acidocaldarius. Potter S, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):813–23 (31 ref.)
Phylogenetic characterization of bacteria in the subsurface microbial culture collection. Balkwill DL, et al. **FEMS Microbiol Rev** 1997 Jul;20(3–4):201–16 (68 ref.)
[The 16S–23s rRNA intergenic spacer regions of mycoplasmas] Harasawa R. **Nippon Saikingaku Zasshi** 1996 Feb;51(2):583–8 (15 ref.) **(Jpn)**

RNA, RIBOSOMAL, 23S

GENETICS

Comparison of functional peptide encoded in the Escherichia coli 23S rRNA with other peptides involved in cis-regulation of translation. Tenson T, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1061–70 (40 ref.)
[The 16S–23s rRNA intergenic spacer regions of mycoplasmas] Harasawa R. **Nippon Saikingaku Zasshi** 1996 Feb;51(2):583–8 (15 ref.) **(Jpn)**

METABOLISM

Recognition determinants for proteins and antibiotics within 23S rRNA. Douthwalte S, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1179–85 (56 ref.)
Peptidyl transferase and beyond. Wower J, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1041–7 (45 ref.)

RNA, RIBOSOMAL, 28S

METABOLISM

Divergence towards a dead end? Cleavage of the divergent domains of ribosomal RNA in apoptosis. Houge G, et al. **Experientia** 1996 Oct 31;52(10–11):963–7 (29 ref.)

RNA RODENT VIRUSES see **RNA VIRUSES**

RNA, SATELLITE

see related
HELPER VIRUSES

Origin and evolution of viroids and viroid-like satellite RNAs. Diener TO. **Virus Genes** 1995;11(2–3):119–31 (61 ref.)

RNA SEQUENCE see **BASE SEQUENCE**

RNA SEQUENCE ANALYSIS see **SEQUENCE ANALYSIS, RNA**

RNA, SMALL NUCLEAR

Sno storm in the nucleolus: new roles for myriad small RNPs [comment] Smith CM, et al. **Cell** 1997 May 30;89(5):669–72 (17 ref.) Comment on: Cell 1997 May 30;89(5):799–809.

CHEMISTRY

Structural features of U6 snRNA and dynamic interactions with other spliceosomal components leading to pre-mRNA splicing. Forné T, et al. **Biochimie** 1996;78(6):436–42 (71 ref.)

GENETICS

Novel intron-encoded small nucleolar RNAs with long sequence complementarities to mature rRNAs involved in ribosome biogenesis. Bachellerie JP, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):835–43 (30 ref.)
Small nucleolar RNA. Gerbi SA. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):845–58 (140 ref.)
Trans-acting factors in yeast pre-rRNA and pre-snoRNA processing. Lafontaine D, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):803–12 (71 ref.)

METABOLISM

Structural features of U6 snRNA and dynamic interactions with other spliceosomal components leading to pre-mRNA splicing. Forné T, et al. **Biochimie** 1996;78(6):436–42 (71 ref.)
U3 snoRNA may recycle through different compartments of the nucleolus. Gerbi SA, et al. **Chromosoma** 1997 Jun; 105(7–8):401–6 (70 ref.)

PHYSIOLOGY

Function and synthesis of small nucleolar RNAs. Tollervey D, et al. **Curr Opin Cell Biol** 1997 Jun;9(3):337–42 (49 ref.)

RNA, SMALL NUCLEAR, PRECURSORS see **RNA PRECURSORS**

RNA SPLICING

see related
RNA PRECURSORS
SPLICEOSOMES

The structure and function of proteins involved in mammalian pre-mRNA splicing. Krämer A. **Annu Rev Biochem** 1996;65:367–409 (329 ref.)
RNA–RNA interaction and gene splicing. Verma M, et al. **Cancer Biochem Biophys** 1997 Jun;15(4):211–20 (65 ref.)
Mixed mechanisms in yeast pre-mRNA splicing? [comment] Rosbash M. **Cell** 1996 Nov 1;87(3):357–9 (15 ref.) Comment on: Cell 1996 Nov 1;87(3):391–404. Comment on: Cell 1996 Nov 1;87(3):405–13.
Transposition: mobile introns get into line. Grivell LA. **Curr Biol** 1996 Jan 1;6(1):48–51 (20 ref.)
RNA splicing: unexpected spliceosome diversity. Kreivi JP, et al. **Curr Biol** 1996 Jul 1;6(7):802–5 (9 ref.)
RNA splicing: out of the loop. Newman A. **Curr Biol** 1997 Jul 1;7(7):R418–20 (15 ref.)
Splicing together the unfolded-protein response. Shamu CE. **Curr Biol** 1997 Feb 1;7(2):R67–70 (15 ref.)
Common themes in the function of transcription and splicing enhancers. Hertel KJ, et al. **Curr Opin Cell Biol** 1997 Jun; 9(3):350–7 (68 ref.)
Protein functions in pre-mRNA splicing. Will CL, et al. **Curr Opin Cell Biol** 1997 Jun;9(3):320–8 (92 ref.)
Regulation of pre-mRNA splicing in metazoa. Wang J, et al. **Curr Opin Genet Dev** 1997 Apr;7(2):205–11 (53 ref.)
Regulation of neuronal nitric oxide synthase through alternative transcripts. Brenman JE, et al. **Dev Neurosci** 1997;19(3):224–31 (39 ref.)
Nuclear organization in plants. Shaw PJ. **Essays Biochem** 1996;31:77–89 (31 ref.)
The localization of sites containing nascent RNA and splicing factors. Pombo A, et al. **Exp Cell Res** 1996 Dec 15; 229(2):201–3 (14 ref.)
Ultrastructure of the nucleus in relation to transcription and splicing: roles of perichromatin fibrils and interchromatin granules. Puvion E, et al. **Exp Cell Res** 1996 Dec 15; 229(2):217–25 (54 ref.)
Nematode spliced leaders—ubiquity, evolution and utility. Blaxter M, et al. **Int J Parasitol** 1996 Oct;26(10):1025–33 (51 ref.)
Structural organization of the pre-mRNA splicing commitment: a hypothesis. Melčák I, et al. **J Struct Biol** 1996 Nov–Dec;117(3):189–94 (64 ref.)
Splicing glue: a role for SR proteins in trans splicing? Bruzik JP. **Microb Pathog** 1996 Sep;21(3):149–55 (65 ref.)
Arabidopsis intron mutations and pre-mRNA splicing. Brown JW. **Plant J** 1996 Nov;10(5):771–80 (73 ref.)
Splicing of precursors to mRNA in higher plants: mechanism, regulation and sub-nuclear organisation of the spliceosomal machinery. Simpson GG, et al. **Plant Mol Biol** 1996 Oct; 32(1–2):1–41 (307 ref.)
Pre-mRNA splicing: the discovery of a new spliceosome doubles the challenge. Tarn WY, et al. **Trends Biochem Sci** 1997 Apr;22(4):132–7 (40 ref.)
The SR protein family: pleiotropic functions in pre-mRNA splicing. Valcárcel J, et al. **Trends Biochem Sci** 1996 Aug; 21(8):296–301 (49 ref.)

GENETICS

Structural features of U6 snRNA and dynamic interactions with other spliceosomal components leading to pre-mRNA splicing. Forné T, et al. **Biochimie** 1996;78(6):436–42 (71 ref.)
Tissue-specific splicing of two mutually exclusive exons of the chicken beta-tropomyosin pre-mRNA: positive and negative regulations. Gallego ME, et al. **Biochimie** 1996; 78(6):457–65 (68 ref.)
Biochemistry and regulation of pre-mRNA splicing. Adams MD, et al. **Curr Opin Cell Biol** 1996 Jun;8(3):331–9 (86 ref.)

PHYSIOLOGY

Genetic depletion reveals an essential role for an SR protein splicing factor in vertebrate cells. Mount SM. **Bioessays** 1997 Mar;19(3):189–92 (30 ref.)
Another bridge between kingdoms: tRNA splicing in archaea and eukaryotes. Belfort M, et al. **Cell** 1997 Jun 27; 89(7):1003–6 (17 ref.)
Dynamic organization of pre-mRNA splicing factors. Huang S, et al. **J Cell Biochem** 1996 Aug;62(2):191–7 (53 ref.)
Pararetro- and retrovirus RNA: splicing and the control of nuclear export. Kiss-László Z, et al. **Trends Microbiol** 1996 Dec;4(12):480–5 (52 ref.)

RNA SPLICING, ALTERNATIVE see **ALTERNATIVE SPLICING**

RNA SYNTHESIS INHIBITORS see **NUCLEIC ACID SYNTHESIS INHIBITORS**

RNA, TRANSFER

[Translational control through nonsense suppression] Muramatsu T, et al. **Seikagaku** 1997 Jan;69(1):36–9 (8 ref.) **(Jpn)**

BIOSYNTHESIS

Structure, mechanism and evolution of chloroplast transfer RNA processing systems. Gegenheimer P. **Mol Biol Rep** 1995–96;22(2–3):147–50 (27 ref.)
Enzymatic RNA synthesis and RNase P. Evolutionary aspects. Krupp G. **Mol Biol Rep** 1995–96;22(2–3):177–80 (29 ref.)
tRNA processing in human mitochondrial disorders. Masucci JP, et al. **Mol Biol Rep** 1995–96;22(2–3):187–93 (78 ref.)

CHEMISTRY

The elongating ribosome: structural and functional aspects. Nierhaus KH, et al. **Biochem Cell Biol** 1995 Nov–Dec; 73(11–12):1011–21 (24 ref.)
An oligonucleotide analog approach to the decoding region of 16S rRNA. Stern S, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):899–905 (19 ref.)
Discriminating among the discriminator bases of tRNAs. Hou YM. **Chem Biol** 1997 Feb;4(2):93–6 (22 ref.)
RNase P as hyperprocessing enzyme: a model for formation of a biologically functional tRNA fragment. Kikuchi Y. **Mol Biol Rep** 1995–96;22(2–3):171–5 (17 ref.)
When protein engineering confronts the tRNA world. Schimmel P, et al. **Proc Natl Acad Sci U S A** 1997 Sep 16;94(19):10007–9 (24 ref.)

DRUG EFFECTS

Antibiotic inhibition of the movement of tRNA substrates through a peptidyl transferase cavity. Porse BT, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):877–85 (47 ref.)

GENETICS

Escherichia coli initiator tRNA: structure-function relationships and interactions with the translational machinery. Mangroo D, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1023–31 (51 ref.)
Another bridge between kingdoms: tRNA splicing in archaea and eukaryotes. Belfort M, et al. **Cell** 1997 Jun 27; 89(7):1003–6 (17 ref.)
Transfer RNA gene organization and RNase P. Green CJ. **Mol Biol Rep** 1995–96;22(2–3):181–5 (67 ref.)
tRNA processing in human mitochondrial disorders. Masucci JP, et al. **Mol Biol Rep** 1995–96;22(2–3):187–93 (78 ref.)

METABOLISM

tRNA-ribosome interactions. Ehrenberg M, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):1049–54 (35

ref.)
Peptidyl transferase and beyond. Wower J, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11-12):1041-7 (45 ref.)
Intron-dependent enzymatic formation of modified nucleosides in eukaryotic tRNAs: a review. Grosjean H, et al. **Biochimie** 1997 May;79(5):293-302 (74 ref.)
Enzymatic conversion of adenosine to inosine and to N1-methylinosine in transfer RNAs: a review. Grosjean H, et al. **Biochimie** 1996;78(6):488-501 (98 ref.)
Nonsense suppression in mammalian cells. Kuchino Y, et al. **Biochimie** 1996;78(11-12):1007-15 (32 ref.)
Movement of the 3'-end of tRNA through the peptidyl transferase centre and its inhibition by antibiotics. Kirillov S, et al. **FEBS Lett** 1997 Apr 14;406(3):223-33 (165 ref.)
Translational regulation of yeast GCN4. A window on factors that control initiator-trna binding to the ribosome. Hinnebusch AG. **J Biol Chem** 1997 Aug 29;272(35):21661-4 (61 ref.)
RNase P as hyperprocessing enzyme: a model for formation of a biologically functional tRNA fragment. Kikuchi Y. **Mol Biol Rep** 1995-96;22(2-3):171-5 (17 ref.)
[RNA import into mitochondria] Kazakova EA, et al. **Mol Biol (Mosk)** 1996 Jul-Aug;30(4):748-58 (48 ref.) **(Rus)**

RNA, TRANSFER, AMINO ACID-SPECIFIC

METABOLISM

Elongation factor Tu, a GTPase triggered by codon recognition on the ribosome: mechanism and GTP consumption. Rodnina MV, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11-12):1221-7 (42 ref.)

RNA, TRANSFER, AMINO ACYL

BIOSYNTHESIS

Structural and functional evidence that initiation and elongation of HIV-1 reverse transcription are distinct processes. Lanchy JM, et al. **Biochimie** 1996; 78(11-12):1087-96 (56 ref.)
Aminoacyl-tRNA synthesis: divergent routes to a common goal. Ibba M, et al. **Trends Biochem Sci** 1997 Feb; 22(2):39-42 (37 ref.)

CHEMISTRY

Structural and functional evidence that initiation and elongation of HIV-1 reverse transcription are distinct processes. Lanchy JM, et al. **Biochimie** 1996; 78(11-12):1087-96 (56 ref.)

PHYSIOLOGY

Interplay of tRNA-like structures from plant viral RNAs with partners of the translation and replication machineries [comment] Giegé R. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12078-81 (43 ref.) Comment on: Proc Natl Acad Sci U S A 1996 Oct 29;93(22):12212-6.

RNA, TRANSFER, ASP

CHEMISTRY

Aspartate identity of transfer RNAs. Giegé R, et al. **Biochimie** 1996;78(7):605-23 (108 ref.)
Conformational flexibility of tRNA: structural changes in yeast tRNA(Asp) upon binding to aspartyl-tRNA synthetase. Rees B, et al. **Biochimie** 1996;78(7):624-31 (31 ref.)

RNA, TRANSFER, GLN

CHEMISTRY

Nonsense suppression in mammalian cells. Kuchino Y, et al. **Biochimie** 1996;78(11-12):1007-15 (32 ref.)

METABOLISM

Nonsense suppression in mammalian cells. Kuchino Y, et al. **Biochimie** 1996;78(11-12):1007-15 (32 ref.)

RNA, TRANSFER, LYS

METABOLISM

Mechanisms of tRNA import into yeast mitochondria: an overview. Tarassov IA, et al. **Biochimie** 1996;78(6):502-10 (55 ref.)

RNA, TRANSFER, MET

METABOLISM

Yeast tRNA(Met) recognition by methionyl-tRNA synthetase requires determinants from the primary, secondary and tertiary structure: a review. Senger B, et al. **Biochimie** 1996;78(7):597-604 (58 ref.)

RNA, TRANSFER, METHYLTRANSFERASES

METABOLISM

Intron-dependent enzymatic formation of modified nucleosides in eukaryotic tRNAs: a review. Grosjean H, et al. **Biochimie** 1997 May;79(5):293-302 (74 ref.)

RNA, TRANSFER, PHE

CHEMISTRY

Synthetic and biological applications of tricyclic analogues of guanosine. Golankiewicz B. **Acta Biochim Pol** 1996; 43(1):53-64 (47 ref.)
The ternary complex of aminoacylated tRNA and EF-Tu-GTP. Recognition of a bond and a fold. Nissen P, et al. **Biochimie** 1996;78(11-12):921-33 (62 ref.)

RNA, TRANSFER, PRECURSORS see **RNA PRECURSORS**

RNA, TRANSFER, SER

BIOSYNTHESIS

Processing of human mitochondrial tRNA(Ser(AGY))GCU: a novel pathway in tRNA biosynthesis. Rossmanith W. **J Mol Biol** 1997 Jan 31;265(4):365-71 (26 ref.)

GENETICS

Codon reassignment in Candida species: an evolutionary conundrum. Tuite MF, et al. **Biochimie** 1996; 78(11-12):993-9 (35 ref.)

RNA TUMOR VIRUSES see **RETROVIRIDAE**

RNA, VIRAL

ANALYSIS

Genome rearrangements of rotaviruses. Desselberger U. **Arch Virol Suppl** 1996;12:37-51 (50 ref.)
Development of rotavirus molecular epidemiology: electropherotyping. Holmes IH. **Arch Virol Suppl** 1996; 12:87-91 (29 ref.)
Molecular epidemiology of human rotaviruses: genogrouping by RNA-RNA hybridization. Nakagomi O, et al. **Arch Virol Suppl** 1996;12:93-8 (18 ref.)
Higher order structures of coxsackievirus B 5' nontranslated region RNA. Currey KM, et al. **Curr Top Microbiol Immunol** 1997;223:169-90 (70 ref.)
Genetic variability and molecular epidemiology of human and simian T cell leukemia/lymphoma virus type I. Gessain A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S132-45 (106 ref.)
Quantification of the reservoir of HIV-1. Blacklaws BA. **Trends Microbiol** 1997 Jun;5(6):215-6 (11 ref.)
[Detecting hepatitis C virus RNA by in situ hybridization: a critical analysis] Negro F, et al. **Gastroenterol Clin Biol** 1997;21(2):93-7 (58 ref.) **(Fre)**

BIOSYNTHESIS

Comparison of the replication of positive-stranded RNA viruses of plants and animals. Buck KW. **Adv Virus Res** 1996;47:159-251 (543 ref.)
RNA-protein interactions in the regulation of coronavirus RNA replication and transcription. Lai MM. **Biol Chem** 1997 Jun;378(6):477-81 (32 ref.)
Nuclear organization of adenovirus RNA biogenesis. Bridge E, et al. **Exp Cell Res** 1996 Dec 15;229(2):233-9 (36 ref.)
A proposed mechanism of mRNA synthesis and capping by vesicular stomatitis virus. Shuman S. **Virology** 1997 Jan 6;227(1):1-6 (41 ref.)
[Unique mechanism of coronavirus mRNA transcription] Tsukamoto K. **Uirusu** 1996 Dec;46(2):99-107 (41 ref.) **(Jpn)**

BLOOD

Human immunodeficiency virus (HIV) RNA in plasma as the preferred target for therapy in patients with HIV infection: a critique. Fessel WJ. **Clin Infect Dis** 1997 Feb; 24(2):116-22 (34 ref.)
Effect of antiretroviral therapy on plasma HIV RNA. Saag MS. **J Biol Regul Homeost Agents** 1995 Jul-Sep;9(3):105-6 (23 ref.)
[Causal relationship between GBV-C and fulminant hepatitis] Inoue K, et al. **Nippon Rinsho** 1997 Mar;55(3):578-82 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Detection of GBV-C RNA among non B non C hepatocellular carcinoma patients] Kitamoto M, et al. **Nippon Rinsho** 1997 Mar;55(3):583-6 (6 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Dimerization of retroviral genomic RNAs: structural and functional implications. Paillart JC, et al. **Biochimie** 1996; 78(7):639-53 (138 ref.)
Getting into the major groove. Protein-RNA interactions. Moras D, et al. **Curr Biol** 1996 May 1;6(5):530-2 (15 ref.)

GENETICS

Structure, function, and evolution of adenovirus-associated RNA: a phylogenetic approach. Ma Y, et al. **J Virol** 1996 Aug;70(8):5083-99 (78 ref.)
Double-stranded RNA viruses of Saccharomyces cerevisiae. Wickner RB. **Microbiol Rev** 1996 Mar;60(1):250-65 (172 ref.)
Translational control of cellular and viral mRNAs. Gallie DR. **Plant Mol Biol** 1996 Oct;32(1-2):145-58 (109 ref.)
Gene expression from viral RNA genomes. Maia IG, et al. **Plant Mol Biol** 1996 Oct;32(1-2):367-91 (203 ref.)
Structure and function of the human immunodeficiency virus leader RNA. Berkhout B. **Prog Nucleic Acid Res Mol Biol** 1996;54:1-34 (182 ref.)
Pararetro- and retrovirus RNA: splicing and the control of nuclear export. Kiss-László Z, et al. **Trends Microbiol** 1996 Dec;4(12):480-5 (52 ref.)
New insights into the mechanisms of RNA recombination. Nagy PD, et al. **Virology** 1997 Aug 18;235(1):1-9 (80 ref.)
[Flavivirus RNA replication and involvement of host factors] Takegami T. **Uirusu** 1996 Dec;46(2):91-7 (35 ref.) **(Jpn)**
[Unique mechanism of coronavirus mRNA transcription] Tsukamoto K. **Uirusu** 1996 Dec;46(2):99-107 (41 ref.) **(Jpn)**
[Cell-free system for RNA replication, expression and cloning] Chetverin AB. **Mol Biol (Mosk)** 1996 Sep-Oct; 30(5):981-90 (41 ref.) **(Rus)**

ISOLATION & PURIFICATION

NASBA: a novel, isothermal detection technology for qualitative and quantitative HIV-1 RNA measurements. Romano JW, et al. **Clin Lab Med** 1996 Mar;16(1):89-103 (25 ref.)

METABOLISM

RNA-protein interactions in the regulation of coronavirus RNA replication and transcription. Lai MM. **Biol Chem** 1997 Jun;378(6):477-81 (32 ref.)
Viral RNA export. Hope TJ. **Chem Biol** 1997 May; 4(5):335-44 (82 ref.)
New features in RNA recognition: a Tat-TAR complex. Wemmer DE. **Chem Biol** 1996 Jan;3(1):17-9 (12 ref.)
Self-cleaving ribozymes of hepatitis delta virus RNA. Been MD, et al. **Eur J Biochem** 1997 Aug 1;247(3):741-53 (87 ref.)
RNA-protein interactions in regulation of picornavirus RNA translation. Belsham GJ, et al. **Microbiol Rev** 1996 Sep; 60(3):499-511 (159 ref.)
Plant pathogenic RNAs and RNA catalysis. Symons RH. **Nucleic Acids Res** 1997 Jul 15;25(14):2683-9 (71 ref.)
Mechanism of translation initiation on hepatitis C virus RNA. Nomoto A, et al. **Princess Takamatsu Symp** 1995;25:111-9 (30 ref.)
Pararetro- and retrovirus RNA: splicing and the control of nuclear export. Kiss-László Z, et al. **Trends Microbiol** 1996 Dec;4(12):480-5 (52 ref.)

PHYSIOLOGY

Poliovirus assembly and encapsidation of genomic RNA. Ansardi DC, et al. **Adv Virus Res** 1996;46:1-68 (232 ref.)
Hepadnaviruses: current models of RNA encapsidation and reverse transcription. Fallows DA, et al. **Adv Virus Res** 1996;46:165-94 (138 ref.)
RNA packaging. Berkowitz R, et al. **Curr Top Microbiol Immunol** 1996;214:177-218 (218 ref.)

RNA VIRUSES

[Viral myocarditis] Inoue K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):29-35 (20 ref.) **(Jpn)**
[Virus-induced apoptosis as a host defence mechanism] Koyama AH. **Tanpakushitsu Kakusan Koso** 1996 Jul; 41(9):1363-71; discussion 1396-7 (36 ref.) **(Jpn)**
[Fish viruses] Yoshimizu M. **Uirusu** 1996 Jun;46(1):49-52 (10 ref.) **(Jpn)**

CLASSIFICATION

[Viruses of whales and dolphins] Birkun AA Jr. **Mikrobiol Z** 1996 Sep-Oct;58(5):100-6 (52 ref.) (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Virus-encoded RNA helicases. Kadaré G, et al. **J Virol** 1997 Apr;71(4):2583-90 (65 ref.)

GENETICS

Comparison of the replication of positive-stranded RNA viruses of plants and animals. Buck KW. **Adv Virus Res** 1996;47:159-251 (543 ref.)
Role of host proteins in gene expression of nonsegmented negative strand RNA viruses. De BP, et al. **Adv Virus Res** 1997;48:169-204 (141 ref.)
RNA virus evolution, population dynamics, and nutritional status. Domingo E. **Biol Trace Elem Res** 1997 Jan; 56(1):23-30 (31 ref.)
Rapid evolution of viral RNA genomes. Domingo E.

RNA VIRUSES

J Nutr 1997 May;127(5 Suppl):958S–961S (30 ref.)
Negative-strand RNA viruses: genetic engineering and applications. Palese P, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11354–8 (46 ref.)
Positive strands to the rescue again: a segmented negative-strand RNA virus derived from cloned cDNAs. Rose JK. **Proc Natl Acad Sci U S A** 1996 Dec 24; 93(26):14998–5000 (31 ref.)
Genetic engineering of animal RNA viruses. Conzelmann KK, et al. **Trends Microbiol** 1996 Oct;4(10):386–93 (73 ref.)
New insights into the mechanisms of RNA recombination. Nagy PD, et al. **Virology** 1997 Aug 18;235(1):1–9 (80 ref.)
[Reverse genetics of negative-strand RNA viruses] Enami M. **Uirusu** 1995 Dec;45(2):145–57 (56 ref.) **(Jpn)**

ISOLATION & PURIFICATION

Viruses and oncogenes in brain tumors. Archer GE, et al. **J Neurovirol** 1997 May;3 Suppl 1:S76–7 (7 ref.)

METABOLISM

Viral infection. Santoro MG. **EXS** 1996;77:337–57 (103 ref.)

PHYSIOLOGY

Prions and RNA viruses of Saccharomyces cerevisiae. Wickner RB. **Annu Rev Genet** 1996;30:109–39 (141 ref.)
Amyotrophic lateral sclerosis and viruses. Salazar-Grueso EF, et al. **Clin Neurosci** 1995–96;3(6):360–7 (90 ref.)
Double-stranded RNA viruses of Saccharomyces cerevisiae. Wickner RB. **Microbiol Rev** 1996 Mar;60(1):250–65 (172 ref.)

7S RNA see **RNA, SMALL NUCLEAR**

RNASE see **RIBONUCLEASES**

RNASE A see **RIBONUCLEASE, PANCREATIC**

RNASE H see **RIBONUCLEASE H, CALF THYMUS**

RNASE T1 see **RIBONUCLEASE T1**

RO 15-1788 see **FLUMAZENIL**

ROBOTICS

Robotics and the changing face of the clinical laboratory [see comments] Boyd JC, et al. **Clin Chem** 1996 Dec; 42(12):1901–10 (30 ref.) Comment in: Clin Chem 1996 Dec;42(12):1899–900.
[Computer-assisted orthopedic surgery. From pedicle screw insertion to further applications] Berlemann U, et al. **Orthopade** 1997 May;26(5):463–9 (34 ref.) (Eng. Abstr.) **(Ger)**

ROCHALIMAEA see **BARTONELLA**

ROCHALIMAEA HENSELAE see **BARTONELLA HENSELAE**

ROCHALIMAEA INFECTIONS see **BARTONELLA INFECTIONS**

ROCHALIMAEA QUINTANA see **BARTONELLA QUINTANA**

ROCKY MOUNTAIN SPOTTED FEVER

DRUG THERAPY

Treatment of Rocky Mountain spotted fever in children. Cale DF, et al. **Ann Pharmacother** 1997 Apr;31(4):492–4 (23 ref.)

ROD-CONE DYSTROPHY see **RETINITIS PIGMENTOSA**

ROD MYOPATHY see **NEMALINE MYOPATHY**

ROD PHOTORECEPTORS see **RODS (RETINA)**

RODENT CONTROL

see related
RODENTICIDES

RODENT DISEASES

Rodent models of experimental allergic encephalomyelitis applied to the study of multiple sclerosis. Goverman J, et al. **Lab Anim Sci** 1996 Oct;46(5):482–92 (167 ref.)

EPIDEMIOLOGY

Seroepidemiologic studies of hantavirus infection among wild rodents in California. Jay M, et al. **Emerg Infect Dis** 1997 Apr-Jun;3(2):183–90 (36 ref.)

GENETICS

Murine models of polycystic kidney disease. Schieren G, et al. **Nephrol Dial Transplant** 1996;11 Suppl 6:38–45 (77 ref.)

METABOLISM

Rat models of autosomal dominant polycystic kidney disease. Gretz N, et al. **Nephrol Dial Transplant** 1996;11 Suppl 6:46–51 (33 ref.)

PARASITOLOGY

A survey of Blastocystis sp. in rodents. Chen XQ, et al. **Lab Anim Sci** 1997 Feb;47(1):91–4 (18 ref.)
Cryptosporidiosis in mice in Argentina. Fernández PE, et al. **Lab Anim Sci** 1996 Dec;46(6):685–6 (22 ref.)

PATHOLOGY

Rat models of autosomal dominant polycystic kidney disease. Gretz N, et al. **Nephrol Dial Transplant** 1996;11 Suppl 6:46–51 (33 ref.)

THERAPY

Animal models for nervous system disease in systemic lupus erythematosus. Brey RL, et al. **Ann N Y Acad Sci** 1997 Aug 14;823:97–106 (55 ref.)
Gene therapy for murine mucopolysaccharidosis type VII. Sands MS, et al. **Neuromuscul Disord** 1997 Jul;7(5):352–60 (69 ref.)

VIROLOGY

Rodent parvovirus infections. Jacoby RO, et al. **Lab Anim Sci** 1996 Aug;46(4):370–80 (89 ref.)

RODENTIA

The validity of rodent brain-ischemia models is self-evident [see comments] Ginsberg MD. **Arch Neurol** 1996 Oct; 53(10):1065–7; discussion 1070 (52 ref.) Comment in: Arch Neurol 1997 Apr;54(4):350–1.
Some considerations for the development of diets for mature rodents used in long-term investigations. McDonald RB. **J Nutr** 1997 May;127(5 Suppl):847S–850S (33 ref.)
New nonpurified diet (NTP-2000) for rodents in the National Toxicology Program's toxicology and carcinogenesis studies. Rao GN. **J Nutr** 1997 May;127(5 Suppl):842S–846S (22 ref.)

GENETICS

Issues in the choice of genetic configuration for animal aging models. Austad SN. **Exp Gerontol** 1997 Jan-Apr; 32(1–2):55–63 (25 ref.)
Evolution, expression, and possible function of a master gene for amplification of an interspersed repeated DNA family in rodents. Deininger PL, et al. **Prog Nucleic Acid Res Mol Biol** 1996;52:67–88 (62 ref.)

GROWTH & DEVELOPMENT

Genetic approaches to the function of insulin-like growth factor-binding proteins during rodent development. Pintar JE, et al. **Horm Res** 1996;45(3–5):172–7 (60 ref.)

PHYSIOLOGY

Naked mole-rats on the move. Behavioural ecology. Bromham L, et al. **Curr Biol** 1996 Sep 1;6(9):1082–3 (10 ref.)
Is the rodent hippocampus just for 'place'? Eichenbaum H. **Curr Opin Neurobiol** 1996 Apr;6(2):187–95 (69 ref.)

VIROLOGY

Rodents, human remains, and North American hantaviruses: risk factors and prevention measures for forensic science personnel—a review. Fink TM. **J Forensic Sci** 1996 Nov; 41(6):1052–6 (42 ref.)

RODENTICIDES

TOXICITY

Basic toxicology of pesticides. Costa LG. **Occup Med** 1997 Apr-Jun;12(2):251–68 (50 ref.)

RODS (RETINA)

EMBRYOLOGY

Development of photoreceptor mosaics in the primate retina. Wikler KC, et al. **Perspect Dev Neurobiol** 1996;3(3):161–75 (80 ref.)

PHYSIOLOGY

Neuronal coupling in rod-signal pathways of the retina. Vaney DI. **Invest Ophthalmol Vis Sci** 1997 Feb; 38(2):267–73 (24 ref.)
Long-term rod dark adaptation in man. Threshold measurements, rhodopsin regeneration and allosteric sensitivity regulation. An evaluation. Stabell U, et al. **Scand J Psychol** 1996 Sep;37(3):259–68 (30 ref.)
Regulation of sensitivity in vertebrate rod photoreceptors by calcium. Koutalos Y, et al. **Trends Neurosci** 1996 Feb; 19(2):73–81 (80 ref.)

RODS AND CONES see **PHOTORECEPTORS**

ROENTGEN RAYS see **X-RAYS**

ROENTGENOGRAPHY see **RADIOGRAPHY**

ROENTGENOTHERAPY see **X-RAY THERAPY**

ROGERIAN THERAPY see **NONDIRECTIVE THERAPY**

ROHYPNOL see **FLUNITRAZEPAM**

ROLANDS EPILEPSY see **EPILEPSY, ROLANDIC**

ROLE

Custodial grandparenting: new roles for middle-aged and older adults. Emick MA, et al. **Int J Aging Hum Dev** 1996; 43(2):135–54 (92 ref.)
Role: a concept explored in nursing education. Clifford C. **J Adv Nurs** 1996 Jun;23(6):1135–41 (33 ref.)
Exploring the nursing role in pain management from a post-structuralist perspective. Price K, et al. **J Adv Nurs** 1996 Nov;24(5):899–904 (35 ref.)
The family caregiver's role in Alzheimer's disease. Haley WE. **Neurology** 1997 May;48(5 Suppl 6):S25–9 (63 ref.)

ROLE CONCEPT see **ROLE**

ROMANO-WARD SYNDROME see **LONG QT SYNDROME**

ROMBERG'S DISEASE see **FACIAL HEMIATROPHY**

ROOMS, PATIENT see **PATIENTS' ROOMS**

ROOT CANAL see **DENTAL PULP CAVITY**

ROOT CANAL FILLING MATERIALS

Is there a best retrograde filling material? Jou YT, et al. **Dent Clin North Am** 1997 Jul;41(3):555–61 (24 ref.)

ROOT CANAL SEALANTS see **ROOT CANAL FILLING MATERIALS**

ROOT CANAL THERAPY

Orthodontic management of root-filled teeth. Drysdale C, et al. **Br J Orthod** 1996 Aug;23(3):255–60 (28 ref.)
Soft tissue management in endodontic surgery. Peters LB, et al. **Dent Clin North Am** 1997 Jul;41(3):513–28 (24 ref.)
Endodontic failures--changing the approach. Cheung GS. **Int Dent J** 1996 Jun;46(3):131–8 (30 ref.)
[The role of the traditional radiological methods in conservative therapy and endodontics] Bianchi SD, et al. **Minerva Stomatol** 1996 Dec;45(12):575–87 (27 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

Treatment outcome of surgical and non-surgical management of endodontic failures. Hepworth MJ, et al. **J Can Dent Assoc** 1997 May;63(5):364–71 (30 ref.)

METHODS

Evidence-based dentistry: endodontic failure--how should it be managed? Briggs PF, et al. **Br Dent J** 1997 Sep 13; 183(5):159–64 (24 ref.)
Barrier membrane techniques in endodontic microsurgery. Pecora G, et al. **Dent Clin North Am** 1997 Jul;41(3):585–602 (32 ref.)
Treatment outcome of surgical and non-surgical management of endodontic failures. Hepworth MJ, et al. **J Can Dent Assoc** 1997 May;63(5):364–71 (30 ref.)

ROOT CARIES

DIAGNOSIS

[Root caries. Its diagnosis and therapeutic principles] Hotz PR, et al. **Schweiz Monatsschr Zahnmed** 1996;106(3):248–57 (26 ref.) **(Ger, Fre)**

ROOT RESORPTION

PATHOLOGY

Cervical root resorption. Trope M. **J Am Dent Assoc** 1997 Apr;128 Suppl:56S–59S (11 ref.)

RORSCHACH TEST

STATISTICS & NUMERICAL DATA

Critical bits and the Rorschach response process. Exner JE Jr. **J Pers Assess** 1996 Dec;67(3):464–77 (15 ref.)

ROSA see **PLANTS, MEDICINAL**

ROSACEA see **ACNE ROSACEA**

ROSAI-DORFMAN DISEASE see **HISTIOCYTOSIS, SINUS**

ROSEOLA INFANTUM see **EXANTHEMA SUBITUM**

ROTATION

see related
GRAVITY, ALTERED

ADVERSE EFFECTS

Rotational vertebral artery occlusion: a mechanism of vertebrobasilar insufficiency. Kuether TA, et al. **Neurosurgery** 1997 Aug;41(2):427-32; discussion 432-3 (26 ref.)

ROTATIONAL ATHERECTOMY see **ATHERECTOMY, CORONARY**

ROTATOR CUFF

see related
SHOULDER IMPINGEMENT SYNDROME

Rotator cuff evaluation: imaging and diagnosis. Miniaci A, et al. **Orthop Clin North Am** 1997 Jan;28(1):43-58 (61 ref.)

ANATOMY & HISTOLOGY

Biology of the rotator cuff tendon. Blevins FT, et al. **Orthop Clin North Am** 1997 Jan;28(1):1-16 (121 ref.)

MR arthrography of the rotator cuff and labral-ligamentous complex. Palmer WE. **Semin Ultrasound CT MR** 1997 Aug; 18(4):278-90 (19 ref.)

DRUG EFFECTS

Local corticosteroid injections in the treatment of rotator cuff tendinitis (except for frozen shoulder and calcific tendinitis). Groupe Rhumatologique Français de l'Epaule (G.R.E.P.). Goupille P, et al. **Clin Exp Rheumatol** 1996 Sep-Oct;14(5):561-6 (41 ref.)

INJURIES

Massive rotator cuff tears. Jokiranta J, et al. **Ann Chir Gynaecol** 1996;85(2):128-31 (54 ref.)

Extraarticular pigmented villonodular synovitis of the shoulder: a case report. Sawmiller CJ, et al. **Clin Orthop** 1997 Feb;(335):262-7 (26 ref.)

Shoulder arthroscopy in the throwing athlete. Craig EV. **Clin Sports Med** 1996 Oct;15(4):673-700 (13 ref.)

Arthroscopic treatment of rotator cuff disorders. Peterson CA 2nd, et al. **Clin Sports Med** 1996 Oct;15(4):715-36 (78 ref.)

Diagnosis and treatment of rotator cuff tears in the emergency department [see comments] SooHoo NF, et al. **J Emerg Med** 1996 May-Jun;14(3):309-17 (25 ref.) Comment in: J Emerg Med 1997 Mar-Apr;15(2):248.

Partial-thickness rotator cuff tears. Pathogenesis and treatment. Breazeale NM, et al. **Orthop Clin North Am** 1997 Apr;28(2):145-55 (48 ref.)

Arthroplasty for arthritis and rotator cuff deficiency. Collins DN, et al. **Orthop Clin North Am** 1997 Apr;28(2):225-39 (59 ref.)

The rotator cuff. Large and massive tears. Technique of open repair. Cordasco FA, et al. **Orthop Clin North Am** 1997 Apr;28(2):179-93 (88 ref.)

Results of surgical repair of full-thickness tears of the rotator cuff. Gupta R, et al. **Orthop Clin North Am** 1997 Apr; 28(2):241-8 (46 ref.)

The rotator cuff. Full-thickness tears. Mini-open repair. Pollock RG, et al. **Orthop Clin North Am** 1997 Apr; 28(2):169-77 (28 ref.)

Nonoperative management of full-thickness tears of the rotator cuff. Wirth MA, et al. **Orthop Clin North Am** 1997 Jan;28(1):59-67 (34 ref.)

[Ultrasound diagnosis of the shoulder] Helweg G, et al. **Radiologe** 1996 Dec;36(12):971-80 (28 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Magnetic resonance imaging studies of the shoulder: diagnosis of lesions of the rotator cuff. Recht MP, et al. **Instr Course Lect** 1994;43:483-92 (50 ref.)

Pathology of failure of the rotator cuff tendon. Uhthoff HK, et al. **Orthop Clin North Am** 1997 Jan;28(1):31-41 (21 ref.)

PHYSIOLOGY

Biomechanics of the rotator cuff. Soslowsky LJ, et al. **Orthop Clin North Am** 1997 Jan;28(1):17-30 (71 ref.)

SURGERY

Arthroscopic treatment of rotator cuff disorders. Peterson CA 2nd, et al. **Clin Sports Med** 1996 Oct;15(4):715-36 (78 ref.)

Arthroplasty for arthritis and rotator cuff deficiency. Collins DN, et al. **Orthop Clin North Am** 1997 Apr;28(2):225-39 (59 ref.)

The rotator cuff. Large and massive tears. Technique of open repair. Cordasco FA, et al. **Orthop Clin North Am** 1997 Apr;28(2):179-93 (88 ref.)

Results of surgical repair of full-thickness tears of the rotator cuff. Gupta R, et al. **Orthop Clin North Am** 1997 Apr; 28(2):241-8 (46 ref.)

The rotator cuff. Full-thickness tears. Mini-open repair. Pollock RG, et al. **Orthop Clin North Am** 1997 Apr; 28(2):169-77 (28 ref.)

ROTAVIRUS

Natural history of human rotavirus infection. Bishop RF. **Arch Virol Suppl** 1996;12:119-28 (47 ref.)

Overview of viral gastroenteritis. Kapikian AZ. **Arch Virol Suppl** 1996;12:7-19 (38 ref.)

CLASSIFICATION

VP4 and VP7 typing using monoclonal antibodies. Coulson BS. **Arch Virol Suppl** 1996;12:113-8 (23 ref.)

Development of rotavirus molecular epidemiology: electropherotyping. Holmes IH. **Arch Virol Suppl** 1996; 12:87-91 (29 ref.)

Molecular epidemiology of human rotaviruses: genogrouping by RNA-RNA hybridization. Nakagomi O, et al. **Arch Virol Suppl** 1996;12:93-8 (18 ref.)

GENETICS

Genome rearrangements of rotaviruses. Desselberger U. **Adv Virus Res** 1996;46:69-95 (69 ref.)

Genome rearrangements of rotaviruses. Desselberger U. **Arch Virol Suppl** 1996;12:37-51 (50 ref.)

Development of rotavirus molecular epidemiology: electropherotyping. Holmes IH. **Arch Virol Suppl** 1996; 12:87-91 (29 ref.)

Molecular epidemiology of human rotaviruses: genogrouping by RNA-RNA hybridization. Nakagomi O, et al. **Arch Virol Suppl** 1996;12:93-8 (18 ref.)

Rotavirus vaccines: an overview. Midthun K, et al. **Clin Microbiol Rev** 1996 Jul;9(3):423-34 (153 ref.)

IMMUNOLOGY

WC3 reassortant vaccines in children. Clark HF, et al. **Arch Virol Suppl** 1996;12:187-98 (25 ref.)

Rotavirus immunity in the mouse. Franco MA, et al. **Arch Virol Suppl** 1996;12:141-52 (36 ref.)

Protective immunity against group A rotavirus infection and illness in infants. Matson DO. **Arch Virol Suppl** 1996; 12:129-39 (46 ref.)

The gnotobiotic piglet as a model for studies of disease pathogenesis and immunity to human rotaviruses. Saif LJ, et al. **Arch Virol Suppl** 1996;12:153-61 (24 ref.)

Rotavirus vaccines: an overview. Midthun K, et al. **Clin Microbiol Rev** 1996 Jul;9(3):423-34 (153 ref.)

Rotavirus vaccines [editorial] Ebrahim GJ. **J Trop Pediatr** 1996 Oct;42(5):254-5 (18 ref.)

Rotavirus vaccines: a perspective. Nakagomi O, et al. **Microbiol Immunol** 1996;40(10):701-9 (61 ref.)

ISOLATION & PURIFICATION

Rotavirus an emerging enteropathogen of man and animals: an overview. Malik SV, et al. **J Commun Dis** 1995 Dec; 27(4):199-207 (50 ref.)

METABOLISM

Structure and function of rotavirus NSP1. Taniguchi K, et al. **Arch Virol Suppl** 1996;12:53-8 (22 ref.)

PHYSIOLOGY

A hypothesis about the mechanism of assembly of double-shelled rotavirus particles. Suzuki H. **Arch Virol Suppl** 1996;12:79-85 (30 ref.)

Rotavirus protein expression is important for virus assembly and pathogenesis. Tian P, et al. **Arch Virol Suppl** 1996; 12:69-77 (26 ref.)

ROTAVIRUS INFECTIONS

Natural history of human rotavirus infection. Bishop RF. **Arch Virol Suppl** 1996;12:119-28 (47 ref.)

Human group B rotavirus: adult diarrhea rotavirus. Hong T. **Chin Med J (Engl)** 1996 Jan;109(1):11-2 (0 ref.)

EPIDEMIOLOGY

Rotavirus infection and prevention. Barnes GL, et al. **Curr Opin Pediatr** 1997 Feb;9(1):19-23 (52 ref.)

Rotavirus an emerging enteropathogen of man and animals: an overview. Malik SV, et al. **J Commun Dis** 1995 Dec; 27(4):199-207 (50 ref.)

[Rotaviruses in human and veterinary medicine] Dodet B, et al. **Sante** 1997 May-Jun;7(3):195-9 (7 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Murine model of rotavirus infection. Feng N, et al. **Adv Exp Med Biol** 1997;412:233-40 (25 ref.)

MICROBIOLOGY

[Rotaviruses in human and veterinary medicine] Dodet B, et al. **Sante** 1997 May-Jun;7(3):195-9 (7 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

WC3 reassortant vaccines in children. Clark HF, et al. **Arch Virol Suppl** 1996;12:187-98 (25 ref.)

Rotavirus immunity in the mouse. Franco MA, et al. **Arch Virol Suppl** 1996;12:141-52 (36 ref.)

Jennerian and modified Jennerian approach to vaccination against rotavirus diarrhea using a quadrivalent rhesus rotavirus (RRV) and human-RRV reassortant vaccine. Kapikian AZ, et al. **Arch Virol Suppl** 1996;12:163-75 (30 ref.)

Protective immunity against group A rotavirus infection and illness in infants. Matson DO. **Arch Virol Suppl** 1996; 12:129-39 (46 ref.)

The gnotobiotic piglet as a model for studies of disease pathogenesis and immunity to human rotaviruses. Saif LJ, et al. **Arch Virol Suppl** 1996;12:153-61 (24 ref.)

Rotavirus vaccines: an overview. Midthun K, et al. **Clin Microbiol Rev** 1996 Jul;9(3):423-34 (153 ref.)

Rotavirus infection and prevention. Barnes GL, et al. **Curr Opin Pediatr** 1997 Feb;9(1):19-23 (52 ref.)

Rotavirus vaccines [editorial] Ebrahim GJ. **J Trop Pediatr** 1996 Oct;42(5):254-5 (18 ref.)

Rotavirus vaccines: a perspective. Nakagomi O, et al. **Microbiol Immunol** 1996;40(10):701-9 (61 ref.)

VIROLOGY

Molecular epidemiology of human rotaviruses: genogrouping by RNA-RNA hybridization. Nakagomi O, et al. **Arch Virol Suppl** 1996;12:93-8 (18 ref.)

ROTHMUND-THOMSON SYNDROME see **POIKILODERMA CONGENITALE**

ROUGHAGE see **DIETARY FIBER**

ROUND WINDOW

PHYSIOLOGY

Round window membrane. Structure function and permeability: a review. Goycoolea MV, et al. **Microsc Res Tech** 1997 Feb 1;36(3):201-11 (60 ref.)

ULTRASTRUCTURE

Round window membrane. Structure function and permeability: a review. Goycoolea MV, et al. **Microsc Res Tech** 1997 Feb 1;36(3):201-11 (60 ref.)

ROUS-ASSOCIATED VIRUS see **LEUKOSIS VIRUS, AVIAN**

ROUS SARCOMA see **SARCOMA, AVIAN**

ROUS SARCOMA VIRUS see **SARCOMA VIRUSES, AVIAN**

ROUSSY-LEVY SYNDROME see **CHARCOT-MARIE DISEASE**

ROUTINE DIAGNOSTIC TESTS see **DIAGNOSTIC TESTS, ROUTINE**

ROWSON-PARR VIRUS see **FRIEND VIRUS**

ROXITHROMYCIN

PHARMACOKINETICS

[New pharmacologic approaches to macrolides: example of roxithromycin] Bergogne-Bérézin E. **Presse Med** 1996 Dec 14;25(39):1982-8 (29 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

[New pharmacologic approaches to macrolides: example of roxithromycin] Bergogne-Bérézin E. **Presse Med** 1996 Dec 14;25(39):1982-8 (29 ref.) (Eng. Abstr.) **(Fre)**

[New pharmacological approaches of macrolides. Example of roxithromycin] Bergogne-Bérézin E. **Presse Med** 1997 Mar;26 Suppl 2:4-10 (29 ref.) **(Fre)**

[Roxithromycin—a new macrolide antibiotic] Iakovlev SV, et al. **Ter Arkh** 1995;67(12):61-6 (72 ref.) **(Rus)**

THERAPEUTIC USE

[Antibiotic strategy in bronchial infections. Role of roxithromycin] Gaillat J. **Presse Med** 1997 Mar;26 Suppl 2:16-21 (26 ref.) **(Fre)**

[Asthma and Chlamydia pneumoniae. A future prospect for macrolides in general and roxithromycin in particular?] Mayaud C. **Presse Med** 1997 Mar;26 Suppl 2:27-9 (21 ref.) **(Fre)**

ROYAL FREE DISEASE see **FATIGUE SYNDROME, CHRONIC**

RSH SYNDROME see **SMITH-LEMLI-OPITZ SYNDROME**

RT7 ANTIGENS see **ANTIGENS, CD45**

RU-486 see **MIFEPRISTONE**

RUBBER

ADVERSE EFFECTS

Natural rubber latex allergy. Turjanmaa K, et al. **Allergy** 1996 Sep;51(9):593–602 (96 ref.)

Latex sensitivity in children with spina bifida: implications for occupational therapy practitioners. Scoggin AE, et al. **Am J Occup Ther** 1997 Jul–Aug;51(7):608–11 (21 ref.)

Latex allergy: an emerging clinical and occupational health problem. Kam PC, et al. **Anaesthesia** 1997 Jun;52(6):570–5 (45 ref.)

Latex allergy. Wooding LG, et al. **Compr Ther** 1996 Jun; 22(6):384–92 (30 ref.)

Rubber glove dermatitis: a significant occupational hazard–prevention. Estlander T, et al. **Curr Probl Dermatol** 1996;25:170–6 (32 ref.)

Natural rubber latex allergy: spectrum, diagnostic approach, and therapy. Woods JA, et al. **J Emerg Med** 1997 Jan–Feb; 15(1):71–85 (80 ref.)

Current perspectives on latex allergy [see comments] Landwehr LP, et al. **J Pediatr** 1996 Mar;128(3):305–12 (63 ref.) Comment in: J Pediatr 1996 Nov;129(5):771–2.

Latex allergy. Considerations for the care of pediatric patients and employee safety. Young MA, et al. **Nurs Clin North Am** 1997 Mar;32(1):169–82 (47 ref.)

[Latex allergy—it concerns all of us. Primary, secondary and tertiary prevention from the viewpoint of occupational medicine] Drexler H, et al. **Dtsch Med Wochenschr** 1996 Sep 27;121(39):1198–203 (17 ref.) **(Ger)**

[Latex: an allergological emergency? An update and outlook] La Grutta S, et al. **Pediatr Med Chir** 1996 Nov–Dec; 18(6):545–8 (24 ref.) (Eng. Abstr.) **(Ita)**

[Latex allergy in children with myelomeningocele. Incidence and associated factors] Estornell Moragues F, et al. **Actas Urol Esp** 1997 Mar;21(3):227–35 (46 ref.) (Eng. Abstr.) **(Spa)**

ANALYSIS

Environmental health implications of heavy metal pollution from car tires. Horner JM. **Rev Environ Health** 1996 Oct–Dec;11(4):175–8 (12 ref.)

CHEMISTRY

Mechanical properties of hydrogels and their experimental determination. Anseth KS, et al. **Biomaterials** 1996 Sep; 17(17):1647–57 (51 ref.)

TOXICITY

Rubber tire leachates in the aquatic environment. Evans JJ. **Rev Environ Contam Toxicol** 1997;151:67–115 (125 ref.)

RUBBER SILICONE see **SILICONE ELASTOMERS**

RUBEFACIENTS see **IRRITANTS**

RUBELLA

COMPLICATIONS

[Rubella virus] Abe T, et al. **Nippon Rinsho** 1997 Apr; 55(4):865–9 (14 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Rubella immunization. Kimberlin DW. **Pediatr Ann** 1997 Jun; 26(6):366–70 (22 ref.)

PREVENTION & CONTROL

Control of rubella and congenital rubella syndrome (CRS) in developing countries, Part 1: Burden of disease from CRS. Cutts FT, et al. **Bull World Health Organ** 1997; 75(1):55–68 (104 ref.)

Control of rubella and congenital rubella syndrome (CRS) in developing countries, Part 2: Vaccination against rubella. Robertson SE, et al. **Bull World Health Organ** 1997; 75(1):69–80 (67 ref.)

Rubella immunization. Kimberlin DW. **Pediatr Ann** 1997 Jun; 26(6):366–70 (22 ref.)

[The vaccinal prophylaxis of rubella] Lavrent'eva IN. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Nov–Dec; (6):109–13 (45 ref.) **(Rus)**

RUBELLA SYNDROME, CONGENITAL

[Congenital rubella syndrome] Ozasa H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):464–6 (12 ref.) **(Jpn)**

COMPLICATIONS

[Progressive rubella panencephalitis] Kuroda Y, et al. **Nippon Rinsho** 1997 Apr;55(4):922–5 (11 ref.) (Eng. Abstr.) **(Jpn)**

RUBELLA VACCINE

Control of rubella and congenital rubella syndrome (CRS) in developing countries, Part 2: Vaccination against rubella. Robertson SE, et al. **Bull World Health Organ** 1997; 75(1):69–80 (67 ref.)

Rubella immunization. Kimberlin DW. **Pediatr Ann** 1997 Jun; 26(6):366–70 (22 ref.)

ADMINISTRATION & DOSAGE

[Pre- and postgestational vaccination] Figueroa-Damián R. **Ginecol Obstet Mex** 1996 Jul;64:310–5 (27 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

[The vaccinal prophylaxis of rubella] Lavrent'eva IN. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Nov–Dec; (6):109–13 (45 ref.) **(Rus)**

RUBEOLA see **MEASLES**

RUBIDOMYCIN see **DAUNORUBICIN**

RUBINSTEIN–TAYBI SYNDROME

[Rubinstein–Taybi syndrome] Fukushima Y. **Ryoikibetsu Shokogun Shirizu** 1996;(15):295–6 (6 ref.) **(Jpn)**

RUBOMYCIN see **DAUNORUBICIN**

RUFFINI'S CORPUSCLES see **MECHANORECEPTORS**

RUGBY see **FOOTBALL**

RUMEN

METABOLISM

Relationship between fermentation acid production in the rumen and the requirement for physically effective fiber. Allen MS. **J Dairy Sci** 1997 Jul;80(7):1447–62 (102 ref.)

Quantitative review of ruminal and total tract digestion of mixed diet organic matter and carbohydrates. Archimède H, et al. **Reprod Nutr Dev** 1997;37(2):173–89 (31 ref.)

MICROBIOLOGY

Factors influencing microbial growth and the efficiency of microbial protein synthesis: a review. Fébel H, et al. **Acta Vet Hung** 1996;44(1):39–56 (83 ref.)

Ecology, metabolism, and genetics of ruminal selenomonads. Ricke SC, et al. **Crit Rev Microbiol** 1996;22(1):27–56 (279 ref.)

Are ruminal bacteria armed with bacteriocins? Kalmokoff ML, et al. **J Dairy Sci** 1996 Dec;79(12):2297–306 (53 ref.)

How many ruminal bacteria are there? Krause DO, et al. **J Dairy Sci** 1996 Aug;79(8):1467–75 (85 ref.)

Do ruminal bacteria exchange genetic material? Morrison M. **J Dairy Sci** 1996 Aug;79(8):1476–86 (62 ref.)

Why are ruminal cellulolytic bacteria unable to digest cellulose at low pH? Russell JB, et al. **J Dairy Sci** 1996 Aug;79(8):1503–9 (55 ref.)

Why don't ruminal bacteria digest cellulose faster? Weimer PJ. **J Dairy Sci** 1996 Aug;79(8):1496–502 (45 ref.)

Why do many ruminal bacteria die and lyse so quickly? Wells JE, et al. **J Dairy Sci** 1996 Aug;79(8):1487–95 (97 ref.)

Microbial and animal limitations to fiber digestion and utilization. Varga GA, et al. **J Nutr** 1997 May;127(5 Suppl):819S–823S (34 ref.)

Anaerobic fungi in the digestive tract of mammalian herbivores and their potential for exploitation. Theodorou MK, et al. **Proc Nutr Soc** 1996 Nov;55(3):913–26 (72 ref.)

RUMINANTIA see **RUMINANTS**

RUMINANTS

Cytokines as adjuvants for ruminant vaccines. Lofthouse SA, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):835–42 (57 ref.)

Relationship between soil type and Mycobacterium paratuberculosis. Johnson-Ifearulundu YJ, et al. **J Am Vet Med Assoc** 1997 Jun 15;210(12):1735–40 (44 ref.)

The insulin-like growth factor and epidermal growth factor families in mammary cell growth in ruminants: action and interaction with hormones. Forsyth IA. **J Dairy Sci** 1996 Jun;79(6):1085–96 (84 ref.)

Sustainable helminth control of ruminants in developing countries. Waller PJ. **Vet Parasitol** 1997 Jul 31; 71(2–3):195–207 (33 ref.)

[Bovine spongiform encephalopathy. Second update of data collected since the report of February 6, 1996] Brugère-Picoux J, et al. **Bull Acad Natl Med** 1996 Jun–Jul; 180(6):1443–9; discussion 1450–4 (21 ref.) (Eng. Abstr.) **(Fre)**

ANATOMY & HISTOLOGY

Physical constraints on voluntary intake of forages by ruminants. Allen MS. **J Anim Sci** 1996 Dec;74(12):3063–75 (134 ref.)

EMBRYOLOGY

Comparison between in vivo-derived and in vitro-produced pre-elongation embryos from domestic ruminants. Thompson JG. **Reprod Fertil Dev** 1997;9(3):341–54 (133 ref.)

METABOLISM

Starch utilization by ruminants: from basics to the bunk. Huntington GB. **J Anim Sci** 1997 Mar;75(3):852–67 (117 ref.)

Metabolic constraints on voluntary intake in ruminants. Illius AW, et al. **J Anim Sci** 1996 Dec;74(12):3052–62 (73 ref.)

A review on environmental impacts of nutritional strategies in ruminants. Tamminga S. **J Anim Sci** 1996 Dec; 74(12):3112–24 (60 ref.)

Ruminant nutrition from an environmental perspective: factors affecting whole-farm nutrient balance. Van Horn HH, et al. **J Anim Sci** 1996 Dec;74(12):3082–102 (81 ref.)

Amino acid supply and metabolism by the ruminant mammary gland. Bequette BJ, et al. **Proc Nutr Soc** 1997 Jul;56(2):593–605 (45 ref.)

Modelling post-absorptive protein and amino acid metabolism in the ruminant. Hanigan MD, et al. **Proc Nutr Soc** 1997 Jul;56(2):631–43 (49 ref.)

Regulation of hepatic nitrogen metabolism in ruminants. Lobley GE, et al. **Proc Nutr Soc** 1997 Jul;56(2):547–63 (57 ref.)

MICROBIOLOGY

The pathology and pathogenesis of paratuberculosis in ruminants and other species. Clarke CJ. **J Comp Pathol** 1997 Apr;116(3):217–61 (262 ref.)

PARASITOLOGY

Some relationships between age, immune responsiveness and resistance to parasites in ruminants. Colditz IG, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):869–77 (30 ref.)

Nutrition and parasite interaction. Coop RL, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):951–62 (89 ref.)

Are the 26-kDa somatic and the 24-kDa excretory/secretory antigens of Haemonchus contortus one and the same? Cornelissen AW. **Int J Parasitol** 1996 Oct;26(10):1131 (9 ref.)

Nutritional enhancement of parasite control in small ruminant production systems in developing countries of South-East Asia and the Pacific. Knox M, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):963–70 (44 ref.)

Prospects for the immunological control of ruminant gastrointestinal nematodes: natural immunity, can it be harnessed? Miller HR. **Int J Parasitol** 1996 Aug–Sep; 26(8–9):801–11 (87 ref.)

Controlling internal parasites in grazing ruminants without recourse to anthelmintics: approaches, experiences and prospects. Niezen JH, et al. **Int J Parasitol** 1996 Aug–Sep; 26(8–9):983–92 (35 ref.)

Approaches to the control of fasciolosis in ruminants. Roberts JA, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):971–81 (90 ref.)

Implications of nutrition for the ability of ruminants to withstand gastrointestinal nematode infections. van Houtert MF, et al. **Int J Parasitol** 1996 Nov;26(11):1151–67 (167 ref.)

PHYSIOLOGY

Interferon tau: a novel pregnancy recognition signal. Bazer FW, et al. **Am J Reprod Immunol** 1997 Jun;37(6):412–20 (53 ref.)

Plant phenolic amines: potential effects on sympathoadrenal medullary, hypothalamic-pituitary-adrenal, and hypothalamic-pituitary-gonadal function in ruminants. Vera-Avila HR, et al. **Domest Anim Endocrinol** 1996 Jul; 13(4):285–96 (74 ref.)

Physical constraints on voluntary intake of forages by ruminants. Allen MS. **J Anim Sci** 1996 Dec;74(12):3063–75 (134 ref.)

Peptide regulation of intestinal glucose absorption. Bird AR, et al. **J Anim Sci** 1996 Oct;74(10):2523–40 (267 ref.)

Influence of energy supplementation on grazing ruminants: requirements and responses. Caton JS, et al. **J Anim Sci** 1997 Feb;75(2):533–42 (64 ref.)

Modeling ruminant feed intake with protein, chemostatic, and distention feedbacks. Fisher DS. **J Anim Sci** 1996 Dec; 74(12):3076–81 (13 ref.)

Integration of regulatory signals controlling forage intake in ruminants. Forbes JM. **J Anim Sci** 1996 Dec; 74(12):3029–35 (38 ref.)

Metabolic constraints on voluntary intake in ruminants. Illius AW, et al. **J Anim Sci** 1996 Dec;74(12):3052–62 (73 ref.)

Role of ruminant livestock in sustainable agricultural systems. Oltjen JW, et al. **J Anim Sci** 1996 Jun;74(6):1406–9 (13 ref.)

Acquired aversions as the basis for varied diets of ruminants foraging on rangelands. Provenza FD. **J Anim Sci** 1996 Aug;74(8):2010–20 (167 ref.)

Regulatory and legal aspects of supplementing grazing ruminants. Sellers R. **J Anim Sci** 1997 Feb;75(2):551–5 (5 ref.)

A review on environmental impacts of nutritional strategies in ruminants. Tamminga S. **J Anim Sci** 1996 Dec; 74(12):3112–24 (60 ref.)

Ruminant nutrition from an environmental perspective: factors affecting whole-farm nutrient balance. Van Horn HH, et al. **J Anim Sci** 1996 Dec;74(12):3082–102 (81 ref.)

Plant limitations to fiber digestion and utilization. Buxton DR, et al. **J Nutr** 1997 May;127(5 Suppl):814S–818S (22 ref.)

Analysis of forage fiber and cell walls in ruminant nutrition. **Jung HJ. J Nutr** 1997 May;127(5 Suppl):810S–813S (25 ref.)
Microbial and animal limitations to fiber digestion and utilization. Varga GA, et al. **J Nutr** 1997 May;127(5 Suppl):819S–823S (34 ref.)
Recent developments and potentialities for reducing embryo mortality in ruminants: the role of IFN-tau and other cytokines in early pregnancy. Martal J, et al. **Reprod Fertil Dev** 1997;9(3):355–80 (250 ref.)
[Motor, digestive and secretory processes of the forestomach and the abomasum--a short review] Wolffram S. **Schweiz Arch Tierheilkd** 1996;138(7):343–50 (6 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Physiologic and pathophysiologic considerations for ruminant and swine anesthesia. Jorgensen JS, et al. **Vet Clin North Am Food Anim Pract** 1996 Nov; 12(3):481–500 (64 ref.)
Management and emergency intervention during anesthesia. Kruse-Elliott KT. **Vet Clin North Am Food Anim Pract** 1996 Nov;12(3):563–78 (29 ref.)
Local and regional anesthesia in ruminants and swine. Skarda RT. **Vet Clin North Am Food Anim Pract** 1996 Nov; 12(3):579–626 (140 ref.)
Supplies and technical considerations for ruminant and swine anesthesia. Tobin E, et al. **Vet Clin North Am Food Anim Pract** 1996 Nov;12(3):531–62 (24 ref.)

RUNNING

Dynamic obstruction of the external iliac artery in endurance athletes and its relationship to endothelial function: the case of a long distance runner. Wright IA, et al. **Br J Sports Med** 1997 Jun;31(2):156–8 (10 ref.)

INJURIES

Maintenance of aerobic capacity during recovery from right foot Jones fracture: a case report. Frangolias DD, et al. **Clin J Sport Med** 1997 Jan;7(1):54–7; discussion 57–8 (16 ref.)
Does running exercise cause osteoarthritis? Lahr DD. **Md Med J** 1996 Aug;45(8):641–4 (18 ref.)

PHYSIOLOGY

Running biomechanics. Thordarson DB. **Clin Sports Med** 1997 Apr;16(2):239–47 (9 ref.)
Vitamin C, neutrophil function, and upper respiratory tract infection risk in distance runners: the missing link. Peters-Futre EM. **Exerc Immunol Rev** 1997;3:32–52 (99 ref.)
Measurement of maximal and submaximal anaerobic performance capacity: concluding chapter. Rusko HK, et al. **Int J Sports Med** 1996 Jul;17 Suppl 2:S125–9 (29 ref.)
Nutritional practices of athletes: are they sub-optimal? Hawley JA, et al. **J Sports Sci** 1995 Summer;13 Spec No:S75–81 (73 ref.)
American College of Sports Medicine position stand. Heat and cold illnesses during distance running. Armstrong LE, et al. **Med Sci Sports Exerc** 1996 Dec;28(12):i–x (97 ref.)
Biomechanics and running economy. Anderson T. **Sports Med** 1996 Aug;22(2):76–89 (131 ref.)
Use of blood lactate measurements for prediction of exercise performance and for control of training. Recommendations for long-distance running. Billat LV. **Sports Med** 1996 Sep; 22(3):157–75 (138 ref.)
The effect of endurance training on reproductive function in male runners. A 'volume threshold' hypothesis. De Souza MJ, et al. **Sports Med** 1997 Jun;23(6):357–74 (79 ref.)
Metabolic responses and mechanisms during water immersion running and exercise. Frangolias DD, et al. **Sports Med** 1996 Jul;22(1):38–53 (47 ref.)

RUNT DISEASE see **GRAFT VS HOST DISEASE**

RURAL HEALTH

see related
AGRICULTURAL WORKERS' DISEASES

Epidemiology of pollution-induced airway disease: urban/rural differences in East and West Germany. Nicolai T. **Allergy** 1997;52(38 Suppl):26–9; discussion 35–6 (18 ref.)
Obstetrics in general practice. A rural perspective. Gillett JM. **Aust Fam Physician** 1997 Mar;26(3):263–9 (6 ref.)
An overview of rural health [editorial] Lawrence DJ. **J Manipulative Physiol Ther** 1996 Feb;19(2):75–81 (61 ref.)
Unheard and unseen. Rural women and domestic violence. Adler C. **J Nurse Midwifery** 1996 Nov-Dec;41(6):463–6 (3 ref.)
White, red and black: colour classification and illness management in Northern Ghana. Kirby JP. **Soc Sci Med** 1997 Jan;44(2):215–30 (38 ref.)
[Practical gynecology in the African bush: from humanitarianism to humanism] Géraud R, et al. **Contracept Fertil Sex** 1997 Jun;25(6):482–91 (28 ref.) **(Fre)**
[How to manage HIV seropositive or AIDS patients in rural Burkina Faso?] Taverne B. **Sante** 1997 May-Jun; 7(3):177–86 (16 ref.) (Eng. Abstr.) **(Fre)**

RURAL HEALTH SERVICES

Politics, practical logic, and primary health care in rural Haiti. Brodwin PE. **Med Anthropol Q** 1997 Mar;11(1):69–88 (58 ref.)
Mental health service delivery in rural areas: organizational and clinical issues. Wagenfeld MO, et al. **NIDA Res Monogr** 1997;168:418–37 (59 ref.)

MANPOWER

The role of chiropractors in the delivery of interdisciplinary health care in rural areas. Hawk C, et al. **J Manipulative Physiol Ther** 1996 Feb;19(2):82–91 (65 ref.)

ORGANIZATION & ADMINISTRATION

Mental health services for rural elderly: innovative service strategies. Chalifoux Z, et al. **Community Ment Health J** 1996 Oct;32(5):463–80 (70 ref.)
High touch meets high tech. Distance mental health screening for rural youth using Teleform. Puskar KR, et al. **Comput Nurs** 1996 Nov-Dec;14(6):323–9; quiz 330–2 (31 ref.)

STANDARDS

Reduction of maternal and perinatal mortality in rural and peri-urban settings: what works? Kwast BE. **Eur J Obstet Gynecol Reprod Biol** 1996 Oct;69(1):47–53 (22 ref.)

SUPPLY & DISTRIBUTION

Health care reform and rural mental health: severe mental illness. Kane CF, et al. **Community Ment Health J** 1996 Oct;32(5):445–62 (80 ref.)

TRENDS

Pharmaceutical care for rural patients: ominous trends. Gangeness DE. **J Am Pharm Assoc (Wash)** 1997 Jan-Feb; NS37(1):62–5, 84 (21 ref.)

RURAL HOSPITALS see **HOSPITALS, RURAL**

RURAL POPULATION

Assessment of dietary intake in rural communities in Africa: experiences in Kenya. Kigutha HN. **Am J Clin Nutr** 1997 Apr;65(4 Suppl):1168S–1172S (9 ref.)
Rural physicians, rural networks, and free market health care in the 1990s. Rosenthal TC, et al. **Arch Fam Med** 1997 Jul-Aug;6(4):319–23 (59 ref.)
[Gestational diabetes: an example of a rural region. The DIAGEST Group] Vambergue A, et al. **Journ Annu Diabetol Hotel Dieu** 1997;:69–80 (49 ref.) **(Fre)**

RUSSELL'S VIPER VENOM TIME see **PROTHROMBIN TIME**

RUTHENIUM RED

TOXICITY

Ruthenium red as a tool to study calcium channels, neuronal death and the function of neural pathways. Tapia R, et al. **Neurochem Int** 1997 Feb;30(2):137–47 (59 ref.)

RYANODINE

PHARMACOLOGY

Conformation state of the ryanodine receptor and functional effects of ryanodine on skeletal muscle. Bianchi CP. **Biochem Pharmacol** 1997 Apr 4;53(7):909–12 (30 ref.)
The pharmacology of ryanodine and related compounds. Sutko JL, et al. **Pharmacol Rev** 1997 Mar;49(1):53–98 (196 ref.)

S-ANTIGEN, RETINAL see **ARRESTIN**

S PHASE

[Regulation of cyclin E and Cdk2 expression at G1/S transition: post-transcriptional reguration mediated by delta FosB] Oda S, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1725–31 (43 ref.) **(Jpn)**
[DNA checkpoint control in Saccharomyces cerevisae] Sugimoto K, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep; 41(12 Suppl):1807–12 (20 ref.) **(Jpn)**

GENETICS

Cell cycle control of S phase: a comparison of two yeasts. Huberman JA. **Chromosoma** 1996 Oct;105(4):197–203 (40 ref.)
A quantitative model for the cdc2 control of S phase and mitosis in fission yeast. Stern B, et al. **Trends Genet** 1996 Sep;12(9):345–50 (36 ref.)
[The fission yeast cdc18+ gene links S phase to START and plays a major role in the initiation of DNA replication] Nishitani H. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1761–8 (34 ref.) **(Jpn)**

PHYSIOLOGY

Overview of the regulation of S-phase in Xenopus egg extracts. Chevalier S, et al. **Biochimie** 1995;77(10):808–16 (103 ref.)
S-phase and DNA-damage checkpoints: a tale of two yeasts. Stewart E, et al. **Curr Opin Cell Biol** 1996 Dec;8(6):781–7 (64 ref.)

SABIN VACCINE see **POLIOVIRUS VACCINE, ORAL**

SACCADES

Medical treatments for abnormal eye movements: pharmacological, optical and immunological strategies. Averbuch-Heller L, et al. **Aust N Z J Ophthalmol** 1997 Feb;25(1):7–13 (36 ref.)

PHYSIOLOGY

Suppression of the magnocellular pathway during saccades. Ross J, et al. **Behav Brain Res** 1996 Oct;80(1-2):1–8 (63 ref.)
Sensorimotor processing: charting the frontier. Carpenter RH. **Curr Biol** 1997 Jun 1;7(6):R348–51 (10 ref.)
The anatomical localization of saccades using functional imaging studies and transcranial magnetic stimulation. Carter N, et al. **Curr Opin Neurol** 1997 Feb;10(1):10–7 (47 ref.)
The microscopic anatomy and physiology of the mammalian saccadic system. Moschovakis AK, et al. **Prog Neurobiol** 1996 Oct;50(2-3):133–254 (699 ref.)
Mr. Chips: an ideal-observer model of reading. Legge GE, et al. **Psychol Rev** 1997 Jul;104(3):524–53 (130 ref.)
[Changes and disorders in voluntary saccades during development and aging] Hikosaka O. **No To Hattatsu** 1997 May;29(3):213–9 (21 ref.) (Eng. Abstr.) **(Jpn)**

SACCADIC EYE MOVEMENTS see **SACCADES**

SACCHARIDE-MEDIATED CELL ADHESION MOLECULES see **CELL ADHESION MOLECULES**

SACCHARIN

METABOLISM

Saccharin mechanistic data and risk assessment: urine composition, enhanced cell proliferation, and tumor promotion. Whysner J, et al. **Pharmacol Ther** 1996; 71(1-2):225–52 (172 ref.)

TOXICITY

Saccharin mechanistic data and risk assessment: urine composition, enhanced cell proliferation, and tumor promotion. Whysner J, et al. **Pharmacol Ther** 1996; 71(1-2):225–52 (172 ref.)

SACCHAROMYCES

CYTOLOGY

[MCM protein complex in fission yeast] Adachi Y. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1777–83 (20 ref.) **(Jpn)**
[The fission yeast cdc18+ gene links S phase to START and plays a major role in the initiation of DNA replication] Nishitani H. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1761–8 (34 ref.) **(Jpn)**

METABOLISM

Protein transport from the cytoplasm into the vacuole. Klionsky DJ. **J Membr Biol** 1997 May 15;157(2):105–15 (65 ref.)

SACCHAROMYCES CEREVISIAE

see related
YEAST, DRIED

ACTIN: general principles from studies in yeast. Ayscough KR, et al. **Ann Rev Cell Dev Biol** 1996;12:129–60 (115 ref.)
Nuclear fusion in the yeast Saccharomyces cerevisiae. Rose MD. **Ann Rev Cell Dev Biol** 1996;12:663–95 (131 ref.)

CHEMISTRY

The complete inventory of the yeast Saccharomyces cerevisiae P-type transport ATPases. Catty P, et al. **FEBS Lett** 1997 Jun 16;409(3):325–32 (57 ref.)
Electrophoretic analysis of yeast proteins. Grant CM, et al. **Methods Mol Biol** 1996;53:259–67 (8 ref.)

CYTOLOGY

Saccharomyces cerevisiae as a model organism for studying function and biogenesis of peroxisomes. Skoneczny M, et al. **Acta Microbiol Pol** 1995;44(3-4):209–18 (26 ref.)
Cdc6 and DNA replication: limited to humble origins. Heichman KA. **Bioessays** 1996 Nov;18(11):859–62 (27 ref.)
Cell cycle control and initiation of DNA replication in Saccharomyces cerevisiae. Küntzel H, et al. **Biol Chem** 1996 Jul-Aug;377(7-8):481–7 (74 ref.)
Programming of cell polarity in budding yeast by endogenous and exogenous signals. Herskowitz I, et al.

Cold Spring Harb Symp Quant Biol 1995;60:717–27 (80 ref.)
Establishment of cell polarity in yeast. Pringle JR, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:729–44 (111 ref.)
Cell biology: alternatives to baker's yeast. Glick BS. **Curr Biol** 1996 Dec 1;6(12):1570–2 (23 ref.)
S-phase and DNA-damage checkpoints: a tale of two yeasts. Stewart E, et al. **Curr Opin Cell Biol** 1996 Dec;8(6):781–7 (64 ref.)
Phosphorylation and proteolysis: partners in the regulation of cell division in budding yeast [published erratum appears in Curr Opin Genet Dev 1997 Jun;7(3):424] Deshaies RJ. **Curr Opin Genet Dev** 1997 Feb;7(1):7–16 (80 ref.)
Mini review: mitosis and the spindle pole body in Saccharomyces cerevisiae. Sobel SG. **J Exp Zool** 1997 Feb 1;277(2):120–38 (168 ref.)
New cell cycle-regulated genes in the yeast Saccharomyces cerevisiae. Schuster T, et al. **Recent Results Cancer Res** 1997;143:251–61 (42 ref.)
Cyclins and the wiring of the yeast cell cycle. Futcher B. **Yeast** 1996 Dec;12(16):1635–46 (69 ref.)
Review: an overview of the Saccharomyces cerevisiae microtubule and microfilament cytoskeleton. Winsor B, et al. **Yeast** 1997 Apr;13(5):399–434 (240 ref.)
[Calcineurin-mediated signalling important for growth regulation in yeast] Hirata D, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1695–703 (40 ref.) **(Jpn)**
[Ca2+ signaling in budding yeast] Iida H. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1704–11 (19 ref.) **(Jpn)**
[The Rho1 small GTP-binding protein in cell cycle control in Saccharomyces cerevisiae] Imamura H, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1891–8 (27 ref.) **(Jpn)**
["Inositol" signal transduction in yeast] Nikawa J. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1680–7 (36 ref.) **(Jpn)**
[Regulatory network of the yeast cell cycle by the yeast CDK family] Nishizawa M. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1742–50 (22 ref.) **(Jpn)**
[DNA checkpoint control in Saccharomyces cerevisae] Sugimoto K, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep; 41(12 Suppl):1807–12 (20 ref.) **(Jpn)**
[Regulation of cell cycle progression by proteolysis] Toh-e A. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1820–5 (22 ref.) **(Jpn)**

DRUG EFFECTS

Nystatin-rhodamine B assay for estimating activity of killer toxin from Kluyveromyces lactis. Palková Z, et al. **Methods Mol Biol** 1996;53:325–9 (5 ref.)
Killer plaque technique for selecting hybrids and cybrids obtained by induced protoplast fusion. Palková Z, et al. **Methods Mol Biol** 1996;53:339–42 (2 ref.)
Application of killer toxins in stepwise selection of hybrids and cybrids obtained by induced protoplast fusion. Vondrejs V, et al. **Methods Mol Biol** 1996;53:331–8 (15 ref.)

ENZYMOLOGY

Using yeast to understand drugs that target topoisomerases. Nitiss JL, et al. **Ann N Y Acad Sci** 1996 Dec 13;803:32–43 (62 ref.)
Strategy for RNA recognition by yeast histidyl-tRNA synthetase. Rudinger J, et al. **Bioorg Med Chem** 1997 Jun; 5(6):1001–9 (56 ref.)
The complete inventory of the yeast Saccharomyces cerevisiae P-type transport ATPases. Catty P, et al. **FEBS Lett** 1997 Jun 16;409(3):325–32 (57 ref.)
Purification of yeast RNA polymerase II holoenzymes. Koleske AJ, et al. **Methods Enzymol** 1996;273:176–84 (12 ref.)
Yeast RNA polymerase II holoenzyme. Li Y, et al. **Methods Enzymol** 1996;273:172–5 (11 ref.)
Purification and quantification of Saccharomyces cerevisiae cytochrome P450. Stansfield I, et al. **Methods Mol Biol** 1996;53:355–66 (4 ref.)
Review: subcellular traffic of the plasma membrane H(+)-ATPase in Saccharomyces cerevisiae. de Kerchove d'Exaerde A, et al. **Yeast** 1996 Aug;12(10):907–16 (64 ref.)
Yeast protein serine/threonine phosphatases: multiple roles and diverse regulation. Stark MJ. **Yeast** 1996 Dec; 12(16):1647–75 (200 ref.)

GENETICS

Yeast transcriptional regulatory mechanisms. Struhl K. **Annu Rev Genet** 1995;29:651–74 (151 ref.)
Structure, function, and replication of Saccharomyces cerevisiae telomeres. Zakian VA. **Annu Rev Genet** 1996; 30:141–72 (147 ref.)
The hexose transporter family of Saccharomyces cerevisiae. Kruckeberg AL. **Arch Microbiol** 1996 Nov;166(5):283–92 (70 ref.)
Trans-acting factors in yeast pre-rRNA and pre-snoRNA processing. Lafontaine D, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11–12):803–12 (71 ref.)
The accuracy center of a eukaryotic ribosome. Liebman SW, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11–12):1141–9 (49 ref.)
Relocation of the unusual VAR1 gene from the mitochondrion to the nucleus. Sanchirico M, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11–12):987–95 (46 ref.)
Cell cycle control and initiation of DNA replication in Saccharomyces cerevisiae. Küntzel H, et al. **Biol Chem** 1996 Jul-Aug;377(7–8):481–7 (74 ref.)
Identification and phylogenetic classification of eleven putative P-type calcium transport ATPase genes in the yeasts Saccharomyces cerevisiae and Schizosaccharomyces pombe. Catty P, et al. **Biosci Rep** 1996 Apr;16(2):75–85 (58 ref.)
DNA polymerase zeta and the control of DNA damage induced mutagenesis in eukaryotes. Lawrence CW, et al. **Cancer Surv** 1996;28:21–31 (38 ref.)
Mutator specificity and disease: looking over the FENce [comment] Kunkel TA, et al. **Cell** 1997 Jan 24;88(2):155–8 (20 ref.) Comment on: Cell 1997 Jan 24;88(2):253–63.
Mixed mechanisms in yeast pre-mRNA splicing? [comment] Rosbash M. **Cell** 1996 Nov 1;87(3):357–9 (15 ref.) Comment on: Cell 1996 Nov 1;87(3):391–404. Comment on: Cell 1996 Nov 1;87(3):405–13.
Cell cycle control of S phase: a comparison of two yeasts. Huberman JA. **Chromosoma** 1996 Oct;105(4):197–203 (40 ref.)
Complex multigene family of functionally distinct Hsp70s of yeast. Craig E, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:441–9 (59 ref.)
Sequence comparison of yeast ATP-binding cassette proteins. Michaelis S, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:291–307 (89 ref.)
DNA repair: how yeast repairs radical damage. Cunningham RP. **Curr Biol** 1996 Oct 1;6(10):1230–3 (16 ref.)
The complete code for a eukaryotic cell. Genome sequencing. Johnston M. **Curr Biol** 1996 May 1;6(5):500–3 (29 ref.)
Keeping the centrosome cycle on track. Genome stability. Winey M. **Curr Biol** 1996 Aug 1;6(8):962–4 (13 ref.)
A comparison of mammalian and yeast pre-mRNA 3'-end processing. Keller W, et al. **Curr Opin Cell Biol** 1997 Jun; 9(3):329–36 (52 ref.)
Exploiting the complete yeast genome sequence. Bassett DE Jr, et al. **Curr Opin Genet Dev** 1996 Dec;6(6):763–6 (20 ref.)
From gene to screen with yeast. Oliver SG. **Curr Opin Genet Dev** 1997 Jun;7(3):405–9 (49 ref.)
Morphogenesis at the retrotransposon-retrovirus interface: gypsy and copia families in yeast and Drosophila. Sandmeyer SB, et al. **Curr Top Microbiol Immunol** 1996; 214:261–96 (136 ref.)
Surveillance and genome stability in budding yeast: implications for mammalian carcinogenesis. Spencer F. **Curr Top Microbiol Immunol** 1997;221:19–35 (98 ref.)
Does selective gene activation direct evolution? Wright BE. **FEBS Lett** 1997 Jan 27;402(1):4–8 (42 ref.)
The transcriptional apparatus required for mRNA encoding genes in the yeast Saccharomyces cerevisiae emerges from a jigsaw puzzle of transcription factors. Künzler M, et al. **FEMS Microbiol Rev** 1996 Dec;19(2):117–36 (167 ref.)
Yeast killer toxin K1 and its exploitation in genetic manipulations. Vondrejs V, et al. **Folia Microbiol (Praha)** 1996;41(5):379–93 (88 ref.)
Human genetic diseases: a cross-talk between man and yeast. Foury F. **Gene** 1997 Aug 11;195(1):1–10 (58 ref.)
Application of yeasts in gene expression studies: a comparison of Saccharomyces cerevisiae, Hansenula polymorpha and Kluyveromyces lactis — a review. Gellissen G, et al. **Gene** 1997 Apr 29;190(1):87–97 (94 ref.)
Regulation of phosphatase synthesis in Saccharomyces cerevisiae—a review. Oshima Y, et al. **Gene** 1996 Nov 7; 179(1):171–7 (50 ref.)
Translational regulation of yeast GCN4. A window on factors that control initiator-trna binding to the ribosome. Hinnebusch AG. **J Biol Chem** 1997 Aug 29;272(35):21661–4 (61 ref.)
Yeasts: from genetics to biotechnology. Russo S, et al. **J Environ Pathol Toxicol Oncol** 1995;14(3–4):133–57 (175 ref.)
Role of PSO genes in the repair of photoinduced interstrand cross-links and photooxidative damage in the DNA of the yeast Saccharomyces cerevisiae. Henriques JA, et al. **J Photochem Photobiol B** 1997 Jul;39(3):185–96 (110 ref.)
Yeast metallothionein gene expression in response to metals and oxidative stress. Liu XD, et al. **Methods** 1997 Mar; 11(3):289–99 (56 ref.)
Gene identification using the yeast two-hybrid system. Bai C, et al. **Methods Enzymol** 1996;273:331–47 (17 ref.)
Protoplast fusion in Saccharomyces cerevisiae. Curran BP, et al. **Methods Mol Biol** 1996;53:45–9 (6 ref.)
Insertional mutagenesis by Ty elements in Saccharomyces cerevisiae. Garfinkel DJ. **Methods Mol Biol** 1996;53:227–37 (23 ref.)
Determination of chromosome ploidy in yeast. Hadfield C, et al. **Methods Mol Biol** 1996;53:205–16 (10 ref.)
Preparation and use of yeast cell-free translation lysate. Hartley AD, et al. **Methods Mol Biol** 1996;53:249–57 (9 ref.)
Determination of plasmid copy number in yeast. Jordan BE, et al. **Methods Mol Biol** 1996;53:193–203 (5 ref.)
Yeast colony hybridization. Kleinman MJ. **Methods Mol Biol** 1996;53:189–92 (1 ref.)
Reporter gene systems for assaying gene expression in yeast. Mount RC, et al. **Methods Mol Biol** 1996;53:239–48 (8 ref.)
Transformation of lithium-treated yeast cells and the selection of auxotrophic and dominant markers. Mount RC, et al. **Methods Mol Biol** 1996;53:139–45 (19 ref.)
Chromosome engineering in yeast with a site-specific recombination system from a heterologous yeast plasmid. Oshima Y, et al. **Methods Mol Biol** 1996;53:217–25 (10 ref.)
Induction of heat shock proteins and thermotolerance. Piper P. **Methods Mol Biol** 1996;53:313–7 (15 ref.)
Polysome analysis. Sagliocco FA, et al. **Methods Mol Biol** 1996;53:297–311 (13 ref.)
Rare-mating and cytoduction in Saccharomyces cerevisiae. Spencer JF, et al. **Methods Mol Biol** 1996;53:39–44 (5 ref.)
Mutagenesis in yeast. Spencer JF, et al. **Methods Mol Biol** 1996;53:17–38 (22 ref.)
Genetic regulation of phospholipid biosynthesis in Saccharomyces cerevisiae. Greenberg ML, et al. **Microbiol Rev** 1996 Mar;60(1):1–20 (230 ref.)
Genetic constitution of industrial yeast. Benítez T, et al. **Microbiologia** 1996 Sep;12(3):371–84 (41 ref.)
Saccharomyces cerevisiae DNA repair processes: an update. Ramotar D, et al. **Mol Cell Biochem** 1996 May 10; 158(1):65–75 (98 ref.)
Molecular genetics of yeast TCA cycle isozymes. McAlister-Henn L, et al. **Prog Nucleic Acid Res Mol Biol** 1997;57:317–39 (89 ref.)
New cell cycle-regulated genes in the yeast Saccharomyces cerevisiae. Schuster T, et al. **Recent Results Cancer Res** 1997;143:251–61 (42 ref.)
Life with 6000 genes [see comments] Goffeau A, et al. **Science** 1996 Oct 25;274(5287):546, 563–7 (86 ref.) Comment in: Science 1997 Feb 21;275(5303):1051–2.
3'-end-forming signals of yeast mRNA. Guo Z, et al. **Trends Biochem Sci** 1996 Dec;21(12):477–81 (41 ref.)
The protein kinases of budding yeast: six score and more. Hunter T, et al. **Trends Biochem Sci** 1997 Jan;22(1):18–22 (39 ref.)
Making sense of nonsense in yeast. Ruiz-Echevarria MJ, et al. **Trends Biochem Sci** 1996 Nov;21(11):433–8 (31 ref.)
The yeast genome project: what did we learn? Dujon B. **Trends Genet** 1996 Jul;12(7):263–70 (42 ref.)
Genetic analysis of aging in Saccharomyces cerevisiae. Kennedy BK, et al. **Trends Genet** 1996 Sep;12(9):355–9 (45 ref.)
At the heart of the budding yeast cell cycle. Nasmyth K. **Trends Genet** 1996 Oct;12(10):405–12 (68 ref.)
An uncertain silence [see comments] Sherman JM, et al. **Trends Genet** 1997 Aug;13(8):308–13 (53 ref.) Comment in: Trends Genet 1997 Aug;13(8):293–5.
Mechanisms of transcriptional activation in vivo: two steps forward. Stargell LA, et al. **Trends Genet** 1996 Aug; 12(8):311–5 (54 ref.)
Review: to bud until death: the genetics of ageing in the yeast, Saccharomyces. Austriaco NR Jr. **Yeast** 1996 Jun 15;12(7):623–30 (36 ref.)
Review: the Cct eukaryotic chaperonin subunits of Saccharomyces cerevisiae and other yeasts. Stoldt V, et al. **Yeast** 1996 May;12(6):523–9 (36 ref.)
[Functional screening of p53 status in tumor cells using Saccharomyces cerevisiae] Jia LQ, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(4):466–70 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Role of yeast global repressors, Bel2 and Tup1, in chromatin-and nucleosome-mediated transcriptional regulation] Harashima S. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1187–97 (31 ref.) **(Jpn)**
[Analysis of the mechanism of transcriptional regulation based on yeast system] Horikoshi M, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1148–61 (57 ref.) **(Jpn)**
[Present status and the future of the whole genome analysis of Saccharomyces cerevisiae] Ogasawara N, et al. **Tanpakushitsu Kakusan Koso** 1997 Mar;42(4):673–8 (34 ref.) **(Jpn)**
[Interaction between yeast transcription factor GAL11 and general transcription factors] Sakurai H, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1178–86 (70 ref.) **(Jpn)**
[The role of nuclear genome in regulation of mitochondrial function in Saccharomyces cerevisiae] Boguta M. **Postepy Biochem** 1996;42(3):259–68 (84 ref.) **(Pol)**

GROWTH & DEVELOPMENT

Programming of cell polarity in budding yeast by endogenous and exogenous signals. Herskowitz I, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:717–27 (80 ref.)
Pheromone signalling and polarized morphogenesis in yeast. Leberer E, et al. **Curr Opin Genet Dev** 1997 Feb;7(1):59–66 (60 ref.)
Genetic analysis of aging in Saccharomyces cerevisiae. Kennedy BK, et al. **Trends Genet** 1996 Sep;12(9):355–9 (45 ref.)
Review: to bud until death: the genetics of ageing in the yeast, Saccharomyces. Austriaco NR Jr. **Yeast** 1996 Jun 15;12(7):623–30 (36 ref.)

METABOLISM

Fungal glycoproteins and their biosynthetic pathway as potential targets for antifungal agents. Tanner W, et al. **Acta Biochim Pol** 1995;42(4):505–8 (21 ref.)
Old and new synthetic capacities of baker's yeast. D'Arrigo P, et al. **Adv Appl Microbiol** 1997;44:81–123 (110 ref.)

Expression of the house dust mite allergen Der p2 and mutants in the baker's yeast Saccharomyces cerevisiae. Hakkaart GA, et al. **Adv Exp Med Biol** 1996;409:395–8 (5 ref.)
The proteasome and protein degradation in yeast. Hilt W, et al. **Adv Exp Med Biol** 1996;389:197–202 (28 ref.)
Global regulators of ribosome biosynthesis in yeast. Planta RJ, et al. **Biochem Cell Biol** 1995 Nov–Dec; 73(11–12):825–34 (70 ref.)
Basic helix–loop–helix transcription factors and the cross-regulation of sulphate and phosphate metabolism in yeast. Crowther DJ, et al. **Biochem Soc Trans** 1996 May; 24(2):354–9 (53 ref.)
Protein complexes for remodeling chromatin. Burns LG, et al. **Biochim Biophys Acta** 1997 Feb 7;1350(2):159–68 (73 ref.)
Conservation and diversity in the structure of translation initiation factor EIF3 from humans and yeast. Hershey JW, et al. **Biochimie** 1996;78(11–12):903–7 (24 ref.)
mRNA decapping activities and their biological roles. LaGrandeur TE, et al. **Biochimie** 1996;78(11–12):1049–55 (45 ref.)
Mechanisms of tRNA import into yeast mitochondria: an overview. Tarassov IA, et al. **Biochimie** 1996;78(6):502–10 (55 ref.)
Role of the ubiquitin/proteasome system in regulated protein degradation in Saccharomyces cerevisiae. Smith SE, et al. **Biol Chem** 1996 Jul–Aug;377(7–8):437–46 (107 ref.)
The role of trehalose in cell stress. de–Araujo PS. **Braz J Med Biol Res** 1996 Jul;29(7):873–5 (40 ref.)
Mad cows meet psi–chotic yeast: the expansion of the prion hypothesis. Lindquist S. **Cell** 1997 May 16;89(4):495–8 (21 ref.)
Complex multigene family of functionally distinct Hsp70s of yeast. Craig E, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:441–9 (59 ref.)
The DOA pathway: studies on the functions and mechanisms of ubiquitin–dependent protein degradation in the yeast Saccharomyces cerevisiae. Hochstrasser M, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:503–13 (36 ref.)
Control of exocytosis in yeast. Novick P, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:171–7 (39 ref.)
Translational activator proteins required for cytochrome b synthesis in Saccharomyces cerevisiae. Rödel G. **Curr Genet** 1997 May;31(5):375–9 (56 ref.)
Osmoresponsive proteins and functional assessment strategies in Saccharomyces cerevisiae. Blomberg A. **Electrophoresis** 1997 Aug;18(8):1429–40 (58 ref.)
Polypeptide translocation machinery of the yeast endoplasmic reticulum. Lyman SK, et al. **Experientia** 1996 Dec 15;52(12):1042–9 (63 ref.)
Actin–, myosin– and ubiquitin–dependent endocytosis. Riezman H, et al. **Experientia** 1996 Dec 15;52(12):1033–41 (102 ref.)
Immunogold labeling of yeast cells: an efficient tool for the study of protein targeting and morphological alterations due to overexpression and inactivation of genes. Binder M, et al. **Histochem Cell Biol** 1996 Jul;106(1):115–30 (58 ref.)
RNA polymerase III and class III transcription factors from Saccharomyces cerevisiae. Huet J, et al. **Methods Enzymol** 1996;273:249–67 (70 ref.)
Thiamin transporters in yeast. Iwashima A, et al. **Methods Enzymol** 1997;279:109–17 (15 ref.)
Isotopically labeled precursors and mass spectrometry in elucidating biosynthesis of pyrimidine moiety of thiamin in Saccharomyces cerevisiae. Tazuya K, et al. **Methods Enzymol** 1997;279:97–108 (9 ref.)
mRNA abundance and half–life measurements. Brown AJ, et al. **Methods Mol Biol** 1996;53:277–95 (10 ref.)
Mechanisms and control of mRNA turnover in Saccharomyces cerevisiae. Caponigro G, et al. **Microbiol Rev** 1996 Mar;60(1):233–49 (126 ref.)
Response of Saccharomyces cerevisiae to changes in external osmolarity. Varela JC, et al. **Microbiology** 1996 Apr;142 (Pt 4):721–31 (105 ref.)
The yeast, Saccharomyces cerevisiae, RNase P/MRP ribonucleoprotein endoribonuclease family. Reilly TH, et al. **Mol Biol Rep** 1995–96;22(2–3):87–93 (63 ref.)
Genetic and biochemical analyses of yeast RNase MRP. Tollervey D. **Mol Biol Rep** 1995–96;22(2–3):75–9 (32 ref.)
Molecular biology of iron acquisition in Saccharomyces cerevisiae. Askwith CC, et al. **Mol Microbiol** 1996 Apr; 20(1):27–34 (54 ref.)
Molecular biology of trehalose and the trehalases in the yeast Saccharomyces cerevisiae. Nwaka S, et al. **Prog Nucleic Acid Res Mol Biol** 1998;58:197–237 (178 ref.)
Signaling phosphate starvation. Lenburg ME, et al. **Trends Biochem Sci** 1996 Oct;21(10):383–7 (42 ref.)
Pyruvate metabolism in Saccharomyces cerevisiae. Pronk JT, et al. **Yeast** 1996 Dec;12(16):1607–33 (162 ref.)
[Ras proteins in Saccharomyces cerevisiae, their partners and their activation] Jacquet M. **C R Seances Soc Biol Fil** 1997; 191(2):221–35 (63 ref.) (Eng. Abstr.) **(Fre)**
["Inositol" signal transduction in yeast] Nikawa J. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1680–7 (36 ref.) **(Jpn)**

PHYSIOLOGY

Physiological action of PAF in yeast Saccharomyces cerevisiae. Nakayama R, et al. **Adv Exp Med Biol** 1996; 416:45–50 (15 ref.)
The yeast cell wall, a dynamic structure engaged in growth and morphogenesis. Cabib E, et al. **Biochem Soc Trans** 1997 Feb;25(1):200–4 (30 ref.)
Signaling toward yeast 1,3–beta–glucan synthesis. Inoue SB, et al. **Cell Struct Funct** 1996 Oct;21(5):395–402 (58 ref.)
Vesicle traffic: get your coat! Schimmöller F, et al. **Curr Biol** 1997 Apr 1;7(4):R235–7 (19 ref.)
Splicing together the unfolded–protein response. Shamu CE. **Curr Biol** 1997 Feb 1;7(2):R67–70 (15 ref.)
Motor proteins: myosin V—the multi–purpose transport motor. Titus MA. **Curr Biol** 1997 May 1;7(5):R301–4 (26 ref.)
Coatomer (COPI)–coated vesicles: role in intracellular transport and protein sorting. Cosson P, et al. **Curr Opin Cell Biol** 1997 Aug;9(4):484–7 (29 ref.)
COPII and secretory cargo capture into transport vesicles. Kuehn MJ, et al. **Curr Opin Cell Biol** 1997 Aug;9(4):477–83 (57 ref.)
Exocytosis in excitable cells: a conserved molecular machinery from yeast to neuron. Lledo PM. **Eur J Endocrinol** 1997 Jul;137(1):1–9 (55 ref.)
The induction of cell polarity by pheromone in Saccharomyces cerevisiae. Dorer R, et al. **Harvey Lect** 1994–95;90:95–104 (20 ref.)
Salt tolerance in plants and microorganisms: toxicity targets and defense responses. Serrano R. **Int Rev Cytol** 1996; 165:1–52 (264 ref.)
Motoring to the finish: kinesin and dynein work together to orient the yeast mitotic spindle [comment] Stearns T. **J Cell Biol** 1997 Sep 8;138(5):957–60 (23 ref.) Comment on: J Cell Biol 1997 Sep 8;138(5):1023–40. Comment on: J Cell Biol 1997 Sep 8;138(5):1041–53.
Function of metal–ion homeostasis in the cell division cycle, mitochondrial protein processing, sensitivity to mycobacterial infection and brain function. Supek F, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):321–30 (73 ref.)
The yeast two–hybrid system: forward and reverse [comment] White MA. **Proc Natl Acad Sci U S A** 1996 Sep 17;93(19):10001–3 (12 ref.) Comment on: Proc Natl Acad Sci U S A 1996 Sep 17;93(19):10315–20. Comment on: Proc Natl Acad Sci U S A 1996 Sep 17;93(19):10321–6.
A review of phenotypes in Saccharomyces cerevisiae. Hampsey M. **Yeast** 1997 Sep 30;13(12):1099–133 (204 ref.)
[Autophagy in yeast, bulk protein degradation in the vacuole] Ohsumi Y. **Seikagaku** 1997 Jan;69(1):39–44 (15 ref.) **(Jpn)**

ULTRASTRUCTURE

Molecular model for telomeric heterochromatin in yeast. Grunstein M. **Curr Opin Cell Biol** 1997 Jun;9(3):383–7 (42 ref.)
Immunogold labeling of yeast cells: an efficient tool for the study of protein targeting and morphological alterations due to overexpression and inactivation of genes. Binder M, et al. **Histochem Cell Biol** 1996 Jul;106(1):115–30 (58 ref.)
Peroxisome isolation. Distel B, et al. **Methods Mol Biol** 1996; 53:133–8 (7 ref.)

VIROLOGY

Prions and RNA viruses of Saccharomyces cerevisiae. Wickner RB. **Annu Rev Genet** 1996;30:109–39 (141 ref.)
Double–stranded RNA viruses of Saccharomyces cerevisiae. Wickner RB. **Microbiol Rev** 1996 Mar;60(1):250–65 (172 ref.)

SACCULE AND UTRICLE

PHYSIOLOGY

Interactions within and between the spatial senses. Howard IP. **J Vestib Res** 1997 Jul–Aug;7(4):311–45 (216 ref.)

SACRAL PLEXUS see **LUMBOSACRAL PLEXUS**

SACROILIAC JOINT

Three cases of pyogenic sacro–iliitis, and factors in the relapse of the disease. Tokuda K, et al. **Acta Paediatr Jpn** 1997 Jun;39(3):385–9 (19 ref.)
Recurrent sacro–iliac joint abscess. Eskander MB, et al. **J R Army Med Corps** 1994 Jun;140(2):95–6 (7 ref.)
Treatment of coccidioidal spinal infection: experience in 16 cases. Herron LD, et al. **J Spinal Disord** 1997 Jun; 10(3):215–22 (11 ref.)
Septic sacroiliitis. Zimmermann B 3rd, et al. **Semin Arthritis Rheum** 1996 Dec;26(3):592–604 (89 ref.)
[Sacroiliitis:the key symptom of spondylarthropathies. 2: morphological aspects] Bollow M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Apr;166(4):275–89 (84 ref.) (Eng. Abstr.) **(Ger)**
[Sacroiliitis: the key symptom of spondylathropathies. 1. The clinical aspects] Bollow M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Feb;166(2):95–100 (107 ref.) (Eng. Abstr.) **(Ger)**

INJURIES

Traumatic spondylopelvic dissociation. A case report and literature review [see comments] Bents RT, et al. **Spine** 1996 Aug 1;21(15):1814–9 (25 ref.) Comment in: Spine 1997 Jun 1;22(11):1276.

MICROBIOLOGY

Pneumococcal sacroiliitis. Pinson AG, et al. **South Med J** 1997 Jun;90(6):649–52 (36 ref.)

PATHOLOGY

The sacroiliac joint in the spondyloarthropathies. Braun J, et al. **Curr Opin Rheumatol** 1996 Jul;8(4):275–87 (130 ref.)

RADIOGRAPHY

A 42–year–old woman with low back pain. McGrory BJ, et al. **Am J Orthop** 1996 Sep;25(9):653–4, 657–8 (14 ref.)

SACRUM

An unusual presentation of telangiectatic osteosarcoma. Simon RG, et al. **Am J Orthop** 1996 May;25(5):375–9 (19 ref.)
Sacrococcygeal teratoma and anorectal malformation. Ng WT, et al. **Aust N Z J Surg** 1997 Apr;67(4):218–20 (28 ref.)
Sacrospinous vault fixation. Hogston P. **Br J Hosp Med** 1997 Jan 15–Feb 5;57(1–2):39–40 (4 ref.)
[Giant sacral schwannoma with pelvic extension. Therapeutic strategy. Apropos of a case] Stecken J, et al. **Neurochirurgie** 1996;42(6):294–9 (16 ref.) (Eng. Abstr.) **(Fre)**

ABNORMALITIES

Congenital lumbosacral lipomas. Pierre–Kahn A, et al. **Childs Nerv Syst** 1997 Jun;13(6):298–334; discussion 335 (199 ref.)
[Sacro–coccygeal agenesis with central nervous system malformations: embryogenetic features of a case] Manfrè L, et al. **Radiol Med (Torino)** 1996 Oct;92(4):479–82 (19 ref.) **(Ita)**
[Partial agenesis of the sacrum and microcephaly: an uncommon association] Ruiz Moreno JA, et al. **An Esp Pediatr** 1997 Jun;46(6):607–10 (18 ref.) **(Spa)**

INJURIES

Truncated sciatica as the first manifestation of a fatigue fracture of the sacrum in a young male [letter] Lechevalier D, et al. **Rev Rhum Engl Ed** 1996 Jul–Sep;63(7–8):505 (11 ref.)
[Impalement injury of the colon, iliac vein and sacrum—a rare combination in penetrating abdominal trauma. A case report] Funke M, et al. **Chirurg** 1996 Nov;67(11):1184–7 (27 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Intraradicular, intervertebral disc herniation. A case report. Finkel HZ. **Spine** 1997 May 1;22(9):1028–9 (8 ref.)
Controversy. Fusion of L5–S1 in adult scoliosis. Horton WC, et al. **Spine** 1996 Nov 1;21(21):2520–2 (8 ref.)

SADISM

Archaic sadism. Chessick RD. **J Am Acad Psychoanal** 1996 Winter;24(4):605–18 (37 ref.)

PSYCHOLOGY

Antisocial personality disorder, sexual sadism, malignant narcissism, and serial murder. Geberth VJ, et al. **J Forensic Sci** 1997 Jan;42(1):49–60 (54 ref.)

SAETHRE–CHOTZEN SYNDROME see **ACROCEPHALOSYNDACTYLIA**

SAFETY

Black times: temporal determinants of transport safety. Folkard S. **Accid Anal Prev** 1997 Jul;29(4):417–30 (25 ref.)
Alcohol policy and aviation safety. Cook CC. **Addiction** 1997 Jul;92(7):793–804 (36 ref.)
Crashes: outcome of choice in assessing driver safety? Marottoli RA. **Alzheimer Dis Assoc Disord** 1997 Jun;11 Suppl 1:28–30 (23 ref.)
Passenger safety, health, and comfort: a review. Rayman RB. **Aviat Space Environ Med** 1997 May;68(5):432–40 (43 ref.)
Safety and efficacy of physical restraints for the elderly. Review of the evidence. Frank C, et al. **Can Fam Physician** 1996 Dec;42:2402–9 (42 ref.)
Improving the safety of transfusion therapy. Polesky HF. **Clin Lab Med** 1996 Dec;16(4):975–88 (71 ref.)
Biosafety in the clinical mycobacteriology laboratory. Richmond JY, et al. **Clin Lab Med** 1996 Sep;16(3):527–50 (38 ref.)
Secondary safety of car adaptations for disabled motorists. Turner–Stokes L, et al. **Disabil Rehabil** 1996 Jun; 18(6):317–27 (1 ref.)
Safety in long–term EEG/video monitoring. Sanders PT, et al. **J Neurosci Nurs** 1996 Oct;28(5):305–13 (14 ref.)
Progress towards a fire–safe cigarette. Brigham PA, et al. **J Public Health Policy** 1995;16(4):433–9 (0 ref.)
The scope of gene therapy in humans: scientific, safety and ethical considerations. Karpati G, et al. **Neuromuscul Disord** 1997 Jul;7(5):273–6 (30 ref.)
Latex allergy. Considerations for the care of pediatric patients and employee safety. Young MA, et al.

Nurs Clin North Am 1997 Mar;32(1):169–82 (47 ref.)
Early and midtrimester genetic amniocenteses. Safety and outcomes. Reece EA. **Obstet Gynecol Clin North Am** 1997 Mar;24(1):71–81 (44 ref.)
Application of full-scale fire tests to characterize and improve the aircraft postcrash fire environment. Sarkos CP. **Toxicology** 1996 Dec 31;115(1–3):79–87 (16 ref.)
[An international exchange and dissemination of chemical safety information on the Internet] Ohtake C, et al. **Eisei Shikenjo Hokoku** 1996;(114):76–83 (5 ref.) (Eng. Abstr.) **(Jpn)**
[Concise International Chemical Assessment Document (CICAD): a new chemical safety series in IPCS, internationalizing national reviews] Sekizawa J. **Eisei Shikenjo Hokoku** 1996;(114):89–94 (3 ref.) (Eng. Abstr.) **(Jpn)**

ECONOMICS

Defining total corporate health and safety costs—significance and impact. Review and recommendations. Brady W, et al. **J Occup Environ Med** 1997 Mar;39(3):224–31 (23 ref.)

STANDARDS

Safe motherhood and district health systems. Tarimo E. **Eur J Obstet Gynecol Reprod Biol** 1996 Oct;69(1):5–10 (18 ref.)

SAFETY, CONSUMER PRODUCT see **CONSUMER PRODUCT SAFETY**

SAFETY DEVICES see **PROTECTIVE DEVICES**

SAFETY, EQUIPMENT see **EQUIPMENT SAFETY**

SAFETY MANAGEMENT

Tools for developing a workplace violence prevention program. Askari E. **Occup Med** 1996 Apr–Jun;11(2):363–74 (5 ref.)

METHODS

Improving workplace security. D'Addario FJ. **Occup Med** 1996 Apr–Jun;11(2):349–61 (15 ref.)

STANDARDS

Practical methods to improve transfusion safety by using novel blood unit and patient identification systems. Wenz B, et al. **Am J Clin Pathol** 1997 Apr;107(4 Suppl 1):S12–6 (26 ref.)

SAGUINUS

Cytokines in the cotton top tamarin model of human ulcerative colitis. Warren BF. **Aliment Pharmacol Ther** 1996;10 Suppl 2:45–7; discussion 48 (8 ref.)

SAIDS see **SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME**

SAIDS RETROVIRUS see **RETROVIRUSES TYPE D, SIMIAN**

SAIDS VACCINES

IMMUNOLOGY

Simian retrovirus vaccines: simian retrovirus and simian immunodeficiency lentivirus. Gardner MB, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):399–401 (20 ref.)
Recombinant subunit vaccines against primate lentiviruses. Hu SL. **AIDS Res Hum Retroviruses** 1996 Mar 20; 12(5):451–3 (26 ref.)
Simian immunodeficiency virus live and inactivated experimental vaccines. Norley S, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):447–9 (41 ref.)
"Attenuated" simian immunodeficiency virus in macaque neonates. Ruprecht RM, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):459–60 (3 ref.)

SAIMIRINE HERPESVIRUS 2 see **HERPESVIRUS 2, SAIMIRINE**

SALAAM SEIZURES see **SPASMS, INFANTILE**

SALAMANDERS see **URODELA**

SALAMANDRIDAE

GROWTH & DEVELOPMENT

Salamander pigment patterns: how can they be used to study developmental mechanisms and their evolutionary transformation? Parichy DM. **Int J Dev Biol** 1996 Aug; 40(4):871–84 (130 ref.)
Direct development in the lungless salamanders: what are the consequences for developmental biology, evolution and phylogenesis? Wake DB, et al. **Int J Dev Biol** 1996 Aug; 40(4):859–69 (118 ref.)

PHYSIOLOGY

Mechanisms of retina regeneration in urodeles. Mitashov VI. **Int J Dev Biol** 1996 Aug;40(4):833–44 (140 ref.)

SALBUTAMOL see **ALBUTEROL**

SALDINO–NOONAN SYNDROME see **SHORT RIB–POLYDACTYLY SYNDROME**

SALICYLATES

see related
ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL
CYCLOOXYGENASE INHIBITORS

ADMINISTRATION & DOSAGE

Could salicylates in food have contributed to the decline in cardiovascular disease mortality? A new hypothesis. Ingster LM, et al. **Am J Public Health** 1997 Sep;87(9):1554–7 (27 ref.)

ADVERSE EFFECTS

Potential dangers from topical preparations containing methyl salicylate. Chan TY. **Hum Exp Toxicol** 1996 Sep; 15(9):747–50 (34 ref.)
Health effects of salicylates in foods and drugs. Perry CA, et al. **Nutr Rev** 1996 Aug;54(8):225–40 (47 ref.)

ANALYSIS

Salicylates in foods. Janssen PL, et al. **Nutr Rev** 1996 Nov; 54(11 Pt 1):357–9 (24 ref.)

THERAPEUTIC USE

The actions of bismuth in the treatment of Helicobacter pylori infection. Lambert JR, et al. **Aliment Pharmacol Ther** 1997 Apr;11 Suppl 1:27–33 (62 ref.)

SALICYLAZOSULFAPYRIDINE see **SULFASALAZINE**

SALICYLIC ACIDS

ADMINISTRATION & DOSAGE

Medium-depth chemical peeling. Otley CC, et al. **Semin Cutan Med Surg** 1996 Sep;15(3):145–54 (23 ref.)

METABOLISM

Recent advances in systemic acquired resistance research—a review. Hunt MD, et al. **Gene** 1996 Nov 7;179(1):89–95 (50 ref.)

SALIENTIA see **ANURA**

SALINE see **SODIUM CHLORIDE**

SALINE FRAGILITY see **OSMOTIC FRAGILITY**

SALINE SOLUTION, HYPERTONIC

ADMINISTRATION & DOSAGE

Hypertonic saline dextran (HSD) and intraosseous vascular access for the treatment of haemorrhagic hypotension in the far-forward combat arena. Dubick MA, et al. **Ann Acad Med Singapore** 1997 Jan;26(1):64–9 (48 ref.)

DIAGNOSTIC USE

[Carter-Robbins test] Kimura T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:291–4 (5 ref.) **(Jpn)**
[Clinical studies in antidiuretic hormone secretion] Shoji M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:299–302 (3 ref.) **(Jpn)**

THERAPEUTIC USE

Myelinolysis after correction of hyponatremia [see comments] Laureno R, et al. **Ann Intern Med** 1997 Jan 1;126(1):57–62 (49 ref.) Comment in: Ann Intern Med 1997 Jul 15;127(2):163.
Hypertonic saline: A review of the literature and evaluation of its role in resuscitation of traumatic hypovolaemic shock. Heath KJ. **J R Army Med Corps** 1994 Feb;140(1):37–41 (29 ref.)
Individual patient cohort analysis of the efficacy of hypertonic saline/dextran in patients with traumatic brain injury and hypotension. Wade CE, et al. **J Trauma** 1997 May;42(5 Suppl):S61–5 (22 ref.)
The effects of hypertonic saline in healthy and diseased animals. Cambier C, et al. **Vet Res Commun** 1997 Jul; 21(5):303–16 (52 ref.)

SALIVA

CHEMISTRY

Glycosylation of secretory proteins in salivary glands and saliva studied by lectin-probes. Garrett JR, et al. **Eur J Morphol** 1996 Aug;34(3):177–80 (10 ref.)
[Saliva as a diagnostic fluid] Tenovuo J. **Duodecim** 1995; 111(14):1355–9 (16 ref.) **(Fin)**

IMMUNOLOGY

Salivary mucins in oral mucosal defense. Slomiany BL, et al. **Gen Pharmacol** 1996 Jul;27(5):761–71 (60 ref.)
The anti-HIV-1 activity associated with saliva. Shine N, et al. **J Dent Res** 1997 Feb;76(2):634–40 (86 ref.)

METABOLISM

Drug monitoring in nonconventional biological fluids and matrices [see comments] Pichini S, et al. **Clin Pharmacokinet** 1996 Mar;30(3):211–28 (140 ref.) Comment in: Clin Pharmacokinet 1996 Jul;31(1):81.
Pathogenesis of oral Kaposi's Sarcoma in HIV-infection: relevance of endogenous glucocorticoid excess in blood and saliva. Enwonwu CO. **Eur J Cancer B Oral Oncol** 1996 Jul;32B(4):271–4 (49 ref.)
Saliva as a specimen for therapeutic drug monitoring in pharmacies [editorial; comment] Zuidema J, et al. **Pharm World Sci** 1996 Dec;18(6):193–4 (9 ref.) Comment on: Pharm World Sci 1996 Dec;18(6):211–6.

MICROBIOLOGY

Does assessment of microbial composition of plaque/saliva allow for diagnosis of disease activity of individuals? Bowden GH. **Community Dent Oral Epidemiol** 1997 Feb; 25(1):76–81 (61 ref.)
N-nitrosation at non-gastric sites. Hill MJ. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:105–8 (12 ref.)
Oral carriage of Helicobacter pylori: a review. Madinier IM, et al. **J Periodontol** 1997 Jan;68(1):2–6 (55 ref.)
[Saliva as a diagnostic fluid] Tenovuo J. **Duodecim** 1995; 111(14):1355–9 (16 ref.) **(Fin)**

PHYSIOLOGY

Salivary parameters of relevance for assessing caries activity in individuals and populations. Tenovuo J. **Community Dent Oral Epidemiol** 1997 Feb;25(1):82–6 (48 ref.)
[Saliva and periodontal disease] Giuliana G, et al. **Minerva Stomatol** 1996 Mar;45(3):101–11 (46 ref.) (Eng. Abstr.) **(Ita)**

SECRETION

[Evaluation method of salivary gland function] Nagai T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:89–91 (9 ref.) **(Jpn)**

VIROLOGY

Accuracy of oral specimen testing for human immunodeficiency virus. Emmons W. **Am J Med** 1997 Apr 1;102(4A):15–20 (41 ref.)
Oral diagnostic testing for detecting human immunodeficiency virus-1 antibodies: a technology whose time has come. Malamud D. **Am J Med** 1997 Apr 1; 102(4A):9–14 (37 ref.)

SALIVARY DUCTS

PATHOLOGY

Salivary duct carcinoma: a clinicopathologic study of three cases with a review of the literature. Minamiguchi S, et al. **Pathol Int** 1996 Aug;46(8):614–22 (22 ref.)

SALIVARY GLAND CALCULI

THERAPY

[Current status of minimally invasive treatment methods in sialolithiasis] Iro H, et al. **HNO** 1996 Feb;44(2):78–84 (19 ref.) (Eng. Abstr.) **(Ger)**

SALIVARY GLAND DISEASES

DIAGNOSIS

Fine-needle aspiration of the salivary glands. Zarka MA. **Pathology (Phila)** 1996;4(2):287–318 (52 ref.)
Diagnostic imaging in pediatric AIDS. Haller JO, et al. **Pediatr Clin North Am** 1997 Jun;44(3):721–40 (64 ref.)

ETIOLOGY

Radiation-induced changes in the central nervous system and head and neck. Rabin BM, et al. **Radiographics** 1996 Sep; 16(5):1055–72 (24 ref.)
[Salivary glands and the organism—interrelations and correlating reactions] Seifert G. **Laryngorhinootologie** 1997 Jun;76(6):387–93 (39 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Current concepts of autoimmune exocrinopathy: immunologic mechanisms in the salivary pathology of Sjögren's syndrome. Fox PC, et al. **Crit Rev Oral Biol Med** 1996;7(2):144–58 (111 ref.)

NURSING

A guide to salivary gland disorders. McEwen DR, et al.

AORN J 1997 Mar;65(3):554–6, 559–67; quiz 568–9, 571–2 (36 ref.)

SURGERY

A guide to salivary gland disorders. McEwen DR, et al. **AORN J** 1997 Mar;65(3):554–6, 559–67; quiz 568–9, 571–2 (36 ref.)

SALIVARY GLAND NEOPLASMS

DIAGNOSIS

Poorly-differentiated adenoid cystic carcinoma: cytologic appearance in fine-needle aspirates of distant metastases. Yu GH, et al. **Diagn Cytopathol** 1996 Nov;15(4):296–300 (27 ref.)

IMMUNOLOGY

Salivary gland anlage tumor of the nasopharynx: a clinicopathologic and immunohistochemical study of three cases. Boccon-Gibod LA, et al. **Pediatr Pathol Lab Med** 1996 Nov-Dec;16(6):973–83 (23 ref.)

PATHOLOGY

Primary epithelial tumors of salivary glands--histogenesis, histomorphological and immunohistochemical implications--diagnosis and clinical management. Shrestha P, et al. **Crit Rev Oncol Hematol** 1996 Jul;23(3):239–60 (281 ref.)

Lymphoid infiltrates of the salivary glands: pathology, biology and clinical significance. DiGiuseppe JA, et al. **Curr Opin Oncol** 1996 May;8(3):232–7 (36 ref.)

Fine-needle sampling of salivary gland lesions. IV. Review of 50 cases of mucoepidermoid carcinoma with histologic correlation. Klijanienko J, et al. **Diagn Cytopathol** 1997 Aug;17(2):92–8 (41 ref.)

Poorly-differentiated adenoid cystic carcinoma: cytologic appearance in fine-needle aspirates of distant metastases. Yu GH, et al. **Diagn Cytopathol** 1996 Nov;15(4):296–300 (27 ref.)

Cell proliferation in salivary gland tumors. Skálová A, et al. **Gen Diagn Pathol** 1996 Jun;142(1):7–16 (75 ref.)

Epithelial-myoepithelial carcinoma of the lung: immunohistochemical and ultrastructural observations and review of the literature. Wilson RW, et al. **Hum Pathol** 1997 May;28(5):631–5 (32 ref.)

Pleomorphic adenoma of the palate in a child: 9-year follow-up. de Courten A, et al. **Int J Oral Maxillofac Surg** 1996 Aug;25(4):293–5 (13 ref.)

Pleomorphic adenoma of the palate in children: report of a case. López-Cedrún JL, et al. **Int J Oral Maxillofac Surg** 1996 Jun;25(3):206–7 (11 ref.)

Prenatal development of human major salivary glands. Histological and immunohistochemical characteristics with reference to adult and neoplastic salivary glands. Chi JG. **J Korean Med Sci** 1996 Jun;11(3):203–16 (47 ref.)

Stromal bone formation in pleomorphic adenoma of minor salivary gland origin. Takeda Y, et al. **J Nihon Univ Sch Dent** 1996 Jul;38(2):102–4 (6 ref.)

Sialadenoma papilliferum of the hard palate: a case report and review of literature. Asahina I, et al. **J Oral Maxillofac Surg** 1997 Sep;55(9):1000–3 (25 ref.)

Stromal melanocytosis of an adenoid cystic carcinoma arising from the palatal minor salivary gland. Takeda Y. **Pathol Int** 1996 Jun;46(6):467–70 (19 ref.)

Salivary gland anlage tumor of the nasopharynx: a clinicopathologic and immunohistochemical study of three cases. Boccon-Gibod LA, et al. **Pediatr Pathol Lab Med** 1996 Nov-Dec;16(6):973–83 (23 ref.)

Clear cell tumors of the salivary glands, jaws, and oral mucosa. Maiorano E, et al. **Semin Diagn Pathol** 1997 Aug; 14(3):203–12 (80 ref.)

RADIOTHERAPY

European results in neutron therapy of malignant salivary gland tumors. Krüll A, et al. **Bull Cancer Radiother** 1996; 83 Suppl:125–9s (44 ref.)

THERAPY

Adenoid cystic carcinoma of the salivary glands: a review of 10 years. Sur RK, et al. **Laryngoscope** 1997 Sep; 107(9):1276–80 (9 ref.)

VETERINARY

Tumours of the oral cavity, buccal pouch, oesophagus, forestomach and salivary glands. Takahashi M, et al. **IARC Sci Publ** 1996;(126):59–77 (60 ref.)

SALIVARY GLAND TUMOR, MIXED see **ADENOMA, PLEOMORPHIC**

SALIVARY GLAND VIRUS DISEASE see **CYTOMEGALOVIRUS INFECTIONS**

SALIVARY GLAND VIRUSES see **CYTOMEGALOVIRUS**

SALIVARY GLANDS

CYTOLOGY

Salivary glands: a paradigm for diversity of gland development. Denny PC, et al. **Crit Rev Oral Biol Med** 1997;8(1):51–75 (166 ref.)

Salivary glands, cellular evolution, and adaptive radiation in mammals. Phillips CJ, et al. **Eur J Morphol** 1996 Aug; 34(3):155–61 (30 ref.)

Tuft cells in the main excretory duct epithelia of the three major rat salivary glands. Sato A, et al. **Eur J Morphol** 1996 Aug;34(3):225–8 (17 ref.)

EMBRYOLOGY

Salivary glands: a paradigm for diversity of gland development. Denny PC, et al. **Crit Rev Oral Biol Med** 1997;8(1):51–75 (166 ref.)

Dystroglycan and laminins: glycoconjugates involved in branching epithelial morphogenesis. Durbeej M, et al. **Exp Lung Res** 1997 Mar-Apr;23(2):109–18 (43 ref.)

Prenatal development of human major salivary glands. Histological and immunohistochemical characteristics with reference to adult and neoplastic salivary glands. Chi JG. **J Korean Med Sci** 1996 Jun;11(3):203–16 (47 ref.)

IMMUNOLOGY

The submandibular gland: a key organ in the neuro-immuno-regulatory network? Sabbadini E, et al. **Neuroimmunomodulation** 1995 Jul-Aug;2(4):184–202 (205 ref.)

METABOLISM

Regulation of salivary-gland-specific gene expression. Ann DK, et al. **Crit Rev Oral Biol Med** 1997;8(3):244–52 (62 ref.)

Glycosylation of secretory proteins in salivary glands and saliva studied by lectin-probes. Garrett JR, et al. **Eur J Morphol** 1996 Aug;34(3):177–80 (10 ref.)

PATHOLOGY

Lymphoid infiltrates of the salivary glands: pathology, biology and clinical significance. DiGiuseppe JA, et al. **Curr Opin Oncol** 1996 May;8(3):232–7 (36 ref.)

A hamartoma-like mass on the palate? A possible discussion regarding the components of a pigmented naevus and hyperplastic salivary gland. Harada H, et al. **J Laryngol Otol** 1997 Mar;111(3):296–9 (17 ref.)

Salivary gland. Ranchod M. **Pathology (Phila)** 1996; 3(2):305–19 (12 ref.)

Fine-needle aspiration of the salivary glands. Zarka MA. **Pathology (Phila)** 1996;4(2):287–318 (52 ref.)

PHYSIOLOGY

Platelet-activating factor synthesis and its role in salivary glands. Dohi T, et al. **Adv Exp Med Biol** 1996;416:41–4 (35 ref.)

PHYSIOPATHOLOGY

Gastrointestinal dysfunction in multiple system atrophy. Mathias CJ. **Semin Neurol** 1996 Sep;16(3):251–8 (44 ref.)

RADIONUCLIDE IMAGING

[Evaluation method of salivary gland function] Nagai T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:89–91 (9 ref.) **(Jpn)**

SECRETION

Glycosylation of secretory proteins in salivary glands and saliva studied by lectin-probes. Garrett JR, et al. **Eur J Morphol** 1996 Aug;34(3):177–80 (10 ref.)

[Buccal dryness, xerostomia and measurement of salivary secretory activity] Jehl-Pietri C, et al. **Ann Med Interne (Paris)** 1997;148(3):209–16 (54 ref.) (Eng. Abstr.) **(Fre)**

[Evaluation method of salivary gland function] Nagai T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:89–91 (9 ref.) **(Jpn)**

SURGERY

Salivary gland. Ranchod M. **Pathology (Phila)** 1996; 3(2):305–19 (12 ref.)

ULTRASTRUCTURE

Tuft cells in the main excretory duct epithelia of the three major rat salivary glands. Sato A, et al. **Eur J Morphol** 1996 Aug;34(3):225–8 (17 ref.)

SALIVARY GLANDS, MINOR

PATHOLOGY

Pleomorphic adenoma of the palate in a child: 9-year follow-up. de Courten A, et al. **Int J Oral Maxillofac Surg** 1996 Aug;25(4):293–5 (13 ref.)

Pleomorphic adenoma of the palate in children: report of a case. López-Cedrún JL, et al. **Int J Oral Maxillofac Surg** 1996 Jun;25(3):206–7 (11 ref.)

Stromal bone formation in pleomorphic adenoma of minor salivary gland origin. Takeda Y, et al. **J Nihon Univ Sch Dent** 1996 Jul;38(2):102–4 (6 ref.)

Stromal melanocytosis of an adenoid cystic carcinoma arising from the palatal minor salivary gland. Takeda Y. **Pathol Int** 1996 Jun;46(6):467–70 (19 ref.)

SALIVARY PROTEINS

BIOSYNTHESIS

Toxins produced by arthropod parasites: salivary gland proteins of human body lice and venom proteins of chelonine wasps. Jones D, et al. **Toxicon** 1996 Nov-Dec; 34(11-12):1421–9 (32 ref.)

GENETICS

Regulation of salivary-gland-specific gene expression. Ann DK, et al. **Crit Rev Oral Biol Med** 1997;8(3):244–52 (62 ref.)

METABOLISM

Glycosylation of secretory proteins in salivary glands and saliva studied by lectin-probes. Garrett JR, et al. **Eur J Morphol** 1996 Aug;34(3):177–80 (10 ref.)

SECRETION

Glycosylation of secretory proteins in salivary glands and saliva studied by lectin-probes. Garrett JR, et al. **Eur J Morphol** 1996 Aug;34(3):177–80 (10 ref.)

TOXICITY

Toxins produced by arthropod parasites: salivary gland proteins of human body lice and venom proteins of chelonine wasps. Jones D, et al. **Toxicon** 1996 Nov-Dec; 34(11-12):1421–9 (32 ref.)

SALIVARY STONES see **SALIVARY GLAND CALCULI**

SALIVATION

see related
XEROSTOMIA

SALK VACCINE see **POLIOVIRUS VACCINE**

SALMO GAIRDNERI see **ONCORHYNCHUS MYKISS**

SALMO SALMO see **SALMON**

SALMON

VIROLOGY

[Salmonid herpesvirus] Yoshimizu M. **Uirusu** 1996 Jun; 46(1):53–9 (46 ref.) **(Jpn)**

SALMON, CHINOOK see **SALMON**

SALMON, PINK see **SALMON**

SALMON, SOCKEYE see **SALMON**

SALMONELLA

CLASSIFICATION

[Molecular biological methods for epidemiological typing of Salmonella--a review] Liebisch B, et al. **Berl Munch Tierarztl Wochenschr** 1996 Sep;109(9):348–54 (96 ref.) (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

[The distribution of antibiotically-resistant organisms in the environment with special attention to salmonellae] Tschäpe H. **DTW Dtsch Tierarztl Wochenschr** 1996 Jul;103(7):273–7 (3 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

DNA insertion sequences and the molecular epidemiology of Salmonella and Mycobacterium. Stanley J, et al. **J Med Microbiol** 1996 Oct;45(4):236–51 (116 ref.)

Molecular genetic bases of Salmonella entry into host cells. Galán JE. **Mol Microbiol** 1996 Apr;20(2):263–71 (43 ref.)

The record of horizontal gene transfer in Salmonella. Bäumler AJ. **Trends Microbiol** 1997 Aug;5(8):318–22 (44 ref.)

[The gentic principles for the design of live Salmonella vaccines] Petrovskaia VG, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 May-Jun; (3):25–8 (47 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Hybrid hepatitis B virus core antigen as a vaccine carrier moiety. II. Expression in avirulent Salmonella spp. for mucosal immunization. Schödel F, et al. **Adv Exp Med Biol** 1996;397:15–21 (18 ref.)

Immune deviation: a historical perspective. Parish CR. **Immunol Cell Biol** 1996 Oct;74(5):449–56 (53 ref.)

SALMONELLA

Mucosal immune responses to intestinal bacterial pathogens. Bloom PD, et al. **Semin Gastrointest Dis** 1996 Jul; 7(3):151–66 (125 ref.)

[Use of Salmonellas as a vector in the designing of recombinant vaccines] Boichenko MN, et al. **Vestn Ross Akad Med Nauk** 1997;(3):43–6 (28 ref.) **(Rus)**

ISOLATION & PURIFICATION

Salmonella neck abscess in a patient with beta-thalassemia major: case report and review. Behr MA, et al. **Clin Infect Dis** 1996 Aug;23(2):404–5 (8 ref.)

Principles of ex ovo competitive exclusion and in ovo administration of Lactobacillus reuteri. Edens FW, et al. **Poult Sci** 1997 Jan;76(1):179–96 (120 ref.)

[Epidemiological profile of non-typhi salmonellosis in a hospital in urban Madrid (1980–1994)] Ramos JM, et al. **Enferm Infecc Microbiol Clin** 1996 Jun–Jul;14(6):345–51 (35 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

[Stable expression of heterologous proteins in salmonella: problems and approaches to their designing] Abaev IV, et al. **Vestn Ross Akad Med Nauk** 1997;(6):48–52 (75 ref.) (Eng. Abstr.) **(Rus)**

PATHOGENICITY

The invasion-associated type-III protein secretion system in Salmonella—a review. Collazo CM, et al. **Gene** 1997 Jun 11;192(1):51–9 (76 ref.)

Host responses to pathogenic Salmonella infection. Jones BD. **Genes Dev** 1997 Mar 15;11(6):679–87 (78 ref.)

Molecular genetic bases of Salmonella entry into host cells. Galán JE. **Mol Microbiol** 1996 Apr;20(2):263–71 (43 ref.)

How Salmonella became a pathogen. Groisman EA, et al. **Trends Microbiol** 1997 Sep;5(9):343–9 (74 ref.)

PHYSIOLOGY

Molecular and cellular bases of Salmonella entry into host cells. Galán JE. **Curr Top Microbiol Immunol** 1996; 209:43–60 (103 ref.)

Survival in a cruel world: how Vibrio cholerae and Salmonella respond to an unwilling host. Slauch J, et al. **Genes Dev** 1997 Jul 15;11(14):1761–74 (125 ref.)

Interaction of Salmonella with lysosomes of eukaryotic cells. García-del Portillo F. **Microbiologia** 1996 Jun;12(2):259–66 (30 ref.)

Salmonella invasion and delivery of protein effectors to mammalian cell cytoplasm. Scherer CA, et al. **Trends Microbiol** 1997 Apr;5(4):127–9 (16 ref.)

SALMONELLA ENTERITIDIS

Transient radiological and colonoscopic features of inflammatory bowel disease in a patient with severe Salmonella gastroenteritis. Dagash M, et al. **Am J Gastroenterol** 1997 Feb;92(2):349–51 (6 ref.)

Salmonella enteritidis in an endometriotic ovarian cyst. Burgmans JP, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Apr;72(2):207–11 (18 ref.)

A rare case of Salmonella neck abscess. Ray J, et al. **J Laryngol Otol** 1997 May;111(5):489–90 (4 ref.)

[Osteomyelitis by Salmonella enteritidis and sickle cell hemoglobinopathy. Report of a case and review of the literature] Pierrotti LC, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1996 May–Jun; 51(3):96–8 (8 ref.) (Eng. Abstr.) **(Por)**

ISOLATION & PURIFICATION

Management of Salmonella infections during pregnancy and puerperium. van der Klooster JM, et al. **Neth J Med** 1997 Aug;51(2):83–6 (24 ref.)

[Salmonella enteritidis pericarditis. Apropos of a case and review of the literature] Victor F, et al. **Arch Mal Coeur Vaiss** 1997 Feb;90(2):301–3 (10 ref.) (Eng. Abstr.) **(Fre)**

SALMONELLA FOOD POISONING

DIAGNOSIS

Transient radiological and colonoscopic features of inflammatory bowel disease in a patient with severe Salmonella gastroenteritis. Dagash M, et al. **Am J Gastroenterol** 1997 Feb;92(2):349–51 (6 ref.)

EPIDEMIOLOGY

Estimating the incidence of food-borne Salmonella and the effectiveness of alternative control measures using the Delphi method. Henson S. **Int J Food Microbiol** 1997 Apr 15;35(3):195–204 (18 ref.)

Foodborne salmonellosis. Gomez TM, et al. **World Health Stat Q** 1997;50(1–2):81–9 (35 ref.)

PREVENTION & CONTROL

Estimating the incidence of food-borne Salmonella and the effectiveness of alternative control measures using the Delphi method. Henson S. **Int J Food Microbiol** 1997 Apr 15;35(3):195–204 (18 ref.)

Foodborne salmonellosis. Gomez TM, et al. **World Health Stat Q** 1997;50(1–2):81–9 (35 ref.)

TRANSMISSION

Food- and milk-borne zoonotic infections. Humphrey TJ. **J Med Microbiol** 1997 Jan;46(1):11–3, 28–33 (228 ref.)

SALMONELLA INFECTIONS

Salmonella endocarditis of a ventricular aneurysm: a case report and review of the literature. Amyot R, et al. **Can J Cardiol** 1997 Mar;13(3):299–301 (07 ref.)

Neonatal jaundice, animal-induced injuries and disease, and immunizations. Gerson WT. **Curr Opin Pediatr** 1997 Aug; 9(4):447–55 (45 ref.)

COMPLICATIONS

Salmonella pericarditis and empyema: a case report. Yang CH, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Sep; 56(3):199–204 (25 ref.)

Infectious ileocecitis caused by Yersinia, Campylobacter, and Salmonella: clinical, radiological and US findings. Puylaert JB, et al. **Eur Radiol** 1997;7(1):3–9 (42 ref.)

An uncommon presentation of Salmonella. Deutsch A, et al. **Pediatr Emerg Care** 1996 Aug;12(4):285–7 (16 ref.)

[Salmonella enteritidis pericarditis. Apropos of a case and review of the literature] Victor F, et al. **Arch Mal Coeur Vaiss** 1997 Feb;90(2):301–3 (10 ref.) (Eng. Abstr.) **(Fre)**

[Osteomyelitis by Salmonella enteritidis and sickle cell hemoglobinopathy. Report of a case and review of the literature] Pierrotti LC, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1996 May–Jun; 51(3):96–8 (8 ref.) (Eng. Abstr.) **(Por)**

DIAGNOSIS

Salmonella braenderup sacroiliac osteomyelitis in a nonsickle cell patient: case report. Hunt BK, et al. **Bull Hosp Jt Dis** 1996;55(2):86–7 (9 ref.)

Salmonella osteomyelitis in a patient with human immunodeficiency virus infection [letter] Belzunegui J, et al. **Clin Rheumatol** 1997 May;16(3):319–20 (10 ref.)

Management of Salmonella infections during pregnancy and puerperium. van der Klooster JM, et al. **Neth J Med** 1997 Aug;51(2):83–6 (24 ref.)

EPIDEMIOLOGY

DNA insertion sequences and the molecular epidemiology of Salmonella and Mycobacterium. Stanley J, et al. **J Med Microbiol** 1996 Oct;45(4):236–51 (116 ref.)

[Epidemiological profile of non-typhi salmonellosis in a hospital in urban Madrid (1980–1994)] Ramos JM, et al. **Enferm Infecc Microbiol Clin** 1996 Jun–Jul;14(6):345–51 (35 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Salmonella enteritidis in an endometriotic ovarian cyst. Burgmans JP, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Apr;72(2):207–11 (18 ref.)

Host responses to pathogenic Salmonella infection. Jones BD. **Genes Dev** 1997 Mar 15;11(6):679–87 (78 ref.)

[Non-typhoid salmonellosis and human immunodeficiency virus (HIV) infection] Ramos JM, et al. **Med Clin (Barc)** 1997 Mar 8;108(9):349–55 (168 ref.) **(Spa)**

IMMUNOLOGY

Hybrid hepatitis B virus core antigen as a vaccine carrier moiety. II. Expression in avirulent Salmonella spp. for mucosal immunization. Schödel F, et al. **Adv Exp Med Biol** 1996;397:15–21 (18 ref.)

Salmonellosis: host immune responses and bacterial virulence determinants. Jones BD, et al. **Annu Rev Immunol** 1996; 14:533–61 (155 ref.)

MICROBIOLOGY

Salmonella neck abscess in a patient with beta-thalassemia major: case report and review. Behr MA, et al. **Clin Infect Dis** 1996 Aug;23(2):404–5 (8 ref.)

TRANSMISSION

Management of Salmonella infections during pregnancy and puerperium. van der Klooster JM, et al. **Neth J Med** 1997 Aug;51(2):83–6 (24 ref.)

ULTRASONOGRAPHY

A rare case of Salmonella neck abscess. Ray J, et al. **J Laryngol Otol** 1997 May;111(5):489–90 (4 ref.)

SALMONELLA INFECTIONS, ANIMAL

DIAGNOSIS

Diagnosing emerging bacterial infections: salmonellosis, campylobacteriosis, clostridial toxicosis, and helicobacteriosis. McDonough PL, et al. **Semin Vet Med Surg (Small Anim)** 1996 Aug;11(3):187–97 (32 ref.)

EPIDEMIOLOGY

[Molecular biological methods for epidemiological typing of Salmonella—a review] Liebisch B, et al. **Berl Munch Tierarztl Wochenschr** 1996 Sep;109(9):348–54 (96 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Salmonella enterica infection. Hess J, et al. **Res Immunol** 1996 Oct–Dec;147(8–9):581–6 (24 ref.)

IMMUNOLOGY

Hybrid hepatitis B virus core antigen as a vaccine carrier moiety. II. Expression in avirulent Salmonella spp. for mucosal immunization. Schödel F, et al. **Adv Exp Med Biol** 1996;397:15–21 (18 ref.)

Salmonellosis: host immune responses and bacterial virulence determinants. Jones BD, et al. **Annu Rev Immunol** 1996; 14:533–61 (155 ref.)

Salmonella enterica infection. Hess J, et al. **Res Immunol** 1996 Oct–Dec;147(8–9):581–6 (24 ref.)

SALMONELLA TYPHI

DRUG EFFECTS

Multidrug-resistant Salmonella typhi: a worldwide epidemic. Rowe B, et al. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S106–9 (30 ref.)

GENETICS

[The molecular epidemiology of typhoid] Riapis LA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Jul–Aug;(4):96–9 (39 ref.) **(Rus)**

PATHOGENICITY

Salmonellosis: host immune responses and bacterial virulence determinants. Jones BD, et al. **Annu Rev Immunol** 1996; 14:533–61 (155 ref.)

SALMONELLA TYPHIMURIUM

Pathobiology of lipopolysaccharide. Mayeux PR. **J Toxicol Environ Health** 1997 Aug 8;51(5):415–35 (117 ref.)

DRUG EFFECTS

Anomalous nonidentity between Salmonella genotoxicants and rodent carcinogens: nongenotoxic carcinogens and genotoxic noncarcinogens. Yoshikawa K. **Environ Health Perspect** 1996 Jan;104(1):40–6 (80 ref.)

GENETICS

Predicting rodent carcinogenicity from mutagenic potency measured in the Ames Salmonella assay. Fetterman BA, et al. **Environ Mol Mutagen** 1997;29(3):312–22 (23 ref.)

IMMUNOLOGY

Salmonella enterica infection. Hess J, et al. **Res Immunol** 1996 Oct–Dec;147(8–9):581–6 (24 ref.)

Nonrecombinant and recombinant avirulent Salmonella vaccines for poultry. Curtiss R 3rd, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):365–72 (40 ref.)

METABOLISM

Lipopolysaccharide's role in the association of Salmonella cells to the mouse intestine studied by ribosomal in situ hybridization. Krogfelt KA, et al. **Adv Exp Med Biol** 1996; 408:123–8 (25 ref.)

Acid stress responses in enterobacteria. Bearson S, et al. **FEMS Microbiol Lett** 1997 Feb 15;147(2):173–80 (39 ref.)

Flagellar assembly in Salmonella typhimurium. Aizawa SI. **Mol Microbiol** 1996 Jan;19(1):1–5 (30 ref.)

PATHOGENICITY

Fimbrial adhesins of Salmonella typhimurium. Role in bacterial interactions with epithelial cells. Bäumler AJ, et al. **Adv Exp Med Biol** 1997;412:149–58 (56 ref.)

Salmonellosis: host immune responses and bacterial virulence determinants. Jones BD, et al. **Annu Rev Immunol** 1996; 14:533–61 (155 ref.)

PHYSIOLOGY

Bacterial chemotaxis: a field in motion. Stock AM, et al. **Curr Opin Struct Biol** 1995 Dec;5(6):744–51 (56 ref.)

SALMONELLA TYPHOSA see **SALMONELLA TYPHI**

SALMONELLOSIS see **SALMONELLA INFECTIONS**

SALMONIDAE

Disease problems of salmonid fish in Japan caused by international trade. Yoshimizu M. **Rev Sci Tech** 1996 Jun; 15(2):533–49 (28 ref.)

EMBRYOLOGY

Characteristics of current international trade of live salmonid eggs. Jansen M, et al. **Rev Sci Tech** 1996 Jun;15(2):423–33 (20 ref.)

IMMUNOLOGY

Vaccination strategies in freshwater salmonid aquaculture. Larsen JL, et al. **Dev Biol Stand** 1997;90:391–400 (30 ref.)
Vaccination strategies in seawater cage culture of salmonids. Lillehaug A. **Dev Biol Stand** 1997;90:401–8 (23 ref.)

SALPINGOGRAPHY see **HYSTEROSALPINGOGRAPHY**

SALPINGOSTOMY

METHODS

[Distal tubal surgery: a critical review of 104 laparoscopic distal tuboplasties] Filippini F, et al.
J Gynecol Obstet Biol Reprod (Paris) 1996;25(5):471–8 (31 ref.) (Eng. Abstr.) **(Fre)**

SALSOLINE ALKALOIDS

ANALYSIS

N-methyl-(R)salsolinol as a dopaminergic neurotoxin: from an animal model to an early marker of Parkinson's disease. Naoi M, et al. **J Neural Transm Suppl** 1997;50:89–105 (49 ref.)

SALT GLAND

PHYSIOLOGY

Cellular and molecular biology of chloride secretion in the shark rectal gland: regulation by adenosine receptors. Forrest JN Jr. **Kidney Int** 1996 Jun;49(6):1557–62 (20 ref.)
The rectal gland of Squalus acanthias: a model for the transport of chloride. Silva P, et al. **Kidney Int** 1996 Jun; 49(6):1552–6 (50 ref.)

SALTS

CHEMISTRY

Theory of phase formation in aqueous two-phase systems. Cabezas H Jr. **J Chromatogr B Biomed Appl** 1996 May 17;680(1–2):3–30 (98 ref.)

PHARMACOLOGY

Mineralocorticoids, salt, hypertension: effects on the heart. Young MJ, et al. **Steroids** 1996 Apr;61(4):233–5 (16 ref.)

SALVAGE THERAPY

High-dose chemotherapy in germ-cell tumors. Droz JP, et al. **Ann Oncol** 1996 Dec;7(10):997–1003 (65 ref.)
Design and analysis of trials of salvage therapy in acute myelogenous leukemia. Estey E, et al.
Cancer Chemother Pharmacol 1997;40 Suppl:S9–12 (08 ref.)
Remission of recurrent mixed germ cell tumor of the ovary after treatment with vincristine, carboplatin, fluorouracil, and ifosfamide: a case report and review of the literature. Balat O, et al. **Eur J Gynaecol Oncol** 1996;17(5):342–4 (20 ref.)
Arthrodesis of the first metatarsophalangeal joint to salvage failed silicone implant arthroplasty. Hecht PJ, et al.
Foot Ankle Int 1997 Jul;18(7):383–90 (63 ref.)
Salvage procedures for calcaneus fractures. Sangeorzan BJ. **Instr Course Lect** 1997;46:339–46 (13 ref.)
High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma. Wang WS, et al. **Jpn J Clin Oncol** 1997 Jun;27(3):154–7 (26 ref.)
Paclitaxel combinations as front-line and salvage chemotherapy regimens in advanced breast cancer. Conte PF, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 15):39–42 (10 ref.)
Late relapse of nonseminomatous germ cell tumor of the testis: successful treatment with salvage chemotherapy alone. Papadimitris C, et al. **Urology** 1997 Mar;49(3):469–70 (7 ref.)

METHODS

Is there a place for surgery in central small cell lung cancer? Kohman LJ. **Chest Surg Clin N Am** 1997 Feb;7(1):105–12 (36 ref.)
Limb salvage in periacetabular sarcomas: review of 21 consecutive cases. Windhager R, et al. **Clin Orthop** 1996 Oct;(331):265–76 (33 ref.)
The logistics of damage control. Granchi TS, et al.
Surg Clin North Am 1997 Aug;77(4):921–8 (13 ref.)
Postoperative care and complications of damage control surgery. Martin RR, et al. **Surg Clin North Am** 1997 Aug; 77(4):929–42 (16 ref.)
Limb salvage in peripheral vascular trauma. Adebo O. **West Afr J Med** 1996 Jul–Sep;15(3):139–42 (33 ref.)

SALVELINUS see **TROUT**

SAMPLE SIZE

Study design in clinical research: sample size estimation and power analysis [published erratum appears in Can J Anaesth 1996 Aug;43(8):880] Lerman J. **Can J Anaesth** 1996 Feb;43(2):184–91 (11 ref.)
A user's review of commercial sample size software for design of biomedical studies using survival data. Iwane M, et al. **Control Clin Trials** 1997 Feb;18(1):65–83 (18 ref.)
Critical factors in the determination of focus group size. Tang KC, et al. **Fam Pract** 1995 Dec;12(4):474–5 (13 ref.)
The overemphasis on power analysis. Knapp TR.
Nurs Res 1996 Nov–Dec;45(6):379–81 (18 ref.)
Determining sample size and power in clinical trials: the forgotten essential. Grimes DA, et al.
Semin Reprod Endocrinol 1996 May;14(2):125–31 (16 ref.)
[Practical aspects regarding sample size in clinical research] Vega Ramos B, et al. **Rev Gastroenterol Mex** 1996 Jul–Sep; 61(3):246–51 (12 ref.) (Eng. Abstr.) **(Spa)**

SAMPLING BIAS see **SELECTION BIAS**

SAMPLING STUDIES

Statistical methodology: I. Incorporating the prevalence of disease into the sample size calculation for sensitivity and specificity [see comments] Buderer NM.
Acad Emerg Med 1996 Sep;3(9):895–900 (5 ref.) Comment in: Acad Emerg Med 1996 Sep;3(9):824.
Adaptive sampling in behavioral surveys. Thompson SK.
NIDA Res Monogr 1997;167:296–319 (76 ref.)

SAN MIGUEL SEA LION VIRUSES see **CALICIVIRUS**

SAND-DOLLAR see **SEA URCHINS**

SANDFLIES see **PSYCHODIDAE**

SANDFLY FEVER SICILIAN VIRUS see **PHLEBOVIRUS**

SAO PAULO TYPHUS see **ROCKY MOUNTAIN SPOTTED FEVER**

SAPHENOUS VEIN

Failure patterns of cryopreserved vein grafts in liver transplantation. Kuang AA, et al. **Transplantation** 1996 Sep 27;62(6):742–7 (21 ref.)

PATHOLOGY

Coronary artery and saphenous vein graft remodeling: a review of histologic findings after various interventional procedures—Part V. Waller BF, et al. **Clin Cardiol** 1997 Jan;20(1):67–74 (52 ref.)
Coronary artery and saphenous vein graft remodeling: a review of histologic findings after various interventional procedures—Part VI. Waller BF, et al. **Clin Cardiol** 1997 Feb;20(2):153–60 (25 ref.)
Proliferation, migration, matrix turnover, and death of smooth muscle cells in native coronary and vein graft atherosclerosis. Newby AC, et al. **Curr Opin Cardiol** 1996 Nov;11(6):574–82 (77 ref.)

TRANSPLANTATION

Asymptomatic large coronary artery saphenous vein bypass graft aneurysm: a case report and review of the literature. Wight JN Jr, et al. **Am Heart J** 1997 Apr;133(4):454–60 (37 ref.)
Potential advantages of treatment of transplanted saphenous vein aorto-coronary artery bypass grafts with beta irradiation to prevent graft occlusion. Smith RG.
Artery 1997;22(5):278–86 (25 ref.)
Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein-covered Palmaz stent [see comments] Gurbel PA, et al.
Cathet Cardiovasc Diagn 1997 Jan;40(1):75–8 (12 ref.) Comment in: Cathet Cardiovasc Diagn 1997 Jan;40(1):79.
Proliferation, migration, matrix turnover, and death of smooth muscle cells in native coronary and vein graft atherosclerosis. Newby AC, et al. **Curr Opin Cardiol** 1996 Nov;11(6):574–82 (77 ref.)
[Distal popliteal bypass in the diabetic patient. Clinical case] Cavallini M, et al. **Minerva Chir** 1996 Jul–Aug; 51(7–8):589–95 (23 ref.) (Eng. Abstr.) **(Ita)**

SAPONINS

Novel sweet-tasting saponins of the cycloartane, oleanane, secodammarane, and steroidal types. Kennelly EJ, et al. **Adv Exp Med Biol** 1996;405:13–24 (47 ref.)
Alfalfa saponins: structure, biological activity, and chemotaxonomy. Oleszek W. **Adv Exp Med Biol** 1996; 405:155–70 (85 ref.)
Steroid saponins from fenugreek and some of their biological properties. Sauvaire Y, et al. **Adv Exp Med Biol** 1996; 405:37–46 (21 ref.)
Triterpenoid saponins from a Siberian chemorace of the Thalictrum genus. Semenov AA, et al.
Adv Exp Med Biol 1996;405:193–207 (26 ref.)
Application of saponins in foods and cosmetics: saponins of Mohave yucca and Sapindus mukurossi. Tanaka O, et al. **Adv Exp Med Biol** 1996;405:1–11 (14 ref.)

ADVERSE EFFECTS

Biological effects of feed and forage saponins and their impacts on animal production. Cheeke PR.
Adv Exp Med Biol 1996;405:377–85 (57 ref.)
Do steroidal saponins have a role in hepatogenous photosensitization diseases of sheep? Flåøyen A.
Adv Exp Med Biol 1996;405:395–403 (51 ref.)

CHEMISTRY

A systematic NMR approach for the determination of the molecular structure of steroidal saponins. Agrawal PK.
Adv Exp Med Biol 1996;405:299–315 (117 ref.)
Acylated saponins from Crocosmia plants. Asada Y, et al.
Adv Exp Med Biol 1996;404:459–69 (12 ref.)
Triterpene saponins from plants of the flora of Turkey. Calis I, et al. **Adv Exp Med Biol** 1996;404:485–500 (44 ref.)
Chemistry and biological activity of steroid saponins from Moldovian plants. Kintia PK. **Adv Exp Med Biol** 1996; 404:309–34 (28 ref.)
Saponins and artifacts. Massiot G, et al.
Adv Exp Med Biol 1996;405:183–92 (16 ref.)
Saponins from the compositae plants: structures of the saponins from Aster scaber Thunb. Nagao T, et al.
Adv Exp Med Biol 1996;404:297–307 (8 ref.)
Intensely sweet saponin osladin: synthetic and structural study. Nishizawa M, et al. **Adv Exp Med Biol** 1996; 405:25–36 (41 ref.)
Analysis, heat stability and physiological effects of saponins from oats. Onning G, et al. **Adv Exp Med Biol** 1996; 405:365–75 (49 ref.)
Triterpene saponins from maté, Ilex paraguariensis. Schenkel EP, et al. **Adv Exp Med Biol** 1996;405:47–56 (18 ref.)
Saponins from Medicago Spp.: chemical characterization and biological activity against insects. Tava A, et al.
Adv Exp Med Biol 1996;405:97–109 (42 ref.)
Chemistry and biological activity of triterpenoid glycosides from Medicago sativa. Timbekova AE, et al.
Adv Exp Med Biol 1996;405:171–82 (19 ref.)
Molecular structures of saponins from Quillaja saponaria Molina. van Setten DC, et al. **Adv Exp Med Biol** 1996; 404:185–93 (30 ref.)

IMMUNOLOGY

Saponins as vaccine adjuvants. Kensil CR.
Crit Rev Ther Drug Carrier Syst 1996;13(1–2):1–55 (178 ref.)

ISOLATION & PURIFICATION

New saponins from Vietnamese ginseng: highlights on biogenesis of dammarane triterpenoids. Duc NM, et al.
Adv Exp Med Biol 1996;404:129–49 (24 ref.)
Search for molluscicidal and antifungal saponins from tropical plants. Hostettmann K, et al.
Adv Exp Med Biol 1996;404:117–28 (18 ref.)
Triterpene and steroid saponins isolated from two Melilotus species. Khodakov GV, et al. **Adv Exp Med Biol** 1996; 405:211–22 (17 ref.)
Investigations of molluscicidal saponins from the Endod plant Phytolacca dodecandra. Thiilborg ST, et al.
Adv Exp Med Biol 1996;404:151–64 (52 ref.)
Studies on bioactive saponins from Chinese medicinal plants. Xu R, et al. **Adv Exp Med Biol** 1996;404:371–82 (9 ref.)
Bioactive triterpenoid and steroid saponins from medicinal plants in southwest China. Yang CR, et al.
Adv Exp Med Biol 1996;404:225–38 (20 ref.)

METABOLISM

Oxygen-radical-scavenging activity of DDMP-conjugated saponins and physiological role in leguminous plant. Okubo K, et al. **Adv Exp Med Biol** 1996;405:141–54 (27 ref.)
Saponin detoxification by plant pathogenic fungi. Osbourn AE, et al. **Adv Exp Med Biol** 1996;404:547–55 (44 ref.)
The endogenous digitalis-like factor. Kölbel F, et al.
Mol Cell Biochem 1996 Jul–Aug;160–161:111–5 (51 ref.)

PHARMACOLOGY

New cardioactive steroid saponins and other glycosides from Mexican Tribulus cistoides. Achenbach H, et al.
Adv Exp Med Biol 1996;404:357–70 (17 ref.)
Commercial utilization of plant-derived saponins: an overview of medicinal, pharmaceutical, and industrial applications. Balandrin MF. **Adv Exp Med Biol** 1996; 404:1–14 (43 ref.)
Studies of the phytotoxicity of saponins on weed and crop plants. Hoagland RE, et al. **Adv Exp Med Biol** 1996; 405:57–73 (68 ref.)
Chemistry and biological activity of steroid saponins from Moldovian plants. Kintia PK. **Adv Exp Med Biol** 1996; 404:309–34 (28 ref.)
Anti-tumor-promoting activities or triterpenoid glycosides; cancer chemoprevention by saponins. Konoshima T.
Adv Exp Med Biol 1996;404:87–100 (11 ref.)
Steroidal saponins from the Liliaceae plants and their biological activities. Mimaki Y, et al.
Adv Exp Med Biol 1996;404:101–10 (29 ref.)
Bioactive saponins from solanaceous and leguminous plants. Nohara T, et al. **Adv Exp Med Biol** 1996;404:263–76 (22 ref.)
Analysis, heat stability and physiological effects of saponins

SAPONINS

from oats. Onning G, et al. **Adv Exp Med Biol** 1996; 405:365–75 (49 ref.)
Chemistry and biological activity of triterpenoid glycosides from Medicago sativa. Timbekova AE, et al. **Adv Exp Med Biol** 1996;405:171–82 (19 ref.)
Studies on bioactive saponins from Chinese medicinal plants. Xu R, et al. **Adv Exp Med Biol** 1996;404:371–82 (9 ref.)
Saponins as antimycotic agents: glycosides of medicagenic acid. Zehavi U, et al. **Adv Exp Med Biol** 1996;404:535–46 (37 ref.)
Immunologic effect of traditional Chinese drugs. Yang G. **Chin Med J (Engl)** 1996 Jan;109(1):59–60 (0 ref.)
Vascular effects of selected antihypertensive drugs derived from traditional medicinal herbs. Kwan CY. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S297–9 (12 ref.)

TOXICITY

Investigations of molluscicidal saponins from the Endod plant Phytolacca dodecandra. Thiilborg ST, et al. **Adv Exp Med Biol** 1996;404:151–64 (52 ref.)

SAQUINAVIR

Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Noble S, et al. **Drugs** 1996 Jul;52(1):93–112 (75 ref.)

PHARMACOLOGY

HIV protease inhibitors. Carr A, et al. **AIDS** 1996;10 Suppl A:S151–7 (51 ref.)

THERAPEUTIC USE

Rational approaches to resistance: using saquinavir. Boucher C. **AIDS** 1996 Nov;10 Suppl 1:S15–9 (16 ref.)
Saquinavir. Porche DJ. **J Assoc Nurses AIDS Care** 1996 Jul–Aug;7(4):61–4 (5 ref.)

1-SAR-8-ALA ANGIOTENSIN II see **SARALASIN**

SARALASIN

DIAGNOSTIC USE

[Angiotensin II analogue infusion test] Katsuragi M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:321–4 (10 ref.) **(Jpn)**

SARCOCYSTIS

[Sarcocystosis] Lian Z. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(4):295–9 (34 ref.) **(Chi)**

IMMUNOLOGY

Serum antibodies to Sarcocystis neurona—half the horses in the United States have them! [comment] MacKay RJ. **J Am Vet Med Assoc** 1997 Feb 15;210(4):482–3 (12 ref.) Comment on: J Am Vet Med Assoc 1997 Feb 15;210(4):517–8. Comment on: J Am Vet Med Assoc 1997 Feb 15;210(4):519–24. Comment on: J Am Vet Med Assoc 1997 Feb 15;210(4):525–7.

ISOLATION & PURIFICATION

Equine protozoal myeloencephalitis. MacKay RJ. **Vet Clin North Am Equine Pract** 1997 Apr;13(1):79–96 (72 ref.)

PATHOGENICITY

Gut Coccidia-- Isospora, Cryptosporidium, Cyclospora and Sarcocystis. Ackers JP. **Semin Gastrointest Dis** 1997 Jan; 8(1):33–44 (166 ref.)

SARCOCYSTOSIS

[Sarcocystosis] Lian Z. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(4):295–9 (34 ref.) **(Chi)**

VETERINARY

Serum antibodies to Sarcocystis neurona—half the horses in the United States have them! [comment] MacKay RJ. **J Am Vet Med Assoc** 1997 Feb 15;210(4):482–3 (12 ref.) Comment on: J Am Vet Med Assoc 1997 Feb 15;210(4):517–8. Comment on: J Am Vet Med Assoc 1997 Feb 15;210(4):519–24. Comment on: J Am Vet Med Assoc 1997 Feb 15;210(4):525–7.
Equine protozoal myeloencephalitis. MacKay RJ. **Vet Clin North Am Equine Pract** 1997 Apr;13(1):79–96 (72 ref.)

SARCOIDOSIS

Ulcerative sarcoidosis. Case report and review of the literature. Albertini JG, et al. **Arch Dermatol** 1997 Feb; 133(2):215–9 (50 ref.)
Sarcoid arthropathy. Totemchokchyakarn K, et al. **Bull Rheum Dis** 1997 May;46(3):3–5 (5 ref.)
Sarcoidosis: a clinical overview. Puryear DW, et al. **Compr Ther** 1996 Oct;22(10):649–53 (12 ref.)
An update of the benign proliferative monocyte-macrophage and dendritic cell disorders. Moschella SL. **J Dermatol** 1996 Nov;23(11):805–15 (56 ref.)
Sarcoidosis [published erratum appears in N Engl J Med 1997 Jul 10;337(2):139] Newman LS, et al. **N Engl J Med** 1997 Apr 24;336(17):1224–34 (159 ref.)
Sarcoidosis in children. Pattishall EN, et al. **Pediatr Pulmonol** 1996 Sep;22(3):195–203 (74 ref.)
[Cardiac sarcoidosis] Sekiguchi M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):451–6 (22 ref.) **(Jpn)**

COMPLICATIONS

Pneumococcal pericarditis—out of sight, out of mind? McMechan SR, et al. **Clin Cardiol** 1996 Oct;19(10):829–30 (5 ref.)
Rheumatic features of sarcoidosis. Pettersson T. **Curr Opin Rheumatol** 1997 Jan;9(1):62–7 (42 ref.)
Diffuse intrahepatic biliary strictures in sarcoidosis resembling sclerosing cholangitis. Case report and review of the literature. Alam I, et al. **Dig Dis Sci** 1997 Jun; 42(6):1295–301 (45 ref.)
Chronic pancreatitis: a complication of sarcoidosis? Boruchowicz A, et al. **Eur J Gastroenterol Hepatol** 1996 Nov;8(11):1125–7 (25 ref.)
Sarcoidosis presenting as heart disease. Nelson JE, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Sep;13(2):178–82 (48 ref.)
[Spinal cord compression of sarcoidosis origin: a case] Tieulie N, et al. **Rev Med Interne** 1997 Jul;18(7):578–81 (18 ref.) (Eng. Abstr.) **(Fre)**
[A case of a combination of sarcoidosis and myeloma] Kamaeva OI, et al. **Ter Arkh** 1995;67(12):57–9 (19 ref.) **(Rus)**

DIAGNOSIS

Cardiac sarcoidosis: diagnostic, prognostic, and therapeutic considerations. Sekiguchi M, et al. **Cardiovasc Drugs Ther** 1996 Nov;10(5):495–510 (288 ref.)
Sarcoidosis manifesting as acute appendicitis: report of a case. Cullinane DC, et al. **Dis Colon Rectum** 1997 Jan; 40(1):109–11 (11 ref.)
Sarcoidosis. Stanbury RM, et al. **Int Ophthalmol Clin** 1995 Summer;35(3):123–37 (43 ref.)
Sarcoid masquerading as optic nerve sheath meningioma [see comments] Ing EB, et al. **Mayo Clin Proc** 1997 Jan; 72(1):38–43 (32 ref.) Comment in: Mayo Clin Proc 1997 Aug;72(8):791.
Sarcoidosis and common variable immunodeficiency. Report of 8 cases and review of the literature. Fasano MB, et al. **Medicine (Baltimore)** 1996 Sep;75(5):251–61 (37 ref.)
Sarcoidosis mythology. Teirstein AS, et al. **Mt Sinai J Med** 1996 Oct–Nov;63(5–6):335–41 (51 ref.)
[Neurosarcoidosis mimicking cerebral tumor] Herrero Fernández B, et al. **An Med Interna** 1997 Mar;14(3):139–41 (13 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Sarcoidosis. Stanbury RM, et al. **Int Ophthalmol Clin** 1995 Summer;35(3):123–37 (43 ref.)
Primary care paradigm for management of sarcoidosis, Part 1. Young RC Jr, et al. **J Natl Med Assoc** 1997 Mar; 89(3):181–90 (53 ref.)

ETIOLOGY

Mycobacteria as possible causes of sarcoidosis and Crohn's disease. McFadden JJ, et al. **Soc Appl Bacteriol Symp Ser** 1996;25:47S–52S (45 ref.)
[Etiology of sarcoidosis] Nakada Y. **Arerugi** 1995 Nov; 44(11):1255–61 (53 ref.) **(Jpn)**
[Sarcoidosis representing multiple splenic nodules in a patient with IgA nephropathy] Nishiya H, et al. **Nippon Jinzo Gakkai Shi** 1996 Jan;38(1):40–5 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Sarcoidosis in a patient with autoimmune hemolytic anemia] Yasuda N, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Aug;34(8):931–6 (20 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Rybicki BA, et al. **Am J Epidemiol** 1997 Feb 1;145(3):234–41 (30 ref.)
Finding disease genes. From cystic fibrosis to sarcoidosis. Thomas A. Neff Lecture. Iannuzzi MC, et al. **Chest** 1997 Jun;111(6 Suppl):70S–73S (38 ref.)
[Epidemiology, genetics and familial occurrence of sarcoidosis] Zielonka TM. **Pneumonol Alergol Pol** 1996; 64(5–6):345–51 (45 ref.) **(Pol)**

IMMUNOLOGY

Sarcoidosis and common variable immunodeficiency. Report of 8 cases and review of the literature. Fasano MB, et al. **Medicine (Baltimore)** 1996 Sep;75(5):251–61 (37 ref.)
Immunological, clinical and molecular aspects of sarcoidosis. Agostini C, et al. **Mol Aspects Med** 1997 Apr;18(2):91–165 (170 ref.)

PATHOLOGY

Cutaneous involvement in sarcoidosis. Relationship to systemic disease [editorial] Mañá J, et al. **Arch Dermatol** 1997 Jul;133(7):882–8 (75 ref.)
The role of granulomatous phlebitis and thrombosis in the pathogenesis of cirrhosis and portal hypertension in sarcoidosis. Moreno-Merlo F, et al. **Hepatology** 1997 Sep; 26(3):554–60 (29 ref.)
Oral manifestations of sarcoidosis. Blinder D, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Apr;83(4):458–61 (53 ref.)
Intrascrotal sarcoidosis: case reports and review. Carmody JP, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Sep; 13(2):129–34 (73 ref.)

PHYSIOPATHOLOGY

Renal dysfunction in patients with sarcoidosis [editorial; comment] Sato A. **Intern Med** 1996 Jul;35(7):523–4 (13 ref.) Comment on: Intern Med 1996 Jul;35(7):579–82.

RADIOGRAPHY

CT patterns of nodular hepatic and splenic sarcoidosis: a review of the literature. Scott GC, et al. **J Comput Assist Tomogr** 1997 May–Jun;21(3):369–72 (11 ref.)

SURGERY

Sarcoidosis and transplantation. Padilla ML, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1997 Mar;14(1):16–22 (25 ref.)
[Tumorous neurosarcoidosis—a rare manifestation of Boeck disease—3 cases and review of the literature] Probst-Cousin S, et al. **Zentralbl Neurochir** 1996; 57(1):37–43 (29 ref.) (Eng. Abstr.) **(Ger)**
[The potentials for the surgical treatment of intrathoracic sarcoidosis complicated by chronic pleurisy] Duzhil ID, et al. **Lik Sprava** 1996 Jul–Sep;(7–9):168–70 (12 ref.) (Eng. Abstr.) **(Rus)**

THERAPY

Cardiac sarcoidosis: diagnostic, prognostic, and therapeutic considerations. Sekiguchi M, et al. **Cardiovasc Drugs Ther** 1996 Nov;10(5):495–510 (288 ref.)
Immunological, clinical and molecular aspects of sarcoidosis. Agostini C, et al. **Mol Aspects Med** 1997 Apr;18(2):91–165 (170 ref.)

SARCOIDOSIS, PULMONARY

Pulmonary sarcoidosis: current concepts & controversies. Lynch JP 3rd. **Compr Ther** 1997 Mar;23(3):197–210 (30 ref.)

COMPLICATIONS

Sarcoidosis and spondylarthropathy. Three case-reports. Kremer P, et al. **Rev Rhum Engl Ed** 1996 Jun;63(6):405–11 (36 ref.)
Association between inflammatory bowel disease and sarcoidosis. Report of two cases and review of the literature. Fries W, et al. **Scand J Gastroenterol** 1995 Dec; 30(12):1221–3 (35 ref.)
[Systemic scleroderma and sarcoidosis: 3 new cases] Bandt MD, et al. **Ann Med Interne (Paris)** 1996;147(8):590–4 (10 ref.) (Eng. Abstr.) **(Fre)**
[Chylothorax as a complication of sarcoidosis] Haitsch R, et al. **Pneumologie** 1996 Dec;50(12):912–4 (13 ref.) (Eng. Abstr.) **(Ger)**
[Coincidence of primary sclerosing cholangitis and sarcoidosis—case report and review of the literature] Keller K, et al. **Z Gastroenterol** 1997 Jan;35(1):33–9 (33 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Use of lung function tests in sarcoidosis. Brådvik I. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Mar;13(1):59–62 (14 ref.)

DRUG THERAPY

Primary care paradigm for management of sarcoidosis, Part 1. Young RC Jr, et al. **J Natl Med Assoc** 1997 Mar; 89(3):181–90 (53 ref.)

PATHOLOGY

Pathology of pulmonary granulomatous vasculitis [see comments] Travis WD. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Mar;13(1):14–27 (107 ref.) Comment in: Sarcoidosis Vasc Diffuse Lung Dis 1996 Mar;13(1):13.
[A case of a combination of sarcoidosis and myeloma] Kamaeva OI, et al. **Ter Arkh** 1995;67(12):57–9 (19 ref.) **(Rus)**

RADIOGRAPHY

[Roentgen morphology of pulmonary sarcoidosis] Hald HJ. **Rontgenpraxis** 1996 Aug;49(8):201–6 (38 ref.) **(Ger)**

SARCOLEMMA

CHEMISTRY

Syntrophins: modular adapter proteins at the neuromuscular

junction and the sarcolemma. Froehner SC, et al. **Soc Gen Physiol Ser** 1997;52:197–207 (49 ref.)

METABOLISM

Membrane—vanadium interaction: a toxicokinetic evaluation. Upreti RK. **Mol Cell Biochem** 1995 Dec 6–20; 153(1–2):167–71 (26 ref.)

PHYSIOLOGY

[Dystrophin–glycoprotein complex of skeletal muscle sarcolemma] Jakubiec–Puka A, et al. **Postepy Biochem** 1996;42(2):204–13 (90 ref.) **(Pol)**

SARCOLYSINE see **MELPHALAN**

SARCOMA

see related

SARCOMA VIRUSES, AVIAN

Diagnosis and treatment of soft tissue sarcomas in adults. Dirix LY, et al. **Curr Opin Oncol** 1996 Jul;8(4):289–98 (69 ref.)

Rhabdomyosarcoma and other soft tissue sarcomas in children. Pappo AS. **Curr Opin Oncol** 1996 Jul;8(4):311–6 (20 ref.)

Soft tissue sarcomas. Lewis JJ, et al. **Curr Probl Surg** 1996 Oct;33(10):817–72 (202 ref.)

Biology of sarcomas. Chang HA, et al. **Med Health R I** 1997 Jan;80(1):8–14 (35 ref.)

[Retroperitoneal sarcomas: recent advances in nosographic framework, diagnosis and integrated surgical treatment] Capaldi M, et al. **G Chir** 1997 Jan–Feb;18(1–2):55–60 (17 ref.) (Eng. Abstr.) **(Ita)**

[Primary pulmonary artery sarcoma (e.g. spindle cell sarcoma of the pulmonary artery, pulmonary artery leiomyosarcoma)] Miyahara Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):598–600 (16 ref.) **(Jpn)**

CLASSIFICATION

Sarcoma: a challenging frontier for the oncologist. Wanebo HJ. **Med Health R I** 1997 Jan;80(1):5–7 (30 ref.)

[TNM classification of bone and soft tissue sarcomas] Fukuma H, et al. **Gan To Kagaku Ryoho** 1997 Jun;24(8):1035–40 (9 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Pre leukemic granulocytic sarcoma of vagina. A case report with review of literature. Lakshminarasimhan S, et al. **Indian J Cancer** 1996 Sep;33(3):145–8 (13 ref.)

Aortic intimal sarcoma with acute myocardial infarction. Nanjo H, et al. **Pathol Int** 1996 Sep;46(9):673–81 (40 ref.)

DIAGNOSIS

Follicular dendritic cell sarcoma mimicking diffuse large cell lymphoma: a case report. Fonseca R, et al. **Am J Hematol** 1997 Jul;55(3):148–55 (45 ref.)

Does magnetic resonance imaging make a difference for patients with musculoskeletal sarcoma? Bloem JL, et al. **Br J Radiol** 1997 Apr;70:327–37 (68 ref.)

Pulmonary artery sarcomas: a review of clinical and radiologic features. Cox JE, et al. **J Comput Assist Tomogr** 1997 Sep–Oct;21(5):750–5 (30 ref.)

Thyroid cancers. II. Medullary, anaplastic, lymphoma, sarcoma, squamous cell. Austin JR, et al. **Otolaryngol Clin North Am** 1996 Aug;29(4):611–27 (86 ref.)

[Epithelioid sarcoma. Diagnostic and therapeutic aspects apropos of a coccygeal localization] Tournigand C, et al. **Rev Med Interne** 1997;18(1):50–3 (16 ref.) (Eng. Abstr.) **(Fre)**

[Rare etiology of multiple pulmonary lacunae] Nourdine K, et al. **Rev Pneumol Clin** 1996;52(6):391–7 (32 ref.) (Eng. Abstr.) **(Fre)**

[Retrovesical schwannosarcoma] Gonzalvo Pérez V, et al. **Actas Urol Esp** 1997 Apr;21(4):416–9 (8 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Chemotherapy for soft tissue sarcomas. Indications and advances. Phillips KA, et al. **Acta Orthop Scand Suppl** 1997 Feb;273:133–8 (42 ref.)

Chemotherapy for adult soft tissue sarcoma. Does it work? Saeter G. **Acta Orthop Scand Suppl** 1997 Feb;273:139–44 (35 ref.)

Infusional chemotherapy combined with recombinant human granulocyte colony stimulating factor: advantages and limitations. Weiss AJ, et al. **Am J Clin Oncol** 1997 Feb; 20(1):63–8 (30 ref.)

Intraoperative hyperthermic lavage with cisplatin for peritoneal carcinomatosis and sarcomatosis. Stephens AD, et al. **Cancer Treat Res** 1996;81:15–30 (35 ref.)

Chemotherapy for metastatic soft tissue sarcomas. Steward WP. **Cancer Treat Res** 1997;91:157–72 (71 ref.)

Early postoperative intraperitoneal Adriamycin as an adjuvant treatment for visceral and retroperitoneal sarcoma. Sugarbaker PH. **Cancer Treat Res** 1996;81:7–14 (12 ref.)

Adjuvant chemotherapy of soft tissue sarcomas. Verweij J, et al. **Cancer Treat Res** 1997;91:173–87 (27 ref.)

Chemotherapy for soft tissue sarcomas. Clark JW. **Med Health R I** 1997 Jan;80(1):37–8 (23 ref.)

ETIOLOGY

Sarcoma of bone–cement membrane: a case report and review of the literature. Bell RS, et al. **Can J Surg** 1997 Feb; 40(1):51–5 (32 ref.)

Radiation–induced bone and soft tissue sarcomas: clinical aspects and molecular biology. Spiro IJ, et al. **Cancer Treat Res** 1997;91:143–55 (107 ref.)

[Incidence of malignant soft tissue tumors (sarcomas) after previous radiotherapy] Hernandez–Richter T, et al. **Langenbecks Arch Chir** 1996;381(5):295–8 (19 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Musculoskeletal oncology—advances in cytogenetics and molecular genetics and their clinical implications. Choong PF, et al. **Acta Oncol** 1997;36(3):245–54 (120 ref.)

p53: functions, mutations and sarcomas. Hung J, et al. **Acta Orthop Scand Suppl** 1997 Feb;273:68–73 (65 ref.)

Molecular and cytogenetics of soft tissue sarcomas. Nilbert M. **Acta Orthop Scand Suppl** 1997 Feb;273:60–7 (53 ref.)

Molecular genetics of soft tissue sarcomas. Cooper CS, et al. **Cancer Treat Res** 1997;91:31–50 (93 ref.)

Cytogenetics of soft tissue tumors. Fletcher JA. **Cancer Treat Res** 1997;91:9–29 (114 ref.)

Cytogenetics and experimental models. Toretsky JA, et al. **Curr Opin Oncol** 1997 Jul;9(4):342–7 (42 ref.)

PATHOLOGY

Prognostic factors in soft tissue sarcoma. Rydholm A. **Acta Orthop Scand Suppl** 1997 Feb;273:148–55 (36 ref.)

Prognostic factors in bone sarcomas. Saeter G, et al. **Acta Orthop Scand Suppl** 1997 Feb;273:156–60 (36 ref.)

"Proximal–type" epithelioid sarcoma, a distinctive aggressive neoplasm showing rhabdoid features. Clinicopathologic, immunohistochemical, and ultrastructural study of a series. Guillou L, et al. **Am J Surg Pathol** 1997 Feb;21(2):130–46 (70 ref.)

Needle tract recurrences after closed biopsy for sarcoma: three cases and review of the literature. Schwartz HS, et al. **Ann Surg Oncol** 1997 Apr–May;4(3):228–36 (58 ref.)

Soft tissue Langerhans' cell histiocytosis in an adult. A case presentation with flow cytometric analysis and literature review. al–Abbadi M, et al. **Arch Pathol Lab Med** 1997 Feb;121(2):169–72 (34 ref.)

Follicular dendritic cell sarcoma. Clinicopathologic analysis of 17 cases suggesting a malignant potential higher than currently recognized. Chan JK, et al. **Cancer** 1997 Jan 15; 79(2):294–313 (39 ref.)

Value of peer review of pathology in soft tissue sarcomas. Harris M, et al. **Cancer Treat Res** 1997;91:1–8 (13 ref.)

Soft tissue sarcoma in adults. Dirix LY, et al. **Curr Opin Oncol** 1997 Jul;9(4):348–59 (62 ref.)

Tumours of the oral cavity, buccal pouch, oesophagus, forestomach and salivary glands. Takahashi M, et al. **IARC Sci Publ** 1996;(126):59–77 (60 ref.)

Adult genitourinary sarcomas: a report of seventeen cases and review of the literature. Berkmen F, et al. **J Exp Clin Cancer Res** 1997 Mar;16(1):45–8 (20 ref.)

Uterine sarcoma. Levenback CF, et al. **Obstet Gynecol Clin North Am** 1996 Jun;23(2):457–73 (37 ref.)

A case of sarcomatoid carcinoma of the thymus. Nishimura M, et al. **Pathol Int** 1997 Apr;47(4):260–3 (11 ref.)

Sarcomatoid hepatocellular carcinoma with osteoclast–like giant cells: case report and immunohistochemical observations. Sasaki A, et al. **Pathol Int** 1997 May; 47(5):318–24 (30 ref.)

Soft tissue sarcoma nodal metastases: biologic significance and therapeutic considerations. Skinner KA, et al. **Surg Oncol Clin N Am** 1996 Jan;5(1):121–7 (14 ref.)

[Small cell–sarcomatoid carcinoma of the urinary bladder] Domínguez Iglesias F, et al. **Arch Esp Urol** 1996 Jul–Aug; 49(6):631–5 (15 ref.) (Eng. Abstr.) **(Spa)**

RADIONUCLIDE IMAGING

Nuclear medicine techniques provide unique physiologic characterization of suspected and known soft tissue and bone sarcomas. Hicks RJ. **Acta Orthop Scand Suppl** 1997 Feb;273:25–36 (38 ref.)

PET imaging in soft tissue sarcomas. Miraldi F, et al. **Cancer Treat Res** 1997;91:51–64 (40 ref.)

RADIOTHERAPY

Soft tissue sarcomas: radiation as a therapeutic option. Suit H, et al. **Ann Acad Med Singapore** 1996 Nov;25(6):855–61 (45 ref.)

Brachytherapy for soft tissue sarcomas. Devlin PM, et al. **Cancer Treat Res** 1997;91:107–28 (41 ref.)

Three–dimensional planning and conformal radiotherapy. Harmer C, et al. **Cancer Treat Res** 1997;91:129–41 (24 ref.)

The role of radiation in the management of soft tissue sarcoma. Liu L, et al. **Med Health R I** 1997 Jan;80(1):32–6 (36 ref.)

Role of radiation therapy in retroperitoneal sarcomas. Clark JA, et al. **Oncology (Huntingt)** 1996 Dec;10(12):1867–72; discussion 1872–4 (27 ref.)

Role of brachytherapy in adult soft tissue sarcomas. Hilaris BS, et al. **Semin Surg Oncol** 1997 May–Jun;13(3):196–203 (20 ref.)

[Uterine sarcoma treated by surgery and postoperative radiation therapy. Patterns of relapse, prognostic factors and role of radiation therapy] Coquard R, et al. **Bull Cancer** 1997 Jun;84(6):625–9 (29 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

Treatment of the patient with lung metastases. Roth JA, et al. **Curr Probl Surg** 1996 Nov;33(11):881–952 (326 ref.)

SURGERY

Soft tissue sarcomas: radiation as a therapeutic option. Suit H, et al. **Ann Acad Med Singapore** 1996 Nov;25(6):855–61 (45 ref.)

Chest wall resection and reconstruction. Sabanathan S, et al. **Br J Hosp Med** 1997 Mar 19–Apr 1;57(6):255–9 (21 ref.)

Metastasectomy for soft tissue sarcomas. Pastorino U. **Cancer Treat Res** 1997;91:65–75 (32 ref.)

Limb salvage in periacetabular sarcomas: review of 21 consecutive cases. Windhager R, et al. **Clin Orthop** 1996 Oct;(331):265–76 (33 ref.)

Radical scapulectomy with limb salvage for shoulder girdle soft tissue sarcoma. Volpe CM, et al. **Surg Oncol** 1996 Feb; 5(1):43–8 (20 ref.)

Spindle cell stromal tumor of the pancreas: treatment by pancreatoduodenectomy. Owen CH, et al. **Surgery** 1997 Jul;122(1):105–11 (22 ref.)

[Uterine sarcoma treated by surgery and postoperative radiation therapy. Patterns of relapse, prognostic factors and role of radiation therapy] Coquard R, et al. **Bull Cancer** 1997 Jun;84(6):625–9 (29 ref.) (Eng. Abstr.) **(Fre)**

[Epithelioid sarcoma of the parotid region] Johannssen V, et al. **Laryngorhinootologie** 1996 Sep;75(9):556–9 (29 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Problems and controversies in the management of childhood sarcomas. Womer RB. **Br Med Bull** 1996 Oct;52(4):826–43 (57 ref.)

Post–treatment limb function in soft tissue sarcomas. Robinson MH. **Cancer Treat Res** 1997;91:77–93 (38 ref.)

Soft tissue sarcoma in adults. Dirix LY, et al. **Curr Opin Oncol** 1997 Jul;9(4):348–59 (62 ref.)

The success of TNF alpha in isolated limb perfusion for irresectable extremity soft tissue sarcomas, melanoma and carcinomas: observations in patients and preclinical perfusion models. Eggermont AM. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1357–70 (74 ref.)

Management of soft tissue sarcomas of the extremity in adults. Valle AA, et al. **J Surg Oncol** 1996 Dec;63(4):271–9 (80 ref.)

Soft tissue sarcoma. Avradopoulos DA, et al. **Med Health R I** 1997 Jan;80(1):15–8 (33 ref.)

Sarcoma of bone. Terek RM. **Med Health R I** 1997 Jan; 80(1):19–25 (24 ref.)

Head and neck sarcoma. Wanebo HJ. **Med Health R I** 1997 Jan;80(1):26–30 (24 ref.)

Nonrhabdomyosarcoma soft tissue sarcomas in children. Dillon PW. **Semin Pediatr Surg** 1997 Feb;6(1):24–8 (55 ref.)

VETERINARY

Tumours of soft tissues. Berman LD. **IARC Sci Publ** 1996; (126):321–49 (79 ref.)

Tumours of the nervous system. Cardesa A, et al. **IARC Sci Publ** 1996;(126):427–65 (109 ref.)

Tumours of the testis and accessory male sex glands. Ribas JL, et al. **IARC Sci Publ** 1996;(126):261–80 (94 ref.)

The potential role of inflammation in the development of postvaccinal sarcomas in cats. Macy DW, et al. **Vet Clin North Am Small Anim Pract** 1996 Jan;26(1):103–9 (36 ref.)

Soft tissue sarcomas. Mauldin GN. **Vet Clin North Am Small Anim Pract** 1997 Jan;27(1):139–48 (32 ref.)

SARCOMA, AVIAN

ULTRASTRUCTURE

Ultrastructure of virus–induced soft–tissue tumours. Levenbook IS, et al. **IARC Sci Publ** 1996;(126):351–63 (27 ref.)

VIROLOGY

Injury models of the vascular endothelium: apoptosis and loss of thromboresistance induced by a viral protein. Eldor A, et al. **Haemostasis** 1996 Oct;26 Suppl 4:37–45 (46 ref.)

SARCOMA, CLEAR CELL

SURGERY

[Clear cell chondrosarcoma. Study of 13 clinical cases and review of the literature] Laporte C, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(8):691–9 (21 ref.) (Eng. Abstr.) **(Fre)**

SARCOMA, ENDOMETRIAL STROMAL

DIAGNOSIS

Cytogenetics revealing the diagnosis in a metastatic endometrial stromal sarcoma. Pauwels P, et al. **Histopathology** 1996 Jul;29(1):84–7 (10 ref.)

GENETICS

Cytogenetics revealing the diagnosis in a metastatic endometrial stromal sarcoma. Pauwels P, et al. **Histopathology** 1996 Jul;29(1):84–7 (10 ref.)

PATHOLOGY

Lymphangioleiomyomatosis of the uterus simulating high-stage endometrial stromal sarcoma. Longacre TA, et al. **Gynecol Oncol** 1996 Dec;63(3):404–10 (39 ref.)

SARCOMA, ENGELBRETH-HOLM-SWARM see **SARCOMA, EXPERIMENTAL**

SARCOMA, EPITHELIOID see **SARCOMA**

SARCOMA, EWING'S

Ewing's sarcoma and peripheral primitive neuroectodermal tumor: an interim report. Batsakis JG, et al. **Ann Otol Rhinol Laryngol** 1996 Oct;105(10):838–43 (32 ref.)

Poor prognosis Ewing's sarcoma and peripheral primitive neuroectodermal tumours (PNET). Maurel J, et al. **Cancer Treat Rev** 1996 Nov;22(6):425–36 (80 ref.)

Ewing's sarcoma and extracranial primitive neuroectodermal tumors. Granowetter L. **Curr Opin Oncol** 1996 Jul; 8(4):305–10 (48 ref.)

DIAGNOSIS

Diagnostic difficulties in extraosseous Ewing's sarcoma: a proposal for diagnostic criteria. Christie DR, et al. **Australas Radiol** 1997 Feb;41(1):22–8 (19 ref.)

Small round blue cell tumors in bone: prognostic factors correlated to Ewing's sarcoma and neuroectodermal tumors. Terrier P, et al. **Semin Diagn Pathol** 1996 Aug; 13(3):250–7 (61 ref.)

DRUG THERAPY

Chemotherapy for osteosarcoma and Ewing's sarcoma. Saeter G, et al. **Acta Orthop Scand Suppl** 1997 Feb; 273:120–5 (51 ref.)

GENETICS

Translocations in solid tumours. Cooper CS. **Curr Opin Genet Dev** 1996 Feb;6(1):71–5 (27 ref.)

Biology of EWS/FLI and related fusion genes in Ewing's sarcoma and primitive neuroectodermal tumor. May WA, et al. **Curr Top Microbiol Immunol** 1997;220:143–50 (35 ref.)

Fusion of the EWS1 and WT1 genes as a result of the t(11;22)(p13;q12) translocation in desmoplastic small round cell tumors. Benjamin LE, et al. **Med Pediatr Oncol** 1996 Nov;27(5):434–9 (34 ref.)

PATHOLOGY

[Primary Ewing's sarcoma of the mandible. A clinico-pathological and immunohistochemical case study] Zavaglia V, et al. **Minerva Stomatol** 1997 Apr;46(4):207–12 (8 ref.) (Eng. Abstr.) **(Ita)**

RADIOGRAPHY

Ewing's sarcoma of the hand: a case report. Cook MA, et al. **Bull Hosp Jt Dis** 1996;55(2):75–7 (12 ref.)

SURGERY

Ewing's sarcoma of the skull in an infant. A case report and review. Hadfield MG, et al. **Pediatr Neurosurg** 1996 Aug; 25(2):100–4 (64 ref.)

THERAPY

The Ewing family of tumors. Ewing's sarcoma and primitive neuroectodermal tumors. Grier HE. **Pediatr Clin North Am** 1997 Aug;44(4):991–1004 (84 ref.)

SARCOMA, EXPERIMENTAL

IMMUNOLOGY

Altered MHC class I antigens in tumors. Algarra I, et al. **Int J Clin Lab Res** 1997;27(2):95–102 (63 ref.)

ULTRASTRUCTURE

Ultrastructure of virus-induced soft-tissue tumours. Levenbook IS, et al. **IARC Sci Publ** 1996;(126):351–63 (27 ref.)

SARCOMA, GERMINOBLASTIC see **LYMPHOMA**

SARCOMA, JENSEN see **SARCOMA, EXPERIMENTAL**

SARCOMA, KAPOSI'S

Pulmonary complications of HIV-associated malignancies. White DA. **Clin Chest Med** 1996 Dec;17(4):755–61 (72 ref.)

Management and treatment of Kaposi's sarcoma in AIDS. The Jefferiss Wing Therapeutics and Protocols Group. Tomlinson DR, et al. **Int J STD AIDS** 1996 Nov–Dec; 7(7):466–70 (10 ref.)

HIV-related skin diseases. Geusau A, et al. **J R Coll Physicians Lond** 1997 Jul–Aug;31(4):374–9 (38 ref.)

Kaposi's sarcoma and its management in AIDS patients. Recommendations from a Scandinavian Study Group. **Scand J Infect Dis** 1997;29(1):3–12 (76 ref.)

COMPLICATIONS

Pericardial tamponade from Kaposi's sarcoma: role of early pericardial window. Vijay V, et al. **Am Heart J** 1996 Oct; 132(4):897–9 (6 ref.)

Malignant tumors and AIDS. Nasti G, et al. **Biomed Pharmacother** 1997;51(6–7):243–51 (78 ref.)

Recent advances. HIV infection–II. Beiser C. **BMJ** 1997 Feb 22;314(7080):579–83 (56 ref.)

Perforation of the jejunum secondary to AIDS-related gastrointestinal Kaposi's sarcoma. Yoshida EM, et al. **Can J Gastroenterol** 1997 Jan–Feb;11(1):38–40 (15 ref.)

DIAGNOSIS

Non-AIDS-related primary intraosseous Kaposi's sarcoma: case report and literature review. Chen HH, et al. **Acta Oncol** 1997;36(2):224–7 (14 ref.)

Uncommon cutaneous neoplasms. Harrington AC, et al. **Md Med J** 1997 May–Jun;46(5):255–62 (48 ref.)

DRUG THERAPY

Kaposi's sarcoma: relationship to a novel herpesvirus and advances in therapy. Lee FC, et al. **AIDS** 1996;10 Suppl A:S173–9 (71 ref.)

Polyethylene glycol–liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. Coukell AJ, et al. **Drugs** 1997 Mar; 53(3):520–38 (68 ref.)

Chemotherapy of AIDS-–related Kaposi's sarcoma. Lee FC, et al. **Hematol Oncol Clin North Am** 1996 Oct;10(5):1051–68 (87 ref.)

Kaposi's sarcoma: advances in tumor biology and pharmacotherapy. Sung JC, et al. **Pharmacotherapy** 1997 Jul–Aug;17(4):670–83 (103 ref.)

EPIDEMIOLOGY

The epidemiology of HIV-associated Kaposi's sarcoma: the unraveling mystery. Strathdee SA, et al. **AIDS** 1996;10 Suppl A:S51–7 (112 ref.)

Epidemic and non-epidemic Kaposi's sarcoma: diagnosis, staging and treatment. Iwamasa T, et al. **Crit Rev Oncol Hematol** 1996 Nov;24(3):153–63 (50 ref.)

Kaposi's Sarcoma (KS)-associated herpesvirus and its role in KS. Chang Y, et al. **Infect Agents Dis** 1996 Oct; 5(4):215–22 (71 ref.)

Kaposi's sarcoma in transplant recipients. Penn I. **Transplantation** 1997 Sep 15;64(5):669–73 (52 ref.)

[Kaposi sarcoma and human herpes virus type 8: recent data] Camparo P, et al. **Med Trop (Mars)** 1996;56(3):231–7 (84 ref.) **(Fre)**

ETIOLOGY

Kaposi's sarcoma-–associated herpesvirus: a newly recognized pathogen. Boshoff C, et al. **AIDS Clin Rev** 1997–98;:323–47 (108 ref.)

A new human herpesvirus as a factor in the pathogenesis of Kaposi's sarcoma and body-cavity lymphoma [comment] Sarris A. **Cancer J Sci Am** 1997 May–Jun; 3(3):140–1 (29 ref.) Comment on: Cancer J Sci Am 1997 May–Jun;3(3):153–6.

Pathogenesis of Kaposi's sarcoma. Cooke FJ. **Clin Oncol (R Coll Radiol)** 1996;8(3):189–94 (22 ref.)

Advances in Kaposi's sarcoma. Myskowski PL, et al. **Dermatol Clin** 1997 Jan;15(1):177–88 (122 ref.)

Pathogenesis of oral Kaposi's Sarcoma in HIV-infection: relevance of endogenous glucocorticoid excess in blood and saliva. Enwonwu CO. **Eur J Cancer B Oral Oncol** 1996 Jul;32B(4):271–4 (49 ref.)

Post-transplant Kaposi's sarcoma. Gotti E, et al. **J Am Soc Nephrol** 1997 Jan;8(1):130–7 (98 ref.)

Acquired immunodeficiency syndrome-associated Kaposi's sarcoma. Biology and management. Krown SE. **Med Clin North Am** 1997 Mar;81(2):471–94 (170 ref.)

The spectrum of African Kaposi's sarcoma: is it consequential upon diverse immunological responses? Matondo P, et al. **Scand J Infect Dis** 1996;28(3):225–30 (51 ref.)

[Human herpesvirus 8 infections] Agut H. **Presse Med** 1997 Jan;26 Suppl 1:16–8 (26 ref.) **(Fre)**

[The enigma of Kaposi sarcoma] Rüdlinger R. **Hautarzt** 1996 Feb;47(2):91–5 (43 ref.) (Eng. Abstr.) **(Ger)**

[Kaposi sarcoma-associated herpesvirus; human herpesvirus 8] Kemény L, et al. **Orv Hetil** 1997 Apr 20;138(16):979–83 (49 ref.) (Eng. Abstr.) **(Hun)**

IMMUNOLOGY

The spectrum of African Kaposi's sarcoma: is it consequential upon diverse immunological responses? Matondo P, et al. **Scand J Infect Dis** 1996;28(3):225–30 (51 ref.)

MICROBIOLOGY

Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpesvirus 8: determinants of its pathogenicity? Neipel F, et al. **J Virol** 1997 Jun; 71(6):4187–92 (66 ref.)

PATHOLOGY

Lymphangioma-like variant of Kaposi's sarcoma: clinicopathologic study of seven cases with review of the literature. Cossu S, et al. **Am J Dermatopathol** 1997 Feb; 19(1):16–22 (25 ref.)

Kaposi's sarcoma of the larynx. Schiff NF, et al. **Ann Otol Rhinol Laryngol** 1997 Jul;106(7 Pt 1):563–7 (18 ref.)

Oral pathology of acquired immunodeficiency syndrome and oro-facial Kaposi's sarcoma. Reichart PA. **Curr Top Pathol** 1996;90:97–123 (43 ref.)

Clinical presentation and natural history of AIDS-–related Kaposi's sarcoma. Dezube BJ. **Hematol Oncol Clin North Am** 1996 Oct;10(5):1023–9 (31 ref.)

Pathogenesis of AIDS-–related Kaposi's sarcoma. Evidence of a viral etiology. Miles SA. **Hematol Oncol Clin North Am** 1996 Oct;10(5):1011–21 (80 ref.)

Kaposi's sarcoma: advances in tumor biology and pharmacotherapy. Sung JC, et al. **Pharmacotherapy** 1997 Jul–Aug;17(4):670–83 (103 ref.)

Kaposi's sarcoma-associated herpesvirus: a lymphotropic human herpesvirus associated with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Cesarman E, et al. **Semin Diagn Pathol** 1997 Feb; 14(1):54–66 (153 ref.)

[A case of Kaposi's sarcoma with involvement of the facial skin and the mucosa of the right cheek] Popov NV, et al. **Stomatologiia (Mosk)** 1996;75(3):30–2 (16 ref.) (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

AIDS-related Kaposi sarcoma involving the tarsal bones. Nguyen C, et al. **Skeletal Radiol** 1996 Jan;25(1):100–2 (9 ref.)

[AIDS-associated illnesses in radiologic diagnosis: overview and differential diagnosis] Rademaker J, et al. **Aktuelle Radiol** 1997 Mar;7(2):69–73 (30 ref.) **(Ger)**

RADIOTHERAPY

The role of radiation therapy in the management of HIV-related Kaposi's sarcoma. Swift PS. **Hematol Oncol Clin North Am** 1996 Oct;10(5):1069–80 (71 ref.)

Radiation treatment of oral epidemic Kaposi's sarcoma lesions: potential adverse effects. Fogel SC, et al. **J Assoc Nurses AIDS Care** 1996 Jul–Aug;7(4):25–30 (23 ref.)

Radiation therapy for malignancies in the setting of HIV disease. Swift PS. **Oncology (Huntingt)** 1997 May; 11(5):683–94; discussion 694, 701–2 (82 ref.)

THERAPY

Non-AIDS-related primary intraosseous Kaposi's sarcoma: case report and literature review. Chen HH, et al. **Acta Oncol** 1997;36(2):224–7 (14 ref.)

Overview of the management of AIDS-related Kaposi's sarcoma. Morris AK, et al. **Ann Pharmacother** 1996 Oct; 30(10):1150–63 (81 ref.)

Adoptive CD8+ T-cell immunotherapy of AIDS patients with Kaposi's sarcoma. Patarca R, et al. **Crit Rev Oncog** 1995;6(3–6):179–234 (685 ref.)

Epidemic and non-epidemic Kaposi's sarcoma: diagnosis, staging and treatment. Iwamasa T, et al. **Crit Rev Oncol Hematol** 1996 Nov;24(3):153–63 (50 ref.)

Advances in Kaposi's sarcoma. Myskowski PL, et al. **Dermatol Clin** 1997 Jan;15(1):177–88 (122 ref.)

AIDS-related Kaposi's sarcoma. A template for the translation of molecular pathogenesis into targeted therapeutic approaches. Karp JE, et al. **Hematol Oncol Clin North Am** 1996 Oct;10(5):1031–49 (132 ref.)

VIROLOGY

Kaposi's sarcoma: relationship to a novel herpesvirus and advances in therapy. Lee FC, et al. **AIDS** 1996;10 Suppl A:S173–9 (71 ref.)

The Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) in Kaposi's sarcoma, malignant lymphoma, and other diseases. Knowles DM, et al. **Ann Oncol** 1997; 8 Suppl 2:123–9 (57 ref.)

Viruses in the pathogenesis of Kaposi's sarcoma-–a review. Kempf W, et al. **Biochem Mol Med** 1996 Jun;58(1):1–12 (116 ref.)

Is Kaposi sarcoma caused by new herpesvirus? [letter] Haverkos HW. **Biomed Pharmacother** 1996;50(6–7):318–9 (15 ref.)

Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. Coukell AJ, et al. **Drugs** 1997 Mar; 53(3):520-38 (68 ref.)

HIV-1 and Kaposi's sarcoma. Ensoli B, et al. **Eur J Cancer Prev** 1996 Oct;5(5):410-2 (16 ref.)

Kaposi's Sarcoma (KS)-associated herpesvirus and its role in KS. Chang Y, et al. **Infect Agents Dis** 1996 Oct; 5(4):215-22 (71 ref.)

Human herpesvirus-8: detection of novel herpesvirus-like DNA sequences in Kaposi's sarcoma and other lesions. Memar OM, et al. **J Mol Med** 1995 Dec;73(12):603-9 (49 ref.)

Kaposi's sarcoma: is the hunt for the culprit over now? Schatz O, et al. **J Mol Med** 1997 Jan;75(1):28-34 (58 ref.)

Kaposi's sarcoma associated herpes virus (KSHV/HHV 8): epidemiology, molecular biology and tissue distribution. O'Leary JJ, et al. **Mol Pathol** 1997 Feb;50(1):4-8 (49 ref.)

HHV-8: a new herpesvirus associated with Kaposi's sarcoma. Offermann MK. **Trends Microbiol** 1996 Oct;4(10):383-6 (51 ref.)

[Kaposi sarcoma and human herpes virus type 8: recent data] Camparo P, et al. **Med Trop (Mars)** 1996;56(3):231-7 (84 ref.) **(Fre)**

[The 8th human herpesvirus] Huraux JM, et al. **Presse Med** 1997 Jun 28;26(22):1058-62 (26 ref.) **(Fre)**

SARCOMA, LYMPHATIC see **LYMPHOMA, DIFFUSE**

SARCOMA, MAST-CELL

VETERINARY

Mast cell tumors: dilemmas of diagnosis and treatment. Rogers KS. **Vet Clin North Am Small Anim Pract** 1996 Jan;26(1):87-102 (36 ref.)

SARCOMA, OSTEOGENIC see **OSTEOSARCOMA**

SARCOMA, RETICULUM-CELL see **LYMPHOMA, LARGE-CELL**

SARCOMA, ROUS see **SARCOMA, AVIAN**

SARCOMA, SMALL CELL

DIAGNOSIS

Desmoplastic small round cell tumor. Leuschner I, et al. **Semin Diagn Pathol** 1996 Aug;13(3):204-12 (46 ref.)

Differential diagnosis of small round cell tumors. Meis-Kindblom JM, et al. **Semin Diagn Pathol** 1996 Aug; 13(3):213-41 (196 ref.)

Small round blue cell tumors in bone: prognostic factors correlated to Ewing's sarcoma and neuroectodermal tumors. Terrier P, et al. **Semin Diagn Pathol** 1996 Aug; 13(3):250-7 (61 ref.)

GENETICS

Chromosome translocation-mediated conversion of a tumor suppressor gene into a dominant oncogene: fusion of EWS1 to WT1 in desmoplastic small round cell tumors. Rauscher FJ 3rd. **Curr Top Microbiol Immunol** 1997;220:151-62 (47 ref.)

Fusion of the EWS1 and WT1 genes as a result of the t(11;22)(p13;q12) translocation in desmoplastic small round cell tumors. Benjamin LE, et al. **Med Pediatr Oncol** 1996 Nov;27(5):434-9 (34 ref.)

Molecular genetics of small round cell tumors. López-Terrada D. **Semin Diagn Pathol** 1996 Aug; 13(3):242-9 (93 ref.)

Cytogenetics and tissue culture of small round cell tumors of bone and soft tissue. Noguera R. **Semin Diagn Pathol** 1996 Aug;13(3):171-83 (134 ref.)

IMMUNOLOGY

Histology, immunohistochemistry, and electron microscopy of small round cell tumors of bone. Llombart-Bosch A, et al. **Semin Diagn Pathol** 1996 Aug;13(3):153-70 (147 ref.)

Small round cell tumors of bone and soft tissue. Introduction. Llombart-Bosch A. **Semin Diagn Pathol** 1996 Aug; 13(3):149-52 (47 ref.)

PATHOLOGY

Soft tissue small round cell tumors: morphological parameters. d'Amore ES, et al. **Semin Diagn Pathol** 1996 Aug;13(3):184-203 (105 ref.)

Desmoplastic small round cell tumor. Leuschner I, et al. **Semin Diagn Pathol** 1996 Aug;13(3):204-12 (46 ref.)

Histology, immunohistochemistry, and electron microscopy of small round cell tumors of bone. Llombart-Bosch A, et al. **Semin Diagn Pathol** 1996 Aug;13(3):153-70 (147 ref.)

Small round cell tumors of bone and soft tissue. Introduction. Llombart-Bosch A. **Semin Diagn Pathol** 1996 Aug; 13(3):149-52 (47 ref.)

Cytogenetics and tissue culture of small round cell tumors of bone and soft tissue. Noguera R. **Semin Diagn Pathol** 1996 Aug;13(3):171-83 (134 ref.)

SURGERY

[Small-cell sarcoma of the esophagus as a fourth malignancy. Its palliative therapy with argon gas coagulation] Glaser J, et al. **Dtsch Med Wochenschr** 1997 Aug 22; 122(34-35):1037-40 (8 ref.) (Eng. Abstr.) **(Ger)**

ULTRASTRUCTURE

Soft tissue small round cell tumors: morphological parameters. d'Amore ES, et al. **Semin Diagn Pathol** 1996 Aug;13(3):184-203 (105 ref.)

SARCOMA, SOFT TISSUE see **SARCOMA**

SARCOMA, SPINDLE CELL see **SARCOMA**

SARCOMA, SYNOVIAL

[Synovial sarcoma of the heart] Chin W, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):233-6 (20 ref.) **(Jpn)**

COMPLICATIONS

Tumor-induced hypercalcemia in a patient with extensive soft tissue sarcoma: effects of bisphosphonate therapy and surgery. Oleffe V, et al. **J Surg Oncol** 1996 Oct;63(2):125-9 (25 ref.)

GENETICS

Translocations in solid tumours. Cooper CS. **Curr Opin Genet Dev** 1996 Feb;6(1):71-5 (27 ref.)

PATHOLOGY

Primary monophasic synovial sarcoma of the brachial plexus: report of a case and review of the literature. Tacconi L, et al. **Clin Neurol Neurosurg** 1996 Aug;98(3):249-52 (7 ref.)

Synovial sarcoma of the heart. Nicholson AG, et al. **Histopathology** 1997 Apr;30(4):349-52 (16 ref.)

RADIOTHERAPY

Fractures in children treated with radiotherapy for soft tissue sarcoma. Wall JE, et al. **Orthopedics** 1996 Aug;19(8):657-64 (24 ref.)

SECONDARY

Acute vascular embolus resulting from metastatic endocardial involvement with synovial sarcoma: report of a case and review of the literature. Khoo V, et al. **Australas Radiol** 1997 Feb;41(1):49-52 (71 ref.)

SURGERY

Tumor-induced hypercalcemia in a patient with extensive soft tissue sarcoma: effects of bisphosphonate therapy and surgery. Oleffe V, et al. **J Surg Oncol** 1996 Oct;63(2):125-9 (25 ref.)

SARCOMA VIRUSES, AVIAN

GENETICS

Replication-competent retroviral vectors for expressing genes in avian cells in vitro and in vivo. Bell EJ, et al. **Mol Biotechnol** 1997 Jun;7(3):289-98 (45 ref.)

ISOLATION & PURIFICATION

Ultrastructure of virus-induced soft-tissue tumours. Levenbook IS, et al. **IARC Sci Publ** 1996;(126):351-63 (27 ref.)

PATHOGENICITY

Injury models of the vascular endothelium: apoptosis and loss of thromboresistance induced by a viral protein. Eldor A, et al. **Haemostasis** 1996 Oct;26 Suppl 4:37-45 (46 ref.)

SARCOMERES

PHYSIOLOGY

The super-repeats of titin/connectin and their interactions: glimpses at sarcomeric assembly. Gautel M. **Adv Biophys** 1996;33:27-37 (61 ref.)

Viscoelasticity and function of connectin/titin filaments in skinned muscle fibers. Higuchi H. **Adv Biophys** 1996; 33:159-71 (26 ref.)

Nebulin and nebulin-related proteins in striated muscle. Horowits R, et al. **Adv Biophys** 1996;33:143-50 (32 ref.)

Physiological significance of viscoelastic structures in myoplasm. Takemori S, et al. **Adv Biophys** 1996;33:151-7 (16 ref.)

Functional analysis of the chicken sarcomeric myosin rod: regulation of dimerization, solubility, and fibrillogenesis. Bandman E, et al. **Cell Struct Funct** 1997 Feb;22(1):131-7 (39 ref.)

Optical methods to evaluate the contractile function of unloaded isolated cardiac myocytes. Delbridge LM, et al. **J Mol Cell Cardiol** 1997 Jan;29(1):11-25 (68 ref.)

ULTRASTRUCTURE

Nebulin and nebulin-related proteins in striated muscle. Horowits R, et al. **Adv Biophys** 1996;33:143-50 (32 ref.)

Myomesin, M-protein and the structure of the sarcomeric M-band. Van Der Ven PF, et al. **Adv Biophys** 1996;33:91-9 (37 ref.)

Architecture and function in the muscle sarcomere. Squire JM. **Curr Opin Struct Biol** 1997 Apr;7(2):247-57 (87 ref.)

SARCOPLASMIC RETICULUM

DRUG EFFECTS

Sarcoplasmic reticulum calcium release in frog cut muscle fibers in the presence of a large concentration of EGTA. Jong DS, et al. **Soc Gen Physiol Ser** 1996;51:255-68 (28 ref.)

ENZYMOLOGY

Phosphorylation and regulation of the Ca(2+)-pumping ATPase in cardiac sarcoplasmic reticulum by calcium/calmodulin-dependent protein kinase. Narayanan N, et al. **Basic Res Cardiol** 1997;92 Suppl 1:25-35 (68 ref.)

Ca2+ transport by the sarcoplasmic reticulum ATPase. Mintz E, et al. **Biochim Biophys Acta** 1997 Jan 16; 1318(1-2):52-70 (171 ref.)

Dissection of the functional domains of the sarcoplasmic reticulum Ca(2+)-ATPase by site-directed mutagenesis. Andersen JP. **Biosci Rep** 1995 Oct;15(5):243-61 (45 ref.)

Fluorometric study on conformational changes in the catalytic cycle of sarcoplasmic reticulum Ca(2+)-ATPase. Kanazawa T, et al. **Biosci Rep** 1995 Oct;15(5):317-26 (49 ref.)

Heterologous expression of sarcoplasmic reticulum Ca(2+)-ATPase. Reis EM, et al. **Biosci Rep** 1996 Apr; 16(2):107-13 (20 ref.)

Catalytic and structural modifications of sarcoplasmic reticulum and plasma membrane (Ca(2+) + Mg2+) ATPases induced by organic solutes that accumulate in living systems. Vieyra A. **Biosci Rep** 1996 Apr;16(2):115-27 (53 ref.)

The SERCA3-type of organellar Ca2+ pumps. Wuytack F, et al. **Biosci Rep** 1995 Oct;15(5):299-306 (27 ref.)

SR Ca(2+)-ATPase/phospholamban in cardiomyocyte function. Tada M, et al. **J Card Fail** 1996 Dec;2(4 Suppl):S77-85 (39 ref.)

Plasma membrane and sarcoplasmic reticulum Ca-ATPase and smooth muscle. Gonzalez JM, et al. **Miner Electrolyte Metab** 1996;22(5-6):345-8 (27 ref.)

METABOLISM

Calcium cycling proteins and force-frequency relationship in heart failure. Hasenfuss G, et al. **Basic Res Cardiol** 1996; 91 Suppl 2:17-22 (31 ref.)

Luminal calcium regulation of calcium release from sarcoplasmic reticulum. Hidalgo C, et al. **Biosci Rep** 1995 Oct;15(5):387-97 (85 ref.)

Ca2+ binding and translocation by the sarcoplasmic reticulum ATPase: functional and structural considerations. Inesi G, et al. **Biosci Rep** 1995 Oct;15(5):327-39 (49 ref.)

The mechanism of coupling chemical and physical reactions by the calcium ATPase of sarcoplasmic reticulum and other coupled vectorial systems. Jencks WP. **Biosci Rep** 1995 Oct;15(5):283-7 (4 ref.)

Lipid structure and Ca(2+)-ATPase function. Lee AG, et al. **Biosci Rep** 1995 Oct;15(5):289-98 (50 ref.)

How do Ca2+ ions pass through the sarcoplasmic reticulum membrane. Mintz E, et al. **Biosci Rep** 1995 Oct;15(5):377-85 (64 ref.)

Ligand-gated channel of the sarcoplasmic reticulum Ca2+ transport ATPase. Wolosker H, et al. **Biosci Rep** 1995 Oct; 15(5):365-76 (53 ref.)

Transmembrane Ca2+ gradient and function of membrane proteins. Yang FY, et al. **Biosci Rep** 1995 Oct;15(5):351-64 (44 ref.)

Regulation of calcium release channel in sarcoplasmic reticulum. Kasai M, et al. **Ion Channels** 1996;4:303-31 (41 ref.)

The sarcoplasmic reticulum Ca2+ channel/ryanodine receptor: modulation by endogenous effectors, drugs and disease states. Zucchi R, et al. **Pharmacol Rev** 1997 Mar; 49(1):1-51 (759 ref.)

Regulation of cytosolic calcium levels in vascular smooth muscle. Orallo F. **Pharmacol Ther** 1996;69(3):153-71 (267 ref.)

[Effect of physical load deficiency on the system of calcium transport in the sarcoplasmic reticulum of skeletal muscles amd myocardium] Stepanova VV, et al. **Aviakosm Ekolog Med** 1996;30(5):33-5 (24 ref.) (Eng. Abstr.) **(Rus)**

PATHOLOGY

Early-onset myopathy with tubular aggregates. Tulinius MH, et al. **Pediatr Neurol** 1996 Jul;15(1):68-71 (15 ref.)

PHYSIOLOGY

The role of the calcium release channel of skeletal muscle sarcoplasmic reticulum in malignant hyperthermia. MacLennan DH, et al. **Ann N Y Acad Sci** 1993 Dec 20; 707:294-304 (46 ref.)

Modulation of SERCA2 activity: regulated splicing and interaction with phospholamban. Verboomen H, et al.

SARCOPLASMIC RETICULUM

Biosci Rep 1995 Oct;15(5):307 (48 ref.)
Sarcomeric calcium sparks activated by fiber depolarization and by cytosolic Ca2+ in skeletal muscle [published erratum appears in Cell Calcium 1997 Feb;21(2):173] Schneider MF, et al. **Cell Calcium** 1996 Aug;20(2):123–8 (27 ref.)

1-SARCOSINE-8-ALANINE ANGIOTENSIN II see **SARALASIN**

SARCOSOMES see **MITOCHONDRIA, MUSCLE**

SARCOSPORIDIA see **SARCOCYSTIS**

SARCOSPORIDIOSIS see **SARCOCYSTOSIS**

SARIN

POISONING

Sarin: guidelines on the management of victims of a nerve gas attack [see comments] Volans AP.
J Accid Emerg Med 1996 May;13(3):202–6 (16 ref.)
Comment in: J Accid Emerg Med 1996 Nov;13(6):431–2.

SARKOLYSIN see **MELPHALAN**

SATELLITE COMMUNICATIONS

Remotely sensed surrogates of meteorological data for the study of the distribution and abundance of arthropod vectors of disease. Hay SI, et al.
Ann Trop Med Parasitol 1996 Feb;90(1):1–19 (93 ref.)
Predicting the distribution of tsetse flies in West Africa using temporal Fourier processed meteorological satellite data. Rogers DJ, et al. **Ann Trop Med Parasitol** 1996 Jun; 90(3):225–41 (39 ref.)
The ecology of malaria—as seen from Earth-observation satellites. Thomson MC, et al. **Ann Trop Med Parasitol** 1996 Jun;90(3):243–64 (110 ref.)
Remote sensing operations. Badran F, et al.
Int J Neural Syst 1995 Dec;6(4):447–53 (11 ref.)

SATELLITE DNA see **DNA, SATELLITE**

SATELLITE RNA see **RNA, SATELLITE**

SATELLITE VIRUSES

see related
HELPER VIRUSES
RNA, SATELLITE

SATELLITES, ARTIFICIAL see **SPACECRAFT**

SATIATION

PHYSIOLOGY

Control of food intake. A physiologically complex, motivated behavioral system. Geiselman PJ.
Endocrinol Metab Clin North Am 1996 Dec;25(4):815–29 (123 ref.)
Fat as a risk factor for overconsumption: satiation, satiety, and patterns of eating. Blundell JE, et al.
J Am Diet Assoc 1997 Jul;97(7 Suppl):S63–9 (42 ref.)

SATIETY RESPONSE

DRUG EFFECTS

Relative effects of carbohydrates and protein on satiety — a review of methodology. Reid M, et al.
Neurosci Biobehav Rev 1997 May;21(3):295–308 (83 ref.)

PHYSIOLOGY

Serotonergic control of the organization of feeding and satiety. Simansky KJ. **Behav Brain Res** 1996;73(1–2):37–42 (61 ref.)
Fat as a risk factor for overconsumption: satiation, satiety, and patterns of eating. Blundell JE, et al.
J Am Diet Assoc 1997 Jul;97(7 Suppl):S63–9 (42 ref.)

SATURN

Chemical evolution on Titan: comparisons to the prebiotic earth. Clarke DW, et al. **Orig Life Evol Biosph** 1997 Jun; 27(1–3):225–48 (77 ref.)

SAUNA see **BATHS, FINNISH**

SAVANNA BABOONS see **PAPIO**

SAXITOXIN

METABOLISM

The guanidinium toxin binding site on the sodium channel. Fozzard HA, et al. **Jpn Heart J** 1996 Sep;37(5):683–92 (29 ref.)

SC DISEASE see **HEMOGLOBIN SC DISEASE**

SCABIES

COMPLICATIONS

Crusted scabies associated with systemic lupus erythematosus: response to benzyl benzoate therapy. Chutimunt N. **J Med Assoc Thai** 1996 Jan;79(1):65–8 (10 ref.)

DIAGNOSIS

Bullous scabies [letter] Veraldi S, et al.
Acta Derm Venereol 1996 Mar;76(2):167–8 (11 ref.)
Scabies mimicking systemic lupus erythematosus. Bastian HM, et al. **Am J Med** 1997 Mar;102(3):305–6 (6 ref.)
Bedside testing: the diagnostic cornerstone of dermatology. Brodell RT, et al. **Compr Ther** 1997 Mar;23(3):211–7 (25 ref.)
[Scabies: a common infection nevertheless often misdiagnosed] Barthe L, et al. **Rev Med Liege** 1996 Aug; 51(8):522–6 (27 ref.) **(Fre)**

DRUG THERAPY

A risk–benefit assessment of agents used in the treatment of scabies. Elgart ML. **Drug Saf** 1996 Jun;14(6):386–93 (44 ref.)
Scabies. Peterson CM, et al. **Pediatr Ann** 1996 Feb; 25(2):97–100 (13 ref.)

SCALDED SKIN SYNDROME, NONSTAPHYLOCOCCAL see **EPIDERMAL NECROLYSIS, TOXIC**

SCALDED SKIN SYNDROME, STAPHYLOCOCCAL see **STAPHYLOCOCCAL SCALDED SKIN SYNDROME**

SCALENUS ANTICUS SYNDROME see **THORACIC OUTLET SYNDROME**

SCALP

Subcutaneous granuloma annulare in a patient with rheumatoid arthritis and diabetes mellitus. Tam MM, et al. **Australas J Dermatol** 1996 Nov;37(4):199–201 (8 ref.)
Angiosarcoma of the scalp associated with renal transplantation. Kibe Y, et al. **Br J Dermatol** 1997 May; 136(5):752–6 (24 ref.)
Giant congenital naevus of the scalp and cranium: case report and review of the literature. Madaree A, et al.
Br J Plast Surg 1997 Jan;50(1):20–5 (8 ref.)
Endometrial adenocarcinoma metastatic to the scalp: case report and literature review. Kushner DM, et al.
Gynecol Oncol 1997 Jun;65(3):530–3 (9 ref.)
Cellular blue nevus of the scalp infiltrating the underlying bone: case report and review. Micali G, et al.
Pediatr Dermatol 1997 May–Jun;14(3):199–203 (17 ref.)

ABNORMALITIES

[Adams–Oliver syndrome] Ishikiriyama S.
Ryoikibetsu Shokogun Shirizu 1996;(15):234–5 (10 ref.) **(Jpn)**

BLOOD SUPPLY

Arteriovenous fistula of the scalp secondary to punch autograft hair transplantation: angioarchitecture, histopathology, and endovascular and surgical therapy. Davis AJ, et al. **Plast Reconstr Surg** 1997 Jul;100(1):242–9 (35 ref.)

INJURIES

Cranial defect and decrease in cerebral blood flow resulting from deep contact burn of the scalp in the neonatal period. Matsumura H, et al. **Burns** 1996 Nov;22(7):560–5 (14 ref.)

INNERVATION

Relationship between follicular nerve supply and alopecia. Hordinsky MK, et al. **Dermatol Clin** 1996 Oct;14(4):651–60 (25 ref.)

METABOLISM

Increased scalp skin and serum 5 alpha-reductase reduced androgens in a man relevant to the acquired progressive kinky hair disorder and developing androgenetic alopecia. Boudou P, et al. **Arch Dermatol** 1997 Sep;133(9):1129–33 (44 ref.)

PATHOLOGY

Malignant proliferating trichilemmal tumor [letter] Noto G, et al. **Am J Dermatopathol** 1997 Apr;19(2):202–4 (16 ref.)
Scalp necrosis in giant cell arteritis and review of the literature. Currey J. **Br J Rheumatol** 1997 Jul;36(7):814–6 (24 ref.)
Hibernoma of scalp: case report and review of literature. Naik R, et al. **Indian J Cancer** 1996 Jun;33(2):116–8 (13 ref.)
Myxoid liposarcoma of the scalp: case report and literature review. Herman O, et al. **Plast Reconstr Surg** 1997 Jul; 100(1):84–5 (9 ref.)
Alopecia: histologic diagnosis by transverse sections. Templeton SF, et al. **Semin Diagn Pathol** 1996 Feb; 13(1):2–18 (33 ref.)

RADIONUCLIDE IMAGING

PET for diagnosis of malignant lymphoma of the scalp: comparison of [11C]methyl-L-methionine and [18F]fluoro-2-deoxyglucose. Tsuyuguchi N, et al.
J Comput Assist Tomogr 1997 Jul–Aug;21(4):590–3 (16 ref.)

SURGERY

Cranial defect and decrease in cerebral blood flow resulting from deep contact burn of the scalp in the neonatal period. Matsumura H, et al. **Burns** 1996 Nov;22(7):560–5 (14 ref.)
Subaponeurotic connective tissue: a safe way to reconstruct facial and oropharyngeal defects. Ristić J, et al.
J Craniomaxillofac Surg 1996 Oct;24(5):276–80 (6 ref.)
Concepts in scalp and forehead reconstruction. TerKonda RP, et al. **Otolaryngol Clin North Am** 1997 Aug; 30(4):519–39 (23 ref.)

SCALP DERMATOSES

DRUG THERAPY

Medicated shampoos. Shapiro J, et al. **Clin Dermatol** 1996 Jan–Feb;14(1):123–8 (41 ref.)

ETIOLOGY

Erosive pustular dermatosis of the scalp in skin grafts: report of three cases. Ena P, et al. **Dermatology** 1997;194(1):80–4 (26 ref.)

THERAPY

Head lice in schoolchildren. Ibarra J, et al.
Arch Dis Child 1996 Dec;75(6):471–3 (29 ref.)

SCANNING ELECTRON MICROSCOPY see **MICROSCOPY, ELECTRON, SCANNING**

SCANNING, RADIOISOTOPE see **RADIONUCLIDE IMAGING**

SCANNING TRANSMISSION ELECTRON MICROSCOPY see **MICROSCOPY, ELECTRON, SCANNING TRANSMISSION**

SCANNING TUNNELING MICROSCOPY see **MICROSCOPY, SCANNING TUNNELING**

SCAPULA

Bilateral elastofibroma: a case report and review of the literature. Hoffman JK, et al. **Clin Orthop** 1996 Apr; (325):245–50 (49 ref.)

ANATOMY & HISTOLOGY

[Fundamentals, possibilities and limitations of sonography of osteofibrous tunnels in the shoulder area. 1] Moriggl B.
Anat Anz 1997 Aug;179(4):355–73 (119 ref.) (Eng. Abstr.) **(Ger)**

INJURIES

Concomitant fracture of the coracoid and acromion after direct shoulder trauma. Lim KE, et al.
J Orthop Trauma 1996;10(6):437–9 (14 ref.)

INNERVATION

[Synovial cyst of the supracapsular notch of the shoulder with supracapsular nerve compression in a sportsman. Apropos of a case. Review of the literature] Rochwerger A, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996; 82(4):344–7 (12 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

The influence of the mobility in the cervicothoracic spine and the upper ribs (shoulder girdle) on the mobility of the scapulohumeral joint. Sobel JS, et al.
J Manipulative Physiol Ther 1996 Sep;19(7):469–74 (16 ref.)
Three-dimensional scapular orientation and muscle activity at selected positions of humeral elevation. Ludewig PM, et al. **J Orthop Sports Phys Ther** 1996 Aug;24(2):57–65 (58 ref.)

PHYSIOPATHOLOGY

Scapular instability associated with brachial plexus irritation: a proposed causative relationship with treatment implications. Langley P. **J Hand Ther** 1997 Jan–Mar; 10(1):35–40 (15 ref.)

SURGERY

Snapping scapula syndrome: three case reports and an analysis of the literature. Carlson HL, et al.
Arch Phys Med Rehabil 1997 May;78(5):506–11 (14 ref.)
Radical scapulectomy with limb salvage for shoulder girdle soft tissue sarcoma. Volpe CM, et al. **Surg Oncol** 1996 Feb; 5(1):43–8 (20 ref.)

SCARPA'S GANGLION see **VESTIBULAR NERVE**

SCARS see **CICATRIX**

SCARS, HYPERTROPHIC see **CICATRIX, HYPERTROPHIC**

SCATTER FACTOR see **HEPATOCYTE GROWTH FACTOR**

SCATTERING, RADIATION

The normalized peak scatter factor and normalized scatter functions for high energy photon beams. Day MJ, et al. **Br J Radiol** 1996;Suppl 25:168–76 (18 ref.)

The variation of percentage depth dose and scatter factor with beam quality. Pitchford WG. **Br J Radiol** 1996;Suppl 25:162–7 (3 ref.)

Ultraviolet and visible spectroscopies for tissue diagnostics: fluorescence spectroscopy and elastic-scattering spectroscopy. Bigio IJ, et al. **Phys Med Biol** 1997 May; 42(5):803–14 (75 ref.)

SCH-13521 see **FLUTAMIDE**

SCH-23390

PHARMACOLOGY

Ethopharmacology of aggression: impact on autonomic and mesocorticolimbic activity. Miczek KA, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:60–77 (108 ref.)

SCHAMBERG'S DISEASE see **PIGMENTATION DISORDERS**

SCHAUMANN'S DISEASE see **SARCOIDOSIS**

SCHEDULES, PATIENT see **APPOINTMENTS AND SCHEDULES**

SCHIFF BASES

METABOLISM

Schiff base forming drugs: mechanisms of immune potentiation and therapeutic potential. Chen H, et al. **J Mol Med** 1996 Sep;74(9):497–504 (61 ref.)

SCHILLING TEST

[Absorption test of vitamin] Nakamura T. **Nippon Rinsho** 1997 Apr;55 Suppl 2:113–4 (7 ref.) **(Jpn)**

SCHISTOSOMA

ENZYMOLOGY

Proteolytic degradation of host hemoglobin by schistosomes. Brindley PJ, et al. **Mol Biochem Parasitol** 1997 Oct; 89(1):1–9 (57 ref.)

GENETICS

Some molecular insights into schistosome evolution. Rollinson D, et al. **Int J Parasitol** 1997 Jan;27(1):11–28 (111 ref.)

IMMUNOLOGY

The radiation-attenuated vaccine against schistosomes in animal models: paradigm for a human vaccine? Coulson PS. **Adv Parasitol** 1997;39:271–336 (210 ref.)

PHYSIOLOGY

Uncertainties in the epidemiology and control of schistosomiasis. Gryseels B. **Am J Trop Med Hyg** 1996 Nov;55(5 Suppl):103–8 (53 ref.)

Schistosomiasis. Pathophysiology, diagnosis, and treatment. Elliott DE. **Gastroenterol Clin North Am** 1996 Sep; 25(3):599–625 (150 ref.)

SCHISTOSOMA HAEMATOBIUM

IMMUNOLOGY

Immunity and morbidity in infection due to Schistosoma haematobium. Hagan P. **Am J Trop Med Hyg** 1996 Nov; 55(5 Suppl):116–20 (31 ref.)

SCHISTOSOMA JAPONICUM

IMMUNOLOGY

Immunity and morbidity in schistosomiasis japonicum infection. Olds GR, et al. **Am J Trop Med Hyg** 1996 Nov; 55(5 Suppl):121–6 (29 ref.)

SCHISTOSOMA MANSONI

ENZYMOLOGY

Properties and function in metabolism of schistosomal hexokinase. Tielens AG. **Biochem Soc Trans** 1997 Feb; 25(1):127–31 (27 ref.)

IMMUNOLOGY

Immunity and morbidity in Schistosoma mansoni infection: quantitative aspects. Butterworth AE, et al. **Am J Trop Med Hyg** 1996 Nov;55(5 Suppl):109–15 (26 ref.)

Development of an antipathology vaccine for schistosomiasis. Wynn TA. **Ann N Y Acad Sci** 1996 Oct 25;797:191–5 (27 ref.)

PHYSIOLOGY

Schistosoma mansoni: the ultrastructure of larval morphogenesis in Biomphalaria glabrata and of associated host–parasite interactions. Pan SC. **Jpn J Med Sci Biol** 1996 Aug;49(4):129–49 (27 ref.)

SCHISTOSOMIASIS

Cardiopulmonary manifestations of schistosomiasis. Morris W, et al. **Semin Respir Infect** 1997 Jun;12(2):159–70 (89 ref.)

COMPLICATIONS

[Genital bilharziasis and female infertility. Review of the literature and three case reports] Morice P, et al. **Contracept Fertil Sex** 1996 Jan;24(1):56–61 (25 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Schistosomiasis in women: manifestations in the upper reproductive tract. Helling-Giese G, et al. **Acta Trop** 1996 Dec 30;62(4):225–38 (60 ref.)

Immunodiagnosis of schistosomiasis. Tsang VC, et al. **Immunol Invest** 1997 Jan–Feb;26(1–2):175–88 (27 ref.)

[Schistosomiasis and viral hepatitides: a review] Serufo JC, et al. **Rev Soc Bras Med Trop** 1997 Jul–Aug;30(4):313–22 (94 ref.) (Eng. Abstr.) **(Por)**

ENZYMOLOGY

Proteolytic degradation of host hemoglobin by schistosomes. Brindley PJ, et al. **Mol Biochem Parasitol** 1997 Oct; 89(1):1–9 (57 ref.)

EPIDEMIOLOGY

Uncertainties in the epidemiology and control of schistosomiasis. Gryseels B. **Am J Trop Med Hyg** 1996 Nov;55(5 Suppl):103–8 (53 ref.)

The microsimulation approach to epidemiologic modeling of helminthic infections, with special reference to schistosomiasis. Habbema JD, et al. **Am J Trop Med Hyg** 1996 Nov;55(5 Suppl):165–9 (13 ref.)

Dynamic modeling of epidemiologic patterns of schistosomiasis morbidity. Medley GF, et al. **Am J Trop Med Hyg** 1996 Nov;55(5 Suppl):149–58 (27 ref.)

SCHISTOSIM: a microsimulation model for the epidemiology and control of schistosomiasis. Vlas SJ, et al. **Am J Trop Med Hyg** 1996 Nov;55(5 Suppl):170–5 (16 ref.)

A short review of the previous and current epidemiological situation of schistosomiasis in China. Cen LP. **Rev Soc Bras Med Trop** 1996 Jan–Feb;30(1):57–60 (14 ref.)

IMMUNOLOGY

Immunologic basis of disease and disease regulation in schistosomiasis. Cheever AW, et al. **Chem Immunol** 1997; 66:159–76 (108 ref.)

Immunodiagnosis of schistosomiasis. Tsang VC, et al. **Immunol Invest** 1997 Jan–Feb;26(1–2):175–88 (27 ref.)

PARASITOLOGY

Schistosomiasis. Pathophysiology, diagnosis, and treatment. Elliott DE. **Gastroenterol Clin North Am** 1996 Sep; 25(3):599–625 (150 ref.)

Proteolytic degradation of host hemoglobin by schistosomes. Brindley PJ, et al. **Mol Biochem Parasitol** 1997 Oct; 89(1):1–9 (57 ref.)

[Bilharziasis and genital pathology] Tordjeman N, et al. **Contracept Fertil Sex** 1997 Jan;25(1):15–20 (35 ref.) **(Fre)**

PATHOLOGY

Schistosomiasis in women: manifestations in the upper reproductive tract. Helling-Giese G, et al. **Acta Trop** 1996 Dec 30;62(4):225–38 (60 ref.)

Neuroschistosomiasis. Pittella JE. **Brain Pathol** 1997 Jan; 7(1):649–62 (134 ref.)

PREVENTION & CONTROL

The radiation-attenuated vaccine against schistosomes in animal models: paradigm for a human vaccine? Coulson PS. **Adv Parasitol** 1997;39:271–336 (210 ref.)

Different approaches to modeling the cost-effectiveness of schistosomiasis control. Guyatt HL, et al. **Am J Trop Med Hyg** 1996 Nov;55(5 Suppl):159–64 (27 ref.)

Schistosomiasis vaccine development—the current picture. Waine GJ, et al. **Bioessays** 1997 May;19(5):435–43 (76 ref.)

TRANSMISSION

Modeling the transmission of schistosomiasis: an introductory view. Barbour AD. **Am J Trop Med Hyg** 1996 Nov;55(5 Suppl):135–43 (10 ref.)

Mathematical models of transmission dynamics and control of schistosomiasis. Woolhouse ME. **Am J Trop Med Hyg** 1996 Nov;55(5 Suppl):144–8 (19 ref.)

SCHISTOSOMIASIS HAEMATOBIA

IMMUNOLOGY

Immunity and morbidity in infection due to Schistosoma haematobium. Hagan P. **Am J Trop Med Hyg** 1996 Nov; 55(5 Suppl):116–20 (31 ref.)

PATHOLOGY

[Anatomopathological aspects of 25 cases of bilharzial bladder cancer] Nouhou PH, et al. **Bull Soc Pathol Exot** 1996;89(3):181–4 (6 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Results of renal transplantation in patients with Schistosoma infection. Barrou B, et al. **J Urol** 1997 Apr;157(4):1232–5; discussion 1235–6 (17 ref.)

SCHISTOSOMIASIS, INTESTINAL see **SCHISTOSOMIASIS MANSONI**

SCHISTOSOMIASIS JAPONICA

IMMUNOLOGY

Immunity and morbidity in schistosomiasis japonicum infection. Olds GR, et al. **Am J Trop Med Hyg** 1996 Nov; 55(5 Suppl):121–6 (29 ref.)

PREVENTION & CONTROL

[Progresses in tropical diseases and parasitosis in China, 1996] Zheng J. **Chung Hua I Hsueh Tsa Chih** 1996 Dec; 76(12):898–9 (0 ref.) **(Chi)**

SURGERY

[Intestinal schistosomiasis, a facultative precancerous condition? Review of the literature with reference to Schistosoma japonicum associated rectum carcinoma] Jatzko G, et al. **Chirurg** 1997 Jul;68(7):727–31 (24 ref.) (Eng. Abstr.) **(Ger)**

SCHISTOSOMIASIS MANSONI

COMPLICATIONS

Cytokine regulation of schistosome-induced granuloma and fibrosis. Wahl SM, et al. **Kidney Int** 1997 May;51(5):1370–5 (62 ref.)

[Cardiopulmonary involvement in schistosomiasis] Barbosa MM, et al. **Arq Bras Cardiol** 1995 Oct;65(4):343–8 (59 ref.) **(Por)**

EPIDEMIOLOGY

[Acute schistosomiasis or Katayama syndrome: apropos of 2 mini-epidemics] Loutan L, et al. **Schweiz Med Wochenschr** 1996 Aug 31;126(35):1482–6 (24 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Vasoactive intestinal peptide regulation of granulomatous inflammation in murine Schistosomiasis mansoni. Weinstock JV. **Adv Neuroimmunol** 1996;6(1):95–105 (51 ref.)

Immunity and morbidity in Schistosoma mansoni infection: quantitative aspects. Butterworth AE, et al. **Am J Trop Med Hyg** 1996 Nov;55(5 Suppl):109–15 (26 ref.)

Development of an antipathology vaccine for schistosomiasis. Wynn TA. **Ann N Y Acad Sci** 1996 Oct 25;797:191–5 (27 ref.)

IL-4 in schistosomiasis. Pearce EJ, et al. **Exp Parasitol** 1996 Nov;84(2):295–9 (47 ref.)

Granulomas in murine schistosomiasis mansoni have a somatostatin immunoregulatory circuit. Elliott DE, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):88–90 (37 ref.)

Cellular immune response and pathology in schistosomiasis. Auriault C, et al. **Parasite** 1996 Sep;3(3):199–208 (54 ref.)

PATHOLOGY

Vasoactive intestinal peptide regulation of granulomatous inflammation in murine Schistosomiasis mansoni. Weinstock JV. **Adv Neuroimmunol** 1996;6(1):95–105 (51 ref.)

IL12 as an adjuvant for vaccines designed to prevent infection and immunopathology by schistosomes. Wynn TA, et al. **Res Immunol** 1995 Sep–Oct;146(7–8):582–90 (59 ref.)

PHYSIOPATHOLOGY

Granulomas in murine schistosomiasis mansoni have a somatostatin immunoregulatory circuit. Elliott DE, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):88–90 (37 ref.)

SCHISTOSOMIASIS MANSONI

PREVENTION & CONTROL

IL12 as an adjuvant for vaccines designed to prevent infection and immunopathology by schistosomes. Wynn TA, et al. **Res Immunol** 1995 Sep–Oct;146(7–8):582–90 (59 ref.)

ULTRASONOGRAPHY

[Value of hepatosplenic ultrasonography in the surveillance of Schistosoma mansoni endemics (a study conducted in the Richard Toll region of Senegal)] Lanuit R, et al. **Med Trop (Mars)** 1996;56(3):271–4 (11 ref.) (Eng. Abstr.) **(Fre)**

SCHISTOSOMIASIS, URINARY see **SCHISTOSOMIASIS HAEMATOBIA**

SCHIZOAFFECTIVE DISORDER see **PSYCHOTIC DISORDERS**

SCHIZOMYCETES see **BACTERIA**

SCHIZOPHRENIA

Molecular attributes of dopamine receptors: new potential for antipsychotic drug development. Hartman DS, et al. **Ann Med** 1996 Jun;28(3):211–9 (77 ref.)

The rationale and ethics of medication–free research in schizophrenia [see comments] Carpenter WT Jr, et al. **Arch Gen Psychiatry** 1997 May;54(5):401–7 (58 ref.) Comment in: Arch Gen Psychiatry 1997 May;54(5):412–3. Comment in: Arch Gen Psychiatry 1997 May;54(5):415–6.

ABC of mental health. Schizophrenia. Turner T. **BMJ** 1997 Jul 12;315(7100):108–11 (7 ref.)

Requiem for "Schizophrenia". Howard JS 3rd. **Integr Physiol Behav Sci** 1996 Apr–Jun;31(2):148–54; discussion 147 (37 ref.)

BLOOD

The clinical use of clozapine plasma concentrations in the management of treatment–refractory schizophrenia. Miller DD. **Ann Clin Psychiatry** 1996 Jun;8(2):99–109 (47 ref.)

Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. Peet M, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Aug; 55(1–2):71–5 (33 ref.)

CHEMICALLY INDUCED

Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literature. Dalack GW, et al. **Schizophr Res** 1996 Nov 15;22(2):133–41 (45 ref.)

CLASSIFICATION

Affiliation and neuropsychiatric disorders: the deficit syndrome of schizophrenia. Kirkpatrick B. **Ann N Y Acad Sci** 1997 Jan 15;807:455–68 (69 ref.)

COMPLICATIONS

Alcohol dependence and schizophrenia: what are the interrelationships? Soyka M. **Alcohol Alcohol Suppl** 1994; 2:473–8 (58 ref.)

Schizophrenia and kleptomania: a case report—a biological link? Chong SA. **Ann Acad Med Singapore** 1995 Nov; 24(6):860–2 (23 ref.)

Rehabilitation of frontal/executive impairments in schizophrenia. Delahunty A, et al. **Aust N Z J Psychiatry** 1996 Dec;30(6):760–7 (61 ref.)

Blood pressure and dementia in the elderly: epidemiologic perspectives. Guo Z, et al. **Biomed Pharmacother** 1997; 51(2):68–73 (50 ref.)

Sexually transmitted diseases and unwanted pregnancies in chronically ill psychiatric patients [editorial] [see comments] Coverdale JH, et al. **Med J Aust** 1997 Mar 3; 166(5):231–2 (10 ref.) Comment in: Med J Aust 1997 Jun 16;166(12):665–6. Comment in: Med J Aust 1997 Jun 16;166(12):666. Comment in: Med J Aust 1997 Jun 16;166(12):666–7.

Smoking and vulnerability for schizophrenia. de Leon J. **Schizophr Bull** 1996;22(3):405–9 (19 ref.)

[Memory disturbances in schizophrenia] Brand A, et al. **Fortschr Neurol Psychiatr** 1996 Feb;64(2):49–65 (132 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

The core symptoms of schizophrenia. Flaum M, et al. **Ann Med** 1996 Dec;28(6):525–31 (19 ref.)

Women and schizophrenia: a review. Kulkarni J. **Aust N Z J Psychiatry** 1997 Feb;31(1):46–56 (106 ref.)

Schizophrenia. A cognitive model and its implications for psychological intervention. Hemsley DR. **Behav Modif** 1996 Apr;20(2):139–69 (126 ref.)

The heterogeneity of memory dysfunction in schizophrenia. Stip E, et al. **Can J Psychiatry** 1996 Sep;41(7 Suppl 1):S14–20 (33 ref.)

Construct validity of negative symptoms: an empirical and conceptual review. Earnst KS, et al. **Clin Psychol Rev** 1997; 17(2):167–89 (221 ref.)

How to distinguish between the neuroleptic–induced deficit syndrome, depression and disease–related negative symptoms in schizophrenia. Barnes TR, et al. **Int Clin Psychopharmacol** 1995 Sep;10 Suppl 3:115–21 (63 ref.)

Negative symptoms: diagnosis, treatment and prognosis. Buchanan RW, et al. **Int Clin Psychopharmacol** 1996 May; 11 Suppl 2:3–11 (90 ref.)

Differential diagnosis in acute psychotic episode. Falkai P. **Int Clin Psychopharmacol** 1996 May;11 Suppl 2:13–7 (23 ref.)

Adolescent schizophrenia: a methodologic review of the current neuroimaging and neuropsychologic literature. Findling RL, et al. **J Autism Dev Disord** 1995 Dec; 25(6):627–39 (39 ref.)

Cognitive function in schizophrenic patients. Tollefson GD. **J Clin Psychiatry** 1996;57 Suppl 11:31–9 (62 ref.)

Affective reactivity of symptoms as a process discriminator in schizophrenia. Docherty NM. **J Nerv Ment Dis** 1996 Sep;184(9):535–41 (46 ref.)

Consensus on minimal criteria of clinical and neuropathological diagnosis of schizophrenia and affective disorders for post mortem research. Report from the European Dementia and Schizophrenia Network (BIOMED I). Riederer P, et al. **J Neural Transm Gen Sect** 1995;102(3):255–64 (16 ref.)

Memory deficits in schizophrenia: inadequate assimilation or true amnesia? Findings from the Wechsler Memory Scale—revised. Hawkins KA, et al. **J Psychiatry Neurosci** 1997 May;22(3):169–79 (24 ref.)

The role of the general practitioner in the treatment of schizophrenia: general principles. Carr VJ. **Med J Aust** 1997 Jan 20;166(2):91–4 (34 ref.)

Symptom dimensions of schizophrenia: a selective integration of neurophysiological and neuropsychological correlates. Aderibigbe YA, et al. **Neuropsychobiology** 1996; 34(4):192–200 (89 ref.)

The lipid membrane hypothesis of schizophrenia: implications for possible clinical breath tests. Dodd GH. **Prostaglandins Leukot Essent Fatty Acids** 1996 Aug; 55(1–2):95–9 (24 ref.)

31P magnetic resonance spectroscopy studies in schizophrenia. Williamson PC, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Aug; 55(1–2):115–8 (19 ref.)

Early identification and treatment of schizophrenia: conceptual and ethical considerations. Larsen TK, et al. **Psychiatry** 1996 Winter;59(4):371–80 (65 ref.)

Social cognition in schizophrenia. Penn DL, et al. **Psychol Bull** 1997 Jan;121(1):114–32 (285 ref.)

Adolescence and diagnostics. Zdanowicz N, et al. **Psychol Rep** 1996 Apr;78(2):459–66 (39 ref.)

Perseveration in schizophrenia. Crider A. **Schizophr Bull** 1997;23(1):63–74 (100 ref.)

Early detection and intervention with schizophrenia: rationale. McGlashan TH, et al. **Schizophr Bull** 1996; 22(2):201–22 (132 ref.)

Risk factors of psychosis: identifying vulnerable populations premorbidly. Olin SC, et al. **Schizophr Bull** 1996; 22(2):223–40 (93 ref.)

Time course of cerebral ventricular enlargement in schizophrenia supports the hypothesis of its neurodevelopmental nature. Vita A, et al. **Schizophr Res** 1997 Jan 17;23(1):25–30 (32 ref.)

[Attention models in evaluating schizophrenia] Bernard D, et al. **Encephale** 1997 Mar–Apr;23(2):113–8 (38 ref.) (Eng. Abstr.) **(Fre)**

[Syndromic and diagnostic heterogeneity of schizophrenia] Brazo P, et al. **Encephale** 1997 Apr;23 Spec No 2:20–4 (30 ref.) (Eng. Abstr.) **(Fre)**

[Chronic hallucinatory psychosis and late onset schizophrenia: the same entity?] Dubertret C, et al. **Encephale** 1997 May–Jun;23(3):157–67 (38 ref.) (Eng. Abstr.) **(Fre)**

[The PANSS (Positive And Negative Symptom) Scale] Guelfi JD. **Encephale** 1997 Apr;23 Spec No 2:35–8 (19 ref.) (Eng. Abstr.) **(Fre)**

[Intentional awareness and schizophrenia] Hardy–Baylé MC, et al. **Encephale** 1996 Oct;22 Spec No 3:104–7 (12 ref.) **(Fre)**

[Schizophrenia, from classification to dimensions: value of longitudinal studies] Lecrubier Y. **Encephale** 1997 Apr;23 Spec No 2:39–43 (61 ref.) (Eng. Abstr.) **(Fre)**

[Voluntary mercury poisoning: biological consequences and psychiatric significance (published erratum appears in Schweiz Rundsch Med Prax 1997 Jul 2;86(27–28):1123)] Jornod P, et al. **Schweiz Rundsch Med Prax** 1997 May 28; 86(22):946–51 (51 ref.) (Eng. Abstr.) **(Fre)**

[Significance of primary negative symptoms in schizophrenic and other psychiatric patients] Gerbaldo H, et al. **Fortschr Neurol Psychiatr** 1996 Jun;64(6):221–7 (50 ref.) (Eng. Abstr.) **(Ger)**

[Disorders of early information processing and vigilance as vulnerability markers for schizophrenia] Suslow T, et al. **Fortschr Neurol Psychiatr** 1996 Mar;64(3):90–104 (81 ref.) (Eng. Abstr.) **(Ger)**

[Structural affinities of the incomprehensible in schizophrenic delusion] Feldmann H, et al. **Nervenarzt** 1997 Mar; 68(3):226–30 (31 ref.) (Eng. Abstr.) **(Ger)**

[Electroencephalography in psychiatry—current status and outlook] Herrmann WM, et al. **Nervenarzt** 1996 May; 67(5):348–59 (139 ref.) (Eng. Abstr.) **(Ger)**

[50 years after Manfred Bleuler. What do we know today about late–onset schizophrenia(s)?] Riecher–Rössler A. **Nervenarzt** 1997 Mar;68(3):159–70 (86 ref.) (Eng. Abstr.) **(Ger)**

[Quantitative and topographical analysis of EEG: its application in some psychiatric disorders] Dróżdż W, et al. **Psychiatr Pol** 1995 Nov–Dec;29(6):827–38 (28 ref.) (Eng. Abstr.) **(Pol)**

[Neuroimaging and fundamental symptoms in schizophrenia] Lopez–Ibor MI, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 Jan–Feb;24(1):25–8 (30 ref.) (Eng. Abstr.) **(Spa)**

[Schizophrenia: a psychobiological view] Rodríguez–Arias M, et al. **Rev Neurol** 1996 Oct;24(134):1210–20 (105 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

The role of cognition in the risk—benefit and safety analysis of antipsychotic medication. Borison RL. **Acta Psychiatr Scand Suppl** 1996;389:5–11 (57 ref.)

Minimizing the non–extrapyramidal side–effects of antipsychotics. Keks NA. **Acta Psychiatr Scand Suppl** 1996; 389:18–24 (49 ref.)

Spontaneous and drug–induced movement disorders in schizophrenia. Kopala LC. **Acta Psychiatr Scand Suppl** 1996;389:12–7 (32 ref.)

New drugs for schizophrenia: an update for family physicians. Amadio PB, et al. **Am Fam Physician** 1997 Sep 15; 56(4):1149–56, 1159–60 (19 ref.)

Is clozapine safe in the elderly? Herst L, et al. **Aust N Z J Psychiatry** 1997 Jun;31(3):411–7 (33 ref.)

Drug strategies and treatment–resistant schizophrenia. Pantelis C, et al. **Aust N Z J Psychiatry** 1996 Feb; 30(1):20–37 (184 ref.)

Limitations of controlled augmentation trials in schizophrenia. Stern RG, et al. **Biol Psychiatry** 1997 Jul 15;42(2):138–43 (28 ref.)

Treatment of schizophrenia: advances during the decade of the brain. Buckley PF. **Br J Hosp Med** 1996 Dec 11–1997 Jan 14;56(11):574–80 (31 ref.)

Schizophrenia, violence, clozapine and risperidone: a review. The Special Hospitals Treatment Resistant Schizophrenia Research Group. **Br J Psychiatry Suppl** 1996 Dec; (31):21–30 (60 ref.)

Management of treatment resistant schizophrenia unresponsive to clozapine. Barnes TR, et al. **Br J Psychiatry Suppl** 1996 Dec;(31):31–40 (65 ref.)

Factors which can make patients difficult to treat. Kane JM. **Br J Psychiatry Suppl** 1996 Dec;(31):10–4 (28 ref.)

Management of treatment refractory schizophrenia. Morrison DP. **Br J Psychiatry Suppl** 1996 Dec;(31):15–20 (40 ref.)

Advances in psychopharmacology—schizophrenia. Owens DG. **Br Med Bull** 1996 Jul;52(3):556–74 (90 ref.)

Ethical concerns about relapse studies [see comments] Shamoo AE, et al. **Camb Q Healthc Ethics** 1996 Summer; 5(3):373–86 (51 ref.) Comment in: Camb Q Healthc Ethics 1997 Spring;6(2):233–4.

Neurocognitive impairment in schizophrenia and how it affects treatment options [see comments] Bilder RM. **Can J Psychiatry** 1997 Apr;42(3):255–64 (58 ref.) Comment in: Can J Psychiatry 1997 Apr;42(3):247–8.

Use of cytokines in clozapine–induced agranulocytosis [see comments] Chin–Yee I, et al. **Can J Psychiatry** 1996 Jun; 41(5):280–4 (42 ref.) Comment in: Can J Psychiatry 1996 Nov;41(9):603.

Memory impairment in schizophrenia: perspectives from psychopathology and pharmacotherapy. Stip E. **Can J Psychiatry** 1996 Oct;41(8 Suppl 2):S27–34 (67 ref.)

The promise of new drugs for schizophrenia treatment [see comments] Tamminga CA. **Can J Psychiatry** 1997 Apr; 42(3):265–73 (76 ref.) Comment in: Can J Psychiatry 1997 Apr;42(3):247–8.

A risk–benefit assessment of sulpiride in the treatment of schizophrenia. Mauri MC, et al. **Drug Saf** 1996 May; 14(5):288–98 (73 ref.)

Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes. Fleischhacker WW, et al. **Drugs** 1997 Jun;53(6):915–29 (151 ref.)

Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Fulton B, et al. **Drugs** 1997 Feb; 53(2):281–98 (71 ref.)

Review: treatment of schizophrenia. State of the art. Möller HJ. **Eur Arch Psychiatry Clin Neurosci** 1996;246(5):229–34 (62 ref.)

The expanding indications for clozapine. Young CR, et al. **Exp Clin Psychopharmacol** 1997 Aug;5(3):216–34 (235 ref.)

Novel antipsychotics and the problem of clinical stabilization in schizophrenia: are they "stabilizer" rather than typical compounds? Altamura AC. **Int Clin Psychopharmacol** 1996 Sep;11(3):153–5 (24 ref.)

Improvement of negative symptoms: Concepts, definition and assessment. Andreasen NC. **Int Clin Psychopharmacol** 1997 May;12 Suppl 2:S7–10 (17 ref.)

Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome. Awad AG, et al. **Int Clin Psychopharmacol** 1996 May;11 Suppl 2:55–9 (28 ref.)

Pharmacological treatment strategies in the non–responsive schizophrenic patient. Barnes TR, et al. **Int Clin Psychopharmacol** 1996 May;11 Suppl 2:67–71 (50 ref.)

Negative symptoms: diagnosis, treatment and prognosis. Buchanan RW, et al. **Int Clin Psychopharmacol** 1996 May; 11 Suppl 2:3–11 (90 ref.)

Prediction of response to acute neuroleptic treatment in schizophrenia. Gaebel W. **Int Clin Psychopharmacol** 1996 May;11 Suppl 2:47–54 (31 ref.)

Towards the improvement of compliance: the significance of psycho-education and new antipsychotic drugs. Gaebel W. **Int Clin Psychopharmacol** 1997 Feb;12 Suppl 1:S37–42 (48 ref.)

Antipsychotic dosing strategies in acute schizophrenia. Janicak PG, et al. **Int Clin Psychopharmacol** 1996 May;11 Suppl 2:35–40 (29 ref.)

What can we achieve by implementing a compliance-improvement program? Kane JM. **Int Clin Psychopharmacol** 1997 Feb;12 Suppl 1:S43–6 (21 ref.)

What are the therapeutic needs in schizophrenia and how are they satisfied by new antipsychotics? Kane JM. **Int Clin Psychopharmacol** 1997 May;12 Suppl 2:S3–6 (28 ref.)

Dosing issues and depot medication in the maintenance treatment of schizophrenia. Kane JM. **Int Clin Psychopharmacol** 1995 Sep;10 Suppl 3:65–71 (46 ref.)

Pharmacological treatment strategies in acute schizophrenia. Marder SR. **Int Clin Psychopharmacol** 1996 May;11 Suppl 2:29–34 (24 ref.)

Clinical update on amisulpride in deficit schizophrenia. Rein W, et al. **Int Clin Psychopharmacol** 1997 May;12 Suppl 2:S19–27 (27 ref.)

Amisulpride: from animal pharmacology to therapeutic action. Scatton B, et al. **Int Clin Psychopharmacol** 1997 May;12 Suppl 2:S29–36 (45 ref.)

Neurobiological correlates of acute neuroleptic treatment. Sedvall GC. **Int Clin Psychopharmacol** 1996 May;11 Suppl 2:41–6 (20 ref.)

The new generation of antipsychotic drugs. Tamminga CA, et al. **Int Clin Psychopharmacol** 1996 May;11 Suppl 2:73–6 (15 ref.)

Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. Tamminga CA, et al. **Int Clin Psychopharmacol** 1997 Feb;12 Suppl 1:S29–35 (7 ref.)

Schizophrenia and antipsychotic somatic treatment. Lindström LH, et al. **Int J Technol Assess Health Care** 1996 Fall;12(4):573–84 (94 ref.)

Drug treatment of schizophrenia and delusional disorder in late life. Howard R. **Int Psychogeriatr** 1996 Winter; 8(4):597–608 (60 ref.)

New dimensions in the pharmacologic treatment of schizophrenia and related psychoses. Buckley PF. **J Clin Pharmacol** 1997 May;37(5):363–78 (121 ref.)

Pharmacokinetics and drug interactions: update for new antipsychotics. Ereshefsky L. **J Clin Psychiatry** 1996;57 Suppl 11:12–25 (68 ref.)

Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. Glazer WM, et al. **J Clin Psychiatry** 1997; 58 Suppl 10:50–4 (29 ref.)

Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. Lieberman JA. **J Clin Psychiatry** 1996;57 Suppl 11:68–71 (28 ref.)

Management of treatment-resistant patients with schizophrenia. Marder SR. **J Clin Psychiatry** 1996;57 Suppl 11:26–30 (40 ref.)

Clozapine withdrawal resulting in delirium with psychosis: a report of three cases. Stanilla JK, et al. **J Clin Psychiatry** 1997 Jun;58(6):252–5 (26 ref.)

Atypical antipsychotic drugs and long-term outcome in schizophrenia. Weiden P, et al. **J Clin Psychiatry** 1996;57 Suppl 11:53–60 (36 ref.)

The role of serotonin in the pathophysiology and treatment of schizophrenia. Abi-Dargham A, et al. **J Neuropsychiatry Clin Neurosci** 1997 Winter;9(1):1–17 (243 ref.)

Review the role of dopamine D4 receptors in schizophrenia and antipsychotic action. Sanyal S, et al. **J Psychiatr Res** 1997 Mar-Apr;31(2):219–32 (85 ref.)

Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia. Revicki DA. **J Psychiatry Neurosci** 1997 Jul;22(4):256–66 (55 ref.)

Quality of life measurement during antipsychotic drug therapy of schizophrenia. Voruganti LN, et al. **J Psychiatry Neurosci** 1997 Jul;22(4):267–74 (37 ref.)

What is an atypical antipsychotic? Reynolds GP. **J Psychopharmacol (Oxf)** 1997;11(3):195–9 (45 ref.)

Olanzapine: a new atypical antipsychotic. Littrell K, et al. **J Psychosoc Nurs Ment Health Serv** 1996 Aug;34(8):41–6 (16 ref.)

Psychobiologic correlates of treatment response in schizophrenia. Lieberman JA, et al. **Neuropsychopharmacology** 1996 Mar;14(3 Suppl):13S–21S (35 ref.)

Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment. Meltzer HY, et al. **Neuropsychopharmacology** 1996 Mar; 14(3 Suppl):27S–33S (61 ref.)

Cognitive function in schizophrenia--do neuroleptics make a difference? Mortimer AM. **Pharmacol Biochem Behav** 1997 Apr;56(4):789–95 (74 ref.)

Sedation in acute and chronic agitation. Levy RH. **Pharmacotherapy** 1996 Nov-Dec;16(6 Pt 2):152S–159S; discussion 166S–168S (33 ref.)

Use of novel antipsychotic drugs. Raleigh F. **Pharmacotherapy** 1996 Nov-Dec;16(6 Pt 2):160S–165S; discussion 166S–168S (20 ref.)

Benzodiazepines in schizophrenia. Stimmel GL. **Pharmacotherapy** 1996 Nov-Dec;16(6 Pt 2):148S–151S; discussion 166S–168S (11 ref.)

Oxidative injury and potential use of antioxidants in schizophrenia. Mahadik SP, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Aug; 55(1-2):45–54 (117 ref.)

Clozapine plasma level monitoring: current status. Cooper TB. **Psychiatr Q** 1996 Winter;67(4):297–311 (73 ref.)

Issues in polypharmacotherapy: focus on depression in schizophrenia. Dufresne RL. **Psychopharmacol Bull** 1995; 31(4):789–96 (31 ref.)

Development and implementation of drug use evaluation (DUE) criteria for risperidone in an outpatient psychiatric setting. Shepski JC, et al. **Psychopharmacol Bull** 1996; 32(4):705–19 (45 ref.)

Outcome of first-episode schizophrenia and the new antipsychotics. A literature review. Emsley R. **S Afr Med J** 1996 Jun;86(6 Suppl):729–30, 734 (35 ref.)

The risk of medication-free research. Carpenter WT Jr. **Schizophr Bull** 1997;23(1):11–8 (84 ref.)

Risperidone: how good is the evidence for efficacy? Mattes JA. **Schizophr Bull** 1997;23(1):155–61 (36 ref.)

Placebo washout in trials of antipsychotic drugs. Volavka J, et al. **Schizophr Bull** 1996;22(4):567–76 (40 ref.)

Research in schizophrenia and the discontinuation of antipsychotic medications. Wyatt RJ. **Schizophr Bull** 1997; 23(1):3–9 (40 ref.)

Lack of gender differences in neuroleptic response in patients with schizophrenia. Pinals DA, et al. **Schizophr Res** 1996 Dec 15;22(3):215–22 (38 ref.)

Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist. Bristow LJ, et al. **Trends Pharmacol Sci** 1997 Jun;18(6):186–8 (11 ref.)

[Serotonin and treatment of mental disorders. Present status and future perspectives] Sevčík J, et al. **Cas Lek Cesk** 1997 Jul 14;136(14):431–3 (17 ref.) (Eng. Abstr.) **(Cze)**

[Indications for clozapine] Gaussarès C. **Encephale** 1996 Dec; 22 Spec No 6:12–5 (22 ref.) (Eng. Abstr.) **(Fre)**

[A new study of secondary effects in prescribing practices of neuroleptics] Lachaux B, et al. **Encephale** 1997 Apr;23 Spec No 2:25–34 (56 ref.) (Eng. Abstr.) **(Fre)**

[New chemotherapy approaches to psychoses] Olié JP, et al. **Encephale** 1997 Apr;23 Spec No 2:2–9 (53 ref.) (Eng. Abstr.) **(Fre)**

[New drug therapies] Olié JP, et al. **Encephale** 1996 Oct;22 Spec No 3:63–71; discussion 76 (33 ref.) **(Fre)**

[Schizophrenia and neural transmission: an excess of analogical treatment?] Tassin JP. **Encephale** 1996 Oct;22 Spec No 3:91–8 (55 ref.) **(Fre)**

[Promising effects of the new antipsychotic agents in schizophrenia. But recommendations of the Medical Products Agency are conservative] Sedvall GC. **Lakartidningen** 1997 May 14;94(20):1873–6 (19 ref.) **(Swe)**

ECONOMICS

Economic outcomes and costs in the treatment of schizophrenia. Knapp M, et al. **Clin Ther** 1997 Jan-Feb; 19(1):128–38; discussion 126–7 (32 ref.)

Psychiatric intensive care in acute psychosis. Hyde CE, et al. **Int Clin Psychopharmacol** 1996 May;11 Suppl 2:61–5 (31 ref.)

Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia. Revicki DA. **J Psychiatry Neurosci** 1997 Jul;22(4):256–66 (55 ref.)

ENZYMOLOGY

Tyrosine hydroxylase: human isoforms, structure and regulation in physiology and pathology. Nagatsu T. **Essays Biochem** 1995;30:15–35 (45 ref.)

EPIDEMIOLOGY

Epidemiology of schizophrenia [see comments] Häfner H, et al. **Can J Psychiatry** 1997 Mar;42(2):139–51 (142 ref.) Comment in: Can J Psychiatry 1997 Mar;42(2):131–2.

The Johns Hopkins University Collaborative Schizophrenia Study: an epidemiologic-genetic approach to test the heterogeneity hypothesis and identify schizophrenia susceptibility genes. Pulver AE, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:797–814 (160 ref.)

Wernicke's disease and schizophrenia: a case report and review of the literature. Casanova MF. **Int J Psychiatry Med** 1996;26(3):319–28 (50 ref.)

Familial risks and reproductive fitness in schizophrenia. Battaglia M, et al. **Schizophr Bull** 1996;22(2):191–5 (23 ref.)

Medical comorbidity in schizophrenia. Jeste DV, et al. **Schizophr Bull** 1996;22(3):413–30 (121 ref.)

Schizophrenia and HIV. Sewell DD. **Schizophr Bull** 1996; 22(3):465–73 (39 ref.)

[Schizophrenia and exclusion. Current and future perspectives] Furtos J, et al. **Encephale** 1996 Oct;22 Spec No 3:39–48 (50 ref.) **(Fre)**

ETHNOLOGY

Understanding cross-cultural prognostic variability for schizophrenia. Weisman AG. **Cult Divers Ment Health** 1997;3(1):23–35 (80 ref.)

ETIOLOGY

Schizophrenia: developmental disturbance of brain and mind? Stefan MD, et al. **Acta Paediatr Suppl** 1997 Jul;422:112–6 (63 ref.)

Abnormalities of brain structure and function in schizophrenia: implications for aetiology and pathophysiology. Cannon TD. **Ann Med** 1996 Dec; 28(6):533–9 (49 ref.)

The neurodevelopmental theory of schizophrenia: evidence concerning structure and neuropsychology. Chua SE, et al. **Ann Med** 1996 Dec;28(6):547–55 (128 ref.)

Dopamine in schizophrenia. Hietala J, et al. **Ann Med** 1996 Dec;28(6):557–61 (43 ref.)

Minor physical anomalies and their relationship to the aetiology of schizophrenia [editorial] [see comments] Murphy KC, et al. **Br J Psychiatry** 1996 Feb;168(2):139–42 (29 ref.) Comment in: Br J Psychiatry 1996 Jun;168(6):789–90.

The early origins of schizophrenia. Jones P. **Br Med Bull** 1997 Jan;53(1):135–55 (91 ref.)

Schizophrenia, bacterial toxins and the genetics of redundancy. Morris JA. **Med Hypotheses** 1996 Apr; 46(4):362–6 (23 ref.)

The role of candidate genes in the etiology of schizophrenia. Murphy KC, et al. **Mol Med** 1996 Nov;2(6):665–9 (49 ref.)

Dopaminergic sensitization: implications for the pathogenesis of schizophrenia. Glenthøj BY, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Jan; 21(1):23–46 (93 ref.)

Could schizophrenia be reasonably explained by Dohan's hypothesis on genetic interaction with a dietary peptide overload? Reichelt KL, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Oct; 20(7):1083–114 (205 ref.)

Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Horrobin DF. **Prostaglandins Leukot Essent Fatty Acids** 1996 Aug; 55(1-2):3–7 (46 ref.)

Free radical pathology in schizophrenia: a review. Reddy RD, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Aug;55(1-2):33–43 (137 ref.)

The fate of the ego in contemporary psychiatry with particular reference to etiologic theories of schizophrenia. Diamond DB. **Psychiatry** 1997 Spring;60(1):67–88 (78 ref.)

Is there a viral or immune dysfunction etiology to schizophrenia? Re-evaluation a decade later. DeLisi LE. **Schizophr Res** 1996 Oct 18;22(1):1–4 (10 ref.)

Is schizophrenia a lifetime disorder of brain plasticity, growth and aging? DeLisi LE. **Schizophr Res** 1997 Feb 7; 23(2):119–29 (101 ref.)

Developmental insanity or dementia praecox: was the wrong concept adopted? O'Connell P, et al. **Schizophr Res** 1997 Feb 7;23(2):97–106 (108 ref.)

Lay beliefs about the causes of mental disorders: a new methodological approach. Matschinger H, et al. **Soc Psychiatry Psychiatr Epidemiol** 1996 Nov;31(6):309–15 (37 ref.)

[What is known about the etiology and background of schizophrenia?] Isohanni M, et al. **Duodecim** 1995; 111(18):1745–52 (76 ref.) **(Fin)**

GENETICS

Schizotypal disorder: at the crossroads of genetics and nosology. Battaglia M, et al. **Acta Psychiatr Scand** 1996 Nov;94(5):303–10 (94 ref.)

A critical review of genetic studies of schizophrenia. II. Molecular genetic studies. Portin P, et al. **Acta Psychiatr Scand** 1997 Feb;95(2):73–80 (128 ref.)

A critical review of genetic studies of schizophrenia. I. Epidemiological and brain studies. Portin P, et al. **Acta Psychiatr Scand** 1997 Jan;95(1):1–5 (55 ref.)

Legacy of German psychiatric genetics: hindsight is always 20/20 [editorial] Gottesman II, et al. **Am J Med Genet** 1996 Jul 26;67(4):317–22 (69 ref.)

Schizophrenia and chromosome 6p. Turecki G, et al. **Am J Med Genet** 1997 Apr 18;74(2):195–8 (23 ref.)

Ernst Rüdin (1874–1952) and his genealogic-demographic department in Munich (1917–1986): an introduction to their family studies of schizophrenia. Zerbin-Rüdin E, et al. **Am J Med Genet** 1996 Jul 26;67(4):332–7 (56 ref.)

The molecular genetics of schizophrenia. O'Donovan MC, et al. **Ann Med** 1996 Dec;28(6):541–6 (52 ref.)

Molecular biological investigations into the role of the NMDA receptor in the pathophysiology of schizophrenia. Catts SV, et al. **Aust N Z J Psychiatry** 1997 Feb;31(1):17–26 (110 ref.)

Imaging as a tool in exploring the neurodevelopment and genetics of schizophrenia. Frangou S, et al. **Br Med Bull** 1996 Jul;52(3):587–96 (46 ref.)

Molecular genetic studies of schizophrenia. McGuffin P, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:815–22 (62 ref.)

The Johns Hopkins University Collaborative Schizophrenia Study: an epidemiologic-genetic approach to test the heterogeneity hypothesis and identify schizophrenia susceptibility genes. Pulver AE, et al.

Cold Spring Harb Symp Quant Biol 1996;61:797–814 (160 ref.)

Support for schizophrenia vulnerability loci on chromosomes 6p and 8p from Irish families. Straub RE, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:823–33 (63 ref.)

A gene at 6p? Schizophrenia. Dawson E, et al. **Curr Biol** 1996 Mar 1;6(3):268–71 (20 ref.)

Aetiology of schizophrenia: an evolutionary theory. Crow TJ. **Int Clin Psychopharmacol** 1995 Sep;10 Suppl 3:49–56 (63 ref.)

The molecular genetics of schizophrenia. Murphy KC, et al. **J Mol Neurosci** 1996 Summer;7(2):147–57 (75 ref.)

Abnormal cholecystokinin mRNA levels in entorhinal cortex of schizophrenics. Bachus SE, et al. **J Psychiatr Res** 1997 Mar–Apr;31(2):233–56 (170 ref.)

Cultured skin fibroblasts as a cell model for investigating schizophrenia. Mahadik SP, et al. **J Psychiatr Res** 1996 Nov–Dec;30(6):421–39 (160 ref.)

Familial and developmental abnormalities of front lobe function and neurochemistry in schizophrenia. Deakin FW, et al. **J Psychopharmacol (Oxf)** 1997;11(2):133–42 (110 ref.)

Possible relevance of phospholipid abnormalities and genetic interactions in psychiatric disorders: the relationship between dyslexia and schizophrenia. Horrobin DF, et al. **Med Hypotheses** 1995 Dec;45(6):605–13 (70 ref.)

Schizophrenia, bacterial toxins and the genetics of redundancy. Morris JA. **Med Hypotheses** 1996 Apr; 46(4):362–6 (23 ref.)

The role of candidate genes in the etiology of schizophrenia. Murphy KC, et al. **Mol Med** 1996 Nov;2(6):665–9 (49 ref.)

The molecular genetics of schizophrenia: progress so far. Kirov G, et al. **Mol Med Today** 1997 Mar;3(3):124–30 (39 ref.)

Dissecting the genetic complexity of schizophrenia. Karayiorgou M, et al. **Mol Psychiatry** 1997 May; 2(3):211–23 (161 ref.)

Could schizophrenia be reasonably explained by Dohan's hypothesis on genetic interaction with a dietary peptide overload? Reichelt KL, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Oct; 20(7):1083–114 (205 ref.)

On the trail of the genetics and pathophysiology of schizophrenia. Holzman PS. **Psychiatry** 1996 Summer; 59(2):117–27 (50 ref.)

Does the genotype for schizophrenia often remain unexpressed because of canalization and stochastic events during development? Woolf CM. **Psychol Med** 1997 May; 27(3):659–68 (73 ref.)

Familial risks and reproductive fitness in schizophrenia. Battaglia M, et al. **Schizophr Bull** 1996;22(2):191–5 (23 ref.)

VBR in schizophrenia: relationship to family history of psychosis and season of birth [published erratum appears in Schizophr Res 1997 May 24;25(2):167] DeQuardo JR, et al. **Schizophr Res** 1996 Jul 5;20(3):275–85 (60 ref.)

Schizophrenia, rheumatoid arthritis and natural resistance genes. Rubinstein G. **Schizophr Res** 1997 Jun 20; 25(3):177–81 (40 ref.)

[Risk factors and schizophrenia] d'Amato T, et al. **Encephale** 1996 Oct;22 Spec No 3:3–7; discussion 8 (26 ref.) **(Fre)**

[Dynamic DNA mutations, anticipation and schizophrenia] Thibaut F, et al. **Encephale** 1997 Jan–Feb;23(1):22–7 (35 ref.) (Eng. Abstr.) **(Fre)**

[Molecular genetic approach to schizophrenia: direct analysis of 5-HT receptor genes] Ozaki N. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Oct; 16(5):175–80 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Important current genetic findings in schizophrenia] Lannfelt L, et al. **Nord Med** 1996 Sep;111(7):233–4 (15 ref.) (Eng. Abstr.) **(Swe)**

HISTORY

Ernst Rüdin (1874–1952) and his genealogic-demographic department in Munich (1917–1986): an introduction to their family studies of schizophrenia. Zerbin-Rüdin E, et al. **Am J Med Genet** 1996 Jul 26;67(4):332–7 (56 ref.)

IMMUNOLOGY

Immunological influences in attention-deficit disorder and schizophrenia; is there a link between these two conditions? Holden RJ, et al. **Med Hypotheses** 1995 Dec;45(6):575–87 (121 ref.)

[Changes of humoral and cellular immunity in schizophrenia] Wojtanowska M, et al. **Psychiatr Pol** 1996 Sep–Oct; 30(5):783–99 (83 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

The psychobiology of the acute schizophrenic episode. Müller-Spahn F, et al. **Int Clin Psychopharmacol** 1996 May; 11 Suppl 2:19–28 (50 ref.)

Endogenous neurotoxins relevant to schizophrenia. Smythies J. **J R Soc Med** 1996 Dec;89(12):679–80 (26 ref.)

Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Carlsson A, et al. **Life Sci** 1997;61(2):75–94 (67 ref.)

Possible relevance of phospholipid abnormalities and genetic interactions in psychiatric disorders: the relationship between dyslexia and schizophrenia. Horrobin DF, et al. **Med Hypotheses** 1995 Dec;45(6):605–13 (70 ref.)

Clinical and biological markers for outcome in schizophrenia: a review of a longitudinal follow-up study in Uppsala schizophrenia research project. Lindström LH. **Neuropsychopharmacology** 1996 Mar;14(3 Suppl):23S–26S (13 ref.)

A pivotal role for glutamate in the pathogenesis of schizophrenia, and its cognitive dysfunction. Hirsch SR, et al. **Pharmacol Biochem Behav** 1997 Apr;56(4):797–802 (51 ref.)

Heat stress lipids and schizophrenia. Bates PR, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Aug; 55(1–2):101–7 (66 ref.)

Free radical pathology and antioxidant defense in schizophrenia: a review. Mahadik SP, et al. **Schizophr Res** 1996 Mar;19(1):1–17 (165 ref.)

MORTALITY

Mortality among patients with schizophrenia. Simpson JC, et al. **Schizophr Bull** 1996;22(3):485–99 (72 ref.)

NURSING

The human science basis of psychiatric nursing: theory and practice. Barker PJ, et al. **J Adv Nurs** 1997 Apr;25(4):660–7 (44 ref.)

PATHOLOGY

Recent advances in defining the neuropathology of schizophrenia. Arnold SE, et al. **Acta Neuropathol (Berl)** 1996 Sep;92(3):217–31 (153 ref.)

Schizophrenia: developmental disturbance of brain and mind? Stefan MD, et al. **Acta Paediatr Suppl** 1997 Jul;422:112–6 (63 ref.)

Neuropathology of the cerebellum in schizophrenia--an update: 1996 and future directions. Katsetos CD, et al. **Biol Psychiatry** 1997 Aug 1;42(3):213–24 (160 ref.)

Imaging as a tool in exploring the neurodevelopment and genetics of schizophrenia. Frangou S, et al. **Br Med Bull** 1996 Jul;52(3):587–96 (46 ref.)

A neuropsychiatric disorder associated with dense calcification of the external ears and distal muscle wasting: 'Primrose syndrome'. Lindor NM, et al. **Clin Dysmorphol** 1996 Jan;5(1):27–34 (17 ref.)

The psychobiology of the acute schizophrenic episode. Müller-Spahn F, et al. **Int Clin Psychopharmacol** 1996 May; 11 Suppl 2:19–28 (50 ref.)

The neuropathology of schizophrenia. Bachus SE, et al. **J Clin Psychiatry** 1996;57 Suppl 11:72–83 (240 ref.)

Consensus on minimal criteria of clinical and neuropathological diagnosis of schizophrenia and affective disorders for post mortem research. Report from the European Dementia and Schizophrenia Network (BIOMED I). Riederer P, et al. **J Neural Transm Gen Sect** 1995;102(3):255–64 (16 ref.)

The medial temporal lobe in schizophrenia. Arnold SE. **J Neuropsychiatry Clin Neurosci** 1997 Summer;9(3):460–70 (137 ref.)

Neuropathological studies of brain tissue in schizophrenia. Bunney BG, et al. **J Psychiatr Res** 1997 Mar–Apr; 31(2):159–73 (100 ref.)

A two-process theory of schizophrenia: evidence from studies in post-mortem brain. Deakin JF, et al. **J Psychiatr Res** 1997 Mar–Apr;31(2):277–95 (130 ref.)

Limbic circuits and monoamine receptors: dissecting the effects of antipsychotics from disease processes. Joyce JN, et al. **J Psychiatr Res** 1997 Mar–Apr;31(2):197–217 (70 ref.)

Cortical dopamine in schizophrenia: strategies for postmortem studies. Lewis DA, et al. **J Psychiatr Res** 1997 Mar–Apr;31(2):175–95 (80 ref.)

Development of the prefrontal cortex during adolescence: insights into vulnerable neural circuits in schizophrenia. Lewis DA. **Neuropsychopharmacology** 1997 Jun; 16(6):385–98 (132 ref.)

On the plausibility of "the neurodevelopmental hypothesis" of schizophrenia. Weinberger DR. **Neuropsychopharmacology** 1996 Mar;14(3 Suppl):1S–11S (78 ref.)

PHYSIOPATHOLOGY

Abnormalities of brain structure and function in schizophrenia: implications for aetiology and pathophysiology. Cannon TD. **Ann Med** 1996 Dec; 28(6):533–9 (49 ref.)

Rehabilitation of frontal/executive impairments in schizophrenia. Delahunty A, et al. **Aust N Z J Psychiatry** 1996 Dec;30(6):760–7 (61 ref.)

Could the inflammatory cytokines cause schizophrenia? [letter] Holden RJ, et al. **Aust N Z J Psychiatry** 1995 Dec; 29(4):693–5 (35 ref.)

What have we learned from functional imaging studies in schizophrenia? The role of frontal, striatal and temporal areas. Velakoulis D, et al. **Aust N Z J Psychiatry** 1996 Apr;30(2):195–209 (111 ref.)

Disturbances of one-carbon metabolism in neuropsychiatric disorders: a review. Smythies JR, et al. **Biol Psychiatry** 1997 Jan 15;41(2):230–3 (35 ref.)

Biological determinants of difficult to treat patients with schizophrenia. Sharma T, et al. **Br J Psychiatry Suppl** 1996 Dec;(31):5–9 (45 ref.)

Functional imaging--schizophrenia. Liddle PF. **Br Med Bull** 1996 Jul;52(3):486–94 (28 ref.)

The role of the thalamus in schizophrenia [see comments] Andreasen NC. **Can J Psychiatry** 1997 Feb;42(1):27–33 (48 ref.) Comment in: Can J Psychiatry 1997 Feb;42(1):19–20.

Neonatal insult to the hippocampal region and schizophrenia: a review and a putative animal model. Beauregard M, et al. **Can J Psychiatry** 1996 Sep;41(7):446–56 (145 ref.)

Cortical development and neuropathology in schizophrenia. Jones EG. **Ciba Found Symp** 1995;193:277–95 (75 ref.)

Schizophrenia: a disorder of neurodevelopment? Harrison PJ. **Curr Opin Neurobiol** 1997 Apr;7(2):285–9 (57 ref.)

Neurobiology of treatment-resistant schizophrenia: new insights and new models. Beerpoot LJ, et al. **Eur Neuropsychopharmacol** 1996;6 Suppl 2:S27–34 (117 ref.)

Two faces of cholecystokinin: anxiety and schizophrenia. Bourin M, et al. **Fundam Clin Pharmacol** 1996;10(2):116–26 (140 ref.)

Making sense of schizophrenia. Flaum M. **Hosp Pract (Off Ed)** 1996 Nov 15;31(11):51–2, 55–6, 59–60 passim (7 ref.)

Neurocircuitries and neurotransmitter interactions in schizophrenia. Carlsson A. **Int Clin Psychopharmacol** 1995 Sep;10 Suppl 3:21–8 (42 ref.)

Noise in models of neurological and psychiatric disorders. Spitzer M, et al. **Int J Neural Syst** 1996 Sep;7(4):355–61 (44 ref.)

The biological basis of schizophrenia: new directions. Weinberger DR. **J Clin Psychiatry** 1997;58 Suppl 10:22–7 (47 ref.)

Issues concerning relative speed of processing hypotheses, schizophrenic performance deficits, and prefrontal function: comment on Schooler et al. (1997) [comment] [see comments] Cohen JD, et al. **J Exp Psychol Gen** 1997 Mar;126(1):37–41 (21 ref.) Comment on: J Exp Psychol Gen 1997 Mar;126(1):19–36. Comment in: J Exp Psychol Gen 1997 Mar;126(1):42–4.

Stroop theory, memory, and prefrontal cortical functioning: reply to Cohen et al. (1997) [comment] Schooler C, et al. **J Exp Psychol Gen** 1997 Mar;126(1):42–4 (18 ref.) Comment on: J Exp Psychol Gen 1997 Mar;126(1):37–41.

The role of serotonin in the pathophysiology and treatment of schizophrenia. Abi-Dargham A, et al. **J Neuropsychiatry Clin Neurosci** 1997 Winter;9(1):1–17 (243 ref.)

The role of stress and dopamine-GABA interactions in the vulnerability for schizophrenia. Benes FM. **J Psychiatr Res** 1997 Mar–Apr;31(2):257–75 (105 ref.)

Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia. Busatto GF, et al. **J Psychopharmacol (Oxf)** 1997;11(1):3–12 (127 ref.)

Dopamine, the prefrontal cortex and schizophrenia. Knable MB, et al. **J Psychopharmacol (Oxf)** 1997;11(2):123–31 (180 ref.)

Functional neuroimaging of hallucinations in schizophrenia: toward an integration of bottom-up and top-down approaches. Silbersweig D, et al. **Mol Psychiatry** 1996 Nov; 1(5):367–75 (100 ref.)

Linking the family of D2 receptors to neuronal circuits in human brain: insights into schizophrenia. Joyce JN, et al. **Neuropsychopharmacology** 1997 Jun;16(6):375–84 (78 ref.)

The neurobiology of schizophrenia. Littrell RA, et al. **Pharmacotherapy** 1996 Nov-Dec;16(6 Pt 2):143S–147S; discussion 166S–168S (19 ref.)

A computational approach to prefrontal cortex, cognitive control and schizophrenia: recent developments and current challenges. Cohen JD, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Oct 29; 351(1346):1515–27 (80 ref.)

Prefrontal function in schizophrenia: confounds and controversies. Weinberger DR, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Oct 29; 351(1346):1495–503 (73 ref.)

Arousal and locomotion: from schizophrenia to narcolepsy. Garcia-Rill E, et al. **Prog Brain Res** 1996;107:417–34 (73 ref.)

The niacin challenge test in schizophrenia: past, present and future. Lin A, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Aug; 55(1–2):17–9 (15 ref.)

Gender, estrogen, and schizophrenia. Lindamer LA, et al. **Psychopharmacol Bull** 1997;33(2):221–8 (67 ref.)

Nicotinic receptor function in schizophrenia. Leonard S, et al. **Schizophr Bull** 1996;22(3):431–45 (101 ref.)

A cognitive neuroscience view of schizophrenic thought disorder. Spitzer M. **Schizophr Bull** 1997;23(1):29–50 (110 ref.)

Developmental insanity or dementia praecox: was the wrong concept adopted? O'Connell P, et al. **Schizophr Res** 1997 Feb 7;23(2):97–106 (108 ref.)

The impact of oestradiol on ages at onset in schizophrenia reevaluated through Klinefelter syndrome [letter] Pinabel F, et al. **Schizophr Res** 1997 Feb 28;23(3):269–70 (5 ref.)

Oxidative reactions and schizophrenia: a review-discussion. Smythies JR. **Schizophr Res** 1997 Apr 11;24(3):357–64 (88 ref.)

Developmental trajectory and disease progression in schizophrenia: the conundrum, and insights from a 12-year prospective study in the Monaghan 101. Waddington JL, et al. **Schizophr Res** 1997 Feb 7;23(2):107–18 (141 ref.)

Linking mind and brain in the study of mental illnesses: a project for a scientific psychopathology. Andreasen NC. **Science** 1997 Mar 14;275(5306):1586–93 (55 ref.)

Schizophrenia as failure of hemispheric dominance for language. Crow TJ. **Trends Neurosci** 1997 Aug; 20(8):339–43 (67 ref.)

[Schizophrenia and the corpus callosum: morphologic and functional approach] Antoni F, et al. **Encephale** 1996 Oct; 22 Spec No 3:33–8 (47 ref.) **(Fre)**

[Schizophrenia: receptors and clinical aspects] Azorin JM. **Encephale** 1997 Apr;23 Spec No 2:17–9 (9 ref.) (Eng. Abstr.) **(Fre)**

[Electrophysiologic studies] Bougerol T. **Encephale** 1996 Oct; 22 Spec No 3:13–7 (61 ref.) **(Fre)**

[Dopamine D2 and serotonin 5HT2 receptors: functions, interactions and clinical consequences in schizophrenia] Guise S, et al. **Encephale** 1997 Apr;23 Spec No 2:10–6 (20 ref.) (Eng. Abstr.) **(Fre)**

[Neurodevelopmental models of schizophrenia] Verdoux H. **Encephale** 1996 Oct;22 Spec No 3:85–90 (56 ref.) **(Fre)**

[Synaptogenesis and synaptic pruning: role in triggering schizophrenia] Granger B. **Presse Med** 1996 Nov 2; 25(33):1595–8 (25 ref.) (Eng. Abstr.) **(Fre)**

[Neuroimaging and fundamental symptoms in schizophrenia] Lopez-Ibor MI, et al.
Actas Luso Esp Neurol Psiquiatr Cienc Afines 1996 Jan–Feb;24(1):25–8 (30 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Monitoring and care of young people at incipient risk of psychosis. Yung AR, et al. **Schizophr Bull** 1996; 22(2):283–303 (83 ref.)

RADIONUCLIDE IMAGING

Cerebral blood flow activation and functional lesions in schizophrenia. Taylor SF. **Schizophr Res** 1996 May; 19(2–3):129–40 (42 ref.)

REHABILITATION

Predictors of functional outcome among adolescents and young adults with psychotic disorders. Henry AD, et al. **Am J Occup Ther** 1996 Mar;50(3):171–81 (97 ref.)

The varied outcomes of schizophrenia. Davidson L, et al. **Can J Psychiatry** 1997 Feb;42(1):34–43 (118 ref.)

Studies on relapse, course and outcome of schizophrenia in Japan. Utena H. **Psychiatry Clin Neurosci** 1996 Apr; 50(2):45–9 (45 ref.)

[Family group in schizophrenic diseases. Overview, personal concept and report of experiences] Pott W.
Psychiatr Prax 1996 Sep;23(5):219–25 (36 ref.) (Eng. Abstr.) **(Ger)**

[Positive role of family in coping with schizophrenic illness] Waldner P, et al. **Psychother Psychosom Med Psychol** 1996 Jul;46(7):276–81 (30 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Cognitive theory applied to the treatment of delusions of schizophrenia. Jensen LH, et al. **Arch Psychiatr Nurs** 1996 Dec;10(6):335–41 (23 ref.)

Advances in the treatment of schizophrenia. Kuperberg GR, et al. **Br J Clin Pract** 1996 Sep;50(6):315–23 (190 ref.)

The primary care of patients with schizophrenia: a search for good practice. Burns T, et al. **Br J Gen Pract** 1997 Aug;47(421):515–20 (92 ref.)

The management of difficult to treat patients with schizophrenia, using non-drug therapies. Kuipers E. **Br J Psychiatry Suppl** 1996 Dec;(31):41–51 (100 ref.)

Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. Awad AG, et al. **Int Clin Psychopharmacol** 1995 Sep;10 Suppl 3:123–32 (46 ref.)

Conclusions and treatment recommendations for the acute episode in schizophrenia. Gaebel W, et al.
Int Clin Psychopharmacol 1996 May;11 Suppl 2:93–100 (75 ref.)

Psycho-education and family treatment related to the phase of a psychotic disorder. Goldstein MJ.
Int Clin Psychopharmacol 1996 May;11 Suppl 2:77–83 (21 ref.)

Integration of family and drug treatment strategies in the treatment of schizophrenia: a selective review. Schooler NR. **Int Clin Psychopharmacol** 1995 Sep;10 Suppl 3:73–80 (31 ref.)

The role of the general practitioner in the treatment of schizophrenia: general principles. Carr VJ. **Med J Aust** 1997 Jan 20;166(2):91–4 (34 ref.)

The role of the general practitioner in the treatment of schizophrenia: specific issues [see comments] Carr VJ.
Med J Aust 1997 Feb 3;166(3):143–6 (25 ref.) Comment in: Med J Aust 1997 Feb 3;166(3):117–8.

Treatment of comorbid schizophrenia and substance abuse disorders. Hansell S. **New Dir Ment Health Serv** 1997 Spring;(73):65–73 (47 ref.)

Toward an integrated approach to the study of inpatient treatment of schizophrenia. Olfson M, et al.
New Dir Ment Health Serv 1997 Spring;(73):25–38 (43 ref.)

New directions in the prevention and treatment of schizophrenia: a biological perspective. Wyatt RJ, et al. **Psychiatry** 1996 Winter;59(4):357–70 (90 ref.)

Early detection and intervention with schizophrenia: rationale. McGlashan TH, et al. **Schizophr Bull** 1996; 22(2):201–22 (132 ref.)

Early detection and intervention in schizophrenia: research. McGlashan TH. **Schizophr Bull** 1996;22(2):327–45 (34 ref.)

Earlier detection and intervention in schizophrenia: unsolved questions. Vaglum P. **Schizophr Bull** 1996;22(2):347–51 (11 ref.)

[Results of cognitive psychotherapy in long-term treatment of schizophrenic patients] Chambon O, et al. **Encephale** 1996 Oct;22 Spec No 3:72–5; discussion 76 (23 ref.) **(Fre)**

[Role of behavioral and cognitive techniques in the treatment of schizophrenia] Azaïs F, et al. **Presse Med** 1997 Jul 12; 26(24):1157–61 (17 ref.) (Eng. Abstr.) **(Fre)**

[Psychoeducational family treatment in schizophrenia--a popular concept? A critical evaluation of different treatment models] Klimitz H. **Psychiatr Prax** 1997 May; 24(3):110–6 (71 ref.) (Eng. Abstr.) **(Ger)**

[Insight into the illness by schizophrenic patients: a psychoanalytic perspective] Rittmannsberger H.
Psychother Psychosom Med Psychol 1996 Jul;46(7):269–75 (55 ref.) (Eng. Abstr.) **(Ger)**

SCHIZOPHRENIA, BORDERLINE see **SCHIZOTYPAL PERSONALITY DISORDER**

SCHIZOPHRENIA, DISORGANIZED

DIAGNOSIS

[Organization and representation of action in schizophrenia] Georgieff N. **Encephale** 1996 Oct;22 Spec No 3:108–15 (46 ref.) **(Fre)**

DRUG THERAPY

[Chorea-like motor restlessness in clozapine] Garcí a C, et al. **Fortschr Neurol Psychiatr** 1996 Oct;64(10):418–21 (26 ref.) (Eng. Abstr.) **(Ger)**

SCHIZOPHRENIA, HEBEPHRENIC see **SCHIZOPHRENIA, DISORGANIZED**

SCHIZOPHRENIA, LATENT see **SCHIZOTYPAL PERSONALITY DISORDER**

SCHIZOPHRENIA, PSEUDONEUROTIC see **SCHIZOTYPAL PERSONALITY DISORDER**

SCHIZOPHRENIC DISORDERS see **SCHIZOPHRENIA**

SCHIZOPHRENIC PSYCHOLOGY

A critical review of genetic studies of schizophrenia. I. Epidemiological and brain studies. Portin P, et al.
Acta Psychiatr Scand 1997 Jan;95(1):1–5 (55 ref.)

A critical review of genetic studies of schizophrenia. II. Molecular genetic studies. Portin P, et al.
Acta Psychiatr Scand 1997 Feb;95(2):73–80 (128 ref.)

Affiliation and neuropsychiatric disorders: the deficit syndrome of schizophrenia. Kirkpatrick B.
Ann N Y Acad Sci 1997 Jan 15;807:455–68 (69 ref.)

Women and schizophrenia: a review. Kulkarni J.
Aust N Z J Psychiatry 1997 Feb;31(1):46–56 (106 ref.)

Drug strategies and treatment-resistant schizophrenia. Pantelis C, et al. **Aust N Z J Psychiatry** 1996 Feb; 30(1):20–37 (184 ref.)

Schizophrenia. A cognitive model and its implications for psychological intervention. Hemsley DR. **Behav Modif** 1996 Apr;20(2):139–69 (126 ref.)

Limitations of controlled augmentation trials in schizophrenia. Stern RG, et al. **Biol Psychiatry** 1997 Jul 15;42(2):138–43 (28 ref.)

Schizophrenia, violence, clozapine and risperidone: a review. The Special Hospitals Treatment Resistant Schizophrenia Research Group. **Br J Psychiatry Suppl** 1996 Dec; (31):21–30 (60 ref.)

Management of treatment resistant schizophrenia unresponsive to clozapine. Barnes TR, et al.
Br J Psychiatry Suppl 1996 Dec;(31):31–40 (65 ref.)

Factors which can make patients difficult to treat. Kane JM.
Br J Psychiatry Suppl 1996 Dec;(31):10–4 (28 ref.)

The management of difficult to treat patients with schizophrenia, using non-drug therapies. Kuipers E.
Br J Psychiatry Suppl 1996 Dec;(31):41–51 (100 ref.)

Management of treatment refractory schizophrenia. Morrison DP. **Br J Psychiatry Suppl** 1996 Dec;(31):15–20 (40 ref.)

Biological determinants of difficult to treat patients with schizophrenia. Sharma T, et al. **Br J Psychiatry Suppl** 1996 Dec;(31):5–9 (45 ref.)

Neuropsychology of schizophrenia, what are the implications of intellectual and experiential abnormalities for the neurobiology of schizophrenia? Frith C. **Br Med Bull** 1996 Jul;52(3):618–26 (28 ref.)

The role of the thalamus in schizophrenia [see comments] Andreasen NC. **Can J Psychiatry** 1997 Feb;42(1):27–33 (48 ref.) Comment in: Can J Psychiatry 1997 Feb;42(1):19–20.

Neurocognitive impairment in schizophrenia and how it affects treatment options [see comments] Bilder RM.
Can J Psychiatry 1997 Apr;42(3):255–64 (58 ref.) Comment in: Can J Psychiatry 1997 Apr;42(3):247–8.

Use of cytokines in clozapine-induced agranulocytosis [see comments] Chin-Yee I, et al. **Can J Psychiatry** 1996 Jun; 41(5):280–4 (42 ref.) Comment in: Can J Psychiatry 1996 Nov;41(9):603.

The varied outcomes of schizophrenia. Davidson L, et al. **Can J Psychiatry** 1997 Feb;42(1):34–43 (118 ref.)

Epidemiology of schizophrenia [see comments] Häfner H, et al. **Can J Psychiatry** 1997 Mar;42(2):139–51 (142 ref.) Comment in: Can J Psychiatry 1997 Mar;42(2):131–2.

The heterogeneity of memory dysfunction in schizophrenia. Stip E, et al. **Can J Psychiatry** 1996 Sep;41(7 Suppl 1):S14–20 (33 ref.)

Memory impairment in schizophrenia: perspectives from psychopathology and pharmacotherapy. Stip E.
Can J Psychiatry 1996 Oct;41(8 Suppl 2):S27–34 (67 ref.)

The promise of new drugs for schizophrenia treatment [see comments] Tamminga CA. **Can J Psychiatry** 1997 Apr; 42(3):265–73 (76 ref.) Comment in: Can J Psychiatry 1997 Apr;42(3):247–8.

Understanding cross-cultural prognostic variability for schizophrenia. Weisman AG. **Cult Divers Ment Health** 1997;3(1):23–35 (80 ref.)

Improvement of negative symptoms: Concepts, definition and assessment. Andreasen NC. **Int Clin Psychopharmacol** 1997 May;12 Suppl 2:S7–10 (17 ref.)

Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome. Awad AG, et al. **Int Clin Psychopharmacol** 1996 May;11 Suppl 2:55–9 (28 ref.)

The cognitive abnormalities underlying the symptomatology and the disability of patients with schizophrenia. Frith CD. **Int Clin Psychopharmacol** 1995 Sep;10 Suppl 3:87–98 (57 ref.)

What are the therapeutic needs in schizophrenia and how are they satisfied by new antipsychotics? Kane JM.
Int Clin Psychopharmacol 1997 May;12 Suppl 2:S3–6 (28 ref.)

The psychopathology of schizophrenia: an integrated view on positive symptoms and negative symptoms. Möller HJ. **Int Clin Psychopharmacol** 1995 Sep;10 Suppl 3:57–64 (47 ref.)

Clinical update on amisulpride in deficit schizophrenia. Rein W, et al. **Int Clin Psychopharmacol** 1997 May;12 Suppl 2:S19–27 (27 ref.)

Violence of psychotic patients: how much responsibility can be attributed? Nedopil N. **Int J Law Psychiatry** 1997 Spring;20(2):243–7 (15 ref.)

Cognitive function in schizophrenic patients. Tollefson GD. **J Clin Psychiatry** 1996;57 Suppl 11:31–9 (62 ref.)

Affective reactivity of symptoms as a process discriminator in schizophrenia. Docherty NM. **J Nerv Ment Dis** 1996 Sep;184(9):535–41 (46 ref.)

Abnormal cholecystokinin mRNA levels in entorhinal cortex of schizophrenics. Bachus SE, et al. **J Psychiatr Res** 1997 Mar-Apr;31(2):233–56 (170 ref.)

The role of stress and dopamine-GABA interactions in the vulnerability for schizophrenia. Benes FM.
J Psychiatr Res 1997 Mar-Apr;31(2):257–75 (105 ref.)

Review the role of dopamine D4 receptors in schizophrenia and antipsychotic action. Sanyal S, et al.
J Psychiatr Res 1997 Mar-Apr;31(2):219–32 (85 ref.)

Memory deficits in schizophrenia: inadequate assimilation or true amnesia? Findings from the Wechsler Memory Scale--revised. Hawkins KA, et al.
J Psychiatry Neurosci 1997 May;22(3):169–79 (24 ref.)

Familial and developmental abnormalities of front lobe function and neurochemistry in schizophrenia. Deakin FW, et al. **J Psychopharmacol (Oxf)** 1997;11(2):133–42 (110 ref.)

Olanzapine: a new atypical antipsychotic. Littrell K, et al. **J Psychosoc Nurs Ment Health Serv** 1996 Aug;34(8):41–6 (16 ref.)

Symptom dimensions of schizophrenia: a selective integration of neurophysiological and neuropsychological correlates. Aderibigbe YA, et al. **Neuropsychobiology** 1996; 34(4):192–200 (89 ref.)

A pivotal role for glutamate in the pathogenesis of schizophrenia, and its cognitive dysfunction. Hirsch SR, et al. **Pharmacol Biochem Behav** 1997 Apr;56(4):797–802 (51 ref.)

Cognitive function in schizophrenia--do neuroleptics make a difference? Mortimer AM. **Pharmacol Biochem Behav** 1997 Apr;56(4):789–95 (74 ref.)

On the trail of the genetics and pathophysiology of schizophrenia. Holzman PS. **Psychiatry** 1996 Summer; 59(2):117–27 (50 ref.)

Early identification and treatment of schizophrenia: conceptual and ethical considerations. Larsen TK, et al. **Psychiatry** 1996 Winter;59(4):371–80 (65 ref.)

New directions in the prevention and treatment of schizophrenia: a biological perspective. Wyatt RJ, et al. **Psychiatry** 1996 Winter;59(4):357–70 (90 ref.)

Social cognition in schizophrenia. Penn DL, et al.
Psychol Bull 1997 Jan;121(1):114–32 (285 ref.)

The risk of medication-free research. Carpenter WT Jr.
Schizophr Bull 1997;23(1):11–8 (84 ref.)

Perseveration in schizophrenia. Crider A. **Schizophr Bull** 1997;23(1):63–74 (100 ref.)

Risperidone: how good is the evidence for efficacy? Mattes JA. **Schizophr Bull** 1997;23(1):155–61 (36 ref.)

A cognitive neuroscience view of schizophrenic thought disorder. Spitzer M. **Schizophr Bull** 1997;23(1):29–50 (110 ref.)

Placebo washout in trials of antipsychotic drugs. Volavka J, et al. **Schizophr Bull** 1996;22(4):567–76 (40 ref.)

Research in schizophrenia and the discontinuation of antipsychotic medications. Wyatt RJ. **Schizophr Bull** 1997; 23(1):3–9 (40 ref.)

Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literature. Dalack GW, et al. **Schizophr Res** 1996 Nov 15;22(2):133–41 (45 ref.)

SCHIZOPHRENIC PSYCHOLOGY

Lack of gender differences in neuroleptic response in patients with schizophrenia. Pinals DA, et al. **Schizophr Res** 1996 Dec 15;22(3):215–22 (38 ref.)

Cerebral blood flow activation and functional lesions in schizophrenia. Taylor SF. **Schizophr Res** 1996 May; 19(2–3):129–40 (42 ref.)

Time course of cerebral ventricular enlargement in schizophrenia supports the hypothesis of its neurodevelopmental nature. Vita A, et al. **Schizophr Res** 1997 Jan 17;23(1):25–30 (32 ref.)

[Schizophrenia and the corpus callosum: morphologic and functional approach] Antoni F, et al. **Encephale** 1996 Oct; 22 Spec No 3:33–8 (47 ref.) **(Fre)**

[Schizophrenia: receptors and clinical aspects] Azorin JM. **Encephale** 1997 Apr;23 Spec No 2:17–9 (9 ref.) (Eng. Abstr.) **(Fre)**

[Attention models in evaluating schizophrenia] Bernard D, et al. **Encephale** 1997 Mar–Apr;23(2):113–8 (38 ref.) (Eng. Abstr.) **(Fre)**

[Syndromic and diagnostic heterogeneity of schizophrenia] Brazo P, et al. **Encephale** 1997 Apr;23 Spec No 2:20–4 (30 ref.) (Eng. Abstr.) **(Fre)**

[Results of cognitive psychotherapy in long–term treatment of schizophrenic patients] Chambon O, et al. **Encephale** 1996 Oct;22 Spec No 3:72–5; discussion 76 (23 ref.) **(Fre)**

[Risk factors and schizophrenia] d'Amato T, et al. **Encephale** 1996 Oct;22 Spec No 3:3–7; discussion 8 (26 ref.) **(Fre)**

[Chronic hallucinatory psychosis and late onset schizophrenia: the same entity?] Dubertret C, et al. **Encephale** 1997 May–Jun;23(3):157–67 (38 ref.) (Eng. Abstr.) **(Fre)**

[Schizophrenia and exclusion. Current and future perspectives] Furtos J, et al. **Encephale** 1996 Oct;22 Spec No 3:39–48 (50 ref.) **(Fre)**

[Organization and representation of action in schizophrenia] Georgieff N. **Encephale** 1996 Oct;22 Spec No 3:108–15 (46 ref.) **(Fre)**

[The PANSS (Positive And Negative Symptom) Scale] Guelfi JD. **Encephale** 1997 Apr;23 Spec No 2:35–8 (19 ref.) (Eng. Abstr.) **(Fre)**

[Dopamine D2 and serotonin 5HT2 receptors: functions, interactions and clinical consequences in schizophrenia] Guise S, et al. **Encephale** 1997 Apr;23 Spec No 2:10–6 (20 ref.) (Eng. Abstr.) **(Fre)**

[Intentional awareness and schizophrenia] Hardy–Baylé MC, et al. **Encephale** 1996 Oct;22 Spec No 3:104–7 (12 ref.) **(Fre)**

[A new study of secondary effects in prescribing practices of neuroleptics] Lachaux B, et al. **Encephale** 1997 Apr;23 Spec No 2:25–34 (56 ref.) (Eng. Abstr.) **(Fre)**

[Schizophrenia, from classification to dimensions: value of longitudinal studies] Lecrubier Y. **Encephale** 1997 Apr;23 Spec No 2:39–43 (61 ref.) (Eng. Abstr.) **(Fre)**

[New chemotherapy approaches to psychoses] Olié JP, et al. **Encephale** 1997 Apr;23 Spec No 2:2–9 (53 ref.) (Eng. Abstr.) **(Fre)**

[New drug therapies] Olié JP, et al. **Encephale** 1996 Oct;22 Spec No 3:63–71; discussion 76 (33 ref.) **(Fre)**

[Schizophrenia and neural transmission: an excess of analogical treatment?] Tassin JP. **Encephale** 1996 Oct;22 Spec No 3:91–8 (55 ref.) **(Fre)**

[Voluntary mercury poisoning: biological consequences and psychiatric significance (published erratum appears in Schweiz Rundsch Med Prax 1997 Jul 2;86(27–28):1123)] Jornod P, et al. **Schweiz Rundsch Med Prax** 1997 May 28; 86(22):946–51 (51 ref.) (Eng. Abstr.) **(Fre)**

[Memory disturbances in schizophrenia] Brand A, et al. **Fortschr Neurol Psychiatr** 1996 Feb;64(2):49–65 (132 ref.) (Eng. Abstr.) **(Ger)**

[Significance of primary negative symptoms in schizophrenic and other psychiatric patients] Gerbaldo H, et al. **Fortschr Neurol Psychiatr** 1996 Jun;64(6):221–7 (50 ref.) (Eng. Abstr.) **(Ger)**

[Disturbances of body experience in schizophrenic patients] Röhricht F, et al. **Fortschr Neurol Psychiatr** 1997 Jul; 65(7):323–36 (124 ref.) (Eng. Abstr.) **(Ger)**

[Structural affinities of the incomprehensible in schizophrenic delusion] Feldmann H, et al. **Nervenarzt** 1997 Mar; 68(3):226–30 (31 ref.) (Eng. Abstr.) **(Ger)**

[50 years after Manfred Bleuler. What do we know today about late–onset schizophrenia(s)?] Riecher–Rössler A. **Nervenarzt** 1997 Mar;68(3):159–70 (86 ref.) (Eng. Abstr.) **(Ger)**

[Psychoeducational family treatment in schizophrenia—a popular concept? A critical evaluation of different treatment models] Klimitz H. **Psychiatr Prax** 1997 May; 24(3):110–6 (71 ref.) (Eng. Abstr.) **(Ger)**

[Family group in schizophrenic diseases. Overview, personal concept and report of experiences] Pott W. **Psychiatr Prax** 1996 Sep;23(5):219–25 (36 ref.) (Eng. Abstr.) **(Ger)**

[Insight into the illness by schizophrenic patients: a psychoanalytic perspective] Rittmannsberger H. **Psychother Psychosom Med Psychol** 1996 Jul;46(7):269–75 (55 ref.) (Eng. Abstr.) **(Ger)**

[Positive role of family in coping with schizophrenic illness] Waldner P, et al. **Psychother Psychosom Med Psychol** 1996 Jul;46(7):276–81 (30 ref.) (Eng. Abstr.) **(Ger)**

SCHIZOPHRENIFORM DISORDERS see **PSYCHOTIC DISORDERS**

SCHIZOPHYLLUM

PATHOGENICITY

Brain abscess caused by Schizophyllum commune: an emerging basidiomycete pathogen. Rihs JD, et al. **J Clin Microbiol** 1996 Jul;34(7):1628–32 (13 ref.)

SCHIZOSACCHAROMYCES

The Josef Steiner Lecture: CDKs and cell–cycle control in fission yeast: relevance to other eukaryotes and cancer. Nurse P. **Int J Cancer** 1997 May 29;71(5):707–8 (21 ref.)

CHEMISTRY

M–factor, a farnesylated mating factor from the fission yeast Schizosaccharomyces pombe. Davey J. **Biochem Soc Trans** 1996 Aug;24(3):718–23 (48 ref.)

CYTOLOGY

Cdc6 and DNA replication: limited to humble origins. Heichman KA. **Bioessays** 1996 Nov;18(11):859–62 (27 ref.)

Microtubule function in morphological differentiation: growth zones and growth cones. Vega LR, et al. **Cell** 1997 Jun 13;89(6):825–8 (14 ref.)

S–phase and DNA–damage checkpoints: a tale of two yeasts. Stewart E, et al. **Curr Opin Cell Biol** 1996 Dec;8(6):781–7 (64 ref.)

GENETICS

Identification and phylogenetic classification of eleven putative P–type calcium transport ATPase genes in the yeasts Saccharomyces cerevisiae and Schizosaccharomyces pombe. Catty P, et al. **Biosci Rep** 1996 Apr;16(2):75–85 (58 ref.)

Cell cycle control of S phase: a comparison of two yeasts. Huberman JA. **Chromosoma** 1996 Oct;105(4):197–203 (40 ref.)

Genotoxicity testing in Schizosaccharomyces pombe. McAthey P. **Methods Mol Biol** 1996;53:343–53 (3 ref.)

At the heart of the budding yeast cell cycle. Nasmyth K. **Trends Genet** 1996 Oct;12(10):405–12 (68 ref.)

Review: the Cct eukaryotic chaperonin subunits of Saccharomyces cerevisiae and other yeasts. Stoldt V, et al. **Yeast** 1996 May;12(6):523–9 (36 ref.)

METABOLISM

[A mechanism of mRNA transport in fission yeast: nucleolar involvement and heat shock inhibition in mRNA transport] Tani T. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1193–200 (23 ref.) **(Jpn)**

PHYSIOLOGY

Microtubule function in morphological differentiation: growth zones and growth cones. Vega LR, et al. **Cell** 1997 Jun 13;89(6):825–8 (14 ref.)

Regulation of meiosis in fission yeast. Yamamoto M. **Cell Struct Funct** 1996 Oct;21(5):431–6 (43 ref.)

SCHIZOTYPAL PERSONALITY DISORDER

DIAGNOSIS

Early identification and treatment of schizophrenia: conceptual and ethical considerations. Larsen TK, et al. **Psychiatry** 1996 Winter;59(4):371–80 (65 ref.)

[Disorders of early information processing and vigilance as vulnerability markers for schizophrenia] Suslow T, et al. **Fortschr Neurol Psychiatr** 1996 Mar;64(3):90–104 (81 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Epidemiology of schizophrenia [see comments] Häfner H, et al. **Can J Psychiatry** 1997 Mar;42(2):139–51 (142 ref.) Comment in: Can J Psychiatry 1997 Mar;42(2):131–2.

Familial risks and reproductive fitness in schizophrenia. Battaglia M, et al. **Schizophr Bull** 1996;22(2):191–5 (23 ref.)

GENETICS

Schizotypal disorder: at the crossroads of genetics and nosology. Battaglia M, et al. **Acta Psychiatr Scand** 1996 Nov;94(5):303–10 (94 ref.)

Familial risks and reproductive fitness in schizophrenia. Battaglia M, et al. **Schizophr Bull** 1996;22(2):191–5 (23 ref.)

SCHMIDT'S SYNDROME see **POLYENDOCRINOPATHIES, AUTOIMMUNE**

SCHOENLEIN–HENOCH PURPURA see **PURPURA, SCHOENLEIN–HENOCH**

SCHOLARSHIPS see **FELLOWSHIPS AND SCHOLARSHIPS**

SCHOOL ADMISSION CRITERIA

Modifying the culture of medical education: the first three years of the RWJ Generalist Physician Initiative. Colwill JM, et al. **Acad Med** 1997 Sep;72(9):745–53 (34 ref.)

How useful is selection? Kappelle W. **Int J Psychoanal** 1996 Dec;77 (Pt 6):1213–32 (34 ref.)

SCHOOL HEALTH SERVICES

School–based health services. Ryan S, et al. **Curr Opin Pediatr** 1996 Oct;8(5):453–8 (30 ref.)

Guidelines for school health programs to promote lifelong healthy eating. **J Sch Health** 1997 Jan;67(1):9–26 (229 ref.)

A review of the evaluation of 47 drug abuse prevention curricula available nationally. Dusenbury L, et al. **J Sch Health** 1997 Apr;67(4):127–32 (38 ref.)

Latino families: partners for success in school settings. Pérez MA, et al. **J Sch Health** 1997 May;67(5):182–4 (19 ref.)

Working with education reporters to advocate for comprehensive school health education. Sofalvi AJ, et al. **J Sch Health** 1997 May;67(5):185–6 (19 ref.)

School–based care: clinical challenges and research opportunities. Walker PH, et al. **J Soc Pediatr Nurs** 1996 Jul–Sep;1(2):64–74 (26 ref.)

ORGANIZATION & ADMINISTRATION

School–based health clinics: remaining viable in a changing health care delivery system. Brindis CD, et al. **Annu Rev Public Health** 1997;18:567–87 (26 ref.)

Reducing the harm of adolescent substance use [editorial; comment] Erickson PG. **Can Med Assoc J** 1997 May 15; 156(10):1397–9 (15 ref.) Comment on: Can Med Assoc J 1997 May 15;156(10):1387–93.

School–based health promotion: the physician as advocate. Mackie JW, et al. **Can Med Assoc J** 1997 May 1; 156(9):1301–5 (36 ref.)

Teenage pregnancy prevention programs. Pierre N, et al. **Curr Opin Pediatr** 1997 Aug;9(4):310–6 (23 ref.)

Initiating health programmes in schools and communities. **Int Nurs Rev** 1997 May–Jun;44(3):76–8 (8 ref.)

School health centers and primary care for adolescents: a review of the literature. Santelli J, et al. **J Adolesc Health** 1996 May;18(5):357–66 (56 ref.)

Curricula, competition and conventional bonds: the educational role in drug control. Norland S, et al. **J Drug Educ** 1996;26(3):231–42 (28 ref.)

Guidelines for school and community programs to promote lifelong physical activity among young people. National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and prevention. **J Sch Health** 1997 Aug;67(6):202–19 (276 ref.)

School–based programs for preventing eating disturbances. Neumark–Sztainer D. **J Sch Health** 1996 Feb;66(2):64–71 (55 ref.)

Conducting a comprehensive school health program. Resnicow K, et al. **J Sch Health** 1996 Feb;66(2):59–63 (19 ref.)

Bridging student health risks and academic achievement through comprehensive school health programs. Symons CW, et al. **J Sch Health** 1997 Aug;67(6):220–7 (73 ref.)

[Sensitivity training for debriefing in the school context] Leuenberger JF. **Rev Med Suisse Romande** 1997 May; 117(5):413–8 (0 ref.) **(Fre)**

STANDARDS

A systematic overview of adolescent suicide prevention programs. Ploeg J, et al. **Can J Public Health** 1996 Sep–Oct; 87(5):319–24 (33 ref.)

TRENDS

School–based mental health services in the United States: history, current models and needs. Flaherty LT, et al. **Community Ment Health J** 1996 Aug;32(4):341–52 (27 ref.)

SCHOOL NURSING

Initiating health programmes in schools and communities. **Int Nurs Rev** 1997 May–Jun;44(3):76–8 (8 ref.)

Indoor air pollutants and sick building syndrome: a case study and implications for the community health nurse. Tsacoyianis R. **Public Health Nurs** 1997 Feb;14(1):58–75 (19 ref.)

ORGANIZATION & ADMINISTRATION

High touch meets high tech. Distance mental health screening for rural youth using Teleform. Puskar KR, et al. **Comput Nurs** 1996 Nov–Dec;14(6):323–9; quiz 330–2 (31 ref.)

SCHOOLS

School injuries in an occupational health perspective: what do we learn from community based epidemiological studies? Laflamme L, et al. **Inj Prev** 1997 Mar;3(1):50–6 (30 ref.)

Cognitive function and academic performance in neurofibromatosis. 1: consensus statement from the NF1 Cognitive Disorders Task Force. North KN, et al. **Neurology** 1997 Apr;48(4):1121–7 (57 ref.)

Visual predictors of reading performance in kindergarten and

first grade children. Kulp MT, et al. **Optom Vis Sci** 1996 Apr;73(4):255–62 (99 ref.)
Indoor air pollutants and sick building syndrome: a case study and implications for the community health nurse. Tsacoyianis R. **Public Health Nurs** 1997 Feb;14(1):58–75 (19 ref.)
Treatment of attention deficit hyperactivity disorder: a multi-modal model for schools. Maag JW, et al. **Semin Speech Lang** 1996 Feb;17(1):37–58 (72 ref.)
[Violence in the school—analysis of the problem and possible interventions] Meier U. **Prax Kinderpsychol Kinderpsychiatr** 1997 Mar;46(3):169–81 (31 ref.) (Eng. Abstr.) **(Ger)**
[Tuberculosis outbreak at a public school] Navarro Gracia JF, et al. **Rev Clin Esp** 1997 Mar;197(3):152–7 (59 ref.) (Eng. Abstr.) **(Spa)**

SCHOOLS, MEDICAL

[A need for undergraduate education for laboratory medicine in medical schools] Yamanaka M. **Rinsho Byori** 1996 Aug; 44(8):709–14 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Psychological and moral aspects of physician's training at the phthisiopulmonological clinic of medical university] Khudzik LB, et al. **Probl Tuberk** 1997;(2):58–9 (0 ref.) **(Rus)**

ORGANIZATION & ADMINISTRATION

The meaning and application of medical accreditation standards. Kassebaum DG, et al. **Acad Med** 1997 Sep; 72(9):808–18 (11 ref.)
[Experience with integration of research institutes if the Russian Academy of Medical Sciences with the departments if higher educational establishments of the IM Sechenov is an effective type of teaching and research intensification] Paltsev MA, et al. **Vestn Ross Akad Med Nauk** 1997;(3):54–8 (0 ref.) **(Rus)**

TRENDS

[Surgical school—an anachronism?] Borst HG. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:723–6 (11 ref.) **(Ger)**

SCHOOLS, NURSERY

see related
CHILD DAY CARE CENTERS

SCHOOLS, NURSING

LEGISLATION & JURISPRUDENCE

An issue of conflicting rights: nursing student charged with drug trafficking. Cullen P, et al. **J Prof Nurs** 1997 May–Jun; 13(3):186–92 (23 ref.)

SCHOOLS, PUBLIC HEALTH

[The Masters of Public Health in Cuba. An experience in advanced health education] Rojo Pérez N, et al. **Educ Med Salud** 1995 Jul–Dec;29(3–4):321–30 (11 ref.) **(Spa)**

ORGANIZATION & ADMINISTRATION

The Dutch experience with regard to the training for public health. Doeleman F. **Public Health** 1997 May;111(3):125–7 (0 ref.)

SCHWALBE'S NUCLEUS see **VESTIBULAR NUCLEI**

SCHWANN CELLS

CYTOLOGY

Dynamic roles at the neuromuscular junction. Schwann cells. Balice-Gordon RJ. **Curr Biol** 1996 Sep 1;6(9):1054–6 (11 ref.)
Schwann cell differentiation. Zorick TS, et al. **Curr Opin Cell Biol** 1996 Dec;8(6):870–6 (53 ref.)
Embryonic development of Schwann cells: multiple roles for neuregulins along the pathway. Topilko P, et al. **Mol Cell Neurosci** 1996;8(2–3):71–5 (46 ref.)
Making of a Schwann. Kioussi C, et al. **Trends Genet** 1996 Mar;12(3):84–6 (22 ref.)

DRUG EFFECTS

Schwann cells as targets for neurotoxicants. Morell P, et al. **Neurotoxicology** 1996 Fall–Winter;17(3–4):685–95 (42 ref.)

METABOLISM

Receptor-mediated phosphoinositide metabolism in peripheral nerve and cultured Schwann cells. Eichberg J, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):187–95 (26 ref.)

PHYSIOLOGY

Schwann cell development, differentiation and myelination. Mirsky R, et al. **Curr Opin Neurobiol** 1996 Feb;6(1):89–96 (70 ref.)
Schwann cell invasion of the central nervous system of the myelin mutants. Duncan ID, et al. **J Anat** 1997 Jan;190 (Pt 1):35–49 (58 ref.)
Molecular biology of axon–glia interactions in the peripheral nervous system. Taylor V, et al. **Prog Nucleic Acid Res Mol Biol** 1997;56:225–56 (221 ref.)
Schwann cells induce and guide sprouting and reinnervation of neuromuscular junctions. Son YJ, et al. **Trends Neurosci** 1996 Jul;19(7):280–5 (40 ref.)

TRANSPLANTATION

Schwann cell transplantation and myelin repair of the CNS. Baron-Van Evercooren A, et al. **Mult Scler** 1997 Apr; 3(2):157–61 (50 ref.)

SCHWANNOMA see **NEURILEMMOMA**

SCHWANNOMA, ACOUSTIC see **NEUROMA, ACOUSTIC**

SCHWANNOMA, ACOUSTIC, BILATERAL see **NEUROFIBROMATOSIS 2**

SCHWARTZ–BARTTER SYNDROME see **INAPPROPRIATE ADH SYNDROME**

SCHWARTZ–JAMPEL SYNDROME see **OSTEOCHONDRODYSPLASIAS**

SCIATIC NERVE

see related
SCIATICA

The piriformis syndrome [see comments] Parziale JR, et al. **Am J Orthop** 1996 Dec;25(12):819–23 (33 ref.) Comment in: Am J Orthop 1997 May;26(5):316, 318.
Neuropathy secondary to pigmented villonodular synovitis of the hip. Aboulafia AJ, et al. **Clin Orthop** 1996 Apr; (325):174–80 (19 ref.)

ABNORMALITIES

A case of popliteal pterygium treated along with nerve expansion. Maral T, et al. **Plast Reconstr Surg** 1997 Jul; 100(1):91–5 (15 ref.)

INJURIES

Sciatic nerve palsy following childbirth [see comments] Silva M, et al. **Anaesthesia** 1996 Dec;51(12):1144–8 (53 ref.) Comment in: Anaesthesia 1997 Jun;52(6):605–6.
Exercise training improves functional recovery and motor nerve conduction velocity after sciatic nerve crush lesion in the rat. van Meeteren NL, et al. **Arch Phys Med Rehabil** 1997 Jan;78(1):70–7 (39 ref.)
The pathogenesis of non-freezing cold nerve injury. Observations in the rat. Jia J, et al. **Brain** 1997 Apr;120 (Pt 4):631–46 (121 ref.)
Irreducible open intertrochanteric hip fracture secondary to entrapment of the sciatic nerve in a child. Wiss DA, et al. **J Orthop Trauma** 1997 Jan;11(1):38–40 (10 ref.)
Extensive cortical reorganization following sciatic nerve injury in adult rats versus restricted reorganization after neonatal injury: implications for spatial and temporal limits on somatosensory plasticity. Cusick CG. **Prog Brain Res** 1996;108:379–90 (75 ref.)

PATHOLOGY

Inflammatory pseudotumor of nerve. Weiland TL, et al. **Am J Surg Pathol** 1996 Oct;20(10):1212–8 (17 ref.)

PHYSIOLOGY

Exercise training improves functional recovery and motor nerve conduction velocity after sciatic nerve crush lesion in the rat. van Meeteren NL, et al. **Arch Phys Med Rehabil** 1997 Jan;78(1):70–7 (39 ref.)
Ciliary neurotrophic factor as a motor neuron trophic factor. Kuzis K, et al. **Perspect Dev Neurobiol** 1996;4(1):65–74 (89 ref.)

SURGERY

Primary non-Hodgkin's lymphoma of the sciatic nerve followed by localization in the central nervous system: case report and review of the literature. Roncaroli F, et al. **Neurosurgery** 1997 Mar;40(3):618–21; discussion 621–2 (11 ref.)

SCIATICA

Where does the pain come from? Rydevik BL. **Bull Hosp Jt Dis** 1996;55(4):191–4 (22 ref.)

DIAGNOSIS

Sciatic pain and piriformis syndrome. Douglas S. **Nurse Pract** 1997 May;22(5):166–8, 170, 172 passim (18 ref.)
Truncated sciatica as the first manifestation of a fatigue fracture of the sacrum in a young male [letter] Lechevalier D, et al. **Rev Rhum Engl Ed** 1996 Jul–Sep;63(7–8):505 (11 ref.)

DRUG THERAPY

[Epidural glucocorticoid injection in lumbago sciatica] Ringsdal VS, et al. **Ugeskr Laeger** 1997 Sep 15; 159(38):5653–7 (40 ref.) (Eng. Abstr.) **(Dan)**

ETIOLOGY

The piriformis syndrome [see comments] Parziale JR, et al. **Am J Orthop** 1996 Dec;25(12):819–23 (33 ref.) Comment in: Am J Orthop 1997 May;26(5):316, 318.
Large osteoarthritic bone cyst of the facet joint causing low back pain and sciatica. Shirado O, et al. **Orthopedics** 1997 May;20(5):472–5 (13 ref.)
[Differential sciatica pain diagnosis from the neurologic viewpoint] Lindner A, et al. **Med Klin** 1997 Jun 15; 92(6):335–43 (83 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Minimally invasive disc surgery. Nucleotomy versus fragmentectomy. Onik GM, et al. **Spine** 1997 Apr 1; 22(7):827–8; discussion 828–30 (6 ref.)

THERAPY

The disc at risk in athletes: perspectives on operative and nonoperative care. Young JL, et al. **Med Sci Sports Exerc** 1997 Jul;29(7 Suppl):S222–32 (74 ref.)

SCID see **SEVERE COMBINED IMMUNODEFICIENCY**

SCID-HU MICE see **MICE, SCID**

SCID MICE see **MICE, SCID**

SCIENCE

see related
RELIGION AND SCIENCE

Is there a need to change the American diet? Dwyer J. **Adv Exp Med Biol** 1996;401:189–98 (48 ref.)
Questioning science: how knowledge is socially constructed. Thorogood N. **Br Dent J** 1997 Sep 13;183(5):152–5 (38 ref.)
Scientific knowledge in medicine: a new clinical epistemology? Marshall T. **J Eval Clin Pract** 1997 Apr; 3(2):133–8 (16 ref.)
A Popperian perspective of the term 'evidence-based medicine'. Shahar E. **J Eval Clin Pract** 1997 Apr; 3(2):109–16 (31 ref.)
The magic of science and the science of magic: an essay on the process of healing. Coe RM. **J Health Soc Behav** 1997 Mar;38(1):1–8 (47 ref.)
A pragmatic primer ... lessons from natural science for the profession of dentistry. Nash DA. **J Public Health Dent** 1996;56(5 Spec No):291–300 (25 ref.)
Reconfiguring nature and culture: intersections of medical anthropology and technoscience studies. Casper MJ, et al. **Med Anthropol Q** 1996 Dec;10(4):523–36 (64 ref.)
The scope of gene therapy in humans: scientific, safety and ethical considerations. Karpati G, et al. **Neuromuscul Disord** 1997 Jul;7(5):273–6 (30 ref.)
[Axioms of systematic progress in medicine] Bauer AW. **Internist (Berl)** 1997 Apr;38(4):299–306 (42 ref.) **(Ger)**

EDUCATION

Philosophy of science and physiology education. Refinetti R. **Am J Physiol** 1997 Jun;272(6 Pt 3):S31–5 (30 ref.)
A new PhD training track: a proposal to improve basic science teaching. Smith JJ, et al. **Am J Physiol** 1997 Jun; 272(6 Pt 3):S36–46 (45 ref.)

MANPOWER

Fixing the leaky pipeline: women scientists in academia. Pell AN. **J Anim Sci** 1996 Nov;74(11):2843–8 (30 ref.)

STANDARDS

The uses and abuses of meta-analysis [see comments] Charlton BG. **Fam Pract** 1996 Aug;13(4):397–401 (26 ref.) Comment in: Fam Pract 1997 Feb;14(1):90. Comment in: Fam Pract 1997 Feb;14(1):90–1.
On evidence, embellishment and efficacy. Morgan WK. **J Eval Clin Pract** 1997 Apr;3(2):117–22 (12 ref.)

TRENDS

Reflections from distant cuvettes. Vesell ES. **Drug Metab Rev** 1996 Nov;28(4):493–511 (32 ref.)
Science, imaginable risks, and public policy: anatomy of a mirage. Gori GB. **Regul Toxicol Pharmacol** 1996 Jun; 23(3):304–11 (41 ref.)

SCIENTIFIC MISCONDUCT

[Scientific misconduct] Mäkelä PH. **Duodecim** 1995; 111(19):1851–3 (8 ref.) **(Fin)**

LEGISLATION & JURISPRUDENCE

Science, integrity, and investigators' rights: current challenges. Daniell WE. **Regul Toxicol Pharmacol** 1996 Aug;24(1 Pt 2):S152–62 (72 ref.)

SCIENTIFIC SOCIETIES see **SOCIETIES, SCIENTIFIC**

SCIMITAR SYNDROME

[Scimitar syndrome] Shimizu M.
Ryoikibetsu Shokogun Shirizu 1996;(13):25–8 (13 ref.) **(Jpn)**

DIAGNOSIS

Scimitar syndrome: MR assessment of hemodynamic significance. Henk CB, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):628–30 (9 ref.)

SCINTIGRAPHY see **RADIONUCLIDE IMAGING**

SCINTIGRAPHY, COMPUTED TOMOGRAPHIC see **TOMOGRAPHY, EMISSION-COMPUTED**

SCINTIGRAPHY, EQUILIBRIUM see **GATED BLOOD-POOL IMAGING**

SCINTILLATION CAMERAS see **GAMMA CAMERAS**

SCINTILLATION COUNTING

see related
GAMMA CAMERAS

SCINTIPHOTOGRAPHY see **RADIONUCLIDE IMAGING**

SCIURIDAE

Immunocontraception in rodents: a review of the development of a sperm-based immunocontraceptive vaccine for the grey squirrel (Sciurus carolinensis). Moore HD, et al. **Reprod Fertil Dev** 1997;9(1):125–9 (33 ref.)

SCLERA

see related
LIMBUS CORNEAE
SCLERAL BUCKLING
SCLEROSTOMY

Complications of hydroxyapatite orbital implants. A review of 100 consecutive cases and a comparison of Dexon mesh (polyglycolic acid) with scleral wrapping. Oestreicher JH, et al. **Ophthalmology** 1997 Feb;104(2):324–9 (20 ref.)

ABNORMALITIES

[Clinical contribution to oculo-dermal melanosis or Ota's syndrome] Morra M. **Minerva Oftalmol** 1967 Jul–Aug; 9(4):152–6 (28 ref.) (Eng. Abstr.) **(Ita)**

METABOLISM

Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: implications for uveoscleral outflow. Lindsey JD, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S53–9 (53 ref.)

PHYSIOPATHOLOGY

[Methods for clinical studies of sclera in myopia] Khodzhabekian NV. **Vestn Oftalmol** 1997 May–Jun; 113(3):45–7 (44 ref.) **(Rus)**

SURGERY

Resuturing the scleral flap leads to resolution of hypotony maculopathy. Schwartz GF, et al. **J Glaucoma** 1996 Aug; 5(4):246–51 (50 ref.)

SCLERAL BUCKLING

METHODS

Encirclement of the globe and air in the vitreal cavity--unconsidered aspects. Chawla HB. **Klin Oczna** 1996 Jan;98(1):67–8 (3 ref.)

[Modification of axial length and astigmatism by scleral buckling surgery] Grimm G, et al.
Klin Monatsbl Augenheilkd 1997 Mar;210(3):144–6 (16 ref.) (Eng. Abstr.) **(Ger)**

SCLERAL DISEASES

CHEMICALLY INDUCED

Minocycline-induced scleral pigmentation. Fraunfelder FT, et al. **Ophthalmology** 1997 Jun;104(6):936–8 (11 ref.)

PATHOLOGY

Ophthalmic features of the organoid nevus syndrome. Shields JA, et al. **Trans Am Ophthalmol Soc** 1996;94:65–86; discussion 86–7 (46 ref.)

SCLEREMA NEONATORUM

[Sclerema neonatorum: still a controversial anatomo-clinical entity] Scarani P, et al. **Pathologica** 1997 Feb;89(1):91–2 (8 ref.) **(Ita)**

SCLERITIS

DRUG THERAPY

Combination intravenous ceftazidime and aminoglycosides in the treatment of pseudomonal scleritis. Hehm CJ, et al. **Ophthalmology** 1997 May;104(5):838–43 (30 ref.)

SCLEROCORNEAL LIMBUS see **LIMBUS CORNEAE**

SCLERODERMA, CIRCUMSCRIBED

Localized forms of scleroderma, including morphea, linear scleroderma, and eosinophilic fasciitis. Nelson AM.
Curr Opin Rheumatol 1996 Sep;8(5):473–6 (23 ref.)

Localized scleroderma including morphea, linear scleroderma, and eosinophilic fasciitis. Nelson AM.
Curr Probl Pediatr 1996 Oct;26(9):318–24 (46 ref.)

CHEMICALLY INDUCED

Pseudoscleroderma secondary to phytomenadione (vitamin K1) injections: Texier's disease. Pang BK, et al.
Australas J Dermatol 1996 Feb;37(1):44–7 (11 ref.)

COMPLICATIONS

Linear scleroderma and melorheostosis: case presentation and literature review. Moreno Alvarez MJ, et al.
Clin Rheumatol 1996 Jul;15(4):389–93 (24 ref.)

DIAGNOSIS

'Scléroedème génito-sus-pubien' of the newborn: a forgotten disease? Hernández-Martín A, et al. **Dermatology** 1996; 193(4):347–8 (10 ref.)

A case of linear atrophoderma of Moulin [letter; comment] Braun RP, et al. **J Dermatol** 1996 Sep;23(9):660 (6 ref.) Comment on: J Dermatol 1995 Oct;22(10):767–9.

DRUG THERAPY

Sclerodermatous changes of chronic graft-versus-host-disease treated with puva. Woscoff A, et al. **Int J Dermatol** 1996 Sep;35(9):656–8 (26 ref.)

ETIOLOGY

General and local scleroderma in children and dermatomyositis and associated syndromes. Laxer RM, et al. **Curr Opin Rheumatol** 1997 Sep;9(5):458–64 (44 ref.)

[Edema caused by retroperitoneal and tricuspid fibrosis with sclerodermatous cutaneous involvement disclosing carcinoid tumor. Apropos of a case and review of the literature] Morand JJ, et al. **Rev Med Interne** 1997; 18(5):388–95 (61 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Pseudoscleroderma secondary to phytomenadione (vitamin K1) injections: Texier's disease. Pang BK, et al.
Australas J Dermatol 1996 Feb;37(1):44–7 (11 ref.)

Sclerodermatous changes of chronic graft-versus-host-disease treated with puva. Woscoff A, et al. **Int J Dermatol** 1996 Sep;35(9):656–8 (26 ref.)

THERAPY

General and local scleroderma in children and dermatomyositis and associated syndromes. Laxer RM, et al. **Curr Opin Rheumatol** 1997 Sep;9(5):458–64 (44 ref.)

SCLERODERMA, DIFFUSE see **SCLERODERMA, SYSTEMIC**

SCLERODERMA, LOCALIZED see **SCLERODERMA, CIRCUMSCRIBED**

SCLERODERMA, SYSTEMIC

Systemic and localized scleroderma in children. Lehman TJ.
Curr Opin Rheumatol 1996 Nov;8(6):576–9 (15 ref.)

Childhood scleroderma and its peculiarities. Blaszczyk M, et al. **Cutis** 1996 Aug;58(2):141–4, 148–52 (103 ref.)

New aspects in scleroderma research. Sollberg S, et al.
Int Arch Allergy Immunol 1996 Dec;111(4):330–6 (30 ref.)

Scleroderma and pregnancy. Steen VD.
Rheum Dis Clin North Am 1997 Feb;23(1):133–47 (82 ref.)

[Pregnancy and systemic scleroderma. A case report] Diouf A, et al. **Contracept Fertil Sex** 1996 Dec;24(12):917–22 (21 ref.) (Eng. Abstr.) **(Fre)**

[Progressive systemic sclerosis] Takamoto T.
Ryoikibetsu Shokogun Shirizu 1996;(15):176–8 (8 ref.) **(Jpn)**

COMPLICATIONS

Raynaud's phenomenon and systemic sclerosis. Generini S, et al. **Ann Ital Med Int** 1996 Apr–Jun;11(2):125–31 (78 ref.)

Case report: severe fibrosis in a patient with scleroderma and previous radiotherapy--a case report and literature review. Aref I, et al. **Br J Radiol** 1996 Nov;69(827):1055–6 (9 ref.)

Systemic lupus erythematosus, discoid lupus erythematosus, and progressive systemic sclerosis. Foster CS.
Int Ophthalmol Clin 1997 Spring;37(2):93–110 (76 ref.)

Systemic scleroderma associated with Graves' disease. Anzai H, et al. **J Dermatol** 1996 Dec;23(12):896–8 (9 ref.)

Progressive systemic sclerosis associated with primary small cell carcinoma of the stomach. Shikuwa S, et al.
J Gastroenterol 1997 Aug;32(4):538–42 (14 ref.)

Malignant lymphoma in patients with rheumatic diseases other than Sjögren's syndrome: a clinicopathologic study of five cases and a review of the Japanese literature. Kojima M, et al. **Jpn J Clin Oncol** 1997 Apr;27(2):84–90 (43 ref.)

[Systemic scleroderma and sarcoidosis: 3 new cases] Bandt MD, et al. **Ann Med Interne (Paris)** 1996;147(8):590–4 (10 ref.) (Eng. Abstr.) **(Fre)**

[Systemic scleroderma and cancers: 21 cases and review of the literature] Bielefeld P, et al. **Rev Med Interne** 1996; 17(10):810–3 (34 ref.) (Eng. Abstr.) **(Fre)**

[Spontaneous rupture of the esophagus (Boerhaave syndrome) in a patient with scleroderma treated by continuous ambulatory peritoneal dialysis] Level C, et al. **Rev Med Interne** 1997 Jul;18(7):566–70 (20 ref.) (Eng. Abstr.) **(Fre)**

[Kidney involvement in progressive scleroderma] Blumenstein M, et al. **Dtsch Med Wochenschr** 1997 Feb 14;122(7):200–4 (22 ref.) **(Ger)**

[Cardiopathy in systemic sclerosis] Valentini G, et al.
Recenti Prog Med 1996 Nov;87(11):557–63 (40 ref.) (Eng. Abstr.) **(Ita)**

[Systemic sclerosis with various gastrointestinal problems including pneumoperitoneum, pneumatosis cystoides intestinalis and malabsorption syndrome] Satoh A, et al. **Ryumachi** 1995 Dec;35(6):927–33 (29 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Test performance in systemic sclerosis: anti-centromere and anti-Scl-70 antibodies. Spencer-Green G, et al.
Am J Med 1997 Sep;103(3):242–8 (52 ref.)

Systemic scleroderma associated with Graves' disease. Anzai H, et al. **J Dermatol** 1996 Dec;23(12):896–8 (9 ref.)

Rheumatology. 11. Systemic sclerosis and the inflammatory myopathies. Rasaratnam I, et al. **Med J Aust** 1997 Mar 17;166(6):322–7 (15 ref.)

[Clinical aspects, pathophysiology, diagnosis and therapy of gastrointestinal manifestations of progressive systemic scleroderma] Folwaczny C, et al. **Z Gastroenterol** 1996 Aug;34(8):497–508 (119 ref.) (Eng. Abstr.) **(Ger)**

[A case of a combination of systemic scleroderma with diffuse eosinophilic fasciitis] Krasovskiĭ II, et al. **Ter Arkh** 1996; 68(9):84–5 (8 ref.) **(Rus)**

DRUG THERAPY

Steroid pulse therapy for progressive systemic sclerosis [editorial; comment] Hashimoto H. **Intern Med** 1996 Jul; 35(7):525–6 (13 ref.) Comment on: Intern Med 1996 Jul;35(7):525–6.

EPIDEMIOLOGY

Epidemiology of systemic sclerosis. Silman AJ, et al.
Curr Opin Rheumatol 1996 Nov;8(6):585–9 (38 ref.)

Scleroderma--demographics and survival. Silman AJ.
J Rheumatol Suppl 1997 May;48:58–61 (42 ref.)

Scleroderma epidemiology. Mayes MD.
Rheum Dis Clin North Am 1996 Nov;22(4):751–64 (56 ref.)

ETIOLOGY

General and local scleroderma in children and dermatomyositis and associated syndromes. Laxer RM, et al. **Curr Opin Rheumatol** 1997 Sep;9(5):458–64 (44 ref.)

Connective tissue metabolism in scleroderma, including cytokines. Unemori EN, et al. **Curr Opin Rheumatol** 1996 Nov;8(6):580–4 (28 ref.)

Pathogenesis of scleroderma. Collagen. Jimenez SA, et al.
Rheum Dis Clin North Am 1996 Nov;22(4):647–74 (195 ref.)

Systemic sclerosis. A vascular perspective. LeRoy EC.
Rheum Dis Clin North Am 1996 Nov;22(4):675–94 (52 ref.)

Occupational and environmental influences on scleroderma. Silman AJ, et al. **Rheum Dis Clin North Am** 1996 Nov; 22(4):737–49 (82 ref.)

Immunopathogenesis of systemic sclerosis. White B.
Rheum Dis Clin North Am 1996 Nov;22(4):695–708 (81 ref.)

[Environmental factors and iatrogenic elements in systemic scleroderma and related syndromes. Review of the literature] Hallé O, et al. **Rev Med Interne** 1997; 18(3):219–29 (78 ref.) (Eng. Abstr.) **(Fre)**

[Etiology of diffuse scleroderma--proposal of a hypothesis and subsequent development] Takehara K.
Nihon Rinsho Meneki Gakkai Kaishi 1997 Feb;20(1):1–7 (38 ref.) **(Jpn)**

[The role of free radicals in the etiopathogenesis of systemic sclerosis] Komosińska K, et al. **Postepy Hig Med Dosw** 1997;51(3):285–303 (99 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Hypothesis for the pathogenesis of systemic sclerosis. Furst DE, et al. **J Rheumatol Suppl** 1997 May;48:53–7 (74 ref.)

IMMUNOLOGY

Test performance in systemic sclerosis: anti-centromere and anti-Scl-70 antibodies. Spencer-Green G, et al.
Am J Med 1997 Sep;103(3):242–8 (52 ref.)

Clinical significance of antinuclear antibodies in systemic

rheumatic diseases. Hietarinta M, et al. **Ann Med** 1996 Aug; 28(4):283–91 (84 ref.)
Functional properties and molecular characteristics of autoantibodies associated with tight skin syndrome. Kasturi K, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:253–62 (39 ref.)
Hypothesis for the pathogenesis of systemic sclerosis. Furst DE, et al. **J Rheumatol Suppl** 1997 May;48:53–7 (74 ref.)
Antinuclear antibody in systemic sclerosis (scleroderma). Okano Y. **Rheum Dis Clin North Am** 1996 Nov; 22(4):709–35 (138 ref.)
Immunopathogenesis of systemic sclerosis. White B. **Rheum Dis Clin North Am** 1996 Nov;22(4):695–708 (81 ref.)

PATHOLOGY

Progressive systemic sclerosis associated with multiple mononeuropathy. Nitta Y, et al. **Dermatology** 1996; 193(1):22–6 (19 ref.)

PHYSIOPATHOLOGY

Gastrointestinal manifestations of progressive systemic sclerosis. Lock G, et al. **Am J Gastroenterol** 1997 May; 92(5):763–71 (103 ref.)
Gastrointestinal features of scleroderma. Sjogren RW. **Curr Opin Rheumatol** 1996 Nov;8(6):569–75 (57 ref.)
Connective tissue metabolism in scleroderma, including cytokines. Unemori EN, et al. **Curr Opin Rheumatol** 1996 Nov;8(6):580–4 (28 ref.)
Raynaud's phenomenon and other features of scleroderma, including pulmonary hypertension. Wigley FM. **Curr Opin Rheumatol** 1996 Nov;8(6):561–8 (92 ref.)
Scleroderma and related conditions. Mitchell H, et al. **Med Clin North Am** 1997 Jan;81(1):129–49 (112 ref.)
The nervous system in systemic sclerosis (scleroderma). Clinical features and pathogenetic mechanisms. Cerinic MM, et al. **Rheum Dis Clin North Am** 1996 Nov; 22(4):879–92 (87 ref.)
Cardiac involvement in scleroderma. Deswal A, et al. **Rheum Dis Clin North Am** 1996 Nov;22(4):841–60 (87 ref.)
Muscle abnormalities in scleroderma. Olsen NJ, et al. **Rheum Dis Clin North Am** 1996 Nov;22(4):783–96 (45 ref.)
Scleroderma. Clinical problems. The lungs. Silver RM. **Rheum Dis Clin North Am** 1996 Nov;22(4):825–40 (95 ref.)
Scleroderma renal crisis. Steen VD. **Rheum Dis Clin North Am** 1996 Nov;22(4):861–78 (72 ref.)
Raynaud's phenomenon. Wigley FM, et al. **Rheum Dis Clin North Am** 1996 Nov;22(4):765–81 (121 ref.)
Gastrointestinal manifestations of scleroderma. Young MA, et al. **Rheum Dis Clin North Am** 1996 Nov;22(4):797–823 (117 ref.)

REHABILITATION

Systemic sclerosis (scleroderma): an integrated challenge in rehabilitation. Casale R, et al. **Arch Phys Med Rehabil** 1997 Jul;78(7):767–73 (91 ref.)

THERAPY

Recombinant cytokine treatment for scleroderma. Can the antifibrotic potential of interferon-gamma be realized clinically? [editorial; comment] Varga J. **Arch Dermatol** 1997 May;133(5):637–42 (42 ref.) Comment on: Arch Dermatol 1997 May;133(5):609–13.
Advances in palliative care for the patient with scleroderma. Herrick AL. **Curr Opin Rheumatol** 1996 Nov;8(6):555–60 (27 ref.)
General and local scleroderma in children and dermatomyositis and associated syndromes. Laxer RM, et al. **Curr Opin Rheumatol** 1997 Sep;9(5):458–64 (44 ref.)
Hematopoietic stem cell transplantation for autoimmune diseases. Brooks PM. **J Rheumatol Suppl** 1997 May; 48:19–22 (22 ref.)
Choosing appropriate patients with systemic sclerosis for treatment by autologous stem cell transplantation. Clements PJ, et al. **J Rheumatol Suppl** 1997 May;48:85–8 (13 ref.)
Development of a protocol for allogeneic marrow transplantation for severe systemic sclerosis: paradigm for autoimmune disease. Nash RA, et al. **J Rheumatol Suppl** 1997 May;48:72–8 (51 ref.)
The evolving role of blood and marrow transplantation for the treatment of autoimmune diseases. Sullivan KM, et al. **J Rheumatol Suppl** 1997 May;48:1–4 (59 ref.)
Treatment of systemic sclerosis. Pope JE. **Rheum Dis Clin North Am** 1996 Nov;22(4):893–907 (95 ref.)

SCLEROSING AGENTS see **SCLEROSING SOLUTIONS**

SCLEROSING SOLUTIONS

ADMINISTRATION & DOSAGE

[A case of rectal varices treated with endoscopic injection sclerotherapy] Zeniya A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Jan;94(1):38–43 (19 ref.) **(Jpn)**

THERAPEUTIC USE

Toxicological requirements for sclerosing agents or other chemicals for female sterilization. Heywood R. **Int J Gynaecol Obstet** 1995 Dec;51 Suppl 1:S41–5 (12 ref.)
Transcervical quinacrine sterilization: clinical experience. Sokal DC, et al. **Int J Gynaecol Obstet** 1995 Dec;51 Suppl 1:S57–69 (50 ref.)
Quinacrine: sclerosing agent of the utero-tubal junction in women, with anticarcinogenic actions in transplanted tumors in mice. Zipper J, et al. **Int J Gynaecol Obstet** 1995 Dec;51 Suppl 1:S47–55 (73 ref.)
Sclerotherapy of telangiectases using sodium tetradecyl sulfate (Sotradecol) [see comments] Hren C, et al. **N C Med J** 1996 Jan–Feb;57(1):42–6 (8 ref.) Comment in: N C Med J 1996 May–Jun;57(3):127–8.
[Study on the sclerosing agent for the treatment of simple renal cysts] Akiyama H, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Dec;87(12):1277–80 (18 ref.) (Eng. Abstr.) **(Jpn)**

SCLEROSIS

PATHOLOGY

Sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid: report of two patients, one with distant metastasis, and review of the literature. Sim SJ, et al. **Hum Pathol** 1997 Sep;28(9):1091–6 (15 ref.)

SCLEROSIS, DISSEMINATED see **MULTIPLE SCLEROSIS**

SCLEROSIS, HEREDITARY SPINAL see **FRIEDREICH'S ATAXIA**

SCLEROSIS, PRESENILE see **DEMENTIA, PRESENILE**

SCLEROSIS, PROGRESSIVE SYSTEMIC see **SCLERODERMA, SYSTEMIC**

SCLEROSIS, SYSTEMIC see **SCLERODERMA, SYSTEMIC**

SCLEROSTOMY

METHODS

Holmium laser sclerostomy. Saheb NE. **Can J Ophthalmol** 1996 Aug;31(5):267–8 (16 ref.)

SCLEROTHERAPY

see related
SCLEROSING SOLUTIONS

Sclerotherapy of varicose veins of the lower limbs. Consensus paper. North American Society of Phlebology. Baccaglini U, et al. **Dermatol Surg** 1996 Oct;22(10):883–9 (15 ref.)
Medical prophylaxis of haemorrhage from oesophageal varices in patients with liver cirrhosis. Gross M, et al. **Eur J Gastroenterol Hepatol** 1997 Jun;9(6):603–12 (95 ref.)
Prophylactic endoscopic sclerotherapy in patients with liver cirrhosis, portal hypertension, and esophageal varices. Paquet KJ, et al. **Hepatogastroenterology** 1997 May–Jun; 44(15):625–36 (54 ref.)
Consensus Conference on Sclerotherapy. Padua, 24 September 1994. Baccaglini U. **Int Angiol** 1995 Sep; 14(3):239–40 (0 ref.)
Sclerotherapy of telangiectases using sodium tetradecyl sulfate (Sotradecol) [see comments] Hren C, et al. **N C Med J** 1996 Jan–Feb;57(1):42–6 (8 ref.) Comment in: N C Med J 1996 May–Jun;57(3):127–8.
[Effect of fibroscopic sclerotherapy of hemorrhaging esophageal varices on survival in alcoholic liver cirrhosis (comparative retrospective study)] Kempelen I, et al. **Orv Hetil** 1996 Sep 15;137(37):2019–23 (46 ref.) (Eng. Abstr.) **(Hun)**

ADVERSE EFFECTS

[Obstructive intramural hematoma of the esophagus after sclerotherapy] Benoit R, et al. **Presse Med** 1996 Sep 28; 25(28):1281–4 (18 ref.) (Eng. Abstr.) **(Fre)**

METHODS

[Treatment of a hemorrhagic duodenal varice by endoscopic sclerotherapy] Paupard T, et al. **Gastroenterol Clin Biol** 1995 Dec;19(12):1051–4 (18 ref.) (Eng. Abstr.) **(Fre)**
[Endoscopic sclerotherapy for gastroesophageal varices] Kitano M. **Nippon Geka Gakkai Zasshi** 1996 Jan;97(1):43–8 (22 ref.) **(Jpn)**
[A case of rectal varices treated with endoscopic injection sclerotherapy] Zeniya A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Jan;94(1):38–43 (19 ref.) **(Jpn)**

TRENDS

Sclerotherapy is out--nearly [editorial; comment] Sauerbruch T, et al. **Endoscopy** 1997 May;29(4):281–2 (13 ref.) Comment on: Endoscopy 1997 May;29(4):235–40. Comment on: Endoscopy 1997 May;29(4):241–6.
Is sclerotherapy out? [editorial; comment] Soehendra N, et al. **Endoscopy** 1997 May;29(4):283–4 (10 ref.) Comment on: Endoscopy 1997 May;29(4):235–40. Comment on: Endoscopy 1997 May;29(4):241–6.

SCLEROTINIA see **ASCOMYCETES**

SCOLIOSIS

Idiopathic scoliosis: biomechanics and biology. Millner PA, et al. **Eur Spine J** 1996;5(6):362–73 (84 ref.)

COMPLICATIONS

Lumbar spinal stenosis: indications for arthrodesis and spinal instrumentation. Herkowitz HN. **Instr Course Lect** 1994; 43:425–33 (35 ref.)
Juvenile progressive scoliosis and congenital horizontal gaze palsy. Thomsen M, et al. **J Pediatr Orthop B** 1996 Summer; 5(3):185–9 (22 ref.)
[Severe congenital thoracic–lumbar scoliosis in pregnancy. A case report and review of the literature] Restaino A, et al. **Minerva Ginecol** 1996 Dec;48(12):565–71 (29 ref.) (Eng. Abstr.) **(Ita)**

CONGENITAL

Coffin–Siris syndrome: a case of an extremely low birthweight infant with severe kyphoscoliosis. Suzumura H, et al. **Acta Paediatr Jpn** 1996 Oct;38(5):537–40 (5 ref.)
Hemivertebral excision for congenital scoliosis. Callahan BC, et al. **J Pediatr Orthop** 1997 Jan–Feb;17(1):96–9 (19 ref.)

DIAGNOSIS

Idiopathic scoliosis and kyphosis. Pizzutillo PD. **Instr Course Lect** 1994;43:185–91 (10 ref.)

ETIOLOGY

Dystrophic kyphoscoliosis in neurofibromatosis type I: a report of two cases and review of the literature. Vandenbroucke J, et al. **Eur Spine J** 1997;6(4):273–7 (15 ref.)
Painful scoliosis. Hoeffel C, et al. **Klin Padiatr** 1997 Mar–Apr; 209(2):78–83 (6 ref.)
[Characteristics in the treatment of scoliosis in muscular diseases] Forst R, et al. **Z Orthop Ihre Grenzgeb** 1997 Mar–Apr;135(2):95–105 (84 ref.) (Eng. Abstr.) **(Ger)**
[Scoliosis of sudden evolution due to lumbar osteoblastoma] Amaral J de S, et al. **Acta Med Port** 1997 May;10(5):417–22 (16 ref.) (Eng. Abstr.) **(Por)**

PATHOLOGY

Natural history of adolescent thoracolumbar and lumbar idiopathic scoliosis into adulthood. Cordover AM, et al. **J Spinal Disord** 1997 Jun;10(3):193–6 (11 ref.)

SURGERY

Spinal instrumentation in the management of adolescent scoliosis. Bridwell KH. **Clin Orthop** 1997 Feb;(335):64–72 (29 ref.)
Neurological complications in segmental spinal instrumentation: analysis of 750 patients. Cervellati S, et al. **Eur Spine J** 1996;5(3):161–6 (25 ref.)
Controversies in low back pain: the surgical approach. Hanley EN Jr, et al. **Instr Course Lect** 1994;43:415–23 (56 ref.)
Hemivertebral excision for congenital scoliosis. Callahan BC, et al. **J Pediatr Orthop** 1997 Jan–Feb;17(1):96–9 (19 ref.)
Controversy. Fusion of L5–S1 in adult scoliosis. Horton WC, et al. **Spine** 1996 Nov 1;21(21):2520–2 (8 ref.)
Internal fixation of the spine in traumatic and scoliotic cases. The potential of pedicle screws. Van Brussel K, et al. **Technol Health Care** 1996 Dec;4(4):365–84 (44 ref.)

THERAPY

Idiopathic scoliosis and kyphosis. Pizzutillo PD. **Instr Course Lect** 1994;43:185–91 (10 ref.)
Treatment of adult scoliosis. Albert TJ, et al. **J South Orthop Assoc** 1996 Fall;5(3):229–37 (12 ref.)
[Characteristics in the treatment of scoliosis in muscular diseases] Forst R, et al. **Z Orthop Ihre Grenzgeb** 1997 Mar–Apr;135(2):95–105 (84 ref.) (Eng. Abstr.) **(Ger)**

SCOPOLAMINE

POISONING

Hyoscyamus falezlez C: a poisonous plant of north Africa. el Bahri L, et al. **Vet Hum Toxicol** 1996 Oct;38(5):378–9 (19 ref.)

SCOPOLAMINEBUTYLBROMIDE see **BUTYLSCOPOLAMMONIUM BROMIDE**

SCORBUTUS see **SCURVY**

SCORPION VENOMS

CHEMISTRY

Now we're cooking: new successes for shake-and-bake. Ealick SE. **Structure** 1997 Apr 15;5(4):469–72 (30 ref.)

CLASSIFICATION

[Scorpion toxins] Legros C, et al. **C R Seances Soc Biol Fil** 1997;191(3):345–80 (126 ref.) (Eng. Abstr.) **(Fre)**

SCORPION VENOMS

ISOLATION & PURIFICATION

Toxins and genes isolated from scorpions of the genus Tityus. Becerril B, et al. **Toxicon** 1997 Jun;35(6):821–35 (81 ref.)

SCORPIONS

GENETICS

Toxins and genes isolated from scorpions of the genus Tityus. Becerril B, et al. **Toxicon** 1997 Jun;35(6):821–35 (81 ref.)

SCRAPIE

see related
PRIONS
PRPSC PROTEINS

The biology and molecular biology of scrapie-like diseases. Hope J. **Arch Virol Suppl** 1993;7:201–14 (55 ref.)
Scrapie: recent trends. Parsonson IM. **Aust Vet J** 1996 Nov; 74(5):383–7 (61 ref.)

ETIOLOGY

PrP genetics in sheep and the applications for scrapie and BSE. Hunter N. **Trends Microbiol** 1997 Aug;5(8):331–4 (36 ref.)

GENETICS

Prion protein structure and scrapie replication: theoretical, spectroscopic, and genetic investigations. Bamborough P, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:495–509 (99 ref.)

PATHOLOGY

Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Harper JD, et al. **Annu Rev Biochem** 1997;66:385–407 (97 ref.)
[Prion disease in animals and experimental prion disease] Ikeda S. **No To Shinkei** 1997 Aug;49(8):689–95 (21 ref.) **(Jpn)**

PHYSIOPATHOLOGY

The role of PrP in pathogenesis of experimental scrapie. Weissmann C, et al.
Cold Spring Harb Symp Quant Biol 1996;61:511–22 (76 ref.)

SCRAPIE AGENT see **PRPSC PROTEINS**

SCRAPIE AMYLOID PRECURSOR PROTEIN see **PRPC PROTEINS**

SCRAPIE PRP see **PRPSC PROTEINS**

SCREEN-FILM SYSTEMS, X-RAY see **X-RAY INTENSIFYING SCREENS**

SCROFULA see **TUBERCULOSIS, LYMPH NODE**

SCROTUM

Sclerosing lipogranuloma of the scrotum following a laparoscopic herniorraphy and varicocelectomy—a case report. Baladas HG, et al. **Ann Acad Med Singapore** 1997 Mar;26(2):238–40 (4 ref.)
Scrotal cystic lymphangioma: the misdiagnosed scrotal mass. Hurwitz RS, et al. **J Urol** 1997 Sep;158(3 Pt 2):1182–5 (8 ref.)
The acute scrotum. Siegel MJ. **Radiol Clin North Am** 1997 Jul;35(4):959–76 (41 ref.)
Aggressive angiomyxoma of the scrotum. Sakata K, et al. **Urol Int** 1997;58(4):247–9 (12 ref.)
[Acute obstructive renal failure and scrotal complete hernia of the bladder. Apropos of a case, review of the literature] Mianné D, et al. **J Chir (Paris)** 1996;133(9–10):459–61 (14 ref.) (Eng. Abstr.) **(Fre)**
[Acute scrotum: unusual presentation of Schönlein-Henoch purpura] Suarez González JA, et al. **Actas Urol Esp** 1997 Jan;21(1):78–81 (22 ref.) (Eng. Abstr.) **(Spa)**

ABNORMALITIES

Accessory scrotum and anorectal malformation associated with "pseudo" prune belly in a neonate. Shoshany G, et al. **J Perinatol** 1996 May–Jun;16(3 Pt 1):224–6 (25 ref.)
Agenesis of the scrotum: an extremely rare anomaly. Verga G, et al. **J Urol** 1996 Oct;156(4):1467 (1 ref.)

EMBRYOLOGY

The genitofemoral nerve may link testicular inguinoscrotal descent with congenital inguinal hernia. Clarnette TD, et al. **Aust N Z J Surg** 1996 Sep;66(9):612–7 (66 ref.)

INJURIES

External strangulation of the small bowel following injury to inguinoscrotal hernia. Chaloner EJ, et al. **Injury** 1997 Jan;28(1):69–70 (4 ref.)

PATHOLOGY

Clinical image. MRI of scrotal hemangioma. Aizenstein RI, et al. **J Comput Assist Tomogr** 1996 Nov–Dec;20(6):888–9 (8 ref.)
MR imaging of scrotal, testicular, and penile diseases. Sica GT, et al. **Magn Reson Imaging Clin N Am** 1996 Aug; 4(3):545–63 (27 ref.)
[Scrotal panniculitis due to cold: a pseudo-tumoral lesion in the prepubertal child. Report of a case] Versini P, et al. **Ann Pathol** 1996 Sep;16(4):282–4 (16 ref.) (Eng. Abstr.) **(Fre)**
[A case of malignant mesothelioma associated intrascrotal mass] Wakasugi E, et al.
Nippon Hinyokika Gakkai Zasshi 1997 Mar;88(3):443–6 (21 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Scrotal/testicular thermoregulation and the effects of increased testicular temperature in the bull. Kastelic JP, et al. **Vet Clin North Am Food Anim Pract** 1997 Jul; 13(2):271–82 (36 ref.)

RADIONUCLIDE IMAGING

Scrotal pathology as the cause for hip pain. Diagnostic findings on bone scintigraphy. Sheafor DH, et al.
Clin Nucl Med 1997 May;22(5):287–91 (25 ref.)

SURGERY

[A case of aphallia] Nakaigawa N, et al. **Hinyokika Kiyo** 1996 Sep;42(9):695–7 (10 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Scrotal ultrasound. Dewbury K. **Br J Hosp Med** 1997 Jan 15–Feb 5;57(1–2):10–4 (16 ref.)
Differential diagnosis of scrotal masses by ultrasound. Hamm B. **Eur Radiol** 1997;7(5):668–79 (51 ref.)
Clinical relevance of scrotal and transrectal ultrasonography in andrological patients. Behre HM, et al. **Int J Androl** 1995 Dec;18 Suppl 2:27–31 (19 ref.)
Scrotal ultrasound. Bree RL, et al. **Radiol Clin North Am** 1996 Nov;34(6):1183–205 (38 ref.)
Scrotal imaging. Horstman WG. **Urol Clin North Am** 1997 Aug;24(3):653–71 (106 ref.)

SCURVY

COMPLICATIONS

Scurvy and the gastrointestinal tract. Schuman RW, et al. **Gastrointest Endosc** 1997 Feb;45(2):195–6 (11 ref.)

HISTORY

Three eras of vitamin C discovery. Jacob RA.
Subcell Biochem 1996;25:1–16 (81 ref.)

SCYPHOZOA see **JELLYFISH**

SEA ANEMONE VENOMS see **CNIDARIAN VENOMS**

SEA-BLUE HISTIOCYTE SYNDROME

Syndrome of the sea-blue histiocyte. Hirayama Y, et al.
Intern Med 1996 May;35(5):419–21 (10 ref.)

SEA CUCUMBERS

SJAMP-induced platelet aggregation defect. Shen D.
Chin Med J (Engl) 1996 Jan;109(1):46–8 (10 ref.)

SEA LION SPUMAVIRUS see **SPUMAVIRUS**

SEA LIONS see **SEALS**

SEA URCHINS

EMBRYOLOGY

Looking into the sea urchin embryo you can see local cell interactions regulate morphogenesis. Wilt FH. **Bioessays** 1997 Aug;19(8):665–8 (22 ref.)
Fate specification along the sea urchin embryo animal-vegetal axis. Angerer RC, et al. **Biol Bull** 1997 Feb; 192(1):175–7 (17 ref.)
The cellular basis of sea urchin gastrulation. Hardin J.
Curr Top Dev Biol 1996;33:159–262 (328 ref.)

PHYSIOLOGY

Molecular mechanisms of gamete recognition in sea urchin fertilization. Ohlendieck K, et al. **Curr Top Dev Biol** 1996; 32:39–58 (67 ref.)

SEAFOOD

Multiple myeloma: clusters, clues, and dioxins. Schwartz GG.
Cancer Epidemiol Biomarkers Prev 1997 Jan;6(1):49–56 (84 ref.)

POISONING

Cyanobacterial toxins: occurrence, modes of action, health effects and exposure routes. Codd GA, et al.
Arch Toxicol Suppl 1997;19:399–410 (35 ref.)

SEALANTS, ROOT CANAL see **ROOT CANAL FILLING MATERIALS**

SEALANTS, TOOTH see **PIT AND FISSURE SEALANTS**

SEALED CABIN ECOLOGY see **ECOLOGICAL SYSTEMS, CLOSED**

SEALS

[Seal fingers and other infections transmitted from seals] Krag ML, et al. **Ugeskr Laeger** 1996 Sep 2;158(36):5015–7 (31 ref.) (Eng. Abstr.) **(Dan)**

IMMUNOLOGY

Impaired immunity in harbour seals (Phoca vitulina) exposed to bioaccumulated environmental contaminants: review of a long-term feeding study. de Swart RL, et al.
Environ Health Perspect 1996 Aug;104 Suppl 4:823–8 (34 ref.)
Impaired immunity in harbour seals [Phoca vitulina] fed environmentally contaminated herring. de Swart RL, et al. **Vet Q** 1996;18 Suppl 3:S127–8 (12 ref.)

SEASICKNESS see **MOTION SICKNESS**

SEASONAL AFFECTIVE DISORDER

Rhythm and blues: the theory and treatment of seasonal affective disorder. Dalgleish T, et al. **Br J Clin Psychol** 1996 May;35 (Pt 2):163–82 (140 ref.)

PHYSIOPATHOLOGY

Dopamine and circadian rhythms in seasonal affective disorder. Partonen T. **Med Hypotheses** 1996 Sep; 47(3):191–2 (6 ref.)
Possible pathophysiological mechanisms regulating food intake in seasonal affective disorder. Partonen T.
Med Hypotheses 1996 Sep;47(3):215–6 (7 ref.)

THERAPY

[Phototherapy. An alternative for seasonal affective disorders or sleep disorders] Holsten F, et al.
Tidsskr Nor Laegeforen 1997 Jun 30;117(17):2484–8 (68 ref.) (Eng. Abstr.) **(Nor)**
[Seasonal affective disorder and light therapy] Matías J, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 Jul–Aug;24(4):204–8 (50 ref.) (Eng. Abstr.) **(Spa)**

SEASONAL MOOD DISORDER see **SEASONAL AFFECTIVE DISORDER**

SEASONS

Circannual changes in thyroid hormone physiology: the role of cold environmental temperatures. Reed HL.
Arctic Med Res 1995;54 Suppl 2:9–15 (55 ref.)
Clinical relevance of about-yearly changes in blood pressure and the environment. Halberg F, et al.
Int J Biometeorol 1996 Nov;39(4):161–75 (150 ref.)
Appropriate season for measles immunisation campaign in India. Singh J, et al. **J Commun Dis** 1995 Sep;27(3):164–9 (44 ref.)
A 'clock for all seasons' in the human brain. Wehr TA.
Prog Brain Res 1996;111:321–42 (32 ref.)
Seasonal changes in immune function. Nelson RJ, et al.
Q Rev Biol 1996 Dec;71(4):511–48 (270 ref.)
VBR in schizophrenia: relationship to family history of psychosis and season of birth [published erratum appears in Schizophr Res 1997 May 24;25(2):167] DeQuardo JR, et al. **Schizophr Res** 1996 Jul 5;20(3):275–85 (60 ref.)
[Seasonality and psychiatric emergencies] Díaz RJ, et al.
Actas Luso Esp Neurol Psiquiatr Cienc Afines 1996 Sep–Oct;24(5):253–9 (43 ref.) (Eng. Abstr.) **(Spa)**

SEAT BELTS

Light vehicle occupant ejections—a comprehensive investigation. Malliaris AC, et al. **Accid Anal Prev** 1996 Jan;28(1):1–14 (9 ref.)

ADVERSE EFFECTS

Intestinal stricture following seat belt injury in children. Lynch JM, et al. **J Pediatr Surg** 1996 Oct;31(10):1354–7 (13 ref.)
[Internal carotid artery occlusion related to seat belt shoulder strap: report of two cases] Watanabe Y, et al.
Rinsho Shinkeigaku 1996 May;36(5):670–4 (12 ref.) (Eng. Abstr.) **(Jpn)**

LEGISLATION & JURISPRUDENCE

Impact of the Illinois child passenger protection act: a retrospective look. Rock SM. **Accid Anal Prev** 1996 Jul; 28(4):487–92 (14 ref.)

SEAWATER

see related
GEOLOGIC SEDIMENTS

Effects of open marsh water management on selected tidal

marsh resources: a review. Wolfe RJ.
J Am Mosq Control Assoc 1996 Dec;12(4):701–12 (83 ref.)

CHEMISTRY

The ecotoxicity of chlorate to aquatic organisms: a critical review. van Wijk DJ, et al. **Ecotoxicol Environ Saf** 1995 Dec;32(3):244–53 (54 ref.)

SEBACEOUS CYST see **EPIDERMAL CYST**

SEBACEOUS GLAND NEOPLASMS

Sebaceous gland carcinoma: report of a case and review of literature. Janjua TA, et al. **Am J Otolaryngol** 1997 Jan–Feb;18(1):51–4 (15 ref.)

SEBACEOUS GLANDS

CYTOLOGY

Human pilosebaceous culture. Kealey T, et al.
Methods Mol Biol 1997;75:101–15 (20 ref.)

PATHOLOGY

Eccrine or apocrine poroma? Six poromas with divergent adnexal differentiation. Harvell JD, et al.
Am J Dermatopathol 1996 Feb;18(1):1–9 (30 ref.)
Areolar sebaceous hyperplasia: a case report. Belinchón I, et al. **Cutis** 1996 Jul;58(1):63–4 (8 ref.)
Familial presenile sebaceous gland hyperplasia. Boonchai W, et al. **J Am Acad Dermatol** 1997 Jan;36(1):120–2 (8 ref.)

SEBORRHEA see **DERMATITIS, SEBORRHEIC**

SEBORRHEIC KERATOSIS see **KERATOSIS, SEBORRHEIC**

SECOND-GENERATION ANTIDEPRESSIVE AGENTS see **ANTIDEPRESSIVE AGENTS, SECOND-GENERATION**

SECOND-LOOK SURGERY see **REOPERATION**

SECOND MALIGNANCY see **NEOPLASMS, SECOND PRIMARY**

SECOND MESSENGER SYSTEMS

Neurotransmitters, signal transduction and second-messengers in Alzheimer's disease. Cowburn RF, et al. **Acta Neurol Scand Suppl** 1996;165:25–32 (63 ref.)
The 1996 Massry Prize. Inositol trisphosphate and calcium: two interacting second messengers. Berridge MJ.
Am J Nephrol 1997;17(1):1–11 (94 ref.)
Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Beckman JS, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):C1424–37 (109 ref.)
Adenine nucleotide diphosphates: emerging second messengers acting via intracellular Ca2+ release. Dousa TP, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):C1007–24 (136 ref.)
The heme oxygenase system: a regulator of second messenger gases. Maines MD. **Annu Rev Pharmacol Toxicol** 1997; 37:517–54 (212 ref.)
Regulation of Raf-1 kinase by interaction with the lipid second messenger, phosphatidic acid. Ghosh S, et al.
Biochem Soc Trans 1997 May;25(2):561–5 (19 ref.)
cGMP as second messenger during Dictyostelium chemotaxis. van Haastert PJ, et al. **FEBS Lett** 1997 Jun 23;410(1):25–8 (43 ref.)
Is there evidence for phospho-oligosaccharides as insulin mediators? Field MC. **Glycobiology** 1997 Mar;7(2):161–8 (65 ref.)
The significance of intracellular insulin to insulin action. Duckworth WC, et al. **J Investig Med** 1997 Feb;45(2):20–7 (64 ref.)
Molecular properties of enzymes involved in diacylglycerol and phosphatidate metabolism. Kanoh H, et al.
J Lipid Mediat Cell Signal 1996 Sep;14(1–3):245–50 (18 ref.)
Production and function of lipid second messengers in proliferating and differentiated neuroblastoma cells. Lang D, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):349–59 (38 ref.)
Inositol trisphosphate/Ca2+ as messengers of bradykinin B2 and muscarinic acetylcholine m1–m4 receptors in neuroblastoma-derived hybrid cells. Noda M, et al.
J Lipid Mediat Cell Signal 1996 Sep;14(1–3):175–85 (44 ref.)
Poly-phosphoinositide-mediated messengers in focal cerebral ischemia and reperfusion. Sun GY, et al.
J Lipid Mediat Cell Signal 1996 Sep;14(1–3):137–45 (19 ref.)
Signalling through the lipid products of phosphoinositide-3-OH kinase. Toker A, et al. **Nature** 1997 Jun 12;387(6634):673–6 (47 ref.)
Actions of neurotransmitters and other messengers on Ca2+ channels and K+ channels in smooth muscle cells. Beech DJ. **Pharmacol Ther** 1997;73(2):91–119 (353 ref.)
Biological complexity is under the 'strange attraction' of non-esterified fatty acids. Nunez EA.
Prostaglandins Leukot Essent Fatty Acids 1997 Jul; 57(1):107–10 (36 ref.)
Nitric oxide, the enigmatic neuronal messenger: its role in synaptic plasticity. Hölscher C. **Trends Neurosci** 1997 Jul; 20(7):298–303 (93 ref.)
[Nitric oxide and carbon monoxide—a new generation of neuronal messengers] Gazit V, et al. **Harefuah** 1996 Jun 16;130(12):854–8 (15 ref.) **(Heb)**
[Sphingolipids—a new group of lipid second messengers?] Mesarić M. **Lijec Vjesn** 1996 Jul–Aug;118(7–8):178–83 (81 ref.) (Eng. Abstr.) **(Scr)**

PHYSIOLOGY

Regulation of somatostatin gene transcription by cAMP. Montminy M, et al. **Adv Pharmacol** 1996;36:1–13 (20 ref.)
New physiological importance of two classic residual products: carbon monoxide and bilirubin. Marilena G.
Biochem Mol Med 1997 Aug;61(2):136–42 (43 ref.)
Regulation of second messengers by the inositol polyphosphate 5-phosphatases. Mitchell CA, et al.
Biochem Soc Trans 1996 Nov;24(4):994–1000 (40 ref.)
The function of inositol high polyphosphate binding proteins. Fukuda M, et al. **Bioessays** 1997 Jul;19(7):593–603 (85 ref.)
Insulin second messengers. Strålfors P. **Bioessays** 1997 Apr; 19(4):327–35 (79 ref.)
Second messenger systems in the regulation of cytokines and adhesion molecules in the central nervous system. Benveniste EN, et al. **Brain Behav Immun** 1995 Dec; 9(4):304–14 (79 ref.)
Competition by second messenger systems for receptor interaction and activation: implications for tissue-specific responses and disease therapy. Crouch MF, et al.
Clin Exp Pharmacol Physiol 1997 Aug;24(8):632–8 (22 ref.)
Role of Ca+2 and other second messengers in excitatory amino acid receptor mediated neurodegeneration: clinical perspectives. Schousboe A, et al. **Clin Neurosci** 1997; 4(4):194–8 (87 ref.)
Intracellular signalling: the mad way to do it. Derynck R, et al. **Curr Biol** 1996 Oct 1;6(10):1226–9 (29 ref.)
The roles of free radicals, peroxides and oxidized lipoproteins in second messenger system dysfunction. Czubryt MP, et al. **EXS** 1996;76:57–69 (37 ref.)
Elementary and global aspects of calcium signalling. Berridge MJ. **J Exp Biol** 1997 Jan;200 (Pt 2):315–9 (25 ref.)
Intracellular Ca2+ signalling in secretory cells. Shuttleworth TJ. **J Exp Biol** 1997 Jan;200 (Pt 2):303–14 (90 ref.)
Gaseous second messengers in vertebrate olfaction. Broillet MC, et al. **J Neurobiol** 1996 May;30(1):49–57 (65 ref.)
Second messenger signaling in olfactory transduction. Restrepo D, et al. **J Neurobiol** 1996 May;30(1):37–48 (111 ref.)
Osmoregulation in the renal papilla: membranes, messengers and molecules. Kinne RK, et al. **Kidney Int** 1996 Jun; 49(6):1686–9 (29 ref.)
Lipocortin 1: a second messenger of glucocorticoid action in the hypothalamo-pituitary-adrenocortical axis.
Buckingham JC, et al. **Mol Med Today** 1997 Jul; 3(7):296–302 (39 ref.)
The modulation of calcium currents by the activation of mGluRs. Functional implications. Stefani A, et al.
Mol Neurobiol 1996 Aug;13(1):81–95 (81 ref.)
Nitric oxide: a spatial second messenger. Schulman H.
Mol Psychiatry 1997 Jul;2(4):296–9 (24 ref.)
Bioactive lipids in excitatory neurotransmission and neuronal plasticity. Bazan NG, et al. **Neurochem Int** 1997 Feb; 30(2):225–31 (59 ref.)
The enigma of potassium ion in the management of dentine hypersensitivity: is nitric oxide the elusive second messenger? McCormack K, et al. **Pain** 1996 Nov;68(1):5–11 (89 ref.)
Regulation of entrainment pathways by the suprachiasmatic circadian clock: sensitivities to second messengers. Gillette MU. **Prog Brain Res** 1996;111:121–32 (50 ref.)
Modification of nociceptor responses by inflammatory mediators and second messengers implicated in their action—a study in canine testicular polymodal receptors. Mizumura K, et al. **Prog Brain Res** 1996;113:115–41 (149 ref.)
[Calcium oscillations and waves in a cell] Makowska A, et al. **Postepy Biochem** 1996;42(2):146–53 (54 ref.) **(Pol)**

SECOND NEOPLASM see **NEOPLASMS, SECOND PRIMARY**

SECOND OPINION see **REFERRAL AND CONSULTATION**

SECOND PRIMARY NEOPLASMS see **NEOPLASMS, SECOND PRIMARY**

SECRETIN

see related
GASTROINTESTINAL AGENTS

CHEMISTRY

Speculations on the mechanism of hormone-receptor interactions of the secretin/glucagon family of polypeptide hormones derived from computational structural studies. Momany FA, et al. **Ann N Y Acad Sci** 1996 Dec 26; 805:172–81; discussion 181–3 (18 ref.)

DIAGNOSTIC USE

Clinical perspectives of a sonographic secretin test. Glaser J. **Z Gastroenterol** 1997 Jul;35(7):579–83 (23 ref.)
[Secretin test (S-test)] Oyama H, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:197–201 (4 ref.) **(Jpn)**

IMMUNOLOGY

Sevenspan transmembrane molecules: novel receptors involved in leukocyte adhesion. van Lier RA, et al.
Immunol Lett 1996 Dec;54(2–3):185–7 (13 ref.)

METABOLISM

Transcriptional regulation of secretin gene expression. Nishitani J, et al. **J Clin Gastroenterol** 1995;21 Suppl 1:S50–55 (21 ref.)

SECRETORY GRANULES see **CYTOPLASMIC GRANULES**

SECRETORY IGA see **IGA, SECRETORY**

SECRETORY PHASE see **MENSTRUAL CYCLE**

SEDATION, CONSCIOUS see **CONSCIOUS SEDATION**

SEDATIVES see **HYPNOTICS AND SEDATIVES**

SEDATIVES, BARBITURATE

ADVERSE EFFECTS

Withdrawal strategies for outpatients. Alcohol, benzodiazepine, barbiturate, and opiate addictions. Mezciems PE. **Can Fam Physician** 1996 Sep;42:1745–52 (27 ref.)
Comparative review of the adverse effects of sedatives used in children undergoing outpatient procedures. D'Agostino J, et al. **Drug Saf** 1996 Mar;14(3):146–57 (134 ref.)

SEDATIVES, NONBARBITURATE

ADVERSE EFFECTS

Comparative review of the adverse effects of sedatives used in children undergoing outpatient procedures. D'Agostino J, et al. **Drug Saf** 1996 Mar;14(3):146–57 (134 ref.)

PHARMACOKINETICS

Pharmacokinetics and pharmacodynamics of midazolam given via continuous intravenous infusion in intensive care units. Fragen RJ. **Clin Ther** 1997 May–Jun;19(3):405–19; discussion 367–8 (38 ref.)

PHARMACOLOGY

Pharmacokinetics and pharmacodynamics of midazolam given via continuous intravenous infusion in intensive care units. Fragen RJ. **Clin Ther** 1997 May–Jun;19(3):405–19; discussion 367–8 (38 ref.)

THERAPEUTIC USE

Propofol in chemotherapy-associated nausea and vomiting. Phelps KC, et al. **Ann Pharmacother** 1996 Mar;30(3):290–2 (22 ref.)
A review of etomidate for rapid sequence intubation in the emergency department. Bergen JM, et al. **J Emerg Med** 1997 Mar–Apr;15(2):221–30 (162 ref.)
Midazolam: a review of therapeutic uses and toxicity. Nordt SP, et al. **J Emerg Med** 1997 May–Jun;15(3):357–65 (83 ref.)
Polysomnographic effects of hypnotic drugs. A review. Parrino L, et al. **Psychopharmacology (Berl)** 1996 Jul; 126(1):1–16 (131 ref.)
Long-term subcutaneous infusion of midazolam for refractory delirium in terminal breast cancer. Ramani S, et al. **South Med J** 1996 Nov;89(11):1101–3 (12 ref.)

SEDIMENTS, GEOLOGIC see **GEOLOGIC SEDIMENTS**

SEDIMENTS, MARINE see **GEOLOGIC SEDIMENTS**

SEEDLINGS see **PLANTS**

SEEDS

see related
NUTS

ENZYMOLOGY

Protein proteinase inhibitors in legume seeds—overview. Birk Y. **Arch Latinoam Nutr** 1996 Dec;44(4 Suppl 1):26S–30S (47 ref.)

GENETICS

Seed banks and molecular maps: unlocking genetic potential from the wild. Tanksley SD, et al. **Science** 1997 Aug 22; 277(5329):1063–6 (22 ref.)

METABOLISM

Oleosins and oil bodies in seeds and other organs. Huang AH. **Plant Physiol** 1996 Apr;110(4):1055–61 (27 ref.)

SEEDS

PHYSIOLOGY

Pollen embryogenesis. Reynolds TL. **Plant Mol Biol** 1997 Jan;33(1):1–10 (56 ref.)

SEGMENTATION STAGE, OVUM see **CLEAVAGE STAGE, OVUM**

SEIZURES

Seizures and epilepsy in the elderly. Thomas RJ. **Arch Intern Med** 1997 Mar 24;157(6):605–17 (203 ref.)

Neonatal seizures. Rennie JM. **Eur J Pediatr** 1997 Feb; 156(2):83–7 (47 ref.)

The evaluation and treatment of seizures in the emergency department. Jagoda A, et al. **Mt Sinai J Med** 1997 Sep–Oct; 64(4–5):249–57 (76 ref.)

CHEMICALLY INDUCED

Seizure–inducing effects of antiepileptic drugs: a review. Bauer J. **Acta Neurol Scand** 1996 Dec;94(6):367–77 (146 ref.)

Antidepressants and seizures: clinical anecdotes overshadow neuroscience. Dailey JW, et al. **Biochem Pharmacol** 1996 Nov 8;52(9):1323–9 (65 ref.)

Emergency management of acute alcohol problems. Part 2: Alcohol–related seizures, delirium tremens, and toxic alcohol ingestion. Etherington JM. **Can Fam Physician** 1996 Dec;42:2423–31 (17 ref.)

Chlorambucil–induced seizures. Salloum E, et al. **Cancer** 1997 Mar 1;79(5):1009–13 (2 ref.)

Seizures associated with ofloxacin therapy. Traeger SM, et al. **Clin Infect Dis** 1995 Dec;21(6):1504–6 (7 ref.)

Safe and effective topical application dose of lidocaine for surgery with laryngomicroscopy. Kotaki H, et al. **Clin Pharmacol Ther** 1996 Aug;60(2):229–35 (15 ref.)

Neurotoxicity of carbapenem antibacterials. Norrby SR. **Drug Saf** 1996 Aug;15(2):87–90 (33 ref.)

Inadvertent intrathecal use of ionic contrast agents: treatment with immediate ventriculolumbar lavage [letter] Schwab S, et al. **J Neurol** 1996 Sep;243(9):671–3 (9 ref.)

[MDMA ("Ecstasy") use––an overview of psychiatric and medical sequelae] Thomasius R, et al. **Fortschr Neurol Psychiatr** 1997 Feb;65(2):49–61 (125 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Seizure: a rare and transient cause of portal venous gas. Chen KW, et al. **Am J Gastroenterol** 1997 Feb;92(2):351–2 (10 ref.)

The phenomenology of psychosis associated with complex partial seizure disorder. Brewerton TD. **Ann Clin Psychiatry** 1997 Mar;9(1):31–51 (278 ref.)

DIAGNOSIS

Bilateral perisylvian syndrome not related to malformations: report of two cases. Grasel RP, et al. **Arq Neuropsiquiatr** 1996 Jun;54(2):293–6 (10 ref.)

Spells. Differential diagnosis and management strategies. Preblick–Salib C, et al. **Emerg Med Clin North Am** 1997 Aug;15(3):637–48 (30 ref.)

Provoking nonepileptic seizures: the ethics of deceptive diagnostic testing. Burack JH, et al. **Hastings Cent Rep** 1997 Jul–Aug;27(4):24–33 (25 ref.)

Do seizures beget seizures? An assessment of the clinical evidence in humans. Berg AT, et al. **J Clin Neurophysiol** 1997 Mar;14(2):102–10 (48 ref.)

Intracranial electrode monitoring for seizure localization: indications, methods and the prevention of complications. Dewar S, et al. **J Neurosci Nurs** 1996 Oct;28(5):280–4, 289–92 (30 ref.)

Pseudoseizures in the pediatric emergency department. Selbst SM, et al. **Pediatr Emerg Care** 1996 Jun;12(3):185–8 (19 ref.)

DRUG THERAPY

Evaluation and management of first seizures in adults. Moore–Sledge CM. **Am Fam Physician** 1997 Sep 15; 56(4):1113–20 (22 ref.)

Remacemide hydrochloride: a novel antiepileptic agent. Davies JA. **Gen Pharmacol** 1997 Apr;28(4):499–502 (31 ref.)

Seizure control: how to use the new antiepileptic drugs in older patients. Haider A, et al. **Geriatrics** 1996 Sep; 51(9):42–5 (16 ref.)

Maternal and fetal implications of anticonvulsive therapy during pregnancy. Eller DP, et al. **Obstet Gynecol Clin North Am** 1997 Sep;24(3):523–34 (46 ref.)

New drug therapy for acute seizure management. Morton LD, et al. **Semin Pediatr Neurol** 1997 Mar;4(1):51–63 (76 ref.)

[Neonatal seizures: the beginning and interruption of the treatment] Koenigsberger MR, et al. **Rev Neurol** 1997 May; 25(141):706–8 (28 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Evaluation and management of first seizures in adults. Moore–Sledge CM. **Am Fam Physician** 1997 Sep 15; 56(4):1113–20 (22 ref.)

Neonatal seizures: a clinician's overview. Lombroso CT. **Brain Dev** 1996 Jan–Feb;18(1):1–28 (276 ref.)

A review of the newer antiepileptic drugs and the ketogenic diet. Barron TF, et al. **Clin Pediatr (Phila)** 1997 Sep; 36(9):513–21 (61 ref.)

Seizures in medically complex patients. Boggs JG. **Epilepsia** 1997;38 Suppl 4:S55–9 (24 ref.)

Provoking nonepileptic seizures: the ethics of deceptive diagnostic testing. Burack JH, et al. **Hastings Cent Rep** 1997 Jul–Aug;27(4):24–33 (25 ref.)

Seizures, epilepsy, and functional recovery after traumatic brain injury: a reappraisal. Hernandez TD, et al. **Neurology** 1997 Apr;48(4):803–6 (47 ref.)

Seizures after orthotopic liver transplantation. Wszolek ZK, et al. **Seizure** 1997 Feb;6(1):31–9 (33 ref.)

[The Churg–Strauss syndrome with cerebral seizures and terminal kidney failure] Terjung B, et al. **Dtsch Med Wochenschr** 1997 Jul 4;122(27):853–8 (22 ref.) (Eng. Abstr.) **(Ger)**

[Differential diagnosis of seizures in sleep] Mayer G, et al. **Pneumologie** 1997 Aug;51 Suppl 3:698–705 (31 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Seizure–induced molecular changes, sprouting and synaptogenesis of hippocampal mossy fibers. Pollard H, et al. **Epilepsy Res Suppl** 1996;12:355–63 (32 ref.)

Similarities of EEG and seizures in del(1q) and benign rolandic epilepsy. Vaughn BV, et al. **Pediatr Neurol** 1996 Oct;15(3):261–4 (30 ref.)

METABOLISM

Seizures and the regulation of neurotrophic factor expression: associations with structural plasticity in epilepsy. Gall CM, et al. **Adv Neurol** 1997;72:9–24 (97 ref.)

MICROBIOLOGY

Unusual neurologic manifestation of enteric fever––case report and review of the literature. Liman AS. **Cent Afr J Med** 1996 Oct;42(10):301–2 (6 ref.)

PHYSIOPATHOLOGY

Seizures and the regulation of neurotrophic factor expression: associations with structural plasticity in epilepsy. Gall CM, et al. **Adv Neurol** 1997;72:9–24 (97 ref.)

Molecular and cellular cascades in seizure–induced neosynapse formation. Represa A, et al. **Adv Neurol** 1997; 72:25–34 (60 ref.)

Ontogeny and topography of seizure regulation by the substantia nigra. Moshé SL, et al. **Brain Dev** 1995;17 Suppl:61–72 (113 ref.)

Transition between two types of epileptic seizures in developing rats as a sign of progressive epileptogenesis. Mareš P, et al. **Epilepsy Res Suppl** 1996;12:75–8 (30 ref.)

Auras and experiential responses arising in the temporal lobe. Fried I. **J Neuropsychiatry Clin Neurosci** 1997 Summer; 9(3):420–8 (45 ref.)

A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala–kindled seizures. Post RM, et al. **Mol Neurobiol** 1996 Aug; 13(1):33–60 (132 ref.)

[Generalization mechanisms of limbic seizures] Mori N. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1997 Feb; 17(1):25–9 (26 ref.) (Eng. Abstr.) **(Jpn)**

[The neuropeptide galanin and the seizure reactions of the developing brain] Chepurnov SA, et al. **Usp Fiziol Nauk** 1997 Apr–Jun;28(2):3–20 (102 ref.) (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Role of magnesium sulfate in seizure prevention in patients with eclampsia and pre–eclampsia. Anthony J, et al. **Drug Saf** 1996 Sep;15(3):188–99 (115 ref.)

A practical guide to when (and how) to withdraw antiepileptic drugs in seizure–free patients. Schmidt D, et al. **Drugs** 1996 Dec;52(6):870–4 (17 ref.)

The role of antiseizure prophylaxis following head injury. Brain Trauma Foundation. **J Neurotrauma** 1996 Nov; 13(11):731–4 (14 ref.)

THERAPY

Seizures. Bleck TP. **Baillieres Clin Neurol** 1996 Oct; 5(3):565–76 (29 ref.)

Emergency management of acute alcohol problems. Part 2: Alcohol–related seizures, delirium tremens, and toxic alcohol ingestion. Etherington JM. **Can Fam Physician** 1996 Dec;42:2423–31 (17 ref.)

ULTRASONOGRAPHY

Prenatal ultrasound diagnosis of seizures. Osiovich H, et al. **Am J Perinatol** 1996 Nov;13(8):499–501 (16 ref.)

SEIZURES, FEBRILE see **CONVULSIONS, FEBRILE**

E–SELECTIN

ANALYSIS

Soluble markers of endothelial cell function. Blann A, et al. **Clin Hemorheol Microcirc** 1997 Jan–Feb;17(1):3–11 (100 ref.)

BIOSYNTHESIS

The significance of adhesion molecules in nephrology. Burkhardt K, et al. **Artif Organs** 1996 May;20(5):433–6 (27 ref.)

Vascular endothelial adhesion molecules and tissue inflammation. Malik AB, et al. **Pharmacol Rev** 1996 Jun; 48(2):213–29 (135 ref.)

METABOLISM

Selectin ligands, leukocyte trafficking, and fucosyltransferase genes. Lowe JB. **Kidney Int** 1997 May;51(5):1418–26 (113 ref.)

PHYSIOLOGY

Novel roles for E–selectin in endothelial–leukocyte adhesion. Yoshida M, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:493–7 (12 ref.)

L–SELECTIN

METABOLISM

Expression of an L–selectin ligand on hematopoietic progenitor cells. Sackstein R. **Acta Haematol** 1997; 97(1–2):22–8 (51 ref.)

Selectin ligands, leukocyte trafficking, and fucosyltransferase genes. Lowe JB. **Kidney Int** 1997 May;51(5):1418–26 (113 ref.)

PHYSIOLOGY

High–endothelial–venule ligands for L–selectin: identification and functions. Rosen SD, et al. **Biochem Soc Trans** 1997 May;25(2):428–33 (45 ref.)

L–Selectin––a signalling receptor for lipopolysaccharide. Malhotra R, et al. **Chem Biol** 1997 Aug;4(8):543–7 (29 ref.)

P–SELECTIN

Hypothesis: is soluble P–selectin a new marker of platelet activation? Blann AD, et al. **Atherosclerosis** 1997 Feb 10; 128(2):135–8 (33 ref.)

[Cell adhesion molecules on platelet] Ono M, et al. **Rinsho Byori** 1996 Dec;44(12):1132–7 (28 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Vascular endothelial adhesion molecules and tissue inflammation. Malik AB, et al. **Pharmacol Rev** 1996 Jun; 48(2):213–29 (135 ref.)

METABOLISM

Selectin ligands, leukocyte trafficking, and fucosyltransferase genes. Lowe JB. **Kidney Int** 1997 May;51(5):1418–26 (113 ref.)

PHYSIOLOGY

P–selectin induction of tissue factor biosynthesis and expression. Furie B, et al. **Haemostasis** 1996;26 Suppl 1:60–5 (40 ref.)

Inflammation as an early component of atherosclerosis and vascular damage––a role for P–selectin and platelet–activating factor. Prescott SM, et al. **Jpn Circ J** 1996 Mar;60(3):137–41 (26 ref.)

Leukocyte migration in immune complex glomerulonephritis: role of adhesion receptors. Lefkowith JB. **Kidney Int** 1997 May;51(5):1469–75 (54 ref.)

Leukocyte crosstalk at the vascular wall. Furie B, et al. **Thromb Haemost** 1997 Jul;78(1):306–9 (34 ref.)

SELECTINS

Selectins and their ligands: current concepts and controversies. Kansas GS. **Blood** 1996 Nov 1;88(9):3259–87 (340 ref.)

[The selections, selectin ligands and hemopoitic system] Miyakasa M. **Rinsho Ketsueki** 1996 Jun;37(6):502–5 (0 ref.) **(Jpn)**

DRUG EFFECTS

Anti–adhesion therapy. Cornejo CJ, et al. **Adv Pharmacol** 1997;39:99–142 (200 ref.)

IMMUNOLOGY

The selectins: insights into selectin–induced intracellular signaling in leukocytes. Crockett–Torabi E, et al. **Immunol Res** 1995;14(4):237–51 (116 ref.)

METABOLISM

Involvement of selectins in atherogenesis: a primary or secondary event? Miyasaka M, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:25–34; discussion 34–5 (19 ref.)

Two selectins converge on sulphate. Leukocyte adhesion. Rosen SD, et al. **Curr Biol** 1996 Mar 1;6(3):261–4 (21 ref.)

Ligand–specificity of the selectins. Vestweber D. **J Cell Biochem** 1996 Jun 15;61(4):585–91 (53 ref.)

Selectin ligands: will the real ones please stand up? Varki A. **J Clin Invest** 1997 Jan 15;99(2):158–62 (74 ref.)

PHYSIOLOGY

Cell adhesion and angiogenesis. Bischoff J. **J Clin Invest** 1997 Feb 1;99(3):373–6 (27 ref.)
Therapeutic inhibition of carbohydrate–protein interactions in vivo. Lowe JB, et al. **J Clin Invest** 1997 Mar 1; 99(5):822–6 (39 ref.)
Perspectives series: cell adhesion in vascular biology. Role of PSGL–1 binding to selectins in leukocyte recruitment. McEver RP, et al. **J Clin Invest** 1997 Aug 1;100(3):485–91 (70 ref.)
Selectins, T–cell rolling and inflammation. Rossiter H, et al. **Mol Med Today** 1997 May;3(5):214–22 (49 ref.)
Sialomucin ligands for selectins: a new family of cell adhesion molecules. Lasky LA. **Princess Takamatsu Symp** 1994; 24:81–90 (39 ref.)
Intervention of carbohydrate recognition by proteins and nucleic acids. Sears P, et al.
Proc Natl Acad Sci U S A 1996 Oct 29;93(22):12086–93 (117 ref.)
Selectins and their counter receptors: a bitter sweet attraction. Symon FA, et al. **Thorax** 1996 Nov; 51(11):1155–7 (12 ref.)
Insights into selectin function from knockout mice. Frenette PS, et al. **Thromb Haemost** 1997 Jul;78(1):60–4 (42 ref.)
The role of leukocyte and endothelial adhesion molecules in ischemia–reperfusion injury. Thiagarajan RR, et al.
Thromb Haemost 1997 Jul;78(1):310–4 (35 ref.)
[Regulation of leukocyte migration by adhesion molecules] Spertini O. **Schweiz Med Wochenschr** 1996 Nov 9; 126(45):1926–34 (81 ref.) (Eng. Abstr.) **(Fre)**
[Selectin family] Nakamura S, et al. **Rinsho Byori** 1996 Sep; Suppl 102:24–32 (17 ref.) **(Jpn)**

SELECTION (GENETICS)

On the incomplete architecture of human ontogeny. Selection, optimization, and compensation as foundation of developmental theory. Baltes PB. **Am Psychol** 1997 Apr; 52(4):366–80 (110 ref.)
Beef carcase characteristics that may be of value in selecting for genetic merit. Johnson ER. **Aust Vet J** 1996 Jun; 73(6):233–40 (65 ref.)
Selective breeding for isolation–induced intermale aggression in mice: associated responses and environmental influences. Sandnabba NK. **Behav Genet** 1996 Sep;26(5):477–88 (100 ref.)
tRNA–ribosome interactions. Ehrenberg M, et al.
Biochem Cell Biol 1995 Nov–Dec;73(11–12):1049–54 (35 ref.)
The nature of selection on the major histocompatibility complex. Apanius V, et al. **Crit Rev Immunol** 1997; 17(2):179–224 (388 ref.)
Genetic redundancy: screening for selection in yeast. Brookfield JFY. **Curr Biol** 1997 Jun 1;7(6):R366–8 (6 ref.)
Selection for maximum longevity in mice. Harrison DE, et al. **Exp Gerontol** 1997 Jan–Apr;32(1–2):65–78 (52 ref.)
Prospects for development of genetic markers for resistance to gastrointestinal parasite infection in sheep. Beh KJ, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):879–97 (149 ref.)
Fitness of parasites: pathology and selection. Combes C. **Int J Parasitol** 1997 Jan;27(1):1–10 (45 ref.)
Phenotypic markers for selection of nematode–resistant sheep. Douch PG, et al. **Int J Parasitol** 1996 Aug–Sep; 26(8–9):899–911 (44 ref.)
Does the use of antimicrobial agents in veterinary medicine and animal husbandry select antibiotic–resistant bacteria that infect man and compromise antimicrobial chemotherapy? [see comments] Piddock LJ.
J Antimicrob Chemother 1996 Jul;38(1):1–3 (23 ref.) Comment in: J Antimicrob Chemother 1997 Feb;39(2):285–6. Comment in: J Antimicrob Chemother 1997 Mar;39(3):435.
Killer plaque technique for selecting hybrids and cybrids obtained by induced protoplast fusion. Palková Z, et al. **Methods Mol Biol** 1996;53:339–42 (2 ref.)
Application of killer toxins in stepwise selection of hybrids and cybrids obtained by induced protoplast fusion. Vondrejs V, et al. **Methods Mol Biol** 1996;53:331–8 (15 ref.)
Evolutionary divergence and salinity–mediated selection in halophilic archaea. Dennis PP, et al.
Microbiol Mol Biol Rev 1997 Mar;61(1):90–104 (33 ref.)
Are bacterial biofilms constrained to Darwin's concept of evolution through natural selection? Caldwell DE, et al. **Microbiologia** 1996 Sep;12(3):347–58 (61 ref.)
Short–term selection for four–week body weight in Japanese quail. Anthony NB, et al. **Poult Sci** 1996 Oct;75(10):1192–7 (17 ref.)
Long–term divergent selection for eight–week body weight in white Plymouth rock chickens. Dunnington EA, et al. **Poult Sci** 1996 Oct;75(10):1168–79 (106 ref.)
Direct and correlated responses to long–term selection for increased body weight and egg production in turkeys. Nestor KE, et al. **Poult Sci** 1996 Oct;75(10):1180–91 (54 ref.)
Symposium: the effects of long–term selection on growth of poultry. Introduction. Reddy RP. **Poult Sci** 1996 Oct; 75(10):1164–7 (11 ref.)
The objects of selection. Mayr E.
Proc Natl Acad Sci U S A 1997 Mar 18;94(6):2091–4 (19 ref.)
Familial risks and reproductive fitness in schizophrenia. Battaglia M, et al. **Schizophr Bull** 1996;22(2):191–5 (23 ref.)
Adaptive mutations: a challenge to neo–Darwinism? Savic DJ. **Sci Prog** 1997;80 (Pt 2):125–45 (53 ref.)
Variation and selection in neural function [letter; comment] Changeux JP. **Trends Neurosci** 1997 Jul;20(7):291–3 (20 ref.) Comment on: Trends Neurosci 1996 Nov;19(11):460–4.
Variation and selection in neural function [letter; comment] Sporns O. **Trends Neurosci** 1997 Jul;20(7):291; discussion 293 (20 ref.) Comment on: Trends Neurosci 1996 Nov;19(11):460–4.
[The mutation and the selection of inactivating enzymes against antibiotic resistances] Inoue M, et al.
Nippon Rinsho 1997 May;55(5):1161–6 (7 ref.) (Eng. Abstr.) **(Jpn)**

SELECTION BIAS

The silent ones: a review of sampling issues and biases pertinent to the area of pediatric oncology procedural pain. Williams HA. **J Pediatr Oncol Nurs** 1996 Jan;13(1):31–9 (76 ref.)
Assembling comparison groups to assess the effects of health care. Chalmers I. **J R Soc Med** 1997 Jul;90(7):379–86 (69 ref.)
Handling missing data in survey research. Brick JM, et al. **Stat Methods Med Res** 1996 Sep;5(3):215–38 (96 ref.)
Modelling the sampling design in the analysis of health surveys. Graubard BI, et al. **Stat Methods Med Res** 1996 Sep;5(3):263–81 (53 ref.)
The use of sampling weights for survey data analysis. Pfeffermann D. **Stat Methods Med Res** 1996 Sep; 5(3):239–61 (42 ref.)
Variance estimation for complex surveys using replication techniques. Rust KF, et al. **Stat Methods Med Res** 1996 Sep;5(3):283–310 (52 ref.)

SELECTION CRITERIA see **PATIENT SELECTION**

SELEGILINE

ADMINISTRATION & DOSAGE

Selegiline and mortality in Parkinson's disease [see comments] Olanow CW, et al. **Ann Neurol** 1996 Dec;40(6):841–5 (36 ref.) Comment in: Ann Neurol 1997 Feb;41(2):282–3.
(–)Deprenyl (selegiline) in Parkinson's disease: a pharmacologist's comment [letter] Knoll J.
Biomed Pharmacother 1996;50(6–7):315–7 (29 ref.)

ADVERSE EFFECTS

Retrospective study of selegiline–antidepressant drug interactions and a review of the literature. Ritter JL, et al. **Ann Clin Psychiatry** 1997 Mar;9(1):7–13 (37 ref.)

METABOLISM

Modulation of gene expression rather than monoamine oxidase inhibition: (–)–deprenyl–related compounds in controlling neurodegeneration. Tatton WG, et al.
Neurology 1996 Dec;47(6 Suppl 3):S171–83 (205 ref.)

PHARMACOKINETICS

Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Mahmood I. **Clin Pharmacokinet** 1997 Aug;33(2):91–102 (44 ref.)
Are metabolites of l–deprenyl (selegiline) useful or harmful? Indications from preclinical research. Yasar S, et al.
J Neural Transm Suppl 1996;48:61–73 (50 ref.)

PHARMACOLOGY

Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Mahmood I. **Clin Pharmacokinet** 1997 Aug;33(2):91–102 (44 ref.)
The pharmacology of B–type selective monoamine oxidase inhibitors; milestones in (–)–deprenyl research. Magyar K, et al. **J Neural Transm Suppl** 1996;48:29–43 (65 ref.)
(–)–Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. Tatton WG, et al.
J Neural Transm Suppl 1996;48:45–59 (98 ref.)
Pharmacology of selegiline. Gerlach M, et al. **Neurology** 1996 Dec;47(6 Suppl 3):S137–45 (83 ref.)
(–)Deprenyl reduces delayed neuronal death of hippocampal pyramidal cells. Paterson IA, et al.
Neurosci Biobehav Rev 1997 Mar;21(2):181–6 (27 ref.)

THERAPEUTIC USE

Selegiline in treatment of behavioral and cognitive symptoms of Alzheimer disease. Tolbert SR, et al.
Ann Pharmacother 1996 Oct;30(10):1122–9 (90 ref.)
New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline. Gerlach M, et al.
J Neural Transm Suppl 1996;48:7–21 (63 ref.)
The clinical potential of Deprenyl in neurologic and psychiatric disorders. Kuhn W, et al.
J Neural Transm Suppl 1996;48:85–93 (51 ref.)
Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action. Olanow CW. **J Neural Transm Suppl** 1996;48:75–84 (60 ref.)
Selegiline monotherapy in the treatment of Parkinson's disease. Koller WC. **Neurology** 1996 Dec;47(6 Suppl 3):S196–9 (38 ref.)
Role of selegiline in combination therapy of Parkinson's disease. Myllylä VV, et al. **Neurology** 1996 Dec;47(6 Suppl 3):S200–9 (145 ref.)
Selegiline: current perspectives on issues related to neuroprotection and mortality. Olanow CW. **Neurology** 1996 Dec;47(6 Suppl 3):S210–6 (72 ref.)
Attempts to obtain neuroprotection in Parkinson's disease. Olanow CW. **Neurology** 1997 Jul;49(1 Suppl 1):S26–33 (87 ref.)
Management of canine pituitary–dependent hyperadrenocorticism with l–deprenyl (Anipryl). Bruyette DS, et al. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):273–86 (34 ref.)
[Neuroprotective and neurorestorative therapy in Parkinson's disease] Jiménez–Jiménez FJ, et al. **Rev Neurol** 1997 Aug; 25 Suppl 2:S185–93 (207 ref.) (Eng. Abstr.) **(Spa)**

SELENITE see **SODIUM SELENITE**

SELENIUM

Selenium in health and disease: a review. Foster LH, et al. **Crit Rev Food Sci Nutr** 1997 Apr;37(3):211–28 (122 ref.)

ADMINISTRATION & DOSAGE

Dietary selenium repletion may reduce cancer incidence in people at high risk who live in areas with low soil selenium. Fleet JC. **Nutr Rev** 1997 Jul;55(7):277–9 (9 ref.)

ADVERSE EFFECTS

Selenium as a risk factor for cardiovascular diseases. Nève J. **J Cardiovasc Risk** 1996 Feb;3(1):42–7 (63 ref.)
Selenium–induced "blind staggers" and related myths. A commentary on the extent of historical livestock losses attributed to selenosis on western US rangelands. O'Toole D, et al. **Vet Pathol** 1996 Jan;33(1):109–16 (163 ref.)

ANALYSIS

A protocol for aquatic hazard assessment of selenium. Lemly AD. **Ecotoxicol Environ Saf** 1995 Dec;32(3):280–8 (149 ref.)

BLOOD

Reference values for serum selenium in various areas–evaluated according to the TRACY protocol. Alfthan G, et al. **J Trace Elem Med Biol** 1996 Jun; 10(2):77–87 (81 ref.)
Human selenium supplementation as assessed by changes in blood selenium concentration and glutathione peroxidase activity. Nève J. **J Trace Elem Med Biol** 1995 Jul;9(2):65–73 (32 ref.)
[Selenium, glutathione peroxidase, peroxides and platelet functions] Vitoux D, et al. **Ann Biol Clin (Paris)** 1996; 54(5):181–7 (35 ref.) (Eng. Abstr.) **(Fre)**
[Serum selenium contents in cancer patients] Ujiie S, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(4):401–5 (12 ref.) (Eng. Abstr.) **(Jpn)**

DEFICIENCY

Interacting nutritional and infectious etiologies of Keshan disease. Insights from coxsackie virus B–induced myocarditis in mice deficient in selenium or vitamin E. Levander OA, et al. **Biol Trace Elem Res** 1997 Jan; 56(1):5–21 (75 ref.)
Detecting subclinical deficiency of essential trace elements in children with special reference to zinc and selenium. Salmenperä L. **Clin Biochem** 1997 Mar;30(2):115–20 (49 ref.)
Increased virulence of coxsackievirus B3 in mice due to vitamin E or selenium deficiency. Beck MA. **J Nutr** 1997 May;127(5 Suppl):966S–970S (12 ref.)
Landscapes of longevity: the calcium–selenium–mercury connection in cancer and heart disease. Foster HD.
Med Hypotheses 1997 Apr;48(4):355–60 (76 ref.)

METABOLISM

Regulation of selenoprotein gene expression and thyroid hormone metabolism. Arthur JR, et al.
Biochem Soc Trans 1996 May;24(2):384–8 (50 ref.)
Selenium metabolism and bioavailability. Daniels LA.
Biol Trace Elem Res 1996 Sep;54(3):185–99 (99 ref.)
Sudden infant death syndrome and placental disorders: the thyroid–selenium link. Reid GM, et al. **Med Hypotheses** 1997 Apr;48(4):317–24 (66 ref.)
[Nutritional biochemical aspects of the significance, of the utilization, of metabolism and of the administration of vitamin E and of selenium in sheep (review)] Kolb E, et al. **Berl Munch Tierarztl Wochenschr** 1997 May; 110(5):178–84 (48 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOKINETICS

Metabolism of subtoxic levels of selenium in animals and humans. Whanger P, et al. **Ann Clin Lab Sci** 1996 Mar–Apr; 26(2):99–113 (33 ref.)
Selenium metabolism and bioavailability. Daniels LA.
Biol Trace Elem Res 1996 Sep;54(3):185–99 (99 ref.)
Bioavailability of selenium. Fairweather–Tait SJ.
Eur J Clin Nutr 1997 Jan;51 Suppl 1:S20–3 (45 ref.)

SELENIUM

PHARMACOLOGY

The mutual sparing effects of selenium and vitamin E in animal nutrition may be further explained by the discovery that mammalian thioredoxin reductase is a selenoenzyme. Tamura T, et al. **Biofactors** 1995-96;5(2):99-102 (42 ref.)

Dietary vitamin E and selenium affect mastitis and milk quality. Smith KL, et al. **J Anim Sci** 1997 Jun;75(6):1659-65 (54 ref.)

PHYSIOLOGY

[Role of selenium in human pathophysiology] Andrzejak R, et al. **Postepy Hig Med Dosw** 1996;50(3):293-307 (84 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

The attributes of selenium-enriched garlic in cancer prevention. Ip C, et al. **Adv Exp Med Biol** 1996;401:179-87 (25 ref.)

[Neuroprotective and neurorestorative therapy in Parkinson's disease] Jiménez-Jiménez FJ, et al. **Rev Neurol** 1997 Aug; 25 Suppl 2:S185-93 (207 ref.) (Eng. Abstr.) **(Spa)**

TOXICITY

Metabolism of subtoxic levels of selenium in animals and humans. Whanger P, et al. **Ann Clin Lab Sci** 1996 Mar-Apr; 26(2):99-113 (33 ref.)

[Selenium and oral cancer. Review of the literature] Carinci F, et al. **Minerva Stomatol** 1996 Jul-Aug;45(7-8):345-8 (12 ref.) (Eng. Abstr.) **(Ita)**

SELENIUM COMPOUNDS

ADMINISTRATION & DOSAGE

Human selenium supplementation as assessed by changes in blood selenium concentration and glutathione peroxidase activity. Nève J. **J Trace Elem Med Biol** 1995 Jul;9(2):65-73 (32 ref.)

ADVERSE EFFECTS

Hyperpigmentation associated with selenium sulfide lotion [letter] Gillum RF. **J Natl Med Assoc** 1996 Sep;88(9):551 (4 ref.)

SELENOCYSTEINE

CHEMISTRY

The mutual sparing effects of selenium and vitamin E in animal nutrition may be further explained by the discovery that mammalian thioredoxin reductase is a selenoenzyme. Tamura T, et al. **Biofactors** 1995-96;5(2):99-102 (42 ref.)

METABOLISM

Selenocysteine. Stadtman TC. **Annu Rev Biochem** 1996; 65:83-100 (85 ref.)

RNAs mediating cotranslational insertion of selenocysteine in eukaryotic selenoproteins. Hubert N, et al. **Biochimie** 1996;78(7):590-6 (40 ref.)

SELF see **EGO**

SELF ADMINISTRATION

A review of patient-controlled sedation. Dell R. **Eur J Anaesthesiol** 1996 Nov;13(6):547-52 (31 ref.)

Medication noncompliance. Olfson M, et al. **New Dir Ment Health Serv** 1997 Spring;(73):39-49 (36 ref.)

A critique of fixed and progressive ratio schedules used to examine the neural substrates of drug reinforcement. Arnold JM, et al. **Pharmacol Biochem Behav** 1997 Jul; 57(3):441-7 (70 ref.)

Sensitization and tolerance in psychostimulant self-administration. Schenk S, et al. **Pharmacol Biochem Behav** 1997 Jul;57(3):543-50 (42 ref.)

Nicotine self-administration in animals and humans: similarities and differences. Rose JE, et al. **Psychopharmacology (Berl)** 1997 Mar;130(1):28-40 (108 ref.)

INSTRUMENTATION

Aids to compliance with medication. Corlett AJ. **BMJ** 1996 Oct 12;313(7062):926-9 (5 ref.)

METHODS

Comparison of guidelines and self-management plans in asthma. Meijer RJ, et al. **Eur Respir J** 1997 May; 10(5):1163-72 (45 ref.)

Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. Richardson NR, et al. **J Neurosci Methods** 1996 May; 66(1):1-11 (60 ref.)

SELF ASSESSMENT (PSYCHOLOGY)

Is self-reported pain an appropriate outcome measure in ergonomic-epidemiologic studies of work-related musculoskeletal disorders? Schierhout GH, et al. **Am J Ind Med** 1996 Jul;30(1):93-8 (45 ref.)

The roots of self-knowledge: perceiving self, it, and thou. Neisser U. **Ann N Y Acad Sci** 1997 Jun 18;818:18-33 (36 ref.)

Margaret Holroyd Prize Essay. A patient-centred approach to evaluation and treatment in rheumatoid arthritis: the development of a clinical tool to measure patient-perceived handicap. Carr AJ. **Br J Rheumatol** 1996 Oct;35(10):921-32 (114 ref.)

Shifting attention from objective risk factors to patients' self-assessed health resources: a clinical model for general practice. Hollnagel H, et al. **Fam Pract** 1995 Dec; 12(4):423-9 (50 ref.)

Perspectives unifying symptom interpretation. Teel CS, et al. **Image J Nurs Sch** 1997;29(2):175-81 (47 ref.)

The "self digest": self-knowledge serving self-regulatory functions. Higgins ET. **J Pers Soc Psychol** 1996 Dec; 71(6):1062-83 (175 ref.)

SELF CARE

Approaches for incorporating ovulation detection devices and home kits into learning NFP--implications for service delivery. Kirkman RJ. **Adv Contracept** 1997 Jun-Sep; 13(2-3):269-72 (6 ref.)

Testing for HIV at home: what are the issues? [editorial] [see comments] Schopper D, et al. **AIDS** 1996 Nov; 10(13):1455-65 (97 ref.) Comment in: AIDS 1997 Jun;11(7):936-7.

Interventions to reduce the impact of chronic disease: community-based arthritis patient education. Goeppinger J, et al. **Annu Rev Nurs Res** 1997;15:101-22 (63 ref.)

Spinal cord injury rehabilitation. 3. Functional outcomes. Formal CS, et al. **Arch Phys Med Rehabil** 1997 Mar;78(3 Suppl):S59-64 (58 ref.)

A practical guide for peak expiratory flow monitoring in asthma patients. Jain P, et al. **Cleve Clin J Med** 1997 Apr; 64(4):195-202 (42 ref.)

The role of patient participation in the doctor visit. Implications for adherence to diabetes care. Golin CE, et al. **Diabetes Care** 1996 Oct;19(10):1153-64 (134 ref.)

Conceptual and methodologic issues in quantifying perceptual accuracy in childhood asthma. Fritz GK, et al. **J Pediatr Psychol** 1996 Apr;21(2):153-73 (64 ref.)

Bandura's theory of self-efficacy: applications to oncology. Lev EL. **Sch Inq Nurs Pract** 1997 Spring;11(1):21-37; discussion 39-43 (62 ref.)

Paths to recovery from substance misuse: change of lifestyle and the role of treatment. Biomqvist J. **Subst Use Misuse** 1996 Nov;31(13):1807-52 (109 ref.)

[Self-monitoring of blood pressure] Weber F, et al. **Dtsch Med Wochenschr** 1997 Mar 14;122(11):335-8 (46 ref.) **(Ger)**

METHODS

Self-management plans: uses and limitations. Partridge MR. **Br J Hosp Med** 1996 Feb 7-20;55(3):120-2 (11 ref.)

Take control of high-cost asthma [see comments] Flaum M, et al. **J Asthma** 1997;34(1):5-14 (18 ref.) Comment in: J Asthma 1997 ;34(1):1-3.

Daily symptoms and responses in adults: a review. Burman ME. **Public Health Nurs** 1996 Aug;13(4):294-301 (57 ref.)

STANDARDS

Electronic communication with patients. Evaluation of distance medicine technology. Balas EA, et al. **JAMA** 1997 Jul 9;278(2):152-9 (93 ref.)

SELF CARE (REHABILITATION) see **ACTIVITIES OF DAILY LIVING**

SELF CONCEPT

see related
BODY IMAGE

Body/self awareness and interpersonal communications: fundamental components of reproductive health awareness. Aumack-Yee K. **Adv Contracept** 1997 Jun-Sep; 13(2-3):319-23 (6 ref.)

Competency beliefs and occupational role behavior among adolescents: explication of the personal causation construct. Henry AD, et al. **Am J Occup Ther** 1997 Apr;51(4):267-76 (80 ref.)

The self in relation to others: cognitive and motivational underpinnings. Andersen SM, et al. **Ann N Y Acad Sci** 1997 Jun 18;818:233-75 (220 ref.)

On the rise and fall of self-conception in primates. Gallup GG Jr. **Ann N Y Acad Sci** 1997 Jun 18;818:72-82 (26 ref.)

Self-knowledge and self-awareness. Kihlstrom JF, et al. **Ann N Y Acad Sci** 1997 Jun 18;818:4-17 (30 ref.)

The self in self-conscious emotions. Lewis M. **Ann N Y Acad Sci** 1997 Jun 18;818:118-42 (49 ref.)

A comparison of the self-awareness and kinesthetic-visual matching theories of self-recognition: autistic children and others. Mitchell RW. **Ann N Y Acad Sci** 1997 Jun 18; 818:38-62 (111 ref.)

The roots of self-knowledge: perceiving self, it, and thou. Neisser U. **Ann N Y Acad Sci** 1997 Jun 18;818:18-33 (36 ref.)

Finding one's self in time. Nelson K. **Ann N Y Acad Sci** 1997 Jun 18;818:102-16 (31 ref.)

The self-schema model: a theoretical approach to the self-concept in eating disorders. Stein KF. **Arch Psychiatr Nurs** 1996 Apr;10(2):96-109 (114 ref.)

The concept of "self". Gilhotra J. **Aust N Z J Psychiatry** 1995 Dec;29(4):598-603 (20 ref.)

Reflective capacity and its significance to the attachment concept of the self. West ML. **Br J Med Psychol** 1997 Mar;70 (Pt 1):17-25 (45 ref.)

Rethinking the effects of homelessness on children: resiliency and competency. Douglass A. **Child Welfare** 1996 Nov-Dec;75(6):741-51 (16 ref.)

Racism and the mental health of African Americans: the role of self and system blame. Neighbors HW, et al. **Ethn Dis** 1996 Winter-Spring;6(1-2):167-75 (53 ref.)

Age, socioeconomic status, and exercise self-efficacy [see comments] Clark DO. **Gerontologist** 1996 Apr;36(2):157-64 (53 ref.) Comment in: Gerontologist 1996 Apr;36(2):145-6. Comment in: Gerontologist 1996 Apr;36(2):174-7.

Adherence: a matter of self-efficacy and power. Buchmann WF. **J Adv Nurs** 1997 Jul;26(1):132-7 (11 ref.)

Towards further clarification of the concept 'dignity'. Haddock J. **J Adv Nurs** 1996 Nov;24(5):924-31 (49 ref.)

Dementia and personhood: a focus for care? Jenkins D, et al. **J Adv Nurs** 1996 Jul;24(1):84-90 (26 ref.)

Cognitive behaviour therapy territory model: effective disputing approach. Lam D. **J Adv Nurs** 1997 Jun; 25(6):1205-9 (8 ref.)

Psychoanalysis is self-centered. Rubin JB. **J Am Acad Psychoanal** 1996 Winter;24(4):633-48 (50 ref.)

Dead babies and the birth of desire: maternal erotic transferences and countertransferences. Wrye HK. **J Am Acad Psychoanal** 1996 Spring;24(1):75-94 (14 ref.)

Do brain tissue transplants alter personal identity? Inadequacies of some "standard" arguments [see comments] Northoff G. **J Med Ethics** 1996 Jun;22(3):174-80 (30 ref.) Comment in: J Med Ethics 1996 Jun;22(3):131-2.

Sense of self in children with cancer and in childhood cancer survivors: a critical review. Woodgate R, et al. **J Pediatr Oncol Nurs** 1997 Jul;14(3):137-55 (62 ref.)

The "self digest": self-knowledge serving self-regulatory functions. Higgins ET. **J Pers Soc Psychol** 1996 Dec; 71(6):1062-83 (175 ref.)

Personal construct psychotherapy of addictions. Klion RE, et al. **J Subst Abuse Treat** 1997 Jan-Feb;14(1):37-43 (26 ref.)

Seminal truth: a modern science of male celibacy in north India. Alter JS. **Med Anthropol Q** 1997 Sep;11(3):275-98; discussion 299-301 (110 ref.)

What language reveals about children's categories of personhood. Budwig N, et al. **New Dir Child Dev** 1995 Fall;(69):21-32 (25 ref.)

Naturalistic observation of children with autism: evidence for intersubjectivity. Toomey J, et al. **New Dir Child Dev** 1995 Fall;(69):75-89 (28 ref.)

Gay, lesbian, and bisexual adolescents: providing esteem-enhancing care to a battered population. Nelson JA. **Nurse Pract** 1997 Feb;22(2):94, 99, 103 passim (45 ref.)

Winnicott goes to the movies: the false self in Ordinary People. Newman KM. **Psychoanal Q** 1996 Oct; 65(4):787-807 (9 ref.)

A stitch in time: self-regulation and proactive coping. Aspinwall LG, et al. **Psychol Bull** 1997 May;121(3):417-36 (175 ref.)

Models of the self: self-construals and gender [see comments] Cross SE, et al. **Psychol Bull** 1997 Jul;122(1):5-37 (475 ref.) Comment in: Psychol Bull 1997 Jul;122(1):38-44; discussion 51-5. Comment in: Psychol Bull 1997 Jul;122(1):45-50; discussion 51-5.

Psychological well-being: meaning, measurement, and implications for psychotherapy research. Ryff CD, et al. **Psychother Psychosom** 1996;65(1):14-23 (56 ref.)

Some interesting perturbations of the self in neurology. Feinberg TE. **Semin Neurol** 1997 Jun;17(2):129-35 (66 ref.)

Some conceptual considerations on the sense of coherence. Geyer S. **Soc Sci Med** 1997 Jun;44(12):1771-9 (59 ref.)

The (dis)embodied self in anorexia nervosa. Lester RJ. **Soc Sci Med** 1997 Feb;44(4):479-89 (56 ref.)

[New approaches for understanding borderline personality disorder] Frommer J, et al. **Fortschr Neurol Psychiatr** 1997 Jan;65(1):34-40 (70 ref.) (Eng. Abstr.) **(Ger)**

SELF-DESTRUCTIVE BEHAVIOR see **SELF-INJURIOUS BEHAVIOR**

SELF DETERMINATION see **FREEDOM**

SELF DISCLOSURE

"Reality" and countertransference in the treatment of sexual abuse patients: the false memory controversy. Perlman SD. **J Am Acad Psychoanal** 1996 Spring;24(1):115-35 (32 ref.)

Studies of nonresponse and measurement error in the national household survey on drug abuse. Gfroerer J, et al. **NIDA Res Monogr** 1997;167:273-95 (15 ref.)

Self-reported drug use: results of selected empirical investigations of validity. Hser YI. **NIDA Res Monogr** 1997; 167:320-43 (27 ref.)

Mode of interview and reporting of sensitive issues: design and implementation of audio computer-assisted self-interviewing. Lessler JT, et al. **NIDA Res Monogr** 1997;167:366-82 (27 ref.)

The use of the psychological laboratory to study sensitive survey topics. Willis GB. **NIDA Res Monogr** 1997; 167:416-38 (55 ref.)

SELF ESTEEM see **SELF CONCEPT**

SELF-EVALUATION PROGRAMS

METHODS

Reflective learning: a teaching strategy for critical thinking. Baker CR. **J Nurs Educ** 1996 Jan;35(1):19–22 (14 ref.)

SELF-EXAMINATION

Skin self-examination for melanoma--another golden rule. Howell JB. **Semin Cutan Med Surg** 1997 Jun;16(2):174–8 (19 ref.)

[Self-assessment of peak expiratory flow] Tsukioka K. **Nippon Rinsho** 1997 Apr;55 Suppl 2:31–4 (7 ref.) **(Jpn)**

SELF-EXAMINATION, BREAST see **BREAST SELF-EXAMINATION**

SELF-HELP DEVICES

Fortnightly review. Environmental control systems for people with a disability: an update. Wellings DJ, et al. **BMJ** 1997 Aug 16;315(7105):409–12 (33 ref.)

SELF-HELP GROUPS

Intersubjectivity, social microcosm, and the here-and-now in a support group for nurses. Brandman W. **Arch Psychiatr Nurs** 1996 Dec;10(6):374–8 (8 ref.)

Obsessive-compulsive disorder: adding value to treatment through patient support groups. Broatch JW. **Int Clin Psychopharmacol** 1996 Dec;11 Suppl 5:89–94 (21 ref.)

Change mechanisms of support groups for caregivers of dementia patients. Cuijpers P, et al. **Int Psychogeriatr** 1996 Winter;8(4):575–87 (45 ref.)

[Role of associations in bipolar patients] Attar-Lévy D, et al. **Encephale** 1997 Jan;23 Spec No 1:42–8 (16 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

The online patient meeting. Feenberg AL, et al. **J Neurol Sci** 1996 Aug;139 Suppl:129–31 (20 ref.)

SELF-INJURIOUS BEHAVIOR

COMPLICATIONS

Self-injury in trauma survivors: 1. functions and meanings. Connors R. **Am J Orthopsychiatry** 1996 Apr;66(2):197–206 (50 ref.)

Self-injury in trauma survivors: 2. levels of clinical response. Connors R. **Am J Orthopsychiatry** 1996 Apr;66(2):207–16 (34 ref.)

DIAGNOSIS

Oral self-injurious behavior in the developmentally disabled: review and a case. Saemundsson SR, et al. **ASDC J Dent Child** 1997 May-Jun;64(3):205–9, 228 (42 ref.)

DRUG THERAPY

Trazodone for aggression in an adolescent with hydrocephalus. Mashiko H, et al. **Psychiatry Clin Neurosci** 1996 Jun;50(3):133–6 (16 ref.)

PSYCHOLOGY

Self-injury in trauma survivors: 1. functions and meanings. Connors R. **Am J Orthopsychiatry** 1996 Apr;66(2):197–206 (50 ref.)

An ethological approach to self-injury [editorial] [see comments] Jones IH, et al. **Br J Psychiatry** 1996 Sep; 169(3):263–7 (21 ref.) Comment in: Br J Psychiatry 1997 Feb;170:192–3.

[Self-injury behavior] Hönigl D, et al. **Acta Med Austriaca** 1997;24(1):19–22 (16 ref.) (Eng. Abstr.) **(Ger)**

[Open self-injury behavior with special reference to child and adolescent psychiatry. A review of the literature and first study findings] Wewetzer G, et al. **Z Kinder Jugenpsychiatr** 1997 May;25(2):95–105 (57 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Self-injury in trauma survivors: 2. levels of clinical response. Connors R. **Am J Orthopsychiatry** 1996 Apr;66(2):207–16 (34 ref.)

Managing self-harm: the legal issues. **Drug Ther Bull** 1997 Jun;35(6):41–3 (25 ref.)

SELF-INSTRUCTION PROGRAMS, COMPUTERIZED see **COMPUTER-ASSISTED INSTRUCTION**

SELF MEDICATION

Self-medication and STD prevention [editorial; comment] Nichter M. **Sex Transm Dis** 1996 Sep-Oct;23(5):353–6 (2 ref.) Comment on: Sex Transm Dis 1996 Sep-Oct;23(5):407–12.

Treatment seeking for malaria: a review of recent research. McCombie SC. **Soc Sci Med** 1996 Sep;43(6):933–45 (90 ref.)

ADVERSE EFFECTS

Medication use in seniors: challenges and solutions. Tamblyn R. **Therapie** 1996 May-Jun;51(3):269–82 (186 ref.)

[Pharmacovigilance of self-medication] Montastruc JL, et al. **Therapie** 1997 Mar-Apr;52(2):105–10 (26 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Beers MH. **Arch Intern Med** 1997 Jul 28;157(14):1531–6 (29 ref.)

TRENDS

Changing patterns of pharmaceutical practice in the United States. Vuckovic N, et al. **Soc Sci Med** 1997 May; 44(9):1285–302 (126 ref.)

SELF-MONITORING, BLOOD GLUCOSE see **BLOOD GLUCOSE SELF-MONITORING**

SELF MUTILATION

Self-inflicted injuries. Challenging knowledge, skill, and compassion. Haswell DE, et al. **Can Fam Physician** 1996 Sep;42:1756–8, 1761–4 (11 ref.)

COMPLICATIONS

Acute tibial compartment syndrome secondary to psychosomatic disorder. Eskander MB, et al. **J R Army Med Corps** 1994 Jun;140(2):97–8 (5 ref.)

Sarcoid-like foreign body reaction in body piercing: a report of two cases. Ng KH, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jul;84(1):28–31 (11 ref.)

DIAGNOSIS

Pediatric psychocutaneous disorders. Hansen RC. **Curr Opin Pediatr** 1997 Aug;9(4):367–71 (14 ref.)

The identification and management of self-mutilating patients in primary care. Dallam SJ. **Nurse Pract** 1997 May; 22(5):151–3, 159–65 (34 ref.)

[Voluntary mercury poisoning: biological consequences and psychiatric significance (published erratum appears in Schweiz Rundsch Med Prax 1997 Jul 2;86(27-28):1123)] Jornod P, et al. **Schweiz Rundsch Med Prax** 1997 May 28; 86(22):946–51 (51 ref.) (Eng. Abstr.) **(Fre)**

[Artificially-induced disorders and dissociation] Freyberger HJ, et al. **Med Klin** 1997 Jan 15;92(1):46–8 (11 ref.) **(Ger)**

ETIOLOGY

Oral and maxillofacial manifestations of hereditary sensory neuropathy. Narayanan V. **Br J Oral Maxillofac Surg** 1996 Oct;34(5):446–9 (16 ref.)

PSYCHOLOGY

Oedipism. Aung T, et al. **Aust N Z J Ophthalmol** 1996 May; 24(2):153–7 (34 ref.)

Lethal suicidal intoxication with propafenone, after a history of self-inflicted injuries. Maxeiner H, et al. **Forensic Sci Int** 1997 Sep 19;89(1-2):27–32 (12 ref.)

[Open self-injury behavior with special reference to child and adolescent psychiatry. A review of the literature and first study findings] Wewetzer G, et al. **Z Kinder Jugenpsychiatr** 1997 May;25(2):95–105 (57 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

[Self-induced injuries--surgical aspects] Katzer A, et al. **Unfallchirurgie** 1997 Jun;23(3):105–13 (48 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

The identification and management of self-mutilating patients in primary care. Dallam SJ. **Nurse Pract** 1997 May; 22(5):151–3, 159–65 (34 ref.)

SELF PERCEPTION see **SELF CONCEPT**

SELF PSYCHOLOGY

see related
NARCISSISM

A process view of the self. DeWaele M. **Br J Med Psychol** 1996 Dec;69 (Pt 4):299–311 (66 ref.)

Panic disorder: a bioself-psychological perspective. Miliora MT, et al. **J Am Acad Psychoanal** 1996 Summer; 24(2):217–56 (106 ref.)

Arthur Miller's drama from the standpoint of self psychology. Schneiderman L. **Psychoanal Rev** 1997 Jun;84(3):417–35 (29 ref.)

SELF STIMULATION

PHYSIOLOGY

[Biochemical mechanism of reinforcement: findings in the studies of self-stimulation] Nakajima S. **Shinrigaku Kenkyu** 1996 Feb;66(6):449–56 (57 ref.) (Eng. Abstr.) **(Jpn)**

SELF TOLERANCE

see related
AUTOIMMUNE DISEASES
CLONAL ANERGY
CLONAL DELETION

Balancing immunity, autoimmunity, and self-tolerance. Goodnow CC. **Ann N Y Acad Sci** 1997 Apr 5;815:55–66 (27 ref.)

Autoimmunity: when self-tolerance breaks down. Mueller DL, et al. **Curr Biol** 1997 Apr 1;7(4):R255–7 (10 ref.)

Tolerance: a case of self/not-self discrimination maintained by clonal deletion? Lafferty KJ, et al. **Hum Immunol** 1997 Feb;52(2):119–26 (45 ref.)

Receptor editing, immune diversification, and self-tolerance. Radic MZ, et al. **Immunity** 1996 Dec;5(6):505–11 (50 ref.)

Signal minus 1: a key factor in immunological tolerance to tissue-specific self antigens? Parish CR. **Immunol Cell Biol** 1996 Jun;74(3):278–85 (50 ref.)

The significance of immune suppression in normal self tolerance. McCullagh P. **Immunol Rev** 1996 Feb;149:127–53 (63 ref.)

Immune deviation--the third dimension of nondeletional T cell tolerance. Röcken M, et al. **Immunol Rev** 1996 Feb; 149:175–94 (104 ref.)

(Altered) self peptides and the regulation of self reactivity in the peripheral T cell pool. Van Eden W, et al. **Immunol Rev** 1996 Feb;149:55–73 (44 ref.)

Sites of B lymphocyte selection, activation, and tolerance in spleen. Liu YJ. **J Exp Med** 1997 Aug 29;186(5):625–9 (42 ref.)

Terra firma: a retreat from "danger". Langman RE, et al. **J Immunol** 1996 Nov 15;157(10):4273–6 (15 ref.)

The post-activation refractory phase: a mechanism to measure antigenic complexity and ensure self-tolerance among mature peripheral T lymphocytes. Mannie MD. **Med Hypotheses** 1996 Dec;47(6):467–70 (37 ref.)

[Immunosuppressive substances induced by liver grafting] Kobayashi E. **Tanpakushitsu Kakusan Koso** 1997 Jul; 42(9):1420–6 (40 ref.) **(Jpn)**

IMMUNOLOGY

Initiation of autoimmunity to self-proteins complexed with viral antigens. Reeves WH, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:139–54 (51 ref.)

Mechanisms of tolerance to self. Miller JF, et al. **Curr Opin Immunol** 1996 Dec;8(6):815–21 (67 ref.)

The avian model in the study of tolerance to self. Corbel C. **Curr Top Microbiol Immunol** 1996;212:95–106 (44 ref.)

Premature ovarian failure and ovarian autoimmunity. Hoek A, et al. **Endocr Rev** 1997 Feb;18(1):107–34 (318 ref.)

Interleukin-2 deficient mice: a new model to study autoimmunity and self-tolerance. Horak I, et al. **Immunol Rev** 1995 Dec;148:35–44 (29 ref.)

Immunological tolerance in germinal centres. Pulendran B, et al. **Immunol Today** 1997 Jan;18(1):27–32 (65 ref.)

T cell-mediated maintenance of natural self-tolerance: its breakdown as a possible cause of various autoimmune diseases. Sakaguchi S, et al. **J Autoimmun** 1996 Apr; 9(2):211–20 (58 ref.)

Dysregulation of potentially pathogenic self reactivity is crucial for the manifestation of clinical autoimmunity. Kumar V, et al. **J Neurosci Res** 1996 Aug 15;45(4):334–9 (26 ref.)

A short history of time and space in immune discrimination [see comments] Langman RE, et al. **Scand J Immunol** 1996 Dec;44(6):544–8 (10 ref.) Comment in: Scand J Immunol 1996 Dec;44(6):549–50.

[Clonal deletion and clonal anergy as the mechanism of self-tolerance induction] Ota H, et al. **Nippon Rinsho** 1997 Jun;55(6):1331–6 (20 ref.) (Eng. Abstr.) **(Jpn)**

SELLA TURCICA

see related
EMPTY SELLA SYNDROME

Primary sellar haemorrhagic melanoma: case report and review of the literature. Aubin MJ, et al. **Br J Neurosurg** 1997 Feb;11(1):80–3 (12 ref.)

Intrasellar paraganglioma: report of a case in a sibship of von Hippel-Lindau disease. Scheithauer BW, et al. **Neurosurgery** 1996 Feb;38(2):395–9 (26 ref.)

Intrasellar meningioma: case report and review of the literature. Nozaki K, et al. **Surg Neurol** 1997 May; 47(5):447–52; discussion 452–4 (14 ref.)

[Intra-sellar non-adenomatous expansive process] Rohmer V, et al. **Ann Endocrinol (Paris)** 1997;58(1):11–9 (70 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Sphenoid and sellar tumors. Isaacs RS, et al. **Otolaryngol Clin North Am** 1995 Dec;28(6):1191–229 (77

SELLA TURCICA

ref.)

PHYSIOPATHOLOGY

Hypothalamic disease: neurosecretory dysfunction and parasellar lesions. Bercu BB.
Curr Ther Endocrinol Metab 1997;6:21–6 (14 ref.)

SURGERY

Surgical treatment of anterior basal meningiomas. DeMonte F. **J Neurooncol** 1996 Sep;29(3):239–48 (31 ref.)
Sphenoid and sellar tumors. Isaacs RS, et al.
Otolaryngol Clin North Am 1995 Dec;28(6):1191–229 (77 ref.)

SEMANTICS

Language acquisition: the acquisition of linguistic structure in normal and special populations. McDonald JL.
Annu Rev Psychol 1997;48:215–41 (105 ref.)
Molecular semantics and the origin of life. Matsuno K.
Biosystems 1997;42(2–3):129–39 (43 ref.)
Introduction. The investigation of lexical semantic representation in Alzheimer's disease. Henderson VW.
Brain Lang 1996 Aug;54(2):179–83 (13 ref.)
Semantic category imprecision: a connectionist study of the boundaries of word meanings. Small SL. **Brain Lang** 1997 Apr;57(2):181–94 (31 ref.)
Attention and semantic priming: a review of prime task effects. Maxfield L. **Conscious Cogn** 1997 Jun–Sep; 6(2–3):204–18 (32 ref.)
Disorders of semantic memory [editorial] Garrard P, et al.
J Neurol Neurosurg Psychiatry 1997 May;62(5):431–5 (52 ref.)
Interaction, language and the "narrative turn" in psychotherapy and psychiatry. Brown B, et al.
Soc Sci Med 1996 Dec;43(11):1569–78 (83 ref.)
Meanings in policy: a textual analysis of Canada's "Achieving Health For All" document. Iannantuono A, et al.
Soc Sci Med 1997 Jun;44(11):1611–21 (46 ref.)

SEMEN

see related
SPERMATOZOA

Human semen analysis. Comhaire F, et al.
Hum Reprod Update 1995 Jul;1(4):343–62 (59 ref.)
Donor insemination: the gifting and selling of semen. Daniels KR, et al. **Soc Sci Med** 1996 Jun;42(11):1521–36 (96 ref.)

CHEMISTRY

Shedding of HIV-1 in the genital tract [editorial] Mostad SB, et al. **AIDS** 1996 Oct;10(12):1305–15 (74 ref.)
Prostaglandins in primate semen: biasing the immune system to benefit spermatozoa and virus? Kelly RW.
Prostaglandins Leukot Essent Fatty Acids 1997 Aug; 57(2):113–8 (71 ref.)

CYTOLOGY

Nonsperm cells in human semen: with special reference to seminal leukocytes and their possible influence on fertility. Fedder J. **Arch Androl** 1996 Jan–Feb;36(1):41–65 (94 ref.)
The significance of computer-assisted semen analysis (CASA) for diagnosis in andrology and fertility prognosis. Krause W. **Int J Androl** 1995 Dec;18 Suppl 2:32–5 (14 ref.)
NMR spectroscopy in andrology: research uses and possible clinical applications. Rohr G, et al. **Int J Androl** 1995 Dec; 18 Suppl 2:12–9 (41 ref.)
Use of semen as biopsy material for assessment of health status of the stallion reproductive tract. Veeramachaneni DN, et al. **Vet Clin North Am Equine Pract** 1996 Apr; 12(1):101–10 (6 ref.)

PHYSIOLOGY

Is male reproductive health at risk? Longitudinal semen analysis studies. Paulsen CA, et al. **Adv Contracept** 1997 Jun–Sep;13(2–3):119–21 (15 ref.)
Analysis of stallion semen and its relation to fertility. Graham JK. **Vet Clin North Am Equine Pract** 1996 Apr;12(1):119–30 (39 ref.)

VIROLOGY

Prostaglandins in primate semen: biasing the immune system to benefit spermatozoa and virus? Kelly RW.
Prostaglandins Leukot Essent Fatty Acids 1997 Aug; 57(2):113–8 (71 ref.)

SEMEN PRESERVATION

Preservation of reproductive function before therapy for cancer: new options involving sperm and ovary cryopreservation [editorial] Opsahl MS, et al.
Cancer J Sci Am 1997 Jul–Aug;3(4):189–91 (12 ref.)
Cryopreservation of spermatozoa: a 1996 review. Royere D, et al. **Hum Reprod Update** 1996 Nov–Dec;2(6):553–9 (72 ref.)
What are the chances of infertility and should sperm be banked? Ohl DA, et al. **Semin Urol Oncol** 1996 Feb; 14(1):36–44 (80 ref.)

METHODS

[Treatments of testicular cancer and protection of spermatogenesis] Bujan L, et al. **Contracept Fertil Sex** 1996 Jul–Aug;24(7–8):596–602 (34 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Alternative strategies for the long-term preservation of spermatozoa. Holt WV. **Reprod Fertil Dev** 1997;9(3):309–19 (89 ref.)
Evaluation of sperm damage and techniques for sperm clean-up. Rodriguez-Martinez H, et al.
Reprod Fertil Dev 1997;9(3):297–308 (87 ref.)
Cryopreservation of stallion spermatozoa. Graham JK.
Vet Clin North Am Equine Pract 1996 Apr;12(1):131–47 (39 ref.)

SEMICIRCULAR CANALS

SURGERY

Update on posterior canal occlusion for benign paroxysmal positional vertigo. Parnes LS.
Otolaryngol Clin North Am 1996 Apr;29(2):333–42 (28 ref.)

SEMICONDUCTORS

Molecular manipulation of microstructures: biomaterials, ceramics, and semiconductors. Stupp SI, et al. **Science** 1997 Aug 29;277(5330):1242–8 (64 ref.)

SEMILUNAR CARTILAGES see **MENISCI, TIBIAL**

SEMILUNAR GANGLION see **TRIGEMINAL GANGLION**

SEMINAL PLASMA see **SEMEN**

SEMINAL VESICLES

Bovine seminal vesiculitis. A review and update. Cavalieri J, et al. **Vet Clin North Am Food Anim Pract** 1997 Jul; 13(2):233–41 (30 ref.)

ABNORMALITIES

Congenital anomalies of the vas deferens, epididymis, and seminal vesicles. Vohra S, et al. **Urology** 1997 Mar; 49(3):313–21 (42 ref.)
[Seminal vesicle cyst and ipsilateral kidney failure. Report of 2 cases and review of the literature] Zurkirchen MA, et al. **Urologe A** 1996 Nov;35(6):490–4 (15 ref.) (Eng. Abstr.) **(Ger)**

PARASITOLOGY

Hydatid cysts of the kidney, seminal vesicle and gluteus muscle. Pasaoglu E, et al. **Australas Radiol** 1997 Aug; 41(3):297–9 (12 ref.)

PATHOLOGY

MR imaging of the prostate and seminal vesicles. David V. **Magn Reson Imaging Clin N Am** 1996 Aug;4(3):497–518 (67 ref.)
[Diagnosis and treatment of obstructive seminal vesicle pathology] Coppens L. **Acta Urol Belg** 1997 Jun;65(2):11–9 (55 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Neuropeptides in the seminal vesicles: locations, binding sites and functional implications. Pinho MS, et al.
Histol Histopathol 1997 Apr;12(2):503–12 (86 ref.)

SEMINOMA

DIAGNOSIS

[An interdisciplinary consensus conference on the diagnosis and therapy of testicular tumors] Bamberg M, et al.
Strahlenther Onkol 1997 Aug;173(8):397–406 (28 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

[Follow-up of testicular tumors in the metastatic diffusion phase. Current orientation] Mirone V, et al.
Minerva Urol Nefrol 1997 Jun;49(2):91–4 (13 ref.) (Eng. Abstr.) **(Ita)**

PREVENTION & CONTROL

Laparoscopic removal of gonads containing on occult seminoma in a woman with complete androgen resistance. Chantilis SJ, et al. **J Am Assoc Gynecol Laparosc** 1994 May; 1(3):277–82 (35 ref.)

RADIOTHERAPY

Postradiation lower motor neuron syndrome—a case report and brief literature review. Tallaksen CM, et al.
Acta Oncol 1997;36(3):345–7 (40 ref.)
Management of seminoma of the testis: recommendations based on treatment results. Morgan G, et al.
Aust N Z J Surg 1997 Jan;67(1):15–20 (26 ref.)
Radiotherapy in stage IIA and IIB testicular seminoma with reduced portals: a prospective multicenter study. Schmidberger H, et al. **Int J Radiat Oncol Biol Phys** 1997 Sep 1;39(2):321–6 (39 ref.)
Radiation-induced sarcoma following curative radiotherapy for testicular seminoma: case report and brief review of the literature. Stein ME, et al. **Tumori** 1997 May–Jun; 83(3):721–3 (14 ref.)

SURGERY

Management of seminoma of the testis: recommendations based on treatment results. Morgan G, et al.
Aust N Z J Surg 1997 Jan;67(1):15–20 (26 ref.)
Surgery for a post-chemotherapy residual mass in seminoma. Herr HW, et al. **J Urol** 1997 Mar;157(3):860–2 (15 ref.)

THERAPY

Treatment of advanced seminoma: an update. Sleijfer DT, et al. **Anticancer Drugs** 1997 Feb;8(2):107–12 (56 ref.)
[Metallothionein expression as a marker of therapeutic sensitivity in the early stages of testicular cancer] Eid H, et al. **Orv Hetil** 1997 Jan 19;138(3):135–9 (28 ref.) (Eng. Abstr.) **(Hun)**

SEMIOCHEMICALS see **PHEROMONES**

SEMI-PRIVATE ROOMS see **PATIENTS' ROOMS**

SEMISYNTHETIC VACCINES see **VACCINES, SYNTHETIC**

SEMLIKI FOREST VIRUS

GENETICS

Manipulation of the Semliki Forest virus genome and its potential for vaccine construction. Atkins GJ, et al.
Mol Biotechnol 1996 Feb;5(1):33–8 (29 ref.)

SENDAI VIRUS see **PARAMYXOVIRUS**

SENECIO

see related
PYRROLIZIDINE ALKALOIDS

SENECIO ALKALOIDS see **PYRROLIZIDINE ALKALOIDS**

SENESCENCE see **AGING**

SENESCENCE, CELLULAR see **CELL AGING**

SENILE OSTEOPOROSIS see **OSTEOPOROSIS**

SENNA

CHEMISTRY

Assessment of the genotoxic risk from laxative senna products. Brusick D, et al. **Environ Mol Mutagen** 1997; 29(1):1–9 (33 ref.)

PHARMACOLOGY

Assessment of the genotoxic risk from laxative senna products. Brusick D, et al. **Environ Mol Mutagen** 1997; 29(1):1–9 (33 ref.)

SENSATION

see related
PERCEPTION

The psychobiology of traumatic memory. Clinical implications of neuroimaging studies. Van Der Kolk BA, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:99–113 (58 ref.)
The sensory biology of the living jawless fishes: a phylogenetic assessment. Braun CB. **Brain Behav Evol** 1996; 48(5):262–76 (181 ref.)
The importance of a consideration of qualia to imagery and cognition [see comments] Hubbard TL. **Conscious Cogn** 1996 Sep;5(3):327–58 (100 ref.) Comment in: Conscious Cogn 1996 Sep;5(3):359–67. Comment in: Conscious Cogn 1996 Sep;5(3):368–80.
Recent developments in an animal model of visual evoked potential augmenting/reducing and sensation seeking behavior. Siegel J, et al. **Neuropsychobiology** 1996; 34(3):130–5 (38 ref.)
Corneal sensitivity in health and disease. Lawrenson JG.
Ophthalmic Physiol Opt 1997 Mar;17 Suppl 1:S17–22 (27 ref.)
Misconceptions about classical psychophysics and the measurement of response bias. Gardner RM.
Percept Mot Skills 1997 Apr;84(2):587–94 (19 ref.)

DRUG EFFECTS

Sensory and cognitive effects of developmental methylmercury exposure in monkeys, and a comparison to effects in rodents. Rice DC. **Neurotoxicology** 1996 Spring;17(1):139–54 (58 ref.)

PHYSIOLOGY

Vestibular function and sensory interaction in altered gravity. Kornilova LN. **Adv Space Biol Med** 1997;6:275–313 (73 ref.)
The generation and subtraction of sensory expectations within cerebellum-like structures. Bell C, et al. **Brain Behav Evol** 1997;50 Suppl 1:17–31 (60 ref.)
Sensory signaling in Caenorhabditis elegans. Kaplan JM. **Curr Opin Neurobiol** 1996 Aug;6(4):494–9 (34 ref.)
Sensory hyperacuity in the jamming avoidance response of weakly electric fish. Kawasaki M. **Curr Opin Neurobiol** 1997 Aug;7(4):473–9 (51 ref.)
Synchronous oscillatory activity in sensory systems: new vistas on mechanisms. Ritz R, et al. **Curr Opin Neurobiol** 1997 Aug;7(4):536–46 (93 ref.)
Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Bueno L, et al. **Gastroenterology** 1997 May;112(5):1714–43 (329 ref.)
Supplemental stimulation of premature infants: a treatment model. Dieter JN, et al. **J Pediatr Psychol** 1997 Jun; 22(3):281–95 (77 ref.)
Neurotrophins cause a new sensation. Snider WD, et al. **Neuron** 1996 Feb;16(2):229–32 (26 ref.)
Novelty-seeking in rats--biobehavioral characteristics and possible relationship with the sensation-seeking trait in man. Dellu F, et al. **Neuropsychobiology** 1996;34(3):136–45 (50 ref.)
The psychobiological model for impulsive unsocialized sensation seeking: a comparative approach. Zuckerman M. **Neuropsychobiology** 1996;34(3):125–9 (32 ref.)
Sensory information--the major factor of ontogeny. Raevsky VV, et al. **Neurosci Behav Physiol** 1997 Jul–Aug; 27(4):455–61 (30 ref.)
[Analysis of EEG resonance reactions in evaluation of the effectiveness of sensory stimulation] Fedotchev AI. **Fiziol Cheloveka** 1997 Jul–Aug;23(4):117–23 (67 ref.) **(Rus)**
[The nonspecific mechanisms of CNS adaptation to intermittent stimuli, EEG spectral structure and the optimal parameters of rhythmic sensory actions] Fedotchev AI, et al. **Usp Fiziol Nauk** 1996 Oct–Dec;27(4):44–62 (173 ref.) (Eng. Abstr.) **(Rus)**
[Sensory information--an important factor in ontogeny] Raevskiĭ VV, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 Mar–Apr; 47(2):299–307 (30 ref.) (Eng. Abstr.) **(Rus)**

SENSATION DISORDERS

[A case of Dyke-Davidoff-Masson syndrome with total hemiatrophy] Hozumi A, et al. **Rinsho Shinkeigaku** 1996 Oct;36(10):1143–9 (17 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Differential diagnosis of gait disorders in older adults. Alexander NB. **Clin Geriatr Med** 1996 Nov;12(4):689–703 (74 ref.)
Using technology-based techniques to assess postural control and gait in older adults. Alexander NB. **Clin Geriatr Med** 1996 Nov;12(4):725–44 (135 ref.)
Functional assessment of balance and gait. Berg K, et al. **Clin Geriatr Med** 1996 Nov;12(4):705–23 (68 ref.)
Clinical overview of instability in the elderly. Studenski S, et al. **Clin Geriatr Med** 1996 Nov;12(4):679–88 (16 ref.)
Sensory-perceptual abnormalities in autism: a case for more research? O'Neill M, et al. **J Autism Dev Disord** 1997 Jun; 27(3):283–93 (35 ref.)
Evaluation of postural stability in children: current theories and assessment tools. Westcott SL, et al. **Phys Ther** 1997 Jun;77(6):629–45 (117 ref.)

ETIOLOGY

Differential diagnosis of gait disorders in older adults. Alexander NB. **Clin Geriatr Med** 1996 Nov;12(4):689–703 (74 ref.)
Disorders of posture, balance, and gait in Parkinson's disease. Rogers MW. **Clin Geriatr Med** 1996 Nov;12(4):825–45 (85 ref.)
Evaluation of postural stability in children: current theories and assessment tools. Westcott SL, et al. **Phys Ther** 1997 Jun;77(6):629–45 (117 ref.)
[Pure sensory syndrome due to a lacunar infarct in the protuberance (letter)] Marcos Toledano MM, et al. **Med Clin (Barc)** 1997 Feb 15;108(6):236 (9 ref.) **(Spa)**

IMMUNOLOGY

Autoantibody-associated sensory neuronopathy and intestinal pseudo-obstruction without detectable neoplasia. Briellmann RS, et al. **Eur Neurol** 1996;36(6):369–73 (26 ref.)

PHYSIOPATHOLOGY

Cutaneous sensory disorder. Koo J, et al. **Dermatol Clin** 1996 Jul;14(3):497–502 (23 ref.)
Postural perturbations: new insights for treatment of balance disorders. Horak FB, et al. **Phys Ther** 1997 May; 77(5):517–33 (84 ref.)

PREVENTION & CONTROL

Clinical overview of instability in the elderly. Studenski S, et al. **Clin Geriatr Med** 1996 Nov;12(4):679–88 (16 ref.)

THERAPY

[The use of prisms in postural equilibrium] Preoteasa D. **Oftalmologia** 1996 Oct–Dec;40(4):331–9 (12 ref.) (Eng. Abstr.) **(Rum)**

SENSE ORGANS

see related
RECEPTORS, SENSORY

ANATOMY & HISTOLOGY

The sensory biology of the living jawless fishes: a phylogenetic assessment. Braun CB. **Brain Behav Evol** 1996; 48(5):262–76 (181 ref.)
Structural diversity of the ordinary and specialized lateral line organs. Cernuda-Cernuda R, et al. **Microsc Res Tech** 1996 Jul 1;34(4):302–12 (60 ref.)

CYTOLOGY

Control of daughter cell fates during asymmetric division: interaction of Numb and Notch. Guo M, et al. **Neuron** 1996 Jul;17(1):27–41 (84 ref.)

EMBRYOLOGY

Cell fate determination in Drosophila. Vervoort M, et al. **Curr Opin Neurobiol** 1997 Feb;7(1):21–8 (66 ref.)
Fetal sensory competencies. Lecanuet JP, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Sep;68(1–2):1–23 (249 ref.)
Ontogeny of the cutaneous sensory organs. Saxod R. **Microsc Res Tech** 1996 Jul 1;34(4):313–33 (100 ref.)

GROWTH & DEVELOPMENT

Ontogeny of the cutaneous sensory organs. Saxod R. **Microsc Res Tech** 1996 Jul 1;34(4):313–33 (100 ref.)

INNERVATION

Structural diversity of the ordinary and specialized lateral line organs. Cernuda-Cernuda R, et al. **Microsc Res Tech** 1996 Jul 1;34(4):302–12 (60 ref.)

PHYSIOLOGY

Assessing sensory capacity of animals using operant technology. Arave CW. **J Anim Sci** 1996 Aug; 74(8):1996–2009 (65 ref.)
Multiple factors shape development of olfactory glomeruli: insights from an insect model system. Oland LA, et al. **J Neurobiol** 1996 May;30(1):92–109 (136 ref.)

SENSITIVITY AND SPECIFICITY

Statistical methodology: I. Incorporating the prevalence of disease into the sample size calculation for sensitivity and specificity [see comments] Buderer NM. **Acad Emerg Med** 1996 Sep;3(9):895–900 (5 ref.) Comment in: Acad Emerg Med 1996 Sep;3(9):824.

SENSITIVITY, CONTACT see **DERMATITIS, CONTACT**

SENSITIZATION, IMMUNOLOGIC see **IMMUNIZATION**

SENSORY AIDS

Virtual reality: an assistive technology in neurological rehabilitation. Rose FD, et al. **Curr Opin Neurol** 1996 Dec; 9(6):461–7 (53 ref.)
Reading with magnifiers. Den Brinker BP, et al. **Ergonomics** 1996 Oct;39(10):1231–48 (90 ref.)
Automatic visual to tactile translation--Part I: Human factors, access methods, and image manipulation. Way TP, et al. **IEEE Trans Rehabil Eng** 1997 Mar;5(1):81–94 (90 ref.)

SENSORY AND AUTONOMIC NEUROPATHIES, HEREDITARY see **NEUROPATHIES, HEREDITARY SENSORY AND AUTONOMIC**

SENSORY DEPRIVATION

PHYSIOLOGY

Sensory regulation of immediate-early gene expression in mammalian visual cortex: implications for functional mapping and neural plasticity. Kaczmarek L, et al. **Brain Res Brain Res Rev** 1997 Apr;23(3):237–56 (169 ref.)
A discussion of activity-dependent forms of synaptic weakening and their possible role in ocular dominance plasticity. Dudek SM. **J Physiol Paris** 1996;90(3–4):167–70 (38 ref.)
Sensory deprivation in spinal cord injury--an essay. Crossman MW. **Spinal Cord** 1996 Oct;34(10):573–7 (28 ref.)

SENSORY GANGLIA see **GANGLIA, SENSORY**

SENSORY MOTOR PERFORMANCE see **PSYCHOMOTOR PERFORMANCE**

SENSORY NEUROPATHY, HEREDITARY see **NEUROPATHIES, HEREDITARY SENSORY AND AUTONOMIC**

SENSORY THRESHOLDS

DRUG EFFECTS

Evidence for delayed neurotoxicity produced by methylmercury. Rice DC. **Neurotoxicology** 1996 Fall-Winter;17(3–4):583–96 (31 ref.)

PHYSIOLOGY

Quantitative sensory testing. Yarnitsky D. **Muscle Nerve** 1997 Feb;20(2):198–204 (66 ref.)

SENTINEL HEALTH EVENT see **SENTINEL SURVEILLANCE**

SENTINEL SURVEILLANCE

Communicable diseases surveillance. **Commun Dis Intell** 1997 Jun 12;21(12):166–72 (0 ref.)
An international registry for toxic inhalation and pulmonary edema: notes from work in progress. Guidotti TL. **Int Arch Occup Environ Health** 1996;68(6):380–6 (28 ref.)

SEOUL VIRUS see **HANTAVIRUS**

SEPSIS

Current understanding of sepsis. Wenzel RP, et al. **Clin Infect Dis** 1996 Mar;22(3):407–12 (44 ref.)
Epidemiology, diagnosis, and therapy of fungal infections in surgery. Giamarellou H, et al. **Infect Control Hosp Epidemiol** 1996 Aug;17(8):558–64 (64 ref.)
The cytokine response to critical illness. Foëx BA, et al. **J Accid Emerg Med** 1996 May;13(3):154–62 (58 ref.)
Sepsis in neonates and children: definitions, epidemiology, and outcome. Martinot A, et al. **Pediatr Emerg Care** 1997 Aug;13(4):277–81 (45 ref.)
[Urosepsis] Moen H, et al. **Tidsskr Nor Laegeforen** 1997 Mar 10;117(7):959–62 (13 ref.) (Eng. Abstr.) **(Nor)**
[Current concepts in sepsis] Vasilescu C. **Chirurgia (Bucur)** 1996 Jul–Aug;45(4):159–69 (42 ref.) **(Rum)**

BLOOD

The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Levi M, et al. **Eur J Clin Invest** 1997 Jan;27(1):3–9 (56 ref.)

CLASSIFICATION

Introducing Critical Appraisal to studies of animal models investigating novel therapies in sepsis. Piper RD, et al. **Crit Care Med** 1996 Dec;24(12):2059–70 (111 ref.)
Clinical trials in sepsis: where do we stand? [see comments] Vincent JL. **J Crit Care** 1997 Mar;12(1):3–6 (17 ref.) Comment in: J Crit Care 1997 Mar;12(1):1–2.

COMPLICATIONS

Lactic acidosis in sepsis: a commentary [see comments] Gutierrez G, et al. **Intensive Care Med** 1996 Jan;22(1):6–16 (86 ref.) Comment in: Intensive Care Med 1996 Jan;22(1):3–5.
Liver injury during sepsis. Pastor CM, et al. **J Crit Care** 1995 Dec;10(4):183–97 (141 ref.)
Hemofiltration in multiorgan failure syndrome secondary to sepsis: a critical analysis of heterogeneity [editorial] Gotloib L. **Nephron** 1996;73(2):125–30 (86 ref.)
[Respiratory distress syndrome in adults with trauma or some other diseases] Gembitskiĭ EV, et al. **Klin Med (Mosk)** 1997; 75(6):8–12 (18 ref.) **(Rus)**

CONGENITAL

Intra-amniotic infection and premature rupture of the membranes. Belady PH, et al. **Clin Perinatol** 1997 Mar; 24(1):43–57 (104 ref.)
Group B streptococcus and pregnancy. Mercer BM, et al. **Pediatr Ann** 1996 Apr;25(4):206–14 (93 ref.)

DIAGNOSIS

Case report and review of Chromobacterium sepsis--a gram-negative sepsis mimicking melioidosis. Chong CY, et al. **Singapore Med J** 1997 Jun;38(6):263–5 (19 ref.)

DRUG THERAPY

Prudent selection of antimicrobials for neonatal sepsis. McManus MC. **Am J Health Syst Pharm** 1996 Aug 15; 53(16):1956–60 (52 ref.)
Pharmacotherapy of sepsis. Weikert LF, et al. **Clin Chest Med** 1996 Jun;17(2):289–305 (157 ref.)
Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment [editorial; comment] Zeni F, et al. **Crit Care Med** 1997 Jul;25(7):1095–100 (38 ref.) Comment on: Crit Care Med 1997 Jul;25(7):1115–24.
Rational use of antibiotics in neonatal infections. Musoke RN. **East Afr Med J** 1997 Mar;74(3):147–50 (23 ref.)
Dobutamine and the oxygen uptake/supply relationship in

sepsis: from global to regional--nothing is simple and easy [comment] Vogt J, et al. **Intensive Care Med** 1997 Jul; 23(7):715-7 (33 ref.) Comment on: Intensive Care Med 1997 Jul;23(7):732-7.

Antibiotics, cytokines, and endotoxin: a complex and evolving relationship in gram-negative sepsis. Horn DL, et al. **Scand J Infect Dis Suppl** 1996;101:9-13 (48 ref.)

Evidence for antibiotic-mediated endotoxin release as a contributing factor to lethality in experimental gram-negative sepsis. Morrison DC, et al. **Scand J Infect Dis Suppl** 1996;101:3-8 (25 ref.)

[Therapeutic use of monoclonal antibodies] Baron D. **Naturwissenschaften** 1997 May;84(5):189-98 (7 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Sepsis: a new hypothesis for pathogenesis of the disease process. Bone RC, et al. **Chest** 1997 Jul;112(1):235-43 (57 ref.)

Sepsis outcomes in infants and children with central venous catheters: percutaneous versus surgical insertion. Chathas MK, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Jul-Aug; 25(6):500-6 (39 ref.)

Defining intravascular catheter-related infections: a plea for uniformity. Mermel LA. **Nutrition** 1997 Apr;13(4 Suppl):2S-4S (27 ref.)

Risks of regional anesthesia--infectious, septic. Wedel DJ, et al. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):57-61 (30 ref.)

Neonatal sepsis: pathogenesis and supportive therapy. Wolach B. **Semin Perinatol** 1997 Feb;21(1):28-38 (91 ref.)

Complicated anorectal sepsis. Gilliland R, et al. **Surg Clin North Am** 1997 Feb;77(1):115-53 (205 ref.)

Surgical management and treatment of sepsis associated with gastrointestinal fistulas. Rolandelli R, et al. **Surg Clin North Am** 1996 Oct;76(5):1111-22 (19 ref.)

[Nitric oxide and sepsis] Knobel E. **Arq Bras Cardiol** 1996 Oct;67(4):263-6 (13 ref.) **(Por)**

[Role of bacterial lipopolysaccharides in human diseases: evolution of outlook] Malov VA, et al. **Vestn Ross Akad Med Nauk** 1997;(8):33-8 (36 ref.) (Eng. Abstr.) **(Rus)**

[Infection and sepsis in resuscitation] Rodrigo-Casanova P, et al. **Rev Esp Anestesiol Reanim** 1997 Jun-Jul;44(6):230-43 (101 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Immunological responses to thermal injury. Sparkes BG. **Burns** 1997 Mar;23(2):106-13 (83 ref.)

Current concepts of sepsis and acute lung injury. Sessler CN, et al. **Clin Chest Med** 1996 Jun;17(2):213-35 (151 ref.)

Applied molecular biology of sepsis. Remick DG. **J Crit Care** 1995 Dec;10(4):198-212 (85 ref.)

Cytokine production and its manipulation by vasoactive drugs. Pastores SM, et al. **New Horiz** 1996 May;4(2):252-64 (104 ref.)

Cytokine networks with infection: mycobacterial infections, leishmaniasis, human immunodeficiency virus infection, and sepsis. DiPiro JT. **Pharmacotherapy** 1997 Mar-Apr; 17(2):205-23 (175 ref.)

[Cytokine-mediated biological response to severe infections in surgical patients] Aikawa N, et al. **Nippon Geka Gakkai Zasshi** 1996 Dec;97(12):1054-9 (36 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

The ubiquitin-proteasome pathway: review of a novel intracellular mechanism of muscle protein breakdown during sepsis and other catabolic conditions. Hasselgren PO, et al. **Ann Surg** 1997 Mar;225(3):307-16 (59 ref.)

Sepsis and fat metabolism. Samra JS, et al. **Br J Surg** 1996 Sep;83(9):1186-96 (234 ref.)

Oxygen delivery and consumption during sepsis. Chittock DR, et al. **Clin Chest Med** 1996 Jun;17(2):263-78 (109 ref.)

Metabolic consequences of sepsis. Correlation with altered intracellular calcium homeostasis. Crouser ED, et al. **Clin Chest Med** 1996 Jun;17(2):249-61 (101 ref.)

Sepsis-related alterations in non-immune cell-signaling. Ahmad S. **Compr Ther** 1995 Dec;21(12):737-40 (28 ref.)

The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Aderka D. **Cytokine Growth Factor Rev** 1996 Oct;7(3):231-40 (106 ref.)

Dobutamine and the oxygen uptake/supply relationship in sepsis: from global to regional--nothing is simple and easy [comment] Vogt J, et al. **Intensive Care Med** 1997 Jul; 23(7):715-7 (33 ref.) Comment on: Intensive Care Med 1997 Jul;23(7):732-7.

Metabolic response to injury and sepsis: changes in protein metabolism. Biolo G, et al. **Nutrition** 1997 Sep;13(9 Suppl):52S-57S (52 ref.)

Energy metabolism in sepsis and injury. Chioléro R, et al. **Nutrition** 1997 Sep;13(9 Suppl):45S-51S (78 ref.)

Regulation of skeletal muscle protein turnover during sepsis: mechanisms and mediators. Cooney RN, et al. **Shock** 1997 Jan;7(1):1-16 (170 ref.)

Ca2+, a regulator of the inflammatory response--the good, the bad, and the possibilities [editorial; comment] Hotchkiss RS, et al. **Shock** 1997 Apr;7(4):308-10 (15 ref.) Comment on: Shock 1997 Apr;7(4):304-7.

Platelet-activating factor (PAF) in experimental and clinical sepsis. Mathiak G, et al. **Shock** 1997 Jun;7(6):391-404 (147 ref.)

MICROBIOLOGY

Septic sternoclavicular arthritis caused by group B Streptococcus: case report and review. Carrascosa M, et al. **Clin Infect Dis** 1996 Mar;22(3):579-80 (9 ref.)

Septic bone and joint infections. Hedström SA. **Curr Opin Rheumatol** 1996 Jul;8(4):322-6 (14 ref.)

Trauma, shock, and gut translocation. Deitch EA, et al. **New Horiz** 1996 May;4(2):289-99 (61 ref.)

PHYSIOPATHOLOGY

Cytopathic hypoxia in sepsis. Fink M. **Acta Anaesthesiol Scand Suppl** 1997;110:87-95 (100 ref.)

Sepsis and nitric oxide. Avontuur JA, et al. **Adv Exp Med Biol** 1996;388:551-67 (128 ref.)

Multiple organ failure, multiple organ dysfunction syndrome, and systemic inflammatory response syndrome. Why no magic bullets? Baue AE. **Arch Surg** 1997 Jul;132(7):703-7 (42 ref.)

Nitric oxide in sepsis. Payen D, et al. **Clin Chest Med** 1996 Jun;17(2):333-50 (169 ref.)

The role of nitric oxide in sepsis and ARDS: synopsis of a roundtable conference held in Brussels on 18-20 March 1995. Fink MP, et al. **Intensive Care Med** 1996 Feb; 22(2):158-65 (103 ref.)

Elucidating molecular mechanisms of septic cardiomyopathy--the cardiomyocyte model. Werdan K, et al. **Mol Cell Biochem** 1996 Oct-Nov;163-164:291-303 (73 ref.)

Platelet activating factor and its role in trauma, shock, and sepsis. Ayala A, et al. **New Horiz** 1996 May;4(2):265-75 (91 ref.)

Hypoxic alterations in cellular signal transduction in shock and sepsis. West MA, et al. **New Horiz** 1996 May; 4(2):168-78 (89 ref.)

Sepsis and septic shock. Zanetti G, et al. **Schweiz Med Wochenschr** 1997 Mar 22;127(12):489-99 (77 ref.)

[Similarity and synergy of trauma and sepsis: role of tumor necrosis factor-alpha and interleukin-6 (see comments)] Tang GJ. **Acta Anaesthesiol Sin** 1996 Sep;34(3):141-9 (46 ref.) (Eng. Abstr.) Comment in: Acta Anaesthesiol Sin 1996 Sep;34(3):i. **(Chi)**

[Sepsis and cytokines] Glauser MP. **Kansenshogaku Zasshi** 1996 Oct;70(10):1054-61 (0 ref.) **(Jpn)**

[Sepsis. I. [Definition of the concept and comments on pathophysiology] Makovický P, et al. **Cas Lek Cesk** 1996 Sep 18;135(18):580-3 (34 ref.) (Eng. Abstr.) **(Slo)**

PREVENTION & CONTROL

Prevention of sepsis in total joint arthroplasty. An YH, et al. **J Hosp Infect** 1996 Jun;33(2):93-108 (135 ref.)

Prevention of early onset group B streptococcal sepsis in the newborn. Vigneswaran R, et al. **J Paediatr Child Health** 1995 Dec;31(6):493-4 (13 ref.)

Stephen L. Gans Visiting Guest Lecture: central venous catheters for parenteral nutrition: a double-edged sword. Lloyd DA. **J Pediatr Surg** 1997 Jul;32(7):943-8 (11 ref.)

Bacterial and fungal infection in acute liver failure. Rolando N, et al. **Semin Liver Dis** 1996 Nov;16(4):389-402 (89 ref.)

[Prevention and treatment of postoperative septic MOF and DIC and efficacy of blood purification] Hirasawa H, et al. **Nippon Geka Gakkai Zasshi** 1996 Dec;97(12):1079-84 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Recent advances and treatment of sepsis] Hirata K. **Nippon Geka Gakkai Zasshi** 1996 Dec;97(12):1072-8 (8 ref.) (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE IMAGING

Occult sepsis: fate or challenge? [editorial] Locher JT. **Intensive Care Med** 1996 Sep;22(9):844-6 (10 ref.)

SURGERY

Complicated anorectal sepsis. Gilliland R, et al. **Surg Clin North Am** 1997 Feb;77(1):115-53 (205 ref.)

THERAPY

Granulocyte colony-stimulating factor and modulation of inflammatory cells in sepsis. Nelson S, et al. **Clin Chest Med** 1996 Jun;17(2):319-32 (122 ref.)

Hemodynamic support during sepsis. Ognibene FP. **Clin Chest Med** 1996 Jun;17(2):279-87 (22 ref.)

Immunotherapy for sepsis. Ralston DR, et al. **Clin Chest Med** 1996 Jun;17(2):307-17 (104 ref.)

Novel approaches to the prevention and therapy of neonatal bacterial sepsis. Perez EM, et al. **Clin Perinatol** 1997 Mar; 24(1):213-29 (119 ref.)

Introducing Critical Appraisal to studies of animal models investigating novel therapies in sepsis. Piper RD, et al. **Crit Care Med** 1996 Dec;24(12):2059-70 (111 ref.)

Immune modulation and sepsis. Karzai W, et al. **Int J Clin Pract** 1997 Jun;51(4):232-7 (62 ref.)

Monocyte deactivation--rationale for a new therapeutic strategy in sepsis. Volk HD, et al. **Intensive Care Med** 1996 Oct;22 Suppl 4:S474-81 (24 ref.)

Sepsis and polyspecific intravenous immunoglobulins. Nydegger UE. **J Clin Apheresis** 1997;12(2):93-9 (41 ref.)

Clinical trials in sepsis: where do we stand? [see comments] Vincent JL. **J Crit Care** 1997 Mar;12(1):3-6 (17 ref.) Comment in: J Crit Care 1997 Mar;12(1):1-2.

Advances in the therapy for sepsis in children. Anderson MR, et al. **Pediatr Clin North Am** 1997 Feb;44(1):179-205 (67 ref.)

Can hemodialysis technique modify the hypercatabolic state? Sunder-Plassmann G, et al. **Ren Fail** 1996 May; 18(3):395-404 (70 ref.)

Novel approaches to the treatment of sepsis: lessons learned and future directions. Cross A. **Shock** 1996;6 Suppl 1:S71-4 (19 ref.)

[Nutritional support in sepsis] Saito H. **Nippon Geka Gakkai Zasshi** 1996 Dec;97(12):1085-90 (32 ref.) (Eng. Abstr.) **(Jpn)**

[Immunotherapy of sepsis: myth or reality?] Vinnitskii LI, et al. **Anesteziol Reanimatol** 1997 May-Jun;(3):89-97 (143 ref.) **(Rus)**

[Sepsis. II. Complications and treatment of sepsis] Makovický P, et al. **Cas Lek Cesk** 1996 Oct 9;135(19):614-6 (34 ref.) (Eng. Abstr.) **(Slo)**

SEPSIS SYNDROME

see related

RESPIRATORY DISTRESS SYNDROME, ADULT

Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response. Boyle EM Jr, et al. **Ann Thorac Surg** 1997 Jan;63(1):277-84 (62 ref.)

Systemic inflammatory response syndrome. Davies MG, et al. **Br J Surg** 1997 Jul;84(7):920-35 (165 ref.)

The sepsis syndrome. Definition and general approach to management. Bone RC. **Clin Chest Med** 1996 Jun; 17(2):175-81 (8 ref.)

[Systemic inflammatory response syndrome] Huang Y. **Chung Hua I Hsueh Tsa Chih** 1996 Aug;76(8):629-31 (16 ref.) **(Chi)**

CLASSIFICATION

[History and definition of sepsis--do we need new terminology?] Kreymann G, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Feb; 31(1):9-14 (18 ref.) (Eng. Abstr.) **(Ger)**

[The systemic inflammatory response syndrome: its classification, physiopathology and treatment strategies (editorial)] Baltodano A. **An Esp Pediatr** 1996 May; 44(5):414-21 (54 ref.) **(Spa)**

COMPLICATIONS

[Microcirculatory disturbances after surgical insults--important role of inflammatory cytokines] Wakabayashi G, et al. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):759-64 (14 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Early detection and markers of sepsis. Parsons PE, et al. **Clin Chest Med** 1996 Jun;17(2):199-212 (125 ref.)

[Systemic inflammatory reactions to extracorporeal therapy measures (I): Hemodialysis and hemofiltration] Schlee H, et al. **Wien Klin Wochenschr** 1997 May 9;109(9):301-11 (78 ref.) (Eng. Abstr.) **(Ger)**

[The endogenous intoxication syndrome in sepsis] Makarova NP, et al. **Anesteziol Reanimatol** 1995 Nov-Dec;(6):4-8 (44 ref.) **(Rus)**

DRUG THERAPY

[Microcirculation and hemostasis in inflammatory processes. Modulation by administration of physiologic protease inhibitors as a therapeutic approach] Leithäuser B, et al. **Med Klin** 1997 Jul 15;92(7):426-31 (40 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

MOF/MODS, SIRS: an update. Baue AE. **Shock** 1996;6 Suppl 1:S1-5 (45 ref.)

ETIOLOGY

Sepsis: a new hypothesis for pathogenesis of the disease process. Bone RC, et al. **Chest** 1997 Jul;112(1):235-43 (57 ref.)

Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Wan S, et al. **Chest** 1997 Sep;112(3):676-92 (235 ref.)

The role of the vascular endothelium in inflammatory syndromes, atherogenesis, and the propagation of disease. Hill GE, et al. **J Cardiothorac Vasc Anesth** 1997 May; 11(3):316-21 (76 ref.)

Cardiopulmonary bypass and the inflammatory response: a role for serine protease inhibitors? Murkin JM. **J Cardiothorac Vasc Anesth** 1997 Apr;11(2 Suppl 1):19-23; discussion 24-5 (35 ref.)

IMMUNOLOGY

Cytokine responses to cardiopulmonary bypass: lessons learned from cardiac transplantation. Wan S, et al. **Ann Thorac Surg** 1997 Jan;63(1):269-76 (71 ref.)

The pathogenesis of sepsis. Factors that modulate the response to gram-negative bacterial infection. Marsh CB, et al. **Clin Chest Med** 1996 Jun;17(2):183-97 (203 ref.)

[Cytokines and heart diseases. Attempt at an update] Werdan K. **Med Klin** 1997 Jul 15;92(7):432-8 (29 ref.) (Eng. Abstr.) **(Ger)**

[Systemic inflammatory reactions to extracorporeal therapy measures (II): Cardiopulmonary bypass] Prondzinsky R, et al. **Wien Klin Wochenschr** 1997 May 23;109(10):346–53 (56 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Posttraumatic multiple-organ dysfunction syndrome: role of mediators in systemic inflammation and subsequent organ failure. Pastores SM, et al. **Acad Emerg Med** 1996 Jun; 3(6):611–22 (150 ref.)

Neonatal sepsis. Mathur NB. **Indian Pediatr** 1996 Aug; 33(8):663–74 (77 ref.)

The role of cytokines in cardiac surgery. Tønnesen E, et al. **Int J Cardiol** 1996 Apr 26;53 Suppl:S1–10 (77 ref.)

Cell surface adrenergic receptor stimulation modifies the endothelial response to SIRS. Systemic Inflammatory Response Syndrome. Tighe D, et al. **New Horiz** 1996 Nov; 4(4):426–42 (104 ref.)

Systemic inflammatory response syndrome: interactions between immune cells and the endothelium. Ahmed N, et al. **Shock** 1996;6 Suppl 1:S39–42 (16 ref.)

[Surgical metabolism] Jauch KW. **Chirurg** 1997 Jun; 68(6):551–8 (27 ref.) (Eng. Abstr.) **(Ger)**

[The significance of neurological manifestations from the aspect of aggressology] Aruga T.
Nippon Geka Gakkai Zasshi 1996 Sep;97(9):733–8 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Immune response induced by surgical trauma] Hirota M, et al. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):721–5 (12 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Organ-specific therapy in critical illness: interfacing molecular mechanisms with physiological interventions. Pinsky MR. **J Crit Care** 1996 Jun;11(2):95–107 (75 ref.)

[Is there a reliable immunotherapy in infection?] Grimminger F, et al. **Internist (Berl)** 1997 Jun;38(6):541–52 (40 ref.) **(Ger)**

SEPTAL NUCLEI

ANATOMY & HISTOLOGY

Anatomy and pathology of the septal region. Cavazos JE, et al. **Neuroimaging Clin N Am** 1997 Feb;7(1):67–78 (20 ref.)

PHYSIOLOGY

Insights into the role of the cholinergic component of the septohippocampal pathway: what have we learned from experimental lesion studies? Hörtnagl H, et al.
Brain Res Bull 1997;43(3):245–55 (187 ref.)

SEPTICEMIA

see related
ENDOTOXEMIA

Specific problems of arterial, Swan-Ganz, and hemodialysis catheters. Rello J, et al. **Nutrition** 1997 Apr;13(4 Suppl):36S–41S (55 ref.)

CLASSIFICATION

[History and definition of sepsis--do we need new terminology?] Kreymann G, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Feb; 31(1):9–14 (18 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

[Methyl thionine (methylene blue) in the treatment of sepsis] Bindels AJ, et al. **Ned Tijdschr Geneeskd** 1996 Dec 7; 140(49):2447–50 (20 ref.) **(Dut)**

[Septicemia with gram-negative bacilli. The possibilities and limits of an etiological therapy] Grigore L.
Bacteriol Virusol Parazitol Epidemiol 1996 Jul-Dec; 41(3–4):151–60 (31 ref.) **(Rum)**

EPIDEMIOLOGY

Sepsis and septic complications in the surgical patient: who is at risk? Cheadle WG, et al. **Shock** 1996;6 Suppl 1:S6–9 (42 ref.)

IMMUNOLOGY

Immune dysfunction in murine polymicrobial sepsis: mediators, macrophages, lymphocytes and apoptosis. Ayala A, et al. **Shock** 1996;6 Suppl 1:S27–38 (134 ref.)

PHYSIOPATHOLOGY

The gut in critical illness: evidence from human studies. Marshall JC, et al. **Shock** 1996;6 Suppl 1:S10–6 (92 ref.)

[Cooperation of proinflammatory interleukins in a cytokine rete in patients with septic syndrome] Modzelewski B.
Pol Merkuriusz Lek 1996 Oct;1(4):284–6 (35 ref.) **(Pol)**

PREVENTION & CONTROL

Prevention of catheter-related infections: the skin. Darouiche RO, et al. **Nutrition** 1997 Apr;13(4 Suppl):26S–29S (33 ref.)

THERAPY

Applications of molecular biology and biotechnology: antibody therapy of sepsis. Wheeler AP, et al.
J Crit Care 1996 Jun;11(2):77–94 (102 ref.)

VETERINARY

Immunization with bacterial antigens: edwardsiellosis. Thune RL, et al. **Dev Biol Stand** 1997;90:125–34 (46 ref.)

SEPTUM PELLUCIDUM

Expanding cyst of the septum pellucidum. Case report. Lancon JA, et al. **J Neurosurg** 1996 Dec;85(6):1127–34 (47 ref.)

SEQUENCE ALIGNMENT

The RING finger domain: a recent example of a sequence-structure family. Borden KL, et al.
Curr Opin Struct Biol 1996 Jun;6(3):395–401 (46 ref.)

Protein sequence motifs. Bork P, et al.
Curr Opin Struct Biol 1996 Jun;6(3):366–76 (78 ref.)

Sequences and topology challenges for algorithms and experts [editorial] Brutlag DL, et al.
Curr Opin Struct Biol 1996 Jun;6(3):343–5 (11 ref.)

Hidden Markov models. Eddy SR. **Curr Opin Struct Biol** 1996 Jun;6(3):361–5 (33 ref.)

Scores for sequence searches and alignments. Henikoff S. **Curr Opin Struct Biol** 1996 Jun;6(3):353–60 (64 ref.)

Near-optimal sequence alignment. Vingron M.
Curr Opin Struct Biol 1996 Jun;6(3):346–52 (51 ref.)

Nucleosome DNA sequence pattern revealed by multiple alignment of experimentally mapped sequences. Ioshikhes I, et al. **J Mol Biol** 1996 Sep 20;262(2):129–39 (42 ref.)

Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Altschul SF, et al.
Nucleic Acids Res 1997 Sep 1;25(17):3389–402 (90 ref.)

METHODS

Identifying distantly related protein sequences. Pearson WR.
Comput Appl Biosci 1997 Aug;13(4):325–32 (14 ref.)

A sequence similarity search algorithm based on a probabilistic interpretation of an alignment scoring system. Bucher P, et al. **Ismb** 1996;4:44–51 (25 ref.)

SEQUENCE ANALYSIS

Deciphering isozyme function: exploring cell biology with chemistry in the post-genomic era. Crews CM.
Chem Biol 1996 Dec;3(12):961–5 (31 ref.)

Sequencing and analysis of bacterial genomes. Koonin EV, et al. **Curr Biol** 1996 Apr 1;6(4):404–16 (80 ref.)

Exploiting the complete yeast genome sequence. Bassett DE Jr, et al. **Curr Opin Genet Dev** 1996 Dec;6(6):763–6 (20 ref.)

Complete genome sequences of cellular life forms: glimpses of theoretical evolutionary genomics. Koonin EV, et al.
Curr Opin Genet Dev 1996 Dec;6(6):757–62 (39 ref.)

METHODS

Linguistic approaches to biological sequences. Searls DB.
Comput Appl Biosci 1997 Aug;13(4):333–44 (49 ref.)

Searching for regulatory elements in human noncoding sequences. Duret L, et al. **Curr Opin Struct Biol** 1997 Jun; 7(3):399–406 (48 ref.)

New horizons in sequence analysis. Hubbard TJ.
Curr Opin Struct Biol 1997 Apr;7(2):190–3 (33 ref.)

Identification of cytokine-regulated proteins in normal and malignant cells by the combination of two-dimensional polyacrylamide gel electrophoresis, mass spectrometry, Edman degradation and immunoblotting and approaches to the analysis of their functional roles. Epstein LB, et al.
Electrophoresis 1996 Nov;17(11):1655–70 (75 ref.)

Computational sequence analysis of the tissue inhibitor of metalloproteinase family. Douglas DA, et al.
J Protein Chem 1997 May;16(4):237–55 (88 ref.)

Oligosaccharide sequencing technology. Rudd PM, et al.
Nature 1997 Jul 10;388(6638):205–7 (27 ref.)

SEQUENCE ANALYSIS, DNA

Amplification methods in the molecular diagnosis of genetic diseases. Ben-Ezra JM. **Clin Lab Med** 1995 Dec; 15(4):795–815 (44 ref.)

Sequence-based diagnosis of hemoglobinopathies in the clinical laboratory. Reddy PL, et al. **Clin Lab Med** 1997 Mar;17(1):85–96 (16 ref.)

Sequencing in nanofabricated arrays: a feasibility study. Duke T, et al. **Electrophoresis** 1997 Jan;18(1):17–22 (23 ref.)

The Arabidopsis thaliana cDNA sequencing projects. Delseny M, et al. **FEBS Lett** 1997 Feb 24;403(3):221–4 (30 ref.)

The Arabidopsis thaliana cDNA sequencing projects. Delseny M, et al. **FEBS Lett** 1997 Mar 24;405(2):129–32 (30 ref.)

DNA sequencing. Rees WD. **Proc Nutr Soc** 1996 Mar; 55(1B):605–12 (7 ref.)

The yeast genome project: what did we learn? Dujon B.
Trends Genet 1996 Jul;12(7):263–70 (42 ref.)

Bonsai genomics: sequencing the smallest eukaryotic genomes. McFadden GI, et al. **Trends Genet** 1997 Feb; 13(2):46–9 (16 ref.)

Why sequence the genome of Mycobacterium tuberculosis? Cole ST. **Tuber Lung Dis** 1996 Dec;77(6):486–90 (46 ref.)

[Genetic information database] Minoshima S, et al.
Tanpakushitsu Kakusan Koso 1996 Nov;41(15 Suppl):2464–77 (9 ref.) **(Jpn)**

[What we can learn from the whole genome sequence of an archaeon Methanococcus jannaschii] Yamagishi A, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(2):174–7 (14 ref.) **(Jpn)**

[MtDNA-like sequences and the coordination of the functioning of mammalian nuclear and mitochondrial genomes] Maliarchuk BA. **Tsitol Genet** 1997 Mar-Apr; 31(2):53–61 (51 ref.) (Eng. Abstr.) **(Rus)**

INSTRUMENTATION

[High-throughput of DNA sequencing by automated machines] Hattori M. **Nippon Rinsho** 1996 Apr;54(4):923–7 (0 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Enzymatic and molecular diagnosis of Gaucher disease. Barranger JA, et al. **Clin Lab Med** 1995 Dec;15(4):899–913 (59 ref.)

Perspectives and molecular diagnosis of the fragile X syndrome. Brown WT. **Clin Lab Med** 1995 Dec; 15(4):859–75 (74 ref.)

Molecular diagnosis of cystic fibrosis. Kant JA, et al.
Clin Lab Med 1995 Dec;15(4):877–98 (87 ref.)

Replaceable polymers in DNA sequencing by capillary electrophoresis. Quesada MA. **Curr Opin Biotechnol** 1997 Feb;8(1):82–93 (65 ref.)

High-speed DNA sequencing in ultrathin slab gels. Yager TD, et al. **Curr Opin Biotechnol** 1997 Feb;8(1):107–13 (58 ref.)

Strategies for whole microbial genome sequencing and analysis. Fraser CM, et al. **Electrophoresis** 1997 Aug; 18(8):1207–16 (55 ref.)

Molecular epidemiology: applications of nucleic acid amplification and sequence analysis. McDade JE, et al.
Epidemiol Rev 1996;18(1):90–7 (46 ref.)

DNA recommendations--further report of the DNA Commission of the ISFH regarding the use of short tandem repeat systems. Lincoln PJ. **Forensic Sci Int** 1997 Jun 23; 87(3):181–4 (4 ref.)

Oligonucleotide micro-arrays for identification of unknown mutations: how far from reality? Ginot F. **Hum Mutat** 1997; 10(1):1–10 (50 ref.)

Improving the quality of automatic DNA sequence assembly using fluorescent trace-data classifications. Allex CF, et al. **Ismb** 1996;4:3–14 (16 ref.)

DNA sequencing by mass spectrometry. Murray KK.
J Mass Spectrom 1996 Nov;31(11):1203–15 (87 ref.)

High-speed automated DNA sequencing in ultrathin slab gels. Smith LM, et al. **Methods Enzymol** 1996;271:219–37 (26 ref.)

Strategies for direct sequencing of PCR-amplified DNA. Rao VB. **PCR Methods Appl** 1994 Aug;4(1):S15–23 (19 ref.)

Large-scale EST sequencing in rice. Yamamoto K, et al.
Plant Mol Biol 1997 Sep;35(1–2):135–44 (39 ref.)

[Analysis system of microsatellite polymorphism using automated laser fluorescent DNA sequencer] Tanaka H, et al. **Nippon Rinsho** 1996 Feb;54(2):322–8 (4 ref.) (Eng. Abstr.) **(Jpn)**

[Large-scale sequencing by nested deletions] Hattori M.
Tanpakushitsu Kakusan Koso 1996 Nov;41(15 Suppl):2450–7 (4 ref.) **(Jpn)**

[Shotgun sequencing] Kawasaki K, et al.
Tanpakushitsu Kakusan Koso 1996 Nov;41(15 Suppl):2458–63 (9 ref.) **(Jpn)**

[Development of analytical technologies for human genomic DNA using capillary electrophoresis and their applications] Baba Y. **Yakugaku Zasshi** 1997 May;117(5):265–81 (42 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular biology in medicine. IV. Medical implications of DNA sequencing] Martínez F, et al. **Rev Invest Clin** 1996 Jul-Aug;48(4):321–5 (5 ref.) **(Spa)**

SEQUENCE ANALYSIS, RNA

METHODS

Molecular epidemiology: applications of nucleic acid amplification and sequence analysis. McDade JE, et al.
Epidemiol Rev 1996;18(1):90–7 (46 ref.)

SEQUENCE DATA, MOLECULAR see **MOLECULAR SEQUENCE DATA**

SEQUENCE DELETION

Clinical features in 27 patients with Angelman syndrome resulting from DNA deletion. Smith A, et al.
J Med Genet 1996 Feb;33(2):107–12 (42 ref.)

Ordered deletions using exonuclease III. Clark D, et al.
Methods Mol Biol 1996;57:139–47 (7 ref.)

PCR-assisted mutagenesis for site-directed insertion/deletion of large DNA segments. Tessier DC, et al.
Methods Mol Biol 1996;57:229–37 (17 ref.)

A simple method to introduce internal deletions or mutations into any position of a target DNA sequence. Tomic-Canic

SEQUENCE DELETION

M, et al. **Methods Mol Biol** 1996;57:249–57 (7 ref.)
A universal nested deletion method using an arbitrary primer and elimination of a unique restriction site. Zhu L, et al. **Methods Mol Biol** 1996;57:119–37 (14 ref.)
Developmental genome reorganization in ciliated protozoa: the transposon link. Klobutcher LA, et al. **Prog Nucleic Acid Res Mol Biol** 1997;56:1–62 (153 ref.)
Programmed DNA deletions in Tetrahymena: mechanisms and implications. Yao MC. **Trends Genet** 1996 Jan; 12(1):26–30 (28 ref.)
Targeted deletion of neuronal nitric oxide: a step closer to understanding its functional significance? Good M. **Trends Neurosci** 1996 Mar;19(3):83–4 (11 ref.)

SEQUENCE DETERMINATION see **SEQUENCE ANALYSIS**

SEQUENCE DETERMINATION, DNA see **SEQUENCE ANALYSIS, DNA**

SEQUENCE DETERMINATION, RNA see **SEQUENCE ANALYSIS, RNA**

SEQUENCE HOMOLOGY, AMINO ACID

MutS homologs in mammalian cells. Fishel R, et al. **Curr Opin Genet Dev** 1997 Feb;7(1):105–13 (84 ref.)
A structural explanation for the twilight zone of protein sequence homology. Chung SY, et al. **Structure** 1996 Oct 15;4(10):1123–7 (26 ref.)
[Structure and ligand recognition of pleckstrin homology domain] Terasawa H, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):996–1003 (49 ref.) **(Jpn)**

SEQUENCE HOMOLOGY DETERMINATION see **SEQUENCE ALIGNMENT**

SEQUENCE HOMOLOGY, NUCLEIC ACID

see related
SEQUENCE ALIGNMENT
Turn to the worm! Ahringer J. **Curr Opin Genet Dev** 1997 Jun;7(3):410–5 (42 ref.)
Human genetic diseases: a cross-talk between man and yeast. Foury F. **Gene** 1997 Aug 11;195(1):1–10 (58 ref.)

SEQUENCE TAGGED SITES

Assessment of human gene diversity and expression patterns using expressed sequence tags. Kirkness EF. **Essays Biochem** 1996;31:1–9 (12 ref.)
[Immunocytochemistry with epitope tagging] Iida H. **Nippon Rinsho** 1996 Mar;54(3):731–6 (7 ref.) (Eng. Abstr.) **(Jpn)**

SEQUENTIAL HEMIBODY IRRADIATION see **HEMIBODY IRRADIATION**

SERGENTOMYIA see **PSYCHODIDAE**

SERIAL EXTRACTION

The role of extraction in stability of orthodontic treatment. Kahl-Nieke B. **J Orofac Orthop** 1996 Oct;57(5):272–87 (54 ref.) **(Eng, Ger)**

SERIAL LEARNING

Simple reaction time and perception of temporal order: dissociations and hypotheses. Jaśkowski P. **Percept Mot Skills** 1996 Jun;82(3 Pt 1):707–30 (110 ref.)

PHYSIOLOGY

The serial organisation of behaviour by non-human primates; an evaluation of experimental paradigms. De Lillio C. **Behav Brain Res** 1996 Nov;81(1–2):1–17 (65 ref.)

SERINE

PEST sequences and regulation by proteolysis. Rechsteiner M, et al. **Trends Biochem Sci** 1996 Jul;21(7):267–71 (48 ref.)
[Endogenous free D-aspartate and D-serine in mammals] Hashimoto A, et al. **Seikagaku** 1996 Aug;68(8):1458–62 (17 ref.) **(Jpn)**

METABOLISM

The role of serine/threonine phosphorylation in hematopoietic cytokine receptor signal transduction. Mufson RA. **FASEB J** 1997 Jan;11(1):37–44 (56 ref.)
Free D-aspartate and D-serine in the mammalian brain and periphery. Hashimoto A, et al. **Prog Neurobiol** 1997 Jul; 52(4):325–53 (351 ref.)
Yeast protein serine/threonine phosphatases: multiple roles and diverse regulation. Stark MJ. **Yeast** 1996 Dec; 12(16):1647–75 (200 ref.)

SERINE PHOSPHOGLYCERIDES see **PHOSPHATIDYLSERINES**

SERINE PROTEASE INHIBITORS see **SERINE PROTEINASE INHIBITORS**

SERINE PROTEASES see **SERINE PROTEINASES**

SERINE PROTEINASE ANTAGONISTS see **SERINE PROTEINASE INHIBITORS**

SERINE PROTEINASE INHIBITORS

see related
SERPINS

BLOOD

Serine proteinase inhibitors from insect hemolymph. Polanowski A, et al. **Acta Biochim Pol** 1996;43(3):445–53 (42 ref.)

CHEMISTRY

Squash inhibitor family of serine proteinases. Otlewski J, et al. **Acta Biochim Pol** 1996;43(3):431–44 (81 ref.)
Structure and function of subtilisin BPN' as studied through crystallographic studies on a series of its complexes with genetically engineered proteinaceous inhibitor SSI. Nonaka T, et al. **Adv Exp Med Biol** 1996;379:21–7 (24 ref.)

DEFICIENCY

Antithrombin: molecular basis of deficiency. Bayston TA, et al. **Thromb Haemost** 1997 Jul;78(1):339–43 (35 ref.)

GENETICS

[Regulation of secretory leukoprotease inhibitor gene expression] Kikuchi T, et al. **Nippon Rinsho** 1996 Feb; 54(2):405–10 (20 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Inhibition of cysteine and serine proteinases by the cowpox virus serpin CRMA. Komiyama T, et al. **Adv Exp Med Biol** 1996;389:173–6 (39 ref.)
Protein C inhibitor (PCI). Geiger M, et al. **Immunopharmacology** 1996 May;32(1–3):53–6 (18 ref.)

PHARMACOKINETICS

Pharmacology and pharmacokinetics of LEX 032, a bioengineered serpin: the first of a potential new class of drugs. Sands H, et al. **Drug Metab Rev** 1997 Feb–May; 29(1–2):309–28 (68 ref.)

PHARMACOLOGY

Herpesvirus proteases: targets for novel antiviral drugs. Holwerda BC. **Antiviral Res** 1997 Jun;35(1):1–21 (89 ref.)
Pharmacology and pharmacokinetics of LEX 032, a bioengineered serpin: the first of a potential new class of drugs. Sands H, et al. **Drug Metab Rev** 1997 Feb–May; 29(1–2):309–28 (68 ref.)

PHYSIOLOGY

Regulation and regulatory role of proteinase inhibitors. Roberts RM, et al. **Crit Rev Eukaryot Gene Expr** 1995; 5(3–4):385–436 (404 ref.)
Protein C inhibitor (PCI). Geiger M, et al. **Immunopharmacology** 1996 May;32(1–3):53–6 (18 ref.)

THERAPEUTIC USE

Coagulation in cardiac surgery. Royston D. **Adv Card Surg** 1996;8:19–45 (125 ref.)
Use of secretory leukoprotease inhibitor to augment lung antineutrophil elastase activity. Vogelmeier C, et al. **Chest** 1996 Dec;110(6 Suppl):261S–266S (58 ref.)
Intravenous alpha-1-antitrypsin replacement therapy: case report after one year of treatment. Ward AC, et al. **Ir J Med Sci** 1997 Jan–Mar;166(1):7–9 (10 ref.)
Cardiopulmonary bypass and the inflammatory response: a role for serine protease inhibitors? Murkin JM. **J Cardiothorac Vasc Anesth** 1997 Apr;11(2 Suppl 1):19–23; discussion 24–5 (35 ref.)
Serine protease inhibition prevents both cellular and humoral responses to cardiopulmonary bypass. Royston D. **J Cardiovasc Pharmacol** 1996;27 Suppl 1:S42–9 (60 ref.)

SERINE PROTEINASE INHIBITORS, ENDOGENOUS see **SERINE PROTEINASE INHIBITORS**

SERINE PROTEINASE INHIBITORS, EXOGENOUS see **SERINE PROTEINASE INHIBITORS**

SERINE PROTEINASES

[Virus propagation and proteases: with special emphasis on the newly discovered serine protease in human herpes virus] Maeda H. **Tanpakushitsu Kakusan Koso** 1997 May; 42(6):875–9 (25 ref.) **(Jpn)**

ANALYSIS

[Tryptase--an sign of mastocyte activation] Wrzyszcz M, et al. **Pneumonol Alergol Pol** 1996;64(5–6):366–70 (30 ref.) **(Pol)**
[Tryptase: a diagnostic marker in allergic diseases] Martínez Infante E, et al. **Rev Alerg Mex** 1996 May–Jun;43(3):73–6 (58 ref.) (Eng. Abstr.) **(Spa)**

CHEMISTRY

Herpesvirus proteases: targets for novel antiviral drugs. Holwerda BC. **Antiviral Res** 1997 Jun;35(1):1–21 (89 ref.)
Molecular biology and vaccine aspects of bacterial immunoglobulin A1 proteases. Lomholt H. **APMIS Suppl** 1996;62:5–28 (125 ref.)
Targeting the Achilles' heel of hepatitis C virus. Lemon SM. **Hepatology** 1997 Apr;25(4):1035–7 (10 ref.)
Comparative analysis of haemostatic proteinases: structural aspects of thrombin, factor Xa, factor IXa and protein C. Bode W, et al. **Thromb Haemost** 1997 Jul;78(1):501–11 (97 ref.)
Catalytic hydroxyl/amine dyads within serine proteases. Paetzel M, et al. **Trends Biochem Sci** 1997 Jan;22(1):28–31 (33 ref.)

GENETICS

A regulatory switch involving a Clp ATPase. Lazazzera BA, et al. **Bioessays** 1997 Jun;19(6):455–8 (38 ref.)
Pattern formation: The link between ovary and embryo. Stein D. **Curr Biol** 1995 Dec 1;5(12):1360–3 (16 ref.)
Hypothesis for a serine proteinase-like domain at the COOH terminus of Slowpoke calcium-activated potassium channels. Moss GW, et al. **J Gen Physiol** 1996 Dec; 108(6):473–84 (82 ref.)
Granzymes: a variety of serine protease specificities encoded by genetically distinct subfamilies. Smyth MJ, et al. **J Leukoc Biol** 1996 Nov;60(5):555–62 (107 ref.)
In situ PCR amplification of intracellular mRNA. Chen RH, et al. **Methods Mol Biol** 1997;71:123–32 (20 ref.)
Gene structure of ANCA target antigens: implications for the pathogenesis of vasculitis. Jenne DE. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct;13(3):209–13 (49 ref.)

IMMUNOLOGY

Molecular biology and vaccine aspects of bacterial immunoglobulin A1 proteases. Lomholt H. **APMIS Suppl** 1996;62:5–28 (125 ref.)

METABOLISM

Granzyme B-induced apoptosis. Greenberg AH. **Adv Exp Med Biol** 1996;406:219–28 (69 ref.)
Serine proteinases from cold-adapted organisms. Kristjánsson MM, et al. **Adv Exp Med Biol** 1997;415:27–46 (93 ref.)
Horseshoe crab factor G: a new heterodimeric serine protease zymogen sensitive to (1 --> 3)-beta-D-glucan. Muta T, et al. **Adv Exp Med Biol** 1996;389:79–85 (28 ref.)
Crystallographic study of eglin-C binding to thermitase. Teplyakov A, et al. **Adv Exp Med Biol** 1996;379:5–9 (20 ref.)
Amniotic fluid embolism, anaphylaxis, and tryptase. Benson MD, et al. **Am J Obstet Gynecol** 1996 Sep;175(3 Pt 1):737 (5 ref.)
Protease Ti (Clp), a multi-component ATP-dependent protease in Escherichia coli. Chung CH, et al. **Biol Chem** 1996 Sep;377(9):549–54 (37 ref.)
Angiotensin-converting enzyme-independent pathways of angiotensin II formation in human tissues and cardiovascular diseases. Urata H, et al. **Blood Press Suppl** 1996;2:22–8 (49 ref.)
It all begins with EVE (endogenous vascular elastase). Rabinovitch M. **Isr J Med Sci** 1996 Oct;32(10):803–8; discussion 809–10 (18 ref.)
Mastocytosis: new understandings in cutaneous pathophysiology. Lazarus GS. **J Dermatol** 1996 Nov; 23(11):769–72 (15 ref.)
Serine protease angiotensin II systems. Arakawa K. **J Hypertens Suppl** 1996 Dec;14(5):S3–7 (44 ref.)
Development, significance, and heterogeneity of mast cells with particular regard to the mast cell-specific proteases chymase and tryptase. Welle M. **J Leukoc Biol** 1997 Mar; 61(3):233–45 (177 ref.)
Angiotensin I converting enzyme and chymase in cardiovascular tissues. Nishimura H, et al. **Kidney Int Suppl** 1996 Jun;55:S18–23 (63 ref.)
The lectin pathway of the complement system. Matsushita M. **Microbiol Immunol** 1996;40(12):887–93 (67 ref.)
The chemistry and enzymology of the type I signal peptidases. Dalbey RE, et al. **Protein Sci** 1997 Jun; 6(6):1129–38 (100 ref.)
Subtilases: the superfamily of subtilisin-like serine proteases. Siezen RJ, et al. **Protein Sci** 1997 Mar;6(3):501–23 (77 ref.)
The adipsin-acylation-stimulating protein pathway and microenvironmental metabolic regulation. Sniderman AD, et al. **World Rev Nutr Diet** 1997;80:44–81 (121 ref.)
[Prognostic role of cisteine and serin proteases in gastriC cancer] Herszényi L, et al. **Orv Hetil** 1996 Jul 28; 137(30):1637–41 (47 ref.) (Eng. Abstr.) **(Hun)**
[Function of proline-rich regions in proteins and proline specific peptidases] Maruyama S. **Tanpakushitsu Kakusan Koso** 1997 May;42(6):857–64 (56 ref.) **(Jpn)**

PHYSIOLOGY

Roles of kringle domain-containing serine proteases in epithelial-mesenchymal transitions during embryonic

development. Théry C, et al. **Acta Anat (Basel)** 1996; 156(3):162–72 (101 ref.)
Neutral proteinases and their inhibitors in the loosening of total hip prostheses. Takagi M.
Acta Orthop Scand Suppl 1996 Oct;271:3–29 (198 ref.)
Cellular proteases involved in the pathogenicity of human immunodeficiency and influenza viruses. Kido H, et al.
Adv Exp Med Biol 1996;389:233–40 (24 ref.)
Of mites and men: trypsin-like proteases in the lungs. Caughey GH. **Am J Respir Cell Mol Biol** 1997 Jun; 16(6):621–8 (69 ref.)
Role of serine proteases in aneurysm development. Rao SK, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:131–7 (35 ref.)
New knowledge about T-cell cytotoxicity. Cerottini JC, et al. **Ann Oncol** 1997;8 Suppl 2:75–8 (20 ref.)
Do CTL kill target cells by inducing apoptosis? Henkart PA, et al. **Semin Immunol** 1997 Apr;9(2):135–44 (57 ref.)
The role of granzyme B cluster proteases in cell-mediated cytotoxicity. Pham CT, et al. **Semin Immunol** 1997 Apr; 9(2):127–33 (55 ref.)
[Adipsin system—acylation-stimulation protein (ASP) and hyperapo-B] Rato Q, et al. **Rev Port Cardiol** 1996 May; 15(5):433–8, 366 (39 ref.) (Eng. Abstr.) **(Por)**

SERINE-SPECIFIC TRNA see **RNA, TRANSFER, SER**

SERINE-THREONINE PROTEIN KINASES see **PROTEIN-SERINE-THREONINE KINASES**

SERODIAGNOSIS

Serodiagnosis of tuberculosis. Gupta S, et al.
J Commun Dis 1995 Dec;27(4):208–14 (41 ref.)
Are cardiac troponins reliable serodiagnositic markers of cardiac ischaemia in end-stage renal disease? [editorial] Haller C, et al. **Nephrol Dial Transplant** 1996 Jun; 11(6):941–4 (16 ref.)
[Clinical evaluation of immuno-serological laboratory data] Kasukawa R, et al. **Rinsho Byori** 1996 Dec;44(12):1157–63 (7 ref.) (Eng. Abstr.) **(Jpn)**
[Serological diagnosis for cryptococcosis by the detection of beta-glucan and capsular polysaccharide] Kohno S. **Rinsho Byori** 1996 Jun;44(6):524–7 (6 ref.) (Eng. Abstr.) **(Jpn)**

ECONOMICS

Interpreting serologic tests for hepatitis C virus infection: balancing cost and clarity. Long GS, et al.
Cleve Clin J Med 1996 Sep;63(5):264–8 (25 ref.)

INSTRUMENTATION

[Hepatitis C: screening tools] Pham BN, et al.
Gastroenterol Clin Biol 1997;21(1 Pt 2):S130–9 (70 ref.) **(Fre)**

METHODS

PCR and sero-diagnosis of chronic Chagas' disease. Biotechnological advances. Gomes YM.
Appl Biochem Biotechnol 1997 May;66(2):107–19 (44 ref.)
Viral serology and detection. Greer S, et al.
Baillieres Clin Gastroenterol 1995 Dec;9(4):689–721 (110 ref.)
Are IgG antibody avidity assays useful in the diagnosis of infectious diseases? A review. Gutiérrez J, et al.
Microbios 1996;87(351):113–21 (40 ref.)
Serological and molecular biology screening techniques for HVC infection. De Lamballerie X.
Nephrol Dial Transplant 1996;11 Suppl 4:9–11 (17 ref.)
[Immunodiagnosis and blood biochemical diagnosis of visceral candidiasis and the cutoff limits of positive] Kume H, et al. **Rinsho Byori** 1996 Jun;44(6):505–11 (21 ref.) (Eng. Abstr.) **(Jpn)**

TRENDS

Clinical, bacteriological, and serological aspects of Klebsiella infections and their spondylarthropathic sequelae. Sahly H, et al. **Clin Diagn Lab Immunol** 1997 Jul;4(4):393–9 (104 ref.)

VETERINARY

Validity of using serological tests for diagnosis of diseases in wild animals. Gardner IA, et al. **Rev Sci Tech** 1996 Mar; 15(1):323–35 (20 ref.)
FIV, FeLV, and FIPV: interpretation and misinterpretation of serological test results. Barr MC.
Semin Vet Med Surg (Small Anim) 1996 Aug;11(3):144–53 (34 ref.)
Diagnosis of leptospirosis: a reemerging disease of companion animals. Bolin CA. **Semin Vet Med Surg (Small Anim)** 1996 Aug;11(3):166–71 (33 ref.)
Canine brucellosis: a diagnostician's dilemma. Carmichael LE, et al. **Semin Vet Med Surg (Small Anim)** 1996 Aug; 11(3):161–5 (22 ref.)
Lyme disease: laboratory diagnosis of infected and vaccinated symptomatic dogs. Jacobson RH, et al.
Semin Vet Med Surg (Small Anim) 1996 Aug;11(3):172–82 (37 ref.)

SEROEPIDEMIOLOGIC METHODS

Are serological responses to acellular pertussis antigens sufficient criteria to ensure that new combination vaccines are effective for prevention of disease? Granoff DM, et al. **Dev Biol Stand** 1997;89:379–89 (39 ref.)
Methods for estimating serological correlates of protection. Siber GR. **Dev Biol Stand** 1997;89:283–96 (16 ref.)
How to select and interpret molecular strain typing methods for epidemiological studies of bacterial infections: a review for healthcare epidemiologists. Molecular Typing Working Group of the Society for Healthcare Epidemiology of America. Tenover FC, et al.
Infect Control Hosp Epidemiol 1997 Jun;18(6):426–39 (75 ref.)

SEROLOGY

METHODS

Following the disease course in systemic lupus erythematosus: are serologic variables of any use? [editorial; comment] Swaak AJ, et al. **J Rheumatol** 1996 Nov; 23(11):1842–4 (12 ref.) Comment on: J Rheumatol 1996 Nov;23(11):1891–6.

SEROSITIS

DIAGNOSIS

[Polyserositis in a female patient with hypothyroidism] Stepanenko OS, et al. **Lik Sprava** 1997 Jan–Feb;(1):108–11 (9 ref.) (Eng. Abstr.) **(Ukr)**

ETIOLOGY

[Mixed connective tissue disease: progress in diagnosis and treatment. III. Treatment. 3. Clinical aspects of specific conditions and treatment. 3) Interstitial pulmonary lesions and serositis] Hirakata M, et al.
Nippon Naika Gakkai Zasshi 1996 Aug 10;85(8):1248–53 (6 ref.) **(Jpn)**

SEROTHERAPY see **IMMUNIZATION, PASSIVE**

SEROTONIN

see related
RECEPTORS, SEROTONIN
SEROTONIN AGENTS

ADVERSE EFFECTS

[Serotonin syndrome: critical review of the literature] Baubet T, et al. **Rev Med Interne** 1997;18(5):380–7 (60 ref.) (Eng. Abstr.) **(Fre)**

ANALOGS & DERIVATIVES

Variability in the effects of 5-HT-related compounds in experimental models of anxiety: evidence for multiple mechanisms of 5-HT in anxiety or never ending story? Griebel G. **Pol J Pharmacol** 1996 Mar–Apr;48(2):129–36 (40 ref.)

ANALYSIS

[Neuronal circuit formation of serotonin neuron system] Ueda S. **Kaibogaku Zasshi** 1997 Jun;72(3):187–90 (24 ref.) **(Jpn)**

BIOSYNTHESIS

Renal and intestinal autocrine monoaminergic systems: dopamine versus 5-hydroxytryptamine. Vieira-Coelho MA, et al. **Clin Exp Hypertens** 1997 Jan–Feb;19(1–2):43–58 (22 ref.)
Effects of acute physical exercise on central serotonergic systems. Chaouloff F. **Med Sci Sports Exerc** 1997 Jan; 29(1):58–62 (39 ref.)
[The importance of vitamin B 6 for development of the infant. Human medical and animal experiment studies] Gerster H. **Z Ernahrungswiss** 1996 Dec;35(4):309–17 (50 ref.) (Eng. Abstr.) **(Ger)**

BLOOD

Platelet serotonin acts as a locally releasable antioxidant. Huether G, et al. **Adv Exp Med Biol** 1996;398:299–306 (37 ref.)
The serotonin system in autism. Cook EH, et al.
Curr Opin Pediatr 1996 Aug;8(4):348–54 (81 ref.)
[Tension-type headache: 5-hydroxytryptamine and related substances] Shimomura T. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1342–4 (8 ref.) (Eng. Abstr.) **(Jpn)**
[Common clinical manifestations of serotonin deficiency and intoxication syndromes] Simonenko AP, et al.
Biull Eksp Biol Med 1997 Jun;123(6):604–13 (22 ref.) **(Rus)**

DEFICIENCY

[Common clinical manifestations of serotonin deficiency and intoxication syndromes] Simonenko AP, et al.
Biull Eksp Biol Med 1997 Jun;123(6):604–13 (22 ref.) **(Rus)**

METABOLISM

Tryptophan metabolism and disposition in relation to alcohol and alcoholism. Badawy AA. **Adv Exp Med Biol** 1996; 398:75–82 (28 ref.)
Neuropsychiatric implications of brain tryptophan perturbations appearing in hepatic encephalopathy. Bengtsson F, et al. **Adv Exp Med Biol** 1996;398:387–95 (73 ref.)
Brain Serotonin, Carbohydrate-craving, obesity and depression. Wurtman RJ, et al. **Adv Exp Med Biol** 1996; 398:35–41 (33 ref.)
Stress hormones, genotype, and brain organization. Implications for aggression. De Kloet ER, et al.
Ann N Y Acad Sci 1996 Sep 20;794:179–91 (65 ref.)
Regulation of 5-HT release from enterochromaffin cells. Racké K, et al. **Behav Brain Res** 1996;73(1–2):83–7 (28 ref.)
The role of serotonin in the future of forensic psychiatry [see comments] Bradford JM.
Bull Am Acad Psychiatry Law 1996;24(1):57–72 (87 ref.)
Comment in: Bull Am Acad Psychiatry Law 1996;24(3):419–22.
Serotonin in alcoholic violent offenders. Virkkunen M, et al. **Ciba Found Symp** 1996;194:168–77; discussion 177–82 (47 ref.)
The serotonin syndrome. LoCurto MJ.
Emerg Med Clin North Am 1997 Aug;15(3):665–75 (36 ref.)
Serotonin syndrome and drug combinations: focus on MAOI and RIMA. Hilton SE, et al.
Eur Arch Psychiatry Clin Neurosci 1997;247(3):113–9 (49 ref.)
Preclinical pharmacology of milnacipran. Briley M, et al.
Int Clin Psychopharmacol 1996 Sep;11 Suppl 4:9–14 (24 ref.)
Two actions are better than one: avoiding self-inhibition of serotonergic neurones enhances the effects of serotonin uptake inhibitors. Romero L, et al.
Int Clin Psychopharmacol 1996 Sep;11 Suppl 4:1–8 (50 ref.)
The involvement of serotonin (5-hydroxytryptamine) in photosensitive epilepsy. Anyanwu E, et al.
J Basic Clin Physiol Pharmacol 1994 Jul–Dec; 5(3–4):179–206 (55 ref.)
Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence. McCann UD, et al.
JAMA 1997 Aug 27;278(8):666–72 (107 ref.)
Functional interaction between serotonin and other neuronal systems: focus on in vivo microdialysis studies. Saito H, et al. **Jpn J Pharmacol** 1996 Mar;70(3):203–5 (221 ref.)
Serotonergic mechanisms involved in the discriminative stimulus, reinforcing and subjective effects of cocaine. Walsh SL, et al. **Psychopharmacology (Berl)** 1997 Mar; 130(1):41–58 (157 ref.)
[Biological mechanisms of drug-resistant depression] Suwalska A, et al. **Psychiatr Pol** 1996 Sep–Oct;30(5):713–29 (56 ref.) (Eng. Abstr.) **(Pol)**

PHARMACOLOGY

Serotonergic vasomotor control in fish gills. Sundin L.
Braz J Med Biol Res 1995 Nov–Dec;28(11–12):1217–21 (34 ref.)
I. Serotonin (5-HT) within dopamine reward circuits signals open-field behavior. II. Basis for 5-HT—DA interaction in cocaine dysfunctional behavior. Broderick PA, et al.
Neurosci Biobehav Rev 1997 May;21(3):227–60 (343 ref.)
Serotonin, norepinephrine and associated neuropeptides: effects on somatic motoneuron excitability. White SR, et al. **Prog Brain Res** 1996;107:183–99 (111 ref.)
Presynaptic inhibition by serotonin: a possible mechanism for switching motor output of the hypoglossal nucleus. Singer JH, et al. **Sleep** 1996 Dec;19(10 Suppl):S146–9 (28 ref.)

PHYSIOLOGY

Endogenous kynurenine derivatives and pain. Weil-Fugazza J. **Adv Exp Med Biol** 1996;398:83–7 (27 ref.)
The effect of low brain serotonin on mood and aggression in humans. Influence of baseline mood and genetic factors. Young SN, et al. **Adv Exp Med Biol** 1996;398:45–50 (24 ref.)
Use of serotonin (5-HT) and opiate-based drugs in the pharmacotherapy of alcohol dependence: an overview of the preclinical data. Lê AD, et al. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:27–32 (55 ref.)
A new role for an old molecule: serotonin as a mitogen. Fanburg BL, et al. **Am J Physiol** 1997 May;272(5 Pt 1):L795–806 (156 ref.)
Persistent alterations in behavior and serotonin activity after recovery from anorexia and bulimia nervosa. Kaye WH.
Ann N Y Acad Sci 1997 May 28;817:162–78 (139 ref.)
Heatstroke-induced cerebral ischemia and neuronal damage. Involvement of cytokines and monoamines. Lin MT.
Ann N Y Acad Sci 1997 Mar 15;813:572–80 (54 ref.)
Mucosal protection through active intestinal secretion: neural and paracrine modulation by 5-hydroxytryptamine. Brown DR. **Behav Brain Res** 1996;73(1–2):193–7 (54 ref.)
The role of serotonin in the actions of psychostimulants: molecular and pharmacological analyses. Cunningham KA, et al. **Behav Brain Res** 1996;73(1–2):93–102 (66 ref.)
Serotonergic functions in arousal and motor activity. Geyer MA. **Behav Brain Res** 1996;73(1–2):31–5 (45 ref.)
Serotonergic regulation of associative learning. Harvey JA.

Behav Brain Res 1996;73(1–2):47–50 (22 ref.)

5–HT3 and 5–HT4 receptors in terminal regions of the mesolimbic system. Kilpatrick GJ, et al. **Behav Brain Res** 1996;73(1–2):11–3 (23 ref.)

Neuroendocrine responses to serotonergic agonists as indices of the functional status of central serotonin neurotransmission in humans: a preliminary comparative analysis of neuroendocrine endpoints versus other endpoint measures. Murphy DL, et al. **Behav Brain Res** 1996; 73(1–2):209–14 (51 ref.)

Interactions of descending serotonergic systems with other neurotransmitters in the modulation of nociception. Sawynok J, et al. **Behav Brain Res** 1996;73(1–2):63–8 (42 ref.)

Serotonergic control of the organization of feeding and satiety. Simansky KJ. **Behav Brain Res** 1996;73(1–2):37–42 (61 ref.)

Serotonergic regulation of renin and prolactin secretion. Van de Kar LD, et al. **Behav Brain Res** 1996;73(1–2):203–8 (44 ref.)

Serotonin as a developmental signal. Whitaker–Azmitia PM, et al. **Behav Brain Res** 1996;73(1–2):19–29 (120 ref.)

Serotonergic modulation of behaviour: a phylogenetic overview. Weiger WA. **Biol Rev Camb Philos Soc** 1997 Feb;72(1):61–95 (172 ref.)

The serotonergic and noradrenergic systems of the hippocampus: their interactions and the effects of antidepressant treatments. Mongeau R, et al. **Brain Res Brain Res Rev** 1997 Apr;23(3):145–95 (501 ref.)

Modulation of in vivo neuronal sprouting by serotonin in the adult CNS of the snail. Baker MW, et al. **Cell Mol Neurobiol** 1996 Oct;16(5):561–76 (50 ref.)

Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Fink G, et al. **Cell Mol Neurobiol** 1996 Jun;16(3):325–44 (87 ref.)

Serotonin, dopamine, and motor effects in Parkinson's disease. Miyawaki E, et al. **Clin Neuropharmacol** 1997 Aug; 20(4):300–10 (103 ref.)

Pharmacology of serotonin as related to anesthesia. Gyermek L. **J Clin Anesth** 1996 Aug;8(5):402–25 (232 ref.)

The biological basis of panic disorder. Krystal JH, et al. **J Clin Psychiatry** 1996;57 Suppl 10:23–31; discussion 32–3 (76 ref.)

Direct regulation of mammalian reproductive organs by serotonin and melatonin. Sirotkin AV, et al. **J Endocrinol** 1997 Jul;154(1):1–5 (60 ref.)

The role of serotonin in the pathophysiology and treatment of schizophrenia. Abi–Dargham A, et al. **J Neuropsychiatry Clin Neurosci** 1997 Winter;9(1):1–17 (243 ref.)

The neuroanatomy of 5–HT dysregulation and panic disorder. Grove G, et al. **J Neuropsychiatry Clin Neurosci** 1997 Spring;9(2):198–207 (62 ref.)

Serotonergic receptors as targets for pharmacotherapy. Kirk EE, et al. **J Neurosci Nurs** 1997 Jun;29(3):191–7 (61 ref.)

Limbic circuits and monoamine receptors: dissecting the effects of antipsychotics from disease processes. Joyce JN, et al. **J Psychiatr Res** 1997 Mar–Apr;31(2):197–217 (70 ref.)

Autocrine/paracrine control of renal phosphate transport. Friedlander G, et al. **Kidney Int Suppl** 1996 Dec;57:S148–53 (73 ref.)

Thyroid parafollicular cells. An accessible model for the study of serotonergic neurons. Russo AF, et al. **Mol Neurobiol** 1996 Dec;13(3):257–76 (132 ref.)

Genetically engineered neural transmission. Son JH, et al. **Mol Psychiatry** 1997 Jan;2(1):26–31 (44 ref.)

5–Hydroxytryptamine and functional bowel disorders. Sanger GJ. **Neurogastroenterol Motil** 1996 Dec;8(4):319–31 (145 ref.)

Myoglobinuria, malignant hyperthermia, neuroleptic malignant syndrome and serotonin syndrome. Bertorini TE. **Neurol Clin** 1997 Aug;15(3):649–71 (193 ref.)

Serotonergic mechanisms in neuroleptic–induced catalepsy in the rat. Wadenberg ML. **Neurosci Biobehav Rev** 1996 Summer;20(2):325–39 (135 ref.)

Neurotransmission by neurons that use serotonin, noradrenaline, glutamate, glycine, and gamma–aminobutyric acid in the normal and injured spinal cord. Shapiro S. **Neurosurgery** 1997 Jan;40(1):168–76; discussion 177 (109 ref.)

Cracking the riddle of cancer anorexia. Laviano A, et al. **Nutrition** 1996 Oct;12(10):706–10 (54 ref.)

5–HT systems and anxiety: multiple mechanisms in the elevated X–maze. McCreary AC, et al. **Pol J Pharmacol** 1996 Jan–Feb;48(1):1–12 (87 ref.)

Serotonin, sex, and psychiatric illness [see comments] Heninger GR. **Proc Natl Acad Sci U S A** 1997 May 13; 94(10):4823–4 (26 ref.) Comment in: Proc Natl Acad Sci U S A 1997 May 13;94(10):5308–13.

Serotonin in the regulation of brain microcirculation. Cohen Z, et al. **Prog Neurobiol** 1996 Nov;50(4):335–62 (160 ref.)

The effects of methylenedioxymethamphetamine (MDMA, "Ecstasy") on monoaminergic neurotransmission in the central nervous system. White SR, et al. **Prog Neurobiol** 1996 Aug;49(5):455–79 (136 ref.)

Faulty cortisol/serotonin interplay. Psychopathological and biological characterisation of a new, hypothetical depression subtype (SeCA depression). van Praag HM. **Psychiatry Res** 1996 Dec 20;65(3):143–57 (175 ref.)

Serotonin in early–onset alcoholism. Virkkunen M, et al. **Recent Dev Alcohol** 1997;13:173–89 (117 ref.)

Serotonin, aging and cognitive functions of the hippocampus. Richter–Levin G, et al. **Rev Neurosci** 1996 Apr–Jun; 7(2):103–13 (96 ref.)

[Is it feasible to develop a 5–HT basis for the treatment of depression?] Hamon M. **Encephale** 1995 Dec;21 Spec No 4:27–32 (26 ref.) **(Fre)**

[Migraine and serotonin: mechanisms and treatments] Jacquy J. **J Pharm Belg** 1996 Jan–Feb;51(1):43–6 (0 ref.) **(Fre)**

[The tryptophan depletion test. Basic principles and clinical relevance] Neumeister A, et al. **Nervenarzt** 1997 Jul; 68(7):556–62 (45 ref.) (Eng. Abstr.) **(Ger)**

[Role of serotonin in emesis] Minami M, et al. **Nippon Yakurigaku Zasshi** 1996 Nov;108(5):233–42 (50 ref.) (Eng. Abstr.) **(Jpn)**

[Serotonin--its significance in physiology and pathology of the eye] Andrzejewska–Buczko J, et al. **Klin Oczna** 1996 Feb;98(2):151–4 (42 ref.) (Eng. Abstr.) **(Pol)**

[Serotonin in genetically determined types of defensive behavior] Popova NK. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 Mar–Apr; 47(2):350–7 (46 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Issues in the monopharmacotherapy and polypharmacotherapy of obsessive–compulsive disorder. Laird LK. **Psychopharmacol Bull** 1996;32(4):569–78 (83 ref.)

SEROTONIN ACETYLTRANSFERASE see **ARYLAMINE ACETYLTRANSFERASES**

SEROTONIN AGENTS

[Ecstasy: psychostimulant, hallucinogen and toxic substance] Burnat P, et al. **Presse Med** 1996 Sep 14;25(26):1208–12 (25 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

The serotonin syndrome. LoCurto MJ. **Emerg Med Clin North Am** 1997 Aug;15(3):665–75 (36 ref.)

DIAGNOSTIC USE

Radioligands for PET studies of central 5–HT receptors and re–uptake sites--current status. Pike VW. **Nucl Med Biol** 1995 Nov;22(8):1011–8 (38 ref.)

PHARMACOLOGY

Detection of serotonergic and noradrenergic antidepressants in the rat forced swimming test: the effects of water depth. Detke MJ, et al. **Behav Brain Res** 1996;73(1–2):43–6 (20 ref.)

The stimulus effects of serotonergic hallucinogens in animals. Winter JC. **NIDA Res Monogr** 1994;146:157–82 (73 ref.)

Role of opioidergic and serotonergic mechanisms in cough and antitussives. Kamei J. **Pulm Pharmacol** 1996 Oct–Dec; 9(5–6):349–56 (67 ref.)

THERAPEUTIC USE

Use of serotonin selective pharmacotherapy in the treatment of alcohol dependence. Pettinati HM. **Alcohol Clin Exp Res** 1996 Oct;20(7 Suppl):23A–29A (46 ref.)

The pharmacology of antimyoclonic drugs. Pranzatelli MR. **Clin Neurosci** 1995–96;3(4):246–52 (60 ref.)

Role of serotonin drugs in the treatment of social phobia. Tancer ME, et al. **J Clin Psychiatry** 1997;58 Suppl 5:50–4 (39 ref.)

The role of serotonin in the pathophysiology and treatment of schizophrenia. Abi–Dargham A, et al. **J Neuropsychiatry Clin Neurosci** 1997 Winter;9(1):1–17 (243 ref.)

Serotonergic receptors as targets for pharmacotherapy. Kirk EE, et al. **J Neurosci Nurs** 1997 Jun;29(3):191–7 (61 ref.)

[Migraine and serotonin: mechanisms and treatments] Jacquy J. **J Pharm Belg** 1996 Jan–Feb;51(1):43–6 (0 ref.) **(Fre)**

SEROTONIN AGONISTS

ADVERSE EFFECTS

Headache induced by serotonergic agonists--a key to the interpretation of migraine pathogenesis? Panconesi A, et al. **Cephalalgia** 1997 Feb;17(1):3–14 (147 ref.)

CHEMISTRY

Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent. Nichols DE, et al. **Behav Brain Res** 1996;73(1–2):117–9 (9 ref.)

PHARMACOLOGY

Novel discriminatory ligands for 5–HT2B receptors. Baxter GS. **Behav Brain Res** 1996;73(1–2):149–52 (19 ref.)

Regulation of 5–HT2A receptor mRNA in P11 cells. Ferry RC, et al. **Behav Brain Res** 1996;73(1–2):187–91 (26 ref.)

Neuroendocrine responses to serotonergic agonists as indices of the functional status of central serotonin neurotransmission in humans: a preliminary comparative analysis of neuroendocrine endpoints versus other endpoint measures. Murphy DL, et al. **Behav Brain Res** 1996; 73(1–2):209–14 (51 ref.)

Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent. Nichols DE, et al. **Behav Brain Res** 1996;73(1–2):117–9 (9 ref.)

Role of 5–HT1A autoreceptors in the mechanism of action of serotoninergic antidepressant drugs: recent findings from in vivo microdialysis studies. Gardier AM, et al. **Fundam Clin Pharmacol** 1996;10(1):16–27 (88 ref.)

The role of the hypothalamic–pituitary–adrenocortical axis in memory–related effects of anxiolytics. Korneyev AY. **Neurobiol Learn Mem** 1997 Jan;67(1):1–13 (162 ref.)

Regulation of plasma aldosterone levels by metoclopramide: a reappraisal of its mechanism from dopaminergic antagonism to serotonergic agonism. Rizzi CA, et al. **Neuropharmacology** 1997 Jun;36(6):763–8 (65 ref.)

Neurochemical evidence that hallucinogenic drugs are 5–HT1c receptor agonists: what next? Sanders–Bush E. **NIDA Res Monogr** 1994;146:203–13 (20 ref.)

[A new approach to innovating selective anxiolytics: pharmacological profile of a novel 5–HT1A agonist (tandospirone)] Sasa M. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1997 Apr; 17(2):53–9 (33 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Clinical presentation and treatment of migraine. Skaer TL. **Clin Ther** 1996 Mar–Apr;18(2):229–45; discussion 228 (71 ref.)

Acute migraine therapy: the newer drugs. Schoenen J. **Curr Opin Neurol** 1997 Jun;10(3):237–43 (38 ref.)

Emerging preclinical and clinical profile of 311C90: a poster review and discussion. Ferrari MD. **Eur Neurol** 1996;36 Suppl 2:19–23 (23 ref.)

Inhibition of the trigemino–vascular system with 5–HT1D agonist drugs: selectively targeting additional sites of action. Martin GR. **Eur Neurol** 1996;36 Suppl 2:13–8 (22 ref.)

Sumatriptan relieves migrainelike headaches associated with carbon monoxide exposure. Lipton RB, et al. **Headache** 1997 Jun;37(6):392–5 (39 ref.)

Diagnosis and symptomatic treatment of migraine. Saper JR. **Headache** 1997;37 Suppl 1:S1–14 (56 ref.)

Oral treatments for erectile dysfunction. Riley A. **Int J STD AIDS** 1996;7 Suppl 3:16–8 (12 ref.)

Current concepts of the pathophysiology of migraine. Goadsby PJ. **Neurol Clin** 1997 Feb;15(1):27–42 (42 ref.)

Serotonin 1D (5–HT1D) agonists and other agents in acute migraine. Mathew NT. **Neurol Clin** 1997 Feb;15(1):61–83 (127 ref.)

311C90: increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists. Ferrari MD. **Neurology** 1997 Mar;48(3 Suppl 3):S21–4 (15 ref.)

Increasing the options for effective migraine management. Goadsby PJ, et al. **Neurology** 1997 Mar;48(3 Suppl 3):S1–3 (16 ref.)

[The 5–HT1A receptor: a new effective principle in psychopharmacologic therapy?] Davids E, et al. **Fortschr Neurol Psychiatr** 1996 Nov;64(11):460–72 (135 ref.) (Eng. Abstr.) **(Ger)**

[Pharmacologic and clinical differentiation of prokinetic drugs] May B, et al. **Leber Magen Darm** 1996 Jul; 26(4):193–8 (52 ref.) (Eng. Abstr.) **(Ger)**

SEROTONIN ANTAGONISTS

see related

SEROTONIN UPTAKE INHIBITORS

Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. Balfour JA, et al. **Drugs** 1997 Aug;54(2):273–98 (86 ref.)

5–HT3–receptor antagonists: a review of pharmacology and clinical efficacy. Cunningham RS. **Oncol Nurs Forum** 1997 Aug;24(7 Suppl):33–40 (54 ref.)

[Mechanisms of cytotoxic drug–induced emesis and its prevention] Matsuki N. **Yakugaku Zasshi** 1996 Sep; 116(9):710–8 (32 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent. Nichols DE, et al. **Behav Brain Res** 1996;73(1–2):117–9 (9 ref.)

PHARMACOKINETICS

Clinical pharmacokinetics of ondansetron. A review. Simpson KH, et al. **J Pharm Pharmacol** 1996 Aug; 48(8):774–81 (60 ref.)

PHARMACOLOGY

Ritanserin and alcohol abuse and dependence. Meert TF. **Alcohol Alcohol Suppl** 1994;2:523–30 (33 ref.)

Novel discriminatory ligands for 5–HT2B receptors. Baxter GS. **Behav Brain Res** 1996;73(1–2):149–52 (19 ref.)

Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent. Nichols DE, et al. **Behav Brain Res** 1996;73(1–2):117–9 (9 ref.)

Development of 5–HT1A receptor antagonists. Routledge C. **Behav Brain Res** 1996;73(1–2):153–6 (31 ref.)

GR127935: a potent and selective 5–HT1D receptor antagonist. Skingle M, et al. **Behav Brain Res** 1996;

73(1–2):157–61 (23 ref.)
How do the currently used prophylactic agents work in migraine? Goadsby PJ. **Cephalalgia** 1997 Apr;17(2):85–92 (91 ref.)
Antiemetics revisited. Roila F, et al. **Curr Opin Oncol** 1997 Jul;9(4):321–6 (31 ref.)
Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. Wilde MI, et al. **Drugs** 1996 Nov;52(5):773–94 (185 ref.)
Serotonin 5–HT3 and 5–HT4 receptor antagonists. Gaster LM, et al. **Med Res Rev** 1997 Mar;17(2):163–214 (311 ref.)
A pharmacological analysis of serotonergic receptors: effects of their activation of blockade in learning. Meneses A, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Feb; 21(2):273–96 (121 ref.)
5–HT2 antagonism and EPS benefits: is there a causal connection? Kapur S. **Psychopharmacology (Berl)** 1996 Mar; 124(1–2):35–9 (50 ref.)
Role of opioidergic and serotonergic mechanisms in cough and antitussives. Kamei J. **Pulm Pharmacol** 1996 Oct–Dec; 9(5–6):349–56 (67 ref.)
Acceleration of the effect of selected antidepressant drugs in major depression by 5–HT1A antagonists. Artigas F, et al. **Trends Neurosci** 1996 Sep;19(9):378–83 (66 ref.)
[A new antiemetic ramosetron hydrochloride] Tsukagoshi S. **Gan To Kagaku Ryoho** 1997 Feb;24(3):371–80 (23 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Use of serotonin (5–HT) and opiate–based drugs in the pharmacotherapy of alcohol dependence: an overview of the preclinical data. Lê AD, et al. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:27–32 (55 ref.)
The non–antiemetic uses of serotonin 5–HT3 receptor antagonists. Clinical pharmacology and therapeutic applications. Greenshaw AJ, et al. **Drugs** 1997 Jan; 53(1):20–39 (188 ref.)
Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Stimmel GL, et al. **Pharmacotherapy** 1997 Jan–Feb;17(1):10–21 (60 ref.)
[Serotonin and treatment of mental disorders. Present status and future perspectives] Sevčík J, et al. **Cas Lek Cesk** 1997 Jul 14;136(14):431–3 (17 ref.) (Eng. Abstr.) **(Cze)**
[Recent improvements in antiemetic therapy] Roila F, et al. **Tumori** 1997;83(2 Suppl):S3–14 (63 ref.) (Eng. Abstr.) **(Ita)**

SEROTONIN BLOCKADERS see **SEROTONIN ANTAGONISTS**

SEROTONIN RECEPTOR AGONISTS see **SEROTONIN AGONISTS**

SEROTONIN RECEPTORS see **RECEPTORS, SEROTONIN**

SEROTONIN REUPTAKE INHIBITORS see **SEROTONIN UPTAKE INHIBITORS**

SEROTONIN UPTAKE INHIBITORS

see related
ADRENERGIC UPTAKE INHIBITORS
ANTIDEPRESSIVE AGENTS, SECOND–GENERATION

Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide. Goldberg RJ. **Drugs Aging** 1997 Aug;11(2):119–31 (86 ref.)

ADMINISTRATION & DOSAGE

Dose–response relationship with venlafaxine. Kelsey JE. **J Clin Psychopharmacol** 1996 Jun;16(3 Suppl 2):21S–26S; discussion 26S–28S (22 ref.)
[Increased use of antidepressive agents. A correctly aimed development] Isacsson G, et al. **Lakartidningen** 1997 Apr 16;94(16):1484–6 (46 ref.) **(Swe)**

ADVERSE EFFECTS

How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease? Sheline YI, et al. **Am J Med** 1997 Jan;102(1):54–9 (74 ref.)
Retrospective study of selegiline–antidepressant drug interactions and a review of the literature. Ritter JL, et al. **Ann Clin Psychiatry** 1997 Mar;9(1):7–13 (37 ref.)
Association of SIADH with selective serotonin reuptake inhibitors. Woo MH, et al. **Ann Pharmacother** 1997 Jan; 31(1):108–10 (32 ref.)
SSRIs and hyponatraemia. Lane RM. **Br J Clin Pract** 1997 Apr–May;51(3):144–6 (39 ref.)
Selective serotonin reuptake inhibitors in older patients. A tolerability perspective. Skerritt U, et al. **Drugs Aging** 1997 Mar;10(3):209–18 (74 ref.)
Newer antidepressants and the discontinuation syndrome. Haddad P. **J Clin Psychiatry** 1997;58 Suppl 7:17–21; discussion 22 (367 ref.)
Movement disorders associated with the serotonin selective reuptake inhibitors. Leo RJ. **J Clin Psychiatry** 1996 Oct; 57(10):449–54 (86 ref.)
Safety and tolerability of the new antidepressants. Nelson JC. **J Clin Psychiatry** 1997;58 Suppl 6:26–31 (30 ref.)
Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. Discontinuation Consensus Panel. Schatzberg AF, et al. **J Clin Psychiatry** 1997;58 Suppl 7:23–7 (29 ref.)
Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus panel. Schatzberg AF, et al. **J Clin Psychiatry** 1997;58 Suppl 7:5–10 (32 ref.)
Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. Zajecka J, et al. **J Clin Psychiatry** 1997 Jul;58(7):291–7 (36 ref.)
Drug–drug interactions involving antidepressants: focus on venlafaxine. Ereshefsky L. **J Clin Psychopharmacol** 1996 Jun;16(3 Suppl 2):37S–50S; discussion 50S–53S (66 ref.)
Selective serotonin reuptake inhibitor–induced serotonin syndrome: review. Lane R, et al. **J Clin Psychopharmacol** 1997 Jun;17(3):208–21 (149 ref.)
The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. Rudolph RL, et al. **J Clin Psychopharmacol** 1996 Jun;16(3 Suppl 2):54S–59S; discussion 59S–61S (13 ref.)
Antidepressant drugs and the cardiovascular system: a comparison of tricylics and selective serotonin reuptake inhibitors and their relevance for the treatment of psychiatric patients with cardiovascular problems. Coupland N, et al. **J Psychopharmacol (Oxf)** 1997; 11(1):83–92 (117 ref.)
A critical review of selective serotonin reuptake inhibitor–related sexual dysfunction; incidence, possible aetiology and implications for management. Lane RM. **J Psychopharmacol (Oxf)** 1997;11(1):72–82 (126 ref.)
Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence. McCann UD, et al. **JAMA** 1997 Aug 27;278(8):666–72 (107 ref.)
The safety of fluoxetine during pregnancy and lactation. Nulman I, et al. **Teratology** 1996 May;53(5):304–8 (33 ref.)
[Fluoxetine, akathisia and suicide] Lançon C, et al. **Encephale** 1997 May–Jun;23(3):218–23 (46 ref.) (Eng. Abstr.) **(Fre)**

BLOOD

Analytical methods for the quantitative determination of selective serotonin reuptake inhibitors for therapeutic drug monitoring purposes in patients. Eap CB, et al. **J Chromatogr B Biomed Appl** 1996 Nov 8;686(1):51–63 (73 ref.)

METABOLISM

Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. Harvey AT, et al. **J Clin Psychopharmacol** 1996 Oct;16(5):345–55 (107 ref.)
Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part I. Harvey AT, et al. **J Clin Psychopharmacol** 1996 Aug;16(4):273–85 (130 ref.)

PHARMACOKINETICS

Pharmacokinetic–pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Baumann P. **Clin Pharmacokinet** 1996 Dec;31(6):444–69 (191 ref.)
Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Preskorn SH. **Clin Pharmacokinet** 1997;32 Suppl 1:1–21 (143 ref.)
Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors [published erratum appears in Int Clin Psychopharmacol 1997 Mar;12(2):126] Lane RM. **Int Clin Psychopharmacol** 1996 Dec;11 Suppl 5:31–61 (266 ref.)
Pharmacokinetics of milnacipran in comparison with other antidepressants. Puozzo C, et al. **Int Clin Psychopharmacol** 1996 Sep;11 Suppl 4:15–27 (90 ref.)
Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Richelson E. **Mayo Clin Proc** 1997 Sep;72(9):835–47 (105 ref.)
Pharmacokinetics of selective serotonin reuptake inhibitors: clinical relevance. Catterson ML, et al. **Pharmacol Toxicol** 1996 Apr;78(4):203–8 (52 ref.)

PHARMACOLOGY

Pharmacokinetic–pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Baumann P. **Clin Pharmacokinet** 1996 Dec;31(6):444–69 (191 ref.)
Role of 5–HT1A autoreceptors in the mechanism of action of serotoninergic antidepressant drugs: recent findings from in vivo microdialysis studies. Gardier AM, et al. **Fundam Clin Pharmacol** 1996;10(1):16–27 (88 ref.)
Preclinical pharmacology of milnacipran. Briley M, et al. **Int Clin Psychopharmacol** 1996 Sep;11 Suppl 4:9–14 (24 ref.)
Two actions are better than one: avoiding self–inhibition of serotonergic neurones enhances the effects of serotonin uptake inhibitors. Romero L, et al. **Int Clin Psychopharmacol** 1996 Sep;11 Suppl 4:1–8 (50 ref.)
Pharmacology of the selective serotonin reuptake inhibitors in children and adolescents. Leonard HL, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Jun;36(6):725–36 (109 ref.)
Inhibition of human cytochrome P450–3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies. Greenblatt DJ, et al. **J Clin Pharmacol** 1996 Sep;36(9):792–8 (51 ref.)
The clinician and drug interactions—an update [editorial] Shader RI, et al. **J Clin Psychopharmacol** 1996 Jun; 16(3):197–201 (38 ref.)
Sexual side effects of antidepressants: a review. Margolese HC, et al. **J Sex Marital Ther** 1996 Fall;22(3):209–17 (68 ref.)
The influence of fluoxetine on aggressive behavior [see comments] Fuller RW. **Neuropsychopharmacology** 1996 Feb;14(2):77–81 (36 ref.) Comment in: Neuropsychopharmacology 1997 May;16(5):373–4.
The neurobiology and pharmacology of depression. A comparative overview of serotonin selective antidepressants. Harvey BH. **S Afr Med J** 1997 Apr;87(4 Suppl):540–50, 552 (92 ref.)
Prozac: panacea or puzzle? Stanford SC. **Trends Pharmacol Sci** 1996 Apr;17(4):150–4 (33 ref.)
[Biological mechanisms of drug–resistant depression] Suwalska A, et al. **Psychiatr Pol** 1996 Sep–Oct;30(5):713–29 (56 ref.) (Eng. Abstr.) **(Pol)**

POISONING

Serotonin syndrome. Martin TG. **Ann Emerg Med** 1996 Nov; 28(5):520–6 (100 ref.)

THERAPEUTIC USE

Use of serotonin (5–HT) and opiate–based drugs in the pharmacotherapy of alcohol dependence: an overview of the preclinical data. Lê AD, et al. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:27–32 (55 ref.)
Use of serotonin (5–hydroxytryptamine) reuptake inhibitors in the treatment of alcoholism. Lejoyeux M. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:69–75 (40 ref.)
Pharmacotherapy in alcoholism treatment: integrating and understanding the use of serotonin reuptake inhibitors. George FR. **Alcohol Alcohol Suppl** 1994;2:537–43 (38 ref.)
Syncope: pathophysiology, diagnosis, and pharmacotherapy. Lazarus JC, et al. **Ann Pharmacother** 1996 Sep; 30(9):994–1005 (51 ref.)
Panic disorder and social phobia: possible implications of comorbid depression for drug therapy. Lydiard RB. **Anxiety** 1996;2(2):61–70 (90 ref.)
Alcohol and the brain. Scheepers BD. **Br J Hosp Med** 1997 Jun 4–17;57(11):548–51 (16 ref.)
Advances in psychopharmacology: mood disorders and dementia. Cowen PJ. **Br Med Bull** 1996 Jul;52(3):539–55 (44 ref.)
Placebo response in the treatment of panic disorder. Hirschfeld RM. **Bull Menninger Clin** 1996 Spring;60(2 Suppl A):A76–86 (20 ref.)
The pharmacotherapy of panic disorder. Rosenbaum JF, et al. **Bull Menninger Clin** 1996 Spring;60(2 Suppl A):A54–75 (119 ref.)
New antidepressants: more options for tailoring treatment. Muzina DJ, et al. **Cleve Clin J Med** 1996 Nov–Dec; 63(7):406–12; quiz 420 (20 ref.)
Treatment of severe depression with the selective serotonin reuptake inhibitors. Schatzberg AF. **Depress Anxiety** 1996–97;4(4):182–9 (24 ref.)
Venlafaxine: a novel antidepressant that has a dual mechanism of action. Andrews JM, et al. **Depression** 1996; 4(2):48–56 (40 ref.)
Depression and myocardial infarction. Implications for medical prognosis and options for treatment. Cleophas TJ. **Drugs Aging** 1997 Aug;11(2):111–8 (64 ref.)
Is there a role for a pure noradrenergic drug in the treatment of depression? Montgomery SA. **Eur Neuropsychopharmacol** 1997 Apr;7 Suppl 1:S3–9; discussion S71–3 (40 ref.)
Depression: making the diagnosis and using SSRIs in the older patient. Reynolds CF 3rd. **Geriatrics** 1996 Oct; 51(10):28–34 (25 ref.)
Obsessive–compulsive disorder–related disorders: the role of selective serotonergic reuptake inhibitors. Hollander E. **Int Clin Psychopharmacol** 1996 Dec;11 Suppl 5:75–87 (61 ref.)
Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. Kasper S, et al. **Int Clin Psychopharmacol** 1996 Sep;11 Suppl 4:35–9 (19 ref.)
Risk of suicide in depression and its implication for psychopharmacological treatment. Kasper S, et al. **Int Clin Psychopharmacol** 1996 Jun;11(2):71–9 (100 ref.)
Clinical efficacy of milnacipran: placebo–controlled trials. Lecrubier Y, et al. **Int Clin Psychopharmacol** 1996 Sep;11 Suppl 4:29–33 (13 ref.)
Milnacipran and selective serotonin reuptake inhibitors in major depression. Lopez–Ibor J, et al. **Int Clin Psychopharmacol** 1996 Sep;11 Suppl 4:41–6 (32 ref.)
Efficacy and tolerability of milnacipran: an overview. Montgomery SA, et al. **Int Clin Psychopharmacol** 1996 Sep; 11 Suppl 4:47–51 (24 ref.)
Long–term management of obsessive–compulsive disorder. Montgomery SA. **Int Clin Psychopharmacol** 1996 Dec;11

Suppl 5:23–9 (35 ref.)
The pharmacotherapy of social phobia. Pollack MH, et al. **Int Clin Psychopharmacol** 1996 Jun;11 Suppl 3:71–5 (40 ref.)
The failure of 'adult' interventions with adolescent depression: what does it mean for theory, research and practice? Mueller C, et al. **J Affect Disord** 1997 Jul; 44(2–3):203–15 (88 ref.)
Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. Perry PJ. **J Affect Disord** 1996 Jun 20;39(1):1–6 (22 ref.)
Developments in the drug treatment of panic disorder: what is the place of the selective serotonin reuptake inhibitors? Westenberg HG. **J Affect Disord** 1996 Sep 9;40(1–2):85–93 (56 ref.)
Safety and tolerability of the new antidepressants. Nelson JC. **J Clin Psychiatry** 1997;58 Suppl 6:26–31 (30 ref.)
Management of patients with depression associated with anxiety symptoms. Nutt D. **J Clin Psychiatry** 1997;58 Suppl 8:11–6 (67 ref.)
The role of SSRIs in panic disorder. Sheehan DV, et al. **J Clin Psychiatry** 1996;57 Suppl 10:51–8; discussion 59–60 (65 ref.)
Clinical evaluation of venlafaxine. Ballenger JC. **J Clin Psychopharmacol** 1996 Jun;16(3 Suppl 2):29S–35S; discussion 35S–36S (12 ref.)
Antidepressant options: venlafaxine in perspective. Thase ME. **J Clin Psychopharmacol** 1996 Jun;16(3 Suppl 2):10S–18S; discussion 18S–20S (70 ref.)
Recent developments in the psychopharmacology of anxiety disorders. Lydiard RB, et al. **J Consult Clin Psychol** 1996 Aug;64(4):660–8 (85 ref.)
Tourette syndrome. Medical and surgical treatment of obsessive-compulsive disorder. Rapoport JL, et al. **Neurol Clin** 1997 May;15(2):421–8 (41 ref.)
Are SSRIs true antidepressant drugs? A plea for the re-evaluation of their therapeutic potential and safety. Loonen AJ. **Pharm World Sci** 1997 Apr;19(2):70–2 (13 ref.)
Venlafaxine and nefazodone, two pharmacologically distinct antidepressants. Augustin BG, et al. **Pharmacotherapy** 1997 May–Jun;17(3):511–30 (91 ref.)
The place of selective serotonin reuptake inhibitors in the treatment of panic disorder. DeVane CL. **Pharmacotherapy** 1997 Mar–Apr;17(2):282–92 (65 ref.)
Psychopharmacologic treatment of pathologic aggression. Fava M. **Psychiatr Clin North Am** 1997 Jun;20(2):427–51 (176 ref.)
Trazodone for aggression in an adolescent with hydrocephalus. Mashiko H, et al. **Psychiatry Clin Neurosci** 1996 Jun;50(3):133–6 (16 ref.)
Pharmacologic treatment of body dysmorphic disorder. Phillips KA. **Psychopharmacol Bull** 1996;32(4):597–605 (52 ref.)
[Is it feasible to develop a 5-HT basis for the treatment of depression?] Hamon M. **Encephale** 1995 Dec;21 Spec No 4:27–32 (26 ref.) **(Fre)**
[Therapy with selective serotonin reuptake inhibitors (SSRI). Indications, uses and risks] Ebert D. **Fortschr Med** 1996 Jul 1;114(18–19):243–7 (4 ref.) (Eng. Abstr.) **(Ger)**
[Controlled long-term prevention of unipolar depression with antidepressive agents of the second generation (SSRI)] Zimmermann U. **Psychiatr Prax** 1996 Sep;23(5):240–3 (29 ref.) (Eng. Abstr.) **(Ger)**
[Selective serotonin reuptake inhibitors (SSRI) in childhood and adolescence] Stilke D. **Z Kinder Jugenpsychiatr** 1997 May;25(2):106–16 (60 ref.) **(Ger)**
[Biological mechanisms of drug-resistant depression] Suwalska A, et al. **Psychiatr Pol** 1996 Sep–Oct;30(5):713–29 (56 ref.) (Eng. Abstr.) **(Pol)**
[The treatment of the resistant obsessive-compulsive disorder: an update] Crespo Facorro B, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1997 Jan–Feb;25(1):61–9 (106 ref.) (Eng. Abstr.) **(Spa)**

TOXICITY

Fluoxetine hypophagia. Is there a role for serotonergic mechanisms in some circumstances? [letter; comment] Clifton PG, et al. **Trends Pharmacol Sci** 1997 Jun; 18(6):191–2 (4 ref.) Comment on: Trends Pharmacol Sci 1997 Jan;18(1):21–5.

SEROTYPING

Papillomavirus and HPV typing. de Villiers EM. **Clin Dermatol** 1997 Mar–Apr;15(2):199–206 (83 ref.)

METHODS

The influence of virus structure on antibody responses and virus serotype formation. Bachmann MF, et al. **Immunol Today** 1996 Dec;17(12):553–8 (48 ref.)

SERPENTINE (MINERAL) see **ASBESTOS, SERPENTINE**

SERPENTINE ASBESTOS see **ASBESTOS, SERPENTINE**

SERPIN SUPERFAMILY see **SERPINS**

SERPINS

CHEMISTRY

The biostructural pathology of the serpins: critical function of sheet opening mechanism. Carrell RW, et al. **Biol Chem Hoppe Seyler** 1996 Jan;377(1):1–17 (97 ref.)

CLASSIFICATION

The intracellular serpin family. Korpula-Mastalerz R, et al. **Acta Biochim Pol** 1996;43(3):419–29 (52 ref.)

METABOLISM

Inhibition of cysteine and serine proteinases by the cowpox virus serpin CRMA. Komiyama T, et al. **Adv Exp Med Biol** 1996;389:173–6 (39 ref.)
Crystallographic study of eglin-C binding to thermitase. Teplyakov A, et al. **Adv Exp Med Biol** 1996;379:5–9 (20 ref.)
Biochemistry, regulation and potential function of kallistatin. Chao J, et al. **Biol Chem Hoppe Seyler** 1995 Dec; 376(12):705–13 (69 ref.)

PHARMACOKINETICS

Pharmacology and pharmacokinetics of LEX 032, a bioengineered serpin: the first of a potential new class of drugs. Sands H, et al. **Drug Metab Rev** 1997 Feb–May; 29(1–2):309–28 (68 ref.)

PHARMACOLOGY

Pharmacology and pharmacokinetics of LEX 032, a bioengineered serpin: the first of a potential new class of drugs. Sands H, et al. **Drug Metab Rev** 1997 Feb–May; 29(1–2):309–28 (68 ref.)

PHYSIOLOGY

Thrombin, its receptor and protease nexin I, its potent serpin, in the nervous system. Festoff BW, et al. **Semin Thromb Hemost** 1996;22(3):267–71 (47 ref.)

SERRATIA INFECTIONS

ETIOLOGY

The role of Serratia marcescens in soft contact lens associated ocular infections. A review. Parment PA. **Acta Ophthalmol Scand** 1997 Feb;75(1):67–71 (77 ref.)

PREVENTION & CONTROL

Serratia marcescens infections in neonatal departments: description of an outbreak and review of the literature. van Ogtrop ML, et al. **J Hosp Infect** 1997 Jun;36(2):95–103 (22 ref.)

SERRATIA MARCESCENS

ISOLATION & PURIFICATION

Serratia marcescens infections in neonatal departments: description of an outbreak and review of the literature. van Ogtrop ML, et al. **J Hosp Infect** 1997 Jun;36(2):95–103 (22 ref.)

PHYSIOLOGY

The role of Serratia marcescens in soft contact lens associated ocular infections. A review. Parment PA. **Acta Ophthalmol Scand** 1997 Feb;75(1):67–71 (77 ref.)

SERTOLI CELL TUMOR

PATHOLOGY

Malignant Sertoli cell tumor of the testicle in a black man. Zeitlin SI, et al. **J Urol** 1996 Dec;156(6):2006 (3 ref.)

THERAPY

Metastatic Sertoli cell carcinoma of the testis. Mene MP, et al. **J Am Osteopath Assoc** 1996 Oct;96(10):612–4 (7 ref.)

ULTRASONOGRAPHY

[Calcifying giant-cell Sertoli tumor: description of a case wtih atypical echographic presentation] Moro U, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):105–8 (19 ref.) (Eng. Abstr.) **(Ita)**

SERTOLI CELLS

CYTOLOGY

Transplantation of testis-derived Sertoli cells into the mammalian brain. Sanberg PR, et al. **Transplant Proc** 1997 Jun;29(4):1926–8 (42 ref.)

PHYSIOLOGY

Paracrine control of human Leydig cell and Sertoli cell functions. Carreau S. **Folia Histochem Cytobiol** 1996; 34(3–4):111–9 (90 ref.)

SERTOLI-LEYDIG CELL TUMOR

DRUG THERAPY

Platinum based chemotherapy to treat recurrent Sertoli-Leydig cell ovarian carcinoma during pregnancy. Tomlinson MW, et al. **Eur J Gynaecol Oncol** 1997; 18(1):44–6 (18 ref.)

SERUM A RELATED PROTEIN see **AMYLOID PROTEIN SAA**

SERUM ALBUMIN

Viral infectivity of albumin and plasma protein fraction. Erstad BL. **Pharmacotherapy** 1996 Nov–Dec; 16(6):996–1001 (47 ref.)
[Reality and clinical application of albumin preparation] Kikuchi S, et al. **Nippon Naika Gakkai Zasshi** 1996 Jun 10;85(6):818–23 (5 ref.) **(Jpn)**

ANALYSIS

Serum and urine albumin: a progress report on their measurement and clinical significance. Doumas BT, et al. **Clin Chim Acta** 1997 Feb 3;258(1):3–20 (105 ref.)
Familial dysalbuminemic hyperthyroxinemia and thyroid hormone autoantibodies: interference in current free thyroid hormone assays. Sapin R, et al. **Horm Res** 1996; 45(3–5):139–41 (8 ref.)
[Sero-ascitic gradient of albumin: usefulness and diagnostic limitations] Alba D, et al. **An Med Interna** 1995 Aug; 12(8):404–7 (51 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Clinical aspects and diagnosis of thyroid hormone transport protein anomalies. Langsteger W. **Curr Top Pathol** 1997; 91:129–61 (197 ref.)

METABOLISM

PAF released by preimplantation embryos binds to albumin. Ammit AJ, et al. **Adv Exp Med Biol** 1996;416:263–7 (46 ref.)
Plasma protein (albumin) catabolism by the tumor itself—implications for tumor metabolism and the genesis of cachexia. Stehle G, et al. **Crit Rev Oncol Hematol** 1997 Jul;26(2):77–100 (255 ref.)
Whole body capillary exchange of albumin. Alterations in diabetic microangiopathy. Bent-Hansen L. **Dan Med Bull** 1997 Feb;44(1):40–55 (164 ref.)
Association of serum albumin and mortality risk. Goldwasser P, et al. **J Clin Epidemiol** 1997 Jun;50(6):693–703 (92 ref.)

PHARMACOKINETICS

Whole body capillary exchange of albumin. Alterations in diabetic microangiopathy. Bent-Hansen L. **Dan Med Bull** 1997 Feb;44(1):40–55 (164 ref.)

PHYSIOLOGY

[Factors regulating the function of adhesion molecules] Tagawa S, et al. **Rinsho Byori** 1996 Sep;Suppl 102:60–8 (12 ref.) **(Jpn)**

THERAPEUTIC USE

Use of albumin in neonatal resuscitation. Roberton NR. **Eur J Pediatr** 1997 Jun;156(6):428–31 (38 ref.)
[Clinical application of albumin: a closer look at indications] Smorenburg CH, et al. **Ned Tijdschr Geneeskd** 1997 Apr 12;141(15):719–23 (47 ref.) (Eng. Abstr.) **(Dut)**
[Human albumin solutions in the treatment of burned patients. Current indications] Carsin H. **Presse Med** 1997 Mar 29; 26(10):474–6 (15 ref.) (Eng. Abstr.) **(Fre)**

SERUM ALBUMIN, BOVINE

ADVERSE EFFECTS

Cow's milk, bovine serum albumin, and IDDM: can we settle the controversies? Hammond-McKibben D, et al. **Diabetes Care** 1997 May;20(5):897–901 (59 ref.)

CHEMISTRY

Thermal unfolding of beta-lactoglobulin, alpha-lactalbumin, and bovine serum albumin. A thermodynamic approach. Relkin P. **Crit Rev Food Sci Nutr** 1996 Jul;36(6):565–601 (180 ref.)

IMMUNOLOGY

Cow's milk, bovine serum albumin, and IDDM: can we settle the controversies? Hammond-McKibben D, et al. **Diabetes Care** 1997 May;20(5):897–901 (59 ref.)
Infants diets and insulin-dependent diabetes: evaluating the "cows' milk hypothesis" and a role for anti-bovine serum albumin immunity. Atkinson MA, et al. **J Am Coll Nutr** 1997 Aug;16(4):334–40 (56 ref.)

SERUM AMYLOID PROTEIN A see **AMYLOID PROTEIN SAA**

SERUM COMPLEMENT TITER see **COMPLEMENT**

HEMOLYTIC ACTIVITY ASSAY

SERUM GLOBULINS

[Euglobulin lysis time] Sakuragawa N. **Nippon Rinsho** 1997 Mar;55 Suppl 1:139–44 (4 ref.) **(Jpn)**

SERUM MARKERS see **BIOLOGICAL MARKERS**

SERUM PROTEINS see **BLOOD PROTEINS**

SERUM THYMIC FACTOR see **THYMIC FACTOR, CIRCULATING**

SERVICE, SOCIAL see **SOCIAL WORK**

SESAME OIL

IMMUNOLOGY

Sesame seed and sesame seed oil contain masked allergens of growing importance. Kanny G, et al. **Allergy** 1996 Dec; 51(12):952–7 (23 ref.)

SESAMOID BONES

Sesamoid complex disorders. Oloff LM, et al. **Clin Podiatr Med Surg** 1996 Jul;13(3):497–513 (36 ref.)

The hallucal interphalangeal sesamoid [see comments] Roukis TS, et al. **J Foot Ankle Surg** 1996 Jul–Aug;35(4):303–8; discussion 372 (17 ref.) Comment in: J Foot Ankle Surg 1997 Jan–Feb;36(1):76–7.

SESQUITERPENES

ADMINISTRATION & DOSAGE

[Severe falciparum malaria among travellers to Thailand. Blood exchange and artemisinine treatment are therapeutic alternatives] Ekvall H, et al. **Lakartidningen** 1997 Apr 30; 94(18):1713–5 (15 ref.) **(Swe)**

ADVERSE EFFECTS

Sesquiterpene lactone allergy. Warshaw EM, et al. **Am J Contact Dermat** 1996 Mar;7(1):1–23 (97 ref.)

CHEMISTRY

Sesquiterpenoids from Thapsia species and medicinal chemistry of the thapsigargins. Christensen SB, et al. **Fortschr Chem Org Naturst** 1997;71:129–67 (84 ref.)

METABOLISM

State of the art of the production of the antimalarial compound artemisinin in plants. Van Geldre E, et al. **Plant Mol Biol** 1997 Jan;33(2):199–209 (101 ref.)

PHARMACOLOGY

Antimalarial activity of artemisinin (qinghaosu) and related trioxanes: mechanism(s) of action. Cumming JN, et al. **Adv Pharmacol** 1997;37:253–97 (257 ref.)

The mode of action of the antimalarial artemisinin and its derivatives. Kamchonwongpaisan S, et al. **Gen Pharmacol** 1996 Jun;27(4):587–92 (85 ref.)

THERAPEUTIC USE

Chemotherapy of parasitic diseases. Current status and new directions. Liu Y. **Chin Med J (Engl)** 1996 Aug; 109(8):579–82 (28 ref.)

Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. de Vries PJ, et al. **Drugs** 1996 Dec;52(6):818–36 (116 ref.)

TNP-470 (AGM-1470): mechanisms of action and early clinical development. Castronovo V, et al. **Eur J Cancer** 1996 Dec;32A(14):2520–7 (55 ref.)

TNP-470/minocycline/cytotoxic therapy: a systems approach to cancer therapy. Teicher BA, et al. **Eur J Cancer** 1996 Dec;32A(14):2461–6 (52 ref.)

SET (PSYCHOLOGY)

Construing benefits from adversity: adaptational significance and dispositional underpinnings. Affleck G, et al. **J Pers** 1996 Dec;64(4):899–922 (85 ref.)

SEVENTH-DAY ADVENTISTS see **CHRISTIANITY**

SEVERE COMBINED IMMUNODEFICIENCY

The role of sensitized T-cells in myocarditis and dilated cardiomyopathy. Schwimmbeck PL, et al. **Int J Cardiol** 1996 May;54(2):117–25 (27 ref.)

COMPLICATIONS

Gastrointestinal manifestations of primary immunodeficiency disorders. Lai Ping So A, et al. **Semin Gastrointest Dis** 1997 Jan;8(1):22–32 (75 ref.)

DIAGNOSIS

Malignant B-cell lymphoma in an infant with severe combined immunodeficiency with short-limbed skeletal dysplasia. van den Berg H, et al. **Acta Paediatr** 1997 Jul; 86(7):778–80 (10 ref.)

ENZYMOLOGY

SCID: the role of adenosine deaminase deficiency. Resta R, et al. **Immunol Today** 1997 Aug;18(8):371–4 (25 ref.)

ETIOLOGY

[Purine nucleoside phosphorylase (PNP) deficiency] Sakiyama T. **Nippon Rinsho** 1996 Dec;54(12):3328–32 (10 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Major histocompatibility complex class II deficiency: a disease of gene regulation. Steimle V, et al. **Adv Immunol** 1996;61:327–40 (71 ref.)

Regulation of MHC class II genes: lessons from a disease. Mach B, et al. **Annu Rev Immunol** 1996;14:301–31 (138 ref.)

The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. Sugamura K, et al. **Annu Rev Immunol** 1996;14:179–205 (120 ref.)

[Gene therapy for severe combined immunodeficiency linked to chromosome X] Fischer A. **Hematol Cell Ther** 1997 Apr; 39(2):97 (0 ref.) **(Fre)**

IMMUNOLOGY

Major histocompatibility complex class II deficiency: a disease of gene regulation. Steimle V, et al. **Adv Immunol** 1996;61:327–40 (71 ref.)

The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. Sugamura K, et al. **Annu Rev Immunol** 1996;14:179–205 (120 ref.)

Regulation of human B cell growth and differentiation: lessons from the primary immunodeficiencies. Callard RE, et al. **Chem Immunol** 1997;67:114–32 (102 ref.)

Murine AIDS, a key to understanding retrovirus-induced immunodeficiency. Liang B, et al. **Viral Immunol** 1996; 9(4):225–39 (122 ref.)

[Common gamma chains for cytokine receptors] Nakamura M. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Dec; 19(6):623–8 (30 ref.) **(Jpn)**

[The signal transduction mechanism of IL-4 in X-linked severe combined immunodeficiency patients] Izuhara K. **Rinsho Ketsueki** 1997 Mar;38(3):186–8 (8 ref.) **(Jpn)**

THERAPY

Preclinical investigations that subserve efforts to employ bone marrow transplantation for rheumatoid or autoimmune diseases. Good RA, et al. **J Rheumatol Suppl** 1997 May; 48:5–12 (73 ref.)

Cellular therapy. Flake AW, et al. **Obstet Gynecol Clin North Am** 1997 Mar;24(1):159–77 (20 ref.)

[Gene therapy for hereditary immunodeficiencies] Fischer A, et al. **C R Seances Soc Biol Fil** 1996;190(1):77–93 (54 ref.) (Eng. Abstr.) **(Fre)**

[Gene therapy for severe combined immunodeficiency linked to chromosome X] Fischer A. **Hematol Cell Ther** 1997 Apr; 39(2):97 (0 ref.) **(Fre)**

[The gene therapy for a patient with ADA deficiency; report of the first gene therapy trial in Japan] Ariga T, et al. **Nippon Rinsho** 1997 Jun;55(6):1572–9 (10 ref.) (Eng. Abstr.) **(Jpn)**

SEVERE COMBINED IMMUNODEFICIENT MICE see **MICE, SCID**

SEVERITY OF ILLNESS INDEX

Severity of illness scoring systems to adjust nosocomial infection rates: a review and commentary. Keita-Perse O, et al. **Am J Infect Control** 1996 Dec;24(6):429–34 (20 ref.)

Can we improve upon the International Index? Shipp MA. **Ann Oncol** 1997;8 Suppl 1:43–7 (62 ref.)

Measurement of disease activity and outcome in atopic dermatitis. Finlay AY. **Br J Dermatol** 1996 Oct; 135(4):509–15 (51 ref.)

ICU scoring systems allow prediction of patient outcomes and comparison of ICU performance. Becker RB, et al. **Crit Care Clin** 1996 Jul;12(3):503–14 (53 ref.)

ICU scoring systems do not allow prediction of patient outcomes or comparison of ICU performance. Sherck JP, et al. **Crit Care Clin** 1996 Jul;12(3):515–23 (41 ref.)

Periodontal probing. Hefti AF. **Crit Rev Oral Biol Med** 1997; 8(3):336–56 (113 ref.)

Predicting survival in the intensive care unit. Hunt JP, et al. **Curr Probl Surg** 1997 Jul;34(7):527–99 (188 ref.)

How should multiple organ dysfunction syndrome be assessed? A review of the variations in current scoring systems. Bertleff MJ, et al. **Eur J Surg** 1997 Jun; 163(6):405–9; discussion 410 (36 ref.)

Critical and subcritical ischaemia. Wolfe JH, et al. **Eur J Vasc Endovasc Surg** 1997 Jun;13(6):578–82 (27 ref.)

Symptom assessment. Ingham JM, et al. **Hematol Oncol Clin North Am** 1996 Feb;10(1):21–39 (89 ref.)

Prognostic indices in peritonitis. Ohmann C, et al. **Hepatogastroenterology** 1997 Jul–Aug;44(16):937–46 (53 ref.)

Basics of stratifying for severity of illness. Gross PA. **Infect Control Hosp Epidemiol** 1996 Oct;17(10):675–86 (57 ref.)

"My patients are sicker": adjusting outcomes by severity of illness. Hopkins DS. **Int Anesthesiol Clin** 1995 Fall; 33(4):33–47 (15 ref.)

Severity of childhood asthma by socioeconomic status. Mielck A, et al. **Int J Epidemiol** 1996 Apr;25(2):388–93 (33 ref.)

How severity measures rate hospitalized patients. Hughes JS, et al. **J Gen Intern Med** 1996 May;11(5):303–11 (24 ref.)

Systemic Lupus International Collaborating Clinics conference on assessment of lupus flare and quality of life measures in SLE. Systemic Lupus International Collaborating Clinics Group. Gladman D, et al. **J Rheumatol** 1996 Nov;23(11):1953–5 (14 ref.)

Measuring casemix, severity, and complexity in geriatric patients undergoing rehabilitation. Stineman MG. **Med Care** 1997 Jun;35(6 Suppl):JS90–105; discussion JS106–12 (39 ref.)

Estimating the risks of cardiac surgery [editorial; comment] Dobb GJ. **Med J Aust** 1997 Apr 21;166(8):397–8 (18 ref.) Comment on: Med J Aust 1997 Apr 21;166(8):408–11.

Scoring of severity in patients admitted to a respiratory intensive care unit. Nava S. **Monaldi Arch Chest Dis** 1997 Feb;52(1):71–2 (15 ref.)

Tension-time index of inspiratory muscles in children [editorial; comment] Gaultier C. **Pediatr Pulmonol** 1997 May;23(5):327–9 (18 ref.) Comment on: Pediatr Pulmonol 1997 May;23(5):336–43.

A reappraisal of reliability and validity studies in stroke. D'Olhaberriague L, et al. **Stroke** 1996 Dec;27(12):2331–6 (83 ref.)

[Prognostic scores in intensive care] Unertl K, et al. **Anaesthesist** 1997 Jun;46(6):471–80 (64 ref.) (Eng. Abstr.) **(Ger)**

[The significance of score systems for predicting treatment outcome in intensive care] Schuster HP. **Internist (Berl)** 1996 Dec;37(12):1237–43 (25 ref.) **(Ger)**

[Value of score systems in heart surgery] Falk V, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:303–6 (18 ref.) (Eng. Abstr.) **(Ger)**

[The value of scores for therapy planning and therapy evaluation in individual intensive care patients—basic principles] Neugebauer E, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:293–8 (13 ref.) (Eng. Abstr.) **(Ger)**

[Evaluation of the severity of cardiogenic shock by monitoring of their hemodynamics] Matsuzaki M, et al. **Nippon Naika Gakkai Zasshi** 1996 Jan 10;85(1):27–32 (5 ref.) **(Jpn)**

[Clinical symptoms of cardiogenic shock and important points in evaluating the severity] Saito M. **Nippon Naika Gakkai Zasshi** 1996 Jan 10;85(1):21–6 (10 ref.) **(Jpn)**

[Prognostic evaluation of cardiogenic shock by the severity] Watanabe J, et al. **Nippon Naika Gakkai Zasshi** 1996 Jan 10;85(1):44–7 (6 ref.) **(Jpn)**

[Important points in clinical tests for evaluating the severity of patients with cardiogenic shock] Watanabe Y. **Nippon Naika Gakkai Zasshi** 1996 Jan 10;85(1):33–7 (5 ref.) **(Jpn)**

[Comparison of asthma score and peak flow rate (PEF) monitoring] Okada C. **Nippon Rinsho** 1996 Nov; 54(11):2939–43 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Inflammatory bowel disease activity index: clinical and laboratory indicators] Dichi I, et al. **Arq Gastroenterol** 1995 Jul–Sep;32(3):121–30 (75 ref.) (Eng. Abstr.) **(Por)**

SEWAGE

Metabolism of micro-organisms responsible for enhanced biological phosphorus removal from wastewater. Use of dynamic enrichment cultures. van Loosdrecht MC, et al. **Antonie Van Leeuwenhoek** 1997 Feb;71(1–2):109–16 (34 ref.)

Land application of sewage sludge in China. Wang MJ. **Sci Total Environ** 1997 Apr 30;197(1–3):149–60 (47 ref.)

SEX

see related
LIBIDO
PSYCHOSEXUAL DEVELOPMENT
RELIGION AND SEX

The potential contribution of sexuality and gender awareness. Kopp Z. **Adv Contracept** 1997 Jun–Sep;13(2–3):325–9 (5 ref.)

Gender differences in sexual interest. Baldwin JD, et al. **Arch Sex Behav** 1997 Apr;26(2):181–210 (122 ref.)

Sexual function in menopause and postmenopause. Nachtigall LE. **Curr Ther Endocrinol Metab** 1997;6:632–6 (15 ref.)

Sex differences in ADHD: conference summary. Arnold LE. **J Abnorm Child Psychol** 1996 Oct;24(5):555–69 (55 ref.)

Intra-household allocation of food and health care: current findings and understandings—introduction. Messer E. **Soc Sci Med** 1997 Jun;44(11):1675–84 (46 ref.)

Gender differences in attitudes toward alcohol, tobacco, and

other drugs. Kauffman SE, et al. **Soc Work** 1997 May; 42(3):231–41 (67 ref.)
Sexuality and women with complete spinal cord injury. Whipple B, et al. **Spinal Cord** 1997 Mar;35(3):136–8 (22 ref.)
[Andrological data on male sexuality in the elderly] Andrianne R. **Rev Med Liege** 1997 Apr;52(4):221–3 (0 ref.) **(Fre)**

SEX ATTRACTANTS

PHYSIOLOGY

Chemical signals in gram-positive bacteria: the sex-pheromone system in Enterococcus faecalis. Maqueda M, et al. **Microbiologia** 1997 Mar;13(1):23–36 (64 ref.)
[Hormones and male sexual behavior: physiological and physiopathological data] Buvat J. **Contracept Fertil Sex** 1996 Oct;24(10):767–78 (93 ref.) (Eng. Abstr.) **(Fre)**

SEX BEHAVIOR

see related

SEXUAL PARTNERS

A review of national AIDS-related behavioral surveys. Catania JA, et al. **AIDS** 1996;10 Suppl A:S183–90 (33 ref.)
Faithful but fearful: reducing HIV transmission in stable relationships. de Zoysa I, et al. **AIDS** 1996;10 Suppl A:S197–203 (95 ref.)
Social research on sexuality: contextual and interpersonal approaches. Giami A, et al. **AIDS** 1996;10 Suppl A:S191–6 (52 ref.)
Sex, drugs and escape: a psychological model of HIV-risk sexual behaviours. McKirnan DJ, et al. **AIDS Care** 1996 Dec;8(6):655–69 (93 ref.)
Male bisexual behavior and HIV risk in the United States: synthesis of research with implications for behavioral interventions. Doll LS, et al. **AIDS Educ Prev** 1996 Jun; 8(3):205–25 (95 ref.)
Epidemiology of acquired immunodeficiency syndrome: advancing to an endemic era. Graham NM. **Am J Med** 1997 Apr 1;102(4A):2–8 (34 ref.)
Evolutionary perspectives on primate mating systems and behavior. Dixson AF. **Ann N Y Acad Sci** 1997 Jan 15; 807:42–61 (102 ref.)
Adolescent sexuality. Goldfarb AF. **Ann N Y Acad Sci** 1997 Jun 17;816:395–403 (08 ref.)
Female adolescent sexuality. The risks and management. Haka-Ikse K. **Ann N Y Acad Sci** 1997 Jun 17;816:466–70 (12 ref.)
Regulatory mechanisms of oxytocin-mediated sociosexual behavior. Witt DM. **Ann N Y Acad Sci** 1997 Jan 15; 807:287–301 (80 ref.)
Psychological correlates of male child and adolescent sexual experiences with adults: a review of the nonclinical literature. Bauserman R, et al. **Arch Sex Behav** 1997 Apr; 26(2):105–41 (108 ref.)
Fantasies and facts of the testes. van Basten JP, et al. **Br J Urol** 1996 Nov;78(5):756–62 (63 ref.)
Sex, sexual orientation and sex hormones influence human cognitive function. Kimura D. **Curr Opin Neurobiol** 1996 Apr;6(2):259–63 (43 ref.)
Primary care management of adolescent sexual behavior. Ellen JM, et al. **Curr Opin Pediatr** 1996 Oct;8(5):442–8 (47 ref.)
Sexuality in the mental health system. Patients and practitioners. Gutheil TG, et al. **Int J Law Psychiatry** 1996 Spring;19(2):183–90 (15 ref.)
AIDS in rural Africa: a paradigm for HIV-1 prevention [editorial] Hudson CP. **Int J STD AIDS** 1996 Jul; 7(4):236–43 (64 ref.)
Rectal sexual trauma including foreign bodies [editorial] Irizarry E, et al. **Int J STD AIDS** 1996 May-Jun;7(3):166–9 (21 ref.)
Sex and travel: studies of sexual behaviour, disease and health promotion in international travellers--a global review [editorial] Mulhall BP. **Int J STD AIDS** 1996 Nov-Dec; 7(7):455–65 (108 ref.)
Interventions for homeless men and women with mental illness: reducing sexual risk behaviours for HIV. Susser E, et al. **Int J STD AIDS** 1996;7 Suppl 2:66–70 (28 ref.)
Relationship of alcohol use and risky sexual behavior: a review and analysis of findings. Halpern-Felsher BL, et al. **J Adolesc Health** 1996 Nov;19(5):331–6 (42 ref.)
Sexual health promotion and nursing. Irwin R. **J Adv Nurs** 1997 Jan;25(1):170–7 (110 ref.)
Testosterone and the aging male. Tenover JL. **J Androl** 1997 Mar-Apr;18(2):103–6 (14 ref.)
Research directions in male sex work. Browne J, et al. **J Homosex** 1996;31(4):29–56 (54 ref.)
Sexually transmitted diseases and sexual behavior: insights from mathematical models. Garnett GP, et al. **J Infect Dis** 1996 Oct;174 Suppl 2:S150–61 (43 ref.)
How can psychological theory help to promote condom use in sub-Saharan African developing countries? Campbell T. **J R Soc Health** 1997 Jun;117(3):186–91 (47 ref.)
Verbal intercourse and sexual communication: impediments to STD prevention. Pliskin KL. **Med Anthropol Q** 1997 Mar;11(1):89–109 (76 ref.)
Understanding human sexuality--specifically homosexuality and the paraphilias--in terms of chaos theory and fetal development. Goodman RE. **Med Hypotheses** 1997 Mar; 48(3):237–43 (68 ref.)
Evolutionary sexology: the hypothesis of song and sex. Money J. **Med Hypotheses** 1997 May;48(5):399–402 (14 ref.)
Sexual transmission of HIV. Royce RA, et al. **N Engl J Med** 1997 Apr 10;336(15):1072–8 (97 ref.)
Television viewing and adolescent sexuality [letter] Turner HA. **Nurse Pract** 1996 Nov;21(11):15, 18, 23 (11 ref.)
The promise of integrated representative surveys about sexually transmitted diseases and behavior [see comments] Ku L, et al. **Sex Transm Dis** 1997 May;24(5):299–309 (47 ref.) Comment in: Sex Transm Dis 1997 May;24(5):310–1.
Use and effectiveness of condoms during anal intercourse. A review. Silverman BG, et al. **Sex Transm Dis** 1997 Jan; 24(1):11–7 (37 ref.)
Sex, drugs, intervention, and research: from the individual to the social. Rhodes T, et al. **Subst Use Misuse** 1996 Feb; 31(3):375–407 (130 ref.)
Women and the heterosexual transmission of HIV: risks and prevention strategies. Gavey N, et al. **Women Health** 1997; 25(2):41–64 (115 ref.)
[Menopause and sexuality] Mimoun S. **Contracept Fertil Sex** 1996 Jan;24(1):62–6 (12 ref.) (Eng. Abstr.) **(Fre)**
[Sexual relations between doctors and patients: state of the art] Witztum E, et al. **Harefuah** 1996 Oct;131(7–8):257–9 (18 ref.) **(Heb)**

DRUG EFFECTS

Sexual side effects of antidepressants: a review. Margolese HC, et al. **J Sex Marital Ther** 1996 Fall;22(3):209–17 (68 ref.)
[Hormones and male sexual behavior: physiological and physiopathological data] Buvat J. **Contracept Fertil Sex** 1996 Oct;24(10):767–78 (93 ref.) (Eng. Abstr.) **(Fre)**

ETHNOLOGY

Social vs biological: theories on the transmission of AIDS in Africa. Hunt CW. **Soc Sci Med** 1996 May;42(9):1283–96 (19 ref.)

PHYSIOLOGY

Gender differences in sexual interest. Baldwin JD, et al. **Arch Sex Behav** 1997 Apr;26(2):181–210 (122 ref.)
Frank A. Beach award. Homologies of animal and human sexual behaviors. Pfaus JG. **Horm Behav** 1996 Sep; 30(3):187–200 (86 ref.)
Assessment of sexual function in patients with rheumatic disorders: a critical appraisal. Quarersma MR, et al. **J Rheumatol** 1997 Sep;24(9):1673–6 (19 ref.)

STATISTICS & NUMERICAL DATA

Female adolescents and onset of sexual intercourse: a theory-based review of research from 1984 to 1994. Goodson P, et al. **J Adolesc Health** 1997 Sep;21(3):147–56 (75 ref.)

SEX BEHAVIOR, ANIMAL

Peptides, steroids, and pair bonding. Carter CS, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:260–72 (33 ref.)
Evolutionary perspectives on primate mating systems and behavior. Dixson AF. **Ann N Y Acad Sci** 1997 Jan 15; 807:42–61 (102 ref.)
Molecular aspects of monogamy. Insel TR, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:302–16 (44 ref.)
Ecological constraints and the evolution of hormone-behavior interrelationships. Wingfield JC, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:22–41 (67 ref.)
Regulatory mechanisms of oxytocin-mediated sociosexual behavior. Witt DM. **Ann N Y Acad Sci** 1997 Jan 15; 807:287–301 (80 ref.)
Genetic dissection of sexual behavior in Drosophila melanogaster. Yamamoto D, et al. **Annu Rev Entomol** 1997; 42:551–85 (216 ref.)
Selective breeding for isolation-induced intermale aggression in mice: associated responses and environmental influences. Sandnabba NK. **Behav Genet** 1996 Sep;26(5):477–88 (100 ref.)
Signal processing in the vomeronasal system: modulation of sexual behavior in the female rat. Dudley CA, et al. **Crit Rev Neurobiol** 1996;10(3–4):265–90 (158 ref.)
Sexual behaviour: secrets and flies. O'Dell KM, et al. **Curr Biol** 1997 Jun 1;7(6):R345–7 (18 ref.)
Rebels with a cause. Pomiankowski A. **Curr Biol** 1997 Feb 1;7(2):R92–3 (13 ref.)
Specific involvement of central 5-HT1A receptors in the mediation of male rat ejaculatory behavior. Ahlenius S, et al. **Neurochem Res** 1997 Aug;22(8):1065–70 (34 ref.)
Genetic dissection of sexual orientation: behavioral, cellular, and molecular approaches in Drosophila melanogaster. Yamamoto D, et al. **Neurosci Res** 1996 Oct;26(2):95–107 (117 ref.)
[Neuroethological approach to the vomeronasal function] Mori Y, et al. **Tanpakushitsu Kakusan Koso** 1996 Nov; 41(14):2084–92 (15 ref.) **(Jpn)**

DRUG EFFECTS

Development of VIP agonists and antagonists with tissue and receptor specificity: effects on behavioral maturation, sexual function, and the biologic clock. Gozes I, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:159–69; discussion 169–71 (60 ref.)

PHYSIOLOGY

The testis: the witness of the mating system, the site of mutation and the engine of desire. Short RV. **Acta Paediatr Suppl** 1997 Jul;422:3–7 (26 ref.)
Variation in mate choice and mating preferences: a review of causes and consequences. Jennions MD, et al. **Biol Rev Camb Philos Soc** 1997 May;72(2):283–327 (330 ref.)
Regulation of masculine sexual behavior: involvement of brain opioids and dopamine. van Furth WR, et al. **Brain Res Brain Res Rev** 1995 Sep;21(2):162–84 (312 ref.)
Choice of partners: sexual cell interactions in Dictyostelium discoideum. Urushihara H. **Cell Struct Funct** 1996 Aug; 21(4):231–6 (34 ref.)
Sperm competition: evolution and mechanisms. Birkhead TR. **Curr Top Dev Biol** 1996;33:103–58 (163 ref.)
Do sex differences in the brain explain sex differences in the hormonal induction of reproductive behavior? What 25 years of research on the Japanese quail tells us. Balthazart J, et al. **Horm Behav** 1996 Dec;30(4):627–61 (135 ref.)
Progesterone receptor function from a behavioral perspective. Mani SK, et al. **Horm Behav** 1997 Jun; 31(3):244–55 (80 ref.)
Frank A. Beach award. Homologies of animal and human sexual behaviors. Pfaus JG. **Horm Behav** 1996 Sep; 30(3):187–200 (86 ref.)
Estrogen receptor function as revealed by knockout studies: neuroendocrine and behavioral aspects. Rissman EF, et al. **Horm Behav** 1997 Jun;31(3):232–43 (90 ref.)
Olfaction and brainstem circuits of reproductive behavior in the rat. Shipley MT, et al. **Prog Brain Res** 1996; 107:355–77 (188 ref.)
A concept for the final common pathway of vocalization and lordosis behavior in the cat. VanderHorst VG, et al. **Prog Brain Res** 1996;107:327–42 (83 ref.)
Sexual behavior problems in dogs and cats. Houpt KA. **Vet Clin North Am Small Anim Pract** 1997 May; 27(3):601–15 (18 ref.)

SEX BIAS see **PREJUDICE**

SEX CHARACTERISTICS

Women and men--same eyes? Midelfart A. **Acta Ophthalmol Scand** 1996 Dec;74(6):589–92 (42 ref.)
Gender, sexuality and communication issues that constitute barriers to the use of natural family planning and other fertility awareness-based methods. Diaz M. **Adv Contracept** 1997 Jun-Sep;13(2–3):303–9 (4 ref.)
Gender, ethnicity and transmission category variation in HIV disease progression. Hessol NA, et al. **AIDS** 1996;10 Suppl A:S69–74 (53 ref.)
Gender considerations in hypertension pathophysiology and treatment. Hanes DS, et al. **Am J Med** 1996 Sep 30; 101(3A):10S–21S (90 ref.)
Intrasexual competition and body weight dimorphism in anthropoid primates. Plavcan JM, et al. **Am J Phys Anthropol** 1997 May;103(1):37–68 (162 ref.)
Growth, development, and sexual dimorphism in vervet monkeys (Cercopithecus aethiops) at four sites in Kenya. Turner TR, et al. **Am J Phys Anthropol** 1997 May; 103(1):19–35 (53 ref.)
The basis for gender effects in the connective tissue diseases. Lahita RG. **Ann Med Interne (Paris)** 1996;147(4):241–7 (96 ref.)
The anatomical substrate for a difference in surgical approach to rectal cancer in male and female patients. Verschueren RC, et al. **Anticancer Res** 1997 Jan-Feb;17(1B):637–41 (18 ref.)
Sexual dimorphism in interhemispheric relations: anatomical-behavioral convergence. Zaidel E, et al. **Biol Res** 1995;28(1):27–43 (78 ref.)
Smoking and diseases of the gastrointestinal system: an epidemiological review with special reference to sex differences. Ashley MJ. **Can J Gastroenterol** 1997 May-Jun; 11(4):345–52 (84 ref.)
Sex steroid effects on the development and functioning of the growth hormone axis. Chowen JA, et al. **Cell Mol Neurobiol** 1996 Jun;16(3):297–310 (31 ref.)
Steroid imprinting and modulation of sexual dimorphism in the luteinizing hormone-releasing hormone neuronal system. López FJ, et al. **Cell Mol Neurobiol** 1996 Apr; 16(2):129–41 (30 ref.)
Physiology of the skin--differences between women and men. Tur E. **Clin Dermatol** 1997 Jan-Feb;15(1):5–16 (63 ref.)
Detection of SRY in 45,X/47,XYY mosaicism leading to phenotypic female. Imai A, et al. **Clin Genet** 1997 Feb; 51(2):124–6 (15 ref.)
Sexual development of the fetus and pubertal child. Malasanos TH. **Clin Obstet Gynecol** 1997 Mar;40(1):153–67 (17 ref.)
Sex, sexual orientation and sex hormones influence human cognitive function. Kimura D. **Curr Opin Neurobiol** 1996 Apr;6(2):259–63 (43 ref.)
Male reproductive health and environmental xenoestrogens [see comments] Toppari J, et al. **Environ Health Perspect** 1996 Aug;104 Suppl 4:741–803 (323 ref.) Comment in: Environ Health Perspect 1997

Feb;105(2):162–3.
Risk factors and the sex differential in coronary artery disease. Price JF, et al. **Epidemiology** 1997 Sep;8(5):584–91 (94 ref.)
Genetically triggered sexual differentiation of brain and behavior. Arnold AP. **Horm Behav** 1996 Dec;30(4):495–505 (77 ref.)
Do sex differences in the brain explain sex differences in the hormonal induction of reproductive behavior? What 25 years of research on the Japanese quail tells us. Balthazart J, et al. **Horm Behav** 1996 Dec;30(4):627–61 (135 ref.)
Gender-specific physiology: how real is it? How important is it? Legato MJ. **Int J Fertil Womens Med** 1997 Jan–Feb; 42(1):19–29 (90 ref.)
Sex differences in parasite infections: patterns and processes. Zuk M, et al. **Int J Parasitol** 1996 Oct;26(10):1009–23 (133 ref.)
Nature, nurture, and core gender identity. Robbins M. **J Am Psychoanal Assoc** 1996;44 Suppl:93–117 (107 ref.)
Clinical review 78: Aromatase deficiency in women and men: would you have predicted the phenotypes? Bulun SE. **J Clin Endocrinol Metab** 1996 Mar;81(3):867–71 (27 ref.)
Gender-specific issues. Aulin KP. **J Sports Sci** 1995 Summer; 13 Spec No:S35–9 (42 ref.)
Systemic lupus erythematosus in males. A study of 107 Latin American patients. Molina JF, et al. **Medicine (Baltimore)** 1996 May;75(3):124–30 (72 ref.)
Sexual dimorphism in the harderian gland of the Syrian hamster is controlled and maintained by hormones, despite seasonal fluctuations in hormone levels: functional implications. Buzzell GR. **Microsc Res Tech** 1996 Jun 1; 34(2):133–8 (30 ref.)
What leads to age and gender differences in balance maintenance and recovery? Schultz AB, et al. **Muscle Nerve Suppl** 1997;5:S60–4 (15 ref.)
Endocrine disruptors and sexually dimorphic behaviors: a question of heads and tails. Weiss B. **Neurotoxicology** 1997; 18(2):581–6 (15 ref.)
Gender variations in clinical pain experience. Unruh AM. **Pain** 1996 May–Jun;65(2–3):123–67 (235 ref.)
Serotonin, sex, and psychiatric illness [see comments] Heninger GR. **Proc Natl Acad Sci U S A** 1997 May 13; 94(10):4823–4 (26 ref.) Comment in: Proc Natl Acad Sci U S A 1997 May 13;94(10):5308–13.
Gender, estrogen, and schizophrenia. Lindamer LA, et al. **Psychopharmacol Bull** 1997;33(2):221–8 (67 ref.)
Gender differences in psychotropic drug metabolism. Pollock BG. **Psychopharmacol Bull** 1997;33(2):235–41 (80 ref.)
Coronary heart disease in women: 1996. Wenger NK. **Semin Reprod Endocrinol** 1996 Feb;14(1):5–14 (87 ref.)
Raynaud's syndrome in women. Landry GJ, et al. **Semin Vasc Surg** 1995 Dec;8(4):327–34 (63 ref.)
[Sexual dimorphism of the human brain--a review of the literature] Supprian T, et al. **Fortschr Neurol Psychiatr** 1996 Oct;64(10):382–9 (61 ref.) (Eng. Abstr.) **(Ger)**
[The sexual dimorphism of the accessory olfactory system] Guillermón A, et al. **Ontogenez** 1996 Sep–Oct;27(5):341–8 (56 ref.) **(Rus)**

SEX CHROMATIN

see related
SEX DETERMINATION

SEX CHROMOSOME ABNORMALITIES

XYY male and hematologic malignancy. Oguma N, et al. **Cancer Genet Cytogenet** 1996 Sep;90(2):179–81 (22 ref.)

ETIOLOGY

Sex chromosomal anomalies in pregnancies conceived through intracytoplasmic sperm injection: a case for genetic counselling. Meschede D, et al. **Hum Reprod** 1997 Jun; 12(6):1125–7 (19 ref.)

GENETICS

Molecular cytogenetic identification of four X chromosome duplications. Zhang A, et al. **Am J Med Genet** 1997 Jan 10;68(1):29–38 (38 ref.)
Trisomy X: ACLF (Association des Cytogénéticiens de Langue Française) retrospective study. Guichet A, et al. **Ann Genet** 1996;39(3):117–22 (20 ref.)
Karyotype-phenotype correlation in females with X chromosome abnormalities. Kosmaidou-Aravidou Z. **Ann N Y Acad Sci** 1997 Jun 17;816:373–7 (27 ref.)
Two brothers with multiple congenital anomalies and mental retardation due to disomy (X)(q12-->q13.3) inherited from the mother. Apacik C, et al. **Clin Genet** 1996 Aug; 50(2):63–73 (23 ref.)
New mutations in the X-linked form of Charcot-Marie-Tooth disease. Latour P, et al. **Eur Neurol** 1997;37(1):38–42 (23 ref.)
Kabuki syndrome in son and low grade mosaic 45,X/46,XX in mother. Van Hagen JM, et al. **Genet Couns** 1996; 7(3):201–6 (16 ref.)
Cytogenetics of infertile men. Van Assche E, et al. **Hum Reprod** 1996 Dec;11 Suppl 4:1–24; discussion 25–6 (114 ref.)
Genetic aspects of human infertility. Vogt PH. **Int J Androl** 1995 Dec;18 Suppl 2:3–6 (12 ref.)
[Dyskeratosis congenita. Genetic hematologic-immunologic systemic disease with pancytopenia] Sölder B, et al. **Klin Padiatr** 1996 Nov–Dec;208(6):344–9 (50 ref.) (Eng. Abstr.) **(Ger)**
[X chromosomal bulbospinal neuropathy (X-BSN, Kennedy syndrome): an illness with repetitive triplet sequences. Case report, differential diagnosis and molecular genetics aspects] Abel A, et al. **Nervenarzt** 1996 Dec;67(12):1011–9 (44 ref.) (Eng. Abstr.) **(Ger)**
[Albinism. Current clinical and molecular genetic aspects of an important differential congenital nystagmus diagnosis] Lorenz B. **Ophthalmologe** 1997 Jul;94(7):534–44 (46 ref.) **(Ger)**
[Genetic basis of Turner syndrome (published erratum appears in Pol Arch Med Wewn 1995 Aug;94(2):183)] Slęzak R, et al. **Pol Arch Med Wewn** 1995 Oct;94(4):358–63 (39 ref.) **(Pol)**

SEX CHROMOSOMES

Sex chromosome markers: characterization using fluorescence in situ hybridization and review of the literature. Schwartz S, et al. **Am J Med Genet** 1997 Jul 11;71(1):1–7 (62 ref.)

SEX CORD-STROMAL TUMOR

DIAGNOSIS

Extraovarian sex cord-stromal tumor: case report and review of the literature. Keitoku M, et al. **Int J Gynecol Pathol** 1997 Apr;16(2):180–5 (29 ref.)

PATHOLOGY

Testicular sex cord-stromal tumors in children: clinicopathologic study of sixteen children with review of the literature. Goswitz JJ, et al. **Pediatr Pathol Lab Med** 1996 May–Jun;16(3):451–70 (40 ref.)

SEX COUNSELING

[Sexual problems--possible counseling by the general physician] Loewit K. **Fortschr Med** 1996 Oct 30; 114(30):387–92 (9 ref.) (Eng. Abstr.) **(Ger)**

SEX DETERMINATION

A bird's eye view of human sex determination. Polani PE. **Acta Genet Med Gemellol (Roma)** 1996;45(1–2):137–41 (42 ref.)
The role of SRY in mammalian sex determination. Fechner PY. **Acta Paediatr Jpn** 1996 Aug;38(4):380–9 (112 ref.)
Fetal testis formation: a critical event for sex determination and differentiation. Matsuo N. **Acta Paediatr Jpn** 1996 Aug; 38(4):377–9 (19 ref.)
Sex determining gene on the X chromosome short arm: dosage sensitive sex reversal. Ogata T, et al. **Acta Paediatr Jpn** 1996 Aug;38(4):390–8 (40 ref.)
Sex determination in humans. Schafer AJ, et al. **Bioessays** 1996 Dec;18(12):955–63 (80 ref.)
Early steps in mammalian sex determination. Ramkissoon Y, et al. **Curr Opin Genet Dev** 1996 Jun;6(3):316–21 (58 ref.)
The role of Sry in cellular events underlying mammalian sex determination. Capel B. **Curr Top Dev Biol** 1996;32:1–37 (159 ref.)
Sex determination and the maternal dominance hypothesis. Grant VJ. **Hum Reprod** 1996 Nov;11(11):2371–5 (59 ref.)
Molecular determinants of mammmalian sex. Werner MH, et al. **Trends Biochem Sci** 1996 Aug;21(8):302–8 (49 ref.)
Puzzling out the genetics of mammalian sex determination. Jiménez R, et al. **Trends Genet** 1996 May;12(5):164–6 (34 ref.)
[Sex determination and differentiation in man: from pathology to genes] Veitia R, et al. **Arch Pediatr** 1997;4(2 Suppl 2):118s–120s (18 ref.) **(Fre)**
[Awareness of ovulation time and sex determination in Biblical times] Ben-Noun L. **Harefuah** 1997 May 15; 132(10):726–7 (18 ref.) **(Heb)**

METHODS

SRY and mammalian sex determination. Greenfield A, et al. **Curr Top Dev Biol** 1996;34:1–23 (76 ref.)
The predetermination of embryonic sex using flow cytometrically separated X and Y spermatozoa. Cran DG, et al. **Hum Reprod Update** 1996 Jul–Aug;2(4):355–63 (48 ref.)

SEX DEVIATIONS see **PARAPHILIAS**

SEX DIFFERENCES see **SEX CHARACTERISTICS**

SEX DIFFERENTIATION

Fetal testis formation: a critical event for sex determination and differentiation. Matsuo N. **Acta Paediatr Jpn** 1996 Aug; 38(4):377–9 (19 ref.)
Sexual development of the fetus and pubertal child. Malasanos TH. **Clin Obstet Gynecol** 1997 Mar;40(1):153–67 (17 ref.)
[Ad4BP/SF-1 and sex differentiation of the gonads] Morohashi K, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun; 41(8 Suppl):1033–41 (32 ref.) **(Jpn)**

DRUG EFFECTS

Environmental antiandrogens: developmental effects, molecular mechanisms, and clinical implications. Kelce WR, et al. **J Mol Med** 1997 Mar;75(3):198–207 (110 ref.)
Prenatal exposure to drugs of abuse: methodological considerations and effects on sexual differentiation. McGivern RF, et al. **NIDA Res Monogr** 1996;164:78–124 (219 ref.)
Latent effects of pesticides and toxic substances on sexual differentiation of rodents. Gray LE Jr, et al. **Toxicol Ind Health** 1996 May–Aug;12(3–4):515–31 (38 ref.)

GENETICS

SF-1: a key regulator of development and function in the mammalian reproductive system. Ikeda Y. **Acta Paediatr Jpn** 1996 Aug;38(4):412–9 (45 ref.)
Sex determining gene on the X chromosome short arm: dosage sensitive sex reversal. Ogata T, et al. **Acta Paediatr Jpn** 1996 Aug;38(4):390–8 (40 ref.)
Genetic mechanisms of sex differentiation. Josso N, et al. **Curr Opin Pediatr** 1996 Aug;8(4):396–400 (50 ref.)
Molecular basis governing primary sex in mammals. Nagai K. **Jpn J Hum Genet** 1996 Dec;41(4):363–79 (57 ref.)
Molecular determinants of sexual differentiation. Wiener JS, et al. **World J Urol** 1996;14(5):278–94 (168 ref.)
[SRY gen--primary "switch" in human sex determination?] Michalczak-Janitz K, et al. **Postepy Biochem** 1995; 41(4):212–9 (74 ref.) **(Pol)**

PHYSIOLOGY

The role of SRY in mammalian sex determination. Fechner PY. **Acta Paediatr Jpn** 1996 Aug;38(4):380–9 (112 ref.)
Sexual differentiation of the brain in songbirds. Arnold AP, et al. **Dev Neurosci** 1996;18(1–2):124–36 (88 ref.)
Sex differentiation and ovarian function. An overview. Tsutsumi O, et al. **Horm Res** 1996;46 Suppl 1:1–5 (66 ref.)
Molecular biology and function of the androgen receptor in genital development. Wiener JS, et al. **J Urol** 1997 Apr; 157(4):1377–86 (121 ref.)
Physiology and molecular genetics of 17 beta-hydroxysteroid dehydrogenases. Andersson S, et al. **Steroids** 1997 Jan; 62(1):143–7 (36 ref.)

SEX DIFFERENTIATION DISORDERS

see related
TRANSSEXUALISM
Molecular biology and function of the androgen receptor in genital development. Wiener JS, et al. **J Urol** 1997 Apr; 157(4):1377–86 (121 ref.)

DIAGNOSIS

Clinical indications for the use of urinary steroid profiles in neonates and children. Honour JW, et al. **Ann Clin Biochem** 1997 Jan;34 (Pt 1):45–54 (37 ref.)
Sexual development of the fetus and pubertal child. Malasanos TH. **Clin Obstet Gynecol** 1997 Mar;40(1):153–67 (17 ref.)

EMBRYOLOGY

Intersex disorders: shedding light on male sexual differentiation beyond SRY. MacLean HE, et al. **Clin Endocrinol (Oxf)** 1997 Jan;46(1):101–8 (62 ref.)

GENETICS

Intersex disorders: shedding light on male sexual differentiation beyond SRY. MacLean HE, et al. **Clin Endocrinol (Oxf)** 1997 Jan;46(1):101–8 (62 ref.)
[Sex determination and differentiation in man: from pathology to genes] Veitia R, et al. **Arch Pediatr** 1997;4(2 Suppl 2):118s–120s (18 ref.) **(Fre)**

SURGERY

Evaluation of the infant who has ambiguous genitalia, and principles of operative management. Donahoe PK, et al. **Semin Pediatr Surg** 1996 Feb;5(1):30–40 (44 ref.)

THERAPY

Androgen-resistance syndromes: considerations of gender assignment. Gooren LJ. **Curr Ther Endocrinol Metab** 1997; 6:380–4 (6 ref.)
The infant with ambiguous genitalia. Lee MM, et al. **Curr Ther Endocrinol Metab** 1997;6:216–23 (5 ref.)

SEX DIMORPHISM see **SEX CHARACTERISTICS**

SEX DISORDERS

ABC of mental health. Psychosexual problems. Watson JP, et al. **BMJ** 1997 Jul 26;315(7102):239–42 (4 ref.)

CHEMICALLY INDUCED

Sexual dysfunction as an obstacle to compliance with antihypertensive therapy. Rosen RC. **Blood Press Suppl** 1997;1:47–51 (19 ref.)
Sexual dysfunction in nonseminoma testicular cancer patients

is related to chemotherapy-induced angiopathy. van Basten JP, et al. **J Clin Oncol** 1997 Jun;15(6):2442–8 (55 ref.)
Medications that may contribute to sexual disorders. A guide to assessment and treatment in family practice. Finger WW, et al. **J Fam Pract** 1997 Jan;44(1):33–43 (51 ref.)

DRUG THERAPY

[Drug treatment of sexual disorders in men (see comments)] Slob AK, et al. **Ned Tijdschr Geneeskd** 1996 Oct 12; 140(41):2029–32 (33 ref.) Comment in: Ned Tijdschr Geneeskd 1996 Dec 14;140(50):2528. **(Dut)**

ETIOLOGY

Psychological and sexual aspects of the menopause and HRT. Pearce MJ, et al. **Baillieres Clin Obstet Gynaecol** 1996 Sep; 10(3):385–99 (66 ref.)
Bladder, bowel and sexual function after hysterectomy for benign conditions. Thakar R, et al. **Br J Obstet Gynaecol** 1997 Sep;104(9):983–7 (41 ref.)
Head injury and sexual dysfunction [see comments] Elliott ML, et al. **Brain Inj** 1996 Oct;10(10):703–17 (111 ref.) Comment in: Brain Inj 1997 May;11(5):389–90.
Homeostatic disruption and sexual disorders. Naisberg Y. **Med Hypotheses** 1996 Sep;47(3):243–7 (26 ref.)
[Role of hormones in sexual dysfunctions, homosexuality, transsexualism and deviant sexual behavior: diagnostic and therapeutic consequences] Buvat J, et al. **Contracept Fertil Sex** 1996 Nov;24(11):834–46 (80 ref.) (Eng. Abstr.) **(Fre)**
[Menopause and sexuality] Mimoun S. **Contracept Fertil Sex** 1996 Jan;24(1):62–6 (12 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Premature ejaculation: a psychophysiological review. Metz ME, et al. **J Sex Marital Ther** 1997 Spring;23(1):3–23 (150 ref.)

THERAPY

Use of assisted reproductive techniques for treatment of ejaculatory disorders. Denil J, et al. **Andrologia** 1996;28 Suppl 1:43–51 (62 ref.)

SEX EDUCATION

Sexual behaviour in young people. Wellings K, et al. **Baillieres Clin Obstet Gynaecol** 1996 Apr;10(1):139–160 (58 ref.)
Orgasm without organisms: science or propaganda? Genuis SJ, et al. **Clin Pediatr (Phila)** 1996 Jan;35(1):10–7 (105 ref.)
Developing HIV-preventive behavioural interventions for young people in Scotland. Abraham C, et al. **Int J STD AIDS** 1996;7 Suppl 2:39–42 (27 ref.)
HIV behavioural interventions in young people in The Netherlands. Schaalma H, et al. **Int J STD AIDS** 1996;7 Suppl 2:43–6 (13 ref.)
Women and the heterosexual transmission of HIV: risks and prevention strategies. Gavey N, et al. **Women Health** 1997; 25(2):41–64 (115 ref.)

LEGISLATION & JURISPRUDENCE

State actions on reproductive health issues in 1996. Sollom T. **Fam Plann Perspect** 1997 Jan–Feb;29(1):35–40 (4 ref.)

SEX FACTORS

Treatment of substance abusers: single or mixed gender programs? Hodgins DC, et al. **Addiction** 1997 Jul; 92(7):805–12 (60 ref.)
Vive la différence: males vs females in flies vs worms. Cline TW, et al. **Annu Rev Genet** 1996;30:637–702 (241 ref.)
Tropical diseases and the gender approach. Dias JC. **Bull Pan Am Health Organ** 1996 Sep;30(3):242–60 (94 ref.)
Status of research on gender differences. Berg MJ. **J Am Pharm Assoc (Wash)** 1997 Jan–Feb;NS37(1):43–56 (70 ref.)
Gender differences in psychotropic medications. Lewis-Hall F. **Mt Sinai J Med** 1996 Oct–Nov;63(5–6):326–9 (36 ref.)

SEX HORMONE-BINDING GLOBULIN

ANALYSIS

Clinical utility of sex hormone-binding globulin measurement. Pugeat M, et al. **Horm Res** 1996; 45(3–5):148–55 (68 ref.)

GENETICS

Sex hormone-binding globulin: gene organization and structure/function analyses. Hammond GL, et al. **Horm Res** 1996;45(3–5):197–201 (41 ref.)

METABOLISM

Determinants of steroid hormone bioavailability. Hammond GL. **Biochem Soc Trans** 1997 May;25(2):577–82 (51 ref.)
Sex steroid-binding protein and its membrane receptor in estrogen-dependent breast cancer: biological and pathophysiological impact. Fortunati N, et al. **Horm Res** 1996;45(3–5):202–6 (16 ref.)

PHYSIOLOGY

Sex hormone-binding protein, hyperinsulinemia, insulin resistance and noninsulin-dependent diabetes. Haffner SM. **Horm Res** 1996;45(3–5):233–7 (45 ref.)
Sex hormone-binding globulin: gene organization and structure/function analyses. Hammond GL, et al. **Horm Res** 1996;45(3–5):197–201 (41 ref.)

SEX HORMONES

Natural sex steroids and their xenobiotic analogs in animal production: growth, carcass quality, pharmacokinetics, metabolism, mode of action, residues, methods, and epidemiology. Lone KP. **Crit Rev Food Sci Nutr** 1997 Mar; 37(2):93–209 (1177 ref.)

ADMINISTRATION & DOSAGE

Bioavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy. Fotherby K. **Contraception** 1996 Aug;54(2):59–69 (52 ref.)

BLOOD

Masculinizing and feminizing syndromes caused by functioning tumors. Masiakos PT, et al. **Semin Pediatr Surg** 1997 Aug;6(3):147–55 (64 ref.)

HISTORY

Menopause, only for women? The social construction of menopause as an exclusively female condition. Oudshoorn NE. **J Psychosom Obstet Gynaecol** 1997 Jun;18(2):137–44 (16 ref.)

METABOLISM

Steroid hormones and cancer: (II) Lessons from experimental systems. Miller WR, et al. **Eur J Surg Oncol** 1997 Feb; 23(1):72–83 (160 ref.)
Gonadal cell apoptosis: hormone-regulated cell demise. Billig H, et al. **Hum Reprod Update** 1996 Mar–Apr;2(2):103–17 (167 ref.)

PHARMACOKINETICS

Bioavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy. Fotherby K. **Contraception** 1996 Aug;54(2):59–69 (52 ref.)

PHARMACOLOGY

Hormonal interventions with psychopharmacological potential: an overview. Halbreich U. **Psychopharmacol Bull** 1997;33(2):281–6 (69 ref.)
Effects of sex steroid hormones on lipoproteins, clotting, and the arterial wall. Knopp RH, et al. **Semin Reprod Endocrinol** 1996 Feb;14(1):15–27 (112 ref.)

PHYSIOLOGY

Neuropsychiatric lupus and hormones. Robinson T, et al. **Ann Med Interne (Paris)** 1996;147(4):276–80 (23 ref.)
Sports-related problems in reproductive function. Orley J. **Ann N Y Acad Sci** 1997 Jun 17;816:285–94 (15 ref.)
Sex hormones and the risk of osteoarthritis in women: epidemiological evidence. Nevitt MC, et al. **Ann Rheum Dis** 1996 Sep;55(9):673–6 (47 ref.)
Gonadal steroid modulation of neuroendocrine transduction: a transynaptic view. Alonso-Solís R, et al. **Cell Mol Neurobiol** 1996 Jun;16(3):357–82 (94 ref.)
The amygdala: corticotropin-releasing factor, steroids, and stress. Gray TS, et al. **Crit Rev Neurobiol** 1996;10(2):155–68 (109 ref.)
Sex, sexual orientation and sex hormones influence human cognitive function. Kimura D. **Curr Opin Neurobiol** 1996 Apr;6(2):259–63 (43 ref.)
Biological activity of hormones in preovulatory follicular fluid and serum of women undergoing ovarian stimulation. Andersen CY. **Dan Med Bull** 1997 Jun;44(3):257–73 (180 ref.)
Sexual differentiation of the brain in songbirds. Arnold AP, et al. **Dev Neurosci** 1996;18(1–2):124–36 (88 ref.)
Growth hormones and sex steroid interactions at puberty. Clark PA, et al. **Endocrinol Metab Clin North Am** 1996 Sep;25(3):665–81 (94 ref.)
Paracrine regulation of cellular interactions in the testis: factors in search of a function. Schlatt S, et al. **Eur J Endocrinol** 1997 Aug;137(2):107–17 (124 ref.)
Steroid hormones and cancer: (III) observations from human subjects. Miller WR, et al. **Eur J Surg Oncol** 1997 Apr; 23(2):163–77; quiz 177–8, 183 (228 ref.)
Membrane sex-steroid receptors in the brain. Ramirez VD, et al. **Front Neuroendocrinol** 1996 Oct;17(4):402–39 (200 ref.)
Do sex differences in the brain explain sex differences in the hormonal induction of reproductive behavior? What 25 years of research on the Japanese quail tells us. Balthazart J, et al. **Horm Behav** 1996 Dec;30(4):627–61 (135 ref.)
Growth hormone, insulin-like growth factor-I and lipid metabolism: interactions with sex steroids. Björntorp P. **Horm Res** 1996;46(4–5):188–91 (12 ref.)
Interaction of the signalling pathways of insulin-like growth factor-I and sex steroids in the neuroendocrine hypothalamus. García-Segura LM, et al. **Horm Res** 1996; 46(4–5):160–4 (58 ref.)
Regulation of fetal allograft survival by a hormone-controlled Th1- and Th2-type cytokines. Piccinni MP, et al. **Immunol Res** 1996;15(2):141–50 (54 ref.)
Gender-specific physiology: how real is it? How important is it? Legato MJ. **Int J Fertil Womens Med** 1997 Jan–Feb; 42(1):19–29 (90 ref.)
Molecular aspects of steroid hormone action in the male reproductive axis. Shupnik MA, et al. **J Androl** 1997 Jul–Aug;18(4):341–4 (25 ref.)
The influence of female sex steroids on glucose metabolism and insulin action. Godsland IF. **J Intern Med Suppl** 1996; 738:1–60 (307 ref.)
Sex hormones and Sjögren's syndrome. Sullivan DA. **J Rheumatol** 1997 Sep;24 Suppl 50:17–32 (249 ref.)
Hormones and bones. Rizzoli R, et al. **Lancet** 1997 Mar;349 Suppl 1:sI20–3 (32 ref.)
Mechanisms of action of sex steroid hormones: basic concepts and clinical correlations. Tuohimaa P, et al. **Maturitas** 1996 May;23 Suppl:S3–12 (75 ref.)
Lipids and lipoproteins in women. O'Brien T, et al. **Mayo Clin Proc** 1997 Mar;72(3):235–44 (106 ref.)
Regulation of the aminolevulinate synthase gene in the Syrian hamster Harderian gland: changes during development and circadian rhythm and role of some hormones. Rodriguez C, et al. **Microsc Res Tech** 1996 May 1;34(1):65–70 (50 ref.)
Menstruation, sex hormones, and migraine. MacGregor EA. **Neurol Clin** 1997 Feb;15(1):125–41 (75 ref.)
Promoter- and cell-specific responses to sex steroids. Milgrom E, et al. **Osteoporos Int** 1997;7 Suppl 1:S23–8 (40 ref.)
Combination oral contraceptives and cardiovascular disease. Darney PD. **Semin Reprod Endocrinol** 1996 Feb;14(1):51–61 (98 ref.)
[Hormones and apoptosis] Liu J, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Oct;34(10):712–5 (18 ref.) **(Chi)**
[Role of hormones in sexual dysfunctions, homosexuality, transsexualism and deviant sexual behavior: diagnostic and therapeutic consequences] Buvat J, et al. **Contracept Fertil Sex** 1996 Nov;24(11):834–46 (80 ref.) (Eng. Abstr.) **(Fre)**
[Premenstrual asthma: relation to hormones] Hernández Colin D, et al. **Rev Alerg Mex** 1997 Mar–Apr;44(2):35–8 (33 ref.) (Eng. Abstr.) **(Spa)**

SECRETION

Section III other hormonal causes. Sotos JF. **Clin Pediatr (Phila)** 1996 Dec;35(12):637–48 (35 ref.)

THERAPEUTIC USE

Sex hormones in systemic lupus erythematosus: a controversy for modern times [editorial; comment] Bruce IN, et al. **J Rheumatol** 1997 Aug;24(8):1461–3 (33 ref.) Comment on: J Rheumatol 1997 Aug;24(8):1639–40.

SEX MATURATION

Growth, development, and sexual dimorphism in vervet monkeys (Cercopithecus aethiops) at four sites in Kenya. Turner TR, et al. **Am J Phys Anthropol** 1997 May; 103(1):19–35 (53 ref.)
[Andrology in adolescence: objectives and preventive measures (editorial)] Jacquin P. **Arch Pediatr** 1996 Oct; 3(10):947–50 (21 ref.) **(Fre)**

GENETICS

Estrogen receptor function as revealed by knockout studies: neuroendocrine and behavioral aspects. Rissman EF, et al. **Horm Behav** 1997 Jun;31(3):232–43 (90 ref.)

PHYSIOLOGY

Environmental factors and sexual maturation in rodents. Aubert ML, et al. **Acta Paediatr Suppl** 1996 Oct;417:86–8 (29 ref.)
Environmental factors and puberty in non-human primates. Plant TM. **Acta Paediatr Suppl** 1996 Oct;417:89–91 (14 ref.)
Progesterone receptor function from a behavioral perspective. Mani SK, et al. **Horm Behav** 1997 Jun; 31(3):244–55 (80 ref.)
[Renal infantilism] Ito K. **Ryoikibetsu Shokogun Shirizu** 1997; (16 Pt 1):27–9 (3 ref.) **(Jpn)**

SEX OFFENSES

LEGISLATION & JURISPRUDENCE

Scientific status of the concept of continuing emotional propensity for sexually aberrant acts. Lanyon RI. **J Am Acad Psychiatry Law** 1997;25(1):59–67 (36 ref.)

PREVENTION & CONTROL

Prevention of sexual aggression: Sociocultural risk and protective factors. Hall GC, et al. **Am Psychol** 1997 Jan; 52(1):5–14 (70 ref.)

PSYCHOLOGY

Cognitive distortions in sex offenders: an integrative review.

Ward T, et al. **Clin Psychol Rev** 1997;17(5):479–507 (160 ref.)

TRENDS

Irritable bowel syndrome and sexual/physical abuse history [comment] Drossman DA. **Eur J Gastroenterol Hepatol** 1997 Apr;9(4):327–30 (15 ref.) Comment on: Eur J Gastroenterol Hepatol 1997 Apr;9(4):345–52.

SEX PHEROMONES see **SEX ATTRACTANTS**

SEX PILI see **PILI, SEX**

SEX PREDETERMINATION see **SEX PRESELECTION**

SEX PREFERENCE see **SEX**

SEX PRESELECTION

METHODS

X- and Y-chromosome-bearing sperm selection and detection methods. A review. Gawęcka-Szczygieł M, et al. **Folia Histochem Cytobiol** 1995;33(4):219–27 (55 ref.)

Sperm separation for gender preference: methods and efficacy. Botchan A, et al. **J Androl** 1997 Mar–Apr; 18(2):107–8 (20 ref.)

Application of modern molecular techniques to evaluate sperm sex selection methods. Flaherty SP, et al. **Mol Hum Reprod** 1996 Dec;2(12):937–42 (52 ref.)

VETERINARY

Gender preselection in mammals: an overview. Johnson LA. **DTW Dtsch Tierarztl Wochenschr** 1996 Aug–Sep; 103(8–9):288–91 (19 ref.)

SEX RATIO

Length of the follicular phase, time of insemination, coital rate and the sex of offspring. Martin JF. **Hum Reprod** 1997 Mar;12(3):611–6 (39 ref.)

Sibling sex ratio of boys with gender identity disorder. Zucker KJ, et al. **J Child Psychol Psychiatry** 1997 Jul; 38(5):543–51 (131 ref.)

SEX REVERSAL, GONADAL

Mutations in SOX9 cause both autosomal sex reversal and campomelic dysplasia. Foster JW. **Acta Paediatr Jpn** 1996 Aug;38(4):405–11 (26 ref.)

SEX ROLE see **GENDER IDENTITY**

SEX SELECTION see **SEX PRESELECTION**

SEX STEROID-BINDING PROTEIN see **SEX HORMONE-BINDING GLOBULIN**

SEXISM see **PREJUDICE**

SEXOLOGY see **SEX**

SEXUAL ABSTINENCE

Factors to address when periodic abstinence is offered by multi-method family planning programs. Huezo C. **Adv Contracept** 1997 Jun–Sep;13(2–3):261–7 (10 ref.)

Seminal truth: a modern science of male celibacy in north India. Alter JS. **Med Anthropol Q** 1997 Sep;11(3):275–98; discussion 299–301 (110 ref.)

SEXUAL ABUSE, CHILD see **CHILD ABUSE, SEXUAL**

SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL see **PSYCHOSEXUAL DYSFUNCTIONS**

SEXUAL HARASSMENT

Sexual harassment and hostile environments in the perioperative area. Kaye J. **AORN J** 1996 Feb;63(2):443–6, 448–9 (51 ref.)

PREVENTION & CONTROL

Sexual harassment in nursing. Robbins I, et al. **J Adv Nurs** 1997 Jan;25(1):163–9 (41 ref.)

SEXUAL INTERCOURSE see **COITUS**

SEXUAL ORIENTATION see **SEX BEHAVIOR**

SEXUAL PARTNERS

Sexual behaviour in young people. Wellings K, et al. **Baillieres Clin Obstet Gynaecol** 1996 Apr;10(1):139–160 (58 ref.)

Sexual partners of substance abuse clients: strategies for HIV/AIDS prevention. Wermuth L. **J Subst Abuse Treat** 1996 Nov–Dec;13(6):505–9 (16 ref.)

Verbal intercourse and sexual communication: impediments to STD prevention. Pliskin KL. **Med Anthropol Q** 1997 Mar;11(1):89–109 (76 ref.)

SEXUALITY

see related
PSYCHOSEXUAL DEVELOPMENT

Gender, sexuality and communication issues that constitute barriers to the use of natural family planning and other fertility awareness-based methods. Diaz M. **Adv Contracept** 1997 Jun–Sep;13(2–3):303–9 (4 ref.)

The potential contribution of sexuality and gender awareness. Kopp Z. **Adv Contracept** 1997 Jun–Sep;13(2–3):325–9 (5 ref.)

Themes relating to sexuality that emerged from a discourse analysis of the Nursing Times during 1980–1990. Carr G. **J Adv Nurs** 1996 Jul;24(1):196–212 (129 ref.)

The politics of sex research and constructions of female sexuality: what relevance to sexual health work with young women? Few C. **J Adv Nurs** 1997 Mar;25(3):615–25 (95 ref.)

Is non-judgemental care possible in the context of nurses' attitudes to patients' sexuality? Hayter M. **J Adv Nurs** 1996 Oct;24(4):662–6 (39 ref.)

HIV/AIDS risk in heterosexual college students. A review of a decade of literature. Lewis JE, et al. **J Am Coll Health** 1997 Jan;45(4):147–58 (76 ref.)

Issues in sexuality and gynecologic care of women with developmental disabilities. Sulpizi LK. **J Obstet Gynecol Neonatal Nurs** 1996 Sep;25(7):609–14 (24 ref.)

The middle years: women, sexuality, and the self. Wilmoth MC. **J Obstet Gynecol Neonatal Nurs** 1996 Sep; 25(7):615–21 (34 ref.)

Female adolescent sexuality. Sugar M. **J Pediatr Adolesc Gynecol** 1996 Nov;9(4):175–83 (73 ref.)

[Sexuality and religions] Chaix-Durand G, et al. **Contracept Fertil Sex** 1997 Mar;25(3):I–XIII (26 ref.) **(Fre)**

PHYSIOLOGY

Sexuality and the art of arousal in the geriatric woman. Barber HR. **Clin Obstet Gynecol** 1996 Dec;39(4):970–3 (9 ref.)

PSYCHOLOGY

Seminal truth: a modern science of male celibacy in north India. Alter JS. **Med Anthropol Q** 1997 Sep;11(3):275–98; discussion 299–301 (110 ref.)

SEXUALLY TRANSMITTED DISEASES

STDs in women: what you need to know. Sharts-Hopko NC. **Am J Nurs** 1997 Apr;97(4):46–54; quiz 55 (22 ref.)

Sexual and perinatal transmission of hepatitis C. Dienstag JL. **Hepatology** 1997 Sep;26(3 Suppl 1):66S–70S (41 ref.)

Pelvic inflammatory disease. Mann SN, et al. **Int J STD AIDS** 1996 Aug–Sep;7(5):315–21 (58 ref.)

Sex and travel: studies of sexual behaviour, disease and health promotion in international travellers—a global review [editorial] Mulhall BP. **Int J STD AIDS** 1996 Nov–Dec; 7(7):455–65 (108 ref.)

[Progresses in dermatology and venerology in China, 1996] Zhu T. **Chung Hua I Hsueh Tsa Chih** 1996 Dec; 76(12):932–3 (0 ref.) **(Chi)**

[Sexually transmitted diseases in men] Méria P, et al. **Prog Urol** 1996 Jun;6(3):447–54 (55 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Janus considers the HIV pandemic—harnessing recent advances to enhance AIDS prevention [editorial] St. Louis ME, et al. **Am J Public Health** 1997 Jan;87(1):10–2 (29 ref.)

Sexually transmitted diseases and adverse outcomes of pregnancy. Goldenberg RL, et al. **Clin Perinatol** 1997 Mar; 24(1):23–41 (123 ref.)

Genital ulcer infections in the female patient and the vaginitides. Fiumara NJ. **Dermatol Clin** 1997 Apr; 15(2):233–45 (10 ref.)

Association of sexually transmitted diseases and infection with the human immunodeficiency virus: biological cofactors and markers of behavioural interventions. Quinn TC. **Int J STD AIDS** 1996;7 Suppl 2:17–24 (81 ref.)

Musculoskeletal disorders: genitourinary medicine perspective [editorial] Tayal SC, et al. **Int J STD AIDS** 1996 Oct;7(6):396–9 (38 ref.)

Oculogenital syndromes. Notz RG. **Pa Med** 1996 Mar;99 Suppl:84–7 (30 ref.)

HIV and syphilis seroprevalence among clients with sexually transmitted diseases attending a walk-in clinic at Cook County Hospital. Ansell DA, et al. **Sex Transm Dis** 1994 Mar–Apr;21(2):93–6 (9 ref.)

Human immunodeficiency virus transmission and the role of other sexually transmitted diseases. Measures of association and study design. Boily MC, et al. **Sex Transm Dis** 1996 Jul–Aug;23(4):312–32 (69 ref.)

DIAGNOSIS

Multiplex polymerase chain reaction for the diagnosis of sexually transmitted diseases. Mahony JB. **Clin Lab Med** 1996 Mar;16(1):61–71 (32 ref.)

Sexually transmitted diseases in adolescents: screening & treatment. Saxena SB, et al. **Compr Ther** 1997 Feb; 23(2):108–15 (16 ref.)

The role of the microbiology laboratory in the investigation of child sexual abuse. Dyson C, et al. **J Med Microbiol** 1996 Nov;45(5):313–8 (51 ref.)

Sexually transmitted diseases in pregnancy: diagnosis, impact, and intervention. Ament LA, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Oct;25(8):657–66 (29 ref.)

DRUG THERAPY

Sexually transmitted diseases in adolescents: screening & treatment. Saxena SB, et al. **Compr Ther** 1997 Feb; 23(2):108–15 (16 ref.)

Sexually transmitted diseases in pregnancy. Jackson SL, et al. **Obstet Gynecol Clin North Am** 1997 Sep;24(3):631–44 (41 ref.)

EPIDEMIOLOGY

STDs, AIDS and reproductive health. Johannisson E. **Adv Contracept** 1996 Dec;12(4):281–4 (0 ref.)

Sexually transmitted diseases and oral contraceptive use during adolescence. Creatsas G. **Ann N Y Acad Sci** 1997 Jun 17;816:404–10 (37 ref.)

Adolescent sexuality. Goldfarb AF. **Ann N Y Acad Sci** 1997 Jun 17;816:395–403 (08 ref.)

Sexually transmitted diseases: incidence and distribution. Wang Q. **Chin Med Sci J** 1996 Mar;11(1):56–62 (27 ref.)

The role of epidemiology and surveillance systems in the control of sexually transmitted diseases. Catchpole MA. **Genitourin Med** 1996 Oct;72(5):321–9 (97 ref.)

Sexually transmitted diseases in mobile populations. Mabey D, et al. **Genitourin Med** 1997 Feb;73(1):18–22 (33 ref.)

The development and use of the concept of a sexually transmitted disease core. Thomas JC, et al. **J Infect Dis** 1996 Oct;174 Suppl 2:S134–43 (103 ref.)

Sun, sex and responsibility. The Lumleian Lecture 1996. Adler MW. **J R Coll Physicians Lond** 1997 Jul–Aug; 31(4):425–33 (25 ref.)

The promise of integrated representative surveys about sexually transmitted diseases and behavior [see comments] Ku L, et al. **Sex Transm Dis** 1997 May;24(5):299–309 (47 ref.) Comment in: Sex Transm Dis 1997 May;24(5):310–1.

Model trains of thought [editorial; comment] Rothenberg R. **Sex Transm Dis** 1997 Apr;24(4):201–3 (20 ref.) Comment on: Sex Transm Dis 1997 Apr;24(4):185–200.

Sexual transmission of HIV to women in industrialized countries. Hankins C. **World Health Stat Q** 1996; 49(2):106–14 (102 ref.)

[Screening of sexually transmitted diseases (Mycoplasma hominis, Ureaplasma urealyticum and Chlamydia trachomatis) in young women] Bihari A. **Orv Hetil** 1997 Mar 30;138(13):799–803 (27 ref.) (Eng. Abstr.) **(Hun)**

ETIOLOGY

Sexually transmitted diseases and unwanted pregnancies in chronically ill psychiatric patients [editorial] [see comments] Coverdale JH, et al. **Med J Aust** 1997 Mar 3; 166(5):231–2 (10 ref.) Comment in: Med J Aust 1997 Jun 16;166(12):665–6. Comment in: Med J Aust 1997 Jun 16;166(12):666. Comment in: Med J Aust 1997 Jun 16;166(12):666–7.

STDS in women attending family planning clinics: a case study in Addis Ababa. Duncan ME, et al. **Soc Sci Med** 1997 Feb;44(4):441–54 (101 ref.)

MICROBIOLOGY

Do men become infertile after having sexually transmitted urethritis? An epidemiologic examination. Ness RB, et al. **Fertil Steril** 1997 Aug;68(2):205–13 (73 ref.)

PREVENTION & CONTROL

Providing accessible health care for adolescents with sexually transmitted disease. Brabin L. **Acta Trop** 1996 Dec 30; 62(4):209–16 (20 ref.)

Anti-STD vaginal contraceptive sponges. Hassan E, et al. **Ann N Y Acad Sci** 1997 Jun 17;816:451–6 (35 ref.)

Condoms and the prevention of sexually transmissible diseases. Donovan B. **Br J Hosp Med** 1995 Dec 13–1996 Jan 16;54(11):575–8 (18 ref.)

Orgasm without organisms: science or propaganda? Genuis SJ, et al. **Clin Pediatr (Phila)** 1996 Jan;35(1):10–7 (105 ref.)

Primary care management of adolescent sexual behavior. Ellen JM, et al. **Curr Opin Pediatr** 1996 Oct;8(5):442–8 (47 ref.)

A risk-assessment tool for integrated reproductive health services. Cates W Jr. **Fam Plann Perspect** 1997 Jan–Feb; 29(1):41–3 (12 ref.)

The role of epidemiology and surveillance systems in the control of sexually transmitted diseases. Catchpole MA. **Genitourin Med** 1996 Oct;72(5):321–9 (97 ref.)

Health education and promotion for STD prevention: lessons for the next millennium. Darrow WW. **Genitourin Med** 1997 Apr;73(2):88–94 (86 ref.)

Measuring outcomes of behavioural interventions for STD/HIV prevention. Aral SO, et al. **Int J STD AIDS** 1996;7 Suppl 2:30–8 (27 ref.)

Successful eradication of sexually transmitted diseases in the People's Republic of China: implications for the 21st century. Cohen MS, et al. **J Infect Dis** 1996 Oct;174 Suppl

2:S223–9 (48 ref.)
International perspectives on individual and community approaches to the prevention of sexually transmitted disease and human immunodeficiency virus infection. O'Reilly KR, et al. **J Infect Dis** 1996 Oct;174 Suppl 2:S214–22 (51 ref.)
Verbal intercourse and sexual communication: impediments to STD prevention. Pliskin KL. **Med Anthropol Q** 1997 Mar;11(1):89–109 (76 ref.)
Women's health. Sexually transmitted diseases. Miller KE. **Prim Care** 1997 Mar;24(1):179–93 (34 ref.)
Self-medication and STD prevention [editorial; comment] Nichter M. **Sex Transm Dis** 1996 Sep–Oct;23(5):353–6 (2 ref.) Comment on: Sex Transm Dis 1996 Sep–Oct;23(5):407–12.
Health education and sexually transmitted diseases. Hubley J, et al. **Trop Doct** 1996 Jul;26(3):121–5 (13 ref.)
[Andrology in adolescence: objectives and preventive measures (editorial)] Jacquin P. **Arch Pediatr** 1996 Oct; 3(10):947–50 (21 ref.) **(Fre)**
[Human mobility and sexually transmitted diseases] Carosi G, et al. **Med Trop (Mars)** 1997;57(2):115–9 (28 ref.) **(Fre)**

REHABILITATION

The spa and sexually transmitted diseases. Freedman D, et al. **Clin Dermatol** 1996 Nov–Dec;14(6):577–82 (34 ref.)

THERAPY

Providing accessible health care for adolescents with sexually transmitted disease. Brabin L. **Acta Trop** 1996 Dec 30; 62(4):209–16 (20 ref.)

TRANSMISSION

Probabilities of sexual HIV-1 transmission. Mastro TD, et al. **AIDS** 1996;10 Suppl A:S75–82 (108 ref.)
The role and effectiveness of partner notification in STD control: a review. Cowan FM, et al. **Genitourin Med** 1996 Aug;72(4):247–52 (52 ref.)
Sexually transmitted diseases and sexual behavior: insights from mathematical models. Garnett GP, et al. **J Infect Dis** 1996 Oct;174 Suppl 2:S150–61 (43 ref.)
The development and use of the concept of a sexually transmitted disease core. Thomas JC, et al. **J Infect Dis** 1996 Oct;174 Suppl 2:S134–43 (103 ref.)
The effect of birth control methods on sexually transmitted disease/HIV risk [see comments] O'Connell ML. **J Obstet Gynecol Neonatal Nurs** 1996 Jul–Aug;25(6):476–80 (32 ref.) Comment in: J Obstet Gynecol Neonatal Nurs 1997 Jan–Feb;26(1):16.
[Human mobility and sexually transmitted diseases] Carosi G, et al. **Med Trop (Mars)** 1997;57(2):115–9 (28 ref.) **(Fre)**
[Sexually transmitted diseases in HIV infection] Hartmann M, et al. **Hautarzt** 1997 Mar;48(3):206–13; quiz 213 (90 ref.) **(Ger)**

URINE

Urine-based diagnosis of sexually transmitted infections using amplified DNA techniques: a shift in paradigms? Orr DP. **J Adolesc Health** 1997 Jan;20(1):3–5 (7 ref.)

SEXUALLY TRANSMITTED DISEASES, BACTERIAL

DIAGNOSIS

Sexually transmitted diseases update. McDonald LL, et al. **Dermatol Clin** 1997 Apr;15(2):221–32 (106 ref.)

DRUG THERAPY

Pharmacologic management of sexually transmitted diseases. Roe VA, et al. **J Nurse Midwifery** 1997 May–Jun; 42(3):275–89 (110 ref.)

EPIDEMIOLOGY

Current situation of sexually transmitted Chlamydia trachomatis infections in China. Wang Q. **Chin Med J (Engl)** 1996 Dec;109(12):899–902 (16 ref.)

THERAPY

Sexually transmitted diseases update. McDonald LL, et al. **Dermatol Clin** 1997 Apr;15(2):221–32 (106 ref.)

SEXUALLY TRANSMITTED DISEASES, VIRAL

DIAGNOSIS

Sexually transmitted diseases update. McDonald LL, et al. **Dermatol Clin** 1997 Apr;15(2):221–32 (106 ref.)

DRUG THERAPY

Pharmacologic management of sexually transmitted diseases. Roe VA, et al. **J Nurse Midwifery** 1997 May–Jun; 42(3):275–89 (110 ref.)

EPIDEMIOLOGY

Genital herpes infection: a review. Brugha R, et al. **Int J Epidemiol** 1997 Aug;26(4):698–709 (127 ref.)

THERAPY

Sexually transmitted diseases update. McDonald LL, et al. **Dermatol Clin** 1997 Apr;15(2):221–32 (106 ref.)

SEZARY SYNDROME

Mycosis fungoides and Sezary syndrome [see comments] Diamandidou E, et al. **Blood** 1996 Oct 1;88(7):2385–409 (296 ref.) Comment in: Blood 1997 Apr 15;89(8):3062–4.

DRUG THERAPY

Clinical experience with 2'-deoxycoformycin. Catovsky D. **Hematol Cell Ther** 1996 Dec;38 Suppl 2:S103–7 (25 ref.)

PATHOLOGY

T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL). Bunn PA Jr, et al. **J Cell Biochem Suppl** 1996;24:12–23 (125 ref.)

SGOT see **ASPARTATE AMINOTRANSFERASE**

SGPT see **ALANINE AMINOTRANSFERASE**

SH DOMAINS see **SRC HOMOLOGY DOMAINS**

SHAME

Conceptual and methodological issues in the assessment of shame and guilt. Tangney JP. **Behav Res Ther** 1996 Sep; 34(9):741–54 (85 ref.)
The evolution of social attractiveness and its role in shame, humiliation, guilt and therapy. Gilbert P. **Br J Med Psychol** 1997 Jun;70 (Pt 2):113–47 (140 ref.)
A process model for understanding adaptation to sexual abuse: the role of shame in defining stigmatization. Feiring C, et al. **Child Abuse Negl** 1996 Aug;20(8):767–82 (144 ref.)
[Disappearance of shame and puberty in girls] Kämmerer A, et al. **Prax Kinderpsychol Kinderpsychiatr** 1997 Feb; 46(2):113–21 (35 ref.) (Eng. Abstr.) **(Ger)**

SHARED PARANOID DISORDER

PSYCHOLOGY

Antisocial personality by proxy: the Norton–Sims syndrome. Stawar TL. **J Psychol** 1997 Jan;131(1):5–19 (46 ref.)

SHARED PURCHASING see **GROUP PURCHASING**

SHARKS

IMMUNOLOGY

The immune system of ectothermic vertebrates. Flajnik MF. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):145–50 (33 ref.)

SHARP SYNDROME see **MIXED CONNECTIVE TISSUE DISEASE**

SHEEHAN'S SYNDROME see **HYPOPITUITARISM**

SHEEP

Advances in production of embryos in vitro from juvenile and prepubertal oocytes from the calf and lamb. Armstrong DT, et al. **Reprod Fertil Dev** 1997;9(3):333–9 (24 ref.)
[In vitro oocyte maturation in domestic ruminants] Mermillod P, et al. **Contracept Fertil Sex** 1996 Jul–Aug;24(7–8):552–8 (36 ref.) (Eng. Abstr.) **(Fre)**

EMBRYOLOGY

Foetal endocrine maturation. Challis JR, et al. **Equine Vet J Suppl** 1993 Apr;(14):35–40 (51 ref.)
The development of the ovine fetal adrenal gland and its regulation. Naaman Répérant E, et al. **Reprod Nutr Dev** 1997;37(1):81–95 (106 ref.)

GENETICS

Natural sex steroids and their xenobiotic analogs in animal production: growth, carcass quality, pharmacokinetics, metabolism, mode of action, residues, methods, and epidemiology. Lone KP. **Crit Rev Food Sci Nutr** 1997 Mar; 37(2):93–209 (1177 ref.)
Hair sheep genetic resources and their contribution to diversified small ruminant production in the United States. Wildeus S. **J Anim Sci** 1997 Mar;75(3):630–40 (49 ref.)
PrP genetics in sheep and the applications for scrapie and BSE. Hunter N. **Trends Microbiol** 1997 Aug;5(8):331–4 (36 ref.)

GROWTH & DEVELOPMENT

Intestinal effects of milkborne growth factors in neonates of agricultural importance. Odle J, et al. **J Anim Sci** 1996 Oct;74(10):2509–22 (120 ref.)
Nutritional and economic benefits of Leucaena and Gliricidia as feed supplements for small ruminants in humid West Africa. Jabbar MA, et al. **Trop Anim Health Prod** 1997 Feb;29(1):35–47 (44 ref.)

INJURIES

Traumatic head injury in ruminant livestock. Finnie IW. **Aust Vet J** 1997 Mar;75(3):204–8 (29 ref.)

METABOLISM

Effects of melatonin infused into the III ventricle on prolactin, beta-endorphin and luteotropin secretion in ewes during the different stages of the reproductive cycle. Misztal T, et al. **Acta Neurobiol Exp (Warsz)** 1996; 56(3):769–78 (32 ref.)
The regulation of intestinal metabolism and its impact on whole animal energetics. Cant JP, et al. **J Anim Sci** 1996 Oct;74(10):2541–53 (98 ref.)
Pharmacological basis for hepatic drug metabolism in sheep. Galtier P, et al. **Vet Res** 1996;27(4–5):363–72 (30 ref.)

PHYSIOLOGY

Neural systems mediating the negative feedback actions of estradiol and progesterone in the ewe. Goodman RL. **Acta Neurobiol Exp (Warsz)** 1996;56(3):727–41 (85 ref.)
Stress and nutritional influences on GnRH and somatostatin neuronal systems in the ewe. Polkowska J. **Acta Neurobiol Exp (Warsz)** 1996;56(3):797–806 (38 ref.)
Responses in the hypothalamic monoaminergic system activity in ewes to beta-endorphin, CRF and their antagonists. Przekop F, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(3):807–17 (58 ref.)
Another view of GH neuroregulation: lessons from the sheep. Dutour A, et al. **Eur J Endocrinol** 1997 Jun;136(6):553–65 (133 ref.)
Delivery method and supplement consumption by grazing ruminants: a review. Bowman JG, et al. **J Anim Sci** 1997 Feb;75(2):543–50 (44 ref.)
Intestinal effects of milkborne growth factors in neonates of agricultural importance. Odle J, et al. **J Anim Sci** 1996 Oct;74(10):2509–22 (120 ref.)
Development of a mechanistic model of intake and chewing activities of sheep. Sauvant D, et al. **J Anim Sci** 1996 Nov; 74(11):2785–802 (90 ref.)
tau-Interferon: pregnancy recognition signal in ruminants. Spencer TE, et al. **Proc Soc Exp Biol Med** 1996 Dec; 213(3):215–29 (110 ref.)
Gut regulatory peptides in young cattle and sheep. Guilloteau P, et al. **Zentralbl Veterinarmed A** 1997 Mar;44(1):1–23 (122 ref.)
[Nutritional biochemical aspects of the significance, of the utilization, of metabolism and of the administration of vitamin E and of selenium in sheep (review)] Kolb E, et al. **Berl Munch Tierarztl Wochenschr** 1997 May; 110(5):178–84 (48 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

General anesthetic techniques in ruminants [published erratum appears in Vet Clin North Am Food Anim Pract 1997 Mar;13(1):XI] Carroll GL, et al. **Vet Clin North Am Food Anim Pract** 1996 Nov;12(3):627–61 (125 ref.)

SHEEP DISEASES

Implications of nutrition for the ability of ruminants to withstand gastrointestinal nematode infections. van Houtert MF, et al. **Int J Parasitol** 1996 Nov;26(11):1151–67 (167 ref.)
Strategies to reduce transmission of Toxoplasma gondii to animals and humans. Dubey JP. **Vet Parasitol** 1996 Aug; 64(1–2):65–70 (39 ref.)
Pharmacological basis for hepatic drug metabolism in sheep. Galtier P, et al. **Vet Res** 1996;27(4–5):363–72 (30 ref.)
Recent acute and subacute mycotoxicoses recognized in France. Le Bars J, et al. **Vet Res** 1996;27(4–5):383–94 (36 ref.)

CHEMICALLY INDUCED

Do steroidal saponins have a role in hepatogenous photosensitization diseases of sheep? Flåøyen A. **Adv Exp Med Biol** 1996;405:395–403 (51 ref.)
Selenium-induced "blind staggers" and related myths. A commentary on the extent of historical livestock losses attributed to selenosis on western US rangelands. O'Toole D, et al. **Vet Pathol** 1996 Jan;33(1):109–16 (163 ref.)

DIAGNOSIS

Diagnostic exercise: sheep with enlarged lymph nodes. Rand MS. **Lab Anim Sci** 1996 Jun;46(3):335–7 (10 ref.)
Laboratory diagnostic tests for retrovirus infections of small ruminants. Knowles DP Jr. **Vet Clin North Am Food Anim Pract** 1997 Mar;13(1):1–11 (64 ref.)
Improved laboratory diagnosis of ovine footrot: an update. Liu D, et al. **Vet J** 1997 Jan;153(1):99–105 (39 ref.)

EPIDEMIOLOGY

Paratuberculosis in small ruminants, deer, and South

American camelids. Stehman SM.
Vet Clin North Am Food Anim Pract 1996 Jul;12(2):441–55 (56 ref.)

GENETICS

The immunogenetics of resistance to Trichostrongylus colubriformis and Haemonchus contortus parasites in sheep [see comments] Hohenhaus MA, et al. **Br Vet J** 1995 Mar–Apr;151(2):119–40 (65 ref.) Comment in: Br Vet J 1995 Mar–Apr;151(2):111–3.

The ovine callipyge locus: a paradigm illustrating the importance of non-Mendelian genetics in livestock. Georges M, et al. **Reprod Nutr Dev** 1996;36(6):651–7 (21 ref.)

The genetic basis of resistance to Ostertagia circumcincta in lambs. Stear MJ, et al. **Vet J** 1997 Sep;154(2):111–9 (65 ref.)

[Genetic aspects of sheep resistance to gastrointestinal nematode infections] Doligalska M. **Wiad Parazytol** 1995; 41(4):405–11 (42 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Vaccines for bluetongue. Murray PK, et al. **Aust Vet J** 1996 Jun;73(6):207–10 (33 ref.)

The immunogenetics of resistance to Trichostrongylus colubriformis and Haemonchus contortus parasites in sheep [see comments] Hohenhaus MA, et al. **Br Vet J** 1995 Mar–Apr;151(2):119–40 (65 ref.) Comment in: Br Vet J 1995 Mar–Apr;151(2):111–3.

Prospects for development of genetic markers for resistance to gastrointestinal parasite infection in sheep. Beh KJ, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):879–97 (149 ref.)

Feasibility and implications of breeding sheep for resilience to nematode challenge. Bisset SA, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):857–68 (38 ref.)

Some relationships between age, immune responsiveness and resistance to parasites in ruminants. Colditz IG, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):869–77 (30 ref.)

Phenotypic markers for selection of nematode-resistant sheep. Douch PG, et al. **Int J Parasitol** 1996 Aug–Sep; 26(8–9):899–911 (44 ref.)

Prospects of breeding small ruminants for resistance to internal parasites. Woolaston RR, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):845–55 (63 ref.)

Immunology: resistance to paratuberculosis. Chiodini RJ. **Vet Clin North Am Food Anim Pract** 1996 Jul;12(2):313–43 (122 ref.)

MICROBIOLOGY

Virulence regions and virulence factors of the ovine footrot pathogen, Dichelobacter nodosus. Billington SJ, et al. **FEMS Microbiol Lett** 1996 Dec 1;145(2):147–56 (36 ref.)

MORTALITY

Selenium-induced "blind staggers" and related myths. A commentary on the extent of historical livestock losses attributed to selenosis on western US rangelands. O'Toole D, et al. **Vet Pathol** 1996 Jan;33(1):109–16 (163 ref.)

PHYSIOPATHOLOGY

[Comparative physiopathology of Oestrus ovis (Linne 1761) myiasis in man and animals] Dorchies P.
Bull Acad Natl Med 1997 Apr;181(4):673–83; discussion 683–4 (28 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Vaccines for bluetongue. Murray PK, et al. **Aust Vet J** 1996 Jun;73(6):207–10 (33 ref.)

Controlling internal parasites in grazing ruminants without recourse to anthelmintics: approaches, experiences and prospects. Niezen JH, et al. **Int J Parasitol** 1996 Aug–Sep; 26(8–9):983–92 (35 ref.)

Control of blowfly strike in sheep: current strategies and future prospects. Tellam RL, et al. **Int J Parasitol** 1997 Mar;27(3):261–73 (99 ref.)

A review of the use of B. melitensis Rev 1 vaccine in adult sheep and goats. Blasco JM. **Prev Vet Med** 1997 Aug; 31(3–4):275–83 (37 ref.)

[Genetic aspects of sheep resistance to gastrointestinal nematode infections] Doligalska M. **Wiad Parazytol** 1995; 41(4):405–11 (42 ref.) (Eng. Abstr.) **(Pol)**

TRANSMISSION

Transmission of paratuberculosis. Sweeney RW.
Vet Clin North Am Food Anim Pract 1996 Jul;12(2):305–12 (35 ref.)

VIROLOGY

Retrovirus-associated neoplasms of the respiratory system of sheep and goats. Ovine pulmonary carcinoma and enzootic nasal tumor. DeMartini JC, et al.
Vet Clin North Am Food Anim Pract 1997 Mar;13(1):55–70 (73 ref.)

SHELLFISH

see related
CLAMS
CRAYFISH
LOBSTERS
MUSSELS
OYSTERS
SHRIMP

Quarantine of aquatic animals in Australia. Doyle KA, et al. **Rev Sci Tech** 1996 Jun;15(2):659–73 (25 ref.)

International trade in live molluscs: perspective from the Americas. Elston RA. **Rev Sci Tech** 1996 Jun;15(2):483–90 (6 ref.)

Preparation and applications of the International Aquatic Animal Health Code and Diagnostic Manual for Aquatic Animal Diseases of the Office International des Epizooties. Håstein T. **Rev Sci Tech** 1996 Jun;15(2):723–31 (4 ref.)

Importation of aquaculture seedlings to Japan. Wakabayashi H. **Rev Sci Tech** 1996 Jun;15(2):409–22 (17 ref.)

[Some examples of introductions and transfers of mollusks] Grizel H. **Rev Sci Tech** 1996 Jun;15(2):401–8 (11 ref.) (Eng. Abstr.) **(Fre)**

[International trade in bivalve mollusks and the current situation in France and in Europe] Le Borgne Y.
Rev Sci Tech 1996 Jun;15(2):491–8 (6 ref.) (Eng. Abstr.) **(Fre)**

[International trade in living penaeid shrimp between countries in the Pacific and the Atlantic areas and in Europe] Michel A. **Rev Sci Tech** 1996 Jun;15(2):499–515 (35 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

[Epidemiology of toxic and infectious risk related to shellfish consumption] Desenclos JC.
Rev Epidemiol Sante Publique 1996 Oct;44(5):437–54 (106 ref.) (Eng. Abstr.) **(Fre)**

POISONING

Health effects associated with algal toxins from seafood. Aune T. **Arch Toxicol Suppl** 1997;19:389–97 (25 ref.)

Poisonings: food, fish, shellfish. Mines D, et al.
Emerg Med Clin North Am 1997 Feb;15(1):157–77 (65 ref.)

First European case of gastroenteritis and bacteremia due to Vibrio hollisae. Gras-Rouzet S, et al.
Eur J Clin Microbiol Infect Dis 1996 Nov;15(11):864–6 (13 ref.)

[Epidemiology of toxic and infectious risk related to shellfish consumption] Desenclos JC.
Rev Epidemiol Sante Publique 1996 Oct;44(5):437–54 (106 ref.) (Eng. Abstr.) **(Fre)**

VIROLOGY

New molecular methods for the detection of hepatitis A and Norwalk viruses in shellfish. Romalde JL. **Microbiologia** 1996 Dec;12(4):547–56 (39 ref.)

SHELTERED WORKSHOPS

see related
EMPLOYMENT, SUPPORTED

SHERMAN ANTITRUST ACT see **ANTITRUST LAWS**

SHIGELLA

see related
DYSENTERY, BACILLARY

DRUG EFFECTS

Antibiotic resistance pattern of Vibrio cholerae and Shigella causing diarrhoea outbreaks in the eastern Africa region: 1994–1996 [see comments] Materu SF, et al.
East Afr Med J 1997 Mar;74(3):193–7 (18 ref.) Comment in: East Afr Med J 1997 Mar;74(3):121–3.

IMMUNOLOGY

Clinical trials of Shigella vaccines in Israel. Cohen D, et al. **Adv Exp Med Biol** 1996;397:159–67 (27 ref.)

Shigellosis: from molecular pathogenesis of infection to protective immunity and vaccine development. Sansonetti P, et al. **Res Immunol** 1996 Oct–Dec;147(8–9):595–602 (61 ref.)

Mucosal immune responses to intestinal bacterial pathogens. Bloom PD, et al. **Semin Gastrointest Dis** 1996 Jul; 7(3):151–66 (125 ref.)

PATHOGENICITY

Invasion and the pathogenesis of Shigella infections. Parsot C, et al. **Curr Top Microbiol Immunol** 1996;209:25–42 (113 ref.)

Shigellosis: from molecular pathogenesis of infection to protective immunity and vaccine development. Sansonetti P, et al. **Res Immunol** 1996 Oct–Dec;147(8–9):595–602 (61 ref.)

[The pathogenicity factors of Shigella studied as the bases for the design of diagnostic and prophylactic preparations] Bondarenko VM. **Zh Mikrobiol Epidemiol Immunobiol** 1996 May–Jun;(3):29–34 (71 ref.) (Eng. Abstr.) **(Rus)**

[Molecular biology in the pathogenesis of Shigella sp. and enteroinvasive Escherichia coli] Rico-Martinez MG.
Rev Latinoam Microbiol 1995 Oct–Dec;37(4):367–85 (125 ref.) (Eng. Abstr.) **(Spa)**

SHIGELLA FLEXNERI

CHEMISTRY

Actin and cell pathogenesis. Higley S, et al.
Curr Opin Cell Biol 1997 Feb;9(1):62–9 (63 ref.)

METABOLISM

Acid stress responses in enterobacteria. Bearson S, et al.
FEMS Microbiol Lett 1997 Feb 15;147(2):173–80 (39 ref.)

PATHOGENICITY

Actin and cell pathogenesis. Higley S, et al.
Curr Opin Cell Biol 1997 Feb;9(1):62–9 (63 ref.)

Bacterial entry into epithelial cells: the paradigm of Shigella. Ménard R, et al. **Trends Microbiol** 1996 Jun;4(6):220–6 (50 ref.)

SHIGELLA INFECTIONS see **DYSENTERY, BACILLARY**

SHIITAKE MUSHROOMS see **POLYPORACEAE**

SHINGLES see **HERPES ZOSTER**

SHIPPING FEVER VIRUS see **PARAMYXOVIRUS**

SHIPS

Maritime medicine. Scott J, et al.
Emerg Med Clin North Am 1997 Feb;15(1):241–9 (10 ref.)

Marine hitch hikers--the transport of pathogens in ballast water. Murrison AW. **J R Nav Med Serv** 1996 Spring; 82(1):40–3 (34 ref.)

SHOCK

COMPLICATIONS

Irreversible shock revisited: mechanical support of the cardiovascular system: a case report and review. Lisagor P, et al. **J Trauma** 1997 Jun;42(6):1182–6 (28 ref.)

Should continuous renal replacement therapy be used for 'non-renal' indications in critically ill patients with shock? van Bommel EF. **Resuscitation** 1997 Jan;33(3):257–70 (124 ref.)

DRUG THERAPY

Use of dopamine in the ICU. Hope, hype, belief and facts. Girbes AR, et al. **Clin Exp Hypertens** 1997 Jan–Feb; 19(1–2):191–9 (20 ref.)

METABOLISM

Oxygen transport and oxygen metabolism in shock and critical illness. Invasive and noninvasive monitoring of circulatory dysfunction and shock. Shoemaker WC.
Crit Care Clin 1996 Oct;12(4):939–69 (55 ref.)

MICROBIOLOGY

Trauma, shock, and gut translocation. Deitch EA, et al.
New Horiz 1996 May;4(2):289–99 (61 ref.)

PHYSIOPATHOLOGY

Platelet activating factor and its role in trauma, shock, and sepsis. Ayala A, et al. **New Horiz** 1996 May;4(2):265–75 (91 ref.)

Cell damage after shock. Barber AE, et al. **New Horiz** 1996 May;4(2):161–7 (62 ref.)

Endothelial changes after shock and injury. Maier RV, et al. **New Horiz** 1996 May;4(2):211–23 (77 ref.)

Shock: ischemia, reperfusion, and inflammation. Waxman K. **New Horiz** 1996 May;4(2):153–60 (69 ref.)

Hypoxic alterations in cellular signal transduction in shock and sepsis. West MA, et al. **New Horiz** 1996 May; 4(2):168–78 (89 ref.)

The pathophysiological role of peroxynitrite in shock, inflammation, and ischemia-reperfusion injury. Szabó C. **Shock** 1996 Aug;6(2):79–88 (162 ref.)

SURGERY

[Shock] Okada M. **Ryoikibetsu Shokogun Shirizu** 1996; (12):67–77 (15 ref.) **(Jpn)**

THERAPY

Hypertonic saline: A review of the literature and evaluation of its role in resuscitation of traumatic hypovolaemic shock. Heath KJ. **J R Army Med Corps** 1994 Feb;140(1):37–41 (29 ref.)

Shock in children: the first 60 minutes. Tobias JD.
Pediatr Ann 1996 Jun;25(6):330–8 (18 ref.)

[Indications and role of albumin for vascular loading in trauma patients and during preoperative period] Sztark F.
Ann Fr Anesth Reanim 1996;15(4):473–80 (34 ref.) (Eng. Abstr.) **(Fre)**

[Small-volume resuscitation for hypovolemic shock. Concept, experimental and clinical results] Kreimeier U, et al. **Anaesthesist** 1997 Apr;46(4):309–28 (124 ref.) (Eng. Abstr.) **(Ger)**

SHOCK

ULTRASONOGRAPHY

Diagnostic and therapeutic implications of transesophageal echocardiography in medical ICU patients with unexplained shock, hypoxemia, or suspected endocarditis. Slama MA, et al. **Intensive Care Med** 1996 Sep;22(9):916–22 (24 ref.)

SHOCK, ANAPHYLACTIC see **ANAPHYLAXIS**

SHOCK, CARDIOGENIC

[Therapy of cardiogenic shock due to myocardial infarction] Nonogi H. **Nippon Naika Gakkai Zasshi** 1996 Jan 10; 85(1):54–9 (5 ref.) **(Jpn)**

[Definition and diagnostic criteria of cardiogenic shock] Okubo S, et al. **Nippon Naika Gakkai Zasshi** 1996 Jan 10; 85(1):4–6 (6 ref.) **(Jpn)**

[Therapeutic countermeasures for cardiogenic shock in the aged] Yano K. **Nippon Naika Gakkai Zasshi** 1996 Jan 10; 85(1):78–81 (5 ref.) **(Jpn)**

[Cardiogenic shock] Motohara S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):91–4 (17 ref.) **(Jpn)**

DIAGNOSIS

[Evaluation of the severity of cardiogenic shock by monitoring of their hemodynamics] Matsuzaki M, et al. **Nippon Naika Gakkai Zasshi** 1996 Jan 10;85(1):27–32 (5 ref.) **(Jpn)**

[Clinical symptoms of cardiogenic shock and important points in evaluating the severity] Saito M. **Nippon Naika Gakkai Zasshi** 1996 Jan 10;85(1):21–6 (10 ref.) **(Jpn)**

[Prognostic evaluation of cardiogenic shock by the severity] Watanabe J, et al. **Nippon Naika Gakkai Zasshi** 1996 Jan 10;85(1):44–7 (6 ref.) **(Jpn)**

[Important points in clinical tests for evaluating the severity of patients with cardiogenic shock] Watanabe Y. **Nippon Naika Gakkai Zasshi** 1996 Jan 10;85(1):33–7 (5 ref.) **(Jpn)**

ETIOLOGY

Survival following cardiogenic shock caused by acute left main coronary artery total occlusion. A case report and review of the literature. Itoh T, et al. **Angiology** 1997 Feb; 48(2):163–71 (33 ref.)

Magnesium deficiency and cardiogenic shock after cardiopulmonary bypass. Storm W, et al. **Ann Thorac Surg** 1997 Aug;64(2):572–7 (60 ref.)

[Cardiogenic shock due to cardiac tamponade] Kinoshita M, et al. **Nippon Naika Gakkai Zasshi** 1996 Jan 10;85(1):73–7 (5 ref.) **(Jpn)**

METABOLISM

Nitric oxide and shock. Kilbourn RG, et al. **Dis Mon** 1997 May;43(5):277–348 (317 ref.)

[Humoral and metabolic changes in cardiogenic shock] Ogawa H, et al. **Nippon Naika Gakkai Zasshi** 1996 Jan 10;85(1):12–5 (5 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Role of vasopressin deficiency in the vasodilation of septic shock [editorial; comment] Reid IA. **Circulation** 1997 Mar 4;95(5):1108–10 (21 ref.) Comment on: Circulation 1997 Mar 4;95(5):1122–5.

Alteraion in diaphragmatic function during cardiac insufficiency: potential pharmacology modulation. Aubier M. **J Mol Cell Cardiol** 1996 Nov;28(11):2293–302 (64 ref.)

[Etiology and physiopathology of cardiogenic shock—mechanism of circulatory regulation and disturbance of the function] Sugimachi M, et al. **Nippon Naika Gakkai Zasshi** 1996 Jan 10;85(1):7–11 (5 ref.) **(Jpn)**

THERAPY

[Uni- or biventricular circulatory assist devices. Selection criteria and patients' follow-up, choice of device] Villemot JP, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89 Spec No 6:55–63 (21 ref.) (Eng. Abstr.) **(Fre)**

[High risk PTCA: prevention and treatment of cardiogenic shock with mechanical assist systems] Figulla HR, et al. **Z Kardiol** 1996;85 Suppl 1:33–7 (12 ref.) (Eng. Abstr.) **(Ger)**

[Therapy of cardiogenic shock due to arrhythmia] Abe H, et al. **Nippon Naika Gakkai Zasshi** 1996 Jan 10;85(1):60–5 (6 ref.) **(Jpn)**

[Emergency treatment of cardiogenic shock] Hasebe N, et al. **Nippon Naika Gakkai Zasshi** 1996 Jan 10;85(1):48–53 (5 ref.) **(Jpn)**

[Acute-phase therapy of cardiogenic shock and severe myocarditis using percutaneous cardiopulmonary support] Izumi T, et al. **Nippon Naika Gakkai Zasshi** 1996 Jan 10; 85(1):66–72 (4 ref.) **(Jpn)**

[Clinical application and management of assisted circulation in the treatment of cardiogenic shock] Kodama K, et al. **Nippon Naika Gakkai Zasshi** 1996 Jan 10;85(1):82–7 (10 ref.) **(Jpn)**

[Reality of emergency treatment of cardiogenic shock] Takano T, et al. **Nippon Naika Gakkai Zasshi** 1996 Jan 10;85(1):16–20 (5 ref.) **(Jpn)**

ULTRASONOGRAPHY

[Important points in diagnostic imaging for evaluation of patients with cardiogenic shock] Kinusaki A, et al. **Nippon Naika Gakkai Zasshi** 1996 Jan 10;85(1):38–43 (5 ref.) **(Jpn)**

SHOCK, ENDOTOXIC see **SHOCK, SEPTIC**

SHOCK, HEMORRHAGIC

CHEMICALLY INDUCED

Hepatic bleeding and hemorrhagic shock following thrombolytic therapy in patients with acute myocardial infarction [letter] Garcia-Jiménez A, et al. **Chest** 1997 Jun; 111(6):1787 (5 ref.)

ETIOLOGY

Hemorrhagic shock and encephalopathy syndrome. An unusual cause of sudden death in children. Little D, et al. **Am J Forensic Med Pathol** 1997 Mar;18(1):79–83 (35 ref.)

PHYSIOPATHOLOGY

Regional blood flow and hemorrhage. How far do the protective mechanisms go? [editorial; comment] Hemmer M. **Intensive Care Med** 1996 Oct;22(10):1006–8 (15 ref.) Comment on: Intensive Care Med 1996 Oct;22(10):1026–33.

[Cardiac contractile dysfunction in response to surgical stress including trauma, hemorrhage, and infection] Suzuki K, et al. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):745–51 (20 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Obtaining arterial access in trauma patients. Sclafani SJ. **J Vasc Interv Radiol** 1997 Jul–Aug;8(4):593–4 (0 ref.)

THERAPY

Hypertonic saline dextran (HSD) and intraosseous vascular access for the treatment of haemorrhagic hypotension in the far-forward combat arena. Dubick MA, et al. **Ann Acad Med Singapore** 1997 Jan;26(1):64–9 (48 ref.)

ACOG educational bulletin. Hemorrhagic shock. Number 235, April 1997 (replaces no. 82, December 1984). American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1997 May;57(2):219–26 (15 ref.)

Hypotensive resuscitation [editorial] [see comments] Dries DJ. **Shock** 1996 Nov;6(5):311–6 (41 ref.) Comment in: Shock 1996 Nov;6(5):317–8.

[Contributions and prospects of hemoglobin derivatives] Remy B, et al. **Schweiz Med Wochenschr** 1997 Jun 21; 127(25):1088–96 (57 ref.) (Eng. Abstr.) **(Fre)**

[Hemorrhagic shock] Marzi I. **Anaesthesist** 1996 Oct; 45(10):976–92 (10 ref.) **(Ger)**

VETERINARY

The effects of hypertonic saline in healthy and diseased animals. Cambier C, et al. **Vet Res Commun** 1997 Jul; 21(5):303–16 (52 ref.)

SHOCK LUNG see **RESPIRATORY DISTRESS SYNDROME, ADULT**

SHOCK, SEPTIC

Septic shock. Carcillo JA, et al. **Crit Care Clin** 1997 Jul; 13(3):553–74 (127 ref.)

The toxic shock syndromes. Stevens DL. **Infect Dis Clin North Am** 1996 Dec;10(4):727–46 (128 ref.)

CLASSIFICATION

[History and definition of sepsis—do we need new terminology?] Kreymann G, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Feb; 31(1):9–14 (18 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Simultaneous presentation of Kawasaki disease and toxic shock syndrome in an adolescent male [see comments] Davies HD, et al. **Pediatr Infect Dis J** 1996 Dec; 15(12):1136–8 (14 ref.) Comment in: Pediatr Infect Dis J 1997 Jun;16(6):633–4.

Nonmenstrual toxic shock syndrome in a young child with human immunodeficiency virus infection. Shah A, et al. **Pediatr Infect Dis J** 1996 Jul;15(7):639–41 (12 ref.)

[A case of toxic shock syndrome (TSS) induced by methicillin-resistant staphylococcus aureus (MRSA) presenting as acute renal failure with disseminated intravascular coagulation] Fukuuchi F, et al. **Nippon Jinzo Gakkai Shi** 1996 Jan;38(1):27–32 (20 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Nitric oxide in critical care medicine. Cuthbertson BH, et al. **Br J Hosp Med** 1995 Dec 13–1996 Jan 16;54(11):579–82 (15 ref.)

Issues in the adjunct therapy of severe sepsis. Verhoef J, et al. **J Antimicrob Chemother** 1996 Aug;38(2):167–82 (90 ref.)

Beneficial versus detrimental effects of nitric oxide synthase inhibitors in circulatory shock: lessons learned from experimental and clinical studies. Kilbourn RG, et al. **Shock** 1997 Apr;7(4):235–46 (119 ref.)

[Inhibition of nitric oxide synthase in septic shock. Therapeutic limits and perspectives] Endres S, et al. **Internist (Berl)** 1997 May;38(5):466–9 (17 ref.) **(Ger)**

ETIOLOGY

Mycobacterial sepsis following intravesical instillation of bacillus Calmette-Guérin. Garyfallou GT. **Acad Emerg Med** 1996 Feb;3(2):157–60 (12 ref.)

Septic shock. Shenep JL. **Adv Pediatr Infect Dis** 1996; 12:209–41 (162 ref.)

Toxic shock syndrome in the burned patient. Edwards-Jones V, et al. **Br J Biomed Sci** 1997 Jun;54(2):110–7 (87 ref.)

Molecules and mechanisms operating in septic shock: lessons from knockout mice. Gutierrez-Ramos JC, et al. **Immunol Today** 1997 Jul;18(7):329–34 (48 ref.)

Septic shock: pathogenesis and treatment [see comments] Bansal T, et al. **J Assoc Physicians India** 1996 Jun; 44(6):407–14 (51 ref.) Comment in: J Assoc Physicians India 1996 Jun;44(6):371–4.

Toxic shock syndrome after explantation of breast implants: a case report and review of the literature. Walker LE, et al. **Plast Reconstr Surg** 1997 Mar;99(3):875–9 (19 ref.)

[Septic shock—a lesson to be learned from treatment trials] Naftali T, et al. **Harefuah** 1996 Dec 1;131(11):498–501 (28 ref.) **(Heb)**

IMMUNOLOGY

The role of macrophages in septic shock. Evans TJ. **Immunobiology** 1996 Oct;195(4–5):655–9 (16 ref.)

Gene knockout mice as investigative tools in pathophysiology. Ryffel B. **Int J Exp Pathol** 1996 Aug; 77(4):125–41 (98 ref.)

[Cytokines and heart diseases. Attempt at an update] Werdan K. **Med Klin** 1997 Jul 15;92(7):432–8 (29 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Nitric oxide and septic shock. Thiemermann C. **Gen Pharmacol** 1997 Aug;29(2):159–66 (55 ref.)

Molecules and mechanisms operating in septic shock: lessons from knockout mice. Gutierrez-Ramos JC, et al. **Immunol Today** 1997 Jul;18(7):329–34 (48 ref.)

Macrophage migration inhibitory factor: a counter-regulator of glucocorticoid action and critical mediator of septic shock. Calandra T, et al. **J Inflamm** 1995–96;47(1-2):39–51 (52 ref.)

MICROBIOLOGY

Pyomyositis with toxic shock syndrome presenting as back pain and fever: a case report and literature review. Wolfe MW, et al. **Am J Orthop** 1997 Feb;26(2):135–7 (26 ref.)

Acute meningococcaemia: recent advances in management (with particular reference to children). Kennedy NJ, et al. **Anaesth Intensive Care** 1996 Apr;24(2):197–216 (184 ref.)

Toxic shock syndrome: role of the environment, the host and the microorganism. Chance TD. **Br J Biomed Sci** 1996 Dec;53(4):284–9 (37 ref.)

Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Stevens DL. **Emerg Infect Dis** 1995 Jul–Sep;1(3):69–78 (80 ref.)

Streptococcal toxic shock syndrome in a postpartum woman. Case report and review of the literature. Jorup-Rönström C, et al. **Infection** 1996 Mar–Apr;24(2):164–7 (68 ref.)

Dengue haemorrhagic fever and the dengue shock syndrome in India. Lall R, et al. **Natl Med J India** 1996 Jan–Feb; 9(1):20–3 (74 ref.)

[The detection of Peptostreptococcus asaccharolyticus and Bacillus cereus in clinical materials from a child who died of sepsis with a fulminant clinical course] Beleva S, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Nov–Dec; (6):16–20 (11 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Pathogenesis and innovative treatment of septic shock. Ognibene FP. **Adv Intern Med** 1997;42:313–38 (89 ref.)

Septic shock. Shenep JL. **Adv Pediatr Infect Dis** 1996; 12:209–41 (162 ref.)

The emerging role of MIF in septic shock and infection. Bernhagen J, et al. **Biotherapy** 1994;8(2):123–7 (35 ref.)

Nitric oxide in critical care medicine. Cuthbertson BH, et al. **Br J Hosp Med** 1995 Dec 13–1996 Jan 16;54(11):579–82 (15 ref.)

The microcirculation during endotoxemia. McCuskey RS, et al. **Cardiovasc Res** 1996 Oct;32(4):752–63 (158 ref.)

Role of vasopressin deficiency in the vasodilation of septic shock [editorial; comment] Reid IA. **Circulation** 1997 Mar 4;95(5):1108–10 (21 ref.) Comment on: Circulation 1997 Mar 4;95(5):1122–5.

Cardiac dysfunction during septic shock. Bunnell E, et al. **Clin Chest Med** 1996 Jun;17(2):237–48 (40 ref.)

Impact of knockout mice in toxicology. Ryffel B. **Crit Rev Toxicol** 1997 Mar;27(2):135–54 (120 ref.)

The inflammatory cytokines. New developments in the pathophysiology and treatment of septic shock. Glauser MP. **Drugs** 1996;52 Suppl 2:9–17 (35 ref.)

Cardiovascular derangement in septic shock and nitric oxide [editorial; comment] Lodato RF. **J Crit Care** 1996 Dec; 11(4):151–4 (21 ref.) Comment on: J Crit Care 1996 Dec;11(4):155–66.
Sepsis and septic shock. Zanetti G, et al. **Schweiz Med Wochenschr** 1997 Mar 22;127(12):489–99 (77 ref.)
[Nitric oxide––a basic mediator of vasodilation and septic shock] Vasilev D, et al. **Khirurgiia (Sofiia)** 1996;49(4):14–6 (35 ref.) (Eng. Abstr.) **(Bul)**
[The pathophysiological and intensive care–resuscitation aspects of septic shock] Vasilev D, et al. **Khirurgiia (Sofiia)** 1996;49(4):9–11 (24 ref.) (Eng. Abstr.) **(Bul)**
[Physiopathology and new treatments of septic shock] Offenstadt G, et al. **Presse Med** 1996 Oct 19;25(31):1459–65 (24 ref.) (Eng. Abstr.) **(Fre)**
[The heart in infection and MODS (multiple organ dysfunction syndrome)] Müller–Werdan U, et al. **Wien Klin Wochenschr Suppl** 1997;1:3–24 (200 ref.) (Eng. Abstr.) **(Ger)**
[Active mediators in the pathogenesis of septic shock and the importance of their neutralization in the treatment of patients] Bojić I. **Vojnosanit Pregl** 1996 Nov–Dec; 53(6):511–8 (42 ref.) **(Scr)**

PREVENTION & CONTROL

[Facts and fancy in intensive care. A good example: septic shock (editorial)] Devictor D. **Arch Pediatr** 1996 Sep; 3(9):841–4 (23 ref.) **(Fre)**

SURGERY

Treatment of thromboembolic complications of fulminant meningococcal septic shock. Mele JA 3rd, et al. **Ann Plast Surg** 1997 Mar;38(3):283–90 (29 ref.)

THERAPY

Pathogenesis and innovative treatment of septic shock. Ognibene FP. **Adv Intern Med** 1997;42:313–38 (89 ref.)
Adjunctive treatment of streptococcal toxic shock syndrome using intravenous immunoglobulin: case report and review. Perez CM, et al. **Am J Med** 1997 Jan;102(1):111–3 (15 ref.)
Septic shock. Baxter F. **Can J Anaesth** 1997 Jan;44(1):59–72 (102 ref.)
New perspectives on the management of septic shock in the cancer patient. Toney JF, et al. **Infect Dis Clin North Am** 1996 Jun;10(2):239–53 (95 ref.)
Anti–inflammatory therapies: application of molecular biology techniques in intensive care medicine. Liu M, et al. **Intensive Care Med** 1997 Jul;23(7):718–31 (127 ref.)
Septic shock: pathogenesis and treatment [see comments] Bansal T, et al. **J Assoc Physicians India** 1996 Jun; 44(6):407–14 (51 ref.) Comment in: J Assoc Physicians India 1996 Jun;44(6):371–4.
[The pathophysiological and intensive care–resuscitation aspects of septic shock] Vasilev D, et al. **Khirurgiia (Sofiia)** 1996;49(4):9–11 (24 ref.) (Eng. Abstr.) **(Bul)**
[Is there a reliable immunotherapy in infection?] Grimminger F, et al. **Internist (Berl)** 1997 Jun;38(6):541–52 (40 ref.) **(Ger)**
[Outcomes research exemplified by infection] Witthaut R, et al. **Internist (Berl)** 1996 Dec;37(12):1249–59 (35 ref.) **(Ger)**
[Active mediators in the pathogenesis of septic shock and the importance of their neutralization in the treatment of patients] Bojić I. **Vojnosanit Pregl** 1996 Nov–Dec; 53(6):511–8 (42 ref.) **(Scr)**

TRANSMISSION

A household cluster of fulminant group A streptococcus pneumonia associated with toxic shock syndrome–Quebec. **Can Commun Dis Rep** 1996 Mar 15;22(6):41–3 (6 ref.)

VETERINARY

The effects of hypertonic saline in healthy and diseased animals. Cambier C, et al. **Vet Res Commun** 1997 Jul; 21(5):303–16 (52 ref.)

SHOCK THERAPY, ELECTRIC see **ELECTROCONVULSIVE THERAPY**

SHOCK, TOXIC see **SHOCK, SEPTIC**

SHOCK, TRAUMATIC

PHYSIOPATHOLOGY

Endothelial changes after shock and injury. Maier RV, et al. **New Horiz** 1996 May;4(2):211–23 (77 ref.)

THERAPY

Initial management of burns [see comments] Monafo WW. **N Engl J Med** 1996 Nov 21;335(21):1581–6 (50 ref.) Comment in: N Engl J Med 1997 May 8;336(19):1392–3; discussion 1393. Comment in: N Engl J Med 1997 May 8;336(19):1393.

SHOCK WAVES, HIGH–ENERGY see **HIGH–ENERGY SHOCK WAVES**

SHOCKWAVES, ULTRASONIC see **ULTRASONICS**

SHOES

Shoes and insoles for patients with rheumatoid foot disease. Grifka JK. **Clin Orthop** 1997 Jul;(340):18–25 (15 ref.)
Footwear and stress fractures. Frey C. **Clin Sports Med** 1997 Apr;16(2):249–57 (31 ref.)
Footwear for children. Staheli LT. **Instr Course Lect** 1994; 43:193–7 (50 ref.)
Educating workers on the need for a firm, safe footing. Johnson LF. **Occup Health Saf** 1997 Jul;66(7):20–7, 36 (0 ref.)
[Possibilities and limits of functional conservative therapy of acute Achilles tendon ruptures] Richter J, et al. **Chirurg** 1997 May;68(5):517–24 (37 ref.) (Eng. Abstr.) **(Ger)**

SHORT BOWEL SYNDROME

Short–bowel syndrome. Stollman NH, et al. **Gastroenterologist** 1996 Jun;4(2):118–28 (62 ref.)
Nutrition in short–bowel syndrome. Ladefoged K, et al. **Scand J Gastroenterol Suppl** 1996;216:122–31 (76 ref.)
[Short bowel syndrome and blind loop syndrome] Hatakeyama K. **Nippon Naika Gakkai Zasshi** 1996 Jul 10; 85(7):1072–8 (5 ref.) **(Jpn)**

COMPLICATIONS

Leuconostoc bacteremia in an infant with short–gut syndrome: case report and literature review. Dhodapkar KM, et al. **Mayo Clin Proc** 1996 Dec;71(12):1171–4 (24 ref.)

METABOLISM

Lipid requirements in infants with digestive diseases with references to short bowel syndrome. Goulet O. **Eur J Med Res** 1997 Feb 21;2(2):79–83 (26 ref.)

PHYSIOPATHOLOGY

Short–bowel syndrome. Medical aspects and prospects of intestinal transplantation. Pirenne J. **Acta Chir Belg** 1996 Jul–Aug;96(4):150–4 (27 ref.)
Can the intestine adapt to a changing environment? [editorial; comment] Thompson JS. **Gastroenterology** 1997 Oct; 113(4):1402–5 (32 ref.) Comment on: Gastroenterology 1997 Oct;113(4):1074–81.
[Short bowel syndrome] Greenberg R, et al. **Harefuah** 1997 May 1;132(9):661–5 (44 ref.) **(Heb)**

SURGERY

Short bowel syndrome: new therapeutic approaches. Wilmore DW, et al. **Curr Probl Surg** 1997 May; 34(5):389–444 (154 ref.)
[Current status of surgical treatment of short bowel syndrome] Selzner M, et al. **Zentralbl Chir** 1996;121(1):1–7 (34 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Can the intestine adapt to a changing environment? [editorial; comment] Thompson JS. **Gastroenterology** 1997 Oct; 113(4):1402–5 (32 ref.) Comment on: Gastroenterology 1997 Oct;113(4):1074–81.
Short–bowel syndrome: an update on the therapeutic approach. Sturm A, et al. **Scand J Gastroenterol** 1997 Apr; 32(4):289–96 (80 ref.)
Advances in the management of patients with intestinal failure. Byrne TA, et al. **Transplant Proc** 1996 Oct; 28(5):2683–90 (81 ref.)
[Pathophysiology, clinical aspects and therapy of short bowel syndrome] Krähenbühl L, et al. **Chirurg** 1997 Jun; 68(6):559–67 (50 ref.) (Eng. Abstr.) **(Ger)**
[Short bowel syndrome] Greenberg R, et al. **Harefuah** 1997 May 1;132(9):661–5 (44 ref.) **(Heb)**

SHORT PR–NORMAL QRS COMPLEX SYNDROME see **LOWN–GANONG–LEVINE SYNDROME**

SHORT RIB–POLYDACTYLY SYNDROME

[Saldino–Noonan syndrome (short rib polydactyly syndrome type I)] Fujisawa K. **Ryoikibetsu Shokogun Shirizu** 1996; (15):297–9 (299 ref.) **(Jpn)**

SHORT–TERM PSYCHOTHERAPY see **PSYCHOTHERAPY, BRIEF**

SHORT WAVES see **RADIO WAVES**

SHOTGUNS see **FIREARMS**

SHOULDER

Calcifying tendinitis. Uhthoff HK. **Ann Chir Gynaecol** 1996; 85(2):111–5 (24 ref.)
Accessory nerve palsy and serratus palsy. Vastamäki M. **Ann Chir Gynaecol** 1996;85(2):167–71 (14 ref.)
Management of common shoulder problems. Binder A. **Br J Hosp Med** 1996 Jul 10–Aug 20;56(2–3):66–72 (22 ref.)
Clinical differential diagnosis of shoulder pain. Turner–Stokes L. **Br J Hosp Med** 1996 Jul 10–Aug 20;56(2–3):73–7 (3 ref.)
The nurse's role in the identification of risks and treatment of shoulder dystocia. Hall SP. **J Obstet Gynecol Neonatal Nurs** 1997 Jan–Feb;26(1):25–32 (25 ref.)
Molecular genetics of facioscapulohumeral muscular dystrophy (FSHD). Fisher J, et al. **Neuromuscul Disord** 1997 Jan;7(1):55–62 (69 ref.)
[Recommendations of the Consensus Conference on Imaging of mechanical and degenerative pathology of a non–operated shoulder] Caroit M, et al. **J Radiol** 1997 Apr; 78(4):321–4 (0 ref.) **(Fre)**
[Shoulder dystocia: the obstetrician's nightmare] Blickstein I. **Harefuah** 1997 Feb 2;132(3):204–11 (50 ref.) **(Heb)**

ANATOMY & HISTOLOGY

Shoulder imaging. A review. Tallroth K. **Ann Chir Gynaecol** 1996;85(2):95–103 (12 ref.)

INJURIES

Rehabilitation of the shoulder. Hawkins R, et al. **Ann Chir Gynaecol** 1996;85(2):173–84 (22 ref.)
Physiotherapy for patients with soft tissue shoulder disorders: a systematic review of randomised clinical trials. van der Heijden GJ, et al. **BMJ** 1997 Jul 5;315(7099):25–30 (45 ref.)
Advances in the understanding of throwing injuries of the shoulder. Hackney RG. **Br J Sports Med** 1996 Dec; 30(4):282–8 (28 ref.)
Shoulder pain in golf. Jobe FW, et al. **Clin Sports Med** 1996 Jan;15(1):55–63 (15 ref.)
Shoulder rehabilitation: clinical application, evaluation, and rehabilitation protocols. Kibler WB, et al. **Instr Course Lect** 1997;46:43–51 (11 ref.)
Consensus conference recommendations regarding imaging studies in degenerative disease of the unoperated shoulder. Caroit M, et al. **Rev Rhum Engl Ed** 1997 Mar;64(3):148–52 (0 ref.)
Rehabilitation of injuries in competitive swimmers. Kenal KA, et al. **Sports Med** 1996 Nov;22(5):337–47 (28 ref.)
Swimming injuries. An overview. McMaster WC. **Sports Med** 1996 Nov;22(5):332–6 (26 ref.)

INNERVATION

Compression neuropathies about the shoulder. Goldberg RS, et al. **Ann Chir Gynaecol** 1996;85(2):159–65 (34 ref.)
[Cystic compression of the suprascapular nerve. Value of imaging. Apropos of 6 cases and review of the literature] Lévy P, et al. **J Radiol** 1997 Feb;78(2):123–30 (35 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

The injured shoulder. Primary care assessment. Howard TM, et al. **Arch Fam Med** 1997 Jul–Aug;6(4):376–84 (23 ref.)

PHYSIOLOGY

Current research on muscle activity about the shoulder. Kelly BT, et al. **Instr Course Lect** 1997;46:53–66 (98 ref.)
Investigation of the validity and reliability of four objective techniques for measuring forward shoulder posture. Peterson DE, et al. **J Orthop Sports Phys Ther** 1997 Jan; 25(1):34–42 (28 ref.)
Dynamics of the upper limb during performance of the tasks of everyday living––a review of the current knowledge base. Buckley MA, et al. **Proc Inst Mech Eng [H]** 1996; 210(4):241–7 (44 ref.)

RADIOGRAPHY

[Clinicoradiologic anatomy of the shoulder region] Schmidt HM, et al. **Radiologe** 1996 Dec;36(12):933–43 (54 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Functional assessment, scoring and data collection for shoulder surgery. Bankes MJ, et al. **Ann Chir Gynaecol** 1996;85(2):186–90 (21 ref.)
Extraarticular pigmented villonodular synovitis of the shoulder: a case report. Sawmiller CJ, et al. **Clin Orthop** 1997 Feb;(335):262–7 (26 ref.)
Radical scapulectomy with limb salvage for shoulder girdle soft tissue sarcoma. Volpe CM, et al. **Surg Oncol** 1996 Feb; 5(1):43–8 (20 ref.)

SHOULDER DISLOCATION

Recurrent anterior shoulder dislocation. A review. Vastamäki M. **Ann Chir Gynaecol** 1996;85(2):133–6 (18 ref.)

COMPLICATIONS

Brachial plexus injury in association with fracture–dislocation of the shoulder. Yip KM, et al. **Bull Hosp Jt Dis** 1996; 55(2):92–4 (8 ref.)

DIAGNOSIS

[Imaging methods in traumatology of the shoulder– and elbow joint] Heyer D. **Aktuelle Radiol** 1996 Sep;6(5):225–31 (50 ref.) (Eng. Abstr.) **(Ger)**

SHOULDER DISLOCATION

[Diagnostic imaging of instability of the shoulder joint] Funke M, et al. **Radiologe** 1996 Dec;36(12):951–9 (59 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

[Arthroscopic therapy of the unstable shoulder joint––acceptance and critical considerations] Jerosch J. **Z Orthop Ihre Grenzgeb** 1997 Jan–Feb;135(1):79–83 (40 ref.) (Eng. Abstr.) **(Ger)**

[Surgical treatment for recurrent dislocation and subluxation of the shoulder joint] Yamamoto R. **Nippon Seikeigeka Gakkai Zasshi** 1997 Feb;71(2):112–24 (30 ref.) **(Jpn)**

THERAPY

Anterior shoulder dislocation reduction technique––revisited. Zahiri CA, et al. **Orthopedics** 1997 Jun;20(6):515–21 (25 ref.)

ULTRASONOGRAPHY

[Ultrasound diagnosis of the shoulder] Helweg G, et al. **Radiologe** 1996 Dec;36(12):971–80 (28 ref.) (Eng. Abstr.) **(Ger)**

SHOULDER FRACTURES

DIAGNOSIS

[Imaging methods in traumatology of the shoulder- and elbow joint] Heyer D. **Aktuelle Radiol** 1996 Sep;6(5):225–31 (50 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Traumatic first rib fracture: is angiography necessary? A review of 730 cases. Gupta A, et al. **Cardiovasc Surg** 1997 Feb;5(1):48–53 (21 ref.)

SURGERY

[Subcapital humerus fracture with lesion of the axillary artery. 2 case reports and review of the literature] Marty B, et al. **Unfallchirurg** 1996 Feb;99(2):154–7 (19 ref.) (Eng. Abstr.) **(Ger)**

["Minimal osteosynthesis"––a new concept in the surgical treatment of humeral head and neck fractures] Volpin G, et al. **Harefuah** 1996 Sep;131(5–6):197–200 (29 ref.) **(Heb)**

SHOULDER-GIRDLE NEUROPATHY see **CERVICO-BRACHIAL NEURALGIA**

SHOULDER-HAND SYNDROME see **REFLEX SYMPATHETIC DYSTROPHY**

SHOULDER IMPINGEMENT SYNDROME

Subacromial shoulder impingement. Björkenheim JM. **Ann Chir Gynaecol** 1996;85(2):105–10 (35 ref.)

Nontraumatic glenohumeral instability and coracoacromial impingement in swimmers. Bak K. **Scand J Med Sci Sports** 1996 Jun;6(3):132–44 (76 ref.)

DIAGNOSIS

Tendon problems in athletic individuals. Teitz CC, et al. **Instr Course Lect** 1997;46:569–82 (76 ref.)

MR imaging of shoulder impingement and rotator cuff disease. Uri DS. **Radiol Clin North Am** 1997 Jan;35(1):77–96 (60 ref.)

[Diagnosis of shoulder impingement syndrome] Hodler J. **Radiologe** 1996 Dec;36(12):944–50 (43 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Local corticosteroid injections in the treatment of rotator cuff tendinitis (except for frozen shoulder and calcific tendinitis). Groupe Rhumatologique Français de l'Epaule (G.R.E.P.). Goupille P, et al. **Clin Exp Rheumatol** 1996 Sep–Oct;14(5):561–6 (41 ref.)

SURGERY

Arthroscopic treatment of rotator cuff disorders. Peterson CA 2nd, et al. **Clin Sports Med** 1996 Oct;15(4):715–36 (78 ref.)

Arthroscopic acromioplasty. Current status. Altchek DW, et al. **Orthop Clin North Am** 1997 Apr;28(2):157–68 (40 ref.)

ULTRASONOGRAPHY

[Ultrasound diagnosis of the shoulder] Helweg G, et al. **Radiologe** 1996 Dec;36(12):971–80 (28 ref.) (Eng. Abstr.) **(Ger)**

SHOULDER JOINT

The future of shoulder arthroscopy. Ellman H. **Ann Chir Gynaecol** 1996;85(2):150–5 (5 ref.)

Frozen shoulder: unravelling the enigma. Bunker TD. **Ann R Coll Surg Engl** 1997 May;79(3):210–3 (22 ref.)

Management of common shoulder problems. Binder A. **Br J Hosp Med** 1996 Jul 10–Aug 20;56(2–3):66–72 (22 ref.)

Clinical differential diagnosis of shoulder pain. Turner-Stokes L. **Br J Hosp Med** 1996 Jul 10–Aug 20;56(2–3):73–7 (3 ref.)

Shoulder arthroscopy. New concepts. Burkhart SS. **Clin Sports Med** 1996 Oct;15(4):635–53 (106 ref.)

Rehabilitation of neck/shoulder patients in primary health care clinics. Jordan A, et al. **J Manipulative Physiol Ther** 1996 Jan;19(1):32–5 (43 ref.)

Implementation of neck/shoulder rehabilitation in primary health care clinics. Jordan A, et al. **J Manipulative Physiol Ther** 1996 Jan;19(1):36–40 (25 ref.)

Shoulder pain in the work place. Curtis AS, et al. **Orthop Clin North Am** 1996 Oct;27(4):763–81 (42 ref.)

Common disorders of the shoulder. Belzer JP, et al. **Prim Care** 1996 Jun;23(2):365–88 (26 ref.)

Tumoral calcinosis in hemodialysis patients. A review of three cases. Franco M, et al. **Rev Rhum Engl Ed** 1997 Jan; 64(1):59–62 (19 ref.)

Imaging of bursae around the shoulder joint. Bureau NJ, et al. **Skeletal Radiol** 1996 Aug;25(6):513–7 (16 ref.)

[Recommendations of the Consensus Conference on Imaging of mechanical and degenerative pathology of a non-operated shoulder] Caroit M, et al. **J Radiol** 1997 Apr; 78(4):321–4 (0 ref.) **(Fre)**

[Arthroscopic aspects and chronologic outcome of lesions of the labro-ligament complex in post-traumatic antero-inferior instability of the shoulder. A prospective study of 91 cases] Gleyze P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(4):288–98 (46 ref.) (Eng. Abstr.) **(Fre)**

[Synovial cyst of the supracapsular notch of the shoulder with supracapsular nerve compression in a sportsman. Apropos of a case. Review of the literature] Rochwerger A, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996; 82(4):344–7 (12 ref.) (Eng. Abstr.) **(Fre)**

[Imaging techniques for the shoulder] Ovadia D, et al. **Harefuah** 1997 Mar 16;132(6):431–5 (21 ref.) **(Heb)**

[Localized pigmented villonodular synovitis of the biceps tendon: ultrasonographic study. Report of a case and review of the literature] Chiodi E, et al. **Radiol Med (Torino)** 1996 Jul–Aug;92(1–2):128–9 (10 ref.) **(Ita)**

ANATOMY & HISTOLOGY

Shoulder imaging. A review. Tallroth K. **Ann Chir Gynaecol** 1996;85(2):95–103 (12 ref.)

Magnetic resonance imaging of the musculoskeletal system. Part 6. The Shoulder. Oxner KG. **Clin Orthop** 1997 Jan; (334):354–73 (78 ref.)

The physical examination of the glenohumeral joint: emphasis on the stabilizing structures. Wilk KE, et al. **J Orthop Sports Phys Ther** 1997 Jun;25(6):380–9 (42 ref.)

Current concepts: the stabilizing structures of the glenohumeral joint. Wilk KE, et al. **J Orthop Sports Phys Ther** 1997 Jun;25(6):364–79 (119 ref.)

Biomechanics and design of shoulder arthroplasty. McCullagh PJ. **Proc Inst Mech Eng [H]** 1995;209(4):207–13 (23 ref.)

MR arthrography of the glenohumeral joint. Stoller DW. **Radiol Clin North Am** 1997 Jan;35(1):97–116 (47 ref.)

MR arthrography of the rotator cuff and labral-ligamentous complex. Palmer WE. **Semin Ultrasound CT MR** 1997 Aug; 18(4):278–90 (19 ref.)

[Fundamentals, possibilities and limitations of sonography of osteofibrous tunnels in the shoulder area. 1] Moriggl B. **Anat Anz** 1997 Aug;179(4):355–73 (119 ref.) (Eng. Abstr.) **(Ger)**

INJURIES

Rehabilitation of the shoulder. Hawkins R, et al. **Ann Chir Gynaecol** 1996;85(2):173–84 (22 ref.)

The injured shoulder. Primary care assessment. Howard TM, et al. **Arch Fam Med** 1997 Jul–Aug;6(4):376–84 (23 ref.)

Rehabilitation of the athlete after shoulder arthroscopy. Buuck DA, et al. **Clin Sports Med** 1996 Oct;15(4):655–72 (29 ref.)

Shoulder arthroscopy in the throwing athlete. Craig EV. **Clin Sports Med** 1996 Oct;15(4):673–700 (13 ref.)

Arthroscopic decompression of the shoulder in athletes. Kolowich PA. **Clin Sports Med** 1996 Oct;15(4):701–13 (44 ref.)

Floating clavicle––simultaneous dislocation of both ends of the clavicle. Eni-Olotu DO, et al. **Injury** 1997 May; 28(4):319–20 (4 ref.)

Pathophysiologic alterations in shoulder injury. Kibler WB, et al. **Instr Course Lect** 1997;46:3–6 (30 ref.)

[Assessment of shoulder pain in athletes] Biasca N, et al. **Schweiz Rundsch Med Prax** 1996 Sep 10;85(37):1123–35 (27 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Magnetic resonance imaging of the musculoskeletal system. Part 6. The Shoulder. Oxner KG. **Clin Orthop** 1997 Jan; (334):354–73 (78 ref.)

Magnetic resonance imaging studies of the shoulder: diagnosis of lesions of the rotator cuff. Recht MP, et al. **Instr Course Lect** 1994;43:483–92 (50 ref.)

MR imaging of shoulder impingement and rotator cuff disease. Uri DS. **Radiol Clin North Am** 1997 Jan;35(1):77–96 (60 ref.)

PHYSIOLOGY

Normal shoulder mechanics and function. Kibler WB. **Instr Course Lect** 1997;46:39–42 (45 ref.)

The influence of the mobility in the cervicothoracic spine and the upper ribs (shoulder girdle) on the mobility of the scapulohumeral joint. Sobel JS, et al. **J Manipulative Physiol Ther** 1996 Sep;19(7):469–74 (16 ref.)

Biomechanical investigation of the glenohumeral joint. Itoi E, et al. **J Shoulder Elbow Surg** 1996 Sep–Oct;5(5):407–24 (122 ref.)

Special considerations in the athletic throwing shoulder. Arroyo JS, et al. **Orthop Clin North Am** 1997 Jan; 28(1):69–78 (72 ref.)

Biomechanics and design of shoulder arthroplasty. McCullagh PJ. **Proc Inst Mech Eng [H]** 1995;209(4):207–13 (23 ref.)

PHYSIOPATHOLOGY

Measurement of isometric elbow and shoulder moments: position-dependent strength of posterior deltoid-to-triceps muscle tendon transfer in tetraplegia. Kirsch RF, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):403–9 (10 ref.)

Evaluation of shoulder laxity. McFarland EG, et al. **Sports Med** 1996 Oct;22(4):264–72 (38 ref.)

RADIOGRAPHY

[Clinicoradiologic anatomy of the shoulder region] Schmidt HM, et al. **Radiologe** 1996 Dec;36(12):933–43 (54 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Functional assessment, scoring and data collection for shoulder surgery. Bankes MJ, et al. **Ann Chir Gynaecol** 1996;85(2):186–90 (21 ref.)

Rehabilitation of the athlete after shoulder arthroscopy. Buuck DA, et al. **Clin Sports Med** 1996 Oct;15(4):655–72 (29 ref.)

Arthroscopic decompression of the shoulder in athletes. Kolowich PA. **Clin Sports Med** 1996 Oct;15(4):701–13 (44 ref.)

Arthroscopic Bankart repair. Shea KP. **Clin Sports Med** 1996 Oct;15(4):737–51 (37 ref.)

Complications of humeral head replacement for proximal humeral fractures. Muldoon MP, et al. **Instr Course Lect** 1997;46:15–24 (40 ref.)

The role of shoulder fusion in the era of arthroplasty. González-Díaz R, et al. **Int Orthop** 1997;21(3):204–9 (25 ref.)

Total shoulder arthroplasty. James WC 3rd, et al. **J S C Med Assoc** 1996 Oct;92(10):426–31 (15 ref.)

Indications for glenoid resurfacing in shoulder arthroplasty. Rodosky MW, et al. **J Shoulder Elbow Surg** 1996 May–Jun; 5(3):231–48 (107 ref.)

[Shoulder arthrodesis in deltoid paralysis] Kohn D, et al. **Orthopade** 1997 Jul;26(7):630–3 (21 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Sonography of tendons: patterns of disease. van Holsbeeck M, et al. **Instr Course Lect** 1994;43:475–81 (20 ref.)

SHRIMP

Current status of trade in cultured shrimps. Chen SN. **Rev Sci Tech** 1996 Jun;15(2):517–21 (8 ref.)

[International trade in living penaeid shrimp between countries in the Pacific and the Atlantic areas and in Europe] Michel A. **Rev Sci Tech** 1996 Jun;15(2):499–515 (35 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Arthropod evolution: Brine shrimp add salt to the stew. Williams TA, et al. **Curr Biol** 1995 Dec 1;5(12):1330–3 (18 ref.)

VIROLOGY

Viral pathogens of the penaeid shrimp. Loh PC, et al. **Adv Virus Res** 1997;48:263–312 (150 ref.)

Epizootiology, distribution and the impact on international trade of two penaeid shrimp viruses in the Americas. Lightner DV. **Rev Sci Tech** 1996 Jun;15(2):579–601 (80 ref.)

SHUT-INS see **HOMEBOUND PERSONS**

SHUTTLE VECTORS see **GENETIC VECTORS**

SHY-DRAGER SYNDROME

[Shy-Drager syndrome and multiple system atrophy] Shinotoh H, et al. **Nippon Rinsho** 1997 Jan;55(1):131–4 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Shy-Drager syndrome] Nakamura Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):13–6 (8 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Consensus statement on the definition of orthostatic

hypotension, pure autonomic failure and multiple system atrophy. Kaufmann H. **Clin Auton Res** 1996 Apr;6(2):125–6 (1 ref.)
Gastrointestinal dysfunction in multiple system atrophy. Mathias CJ. **Semin Neurol** 1996 Sep;16(3):251–8 (44 ref.)

SHY–MAGEE SYNDROME see **NEMALINE MYOPATHY**

SH1 DOMAIN see **SRC HOMOLOGY DOMAINS**

SH2 DOMAIN see **SRC HOMOLOGY DOMAINS**

SH3 DOMAIN see **SRC HOMOLOGY DOMAINS**

SIADH see **INAPPROPRIATE ADH SYNDROME**

SIALADENITIS

CLASSIFICATION

Aetiological and histological classification of sialadenitis [editorial] Seifert G. **Pathologica** 1997 Feb;89(1):7–17 (113 ref.)

PATHOLOGY

Lymphoid infiltrates of the salivary glands: pathology, biology and clinical significance. DiGiuseppe JA, et al. **Curr Opin Oncol** 1996 May;8(3):232–7 (36 ref.)

SIALIC ACID see **N–ACETYLNEURAMINIC ACID**

SIALIC ACIDS

[Recent advances in glycobiology on KDN–containing glycoconjugates] Kitajima K, et al. **Seikagaku** 1997 Jan; 69(1):44–51 (33 ref.) **(Jpn)**

BIOSYNTHESIS

Coating the surface: a model for expression of capsular polysialic acid in Escherichia coli K1. Bliss JM, et al. **Mol Microbiol** 1996 Jul;21(2):221–31 (68 ref.)

CHEMISTRY

Sialic acids
structure–analysis–metabolism–occurrence–recognition.
Reuter G, et al. **Biol Chem Hoppe Seyler** 1996 Jun; 377(6):325–42 (315 ref.)

METABOLISM

Sialic acids
structure–analysis–metabolism–occurrence–recognition.
Reuter G, et al. **Biol Chem Hoppe Seyler** 1996 Jun; 377(6):325–42 (315 ref.)
Polysialic acid and the regulation of cell interactions. Rutishauser U. **Curr Opin Cell Biol** 1996 Oct;8(5):679–84 (46 ref.)
Sialic acids as ligands in recognition phenomena. Varki A. **FASEB J** 1997 Mar;11(4):248–55 (100 ref.)
Sialic acid––marker of development and differentiation. Kraml J, et al. **Sb Lek** 1994;95(4):271–75 (33 ref.)

PHYSIOLOGY

The role of polysialic acid and other carbohydrate polymers in neural structural plasticity. Fryer HJ, et al.
Curr Opin Neurobiol 1996 Feb;6(1):113–8 (49 ref.)
Role of polysialic acid in peripheral myelinated axons. Carratù MR, et al. **Microsc Res Tech** 1996 Aug 15; 34(6):489–91 (13 ref.)
Polysialic acid in the vertebrate nervous system: a promoter of plasticity in cell–cell interactions. Rutishauser U, et al. **Trends Neurosci** 1996 Oct;19(10):422–7 (63 ref.)
[Expression and function of neural cell adhesion molecule (NCAM) and its polysialic acid moiety in the nervous system] Oka S, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):535–41 (50 ref.) **(Jpn)**

SIALIDASE see **NEURAMINIDASE**

SIALOGLYCOPEPTIDES see **SIALOGLYCOPROTEINS**

SIALOGLYCOPROTEINS

ANALYSIS

Expression of bone matrix proteins in human breast cancer: potential roles in microcalcification formation and in the genesis of bone metastases. Bellahcène A, et al.
Bull Cancer 1997 Jan;84(1):17–24 (60 ref.)

BIOSYNTHESIS

Induction of interleukin–1 and interleukin–1 receptor antagonist. Dinarello CA. **Semin Oncol** 1997 Jun;24(3 Suppl 9):S9–81–S9–93 (117 ref.)

CHEMISTRY

Extracellular matrix proteins of dentine. Butler WT, et al. **Ciba Found Symp** 1997;205:107–15; discussion 115–7 (28 ref.)
Bone sialoprotein––a mucin in disguise? Midura RJ, et al. **Glycobiology** 1996 Oct;6(7):677–81 (30 ref.)

CLASSIFICATION

Chemokines: what chemokine is that? Mackay CR. **Curr Biol** 1997 Jun 1;7(6):R384–6 (14 ref.)

IMMUNOLOGY

The immunology of Eta–1/osteopontin. Weber GF, et al. **Cytokine Growth Factor Rev** 1996 Oct;7(3):241–8 (50 ref.)
Interaction between CD44 and osteopontin as a potential basis for metastasis formation. Weber GF, et al.
Proc Assoc Am Physicians 1997 Jan;109(1):1–9 (67 ref.)

METABOLISM

Interleukin–1 and interleukin–1 receptor antagonist in inflammatory bowel disease. Cominelli F, et al.
Aliment Pharmacol Ther 1996;10 Suppl 2:49–53; discussion 54 (39 ref.)
Osteopontin: an interfacial extracellular matrix protein in mineralized tissues. McKee MD, et al.
Connect Tissue Res 1996;35(1–4):197–205 (30 ref.)

PHARMACOLOGY

Interleukin–1 receptor antagonism. Nikolic–Paterson DJ, et al. **Semin Nephrol** 1996 Nov;16(6):583–90 (38 ref.)

SECRETION

The immunology of Eta–1/osteopontin. Weber GF, et al. **Cytokine Growth Factor Rev** 1996 Oct;7(3):241–8 (50 ref.)

SIALOLITHIASIS see **SALIVARY GLAND CALCULI**

SIALOMETAPLASIA, NECROTIZING

DIAGNOSIS

[Necrotizing sialometaplasia: apropos of a case and review of the literature] De Saint Aubain Somerhausen N, et al. **Acta Stomatol Belg** 1996 Jun;93(2):61–3 (13 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

[Necrotizing sialometaplasia. The clinico–pathological analysis of 6 cases] Favia G, et al. **Minerva Stomatol** 1996 Mar;45(3):121–7 (23 ref.) (Eng. Abstr.) **(Ita)**

SIALOPROTEINS see **SIALOGLYCOPROTEINS**

SIALYL SSEA–1 see **ANTIGENS, CD15**

SIALYLTRANSFERASES

Molecular cloning and functional analysis of sialyltransferases. Tsuji S. **J Biochem (Tokyo)** 1996 Jul; 120(1):1–13 (80 ref.)

METABOLISM

Neisseria sialytransferases and their role in pathogenesis. Rest RF, et al. **Microb Pathog** 1995 Dec;19(6):379–90 (66 ref.)

SIBLING RELATIONS

The more the merrier? Effects of family size and sibling spacing on sibling relationships. Newman J.
Child Care Health Dev 1996 Sep;22(5):285–302 (70 ref.)
Sibling rivalry in the 1990s. Renshaw DC. **Compr Ther** 1996 Jul;22(7):415–9 (11 ref.)
Sibling sex ratio of boys with gender identity disorder. Zucker KJ, et al. **J Child Psychol Psychiatry** 1997 Jul; 38(5):543–51 (131 ref.)
[Research on siblings of mentally ill and retarded persons. Review of literature] Namysłowska I. **Psychiatr Pol** 1996 Nov–Dec;30(6):907–18 (29 ref.) (Eng. Abstr.) **(Pol)**

SICCA SYNDROME see **SJOGREN'S SYNDROME**

SICK BUILDING SYNDROME

Sick–building syndrome [see comments] Redlich CA, et al. **Lancet** 1997 Apr 5;349(9057):1013–6 (24 ref.) Comment in: Lancet 1997 Jun 28;349(9069):1913.

DIAGNOSIS

Building–related illness and sick building syndrome: from the specific to the vague. Horvath EP. **Cleve Clin J Med** 1997 Jun;64(6):303–9 (36 ref.)

ETIOLOGY

[Sanitary impact of air conditioning: what is the relation to sick building syndrome?] Vincent D, et al.
Rev Med Interne 1997;18(6):460–9 (37 ref.) (Eng. Abstr.) **(Fre)**

[Sick building syndrome] Brede–Weisflog B.
Versicherungsmedizin 1996 Oct 1;48(5):170–4 (17 ref.) (Eng. Abstr.) **(Ger)**

NURSING

Indoor air pollutants and sick building syndrome: a case study and implications for the community health nurse. Tsacoyianis R. **Public Health Nurs** 1997 Feb;14(1):58–75 (19 ref.)

PSYCHOLOGY

Sick building syndrome, work factors and occupational stress. Crawford JO, et al. **Scand J Work Environ Health** 1996 Aug;22(4):243–50 (71 ref.)

THERAPY

Building–related illness and sick building syndrome: from the specific to the vague. Horvath EP. **Cleve Clin J Med** 1997 Jun;64(6):303–9 (36 ref.)

SICK ROLE

Assisted suicide and euthanasia: what about the clinical issues? [see comments] Kelly BJ, et al.
Aust N Z J Psychiatry 1996 Feb;30(1):3–8 (34 ref.) Comment in: Aust N Z J Psychiatry 1996 Aug;30(4):557–8.
Psychiatric manifestations of multiple sclerosis: a review [see comments] Rodgers J, et al. **Can J Psychiatry** 1996 Sep; 41(7):441–5 (41 ref.) Comment in: Can J Psychiatry 1997 Apr;42(3):324–5.
Posttraumatic stress symptoms and medical procedures in children. Wintgens A, et al. **Can J Psychiatry** 1997 Aug; 42(6):611–6 (44 ref.)
General principles in child liaison consultation service: a literature review. Ortiz P. **Eur Child Adolesc Psychiatry** 1997 Mar;6(1):1–6 (46 ref.)
Adult adjustment to chronic illness: a review of the literature. Sidell NL. **Health Soc Work** 1997 Feb;22(1):5–11 (45 ref.)
The biopsychosocial disease consequence model in rehabilitation: model development in the Finnish 'work hardening' programme for chronic pain. Talo S, et al.
Int J Rehabil Res 1996 Jun;19(2):93–109 (35 ref.)
Assessment of quality of life: preservation of the self. Ronch JL. **Int Psychogeriatr** 1996 Summer;8(2):267–75 (35 ref.)
Illness behaviour, personality traits, anxiety, and depression in patients with Menière's disease. Savastano M, et al.
J Otolaryngol 1996 Oct;25(5):329–33 (12 ref.)
A child with chronic illness and the process of family adaptation. Clawson JA. **J Pediatr Nurs** 1996 Feb; 11(1):52–61 (37 ref.)
Construing benefits from adversity: adaptational significance and dispositional underpinnings. Affleck G, et al.
J Pers 1996 Dec;64(4):899–922 (85 ref.)
Patient adherence in chronic illness: personality and coping in context. Wiebe JS, et al. **J Pers** 1996 Dec;64(4):815–35 (95 ref.)
The impact of dementia on the sufferer and available treatment interventions: an overview. Midence K, et al.
J Psychol 1996 Nov;130(6):589–602 (70 ref.)
Depression in Parkinson's disease. Murray JB. **J Psychol** 1996 Nov;130(6):659–67 (52 ref.)
Reappraising reassurance––the role of investigations [editorial] Howard LM, et al. **J Psychosom Res** 1996 Oct; 41(4):307–11 (26 ref.)
How are alexithymia and physical illness linked? A review and critique of pathways. Lumley MA, et al.
J Psychosom Res 1996 Dec;41(6):505–18 (101 ref.)
Psychosocial factors and physical illness in primary care: promoting the biopsychosocial model in medical practice [editorial] Zimmermann C, et al. **J Psychosom Res** 1996 Apr;40(4):351–8 (60 ref.)
Fibromyalgia, chronic fatigue, and other iatrogenic diagnostic algorithms. Do some labels escalate illness in vulnerable patients? Hadler NM. **Postgrad Med** 1997 Aug; 102(2):161–2, 165–6, 171–2 passim (46 ref.)
Advances in comprehensive pain management. Koenig TW, et al. **Psychiatr Clin North Am** 1996 Sep;19(3):589–611 (165 ref.)
Use of stimulants in the medically ill. Masand PS, et al.
Psychiatr Clin North Am 1996 Sep;19(3):515–47 (129 ref.)
Psychiatric aspects of rheumatology. Moran MG.
Psychiatr Clin North Am 1996 Sep;19(3):575–87 (53 ref.)
Psychiatric interventions in the medically ill. Outcome and effectiveness research. Saravay SM.
Psychiatr Clin North Am 1996 Sep;19(3):467–80 (66 ref.)
Psychiatric aspects of cardiovascular disease. Shapiro PA.
Psychiatr Clin North Am 1996 Sep;19(3):613–29 (70 ref.)
Chronic fatigue syndrome. Sharpe M.
Psychiatr Clin North Am 1996 Sep;19(3):549–73 (122 ref.)
New antidepressant drugs and the treatment of depression in the medically ill patient. Stoudemire A.
Psychiatr Clin North Am 1996 Sep;19(3):495–514 (85 ref.)
Psychiatric sequelae in seriously ill children and their families. Stuber ML. **Psychiatr Clin North Am** 1996 Sep; 19(3):481–93 (71 ref.)
Fear of cancer recurrence––a literature review and proposed cognitive formulation to explain exacerbation of recurrence fears. Lee–Jones C, et al. **Psychooncology** 1997 Jun; 6(2):95–105 (41 ref.)
Quality of life: a dynamic construct. Allison PJ, et al.
Soc Sci Med 1997 Jul;45(2):221–30 (60 ref.)
Sex differences in physical symptoms: the contribution of symptom perception theory. van Wijk CM, et al.
Soc Sci Med 1997 Jul;45(2):231–46 (100 ref.)
[Medical consultation with curable cancer patients] de Maddalena H. **HNO** 1996 Nov;44(11):645–54 (17 ref.) **(Ger)**

SICK ROLE

[Research in psychosocial aspects of ENT tumor surgery (excluding laryngectomy): 4-part analysis of the literature. 3: Results of research] Kollbrunner J, et al. **HNO** 1997 Jul;45(7):523-32 (0 ref.) (Eng. Abstr.) **(Ger)**

[Family-oriented management of children and adolescents with cancer] Häberle H, et al. **Prax Kinderpsychol Kinderpsychiatr** 1997 Jul-Aug; 46(6):405-19 (50 ref.) (Eng. Abstr.) **(Ger)**

[Psychological aspects of severe burn injuries in childhood and adolescence] Landolt M. **Prax Kinderpsychol Kinderpsychiatr** 1996 Feb;45(2):47-56 (125 ref.) (Eng. Abstr.) **(Ger)**

[Health related quality of life and subjective health. Overview of the status of research for new evaluation criteria in medicine] Bullinger M. **Psychother Psychosom Med Psychol** 1997 Mar-Apr; 47(3-4):76-91 (165 ref.) (Eng. Abstr.) **(Ger)**

[Do psychological factors modify survival of cancer patients? I: Review of the literature] Faller H. **Psychother Psychosom Med Psychol** 1997 May;47(5):163-9 (65 ref.) (Eng. Abstr.) **(Ger)**

[Personal values and goal orientations of chronically ill adolescents and young adults] Schmitt GM. **Psychother Psychosom Med Psychol** 1997 Jun;47(6):189-97 (80 ref.) (Eng. Abstr.) **(Ger)**

[The Bern Coping Forms BEFO--an instrument for self- and observer rating of coping with illness] Heim E, et al. **Rehabilitation (Stuttg)** 1996 Nov;35(4):XXXI-XLI (60 ref.) (Eng. Abstr.) **(Ger)**

[The physically ill patient needs psychotherapy] Barolin GS. **Wien Med Wochenschr** 1996;146(12):245-52 (19 ref.) (Eng. Abstr.) **(Ger)**

[Patient education--support--help with decisions: ethical aspects in treatment of amyotrophic lateral sclerosis] Meran JG, et al. **Wien Med Wochenschr** 1996;146(9-10):190-4 (21 ref.) (Eng. Abstr.) **(Ger)**

[Clinical dimensions of contemporary cultural psychiatry] Alarcón RD. **Acta Psiquiatr Psicol Am Lat** 1995 Dec; 41(4):265-74 (73 ref.) (Eng. Abstr.) **(Spa)**

SICK SINUS SYNDROME

[Sick sinus syndrome] Hiejima K. **Ryoikibetsu Shokogun Shirizu** 1996;(12):411-5 (10 ref.) **(Jpn)**

[Sinus pause, sinus arrest] Wakatsuki T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):407-10 (11 ref.) **(Jpn)**

COMPLICATIONS

Sick sinus syndrome in association with malignant lymphoma [letter] Suzuki T, et al. **Eur Heart J** 1996 Jun;17(6):968 (5 ref.)

ETIOLOGY

Hyperthyroidism complicated with sick sinus syndrome. Namura M, et al. **Jpn Circ J** 1995 Dec;59(12):824-8 (22 ref.)

PHYSIOPATHOLOGY

[Atrioventricular junctional rhythm] Sekiguchi A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):505-8 (4 ref.) **(Jpn)**

THERAPY

Advances in pacing for the patient with sick sinus syndrome. Alagona P Jr. **Curr Opin Cardiol** 1997 Jan;12(1):3-11 (114 ref.)

SICKLE CELL HEMOGLOBIN C DISEASE see **HEMOGLOBIN SC DISEASE**

SICKLE CELL TRAIT

COMPLICATIONS

[Prevention and treatment of erectile disorders in sickle cell disease] Bachir D, et al. **Rev Med Interne** 1997;18 Suppl 1:46s-51s (17 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Sudden exertional death in a soldier with sickle cell trait. Murray MJ, et al. **Mil Med** 1996 May;161(5):303-5 (18 ref.)

SICKNESS IMPACT PROFILE

Assessing the responsiveness of a functional status measure: the Sickness Impact Profile versus the SIP68. de Bruin AF, et al. **J Clin Epidemiol** 1997 May;50(5):529-40 (38 ref.)

SIDEROPHILIN see **TRANSFERRIN**

SIDEROPHORES

PHYSIOLOGY

Fungal siderophores in plant-microbe interactions. Riquelme M. **Microbiologia** 1996 Dec;12(4):537-46 (60 ref.)

SIDEROSIS

see related
HEMOSIDEROSIS

DIAGNOSIS

Superficial siderosis of the central nervous system: MRI findings and clinical significance. Offenbacher H, et al. **Neuroradiology** 1996 May;38 Suppl 1:S51-6 (20 ref.)

PATHOLOGY

Intra-alveolar pulmonary siderophages in sudden infant death: a marker for previous imposed suffocation. Becroft DM, et al. **Pathology** 1997 Feb;29(1):60-3 (19 ref.)

SIDS see **SUDDEN INFANT DEATH**

SIGA see **IGA, SECRETORY**

SIGMA ELEMENT see **SIGMA FACTOR**

SIGMA FACTOR

CHEMISTRY

Identification of a prime suspect. Buc H. **Curr Biol** 1997 Feb 1;7(2):R97-9 (13 ref.)

Sigma domain structure: one down, one to go. Chan CL, et al. **Structure** 1996 Nov 15;4(11):1235-8 (34 ref.)

GENETICS

Role of Escherichia coli rpoS and associated genes in defense against oxidative damage. Eisenstark A, et al. **Free Radic Biol Med** 1996;21(7):975-93 (130 ref.)

RNA polymerase sigma factors and cell-specific gene transcription in a simple developing organism. Losick R. **Harvey Lect** 1994-95;90:1-17 (44 ref.)

ISOLATION & PURIFICATION

Purification of overproduced Escherichia coli RNA polymerase sigma factors by solubilizing inclusion bodies and refolding from Sarkosyl. Burgess RR. **Methods Enzymol** 1996;273:145-9 (7 ref.)

Sigma factors: purification and DNA binding. Dombroski AJ. **Methods Enzymol** 1996;273:134-44 (25 ref.)

RNA polymerase sigma factors of Bacillus subtilis: purification and characterization. Tatti KM, et al. **Methods Enzymol** 1996;273:149-62 (20 ref.)

METABOLISM

Identification of a prime suspect. Buc H. **Curr Biol** 1997 Feb 1;7(2):R97-9 (13 ref.)

Back to log phase: sigma S as a global regulator in the osmotic control of gene expression in Escherichia coli. Hengge-Aronis R. **Mol Microbiol** 1996 Sep;21(5):887-93 (65 ref.)

Role of alternate sigma factors in starvation protein synthesis--novel mechanisms of catabolite repression. Matin A. **Res Microbiol** 1996 Jul-Sep;147(6-7):494-505 (73 ref.)

[Regulation of the phosphorelay at the initiation of sporulation and activation of sporulation-specific sigma factors in Bacillus subtilis] Tochikubo K, et al. **Nippon Saikingaku Zasshi** 1996 Aug;51(3):789-801 (73 ref.) **(Jpn)**

PHYSIOLOGY

Regulation and conservation of the heat-shock transcription factor sigma32. Yura T. **Genes Cells** 1996 Mar;1(3):277-84 (50 ref.)

SIGMA INITIATION FACTOR see **SIGMA FACTOR**

SIGMA RECEPTORS see **RECEPTORS, SIGMA**

SIGMA SUBUNIT see **SIGMA FACTOR**

SIGMODON see **HESPEROMYINAE**

SIGMOID

see related
SIGMOIDOSCOPY

Laparoscopic closure for perforation of the sigmoid colon by endoscopic linear stapler. Hayashi K, et al. **Surg Laparosc Endosc** 1996 Oct;6(5):411-3 (13 ref.)

INJURIES

Perforation of the sigmoid colon by hydrostatic pressure of a public water fountain. Farbin S, et al. **J Emerg Med** 1996 Nov-Dec;14(6):703-6 (30 ref.)

SURGERY

Idiopathic non-familial rectal and colonic varices requiring sigmoidorectal resection and coloanal anastomosis. Detry RJ, et al. **Eur J Gastroenterol Hepatol** 1996 Oct; 8(10):1023-6 (32 ref.)

TRANSPLANTATION

[Distal detubularized sigmoidoplasty. Description of the technique] Isorna Martínez de la Riva S. **Arch Esp Urol** 1996 Sep;49(7):657-66 (44 ref.) (Eng. Abstr.) **(Spa)**

SIGMOID DISEASES

COMPLICATIONS

Infected abdominal aortic aneurysm associated with a psoas abscess, aorto-duodenal and sigmoid fistulas. Case report and review of the literature. Louagie YA, et al. **Acta Chir Belg** 1997 Jan-Feb;97(1):39-43 (22 ref.)

Plasmacytoma of the sigmoid colon associated with a diverticular stricture: case report and review of the literature. Holland AJ, et al. **J R Coll Surg Edinb** 1997 Feb;42(1):47-9 (24 ref.)

DIAGNOSIS

Eosinophilic colitis presenting as a left-sided colocolonic intussusception with secondary large bowel obstruction: an uncommon entity with a rare presentation. Box JC, et al. **Am Surg** 1997 Aug;63(8):741-3 (16 ref.)

Amyloidosis localized in the sigmoid colon. Matsui H, et al. **J Gastroenterol** 1996 Aug;31(4):607-11 (15 ref.)

[Intestinal endometriosis] Higgs H, et al. **Acta Med Port** 1995 Nov;8(11):635-8 (19 ref.) (Eng. Abstr.) **(Por)**

PATHOLOGY

Solitary "amyloid ulcer" localized in the sigmoid colon without evidence of systemic amyloidosis. Hirata K, et al. **Am J Gastroenterol** 1997 Feb;92(2):356-7 (11 ref.)

Lethal complications in a case of sigmoid diverticulitis. A case report. Oehler U, et al. **Gen Diagn Pathol** 1997 Feb; 142(3-4):231-4 (11 ref.)

RADIOGRAPHY

Giant colonic diverticulum: presentation of one case and review of the literature. Roger T, et al. **Abdom Imaging** 1996 Nov-Dec;21(6):530-3 (17 ref.)

Computed tomography of the rectosigmoid region. Dixon AK. **Eur J Radiol** 1996 May;22(2):107-15 (39 ref.)

[The computed tomographic finding of sigmoid-rectal invagination and the radiological-macropathological correlation] Rodekohr S, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Jan;166(1):78-80 (10 ref.) **(Ger)**

SURGERY

Retractile mesenteritis of the large bowel: report of a case and review of the literature. Ikoma A, et al. **Surg Today** 1996;26(6):435-8 (21 ref.)

[Value of Hartmann's operation as an emergency intervention in sigmoid diverticulitis] Röthlin M, et al. **Swiss Surg** 1997; 3(3):107-11 (15 ref.) (Eng. Abstr.) **(Ger)**

SIGMOID NEOPLASMS

Self-expandable nitinol coil stent for management of colonic obstruction due to a malignant anastomotic stricture. Bashir RM, et al. **Gastrointest Endosc** 1996 Oct;44(4):497-501 (44 ref.)

[Plasma-cell granuloma of the sigmoid colon concomitant with adenocarcinoma of the cecum. Viewpoint for debate, literature review on pseudotumors, idiopathic colitis and cancer] De Monti M, et al. **Ann Ital Chir** 1997 Mar-Apr; 68(2):245-51 (55 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

Plasmacytoma of the sigmoid colon associated with a diverticular stricture: case report and review of the literature. Holland AJ, et al. **J R Coll Surg Edinb** 1997 Feb;42(1):47-9 (24 ref.)

PATHOLOGY

Primary Hodgkin's disease of the sigmoid colon: a case report and review of the literature. Thomas DB, et al. **Arch Pathol Lab Med** 1997 May;121(5):528-32 (22 ref.)

Gastrointestinal hepatoid adenocarcinoma: venous permeation and mimicry of hepatocellular carcinoma, a report of four cases. Ishikura H, et al. **Histopathology** 1997 Jul;31(1):47-54 (28 ref.)

Isolated splenic metastases from colon cancer. Indudhara R, et al. **South Med J** 1997 Jun;90(6):633-6 (24 ref.)

Cronkhite-Canada syndrome associated with carcinoma of the sigmoid colon: report of a case. Nakatsubo N, et al. **Surg Today** 1997;27(4):345-8 (28 ref.)

RADIOGRAPHY

Computed tomography of the rectosigmoid region. Dixon AK. **Eur J Radiol** 1996 May;22(2):107-15 (39 ref.)

RADIOTHERAPY

Treatment planning for adenocarcinoma of the rectum and sigmoid: a patterns of care study. PCS Committee. Kline RW, et al. **Int J Radiat Oncol Biol Phys** 1997 Jan 15; 37(2):305-11 (3 ref.)

SIGMOIDOSCOPY

Endoscopic screening for colorectal cancer. Lieberman D. **Gastroenterol Clin North Am** 1997 Mar;26(1):71–83 (37 ref.)
Colon cancer screening. Sigmoidoscopy or colonoscopy. Khullar SK, et al. **Gastrointest Endosc Clin N Am** 1997 Jul;7(3):365–86 (113 ref.)

ADVERSE EFFECTS

Laparoscopic closure for perforation of the sigmoid colon by endoscopic linear stapler. Hayashi K, et al. **Surg Laparosc Endosc** 1996 Oct;6(5):411–3 (13 ref.)

METHODS

Office procedures. Flexible sigmoidoscopy. Harper MB, et al. **Prim Care** 1997 Jun;24(2):341–57 (25 ref.)

SIGN LANGUAGE

[Combined verbal and sign language for promoting communication development in non-verbal or or pre-verbal children and adolescents with mental retardation] Wilken E. **Rehabilitation (Stuttg)** 1996 Nov; 35(4):228–32 (11 ref.) (Eng. Abstr.) **(Ger)**

SIGNAL DETECTION (PSYCHOLOGY)

PHYSIOLOGY

Neuromodulation of transduction and signal processing in the end organs of taste. Nagai T, et al. **Chem Senses** 1996 Jun;21(3):353–65 (106 ref.)

SIGNAL INTERPRETATION, COMPUTER-ASSISTED see **SIGNAL PROCESSING, COMPUTER-ASSISTED**

SIGNAL PATHWAYS see **SIGNAL TRANSDUCTION**

SIGNAL PEPTIDES

Prediction of N-terminal protein sorting signals. Claros MG, et al. **Curr Opin Struct Biol** 1997 Jun;7(3):394–8 (41 ref.)
[Characterization of topogenic sequences which regulate the integration and membrane topology of proteins in the endoplasmic reticulum membrane] Sakaguchi M. **Seikagaku** 1997 Jan;69(1):1–15 (90 ref.) **(Jpn)**
[Structure and function of a cell adhesive signal, Arg–Gly–Asp sequence] Yamada T. **Tanpakushitsu Kakusan Koso** 1997 Jan;42(1):31–41 (44 ref.) **(Jpn)**

CHEMISTRY

A common export pathway for proteins binding complex redox cofactors? Berks BC. **Mol Microbiol** 1996 Nov; 22(3):393–404 (90 ref.)

GENETICS

Signal sequences: the same yet different. Zheng N, et al. **Cell** 1996 Sep 20;86(6):849–52 (21 ref.)
The role of sonic hedgehog in vertebrate development. Weed M, et al. **Matrix Biol** 1997 May;16(2):53–8 (53 ref.)

METABOLISM

Rhizobium lipo-chitooligosaccharide nodulation factors: signaling molecules mediating recognition and morphogenesis. Dénarié J, et al. **Annu Rev Biochem** 1996; 65:503–35 (185 ref.)
The major pathways of protein translocation across membranes. Ito K. **Genes Cells** 1996 Apr;1(4):337–46 (64 ref.)
Signals and signal-transduction systems in the control of development in Hydra and Hydractinia. Hassel M, et al. **Int J Dev Biol** 1996 Feb;40(1):323–30 (49 ref.)
Nuclear export and its significance in retroviral infection. Yoneda Y. **Trends Microbiol** 1996 Jan;4(1):1–2 (15 ref.)

PHYSIOLOGY

Signal sequences: the same yet different. Zheng N, et al. **Cell** 1996 Sep 20;86(6):849–52 (21 ref.)
Nematode spliced leaders—ubiquity, evolution and utility. Blaxter M, et al. **Int J Parasitol** 1996 Oct;26(10):1025–33 (51 ref.)
A common export pathway for proteins binding complex redox cofactors? Berks BC. **Mol Microbiol** 1996 Nov; 22(3):393–404 (90 ref.)
Signal peptide-induced sensory behavior in free ciliates: bioassays and cellular mechanisms. Leick V, et al. **Prog Mol Subcell Biol** 1996;17:61–79 (69 ref.)

SIGNAL PROCESSING, COMPUTER-ASSISTED

The fetal electrocardiogram. van Wijngaarden WJ, et al. **Baillieres Clin Obstet Gynaecol** 1996 Jun;10(2):273–94 (80 ref.)
The pathologist's workstation. Aller RD. **Clin Lab Med** 1997 Jun;17(2):201–28 (22 ref.)
Imaging input technology. Balis UJ. **Clin Lab Med** 1997 Jun; 17(2):151–74 (27 ref.)
Telemedicine and telepathology. Balis UJ. **Clin Lab Med** 1997 Jun;17(2):245–61 (34 ref.)
Digital imaging as a teaching tool for pathologists. Weinberg DS. **Clin Lab Med** 1997 Jun;17(2):229–44 (23 ref.)
Non-linear algorithms for processing biological signals. Cerutti S, et al. **Comput Methods Programs Biomed** 1996 Oct;51(1–2):51–73 (40 ref.)
The rationale and utility of neurophysiological investigations in clinical monitoring for brain and spinal cord ischaemia during surgery and intensive care. Prior P. **Comput Methods Programs Biomed** 1996 Oct;51(1–2):13–27 (101 ref.)
Digital signal processing of the phonocardiogram: review of the most recent advancements. Durand LG, et al. **Crit Rev Biomed Eng** 1995;23(3–4):163–219 (187 ref.)
Advances in time–frequency analysis of biomedical signals. Lin Z, et al. **Crit Rev Biomed Eng** 1996;24(1):1–72 (163 ref.)
Recent developments in air-conduction hearing aids. Arlinger S. **Ear Nose Throat J** 1997 May;76(5):310–5 (7 ref.)
Wavelets, adapted waveforms and de-noising. Coifman RR, et al. **Electroencephalogr Clin Neurophysiol Suppl** 1996; 45:57–78 (21 ref.)
Hidden Markov models for speech and signal recognition. Rose RC, et al. **Electroencephalogr Clin Neurophysiol Suppl** 1996;45:137–52 (43 ref.)
Digital storage and retrieval: the future in echocardiography. Thomas JD. **Heart** 1997 Aug;78 Suppl 1:19–22 (12 ref.)
New trends in computer ECG analysis. van Bemmel JH. **J Electrocardiol** 1996;29 Suppl:1–4 (23 ref.)
Computerization of Fujimori's method of waveform recognition. A review and methodological considerations for its application to all-night sleep EEG. Uchida S, et al. **J Neurosci Methods** 1996 Jan;64(1):1–12 (60 ref.)
[Digital filing system for medical image data] Mitani M, et al. **Rinsho Byori** 1997 May;45(5):447–55 (8 ref.) (Eng. Abstr.) **(Jpn)**
[Record and preservation of ultrasound images and computer-assistant analysis—estimation of digital filing system and texture analysis] Taniguchi N, et al. **Rinsho Byori** 1997 May;45(5):442–6 (5 ref.) (Eng. Abstr.) **(Jpn)**
[Visualization of neural excitation] Iijima T, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1100–5 (12 ref.) **(Jpn)**

INSTRUMENTATION

Home assessment of sleep disorders by portable monitoring. Broughton R, et al. **J Clin Neurophysiol** 1996 Jul; 13(4):272–84 (75 ref.)
Past and future of computer-assisted sleep analysis and drowsiness assessment. Hasan J. **J Clin Neurophysiol** 1996 Jul;13(4):295–313 (190 ref.)
Physiology and interpretation of the electromyogram. Kamen G, et al. **J Clin Neurophysiol** 1996 Sep;13(5):366–84 (200 ref.)
The future of computer-assisted investigation of the polysomnogram: sleep microstructure. Kubicki S, et al. **J Clin Neurophysiol** 1996 Jul;13(4):285–94 (70 ref.)
Analysis of the electromyographic interference pattern. Sanders DB, et al. **J Clin Neurophysiol** 1996 Sep; 13(5):385–400 (36 ref.)
Quantitative motor unit potential analysis. Stålberg E, et al. **J Clin Neurophysiol** 1996 Sep;13(5):401–22 (105 ref.)
Time-domain signal-averaged electrocardiogram in nonischemic ventricular tachycardia. Fauchier JP, et al. **Pacing Clin Electrophysiol** 1996 Feb;19(2):231–44 (87 ref.)
Calculation of area of stabilometric signals using principal component analysis. Oliveira LF, et al. **Physiol Meas** 1996 Nov;17(4):305–12 (12 ref.)
Imaging of the elastic properties of tissue—a review. Gao L, et al. **Ultrasound Med Biol** 1996;22(8):959–77 (65 ref.)
Automated blood pressure measurement in children. Steiss JO, et al. **Z Kardiol** 1996;85 Suppl 3:81–4 (36 ref.)
[How relevant are calculations of mean intracompartmental pressure in functional compartment syndrome?] Jerosch J, et al. **Biomed Tech (Berl)** 1997 Mar;42(3):42–7 (12 ref.) (Eng. Abstr.) **(Ger)**
[Diagnostic methods and standards in sleep medicine] Penzel T, et al. **Internist (Berl)** 1996 May;37(5):442–53 (45 ref.) **(Ger)**

SIGNAL PROCESSING, DIGITAL see **SIGNAL PROCESSING, COMPUTER-ASSISTED**

SIGNAL RECOGNITION PARTICLE

[Identification of eubacterial SRP RNA as a multifunctional molecule] Nakamura K, et al. **Seikagaku** 1997 Mar; 69(3):192–6 (15 ref.) **(Jpn)**
[Bacterial signal recognition particles (SRP): comparisons with mammalian SRP on their structure and function] Yamane K, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep; 41(11):1569–79 (57 ref.) **(Jpn)**

GENETICS

[Selective transfection of animal cells by non viral vectors: polylysine carrying recognition signals] Monsigny M, et al. **C R Seances Soc Biol Fil** 1996;190(1):39–43 (14 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

The E. coli SRP: preferences of a targeting factor. De Gier JW, et al. **FEBS Lett** 1997 May 12;408(1):1–4 (33 ref.)
Signal sequence recognition and protein targeting to the endoplasmic reticulum membrane. Walter P. **Harvey Lect** 1995–96;91:115–31 (28 ref.)
The signal recognition particle and related small cytoplasmic ribonucleoprotein particles. Bovia F, et al. **J Cell Sci** 1996 Nov;109 (Pt 11):2601–8 (64 ref.)

SIGNAL SEQUENCES see **SIGNAL PEPTIDES**

SIGNAL SEQUENCES, PEPTIDES see **SIGNAL PEPTIDES**

SIGNAL TRANSDUCTION

see related
ION CHANNELS
Nodulation genes in the Rhizobium—plant signal exchange. Lorkiewicz Z. **Acta Biochim Pol** 1997;44(1):1–12 (94 ref.)
Advances with phospholipid signalling as a target for anticancer drug development. Powis G, et al. **Acta Biochim Pol** 1995;42(4):395–403 (51 ref.)
Insulin receptor/IRS-1/PI 3-kinase signaling system in corticosteroid-induced insulin resistance. Folli F, et al. **Acta Diabetol** 1996 Sep;33(3):185–92 (82 ref.)
Neurotransmitters, signal transduction and second-messengers in Alzheimer's disease. Cowburn RF, et al. **Acta Neurol Scand Suppl** 1996;165:25–32 (63 ref.)
Ca(2+)-signalling in human T-lymphocytes. Potential roles for cyclic ADP-ribose and 2'-phospho-cyclic ADP-ribose. Guse AH, et al. **Adv Exp Med Biol** 1997; 419:431–6 (16 ref.)
ADP-ribosyl cyclase and CD38. Multi-functional enzymes in Ca+2 signaling. Lee HC, et al. **Adv Exp Med Biol** 1997; 419:411–9 (29 ref.)
Signal transduction via GPI-anchored membrane proteins. Robinson PJ. **Adv Exp Med Biol** 1997;419:365–70 (22 ref.)
Intramolecular ADP-ribose transfer reactions and calcium signalling. Potential role of 2'-phospho-cyclic ADP-ribose in oxidative stress. Vu CQ, et al. **Adv Exp Med Biol** 1997; 419:381–8 (31 ref.)
Novel protein phosphatases that may participate in cell signaling. Cohen PT, et al. **Adv Pharmacol** 1996;36:67–89 (74 ref.)
Redox signaling and the control of cell growth and death. Powis G, et al. **Adv Pharmacol** 1997;38:329–59 (204 ref.)
Signal transductions of SH2/SH3: Ash/Grb-2 downstream signaling. Takenawa T, et al. **Adv Pharmacol** 1996; 36:139–53 (24 ref.)
Protein tyrosine phosphatases and the control of cellular signaling responses. Tonks NK. **Adv Pharmacol** 1996; 36:91–119 (104 ref.)
Multiple signaling pathways involved in the metabolic effects of insulin. Moule SK, et al. **Am J Cardiol** 1997 Aug 4; 80(3A):41A–49A (62 ref.)
Turning off the signal: mechanisms that attenuate signaling by G protein-coupled receptors. Grady EF, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):G586–601 (132 ref.)
New perspectives in a gustatory physiology: transduction, development, and plasticity. Stewart RE, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):C1–26 (203 ref.)
Integrins: role in cell adhesion and communication. Gille J, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:93–106 (87 ref.)
PACAP/VIP receptor subtypes, signal transducers, and effectors in pituitary cells. Hezareh M, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:315–27; discussion 327–8 (41 ref.)
Ion channels and calcium signaling in mast cells. Hoth M, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:198–209 (49 ref.)
Fluid shear stress-mediated signal transduction: how do endothelial cells transduce mechanical force into biological responses? Ishida T, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:12–23; discussion 23–4 (53 ref.)
Signal transduction of PACAP and GLP-1 in pancreatic beta cells. Leech CA, et al. **Ann N Y Acad Sci** 1996 Dec 26; 805:81–92; discussion 92–3 (44 ref.)
The growth-hormone-releasing hormone receptor: signal transduction, gene expression, and physiological function in growth regulation. Mayo KE, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:184–203 (35 ref.)
In vivo imaging of fatty acid incorporation into brain to examine signal transduction and neuroplasticity involving phospholipids. Rapoport SI, et al. **Ann N Y Acad Sci** 1997 May 30;820:56–73; discussion 73–4 (35 ref.)
Signal transduction for PDGF-induced chemotaxis of vascular smooth muscle cells. Shimokado K, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:130–3 (14 ref.)
Bacterial adherence and mucosal cytokine responses. Receptors and transmembrane signaling. Svanborg C, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:177–90 (49 ref.)
Signal transduction in animal models of normotension and hypertension. Witte K, et al. **Ann N Y Acad Sci** 1996 Aug 15;783:71–83 (35 ref.)
Genetic dissection of signal transduction mechanisms underlying PACAP-like neuropeptide transmission in Drosophila: synergy of cAMP and Ras/Raf pathways. Zhong Y. **Ann N Y Acad Sci** 1996 Dec 26;805:67–79; discussion 79–80 (36 ref.)
A conserved signaling pathway: the Drosophila toll–dorsal pathway. Belvin MP, et al. **Ann Rev Cell Dev Biol** 1996;

12:393–416 (107 ref.)
Signaling by extracellular nucleotides. Brake AJ, et al. **Ann Rev Cell Dev Biol** 1996;12:519–41 (111 ref.)
Focal adhesions, contractility, and signaling. Burridge K, et al. **Ann Rev Cell Dev Biol** 1996;12:463–518 (385 ref.)
Cross-talk between bacterial pathogens and their host cells. Galán JE, et al. **Ann Rev Cell Dev Biol** 1996;12:221–55 (172 ref.)
Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Lemberger T, et al. **Ann Rev Cell Dev Biol** 1996;12:335–63 (116 ref.)
Endocytosis and molecular sorting. Mellman I. **Ann Rev Cell Dev Biol** 1996;12:575–625 (297 ref.)
Fc receptors and their interactions with immunoglobulins. Raghavan M, et al. **Ann Rev Cell Dev Biol** 1996;12:181–220 (158 ref.)
RGD and other recognition sequences for integrins. Ruoslahti E. **Ann Rev Cell Dev Biol** 1996;12:697–715 (103 ref.)
Ah receptor signaling pathways. Schmidt JV, et al. **Ann Rev Cell Dev Biol** 1996;12:55–89 (142 ref.)
Signal-mediated sorting of membrane proteins between the endoplasmic reticulum and the golgi apparatus. Teasdale RD, et al. **Ann Rev Cell Dev Biol** 1996;12:27–54 (115 ref.)
Cytokine receptor signal transduction and the control of hematopoietic cell development. Watowich SS, et al. **Ann Rev Cell Dev Biol** 1996;12:91–128 (280 ref.)
The neurotrophins and CNTF: two families of collaborative neurotrophic factors. Ip NY, et al. **Annu Rev Neurosci** 1996; 19:491–515 (137 ref.)
Intracellular signaling pathways activated by neurotrophic factors. Segal RA, et al. **Annu Rev Neurosci** 1996;19:463–89 (208 ref.)
The role of the hsp90-based chaperone system in signal transduction by nuclear receptors and receptors signaling via MAP kinase. Pratt WB. **Annu Rev Pharmacol Toxicol** 1997;37:297–326 (183 ref.)
Spatial relationships in early signaling events of flow-mediated endothelial mechanotransduction. Davies PF, et al. **Annu Rev Physiol** 1997;59:527–49 (48 ref.)
Tensegrity: the architectural basis of cellular mechanotransduction. Ingber DE. **Annu Rev Physiol** 1997; 59:575–99 (80 ref.)
Molecular modeling of mechanotransduction in the nematode Caenorhabditis elegans. Tavernarakis N, et al. **Annu Rev Physiol** 1997;59:659–89 (93 ref.)
Early activation signals in endothelial cells. Stimulation by cytokines. Introna M, et al. **Arterioscler Thromb Vasc Biol** 1997 Mar;17(3):423–8 (76 ref.)
Growth hormone receptor signalling. Postel-Vinay MC, et al. **Baillieres Clin Endocrinol Metab** 1996 Jul;10(3):323–36 (79 ref.)
Autoimmune disease results from multiple interactive defects in apoptosis induction molecules and signaling pathways. Mountz JD, et al. **Behring Inst Mitt** 1996 Oct;(97):200–19 (116 ref.)
Exploring cell death mechanisms by analyzing signaling cascades of the TNF/NGF receptor family. Wallach D, et al. **Behring Inst Mitt** 1996 Oct;(97):144–55 (69 ref.)
Gene regulation by nuclear and cytoplasmic calcium signals. Bading H, et al. **Biochem Biophys Res Commun** 1997 Jul 30;236(3):541–3 (34 ref.)
"Cross talk" between the bioactive glycerolipids and sphingolipids in signal transduction. Brindley DN, et al. **Biochem Cell Biol** 1996;74(4):469–76 (61 ref.)
Signal transduction and TGF-beta superfamily receptors. Kolodziejczyk SM, et al. **Biochem Cell Biol** 1996; 74(3):299–314 (133 ref.)
Palmitoylation: a post-translational modification that regulates signalling from G-protein coupled receptors. Morello JP, et al. **Biochem Cell Biol** 1996;74(4):449–57 (70 ref.)
Protein kinase C mediation of Ca(2+)-independent contractions of vascular smooth muscle. Walsh MP, et al. **Biochem Cell Biol** 1996;74(4):485–502 (214 ref.)
Role of long-chain fatty acyl-CoA esters in the regulation of metabolism and in cell signalling. Faergeman NJ, et al. **Biochem J** 1997 Apr 1;323 (Pt 1):1–12 (185 ref.)
Logical analysis of timing-dependent receptor signalling specificity: application to the insulin receptor metabolic and mitogenic signalling pathways. Shymko RM, et al. **Biochem J** 1997 Sep 1;326 (Pt 2):463–9 (51 ref.)
Role of subunit diversity in signaling by heterotrimeric G proteins. Hildebrandt JD. **Biochem Pharmacol** 1997 Aug 1;54(3):325–39 (229 ref.)
Retinoid signalling and retinoid receptors in amphibian limb regeneration. Brockes JP. **Biochem Soc Symp** 1996; 62:137–42 (22 ref.)
Hijacking host cell signal transduction mechanisms during infection with enteropathogenic Escherichia coli. Baldwin TJ, et al. **Biochem Soc Trans** 1996 May;24(2):552–8 (56 ref.)
CD28 co-receptor signal transduction in T-cell activation. Blair PJ, et al. **Biochem Soc Trans** 1997 May;25(2):651–7 (57 ref.)
Interleukin 4 and interleukin 13: same response, different receptors. Callard RE, et al. **Biochem Soc Trans** 1997 May; 25(2):451–5 (44 ref.)
Tyrosine phosphatases in T-cell development and signalling. Conroy LA, et al. **Biochem Soc Trans** 1997 May; 25(2):445–51 (41 ref.)
Regulation of the stress response by ceramide. Dbaibo GS. **Biochem Soc Trans** 1997 May;25(2):557–61 (45 ref.)
Regulation of lipogenic enzyme expression by glucose in liver and adipose tissue: is glucose 6-phosphate the signalling metabolite? Foufelle F, et al. **Biochem Soc Trans** 1996 May; 24(2):372–8 (43 ref.)
Stat4- and Stat6-deficient mice as models for manipulating T helper cell responses. Grusby MJ. **Biochem Soc Trans** 1997 May;25(2):359–60 (23 ref.)
Cell death signal transduction and Bcl-2 function. Herrmann JL, et al. **Biochem Soc Trans** 1996 Nov;24(4):1059–65 (64 ref.)
Novel components of mammalian stress-activated protein kinase cascades. Kiefer F, et al. **Biochem Soc Trans** 1997 May;25(2):491–8 (68 ref.)
The identification of Bruton's tyrosine kinase and Wiskott-Aldrich syndrome protein associated proteins and signalling pathways. Kinnon C, et al. **Biochem Soc Trans** 1997 May;25(2):648–50 (27 ref.)
Molecular mechanisms regulating B-cell negative selection. Monroe JG. **Biochem Soc Trans** 1997 May;25(2):643–7 (25 ref.)
Intracellular signalling pathways regulating initiation factor eIF4E phosphorylation during the activation of cell growth. Morley SJ. **Biochem Soc Trans** 1997 May; 25(2):503–9 (65 ref.)
Steroid-independent activation of steroid receptors in mammalian and yeast cells and in breast cancer. Picard D, et al. **Biochem Soc Trans** 1997 May;25(2):597–602 (50 ref.)
cGMP signal termination. Pyne NJ, et al. **Biochem Soc Trans** 1996 Nov;24(4):1019–22 (23 ref.)
Sphingolipids as differential regulators of cellular signalling processes. Pyne S, et al. **Biochem Soc Trans** 1997 May; 25(2):549–56 (59 ref.)
cAMP and 'death signals' in a myeloid leukaemia cell: from membrane receptors to nuclear responses: a review. Ruchaud S, et al. **Biochem Soc Trans** 1997 May;25(2):410–5 (56 ref.)
Role of the double-stranded RNA-activated protein kinase (PKR) in cell regulation. Williams BR. **Biochem Soc Trans** 1997 May;25(2):509–13 (28 ref.)
Structure and function of proteins in G-protein-coupled signal transfer. Helmreich EJ, et al. **Biochim Biophys Acta** 1996 Oct 29;1286(3):285–322 (525 ref.)
Controlling growth of the wing: vestigial integrates signals from the compartment boundaries. Cohen SM. **Bioessays** 1996 Nov;18(11):855–8 (42 ref.)
Signaling through focal adhesion kinase. Hanks SK, et al. **Bioessays** 1997 Feb;19(2):137–45 (70 ref.)
Wnt signalling goes nuclear. Kühl M, et al. **Bioessays** 1997 Feb;19(2):101–4 (29 ref.)
Mechanism of gene expression by the glucocorticoid receptor: role of protein-protein interactions. McEwan IJ, et al. **Bioessays** 1997 Feb;19(2):153–60 (70 ref.)
PDZ domains: targeting signalling molecules to sub-membranous sites. Ponting CP, et al. **Bioessays** 1997 Jun;19(6):469–79 (88 ref.)
Death substrates come alive. Porter AG, et al. **Bioessays** 1997 Jun;19(6):501–7 (60 ref.)
GnRH signaling in goldfish pituitary cells. Chang JP, et al. **Biol Signals** 1996 Mar-Apr;5(2):70–80 (33 ref.)
Cyclic ADP-ribose and calcium signaling in eggs. Lee HC. **Biol Signals** 1996 Mar-Apr;5(2):101–10 (58 ref.)
The structural and functional basis of cytokine receptor activation: lessons from the common beta subunit of the granulocyte-macrophage colony-stimulating factor, interleukin-3 (IL-3), and IL-5 receptors. Bagley CJ, et al. **Blood** 1997 Mar 1;89(5):1471–82 (87 ref.)
Distribution and signal transduction of angiotensin II AT1 and AT2 receptors. Capponi AM. **Blood Press Suppl** 1996; 2:41–6 (55 ref.)
Angiotensin-converting enzyme-independent pathways of angiotensin II formation in human tissues and cardiovascular diseases. Urata H, et al. **Blood Press Suppl** 1996;2:22–8 (49 ref.)
Gut reaction to Wnt signaling in worms [comment] Han M. **Cell** 1997 Aug 22;90(4):581–4 (16 ref.) Comment on: Cell 1997 Aug 22;90(4):695–705. Comment on: Cell 1997 Aug 22;90(4):707–16.
Microdomains and elemental events in calcium signalling. Berridge MJ. **Cell Calcium** 1996 Aug;20(2):95–6 (0 ref.)
Hormone-evoked subcellular Ca2+ signals in HeLa cells. Bootman MD. **Cell Calcium** 1996 Aug;20(2):97–104 (53 ref.)
Localized calcium signalling and neuronal integration in cerebellar Purkinje neurones. Eilers J, et al. **Cell Calcium** 1996 Aug;20(2):215–26 (65 ref.)
Calcium, BOBs, QEDs, microdomains and a cellular decision: control of mitotic cell division in sand dollar blastomeres. Silver RB. **Cell Calcium** 1996 Aug;20(2):161–79 (99 ref.)
Spatial domains of Ca2+ signaling in secretory epithelial cells. Thorn P. **Cell Calcium** 1996 Aug;20(2):203–14 (85 ref.)
Signal transduction in the retina and inherited retinopathies. Shastry BS. **Cell Mol Life Sci** 1997 May;53(5):419–29 (160 ref.)
An evaluation of strategies available for the identification of GTP-binding proteins required in intracellular signalling pathways. Barritt GJ, et al. **Cell Signal** 1997 May-Jun; 9(3-4):207–18 (115 ref.)
Signaling by the G12 class of G proteins. Dhanasekaran N, et al. **Cell Signal** 1996 Jun;8(4):235–45 (80 ref.)
Oncoprotein signalling and mitosis. Laird AD, et al. **Cell Signal** 1997 May-Jun;9(3-4):249–55 (126 ref.)
Glutamate receptors and gene induction: signalling from receptor to nucleus. Lerea LS. **Cell Signal** 1997 May-Jun; 9(3-4):219–26 (72 ref.)
Signal transduction in gastrointestinal smooth muscle. Makhlouf GM, et al. **Cell Signal** 1997 May-Jun; 9(3-4):269–76 (92 ref.)
G proteins and opioid receptor-mediated signalling. Standifer KM, et al. **Cell Signal** 1997 May-Jun;9(3-4):237–48 (166 ref.)
Feeling force: mechanical transduction by vertebrates and invertebrates. Gillespie PG. **Chem Biol** 1996 Apr;3(4):223–7 (19 ref.)
Social senses: G-protein-coupled receptor signaling pathways in Dictyostelium discoideum. Kim JY, et al. **Chem Biol** 1996 Apr;3(4):239–43 (21 ref.)
Disruption of brain cell ion homeostasis in Alzheimer's disease by oxy radicals, and signaling pathways that protect therefrom. Mattson MP, et al. **Chem Res Toxicol** 1997 May; 10(5):507–17 (85 ref.)
Ultrastructural aspects of olfactory signaling. Menco BP. **Chem Senses** 1997 Jun;22(3):295–311 (128 ref.)
Role of mesangial cells in macula densa to afferent arteriole information transfer. Goligorsky MS, et al. **Clin Exp Pharmacol Physiol** 1997 Jul;24(7):527–31 (44 ref.)
Signal processing in the vomeronasal system: modulation of sexual behavior in the female rat. Dudley CA, et al. **Crit Rev Neurobiol** 1996;10(3–4):265–90 (158 ref.)
Dopamine D2 receptors in signal transduction and behavior. Picetti R, et al. **Crit Rev Neurobiol** 1997;11(2–3):121–42 (130 ref.)
The VAV family of signal transduction molecules. Bustelo XR. **Crit Rev Oncog** 1996;7(1–2):65–88 (114 ref.)
Oncogene-initiated aberrant signaling engenders the metastatic phenotype: synergistic transcription factor interactions are targets for cancer therapy. Denhardt DT. **Crit Rev Oncog** 1996;7(3–4):261–91 (238 ref.)
Vav: Captain Hook for signal transduction? Katzav S. **Crit Rev Oncog** 1995;6(2):87–97 (82 ref.)
The growing family of MAP kinases: regulation and specificity. Kortenjann M, et al. **Crit Rev Oncog** 1995; 6(2):99–115 (188 ref.)
HIV-1: is Nef a PAK animal? Cullen BR. **Curr Biol** 1996 Dec 1;6(12):1557–9 (15 ref.)
Cell cycle: routine role for Ras. Downward J. **Curr Biol** 1997 Apr 1;7(4):R258–60 (26 ref.)
Rho is only ARF the story. Phospholipid signalling. Frohman MA, et al. **Curr Biol** 1996 Aug 1;6(8):945–7 (24 ref.)
Calcium signalling: setting store by calcium channels. Hardie RC. **Curr Biol** 1996 Nov 1;6(11):1371–3 (19 ref.)
Plant meristems: cell signalling keeps the balance. Hudson A, et al. **Curr Biol** 1997 Jul 1;7(7):R427–9 (10 ref.)
Inositol phosphates – whither bound? Intracellular signalling. Irvine R, et al. **Curr Biol** 1996 May 1;6(5):537–40 (17 ref.)
Signal selection by cortical feedback. King AJ. **Curr Biol** 1997 Feb 1;7(2):R85–8 (21 ref.)
Signal transduction: clamping down on Src activity. Mayer BJ. **Curr Biol** 1997 May 1;7(5):R295–8 (13 ref.)
Kinase connections on the cellular intranet. Signalling pathways. Pelech SL. **Curr Biol** 1996 May 1;6(5):551–4 (19 ref.)
Splicing together the unfolded-protein response. Shamu CE. **Curr Biol** 1997 Feb 1;7(2):R67–70 (15 ref.)
Structural aspects of heterotrimeric G-protein signaling. Bohm A, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):480–7 (52 ref.)
The state of the STATs: recent developments in the study of signal transduction to the nucleus. Horvath CM, et al. **Curr Opin Cell Biol** 1997 Apr;9(2):233–9 (72 ref.)
Signal transduction by the neurotrophin receptors. Kaplan DR, et al. **Curr Opin Cell Biol** 1997 Apr;9(2):213–21 (79 ref.)
Reversible palmitoylation of signaling proteins. Mumby SM. **Curr Opin Cell Biol** 1997 Apr;9(2):148–54 (60 ref.)
Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways. Parsons JT, et al. **Curr Opin Cell Biol** 1997 Apr;9(2):187–92 (56 ref.)
T cell antigen receptor signal transduction. Qian D, et al. **Curr Opin Cell Biol** 1997 Apr;9(2):205–12 (71 ref.)
The role of lipid signaling in constitutive membrane traffic. Roth MG, et al. **Curr Opin Cell Biol** 1997 Aug;9(4):519–26 (64 ref.)
Transducing signals of life and death. Yuan J. **Curr Opin Cell Biol** 1997 Apr;9(2):247–51 (31 ref.)
Interacting signaling pathways controlling multicellular development in Dictyostelium. Firtel RA. **Curr Opin Genet Dev** 1996 Oct;6(5):545–54 (64 ref.)
Responses to DNA damage and regulation of cell cycle checkpoints by the ATM protein kinase family. Hoekstra MF. **Curr Opin Genet Dev** 1997 Apr;7(2):170–5 (48 ref.)
Serine/threonine kinase receptors and ligands. Josso N, et al. **Curr Opin Genet Dev** 1997 Jun;7(3):371–7 (68 ref.)
Cell signaling in root development. Scheres B. **Curr Opin Genet Dev** 1997 Aug;7(4):501–6 (27 ref.)
Notch signalling in development: on equivalence groups and asymmetric developmental potential. Simpson P. **Curr Opin Genet Dev** 1997 Aug;7(4):537–42 (47 ref.)
Roles of the JAK-STAT system in signal transduction via cytokine receptors. Watanabe S, et al. **Curr Opin Genet Dev** 1996 Oct;6(5):587–96 (54 ref.)
Integrin-ligand interactions: scratching the surface.

Kanazashi SI, et al. **Curr Opin Hematol** 1997 Jan;4(1):67–74 (86 ref.)

Erythrocyte signal transduction pathways and their possible functions. Minetti G, et al. **Curr Opin Hematol** 1997 Mar; 4(2):116–21 (90 ref.)

Hedgehog signaling in Drosophila eye and limb development – conserved machinery, divergent roles? Burke R, et al. **Curr Opin Neurobiol** 1997 Feb;7(1):55–61 (65 ref.)

Sensory signaling in Caenorhabditis elegans. Kaplan JM. **Curr Opin Neurobiol** 1996 Aug;6(4):494–9 (34 ref.)

Mechanisms of taste transduction. Kinnamon SC, et al. **Curr Opin Neurobiol** 1996 Aug;6(4):506–13 (76 ref.)

The Notch pathway: democracy and aristocracy in the selection of cell fate. Kopan R, et al. **Curr Opin Neurobiol** 1996 Oct;6(5):594–601 (61 ref.)

Phototransduction in transgenic mice. Lem J, et al. **Curr Opin Neurobiol** 1996 Aug;6(4):453–8 (45 ref.)

Pheromone transduction in the vomeronasal organ. Liman ER. **Curr Opin Neurobiol** 1996 Aug;6(4):487–93 (63 ref.)

Rho family GTP-binding proteins in growth cone signalling. Luo L, et al. **Curr Opin Neurobiol** 1997 Feb;7(1):81–6 (43 ref.)

Signalling events elicited in plants by defined oligosaccharide structures. Promé JC. **Curr Opin Struct Biol** 1996 Oct; 6(5):671–8 (48 ref.)

Signaling via the insulin-like growth factor-I receptor: does it differ from insulin receptor signaling? Blakesley VA, et al. **Cytokine Growth Factor Rev** 1996 Aug;7(2):153–9 (52 ref.)

The type-I interferon receptor. The long and short of it. Domanski P, et al. **Cytokine Growth Factor Rev** 1996 Aug; 7(2):143–51 (68 ref.)

Phospholipase C-gamma1: regulation of enzyme function and role in growth factor-dependent signal transduction. Kamat A, et al. **Cytokine Growth Factor Rev** 1997 Jun; 8(2):109–17 (86 ref.)

Cell contact-dependent signaling. Fagotto F, et al. **Dev Biol** 1996 Dec 15;180(2):445–54 (89 ref.)

Adhesion-growth factor interactions during differentiation: an integrated biological response. Sastry SK, et al. **Dev Biol** 1996 Dec 15;180(2):455–67 (137 ref.)

Signaling pathways that regulate specification of neurons in developing cerebral cortex. Levitt P, et al. **Dev Neurosci** 1997;19(1):6–8 (39 ref.)

Protein kinase C signalling in pancreatic beta-cells: cellular and molecular approaches. Persaud SJ. **Digestion** 1997;58 Suppl 2:86–92 (32 ref.)

Signalling pathway of GH. Carter-Su C, et al. **Endocr J** 1996 Oct;43 Suppl:S65–70 (33 ref.)

Signal transduction of GnRH receptor in the reproductive tract tumor. Imai A, et al. **Endocr J** 1996 Jun;43(3):249–60 (139 ref.)

Signal transduction mechanism of insulin and insulin-like growth factor-1. Kadowaki T, et al. **Endocr J** 1996 Oct; 43 Suppl:S33–41 (47 ref.)

Analysis of glucocorticoid and mineralocorticoid signalling by gene targeting. Berger S, et al. **Endocr Res** 1996 Nov; 22(4):641–52 (19 ref.)

The regulation of growth and intracellular signaling by integrins. Meredith JE Jr, et al. **Endocr Rev** 1996 Jun; 17(3):207–20 (199 ref.)

Mitogenic signaling via G protein-coupled receptors. van Biesen T, et al. **Endocr Rev** 1996 Dec;17(6):698–714 (272 ref.)

The path less traveled by [editorial; comment] Baserga R. **Endocrinology** 1997 Jun;138(6):2217–8 (9 ref.) Comment on: Endocrinology 1997 Jun;138(6):2219–26.

The interleukin-1 receptor complex and interleukin-1 signal transduction. Martin MU, et al. **Eur Cytokine Netw** 1997 Mar;8(1):5–17 (65 ref.)

Cell signalling through guanine-nucleotide-binding regulatory proteins (G proteins) and phospholipases. Exton JH. **Eur J Biochem** 1997 Jan 15;243(1–2):10–20 (110 ref.)

Regulation of phosphorylation pathways by p21 GTPases. The p21 Ras-related Rho subfamily and its role in phosphorylation signalling pathways. Lim L, et al. **Eur J Biochem** 1996 Dec 1;242(2):171–85 (123 ref.)

Retinoid signalling during embryogenesis. Pijnappel WW, et al. **Eur J Clin Nutr** 1996 Jul;50 Suppl 3:S29–31 (20 ref.)

GnRH receptor signaling: cross-talk of Ca2+ and protein kinase C. Naor Z. **Eur J Endocrinol** 1997 Feb;136(2):123–7 (39 ref.)

IgE receptor (Fc epsilon RI) and signal transduction. Kinet JP, et al. **Eur Respir J Suppl** 1996 Aug;22:116s–118s (31 ref.)

Early events in erythropoietin-induced signaling. Damen JE, et al. **Exp Hematol** 1996 Nov;24(13):1455–9 (55 ref.)

Targets for gene therapy of Parkinson's disease: growth factors, signal transduction, and promoters. During MJ, et al. **Exp Neurol** 1997 Mar;144(1):74–81 (65 ref.)

Dysfunction of the endothelial nitric oxide signalling pathway in diabetes and hyperglycaemia. Sobrevia L, et al. **Exp Physiol** 1997 May;82(3):423–52 (188 ref.)

Heritable diseases of the skeleton. Part I: Molecular insights into skeletal development-transcription factors and signaling pathways. Mundlos S, et al. **FASEB J** 1997 Feb; 11(2):125–32 (60 ref.)

Spatial and temporal aspects of cellular calcium signaling. Thomas AP, et al. **FASEB J** 1996 Nov;10(13):1505–17 (94 ref.)

The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. Alroy I, et al. **FEBS Lett** 1997 Jun 23;410(1):83–6 (47 ref.)

Phosphatidylinositol transfer proteins: requirements in phospholipase C signaling and in regulated exocytosis. Cockcroft S. **FEBS Lett** 1997 Jun 23;410(1):44–8 (31 ref.)

PDK1, one of the missing links in insulin signal transduction? Cohen P, et al. **FEBS Lett** 1997 Jun 23;410(1):3–10 (71 ref.)

Cyclic AMP signalling and cellular proliferation: regulation of CREB and CREM. Della Fazia MA, et al. **FEBS Lett** 1997 Jun 23;410(1):22–4 (22 ref.)

Simultaneous induction of stimulatory and inhibitory signals by PDGF. Heldin CH. **FEBS Lett** 1997 Jun 23;410(1):17–21 (47 ref.)

Regulation of proliferation and apoptosis by Ras and Rho GTPases through specific phospholipid-dependent signaling. Lacal JC. **FEBS Lett** 1997 Jun 23;410(1):73–7 (59 ref.)

Molecular diversity of sphingolipid signalling. Meyer zu Heringdorf D, et al. **FEBS Lett** 1997 Jun 23;410(1):34–8 (57 ref.)

Communication between the extracellular environment, cytoplasmic signalling cascades and the nuclear cell-cycle machinery. Peeper DS, et al. **FEBS Lett** 1997 Jun 23; 410(1):11–6 (129 ref.)

Endothelins as cell growth regulators. Sedo A, et al. **Folia Biol (Praha)** 1996;42(3):79–82 (43 ref.)

Redox modulation of tyrosine phosphorylation-dependent signal transduction pathways. Monteiro HP, et al. **Free Radic Biol Med** 1996;21(3):323–33 (106 ref.)

Expression and signal transduction pathways of endothelin receptors in neuroendocrine cells. Stojilkovic SS, et al. **Front Neuroendocrinol** 1996 Jul;17(3):327–69 (224 ref.)

Closing in on the signals of hepatic fibrosis [editorial; comment] Friedman SL. **Gastroenterology** 1997 Apr; 112(4):1406–9 (32 ref.) Comment on: Gastroenterology 1997 Apr;112(4):1297–306.

Intracellular and molecular aspects of Ca(2+)-mediated signal transduction in neuronal cells. Račay P, et al. **Gen Physiol Biophys** 1996 Aug;15(4):273–89 (89 ref.)

SH2 and SH3-containing adaptor proteins: redundant or independent mediators of intracellular signal transduction. Birge RB, et al. **Genes Cells** 1996 Jul;1(7):595–613 (198 ref.)

Signal transduction via the histidyl-aspartyl phosphorelay. Egger LA, et al. **Genes Cells** 1997 Mar;2(3):167–84 (148 ref.)

Propagation of traveling waves in excitable media. Sager BM. **Genes Dev** 1996 Sep 15;10(18):2237–50 (136 ref.)

Rho GTPases and signaling networks. Van Aelst L, et al. **Genes Dev** 1997 Sep 15;11(18):2295–322 (295 ref.)

Molecules making waves in axon guidance. Varela-Echavarría A, et al. **Genes Dev** 1997 Mar 1; 11(5):545–57 (96 ref.)

Signal perception and transduction in plant defense responses. Yang Y, et al. **Genes Dev** 1997 Jul 1;11(13):1621–39 (239 ref.)

The plasma membrane calcium pump: not just another pretty ion translocase. Brandt PC, et al. **Glycobiology** 1996 Oct; 6(7):665–8 (30 ref.)

Interaction of the signalling pathways of insulin-like growth factor-I and sex steroids in the neuroendocrine hypothalamus. García-Segura LM, et al. **Horm Res** 1996; 46(4–5):160–4 (58 ref.)

Signals and molecular pathways involved in apoptosis, with special emphasis on human endometrium. Tabibzadeh S. **Hum Reprod Update** 1995 Jul;1(4):303–23 (211 ref.)

Receptors for fibroblast growth factors. Coutts JC, et al. **Immunol Cell Biol** 1995 Dec;73(6):584–9 (64 ref.)

Intracellular signaling and endosomal trafficking of immunoreceptors. Shared effectors underlying MHC class II-restricted antigen presentation. Bonnerot C, et al. **Immunol Lett** 1997 Jun 1;57(1–3):1–4 (35 ref.)

Molecular analysis of the fyn-complex: cloning of SKAP55 and SLAP-130, two novel adaptor proteins which associate with fyn and may participate in the regulation of T cell receptor-mediated signaling. Schraven B, et al. **Immunol Lett** 1997 Jun 1;57(1–3):165–9 (26 ref.)

The role of CTLA-4 in the regulation and initiation of T-cell responses. Chambers CA, et al. **Immunol Rev** 1996 Oct; 153:27–46 (90 ref.)

Signaling thresholds and interclonal competition in preimmune B-cell selection. Cyster JG. **Immunol Rev** 1997 Apr;156:87–101 (142 ref.)

Regulation of signalling through B-lymphocyte antigen receptors by cell-cell interaction molecules. Law CL, et al. **Immunol Rev** 1996 Oct;153:123–54 (200 ref.)

Fc epsilon RI and the FcR-beta amplifier. Scharenberg AM, et al. **Int Arch Allergy Immunol** 1997 May-Jul; 113(1–3):42–4 (18 ref.)

Growth factor-dependent phosphoinositide signalling. Hsuan JJ, et al. **Int J Biochem Cell Biol** 1997 Mar;29(3):415–35 (204 ref.)

Lens induction in axolotls: comparison with inductive signaling mechanisms in Xenopus laevis. Servetnick MD, et al. **Int J Dev Biol** 1996 Aug;40(4):755–61 (36 ref.)

TGF-beta receptors and signal transduction. Miyazono K. **Int J Hematol** 1997 Feb;65(2):97–104 (42 ref.)

Signal transduction in cell-matrix interactions. Guan JL, et al. **Int Rev Cytol** 1996;168:81–121 (244 ref.)

Insights into T cell development and signal transduction provided by TCR-zeta chain deficient mice. Shores EW, et al. **Int Rev Immunol** 1996;13(4):301–15 (97 ref.)

Adenine dinucleotides: a novel class of signalling molecules. Ogilvie A, et al. **J Auton Pharmacol** 1996 Dec;16(6):325–8 (33 ref.)

Endothelial P2-purinoceptors: subtypes and signal transduction. Pirotton S, et al. **J Auton Pharmacol** 1996 Dec;16(6):353–6 (26 ref.)

Extracellular nucleotides as signalling molecules for renal mesangial cells. Schulze-Lohoff E, et al. **J Auton Pharmacol** 1996 Dec;16(6):381–4 (16 ref.)

Intramembrane signaling mediated by hydrogen-bonding of water and carboxyl groups in bacteriorhodopsin and rhodopsin. Maeda A, et al. **J Biochem (Tokyo)** 1997 Mar; 121(3):399–406 (62 ref.)

Ca2+ signaling and intracellular Ca2+ binding proteins. Niki I, et al. **J Biochem (Tokyo)** 1996 Oct;120(4):685–98 (221 ref.)

Regulation of connexin43 function by activated tyrosine protein kinases. Lau AF, et al. **J Bioenerg Biomembr** 1996 Aug;28(4):359–68 (47 ref.)

Protein kinase A anchoring. Dell'Acqua ML, et al. **J Biol Chem** 1997 May 16;272(20):12881–4 (59 ref.)

Prolactin signaling in mammary gland development. Hennighausen L, et al. **J Biol Chem** 1997 Mar 21; 272(12):7567–9 (40 ref.)

Proteases in Fas-mediated apoptosis. Zhivotovsky B, et al. **J Cell Biochem** 1997 Jan;64(1):43–9 (54 ref.)

Involvement of signal transduction pathways in lung cancer biology. Viallet J, et al. **J Cell Biochem Suppl** 1996; 24:228–36 (53 ref.)

Switches, latches, and amplifiers: common themes of G proteins and molecular motors. Vale RD. **J Cell Biol** 1996 Oct;135(2):291–302 (92 ref.)

Focal adhesion kinase: at the crossroads of signal transduction. Ilić D, et al. **J Cell Sci** 1997 Feb;110 (Pt 4):401–7 (72 ref.)

Yersinia proteins that target host cell signaling pathways. Fällman M, et al. **J Clin Invest** 1997 Mar 15;99(6):1153–7 (35 ref.)

The biology of PECAM-1. Newman PJ. **J Clin Invest** 1997 Jan 1;99(1):3–8 (49 ref.)

Perspectives series: cell adhesion in vascular biology. Integrin signaling in vascular biology. Shattil SJ, et al. **J Clin Invest** 1997 Jul 1;100(1):1–5 (77 ref.)

Signal transduction in normal and neoplastic keratinocytes. Dlugosz AA. **J Dermatol** 1996 Nov;23(11):751–5 (40 ref.)

Inhibitors of the Ras signal transduction pathway as potential antitumour agents. Perrin D, et al. **J Enzyme Inhib** 1996 Oct;11(2):77–95 (103 ref.)

Understanding the mechanisms of sustained signaling and T cell activation [comment] Lanzavecchia A. **J Exp Med** 1997 May 19;185(10):1717–9 (20 ref.) Comment on: J Exp Med 1997 May 19;185(10):1803–13. Comment on: J Exp Med 1997 May 19;185(10):1815–25. Comment on: J Exp Med 1997 May 19;185(10):1859–64.

Atrial natriuretic peptide-C receptor and membrane signalling in hypertension. Anand-Srivastava MB. **J Hypertens** 1997 Aug;15(8):815–26 (134 ref.)

Signal transduction in vascular smooth muscle. Alexander RW, et al. **J Hypertens Suppl** 1996 Dec;14(5):S51–4 (35 ref.)

Identification of p55 tumor necrosis factor receptor-associated proteins that couple to signaling pathways not initiated by the death domain. Adam D, et al. **J Inflamm** 1995–96;47(1–2):61–6 (35 ref.)

Tumor necrosis factor (TNF) receptors in cellular signaling of soluble and membrane-expressed TNF. Grell M. **J Inflamm** 1995–96;47(1–2):8–17 (28 ref.)

Beta 2 (CD11/CD18) integrins can serve as signaling partners for other leukocyte receptors. Todd RF 3rd, et al. **J Lab Clin Med** 1997 May;129(5):492–8 (64 ref.)

Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency. Johnston JA, et al. **J Leukoc Biol** 1996 Oct;60(4):441–52 (153 ref.)

Receptor-mediated phosphoinositide metabolism in peripheral nerve and cultured Schwann cells. Eichberg J, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):187–95 (26 ref.)

Ceramide: role in growth inhibitory cascades. Jayadev S, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):295–301 (30 ref.)

Effects of acid phospholipids on ARF activities: potential roles in membrane traffic. Kahn RA, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):209–14 (22 ref.)

Regulation of phospholipase D by low molecular weight GTP-binding proteins. Kanaho Y, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):223–7 (15 ref.)

Molecular properties of enzymes involved in diacylglycerol and phosphatidate metabolism. Kanoh H, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):245–50 (18 ref.)

Phospholipase D: role in signal transduction and membrane traffic. Liscovitch M. **J Lipid Mediat Cell Signal** 1996 Sep; 14(1–3):215–21 (38 ref.)

Phosphatidylcholine hydrolysis and protein kinase C activation for intracellular signaling network. Nakamura S. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):197–202 (16 ref.)

Inositol trisphosphate/Ca2+ as messengers of bradykinin B2 and muscarinic acetylcholine m1-m4 receptors in neuroblastoma-derived hybrid cells. Noda M, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):175–85 (44 ref.)

Intra- and intercellular calcium signaling in human neuroepithelioma cells. Palmer RK, et al.

J Lipid Mediat Cell Signal 1996 Sep;14(1–3):169–74 (6 ref.)
Platelet-activating factor and somatostatin activate mitogen-activated protein kinase (MAP kinase) and arachidonate release. Shimizu T, et al.
J Lipid Mediat Cell Signal 1996 Sep;14(1–3):103–8 (22 ref.)
Poly-phosphoinositide-mediated messengers in focal cerebral ischemia and reperfusion. Sun GY, et al.
J Lipid Mediat Cell Signal 1996 Sep;14(1–3):137–45 (19 ref.)
New evidence for the occurrence of a glycolipid-mediated signal transduction system. Tsuji S, et al.
J Lipid Mediat Cell Signal 1996 Sep;14(1–3):289–94 (9 ref.)
Acute regulation of the receptor-mediated phosphoinositide signal transduction pathway. Willars GB, et al.
J Lipid Mediat Cell Signal 1996 Sep;14(1–3):157–68 (35 ref.)
Plasmalogen-selective phospholipase A2 and its role in signal transduction. Yang HC, et al.
J Lipid Mediat Cell Signal 1996 Sep;14(1–3):9–13 (13 ref.)
Targeting G protein-coupled receptor kinases to their receptor substrates. Stoffel RH 3rd, et al.
J Membr Biol 1997 May 1;157(1):1–8 (49 ref.)
The role of phosphoinositide 3-kinase in insulin signalling. Shepherd PR, et al. **J Mol Endocrinol** 1996 Dec; 17(3):175–84 (92 ref.)
Protein kinase mediators of integrin signal transduction. Hannigan GE, et al. **J Mol Med** 1997 Jan;75(1):35–44 (116 ref.)
The role of tyrosine phosphorylation in angiotensin II mediated intracellular signaling and cell growth. Schieffer B, et al. **J Mol Med** 1996 Feb;74(2):85–91 (57 ref.)
STAT6: its role in interleukin 4-mediated biological functions. Takeda K, et al. **J Mol Med** 1997 May; 75(5):317–26 (120 ref.)
Cardiotrophin-1 and the role of gp130-dependent signaling pathways in cardiac growth and development. Wollert KC, et al. **J Mol Med** 1997 Jul;75(7):492–501 (98 ref.)
A phosphorylation cascade in the basal ganglia of the mammalian brain: regulation by the D-1 dopamine receptor. A mathematical model of known biochemical reactions. Kebabian JW. **J Neural Transm Suppl** 1997; 49:145–53 (14 ref.)
Neural cell adhesion molecule L1: signaling pathways and growth cone motility. Kamiguchi H, et al.
J Neurosci Res 1997 Jul 1;49(1):1–8 (81 ref.)
Overview: temporal and spatial relationships in shear stress-mediated endothelial signalling. Davies PF.
J Vasc Res 1997 May-Jun;34(3):208–11 (21 ref.)
Signal transduction mechanisms mediating the vascular actions of endothelin. Douglas SA, et al. **J Vasc Res** 1997 May-Jun;34(3):152–64 (123 ref.)
Cytochrome P450 metabolites of arachidonic acid as intracellular signaling molecules in vascular tissue. Harder DR, et al. **J Vasc Res** 1997 May-Jun;34(3):237–43 (35 ref.)
Potential cellular signaling mechanisms mediating upregulation of endothelial nitric oxide production by estrogen. Kauser K, et al. **J Vasc Res** 1997 May-Jun; 34(3):229–36 (72 ref.)
Mechanotransduction in endothelial cells: temporal signaling events in response to shear stress. Takahashi M, et al.
J Vasc Res 1997 May-Jun;34(3):212–9 (55 ref.)
Alterations of signal transduction system in heart failure. Kawaguchi H, et al. **Jpn Heart J** 1997 May;38(3):317–32 (48 ref.)
Cellular approach to auditory signal transmission. Koyano K, et al. **Jpn J Physiol** 1996 Aug;46(4):289–310 (195 ref.)
Cytokine regulation: an overview. Miyajima A. **Leukemia** 1997 Apr;11 Suppl 3:413–5 (5 ref.)
Signal transduction by the GM-CSF, IL-3 and IL-5 receptors. Miyajima A, et al. **Leukemia** 1997 Apr;11 Suppl 3:418–22 (16 ref.)
Emerging paradigms in granulocyte-macrophage colony-stimulating factor signaling. Gomez-Cambronero J, et al. **Life Sci** 1996;59(25–26):2099–111 (64 ref.)
Modeling signal transduction in normal and cancer cells using complex adaptive systems. Schwab ED, et al.
Med Hypotheses 1997 Feb;48(2):111–23 (55 ref.)
Somatostatin receptor subtypes: specific expression and signaling properties. Schonbrunn A, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):8–11 (24 ref.)
Nitric oxide signaling in the nervous system. Brenman JE, et al. **Methods Enzymol** 1996;269:119–29 (78 ref.)
Nitric oxide-cyclic GMP signal transduction system. Hobbs AJ, et al. **Methods Enzymol** 1996;269:134–48 (13 ref.)
Nitric oxide-cyclic GMP pathway in brain slices. Southam E, et al. **Methods Enzymol** 1996;269:129–33 (13 ref.)
Use of L-arginine and its analogs to study nitric oxide pathway in humans. Vallance P. **Methods Enzymol** 1996; 269:453–9 (25 ref.)
Use of antisense-generating plasmids to probe the function of signal transduction proteins in primary neurons. Abogadie FC, et al. **Methods Mol Biol** 1997;83:217–25 (7 ref.)
Heterologous expression of receptors and signaling proteins in adult mammalian sympathetic neurons by microinjection. Ikeda SR. **Methods Mol Biol** 1997;83:191–202 (15 ref.)
Kinase cascades regulating entry into apoptosis. Anderson P. **Microbiol Mol Biol Rev** 1997 Mar;61(1):33–46 (189 ref.)
Signal transduction and virulence regulation in Bordetella pertussis. Beier D, et al. **Microbiologia** 1996 Jun; 12(2):185–96 (60 ref.)
Microbial utilization of human signalling molecules. Virji M. **Microbiology** 1996 Dec;142 (Pt 12):3319–36 (107 ref.)
Direct regulation of the Na,K pump by signal transduction mechanisms. Middleton JP. **Miner Electrolyte Metab** 1996; 22(5–6):293–302 (84 ref.)
hCG-receptor binding and transmembrane signaling. Puett D, et al. **Mol Cell Endocrinol** 1996 Dec 20;125(1–2):55–64 (61 ref.)
Telling axons where to grow: a role for Eph receptor tyrosine kinases in guidance. Brambilla R, et al.
Mol Cell Neurosci 1995 Dec;6(6):487–95 (65 ref.)
Notch signaling in vertebrate development and disease. Gridley T. **Mol Cell Neurosci** 1997;9(2):103–8 (43 ref.)
The ins and outs of notch signaling. Weinmaster G.
Mol Cell Neurosci 1997;9(2):91–102 (118 ref.)
Modulation of glial cell signaling by adenosine and pharmacological reinforcement. A neuroprotective strategy? Schubert P, et al. **Mol Chem Neuropathol** 1996 May-Aug;28(1–3):185–90 (19 ref.)
Nuclear receptor coactivators and corepressors. Horwitz KB, et al. **Mol Endocrinol** 1996 Oct;10(10):1167–77 (87 ref.)
Calcium influx pathways in human spermatozoa. Foresta C, et al. **Mol Hum Reprod** 1997 Jan;3(1):1–4 (38 ref.)
Signal transduction-based strategies for the treatment of chronic myelogenous leukemia. Senechal K, et al.
Mol Med Today 1996 Dec;2(12):503–9 (43 ref.)
Regulation of targeting signals in membrane proteins. [review] Stanley KK. **Mol Membr Biol** 1996 Jan-Mar; 13(1):19–27 (108 ref.)
Quorum sensing by peptide pheromones and two-component signal-transduction systems in Gram-positive bacteria. Kleerebezem M, et al. **Mol Microbiol** 1997 Jun; 24(5):895–904 (38 ref.)
Bacterial signalling involving eukaryotic-type protein kinases. Zhang CC. **Mol Microbiol** 1996 Apr;20(1):9–15 (32 ref.)
Role of Drosophila TRP in inositide-mediated Ca2+ entry. Minke B, et al. **Mol Neurobiol** 1996 Apr;12(2):163–80 (83 ref.)
beta-Catenin—one player, two games [news] Resnik E.
Nat Genet 1997 May;16(1):9–11 (18 ref.)
Nucleocytoplasmic transport: signals, mechanisms and regulation. Nigg EA. **Nature** 1997 Apr 24;386(6627):779–87 (137 ref.)
Signal transduction and protein kinases: the long way from the plasma membrane into the nucleus. Hucho F, et al. **Naturwissenschaften** 1997 Jul;84(7):281–90 (88 ref.)
Signal transduction molecules in the rat pineal organ: Ca2+, pCREB, and ICER. Korf HW, et al.
Naturwissenschaften 1996 Dec;83(12):535–43 (44 ref.)
Gene activation pathways of nerve growth factor signaling: a minireview. Szeberényi J. **Neurobiology (Bp)** 1996; 4(1–2):1–11 (19 ref.)
Signal transduction from membrane to nucleus: the special case for neurons. Johanson SO, et al. **Neurochem Res** 1996 Jul;21(7):779–85 (38 ref.)
Neurotransmitter receptor/G-protein mediated signal transduction in Alzheimer's disease brain. Cowburn RF, et al. **Neurodegeneration** 1996 Dec;5(4):483–8 (37 ref.)
Hypoxic alterations in cellular signal transduction in shock and sepsis. West MA, et al. **New Horiz** 1996 May; 4(2):168–78 (89 ref.)
Neuropeptide genes: targets of activity-dependent signal transduction. MacArthur L, et al. **Peptides** 1996;17(4):721–8 (109 ref.)
Signal transduction in vertebrate growth cones navigating in vivo. Chien CB, et al. **Perspect Dev Neurobiol** 1996; 4(2–3):253–66 (77 ref.)
Shared cell adhesion molecule (CAM) homology domains point to CAMs signalling via FGF receptors. Doherty P, et al. **Perspect Dev Neurobiol** 1996;4(2–3):157–68 (55 ref.)
Signal transduction pathways activated by ciliary neurotrophic factor and related cytokines. Frank DA, et al. **Perspect Dev Neurobiol** 1996;4(1):3–18 (108 ref.)
Extrinsic signals in the developing nervous system: the role of neurokines during neurogenesis. Heller S, et al.
Perspect Dev Neurobiol 1996;4(1):19–34 (135 ref.)
Investigations of signaling pathways in axon growth and guidance. Klostermann S, et al. **Perspect Dev Neurobiol** 1996;4(2–3):237–52 (53 ref.)
Selective neural cell adhesion molecule signaling by Src family tyrosine kinases and tyrosine phosphatases. Maness PF, et al. **Perspect Dev Neurobiol** 1996;4(2–3):169–81 (169 ref.)
Functional compartmentalization of the neuronal growth cone: determining calcium's place in signaling cascades. Rehder V, et al. **Perspect Dev Neurobiol** 1996;4(2–3):215–26 (57 ref.)
Signal transduction during axon guidance: a genetic analysis in Drosophila. Vanberkum MF. **Perspect Dev Neurobiol** 1996;4(2–3):227–36 (89 ref.)
Signal transduction by the oncogenic receptor tyrosine kinase Xmrk in melanoma formation of Xiphophorus. Wellbrock C, et al. **Pigment Cell Res** 1997 Feb–Apr;10(1–2):34–40 (60 ref.)
Signal transduction in Rhizobium-induced nodule formation. Geurts R, et al. **Plant Physiol** 1996 Oct;112(2):447–53 (42 ref.)
Genetic analysis of abscisic acid signal transduction. Merlot S, et al. **Plant Physiol** 1997 Jul;114(3):751–7 (46 ref.)
Principles of receptor-based inhibition of erbB family receptor kinases: prospects for new therapies for human cancers. O'Rourke DM, et al.
Proc Assoc Am Physicians 1997 May;109(3):209–19 (78 ref.)
Eubacterial signal transduction by ligands of the mammalian peripheral benzodiazepine receptor complex [see comments] Donohue TJ. **Proc Natl Acad Sci U S A** 1997 May 13;94(10):4821–2 (18 ref.) Comment in: Proc Natl Acad Sci U S A 1997 May 13;94(10):5101–6.
Nutrient-hormone signals regulating muscle protein turnover in pigs. Sève B, et al. **Proc Nutr Soc** 1997 Jul;56(2):565–80 (62 ref.)
Regulation of growth factor-induced signaling by protein-tyrosine-phosphatases. Byon JC, et al.
Proc Soc Exp Biol Med 1997 Oct;216(1):1–20 (152 ref.)
Ras and its effectors. Herrmann C, et al.
Prog Biophys Mol Biol 1996;66(1):1–41 (177 ref.)
Muscarinic receptors and cell signalling. Löffelholz K.
Prog Brain Res 1996;109:191–4 (33 ref.)
Participation of small GTP-binding proteins in m3 muscarinic acetylcholine receptor signalling to phospholipase D and C. Rümenapp U, et al.
Prog Brain Res 1996;109:209–16 (42 ref.)
Cellular fatty acid-binding proteins: their function and physiological significance. Glatz JF, et al.
Prog Lipid Res 1996 Sep;35(3):243–82 (450 ref.)
The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. Maitre M.
Prog Neurobiol 1997 Feb;51(3):337–61 (236 ref.)
The nitric oxide system in insects. Müller U.
Prog Neurobiol 1997 Feb;51(3):363–81 (146 ref.)
Cytokines which signal through the LIF receptor and their actions in the nervous system. Murphy M, et al.
Prog Neurobiol 1997 Aug;52(5):355–78 (196 ref.)
Phosphoinositide signaling in human brain. Pacheco MA, et al. **Prog Neurobiol** 1996 Oct;50(2–3):255–73 (65 ref.)
Intracellular signal modulation: a pivotal role for protein kinase C [see comments] Casabona G.
Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr; 21(3):407–25 (75 ref.) Comment in: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):373–8.
Stimulation of kinase cascades by growth hormone: a paradigm for cytokine signaling. Wood TJ, et al.
Prog Nucleic Acid Res Mol Biol 1997;57:73–94 (107 ref.)
Interaction, signal generation, signal divergence, and signal transduction of LH/CG and the receptor. Ji TH, et al.
Recent Prog Horm Res 1997;52:431–53; discussion 454 (78 ref.)
Estrogen: nontranscriptional signaling pathway. Moss RL, et al. **Recent Prog Horm Res** 1997;52:33–68; discussion 68–9 (219 ref.)
Signal transduction as target of gene therapy. Moelling K, et al. **Recent Results Cancer Res** 1996;142:63–71 (18 ref.)
Signaling in plant-microbe interactions. Baker B, et al.
Science 1997 May 2;276(5313):726–33 (133 ref.)
STATs and gene regulation. Darnell JE Jr. **Science** 1997 Sep 12;277(5332):1630–5 (99 ref.)
Functions of ceramide in coordinating cellular responses to stress. Hannun YA. **Science** 1996 Dec 13;274(5294):1855–9 (55 ref.)
Akt signaling: linking membrane events to life and death decisions [comment] Hemmings BA. **Science** 1997 Jan 31; 275(5300):628–30 (25 ref.) Comment on: Science 1997 Jan 31;275(5300):661–5. Comment on: Science 1997 Jan 31;275(5300):665–8.
Portrait of an executioner: the molecular mechanism of FAS/APO-1-induced apoptosis. Chinnaiyan AM, et al.
Semin Immunol 1997 Feb;9(1):69–76 (84 ref.)
The structure of MHC class II: a role for dimer of dimers. Schafer PH, et al. **Semin Immunol** 1995 Dec;7(6):389–98 (54 ref.)
Genes involved in T-cell receptor-mediated apoptosis of thymocytes and T-cell hybridomas. Winoto A.
Semin Immunol 1997 Feb;9(1):51–8 (79 ref.)
Interacting pathways of interferon signaling. Williams BR, et al. **Semin Oncol** 1997 Jun;24(3 Suppl 9):S9-70–S9-77 (85 ref.)
Regulation of thrombin-mediated endothelial cell contraction and permeability. Garcia JG, et al.
Semin Thromb Hemost 1996;22(4):309–15 (50 ref.)
Synergy and specificity in induction of gene activity by proinflammatory cytokines: potential therapeutic targets. Spink J, et al. **Shock** 1997 Jun;7(6):405–12 (77 ref.)
Function and signal transduction mediated by the interleukin 3 receptor system in hematopoiesis. Hara T, et al.
Stem Cells 1996 Nov;14(6):605–18 (99 ref.)
Regulation of T cell apoptosis via T cell receptors and steroid receptors. Iwata M, et al. **Stem Cells** 1996 Nov;14(6):632–41 (66 ref.)
Signal transduction pathways in apoptosis. McConkey DJ, et al. **Stem Cells** 1996 Nov;14(6):619–31 (175 ref.)
Cytoplasmic signalling domains: the next generation. Bork P, et al. **Trends Biochem Sci** 1997 Aug;22(8):296–8 (20 ref.)
Three-part inventions: intracellular signaling and induced proximity. Crabtree GR, et al. **Trends Biochem Sci** 1996 Nov;21(11):418–22 (46 ref.)
Evidence for a Ras/Ral signaling cascade. Feig LA, et al.
Trends Biochem Sci 1996 Nov;21(11):438–41 (49 ref.)
Tripping the switch fantastic: how a protein kinase cascade can convert graded inputs into switch-like outputs [see comments] Ferrell JE Jr. **Trends Biochem Sci** 1996 Dec; 21(12):460–6 (32 ref.) Comment in: Trends Biochem Sci 1997 Aug;22(8):288.
Distinct and specific functions of cGMP-dependent protein kinases. Lohmann SM, et al. **Trends Biochem Sci** 1997 Aug; 22(8):307–12 (50 ref.)

p70 S6 kinase: an enigma with variations. Proud CG. **Trends Biochem Sci** 1996 May;21(5):181–5 (49 ref.)
Iron–sulfur clusters as biosensors of oxidants and iron [published erratum appears in Trends Biochem Sci 1996 Jul;21(7):246] [see comments] Rouault TA, et al. **Trends Biochem Sci** 1996 May;21(5):174–7 (48 ref.) Comment in: Trends Biochem Sci 1996 Aug;21(8):282–3.
Phosphoinositide 3-kinases: a conserved family of signal transducers. Vanhaesebroeck B, et al. **Trends Biochem Sci** 1997 Jul;22(7):267–72 (53 ref.)
Two-component signal transducers and MAPK cascades. Wurgler-Murphy SM, et al. **Trends Biochem Sci** 1997 May; 22(5):172–6 (38 ref.)
Olfaction in Drosophila: from odor to behavior. Carlson JR. **Trends Genet** 1996 May;12(5):175–80 (49 ref.)
Vulval development in Caenorhabditis elegans. Kornfeld K. **Trends Genet** 1997 Feb;13(2):55–61 (45 ref.)
The Eph receptor family: axonal guidance by contact repulsion. Orioli D, et al. **Trends Genet** 1997 Sep; 13(9):354–9 (49 ref.)
The GDNF–RET signalling partnership. Robertson K, et al. **Trends Genet** 1997 Jan;13(1):1–3 (36 ref.)
Creating conditional mutations in mammals. Spencer DM. **Trends Genet** 1996 May;12(5):181–7 (31 ref.)
Intercellular communication and group behavior in bacteria. Gray KM. **Trends Microbiol** 1997 May;5(5):184–8 (30 ref.)
Signal transduction in the cell cycle regulation of Caulobacter differentiation. Ohta N, et al. **Trends Microbiol** 1996 Aug;4(8):326–32 (45 ref.)
Signal transduction pathways combining peptide hormones and steroidogenesis. Waterman MR, et al. **Vitam Horm** 1996;52:129–48 (62 ref.)
The "syncytial tissue triad": a model for understanding how gap junctions participate in the local control of penile erection. Christ GJ. **World J Urol** 1997;15(1):36–44 (49 ref.)
Signal transduction in cavernous smooth muscle. Stief CG, et al. **World J Urol** 1997;15(1):27–31 (29 ref.)
[Signal transduction by Rac small G proteins in phagocytes] Dorseuil O, et al. **C R Seances Soc Biol Fil** 1997; 191(2):237–46 (49 ref.) (Eng. Abstr.) **(Fre)**
[Beta adrenergic signal transduction and heart adenyl cyclase] Mercadier JJ, et al. **C R Seances Soc Biol Fil** 1996; 190(2–3):207–18 (23 ref.) (Eng. Abstr.) **(Fre)**
[OB protein and its receptor: signal transduction between adipose tissue and central nervous system] Campfield LA, et al. **Journ Annu Diabetol Hotel Dieu** 1997;:131–48 (63 ref.) **(Fre)**
[PO2-affinity of oxygen-sensitive intracellular signal cascades] Acker H. **Pneumologie** 1997 Apr;51 Suppl 2:403–5 (22 ref.) (Eng. Abstr.) **(Ger)**
[Cell signaling and CDDP resistance] Masumoto N, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(4):424–30 (36 ref.) (Eng. Abstr.) **(Jpn)**
[Signal transduction system in cardiac cells] Kaibara M, et al. **Nippon Rinsho** 1996 Aug;54(8):2041–4 (4 ref.) (Eng. Abstr.) **(Jpn)**
[Function of HS1 protein in B-cell antigen-receptor signaling and induction of apoptosis] Kitamura D. **Nippon Rinsho** 1996 Jul;54(7):1773–8 (23 ref.) (Eng. Abstr.) **(Jpn)**
[Ceramide: a lipid mediator of apoptotic signal transduction] Sawai H, et al. **Nippon Rinsho** 1996 Jul;54(7):1803–8 (21 ref.) (Eng. Abstr.) **(Jpn)**
[Adaptive responses and signal transduction in bacteria] Aiba H, et al. **Nippon Saikingaku Zasshi** 1996 Feb;51(2):549–57 (34 ref.) **(Jpn)**
[Signal-transduction therapy] Hidaka H, et al. **Nippon Yakurigaku Zasshi** 1996 Sep;108(3):119–21 (0 ref.) **(Jpn)**
[ATP receptor and intracellular signaling] Katsuragi T, et al. **Nippon Yakurigaku Zasshi** 1996 Sep;108(3):166–8 (0 ref.) **(Jpn)**
[Signal transduction in mechanism of opioid dependence formed in human body and the molecular study] Miki M, et al. **Nippon Yakurigaku Zasshi** 1996 Sep;108(3):111–2 (0 ref.) **(Jpn)**
[Cell adhesion molecules on lymphocytes and their role on signal transduction] Munakata Y. **Rinsho Byori** 1996 Dec; 44(12):1152–6 (0 ref.) (Eng. Abstr.) **(Jpn)**
[The signal transduction mechanism of IL-4 in X-linked severe combined immunodeficiency patients] Izuhara K. **Rinsho Ketsueki** 1997 Mar;38(3):186–8 (8 ref.) **(Jpn)**
[Signaling pathway of macrophage colony-stimulating factor receptor] Kimura F, et al. **Rinsho Ketsueki** 1997 Mar; 38(3):189–92 (10 ref.) **(Jpn)**
[Signal transduction through G-CSF receptors] Shimoda K, et al. **Rinsho Ketsueki** 1997 Mar;38(3):193–5 (10 ref.) **(Jpn)**
[Thrombopoietin signal transduction via its receptor encoded by c-mpl: its association with hematological diseases] Takatoku M, et al. **Rinsho Ketsueki** 1997 Mar;38(3):203–8 (13 ref.) **(Jpn)**
[Signal transduction of the erythropoietin receptor] Yoshimura A, et al. **Rinsho Ketsueki** 1997 Mar;38(3):196–9 (10 ref.) **(Jpn)**
[RalGDS mediates an intracellular signal-transduction system from a proto-oncogene product Ras] Koyama S, et al. **Seikagaku** 1996 Oct;68(10):1646–50 (20 ref.) **(Jpn)**
[MAP kinase cascade regulating TGF beta signaling pathway] Matsumoto K, et al. **Seikagaku** 1996 Dec; 68(12):1824–8 (8 ref.) **(Jpn)**
[Cell adhesion mediated by cadherin-catenin machinery and signal transduction] Shibamoto S. **Seikagaku** 1996 Oct; 68(10):1650–3 (14 ref.) **(Jpn)**
[Activin: diversity of functions and signal transduction] Sugino H, et al. **Seikagaku** 1996 Aug;68(8):1405–28 (110 ref.) **(Jpn)**
[Redox regulation of cellular signaling] Suzuki Y. **Seikagaku** 1997 Mar;69(3):187–91 (15 ref.) **(Jpn)**
[Transcription factors NF-IL6 and STAT3 involved in cytokine signal transductions] Akira S. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1237–48 (65 ref.) **(Jpn)**
[Cross-point of cAMP and Ca2+ signals to the transcription factors] Hagiwara M, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1282–7 (18 ref.) **(Jpn)**
[Calcineurin-mediated signalling important for growth regulation in yeast] Hirata D, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1695–703 (40 ref.) **(Jpn)**
[Cytoskeletons in the signal transduction] Hisanaga S. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):453–63 (72 ref.) **(Jpn)**
[Ca2+ signaling in budding yeast] Iida H. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1704–11 (19 ref.) **(Jpn)**
[Cytokinin signal transduction: implication of a two-component regulatory system] Kakimoto T. **Tanpakushitsu Kakusan Koso** 1997 Apr;42(5):727–35 (39 ref.) **(Jpn)**
[Alpha beta gamma-heterotrimeic GTP-binding proteins] Katada T. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):353–63 (70 ref.) **(Jpn)**
[Signal transduction pathways mediated by small GTPases and protein kinases] Kuroda S, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1258–64 (44 ref.) **(Jpn)**
[Signal transduction in the cells] Miyamoto E. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):349–52 (0 ref.) **(Jpn)**
[Visual review: signal transduction in T cells] Nakayama T. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1092–9 (5 ref.) **(Jpn)**
["Inositol" signal transduction in yeast] Nikawa J. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1680–7 (36 ref.) **(Jpn)**
[Phosphoprotein phosphatases and signal transduction in plant cells] Oka A, et al. **Tanpakushitsu Kakusan Koso** 1997 Apr;42(5):736–43 (48 ref.) **(Jpn)**
[Protein kinase C in neuronal signaling] Suzuki A, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):411–7 (35 ref.) **(Jpn)**
[Signal transduction of steroids and vitamins mediated by nuclear receptor proteins] Umesono K. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1265–72 (37 ref.) **(Jpn)**
[Cellular interactions which control differentiation and morphogenesis in dictyostelium] Yamada Y, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(11):1560–8 (44 ref.) **(Jpn)**
[Signal reception, protein kinesis and aging] García de Jalón P. **An R Acad Nac Med (Madr)** 1996;113(3):593–610; discussion 610–3 (41 ref.) **(Spa)**

DRUG EFFECTS

Immunoregulatory role of neurotransmitters. Qiu Y, et al. **Adv Neuroimmunol** 1996;6(3):223–31 (51 ref.)
Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design. Lerner EC, et al. **Anticancer Drug Des** 1997 Jun;12(4):229–38 (55 ref.)
Antisense-protein kinase A: a single-gene-based therapeutic approach. Cho-Chung YS, et al. **Antisense Nucleic Acid Drug Dev** 1997 Jun;7(3):217–23 (20 ref.)
Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors. Altmann KH, et al. **Biochem Soc Trans** 1996 Aug;24(3):630–7 (46 ref.)
Antisense oligonucleotides as inhibitors of signal transduction: development from research tools to therapeutic agents. Dean NM, et al. **Biochem Soc Trans** 1996 Aug;24(3):623–9 (41 ref.)
Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Kelloff GJ, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Aug;5(8):657–66 (108 ref.)
Cell death, survival and proliferation in Tetrahymena thermophila. Effects of insulin, sodium nitroprusside, 8-Bromo cyclic GMP, NG-methyl-L-arginine and methylene blue. Christensen ST, et al. **Cell Biol Int** 1996 Oct;20(10):653–66 (78 ref.)
Targeting signal transduction in the discovery of antiproliferative drugs. Saltiel AR, et al. **Chem Biol** 1996 Nov;3(11):887–93 (29 ref.)
Oncogene products as therapeutic targets for cancer. Huang PS, et al. **Curr Opin Oncol** 1997 Jan;9(1):94–100 (83 ref.)
An essential role for free radicals and derived species in signal transduction. Lander HM. **FASEB J** 1997 Feb;11(2):118–24 (90 ref.)
Oxidants as stimulators of signal transduction. Suzuki YJ, et al. **Free Radic Biol Med** 1997;22(1–2):269–85 (184 ref.)
Effects of tenidap on intracellular signal transduction and the induction of proinflammatory cytokines: a review. Bondeson J. **Gen Pharmacol** 1996 Sep;27(6):943–56 (68 ref.)
The mechanisms of action of disease-modifying antirheumatic drugs: a review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines. Bondeson J. **Gen Pharmacol** 1997 Aug;29(2):127–50 (287 ref.)
The CD19–CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Tedder TF, et al. **Immunity** 1997 Feb;6(2):107–18 (94 ref.)
Negative signaling in B cells by surface immunoglobulins. Mayumi M, et al. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 2):S238–47 (102 ref.)
Inside-out signaling through integrins. Faull RJ, et al. **J Am Soc Nephrol** 1996 Aug;7(8):1091–7 (81 ref.)
Bacterial toxins that target Rho proteins. Aktories K. **J Clin Invest** 1997 Mar 1;99(5):827–9 (10 ref.)
Regulation of signal transduction pathways by mood-stabilizing agents: implications for the delayed onset of therapeutic efficacy. Manji HK, et al. **J Clin Psychiatry** 1996;57 Suppl 13:34–46; discussion 47–8 (109 ref.)
G protein-mediated signal transduction as a target of antidepressant and antibipolar drug action: evidence from model systems. Rasenick MM, et al. **J Clin Psychiatry** 1996; 57 Suppl 13:49–55; discussion 56–8 (38 ref.)
TNF-induced intracellular signaling leading to gene induction or to cytotoxicity by necrosis or by apoptosis. Fiers W, et al. **J Inflamm** 1995–96;47(1–2):67–75 (27 ref.)
Inhibitory effect of wortmannin on phosphatidylinositol 3-kinase-mediated cellular events. Hazeki O, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):259–61 (8 ref.)
Epidermal growth factor receptor family and chemosensitization [editorial; comment] Mendelsohn J, et al. **J Natl Cancer Inst** 1997 Mar 5;89(5):341–3 (45 ref.) Comment on: J Natl Cancer Inst 1997 Mar 5;89(5):365–73.
The effect of immunosuppressive drugs on T cell signalling pathways: non-redundant steps in the T cell response. Halloran PF. **Kidney Blood Press Res** 1996;19(3–4):174–6 (19 ref.)
Peroxovanadium compounds: biological actions and mechanism of insulin-mimesis. Bevan AP, et al. **Mol Cell Biochem** 1995 Dec 6–20;153(1–2):49–58 (52 ref.)
Modulation of insulin action by vanadate: evidence of a role for phosphotyrosine phosphatase activity to alter cellular signaling. Fantus IG, et al. **Mol Cell Biochem** 1995 Dec 6–20;153(1–2):103–12 (76 ref.)
Molecular mechanisms of drug addiction: adaptations in signal transduction pathways. Nestler EJ, et al. **Mol Psychiatry** 1996 Jul;1(3):190–9 (65 ref.)
Neuroprotective signal transduction: relevance to stroke. Mattson MP. **Neurosci Biobehav Rev** 1997 Mar; 21(2):193–206 (127 ref.)
Cellular and molecular neuroscience of alcoholism. Diamond I, et al. **Physiol Rev** 1997 Jan;77(1):1–20 (375 ref.)
Individual and combined effects of ethanol and cocaine on intracellular signals and gene expression. Torres G, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 May; 20(4):561–96 (154 ref.)
Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach. Slovin SF, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 14):41–8 (61 ref.)
Cadmium, gene regulation, and cellular signalling in mammalian cells. Beyersmann D, et al. **Toxicol Appl Pharmacol** 1997 Jun;144(2):247–61 (137 ref.)
[Antidepressive agents and the cerebral signal transduction system—hippocampal neuromodulation and the action mechanism of antidepressants] Tajima O, et al. **Seishin Shinkeigaku Zasshi** 1996;98(11):909–15 (4 ref.) **(Jpn)**

GENETICS

Molecular genetics of signal transduction in Dictyostelium. Parent CA, et al. **Annu Rev Biochem** 1996;65:411–40 (173 ref.)
Genetic networks controlling the initiation of sporulation and the development of genetic competence in Bacillus subtilis. Grossman AD. **Annu Rev Genet** 1995;29:477–508 (121 ref.)
Signaling pathways that establish the dorsal-ventral pattern of the Drosophila embryo. Morisato D, et al. **Annu Rev Genet** 1995;29:371–99 (165 ref.)
Regulation of genomic instability in preneoplastic cells. Tlsty TD. **Cancer Surv** 1996;28:217–24 (14 ref.)
A versatile transcriptional effector of Wingless signaling. Nusse R. **Cell** 1997 May 2;89(3):321–3 (21 ref.)
Signals for activation of the GM-CSF promoter and enhancer in T cells. Shannon MF, et al. **Crit Rev Immunol** 1997;17(3–4):301–23 (161 ref.)
Plant pathology: many roads lead to resistance. Boyes DC, et al. **Curr Biol** 1996 Jun 1;6(6):634–7 (25 ref.)
Defining the regulatory networks for muscle development. Molkentin JD, et al. **Curr Opin Genet Dev** 1996 Aug; 6(4):445–53 (58 ref.)
Ataxia-telangiectasia: a multifaceted genetic disorder associated with defective signal transduction. Lavin MF, et al. **Curr Opin Immunol** 1996 Aug;8(4):459–64 (47 ref.)
The use of dominant-negative mutations to elucidate signal transduction pathways in lymphocytes. Perlmutter RM, et al. **Curr Opin Immunol** 1996 Apr;8(2):285–90 (48 ref.)
Xid and Xid-like immunodeficiencies from a signaling point of view. Tarakhovsky A. **Curr Opin Immunol** 1997 Jun; 9(3):319–23 (50 ref.)
Determination of Xenopus cell lineage by maternal factors and cell interactions. Moody SA, et al.

Curr Top Dev Biol 1996;32:103–38 (160 ref.)
Surveillance and genome stability in budding yeast: implications for mammalian carcinogenesis. Spencer F. **Curr Top Microbiol Immunol** 1997;221:19–35 (98 ref.)
Adenoviral/retroviral vector chimeras: a novel strategy to achieve high-efficiency stable transduction in vivo. Bilbao G, et al. **FASEB J** 1997 Jul;11(8):624–34 (112 ref.)
Osmotic regulation of gene expression. Burg MB, et al. **FASEB J** 1996 Dec;10(14):1598–606 (39 ref.)
Abnormal transduction mechanisms in pituitary adenomas. Barlier A, et al. **Horm Res** 1997;47(4–6):227–34 (61 ref.)
Inborn errors of signal transduction: mutations in G proteins and G protein-coupled receptors as a cause of disease. Spiegel AM. **J Inherit Metab Dis** 1997 Jun;20(2):113–21 (20 ref.)
Molecular understanding of hematopoietin/cytokine receptor signaling defects in hematopoietic disorders. Soede-Bobok AA, et al. **J Mol Med** 1997 Jul;75(7):470–7 (80 ref.)
Cultured skin fibroblasts as a cell model for investigating schizophrenia. Mahadik SP, et al. **J Psychiatr Res** 1996 Nov-Dec;30(6):421–39 (160 ref.)
Cascade of gene expression induced by Ca2+ signals in neurons. Tsuda M. **Neurochem Int** 1996 Nov;29(5):443–51 (49 ref.)
What's new in ras genes? Physiological role of ras genes in signal transduction and significance of ras gene activation in tumorigenesis. Waldmann V, et al. **Pathol Res Pract** 1996 Sep;192(9):883–91 (119 ref.)
Comparative aspects of Notch signaling in lower and higher eukaryotes. Blaumueller CM, et al. **Perspect Dev Neurobiol** 1997;4(4):325–43 (123 ref.)
Tumor suppressor genes and signal transduction in Drosophila. Woods DF, et al. **Princess Takamatsu Symp** 1994;24:1–13 (69 ref.)
Potentiation of beta-adrenergic signaling by gene transfer. Drazner MH, et al. **Proc Assoc Am Physicians** 1997 May; 109(3):220–7 (54 ref.)
[Molecular biology, pharmacology and signal transduction of 5 cloned human somatostatin receptors] Fehmann HC, et al. **Z Gastroenterol** 1996 Nov;34(11):767–74 (53 ref.) (Eng. Abstr.) **(Ger)**
[Wingless/Wnt signal transduction mechanism] Yanagawa S. **Tanpakushitsu Kakusan Koso** 1997 Jan;42(1):22–30 (42 ref.) **(Jpn)**
[The Anders Jahres Prize. Intracellular signal transmission via dioxin receptors] Poellinger L. **Nord Med** 1996 Feb; 111(2):45–8 (15 ref.) (Eng. Abstr.) **(Swe)**

IMMUNOLOGY

Regulation of B cell apoptosis. Ashman RF, et al. **Adv Exp Med Biol** 1996;406:145–54 (21 ref.)
Signals for survival and apoptosis in normal and neoplastic B lymphocytes. Gordon J, et al. **Adv Exp Med Biol** 1996; 406:139–44 (10 ref.)
Regulation of interleukin-12 signalling during T helper phenotype development. Jacobson NG, et al. **Adv Exp Med Biol** 1996;409:61–73 (31 ref.)
The role of FasL and TNF in the homeostatic regulation of immune responses. Lynch DH. **Adv Exp Med Biol** 1996; 406:135–8 (23 ref.)
Autoimmunity due to defective Nur77, Fas, and TNF-RI apoptosis. Mountz JD, et al. **Adv Exp Med Biol** 1996; 406:241–62 (93 ref.)
Regulation of T cell activation by CD28 and CTLA4. Noel PJ, et al. **Adv Exp Med Biol** 1996;406:209–17 (27 ref.)
The thymus and T cell death. Sprent J, et al. **Adv Exp Med Biol** 1996;406:191–8 (35 ref.)
Role of antibody signaling in inducing tumor dormancy. Uhr JW, et al. **Adv Exp Med Biol** 1996;406:69–74 (32 ref.)
Interleukin-2 receptor signaling mechanisms. Karnitz LM, et al. **Adv Immunol** 1996;61:147–99 (255 ref.)
CD40–CD40 ligand: a multifunctional receptor–ligand pair. Van Kooten C, et al. **Adv Immunol** 1996;61:1–77 (371 ref.)
Functional and molecular characterization of VIP receptors and signal transduction in human and rodent immune systems. Calvo JR, et al. **Adv Neuroimmunol** 1996; 6(1):39–47 (52 ref.)
Immunoregulatory role of neurotransmitters. Qiu Y, et al. **Adv Neuroimmunol** 1996;6(3):223–31 (51 ref.)
Unraveling the function of HIV type 1 Nef. Geleziunas R, et al. **AIDS Res Hum Retroviruses** 1996 Nov 20; 12(17):1579–82 (31 ref.)
Nucleosome-driven autoimmune response in lupus. Pathogenic T helper cell epitopes and costimulatory signals. Datta SK, et al. **Ann N Y Acad Sci** 1997 Apr 5; 815:155–70 (168 ref.)
T cell antigen receptor signal transduction pathways. Cantrell D. **Annu Rev Immunol** 1996;14:259–74 (91 ref.)
Orchestrated information transfer underlying leukocyte endothelial interactions. Ebnet K, et al. **Annu Rev Immunol** 1996;14:155–77 (132 ref.)
Positive and negative signal co-operativity in the immune system: the BCR, Fc gamma RIIB, CR2 paradigm. Cambier JC. **Biochem Soc Trans** 1997 May;25(2):441–5 (21 ref.)
Antigen receptor signaling gives lymphocytes a long life [comment] Neuberger MS. **Cell** 1997 Sep 19;90(6):971–3 (8 ref.) Comment on: Cell 1997 Sep 19;90(6):1073–83.
T cell signalling through CD73. Resta R, et al. **Cell Signal** 1997 Feb;9(2):131–9 (92 ref.)
Signal transduction during NK cell activation. Bonnema JD, et al. **Chem Immunol** 1996;64:28–43 (102 ref.)
Recognition and signaling by mouse Ly-49 receptors. Seaman WE, et al. **Chem Immunol** 1996;64:19–27 (31 ref.)
Signal transduction in eosinophils. van der Bruggen T, et al. **Clin Exp Allergy** 1996 Aug;26(8):880–91 (142 ref.)
Protein tyrosine phosphatase roles in the regulation of lymphocyte signaling. Pani G, et al. **Clin Immunol Immunopathol** 1997 Jul;84(1):1–16 (110 ref.)
Lymphocyte activation in health and disease. Berridge MJ. **Crit Rev Immunol** 1997;17(2):155–78 (155 ref.)
Biochemistry of antigen receptor signaling in mature and developing B lymphocytes. Bireland ML, et al. **Crit Rev Immunol** 1997;17(3–4):353–85 (228 ref.)
Functions of IL-4 and control of its expression. Brown MA, et al. **Crit Rev Immunol** 1997;17(1):1–32 (257 ref.)
Accessory molecule and costimulation requirements for CD4 T cell response. Croft M, et al. **Crit Rev Immunol** 1997; 17(1):89–118 (159 ref.)
Genes responsible for quantitative regulation of antibody production. Puel A, et al. **Crit Rev Immunol** 1996; 16(3):223–50 (262 ref.)
Signals for activation of the GM-CSF promoter and enhancer in T cells. Shannon MF, et al. **Crit Rev Immunol** 1997;17(3–4):301–23 (161 ref.)
Structural aspects of signal transduction in B-cells. Vihinen M, et al. **Crit Rev Immunol** 1996;16(3):251–75 (254 ref.)
Hemidesmosomes: roles in adhesion, signaling and human diseases. Borradori L, et al. **Curr Opin Cell Biol** 1996 Oct; 8(5):647–56 (74 ref.)
Integrins and cancer. Varner JA, et al. **Curr Opin Cell Biol** 1996 Oct;8(5):724–30 (77 ref.)
Recent advances in tumor necrosis factor and CD40 signaling. Tewari M, et al. **Curr Opin Genet Dev** 1996 Feb; 6(1):39–44 (52 ref.)
Downstream signals initiated in mast cells by Fc epsilon RI and other receptors. Beaven MA, et al. **Curr Opin Immunol** 1996 Dec;8(6):766–72 (66 ref.)
Co-stimulation in T cell responses. Chambers CA, et al. **Curr Opin Immunol** 1997 Jun;9(3):396–404 (83 ref.)
Regulation of antigen receptor signal transduction by protein tyrosine kinases. Chan AC, et al. **Curr Opin Immunol** 1996 Jun;8(3):394–401 (61 ref.)
The complexity of signaling pathways activated by the BCR. DeFranco AL. **Curr Opin Immunol** 1997 Jun;9(3):296–308 (120 ref.)
Activation of B lymphocytes: integrating signals from CD19, CD22 and Fc gamma RIIb1. Doody GM, et al. **Curr Opin Immunol** 1996 Jun;8(3):378–82 (47 ref.)
Molecular mechanisms in B cell antigen receptor signaling. Kurosaki T. **Curr Opin Immunol** 1997 Jun;9(3):309–18 (84 ref.)
Natural killer cell receptors. Long EO, et al. **Curr Opin Immunol** 1997 Jun;9(3):344–50 (69 ref.)
Role of phosphatases in lymphocyte activation. Neel BG. **Curr Opin Immunol** 1997 Jun;9(3):405–20 (124 ref.)
Lymphocyte activation and effector functions. How signals are integrated in the immune system. Nussenzweig M, et al. **Curr Opin Immunol** 1997 Jun;9(3):293–5 (0 ref.)
Co-receptors of B lymphocytes. O'Rourke L, et al. **Curr Opin Immunol** 1997 Jun;9(3):324–9 (65 ref.)
Signalling in lymphocyte development. Owen MJ, et al. **Curr Opin Immunol** 1996 Apr;8(2):191–8 (64 ref.)
The use of dominant-negative mutations to elucidate signal transduction pathways in lymphocytes. Perlmutter RM, et al. **Curr Opin Immunol** 1996 Apr;8(2):285–90 (48 ref.)
Signals and susceptibility to programmed death in b cells. Rothstein TL. **Curr Opin Immunol** 1996 Jun;8(3):362–71 (133 ref.)
T cell clonal anergy. Schwartz RH. **Curr Opin Immunol** 1997 Jun;9(3):351–7 (44 ref.)
Signal transduction in plant immunity. Shirasu K, et al. **Curr Opin Immunol** 1996 Feb;8(1):3–7 (55 ref.)
TCR zeta chain in T cell development and selection. Shores EW, et al. **Curr Opin Immunol** 1997 Jun;9(3):380–9 (96 ref.)
Mitogen-activated protein kinase cascades and regulation of gene expression. Su B, et al. **Curr Opin Immunol** 1996 Jun; 8(3):402–11 (95 ref.)
Inhibitory receptors, ITIM sequences and phosphatases. Unkeless JC, et al. **Curr Opin Immunol** 1997 Jun;9(3):338–43 (42 ref.)
Functions of CD40 on B cells, dendritic cells and other cells. van Kooten C, et al. **Curr Opin Immunol** 1997 Jun; 9(3):330–7 (64 ref.)
Biophysical and structural studies of TCRs and ligands: implications for T cell signaling. Ward ES, et al. **Curr Opin Immunol** 1997 Feb;9(1):97–106 (59 ref.)
Pathways leading to cell death in T cells. Wong B, et al. **Curr Opin Immunol** 1997 Jun;9(3):358–64 (69 ref.)
Eosinophil priming by cytokines: from cellular signal to in vivo modulation. Koenderman L, et al. **Eur Respir J Suppl** 1996 Aug;22:119s–125s (83 ref.)
Tuning antigen receptor signaling by CD22: integrating cues from antigens and the microenvironment. Cyster JG, et al. **Immunity** 1997 May;6(5):509–17 (72 ref.)
TNF-alpha-induced regulation and signalling in macrophages. Riches DW, et al. **Immunobiology** 1996 Oct; 195(4–5):477–90 (31 ref.)
Signal minus 1: a key factor in immunological tolerance to tissue-specific self antigens? Parish CR. **Immunol Cell Biol** 1996 Jun;74(3):278–85 (50 ref.)
Where the outside meets the inside: integrins as activators and targets of signal transduction cascades. Brown E, et al. **Immunol Lett** 1996 Dec;54(2–3):189–93 (35 ref.)
Granulocyte signal transduction and priming: cause without effect? Coffer PJ, et al. **Immunol Lett** 1997 Jun 1; 57(1–3):27–31 (58 ref.)
ITIMs and ITAMs. The Yin and Yang of antigen and Fc receptor-linked signaling machinery. Isakov N. **Immunol Res** 1997 Feb;16(1):85–100 (112 ref.)
Regulation of cell signaling by the protein tyrosine phosphatases, CD45 and SHP-1. Ulyanova T, et al. **Immunol Res** 1997 Feb;16(1):101–13 (117 ref.)
Signal transduction by human NK cell MHC-recognizing receptors. Binstadt BA, et al. **Immunol Rev** 1997 Feb; 155:197–203 (70 ref.)
Role of the common cytokine receptor gamma chain in cytokine signaling and lymphoid development. Leonard WJ, et al. **Immunol Rev** 1995 Dec;148:97–114 (77 ref.)
Transduction of cytotoxic signals in natural killer cells: a general model of fine tuning between activatory and inhibitory pathways in lymphocytes. Renard V, et al. **Immunol Rev** 1997 Feb;155:205–21 (153 ref.)
Early T-cell development in CD3-deficient mice. Tanaka Y, et al. **Immunol Rev** 1995 Dec;148:171–99 (89 ref.)
Protein tyrosine phosphatases in T-cell development, apoptosis and signalling. Frearson JA, et al. **Immunol Today** 1996 Aug;17(8):385–91 (57 ref.)
TCR signaling regulates thymic organization: lessons from TCR-transgenic mice. Goverman J, et al. **Immunol Today** 1997 May;18(5):204–8 (22 ref.)
CSF-I signal transduction: what is of functional significance? Hamilton JA. **Immunol Today** 1997 Jul;18(7):313–7 (34 ref.)
Alterations in T cells of cancer-bearers: whence specificity? Levey DL, et al. **Immunol Today** 1996 Aug;17(8):365–8 (39 ref.)
Integrins as promiscuous signal transduction devices. Petty HR, et al. **Immunol Today** 1996 May;17(5):209–12 (23 ref.)
Negative signaling in B cells: SHIP Grbs Shc. Tridandapani S, et al. **Immunol Today** 1997 Sep;18(9):424–7 (48 ref.)
Development of Th 1- or Th 2-dominated immune responses: what about the polarizing signals? Romagnani S. **Int J Clin Lab Res** 1996;26(2):83–98 (176 ref.)
Negative signaling in B cells by surface immunoglobulins. Mayumi M, et al. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 2):S238–47 (102 ref.)
Roles of JAK kinases in human GM-CSF receptor signal transduction. Watanabe S, et al. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 2):S183–91 (26 ref.)
Partial activation of foreign antigen specific T lymphocytes by a self peptide: possible roles of altered peptide ligands in regulating T lymphocyte mediated immune response. Cao W, et al. **J Mol Med** 1996 Oct;74(10):573–82 (104 ref.)
IL-6 cytokine family and signal transduction: a model of the cytokine system. Hibi M, et al. **J Mol Med** 1996 Jan; 74(1):1–12 (168 ref.)
Cytokine signal networks and a new era in biomedical research. Arai K, et al. **Mol Cells** 1997 Feb 28;7(1):1–12 (40 ref.)
Interleukin 8 as a novel target for intervention therapy in acute inflammatory diseases. Harada A, et al. **Mol Med Today** 1996 Nov;2(11):482–9 (30 ref.)
Viewpoint: signal transduction during natural killer cell activation. Leibson P. **Nat Immun** 1995;14(3):117–22 (38 ref.)
Interaction of natural killer cells with extracellular matrix induces early intracellular signalling events and enhances cytotoxic functions. Palmieri G, et al. **Nat Immun** 1996–97; 15(2–3):147–53 (50 ref.)
Divergent signal transduction pathways and effects on natural killer cell functions induced by interaction of Fc receptors with physiologic ligands or antireceptor antibodies. Sulica A, et al. **Nat Immun** 1995;14(3):123–33 (58 ref.)
Regulation of interleukin-12 signal transduction during T helper phenotype development. Jacobson NG, et al. **Res Immunol** 1995 Sep-Oct;146(7–8):446–56 (23 ref.)
The lectin pathway. Matsushita M, et al. **Res Immunol** 1996 Feb;147(2):115–8 (21 ref.)
NK receptors and signalling. Palmieri G, et al. **Res Immunol** 1997 Mar-Apr;148(3):184–90 (55 ref.)
The lectin pathway of complement activation. Turner MW. **Res Immunol** 1996 Feb;147(2):110–5 (33 ref.)
Intracellular signaling in neutrophil priming and activation. Downey GP, et al. **Semin Cell Biol** 1995 Dec;6(6):345–56 (61 ref.)
Signalling heterogeneity as a contributing factor in macrophage functional diversity. Riches DW. **Semin Cell Biol** 1995 Dec;6(6):377–84 (40 ref.)
Variant TCR ligands: new insights into the molecular basis of antigen-dependent signal transduction and T-cell activation. Madrenas J, et al. **Semin Immunol** 1996 Apr; 8(2):83–101 (99 ref.)
Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules. Kiessling R, et al. **Springer Semin Immunopathol** 1996;18(2):227–42 (100 ref.)

PHYSIOLOGY

GIP receptors and signal-transduction mechanisms. McIntosh CH, et al. **Acta Physiol Scand** 1996 Jul; 157(3):361–5 (30 ref.)
Transforming growth factor-beta system and its regulation by members of the steroid-thyroid hormone superfamily. Koli K, et al. **Adv Cancer Res** 1996;70:63–94 (133 ref.)
PO2 affinities, heme proteins, and reactive oxygen intermediates involved in intracellular signal cascades for

sensing oxygen. Acker H. **Adv Exp Med Biol** 1996; 410:59–64 (36 ref.)
Granzyme B–induced apoptosis. Greenberg AH. **Adv Exp Med Biol** 1996;406:219–28 (69 ref.)
Fas splicing variants and their effect on apoptosis. Ruberti G, et al. **Adv Exp Med Biol** 1996;406:125–34 (67 ref.)
Cardiac effects of AII. AT1A receptor signaling, desensitization, and internalization. Thomas WG, et al. **Adv Exp Med Biol** 1996;396:59–69 (60 ref.)
Redox regulation of AP–1: a link between transcription factor signaling and DNA repair. Xanthoudakis S, et al. **Adv Exp Med Biol** 1996;387:69–75 (45 ref.)
Platelet–activating factor (PAF): signalling and adhesion in cell–cell interactions. Zimmerman GA, et al. **Adv Exp Med Biol** 1996;416:297–304 (34 ref.)
Intracellular signal transduction in the postischemic brain. Wieloch T, et al. **Adv Neurol** 1996;71:371–87; discussion 387–8 (147 ref.)
Dissection of protein kinase cascades that mediate cellular response to cytokines and cellular stress. Cohen P. **Adv Pharmacol** 1996;36:15–27 (29 ref.)
Sphingolipid–dependent protein kinases. Hakomori S. **Adv Pharmacol** 1996;36:155–71 (33 ref.)
Roles of the MAP kinase cascade in vertebrates. Moriguchi T, et al. **Adv Pharmacol** 1996;36:121–37 (124 ref.)
Protein tyrosine phosphatases and the control of cellular signaling responses. Tonks NK. **Adv Pharmacol** 1996; 36:91–119 (104 ref.)
Apoptosis: an overview of the process and its relevance in disease. Webb SJ, et al. **Adv Pharmacol** 1997;41:1–34 (174 ref.)
Antigen receptor signalling. Monteseirín J, et al. **Allergol Immunopathol (Madr)** 1996 Sep–Oct;24(5):185–92 (9 ref.)
Protein families that mediate Ca2+ signaling in the cardiovascular system. Katz AM. **Am J Cardiol** 1996 Nov 7;78(9A):2–6 (49 ref.)
The signal transducer gp130 is shared by interleukin–6 family of haematopoietic and neurotrophic cytokines. Taga T. **Ann Med** 1997 Feb;29(1):63–72 (88 ref.)
Transduction is a major factor influencing receptor characterization. Spedding M, et al. **Ann N Y Acad Sci** 1997 May 30;812:29–40 (49 ref.)
Structural and biological features of the TNF receptor and TNF ligand superfamilies: interactive signals in the pathobiology of Hodgkin's disease. Gruss HJ, et al. **Ann Oncol** 1996;7 Suppl 4:19–26 (66 ref.)
Molecular mechanism of photosignaling by archaeal sensory rhodopsins. Hoff WD, et al. **Annu Rev Biophys Biomol Struct** 1997;26:223–58 (174 ref.)
Antigen–mediated IGE receptor aggregation and signaling: a window on cell surface structure and dynamics. Holowka D, et al. **Annu Rev Biophys Biomol Struct** 1996;25:79–112 (149 ref.)
Modular peptide recognition domains in eukaryotic signaling. Kuriyan J, et al. **Annu Rev Biophys Biomol Struct** 1997; 26:259–88 (102 ref.)
Functional and structural complexity of signal transduction via G–protein–coupled receptors. Gudermann T, et al. **Annu Rev Neurosci** 1997;20:399–427 (192 ref.)
Cytokine receptor signal transduction through Jak tyrosine kinases and Stat transcription factors. Silvennoinen O, et al. **APMIS** 1997 Jul;105(7):497–509 (67 ref.)
Protein tyrosine phosphorylation and signal transduction during capacitation–acrosome reaction and zona pellucida binding in human sperm. Naz RK. **Arch Androl** 1996 Jul–Aug;37(1):47–55 (48 ref.)
Retrograde transport of acidic fibroblast growth factor as a part of the growth factor signaling. Więdłocha A. **Arch Immunol Ther Exp (Warsz)** 1996;44(4):201–7 (64 ref.)
Ecdysone signaling cascade and regulation of Drosophila metamorphosis. Baehrecke EH. **Arch Insect Biochem Physiol** 1996;33(3–4):231–44 (69 ref.)
Multiple signaling pathways establish both the individuation and the polarity of the oocyte follicle in Drosophila. Morgan MM, et al. **Arch Insect Biochem Physiol** 1996; 33(3–4):211–30 (83 ref.)
Mechanisms of beta–adrenergic receptor desensitization: from molecular biology to heart failure. Lohse MJ, et al. **Basic Res Cardiol** 1996;91 Suppl 2:29–34 (62 ref.)
Angiotensin II type 1 receptor induced signal–transduction pathways as new targets for pharmacological treatment of the renin–angiotensin system. Schorb W, et al. **Basic Res Cardiol** 1996;91 Suppl 2:91–6 (35 ref.)
Regulatory mechanisms that modulate signalling by G–protein–coupled receptors. Böhm SK, et al. **Biochem J** 1997 Feb 15;322 (Pt 1):1–18 (237 ref.)
Signal–transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling. Denhardt DT. **Biochem J** 1996 Sep 15;318 (Pt 3):729–47 (228 ref.)
Signalling functions and biochemical properties of pertussis toxin–resistant G–proteins. Fields TA, et al. **Biochem J** 1997 Feb 1;321 (Pt 3):561–71 (242 ref.)
Regulation of dorsal–ventral axis formation in Xenopus by intercellular and intracellular signalling. Kimelman D, et al. **Biochem Soc Symp** 1996;62:13–23 (57 ref.)
Activin receptors: cellular signalling by receptor serine kinases. Zimmerman CM, et al. **Biochem Soc Symp** 1996; 62:25–38 (47 ref.)
Regulation of 'signalling diacylglycerol' in cells: the importance of diacylglycerol kinase. Hodgkin MN, et al. **Biochem Soc Trans** 1996 Nov;24(4):991–4 (15 ref.)
Regulators of G–protein–mediated signalling. Lohse MJ, et al. **Biochem Soc Trans** 1996 Nov;24(4):975–80 (52 ref.)
Transduction of Ca2+ signals in plant cells and compartmentalization of the Ca2+ signal. Trewavas A, et al. **Biochem Soc Trans** 1996 Nov;24(4):971–4 (24 ref.)
Signalling and adhesive properties of the integrin leucocyte function–associated antigen 1 (LFA–1). van Kooyk Y, et al. **Biochem Soc Trans** 1997 May;25(2):515–20 (51 ref.)
Virocrine transformation. Drummond–Barbosa D, et al. **Biochim Biophys Acta** 1997 Feb 22;1332(1):M1–17 (148 ref.)
Transforming growth factor–beta: the breaking open of a black box. Alevizopoulos A, et al. **Bioessays** 1997 Jul; 19(7):581–91 (93 ref.)
STATs and MAPKs: obligate or opportunistic partners in signaling. Ihle JN. **Bioessays** 1996 Feb;18(2):95–8 (13 ref.)
Cooperation between soluble factors and integrin–mediated cell anchorage in the control of cell growth and differentiation. Juliano R. **Bioessays** 1996 Nov;18(11):911–7 (77 ref.)
The phytochromes: a biochemical mechanism of signaling in sight? Quail PH. **Bioessays** 1997 Jul;19(7):571–9 (56 ref.)
The IRS–signalling system during insulin and cytokine action. Yenush L, et al. **Bioessays** 1997 Jun;19(6):491–500 (81 ref.)
Multiple myosin motors and mechanoelectrical transduction by hair cells. Gillespie PG. **Biol Bull** 1997 Feb; 192(1):186–90 (21 ref.)
Endosomes, receptor tyrosine kinase internalization and signal transduction. Bergeron JJ, et al. **Biosci Rep** 1995 Dec;15(6):411–8 (41 ref.)
Signal transduction and motility of Dictyostelium. Newell PC. **Biosci Rep** 1995 Dec;15(6):445–62 (79 ref.)
Interferon signal transduction. Larner A, et al. **Biotherapy** 1996;8(3–4):175–81 (60 ref.)
Bone morphogenetic proteins and C–FOS: early signals in endochondral bone formation. Kaplan FS, et al. **Bone** 1996 Jul;19(1 Suppl):13S–21S (69 ref.)
Superoxide, hydrogen peroxide and nitric oxide as signalling molecules: their production and role in disease. Hancock JT. **Br J Biomed Sci** 1997 Mar;54(1):38–46 (110 ref.)
Plasmalogens, phospholipases A2 and signal transduction. Farooqui AA, et al. **Brain Res Brain Res Rev** 1995 Sep; 21(2):152–61 (87 ref.)
Cellular signalling in vertebrate pigment cells. deOliveira AR, et al. **Braz J Med Biol Res** 1996 Dec;29(12):1743–9 (51 ref.)
Let there be light: signal transduction in a mammalian circadian system. Golombek DA, et al. **Braz J Med Biol Res** 1996 Jan;29(1):131–40 (77 ref.)
Mechanisms of increased endothelial permeability. Lum H, et al. **Can J Physiol Pharmacol** 1996 Jul;74(7):787–800 (80 ref.)
T cell antigen receptor signal transduction pathways. Cantrell DA. **Cancer Surv** 1996;27:165–75 (165 ref.)
The p70S6K signalling pathway: a novel signalling system involved in growth regulation. Grammer TC, et al. **Cancer Surv** 1996;27:271–92 (97 ref.)
Protein tyrosine kinase receptors. Heldin CH. **Cancer Surv** 1996;27:7–24 (82 ref.)
The control of inositol lipid hydrolysis. Katan M. **Cancer Surv** 1996;27:199–211 (67 ref.)
Control of the ERK MAP kinase cascade by Ras and Raf. Marais R, et al. **Cancer Surv** 1996;27:101–25 (125 ref.)
Serine/threonine kinase receptors: mediators of transforming growth factor beta family signals. Massagué J, et al. **Cancer Surv** 1996;27:41–64 (128 ref.)
Organization of transmembrane signalling by heterotrimeric G proteins. Offermanns S, et al. **Cancer Surv** 1996;27:177–98 (129 ref.)
The JAK/STAT pathway. Wilks AF, et al. **Cancer Surv** 1996;27:139–63 (113 ref.)
The stress activated protein kinase pathway. Woodgett JR, et al. **Cancer Surv** 1996;27:127–38 (41 ref.)
Actions of insulin on the mammalian heart: metabolism, pathology and biochemical mechanisms. Brownsey RW, et al. **Cardiovasc Res** 1997 Apr;34(1):3–24 (263 ref.)
Renal dopamine receptors: mechanisms of action and developmental aspects. Cheung PY, et al. **Cardiovasc Res** 1996 Jan;31(1):2–6 (54 ref.)
Regulation of contractile proteins in diabetic heart. Malhotra A, et al. **Cardiovasc Res** 1997 Apr;34(1):34–40 (72 ref.)
Signal transduction via the multi–step phosphorelay: not necessarily a road less traveled. Appleby JL, et al. **Cell** 1996 Sep 20;86(6):845–8 (18 ref.)
BRI–ghtening the pathway to steroid hormone signaling events in plants [comment] Ecker JR. **Cell** 1997 Sep 5; 90(5):825–7 (18 ref.) Comment on: Cell 1997 Sep 5;90(5):929–38.
There must be 50 ways to rule the signal: the case of the Drosophila EGF receptor. Perrimon N, et al. **Cell** 1997 Apr 4;89(1):13–6 (18 ref.)
The emerging field of receptor–mediated inhibitory signaling: SHP or SHIP? Scharenberg AM, et al. **Cell** 1996 Dec 13; 87(6):961–4 (16 ref.)
From form to function: signaling by protein tyrosine phosphatases [see comments] Tonks NK, et al. **Cell** 1996 Nov 1;87(3):365–8 (21 ref.) Comment in: Cell 1996 Nov 1;87(3):361–4.
Review: a role for the FGF receptor in the axonal growth response stimulated by cell adhesion molecules? Hall H, et al. **Cell Adhes Commun** 1996 Apr;3(6):441–50 (97 ref.)
Receptor tyrosine kinase signaling in vascular development. Merenmies J, et al. **Cell Growth Differ** 1997 Jan;8(1):3–10 (93 ref.)
Traction fibre: toward a "tensegral" model of the spindle. Pickett–Heaps JD, et al. **Cell Motil Cytoskeleton** 1997; 37(1):1–6 (32 ref.)
Signal transduction pathways in macroautophagy. Codogno P, et al. **Cell Signal** 1997 Feb;9(2):125–30 (102 ref.)
Phosphatidic acid: a lipid messenger involved in intracellular and extracellular signalling. English D. **Cell Signal** 1996 Aug;8(5):341–7 (98 ref.)
The role of prenylation in G–protein assembly and function. Higgins JB, et al. **Cell Signal** 1996 Sep;8(6):433–7 (50 ref.)
Signalling to the nucleus by members of the transforming growth factor–beta (TGF–beta) superfamily. Hill CS. **Cell Signal** 1996 Dec;8(8):533–44 (125 ref.)
Signal transduction pathways modulated by the D2 subfamily of dopamine receptors. Huff RM. **Cell Signal** 1996 Sep; 8(6):453–9 (91 ref.)
Cellular signalling: the role of the peroxisome. Masters CJ. **Cell Signal** 1996 Mar;8(3):197–208 (42 ref.)
Emerging components of the Crk oncogene product: the first identified adaptor protein. Matsuda M, et al. **Cell Signal** 1996 Aug;8(5):335–40 (68 ref.)
Does subunit dissociation necessarily accompany the activation of all heterotrimeric G proteins? Rebois RV, et al. **Cell Signal** 1997 Feb;9(2):141–51 (154 ref.)
Regulation of cellular signalling by fatty acid acylation and prenylation of signal transduction proteins. Resh MD. **Cell Signal** 1996 Sep;8(6):403–12 (134 ref.)
Heterotrimeric G proteins in heart disease. Schnabel P, et al. **Cell Signal** 1996 Sep;8(6):413–23 (126 ref.)
Ras–GTPase activating protein (GAP): a putative effector for Ras. Tocque B, et al. **Cell Signal** 1997 Feb;9(2):153–8 (72 ref.)
Protein kinase modulation of mu opioid receptor signalling. Yu L. **Cell Signal** 1996 Aug;8(5):371–4 (36 ref.)
Signaling toward yeast 1,3–beta–glucan synthesis. Inoue SB, et al. **Cell Struct Funct** 1996 Oct;21(5):395–402 (58 ref.)
Signal transduction from the extracellular matrix—a role for the focal adhesion protein–tyrosine kinase FAK. Schlaepfer DD, et al. **Cell Struct Funct** 1996 Oct;21(5):445–50 (90 ref.)
Getting it together: signal transduction in G–protein coupled receptors by association of receptor domains. Underwood DJ, et al. **Chem Biol** 1997 Apr;4(4):239–48 (81 ref.)
Neuromodulation of transduction and signal processing in the end organs of taste. Nagai T, et al. **Chem Senses** 1996 Jun;21(3):353–65 (106 ref.)
P2U purinoceptors: cDNA cloning, signal transduction mechanisms and structure–function analysis. Lustig KD, et al. **Ciba Found Symp** 1996;198:193–204; discussion 204–7 (28 ref.)
Trophic actions of extracellular ATP on astrocytes, synergistic interactions with fibroblast growth factors and underlying signal transduction mechanisms. Neary JT. **Ciba Found Symp** 1996;198:130–9; discussion 139–41 (31 ref.)
Transduction mechanisms of P2Z purinoceptors. Wiley JS, et al. **Ciba Found Symp** 1996;198:149–60; discussion 160–5 (52 ref.)
The multiple role of the pheromone–binding protein in olfactory transduction. Ziegelberger G. **Ciba Found Symp** 1996;200:267–75; discussion 275–80 (41 ref.)
Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases. Berk BC, et al. **Circ Res** 1997 May; 80(5):607–16 (19 ref.)
The adenylyl cyclases as integrators of transmembrane signal transduction. Ishikawa Y, et al. **Circ Res** 1997 Mar; 80(3):297–304 (89 ref.)
Dopamine–1 receptor G–protein coupling and the involvement of phospholipase A2 in dopamine–1 receptor mediated cellular signaling mechanisms in the proximal tubules of SHR. Hussain T, et al. **Clin Exp Hypertens** 1997 Jan–Feb;19(1–2):131–40 (31 ref.)
Calcium and calcium–related signalling pathways in glomerular mesangial cells. Bonventre JV. **Clin Exp Pharmacol Physiol** 1996 Jan;23(1):65–70 (34 ref.)
Competition by second messenger systems for receptor interaction and activation: implications for tissue–specific responses and disease therapy. Crouch MF, et al. **Clin Exp Pharmacol Physiol** 1997 Aug;24(8):632–8 (22 ref.)
Imidazoline binding sites and signal transduction pathways. Musgrave IF, et al. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov;23(10–11):990–4 (35 ref.)
Visualizing signal transduction: receptors, G–proteins, and adenylate cyclases [published erratum appears in Clin Sci (Colch) 1997 Feb;92(2):223] Dessauer CW, et al. **Clin Sci (Colch)** 1996 Nov;91(5):527–37 (56 ref.)
Signalling pathways involved in the mitogenic effects of cAMP. Withers DJ. **Clin Sci (Colch)** 1997 May;92(5):445–51 (21 ref.)
Oxygen sensing and signal transduction in metabolic defense against hypoxia: lessons from vertebrate facultative anaerobes. Hochachka PW, et al. **Comp Biochem Physiol A Physiol** 1997 Sep;118(1):23–9 (40 ref.)
Cell signalling by inositol phosphoglycans from different species. Varela–Nieto I, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Oct; 115(2):223–41 (204 ref.)
Sepsis–related alterations in non–immune cell–signaling.

Ahmad S. **Compr Ther** 1995 Dec;21(12):737–40 (28 ref.)

Inositol 1,4,5–trisphosphate receptors and calcium signaling. Michikawa T, et al. **Crit Rev Neurobiol** 1996;10(1):39–55 (117 ref.)

Aryl hydrocarbon receptor–mediated signal transduction. Rowlands JC, et al. **Crit Rev Toxicol** 1997 Mar;27(2):109–34 (223 ref.)

Cell signalling: MAGUK magic. Anderson JM. **Curr Biol** 1996 Apr 1;6(4):382–4 (13 ref.)

Calcium signalling: sphingosine kinase versus phospholipase C? Beaven MA. **Curr Biol** 1996 Jul 1;6(7):798–801 (14 ref.)

Signalling enzymes: bursting with potential. Braselmann S, et al. **Curr Biol** 1997 Aug 1;7(8):R470–3 (22 ref.)

Signalling pathways: jack of all cascades. Cahill MA, et al. **Curr Biol** 1996 Jan 1;6(1):16–9 (17 ref.)

Intracellular signalling: more jobs for G beta gamma. Clapham DE. **Curr Biol** 1996 Jul 1;6(7):814–6 (12 ref.)

Retinal development: on the crest of an exciting wave. Copenhagen DR. **Curr Biol** 1996 Nov 1;6(11):1368–70 (32 ref.)

Apoptosis: does stress kill? Cosulich S, et al. **Curr Biol** 1996 Dec 1;6(12):1586–8 (18 ref.)

Mitosis: don't get mad, get even. Glotzer M. **Curr Biol** 1996 Dec 1;6(12):1592–4 (16 ref.)

Object recognition: the man who mistook his dog for a cat. Humphreys GW. **Curr Biol** 1996 Jul 1;6(7):821–4 (20 ref.)

Chemoreception: tasting the sweet and the bitter. Lindemann B. **Curr Biol** 1996 Oct 1;6(10):1234–7 (20 ref.)

Neural patterning: A forward role for hedgehog. Lumsden A, et al. **Curr Biol** 1995 Dec 1;5(12):1347–50 (25 ref.)

Receptor signalling: to sevenless, a daughter. MacDougall LK, et al. **Curr Biol** 1996 Oct 1;6(10):1250–3 (12 ref.)

Neural induction: do fibroblast growth factors strike a cord? Mason I. **Curr Biol** 1996 Jun 1;6(6):672–5 (12 ref.)

Visual attention: spotlights, highlights and visual awareness. Newsome WT. **Curr Biol** 1996 Apr 1;6(4):357–60 (19 ref.)

Protein kinase C: ports of anchor in the cell. Newton AC. **Curr Biol** 1996 Jul 1;6(7):806–9 (20 ref.)

Cell–cell signalling: Wingless lands at last. Orsulic S, et al. **Curr Biol** 1996 Nov 1;6(11):1363–7 (28 ref.)

Rho: theme and variations. Ridley AJ. **Curr Biol** 1996 Oct 1;6(10):1256–64 (73 ref.)

Neurophysiology: the changing face of inhibition. Singer W. **Curr Biol** 1996 Apr 1;6(4):395–7 (10 ref.)

Neural coding: The enigma of the brain. Stevens CF, et al. **Curr Biol** 1995 Dec 1;5(12):1370–1 (10 ref.)

Receptor signaling: dimerization and beyond. Stock J. **Curr Biol** 1996 Jul 1;6(7):825–7 (18 ref.)

Axon guidance: motor–way madness. Stoker AW. **Curr Biol** 1996 Jul 1;6(7):794–7 (17 ref.)

Visual cortex: looking into a Klein bottle. Swindale NV. **Curr Biol** 1996 Jul 1;6(7):776–9 (11 ref.)

Working memory: trouble in mind. Tovée MJ, et al. **Curr Biol** 1996 Jan 1;6(1):13–5 (23 ref.)

Plant photomorphogenesis: a green light for cryptochrome research. Whitelam G. **Curr Biol** 1995 Dec 1;5(12):1351–3 (7 ref.)

Signalling pathways: a common theme in plants and animals? Wilson I, et al. **Curr Biol** 1997 Mar 1;7(3):R175–8 (10 ref.)

Intracellular signalling: putting JAKs on the kinase MAP. Winston LA, et al. **Curr Biol** 1996 Jun 1;6(6):668–71 (25 ref.)

Cell–cell signalling: frog frizbees. Zorn AM. **Curr Biol** 1997 Aug 1;7(8):R501–4 (18 ref.)

Myosins on the move to signal transduction. Bähler M. **Curr Opin Cell Biol** 1996 Feb;8(1):18–22 (43 ref.)

Integrin cytoplasmic interactions and bidirectional transmembrane signalling. Dedhar S, et al. **Curr Opin Cell Biol** 1996 Oct;8(5):657–69 (86 ref.)

Cell–to–cell contact and extracellular matrix. A multifaceted approach emerging. Ekblom P, et al. **Curr Opin Cell Biol** 1996 Oct;8(5):599–601 (5 ref.)

Desmosomes: differentiation, development, dynamics and disease. Garrod D, et al. **Curr Opin Cell Biol** 1996 Oct; 8(5):670–8 (73 ref.)

Cadherins and catenins in development. Huber O, et al. **Curr Opin Cell Biol** 1996 Oct;8(5):685–91 (67 ref.)

Integrin activation: the link between ligand binding and signal transduction. Humphries MJ. **Curr Opin Cell Biol** 1996 Oct; 8(5):632–40 (59 ref.)

ERM (ezrin/radixin/moesin) family: from cytoskeleton to signal transduction. Tsukita S, et al. **Curr Opin Cell Biol** 1997 Feb;9(1):70–5 (42 ref.)

Cell adhesion molecules and neuronal regeneration. Walsh FS, et al. **Curr Opin Cell Biol** 1996 Oct;8(5):707–13 (53 ref.)

Signal transduction and actin filament organization. Zigmond SH. **Curr Opin Cell Biol** 1996 Feb;8(1):66–73 (90 ref.)

p53 in signaling checkpoint arrest or apoptosis. Bates S, et al. **Curr Opin Genet Dev** 1996 Feb;6(1):12–8 (68 ref.)

MEKKs, GCKs, MLKs, PAKs, TAKs, and tpls: upstream regulators of the c–Jun amino–terminal kinases? Fanger GR, et al. **Curr Opin Genet Dev** 1997 Feb;7(1):67–74 (58 ref.)

The recognition of DNA damage. Jackson SP. **Curr Opin Genet Dev** 1996 Feb;6(1):19–25 (66 ref.)

Signal transduction from multiple Ras effectors. Katz ME, et al. **Curr Opin Genet Dev** 1997 Feb;7(1):75–9 (50 ref.)

Pheromone signalling and polarized morphogenesis in yeast. Leberer E, et al. **Curr Opin Genet Dev** 1997 Feb;7(1):59–66 (60 ref.)

From DNA damage to cell cycle arrest and suicide: a budding yeast perspective. Lydall D, et al. **Curr Opin Genet Dev** 1996 Feb;6(1):4–11 (62 ref.)

Novel mechanisms of RTK signal generation. Weiss FU, et al. **Curr Opin Genet Dev** 1997 Feb;7(1):80–6 (50 ref.)

Advances in understanding postreceptor signaling in response to granulocyte colony–stimulating factor. Tidow N, et al. **Curr Opin Hematol** 1997 May;4(3):171–5 (27 ref.)

Synaptic signaling by nitric oxide. Brenman JE, et al. **Curr Opin Neurobiol** 1997 Jun;7(3):374–8 (43 ref.)

Signalling through the neurotrophin receptor p75NTR. Dechant G, et al. **Curr Opin Neurobiol** 1997 Jun;7(3):413–8 (58 ref.)

Dendritic signal integration. Eilers J, et al. **Curr Opin Neurobiol** 1997 Jun;7(3):385–90 (55 ref.)

The role of positive and negative signals in somite patterning. Lassar AB, et al. **Curr Opin Neurobiol** 1996 Feb;6(1):57–63 (64 ref.)

The InsP3 receptor and intracellular Ca2+ signaling. Mikoshiba K. **Curr Opin Neurobiol** 1997 Jun;7(3):339–45 (70 ref.)

Activation and inactivation steps in the visual transduction pathway. Palczewski K, et al. **Curr Opin Neurobiol** 1997 Aug;7(4):500–4 (40 ref.)

Tripartite signaling of pattern: interactions between Hedgehogs, BMPs and Wnts in the control of vertebrate development. Roelink H. **Curr Opin Neurobiol** 1996 Feb; 6(1):33–40 (78 ref.)

Oncogenic signaling. Jones CL, et al. **Curr Opin Oncol** 1996 Jan;8(1):54–9 (67 ref.)

Paradigms to study signal transduction pathways in Drosophila. Engstrom L, et al. **Curr Top Dev Biol** 1997; 35:229–61 (111 ref.)

beta–Catenin is a target for extracellular signals controlling cadherin function: the neurocan–GalNAcPTase connection. Lilien J, et al. **Curr Top Dev Biol** 1997; 35:161–89 (137 ref.)

Role of Tiam 1 in Rac–mediated signal transduction pathways. Collard JG, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 2):253–65 (73 ref.)

ISGF3 gamma p48, a specificity switch for interferon activated transcription factors. Bluyssen AR, et al. **Cytokine Growth Factor Rev** 1996 Jun;7(1):11–7 (54 ref.)

Cardiotrophin–1: a multifunctional cytokine that signals via LIF receptor–gp 130 dependent pathways. Pennica D, et al. **Cytokine Growth Factor Rev** 1996 Jun;7(1):81–91 (63 ref.)

Cell volume signalling, osmolytes and liver function. Häussinger D, et al. **Digestion** 1997;58 Suppl 1:21–3 (17 ref.)

Biological roles of fibroblast growth factor–2. Bikfalvi A, et al. **Endocr Rev** 1997 Feb;18(1):26–45 (340 ref.)

Multiple pathways for the regulation of telomerase activity. Holt SE, et al. **Eur J Cancer** 1997 Apr;33(5):761–6 (52 ref.)

Proliferative lifespan checkpoints: cell–type specificity and influence on tumour biology. Wynford–Thomas D. **Eur J Cancer** 1997 Apr;33(5):716–26 (87 ref.)

Taking the message to the nucleus: MAD protein as a mediator of bone morphogenetic protein signaling. Hofbauer LC, et al. **Eur J Endocrinol** 1996 Dec; 135(6):654–5 (13 ref.)

Connexins, gap junctions and cell–cell signalling in the nervous system. Bruzzone R, et al. **Eur J Neurosci** 1997 Jan;9(1):1–6 (24 ref.)

Nigrostriatal dopamine system may contribute to behavioral learning through providing reinforcement signals to the striatum. Kimura M, et al. **Eur Neurol** 1997;38 Suppl 1:11–7 (33 ref.)

Disruption of vascular signalling by the reaction of nitric oxide with superoxide: implications for cardiovascular disease. Darley–Usmar V, et al. **Exp Physiol** 1997 Mar; 82(2):305–16 (85 ref.)

Intracellular signalling pathways that regulate vascular cell proliferation: effect of hypoxia. Scott PH, et al. **Exp Physiol** 1997 Mar;82(2):317–26 (29 ref.)

Signaling events controlling the molecular response to genotoxic stress. Holbrook NJ, et al. **EXS** 1996;77:273–88 (72 ref.)

Signal transduction mechanisms in the ischemic and reperfused myocardium. Ward CA, et al. **EXS** 1996; 76:191–207 (71 ref.)

Lipid biochemistry: functions of glycerolipids and sphingolipids in cellular signaling. Ghosh S, et al. **FASEB J** 1997 Jan;11(1):45–50 (55 ref.)

Regulation of STAT–dependent pathways by growth factors and cytokines. Leaman DW, et al. **FASEB J** 1996 Dec; 10(14):1578–88 (104 ref.)

The role of serine/threonine phosphorylation in hematopoietic cytokine receptor signal transduction. Mufson RA. **FASEB J** 1997 Jan;11(1):37–44 (56 ref.)

Cell survival and multiplication. The overriding need for signals: from unicellular to multicellular systems. Rasmussen L, et al. **FEMS Microbiol Lett** 1996 Apr 1; 137(2–3):123–8 (41 ref.)

The HGF receptor family: unconventional signal transducers for invasive cell growth. Comoglio PM, et al. **Genes Cells** 1996 Apr;1(4):347–54 (70 ref.)

Signal transduction through beta–catenin and specification of cell fate during embryogenesis. Miller JR, et al. **Genes Dev** 1996 Oct 15;10(20):2527–39 (118 ref.)

Alzheimer's, ageing and amyloid: an absurd allegory? Fowler CJ, et al. **Gerontology** 1997;43(1–2):132–42 (97 ref.)

Platelet activation via trimeric GTP–binding proteins. Akkerman JW, et al. **Haemostasis** 1996 Oct;26 Suppl 4:199–209 (35 ref.)

The molecular basis of signaling by vitamin A and its metabolites. Evans RM. **Harvey Lect** 1994–95;90:105–17 (42 ref.)

Immunophilins, ligands, and the control of signal transduction. Schreiber SL, et al. **Harvey Lect** 1995–96; 91:99–114 (89 ref.)

Growth hormone signalling mechanisms: involvement of the tyrosine kinase JAK2. Argetsinger LS, et al. **Horm Res** 1996;45 Suppl 1:22–4 (19 ref.)

Role of NPY neurones in GH–dependent feedback signalling to the brain. Chan YY, et al. **Horm Res** 1996;45 Suppl 1:12–4 (10 ref.)

Integrins in cell adhesion and signaling. Akiyama SK. **Hum Cell** 1996 Sep;9(3):181–6 (51 ref.)

Beta 1 integrin–mediated signaling in human T cells. Morimoto C, et al. **Hum Cell** 1996 Sep;9(3):163–8 (34 ref.)

Tyrosine phosphorylation of p130Cas in cell adhesion and transformation. Nojima Y, et al. **Hum Cell** 1996 Sep; 9(3):169–74 (19 ref.)

Intracellular signaling pathways and the regulation of cell adhesion. Shimizu Y. **Hum Cell** 1996 Sep;9(3):175–80 (37 ref.)

A coiled–coil tetramerization domain of BCR–ABL is essential for the interactions of SH2–containing signal transduction molecules. Tauchi T, et al. **Hum Cell** 1996 Dec;9(4):333–6 (18 ref.)

Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet? O'Shea JJ. **Immunity** 1997 Jul;7(1):1–11 (126 ref.)

Activation of signaling pathways and prevention of apoptosis by cytokines in eosinophils. Yousefi S, et al. **Int Arch Allergy Immunol** 1997 Jan;112(1):9–12 (29 ref.)

Integrative erectile biology: the role of signal transduction and cell–to–cell communication in coordinating corporal smooth muscle tone and penile erection. Christ GJ, et al. **Int J Impot Res** 1997 Jun;9(2):69–84 (65 ref.)

Spontaneous signalling in small central neurons: mechanisms and roles of spike–amplitude and spike–interval fluctuations. Arhem P, et al. **Int J Neural Syst** 1996 Sep; 7(4):369–76 (39 ref.)

Insulin internalization and other signaling pathways in the pleiotropic effects of insulin. Smith RM, et al. **Int Rev Cytol** 1997;173:243–80 (139 ref.)

Signal transduction in cellular senescence. Obeid LM, et al. **J Am Geriatr Soc** 1997 Mar;45(3):361–6 (56 ref.)

Ion channels in plasma membrane signal transduction. Catterall WA. **J Bioenerg Biomembr** 1996 Jun;28(3):217–8 (3 ref.)

Roles of gp130 signaling pathways in cardiac myocytes: recent advances and implications for cardiovascular disease. Yamauchi–Takihara K, et al. **J Card Fail** 1996 Dec; 2(4 Suppl):S63–8 (44 ref.)

Syndecans, signaling, and cell adhesion. Couchman JR, et al. **J Cell Biochem** 1996 Jun 15;61(4):578–84 (34 ref.)

HA receptors: regulators of signalling to the cytoskeleton. Entwistle J, et al. **J Cell Biochem** 1996 Jun 15;61(4):569–77 (51 ref.)

Integrin–dependent signal transduction. Lafrenie RM, et al. **J Cell Biochem** 1996 Jun 15;61(4):543–53 (69 ref.)

Structural and functional diversity of cadherin superfamily: are new members of cadherin superfamily involved in signal transduction pathway? Suzuki ST. **J Cell Biochem** 1996 Jun 15;61(4):531–42 (40 ref.)

Nuclear matrix as an anchor for protein kinase CK2 nuclear signalling. Tawfic S, et al. **J Cell Biochem** 1996 Aug; 62(2):165–71 (36 ref.)

Signal transduction by the alpha 6 beta 4 integrin: charting the path between laminin binding and nuclear events. Giancotti FG. **J Cell Sci** 1996 Jun;109 (Pt 6):1165–72 (84 ref.)

Histidine kinases in signal transduction pathways of eukaryotes. Loomis WF, et al. **J Cell Sci** 1997 May;110 (Pt 10):1141–5 (26 ref.)

Tyrosines 113, 128, and 145 of SLP–76 are required for optimal augmentation of NFAT promoter activity. Fang N, et al. **J Immunol** 1996 Nov 1;157(9):3769–73 (16 ref.)

Disruption of cytokine signaling in lymphoid development: unique contributions of the common cytokine gamma chain and the Jak3 kinase. Eynon EE, et al. **J Interferon Cytokine Res** 1996 Sep;16(9):677–84 (32 ref.)

Regulation of signal transduction through the T cell antigen receptor. Zhao H, et al. **J Lab Clin Med** 1997 Aug; 130(2):126–31 (56 ref.)

Early events in TNF signaling: a story of associations and dissociations. Darnay BG, et al. **J Leukoc Biol** 1997 May; 61(5):559–66 (47 ref.)

Immunoreceptor tyrosine–based activation motif (ITAM), a unique module linking antigen and Fc receptors to their signaling cascades. Isakov N. **J Leukoc Biol** 1997 Jan; 61(1):6–16 (123 ref.)

Signaling mechanisms and the activation of leukocyte integrins. Newton RA, et al. **J Leukoc Biol** 1997 Apr; 61(4):422–6 (54 ref.)

Integrin signaling in leukocytes: lessons from the alpha6beta1 integrin. Wei J, et al. **J Leukoc Biol** 1997 Apr;61(4):397–407 (119 ref.)

The cell nucleus: an Eldorado to future calcium research? Santella L. **J Membr Biol** 1996 Sep;153(2):83–92 (100 ref.)

Control of T lymphocyte signal transduction through clonal

anergy. Fields P, et al. **J Mol Med** 1996 Nov;74(11):673–83 (141 ref.)

Molecular understanding of hematopoietin/cytokine receptor signaling defects in hematopoietic disorders. Soede-Bobok AA, et al. **J Mol Med** 1997 Jul;75(7):470–7 (80 ref.)

Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. Whitmarsh AJ, et al. **J Mol Med** 1996 Oct;74(10):589–607 (234 ref.)

Functional role of receptor neurons in encoding olfactory information. Trotier D, et al. **J Neurobiol** 1996 May; 30(1):58–66 (40 ref.)

Cyclic GMP-dependent protein kinase and cellular signaling in the nervous system. Wang X, et al. **J Neurochem** 1997 Feb;68(2):443–56 (120 ref.)

Neurotrophin signal transduction in medulloblastoma. Chou TT, et al. **J Neurosci Res** 1997 Sep 1;49(5):522–7 (51 ref.)

Growth-hormone signal transduction. Campbell GS. **J Pediatr** 1997 Jul;131(1 Pt 2):S42–4 (22 ref.)

Elementary and global aspects of calcium signalling. Berridge MJ. **J Physiol (Lond)** 1997 Mar 1;499 (Pt 2):290–306 (117 ref.)

To quark or to spark, that is the question. Lipp P, et al. **J Physiol (Lond)** 1997 Jul 1;502 (Pt 1):1 (8 ref.)

Signal transduction by G proteins: 1994 edition. Birnbaumer L, et al. **J Recept Signal Transduct Res** 1995 Jan-Mar; 15(1–4):213–52 (117 ref.)

Signal transduction of cell-cycle regulation: its temporo-spacial architecture. Takuwa N, et al. **Jpn J Physiol** 1996 Dec;46(6):431–49 (204 ref.)

Angiotensin II signal transduction in vascular smooth muscle cells: role of tyrosine kinases. Ishida M, et al. **Keio J Med** 1997 Jun;46(2):61–8 (86 ref.)

Signaling molecules and neuroglial activation in the injured central nervous system. Raivich G, et al. **Keio J Med** 1996 Sep;45(3):239–47 (115 ref.)

Regulation of the intracellular calcium concentration in epithelial cells. Leipziger J, et al. **Kidney Blood Press Res** 1996;19(3–4):148–50 (21 ref.)

Signaling from the matrix to the cytoskeleton: role of cell surface proteoglycans in matrix assembly. Woods A, et al. **Kidney Int Suppl** 1996 May;54:S64–7 (33 ref.)

SHIP, a new player in cytokine-induced signalling. Liu L, et al. **Leukemia** 1997 Feb;11(2):181–4 (38 ref.)

Signal transduction: specificity of growth factors explained by parallel distributed processing. Schamel WW, et al. **Med Hypotheses** 1996 Sep;47(3):249–55 (25 ref.)

Analysis of two-component signal transduction systems involved in transcriptional regulation. Hakenbeck R, et al. **Methods Enzymol** 1996;273:281–300 (96 ref.)

Protein tyrosine phosphorylation modulates microvessel permeability in frog mesentery. Adamson RH. **Microcirculation** 1996 Jun;3(2):245–7 (13 ref.)

Synergism in estrogen-regulated gene expression. Arnold SF, et al. **Mol Cell Endocrinol** 1996 Oct 30;123(2):119–22 (14 ref.)

CAM-FGF receptor interactions: a model for axonal growth. Doherty P, et al. **Mol Cell Neurosci** 1996;8(2–3):99–111 (77 ref.)

The signals and molecular pathways involved in human menstruation, a unique process of tissue destruction and remodelling. Tabibzadeh S. **Mol Hum Reprod** 1996 Feb; 2(2):77–92 (173 ref.)

Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy. Emanuel PD, et al. **Mol Med Today** 1996 Nov;2(11):468–75 (40 ref.)

Dynamin, endocytosis and intracellular signalling (review). McClure SJ, et al. **Mol Membr Biol** 1996 Oct-Dec; 13(4):189–215 (223 ref.)

Control of bacterial chemotaxis. Eisenbach M. **Mol Microbiol** 1996 Jun;20(5):903–10 (56 ref.)

Photobiology of microorganisms: how photosensors catch a photon to initialize signalling. Hellingwerf KJ, et al. **Mol Microbiol** 1996 Aug;21(4):683–93 (76 ref.)

Priming events and retrograde injury signals. A new perspective on the cellular and molecular biology of nerve regeneration. Ambron RT, et al. **Mol Neurobiol** 1996 Aug; 13(1):61–79 (98 ref.)

The early intracellular signaling pathway for the insulin/insulin-like growth factor receptor family in the mammalian central nervous system. Folli F, et al. **Mol Neurobiol** 1996 Oct;13(2):155–83 (162 ref.)

Phosphatidylcholine signaling in response to CSF-1. Jackowski S, et al. **Mol Reprod Dev** 1997 Jan;46(1):24–30 (23 ref.)

G proteins: out of the cytoskeletal closet. Rodbell M. **Mt Sinai J Med** 1996 Oct-Nov;63(5–6):381–6 (62 ref.)

Can cysteine direct tyrosine in signal transduction for environment-oriented gene control? Nakashima I. **Nagoya J Med Sci** 1996 Mar;59(1–2):1–10 (72 ref.)

Cardiac alpha(1)-adrenoceptors that regulate contractile function: subtypes and subcellular signal transduction mechanisms. Endoh M. **Neurochem Res** 1996 Feb; 21(2):217–29 (100 ref.)

The LHRH-astroglial network of signals as a model to study neuroimmune interactions: assessment of messenger systems and transduction mechanisms at cellular and molecular levels. Marchetti B. **Neuroimmunomodulation** 1996 Jan-Feb;3(1):1–27 (179 ref.)

Scentsational ion channels. Firestein S. **Neuron** 1996 Nov; 17(5):803–6 (20 ref.)

(S)NO signals: translocation, regulation, and a consensus motif. Stamler JS, et al. **Neuron** 1997 May;18(5):691–6 (60 ref.)

Molecular mechanisms of angiogenesis: experimental models define cellular trafficking of FGF-1. Hicks KK, et al. **P R Health Sci J** 1996 Sep;15(3):179–86 (46 ref.)

Role of suppressor of hairless in the delta-activated Notch signaling pathway. Lecourtois M, et al. **Perspect Dev Neurobiol** 1997;4(4):305–11 (50 ref.)

Notch signaling in development. Simpson P. **Perspect Dev Neurobiol** 1997;4(4):297–304 (67 ref.)

Molecular basis of signal recognition in olfaction. Breer H. **Pflugers Arch** 1996;431(6 Suppl 2):R311–2 (5 ref.)

Intracellular transducing mechanisms coupled to brain somatostatin receptors. Florio T, et al. **Pharmacol Res** 1996 Jun;33(6):297–305 (94 ref.)

Signaling molecules that mediate the actions of FGF. Demo SD, et al. **Princess Takamatsu Symp** 1994;24:243–9 (23 ref.)

Insights into the physiology of TGF alpha and signaling through the EGF receptor revealed by gene targeting and acts of nature. Dunn AR, et al. **Princess Takamatsu Symp** 1994;24:276–89 (63 ref.)

A structural basis for bidirectional integrin signalling. Filardo EJ, et al. **Princess Takamatsu Symp** 1994;24:106–17 (54 ref.)

Integrin signals and tumor growth control. Juliano RL. **Princess Takamatsu Symp** 1994;24:118–24 (33 ref.)

Tyrosine kinase signalling pathways. Pawson T. **Princess Takamatsu Symp** 1994;24:303–22 (120 ref.)

Possible involvement of VEGF-FLT tyrosine kinase receptor system in normal and tumor angiogenesis. Shibuya M, et al. **Princess Takamatsu Symp** 1994;24:162–70 (23 ref.)

Mechanisms of signal-mediated protein sorting in the endocytic and secretory pathways. Bonifacino JS, et al. **Proc Assoc Am Physicians** 1996 Jul;108(4):285–95 (76 ref.)

Polypeptide signaling for plant defensive genes exhibits analogies to defense signaling in animals. Bergey DR, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12053–8 (44 ref.)

Intervention of carbohydrate recognition by proteins and nucleic acids. Sears P, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12086–93 (117 ref.)

Insulin-sensitive phospholipid signaling systems and glucose transport: an update. Farese RV. **Proc Soc Exp Biol Med** 1996 Oct;213(1):1–12 (103 ref.)

A hierarchical concept of cellular and subcellular Ca(2+)-signalling. Lipp P, et al. **Prog Biophys Mol Biol** 1996;65(3):265–96 (100 ref.)

Signal transduction in nociceptive afferent neurons in inflammatory conditions. Bevan S. **Prog Brain Res** 1996; 113:201–13 (54 ref.)

Developmental mechanisms for regulating signal amplification at excitatory synapses in the neocortex. Friedlander MJ, et al. **Prog Brain Res** 1996;108:245–62 (99 ref.)

Bradykinin B2 receptors and signal transduction analyzed in NG108-15 neuroblastoma x glioma hybrid cells, B2 receptor-transformed CHO cells and ras-transformed NIH/3T3 fibroblasts. Higashida H, et al. **Prog Brain Res** 1996;113:215–30 (82 ref.)

Light entrainment and activation of signal transduction pathways in the SCN. Kornhauser JM, et al. **Prog Brain Res** 1996;111:133–46 (80 ref.)

The polymodal receptor: bio-warning and defense system. Kumazawa T. **Prog Brain Res** 1996;113:3–18 (129 ref.)

Prostanoid receptors and signal transduction. Narumiya S. **Prog Brain Res** 1996;113:231–41 (70 ref.)

Phospholipase D: regulation by GTPases and protein kinase C and physiological relevance. Cockcroft S. **Prog Lipid Res** 1996 Dec;35(4):345–70 (270 ref.)

The neurotrophic action and signalling of epidermal growth factor. Yamada M, et al. **Prog Neurobiol** 1997 Jan; 51(1):19–37 (285 ref.)

The niacin challenge test in schizophrenia: past, present and future. Lin A, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Aug; 55(1–2):17–9 (15 ref.)

New concepts in extracellular signaling for insulin action: the single gateway hypothesis. Bergman RN. **Recent Prog Horm Res** 1997;52:359–85; discussion 385–7 (68 ref.)

Coupling signalling pathways to transcriptional control: nuclear factors responsive to cAMP. Tamai KT, et al. **Recent Prog Horm Res** 1997;52:121–39; discussion 139–40 (93 ref.)

Signaling across membranes: a one and a two and a... [comment] Stock J. **Science** 1996 Oct 18;274(5286):370–1 (10 ref.) Comment on: Science 1996 Oct 18;274(5286):423–5. Comment on: Science 1996 Oct 18;274(5286):425–6.

Inositol (1,4,5)-trisphosphate receptors: functional properties, modulation, and role in calcium wave propagation. Bezprozvanny I. **Soc Gen Physiol Ser** 1996;51:75–86 (55 ref.)

Functional properties of inositol 1,4,5-trisphosphate receptor and Ca2+ signaling. Iino M. **Soc Gen Physiol Ser** 1996; 51:67–73 (29 ref.)

Mechanical transduction by ion channels: how forces reach the channel. Sachs F. **Soc Gen Physiol Ser** 1997;52:209–18 (52 ref.)

Signaling through the focal adhesion kinase. Schaller MD. **Soc Gen Physiol Ser** 1997;52:241–55 (106 ref.)

Dissection of protein kinase and phosphatase targeting interactions. Scott JD. **Soc Gen Physiol Ser** 1997;52:227–39 (36 ref.)

MscL: a mechanosensitive channel in Escherichia coli. Sukharev SI, et al. **Soc Gen Physiol Ser** 1996;51:133–41 (34 ref.)

Signaling mechanisms in growth factor-stimulated cell motility. Anand-Apte B, et al. **Stem Cells** 1997;15(4):259–67 (112 ref.)

Vav: function and regulation in hematopoietic cell signaling. Bonnefoy-Bérard N, et al. **Stem Cells** 1996 May; 14(3):250–68 (125 ref.)

Signaling molecules derived from the cholesterol biosynthetic pathway. Jackson SM, et al. **Subcell Biochem** 1997;28:1–21 (93 ref.)

Signal transduction and gene expression in the eye: a contemporary view of the pro-inflammatory, anti-inflammatory and modulatory roles of prostaglandins and other bioactive lipids. Bazan NG, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S23–34 (100 ref.)

Signaling through G proteins in platelets: to the integrins and beyond. Brass LF, et al. **Thromb Haemost** 1997 Jul; 78(1):581–9 (98 ref.)

Not just another pretty face: regulation of platelet function at the cytoplasmic face of integrin alpha IIb beta 3. Shattil SJ, et al. **Thromb Haemost** 1997 Jul;78(1):220–5 (61 ref.)

Not all Shc's roads lead to Ras. Bonfini L, et al. **Trends Biochem Sci** 1996 Jul;21(7):257–61 (51 ref.)

The growing phospholipase A2 superfamily of signal transduction enzymes. Dennis EA. **Trends Biochem Sci** 1997 Jan;22(1):1–2 (26 ref.)

Tailoring cAMP-signalling responses through isoform multiplicity. Houslay MD, et al. **Trends Biochem Sci** 1997 Jun;22(6):217–24 (49 ref.)

Signaling through chemoattractant receptors in Dictyostelium. Chen MY, et al. **Trends Genet** 1996 Feb; 12(2):52–7 (43 ref.)

Protein aspartate phosphatases control the output of two-component signal transduction systems. Perego M, et al. **Trends Genet** 1996 Mar;12(3):97–101 (29 ref.)

Signalling from neurones to glial cells in invertebrates. Coles JA, et al. **Trends Neurosci** 1996 Aug;19(8):358–62 (35 ref.)

Calcium signalling in glial cells. Verkhratsky A, et al. **Trends Neurosci** 1996 Aug;19(8):346–52 (89 ref.)

Signal properties of brain gangliosides. Kalueff AV. **Ukr Biokhim Zh** 1996 Mar-Apr;68(2):15–9 (22 ref.)

The roles of 14–3–3 proteins in signal transduction. Reuther GW, et al. **Vitam Horm** 1996;52:149–75 (97 ref.)

[Regulatory mechanisms of receptor-mediated signal transduction] Mysliveček J. **Cesk Fysiol** 1996 Dec; 45(4):190–202 (60 ref.) (Eng. Abstr.) **(Cze)**

[Effects of hyperglycemia in the transmission of the insulin message] Hauguel-de Mouzon S, et al. **Journ Annu Diabetol Hotel Dieu** 1996;:145–56 (85 ref.) **(Fre)**

[Cell membrane receptors and intracellular signalling. Characterization in cultivated, contractile and endothelial cells] Briner V. **Fortschr Med** 1996 Oct 20;114(29):384–6 (18 ref.) (Eng. Abstr.) **(Ger)**

[The TRAF family protein-mediated B cell proliferation signal and the mechanism of LMP1-induced B cell transformation] Inoue J. **Nippon Rinsho** 1997 Feb; 55(2):299–304 (18 ref.) (Eng. Abstr.) **(Jpn)**

[The methods of analysis of signal transduction through adhesion molecules] Hamasaki K, et al. **Rinsho Byori** 1996 Sep;Suppl 102:147–52 (12 ref.) **(Jpn)**

[Signal transduction via adhesion molecules] Nojima Y. **Rinsho Byori** 1996 Sep;Suppl 102:90–6 (23 ref.) **(Jpn)**

[Cytokine and adhesion molecules] Tanaka Y. **Rinsho Byori** 1996 Sep;Suppl 102:69–77 (28 ref.) **(Jpn)**

[TGF-beta signal transduction and Smad] Miyazono K, et al. **Seikagaku** 1997 Jun;69(6):424–8 (16 ref.) **(Jpn)**

[Changes in cAMP signal transduction function and gene expression related to the onset of affective disturbance—the relationship between stress, antidepressants and expression of BDNF mRNA] Morinobu S, et al. **Seishin Shinkeigaku Zasshi** 1996;98(11):937–42; discussion 942–6 (7 ref.) **(Jpn)**

[Signal transduction in the cell. Phospholipids as messenger molecules] Barańska J, et al. **Postepy Biochem** 1996; 42(2):140–5 (43 ref.) **(Pol)**

[Sphingomyelin and its metabolites as an intermediate in cellular signal transduction] Dzik JM, et al. **Postepy Biochem** 1996;42(3):299–309 (109 ref.) **(Pol)**

[Eicosanoids—brain signal transducers] Lachowicz L, et al. **Postepy Biochem** 1996;42(4):363–8 (23 ref.) **(Pol)**

[Regulation of intracellular Ca2+ concentration in non excitable cells] Niewczas B. **Postepy Biochem** 1995; 41(4):283–9 (79 ref.) **(Pol)**

[Subunits gamma and zeta of Fc receptors. Structure and function] Mikulska J. **Postepy Hig Med Dosw** 1996; 50(4):351–61 (50 ref.) (Eng. Abstr.) **(Pol)**

[Humoral and metabolic regulation of pulmonary surfactant production] Serebrovskaia IA, et al. **Fiziol Cheloveka** 1997 Jul-Aug;23(4):83–9 (88 ref.) **(Rus)**

[Hydrogen peroxide as a signal molecule] Gamaleĭ IA, et al. **Tsitologiia** 1996;38(12):1233–47 (155 ref.) (Eng. Abstr.) **(Rus)**

[Nitric oxide and carbon monoxide—a new class of signal molecules] Markov KhM. **Usp Fiziol Nauk** 1996 Oct-Dec; 27(4):30–43 (107 ref.) (Eng. Abstr.) **(Rus)**

[The intracellular signal systems of the smooth muscles in the gastrointestinal tract] Medvedev MA, et al. **Vestn Ross Akad Med Nauk** 1996;(1):21–9 (33 ref.) (Eng.

SIGNAL TRANSDUCTION

Abstr.) **(Rus)**
[Current achievements in the study of the signal mechanisms of the action of insulin and related peptides] Pertseva MN, et al. **Zh Evol Biokhim Fiziol** 1996 May-Jun;32(3):318-40 (109 ref.) **(Rus)**

RADIATION EFFECTS

Potential molecular targets for manipulating the radiation response. Maity A, et al. **Int J Radiat Oncol Biol Phys** 1997 Feb 1;37(3):639-53 (180 ref.)
UV-induced signal transduction. Bender K, et al. **J Photochem Photobiol B** 1997 Jan;37(1-2):1-17 (187 ref.)
Signal transduction mechanisms in photocarcinogenesis. Pentland AP. **Photochem Photobiol** 1996 Apr;63(4):379-80 (11 ref.)
Light signal transduction in plants. Staub JM, et al. **Photochem Photobiol** 1996 Dec;64(6):897-905 (109 ref.)

SIGNAL TRANSDUCTION, LIGHT see **PHOTOTRANSDUCTION**

SILANES

CHEMISTRY

Synthesis of silane coupling agents containing fluorocarbon chain and applications to dentistry: plaque-controlling surface modifiers. Yoshino N, et al. **J Biomater Sci Polym Ed** 1997;8(8):623-53 (38 ref.)

SILICA see **SILICON DIOXIDE**

SILICATES

ADVERSE EFFECTS

Some silicates. **IARC Monogr Eval Carcinog Risks Hum** 1997; 68:243-333 (244 ref.)

SILICON

[Development of a silicon-mediated [3 + 2] annulation and its application to the synthesis of natural products] Takeda K. **Yakugaku Zasshi** 1997 Jun;117(6):368-77 (27 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Bacterial evolution and silicon. Trevors JT. **Antonie Van Leeuwenhoek** 1997 Mar;71(3):271-6 (33 ref.)

SILICON COMPOUNDS

Mineralogical characteristics of silica polymorphs in relation to their biological activities. Guthrie GD Jr, et al. **Scand J Work Environ Health** 1995;21 Suppl 2:5-8 (20 ref.)

SILICON DIOXIDE

The link between silica dust levels, risk assessments, and regulations. Goldsmith DF. **J Expo Anal Environ Epidemiol** 1997 Jul-Sep;7(3):385-95 (58 ref.)
Sand aspiration: a case report. Choy IO, et al. **J Pediatr Surg** 1996 Oct;31(10):1448-50 (5 ref.)
Biogenic amorphous silica. Rabovsky J. **Scand J Work Environ Health** 1995;21 Suppl 2:108-10 (31 ref.)

ADVERSE EFFECTS

Adverse effects of crystalline silica exposure. American Thoracic Society Committee of the Scientific Assembly on Environmental and Occupational Health. **Am J Respir Crit Care Med** 1997 Feb;155(2):761-8 (146 ref.)
ANCA-associated diseases and silica exposure. Gregorini G, et al. **Clin Rev Allergy Immunol** 1997 Spring;15(1):21-40 (80 ref.)
Silica. **IARC Monogr Eval Carcinog Risks Hum** 1997; 68:41-242 (539 ref.)
Noncancer inhalation toxicology of crystalline silica: exposure-response assessment. Gift JS, et al. **J Expo Anal Environ Epidemiol** 1997 Jul-Sep;7(3):345-58 (42 ref.)
Evidence for silica's neoplastic risk among workers and derivation of cancer risk assessment. Goldsmith DF. **J Expo Anal Environ Epidemiol** 1997 Jul-Sep;7(3):291-301 (46 ref.)
Silica-associated systemic erythematosus lupus or mineral dust lupus? Masson C, et al. **Lupus** 1997;6(1):1-3 (8 ref.)
Al Eskan disease: Persian Gulf syndrome [see comments] Korényi-Both AL, et al. **Mil Med** 1997 Jan;162(1):1-13 (75 ref.) Comment in: Mil Med 1997 Mar;162(3):ii.
Cancer risk assessment for crystalline silica to implement California's hot spots act. Collins JF, et al. **Scand J Work Environ Health** 1995;21 Suppl 2:99-103 (35 ref.)
Comparative cancer potency for silica from extrapolations of human and animal findings. Goldsmith DF, et al. **Scand J Work Environ Health** 1995;21 Suppl 2:104-7 (27 ref.)
Evaluation of crystalline silica as a threshold carcinogen. Klein AK, et al. **Scand J Work Environ Health** 1995;21 Suppl 2:95-8 (40 ref.)
Assessment of silicosis risk for occupational exposure to crystalline silica. Rice FL, et al. **Scand J Work Environ Health** 1995;21 Suppl 2:87-90 (27 ref.)

ANALYSIS

Ambient PM10 emissions: contributions and impact on silica emissions. Ruble R, et al. **J Expo Anal Environ Epidemiol** 1997 Jul-Sep;7(3):327-44 (54 ref.)

CHEMISTRY

Fossilization processes in siliceous thermal springs: trends in preservation along thermal gradients. Cady SL, et al. **Ciba Found Symp** 1996;202:150-70; discussion 170-3 (23 ref.)
Physicochemical properties of crystalline silica dusts and their possible implication in various biological responses. Fubini B, et al. **Scand J Work Environ Health** 1995;21 Suppl 2:9-14 (34 ref.)

TOXICITY

Laboratory studies on silica induced toxicity and relationship to carcinogenicity. Rabovsky J. **J Expo Anal Environ Epidemiol** 1997 Jul-Sep;7(3):267-78 (51 ref.)

SILICONE ELASTOMERS

Hemorrhagic complications in association with silastic dural substitute: pediatric and adult case reports with a review of the literature. Robertson SC, et al. **Neurosurgery** 1997 Jan;40(1):201-5; discussion 205-6 (28 ref.)

SILICONE OILS

ADMINISTRATION & DOSAGE

The Silicone Study. A small piece of the PVR puzzle is put into place [editorial; comment] Campochiaro PA. **Arch Ophthalmol** 1997 Mar;115(3):407-8 (6 ref.) Comment on: Arch Ophthalmol 1997 Mar;115(3):335-44.
Fluid vitreous substitutes in vitreo retinal surgery. Saxena S, et al. **Indian J Ophthalmol** 1996 Dec;44(4):191-206 (142 ref.)

SILICONE RUBBER see **SILICONE ELASTOMERS**

SILICONES

Arthrodesis of the first metatarsophalangeal joint to salvage failed silicone implant arthroplasty. Hecht PJ, et al. **Foot Ankle Int** 1997 Jul;18(7):383-90 (63 ref.)
Laparoscopic adjustable silicone gastric banding in the treatment of super obesity in the Jeddah area, Saudi Arabia. A preliminary report. Ashy AA, et al. **Int Surg** 1996 Jul-Sep;81(3):289-91 (16 ref.)
Silicone breast implants. Can emerging medical, legal, and scientific concepts be reconciled? Snyder JW. **J Leg Med** 1997 Jun;18(2):133-220 (421 ref.)
Silicone breast implants and neurologic disorders. Report of the Practice Committee of the American Academy of Neurology. Ferguson JH. **Neurology** 1997 Jun;48(6):1504-7 (16 ref.)

ADVERSE EFFECTS

An analytical review of silicone immunology [see comments] Marcus DM. **Arthritis Rheum** 1996 Oct;39(10):1619-26 (75 ref.) Comment in: Arthritis Rheum 1996 Oct;39(10):1615-8.
A review of the possible health implications of silicone breast implants. Noone RB. **Cancer** 1997 May 1;79(9):1747-56 (88 ref.)
Allergy to silicone: is it real? Finegold I. **Compr Ther** 1996 Jun;22(6):393-8 (36 ref.)
Silicone-associated rheumatic disease: an unsupported myth. Blackburn WD Jr, et al. **Plast Reconstr Surg** 1997 Apr; 99(5):1362-7 (45 ref.)
Synovitis and silicone joint implants: a summary of reported cases. Foliart DE. **Plast Reconstr Surg** 1997 Jan; 99(1):245-52 (59 ref.)
Silicone breast implants: pathology. Raso DS, et al. **Ultrastruct Pathol** 1997 May-Jun;21(3):263-71 (46 ref.)
[Silicone breast implants and breast cancer (see comments)] Kjøller KH, et al. **Ugeskr Laeger** 1997 Mar 17; 159(12):1744-8 (37 ref.) (Eng. Abstr.) Comment in: Ugeskr Laeger 1997 Jul 7;159(28):4410-1. **(Dan)**

THERAPEUTIC USE

[Peri-ureteral injections for stress urinary incontinence] Haab F. **Prog Urol** 1997 Apr;7(2):293-6 (15 ref.) **(Fre)**

SILICOSIS

Asbestosis and silicosis. Wagner GR. **Lancet** 1997 May 3; 349(9061):1311-5 (36 ref.)
Policy development for compensating workers exposed to crystalline silica in Ontario, Canada. Elinson L, et al. **Scand J Work Environ Health** 1995;21 Suppl 2:111-4 (14 ref.)
Future research needs in the silica, silicosis and cancer field. Goldsmith DF, et al. **Scand J Work Environ Health** 1995; 21 Suppl 2:115-7 (32 ref.)

COMPLICATIONS

Evaluation of crystalline silica as a threshold carcinogen. Klein AK, et al. **Scand J Work Environ Health** 1995;21 Suppl 2:95-8 (40 ref.)

EPIDEMIOLOGY

Assessment of silicosis risk for occupational exposure to crystalline silica. Rice FL, et al. **Scand J Work Environ Health** 1995;21 Suppl 2:87-90 (27 ref.)

ETIOLOGY

Al Eskan disease: Persian Gulf syndrome [see comments] Korényi-Both AL, et al. **Mil Med** 1997 Jan;162(1):1-13 (75 ref.) Comment in: Mil Med 1997 Mar;162(3):ii.

IMMUNOLOGY

Photosensitivity and autoantibodies to Sm, Ro, and La in a patient with silicosis [letter] Vidaller A, et al. **Int J Dermatol** 1996 Sep;35(9):679-80 (10 ref.)

PHYSIOPATHOLOGY

Laboratory studies on silica induced toxicity and relationship to carcinogenicity. Rabovsky J. **J Expo Anal Environ Epidemiol** 1997 Jul-Sep;7(3):267-78 (51 ref.)

SILKWORMS

EMBRYOLOGY

[Developmental expression patterns and target assignment of the bombyx fork head and POU-M1 genes] Suzuki Y, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1083-7 (25 ref.) **(Jpn)**

GENETICS

[Developmental expression patterns and target assignment of the bombyx fork head and POU-M1 genes] Suzuki Y, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1083-7 (25 ref.) **(Jpn)**

SILOXANES

Mixed self-assembled monolayers in chemical separations. Wirth MJ, et al. **Science** 1997 Jan 3;275(5296):44-7 (32 ref.)

CHEMISTRY

Using self-assembled monolayers to understand the interactions of man-made surfaces with proteins and cells. Mrksich M, et al. **Annu Rev Biophys Biomol Struct** 1996; 25:55-78 (87 ref.)

SILVER

Silverpoint drawing for scientific illustration. Hodge GP. **J Biocommun** 1996;23(3):18-21 (5 ref.)
Silver-coated catheters in peritoneal dialysis. Dasgupta MK. **Perit Dial Int** 1997;17 Suppl 2:S142-5 (17 ref.)
[Clinical and preclinical efficacy of antimicrobial catheters] Schierholz JM, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 May; 32(5):298-305 (102 ref.) (Eng. Abstr.) **(Ger)**

SILVER NITRATE STAINING see **SILVER STAINING**

SILVER STAINING

Standardized AgNOR analysis: its usefulness in surgical oncology. Ofner D, et al. **Histochem Cell Biol** 1996 Aug; 106(2):193-6 (32 ref.)

SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME

COMPLICATIONS

Neuropathogenesis of simian immunodeficiency virus infection in macaque monkeys. Sasseville VG, et al. **J Neurovirol** 1997 Feb;3(1):1-9 (104 ref.)

ETIOLOGY

Simian immunodeficiency virus as a model of HIV pathogenesis. Norley S, et al. **Springer Semin Immunopathol** 1997;18(3):391-405 (72 ref.)

IMMUNOLOGY

SIVagm infection of its natural African green monkey host. Norley SG. **Immunol Lett** 1996 Jun;51(1-2):53-8 (24 ref.)
Upregulation of Fas ligand by simian immunodeficiency virus - a nef-arious mechanism of immune evasion? Johnson RP. **J Exp Med** 1997 Jul 7;186(1):1-5 (50 ref.)

Long-term non-progressive human immunodeficiency virus infection: new insights from the simian immunodeficiency virus model. Dittmer U, et al. **J Gen Virol** 1997 May;78 (Pt 5):979-84 (55 ref.)
Do cytotoxic T lymphocytes clear some HIV/SIV infections? Ada G. **J Med Primatol** 1996 Jun;25(3):158-62 (33 ref.)

PHYSIOPATHOLOGY

The history of simian AIDS. Gardner MB. **J Med Primatol** 1996 Jun;25(3):148-57 (91 ref.)
The value of primate models for studying human immunodeficiency virus pathogenesis. Levy JA. **J Med Primatol** 1996 Jun;25(3):163-74 (44 ref.)

PREVENTION & CONTROL

Protection against human immunodeficiency virus type 2 and simian immunodeficiency virus in macaques vaccinated against human immunodeficiency virus type 2. Biberfeld G, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20; 12(5):443-6 (22 ref.)
Recombinant subunit vaccines against primate lentiviruses. Hu SL. **AIDS Res Hum Retroviruses** 1996 Mar 20; 12(5):451-3 (26 ref.)
Simian immunodeficiency virus live and inactivated experimental vaccines. Norley S, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):447-9 (41 ref.)

SIMIAN AIDS see **SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME**

SIMIAN AIDS RETROVIRUS see **RETROVIRUSES TYPE D, SIMIAN**

SIMIAN AIDS VACCINES see **SAIDS VACCINES**

SIMIAN FOAMY VIRUSES see **SPUMAVIRUS**

SIMIAN IMMUNODEFICIENCY VIRUSES see **SIV**

SIMIAN LENTIVIRUSES see **SIV**

SIMIAN T-LYMPHOTROPIC VIRUS TYPE I see **STLV**

SIMIAN T-LYMPHOTROPIC VIRUS TYPE III see **SIV**

SIMIAN RETROVIRUSES, TYPE D see **RETROVIRUSES TYPE D, SIMIAN**

SIMIAN VIRUS 40 see **POLYOMAVIRUS MACACAE**

SIMMONDS' DISEASE see **HYPOPITUITARISM**

SIMPLE REPETITIVE SEQUENCE see **REPETITIVE SEQUENCES, NUCLEIC ACID**

SIMPLEXVIRUS

Cannabinoids and immunity to viruses. Specter S. **Adv Exp Med Biol** 1996;402:131-4 (11 ref.)
The roles of herpes simplex virus in neuroscience. Turner SL, et al. **J Neurovirol** 1997 Apr;3(2):110-25 (154 ref.)
The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Andreansky SS, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11313-8 (53 ref.)

DRUG EFFECTS

Analysis of resistance mutants of viral polymerases. Oxford JS, et al. **Methods Enzymol** 1996;275:555-600 (179 ref.)
[The course for a successor for acyclovir] Ramos JM, et al. **Rev Clin Esp** 1996 Nov;196(11):761-5 (66 ref.) **(Spa)**

ENZYMOLOGY

[Virus propagation and proteases: with special emphasis on the newly discovered serine protease in human herpes virus] Maeda H. **Tanpakushitsu Kakusan Koso** 1997 May; 42(6):875-9 (25 ref.) **(Jpn)**

GENETICS

Herpes simplex virus-based vectors: problems and some solutions. Fink DJ, et al. **Adv Neurol** 1997;72:149-56 (17 ref.)
Engineering herpes simplex virus vectors for human gene therapy. Glorioso JC, et al. **Adv Pharmacol** 1997;40:103-36 (195 ref.)
Targeted gene therapy for cancer: herpes simplex virus thymidine kinase gene-mediated cell killing leads to anti-tumour immunity that can be augmented by co-expression of cytokines in the tumour cells. Vile RG, et al. **Biochem Soc Trans** 1997 May;25(2):717-22 (51 ref.)
Potential use of herpes simplex virus (HSV) vectors for gene therapy of neurological disorders. Kennedy PG. **Brain** 1997 Jul;120 (Pt 7):1245-59 (80 ref.)
Advances in the development of herpes simplex virus-based gene transfer vectors for the nervous system. Fink DJ, et al. **Clin Neurosci** 1995-96;3(5):284-91 (41 ref.)
Use of viral vectors to promote neuroregeneration. Verhaagen J, et al. **Clin Neurosci** 1995-96;3(5):275-83 (59 ref.)
Development of an HSV-based vector for the treatment of Parkinson's disease. Fink DJ, et al. **Exp Neurol** 1997 Mar; 144(1):103-21 (87 ref.)
Defective viral vectors as agents for gene transfer in the nervous system. Kaplitt MG, et al. **J Neurosci Methods** 1997 Jan;71(1):125-32 (87 ref.)
The molecular genetics of herpes simplex virus latency and pathogenesis: a puzzle with many pieces still missing [editorial; comment] Bennett JL, et al. **J Neurovirol** 1996 Aug;2(4):225-9 (51 ref.) Comment on: J Neurovirol 1996 Aug;2(4):268-78. Comment on: J Neurovirol 1996 Aug;2(4):279-88. Comment on: J Neurovirol 1996 Aug;2(4):289-95.
Gene transfer to muscle using herpes simplex virus-based vectors. Huard J, et al. **Neuromuscul Disord** 1997 Jul; 7(5):299-313 (101 ref.)
Replication-defective herpes simplex virus vectors for gene transfer in vivo. Marconi P, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11319-20 (13 ref.)
The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors. Roizman B. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11307-12 (45 ref.)
[Herpetic infection] Briazzhikova TS, et al. **Klin Med (Mosk)** 1996;74(7):7-9 (36 ref.) **(Rus)**

IMMUNOLOGY

Subversion of the MHC class I antigen-presentation pathway by adenoviruses and herpes simplex viruses. Burgert HG. **Trends Microbiol** 1996 Mar;4(3):107-12 (61 ref.)
[Herpes simplex virus and macrophages] Scieux C. **Pathol Biol (Paris)** 1997 Feb;45(2):159-64 (37 ref.) (Eng. Abstr.) **(Fre)**

PATHOGENICITY

The molecular genetics of herpes simplex virus latency and pathogenesis: a puzzle with many pieces still missing [editorial; comment] Bennett JL, et al. **J Neurovirol** 1996 Aug;2(4):225-9 (51 ref.) Comment on: J Neurovirol 1996 Aug;2(4):268-78. Comment on: J Neurovirol 1996 Aug;2(4):279-88. Comment on: J Neurovirol 1996 Aug;2(4):289-95.

PHYSIOLOGY

Experimental investigation of herpes simplex virus latency. Wagner EK, et al. **Clin Microbiol Rev** 1997 Jul;10(3):419-43 (332 ref.)
Herpes simplex: evolving concepts. Pereira FA. **J Am Acad Dermatol** 1996 Oct;35(4):503-20; quiz 521-2 (182 ref.)
Herpes simplex virus vectors for gene transfer to the nervous system. Goins WF, et al. **J Neurovirol** 1997 May;3 Suppl 1:S80-8 (91 ref.)

SIMULIIDAE

Black fly (Diptera:Simuliidae) salivary secretions: importance in vector competence and disease. Cupp EW, et al. **J Med Entomol** 1997 Mar;34(2):87-94 (76 ref.)

SIMULIUM see **SIMULIIDAE**

SIN-10 see **MOLSIDOMINE**

SINCALIDE

see related
APPETITE DEPRESSANTS
GASTROINTESTINAL AGENTS

SINCALIDE RECEPTORS see **RECEPTORS, CHOLECYSTOKININ**

SINDBIS VIRUS

GENETICS

Sindbis virus vectors for expression in animal cells. Huang HV. **Curr Opin Biotechnol** 1996 Oct;7(5):531-5 (47 ref.)

SINGLE PARENT

The partners of welfare mothers: potential earnings and child support. Brien MJ, et al. **Future Child** 1997 Spring; 7(1):65-73 (29 ref.)
Welfare to work: analysis and recommendations. Larner MB, et al. **Future Child** 1997 Spring;7(1):4-19 (57 ref.)
The mother-headed single-parent family: a feminist critique of the nursing literature [see comments] Ford-Gilboe M, et al. **Nurs Outlook** 1996 Jul-Aug;44(4):173-83 (49 ref.) Comment in: Nurs Outlook 1997 Mar-Apr;45(2):93.
[Being raised by lesbian parents or in a single-parent family is no risk factor for problem behavior, however being raised as an adopted child is] Verhulst FC, et al. **Ned Tijdschr Geneeskd** 1997 Mar 1;141(9):414-8 (29 ref.) (Eng. Abstr.) **(Dut)**

PSYCHOLOGY

Single motherhood and mental health: implications for primary prevention [editorial; comment] Avison WR. **Can Med Assoc J** 1997 Mar 1;156(5):661-3 (9 ref.) Comment on: Can Med Assoc J 1997 Mar 1;156(5):639-45.

SINGLE-PARENT FAMILY see **SINGLE PARENT**

SINGLE PERSON

see related
WIDOWHOOD

Poverty among single elderly women under different systems of old-age security: a comparative review. Siegenthaler JK. **Soc Secur Bull** 1996 Fall;59(3):31-44 (59 ref.)

SINGLE-PHOTON ABSORPTIOMETRY see **ABSORPTIOMETRY, PHOTON**

SINGLE-PHOTON EMISSION-COMPUTED TOMOGRAPHY see **TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON**

SINGLE-STRANDED CONFORMATIONAL POLYMORPHISM see **POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL**

SINGLE-STRANDED DNA see **DNA, SINGLE-STRANDED**

SINGLE-STRANDED DNA BINDING PROTEINS see **DNA-BINDING PROTEINS**

SINGLE-TOOTH IMPLANTS see **DENTAL IMPLANTS, SINGLE-TOOTH**

SINOATRIAL BLOCK

[Sino-atrial block] Ueyama C, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):416-9 (14 ref.) **(Jpn)**

SINOATRIAL NODAL REENTRY TACHYCARDIA see **TACHYCARDIA, SINOATRIAL NODAL REENTRY**

SINOATRIAL NODE

ABNORMALITIES

[Sinus node hypoplasia] Baba K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):286-9 (19 ref.) **(Jpn)**

DRUG EFFECTS

Carbamazepine-induced sinus node dysfunction. Johnson CD, et al. **P R Health Sci J** 1997 Mar;16(1):45-9 (37 ref.)

PATHOLOGY

[Sinus node hypoplasia] Baba K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):286-9 (19 ref.) **(Jpn)**

PHYSIOLOGY

Origin of the sinus impulse. Schuessler RB, et al. **J Cardiovasc Electrophysiol** 1996 Mar;7(3):263-74 (57 ref.)
Ionic mechanisms of the cardiac pacemaker potential. Noma A. **Jpn Heart J** 1996 Sep;37(5):673-82 (29 ref.)
[Autonomic regulation of pacemaker activity in the sinoatrial node] Honjo H, et al. **Nippon Rinsho** 1996 Aug; 54(8):2035-40 (17 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

[Overdrive suppression test] Fukushima K, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:685-7 (11 ref.) **(Jpn)**
[Measurement of sinus node recovery time (SNRT) and sinoatrial conduction time (SACT)] Tani M, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:680-4 (8 ref.) **(Jpn)**

SINUS ARRHYTHMIA see **ARRHYTHMIA, SINUS**

SINUS OF VALSALVA

Sinus of Valsalva aneurysm presenting as myocardial infarction during dobutamine stress test. Ferreira AC, et al. **Cathet Cardiovasc Diagn** 1996 Dec;39(4):400-2 (7 ref.)
[Aneurysm of the sinus of Valsalva] Sugama M. **Ryoikibetsu Shokogun Shirizu** 1996;(13):323-5 (19 ref.) **(Jpn)**

ABNORMALITIES

[Anomalous origin of the coronary arteries from the other sinus of Valsalva] Kitaoka S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):813-6 (16 ref.) **(Jpn)**
[Valsalva fistula] Sugama M. **Ryoikibetsu Shokogun Shirizu** 1996;(13):326 (8 ref.) **(Jpn)**

ULTRASONOGRAPHY

Echocardiographic diagnosis of right and left sinus of Valsalva aneurysms dissecting into the ventricular septum.

SINUS OF VALSALVA

Silance PG, et al. **J Am Soc Echocardiogr** 1996 Mar–Apr; 9(2):190–4 (12 ref.)
[The echocardiographic diagnosis of a rare complication of an aneurysm of the sinus of Valsalva] Cabral S, et al. **Rev Port Cardiol** 1997 Apr;16(4):393–6, 352 (11 ref.) (Eng. Abstr.) **(Por)**

SINUS TACHYCARDIA see **TACHYCARDIA, SINUS**

SINUS THROMBOSIS

COMPLICATIONS

Transverse sinus thrombosis: an unusual cause of headache. Wasson J, et al. **Headache** 1997 Jul–Aug;37(7):457–9 (18 ref.)
[Thrombosis of the superior longitudinal sinus in patients with AIDS. A review of the literature] Pedraza S, et al. **Rev Neurol** 1997 Feb;25(138):247–9 (16 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

MRA of venous sinus thrombosis. Wang AM. **Clin Neurosci** 1997;4(3):158–64 (15 ref.)
Cavernous sinus thrombophlebitis: case report. Kriss TC, et al. **Neurosurgery** 1996 Aug;39(2):385–9 (31 ref.)

DRUG THERAPY

Emergency endovascular treatment of stroke. Connors JJ 3rd, et al. **J La State Med Soc** 1996 Nov;148(11):490–7 (10 ref.)

ETIOLOGY

[Cerebral sinus thrombosis in a patient with protein S deficiency: a case report] Fujita A, et al. **No Shinkei Geka** 1997 May;25(5):467–72 (22 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Angiography in the evaluation of head and neck trauma. Gaskill-Shipley MF, et al. **Neuroimaging Clin N Am** 1996 Aug;6(3):607–24 (69 ref.)

SINUSITIS

Allergic fungal sinusitis/polyposis. Bent JP 3rd, et al. **Allergy Asthma Proc** 1996 Sep–Oct;17(5):259–68 (30 ref.)
Rhinosinusitis. Lund VJ. **Br J Hosp Med** 1997 Apr 2–15; 57(7):308–12 (18 ref.)
Changing diagnostic and treatment strategies for chronic sinusitis. Wagner W. **Cleve Clin J Med** 1996 Nov–Dec; 63(7):396–405; quiz 420 (34 ref.)
Acute community-acquired sinusitis. Gwaltney JM Jr. **Clin Infect Dis** 1996 Dec;23(6):1209–23; quiz 1224–5 (79 ref.)
Sinusitis: bench to bedside. Current findings, future directions. Kaliner MA, et al. **J Allergy Clin Immunol** 1997 Jun;99(6 Pt 3):S829–48 (89 ref.)
Pediatric sinusitis: a literature review with emphasis on the role of allergy. Gungor A, et al. **Otolaryngol Head Neck Surg** 1997 Jan;116(1):4–15 (77 ref.)
Sinusitis: bench to bedside. Current findings, future directions. Kaliner MA, et al. **Otolaryngol Head Neck Surg** 1997 Jun;116(6 Pt 2):S1–20 (89 ref.)
Sinusitis in childhood. Isaacson G. **Pediatr Clin North Am** 1996 Dec;43(6):1297–318 (104 ref.)

COMPLICATIONS

Invasive Aspergillus sinusitis in patients with human immunodeficiency virus infection. Report of 2 cases and review. Mylonakis E, et al. **Medicine (Baltimore)** 1997 Jul; 76(4):249–55 (18 ref.)
[Paranasal sinuses, middle ear, and allergy] Mogi G. **Arerugi** 1995 Dec;44(12):1355–60 (21 ref.) **(Jpn)**

DIAGNOSIS

Diagnosis and management of sinusitis in children. Wald ER. **Adv Pediatr Infect Dis** 1996;12:1–20 (44 ref.)
Sinusitis. Drake-Lee A. **Br J Hosp Med** 1996 Jun 5–18; 55(11):674–8 (15 ref.)
Otitis media and sinusitis: similar diseases. Parsons DS, et al. **Otolaryngol Clin North Am** 1996 Feb;29(1):11–25 (28 ref.)
Acute sinusitis in adults. Difficult to diagnose, essential to treat. Kankam CG, et al. **Postgrad Med** 1997 Aug; 102(2):253–8 (7 ref.)
Sinusitis in children and adolescents. Newton DA. **Prim Care** 1996 Dec;23(4):701–17 (41 ref.)
[Difficulties in diagnosing sinusitis in primary care practice] Leshem J, et al. **Harefuah** 1996 Jul;131(1–2):50–4 (33 ref.) **(Heb)**
[The role of endoscopic surgery in the treatment of chronic inflammation of paranasal sinuses] Krzeski A, et al. **Otolaryngol Pol** 1996;50(1):37–45 (15 ref.) (Eng. Abstr.) **(Pol)**
[Diagnosis of chronic rhinosinusitis] Canseco Villarreal JI. **Rev Alerg Mex** 1996;43 Spec No:6–7 (10 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Effects of corticosteroid therapy in non-allergic rhinosinusitis. Mygind N. **Acta Otolaryngol (Stockh)** 1996 Mar;116(2):164–6 (25 ref.)
Medical management of sinusitis in pediatric patients. Hopp R, et al. **Curr Probl Pediatr** 1997 May–Jun;27(5):178–86 (43 ref.)
The antibiotic treatment of acute otitis media and sinusitis in children. Cohen R. **Diagn Microbiol Infect Dis** 1997 Jan–Feb;27(1–2):35–9 (19 ref.)
Microbiology and management of sinusitis. Brook I. **J Otolaryngol** 1996 Aug;25(4):249–56 (44 ref.)
Antimicrobial therapy for sinusitis. Poole MD. **Otolaryngol Clin North Am** 1997 Jun;30(3):331–9 (25 ref.)
Shortened course of antibiotic therapy for acute otitis media, sinusitis and tonsillopharyngitis. Pichichero ME, et al. **Pediatr Infect Dis J** 1997 Jul;16(7):680–95 (144 ref.)
Acute sinusitis in adults. Difficult to diagnose, essential to treat. Kankam CG, et al. **Postgrad Med** 1997 Aug; 102(2):253–8 (7 ref.)
Sinusitis in children and adolescents. Newton DA. **Prim Care** 1996 Dec;23(4):701–17 (41 ref.)

EPIDEMIOLOGY

[Prevalence of rhinosinusitis. Statistics: January–December 1993] González Escamilla JA, et al. **Rev Alerg Mex** 1996; 43 Spec No:8–11 (31 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Paranasal sinusitis following allogeneic bone marrow transplant. Savage DG, et al. **Bone Marrow Transplant** 1997 Jan;19(1):55–9 (29 ref.)
Sinusitis in mechanically ventilated patients and its role in the pathogenesis of nosocomial pneumonia. Bert F., et al. **Eur J Clin Microbiol Infect Dis** 1996 Jul;15(7):533–44 (84 ref.)
Chronic sinusitis in children. Calderon E, et al. **J Investig Allergol Clin Immunol** 1996 Jan–Feb;6(1):5–13 (52 ref.)
Allergic rhinosinusitis in the pediatric population. Cook PR, et al. **Otolaryngol Clin North Am** 1996 Feb;29(1):39–56 (67 ref.)
Antimicrobial therapy for sinusitis. Poole MD. **Otolaryngol Clin North Am** 1997 Jun;30(3):331–9 (25 ref.)
Lethal disseminated Fusarium infection with sinus involvement in the immunocompromised host: case report and review of the literature. Rombaux P, et al. **Rhinology** 1996 Dec;34(4):237–41 (27 ref.)

IMMUNOLOGY

Immunologic considerations in the child with recurrent or persistent sinusitis. Herrod HG. **Allergy Asthma Proc** 1997 May–Jun;18(3):145–8 (20 ref.)

MICROBIOLOGY

Effects of viral and bacterial infection on nasal and sinus mucosa. van Cauwenberge P, et al. **Acta Otolaryngol (Stockh)** 1996 Mar;116(2):316–21 (25 ref.)
The microbiology of chronic sinusitis in children. A review. Wald ER. **Acta Otorhinolaryngol Belg** 1997;51(1):51–4 (8 ref.)
Paecilomyces sinusitis in an immunocompromised adult patient: case report and review. Gucalp R, et al. **Clin Infect Dis** 1996 Aug;23(2):391–3 (10 ref.)
Allergic fungal sinusitis: a clinicopathologic study of 16 cases. Torres C, et al. **Hum Pathol** 1996 Aug;27(8):793–9 (50 ref.)
Microbiology and management of sinusitis. Brook I. **J Otolaryngol** 1996 Aug;25(4):249–56 (44 ref.)
Invasive Aspergillus sinusitis in patients with human immunodeficiency virus infection. Report of 2 cases and review. Mylonakis E, et al. **Medicine (Baltimore)** 1997 Jul; 76(4):249–55 (18 ref.)
Fungal sinusitis. deShazo RD, et al. **N Engl J Med** 1997 Jul 24;337(4):254–9 (50 ref.)
Recovery from rhinocerebral mucormycosis with carotid artery occlusion: a pediatric case and review of the literature. Shah PD, et al. **Pediatr Infect Dis J** 1997 Jan; 16(1):68–71 (27 ref.)

PARASITOLOGY

Microsporidium-associated sinusitis. Moss RB, et al. **Ear Nose Throat J** 1997 Feb;76(2):95–101 (19 ref.)

PHYSIOPATHOLOGY

Immunologic considerations in the child with recurrent or persistent sinusitis. Herrod HG. **Allergy Asthma Proc** 1997 May–Jun;18(3):145–8 (20 ref.)
[Physiopathology of chronic rhinosinusitis] González Díaz SN. **Rev Alerg Mex** 1996;43 Spec No:12–5 (46 ref.) (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

Anatomic variation in pediatric chronic sinusitis: a CT study. Lusk RP, et al. **Otolaryngol Clin North Am** 1996 Feb; 29(1):75–91 (25 ref.)

SURGERY

Extended applications of endoscopic sinus surgery—the territorial imperative [editorial] Lund VJ. **J Laryngol Otol** 1997 Apr;111(4):313–5 (13 ref.)
Endoscopic sinus surgery. A review. Kennedy DW, et al. **Otolaryngol Clin North Am** 1997 Jun;30(3):313–30 (57 ref.)
Current concepts in the surgical management of chronic frontal sinusitis. Nguyen QA, et al. **Otolaryngol Clin North Am** 1997 Jun;30(3):355–70 (80 ref.)
[The role of endoscopic surgery in the treatment of chronic inflammation of paranasal sinuses] Krzeski A, et al. **Otolaryngol Pol** 1996;50(1):37–45 (15 ref.) (Eng. Abstr.) **(Pol)**

THERAPY

Diagnosis and management of sinusitis in children. Wald ER. **Adv Pediatr Infect Dis** 1996;12:1–20 (44 ref.)
Recurrent sinusitis: examining medical treatment options. Kaliner MA. **Am J Rhinol** 1997 Mar–Apr;11(2):123–32 (44 ref.)
Chronic sinusitis: a medical or surgical disease? Parsons DS. **Otolaryngol Clin North Am** 1996 Feb;29(1):1–9 (19 ref.)
Upper respiratory tract infections - otitis media, sinusitis and pharyngitis. Oh HM. **Singapore Med J** 1995 Aug; 36(4):428–31 (23 ref.)
[Treatment of chronic rhinosinusitis] Galindo de Jaime G. **Rev Alerg Mex** 1996;43 Spec No:19–21 (11 ref.) (Eng. Abstr.) **(Spa)**

VIROLOGY

Effects of viral and bacterial infection on nasal and sinus mucosa. van Cauwenberge P, et al. **Acta Otolaryngol (Stockh)** 1996 Mar;116(2):316–21 (25 ref.)

SINUSITIS, ETHMOID see **ETHMOID SINUSITIS**

SINUSITIS, FRONTAL see **FRONTAL SINUSITIS**

SINUSITIS, MAXILLARY see **MAXILLARY SINUSITIS**

SIPHONAPTERA see **FLEAS**

SIPPLE SYNDROME see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A**

SIPUNCULIDA see **NEMATODA**

SIRENOMELIA see **ECTROMELIA**

SIS GENES see **ONCOGENES**

SISTER CHROMATID EXCHANGE

Chromosome aberrations, micronuclei, aneuploidy, sister chromatid exchanges, and cancer risk assessment. Tucker JD, et al. **Mutat Res** 1996 Sep;365(1–3):147–59 (47 ref.)

GENETICS

Age-related increase of baseline frequencies of sister chromatid exchanges, chromosome aberrations, and micronuclei in human lymphocytes. Bolognesi C, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Apr;6(4):249–56 (112 ref.)

SITE-DIRECTED MUTAGENESIS see **MUTAGENESIS, SITE-DIRECTED**

SITE MAPPING, RESTRICTION see **RESTRICTION MAPPING**

SITE-SPECIFIC MUTAGENESIS see **MUTAGENESIS, SITE-DIRECTED**

SITOSTEROLS

BLOOD

Abnormal cholesterol biosynthesis in sitosterolaemia and the Smith-Lemli-Opitz syndrome. Salen G, et al. **J Inherit Metab Dis** 1996;19(4):391–400 (25 ref.)
Sitosterolemia. Salen G, et al. **Subcell Biochem** 1997; 28:453–76 (49 ref.)
[Sitosterolemia] Takahashi M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):48–51 (9 ref.) **(Jpn)**

SITUATIONAL ETHICS see **ETHICS**

SITUATIONAL THERAPY see **MILIEU THERAPY**

SITUS INVERSUS

COMPLICATIONS

Coronary arteriography in the presence of dextrocardia and situs inversus. Shah RP, et al. **Ann Acad Med Singapore** 1996 Sep;25(5):759–60 (10 ref.)

DIAGNOSIS

Sirenomelia and situs inversus: case report and review of the literature. Langer B, et al. **Fetal Diagn Ther** 1996 Jan–Feb;11(1):79–84 (22 ref.)

GENETICS

Defects in the determination of left-right asymmetry [see comments] Splitt MP, et al. **J Med Genet** 1996 Jun; 33(6):498-503 (96 ref.) Comment in: J Med Genet 1996 Dec;33(12):1052.

PATHOLOGY

[Isolated atrial noninversion] Yoshii S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):508-11 (9 ref.) **(Jpn)**

SIV

The history of simian AIDS. Gardner MB. **J Med Primatol** 1996 Jun;25(3):148-57 (91 ref.)

IMMUNOLOGY

Protection against human immunodeficiency virus type 2 and simian immunodeficiency virus in macaques vaccinated against human immunodeficiency virus type 2. Biberfeld G, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20; 12(5):443-6 (22 ref.)

Simian retrovirus vaccines: simian retrovirus and simian immunodeficiency lentivirus. Gardner MB, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):399-401 (20 ref.)

Recombinant subunit vaccines against primate lentiviruses. Hu SL. **AIDS Res Hum Retroviruses** 1996 Mar 20; 12(5):451-3 (26 ref.)

Simian immunodeficiency virus live and inactivated experimental vaccines. Norley S, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):447-9 (41 ref.)

"Attenuated" simian immunodeficiency virus in macaque neonates. Ruprecht RM, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):459-60 (3 ref.)

Macaque models for AIDS vaccine development. Johnson RP. **Curr Opin Immunol** 1996 Aug;8(4):554-60 (42 ref.)

SIVagm infection of its natural African green monkey host. Norley SG. **Immunol Lett** 1996 Jun;51(1-2):53-8 (24 ref.)

Upregulation of Fas ligand by simian immunodeficiency virus - a nef-arious mechanism of immune evasion? Johnson RP. **J Exp Med** 1997 Jul 7;186(1):1-5 (50 ref.)

Long-term non-progressive human immunodeficiency virus infection: new insights from the simian immunodeficiency virus model. Dittmer U, et al. **J Gen Virol** 1997 May;78 (Pt 5):979-84 (55 ref.)

PATHOGENICITY

Nef and PAK: virulence factor and cellular accomplice. Trono D, et al. **Chem Biol** 1997 Jan;4(1):13-5 (23 ref.)

The value of primate models for studying human immunodeficiency virus pathogenesis. Levy JA. **J Med Primatol** 1996 Jun;25(3):163-74 (44 ref.)

Simian immunodeficiency virus as a model of HIV pathogenesis. Norley S, et al. **Springer Semin Immunopathol** 1997;18(3):391-405 (72 ref.)

PHYSIOLOGY

Towards a consensus for a role of Nef in both viral replication and immunomodulation? Collette Y. **Res Virol** 1997 Jan-Feb;148(1):23-30 (43 ref.)

Nef and the Nef-associated kinase. Sawai ET, et al. **Res Virol** 1997 Jan-Feb;148(1):47-52 (59 ref.)

SIV VACCINE see **SAIDS VACCINES**

SIV-1 see **SIV**

SIV-2 see **SIV**

SIXTH DISEASE see **EXANTHEMA SUBITUM**

SIZE PERCEPTION

Reading with magnifiers. Den Brinker BP, et al. **Ergonomics** 1996 Oct;39(10):1231-48 (90 ref.)

SJOGREN-LARSSON SYNDROME

Update on Sjögren-Larsson syndrome. Lacour M. **Dermatology** 1996;193(2):77-82 (47 ref.)

SJOGREN'S SYNDROME

see related
KERATOCONJUNCTIVITIS SICCA

Clinical features, pathogenesis, and treatment of Sjögren's syndrome. Fox RI. **Curr Opin Rheumatol** 1996 Sep; 8(5):438-45 (104 ref.)

Primary Sjögren's syndrome: diagnostic criteria, clinical features, and disease activity. Manthorpe R, et al. **J Rheumatol** 1997 Sep;24 Suppl 50:8-11 (14 ref.)

[Sjögren's syndrome and anti-Ro syndrome] Tanaka M. **Ryoikibetsu Shokogun Shirizu** 1996;(15):379-82 (17 ref.) **(Jpn)**

COMPLICATIONS

Sjögren's syndrome with membranous glomerulonephritis detected by urine screening of schoolchildren. Yoshida K, et al. **Acta Paediatr Jpn** 1996 Oct;38(5):533-6 (13 ref.)

Primary biliary cirrhosis associated with mixed type autoimmune hemolytic anemia and sicca syndrome: a case report and review of literature. Chen CY, et al. **Am J Gastroenterol** 1997 Sep;92(9):1547-9 (21 ref.)

Autoimmune thyroid disease in systemic lupus erythematosus and Sjögren's syndrome. Scofield RH. **Clin Exp Rheumatol** 1996 May-Jun;14(3):321-30 (100 ref.)

A case of Sjögren's syndrome associated with Sweet's syndrome. Osawa H, et al. **Clin Rheumatol** 1997 Jan; 16(1):101-5 (16 ref.)

Sjögren's syndrome associated with hypokalemic myopathy due to Bartter's syndrome [letter] Higashi K, et al. **J Rheumatol** 1997 Aug;24(8):1663-4 (17 ref.)

Sjögren's syndrome in patients with newly diagnosed untreated non-Hodgkin's lymphoma. Andonopoulos AP, et al. **Rev Rhum Engl Ed** 1997 May;64(5):287-92 (21 ref.)

[Systemic manifestations of primary Gougerot-Sjögren syndrome. Nature and incidence apropos of 34 cases] Ecoiffier EB, et al. **Presse Med** 1997 Jun 21;26(21):995-9 (15 ref.) (Eng. Abstr.) **(Fre)**

[Involvements of the peripheral nervous system and primary Gougerot-Sjögren syndrome] Rodier G, et al. **Rev Med Interne** 1996;17(7):558-62 (30 ref.) (Eng. Abstr.) **(Fre)**

[Coping with pathological changes in digestive system and kidney in collagen diseases--special reference to Sjogren's syndrome and interstitial nephritis] Matsumura R, et al. **Nippon Naika Gakkai Zasshi** 1996 Nov 10;85(11):1867-71 (5 ref.) **(Jpn)**

[Sjögren's syndrome with presenting as aseptic meningoencephaloradiculopathy in an elderly woman] Miyachi T, et al. **Nippon Ronen Igakkai Zasshi** 1997 May; 34(5):415-20 (12 ref.) (Eng. Abstr.) **(Jpn)**

[A case of Sjögren's syndrome and systemic lupus erythematosus complicated with necrotizing angiitis of the gallbladder] Suwa A, et al. **Ryumachi** 1995 Dec;35(6):904-9 (19 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Sjögren's syndrome: the persisting conundrum [editorial] Buchanan WW. **J Rheumatol** 1997 Sep;24(9):1667-9 (30 ref.)

[Sjögren's syndrome. New diagnostic aspects] Haga HJ, et al. **Tidsskr Nor Laegeforen** 1997 Jun 10;117(15):2197-200 (18 ref.) (Eng. Abstr.) **(Nor)**

[Acute tetraplegia in a patient with Sjögren's syndrome (letter)] Sánchez-Chaparro MA, et al. **Med Clin (Barc)** 1997 Mar 8;108(9):356-7 (10 ref.) **(Spa)**

DRUG THERAPY

Antimalarials in Sjögren's syndrome--the Greek experience. Manoussakis MN, et al. **Lupus** 1996 Jun;5 Suppl 1:S28-30 (15 ref.)

ETIOLOGY

Pathogenesis and treatment of Sjögren's syndrome. Fox RI, et al. **Curr Opin Rheumatol** 1997 Sep;9(5):393-9 (118 ref.)

[Extrahepatic diseases in patients with hepatitis C virus infection. Probable or possible associations] Durand JM. **Presse Med** 1997 Jun 21;26(21):1023-8 (118 ref.) **(Fre)**

IMMUNOLOGY

Clinical significance of antinuclear antibodies in systemic rheumatic diseases. Hietarinta M, et al. **Ann Med** 1996 Aug; 28(4):283-91 (84 ref.)

T-cell receptor in Sjögren's syndrome. Sumida T, et al. **Br J Rheumatol** 1997 Jun;36(6):622-9 (52 ref.)

Current concepts of autoimmune exocrinopathy: immunologic mechanisms in the salivary pathology of Sjögren's syndrome. Fox PC, et al. **Crit Rev Oral Biol Med** 1996;7(2):144-58 (111 ref.)

Sex hormones and Sjögren's syndrome. Sullivan DA. **J Rheumatol** 1997 Sep;24 Suppl 50:17-32 (249 ref.)

Cutaneous diseases in adults associated with anti-Ro/SS-A autoantibody production. McCauliffe DP. **Lupus** 1997; 6(2):158-66 (100 ref.)

[Analysis of infiltrating T-cell receptor in multiple organ lesions of patients with Sjogren's syndrome] Sumida T, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec; 18(6):653-9 (20 ref.) **(Jpn)**

PATHOLOGY

[Study of apoptosis in Sjögren's syndrome] Ogawa N, et al. **Rinsho Byori** 1997 Jul;45(7):643-8 (11 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Neuroendocrine changes in systemic lupus erythematosus and Sjögren's syndrome. Fox RA, et al. **Baillieres Clin Rheumatol** 1996 May;10(2):333-47 (86 ref.)

THERAPY

Pathogenesis and treatment of Sjögren's syndrome. Fox RI, et al. **Curr Opin Rheumatol** 1997 Sep;9(5):393-9 (118 ref.)

Sjögren's syndrome therapy: future directions. Moutsopoulos HM. **J Rheumatol** 1997 Sep;24 Suppl 50:33-4 (11 ref.)

VIROLOGY

HTLV-I arthropathy and Sjögren syndrome. Nishioka K. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S57-62 (34 ref.)

Viruses in the etiopathogenesis of Sjögren's syndrome. Venables PJ, et al. **J Rheumatol** 1997 Sep;24 Suppl 50:3-5 (28 ref.)

[Potential role of Epstein-Barr virus in Sjögren's syndrome] Saito I. **Nippon Rinsho** 1997 Jun;55(6):1505-11 (19 ref.) (Eng. Abstr.) **(Jpn)**

SKATEBOARDING see **SKATING**

SKATES (FISH)

BLOOD

Band 3 in cell volume regulation in fish erythrocytes. Perlman DF, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 Nov;42(7):975-84 (31 ref.)

SKATING

INJURIES

Late presentation of triceps rupture. A case report and review of the literature. Inhofe PD, et al. **Am J Orthop** 1996 Nov; 25(11):790-2 (10 ref.)

Skateboarding injuries. Fountain JL, et al. **Sports Med** 1996 Dec;22(6):360-6 (46 ref.)

SKELETAL AGE MEASUREMENT see **AGE DETERMINATION BY SKELETON**

SKELETAL FIXATION see **FRACTURE FIXATION**

SKELETAL MUSCLE see **MUSCLE, SKELETAL**

SKELETAL MUSCLE RELAXANTS see **NEUROMUSCULAR AGENTS**

SKELETAL MUSCLE VENTRICLE see **CARDIOMYOPLASTY**

SKELETIN see **DESMIN**

SKELETON

see related
BONE AND BONES

Functional morphological similarities in the locomotor skeleton of miocene catarrhines and platyrrhine monkeys. Rose MD. **Folia Primatol (Basel)** 1996;66(1-4):7-14 (66 ref.)

SKID ROW ALCOHOLICS see **HOMELESS PERSONS**

SKIING

INJURIES

Post-traumatic osteolysis of the distal clavicle. Reber P, et al. **Arch Orthop Trauma Surg** 1996;115(2):120-2 (17 ref.)

Recurrent traumatic dislocation of the hip: report of a case and review of the literature. Weber M, et al. **J Orthop Trauma** 1997 Jul;11(5):382-5 (16 ref.)

Trends in ski and snowboard injuries. Chissell HR, et al. **Sports Med** 1996 Sep;22(3):141-5 (24 ref.)

Injuries in cross-country skiing: a critical appraisal of the literature. Smith M, et al. **Sports Med** 1996 Mar; 21(3):239-50 (42 ref.)

[Snowboard sports technique, injury pattern, prevention] Dingerkus ML, et al. **Fortschr Med** 1997 Feb 20; 115(5):26-8, 30-1 (16 ref.) (Eng. Abstr.) **(Ger)**

SKILLED NURSING FACILITIES

OBRA regulations and the use of psychotropic drugs in long-term care facilities: impact and implications for geropsychiatric care. Stoudemire A, et al. **Gen Hosp Psychiatry** 1996 Mar;18(2):77-94 (138 ref.)

SKIN

see related
DERMATOLOGIC AGENTS
KERATINOCYTES

Soaps and detergents in children. Yamamoto K. **Clin Dermatol** 1996 Jan-Feb;14(1):81-4 (8 ref.)

ABNORMALITIES

Intestinal malrotation in a child with cardio-facio-cutaneous syndrome. McDaniel CH, et al. **Am J Med Genet** 1997 Jun 13;70(3):284-6 (30 ref.)

Patients with geleophysic dysplasia are not always geleophysic. Santolaya JM, et al. **Am J Med Genet** 1997 Oct 3;72(1):85-90 (12 ref.)

Cardio-facio-cutaneous (CFC) syndrome--a distinct entity? Report of three patients demonstrating the diagnostic difficulties in delineation of CFC syndrome. Wieczorek D, et al. **Clin Genet** 1997 Jul;52(1):37-46 (57 ref.)

Cutaneous hemangiomas, vascular stains and malformations, and associated syndromes. Esterly NB.

Curr Probl Pediatr 1996 Jan;26(1):3–39 (272 ref.)

Molecular genetics and neurobiology of neurodegenerative and neurodevelopmental disorders. Zoghbi HY. **Pediatr Res** 1997 May;41(5):722–6 (33 ref.)

A case of popliteal pterygium treated along with nerve expansion. Maral T, et al. **Plast Reconstr Surg** 1997 Jul; 100(1):91–5 (15 ref.)

ANATOMY & HISTOLOGY

Stratum corneum architecture, metabolic activity and interactivity with subjacent cell layers. Elias PM. **Exp Dermatol** 1996 Aug;5(4):191–201 (77 ref.)

Tumours of the skin. Ghadially FN, et al. **IARC Sci Publ** 1996;(126):1–43 (111 ref.)

The stratum corneum revisited. Elias PM. **J Dermatol** 1996 Nov;23(11):756–8 (77 ref.)

Inherited ichthyoses: a review of the histology of the skin. Scheimberg I, et al. **Pediatr Pathol Lab Med** 1996 May–Jun; 16(3):359–78 (86 ref.)

BLOOD SUPPLY

Improvement of microcirculatory blood flow under epidural spinal cord stimulation in patients with nonreconstructible peripheral arterial occlusive disease. Claeys LG. **Artif Organs** 1997 Mar;21(3):201–6 (36 ref.)

Small vessel vasculitis and vasculitis confined to skin. Mat C, et al. **Baillieres Clin Rheumatol** 1997 May;11(2):237–57 (52 ref.)

Fasciocutaneous blood supply in below–knee amputation. Humzah MD, et al. **J Bone Joint Surg Br** 1997 May; 79(3):441–3 (21 ref.)

Glaucoma in phakomatosis pigmentovascularis. Teekhasaenee C, et al. **Ophthalmology** 1997 Jan; 104(1):150–7 (66 ref.)

[Cutaneous reactions in Crohn disease. Vasculitis in various skin segments] Schlehaider UK, et al. **Hautarzt** 1997 May; 48(5):328–31 (17 ref.) (Eng. Abstr.) **(Ger)**

[Microscopic polyangiitis with eosinophilia––an overlap syndrome or separate disease entity? A case report and review of the literature] Weninger W, et al. **Hautarzt** 1997 May;48(5):332–8 (48 ref.) (Eng. Abstr.) **(Ger)**

[Abdominothoracic large–caliber skin vein––a symptom of vena cava discontinuity] Wildberger JE, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Jul;167(1):101–2 (9 ref.) **(Ger)**

CHEMISTRY

Nonerythroid membrane skeletal proteins in normal and diseased human skin. Shimizu T, et al. **Histol Histopathol** 1996 Apr;11(2):495–501 (72 ref.)

Chromophores in human skin. Young AR. **Phys Med Biol** 1997 May;42(5):789–802 (60 ref.)

[A standing wave of chemical reaction on the skin of animals] Kondo S. **Tanpakushitsu Kakusan Koso** 1996 Dec; 41(16):2564–8 (5 ref.) **(Jpn)**

CYTOLOGY

Role of mitochondria–rich cells in epithelial chloride uptake. Larsen EH, et al. **Exp Physiol** 1996 May;81(3):525–34 (25 ref.)

Apoptosis and cutaneous biology. Raskin CA. **J Am Acad Dermatol** 1997 Jun;36(6 Pt 1):885–96; quiz 897–8 (93 ref.)

Epidermal T cells: their functional role and disease relevance for dermatologists. Shiohara T, et al. **J Invest Dermatol** 1997 Sep;109(3):271–5 (45 ref.)

Aging of cultured human skin fibroblasts. Harley CB, et al. **Methods Mol Biol** 1997;75:23–30 (8 ref.)

Establishment, maintenance, and cloning of human dermal fibroblasts. Jones GE, et al. **Methods Mol Biol** 1997; 75:13–21 (4 ref.)

Melanoma and stroma: an interaction of biological and prognostic importance. Smolle J, et al. **Semin Cutan Med Surg** 1996 Dec;15(4):326–35 (108 ref.)

[Stress and skin: experimental approach] Gauthier Y. **Pathol Biol (Paris)** 1996 Dec;44(10):882–7 (30 ref.) (Eng. Abstr.) **(Fre)**

[Merkel cell and neuro–cutaneous system] Misery L, et al. **Pathol Biol (Paris)** 1996 Dec;44(10):849–55 (81 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Moisturizers: adjunct therapy and advising patients. Jackson EM. **Am J Contact Dermat** 1996 Dec;7(4):247–50 (9 ref.)

The accuracy of indirect immunofluorescence on sodium chloride–split skin in differentiating subepidermal bullous diseases [editorial; comment] Mutasim DF. **Arch Dermatol** 1997 Sep;133(9):1158–60 (23 ref.) Comment on: Arch Dermatol 1997 Sep;133(9):1102–7.

Effects of detergents on acne. Solomon BA, et al. **Clin Dermatol** 1996 Jan–Feb;14(1):95–9 (8 ref.)

Action of cholinesters on sensory nerve endings in skin and muscle. Carr RW, et al. **Clin Exp Pharmacol Physiol** 1996 May;23(5):355–62 (81 ref.)

Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. Cevc G. **Crit Rev Ther Drug Carrier Syst** 1996;13(3–4):257–388 (331 ref.)

Pharmacology and chemistry of adapalene. Shroot B, et al. **J Am Acad Dermatol** 1997 Jun;36(6 Pt 2):S96–103 (14 ref.)

[Skin reactions to bradykinin] Rihoux JP, et al. **Allerg Immunol (Paris)** 1995 Oct;27(8):279–83 (33 ref.) (Eng. Abstr.) **(Fre)**

[Neuromediators in dermatology. Therapeutic prospectives] Claudy A. **Pathol Biol (Paris)** 1996 Dec;44(10):888–94 (69 ref.) (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

The mitogen–activated protein kinases system (MAP kinase cascade): its role in skin signal transduction. A review. Geilen CC, et al. **J Dermatol Sci** 1996 Sep;12(3):255–62 (44 ref.)

GROWTH & DEVELOPMENT

Distribution of minor collagens during skin development. Garrone R, et al. **Microsc Res Tech** 1997 Aug 15; 38(4):407–12 (35 ref.)

Elastic fiber during development and aging. Pasquali–Ronchetti I, et al. **Microsc Res Tech** 1997 Aug 15;38(4):428–35 (85 ref.)

Molecular histology in skin appendage morphogenesis. Widelitz RB, et al. **Microsc Res Tech** 1997 Aug 15; 38(4):452–65 (70 ref.)

IMMUNOLOGY

"HIV–peplotion vaccine"––a novel approach to protection against AIDS by transepithelial transport of viral peptides to Langerhans cells for long–term antiviral CTL response. (A review). Becker Y. **Acta Microbiol Immunol Hung** 1996; 43(1):1–17 (83 ref.)

The role of basophils and mast cells in acute and late reactions in the skin. Charlesworth EN. **Allergy** 1997;52(34 Suppl):31–43 (73 ref.)

Stochastic resonance and angry back syndrome: noisy skin. Rietschel RL. **Am J Contact Dermat** 1996 Sep;7(3):152–4 (13 ref.)

The role of dendritic cells in cutaneous immunity. Lappin MB, et al. **Arch Dermatol Res** 1996 Mar;288(3):109–21 (138 ref.)

Mineral waters: instead of soap or better than soap? Lotti TM, et al. **Clin Dermatol** 1996 Jan–Feb;14(1):101–4 (28 ref.)

The skin as an organ of immunity. Bos JD. **Clin Exp Immunol** 1997 Jan;107 Suppl 1:3–5 (9 ref.)

The desmosome and hemidesmosome in cutaneous autoimmunity. Lin MS, et al. **Clin Exp Immunol** 1997 Jan; 107 Suppl 1:9–15 (55 ref.)

Cadherins and Langerhans cell immunobiology. Udey MC. **Clin Exp Immunol** 1997 Jan;107 Suppl 1:6–8 (32 ref.)

Regulation of the immune response by epidermal cytokines and neurohormones. Luger TA, et al. **J Dermatol Sci** 1996 Oct;13(1):5–10 (51 ref.)

The influence of ultraviolet light on immunological cytotoxicity in the skin. Norris DA, et al. **Photochem Photobiol** 1997 Apr;65(4):636–46 (117 ref.)

Impact of UVB radiation on the epidermal cytokine network. Takashima A, et al. **Photochem Photobiol** 1996 Apr; 63(4):397–400 (80 ref.)

T–cell receptor alpha beta and gamma delta T cells in rat and human skin––are they equivalent? Elbe A, et al. **Semin Immunol** 1996 Dec;8(6):341–9 (82 ref.)

[Ultraviolet light, skin urocanic acid and immune tolerance (editorial)] Laihia J, et al. **Duodecim** 1995;111(10):905–6 (17 ref.) **(Fin)**

[The immunocompetent structures of the skin and their role in the development of primary skin lymphomas (editorial)] Vavilov AM, et al. **Arkh Patol** 1996 Nov–Dec;58(6):7–12 (52 ref.) (Eng. Abstr.) **(Rus)**

[Langerhans cells and the immunological function of the skin] Buianova AV. **Lik Sprava** 1996 Mar–Apr;(3–4):24–7 (34 ref.) (Eng. Abstr.) **(Rus)**

INJURIES

Complications in the use of diathermy. Aigner N, et al. **Burns** 1997 May;23(3):256–64 (25 ref.)

Wound measurement. Wysocki AB. **Int J Dermatol** 1996 Feb; 35(2):82–91 (57 ref.)

Cultured epithelial autografts: diving from surgery into matrix biology. Raghunath M, et al. **Pediatr Surg Int** 1997 Sep;12(7):478–83 (52 ref.)

[Recognizing the signs of child abuse on the skin] Piérard GE. **Rev Med Liege** 1997 May;52(5):320–3 (25 ref.) **(Fre)**

[Cutaneous wound healing: clinical evaluation of locally active growth factors––an overview] Coerper S, et al. **Zentralbl Chir** 1996;121 Suppl:49–51 (21 ref.) **(Ger)**

[Use of cell and molecular biology in a model and the clinic] Vogt PM. **Zentralbl Chir** 1996;121 Suppl:25–8 (43 ref.) **(Ger)**

INNERVATION

Action of cholinesters on sensory nerve endings in skin and muscle. Carr RW, et al. **Clin Exp Pharmacol Physiol** 1996 May;23(5):355–62 (81 ref.)

The sympathetic skin response: a neurological perspective. Marchello L, et al. **Funct Neurol** 1996 Nov–Dec; 11(6):283–99 (104 ref.)

Structural diversity of the ordinary and specialized lateral line organs. Cernuda–Cernuda R, et al. **Microsc Res Tech** 1996 Jul 1;34(4):302–12 (60 ref.)

Enzyme histochemistry of cutaneous sensory nerve formations. Dubový P. **Microsc Res Tech** 1996 Jul 1; 34(4):334–50 (110 ref.)

Degeneration and regeneration of cutaneous sensory nerve formations. Dubový P, et al. **Microsc Res Tech** 1996 Jul 1;34(4):362–75 (110 ref.)

Sensory nerve formations in the skin and their classification [see comments] Malinovský L. **Microsc Res Tech** 1996 Jul 1;34(4):283–301 (135 ref.) Comment in: Microsc Res Tech 1996 Jul 1;34(4):281–2.

Ontogeny of the cutaneous sensory organs. Saxod R. **Microsc Res Tech** 1996 Jul 1;34(4):313–33 (100 ref.)

Immunohistochemistry of human cutaneous Meissner and pacinian corpuscles. Vega JA, et al. **Microsc Res Tech** 1996 Jul 1;34(4):351–61 (110 ref.)

Cutaneous sensory nerve formations: an overview [comment] Vega JA. **Microsc Res Tech** 1996 Jul 1;34(4):281–2 (33 ref.) Comment on: Microsc Res Tech 1996 Jul 1;34(4):283–301.

Mammalian cutaneous mechanoreceptors. Hamann W. **Prog Biophys Mol Biol** 1995;64(1):81–104 (140 ref.)

Spinal cord mechanisms of hyperalgesia and allodynia: role of peripheral input from nociceptors. Cervero F. **Prog Brain Res** 1996;113:413–22 (32 ref.)

Peptides and cutaneous polymodal nociceptor neurones. Lawson SN. **Prog Brain Res** 1996;113:369–85 (75 ref.)

Neurogenic inflammation caused by cutaneous polymodal receptors. Lynn B. **Prog Brain Res** 1996;113:361–8 (43 ref.)

Cutaneous polymodal receptors: characteristics and plasticity. Perl ER. **Prog Brain Res** 1996;113:21–37 (49 ref.)

Sympathetic modulation of cutaneous polymodal receptors in chronically inflamed and diabetic rats. Sato J, et al. **Prog Brain Res** 1996;113:153–9 (41 ref.)

[Merkel cell and neuro–cutaneous system] Misery L, et al. **Pathol Biol (Paris)** 1996 Dec;44(10):849–55 (81 ref.) (Eng. Abstr.) **(Fre)**

[Neuro–immuno–cutaneous system (NICS)] Misery L. **Pathol Biol (Paris)** 1996 Dec;44(10):867–74 (86 ref.) (Eng. Abstr.) **(Fre)**

[Development of the cutaneous nervous system] Saxod R, et al. **Pathol Biol (Paris)** 1996 Dec;44(10):838–48 (40 ref.) (Eng. Abstr.) **(Fre)**

[Sympathetic skin response (SSR)] Deguchi K, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:494–7 (12 ref.) **(Jpn)**

[Cutaneous innervation: anatomy and physiology. Neuropeptides] Casado–Olea JA. **Rev Neurol** 1997 Sep;25 Suppl 3:S207–13 (31 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Immunohistochemical, ultrastructural, and molecular features of Kindler syndrome distinguish it from dystrophic epidermolysis bullosa. Shimizu H, et al. **Arch Dermatol** 1997 Sep;133(9):1111–7 (47 ref.)

200 years of amphibian water economy: from Robert Townson to the present. Jørgensen CB. **Biol Rev Camb Philos Soc** 1997 May;72(2):153–237 (390 ref.)

Methods for measuring the skin–cleansing effect of surfactants in comparison with skin roughness and compatibility. Schrader K, et al. **Clin Dermatol** 1996 Jan–Feb;14(1):57–65 (15 ref.)

The effects of detergents on hydration and skin surface lipids. Thune P. **Clin Dermatol** 1996 Jan–Feb;14(1):29–33 (33 ref.)

Aspects of exposure to UVA tanning sources. Carcinogenic effect in mice and melanogenic effect in man and mice. Bech–Thomsen N. **Dan Med Bull** 1997 Jun;44(3):242–56 (116 ref.)

Stratum corneum architecture, metabolic activity and interactivity with subjacent cell layers. Elias PM. **Exp Dermatol** 1996 Aug;5(4):191–201 (77 ref.)

Influence of solubility and permeant size on absorption and metabolism of xenobiotics in rabbit skin. Bast GE. **Hum Exp Toxicol** 1997 Aug;16(8):435–40 (20 ref.)

The stratum corneum revisited. Elias PM. **J Dermatol** 1996 Nov;23(11):756–8 (77 ref.)

Transdermal drug delivery: useful paradigms. Potts RO, et al. **J Drug Target** 1995;3(4):247–51 (32 ref.)

The key role of the H+ V–ATPase in acid–base balance and Na+ transport processes in frog skin. Ehrenfeld J, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):247–56 (78 ref.)

Roles of E– and P–cadherin in the human skin. Furukawa F, et al. **Microsc Res Tech** 1997 Aug 15;38(4):343–52 (65 ref.)

Distribution of minor collagens during skin development. Garrone R, et al. **Microsc Res Tech** 1997 Aug 15; 38(4):407–12 (35 ref.)

Topography and biological role of integrins in human skin. Marchisio PC, et al. **Microsc Res Tech** 1997 Aug 15; 38(4):353–60 (80 ref.)

Elastic fiber during development and aging. Pasquali–Ronchetti I, et al. **Microsc Res Tech** 1997 Aug 15;38(4):428–35 (85 ref.)

In vitro viable skin model. Bronaugh RL. **Pharm Biotechnol** 1996;8:375–86 (13 ref.)

Isolated perfused porcine skin flap systems. Riviere JE. **Pharm Biotechnol** 1996;8:387–407 (42 ref.)

[Stress and skin: experimental approach] Gauthier Y. **Pathol Biol (Paris)** 1996 Dec;44(10):882–7 (30 ref.) (Eng. Abstr.) **(Fre)**

[Substance P and human skin] Staniek V, et al. **Pathol Biol (Paris)** 1996 Dec;44(10):860–6 (63 ref.) (Eng. Abstr.) **(Fre)**

[Fatty acids and the epidermis] Schneider IM, et al. **Hautarzt** 1997 May;48(5):303–10 (81 ref.) (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

The effect of detergents on skin pH and its consequences. Korting HC, et al. **Clin Dermatol** 1996 Jan–Feb;14(1):23–7 (29 ref.)

Prevention of catheter-related infections: the skin. Darouiche RO, et al. **Nutrition** 1997 Apr;13(4 Suppl):26S–29S (33 ref.)

PATHOLOGY

How to submit a specimen for cutaneous pathology analysis. Using the 5 D's to get the most from biopsies. Boyd AS, et al. **Arch Fam Med** 1997 Jan–Feb;6(1):64–6 (10 ref.)

Small vessel vasculitis and vasculitis confined to skin. Mat C, et al. **Baillieres Clin Rheumatol** 1997 May;11(2):237–57 (52 ref.)

Blistering skin diseases: models for studies on epidermal–dermal adhesion. Bruckner-Tuderman L. **Biochem Cell Biol** 1996;74(6):729–36 (53 ref.)

A review of skin ageing and its medical therapy. Gilchrest BA. **Br J Dermatol** 1996 Dec;135(6):867–75 (50 ref.)

Clinical and pathological heterogeneity in cutaneous gamma–delta T-cell lymphoma: a report of three cases and a review of the literature. Munn SE, et al. **Br J Dermatol** 1996 Dec;135(6):976–81 (17 ref.)

Case report: severe fibrosis in a patient with scleroderma and previous radiotherapy—a case report and literature review. Aref I, et al. **Br J Radiol** 1996 Nov;69(827):1055–6 (9 ref.)

Mononuclear phagocytes and dendritic leukocytes in the skin. Milon G, et al. **Clin Dermatol** 1996 Sep–Oct;14(5):465–70 (65 ref.)

Pityriasis rotunda. Pinto GM, et al. **Cutis** 1996 Dec; 58(6):406–8 (20 ref.)

Histology of laser resurfacing. Kauvar AN, et al. **Dermatol Clin** 1997 Jul;15(3):459–67 (64 ref.)

Peritumoral B cell infiltrate associated with chronic lymphocytic leukemia obscuring margin evaluation during Mohs micrographic surgery [letter] Humphreys TR, et al. **Dermatol Surg** 1996 Oct;22(10):894–6 (21 ref.)

Heterogeneous reactivity with LH7.2 and the first prenatal diagnosis of generalized recessive dystrophic epidermolysis bullosa among Japanese patients. Shimizu H, et al. **Dermatology** 1996;192(3):203–7 (29 ref.)

Wound measurement. Wysocki AB. **Int J Dermatol** 1996 Feb; 35(2):82–91 (57 ref.)

Specific skin infiltration as first sign of chronic myelomonocytic leukemia with an unusual phenotype. Braga D, et al. **J Am Acad Dermatol** 1996 Nov;35(5 Pt 2):804–7 (17 ref.)

Widespread cutaneous necrosis and antiphospholipid antibodies: two episodes related to surgical manipulation and urinary tract infection. Del Castillo LF, et al. **J Am Acad Dermatol** 1997 May;36(5 Pt 2):872–5 (15 ref.)

Linear focal elastosis: a review of three cases in young Japanese men. Tamada Y, et al. **J Am Acad Dermatol** 1997 Feb;36(2 Pt 2):301–3 (7 ref.)

A case of linear atrophoderma of Moulin [letter; comment] Braun RP, et al. **J Dermatol** 1996 Sep;23(9):660 (6 ref.) Comment on: J Dermatol 1995 Oct;22(10):767–9.

Skin. Smoller BR, et al. **Pathology (Phila)** 1996;3(2):285–98 (15 ref.)

Electronmicroscopic observation of the basement membrane zone in focal dermal hypoplasia. Lee IJ, et al. **Pediatr Dermatol** 1996 Jan–Feb;13(1):5–9 (18 ref.)

Phakomatosis pigmentovascularis: report of a case. Mahroughan M, et al. **Pediatr Dermatol** 1996 Jan–Feb; 13(1):36–8 (8 ref.)

Crohn's disease of the prepuce in a 12-year-old boy: a case report and review of the literature. Phillips SS, et al. **Pediatr Pathol Lab Med** 1997 May–Jun;17(3):497–502 (24 ref.)

Juvenile dermatomyositis presenting with rash alone. Eisenstein DM, et al. **Pediatrics** 1997 Sep;100(3 Pt 1):391–2 (13 ref.)

Aesthetic and anatomic analysis of the aging skin. Glogau RG. **Semin Cutan Med Surg** 1996 Sep;15(3):134–8 (5 ref.)

Eosinophilic and neutrophilic spongiosis: clues to the diagnosis of immunobullous diseases and other inflammatory disorders. Machado-Pinto J, et al. **Semin Cutan Med Surg** 1996 Dec;15(4):308–16 (45 ref.)

Melanoma and stroma: an interaction of biological and prognostic importance. Smolle J, et al. **Semin Cutan Med Surg** 1996 Dec;15(4):326–35 (108 ref.)

Immunoperoxidase techniques in the evaluation of cutaneous lymphocytic infiltrates. Smoller BR. **Semin Cutan Med Surg** 1996 Dec;15(4):300–7 (30 ref.)

Utility of skin biopsy in diabetic neuropathy. Kennedy WR, et al. **Semin Neurol** 1996 Jun;16(2):163–71 (40 ref.)

Atrophie blanche—a special form of vasculopathy. Kwok CY, et al. **Singapore Med J** 1997 Mar;38(3):123–4 (12 ref.)

Warfarin and heparin-induced skin necrosis and the purple toe syndrome: infrequent complications of anticoagulant treatment. Sallah S, et al. **Thromb Haemost** 1997 Aug; 78(2):785–90 (96 ref.)

[Stratum corneum] Plewig G, et al. **Hautarzt** 1997 Jul; 48(7):510–21; quiz 520 (26 ref.) **(Ger)**

[Diagnosis of neurometabolic and neurodegenerative diseases by cutaneous biopsy] Idoate Gastearena MA, et al. **Rev Neurol** 1997 Sep;25 Suppl 3:S269–80 (64 ref.) (Eng. Abstr.) **(Spa)**

[Adverse cutaneous reactions to drugs in neurology] Redondo Bellón P. **Rev Neurol** 1997 Sep;25 Suppl 3:S309–19 (73 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Cutaneous microdialysis. Methodology and validation. Groth L. **Acta Derm Venereol Suppl (Stockh)** 1996;197:1–61 (200 ref.)

Physiological changes in the skin during pregnancy. Elling SV, et al. **Clin Dermatol** 1997 Jan–Feb;15(1):35–43 (39 ref.)

Physiology of the skin—differences between women and men. Tur E. **Clin Dermatol** 1997 Jan–Feb;15(1):5–16 (63 ref.)

Hair keratinization in health and disease. Jones LN, et al. **Dermatol Clin** 1996 Oct;14(4):633–50 (104 ref.)

The use of dermal papilla cells in studies of normal and abnormal hair follicle biology. Randall VA. **Dermatol Clin** 1996 Oct;14(4):585–94 (55 ref.)

Reconstructed human skin: transplant, graft or biological dressing? Wood EJ, et al. **Essays Biochem** 1995;29:65–85 (52 ref.)

Hyaluronic acid and skin: wound healing and aging. Manuskiatti W, et al. **Int J Dermatol** 1996 Aug;35(8):539–44 (82 ref.)

A novel approach to the understanding of human skin barrier function. Forslind B, et al. **J Dermatol Sci** 1997 Feb; 14(2):115–25 (28 ref.)

Aspects on the physiology of human skin: studies using particle probe analysis. Forslind B, et al. **Microsc Res Tech** 1997 Aug 15;38(4):373–86 (40 ref.)

Microfibrillar elements of the dermal matrix. Kielty CM, et al. **Microsc Res Tech** 1997 Aug 15;38(4):413–27 (150 ref.)

Cultured epithelial autografts: diving from surgery into matrix biology. Raghunath M, et al. **Pediatr Surg Int** 1997 Sep;12(7):478–83 (52 ref.)

The Merkel cell as a possible mechanoreceptor cell. Ogawa H. **Prog Neurobiol** 1996 Jul;49(4):317–34 (79 ref.)

Human skin physiology studied by particle probe microanalysis. Forslind B, et al. **Scanning Microsc** 1995; 9(4):1011–25; discussion 1025–6 (48 ref.)

Wound healing—aiming for perfect skin regeneration. Martin P. **Science** 1997 Apr 4;276(5309):75–81 (92 ref.)

[Neuro–immuno–cutaneous system (NICS)] Misery L. **Pathol Biol (Paris)** 1996 Dec;44(10):867–74 (86 ref.) (Eng. Abstr.) **(Fre)**

[A standing wave of chemical reaction on the skin of animals] Kondo S. **Tanpakushitsu Kakusan Koso** 1996 Dec; 41(16):2564–8 (5 ref.) **(Jpn)**

[Cutaneous innervation: anatomy and physiology. Neuropeptides] Casado-Olea JA. **Rev Neurol** 1997 Sep;25 Suppl 3:S207–13 (31 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Wound healing in elderly human skin. Strigini L, et al. **Clin Dermatol** 1996 Mar–Apr;14(2):197–206 (53 ref.)

Skin and diabetes. Sibbald RG, et al. **Endocrinol Metab Clin North Am** 1996 Jun;25(2):463–72 (40 ref.)

RADIATION EFFECTS

Photoaging of the connective tissue of skin: its prevention and therapy. Scharffetter-Kochanek K. **Adv Pharmacol** 1997;38:639–55 (116 ref.)

The effect of photodamage on dermal extracellular matrix. Bernstein EF, et al. **Clin Dermatol** 1996 Mar–Apr; 14(2):143–51 (72 ref.)

UV-induced cutaneous photobiology. Beissert S, et al. **Crit Rev Biochem Mol Biol** 1996 Dec;31(5–6):381–404 (150 ref.)

Aspects of exposure to UVA tanning sources. Carcinogenic effect in mice and melanogenic effect in man and mice. Bech-Thomsen N. **Dan Med Bull** 1997 Jun;44(3):242–56 (116 ref.)

Sunscreens: progress and perspectives on photoprotection of human skin against UVB and UVA radiation. Pathak MA. **J Dermatol** 1996 Nov;23(11):783–800 (25 ref.)

The influence of ultraviolet light on immunological cytotoxicity in the skin. Norris DA, et al. **Photochem Photobiol** 1997 Apr;65(4):636–46 (117 ref.)

Impact of UVB radiation on the epidermal cytokine network. Takashima A, et al. **Photochem Photobiol** 1996 Apr; 63(4):397–400 (80 ref.)

Chromophores in human skin. Young AR. **Phys Med Biol** 1997 May;42(5):789–802 (60 ref.)

SURGERY

Laser resurfacing of rhytides. Fitzpatrick RE. **Dermatol Clin** 1997 Jul;15(3):431–47 (56 ref.)

Histology of laser resurfacing. Kauvar AN, et al. **Dermatol Clin** 1997 Jul;15(3):459–67 (64 ref.)

Laser treatment of tattoos. Kilmer SL. **Dermatol Clin** 1997 Jul;15(3):409–17 (50 ref.)

Complications of laser surgery. Nanni C. **Dermatol Clin** 1997 Jul;15(3):521–34 (84 ref.)

Dermatologic laser surgery. A review. Alster TS, et al. **Dermatol Surg** 1996 Sep;22(9):797–805 (125 ref.)

Topical anesthetic agents in dermatologic surgery. A review. Lener EV, et al. **Dermatol Surg** 1997 Aug;23(8):673–83 (58 ref.)

Drug management in skin surgery. Lawrence C. **Drugs** 1996 Dec;52(6):805–17 (109 ref.)

Millisecond CO2 laser skin resurfacing. Khan JA. **Int Ophthalmol Clin** 1997 Summer;37(3):29–68 (24 ref.)

Skin. Smoller BR, et al. **Pathology (Phila)** 1996;3(2):285–98 (15 ref.)

ULTRASTRUCTURE

Immunohistochemical, ultrastructural, and molecular features of Kindler syndrome distinguish it from dystrophic epidermolysis bullosa. Shimizu H, et al. **Arch Dermatol** 1997 Sep;133(9):1111–7 (47 ref.)

Linear and whorled nevoid hypermelanosis versus incontinentia pigmenti: is pigmentary incontinence really a distinctive feature? Delaporte E, et al. **Dermatology** 1996; 192(1):70–2 (17 ref.)

Immunodissection of the connective tissue matrix in human skin. Keene DR, et al. **Microsc Res Tech** 1997 Aug 15; 38(4):394–406 (110 ref.)

Microfibrillar elements of the dermal matrix. Kielty CM, et al. **Microsc Res Tech** 1997 Aug 15;38(4):413–27 (150 ref.)

Molecular complexity of the cutaneous basement membrane zone. Uitto J, et al. **Mol Biol Rep** 1996;23(1):35–46 (56 ref.)

Kindler syndrome: report of a case with ultrastructural study and review of the literature. Patrizi A, et al. **Pediatr Dermatol** 1996 Sep–Oct;13(5):397–402 (21 ref.)

The Merkel cell as a possible mechanoreceptor cell. Ogawa H. **Prog Neurobiol** 1996 Jul;49(4):317–34 (79 ref.)

SKIN ABSORPTION

see related

ADMINISTRATION, CUTANEOUS

Influence of solubility and permeant size on absorption and metabolism of xenobiotics in rabbit skin. Bast GE. **Hum Exp Toxicol** 1997 Aug;16(8):435–40 (20 ref.)

Toxicology of topical local anesthetics. Bangha E, et al. **Skin Pharmacol** 1996;9(6):376–80 (28 ref.)

DRUG EFFECTS

Moisturizers in the prevention of contact dermatitis. Hannuksela M. **Curr Probl Dermatol** 1996;25:214–20 (31 ref.)

Percutaneous penetration (dermatopharmacokinetics) in evaluating barrier creams. Zhai H, et al. **Curr Probl Dermatol** 1996;25:193–205 (24 ref.)

[Modulation of drug penetration in the skin] Kalbitz J, et al. **Pharmazie** 1996 Sep;51(9):619–37 (124 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

In vitro viable skin model. Bronaugh RL. **Pharm Biotechnol** 1996;8:375–86 (13 ref.)

Isolated perfused porcine skin flap systems. Riviere JE. **Pharm Biotechnol** 1996;8:387–407 (42 ref.)

[The value of oil baths for adjuvant basic therapy of inflammatory dermatoses with dry, barrier-disrupted skin] Melnik B, et al. **Hautarzt** 1996 Sep;47(9):665–72 (62 ref.) (Eng. Abstr.) **(Ger)**

SKIN AGING

The hairless mouse model for photoaging. Kligman LH. **Clin Dermatol** 1996 Mar–Apr;14(2):183–95 (101 ref.)

Psychologic aspects of aging and the skin. Koblenzer CS. **Clin Dermatol** 1996 Mar–Apr;14(2):171–7 (65 ref.)

Therapeutic skin care in the mature patient. Draelos ZD. **Clin Plast Surg** 1997 Apr;24(2):369–77 (45 ref.)

Laser resurfacing of rhytides. Fitzpatrick RE. **Dermatol Clin** 1997 Jul;15(3):431–47 (56 ref.)

The aging upper and middle face: an overview for the aesthetic surgeon. Heinz GW, et al. **Int Ophthalmol Clin** 1997 Summer;37(3):1–10 (8 ref.)

Skin aging: observations at the cellular and molecular levels. Yaar M. **Isr J Med Sci** 1996 Nov;32(11):1053–8 (37 ref.)

Cutaneous facial resurfacing with the carbon dioxide laser. Biesman BS. **Ophthalmic Surg Lasers** 1996 Aug; 27(8):685–98 (62 ref.)

Diagonal earlobe crease: a coronary risk factor, a genetic marker of coronary heart disease, or a mere wrinkle. Ancient Greco-Roman evidence. Gutiu IA, et al. **Rom J Intern Med** 1996 Jul–Dec;34(3–4):271–8 (27 ref.)

DRUG EFFECTS

Injection of all-trans retinoic acid for treatment of thin wrinkles. Personelle J, et al. **Aesthetic Plast Surg** 1997 May–Jun;21(3):196–204 (49 ref.)

Cosmetic use of alpha-hydroxy acids. Vidt DG, et al. **Cleve Clin J Med** 1997 Jun;64(6):327–9 (11 ref.)

Topical vitamin C in aging. Colven RM, et al. **Clin Dermatol** 1996 Mar–Apr;14(2):227–34 (58 ref.)

Retinoids in aging. Torras H. **Clin Dermatol** 1996 Mar–Apr; 14(2):207–15 (53 ref.)

Alpha-hydroxyacids in the treatment of signs of photoaging. Van Scott EJ, et al. **Clin Dermatol** 1996 Mar–Apr; 14(2):217–26 (16 ref.)

Topical retinoic acid (tretinoin) for photoaging: conceptions and misperceptions. Kligman AM. **Cutis** 1996 Mar; 57(3):142–4 (11 ref.)

SKIN AGING

Cosmetic botulinum toxin injections. Carter SR, et al. **Int Ophthalmol Clin** 1997 Summer;37(3):69–79 (51 ref.)
Treatment of photodamage with topical tretinoin: an overview. Gilchrest BA. **J Am Acad Dermatol** 1997 Mar; 36(3 Pt 2):S27–36 (29 ref.)
Topical treatments for photoaged skin. Separating the reality from the hype. Kligman AM. **Postgrad Med** 1997 Aug; 102(2):115–8, 123–6 (11 ref.)
Resurfacing with topical agents. Lewis AB, et al. **Semin Cutan Med Surg** 1996 Sep;15(3):139–44 (26 ref.)
Deep chemical peeling. Matarasso SL, et al. **Semin Cutan Med Surg** 1996 Sep;15(3):155–61 (33 ref.)

PATHOLOGY

A review of skin ageing and its medical therapy. Gilchrest BA. **Br J Dermatol** 1996 Dec;135(6):867–75 (50 ref.)
Elastic fiber during development and aging. Pasquali-Ronchetti I, et al. **Microsc Res Tech** 1997 Aug 15;38(4):428–35 (85 ref.)
Aesthetic and anatomic analysis of the aging skin. Glogau RG. **Semin Cutan Med Surg** 1996 Sep;15(3):134–8 (5 ref.)
[From cellular senescence to seven ways of skin aging] Piérard GE, et al. **Rev Med Liege** 1997 Apr;52(4):285–8 (23 ref.) **(Fre)**

PHYSIOLOGY

Skin aging and photoaging: an outlook. Goihman-Yahr M. **Clin Dermatol** 1996 Mar–Apr;14(2):153–60 (58 ref.)
Soaps and detergents in the elderly. Graham-Brown R. **Clin Dermatol** 1996 Jan–Feb;14(1):85–7 (28 ref.)
The premature aging syndromes. Pesce K, et al. **Clin Dermatol** 1996 Mar–Apr;14(2):161–70 (70 ref.)
Wound healing in elderly human skin. Strigini L, et al. **Clin Dermatol** 1996 Mar–Apr;14(2):197–206 (53 ref.)
Hyaluronic acid and skin: wound healing and aging. Manuskiatti W, et al. **Int J Dermatol** 1996 Aug;35(8):539–44 (82 ref.)
The aging skin. Bergfeld WF. **Int J Fertil Womens Med** 1997 Mar–Apr;42(2):57–66 (20 ref.)
[From cellular senescence to seven ways of skin aging] Piérard GE, et al. **Rev Med Liege** 1997 Apr;52(4):285–8 (23 ref.) **(Fre)**
[Skin aging] **Gac Med Mex** 1994 Jul–Aug;130(4):275–7 (0 ref.) **(Spa)**

RADIATION EFFECTS

Sun exposure, sunscreens, and skin cancer prevention: a year-round concern. Farmer KC, et al. **Ann Pharmacother** 1996 Jun;30(6):662–73 (87 ref.)
The effect of photodamage on dermal extracellular matrix. Bernstein EF, et al. **Clin Dermatol** 1996 Mar–Apr; 14(2):143–51 (72 ref.)

SKIN APPENDAGE DISEASES

PATHOLOGY

Areolar sebaceous hyperplasia: a case report. Belinchón I, et al. **Cutis** 1996 Jul;58(1):63–4 (8 ref.)

SKIN, ARTIFICIAL

In vitro reconstructed skin models for wound coverage in deep burns. Berthod F, et al. **Br J Dermatol** 1997 Jun; 136(6):809–16 (71 ref.)

SKIN CARE

New developments in cosmetics and skin care products. Draelos ZD. **Adv Dermatol** 1997;12:3–17; discussion 18 (74 ref.)
Moisturizers: adjunct therapy and advising patients. Jackson EM. **Am J Contact Dermat** 1996 Dec;7(4):247–50 (9 ref.)
Moisturizers in the prevention of contact dermatitis. Hannuksela M. **Curr Probl Dermatol** 1996;25:214–20 (31 ref.)

ADVERSE EFFECTS

The effect of detergents on skin pH and its consequences. Korting HC, et al. **Clin Dermatol** 1996 Jan–Feb;14(1):23–7 (29 ref.)
The effects of detergents on hydration and skin surface lipids. Thune P. **Clin Dermatol** 1996 Jan–Feb;14(1):29–33 (33 ref.)
Skin scraping, cupping, and moxibustion that may mimic physical abuse. Look KM, et al. **J Forensic Sci** 1997 Jan; 42(1):103–5 (9 ref.)

METHODS

Soaps and detergents in the elderly. Graham-Brown R. **Clin Dermatol** 1996 Jan–Feb;14(1):85–7 (28 ref.)
Soaps and detergents in skin diseases. Hannuksela A, et al. **Clin Dermatol** 1996 Jan–Feb;14(1):77–80 (37 ref.)
Mineral waters: instead of soap or better than soap? Lotti TM, et al. **Clin Dermatol** 1996 Jan–Feb;14(1):101–4 (28 ref.)
Effects of detergents on acne. Solomon BA, et al. **Clin Dermatol** 1996 Jan–Feb;14(1):95–9 (8 ref.)
Soaps and detergents in children. Yamamoto K. **Clin Dermatol** 1996 Jan–Feb;14(1):81–4 (8 ref.)
Pressure ulcers. Local wound care. Goode PS, et al. **Clin Geriatr Med** 1997 Aug;13(3):543–52 (20 ref.)
Therapeutic skin care in the mature patient. Draelos ZD. **Clin Plast Surg** 1997 Apr;24(2):369–77 (45 ref.)
Skin care of the normal newborn. Liou LW, et al. **Cutis** 1997 Apr;59(4):171–4 (43 ref.)
The aging skin. Bergfeld WF. **Int J Fertil Womens Med** 1997 Mar–Apr;42(2):57–66 (20 ref.)

STANDARDS

Skin integrity in the pediatric population: preventing and managing pressure ulcers. Quigley SM, et al. **J Soc Pediatr Nurs** 1996 Apr–Jun;1(1):7–18 (35 ref.)

SKIN DISEASES

see related

DERMATOLOGIC AGENTS

Dermatoses in newborns. Treadwell PA. **Am Fam Physician** 1997 Aug;56(2):443–50 (19 ref.)
Vulval skin disease and the gynaecologist. Evans S. **Br J Hosp Med** 1997 Jun 4–17;57(11):579–81 (3 ref.)
Dermatologic problems in podiatric sports medicine. King MJ. **Clin Podiatr Med Surg** 1997 Jul;14(3):511–24 (9 ref.)
Skin disorders in black children. Laude TA. **Curr Opin Pediatr** 1996 Aug;8(4):381–5 (28 ref.)
Common dermatologic manifestations of cutaneous exposure to petroleum and its derivatives. Beasley KL, et al. **Cutis** 1996 Jul;58(1):59–62 (13 ref.)
Psychopharmacology for dermatologic patients. Koo J, et al. **Dermatol Clin** 1996 Jul;14(3):509–23 (53 ref.)
Mastocytosis: new understandings in cutaneous pathophysiology. Lazarus GS. **J Dermatol** 1996 Nov; 23(11):769–72 (15 ref.)
An update of the benign proliferative monocyte–macrophage and dendritic cell disorders. Moschella SL. **J Dermatol** 1996 Nov;23(11):805–15 (56 ref.)
Dermatologic complications of HIV infection. Myskowski PL, et al. **Med Clin North Am** 1996 Nov;80(6):1415–35 (75 ref.)
Mucocutaneous paraneoplastic syndromes. Cohen PR, et al. **Semin Oncol** 1997 Jun;24(3):334–59 (87 ref.)
[Dermatological examination and treatment on the aged] Yamamoto T. **Nippon Ronen Igakkai Zasshi** 1996 Jun; 33(6):424–9 (7 ref.) **(Jpn)**
[Anticentromere antibodies and lung disease without skin involvement] Fernández-Fernández FJ, et al. **An Med Interna** 1997 Apr;14(4):196–8 (15 ref.) (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

Sensitive skin: perceptions, evaluation, and treatment. Draelos ZD. **Am J Contact Dermat** 1997 Jun;8(2):67–78 (113 ref.)
Cutaneous complications of hormonal replacement therapy. Mor Z, et al. **Clin Dermatol** 1997 Jan–Feb;15(1):147–54 (88 ref.)
Cytokines. Shrum JP. **Clin Dermatol** 1996 Jul–Aug; 14(4):331–6 (67 ref.)
Skin reactions to pesticides. O'Malley MA. **Occup Med** 1997 Apr–Jun;12(2):327–45 (81 ref.)
Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Bocquet H, et al. **Semin Cutan Med Surg** 1996 Dec;15(4):250–7 (70 ref.)
Warfarin and heparin-induced skin necrosis and the purple toe syndrome: infrequent complications of anticoagulant treatment. Sallah S, et al. **Thromb Haemost** 1997 Aug; 78(2):785–90 (96 ref.)

CLASSIFICATION

"New" diseases in dermatopathology. Rapini RP. **Adv Dermatol** 1997;12:213–35; discussion 236 (78 ref.)

COMPLICATIONS

Human immunodeficiency virus in women: mucocutaneous manifestations. Wright SW, et al. **Clin Dermatol** 1997 Jan–Feb;15(1):93–111 (202 ref.)
Dermatologic disorders associated with viral hepatitis infections [see comments] Parsons ME, et al. **Int J Dermatol** 1996 Feb;35(2):77–81 (47 ref.) Comment in: Int J Dermatol 1997 Mar;36(3):237–8.
Cutaneous manifestations of chronic granulomatous disease. A report of four cases and review of the literature. Dohil M, et al. **J Am Acad Dermatol** 1997 Jun;36(6 Pt 1):899–907 (50 ref.)
Antiphospholipid syndrome and the skin. Gibson GE, et al. **J Am Acad Dermatol** 1997 Jun;36(6 Pt 1):970–82 (83 ref.)
Granulomatous lymphangitis of the penile skin as a cause of penile swelling in children. Mor Y, et al. **J Urol** 1997 Aug;158(2):591–2 (12 ref.)
Progress and new directions in the investigation of the specific dermatoses of pregnancy. Black MM. **Keio J Med** 1997 Mar;46(1):40–1 (13 ref.)
[Neurocutaneous syndrome with hair alterations] Camacho-Martínez F. **Rev Neurol** 1997 Sep;25 Suppl 3:S243–9 (51 ref.) (Eng. Abstr.) **(Spa)**
[Neural tube dysfunction and cutaneous lesions] Vanaclocha-Vanaclocha V, et al. **Rev Neurol** 1997 Sep;25 Suppl 3:S232–7 (80 ref.) (Eng. Abstr.) **(Spa)**

CONGENITAL

Restrictive dermopathy: report and review. Mau U, et al. **Am J Med Genet** 1997 Aug 8;71(2):179–85 (37 ref.)
Congenital smooth muscle hamartoma presenting as a linear atrophic plaque: case report and review of the literature. Grau-Massanes M, et al. **Pediatr Dermatol** 1996 May–Jun; 13(3):222–5 (28 ref.)
[Cutis marmorata teleangiectatica congenita. Important aspects for dermatologic practice] Rupprecht R, et al. **Hautarzt** 1997 Jan;48(1):21–5 (30 ref.) (Eng. Abstr.) **(Ger)**
[Familial cutaneous collagenoma] Suenaga Y. **Ryoikibetsu Shokogun Shirizu** 1996;(15):264–6 (5 ref.) **(Jpn)**

DIAGNOSIS

Polymerase chain reaction and its application for the diagnosis and management of skin diseases. Feldman SR, et al. **Adv Dermatol** 1997;12:115–36; discussion 137 (128 ref.)
Principles of skin biopsies for the family physician. Achar S. **Am Fam Physician** 1996 Dec;54(8):2411–8 (14 ref.)
Dermatologic problems encountered in the emergency department. Ferrera PC, et al. **Am J Emerg Med** 1996 Oct; 14(6):588–601 (97 ref.)
How to submit a specimen for cutaneous pathology analysis. Using the '5 D's' to get the most from biopsies. Boyd AS, et al. **Arch Fam Med** 1997 Jan–Feb;6(1):64–6 (10 ref.)
Cutaneous manifestations of chronic graft-versus-host disease. Andrews ML, et al. **Australas J Dermatol** 1997 May;38(2):53–62; quiz 63–4 (79 ref.)
Dermatologic nondisease. Cotterill JA. **Dermatol Clin** 1996 Jul;14(3):439–45 (68 ref.)
Pediatric dermatology. Hartley AH, et al. **Dermatol Clin** 1997 Jan;15(1):111–9 (50 ref.)
Simulators of hand infections. Kann SE, et al. **Instr Course Lect** 1997;46:69–82 (169 ref.)
Dermatoses of the glans penis and prepuce. English JC 3rd, et al. **J Am Acad Dermatol** 1997 Jul;37(1):1–24; quiz 25–6 (352 ref.)
Cutaneous Crohn's disease in children. Ploysangam T, et al. **J Am Acad Dermatol** 1997 May;36(5 Pt 1):697–704 (69 ref.)
Is cutaneous plasmacytosis a distinct clinical entity? Shimizu S, et al. **J Am Acad Dermatol** 1997 May;36(5 Pt 2):876–80 (30 ref.)
Prenatal diagnosis of inherited skin diseases. Shimizu H. **Keio J Med** 1996 Mar;45(1):28–36 (55 ref.)
Neonatal dermatologic challenges. Johr RH, et al. **Pediatr Rev** 1997 Mar;18(3):86–94 (7 ref.)
Cutaneous clues to systemic disease. Kirsner RS, et al. **Postgrad Med** 1997 Jun;101(6):137–9, 144, 147–50 (28 ref.)
[Transient acantholytic dermatosis (Grover disease)] Maghraoui S, et al. **Ann Dermatol Venereol** 1995; 122(11–12):801–6 (41 ref.) **(Fre)**
[Imaging methods in dermatology] el Gammal S, et al. **Hautarzt** 1997 Jun;48(6):432–50; quiz 448 (74 ref.) **(Ger)**
[Activation of epidermal melanocytes is independent of epithelial proliferation and vascularization. Immunohistologic study using HMB-45 antibody with review of the literature] Lommel K, et al. **Hautarzt** 1996 Aug;47(8):616–23 (65 ref.) (Eng. Abstr.) **(Ger)**
[HIV-associated skin diseases] Plettenberg A, et al. **Hautarzt** 1997 Jan;48(1):58–72 (75 ref.) **(Ger)**
[Infections with cutaneous and nervous system alterations] Losada-Campa A, et al. **Rev Neurol** 1997 Sep;25 Suppl 3:S281–93 (76 ref.) (Eng. Abstr.) **(Spa)**
[Systemic autoimmune diseases with neurocutaneous alterations] Oliveros-Cid A, et al. **Rev Neurol** 1997 Sep; 25 Suppl 3:S294–308 (170 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Moisturizers: adjunct therapy and advising patients. Jackson EM. **Am J Contact Dermat** 1996 Dec;7(4):247–50 (9 ref.)
Cyclosporin in less common immune-mediated skin diseases. Ruzicka T. **Br J Dermatol** 1996 Sep;135 Suppl 48:40–2 (20 ref.)
Neoral (cyclosporin) in dermatology: technical aspects. Smith SG. **Br J Dermatol** 1996 Sep;135 Suppl 48:2–4 (13 ref.)
Current status of photodynamic therapy in dermatology. Bissonnette R, et al. **Dermatol Clin** 1997 Jul;15(3):507–19 (91 ref.)
The 5 alpha-reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders. Chen W, et al. **Dermatology** 1996;193(3):177–84 (58 ref.)
Current use and future potential role of retinoids in dermatology. Orfanos CE, et al. **Drugs** 1997 Mar; 53(3):358–88 (262 ref.)
Advances in dermatopharmacology—strength and weakness of recently of approved drugs (I). Chang YC, et al. **Int J Clin Pharmacol Ther** 1997 May;35(5):188–94 (32 ref.)
5 alpha-reductase inhibitors--a new hope in dermatology? Amichai B, et al. **Int J Dermatol** 1997 Mar;36(3):182–4 (28 ref.)
Antiandrogen therapy in dermatology. Shaw JC. **Int J Dermatol** 1996 Nov;35(11):770–8 (86 ref.)
Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. Tseng S, et al. **J Am Acad Dermatol** 1996 Dec;35(6):969–79 (101 ref.)
Dermatology 1945–95: the golden age of treatment. Fitzpatrick TB. **J Dermatol** 1996 Nov;23(11):728–34 (22

ref.)
Perspectives in cutaneous photodynamic sensitization. Ortel B, et al. **J Photochem Photobiol B** 1996 Nov;36(2):209–11 (14 ref.)
Antihistamines and their role in dermatology. Hafeez ZH. **JPMA J Pak Med Assoc** 1996 Nov;46(11):264–7 (42 ref.)
A reappraisal of topical steroid potency. Hepburn DJ, et al. **Pediatr Dermatol** 1996 May–Jun;13(3):239–45 (64 ref.)
Cytochrome P–450 and drug development for skin diseases. Ahmad N, et al. **Skin Pharmacol** 1996;9(4):231–41 (67 ref.)
[Therapeutic alternatives to systemic corticotherapy in severe and chronic dermatologic disorders in the elderly patient] de la Brassinne M. **Rev Med Liege** 1997 Apr;52(4):296–8 (0 ref.) **(Fre)**
[Photodynamic therapy at the threshold of clinical use in disseminated dermatoses] Boehncke WH, et al. **Hautarzt** 1996 Nov;47(11):825–31 (48 ref.) (Eng. Abstr.) **(Ger)**
[Neuropeptides in dermatologic therapy] Gómez–Bezares P, et al. **Rev Neurol** 1997 Sep;25 Suppl 3:S320–4 (60 ref.) (Eng. Abstr.) **(Spa)**
[Tetracyclines as anti–inflammatory treatment in skin diseases] Autio P, et al. **Nord Med** 1996 Dec;111(10):348–51 (15 ref.) (Eng. Abstr.) **(Swe)**

ENZYMOLOGY

Cytochrome P–450 and drug development for skin diseases. Ahmad N, et al. **Skin Pharmacol** 1996;9(4):231–41 (67 ref.)

EPIDEMIOLOGY

Dermatoepidemiology. II: Causal inference established by a rule called "ASSOCIATED". Chuang TY, et al. **Int J Dermatol** 1997 Jun;36(6):412–5 (27 ref.)
Skin disease and socioeconomic conditions in rural Africa: Tanzania. Gibbs S. **Int J Dermatol** 1996 Sep;35(9):633–9 (19 ref.)
Epidemiology of Behçet's syndrome in Turkey. Tüzün Y, et al. **Int J Dermatol** 1996 Sep;35(9):618–20 (15 ref.)

ETIOLOGY

The princess and the pea. An unusual complication after a laparoscopic cholecystectomy. Pharr ME, et al. **Arch Fam Med** 1997 Mar–Apr;6(2):188–9 (10 ref.)
Scalp necrosis in giant cell arteritis and review of the literature. Currey J. **Br J Rheumatol** 1997 Jul;36(7):814–6 (24 ref.)
Physiological changes in the skin during pregnancy. Elling SV, et al. **Clin Dermatol** 1997 Jan–Feb;15(1):35–43 (39 ref.)
Perimenstrual eruptions. Stephens CJ. **Clin Dermatol** 1997 Jan–Feb;15(1):31–4 (33 ref.)
Metabolic–associated skin disorders. Giacalone VF, et al. **Clin Podiatr Med Surg** 1996 Jan;13(1):119–38 (90 ref.)
Skin disorders associated with rheumatic disease. Kaminski MJ. **Clin Podiatr Med Surg** 1996 Jan;13(1):139–53 (46 ref.)
Complications of laser surgery. Nanni C. **Dermatol Clin** 1997 Jul;15(3):521–34 (84 ref.)
'Normolipidemic' tendinous and tuberous xanthomatosis. Mancuso G, et al. **Dermatology** 1996;193(1):27–32 (25 ref.)
Skin and diabetes. Sibbald RG, et al. **Endocrinol Metab Clin North Am** 1996 Jun;25(2):463–72 (40 ref.)
Epidemiology of Behçet's syndrome in Turkey. Tüzün Y, et al. **Int J Dermatol** 1996 Sep;35(9):618–20 (15 ref.)
Cutaneous manifestations of sports participation. Pharis DB, et al. **J Am Acad Dermatol** 1997 Mar;36(3 Pt 1):448–59 (110 ref.)
Milia arising in herpes zoster scars. Lee WS, et al. **J Dermatol** 1996 Aug;23(8):556–8 (10 ref.)
Microscopic polyangiitis after influenza vaccination. Kelsall JT, et al. **J Rheumatol** 1997 Jun;24(6):1198–202 (15 ref.)
Renal transplantation and skin diseases: review of the literature and results of a 5–year follow–up of 285 patients. Barba A, et al. **Nephron** 1996;73(2):131–6 (40 ref.)
The cutaneous manifestations of gastrointestinal disease. Katz SK, et al. **Prim Care** 1996 Sep;23(3):455–76 (63 ref.)
[Closed spinal dysraphism. Apropos of 3 cases] Benzekri L, et al. **Ann Dermatol Venereol** 1996;123(6–7):378–81 (12 ref.) (Eng. Abstr.) **(Fre)**
[Eosinophilia and skin: current data] Dubost–Brama A, et al. **Ann Dermatol Venereol** 1996;123(8):498–509 (103 ref.) **(Fre)**
[Cutaneous vasculitis disclosing parvovirus B19 infection (letter)] Andrès E, et al. **Ann Med Interne (Paris)** 1997; 148(1):107–8 (9 ref.) **(Fre)**
[Cutaneous manifestations related to malignant hematologic diseases] Aractingi S, et al. **Presse Med** 1997 Apr 26; 26(14):678–83 (25 ref.) **(Fre)**
[Extrahepatic diseases in patients with hepatitis C virus infection. Probable or possible associations] Durand JM. **Presse Med** 1997 Jun 21;26(21):1023–8 (118 ref.) **(Fre)**
[Cutaneous metastatic Crohn disease. Apropos of a case] Gisserot O, et al. **Rev Med Interne** 1997;18(6):477–80 (23 ref.) (Eng. Abstr.) **(Fre)**
[Cutaneous manifestations of diabetes] Piérard–Franchimont C, et al. **Rev Med Liege** 1996 May;51(5):348–54 (25 ref.) **(Fre)**
[The skin of tobacco smokers] Rahier S, et al. **Rev Med Liege** 1996 Sep;51(9):582–85 (33 ref.) **(Fre)**
[Skin manifestation of allergic diseases and collagen disease] Nishioka K. **Arerugi** 1996 Nov;45(11):1149–53 (17 ref.) **(Jpn)**
[Cutaneous manifestations of diabetes mellitus] Nakayama H. **Nippon Rinsho** 1996 Oct;54(10):2790–4 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Cutaneous manifestations in rheumatic diseases] Kaneko F, et al. **Ryumachi** 1996 Aug;36(4):676–87 (33 ref.) **(Jpn)**
[Skin manifestations of chronic intestinal inflammatory disease] Ferrándiz C. **Gastroenterol Hepatol** 1996 Jan; 19(1):16–20 (21 ref.) **(Spa)**

GENETICS

Genetic approaches to understanding the keratinopathies. Bale SJ, et al. **Adv Dermatol** 1997;12:99–113; discussion 114 (63 ref.)
Restrictive dermopathy: report and review. Mau U, et al. **Am J Med Genet** 1997 Aug 8;71(2):179–85 (37 ref.)
Genodermatoses in women. Mevorah B, et al. **Clin Dermatol** 1997 Jan–Feb;15(1):17–29 (98 ref.)
The genetics of human skin diseases. Epstein EH Jr. **Curr Opin Genet Dev** 1996 Jun;6(3):295–300 (42 ref.)
The plakin family: versatile organizers of cytoskeletal architecture. Ruhrberg C, et al. **Curr Opin Genet Dev** 1997 Jun;7(3):392–7 (48 ref.)
Cutaneous gene therapy. Khavari PA, et al. **Dermatol Clin** 1997 Jan;15(1):27–35 (54 ref.)
Human keratin diseases: hereditary fragility of specific epithelial tissues. Corden LD, et al. **Exp Dermatol** 1996 Dec;5(6):297–307 (102 ref.)
Common genodermatoses. Kumar S, et al. **Int J Dermatol** 1996 Oct;35(10):685–94 (171 ref.)
Prenatal diagnosis of inherited skin diseases. Shimizu H. **Keio J Med** 1996 Mar;45(1):28–36 (55 ref.)
Current knowledge and research directions in heritable disorders of connective tissue. Sakai LY, et al. **Matrix Biol** 1996 Sep;15(4):211–29 (91 ref.)
Keith R. Porter Lecture, 1996. Of mice and men: genetic disorders of the cytoskeleton. Fuchs E. **Mol Biol Cell** 1997 Feb;8(2):189–203 (111 ref.)
[Animal and human genetic skin diseases. Parallelism and use] Larrègue M, et al. **Ann Dermatol Venereol** 1996; 123(6–7):417–25 (49 ref.) **(Fre)**
[Dyskeratosis congenita. Genetic hematologic–immunologic systemic disease with pancytopenia] Sölder B, et al. **Klin Padiatr** 1996 Nov–Dec;208(6):344–9 (50 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Immunologic aspects: immunology of mineral water spas. Ghersetich I, et al. **Clin Dermatol** 1996 Nov–Dec; 14(6):563–6 (36 ref.)
The utility of transgenic mouse models in the study of cutaneous immunology and inflammation. Kupper TS. **J Dermatol** 1996 Nov;23(11):741–5 (26 ref.)

METABOLISM

Epidermal structural proteins in skin disorders. Manabe M, et al. **J Dermatol Sci** 1997 Sep;15(3):143–65 (167 ref.)

MICROBIOLOGY

Cutaneous and muscular abscesses secondary to Actinomyces meyeri pneumonia. Liaudet L, et al. **Clin Infect Dis** 1996 Jan;22(1):185–6 (9 ref.)

PATHOLOGY

Conjunctival keratoacanthoma. Schellini SA, et al. **Acta Ophthalmol Scand** 1997 Jun;75(3):335–7 (22 ref.)
Cutaneous involvement in sarcoidosis. Relationship to systemic disease [editorial] Mañá J, et al. **Arch Dermatol** 1997 Jul;133(7):882–8 (75 ref.)
Granuloma faciale entirely in an extrafacial location [letter] Castaño E, et al. **Br J Dermatol** 1997 Jun;136(6):978–9 (9 ref.)
Linear atrophoderma of Moulin: a disease which follows Blaschko's lines. Wollenberg A, et al. **Br J Dermatol** 1996 Aug;135(2):277–9 (34 ref.)
Scalp necrosis in giant cell arteritis and review of the literature. Currey J. **Br J Rheumatol** 1997 Jul;36(7):814–6 (24 ref.)
Dermatologic problems of the menopause. Graham–Brown R. **Clin Dermatol** 1997 Jan–Feb;15(1):143–5 (19 ref.)
Basement membrane zone. Ray MC, et al. **Clin Dermatol** 1996 Jul–Aug;14(4):321–30 (48 ref.)
Unilateral naevoid telangiectasia syndrome in pregnancy. Woollons A, et al. **Clin Exp Dermatol** 1996 Nov; 21(6):459–60 (6 ref.)
Clinical evaluation of cutaneous lesions of the back: spinal signatures that do not go away. Humphreys RP. **Clin Neurosurg** 1996;43:175–87 (6 ref.)
Mucocutaneous conditions affecting the mouth. Williams DM. **Curr Top Pathol** 1996;90:1–28 (92 ref.)
The non–Langerhans' cell histiocytoses in childhood. Burgdorf WH, et al. **Cutis** 1996 Sep;58(3):201–7 (69 ref.)
Cutaneous granulomas as a presenting sign in ataxia–telangiectasia. Drolet BA, et al. **Dermatology** 1997; 194(3):273–5 (16 ref.)
Human keratin diseases: hereditary fragility of specific epithelial tissues. Corden LD, et al. **Exp Dermatol** 1996 Dec;5(6):297–307 (102 ref.)
Nonerythroid membrane skeletal proteins in normal and diseased human skin. Shimizu T, et al. **Histol Histopathol** 1996 Apr;11(2):495–501 (72 ref.)
Multiple eruptive milia: report of a case, review of the literature, and a classification. Langley RG, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):353–6 (34 ref.)
A clinicopathologic approach to granulomatous dermatoses. Rabinowitz LO, et al. **J Am Acad Dermatol** 1996 Oct; 35(4):588–600 (70 ref.)
Tumoral calcinosis: report of a case and brief review of the literature. Abraham Z, et al. **J Dermatol** 1996 Aug; 23(8):545–50 (41 ref.)
Multiple basaloid cell hamartoma with alopecia and autoimmune disease (systemic lupus erythematosus). Akasaka T, et al. **J Dermatol** 1996 Nov;23(11):821–4 (12 ref.)
Primary Anetoderma in children: report of two cases and literature review. Karrer S, et al. **Pediatr Dermatol** 1996 Sep–Oct;13(5):382–5 (22 ref.)
Neoplastic progression and prognosis in melanoma. Elder DE, et al. **Semin Cutan Med Surg** 1996 Dec;15(4):336–48 (87 ref.)
Immunohistochemistry: a prognostic as well as diagnostic tool? Mehregan D, et al. **Semin Cutan Med Surg** 1996 Dec; 15(4):317–25 (85 ref.)
Cutaneous neural heterotopias and related tumors relevant for the dermatopathologist. Argenyi ZB. **Semin Diagn Pathol** 1996 Feb;13(1):60–71 (62 ref.)
Cutaneous gangrene secondary to metastatic calcification in end stage renal failure—a case report. Tan HH, et al. **Singapore Med J** 1996 Aug;37(4):438–40 (12 ref.)
Primary breast cancer in aberrant breast tissue in the axilla. Yerra L, et al. **South Med J** 1997 Jun;90(6):661–2 (9 ref.)
Staging evaluation and surveillance for melanoma patients in a fiscally restrictive medical environment. A commentary. Ross MI. **Surg Clin North Am** 1996 Dec; 76(6):1423–32 (43 ref.)
Ophthalmic features of the organoid nevus syndrome. Shields JA, et al. **Trans Am Ophthalmol Soc** 1996;94:65–86; discussion 86–7 (46 ref.)
[Clinical signs of connective tissue diseases in children] Piérard GE, et al. **Rev Med Liege** 1997;52(7):452–6 (23 ref.) **(Fre)**
[Flow cytometry in dermatology] Bauer R, et al. **Hautarzt** 1996 Jul;47(7):561–78 (36 ref.) **(Ger)**
[Applications of electron microscopy in dermatology] Sterniczky B, et al. **Hautarzt** 1996 Feb;47(2):148–65 quiz 162–3 (41 ref.) **(Ger)**

PHYSIOPATHOLOGY

Role of reactive oxygen species in dermatologic diseases. Boh EE. **Clin Dermatol** 1996 Jul–Aug;14(4):343–52 (53 ref.)
Pediatric dermatology. Hartley AH, et al. **Dermatol Clin** 1997 Jan;15(1):111–9 (50 ref.)
Cutaneous sensory disorder. Koo J, et al. **Dermatol Clin** 1996 Jul;14(3):497–502 (23 ref.)
[Role of neuropeptides in dermatology] Sánchez–Carpintero I, et al. **Rev Neurol** 1997 Sep;25 Suppl 3:S222–31 (88 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Photoaging of the connective tissue of skin: its prevention and therapy. Scharffetter–Kochanek K. **Adv Pharmacol** 1997;38:639–55 (116 ref.)

PSYCHOLOGY

Psychodermatology of women. Koblenzer CS. **Clin Dermatol** 1997 Jan–Feb;15(1):127–41 (127 ref.)
Dermatologic nondisease. Cotterill JA. **Dermatol Clin** 1996 Jul;14(3):439–45 (68 ref.)
The psychosocial impact of skin disease. An overview. Ginsburg IH. **Dermatol Clin** 1996 Jul;14(3):473–84 (69 ref.)
Psychophysiology of stress in dermatology. The psychobiologic pattern of psychosomatics. Panconesi E, et al. **Dermatol Clin** 1996 Jul;14(3):399–421 (117 ref.)
[Skin and stress] Consoli S. **Pathol Biol (Paris)** 1996 Dec; 44(10):875–81 (28 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Skin and bones: dermatologic conditions with skeletal abnormalities. Harlow CL, et al. **Skeletal Radiol** 1997 Apr; 26(4):201–13 (48 ref.)

REHABILITATION

Mineral water and spas in Italy. Andreassi L, et al. **Clin Dermatol** 1996 Nov–Dec;14(6):627–32 (16 ref.)
Mineral water and spas in France. Karam P. **Clin Dermatol** 1996 Nov–Dec;14(6):607–10 (21 ref.)
Mineral water and spas in Spain. Ledo E. **Clin Dermatol** 1996 Nov–Dec;14(6):641–6 (19 ref.)
[Bath additives in dermatologic balneotherapy. Indications and approaches in current research] Schempp CM, et al. **Hautarzt** 1996 Dec;47(12):894–900 (49 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Cutaneous lasers: a review. Rosenbach A, et al. **Ann Plast Surg** 1996 Aug;37(2):220–31 (146 ref.)
What is new in cutaneous laser research. Grossman MC. **Dermatol Clin** 1997 Jan;15(1):1–8 (58 ref.)
Laser treatment of warts and other epidermal and dermal lesions. Hruza GJ. **Dermatol Clin** 1997 Jul;15(3):487–506 (129 ref.)

SKIN DISEASES

Laser medicine in dermatology. Anderson RR. **J Dermatol** 1996 Nov;23(11):778–82 (17 ref.)
Cutaneous applications of lasers. Ries WR, et al. **Otolaryngol Clin North Am** 1996 Dec;29(6):915–29 (45 ref.)
Office procedures. Cryotherapy of dermal abnormalities. Jester DM. **Prim Care** 1997 Jun;24(2):269–80 (12 ref.)
Laser skin resurfacing. Dover JS, et al. **Semin Cutan Med Surg** 1996 Sep;15(3):177–88 (66 ref.)
Preoperative anesthesia and postoperative considerations in laser resurfacing. Fitzpatrick RE, et al. **Semin Cutan Med Surg** 1996 Sep;15(3):170–6 (11 ref.)
Dermabrasion. Mandy SH. **Semin Cutan Med Surg** 1996 Sep; 15(3):162–9 (20 ref.)
[Fibrous hamartoma in childhood—a report of a rare case from practice] Maínkhard K, et al. **Khirurgiia (Sofiia)** 1996; 49(3):51–2 (9 ref.) **(Bul)**
[Dermatological laser treatment. A review of therapeutic possibilities and equipment] Haedersdal M, et al. **Ugeskr Laeger** 1997 May 26;159(22):3376–82 (40 ref.) (Eng. Abstr.) **(Dan)**
[Q-switched ruby laser in dermatologic therapy. Use and indications] Michel S, et al. **Hautarzt** 1997 Jul;48(7):462–70 (81 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Photoaging of the connective tissue of skin: its prevention and therapy. Scharffetter-Kochanek K. **Adv Pharmacol** 1997;38:639–55 (116 ref.)
Dermatologic problems encountered in the emergency department. Ferrera PC, et al. **Am J Emerg Med** 1996 Oct; 14(6):588–601 (97 ref.)
Bioclimatology at the Dead Sea in Israel. Abels DJ, et al. **Clin Dermatol** 1996 Nov–Dec;14(6):653–8 (41 ref.)
Soaps and detergents in skin diseases. Hannuksela A, et al. **Clin Dermatol** 1996 Jan–Feb;14(1):77–80 (37 ref.)
Spa therapy in Poland. Omulecki A, et al. **Clin Dermatol** 1996 Nov–Dec;14(6):679–83 (15 ref.)
Mineral water and spas in Bulgaria. Vassileva S. **Clin Dermatol** 1996 Nov–Dec;14(6):601–5 (16 ref.)
Cutaneous gene therapy. Khavari PA, et al. **Dermatol Clin** 1997 Jan;15(1):27–35 (54 ref.)
Gene delivery to the epidermis. Trainer AH, et al. **Hum Mol Genet** 1997;6(10):1761–7 (63 ref.)
The need for evidence-based management of skin diseases. Ladhani S. **Int J Dermatol** 1997 Jan;36(1):17–22 (74 ref.)
Indications, contraindications and possible side-effects of climatotherapy at the Dead-Sea. Shani J, et al. **Int J Dermatol** 1997 Jul;36(7):481–92 (47 ref.)
Medical issues and emergencies in the dermatology office. Fader DJ, et al. **J Am Acad Dermatol** 1997 Jan;36(1):1–16; quiz 16–8 (141 ref.)
Combining surgical methods for skin resurfacing. Coleman WP 3rd, et al. **Semin Cutan Med Surg** 1996 Sep;15(3):194–9 (11 ref.)
Complications of resurfacing. Ragland HP, et al. **Semin Cutan Med Surg** 1996 Sep;15(3):200–7 (23 ref.)
The place of laser resurfacing within the range of medical and surgical skin resurfacing techniques. Roenigk HH Jr. **Semin Cutan Med Surg** 1996 Sep;15(3):208–13 (13 ref.)

VIROLOGY

What is new in clinical research of viral diseases of the skin. Walther RR. **Dermatol Clin** 1997 Jan;15(1):189–96 (65 ref.)

SKIN DISEASES, BACTERIAL

DIAGNOSIS

Current aspects of bacterial infections of the skin. Sadick NS. **Dermatol Clin** 1997 Apr;15(2):341–9 (50 ref.)
[Atypical mycobacterial skin infections] Gbery IP, et al. **Sante** 1996 Sep–Oct;6(5):317–22 (31 ref.) (Eng. Abstr.) **(Fre)**
[Detection of Helicobacter pylori in dermatoses. Clinical incidental finding or pathogenetic association?] Tebbe B, et al. **Hautarzt** 1996 Aug;47(8):587–90 (29 ref.) (Eng. Abstr.) **(Ger)**
[Cutaneous infections by Mycobacterium marinum. Description of 3 cases and review of the literature] Dorronsoro I, et al. **Enferm Infecc Microbiol Clin** 1997 Feb;15(2):82–4 (22 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Antimicrobial agents for the dermatologist. II. Macrolides, fluoroquinolones, rifamycins, tetracyclines, trimethoprim-sulfamethoxazole, and clindamycin. Epstein ME, et al. **J Am Acad Dermatol** 1997 Sep;37(3 Pt 1):365–81; quiz 382–4 (181 ref.)
Antimicrobial agents for the dermatologist. I. Beta-lactam antibiotics and related compounds. Epstein ME, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 1):149–65; quiz 166–8 (143 ref.)
Primary care management of common dermatologic disorders in women. Pharmacologic considerations. Emmons L, et al. **J Nurse Midwifery** 1997 May–Jun; 42(3):228–53 (54 ref.)
Oral antibiotic therapy for uncomplicated bacterial skin infections in children. Darmstadt GL. **Pediatr Infect Dis J** 1997 Feb;16(2):227–40 (182 ref.)

IMMUNOLOGY

A case of lymphocutaneous nocardiosis with a review of lymphocutaneous nocardiosis reported in Japan [see comments] Ye Z, et al. **J Dermatol** 1996 Feb;23(2):120–4 (29 ref.) Comment in: J Dermatol 1997 Jan;24(1):68.

MICROBIOLOGY

[Skin infections due to Staphylococcus aureus and Streptococcus pyogenes] Arata J. **Nippon Rai Gakkai Zasshi** 1996 Jul;65(2):83–7 (10 ref.) **(Jpn)**

THERAPY

Current aspects of bacterial infections of the skin. Sadick NS. **Dermatol Clin** 1997 Apr;15(2):341–9 (50 ref.)

VETERINARY

Antimicrobial therapy of skin and ear infections. Dowling PM. **Can Vet J** 1996 Nov;37(11):695–9 (6 ref.)
The pathogenesis of dermatophilosis. Ambrose NC. **Trop Anim Health Prod** 1996 May;28(2 Suppl):29S–37S (24 ref.)

SKIN DISEASES, BULLOUS see **SKIN DISEASES, VESICULOBULLOUS**

SKIN DISEASES, ECZEMATOUS

DRUG THERAPY

Eczema/dermatitis: management & tips. Edwards L. **Compr Ther** 1997 Feb;23(2):148–54 (10 ref.)

IMMUNOLOGY

Aeroallergen contact dermatitis. Taïeb A, et al. **Clin Rev Allergy Immunol** 1996 Summer;14(2):209–23 (64 ref.)

SKIN DISEASES, FUNGAL see **DERMATOMYCOSES**

SKIN DISEASES, INFECTIOUS

Childhood dermatitis in the tropics: with special emphasis on infective dermatitis, a marker for infection with human T-cell leukemia virus-I. La Grenade L, et al. **Cutis** 1996 Aug;58(2):115–8 (41 ref.)
HIV-related skin diseases. Geusau A, et al. **J R Coll Physicians Lond** 1997 Jul–Aug;31(4):374–9 (38 ref.)

DIAGNOSIS

Distinguishing vesicular and pustular disorders in the neonate. Wagner A. **Curr Opin Pediatr** 1997 Aug; 9(4):396–405 (86 ref.)
Dermatology and the recently returned traveler: infectious diseases with dermatologic manifestations. Lucchina LC, et al. **Int J Dermatol** 1997 Mar;36(3):167–81 (55 ref.)
[HIV-associated skin diseases. 1: Follow-up and epidemiology of HIV infection, pathogen-induced HIV-associated dermatoses] Ramsauer J, et al. **Hautarzt** 1996 Oct;47(10):795–813 (73 ref.) **(Ger)**

DRUG THERAPY

Drug treatment of skin and soft tissue infections in elderly long-term care residents. Lertzman BH, et al. **Drugs Aging** 1996 Aug;9(2):109–21 (41 ref.)
Pediatric dermatology: advances in therapy. Chapel KL, et al. **J Am Acad Dermatol** 1997 Apr;36(4):513–26; quiz 527–30 (149 ref.)

EPIDEMIOLOGY

Infectious considerations in the world traveler. Tornieporth NG, et al. **Dermatol Clin** 1997 Apr;15(2):285–93 (34 ref.)

ETIOLOGY

Distinguishing vesicular and pustular disorders in the neonate. Wagner A. **Curr Opin Pediatr** 1997 Aug; 9(4):396–405 (86 ref.)
[Cutaneous manifestations related to malignant hematologic diseases] Aractingi S, et al. **Presse Med** 1997 Apr 26; 26(14):678–83 (25 ref.) **(Fre)**

PATHOLOGY

Tropical diseases and women. Kaur V. **Clin Dermatol** 1997 Jan–Feb;15(1):171–8 (60 ref.)

SKIN DISEASES, PAPULOSQUAMOUS

CHEMICALLY INDUCED

Acute generalized exanthematous pustulosis induced by paracetamol. A case with severe hemodynamic disturbances. De Coninck AL, et al. **Dermatology** 1996; 193(4):338–41 (35 ref.)
Acute generalized exanthematous pustulosis induced by dexamethasone injection. Demitsu T, et al. **Dermatology** 1996;193(1):56–8 (14 ref.)
Acute generalized exanthematous pustulosis. Beylot C, et al. **Semin Cutan Med Surg** 1996 Dec;15(4):244–9 (34 ref.)

COMPLICATIONS

Small bowel fistulae in Degos' disease: a case report and literature review. Atchabahian A, et al. **Am J Gastroenterol** 1996 Oct;91(10):2208–11 (57 ref.)
Papular mucinosis associated with human-immunodeficiency-virus infection. Azaña JM, et al. **Int J Dermatol** 1996 Sep;35(9):652–4 (15 ref.)

DIAGNOSIS

Acrokeratoelastoidosis. Dyall-Smith D. **Australas J Dermatol** 1996 Nov;37(4):213–4 (6 ref.)
[Rheumatoid neutrophilic dermatitis—a rare dermatosis in patients with active rheumatoid arthritis] Mrowietz U, et al. **Hautarzt** 1996 Dec;47(12):921–6 (8 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Non-infective mucocutaneous presentations of human immunodeficiency virus infection. Hamann ID, et al. **Australas J Dermatol** 1997 Aug;38(3):105–12; quiz 113–4 (43 ref.)
Acute generalized exanthematous pustulosis induced by hydroxychloroquine [letter] Assier-Bonnet H, et al. **Dermatology** 1996;193(1):70–1 (9 ref.)
Acquired Blaschko dermatitis: acquired relapsing self-healing Blaschko dermatitis. Lee HJ, et al. **J Dermatol** 1996 Sep; 23(9):639–42 (16 ref.)

PATHOLOGY

Benign persistent papular acantholytic and dyskeratotic eruption with features of warty dyskeratoma [letter] Urbani CE, et al. **Australas J Dermatol** 1996 Nov;37(4):225–6 (13 ref.)
Pearly penile papules [comment] Oates JK. **Genitourin Med** 1997 Apr;73(2):137–8 (13 ref.) Comment on: Genitourin Med 1997 Apr;73(2):136.

SKIN DISEASES, PARASITIC

see related
ECTOPARASITIC INFESTATIONS

DRUG THERAPY

Primary care management of common dermatologic disorders in women. Pharmacologic considerations. Emmons L, et al. **J Nurse Midwifery** 1997 May–Jun; 42(3):228–53 (54 ref.)
[Ivermectin and tropical dermatoses] Caumes E. **Bull Soc Pathol Exot** 1997;90(1):37–8 (17 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Infectious considerations in the world traveler. Tornieporth NG, et al. **Dermatol Clin** 1997 Apr;15(2):285–93 (34 ref.)

ETIOLOGY

[Subcutaneous cysticercosis] Del Giudice P, et al. **Ann Dermatol Venereol** 1996;123(8):474–7 (30 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Cutaneous amebiasis in an Iranian immunodeficient alcoholic: immunochemical and histological study [letter] Loschiavo F, et al. **Dermatology** 1997;194(4):370–1 (16 ref.)

PARASITOLOGY

Fatal granulomatous amoebic encephalitis caused by Balamuthia mandrillaris. Reed RP, et al. **Med J Aust** 1997 Jul 21;167(2):82–4 (10 ref.)

PATHOLOGY

Acanthamoeba infection. Wortman PD. **Int J Dermatol** 1996 Jan;35(1):48–51 (31 ref.)

SKIN DISEASES, VASCULAR

Cutaneous necrotizing vasculitis. Lotti T, et al. **Int J Dermatol** 1996 Jul;35(7):457–74 (242 ref.)

CHEMICALLY INDUCED

Methotrexate related cutaneous vasculitis [letter] Torner O, et al. **Clin Rheumatol** 1997 Jan;16(1):108–9 (7 ref.)

CLASSIFICATION

Cutaneous lymphocytic vasculitis: a definition, a review, and a proposed classification. Carlson JA, et al. **Semin Diagn Pathol** 1996 Feb;13(1):72–90 (57 ref.)

COMPLICATIONS

Erythema elevatum diutinum in human immunodeficiency virus-infected patients—report of a case and review of the literature. Dronda F, et al. **Clin Exp Dermatol** 1996 May; 21(3):222–5 (14 ref.)
Leukocytoclastic vasculitis in subacute cutaneous lupus erythematosus: clinicopathologic study of three cases and

review of the literature. Sánchez-Pérez J, et al. **Dermatology** 1996;193(3):230-5 (22 ref.)

CONGENITAL

Cutaneous hemangiomas, vascular stains and malformations, and associated syndromes. Esterly NB. **Curr Probl Pediatr** 1996 Jan;26(1):3-39 (272 ref.)

DIAGNOSIS

Necrosing livedo reticularis in a patient with recurrent pulmonary hemorrhage. Aronoff DM, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):300-2 (15 ref.)

Diagnosis and treatment of the systemic and cutaneous necrotizing vasculitis syndromes. Allen NB, et al. **Med Clin North Am** 1997 Jan;81(1):243-59 (39 ref.)

[Neurocutaneous syndromes with vascular alterations] de Felipe I, et al. **Rev Neurol** 1997 Sep;25 Suppl 3:S250-8 (74 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Livedo reticularis, rhabdomyolysis, massive intestinal infarction, and death after carbon dioxide arteriography. Rundback JH, et al. **J Vasc Surg** 1997 Aug;26(2):337-40 (13 ref.)

IMMUNOLOGY

Cutaneous manifestations in systemic vasculitis. Decleva I, et al. **Clin Rev Allergy Immunol** 1997 Spring;15(1):5-20 (84 ref.)

PATHOLOGY

Dabska tumor developing within a preexisting vascular malformation. Quecedo E, et al. **Am J Dermatopathol** 1996 Jun;18(3):302-7 (14 ref.)

Cutaneous manifestations in systemic vasculitis. Decleva I, et al. **Clin Rev Allergy Immunol** 1997 Spring;15(1):5-20 (84 ref.)

Cutaneous lymphocytic vasculitis: a definition, a review, and a proposed classification. Carlson JA, et al. **Semin Diagn Pathol** 1996 Feb;13(1):72-90 (57 ref.)

SURGERY

Laser treatment of acquired vascular lesions. Ross BS, et al. **Dermatol Clin** 1997 Jul;15(3):385-96 (67 ref.)

SKIN DISEASES, VESICULAR see **SKIN DISEASES, VESICULOBULLOUS**

SKIN DISEASES, VESICULOBULLOUS

[SAPHO syndrome: common denominator for various bone and skin diseases] Jahangier ZN, et al. **Ned Tijdschr Geneeskd** 1997 Apr 19;141(16):764-9 (37 ref.) (Eng. Abstr.) **(Dut)**

CHEMICALLY INDUCED

Generalized pustular dermatosis following paclitaxel therapy [letter] Weinberg JM, et al. **Int J Dermatol** 1997 Jul; 36(7):559-60 (8 ref.)

Penicillamine-induced bullous dermatoses. Bialy-Golan A, et al. **J Am Acad Dermatol** 1996 Nov;35(5 Pt 1):732-42 (113 ref.)

COMPLICATIONS

Linear IgA disease in a patient with bladder carcinoma. Ródenas JM, et al. **Br J Dermatol** 1997 Feb;136(2):257-9 (26 ref.)

Papuloerythroderma of Ofuji: a report of 2 cases including the first European case associated with visceral carcinoma. Schepers C, et al. **Dermatology** 1996;193(2):131-5 (22 ref.)

CONGENITAL

A new case of extensive congenital erosions and vesicles healing with reticulate scarring. Fernández-Pugnaire MA, et al. **Dermatology** 1997;194(3):278-80 (16 ref.)

DIAGNOSIS

The accuracy of indirect immunofluorescence on sodium chloride-split skin in differentiating subepidermal bullous diseases [editorial; comment] Mutasim DF. **Arch Dermatol** 1997 Sep;133(9):1158-60 (23 ref.) Comment on: Arch Dermatol 1997 Sep;133(9):1102-7.

Blistering diseases of the skin. Buchman JS. **Clin Podiatr Med Surg** 1996 Jan;13(1):91-108 (39 ref.)

Distinguishing vesicular and pustular disorders in the neonate. Wagner A. **Curr Opin Pediatr** 1997 Aug; 9(4):396-405 (86 ref.)

Eosinophilic pustular folliculitis (Ofuji disease) in a child. Lazarov A, et al. **Cutis** 1996 Aug;58(2):135-8 (14 ref.)

Hereditary bullous acrokeratotic poikiloderma of Weary-Kindler associated with pseudoainhum and sclerotic bands. Krunic AL, et al. **Int J Dermatol** 1997 Jul; 36(7):529-33 (18 ref.)

Uncommon cutaneous manifestations of lupus erythematosus. Mascaro JM, et al. **Lupus** 1997;6(2):122-31 (84 ref.)

Diagnosis and treatment of pustular disorders in the neonate. Van Praag MC, et al. **Pediatr Dermatol** 1997 Mar-Apr; 14(2):131-43 (77 ref.)

Eosinophilic and neutrophilic spongiosis: clues to the diagnosis of immunobullous diseases and other inflammatory disorders. Machado-Pinto J, et al. **Semin Cutan Med Surg** 1996 Dec;15(4):308-16 (45 ref.)

DRUG THERAPY

Diagnosis and treatment of pustular disorders in the neonate. Van Praag MC, et al. **Pediatr Dermatol** 1997 Mar-Apr; 14(2):131-43 (77 ref.)

ETIOLOGY

Distinguishing vesicular and pustular disorders in the neonate. Wagner A. **Curr Opin Pediatr** 1997 Aug; 9(4):396-405 (86 ref.)

Erosive pustular dermatosis of the scalp in skin grafts: report of three cases. Ena P, et al. **Dermatology** 1997;194(1):80-4 (26 ref.)

Acquired Blaschko dermatitis: acquired relapsing self-healing Blaschko dermatitis. Lee HJ, et al. **J Dermatol** 1996 Sep; 23(9):639-42 (16 ref.)

Bullous skin disease in lupus erythematosus. Yell JA, et al. **Lupus** 1997;6(2):112-21 (67 ref.)

GENETICS

The genetic basis of hereditary blistering disorders. Paller AS. **Curr Opin Pediatr** 1996 Aug;8(4):367-71 (38 ref.)

IMMUNOLOGY

Autoimmune bullous diseases. Rye B, et al. **Am Fam Physician** 1997 Jun;55(8):2709-18 (26 ref.)

The immunology of bullous oculo-muco-cutaneous disorders. Pleyer U, et al. **Immunol Today** 1996 Mar; 17(3):111-3 (12 ref.)

PATHOLOGY

Bullous systemic lupus erythematosus--a case report and review. Tay YK, et al. **Ann Acad Med Singapore** 1995 Nov; 24(6):879-82 (14 ref.)

SKIN DISEASES, VIRAL

Segmental zoster paresis of limbs. Merchut MP, et al. **Electromyogr Clin Neurophysiol** 1996 Sep;36(6):369-75 (21 ref.)

DIAGNOSIS

[Zoster. The manifestation forms in the skin, complications and therapy] Gross G. **Dtsch Med Wochenschr** 1997 Jan 31;122(5):132-9 (50 ref.) **(Ger)**

[Acute generalized exanthematous pustulosis due to Coxsackie B4 virus] Feio AB, et al. **Acta Med Port** 1997 Jun-Jul;10(6-7):487-91 (9 ref.) (Eng. Abstr.) **(Por)**

[Cutaneous infection with the cytomegalovirus virus in AIDS patients] Franca I, et al. **Acta Med Port** 1997 Jun-Jul; 10(6-7):479-84 (21 ref.) (Eng. Abstr.) **(Por)**

DRUG THERAPY

Primary care management of common dermatologic disorders in women. Pharmacologic considerations. Emmons L, et al. **J Nurse Midwifery** 1997 May-Jun; 42(3):228-53 (54 ref.)

ETIOLOGY

Dermatologic manifestations of hepatitis C infection. Schwaber MJ, et al. **Int J Dermatol** 1997 Apr;36(4):251-4 (25 ref.)

IMMUNOLOGY

Cellular immunity in cutaneous and genital HPV infections. Malejczyk J, et al. **Clin Dermatol** 1997 Mar-Apr; 15(2):261-74 (131 ref.)

SKIN DRUG ADMINISTRATION see **ADMINISTRATION, CUTANEOUS**

SKIN ELECTRIC CONDUCTANCE see **GALVANIC SKIN RESPONSE**

SKIN FISTULA see **CUTANEOUS FISTULA**

SKIN NEOPLASMS

Cutaneous malignant melanoma. Ringborg U. **Acta Otolaryngol (Stockh)** 1996 Sep;116(5):641-6 (25 ref.)

Malignant melanoma in children. A review [published erratum appears in Arch Dermatol 1997 Jul;133(7):833] Ruiz-Maldonado R, et al. **Arch Dermatol** 1997 Mar; 133(3):363-71 (133 ref.)

Management of cutaneous lymphoma. Russell-Jones R, et al. **Baillieres Clin Haematol** 1996 Dec;9(4):743-67 (125 ref.)

Mycosis fungoides and Sezary syndrome [see comments] Diamandidou E, et al. **Blood** 1996 Oct 1;88(7):2385-409 (296 ref.) Comment in: Blood 1997 Apr 15;89(8):3062-4.

Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Tsao H, et al. **Cancer** 1997 Jun 15; 79(12):2361-70 (29 ref.)

Animal models of melanoma. Kusewitt DF, et al. **Cancer Surv** 1996;26:35-70 (199 ref.)

Etiology and pathogenesis of squamous cell carcinoma. Markey AC. **Clin Dermatol** 1995 Nov-Dec;13(6):537-43 (99 ref.)

Etiology and pathogenesis of basal cell carcinoma. Miller SJ. **Clin Dermatol** 1995 Nov-Dec;13(6):527-36 (185 ref.)

Radiation therapy for skin neoplasms. Parker RG. **Clin Dermatol** 1995 Nov-Dec;13(6):579-88 (51 ref.)

Cancer of the skin in the older patient. Keller KL, et al. **Clin Geriatr Med** 1997 May;13(2):339-61 (43 ref.)

Malignant & premalignant tumors. Scheinberg RS. **Compr Ther** 1997 Mar;23(3):190-6 (10 ref.)

Cutaneous hemangiomas, vascular stains and malformations, and associated syndromes. Esterly NB. **Curr Probl Pediatr** 1996 Jan;26(1):3-39 (272 ref.)

Angiokeratomas: an update. Schiller PI, et al. **Dermatology** 1996;193(4):275-82 (57 ref.)

Dermatofibrosarcoma protuberans of the upper lip: an overview and a case report. Vandeweyer E, et al. **Eur J Surg Oncol** 1997 Jun;23(3):275-7 (22 ref.)

HIV-related skin diseases. Geusau A, et al. **J R Coll Physicians Lond** 1997 Jul-Aug;31(4):374-9 (38 ref.)

Skin cancer. Rees J. **J R Coll Physicians Lond** 1997 May-Jun; 31(3):246-50 (22 ref.)

Malignant melanoma: Mayo Clinic experience. Sim FH, et al. **Mayo Clin Proc** 1997 Jun;72(6):565-9 (35 ref.)

The multidisciplinary melanoma center. Sagebiel RW. **Surg Clin North Am** 1996 Dec;76(6):1433-9 (6 ref.)

[Merkel cell carcinoma: primary cutaneous neuroendocrine tumor] Brousse C, et al. **Rev Med Interne** 1996; 17(12):1025-8 (23 ref.) (Eng. Abstr.) **(Fre)**

[Cutaneous lymphoma] Hauschild A, et al. **Dtsch Med Wochenschr** 1996 Oct 25;121(43):1335-40 (32 ref.) **(Ger)**

[Acquired melanocytic nevi in children--a beauty spot or warning sign?] Azizi E, et al. **Harefuah** 1997 Mar 16; 132(6):416-20 (41 ref.) **(Heb)**

[Primary cutaneous lymphoma--mycosis fungoides] Nagatani T, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(1):23-9 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Hemangioma, angiosarcoma] Fukushige J. **Ryoikibetsu Shokogun Shirizu** 1996;(14):455-7 (10 ref.) **(Jpn)**

CHEMICALLY INDUCED

Cutaneous carcinoma during long-term hydroxyurea therapy: a report of 5 cases [letter] Callot-Mellot C, et al. **Arch Dermatol** 1996 Nov;132(11):1395-7 (5 ref.)

Arsenic and the skin. Schwartz RA. **Int J Dermatol** 1997 Apr;36(4):241-50 (144 ref.)

Malignant melanoma and levodopa: is there a relationship? Two new cases and a review of the literature. Pfützner W, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):332-6 (68 ref.)

[Metastatic malignant melanoma in treated non-Hodgkin's lymphoma] Falk S, et al. **Hautarzt** 1996 Sep;47(9):716-8 (21 ref.) (Eng. Abstr.) **(Ger)**

CLASSIFICATION

"New" diseases in dermatopathology. Rapini RP. **Adv Dermatol** 1997;12:213-35; discussion 236 (78 ref.)

Primary B-cell lymphomas of the skin. Kerl H, et al. **Ann Oncol** 1997;8 Suppl 2:29-32 (26 ref.)

EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Willemze R, et al. **Blood** 1997 Jul 1;90(1):354-71 (130 ref.)

The Revised European-American Classification of Lymphoid Neoplasms (REAL): a new perspective for the classification of cutaneous lymphomas. Sander CA, et al. **J Cutan Pathol** 1997 Jul;24(6):329-41 (93 ref.)

The classification of melanoma: time for a further revision? Cochran AJ, et al. **Melanoma Res** 1997 Feb;7(1):4-9 (12 ref.)

Cutaneous malignant melanoma: classification and clinical diagnosis. Porras BH, et al. **Semin Cutan Med Surg** 1997 Jun;16(2):88-96 (34 ref.)

Variants of melanoma. Reed RJ, et al. **Semin Cutan Med Surg** 1997 Jun;16(2):137-58 (12 ref.)

[Frequent skin tumors in geriatrics] Piérard-Franchimont C, et al. **Rev Med Liege** 1997 Apr;52(4):289-95 (20 ref.) **(Fre)**

COMPLICATIONS

Extramammary Paget's disease of the axilla with an underlying apocrine carcinoma [letter] [see comments] Morgan JM, et al. **Acta Derm Venereol** 1996 Mar; 76(2):173-4 (8 ref.) Comment in: Acta Derm Venereol 1997 Jan;77(1):78.

Squamous cell carcinoma arising in chronic lymphoedema. Lister RK, et al. **Br J Dermatol** 1997 Mar;136(3):384-7 (19 ref.)

Epidermodysplasia verruciformis. Immunological and nonimmunological surveillance mechanisms: role in tumor progression. Majewski S, et al. **Clin Dermatol** 1997 May-Jun;15(3):321-34 (122 ref.)

Coexistence of multiple perifollicular fibromas and colonic polyp and cancer. Sasai S, et al. **Dermatology** 1996; 192(3):262-3 (11 ref.)

A case of Cobb syndrome associated with lymphangioma

circumscriptum. Shim JH, et al. **Dermatology** 1996; 193(1):45–7 (11 ref.)

Colosplenic fistula in a patient treated with interleukin-2 for malignant melanoma. Chun ES, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):674–6 (8 ref.)

Multiple dermatofibromas accompanied by eruptive benign keratoses in a patient with systemic lupus erythematosus. Kuniyuki S, et al. **J Dermatol** 1996 Sep;23(9):619–22 (14 ref.)

Extramedullary myeloid cell tumors in myelodysplastic-syndromes: not a true indication of impending acute myeloid leukemia. Byrd JC, et al. **Leuk Lymphoma** 1996 Mar;21(1–2):153–9 (50 ref.)

Glaucoma in phakomatosis pigmentovascularis. Teekhasaenee C, et al. **Ophthalmology** 1997 Jan; 104(1):150–7 (66 ref.)

Crouzon disease with acanthosis nigricans and melanocytic nevi. Gines E, et al. **Pediatr Dermatol** 1996 Jan–Feb; 13(1):18–21 (16 ref.)

Phakomatosis pigmentovascularis: report of a case. Mahroughan M, et al. **Pediatr Dermatol** 1996 Jan–Feb; 13(1):36–8 (8 ref.)

Linear sebaceous nevus syndrome: report of a patient with unusual associated abnormalities. Palazzi P, et al. **Pediatr Dermatol** 1996 Jan–Feb;13(1):22–4 (16 ref.)

CONGENITAL

Giant congenital naevus of the scalp and cranium: case report and review of the literature. Madaree A, et al. **Br J Plast Surg** 1997 Jan;50(1):20–5 (8 ref.)

A study of large congenital melanocytic nevi and associated malignant melanomas: review of cases in the New York University Registry and the world literature. DeDavid M, et al. **J Am Acad Dermatol** 1997 Mar;36(3 Pt 1):409–16 (106 ref.)

Neurocutaneous melanosis: clinical features of large congenital melanocytic nevi in patients with manifest central nervous system melanosis. DeDavid M, et al. **J Am Acad Dermatol** 1996 Oct;35(4):529–38 (104 ref.)

Spontaneous remission of congenital leukemia [see comments] Dinulos JG, et al. **J Pediatr** 1997 Aug;131(2):300–3 (17 ref.) Comment in: J Pediatr 1997 Aug;131(2):176–7.

A solitary congenital self-healing histiocytosis. Report of a case and review of the literature. Shy SW, et al. **Pathol Res Pract** 1996 Aug;192(8):869–74; discussion 875–6 (23 ref.)

DIAGNOSIS

Dermal melanocytosis: a clinical spectrum. Stanford DG, et al. **Australas J Dermatol** 1996 Feb;37(1):19–25 (35 ref.)

Screening for melanoma. Elwood JM. **Cancer Treat Res** 1996; 86:129–47 (76 ref.)

Diagnosis of nonmelanoma skin cancer. Brodland DG. **Clin Dermatol** 1995 Nov–Dec;13(6):551–7 (6 ref.)

Malignant primary skin tumors in children. Sasson M, et al. **Curr Opin Pediatr** 1996 Aug;8(4):372–7 (34 ref.)

Indurated plaques of mycosis fungoides in a woman with fulminant hepatic failure. Vannucci SA, et al. **Cutis** 1996 Mar;57(3):159–62 (11 ref.)

Superficial spreading melanoma resembling Spitz nevus on the plantar surface [letter] Kato T, et al. **Dermatology** 1996; 193(4):353–4 (17 ref.)

Mimics of pilomatrixomas in fine-needle aspirates. Sánchez Sánchez C, et al. **Diagn Cytopathol** 1996 Feb;14(1):75–83 (28 ref.)

Care of the skin at midlife: diagnosis of pigmented lesions. Gordon ML, et al. **Geriatrics** 1997 Aug;52(8):56–8, 67–8; quiz 69 (16 ref.)

Simulators of hand infections. Kann SE, et al. **Instr Course Lect** 1997;46:69–82 (169 ref.)

Multiple painful keratoacanthomas. Frank TL, et al. **Int J Dermatol** 1996 Sep;35(9):648–50 (24 ref.)

Pigmented lesions of the conjunctiva. Farber M, et al. **J Dermatol** 1996 Nov;23(11):746–50 (8 ref.)

Squamous cell carcinoma arising from lupus vulgaris on an old burn scar: diagnosis by polymerase chain reaction. Hagiwara K, et al. **J Dermatol** 1996 Dec;23(12):883–9 (17 ref.)

Multiple nodular lesions seen in a patient with neurocutaneous melanosis. Sasaki Y, et al. **J Dermatol** 1996 Nov;23(11):828–31 (11 ref.)

Malignant melanoma: differential diagnosis of pigmented lesions. Le AD, et al. **J Fla Med Assoc** 1997 Mar; 84(3):166–74 (45 ref.)

Malignant melanoma: prognostic indicators. Ahmed I. **Mayo Clin Proc** 1997 Apr;72(4):356–61 (40 ref.)

Mucosal, genital, and unusual clinical variants of melanoma. Rogers RS 3rd, et al. **Mayo Clin Proc** 1997 Apr;72(4):362–6 (15 ref.)

Uncommon cutaneous neoplasms. Harrington AC, et al. **Md Med J** 1997 May–Jun;46(5):255–62 (48 ref.)

Nonmelanoma skin cancer. Katz MH. **Md Med J** 1997 May–Jun;46(5):239–42 (20 ref.)

Diagnosis of pigmented skin lesions aided by epiluminescence microscopy. Peck GL. **Md Med J** 1997 May–Jun; 46(5):247–50 (5 ref.)

Systematic review of the diagnostic accuracy of dermatoscopy in detecting malignant melanoma. Mayer J. **Med J Aust** 1997 Aug 18;167(4):206–10 (25 ref.)

Basal and squamous cell carcinomas. What every primary care physician should know. Marghoob AA. **Postgrad Med** 1997 Aug;102(2):139–42, 146, 152–4 passim (20 ref.)

Cutaneous malignant melanoma: classification and clinical diagnosis. Porras BH, et al. **Semin Cutan Med Surg** 1997 Jun;16(2):88–96 (34 ref.)

Malignant melanoma from the dermatologic perspective. Swetter SM. **Surg Clin North Am** 1996 Dec;76(6):1287–98 (64 ref.)

[Merkel cell tumor of the skin] Hauschild A, et al. **Dtsch Med Wochenschr** 1997 Jun 6;122(23):753–6 (25 ref.) **(Ger)**

[Adenoid cystic cribriform trichoblastoma] Betti R, et al. **Hautarzt** 1997 Jun;48(6):417–9 (13 ref.) (Eng. Abstr.) **(Ger)**

[Imaging methods in dermatology] el Gammal S, et al. **Hautarzt** 1997 Jun;48(6):432–50; quiz 448 (74 ref.) **(Ger)**

[Rare variants of cutaneous T-cell lymphomas] Goerdt S, et al. **Hautarzt** 1996 Feb;47(2):96–105 (68 ref.) (Eng. Abstr.) **(Ger)**

[Activation of epidermal melanocytes is independent of epithelial proliferation and vascularization. Immunohistologic study using HMB-45 antibody with review of the literature] Lommel K, et al. **Hautarzt** 1996 Aug;47(8):616–23 (65 ref.) (Eng. Abstr.) **(Ger)**

[Clinical diagnosis of primary melanoma of the skin] Barchuk AS, et al. **Vopr Onkol** 1996;42(5):96–100 (18 ref.) (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Platinum-based cytotoxic therapy in basal cell carcinoma--a review of the literature. Moeholt K, et al. **Acta Oncol** 1996; 35(6):677–82 (33 ref.)

Mortality, major amputation rates, and leukopenia after isolated limb perfusion with phenylalanine mustard for the treatment of melanoma. Taber SW, et al. **Ann Surg Oncol** 1997 Jul–Aug;4(5):440–5 (30 ref.)

Tufted angioma associated with platelet trapping syndrome: response to aspirin. Léauté-Labrèze C, et al. **Arch Dermatol** 1997 Sep;133(9):1077–9 (12 ref.)

Photochemotherapy for mycosis fungoides: current status. Watson A. **Australas J Dermatol** 1997 Feb;38(1):9–11 (20 ref.)

Retinoids in the management of non-melanoma skin cancer and melanoma. Craven NM, et al. **Cancer Surv** 1996; 26:267–88 (145 ref.)

The treatment of disseminated malignant melanoma with special reference to the role of interferons, vinca alkaloids and tamoxifen. Bezwoda WR. **Cancer Treat Rev** 1997 Jan; 23(1):17–34 (144 ref.)

Chemotherapy for metastatic melanoma during pregnancy. Dipaola RS, et al. **Gynecol Oncol** 1997 Sep;66(3):526–30 (21 ref.)

Retinoid-interferon therapy of solid tumors. Lippman SM, et al. **Int J Cancer** 1997 Feb 7;70(4):481–3 (27 ref.)

Pediatric dermatology: advances in therapy. Chapel KL, et al. **J Am Acad Dermatol** 1997 Apr;36(4):513–26; quiz 527–30 (149 ref.)

The role of interferon alfa in the treatment of metastatic melanoma. Legha SS. **Semin Oncol** 1997 Feb;24(1 Suppl 4):S24–31 (35 ref.)

Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. Legha SS. **Semin Oncol** 1997 Feb;24(1 Suppl 4):S39–43 (25 ref.)

Treatment of malignant melanoma with interleukin-2. Philip PA, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 4):S32–8 (64 ref.)

Medical treatment of metastatic melanoma. Houghton AN, et al. **Surg Clin North Am** 1996 Dec;76(6):1343–54 (113 ref.)

[Photodynamic therapy at the threshold of clinical use in disseminated dermatoses] Boehncke WH, et al. **Hautarzt** 1996 Nov;47(11):825–31 (48 ref.) (Eng. Abstr.) **(Ger)**

[Photodynamic therapy (PDT)] Wolf P. **Hautarzt** 1997 Feb; 48(2):137–48; quiz 148 (10 ref.) **(Ger)**

[Chemotherapy for advanced adenocarcinoma of the skin: experience with combination chemotherapy and a review of the literature] Yamazaki N. **Gan To Kagaku Ryoho** 1997 Jan;24(1):30–6 (15 ref.) (Eng. Abstr.) **(Jpn)**

[L-MTP-PE--a potential antineoplastic agent] Dzierzbicka K, et al. **Postepy Hig Med Dosw** 1997;51(2):227–36 (37 ref.) (Eng. Abstr.) **(Pol)**

ENZYMOLOGY

The plasminogen activation system in melanoma cell lines and in melanocytic lesions. de Vries TJ, et al. **Melanoma Res** 1996 Apr;6(2):79–88 (93 ref.)

Polymorphism in detoxifying enzymes and susceptibility to skin cancer. Lear J, et al. **Photochem Photobiol** 1996 Apr; 63(4):424–8 (24 ref.)

EPIDEMIOLOGY

Epidemiology of nonmelanoma skin cancer: a review. Corona R. **Ann Ist Super Sanita** 1996;32(1):37–42 (60 ref.)

Molecular epidemiology of skin cancers: DNA repair and non-melanocytic skin cancer. Hall J, et al. **Ann Ist Super Sanita** 1996;32(1):43–51 (56 ref.)

Differences in malignant melanoma between children and adolescents. A 35-year epidemiological study. Berg P, et al. **Arch Dermatol** 1997 Mar;133(3):295–7 (20 ref.)

Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992. Gray DT, et al. **Arch Dermatol** 1997 Jun; 133(6):735–40 (29 ref.)

Epidemiology of sun exposure and skin cancer. Armstrong BK, et al. **Cancer Surv** 1996;26:133–53 (46 ref.)

Melanoma epidemiology [see comments] Berwick M, et al. **Curr Opin Oncol** 1997 Mar;9(2):178–82 (55 ref.) Comment in: Curr Opin Oncol 1997 Mar;9(2):175–7.

Photocarcinogenesis: an overview. Black HS, et al. **J Photochem Photobiol B** 1997 Aug;40(1):29–47 (194 ref.)

Malignant melanoma: incidence issues and their effect on diagnosis and treatment in the 1990s. Rigel DS. **Mayo Clin Proc** 1997 Apr;72(4):367–71 (35 ref.)

Melanoma and sun exposure. Elwood JM. **Semin Oncol** 1996 Dec;23(6):650–66 (69 ref.)

Dysplastic nevi and other risk markers for melanoma. Seykora J, et al. **Semin Oncol** 1996 Dec;23(6):682–7 (52 ref.)

Epidemiology of malignant melanoma. Liu T, et al. **Surg Clin North Am** 1996 Dec;76(6):1205–22 (66 ref.)

ETIOLOGY

Radiation therapy for squamous cell carcinoma in dystrophic epidermolysis bullosa: case reports and literature review. Bastin KT, et al. **Am J Clin Oncol** 1997 Feb;20(1):55–8 (23 ref.)

Malignancy arising in seborrheic keratosis: a report of two cases. Yap WM, et al. **Ann Acad Med Singapore** 1997 Mar; 26(2):235–7 (15 ref.)

Angiosarcoma of the scalp associated with renal transplantation. Kibe Y, et al. **Br J Dermatol** 1997 May; 136(5):752–6 (24 ref.)

Sun and skin cancer. Whittaker S. **Br J Hosp Med** 1996 Nov 20–Dec 10;56(10):515–8 (13 ref.)

A shorter lag period of mesenchymal malignancy on Marjolin's ulcer. Celiköz B, et al. **Burns** 1997 Feb; 23(1):72–4 (10 ref.)

Basal cell carcinoma developing on a burn scar. Koga Y, et al. **Burns** 1997 Feb;23(1):75–7 (11 ref.)

The role of UVA in the aetiology of non-melanoma skin cancer. de Laat JM, et al. **Cancer Surv** 1996;26:173–91 (109 ref.)

Relevance of in vitro melanocytic cell studies to the understanding of melanoma. Linge C. **Cancer Surv** 1996; 26:71–87 (49 ref.)

The genetic basis of xeroderma pigmentosum and trichothiodystrophy syndromes. Stary A, et al. **Cancer Surv** 1996;26:155–71 (54 ref.)

Photoimmunology of non-melanoma skin cancer. Streilein JW. **Cancer Surv** 1996;26:207–17 (40 ref.)

Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis. Rook AH, et al. **Clin Exp Immunol** 1997 Jan;107 Suppl 1:16–20 (35 ref.)

Pathogenesis of Kaposi's sarcoma. Cooke FJ. **Clin Oncol (R Coll Radiol)** 1996;8(3):189–94 (22 ref.)

UV-induced cutaneous photobiology. Beissert S, et al. **Crit Rev Biochem Mol Biol** 1996 Dec;31(5–6):381–404 (150 ref.)

Sunburn, sunscreen, and melanoma. Donawho C, et al. **Curr Opin Oncol** 1996 Mar;8(2):159–66 (57 ref.)

Bowen's disease and arsenism from tobacco smoke: an association? Person JR. **Cutis** 1996 Jul;58(1):65–6 (17 ref.)

Aspects of exposure to UVA tanning sources. Carcinogenic effect in mice and melanogenic effect in man and mice. Bech-Thomsen N. **Dan Med Bull** 1997 Jun;44(3):242–56 (116 ref.)

Advances in Kaposi's sarcoma. Myskowski PL, et al. **Dermatol Clin** 1997 Jan;15(1):177–88 (122 ref.)

The development of a Marjolin's cancer in a human immunodeficiency virus-positive hemophilic man and review of the literature. Rahimizadeh A, et al. **Dermatol Surg** 1997 Jul;23(7):560–3 (40 ref.)

Ultraviolet exposure and cancer. Wolf P. **Eur J Cancer Prev** 1996 Oct;5(5):381–3 (7 ref.)

The aging skin. Bergfeld WF. **Int J Fertil Womens Med** 1997 Mar–Apr;42(2):57–66 (20 ref.)

Actinic keratoses. Callen JP, et al. **J Am Acad Dermatol** 1997 Apr;36(4):650–3 (14 ref.)

Eruptive melanocytic nevi after Stevens-Johnson syndrome. Shoji T, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):337–9 (14 ref.)

The skin cancer cascade: from ozone depletion to melanoma--some definitions and some new interpretation, 1996. Fitzpatrick TB. **J Dermatol** 1996 Nov;23(11):816–20 (11 ref.)

Therapy with orally administered methoxsalen and ultraviolet A radiation during childhood increases the risk of basal cell carcinoma. The PUVA Follow-up Study. Stern RS, et al. **J Pediatr** 1996 Dec;129(6):915–7 (8 ref.)

The p53 tumour suppressor gene: a model for molecular epidemiology of human cancer. Soussi T. **Mol Med Today** 1996 Jan;2(1):32–7 (43 ref.)

Basal cell carcinoma in a girl after cobalt irradiation to the cranium for acute lymphoblastic leukemia: case report and literature review. Garcia-Silva J, et al. **Pediatr Dermatol** 1996 Jan–Feb;13(1):54–7 (13 ref.)

Oncogenes and tumor suppressor genes in photocarcinogenesis. Ananthaswamy HN, et al. **Photochem Photobiol** 1996 Apr;63(4):428–32 (36 ref.)

Photobiology of photocarcinogenesis. de Gruijl FR. **Photochem Photobiol** 1996 Apr;63(4):372–5 (21 ref.)

Relevance of animal models of photocarcinogenesis to humans. Forbes PD. **Photochem Photobiol** 1996 Apr; 63(4):357–62 (39 ref.)
Cytokines and photocarcinogenesis. Granstein RD. **Photochem Photobiol** 1996 Apr;63(4):390–4 (54 ref.)
Lessons learned from xeroderma pigmentosum. Kraemer KH. **Photochem Photobiol** 1996 Apr;63(4):420–2 (19 ref.)
Analysis of rodent photo cocarcinogenicity models for hazard evaluation and risk assessment: industry viewpoint. Kraus AL. **Photochem Photobiol** 1996 Apr;63(4):365–9 (54 ref.)
Signal transduction mechanisms in photocarcinogenesis. Pentland AP. **Photochem Photobiol** 1996 Apr;63(4):379–80 (11 ref.)
Relevance of in vivo models in melanoma skin cancer. Setlow RB. **Photochem Photobiol** 1996 Apr;63(4):410–2 (18 ref.)
Immunogenetics of sunlight-induced skin cancer. Streilein JW. **Photochem Photobiol** 1996 Apr;63(4):422–4 (21 ref.)
Mutagenic lesions in carcinogenesis: induction and repair of pyrimidine dimers. Sutherland BM. **Photochem Photobiol** 1996 Apr;63(4):375–7 (27 ref.)
Oxidant, antioxidant status and photocarcinogenesis: the role of gene activation. Tyrrell RM. **Photochem Photobiol** 1996 Apr;63(4):380–3 (31 ref.)
Controversies in the role of sunlight in the pathogenesis of cutaneous melanoma. Weinstock MA. **Photochem Photobiol** 1996 Apr;63(4):406–10 (33 ref.)
Tumor suppressor gene mutations and photocarcinogenesis. Ziegler A, et al. **Photochem Photobiol** 1996 Apr;63(4):432–5 (38 ref.)
Sunlight and skin cancer: another link revealed [comment] Kraemer KH. **Proc Natl Acad Sci U S A** 1997 Jan 7; 94(1):11–4 (56 ref.) Comment on: Proc Natl Acad Sci U S A 1996 Nov 26;93(24):14025–9.
Melanoma and sun exposure. Elwood JM. **Semin Oncol** 1996 Dec;23(6):650–66 (69 ref.)
Linear basal cell carcinomas: report of multiple sequential tumors localized to a radiotherapy port and review of the literature. Chopra KF, et al. **Tex Med** 1997 Jul;93(7):57–9 (10 ref.)
[Metastatic epidermoid carcinoma in idiopathic CD4+ T lymphocytopenia syndrome] Michel JL, et al. **Ann Dermatol Venereol** 1996;123(8):478–82 (24 ref.) (Eng. Abstr.) **(Fre)**
[The enigma of Kaposi sarcoma] Rüdlinger R. **Hautarzt** 1996 Feb;47(2):91–5 (43 ref.) (Eng. Abstr.) **(Ger)**
[Etiology of malignant melanoma—what do we know?] Helsing P. **Tidsskr Nor Laegeforen** 1997 Mar 10; 117(7):969–71 (33 ref.) (Eng. Abstr.) **(Nor)**

GENETICS

Genetic alterations in skin cancer. D'errico M, et al. **Ann Ist Super Sanita** 1996;32(1):53–63 (75 ref.)
Molecular pathology of melanoma. Newton Bishop JA. **Cancer Metastasis Rev** 1997 Jun;16(1–2):141–54 (114 ref.)
Transgenic models of epidermal neoplasia and multistage carcinogenesis. Arbeit JM. **Cancer Surv** 1996;26:7–34 (103 ref.)
DNA damage and repair in melanoma and non-melanoma skin cancer. Camplejohn RS. **Cancer Surv** 1996;26:193–206 (46 ref.)
CDKN2 mutations in melanoma. Dracopoli NC, et al. **Cancer Surv** 1996;26:115–32 (72 ref.)
The role of atypical mole syndrome and cutaneous naevi in the development of melanoma. Easton D. **Cancer Surv** 1996;26:237–49 (43 ref.)
Detection of melanoma cells in peripheral blood using reverse transcription polymerase chain reaction assay for tyrosinase mRNA. Jung FA, et al. **Cancer Surv** 1996;26:251–65 (38 ref.)
Multigenic control of skin tumour development in mice. Nagase H, et al. **Ciba Found Symp** 1996;197:156–68; discussion 168–80 (85 ref.)
Molecular genetic approaches to non-melanoma and melanoma skin cancer. Rees JL, et al. **Clin Exp Dermatol** 1996 Jul;21(4):253–62 (141 ref.)
Familial leiomyomata. Vellanki LS, et al. **Cutis** 1996 Jul; 58(1):80–2 (9 ref.)
The molecular basis of xeroderma pigmentosum. Copeland NE, et al. **Dermatol Surg** 1997 Jun;23(6):447–55 (52 ref.)
Cancer proneness of linear porokeratosis may be explained by allelic loss. Happle R. **Dermatology** 1997;195(1):20–5 (73 ref.)
Target of skin tumorigenesis: cyclin D1–cdk4. Inohara S, et al. **Int J Dermatol** 1996 Sep;35(9):609–13 (59 ref.)
Developmental genes and cancer: role of patched in basal cell carcinoma of the skin. Gailani MR, et al. **J Natl Cancer Inst** 1997 Aug 6;89(15):1103–9 (98 ref.)
Screening for CDKN2A mutations in hereditary melanoma [editorial; comment] Goldstein AM, et al. **J Natl Cancer Inst** 1997 May 21;89(10):676–8 (33 ref.) Comment on: J Natl Cancer Inst 1997 May 21;89(10):697–702.
Genetics of cutaneous melanoma and nevi. Greene MH. **Mayo Clin Proc** 1997 May;72(5):467–74 (75 ref.)
Oncogenes and tumor suppressor genes in cutaneous malignant melanoma. Albino AP, et al. **Photochem Photobiol** 1996 Apr;63(4):412–8 (79 ref.)
Oncogenes and tumor suppressor genes in photocarcinogenesis. Ananthaswamy HN, et al. **Photochem Photobiol** 1996 Apr;63(4):428–32 (36 ref.)
Polymorphism in detoxifying enzymes and susceptibility to skin cancer. Lear J, et al. **Photochem Photobiol** 1996 Apr; 63(4):424–8 (24 ref.)
Tumor suppressor gene mutations and photocarcinogenesis. Ziegler A, et al. **Photochem Photobiol** 1996 Apr;63(4):432–5 (38 ref.)
Genetic susceptibility to tumor progression in mouse skin carcinogenesis. Stern MC, et al. **Prog Clin Biol Res** 1996; 395:47–55 (19 ref.)
Nevoid basal-cell syndrome: literature review and case report in a family. José Tincani A, et al. **Rev Paul Med** 1995 May–Jun;113(3):917–21 (19 ref.)
A review of inherited predisposition to melanoma. Cannon-Albright LA, et al. **Semin Oncol** 1996 Dec; 23(6):667–72 (66 ref.)
Clinical implications of cytogenetic abnormalities in melanoma. Nelson MA, et al. **Surg Clin North Am** 1996 Dec;76(6):1257–71 (65 ref.)
[Cell cycle control, genetic instability and cancer] Funk JO, et al. **Hautarzt** 1997 Mar;48(3):157–65 (62 ref.) (Eng. Abstr.) **(Ger)**
[Type 1 neurofibromatosis. Molecular and clinical aspects] Schweigerer L. **Hautarzt** 1996 Aug;47(8):591–8 (41 ref.) (Eng. Abstr.) **(Ger)**
[Molecular biology of melanoma—1997] Zlotogorski A, et al. **Harefuah** 1997 Jun 15;132(12):855–8 (33 ref.) **(Heb)**
[Dyscromic neurocutaneous syndromes] Sola-Casas MA, et al. **Rev Neurol** 1997 Sep;25 Suppl 3:S259–64 (23 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Dermatopathologic advances in clinical research. The expression of antibody to CD34 in mucocutaneous lesions. off Cohen PR, et al. **Dermatol Clin** 1997 Jan;15(1):159–76 (76 ref.)
[The immunocompetent structures of the skin and their role in the development of primary skin lymphomas (editorial)] Vavilov AM, et al. **Arkh Patol** 1996 Nov–Dec;58(6):7–12 (52 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Immunohistochemical characterization of dermatofibrosarcoma protuberans with practical applications for diagnosis and treatment. Haycox CL, et al. **J Am Acad Dermatol** 1997 Sep;37(3 Pt 1):438–44 (38 ref.)
Markers of melanogenesis in malignant melanoma. Matous B, et al. **Sb Lek** 1994;95(4):333–38 (20 ref.)

MORTALITY

Gender and cutaneous melanoma. Miller JG, et al. **Br J Dermatol** 1997 May;136(5):657–65 (58 ref.)

PATHOLOGY

Cutaneous lymphoepithelial neoplasms. Okamura JM, et al. **Adv Dermatol** 1997;12:277–94; discussion 295 (34 ref.)
Carcinosarcoma of the skin. Case report and literature review. Biernat W, et al. **Am J Dermatopathol** 1996 Dec; 18(6):614–9 (15 ref.)
Hypermelanotic nevus: clinical, histopathologic, and ultrastructural features in 316 cases. Cohen LM, et al. **Am J Dermatopathol** 1997 Feb;19(1):23–30 (9 ref.)
Myxoid metastases of melanoma: report of three cases and review of the literature. Collina G, et al. **Am J Dermatopathol** 1997 Feb;19(1):52–7 (23 ref.)
Lymphangioma-like variant of Kaposi's sarcoma: clinicopathologic study of seven cases with review of the literature. Cossu S, et al. **Am J Dermatopathol** 1997 Feb; 19(1):16–22 (25 ref.)
Metastatic endometrial adenocarcinoma to the skin of a toe. Giardina VN, et al. **Am J Dermatopathol** 1996 Feb; 18(1):94–8 (40 ref.)
Eccrine or apocrine poroma? Six poromas with divergent adnexal differentiation. Harvell JD, et al. **Am J Dermatopathol** 1996 Feb;18(1):1–9 (30 ref.)
Reactive angioendotheliomatosis. Case report and review of the literature. Lazova R, et al. **Am J Dermatopathol** 1996 Feb;18(1):63–9 (26 ref.)
Lymphomatoid papulosis and cutaneous CD30+ lymphoma. LeBoit PE. **Am J Dermatopathol** 1996 Jun;18(3):221–35 (61 ref.)
Malignant proliferating trichilemmal tumor [letter] Noto G, et al. **Am J Dermatopathol** 1997 Apr;19(2):202–4 (16 ref.)
Primary metaplastic carcinoma (carcinosarcoma) of the skin. A clinicopathologic study of four cases and review of the literature. Patel NK, et al. **Am J Dermatopathol** 1997 Aug; 19(4):363–72 (24 ref.)
Dabska tumor developing within a preexisting vascular malformation. Quecedo E, et al. **Am J Dermatopathol** 1996 Jun;18(3):302–7 (14 ref.)
Case of dermatofibroma with monster cells: a review and an immunohistochemical study. Setoyama M, et al. **Am J Dermatopathol** 1997 Jun;19(3):312–5 (6 ref.)
Dermal and subcutaneous variants of plexiform fibrohistiocytic tumor. Zelger B, et al. **Am J Surg Pathol** 1997 Feb;21(2):235–41 (17 ref.)
Basal cell and squamous cell carcinomas. Clinico-histological features. Annessi G, et al. **Ann Ist Super Sanita** 1996; 32(1):29–36 (28 ref.)
Sentinel lymph node evaluation in melanoma. Brady MS, et al. **Arch Dermatol** 1997 Aug;133(8):1014–20 (32 ref.)
Multiple, hereditary dome-shaped papules and acrochordons. Birt-Hogg-Dubé syndrome. Haimowitz JE, et al. **Arch Dermatol** 1997 Sep;133(9):1163, 1166 (8 ref.)
Mucinous nevus [letter] Rongioletti F, et al. **Arch Dermatol** 1996 Dec;132(12):1522–3 (8 ref.)
Primary choroidal melanoma in a patient with previous cutaneous melanoma. Scull JJ, et al. **Arch Ophthalmol** 1997 Jun;115(6):796–8 (16 ref.)
Pigmented squamous cell carcinoma with dendritic melanocytes. Kossard S, et al. **Australas J Dermatol** 1997 Aug;38(3):145–7 (16 ref.)
Primary leiomyosarcoma of the skin. Wargon O. **Australas J Dermatol** 1997 Feb;38(1):26–8 (6 ref.)
Malignant melanoma presenting as bilateral breast masses. Jayalakshmi S, et al. **Australas Radiol** 1997 Feb;41(1):38–40 (11 ref.)
Acute cholecystitis from metastatic melanoma to the gall-bladder in a patient with a low-risk melanoma. Langley RG, et al. **Br J Dermatol** 1997 Feb;136(2):279–82 (25 ref.)
Merkel cell carcinoma of the skin. Al-Ghazal SK, et al. **Br J Plast Surg** 1996 Oct;49(7):491–6 (28 ref.)
Molecular pathology of melanoma. Newton Bishop JA. **Cancer Metastasis Rev** 1997 Jun;16(1–2):141–54 (114 ref.)
Histopathology of cutaneous squamous cell carcinoma. Maguire B, et al. **Clin Dermatol** 1995 Nov–Dec; 13(6):559–68 (75 ref.)
Histology of basal cell carcinoma. Maloney ME. **Clin Dermatol** 1995 Nov–Dec;13(6):545–9 (26 ref.)
Comparative aspects of nonmelanoma skin cancer. Walder EJ. **Clin Dermatol** 1995 Nov–Dec;13(6):569–78 (21 ref.)
Agminate Spitz naevi occurring in an adult after the excision of a solitary Spitz naevus—report of a case and review of the literature. Sabroe RA, et al. **Clin Exp Dermatol** 1996 May;21(3):197–200 (16 ref.)
Clinical evaluation of cutaneous lesions of the back: spinal signatures that do not go away. Humphreys RP. **Clin Neurosurg** 1996;43:175–87 (6 ref.)
Skin disorders of the lower extremity in adults as reported in the current literature. Black JR, et al. **Clin Podiatr Med Surg** 1996 Jan;13(1):109–17 (38 ref.)
Primary and metastatic malignant tumors in soft tissue of skin. Diagnostic, surgical, and prognostic considerations for the foot. Potter GK, et al. **Clin Podiatr Med Surg** 1996 Jan;13(1):155–72 (85 ref.)
Cutaneous squamous cell carcinoma metastatic to the parotid gland in a transplant patient. Christiansen TN, et al. **Clin Transplant** 1996 Dec;10(6 Pt 1):561–3 (23 ref.)
Of mice and men: a critical reappraisal of the two-stage theory of carcinogenesis. Iversen OH. **Crit Rev Oncog** 1995; 6(3–6):357–405 (184 ref.)
Pathology of malignant melanoma, including new markers and techniques in diagnosis and prognosis. De Wit PE, et al. **Curr Opin Oncol** 1996 Mar;8(2):143–51 (69 ref.)
A pigmented scalp nodule: malignant blue nevus. English JC 3rd, et al. **Cutis** 1996 Jul;58(1):40–2 (6 ref.)
Juvenile melanoma (Spitz nevus). Helm KF, et al. **Cutis** 1996 Jul;58(1):35–9 (63 ref.)
Giant polypoid basal cell carcinoma. McElroy J, et al. **Cutis** 1996 Oct;58(4):289–92 (25 ref.)
An unusual case of giant dermatofibroma in a patient with diabetes mellitus and necrobiosis lipoidica. Omulecki A, et al. **Cutis** 1996 Oct;58(4):282–5 (20 ref.)
Granular cell basal cell carcinoma. Reichel M. **Cutis** 1997 Feb;59(2):88–90 (6 ref.)
Subcutaneous T-cell lymphoma: a case report and additional observations. Sajben FP, et al. **Cutis** 1996 Oct;58(4):297–302 (42 ref.)
Dermoscopy (epiluminescence microscopy) of pigmented skin lesions. Current status and evolving trends. Argenyi ZB. **Dermatol Clin** 1997 Jan;15(1):79–95 (43 ref.)
Dermatopathologic advances in clinical research. The expression of antibody to CD34 in mucocutaneous lesions. off Cohen PR, et al. **Dermatol Clin** 1997 Jan;15(1):159–76 (76 ref.)
The dynamic interplay of malignant and benign T cells in cutaneous T-cell lymphoma. Herrick C, et al. **Dermatol Clin** 1997 Jan;15(1):149–57 (36 ref.)
Tumors with smooth muscle differentiation. Spencer JM, et al. **Dermatol Surg** 1996 Sep;22(9):761–8 (61 ref.)
Correlation between the histopathology and the epiluminescence microscopy features of malignant blue nevus. Stanganelli I, et al. **Dermatol Surg** 1996 Oct; 22(10):846–8 (13 ref.)
Solitary eccrine syringofibroadenoma (or eccrine syringofibroadenomatous hyperplasia?) and diabetic polyneuropathy. Gambini C, et al. **Dermatology** 1996; 193(1):68–9 (13 ref.)
Squamous cell carcinoma arising in a verrucous epidermal nevus. Ichikawa T, et al. **Dermatology** 1996;193(2):135–8 (18 ref.)
Dermatofibrosarcoma protuberans of the sole. Mizushima J, et al. **Dermatology** 1996;192(3):280–2 (11 ref.)
Proliferating tricholemmal cyst should always be considered as a low-grade carcinoma [letter] Noto G, et al. **Dermatology** 1997;194(4):374–5 (16 ref.)
Porokeratotic eccrine ostial and dermal duct nevus of late onset: more frequent than previously suggested? Valks R, et al. **Dermatology** 1996;193(2):138–40 (17 ref.)
Mimics of pilomatrixomas in fine-needle aspirates. Sánchez Sánchez C, et al. **Diagn Cytopathol** 1996 Feb;14(1):75–83 (28 ref.)

Dermatofibrosarcoma protuberans: a clinicopathological study in an African population. Mbonde MP, et al. **East Afr Med J** 1996 Jun;73(6):410–3 (21 ref.)

Intermediate filament aggregates in mitoses of primary cutaneous neuroendocrine (Merkel cell) carcinoma. Alvarez-Gago T, et al. **Histopathology** 1996 Apr; 28(4):349–55 (30 ref.)

Hibernoma of scalp: case report and review of literature. Naik R, et al. **Indian J Cancer** 1996 Jun;33(2):116–8 (13 ref.)

From melanotic to amelanotic lentigo maligna: an aggressive variant presenting as an inflammatory lesion. Kiene P, et al. **Int J Dermatol** 1997 Feb;36(2):123–5 (13 ref.)

Subcutaneous panniculitic T-cell lymphoma. Wang CY, et al. **Int J Dermatol** 1996 Jan;35(1):1–8 (34 ref.)

Plantar granulomatous cutaneous T-cell lymphoma. Gibson GE, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):326–8 (13 ref.)

Mucinous nevus: report of two cases and review of the literature. Suhr KB, et al. **J Am Acad Dermatol** 1997 Aug; 37(2 Pt 2):312–3 (4 ref.)

Lymphocytic aleukemic leukemia cutis. Taniguchi S, et al. **J Am Acad Dermatol** 1996 Nov;35(5 Pt 2):849–50 (7 ref.)

T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL). Bunn PA Jr, et al. **J Cell Biochem Suppl** 1996;24:12–23 (125 ref.)

Clear-cell atypical fibroxanthoma: an uncommon histopathologic variant of atypical fibroxanthoma. Requena L, et al. **J Cutan Pathol** 1997 Mar;24(3):176–82 (34 ref.)

Retiform hemangioendothelioma. A new case in a child with diffuse endovascular papillary endothelial proliferation. Sanz-Trelles A, et al. **J Cutan Pathol** 1997 Aug;24(7):440–4 (12 ref.)

A case of multiple nevoid hypertrichosis. Chang SN, et al. **J Dermatol** 1997 May;24(5):337–41 (10 ref.)

A case of subcutaneous malignant fibrous histiocytoma circumscribed by fibrous tissue. Fukunaka H, et al. **J Dermatol** 1996 Nov;23(11):836–9 (14 ref.)

A case of apple-shaped pedunculated lipofibroma. Kwon KS, et al. **J Dermatol** 1997 Apr;24(4):258–61 (8 ref.)

Familial atypical mole syndrome manifesting as polypoid melanoma: a case report and review of the Japanese literature. Misago N, et al. **J Dermatol** 1996 Oct; 23(10):689–96 (38 ref.)

A case of Bednar tumor recurring after 23 years. Mochizuki Y, et al. **J Dermatol** 1996 Sep;23(9):614–8 (17 ref.)

Lentiginous melanocytic hyperplasia overlying dermatofibroma. Toda S, et al. **J Dermatol** 1996 Nov; 23(11):840–4 (13 ref.)

The life of a skin cancer. Brodland DG. **Mayo Clin Proc** 1997 May;72(5):475–8 (15 ref.)

Dermatopathologic variants of malignant melanoma. Perniciaro C. **Mayo Clin Proc** 1997 Mar;72(3):273–9 (38 ref.)

Malignant melanoma: basic approach to clinicopathologic correlation. Su WP. **Mayo Clin Proc** 1997 Mar;72(3):267–72 (5 ref.)

Birt-Hogg-Dubé syndrome: a review and presentation of the first case with oral lesions. Nadershahi NA, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Apr;83(4):496–500 (19 ref.)

Malignant rhabdoid tumor in adults—heterogenous tumors with a unique morphological phenotype. Leong FJ, et al. **Pathol Res Pract** 1996 Aug;192(8):796–807 (34 ref.)

A solitary congenital self-healing histiocytosis. Report of a case and review of the literature. Shy SW, et al. **Pathol Res Pract** 1996 Aug;192(8):869–74; discussion 875–6 (23 ref.)

Cellular blue nevus of the scalp infiltrating the underlying bone: case report and review. Micali G, et al. **Pediatr Dermatol** 1997 May-Jun;14(3):199–203 (17 ref.)

Linear sebaceous nevus syndrome: report of a patient with unusual associated abnormalities. Palazzi P, et al. **Pediatr Dermatol** 1996 Jan-Feb;13(1):22–4 (16 ref.)

Myxoid liposarcoma of the scalp: case report and literature review. Herman O, et al. **Plast Reconstr Surg** 1997 Jul; 100(1):84–5 (9 ref.)

Amelanotic malignant melanoma. Adler MJ, et al. **Semin Cutan Med Surg** 1997 Jun;16(2):122–30 (52 ref.)

Staging and prognosis of melanoma. Brown M. **Semin Cutan Med Surg** 1997 Jun;16(2):113–21 (51 ref.)

Biopsy technique for pigmented lesions. Cockerell CJ. **Semin Cutan Med Surg** 1997 Jun;16(2):108–12 (15 ref.)

Melanoma and melanoma in situ: build a better diagnosis through architecture. McCalmont TH. **Semin Cutan Med Surg** 1997 Jun;16(2):97–107 (7 ref.)

Immunohistochemistry: a prognostic as well as diagnostic tool? Mehregan D, et al. **Semin Cutan Med Surg** 1996 Dec; 15(4):317–25 (85 ref.)

Melanoma and stroma: an interaction of biological and prognostic importance. Smolle J, et al. **Semin Cutan Med Surg** 1996 Dec;15(4):326–35 (108 ref.)

Desmoplastic neurotropic melanoma. Tsao H, et al. **Semin Cutan Med Surg** 1997 Jun;16(2):131–6 (24 ref.)

Mucocutaneous neoplasms in patients with human immunodeficiency virus infection. Cockerell CJ. **Semin Diagn Pathol** 1996 Feb;13(1):19–39 (131 ref.)

Clear cell tumors of the skin. Suster S. **Semin Diagn Pathol** 1996 Feb;13(1):40–59 (74 ref.)

Lymphoscintigraphy, the sentinel node concept, and the intraoperative gamma probe in melanoma, breast cancer, and other potential cancers. Alazraki NP, et al. **Semin Nucl Med** 1997 Jan;27(1):55–67 (51 ref.)

Prognosis and staging in melanoma. Garrison M, et al. **Semin Oncol** 1996 Dec;23(6):725–33 (77 ref.)

Pregnancy and the prognosis of malignant melanoma. Grin CM, et al. **Semin Oncol** 1996 Dec;23(6):734–6 (20 ref.)

The clinical and histological differential diagnosis of malignant melanoma. Keller JM, et al. **Semin Oncol** 1996 Dec;23(6):693–702 (25 ref.)

Melanoma: criteria for histological diagnosis and its reporting. Metcalf JS. **Semin Oncol** 1996 Dec;23(6):688–92 (11 ref.)

Detection of occult melanoma cells in sentinel lymph nodes and blood. Reintgen DS, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 4):S11–5 (23 ref.)

Pathology of malignant melanoma. Heasley DD, et al. **Surg Clin North Am** 1996 Dec;76(6):1223–55 (34 ref.)

Prognostic factors for cutaneous squamous cell and basal cell carcinoma. Determinants of risk of recurrence, metastasis, and development of subsequent skin cancers. Barksdale SK, et al. **Surg Oncol Clin N Am** 1997 Jul;6(3):625–38 (53 ref.)

Prognostic factors in malignant melanoma. Kashani-Sabet M, et al. **Surg Oncol Clin N Am** 1997 Jul;6(3):599–623 (143 ref.)

Melanoma nodal metastases: biologic significance and therapeutic considerations. Reintgen D. **Surg Oncol Clin N Am** 1996 Jan;5(1):105–20 (24 ref.)

Recommendations for the reporting of tissues removed as part of the surgical treatment of cutaneous melanoma. Association of Directors of Anatomic and Surgical Pathology. **Virchows Arch** 1997 Aug;431(2):79–81 (7 ref.)

[Clinico-pathologic spectrum of cutaneous angiosarcoma and the difficulties of pathologic diagnosis] Laporte JL, et al. **Ann Pathol** 1996 Sep;16(4):247–53 (62 ref.) **(Fre)**

[Synopsis of primary cutaneous lymphomas] Piérard GE, et al. **Rev Med Liege** 1996 Dec;51(12):754–8 (23 ref.) **(Fre)**

[Frequent skin tumors in geriatrics] Piérard-Franchimont C, et al. **Rev Med Liege** 1997 Apr;52(4):289–95 (20 ref.) **(Fre)**

[Flow cytometry in dermatology] Bauer R, et al. **Hautarzt** 1996 Jul;47(7):561–78 (36 ref.) **(Ger)**

[Reactive angioendotheliomatosis in chronic lymphatic leukemia] Schmidt K, et al. **Hautarzt** 1996 Jul;47(7):550–5 (33 ref.) (Eng. Abstr.) **(Ger)**

[Applications of electron microscopy in dermatology] Sterniczky B, et al. **Hautarzt** 1996 Feb;47(2):148–65 quiz 162–3 (41 ref.) **(Ger)**

[Multiple metastases of malignant cutaneous melanoma into the upper urinary tract] Török P, et al. **Orv Hetil** 1997 Feb 2;138(5):285–7 (13 ref.) (Eng. Abstr.) **(Hun)**

[Early stage Stewart-Treves syndrome: report of 2 cases and review of the literature] Bisceglia M, et al. **Pathologica** 1996 Dec;88(6):483–90 (97 ref.) (Eng. Abstr.) **(Ita)**

[A case of von Recklinghausen's disease complicated by adenocarcinoma of the papilla of Vater] Nagayama K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Feb;94(2):123–8 (16 ref.) **(Jpn)**

[Homogeneous clinical behavior of a group of cutaneous B-cell lymphomas] de Misa RF, et al. **Sangre (Barc)** 1995 Dec;40(6):465–70 (21 ref.) (Eng. Abstr.) **(Spa)**

[Melanocytic tumors. Liberal nevus surgery and histopathological scrutiny reduce mortality] Larsson O, et al. **Lakartidningen** 1997 Jul 9;94(28–29):2545–7 (10 ref.) **(Swe)**

PHYSIOPATHOLOGY

The life of a skin cancer. Brodland DG. **Mayo Clin Proc** 1997 May;72(5):475–8 (15 ref.)

PREVENTION & CONTROL

Sun exposure, sunscreens, and skin cancer prevention: a year-round concern. Farmer KC, et al. **Ann Pharmacother** 1996 Jun;30(6):662–73 (87 ref.)

The case for sunscreens. A review of their use in preventing actinic damage and neoplasia. Naylor MF, et al. **Arch Dermatol** 1997 Sep;133(9):1146–54 (50 ref.)

Chemoprevention of ultraviolet radiation-induced skin cancer. Ley RD, et al. **Environ Health Perspect** 1997 Jun; 105 Suppl 4:981–4 (50 ref.)

How to decrease morbidity and mortality of skin cancer: primary prevention of skin cancer/screening of skin cancer. Report of a workshop held under the auspices of the Society of Dermatological Prevention (ADP e.V.), Commission of Early Detection and Prevention of Skin Cancer. 11 May 1994, Hamburg, Germany. **Eur J Cancer Prev** 1996 Aug;5(4):297–9 (3 ref.)

Chemoprevention of skin cancer. Green A. **IARC Sci Publ** 1996;(136):111–9 (68 ref.)

Sunscreens: progress and perspectives on photoprotection of human skin against UVB and UVA radiation. Pathak MA. **J Dermatol** 1996 Nov;23(11):783–800 (25 ref.)

Atypical mole syndrome: a brief overview for the primary care physician. Henneberry JM, et al. **Md Med J** 1997 May-Jun;46(5):243–6 (15 ref.)

Chemoprevention of photocarcinogenesis. Agarwal R, et al. **Photochem Photobiol** 1996 Apr;63(4):440–4 (50 ref.)

Sunscreens and photocarcinogenesis: an objective assessment. Elmets CA, et al. **Photochem Photobiol** 1996 Apr; 63(4):435–40 (46 ref.)

DNA repair enzymes in prevention of photocarcinogenesis. Yarosh DB, et al. **Photochem Photobiol** 1996 Apr; 63(4):445–7 (25 ref.)

Skin self-examination for melanoma--another golden rule. Howell JB. **Semin Cutan Med Surg** 1997 Jun;16(2):174–8 (19 ref.)

PSYCHOLOGY

The psychological challenges facing melanoma patients. Kneier AW. **Surg Clin North Am** 1996 Dec;76(6):1413–21 (23 ref.)

RADIONUCLIDE IMAGING

PET for diagnosis of malignant lymphoma of the scalp: comparison of [11C]methyl-L-methionine and [18F]fluoro-2-deoxyglucose. Tsuyuguchi N, et al. **J Comput Assist Tomogr** 1997 Jul-Aug;21(4):590–3 (16 ref.)

The role of lymphoscintigraphy and sentinel node mapping in assessing patient risk in melanoma. Essner R. **Semin Oncol** 1997 Feb;24(1 Suppl 4):S8–10 (15 ref.)

RADIOTHERAPY

Radiation therapy for squamous cell carcinoma in dystrophic epidermolysis bullosa: case reports and literature review. Bastin KT, et al. **Am J Clin Oncol** 1997 Feb;20(1):55–8 (23 ref.)

Multimodality treatment of squamous cell carcinoma complicating pilonidal disease. Kulaylat MN, et al. **Am Surg** 1996 Nov;62(11):922–9 (59 ref.)

Treatment of lentigo maligna. Gaspar ZS, et al. **Australas J Dermatol** 1997 Feb;38(1):1–6; quiz 7–8 (40 ref.)

Mycosis fungoides and total skin electron beam radiation [letter; comment] Jones GW, et al. **Blood** 1997 Apr 15; 89(8):3062–4 (12 ref.) Comment on: Blood 1996 Oct 1;88(7):2385–409.

Ki-1 skin lymphoproliferative disorders: management with radiation therapy. Kaufmann TP, et al. **Cancer Invest** 1997; 15(2):91–7 (30 ref.)

Benign and low-grade tumors of the soft tissues: role for radiation therapy. Suit HD, et al. **Cancer Treat Res** 1997; 91:95–105 (34 ref.)

Radiation therapy for skin neoplasms. Parker RG. **Clin Dermatol** 1995 Nov-Dec;13(6):579–88 (51 ref.)

Radiation therapy for patients with xeroderma pigmentosum. Sakata K, et al. **Radiat Med** 1996 Mar-Apr;14(2):87–90 (16 ref.)

New approaches to treating advanced melanoma: adjuvant treatment of high-risk primary melanoma and boron neutron capture therapy. Rogers GS, et al. **Semin Cutan Med Surg** 1997 Jun;16(2):165–73 (40 ref.)

Malignant melanoma: the role of radiation therapy revisited. Jenrette JM. **Semin Oncol** 1996 Dec;23(6):759–62 (33 ref.)

Radiation therapy for malignant melanoma. Geara FB, et al. **Surg Clin North Am** 1996 Dec;76(6):1383–98 (84 ref.)

SECONDARY

Metastatic endometrial adenocarcinoma to the skin of a toe. Giardina VN, et al. **Am J Dermatopathol** 1996 Feb; 18(1):94–8 (40 ref.)

Metastatic testicular choriocarcinoma of the skin. Report and review of the literature. Shimizu S, et al. **Am J Dermatopathol** 1996 Dec;18(6):633–6 (9 ref.)

Cutaneous metastasis of ocular malignant melanoma. An unusual presentation simulating blue nevi. Wieselthier JS, et al. **Am J Dermatopathol** 1996 Jun;18(3):289–95 (17 ref.)

Cutaneous metastases from gastric adenocarcinoma. Report of two cases and review of the literature. Boscaino A, et al. **Arch Anat Cytol Pathol** 1996;44(1):60–4 (8 ref.)

Endometrial adenocarcinoma metastatic to the scalp: case report and literature review. Kushner DM, et al. **Gynecol Oncol** 1997 Jun;65(3):530–3 (9 ref.)

Cutaneous metastases from pancreatic cancer. Miyahara M, et al. **Int J Pancreatol** 1996 Oct;20(2):127–30 (17 ref.)

Clinical features of skin metastasis from lung cancer. Hidaka T, et al. **Intern Med** 1996 Jun;35(6):459–62 (13 ref.)

Thyroid carcinoma metastatic to the skin: a cutaneous manifestation of a widely disseminated malignancy. Dahl PR, et al. **J Am Acad Dermatol** 1997 Apr;36(4):531–7 (40 ref.)

Mucoepidermoid carcinoma with cutaneous presentation. Yen A, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):340–2 (17 ref.)

[Umbilical metastasis of an endometrial adenocarcinoma: "Sister (Mary) Joseph's nodule". Review of the literature] Poncelet C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(8):799–803 (13 ref.) (Eng. Abstr.) **(Fre)**

[Subcutaneous metastasis as the first manifestation of kidney cancer dissemination] Martínez Sarmiento M, et al. **Actas Urol Esp** 1997 Apr;21(4):402–5 (21 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Multimodality treatment of squamous cell carcinoma complicating pilonidal disease. Kulaylat MN, et al. **Am Surg** 1996 Nov;62(11):922–9 (59 ref.)

Dermatofibrosarcoma protuberans (DFSP): growth characteristics based on tumor modeling and a review of cases treated with Mohs micrographic surgery. Haycox CL, et al. **Ann Plast Surg** 1997 Mar;38(3):246–51 (32 ref.)

Recent advances in the care of the patient with malignant

melanoma [see comments] Reintgen D, et al. **Ann Surg** 1997 Jan;225(1):1–14 (51 ref.) Comment in: Ann Surg 1997 Jan;225(1):15–6.

Lymphangiectomy and treatment modalities in Merkel cell carcinoma: a report of five new cases. Vandeput JJ, et al. **Anticancer Res** 1996 Nov–Dec;16(6B):3887–93 (49 ref.)

Theoretical and empirical arguments in relation to elective lymph node dissection for melanoma. Piepkorn M, et al. **Arch Dermatol** 1997 Aug;133(8):995–1002 (110 ref.)

Treatment of lentigo maligna. Gaspar ZS, et al. **Australas J Dermatol** 1997 Feb;38(1):1–6; quiz 7–8 (40 ref.)

Principles of reconstruction following excision of nonmelanoma skin cancer. Fazio MJ, et al. **Clin Dermatol** 1995 Nov–Dec;13(6):601–16 (29 ref.)

Mohs micrographic surgery for nonmelanoma skin cancer. Telfer NR. **Clin Dermatol** 1995 Nov–Dec;13(6):593–600 (54 ref.)

Surgical issues in the management of melanoma [see comments] Fraker DL. **Curr Opin Oncol** 1997 Mar; 9(2):183–8 (40 ref.) Comment in: Curr Opin Oncol 1997 Mar;9(2):175–7.

Recurrent lentigo maligna invading a skin graft successfully treated with Mohs' micrographic surgery. Cohen LM, et al. **Cutis** 1996 Mar;57(3):175–8 (26 ref.)

Laser treatment of port-wine stains and hemangiomas. Garden JM, et al. **Dermatol Clin** 1997 Jul;15(3):373–83 (47 ref.)

Advances in dermatologic surgery. Perez M. **Dermatol Clin** 1997 Jan;15(1):9–18 (61 ref.)

Sentinel node dissection in the treatment of melanoma. Report of three cases and review of the literature. Cottingham T, et al. **Dermatol Surg** 1997 Feb;23(2):113–8; discussion 118–9 (33 ref.)

Fractional cryosurgery. A new technique for basal cell carcinoma of the eyelids and periorbital area. Gonçalves JC. **Dermatol Surg** 1997 Jun;23(6):475–81 (26 ref.)

Peritumoral B cell infiltrate associated with chronic lymphocytic leukemia obscuring margin evaluation during Mohs micrographic surgery [letter] Humphreys TR, et al. **Dermatol Surg** 1996 Oct;22(10):894–6 (21 ref.)

Endoscopic polypectomy under laparotomy throughout the alimentary tract for a patient with blue rubber bleb nevus syndrome. Shimada S, et al. **Gastrointest Endosc** 1997 May; 45(5):423–7 (25 ref.)

Surgery and laser therapy. Lawrence CM. **J R Coll Physicians Lond** 1997 Jul–Aug;31(4):369–73 (25 ref.)

The surgical management of invasive primary melanoma: an update. Lange JR. **Md Med J** 1997 May–Jun;46(5):251–4 (21 ref.)

Mohs micrographic surgery for the treatment of difficult skin cancers. Skouge JW. **Md Med J** 1997 May–Jun;46(5):231–7 (42 ref.)

Role of sentinel node biopsy in the management of malignant melanoma. North JH Jr, et al. **Oncology (Huntingt)** 1996 Aug;10(8):1237–42; discussion 1242–6 (20 ref.)

Conceptual considerations in head & neck reconstruction. Defect analysis and options for reconstruction. Clevens RA, et al. **Otolaryngol Clin North Am** 1997 Aug; 30(4):495–517 (17 ref.)

Surgical treatment of malignant melanoma. Huth JF. **Semin Cutan Med Surg** 1997 Jun;16(2):159–64 (19 ref.)

The surgical management of melanoma: from diagnosis to local treatment. Baron PL. **Semin Oncol** 1996 Dec; 23(6):714–8 (34 ref.)

Surgical management of patients with intermediate thickness melanoma: current role of elective lymph node dissection. Cole DJ, et al. **Semin Oncol** 1996 Dec;23(6):719–24 (41 ref.)

Surgical therapy of primary cutaneous melanoma. Geraghty PJ, et al. **Semin Surg Oncol** 1996 Nov–Dec;12(6):386–93 (33 ref.)

The role of plastic surgery in the treatment of malignant melanoma. Eshima I. **Surg Clin North Am** 1996 Dec; 76(6):1331–42 (37 ref.)

Surgical treatment of malignant melanoma. Karakousis CP. **Surg Clin North Am** 1996 Dec;76(6):1299–312 (58 ref.)

Reconstructive surgery in melanoma patients. Ariyan S. **Surg Oncol Clin N Am** 1996 Oct;5(4):785–807 (09 ref.)

Oncologic and reconstructive considerations in nonmelanotic skin and lip cancers. Luce EA, et al. **Surg Oncol Clin N Am** 1996 Oct;5(4):751–84 (60 ref.)

Melanoma nodal metastases: biologic significance and therapeutic considerations. Reintgen D. **Surg Oncol Clin N Am** 1996 Jan;5(1):105–20 (24 ref.)

[Lymph node dissections in malignant melanoma] Hohenberger W, et al. **Chirurg** 1996 Aug;67(8):779–87 (24 ref.) (Eng. Abstr.) **(Ger)**

[Merkel cell tumor of the hand in a 104-year-old patient. Case report with review of the literature] Sonak RA, et al. **Handchir Mikrochir Plast Chir** 1996 Jan;28(1):43–5 (21 ref.) (Eng. Abstr.) **(Ger)**

[Basic principles of melanoma surgery] Walz MK. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:111–4 (18 ref.) (Eng. Abstr.) **(Ger)**

[Squamous cell carcinoma and basal cell carcinoma] Suzuki T, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(1):16–22 (10 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Merkel cell carcinoma of the skin. Treatment of primary, recurrent, and metastatic disease: review of clinical cases. Queirolo P, et al. **Anticancer Res** 1997 Jan–Feb; 17(1B):673–7 (22 ref.)

The development of therapeutic vaccines of the management of malignant melanoma. Dalgleish AG, et al. **Cancer Surv** 1996;26:289–319 (158 ref.)

Treatment of melanoma in-transit metastases confined to the limb. Eggermont AM. **Cancer Surv** 1996;26:335–49 (65 ref.)

Current immunotherapy for melanoma. Newton Bishop JA. **Cancer Surv** 1996;26:321–33 (54 ref.)

Cryotherapy of nonmelanoma skin cancer. August PJ. **Clin Dermatol** 1995 Nov–Dec;13(6):589–92 (14 ref.)

Use of vaccines in treatment of malignant melanoma. Bystryn JC, et al. **Clin Dermatol** 1996 Jul–Aug;14(4):337–41 (13 ref.)

Comparison of treatment modalities for squamous cell carcinoma. Geisse JK. **Clin Dermatol** 1995 Nov–Dec; 13(6):621–6 (31 ref.)

Comparison of treatment modalities for basal cell carcinoma. Rowe DE. **Clin Dermatol** 1995 Nov–Dec;13(6):617–20 (15 ref.)

The treatment of metastatic melanoma with chemotherapy and biologics [see comments] Atkins MB. **Curr Opin Oncol** 1997 Mar;9(2):205–13 (71 ref.) Comment in: Curr Opin Oncol 1997 Mar;9(2):175–7.

Melanoma and other skin neoplasms [editorial; comment] Schuchter LM. **Curr Opin Oncol** 1997 Mar;9(2):175–7 (7 ref.) Comment on: Curr Opin Oncol 1997 Mar;9(2):178–82. Comment on: Curr Opin Oncol 1997 Mar;9(2):183–8. Comment on: Curr Opin Oncol 1997 Mar;9(2):189–204. Comment on: Curr Opin Oncol 1997 Mar;9(2):205–13.

Adjuvant therapy for melanoma [see comments] Sondak VK, et al. **Curr Opin Oncol** 1997 Mar;9(2):189–204 (119 ref.) Comment in: Curr Opin Oncol 1997 Mar;9(2):175–7.

Advances in Kaposi's sarcoma. Myskowski PL, et al. **Dermatol Clin** 1997 Jan;15(1):177–88 (122 ref.)

Actinic cheilitis. A treatment review. Dufresne RG Jr, et al. **Dermatol Surg** 1997 Jan;23(1):15–21 (38 ref.)

Current status of melanoma vaccines. Kuhn CA, et al. **Dermatol Surg** 1997 Aug;23(8):649–54; discussion 654–5 (33 ref.)

Interleukin-7. Biology and implications for dermatology. Möller P, et al. **Exp Dermatol** 1996 Jun;5(3):129–37 (91 ref.)

The success of TNF alpha in isolated limb perfusion for irresectable extremity soft tissue sarcomas, melanoma and carcinomas: observations in patients and preclinical perfusion models. Eggermont AM. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1357–70 (74 ref.)

Adjuvant therapy for cutaneous malignant melanoma. Demierre MF, et al. **J Am Acad Dermatol** 1997 May;36(5 Pt 1):747–64 (153 ref.)

Proceedings of the International Consensus Conference on Cutaneous T-cell Lymphoma (CTCL) Treatment Recommendations. Boston, Massachusetts, Oct. 1 and 2, 1994. Demierre MF, et al. **J Am Acad Dermatol** 1997 Mar; 36(3 Pt 1):460–6 (44 ref.)

Hemangiomas and vascular malformations. Morelli JG. **Pediatr Ann** 1996 Feb;25(2):91, 94–6 (20 ref.)

Adjuvant application of interferons. el Kassas H, et al. **Semin Oncol** 1996 Dec;23(6):737–43 (35 ref.)

Active specific immunization in the treatment of patients with melanoma. Mastrangelo MJ, et al. **Semin Oncol** 1996 Dec; 23(6):773–81 (57 ref.)

Immunotherapy of malignant melanoma. Leong SP. **Surg Clin North Am** 1996 Dec;76(6):1355–81 (165 ref.)

Computer database for melanoma registry. A clinical management and research tool to monitor outcomes and ensure continuous quality improvement. Reintgen D, et al. **Surg Clin North Am** 1996 Dec;76(6):1273–85 (20 ref.)

[Current therapy concepts in cutaneous T-cell lymphomas] Nestle FO, et al. **Schweiz Med Wochenschr** 1997 Feb 22; 127(8):311–20 (62 ref.) (Eng. Abstr.) **(Ger)**

[Modern tumor therapy as seen in melanoma] Dummer R, et al. **Schweiz Rundsch Med Prax** 1996 Dec 10; 85(50):1609–14 (32 ref.) (Eng. Abstr.) **(Ger)**

[Malignant melanoma in childhood and adolescence] Karplus G, et al. **Harefuah** 1996 Jun 16;130(12):843–50 (43 ref.) **(Heb)**

[Treatment of malignant melanoma: recent advances and perspectives] Saida T. **Gan To Kagaku Ryoho** 1997 Jan; 24(1):10–5 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Treatment of basocellular carcinoma] Karadaglić D. **Vojnosanit Pregl** 1996 Mar–Apr;53(2):137–40 (20 ref.) **(Scr)**

ULTRASONOGRAPHY

[Non-invasive high resolution ultrasound of malignant melanoma of the skin. Possibilities, limits, alternatives] Freitag M, et al. **Fortschr Med** 1996 Jul 20;114(20–21):251–6 (0 ref.) (Eng. Abstr.) **(Ger)**

[Ultrasound morphology of peripheral lymph nodes] Abolmaali N, et al. **Z Arztl Fortbild Qualitatssich** 1997 Jul; 91(4):355–60 (11 ref.) (Eng. Abstr.) **(Ger)**

[High resolution 20 MHz ultrasound diagnosis in dermatology for noninvasive imaging of malignant melanomas] Happe M, et al. **Z Arztl Fortbild Qualitatssich** 1997 Jul;91(4):347–53 (0 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Tumours of the skin. Ghadially FN, et al. **IARC Sci Publ** 1996;(126):1–43 (111 ref.)

Tumors of the skin and associated structures. Meleo KA. **Vet Clin North Am Small Anim Pract** 1997 Jan;27(1):73–94 (67 ref.)

VIROLOGY

The role of papillomaviruses in human non-melanoma skin cancer. McGregor JM, et al. **Cancer Surv** 1996;26:219–36 (94 ref.)

The rabbit viral skin papillomas and carcinomas: a model for the immunogenetics of HPV-associated carcinogenesis. Breitburd F, et al. **Clin Dermatol** 1997 Mar–Apr; 15(2):237–47 (111 ref.)

Role of HPV in cutaneous premalignant and malignant tumors. Pfister H, et al. **Clin Dermatol** 1997 May–Jun; 15(3):335–47 (101 ref.)

Human papillomavirus-associated tumors of the skin and mucosa. Majewski S, et al. **J Am Acad Dermatol** 1997 May; 36(5 Pt 1):659–85; quiz 686–8 (272 ref.)

Virus infection and cancer risk in transplant recipients. McGregor JM, et al. **Trends Microbiol** 1996 Jan;4(1):2–3 (14 ref.)

SKIN PIGMENTATION

Ageing of bruising in children. Stephenson T. **J R Soc Med** 1997 Jun;90(6):312–4 (14 ref.)

Atrophie blanche—a special form of vasculopathy. Kwok CY, et al. **Singapore Med J** 1997 Mar;38(3):123–4 (12 ref.)

GENETICS

The genetics of pigmentation: from fancy genes to complex traits. Barsh GS. **Trends Genet** 1996 Aug;12(8):299–305 (53 ref.)

PHYSIOLOGY

What insights into vertebrate pigmentation has the axolotl model system provided? Frost-Mason SK, et al. **Int J Dev Biol** 1996 Aug;40(4):685–93 (44 ref.)

Salamander pigment patterns: how can they be used to study developmental mechanisms and their evolutionary transformation? Parichy DM. **Int J Dev Biol** 1996 Aug; 40(4):871–84 (130 ref.)

SKIN SUBSTITUTES see **SKIN, ARTIFICIAL**

SKIN TESTS

Methods for measuring the skin-cleansing effect of surfactants in comparison with skin roughness and compatibility. Schrader K, et al. **Clin Dermatol** 1996 Jan–Feb;14(1):57–65 (15 ref.)

Wash tests: evaluation by instrument methodology. Tupker RA, et al. **Clin Dermatol** 1996 Jan–Feb;14(1):51–5 (23 ref.)

Skin tests in the diagnosis of food allergy. Dreborg S. **Pediatr Allergy Immunol** 1995;6 Suppl 8:38–43 (29 ref.)

METHODS

Wash tests: evaluation by instrument methodology. Tupker RA, et al. **Clin Dermatol** 1996 Jan–Feb;14(1):51–5 (23 ref.)

The value and limitations of rechallenge in the guinea pig maximization test. Frankild S, et al. **Contact Dermatitis** 1996 Sep;35(3):135–40 (45 ref.)

Appraisal of the validity of histamine-induced wheal and flare to predict the clinical efficacy of antihistamines. Monroe EW, et al. **J Allergy Clin Immunol** 1997 Feb; 99(2):S798–806 (65 ref.)

STANDARDS

The local lymph node assay: a viable alternative to currently accepted skin sensitization tests. Basketter DA, et al. **Food Chem Toxicol** 1996 Oct;34(10):985–97 (70 ref.)

The local lymph node assay: status of validation. Chamberlain M, et al. **Food Chem Toxicol** 1996 Oct;34(10):999–1002 (20 ref.)

SKIN TRANSPLANTATION

see related

SURGICAL FLAPS

Treatment of thromboembolic complications of fulminant meningococcal septic shock. Mele JA 3rd, et al. **Ann Plast Surg** 1997 Mar;38(3):283–90 (29 ref.)

Tissue xenografts as a model system for study of the pathogenesis of papillomaviruses. Howett MK, et al. **Clin Dermatol** 1997 Mar–Apr;15(2):229–36 (53 ref.)

Reconstructed human skin: transplant, graft or biological dressing? Wood EJ, et al. **Essays Biochem** 1995;29:65–85 (52 ref.)

Anatomy of upper extremity skin flaps. Birkbeck DP, et al. **Hand Clin** 1997 May;13(2):175–87 (71 ref.)

Current concepts in oromandibular reconstruction. Burkey BB, et al. **Otolaryngol Clin North Am** 1997 Aug; 30(4):607–30 (47 ref.)

Conceptual considerations in head & neck reconstruction. Defect analysis and options for reconstruction. Clevens RA, et al. **Otolaryngol Clin North Am** 1997 Aug; 30(4):495–517 (17 ref.)

[Value of cutaneous allografts in the treatment of severe burns] Schlotterer M. **Chirurgie** 1997;122(1):6–8; discussion 9 (30 ref.) (Eng. Abstr.) **(Fre)**

SKIN TRANSPLANTATION

ADVERSE EFFECTS

HIV transmission by transplantation of allograft skin: a review of the literature. Pirnay JP, et al. **Burns** 1997 Feb; 23(1):1–5 (60 ref.)

Erosive pustular dermatosis of the scalp in skin grafts: report of three cases. Ena P, et al. **Dermatology** 1997;194(1):80–4 (26 ref.)

IMMUNOLOGY

[Cyclophosphamide-induced immunological tolerance: an overview] Mayumi H. **Nippon Geka Gakkai Zasshi** 1996 Dec;97(12):1097–108 (101 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Split-thickness skin grafting for lower extremity ulcerations. Kirsner RS, et al. **Dermatol Surg** 1997 Feb;23(2):85–91; quiz 92–3 (59 ref.)

Lower eyelid reconstruction using pedicled skin flap and palatal mucoperiosteum. Perry MJ, et al. **Dermatol Surg** 1997 May;23(5):395–7; discussion 397–8 (10 ref.)

The physiology and technique of skin grafting. Ablove RH, et al. **Hand Clin** 1997 May;13(2):163–73 (19 ref.)

The use of free tissue transfer in burn reconstruction. Abramson DL, et al. **J Burn Care Rehabil** 1996 Sep–Oct; 17(5):402–8 (16 ref.)

The use of skin from a monozygotic twin combined with cultured epithelial autografts as coverage for a large surface area burn: a case report and review of the literature. Caruso DM, et al. **J Burn Care Rehabil** 1996 Sep–Oct;17(5):432–4 (18 ref.)

Burns (Part 2). Tops and flops using cultured epithelial autografts in children. Meuli M, et al. **Pediatr Surg Int** 1997 Sep;12(7):471–7 (73 ref.)

Cultured epithelial autografts: diving from surgery into matrix biology. Raghunath M, et al. **Pediatr Surg Int** 1997 Sep;12(7):478–83 (52 ref.)

Reconstructive surgery in melanoma patients. Ariyan S. **Surg Oncol Clin N Am** 1996 Oct;5(4):785–807 (09 ref.)

Soft-tissue reconstruction following extravasation of chemotherapeutic agents. Shenaq SM, et al. **Surg Oncol Clin N Am** 1996 Oct;5(4):825–45 (35 ref.)

[New developments in covering post-traumatic soft tissue defects] Berger A, et al. **Orthopade** 1997 May;26(5):470–80 (34 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

The physiology and technique of skin grafting. Ablove RH, et al. **Hand Clin** 1997 May;13(2):163–73 (19 ref.)

SKIN TUBERCULOSIS see **TUBERCULOSIS, CUTANEOUS**

SKIN ULCER

Ulcerative sarcoidosis. Case report and review of the literature. Albertini JG, et al. **Arch Dermatol** 1997 Feb; 133(2):215–9 (50 ref.)

CHEMICALLY INDUCED

Livedo-like dermatitis (Nicolau's syndrome): a review of three cases. Ruffieux P, et al. **Dermatology** 1996; 193(4):368–71 (16 ref.)

An ulcerated lesion at the BCG vaccination site during the course of Kawasaki disease. Kuniyuki S, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):303–4 (15 ref.)

Severe cutaneous and venous damage after DIC therapy. Yuasa T, et al. **J Dermatol** 1997 Jul;24(7):466–70 (14 ref.)

COMPLICATIONS

A shorter lag period of mesenchymal malignancy on Marjolin's ulcer. Celiköz B, et al. **Burns** 1997 Feb; 23(1):72–4 (10 ref.)

ETIOLOGY

Herpes zoster-associated trigeminal neurotrophic ulcer [letter] Nielsen NH, et al. **Acta Derm Venereol** 1996 Mar; 76(2):159–60 (8 ref.)

Cutaneous ulcerations resulting from intramuscular injections of interferon alfa [letter; comment] Konohana A, et al. **J Am Acad Dermatol** 1996 Nov;35(5 Pt 1):788–9 (9 ref.) Comment on: J Am Acad Dermatol 1995 Sep;33(3):393–410; quiz 410–2.

[Coping with intractable skin ulcers in patients with collagen diseases] Kubota Y, et al. **Nippon Naika Gakkai Zasshi** 1996 Nov 10;85(11):1877–81 (5 ref.) **(Jpn)**

SKIN WRINKLING see **SKIN AGING**

SKINFOLD THICKNESS

[Screening for fetal chromosome aberrations. Ultrasonic measurement of nuchal translucency thickness is most efficient] Valentin L. **Lakartidningen** 1997 Aug 20; 94(34):2810–2, 2815–6 (52 ref.) **(Swe)**

SKULL

see related
CEPHALOMETRY

CRANIOTOMY

INTRACRANIAL PRESSURE

[Polyostotic fibrous dysplasia. A clinical case report] Gallesio C, et al. **Minerva Stomatol** 1996 Nov;45(11):533–40 (16 ref.) (Eng. Abstr.) **(Ita)**

ABNORMALITIES

Reconstruction of midfacial and anterior skull-base defects. Hochman M. **Otolaryngol Clin North Am** 1995 Dec; 28(6):1269–77 (13 ref.)

Craniofacial manifestations of the amniotic band syndrome. Bagatin M, et al. **Otolaryngol Head Neck Surg** 1997 Apr; 116(4):525–8 (15 ref.)

[Mohr-Claussen syndrome] Nakano M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):281–3 (10 ref.) **(Jpn)**

ANATOMY & HISTOLOGY

Concordance of cranial and dental morphological traits and evidence for endogamy in ancient Egypt. Prowse TL, et al. **Am J Phys Anthropol** 1996 Oct;101(2):237–46 (98 ref.)

Developmental patterning and evolution of the mammalian viscerocranium: genetic insights into comparative morphology. Kuratani S, et al. **Dev Dyn** 1997 Jun; 209(2):139–55 (145 ref.)

[Combined supra- and infratentorial transpetrosal approach] Sawamura Y. **No Shinkei Geka** 1996 Dec;24(12):1079–85 (9 ref.) **(Jpn)**

EMBRYOLOGY

The influence of ethyl alcohol on the development of the chondrocranium of Gallus gallus. Heyns M. **Adv Anat Embryol Cell Biol** 1997;134:1–127 (90 ref.)

Genetic analysis of craniofacial development in the vertebrate embryo. Schilling TF. **Bioessays** 1997 Jun;19(6):459–68 (56 ref.)

Mammalian craniofacial embryology in vitro. Osumi-Yamashita N, et al. **Int J Dev Biol** 1997 Apr; 41(2):187–94 (73 ref.)

Embryonic neural chimeras in the study of vertebrate brain and head development. Le Douarin NM, et al. **Int Rev Cytol** 1997;175:241–309 (200 ref.)

Neural crest apoptosis and the establishment of craniofacial pattern: an honorable death. Graham A, et al. **Mol Cell Neurosci** 1996;8(2–3):76–83 (26 ref.)

GROWTH & DEVELOPMENT

Some methods of assessing postnatal craniofaciodental growth: a retrospective of personal research. Sarnat BG. **Cleft Palate Craniofac J** 1997 Mar;34(2):159–72 (57 ref.)

Craniofacial development: knockout mice take one on the chin. Richman J, et al. **Curr Biol** 1996 Apr 1;6(4):364–7 (23 ref.)

INJURIES

Perioperative nursing care of patients with craniofacial injuries. Hayes KM, et al. **AORN J** 1996 Sep;64(3):385–98; quiz 407–10, 413–4 (44 ref.)

MICROBIOLOGY

Eikenella corrodens skull infection: a case report with review of the literature. Arana E, et al. **Surg Neurol** 1997 Apr; 47(4):389–91 (9 ref.)

PATHOLOGY

Giant congenital naevus of the scalp and cranium: case report and review of the literature. Madaree A, et al. **Br J Plast Surg** 1997 Jan;50(1):20–5 (8 ref.)

Cranio-facial fibro-osseous dysplasia. A case report and overview of the management of the condition. Delap TG, et al. **Int J Pediatr Otorhinolaryngol** 1996 Oct;37(2):179–91 (37 ref.)

Fibro-osseous lesions of the head and neck. Beasley DJ, et al. **J La State Med Soc** 1996 Oct;148(10):413–5 (12 ref.)

[The keratocyst or epidermoid cyst: the current state of understanding apropos of a case with intracranial involvement] Franc C, et al. **Rev Stomatol Chir Maxillofac** 1996 Oct;97(5):270–82 (134 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Entrainment and the cranial rhythmic impulse. McPartland JM, et al. **Altern Ther Health Med** 1997 Jan;3(1):40–5 (80 ref.)

The controversy of cranial bone motion. Rogers JS, et al. **J Orthop Sports Phys Ther** 1997 Aug;26(2):95–103 (50 ref.)

PHYSIOPATHOLOGY

[Cranial fasciitis in childhood: a case report and literature review] Méndez Gallart R, et al. **An Esp Pediatr** 1996 Nov; 45(5):530–2 (16 ref.) **(Spa)**

RADIONUCLIDE IMAGING

Abnormal skull uptake on bone scan. Ackerman L, et al. **Semin Nucl Med** 1997 Apr;27(2):190–3 (46 ref.)

SURGERY

Presigmoid approaches to skull base lesions. Lawton MT, et al. **Adv Tech Stand Neurosurg** 1997;23:189–204 (28 ref.)

Transfacial approaches to the skull base. Uttley D. **Adv Tech Stand Neurosurg** 1997;23:145–88 (77 ref.)

Computer-assisted intraoperative navigation during skull base surgery. Carrau RL, et al. **Am J Otolaryngol** 1996 Mar–Apr;17(2):95–101 (20 ref.)

Paediatric craniofacial surgery: historical perspectives, recent advancements and refinements. Posnick JC. **Br J Oral Maxillofac Surg** 1995 Dec;33(6):343–61 (88 ref.)

The craniofacial dysostosis syndromes. Staging of reconstruction and management of secondary deformities. Posnick JC. **Clin Plast Surg** 1997 Jul;24(3):429–46 (43 ref.)

Secondary craniofacial management following initial correction of nonsyndromic craniosynostosis. Shin JH, et al. **Clin Plast Surg** 1997 Jul;24(3):415–28 (26 ref.)

Reconstruction of midfacial and anterior skull-base defects. Hochman M. **Otolaryngol Clin North Am** 1995 Dec; 28(6):1269–77 (13 ref.)

Eikenella corrodens skull infection: a case report with review of the literature. Arana E, et al. **Surg Neurol** 1997 Apr; 47(4):389–91 (9 ref.)

Cranioplasty: cosmetic or therapeutic? Dujovny M, et al. **Surg Neurol** 1997 Mar;47(3):238–41 (23 ref.)

Symptomatic patients after craniectomy. Schiffer J, et al. **Surg Neurol** 1997 Mar;47(3):231–7 (22 ref.)

SKULL BASE

Primary eosinophilic granuloma invading the skull base: case report and critical review of the literature. Lunardi P, et al. **Tumori** 1996 Jul–Aug;82(4):397–400 (20 ref.)

ABNORMALITIES

The craniocervical junction in man, the osseous variations, their significance and differential diagnosis. Prescher A. **Anat Anz** 1997 Feb;179(1):1–19 (208 ref.)

ANATOMY & HISTOLOGY

The craniocervical junction in man, the osseous variations, their significance and differential diagnosis. Prescher A. **Anat Anz** 1997 Feb;179(1):1–19 (208 ref.)

PATHOLOGY

Osteoblastoma of the nasal cavity invading the anterior skull base in a young child. Case report. Imai K, et al. **J Neurosurg** 1997 Oct;87(4):625–8 (9 ref.)

Skull base osteomyelitis. Malignant external otitis. Slattery WH 3rd, et al. **Otolaryngol Clin North Am** 1996 Oct; 29(5):795–806 (30 ref.)

SURGERY

Innovations in surgical approach: lateral cranial base approaches. Day JD, et al. **Clin Neurosurg** 1996;43:72–90 (29 ref.)

Anterior midline approaches to the central skull base. Harsh GR 4th, et al. **Clin Neurosurg** 1996;43:15–43 (41 ref.)

Transpetrosal and combination approaches to skull base lesions. Lawton MT, et al. **Clin Neurosurg** 1996;43:91–112 (29 ref.)

Innovations in cranial approaches and exposures: anterolateral approaches. Van Loveren HR, et al. **Clin Neurosurg** 1996;43:44–52 (26 ref.)

Secondary craniofacial problems following skull base surgery. Beals SP, et al. **Clin Plast Surg** 1997 Jul; 24(3):565–81 (45 ref.)

Visual evoked potentials in endoscopic and anterior skull base surgery: a review. Jones NS. **J Laryngol Otol** 1997 Jun; 111(6):513–6 (33 ref.)

Eosinophilic granuloma of the clivus: case report, follow-up of two previously reported cases, and review of the literature on cranial base eosinophilic granuloma. Brisman JL, et al. **Neurosurgery** 1997 Jul;41(1):273–8; discussion 278–9 (43 ref.)

Update on skull base surgery. Chang CY, et al. **Otolaryngol Clin North Am** 1996 Jun;29(3):467–501 (86 ref.)

[The facial approach to the median structures of the skull base] Beziat JL, et al. **Rev Stomatol Chir Maxillofac** 1997 Sep;98(3):183–206 (91 ref.) (Eng. Abstr.) **(Fre)**

SKULL BASE NEOPLASMS

DIAGNOSIS

Imaging of the skull base. Weber AL. **Eur J Radiol** 1996 Mar;22(1):68–81 (68 ref.)

Maffucci's syndrome associated with a cranial base chondrosarcoma: case report and literature review. Ramina R, et al. **Neurosurgery** 1997 Jul;41(1):269–72 (28 ref.)

MORTALITY

Why is female sex an independent predictor of shortened overall survival after proton/photon radiation therapy for skull base chordomas? Halperin EC. **Int J Radiat Oncol Biol Phys** 1997 May 1;38(2):225–30 (48 ref.)

PATHOLOGY

[Dedifferentiated (sarcomatoid) chordoma in the base of the skull. Report of a case] Losi L, et al. **Pathologica** 1996 Dec;88(6):514–8 (25 ref.) (Eng. Abstr.) **(Ita)**

RADIOTHERAPY

Why is female sex an independent predictor of shortened overall survival after proton/photon radiation therapy for skull base chordomas? Halperin EC.
Int J Radiat Oncol Biol Phys 1997 May 1;38(2):225–30 (48 ref.)

SURGERY

Surgical treatment of anterior basal meningiomas. DeMonte F. **J Neurooncol** 1996 Sep;29(3):239–48 (31 ref.)
Petroclival and foramen magnum meningiomas: surgical approaches and pitfalls. Sekhar LN, et al. **J Neurooncol** 1996 Sep;29(3):249–59 (22 ref.)
Fronto–ethmoidal and orbital osteomas with intracranial extension. Report of two cases. Maiuri F, et al.
J Neurosurg Sci 1996 Mar;40(1):65–70 (24 ref.)
Cerebellar mutism after posterior cranial fossa surgery. Salvati M, et al. **J Neurosurg Sci** 1996 Mar;40(1):59–63 (21 ref.)
Update on skull base surgery. Chang CY, et al.
Otolaryngol Clin North Am 1996 Jun;29(3):467–501 (86 ref.)

SKULL FRACTURES

Penetrating cranio–cerebral injuries. Buxton N.
J R Army Med Corps 1997 Jun;143(2):112–4 (34 ref.)

CLASSIFICATION

Temporal bone fractures inducing facial nerve paralysis: a new classification and its clinical significance [see comments] Yanagihara N, et al. **Ear Nose Throat J** 1997 Feb;76(2):79–80, 83–6 (10 ref.) Comment in: Ear Nose Throat J 1997 Feb;76(2):64.

COMPLICATIONS

Temporal bone fractures inducing facial nerve paralysis: a new classification and its clinical significance [see comments] Yanagihara N, et al. **Ear Nose Throat J** 1997 Feb;76(2):79–80, 83–6 (10 ref.) Comment in: Ear Nose Throat J 1997 Feb;76(2):64.
A case of gustatory rhinorrhoea. Franceschini SS, et al.
Rhinology 1997 Mar;35(1):41–3 (15 ref.)
[Restoration of vision after surgical treatment of traumatic optic neuropathy of an uncommon type. Case report and literature review] Haninec P, et al. **Cesk Slov Oftalmol** 1996 Sep;52(4):249–52 (15 ref.) (Eng. Abstr.) **(Cze)**

DIAGNOSIS

Evaluation and management of facial fractures. Carithers JS, et al. **Am Fam Physician** 1997 Jun;55(8):2675–82 (10 ref.)
Occipital condyle fractures. Tuli S, et al. **Neurosurgery** 1997 Aug;41(2):368–76; discussion 376–7 (42 ref.)
Growing fracture of the orbital roof. Jamjoom ZA.
Surg Neurol 1997 Aug;48(2):184–8 (15 ref.)

SURGERY

Pediatric depressed skull fractures: analysis of 530 cases. Erşahin Y, et al. **Childs Nerv Syst** 1996 Jun;12(6):323–31 (15 ref.)
Posttraumatic intradiploic arachnoid cyst of the posterior fossa. Martínez–Lage JF, et al. **Childs Nerv Syst** 1997 May; 13(5):293–6 (15 ref.)
[Modern principles in treatment of complex injuries of the facial bones] Schierle HP, et al. **Unfallchirurg** 1997 May; 100(5):330–7 (30 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Evaluation and management of facial fractures. Carithers JS, et al. **Am Fam Physician** 1997 Jun;55(8):2675–82 (10 ref.)
Intracranial placement of a nasotracheal tube after facial fracture: a rare complication [see comments] Marlow TJ, et al. **J Emerg Med** 1997 Mar–Apr;15(2):187–91 (12 ref.) Comment in: J Emerg Med 1997 Mar–Apr;15(2):243–4.
Occipital condyle fractures. Tuli S, et al. **Neurosurgery** 1997 Aug;41(2):368–76; discussion 376–7 (42 ref.)

SKULL NEOPLASMS

Chondromyxoid fibroma of the temporal bone. LeMay DR, et al. **Surg Neurol** 1997 Aug;48(2):148–52 (23 ref.)
[Temporo–sphenoidal giant cell tumors, apropos of a case] Barnabé D, et al. **Rev Laryngol Otol Rhinol (Bord)** 1997; 118(2):133–7 (30 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

Cranial osteomas: their classification and management. Report on a giant osteoma and review of the literature. Haddad FS, et al. **Surg Neurol** 1997 Aug;48(2):143–7 (32 ref.)

COMPLICATIONS

Papillary adenoma of endolymphatic sac origin: a temporal bone tumor in von Hippel–Lindau disease. Case report. Ouallet JC, et al. **J Neurosurg** 1997 Sep;87(3):445–9 (11 ref.)
Intrasellar paraganglioma: report of a case in a sibship of von Hippel–Lindau disease. Scheithauer BW, et al.
Neurosurgery 1996 Feb;38(2):395–9 (26 ref.)

DIAGNOSIS

Chondromyxoid fibroma of the skull base: a tumor which may be confused with chordoma and chondrosarcoma. A report of three cases and review of the literature. Keel SB, et al. **Am J Surg Pathol** 1997 May;21(5):577–82 (25 ref.)
Zygomatic leiomyoma. Case report. Robiony M, et al.
Minerva Stomatol 1996 Dec;45(12):593–7 (17 ref.)
Multiple calvarial cavernous haemangiomas: case report and review of the literature. Kumar NA, et al.
Neuroradiology 1996 May;38 Suppl 1:S83–5 (10 ref.)
Osteoblastoma of the calvaria: report of two cases diagnosed with MRI and clinical review. Cervoni L, et al.
Neurosurg Rev 1997;20(1):51–4 (16 ref.)
Verrucous carcinoma of maxillary antrum. Indudharan R, et al. **Singapore Med J** 1996 Oct;37(5):559–61 (17 ref.)
[Osteoma of the mastoid: apropos of 2 cases] Guérin N, et al. **Rev Laryngol Otol Rhinol (Bord)** 1996;117(2):127–32 (30 ref.) (Eng. Abstr.) **(Fre)**
[A giant–cell tumor of the parietal skull bones in childhood (a clinical case)] Govenʹko FS, et al.
Zh Vopr Neirokhir Im N N Burdenko 1996 Jul–Sep;(3):37–9 (28 ref.) **(Rus)**

DRUG THERAPY

Effect of chemotherapy on survival of craniofacial osteosarcoma: a systematic review of 201 patients. Smeele LE, et al. **J Clin Oncol** 1997 Jan;15(1):363–7 (27 ref.)

EPIDEMIOLOGY

Primary non–Hodgkin's lymphoma of the cranial vault. Bhatia S, et al. **Clin Oncol (R Coll Radiol)** 1997;9(3):195–6 (7 ref.)

MORTALITY

Effect of chemotherapy on survival of craniofacial osteosarcoma: a systematic review of 201 patients. Smeele LE, et al. **J Clin Oncol** 1997 Jan;15(1):363–7 (27 ref.)

PATHOLOGY

Intracranial chondromyxoid fibroma. Report of a case and review of the literature. Wolf DA, et al.
Arch Pathol Lab Med 1997 Jun;121(6):626–30 (23 ref.)
Primary sellar haemorrhagic melanoma: case report and review of the literature. Aubin MJ, et al.
Br J Neurosurg 1997 Feb;11(1):80–3 (12 ref.)
Malignant granular cell tumor: a case report and review of the recent literature. Simsir A, et al. **Hum Pathol** 1996 Aug; 27(8):853–8 (40 ref.)
Osteoblastoma of the nasal cavity invading the anterior skull base in a young child. Case report. Imai K, et al.
J Neurosurg 1997 Oct;87(4):625–8 (9 ref.)
Cancer of the external auditory canal and temporal bone. Kuhel WI, et al. **Otolaryngol Clin North Am** 1996 Oct; 29(5):827–52 (88 ref.)

SECONDARY

Extracranial metastasis of glioblastoma multiforme diagnosed by fine–needle aspiration: a report of two cases and a review of the literature. Vural G, et al.
Diagn Cytopathol 1996 Jul;15(1):60–5 (29 ref.)
Temporomandibular joint metastasis from rectal carcinoma: CT findings before and after radiotherapy. A case report. Balestreri L, et al. **Tumori** 1997 May–Jun;83(3):718–20 (6 ref.)

SURGERY

Primary intraosseous meningioma of the temporal bone in an infant. A case report. Kuzeyli K, et al.
Neurosurg Rev 1996;19(3):197–9 (15 ref.)
Ewing's sarcoma of the skull in an infant. A case report and review. Hadfield MG, et al. **Pediatr Neurosurg** 1996 Aug; 25(2):100–4 (64 ref.)
Use of hydroxyapatite for reconstruction after surgical removal of intraosseous hemangioma in the zygomatic bone. Hirano S, et al. **Plast Reconstr Surg** 1997 Jul; 100(1):86–90 (18 ref.)
Cranial osteomas: their classification and management. Report on a giant osteoma and review of the literature. Haddad FS, et al. **Surg Neurol** 1997 Aug;48(2):143–7 (32 ref.)

SLAUGHTERHOUSES see **ABATTOIRS**

SLEEP

see related
POLYSOMNOGRAPHY

The relationship between sleep and cognitive functions during wakefulness: an introduction. Schulz H, et al.
Acta Neurol Belg 1997 Jun;97(2):93–5 (8 ref.)
Methods of testing for sleepiness [corrected] [published erratum appears in Behav Med 1996 Spring;22(1):following table of contents] Mitler MM, et al. **Behav Med** 1996 Winter;21(4):171–83 (67 ref.)
Managing fatigue in operational settings. 1: Physiological considerations and countermeasures. Rosekind MR, et al. **Behav Med** 1996 Winter;21(4):157–65 (41 ref.)
Nocturnal noninvasive positive pressure ventilatory assistance [see comments] Claman DM, et al. **Chest** 1996 Dec;110(6):1581–8 (71 ref.) Comment in: Chest 1997 May;111(5):1471–2.
Cheyne–Stokes respiration during sleep in congestive heart failure. Quaranta AJ, et al. **Chest** 1997 Feb;111(2):467–73 (49 ref.)
Promoting sleep in shiftworkers and intercontinental travelers. Stone BM, et al. **Chronobiol Int** 1997 Mar; 14(2):133–43 (64 ref.)
Short–lived head pains. Raskin NH. **Neurol Clin** 1997 Feb; 15(1):143–52 (44 ref.)
Risk of infection from sleeping with contact lenses on: causes of risk. Goodlaw E. **Optom Vis Sci** 1996 Mar;73(3):156–8 (29 ref.)
We are chronically sleep deprived. Bonnet MH, et al.
Sleep 1995 Dec;18(10):908–11 (34 ref.)
[Sleeping position, prevention of sudden death syndrome and gastroesophageal reflux] Faure C, et al. **Arch Pediatr** 1996 Jun;3(6):598–601 (16 ref.) (Eng. Abstr.) **(Fre)**
[Chronic obstructive lung disease and sleep] Bishara H.
Harefuah 1996 Jun 2;130(11):775–7 (41 ref.) **(Heb)**
[Respiratory disorders during sleep in chronic obstructive lung disease] Togores Solivellas B, et al.
Arch Bronconeumol 1996 Jan;32(1):32–9 (78 ref.) **(Spa)**

DRUG EFFECTS

Polysomnography in drug development. Dietrich B.
J Clin Pharmacol 1997 Jan;37(1 Suppl):70S–78S (81 ref.)
Effects of drugs on sleep. Obermeyer WH, et al.
Neurol Clin 1996 Nov;14(4):827–40 (116 ref.)

GENETICS

Genetics of narcolepsy and other sleep disorders. Mignot E. **Am J Hum Genet** 1997 Jun;60(6):1289–302 (199 ref.)

PHYSIOLOGY

Human sleep/wake regulation. Gillberg M.
Acta Anaesthesiol Scand Suppl 1997;110:8–10 (11 ref.)
Functional uncertainty, aging and memory processes during sleep. Salzarulo P, et al. **Acta Neurol Belg** 1997 Jun; 97(2):118–22 (31 ref.)
Sleep and arousal: thalamocortical mechanisms. McCormick DA, et al. **Annu Rev Neurosci** 1997;20:185–215 (122 ref.)
Introduction to the neurophysiological study of sleep: central regulation of skeletal and ocular activities. Gottesmann C.
Arch Ital Biol 1997 Jun;135(3):279–314 (274 ref.)
Sleep, genes and death: fatal familial insomnia. Fiorino AS.
Brain Res Brain Res Rev 1996 Oct;22(3):258–64 (51 ref.)
Origin and evolution of sleep: roles of vision and endothermy. Kavanau JL. **Brain Res Bull** 1997;42(4):245–64 (239 ref.)
Interactions between sleep, other body rhythms, immune responses, and exercise. Shephard RJ, et al.
Can J Appl Physiol 1997 Apr;22(2):95–116 (219 ref.)
Impact of sleep in respiratory failure. McNicholas WT.
Eur Respir J 1997 Apr;10(4):920–33 (185 ref.)
Molecular mechanism of sleep regulation by prostaglandin D2. Urade Y, et al. **J Lipid Mediat Cell Signal** 1996 Sep; 14(1–3):71–82 (47 ref.)
Sleep and neurological diseases. Autret A. **J Neurol** 1997 Apr;244(4 Suppl 1):S1–2 (17 ref.)
Sleep and the epilepsies. Autret A, et al. **J Neurol** 1997 Apr; 244(4 Suppl 1):S10–7 (73 ref.)
Sleep in patients with amyotrophic lateral sclerosis. Hetta J, et al. **J Neurol** 1997 Apr;244(4 Suppl 1):S7–9 (10 ref.)
Positron emission tomography studies of sleep and sleep disorders. Maquet P. **J Neurol** 1997 Apr;244(4 Suppl 1):S23–8 (46 ref.)
Computerization of Fujimori's method of waveform recognition. A review and methodological considerations for its application to all–night sleep EEG. Uchida S, et al. **J Neurosci Methods** 1996 Jan;64(1):1–12 (60 ref.)
Melatonin, sleep, aging, and the health protection branch [editorial] Young SN. **J Psychiatry Neurosci** 1996 May; 21(3):161–4 (34 ref.)
Sleep in psychiatric disorders. Benca RM. **Neurol Clin** 1996 Nov;14(4):739–64 (140 ref.)
Sleep and degenerative neurologic disorders. Chokroverty S. **Neurol Clin** 1996 Nov;14(4):807–26 (87 ref.)
Sleep and neuromuscular disorders. Culebras A.
Neurol Clin 1996 Nov;14(4):791–805 (41 ref.)
Sleep–related erectile activity. Hirshkowitz M, et al.
Neurol Clin 1996 Nov;14(4):721–37 (90 ref.)
Sleep and epilepsy. Malow BA. **Neurol Clin** 1996 Nov; 14(4):765–89 (80 ref.)
Body temperature regulation in the newborn infant: interaction with sleep and clinical implications. Bach V, et al. **Neurophysiol Clin** 1996;26(6):379–402 (147 ref.)
c–Fos expression during wakefulness and sleep. Pompeiano M, et al. **Neurophysiol Clin** 1995;25(6):329–41 (56 ref.)
The transition from slow–wave sleep to paradoxical sleep: evolving facts and concepts of the neurophysiological processes underlying the intermediate stage of sleep. Gottesmann C. **Neurosci Biobehav Rev** 1996 Autumn; 20(3):367–87 (167 ref.)
Memory, sleep and the evolution of mechanisms of synaptic

efficacy maintenance. Kavanau JL. **Neuroscience** 1997 Jul; 79(1):7–44 (347 ref.)

Sleep regulation: relation to photoperiod, sleep duration, waking activity, and torpor. Borbély AA, et al. **Prog Brain Res** 1996;111:343–8 (29 ref.)

The present and the future of sleep research in Asia. Okuma T. **Psychiatry Clin Neurosci** 1995 May;49(2):91–7 (22 ref.)

We are chronically sleep deprived. Bonnet MH, et al. **Sleep** 1995 Dec;18(10):908–11 (34 ref.)

Should we be taking more sleep? Harrison Y, et al. **Sleep** 1995 Dec;18(10):901–7 (54 ref.)

Physiological regulation of the human growth hormone (GH)–insulin–like growth factor type I (IGF–I) axis: predominant impact of age, obesity, gonadal function, and sleep. Veldhuis JD, et al. **Sleep** 1996 Dec;19(10 Suppl):S221–4 (17 ref.)

[Respiratory disorders during sleep in children] Kirjavainen T, et al. **Duodecim** 1995;111(12):1154–64 (44 ref.) **(Fin)**

[Increased resistance of the upper respiratory airways during sleep] Tuunainen A, et al. **Duodecim** 1995;111(12):1148–53 (25 ref.) **(Fin)**

[The quality of sleep: an underestimated factor in glycemic regulation?] Scheen AJ, et al. **Journ Annu Diabetol Hotel Dieu** 1996;:253–65 (49 ref.) **(Fre)**

[Melatonin in humans: a biochemical marker of the circadian clock and an endogenous synchronizer] Claustrat B, et al. **Neurophysiol Clin** 1995;25(6):351–9 (43 ref.) (Eng. Abstr.) **(Fre)**

[Propensity for sleep and diurnal somnolence in the course of sleep apnea syndrome] Krieger J, et al. **Neurophysiol Clin** 1996;26(3):131–7 (32 ref.) (Eng. Abstr.) **(Fre)**

[Contribution of positron emission tomography in the study of wakefulness and sleep. Status of the question] Maquet P. **Neurophysiol Clin** 1995;25(6):342–50 (35 ref.) (Eng. Abstr.) **(Fre)**

[Circadian rhythm in normal and pathological sleep] Billiard M, et al. **Pathol Biol (Paris)** 1996 Jun;44(6):509–17 (23 ref.) (Eng. Abstr.) **(Fre)**

[Sleep, breathing and gastroesophageal reflux] Rasche K, et al. **Dtsch Med Wochenschr** 1997 May 16;122(20):659–63 (46 ref.) **(Ger)**

[Polysomnography (PSG)] Hayakawa T, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:383–5 (5 ref.) **(Jpn)**

[Circadian variation of lung function in health persons] Franczuk M, et al. **Pneumonol Alergol Pol** 1997; 65(1–2):96–103 (26 ref.) **(Pol)**

[New data on the characteristics of sleep and the organization of the wakefulness–sleep cycle in cold–blooded vertebrates] Karmanova IG. **Zh Evol Biokhim Fiziol** 1996 Jul–Aug; 32(4):511–35 (10 ref.) **(Rus)**

SLEEP APNEA SYNDROMES

Obstructive sleep apnoea. The clinical consequences. Fogarty P. **Aust Fam Physician** 1996 Feb;25(2):170, 172, 174 passim (16 ref.)

Health effects of obstructive sleep apnoea and the effectiveness of continuous positive airways pressure: a systematic review of the research evidence [see comments] Wright J, et al. **BMJ** 1997 Mar 22;314(7084):851–60 (144 ref.) Comment in: BMJ 1997 Mar 22;314(7084):839–40. Comment in: BMJ 1997 Aug 9;315(7104):367; discussion 369. Comment in: BMJ 1997 Aug 9;315(7104):367–8. Comment in: BMJ 1997 Aug 9;315(7104):368; discussion 369. Comment in: BMJ 1997 Aug 9;315(7104):368–9. Comment in: BMJ 1997 Aug 9;315(7104):369. Comment in: ACP J Club 1997 Sep–Oct;127(2):45.

Sleep apnea and its imitators. Feinsilver SH. **Compr Ther** 1996 Oct;22(10):661–4 (5 ref.)

Rx for a good night's sleep: diagnosing and treating sleep apnea. Dordick V. **Iowa Med** 1997 Apr;87(4):159–60 (0 ref.)

Obstructive sleep apnoea. Part I: Diagnosis, aetiology, and current treatment. Robertson CJ. **N Z Dent J** 1996 Dec; 92(410):110–3 (49 ref.)

Central sleep apnea. Thalhofer S, et al. **Respiration** 1997; 64(1):2–9 (79 ref.)

COMPLICATIONS

Nasal obstruction and obstructive sleep apnea: a review. Kushida CA, et al. **Allergy Asthma Proc** 1997 Mar–Apr; 18(2):69–71 (27 ref.)

Three sudden postoperative respiratory arrests associated with epidural opioids in patients with sleep apnea. Ostermeier AM, et al. **Anesth Analg** 1997 Aug;85(2):452–60 (45 ref.)

Anaesthetic management of patients with sleep apnoea syndrome [published erratum appears in Can J Anaesth 1996 Nov;43(11):1184] Boushra NN. **Can J Anaesth** 1996 Jun;43(6):599–616 (139 ref.)

Aortic root dilatation in Marfan's syndrome: a contribution from obstructive sleep apnea? Cistulli PA, et al. **Chest** 1997 Jun;111(6):1763–6 (16 ref.)

Pulmonary hypertension in the obstructive sleep apnoea syndrome: prevalence, causes and therapeutic consequences. Kessler R, et al. **Eur Respir J** 1996 Apr; 9(4):787–94 (55 ref.)

Is sleep apnea a cause of reversible dementia in old age? [editorial; comment] Bliwise DL. **J Am Geriatr Soc** 1996 Nov;44(11):1407–9 (62 ref.) Comment on: J Am Geriatr Soc 1996 Nov;44(11):1287–94.

Essential and secondary hypertension and sleep–disordered breathing: a unifying hypothesis. Silverberg DS, et al. **J Hum Hypertens** 1996 Jun;10(6):353–63 (207 ref.)

Obstructive sleep apnoea and cardiovascular morbidity. Fletcher EC. **Monaldi Arch Chest Dis** 1996 Feb;51(1):77–80 (30 ref.)

Floppy eyelid syndrome and obstructive sleep apnea. McNab AA. **Ophthal Plast Reconstr Surg** 1997 Jun;13(2):98–114 (45 ref.)

Sleep–induced breathing instability. University of Wisconsin–Madison Sleep and respiration Research Group. Dempsey JA, et al. **Sleep** 1996 Apr;19(3):236–47 (61 ref.)

Arousals and the sleep apnea/hypopnea syndrome. Douglas NJ, et al. **Sleep** 1996 Dec;19(10 Suppl):S196–7 (7 ref.)

Can the treatment of sleep apnea syndrome prevent the cardiovascular consequences? Fletcher EC. **Sleep** 1996 Nov;19(9 Suppl):S67–70 (9 ref.)

Vascular function in OSA. Hedner J. **Sleep** 1996 Dec;19(10 Suppl):S213–7 (27 ref.)

Management of simple snoring, upper airway resistance syndrome, and moderate sleep apnea syndrome. Lévy P, et al. **Sleep** 1996 Nov;19(9 Suppl):S101–10 (80 ref.)

Acute and chronic cardiovascular responses to sleep disordered breathing. Morgan BJ. **Sleep** 1996 Dec;19(10 Suppl):S206–9 (17 ref.)

Critical analysis of the results of surgery in the treatment of snoring, upper airway resistance syndrome (UARS), and obstructive sleep apnea (OSA). Pépin JL, et al. **Sleep** 1996 Nov;19(9 Suppl):S90–100 (92 ref.)

Obesity and weight loss in obstructive sleep apnea: a critical review. Strobel RJ, et al. **Sleep** 1996 Feb;19(2):104–15 (82 ref.)

Diabetes and sleep apnea. Strohl KP. **Sleep** 1996 Dec;19(10 Suppl):S225–8 (29 ref.)

Central sleep apnea. Koenig SM. **Va Med Q** 1996 Fall; 123(4):247–50 (17 ref.)

[Sleep apnea and anesthesia] Lindgren L. **Duodecim** 1995; 111(12):1131–3 (17 ref.) **(Fin)**

[Sleep apnea as a risk factor] Zeitlhofer J, et al. **Acta Med Austriaca** 1995;22(4):64–8 (51 ref.) (Eng. Abstr.) **(Ger)**

[Arterial hypertension and obstructive sleep apnea] Sturm A. **Dtsch Med Wochenschr** 1997 Apr 4;122(14):455–9 (54 ref.) **(Ger)**

[Obstructive sleep apnea syndrome in children with Down's syndrome] Levanon A, et al. **Harefuah** 1996 Sep; 131(5–6):193–6 (23 ref.) **(Heb)**

[Gastro–esophageal reflux, sleep apnea syndrome, and their association] Pillar G, et al. **Harefuah** 1996 Nov 1; 131(9):352–6 (42 ref.) **(Heb)**

[The obstructive sleep apnea syndrome with visceral involvement] Mihăiţan F, et al. **Pneumoftiziologia** 1996 Jul–Dec;45(3–4):169–72 (13 ref.) (Eng. Abstr.) **(Rum)**

DIAGNOSIS

Snoring: analysis, measurement, clinical implications and applications. Dalmasso F, et al. **Eur Respir J** 1996 Jan; 9(1):146–59 (92 ref.)

Clinical diagnosis and assessment of obstructive sleep apnoea syndrome. McNicholas WT. **Monaldi Arch Chest Dis** 1997 Feb;52(1):37–42 (43 ref.)

Obstructive sleep apnea in pregnancy. Lefcourt LA, et al. **Obstet Gynecol Surv** 1996 Aug;51(8):503–6 (14 ref.)

Limitations and promise in the diagnosis and treatment of obstructive sleep apnoea. Aboussouan LS, et al. **Respir Med** 1997 Apr;91(4):181–91 (112 ref.)

Obstructive sleep apnea in children. Marcus CL, et al. **Semin Pediatr Neurol** 1996 Mar;3(1):23–8 (21 ref.)

The diagnosis of sleep apnea: questionnaires and home studies. Flemons WW, et al. **Sleep** 1996 Dec;19(10 Suppl):S243–7 (15 ref.)

Acute and chronic cardiovascular responses to sleep disordered breathing. Morgan BJ. **Sleep** 1996 Dec;19(10 Suppl):S206–9 (17 ref.)

Is it necessary to record sleep? Stradling JR, et al. **Sleep** 1996 Dec;19(10 Suppl):S251–4 (25 ref.)

Complex home monitoring. White DP. **Sleep** 1996 Dec;19(10 Suppl):S248–50 (10 ref.)

[Sleep apnea syndrome. Differential diagnostic reflections from the point of view of sleep medicine] Kraemer S, et al. **Dtsch Med Wochenschr** 1997 Jun 13;122(24):789–93 (11 ref.) **(Ger)**

[Diagnostic methods and standards in sleep medicine] Penzel T, et al. **Internist (Berl)** 1996 May;37(5):442–53 (45 ref.) **(Ger)**

[Differential diagnosis of seizures in sleep] Mayer G, et al. **Pneumologie** 1997 Aug;51 Suppl 3:698–705 (31 ref.) (Eng. Abstr.) **(Ger)**

[Sleep related respiratory disorders] Peter JH. **Pneumologie** 1996 Sep;50 Suppl 2:607–10 (24 ref.) **(Ger)**

DRUG THERAPY

Medroxyprogesterone acetate in the treatment of obstructive sleep apnea. Terra SG, et al. **Ann Pharmacother** 1997 Jun; 31(6):776–8 (15 ref.)

EPIDEMIOLOGY

The epidemiology of sleep apnoea. Davies RJ, et al. **Thorax** 1996 Aug;51 Suppl 2:S65–70 (38 ref.)

[Driving performance and auto accidents in patients with sleep apnea] Findley LJ. **Wien Med Wochenschr** 1996; 146(13–14):335–6 (16 ref.) (Eng. Abstr.) **(Ger)**

[Diagnosis and treatment of sleep apnea syndrome in Japan —comparison with other countries] Kimura H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Dec;33 Suppl:85–9 (89 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Otolaryngologic manifestations of neurofibromatosis in children. Sobol SE, et al. **J Otolaryngol** 1997 Feb;26(1):13–9 (39 ref.)

Sleep–related breathing disturbances: their pathogenesis and potential interest to the nephrologist. Silverberg DS, et al. **Nephrol Dial Transplant** 1997 Apr;12(4):680–3 (37 ref.)

Sleep–related hypoxaemia in chronic obstructive pulmonary disease: causes, consequences and treatment. Weitzenblum E, et al. **Respiration** 1997;64(3):187–93 (42 ref.)

[A case of sleep apnea syndrome due to a nasopharyngeal tumor] Shibata N, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Jan;99(1):6–12 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Disorders of respiration during sleep (editorial)] Pierzchała W, et al. **Pol Merkuriusz Lek** 1996 Jul;1(1):5–7 (30 ref.) **(Pol)**

METABOLISM

Metabolic aspects of sleep apnea. Grunstein RR. **Sleep** 1996 Dec;19(10 Suppl):S218–20 (14 ref.)

PHYSIOPATHOLOGY

Nasal obstruction and obstructive sleep apnea: a review. Kushida CA, et al. **Allergy Asthma Proc** 1997 Mar–Apr; 18(2):69–71 (27 ref.)

Obstructive sleep apnoea: fact not fiction. Battagel JM. **Br J Orthod** 1996 Nov;23(4):315–24 (38 ref.)

Respiratory sleep disorders and high blood pressure. Fletcher EC. **Cardiologia** 1997 May;42(5):469–79 (78 ref.)

The pharyngeal critical pressure. The whys and hows of using nasal continuous positive airway pressure diagnostically. Gold AR, et al. **Chest** 1996 Oct; 110(4):1077–88 (48 ref.)

Pathophysiologic and therapeutic implications of sleep apnea in congestive heart failure. Bradley TD, et al. **J Card Fail** 1996 Sep;2(3):223–40 (150 ref.)

Is sleep apnea a predisposing factor for tobacco use? Schrand JR. **Med Hypotheses** 1996 Dec;47(6):443–8 (37 ref.)

Acute and chronic influences of obstructive sleep apnoea on the pulmonary circulation. Marrone O, et al. **Monaldi Arch Chest Dis** 1997 Jun;52(3):263–7 (42 ref.)

Obstructive sleep apnea and related disorders. Chervin RD, et al. **Neurol Clin** 1996 Aug;14(3):583–609 (145 ref.)

Central sleep apnea. Guilleminault C, et al. **Neurol Clin** 1996 Aug;14(3):611–28 (74 ref.)

Motor control of the pharyngeal musculature and implications for the pathogenesis of obstructive sleep apnea. Horner RL. **Sleep** 1996 Dec;19(10):827–53 (272 ref.)

Sleep fragmentation in obstructive sleep apnea. Kimoff RJ. **Sleep** 1996 Nov;19(9 Suppl):S61–6 (65 ref.)

Respiratory dreams and nightmares. Douglas N. **Thorax** 1996 Sep;51(9):882–6 (30 ref.)

[Propensity for sleep and diurnal somnolence in the course of sleep apnea syndrome] Krieger J, et al. **Neurophysiol Clin** 1996;26(3):131–7 (32 ref.) (Eng. Abstr.) **(Fre)**

[Respiratory disorders during sleep] Teculescu D, et al. **Rev Epidemiol Sante Publique** 1997 Mar;45(1):64–77 (114 ref.) (Eng. Abstr.) **(Fre)**

[Sleep—respiration—hemodynamics] Grote L. **Internist (Berl)** 1996 May;37(5):470–82 (76 ref.) **(Ger)**

[Clinical significance of snoring] Bloch KE. **Schweiz Med Wochenschr** 1997 Feb 1;127(5):170–5 (28 ref.) (Eng. Abstr.) **(Ger)**

[Breathing disorders during sleep: current developments (editorial)] Gugger M. **Schweiz Med Wochenschr** 1997 Feb 8;127(6):204–7 (27 ref.) **(Ger)**

[Sleep apnea syndrome (SAS)] Shiomi T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):457–9 (8 ref.) **(Jpn)**

PREVENTION & CONTROL

[Portable home monitoring system in screening for sleep–disordered breathing] Hida W, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Dec;33 Suppl:46–9 (11 ref.) (Eng. Abstr.) **(Jpn)**

PSYCHOLOGY

Quality of life consequences of sleep–disordered breathing. Flemons WW, et al. **J Allergy Clin Immunol** 1997 Feb; 99(2):S750–6 (76 ref.)

REHABILITATION

Oral appliance therapy for the treatment of obstructive sleep apnea. Fleetham JA, et al. **Sleep** 1996 Dec;19(10 Suppl):S288–90 (5 ref.)

Treatment of obstructive sleep apnea syndrome. A review of surgical approaches. Givens CD Jr, et al. **Va Med Q** 1996 Fall;123(4):266–9 (24 ref.)

[Value of various intra– and extraoral therapeutic procedures for treatment of obstructive sleep apnea and snoring] Schönhofer B, et al. **Med Klin** 1997 Mar 15;92(3):167–74

(35 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Obstructive sleep apnoea: the role of the oral and maxillofacial surgeon. Dimitroulis G. **Aust Dent J** 1997 Feb;42(1):25–9 (26 ref.)

An unusual appearance of velopharyngeal closure in a post–uvulopalatopharyngoplasty patient. Yanagisawa E, et al. **Ear Nose Throat J** 1997 Jan;76(1):14–5 (5 ref.)

Surgical treatment of sleep apnea syndrome. Pillar G, et al. **Isr J Med Sci** 1996 Sep;32(9):710–5 (48 ref.)

Hyoid myotomy and suspension for obstructive sleep apnea syndrome [see comments] Schmitz JP, et al. **J Oral Maxillofac Surg** 1996 Nov;54(11):1339–45 (19 ref.) Comment in: J Oral Maxillofac Surg 1997 Jun;55(6):656.

The efficacy of surgical modifications of the upper airway in adults with obstructive sleep apnea syndrome. Sher AE, et al. **Sleep** 1996 Feb;19(2):156–77 (97 ref.)

[Principles of surgical treatment of obstructive sleep apnea by interventions on the facial bones] Reinert S, et al. **Wien Med Wochenschr** 1996;146(13–14):368–72 (20 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Dentistry's role in obstructive sleep apnoea. Review and case report. Miles PG, et al. **Aust Dent J** 1996 Aug;41(4):248–51 (18 ref.)

The pharyngeal critical pressure. The whys and hows of using nasal continuous positive airway pressure diagnostically. Gold AR, et al. **Chest** 1996 Oct; 110(4):1077–88 (48 ref.)

The unacceptable face of evidence–based medicine [editorial] Stradling JR, et al. **J Eval Clin Pract** 1997 Apr;3(2):99–103 (39 ref.)

Therapy for sleep apnea: who should be treated with CPAP? Chaudhary BA, et al. **J Med Assoc Ga** 1997 Sep;86(3):230–2 (26 ref.)

Obstructive sleep apnea in pregnancy. Lefcourt LA, et al. **Obstet Gynecol Surv** 1996 Aug;51(8):503–6 (14 ref.)

Limitations and promise in the diagnosis and treatment of obstructive sleep apnoea. Aboussouan LS, et al. **Respir Med** 1997 Apr;91(4):181–91 (112 ref.)

Sleep–related hypoxaemia in chronic obstructive pulmonary disease: causes, consequences and treatment. Weitzenblum E, et al. **Respiration** 1997;64(3):187–93 (42 ref.)

Can the treatment of sleep apnea syndrome prevent the cardiovascular consequences? Fletcher EC. **Sleep** 1996 Nov;19(9 Suppl):S67–70 (9 ref.)

How and why should we stabilize the upper airway? Hoffstein V. **Sleep** 1996 Nov;19(9 Suppl):S57–60 (30 ref.)

Evaluation of treatment efficacy in sleep apnea hypopnea syndrome. Sériès F. **Sleep** 1996 Nov;19(9 Suppl):S71–6 (29 ref.)

New approaches to monitoring sleep–related breathing disorders. Stradling JR, et al. **Sleep** 1996 Nov;19(9 Suppl):S77–84 (49 ref.)

[Treatment of obstructive sleep apnea syndrome using a mandibular advancement prosthesis: review of the literature] Lockhart R, et al. **Rev Stomatol Chir Maxillofac** 1996 Dec;97(6):365–73 (56 ref.) (Eng. Abstr.) **(Fre)**

[Concepts of noninvasive ventilation] Becker HF, et al. **Internist (Berl)** 1996 May;37(5):500–10 (82 ref.) **(Ger)**

[Complications of nasal CPAP therapy. Consequences for general practice] Fietze I, et al. **Med Klin** 1996 Dec 15; 91(12):758–65 (67 ref.) (Eng. Abstr.) **(Ger)**

[Current concepts and techniques in home ventilation therapy] Raschke F, et al. **Pneumologie** 1997 Apr;51 Suppl 2:450–5 (18 ref.) (Eng. Abstr.) **(Ger)**

SLEEP DEPRIVATION

PHYSIOLOGY

Effects of sleep deprivation with reference to military operations. Giam GC. **Ann Acad Med Singapore** 1997 Jan; 26(1):88–93 (20 ref.)

Some measures to reduce effects of prolonged sleep deprivation. Lagarde D, et al. **Neurophysiol Clin** 1995; 25(6):376–85 (28 ref.) (Eng. Abstr.)

The impact of inadequate sleep on children's daytime cognitive function. Dahl RE. **Semin Pediatr Neurol** 1996 Mar;3(1):44–50 (50 ref.)

SLEEP–DISORDERED BREATHING see **SLEEP APNEA SYNDROMES**

SLEEP DISORDERS

Sleep disorders in the elderly. Flamer HE. **Aust N Z J Med** 1996 Feb;26(1):96–104 (60 ref.)

Children's nighttime fears. King N, et al. **Clin Psychol Rev** 1997;17(4):431–43 (44 ref.)

Pediatric sleep disorders: a review of the past 10 years. Anders TF, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Jan;36(1):9–20 (46 ref.)

Sleep disorders in the elderly: a primary care perspective. Bliwise DL. **J Med Assoc Ga** 1997 Apr;86(2):115–8 (14 ref.)

Consultation in sleep medicine. Brown LK. **Mt Sinai J Med** 1996 Jan;63(1):24–38 (54 ref.)

Childhood sleep disorders. Ferber R. **Neurol Clin** 1996 Aug; 14(3):493–511 (87 ref.)

Periodic limb movements and restless legs syndrome. Trenkwalder C, et al. **Neurol Clin** 1996 Aug;14(3):629–50 (138 ref.)

Parasomnias in children. Wise MS. **Pediatr Ann** 1997 Jul; 26(7):427–33 (27 ref.)

'My child won't sleep'. Haslam D. **Practitioner** 1995 Dec; 239(1557):730–2 (1 ref.)

[Excessive daytime sleepiness] Petiau C, et al. **Rev Med Interne** 1997;18(3):210–8 (58 ref.) (Eng. Abstr.) **(Fre)**

[Sleep disorders viewed from clinical psychiatry] Ora T. **Seishin Shinkeigaku Zasshi** 1996;98(9):629–41 (20 ref.) **(Jpn)**

CHEMICALLY INDUCED

Drug–induced sleep disturbances. Focus on nonpsychotropic medications. Novak M, et al. **Drug Saf** 1997 Feb; 16(2):133–49 (124 ref.)

CLASSIFICATION

[Parasomnias] Culebras A. **Rev Neurol** 1997 Jan; 25(137):106–10 (3 ref.) **(Spa)**

COMPLICATIONS

Sleep disorders. Overview and relationship to orofacial pain. Bailey DR. **Dent Clin North Am** 1997 Apr;41(2):189–209 (35 ref.)

Sleep disorder related to Parkinson's disease. Partinen M. **J Neurol** 1997 Apr;244(4 Suppl 1):S3–6 (25 ref.)

Periodic limb movements of sleep and the restless legs syndrome. Williams DC. **Va Med Q** 1996 Fall;123(4):260–5 (50 ref.)

DIAGNOSIS

Standards for polysomnography in Canada. The Standards Committees of the Canadian Sleep Society and the Canadian Thoracic Society [see comments] George CF. **Can Med Assoc J** 1996 Dec 15;155(12):1673–8 (10 ref.) Comment in: Can Med Assoc J 1996 Dec 15;155(12):1693–4. Comment in: Can Med Assoc J 1997 May 15;156(10):1379.

Home assessment of sleep disorders by portable monitoring. Broughton R, et al. **J Clin Neurophysiol** 1996 Jul; 13(4):272–84 (75 ref.)

[Poorly understood sleep disorders in depression] Tiberge M. **Encephale** 1995 Dec;21 Spec No 7:29–33 (27 ref.) (Eng. Abstr.) **(Fre)**

[Diagnostic methods and standards in sleep medicine] Penzel T, et al. **Internist (Berl)** 1996 May;37(5):442–53 (45 ref.) **(Ger)**

[Differential diagnostic concepts in sleep medicine and their particular significance for the internist] Peter JH. **Internist (Berl)** 1996 May;37(5):454–62 (33 ref.) **(Ger)**

[Aspects of medical expert assessment of sleep–waking disorders] Mayer G. **Wien Med Wochenschr** 1996; 146(13–14):391–5 (24 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Use of melatonin in the treatment of paediatric sleep disorders. Jan JE, et al. **J Pineal Res** 1996 Nov;21(4):193–9 (61 ref.)

Melatonin: media hype or therapeutic breakthrough? Kendler BS. **Nurse Pract** 1997 Feb;22(2):66–7, 71–2, 77 (75 ref.)

[Use of antidepressants in sleep disorders: practical considerations] Touchon J. **Encephale** 1995 Dec;21 Spec No 7:41–7 (24 ref.) (Eng. Abstr.) **(Fre)**

[Biological models of depression: effect of antidepressants on sleep] Viot–Blanc V. **Encephale** 1995 Dec;21 Spec No 7:35–40 (25 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

[Sleep behavior in the first 3 years of life] Fegert JM, et al. **Prax Kinderpsychol Kinderpsychiatr** 1997 Feb; 46(2):69–91 (50 ref.) (Eng. Abstr.) **(Ger)**

ETHNOLOGY

Sleep in Korea: a developmental perspective. Jeong DU. **Psychiatry Clin Neurosci** 1995 May;49(2):115–7 (5 ref.)

ETIOLOGY

Sleep problems in older adults: putting myths to bed. Ancoli–Israel S. **Geriatrics** 1997 Jan;52(1):20–30 (30 ref.)

Practitioner review: assessment and treatment of sleep disorders in children and adolescents. Stores G. **J Child Psychol Psychiatry** 1996 Nov;37(8):907–25 (100 ref.)

Sleep disorders and aging: understanding the causes. Vitiello MV. **J Gerontol A Biol Sci Med Sci** 1997 Jul;52(4):M189–91 (23 ref.)

Sleep in Korea: a developmental perspective. Jeong DU. **Psychiatry Clin Neurosci** 1995 May;49(2):115–7 (5 ref.)

[Differential diagnosis of seizures in sleep] Mayer G, et al. **Pneumologie** 1997 Aug;51 Suppl 3:698–705 (31 ref.) (Eng. Abstr.) **(Ger)**

[Sleep respiratory disorders in fibromyalgia syndrome] Alvarez Lario B, et al. **Arch Bronconeumol** 1997 Mar; 33(3):143–7 (73 ref.) **(Spa)**

GENETICS

Genetics of narcolepsy and other sleep disorders. Mignot E. **Am J Hum Genet** 1997 Jun;60(6):1289–302 (199 ref.)

PHYSIOPATHOLOGY

Blood pressure rhythms in sleep disorders and dysautonomia. Cortelli P, et al. **Ann N Y Acad Sci** 1996 Aug 15;783:204–21 (122 ref.)

Psychobiology of sleep disturbances in posttraumatic stress disorder. Mellman TA. **Ann N Y Acad Sci** 1997 Jun 21; 821:142–9 (44 ref.)

Circadian rhythm sleep disorders: pathophysiology and treatment. Richardson GS, et al. **J Clin Neurophysiol** 1996 Jan;13(1):17–31 (110 ref.)

Circadian rhythm, sleep, and epilepsy. Shouse MN, et al. **J Clin Neurophysiol** 1996 Jan;13(1):32–50 (200 ref.)

Positron emission tomography studies of sleep and sleep disorders. Maquet P. **J Neurol** 1997 Apr;244(4 Suppl 1):S23–8 (46 ref.)

Restless legs and periodic leg movements in sleep syndromes. Wetter TC, et al. **J Neurol** 1997 Apr;244(4 Suppl 1):S37–45 (104 ref.)

NREM sleep parasomnias. Mahowald MW, et al. **Neurol Clin** 1996 Nov;14(4):675–96 (213 ref.)

REM sleep parasomnias. Schenck CH, et al. **Neurol Clin** 1996 Nov;14(4):697–720 (96 ref.)

Disorders of the circadian sleep–wake cycle. Wagner DR. **Neurol Clin** 1996 Aug;14(3):651–70 (107 ref.)

The sleepwalking/night terrors syndrome in adults. Crisp AH. **Postgrad Med J** 1996 Oct;72(852):599–604 (16 ref.)

The present and the future of sleep research in Asia. Okuma T. **Psychiatry Clin Neurosci** 1995 May;49(2):91–7 (22 ref.)

The impact of inadequate sleep on children's daytime cognitive function. Dahl RE. **Semin Pediatr Neurol** 1996 Mar;3(1):44–50 (50 ref.)

[Increased resistance of the upper respiratory airways during sleep] Tuunainen A, et al. **Duodecim** 1995;111(12):1148–53 (25 ref.) **(Fin)**

[Circadian rhythm in normal and pathological sleep] Billiard M, et al. **Pathol Biol (Paris)** 1996 Jun;44(6):509–17 (23 ref.) (Eng. Abstr.) **(Fre)**

[Sleep—respiration—hemodynamics] Grote L. **Internist (Berl)** 1996 May;37(5):470–82 (76 ref.) **(Ger)**

[Effect of biological rhythm on sleep–wakefulness regulation] Zulley J. **Internist (Berl)** 1996 May;37(5):463–9 (12 ref.) **(Ger)**

[Sleep fragmentation as the cause of daytime sleepiness and reduced performance] Bonnet MH. **Wien Med Wochenschr** 1996;146(13–14):332–4 (14 ref.) (Eng. Abstr.) **(Ger)**

[Chronic obstructive lung disease and sleep] Bishara H. **Harefuah** 1996 Jun 2;130(11):775–7 (41 ref.) **(Heb)**

PREVENTION & CONTROL

Treatment of circadian rhythm disorders—melatonin. Arendt J, et al. **Chronobiol Int** 1997 Mar;14(2):185–204 (74 ref.)

PSYCHOLOGY

Psychobiology of sleep disturbances in posttraumatic stress disorder. Mellman TA. **Ann N Y Acad Sci** 1997 Jun 21; 821:142–9 (44 ref.)

[Sleep disorders in prison] Bourgeois D. **Encephale** 1997 May–Jun;23(3):180–3 (11 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Effects of sleep deprivation with reference to military operations. Giam GC. **Ann Acad Med Singapore** 1997 Jan; 26(1):88–93 (20 ref.)

Behavioral intervention strategies for sleep–activity disruption. Dowling GA. **Int Psychogeriatr** 1996;8 Suppl 1:77–86 (34 ref.)

[Phototherapy of jet lag, night work and sleep disorders] Bjorvatn B, et al. **Tidsskr Nor Laegeforen** 1997 Jun 30; 117(17):2489–92 (33 ref.) (Eng. Abstr.) **(Nor)**

[Phototherapy. An alternative for seasonal affective disorders or sleep disorders] Holsten F, et al. **Tidsskr Nor Laegeforen** 1997 Jun 30;117(17):2484–8 (68 ref.) (Eng. Abstr.) **(Nor)**

SLEEP, REM

Reverse learning and the physiological basis of eye movement desensitization. Hassard A. **Med Hypotheses** 1996 Oct; 47(4):277–82 (45 ref.)

Sleep–related hypoxaemia in chronic obstructive pulmonary disease: causes, consequences and treatment. Weitzenblum E, et al. **Respiration** 1997;64(3):187–93 (42 ref.)

Sleep–induced breathing instability. University of Wisconsin–Madison Sleep and respiration Research Group. Dempsey JA, et al. **Sleep** 1996 Apr;19(3):236–47 (61 ref.)

Autonomic consequences of arousal from sleep: mechanisms and implications. Horner RL. **Sleep** 1996 Dec;19(10 Suppl):S193–5 (10 ref.)

PHYSIOLOGY

Sleep, dreams, and sudden death: the case for sleep as an autonomic stress test for the heart. Verrier RL, et al. **Cardiovasc Res** 1996 Feb;31(2):181–211 (268 ref.)

Cellular basis of pontine ponto–geniculo–occipital wave generation and modulation. Datta S. **Cell Mol Neurobiol**

1997 Jun;17(3):341–65 (172 ref.)
Bilirubin, REM sleep, and phototransduction of environmental time cues. A hypothesis. Oren DA. **Chronobiol Int** 1997 May;14(3):319–29 (75 ref.)
The future of computer-assisted investigation of the polysomnogram: sleep microstructure. Kubicki S, et al. **J Clin Neurophysiol** 1996 Jul;13(4):285–94 (70 ref.)
Evaluation of erectile dysfunction and sleep-related erections [see comments] Moore CA, et al. **J Psychosom Res** 1997 Jun;42(6):531–9 (32 ref.) Comment in: J Psychosom Res 1997 Jun;42(6):515–6.
Cardiovascular disease and sleep-related erections [see comments] Rosen RC, et al. **J Psychosom Res** 1997 Jun; 42(6):517–30 (25 ref.) Comment in: J Psychosom Res 1997 Jun;42(6):515–6.
Prostaglandin D synthase (beta-trace protein): a molecular clock to trace the origin of REM sleep? Sri Kantha S. **Med Hypotheses** 1997 May;48(5):411–2 (21 ref.)
REM sleep parasomnias. Schenck CH, et al. **Neurol Clin** 1996 Nov;14(4):697–720 (96 ref.)
The transition from slow-wave sleep to paradoxical sleep: evolving facts and concepts of the neurophysiological processes underlying the intermediate stage of sleep. Gottesmann C. **Neurosci Biobehav Rev** 1996 Autumn; 20(3):367–87 (167 ref.)
Lucid dreaming and the mind-body relationship: a model for the cognitive and physiological variations in rapid eye movement sleep. Lequerica A. **Percept Mot Skills** 1996 Aug;83(1):331–6 (17 ref.)
Possible involvement of an endogenous benzodiazepine receptor ligand of the inverse agonist type in the regulation of rapid-eye movement (REM) sleep: an hypothesis. Wichlinski LJ. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Jan; 20(1):1–44 (182 ref.)
Effect of ventilatory drive on upper airway patency in humans during NREM sleep. Badr MS. **Respir Physiol** 1996 Jan;103(1):1–10 (33 ref.)
Dreaming as delirium: a mental status analysis of our nightly madness. Hobson JA. **Semin Neurol** 1997 Jun;17(2):121–8 (12 ref.)
Excitatory drive to the respiratory system in REM sleep. Orem J. **Sleep** 1996 Dec;19(10 Suppl):S154–6 (18 ref.)
[Nocturnal penile tumescence] Takanami M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:393–6 (6 ref.) **(Jpn)**

SLEEP STAGES

Anorexia and cachexia, asthenia, and lethargy. Watanabe S, et al. **Hematol Oncol Clin North Am** 1996 Feb;10(1):189–206 (100 ref.)
[Sleep behavior in the first 3 years of life] Fegert JM, et al. **Prax Kinderpsychol Kinderpsychiatr** 1997 Feb; 46(2):69–91 (50 ref.) (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Sedation and performance issues in the treatment of allergic conditions [see comments] Adelsberg BR. **Arch Intern Med** 1997 Mar 10;157(5):494–500 (42 ref.) Comment in: ACP J Club 1997 Jul–Aug;127(1):10.
The link between sleep and depression: the effects of antidepressants on EEG sleep. van Bemmel AL. **J Psychosom Res** 1997 Jun;42(6):555–64 (77 ref.)
[Biological models of depression: effect of antidepressants on sleep] Viot-Blanc V. **Encephale** 1995 Dec;21 Spec No 7:35–40 (25 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Changes in gene expression during the sleep-waking cycle: a new view of activating systems. Tononi G, et al. **Arch Ital Biol** 1995 Dec;134(1):21–37 (121 ref.)

PHYSIOLOGY

Circadian rhythms: basic neurobiology and clinical applications. Moore RY. **Annu Rev Med** 1997;48:253–66 (59 ref.)
Hypothalamic homeothermy across the ultradian sleep cycle. Parmeggiani PL. **Arch Ital Biol** 1995 Dec;134(1):101–7 (25 ref.)
Sleep states, memory processes and synaptic plasticity. Smith C. **Behav Brain Res** 1996 Jun;78(1):49–56 (71 ref.)
Past and future of computer-assisted sleep analysis and drowsiness assessment. Hasan J. **J Clin Neurophysiol** 1996 Jul;13(4):295–313 (190 ref.)
The future of computer-assisted investigation of the polysomnogram: sleep microstructure. Kubicki S, et al. **J Clin Neurophysiol** 1996 Jul;13(4):285–94 (70 ref.)
Neurodegeneration, sleep, and cerebral energy metabolism: a testable hypothesis. Mamelak M. **J Geriatr Psychiatry Neurol** 1997 Jan;10(1):29–32 (42 ref.)
Sleep in women [editorial] Driver HS. **J Psychosom Res** 1996 Mar;40(3):227–30 (21 ref.)
Work hours and sleepiness. Akerstedt T. **Neurophysiol Clin** 1995;25(6):367–75 (68 ref.) (Eng. Abstr.)
Memory, sleep, and dynamic stabilization of neural circuitry: evolutionary perspectives. Kavanau JL. **Neurosci Biobehav Rev** 1996 Summer;20(2):289–311 (236 ref.)
The relationship between sleep and epilepsy in children. Bourgeois B. **Semin Pediatr Neurol** 1996 Mar;3(1):29–35 (40 ref.)
Sleep fragmentation in obstructive sleep apnea. Kimoff RJ. **Sleep** 1996 Nov;19(9 Suppl):S61–6 (65 ref.)
Effect of nocturnal blood pressure measurement on sleep and blood pressure during sleep. Middeke M. **Z Kardiol** 1996; 85 Suppl 3:99–105 (14 ref.)
[Sleep—respiration—hemodynamics] Grote L. **Internist (Berl)** 1996 May;37(5):470–82 (76 ref.) **(Ger)**
[Effect of biological rhythm on sleep-wakefulness regulation] Zulley J. **Internist (Berl)** 1996 May;37(5):463–9 (12 ref.) **(Ger)**
[Sleep fragmentation as the cause of daytime sleepiness and reduced performance] Bonnet MH. **Wien Med Wochenschr** 1996;146(13–14):332–4 (14 ref.) (Eng. Abstr.) **(Ger)**

SLEEP TERROR DISORDER see **SLEEP DISORDERS**

SLEEPWALKING see **SOMNAMBULISM**

SLIM DISEASE see **HIV WASTING SYNDROME**

SLIME BACTERIA see **MYXOCOCCALES**

SLIPPED DISK see **INTERVERTEBRAL DISK DISPLACEMENT**

SLOW ALPHA 2-MACROGLOBULINS see **ALPHA-MACROGLOBULINS**

SLOW REACTING SUBSTANCE OF ANAPHYLAXIS see **SRS-A**

SLOW-REACTING SUBSTANCES see **AUTACOIDS**

SLOW VIRUS DISEASES

see related
PRION DISEASES

VIROLOGY

[Neurotropic viruses—classification, structure and characteristics] Hotta H. **Nippon Rinsho** 1997 Apr; 55(4):777–82 (7 ref.) (Eng. Abstr.) **(Jpn)**

SLUDGE see **SEWAGE**

SLUDGE, BILIARY see **BILE**

SLUMS see **POVERTY AREAS**

SLY SYNDROME see **MUCOPOLYSACCHARIDOSIS VII**

SMALL NUCLEAR RIBONUCLEOPROTEINS see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

SMALL NUCLEAR RIBONUCLEOPROTEINS, U1 see **RIBONUCLEOPROTEINS, SMALL, U1**

SMALL NUCLEAR RIBONUCLEOPROTEINS, U3 see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

SMALL NUCLEAR RIBONUCLEOPROTEINS, U7 see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

SMALL NUCLEAR RNA see **RNA, SMALL NUCLEAR**

SMALL ROUND-STRUCTURED VIRUSES see **NORWALK VIRUS**

SMALLPOX

HISTORY

[Smallpox: an historical review] Theves G. **Bull Soc Sci Med Grand Duche Luxemb** 1997;134(1):31–51 (48 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Moss B. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11341–8 (180 ref.)

PREVENTION & CONTROL

[Smallpox: an historical review] Theves G. **Bull Soc Sci Med Grand Duche Luxemb** 1997;134(1):31–51 (48 ref.) (Eng. Abstr.) **(Ger)**
[Nonparenteral immunization methods against smallpox] Vorob'ev AA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Sep–Oct; (5):117–21 (31 ref.) **(Rus)**

SMALLPOX VACCINE

ADMINISTRATION & DOSAGE

[Nonparenteral immunization methods against smallpox] Vorob'ev AA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Sep–Oct; (5):117–21 (31 ref.) **(Rus)**

HISTORY

[Jenner's cowpox vaccine in light of current vaccinology] Huygelen C. **Verh K Acad Geneeskd Belg** 1996; 58(5):479–536; discussion 537–8 (144 ref.) (Eng. Abstr.) **(Dut)**

SMELL

see related
ANOSMIA
ODORS

Information coding in the vertebrate olfactory system. Buck LB. **Annu Rev Neurosci** 1996;19:517–44 (187 ref.)
Coding mechanisms in insect olfaction. Mustaparta H. **Ciba Found Symp** 1996;200:149–57 (51 ref.)
The role of mosquito olfaction in oviposition site location and in the avoidance of unsuitable hosts. Pickett JA, et al. **Ciba Found Symp** 1996;200:109–19; discussion 119–23, 178–83 (42 ref.)
On the scent of asthma. Kerrigan P. **Practitioner** 1997 Jan; 241(1570):48 (0 ref.)

DRUG EFFECTS

Disturbances of taste and smell induced by drugs. Ackerman BH, et al. **Pharmacotherapy** 1997 May–Jun;17(3):482–96 (126 ref.)

GENETICS

Genetic and molecular studies of olfaction in Drosophila. Hekmat-Scafe DS, et al. **Ciba Found Symp** 1996; 200:285–96; discussion 296–301 (54 ref.)
Olfaction in Drosophila: from odor to behavior. Carlson JR. **Trends Genet** 1996 May;12(5):175–80 (49 ref.)

PHYSIOLOGY

Mechanisms of olfactory discrimination: converging evidence for common principles across phyla. Hildebrand JG, et al. **Annu Rev Neurosci** 1997;20:595–631 (237 ref.)
Olfaction, GABAergic neurotransmission in the olfactory bulb, and intermale aggression in mice: modulation by steroids. Guillot PV, et al. **Behav Genet** 1996 Sep; 26(5):497–504 (65 ref.)
A possible protocognitive role for odor in human infant development. Van Toller S, et al. **Brain Cogn** 1995 Dec; 29(3):275–93 (98 ref.)
Olfactory receptors, vomeronasal receptors, and the organization of olfactory information. Bargmann CI. **Cell** 1997 Aug 22;90(4):585–7 (17 ref.)
Cognitive processes in odorant mixture assessment. Booth DA. **Chem Senses** 1995 Dec;20(6):639–43 (19 ref.)
Biological responsiveness to pheromones provides fundamental and unique insight into olfactory function. Sorensen PW. **Chem Senses** 1996 Apr;21(2):245–56 (86 ref.)
Information coding in the mammalian olfactory system. Buck LB. **Cold Spring Harb Symp Quant Biol** 1996;61:147–55 (57 ref.)
Olfactory recognition and discrimination in Caenorhabditis elegans. Chou JH, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:157–64 (23 ref.)
The molecular biology of olfactory perception. Mombaerts P, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:135–45 (41 ref.)
Genetic approaches to mammalian olfaction. Reed RR. **Cold Spring Harb Symp Quant Biol** 1996;61:165–72 (53 ref.)
Olfactory processing: maps, time and codes. Laurent G. **Curr Opin Neurobiol** 1997 Aug;7(4):547–53 (55 ref.)
Targeting olfaction. Mombaerts P. **Curr Opin Neurobiol** 1996 Aug;6(4):481–6 (25 ref.)
Olfactory mechanisms in Drosophila melanogaster. Smith DP. **Curr Opin Neurobiol** 1996 Aug;6(4):500–5 (52 ref.)
Fetal alcohol syndrome: early olfactory learning as a model system to study neurobehavioral deficits. Kirstein CL, et al. **Int J Neurosci** 1997 Jan;89(1–2):119–32 (128 ref.)
Olfactory recognition memory. Keverne EB, et al. **J Physiol Paris** 1996;90(5–6):399–401 (13 ref.)
Behavioral, neural and cellular components underlying olfactory learning in the honeybee. Menzel R, et al. **J Physiol Paris** 1996;90(5–6):395–8 (36 ref.)
Molecular mechanisms of olfactory processing in the mammalian olfactory epithelium. Hatt H. **ORL J Otorhinolaryngol Relat Spec** 1996 Jul–Aug; 58(4):183–94 (56 ref.)
Molecular basis of signal recognition in olfaction. Breer H. **Pflugers Arch** 1996;431(6 Suppl 2):R311–2 (5 ref.)
Olfaction and brainstem circuits of reproductive behavior in the rat. Shipley MT, et al. **Prog Brain Res** 1996; 107:355–77 (188 ref.)
Neural mechanisms of mammalian olfactory learning. Brennan PA, et al. **Prog Neurobiol** 1997 Mar;51(4):457–81 (160 ref.)
[Clinical olfaction tests] Ishimaru T, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:484–6 (8 ref.) **(Jpn)**
[An olfactory memory formed in the vomeronasal system] Kaba H. **Tanpakushitsu Kakusan Koso** 1996 Nov; 41(14):2077–83 (29 ref.) **(Jpn)**
[Food smell as a problem in trophology] Ugolev DA, et al. **Fiziol Zh Im I M Sechenova** 1996 Mar;82(3):66–73 (33 ref.) **(Rus)**

SMITH-LEMLI-OPITZ SYNDROME

[Smith Lemli-Opitz syndrome] Ieshima A. **Ryoikibetsu Shokogun Shirizu** 1996;(15):302-4 (16 ref.) **(Jpn)**

ENZYMOLOGY

Abnormal cholesterol biosynthesis in sitosterolaemia and the Smith-Lemli-Opitz syndrome. Salen G, et al. **J Inherit Metab Dis** 1996;19(4):391-400 (25 ref.)

METABOLISM

Abnormal cholesterol metabolism in Smith-Lemli-Opitz syndrome. Elias ER, et al. **Curr Opin Pediatr** 1995 Dec; 7(6):710-4 (27 ref.)

Abnormal cholesterol biosynthesis in the Smith-Lemli-Opitz syndrome. Salen G, et al. **J Lipid Res** 1996 Jun; 37(6):1169-80 (64 ref.)

The Smith-Lemli-Opitz syndrome: a potentially fatal birth defect caused by a block in the last enzymatic step in cholesterol biosynthesis. Tint GS, et al. **Subcell Biochem** 1997;28:117-44 (135 ref.)

PATHOLOGY

Cardiovascular malformations in Smith-Lemli-Opitz syndrome. Lin AE, et al. **Am J Med Genet** 1997 Jan 31; 68(3):270-8 (102 ref.)

SMITTIA see **CHIRONOMIDAE**

SMOKE

Aircraft fires, smoke toxicity, and survival. Chaturvedi AK, et al. **Aviat Space Environ Med** 1996 Mar;67(3):275-8 (18 ref.)

ADVERSE EFFECTS

Health and respirable particulate (PM10) air pollution: a causal or statistical association? Gamble JF, et al. **Environ Health Perspect** 1996 Aug;104(8):838-50 (97 ref.)

Situational smoke toxicity testing: hazard assessment as the 'front end' of a smoke toxicity test. Clarke FB, et al. **Toxicology** 1996 Dec 31;115(1-3):179-84 (7 ref.)

Overview of combustion toxicology. Hartzell GE. **Toxicology** 1996 Dec 31;115(1-3):7-23 (70 ref.)

Reactions to particles in smoke. Hill IR. **Toxicology** 1996 Dec 31;115(1-3):119-22 (17 ref.)

Behavioural impairment in smoke environments. Purser D. **Toxicology** 1996 Dec 31;115(1-3):25-40 (17 ref.)

[Alcohol and smoking. The risk factors for the oral cavity] Weinstein RL, et al. **Minerva Stomatol** 1996 Sep; 45(9):405-13 (100 ref.) (Eng. Abstr.) **(Ita)**

SMOKE INHALATION INJURY

Smoke inhalation is a multilevel insult to the pulmonary system. Lentz CW, et al. **Curr Opin Pulm Med** 1997 May; 3(3):221-6 (28 ref.)

Smoke inhalation among firefighters. Bizovi KE, et al. **Occup Med** 1995 Oct-Dec;10(4):721-33 (52 ref.)

Burn injuries in firefighters. Cimino VG, et al. **Occup Med** 1995 Oct-Dec;10(4):707-20 (34 ref.)

ETIOLOGY

Reactions to particles in smoke. Hill IR. **Toxicology** 1996 Dec 31;115(1-3):119-22 (17 ref.)

PHYSIOPATHOLOGY

Pulmonary effects of firefighting. Scannell CH, et al. **Occup Med** 1995 Oct-Dec;10(4):789-801 (42 ref.)

Application of full-scale fire tests to characterize and improve the aircraft postcrash fire environment. Sarkos CP. **Toxicology** 1996 Dec 31;115(1-3):79-87 (16 ref.)

PREVENTION & CONTROL

New research avenues in toxicology: 7-gas N-Gas Model, toxicant suppressants, and genetic toxicology. Levin BC. **Toxicology** 1996 Dec 31;115(1-3):89-106 (41 ref.)

The management of aircraft passenger survival in fire. Trimble EJ. **Toxicology** 1996 Dec 31;115(1-3):41-61 (25 ref.)

THERAPY

Prehospital care of the burned patient. Crawford ME, et al. **Eur J Emerg Med** 1996 Dec;3(4):247-51 (28 ref.)

SMOKELESS TOBACCO see **TOBACCO, SMOKELESS**

SMOKING

see related
TOBACCO SMOKE POLLUTION
TOBACCO USE DISORDER

Smoking cessation in pregnancy. Brown DC. **Can Fam Physician** 1996 Jan;42:102-5 (18 ref.)

Target marketing of tobacco and alcohol-related products to ethnic minority groups in the United States. Moore DJ, et al. **Ethn Dis** 1996 Winter-Spring;6(1-2):83-98 (56 ref.)

Smoking and quality of life in Crohn's disease--as many questions answered as unanswered [comment] Hodgson HJ, et al. **Eur J Gastroenterol Hepatol** 1996 Nov;8(11):1067-9 (19 ref.) Comment on: Eur J Gastroenterol Hepatol 1996 Nov;8(11):1075-81.

Cigarette smoking, plastic surgery, and microsurgery. Chang LD, et al. **J Reconstr Microsurg** 1996 Oct;12(7):467-74 (79 ref.)

The renal risks of smoking. Orth SR, et al. **Kidney Int** 1997 Jun;51(6):1669-77 (154 ref.)

Prostate cancer and smoking: a review of case-control and cohort studies [published erratum appears in Prostate 1996 Dec;29(6):402] Lumey LH. **Prostate** 1996 Oct;29(4):249-60 (71 ref.)

Tobacco and aging: a call for papers for the global coordinated theme issues of 1997 [editorial] Davis RM. **Tob Control** 1996 Winter;5(4):257-8 (18 ref.)

[How I recognize and treat tobacco use in diabetes] Lebeau B. **Journ Annu Diabetol Hotel Dieu** 1997;:229-36 (8 ref.) **(Fre)**

[Smoking. Factors involved in its addiction and maintenance] Casas Anguita J, et al. **Med Clin (Barc)** 1996 Nov 23; 107(18):706-10 (32 ref.) **(Spa)**

ADVERSE EFFECTS

Cigarette smoking and its orthopedic consequences. Kwiatkowski TC, et al. **Am J Orthop** 1996 Sep;25(9):590-7 (112 ref.)

Longitudinal studies of active and passive smoking. Samet JM, et al. **Am J Respir Crit Care Med** 1996 Dec;154(6 Pt 2):S257-65 (77 ref.)

Molecular epidemiology of bladder cancer. Vineis P, et al. **Ann Ist Super Sanita** 1996;32(1):21-7 (39 ref.)

How smoking affects blood pressure. Omvik P. **Blood Press** 1996 Mar;5(2):71-7 (69 ref.)

Smoking and postmenopausal hormone replacement therapy. Jensen J. **Br J Clin Pract Symp Suppl** 1996 Sep;86:6-8 (25 ref.)

Smoking and diseases of the gastrointestinal system: an epidemiological review with special reference to sex differences. Ashley MJ. **Can J Gastroenterol** 1997 May-Jun; 11(4):345-52 (84 ref.)

Childhood brain tumors and exposure to tobacco smoke. Norman MA, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Feb;5(2):85-91 (52 ref.)

Cigarette smoking and coronary heart disease: risks and management. Rigotti NA, et al. **Cardiol Clin** 1996 Feb; 14(1):51-68 (113 ref.)

Basic science of small cell lung cancer. Williams CL. **Chest Surg Clin N Am** 1997 Feb;7(1):1-19 (140 ref.)

Bowen's disease and arsenism from tobacco smoke: an association? Person JR. **Cutis** 1996 Jul;58(1):65-6 (17 ref.)

DNA adducts in human tissues: biomarkers of exposure to carcinogens in tobacco smoke. Phillips DH. **Environ Health Perspect** 1996 May;104 Suppl 3:453-8 (55 ref.)

Cigarette smoke radicals and the role of free radicals in chemical carcinogenicity. Pryor WA. **Environ Health Perspect** 1997 Jun;105 Suppl 4:875-82 (110 ref.)

Haemoglobin adducts of N-nitroso compounds. Richter E. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:115-9 (32 ref.)

Tobacco-specific nitrosamines. Spiegelhalder B, et al. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:33-8 (38 ref.)

Smoking and cancer with emphasis on Italy. Talamini R, et al. **Eur J Cancer Prev** 1996 Oct;5(5):396-7 (9 ref.)

Does cigarette smoking impair natural or assisted fecundity? Hughes EG, et al. **Fertil Steril** 1996 Nov;66(5):679-89 (71 ref.)

Role of oxidants/antioxidants in smoking-induced lung diseases. Rahman I, et al. **Free Radic Biol Med** 1996; 21(5):669-81 (155 ref.)

Chemoprevention of respiratory tract cancer. Khuri FR, et al. **Hematol Oncol Clin North Am** 1997 Jun;11(3):387-408 (72 ref.)

Lung cancer and chronic obstructive pulmonary disease. Petty TL. **Hematol Oncol Clin North Am** 1997 Jun; 11(3):531-41 (19 ref.)

Biomonitoring exposure to environmental tobacco smoke (ETS): a critical reappraisal. Scherer G, et al. **Hum Exp Toxicol** 1997 Aug;16(8):449-59 (119 ref.)

Cancer-related issues for women. Rospond RM. **J Am Pharm Assoc (Wash)** 1996 Nov;NS36(11):655-60 (26 ref.)

The effects of smoking on periodontal structures: a literature review. Bouclin R, et al. **J Can Dent Assoc** 1997 May; 63(5):356, 360-3 (59 ref.)

Tobacco smoking and periodontal diseases. Qandil R, et al. **J Can Dent Assoc** 1997 Mar;63(3):187-92, 194-5 (60 ref.)

The smoking addiction of pregnant women and the consequences on their offspring's intellectual development. Frydman M. **J Environ Pathol Toxicol Oncol** 1996; 15(2-4):169-72 (11 ref.)

Smoking and the digestive system. Kamada T, et al. **J Gastroenterol** 1995 Dec;30(6):803-8 (76 ref.)

Tobacco, colorectal cancer, and adenomas: a review of the evidence. Giovannucci E, et al. **J Natl Cancer Inst** 1996 Dec 4;88(23):1717-30 (118 ref.)

In harm's way: childbearing women and nicotine. Scheibmeir M, et al. **J Obstet Gynecol Neonatal Nurs** 1997 Jul-Aug; 26(4):477-84 (49 ref.)

Response to periodontal therapy in diabetics and smokers. Grossi SG, et al. **J Periodontol** 1996 Oct;67(10 Suppl):1094-102 (60 ref.)

Progress towards a fire-safe cigarette. Brigham PA, et al. **J Public Health Policy** 1995;16(4):433-9 (0 ref.)

Psychosocial and pharmacologic explanations of nicotine's "gateway drug" function. Lindsay GB, et al. **J Sch Health** 1997 Apr;67(4):123-6 (27 ref.)

Cancer, cigarette smoking and premature death in Europe: a review including the Recommendations of European Cancer Experts Consensus Meeting, Helsinki, October 1996. Boyle P. **Lung Cancer** 1997 May;17(1):1-60 (285 ref.)

Aspects of the epidemiology of lung cancer in smokers and nonsmokers in the United States. Kabat GC. **Lung Cancer** 1996 Aug;15(1):1-20 (55 ref.)

Fish oil may be an antidote for the cardiovascular risk of smoking. McCarty MF. **Med Hypotheses** 1996 Apr; 46(4):337-47 (166 ref.)

Smoking and diabetes mellitus [see comments] Dierkx RI, et al. **Neth J Med** 1996 Apr;48(4):150-62 (108 ref.) Comment in: Neth J Med 1996 Apr;48(4):125-7.

Smoking and the human vertebral column: a review of the impact of cigarette use on vertebral bone metabolism and spinal fusion. Hadley MN, et al. **Neurosurgery** 1997 Jul; 41(1):116-24 (138 ref.)

Beta-carotene increases lung cancer incidence in cigarette smokers. De Luca LM, et al. **Nutr Rev** 1996 Jun; 54(6):178-80 (17 ref.)

Sudden infant death syndrome and parental smoking--a literature review. Golding J. **Paediatr Perinat Epidemiol** 1997 Jan;11(1):67-77 (29 ref.)

The additive effects of smoking and hypertension. More reasons to help your patients kick the habit. Kochar MS, et al. **Postgrad Med** 1996 Nov;100(5):147-8, 151-4, 159-60 (13 ref.)

Is screening for chronic obstructive pulmonary disease justified? Badgett RG, et al. **Prev Med** 1997 Jul-Aug; 26(4):466-72 (86 ref.)

The role of nicotine in smoking-related cardiovascular disease. Benowitz NL. **Prev Med** 1997 Jul-Aug;26(4):412-7 (45 ref.)

The changing cigarette. Hoffmann D, et al. **Prev Med** 1997 Jul-Aug;26(4):427-34 (57 ref.)

Molecular epidemiology of breast cancer. Ambrosone CB, et al. **Prog Clin Biol Res** 1997;396:83-99 (100 ref.)

Differences between studies in reported relative risks associated with smoking: an overview. van de Mheen PJ, et al. **Public Health Rep** 1996 Sep-Oct;111(5):420-6; discussion 427 (40 ref.)

Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literature. Dalack GW, et al. **Schizophr Res** 1996 Nov 15;22(2):133-41 (45 ref.)

Prevention of lung cancer: the key is to stop smoking. Risser NL. **Semin Oncol Nurs** 1996 Nov;12(4):260-9 (69 ref.)

Biology of lung cancer. Works CR, et al. **Semin Oncol Nurs** 1996 Nov;12(4):276-84 (90 ref.)

The association of cigarette smoking with placenta previa and abruptio placentae. Andres RL. **Semin Perinatol** 1996 Apr;20(2):154-9 (43 ref.)

The maternal and fetal physiologic effects of nicotine. Lambers DS, et al. **Semin Perinatol** 1996 Apr;20(2):115-26 (47 ref.)

The effects of smoking on exercise performance. Huie MJ. **Sports Med** 1996 Dec;22(6):355-9 (34 ref.)

Teratogen update: smoking and reproductive outcomes. Werler MM. **Teratology** 1997 Jun;55(6):382-8 (101 ref.)

Carcinoma of the lung after heart transplantation. Goldstein DJ, et al. **Transplantation** 1996 Sep 27;62(6):772-5 (18 ref.)

African-American smokers and cancers of the lung and of the upper respiratory and digestive tracts. Is menthol part of the puzzle? Richardson TL. **West J Med** 1997 Mar; 166(3):189-94 (44 ref.)

Passive smoking, platelet function and atherosclerosis. Kritz H, et al. **Wien Klin Wochenschr** 1996;108(18):582-8 (50 ref.)

["Active" and "passive" smoking of pregnant women and risks to the child] Kaminski M. **Bull Acad Natl Med** 1997 Apr; 181(4):754-63 (52 ref.) **(Fre)**

[The skin of tobacco smokers] Rahier S, et al. **Rev Med Liege** 1996 Sep;51(9):582-85 (33 ref.) **(Fre)**

[Nicotine and worsening myasthenia] Moreau T, et al. **Rev Neurol (Paris)** 1997 Mar;153(2):141-3 (10 ref.) (Eng. Abstr.) **(Fre)**

[Smoking and the periodontium (I). History and clinical aspects. A review of the literature] Brochut PF, et al. **Schweiz Monatsschr Zahnmed** 1997;107(8):672-86 (89 ref.) **(Fre, Ger)**

[Molecular biology of tobacco smoke associated neoplasia] Zojer N, et al. **Wien Klin Wochenschr** 1996;108(18):574-81 (79 ref.) (Eng. Abstr.) **(Ger)**

[Pathophysioiogy of the harmful influence of smoking on the course of gastric and duodenal ulcer diseases] Budzyński J, et al. **Przegl Lek** 1996;53(11):811-5 (26 ref.) (Eng. Abstr.) **(Pol)**

[Smoking and inflammatory bowel disease: an epidemiological case-control study] Martins Júnior EV, et al. **Arq Gastroenterol** 1996 Apr-Jun;33(2):74-8 (49 ref.) (Eng. Abstr.) **(Por)**

[The effect of smoking on the general somatic and stomatological status of the population] Alimskii AV, et al. **Stomatologiia (Mosk)** 1996;75(2):70-9 (168 ref.) **(Rus)**

BLOOD

Cigarettes and the wages of sn-2: oxidized species of PAF in smoking hamsters [editorial; comment] FitzGerald GA.

SMOKING

J Clin Invest 1997 May 15;99(10):2300–1 (10 ref.) Comment on: J Clin Invest 1997 May 15;99(10):2358–64.

EPIDEMIOLOGY

Consensus conference: smoking and prostate cancer. Colditz G. **Cancer Causes Control** 1996 Sep;7(5):560–2 (7 ref.)

Smoking among adolescent girls: prevalence and etiology. French SA, et al. **J Am Med Womens Assoc** 1996 Jan–Apr; 51(1–2):25–8 (35 ref.)

Cigarette smoking and its comorbidity. Glassman AH. **NIDA Res Monogr** 1997;172:52–60 (22 ref.)

ETHNOLOGY

Cardiovascular implications of smoking: the surgeon general's point of view. Manley AF. **J Health Care Poor Underserved** 1997 Aug;8(3):303–10 (15 ref.)

GENETICS

[Genetic polymorphisms of drug–metabolizing enzymes and susceptibility to lung cancer--relevance to smoking] Uematsu F. **Nippon Rinsho** 1996 Feb;54(2):513–7 (27 ref.) (Eng. Abstr.) **(Jpn)**

HISTORY

[Smoking and the periodontium (I). History and clinical aspects. A review of the literature] Brochut PF, et al. **Schweiz Monatsschr Zahnmed** 1997;107(8):672–86 (89 ref.) **(Fre, Ger)**

IMMUNOLOGY

Smoking and immunity: an additional player in the mosaic of autoimmunity. George J, et al. **Scand J Immunol** 1997 Jan;45(1):1–6 (51 ref.)

LEGISLATION & JURISPRUDENCE

Public policy: effective treatment for tobacco disease. Scheg KE. **J Am Med Womens Assoc** 1996 Jan–Apr;51(1–2):52–6; 69 (61 ref.)

Breaking through the tobacco industry's smoke screen: state lawsuits for reimbursement of medical expenses. Meade KE. **J Leg Med** 1996 Mar;17(1):113–41 (311 ref.)

METABOLISM

Smoking, alcohol and lipoprotein metabolism. Porkka KV, et al. **Curr Opin Lipidol** 1996 Jun;7(3):162–6 (47 ref.)

MORTALITY

Mortality from tobacco in developed countries: are indirect estimates reliable? Lee PN. **Regul Toxicol Pharmacol** 1996 Aug;24(1 Pt 1):60–8 (25 ref.)

PHYSIOPATHOLOGY

Smoking and male reproduction: a review. Vine MF. **Int J Androl** 1996 Dec;19(6):323–37 (110 ref.)

Is sleep apnea a predisposing factor for tobacco use? Schrand JR. **Med Hypotheses** 1996 Dec;47(6):443–8 (37 ref.)

The role of cigarettes and nicotine in the onset and treatment of ulcerative colitis. Birtwistle J. **Postgrad Med J** 1996 Dec; 72(854):714–8 (58 ref.)

Stress, hormonal changes, alcohol, food constituents and drugs: factors that advance the incidence of tobacco smoke–related cancer? Maser E. **Trends Pharmacol Sci** 1997 Aug;18(8):270–5 (95 ref.)

PREVENTION & CONTROL

Children and tobacco: the FDA's final rule. Rheinstein PH, et al. **Am Fam Physician** 1997 Mar;55(4):1441–4 (12 ref.)

European Cancer Experts recommendations for tobacco control. Helsinki Tobacco Consensus Conference. Boyle P. **Ann Oncol** 1997 Jan;8(1):9–13 (18 ref.)

Smoking cessation. 2: Components of effective intervention. Tsoh JY, et al. **Behav Med** 1997 Spring;23(1):15–27 (66 ref.)

Reducing the harm of adolescent substance use [editorial; comment] Erickson PG. **Can Med Assoc J** 1997 May 15; 156(10):1397–9 (15 ref.) Comment on: Can Med Assoc J 1997 May 15;156(10):1387–93.

The role of the pediatrician in smoking prevention. Sockrider MM. **Curr Opin Pediatr** 1997 Jun;9(3):225–9 (39 ref.)

Social patterns of smoking behavior: trends and practice implications. Kaplan MS, et al. **Health Soc Work** 1997 Feb; 22(1):47–52 (60 ref.)

Tobacco control: a brief review of its history and prospects for the future. Emmons KM, et al. **Hematol Oncol Clin North Am** 1997 Apr;11(2):177–95 (103 ref.)

How clinicians can affect patient smoking behavior through community involvement and clinical practice. Epps RP, et al. **J Am Med Womens Assoc** 1996 Jan–Apr;51(1–2):43–7 (8 ref.)

Public policy: effective treatment for tobacco disease. Scheg KE. **J Am Med Womens Assoc** 1996 Jan–Apr;51(1–2):52–6; 69 (61 ref.)

Tobacco use among pediatric cancer patients: recommendations for developing clinical smoking interventions [see comments] Tyc VL, et al. **J Clin Oncol** 1997 Jun;15(6):2194–204 (81 ref.) Comment in: J Clin Oncol 1997 Jun;15(6):2181–2.

Cardiovascular implications of smoking: the surgeon general's point of view. Manley AF. **J Health Care Poor Underserved** 1997 Aug;8(3):303–10 (15 ref.)

A smoking cessation plan for pregnant women. Kilby JW. **J Obstet Gynecol Neonatal Nurs** 1997 Jul–Aug; 26(4):397–402 (25 ref.)

In harm's way: childbearing women and nicotine. Scheibmeir M, et al. **J Obstet Gynecol Neonatal Nurs** 1997 Jul–Aug; 26(4):477–84 (49 ref.)

The National Women's Tobacco Control Plan. McLellan DL, et al. **J Public Health Policy** 1996;17(1):47–58 (02 ref.)

Power of one: nurses and tobacco control. Gallagher J, et al. **Semin Oncol Nurs** 1996 Nov;12(4):270–5 (14 ref.)

Prevention of lung cancer: the key is to stop smoking. Risser NL. **Semin Oncol Nurs** 1996 Nov;12(4):260–9 (69 ref.)

PSYCHOLOGY

Co–factors for smoking and evolutionary psychobiology. Pomerleau CS. **Addiction** 1997 Apr;92(4):397–408 (115 ref.)

Helping your patients to quit smoking. Danis PG, et al. **Am Fam Physician** 1997 Mar;55(4):1207–14, 1217–8 (35 ref.)

Smoking and attention: a review and reformulation of the stimulus–filter hypothesis. Kassel JD. **Clin Psychol Rev** 1997;17(5):451–78 (200 ref.)

The effect of a reduced energy diet and meal patterns on smoking and coffee drinking in women. Lawson RH, et al. **Int J Eat Disord** 1997 Mar;21(2):137–45 (36 ref.)

The smoking addiction of pregnant women and the consequences on their offspring's intellectual development. Frydman M. **J Environ Pathol Toxicol Oncol** 1996; 15(2–4):169–72 (11 ref.)

Subliminal manipulation of smoking. Frydman M. **J Environ Pathol Toxicol Oncol** 1996;15(2–4):173–6 (8 ref.)

Smoking and vulnerability for schizophrenia. de Leon J. **Schizophr Bull** 1996;22(3):405–9 (19 ref.)

TRENDS

Women and smoking: an update for the 1990s. Kendrick JS, et al. **Am J Obstet Gynecol** 1996 Sep;175(3 Pt 1):528–35 (62 ref.)

The changing cigarette, 1950–1995. Hoffmann D, et al. **J Toxicol Environ Health** 1997 Mar;50(4):307–64 (176 ref.)

Changing smoking patterns and mortality from chronic obstructive pulmonary disease. Wise RA. **Prev Med** 1997 Jul–Aug;26(4):418–21 (23 ref.)

SMOKING CESSATION

Tobacco cessation interventions in health care settings: rationale, model, outcomes. Lichtenstein E, et al. **Addict Behav** 1996 Nov–Dec;21(6):709–20 (45 ref.)

Smoking cessation. 1: An overview of research. Skaar KL, et al. **Behav Med** 1997 Spring;23(1):5–13 (55 ref.)

Smoking cessation. 2: Components of effective intervention. Tsoh JY, et al. **Behav Med** 1997 Spring;23(1):15–27 (66 ref.)

Cigarette smoking and coronary heart disease: risks and management. Rigotti NA, et al. **Cardiol Clin** 1996 Feb; 14(1):51–68 (113 ref.)

Current approaches in smoking cessation. Skaar K, et al. **Curr Opin Oncol** 1996 Sep;8(5):434–40 (19 ref.)

Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. Benowitz NL, et al. **J Am Coll Cardiol** 1997 Jun;29(7):1422–31 (123 ref.)

Smoking cessation and gender: the influence of physiological, psychological, and behavioral factors. Gritz ER, et al. **J Am Med Womens Assoc** 1996 Jan–Apr;51(1–2):35–42 (86 ref.)

A pathophysiological basis for informed preoperative smoking cessation counseling. Akrawi W, et al. **J Cardiothorac Vasc Anesth** 1997 Aug;11(5):629–40 (161 ref.)

Smoking cessation. Schlede CM. **J Fla Med Assoc** 1996 Feb; 83(2):108–12 (30 ref.)

Tobacco addiction and hypertension. Pipe A. **J Hum Hypertens** 1996 Feb;10 Suppl 2:S13–6 (24 ref.)

Measuring tobacco withdrawal: a review of self–report questionnaires. Patten CA, et al. **J Subst Abuse** 1996; 8(1):93–113 (75 ref.)

Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Balfour DJ, et al. **Pharmacol Ther** 1996;72(1):51–81 (289 ref.)

ECONOMICS

The economics of smoking cessation [comment] Haxby DG, et al. **Am J Health Syst Pharm** 1996 Jan 1;53(1):77–9 (13 ref.) Comment on: Am J Health Syst Pharm 1996 Jan 1;53(1):45–52.

METHODS

Current issues in behavioral and pharmacological approaches to smoking cessation. Hajek P. **Addict Behav** 1996 Nov–Dec;21(6):699–707 (40 ref.)

Retracing the steps of Marco Polo: from clinical trials to diffusion of interventions for smokers. Richmond RL. **Addict Behav** 1996 Nov–Dec;21(6):683–97 (65 ref.)

The future of smoking cessation therapy in the United States. Hughes JR. **Addiction** 1996 Dec;91(12):1797–802 (66 ref.)

Helping your patients to quit smoking. Danis PG, et al. **Am Fam Physician** 1997 Mar;55(4):1207–14, 1217–8 (35 ref.)

The role of the dental team in the promotion of smoking cessation. Newton JT, et al. **Br Dent J** 1997 May 10; 182(9):353–5 (17 ref.)

Smoking cessation in pregnancy. Brown DC. **Can Fam Physician** 1996 Jan;42:102–5 (18 ref.)

Pharmacologic management of patients using smoking cessation aids. Ostrowski DJ, et al. **Dent Clin North Am** 1996 Jul;40(3):779–801 (68 ref.)

The benefits of stopping smoking and the role of nicotine replacement therapy in older patients. Gourlay SG, et al. **Drugs Aging** 1996 Jul;9(1):8–23 (125 ref.)

Smoking cessation: a four–step plan to help older patients quit. Boyd NR. **Geriatrics** 1996 Nov;51(11):52–7; quiz 58 (21 ref.)

Smoking cessation techniques. Lando HA, et al. **J Am Med Womens Assoc** 1996 Jan–Apr;51(1–2):31–4, 47 (46 ref.)

A smoking cessation plan for pregnant women. Kilby JW. **J Obstet Gynecol Neonatal Nurs** 1997 Jul–Aug; 26(4):397–402 (25 ref.)

In harm's way: childbearing women and nicotine. Scheibmeir M, et al. **J Obstet Gynecol Neonatal Nurs** 1997 Jul–Aug; 26(4):477–84 (49 ref.)

PSYCHOLOGY

The impact of depression on smoking cessation in women. Borrelli B, et al. **Am J Prev Med** 1996 Sep–Oct;12(5):378–87 (121 ref.)

Can psychiatric and chemical dependency treatment units be smoke free? Patten CA, et al. **J Subst Abuse Treat** 1996 Mar–Apr;13(2):107–18 (77 ref.)

Addressing women's concerns about weight gain due to smoking cessation. Perkins KA, et al. **J Subst Abuse Treat** 1997 Mar–Apr;14(2):173–82 (65 ref.)

Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literature. Dalack GW, et al. **Schizophr Res** 1996 Nov 15;22(2):133–41 (45 ref.)

SMOKING, PASSIVE see **TOBACCO SMOKE POLLUTION**

SMOOTH MUSCLE TUMOR

PATHOLOGY

Primary smooth muscle tumors of the thyroid gland. Thompson LD, et al. **Cancer** 1997 Feb 1;79(3):579–87 (60 ref.)

SMS 201–995 see **OCTREOTIDE**

SNAIL VENOMS see **MOLLUSK VENOMS**

SNAILS

IMMUNOLOGY

[Fluke invasion and the immune system of the snail] Kofta W. **Wiad Parazytol** 1997;43(1):27–38 (40 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

The dolastatins. Pettit GR. **Fortschr Chem Org Naturst** 1997; 70:1–79 (175 ref.)

PARASITOLOGY

Parasitic effects on host life–history traits: a review of recent studies. Michalakis Y, et al. **Parasite** 1994 Dec;1(4):291–4 (20 ref.)

[Fluke invasion and the immune system of the snail] Kofta W. **Wiad Parazytol** 1997;43(1):27–38 (40 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Studying the snail's clock at better than a snail's pace. Block GD. **Braz J Med Biol Res** 1996 Jan;29(1):71–5 (26 ref.)

Modulation of in vivo neuronal sprouting by serotonin in the adult CNS of the snail. Baker MW, et al. **Cell Mol Neurobiol** 1996 Oct;16(5):561–76 (50 ref.)

SNAKE BITES

see related
ANTIVENINS

[Envenomation by exotic snakes] Aubert M, et al. **Med Trop (Mars)** 1996;56(4):384–92 (10 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Incidence, pathology, and treatment of adder (Vipera berus L.) bites in man. Reading CJ. **J Accid Emerg Med** 1996 Sep;13(5):346–51 (32 ref.)

ETIOLOGY

A case of local tissue necrosis following a bite by the Australian tiger snake Notechis scutatus. Penington A, et al. **Aust N Z J Surg** 1997 Jun;67(6):385–8 (20 ref.)

PATHOLOGY

The Gaboon viper, Bitis gabonica: hemorrhagic, metabolic, cardiovascular and clinical effects of the venom. Marsh N, et al. **Life Sci** 1997;61(8):763–9 (35 ref.)

SURGERY

A case of local tissue necrosis following a bite by the Australian tiger snake Notechis scutatus. Penington A, et al. **Aust N Z J Surg** 1997 Jun;67(6):385–8 (20 ref.)

THERAPY

Management of snake and spider bite in pregnancy. Pantanowitz L, et al. **Obstet Gynecol Surv** 1996 Oct; 51(10):615–20 (48 ref.)

Snakebite by the bushmaster (Lachesis muta) in Brazil: case report and review of the literature. Jorge MT, et al. **Toxicon** 1997 Apr;35(4):545–54 (33 ref.)

[Antivenom serum doses in the treatment of poisoning by a venomous snake of the genus Bothrops] Jorge MT, et al. **Rev Assoc Med Bras** 1997 Jan–Mar;43(1):74–6 (18 ref.) **(Por)**

SNAKE ENVENOMATION see **SNAKE BITES**

SNAKE VENOMS

see related
ANTIVENINS

CHEMISTRY

Overview of snake venom chemistry. Tu AT. **Adv Exp Med Biol** 1996;391:37–62 (97 ref.)

ENZYMOLOGY

[Acetylcholinesterase from snake venoms] Cousin X, et al. **C R Seances Soc Biol Fil** 1997;191(3):381–400 (78 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Nerve growth factors from snake venoms: chemical properties, mode of action and biological significance. Kostiza T, et al. **Toxicon** 1996 Jul;34(7):787–806 (75 ref.)

PHARMACOLOGY

Snake venom proteins modulating the interaction between von Willebrand factor and platelet glycoprotein Ib. Fujimura Y, et al. **Thromb Haemost** 1996 Nov;76(5):633–9 (62 ref.)

Snake venom, fertilization and neurogenesis. Yedvobnick B. **Trends Neurosci** 1996 Dec;19(12):528–30 (17 ref.)

POISONING

[Renal dysfunction caused by animal poisons (snake venoms, bite and punctured poisoning)] Suda M, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):571–3 (16 ref.) **(Jpn)**

THERAPEUTIC USE

Ancrod: the use of snake venom in the treatment of patients with heparin-induced thrombocytopenia and thrombosis undergoing coronary artery bypass grafting: nursing management. Lathan LO, et al. **Heart Lung** 1996 Nov–Dec; 25(6):451–60; quiz 461–2 (27 ref.)

SNAKES

see related
SNAKE BITES
SNAKE VENOMS

CLASSIFICATION

Reviews of venomous snake systematics in Toxicon [letter; comment] Wüster W, et al. **Toxicon** 1996 Apr;34(4):397–8 (1 ref.) Comment on: Toxicon 1996 Apr;34(4):399–406.

Synopsis of recent developments in venomous snake systematics. Wüster W, et al. **Toxicon** 1997 Mar; 35(3):319–40 (103 ref.)

SNEDDON-CHAMPION SYNDROME see **SNEDDON SYNDROME**

SNEDDON SYNDROME

DIAGNOSIS

Sneddon's syndrome (livedo racemosa and cerebral infarction) presenting psychiatric disturbance and shortening of fingers and toes. Kume M, et al. **Intern Med** 1996 Aug;35(8):668–73 (15 ref.)

SNEDDON-WILKINSON DISEASE see **SKIN DISEASES, VESICULOBULLOUS**

SNORING

COMPLICATIONS

Is snoring dangerous to your health? Hoffstein V. **Sleep** 1996 Jul;19(6):506–16 (34 ref.)

Management of simple snoring, upper airway resistance syndrome, and moderate sleep apnea syndrome. Lévy P, et al. **Sleep** 1996 Nov;19(9 Suppl):S101–10 (80 ref.)

PHYSIOPATHOLOGY

Snoring: analysis, measurement, clinical implications and applications. Dalmasso F, et al. **Eur Respir J** 1996 Jan; 9(1):146–59 (92 ref.)

[Respiratory disorders during sleep] Teculescu D, et al. **Rev Epidemiol Sante Publique** 1997 Mar;45(1):64–77 (114 ref.) (Eng. Abstr.) **(Fre)**

[Clinical significance of snoring] Bloch KE. **Schweiz Med Wochenschr** 1997 Feb 1;127(5):170–5 (28 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

[Value of various intra- and extraoral therapeutic procedures for treatment of obstructive sleep apnea and snoring] Schönhofer B, et al. **Med Klin** 1997 Mar 15;92(3):167–74 (35 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

Management of simple snoring, upper airway resistance syndrome, and moderate sleep apnea syndrome. Lévy P, et al. **Sleep** 1996 Nov;19(9 Suppl):S101–10 (80 ref.)

SURGERY

The surgical treatment of snoring [see comments] Harries PG, et al. **J Laryngol Otol** 1996 Dec;110(12):1103–4 (9 ref.) Comment in: J Laryngol Otol 1997 Jun;111(6):598.

Critical analysis of the results of surgery in the treatment of snoring, upper airway resistance syndrome (UARS), and obstructive sleep apnea (OSA). Pépin JL, et al. **Sleep** 1996 Nov;19(9 Suppl):S90–100 (92 ref.)

SNRNP see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

U1 SNRNP see **RIBONUCLEOPROTEINS, SMALL, U1**

U3 SNRNP see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

U7 SNRNP see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

SNUFF see **TOBACCO, SMOKELESS**

SOAPS

ADMINISTRATION & DOSAGE

Mineral waters: instead of soap or better than soap? Lotti TM, et al. **Clin Dermatol** 1996 Jan–Feb;14(1):101–4 (28 ref.)

THERAPEUTIC USE

Poison ivy/oak dermatitis. Part I: Prevention—soap and water, topical barriers, hyposensitization. Fisher AA. **Cutis** 1996 Jun;57(6):384–6 (13 ref.)

SOCCER

INJURIES

Closed complete rupture of the flexor hallucis longus tendon at the groove of the talus. Inokuchi S, et al. **Foot Ankle Int** 1997 Jan;18(1):47–9 (10 ref.)

Football injuries: tackling the damage. Crisp T. **Practitioner** 1995 Dec;239(1557):703–9 (3 ref.)

Escherichia vulneris in a Danish soccer wound. Jepsen CF, et al. **Scand J Infect Dis** 1997;29(3):313–4 (6 ref.)

Soccer injuries. II: Aetiology and prevention. Inklaar H. **Sports Med** 1994 Aug;18(2):81–93 (83 ref.)

Common soccer injuries. Diagnosis, treatment and rehabilitation. Tucker AM. **Sports Med** 1997 Jan; 23(1):21–32 (41 ref.)

PSYCHOLOGY

Dynamic-system analysis of opponent relationships in collective actions in soccer. Gréhaigne JF, et al. **J Sports Sci** 1997 Apr;15(2):137–49 (26 ref.)

STANDARDS

Dynamic-system analysis of opponent relationships in collective actions in soccer. Gréhaigne JF, et al. **J Sports Sci** 1997 Apr;15(2):137–49 (26 ref.)

SOCIAL ACCOUNTABILITY see **SOCIAL RESPONSIBILITY**

SOCIAL ADJUSTMENT

Psychosocial problem assessment and end-stage renal disease patient outcomes. Vourlekis BS, et al. **Adv Ren Replace Ther** 1997 Apr;4(2):136–44 (18 ref.)

Empowerment theory, research, and application. Perkins DD, et al. **Am J Community Psychol** 1995 Oct;23(5):569–79 (14 ref.)

Resilience in highly stressed urban children: concepts and findings. Cowen EL, et al. **Bull N Y Acad Med** 1996 Winter; 73(2):267–84 (46 ref.)

Widening perspectives: quality of life as a measure of outcome in the treatment of patients with cancers of the head and neck. Morris J. **Eur J Cancer B Oral Oncol** 1994 Jan;30B(1):29–31 (19 ref.)

Long-term effects of early childhood programs on social outcomes and delinquency. Yoshikawa H. **Future Child** 1995 Winter;5(3):51–75 (83 ref.)

The biopsychosocial disease consequence model in rehabilitation: model development in the Finnish 'work hardening' programme for chronic pain. Talo S, et al. **Int J Rehabil Res** 1996 Jun;19(2):93–109 (35 ref.)

Lesbian coming out as a multidimensional process. Morris JF. **J Homosex** 1997;33(2):1–22 (42 ref.)

Social and educational resources for patients with Tourette syndrome. Packer LE. **Neurol Clin** 1997 May;15(2):457–73 (51 ref.)

Assessing clinical outcomes: the community functioning of persons with serious mental illness. Dickerson FB. **Psychiatr Serv** 1997 Jul;48(7):897–902 (51 ref.)

[Psychosocial adjustment of unipolar and bipolar patients] Escande M, et al. **Encephale** 1995 Dec;21 Spec No 4:55–9 (29 ref.) **(Fre)**

[Psychosocial aspects of ENT tumor surgery (excluding laryngectomy). 2: Analysis of empirical studies (see comments)] Kollbrunner J, et al. **HNO** 1997 Jun; 45(6):433–41 (0 ref.) (Eng. Abstr.) Comment in: HNO 1997 Jun;45(6):424. **(Ger)**

SOCIAL ALIENATION

Public mental health. II: The psychological dimension. Curle A. **Med Confl Surviv** 1997 Jan–Mar;13(1):26–36 (3 ref.)

SOCIAL BEHAVIOR

Reducing HIV incidence in developing countries with structural and environmental interventions. Sweat MD, et al. **AIDS** 1995;9 Suppl A:S251–7 (55 ref.)

Psychological empowerment: issues and illustrations. Zimmerman MA. **Am J Community Psychol** 1995 Oct; 23(5):581–99 (51 ref.)

A neurobiological basis of social attachment. Insel TR. **Am J Psychiatry** 1997 Jun;154(6):726–35 (84 ref.)

Specific neuroendocrine mechanisms not involving generalized stress mediate social regulation of female reproduction in cooperatively breeding marmoset monkeys. Abbott DH, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:219–38 (106 ref.)

Integrative functions of lactational hormones in social behavior and stress management. Carter CS, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:164–74 (78 ref.)

Species diversity and the evolution of behavioral controlling mechanisms. Crews D. **Ann N Y Acad Sci** 1997 Jan 15; 807:1–21 (64 ref.)

Brain sexual dimorphism and sex differences in parental and other social behaviors. De Vries GJ, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:273–86 (89 ref.)

Conflict resolution and distress alleviation in monkeys and apes. de Wall FB, et al. **Ann N Y Acad Sci** 1997 Jan 15; 807:317–28 (57 ref.)

Evolutionary perspectives on primate mating systems and behavior. Dixson AF. **Ann N Y Acad Sci** 1997 Jan 15; 807:42–61 (102 ref.)

Social behavior in autism. Grossman JB, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:440–54 (120 ref.)

Molecular aspects of monogamy. Insel TR, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:302–16 (44 ref.)

Affiliation and neuropsychiatric disorders: the deficit syndrome of schizophrenia. Kirkpatrick B. **Ann N Y Acad Sci** 1997 Jan 15;807:455–68 (69 ref.)

Psychobiology of early social attachment in rhesus monkeys. Clinical implications. Kraemer GW. **Ann N Y Acad Sci** 1997 Jan 15;807:401–18 (34 ref.)

Psychobiological consequences of social relationships. Levine S, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:210–8 (58 ref.)

Attachment relationships in New World primates. Mendoza SP, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:203–9 (24 ref.)

Affiliative processes and vocal development. Snowdon CT. **Ann N Y Acad Sci** 1997 Jan 15;807:340–51 (36 ref.)

Physiological and endocrine effects of social contact. Uvnäs-Moberg K. **Ann N Y Acad Sci** 1997 Jan 15; 807:146–63 (90 ref.)

Ecological constraints and the evolution of hormone-behavior interrelationships. Wingfield JC, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:22–41 (67 ref.)

Regulatory mechanisms of oxytocin-mediated sociosexual behavior. Witt DM. **Ann N Y Acad Sci** 1997 Jan 15; 807:287–301 (80 ref.)

Issues in the genetics of social behavior: revisited. Hahn ME, et al. **Behav Genet** 1996 Sep;26(5):463–70 (24 ref.)

Determinants of primate social organization: comparative evidence and new insights from Malagasy lemurs. Kappeler PM. **Biol Rev Camb Philos Soc** 1997 Feb;72(1):111–51 (248 ref.)

Emotions are social. Parkinson B. **Br J Psychol** 1996 Nov; 87 (Pt 4):663–83 (86 ref.)

Early determinants of behaviour: evidence from primate studies. Suomi SJ. **Br Med Bull** 1997 Jan;53(1):170–84 (59

SOCIAL BEHAVIOR

ref.)
The origin and formulation of Chinese character: an introduction to confucianism and its influence on Chinese behavior patterns. Huang DD, et al. **Cult Divers Ment Health** 1996;2(1):35–42 (24 ref.)
Gene targeting approaches to neuroendocrinology: oxytocin, maternal behavior, and affiliation. Young LJ, et al. **Horm Behav** 1997 Jun;31(3):221–31 (34 ref.)
Impact of information compression on intellectual activities in the brain. Eriksson JT. **Int J Neural Syst** 1996 Sep; 7(4):543–50 (14 ref.)
Delivery method and supplement consumption by grazing ruminants: a review. Bowman JG, et al. **J Anim Sci** 1997 Feb;75(2):543–50 (44 ref.)
Frontal–subcortical circuits: the anatomic basis of executive, social and motivated behaviors. Masterman DL, et al. **J Psychopharmacol (Oxf)** 1997;11(2):107–14 (60 ref.)
Cooperative care of young in mammals. König B. **Naturwissenschaften** 1997 Mar;84(3):95–104 (95 ref.)
The neurobiology of social play behavior in rats. Vanderschuren LJ, et al. **Neurosci Biobehav Rev** 1997 May; 21(3):309–26 (276 ref.)
On mouse pups and their lactating dams: behavioral consequences of early exposure to oxazepam and interacting factors. Laviola G. **Pharmacol Biochem Behav** 1996 Dec;55(4):459–74 (130 ref.)
Machiavellianism: a synthesis of the evolutionary and psychological literatures. Wilson DS, et al. **Psychol Bull** 1996 Mar;119(2):285–99 (152 ref.)
Social behavior and aggressive problems of cats. Crowell-Davis SL, et al. **Vet Clin North Am Small Anim Pract** 1997 May; 27(3):549–68 (31 ref.)
Social dynamics and behavior problems in multiple-dog households. Juarbe-Díaz SV. **Vet Clin North Am Small Anim Pract** 1997 May; 27(3):497–514 (11 ref.)
Puppy socialization classes. Seksel K. **Vet Clin North Am Small Anim Pract** 1997 May; 27(3):465–77 (48 ref.)
Behavior problems of pet pigs. Tynes VV. **Vet Clin North Am Small Anim Pract** 1997 May; 27(3):667–90 (35 ref.)
[Social dominance and rank relationships in domestic pigs: a critical review] Puppe B. **Berl Munch Tierarztl Wochenschr** 1996 Nov-Dec; 109(11–12):457–64 (91 ref.) (Eng. Abstr.) **(Ger)**

SOCIAL BEHAVIOR DISORDERS

see related
ANTISOCIAL PERSONALITY DISORDER

CHEMICALLY INDUCED

Differentiating behavioral disturbances of dementia from drug side effects. Eastham JH, et al. **Int Psychogeriatr** 1996; 8 Suppl 3:429–34; discussion 447–8 (57 ref.)

DIAGNOSIS

Behavioral disorders in dementia. Marini G, et al. **Funct Neurol** 1997 May-Aug;12(3–4):207–10 (15 ref.)
Diagnostic classification of neuropsychiatric signs and symptoms in patients with dementia. Caine ED. **Int Psychogeriatr** 1996;8 Suppl 3:273–9; discussion 289–91 (12 ref.)
Conceptualization of agitation: results based on the Cohen-Mansfield Agitation Inventory and the Agitation Behavior Mapping Instrument. Cohen-Mansfield J. **Int Psychogeriatr** 1996;8 Suppl 3:309–15; discussion 351–4 (45 ref.)
Theories behind existing scales for rating behavior in dementia. Cummings JL. **Int Psychogeriatr** 1996;8 Suppl 3:293–300 (34 ref.)
Behavioral pathology in Alzheimer's disease (BEHAVE-AD) rating scale. Reisberg B, et al. **Int Psychogeriatr** 1996;8 Suppl 3:301–8; discussion 351–4 (14 ref.)
Neuroimaging and the origin of psychiatric symptoms in dementia. Sultzer DL. **Int Psychogeriatr** 1996;8 Suppl 3:239–43; discussion 269–72 (11 ref.)
Behavioral manifestations of dementia: a research agenda. Tariot PN. **Int Psychogeriatr** 1996;8 Suppl 1:31–8 (11 ref.)
Disinhibition, apathy, indifference, fatigability, complaining, and negativism. Webster J, et al. **Int Psychogeriatr** 1996; 8 Suppl 3:403–8 (27 ref.)
Behavioral disturbances of dementia in DSM-IV and ICD-10: fact or fiction? Zaudig M. **Int Psychogeriatr** 1996; 8 Suppl 3:285–8 (10 ref.)

DRUG THERAPY

From transmitters to treatment: the pharmacotherapy of behavioural disturbances in dementia. Herrmann N, et al. **Can J Psychiatry** 1997 Jun;42 Suppl 1:51S–64S (193 ref.)
Acute disturbed or violent behaviour: principles of treatment. Kerr IB, et al. **J Psychopharmacol (Oxf)** 1997;11(3):271–7 (40 ref.)
Psychopharmacological treatment of aggressive behavior: implications for domestically violent men. Maiuro RD, et al. **Violence Vict** 1996 Fall;11(3):239–61 (108 ref.)

EPIDEMIOLOGY

The overlap of attention deficit hyperactivity disorder with other common mental disorders. Hazell P. **J Paediatr Child Health** 1997 Apr;33(2):131–7 (60 ref.)

ETIOLOGY

Childhood adversities and psychosocial disorders. Maughan B, et al. **Br Med Bull** 1997 Jan;53(1):156–69 (50 ref.)

NURSING

Perspective of an institution-based research nurse. Norberg A. **Int Psychogeriatr** 1996;8 Suppl 3:459–63; discussion 469–73 (30 ref.)

PSYCHOLOGY

Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Finkel SI, et al. **Int Psychogeriatr** 1996;8 Suppl 3:497–500 (0 ref.)
Social cognition in schizophrenia. Penn DL, et al. **Psychol Bull** 1997 Jan;121(1):114–32 (285 ref.)

REHABILITATION

A behavioral diagnostic paradigm for integrating behavior-analytic and psychopharmacological interventions for people with a dual diagnosis. Pyles DA, et al. **Res Dev Disabil** 1997 May-Jun;18(3):185–214 (60 ref.)

THERAPY

Interventions for the behavioral complications of Alzheimer's disease: behavioral approaches. Burgio L. **Int Psychogeriatr** 1996;8 Suppl 1:45–52 (35 ref.)
Neuropsychiatric assessment and intervention in Alzheimer's disease. Cummings JL. **Int Psychogeriatr** 1996;8 Suppl 1:25–30 (15 ref.)
Behavioral intervention strategies for sleep-activity disruption. Dowling GA. **Int Psychogeriatr** 1996;8 Suppl 1:77–86 (34 ref.)
Behavioral treatment of Alzheimer's disease. Ferris SH, et al. **Int Psychogeriatr** 1996;8 Suppl 1:87–90 (3 ref.)
A research agenda for disruptive behaviors in Alzheimer's disease: a combined biomedical and behavioral approach. Raskind M. **Int Psychogeriatr** 1996;8 Suppl 1:53–8 (29 ref.)
Management of geriatric behavior problems. Dyck G. **Psychiatr Clin North Am** 1997 Mar;20(1):165–80 (34 ref.)

SOCIAL CHANGE

Commentary: change. Middleman EL, et al. **Am J Med Qual** 1997 Spring;12(1):44–7 (6 ref.)
Does marriage matter? Waite LJ. **Demography** 1995 Nov; 32(4):483–507 (62 ref.)
The market is a strange creature: family medicine meeting the challenges of the changing political and socioeconomic structure. Westin S. **Fam Pract** 1995 Dec;12(4):394–401 (37 ref.)
Gender, the state, and constructing the old as dependent: lessons from the economic transition in Poland. Calasanti TM, et al. **Gerontologist** 1997 Aug;37(4):452–61 (34 ref.)
Modernity, postmodernity and disability in developing countries. Lysack C. **Int J Rehabil Res** 1997 Jun;20(2):121–8 (17 ref.)
The art of nursing in a 'postmodern' context. Lister P. **J Adv Nurs** 1997 Jan;25(1):38–44 (50 ref.)
Looking at discourse in a literature review of nursing texts. Traynor M. **J Adv Nurs** 1996 Jun;23(6):1155–61 (46 ref.)
Macrosocial transition and health hazards. Schröder H, et al. **Rev Environ Health** 1996 Jan-Jun;11(1–2):1–5 (9 ref.)
Cultural problems of ageing especially regarding gender and intergenerational equity. Henrard JC. **Soc Sci Med** 1996 Sep;43(5):667–80 (115 ref.)
Cultural aspects of ageing: gender and inter-generational issues. Jefferys M. **Soc Sci Med** 1996 Sep;43(5):681–7 (36 ref.)
The impact of globalization on the determination and management of ethical choices in the health arena. Kalekin-Fishman D. **Soc Sci Med** 1996 Sep;43(5):809–22 (126 ref.)

SOCIAL CLASS

Earnings and schooling: an overview of economic research based on the Australian Twin Register. Miller P, et al. **Acta Genet Med Gemellol (Roma)** 1996;45(4):417–29 (19 ref.)
Concordance of cranial and dental morphological traits and evidence for endogamy in ancient Egypt. Prowse TL, et al. **Am J Phys Anthropol** 1996 Oct;101(2):237–46 (98 ref.)
Culture as a stressor: a revised model of biocultural interaction. Schell LM. **Am J Phys Anthropol** 1997 Jan; 102(1):67–77 (49 ref.)
The body politic and the power of socioeconomic status [editorial; comment] Moss N. **Am J Public Health** 1997 Sep;87(9):1411–3 (18 ref.) Comment on: Am J Public Health 1997 Sep;87(9):1484–90.
Gender, racial, ethnic, sexual, and class identities. Frable DE. **Annu Rev Psychol** 1997;48:139–62 (185 ref.)
Measuring social class in US public health research: concepts, methodologies, and guidelines. Krieger N, et al. **Annu Rev Public Health** 1997;18:341–78 (202 ref.)
Socioeconomic determinants of health. The contribution of nutrition to inequalities in health. James WP, et al. **BMJ** 1997 May 24;314(7093):1545–9 (31 ref.)
Socioeconomic status and obesity. Stunkard AJ. **Ciba Found Symp** 1996;201:174–82; discussion 182–7, 188–93 (28 ref.)
The age of extremes: a revisionist perspective [comment] Farley R. **Demography** 1996 Nov;33(4):417–20; discussion 427–8 (17 ref.) Comment on: Demography 1996 Nov;33(4):395–412; discussion 413–6.
The political economy of inequality in the "age of extremes" [see comments] Hout M, et al. **Demography** 1996 Nov; 33(4):421–5; discussion 427–8 (22 ref.) Comment in: Demography 1996 Nov;33(4):395–412; discussion 413–6.
The age of extremes: concentrated affluence and poverty in the twenty-first century [see comments] Massey DS. **Demography** 1996 Nov;33(4):395–412; discussion 413–6 (100 ref.) Comment in: Demography 1996 Nov;33(4):417–20; discussion 427–8. Comment in: Demography 1996 Nov;33(4):421–5; discussion 427–8.
Obesity, social class and Western diet: a link to breast cancer prognosis. Stoll BA. **Eur J Cancer** 1996 Jul;32A(8):1293–5 (56 ref.)
Severity of childhood asthma by socioeconomic status. Mielck A, et al. **Int J Epidemiol** 1996 Apr;25(2):388–93 (33 ref.)
Race/ethnicity and socioeconomic status: measurement and methodological issues. Williams DR. **Int J Health Serv** 1996;26(3):483–505 (81 ref.)
The class analysis of poverty: a response to Tony Novak [comment] Wright EO. **Int J Health Serv** 1996;26(2):371–9 (6 ref.) Comment on: Int J Health Serv 1995;25(1):85–100. Comment on: Int J Health Serv 1996;26(1):187–95.
Guidelines for adolescent health research: issues of race and class. Jenkins RR, et al. **J Adolesc Health** 1995 Nov; 17(5):314–22 (43 ref.)
Variation in menarcheal age of Assamese girls. Sengupta S, et al. **J Indian Med Assoc** 1996 Mar;94(3):88–90 (10 ref.)
Down at heart—the meaning and implications of social inequalities in cardiovascular disease. Smith GD. **J R Coll Physicians Lond** 1997 Jul-Aug;31(4):414–24 (71 ref.)
The Black Report and beyond: what are the issues? Macintyre S. **Soc Sci Med** 1997 Mar;44(6):723–45 (196 ref.)

SOCIAL CLUBS, THERAPEUTIC see **SELF-HELP GROUPS**

SOCIAL CONDITIONS

Living conditions, inequalities in health, human rights and security: a European perspective in a global context. Middleton J. **Med Confl Surviv** 1996 Jul-Sep;12(3):240–53 (76 ref.)
[Colombia 1996: social and health situation] Botero D. **Med Trop (Mars)** 1996;56(2):123–8 (12 ref.) **(Fre)**

SOCIAL CONFORMITY

A critique of social bonding and control theory of delinquency using the principles of Psychology of Mind. Kelley TM. **Adolescence** 1996 Summer;31(122):321–37 (31 ref.)
Living systems theory as a paradigm for organizational behavior: understanding humans, organizations, and social processes. Vancouver JB. **Behav Sci** 1996 Jul;41(3):165–204 (200 ref.)
Era-related changes in the Japanese cultural and social structure and conformist personality pathology—with a particular emphasis on borderline personality disorder. Tamai K. **Fukuoka Igaku Zasshi** 1997 Apr;88(4):84–9 (2 ref.)
For an anthropology of vulnerability. Stanghellini G. **Psychopathology** 1997;30(1):1–11 (71 ref.)
Beyond the orthodox: heresy in medicine and the social sciences from a cross-cultural perspective. Gürsoy A. **Soc Sci Med** 1996 Sep;43(5):577–99 (156 ref.)

SOCIAL CONTROL, FORMAL

A critique of social bonding and control theory of delinquency using the principles of Psychology of Mind. Kelley TM. **Adolescence** 1996 Summer;31(122):321–37 (31 ref.)
Disasters, the media and social structures: a typology of credibility hierarchy persistence based on a newspaper coverage of the Love Canal and six other disasters. Ploughman P. **Disasters** 1997 Jun;21(2):118–37 (79 ref.)
Disciplining children with disabilities under the Individuals with Disabilities Education Act. Ramsingh OM. **J Contemp Health Law Policy** 1995 Fall;12(1):155–81 (211 ref.)
Environmental risk harmonization: federal/state approaches to risk assessment and management. Kamrin MA. **Regul Toxicol Pharmacol** 1997 Apr;25(2):158–65 (16 ref.)

SOCIAL DESIRABILITY

The evolution of social attractiveness and its role in shame, humiliation, guilt and therapy. Gilbert P. **Br J Med Psychol** 1997 Jun;70 (Pt 2):113–47 (140 ref.)

SOCIAL DISCRIMINATION see **PREJUDICE**

SOCIAL DISORGANIZATION see **ANOMIE**

SOCIAL DOMINANCE

Sex determination and the maternal dominance hypothesis. Grant VJ. **Hum Reprod** 1996 Nov;11(11):2371–5 (59 ref.)

Medical practice and social authority [see comments] Pippin RB. **J Med Philos** 1996 Aug;21(4):417–37 (19 ref.) Comment in: J Med Philos 1996 Aug;21(4):357–73.

Stress and behaviorally induced reproductive dysfunction in primates. Cameron JL. **Semin Reprod Endocrinol** 1997 Feb; 15(1):37–45 (56 ref.)

Assessment, management, and prognosis of canine dominance-related aggression. Reisner IR. **Vet Clin North Am Small Anim Pract** 1997 May; 27(3):479–95 (75 ref.)

[Social dominance and rank relationships in domestic pigs: a critical review] Puppe B. **Berl Munch Tierarztl Wochenschr** 1996 Nov–Dec; 109(11–12):457–64 (91 ref.) (Eng. Abstr.) **(Ger)**

SOCIAL ENVIRONMENT

see related
LIFE STYLE

Do young women in tropical regions constitute a recognized social category? Ahlberg BM. **Acta Trop** 1996 Dec 30; 62(4):201–7 (15 ref.)

Social and behavioral issues in phase III HIV preventive vaccine trials. Grinstead OA. **AIDS** 1995;9 Suppl A:S245–50 (32 ref.)

Reducing HIV incidence in developing countries with structural and environmental interventions. Sweat MD, et al. **AIDS** 1995;9 Suppl A:S251–7 (55 ref.)

Familial factors in illicit drug abuse: an interdisciplinary perspective. Ripple CH, et al. **Am J Drug Alcohol Abuse** 1996 May;22(2):147–72 (54 ref.)

On the incomplete architecture of human ontogeny. Selection, optimization, and compensation as foundation of developmental theory. Baltes PB. **Am Psychol** 1997 Apr; 52(4):366–80 (110 ref.)

Social ties and health: the benefits of social integration. Seeman TE. **Ann Epidemiol** 1996 Sep;6(5):442–51 (69 ref.)

Health psychology: what is an unhealthy environment and how does it get under the skin? Taylor SE, et al. **Annu Rev Psychol** 1997;48:411–47 (215 ref.)

Searching for the biological pathways between stress and health. Kelly S, et al. **Annu Rev Public Health** 1997; 18:437–62 (177 ref.)

Selective breeding for isolation-induced intermale aggression in mice: associated responses and environmental influences. Sandnabba NK. **Behav Genet** 1996 Sep;26(5):477–88 (100 ref.)

Behavioral momentum. Implications and development from reinforcement theories. Plaud JJ, et al. **Behav Modif** 1996 Apr;20(2):183–201 (38 ref.)

Stimulus configuration, occasion setting, and the hippocampus. Schmajuk NA, et al. **Behav Neurosci** 1997 Apr;111(2):235–57; appendix 258 (90 ref.)

Adolescent alcohol use: social determinants and the case for early family-centered prevention. Family-focused prevention of adolescent drinking. Schor EL. **Bull N Y Acad Med** 1996 Winter;73(2):335–56 (86 ref.)

Aggression from a developmental perspective: genes, environments and interactions. Cairns RB. **Ciba Found Symp** 1996;194:45–56; discussion 57–60 (31 ref.)

Bio-ecological approach to cognitive assessment. Armour-Thomas E, et al. **Cult Divers Ment Health** 1997; 3(2):131–44 (15 ref.)

Epigenetic approaches to developmental psychopathology. Goldsmith HH, et al. **Dev Psychopathol** 1997 Spring; 9(2):365–87 (105 ref.)

Integrating nature and nurture: implications of person-environment correlations and interactions for developmental psychopathology. Rutter M, et al. **Dev Psychopathol** 1997 Spring;9(2):335–64 (270 ref.)

Rethinking the relationships between disability, rehabilitation, and society. Imrie R. **Disabil Rehabil** 1997 Jul;19(7):263–71 (37 ref.)

Models of disability. Marks D. **Disabil Rehabil** 1997 Mar; 19(3):85–91 099 (57 ref.)

Environmental causes and impact of refugee movements: a critique of the current debate. Kibreab G. **Disasters** 1997 Mar;21(1):20–38 (90 ref.)

Era-related changes in the Japanese cultural and social structure and conformist personality pathology—with a particular emphasis on borderline personality disorder. Tamai K. **Fukuoka Igaku Zasshi** 1997 Apr;88(4):84–9 (2 ref.)

A transactional analysis of biobehavioral systems. Germana J. **Integr Physiol Behav Sci** 1996 Jul–Sep;31(3):210–8 (35 ref.)

Social interventions for homeless substance abusers: evaluating treatment outcomes [editorial] Stahler GJ. **J Addict Dis** 1995;14(4):xv–xxvi (41 ref.)

Importance of nonshared environmental factors for childhood and adolescent psychopathology. Pike A, et al. **J Am Acad Child Adolesc Psychiatry** 1996 May; 35(5):560–70 (59 ref.)

What genetic research on intelligence tells us about the environment. Plomin R, et al. **J Biosoc Sci** 1996 Oct; 28(4):587–606 (64 ref.)

Schools, families, and early adolescents: what are we doing wrong and what can we do instead? Eccles JS, et al. **J Dev Behav Pediatr** 1996 Aug;17(4):267–76 (65 ref.)

Health care of Latina women. Sociocultural factors. Vera MI. **J Fla Med Assoc** 1996 Aug–Sep;83(7):494–7 (15 ref.)

The social context of mental illness and violence. Hiday VA. **J Health Soc Behav** 1995 Jun;36(2):122–37 (143 ref.)

The interactional context of problem-, emotion-, and relationship-focused coping: the role of the big five personality factors. O'Brien TB, et al. **J Pers** 1996 Dec; 64(4):775–813 (100 ref.)

Psychosocial factors and physical illness in primary care: promoting the biopsychosocial model in medical practice [editorial] Zimmermann C, et al. **J Psychosom Res** 1996 Apr;40(4):351–8 (60 ref.)

Estimating genetic and environmental effects of alcohol use and dependence from a national survey: a "quasi-adoption" study. Light JM, et al. **J Stud Alcohol** 1996 Sep; 57(5):507–20 (45 ref.)

Handedness and speech: a critical reappraisal of the role of genetic and environmental factors in the cerebral lateralization of function. Provins KA. **Psychol Rev** 1997 Jul;104(3):554–71 (310 ref.)

Menstrual variability and the measurement of menstrual synchrony. Weller L, et al. **Psychoneuroendocrinology** 1997 Feb;22(2):115–28 (35 ref.)

Impact of social environment characteristics on neuroendocrine regulation. Seeman TE, et al. **Psychosom Med** 1996 Sep–Oct;58(5):459–71 (159 ref.)

Normal aging and environmental effects on communication. Lubinski R, et al. **Semin Speech Lang** 1997 May; 18(2):107–25; quiz 125–6 (90 ref.)

Race/ethnicity, the social environment, and health. Lillie-Blanton M, et al. **Soc Sci Med** 1996 Jul;43(1):83–91 (41 ref.)

Comparison of home and clinical blood pressure measurements: clinical applications. de Gaudemaris R, et al. **Z Kardiol** 1996;85 Suppl 3:60–5 (37 ref.)

[Ethology of panic disorders] Cyrulnik B. **Encephale** 1996 Dec;22 Spec No 5:42–5 (10 ref.) (Eng. Abstr.) **(Fre)**

[Violence in the school—analysis of the problem and possible interventions] Meier U. **Prax Kinderpsychol Kinderpsychiatr** 1997 Mar;46(3):169–81 (31 ref.) (Eng. Abstr.) **(Ger)**

SOCIAL FACILITATION

On the importance of peer influence for adolescent drug use: commonly neglected considerations. Bauman KE, et al. **Addiction** 1996 Feb;91(2):185–98 (116 ref.)

Taxonomy of high-risk situations for alcohol relapse: evolution and development of a cognitive-behavioral model. Marlatt GA. **Addiction** 1996 Dec;91 Suppl:S37–49 (30 ref.)

Socio-cultural determinants of meal size and frequency. De Castro JM. **Br J Nutr** 1997 Apr;77 Suppl 1:S39–54; discussion S54–5 (74 ref.)

Social patterns of smoking behavior: trends and practice implications. Kaplan MS, et al. **Health Soc Work** 1997 Feb; 22(1):47–52 (60 ref.)

SOCIAL IDENTIFICATION

Gender, racial, ethnic, sexual, and class identities. Frable DE. **Annu Rev Psychol** 1997;48:139–62 (185 ref.)

Living systems theory as a paradigm for organizational behavior: understanding humans, organizations, and social processes. Vancouver JB. **Behav Sci** 1996 Jul;41(3):165–204 (200 ref.)

'Oh, don't you envy us our privileged lives?' A review of the disability culture movement. Brown SE. **Disabil Rehabil** 1997 Aug;19(8):339–49 (25 ref.)

Analysis of affiliation-related traits in terms of the PAD Temperament Model. Mehrabian A. **J Psychol** 1997 Jan; 131(1):101–17 (42 ref.)

[Psychiatrists and their identity] Kasahara Y. **Seishin Shinkeigaku Zasshi** 1996;98(9):597–602 (4 ref.) **(Jpn)**

SOCIAL INSURANCE see **SOCIAL SECURITY**

SOCIAL INTERACTION see **INTERPERSONAL RELATIONS**

SOCIAL ISOLATION

Selective breeding for isolation-induced intermale aggression in mice: associated responses and environmental influences. Sandnabba NK. **Behav Genet** 1996 Sep;26(5):477–88 (100 ref.)

An ethological approach to self-injury [editorial] [see comments] Jones IH, et al. **Br J Psychiatry** 1996 Sep; 169(3):263–7 (21 ref.) Comment in: Br J Psychiatry 1997 Feb;170:192–3.

Multiple regulators of ultrasonic vocalization in the infant rat [published erratum appears in Psychoneuroendocrinology 1996 Jul;21(5):501] Hofer MA. **Psychoneuroendocrinology** 1996 Feb;21(2):203–17 (72 ref.)

[Schizophrenia and exclusion. Current and future perspectives] Furtos J, et al. **Encephale** 1996 Oct;22 Spec No 3:39–48 (50 ref.) **(Fre)**

PSYCHOLOGY

Hypothalamic-pituitary-adrenal responses to brief social separation. Hennessy MB. **Neurosci Biobehav Rev** 1997 Jan; 21(1):11–29 (148 ref.)

SOCIAL JUSTICE

see related
CIVIL RIGHTS
HUMAN RIGHTS

Do we really mean preventive medicine for all? O'Hanlan KA. **Am J Prev Med** 1996 Sep–Oct;12(5):411–4 (57 ref.)

Reframing women's risk: social inequalities and HIV infection. Zierler S, et al. **Annu Rev Public Health** 1997; 18:401–36 (168 ref.)

Group differences: is the good society impossible? Flynn JR. **J Biosoc Sci** 1996 Oct;28(4):573–85 (24 ref.)

Working towards social justice in health. Whitehead M. **J R Soc Health** 1996 Aug;116(4):256–63 (55 ref.)

Equitable access to cancer services in the 21st century. Facione NC, et al. **Nurs Outlook** 1997 May–Jun; 45(3):118–24 (32 ref.)

An integrative framework for explaining reactions to decisions: interactive effects of outcomes and procedures. Brockner J, et al. **Psychol Bull** 1996 Sep;120(2):189–208 (73 ref.)

Radicalizing recovery: addiction, spirituality, and politics. Morell C. **Soc Work** 1996 May;41(3):306–12 (34 ref.)

Gender justice in genetics. Mahowald MB. **Womens Health Issues** 1997 Jul–Aug;7(4):230–3 (4 ref.)

STANDARDS

The juvenile court: analysis and recommendations. Stevenson CS, et al. **Future Child** 1996 Winter;6(3):4–28 (109 ref.)

SOCIAL MEDICINE

Causes of change in the health of populations: a biopsychosocial viewpoint. Arnetz BB. **Soc Sci Med** 1996 Sep;43(5):605–8 (31 ref.)

Disease ecology and a reformist alternative: the case of infant mortality. Gesler WM, et al. **Soc Sci Med** 1997 Mar; 44(5):657–71 (106 ref.)

Urban violence and health—South Africa 1995. Gilbert L. **Soc Sci Med** 1996 Sep;43(5):873–86 (74 ref.)

Child development and long-term outcomes: a population health perspective and summary of successful interventions. Hertzman C, et al. **Soc Sci Med** 1996 Oct;43(7):1083–95 (84 ref.)

How religion influences morbidity and health: reflections on natural history, salutogenesis and host resistance. Levin JS. **Soc Sci Med** 1996 Sep;43(5):849–64 (67 ref.)

Disease ecology at a crossroads: man-made environments, human rights and perpetual development utopias. Pedersen D. **Soc Sci Med** 1996 Sep;43(5):745–58 (80 ref.)

EDUCATION

The Dutch experience with regard to the training for public health. Doeleman F. **Public Health** 1997 May;111(3):125–7 (0 ref.)

SOCIAL MOBILITY

The dynamics of childhood poverty. Corcoran ME, et al. **Future Child** 1997 Summer-Fall;7(2):40–54 (41 ref.)

SOCIAL PERCEPTION

see related
STEREOTYPING

A Malay crosscultural worldview and forensic review of amok. Hatta SM. **Aust N Z J Psychiatry** 1996 Aug; 30(4):505–10 (30 ref.)

Social epistemology, gender and nursing theory. Cash K. **Int J Nurs Stud** 1997 Apr;34(2):137–43 (27 ref.)

Counterfactual thinking. Roese NJ. **Psychol Bull** 1997 Jan; 121(1):133–48 (165 ref.)

[Intentional awareness and schizophrenia] Hardy-Baylé MC, et al. **Encephale** 1996 Oct;22 Spec No 3:104–7 (12 ref.) **(Fre)**

SOCIAL PLANNING

Conflict, the continuum and chronic emergencies: a critical analysis of the scope for linking relief, rehabilitation and development planning in Sudan. Macrae J, et al. **Disasters** 1997 Sep;21(3):223–43 (23 ref.)

SOCIAL POLICY see **PUBLIC POLICY**

SOCIAL PROBLEMS

see related
ALCOHOLISM
SUBSTANCE DEPENDENCE

Reframing women's risk: social inequalities and HIV infection. Zierler S, et al. **Annu Rev Public Health** 1997; 18:401–36 (168 ref.)

Dissecting people and ignoring social structure: an analysis of individualism, public policy, and genetic labeling. Miringoff ML. **Behav Sci Law** 1996 Autumn;14(4):433–42

SOCIAL PROBLEMS

(36 ref.)
Social inequalities and emerging infectious diseases. Farmer P. **Emerg Infect Dis** 1996 Oct–Dec;2(4):259–69 (60 ref.)
Sydney Anglicans and homosexuality. Hilliard D. **J Homosex** 1997;33(2):101–23 (48 ref.)
Macrosocial transition and health hazards. Schröder H, et al. **Rev Environ Health** 1996 Jan–Jun;11(1–2):1–5 (9 ref.)
Health dilemmas at the borders—a global challenge. Kamel WW. **World Health Forum** 1997;18(1):9–16 (22 ref.)
[Alzheimer's disease. A medical and social challenge] Forette F. **Bull Acad Natl Med** 1996 Oct;180(7):1731–45; discussion 1745–6 (61 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Harm reduction: come as you are. Marlatt GA. **Addict Behav** 1996 Nov–Dec;21(6):779–88 (18 ref.)
Psychosocial disorders in young people: on the agenda but not on the mend. Eckersley R. **Med J Aust** 1997 Apr 21; 166(8):423–4 (23 ref.)

PSYCHOLOGY

Heroin addicts in the community and in treatment compared for severity of problems and need for help. Eland–Goossensen A, et al. **Subst Use Misuse** 1997 Aug; 32(10):1313–30 (24 ref.)

STATISTICS & NUMERICAL DATA

Overview of studies on drinking patterns and consequences. Bondy SJ. **Addiction** 1996 Nov;91(11):1663–74 (95 ref.)

SOCIAL PSYCHIATRY see **COMMUNITY PSYCHIATRY**

SOCIAL PSYCHOLOGY see **PSYCHOLOGY, SOCIAL**

SOCIAL RESPONSIBILITY

Can we achieve accountability for long–term outcomes? Batterham RW, et al. **Arch Phys Med Rehabil** 1996 Dec; 77(12):1219–25 (76 ref.)
Social contract and deterring famine: first thoughts. de Waal A. **Disasters** 1996 Sep;20(3):194–205 (25 ref.)
Geographies of responsibility. Walker M. **Hastings Cent Rep** 1997 Jan–Feb;27(1):38–44 (15 ref.)
Who is holding whom accountable for quality? [see comments] Gosfield AG. **Health Aff (Millwood)** 1997 May–Jun;16(3):26–40 (21 ref.) Comment in: Health Aff (Millwood) 1997 May–Jun;16(3):41–3.
Dimensions of accountability for not–for–profit hospitals and health systems. Gamm LD. **Health Care Manage Rev** 1996 Spring;21(2):74–86 (72 ref.)
Sleepwalking disorder and mens rea: a review and case report. Maricopa County Superior Court. Thomas TN. **J Forensic Sci** 1997 Jan;42(1):17–24 (51 ref.)
Economic analyses, the medical commons, and patients' dilemmas: what is the physician's role? Wynia MK. **J Investig Med** 1997 Feb;45(2):35–43 (62 ref.)
The merchants, not the customers: resisting the alcohol and tobacco industries' strategy to blame young people for illegal alcohol and tobacco sales. Mosher JF. **J Public Health Policy** 1995;16(4):412–32 (47 ref.)
Responsibilities and rights in the promotion of health: differing positions of the individual and the state. Bell NK. **Soc Sci Med** 1996 Sep;43(5):775–82 (16 ref.)
Psychosocial work environment in human service organizations: a conceptual analysis and development of the demand–control model. Söderfeldt B, et al. **Soc Sci Med** 1996 May;42(9):1217–26 (50 ref.)
Engagement and suffering in responsible caregiving: on overcoming maleficience in health care. Schultz DS, et al. **Theor Med** 1996 Sep;17(3):189–207 (17 ref.)
Genetic accountability and pregnant women. Rothenberg KH. **Womens Health Issues** 1997 Jul–Aug;7(4):215–9 (12 ref.)
[Responsibility for the individual or the whole? Ethical considerations on medical responsibility] Vollmann J, et al. **Z Arztl Fortbild (Jena)** 1996 Oct;90(6):527–32 (22 ref.) (Eng. Abstr.) **(Ger)**

SOCIAL SCIENCES

The politics of collaboration as viewed through the lens of a collaborative nursing research project. Beattie J, et al. **J Adv Nurs** 1996 Oct;24(4):682–7 (26 ref.)
Beyond the orthodox: heresy in medicine and the social sciences from a cross–cultural perspective. Gürsoy A. **Soc Sci Med** 1996 Sep;43(5):577–99 (156 ref.)

TRENDS

Behavioral and social research in rheumatology [see comments] Callahan LF, et al. **Curr Opin Rheumatol** 1997 Mar;9(2):126–32 (40 ref.) Comment in: Curr Opin Rheumatol 1997 Mar;9(2):87–9.

SOCIAL SECURITY

ECONOMICS

The welfare state, pensions, privatization: the case of Social Security in the United States. Du Boff RB. **Int J Health Serv** 1997;27(1):1–23 (23 ref.)
Research Grant Summary. **Soc Secur Bull** 1996 Winter; 59(4):71–4 (11 ref.)
Poverty among single elderly women under different systems of old–age security: a comparative review. Siegenthaler JK. **Soc Secur Bull** 1996 Fall;59(3):31–44 (59 ref.)

LEGISLATION & JURISPRUDENCE

[Depressive disorders] Niskanen P, et al. **Duodecim** 1995; 111(17):1677–9 (7 ref.) **(Fin)**
[The Parkinson patient in expert social medicine assessment with special reference to the nursing care law] Semsch–Poppe B, et al. **Gesundheitswesen** 1996 Dec; 58(12):635–40 (18 ref.) (Eng. Abstr.) **(Ger)**
[Minimum requirements in medical expert assessment of occupational disability of patients with chronic nonspecific pain] Raspe HH. **Versicherungsmedizin** 1997 Aug 1; 49(4):118–25 (31 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Privatizing Social Security: the Chilean experience. Kritzer BE. **Soc Secur Bull** 1996 Fall;59(3):45–55 (53 ref.)

TRENDS

[Social security in Finland] Lehto M. **Duodecim** 1995; 111(17):1653–6 (0 ref.) **(Fin)**

SOCIAL SERVICE see **SOCIAL WORK**

SOCIAL SERVICE, PSYCHIATRIC see **SOCIAL WORK, PSYCHIATRIC**

SOCIAL SUPPORT

see related

SELF–HELP GROUPS

Peer resource consulting: redesigning a new future. Kapron K, et al. **Adv Ren Replace Ther** 1997 Jul;4(3):267–74 (24 ref.)
Neglected victims of homicide: the needs of young siblings of murder victims. Freeman LN, et al. **Am J Orthopsychiatry** 1996 Jul;66(3):337–45 (30 ref.)
Integrating social–skills training interventions with parent training and family–focused support to prevent conduct disorder in high–risk populations. The Fast Track Multisite Demonstration Project. The Conduct Problems Prevention Research Group. Bierman KL. **Ann N Y Acad Sci** 1996 Sep 20;794:256–64 (21 ref.)
Social support, social networks and coronary artery disease rehabilitation: a review. Anderson D, et al. **Can J Cardiol** 1996 Aug;12(8):739–44 (52 ref.)
Integration of coping and social support perspectives: implications for the study of adaptation to chronic diseases. Schreurs KM, et al. **Clin Psychol Rev** 1997;17(1):89–112 (126 ref.)
Looking beyond age and race: the structure of networks, functions of support, and chronic stress [editorial; comment] Berkman LF. **Epidemiology** 1997 Sep;8(5):469–70 (9 ref.) Comment on: Epidemiology 1997 Sep;8(5):475–81. Comment on: Epidemiology 1997 Sep;8(5):482–7.
Interventions for caregivers of patients with Alzheimer's disease: a review and analysis of content, process, and outcomes. Bourgeois MS, et al. **Int J Aging Hum Dev** 1996; 43(1):35–92 (117 ref.)
Social relationships in later life: a review of the research literature [editorial] Phillipson C. **Int J Geriatr Psychiatry** 1997 May;12(5):505–12 (61 ref.)
The contributions of nursing science to social support. Stewart MJ, et al. **Int J Nurs Stud** 1995 Dec;32(6):535–44 (87 ref.)
Social interventions for homeless substance abusers: evaluating treatment outcomes [editorial] Stahler GJ. **J Addict Dis** 1995;14(4):xv–xxvi (41 ref.)
The relationship of partner support to outcomes for teenage mothers and their children: a review. Roye CF, et al. **J Adolesc Health** 1996 Aug;19(2):86–93 (45 ref.)
Social support: a conceptual analysis. Langford CP, et al. **J Adv Nurs** 1997 Jan;25(1):95–100 (53 ref.)
Promoting wellness in cardiac rehabilitation: exploring the role of altruism. Sullivan GB, et al. **J Cardiovasc Nurs** 1997 Apr;11(3):43–52 (47 ref.)
Faculty commitment: retaining minority nursing students in majority institutions. Campbell AR, et al. **J Nurs Educ** 1996 Oct;35(7):298–303 (28 ref.)
Coronary heart disease: a review of the role of psychosocial stress and social support. Greenwood DC, et al. **J Public Health Med** 1996 Jun;18(2):221–31 (52 ref.)
Practical issues in psychosocial measures. Wolfe F. **J Rheumatol** 1997 May;24(5):990–3 (35 ref.)
Supporting the adoptive family: a developmental approach. Peterson EA. **MCN Am J Matern Child Nurs** 1997 May–Jun;22(3):147–52 (8 ref.)
Stress, social support and pregnancy outcome: a reassessment based on recent research. Hoffman S, et al. **Paediatr Perinat Epidemiol** 1996 Oct;10(4):380–405 (144 ref.)
Engaging significant others: the Tom Sawyer approach to case management. Kanter J. **Psychiatr Serv** 1996 Aug; 47(8):799–801 (20 ref.)
Social networks, social support and coping with serious illness: the family connection. Ell K. **Soc Sci Med** 1996 Jan;42(2):173–83 (173 ref.)
[Role of associations in bipolar patients] Attar–Lévy D, et al. **Encephale** 1997 Jan;23 Spec No 1:42–8 (16 ref.) (Eng. Abstr.) **(Fre)**
[Home visits during pregnancy. Review of randomized studies and further questions] Blondel B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(5):515–22 (26 ref.) (Eng. Abstr.) **(Fre)**
[What is supportive psychotherapy?] Wöller W, et al. **Nervenarzt** 1996 Mar;67(3):249–52 (17 ref.) (Eng. Abstr.) **(Ger)**
[Positive role of family in coping with schizophrenic illness] Waldner P, et al. **Psychother Psychosom Med Psychol** 1996 Jul;46(7):276–81 (30 ref.) (Eng. Abstr.) **(Ger)**
[The concept of social network as an example of modern diagnostic processes in forensic psychiatry] Gierowski JK, et al. **Psychiatr Pol** 1995 Nov–Dec;29(6):731–42 (12 ref.) (Eng. Abstr.) **(Pol)**

SOCIAL VALUES

Values in psychotherapy. Holmes J. **Am J Psychother** 1996 Summer;50(3):259–73 (31 ref.)
The risk society in an age of anxiety: situating fear of crime. Hollway W, et al. **Br J Sociol** 1997 Jun;48(2):255–66 (15 ref.)
Myths, realities, and the political world: the anthropology of insanity defense attitudes [see comments] Perlin ML. **Bull Am Acad Psychiatry Law** 1996;24(1):5–26 (138 ref.) Comment in: Bull Am Acad Psychiatry Law 1996;24(3):423–6. Comment in: Bull Am Acad Psychiatry Law 1996;24(3):426–7.
The origin and formulation of Chinese character: an introduction to confucianism and its influence on Chinese behavior patterns. Huang DD, et al. **Cult Divers Ment Health** 1996;2(1):35–42 (24 ref.)
Cultures in psychiatric nosology: the CCMD–2–R and international classification of mental disorders. Lee S. **Cult Med Psychiatry** 1996 Dec;20(4):421–72 (115 ref.)
Ethics, values, and world culture: the impact on rehabilitation. Banja JD. **Disabil Rehabil** 1996 Jun; 18(6):279–84 (7 ref.)
Trends, issues, perspectives, and values for the aging of the baby boom cohorts. Cornman JM, et al. **Gerontologist** 1996 Feb;36(1):15–26 (70 ref.)
Nursing science in the global community. Ketefian S, et al. **Image J Nurs Sch** 1997 Spring;29(1):11–5 (27 ref.)
Bioethics and the construction of medical reality [comment] Cherry MJ. **J Med Philos** 1996 Aug;21(4):357–73 (54 ref.) Comment on: J Med Philos 1996 Aug;21(4):375–416. Comment on: J Med Philos 1996 Aug;21(4):417–37. Comment on: J Med Philos 1996 Aug;21(4):439–66.
The social construction of drug debates. Dingelstad D, et al. **Soc Sci Med** 1996 Dec;43(12):1829–38 (65 ref.)
[Disappearance of shame and puberty in girls] Kämmerer A, et al. **Prax Kinderpsychol Kinderpsychiatr** 1997 Feb; 46(2):113–21 (35 ref.) (Eng. Abstr.) **(Ger)**
[Personal values and goal orientations of chronically ill adolescents and young adults] Schmitt GM. **Psychother Psychosom Med Psychol** 1997 Jun;47(6):189–97 (80 ref.) (Eng. Abstr.) **(Ger)**
[Value priorities and drug addiction] Tamayo A, et al. **Acta Psiquiatr Psicol Am Lat** 1995 Dec;41(4):300–7 (31 ref.) (Eng. Abstr.) **(Spa)**

SOCIAL WELFARE

Building community capacity to promote social and public health: challenges for universities [editorial] Poole DL. **Health Soc Work** 1997 Aug;22(3):163–70 (48 ref.)
Health as an irreversible part of the welfare state: Canadian government policy under the Tories. O'Neill MA. **Int J Health Serv** 1996;26(3):547–59 (41 ref.)
Rethinking the western construction of the welfare state. Walker A, et al. **Int J Health Serv** 1996;26(1):67–92 (69 ref.)
Agricultural policy and social returns to eradication programs: the case of Aujeszky's disease in Sweden. Andersson H, et al. **Prev Vet Med** 1997 Feb;29(4):311–28 (30 ref.)
Hunger, food security and welfare policies: issues and debates in First World societies. Riches G. **Proc Nutr Soc** 1997 Mar;56(1A):63–74 (26 ref.)

ECONOMICS

The welfare state, pensions, privatization: the case of Social Security in the United States. Du Boff RB. **Int J Health Serv** 1997;27(1):1–23 (23 ref.)
Can markets give us the health system we want? [see comments] Rice T. **J Health Polit Policy Law** 1997 Apr; 22(2):383–426 (76 ref.) Comment in: J Health Polit Policy Law 1997 Apr;22(2):467–73. Comment in: J Health Polit Policy Law 1997 Apr;22(2):475–96.

LEGISLATION & JURISPRUDENCE

Changing welfare as we know it: some thoughts about the impact on children. Waldman HB. **ASDC J Dent Child** 1997 Mar–Apr;64(2):135–40 (19 ref.)
Speaking of personal responsibility and individual accountability.... Keigher SM. **Health Soc Work** 1996 Nov; 21(4):304–11 (9 ref.)
America's most cruel xenophobia. Keigher SM. **Health Soc Work** 1997 Aug;22(3):232–7 (15 ref.)

SOCIAL WORK

see related
COMMUNITY HEALTH SERVICES
RELIEF WORK

Psychosocial problem assessment and end-stage renal disease patient outcomes. Vourlekis BS, et al. **Adv Ren Replace Ther** 1997 Apr;4(2):136–44 (18 ref.)

Community care and social services. Renwick D. **BMJ** 1996 Oct 5;313(7061):869–72 (9 ref.)

Understanding and countering racism with first nations children in out-of-home care. Palmer S, et al. **Child Welfare** 1996 Nov–Dec;75(6):709–25 (20 ref.)

The socially complex family. New dilemmas for the neonatal social worker. Carson DP. **Clin Perinatol** 1996 Sep; 23(3):609–20 (5 ref.)

Social patterns of smoking behavior: trends and practice implications. Kaplan MS, et al. **Health Soc Work** 1997 Feb; 22(1):47–52 (60 ref.)

America's most cruel xenophobia. Keigher SM. **Health Soc Work** 1997 Aug;22(3):232–7 (15 ref.)

Heart disease and associated risk factors among Hawaiians: culturally responsive strategies. Mokuau N, et al. **Health Soc Work** 1995 Feb;20(1):46–51 (20 ref.)

Psychosocial work environment in human service organizations: a conceptual analysis and development of the demand-control model. Söderfeldt B, et al. **Soc Sci Med** 1996 May;42(9):1217–26 (50 ref.)

Mental retardation and domestic violence: an ecological approach to intervention. Carlson BE. **Soc Work** 1997 Jan; 42(1):79–89 (30 ref.)

Case advocacy in child welfare. Litzelfelner P, et al. **Soc Work** 1997 Jul;42(4):392–402 (56 ref.)

Should social work clients have the right to effective treatment? Myers LL, et al. **Soc Work** 1997 May; 42(3):288–98 (56 ref.)

Perinatal social work and the high risk obstetrics patient. Bachman DH, et al. **Soc Work Health Care** 1997; 24(3–4):3–19 (36 ref.)

The profile of HIV infection in women: a challenge to the profession. Katz DA. **Soc Work Health Care** 1997; 24(3–4):127–34 (18 ref.)

Perinatal loss: considerations in social work practice. Mahan CK, et al. **Soc Work Health Care** 1997;24(3–4):141–52 (17 ref.)

A birth father and adoption in the perinatal setting. Menard BJ. **Soc Work Health Care** 1997;24(3–4):153–63 (18 ref.)

EDUCATION

Values in health care professional socialization: implications for geriatric education in interdisciplinary teamwork. Clark PG. **Gerontologist** 1997 Aug;37(4):441–51 (80 ref.)

METHODS

The acquisition of life skills through adventure-based activities and programs: a review of the literature. Moote GT Jr, et al. **Adolescence** 1997 Spring;32(125):143–67 (102 ref.)

Developing delinquent youths: a reintegrative model for rehabilitation and a new role for the juvenile justice system. Bazemore G, et al. **Child Welfare** 1997 Sep–Oct; 76(5):665–716 (91 ref.)

In the aftermath: serial crisis intervention for people with HIV. Poindexter CC. **Health Soc Work** 1997 May; 22(2):125–32 (51 ref.)

Humor in the emergency room: a social work perspective. van Wormer K, et al. **Health Soc Work** 1997 May; 22(2):87–92 (17 ref.)

Perinatal social work with childbearing adolescents. Adams D, et al. **Soc Work Health Care** 1997;24(3–4):85–97 (37 ref.)

Perinatal social work and the family of the newborn intensive care infant. Bachman DH, et al. **Soc Work Health Care** 1997;24(3–4):21–37 (15 ref.)

The role of the social worker in perinatal substance-abuse. Cook C. **Soc Work Health Care** 1997;24(3–4):65–83 (46 ref.)

Counseling prenatal diagnosis patients: the role of the social worker. Fertel PE, et al. **Soc Work Health Care** 1997; 24(3–4):47–63 (28 ref.)

Infertility and assisted reproductive technology: the role of the perinatal social worker. Greenfeld DA. **Soc Work Health Care** 1997;24(3–4):39–46 (12 ref.)

Postpartum depression: a review for perinatal social workers. Walther VN. **Soc Work Health Care** 1997;24(3–4):99–111 (12 ref.)

ORGANIZATION & ADMINISTRATION

Confidentiality and managed care: ethical and legal concerns. Davidson JR, et al. **Health Soc Work** 1996 Aug; 21(3):208–15 (23 ref.)

What role for social work in the new health care practice paradigm? Keigher SM. **Health Soc Work** 1997 May; 22(2):149–55 (17 ref.)

Medicaid managed care and urban poor people: implications for social work. Perloff JD. **Health Soc Work** 1996 Aug; 21(3):189–95 (33 ref.)

Keeping managed care in balance [editorial] Poole DL. **Health Soc Work** 1996 Aug;21(3):163–6 (29 ref.)

Developments in the UK: work of the Low Income Project Team. Nelson M. **Proc Nutr Soc** 1997 Mar;56(1A):91–100 (13 ref.)

Afrocentricity: an emerging paradigm in social work practice. Schiele JH. **Soc Work** 1996 May;41(3):284–94 (63 ref.)

[The concept of sociomedical work in Russia in the late 1990] Martynenko AV. **Vestn Ross Akad Med Nauk** 1997; (8):44–50 (21 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

Ethical dilemmas in discharge planning for patients with Alzheimer's disease. Cummings SM, et al. **Health Soc Work** 1997 May;22(2):101–8 (39 ref.)

Pseudoissues in practice evaluation: impediments to responsible practice. Staudt M. **Soc Work** 1997 Jan; 42(1):99–106 (36 ref.)

STATISTICS & NUMERICAL DATA

Assessing social work effectiveness in child care practice: the contribution of randomized controlled trials [see comments] Newman T, et al. **Child Care Health Dev** 1997 Jul;23(4):287–96 (25 ref.) Comment in: Child Care Health Dev 1997 Jul;23(4):283–5.

SOCIAL WORK DEPARTMENT, HOSPITAL

ORGANIZATION & ADMINISTRATION

What role for social work in the new health care practice paradigm? Keigher SM. **Health Soc Work** 1997 May; 22(2):149–55 (17 ref.)

STANDARDS

Ethical dilemmas in discharge planning for patients with Alzheimer's disease. Cummings SM, et al. **Health Soc Work** 1997 May;22(2):101–8 (39 ref.)

SOCIAL WORK, PSYCHIATRIC

The social worker's record of the hospitalized patient: a physician's perspective. Benbassat J. **Isr J Psychiatry Relat Sci** 1996;33(4):246–52 (27 ref.)

Supportive care of the patient with pancreatic cancer: the role of the oncology social worker. Kennedy VN. **Oncology (Huntingt)** 1996 Sep;10(9 Suppl):35–7 (9 ref.)

Engaging significant others: the Tom Sawyer approach to case management. Kanter J. **Psychiatr Serv** 1996 Aug; 47(8):799–801 (20 ref.)

ORGANIZATION & ADMINISTRATION

Documentation of client dangerousness in a managed care environment. Callahan J. **Health Soc Work** 1996 Aug; 21(3):202–7 (34 ref.)

Managed care and people with severe mental illness: challenges and opportunities for social work. Shera W. **Health Soc Work** 1996 Aug;21(3):196–201 (56 ref.)

Radicalizing recovery: addiction, spirituality, and politics. Morell C. **Soc Work** 1996 May;41(3):306–12 (34 ref.)

The strengths perspective in social work practice: extensions and cautions. Saleebey D. **Soc Work** 1996 May; 41(3):296–305 (55 ref.)

SOCIAL WORKERS see **SOCIAL WORK**

SOCIALISM

Adolescence and senescence: new challenges for the Formerly Socialist Economies of Europe (FSE). Balogh A. **Adv Contracept** 1996 Dec;12(4):315–8 (13 ref.)

Disease ecology and a reformist alternative: the case of infant mortality. Gesler WM, et al. **Soc Sci Med** 1997 Mar; 44(5):657–71 (106 ref.)

SOCIALIZATION

The acquisition of life skills through adventure-based activities and programs: a review of the literature. Moote GT Jr, et al. **Adolescence** 1997 Spring;32(125):143–67 (102 ref.)

Parental influence on children's socialization to gender roles. Witt SD. **Adolescence** 1997 Summer;32(126):253–9 (42 ref.)

Spinal cord injury rehabilitation. 5. Through the lifespan. Cawley MF, et al. **Arch Phys Med Rehabil** 1997 Mar;78(3 Suppl):S73–8 (75 ref.)

Consultation to residential psychosocial rehabilitation agencies. Kupers TA. **Community Ment Health J** 1996 Aug; 32(4):403–13; discussion 415–8 (32 ref.)

Values in health care professional socialization: implications for geriatric education in interdisciplinary teamwork. Clark PG. **Gerontologist** 1997 Aug;37(4):441–51 (80 ref.)

Practitioner review: psychosocial treatments for conduct disorder in children. Kazdin AE. **J Child Psychol Psychiatry** 1997 Feb;38(2):161–78 (150 ref.)

Culture and child behavior and psychosocial development. Pachter LM, et al. **J Dev Behav Pediatr** 1996 Jun; 17(3):191–8 (44 ref.)

The social context of mental illness and violence. Hiday VA. **J Health Soc Behav** 1995 Jun;36(2):122–37 (143 ref.)

Incorporating political socialization theory into baccalaureate nursing education. Brown SG. **Nurs Outlook** 1996 May–Jun;44(3):120–3 (29 ref.)

SOCIALIZED MEDICINE see **STATE MEDICINE**

SOCIETIES

Position of the American Dietetic Association: food and water safety. **J Am Diet Assoc** 1997 Feb;97(2):184–9 (44 ref.)

Position of the American Dietetic Association: nutrition in comprehensive program planning for persons with developmental disabilities. **J Am Diet Assoc** 1997 Feb; 97(2):189–93 (39 ref.)

Position of the American Dietetic Association: nutrition education for the public. **J Am Diet Assoc** 1996 Nov; 96(11):1183–7 (40 ref.)

Position of the American Dietetic Association: nutrition, aging, and the continuum of care. Weddle D, et al. **J Am Diet Assoc** 1996 Oct;96(10):1048–52 (46 ref.)

SOCIETIES, MEDICAL

Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Hirsh J, et al. **Circulation** 1996 Jun 15; 93(12):2212–45 (451 ref.)

Fiber, lipids, and coronary heart disease. A statement for healthcare professionals from the Nutrition Committee, American Heart Association. Van Horn L. **Circulation** 1997 Jun 17;95(12):2701–4 (53 ref.)

The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance. Jones RN. **Diagn Microbiol Infect Dis** 1996 Aug;25(4):153–61 (57 ref.)

Quality control by the Society of Hair Testing. Sachs H. **Forensic Sci Int** 1997 Jan 17;84(1–3):145–50 (4 ref.)

Report on consensus conference on colorectal cancer: Royal College of Surgeons of Edinburgh 1993. Fearon KC, et al. **Health Bull (Edinb)** 1996 Jan;54(1):22–31 (17 ref.)

Infertility revisited: the state of the art today and tomorrow. The ESHRE Capri Workshop. European Society for Human Reproduction and Embryology. **Hum Reprod** 1996 Aug;11(8):1779–807 (254 ref.)

Torture and medical profession—an overview. Umesh MS. **J Indian Med Assoc** 1996 Jul;94(7):257–8, 261 (17 ref.)

Oral presentations for surgical meetings. Edwards MJ, et al. **J Surg Res** 1997 Feb 15;68(1):87–90 (4 ref.)

MSNJ's expert panel on late-term abortion. Medical Society of New Jersey. Caggiano AP Jr, et al. **N J Med** 1997 Aug; 94(8):25–8 (0 ref.)

Forty years of randomised trials in the New Zealand Medical Journal. Neal B, et al. **N Z Med J** 1996 Oct 11; 109(1031):372–3 (6 ref.)

Errors by the American Psychiatric Association, the American Psychological Association, and the National Educational, Association in representing homosexuality in amicus briefs about Amendment 2 to the U.S. Supreme Court. Cameron P, et al. **Psychol Rep** 1996 Oct; 79(2):383–404 (70 ref.)

Paediatric life support. An advisory statement by the Paediatric Life Support Working Group of the International Liaison Committee on Resuscitation. Nadkarni V, et al. **Resuscitation** 1997 Apr;34(2):115–27 (69 ref.)

[Palliative care--objectives and accomplishments of the Association for the Development of Palliative Care] Kermarec J. **Bull Acad Natl Med** 1996 Nov;180(8):1951–64; discussion 1964–5 (13 ref.) (Eng. Abstr.) **(Fre)**

[Mexican consensus on Helicobacter pylori. National Consensus Group of the Mexican Association of Gastroenterology] **Rev Gastroenterol Mex** 1997 Jan–Mar; 62(1):41–5 (0 ref.) **(Spa)**

ORGANIZATION & ADMINISTRATION

Ophthalmology and the Internet [editorial] Lindstrom RL. **J Cataract Refract Surg** 1996 Nov;22(9):1127–9 (11 ref.)

The scientific platform and activity of the Ukrainian INEC Section. Rubenchik BL, et al. **J Environ Pathol Toxicol Oncol** 1996;15(2–4):299–301 (4 ref.)

STANDARDS

Cytopathology laboratory improvement programs of the College of American Pathologists: Laboratory Accreditation Program (CAP LAP) and Performance Improvement Program in Cervicovaginal Cytology (CAP PAP). Nielsen ML. **Arch Pathol Lab Med** 1997 Mar; 121(3):256–9 (26 ref.)

TRENDS

Quality and liability issues with the Papanicolaou smear: the role of professional organizations in reform initiatives. Stanley MW. **Arch Pathol Lab Med** 1997 Mar;121(3):321–6 (10 ref.)

SOCIETIES, NURSING

Domestic violence. Implications for the American College of Nurse-Midwives and its members. Paluzzi PA, et al. **J Nurse Midwifery** 1996 Nov–Dec;41(6):430–5 (14 ref.)

SOCIETIES, SCIENTIFIC

Health Care Financing Administration/American Society for Cytotechnology inspections: government assessment of cytology laboratory practice under the regulations of the Clinical Laboratory Improvement Amendments of 1988. Triol JH, et al. **Arch Pathol Lab Med** 1997 Mar; 121(3):264–6 (3 ref.)

Errors by the American Psychiatric Association, the American Psychological Association, and the National Educational, Association in representing homosexuality in amicus briefs about Amendment 2 to the U.S. Supreme Court. Cameron P, et al. **Psychol Rep** 1996 Oct; 79(2):383–404 (70 ref.)

STANDARDS

American Society of Cytopathology Laboratory Accreditation Program. Gupta PK, et al. **Arch Pathol Lab Med** 1997 Mar;121(3):260–3 (25 ref.)

Health Care Financing Administration/American Society for Cytotechnology inspections: government assessment of cytology laboratory practice under the regulations of the Clinical Laboratory Improvement Amendments of 1988. Triol JH, et al. **Arch Pathol Lab Med** 1997 Mar; 121(3):264–6 (3 ref.)

SOCIOECONOMIC FACTORS

Difficulties in mobility among elderly people and their association with socioeconomic factors, dwelling environment and use of services. Sakari-Rantala R, et al. **Aging (Milano)** 1995 Dec;7(6):433–40 (58 ref.)

Whither studies on the socioeconomic foundations of population health? [editorial; comment] Kaplan GA, et al. **Am J Public Health** 1997 Sep;87(9):1409–11 (18 ref.) Comment on: Am J Public Health 1997 Sep;87(9):1476–83. Comment on: Am J Public Health 1997 Sep;87(9):1491–8. Comment on: Am J Public Health 1997 Sep;87(9):1499–503. Comment on: Am J Public Health 1997 Sep;87(9):1504–6.

The socio-economic aspects of malnutrition in Sicily. La Grutta A, et al. **Ann Ist Super Sanita** 1995;31(4):441–4 (14 ref.)

Changing social factors and their long-term implications for health. Wadsworthx ME. **Br Med Bull** 1997 Jan; 53(1):198–209 (67 ref.)

Race and ethnicity as determinants of child health: a personal view. Spencer N. **Child Care Health Dev** 1996 Sep; 22(5):327–45 (66 ref.)

The dismantling of a myth: a review of eating disorders and socioeconomic status. Gard MC, et al. **Int J Eat Disord** 1996 Jul;20(1):1–12 (40 ref.)

Socio-economic factors in cardiovascular disease. Marmot MG. **J Hypertens Suppl** 1996 Dec;14(5):S201–5 (12 ref.)

Socio-economic differentials in health: the role of nutrition. Smith GD, et al. **Proc Nutr Soc** 1997 Mar;56(1A):75–90 (75 ref.)

Prostate cancer, race, and socioeconomic status: inadequate adjustment for social factors in assessing racial differences. Dale W, et al. **Prostate** 1996 Nov;29(5):271–81 (53 ref.)

The role of ethnic versus nonethnic sociocultural factors in substance use and misuse. Collins RL. **Subst Use Misuse** 1996 Jan;31(1):95–101 (27 ref.)

[A concept of control of antituberculous measures under new socioeconomic conditions in Russia] Karpov LP. **Probl Tuberk** 1997;(1):6–8 (6 ref.) **(Rus)**

[The impact of ecological pressing on tuberculosis and nonspecific lung diseases in the Astrakhan' region] Vinnik LA. **Probl Tuberk** 1997;(1):27–30 (6 ref.) (Eng. Abstr.) **(Rus)**

[Present day socioeconomic conditions and the populations health] Ovcharov VK. **Vestn Ross Akad Med Nauk** 1997; (1):51–9 (18 ref.) (Eng. Abstr.) **(Rus)**

SOCIOECONOMIC STATUS see **SOCIAL CLASS**

SOCIOENVIRONMENTAL THERAPY

Psychosocial rehabilitation and psychiatry: what are the boundaries? Bachrach LL. **Can J Psychiatry** 1996 Feb; 41(1):28–35 (55 ref.)

SOCIOLOGY

see related
GROUP PROCESSES

The modification of human society by natural systems: discontinuities caused by the exploitation of endemic species and the introduction of exotics. Cairns J Jr, et al. **Environ Health Perspect** 1996 Nov;104(11):1142–5 (28 ref.)

Theory, explanation, and a third generation of theoretical development in social gerontology. Bengtson VL, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 Mar;52(2):S72–88 (154 ref.)

EDUCATION

Assimilating sociology: critical reflections on the 'sociology in nursing' debate. Mulholland J. **J Adv Nurs** 1997 Apr; 25(4):844–52 (27 ref.)

SOCIOLOGY, MEDICAL

The development and use of the concept of a sexually transmitted disease core. Thomas JC, et al. **J Infect Dis** 1996 Oct;174 Suppl 2:S134–43 (103 ref.)

Medical practice and social authority [see comments] Pippin RB. **J Med Philos** 1996 Aug;21(4):417–37 (19 ref.) Comment in: J Med Philos 1996 Aug;21(4):357–73.

Toward a political ecology of health in medical anthropology [comment] Baer HA. **Med Anthropol Q** 1996 Dec; 10(4):451–4 (15 ref.) Comment on: Med Anthropol Q 1996 Dec;10(4):455–75. Comment on: Med Anthropol Q 1996 Dec;10(4):476–95. Comment on: Med Anthropol Q 1996 Dec;10(4):496–515.

Reconfiguring nature and culture: intersections of medical anthropology and technoscience studies. Casper MJ, et al. **Med Anthropol Q** 1996 Dec;10(4):523–36 (64 ref.)

Technology and alternative cancer therapies: an analysis of heterodoxy and constructivism. Hess DJ. **Med Anthropol Q** 1996 Dec;10(4):657–74 (62 ref.)

Death in technological time: locating the end of meaningful life. Lock M. **Med Anthropol Q** 1996 Dec;10(4):575–600 (63 ref.)

The social construction of drug debates. Dingelstad D, et al. **Soc Sci Med** 1996 Dec;43(12):1829–38 (65 ref.)

[Antinomies and epistemological "sutures" between the socio-biological and the collective-individual characteristics within the field of social epidemiology] de Melo-Filho DA. **Rev Saude Publica** 1996 Aug;30(4):383–91 (22 ref.) (Eng. Abstr.) **(Por)**

METHODS

Personal risk taking and the spread of disease: beyond core groups. Rothenberg RB, et al. **J Infect Dis** 1996 Oct;174 Suppl 2:S144–9 (36 ref.)

SOCIOPATHIC PERSONALITY see **ANTISOCIAL PERSONALITY DISORDER**

SODIUM

see related
HYPERNATREMIA
HYPONATREMIA
NATRIURESIS

Mineralocorticoid receptors, salt, and hypertension. Funder JW, et al. **Recent Prog Horm Res** 1997;52:247–60; discussion 261–2 (54 ref.)

ANALYSIS

International consensus on the standardization of sodium and potassium measurements by ion-selective electrodes in undiluted samples. Külpmann WR, et al. **Scand J Clin Lab Invest Suppl** 1996;224:145–60 (6 ref.)

METABOLISM

Heterogeneity and functional properties of subtypes of sodium-dependent glutamate transporters in the mammalian central nervous system. Robinson MB, et al. **Adv Pharmacol** 1997;37:69–115 (210 ref.)

Genetic and nongenetic determinants of salt sensitivity and blood pressure. Cowley AW Jr. **Am J Clin Nutr** 1997 Feb; 65(2 Suppl):587S–593S (50 ref.)

Mechanisms of abnormal renal sodium handling in obesity hypertension. Hall JE. **Am J Hypertens** 1997 May;10(5 Pt 2):49S–55S (48 ref.)

Molecular biology of Na+ absorption. Barbry P, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):G571–85 (155 ref.)

Primary sodium ion translocating enzymes. Dimroth P. **Biochim Biophys Acta** 1997 Jan 16;1318(1-2):11–51 (273 ref.)

Regulation of sodium transport by endogenous dopamine production in proximal tubular and OK cells. Baines AD, et al. **Clin Exp Hypertens** 1997 Jan-Feb;19(1-2):87–91 (14 ref.)

Regulation of renal tubular sodium transport by angiotensin II and atrial natriuretic factor. Harris PJ, et al. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S112–8 (74 ref.)

Interactions between arterial pressure and sodium excretion. Navar LG, et al. **Curr Opin Nephrol Hypertens** 1996 Jan; 5(1):64–71 (89 ref.)

Sodium balance in renal failure. Shemin D, et al. **Curr Opin Nephrol Hypertens** 1997 Mar;6(2):128–32 (39 ref.)

Sodium channel expression: a dynamic process in neurons and non-neuronal cells. Black JA, et al. **Dev Neurosci** 1996; 18(3):139–52 (101 ref.)

Polymorphism in the beta subunit and Na+ transport [editorial] Warnock DG. **J Am Soc Nephrol** 1996 Dec; 7(12):2490–4 (62 ref.)

Gene expression of the Na-Ca exchanger in cardiac hypertrophy. Menick DR, et al. **J Card Fail** 1996 Dec;2(4 Suppl):S69–76 (40 ref.)

Role of intracellular sodium overload in the genesis of cardiac arrhythmias. Levi AJ, et al. **J Cardiovasc Electrophysiol** 1997 Jun;8(6):700–21 (209 ref.)

Potassium, sodium, and cancer: a review. Jansson B. **J Environ Pathol Toxicol Oncol** 1996;15(2-4):65–73 (12 ref.)

The renal electrogenic Na+:HCO-3 cotransporter. Boron VF, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):263–8 (24 ref.)

The key role of the H+ V-ATPase in acid-base balance and Na+ transport processes in frog skin. Ehrenfeld J, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):247–56 (78 ref.)

Sodium and the kidney in essential hypertension. de Wardener HE. **J Hum Hypertens** 1996 Oct;10(10):645–8 (65 ref.)

Does primary salt wasting occur in 11-beta-hydroxylase deficiency? Singer-Granick C, et al. **J Pediatr Endocrinol Metab** 1995 Oct-Dec;8(4):275–80 (21 ref.)

Molecular mechanisms in the regulation of renal proximal tubular Na/phosphate cotransport. Murer H, et al. **Kidney Blood Press Res** 1996;19(3-4):151–4 (27 ref.)

Cellular mechanisms for bi-directional regulation of tubular sodium reabsorption. Aperia A, et al. **Kidney Int** 1996 Jun; 49(6):1743–7 (44 ref.)

Pathogenesis of water and sodium retention in cirrhosis. Martin PY, et al. **Kidney Int Suppl** 1997 Jun;59:S43–9 (66 ref.)

Sodium and water retention in heart failure: pathogenesis and treatment. Martin PY, et al. **Kidney Int Suppl** 1997 Jun;59:S57–61 (39 ref.)

Some sodium, potassium and water changes in the elderly and their treatment. Andreucci VE, et al. **Nephrol Dial Transplant** 1996;11 Suppl 9:9–17 (113 ref.)

A view of type I and II Na+/P(i) transporters through microelectrodes [editorial] Busch AE. **Nephrol Dial Transplant** 1997 Apr;12(4):638–40 (11 ref.)

Sodium and water profiling in chronic uraemia. Churchill DN. **Nephrol Dial Transplant** 1996;11 Suppl 8:38–41 (15 ref.)

Urea, sodium, and water changes in profiling dialysis. Mann H, et al. **Nephrol Dial Transplant** 1996;11 Suppl 8:10–5 (12 ref.)

Electrolyte modelling: sodium. Is dialysate sodium profiling actually useful? Petitclerc T, et al. **Nephrol Dial Transplant** 1996;11 Suppl 2:35–8 (21 ref.)

Sodium profiling in elderly haemodialysis patients. Raja RM. **Nephrol Dial Transplant** 1996;11 Suppl 8:42–5 (16 ref.)

Long-term control of blood pressure and sodium balance: is the baseline nocturnal? Michell A. **Perspect Biol Med** 1997 Summer;40(4):516–28 (61 ref.)

[Essential hypertension] Ando K, et al. **Nippon Rinsho** 1996 Mar;54(3):770–5 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Na+/K+/2Cl- cotransport protein, Na+/Cl- cotransport protein] Inoue T, et al. **Nippon Rinsho** 1996 Mar; 54(3):625–31 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Na+ -dependent amino acid transporters: their structure and function] Kanai Y. **Nippon Rinsho** 1996 Mar; 54(3):368–45 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Na+ -Ca2+ exchanger] Matsuda T, et al. **Nippon Rinsho** 1996 Mar;54(3):612–7 (27 ref.) (Eng. Abstr.) **(Jpn)**

[Sodium-losing nephropathy] Terano T, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):674–7 (4 ref.) **(Jpn)**

[The effect of physical factors on the active transport of sodium ions across cell membranes] Tereshin SIu. **Vopr Kurortol Fizioter Lech Fiz Kult** 1997 Mar-Apr; (2):41–3 (31 ref.) **(Rus)**

PHARMACOLOGY

Sodium- and chloride-dependent transport of taurine at the blood-brain barrier. Tsuji A, et al. **Adv Exp Med Biol** 1996; 403:385–91 (12 ref.)

Sodium, potassium, and blood pressure. Weinberger MH. **Am J Hypertens** 1997 May;10(5 Pt 2):46S–48S (19 ref.)

PHYSIOLOGY

The amiloride-sensitive epithelial Na+ channel: binding sites and channel densities. Blazer-Yost BL, et al. **Am J Physiol** 1997 Mar;272(3 Pt 1):C761–9 (87 ref.)

Regulation of Na+/H+ antiporter in trout red blood cells. Malapert M, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):353–60 (48 ref.)

SODIUM BICARBONATE

PHARMACOLOGY

The effects of sodium bicarbonate ingestion on exercise performance. Linderman JK, et al. **Sports Med** 1994 Aug; 18(2):75–80 (34 ref.)

THERAPEUTIC USE

Sodium bicarbonate in cardiac arrest: a reappraisal. Vukmir RB, et al. **Am J Emerg Med** 1996 Mar;14(2):192–206 (184 ref.)

[Controversies concerning the use of sodium bicarbonate in metabolic acidosis] Bogdanik T. **Przegl Lek** 1995; 52(10):513–7 (21 ref.) **(Pol)**

SODIUM CHANNELS

see related
NA(+)-K(+)-EXCHANGING ATPASE

[The amiloride sensitive sodium channel] Barbry P, et al. **Nephrologie** 1996;17(7):389–93 (26 ref.) (Eng. Abstr.) **(Fre)**

[Recent progress in sodium channel structures relevant to their functions] Nakayama H. **Nippon Rinsho** 1996 Mar; 54(3):652–9 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Structure, function and regulation of voltage-gated sodium channel] Okamura Y. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):208–12 (22 ref.) **(Jpn)**

ANALYSIS

Immunocytochemical investigations of sodium channels along nodal and internodal portions of demyelinated axons. England JD, et al. **Microsc Res Tech** 1996 Aug 1; 34(5):445–51 (51 ref.)

ANTAGONISTS & INHIBITORS

Sodium channels and therapy of central nervous system diseases. Taylor CP, et al. **Adv Pharmacol** 1997;39:47–98 (300 ref.)

Biophysical and molecular properties of amiloride-inhibitable Na+ channels in alveolar epithelial cells. Matalon S, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):L1–22 (152 ref.)

Adverse effects of class I antiarrhythmic drugs. Caron J, et al. **Drug Saf** 1997 Jul;17(1):8–36 (366 ref.)

BIOSYNTHESIS

Immature epithelial Na+ channel expression is one of the pathogenetic mechanisms leading to human neonatal respiratory distress syndrome. O'Brodovich HM. **Proc Assoc Am Physicians** 1996 Sep;108(5):345–55 (86 ref.)

CHEMISTRY

Structure and modulation of Na+ and Ca2+ channels. Catterall WA. **Ann N Y Acad Sci** 1993 Dec 20;707:1–19 (79 ref.)

Molecular aspects of ion permeation through channels. Imoto K. **Ann N Y Acad Sci** 1993 Dec 20;707:38–50 (28 ref.)

Structure and function of sodium channels. Noda M. **Ann N Y Acad Sci** 1993 Dec 20;707:20–37 (32 ref.)

Molecular and physicochemical aspects of local anesthetic-membrane interaction. de-Paula E, et al. **Braz J Med Biol Res** 1996 Jul;29(7):877–94 (199 ref.)

DRUG EFFECTS

Sodium and potassium channel modulators: their role in neuroprotection. Obrenovitch TP. **Int Rev Neurobiol** 1997; 40:109–35 (159 ref.)

Application of physiologically active substances isolated from natural resources to pharmacological studies. Ohizumi Y. **Jpn J Pharmacol** 1997 Apr;73(4):263–89 (142 ref.)

Diversity and regulation of amiloride-sensitive Na+ channels. Benos DJ, et al. **Kidney Int** 1996 Jun;49(6):1632–7 (35 ref.)

Neuronal ion channels as the target sites of insecticides. Narahashi T. **Pharmacol Toxicol** 1996 Jul;79(1):1–14 (146 ref.)

GENETICS

Molecular biology of Na+ absorption. Barbry P, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):G571–85 (155 ref.)

Structure and function of cardiac sodium and potassium channels. Roden DM, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):H511–25 (166 ref.)

Ion channel mutations in periodic paralysis and related myotonic diseases. Brown RH Jr. **Ann N Y Acad Sci** 1993 Dec 20;707:305–16 (51 ref.)

Sodium channel defects in myotonia and periodic paralysis. Cannon SC. **Annu Rev Neurosci** 1996;19:141–64 (78 ref.)

Polymorphism in the beta subunit and Na+ transport [editorial] Warnock DG. **J Am Soc Nephrol** 1996 Dec; 7(12):2490–4 (62 ref.)

Hereditary dysfunction of voltage-gated sodium channels: from clinical phenotype to molecular mechanisms. George AL Jr. **Nephrol Dial Transplant** 1996 Sep;11(9):1730–7 (71 ref.)

The ENaC channel as the primary determinant of two human diseases: Liddle syndrome and pseudohypoaldosteronism. Schild L. **Nephrologie** 1996;17(7):395–400 (27 ref.)

From mutation to myotonia in sodium channel disorders. Cannon SC. **Neuromuscul Disord** 1997 Jun;7(4):241–9 (44 ref.)

Epithelial sodium channels: function, structure, and regulation. Garty H, et al. **Physiol Rev** 1997 Apr; 77(2):359–96 (451 ref.)

[Long QT syndrome] Nakajima T, et al. **Nippon Rinsho** 1996 Mar;54(3):776–81 (10 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

The renal epithelial sodium channel: new insights in understanding hypertension. Rossier BC. **Adv Nephrol Necker Hosp** 1996;25:275–86 (38 ref.)

Sodium transporters in health and disease. Warnock DG. **Curr Opin Nephrol Hypertens** 1997 Jul;6(4):372–6 (32 ref.)

Sodium channel expression: a dynamic process in neurons and non-neuronal cells. Black JA, et al. **Dev Neurosci** 1996; 18(3):139–52 (101 ref.)

Structure and regulation of the amiloride-sensitive epithelial sodium channel. Barbry P, et al. **Ion Channels** 1996;4:115–67 (255 ref.)

1996 Homer Smith Award Lecture. Cum grano salis: the epithelial sodium channel and the control of blood pressure. Rossier BC. **J Am Soc Nephrol** 1997 Jun;8(6):980–92 (81 ref.)

Polymorphism in the beta subunit and Na+ transport [editorial] Warnock DG. **J Am Soc Nephrol** 1996 Dec; 7(12):2490–4 (62 ref.)

The guanidinium toxin binding site on the sodium channel. Fozzard HA, et al. **Jpn Heart J** 1996 Sep;37(5):683–92 (29 ref.)

Hereditary dysfunction of voltage-gated sodium channels: from clinical phenotype to molecular mechanisms. George AL Jr. **Nephrol Dial Transplant** 1996 Sep;11(9):1730–7 (71 ref.)

[Liddle syndrome] Tamura H, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):612–5 (13 ref.) **(Jpn)**

PHYSIOLOGY

Sodium channels and therapy of central nervous system diseases. Taylor CP, et al. **Adv Pharmacol** 1997;39:47–98 (300 ref.)

Molecular biology of Na+ absorption. Barbry P, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):G571–85 (155 ref.)

The amiloride-sensitive epithelial Na+ channel: binding sites and channel densities. Blazer-Yost BL, et al. **Am J Physiol** 1997 Mar;272(3 Pt 1):C761–9 (87 ref.)

Biophysical and molecular properties of amiloride-inhibitable Na+ channels in alveolar epithelial cells. Matalon S, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):L1–22 (152 ref.)

Structure and function of cardiac sodium and potassium channels. Roden DM, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):H511–25 (166 ref.)

Structure and modulation of Na+ and Ca2+ channels. Catterall WA. **Ann N Y Acad Sci** 1993 Dec 20;707:1–19 (79 ref.)

Molecular aspects of ion permeation through channels. Imoto K. **Ann N Y Acad Sci** 1993 Dec 20;707:38–50 (28 ref.)

Structure and function of sodium channels. Noda M. **Ann N Y Acad Sci** 1993 Dec 20;707:20–37 (32 ref.)

Revisiting the ionic selectivity of Na+ channels [comment] Heginbotham L. **Biophys J** 1996 Dec;71(6):2916–8 (11 ref.) Comment on: Biophys J 1996 Dec;71(6):3110–25.

A reappraisal of aldosterone effects on the kidney: new insights provided by epithelial sodium channel cloning. Gründer S, et al. **Curr Opin Nephrol Hypertens** 1997 Jan; 6(1):35–9 (50 ref.)

Mechanisms of paresthesiae, dysesthesiae, and hyperesthesiae: role of Na+ channel heterogeneity. Rizzo MA, et al. **Eur Neurol** 1996;36(1):3–12 (44 ref.)

Molecular biology of the amiloride-sensitive epithelial Na+ channel. Lingueglia E, et al. **Exp Physiol** 1996 May; 81(3):483–92 (30 ref.)

Molecular properties of sodium and calcium channels. Catterall WA. **J Bioenerg Biomembr** 1996 Jun;28(3):219–30 (63 ref.)

Epithelial sodium channels and hypertension [editorial] Fuller PJ. **J Hypertens** 1996 Dec;14(12):1383–6 (32 ref.)

Physiological and pathophysiological role of the epithelial sodium channel in the control of blood pressure. Hummler E, et al. **Kidney Blood Press Res** 1996;19(3–4):160–5 (49 ref.)

Diversity and regulation of amiloride-sensitive Na+ channels. Benos DJ, et al. **Kidney Int** 1996 Jun;49(6):1632–7 (35 ref.)

Clustering sodium channels at the node of Ranvier: close encounters of the axon-glia kind. Salzer JL. **Neuron** 1997 Jun;18(6):843–6 (24 ref.)

The membrane transporters regulating epithelial NaCl secretion. Greger R. **Pflugers Arch** 1996 Aug;432(4):579–88 (97 ref.)

Epithelial sodium channels: function, structure, and regulation. Garty H, et al. **Physiol Rev** 1997 Apr; 77(2):359–96 (451 ref.)

Voltage-gated Na+ channels in glia: properties and possible functions. Sontheimer H, et al. **Trends Neurosci** 1996 Aug; 19(8):325–31 (67 ref.)

[CFTR as cAMP-dependent chloride channels and as cAMP-dependent regulator of sodium channels] Tohyama M. **Nippon Rinsho** 1996 Feb;54(2):429–33 (17 ref.) (Eng. Abstr.) **(Jpn)**

SODIUM CHLORIDE

see related
DIET, SODIUM-RESTRICTED

Renal P450 metabolites of arachidonic acid and the development of hypertension in Dahl salt-sensitive rats. Roman RJ, et al. **Am J Hypertens** 1997 May;10(5 Pt 2):63S–67S (33 ref.)

Oxidative stress and responses in Arabidopsis thaliana and Oryza sativa subjected to chilling and salinity stress. Burdon RH, et al. **Biochem Soc Trans** 1996 May; 24(2):469–72 (17 ref.)

ADMINISTRATION & DOSAGE

Salt intake and reductions in arterial pressure and proteinuria. Is there a direct link? Bakris GL, et al. **Am J Hypertens** 1996 Dec;9(12 Pt 2):200S–206S (75 ref.)

ADVERSE EFFECTS

Salt--more adverse effects. MacGregor GA. **Am J Hypertens** 1997 May;10(5 Pt 2):37S–41S (23 ref.)

DIAGNOSTIC USE

The accuracy of indirect immunofluorescence on sodium chloride-split skin in differentiating subepidermal bullous diseases [editorial; comment] Mutasim DF. **Arch Dermatol** 1997 Sep;133(9):1158–60 (23 ref.) Comment on: Arch Dermatol 1997 Sep;133(9):1102–7.

Provoking nonepileptic seizures: the ethics of deceptive diagnostic testing. Burack JH, et al. **Hastings Cent Rep** 1997 Jul–Aug;27(4):24–33 (25 ref.)

Three-dimensional saline contrast hysterosonography and surface rendering of uterine cavity pathology. Weinraub Z, et al. **Ultrasound Obstet Gynecol** 1996 Oct;8(4):277–82 (16 ref.)

[Saline infusion test] Niimura S, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:337–40 (5 ref.) **(Jpn)**

HISTORY

The history of salt – aspects of interest to the nephrologist. Ritz E. **Nephrol Dial Transplant** 1996 Jun;11(6):969–75 (7 ref.)

METABOLISM

Salt and water transport across alveolar and distal airway epithelia in the adult lung. Matthay MA, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):L487–503 (145 ref.)

Role of mitochondria-rich cells in epithelial chloride uptake. Larsen EH, et al. **Exp Physiol** 1996 May;81(3):525–34 (25 ref.)

Role of ion exchangers in mediating NaCl transport in the proximal tubule. Aronson PS. **Kidney Int** 1996 Jun; 49(6):1665–70 (58 ref.)

Plants as a source of salt. Aliotta G, et al. **Kidney Int Suppl** 1997 Jun;59:S114–7 (16 ref.)

The membrane transporters regulating epithelial NaCl secretion. Greger R. **Pflugers Arch** 1996 Aug;432(4):579–88 (97 ref.)

Ion exchangers mediating NaCl transport in the proximal tubule. Aronson PS. **Wien Klin Wochenschr** 1997 Jun 27; 109(12–13):435–40 (58 ref.)

PHARMACOLOGY

The implication of renin-angiotensin system on renal injury seen in Dahl salt-sensitive rats. Hirawa N, et al. **Am J Hypertens** 1997 May;10(5 Pt 2):102S–106S (19 ref.)

Salt and blood pressure: population and individual perspectives. Kuller LH. **Am J Hypertens** 1997 May;10(5 Pt 2):29S–36S (35 ref.)

Epidemiologic evidence on salt and blood pressure. Law MR. **Am J Hypertens** 1997 May;10(5 Pt 2):42S–45S (19 ref.)

Long-term infusion of kallikrein attenuates renal injury in Dahl salt-sensitive rats. Uehara Y, et al. **Am J Hypertens** 1997 May;10(5 Pt 2):83S–88S (23 ref.)

Insulin resistance and salt sensitivity. A renal hemodynamic abnormality? Weir MR. **Am J Hypertens** 1996 Dec;9(12 Pt 2):193S–199S (74 ref.)

Salt sensitivity: does it play an important role in the pathogenesis and treatment of hypertension? Weinberger MH. **Curr Opin Nephrol Hypertens** 1996 May;5(3):205–8 (20 ref.)

The neuroendocrinology of thirst and salt appetite: visceral sensory signals and mechanisms of central integration. Johnson AK, et al. **Front Neuroendocrinol** 1997 Jul; 18(3):292–353 (369 ref.)

Salt tolerance in plants and microorganisms: toxicity targets and defense responses. Serrano R. **Int Rev Cytol** 1996; 165:1–52 (264 ref.)

Salt sensitivity as a phenotype for genetic studies of human hypertension [editorial] Sharma AM. **Nephrol Dial Transplant** 1996 Jun;11(6):927–9 (14 ref.)

THERAPEUTIC USE

Endometrial ablation by hysteroscopic instillation of hot saline solution. Goldrath MH, et al. **J Am Assoc Gynecol Laparosc** 1997 Feb;4(2):235–40 (13 ref.)

SODIUM CHLORIDE, DIETARY

The taste for salt in humans. Mattes RD. **Am J Clin Nutr** 1997 Feb;65(2 Suppl):692S–697S (73 ref.)

ADMINISTRATION & DOSAGE

Blood pressure response to sodium in children and adolescents. Falkner B, et al. **Am J Clin Nutr** 1997 Feb; 65(2 Suppl):618S–621S (27 ref.)

Salt and blood pressure in community-based intervention trials. Staessen JA, et al. **Am J Clin Nutr** 1997 Feb;65(2 Suppl):661S–670S (99 ref.)

Central inhibition of salt appetite by oxytocin in rats. Stricker EM, et al. **Regul Pept** 1996 Oct 8;66(1–2):83–5 (25 ref.)

The role of angiotensin II in ingestive behaviour: a brief review of angiotensin II, thirst and Na appetite. Weisinger RS, et al. **Regul Pept** 1996 Oct 8;66(1–2):73–81 (100 ref.)

[Salt--an analysis of the connection between intake and health] Pedersen OB, et al. **Ugeskr Laeger** 1996 Nov 4; 158(45):6415–20 (40 ref.) (Eng. Abstr.) **(Dan)**

[Salt-sensitive hypertension] Suzuki H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):59–62 (21 ref.) **(Jpn)**

SODIUM CHLORIDE, DIETARY

ADVERSE EFFECTS

Genetic and nongenetic determinants of salt sensitivity and blood pressure. Cowley AW Jr. **Am J Clin Nutr** 1997 Feb; 65(2 Suppl):587S–593S (50 ref.)

Overview of dietary sodium effects on and interactions with cardiovascular and neuroendocrine functions. Ely DL. **Am J Clin Nutr** 1997 Feb;65(2 Suppl):594S–605S (163 ref.)

Nature and role of observational studies in public health policy concerning the effects of dietary salt intake on blood pressure. Haynes RB. **Am J Clin Nutr** 1997 Feb;65(2 Suppl):622S–625S (7 ref.)

Dietary sodium and blood pressure: interactions with other nutrients. Kotchen TA, et al. **Am J Clin Nutr** 1997 Feb; 65(2 Suppl):708S–711S (61 ref.)

Heterogeneous responses to changes in dietary salt intake: the salt-sensitivity paradigm. Luft FC, et al. **Am J Clin Nutr** 1997 Feb;65(2 Suppl):612S–617S (49 ref.)

Role of adequate dietary calcium intake in the prevention and management of salt–sensitive hypertension. McCarron DA. **Am J Clin Nutr** 1997 Feb;65(2 Suppl):712S–716S (24 ref.)

The INTERSALT Study: background, methods, findings, and implications. Stamler J. **Am J Clin Nutr** 1997 Feb;65(2 Suppl):626S–642S (153 ref.)

Dietary sodium chloride and potassium have effects on the pathophysiology of hypertension in humans and animals. Tobian L. **Am J Clin Nutr** 1997 Feb;65(2 Suppl):606S–611S (21 ref.)

Salt–sensitive hypertension: lessons from animal models. Sanders PW. **Am J Kidney Dis** 1996 Nov;28(5):775–82 (79 ref.)

Evaluation of the aetiological role of dietary salt exposure in gastric and other cancers in humans. Cohen AJ, et al. **Food Chem Toxicol** 1997 Feb;35(2):271–93 (161 ref.)

Salt intake, cardiovascular disease and public health [editorial; comment] Beilin LJ. **Med J Aust** 1997 Apr 21; 166(8):396–7 (12 ref.) Comment on: Med J Aust 1997 Apr 21;166(8):404–7.

SODIUM CHLORIDE SOLUTION, HYPERTONIC see **SALINE SOLUTION, HYPERTONIC**

SODIUM COMPOUNDS

DIAGNOSTIC USE

[In vivo test of thyroid radioactive iodide uptake, pertechnetate 99m uptake and thyroid scintigraphy] Ochi Y, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:317–20 (5 ref.) **(Jpn)**

SODIUM CROMOGLYCATE see **CROMOLYN SODIUM**

SODIUM, DIETARY

[Sodium and hypertension] de Wardener HE. **Arch Mal Coeur Vaiss** 1996 Sep;89 Spec No 4:9–15 (27 ref.) (Eng. Abstr.) **(Fre)**

ADMINISTRATION & DOSAGE

Dietary sodium and blood pressure: interactions with other nutrients. Kotchen TA, et al. **Am J Clin Nutr** 1997 Feb; 65(2 Suppl):708S–711S (61 ref.)

The neuronal role of angiotensin II in thirst, sodium appetite, cognition and memory. Mosimann R, et al. **Biol Rev Camb Philos Soc** 1996 Nov;71(4):545–59 (117 ref.)

Aldosterone, salt and cardiac fibrosis. Funder JW. **Clin Exp Hypertens** 1997 Jul–Aug;19(5–6):885–99 (25 ref.)

Dietary sodium and plasma volume levels with exercise. Luetkemeier MJ, et al. **Sports Med** 1997 May;23(5):279–86 (37 ref.)

ADVERSE EFFECTS

Salt sensitivity and insulin resistance: Is there a link? Sharma AM, et al. **Blood Press Suppl** 1996;1:59–63 (33 ref.)

Dietary salt, urinary calcium, and bone loss [see comments] Massey LK, et al. **J Bone Miner Res** 1996 Jun;11(6):731–6 (50 ref.) Comment in: J Bone Miner Res 1997 Feb;12(2):298–9.

PHARMACOLOGY

Kidney, salt, and hypertension: how and why. Kurokawa K. **Kidney Int Suppl** 1996 Jun;55:S46–51 (27 ref.)

SODIUM ETIDRONATE see **ETIDRONATE DISODIUM**

SODIUM FLUORIDE

THERAPEUTIC USE

Sustained–release sodium fluoride in the management of established postmenopausal osteoporosis. Pak CY, et al. **Am J Med Sci** 1997 Jan;313(1):23–32 (30 ref.)

Slow–release sodium fluoride in osteoporosis. Pak CY, et al. **J Bone Miner Res** 1996 May;11(5):561–4 (16 ref.)

Update on pharmacologic therapies for osteoporosis. Kessenich CR. **Nurse Pract** 1996 Aug;21(8):19–24 (19 ref.)

SODIUM GAMMA–HYDROXYBUTYRATE see **SODIUM OXYBATE**

SODIUM–GLUCOSE TRANSPORT SYSTEM see **MONOSACCHARIDE TRANSPORT PROTEINS**

SODIUM GOLD THIOMALATE see **GOLD SODIUM THIOMALATE**

SODIUM–HYDROGEN ANTIPORTER

[Na+/H+ exchanger] Kuro–o M. **Nippon Rinsho** 1996 Mar; 54(3):607–11 (8 ref.) (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

The sodium–hydrogen exchange system in the heart: its role in ischemic and reperfusion injury and therapeutic implications. Karmazyn M. **Can J Cardiol** 1996 Oct; 12(10):1074–82 (73 ref.)

BLOOD

Posttranslational effects of protein kinase C and insulin on red cell membrane phosphorylation and cation heteroexchange in hypertension. Semplicini A, et al. **Blood Press Suppl** 1996;1:55–8 (25 ref.)

Regulation of Na+/H+ antiporter in trout red blood cells. Malapert M, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):353–60 (48 ref.)

GENETICS

Can the Na+/H+ exchange serve as an intermediate phenotype for essential hypertension? [see comments] Aviv A. **Eur J Clin Invest** 1997 Jul;27(7):566–7 (8 ref.) Comment in: Eur J Clin Invest 1997 Jul;27(7):558–65.

METABOLISM

The links between cellular Ca2+ and Na+/H+ exchange in the pathophysiology of essential hypertension. Aviv A. **Am J Hypertens** 1996 Jul;9(7):703–7 (21 ref.)

Na+/H+ exchange in hypertension and in diabetes mellitus—facts and hypotheses. Siffert W, et al. **Basic Res Cardiol** 1996 May–Jun;91(3):179–90 (99 ref.)

Recent advances in cellular Ca2+ homeostasis: implications to altered regulations of cellular Ca2+ and Na(+)–H+ exchange in essential hypertension. Aviv A. **Curr Opin Cardiol** 1996 Sep;11(5):477–82 (63 ref.)

Sodium–hydrogen exchange in myocardial ischemia and reperfusion: a critical determinant of injury? Avkiran M. **EXS** 1996;76:299–311 (60 ref.)

Na+/H+ exchangers of mammalian cells. Orlowski J, et al. **J Biol Chem** 1997 Sep 5;272(36):22373–6 (67 ref.)

Ion transport in hepatocytes: mechanisms and correlations to cell volume, hormone actions and metabolism. Graf J, et al. **J Hepatol** 1996;24 Suppl 1:53–77 (315 ref.)

Genetically fixed enhanced G protein activation in essential hypertension. Siffert W. **Kidney Blood Press Res** 1996; 19(3–4):172–3 (16 ref.)

Expression of Na(+)–H+ exchanger isoforms in the kidney—implications for renal function and disease [editorial] Rutherford PA. **Nephrol Dial Transplant** 1996 Sep;11(9).1711–3 (18 ref.)

Sodium–hydrogen antiporter: its possible role in the genesis of diabetic nephropathy [editorial] Trevisan R, et al. **Nephrol Dial Transplant** 1997 Apr;12(4):643–5 (21 ref.)

[Molecular aspects of Na+/H+ exchange in the renal tubule: localization and adaptation to the acid–base state] Borensztein P, et al. **Nephrologie** 1996;17(7):377–81 (21 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

The role of Na+/H+ exchange in ischemia–reperfusion. Piper HM, et al. **Basic Res Cardiol** 1996 May–Jun; 91(3):191–202 (91 ref.)

The sodium–hydrogen exchange system in the heart: its role in ischemic and reperfusion injury and therapeutic implications. Karmazyn M. **Can J Cardiol** 1996 Oct; 12(10):1074–82 (73 ref.)

Na+/H+ exchanger subtypes in the renal tubule: function and regulation in physiology and disease. Paillard M. **Exp Nephrol** 1997 Jul–Aug;5(4):277–84 (59 ref.)

Molecular physiology of vertebrate Na+/H+ exchangers. Wakabayashi S, et al. **Physiol Rev** 1997 Jan;77(1):51–74 (310 ref.)

SODIUM HYDROXIDE

CHEMISTRY

Alkaline–fermented foods: a review with emphasis on pidan fermentation. Wang J, et al. **Crit Rev Microbiol** 1996; 22(2):101–38 (81 ref.)

SODIUM NITRITE

THERAPEUTIC USE

Hydrogen sulfide poisoning: an antidotal role for sodium nitrite? Hall AH, et al. **Vet Hum Toxicol** 1997 Jun; 39(3):152–4 (25 ref.)

SODIUM NITROPRUSSIDE see **NITROPRUSSIDE**

SODIUM OXYBATE

PHARMACOLOGY

Does gamma–hydroxybutyrate inhibit or stimulate central DA release? Feigenbaum JJ, et al. **Int J Neurosci** 1996 Nov;88(1–2):53–69 (99 ref.)

Gamma hydroxybutyrate is not a GABA agonist. Feigenbaum JJ, et al. **Prog Neurobiol** 1996 Sep;50(1):1–7 (94 ref.)

POISONING

Gamma butyrolactone poisoning and its similarities to gamma hydroxybutyric acid: two case reports. Rambourg–Schepens MO, et al. **Vet Hum Toxicol** 1997 Aug;39(4):234–5 (8 ref.)

SODIUM OXYBUTYRATE see **SODIUM OXYBATE**

SODIUM PERTECHNETATE TC 99M

DIAGNOSTIC USE

[Regional evaluation of ventilation by RI] Kawakami K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:42–4 (3 ref.) **(Jpn)**

SODIUM, POTASSIUM ADENOSINETRIPHOSPHATASE see **NA(+)–K(+)–EXCHANGING ATPASE**

SODIUM, POTASSIUM ATPASE see **NA(+)–K(+)–EXCHANGING ATPASE**

SODIUM–POTASSIUM PUMP see **NA(+)–K(+)–EXCHANGING ATPASE**

SODIUM PUMP see **NA(+)–K(+)–EXCHANGING ATPASE**

SODIUM SELENITE

ADMINISTRATION & DOSAGE

Human selenium supplementation as assessed by changes in blood selenium concentration and glutathione peroxidase activity. Nève J. **J Trace Elem Med Biol** 1995 Jul;9(2):65–73 (32 ref.)

PHARMACOLOGY

[Selenium in the cytotoxicity of cisplatin] Olas B, et al. **Postepy Hig Med Dosw** 1997;51(1):95–108 (82 ref.) (Eng. Abstr.) **(Pol)**

SODIUM TETRADECYL SULFATE

THERAPEUTIC USE

Sclerotherapy of telangiectases using sodium tetradecyl sulfate (Sotradecol) [see comments] Hren C, et al. **N C Med J** 1996 Jan–Feb;57(1):42–6 (8 ref.) Comment in: N C Med J 1996 May–Jun;57(3):127–8.

SODIUM VALPROATE see **VALPROIC ACID**

SOFT CONTACT LENSES see **CONTACT LENSES, HYDROPHILIC**

SOFT TISSUE INFECTIONS

see related
SKIN DISEASES, INFECTIOUS

Necrotizing soft tissue infections of the chest wall. Urschel JD, et al. **Ann Thorac Surg** 1997 Jul;64(1):276–9 (28 ref.)

[Anaerobic infections of the soft tissues] Mathieu D, et al. **Ann Chir** 1997;51(3):272–87 (120 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

The use of intravenous contrast in MRI of extremity infection. Towers JD. **Semin Ultrasound CT MR** 1997 Aug; 18(4):269–75 (14 ref.)

[Soft tissue infection] Schneider U, et al. **Unfallchirurg** 1997 Feb;100(2):146–53 (8 ref.) **(Ger)**

DRUG THERAPY

Soft tissue infections and the diabetic foot. Smith AJ, et al. **Am J Surg** 1996 Dec;172(6A):7S–12S (26 ref.)

Drug treatment of skin and soft tissue infections in elderly long–term care residents. Lertzman BH, et al. **Drugs Aging** 1996 Aug;9(2):109–21 (41 ref.)

Local treatment of bone and soft tissue infections with the collagen–gentamicin sponge. Stemberger A, et al. **Eur J Surg Suppl** 1997;(578):17–26 (80 ref.)

ETIOLOGY

Invasive soft tissue infections with Streptococcus pneumoniae in patients with systemic lupus erythematosus: case report and review of the literature. Hill MD, et al. **Arthritis Rheum** 1997 Sep;40(9):1716–9 (16 ref.)

Complicated soft tissue infection with prepatellar bursitis caused by Paecilomyces lilacinus in an immunocompetent host: case report and review. Westenfeld F, et al. **J Clin Microbiol** 1996 Jun;34(6):1559–62 (29 ref.)

MICROBIOLOGY

Necrotizing fasciitis: flesh-eating microbes [editorial; comment] Moses AE. **Isr J Med Sci** 1996 Sep;32(9):781–4 (26 ref.) Comment on: Isr J Med Sci 1996 Sep;32(9):745–9.

PARASITOLOGY

Musculoskeletal involvement in cystic echinococcosis: report of eight cases and review of the literature. Merkle EM, et al. **AJR Am J Roentgenol** 1997 Jun;168(6):1531–4 (12 ref.)

RADIONUCLIDE IMAGING

Radionuclide imaging of infection in soft tissue and bone. Strauss HW, et al. **Curr Clin Top Infect Dis** 1997;17:95–109 (64 ref.)

SURGERY

Soft tissue infections and the diabetic foot. Smith AJ, et al. **Am J Surg** 1996 Dec;172(6A):7S–12S (26 ref.)

THERAPY

Is instillation drainage for the treatment of infected joints, bones and soft tissues still up to date? Schmidt J, et al. **Arch Orthop Trauma Surg** 1996;115(3–4):149–52 (16 ref.)

SOFT TISSUE INJURIES

Soft-tissue injuries and muscle tears. Best TM. **Clin Sports Med** 1997 Jul;16(3):419–34 (44 ref.)

Sports-related and other soft-tissue injuries, tendinitis, bursitis, and occupation-related syndromes [see comments] Biundo JJ Jr, et al. **Curr Opin Rheumatol** 1997 Mar; 9(2):151–4 (20 ref.) Comment in: Curr Opin Rheumatol 1997 Mar;9(2):133–43.

Occupational soft-tissue and tendon disorders. Kasdan ML, et al. **Orthop Clin North Am** 1996 Oct;27(4):795–803 (20 ref.)

DIAGNOSIS

Wound care. Howell JM, et al. **Emerg Med Clin North Am** 1997 May;15(2):417–25 (33 ref.)

MR imaging of soft-tissue masses in children. Bissett GS 3rd. **Magn Reson Imaging Clin N Am** 1996 Nov; 4(4):697–719 (39 ref.)

Imaging of skeletal and soft tissue injuries in and around the knee. Walker CW, et al. **Radiol Clin North Am** 1997 May; 35(3):631–53 (61 ref.)

ETIOLOGY

Impingement syndrome of the ankle caused by a medial meniscoid lesion. Egol KA, et al. **Arthroscopy** 1997 Aug; 13(4):522–5 (10 ref.)

Orthopedic aspects of child abuse. Beaty JH. **Curr Opin Pediatr** 1997 Feb;9(1):100–3 (17 ref.)

Ring avulsion injuries in a field environment. Varela CD. **Mil Med** 1996 May;161(5):308–10 (9 ref.)

Radiation-induced changes in the central nervous system and head and neck. Rabin BM, et al. **Radiographics** 1996 Sep; 16(5):1055–72 (24 ref.)

PHYSIOPATHOLOGY

Integrated processes responsible for soft tissue healing. Wong ME, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Nov;82(5):475–92 (109 ref.)

PREVENTION & CONTROL

Seat cushion design for elderly wheelchair users based on minimization of soft tissue deformation using stiffness and pressure measurements. Brienza DM, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):320–7 (27 ref.)

SURGERY

Current treatment of post-traumatic deformities. Residual orbital, adnexal, and soft-tissue abnormalities. Spinelli HM, et al. **Clin Plast Surg** 1997 Jul;24(3):519–30 (47 ref.)

[New developments in covering post-traumatic soft tissue defects] Berger A, et al. **Orthopade** 1997 May;26(5):470–80 (34 ref.) (Eng. Abstr.) **(Ger)**

[Covering soft tissue defects] Kinzl L, et al. **Unfallchirurg** 1996 Oct;99(10):714–26 (29 ref.) (Eng. Abstr.) **(Ger)**

[Complex trauma of the knee joint. Diagnosis—management—therapeutic principles] Krettek C, et al. **Unfallchirurg** 1996 Sep;99(9):616–27 (56 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Physiotherapy for patients with soft tissue shoulder disorders: a systematic review of randomised clinical trials. van der Heijden GJ, et al. **BMJ** 1997 Jul 5;315(7099):25–30 (45 ref.)

Wound care. Howell JM, et al. **Emerg Med Clin North Am** 1997 May;15(2):417–25 (33 ref.)

Hyperbaric oxygen chambers and the treatment of sports injuries. Staples J, et al. **Sports Med** 1996 Oct;22(4):219–27 (78 ref.)

SOFT TISSUE NEOPLASMS

Soft tissue sarcomas. Lewis JJ, et al. **Curr Probl Surg** 1996 Oct;33(10):817–72 (202 ref.)

Fibrosarcoma of the foot: a case presentation and review of the literature. Blume PA, et al. **J Foot Ankle Surg** 1997 Jan–Feb;36(1):51–4 (17 ref.)

CLASSIFICATION

Recent developments in soft tissue tumors. Goodlad JR, et al. **Histopathology** 1995 Aug;27(2):103–20 (111 ref.)

Malignant fibrous histiocytoma: histomorphological pattern or tumor type. Meister P. **Pathol Res Pract** 1996 Aug; 192(8):877–81 (36 ref.)

The role of cytogenetics in the classification of soft tissue tumours. Dei Tos AP, et al. **Virchows Arch** 1997 Aug; 431(2):83–94 (110 ref.)

[TNM classification of bone and soft tissue sarcomas] Fukuma H, et al. **Gan To Kagaku Ryoho** 1997 Jun;24(8):1035–40 (9 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Diagnostic difficulties in extraosseous Ewing's sarcoma: a proposal for diagnostic criteria. Christie DR, et al. **Australas Radiol** 1997 Feb;41(1):22–8 (19 ref.)

Diagnostic strategy for bone and soft-tissue tumors. Simon MA, et al. **Instr Course Lect** 1994;43:527–36 (57 ref.)

Clinical image. Malignant mesenchymoma of the buttock. Johnson GL, et al. **J Comput Assist Tomogr** 1996 Nov–Dec; 20(6):999–1001 (13 ref.)

Clinical image. Lipoblastoma of the thigh: MR appearance. Katz DS, et al. **J Comput Assist Tomogr** 1996 Nov–Dec; 20(6):1002–3 (8 ref.)

Spindle cell hemangioendothelioma: a case presentation and literature review of a rare lower extremity tumor. Patel SV, et al. **J Foot Ankle Surg** 1996 Jul–Aug;35(4):309–11 (8 ref.)

Plantar fibromatosis of the heel in children: a report of 14 cases. Godette GA, et al. **J Pediatr Orthop** 1997 Jan–Feb; 17(1):16–7 (5 ref.)

MR imaging of soft-tissue masses in children. Bissett GS 3rd. **Magn Reson Imaging Clin N Am** 1996 Nov; 4(4):697–719 (39 ref.)

MR imaging of musculoskeletal tumors in the elbow region. Steinbach LS, et al. **Magn Reson Imaging Clin N Am** 1997 Aug;5(3):619–53 (194 ref.)

Fine-needle aspiration of soft tissue lesions. Epstein HD. **Pathology (Phila)** 1996;4(2):463–92 (69 ref.)

Orthopedic soft-tissue tumors. Concepts for the primary care physician. Randall RL, et al. **Prim Care** 1996 Jun; 23(2):241–61 (51 ref.)

Primary tumors of the musculoskeletal system. Vanel D, et al. **Radiol Clin North Am** 1997 Jan;35(1):213–37 (48 ref.)

Differential diagnosis of small round cell tumors. Meis-Kindblom JM, et al. **Semin Diagn Pathol** 1996 Aug; 13(3):213–41 (196 ref.)

The use of gadolinium in the MR evaluation of soft tissue tumors. Kransdorf MJ, et al. **Semin Ultrasound CT MR** 1997 Aug;18(4):251–68 (25 ref.)

The use of gadolinium in the MR evaluation of musculoskeletal tumors. Kransdorf MJ. **Top Magn Reson Imaging** 1996 Feb;8(1):15–23 (25 ref.)

[Diagnostic imaging of bone and soft tissue tumors] Saotome K. **Nippon Seikeigeka Gakkai Zasshi** 1996 Sep;70(9):559–72 (26 ref.) **(Jpn)**

[A giant histiocytoma of the occipital area] Makhmudov UB, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1997 Apr–Jun; (2):29–31 (12 ref.) **(Rus)**

DRUG THERAPY

Chemotherapy for soft tissue sarcomas. Indications and advances. Phillips KA, et al. **Acta Orthop Scand Suppl** 1997 Feb;273:133–8 (42 ref.)

Chemotherapy for adult soft tissue sarcoma. Does it work? Saeter G. **Acta Orthop Scand Suppl** 1997 Feb;273:139–44 (35 ref.)

Chemotherapy for metastatic soft tissue sarcomas. Steward WP. **Cancer Treat Res** 1997;91:157–72 (71 ref.)

Adjuvant chemotherapy of soft tissue sarcomas. Verweij J, et al. **Cancer Treat Res** 1997;91:173–87 (27 ref.)

ETIOLOGY

Radiation-induced bone and soft tissue sarcomas: clinical aspects and molecular biology. Spiro IJ, et al. **Cancer Treat Res** 1997;91:143–55 (107 ref.)

[Incidence of malignant soft tissue tumors (sarcomas) after previous radiotherapy] Hernandez-Richter T, et al. **Langenbecks Arch Chir** 1996;381(5):295–8 (19 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Molecular and cytogenetics of soft tissue sarcomas. Nilbert M. **Acta Orthop Scand Suppl** 1997 Feb;273:60–7 (53 ref.)

The clinical role of molecular genetics in soft tissue tumor pathology. Busam KJ, et al. **Cancer Metastasis Rev** 1997 Jun;16(1–2):207–27 (138 ref.)

Molecular genetics of soft tissue sarcomas. Cooper CS, et al. **Cancer Treat Res** 1997;91:31–50 (93 ref.)

Cytogenetics of soft tissue tumors. Fletcher JA. **Cancer Treat Res** 1997;91:9–29 (114 ref.)

The marriage of pathology and genetics in soft tissue tumours: EACR—Mühlbock Memorial Lecture. Van den Berghe H. **Eur J Cancer** 1996 Oct;32A(11):1849–56 (39 ref.)

Alterations of p53 gene in soft tissue and bone tumors. Roessner A, et al. **Gen Diagn Pathol** 1997 Jul;143(1):1–13 (61 ref.)

New genetic loci in neuroblastoma. Schwab M, et al. **Klin Padiatr** 1997 Jul–Aug;209(4):147–9 (21 ref.)

Molecular genetics of small round cell tumors. López-Terrada D. **Semin Diagn Pathol** 1996 Aug; 13(3):242–9 (93 ref.)

Cytogenetics and tissue culture of small round cell tumors of bone and soft tissue. Noguera R. **Semin Diagn Pathol** 1996 Aug;13(3):171–83 (134 ref.)

The role of cytogenetics in the classification of soft tissue tumours. Dei Tos AP, et al. **Virchows Arch** 1997 Aug; 431(2):83–94 (110 ref.)

IMMUNOLOGY

Small round cell tumors of bone and soft tissue. Introduction. Llombart-Bosch A. **Semin Diagn Pathol** 1996 Aug; 13(3):149–52 (47 ref.)

METABOLISM

p53, proliferating cell nuclear antigen, and Ki-67 expression in extrauterine leiomyosarcomas. O'Reilly PE, et al. **Mod Pathol** 1997 Feb;10(2):91–7 (28 ref.)

PATHOLOGY

Prognostic factors in soft tissue sarcoma. Rydholm A. **Acta Orthop Scand Suppl** 1997 Feb;273:148–55 (36 ref.)

"Proximal-type" epithelioid sarcoma, a distinctive aggressive neoplasm showing rhabdoid features. Clinicopathologic, immunohistochemical, and ultrastructural study of a series. Guillou L, et al. **Am J Surg Pathol** 1997 Feb;21(2):130–46 (70 ref.)

Polymorphous hemangioendothelioma: a report of two cases, one affecting extranodal soft tissues, and review of the literature. Nascimento AG, et al. **Am J Surg Pathol** 1997 Sep;21(9):1083–9 (8 ref.)

Giant hemangioma in infant. A case presentation and literature review. Malamou-Mitsi VD, et al. **Arch Anat Cytol Pathol** 1996;44(4):199–201 (14 ref.)

The clinical role of molecular genetics in soft tissue tumor pathology. Busam KJ, et al. **Cancer Metastasis Rev** 1997 Jun;16(1–2):207–27 (138 ref.)

Value of peer review of pathology in soft tissue sarcomas. Harris M, et al. **Cancer Treat Res** 1997;91:1–8 (13 ref.)

Bilateral elastofibroma: a case report and review of the literature. Hoffman JK, et al. **Clin Orthop** 1996 Apr; (325):245–50 (49 ref.)

Primary and metastatic malignant tumors in soft tissue of skin. Diagnostic, surgical, and prognostic considerations for the foot. Potter GK, et al. **Clin Podiatr Med Surg** 1996 Jan;13(1):155–72 (85 ref.)

Hypertrophic pulmonary osteoarthropathy in pulmonary metastasis—a case report. Aderaye G. **Ethiop Med J** 1996 Oct;34(4):251–4 (13 ref.)

The marriage of pathology and genetics in soft tissue tumours: EACR—Mühlbock Memorial Lecture. Van den Berghe H. **Eur J Cancer** 1996 Oct;32A(11):1849–56 (39 ref.)

Staging systems for musculoskeletal neoplasia. Springfield DS. **Instr Course Lect** 1994;43:537–42 (11 ref.)

Ossifying fibromyxoid tumor of soft parts: a case report and review. Barrett TL, et al. **J Cutan Pathol** 1996 Aug; 23(4):378–80 (8 ref.)

Malignant fibrous histiocytoma: histomorphological pattern or tumor type. Meister P. **Pathol Res Pract** 1996 Aug; 192(8):877–81 (36 ref.)

Soft tissue. Kempson RL. **Pathology (Phila)** 1996;3(2):545–53 (11 ref.)

Symmetrical multifocal liposarcoma. Kulhavy M, et al. **S Afr J Surg** 1997 May;35(2):68–9 (14 ref.)

Soft tissue small round cell tumors: morphological parameters. d'Amore ES, et al. **Semin Diagn Pathol** 1996 Aug;13(3):184–203 (105 ref.)

Small round cell tumors of bone and soft tissue. Introduction. Llombart-Bosch A. **Semin Diagn Pathol** 1996 Aug; 13(3):149–52 (47 ref.)

Cytogenetics and tissue culture of small round cell tumors of bone and soft tissue. Noguera R. **Semin Diagn Pathol** 1996 Aug;13(3):171–83 (134 ref.)

Soft tissue sarcoma nodal metastases: biologic significance and therapeutic considerations. Skinner KA, et al. **Surg Oncol Clin N Am** 1996 Jan;5(1):121–7 (14 ref.)

Low-grade fibromyxoid sarcoma. Fukunaga M, et al. **Virchows Arch** 1996 Nov;429(4–5):301–3 (1 ref.)

[Malignant granular cell tumor. Report of a clinico-pathologic case] Rochaix P, et al. **Ann Pathol** 1996 Sep;16(4):292–5 (32 ref.) (Eng. Abstr.) **(Fre)**

[Neurosarcoma associated with neurofibromatosis I. Apropos of a case and review of the literature] Ligneau B, et al. **Presse Med** 1997 Mar 29;26(10):458–63 (24 ref.) (Eng. Abstr.) **(Fre)**

[Extraosseus osteogenic sarcoma: report of a case with atypical secondary involvement of the lung] Pezzullo L, et al. **Radiol Med (Torino)** 1997 Mar;93(3):296–8 (16 ref.)

SOFT TISSUE NEOPLASMS

(Ita)

[On the histogenesis and classification of fibrous, lipomatous, fibrohistiocytic and related tumors of bone and soft tissues] **Hizawa K. Nippon Seikeigeka Gakkai Zasshi** 1996 Oct; 70(10):685–95 (30 ref.) **(Jpn)**

[Pathologic diagnosis on bone and soft tissue tumors by molecular biological methods] Nojima T, et al. **Rinsho Byori** 1997 Jul;45(7):661–6 (17 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Paraarticular osteochondroma of the knee: report of 2 cases and review of the literature. Reith JD, et al. **Clin Orthop** 1997 Jan;(334):225–32 (17 ref.)

RADIONUCLIDE IMAGING

Nuclear medicine techniques provide unique physiologic characterization of suspected and known soft tissue and bone sarcomas. Hicks RJ. **Acta Orthop Scand Suppl** 1997 Feb;273:25–36 (38 ref.)

PET imaging in soft tissue sarcomas. Miraldi F, et al. **Cancer Treat Res** 1997;91:51–64 (40 ref.)

RADIOTHERAPY

Brachytherapy for soft tissue sarcomas. Devlin PM, et al. **Cancer Treat Res** 1997;91:107–28 (41 ref.)

Three-dimensional planning and conformal radiotherapy. Harmer C, et al. **Cancer Treat Res** 1997;91:129–41 (24 ref.)

Benign and low-grade tumors of the soft tissues: role for radiation therapy. Suit HD, et al. **Cancer Treat Res** 1997; 91:95–105 (34 ref.)

[Clinical significance of heavy particle therapy for malignant tumor of the bone and soft tissues] Morita K. **Nippon Seikeigeka Gakkai Zasshi** 1997 Jan;71(1):11–7 (17 ref.) **(Jpn)**

SURGERY

Microsurgery—its role in soft tissue and bone tumour reconstruction. Rostek M, et al. **Acta Orthop Scand Suppl** 1997 Feb;273:95–100 (50 ref.)

Metastasectomy for soft tissue sarcomas. Pastorino U. **Cancer Treat Res** 1997;91:65–75 (32 ref.)

Soft tissue. Kempson RL. **Pathology (Phila)** 1996;3(2):545–53 (11 ref.)

Radical scapulectomy with limb salvage for shoulder girdle soft tissue sarcoma. Volpe CM, et al. **Surg Oncol** 1996 Feb; 5(1):43–8 (20 ref.)

THERAPY

Post-treatment limb function in soft tissue sarcomas. Robinson MH. **Cancer Treat Res** 1997;91:77–93 (38 ref.)

Squamous cell carcinoma of the nail bed. Lai CS, et al. **Cutis** 1996 May;57(5):341–5 (25 ref.)

The success of TNF alpha in isolated limb perfusion for irresectable extremity soft tissue sarcomas, melanoma and carcinomas: observations in patients and preclinical perfusion models. Eggermont AM. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1357–70 (74 ref.)

Management of soft tissue sarcomas of the extremity in adults. Valle AA, et al. **J Surg Oncol** 1996 Dec;63(4):271–9 (80 ref.)

ULTRASTRUCTURE

Soft tissue small round cell tumors: morphological parameters. d'Amore ES, et al. **Semin Diagn Pathol** 1996 Aug;13(3):184–203 (105 ref.)

VETERINARY

Tumours of soft tissues. Berman LD. **IARC Sci Publ** 1996; (126):321–49 (79 ref.)

Tumours of the skin. Ghadially FN, et al. **IARC Sci Publ** 1996;(126):1–43 (111 ref.)

Ultrastructure of virus-induced soft-tissue tumours. Levenbook IS, et al. **IARC Sci Publ** 1996;(126):351–63 (27 ref.)

Tumours of the pancreas. Pour PM, et al. **IARC Sci Publ** 1996;(126):149–73 (29 ref.)

Tumours of the intestine. Takahashi M, et al. **IARC Sci Publ** 1996;(126):137–47 (29 ref.)

Tumours of the glandular stomach. Takahashi M, et al. **IARC Sci Publ** 1996;(126):127–35 (29 ref.)

Tumours of the gallbladder. Turusov VS, et al. **IARC Sci Publ** 1996;(126):109–25 (21 ref.)

The potential role of inflammation in the development of postvaccinal sarcomas in cats. Macy DW, et al. **Vet Clin North Am Small Anim Pract** 1996 Jan;26(1):103–9 (36 ref.)

Soft tissue sarcomas. Mauldin GN. **Vet Clin North Am Small Anim Pract** 1997 Jan;27(1):139–48 (32 ref.)

SOFTBALL see **BASEBALL**

SOFTWARE

SCHISTOSIM: a microsimulation model for the epidemiology and control of schistosomiasis. Vlas SJ, et al. **Am J Trop Med Hyg** 1996 Nov;55(5 Suppl):170–5 (16 ref.)

Modeling the structure of the ribosome. Easterwood TR, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11–12):751–6 (35 ref.)

Medical software and information technology transfer methods. Schertzer RM. **Can J Ophthalmol** 1996 Feb; 31(1):45–50 (11 ref.)

Automated selection of statistical quality-control procedures to assure meeting clinical or analytical quality requirements. Westgard JO, et al. **Clin Chem** 1997 Feb;43(2):400–3 (32 ref.)

Computerized NCLEX-RN preparation programs. A comparative review. Billings D, et al. **Comput Nurs** 1996 Sep–Oct;14(5):272–86 (27 ref.)

A user's review of commercial sample size software for design of biomedical studies using survival data. Iwane M, et al. **Control Clin Trials** 1997 Feb;18(1):65–83 (18 ref.)

Concepts, properties, and applications of linear systems to describe distribution, identify input, and control endogenous substances and drugs in biological systems. Verotta D. **Crit Rev Biomed Eng** 1996;24(2–3):73–139 (119 ref.)

WHONET: removing obstacles to the full use of information about antimicrobial resistance. O'Brien TF, et al. **Diagn Microbiol Infect Dis** 1996 Aug;25(4):162–8 (21 ref.)

Expert-novice knowledge of computer programming at different levels of abstraction. Ye N, et al. **Ergonomics** 1996 Mar;39(3):461–81 (28 ref.)

Interactive multimedia software design: concepts, process, and evaluation. Hardin PC, et al. **Health Educ Behav** 1997 Feb;24(1):35–53 (36 ref.)

A quantitative approach in the treatment of hemiplegic patients using an electropneumatic platform. Pepino A, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):410–5 (9 ref.)

Automatic visual to tactile translation—Part I: Human factors, access methods, and image manipulation. Way TP, et al. **IEEE Trans Rehabil Eng** 1997 Mar;5(1):81–94 (90 ref.)

The megaprior heuristic for discovering protein sequence patterns. Bailey TL, et al. **Ismb** 1996;4:15–24 (12 ref.)

Understanding and using DICOM, the data interchange standard for biomedical imaging [see comments] Bidgood WD Jr, et al. **J Am Med Inform Assoc** 1997 May–Jun; 4(3):199–212 (21 ref.) Comment in: J Am Med Inform Assoc 1997 May–Jun;4(3):252–3.

The Digital Anatomist distributed framework and its applications to knowledge-based medical imaging [see comments] Brinkley JF, et al. **J Am Med Inform Assoc** 1997 May–Jun;4(3):165–83 (55 ref.) Comment in: J Am Med Inform Assoc 1997 May–Jun;4(3):252–3.

Etrank: a ranking procedure for handling missing data in clinical trials: application to venlafaxine extended-release depression clinical trial. Entsuah R. **J Biopharm Stat** 1996 Nov;6(4):457–75 (30 ref.)

Automated serial ECG comparison based on the Minnesota code. Macfarlane PW, et al. **J Electrocardiol** 1996;29 Suppl:29–34 (22 ref.)

Strategy for designing specific antisense oligonucleotide sequences. Mitsuhashi M. **J Gastroenterol** 1997 Apr; 32(2):282–7 (37 ref.)

The potentials of virtual environments in the education and training of people with learning disabilities. Cromby JJ, et al. **J Intellect Disabil Res** 1996 Dec;40 (Pt 6):489–501 (80 ref.)

Automated docking of flexible ligands: applications of AutoDock. Goodsell DS, et al. **J Mol Recognit** 1996 Jan–Feb;9(1):1–5 (23 ref.)

Molecular docking towards drug discovery. Gschwend DA, et al. **J Mol Recognit** 1996 Mar–Apr;9(2):175–86 (112 ref.)

Data processing in multidimensional NMR. Pelczer I, et al. **Methods Mol Biol** 1997;60:71–155 (388 ref.)

Software for genetic linkage analysis: an update. Bryant SP. **Mol Biotechnol** 1996 Feb;5(1):49–61 (58 ref.)

Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Altschul SF, et al. **Nucleic Acids Res** 1997 Sep 1;25(17):3389–402 (90 ref.)

Computational tools for structure-based ligand design. Böhm HJ. **Prog Biophys Mol Biol** 1996;66(3):197–210 (106 ref.)

The use of computers in cancer pain management. Frandsen JL. **Semin Oncol Nurs** 1997 Feb;13(1):49–56 (21 ref.)

Computational predictive programs (expert systems) in toxicology. Benfenati E, et al. **Toxicology** 1997 May 16; 119(3):213–25 (41 ref.)

New PC versions of the kinetic-simulation and fitting programs, KINSIM and FITSIM. Dang Q, et al. **Trends Biochem Sci** 1997 Aug;22(8):317 (6 ref.)

Cn3D: a new generation of three-dimensional molecular structure viewer. Hogue CW. **Trends Biochem Sci** 1997 Aug;22(8):314–6 (9 ref.)

[Computerized assessment of electric heart signals and cardiovascular images] De Biase L, et al. **Cardiologia** 1995 Dec;40(12 Suppl 1):491–9 (34 ref.) **(Ita)**

[Software for image processing and its practical use] Matsumoto S. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):936–42 (13 ref.) **(Jpn)**

[3-D softwares and their practice] Sakai T, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):943–8 (10 ref.) **(Jpn)**

SOFTWARE DESIGN

[Computer softwares for DNA diagnosis: GeneViewPLUS and Mutation View] Shimizu N, et al. **Rinsho Byori** 1997 Mar;45(3):209–12 (4 ref.) (Eng. Abstr.) **(Jpn)**

[Software for automated follow-up of chronic outpatients] Lapochkin VI, et al. **Vestn Oftalmol** 1997 May–Jun; 113(3):30–2 (0 ref.) (Eng. Abstr.) **(Rus)**

SOFTWARE ENGINEERING see **SOFTWARE**

SOFTWARE TOOLS see **SOFTWARE**

SOFTWARE VALIDATION

Computerized test development software a comparative review. Kirkpatrick JM, et al. **Comput Nurs** 1996 Mar–Apr; 14(2):113–5 (12 ref.)

High touch meets high tech. Distance mental health screening for rural youth using Teleform. Puskar KR, et al. **Comput Nurs** 1996 Nov–Dec;14(6):323–9; quiz 330–2 (31 ref.)

[Validation of a new interactive software monitoring a controlled-flow infusion pump for cisplatin dosage regimen adjustment] Cupissol D, et al. **Bull Cancer** 1996 Aug; 83(8):664–76 (36 ref.) (Eng. Abstr.) **(Fre)**

SOFTWARE VERIFICATION see **SOFTWARE VALIDATION**

SOIL

DNA in soil: adsorption, genetic transformation, molecular evolution and genetic microchip. Trevors JT. **Antonie Van Leeuwenhoek** 1996 Jul;70(1):1–10 (62 ref.)

ANALYSIS

Relationship between soil type and Mycobacterium paratuberculosis. Johnson-Ifearulundu YJ, et al. **J Am Vet Med Assoc** 1997 Jun 15;210(12):1735–40 (44 ref.)

Dietary selenium repletion may reduce cancer incidence in people at high risk who live in areas with low soil selenium. Fleet JC. **Nutr Rev** 1997 Jul;55(7):277–9 (9 ref.)

SOIL MICROBIOLOGY

Osmoadaptation by rhizosphere bacteria. Miller KJ, et al. **Annu Rev Microbiol** 1996;50:101–36 (167 ref.)

Relationship between soil type and Mycobacterium paratuberculosis. Johnson-Ifearulundu YJ, et al. **J Am Vet Med Assoc** 1997 Jun 15;210(12):1735–40 (44 ref.)

The lung and the world about it. The Tudor Edwards Lecture 1996. Seaton A. **J R Coll Physicians Lond** 1996 May–Jun;30(3):232–7 (33 ref.)

Isolation and identification of yeasts from natural habitats. Spencer JF, et al. **Methods Mol Biol** 1996;53:1–4 (8 ref.)

Fate and activity of microorganisms introduced into soil. van Veen JA, et al. **Microbiol Mol Biol Rev** 1997 Jun; 61(2):121–35 (173 ref.)

Soil microorganisms as controllers of atmospheric trace gases (H2, CO, CH4, OCS, N2O, and NO). Conrad R. **Microbiol Rev** 1996 Dec;60(4):609–40 (602 ref.)

Extracellular bacterial mineralization within the context of geomicrobiology. Ben Omar N, et al. **Microbiologia** 1997 Jun;13(2):161–72 (40 ref.)

[Effects of residues of anti-infective agents in animal excretions on slurry treatment and the soil] Böhm R. **DTW Dtsch Tierarztl Wochenschr** 1996 Jul;103(7):264–8 (12 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

Soil and solid poultry waste nutrient management and water quality. Chapman SL. **Poult Sci** 1996 Jul;75(7):862–6 (26 ref.)

SOIL POLLUTANTS

ADVERSE EFFECTS

Breast-feeding exposure of infants to environmental contaminants—a public health risk assessment viewpoint: chlorinated dibenzodioxins and chlorinated dibenzofurans. Pohl HR, et al. **Toxicol Ind Health** 1996 Sep–Oct; 12(5):593–611 (98 ref.)

ANALYSIS

Behaviour and ecotoxicology of aluminium in soil and water—review of the scientific literature. Klöppel H, et al. **Chemosphere** 1997 Jul;35(1–2):353–63 (33 ref.)

Calculation of soil-water and benthic sediment partition coefficients for mercury. Lyon BF, et al. **Chemosphere** 1997 Aug;35(4):791–808 (30 ref.)

Official multiresidue methods of pesticide analysis in vegetables, fruits and soil. Motohashi N, et al. **J Chromatogr A** 1996 Nov 22;754(1–2):333–46 (64 ref.)

Factors affecting atrazine fate in north central U.S. soils. Koskinen WC, et al. **Rev Environ Contam Toxicol** 1997; 151:117–65 (225 ref.)

[Degradation of soil quality: health and environmental risks] Robert M. **Bull Acad Natl Med** 1997 Jan;181(1):21–40; discussion 40–2 (29 ref.) (Eng. Abstr.) **(Fre)**

[Mineral oil hydrocarbons as ground water contaminants] Schewe C, et al. **Schriftenr Ver Wasser Boden Lufthyg** 1996; 98:III–XVI, 1–92 (72 ref.) **(Ger)**

ISOLATION & PURIFICATION

Phytoremediation of soil metals. Chaney RL, et al. **Curr Opin Biotechnol** 1997 Jun;8(3):279–84 (63 ref.)

PHARMACOKINETICS

Phytoremediation of soil metals. Chaney RL, et al. **Curr Opin Biotechnol** 1997 Jun;8(3):279–84 (63 ref.)

TOXICITY

Behaviour and ecotoxicology of aluminium in soil and water—review of the scientific literature. Klöppel H, et al. **Chemosphere** 1997 Jul;35(1–2):353–63 (33 ref.)

Environmental quality objectives for 10 polycyclic aromatic hydrocarbons (PAHs). Kalf DF, et al. **Ecotoxicol Environ Saf** 1997 Feb;36(1):89–97 (46 ref.)

Hexavalent chromium-contaminated soils: options for risk assessment and risk management. Felter SP, et al. **Regul Toxicol Pharmacol** 1997 Feb;25(1):43–59 (65 ref.)

Estimating relative potency for receptor-mediated toxicity: reevaluating the toxicity equivalence factor (TEF) model. Putzrath RM. **Regul Toxicol Pharmacol** 1997 Feb; 25(1):68–78 (45 ref.)

[Heavy metals in the soil–plant–man system (review)] Mudryĭ IV. **Gig Sanit** 1997 Jan–Feb;(1):14–7 (23 ref.) **(Rus)**

SOLANACEOUS ALKALOIDS

see related
PARASYMPATHOLYTICS

ADVERSE EFFECTS

Natural inhibitors of cholinesterases: implications for adverse drug reactions. Krasowski MD, et al. **Can J Anaesth** 1997 May;44(5 Pt 1):525–34 (69 ref.)

PHARMACOLOGY

Bioactive saponins from solanaceous and leguminous plants. Nohara T, et al. **Adv Exp Med Biol** 1996;404:263–76 (22 ref.)

SOLANUM ALKALOIDS see **SOLANACEOUS ALKALOIDS**

SOLANUM TUBEROSUM see **POTATOES**

SOLAR AGING OF SKIN see **SKIN AGING**

SOLAR PLEXUS see **CELIAC PLEXUS**

SOLAR SYSTEM

The early solar system. Gaffey MJ. **Orig Life Evol Biosph** 1997 Jun;27(1–3):185–203 (39 ref.)

Analogs of the early solar system. Koerner DW. **Orig Life Evol Biosph** 1997 Jun;27(1–3):157–84 (178 ref.)

Physics and chemistry of the solar nebula. Lunine JI. **Orig Life Evol Biosph** 1997 Jun;27(1–3):205–24 (46 ref.)

SOLEUS MUSCLE see **MUSCLE, SKELETAL**

SOLITARY CYSTS see **BONE CYSTS**

SOLITARY NUCLEUS

ANATOMY & HISTOLOGY

Immunohistochemical localization of neuropeptides and neurotransmitters in the nucleus solitarius. Maley BE. **Chem Senses** 1996 Jun;21(3):367–76 (67 ref.)

METABOLISM

Immunohistochemical localization of neuropeptides and neurotransmitters in the nucleus solitarius. Maley BE. **Chem Senses** 1996 Jun;21(3):367–76 (67 ref.)

PHYSIOLOGY

Carotid chemoreflex. Neural pathways and transmitters. Sapru HN. **Adv Exp Med Biol** 1996;410:357–64 (22 ref.)

Glutamatergic transmission in the nucleus tractus solitarii: from server to peripherals in the cardiovascular information superhighway. Talman WT. **Braz J Med Biol Res** 1997 Jan;30(1):1–7 (66 ref.)

Sensory afferent neurotransmission in caudal nucleus tractus solitarius—common denominators. Andresen MC, et al. **Chem Senses** 1996 Jun;21(3):387–95 (68 ref.)

Neurotransmitter and neuromodulator activity in the gustatory zone of the nucleus tractus solitarius. Bradley RM, et al. **Chem Senses** 1996 Jun;21(3):377–85 (55 ref.)

Role of selected peptides in the vagal regulation of gastric motor and endocrine pancreatic function. Krowicki ZK. **J Physiol Pharmacol** 1996 Sep;47(3):399–409 (55 ref.)

SOLO PRACTICE see **PRIVATE PRACTICE**

SOLUBLE INDIGO BLUE see **INDIGO CARMINE**

SOLUTIONS

ADVERSE EFFECTS

Prevention by exposure assessment. Flyvholm MA. **Curr Probl Dermatol** 1996;25:97–105 (29 ref.)

[Urologic irrigation solutions are not safe. Serious adverse effects are documented] Hahn R. **Lakartidningen** 1997 Feb 5;94(6):437–8 (32 ref.) **(Swe)**

CHEMISTRY

Compatibility of nebulizer solution admixtures. Joseph JC. **Ann Pharmacother** 1997 Apr;31(4):487–9 (17 ref.)

Applications of the ion–pair concept to hydrophilic substances with special emphasis on peptides. Quintanar-Guerrero D, et al. **Pharm Res** 1997 Feb; 14(2):119–27 (53 ref.)

SOLUTIONS, HEMODIALYSIS see **HEMODIALYSIS SOLUTIONS**

SOLVENTS

Predicting the behaviour of lipases in low-water media. Halling PJ. **Biochem Soc Trans** 1997 Feb;25(1):170–4 (31 ref.)

Dry cleaning. **IARC Monogr Eval Carcinog Risks Hum** 1995; 63:33–71 (119 ref.)

Trichloroethylene. **IARC Monogr Eval Carcinog Risks Hum** 1995;63:75–158 (374 ref.)

Tetrachloroethylene. **IARC Monogr Eval Carcinog Risks Hum** 1995;63:159–221 (272 ref.)

Multiple exposure to solvents in the workplace. Alessio L. **Int Arch Occup Environ Health** 1996;69(1):1–4 (29 ref.)

Clinical studies with solvent detergent-treated products. Pehta JC. **Transfus Med Rev** 1996 Oct;10(4):303–11 (39 ref.)

ADMINISTRATION & DOSAGE

Ethanol injection for the treatment of hepatic tumours. Bartolozzi C, et al. **Eur Radiol** 1996;6(5):682–96 (99 ref.)

ADVERSE EFFECTS

Exposure to organic solvents and breast cancer in women: a hypothesis. Labrèche FP, et al. **Am J Ind Med** 1997 Jul; 32(1):1–14 (125 ref.)

Behavioral methods and organic solvents: questions and consequences. Iregren A. **Environ Health Perspect** 1996 Apr;104 Suppl 2:361–6 (56 ref.)

In search of dose-response relationships of solvent mixtures to neurobehavioural effects in paint manufacturing and painters. Seeber A, et al. **Food Chem Toxicol** 1996 Nov–Dec;34(11–12):1113–20 (22 ref.)

Assessment of the health effects of trichloroethylene. Kaneko T, et al. **Ind Health** 1997 Jul;35(3):301–24 (97 ref.)

Solvents and neurotoxicity. White RF, et al. **Lancet** 1997 Apr 26;349(9060):1239–43 (39 ref.)

Bilateral optic neuritis in occupational exposure to trichloroethylene. Abecia E, et al. **Med Lav** 1996 Sep–Oct; 87(5):432–6 (25 ref.)

Exposure to organic solvents and multiple sclerosis. Landtblom AM. **Neurology** 1997 Aug;49(2 Suppl 2):S70–4 (26 ref.)

Occupational and environmental renal disease. Wedeen RP. **Semin Nephrol** 1997 Jan;17(1):46–53 (35 ref.)

Battery of neurobehavioral tests recommended to ATSDR: solvent-induced deficits in microelectronic workers. Hudnell HK, et al. **Toxicol Ind Health** 1996 Mar–Apr; 12(2):235–43 (6 ref.)

[Nephropathy induced by non-drug chemical agents] Miyazaki K, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):577–9 (15 ref.) **(Jpn)**

[Alcohol and stomach] Makolkin VI, et al. **Klin Med (Mosk)** 1997;75(4):14–8 (39 ref.) **(Rus)**

ANALYSIS

Occupational chronic exposure to organic solvents. XVI. Ambient and biological monitoring of workers exposed to toluene. Angerer J, et al. **Int Arch Occup Environ Health** 1997;69(2):91–6 (38 ref.)

Low-level chemical sensitivity: current perspectives. Ashford NA, et al. **Int Arch Occup Environ Health** 1996; 68(6):367–76 (28 ref.)

[Total environmental exposure to chlorinated solvents: studies of exposure markers] Pregliasco F, et al. **Ann Ig** 1996 May–Jun;8(3):361–75 (56 ref.) (Eng. Abstr.) **(Ita)**

CHEMISTRY

Solvation: how to obtain microscopic energies from partitioning and solvation experiments. Chan HS, et al. **Annu Rev Biophys Biomol Struct** 1997;26:425–59 (119 ref.)

Theory of phase formation in aqueous two-phase systems. Cabezas H Jr. **J Chromatogr B Biomed Appl** 1996 May 17;680(1–2):3–30 (98 ref.)

METABOLISM

Strategies for the aerobic co-metabolism of chlorinated solvents. Semprini L. **Curr Opin Biotechnol** 1997 Jun; 8(3):296–308 (63 ref.)

The urinary excretion of solvents and gases for the biological monitoring of occupational exposure: a review. Gobba F, et al. **Sci Total Environ** 1997 Jun 20;199(1–2):3–12 (46 ref.)

[Uptake of the irrigating fluid during surgical endoscopy. Measure the absorption by ethanol indication] Hahn R. **Lakartidningen** 1997 Feb 5;94(6):440–3 (33 ref.) **(Swe)**

PHARMACOLOGY

Adaptation mechanisms of microorganisms to the toxic effects of organic solvents on membranes. Weber FJ, et al. **Biochim Biophys Acta** 1996 Oct 29;1286(3):225–45 (214 ref.)

POISONING

Acute intoxication and recovery following massive turpentine ingestion: clinical and toxicological data. Troulakis G, et al. **Vet Hum Toxicol** 1997 Jun;39(3):155–7 (10 ref.)

TOXICITY

Mechanisms and models of neurotoxicity of n-hexane and related solvents. Tähti H, et al. **Arch Toxicol Suppl** 1997; 19:337–45 (40 ref.)

Dimethyl formamide (DMFA) and ethylene glycol (EG) are estrogenic in rainbow trout. Ren L, et al. **Chem Biol Interact** 1996 Sep 27;102(1):63–7 (6 ref.)

Potential biomarkers of benzene exposure. Medeiros AM, et al. **J Toxicol Environ Health** 1997 Aug 29;51(6):519–39 (73 ref.)

Trichloroethylene cancer risk: simplified calculation of PBPK-based MCLs for cytotoxic end points. Bogen KT, et al. **Regul Toxicol Pharmacol** 1997 Feb;25(1):26–42 (121 ref.)

SOMAN

POISONING

Present views on toxidynamics of soman poisoning. Bajgar J. **Acta Medica (Hradec Kralove)** 1996;39(3):101–5 (76 ref.)

SOMATIC CELL HYBRIDS see **HYBRID CELLS**

SOMATIC GENE THERAPY see **GENE THERAPY**

SOMATIZATION DISORDER see **SOMATOFORM DISORDERS**

SOMATOCRININ see **SOMATOTROPIN-RELEASING HORMONE**

SOMATOFORM DISORDERS

Rethinking somatization. McWhinney IR, et al. **Ann Intern Med** 1997 May 1;126(9):747–50 (26 ref.)

CLASSIFICATION

[Debatable issues in the problem of somatoform and related disorders] Zharikov NM, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(4):5–11 (45 ref.) (Eng. Abstr.) **(Rus)**

COMPLICATIONS

How are alexithymia and physical illness linked? A review and critique of pathways. Lumley MA, et al. **J Psychosom Res** 1996 Dec;41(6):505–18 (101 ref.)

DIAGNOSIS

Diagnosis of functional neurological disease. Hawkes CH. **Br J Hosp Med** 1997 Apr 16–May 6;57(8):373–7 (2 ref.)

Body dysmorphic disorder. Cotterill JA. **Dermatol Clin** 1996 Jul;14(3):457–63 (13 ref.)

General principles in child liaison consultation service: a literature review. Ortiz P. **Eur Child Adolesc Psychiatry** 1997 Mar;6(1):1–6 (46 ref.)

[Somatization as a clinical problem] Karlsson H, et al. **Duodecim** 1995;111(18):1791–7 (42 ref.) **(Fin)**

[Somatoform disorders in urology] Csef H. **Urologe A** 1997 Jan;36(1):87–99; quiz 97–8 (9 ref.) **(Ger)**

DRUG THERAPY

Overview of somatization: diagnosis, epidemiology, and management. Escobar JI. **Psychopharmacol Bull** 1996; 32(4):589–96 (37 ref.)

Pharmacologic treatment of body dysmorphic disorder. Phillips KA. **Psychopharmacol Bull** 1996;32(4):597–605 (52 ref.)

EPIDEMIOLOGY

Sociopsychological factors in chronic pelvic pain: a review. Fry RP, et al. **J Psychosom Res** 1997 Jan;42(1):1–15 (53 ref.)

ETIOLOGY

Recognizing and treating the patient with somatic manifestations of depression. De Wester JN. **J Fam Pract** 1996 Dec;43(6 Suppl):S3–15 (109 ref.)

SOMATOFORM DISORDERS

PHYSIOPATHOLOGY

Plasma neurotransmitters and functional illness. Lechin F, et al. **Psychother Psychosom** 1996;65(6):293–318 (203 ref.)

PSYCHOLOGY

Health psychology: what is an unhealthy environment and how does it get under the skin? Taylor SE, et al. **Annu Rev Psychol** 1997;48:411–47 (215 ref.)

The postconcussional syndrome: a rose by any other name [editorial] McClelland RJ. **J Psychosom Res** 1996 Jun; 40(6):563–8 (41 ref.)

Psychosocial factors and physical illness in primary care: promoting the biopsychosocial model in medical practice [editorial] Zimmermann C, et al. **J Psychosom Res** 1996 Apr;40(4):351–8 (60 ref.)

[Stress theories and the somatization process] Dantzer R. **Encephale** 1995 Dec;21 Spec No 7:3–9 (21 ref.) (Eng. Abstr.) **(Fre)**

[Phenomenologic analysis of somatic symptoms in melancholia] Kraus A. **Encephale** 1995 Dec;21 Spec No 7:11–5 (37 ref.) (Eng. Abstr.) **(Fre)**

[Psychophysiologic and psychoneuroimmunologic studies in neurodermatitis. Overview and critical evaluation] Buhk H, et al. **Hautarzt** 1997 Jan;48(1):5–11 (24 ref.) (Eng. Abstr.) **(Ger)**

[Cardiovascular diseases caused by unemployment? An analysis from the viewpoint of social medicine (see comments)] Weber A, et al. **Wien Klin Wochenschr** 1997 Mar 28;109(6):202–10 (50 ref.) (Eng. Abstr.) Comment in: Wien Klin Wochenschr 1997 Mar 28;109(6):177–9. **(Ger)**

[The induction of psychopathology by somatic disorders, medications, toxins and drugs after systemic disorders] García Toro M, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1997 Jan–Feb;25(1):50–60 (93 ref.) (Eng. Abstr.) **(Spa)**

REHABILITATION

[Psychosomatic rehabilitation] Lamprecht F. **Z Arztl Fortbild (Jena)** 1996 Oct;90(6):511–7 (13 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Reappraising reassurance—the role of investigations [editorial] Howard LM, et al. **J Psychosom Res** 1996 Oct; 41(4):307–11 (26 ref.)

Morita therapy: 1919 to 1995. Kitanishi K, et al. **Psychiatry Clin Neurosci** 1995 Dec;49(5–6):245–54 (142 ref.)

[Management of somatization in depression] Azorin JM. **Encephale** 1995 Dec;21 Spec No 7:17–22 (47 ref.) (Eng. Abstr.) **(Fre)**

SOMATOMAMMOTROPIN, CHORIONIC see **PLACENTAL LACTOGEN**

SOMATOMAMMOTROPIN RECEPTORS see **RECEPTORS, SOMATOTROPIN**

SOMATOMEDIN-BINDING PROTEINS see **INSULIN-LIKE GROWTH-FACTOR-BINDING PROTEINS**

SOMATOMEDIN C see **INSULIN-LIKE GROWTH FACTOR I**

SOMATOMEDIN C RECEPTORS see **RECEPTORS, INSULIN-LIKE-GROWTH FACTOR I**

SOMATOMEDIN MSA see **INSULIN-LIKE GROWTH FACTOR II**

SOMATOMEDIN RECEPTORS see **RECEPTORS, SOMATOMEDIN**

SOMATOMEDINS

see related
RECEPTORS, SOMATOMEDIN

[Insulin-like growth factor in normalcy and in osteogenic sarcoma] KushlinskiiNE, et al. **Vopr Onkol** 1996;42(6):7–12 (39 ref.) **(Rus)**

DEFICIENCY

Biochemical diagnostic strategies in the evaluation of short stature: the diagnosis of insulin-like growth factor deficiency. Rosenfeld RG. **Horm Res** 1996;46(4–5):170–3 (17 ref.)

METABOLISM

Insulin-like growth factors in breast cancer. Helle SI, et al. **Acta Oncol** 1996;35 Suppl 5:19–22 (29 ref.)

Neuroblastoma and insulin-like growth factor system. New insights and clinical perspectives. Cianfarani S, et al. **Eur J Pediatr** 1997 Apr;156(4):256–61 (65 ref.)

IGFs and their binding proteins. Gourmelen M, et al. **Nucl Med Biol** 1994 Apr;21(3):297–302 (20 ref.)

Formation of 150-kDa binary complexes of insulin-like growth factor binding protein-3 and the acid-labile subunit in vitro and in vivo. Lee CY, et al. **Prog Growth Factor Res** 1995;6(2–4):241–51 (12 ref.)

Cellular localization and hormonal regulation of biosynthesis of insulin-like growth factor binding proteins and of the acid-labile subunit within rat liver. Scharf JG, et al. **Prog Growth Factor Res** 1995;6(2–4):175–80 (23 ref.)

Insulin-like growth factors (IGF) and IGF binding proteins in children with chronic renal failure. Tönshoff B, et al. **Prog Growth Factor Res** 1995;6(2–4):481–91 (49 ref.)

[Insulin-like growth factors (IGFs) and their binding proteins (IGFBPs)in physiologic and pathologic states] Marek B, et al. **Pol Arch Med Wewn** 1996 Sep;96(3):290–6 (82 ref.) **(Pol)**

PHARMACOLOGY

[Somatomedins—structure, mechanism of action and clinical significance] Zdrojewicz Z, et al. **Pol Arch Med Wewn** 1997 Jan;97(1):78–84 (47 ref.) **(Pol)**

PHYSIOLOGY

Fetal growth retardation: underlying endocrine mechanisms and postnatal consequences. Gluckman PD, et al. **Acta Paediatr Suppl** 1997 Jul;422:69–72 (32 ref.)

Growth factors for bone growth and repair: IGF, TGF beta and BMP. Linkhart TA, et al. **Bone** 1996 Jul;19(1 Suppl):1S–12S (96 ref.)

Up and down the growth hormone cascade. Clark RG, et al. **Cytokine Growth Factor Rev** 1996 Jun;7(1):65–80 (128 ref.)

Growth hormone, the insulin-like growth factor system, and the kidney. Feld S, et al. **Endocr Rev** 1996 Oct;17(5):423–80 (725 ref.)

Growth hormone and the insulin-like growth factor system in myogenesis. Florini JR, et al. **Endocr Rev** 1996 Oct; 17(5):481–517 (465 ref.)

The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action. Collett-Solberg PF, et al. **Endocrinol Metab Clin North Am** 1996 Sep;25(3):591–614 (114 ref.)

Insulin-like growth factors and their receptors in growth. D'Ercole AJ. **Endocrinol Metab Clin North Am** 1996 Sep; 25(3):573–90 (44 ref.)

The mechanisms by which growth hormone brings about growth. The relative contributions of growth hormone and insulin-like growth factors. Spagnoli A, et al. **Endocrinol Metab Clin North Am** 1996 Sep;25(3):615–31 (94 ref.)

Growth hormone, insulin-like growth factors and bone remodelling. Eriksen EF, et al. **Eur J Clin Invest** 1996 Jul; 26(7):525–34 (90 ref.)

Use of transgenic mice for understanding the physiology of insulin-like growth factors. D'Ercole AJ, et al. **Horm Res** 1996;45 Suppl 1:5–7 (11 ref.)

Insulin-like growth factor system components and the coupling of bone formation to resorption. Mohan S, et al. **Horm Res** 1996;45 Suppl 1:59–62 (15 ref.)

The role of insulin-like growth factors in prostate biology. Peehl DM, et al. **J Androl** 1996 Jan–Feb;17(1):2–4 (14 ref.)

Insulin-like growth factor (IGF)-binding proteins in serum—do they have additional roles besides modulating the endocrine IGF actions? [editorial] Mohan S, et al. **J Clin Endocrinol Metab** 1996 Nov;81(11):3817–20 (34 ref.)

Effects of renal failure on the growth hormone–insulin-like growth factor axis. Powell DR. **J Pediatr** 1997 Jul;131(1 Pt 2):S13–6 (21 ref.)

The role of the insulin-like growth factors in the central nervous system. D'Ercole AJ, et al. **Mol Neurobiol** 1996 Dec;13(3):227–55 (190 ref.)

The early intracellular signaling pathway for the insulin/insulin-like growth factor receptor family in the mammalian central nervous system. Folli F, et al. **Mol Neurobiol** 1996 Oct;13(2):155–83 (162 ref.)

Role of insulin-like growth factor binding proteins in the control of IGF actions. Clemmons DR, et al. **Prog Growth Factor Res** 1995;6(2–4):357–66 (23 ref.)

Cell migration: interactions among integrins, IGFs and IGFBPs. Jones JI, et al. **Prog Growth Factor Res** 1995; 6(2–4):319–27 (25 ref.)

Structure and regulation of the ALS gene. Ooi GT, et al. **Prog Growth Factor Res** 1995;6(2–4):151–7 (30 ref.)

Growth factors in normal ovarian follicle development. Giudice LC, et al. **Semin Reprod Endocrinol** 1996 Aug; 14(3):179–96 (255 ref.)

[Current achievements in the study of the signal mechanisms of the action of insulin and related peptides] Pertseva MN, et al. **Zh Evol Biokhim Fiziol** 1996 May–Jun;32(3):318–40 (109 ref.) **(Rus)**

[Growth factors—particular aspects of insulin-like growth factors] Svrzić DD, et al. **Srp Arh Celok Lek** 1996 Sep–Oct; 124(9–10):271–5 (39 ref.) (Eng. Abstr.) **(Scc)**

SOMATOSENSORY CORTEX

ANATOMY & HISTOLOGY

The anatomy of manual dexterity. The new connectivity of the primate sensorimotor thalamus and cerebral cortex. Darian-Smith I, et al. **Adv Anat Embryol Cell Biol** 1996; 133:1–140 (400 ref.)

The callosal connections of the hierarchically organized somatosensory areas of primates. Manzoni T. **J Neurosurg Sci** 1997 Mar;41(1):1–22 (247 ref.)

Functional magnetic resonance imaging of the somatosensory cortex. Mueller WM, et al. **Neurosurg Clin N Am** 1997 Jul;8(3):373–81 (49 ref.)

PHYSIOLOGY

Mechanisms of compensatory plasticity in the cerebral cortex. Rauschecker JP. **Adv Neurol** 1997;73:137–46 (58 ref.)

Cooperative structures for visually guided reach. MacKay WA. **Can J Physiol Pharmacol** 1996 Apr;74(4):463–8 (46 ref.)

The premotor cortex and nonstandard sensorimotor mapping. Wise SP, et al. **Can J Physiol Pharmacol** 1996 Apr; 74(4):469–82 (92 ref.)

Parallel organization of somatosensory cortical areas I and II for tactile processing. Rowe MJ, et al. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov;23(10–11):931–8 (30 ref.)

Interactions between motor commands and somatic perception in sensorimotor cortex. Nelson RJ. **Curr Opin Neurobiol** 1996 Dec;6(6):801–10 (79 ref.)

The medullary raphe nuclei: a system for integration and gain control in autonomic and somatomotor responsiveness? Lovick TA. **Exp Physiol** 1997 Jan; 82(1):31–41 (32 ref.)

Low-frequency oscillations of visual, auditory and somatosensory cortical neurons evoked by sensory stimulation. Dinse HR, et al. **Int J Psychophysiol** 1997 Jun; 26(1–3):205–27 (31 ref.)

Central nervous system pathways for pain transmission and pain control: issues relevant to the practicing clinician. Robinson AJ. **J Hand Ther** 1997 Apr–Jun;10(2):64–77 (66 ref.)

Neurobiological basis of motor learning in mammals. Asanuma H, et al. **Neuroreport** 1997 Mar 3;8(4):i–vi (59 ref.)

Somatosensory and visceral input to the hypothalamus and limbic system. Burstein R. **Prog Brain Res** 1996;107:257–67 (92 ref.)

Extensive cortical reorganization following sciatic nerve injury in adult rats versus restricted reorganization after neonatal injury: implications for spatial and temporal limits on somatosensory plasticity. Cusick CG. **Prog Brain Res** 1996;108:379–90 (75 ref.)

The role of excitatory amino acid transmission in development and plasticity of SI barrel cortex. Fox K. **Prog Brain Res** 1996;108:219–34 (56 ref.)

The somatic motor system. Holstege G. **Prog Brain Res** 1996; 107:9–26 (81 ref.)

The vestibular system as a model of sensorimotor transformations. A combined in vivo and in vitro approach to study the cellular mechanisms of gaze and posture stabilization in mammals. Vibert N, et al. **Prog Neurobiol** 1997 Feb;51(3):243–86 (269 ref.)

Sensorimotor stimulation to improve locomotor recovery after spinal cord injury. Muir GD, et al. **Trends Neurosci** 1997 Feb;20(2):72–7 (60 ref.)

[Clinical application of functional mapping; the present state of the art and its future prospects: (series 2) Identification of motor, sensory, visual and speech cortex by functional MRI] Ito T, et al. **No Shinkei Geka** 1996 Feb;24(2):109–18 (23 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Cortical myoclonus: an insight into the organization of normal movement in man. Brown P. **Clin Neurosci** 1995–96; 3(4):193–7 (44 ref.)

Pathophysiology of sensorimotor cortex in cortical myoclonus. Ugawa Y, et al. **Clin Neurosci** 1995–96; 3(4):198–202 (21 ref.)

SOMATOSENSORY EVOKED POTENTIALS see **EVOKED POTENTIALS, SOMATOSENSORY**

SOMATOSTATIN

see related
RECEPTORS, SOMATOSTATIN

[Somatostatin and its receptors] Yamada Y, et al. **Nippon Rinsho** 1996 Apr;54(4):1109–14 (12 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Improved analogs and novel delivery systems for somatostatin octapeptides. Moreau JP, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):24–6 (7 ref.)

[Indications for the use of somatostatin and octreotide in digestive pathology] Zan S, et al. **Minerva Gastroenterol Dietol** 1996 Jun;42(2):107–14 (38 ref.) (Eng. Abstr.) **(Ita)**

[Analgesic effects of natural growth hormone release inhibitors and their synthetic analogs. Intraspinal administration] Beltrutti D, et al. **Minerva Med** 1997 Jan–Feb;88(1–2):39–47 (86 ref.) (Eng. Abstr.) **(Ita)**

AGONISTS

The role of somatostatin agonistic analogs in the treatment of acromegaly. Tolis G. **Metabolism** 1996 Aug;45(8 Suppl

1):109–10 (16 ref.)

ANALOGS & DERIVATIVES

Radiolabelled somatostatin analogue scintigraphy in oncology. O'Byrne KJ, et al. **Anticancer Drugs** 1996 Jan; 7 Suppl 1:33–44 (79 ref.)

Clinical aspects of local and regional tumor therapy with 188Re-RC-160. Bender H, et al. **Anticancer Res** 1997 May-Jun;17(3B):1705–12 (31 ref.)

Pre-clinical experience with Re-188-RC-160, a radiolabeled somatostatin analog for use in peptide-targeted radiotherapy. Zamora PO, et al. **Anticancer Res** 1997 May-Jun;17(3B):1803–8 (33 ref.)

Somatostatin analogs and receptors. Diagnostic and therapeutic applications. Hofland LJ, et al. **Cancer Treat Res** 1997;89:365–82 (91 ref.)

Clinical use of somatostatin analogues in paediatric oncology. Albers AR, et al. **Digestion** 1996;57 Suppl 1:38–41 (32 ref.)

The role of somatostatin analogues in the treatment of gastro-enteropancreatic endocrine tumours. Bajetta E, et al. **Digestion** 1996;57 Suppl 1:72–6 (11 ref.)

Somatostatin analogues and pancreatic fistulas. Bassi C, et al. **Digestion** 1996;57 Suppl 1:94–6 (9 ref.)

The role of somatostatin analogues in the treatment of refractory diarrhoea. Farthing MJ. **Digestion** 1996;57 Suppl 1:107–13 (52 ref.)

Internalisation of isotope-coupled somatostatin analogues. Hofland LJ, et al. **Digestion** 1996;57 Suppl 1:2–6 (32 ref.)

Enhancement of the anti-neoplastic effects of tamoxifen by somatostatin analogues. Pollak M. **Digestion** 1996;57 Suppl 1:29–33 (37 ref.)

Somatostatin receptor manipulation. Visser-Wisselaar HA, et al. **Digestion** 1996;57 Suppl 1:7–10 (32 ref.)

Enhanced bilateral somatostatin receptor expression in mediastinal lymph nodes ("chimney sign") in occult metastatic medullary thyroid cancer: a typical site of tumour manifestation? Behr TM, et al. **Eur J Nucl Med** 1997 Feb;24(2):184–91 (20 ref.)

Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action. Woltering EA, et al. **Invest New Drugs** 1997;15(1):77–86 (03 ref.)

Receptor-specific somatostatin analogs: correlations with biological activity. Coy DH, et al. **Metabolism** 1996 Aug; 45(8 Suppl 1):21–3 (14 ref.)

Is there a role for somatostatin and its analogs in Cushing's syndrome? de Herder WW, et al. **Metabolism** 1996 Aug; 45(8 Suppl 1):83–5 (17 ref.)

Improved analogs and novel delivery systems for somatostatin octapeptides. Moreau JP, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):24–6 (7 ref.)

The role of somatostatin agonistic analogs in the treatment of acromegaly. Tolis G. **Metabolism** 1996 Aug;45(8 Suppl 1):109–10 (16 ref.)

Somatostatin analogs in ectopic corticotropin production. von Werder K, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):129–31 (16 ref.)

Angiopeptin--an immunological review. Motomura N, et al. **Transpl Immunol** 1996 Jun;4(2):99–104 (72 ref.)

Somatostatin and its analogues in G.I. tract, liver and pancreatic disorders. Dhar A, et al. **Trop Gastroenterol** 1995 Jul-Sep;16(3):3–7 (22 ref.)

[Lanreotide++: a new therapeutic option in acromegaly] Diez JJ. **Med Clin (Barc)** 1996 Sep 7;107(7):257–69 (200 ref.) **(Spa)**

BLOOD

Neural monitoring system for circulating somatostatin in the hepatoportal area. Nakabayashi H. **Nutrition** 1997 Mar; 13(3):225–9 (17 ref.)

DIAGNOSTIC USE

Radiolabelled somatostatin analogue scintigraphy in oncology. O'Byrne KJ, et al. **Anticancer Drugs** 1996 Jan; 7 Suppl 1:33–44 (79 ref.)

Somatostatin and cancer. Robbins RJ. **Metabolism** 1996 Aug; 45(8 Suppl 1):98–100 (41 ref.)

[Somatostatin stimulation test] Sakai Y, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:428–31 (6 ref.) **(Jpn)**

GENETICS

Regulation of somatostatin gene transcription by cAMP. Montminy M, et al. **Adv Pharmacol** 1996;36:1–13 (20 ref.)

Regulation of somatostatin gene transcription by cyclic adenosine monophosphate. Montminy M, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):4–7 (12 ref.)

Molecular control of peptide hormone and receptor expression. Dimaline R. **Proc Nutr Soc** 1996 Mar; 55(1B):265–77 (77 ref.)

METABOLISM

Target tissue influence on somatostatin expression in the avian ciliary ganglion. Coulombe JN, et al. **Ann N Y Acad Sci** 1997 Apr 24;814:209–25 (54 ref.)

Platelet-activating factor and somatostatin activate mitogen-activated protein kinase (MAP kinase) and arachidonate release. Shimizu T, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):103–8 (22 ref.)

Receptor-specific somatostatin analogs: correlations with biological activity. Coy DH, et al. **Metabolism** 1996 Aug; 45(8 Suppl 1):21–3 (14 ref.)

PHARMACOKINETICS

Internalisation of isotope-coupled somatostatin analogues. Hofland LJ, et al. **Digestion** 1996;57 Suppl 1:2–6 (32 ref.)

PHARMACOLOGY

Effects of somatostatin analogues on human gastrointestinal motility. Camilleri M. **Digestion** 1996;57 Suppl 1:90–2 (10 ref.)

Enhancement of the anti-neoplastic effects of tamoxifen by somatostatin analogues. Pollak M. **Digestion** 1996;57 Suppl 1:29–33 (37 ref.)

Somatostatin receptor manipulation. Visser-Wisselaar HA, et al. **Digestion** 1996;57 Suppl 1:7–10 (32 ref.)

Molecular mechanisms of antiproliferative effect of somatostatin: involvement of a tyrosine phosphatase. Lopez F, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):14–6 (24 ref.)

PHYSIOLOGY

Stress and nutritional influences on GnRH and somatostatin neuronal systems in the ewe. Polkowska J. **Acta Neurobiol Exp (Warsz)** 1996;56(3):797–806 (38 ref.)

Granulomas in murine schistosomiasis mansoni have a somatostatin immunoregulatory circuit. Elliott DE, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):88–90 (37 ref.)

Somatostatin, growth hormone, insulin-like growth factor-1, and diabetes: friends or foes? Orskov H. **Metabolism** 1996 Aug;45(8 Suppl 1):91–5 (67 ref.)

Somatostatin receptors in the central nervous system. Schindler M, et al. **Prog Neurobiol** 1996 Sep;50(1):9–47 (255 ref.)

Somatostatin: the neuroendocrine story. Gillies G. **Trends Pharmacol Sci** 1997 Mar;18(3):87–95 (45 ref.)

SECRETION

Sex steroid effects on the development and functioning of the growth hormone axis. Chowen JA, et al. **Cell Mol Neurobiol** 1996 Jun;16(3):297–310 (31 ref.)

THERAPEUTIC USE

Advances in the use of somatostatins in the management of endocrine tumors [see comments] Chaudhry A, et al. **Curr Opin Oncol** 1996 Jan;8(1):44–8 (34 ref.) Comment in: Curr Opin Oncol 1996 Jan;8(1):29.

Clinical use of somatostatin analogues in paediatric oncology. Albers AR, et al. **Digestion** 1996;57 Suppl 1:38–41 (32 ref.)

The role of somatostatin analogues in the treatment of gastro-enteropancreatic endocrine tumours. Bajetta E, et al. **Digestion** 1996;57 Suppl 1:72–6 (11 ref.)

Somatostatin analogues and pancreatic fistulas. Bassi C, et al. **Digestion** 1996;57 Suppl 1:94–6 (9 ref.)

The role of somatostatin analogues in the treatment of refractory diarrhoea. Farthing MJ. **Digestion** 1996;57 Suppl 1:107–13 (52 ref.)

Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action. Woltering EA, et al. **Invest New Drugs** 1997;15(1):77–86 (03 ref.)

Recurrent pericardial effusion as a result of chronic pancreatitis. Successful treatment with somatostatin. Schoonjans R, et al. **J Clin Gastroenterol** 1996 Oct; 23(3):224–7 (20 ref.)

Is there a role for somatostatin and its analogs in Cushing's syndrome? de Herder WW, et al. **Metabolism** 1996 Aug; 45(8 Suppl 1):83–5 (17 ref.)

Somatostatin and cancer. Robbins RJ. **Metabolism** 1996 Aug; 45(8 Suppl 1):98–100 (41 ref.)

Somatostatin analogue treatment of neuroendocrine tumours. de Herder WW, et al. **Postgrad Med J** 1996 Jul; 72(849):403–8 (32 ref.)

Somatostatin and its analogues in G.I. tract, liver and pancreatic disorders. Dhar A, et al. **Trop Gastroenterol** 1995 Jul-Sep;16(3):3–7 (22 ref.)

SOMATOSTATIN RECEPTORS see **RECEPTORS, SOMATOSTATIN**

SOMATOSTATIN-14 see **SOMATOSTATIN**

SOMATOSTATINOMA

DIAGNOSIS

[Somatostatinoma. Apropos of a case] Masson B, et al. **J Chir (Paris)** 1997 May;134(1):22–6 (28 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

[Somatostatinoma. Apropos of a case] Masson B, et al. **J Chir (Paris)** 1997 May;134(1):22–6 (28 ref.) (Eng. Abstr.) **(Fre)**

SOMATOTROPIN

see related
RECEPTORS, SOMATOTROPIN

Immunoregulatory properties of growth hormone and prolactin. Weigent DA. **Pharmacol Ther** 1996;69(3):237–57 (258 ref.)

ADMINISTRATION & DOSAGE

Controlled delivery of somatotropins. Cady SM, et al. **Pharm Biotechnol** 1997;10:289–317 (70 ref.)

ADVERSE EFFECTS

Unlabeled milk from cows treated with biosynthetic growth hormones: a case of regulatory abdication. Epstein SS. **Int J Health Serv** 1996;26(1):173–85 (66 ref.)

Bone disease in patients receiving growth hormone. Watkins SL. **Kidney Int Suppl** 1996 Jan;53:S126–7 (17 ref.)

[Benign intracranial hypertension as a secondary effect of treatment with a biosynthetic growth hormone] Bermúdez de la Vega JA, et al. **An Esp Pediatr** 1996 May;44(5):507–8 (6 ref.) **(Spa)**

ANALYSIS

Prolactin, growth hormone, and insulin-like growth factor-I in the immune system. Kooijman R, et al. **Adv Immunol** 1996;63:377–454 (364 ref.)

BIOSYNTHESIS

Role of Pit-1 in the gene expression of growth hormone, prolactin, and thyrotropin. Cohen LE, et al. **Endocrinol Metab Clin North Am** 1996 Sep;25(3):523–40 (94 ref.)

Dual expression of p80 type I and p68 type II interleukin-1 receptors on anterior pituitary cells synthesizing growth hormone. French RA, et al. **Endocrinology** 1996 Sep; 137(9):4027–36 (84 ref.)

BLOOD

Nutritional regulation of the growth hormone and insulin-like growth factor-binding proteins. Ketelslegers JM, et al. **Horm Res** 1996;45(3–5):252–7 (48 ref.)

Acromegaly. Melmed S. **Metabolism** 1996 Aug;45(8 Suppl 1):51–2 (5 ref.)

Growth hormone binding protein and free growth hormone in chronic renal failure. Baumann G. **Pediatr Nephrol** 1996 Jun;10(3):328–30 (32 ref.)

A view on noradrenergic, hypothalamic-pituitary-adrenal axis and extrahypothalamic corticotrophin-releasing factor function in anxiety and affective disorders: the reduced growth hormone response to clonidine. Coplan JD, et al. **Psychopharmacol Bull** 1997;33(2):193–204 (93 ref.)

CHEMISTRY

Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen, and related proteins in mammals. Goffin V, et al. **Endocr Rev** 1996 Aug;17(4):385–410 (244 ref.)

Structure and function of bovine growth hormone. Bovine growth hormone as an experimental model for studies of protein-protein interactions. Secchi C, et al. **J Chromatogr B Biomed Appl** 1997 Jan 24;688(2):161–77 (88 ref.)

DEFICIENCY

Interstitial deletion of long arm of chromosome no. 5 with growth hormone deficiency--an emerging syndrome? Krishna J, et al. **Clin Genet** 1997 Jan;51(1):48–51 (3 ref.)

Growth hormone insensitivity. Rosenfeld RG, et al. **Curr Ther Endocrinol Metab** 1997;6:68–70 (4 ref.)

Growth hormone deficiency in the elderly. Toogood AA, et al. **Curr Ther Endocrinol Metab** 1997;6:645–9 (11 ref.)

Diagnosis of growth hormone deficiency in adulthood. Casanueva FF. **Eur J Endocrinol** 1996 Aug;135(2):168–70 (13 ref.)

Adult growth hormone deficiency and bone mass. Holmes SJ, et al. **Horm Res** 1996;45 Suppl 1:69–71 (16 ref.)

Bone mineral density and biochemical parameters of bone turnover in children with growth hormone deficiency. Saggese G, et al. **Horm Res** 1996;45 Suppl 1:67–8 (10 ref.)

Long-term growth hormone deficiency as a cause of cardiomyopathy and its reversibility with specific replacement therapy. Fazio S, et al. **J Clin Endocrinol Metab** 1996 Mar;81(3):887–90 (19 ref.)

Jacobsen syndrome: report of a patient with severe eye anomalies, growth hormone deficiency, and hypothyroidism associated with deletion 11 (q23q25) and review of 52 cases. Pivnick EK, et al. **J Med Genet** 1996 Sep;33(9):772–8 (61 ref.)

Is testing for growth hormone release necessary? Wilson DM. **Kidney Int Suppl** 1996 Jan;53:s123–5 (20 ref.)

Spontaneous growth and response to growth hormone treatment in children with growth hormone deficiency and idiopathic short stature. Wit JM, et al. **Pediatr Res** 1996 Feb;39(2):295–302 (79 ref.)

[Growth hormone treatment in adults (editorial)] Välimäki MJ. **Duodecim** 1995;111(11):999–1001 (20 ref.) **(Fin)**

[Growth hormone deficiency in adults] Meling TR, et al. **Tidsskr Nor Laegeforen** 1996 Nov 30;116(29):3476–80 (73 ref.) (Eng. Abstr.) **(Nor)**

[Towards a concept of growth hormone deficiency syndrome in adults] Diez JJ, et al. **Med Clin (Barc)** 1996 Jul 6; 107(6):218–23 (111 ref.) **(Spa)**

GENETICS

Hormonal and cell-specific regulation of the human growth hormone and chorionic somatomammotropin genes.

SOMATOTROPIN

Eberhardt NL, et al. **Prog Nucleic Acid Res Mol Biol** 1996; 54:127–63 (180 ref.)

METABOLISM

Growth hormone–binding proteins—an overview. Baumann G. **Acta Paediatr Suppl** 1996 Oct;417:95–7 (25 ref.)
Growth hormone–binding protein in short children. Carlsson L. **Acta Paediatr Suppl** 1996 Oct;417:105–7 (27 ref.)
Regulation of growth hormone–binding protein. Massa GG. **Acta Paediatr Suppl** 1996 Oct;417:102–4 (40 ref.)
Growth hormone–binding protein: biological significance. Postel-Vinay MC. **Acta Paediatr Suppl** 1996 Oct; 417:98–101 (28 ref.)
Acquired growth hormone resistance in catabolic states. Jenkins RC, et al. **Baillieres Clin Endocrinol Metab** 1996 Jul;10(3):411–9 (39 ref.)
Growth hormone–releasing peptides. Ghigo E, et al. **Eur J Endocrinol** 1997 May;136(5):445–60 (183 ref.)
The serum growth hormone binding protein: pregnant with possibilities. Barnard R, et al. **J Endocrinol** 1997 Apr; 153(1):1–14 (151 ref.)
Growth hormone receptor/binding protein—clinical implications. Postel-Vinay MC. **J Pediatr Endocrinol Metab** 1996 Jun;9 Suppl 3:279–83 (38 ref.)
The hypothalamo–pituitary–growth hormone insulin–like growth factor 1 axis in children with chronic renal failure. Rees L, et al. **Kidney Int Suppl** 1996 Jan;53:S109–14 (16 ref.)
[Growth hormone, IGF and bone metabolism in adults] Bonjour JP, et al. **Ann Endocrinol (Paris)** 1996;57(3):147–9 (36 ref.) **(Fre)**

PHARMACOLOGY

Interaction between insulin–like growth factor I, growth hormone, parathyroid hormone, 1 alpha,25–dihydroxyvitamin D3 and steroids on epiphyseal chondrocytes [see comments] Klaus G, et al. **Acta Paediatr Suppl** 1996 Oct;417:69–71 (28 ref.) Comment in: Acta Paediatr Suppl 1996 Oct;417 :80.
Clinical applications of growth hormone for ovarian stimulation. Homburg R, et al. **Hum Reprod Update** 1995 May;1(3):264–75 (42 ref.)

PHYSIOLOGY

Effects of growth hormone on neuroendocrine function. Bartke A, et al. **Acta Neurobiol Exp (Warsz)** 1996; 56(3):833–42 (66 ref.)
Modifications of growth hormone secretion during female puberty. Toublanc JE. **Ann N Y Acad Sci** 1997 Jun 17; 816:60–75 (73 ref.)
Growth hormone and the maintenance of adult bone mineral density. Inzucchi SE, et al. **Clin Endocrinol (Oxf)** 1996 Dec; 45(6):665–73 (80 ref.)
Up and down the growth hormone cascade. Clark RG, et al. **Cytokine Growth Factor Rev** 1996 Jun;7(1):65–80 (128 ref.)
Growth hormone and the insulin–like growth factor system in myogenesis. Florini JR, et al. **Endocr Rev** 1996 Oct; 17(5):481–517 (465 ref.)
Growth hormone, insulin–like growth factors and bone remodelling. Eriksen EF, et al. **Eur J Clin Invest** 1996 Jul; 26(7):525–34 (90 ref.)
Another view of GH neuroregulation: lessons from the sheep. Dutour A, et al. **Eur J Endocrinol** 1997 Jun;136(6):553–65 (133 ref.)
The growth hormone axis: control and effects. Argente J, et al. **Horm Res** 1996;45 Suppl 1:9–11 (10 ref.)
Growth hormone signalling mechanisms: involvement of the tyrosine kinase JAK2. Argetsinger LS, et al. **Horm Res** 1996;45 Suppl 1:22–4 (19 ref.)
Role of NPY neurones in GH–dependent feedback signalling to the brain. Chan YY, et al. **Horm Res** 1996;45 Suppl 1:12–4 (10 ref.)
Human aging and the GH–IGF–I axis. Ghigo E, et al. **J Pediatr Endocrinol Metab** 1996 Jun;9 Suppl 3:271–8 (74 ref.)
Unwanted effects of growth hormone excess in the adult. Melmed S. **J Pediatr Endocrinol Metab** 1996 Jun;9 Suppl 3:369–74 (31 ref.)
Growth hormone and insulin–like growth factor in non–uremic acidosis and uremic acidosis. Kuemmerle N, et al. **Kidney Int Suppl** 1997 Mar;58:S102–5 (39 ref.)
Somatostatin, growth hormone, insulin–like growth factor–1, and diabetes: friends or foes? Orskov H. **Metabolism** 1996 Aug;45(8 Suppl 1):91–5 (67 ref.)
Control of the thymic microenvironment by growth hormone/insulin–like growth factor–I–mediated circuits. Savino W, et al. **Neuroimmunomodulation** 1995 Nov–Dec; 2(6):313–8 (38 ref.)
Growth hormone insensitivity. Rosenbloom AL, et al. **Pediatr Clin North Am** 1997 Apr;44(2):423–42 (65 ref.)
Stimulation of kinase cascades by growth hormone: a paradigm for cytokine signaling. Wood TJ, et al. **Prog Nucleic Acid Res Mol Biol** 1997;57:73–94 (107 ref.)
Physiological regulation of the human growth hormone (GH)–insulin–like growth factor type I (IGF–I) axis: predominant impact of age, obesity, gonadal function, and sleep. Veldhuis JD, et al. **Sleep** 1996 Dec;19(10 Suppl):S221–4 (17 ref.)

SECRETION

Interaction between glucocorticoids and the somatotrophic axis [see comments] Tönshoff B, et al. **Acta Paediatr Suppl** 1996 Oct;417:72–5 (30 ref.) Comment in: Acta Paediatr Suppl 1996 Oct;417 :80.
Modifications of growth hormone secretion during female puberty. Toublanc JE. **Ann N Y Acad Sci** 1997 Jun 17; 816:60–75 (73 ref.)
GnRH signaling in goldfish pituitary cells. Chang JP, et al. **Biol Signals** 1996 Mar–Apr;5(2):70–80 (33 ref.)
Growth, short stature, and the use of growth hormone: considerations for the practicing pediatrician—an update. Schwartz ID, et al. **Curr Probl Pediatr** 1997 Jan;27(1):14–40 (177 ref.)
Growth hormone–releasing peptides: clinical and basic aspects. Argente J, et al. **Horm Res** 1996;46(4–5):155–9 (36 ref.)
Regulation of growth hormone secretion. Scanlon MF, et al. **Horm Res** 1996;46(4–5):149–54 (41 ref.)
Oral growth hormone secretagogues—better than Alice in Wonderland's growth elixir? [editorial; comment] Saenger P. **J Clin Endocrinol Metab** 1996 Aug;81(8):2773–5 (28 ref.) Comment on: J Clin Endocrinol Metab 1996 Aug;81(8):2776–82.
Role of glucocorticoids in the neuroregulation of growth hormone secretion. Dieguez C, et al. **J Pediatr Endocrinol Metab** 1996 Jun;9 Suppl 3:255–60 (26 ref.)
New insights into the regulation of somatotrope function using genetic and transgenic models. Frohman LA. **Metabolism** 1996 Aug;45(8 Suppl 1):1–3 (14 ref.)

THERAPEUTIC USE

Does growth hormone treatment prevent corticosteroid–induced osteoporosis? Tanaka H, et al. **Bone** 1996 Jun;18(6):493–4 (28 ref.)
Treatment of male infertility with growth hormone. Ng SC, et al. **Clin Sci (Colch)** 1996 Sep;91(3):254–5 (18 ref.)
Clinical utility of adjuvant growth hormone in the treatment of patients with polycystic ovaries undergoing in vitro fertilization. Artini PG, et al. **J Assist Reprod Genet** 1997 Jan;14(1):4–7 (24 ref.)
Long–term growth hormone deficiency as a cause of cardiomyopathy and its reversibility with specific replacement therapy. Fazio S, et al. **J Clin Endocrinol Metab** 1996 Mar;81(3):887–90 (19 ref.)
Recombinant human growth hormone in children with chronic renal insufficiency—clinical update: 1995. Fine RN. **Kidney Int Suppl** 1996 Jan;53:S115–8 (22 ref.)
Testing for growth hormone release is not necessary prior to treatment of children with chronic renal insufficiency with recombinant human growth hormone. Kohaut EC, et al. **Kidney Int Suppl** 1996 Jan;53:S119–22 (26 ref.)
The safety and effectiveness of human growth hormone using pharmacological dosing. Slyper A. **Med Hypotheses** 1995 Dec;45(6):523–8 (59 ref.)
Spontaneous growth and response to growth hormone treatment in children with growth hormone deficiency and idiopathic short stature. Wit JM, et al. **Pediatr Res** 1996 Feb;39(2):295–302 (79 ref.)
Growth hormone therapy for protein catabolism. Jenkins RC, et al. **QJM** 1996 Nov;89(11):813–9 (47 ref.)
[Possibilities to increase the efficacy of growth hormone therapy in Turner syndrome] Ságodi L, et al. **Orv Hetil** 1997 Jun 8;138(23):1501–5 (36 ref.) (Eng. Abstr.) **(Hun)**

SOMATOTROPIN (HUMAN) see **SOMATROPIN**

SOMATOTROPIN RECEPTORS see **RECEPTORS, SOMATOTROPIN**

SOMATOTROPIN RELEASE–INHIBITING HORMONE see **SOMATOSTATIN**

SOMATOTROPIN–RELEASING FACTOR 44 see **SOMATOTROPIN–RELEASING HORMONE**

SOMATOTROPIN–RELEASING HORMONE

ANALOGS & DERIVATIVES

Role of the new growth hormone–releasing secretagogues in the diagnosis of some hypothalamopituitary pathologies. Casanueva FF, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):123–6 (25 ref.)
[Growth hormone–releasing peptides (GHRP) and their analogues] Korbonits M, et al. **Orv Hetil** 1996 Nov 10; 137(45):2503–9 (73 ref.) (Eng. Abstr.) **(Hun)**

ANTAGONISTS & INHIBITORS

[Analgesic effects of natural growth hormone release inhibitors and their synthetic analogs. Intraspinal administration] Beltrutti D, et al. **Minerva Med** 1997 Jan–Feb;88(1–2):39–47 (86 ref.) (Eng. Abstr.) **(Ita)**

CHEMISTRY

Structural simplification of potent growth hormone–releasing hormone analogs: implications for other members of the VIP/GHRH/PACAP family. Coy DH, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:149–58 (15 ref.)

DIAGNOSTIC USE

Evaluation of pituitary function in children using growth hormone secretagogues. Bercu BB, et al. **J Pediatr Endocrinol Metab** 1996 Jun;9 Suppl 3:325–32 (12 ref.)
Growth hormone releasing hexapeptide–6 (GHRP–6) test in the diagnosis of GH–deficiency. Pombo M, et al. **J Pediatr Endocrinol Metab** 1996 Jun;9 Suppl 3:333–8 (35 ref.)
Evaluation of pituitary GH reserve with GHRP–6. Popovic V, et al. **J Pediatr Endocrinol Metab** 1996 Jun;9 Suppl 3:289–98 (23 ref.)
[GRH test] Inoue K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:217–8 (7 ref.) **(Jpn)**

PHARMACOLOGY

Diagnosis of growth hormone deficiency in adulthood. Casanueva FF. **Eur J Endocrinol** 1996 Aug;135(2):168–70 (13 ref.)
Oral growth hormone secretagogues—better than Alice in Wonderland's growth elixir? [editorial; comment] Saenger P. **J Clin Endocrinol Metab** 1996 Aug;81(8):2773–5 (28 ref.) Comment on: J Clin Endocrinol Metab 1996 Aug;81(8):2776–82.

PHYSIOLOGY

Structural simplification of potent growth hormone–releasing hormone analogs: implications for other members of the VIP/GHRH/PACAP family. Coy DH, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:149–58 (15 ref.)
The growth–hormone–releasing hormone receptor: signal transduction, gene expression, and physiological function in growth regulation. Mayo KE, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:184–203 (35 ref.)
Up and down the growth hormone cascade. Clark RG, et al. **Cytokine Growth Factor Rev** 1996 Jun;7(1):65–80 (128 ref.)
Physiological regulation of the human growth hormone (GH)–insulin–like growth factor type I (IGF–I) axis: predominant impact of age, obesity, gonadal function, and sleep. Veldhuis JD, et al. **Sleep** 1996 Dec;19(10 Suppl):S221–4 (17 ref.)

SECRETION

Growth hormone– and growth–hormone–releasing hormone–producing tumors. Shimon I, et al. **Cancer Treat Res** 1997;89:1–24 (78 ref.)
Sex steroid effects on the development and functioning of the growth hormone axis. Chowen JA, et al. **Cell Mol Neurobiol** 1996 Jun;16(3):297–310 (31 ref.)
Pathophysiology and clinical aspects of the ectopic GH–releasing hormone syndrome. Losa M, et al. **Clin Endocrinol (Oxf)** 1997 Aug;47(2):123–35 (93 ref.)

SOMATOTROPINS, RECOMBINANT

ADVERSE EFFECTS

Unwanted effects of growth hormone excess in the adult. Melmed S. **J Pediatr Endocrinol Metab** 1996 Jun;9 Suppl 3:369–74 (31 ref.)

CONTRAINDICATIONS

Is severe renal osteodystrophy a contraindication for recombinant human growth hormone treatment? Watkins SL. **Pediatr Nephrol** 1996 Jun;10(3):351–4 (22 ref.)

PHARMACOLOGY

The role of growth hormone in the regulation of body composition in the adult. Russell–Jones DL, et al. **Growth Regul** 1996 Dec;6(4):247–52 (42 ref.)
Metabolic effects of recombinant human insulin–like growth factor–I in humans: comparison with recombinant human growth hormone. Mauras N, et al. **Pediatr Nephrol** 1996 Jun;10(3):318–23 (70 ref.)

THERAPEUTIC USE

Recombinant growth hormone: a new cardiovascular drug therapy. Gomberg–Maitland M, et al. **Am Heart J** 1996 Dec;132(6):1244–62 (145 ref.)
Short stature. Underwood LE. **Curr Ther Endocrinol Metab** 1997;6:66–8 (4 ref.)
Growth hormone treatment for burned children. Herndon DN, et al. **Horm Res** 1996;45 Suppl 1:29–31 (9 ref.)
Growth hormone treatment for growth hormone deficient adults. Clark W, et al. **J Clin Pharm Ther** 1996 Dec; 21(6):367–72 (24 ref.)
Growth hormone and body composition. Christiansen JS. **J Pediatr Endocrinol Metab** 1996 Jun;9 Suppl 3:365–8 (24 ref.)
Constitutional delay in growth and puberty: a comparison of final height achieved between treated and untreated children. Ferrández Longás A, et al. **J Pediatr Endocrinol Metab** 1996 Jun;9 Suppl 3:345–57 (39 ref.)
Growth hormone treatment in children before and after renal

transplantation. Hokken-Koelega AC.
J Pediatr Endocrinol Metab 1996 Jun;9 Suppl 3:359-64 (41 ref.)

SOMATOTYPES

Body habitus and coronary heart disease in men. A review with reference to methods of body habitus assessment. Williams SR, et al. **Eur Heart J** 1997 Mar;18(3):376-93 (114 ref.)

[Somatotypes and the paradigm of individual constitutions. The development of the theory of human constitutions in Russia in the 2nd half of the 20th century] Kliorin AI. **Fiziol Zh Im I M Sechenova** 1996 Mar;82(3):151-65 (50 ref.) **(Rus)**

SOMATROPIN

ADMINISTRATION & DOSAGE

Long-term use of recombinant human growth hormone in children with chronic renal insufficiency. Yadin O, et al. **Kidney Int Suppl** 1997 Mar;58:S114-7 (30 ref.)

ANALYSIS

Apparent growth hormone levels in plasma and urine. Methodological "artefacts". Girard J. **Nucl Med Biol** 1994 Apr;21(3):381-92 (31 ref.)

BLOOD

Factors modifying growth hormone estimates in immunoassays. Fisker S, et al. **Horm Res** 1996; 46(4-5):183-7 (35 ref.)

Growth hormone secretion assessment in the diagnosis of short stature. Audi L, et al.
J Pediatr Endocrinol Metab 1996 Jun;9 Suppl 3:313-24 (74 ref.)

Derangements of the somatotropic hormone axis in chronic renal failure. Tönshoff B, et al. **Kidney Int Suppl** 1997 Mar; 58:S106-13 (66 ref.)

Heterogeneity of circulating growth hormone. Baumann G, et al. **Nucl Med Biol** 1994 Apr;21(3):369-79 (36 ref.)

DEFICIENCY

Management of puberty in growth hormone deficient children. Rogol AD. **Endocr J** 1996 Oct;43 Suppl:S5-11 (28 ref.)

Diagnosis of growth hormone deficiency in adults. Korbonits M, et al. **Horm Res** 1996;46(4-5):174-82 (62 ref.)

Making a rational diagnosis of growth-hormone deficiency. Preece MA. **J Pediatr** 1997 Jul;131(1 Pt 2):S61-4 (20 ref.)

Growth hormone and body composition. Christiansen JS. **J Pediatr Endocrinol Metab** 1996 Jun;9 Suppl 3:365-8 (24 ref.)

Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency. Pombo M, et al.
J Pediatr Endocrinol Metab 1996 Jun;9 Suppl 3:333-8 (35 ref.)

Endocrinologic disorders and optic pathway gliomas in children with neurofibromatosis type 1. Cnossen MH, et al. **Pediatrics** 1997 Oct;100(4):667-70 (24 ref.)

Clinical information on serum IGFBP-3 levels and IGFBP-3 proteolytic activity in childhood. Hasegawa Y, et al.
Prog Growth Factor Res 1995;6(2-4):457-63 (19 ref.)

[The Wolfram syndrome: diabetes mellitus, hypacusis, optic atrophy and short stature in STH deficiency] Hofmann M, et al. **Dtsch Med Wochenschr** 1997 Jan 24;122(4):86-90 (13 ref.) (Eng. Abstr.) **(Ger)**

[Diagnostic criteria for the indication of growth hormone substitution in adults. The Hypophysis and Hypophyseal Tumor Working Group of the German Society for Endocrinology] Strasburger CJ, et al.
Dtsch Med Wochenschr 1997 Jul 4;122(27):861-3 (12 ref.) **(Ger)**

GENETICS

Molecular biology of growth-hormone-secreting human pituitary tumours: biochemical consequences and potential clinical significance. Adams EF, et al.
Acta Neurochir Suppl (Wien) 1996;65:7-10 (18 ref.)

The spectrum of growth-hormone insensitivity. Parks JS, et al. **J Pediatr** 1997 Jul;131(1 Pt 2):S45-50 (20 ref.)

METABOLISM

Molecular basis of inherited growth hormone resistance in childhood. Amselem S, et al.
Baillieres Clin Endocrinol Metab 1996 Jul;10(3):353-69 (63 ref.)

Metabolic actions of growth hormone: direct and indirect. Berneis K, et al. **Baillieres Clin Endocrinol Metab** 1996 Jul; 10(3):337-52 (78 ref.)

Partial growth hormone insensitivity in childhood. Carlsson LM. **Baillieres Clin Endocrinol Metab** 1996 Jul; 10(3):389-400 (49 ref.)

Insulin-like growth factor bioactivity and its modification in growth hormone resistant states. Donaghy AJ, et al. **Baillieres Clin Endocrinol Metab** 1996 Jul;10(3):421-46 (101 ref.)

Growth hormone-releasing peptides. Ghigo E, et al.
Eur J Endocrinol 1997 May;136(5):445-60 (183 ref.)

Growth hormone and insulin-like growth factors in critical illness. Gibson FA, et al. **Intensive Care Med** 1997 Apr; 23(4):369-78 (84 ref.)

Evaluation of pituitary function in children using growth hormone secretagogues. Bercu BB, et al.
J Pediatr Endocrinol Metab 1996 Jun;9 Suppl 3:325-32 (12 ref.)

Evaluation of pituitary GH reserve with GHRP-6. Popovic V, et al. **J Pediatr Endocrinol Metab** 1996 Jun;9 Suppl 3:289-98 (23 ref.)

PHARMACOLOGY

Is growth hormone good for the heart? Silverman BL, et al. **J Pediatr** 1997 Jul;131(1 Pt 2):S70-4 (23 ref.)

PHYSIOLOGY

Up and down the growth hormone cascade. Clark RG, et al. **Cytokine Growth Factor Rev** 1996 Jun;7(1):65-80 (128 ref.)

Signalling pathway of GH. Carter-Su C, et al. **Endocr J** 1996 Oct;43 Suppl:S65-70 (33 ref.)

Metabolic actions of growth hormone in man. Ho KK, et al. **Endocr J** 1996 Oct;43 Suppl:S57-63 (38 ref.)

Growth hormone, the insulin-like growth factor system, and the kidney. Feld S, et al. **Endocr Rev** 1996 Oct;17(5):423-80 (725 ref.)

Growth hormones and sex steroid interactions at puberty. Clark PA, et al. **Endocrinol Metab Clin North Am** 1996 Sep;25(3):665-81 (94 ref.)

The growth without growth hormone syndrome. Geffner ME. **Endocrinol Metab Clin North Am** 1996 Sep; 25(3):649-63 (90 ref.)

The mechanisms by which growth hormone brings about growth. The relative contributions of growth hormone and insulin-like growth factors. Spagnoli A, et al.
Endocrinol Metab Clin North Am 1996 Sep;25(3):615-31 (94 ref.)

Protein anabolic action of insulin, growth hormone and insulin-like growth factor I. Russell-Jones DL, et al.
Eur J Endocrinol 1996 Dec;135(6):631-42 (144 ref.)

The role of growth hormone in the regulation of body composition in the adult. Russell-Jones DL, et al.
Growth Regul 1996 Dec;6(4):247-52 (42 ref.)

Growth hormone, insulin-like growth factor-I and lipid metabolism: interactions with sex steroids. Björntorp P.
Horm Res 1996;46(4-5):188-91 (12 ref.)

Role of growth hormone in glucose counterregulation. Cryer PE. **Horm Res** 1996;46(4-5):192-4 (18 ref.)

Growth-hormone signal transduction. Campbell GS.
J Pediatr 1997 Jul;131(1 Pt 2):S42-4 (22 ref.)

Effects of renal failure on the growth hormone-insulin-like growth factor axis. Powell DR. **J Pediatr** 1997 Jul;131(1 Pt 2):S13-6 (21 ref.)

Exercise and growth hormone: does one affect the other? Roemmich JN, et al. **J Pediatr** 1997 Jul;131(1 Pt 2):S75-80 (44 ref.)

The role of growth hormone (GH), GH-receptor and GH-binding protein in reproduction and ovulation induction. Blumenfeld Z, et al.
J Pediatr Endocrinol Metab 1996 Mar-Apr;9(2):145-62 (82 ref.)

Growth hormone physiology in health and disease: insights using genetic and transgenic models. Frohman LA.
J Pediatr Endocrinol Metab 1996 Jun;9 Suppl 3:233-6 (19 ref.)

New modalities for understanding dynamic regulation of the somatotropic (GH) axis: explication of gender differences in GH neuroregulation in the human. Veldhuis JD.
J Pediatr Endocrinol Metab 1996 Jun;9 Suppl 3:237-53 (81 ref.)

Role of growth hormone in ovarian physiology and onset of puberty. Sharara FI, et al. **J Soc Gynecol Investig** 1997 Jan-Feb;4(1):2-7 (82 ref.)

Role of growth hormone in polycystic ovarian syndrome. Morales AJ. **Semin Reprod Endocrinol** 1997 May; 15(2):177-82 (50 ref.)

SECRETION

Growth hormone- and growth-hormone-releasing hormone-producing tumors. Shimon I, et al.
Cancer Treat Res 1997;89:1-24 (78 ref.)

The regulation of growth hormone secretion. Cuttler L.
Endocrinol Metab Clin North Am 1996 Sep;25(3):541-71 (206 ref.)

Nuclear effects of the cAMP pathway activation in somatotrophs. Bertherat J. **Horm Res** 1997;47(4-6):245-50 (48 ref.)

An unusual treatment-related complication in a patient with growth hormone-secreting pituitary tumor. Ahmed M, et al. **J Clin Endocrinol Metab** 1997 Sep;82(9):2816-20 (19 ref.)

Oral glucose tolerance test: an inhibitory or a stimulatory input to growth hormone secretion? Valcavi R.
J Endocrinol Invest 1996 Apr;19(4):253-5 (24 ref.)

Nutrition, body composition, physical activity and growth hormone secretion. Vance ML.
J Pediatr Endocrinol Metab 1996 Jun;9 Suppl 3:299-301 (22 ref.)

Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging. Thorner MO, et al. **Recent Prog Horm Res** 1997;52:215-44; discussion 244-6 (63 ref.)

[Strategy of exploration of states of growth hormone hypersecretion] Sassolas G, et al. **Nucl Med Biol** 1994 Apr; 21(3):393-400 (12 ref.) (Eng. Abstr.) **(Fre)**

[GRH test] Inoue K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:217-8 (7 ref.) **(Jpn)**

THERAPEUTIC USE

Growth hormone and IGF-I therapy in the hypercatabolic patient. Wolf SE, et al.
Baillieres Clin Endocrinol Metab 1996 Jul;10(3):447-63 (75 ref.)

Ethical issues in emerging new treatments such as growth hormone therapy for children with Down syndrome and Prader-Willi syndrome. Kodish E, et al.
Curr Opin Pediatr 1996 Aug;8(4):401-5 (28 ref.)

Combined GH and LHRH analog treatment in short children. Tanaka T, et al. **Endocr J** 1996 Oct;43 Suppl:S13-7 (8 ref.)

Current and potential therapeutic uses of growth hormone and insulin-like growth factor I. Hintz RL.
Endocrinol Metab Clin North Am 1996 Sep;25(3):759-73 (75 ref.)

Growth hormone therapy in elderly people: an age-delaying drug? Bouillanne O, et al. **Fundam Clin Pharmacol** 1996; 10(5):416-30 (168 ref.)

Persistent short stature in children with intrauterine growth retardation: use of growth hormone treatment. Albanese A, et al. **Horm Res** 1997;48 Suppl 1:63-6 (21 ref.)

The rationale for the use of recombinant human growth hormone and insulin-like growth factor-I for catabolic conditions in humans. Haymond MW, et al. **Horm Res** 1996; 46(4-5):202-7 (28 ref.)

Growth hormone treatment of idiopathic short stature. Hintz RL. **Horm Res** 1996;46(4-5):208-14 (35 ref.)

Use of human recombinant growth hormone and human recombinant insulin-like growth factor-I in patients with human immunodeficiency virus infection. Hirschfeld S.
Horm Res 1996;46(4-5):215-21 (105 ref.)

Growth hormone as a new treatment modality for short children with chronic renal failure. The German Study Group for Growth Hormone Treatment in Chronic Renal Failure. Mehls O, et al. **Horm Res** 1996;46(4-5):230-5 (54 ref.)

Recombinant human growth hormone in chronic and acute respiratory insufficiency. Pichard C, et al. **Horm Res** 1996; 46(4-5):222-9 (72 ref.)

Growth hormone treatment in short children born small for gestational age: from controversy towards consensus. Ranke MB, et al. **Horm Res** 1997;48 Suppl 1:72-4 (8 ref.)

Growth hormone in adults: indications and implications. Inzucchi SE. **Hosp Pract (Off Ed)** 1997 Jan 15;32(1):79-86, 90-1, 95-6 (15 ref.)

Growth hormone and insulin-like growth factors in critical illness. Gibson FA, et al. **Intensive Care Med** 1997 Apr; 23(4):369-78 (84 ref.)

Growth hormone cotreatment with gonadotropins in ovulation induction. Artini PG, et al.
J Endocrinol Invest 1996 Dec;19(11):763-79 (128 ref.)

Growth hormone is safe in children after renal transplantation. Benfield MR, et al. **J Pediatr** 1997 Jul;131(1 Pt 2):S28-31 (26 ref.)

Growth hormone is not safe for children with renal transplants. Friedman AL. **J Pediatr** 1997 Jul;131(1 Pt 2):S25-7 (38 ref.)

Effects of growth hormone and insulin-like growth factor I on renal growth and function. Hammerman MR, et al.
J Pediatr 1997 Jul;131(1 Pt 2):S17-9 (16 ref.)

The use of anti-aging hormones. Melatonin, growth hormone, testosterone, and dehydroepiandrosterone: consumer enthusiasm for unproven therapies. Shomali ME.
Md Med J 1997 Apr;46(4):181-6 (45 ref.)

The case for growth hormone replacement in adult hypopituitarism. Florkowski CM, et al. **N Z Med J** 1996 Sep 27;109(1030):349-51 (30 ref.)

Growth hormone treatment of short children with chronic renal failure before and after renal transplantation: rationale and recent results. Mehls O, et al.
Nephrol Dial Transplant 1996 Sep;11(9):1747-50 (39 ref.)

Growth retardation in children with chronic renal insufficiency [editorial] Fine RN. **Nephron** 1997;76(2):125-9 (45 ref.)

New peptide and protein drugs. Vermeij P, et al.
Pharm World Sci 1996 Jun;18(3):87-93 (81 ref.)

[Growth hormone treatment in adults (editorial)] Välimäki MJ. **Duodecim** 1995;111(11):999-1001 (20 ref.) **(Fin)**

[Diagnostic criteria for the indication of growth hormone substitution in adults. The Hypophysis and Hypophyseal Tumor Working Group of the German Society for Endocrinology] Strasburger CJ, et al.
Dtsch Med Wochenschr 1997 Jul 4;122(27):861-3 (12 ref.) **(Ger)**

SOMNAMBULISM

PHYSIOPATHOLOGY

Sleepwalking disorder and mens rea: a review and case report. Maricopa County Superior Court. Thomas TN.
J Forensic Sci 1997 Jan;42(1):17-24 (51 ref.)

The sleepwalking/night terrors syndrome in adults. Crisp

SOMNAMBULISM

AH. **Postgrad Med J** 1996 Oct;72(852):599–604 (16 ref.)

SOMNOGRAPHY see **POLYSOMNOGRAPHY**

SONOGRAPHY, TRANSCRANIAL DOPPLER see **ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL**

SOR GENES see **GENES, VIF**

SORBITAN DERIVATIVES see **POLYSORBATES**

SORE THROAT see **PHARYNGITIS**

SORPTION DETOXIFICATION

[Complications after administration of contrast media in high-risk patients. Is a prophylactic dialysis meaningful?] Liebl R, et al. **Dtsch Med Wochenschr** 1996 Nov 22; 121(47):1475–9 (47 ref.) **(Ger)**

[Wound sorption] Bondarchuk OI, et al. **Klin Khir** 1996; (9):41–4 (50 ref.) **(Rus)**

METHODS

[Indirect electrochemical detoxication] Fedorovskii NM. **Anesteziol Reanimatol** 1995 Nov–Dec;(6):46–51 (54 ref.) **(Rus)**

SOS RESPONSE (GENETICS)

GENETICS

SOS response as an adaptive response to DNA damage in prokaryotes. Shinagawa H. **EXS** 1996;77:221–35 (64 ref.)

SOTALOL

THERAPEUTIC USE

Beta-blockers for ventricular arrhythmias: have we underestimated their value? Campbell TJ. **Aust N Z J Med** 1996 Oct;26(5):689–96 (59 ref.)

New antiarrhythmic drug in pediatric use: sotalol. Pfammatter JP, et al. **Pediatr Cardiol** 1997 Jan–Feb; 18(1):28–34 (62 ref.)

Class III antiarrhythmic agents: the next wave. Bauman JL. **Pharmacotherapy** 1997 Mar–Apr;17(2 Pt 2):76S–83S; discussion 89S–91S (28 ref.)

SOUND

see related
ACOUSTIC STIMULATION
NOISE

Protection against noise trauma by sound conditioning. Canlon B. **Ear Nose Throat J** 1997 Apr;76(4):248–50, 253–5 (23 ref.)

Attraction of male mosquitoes to sound. Belton P. **J Am Mosq Control Assoc** 1994 Jun;10(2 Pt 2):297–301 (27 ref.)

[Critical bands and the analysis of biologically important sound parameters in the auditory system of different representatives of the animal world] Vartanian IA, et al. **Zh Evol Biokhim Fiziol** 1996 Sep–Oct;32(5):642–50 (48 ref.) **(Rus)**

ADVERSE EFFECTS

[Infrasound: body's effects and hygienic regulation] Izmerov NF, et al. **Vestn Ross Akad Med Nauk** 1997;(7):39–46 (26 ref.) (Eng. Abstr.) **(Rus)**

SOUTHERN BLOTTING see **BLOTTING, SOUTHERN**

SOY BEANS see **SOYBEANS**

SOY PROTEINS

ANALYSIS

Composition and characterization of soyabean and related products. García MC, et al. **Crit Rev Food Sci Nutr** 1997 Jun;37(4):361–91 (240 ref.)

CHEMISTRY

Enzymatic modification of food proteins to improve the functional properties. Kamata Y. **Adv Exp Med Biol** 1997; 415:47–65 (52 ref.)

METABOLISM

Molecular design of soybean glycinins with enhanced food qualities and development of crops producing such glycinins. Utsumi S, et al. **Adv Exp Med Biol** 1997;415:1–15 (54 ref.)

Soy protein and serum lipids. Potter SM. **Curr Opin Lipidol** 1996 Aug;7(4):260–4 (32 ref.)

SOYBEAN PROTEINS see **SOY PROTEINS**

SOYBEANS

Beneficial effects of tempeh in disease prevention and treatment. Karyadi D, et al. **Nutr Rev** 1996 Nov;54(11 Pt 2):S94–8 (19 ref.)

[Physico-chemical characterization and application for drug carrier of soybean-derived sterols and their glucosides-containing liposomes] Maitani Y. **Yakugaku Zasshi** 1996 Dec;116(12):901–10 (28 ref.) (Eng. Abstr.) **(Jpn)**

[Allergic reactions to peanuts and soya. The life-threatening/fatal cases can be prevented] Kjellman NI, et al. **Lakartidningen** 1997 Jul 23;94(30–31):2633–4 (11 ref.) **(Swe)**

ADVERSE EFFECTS

Comparison of soybean epidemic asthma and occupational asthma. Antó JM, et al. **Thorax** 1996 Jul;51(7):743–9 (39 ref.)

CHEMISTRY

Oxygen-radical-scavenging activity of DDMP-conjugated saponins and physiological role in leguminous plant. Okubo K, et al. **Adv Exp Med Biol** 1996;405:141–54 (27 ref.)

Composition and characterization of soyabean and related products. García MC, et al. **Crit Rev Food Sci Nutr** 1997 Jun;37(4):361–91 (240 ref.)

METABOLISM

Molecular design of soybean glycinins with enhanced food qualities and development of crops producing such glycinins. Utsumi S, et al. **Adv Exp Med Biol** 1997;415:1–15 (54 ref.)

SP1-BINDING SITE, HIV see **HIV LONG TERMINAL REPEAT**

SP1 TRANSCRIPTION FACTOR see **TRANSCRIPTION FACTOR, SP1**

SP-K RECEPTORS see **RECEPTORS, NEUROKININ-2**

SP-P RECEPTORS see **RECEPTORS, NEUROKININ-1**

SPACE (ASTRONOMY) see **EXTRATERRESTRIAL ENVIRONMENT**

SPACE CLOSURE, ORTHODONTIC see **ORTHODONTIC SPACE CLOSURE**

SPACE CRAFT see **SPACECRAFT**

SPACE EXPLORATION see **SPACE FLIGHT**

SPACE FLIGHT

see related
ASTRONAUTS
ECOLOGICAL SYSTEMS, CLOSED
EXTRATERRESTRIAL ENVIRONMENT
SPACECRAFT
WEIGHTLESSNESS

Medical monitoring in long-term space missions. Grigoriev AI, et al. **Adv Space Biol Med** 1997;6:167–91 (36 ref.)

Psychosocial value of space simulation for extended spaceflight. Kanas N. **Adv Space Biol Med** 1997;6:81–91 (38 ref.)

Vestibular function and sensory interaction in altered gravity. Kornilova LN. **Adv Space Biol Med** 1997;6:275–313 (73 ref.)

Plant gravitropic response. Merkys A, et al. **Adv Space Biol Med** 1997;6:213–30 (56 ref.)

Pharmacology in space: pharmacokinetics. Saivin S, et al. **Adv Space Biol Med** 1997;6:107–21 (26 ref.)

Human life support for advanced space exploration. Schwartzkopf SH. **Adv Space Biol Med** 1997;6:231–53 (23 ref.)

Regulation of body fluid volume and electrolyte concentrations in spaceflight. Smith SM, et al. **Adv Space Biol Med** 1997;6:123–65 (87 ref.)

Changes in the immune system during and after spaceflight. Taylor GR, et al. **Adv Space Biol Med** 1997;6:1–32 (92 ref.)

Bioregeneration with maltose excreting Chlorella: system concept, technological development, and experiments. Wolf L. **Adv Space Biol Med** 1997;6:255–74 (16 ref.)

Human physiology in space. Vernikos J. **Bioessays** 1996 Dec; 18(12):1029–37 (50 ref.)

Life sciences space missions. Overview. Sulzman FM. **J Appl Physiol** 1996 Jul;81(1):3–6 (26 ref.)

A review of adaptive change in musculoskeletal impedance during space flight and associated implications for postflight head movement control. McDonald PV, et al. **J Vestib Res** 1997 Mar–Jun;7(2–3):239–50 (63 ref.)

Neocytolysis: physiological down-regulator of red-cell mass. Alfrey CP, et al. **Lancet** 1997 May 10;349(9062):1389–90 (18 ref.)

Effect of spaceflight on the functional, biochemical, and metabolic properties of skeletal muscle. Baldwin KM. **Med Sci Sports Exerc** 1996 Aug;28(8):983–7 (25 ref.)

Regulation of the systemic circulation at microgravity and during readaptation to 1G. Blomqvist GC. **Med Sci Sports Exerc** 1996 Oct;28(10 Suppl):S9–13 (24 ref.)

Lessons from operational cardiovascular studies in space. Charles JB, et al. **Med Sci Sports Exerc** 1996 Oct;28(10 Suppl):S18–22 (28 ref.)

Clinical aspects of the control of plasma volume at microgravity and during return to one gravity. Convertino VA. **Med Sci Sports Exerc** 1996 Oct;28(10 Suppl):S45–52 (44 ref.)

Exercise as a countermeasure for physiological adaptation to prolonged spaceflight. Convertino VA. **Med Sci Sports Exerc** 1996 Aug;28(8):999–1014 (99 ref.)

Space research activities during missions of the past. Frey MA. **Med Sci Sports Exerc** 1996 Oct;28(10 Suppl):S3–8 (28 ref.)

Cardiovascular adaptation to spaceflight. Hargens AR, et al. **Med Sci Sports Exerc** 1996 Aug;28(8):977–82 (57 ref.)

Pulmonary function and cardiopulmonary interactions at microgravity. Linnarsson D. **Med Sci Sports Exerc** 1996 Oct;28(10 Suppl):S14–7 (21 ref.)

Role of arginine vasopressin in the regulation of extracellular fluid volume. Norsk P. **Med Sci Sports Exerc** 1996 Oct; 28(10 Suppl):S36–41 (25 ref.)

Neuroendocrine and immune system responses with spaceflights. Tipton CM, et al. **Med Sci Sports Exerc** 1996 Aug;28(8):988–98 (78 ref.)

The search for life on Mars. McKay CP. **Orig Life Evol Biosph** 1997 Jun;27(1–3):263–89 (123 ref.)

[The theory and practice of medical support of long-term space missions] Grigoriev AI, et al. **Aviakosm Ekolog Med** 1997;31(1):14–25 (21 ref.) (Eng. Abstr.) **(Rus)**

[Evolution of methodical approaches to solve problem of evaluating and predicting the thermal status of cosmonauts in the real flight] Kuznets EI, et al. **Aviakosm Ekolog Med** 1996;30(5):52–4 (7 ref.) (Eng. Abstr.) **(Rus)**

[The problem of adaptation to space flight] Malkin VB, et al. **Aviakosm Ekolog Med** 1996;30(6):64–6 (14 ref.) (Eng. Abstr.) **(Rus)**

[Adaptive potentials of mammals under conditions of weightlessness] Serova LV. **Aviakosm Ekolog Med** 1996; 30(2):5–11 (69 ref.) (Eng. Abstr.) **(Rus)**

[Physiologic effects of weightlessness on man under spaceflight conditions] Gazenko OG, et al. **Fiziol Cheloveka** 1997 Mar–Apr;23(2):138–46 (29 ref.) **(Rus)**

[Medico-biological aspects of a Mars expedition] Grigor'ev AI, et al. **Fiziol Cheloveka** 1997 Jan–Feb;23(1):88–92 (30 ref.) **(Rus)**

SPACE MEDICINE see **AEROSPACE MEDICINE**

SPACE PERCEPTION

The bailiwick of visuo-spatial working memory: evidence from unilateral spatial neglect. Ellis AX, et al. **Brain Res Cogn Brain Res** 1996 Mar;3(2):71–8 (39 ref.)

Impairment of visuospatial function in idiopathic spasmodic torticollis. Hinse P, et al. **J Neurol** 1996 Jan;243(1):29–33 (39 ref.)

Representation of space in blind persons: vision as a spatial sense? Thinus-Blanc C, et al. **Psychol Bull** 1997 Jan; 121(1):20–42 (150 ref.)

Raster-scan cathode-ray tubes for vision research--limits of resolution in space, time and intensity, and some solutions. Bach M, et al. **Spat Vis** 1997;10(4):403–14 (48 ref.)

PHYSIOLOGY

Multimodal representation of space in the posterior parietal cortex and its use in planning movements. Andersen RA, et al. **Annu Rev Neurosci** 1997;20:303–30 (72 ref.)

Spatial representations for action in parietal cortex. Colby CL, et al. **Brain Res Cogn Brain Res** 1996 Dec; 5(1–2):105–15 (34 ref.)

Representation of object-centered space in the primate frontal lobe. Olson CR, et al. **Brain Res Cogn Brain Res** 1996 Dec;5(1–2):147–56 (32 ref.)

Stimulus-driven facilitation and inhibition of visual information processing in environmental and retinotopic representations of space. Shimojo S, et al. **Brain Res Cogn Brain Res** 1996 Dec;5(1–2):11–21 (14 ref.)

Fast and slow feedback loops for the visual correction of spatial errors in a pointing task: a reappraisal. Paillard J. **Can J Physiol Pharmacol** 1996 Apr;74(4):401–17 (136 ref.)

The neuropsychology of spatial cognition in the rat. Poucet B, et al. **Crit Rev Neurobiol** 1997;11(2–3):101–20 (187 ref.)

Head direction cells: properties and functional significance. Muller RU, et al. **Curr Opin Neurobiol** 1996 Apr; 6(2):196–206 (40 ref.)

Brain representation of object-centered space. Olson CR, et al. **Curr Opin Neurobiol** 1996 Apr;6(2):165–70 (40 ref.)

New perspectives on the mechanisms for orientation selectivity. Sompolinsky H, et al. **Curr Opin Neurobiol** 1997 Aug;7(4):514–22 (50 ref.)

Spatio-temporal dynamics of alpha brain electric fields, and cognitive modes. Lehmann D, et al. **Int J Psychophysiol** 1997 Jun;26(1–3):99–112 (51 ref.)

An intracellular study of space and time representation in primary visual cortical receptive fields. Frégnac Y, et al. **J Physiol Paris** 1996;90(3–4):189–97 (57 ref.)

Interactions within and between the spatial senses. Howard IP. **J Vestib Res** 1997 Jul–Aug;7(4):311–45 (216 ref.)

Lateralization of brain mechanisms underlying automatic and controlled forms of spatial orienting of attention. Gainotti G. **Neurosci Biobehav Rev** 1996 Winter;20(4):617–22 (48 ref.)

The role of vision and spatial orientation in the maintenance of posture. Wade MG, et al. **Phys Ther** 1997 Jun; 77(6):619–28 (58 ref.)
Biologically based artificial navigation systems: review and prospects. Trullier O, et al. **Prog Neurobiol** 1997 Apr; 51(5):483–544 (153 ref.)

SPACE SIMULATION

see related
WEIGHTLESSNESS SIMULATION

ADVERSE EFFECTS

Changes in the immune system during and after spaceflight. Taylor GR, et al. **Adv Space Biol Med** 1997;6:1–32 (92 ref.)

PSYCHOLOGY

Psychosocial value of space simulation for extended spaceflight. Kanas N. **Adv Space Biol Med** 1997;6:81–91 (38 ref.)

SPACE-TIME CLUSTERING

see related
DISEASE OUTBREAKS

Disease cluster statistics for imprecise space-time locations. Jacquez GM. **Stat Med** 1996 Apr 15–May 15; 15(7–9):873–85 (29 ref.)

SPACECRAFT

Blunt trauma and operative care in microgravity: a review of microgravity physiology and surgical investigations with implications for critical care and operative treatment in space. Kirkpatrick AW, et al. **J Am Coll Surg** 1997 May; 184(5):441–53 (120 ref.)

SPACER DNA see **DNA, RIBOSOMAL**

SPANISH AMERICANS see **HISPANIC AMERICANS**

SPARC GLYCOPROTEIN see **OSTEONECTIN**

SPARGANOSIS

see related
DIPHYLLOBOTHRIASIS

SPARTEINE

PHARMACOKINETICS

Prediction of CYP2D6-mediated polymorphic drug metabolism (sparteine type) based on in vitro investigations. Engel G, et al. **J Chromatogr B Biomed Appl** 1996 Mar 29;678(1):93–103 (73 ref.)

SPASM

see related
MUSCLE CRAMP
MYOTONIA

COMPLICATIONS

Surgical treatment of spasmodic torticollis: is there a role for microvascular decompression? With an illustrative case report. Brunori A, et al. **J Neurosurg Sci** 1996 Mar; 40(1):43–51 (41 ref.)

DIAGNOSIS

[Painful muscle spasms] Popelianskiĭ IaIu.
Zh Nevropatol Psikhiatr Im S S Korsakova 1997;97(3):64–7 (36 ref.) **(Rus)**
[Muscle spasms] Schimrich K.
Zh Nevropatol Psikhiatr Im S S Korsakova 1997;97(3):61–3 (45 ref.) **(Rus)**

DRUG THERAPY

Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects. Dutton JJ. **Surv Ophthalmol** 1996 Jul–Aug;41(1):51–65 (145 ref.)
[Use of botulinum toxin in ophthalmology: current concepts and problems] Tapiero B, et al. **J Fr Ophtalmol** 1997; 20(2):134–45 (21 ref.) **(Fre)**
[Use of botulinum toxin in ophthalmology] Huber A.
Klin Monatsbl Augenheilkd 1997 May;210(5):289–92 (28 ref.) (Eng. Abstr.) **(Ger)**
[Treatment of spasms of visceral smooth muscles] Milovanović DR, et al. **Med Pregl** 1997 May–Jun; 50(5–6):194–200 (50 ref.) (Eng. Abstr.) **(Scr)**

PHYSIOPATHOLOGY

Impairment of visuospatial function in idiopathic spasmodic torticollis. Hinse P, et al. **J Neurol** 1996 Jan;243(1):29–33 (39 ref.)

SURGERY

[Results of treatment of hemifacial spasm by surgical and endoscopic neurovascular decompression. Analysis of 60 records] Cacès F, et al.
Ann Otolaryngol Chir Cervicofac 1996;113(3):119–31 (39 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

[Neurovascular compression syndrome—treatment of facial spasm, trigeminal neuralgia and disabling vertigo] Hashimoto T. **Ryoikibetsu Shokogun Shiritzu** 1996; (14):540–4 (7 ref.) **(Jpn)**

SPASMOLYTICS see **PARASYMPATHOLYTICS**

SPASMOPHILIA see **TETANY**

SPASMS, INFANTILE

COMPLICATIONS

[Hypertrophic myocardiopathy during the corticotropin treatment of infantile spasms] Hortelano López M, et al.
An Esp Pediatr 1996 May;44(5):515–6 (11 ref.) **(Spa)**

DIAGNOSIS

Infantile spasms. Garg RK. **Indian Pediatr** 1997 Mar; 34(3):220–6 (31 ref.)
[Aicardi syndrome and choroid plexus papilloma: a rare association. Case report] Aguiar MD, et al.
Arq Neuropsiquiatr 1996 Jun;54(2):313–7 (16 ref.) (Eng. Abstr.) **(Por)**
[Aicardi's syndrome: agenesis of the corpus callosum, infantile flexor spasms and macular dystrophy] Badalian LO, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996; 96(5):87–90 (13 ref.) **(Rus)**
[Infantile spasms (West's syndrome): characteristics and therapeutic options] Prats-Viñas JM, et al. **Rev Neurol** 1996 Nov;24(135):1411–4 (65 ref.) **(Spa)**

DRUG THERAPY

Comment on the ACTH treatment of the West syndrome [comment] Fois A, et al. **Brain Dev** 1996 Nov–Dec; 18(6):469–70 (6 ref.) Comment on: Brain Dev 1996 Nov–Dec;18(6):456–60.
West syndrome: individualized ACTH therapy, by Heiskala et al [comment] Snead OC 3rd. **Brain Dev** 1996 Nov–Dec; 18(6):466–8 (24 ref.) Comment on: Brain Dev 1996 Nov–Dec;18(6):456–60.
[Low dose ACTH therapy in West syndrome] Gaszner A, et al. **Orv Hetil** 1997 Feb 2;138(5):281–3 (32 ref.) (Eng. Abstr.) **(Hun)**
[Treatment of West syndrome: present and future perspectives] Seki T. **No To Hattatsu** 1997 Mar;29(2):91–9 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Hypertrophic myocardiopathy during the corticotropin treatment of infantile spasms] Hortelano López M, et al.
An Esp Pediatr 1996 May;44(5):515–6 (11 ref.) **(Spa)**
[Infantile spasms (West's syndrome): characteristics and therapeutic options] Prats-Viñas JM, et al. **Rev Neurol** 1996 Nov;24(135):1411–4 (65 ref.) **(Spa)**

GENETICS

[PEHO syndrome (progressive encephalopathy, edema, hypsarrhythmia. optic atrophy)] Hollódy K, et al.
Orv Hetil 1997 Feb 16;138(7):425–8 (7 ref.) (Eng. Abstr.) **(Hun)**

THERAPY

Infantile spasms. Garg RK. **Indian Pediatr** 1997 Mar; 34(3):220–6 (31 ref.)

SPASMUS NUTANS see **SPASMS, INFANTILE**

SPASTIC DIPLEGIA see **CEREBRAL PALSY**

SPASTIC PARAPARESIS see **PARAPARESIS, TROPICAL SPASTIC**

SPASTIC PARAPLEGIA see **PARAPLEGIA**

SPASTIC PARAPLEGIA, HEREDITARY

DIAGNOSIS

Advances in hereditary spastic paraplegia. Fink JK. **Curr Opin Neurol** 1997 Aug;10(4):313–8 (47 ref.)

GENETICS

A family with hereditary spastic paraparesis and epilepsy. Webb S, et al. **Epilepsia** 1997 Apr;38(4):495–9 (40 ref.)
Molecular genetics of familial spastic paraplegia: a multitude of responsible genes. Kobayashi H, et al. **J Neurol Sci** 1996 May;137(2):131–8 (40 ref.)

PHYSIOPATHOLOGY

Advances in hereditary spastic paraplegia. Fink JK. **Curr Opin Neurol** 1997 Aug;10(4):313–8 (47 ref.)

SPASTICITY, MUSCLE see **MUSCLE SPASTICITY**

SPATIAL BEHAVIOR

PHYSIOLOGY

Orienting a spatial attention—its reflexive, compensatory, and voluntary mechanisms. Hikosaka O, et al.
Brain Res Cogn Brain Res 1996 Dec;5(1–2):1–9 (32 ref.)
Hippocampal lesions and path integration. Whishaw IQ, et al. **Curr Opin Neurobiol** 1997 Apr;7(2):228–34 (64 ref.)
Time-varying characteristics of visually induced postural sway. Loughlin PJ, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):416–24 (36 ref.)
A new case of atypical cerebral dominance. Posteraro L, et al. **Ital J Neurol Sci** 1996 Jun;17(3):237–40 (19 ref.)
Place cells and place navigation. Bures J, et al.
Proc Natl Acad Sci U S A 1997 Jan 7;94(1):343–50 (63 ref.)
Spatial, behavioral and sensory correlates of hippocampal CA1 complex spike cell activity: implications for information processing functions. Wiener SI.
Prog Neurobiol 1996 Jul;49(4):335–61 (104 ref.)

SPEARMAN RANK CORRELATION COEFFICIENT see **STATISTICS, NONPARAMETRIC**

SPECIALISM

In the realm of ideas: the advent of advanced surgery of the human cerebrum and neurosurgical education. Apuzzo ML. **Acta Neurochir Suppl (Wien)** 1997;69:145–50 (29 ref.)
Managed care and the infectious diseases specialist. Tice AD, et al. **Clin Infect Dis** 1996 Aug;23(2):341–68 (99 ref.)
The integration of clinical and experimental work. Covino NA. **Int J Clin Exp Hypn** 1997 Apr;45(2):109–25 (70 ref.)
The concept of the specialist community nurse. Kelly A. **J Adv Nurs** 1996 Jul;24(1):42–52 (51 ref.)
A rationale for family therapy specialization in early intervention. Malone DM, et al. **J Marital Fam Ther** 1997 Jan;23(1):65–79 (69 ref.)
The bases of practice—neurological physiotherapy [see comments] Partridge C, et al. **Physiother Res Int** 1996; 1(3):205–8 (13 ref.) Comment in: Physiother Res Int 1996;1(4):265–8. Comment in: Physiother Res Int 1997;2(2):62–4.
The women's health specialty: curriculum implications. Hunt L. **Womens Health Issues** 1997 Mar–Apr;7(2):116–20 (14 ref.)
[The zoo veterinarian in changing times] Hatt JM, et al.
Schweiz Arch Tierheilkd 1996;138(12):573–8 (21 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

The explosion of neurogenetics [editorial] Hurko O.
Curr Opin Neurol 1997 Apr;10(2):77–83 (103 ref.)
[Professionalization of nursing care for elderly persons] Entzian H, et al. **Z Gerontol Geriatr** 1996 Nov–Dec; 29(6):404–10 (8 ref.) (Eng. Abstr.) **(Ger)**

SPECIALTIES, MEDICAL

Fever, famine, and war: William Osler as an infectious diseases specialist. Bryan CS. **Clin Infect Dis** 1996 Nov; 23(5):1139–49 (133 ref.)
Critical care in the United States. Who are we and how did we get here? Calvin JE, et al. **Crit Care Clin** 1997 Apr; 13(2):363–76 (36 ref.)
Does a full-time, 24-hour intensivist improve care and efficiency? Carlson RW, et al. **Crit Care Clin** 1996 Jul; 12(3):525–51 (63 ref.)
Intensive care in Australia and New Zealand. No nonsense "down under". Dobb GJ. **Crit Care Clin** 1997 Apr; 13(2):299–316 (18 ref.)
Critical care. A specialty without frontiers. Fisher MM.
Crit Care Clin 1997 Apr;13(2):235–43 (16 ref.)
Critical care in Africa. North to south and the future with special reference to southern Africa. Lipman J, et al.
Crit Care Clin 1997 Apr;13(2):255–65 (38 ref.)
Critical care in East Asia. Little dragons and sleeping giants. Mustafa I, et al. **Crit Care Clin** 1997 Apr;13(2):287–98 (17 ref.)
Critical care in Canada. The North American difference. Sibbald WJ, et al. **Crit Care Clin** 1997 Apr;13(2):347–62 (13 ref.)
Critical care in Europe. Vincent JL, et al. **Crit Care Clin** 1997 Apr;13(2):245–54 (14 ref.)
Critical care in Japan and Korea. The market of excellence. Yoshiya I, et al. **Crit Care Clin** 1997 Apr;13(2):267–85 (11 ref.)
The gastroenterologist and his endoscope: the embodiment of technology and the necessity for a medical ethics. Cooper MW. **Theor Med** 1996 Dec;17(4):379–98 (56 ref.)
[Thoracic surgery and certification of the specialty] Watanabe Y. **Kyobu Geka** 1997 Jan;50(1):46–4 (5 ref.) **(Jpn)**
[Psychiatrists and their identity] Kasahara Y.
Seishin Shinkeigaku Zasshi 1996;98(9):597–602 (4 ref.) **(Jpn)**
[Problems in establishment of psychiatry specialty certification—viewed from an experience at Musashi National Hospital in Japan] Uno S.
Seishin Shinkeigaku Zasshi 1997;99(5):278–81 (0 ref.) **(Jpn)**

SPECIALTIES, MEDICAL

ECONOMICS

Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. John JF Jr, et al. **Clin Infect Dis** 1997 Mar;24(3):471–85 (89 ref.)

Development of provider networks for specific diseases. Pristave RJ, et al. **J Health Care Finance** 1995 Winter; 22(2):27–41 (17 ref.)

EDUCATION

Training in laparoscopic surgery—have we got it right yet? Ooi LL. **Ann Acad Med Singapore** 1996 Sep;25(5):732–6 (34 ref.)

Assessment of competence of trainees in the medical specialties. Banning AP, et al. **Br J Hosp Med** 1996 Dec 11–1997 Jan 14;56(11):588–9 (4 ref.)

Teaching in the outpatient clinic. Practical tips. McGee SR, et al. **J Gen Intern Med** 1997 Apr;12 Suppl 2:S34–40 (29 ref.)

MANPOWER

Downsizing the physician workforce [see comments] McClendon BJ, et al. **Public Health Rep** 1997 May–Jun; 112(3):231–9 (48 ref.) Comment in: Public Health Rep 1997 May–Jun;112(3):219–21.

TRENDS

Specialist management: needs and benefits. Stucki G. **Baillieres Clin Rheumatol** 1997 Feb;11(1):97–107 (49 ref.)

An osteopathic prescription for medical education reform: Part 2. Specialty mix and community integration. Ross–Lee B, et al. **J Am Osteopath Assoc** 1997 Aug;97(8):463–8 (18 ref.)

SPECIALTIES, NURSING

EDUCATION

Conceptualizing advanced nursing practice: curriculum issues to consider in the educational preparation of advanced practice nurses in the UK. Woods LP. **J Adv Nurs** 1997 Apr;25(4):820–8 (37 ref.)

METHODS

The impact of child sexual abuse on the children of survivors. Implications for forensic nursing. Palmer L. **J Psychosoc Nurs Ment Health Serv** 1996 Oct;34(10):42–6 (19 ref.)

STANDARDS

British studies which measure patient outcome, 1990–1994. French B. **J Adv Nurs** 1997 Aug;26(2):320–8 (27 ref.)

SPECIALTIES, SURGICAL

TRENDS

The future of oesophageal and gastric surgery. Siewert JR. **Ann Chir Gynaecol** 1996;85(3):196–200 (1 ref.)

SPECIALTY BOARDS

LEGISLATION & JURISPRUDENCE

Legal implications of specialty board certification. Smith JJ. **J Leg Med** 1996 Mar;17(1):73–111 (201 ref.)

SPECIES SPECIFICITY

Vive la différence: males vs females in flies vs worms. Cline TW, et al. **Annu Rev Genet** 1996;30:637–702 (241 ref.)

Interspecies comparison of liver carcinogenesis: implications for cancer risk assessment. Grisham JW. **Carcinogenesis** 1997 Jan;18(1):59–81 (418 ref.)

[Cytochrome P450—its significance in the biotransformation of xenobiotics and interspecies comparisons] Hrubý K, et al. **Cesk Fysiol** 1997 Mar;46(1):34–9 (24 ref.) (Eng. Abstr.) **(Cze)**

SPECIESISM see **ANIMAL RIGHTS**

SPECIFIC PATHOGEN-FREE ORGANISMS

Considerations of specific pathogen-free swine (SPF) in xenotransplantation. Swindle MM. **J Invest Surg** 1996 Jul–Aug;9(4):267–71 (17 ref.)

SPECIFICITY see **SENSITIVITY AND SPECIFICITY**

SPECIMEN HANDLING

Complications associated with harvesting autogenous iliac bone graft. Fowler BL, et al. **Am J Orthop** 1995 Dec; 24(12):895–903 (39 ref.)

From delivery suite to laboratory: optimizing returns from placental examination in medico–legal defence. Khong TY. **Aust N Z J Obstet Gynaecol** 1997 Feb;37(1):1–5 (46 ref.)

Post-coital sperm retrieval could lead to the wider approval of assisted conception by some religions. Hirsh A. **Hum Reprod** 1996 Feb;11(2):245–7 (26 ref.)

Collection of biological materials in biodiversity prospecting in India: problems and solutions. Mehrotra BN. **J Ethnopharmacol** 1996 Apr;51(1–3):161–5 (0 ref.)

METHODS

The ThinPrep Pap test. A review of clinical studies. Linder J, et al. **Acta Cytol** 1997 Jan–Feb;41(1):30–8 (22 ref.)

Sample preparation for gas chromatography with solid–phase extraction and solid–phase microextraction. Penton ZE. **Adv Chromatogr** 1997;37:205–36 (67 ref.)

How to submit a specimen for cutaneous pathology analysis. Using the '5 D's' to get the most from biopsies. Boyd AS, et al. **Arch Fam Med** 1997 Jan–Feb;6(1):64–6 (10 ref.)

Biological and environmental specimen banking at the Centers for Disease Control and Prevention. Gunter EW. **Chemosphere** 1997 May;34(9–10):1945–53 (11 ref.)

Specimen banking—a planning in advance. Olsson M, et al. **Chemosphere** 1997 May;34(9–10):1961–74 (23 ref.)

The problem of gaining access to interstitial fluid. An attempt to rationalize a wicked discussion on wicks. Aukland K, et al. **Lymphology** 1997 Sep;30(3):111–5 (33 ref.)

Scanning force microscopy of biological samples. Lekka M, et al. **Pol J Pathol** 1996;47(2):51–5 (17 ref.)

STANDARDS

Primary processing of specimens and isolation and cultivation of mycobacteria. Hall GS. **Clin Lab Med** 1996 Sep; 16(3):551–67 (47 ref.)

SPECT see **TOMOGRAPHY, EMISSION–COMPUTED, SINGLE–PHOTON**

SPECTACLES see **EYEGLASSES**

SPECTRIN

CHEMISTRY

Spectrin: on the path from structure to function. Viel A, et al. **Curr Opin Cell Biol** 1996 Feb;8(1):49–55 (42 ref.)

[Molecular defects of erythrocyte membrane proteins] Storozhok SA, et al. **Vopr Med Khim** 1996 Apr–Jun; 42(2):103–10 (73 ref.) **(Rus)**

GENETICS

Evolution of the spectrin repeat. Pascual J, et al. **Bioessays** 1997 Sep;19(9):811–7 (57 ref.)

PHYSIOLOGY

The spectrin–based membrane skeleton as a membrane protein–sorting machine. Beck KA, et al. **Am J Physiol** 1996 May;270(5 Pt 1):C1263–70 (67 ref.)

Spectrin: on the path from structure to function. Viel A, et al. **Curr Opin Cell Biol** 1996 Feb;8(1):49–55 (42 ref.)

SPECTROFLUOROMETRY see **SPECTROMETRY, FLUORESCENCE**

SPECTROMETRY, FLUORESCENCE

Fluorescence spectrometry in studies of carbohydrate–protein interactions. Lee YC. **J Biochem (Tokyo)** 1997 May;121(5):818–25 (66 ref.)

Ultraviolet and visible spectroscopies for tissue diagnostics: fluorescence spectroscopy and elastic–scattering spectroscopy. Bigio IJ, et al. **Phys Med Biol** 1997 May; 42(5):803–14 (75 ref.)

METHODS

Quantitative optical spectroscopy for tissue diagnosis. Richards–Kortum R, et al. **Annu Rev Phys Chem** 1996; 47:555–606 (282 ref.)

Total internal reflection fluorescence: applications in cellular biophysics. Thompson NL, et al. **Curr Opin Biotechnol** 1997 Feb;8(1):58–64 (64 ref.)

Fluorescence studies of DNA and RNA structure and dynamics. Millar DP. **Curr Opin Struct Biol** 1996 Jun; 6(3):322–6 (38 ref.)

Time–resolved fluorescence spectroscopy. Millar DP. **Curr Opin Struct Biol** 1996 Oct;6(5):637–42 (46 ref.)

Fluorescence correlation spectroscopy (FCS)—a highly sensitive method to analyze drug/target interactions. Sterrer S, et al. **J Recept Signal Transduct Res** 1997 Jan–May;17(1–3):511–20 (10 ref.)

Picosecond fluorescence decay curves collected on millisecond time scale: direct measurement of hydrodynamic radii, local/global mobility, and intramolecular distances during protein–folding reactions. Beechem JM. **Methods Enzymol** 1997;278:24–49 (13 ref.)

Fluorescence methods for studying equilibrium macromolecule–ligand interactions. Eftink MR. **Methods Enzymol** 1997;278:221–57 (67 ref.)

Fluorescence methods for studying kinetics of protein–folding reactions. Eftink MR, et al. **Methods Enzymol** 1997;278:258–86 (68 ref.)

Fluorescence studies of zinc finger peptides and proteins. Eis PS. **Methods Enzymol** 1997;278:330–43 (32 ref.)

Fluorescence approaches to study of protein–nucleic acid complexation. Hill JJ, et al. **Methods Enzymol** 1997; 278:390–416 (67 ref.)

Determination of ground–state dissociation constant by fluorescence spectroscopy. Kowalczyk A, et al. **Methods Enzymol** 1997;278:94–113 (20 ref.)

Fluorescence assays for DNA cleavage. Lee SP, et al. **Methods Enzymol** 1997;278:343–63 (49 ref.)

Applications of fluorescence resonance energy transfer to structure and mechanism of chloroplast ATP synthase. McCarty RE. **Methods Enzymol** 1997;278:528–38 (22 ref.)

Time–resolved fluorescence of constrained tryptophan derivatives: implications for protein fluorescence. McLaughlin ML, et al. **Methods Enzymol** 1997;278:190–202 (22 ref.)

Enhancement of protein spectra with tryptophan analogs: fluorescence spectroscopy of protein–protein and protein–nucleic acid interactions. Ross JB, et al. **Methods Enzymol** 1997;278:151–90 (110 ref.)

Time–resolved room temperature tryptophan phosphorescence in proteins. Schauerte JA, et al. **Methods Enzymol** 1997;278:49–71 (89 ref.)

Fluorescence line narrowing spectroscopy: a tool for studying proteins. Vanderkooi JM, et al. **Methods Enzymol** 1997;278:71–94 (76 ref.)

N–terminal modification of proteins for fluorescence measurements. Wu P, et al. **Methods Enzymol** 1997; 278:321–30 (17 ref.)

In vivo fluorescence imaging for tissue diagnostics. Andersson–Engels S, et al. **Phys Med Biol** 1997 May; 42(5):815–24 (100 ref.)

[Practical use of luminogenic reagents specific for guanine–containing compounds] Kai M. **Tanpakushitsu Kakusan Koso** 1997 Apr;42(5):777–83 (16 ref.) **(Jpn)**

[Tissue spectroscopy. New generation of optical methods for cancer detection] Chwirot B, et al. **Pol Merkuriusz Lek** 1996 Nov;1(5):355–8 (29 ref.) (Eng. Abstr.) **(Pol)**

TRENDS

[Laser fluorescence spectroscopy in cardiology: the problems and outlook] Zalesskyĭ VM, et al. **Lik Sprava** 1995 Sep–Dec;(9–12):7–10 (32 ref.) **(Ukr)**

SPECTROMETRY, MASS see **SPECTRUM ANALYSIS, MASS**

SPECTROMETRY, MASS–GAS CHROMATOGRAPHY see **MASS FRAGMENTOGRAPHY**

SPECTROMETRY, MASS, MATRIX–ASSISTED LASER DESORPTION–IONIZATION

METHODS

Identification of oligosaccharides by matrix–assisted laser desorption ionization and electrospray MS. Harvey DJ, et al. **Biochem Soc Trans** 1996 Aug;24(3):905–12 (40 ref.)

TRENDS

Matrix–assisted laser desorption ionization MS: a progress report. Karas M. **Biochem Soc Trans** 1996 Aug; 24(3):897–900 (40 ref.)

SPECTROMETRY, NEAR–INFRARED see **SPECTROSCOPY, NEAR–INFRARED**

SPECTROMETRY, PARTICLE–INDUCED X–RAY EMISSION see **SPECTROMETRY, X–RAY EMISSION**

SPECTROMETRY, PROTON–INDUCED X–RAY EMISSION see **SPECTROMETRY, X–RAY EMISSION**

SPECTROMETRY, X–RAY EMISSION

A review of nuclear microscopy and applications in medicine. Thong PS, et al. **Singapore Med J** 1996 Oct;37(5):527–31 (23 ref.)

METHODS

Nuclear microprobe: a microanalytical technique in biology. Moretto P. **Cell Mol Biol (Noisy–le–grand)** 1996 Feb; 42(1):1–16 (69 ref.)

Nuclear microscope analysis in Alzheimer's and Parkinson's disease: A review. Watt F. **Cell Mol Biol (Noisy–le–grand)** 1996 Feb;42(1):17–26 (34 ref.)

Aspects on the physiology of human skin: studies using particle probe analysis. Forslind B, et al. **Microsc Res Tech** 1997 Aug 15;38(4):373–86 (40 ref.)

SPECTROMETRY, X–RAY EMISSION, ELECTRON MICROSCOPIC see **ELECTRON PROBE MICROANALYSIS**

SPECTROMETRY, X–RAY EMISSION, ELECTRON PROBE see **ELECTRON PROBE MICROANALYSIS**

SPECTROMETRY, X–RAY FLUORESCENCE see **SPECTROMETRY, X–RAY EMISSION**

SPECTROPHOTOMETRY

METHODS

Applications of impedance spectroscopy in biochemistry and biophysics. Janshoff A, et al. **Acta Biochim Pol** 1996; 43(2):339–48 (19 ref.)

Quantitative optical spectroscopy for tissue diagnosis. Richards-Kortum R, et al. **Annu Rev Phys Chem** 1996; 47:555–606 (282 ref.)

A few selected applications of surface nonlinear optical spectroscopy. Shen YR. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12104–11 (74 ref.)

SPECTROPHOTOMETRY, INFRARED

Infrared analysis in clinical chemistry: its use in the laboratory and in non-invasive near patient testing. Stevens JF, et al. **Ann Clin Biochem** 1997 May;34 (Pt 3):215–21 (33 ref.)

METHODS

The role of remote sensing in finding hydrothermal mineral deposits on earth. Huntington JF. **Ciba Found Symp** 1996; 202:214–31; discussion 231–5 (19 ref.)

Imaging brain structure and function, infection and gene expression in the body using light. Benaron DA, et al. **Philos Trans R Soc Lond B Biol Sci** 1997 Jun 29; 352(1354):755–61 (18 ref.)

Optical investigations of physiology: a study of intrinsic and extrinsic biomedical contrast. Chance B, et al. **Philos Trans R Soc Lond B Biol Sci** 1997 Jun 29; 352(1354):707–16 (30 ref.)

Measurement of cytochrome oxidase and mitochondrial energetics by near-infrared spectroscopy. Cooper CE, et al. **Philos Trans R Soc Lond B Biol Sci** 1997 Jun 29; 352(1354):669–76 (62 ref.)

Use of near-infrared spectroscopy in the adult. Kirkpatrick PJ. **Philos Trans R Soc Lond B Biol Sci** 1997 Jun 29; 352(1354):701–5 (11 ref.)

SPECTROSCOPY see **SPECTRUM ANALYSIS**

SPECTROSCOPY, FOURIER TRANSFORM INFRARED

METHODS

Orientational order determination by internal reflection infrared spectroscopy. Axelsen PH, et al. **Prog Biophys Mol Biol** 1996;66(3):227–53 (107 ref.)

SPECTROSCOPY, INFRARED, FOURIER TRANSFORM see **SPECTROSCOPY, FOURIER TRANSFORM INFRARED**

SPECTROSCOPY, MAGNETIC RESONANCE see **NUCLEAR MAGNETIC RESONANCE**

SPECTROSCOPY, MASS see **SPECTRUM ANALYSIS, MASS**

SPECTROSCOPY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION see **SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION**

SPECTROSCOPY, NEAR-INFRARED

Measurement of cytochrome oxidase redox state by near infrared spectroscopy. Cooper CE, et al. **Adv Exp Med Biol** 1997;413:63–73 (48 ref.)

A role for near infrared spectroscopy in psychiatry? Hock C, et al. **Adv Exp Med Biol** 1997;413:105–23 (25 ref.)

Near-infrared spectroscopy in functional activation studies. Can NIRS demonstrate cortical activation? Obrig H, et al. **Adv Exp Med Biol** 1997;413:113–27 (49 ref.)

Cerebral oxygenation states as revealed by near-infrared spectrophotometry. Tamura M, et al. **Adv Exp Med Biol** 1997;413:91–6 (22 ref.)

Near-infrared spectroscopy. Clinical applications. Simonson SG, et al. **Crit Care Clin** 1996 Oct;12(4):1019–29 (40 ref.)

Near-infrared spectroscopy for the in vivo study of cerebral hemodynamics and oxygenation. du Plessis AJ. **Curr Opin Pediatr** 1995 Dec;7(6):632–9 (37 ref.)

Recent developments in cerebral monitoring--near-infrared light spectroscopy. An overview. Williams IM, et al. **Eur J Vasc Endovasc Surg** 1996 Oct;12(3):263–71 (53 ref.)

METHODS

Near-infrared imaging and spectroscopy in stroke research: lipoprotein distribution and disease. Dempsey RJ, et al. **Ann N Y Acad Sci** 1997 May 30;820:149–69 (37 ref.)

Applications of fourier transform infrared imaging microscopy in neurotoxicity. Lewis EN, et al. **Ann N Y Acad Sci** 1997 May 30;820:234–46; discussion 246–7 (26 ref.)

Near infrared spectroscopy applied to intrapartum fetal monitoring. Hamilton RJ, et al. **Baillieres Clin Obstet Gynaecol** 1996 Jun;10(2):307–24 (40 ref.)

Noninvasive brain monitoring with near infrared spectroscopy in newborn infants. Skov L. **Dan Med Bull** 1996 Jun;43(3):277–84 (100 ref.)

Non-invasive monitoring of metabolites using near infrared spectroscopy: state of the art. Heise HM. **Horm Metab Res** 1996 Oct;28(10):527–34 (55 ref.)

SPECTROSCOPY, NMR see **NUCLEAR MAGNETIC RESONANCE**

SPECTROSCOPY, NUCLEAR MAGNETIC RESONANCE see **NUCLEAR MAGNETIC RESONANCE**

SPECTRUM ANALYSIS

Tissue spectroscopy for gastrointestinal diseases. Bohorfoush AG. **Endoscopy** 1996 May;28(4):372–80 (57 ref.)

METHODS

Near-field scanning optical microscopy and near-field confocal optical spectroscopy: emerging techniques in biology. Marchese-Ragona SP, et al. **Ann N Y Acad Sci** 1997 May 30;820:196–206; discussion 206–7 (6 ref.)

Multiecho approaches to spectroscopic imaging of the brain. Mulkern RV, et al. **Ann N Y Acad Sci** 1997 May 30; 820:97–122 (42 ref.)

Nanosecond time-resolved spectroscopy of biomolecular processes. Chen E, et al. **Annu Rev Biophys Biomol Struct** 1997;26:327–55 (79 ref.)

Practical aspects of electron energy loss spectroscopy (EELS) in biology. Jeanguillaume C, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 May;42(3):439–50 (20 ref.)

Spectral methods for the characterization of polymorphs and solvates. Brittain HG. **J Pharm Sci** 1997 Apr;86(4):405–12 (71 ref.)

SPECTRUM ANALYSIS, MASS

Organic SIMS of biologic tissue. Todd PJ, et al. **Anal Chem** 1997 Sep 1;69(17):529A–535A (22 ref.)

Mining genomes with MS. Yates JR 3rd, et al. **Anal Chem** 1996 Sep 1;68(17):534A–540A (35 ref.)

Applications of mass isotopomer analysis to nutrition research. Brunengraber H, et al. **Annu Rev Nutr** 1997; 17:559–96 (135 ref.)

Detection of DNA adducts by electron capture mass spectrometry. Giese RW. **Chem Res Toxicol** 1997 Mar; 10(3):255–70 (77 ref.)

DNA sequencing by mass spectrometry. Murray KK. **J Mass Spectrom** 1996 Nov;31(11):1203–15 (87 ref.)

Proton transfer reactivity of large multiply charged ions. Williams ER. **J Mass Spectrom** 1996 Aug;31(8):831–42 (132 ref.)

Trace structural analysis of proteins. Swiderek KM, et al. **Methods Enzymol** 1996;271:68–86 (9 ref.)

Quantitative analysis of multivariate data using artificial neural networks: a tutorial review and applications to the deconvolution of pyrolysis mass spectra. Goodacre R, et al. **Zentralbl Bakteriol** 1996 Aug;284(4):516–39 (114 ref.)

Curie-point pyrolysis mass spectrometry as a tool in clinical microbiology. Goodfellow M, et al. **Zentralbl Bakteriol** 1997 Jan;285(2):133–56 (159 ref.)

[Analysis of protein primary structures by mass spectrometry] Takao T. **Seikagaku** 1996 Jan;68(1):1–13 (64 ref.) **(Jpn)**

INSTRUMENTATION

The quadrupole ion trap mass spectrometer--a small solution to a big challenge. Jonscher KR, et al. **Anal Biochem** 1997 Jan 1;244(1):1–15 (69 ref.)

Mass spectrometry. Ionization methods and instrumentation. Chapman JR. **Methods Mol Biol** 1996;61:9–28 (16 ref.)

METHODS

Mass spectrometric investigations on proteinaceous toxins and antibodies. Krishnamurthy T, et al. **Adv Exp Med Biol** 1996;391:439–63 (53 ref.)

Analysis of hydrophobic proteins and peptides by electrospray ionization MS. Fearnley IM, et al. **Biochem Soc Trans** 1996 Aug;24(3):912–7 (16 ref.)

Qualitative and quantitative MS analysis of cyclic nucleotides and related enzymes. Newton RP. **Biochem Soc Trans** 1996 Aug;24(3):938–43 (38 ref.)

The use of electrospray ionization MS to determine the structure of glycans in intact glycoproteins. Oliver RW, et al. **Biochem Soc Trans** 1996 Aug;24(3):917–27 (20 ref.)

Use of continuous-flow combustion MS in studies of human metabolism. Rennie MJ, et al. **Biochem Soc Trans** 1996 Aug; 24(3):927–32 (19 ref.)

Beyond enzyme kinetics: direct determination of mechanisms by stopped-flow mass spectrometry. Northrop DB, et al. **Bioorg Med Chem** 1997 Apr;5(4):641–4 (27 ref.)

Excursions in biomedical mass spectrometry. Taylor GW, et al. **Br J Clin Pharmacol** 1996 Jul;42(1):119–26 (37 ref.)

Biochemical mass spectrometry: worth the weight? Fitzgerald MC, et al. **Chem Biol** 1996 Sep;3(9):707–15 (47 ref.)

Mass spectrometry in protein studies from genome to function. Roepstorff P. **Curr Opin Biotechnol** 1997 Feb; 8(1):6–13 (96 ref.)

Identification of cytokine-regulated proteins in normal and malignant cells by the combination of two-dimensional polyacrylamide gel electrophoresis, mass spectrometry, Edman degradation and immunoblotting and approaches to the analysis of their functional roles. Epstein LB, et al. **Electrophoresis** 1996 Nov;17(11):1655–70 (75 ref.)

Applications of liquid chromatography--mass spectrometry in analytical toxicology: a review. Hoja H, et al. **J Anal Toxicol** 1997 Mar–Apr;21(2):116–26 (119 ref.)

Applications of liquid chromatography-mass spectrometry interfacing systems in food analysis: pesticide, drug and toxic substance residues. Careri M, et al. **J Chromatogr A** 1996 Mar 15;727(2):153–84 (162 ref.)

Future potential of targeted component analysis by multidimensional liquid chromatography-mass spectrometry. Regnier F, et al. **J Chromatogr A** 1996 Oct 25;750(1–2):3–10 (26 ref.)

A multidimensional approach to protein characterization. Anderegg RJ, et al. **J Protein Chem** 1997 Jul;16(5):523–6 (25 ref.)

Measurement of pantothenic acid and hopantenic acid by gas chromatography-mass spectroscopy. Banno K. **Methods Enzymol** 1997;279:213–9 (16 ref.)

Gas chromatographic/mass spectrometric measurement of ascorbic acid and analysis of ascorbic acid degradation in solution. Deutsch JC. **Methods Enzymol** 1997;279:13–24 (10 ref.)

Peptide characterization by mass spectrometry. Gillece-Castro BL, et al. **Methods Enzymol** 1996; 271:427–48 (63 ref.)

Reversed-phase peptide mapping of glycoproteins using liquid chromatography/electrospray ionization-mass spectrometry. Hancock WS, et al. **Methods Enzymol** 1996; 271:403–27 (34 ref.)

Carbohydrate sequence analysis by electrospray ionization-mass spectrometry. Reinhold VN, et al. **Methods Enzymol** 1996;271:377–402 (26 ref.)

Capillary electrophoresis-mass spectrometry. Smith RD, et al. **Methods Enzymol** 1996;271:448–86 (90 ref.)

Isotopically labeled precursors and mass spectrometry in elucidating biosynthesis of pyrimidine moiety of thiamin in Saccharomyces cerevisiae. Tazuya K, et al. **Methods Enzymol** 1997;279:97–108 (9 ref.)

Protein structure analysis by mass spectrometry. Yates JR. **Methods Enzymol** 1996;271:351–77 (40 ref.)

Mass spectrometry. Ionization methods and instrumentation. Chapman JR. **Methods Mol Biol** 1996;61:9–28 (16 ref.)

Mass spectrometry in the analysis of peptides and proteins, past and present. Roepstorff P. **Methods Mol Biol** 1996; 61:1–7 (16 ref.)

Charged derivatives for peptide sequencing using a magnetic sector instrument. Zaia J. **Methods Mol Biol** 1996;61:29–41 (29 ref.)

[Structural analysis of proteins by mass spectrometry] Nakayama H, et al. **Seikagaku** 1996 Oct;68(10):1615–36 (132 ref.) **(Jpn)**

[Prospects for using mass spectrometric methods for analyzing biopolymer structure. Use and perspectives] Orlov VM, et al. **Mol Biol (Mosk)** 1996 Jul–Aug; 30(4):759–72 (112 ref.) **(Rus)**

SPECTRUM ANALYSIS, MASS-GAS CHROMATOGRAPHY see **MASS FRAGMENTOGRAPHY**

SPECTRUM ANALYSIS, RAMAN

METHODS

Quantitative optical spectroscopy for tissue diagnosis. Richards-Kortum R, et al. **Annu Rev Phys Chem** 1996; 47:555–606 (282 ref.)

SPEECH

see related
VERBAL BEHAVIOR

Speaker identification using time-delay HMEs. Chen K, et al. **Int J Neural Syst** 1996 Mar;7(1):29–43 (38 ref.)

CNN: a speaker recognition system using a cascaded neural network [letter] Zaki M, et al. **Int J Neural Syst** 1996 May; 7(2):203–12 (29 ref.)

Speech and swallowing rehabilitation for head and neck cancer patients. Logemann JA, et al. **Oncology (Huntingt)** 1997 May;11(5):651–6, 659; discussion 659, 663–4 (38 ref.)

PHYSIOLOGY

What words are telling us about the brain. Raichle ME. **Cold Spring Harb Symp Quant Biol** 1996;61:9–14 (25 ref.)

Constraints on awareness, attention, processing, and memory: some recent investigations with ignored speech. Cowan N, et al. **Conscious Cogn** 1997 Jun–Sep;6(2–3):182–203 (34 ref.)

Listeners do hear sounds, not tongues. Fowler CA. **J Acoust Soc Am** 1996 Mar;99(3):1730–41 (77 ref.)

Handedness and speech: a critical reappraisal of the role of genetic and environmental factors in the cerebral lateralization of function. Provins KA. **Psychol Rev** 1997 Jul;104(3):554–71 (310 ref.)

Normal aging and human physiology. Chodzko-Zajko WJ. **Semin Speech Lang** 1997 May;18(2):95–104; quiz 104–5 (34 ref.)

SPEECH

[Neuroradiologic activation studies of cerebral organization of language capacities. A review of the literature] Ackermann H, et al. **Fortschr Neurol Psychiatr** 1997 Apr; 65(4):182–94 (125 ref.) (Eng. Abstr.) **(Ger)**

[Clinical application of functional mapping; the present state of the art and its future prospects: (series 2) Identification of motor, sensory, visual and speech cortex by functional MRI] Ito T, et al. **No Shinkei Geka** 1996 Feb;24(2):109–18 (23 ref.) **(Jpn)**

SPEECH, ALARYNGEAL

see related
LARYNX, ARTIFICIAL

Speech rehabilitation after treatment of laryngeal carcinoma. Blalock D. **Otolaryngol Clin North Am** 1997 Apr; 30(2):179–88 (20 ref.)

Speech outcomes after laryngeal cancer management. Simpson CB, et al. **Otolaryngol Clin North Am** 1997 Apr; 30(2):189–205 (71 ref.)

[Sequelae of total laryngectomy with special reference to rehabilitation of the voice and lower airways] Ackerstaff AH, et al. **HNO** 1997 Feb;45(2):97–104 (26 ref.) **(Ger)**

SPEECH DISCRIMINATION see **SPEECH PERCEPTION**

SPEECH DISCRIMINATION TESTS

Verbal auditory closure and the speech perception in noise (SPIN) Test. Elliott LL. **J Speech Hear Res** 1995 Dec; 38(6):1363–76 (81 ref.)

SPEECH DISORDERS

see related
LANGUAGE DISORDERS

DIAGNOSIS

Hearing, speech, language, and vestibular disorders in the fetal alcohol syndrome: a literature review. Church MW, et al. **Alcohol Clin Exp Res** 1997 May;21(3):495–512 (163 ref.)

Bilateral perisylvian syndrome not related to malformations: report of two cases. Grasel RP, et al. **Arq Neuropsiquiatr** 1996 Jun;54(2):293–6 (10 ref.)

Psychopathology of catatonic speech disorders and the dilemma of catatonia: a selective review. Ungvari GS, et al. **Aust N Z J Psychiatry** 1995 Dec;29(4):653–60 (54 ref.)

Cognition, language, and speech in amyotrophic lateral sclerosis: a review. Strong MJ, et al. **J Clin Exp Neuropsychol** 1996 Apr;18(2):291–303 (70 ref.)

ETIOLOGY

Otolaryngologic manifestations of neurofibromatosis in children. Sobol SE, et al. **J Otolaryngol** 1997 Feb;26(1):13–9 (39 ref.)

Age-related effects on speech fluency. Caruso AJ, et al. **Semin Speech Lang** 1997 May;18(2):171–9; quiz 179–80 (50 ref.)

PHYSIOPATHOLOGY

Characteristics of cleft palate speech. Harding A, et al. **Eur J Disord Commun** 1996;31(4):331–57 (60 ref.)

Thought disorder, working memory and attention: interrelationships and the effects of neuroleptic medications. Goldberg TE, et al. **Int Clin Psychopharmacol** 1995 Sep;10 Suppl 3:99–104 (46 ref.)

PREVENTION & CONTROL

Current status of larynx preservation trials. Lefebvre JL, et al. **Curr Opin Oncol** 1996 May;8(3):209–14 (55 ref.)

SURGERY

Recent progress in treating patients with cleft palate. Kawano M, et al. **Folia Phoniatr Logop** 1997;49(3–4):117–38 (17 ref.)

THERAPY

Stimulability: a useful clinical tool. Powell TW, et al. **J Commun Disord** 1996 Jul–Aug;29(4):237–53 (56 ref.)

[Biofeedback in speech therapy after cleft palate surgery] Chen R, et al. **Chung Hua Kou Chiang Hsueh Tsa Chih** 1995 Sep;30(5):314–6 (27 ref.) **(Chi)**

SPEECH, ESOPHAGEAL

The role of the speech and language therapist in voice restoration after laryngectomy [editorial] Perry A. **J Laryngol Otol** 1997 Jan;111(1):4–7 (33 ref.)

SPEECH INTELLIGIBILITY

see related
SPEECH PRODUCTION MEASUREMENT

Speaking at medical meetings. Harikrishnan KM. **J Assoc Physicians India** 1996 Jul;44(7):486–7 (3 ref.)

SPEECH-LANGUAGE PATHOLOGY

EDUCATION

Epidemiology: an essential science for speech-language pathology and audiology. Lubker BB. **J Commun Disord** 1997 Jul–Aug;30(4):251–65; quiz 265–7 (33 ref.)

MANPOWER

Formulating a functional model of attention deficit hyperactivity disorder for the practicing speech-language pathologist. Damico JS, et al. **Semin Speech Lang** 1996 Feb; 17(1):5–19 (88 ref.)

SPEECH PATHOLOGY see **SPEECH-LANGUAGE PATHOLOGY**

SPEECH PERCEPTION

The perceptual evaluation of voice disorders. De Bodt MS, et al. **Acta Otorhinolaryngol Belg** 1996;50(4):283–91 (40 ref.)

Input and learning processes in first language acquisition. Moerk EL. **Adv Child Dev Behav** 1996;26:181–228 (275 ref.)

Behavioral and electrophysiological indices of voicing-cue discrimination: laterality patterns and development. Simos PG, et al. **Brain Lang** 1997 Mar;57(1):122–50 (84 ref.)

Hidden Markov models for speech and signal recognition. Rose RC, et al. **Electroencephalogr Clin Neurophysiol Suppl** 1996;45:137–52 (43 ref.)

Listeners do hear sounds, not tongues. Fowler CA. **J Acoust Soc Am** 1996 Mar;99(3):1730–41 (77 ref.)

Speech perception in older adults: the importance of speech-specific cognitive abilities. Sommers MS. **J Am Geriatr Soc** 1997 May;45(5):633–7 (23 ref.)

Verbal auditory closure and the speech perception in noise (SPIN) Test. Elliott LL. **J Speech Hear Res** 1995 Dec; 38(6):1363–76 (81 ref.)

Unique hearing protection devices--the search for a balance. Gasaway DC. **Occup Health Saf** 1997 Jun;66(6):60–4 (4 ref.)

PHYSIOLOGY

Neurobiology of speech perception. Fitch RH, et al. **Annu Rev Neurosci** 1997;20:331–53 (103 ref.)

A theory of neurolinguistic development. Locke JL. **Brain Lang** 1997 Jun 15;58(2):265–326 (405 ref.)

SPEECH PRODUCTION MEASUREMENT

Speech production of normally aging adults. Benjamin BJ. **Semin Speech Lang** 1997 May;18(2):135–41 (54 ref.)

Age-related effects on speech fluency. Caruso AJ, et al. **Semin Speech Lang** 1997 May;18(2):171–9; quiz 179–80 (50 ref.)

METHODS

Phonetography in voice diagnoses. Heylen LG, et al. **Acta Otorhinolaryngol Belg** 1996;50(4):299–308 (54 ref.)

Aerodynamic measurements of voice production. Raes JP, et al. **Acta Otorhinolaryngol Belg** 1996;50(4):293–8 (22 ref.)

SPEECH SOUNDS see **PHONETICS**

SPEECH THERAPY

see related
VOICE TRAINING

METHODS

[Biofeedback in speech therapy after cleft palate surgery] Chen R, et al. **Chung Hua Kou Chiang Hsueh Tsa Chih** 1995 Sep;30(5):314–6 (27 ref.) **(Chi)**

TRENDS

Recent advances in speech and language therapy. Appleton J, et al. **Br J Hosp Med** 1996 May 1–14;55(9):582–5 (19 ref.)

SPERM see **SPERMATOZOA**

SPERM CAPACITATION

Protein tyrosine phosphorylation and signal transduction during capacitation-acrosome reaction and zona pellucida binding in human sperm. Naz RK. **Arch Androl** 1996 Jul–Aug;37(1):47–55 (48 ref.)

Capacitation mechanisms, and the role of capacitation as seen in eutherian mammals. Harrison RA. **Reprod Fertil Dev** 1996;8(4):581–94 (106 ref.)

Capacitation and the acrosome reaction in marsupial spermatozoa. Mate KE, et al. **Reprod Fertil Dev** 1996; 8(4):595–603 (46 ref.)

PHYSIOLOGY

Capacitation as a regulatory event that primes spermatozoa for the acrosome reaction and fertilization. de Lamirande E, et al. **Mol Hum Reprod** 1997 Mar;3(3):175–94 (178 ref.)

Methods for induction of capacitation and the acrosome reaction of stallion spermatozoa. Graham JK. **Vet Clin North Am Equine Pract** 1996 Apr;12(1):111–7 (42 ref.)

SPERM COUNT

see related
OLIGOSPERMIA

Decreasing sperm counts? A critical (re)view. Lerchl A, et al. **Exp Clin Endocrinol Diabetes** 1996;104(4):301–7 (33 ref.)

Worldwide variations in sperm counts. Fisch H, et al. **Urology** 1996 Dec;48(6):909–11 (30 ref.)

SPERM MATURATION

PHYSIOLOGY

The role of the epididymis in the protection of spermatozoa. Hinton BT, et al. **Curr Top Dev Biol** 1996;33:61–102 (277 ref.)

Role of free L-carnitine and acetyl-L-carnitine in post-gonadal maturation of mammalian spermatozoa. Jeulin C, et al. **Hum Reprod Update** 1996 Mar–Apr;2(2):87–102 (119 ref.)

Epididymal sperm maturation proteins. Hegde UC. **Indian J Biochem Biophys** 1996 Apr;33(2):103–10 (93 ref.)

SPERM MOTILITY

Regulation of the motility and metabolism of spermatozoa for storage in the epididymis of eutherian and marsupial mammals. Jones RC, et al. **Reprod Fertil Dev** 1996; 8(4):553–68 (169 ref.)

PHYSIOLOGY

How does poor motility alter sperm fertilizing ability? Olds-Clarke P. **J Androl** 1996 May–Jun;17(3):183–6 (17 ref.)

Hyperactivated motility in sperm. Suarez SS. **J Androl** 1996 Jul–Aug;17(4):331–5 (39 ref.)

SPERM NUMBER see **SPERM COUNT**

SPERM-OVUM INTERACTIONS

Mitosis in the human embryo: the vital role of the sperm centrosome (centriole). Sathananthan AH. **Histol Histopathol** 1997 Jul;12(3):827–56 (86 ref.)

The role of carbohydrate residues in mammalian fertilization. Shalgi R, et al. **Histol Histopathol** 1997 Jul;12(3):813–22 (105 ref.)

Length of the follicular phase, time of insemination, coital rate and the sex of offspring. Martin JF. **Hum Reprod** 1997 Mar;12(3):611–6 (39 ref.)

TEST-yolk media and sperm quality. Jeyendran RS, et al. **Hum Reprod Update** 1995 Jan;1(1):73–9 (60 ref.)

Reactive oxygen species and human spermatozoa: physiology and pathology. Griveau JF, et al. **Int J Androl** 1997 Apr; 20(2):61–9 (79 ref.)

Sperm-associated protein candidates for primary zona pellucida-binding molecules: structure-function correlations of boar spermadhesins. Töpfer-Petersen E, et al. **J Reprod Fertil Suppl** 1996;50:55–61 (44 ref.)

How and why spermatozoa cause calcium oscillations in mammalian oocytes. Swann K, et al. **Mol Hum Reprod** 1996 Jun;2(6):388–90 (42 ref.)

[The intracytoplasmatic spermatozoa injection--the way out of the "male fertility crisis"?] Michelmann HW. **DTW Dtsch Tierarztl Wochenschr** 1996 Oct;103(10):384–6 (14 ref.) (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

[The future of male contraception: immunocontraception by preventing gamete interaction] Hamamah S, et al. **Contracept Fertil Sex** 1997 Feb;25(2):136–40 (37 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

[The problem of breeding for fertility] Jansen S, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Oct;103(10):414–6 (14 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

[The future of male contraception: immunocontraception by preventing gamete interaction] Hamamah S, et al. **Contracept Fertil Sex** 1997 Feb;25(2):136–40 (37 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

The mammalian acrosome reaction: gateway to sperm fusion with the oocyte? Allen CA, et al. **Bioessays** 1997 Mar; 19(3):241–7 (46 ref.)

Why did the sperm cross the cumulus? To get to the oocyte. Functions of the sperm surface proteins PH-20 and fertilin in arriving at, and fusing with, the egg. Myles DG, et al. **Biol Reprod** 1997 Feb;56(2):320–7 (58 ref.)

Early steps of sperm-egg interactions during mammalian fertilization. Barros C, et al. **Cell Biol Int** 1996 Jan; 20(1):33–9 (49 ref.)

Sperm competition: evolution and mechanisms. Birkhead TR. **Curr Top Dev Biol** 1996;33:103–58 (163 ref.)
Ion channels: key elements in gamete signaling. Darszon A, et al. **Curr Top Dev Biol** 1996;34:117–67 (448 ref.)
Paternal investment and intracellular sperm–egg interactions during and following fertilization in Drosophila. Karr TL. **Curr Top Dev Biol** 1996;34:89–115 (90 ref.)
Molecular mechanisms of gamete recognition in sea urchin fertilization. Ohlendieck K, et al. **Curr Top Dev Biol** 1996; 32:39–58 (67 ref.)
Transforming sperm nuclei into male pronuclei in vivo and in vitro. Poccia D, et al. **Curr Top Dev Biol** 1996;34:25–88 (250 ref.)
Fertilization and development in humans. Trounson A, et al. **Curr Top Dev Biol** 1996;32:59–101 (172 ref.)
The human sperm acrosome reaction: physiology and regulatory mechanisms. An update. Brucker C, et al. **Hum Reprod Update** 1995 Jan;1(1):51–62 (103 ref.)
The role of carbohydrate in sperm–ZP3 adhesion. Chapman NR, et al. **Mol Hum Reprod** 1996 Oct;2(10):767–74 (74 ref.)
Sperm factor: what is it and what does it do? Wilding M, et al. **Mol Hum Reprod** 1997 Mar;3(3):269–73 (74 ref.)
[Mini-review: oocyte activation mechanisms. Different models, comparison: marine invertebrate and mammal] Ciapa B, et al. **Contracept Fertil Sex** 1996 Jul–Aug; 24(7–8):564–70 (47 ref.) (Eng. Abstr.) **(Fre)**
[Physiological mechanisms of oocyte activation] Ozil JP. **Contracept Fertil Sex** 1996 Jul–Aug;24(7–8):571–6 (38 ref.) (Eng. Abstr.) **(Fre)**
[Physiology of human gamete interaction] Wolf JP, et al. **Contracept Fertil Sex** 1997 Jan;25(1):69–78 (20 ref.) (Eng. Abstr.) **(Fre)**

SPERM PENETRATION see **SPERM–OVUM INTERACTIONS**

SPERM PRESERVATION see **SEMEN PRESERVATION**

SPERM TRANSPORT

PHYSIOLOGY

The role of the epididymis in the protection of spermatozoa. Hinton BT, et al. **Curr Top Dev Biol** 1996;33:61–102 (277 ref.)

SPERMATIC CORD

Malignant mesenchymoma of the spermatic cord with a brief review of the literature. Inagaki T, et al. **Int J Urol** 1997 Mar;4(2):225–8 (13 ref.)
Papillary cystadenoma located in the spermatic cord. Geenen RW, et al. **J Urol** 1997 Aug;158(2):546 (3 ref.)
Primary osteosarcoma of the spermatic cord with synchronous bilateral renal cell carcinoma. Beiswanger JC, et al. **Urology** 1997 Jun;49(6):957–9 (14 ref.)
Combined myxoid liposarcoma and angiolipoma of the spermatic cord. Ikinger U, et al. **Urology** 1997 Apr; 49(4):635–7 (15 ref.)
[Cystic lymphangioma of the spermatic cord. Report of a new case] Jung JL, et al. **Prog Urol** 1996 Dec;6(6):948–9 (6 ref.) (Eng. Abstr.) **(Fre)**

PARASITOLOGY

[Dirofilaria (Nochtiella) repens in the spermatic cord: a new human case in Italy] Pampiglione S, et al. **Bull Soc Pathol Exot** 1997;90(1):22–4 (13 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Leiomyosarcoma with osteoclast-like giant cells of the spermatic cord. A case report and review of the literature. Konety BR, et al. **Urol Int** 1996;56(4):259–62 (14 ref.)

SURGERY

[Leiomyosarcoma of the spermatic cord. A case report with review of the literature] Wiebel T, et al. **Urologe A** 1996 Jan;35(1):54–6 (21 ref.) (Eng. Abstr.) **(Ger)**

SPERMATIC CORD TORSION

SURGERY

[A case of bilateral testicular torsion in a neonate] Konya E, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Jul; 87(7):1004–7 (15 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Ultrasound in the assessment of the acute scrotum. Herbener TE. **J Clin Ultrasound** 1996 Oct;24(8):405–21 (52 ref.)

SPERMATIDS

Spermatid conception: a stage too early, or a time too soon? [editorial] Fishel S, et al. **Hum Reprod** 1996 Jul;11(7):1371–5 (48 ref.)

TRANSPLANTATION

[Medically assisted reproduction with immature spermatozoa. Clinical examination and surgical technics] Schoysman R, et al. **Acta Urol Belg** 1997 Jun;65(2):21–6 (32 ref.) (Eng. Abstr.) **(Fre)**

SPERMATOBLASTS see **SPERMATIDS**

SPERMATOCIDAL AGENTS

[Local vaginal therapies] Cohen J. **Contracept Fertil Sex** 1997 Mar;25(3):196–201 (0 ref.) **(Fre)**

PHARMACOLOGY

Review: in vitro spermicidal tests. Lee CH. **Contraception** 1996 Sep;54(3):131–47 (151 ref.)

SPERMATOCYTES

see related
SPERM MATURATION

SPERMATOGENESIS

Germ cell development in Drosophila. Williamson A, et al. **Ann Rev Cell Dev Biol** 1996;12:365–91 (122 ref.)
Transcriptional checkpoints determining the fate of male germ cells. Sassone-Corsi P. **Cell** 1997 Jan 24;88(2):163–6 (22 ref.)
Effect of diabetes mellitus upon male reproductive function. Sexton WJ, et al. **Urology** 1997 Apr;49(4):508–13 (45 ref.)
[Treatments of testicular cancer and protection of spermatogenesis] Bujan L, et al. **Contracept Fertil Sex** 1996 Jul–Aug;24(7–8):596–602 (34 ref.) (Eng. Abstr.) **(Fre)**
[Evaluation of spermatogenic function] Isurugi K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:385–9 (11 ref.) **(Jpn)**

DRUG EFFECTS

Treatment of male infertility with growth hormone. Ng SC, et al. **Clin Sci (Colch)** 1996 Sep;91(3):254–5 (18 ref.)
Fertility after chemotherapy for testicular germ cell cancer. Pont J, et al. **Fertil Steril** 1997 Jul;68(1):1–5 (45 ref.)
Evaluation of testicular toxicity in safety evaluation studies: the appropriate use of spermatogenic staging. Creasy DM. **Toxicol Pathol** 1997 Mar–Apr;25(2):119–31 (61 ref.)

GENETICS

The azoospermic factor on the Y chromosome. Shinka T, et al. **Acta Paediatr Jpn** 1996 Aug;38(4):399–404 (34 ref.)
The molecular genetics of male infertility. Elliott DJ, et al. **Bioessays** 1997 Sep;19(9):801–9 (73 ref.)
Regulation of hsp expression during rodent spermatogenesis. Sarge KD, et al. **Cell Mol Life Sci** 1997 Feb;53(2):191–7 (38 ref.)
Stage and developmental specific gene expression during mammalian spermatogenesis. Nayernia K, et al. **Int J Dev Biol** 1996 Feb;40(1):379–83 (48 ref.)
POU-domain gene expression during spermatogenesis. Zini A, et al. **World J Urol** 1996;14(5):274–7 (20 ref.)

PHYSIOLOGY

New therapeutic possibilities handling residual azoospermia. Schoysman R, et al. **Acta Eur Fertil** 1995 Jul–Aug; 26(4):131–6 (21 ref.)
Spermatogenesis in Drosophila. Hennig W. **Int J Dev Biol** 1996 Feb;40(1):167–76 (64 ref.)
Growth factors and testicular function: relevance to disorders of spermatogenesis in humans. Smith EP, et al. **Semin Reprod Endocrinol** 1996 Aug;14(3):209–17 (114 ref.)
[The regulation of spermatogenesis in mammals] Stefanini M, et al. **Ital J Anat Embryol** 1995 Oct–Dec;100(4):73–112 (0 ref.) **(Ita)**

SPERMATOGONIA

GROWTH & DEVELOPMENT

[Regulation of growth and survival of germ cells] Matsui Y. **Hum Cell** 1997 Mar;10(1):63–8 (22 ref.) (Eng. Abstr.) **(Jpn)**

SPERMATOPHORES see **SPERMATOGONIA**

SPERMATOZOA

see related
OLIGOSPERMIA
SPERMATOCIDAL AGENTS

Analysis of structural and numerical chromosome abnormalities in sperm of normal men and carriers of constitutional chromosome aberrations. A review. Guttenbach M, et al. **Hum Genet** 1997 Jul;100(1):1–21 (143 ref.)
Information access and donated gametes: how much do we know about who wants to know? Broderick P, et al. **Hum Reprod** 1995 Dec;10(12):3338–41 (40 ref.)
Post-coital sperm retrieval could lead to the wider approval of assisted conception by some religions. Hirsh A. **Hum Reprod** 1996 Feb;11(2):245–7 (26 ref.)
Microsurgical epididymal sperm aspiration: review of techniques, preoperative considerations, and results. Girardi SK, et al. **J Androl** 1996 Jan–Feb;17(1):5–9 (13 ref.)
Intracytoplasmic sperm injection for treatment of the infertile male. Kim ED, et al. **Tex Med** 1997 Jul;93(7):50–6 (41 ref.)
[Genetic risks associated with intracytoplasmic sperm injection] Plachot M. **Contracept Fertil Sex** 1996 Jul–Aug; 24(7–8):577–80 (14 ref.) (Eng. Abstr.) **(Fre)**
[Intracytoplasmic injection of spermatozoa] Olivennes F, et al. **Presse Med** 1996 Nov 2;25(33):1599–603 (25 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Lipids of the sperm plasma membrane: from polyunsaturated fatty acids considered as markers of sperm function to possible scavenger therapy. Lenzi A, et al. **Hum Reprod Update** 1996 May–Jun;2(3):246–56 (63 ref.)

CLASSIFICATION

Sperm morphology assessment: historical review in relation to fertility. Ombelet W, et al. **Hum Reprod Update** 1995 Nov;1(6):543–57 (152 ref.)
Multipoint linkage map from sperm typing data. Lien S. **Reprod Nutr Dev** 1996;36(6):637–42 (16 ref.)

CYTOLOGY

Azoospermia and intracytoplasmic sperm injection. Ubaldi F, et al. **Acta Eur Fertil** 1995 Jan–Feb;26(1):21–4 (16 ref.)
Approaches for obtaining sperm in patients with male factor infertility. Cha KY, et al. **Fertil Steril** 1997 Jun;67(6):985–95 (86 ref.)
The predetermination of embryonic sex using flow cytometrically separated X and Y spermatozoa. Cran DG, et al. **Hum Reprod Update** 1996 Jul–Aug;2(4):355–63 (48 ref.)
Advantages of strict (Tygerberg) criteria for evaluation of sperm morphology. Menkveld R, et al. **Int J Androl** 1995 Dec;18 Suppl 2:36–42 (43 ref.)
NMR spectroscopy in andrology: research uses and possible clinical applications. Rohr G, et al. **Int J Androl** 1995 Dec; 18 Suppl 2:12–9 (41 ref.)
Sperm separation for gender preference: methods and efficacy. Botchan A, et al. **J Androl** 1997 Mar–Apr; 18(2):107–8 (20 ref.)
Do sperm cells age? A review of the physiological changes in sperm during storage at ambient temperature. Vishwanath R, et al. **Reprod Fertil Dev** 1997;9(3):321–31 (110 ref.)
Use of semen as biopsy material for assessment of health status of the stallion reproductive tract. Veeramachaneni DN, et al. **Vet Clin North Am Equine Pract** 1996 Apr; 12(1):101–10 (6 ref.)
[Separation techniques ro achieve vital and reproduction competent equine spermatozoa populations--a survey] Sieme H, et al. **DTW Dtsch Tierarztl Wochenschr** 1997 Aug; 104(8):298–302 (61 ref.) (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Review: in vitro spermicidal tests. Lee CH. **Contraception** 1996 Sep;54(3):131–47 (151 ref.)

ENZYMOLOGY

Physiological functions of proteasomes in ascidian fertilization and embryonic cell cycle. Sawada H, et al. **Adv Exp Med Biol** 1996;389:229–32 (12 ref.)

GROWTH & DEVELOPMENT

Evaluation of testicular toxicity in safety evaluation studies: the appropriate use of spermatogenic staging. Creasy DM. **Toxicol Pathol** 1997 Mar–Apr;25(2):119–31 (61 ref.)

IMMUNOLOGY

Assisted conception and immunological infertility. Cimino C, et al. **Acta Eur Fertil** 1995 Jan–Feb;26(1):13–20 (46 ref.)
Sperm antigens and their use in the development of an immunocontraceptive. Diekman AB, et al. **Am J Reprod Immunol** 1997 Jan;37(1):111–7 (74 ref.)
Contraceptive vaccines. Jones WR. **Baillieres Clin Obstet Gynaecol** 1996 Apr;10(1):69–86 (65 ref.)
Development of contraceptive vaccines for humans using antigens derived from gametes (spermatozoa and zona pellucida) and hormones (human chorionic gonadotrophin): current status. Naz RK, et al. **Hum Reprod Update** 1995 Jan;1(1):1–18 (133 ref.)
Prostaglandins in primate semen: biasing the immune system to benefit spermatozoa and virus? Kelly RW. **Prostaglandins Leukot Essent Fatty Acids** 1997 Aug; 57(2):113–8 (71 ref.)
Immunocontraception in rodents: a review of the development of a sperm-based immunocontraceptive vaccine for the grey squirrel (Sciurus carolinensis). Moore HD, et al. **Reprod Fertil Dev** 1997;9(1):125–9 (33 ref.)
Ly-6-domain proteins--new insights and new members: a C-terminal Ly-6 domain in sperm acrosomal protein SP-10. Palfree RG. **Tissue Antigens** 1996 Aug;48(2):71–9 (77 ref.)
[Immunologic response against spermatozoa in the human genital tract] Domagała A, et al. **Ginekol Pol** 1996 Jun; 67(6):304–8 (26 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Amino acid neurotransmitter receptor/chloride channels of

mammalian sperm and the acrosome reaction. Meizel S. **Biol Reprod** 1997 Mar;56(3):569–74 (86 ref.)
Transcriptional checkpoints determining the fate of male germ cells. Sassone-Corsi P. **Cell** 1997 Jan 24;88(2):163–6 (22 ref.)
The unique, complex organization of the transcriptionally silent sperm chromatin. Ward WS, et al. **Crit Rev Eukaryot Gene Expr** 1996;6(2–3):139–47 (51 ref.)
Regulation of membrane stability and the acrosome reaction in mammalian sperm. Nolan JP, et al. **FASEB J** 1997 Jul; 11(8):670–82 (103 ref.)
Molecular mechanisms of the interaction between sperm and the zona pellucida in mammals: studies on the pig. Töpfer-Petersen E, et al. **Int J Androl** 1995 Dec;18 Suppl 2:20–6 (56 ref.)
Sperm-associated protein candidates for primary zona pellucida-binding molecules: structure-function correlations of boar spermadhesins. Töpfer-Petersen E, et al. **J Reprod Fertil Suppl** 1996;50:55–61 (44 ref.)
The role of carbohydrate in sperm-ZP3 adhesion. Chapman NR, et al. **Mol Hum Reprod** 1996 Oct;2(10):767–74 (74 ref.)
Application of modern molecular techniques to evaluate sperm sex selection methods. Flaherty SP, et al. **Mol Hum Reprod** 1996 Dec;2(12):937–42 (52 ref.)
Calcium influx pathways in human spermatozoa. Foresta C, et al. **Mol Hum Reprod** 1997 Jan;3(1):1–4 (38 ref.)
RNA in spermatozoa: implications for the alternative haploid genome. Kramer JA, et al. **Mol Hum Reprod** 1997 Jun; 3(6):473–8 (58 ref.)
Biochemistry of the induction and prevention of lipoperoxidative damage in human spermatozoa. Storey BT. **Mol Hum Reprod** 1997 Mar;3(3):203–13 (91 ref.)
Regulation of the motility and metabolism of spermatozoa for storage in the epididymis of eutherian and marsupial mammals. Jones RC, et al. **Reprod Fertil Dev** 1996; 8(4):553–68 (169 ref.)

PATHOLOGY

Lipids of the sperm plasma membrane: from polyunsaturated fatty acids considered as markers of sperm function to possible scavenger therapy. Lenzi A, et al. **Hum Reprod Update** 1996 May-Jun;2(3):246–56 (63 ref.)
Reactive oxygen species and human spermatozoa: physiology and pathology. Griveau JF, et al. **Int J Androl** 1997 Apr; 20(2):61–9 (79 ref.)
Identifying environmental risk to male reproductive function by occupational sperm studies: logistics and design options. Bonde JP, et al. **Occup Environ Med** 1996 Aug;53(8):511–9 (56 ref.)
The significance to bull fertility of morphologically abnormal sperm. Johnson WH. **Vet Clin North Am Food Anim Pract** 1997 Jul;13(2):255–70 (30 ref.)

PHYSIOLOGY

The testis: the witness of the mating system, the site of mutation and the engine of desire. Short RV. **Acta Paediatr Suppl** 1997 Jul;422:3–7 (26 ref.)
Sperm competition: evolution and mechanisms. Birkhead TR. **Curr Top Dev Biol** 1996;33:103–58 (163 ref.)
Decreasing sperm counts? A critical (re)view. Lerchl A, et al. **Exp Clin Endocrinol Diabetes** 1996;104(4):301–7 (33 ref.)
X- and Y-chromosome-bearing sperm selection and detection methods. A review. Gawęcka-Szczygieł M, et al. **Folia Histochem Cytobiol** 1995;33(4):219–27 (55 ref.)
Cytogenetics of infertile men. Van Assche E, et al. **Hum Reprod** 1996 Dec;11 Suppl 4:1–24; discussion 25–6 (114 ref.)
Human semen analysis. Comhaire F, et al. **Hum Reprod Update** 1995 Jul;1(4):343–62 (59 ref.)
TEST-yolk media and sperm quality. Jeyendran RS, et al. **Hum Reprod Update** 1995 Jan;1(1):73–9 (60 ref.)
Reactive oxygen species and human spermatozoa: physiology and pathology. Griveau JF, et al. **Int J Androl** 1997 Apr; 20(2):61–9 (79 ref.)
Transcriptional regulatory strategies in male germ cells. Goldberg E. **J Androl** 1996 Nov-Dec;17(6):628–32 (27 ref.)
Stem cell factor and c-kit in the mammalian testis: lessons originating from Mother Nature's gene knockouts. Loveland KL, et al. **J Endocrinol** 1997 Jun;153(3):337–44 (71 ref.)
Analysis of sperm aneuploidy by PRINS. Pellestor F, et al. **Methods Mol Biol** 1997;71:23–9 (12 ref.)
Molecular mechanisms regulating human sperm function. Aitken RJ. **Mol Hum Reprod** 1997 Mar;3(3):169–73 (44 ref.)
Molecular approaches to the diagnosis of male infertility. Jeremias J, et al. **Mol Hum Reprod** 1996 Mar;2(3):195–202 (60 ref.)
Cell-to-cell transfer of glycosylphosphatidylinositol-anchored membrane proteins during sperm maturation. Kirchhoff C, et al. **Mol Hum Reprod** 1996 Mar;2(3):177–84 (77 ref.)
Sperm factor: what is it and what does it do? Wilding M, et al. **Mol Hum Reprod** 1997 Mar;3(3):269–73 (74 ref.)
Ovarian control of very low sperm/egg ratios at the commencement of mammalian fertilisation to avoid polyspermy. Hunter RH. **Mol Reprod Dev** 1996 Jul; 44(3):417–22 (73 ref.)
What marsupial gametes disclose about gamete function in eutherian mammals. Bedford JM. **Reprod Fertil Dev** 1996; 8(4):569–80 (65 ref.)
Capacitation mechanisms, and the role of capacitation as seen in eutherian mammals. Harrison RA. **Reprod Fertil Dev** 1996;8(4):581–94 (106 ref.)
Capacitation and the acrosome reaction in marsupial spermatozoa. Mate KE, et al. **Reprod Fertil Dev** 1996; 8(4):595–603 (46 ref.)
Gamete biology of the new world marsupial, the grey short-tailed opossum, Monodelphis domestica. Moore HD. **Reprod Fertil Dev** 1996;8(4):605–15 (38 ref.)
Do sperm cells age? A review of the physiological changes in sperm during storage at ambient temperature. Vishwanath R, et al. **Reprod Fertil Dev** 1997;9(3):321–31 (110 ref.)
Methods for induction of capacitation and the acrosome reaction of stallion spermatozoa. Graham JK. **Vet Clin North Am Equine Pract** 1996 Apr;12(1):111–7 (42 ref.)
Cryopreservation of stallion spermatozoa. Graham JK. **Vet Clin North Am Equine Pract** 1996 Apr;12(1):131–47 (39 ref.)
[Separation techniques ro achieve vital and reproduction competent equine spermatozoa populations--a survey] Sieme H, et al. **DTW Dtsch Tierarztl Wochenschr** 1997 Aug; 104(8):298–302 (61 ref.) (Eng. Abstr.) **(Ger)**

ULTRASTRUCTURE

Transforming sperm nuclei into male pronuclei in vivo and in vitro. Poccia D, et al. **Curr Top Dev Biol** 1996;34:25–88 (250 ref.)
Mitosis in the human embryo: the vital role of the sperm centrosome (centriole). Sathananthan AH. **Histol Histopathol** 1997 Jul;12(3):827–56 (86 ref.)
Detection of chromosomes and estimation of aneuploidy in human spermatozoa using fluorescence in-situ hybridization. Downie SE, et al. **Mol Hum Reprod** 1997 Jul;3(7):585–98 (108 ref.)
Application of modern molecular techniques to evaluate sperm sex selection methods. Flaherty SP, et al. **Mol Hum Reprod** 1996 Dec;2(12):937–42 (52 ref.)
Evaluation of sperm damage and techniques for sperm clean-up. Rodriguez-Martinez H, et al. **Reprod Fertil Dev** 1997;9(3):297–308 (87 ref.)

SPERMICIDAL AGENTS see **SPERMATOCIDAL AGENTS**

SPERMIDINE

METABOLISM

Ethanol and polyamine metabolism: physiologic and pathologic implications: a review. Sessa A, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):318–25 (121 ref.)

SPERMINE

METABOLISM

Ethanol and polyamine metabolism: physiologic and pathologic implications: a review. Sessa A, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):318–25 (121 ref.)

SPERMOPHILUS see **SCIURIDAE**

SPHAEROPHORUS INFECTIONS see **FUSOBACTERIUM INFECTIONS**

SPHAEROPHORUS NECROPHORUS see **FUSOBACTERIUM NECROPHORUM**

SPHAEROTILUS see **GRAM-NEGATIVE AEROBIC BACTERIA**

SPHAGNUM see **MOSSES**

SPHENOID BONE

Primary eosinophilic granuloma invading the skull base: case report and critical review of the literature. Lunardi P, et al. **Tumori** 1996 Jul-Aug;82(4):397–400 (20 ref.)
[Temporo-sphenoidal giant cell tumors, apropos of a case] Barnabé D, et al. **Rev Laryngol Otol Rhinol (Bord)** 1997; 118(2):133–7 (30 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Intracranial chondromyxoid fibroma. Report of a case and review of the literature. Wolf DA, et al. **Arch Pathol Lab Med** 1997 Jun;121(6):626–30 (23 ref.)

SURGERY

Craniopharyngioma: transsphenoidal surgery. Laws ER Jr. **Curr Ther Endocrinol Metab** 1997;6:35–8 (6 ref.)
Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Ciric I, et al. **Neurosurgery** 1997 Feb; 40(2):225–36; discussion 236–7 (101 ref.)

SPHENOID SINUS

Choanal polyp of sphenoidal origin. Report of two cases. Eloy P, et al. **Acta Otorhinolaryngol Belg** 1996;50(3):183–9 (22 ref.)
Metastatic follicular thyroid carcinoma to the paranasal sinuses: a case report and review. Altman KW, et al. **J Laryngol Otol** 1997 Jul;111(7):647–51 (22 ref.)
[Surgical treatment under endoscopic control of cerebrospinal fluid rhinorrhea of sphenoid origin. A propos of 5 cases] Righini C, et al. **Ann Otolaryngol Chir Cervicofac** 1996;113(4):188–95 (36 ref.) (Eng. Abstr.) **(Fre)**

ABNORMALITIES

Focal atrophy and cerebrospinal fluid rhinorrhea. Ator CB, et al. **J Am Osteopath Assoc** 1997 Jan;97(1):40–2 (15 ref.)
Agenesis of sphenoid sinus. Case report. Antoniades K, et al. **ORL J Otorhinolaryngol Relat Spec** 1996 Nov-Dec; 58(6):347–9 (7 ref.)

PATHOLOGY

Focal atrophy and cerebrospinal fluid rhinorrhea. Ator CB, et al. **J Am Osteopath Assoc** 1997 Jan;97(1):40–2 (15 ref.)
Sphenoid and sellar tumors. Isaacs RS, et al. **Otolaryngol Clin North Am** 1995 Dec;28(6):1191–229 (77 ref.)

SURGERY

Sphenoid and sellar tumors. Isaacs RS, et al. **Otolaryngol Clin North Am** 1995 Dec;28(6):1191–229 (77 ref.)

SPHEROCYTOSIS, HEREDITARY

see related
ANEMIA, SIDEROBLASTIC
Hereditary spherocytosis: a review of the clinical and molecular aspects of the disease. Hassoun H, et al. **Blood Rev** 1996 Sep;10(3):129–47 (128 ref.)

BLOOD

[Hereditary spherocytosis] Ideguchi H. **Nippon Rinsho** 1996 Sep;54(9):2478–83 (14 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

[Anatomic correction of double-outlet right ventricle associated with hereditary spherocytosis--a case report] Kaminishi Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Dec;44(12):2164–71 (17 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Molecular genetics of hereditary elliptocytosis and hereditary spherocytosis. Delaunay J, et al. **Ann Genet** 1996; 39(4):209–21 (93 ref.)

SURGERY

Effectiveness of partial splenectomy in hereditary spherocytosis. Tchernia G, et al. **Curr Opin Hematol** 1997 Mar;4(2):136–41 (37 ref.)

SPHEROIDS

PATHOLOGY

Mathematical modelling of avascular-tumour growth. Ward JP, et al. **IMA J Math Appl Med Biol** 1997 Mar;14(1):39–69 (50 ref.)

SPHINCTEROTOMY, ENDOSCOPIC

Endoscopic pancreatic intervention. Liguory C, et al. **Abdom Imaging** 1997 Sep-Oct;22(5):489–95 (42 ref.)
Sphincterotomy techniques and risks. Shields SJ, et al. **Gastrointest Endosc Clin N Am** 1996 Jan;6(1):17–42 (80 ref.)
Endoscopic treatment of biliary colic resulting from hemobilia after nonoperative management of blunt hepatic injury: case report and review of the literature. Clancy TE, et al. **J Trauma** 1997 Sep;43(3):527–9 (23 ref.)
[Endoscopic treatment in acute biliary pancreatitis (editorial)] Prat F, et al. **Presse Med** 1996 Nov 9;25(34):1620–2 (11 ref.) (Eng. Abstr.) **(Fre)**
[Surgical therapy of hemorrhage after endoscopic sphincterotomy. Indications and technique] Sulkowski U, et al. **Chirurg** 1996 Jan;67(1):26–31 (19 ref.) (Eng. Abstr.) **(Ger)**
[Acute pancreatitis--is endoscopic papillotomy a reliable therapy?] van Husen N. **Wien Med Wochenschr** 1997; 147(1):6–9 (26 ref.) (Eng. Abstr.) **(Ger)**
[The "sump syndrome": a case treated by surgical endoscopy. A discussion about biliodigestive diversions and endoscopic sphincterotomies] De Monti M, et al. **Minerva Gastroenterol Dietol** 1996 Jun;42(2):93–7 (22 ref.) (Eng. Abstr.) **(Ita)**
[A retroperitoneal abscess after endoscopic sphincterotomy: a severe and infrequent complication] Fernández Pérez FJ, et al. **Rev Esp Enferm Dig** 1997 Feb;89(2):139–41 (11 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Bleeding causing biliary obstruction after endoscopic sphincterotomy. Mosenkis BN, et al. **Am J Gastroenterol** 1997 Apr;92(4):708–9 (5 ref.)

Complications of endoscopic biliary sphincterotomy: a review. Freeman ML. **Endoscopy** 1997 May;29(4):288–97 (79 ref.)
Endoscopic sphincterotomy in the young patient: is there cause for concern? Tham TC, et al. **Gut** 1997 Jun; 40(6):697–700 (60 ref.)

INSTRUMENTATION

Transpapillary stenting of proximal biliary strictures: does biliary sphincterotomy reduce the risk of postprocedure pancreatitis? Tarnasky PR, et al. **Gastrointest Endosc** 1997 Jan;45(1):46–51 (27 ref.)

METHODS

A new approach to sphincterotomy in patients with Billroth II gastrectomy. Al-Kawas FH, et al. **Gastrointest Endosc** 1996 Mar;43(3):253–5 (8 ref.)

SPHINGOGLYCOLIPIDS see **GLYCOSPHINGOLIPIDS**

SPHINGOLIPIDS

[Frontiers in sphingolipid research] Hirabayashi Y. **Seikagaku** 1996 Jun;68(6):423–30 (45 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Importance of sphingolipids and inhibitors of sphingolipid metabolism as components of animal diets. Merrill AH Jr, et al. **J Nutr** 1997 May;127(5 Suppl):830S–833S (22 ref.)

ANTAGONISTS & INHIBITORS

Importance of sphingolipids and inhibitors of sphingolipid metabolism as components of animal diets. Merrill AH Jr, et al. **J Nutr** 1997 May;127(5 Suppl):830S–833S (22 ref.)

BIOSYNTHESIS

Fumonisin toxicity and sphingolipid biosynthesis. Merrill AH Jr, et al. **Adv Exp Med Biol** 1996;392:297–306 (39 ref.)

METABOLISM

"Cross talk" between the bioactive glycerolipids and sphingolipids in signal transduction. Brindley DN, et al. **Biochem Cell Biol** 1996;74(4):469–76 (61 ref.)
Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Hakomori S. **Cancer Res** 1996 Dec 1;56(23):5309–18 (133 ref.)
Caveolae, DIGs, and the dynamics of sphingolipid–cholesterol microdomains. Harder T, et al. **Curr Opin Cell Biol** 1997 Aug;9(4):534–42 (75 ref.)
Sphingolipid activator proteins. Suzuki K. **Essays Biochem** 1995;29:25–37 (28 ref.)
Sphingolipid metabolism and cell growth regulation. Spiegel S, et al. **FASEB J** 1996 Oct;10(12):1388–97 (130 ref.)
Molecular diversity of sphingolipid signalling. Meyer zu Heringdorf D, et al. **FEBS Lett** 1997 Jun 23;410(1):34–8 (57 ref.)
[Saposins and sphingolipid metabolisms] Hiraiwa M, et al. **Seikagaku** 1996 Jun;68(6):464–74 (67 ref.) **(Jpn)**

PHYSIOLOGY

Sphingolipids as differential regulators of cellular signalling processes. Pyne S, et al. **Biochem Soc Trans** 1997 May; 25(2):549–56 (59 ref.)
Lipid biochemistry: functions of glycerolipids and sphingolipids in cellular signaling. Ghosh S, et al. **FASEB J** 1997 Jan;11(1):45–50 (55 ref.)
Sphingolipids—the enigmatic lipid class: biochemistry, physiology, and pathophysiology. Merrill AH Jr, et al. **Toxicol Appl Pharmacol** 1997 Jan;142(1):208–25 (168 ref.)
[Sphingolipids—a new group of lipid second messengers?] Mesarić M. **Lijec Vjesn** 1996 Jul–Aug;118(7–8):178–83 (81 ref.) (Eng. Abstr.) **(Scr)**

SPHINGOMYELIN CHOLINEPHOSPHOHYDROLASE see **SPHINGOMYELIN PHOSPHODIESTERASE**

SPHINGOMYELIN CLEAVING ENZYME see **SPHINGOMYELIN PHOSPHODIESTERASE**

SPHINGOMYELIN PHOSPHODIESTERASE

see related
NIEMANN-PICK DISEASE

METABOLISM

Identification of p55 tumor necrosis factor receptor-associated proteins that couple to signaling pathways not initiated by the death domain. Adam D, et al. **J Inflamm** 1995–96;47(1–2):61–6 (35 ref.)

SPHINGOMYELINASE see **SPHINGOMYELIN PHOSPHODIESTERASE**

SPHINGOMYELINS

METABOLISM

Stress-induced apoptosis and the sphingomyelin pathway. Peña LA, et al. **Biochem Pharmacol** 1997 Mar 7; 53(5):615–21 (63 ref.)
Cholesterol–sphingomyelin interactions in cells—effects on lipid metabolism. Slotte JP. **Subcell Biochem** 1997; 28:277–93 (86 ref.)
[Sphingomyelin and its catabolism in cell nucleus: their possible roles in regulation mechanism of DNA replication] Tamiya-Koizumi K. **Seikagaku** 1996 Jun;68(6):453–63 (30 ref.) **(Jpn)**
[Sphingomyelin and its metabolites as an intermediate in cellular signal transduction] Dzik JM, et al. **Postepy Biochem** 1996;42(3):299–309 (109 ref.) **(Pol)**

PHYSIOLOGY

Sphingomyelin breakdown and cell fate. Testi R. **Trends Biochem Sci** 1996 Dec;21(12):468–71 (51 ref.)
[Sphingomyelin cycle: role in cell functions inducing apoptosis] Okazaki T. **Seikagaku** 1996 Jun;68(6):431–43 (84 ref.) **(Jpn)**

THERAPEUTIC USE

Cows' milk fat components as potential anticarcinogenic agents. Parodi PW. **J Nutr** 1997 Jun;127(6):1055–60 (71 ref.)

SPHINGOSINE

ANALOGS & DERIVATIVES

Sphingolipid metabolism and cell growth regulation. Spiegel S, et al. **FASEB J** 1996 Oct;10(12):1388–97 (130 ref.)

PHYSIOLOGY

["Sphingosine pathway": a novel apoptosis inducing pathway] Kozutsumi Y, et al. **Seikagaku** 1996 Jun;68(6):444–52 (41 ref.) **(Jpn)**

SPHYGMOMANOMETERS, CONTINUOUS see **BLOOD PRESSURE MONITORS**

SPIDER BITE see **ARACHNIDISM**

SPIDER MONKEY see **CEBIDAE**

SPIDERS

[Spider silk: protein science] Osaki S. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(14):2108–16 (7 ref.) **(Jpn)**

SPIN LABELS

see related
ELECTRON SPIN RESONANCE SPECTROSCOPY
SPIN TRAPPING

SPIN TRAPPING

METHODS

A water soluble C-nitroso-aromatic spin-trap-3,5-dibromo-4-nitrosobenzenesulphonic acid. 'The Perkins spin-trap'. Kaur H. **Free Radic Res** 1996 Jun; 24(6):409–20 (63 ref.)
Nitrone-based free radical traps as neuroprotective agents in cerebral ischaemia and other pathologies. Hensley K, et al. **Int Rev Neurobiol** 1997;40:299–317 (105 ref.)

SPINA BIFIDA see **SPINAL DYSRAPHISM**

SPINA BIFIDA OCCULTA

[Current status of tethered cord syndrome] Shi Z, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Dec;33(12):734–7 (25 ref.) **(Chi)**

COMPLICATIONS

Injury risk for research subjects with spina bifida occulta in a repeated impact study: a case review. Albano JP, et al. **Aviat Space Environ Med** 1996 Aug;67(8):767–9 (15 ref.)

DIAGNOSIS

[Tethered spinal cord syndrome in adults] Kothbauer K, et al. **Nervenarzt** 1997 Apr;68(4):285–91 (102 ref.) (Eng. Abstr.) **(Ger)**
[The tethered spinal cord: diagnosis and surgical considerations] Roszkowski M, et al. **Pediatr Pol** 1996 Feb; 71(2):135–41 (17 ref.) (Eng. Abstr.) **(Pol)**
[Gram-negative meningitis secondary to congenital dermal sinus demonstrated by magnetic resonance] Verdú Pérez A, et al. **An Esp Pediatr** 1996 May;44(5):491–2 (9 ref.) **(Spa)**

PATHOLOGY

Clinical evaluation of cutaneous lesions of the back: spinal signatures that do not go away. Humphreys RP. **Clin Neurosurg** 1996;43:175–87 (6 ref.)
The borderlands of the primary tethered cord syndrome. Oakes WJ. **Clin Neurosurg** 1996;43:188–202 (30 ref.)

SURGERY

Neurenteric cyst of the anterior cranial fossa [see comments] Bavetta S, et al. **Br J Neurosurg** 1996 Apr;10(2):225–7 (24 ref.) Comment in: Br J Neurosurg 1996 Oct;10(5):526–7.
The borderlands of the primary tethered cord syndrome. Oakes WJ. **Clin Neurosurg** 1996;43:188–202 (30 ref.)
[The tethered spinal cord: diagnosis and surgical considerations] Roszkowski M, et al. **Pediatr Pol** 1996 Feb; 71(2):135–41 (17 ref.) (Eng. Abstr.) **(Pol)**

ULTRASONOGRAPHY

Prenatal diagnosis of diastematomyelia: case reports and review of the literature. Sepulveda W, et al. **Prenat Diagn** 1997 Feb;17(2):161–5 (11 ref.)

SPINAL ACCESSORY NERVE see **ACCESSORY NERVE**

SPINAL BIFIDA, CLOSED see **SPINA BIFIDA OCCULTA**

SPINAL CANAL

Epidural anaesthesia and spinal haematoma. Wulf H. **Can J Anaesth** 1996 Dec;43(12):1260–71 (103 ref.)
Spinal chondroma of the lumbar tract: case report. Gaetani P, et al. **Surg Neurol** 1996 Dec;46(6):534–9 (32 ref.)

PATHOLOGY

Clinical evaluation of cutaneous lesions of the back: spinal signatures that do not go away. Humphreys RP. **Clin Neurosurg** 1996;43:175–87 (6 ref.)

SPINAL CORD

see related
CORDOTOMY
MOTOR NEURONS
MYELOGRAPHY
Spinal cord stimulation [editorial] Simpson BA. **Br J Neurosurg** 1997 Feb;11(1):5–11 (65 ref.)
Enhanced limb salvage for peripheral vascular disease with the use of spinal cord stimulation. Huber SJ, et al. **W V Med J** 1996 Mar–Apr;92(2):89–91 (14 ref.)

ABNORMALITIES

Toxoplasmosis of the spinal cord in a patient with AIDS: case report and review. Vyas R, et al. **Clin Infect Dis** 1996 Nov;23(5):1061–5 (29 ref.)

ANATOMY & HISTOLOGY

Neuroanatomy of the pain system and of the pathways that modulate pain. Willis WD, et al. **J Clin Neurophysiol** 1997 Jan;14(1):2–31 (393 ref.)

BLOOD SUPPLY

Spinal dural arterio-venous fistula: an underdiagnosed disease? Grandin C, et al. **Acta Neurol Belg** 1997 Mar; 97(1):17–21 (6 ref.)
Treatment of spinal injuries. On relating anatomical facts to clinical practice. Crock HV. **Acta Orthop Scand** 1997 Aug; 68(4):315–8 (13 ref.)
Symptomatic lumbar foraminal epidural varix. Case report and review of the literature. Pekindil G, et al. **Br J Neurosurg** 1997 Apr;11(2):159–60 (11 ref.)
Spine MR angiography. Bowen BC, et al. **Clin Neurosci** 1997; 4(3):165–73 (45 ref.)
The rationale and utility of neurophysiological investigations in clinical monitoring for brain and spinal cord ischaemia during surgery and intensive care. Prior P. **Comput Methods Programs Biomed** 1996 Oct;51(1–2):13–27 (101 ref.)
Pathophysiological classification of human spinal cord ischemia. Castro-Moure F, et al. **J Spinal Cord Med** 1997 Jan;20(1):74–87 (178 ref.)
Isolated stab wound to the artery of Adamkiewicz: case report and review of the literature. Rogers FB, et al. **J Trauma** 1997 Sep;43(3):549–51 (18 ref.)
Vertebrospinal angiography in the evaluation of vertebral and spinal cord disease. Nelson PK, et al. **Neuroimaging Clin N Am** 1996 Aug;6(3):589–605 (61 ref.)
Embolization of spinal dural arteriovenous fistulae: results and follow-up. Niimi Y, et al. **Neurosurgery** 1997 Apr; 40(4):675–82; discussion 682–3 (13 ref.)
[Intravascular lymphomatosis of the nervous system—case report and review of the literature] Heesen C, et al. **Fortschr Neurol Psychiatr** 1996 Jun;64(6):234–41 (104 ref.) (Eng. Abstr.) **(Ger)**
[Surgical approaches to spinal arteriovenous malformations: anatomy and operative methods] Miyamoto S, et al. **No Shinkei Geka** 1997 Feb;25(2):109–15 (30 ref.) **(Jpn)**

CYTOLOGY

The projections to the spinal cord of the ra: during development: a timetable of descent. Lakke EA. **Adv Anat Embryol Cell Biol** 1997;135:I–XIV, 1–143 (456

ref.)
Origins of spinal cord oligodendrocytes: possible developmental and evolutionary relationships with motor neurons. Richardson WD, et al. **Dev Neurosci** 1997; 19(1):58–68 (44 ref.)
Spinal interneurons and preganglionic neurons in sacral autonomic reflex pathways. deGroat WC, et al. **Prog Brain Res** 1996;107:97–111 (90 ref.)
The ventro-medial medullary projections to spinal motoneurons: ultrastructure, transmitters and functional aspects. Holstege JC. **Prog Brain Res** 1996;107:159–81 (167 ref.)

DRUG EFFECTS

Update on spinal cord pharmacology in pain. Eisenach J. **Acta Anaesthesiol Scand Suppl** 1997;110:124–6 (21 ref.)
Spinal actions of nonsteroidal anti-inflammatory drugs [see comments] Cherng CH, et al. **Acta Anaesthesiol Sin** 1996 Jun;34(2):81–8 (55 ref.) Comment in: Acta Anaesthesiol Sin 1996 Jun;34(2):i–ii.
Pharmacology of reticulospinal vasomotor neurons in cardiovascular regulation. Sun MK. **Pharmacol Rev** 1996 Dec;48(4):465–94 (408 ref.)
Serotonin, norepinephrine and associated neuropeptides: effects on somatic motoneuron excitability. White SR, et al. **Prog Brain Res** 1996;107:183–99 (111 ref.)
[Neurotoxicity of intrathecally administrated agents] Malinovsky JM, et al. **Ann Fr Anesth Reanim** 1996; 15(5):647–58 (128 ref.) (Eng. Abstr.) **(Fre)**

EMBRYOLOGY

The projections to the spinal cord of the rat during development: a timetable of descent. Lakke EA. **Adv Anat Embryol Cell Biol** 1997;135:I–XIV, 1–143 (456 ref.)
Diversity and pattern in the developing spinal cord [published erratum appears in Science 1997 Apr 4;276(5309):21] Tanabe Y, et al. **Science** 1996 Nov 15;274(5290):1115–23 (114 ref.)

ENZYMOLOGY

Expression of nitric oxide synthase type II in the spinal cord under conditions producing thermal hyperalgesia. Grzybicki D, et al. **J Chem Neuroanat** 1996 Jun; 10(3–4):221–9 (55 ref.)

METABOLISM

Receptor localization in the mammalian dorsal horn and primary afferent neurons. Coggeshall RE, et al. **Brain Res Brain Res Rev** 1997 Jun;24(1):28–66 (341 ref.)
Studies of the release of immunoreactive galanin and dynorphin A(1–8) in the spinal cord of the rat. Duggan AW, et al. **Prog Brain Res** 1996;110:137–47 (74 ref.)
Acute mechanical hyperalgesia in the rat can be produced by coactivation of spinal ionotropic AMPA and metabotropic glutamate receptors, activation of phospholipase A2 and generation of cyclooxygenase products. Meller ST, et al. **Prog Brain Res** 1996;110:177–92 (69 ref.)

PATHOLOGY

Management of spinal epidural hematoma after tissue plasminogen activator. A case report. Connolly ES Jr, et al. **Spine** 1996 Jul 15;21(14):1694–8 (29 ref.)
Spontaneous thoracic spinal cord herniation. A case report. Sioutos P, et al. **Spine** 1996 Jul 15;21(14):1710–3 (13 ref.)
[Inflammatory diseases of the spinal cord and spinal nerve roots in the MRI] Sartoretti-Schefer S, et al. **Radiologe** 1996 Nov;36(11):897–913 (159 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Endogenous kynurenine derivatives and pain. Weil-Fugazza J. **Adv Exp Med Biol** 1996;398:83–7 (27 ref.)
Exercise pressor reflex: studies on the effect of skeletal muscle fiber type and spinal cord transmission. Wilson LB, et al. **Adv Exp Med Biol** 1995;381:187–97 (34 ref.)
Postural orientation, equilibrium, and the spinal cord. Macpherson JM, et al. **Adv Neurol** 1997;72:227–32 (21 ref.)
Improvement of microcirculatory blood flow under epidural spinal cord stimulation in patients with nonreconstructible peripheral arterial occlusive disease. Claeys LG. **Artif Organs** 1997 Mar;21(3):201–6 (36 ref.)
The activation of bulbo-spinal controls by peripheral nociceptive inputs: diffuse noxious inhibitory controls. Villanueva L, et al. **Biol Res** 1995;28(1):113–25 (96 ref.)
On the translation of directional motor cortical commands to activation of muscles via spinal interneuronal systems. Georgopoulos AP. **Brain Res Cogn Brain Res** 1996 Mar; 3(2):151–5 (23 ref.)
Modulation of corticospinal influence over hand muscles during gripping tasks in man and monkey. Lemon RN, et al. **Can J Physiol Pharmacol** 1996 Apr;74(4):547–58 (67 ref.)
Supraspinal and segmental interactions. McCrea DA. **Can J Physiol Pharmacol** 1996 Apr;74(4):513–7 (50 ref.)
Neuronal progenitors as tools for cell replacement in the nervous system. Brüstle O, et al. **Curr Opin Neurobiol** 1996 Oct;6(5):688–95 (81 ref.)
Escape behavior – brainstem and spinal cord circuitry and function. Korn H, et al. **Curr Opin Neurobiol** 1996 Dec; 6(6):826–32 (50 ref.)
Spinal cord regeneration: a phenomenon unique to urodeles? Chernoff EA. **Int J Dev Biol** 1996 Aug;40(4):823–31 (78 ref.)
Nerve fibre regeneration across the peripheral-central transitional zone. Carlstedt T. **J Anat** 1997 Jan;190 (Pt 1):51–6 (40 ref.)
Central nervous system pathways for pain transmission and pain control: issues relevant to the practicing clinician. Robinson AJ. **J Hand Ther** 1997 Apr–Jun;10(2):64–77 (66 ref.)
Ultrastructural view of central catecholaminergic transmission: immunocytochemical localization of synthesizing enzymes, transporters and receptors. Pickel VM, et al. **J Neurocytol** 1996 Dec;25(12):843–56 (141 ref.)
Intraspinal opioid therapy for chronic nonmalignant pain: current practice and clinical guidelines. Krames ES. **J Pain Symptom Manage** 1996 Jun;11(6):333–52 (78 ref.)
The neuronal network for locomotion in the lamprey spinal cord: evidence for the involvement of commissural interneurons. Buchanan JT, et al. **J Physiol Paris** 1995; 89(4–6):221–33 (54 ref.)
Spinal cord stimulation in severe angina pectoris--presentation of current studies, indications and clinical experience. Eliasson T, et al. **Pain** 1996 May-Jun; 65(2–3):169–79 (137 ref.)
Evidence for a spinal stepping generator in man. Bussel B, et al. **Paraplegia** 1996 Feb;34(2):91–2 (24 ref.)
Involvement of the spino-parabrachio -amygdaloid and -hypothalamic pathways in the autonomic and affective emotional aspects of pain. Bernard JF, et al. **Prog Brain Res** 1996;107:243–55 (80 ref.)
Some principles of the spinal organization of the sympathetic preganglionic outflow. Cabot JB. **Prog Brain Res** 1996; 107:29–42 (81 ref.)
Spinal cord mechanisms of hyperalgesia and allodynia: role of peripheral input from nociceptors. Cervero F. **Prog Brain Res** 1996;113:413–22 (32 ref.)
An ascending general homeostatic afferent pathway originating in lamina I. Craig AD. **Prog Brain Res** 1996; 107:225–42 (78 ref.)
Spinal cord reflex organization of sympathetic systems. Jänig W. **Prog Brain Res** 1996;107:43–77 (131 ref.)
Plasticity of excitatory synaptic transmission in the spinal cord dorsal horn. Randić M. **Prog Brain Res** 1996; 113:463–506 (338 ref.)
On the role of tachykinins and calcitonin gene-related peptide in the spinal mechanisms of nociception and in the induction and maintenance of inflammation-evoked hyperexcitability in spinal cord neurons (with special reference to nociception in joints). Schaible HG. **Prog Brain Res** 1996;113:423–41 (152 ref.)
Neurophysiology of chronic inflammatory pain: electrophysiological recordings from spinal cord neurons in rats with prolonged acute and chronic unilateral inflammation at the ankle. Schaible HG, et al. **Prog Brain Res** 1996;110:167–76 (56 ref.)
Spinal organization of C-fiber afferents related with nociception or non-nociception. Sugiura Y. **Prog Brain Res** 1996;113:320–39 (116 ref.)
Involvement of glutamatergic neurotransmission and protein kinase C in spinal plasticity and the development of chronic pain. Tölle TR, et al. **Prog Brain Res** 1996;110:193–206 (54 ref.)
Slow synaptic transmission in the spinal dorsal horn. Yoshimura M. **Prog Brain Res** 1996;113:443–62 (149 ref.)
Sensori-sensory afferent conditioning with leg movement: gain control in spinal reflex and ascending paths. Brooke JD, et al. **Prog Neurobiol** 1997 Mar;51(4):393–421 (180 ref.)
Primary motor cortex influences on the descending and ascending systems. Canedo A. **Prog Neurobiol** 1997 Feb; 51(3):287–335 (531 ref.)
Transmission of the cortical command for human voluntary movement through cervical propriospinal premotoneurons. Pierrot-Deseilligny E. **Prog Neurobiol** 1996 Mar–Apr; 48(4–5):489–517 (60 ref.)
The spinal cord and its brain: representations and models. To what extent do forebrain mechanisms appear at brainstem spinal cord levels? Windhorst U. **Prog Neurobiol** 1996 Aug;49(5):381–414 (251 ref.)
On the role of recurrent inhibitory feedback in motor control. Windhorst U. **Prog Neurobiol** 1996 Aug;49(6):517–87 (367 ref.)
Regeneration of lesioned corticospinal tract fibers in the adult rat spinal cord under experimental conditions. Schwab ME, et al. **Spinal Cord** 1997 Jul;35(7):469–73 (52 ref.)
Maturation of the mammalian dorsal root entry zone--from entry to no entry. Golding J, et al. **Trends Neurosci** 1997 Jul;20(7):303–8 (53 ref.)
GABA and its receptors in the spinal cord. Malcangio M, et al. **Trends Pharmacol Sci** 1996 Dec;17(12):457–62 (59 ref.)
Spinal control of penile erection. Rampin O, et al. **World J Urol** 1997;15(1):2–13 (181 ref.)
[Spinal neural mechanisms in voluntary movements] Shindo M. **Rinsho Shinkeigaku** 1995 Dec;35(12):1509–11 (7 ref.) (Eng. Abstr.) **(Jpn)**
[Spinal cord: afferent interactions] Pleshchinskii IN, et al. **Fiziol Cheloveka** 1996 Jan–Feb;22(1):123–30 (97 ref.) **(Rus)**

PHYSIOPATHOLOGY

Propriospinal myoclonus. Chokroverty S. **Clin Neurosci** 1995–96;3(4):219–22 (19 ref.)
The pharmacology of excitatory and inhibitory amino acid-mediated events in the transmission and modulation of pain in the spinal cord. Dickenson AH, et al. **Gen Pharmacol** 1997 May;28(5):633–8 (62 ref.)
Does astrocytic glycogen benefit axon function and survival in CNS white matter during glucose deprivation? Ransom BR, et al. **Glia** 1997 Sep;21(1):134–41 (53 ref.)
Growth factors and myelin regeneration in multiple sclerosis. Webster HD. **Mult Scler** 1997 Apr;3(2):113–20 (128 ref.)
Post-sympathectomy neuralgia: hypotheses on peripheral and central neuronal mechanisms [see comments] Kramis RC, et al. **Pain** 1996 Jan;64(1):1–9 (66 ref.) Comment in: Pain 1996 Sep;67(1):218–20. Comment in: Pain 1997 Apr;70(2–3):290–1.
Balances between excitatory and inhibitory events in the spinal cord and chronic pain. Dickenson AH. **Prog Brain Res** 1996;110:225–31 (31 ref.)
The possible role of substance P in eliciting and modulating deep somatic pain. Mense S, et al. **Prog Brain Res** 1996; 110:125–35 (55 ref.)
Neurobiology of spinal nociception: new concepts. Sandkühler J. **Prog Brain Res** 1996;110:207–24 (50 ref.)
The organization and function of endogenous antinociceptive systems. Sandkühler J. **Prog Neurobiol** 1996 Sep; 50(1):49–81 (172 ref.)
Central pain of spinal origin. Bowsher D. **Spinal Cord** 1996 Dec;34(12):707–10 (38 ref.)
Spinal cord stimulation in refractory angina pectoris--clinical results and mechanisms. Oosterga M, et al. **Z Kardiol** 1997; 86 Suppl 1:107–13 (36 ref.)
[Spinal cord trauma: the current concepts of the mechanisms of the damage, regeneration and means for its correction] Grishenkova LN, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1997 Apr–Jun; (2):37–44 (173 ref.) **(Rus)**

RADIATION EFFECTS

Glial-glial and glial-neuronal interfaces in radiation-induced, glia-depleted spinal cord. Gilmore SA, et al. **J Anat** 1997 Jan;190 (Pt 1):5–21 (51 ref.)

SURGERY

Spinal cord surgery and galactorrhea: a case report. Faubion WA, et al. **Am J Obstet Gynecol** 1997 Aug;177(2):465–6 (2 ref.)
Surgical interruption of a midline dorsal column visceral pain pathway. Case report and review of the literature. Nauta HJ, et al. **J Neurosurg** 1997 Mar;86(3):538–42 (20 ref.)
Intraoperative monitoring of motor evoked potentials: a review of 116 cases. Nagle KJ, et al. **Neurology** 1996 Oct; 47(4):999–1004 (32 ref.)
On the dorsal columns: translating basic research hypotheses to the clinic [editorial] Berkley KJ. **Pain** 1997 Apr; 70(2–3):103–7 (35 ref.)
Commissural myelotomy revisited [editorial] Gybels J. **Pain** 1997 Mar;70(1):1–2 (12 ref.)
[Surgical treatment for syringomyelia] Iwasaki Y, et al. **No Shinkei Geka** 1996 Aug;24(8):709–16 (28 ref.) **(Jpn)**

TRANSPLANTATION

Embryonic spinal cord transplants enhance locomotor performance in spinalized newborn rats. Tessler A, et al. **Adv Neurol** 1997;72:291–303 (52 ref.)

ULTRASTRUCTURE

Lesion-induced neuronal reorganization in the spinal cord: morphological aspects. Nacimiento W, et al. **Adv Neurol** 1997;73:37–59 (102 ref.)

SPINAL CORD COMPRESSION

COMPLICATIONS

Spinal cord compression due to concomitant primary lymphoma and Mycobacterium avium-intracellulare infection of the paravertebral muscles in an AIDS patient [letter] Moulignier A, et al. **Eur J Clin Microbiol Infect Dis** 1996 Nov;15(11):891–3 (15 ref.)
Delayed post-traumatic syringohydromyelia after an uncomplicated fracture of the spine: case report and literature review. Güler-Uysal F, et al. **Spinal Cord** 1996 May;34(5):301–4 (14 ref.)
Nonfunctioning malignant paraganglioma of the posterior mediastinum with spinal cord compression. A case report. Noorda RJ, et al. **Spine** 1996 Jul 15;21(14):1703–9 (61 ref.)

DRUG THERAPY

Ketoconazole-induced adrenal crisis in a patient with metastatic prostatic adenocarcinoma: case report and review of the literature. Sarver RG, et al. **Urology** 1997 May;49(5):781–5 (27 ref.)

ETIOLOGY

Spinal canal compromise in Proteus syndrome: case report and review of the literature. Ring D, et al.

Am J Orthop 1997 Apr;26(4):275–8 (14 ref.)

Cervical spinal cord compression in hereditary multiple exostoses. Report of a case and a review of the literature. Mikawa Y, et al. **Arch Orthop Trauma Surg** 1997; 116(1–2):112–5 (18 ref.)

Thoracic spinal cord compression caused by hypophosphataemic rickets: a case report and review of the world literature. Dunlop DJ, et al. **Eur Spine J** 1996; 5(4):272–4 (7 ref.)

Comparison of neurologic deficits with atlanto–dens intervals in patients with Down syndrome. Ferguson RL, et al. **J Spinal Disord** 1997 Jun;10(3):246–52 (30 ref.)

Acute spontaneous spinal epidural hematoma––a life–threatening emergency. Rahman NU, et al. **JPMA J Pak Med Assoc** 1997 May;47(5):148–50 (17 ref.)

Spinal cord compression from metastatic Leydig's cell tumor of the testis: case report. Sawin PD, et al. **Neurosurgery** 1996 Feb;38(2):407–11 (53 ref.)

Unusual case of inflammatory spinal epidural mass (Castleman syndrome). Alper G, et al. **Pediatr Neurol** 1996 Jul;15(1):60–2 (15 ref.)

Spinal epidural non–Hodgkin's lymphoma: case reports of three patients presenting with spinal cord compression. Lim CC, et al. **Singapore Med J** 1996 Oct;37(5):497–500 (19 ref.)

Cervical myelopathy caused by the anomalous vertebral artery. A case report. Furumoto T, et al. **Spine** 1996 Oct 1;21(19):2280–3 (7 ref.)

[Thoracic spondylotic myelopathies. Apropos of 4 new cases] Stecken J, et al. **Neurochirurgie** 1996;42(3):147–52 (40 ref.) (Eng. Abstr.) **(Fre)**

[Spinal cord compression of sarcoidosis origin: a case] Tieulie N, et al. **Rev Med Interne** 1997 Jul;18(7):578–81 (18 ref.) (Eng. Abstr.) **(Fre)**

[Spinal cord compression by extramedullary hematopoiesis in thalassemia major] Müller–Lisse GU, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Nov;165(5):505–7 (8 ref.) **(Ger)**

[Chondromyxoid fibroma of the thoracic spine: a case report and review of the literature] Leal Filho MB, et al. **Arq Neuropsiquiatr** 1995 Dec;53(4):837–40 (12 ref.) (Eng. Abstr.) **(Por)**

PHYSIOPATHOLOGY

[Left hand clumsiness due to disturbance of kinesthesia after damage to the dorsal column of the high cervical cord] Hashimoto R, et al. **Rinsho Shinkeigaku** 1997 Apr; 37(4):319–25 (22 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Epidural lipomatosis: case report and literature review. Hierholzer J, et al. **Neuroradiology** 1996 May;38(4):343–8 (25 ref.)

SURGERY

Spinal epidural abscess––review of 10 cases. Tacconi L, et al. **Acta Neurochir (Wien)** 1996;138(5):520–3 (17 ref.)

Operative treatment of spontaneous spinal epidural hematomas: a study of the factors determining postoperative outcome. Groen RJ, et al. **Neurosurgery** 1996 Sep;39(3):494–508; discussion 508–9 (22 ref.)

Idiopathic spinal epidural lipomatosis. Robertson SC, et al. **Neurosurgery** 1997 Jul;41(1):68–74; discussion 74–5 (41 ref.)

Extradural tethering effect as one mechanism of radiculopathy complicating posterior decompression of the cervical spinal cord [see comments] Tsuzuki N, et al. **Spine** 1996 Jan 15;21(2):203–11 (14 ref.) Comment in: Spine 1996 Aug 1;21(15):1839–40.

SPINAL CORD DISEASES

Central nervous system abscesses due to Coccidioides species. Bañuelos AF, et al. **Clin Infect Dis** 1996 Feb;22(2):240–50 (26 ref.)

Spinal cord syndromes. Wagner R, et al. **Emerg Med Clin North Am** 1997 Aug;15(3):699–711 (56 ref.)

CHEMICALLY INDUCED

Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Wagstaff AJ, et al. **Drugs** 1997 Mar;53(3):435–52 (112 ref.)

Spinal cord toxicity of epidural and subarachnoid analgesics. Abram SE. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):84–8 (44 ref.)

COMPLICATIONS

Central pain of spinal origin. Bowsher D. **Spinal Cord** 1996 Dec;34(12):707–10 (38 ref.)

DIAGNOSIS

Thoracic intraspinal Paracoccidioidomycosis. Case report. Pacheco RA, et al. **Arq Neuropsiquiatr** 1996 Sep; 54(3):474–8 (10 ref.)

Spine MR angiography. Bowen BC, et al. **Clin Neurosci** 1997; 4(3):165–73 (45 ref.)

The rationale and utility of neurophysiological investigations in clinical monitoring for brain and spinal cord ischaemia during surgery and intensive care. Prior P. **Comput Methods Programs Biomed** 1996 Oct;51(1–2):13–27 (101 ref.)

Spinal cord herniation: report of two cases and review of the literature. Uchino A, et al. **Eur Radiol** 1997;7(2):289–92 (11 ref.)

Use of gadolinium chelates in MR imaging of the spine. Bradley WG. **J Magn Reson Imaging** 1997 Jan–Feb; 7(1):38–46 (24 ref.)

Spinal cord lesions in patients with AIDS. Quencer RM, et al. **Neuroimaging Clin N Am** 1997 May;7(2):359–73 (14 ref.)

Diagnostic imaging of infections and neoplasms affecting the spine in patients with AIDS. Thurnher MM, et al. **Neuroimaging Clin N Am** 1997 May;7(2):341–57 (86 ref.)

Brain and spine imaging findings in AIDS patients. Provenzale JM, et al. **Radiol Clin North Am** 1997 Sep; 35(5):1127–66 (146 ref.)

Low–grade spinal epidural infection. Report of a case. Berthelot JM, et al. **Rev Rhum Engl Ed** 1996 Jan; 63(1):59–61 (17 ref.)

Intraradicular, intervertebral disc herniation. A case report. Finkel HZ. **Spine** 1997 May 1;22(9):1028–9 (8 ref.)

Spontaneous thoracic spinal cord herniation. A case report. Sioutos P, et al. **Spine** 1996 Jul 15;21(14):1710–3 (13 ref.)

[Thoracic medullary epidermoid cyst. Apropos of a case with MRI and review of the literature] Elazhari A, et al. **Neurochirurgie** 1996;42(6):309–11 (10 ref.) (Eng. Abstr.) **(Fre)**

[Diagnosis and treatment of thoracic myelopathy] Fujimura Y. **Nippon Seikeigeka Gakkai Zasshi** 1997 Feb;71(2):91–105 (30 ref.) **(Jpn)**

DRUG THERAPY

Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Wagstaff AJ, et al. **Drugs** 1997 Mar;53(3):435–52 (112 ref.)

ETIOLOGY

Synovial cyst and degeneration of the transverse ligament: an unusual cause of high cervical myelopathy. Case report. Fransen P, et al. **J Neurosurg** 1997 Jun;86(6):1027–30 (17 ref.)

Dural arteriovenous fistula of the spinal cord: an uncommon cause of myelopathy. Wityk RJ. **Semin Neurol** 1996 Mar; 16(1):27–32 (29 ref.)

Spinal cord dysfunction caused by non–traumatic hematomyelia. Karavelis A, et al. **Spinal Cord** 1996 May; 34(5):268–71 (20 ref.)

[Peripheral nerve and spinal cord complication in intravenous heroin addiction] Bernasconi A, et al. **Rev Neurol (Paris)** 1996 Nov;152(11):688–94 (53 ref.) (Eng. Abstr.) **(Fre)**

PARASITOLOGY

[Hydatid cyst of the spine and spinal cord. Study of 24 cases] Sami A, et al. **Neurochirurgie** 1996;42(6):281–7 (36 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Neuroschistosomiasis. Pittella JE. **Brain Pathol** 1997 Jan; 7(1):649–62 (134 ref.)

[Symptoms and pathological anatomy of the degenerative cervical spine] Ohwada T, et al. **Orthopade** 1996 Nov; 25(6):496–504 (31 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Vertebrospinal angiography in the evaluation of vertebral and spinal cord disease. Nelson PK, et al. **Neuroimaging Clin N Am** 1996 Aug;6(3):589–605 (61 ref.)

SURGERY

Magnetic resonance imaging of the postoperative spine. Genant HK. **Instr Course Lect** 1994;43:471–3 (12 ref.)

Idiopathic spinal epidural lipomatosis. Robertson SC, et al. **Neurosurgery** 1997 Jul;41(1):68–74; discussion 74–5 (41 ref.)

[Anterior and antero–lateral surgery of the lower cervical spine (25 years after H. Verbiest). 2: Indications, results, complications)] Brunon J, et al. **Neurochirurgie** 1996; 42(4–5):229–48 (93 ref.) (Eng. Abstr.) **(Fre)**

[Surgical therapy of spondylogenic cervical myelopathy. Indications and techniques] Hohmann D, et al. **Orthopade** 1996 Nov;25(6):558–66 (51 ref.) (Eng. Abstr.) **(Ger)**

[The dorsal approach in degeneratively changed cervical spine] Yonenobu K, et al. **Orthopade** 1996 Nov;25(6):533–41 (34 ref.) (Eng. Abstr.) **(Ger)**

[Diagnosis and treatment of thoracic myelopathy] Fujimura Y. **Nippon Seikeigeka Gakkai Zasshi** 1997 Feb;71(2):91–105 (30 ref.) **(Jpn)**

[A case of idiopathic spinal cord herniation] Matsumura T, et al. **Rinsho Shinkeigaku** 1996 Apr;36(4):566–70 (15 ref.) (Eng. Abstr.) **(Jpn)**

VETERINARY

Conditions of the lumbosacral spinal cord and cauda equina. Ferguson HR. **Semin Vet Med Surg (Small Anim)** 1996 Nov; 11(4):254–8 (15 ref.)

Conditions of the thoracolumbar spine. Seim HB 3rd. **Semin Vet Med Surg (Small Anim)** 1996 Nov;11(4):235–53 (24 ref.)

Postanesthetic hemorrhagic myelopathy or myelomalacia. Trim CM. **Vet Clin North Am Equine Pract** 1997 Apr; 13(1):73–7 (23 ref.)

SPINAL CORD INJURIES

Isolated stab wound to the artery of Adamkiewicz: case report and review of the literature. Rogers FB, et al. **J Trauma** 1997 Sep;43(3):549–51 (18 ref.)

CLASSIFICATION

Athletes with cervical spine injury. Maroon JC, et al. **Spine** 1996 Oct 1;21(19):2294–9 (21 ref.)

COMPLICATIONS

Spinal cord injury rehabilitation. 2. Medical complications. Bergman SB, et al. **Arch Phys Med Rehabil** 1997 Mar;78(3 Suppl):S53–8 (100 ref.)

Autonomic dysreflexia: pharmacological management of hypertensive crises in spinal cord injured patients. Naftchi NE, et al. **J Spinal Cord Med** 1997 Jul;20(3):355–60 (34 ref.)

The use of urine cytology for diagnosing bladder cancer in spinal cord injured patients [see comments] Stonehill WH, et al. **J Urol** 1997 Jun;157(6):2112–4 (12 ref.) Comment in: J Urol 1997 Jun;157(6):2115.

Pain following spinal cord injury: the clinical problem and experimental studies. Yezierski RP. **Pain** 1996 Dec; 68(2–3):185–94 (76 ref.)

Major risk factors for pressure ulcers in the spinal cord disabled: a literature review. Byrne DW, et al. **Spinal Cord** 1996 May;34(5):255–63 (190 ref.)

Prevention of urinary tract infection in patients with spinal cord injury––a microbiological review. Galloway A. **Spinal Cord** 1997 Apr;35(4):198–204 (87 ref.)

Classification of pain following spinal cord injury. Siddall PJ, et al. **Spinal Cord** 1997 Feb;35(2):69–75 (44 ref.)

Spine update. Urological management in patients with spinal cord injuries. Nygaard IE, et al. **Spine** 1996 Jan 1; 21(1):128–32 (18 ref.)

[Prevention of sterility in spinal cord injured men] Tollon C, et al. **Prog Urol** 1997 Apr;7(2):203–8 (43 ref.) (Eng. Abstr.) **(Fre)**

[Bladder cancer in patients with spinal cord injury: report of two cases] Sugimoto K, et al. **Hinyokika Kiyo** 1997 May; 43(5):359–62 (22 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Development of the NMDA ion–channel blocker, aptiganel hydrochloride, as a neuroprotective agent for acute CNS injury. McBurney RN. **Int Rev Neurobiol** 1997;40:173–95 (28 ref.)

Gene therapy for central nervous system injury: the use of cationic liposomes: an invited review. Yang K, et al. **J Neurotrauma** 1997 May;14(5):281–97 (118 ref.)

Pharmacological management of spinal cord injury: current status of drugs designed to augment functional recovery of the injured human spinal cord. Greene KA, et al. **J Spinal Disord** 1996 Oct;9(5):355–66 (130 ref.)

Clinical applications of pharmacologic therapies for spinal cord injury. Zeidman SM, et al. **J Spinal Disord** 1996 Oct; 9(5):367–80 (72 ref.)

Effect of a single huge dose of methylprednisolone on blood flow, evoked potentials, and histology after acute spinal cord injury in the rat. Koyanagi I, et al. **Neurol Res** 1997 Jun;19(3):289–99 (49 ref.)

ECONOMICS

Functional outcomes in spinal cord injury (SCI): quality care versus cost containment. Ditunno JF Jr. **J Spinal Cord Med** 1997 Jan;20(1):1–7 (36 ref.)

ETIOLOGY

Spinal injuries in the pediatric age group: a review of 82 cases of spinal cord and vertebral column injuries. Turgut M, et al. **Eur Spine J** 1996;5(3):148–52 (31 ref.)

Unique management needs of pediatric spinal cord injury patients: etiology and pathophysiology. Vogel LC. **J Spinal Cord Med** 1997 Jan;20(1):10–3 (31 ref.)

Chiari I malformation and spinal cord injury: cause for concern in contact athletes? Callaway GH, et al. **Med Sci Sports Exerc** 1996 Oct;28(10):1218–20 (17 ref.)

New and future approaches for spinal cord protection. Svensson LG. **Semin Thorac Cardiovasc Surg** 1997 Jul; 9(3):206–21 (104 ref.)

[Spinal cord trauma: the current concepts of the mechanisms of the damage, regeneration and means for its correction] Grishenkova LN, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1997 Apr–Jun; (2):37–44 (173 ref.) **(Rus)**

IMMUNOLOGY

Immune system–neuroendocrine dysregulation in spinal cord injury. Cruse JM, et al. **Immunol Res** 1996;15(4):306–14 (46 ref.)

Concept of autoimmunity following spinal cord injury: possible roles for T lymphocytes in the traumatized central nervous system. Popovich PG, et al. **J Neurosci Res** 1996 Aug 15;45(4):349–63 (120 ref.)

SPINAL CORD INJURIES

PATHOLOGY

Long-term changes in spinal motor neurons after injury. Bowe CM, et al. **Adv Neurol** 1997;72:201–17 (86 ref.)

Neuropathology of human spinal cord injury. Croul SE, et al. **Adv Neurol** 1997;72:317–23 (31 ref.)

Update on the pathophysiology and pathology of acute spinal cord injury. Tator CH. **Brain Pathol** 1995 Oct;5(4):407–13 (46 ref.)

Regeneration of immature mammalian spinal cord after injury. Nicholls J, et al. **Trends Neurosci** 1996 Jun; 19(6):229–34 (56 ref.)

PHYSIOPATHOLOGY

Modification of urinary bladder function after spinal cord injury. de Groat WC, et al. **Adv Neurol** 1997;72:347–64 (65 ref.)

Motor control physiology below spinal cord injury: residual volitional control of motor units in paretic and paralyzed muscles. Dimitrijevic MR, et al. **Adv Neurol** 1997;72:335–45 (32 ref.)

Neurological assessment in spinal cord injury. Ditunno JF Jr, et al. **Adv Neurol** 1997;72:325–33 (53 ref.)

Strategies and mechanisms of recovery after spinal cord injury. Murray M. **Adv Neurol** 1997;72:219–25 (43 ref.)

Neurogenic bowel dysfunction after spinal cord injury: clinical evaluation and rehabilitative management. Stiens SA, et al. **Arch Phys Med Rehabil** 1997 Mar;78(3 Suppl):S86–102 (131 ref.)

Update on the pathophysiology and pathology of acute spinal cord injury. Tator CH. **Brain Pathol** 1995 Oct;5(4):407–13 (46 ref.)

SCIWORA (spinal cord injury without radiographic abnormality) in infants and children. Kriss VM, et al. **Clin Pediatr (Phila)** 1996 Mar;35(3):119–24 (18 ref.)

The child with a spinal cord injury. Vogel L, et al. **Dev Med Child Neurol** 1997 Mar;39(3):202–7 (82 ref.)

Management of pain in persons with spinal cord injury. Ragnarsson KT. **J Spinal Cord Med** 1997 Apr;20(2):186–99 (79 ref.)

Experimental and clinical studies of the pathophysiology and management of acute spinal cord injury. Tator CH. **J Spinal Cord Med** 1996 Oct;19(4):206–14 (87 ref.)

Role of fibroblast growth factors in neural trauma. Cuevas P, et al. **Neurol Res** 1997 Jun;19(3):254–6 (24 ref.)

Neurotransmission by neurons that use serotonin, noradrenaline, glutamate, glycine, and gamma-aminobutyric acid in the normal and injured spinal cord. Shapiro S. **Neurosurgery** 1997 Jan;40(1):168–76; discussion 177 (109 ref.)

Regeneration of injured axons in the adult mammalian central nervous system. Tatagiba M, et al. **Neurosurgery** 1997 Mar; 40(3):541–6; discussion 546–7 (45 ref.)

Male fertility following spinal cord injury: facts and fiction. Brackett NL, et al. **Phys Ther** 1996 Nov;76(11):1221–31 (95 ref.)

Locomotion in patients with spinal cord injuries. Dietz V, et al. **Phys Ther** 1997 May;77(5):508–16 (52 ref.)

Sensory deprivation in spinal cord injury—an essay. Crossman MW. **Spinal Cord** 1996 Oct;34(10):573–7 (28 ref.)

Thermoregulation in spinal cord injury: the challenge of the Atlanta Paralympics. McCann BC. **Spinal Cord** 1996 Jul; 34(7):433–6 (19 ref.)

Sexuality and women with complete spinal cord injury. Whipple B, et al. **Spinal Cord** 1997 Mar;35(3):136–8 (22 ref.)

Body composition of spinal cord injured adults. Kocina P. **Sports Med** 1997 Jan;23(1):48–60 (87 ref.)

Sensorimotor stimulation to improve locomotor recovery after spinal cord injury. Muir GD, et al. **Trends Neurosci** 1997 Feb;20(2):72–7 (60 ref.)

PREVENTION & CONTROL

New and future approaches for spinal cord protection. Svensson LG. **Semin Thorac Cardiovasc Surg** 1997 Jul; 9(3):206–21 (104 ref.)

PSYCHOLOGY

Spinal cord injury rehabilitation. 4. Individual experience, personal adaptation, and social perspectives. Stiens SA, et al. **Arch Phys Med Rehabil** 1997 Mar;78(3 Suppl):S65–72 (97 ref.)

Depression following a spinal cord injury. Boekamp JR, et al. **Int J Psychiatry Med** 1996;26(3):329–49 (97 ref.)

Unique management needs of pediatric spinal cord injury patients: psychosocial issues. Anderson CJ. **J Spinal Cord Med** 1997 Jan;20(1):21–4 (35 ref.)

Sexuality and women with complete spinal cord injury. Whipple B, et al. **Spinal Cord** 1997 Mar;35(3):136–8 (22 ref.)

RADIOGRAPHY

SCIWORA (spinal cord injury without radiographic abnormality) in infants and children. Kriss VM, et al. **Clin Pediatr (Phila)** 1996 Mar;35(3):119–24 (18 ref.)

REHABILITATION

Rehabilitation challenges in craniospinal injury: two case reports. Nam AM, et al. **Ann Acad Med Singapore** 1996 Nov;25(6):873–7 (19 ref.)

Spinal cord injury rehabilitation. 2. Medical complications. Bergman SB, et al. **Arch Phys Med Rehabil** 1997 Mar;78(3 Suppl):S53–8 (100 ref.)

Spinal cord injury rehabilitation. 5. Through the lifespan. Cawley MF, et al. **Arch Phys Med Rehabil** 1997 Mar;78(3 Suppl):S73–8 (75 ref.)

Spinal cord injury rehabilitation. 3. Functional outcomes. Formal CS, et al. **Arch Phys Med Rehabil** 1997 Mar;78(3 Suppl):S59–64 (58 ref.)

Spinal cord injury rehabilitation. 4. Individual experience, personal adaptation, and social perspectives. Stiens SA, et al. **Arch Phys Med Rehabil** 1997 Mar;78(3 Suppl):S65–72 (97 ref.)

Spinal cord injury rehabilitation. 1. Assessment and management during acute care. Yarkony GM, et al. **Arch Phys Med Rehabil** 1997 Mar;78(3 Suppl):S48–52 (43 ref.)

Effect of long-term implanted nerve cuff electrodes on the electrophysiological properties of human sensory nerves. Slot PJ, et al. **Artif Organs** 1997 Mar;21(3):207–9 (7 ref.)

Unique management needs of pediatric spinal cord injury patients: orthopedic problems in the child with spinal cord injury. Betz RR. **J Spinal Cord Med** 1997 Jan;20(1):14–6 (15 ref.)

Orthostatic hypotension in spinal cord injured patients. Blackmer J. **J Spinal Cord Med** 1997 Apr;20(2):212–7 (46 ref.)

Unique management needs of pediatric spinal cord injury patients: rehabilitation. Mulcahey MJ. **J Spinal Cord Med** 1997 Jan;20(1):25–30 (49 ref.)

Unique management needs of pediatric spinal cord injury patients: medical issues. Vogel LC. **J Spinal Cord Med** 1997 Jan;20(1):17–20 (49 ref.)

Transcutaneous functional neuromuscular stimulation of certain traumatic complete thoracic paraplegics for independent short-distance ambulation. Graupe D, et al. **Neurol Res** 1997 Jun;19(3):323–33 (16 ref.)

[Prognosis of traumatic spinal cord lesions. Significance of clinical and electrophysiological findings] Curt A, et al. **Nervenarzt** 1997 Jun;68(6):485–95 (154 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Fetal neural grafts and repair of the injured spinal cord. Anderson DK, et al. **Brain Pathol** 1995 Oct;5(4):451–57 (58 ref.)

Trauma systems and the neurosurgeon. Brain Trauma Foundation. **J Neurotrauma** 1996 Nov;13(11):647–51 (13 ref.)

[Motor neurons regenerate axons after CNS-injury. Surgery in cases of rotavulsion restore motor functions] Cullheim S, et al. **Lakartidningen** 1996 Dec 4;93(49):4537–41 (20 ref.) **(Swe)**

THERAPY

Intervention strategies to enhance anatomical plasticity and recovery of function after spinal cord injury. Bregman BS, et al. **Adv Neurol** 1997;72:257–75 (78 ref.)

Therapeutic approaches to spinal cord injury. Faden AI. **Adv Neurol** 1997;72:377–86 (111 ref.)

Recovery of walking after spinal cord injury. Ladouceur M, et al. **Adv Neurol** 1997;72:249–55 (33 ref.)

Strategies and mechanisms of recovery after spinal cord injury. Murray M. **Adv Neurol** 1997;72:219–25 (43 ref.)

Embryonic spinal cord transplants enhance locomotor performance in spinalized newborn rats. Tessler A, et al. **Adv Neurol** 1997;72:291–303 (52 ref.)

Ex vivo gene therapy for Alzheimer's disease and spinal cord injury. Blesch A, et al. **Clin Neurosci** 1995–96;3(5):268–74 (51 ref.)

The child with a spinal cord injury. Vogel L, et al. **Dev Med Child Neurol** 1997 Mar;39(3):202–7 (82 ref.)

The management of acute spinal trauma: prehospital and in-hospital emergency care. Vaccaro AR, et al. **Instr Course Lect** 1997;46:113–25 (59 ref.)

Emergency department approach to acute thoracolumbar spine injury. Savitsky E, et al. **J Emerg Med** 1997 Jan–Feb; 15(1):49–60 (72 ref.)

Neural signals for command control and feedback in functional neuromuscular stimulation: a review. Hoffer JA, et al. **J Rehabil Res Dev** 1996 Apr;33(2):145–57 (48 ref.)

Experimental and clinical studies of the pathophysiology and management of acute spinal cord injury. Tator CH. **J Spinal Cord Med** 1996 Oct;19(4):206–14 (87 ref.)

Urinary bladder control by electrical stimulation: review of electrical stimulation techniques in spinal cord injury. Rijkhoff NJ, et al. **Neurourol Urodyn** 1997;16(1):39–53 (82 ref.)

The International Spinal Research Trust's strategic approach to the development of treatments for the repair of spinal cord injury. Harper GP, et al. **Spinal Cord** 1996 Aug; 34(8):449–59 (57 ref.)

Treatment of patients with spinal cord lesions in Germany 1996—state of the art. Meinecke FW, et al. **Spinal Cord** 1997 Jul;35(7):411–4 (8 ref.)

Athletes with cervical spine injury. Maroon JC, et al. **Spine** 1996 Oct 1;21(19):2294–9 (21 ref.)

VETERINARY

The pathophysiology of spinal cord injury and its clinical implications. Kraus KH. **Semin Vet Med Surg (Small Anim)** 1996 Nov;11(4):201–7 (42 ref.)

SPINAL CORD NEOPLASMS

Intramedullary subependymoma of the spinal cord [see comments] Jallo GI, et al. **Neurosurgery** 1996 Feb; 38(2):251–7 (27 ref.) Comment in: Neurosurgery 1996 Oct;39(4):879.

Intramedullary teratoma: case report and review of the literature. Caruso R, et al. **Tumori** 1996 Nov–Dec; 82(6):616–20 (34 ref.)

COMPLICATIONS

A case of Cobb syndrome associated with lymphangioma circumscriptum. Shim JH, et al. **Dermatology** 1996; 193(1):45–7 (11 ref.)

[Chondromyxoid fibroma of the thoracic spine: a case report and review of the literature] Leal Filho MB, et al. **Arq Neuropsiquiatr** 1995 Dec;53(4):837–40 (12 ref.) (Eng. Abstr.) **(Por)**

DIAGNOSIS

Spinal meningiomas in pregnancy: report of two cases and review of the literature. Cioffi F, et al. **Eur J Gynaecol Oncol** 1996;17(5):384–8 (40 ref.)

Giant spinal cord ependymoma in a child. Case report. Gangemi M, et al. **J Neurosurg Sci** 1996 Mar;40(1):71–5 (23 ref.)

A serial CT scan and MRI verification of diffuse cerebrospinal gliomatosis: a case report with stereotactic diagnosis and radiological confirmation. Onal C, et al. **Pediatr Neurosurg** 1996 Aug;25(2):94–9 (50 ref.)

[Sacrococcygeal chordoma simulating pilonidal cyst] Del Buono G, et al. **Minerva Chir** 1997 Jan–Feb;52(1–2):131–7 (30 ref.) (Eng. Abstr.) **(Ita)**

[Intramedullary cervical neurinoma. A case report and review of the literature] Innocenzi G, et al. **Minerva Chir** 1997 May;52(5):679–82 (15 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Intraspinal high-grade astrocytoma in a child--rationale for chemotherapy and more intensive radiotherapy? Weiss E, et al. **Childs Nerv Syst** 1997 Feb;13(2):108–12 (42 ref.)

GENETICS

[Familial multiple cavernous angioma in the brain and spinal cord] Kimura T, et al. **No To Shinkei** 1996 Oct;48(10):955–9 (21 ref.) (Eng. Abstr.) **(Jpn)**

NURSING

Transoral resection of spinal cord tumors and posterior cervical spine stabilization. Walton PG, et al. **AORN J** 1997 Jan;65(1):48–50, 52–9, 62–8; quiz 69–74 (45 ref.)

PATHOLOGY

Spinal intradural extramedullary cavernous angiomas: report of four cases and review of the literature. Rao GP, et al. **Br J Neurosurg** 1997 Jun;11(3):228–32 (17 ref.)

Primary melanocytomas of the spinal cord: a report of seven cases. Glick R, et al. **Clin Neuropathol** 1997 May–Jun; 16(3):127–32 (11 ref.)

[Intracranial dissemination of intramedullary malignant glioma. Report of a pediatric case] Orejón de Luna G, et al. **An Esp Pediatr** 1996 Sep;45(3):293–5 (23 ref.) **(Spa)**

RADIOTHERAPY

Radiotherapy in recurrent malignant meningiomas with multiple spinal manifestations. Schiebe ME, et al. **Acta Oncol** 1997;36(1):88–90 (18 ref.)

SURGERY

Transoral resection of spinal cord tumors and posterior cervical spine stabilization. Walton PG, et al. **AORN J** 1997 Jan;65(1):48–50, 52–9, 62–8; quiz 69–74 (45 ref.)

Intraparenchymal schwannomas of the central nervous system: an additional case report and review. Beşkonakli E, et al. **Neurosurg Rev** 1997;20(2):139–44 (62 ref.)

Pediatric intracranial hemangioendotheliomas: case report. Chen TC, et al. **Neurosurgery** 1997 Feb;40(2):410–4 (22 ref.)

Intramedullary neuroma of the cervical spinal cord: case report. Melancia JL, et al. **Neurosurgery** 1996 Sep; 39(3):594–8 (45 ref.)

Intraspinal meningiomas: review of 54 cases with discussion of poor prognosis factors and modern therapeutic management. Roux FX, et al. **Surg Neurol** 1996 Nov; 46(5):458–63; discussion 463–4 (28 ref.)

[Progresses in neurosurgery in China, 1996] Zhao Y. **Chung Hua I Hsueh Tsa Chih** 1996 Dec;76(12):900–2 (0 ref.) **(Chi)**

ULTRASONOGRAPHY

Sonographic detection of lipomyelomeningocele: a retrospective documentation. Chreston J, et al. **J Clin Ultrasound** 1997 Jan;25(1):50–1 (5 ref.)

VETERINARY

Surgical conditions of the cervical spine. Tomlinson J. **Semin Vet Med Surg (Small Anim)** 1996 Nov;11(4):225–34 (28 ref.)

SPINAL DISEASES

Diagnostic and classification criteria, clinical and functional assessment, and therapeutic advances for spondyloarthropathies. Olivieri I, et al. **Curr Opin Rheumatol** 1997 Jul;9(4):284–90 (85 ref.)

Spine update. Administrative databases in spine research. Faciszewski T. **Spine** 1997 Jun 1;22(11):1270–5 (35 ref.)

Spine update. Clinical pathways. Ibarra VL. **Spine** 1997 Feb 1;22(3):352–7 (11 ref.)

[Rigid spine syndrome] Yonesaka S. **Ryoikibetsu Shokogun Shirizu** 1996;(15):339–41 (16 ref.) **(Jpn)**

CHEMICALLY INDUCED

[Spinal para-medullary conduction anesthesia in therapy with anticoagulant drugs] Hesse T, et al. **Anaesthesiol Reanim** 1996;21(5):116–21 (74 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Anesthetic implications of chronic disease of the cervical spine. Popitz MD. **Anesth Analg** 1997 Mar;84(3):672–83 (78 ref.)

Transient paraparesis after postdural puncture spinal hematoma in a patient receiving ketorolac. Gerancher JC, et al. **Anesthesiology** 1997 Feb;86(2):490–4 (26 ref.)

Back pain in children. Hollingworth P. **Br J Rheumatol** 1996 Oct;35(10):1022–8 (64 ref.)

Back pain: can we make a contribution? [editorial] Cook GJR, et al. **Eur J Nucl Med** 1997 Apr;24(4):363–7 (41 ref.)

Painful scoliosis. Hoeffel C, et al. **Klin Padiatr** 1997 Mar–Apr; 209(2):78–83 (6 ref.)

Charcot spinal arthropathy in congenital insensitivity to pain. Igram CM, et al. **Orthopedics** 1996 Mar;19(3):251–55 (44 ref.)

[Headache and the cervical spine. A critical review] Pöllmann W, et al. **Nervenarzt** 1996 Oct;67(10):821–36 (202 ref.) (Eng. Abstr.) **(Ger)**

[Rigid spine syndrome associated with marked hypoxemia and hypercapnia] Toh Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 May; 34(5):605–9 (10 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Shadows of the truth in patients with spinal pain: a review. Giles LG, et al. **Can J Psychiatry** 1997 Feb;42(1):44–8 (80 ref.)

Radiologic interpretation of vacuum phenomena. Balkissoon AR. **Crit Rev Diagn Imaging** 1996 Oct;37(5):435–60 (25 ref.)

Spinal epidural abscess: the nurse's role in early detection and intervention. Hoppe B. **Heart Lung** 1996 Nov–Dec; 25(6):463–6 (34 ref.)

The anatomical basis for spinal pain syndromes. Bogduk N. **J Manipulative Physiol Ther** 1995 Nov–Dec;18(9):603–5 (27 ref.)

Diagnosis and indications for elective spinal surgery. McGuire RA Jr. **J South Orthop Assoc** 1996 Fall; 5(3):213–20 (20 ref.)

Solid variant of an aneurysmal bone cyst (giant cell reparative granuloma) of the 3rd lumbar vertebra. Sato K, et al. **Nagoya J Med Sci** 1996 Dec;59(3–4):159–65 (22 ref.)

Diagnostic imaging of infections and neoplasms affecting the spine in patients with AIDS. Thurnher MM, et al. **Neuroimaging Clin N Am** 1997 May;7(2):341–57 (86 ref.)

Diagnostic and therapeutic spinal arthroscopy. Kambin P. **Neurosurg Clin N Am** 1996 Jan;7(1):65–76 (49 ref.)

Epidural lipomatosis with lumbar radiculopathy in one obese patient. Case report and review of the literature. Qasho R, et al. **Neurosurg Rev** 1997;20(3):206–9 (28 ref.)

Candida osteomyelitis and disc space infection of the lumbar spine. Munk PL, et al. **Skeletal Radiol** 1997 Jan;26(1):42–6 (17 ref.)

[Vertebral pain in advanced age: radiological diagnosis] Zanetti M, et al. **Schweiz Rundsch Med Prax** 1996 Oct 22; 85(43):1360–72 (29 ref.) (Eng. Abstr.) **(Ger)**

[Diagnostic problems and prophylaxis of paraoccupational diseases of the spine] Iżycki J. **Med Pr** 1996;47(6):651–5 (31 ref.) (Eng. Abstr.) **(Pol)**

EPIDEMIOLOGY

Predisposing factors to spondyloarthropathies. Brown M, et al. **Curr Opin Rheumatol** 1997 Jul;9(4):308–14 (91 ref.)

ETIOLOGY

Epidural lipomatosis not induced by corticosteroid therapy. Three cases including one in a patient with primary Cushing's disease (review of the literature). Benamou PH, et al. **Rev Rhum Engl Ed** 1996 Mar;63(3):207–12 (18 ref.)

Intrathecal granuloma after implantation of a morphine pump: case report and review of the literature. Bejjani GK, et al. **Surg Neurol** 1997 Sep;48(3):288–91 (23 ref.)

[Spinal pseudarthroses] Räber D, et al. **Orthopade** 1996 Sep; 25(5):435–40 (53 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Predisposing factors to spondyloarthropathies. Brown M, et al. **Curr Opin Rheumatol** 1997 Jul;9(4):308–14 (91 ref.)

IMMUNOLOGY

Pathogenic role of gut inflammation in the spondyloarthropathies. Gaston JS. **Curr Opin Rheumatol** 1997 Jul;9(4):302–7 (62 ref.)

MICROBIOLOGY

Clinical, bacteriological, and serological aspects of Klebsiella infections and their spondylarthropathic sequelae. Sahly H, et al. **Clin Diagn Lab Immunol** 1997 Jul;4(4):393–9 (104 ref.)

Vertebral osteomyelitis due to Capnocytophaga species in immunocompetent patients: report of two cases and review. Duong M, et al. **Clin Infect Dis** 1996 Jun;22(6):1099–101 (15 ref.)

PARASITOLOGY

[Hydatid cyst of the spine and spinal cord. Study of 24 cases] Sami A, et al. **Neurochirurgie** 1996;42(6):281–7 (36 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Fibrous dysplasia of the spine with sarcomatous transformation: a case report and review of the literature. Yalniz E, et al. **Eur Spine J** 1995;4(6):372–4 (21 ref.)

Hypertrophic spinal pachymeningitis. A case report. Kanamori M, et al. **Spine** 1997 Aug 1;22(15):1787–90 (22 ref.)

PHYSIOPATHOLOGY

Spondyloarthropathies [editorial] Khan MA. **Curr Opin Rheumatol** 1997 Jul;9(4):281–3 (4 ref.)

Smoking and the human vertebral column: a review of the impact of cigarette use on vertebral bone metabolism and spinal fusion. Hadley MN, et al. **Neurosurgery** 1997 Jul; 41(1):116–24 (138 ref.)

[Biomechanics of lumbar instability] Krismer M, et al. **Orthopade** 1997 Jun;26(6):516–20 (37 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Interventional radiology techniques in musculoskeletal disease. Gibbon WW. **Baillieres Clin Rheumatol** 1996 Nov; 10(4):711–27 (22 ref.)

Vertebrospinal angiography in the evaluation of vertebral and spinal cord disease. Nelson PK, et al. **Neuroimaging Clin N Am** 1996 Aug;6(3):589–605 (61 ref.)

RADIONUCLIDE IMAGING

Bone SPECT imaging of the painful back. Gates GF. **Clin Nucl Med** 1996 Jul;21(7):560–71 (33 ref.)

REHABILITATION

Rehabilitation and chiropractic practice. Liebenson C. **J Manipulative Physiol Ther** 1996 Feb;19(2):134–40 (50 ref.)

The physics of spinal manipulation: a critical review of four articles by Haas. Solinger AB. **J Manipulative Physiol Ther** 1996 Feb;19(2):141–5 (21 ref.)

An update on orthotic devices for the lumbar spine based on a review of the literature. Calmels P, et al. **Rev Rhum Engl Ed** 1996 Apr;63(4):285–91 (52 ref.)

Objectification of functional improvement after nonoperative care. Flores L, et al. **Spine** 1997 Jul 15;22(14):1622–33 (128 ref.)

Spinal manipulation for low back pain. An updated systematic review of randomized clinical trials. Koes BW, et al. **Spine** 1996 Dec 15;21(24):2860–71; discussion 2872–3 (72 ref.)

SURGERY

Spinal epidural abscess—review of 10 cases. Tacconi L, et al. **Acta Neurochir (Wien)** 1996;138(5):520–3 (17 ref.)

Anterior approaches to non-traumatic lesions of the thoracic spine. Trindade AM, et al. **Adv Tech Stand Neurosurg** 1997; 23:205–48 (82 ref.)

Reoperations on the spine—outcome studies. Fraser RD. **Bull Hosp Jt Dis** 1996;55(4):217–20 (54 ref.)

Basic science of spinal instrumentation. Goel VK, et al. **Clin Orthop** 1997 Feb;(335):10–31 (118 ref.)

Endoscopic techniques in spinal surgery. Regan JJ, et al. **Clin Orthop** 1997 Feb;(335):122–39 (45 ref.)

Spinal instrumentation in the management of degenerative disorders of the lumbar spine. Sidhu KS, et al. **Clin Orthop** 1997 Feb;(335):39–53 (41 ref.)

Pedicle screw fixation in spinal disorders: a European view. Boos N, et al. **Eur Spine J** 1997;6(1):2–18 (195 ref.)

Magnetic resonance imaging of the postoperative spine. Genant HK. **Instr Course Lect** 1994;43:471–3 (12 ref.)

Minimally invasive approaches to the spine. Regan JJ, et al. **Instr Course Lect** 1997;46:127–41 (44 ref.)

The causes of failure of lumbar transpedicular spinal instrumentation and fusion: a prospective study. Hadjipavlou A, et al. **Int Orthop** 1996;20(1):35–42 (53 ref.)

Operative treatment of degenerative cervical disk disease. Heller JG, et al. **J South Orthop Assoc** 1996 Fall; 5(3):188–206 (44 ref.)

Diagnosis and indications for elective spinal surgery. McGuire RA Jr. **J South Orthop Assoc** 1996 Fall; 5(3):213–20 (20 ref.)

Diagnostic and therapeutic spinal arthroscopy. Kambin P. **Neurosurg Clin N Am** 1996 Jan;7(1):65–76 (49 ref.)

The surgical management of patients with rheumatoid cervical spine disease. Gurley JP, et al. **Rheum Dis Clin North Am** 1997 May;23(2):317–32 (49 ref.)

Lumbar disc disease with discogenic pain. What surgical treatment is most effective? Nachemson A, et al. **Spine** 1996 Aug 1;21(15):1835–8 (21 ref.)

Neurologic safety in spinal deformity surgery. Winter RB. **Spine** 1997 Jul 1;22(13):1527–33 (49 ref.)

[Percutaneous drainage of a presacral and spinal extra-dural abscess complicating Crohn's disease] Cassagnou M, et al. **Gastroenterol Clin Biol** 1996;20(8–9):689–92 (13 ref.) (Eng. Abstr.) **(Fre)**

[Anterior and anterolateral surgery of the lower cervical spine (25 years after H. Verbiest). I: Technical bases] Brunon J, et al. **Neurochirurgie** 1996;42(2):105–22 (67 ref.) (Eng. Abstr.) **(Fre)**

[Surgical therapy of spondylogenic cervical myelopathy. Indications and techniques] Hohmann D, et al. **Orthopade** 1996 Nov;25(6):558–66 (51 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Interventional radiology techniques in musculoskeletal disease. Gibbon WW. **Baillieres Clin Rheumatol** 1996 Nov; 10(4):711–27 (22 ref.)

Arterial tonometry and assessment of cardiovascular alterations with chiropractic spinal manipulative therapy. Driscoll MD. **J Manipulative Physiol Ther** 1997 Jan; 20(1):47–55 (95 ref.)

Conservative management of spinal osteoarthritis with glucosamine sulfate and chiropractic treatment. Gottlieb MS. **J Manipulative Physiol Ther** 1997 Jul–Aug; 20(6):400–14 (157 ref.)

Cervical spine manipulation: summary report of a systematic review of the literature and a multidisciplinary expert panel. Shekelle PG, et al. **J Spinal Disord** 1997 Jun;10(3):223–8 (21 ref.)

Objectification of functional improvement after nonoperative care. Flores L, et al. **Spine** 1997 Jul 15;22(14):1622–33 (128 ref.)

ULTRASONOGRAPHY

A review of diagnostic ultrasound of the spine and soft tissue. Rhodes DW, et al. **J Manipulative Physiol Ther** 1997 May; 20(4):267–73 (92 ref.)

VETERINARY

Surgical conditions of the cervical spine. Tomlinson J. **Semin Vet Med Surg (Small Anim)** 1996 Nov;11(4):225–34 (28 ref.)

SPINAL DYSRAPHISM

[Closed spinal dysraphism. Apropos of 3 cases] Benzekri L, et al. **Ann Dermatol Venereol** 1996;123(6–7):378–81 (12 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Latex sensitivity in children with spina bifida: implications for occupational therapy practitioners. Scoggin AE, et al. **Am J Occup Ther** 1997 Jul–Aug;51(7):608–11 (21 ref.)

DIAGNOSIS

MR imaging of the pediatric spine. Byrd SE, et al. **Magn Reson Imaging Clin N Am** 1996 Nov;4(4):797–833 (31 ref.)

EMBRYOLOGY

Embryogenesis. Why do we need a new explanation for the emergence of spina bifida with lipoma? Catala M. **Childs Nerv Syst** 1997 Jun;13(6):336–40 (28 ref.)

ETIOLOGY

[The main etiopathogenic mechanisms of neurocutaneous diseases] Vicente FJ, et al. **Rev Neurol** 1997 Sep;25 Suppl 3:S214–21 (63 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Spina bifida. Sarwark JF. **Pediatr Clin North Am** 1996 Oct; 43(5):1151–8 (21 ref.)

SPINAL FLUID PRESSURE see **CEREBROSPINAL FLUID PRESSURE**

SPINAL FRACTURES

CLASSIFICATION

Emergency department approach to acute thoracolumbar spine injury. Savitsky E, et al. **J Emerg Med** 1997 Jan–Feb; 15(1):49–60 (72 ref.)

SPINAL FRACTURES

COMPLICATIONS

Clinical consequences of vertebral fractures. Ross PD. **Am J Med** 1997 Aug 18;103(2A):30S–42S; discussion 42S–43S (97 ref.)

Pneumocephalus associated with fracture of thoracic spine: case report. Uemura K, et al. **Br J Neurosurg** 1997 Jun; 11(3):253–6 (16 ref.)

Exogenous lumbar spondylodiscitis following a stabwound injury and vertebral fracture. A case report and review of the literature. Schulze CJ, et al. **Eur Spine J** 1995; 4(6):357–9 (16 ref.)

Delayed post-traumatic syringohydromyelia after an uncomplicated fracture of the spine: case report and literature review. Güler-Uysal F, et al. **Spinal Cord** 1996 May;34(5):301–4 (14 ref.)

Traumatic spondylopelvic dissociation. A case report and literature review [see comments] Bents RT, et al. **Spine** 1996 Aug 1;21(15):1814–9 (25 ref.) Comment in: Spine 1997 Jun 1;22(11):1276.

DIAGNOSIS

The role of imaging in the diagnosis and management of thoracolumbar burst fractures: current concepts and a review of the literature. Saifuddin A, et al. **Skeletal Radiol** 1996 Oct;25(7):603–13 (49 ref.)

Late displacement of a fracture dislocation at the lumbosacral junction. A case study. Steinitz DK, et al. **Spine** 1997 May 1;22(9):1024–7 (9 ref.)

DRUG THERAPY

Fluoride therapy for bone disease. Orcel P, et al. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):63S–69S (47 ref.)

ETIOLOGY

Osteoporotic vertebral fractures in postmenopausal women. Millard PS, et al. **Am Fam Physician** 1997 Mar; 55(4):1315–22 (26 ref.)

Vertebral fractures associated with osteoporosis: patient management. Tamayo-Orozco J, et al. **Am J Med** 1997 Aug 18;103(2A):44S–48S; discussion 48S–50S (20 ref.)

Injuries from hovercraft racing. Cattermole HR. **Injury** 1997 Jan;28(1):25–7 (0 ref.)

Biomechanical considerations of hip and spine fractures in osteoporotic bone. Hayes WC, et al. **Instr Course Lect** 1997; 46:431–8 (59 ref.)

Osteoporotic vertebral fractures in a man under high-dose inhaled glucocorticoid therapy. A case-report with a review of the literature. Laroche M, et al. **Rev Rhum Engl Ed** 1997 Apr;64(4):267–70 (16 ref.)

PATHOLOGY

Idiopathic avascular necrosis of a vertebral body. Case report and literature review. Chou LH, et al. **Spine** 1997 Aug 15;22(16):1928–32 (18 ref.)

SURGERY

Typical and atypical fractures of the odontoid process in young children. Report of two cases and a review of the literature. Schippers N, et al. **Acta Neurochir (Wien)** 1996; 138(5):524–30 (38 ref.)

Odontoid fractures in the child with neurological injury. Direct anterior osteosynthesis with a cortico-spongious screw and literature review. Godard J, et al. **Childs Nerv Syst** 1997 Feb;13(2):105–7 (14 ref.)

Posterior cervical fixation for fracture and degenerative disc disease. An HS, et al. **Clin Orthop** 1997 Feb;(335):101–11 (33 ref.)

Anterior instrumentation in the management of thoracolumbar burst fractures. Ghanayem AJ, et al. **Clin Orthop** 1997 Feb;(335):89–100 (38 ref.)

Posterior instrumentation for thoracolumbar trauma. Stambough JL. **Clin Orthop** 1997 Feb;(335):73–88 (131 ref.)

Internal fixation of the spine in traumatic and scoliotic cases. The potential of pedicle screws. Van Brussel K, et al. **Technol Health Care** 1996 Dec;4(4):365–84 (44 ref.)

[New developments in surgery of the injured spine] Blauth M, et al. **Orthopade** 1997 May;26(5):437–49 (49 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Treatment protocol for fractures of the odontoid process. Chiba K, et al. **J Spinal Disord** 1996 Aug;9(4):267–76 (25 ref.)

Managing osteoporotic fractures: minimizing pain and disability. Von Feldt JM. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):78S–80S (13 ref.)

VETERINARY

Principles of vertebral fracture management. Bruecker KA. **Semin Vet Med Surg (Small Anim)** 1996 Nov;11(4):259–72 (27 ref.)

SPINAL FUSION

see related

LAMINECTOMY

Indications for fusion in the lumbar spine. Hanley EN Jr. **Bull Hosp Jt Dis** 1996;55(3):154–7 (38 ref.)

The causes of failure of lumbar transpedicular spinal instrumentation and fusion: a prospective study. Hadjipavlou A, et al. **Int Orthop** 1996;20(1):35–42 (53 ref.)

Materials and design of spinal implants--a review. Martz EO, et al. **J Biomed Mater Res** 1997 Fall;38(3):267–88 (130 ref.)

Adult spondylolisthesis treated with posterolateral lumbar fusion and pedicular instrumentation with AO DC plates. Thalgott JS, et al. **J Spinal Disord** 1997 Jun;10(3):204–8 (15 ref.)

Smoking and the human vertebral column: a review of the impact of cigarette use on vertebral bone metabolism and spinal fusion. Hadley MN, et al. **Neurosurgery** 1997 Jul; 41(1):116–24 (138 ref.)

When is spinal fusion warranted in degenerative lumbar spinal stenosis? Brunon J, et al. **Rev Rhum Engl Ed** 1996 Jan; 63(1):44–50 (35 ref.)

Superior gluteal artery injury during iliac bone grafting for spinal fusion. A case report and literature review. Lim EV, et al. **Spine** 1996 Oct 15;21(20):2376–8 (10 ref.)

ADVERSE EFFECTS

Neurologic safety in spinal deformity surgery. Winter RB. **Spine** 1997 Jul 1;22(13):1527–33 (49 ref.)

INSTRUMENTATION

Spinal instrumentation in the management of adolescent scoliosis. Bridwell KH. **Clin Orthop** 1997 Feb;(335):64–72 (29 ref.)

Anterior instrumentation in the management of thoracolumbar burst fractures. Ghanayem AJ, et al. **Clin Orthop** 1997 Feb;(335):89–100 (38 ref.)

Basic science of spinal instrumentation. Goel VK, et al. **Clin Orthop** 1997 Feb;(335):10–31 (118 ref.)

Transpedicle instrumentation in the degenerative spine. Heim SE. **Clin Orthop** 1997 Apr;(337):97–110 (146 ref.)

Posterior instrumentation for thoracolumbar trauma. Stambough JL. **Clin Orthop** 1997 Feb;(335):73–88 (131 ref.)

Anterior plate instrumentation for disorders of the subaxial cervical spine. Vaccaro AR, et al. **Clin Orthop** 1997 Feb; (335):112–21 (31 ref.)

Neurological complications in segmental spinal instrumentation: analysis of 750 patients. Cervellati S, et al. **Eur Spine J** 1996;5(3):161–6 (25 ref.)

Lumbar spinal stenosis: indications for arthrodesis and spinal instrumentation. Herkowitz HN. **Instr Course Lect** 1994; 43:425–33 (35 ref.)

Management of iatrogenic spinal stenosis complicating placement of a fusion cage. A case report. Glassman SD, et al. **Spine** 1996 Oct 15;21(20):2383–6 (16 ref.)

Lumbar disc disease with discogenic pain. What surgical treatment is most effective? Nachemson A, et al. **Spine** 1996 Aug 1;21(15):1835–8 (21 ref.)

[Computer-assisted orthopedic surgery. From pedicle screw insertion to further applications] Berlemann U, et al. **Orthopade** 1997 May;26(5):463–9 (34 ref.) (Eng. Abstr.) **(Ger)**

[New developments in surgery of the injured spine] Blauth M, et al. **Orthopade** 1997 May;26(5):437–49 (49 ref.) (Eng. Abstr.) **(Ger)**

[Minimally invasive approach and surgical procedures in the lumbar spine] Ogon M, et al. **Orthopade** 1997 Jun; 26(6):553–61 (49 ref.) (Eng. Abstr.) **(Ger)**

[Is instrumented pedicle fixation of the lumbar vertebrae used on too large a scale?--thoughts on indication] Schulitz KP. **Z Orthop Ihre Grenzgeb** 1996 Sep-Oct;134(5):472–6; discussion 476–8 (29 ref.) (Eng. Abstr.) **(Ger)**

METHODS

How to fuse the lumbar spine. Fraser RD. **Bull Hosp Jt Dis** 1996;55(3):158–61 (10 ref.)

Outcome of fusion: assessment techniques and comparison of anterior fusion with posterolateral fusion. Greenough CG. **Bull Hosp Jt Dis** 1996;55(3):162–5 (14 ref.)

The case for posterior lumbar interbody fusion. Branch CL Jr. **Clin Neurosurg** 1996;43:252–67 (62 ref.)

Spinal instrumentation for degenerative disease. Fessler RG. **Clin Neurosurg** 1996;43:268–74 (8 ref.)

Posterior cervical fixation for fracture and degenerative disc disease. An HS, et al. **Clin Orthop** 1997 Feb;(335):101–11 (33 ref.)

Spinal fusion in situ in osteogenesis imperfecta. Livesley PJ, et al. **Int Orthop** 1996;20(1):43–6 (19 ref.)

Percutaneous endoscopic lumbar spine fusion. Leu HF, et al. **Neurosurg Clin N Am** 1996 Jan;7(1):107–17 (20 ref.)

Controversy. Fusion of L5-S1 in adult scoliosis. Horton WC, et al. **Spine** 1996 Nov 1;21(21):2520–2 (8 ref.)

Spine update. The use of adjunctive electrical stimulation to enhance the healing of spine fusions. Kahanovitz N. **Spine** 1996 Nov 1;21(21):2523–5 (16 ref.)

[Giant cell tumors of the spine. Report of a case, literature review] Laffargue P, et al. **Acta Orthop Belg** 1997 Mar; 63(1):28–34 (32 ref.) (Eng. Abstr.) **(Fre)**

[Perforation of the cervical esophagus after ventral fusion of the cervical spine. Defect coverage by muscle-plasty with the sternocleidomastoid muscle: case report and review of the literature] Lamesch P, et al. **Chirurg** 1997 May;68(5):543–7 (30 ref.) (Eng. Abstr.) **(Ger)**

SPINAL GANGLIA see **GANGLIA, SPINAL**

SPINAL INJURIES

CLASSIFICATION

Epidemiology, classification, mechanism, and tolerance of human cervical spine injuries. Myers BS, et al. **Crit Rev Biomed Eng** 1995;23(5–6):307–409 (365 ref.)

Athletes with cervical spine injury. Maroon JC, et al. **Spine** 1996 Oct 1;21(19):2294–9 (21 ref.)

COMPLICATIONS

Exogenous lumbar spondylodiscitis following a stabwound injury and vertebral fracture. A case report and review of the literature. Schulze CJ, et al. **Eur Spine J** 1995; 4(6):357–9 (16 ref.)

Bilateral vertebral artery lesion after dislocating cervical spine trauma. A case report. Wirbel R, et al. **Spine** 1996 Jun 1;21(11):1375–9; discussion 1380 (22 ref.)

Traumatic spinal subarachnoid hematoma: report of a case with MRI. Gupta SK, et al. **Surg Neurol** 1997 Aug; 48(2):189–92 (36 ref.)

DIAGNOSIS

The extremities and spine. Graeme KA, et al. **Emerg Med Clin North Am** 1997 May;15(2):365–79 (42 ref.)

[Injuries of the spine: current concepts in radiologic diagnosis] du Mesnil de Rochemont R, et al. **Aktuelle Radiol** 1997 Jan;7(1):1–13 (51 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

New pharmacologic strategies for acute neuronal injury. Luer MS, et al. **Pharmacotherapy** 1996 Sep-Oct; 16(5):830–48 (242 ref.)

EPIDEMIOLOGY

Epidemiology, classification, mechanism, and tolerance of human cervical spine injuries. Myers BS, et al. **Crit Rev Biomed Eng** 1995;23(5–6):307–409 (365 ref.)

ETIOLOGY

Stress fractures in the pediatric athlete. Coady CM, et al. **Clin Sports Med** 1997 Apr;16(2):225–38 (43 ref.)

Spinal injuries in the pediatric age group: a review of 82 cases of spinal cord and vertebral column injuries. Turgut M, et al. **Eur Spine J** 1996;5(3):148–52 (31 ref.)

Spine problems in the athlete. Stinson JT. **Md Med J** 1996 Aug;45(8):655–8 (25 ref.)

PREVENTION & CONTROL

[Examination methods for the prevention of traumatic and nontraumatic osteoarthropathies related to flying activity] Rotondo G. **Riv Med Aeronaut Spaz** 1975 Oct-Dec; 38(4):375–91 (25 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Treatment of spinal injuries. On relating anatomical facts to clinical practice. Crock HV. **Acta Orthop Scand** 1997 Aug; 68(4):315–8 (13 ref.)

Posterior instrumentation for thoracolumbar trauma. Stambough JL. **Clin Orthop** 1997 Feb;(335):73–88 (131 ref.)

Indications for surgery in upper cervical spine injury. Pospiech J, et al. **Neurosurg Rev** 1996;19(2):73–9 (30 ref.)

[Impalement injury of the colon, iliac vein and sacrum--a rare combination in penetrating abdominal trauma. A case report] Funke M, et al. **Chirurg** 1996 Nov;67(11):1184–7 (27 ref.) (Eng. Abstr.) **(Ger)**

[New developments in surgery of the injured spine] Blauth M, et al. **Orthopade** 1997 May;26(5):437–49 (49 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Management guidelines for participation in collision activities with congenital, developmental, or post-injury lesions involving the cervical spine. Torg JS, et al. **Clin Sports Med** 1997 Jul;16(3):501–30 (18 ref.)

The extremities and spine. Graeme KA, et al. **Emerg Med Clin North Am** 1997 May;15(2):365–79 (42 ref.)

A review of spinal immobilization techniques. De Lorenzo RA. **J Emerg Med** 1996 Sep-Oct;14(5):603–13 (91 ref.)

Athletes with cervical spine injury. Maroon JC, et al. **Spine** 1996 Oct 1;21(19):2294–9 (21 ref.)

SPINAL MUSCULAR ATROPHY see **MUSCULAR ATROPHY, SPINAL**

SPINAL MUSCULAR ATROPHY, INFANTILE see **WERDNIG-HOFFMANN DISEASE**

SPINAL NEOPLASMS

Spinal chondroma of the lumbar tract: case report. Gaetani P, et al. **Surg Neurol** 1996 Dec;46(6):534–9 (32 ref.)

[Primary spinal osteosarcomas] Khalfallah M, et al. **Neurochirurgie** 1997;43(1):28–34 (56 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

Chordoma: a case report. Jallo J, et al. **Surg Neurol** 1997 Jul;48(1):46–8 (14 ref.)

COMPLICATIONS

Primary osteosarcoma of the L2 lamina presenting as "silent" paraplegia: case report and review of the literature. Korovessis P, et al. **Eur Spine J** 1995;4(6):375–8 (18 ref.)

Multiple endocrine neoplasia type 1 associated with spinal ependymoma. Kato H, et al. **Intern Med** 1996 Apr; 35(4):285–9 (18 ref.)

[Scoliosis of sudden evolution due to lumbar osteoblastoma] Amaral J de S, et al. **Acta Med Port** 1997 May;10(5):417–22 (16 ref.) (Eng. Abstr.) **(Por)**

DIAGNOSIS

Spinal angiolipomas revisited: two case reports. Trabulo A, et al. **Acta Neurochir (Wien)** 1996;138(11):1311–9 (21 ref.)

Spinal canal compromise in Proteus syndrome: case report and review of the literature. Ring D, et al. **Am J Orthop** 1997 Apr;26(4):275–8 (14 ref.)

Increased phantom limb pain as an initial symptom of spinal–neoplasia [published erratum appears in J Pain Symptom Manage 1997 Sep;14(3):135] Chang VT, et al. **J Pain Symptom Manage** 1997 Jun;13(6):362–4 (18 ref.)

Epithelioid hemangioendothelioma of the lumbar vertebral column: case report and review of literature. Ellis TS, et al. **Neurosurgery** 1996 Feb;38(2):402–7 (51 ref.)

Neuroectodermal cyst may be a rare differential diagnosis of fetal sacrococcygeal teratoma: first case report of a prenatally observed neuroectodermal cyst. Bloechle M, et al. **Ultrasound Obstet Gynecol** 1996 Jan;7(1):64–7 (11 ref.)

[Giant cell tumors of the spine. Report of a case, literature review] Laffargue P, et al. **Acta Orthop Belg** 1997 Mar; 63(1):28–34 (32 ref.) (Eng. Abstr.) **(Fre)**

[Vertebral hemangioma symptomatic during pregnancy. A case report and review of the literature] Abi-Fadel W, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(1):90–4 (20 ref.) (Eng. Abstr.) **(Fre)**

[Epithelioid sarcoma. Diagnostic and therapeutic aspects apropos of a coccygeal localization] Tournigand C, et al. **Rev Med Interne** 1997;18(1):50–3 (16 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Burkitt's lymphoma–leukemia in patients treated for Hodgkin's disease. Salloum E, et al. **Cancer Invest** 1996; 14(6):527–33 (47 ref.)

EMBRYOLOGY

Embryogenesis. Why do we need a new explanation for the emergence of spina bifida with lipoma? Catala M. **Childs Nerv Syst** 1997 Jun;13(6):336–40 (28 ref.)

GENETICS

Congenital lumbosacral lipomas. Pierre-Kahn A, et al. **Childs Nerv Syst** 1997 Jun;13(6):298–334; discussion 335 (199 ref.)

PATHOLOGY

Fibrous dysplasia of the spine with sarcomatous transformation: a case report and review of the literature. Yalniz E, et al. **Eur Spine J** 1995;4(6):372–4 (21 ref.)

Osteoid osteoma of the vertebral body with extension across the intervertebral disc. Hurtgen KL, et al. **J Manipulative Physiol Ther** 1996 Feb;19(2):118–23 (31 ref.)

Epithelioid hemangioendothelioma of the lumbar vertebral column: case report and review of literature. Ellis TS, et al. **Neurosurgery** 1996 Feb;38(2):402–7 (51 ref.)

From the archives of the AFIP. Primary tumors of the spine: radiologic pathologic correlation. Murphey MD, et al. **Radiographics** 1996 Sep;16(5):1131–58 (70 ref.)

Primary bone tumors of the spine. Terminology and surgical staging. Boriani S, et al. **Spine** 1997 May 1;22(9):1036–44 (28 ref.)

RADIOGRAPHY

From the archives of the AFIP. Primary tumors of the spine: radiologic pathologic correlation. Murphey MD, et al. **Radiographics** 1996 Sep;16(5):1131–58 (70 ref.)

Chondromyxoid fibroma of the lumbar spine. Cabral CE, et al. **Skeletal Radiol** 1997 Aug;26(8):488–92 (24 ref.)

RADIOTHERAPY

Fast neutron therapy for inoperable or recurrent sacrococcygeal chordomas. Breteau N, et al. **Bull Cancer Radiother** 1996;83 Suppl:142s–5s (19 ref.)

Radiotherapy in the treatment of symptomatic vertebral hemangiomas: technical case report. Bremnes RM, et al. **Neurosurgery** 1996 Nov;39(5):1054–8 (37 ref.)

[Radiotherapy of spinal metastases in breast cancer. Apropos of a series of 108 patients] Prié L, et al. **Cancer Radiother** 1997;1(3):234–9 (30 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

Models for cancer skeletal metastasis: a reappraisal of Batson's plexus. Geldof AA. **Anticancer Res** 1997 May–Jun; 17(3A):1535–9 (45 ref.)

Spine surgery for cancer. Gokaslan ZL. **Curr Opin Oncol** 1996 May;8(3):178–81 (19 ref.)

Increased phantom limb pain as an initial symptom of spinal–neoplasia [published erratum appears in J Pain Symptom Manage 1997 Sep;14(3):135] Chang VT, et al. **J Pain Symptom Manage** 1997 Jun;13(6):362–4 (18 ref.)

Surgical indications and prognosis in spinal metastases. Nanassis K, et al. **Neurosurg Rev** 1997;20(2):99–103 (32 ref.)

[Radiotherapy of spinal metastases in breast cancer. Apropos of a series of 108 patients] Prié L, et al. **Cancer Radiother** 1997;1(3):234–9 (30 ref.) (Eng. Abstr.) **(Fre)**

[Diagnostic imaging of bone and soft tissue tumors] Saotome K. **Nippon Seikeigeka Gakkai Zasshi** 1996 Sep;70(9):559–72 (26 ref.) **(Jpn)**

SURGERY

Sacrococcygeal teratoma and anorectal malformation. Ng WT, et al. **Aust N Z J Surg** 1997 Apr;67(4):218–20 (28 ref.)

Surgical treatment of spinal tumors. Bell GR. **Clin Orthop** 1997 Feb;(335):54–63 (31 ref.)

Spine surgery for cancer. Gokaslan ZL. **Curr Opin Oncol** 1996 May;8(3):178–81 (19 ref.)

Single-stage posterior vertebrectomy and replacement combined with posterior instrumentation for spinal metastasis. Akeyson EW, et al. **J Neurosurg** 1996 Aug; 85(2):211–20 (52 ref.)

The surgical treatment of metastatic spinal tumors within the intradural extramedullary compartment [see comments] Chow TS, et al. **J Neurosurg** 1996 Aug;85(2):225–30 (46 ref.) Comment in: J Neurosurg 1997 Mar;86(3):576–7.

Intraosseous glomus tumor of the spine. Case report and review of the literature. Robinson JC, et al. **J Neurosurg** 1996 Aug;85(2):344–7 (20 ref.)

Biomechanics of cervical spine surgery for tumor and degenerative diseases. Benzel EC. **Neurol Med Chir (Tokyo)** 1997 Aug;37(8):583–93 (44 ref.)

Primary hemangiopericytoma in the axis bone: case report and review of literature. Lin YJ, et al. **Neurosurgery** 1996 Aug;39(2):397–9; discussion 399–400 (32 ref.)

[Giant sacral schwannoma with pelvic extension. Therapeutic strategy. Apropos of a case] Stecken J, et al. **Neurochirurgie** 1996;42(6):294–9 (16 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Successful treatment of spinal osteosarcoma with radiation and chemotherapy. Hershey A, et al. **Orthopedics** 1996 Jul; 19(7):617–8 (7 ref.)

SPINAL NERVE ROOTS

see related
POLYRADICULITIS
RADICULITIS
RHIZOTOMY

Cervical root entrapment. An HS. **Hand Clin** 1996 Nov; 12(4):719–30 (27 ref.)

The diagnosis and treatment of cervical radiculopathy. Malanga GA. **Med Sci Sports Exerc** 1997 Jul;29(7 Suppl):S236–45 (88 ref.)

Third cervical nerve root and ganglion compression: clinical syndrome, surgical anatomy, and pathological findings. Poletti CE. **Neurosurgery** 1996 Nov;39(5):941–8; discussion 948–9 (63 ref.)

Recent data on the pathophysiology of nerve root compression and pain. Boulu P, et al. **Rev Rhum Engl Ed** 1996 May;63(5):358–63 (33 ref.)

Giant intrasacral schwannoma forming a presacral mass: a report of an unusual cause of lumbosacral radiculopathy. Turgut M, et al. **Zentralbl Neurochir** 1996;57(4):201–5 (19 ref.)

[Consensus on diagnosis and treatment of the lumbosacral radicular syndrome. Dutch Society for Neurology] Stam J. **Ned Tijdschr Geneeskd** 1996 Dec 28;140(52):2621–7 (31 ref.) (Eng. Abstr.) **(Dut)**

[Acute lumbar disk displacement with nerve root compression. Indications for peridural steroid injection] Schlumpf U, et al. **Schweiz Rundsch Med Prax** 1997 Feb 18;86(8):292–5 (29 ref.) (Eng. Abstr.) **(Ger)**

[Variety in radicular symptoms and signs at the lumbosacral region] Hasue M. **Nippon Seikeigeka Gakkai Zasshi** 1996 Jan;70(1):1–6 (28 ref.) **(Jpn)**

ABNORMALITIES

Presurgical identification of extradural nerve root anomalies by coronal fat-suppressed magnetic resonance imaging: a report of six cases and a review of the literature. Aota Y, et al. **J Spinal Disord** 1997 Apr;10(2):167–75 (19 ref.)

INJURIES

Distal, "Tinel-like" percussion paresthesiae, with proximal nerve lesions. Jabre JF. **Electromyogr Clin Neurophysiol** 1996 Apr–May;36(3):175–8 (16 ref.)

Nerve fibre regeneration across the peripheral–central transitional zone. Carlstedt T. **J Anat** 1997 Jan;190 (Pt 1):51–6 (40 ref.)

Extradural tethering effect as one mechanism of radiculopathy complicating posterior decompression of the cervical spinal cord [see comments] Tsuzuki N, et al. **Spine** 1996 Jan 15;21(2):203–11 (14 ref.) Comment in: Spine 1996 Aug 1;21(15):1839–40.

[Pain management after post-traumatic brachial plexus lesions. Conservative and surgical therapy possibilities] Carvalho GA, et al. **Orthopade** 1997 Jul;26(7):621–5 (30 ref.) (Eng. Abstr.) **(Ger)**

[Nerve transfer (neurotization) for functional reconstruction of arm functions in cervical root avulsions] Nikkhah G, et al. **Orthopade** 1997 Jul;26(7):606–11 (21 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Neurophysiologic tests in diagnosis of nerve root compression caused by disc herniation. Dvořák J. **Spine** 1996 Dec 15;21(24 Suppl):39S–44S (33 ref.)

[Inflammatory diseases of the spinal cord and spinal nerve roots in the MRI] Sartoretti-Schefer S, et al. **Radiologe** 1996 Nov;36(11):897–913 (159 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Maturation of the mammalian dorsal root entry zone—from entry to no entry. Golding J, et al. **Trends Neurosci** 1997 Jul;20(7):303–8 (53 ref.)

SURGERY

Spinal meningeal melanocytoma: a case report and review of the literature. Sankhla SK, et al. **Br J Neurosurg** 1996 Apr;10(2):205–9 (28 ref.)

Intraradicular, intervertebral disc herniation. A case report. Finkel HZ. **Spine** 1997 May 1;22(9):1028–9 (8 ref.)

ULTRASTRUCTURE

Development of nodes of Ranvier in feline nerves: an ultrastructural presentation. Berthold CH. **Microsc Res Tech** 1996 Aug 1;34(5):399–421 (95 ref.)

SPINAL NERVES

Spinal nerves and acupuncture. Yamamura Y, et al. **Rev Assoc Med Bras** 1996 Apr–Jun;42(2):115–8 (118 ref.)

SPINAL OSTEOPHYTOSIS

COMPLICATIONS

Current opinions in etiopathogenesis of headaches caused by cervical spine pathology. Wojczal J. **Ann Univ Mariae Curie Sklodowska [Med]** 1995;50:95–101 (16 ref.)

An unusual cause of dysphagia. Tung MY, et al. **Singapore Med J** 1996 Jun;37(3):315–7 (10 ref.)

ETIOLOGY

[Destructive spondyloarthropathy of the cervical spine in hemodialyzed patients] Fukutake T, et al. **No To Shinkei** 1997 Aug;49(8):713–22 (18 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

[Neuropathology of cervical spondylotic myelopathy] Ito T, et al. **No To Shinkei** 1996 Aug;48(8):697–702 (19 ref.) **(Jpn)**

THERAPY

Cervical spondylosis. An update. McCormack BM, et al. **West J Med** 1996 Jul–Aug;165(1–2):43–51 (116 ref.)

SPINAL PUNCTURE

Alpha-hemolytic streptococci: a major pathogen of iatrogenic meningitis following lumbar puncture. Case reports and a review of the literature. Schneeberger PM, et al. **Infection** 1996 Jan–Feb;24(1):29–33 (38 ref.)

ADVERSE EFFECTS

Pharmacologic management of postdural puncture headache. Choi A, et al. **Ann Pharmacother** 1996 Jul–Aug; 30(7–8):831–9 (62 ref.)

Central nervous side effects after lumbar puncture. A review of the possible pathogenesis of the syndrome of postdural puncture headache and associated symptoms. Wang LP, et al. **Dan Med Bull** 1997 Feb;44(1):79–81 (40 ref.)

Symptomatic spinal intradural arachnoid cyst development after lumbar myelography. Case report and review of the literature. Kriss TC, et al. **Spine** 1997 Mar 1;22(5):568–72 (50 ref.)

[Deafness secondary to lumbar puncture] Conde M, et al. **Rev Neurol** 1997 Aug;25(144):1218–20 (11 ref.) (Eng. Abstr.) **(Spa)**

SPINAL ROOTS see **SPINAL NERVE ROOTS**

SPINAL STENOSIS

Management of lumbar spinal stenosis. Postacchini F. **J Bone Joint Surg Br** 1996 Jan;78(1):154–64 (35 ref.)

SPINAL STENOSIS

COMPLICATIONS

[Thoracic spondylotic myelopathies. Apropos of 4 new cases] Stecken J, et al. **Neurochirurgie** 1996;42(3):147–52 (40 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Spinal stenosis: history and physical examination. Mirkovic S, et al. **Instr Course Lect** 1994;43:435–40 (41 ref.)

Lumbar spinal stenosis: a review. Berthelot JM, et al. **Rev Rhum Engl Ed** 1997 May;64(5):315–25 (83 ref.)

Spinal stenosis and neurogenic claudication. Porter RW. **Spine** 1996 Sep 1;21(17):2046–52 (12 ref.)

[Consensus on diagnosis and treatment of the lumbosacral radicular syndrome. Dutch Society for Neurology] Stam J. **Ned Tijdschr Geneeskd** 1996 Dec 28;140(52):2621–7 (31 ref.) (Eng. Abstr.) **(Dut)**

[Radiology of lumbar spinal canal stenosis] Hähnel S, et al. **Aktuelle Radiol** 1996 Jul;6(4):165–70 (38 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Causes and management of unstable degenerative spinal stenosis. Fellrath RF Jr, et al. **J South Orthop Assoc** 1996 Fall;5(3):221–8 (24 ref.)

PATHOLOGY

Acquired lumbar spinal stenosis. Jane JA Sr, et al. **Clin Neurosurg** 1996;43:275–99 (89 ref.)

PHYSIOPATHOLOGY

[Stenosis of the lumbar spinal canal. Pathophysiology, clinical aspects and therapy] Benini A. **Orthopade** 1997 May; 26(5):503–14 (6 ref.) **(Ger)**

REHABILITATION

Management of iatrogenic spinal stenosis complicating placement of a fusion cage. A case report. Glassman SD, et al. **Spine** 1996 Oct 15;21(20):2383–6 (16 ref.)

SURGERY

Indications for fusion in the lumbar spine. Hanley EN Jr. **Bull Hosp Jt Dis** 1996;55(3):154–7 (38 ref.)

Acquired lumbar spinal stenosis. Jane JA Sr, et al. **Clin Neurosurg** 1996;43:275–99 (89 ref.)

The surgery of spinal stenosis. Booth RE Jr, et al. **Instr Course Lect** 1994;43:441–9 (31 ref.)

Spinal stenosis: indications for laminectomy. Garfin SR, et al. **Instr Course Lect** 1994;43:411–4 (24 ref.)

Lumbar spinal stenosis: indications for arthrodesis and spinal instrumentation. Herkowitz HN. **Instr Course Lect** 1994; 43:425–33 (35 ref.)

Minimally invasive arthroscopic spinal surgery. Kambin P, et al. **Instr Course Lect** 1997;46:143–61 (79 ref.)

When is spinal fusion warranted in degenerative lumbar spinal stenosis? Brunon J, et al. **Rev Rhum Engl Ed** 1996 Jan; 63(1):44–50 (35 ref.)

THERAPY

Causes and management of unstable degenerative spinal stenosis. Fellrath RF Jr, et al. **J South Orthop Assoc** 1996 Fall;5(3):221–8 (24 ref.)

Lumbar spinal stenosis: a review. Berthelot JM, et al. **Rev Rhum Engl Ed** 1997 May;64(5):315–25 (83 ref.)

[Consensus on diagnosis and treatment of the lumbosacral radicular syndrome. Dutch Society for Neurology] Stam J. **Ned Tijdschr Geneeskd** 1996 Dec 28;140(52):2621–7 (31 ref.) (Eng. Abstr.) **(Dut)**

SPINDLE APPARATUS, MITOTIC see **MITOTIC SPINDLE APPARATUS**

SPINE

see related
LAMINECTOMY

Basic science research in chiropractic: the state of the art and recommendations for a research agenda. Brennan PC, et al. **J Manipulative Physiol Ther** 1997 Mar–Apr; 20(3):150–68 (182 ref.)

ABNORMALITIES

Humero-spinal dysostosis: report of the fourth case with emphasis on generalized skeletal involvement, abnormal craniofacial features, and mitral valve thickening. Hall BD. **J Pediatr Orthop B** 1997 Jan;6(1):11–4 (3 ref.)

ANATOMY & HISTOLOGY

Finite element methods in spine biomechanics research. Gilbertson LG, et al. **Crit Rev Biomed Eng** 1995; 23(5–6):411–73 (123 ref.)

A normal sagittal spinal configuration: a desirable clinical outcome [see comments] Harrison DD, et al. **J Manipulative Physiol Ther** 1996 Jul–Aug;19(6):398–405 (57 ref.) Comment in: J Manipulative Physiol Ther 1997 Feb;20(2):130–1; discussion 131–3. Comment in: J Manipulative Physiol Ther 1997 Feb;20(2):133–4; discussion 134–5. Comment in: J Manipulative Physiol Ther 1997 Feb;20(2):136–7; discussion 137–9. Comment in: J Manipulative Physiol Ther 1997 May;20(4):288–93.

BLOOD SUPPLY

Vertebrospinal angiography in the evaluation of vertebral and spinal cord disease. Nelson PK, et al. **Neuroimaging Clin N Am** 1996 Aug;6(3):589–605 (61 ref.)

EMBRYOLOGY

[Subdivision of the mesoderm along the dorso-ventral axis] Takahashi Y, et al. **Tanpakushitsu Kakusan Koso** 1996 Dec; 41(16):2532–41 (29 ref.) **(Jpn)**

METABOLISM

Vertebral morphometry studies using dual-energy x-ray absorptiometry. Blake GM, et al. **Semin Nucl Med** 1997 Jul;27(3):276–90 (47 ref.)

PATHOLOGY

MR imaging of the pediatric spine. Byrd SE, et al. **Magn Reson Imaging Clin N Am** 1996 Nov;4(4):797–833 (31 ref.)

From the archives of the AFIP. Primary tumors of the spine: radiologic pathologic correlation. Murphey MD, et al. **Radiographics** 1996 Sep;16(5):1131–58 (70 ref.)

Primary bone tumors of the spine. Terminology and surgical staging. Boriani S, et al. **Spine** 1997 May 1;22(9):1036–44 (28 ref.)

[Dysphagia as a symptom of diffuse idiopathic skeletal hyperostosis (Forestier-Rotes disease). A case report and literature review] Escobar C, et al. **Acta Otorrinolaringol Esp** 1997 Mar;48(2):161–3 (16 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Finite element methods in spine biomechanics research. Gilbertson LG, et al. **Crit Rev Biomed Eng** 1995; 23(5–6):411–73 (123 ref.)

Posteroanterior spinal mobilization: state of the art review and discussion. Björnsdóttir SV, et al. **Disabil Rehabil** 1997 Feb;19(2):39–46 (40 ref.)

Torque: an appraisal of misuse of terminology in chiropractic literature and technique. Harrison DD, et al. **J Manipulative Physiol Ther** 1996 Sep;19(7):454–62 (57 ref.)

PHYSIOPATHOLOGY

What happens in the motion segment? Panjabi MM. **Bull Hosp Jt Dis** 1996;55(3):149–53 (14 ref.)

The mysteries of segmental instability. Szpalski M. **Bull Hosp Jt Dis** 1996;55(3):147–8 (10 ref.)

Spinal pain mechanisms. Siddall PJ, et al. **Spine** 1997 Jan 1;22(1):98–104 (20 ref.)

RADIOGRAPHY

From the archives of the AFIP. Primary tumors of the spine: radiologic pathologic correlation. Murphey MD, et al. **Radiographics** 1996 Sep;16(5):1131–58 (70 ref.)

Vertebral morphometry studies using dual-energy x-ray absorptiometry. Blake GM, et al. **Semin Nucl Med** 1997 Jul;27(3):276–90 (47 ref.)

Spinal radiographic findings and nonspecific low back pain. A systematic review of observational studies. van Tulder MW, et al. **Spine** 1997 Feb 15;22(4):427–34 (58 ref.)

SURGERY

Thoracoscopic spinal surgery. Dickman CA, et al. **Clin Neurosurg** 1996;43:392–422 (42 ref.)

Neurologic safety in spinal deformity surgery. Winter RB. **Spine** 1997 Jul 1;22(13):1527–33 (49 ref.)

[Spinal cord monitoring during spinal surgery] Hu J, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1996 Feb; 18(1):72–5 (30 ref.) **(Chi)**

SPINOCEREBELLAR ATAXIAS see **SPINOCEREBELLAR DEGENERATION**

SPINOCEREBELLAR DEGENERATION

[Striatonigral degeneration] Mochizuki A, et al. **Nippon Rinsho** 1997 Jan;55(1):123–6 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Spinocerebellar degeneration] Iwasaki Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):96–9 (5 ref.) **(Jpn)**

CLASSIFICATION

[Classification and clinical topics on familial spinocerebellar degeneration] Abe K. **No To Shinkei** 1997 Jul;49(7):591–601 (51 ref.) **(Jpn)**

COMPLICATIONS

[Image diagnosis and functional tests--vertigo due to cerebellar and brain stem disorders] Kitamura T. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Jul;99(7):1036–9 (9 ref.) **(Jpn)**

DIAGNOSIS

[Image diagnosis and functional tests--vertigo due to cerebellar and brain stem disorders] Kitamura T. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Jul;99(7):1036–9 (9 ref.) **(Jpn)**

[Cortico-basal degeneration] Morimatsu M. **Nippon Rinsho** 1997 Jan;55(1):139–43 (12 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Inherited neurodegenerative diseases and transgenic models. Price DL, et al. **Brain Pathol** 1996 Oct;6(4):467–80 (220 ref.)

Toward understanding polyglutamine-induced neurological disease in spinocerebellar ataxia type 1. Orr HT, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:649–57 (47 ref.)

Transgenic models of neurodegenerative diseases. Lee MK, et al. **Curr Opin Neurobiol** 1996 Oct;6(5):651–60 (115 ref.)

Trinucleotide repeat disorders in humans: discussions of mechanisms and medical issues. Timchenko LT, et al. **FASEB J** 1996 Dec;10(14):1589–97 (70 ref.)

Clinicopathology of spinocerebellar degeneration: its correlation to the unstable CAG repeat of the affected gene. Yagishita S, et al. **Pathol Int** 1997 Jan;47(1):1–15 (114 ref.)

Molecular genetics and neurobiology of neurodegenerative and neurodevelopmental disorders. Zoghbi HY. **Pediatr Res** 1997 May;41(5):722–6 (33 ref.)

[Genetic diagnosis, classification and clinical hereditary ataxia disease entities] Schöls L, et al. **Fortschr Neurol Psychiatr** 1997 Feb;65(2):79–89 (139 ref.) (Eng. Abstr.) **(Ger)**

[Spinocerebellar ataxia: advances in genetic research and its clinical implication] Sasaki H. **Hokkaido Igaku Zasshi** 1997 Jan;72(1):13–20 (36 ref.) (Eng. Abstr.) **(Jpn)**

[Diseases in the field of internal medicine and gene abnormalities. 5. Nervous system diseases--molecular genetics of hereditary spinocerebellar degeneration] Tsuji S. **Nippon Naika Gakkai Zasshi** 1996 Sep 10;85(9):1514–9 (20 ref.) **(Jpn)**

[Variable clinical manifestations of familial amyloid polyneuropathy and living related liver transplantation] Ikeda S, et al. **Rinsho Shinkeigaku** 1995 Dec;35(12):1433–5 (11 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Clinicopathology of spinocerebellar degeneration: its correlation to the unstable CAG repeat of the affected gene. Yagishita S, et al. **Pathol Int** 1997 Jan;47(1):1–15 (114 ref.)

[Glial cytoskeletal abnormality in neurodegenerative diseases: multiple system atrophy] Mizusawa H. **No To Shinkei** 1996 Oct;48(10):915–24 (55 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Molecular genetics and neurobiology of neurodegenerative and neurodevelopmental disorders. Zoghbi HY. **Pediatr Res** 1997 May;41(5):722–6 (33 ref.)

SPINOTHALAMIC TRACTS

PHYSIOLOGY

Central nervous system pathways for pain transmission and pain control: issues relevant to the practicing clinician. Robinson AJ. **J Hand Ther** 1997 Apr–Jun;10(2):64–77 (66 ref.)

SPIPERONE

ANALOGS & DERIVATIVES

[Striatal dopamine D2 receptor in Parkinson disease and its related disorders assessed by C-11 NMSP and PET] Momose T, et al. **Nippon Rinsho** 1997 Jan;55(1):227–32 (4 ref.) (Eng. Abstr.) **(Jpn)**

SPIRAMYCIN

ADVERSE EFFECTS

[Torsades de pointe with spiramycine and metiquazine therapy. Apropos of a case] Verdun F, et al. **Arch Mal Coeur Vaiss** 1997 Jan;90(1):103–6 (10 ref.) (Eng. Abstr.) **(Fre)**

SPIRAMYCIN ADIPATE see **SPIRAMYCIN**

SPIRITUAL HEALING see **MENTAL HEALING**

SPIRITUALISM

Acknowledging a spiritual dimension in occupational therapy practice. Christiansen C. **Am J Occup Ther** 1997 Mar; 51(3):169–72 (34 ref.)

Occupation as spiritual activity. Howard BS, et al. **Am J Occup Ther** 1997 Mar;51(3):181–5 (31 ref.)

A Copernican revolution in clinical ethics: engagement versus disengagement. Van Amburg R. **Am J Occup Ther** 1997 Mar;51(3):186–90 (20 ref.)

SPIROCERCA see **THELAZIOIDEA**

SPIROCHAETALES

ENZYMOLOGY

The peptidolytic capacity of the spirochete system. Mäkinen KK, et al. **Med Microbiol Immunol (Berl)** 1996 May; 185(1):1–10 (78 ref.)

GROWTH & DEVELOPMENT

The challenge of growing oral spirochaetes. Wardle HM. **J Med Microbiol** 1997 Feb;46(2):104–16 (77 ref.)

SPIROLACTONE see **SPIRONOLACTONE**

SPIROMETRA

PHYSIOLOGY

An unusual host–parasite relationship: the growth hormone–like factor from plerocercoids of spirometrid tapeworms. Phares K. **Int J Parasitol** 1996 Jun;26(6):575–88 (80 ref.)

SPIROMETRY

Peak flow meters and spirometers in general practice. **Drug Ther Bull** 1997 Jul;35(7):52–5 (20 ref.)

Analysis of variability in interpretation of spirometric tests. Quadrelli SA, et al. **Respiration** 1996;63(3):131–6 (28 ref.)

A guide to spirometry as applied to occupational health. White N, et al. **S Afr Med J** 1996 Jul;86(7):807–13 (39 ref.)

INSTRUMENTATION

Office spirometry: equipment selection and training of staff in the private practice setting. Wanger J, et al. **J Asthma** 1997;34(2):93–104 (24 ref.)

STANDARDS

Office spirometry: equipment selection and training of staff in the private practice setting. Wanger J, et al. **J Asthma** 1997;34(2):93–104 (24 ref.)

SPIRONOLACTONE

THERAPEUTIC USE

[Spironolactone: renaissance of anti–aldosterone therapy in heart failure?] Brilla CG, et al. **Schweiz Rundsch Med Prax** 1997 Apr 2;86(14):566–74 (38 ref.) (Eng. Abstr.) **(Ger)**

[Potassium–sparing diuretics (spironolactone, triamterene, amylorid)] Haris A, et al. **Orv Hetil** 1996 Sep 1; 137(35):1907–14 (72 ref.) (Eng. Abstr.) **(Hun)**

[Hyperaldosteronism, spironolactone and liver cirrhosis] Sort P, et al. **Gastroenterol Hepatol** 1997 Mar;20(3):151–9 (80 ref.) **(Spa)**

SPIROPERIDOL see **SPIPERONE**

SPIROPERONE see **SPIPERONE**

SPIROPLASMA

Spiroplasmas: infectious agents of plants, arthropods and vertebrates. Bové JM. **Wien Klin Wochenschr** 1997 Aug 8;109(14–15):604–12 (70 ref.)

SPIRURIDA INFECTIONS

ETIOLOGY

Eye infestation with Thelazia species. Mahanta J, et al. **Indian J Ophthalmol** 1996 Jun;44(2):99–101 (6 ref.)

SPITZ NEVUS see **NEVUS, EPITHELIOID AND SPINDLE CELL**

SPLANCHNIC CIRCULATION

Uncommon splanchnic artery aneurysms: pancreaticoduodenal, gastroduodenal, superior mesenteric, inferior mesenteric, and colic. Shanley CJ, et al. **Ann Vasc Surg** 1996 Sep;10(5):506–15 (147 ref.)

The role of splanchnic glucose appearance in determining carbohydrate tolerance. Rizza R. **Diabet Med** 1996 Sep;13(9 Suppl 5):S23–7 (13 ref.)

Systemic inflammatory response and the splanchnic bed in cardiopulmonary bypass. Ohri SK. **Perfusion** 1996 May; 11(3):200–12 (68 ref.)

Mesenteric revascularization during aneurysmectomy. Donaldson MC, et al. **Surg Clin North Am** 1997 Apr; 77(2):443–59 (51 ref.)

Duplex ultrasonography in evaluation of splanchnic artery stenosis. Nicoloff AD, et al. **Surg Clin North Am** 1997 Apr; 77(2):339–55 (18 ref.)

The mesenteric circulation. Anatomy and physiology. Rosenblum JD, et al. **Surg Clin North Am** 1997 Apr; 77(2):289–306 (23 ref.)

DRUG EFFECTS

Pharmacological manipulation of human gastrointestinal blood flow. Mathias CJ. **Fundam Clin Pharmacol** 1997; 11(1):29–34 (47 ref.)

Dobutamine and the oxygen uptake/supply relationship in sepsis: from global to regional—nothing is simple and easy [comment] Vogt J, et al. **Intensive Care Med** 1997 Jul; 23(7):715–7 (33 ref.) Comment on: Intensive Care Med 1997 Jul;23(7):732–7.

SPLEEN

see related
SPLENECTOMY

ABNORMALITIES

Ivemark syndrome. A case with successful surgical intervention. Tkebuchava T, et al. **Scand Cardiovasc J** 1997; 31(3):173–5 (8 ref.)

Wandering spleen: a challenging diagnosis. Desai DC, et al. **South Med J** 1997 Apr;90(4):439–43 (41 ref.)

Laparoscopic accessory splenectomy for recurrent idiopathic thrombocytopenic purpura. Amaral JF, et al. **Surg Laparosc Endosc** 1997 Aug;7(4):340–4 (15 ref.)

[Polysplenia syndrome] Abukawa T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):328–30 (15 ref.) **(Jpn)**

[Asplenia syndrome (Ivemark syndrome)] Ohashi H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):334–6 (25 ref.) **(Jpn)**

[Radiation diagnosis of spleen diseases] Vlasov PV, et al. **Vestn Rentgenol Radiol** 1997 May–Jun;(3):27–34 (28 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

A comparison of the performance in vitro of precision cut tissue slices and suspensions of human spleen with special reference to immunoglobulin and cytokine production. James K, et al. **Hum Antibodies Hybridomas** 1996; 7(4):138–50 (30 ref.)

Sites of B lymphocyte selection, activation, and tolerance in spleen. Liu YJ. **J Exp Med** 1997 Aug 29;186(5):625–9 (42 ref.)

INJURIES

The increasing frequency of nonoperative management of patients with liver and spleen injury. Rutledge R. **Adv Surg** 1996;30:385–415 (72 ref.)

PATHOLOGY

Granulomatous hepatitis and necrotizing splenitis due to Bartonella henselae in a patient with cancer: case report and review of hepatosplenic manifestations of bartonella infection. Liston TE, et al. **Clin Infect Dis** 1996 Jun; 22(6):951–7 (45 ref.)

Autosplenectomy in systemic lupus erythematosus. Uthman I, et al. **J Rheumatol** 1996 Oct;23(10):1806–10 (18 ref.)

SPLENECTOMY

Nephrotic syndrome associated with chronic lymphocytic leukemia resistant to immunosuppressive drugs: remission obtained by splenectomy [see comments] Halimi JM, et al. **Clin Nephrol** 1996 Apr;45(4):273–6 (19 ref.) Comment in: Clin Nephrol 1997 Feb;47(2):131–3.

Effectiveness of partial splenectomy in hereditary spherocytosis. Tchernia G, et al. **Curr Opin Hematol** 1997 Mar;4(2):136–41 (37 ref.)

Dental considerations in asplenic patients. De Rossi SS, et al. **J Am Dent Assoc** 1996 Sep;127(9):1359–63 (40 ref.)

[HIV infection and splenectomy: 3 cases and literature review] Greub G, et al. **Schweiz Med Wochenschr** 1996 Sep 7;126(36):1524–9 (36 ref.) (Eng. Abstr.) **(Fre)**

[The current status of vaccination and antibiotic prophylaxis in splenectomy. I: Adults] Funk EM, et al. **Chirurg** 1997 Jun;68(6):586–90 (25 ref.) (Eng. Abstr.) **(Ger)**

[Current status of vaccination and antibiotic prophylaxis in splenectomy. II: Children] Funk EM, et al. **Chirurg** 1997 Jun;68(6):591–5 (28 ref.) (Eng. Abstr.) **(Ger)**

[Diagnostic and therapeutic splenectomy in hematological diseases] Böhner H, et al. **Dtsch Med Wochenschr** 1997 Feb 7;122(6):163–6 (18 ref.) **(Ger)**

[Laparoscopic splenic surgery—report of 17 personal cases] Schwetling R, et al. **Zentralbl Chir** 1997;122(4):291–4 (15 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Overwhelming postsplenectomy infection. Lynch AM, et al. **Infect Dis Clin North Am** 1996 Dec;10(4):693–707 (107 ref.)

[A fatal case of overwhelming postsplenectomy infection syndrome developing 10 years after splenectomy] Urata Y, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1997 Jun; 20(3):184–90 (16 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Splenic conservation in the management of large splenic cysts: case report and literature review. Liew SH, et al. **J R Coll Surg Edinb** 1997 Apr;42(2):135–7 (35 ref.)

Laparoscopic accessory splenectomy for recurrent idiopathic thrombocytopenic purpura. Amaral JF, et al. **Surg Laparosc Endosc** 1997 Aug;7(4):340–4 (15 ref.)

SPLENIC ARTERY

Common splanchnic artery aneurysms: splenic, hepatic, and celiac. Shanley CJ, et al. **Ann Vasc Surg** 1996 May; 10(3):315–22 (124 ref.)

Rupture of splenic artery aneurysm after liver transplantation. Jovine E, et al. **Clin Transplant** 1996 Oct;10(5):451–4 (19 ref.)

A case of splenic artery aneurysm with Cushing's syndrome. Yoshitomi Y, et al. **Int J Cardiol** 1996 Jun;54(3):263–5 (5 ref.)

Visceral artery aneurysms. Messina LM, et al. **Surg Clin North Am** 1997 Apr;77(2):425–42 (40 ref.)

SPLENIC DISEASES

Splenic abscesses from 1987 to 1995. Ooi LL, et al. **Am J Surg** 1997 Jul;174(1):87–93 (95 ref.)

[Splenic abscess. Diagnosis and treatment] Rerbakken G, et al. **Tidsskr Nor Laegeforen** 1997 May 20;117(13):1908–10 (35 ref.) (Eng. Abstr.) **(Nor)**

CHEMICALLY INDUCED

Colosplenic fistula in a patient treated with interleukin–2 for malignant melanoma. Chun ES, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):674–6 (8 ref.)

COMPLICATIONS

Thrombocytopenia in association with a wandering spleen. Moll S, et al. **Am J Hematol** 1996 Dec;53(4):259–63 (17 ref.)

Autosplenectomy in systemic lupus erythematosus. Uthman I, et al. **J Rheumatol** 1996 Oct;23(10):1806–10 (18 ref.)

Hepatosplenic abscess caused by Curvularia boedijn in a patient with acute monocytic leukemia. Shigemori M, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1128–9 (11 ref.)

DIAGNOSIS

Autosplenectomy in systemic lupus erythematosus. Uthman I, et al. **J Rheumatol** 1996 Oct;23(10):1806–10 (18 ref.)

Inflammatory pseudotumor of the spleen in a young child. Aru GM, et al. **Pediatr Surg Int** 1997 Apr;12(4):299–301 (27 ref.)

Wandering spleen: a challenging diagnosis. Desai DC, et al. **South Med J** 1997 Apr;90(4):439–43 (41 ref.)

ETIOLOGY

[Sweet's syndrome and aseptic abscess of the spleen] Quilichini R, et al. **Rev Med Interne** 1996;17(12):1029–31 (15 ref.) (Eng. Abstr.) **(Fre)**

[Sarcoidosis representing multiple splenic nodules in a patient with IgA nephropathy] Nishiya H, et al. **Nippon Jinzo Gakkai Shi** 1996 Jan;38(1):40–5 (16 ref.) (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

Infective endocarditis and occult splenic abscess caused by Brucella melitensis infection: a case report and review of the literature. Saadeh AM, et al. **Acta Cardiol** 1996; 51(3):279–85 (32 ref.)

Candida splenic abscess in the absence of obvious immunodeficiency. Kapur A, et al. **Am J Gastroenterol** 1997 Mar;92(3):509–12 (29 ref.)

Actinomycotic splenic abscesses presenting with arthritis. Quintero–Del–Rio AI, et al. **Clin Exp Rheumatol** 1997 Jul–Aug;15(4):445–8 (13 ref.)

Granulomatous hepatitis and necrotizing splenitis due to Bartonella henselae in a patient with cancer: case report and review of hepatosplenic manifestations of bartonella infection. Liston TE, et al. **Clin Infect Dis** 1996 Jun; 22(6):951–7 (45 ref.)

Hepatosplenic abscesses due to Brucella melitensis: report of a case involving a child and review of the literature. Vallejo JG, et al. **Clin Infect Dis** 1996 Mar;22(3):485–9 (22 ref.)

RADIOGRAPHY

Abdominal visceral calcification in primary amyloidosis: CT findings. Jacobs JE, et al. **Abdom Imaging** 1997 Sep–Oct; 22(5):519–21 (8 ref.)

CT patterns of nodular hepatic and splenic sarcoidosis: a review of the literature. Scott GC, et al. **J Comput Assist Tomogr** 1997 May–Jun;21(3):369–72 (11 ref.)

[Radiation diagnosis of spleen diseases] Vlasov PV, et al. **Vestn Rentgenol Radiol** 1997 May–Jun;(3):27–34 (28 ref.) (Eng. Abstr.) **(Rus)**

SURGERY

Splenic conservation in the management of large splenic cysts: case report and literature review. Liew SH, et al. **J R Coll Surg Edinb** 1997 Apr;42(2):135–7 (35 ref.)

[Percutaneous ultrasound controlled drainage of large splenic abscesses] Schäberle W, et al. **Chirurg** 1997 Jul;68(7):744–8 (29 ref.) (Eng. Abstr.) **(Ger)**

[Splenic cyst—a classical "incidental finding"] Klee FE, et al. **Zentralbl Chir** 1996;121(10):805–16 (192 ref.) (Eng. Abstr.) **(Ger)**

[Laparoscopic splenic surgery—report of 17 personal cases]

SPLENIC DISEASES

Schwetling R, et al. **Zentralbl Chir** 1997;122(4):291–4 (15 ref.) (Eng. Abstr.) **(Ger)**
[Unusual pathology of the spleen] Costantini R, et al. **G Chir** 1997 Mar;18(3):143–9 (62 ref.) (Eng. Abstr.) **(Ita)**

SPLENIC INFARCTION

DIAGNOSIS

Splenic emergencies. Emery KH. **Radiol Clin North Am** 1997 Jul;35(4):831–43 (33 ref.)

ETIOLOGY

Isolated splenic infarction following left cardiac catheterization: case report and a review of the literature. Knobel B, et al. **Cathet Cardiovasc Diagn** 1996 Aug; 38(4):365–8 (20 ref.)
Liver–spleen infarcts following transcatheter chemoembolization: a case report and review of the literature on adverse effects. Cohen SE, et al. **Dig Dis Sci** 1997 May;42(5):938–43 (29 ref.)
[Splenic infarction in a HIV-infected patient. Apropos of a case and review of the literature] Aouad K, et al. **J Chir (Paris)** 1996;133(8):392–5 (19 ref.) (Eng. Abstr.) **(Fre)**

SPLENIC NEOPLASMS

Gamma/delta T-cell hepatosplenic lymphoma: review of the literature, diagnosis by flow cytometry and concomitant autoimmune hemolytic anemia. Sallah S, et al. **Ann Hematol** 1997 Mar;74(3):139–42 (15 ref.)
Current approach to the biology and treatment of chronic lymphoid malignancies other than CLL. Catovsky D. **Hematol Cell Ther** 1996 Dec;38 Suppl 2:S63–6 (27 ref.)

COMPLICATIONS

Case report: primary splenic non-Hodgkin's B cell lymphoma in a patient with chronic hepatitis C. Fukutomi T, et al. **J Gastroenterol Hepatol** 1996 Aug;11(8):724–7 (29 ref.)

GENETICS

Hepatosplenic gamma/delta T-cell lymphoma: a report of two cases in immunocompromised patients, associated with isochromosome 7q. François A, et al. **Am J Surg Pathol** 1997 Jul;21(7):781–90 (43 ref.)

PATHOLOGY

[Lymphoma of the marginal zone of the spleen. A case study] Navarro JT, et al. **Med Clin (Barc)** 1996 Feb 3;106(4):141–3 (15 ref.) (Eng. Abstr.) **(Spa)**

SECONDARY

Isolated splenic metastases from colon cancer. Indudhara R, et al. **South Med J** 1997 Jun;90(6):633–6 (24 ref.)
[A case of solitary metastatic splenic tumor of ovarian carcinoma] Kobayashi A, et al. **Gan To Kagaku Ryoho** 1997 Aug;24(10):1341–5 (7 ref.) (Eng. Abstr.) **(Jpn)**
[A case of cecum cancer metastasizing to the spleen after right hemicolectomy] Fuku A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Jan;94(1):33–7 (8 ref.) **(Jpn)**

SPLENIC RUPTURE

CHEMICALLY INDUCED

[Spontaneous splenic rupture due to heparin. Report of a case and review of the literature] Jabbour M, et al. **J Med Liban** 1995;43(2):107–9 (29 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Spontaneous rupture of the spleen associated with pneumonia. Domingo P, et al. **Eur J Clin Microbiol Infect Dis** 1996 Sep;15(9):733–6 (20 ref.)
Ruptured splenic abscess as cause of pneumoperitoneum. Puhakka KB, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Mar;166(3):273–4 (6 ref.)

DIAGNOSIS

Splenic rupture: an unusual complication of colonoscopy. Ahmed A, et al. **Am J Gastroenterol** 1997 Jul;92(7):1201–4 (31 ref.)
Splenic emergencies. Emery KH. **Radiol Clin North Am** 1997 Jul;35(4):831–43 (33 ref.)
[Delayed rupture of the spleen in a multiply injured patient] Lică I, et al. **Chirurgia (Bucur)** 1997 May–Jun;92(3):205–10 (12 ref.) (Eng. Abstr.) **(Rum)**

ETIOLOGY

Splenic rupture: an unusual complication of colonoscopy. Ahmed A, et al. **Am J Gastroenterol** 1997 Jul;92(7):1201–4 (31 ref.)
Splenic rupture after colonoscopy. Moses RE, et al. **J Clin Gastroenterol** 1997 Jun;24(4):257–8 (21 ref.)
Spontaneous rupture of the spleen in a patient with systemic lupus erythematosus. Tolaymat A, et al. **J Rheumatol** 1995 Dec;22(12):2344–5 (15 ref.)
Splenic rupture from colonoscopy. A report of two cases and review of the literature. Espinal EA, et al. **Surg Endosc** 1997 Jan;11(1):71–3 (19 ref.)

PATHOLOGY

Pathologic rupture of the spleen in hematologic malignancies: two additional cases. Giagounidis AA, et al. **Ann Hematol** 1996 Dec;73(6):297–302 (110 ref.)

SPLENOMEGALY

COMPLICATIONS

Porto-hepatic venous shunt via portal vein aneurysm with splenomegaly. Hanatate F, et al. **J Gastroenterol** 1995 Dec; 30(6):786–9 (21 ref.)

ETIOLOGY

Hyperreactive malarial syndrome. Ackerman L. **J Am Board Fam Pract** 1996 Sep–Oct;9(5):356–9 (12 ref.)

SPLENOPORTOGRAPHY see **PORTOGRAPHY**

SPLENORENAL SHUNT, SURGICAL

Should the distal splenorenal shunt be combined with gastric disconnection and transection? Henderson JM. **HPB Surg** 1997;10(3):184–5 (10 ref.)

METHODS

[Distal splenorenal shunt (Warren's operation) in the treatment of portal hypertension. Apropos 3 cases] Popescu I, et al. **Chirurgia (Bucur)** 1996;45(1):21–5 (27 ref.) (Eng. Abstr.) **(Rum)**

SPLICED LEADER PEPTIDES see **SIGNAL PEPTIDES**

SPLICEOSOMES

see related
RNA SPLICING

GENETICS

Pre-mRNA splicing: the discovery of a new spliceosome doubles the challenge. Tarn WY, et al. **Trends Biochem Sci** 1997 Apr;22(4):132–7 (40 ref.)

METABOLISM

Structural features of U6 snRNA and dynamic interactions with other spliceosomal components leading to pre-mRNA splicing. Forné T, et al. **Biochimie** 1996;78(6):436–42 (71 ref.)
The spliceosome is a dynamic ribonucleoprotein machine. Guthrie C. **Harvey Lect** 1994–95;90:59–80 (77 ref.)
Splicing glue: a role for SR proteins in trans splicing? Bruzik JP. **Microb Pathog** 1996 Sep;21(3):149–55 (65 ref.)
Pre-mRNA splicing: the discovery of a new spliceosome doubles the challenge. Tarn WY, et al. **Trends Biochem Sci** 1997 Apr;22(4):132–7 (40 ref.)

PHYSIOLOGY

Protein functions in pre-mRNA splicing. Will CL, et al. **Curr Opin Cell Biol** 1997 Jun;9(3):320–8 (92 ref.)

ULTRASTRUCTURE

Splicing of precursors to mRNA in higher plants: mechanism, regulation and sub-nuclear organisation of the spliceosomal machinery. Simpson GG, et al. **Plant Mol Biol** 1996 Oct; 32(1–2):1–41 (307 ref.)

SPLICING, ALTERNATIVE see **ALTERNATIVE SPLICING**

SPLICING, RNA see **RNA SPLICING**

SPLINTS

see related
STENTS

The Thomas splint. Questionable boast of an indispensable tool. Henry BJ, et al. **Am J Orthop** 1996 Sep;25(9):602–4 (12 ref.)
To splint or not to splint--past philosophy and present practice: Part I. Richard R, et al. **J Burn Care Rehabil** 1996 Sep–Oct;17(5):444–53 (112 ref.)
Splinting the wrist: mobilization and protection. Schultz-Johnson K. **J Hand Ther** 1996 Apr–Jun; 9(2):165–77 (54 ref.)
[Possibilities and limits of functional conservative therapy of acute Achilles tendon ruptures] Richter J, et al. **Chirurg** 1997 May;68(5):517–24 (37 ref.) (Eng. Abstr.) **(Ger)**

SPLINTS, OCCLUSAL see **OCCLUSAL SPLINTS**

SPLIT GENES see **GENES**

SPODOPTERA

METABOLISM

Endogenous chloride channels of insect sf9 cells. Evidence for coordinated activity of small elementary channel units. Larsen EH, et al. **J Gen Physiol** 1996 Jun;107(6):695–714 (38 ref.)

SPODOPTERA FRUGIPERDA see **SPODOPTERA**

SPONDYLARTHRITIS ANKYLOPOIETICA see **SPONDYLITIS, ANKYLOSING**

SPONDYLITIS

Pyogenic infectious spondylitis in children. The evolution to current thought. Ring D, et al. **Am J Orthop** 1996 May; 25(5):342–8 (69 ref.)
[Seronegative spondylarthropathy] Baba H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):360–4 (15 ref.) **(Jpn)**

COMPLICATIONS

Psoriatic spondyloarthropathy with secondary amyloidosis. Ahmed Q, et al. **J Rheumatol** 1996 Jun;23(6):1107–10 (28 ref.)

DIAGNOSIS

Spondylarthropathies. Edmonds JP. **Med J Aust** 1997 Feb 17;166(4):214–9 (12 ref.)
[Infectious spondylitis in adults] Vorbeck F, et al. **Radiologe** 1996 Oct;36(10):795–804 (17 ref.) (Eng. Abstr.) **(Ger)**
[Sacroiliitis:the key symptom of spondylarthropathies. 2: morphological aspects] Bollow M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Apr;166(4):275–89 (84 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Spondylarthropathies. Edmonds JP. **Med J Aust** 1997 Feb 17;166(4):214–9 (12 ref.)

ETIOLOGY

The role of gut inflammation in the pathogenesis of spondyloarthropathies. Mielants H, et al. **Acta Clin Belg** 1996;51(5):340–9 (60 ref.)
Vertebral osteomyelitis in diabetes mellitus [editorial; comment] Toyota T. **Intern Med** 1997 Jun;36(6):382–3 (12 ref.) Comment on: Intern Med 1997 Jun;36(6):443–5.
[Infectious complications after peridural obstetric anesthesia] Marsaudon E, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(2):159–62 (20 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

HLA-B27 and bacteria. Uksila J, et al. **Clin Rheumatol** 1996 Jan;15 Suppl 1:44–7 (27 ref.)

RADIOGRAPHY

Radiology and spondylarthritis. Calin A. **Baillieres Clin Rheumatol** 1996 Aug;10(3):455–76 (16 ref.)
The seronegative spondyloarthropathies. Kettering JM, et al. **Semin Roentgenol** 1996 Jul;31(3):220–8 (18 ref.)

SURGERY

Transpedicle instrumentation in the degenerative spine. Heim SE. **Clin Orthop** 1997 Apr;(337):97–110 (146 ref.)
[Role of surgery in the treatment of Pott's disease in adults. Apropos of 29 cases] Ghadouane M, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(7):620–8 (26 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Treatment of coccidioidal spinal infection: experience in 16 cases. Herron LD, et al. **J Spinal Disord** 1997 Jun; 10(3):215–22 (11 ref.)

SPONDYLITIS, ANKYLOSING

Molecular mimicry: the geographical distribution of immune responses to Klebsiella in ankylosing spondylitis and its relevance to therapy. Ebringer A, et al. **Clin Rheumatol** 1996 Jan;15 Suppl 1:57–61 (24 ref.)
Spondyloarthropathies–spondylarthropathies [editorial] Khan MA. **Curr Opin Rheumatol** 1996 Jul;8(4):267–8 (8 ref.)
Clinical and therapeutic aspects of juvenile-onset spondyloarthropathies. Malleson PN, et al. **Curr Opin Rheumatol** 1997 Jul;9(4):291–4 (20 ref.)
Juvenile-onset spondyloarthropathies. Burgos-Vargas R, et al. **Rheum Dis Clin North Am** 1997 Aug;23(3):569–98 (190 ref.)
[Ankylosing spondylitis] Baba H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):350–3 (11 ref.) **(Jpn)**

COMPLICATIONS

Unusual presentation of primary sclerosing cholangitis.

Pineau BC, et al. **Can J Gastroenterol** 1997 Jan-Feb; 11(1):45-8 (34 ref.)

Spontaneous avulsion injuries of tendons in patients with ankylosing spondylitis. Groupe de Recherche en Immuno-pathologie (GRIMP) [letter] Da Silva LF, et al. **Rev Rhum Engl Ed** 1996 Jul-Sep;63(7-8):504 (5 ref.)

Sarcoidosis and spondylarthropathy. Three case-reports. Kremer P, et al. **Rev Rhum Engl Ed** 1996 Jun;63(6):405-11 (36 ref.)

Simultaneous occurrence of diffuse idiopathic skeletal hyperostosis and ankylosing spondylitis. Moreno AC, et al. **Rev Rhum Engl Ed** 1996 Apr;63(4):292-5 (12 ref.)

DIAGNOSIS

Clinical and epidemiologic aspects of ankylosing spondylitis and spondyloarthropathies. van der Linden S, et al. **Curr Opin Rheumatol** 1996 Jul;8(4):269-74 (48 ref.)

Diagnosis of ankylosing spondylitis. Krongard DF, et al. **Radiol Technol** 1996 Nov-Dec;68(2):163-5 (7 ref.)

[Sacroiliitis: the key symptom of spondylathropathies. 1. The clinical aspects] Bollow M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Feb;166(2):95-100 (107 ref.) (Eng. Abstr.) **(Ger)**

[The rheumatoid patient as back pain patient. Diagnosis and differential diagnosis of seronegative spondylarthropathies] Lakomek HJ. **Versicherungsmedizin** 1997 Jun 1;49(3):78-81 (8 ref.) (Eng. Abstr.) **(Ger)**

DIET THERAPY

The use of a low starch diet in the treatment of patients suffering from ankylosing spondylitis. Ebringer A, et al. **Clin Rheumatol** 1996 Jan;15 Suppl 1:62-66 (15 ref.)

EPIDEMIOLOGY

Epidemiology of HLA-B27 and Arthritis. Khan MA. **Clin Rheumatol** 1996 Jan;15 Suppl 1:10-2 (16 ref.)

Clinical and epidemiologic aspects of ankylosing spondylitis and spondyloarthropathies. van der Linden S, et al. **Curr Opin Rheumatol** 1996 Jul;8(4):269-74 (48 ref.)

ETIOLOGY

Etiopathogenesis and biochemical and immunologic evaluation of spondyloarthropathies. Scofield RH. **Curr Opin Rheumatol** 1996 Jul;8(4):309-15 (71 ref.)

[New aspects in the pathogenesis of Bechterew disease] Märker-Hermann E, et al. **Z Rheumatol** 1996 Jan-Feb; 55(1):4-18 (92 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

HLA-B27 and HLA-B73 polymorphism and its role on antigenicity, peptide presentation, and disease susceptibility. Lopez De Castro JA. **Clin Rheumatol** 1996 Jan;15 Suppl 1:67-71 (24 ref.)

Experimental spondyloarthropathy in HLA-B27 transgenic rats. Taurog JD, et al. **Clin Rheumatol** 1996 Jan;15 Suppl 1:22-7 (22 ref.)

HLA-B27 structure, function, and disease association. López-Larrea C, et al. **Curr Opin Rheumatol** 1996 Jul; 8(4):296-308 (96 ref.)

Etiopathogenesis and biochemical and immunologic evaluation of spondyloarthropathies. Scofield RH. **Curr Opin Rheumatol** 1996 Jul;8(4):309-15 (71 ref.)

[Explanatory models for HLA-b27 association of reactive arthritis as a paradigm for spondyloarthropathy] Braun J, et al. **Med Klin** 1996 Sep 15;91(9):574-9 (54 ref.) **(Ger)**

PATHOLOGY

The sacroiliac joint in the spondyloarthropathies. Braun J, et al. **Curr Opin Rheumatol** 1996 Jul;8(4):275-87 (130 ref.)

PHYSIOPATHOLOGY

Anatomic predilection of the spondyloarthropathies(-)a case of the nerves? Segal AH. **J Rheumatol** 1996 Mar; 23(3):491-4 (60 ref.)

RADIOGRAPHY

The seronegative spondyloarthropathies. Kettering JM, et al. **Semin Roentgenol** 1996 Jul;31(3):220-8 (18 ref.)

SURGERY

Primary noncemented total hip arthroplasty in patients with ankylosing spondylitis. Clinical and radiographic results at an average follow-up period of 6 years. Brinker MR, et al. **J Arthroplasty** 1996 Oct;11(7):802-12 (48 ref.)

THERAPY

Management of spondyloarthropathies. Cuellar ML, et al. **Curr Opin Rheumatol** 1996 Jul;8(4):288-95 (52 ref.)

SPONDYLODESIS see **SPINAL FUSION**

SPONDYLODISCITIS see **DISCITIS**

SPONDYLOEPIPHYSEAL DYSPLASIA see **OSTEOCHONDRODYSPLASIAS**

SPONDYLOLISTHESIS

[Degenerative lumbar spondylolisthesis] Eshkenazi AU, et al. **Harefuah** 1997 Feb 2;132(3):229-32 (34 ref.) **(Heb)**

COMPLICATIONS

Lumbar spinal stenosis: indications for arthrodesis and spinal instrumentation. Herkowitz HN. **Instr Course Lect** 1994; 43:425-33 (35 ref.)

ETIOLOGY

Spine problems in the athlete. Stinson JT. **Md Med J** 1996 Aug;45(8):655-8 (25 ref.)

RADIOGRAPHY

[Significance of isthmic spondylolisthesis in expert assessment of occupational disease of the lumbar spine] Grosser V, et al. **Unfallchirurg** 1996 Jul;99(7):470-6 (16 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Indications for fusion in the lumbar spine. Hanley EN Jr. **Bull Hosp Jt Dis** 1996;55(3):154-7 (38 ref.)

The case for posterior lumbar interbody fusion. Branch CL Jr. **Clin Neurosurg** 1996;43:252-67 (62 ref.)

Controversies in low back pain: the surgical approach. Hanley EN Jr, et al. **Instr Course Lect** 1994;43:415-23 (56 ref.)

Adult spondylolisthesis treated with posterolateral lumbar fusion and pedicular instrumentation with AO DC plates. Thalgott JS, et al. **J Spinal Disord** 1997 Jun;10(3):204-8 (15 ref.)

When is spinal fusion warranted in degenerative lumbar spinal stenosis? Brunon J, et al. **Rev Rhum Engl Ed** 1996 Jan; 63(1):44-50 (35 ref.)

SPONDYLOLYSIS

RADIOGRAPHY

[Cervical spondylolysis in children. Apropos of 4 cases. Review of the literature] Garin C, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(7):626-30 (16 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Biomechanics of cervical spine surgery for tumor and degenerative diseases. Benzel EC. **Neurol Med Chir (Tokyo)** 1997 Aug;37(8):583-93 (44 ref.)

SPONDYLOSIS see **SPINAL OSTEOPHYTOSIS**

SPONDYLOSIS DEFORMANS see **SPINAL OSTEOPHYTOSIS**

SPONDYLOSYNDESIS see **SPINAL FUSION**

SPONGES (ZOOLOGY) see **PORIFERA**

SPONGIFORM ENCEPHALOPATHIES, TRANSMISSIBLE see **PRION DISEASES**

SPONGIFORM ENCEPHALOPATHY, BOVINE see **ENCEPHALOPATHY, BOVINE SPONGIFORM**

SPONGURIDINE see **ARABINOFURANOSYLURACIL**

SPORES, BACTERIAL

GENETICS

Genetic networks controlling the initiation of sporulation and the development of genetic competence in Bacillus subtilis. Grossman AD. **Annu Rev Genet** 1995;29:477-508 (121 ref.)

Molecular genetics of sporulation in Bacillus subtilis. Stragier P, et al. **Annu Rev Genet** 1996;30:297-41 (118 ref.)

GROWTH & DEVELOPMENT

Genetic networks controlling the initiation of sporulation and the development of genetic competence in Bacillus subtilis. Grossman AD. **Annu Rev Genet** 1995;29:477-508 (121 ref.)

SPORES, FUNGAL

Special transformation processes using fungal spores and immobilized cells. Larroche C, et al. **Adv Biochem Eng Biotechnol** 1997;55:179-220 (324 ref.)

SPOROTHRIX see **SPOROTRICHUM**

SPOROTRICHOSIS

Sporotrichosis. Davis BA. **Dermatol Clin** 1996 Jan; 14(1):69-76 (38 ref.)

EPIDEMIOLOGY

Spook house sporotrichosis. A point-source outbreak of sporotrichosis associated with hay bale props in a Halloween haunted-house. Dooley DP, et al. **Arch Intern Med** 1997 Sep 8;157(16):1885-7 (09 ref.)

ETIOLOGY

Spook house sporotrichosis. A point-source outbreak of sporotrichosis associated with hay bale props in a Halloween haunted-house. Dooley DP, et al. **Arch Intern Med** 1997 Sep 8;157(16):1885-7 (09 ref.)

SPOROTRICHUM

ISOLATION & PURIFICATION

Sporotrichosis. Davis BA. **Dermatol Clin** 1996 Jan; 14(1):69-76 (38 ref.)

PATHOGENICITY

Virulence factors of medically important fungi. Hogan LH, et al. **Clin Microbiol Rev** 1996 Oct;9(4):469-88 (326 ref.)

SPORTS

see related
ATHLETIC INJURIES
DOPING IN SPORTS

Nutrition and exercise in children. Caldarone G, et al. **Ann Ist Super Sanita** 1995;31(4):445-53 (26 ref.)

Sports-related problems in reproductive function. Orley J. **Ann N Y Acad Sci** 1997 Jun 17;816:285-94 (15 ref.)

Athletic amenorrhea. Wolf AS, et al. **Ann N Y Acad Sci** 1997 Jun 17;816:295-304 (36 ref.)

Effect of meal frequency and timing on physical performance. Hawley JA, et al. **Br J Nutr** 1997 Apr;77 Suppl 1:S91-103 (82 ref.)

Androgen use by athletes: a reevaluation of the health risks. Street C, et al. **Can J Appl Physiol** 1996 Dec;21(6):421-40 (82 ref.)

The power athlete. Longhurst JC, et al. **Cardiol Clin** 1997 Aug;15(3):413-29 (115 ref.)

Risk profiles and cardiovascular preparticipation screening of competitive athletes. Maron BJ. **Cardiol Clin** 1997 Aug; 15(3):473-83 (75 ref.)

Causes of sudden death in young and middle-aged competitive athletes. Virmani R, et al. **Cardiol Clin** 1997 Aug;15(3):439-66 (79 ref.)

Issues in detecting abuse of xenobiotic anabolic steroids and testosterone by analysis of athletes' urine. Catlin DH, et al. **Clin Chem** 1997 Jul;43(7):1280-8 (56 ref.)

The clinical value of serum ferritin tests in endurance athletes. Garza D, et al. **Clin J Sport Med** 1997 Jan;7(1):46-53 (54 ref.)

Infracalcaneal heel pain in the athlete. Agostinelli J, et al. **Clin Podiatr Med Surg** 1997 Jul;14(3):503-9 (14 ref.)

Dermatologic problems in podiatric sports medicine. King MJ. **Clin Podiatr Med Surg** 1997 Jul;14(3):511-24 (9 ref.)

Hallux limitus in the athlete. Lichniak JE. **Clin Podiatr Med Surg** 1997 Jul;14(3):407-26 (24 ref.)

Management of Morton's neuroma in athletes. Nunan PJ, et al. **Clin Podiatr Med Surg** 1997 Jul;14(3):489-501 (21 ref.)

Angular surgical corrections for hallux valgus. Pagliano JW. **Clin Podiatr Med Surg** 1997 Jul;14(3):427-45 (21 ref.)

Posterior tibial tendon dysfunction in the athlete. Ross JA. **Clin Podiatr Med Surg** 1997 Jul;14(3):479-88 (21 ref.)

Arthroscopic treatment of the degenerative knee in older athletes. Goldman RT, et al. **Clin Sports Med** 1997 Jan; 16(1):51-68 (45 ref.)

Nutritional aspects of amenorrhea in the female athlete triad. Benson JE, et al. **Int J Sport Nutr** 1996 Jun;6(2):134-45 (71 ref.)

Assessment of body composition in youths and relationship to sport. Houtkooper LB. **Int J Sport Nutr** 1996 Jun; 6(2):146-64 (48 ref.)

The thoracic outlet syndrome in athletes. Nichols AW. **J Am Board Fam Pract** 1996 Sep-Oct;9(5):346-55 (43 ref.)

Current issues in the mechanics of athletic activities. A position paper. Bartlett RM. **J Biomech** 1997 May; 30(5):477-86 (98 ref.)

The female athlete triad. Grooms AM. **J Fla Med Assoc** 1996 Aug-Sep;83(7):479-81 (20 ref.)

Fatal air transport accidents involving athletic teams from the United States. Murphy GK. **J Forensic Sci** 1997 Jan; 42(1):74-8 (14 ref.)

HIV-infected competitive athletes. What are the risks? What precautions should be taken? Feller A, et al. **J Gen Intern Med** 1997 Apr;12(4):243-6 (30 ref.)

Diets of elite athletes: has the discipline of sports nutrition made an impact? Grandjean AC. **J Nutr** 1997 May;127(5 Suppl):874S-877S (21 ref.)

From Olympia to Atlanta: a cultural-historical perspective on diet and athletic training. Grivetti LE, et al. **J Nutr** 1997 May;127(5 Suppl):860S-868S (60 ref.)

Professional burnout [editorial] Sullivan PA, et al. **J Sports Med Phys Fitness** 1996 Dec;36(4):231-5 (55 ref.)

Practical issues in nutrition for athletes. Burke L. **J Sports Sci** 1995 Summer;13 Spec No:S83-90 (22 ref.)

Macronutrients and performance. Williams C. **J Sports Sci** 1995 Summer;13 Spec No:S1-10 (88 ref.)

Sports after total joint replacement. Cirincione RJ. **Md Med J** 1996 Aug;45(8):644-7 (12 ref.)

Sport practice and osteoarthritis of the limbs. Lequesne MG, et al. **Osteoarthritis Cartilage** 1997 Mar;5(2):75-86 (68 ref.)

Physical activity, sport, and health: toward the next century. Haskell WL. **Res Q Exerc Sport** 1996 Sep;67(3

Suppl):S37–47 (59 ref.)
Adaptation to training and performance in elite athletes. Keul J, et al. **Res Q Exerc Sport** 1996 Sep;67(3 Suppl):S29–36 (45 ref.)
Ergogenic aids: a means to Citius, Altius, Fortius, and Olympic gold? Williams MH. **Res Q Exerc Sport** 1996 Sep; 67(3 Suppl):S58–64 (46 ref.)
Considerations in child and adolescent athletes. Emery HM. **Rheum Dis Clin North Am** 1996 Aug;22(3):499–513 (30 ref.)
The elite athlete and exercise in pregnancy. Hale RW, et al. **Semin Perinatol** 1996 Aug;20(4):277–84 (43 ref.)
Diagnosis, prophylaxis, and treatment of headaches in the athlete. Swain RA, et al. **South Med J** 1997 Sep; 90(9):878–88 (52 ref.)
Thermoregulation in spinal cord injury: the challenge of the Atlanta Paralympics. McCann BC. **Spinal Cord** 1996 Jul; 34(7):433–6 (19 ref.)
Drug use amongst young athletes. Do any of us really know what we're talking about? Albrecht RR. **Sports Med** 1996 Dec;22(6):351–4 (17 ref.)
Psychological and behavioural effects of endogenous testosterone and anabolic-androgenic steroids. An update. Bahrke MS, et al. **Sports Med** 1996 Dec;22(6):367–90 (157 ref.)
Effects of exercise on chromium levels. Is supplementation required? Clarkson PM. **Sports Med** 1997 Jun;23(6):341–9 (48 ref.)
Cardiovascular evaluation of the athlete. Issues regarding performance, screening and sudden cardiac death. Franklin BA, et al. **Sports Med** 1997 Aug;24(2):97–119 (139 ref.)
Eye injuries in athletics and recreation. Napier SM, et al. **Surv Ophthalmol** 1996 Nov–Dec;41(3):229–44 (70 ref.)
Exercise intolerance and poor performance in western performance and sprint horses. Kobluk CN, et al. **Vet Clin North Am Equine Pract** 1996 Dec;12(3):581–606 (49 ref.)
Diagnostic approach to exercise intolerance in racehorses. Lilich JD, et al. **Vet Clin North Am Equine Pract** 1996 Dec;12(3):555–64 (15 ref.)
Aspects of dehydration and rehydration in sport. Brouns F. **World Rev Nutr Diet** 1997;82:63–80 (61 ref.)
The 'Are' Sport Nutratherapy Program: the rationale for food supplements in sports medicine. Göransson U, et al. **World Rev Nutr Diet** 1997;82:101–21 (61 ref.)
[Sports activity and risk of arthrosis] Gross P, et al. **Schweiz Med Wochenschr** 1997 Jun 7;127(23):967–77 (60 ref.) (Eng. Abstr.) **(Ger)**
[Insulin therapy and sports] Aigner A. **Wien Med Wochenschr** 1997;147(9):222–5 (22 ref.) (Eng. Abstr.) **(Ger)**
[Exertional heatstroke—diagnosis, treatment and prevention] Albukrek D, et al. **Harefuah** 1996 Jun 16;130(12):828–33 (41 ref.) **(Heb)**
[Resistance-training in children and adolescents] Falk B. **Harefuah** 1996 Jun 2;130(11):778–83 (44 ref.) **(Heb)**
[Athlete's heart] Sunagawa O, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):578–81 (18 ref.) **(Jpn)**
[Energy and nutrients needs in athletes. The most common deficiencies] Vega Romero F, et al. **Rev Clin Esp** 1996 Jun;196(6):381–7 (66 ref.) **(Spa)**

PHYSIOLOGY

Exercise and bones. Lessons learned from female athletes. Drinkwater BL. **Am J Sports Med** 1996;24(6 Suppl):S33–5 (20 ref.)
Muscle function in movement and sports. Herzog W. **Am J Sports Med** 1996;24(6 Suppl):S14–9 (17 ref.)
New aspects of altitude training. Rusko HR. **Am J Sports Med** 1996;24(6 Suppl):S48–52 (29 ref.)
Physiological implications of altitude training for endurance performance at sea level: a review. Bailey DM, et al. **Br J Sports Med** 1997 Sep;31(3):183–90 (111 ref.)
Effect of altered reproductive function and lowered testosterone levels on bone density in male endurance athletes. Bennell KL, et al. **Br J Sports Med** 1996 Sep; 30(3):205–8 (59 ref.)
Factors influencing the restoration of fluid and electrolyte balance after exercise in the heat. Maughan RJ, et al. **Br J Sports Med** 1997 Sep;31(3):175–82 (26 ref.)
Mechanics of left ventricular systolic and diastolic function in physiologic hypertrophy of the athlete's heart. Colan SD. **Cardiol Clin** 1997 Aug;15(3):355–72 (112 ref.)
Impact of different sports and training on cardiac structure and function. Fagard RH. **Cardiol Clin** 1997 Aug; 15(3):397–412 (128 ref.)
Considerations for racial differences in the athlete's heart and related cardiovascular disease. Lewis JF. **Cardiol Clin** 1997 Aug;15(3):485–91 (64 ref.)
Outer limits of the athlete's heart, the effect of gender, and relevance to the differential diagnosis with primary cardiac diseases. Pelliccia A, et al. **Cardiol Clin** 1997 Aug; 15(3):381–96 (88 ref.)
The morphologic consequences of systemic training. Shapiro LM. **Cardiol Clin** 1997 Aug;15(3):373–9 (34 ref.)
Sport-related hematuria: a review. Jones GR, et al. **Clin J Sport Med** 1997 Apr;7(2):119–25 (64 ref.)
Assessment of left ventricular dimensions and functions in athletes and sedentary subjects at rest and during exercise using echocardiography, Doppler sonography and radionuclide ventriculography. Huonker M, et al. **Int J Sports Med** 1996 Nov;17 Suppl 3:S173–9 (64 ref.)
Structural and functional adaptations of the cardiovascular system by training. Huonker M, et al. **Int J Sports Med** 1996 Nov;17 Suppl 3:S164–72 (74 ref.)
Determinants of morphologic cardiac adaptation in elite athletes: the role of athletic training and constitutional factors. Pelliccia A. **Int J Sports Med** 1996 Nov;17 Suppl 3:S157–63 (85 ref.)
Preparticipation physical examinations. Sanders B, et al. **J Orthop Sports Phys Ther** 1996 Feb;23(2):149–63 (48 ref.)
The female athlete. Thein LA, et al. **J Orthop Sports Phys Ther** 1996 Feb;23(2):134–48 (93 ref.)
Training and overtraining: an overview and experimental results in endurance sports. Lehmann MJ, et al. **J Sports Med Phys Fitness** 1997 Mar;37(1):7–17 (51 ref.)
Immunity in athletes. Pedersen BK, et al. **J Sports Med Phys Fitness** 1996 Dec;36(4):236–45 (97 ref.)
The young athlete: some physiological considerations. Bar-Or O. **J Sports Sci** 1995 Summer;13 Spec No:S31–3 (22 ref.)
Nutritional ergogenics in athletics. Williams MH. **J Sports Sci** 1995 Summer;13 Spec No:S63–74 (90 ref.)
Special considerations in the athletic throwing shoulder. Arroyo JS, et al. **Orthop Clin North Am** 1997 Jan; 28(1):69–78 (72 ref.)
Impact of physical activity and sport on the immune system. Shepard RJ, et al. **Rev Environ Health** 1996 Jul–Sep; 11(3):133–47 (98 ref.)
Nutrition for improved sports performance. Current issues on ergogenic aids. Clarkson PM. **Sports Med** 1996 Jun; 21(6):393–401 (89 ref.)
Biomechanics of overhand throwing with implications for injuries. Fleisig GS, et al. **Sports Med** 1996 Jun;21(6):421–37 (68 ref.)
Biology and medicine of sailing. An update. Shephard RJ. **Sports Med** 1997 Jun;23(6):350–6 (49 ref.)
The use of isometric tests of muscular function in athletic assessment. Wilson GJ, et al. **Sports Med** 1996 Jul; 22(1):19–37 (89 ref.)
[New aspects in the evaluation of cardiologic fitness in sport activities. From the Bethesda Conference in 1994 to the Italian COCIS in 1996. Cardiologic Organizational Committee for Cardiovascular Fitness in Sport] Naccarella F, et al. **G Ital Cardiol** 1996 Dec;26(12):1507–39 (296 ref.) **(Ita)**
[Cardiomyopathy and enlarged hearts of athletes] Sugishita Y. **Nippon Naika Gakkai Zasshi** 1997 Mar 10;86(3):473–6 (4 ref.) **(Jpn)**

PSYCHOLOGY

Review of recent Chinese research on field dependence–independence in high-level athletes. Liu WH. **Percept Mot Skills** 1996 Dec;83(3 Pt 2):1187–93 (42 ref.)
[Horseback riding as a means of treatment and rehabilitation in neurology and psychiatry] Gurvich PT. **Zh Nevrol Psikhiatr Im S S Korsakova** 1997;97(8):65–7 (0 ref.) **(Rus)**

STANDARDS

Sports participation in children and adolescents with neurological impairments. Rothner AD. **Va Med Q** 1996 Spring;123(2):94–7, 114 (30 ref.)

SPORTS MEDICINE

see related
ATHLETIC INJURIES
PROTECTIVE DEVICES

Androgen use by athletes: a reevaluation of the health risks. Street C, et al. **Can J Appl Physiol** 1996 Dec;21(6):421–40 (82 ref.)
Sports medicine and the Americans with Disabilities Act. Nichols AW. **Clin J Sport Med** 1996 Jul;6(3):190–5 (21 ref.)
Cutaneous manifestations of sports participation. Pharis DB, et al. **J Am Acad Dermatol** 1997 Mar;36(3 Pt 1):448–59 (110 ref.)
Scientific application of sports medicine principles for acute low back problems. The Agency for Health Care Policy and Research Low Back Guideline Panel (AHCPR, Guideline #14) [see comments] Bigos SJ, et al. **J Orthop Sports Phys Ther** 1996 Oct;24(4):192–207 (5 ref.) Comment in: J Orthop Sports Phys Ther 1997 Aug;26(2):105–8.
Were you knocked out? A team physician's approach to initial concussion management. McCrory PR. **Med Sci Sports Exerc** 1997 Jul;29(7 Suppl):S207–12 (55 ref.)
Special considerations in exercise testing. Protocols, equipment, and testing athletes. Grumet J, et al. **Prim Care** 1994 Sep;21(3):459–74 (37 ref.)
The 'Are' Sport Nutratherapy Program: the rationale for food supplements in sports medicine. Göransson U, et al. **World Rev Nutr Diet** 1997;82:101–21 (61 ref.)
[Resistance-training in children and adolescents] Falk B. **Harefuah** 1996 Jun 2;130(11):778–83 (44 ref.) **(Heb)**

METHODS

The preparticipation athletic examination: a closer look. Krowchuk DP. **Pediatr Ann** 1997 Jan;26(1):37–49 (34 ref.)
Pediatric and adolescent sports medicine. Saperstein AL, et al. **Pediatr Clin North Am** 1996 Oct;43(5):1013–33 (59 ref.)

TRENDS

Trends in orthopedic sports medicine for the 21st century. Magee MJ, et al. **Md Med J** 1996 Aug;45(8):678–81 (11 ref.)

SPOUSE ABUSE

Sequelae of abuse. Health effects of childhood sexual abuse, domestic battering, and rape. Bohn DK, et al. **J Nurse Midwifery** 1996 Nov–Dec;41(6):442–56 (106 ref.)

DIAGNOSIS

Injuries and illnesses of domestic violence. Abbott J. **Ann Emerg Med** 1997 Jun;29(6):781–5 (23 ref.)
Documenting wife abuse: a guide for physicians. Ferris LE, et al. **Can Med Assoc J** 1997 Apr 1;156(7):1015–22 (49 ref.)
Domestic violence: identification and management for the clinician. Shadigian E. **Compr Ther** 1996 Jul;22(7):424–8 (22 ref.)
Selections from current literature: clinical detection of abuse. Kelso EB, et al. **Fam Pract** 1996 Aug;13(4):408–13 (21 ref.)
Recognizing abuse. Davidhizar R, et al. **Int Nurs Rev** 1996 Sep–Oct;43(5):145–50 (53 ref.)
Skin scraping, cupping, and moxibustion that may mimic physical abuse. Look KM, et al. **J Forensic Sci** 1997 Jan; 42(1):103–5 (9 ref.)
Woman abuse. The role of nurse-midwives in assessment. King MC, et al. **J Nurse Midwifery** 1996 Nov–Dec; 41(6):436–41 (13 ref.)
Forensic documentation of battered pregnant women. Sheridan DJ. **J Nurse Midwifery** 1996 Nov–Dec; 41(6):467–72 (14 ref.)
The importance of screening for domestic violence in all women. Poirier L. **Nurse Pract** 1997 May;22(5):105–8, 111–2, 115 passim (24 ref.)

ETHNOLOGY

Cultural competence in the care of abused women. Campbell JC, et al. **J Nurse Midwifery** 1996 Nov–Dec;41(6):457–62 (22 ref.)
Forensic nursing in Pakistan. Bridging the gap between victimized women and health care delivery systems. Carbonu DM, et al. **J Psychosoc Nurs Ment Health Serv** 1997 Jun;35(6):19–27 (41 ref.)
Alcohol and spouse abuse ethnic differences. Kantor GK. **Recent Dev Alcohol** 1997;13:57–79 (88 ref.)

LEGISLATION & JURISPRUDENCE

Effective advocacy for domestic violence victims. Role of the nurse-midwife. Orloff LE. **J Nurse Midwifery** 1996 Nov–Dec;41(6):473–94 (74 ref.)

PREVENTION & CONTROL

Injuries and illnesses of domestic violence. Abbott J. **Ann Emerg Med** 1997 Jun;29(6):781–5 (23 ref.)
Domestic violence: identification and management for the clinician. Shadigian E. **Compr Ther** 1996 Jul;22(7):424–8 (22 ref.)
Unheard and unseen. Rural women and domestic violence. Adler C. **J Nurse Midwifery** 1996 Nov–Dec;41(6):463–6 (3 ref.)
Cultural competence in the care of abused women. Campbell JC, et al. **J Nurse Midwifery** 1996 Nov–Dec;41(6):457–62 (22 ref.)
Effective advocacy for domestic violence victims. Role of the nurse-midwife. Orloff LE. **J Nurse Midwifery** 1996 Nov–Dec;41(6):473–94 (74 ref.)
Forensic nursing in Pakistan. Bridging the gap between victimized women and health care delivery systems. Carbonu DM, et al. **J Psychosoc Nurs Ment Health Serv** 1997 Jun;35(6):19–27 (41 ref.)
Domestic violence: the new standard of care. Holtz HA. **N J Med** 1996 Aug;93(8):33–6 (10 ref.)
Issues in the linkage of alcohol and domestic violence services. Collins JJ, et al. **Recent Dev Alcohol** 1997; 13:387–405 (91 ref.)
Empowering battered women transnationally: the case for postmodern interventions. Mills L. **Soc Work** 1996 May; 41(3):261–8 (38 ref.)

PSYCHOLOGY

Morbid jealousy as a variant of obsessive-compulsive disorder. Parker G, et al. **Aust N Z J Psychiatry** 1997 Feb; 31(1):133–8 (16 ref.)
Anger and hostility in maritally violent men: conceptual distinctions, measurement issues, and literature review. Eckhardt CI, et al. **Clin Psychol Rev** 1997;17(4):333–58 (111 ref.)
When your patient is a batterer. What you need to know before treating perpetrators of domestic violence. Mintz HA, et al. **Postgrad Med** 1997 Apr;101(4):219–21, 225–8 (15 ref.)
When women are under the influence. Does drinking or drug use by women provoke beatings by men? Kantor GK, et al. **Recent Dev Alcohol** 1997;13:315–36 (91 ref.)

STATISTICS & NUMERICAL DATA

Psychotropic drug use by women: could violence account for the gender difference? Mazza D, et al. **J Psychosom Obstet Gynaecol** 1996 Dec;17(4):229–34 (43 ref.)

How far have we come? A critical review of the research on men who batter. Lee WV, et al. **Recent Dev Alcohol** 1997;13:337–56 (75 ref.)

SPOUSE CAREGIVERS see **CAREGIVERS**

SPOUSES

Couples and reproductive health: a review of couple studies. Becker S. **Stud Fam Plann** 1996 Nov–Dec;27(6):291–306 (116 ref.)

PSYCHOLOGY

Dementia: an intimate death. Garner J. **Br J Med Psychol** 1997 Jun;70 (Pt 2):177–84 (37 ref.)

Unilateral interventions for women living with heavy drinkers. Barber JG, et al. **Soc Work** 1997 Jan;42(1):69–78 (38 ref.)

SPRAINS AND STRAINS

Medial collateral ligament injuries in athletes. Reider B. **Sports Med** 1996 Feb;21(2):147–56 (56 ref.)

COMPLICATIONS

Current opinions in etiopathogenesis of headaches caused by cervical spine pathology. Wojczal J. **Ann Univ Mariae Curie Sklodowska [Med]** 1995;50:95–101 (16 ref.)

PHYSIOPATHOLOGY

Muscle strain injuries. Garrett WE Jr. **Am J Sports Med** 1996; 24(6 Suppl):S2–8 (28 ref.)

REHABILITATION

Management of ankle sprains. Chorley JN, et al. **Pediatr Ann** 1997 Jan;26(1):56–64 (21 ref.)

SURGERY

[The unstable upper ankle joint. Treatment of acute ligament rupture—a review of the literature] Sommer CJ. **Sportverletz Sportschaden** 1996 Dec;10(4):76–8 (34 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Role of ankle taping and bracing in the athlete. Callaghan MJ. **Br J Sports Med** 1997 Jun;31(2):102–8 (64 ref.)

SPREADING CORTICAL DEPRESSION

PHYSIOLOGY

Periinfarct depolarizations. Hossmann KA. **Cerebrovasc Brain Metab Rev** 1996 Fall;8(3):195–208 (81 ref.)

Role of astrocytes in the spreading depression signal between ischemic core and penumbra. Walz W. **Neurosci Biobehav Rev** 1997 Mar;21(2):135–42 (38 ref.)

SPRUE see **CELIAC DISEASE**

SPRUE, TROPICAL

Malabsorption syndrome in India. Ramakrishna BS. **Indian J Gastroenterol** 1996 Oct;15(4):135–41 (109 ref.)

ETIOLOGY

Tropical sprue and subclinical enteropathy: a vision for the nineties. Haghighi P, et al. **Crit Rev Clin Lab Sci** 1997 Aug; 34(4):313–41 (192 ref.)

PATHOLOGY

Tropical sprue and subclinical enteropathy: a vision for the nineties. Haghighi P, et al. **Crit Rev Clin Lab Sci** 1997 Aug; 34(4):313–41 (192 ref.)

SPUMAVIRINAE see **SPUMAVIRUS**

SPUMAVIRUS

GENETICS

Unexpected replication pathways of foamy viruses. Rethwilm A. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S248–53 (52 ref.)

Molecular biology of the human foamy virus. Saïb A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S254–60 (69 ref.)

Analysis of the phylogenetic placement of different spumaretroviral genes reveals complex pattern of foamy virus evolution. Dias HW, et al. **Virus Genes** 1995; 11(2–3):183–90 (29 ref.)

GROWTH & DEVELOPMENT

Molecular biology of the human foamy virus. Saïb A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S254–60 (69 ref.)

SPUTUM

Selected mimics of malignancy in sputum and bronchoscopic cytology specimens. Naryshkin S, et al. **Diagn Cytopathol** 1995 Dec;13(5):443–7 (12 ref.)

CYTOLOGY

Comparison of the sensitivity of sputum and brush cytology in the diagnosis of lung carcinomas. Sing A, et al. **Acta Cytol** 1997 Mar–Apr;41(2):399–408 (67 ref.)

The investigation of airway inflammation in asthma: sputum examination. Hargreave FE. **Clin Exp Allergy** 1997 May; 27 Suppl 1:36–40 (39 ref.)

IMMUNOLOGY

The use of induced sputum to investigate airway inflammation [editorial] Pavord ID, et al. **Thorax** 1997 Jun; 52(6):498–501 (39 ref.)

MICROBIOLOGY

[Neisseria meningitidis: isolation from low respiratory tract secretions of adult patients] Ferrer Marcellés A, et al. **Rev Clin Esp** 1996 Nov;196(11):741–6 (36 ref.) (Eng. Abstr.) **(Spa)**

SQUALENE

PHARMACOLOGY

Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. O'Hagan DT, et al. **Mol Med Today** 1997 Feb;3(2):69–75 (47 ref.)

SQUALUS see **DOGFISH**

SQUASH see **RACQUET SPORTS**

SQUID

MICROBIOLOGY

Lessons from a cooperative, bacterial–animal association: the Vibrio fischeri–Euprymna scolopes light organ symbiosis. Ruby EG. **Annu Rev Microbiol** 1996;50:591–624 (138 ref.)

SQUINT see **STRABISMUS**

SQUIRRELS see **SCIURIDAE**

SRC-FAMILY KINASES

CHEMISTRY

A crystal milestone: the structure of regulated Src. Superti-Furga G, et al. **Bioessays** 1997 Jun;19(6):447–50 (31 ref.)

Signal transduction: clamping down on Src activity. Mayer BJ. **Curr Biol** 1997 May 1;7(5):R295–8 (13 ref.)

Lyn, a src-like tyrosine kinase. Hibbs ML, et al. **Int J Biochem Cell Biol** 1997 Mar;29(3):397–400 (12 ref.)

METABOLISM

Signal transduction: clamping down on Src activity. Mayer BJ. **Curr Biol** 1997 May 1;7(5):R295–8 (13 ref.)

Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways. Parsons JT, et al. **Curr Opin Cell Biol** 1997 Apr;9(2):187–92 (56 ref.)

Analysis of the interactions between Nef and cellular proteins. Coates K, et al. **Res Virol** 1997 Jan–Feb; 148(1):68–70 (14 ref.)

The role of HIV1 Nef in T-cell activation: Nef impairs induction of Th1 cytokines and interacts with the Src family tyrosine kinase Lck. Collette Y, et al. **Res Virol** 1997 Jan–Feb;148(1):52–8 (44 ref.)

The role of Src family kinases in the normal and neoplastic gastrointestinal tract. Banker N, et al. **Surg Oncol** 1996 Oct–Dec;5(5–6):201–10 (92 ref.)

PHYSIOLOGY

Lyn, a src-like tyrosine kinase. Hibbs ML, et al. **Int J Biochem Cell Biol** 1997 Mar;29(3):397–400 (12 ref.)

Immunoreceptor tyrosine-based activation motif (ITAM), a unique module linking antigen and Fc receptors to their signaling cascades. Isakov N. **J Leukoc Biol** 1997 Jan; 61(1):6–16 (123 ref.)

Selective neural cell adhesion molecule signaling by Src family tyrosine kinases and tyrosine phosphatases. Maness PF, et al. **Perspect Dev Neurobiol** 1996;4(2–3):169–81 (169 ref.)

Possible involvement of adherens junction plaque proteins in tumorigenesis and metastasis. Tsukita S, et al. **Princess Takamatsu Symp** 1994;24:38–50 (69 ref.)

SRC HOMOLOGY DOMAINS

Modular peptide recognition domains in eukaryotic signaling. Kuriyan J, et al. **Annu Rev Biophys Biomol Struct** 1997; 26:259–88 (102 ref.)

Intracellular targeting, interaction with Src homology 3 (SH3) domains and rolipram-detected conformational switches in cAMP-specific PDE4A phosphodiesterase. Houslay MD, et al. **Biochem Soc Trans** 1997 May; 25(2):374–81 (50 ref.)

How pathogens exploit interactions mediated by SH3 domains. Bliska J. **Chem Biol** 1996 Jan;3(1):7–11 (23 ref.)

Much more than the sum of the parts: structures of the dual SH2 domains of ZAP-70 and Syp. Cowburn D. **Chem Biol** 1996 Feb;3(2):79–82 (18 ref.)

SH2 and SH3-containing adaptor proteins: redundant or independent mediators of intracellular signal transduction. Birge RB, et al. **Genes Cells** 1996 Jul;1(7):595–613 (198 ref.)

Cytoplasmic signalling domains: the next generation. Bork P, et al. **Trends Biochem Sci** 1997 Aug;22(8):296–8 (20 ref.)

GENETICS

Reading between the lines: SH3 recognition of an intact protein. Lim WA. **Structure** 1996 Jun 15;4(6):657–9 (23 ref.)

PHYSIOLOGY

Signal transductions of SH2/SH3: Ash/Grb-2 downstream signaling. Takenawa T, et al. **Adv Pharmacol** 1996; 36:139–53 (24 ref.)

[Domains in biological membranes and their physiological importance] Bandorowicz-Pikuła J. **Postepy Biochem** 1995; 41(4):247 (104 ref.) **(Pol)**

SRC ONCOGENE PROTEIN PP60 see **ONCOGENE PROTEIN PP60(V-SRC)**

SRC PROTO-ONCOGENE PROTEIN PP60 see **PROTO-ONCOGENE PROTEIN PP60(C-SRC)**

SRP see **SIGNAL RECOGNITION PARTICLE**

SRS-A

THERAPEUTIC USE

Alternative treatments in the patient with intractable asthma. Spector SL. **Curr Opin Pulm Med** 1997 Jan;3(1):23–9 (64 ref.)

SRS-A RECEPTORS see **RECEPTORS, LEUKOTRIENE**

SRV-1 see **RETROVIRUSES TYPE D, SIMIAN**

SRV-2 see **RETROVIRUSES TYPE D, SIMIAN**

SRV-4 see **RETROVIRUSES TYPE D, SIMIAN**

SRV-5 see **RETROVIRUSES TYPE D, SIMIAN**

SSCP see **POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL**

SSEA-1 see **ANTIGENS, CD15**

SSEA-1 DETERMINANT see **ANTIGENS, CD15**

SSPE see **SUBACUTE SCLEROSING PANENCEPHALITIS**

ST. ANTHONY'S FIRE see **ERGOTISM**

STA-MCA BYPASS see **CEREBRAL REVASCULARIZATION**

STABILIZING AGENTS see **EXCIPIENTS**

STABLE FACTOR see **FACTOR VII**

STABLE FLY see **MUSCIDAE**

STAFF DEVELOPMENT

ECONOMICS

A framework for the management of intellectual capital in the health care industry. Grantham CE, et al. **J Health Care Finance** 1997 Spring;23(3):1–19 (52 ref.)

METHODS

An evolutionary concept analysis of mentoring in nursing. Stewart BM, et al. **J Prof Nurs** 1996 Sep–Oct;12(5):311–21 (83 ref.)

ORGANIZATION & ADMINISTRATION

The sabbatical year: letting the fields lay fallow. Tiedje LB, et al. **Nurs Outlook** 1996 Sep–Oct;44(5):235–8 (11 ref.)

STAFF WORKLOAD see **WORKLOAD**

STAFFING AND SCHEDULING see **PERSONNEL STAFFING AND SCHEDULING**

STAGE-SPECIFIC EMBRYONIC ANTIGEN-1 see **ANTIGENS, CD15**

STAGGERER MICE see **MICE, NEUROLOGIC MUTANTS**

STAGING, NEOPLASM see **NEOPLASM STAGING**

STAINING

see related
DYES

The Gram stain after more than a century. Popescu A, et al. **Biotech Histochem** 1996 May;71(3):145–51 (60 ref.)

Staining of the nucleolar organizer regions: relevance in hematology. Baatout S. **Blood Rev** 1996 Sep;10(3):185–8 (33 ref.)

METHODS

Rapid diagnosis of acute eosinophilic pneumonia (AEP) in a patient with respiratory failure using bronchoalveolar lavage (BAL) with calcofluor white (CW) staining. Hogan TF, et al. **J Clin Lab Anal** 1997;11(4):202–7 (65 ref.)

Probing bacterial gene expression within host cells. Valdivia RH, et al. **Trends Microbiol** 1997 Sep;5(9):360–3 (16 ref.)

STAINS see **DYES**

STAMMERING see **STUTTERING**

STANDARD PREPARATIONS see **REFERENCE STANDARDS**

STANDARDS, REFERENCE see **REFERENCE STANDARDS**

STANNUM see **TIN**

STANOLONE

METABOLISM

Androgens, androgen receptors, antiandrogens and the treatment of prostate cancer. Griffiths K, et al. **Eur Urol** 1997;32 Suppl 3:24–40 (82 ref.)

PHARMACOKINETICS

[Finasteride: a new drug for the treatment of male hirsutism and androgenetic alopecia?] Spinucci G, et al. **Clin Ter** 1996 Jun;147(6):305–15 (41 ref.) (Eng. Abstr.) **(Ita)**

THERAPEUTIC USE

[Treatment of erectile disorders with androgens: When? How?] Tostain J, et al. **Prog Urol** 1997 Apr;7(2):314–9 (18 ref.) (Eng. Abstr.) **(Fre)**

STANOZOLOL

ADVERSE EFFECTS

Anticardiolipin (aCL) antibodies in a patient with Behçet's syndrome with vena cava inferior thrombosis. Ebo DG, et al. **Clin Rheumatol** 1997 Jan;16(1):96–8 (15 ref.)

STAPEDECTOMY see **STAPES SURGERY**

STAPEDIUS

SURGERY

Stapedius tendon reconstruction during stapedotomy: technique and results. Causse JB, et al. **Ear Nose Throat J** 1997 Apr;76(4):256–8, 260–9 (29 ref.)

STAPES

ANATOMY & HISTOLOGY

On the role played by ontogenetic remodeling and functional transformation in the evolution of terrestrial hearing. Fritzsch B. **Brain Behav Evol** 1997 Jul;50(1):38–49 (75 ref.)

STAPES SURGERY

Revision stapedectomy: intraoperative findings, results, and review of the literature. Han WW, et al. **Laryngoscope** 1997 Sep;107(9):1185–92 (24 ref.)

METHODS

Stapedius tendon reconstruction during stapedotomy: technique and results. Causse JB, et al. **Ear Nose Throat J** 1997 Apr;76(4):256–8, 260–9 (29 ref.)

STAPHYLOCOAGULASE see **COAGULASE**

STAPHYLOCOCCAL CLUMPING FACTOR see **COAGULASE**

STAPHYLOCOCCAL INFECTIONS

see related
CROSS INFECTION

The progressive intercontinental spread of methicillin-resistant Staphylococcus aureus. Ayliffe GA. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S74–9 (60 ref.)

Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Kluytmans J, et al. **Clin Microbiol Rev** 1997 Jul;10(3):505–20 (218 ref.)

Management of staphylococcal and streptococcal infections. Tan JS, et al. **Clin Podiatr Med Surg** 1996 Oct;13(4):793–816 (56 ref.)

Successful treatment of Staphylococcus lugdunensis endocarditis complicated by multiple emboli: a case report and review of the literature. Koh TW, et al. **Int J Cardiol** 1996 Jul 26;55(2):193–7 (18 ref.)

[The role of capsule in staphylococcal infection and immunity] Ichiman Y. **Nippon Saikingaku Zasshi** 1996 Feb; 51(2):601–11 (15 ref.) **(Jpn)**

COMPLICATIONS

Spontaneous obliteration of a pseudo-aneurysm complicating an aortic homograft. Federmann M, et al. **Eur J Cardiothorac Surg** 1996;10(8):705–6 (5 ref.)

Nontropical pyomyositis in patients with AIDS. Antony SJ, et al. **J Natl Med Assoc** 1996 Sep;88(9):565–9 (45 ref.)

Concomitant crystal and septic arthritis. Ilahi OA, et al. **Orthopedics** 1996 Jul;19(7):613–7 (31 ref.)

Staphylococcal tracheitis, pneumonia, and adult respiratory distress syndrome. Horowitz IN. **Pediatr Emerg Care** 1996 Aug;12(4):288–90 (14 ref.)

Simultaneous presentation of Kawasaki disease and toxic shock syndrome in an adolescent male [see comments] Davies HD, et al. **Pediatr Infect Dis J** 1996 Dec; 15(12):1136–8 (14 ref.) Comment in: Pediatr Infect Dis J 1997 Jun;16(6):633–4.

Nonmenstrual toxic shock syndrome in a young child with human immunodeficiency virus infection. Shah A, et al. **Pediatr Infect Dis J** 1996 Jul;15(7):639–41 (12 ref.)

[A case of toxic shock syndrome (TSS) induced by methicillin-resistant staphylococcus aureus (MRSA) presenting as acute renal failure with disseminated intravascular coagulation] Fukuuchi F, et al. **Nippon Jinzo Gakkai Shi** 1996 Jan;38(1):27–32 (20 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Pyomyositis as a nontropical disease. Harbarth SJ, et al. **Curr Clin Top Infect Dis** 1997;17:37–50 (74 ref.)

Coagulase-negative staphylococcal infections: an update regarding recognition and management. Rupp ME. **Curr Clin Top Infect Dis** 1997;17:51–87 (261 ref.)

Spinal epidural abscess: the nurse's role in early detection and intervention. Hoppe B. **Heart Lung** 1996 Nov–Dec; 25(6):463–6 (34 ref.)

A case of muscle abscess presenting to an accident and emergency department. Howell MA, et al. **J Accid Emerg Med** 1997 May;14(3):180–2 (22 ref.)

Acute non-tuberculous retropharyngeal abscess in an adult. A case report and review of the literature. Karkanevatos A, et al. **J Laryngol Otol** 1997 Feb;111(2):169–71 (9 ref.)

Pyomyositis: clinical features and predisposing conditions. Patel SR, et al. **J Rheumatol** 1997 Sep;24(9):1734–8 (61 ref.)

MRI of pituitary abscess: two cases and review of the literature. Wolansky LJ, et al. **Neuroradiology** 1997 Jul; 39(7):499–503 (35 ref.)

Low-grade spinal epidural infection. Report of a case. Berthelot JM, et al. **Rev Rhum Engl Ed** 1996 Jan; 63(1):59–61 (17 ref.)

DRUG THERAPY

Managing methicillin-resistant Staphylococcus aureus in hospital: the balance of risk. Stone SP. **Age Ageing** 1997 May;26(3):165–8 (45 ref.)

Epidemiology, control and treatment of methicillin-resistant Staphylococcus aureus. Peters G, et al. **Drugs** 1996;52 Suppl 2:50–4 (11 ref.)

Methicillin-resistant Staphylococcus aureus in nursing homes. Epidemiology, prevention and management. Bradley SF. **Drugs Aging** 1997 Mar;10(3):185–98 (90 ref.)

Mupirocin resistance and methicillin-resistant Staphylococcus aureus (MRSA). Eltringham I. **J Hosp Infect** 1997 Jan;35(1):1–8 (44 ref.)

The treatment of staphylococcal infections with special reference to pharmacokinetic, pharmacodynamic and pharmacoeconomic considerations. Janknegt R. **Pharm World Sci** 1997 Jun;19(3):133–41 (45 ref.)

Staphylococcus aureus, trimethoprim-sulfamethoxazole, and Wegener's granulomatosis. Kallenberg CG, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct;13(3):253–5 (19 ref.)

[Nosocomial infections caused by multiresistant pathogens. Clinical management exemplified by multiresistant Staphylococcus aureus] Knopf HJ. **Urologe A** 1997 May; 36(3):248–54 (27 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

The epidemiology of methicillin-resistant Staphylococcus aureus: surgical relevance 20 years on. McDonald M. **Aust N Z J Surg** 1997 Oct;67(10):682–5 (32 ref.)

ETIOLOGY

Clinical considerations in hemodialysis access infection. Albers FJ. **Adv Ren Replace Ther** 1996 Jul;3(3):208–17 (46 ref.)

Peritoneal catheter exit-site and tunnel infections. Piraino B. **Adv Ren Replace Ther** 1996 Jul;3(3):222–7 (56 ref.)

Systemic infection related to endocarditis on pacemaker leads: clinical presentation and management. Klug D, et al. **Circulation** 1997 Apr 15;95(8):2098–107 (36 ref.)

Catheter-associated Staphylococcus aureus bacteremia. Gold HS, et al. **Hosp Pract (Off Ed)** 1996 Sep 15;31(9):133–7, 142–4, 150 (14 ref.)

Asymptomatic posterior orbital cellulitis resulting from ethmoid/maxillary sinusitis. Filips RF, et al. **J Am Optom Assoc** 1997 Jan;68(1):55–60 (18 ref.)

Mycotic aortic aneurysms after orthotopic heart transplantation: a three-case report and review of the literature. Knosalla C, et al. **J Heart Lung Transplant** 1996 Aug;15(8):827–39 (27 ref.)

Toxic shock syndrome after explantation of breast implants: a case report and review of the literature. Walker LE, et al. **Plast Reconstr Surg** 1997 Mar;99(3):875–9 (19 ref.)

[Infectious complications of cardioverter/defibrillators--case report and review of the literature] Hollenstein U, et al. **Acta Med Austriaca** 1996;23(5):164–7 (20 ref.) (Eng. Abstr.) **(Ger)**

[Epiduritis after long-term pain therapy with an epidural catheter--review of the literature with a current case report] Michel H, et al. **Anaesthesiol Reanim** 1997; 22(3):69–79 (105 ref.) (Eng. Abstr.) **(Ger)**

[A case report of postcoarctation mycotic aneurysm after surgical treatment for cerebral arterial aneurysms] Kido M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jul; 45(7):1006–10 (7 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

[Superantigens and glomerulonephritis] Koyama T, et al. **Nippon Naika Gakkai Zasshi** 1997 Apr 10;86(4):695–701 (14 ref.) **(Jpn)**

MICROBIOLOGY

Mycotic aneurysm of the carotid artery. A case report and review of the literature. Michielsen D, et al. **Acta Chir Belg** 1997 Jan–Feb;97(1):44–6 (14 ref.)

Destructive endocarditis caused by Staphylococcus lugdunensis. Case report and review of the literature. De Hondt G, et al. **Acta Clin Belg** 1997;52(1):27–30 (10 ref.)

Pyomyositis with toxic shock syndrome presenting as back pain and fever: a case report and literature review. Wolfe MW, et al. **Am J Orthop** 1997 Feb;26(2):135–7 (26 ref.)

Methicillin-resistant Staphylococcus aureus in nursing homes. Epidemiology, prevention and management. Bradley SF. **Drugs Aging** 1997 Mar;10(3):185–98 (90 ref.)

Methicillin resistant Staphylococcus aureus (MRSA): disease spectrum, biological characteristics, resistant mechanisms, and typing methods. Abdo RA, et al. **J Med Liban** 1996; 44(1):21–30 (90 ref.)

Cross infections due to coagulase-negative staphylococci in high-risk patients. Hübner J, et al. **Zentralbl Bakteriol** 1995 Dec;283(2):169–74 (23 ref.)

[Clinically isolated bacterii seen in complicated infections] Iwai S. **Nippon Geka Gakkai Zasshi** 1996 Dec;97(12):1091–6 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Skin infections due to Staphylococcus aureus and Streptococcus pyogenes] Arata J. **Nippon Rai Gakkai Zasshi** 1996 Jul;65(2):83–7 (10 ref.) **(Jpn)**

[MRSA-related glomerulonephritis] Muro K, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):99–101 (8 ref.) **(Jpn)**

PREVENTION & CONTROL

Staphylococcus aureus vaccination for dialysis patients--an update. Fattom AI, et al. **Adv Ren Replace Ther** 1996 Oct; 3(4):302–8 (57 ref.)

The epidemiology of methicillin-resistant Staphylococcus aureus: surgical relevance 20 years on. McDonald M. **Aust N Z J Surg** 1997 Oct;67(10):682–5 (32 ref.)

Review of methicillin resistant Staphylococcus aureus with special reference to handling of surgical patients. Gakuu LN. **East Afr Med J** 1997 Mar;74(3):198–202 (22 ref.)

Preventing staphylococcal infections by eradicating nasal carriage of Staphylococcus aureus: proceeding with caution [editorial; comment] Boyce JM. **Infect Control Hosp Epidemiol** 1996 Dec;17(12):775–9 (50 ref.) Comment on: Infect Control Hosp Epidemiol 1996 Dec;17(12):780–5. Comment on: Infect Control Hosp Epidemiol 1996 Dec;17(12):786–92. Comment on: Infect Control Hosp Epidemiol 1996 Dec;17(12):813–6.

Methicillin-resistant Staphylococcus aureus (MRSA)--a re-appraisal of control measures in the light of changing circumstances. Humphreys H, et al. **J Hosp Infect** 1997 Jul;36(3):167–70 (20 ref.)

Is control of methicillin-resistant Staphylococcus aureus justified? Bowler IC. **QJM** 1997 Apr;90(4):243–6 (26 ref.)

[Control of Nosocomial infections: prevention of respiratory infections in the elderly] Nagatake T, et al. **Nippon Saikingaku Zasshi** 1996 Aug;51(3):871–6 (14 ref.)

(Jpn)

RADIOGRAPHY

[Septic arthritis of posterior lumbar facet joint] Ben Hamouda M, et al. **J Radiol** 1997 May;78(5):373–6 (10 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

[Tricuspid valvulectomy in antibiotic-refractory right-heart endocarditis] Hust MH, et al. **Dtsch Med Wochenschr** 1997 Jan 24;122(4):80–5 (36 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Coagulase-negative staphylococcal infections: an update regarding recognition and management. Rupp ME. **Curr Clin Top Infect Dis** 1997;17:51–87 (261 ref.)

[A case of successful treatment of mediastinitis and prosthetic graft infection after aortic arch and thoracoabdominal aortic reconstruction] Kawashima T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Feb;45(2):220–4 (12 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Transesophageal echocardiographic diagnosis of eustachian valve endocarditis. Georgeson R, et al. **J Am Soc Echocardiogr** 1996 Mar–Apr;9(2):206–8 (14 ref.)

STAPHYLOCOCCAL PROTEIN A

CHEMISTRY

Protein glycosylation in the endoplasmic reticulum and the Golgi apparatus and cell type-specificity of cell surface glycoconjugate expression: analysis by the protein A–gold and lectin–gold techniques. Roth J. **Histochem Cell Biol** 1996 Jul;106(1):79–92 (130 ref.)

GENETICS

The use of gene fusions to protein A and protein G in immunology and biotechnology. Ståhl S, et al. **Pathol Biol (Paris)** 1997 Jan;45(1):66–76 (99 ref.)

ISOLATION & PURIFICATION

[A case of the successful use of protein A adsorption in a patient with acute kidney failure in rapidly progressing lupus glomerulonephritis] Aksenov VA, et al. **Ter Arkh** 1997;69(2):66–8 (14 ref.) **(Rus)**

[The clinical use of protein-A immunoadsorption] Aksenov VA. **Ter Arkh** 1996;68(11):83–5 (35 ref.) **(Rus)**

METABOLISM

Staphylococcal protein A binding to VH3 encoded immunoglobulins. Potter KN, et al. **Int Rev Immunol** 1997; 14(4):291–308 (55 ref.)

CcpA and HPr(ser-P): mediators of catabolite repression in Bacillus subtilis. Chauvaux S. **Res Microbiol** 1996 Jul–Sep; 147(6–7):518–22 (20 ref.)

STAPHYLOCOCCAL SCALDED SKIN SYNDROME

COMPLICATIONS

Stevens-Johnson syndrome, epidermolysis bullosa, staphylococcal scalded skin syndrome, and dermatitis herpetiformis. Hochman MA, et al. **Int Ophthalmol Clin** 1997 Spring;37(2):77–92 (87 ref.)

STAPHYLOCOCCAL VACCINES

Staphylococcal vaccines: a realistic dream. Fattom AI, et al. **Ann Med** 1996 Feb;28(1):43–6 (20 ref.)

STAPHYLOCOCCUS

CHEMISTRY

The staphylococcal and streptococcal pyrogenic toxin family. Bohach GA, et al. **Adv Exp Med Biol** 1996;391:131–54 (116 ref.)

CLASSIFICATION

Cross infections due to coagulase-negative staphylococci in high-risk patients. Hübner J, et al. **Zentralbl Bakteriol** 1995 Dec;283(2):169–74 (23 ref.)

DRUG EFFECTS

Emerging resistance to antimicrobial agents in gram-positive bacteria. Enterococci, staphylococci and nonpneumococcal streptococci. Cormican MG, et al. **Drugs** 1996;51 Suppl 1:6–12 (38 ref.)

Antibiotic resistance in the staphylococci. Noble WC. **Sci Prog** 1997;80 (Pt 1):5–20 (39 ref.)

[Mechanisms of resistance to glycopeptides] Navarro F. **Enferm Infecc Microbiol Clin** 1996 May;14(5):317–23 (101 ref.) **(Spa)**

ENZYMOLOGY

[Bacteriolytic enzymes produced by the staphylococci] Sugai M, et al. **Nippon Saikingaku Zasshi** 1997 Apr;52(2):461–73 (61 ref.) **(Jpn)**

GENETICS

The biosynthesis of the lantibiotics epidermin, gallidermin, Pep5 and epilancin K7. Bierbaum G, et al. **Antonie Van Leeuwenhoek** 1996 Feb;69(2):119–127 (42 ref.)

Mechanisms of methicillin resistance in staphylococci. Brakstad OG, et al. **APMIS** 1997 Apr;105(4):264–76 (112 ref.)

ISOLATION & PURIFICATION

Destructive endocarditis caused by Staphylococcus lugdunensis. Case report and review of the literature. De Hondt G, et al. **Acta Clin Belg** 1997;52(1):27–30 (10 ref.)

METABOLISM

Detection of the staphylococcal toxins. Bergdoll MS. **Adv Exp Med Biol** 1996;391:465–79 (38 ref.)

PHYSIOLOGY

[Antimicrobial agents and adhesion of coagulase-negative staphylococci] Gómez-García AC, et al. **Enferm Infecc Microbiol Clin** 1996 Apr;14(4):261–6 (55 ref.) **(Spa)**

STAPHYLOCOCCUS AUREUS

Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Kluytmans J, et al. **Clin Microbiol Rev** 1997 Jul;10(3):505–20 (218 ref.)

Pyomyositis as a nontropical disease. Harbarth SJ, et al. **Curr Clin Top Infect Dis** 1997;17:37–50 (74 ref.)

Catheter-associated Staphylococcus aureus bacteremia. Gold HS, et al. **Hosp Pract (Off Ed)** 1996 Sep 15;31(9):133–7, 142–4, 150 (14 ref.)

Preventing staphylococcal infections by eradicating nasal carriage of Staphylococcus aureus: proceeding with caution [editorial; comment] Boyce JM. **Infect Control Hosp Epidemiol** 1996 Dec;17(12):775–9 (50 ref.) Comment on: Infect Control Hosp Epidemiol 1996 Dec;17(12):780–5. Comment on: Infect Control Hosp Epidemiol 1996 Dec;17(12):786–92. Comment on: Infect Control Hosp Epidemiol 1996 Dec;17(12):813–6.

Mupirocin resistance and methicillin-resistant Staphylococcus aureus (MRSA). Eltringham I. **J Hosp Infect** 1997 Jan;35(1):1–8 (44 ref.)

Methicillin-resistant Staphylococcus aureus (MRSA)—a re-appraisal of control measures in the light of changing circumstances. Humphreys H, et al. **J Hosp Infect** 1997 Jul;36(3):167–70 (20 ref.)

[A case of toxic shock syndrome (TSS) induced by methicillin-resistant staphylococcus aureus (MRSA) presenting as acute renal failure with disseminated intravascular coagulation] Fukuuchi F, et al. **Nippon Jinzo Gakkai Shi** 1996 Jan;38(1):27–32 (20 ref.) (Eng. Abstr.) **(Jpn)**

[A case report of postcoarctation mycotic aneurysm after surgical treatment for cerebral arterial aneurysms] Kido M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jul; 45(7):1006–10 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Studies on Staphylococcus aureus: from the past to the future] Hashimoto H. **Nippon Saikingaku Zasshi** 1996 Aug; 51(3):841–52 (15 ref.) **(Jpn)**

[The role of capsule in staphylococcal infection and immunity] Ichiman Y. **Nippon Saikingaku Zasshi** 1996 Feb; 51(2):601–11 (15 ref.) **(Jpn)**

CLASSIFICATION

Quantitative analysis of multivariate data using artificial neural networks: a tutorial review and applications to the deconvolution of pyrolysis mass spectra. Goodacre R, et al. **Zentralbl Bakteriol** 1996 Aug;284(4):516–39 (114 ref.)

DRUG EFFECTS

The epidemiology of methicillin-resistant Staphylococcus aureus: surgical relevance 20 years on. McDonald M. **Aust N Z J Surg** 1997 Oct;67(10):682–5 (32 ref.)

The progressive intercontinental spread of methicillin-resistant Staphylococcus aureus. Ayliffe GA. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S74–9 (60 ref.)

Methicillin-resistant Staphylococcus aureus in nursing homes. Epidemiology, prevention and management. Bradley SF. **Drugs Aging** 1997 Mar;10(3):185–98 (90 ref.)

Review of methicillin resistant Staphylococcus aureus with special reference to handling of surgical patients. Gakuu LN. **East Afr Med J** 1997 Mar;74(3):198–202 (22 ref.)

Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities. Michel M, et al. **Lancet** 1997 Jun 28; 349(9069):1901–6 (63 ref.)

Borderline susceptibility to methicillin in Staphylococcus aureus: a new mechanism of resistance? Montanari MP, et al. **Microb Drug Resist** 1996 Summer;2(2):257–60 (27 ref.)

[Molecular design of anti-MRSA drugs] Hanaki H. **Nippon Rinsho** 1997 May;55(5):1281–6 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Antiseptic-resistance in Staphylococcus aureus] Sasatsu M. **Nippon Saikingaku Zasshi** 1996 Aug;51(3):755–65 (61 ref.) **(Jpn)**

[Mechanisms of bacterial resistance to quinolones] Yoshida H. **Nippon Saikingaku Zasshi** 1996 Oct;51(4):973–92 (126 ref.) **(Jpn)**

[Mini review: a factor enhanced the antibacterial effect of beta-lactams on methicillin-resistant Staphylococcus aureus] Tajima Y. **Rinsho Byori** 1996 Nov;44(11):1093–9 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Role of prophages in the formation of antibiotic-resistant populations of Staphylococcus in the process of transformation, transduction and conjugation] Zueva VS, et al. **Antibiot Khimioter** 1996;41(10):35–42 (35 ref.) **(Rus)**

GENETICS

Molecular evolution of multiply-antibiotic-resistant staphylococci. Skurray RA, et al. **Ciba Found Symp** 1997; 207:167–83; discussion 183–91 (47 ref.)

Plasmids and bacterial resistance to biocides. Russell AD. **J Appl Microbiol** 1997 Aug;83(2):155–65 (120 ref.)

Borderline susceptibility to methicillin in Staphylococcus aureus: a new mechanism of resistance? Montanari MP, et al. **Microb Drug Resist** 1996 Summer;2(2):257–60 (27 ref.)

[Genetics of multiresistant MRSA] Ito T, et al. **Nippon Rinsho** 1997 May;55(5):1200–5 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Genetic basis for molecular epidemiology of MRSA] Kondo N, et al. **Nippon Saikingaku Zasshi** 1997 Apr;52(2):417–34 (57 ref.) **(Jpn)**

IMMUNOLOGY

Adhesins of Staphylococcus aureus that bind Lewis(a) antigen. Relationship to sudden infant death syndrome. Blackwell CC, et al. **Adv Exp Med Biol** 1996;408:95–105 (55 ref.)

Staphylococcal vaccines: a realistic dream. Fattom AI, et al. **Ann Med** 1996 Feb;28(1):43–6 (20 ref.)

Simultaneous presentation of Kawasaki disease and toxic shock syndrome in an adolescent male [see comments] Davies HD, et al. **Pediatr Infect Dis J** 1996 Dec; 15(12):1136–8 (14 ref.) Comment in: Pediatr Infect Dis J 1997 Jun;16(6):633–4.

"Bazinc" instinct: how SEA attracts MHC class II molecules. Thibodeau J, et al. **Res Immunol** 1997 May;148(4):217–29 (72 ref.)

ISOLATION & PURIFICATION

Pyomyositis with toxic shock syndrome presenting as back pain and fever: a case report and literature review. Wolfe MW, et al. **Am J Orthop** 1997 Feb;26(2):135–7 (26 ref.)

Deep neck infections. Marra S, et al. **Am J Otolaryngol** 1996 Sep–Oct;17(5):287–98 (15 ref.)

[Clinically isolated bacterii seen in complicated infections] Iwai S. **Nippon Geka Gakkai Zasshi** 1996 Dec;97(12):1091–6 (12 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Iron depletion and virulence in Staphylococcus aureus. Trivier D, et al. **FEMS Microbiol Lett** 1996 Aug 1; 141(2–3):117–27 (51 ref.)

[Causative agent of impetigo: staphylococcal exfoliative toxin and regulation of the toxin production in Staphylococcus aureus] Sakurai S. **Nippon Saikingaku Zasshi** 1996 Aug; 51(3):813–22 (15 ref.) **(Jpn)**

PATHOGENICITY

The pathogenesis of Staphylococcus aureus in the trauma patient and potential future therapies. Villavicencio RT, et al. **Am J Surg** 1996 Sep;172(3):291–6 (76 ref.)

Host-bacteria interactions in foreign body infections. François P, et al. **Infect Control Hosp Epidemiol** 1996 Aug; 17(8):514–20 (63 ref.)

[Causative agent of impetigo: staphylococcal exfoliative toxin and regulation of the toxin production in Staphylococcus aureus] Sakurai S. **Nippon Saikingaku Zasshi** 1996 Aug; 51(3):813–22 (15 ref.) **(Jpn)**

PHYSIOLOGY

Methicillin resistant Staphylococcus aureus (MRSA): disease spectrum, biological characteristics, resistant mechanisms, and typing methods. Abdo RA, et al. **J Med Liban** 1996; 44(1):21–30 (90 ref.)

[How does Staphylococcus aureus adapt to environmental stresses?] Ohta T. **Nippon Saikingaku Zasshi** 1996 Feb; 51(2):627–33 (14 ref.) **(Jpn)**

STAPHYLOCOCCUS EPIDERMIDIS

[Infectious complications of cardioverter/defibrillators—case report and review of the literature] Hollenstein U, et al. **Acta Med Austriaca** 1996;23(5):164–7 (20 ref.) (Eng. Abstr.) **(Ger)**

[Epiduritis after long-term pain therapy with an epidural catheter—review of the literature with a current case report] Michel H, et al. **Anaesthesiol Reanim** 1997; 22(3):69–79 (105 ref.) (Eng. Abstr.) **(Ger)**

[A case of successful treatment of mediastinitis and prosthetic graft infection after aortic arch and thoracoabdominal

aortic reconstruction] Kawashima T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Feb;45(2):220–4 (12 ref.) (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

Cross infections due to coagulase-negative staphylococci in high-risk patients. Hübner J, et al. **Zentralbl Bakteriol** 1995 Dec;283(2):169–74 (23 ref.)

ISOLATION & PURIFICATION

Spontaneous obliteration of a pseudo-aneurysm complicating an aortic homograft. Federmann M, et al. **Eur J Cardiothorac Surg** 1996;10(8):705–6 (5 ref.)

METABOLISM

Coagulase-negative staphylococcal infections: an update regarding recognition and management. Rupp ME. **Curr Clin Top Infect Dis** 1997;17:51–87 (261 ref.)

STAPHYLOMYCIN see **VIRGINIAMYCIN**

STARCH

Starch-gum interactions: nutritional and technological implications. Sudhakar V, et al. **Int J Food Sci Nutr** 1996 Mar;47(2):117–29 (90 ref.)

The role of modified food starches in baby food. Lanciers S, et al. **J La State Med Soc** 1997 Jun;149(6):211–4 (20 ref.)

Complex carbohydrates and resistant starch. Brown I. **Nutr Rev** 1996 Nov;54(11 Pt 2):S115–9 (29 ref.)

ADMINISTRATION & DOSAGE

Spherex (degradable starch microspheres) chemo-occlusion--enhancement of tumor drug concentration and therapeutic efficacy: an overview. Håkansson L, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 6):S6-100–S6-109 (64 ref.)

ADVERSE EFFECTS

Mechanisms of adhesion development and effects on wound healing. Holmdahl L. **Eur J Surg Suppl** 1997;(579):7–9 (11 ref.)

Surgical glove lubricants: from toxicity to opportunity. Woods JA, et al. **J Emerg Med** 1997 Mar-Apr;15(2):209–20 (59 ref.)

METABOLISM

Starch utilization by ruminants: from basics to the bunk. Huntington GB. **J Anim Sci** 1997 Mar;75(3):852–67 (117 ref.)

THERAPEUTIC USE

Pharmacokinetic rationale for chemotherapeutic drugs combined with intra-arterial degradable starch microspheres (Spherex). Johansson CJ. **Clin Pharmacokinet** 1996 Sep;31(3):231–40 (44 ref.)

STARTLE REACTION

Hyperekplexia: abnormal startle response due to glycine receptor mutations. Andrew M, et al. **Br J Psychiatry** 1997 Feb;170:106–8 (30 ref.)

[Familial hyperekplexia: startle disease. Clinical, electrophysiological and genetic study of a family] Bernasconi A, et al. **Rev Neurol (Paris)** 1996 Jun-Jul; 152(6-7):447–50 (31 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Roles of the amygdala and bed nucleus of the stria terminalis in fear and anxiety measured with the acoustic startle reflex. Possible relevance to PTSD. Davis M, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:305–31 (76 ref.)

The acoustic startle reflex: neurons and connections. Yeomans JS, et al. **Brain Res Brain Res Rev** 1995 Nov; 21(3):301–14 (79 ref.)

Brainstem encephalopathy with stimulus-sensitive myoclonus leading to respiratory arrest, but with recovery: a description of two cases and review of the literature. Kullmann DM, et al. **Mov Disord** 1996 Nov;11(6):715–8 (22 ref.)

STARVATION

see related
HUNGER

The consumption bomb. Butler CD. **Med Confl Surviv** 1997 Jul-Sep;13(3):209–18 (50 ref.)

METABOLISM

Human pattern of food intake and fuel-partitioning during weight recovery after starvation: a theory of autoregulation of body composition. Dulloo AG. **Proc Nutr Soc** 1997 Mar; 56(1A):25–40 (43 ref.)

PHYSIOPATHOLOGY

Regulatory peptides in the control of metabolism during starvation and exercise. Buchanan KD, et al. **Biochem Soc Trans** 1996 May;24(2):591–3 (25 ref.)

Seminars in medicine of the Beth Israel Deaconess Medical Center. Neuroendocrine responses to starvation and weight loss. Schwartz MW, et al. **N Engl J Med** 1997 Jun 19; 336(25):1802–11 (87 ref.)

Neuropeptide abnormalities in anorexia nervosa. Kaye WH. **Psychiatry Res** 1996 Apr 16;62(1):65–74 (75 ref.)

PREVENTION & CONTROL

Social contract and deterring famine: first thoughts. de Waal A. **Disasters** 1996 Sep;20(3):194–205 (25 ref.)

Childhood hunger. Lewit EM, et al. **Future Child** 1997 Spring;7(1):128–44 (23 ref.)

STASIS ULCER see **VARICOSE ULCER**

STATE GOVERNMENT

State policy issues in nonprofit conversions. Butler PA. **Health Aff (Millwood)** 1997 Mar-Apr;16(2):69–84 (38 ref.)

State experience in regulating a changing health care system. Shriber D. **Health Aff (Millwood)** 1997 Mar-Apr; 16(2):48–68 (38 ref.)

Physician-assisted suicide: landmark Supreme Court decisions and a summary of state law. Wolfson LA. **J Ky Med Assoc** 1997 Aug;95(8):311–2 (0 ref.)

STATE HEALTH PLANNING, UNITED STATES see **HEALTH PLANNING**

STATE HEALTH PLANS

ECONOMICS

Markets and public programs: insights from Oregon and Tennessee. Gold M. **J Health Polit Policy Law** 1997 Apr; 22(2):633–66 (26 ref.)

LEGISLATION & JURISPRUDENCE

Translating ideas into actions: entrepreneurial leadership in state health care reforms [see comments] Oliver TR, et al. **J Health Polit Policy Law** 1997 Jun;22(3):721–88 (98 ref.) Comment in: J Health Polit Policy Law 1997 Jun;22(3):879–96. Comment in: J Health Polit Policy Law 1997 Jun;22(3):897–906.

ORGANIZATION & ADMINISTRATION

An evaluation of Oregon's Medicaid rationing algorithms [editorial] Tengs TO. **Health Econ** 1996 May-Jun; 5(3):171–81 (16 ref.)

Medicaid and the politics of groups: recipients, providers, and policy making [see comments] Kronebusch K. **J Health Polit Policy Law** 1997 Jun;22(3):839–78 (54 ref.) Comment in: J Health Polit Policy Law 1997 Jun;22(3):879–96. Comment in: J Health Polit Policy Law 1997 Jun;22(3):897–906.

Laboratories and the health care marketplace: the limits of state workforce policy [see comments] Sparer MS. **J Health Polit Policy Law** 1997 Jun;22(3):789–814 (39 ref.) Comment in: J Health Polit Policy Law 1997 Jun;22(3):879–96. Comment in: J Health Polit Policy Law 1997 Jun;22(3):897–906.

The ethical dilemmas of the Oregon health plan. Burton L. **Nurse Pract** 1996 Feb;21(2):62, 65–6, 71–2 (20 ref.)

TRENDS

The Medicaid managed care policy consensus for welfare recipients: a reflection of traditional welfare concerns [see comments] Grogan CM. **J Health Polit Policy Law** 1997 Jun;22(3):815–38 (17 ref.) Comment in: J Health Polit Policy Law 1997 Jun;22(3):879–96. Comment in: J Health Polit Policy Law 1997 Jun;22(3):897–906.

STATE MEDICINE

A national strategy for research and development: lessons from England. Black N. **Annu Rev Public Health** 1997; 18:485–505 (48 ref.)

Safety among health-care workers in the NHS. Bojanowski LM. **Br J Hosp Med** 1997 Jan 15-Feb 5;57(1-2):47–8 (5 ref.)

Getting research into practice. Sibbald B, et al. **J Eval Clin Pract** 1997 Feb;3(1):15–21 (51 ref.)

Autonomy: the need for limits. Jiwa M. **J Med Ethics** 1996 Dec;22(6):340–3 (18 ref.)

ECONOMICS

From managed competition to managed cooperation: theory and lessons from the British experience. Light DW. **Milbank Q** 1997;75(3):297–341 (131 ref.)

Head injury rehabilitation in the U.K.: an economic perspective. McGregor K, et al. **Soc Sci Med** 1997 Jul; 45(2):295–303 (65 ref.)

LEGISLATION & JURISPRUDENCE

The Health of the Nation 4 years on: what have we done, what must we do? Troop P, et al. **Br J Hosp Med** 1997 Feb 5-18;57(3):81–2, 99–100 (9 ref.)

ORGANIZATION & ADMINISTRATION

Psychiatry and the Health of the Nation: the view from the Department of Health. Jenkins R. **Br J Hosp Med** 1996 Aug 21-Sep 3;56(4):155–8 (26 ref.)

Organizational development. Oakley P. **Br J Hosp Med** 1996 May 1-14;55(9):591–2 (14 ref.)

UK general practice fundholding [editorial] Peckham S. **Can Fam Physician** 1997 Sep;43:1485–7, 1492–5 (19 ref.) **(Eng, Fre)**

Renewing the National Health Service: Labour's agenda for a healthier Britain. **Int J Health Serv** 1996;26(2):269–308 (0 ref.)

Health care system reforms in western European countries: the relevance of health care organization. Elola J. **Int J Health Serv** 1996;26(2):239–51 (56 ref.)

Policy and ideology: the politics of post-reform health policy in the United Kingdom. Fierlbeck K. **Int J Health Serv** 1996;26(3):529–46 (43 ref.)

Rethinking the western construction of the welfare state. Walker A, et al. **Int J Health Serv** 1996;26(1):67–92 (69 ref.)

An analysis of nursing in context: the effects of current health policy. Antrobus S. **J Adv Nurs** 1997 Mar;25(3):447–53 (36 ref.)

Utiiizing research findings in nursing: policy and practice considerations. Cavanagh SJ, et al. **J Adv Nurs** 1996 Nov; 24(5):1083–8 (48 ref.)

Rationing and evidence-based medicine [editorial] Hunter DJ. **J Eval Clin Pract** 1996 Feb;2(1):5–8 (12 ref.)

In practice: the NHS market in the United Kingdom. Health Policy Network of the National Health Service Consultant's Association and the National Health Service Support Federation. **J Public Health Policy** 1995; 16(4):452–91 (53 ref.)

STANDARDS

User involvement in clinical audit: a review of developments and issues of good practice. Kelson M. **J Eval Clin Pract** 1996 May;2(2):97–109 (109 ref.)

Purchasing quality in clinical practice: what on Earth do we mean? Miles A, et al. **J Eval Clin Pract** 1995 Nov; 1(2):87–95 (57 ref.)

Clinical audit in the National Health Service: fact or fiction? Miles A, et al. **J Eval Clin Pract** 1996 Feb;2(1):29–35 (53 ref.)

The Total Health Care Audit System: a systematic methodology for clinical practice evaluation and development in NHS provider organizations. Miles A, et al. **J Eval Clin Pract** 1996 Feb;2(1):37–64 (53 ref.)

The involvement of pharmacists in professional and clinical audit in the UK: a review and assessment of their potential role. Panton R, et al. **J Eval Clin Pract** 1996 Aug;2(3):193–8 (53 ref.)

Quality improvement in Swedish health care. Palmberg M. **Jt Comm J Qual Improv** 1997 Jan;23(1):47–54 (1 ref.)

TRENDS

The ghost of health services past: comparing British health policy of the 1930s with the 1980s and 1990s. Powell MA. **Int J Health Serv** 1996;26(2):253–68 (80 ref.)

Health sector reform: lessons from China. Bloom G, et al. **Soc Sci Med** 1997 Aug;45(3):351–60 (45 ref.)

Staying single in the 1990s: single-handed practitioners in the new National Health Service. Lunt N, et al. **Soc Sci Med** 1997 Aug;45(3):341–9 (47 ref.)

STATE-OF-THE-ART REVIEW see **REVIEW LITERATURE**

STATIC ELECTRICITY see **ELECTROSTATICS**

STATISTICAL BIAS see **BIAS (EPIDEMIOLOGY)**

STATISTICAL COMPUTING see **MATHEMATICAL COMPUTING**

STATISTICAL MODELS see **MODELS, STATISTICAL**

STATISTICAL REGRESSION see **REGRESSION ANALYSIS**

STATISTICS

see related
BIBLIOMETRICS
BIOMETRY
META-ANALYSIS
MODELS, STATISTICAL
PSYCHOMETRICS

Statistics notes. Units of analysis. Altman DG, et al. **BMJ** 1997 Jun 28;314(7098):1874 (7 ref.)

How to read a paper. Statistics for the non-statistician. I: Different types of data need different statistical tests. Greenhalgh T. **BMJ** 1997 Aug 9;315(7104):364–6 (11 ref.)

Nuclear medicine and mathematics [see comments] Pedroso de Lima JJ. **Eur J Nucl Med** 1996 Jun;23(6):705–19 (36 ref.) Comment in: Eur J Nucl Med 1997 Feb;24(2):234.

Statistical process control methods for expert system performance monitoring. Kahn MG, et al. **J Am Med Inform Assoc** 1996 Jul-Aug;3(4):258–69 (22 ref.)

Discussion of individual bioequivalence by M.-L. Chen.

Gould AL. **J Biopharm Stat** 1997 Mar;7(1):23–9 (22 ref.)
[Prognostic studies in cancer of the breast: optimal use of current statistical tools] Bonichon F. **Bull Cancer** 1996 Dec; 83(12):1046–52 (20 ref.) **(Fre)**

METHODS

Treating grouped data as continuous in alcohol consumption measures. de Burgh S, et al. **Addiction** 1997 Jun; 92(6):667–72 (10 ref.)
Quantitative radiography in osteoarthritis: analysis. Hochberg MC. **Baillieres Clin Rheumatol** 1996 Aug;10(3):421–8 (55 ref.)
Multistage designs for phase II clinical trials: statistical issues in cancer research. Kramar A, et al. **Br J Cancer** 1996 Oct;74(8):1317–20 (5 ref.)
Comparing methods of measurements. Ludbrook J. **Clin Exp Pharmacol Physiol** 1997 Feb;24(2):193–203 (34 ref.)
Multiparous species present problems (and possibilities) to developmentalists. Zorrilla EP. **Dev Psychobiol** 1997 Mar; 30(2):141–50 (49 ref.)
An improved statistical approach: can it clarify the role of new prognostic factors for breast cancer? Chapman JW, et al. **Eur J Cancer** 1996 Oct;32A(11):1949–56 (33 ref.)
Statistical planning and analysis considerations in the evaluation of in vitro alternatives to whole animal use for eye irritation testing. Feder P, et al. **Food Chem Toxicol** 1997 Jan;35(1):167–74 (6 ref.)
Assessment of clinical significance: the number needed to treat. Thomas R, et al. **Indian J Ophthalmol** 1996 Jun; 44(2):113–5 (9 ref.)
Challenging the validity of conclusions based on P-values alone: a critique of contemporary clinical research design and methods. Ebramzadeh E, et al. **Instr Course Lect** 1994; 43:587–600 (26 ref.)
Etrank: a ranking procedure for handling missing data in clinical trials: application to venlafaxine extended-release depression clinical trial. Entsuah R. **J Biopharm Stat** 1996 Nov;6(4):457–75 (30 ref.)
Discussion of individual bioequivalence by M.-L. Chen. Gould AL. **J Biopharm Stat** 1997 Mar;7(1):23–9 (22 ref.)
A review of nonparametric tests for changepoint problems, with application to a recombinant drug therapy clinical trial. Koziol JA, et al. **J Biopharm Stat** 1996 Nov; 6(4):425–41 (25 ref.)
Analysis of 24-hour blood pressure data. Rodda B, et al. **J Biopharm Stat** 1996 Nov;6(4):495–513 (20 ref.)
Survival analysis in observational studies. Bull K, et al. **Stat Med** 1997 May 15;16(9):1041–74 (31 ref.)
Statistical methods for two-sequence three-period cross-over designs with incomplete data. Chow SC, et al. **Stat Med** 1997 May 15;16(9):1031–9 (7 ref.)
A comparison of goodness-of-fit tests for the logistic regression model. Hosmer DW, et al. **Stat Med** 1997 May 15;16(9):965–80 (24 ref.)

STATISTICS, NONPARAMETRIC

The use and interpretation of the Friedman test in the analysis of ordinal-scale data in repeated measures designs. Sheldon MR, et al. **Physiother Res Int** 1996;1(4):221–8 (28 ref.)

STATOCONIA see **OTOLITHIC MEMBRANE**

STATUS ASTHMATICUS

CHEMICALLY INDUCED

Near-death asthmatic reaction induced by disodium cromoglycate [see comments] Katayama H, et al. **Intern Med** 1996 Dec;35(12):976–8 (14 ref.) Comment in: Intern Med 1996 Dec;35(12):922–3.

CLASSIFICATION

Classification of severe asthma exacerbations: a proposal. Picado C. **Eur Respir J** 1996 Sep;9(9):1775–8 (33 ref.)

COMPLICATIONS

[Acute iatrogenic myopathy during treatment of status asthmaticus. Our experience and review of the literature] Pacini D, et al. **Minerva Anestesiol** 1997 Mar;63(3):81–91 (45 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

[Status asthmaticus] Malyshev VD. **Anesteziol Reanimatol** 1996 May-Jun;(3):57–60 (4 ref.) **(Rus)**

EPIDEMIOLOGY

Near-fatal asthma in South Australia: descriptive features and medication use [editorial; comment] Garrett JE, et al. **Aust N Z J Med** 1996 Aug;26(4):487–9 (24 ref.) Comment on: Aust N Z J Med 1996 Jun;26(3):356–62.

PHYSIOPATHOLOGY

Acute severe asthma: pathophysiology and pathobiology of gas exchange abnormalities. Rodriguez-Roisin R. **Eur Respir J** 1997 Jun;10(6):1359–71 (82 ref.)

THERAPY

Status asthmaticus. Cohen NH, et al. **Crit Care Clin** 1997 Jul;13(3):459–76 (93 ref.)
Continuous ketamine infusion for the treatment of refractory asthma in a mechanically ventilated infant: case report and review of the pediatric literature. Nehama J, et al. **Pediatr Emerg Care** 1996 Aug;12(4):294–7 (20 ref.)

STATUS DYSRAPHICUS see **SPINAL DYSRAPHISM**

STATUS EPILEPTICUS

Status epilepticus. Treiman DM. **Baillieres Clin Neurol** 1996 Dec;5(4):821–39 (111 ref.)
Status epilepticus in children and adults. Weise KL, et al. **Crit Care Clin** 1997 Jul;13(3):629–46 (68 ref.)
Management of status epilepticus. DeLorenzo RJ. **Va Med Q** 1996 Spring;123(2):103–11 (25 ref.)
[Status epilepticus] Gonçalves M, et al. **Acta Med Port** 1996 Apr-Jun;9(4–6):171–5 (13 ref.) (Eng. Abstr.) **(Por)**

CHEMICALLY INDUCED

Unusual cause of seizure. Gouin S, et al. **Pediatr Emerg Care** 1996 Aug;12(4):298–300 (13 ref.)

DIAGNOSIS

Ring chromosome 20 and nonconvulsive status epilepticus. A new epileptic syndrome. Inoue Y, et al. **Brain** 1997 Jun; 120 (Pt 6):939–53 (38 ref.)
[Status epilepticus] Salas-Puig J, et al. **Neurologia** 1996 Dec; 11 Suppl 4:108–21 (59 ref.) (Eng. Abstr.) **(Spa)**
[Status epilepticus] Telleria-Díaz A, et al. **Rev Neurol** 1997 Aug;25(144):1246–56 (61 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Status epilepticus. Payne TA, et al. **Crit Care Clin** 1997 Jan; 13(1):17–38 (64 ref.)

ETIOLOGY

Severe eclampsia in an adolescent: a case report and review of the literature. Scribano PV, et al. **Pediatr Emerg Care** 1996 Dec;12(6):425–7 (6 ref.)

GENETICS

Ring chromosome 20 and nonconvulsive status epilepticus. A new epileptic syndrome. Inoue Y, et al. **Brain** 1997 Jun; 120 (Pt 6):939–53 (38 ref.)

PHYSIOPATHOLOGY

Status epilepticus. Payne TA, et al. **Crit Care Clin** 1997 Jan; 13(1):17–38 (64 ref.)
Nonconvulsive status epilepticus. Kaplan PW. **Semin Neurol** 1996 Mar;16(1):33–40 (88 ref.)
[Status epilepticus] Salas-Puig J, et al. **Neurologia** 1996 Dec; 11 Suppl 4:108–21 (59 ref.) (Eng. Abstr.) **(Spa)**

STAUROSPORINE

TOXICITY

K252a and staurosporine microbial alkaloid toxins as prototype of neurotropic drugs. Lazarovici P, et al. **Adv Exp Med Biol** 1996;391:367–77 (32 ref.)

STAVUDINE

PHARMACOLOGY

Newer nucleosides: lamivudine and stavudine. Katlama C, et al. **AIDS** 1996;10 Suppl A:S135–43 (58 ref.)
Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection. Lea AP, et al. **Drugs** 1996 May;51(5):846–64 (114 ref.)

THERAPEUTIC USE

Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection. Lea AP, et al. **Drugs** 1996 May;51(5):846–64 (114 ref.)

STEALING see **THEFT**

STEATORRHEA see **CELIAC DISEASE**

STEEL FACTOR see **STEM CELL FACTOR**

STEELE-RICHARDSON-OLSZEWSKI SYNDROME see **SUPRANUCLEAR PALSY, PROGRESSIVE**

STEELHEAD see **ONCORHYNCHUS MYKISS**

STEELY HAIR SYNDROME see **KINKY HAIR SYNDROME**

STEIN-LEVENTHAL SYNDROME see **POLYCYSTIC OVARY SYNDROME**

STEINERT'S DISEASE see **MYOTONIA ATROPHICA**

STELLATE GANGLION

[Can superior cervical ganglionectomy be an experimental model of stellate ganglion block?] Iwama H. **Masui** 1997 Apr;46(4):565–7 (4 ref.) **(Jpn)**

ANATOMY & HISTOLOGY

Cardiac neurones of autonomic ganglia. Wallis D, et al. **Microsc Res Tech** 1996 Sep 1;35(1):69–79 (80 ref.)

STEM see **MICROSCOPY, ELECTRON, SCANNING TRANSMISSION**

STEM CELL ASSAY, TUMOR see **TUMOR STEM CELL ASSAY**

STEM CELL FACTOR

CHEMISTRY

Differences between membrane-bound and secreted isoforms of stem cell factor. **Ciba Found Symp** 1997;204:57–9 (5 ref.)

PHYSIOLOGY

Stem cell factor and hematopoiesis. Broudy VC. **Blood** 1997 Aug 15;90(4):1345–64 (313 ref.)
Stem cell factor and c-kit in the mammalian testis: lessons originating from Mother Nature's gene knockouts. Loveland KL, et al. **J Endocrinol** 1997 Jun;153(3):337–44 (71 ref.)

STEM CELL FACTOR RECEPTORS see **PROTO-ONCOGENE PROTEINS C-KIT**

STEM CELL TRANSPLANTATION see **HEMATOPOIETIC STEM CELL TRANSPLANTATION**

STEM CELLS

Primitive hematopoietic stem and progenitor cells in human umbilical cord blood: an alternative source of transplantable cells. Broxmeyer HE. **Cancer Treat Res** 1996; 84:139–48 (72 ref.)
Hepatic stem cells in liver regeneration. Thorgeirsson SS. **FASEB J** 1996 Sep;10(11):1249–56 (68 ref.)
Reflections on the biology of embryonic stem (ES) cells. Gardner RL, et al. **Int J Dev Biol** 1997 Apr;41(2):235–43 (95 ref.)
Comparative stem cell biology. Hollands P. **Int J Dev Biol** 1997 Apr;41(2):245–54 (184 ref.)
Embryonic stem-cell-like cell lines of the species rat and Bovinae. Stranzinger GF. **Int J Exp Pathol** 1996 Dec; 77(6):263–7 (12 ref.)
Gene targeting in embryonic stem cells: the new physiology and metabolism. Moreadith RW, et al. **J Mol Med** 1997 Mar;75(3):208–16 (81 ref.)
Neural precursor cells: applications for the study and repair of the central nervous system. Fisher LJ. **Neurobiol Dis** 1997;4(1):1–22 (119 ref.)
Cell vehicles for gene transfer to the brain. Taylor R. **Neuromuscul Disord** 1997 Jul;7(5):343–51 (64 ref.)
Retroviral stem cell gene therapy. Havenga M, et al. **Stem Cells** 1997;15(3):162–79 (144 ref.)
Is telomerase activity in cancer due to selection of stem cells and differentiation arrest? Greaves M. **Trends Genet** 1996 Apr;12(4):127–8 (34 ref.)

CHEMISTRY

TGF-beta latency: biological significance and mechanisms of activation. Gleizes PE, et al. **Stem Cells** 1997;15(3):190–7 (70 ref.)

CYTOLOGY

Gene regulation in the formation of the central nervous system. Lendahl U. **Acta Paediatr Suppl** 1997 Jul;422:8–11 (51 ref.)
Stem cells in lung development, disease, and therapy. Mason RJ, et al. **Am J Respir Cell Mol Biol** 1997 Apr;16(4):355–63 (68 ref.)
Epithelial stem cells. Jones PH. **Bioessays** 1997 Aug; 19(8):683–90 (64 ref.)
Epithelial apoptosis. Metcalfe A, et al. **Bioessays** 1997 Aug; 19(8):711–20 (90 ref.)
Ex vivo expansion of hematopoietic stem and progenitor cells for transplantation. LaLuppa JA, et al. **Cancer Treat Res** 1997;77:159–86 (125 ref.)
Regulatory mechanisms in stem cell biology. Morrison SJ, et al. **Cell** 1997 Feb 7;88(3):287–98 (112 ref.)
Pluripotential liver stem cells: facultative stem cells located in the biliary tree. Alison MR, et al. **Cell Prolif** 1996 Jul; 29(7):373–402 (150 ref.)
Gene transfer to the mammalian brain using neural stem cells: a focus on trophic factors, neuroregeneration, and cholinergic neuron systems. Martínez-Serrano A, et al. **Clin Neurosci** 1995–96;3(5):301–9 (97 ref.)
Control of the differentiation commitment by nuclear hormone receptors in chicken erythrocytic progenitor cells. Samarut J. **Curr Top Microbiol Immunol** 1996;212:163–73 (35 ref.)
Reactive biliary epithelium: the product of a pluripotential stem cell compartment? Golding M, et al. **Hum Pathol** 1996

Sep;27(9):872–84 (154 ref.)
Stem cells of the respiratory epithelium and their in vitro cultivation. Emura M. **In Vitro Cell Dev Biol Anim** 1997 Jan;33(1):3–14 (100 ref.)
The interstitial cell lineage of hydra: a stem cell system that arose early in evolution. Bode HR. **J Cell Sci** 1996 Jun; 109 (Pt 6):1155–64 (76 ref.)
Does an inability to eradicate normal stem cells preclude the cure of some cancers? Anderson KM, et al. **Med Hypotheses** 1996 Jul;47(1):31–4 (24 ref.)
Derivation and maintenance of embryonic stem cell cultures. Robertson EJ. **Methods Mol Biol** 1997;75:173–84 (7 ref.)
Stem cell–fed maturational lineages and gradients in signals: relevance to differentiation of epithelia. Reid LM. **Mol Biol Rep** 1996;23(1):21–33 (92 ref.)
Regulation and clinical implications of corneal epithelial stem cells. Tseng SC. **Mol Biol Rep** 1996;23(1):47–58 (4 ref.)
Control of daughter cell fates during asymmetric division: interaction of Numb and Notch. Guo M, et al. **Neuron** 1996 Jul;17(1):27–41 (84 ref.)
Neural stem cells are blasting off. Stemple DL, et al. **Neuron** 1997 Jan;18(1):1–4 (26 ref.)
Regulators of adipocyte precursor cells. Butterwith SC. **Poult Sci** 1997 Jan;76(1):118–23 (58 ref.)
Stem cells in the central nervous system. McKay R. **Science** 1997 Apr 4;276(5309):66–71 (72 ref.)
Marrow stromal cells as stem cells for nonhematopoietic tissues. Prockop DJ. **Science** 1997 Apr 4;276(5309):71–4 (32 ref.)
B–cell development and differentiation. Duchosal MA. **Semin Hematol** 1997 Jan;34(1 Suppl 1):2–12 (146 ref.)
Parameters of cell freezing: implications for the cryopreservation of stem cells. Hubel A. **Transfus Med Rev** 1997 Jul;11(3):224–33 (53 ref.)
Rat embryonic stem cells: a progress report. Brenin D, et al. **Transplant Proc** 1997 May;29(3):1761–5 (29 ref.)
Future trends in the transplantation of hematopoietic cells. Wiktor–Jedrzejczak W. **Transplant Proc** 1996 Dec; 28(6):3423–5 (24 ref.)
[Stem cell–fed maturational lineages and epithelial organogenesis] Kubota H, et al. **Hum Cell** 1997 Mar; 10(1):51–62 (86 ref.) (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Moses MA. **Stem Cells** 1997;15(3):180–9 (88 ref.)

IMMUNOLOGY

Allorecognition by murine natural killer cells: studies with bone marrow transplants and lysis of T lymphoblasts. Liu J, et al. **Chem Immunol** 1996;64:164–80 (23 ref.)

METABOLISM

TGF–beta latency: biological significance and mechanisms of activation. Gleizes PE, et al. **Stem Cells** 1997;15(3):190–7 (70 ref.)

PATHOLOGY

Myeloma stem cell phenotype. Implications for treatment. Epstein J. **Hematol Oncol Clin North Am** 1997 Feb; 11(1):43–9 (38 ref.)

PHYSIOLOGY

Potential of neural "stem–like" cells for gene therapy and repair of the degenerating central nervous system. Snyder EY, et al. **Adv Neurol** 1997;72:121–32 (69 ref.)
Epithelial stem cells. Jones PH. **Bioessays** 1997 Aug; 19(8):683–90 (64 ref.)
Epithelial apoptosis. Metcalfe A, et al. **Bioessays** 1997 Aug; 19(8):711–20 (90 ref.)
Set–aside cells in maximal indirect development: evolutionary and developmental significance. Peterson KJ, et al. **Bioessays** 1997 Jul;19(7):623–31 (39 ref.)
Regulatory mechanisms in stem cell biology. Morrison SJ, et al. **Cell** 1997 Feb 7;88(3):287–98 (112 ref.)
Vertebrate neural progenitor cells: subtypes and regulation. Temple S, et al. **Curr Opin Neurobiol** 1996 Feb;6(1):11–7 (65 ref.)
Central nervous system cell transplantation: a novel therapy for storage diseases? Snyder EY, et al. **Curr Opin Neurol** 1996 Apr;9(2):126–36 (103 ref.)
Chick stem cells. Stern CD. **Curr Top Microbiol Immunol** 1996;212:195–206 (44 ref.)
Fate determination and migration of progenitors in the postnatal mammalian CNS. Goldman JE, et al. **Dev Neurosci** 1997;19(1):42–8 (68 ref.)
neurogenins, a novel family of atonal–related bHLH transcription factors, are putative mammalian neuronal determination genes that reveal progenitor cell heterogeneity in the developing CNS and PNS. Sommer L, et al. **Mol Cell Neurosci** 1996;8(4):221–41 (51 ref.)
To what extent is oligodendrocyte progenitor migration a limiting factor in the remyelination of multiple sclerosis lesions? Franklin RJ, et al. **Mult Scler** 1997 Apr;3(2):84–7 (29 ref.)
Regulation and significance of apoptosis in the stem cells of the gastrointestinal epithelium. Potten CS, et al. **Stem Cells** 1997;15(2):82–93 (96 ref.)
The role of motility proteins and metastasis–suppressor genes in prostate cancer progression. Rinker–Schaeffer CW, et al. **Stem Cells** 1996 Sep;14(5):508–16 (50 ref.)
Rat embryonic stem cells: a progress report. Brenin D, et al. **Transplant Proc** 1997 May;29(3):1761–5 (29 ref.)
Neuroblasts: a model for the asymmetric division of stem cells. Lin H, et al. **Trends Genet** 1997 Jan;13(1):33–9 (48 ref.)
Is there a neural stem cell in the mammalian forebrain? [see comments] Weiss S, et al. **Trends Neurosci** 1996 Sep; 19(9):387–93 (68 ref.) Comment in: Trends Neurosci 1997 May;20(5):203–4.
[Limbus stem cells and their significance for regeneration of of the corneal surface] Kruse FE. **Ophthalmologe** 1996 Oct;93(5):633–43 (32 ref.) **(Ger)**

TRANSPLANTATION

High–dose chemotherapy with autologous stem cell support for the treatment of advanced ovarian cancer––initial experience in Uppsala and Turku. Grenman S, et al. **Acta Obstet Gynecol Scand** 1997 Apr;76(4):363–8 (31 ref.)
Gene therapy and the use of stem cells for central nervous system regeneration. Whittemore SR, et al. **Adv Neurol** 1997;72:113–9 (34 ref.)
Aggressive treatment in follicular non–Hodgkin's lymphoma. Schouten HC. **Br J Hosp Med** 1996 Nov 20–Dec 10; 56(10):525–8 (32 ref.)
Adenovirus for neurodegenerative diseases: in vivo strategies and ex vivo gene therapy using human neural progenitors. Sabaté O, et al. **Clin Neurosci** 1995–96;3(5):317–21 (42 ref.)
Multipotent neural progenitor or stem–like cells may be uniquely suited for therapy for some neurodegenerative conditions. Snyder EY, et al. **Clin Neurosci** 1995–96; 3(5):310–6 (43 ref.)
Understanding the molecular basis of cell migration; implications for clinical therapy in multiple sclerosis. Milner R. **Clin Sci (Colch)** 1997 Feb;92(2):113–22 (57 ref.)
The evolution of epithelial transplantation for severe ocular surface disease and a proposed classification system. Holland EJ, et al. **Cornea** 1996 Nov;15(6):549–56 (42 ref.)
Stem cell transplantation in autoimmune disease [editorial] Brooks PM, et al. **J Rheumatol** 1995 Oct;22(10):1809–11 (31 ref.)

STEM CELLS, ERYTHROID see **ERYTHROID PROGENITOR CELLS**

STEM CELLS, HEMATOPOIETIC see **HEMATOPOIETIC STEM CELLS**

STEM CELLS, NEOPLASTIC see **TUMOR STEM CELLS**

STENOCARDIA see **ANGINA PECTORIS**

STENTS

Review article: update on the role of transjugular intrahepatic portosystemic stent–shunt (TIPSS) in the management of complications of portal hypertension. Stanley AJ, et al. **Aliment Pharmacol Ther** 1997 Apr;11(2):261–72 (103 ref.)
Endovascular stenting. Sullivan TM. **Am J Surg** 1997 Jan; 173(1):27–9; discussion 30–1 (17 ref.)
Pictorial review: endovascular repair of abdominal aortic aneurysms. Dyet JF. **Br J Radiol** 1996 Nov;69(827):1069–74 (8 ref.)
Public policy and coronary stenting: report of an expert panel to the cardiac Care Network of Ontario. Cardiac Care Network of Ontario Expert Panel on Intracoronary Stents. **Can J Cardiol** 1997 Aug;13(8):731–46 (121 ref.)
Ultrasound–guided stent placement. Russo RJ. **Cardiol Clin** 1997 Feb;15(1):49–61 (64 ref.)
Vascular stents and stent grafts: a vascular surgeon's view. Taylor PR. **Cardiovasc Intervent Radiol** 1997 Jan–Feb; 20(1):1–4 (37 ref.)
Stenting the stent: alternative strategy for treating in–stent restenosis [see comments] Ceceña FA. **Cathet Cardiovasc Diagn** 1996 Dec;39(4):377–82 (11 ref.) Comment in: Cathet Cardiovasc Diagn 1997 May;41(1):94–5.
Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein–covered Palmaz stent [see comments] Gurbel PA, et al. **Cathet Cardiovasc Diagn** 1997 Jan;40(1):75–8 (12 ref.) Comment in: Cathet Cardiovasc Diagn 1997 Jan;40(1):79.
Stenting for treatment of coronary vasospasm. Rabinowitz A, et al. **Cathet Cardiovasc Diagn** 1996 Dec;39(4):372–5 (10 ref.)
Arterial autologous graft–stent for treatment of coronary artery disease: a new technique. Stefanadis C, et al. **Cathet Cardiovasc Diagn** 1997 Mar;40(3):302–7 (23 ref.)
Elective stenting of unprotected left main coronary disease. Wong P, et al. **Cathet Cardiovasc Diagn** 1996 Dec; 39(4):347–54 (19 ref.)
Early clinical experience with the Multi–Link coronary stent. Wong P, et al. **Cathet Cardiovasc Diagn** 1996 Dec; 39(4):413–9 (6 ref.)
Update on biliary stent occlusion. Liu Y, et al. **Chin Med J (Engl)** 1996 Nov;109(11):892–6 (25 ref.)
Intravascular stent endothelialization. A goal worth pursuing? [editorial; comment] Schneider DB, et al. **Circulation** 1997 Jan 21;95(2):308–10 (29 ref.) Comment on: Circulation 1997 Jan 21;95(2):438–48.
Beta–particle–emitting stents radiate enthusiasm in the search for effective prevention of restenosis [editorial; comment] van der Giessen WJ, et al. **Circulation** 1996 Nov 15; 94(10):2358–60 (18 ref.) Comment on: Circulation 1996 Nov 15;94(10):2364–8.
Endovascular stents in the arterial system––current status. Dyet JF. **Clin Radiol** 1997 Feb;52(2):83–108 (80 ref.)
Current approaches to coronary intervention. King SB 3rd. **Compr Ther** 1996 Nov;22(11):731–6 (24 ref.)
Coronary stent placement as a bridge to coronary artery bypass surgery in an unstable, anemic Jehovah's Witness patient: a case report and review of bloodless surgery techniques. Dougherty JE, et al. **Conn Med** 1997 Apr; 61(4):195–9 (22 ref.)
New interventions in cerebrovascular disease: the role of thrombolytic therapy and balloon angioplasty. Balousek PA, et al. **Curr Opin Cardiol** 1996 Sep;11(5):550–7 (67 ref.)
Self–expanding metal stents for palliation of stenosing tumors of the esophagus and cardia: a critical review. Ell C, et al. **Endoscopy** 1997 Jun;29(5):392–8 (40 ref.)
Application of self–expanding stents in prostate cancer with rectal involvement. Report of two cases and review of the literature. Lujan M, et al. **Eur Urol** 1997;31(2):251–3 (13 ref.)
Coronary restenosis after optimal (stent–like) initial angiographic results obtained by traditional balloon angioplasty. Di Luzio V, et al. **G Ital Cardiol** 1997 Jul; 27(7):645–53 (38 ref.)
Management of a refractory benign esophageal stricture with a new biodegradable stent. Fry SW, et al. **Gastrointest Endosc** 1997 Feb;45(2):179–82 (12 ref.)
A rare indication for stenting: persistent coronary artery spasm. Kültürsay H, et al. **Heart Vessels** 1996;11(3):165–8 (13 ref.)
Stent or surgery for malignant low bile duct obstruction? Ihse I, et al. **HPB Surg** 1997;10(3):179–81 (15 ref.)
Endoscopic stenting of minor papilla for symptomatic pancreas divisum. Bhasin DK, et al. **Indian J Gastroenterol** 1997 Jan;16(1):30–1 (7 ref.)
Endoscopic placement of expandable biliary stents: current applicability. Dhir V, et al. **Indian J Gastroenterol** 1996 Oct;15(4):142–6 (30 ref.)
Endovascular stents: a 'break through technology', future challenges. Violaris AG, et al. **Int J Card Imaging** 1997 Feb;13(1):3–13 (59 ref.)
The role of stents in cardiology: advantages and complications [editorial; comment] Eldar M. **Isr J Med Sci** 1996 Sep;32(9):777–8 (19 ref.) Comment on: Isr J Med Sci 1996 Sep;32(9):722–5.
Interventional cardiology: present and future. Chambers CE, et al. **J Cardiothorac Vasc Anesth** 1997 Apr;11(2):211–9 (91 ref.)
Techniques for endovascular recanalization of supra–aortic trunks. Criado FJ, et al. **J Endovasc Surg** 1996 Nov; 3(4):405–13 (48 ref.)
The need for clinical trials of endovascular abdominal aortic aneurysm stent–graft repair: The EUROSTAR Project. EUROpean collaborators on Stent–graft Techniques for abdominal aortic Aneurysm Repair. Harris PL, et al. **J Endovasc Surg** 1997 Feb;4(1):72–7; discussion 78–9 (15 ref.)
The ins and outs of the excluded abdominal aortic aneurysm: decreasing diameters and dilating necks [comment] May J. **J Endovasc Surg** 1997 Feb;4(1):31–2 (6 ref.) Comment on: J Endovasc Surg 1997 Feb;4(1):23–30.
Malignant tracheo–esophageal fistula: use of esophageal endoprosthesis. Spivak F, et al. **J Surg Oncol** 1996 Sep; 63(1):65–70 (36 ref.)
Autologous vein–covered stent for the endovascular management of an iliac artery–ureteral fistula: case report and review of the literature. Kerns DB, et al. **J Vasc Surg** 1996 Oct;24(4):680–6 (46 ref.)
Stenting of central venous stenoses in hemodialysis patients: long–term results. Mickley V, et al. **Kidney Int** 1997 Jan; 51(1):277–80 (31 ref.)
Use of intravascular stents for superior vena caval obstruction after the Mustard operation. MacLellan–Tobert SG, et al. **Mayo Clin Proc** 1996 Nov;71(11):1071–6 (23 ref.)
Coronary artery stents. Stewart AJ, et al. **Postgrad Med J** 1996 May;72(847):274–6 (18 ref.)
Percutaneous therapy of structural heart disease: pediatric disease. Verma R, et al. **Prog Cardiovasc Dis** 1997 Jul–Aug; 40(1):37–54 (70 ref.)
Implantation and imaging of coronary stents. Haas R. **Radiol Technol** 1996 Jan–Feb;67(3):233–44; quiz 245–8 (22 ref.)
The role of intracoronary stents in the prevention of restenosis––facts and fallacies. Lau KW. **Singapore Med J** 1996 Oct;37(5):522–6 (31 ref.)
[Antiplatelet therapy during coronary endoprosthesis placement] Barragan P, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1515–20 (42 ref.) (Eng. Abstr.) **(Fre)**
[Loss of a stent in the left main coronary artery and secondary migration into the left circumflex artery needing surgical extraction. Apropos of a case] Bedossa M, et al. **Arch Mal Coeur Vaiss** 1996 Dec;89(12):1677–80 (10 ref.) (Eng. Abstr.) **(Fre)**
[Complications of double J ureteral stents] el Khader K. **J Urol (Paris)** 1996;102(4):173–5 (25 ref.) (Eng. Abstr.) **(Fre)**
[Why so many stents?] Guyon P, et al. **Presse Med** 1997 Apr 5;26(11):526–31 (19 ref.) (Eng. Abstr.) **(Fre)**
[Current possibilities for endoluminal arterial vascular

procedures] Morin D, et al. **Rev Med Suisse Romande** 1997 Feb;117(2):117–25 (10 ref.) **(Fre)**

[Stent implantation in coronary arteries—current status] Frombach R, et al. **Gesundheitswesen** 1997 Jul;59(7):447–51 (27 ref.) (Eng. Abstr.) **(Ger)**

[Current status of stent implantation] Kaufmann U, et al. **Internist (Berl)** 1997 Jan;38(1):20–6 (29 ref.) **(Ger)**

[Esophageal carcinoma: downstaging or stent?] Grund KE, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996; 113:755–8 (15 ref.) (Eng. Abstr.) **(Ger)**

[Interventional pneumology: procedures for pulmonary hemorrhage and tumor-induced superior vena cava syndrome] Witt C, et al. **Pneumologie** 1996 Feb;50(2):202–8 (51 ref.) (Eng. Abstr.) **(Ger)**

[Anti-thrombosis therapy following coronary stent implantation] Schuiki E, et al.
Schweiz Rundsch Med Prax 1996 Oct 15;85(42):1316–9 (28 ref.) (Eng. Abstr.) **(Ger)**

[The significance of intravascular ultrasound in differential diagnosis and therapy of coronary stenoses] Görge G, et al. **Z Kardiol** 1996;85 Suppl 1:73–80 (41 ref.) (Eng. Abstr.) **(Ger)**

[Vascular stents and development of endoluminal therapy of aortic aneurysm] Blum U, et al. **Zentralbl Chir** 1996; 121(9):714–20 (47 ref.) (Eng. Abstr.) **(Ger)**

[Evolution in coronary stenting: use of ticlopidine with and without oral anticoagulants] Zanini R, et al. **Cardiologia** 1997 Aug;42(8):837–43 (32 ref.) (Eng. Abstr.) **(Ita)**

[Urgent medical situation and therapeutic strategy in patients undergoing digestive cancer surgery (inflammation, stenosis, hemorrhage)] Mizobuchi N, et al.
Gan To Kagaku Ryoho 1997 Feb;24(3):279–84 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Surgical emergency induced by chest tumors] Yamaguchi Y, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(3):272–8 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Balloon angioplasty and metallic stent] Nishimine K, et al. **Nippon Geka Gakkai Zasshi** 1996 Jul;97(7):532–9 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Airway stenosis and stents] Miyazawa T, et al.
Nippon Naika Gakkai Zasshi 1996 Dec 10;85(12):2086–90 (11 ref.) **(Jpn)**

[Biliary endoprosthesis using metallic stents in management of malignant biliary strictures] Ogawa K, et al.
Nippon Rinsho 1996 Nov;54(11):3143–56 (28 ref.) (Eng. Abstr.) **(Jpn)**

[The use of endoprosthesis in treating tracheal and bronchial stenosis] Grubnik VV, et al. **Klin Khir** 1996;(11–12):38–41 (48 ref.) **(Rus)**

[The role of non-angiographic observations (IVUS, angioscopy, doppler) in coronary stenting] Alfonso F, et al. **Rev Esp Cardiol** 1997;50 Suppl 2:52–62 (67 ref.) (Eng. Abstr.) **(Spa)**

[Intracoronary stents in the treatment of angioplasty complications] Cequier A, et al. **Rev Esp Cardiol** 1997;50 Suppl 2:21–30 (121 ref.) (Eng. Abstr.) **(Spa)**

[Is there one type of stent for every lesion?] García E, et al. **Rev Esp Cardiol** 1997;50 Suppl 2:44–51 (49 ref.) (Eng. Abstr.) **(Spa)**

[Future perspectives in coronary stenting] Hernández Antolín RA, et al. **Rev Esp Cardiol** 1997;50 Suppl 2:95–106 (132 ref.) (Eng. Abstr.) **(Spa)**

[The effectiveness of stents in restinotic lesions and coronary grafts] Valdés M, et al. **Rev Esp Cardiol** 1997;50 Suppl 2:10–20 (57 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Peritoneal and pleural infection following placement of an internal biliary stent for a large bile leak. Weiss K, et al. **Am J Gastroenterol** 1997 Feb;92(2):347–8 (9 ref.)

Ticlopidine and aspirin therapy following implantation of coronary artery stents. Hobson AG, et al.
Ann Pharmacother 1997 Jun;31(6):770–2 (16 ref.)

Cardiac tamponade following stent implantation with adjuvant platelet IIb/IIIa receptor inhibitor administration. Bottner RK, et al. **Cathet Cardiovasc Diagn** 1997 Apr; 40(4):380–2 (4 ref.)

Fatal infection of coronary stent implantation. Leroy O, et al. **Cathet Cardiovasc Diagn** 1996 Oct;39(2):168–70; discussion 171 (6 ref.)

Stent thrombosis in a patient receiving chemotherapy. Smith SC, et al. **Cathet Cardiovasc Diagn** 1997 Apr;40(4):383–6 (24 ref.)

The stenotic stent: mechanisms and revascularization options. Topaz O, et al. **Cathet Cardiovasc Diagn** 1996 Mar; 37(3):293–9 (40 ref.)

Stent thrombosis. Closing in on the best preventive treatment [editorial; comment] Baim DS, et al. **Circulation** 1997 Mar 4;95(5):1098–100 (14 ref.) Comment on: Circulation 1997 Mar 4;95(5):1145–56.

Massive hemorrhage caused by a perforating Gianturco–Z stent resulting in an aortoesophageal fistula. Siersema PD, et al. **Endoscopy** 1997 Jun;29(5):416–20 (44 ref.)

Stent thrombosis revisited. Gershlick AH, et al.
Eur Heart J 1996 Nov;17(11):1623–8 (39 ref.)

Transpapillary stenting of proximal biliary strictures: does biliary sphincterotomy reduce the risk of postprocedure pancreatitis? Tarnasky PR, et al. **Gastrointest Endosc** 1997 Jan;45(1):46–51 (27 ref.)

Management of subacute stent closure. Hasdai D, et al.
Int J Cardiol 1996 Jul 26;55(2):115–6 (10 ref.)

Complications of endopyelotomy. Bellman GC.
J Endourol 1996 Apr;10(2):177–81 (18 ref.)

Antithrombotic therapy after intracoronary stenting. Spinler S, et al. **Pharmacotherapy** 1997 Jan–Feb;17(1):74–90 (68 ref.)

[Medical treatment after implantation of intracoronary stents] Caussin C, et al. **Presse Med** 1997 Apr 5;26(11):532–5 (14 ref.) (Eng. Abstr.) **(Fre)**

[An unusual complication of anterograde endopyelotomy: ureteral intussusception (a case report)] el Khader K, et al. **Prog Urol** 1997 Apr;7(2):273–6 (14 ref.) (Eng. Abstr.) **(Fre)**

[Early stent-induced thrombosis in the pelvic circulation: a complication in APC resistance] Lenglinger FX, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1997 Mar;166(3):260–2 (11 ref.) **(Ger)**

[The penetration of a bile duct metal stent into the duodenal bulb as a late complication of combined stent/radiotherapy in Klatskin's tumor] Wingen M, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1997 Jan;166(1):75–7 (10 ref.) **(Ger)**

[Post-implant antithrombotic treatment after intracoronary stents. Thrombotic occlusion] Alonso Martín JJ, et al.
Rev Esp Cardiol 1997;50 Suppl 2:31–43 (97 ref.) (Eng. Abstr.) **(Spa)**

[Complications at the first month following various types of intracoronary stents, implanted with high pressure without intracoronary ultrasonography or anticoagulation] Valdés M, et al. **Rev Esp Cardiol** 1996 Jun;49(6):432–8 (35 ref.) (Eng. Abstr.) **(Spa)**

CLASSIFICATION

[Different types of coronary stents] Bourachot ML, et al. **Presse Med** 1997 Apr 5;26(11):536–40 (15 ref.) (Eng. Abstr.) **(Fre)**

[Effectiveness of the Palmaz Schatz stent in elderly patients with unstable angina: factors predictive of short-term and long-term events] Klugmann S, et al. **G Ital Cardiol** 1997 Jul;27(7):659–68 (35 ref.) (Eng. Abstr.) **(Ita)**

ECONOMICS

[Intracoronary prosthesis (stent): an approach to the analysis of cost-effectiveness] Iñiguez Romo A. **Rev Esp Cardiol** 1997;50 Suppl 2:83–94 (67 ref.) (Eng. Abstr.) **(Spa)**

STANDARDS

Endovascular stents in congenital heart disease. Benson LN, et al. **Prog Cardiovasc Dis** 1996 Sep–Oct;39(2):165–86 (76 ref.)

Coronary artery stenting: indications and cost implications. Cohen EA, et al. **Prog Cardiovasc Dis** 1996 Sep–Oct; 39(2):83–110 (169 ref.)

Contemporary stent designs: technical considerations, complications, role of intravascular ultrasound, and anticoagulation therapy. Popma JJ, et al.
Prog Cardiovasc Dis 1996 Sep–Oct;39(2):111–28 (166 ref.)

Noncoronary vascular stenting. Sniderman KW.
Prog Cardiovasc Dis 1996 Sep–Oct;39(2):141–64 (134 ref.)

Nonvascular stents. Vanderburgh L, et al.
Prog Cardiovasc Dis 1996 Sep–Oct;39(2):187–200 (75 ref.)

Pitfalls in coronary stenting. A review of current strategies. Thomas MR. **S Afr Med J** 1997 Jun;87 Suppl 3:C167–70 (24 ref.)

SUPPLY & DISTRIBUTION

New stent technologies. Ozaki Y, et al.
Prog Cardiovasc Dis 1996 Sep–Oct;39(2):129–40 (59 ref.)

TRENDS

[Stents: new studies—new trends] Dietz R, et al.
Z Kardiol 1997 Feb;86(2):65–70 (53 ref.) (Eng. Abstr.) **(Ger)**

UTILIZATION

Esophageal self-expandable metallic stents [editorial; comment] Shields SJ. **Gastrointest Endosc** 1997 May; 45(5):439–42 (50 ref.) Comment on: Gastrointest Endosc 1997 May;45(5):360–4.

STEP TEST see **EXERCISE TEST**

STEPFAMILY see **FAMILY**

STEPHANURUS DENTATUS INFECTIONS see **STRONGYLIDA INFECTIONS**

STEP-PARENTS see **PARENTS**

STEREOGNOSIS

Dynamic touch. Turvey MT. **Am Psychol** 1996 Nov; 51(11):1134–52 (50 ref.)

STEREOISOMERISM

Recent progress in liquid chromatographic enantioseparation based upon diastereomer formation with fluorescent chiral derivatization reagents. Toyo'oka T. **Biomed Chromatogr** 1996 Nov–Dec;10(6):265–77 (81 ref.)

How nature deals with stereoisomers. Lamzin VS, et al.
Curr Opin Struct Biol 1995 Dec;5(6):830–6 (45 ref.)

Drug chirality and its clinical significance. Hutt AJ, et al.
Drugs 1996;52 Suppl 5:1–12 (78 ref.)

Enantioselective assays in comparative bioavailability studies of racemic drug formulations: nice to know or need to know? Karim A. **J Clin Pharmacol** 1996 Jun;36(6):490–9 (68 ref.)

Origin of the homochirality of biomolecules. Keszthelyi L.
Q Rev Biophys 1995 Nov;28(4):473–507 (110 ref.)

[Simultaneous stereoinversion, racemization and isomerization at specific amino acid residues in the proteins during aging] Fujii N. **Seikagaku** 1996 Oct;68(10):1641–5 (12 ref.) **(Jpn)**

[Can the enantiomer of the substrate be the substrate for the same enzyme?] Kraevskiĭ AA, et al. **Mol Biol (Mosk)** 1996 Sep–Oct;30(5):991–1001 (56 ref.) **(Rus)**

STEREOISOMERS see **STEREOISOMERISM**

STEREOPSIS see **DEPTH PERCEPTION**

STEREOSCOPIC VISION see **DEPTH PERCEPTION**

STEREOTACTIC RADIOSURGERY see **RADIOSURGERY**

STEREOTAXIC TECHNIQUES

see related
BRAIN MAPPING

Controversies in pallidal surgery. Hariz MI.
Acta Neurochir Suppl (Wien) 1997;68:1–10 (88 ref.)

Stereotactic pallidotomy for treatment of Parkinson's disease. Eller TW, et al. **AORN J** 1997 May;65(5):903–4, 907–16; quiz 917–20 (16 ref.)

Stereotactic 14 gauge core-biopsy of the breast: results from 101 patients [see comments] Frayne J, et al.
Aust N Z J Surg 1996 Sep;66(9):585–91 (26 ref.) Comment in: Aust N Z J Surg 1996 Sep;66(9):577–9.

Minimalism through stereotactic technique. Ross DA.
Clin Neurosurg 1996;43:317–23 (33 ref.)

Stereotactic procedures for molecular neurosurgery. Kelly PJ. **Exp Neurol** 1997 Mar;144(1):157–9 (11 ref.)

Fractionated stereotactic radiotherapy. Shrieve DC, et al.
Important Adv Oncol 1996;:205–24 (67 ref.)

Role of stereotaxis in the treatment of cerebral palsy. De Salles AA. **J Child Neurol** 1996 Nov;11 Suppl 1:S43–50 (38 ref.)

Review of magnetic neurosurgery research. Howard MA 3rd, et al. **J Image Guid Surg** 1995;1(6):295–9 (11 ref.)

Stereotactic radiosurgery of pituitary adenomas. Motti ED, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):111–4 (11 ref.)

Diagnosis of suspected intracranial metastases. Role of direct tissue examination. Carter BS, et al.
Neurosurg Clin N Am 1996 Jul;7(3):425–33 (23 ref.)

Stereotactic lumbar microdiscectomy. Koutrouvelis PG, et al. **Neurosurg Clin N Am** 1996 Jan;7(1):49–57 (14 ref.)

A serial CT scan and MRI verification of diffuse cerebrospinal gliomatosis: a case report with stereotactic diagnosis and radiological confirmation. Onal C, et al.
Pediatr Neurosurg 1996 Aug;25(2):94–9 (50 ref.)

Role of stereotactic breast biopsy. Bernstein JR.
Semin Surg Oncol 1996 Sep–Oct;12(5):290–9 (39 ref.)

Stereotactic high-activity brachytherapy for malignant intra-axial brain tumors. Status report as of March, 1995. Bernstein M, et al. **Stereotact Funct Neurosurg** 1995; 65(1–4):167–70 (9 ref.)

The role of stereotactic biopsy in abnormal mammograms. Fajardo LL, et al. **Surg Oncol Clin N Am** 1997 Apr; 6(2):285–99 (24 ref.)

[Image-guided surgery] Gybels J, et al.
Verh K Acad Geneeskd Belg 1997;59(1):35–57; discussion 57–9 (31 ref.) (Eng. Abstr.) **(Dut)**

[Stereotaxic mammary microbiopsy. I. Technical aspects] Thiesse P, et al. **Ann Chir** 1996;50(6):457–62 (32 ref.) (Eng. Abstr.) **(Fre)**

[Stereotaxic mammary core biopsy. II. Complementarity or competition with surgical biopsy] Thiesse P, et al.
Ann Chir 1996;50(6):463–9 (51 ref.) (Eng. Abstr.) **(Fre)**

[Stereotaxic radiotherapy of cerebral arteriovenous malformations: the role of neuroradiology] Meder JF, et al. **J Neuroradiol** 1997 Aug;24(2):126–33 (57 ref.) (Eng. Abstr.) **(Fre)**

[Current therapy of idiopathic Parkinson disease. 2: Recent and alternative therapies] Müller T, et al. **Fortschr Med** 1997 May 10;115(13):37–41 (0 ref.) (Eng. Abstr.) **(Ger)**

[Stereotactic treatment of movement disorders] Ostertag CB, et al. **Nervenarzt** 1997 Jun;68(6):477–84 (70 ref.) (Eng. Abstr.) **(Ger)**

[Improvement in function-preservation in radiotherapy for pediatric malignancies] Sumi M, et al.
Gan To Kagaku Ryoho 1997 Apr;24(6):657–65 (33 ref.) (Eng. Abstr.) **(Jpn)**

[Resection of glioma located in deep or eloquent area: application of functional mapping, intraoperative monitoring and navigation with CT or MRI-assisted stereotactic guidance] Matsumoto K, et al.
No Shinkei Geka 1997 Jan;25(1):17–28 (58 ref.) **(Jpn)**

INSTRUMENTATION

Intracerebral depth electrode monitoring in partial epilepsy: the morbidity and efficacy of placement using magnetic resonance image-guided stereotactic surgery. Ross DA, et

STEREOTAXIC TECHNIQUES

al. **Neurosurgery** 1996 Aug;39(2):327–33; discussion 333–4 (39 ref.)
Use of the Horsley–Clarke stereotactic frame in humans. Jensen RL, et al. **Stereotact Funct Neurosurg** 1995; 65(1–4):194–7 (21 ref.)
Image-guided stereotactic neurosurgery with the multicoordinate manipulator microscope. Pillay PK. **Surg Neurol** 1997 Feb;47(2):171–6; discussion 176–7 (10 ref.)
[Presurgical diagnosis of epilepsy and surgical epilepsy treatment] Baumgartner C, et al. **Wien Klin Wochenschr** 1997 Mar 28;109(6):180–91 (64 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

Use of the Horsley–Clarke stereotactic frame in humans. Jensen RL, et al. **Stereotact Funct Neurosurg** 1995; 65(1–4):194–7 (21 ref.)

STEREOTYPED BEHAVIOR

Agitation, wandering, pacing, restlessness, and repetitive mannerisms. Neistein S, et al. **Int Psychogeriatr** 1996;8 Suppl 3:399–402 (13 ref.)
Perseveration in schizophrenia. Crider A. **Schizophr Bull** 1997;23(1):63–74 (100 ref.)
Epilepsy or stereotypy? Diagnostic issues in learning disabilities. Paul A. **Seizure** 1997 Apr;6(2):111–20 (42 ref.)

PHYSIOLOGY

Dopamine/glutamate interaction as studied by combining turning behaviour and c-Fos expression. Morelli M. **Neurosci Biobehav Rev** 1997 Jul;21(4):505–9 (36 ref.)

STEREOTYPING

Sources of stigma associated with women with HIV. Bunting SM. **ANS Adv Nurs Sci** 1996 Dec;19(2):64–73 (41 ref.)
Rethinking the relationships between disability, rehabilitation, and society. Imrie R. **Disabil Rehabil** 1997 Jul;19(7):263–71 (37 ref.)
The dismantling of a myth: a review of eating disorders and socioeconomic status. Gard MC, et al. **Int J Eat Disord** 1996 Jul;20(1):1–12 (40 ref.)
Some contributions from the social system to gender inequalities in heart disease [published erratum appears in J Health Soc Behav 1996 Jun;37(2):preceding 121] McKinlay JB. **J Health Soc Behav** 1996 Mar;37(1):1–26 (102 ref.)
Menopause, only for women? The social construction of menopause as an exclusively female condition. Oudshoorn NE. **J Psychosom Obstet Gynaecol** 1997 Jun;18(2):137–44 (16 ref.)

STERILITY see **INFERTILITY**

STERILITY, FEMALE see **INFERTILITY, FEMALE**

STERILITY, MALE see **INFERTILITY, MALE**

STERILIZATION

Process simulation testing for aseptically filled products. Parenteral Drug Association. **PDA J Pharm Sci Technol** 1996;50 Suppl 1:S1–16 (13 ref.)
[Cryopreserved homograft cardiac valves: structural modifications brought about by the use of sterilization and cryopreservation methods] Porqueddu M, et al. **Cardiologia** 1997 Apr;42(4):351–7 (52 ref.) **(Ita)**

INSTRUMENTATION

Thermal processing of foods, a retrospective, Part II: On-line methods for ensuring commercial sterility. Ramesh MN, et al. **Adv Appl Microbiol** 1997;44:315–45 (60 ref.)

METHODS

APIC guideline for selection and use of disinfectants. 1994, 1995, and 1996 APIC Guidelines Committee. Association for Professionals in Infection Control and Epidemiology, Inc. Rutala WA. **Am J Infect Control** 1996 Aug; 24(4):313–42 (294 ref.)
Heat transfer and lethality considerations in aseptic processing of liquid/particle mixtures: a review. Ramaswamy HS, et al. **Crit Rev Food Sci Nutr** 1997 Apr; 37(3):253–86 (163 ref.)
Public health and nonpasteurized fruit juices. Parish ME. **Crit Rev Microbiol** 1997;23(2):109–19 (61 ref.)
Instrument sterilization, skin preparation, and wound management. Southwood LL, et al. **Vet Clin North Am Equine Pract** 1996 Aug;12(2):173–94 (79 ref.)
[Disinfection of human donor corneas during preparation and preservation] Hagenah M, et al. **Klin Monatsbl Augenheilkd** 1996 Jul;209(1):1–6; discussion 1 (58 ref.) (Eng. Abstr.) **(Ger)**
[Health hazards in hospital personnel related to use of ethylene oxide in sterilization processes] Tyras H. **Med Pr** 1997;48(3):325–33 (48 ref.) (Eng. Abstr.) **(Pol)**

STATISTICS & NUMERICAL DATA

Thermal processing of foods, a retrospective, Part I: Uncertainties in thermal processing and statistical analysis. Ramesh MN, et al. **Adv Appl Microbiol** 1997;44:287–314 (90 ref.)

STERILIZATION REVERSAL

Vasectomy and vasectomy reversal. Goldstein M, et al. **Curr Ther Endocrinol Metab** 1997;6:371–80 (6 ref.)

STERILIZATION, SEXUAL

see related
PEST CONTROL, BIOLOGICAL

METHODS

100,000 quinacrine sterilizations. Kessel E. **Adv Contracept** 1996 Jun;12(2):69–76 (37 ref.)

STERILIZATION, TUBAL

see related
STERILIZATION REVERSAL

ADVERSE EFFECTS

Is tubal sterilization associated with an increased risk of subsequent hysterectomy but a decreased risk of ovarian cancer? A review of recent literature. Chi IC. **Adv Contracept** 1996 Jun;12(2):77–99 (64 ref.)
Torsion of a fallopian tube following Pomeroy tubal ligation: a rare case report and review of the literature. Krissi H, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Mar; 72(1):107–9 (20 ref.)
Evisceration after laparoscopic sterilization. Lopez A, et al. **J Am Assoc Gynecol Laparosc** 1995 Nov;3(1):109–11 (11 ref.)
Pregnancy after failed tubal sterilization. Napolitano PG, et al. **J Reprod Med** 1996 Aug;41(8):609–13 (30 ref.)

INSTRUMENTATION

New methods for transcervical cannulation of the fallopian tube. Kerin JF. **Int J Gynaecol Obstet** 1995 Dec;51 Suppl 1:S29–39 (39 ref.)

METHODS

Sterilization. Wilson EW. **Baillieres Clin Obstet Gynaecol** 1996 Apr;10(1):103–19 (96 ref.)
Outpatient laparoscopic interval female sterilization. Intaraprasert S, et al. **Contraception** 1997 May;55(5):283–6 (17 ref.)
A fifteen-year review of female sterilization by minilaparotomy under local anesthesia in Kenya. Ruminjo JK, et al. **Contraception** 1997 Apr;55(4):249–60 (45 ref.)
Toxicological requirements for sclerosing agents or other chemicals for female sterilization. Heywood R. **Int J Gynaecol Obstet** 1995 Dec;51 Suppl 1:S41–5 (12 ref.)
Update on transcervical sterilization. Neuwirth RS. **Int J Gynaecol Obstet** 1995 Dec;51 Suppl 1:S23–8 (35 ref.)
Transcervical quinacrine sterilization: clinical experience. Sokal DC, et al. **Int J Gynaecol Obstet** 1995 Dec;51 Suppl 1:S57–69 (50 ref.)
The potential for improved abdominal procedures and approaches for tubal occlusion. Steele SJ. **Int J Gynaecol Obstet** 1995 Dec;51 Suppl 1:S17–22 (18 ref.)
The evolution of methods for female sterilization. Wilson EW. **Int J Gynaecol Obstet** 1995 Dec;51 Suppl 1:S3–13 (81 ref.)
Quinacrine: sclerosing agent of the utero–tubal junction in women, with anticarcinogenic actions in transplanted tumors in mice. Zipper J, et al. **Int J Gynaecol Obstet** 1995 Dec;51 Suppl 1:S47–55 (73 ref.)

NURSING

A comprehensive and efficient process for counseling patients desiring sterilization. Haws JM, et al. **Nurse Pract** 1997 Jun;22(6):52, 55–6, 59–61 passim (40 ref.)

TRENDS

The evolution of methods for female sterilization. Wilson EW. **Int J Gynaecol Obstet** 1995 Dec;51 Suppl 1:S3–13 (81 ref.)

STERNOCLAVICULAR JOINT

ABNORMALITIES

MR imaging of the abnormal sternoclavicular joint—a pictorial essay. Klein MA, et al. **Clin Imaging** 1997 Mar–Apr;21(2):138–43 (14 ref.)

INJURIES

[Retrosternal luxation of the clavicle. Apropos of 4 cases surgically treated using a temporary screwed anterior plate and review of the literature] Asfazadourian H, et al. **Ann Chir Main Memb Super** 1997;16(2):152–69 (114 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Septic sternoclavicular arthritis caused by group B Streptococcus: case report and review. Carrascosa M, et al. **Clin Infect Dis** 1996 Mar;22(3):579–80 (9 ref.)

PATHOLOGY

MR imaging of the abnormal sternoclavicular joint—a pictorial essay. Klein MA, et al. **Clin Imaging** 1997 Mar–Apr;21(2):138–43 (14 ref.)

STERNOCOSTOCLAVICULAR HYPEROSTOSIS see **HYPEROSTOSIS, STERNOCOSTOCLAVICULAR**

STERNUM

Mycobacterium fortuitum infection of the sternum. Review of the literature and case illustration. Samuels LE, et al. **Arch Surg** 1996 Dec;131(12):1344–6 (7 ref.)
[Solitary plasmacytoma of sternum—a case report and review of the Japanese literature] Ohtake Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 May;44(5):717–22 (24 ref.) (Eng. Abstr.) **(Jpn)**

ABNORMALITIES

Case report: bronchial atresia associated with pectus excavatum. Scholl RJ 3rd, et al. **Conn Med** 1997 May; 61(5):263–7 (15 ref.)

INJURIES

[Surgical treatment of aortic valve regurgitation due to nonpenetrating trauma of the chest—a case report and review of the literature in Japan] Ashida Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Feb;45(2):207–12 (24 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

Bilateral thoracotomy and inferior sternotomy for bypass grafting after esophagostomy. Smedira NG, et al. **Ann Thorac Surg** 1997 Mar;63(3):847–9 (4 ref.)
Tubercular sternal osteomyelitis and mediastinitis after open heart surgery. Aggarwal B, et al. **Indian Heart J** 1997 May–Jun;49(3):313–4 (4 ref.)
Sternotomy infection with Mycoplasma hominis: a cause of "culture negative" wound infection. Mossad SB, et al. **J Cardiovasc Surg (Torino)** 1996 Oct;37(5):505–9 (29 ref.)
Profuse mediastinal haemorrhage due to mediastinitis after sternotomy. Report of three cases and review of the literature. Partanen J, et al. **Scand J Thorac Cardiovasc Surg** 1996;30(3–4):167–73 (31 ref.)
[Mediastinitis following sternotomy: a potential complication of heart transplantation] Bouza E, et al. **Rev Clin Esp** 1995 Oct;195 Spec No:30–6 (73 ref.) **(Spa)**
[Aortic valve replacement via ministernotomy] Rodríguez JE, et al. **Rev Esp Cardiol** 1996 Dec;49(12):928–30 (4 ref.) (Eng. Abstr.) **(Spa)**

STEROID 11-HYDROXYLASE see **STEROID 11 BETA-MONOOXYGENASE**

STEROID 17-HYDROXYLASE see **STEROID 17 ALPHA-MONOOXYGENASE**

STEROID 18-HYDROXYLASE see **CYTOCHROME P-450 CYP11B2**

STEROID HYDROXYLASES

GENETICS

Mechanisms of ACTH(cAMP)-dependent transcription of adrenal steroid hydroxylases. Waterman MR, et al. **Endocr Res** 1996 Nov;22(4):615–20 (13 ref.)
Cytochromes P450 12: diversity of ACTH (cAMP)-dependent transcription of bovine steroid hydroxylase genes. Waterman MR, et al. **FASEB J** 1997 May;11(6):419–27 (42 ref.)

STEROID ISOMERASES

GENETICS

Molecular biology and genetics of the 3 beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. Simard J, et al. **J Endocrinol** 1996 Sep;150 Suppl:S189–207 (147 ref.)

STEROID 17 ALPHA-MONOOXYGENASE

CHEMISTRY

The regulation of 17,20 lyase activity. Miller WL, et al. **Steroids** 1997 Jan;62(1):133–42 (77 ref.)

GENETICS

Mutation of cytochrome P-45017 alpha gene (CYP17) in a Japanese patient previously reported as having glucocorticoid-responsive hyperaldosteronism: with a review of Japanese patients with mutations of CYP17. Miura K, et al. **J Clin Endocrinol Metab** 1996 Oct; 81(10):3797–801 (36 ref.)

METABOLISM

Hypersecretion of androgens by polycystic ovaries: the role of genetic factors in the regulation of cytochrome P450c17 alpha. Franks S, et al. **Baillieres Clin Endocrinol Metab** 1996 Apr;10(2):193–203 (33 ref.)

The role of cytochrome P450 17 alpha-hydroxylase and 3 beta-hydroxysteroid dehydrogenase in the integration of gonadal and adrenal steroidogenesis via the delta 5 and delta 4 pathways of steroidogenesis in mammals. Conley AJ, et al. **Biol Reprod** 1997 Apr;56(4):789–99 (147 ref.)

STEROID 11 BETA-MONOOXYGENASE

see related
ADRENAL HYPERPLASIA, CONGENITAL

DEFICIENCY

Does primary salt wasting occur in 11-beta-hydroxylase deficiency? Singer-Granick C, et al.
J Pediatr Endocrinol Metab 1995 Oct-Dec;8(4):275–80 (21 ref.)

STEROID 17-MONOOXYGENASE see **STEROID 17 ALPHA-MONOOXYGENASE**

STEROID 21-MONOOXYGENASE

DEFICIENCY

21-hydroxylase deficiency. Newfield RS, et al.
Ann N Y Acad Sci 1997 Jun 17;816:219–29 (25 ref.)

Molecular analysis of CYP21 and C4 genes in Brazilian families with the classical form of steroid 21-hydroxylase deficiency. de-Araujo M, et al. **Braz J Med Biol Res** 1996 Jan;29(1):1–13 (37 ref.)

Molecular approaches for the diagnosis of 21-hydroxylase deficiency and congenital adrenal hyperplasia. Wedell A. **Clin Lab Med** 1996 Mar;16(1):125–37 (45 ref.)

The 21-hydroxylase-deficient adrenal hyperplasias: more than ACTH oversecretion. Azziz R, et al.
J Soc Gynecol Investig 1996 Nov-Dec;3(6):297–302 (39 ref.)

GENETICS

Molecular approaches for the diagnosis of 21-hydroxylase deficiency and congenital adrenal hyperplasia. Wedell A. **Clin Lab Med** 1996 Mar;16(1):125–37 (45 ref.)

STEROID MONOOXYGENASES see **STEROID HYDROXYLASES**

STEROID RECEPTORS see **RECEPTORS, STEROID**

STEROID 21-HYDROXYLASE see **STEROID 21-MONOOXYGENASE**

STEROIDAL ANTI-INFLAMMATORY AGENTS see **ANTI-INFLAMMATORY AGENTS, STEROIDAL**

STEROIDS

see related
RECEPTORS, STEROID

Novel sweet-tasting saponins of the cycloartane, oleanane, secodammarane, and steroidal types. Kennelly EJ, et al. **Adv Exp Med Biol** 1996;405:13–24 (47 ref.)

Steroid saponins from fenugreek and some of their biological properties. Sauvaire Y, et al. **Adv Exp Med Biol** 1996; 405:37–46 (21 ref.)

Steroid hormones and cancer: (I) basic biology and endocrinology. Miller WR. **Eur J Surg Oncol** 1996 Dec; 22(6):627–33 (25 ref.)

ADMINISTRATION & DOSAGE

The topical treatment of distal ulcerative colitis. Ardizzone S, et al. **Eur J Gastroenterol Hepatol** 1996 Jun;8(6):599–602 (14 ref.)

Steroid pulse therapy for progressive systemic sclerosis [editorial; comment] Hashimoto H. **Intern Med** 1996 Jul; 35(7):525–6 (13 ref.) Comment on: Intern Med 1996 Jul;35(7):525–6.

ADVERSE EFFECTS

Do steroidal saponins have a role in hepatogenous photosensitization diseases of sheep? Flåøyen A.
Adv Exp Med Biol 1996;405:395–403 (51 ref.)

Glucocorticoid medication, memory and steroid psychosis in medical illness. Wolkowitz OM, et al.
Ann N Y Acad Sci 1997 Aug 14;823:81–96 (99 ref.)

Arterial hypertension in renal transplantation. Sandrini S, et al. **Contrib Nephrol** 1996;119:16–25 (61 ref.)

Bone densitometry: patients receiving prolonged steroid therapy. Erlichman M, et al. **Health Technol Assess** 1996 Sep;(9):i–vi, 1–31 (198 ref.)

Respiratory muscle pharmacology. Decramer M.
Monaldi Arch Chest Dis 1996 Dec;51(6):499–503 (47 ref.)

ANALYSIS

Steroidal glycoalkaloids in Andean potatoes. Kubo I, et al.
Adv Exp Med Biol 1996;405:405–17 (30 ref.)

Steroid profiling. Honour JW. **Ann Clin Biochem** 1997 Jan; 34 (Pt 1):32–44 (49 ref.)

BIOSYNTHESIS

New saponins from Vietnamese ginseng: highlights on biogenesis of dammarane triterpenoids. Duc NM, et al.
Adv Exp Med Biol 1996;404:129–49 (24 ref.)

The role of cytochrome P450 17 alpha-hydroxylase and 3 beta-hydroxysteroid dehydrogenase in the integration of gonadal and adrenal steroidogenesis via the delta 5 and delta 4 pathways of steroidogenesis in mammals. Conley AJ, et al. **Biol Reprod** 1997 Apr;56(4):789–99 (147 ref.)

A StAR search: implications in controlling steroidgenesis. Stocco DM. **Biol Reprod** 1997 Feb;56(2):328–36 (116 ref.)

Regulation of the acute production of steroids in steroidogenic cells. Stocco DM, et al. **Endocr Rev** 1996 Jun;17(3):221–44 (268 ref.)

The ontogenesis of the steroidogenic tissues. Morohashi K.
Genes Cells 1997 Feb;2(2):95–106 (106 ref.)

Role of the Golgi complex in adrenocortical steroidogenesis. Cheng B, et al. **Microsc Res Tech** 1997 Mar 15;36(6):503–9 (47 ref.)

Roles of microfilaments and intermediate filaments in adrenal steroidogenesis. Hall PF, et al. **Microsc Res Tech** 1997 Mar 15;36(6):463–79 (108 ref.)

Light and electron microscopic immunohistochemistry of the localization of adrenal steroidogenic enzymes. Ishimura K, et al. **Microsc Res Tech** 1997 Mar 15;36(6):445–53 (76 ref.)

Peroxisomes in adrenal steroidogenesis. Magalhães MM, et al. **Microsc Res Tech** 1997 Mar 15;36(6):493–502 (98 ref.)

Lipoproteins, lipid droplets, lysosomes, and adrenocortical steroid hormone synthesis: morphological studies. Tóth IE, et al. **Microsc Res Tech** 1997 Mar 15;36(6):480–92 (107 ref.)

The roles of calmodulin, actin, and vimentin in steroid synthesis by adrenal cells. Hall PF. **Steroids** 1997 Jan; 62(1):185–9 (34 ref.)

Signal transduction pathways combining peptide hormones and steroidogenesis. Waterman MR, et al. **Vitam Horm** 1996;52:129–48 (62 ref.)

BLOOD

Determinants of steroid hormone bioavailability. Hammond GL. **Biochem Soc Trans** 1997 May;25(2):577–82 (51 ref.)

The 21-hydroxylase-deficient adrenal hyperplasias: more than ACTH oversecretion. Azziz R, et al.
J Soc Gynecol Investig 1996 Nov-Dec;3(6):297–302 (39 ref.)

CHEMISTRY

A systematic NMR approach for the determination of the molecular structure of steroidal saponins. Agrawal PK.
Adv Exp Med Biol 1996;405:299–315 (117 ref.)

Proton and carbon-13 NMR studies of steroids and triterpenes. Cordell GA, et al. **Adv Exp Med Biol** 1996; 405:281–97 (96 ref.)

Chemistry and biological activity of steroid saponins from Moldovian plants. Kintia PK. **Adv Exp Med Biol** 1996; 404:309–34 (28 ref.)

Steroid and triterpenoid oligoglycosides of marine origin. Minale L, et al. **Adv Exp Med Biol** 1996;404:335–56 (63 ref.)

EPR/ENDOR investigations of gamma-irradiated steroid hormone single crystals. Szyczewski A.
Appl Radiat Isot 1996 Nov-Dec;47(11-12):1675–81 (30 ref.)

Diterpenoid and steroidal alkaloids. Atta-ur-Rahman, et al. **Nat Prod Rep** 1997 Apr;14(2):191–203 (53 ref.)

Brassinosteroids. Fujioka S, et al. **Nat Prod Rep** 1997 Feb; 14(1):1–10 (105 ref.)

Steroids: reactions and partial synthesis. Hanson JR.
Nat Prod Rep 1997 Aug;14(4):373–86 (242 ref.)

ISOLATION & PURIFICATION

Triterpene and steroid saponins isolated from two Melilotus species. Khodakov GV, et al. **Adv Exp Med Biol** 1996; 405:211–22 (17 ref.)

Bioactive triterpenoid and steroid saponins from medicinal plants in southwest China. Yang CR, et al.
Adv Exp Med Biol 1996;404:225–38 (20 ref.)

METABOLISM

Novel microbial transformations of steroids. Madyastha KM.
Adv Exp Med Biol 1996;405:259–70 (43 ref.)

Steroid profiling. Honour JW. **Ann Clin Biochem** 1997 Jan; 34 (Pt 1):32–44 (49 ref.)

Clinical indications for the use of urinary steroid profiles in neonates and children. Honour JW, et al.
Ann Clin Biochem 1997 Jan;34 (Pt 1):45–54 (37 ref.)

The fascinating complexities of steroid-binding enzymes. Duax WL, et al. **Curr Opin Struct Biol** 1996 Dec; 6(6):813–23 (52 ref.)

Cholestatic properties and hepatic transport of steroid glucuronides. Vore M, et al. **Drug Metab Rev** 1997 Feb-May;29(1-2):183–203 (49 ref.)

Steroid sulfotransferases. Strott CA. **Endocr Rev** 1996 Dec; 17(6):670–97 (229 ref.)

Metabolism of steroids in the brain: a new insight into the role of 5alpha-reductase and aromatase in brain differentiation and functions. Negri-Cesi P, et al.
J Steroid Biochem Mol Biol 1996 Aug;58(5-6):455–66 (116 ref.)

Vascularization of the adrenal cortex: its possible involvement in the regulation of steroid hormone release. Bassett JR, et al. **Microsc Res Tech** 1997 Mar 15; 36(6):546–57 (109 ref.)

Apoptosis in steroidogenic cells: structure-function analysis. Amsterdam A, et al. **Steroids** 1997 Jan;62(1):207–11 (33 ref.)

Transcriptional regulation by steroid hormones. Beato M, et al. **Steroids** 1996 Apr;61(4):240–51 (176 ref.)

Advances in microbial steroid biotransformation. Mahato SB, et al. **Steroids** 1997 Apr;62(4):332–45 (133 ref.)

Peripheral benzodiazepine receptor in cholesterol transport and steroidogenesis. Papadopoulos V, et al. **Steroids** 1997 Jan;62(1):21–8 (66 ref.)

The role of the steroidogenic acute regulatory protein in steroidogenesis. Stocco DM, et al. **Steroids** 1997 Jan; 62(1):29–36 (87 ref.)

[Signal transduction of steroids and vitamins mediated by nuclear receptor proteins] Umesono K.
Tanpakushitsu Kakusan Koso 1996 Jun;41(8 Suppl):1265–72 (37 ref.) **(Jpn)**

PHARMACOLOGY

New cardioactive steroid saponins and other glycosides from Mexican Tribulus cistoides. Achenbach H, et al.
Adv Exp Med Biol 1996;404:357–70 (17 ref.)

New biologically active steroidal and triterpenoid glycosides from medicinal plants. Aquino R, et al.
Adv Exp Med Biol 1996;404:401–14 (30 ref.)

Chemistry and biological activity of steroid saponins from Moldovian plants. Kintia PK. **Adv Exp Med Biol** 1996; 404:309–34 (28 ref.)

Modified steroid receptors and steroid-inducible promoters as genetic switches for gene therapy. White JH.
Adv Pharmacol 1997;40:339–67 (155 ref.)

Natural steroids counteracting some actions of putative depressogenic steroids on the central nervous system: potential therapeutic benefits. Dubrovsky B.
Med Hypotheses 1997 Jul;49(1):51–5 (78 ref.)

Diterpenoid and steroidal alkaloids. Atta-ur-Rahman, et al. **Nat Prod Rep** 1997 Apr;14(2):191–203 (53 ref.)

Pharmacology of lazaroids and brain energy metabolism: a review. Villa RF, et al. **Pharmacol Rev** 1997 Mar; 49(1):99–136 (274 ref.)

In search of ideal inotropic steroids: recent progress. Repke KR, et al. **Prog Drug Res** 1996;47:9–52 (172 ref.)

Nongenomic actions of steroids on gonadotropin release. Wiebe JP. **Recent Prog Horm Res** 1997;52:71–99; discussion 99–101 (133 ref.)

Effects of sex steroid hormones on lipoproteins, clotting, and the arterial wall. Knopp RH, et al.
Semin Reprod Endocrinol 1996 Feb;14(1):15–27 (112 ref.)

PHYSIOLOGY

Transforming growth factor-beta system and its regulation by members of the steroid-thyroid hormone superfamily. Koli K, et al. **Adv Cancer Res** 1996;70:63–94 (133 ref.)

Steroidal glycoalkaloids: nature and consequences of bioactivity. Roddick JG. **Adv Exp Med Biol** 1996; 404:277–95 (131 ref.)

Peptides, steroids, and pair bonding. Carter CS, et al.
Ann N Y Acad Sci 1997 Jan 15;807:260–72 (33 ref.)

Specific, nongenomic actions of steroid hormones. Wehling M. **Annu Rev Physiol** 1997;59:365–93 (151 ref.)

Gonadal steroids and astroglial plasticity. Garcia-Segura LM, et al. **Cell Mol Neurobiol** 1996 Apr;16(2):225–37 (80 ref.)

Neurosteroid modulation of native and recombinant GABAA receptors. Lambert JJ, et al. **Cell Mol Neurobiol** 1996 Apr; 16(2):155–74 (100 ref.)

Steroid imprinting and modulation of sexual dimorphism in the luteinizing hormone-releasing hormone neuronal system. López FJ, et al. **Cell Mol Neurobiol** 1996 Apr; 16(2):129–41 (30 ref.)

Gonadal and adrenal steroids regulate neurochemical and structural plasticity of the hippocampus via cellular mechanisms involving NMDA receptors. McEwen BS.
Cell Mol Neurobiol 1996 Apr;16(2):103–16 (75 ref.)

Cell culture approaches to understanding the actions of steroid hormones on the insect nervous system. Levine RB, et al. **Dev Neurosci** 1996;18(1-2):73–86 (72 ref.)

Development and regeneration of the nervous system: a role for neurosteroids. Schumacher M, et al. **Dev Neurosci** 1996; 18(1-2):6–21 (135 ref.)

From steroid signals to local regulatory factors involved in endometrial bleeding. Tabibzadeh S, et al.
Eur J Obstet Gynecol Reprod Biol 1996 Dec;70(1):25–7 (34 ref.)

Steroid hormones and excitability in the mammalian brain. Joëls M. **Front Neuroendocrinol** 1997 Jan;18(1):2–48 (235 ref.)

Molecular aspects of steroid hormone action in the male reproductive axis. Shupnik MA, et al. **J Androl** 1997 Jul-Aug;18(4):341–4 (25 ref.)

Morphological and functional studies of the paracrine interaction between cortex and medulla in the adrenal gland. Bornstein SR, et al. **Microsc Res Tech** 1997 Mar 15;36(6):520–33 (123 ref.)

Nuclear factor-kappa-B/steroid hormone receptor interactions as a functional basis of anti-inflammatory action of steroids in reproductive organs. van der Burg B, et al. **Mol Hum Reprod** 1996 Jun;2(6):433–8 (57 ref.)

STEROIDS

Neurosteroids: of the nervous system, by the nervous system, for the nervous system. Baulieu EE.
Recent Prog Horm Res 1997;52:1-32 (107 ref.)
Steroid and growth factor regulation of matrix metalloproteinase expression and endometriosis. Osteen KG, et al. **Semin Reprod Endocrinol** 1996 Aug;14(3):247-55 (75 ref.)
Plant steroid hormones emerge from the dark. Hooley R. **Trends Genet** 1996 Aug;12(8):281-3 (14 ref.)

RADIATION EFFECTS

EPR/ENDOR investigations of gamma-irradiated steroid hormone single crystals. Szyczewski A.
Appl Radiat Isot 1996 Nov-Dec;47(11-12):1675-81 (30 ref.)

THERAPEUTIC USE

Management of nephrotic syndrome in children: a review. Khan MA, et al. **JPMA J Pak Med Assoc** 1996 May; 46(5):113-6 (32 ref.)
Steroid-resistant nephrotic focal segmental glomerulosclerosis: a treatable disease. Tune BM, et al. **Pediatr Nephrol** 1996 Dec;10(6):772-8 (53 ref.)
[Severe preeclampsia: management. Is conservative treatment justified?] Merviel P, et al.
J Gynecol Obstet Biol Reprod (Paris) 1997;26(3):238-49 (61 ref.) (Eng. Abstr.) **(Fre)**

TOXICITY

Cholestatic properties and hepatic transport of steroid glucuronides. Vore M, et al. **Drug Metab Rev** 1997 Feb-May;29(1-2):183-203 (49 ref.)

URINE

Clinical indications for the use of urinary steroid profiles in neonates and children. Honour JW, et al.
Ann Clin Biochem 1997 Jan;34 (Pt 1):45-54 (37 ref.)

STEROIDS, ANABOLIC see **ANABOLIC STEROIDS**

STEROIDS, HETEROCYCLIC

CHEMISTRY

Brassinosteroids. Fujioka S, et al. **Nat Prod Rep** 1997 Feb; 14(1):1-10 (105 ref.)

METABOLISM

BRI-ghtening the pathway to steroid hormone signaling events in plants [comment] Ecker JR. **Cell** 1997 Sep 5; 90(5):825-7 (18 ref.) Comment on: Cell 1997 Sep 5;90(5):929-38.
Plant hormones: brassinosteroids in the spotlight. Clouse SD. **Curr Biol** 1996 Jun 1;6(6):658-61 (14 ref.)
Oligosaccharins, brassinolides, and jasmonates: nontraditional regulators of plant growth, development, and gene expression. Creelman RA, et al. **Plant Cell** 1997 Jul; 9(7):1211-23 (160 ref.)

STEROLS

[Physico-chemical characterization and application for drug carrier of soybean-derived sterols and their glucosides-containing liposomes] Maitani Y.
Yakugaku Zasshi 1996 Dec;116(12):901-10 (28 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Antifungal sterol biosynthesis inhibitors. Guo DA, et al.
Subcell Biochem 1997;28:89-116 (92 ref.)

CHEMISTRY

Review of progress in sterol oxidations: 1987-1995. Smith LL. **Lipids** 1996 May;31(5):453-87 (1152 ref.)

ISOLATION & PURIFICATION

The extraction and analysis of sterols from yeast. Quail MA, et al. **Methods Mol Biol** 1996;53:123-31 (7 ref.)

METABOLISM

Molecular aspects of intracellular sterol esterification: the acyl coenzyme A: cholesterol acyltransferase reaction. Sturley SL. **Curr Opin Lipidol** 1997 Jun;8(3):167-73 (58 ref.)
Review of progress in sterol oxidations: 1987-1995. Smith LL. **Lipids** 1996 May;31(5):453-87 (1152 ref.)

STETHOSCOPES

Stethoscopy during anaesthesia. McIntyre JW.
Can J Anaesth 1997 May;44(5 Pt 1):535-42 (88 ref.)

STEVENS-JOHNSON SYNDROME

CHEMICALLY INDUCED

Severe drug-induced blistering disorders. Roujeau JC.
Rev Rhum Engl Ed 1997 Jan;64(1):5-9 (41 ref.)

COMPLICATIONS

Stevens-Johnson syndrome, epidermolysis bullosa, staphylococcal scalded skin syndrome, and dermatitis herpetiformis. Hochman MA, et al. **Int Ophthalmol Clin** 1997 Spring;37(2):77-92 (87 ref.)
Eruptive melanocytic nevi after Stevens-Johnson syndrome. Shoji T, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):337-9 (14 ref.)
Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra). Tay YK, et al. **J Am Acad Dermatol** 1996 Nov; 35(5 Pt 1):757-60 (48 ref.)

DIAGNOSIS

Advances in toxic epidermal necrolysis. Revuz JE, et al.
Semin Cutan Med Surg 1996 Dec;15(4):258-66 (63 ref.)
[Toxic epidermal necrolysis (syndrome Lyell) versus Stevens-Johnson syndrome] Jezierska-Krupa B, et al.
Pediatr Pol 1996 Jul;71(7):615-20 (15 ref.) (Eng. Abstr.) **(Pol)**

EPIDEMIOLOGY

Epidemiology of drug-induced severe skin reactions. Mockenhaupt M, et al. **Semin Cutan Med Surg** 1996 Dec; 15(4):236-43 (35 ref.)

STICKLEBACKS see **FISHES**

STIFF-MAN SYNDROME

ETIOLOGY

Stiff-persons' syndrome associated with thymoma and subsequent myasthenia gravis. Nicholas AP, et al.
Muscle Nerve 1997 Apr;20(4):493-8 (49 ref.)

STIGMATA see **CHRISTIANITY**

STIGMATIZATION see **STEREOTYPING**

STILBENES

Resveratrol: a molecule whose time has come? And gone? Soleas GJ, et al. **Clin Biochem** 1997 Mar;30(2):91-113 (183 ref.)

METABOLISM

Allosteric effects in stilbenedisulfonate binding to band 3 protein (AE1). Salhany JM.
Cell Mol Biol (Noisy-le-grand) 1996 Nov;42(7):1065-96 (107 ref.)

STILBESTROL see **DIETHYLSTILBESTROL**

STILLBIRTH see **FETAL DEATH**

STILL'S DISEASE, ADULT-ONSET

[Still's disease] Amano M, et al.
Ryoikibetsu Shokogun Shirizu 1996;(15):165-7 (21 ref.) **(Jpn)**

COMPLICATIONS

Adult Still's disease: part I. Manifestations and complications in sixty-five cases in France. Masson C, et al.
Rev Rhum Engl Ed 1995 Dec;62(11):748-57 (104 ref.)
[Severe pulmonary manifestation in adult-onset Still's disease] Paccalin M, et al. **Rev Med Interne** 1997 Jul; 18(7):575-7 (12 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Comparative study of 6 types of criteria in adult Still's disease. Masson C, et al. **J Rheumatol** 1996 Mar;23(3):495-7 (15 ref.)
Severe sore throat as a presenting symptom of adult onset Still's disease: a case series and review of the literature. Nguyen KH, et al. **J Rheumatol** 1997 Mar;24(3):592-7 (63 ref.)
[Still disease in the elderly (letter)] Bonnet F, et al.
Rev Med Interne 1997;18(2):170-1 (13 ref.) **(Fre)**
[Pseudo-Still disease and deep neoplasm] Routier G, et al.
Rev Med Interne 1997;18(1):47-9 (4 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Adult Still's disease. Part II. Management, outcome, and prognostic factors. Masson C, et al. **Rev Rhum Engl Ed** 1995 Dec;62(11):758-65 (56 ref.)
[A refractory case of adult-onset Still's disease] Nishio J, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1997 Jun; 20(3):191-8 (28 ref.) (Eng. Abstr.) **(Jpn)**
[A case report of pregnancy complicated with adult Still's disease] Yunohara N, et al.
Nippon Sanka Fujinka Gakkai Zasshi 1996 Jun;48(6):431-4 (15 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Adult Still's disease: part I. Manifestations and complications in sixty-five cases in France. Masson C, et al.
Rev Rhum Engl Ed 1995 Dec;62(11):748-57 (104 ref.)

STILL'S DISEASE, JUVENILE-ONSET see **ARTHRITIS, JUVENILE RHEUMATOID**

STIMULATION, ACOUSTIC see **ACOUSTIC STIMULATION**

STIMULATION, AUDITORY see **ACOUSTIC STIMULATION**

STIMULATION, CHEMICAL

see related
ENZYME INDUCTION

Functional evaluation of patients with coronary artery disease: selection of appropriate pharmacologic agents and imaging modalities. Bonow RO. **Eur Heart J** 1995 Nov; 16 Suppl M:11-6 (84 ref.)
Pharmacological stress testing and imaging: concluding remarks. Piérard LA. **Eur Heart J** 1995 Nov;16 Suppl M:28-31 (31 ref.)

STIMULATION, ELECTRIC see **ELECTRIC STIMULATION**

STIMULATION, PHOTIC see **PHOTIC STIMULATION**

STIMULATION, PHYSICAL see **PHYSICAL STIMULATION**

STINGS see **BITES AND STINGS**

STIPPLED EPIPHYSES see **CHONDRODYSPLASIA PUNCTATA**

STLV

GENETICS

Genetic variability and molecular epidemiology of human and simian T cell leukemia/lymphoma virus type I. Gessain A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S132-45 (106 ref.)

STLV-I see **STLV**

STLV-III see **SIV**

STOCKINGS, COMPRESSION see **BANDAGES**

STOCKINGS, ELASTIC see **BANDAGES**

STOICISM see **PHILOSOPHY**

STOKES-ADAMS ATTACKS see **ADAMS-STOKES SYNDROME**

STOMACH

see related
FUNDOPLICATION
GASTRECTOMY
GASTROENTEROSTOMY
GASTROPLASTY
GASTROSCOPY
GASTROSTOMY

Bezoars and foreign bodies of the stomach. Lee J.
Gastrointest Endosc Clin N Am 1996 Jul;6(3):605-19 (64 ref.)
Can a bezoar cause acute pancreatitis? Katapadi M, et al.
J Clin Gastroenterol 1997 Mar;24(2):120-1 (12 ref.)
[Alcohol and stomach] Makolkin VI, et al.
Klin Med (Mosk) 1997;75(4):14-8 (39 ref.) **(Rus)**

ABNORMALITIES

Double common bile duct with ectopic drainage of the left lobe into the stomach. Case report and review of the literature. Horsmans Y, et al. **Acta Gastroenterol Belg** 1996 Oct-Dec;59(4):256-7 (20 ref.)
Continuous communicating esophageal and gastric duplication. Mazziotti MV, et al. **J Pediatr Surg** 1997 May; 32(5):775-8 (24 ref.)
Pancreatitis caused by a gastric duplication communicating with an aberrant pancreatic lobe. Moss RL, et al.
J Pediatr Surg 1996 May;31(5):733-6 (14 ref.)
Microgastria as an isolated anomaly. Ramos CT, et al.
J Pediatr Surg 1996 Oct;31(10):1445-7 (24 ref.)

ANATOMY & HISTOLOGY

[The structure and histotopography of the gastroenteropancreatic endocrine system in teleost fish] Shirkina NI. **Morfologiia** 1995;108(3):78-83 (66 ref.) **(Rus)**

BLOOD SUPPLY

Ischemic conditioning of the stomach may reduce the incidence of esophagogastric anastomotic leaks complicating esophagectomy: a hypothesis. Urschel JD.
Dis Esophagus 1997 Jul;10(3):217-9 (23 ref.)
Hereditary hemorrhagic telangiectasia and other intestinal

vascular anomalies. Korzenik JR. **Gastroenterologist** 1996 Sep;4(3):203–10 (75 ref.)
An aneurysm of the right gastroepiploic artery. Funahashi S, et al. **J Cardiovasc Surg (Torino)** 1997 Aug;38(4):385–8 (11 ref.)
Total arterial myocardial revascularization [editorial] Calafiore AM. **Thorac Cardiovasc Surg** 1997 Jun; 45(3):105–8 (17 ref.)
[Gastroduodenal arterial aneurysm and chronic pancreatitis. A case and review of the literature] Benoit L, et al. **Ann Chir** 1996;50(10):918–20 (17 ref.) (Eng. Abstr.) **(Fre)**

CYTOLOGY

Physiology of isolated gastric endocrine cells. Sachs G, et al. **Annu Rev Physiol** 1997;59:243–56 (70 ref.)
The G cell. Sawada M, et al. **Annu Rev Physiol** 1997; 59:273–98 (147 ref.)
Modulation of growth of human gastric enterochromaffin–like cells. Delle Fave G, et al. **Digestion** 1996;57 Suppl 1:15–6 (16 ref.)
The gastric enterochromaffin–like cell: an enigmatic cellular link. Modlin IM, et al. **Gastroenterology** 1996 Sep; 111(3):783–810 (223 ref.)

DRUG EFFECTS

PAF and the digestive tract. A review. Izzo AA. **J Pharm Pharmacol** 1996 Nov;48(11):1103–11 (118 ref.)
Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. Charman WN, et al. **J Pharm Sci** 1997 Mar;86(3):269–82 (263 ref.)
[Gastric protection in the treatment with NSAIDs (see comments)] Gené Badla J, et al. **Aten Primaria** 1997 Mar 15;19(4):207–10 (23 ref.) Comment in: Aten Primaria 1997 Jun 15;20(1):1–2. **(Spa)**

INJURIES

[Chemical burns of the esophagus and stomach—role of endoscopic examination] Nieżychowski W. **Pol Tyg Lek** 1996 Apr;51(14–18):239–41 (22 ref.) **(Pol)**

INNERVATION

Development of the insect stomatogastric nervous system. Hartenstein V. **Trends Neurosci** 1997 Sep;20(9):421–7 (21 ref.)

METABOLISM

The G cell. Sawada M, et al. **Annu Rev Physiol** 1997; 59:273–98 (147 ref.)
Signal transduction in gastrointestinal smooth muscle. Makhlouf GM, et al. **Cell Signal** 1997 May–Jun; 9(3–4):269–76 (92 ref.)
Roles for transforming growth factor–alpha in the stomach. Coffey RJ, et al. **J Clin Gastroenterol** 1995;21 Suppl 1:S36–9 (29 ref.)
Tachykinins in the gut. Part I. Expression, release and motor function. Holzer P, et al. **Pharmacol Ther** 1997; 73(3):173–217 (504 ref.)

MICROBIOLOGY

Endoscopic methods for the diagnosis of Helicobacter pylori. Cohen H, et al. **Aliment Pharmacol Ther** 1997 Apr;11 Suppl 1:3–9 (28 ref.)
Role of colonization of the upper intestinal tract in the pathogenesis of ventilator–associated pneumonia [see comments] Bonten MJ, et al. **Clin Infect Dis** 1997 Mar; 24(3):309–19 (80 ref.) Comment in: Clin Infect Dis 1997 Mar;24(3):320–3.
Stomach as a source of colonization of the respiratory tract during mechanical ventilation: association with ventilator–associated pneumonia. Torres A, et al. **Eur Respir J** 1996 Aug;9(8):1729–35 (55 ref.)

PATHOLOGY

Gastric pathology in Meckel's diverticulum. Review of cases resected between 1965 and 1995. Cserni G. **Am J Clin Pathol** 1996 Dec;106(6):782–5 (28 ref.)
Consequences of attachment of Helicobacter pylori to gastric cells. Segal ED. **Biomed Pharmacother** 1997;51(1):5–12 (69 ref.)
Gastric pathology as an initiator and potentiator of gastroesophageal reflux disease. DeMeester TR, et al. **Dis Esophagus** 1997 Jan;10(1):1–8 (11 ref.)
Gastric epithelial dysplasia and adenoma: historical review and histological criteria for grading. Goldstein NS, et al. **Hum Pathol** 1997 Feb;28(2):127–33 (100 ref.)
[Gastric neoplasms: their characterization, assessment of the degree of parietal infiltration and check on recurrence. The potentials and limits of CT, endoscopic US and MR] Gualdi GF, et al. **Clin Ter** 1996 Nov;147(11):585–94 (20 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

Physiology of isolated gastric endocrine cells. Sachs G, et al. **Annu Rev Physiol** 1997;59:243–56 (70 ref.)
Physiological regulation of gastric emptying and glucose absorption. Macdonald IA. **Diabet Med** 1996 Sep;13(9 Suppl 5):S11–5 (12 ref.)
The stomach as an endocrine organ. DelValle J. **Digestion** 1997;58 Suppl 1:4–7 (23 ref.)
Gastric physiology and function: effects of fruit juices. Moukarzel AA, et al. **J Am Coll Nutr** 1996 Oct;15(5 Suppl):18S–25S (41 ref.)
Targeting of drugs and delivery systems to specific sites in the gastrointestinal tract. Fell JT. **J Anat** 1996 Dec;189 (Pt 3):517–9 (12 ref.)
Role of selected peptides in the vagal regulation of gastric motor and endocrine pancreatic function. Krowicki ZK. **J Physiol Pharmacol** 1996 Sep;47(3):399–409 (55 ref.)
[Electrogastrography (EGG)] Ishii T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:153–5 (6 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Gastric emptying in type 2 diabetes: quick or slow? Smith U. **Diabet Med** 1996 Sep;13(9 Suppl 5):S31–3 (22 ref.)
Cyclooxygenase 2 and wound healing in the stomach [editorial; comment] Stenson WF. **Gastroenterology** 1997 Feb;112(2):645–8 (32 ref.) Comment on: Gastroenterology 1997 Feb;112(2):387–97.
Gastric accommodation in functional dyspepsia. Berstad A, et al. **Scand J Gastroenterol** 1997 Mar;32(3):193–7 (57 ref.)
Helicobacter pylori and disturbance of gastric function associated with duodenal ulcer disease and gastric cancer. McColl KE, et al. **Scand J Gastroenterol Suppl** 1996; 215:32–7 (40 ref.)
[The morphofunctional changes in the duodenogastric portion of the gastrointestinal tract in patients with rheumatoid arthritis] Barashkov VG, et al. **Vestn Khir Im I I Grek** 1996;155(3):93–5 (47 ref.) **(Rus)**

RADIOGRAPHY

CT of the stomach: spectrum of disease. Fishman EK, et al. **Radiographics** 1996 Sep;16(5):1035–54 (57 ref.)
[Gastric neoplasms: their characterization, assessment of the degree of parietal infiltration and check on recurrence. The potentials and limits of CT, endoscopic US and MR] Gualdi GF, et al. **Clin Ter** 1996 Nov;147(11):585–94 (20 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Minimally invasive surgery of the esophagus and stomach. Trus TL, et al. **Am J Surg** 1997 Mar;173(3):242–55 (90 ref.)
Simple technique for pancreatogast•ostomy and the histological findings of pancreatogastric anastomosis. Yamamoto J, et al. **Arch Surg** 1997 Jul;132(7):785–8 (08 ref.)
Oesophagogastrectomy with an anastomosis using linear staplers. Bird P, et al. **Aust N Z J Surg** 1996 Nov; 66(11):757–63 (17 ref.)
Should the distal splenorenal shunt be combined with gastric disconnection and transection? Henderson JM. **HPB Surg** 1997;10(3):184–5 (10 ref.)
Jejunum or stomach for the pancreatic anastomosis after pancreaticoduodenectomy. Warshaw AL. **HPB Surg** 1997; 10(3):191–3 (4 ref.)
Endoluminal surgery. Spivak H, et al. **Surg Endosc** 1997 Apr; 11(4):321–5 (19 ref.)
Laparoscopic removal of a swallowed toothbrush. Wishner JD, et al. **Surg Endosc** 1997 May;11(5):472–3 (7 ref.)
[Complications of two types of pancreatic anastomosis after pancreaticoduodenectomy] Andivot T, et al. **Ann Chir** 1996;50(6):431–7 (37 ref.) (Eng. Abstr.) **(Fre)**
[Endoscopic repositioning of the upside–down stomach and its fixation by percutaneous endoscopic gastrostomy] Januschowski R. **Dtsch Med Wochenschr** 1996 Oct 11; 121(41):1261–4 (19 ref.) (Eng. Abstr.) **(Ger)**
[The techniques to protect the anastomotic leakage of esophagogastrostomy at the neck] Watanabe H. **Nippon Geka Gakkai Zasshi** 1996 Jun;97(6):432–6 (3 ref.) (Eng. Abstr.) **(Jpn)**
[Clinical evaluation of factor XIII for postoperative stomal leakage and fistulae after gastrointestinal surgery] Ishibiki K. **Rinsho Byori** 1997 Feb;Suppl 104:17–24 (7 ref.) **(Jpn)**
[Advantages and disadvantages of stomach resection with PU anastomosis in treatment of gastric and duodenal peptic ulcers] Maiorova IV, et al. **Khirurgiia (Mosk)** 1996;(5):61–6 (120 ref.) **(Rus)**
[The use of the mechanical suture in surgery on the stomach and intestines] Mel'nik VM, et al. **Klin Khir** 1996;(9):37–40 (65 ref.) **(Rus)**

ULTRASONOGRAPHY

Ultrasonography of the human stomach. Berstad A, et al. **Scand J Gastroenterol Suppl** 1996;220:75–82 (60 ref.)
[Gastric neoplasms: their characterization, assessment of the degree of parietal infiltration and check on recurrence. The potentials and limits of CT, endoscopic US and MR] Gualdi GF, et al. **Clin Ter** 1996 Nov;147(11):585–94 (20 ref.) (Eng. Abstr.) **(Ita)**

STOMACH DILATATION

DIAGNOSIS

The superior mesenteric artery syndrome and acute gastric dilatation in eating disorders: a report of two cases and a review of the literature. Adson DE, et al. **Int J Eat Disord** 1997 Mar;21(2):103–14 (59 ref.)

STOMACH DISEASES

Acute gastric anisakiasis: 28 cases during the last 10 years. Muraoka A, et al. **Dig Dis Sci** 1996 Dec;41(12):2362–5 (20 ref.)
Watermelon stomach. Abedi M, et al. **Gastroenterologist** 1997 Sep;5(3):179–84 (32 ref.)
The use of endoscopic ultrasonography in the evaluation and diagnosis of gastric lesions. Jaffe PE. **Gastrointest Endosc Clin N Am** 1996 Jul;6(3):565–84 (52 ref.)
Crohn's disease of the upper gastrointestinal tract. Wagtmans MJ, et al. **Neth J Med** 1997 Feb;50(2):S2–7 (58 ref.)
Functional disorders of the stomach. Koch KL, et al. **Semin Gastrointest Dis** 1996 Oct;7(4):185–95 (52 ref.)

CHEMICALLY INDUCED

Initial description of gastric melanosis in a laxative–abusing patient. Mitty RD, et al. **Am J Gastroenterol** 1997 Apr; 92(4):707–8 (4 ref.)
Toxicity of nonsteroidal anti–inflammatory drugs in the elderly: is advanced age a risk factor? Solomon DH, et al. **Am J Med** 1997 Feb;102(2):208–15 (97 ref.)

COMPLICATIONS

Surgical management and treatment of sepsis associated with gastrointestinal fistulas. Rolandelli R, et al. **Surg Clin North Am** 1996 Oct;76(5):1111–22 (19 ref.)

DIAGNOSIS

Gastroduodenal pneumatosis: endoscopic and histological findings. Cordum NR, et al. **Am J Gastroenterol** 1997 Apr; 92(4):692–5 (22 ref.)
Role of polymerase chain reaction in the diagnosis of gastric syphilis [editorial; comment] Norris SJ, et al. **Hum Pathol** 1996 Aug;27(8):749–50 (11 ref.) Comment on: Hum Pathol 1996 Aug;27(8):761–5.
Diagnosis of Helicobacter pylori infection. Review of diagnostic techniques and recommendations for their use in different clinical settings. de Boer WA. **Scand J Gastroenterol Suppl** 1997;223:35–42 (93 ref.)
[Errors in the diagnosis of a cardial syndrome in reflux esophagitis] Nesterov IuI, et al. **Ter Arkh** 1996;68(4):53–4 (9 ref.) (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Prophylaxis and treatment of NSAID–induced gastropathy. Ament PW, et al. **Am Fam Physician** 1997 Mar; 55(4):1323–6, 1331–2 (34 ref.)
CCKB/gastrin receptor antagonists: recent advances and potential uses in gastric secretory disorders. Jensen RT. **Yale J Biol Med** 1996 May–Jun;69(3):245–59 (106 ref.)
[Disorders of gastric emptying in diabetes. II. Treatment] Czambor–Książek E, et al. **Wiad Lek** 1997;50(1–3):39–41 (20 ref.) (Eng. Abstr.) **(Pol)**
[Nizatidine++ among the drugs usable in the treatment of acid–dependent gastric diseases] German SV. **Klin Med (Mosk)** 1997;75(5):34–41 (103 ref.) **(Rus)**

EPIDEMIOLOGY

Epidemiology of gastrointestinal polyps. Jacobson JS, et al. **Surg Oncol Clin N Am** 1996 Jul;5(3):531–44 (115 ref.)
[Gastrointestinal tuberculosis] Miagkova LP. **Klin Med (Mosk)** 1997;75(8):9–12 (15 ref.) **(Rus)**

ETIOLOGY

Gastric Crohn's disease complicated by adenocarcinoma of the stomach: case report and review of the literature. Patel M, et al. **Am J Gastroenterol** 1997 Aug;92(8):1368–71 (19 ref.)
Pitfalls and complications of antireflux surgery. Nissen and Collis–Nissen techniques. Ferguson MK. **Chest Surg Clin N Am** 1997 Aug;7(3):489–509; discussion 510–1 (85 ref.)
Gastric volvulus: an old disease process with some new twists. Schaefer DC, et al. **Gastroenterologist** 1997 Mar; 5(1):41–5 (19 ref.)
[Gastropathy due to portal hypertension] Hermann R. **Schweiz Rundsch Med Prax** 1997 Jan 21;86(4):109–11 (17 ref.) (Eng. Abstr.) **(Ger)**
[Unusual cause of gastric bleeding: leiomyoma] Alberti P, et al. **Minerva Chir** 1996 Oct;51(10):779–83 (22 ref.) (Eng. Abstr.) **(Ita)**
[Gastric motility disorders in diabetes. I. Pathophysiology, symptomatology and methods for additional testing] Zelechowski M, et al. **Wiad Lek** 1997;50(1–3):32–8 (20 ref.) (Eng. Abstr.) **(Pol)**
[High obstruction in strangulated diaphragmatic hernia] Angelescu N, et al. **Chirurgia (Bucur)** 1997 Jan–Feb; 92(1):33–8 (13 ref.) (Eng. Abstr.) **(Rum)**
[Helicobacter pylori and gastroduodenal pathology: its pathogenesis, diagnosis and therapeutic guidelines] Muñoz Gutiérrez J, et al. **Aten Primaria** 1997 Apr 30;19(7):377–82 (51 ref.) **(Spa)**

METABOLISM

CCKB/gastrin receptor antagonists: recent advances and

potential uses in gastric secretory disorders. Jensen RT. **Yale J Biol Med** 1996 May-Jun;69(3):245-59 (106 ref.)

MICROBIOLOGY

The expanding genus of Helicobacter: pathogenic and zoonotic potential. Fox JG. **Semin Gastrointest Dis** 1997 Jul;8(3):124-41 (165 ref.)

Helicobacter pylori-associated gastroduodenal disease in childhood. Blecker U. **South Med J** 1997 Jun;90(6):570-6; quiz 577 (75 ref.)

Nonfatal gastric mucormycosis in a renal transplant recipient. Martinez EJ, et al. **South Med J** 1997 Mar;90(3):341-4 (39 ref.)

[Clinical pictures of orointestinal candidiasis. Fiction or reality?] Knoke M. **Mycoses** 1996;39 Suppl 1:40-3 (22 ref.) (Eng. Abstr.) **(Ger)**

PARASITOLOGY

Gastric toxoplasmosis: case report and review of the literature. Kofman E, et al. **Am J Gastroenterol** 1996 Nov; 91(11):2436-8 (8 ref.)

Gastric cryptosporidiosis complicating HIV infection: case report and review of the literature. Ventura G, et al. **Eur J Gastroenterol Hepatol** 1997 Mar;9(3):307-10 (18 ref.)

PHYSIOPATHOLOGY

Cyclooxygenase 2 and wound healing in the stomach [editorial; comment] Stenson WF. **Gastroenterology** 1997 Feb;112(2):645-8 (32 ref.) Comment on: Gastroenterology 1997 Feb;112(2):387-97.

PREVENTION & CONTROL

Regulation of intracellular pH: role in gastric mucosal defence. Kaunitz JD, et al. **Keio J Med** 1996 Sep; 45(3):155-60 (46 ref.)

RADIOGRAPHY

Computed tomography of the gastro-duodenal region. Small JH, et al. **Eur J Radiol** 1996 May;22(2):95-103 (39 ref.)

Emphysema of the stomach: a roentgenologic alarm. Report of a case and review of the literature. Rosen A, et al. **J Clin Gastroenterol** 1996 Oct;23(3):211-3 (13 ref.)

CT of the stomach: spectrum of disease. Fishman EK, et al. **Radiographics** 1996 Sep;16(5):1035-54 (57 ref.)

Radiologic investigation and treatment of gastrointestinal fistulas. Thomas HA. **Surg Clin North Am** 1996 Oct; 76(5):1081-94 (46 ref.)

SURGERY

Factors influencing outcome in patients with gastrointestinal fistula. Campos AC, et al. **Surg Clin North Am** 1996 Oct; 76(5):1191-8 (37 ref.)

Radiologic investigation and treatment of gastrointestinal fistulas. Thomas HA. **Surg Clin North Am** 1996 Oct; 76(5):1081-94 (46 ref.)

THERAPY

Surgical management and treatment of gastric and duodenal fistulas. Chung MA, et al. **Surg Clin North Am** 1996 Oct; 76(5):1137-46 (34 ref.)

General management of gastrointestinal fistulas. Recognition, stabilization, and correction of fluid and electrolyte imbalances. Foster CE 3rd, et al. **Surg Clin North Am** 1996 Oct;76(5):1019-33 (60 ref.)

Nutritional management of patients with gastrointestinal fistulas. Meguid MM, et al. **Surg Clin North Am** 1996 Oct; 76(5):1035-80 (114 ref.)

ULTRASONOGRAPHY

[The ultrasonic diagnosis of tumorous diseases of the stomach and intestines] al-Abbas B, et al. **Vestn Khir Im I I Grek** 1995;154(4-6):132-4 (41 ref.) **(Rus)**

VETERINARY

Pathogenic role of gastric Helicobacter sp in domestic carnivores. Lecoindre P, et al. **Vet Res** 1997 May-Jun; 28(3):207-15 (34 ref.)

[The surgical treatment of left-sided abomasal displacement in the cow: a literature review] Steiner A. **Schweiz Arch Tierheilkd** 1996;138(7):353-60 (16 ref.) (Eng. Abstr.) **(Ger)**

STOMACH DIVERTICULUM

[Gastric diverticulosis] Kurguzov OP, et al. **Khirurgiia (Mosk)** 1996;(3):67-71 (100 ref.) **(Rus)**

STOMACH NEOPLASMS

Recent advances in gastric cancer. Nagawa H, et al. **Digestion** 1997;58 Suppl 1:62-4 (3 ref.)

Gastric cancer. Johnson RC. **Hepatogastroenterology** 1996 Jul-Aug;43(10):1092-6 (47 ref.)

Carcinoid tumours. Janmohamed S, et al. **Postgrad Med J** 1997 Apr;73(858):207-14 (39 ref.)

Helicobacter pylori and gastric carcinogenesis. Kuipers EJ, et al. **Scand J Gastroenterol Suppl** 1996;218:103-5 (33 ref.)

CHEMICALLY INDUCED

Inhibition by vitamins C and E of in vivo nitrosation and vitamin C occurrence in the stomach. Mirvish SS. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:131-6 (37 ref.)

Evaluation of the aetiological role of dietary salt exposure in gastric and other cancers in humans. Cohen AJ, et al. **Food Chem Toxicol** 1997 Feb;35(2):271-93 (161 ref.)

CLASSIFICATION

The biological relevance of gastric neuroendocrine tumors. Klöppel G, et al. **Yale J Biol Med** 1996 Jan-Feb;69(1):69-74 (42 ref.)

COMPLICATIONS

Eczema craquelé as a pointer of internal malignancy--a case report. Guillet MH, et al. **Clin Exp Dermatol** 1996 Nov; 21(6):431-3 (24 ref.)

Peroral insertion techniques of self-expanding metal stents for malignant gastric outlet and duodenal stenoses. Maetani I, et al. **Gastrointest Endosc** 1996 Oct;44(4):468-71 (12 ref.)

Endoscopic injection of gelatin solution for severe hemorrhagic gastric cancer. Tajika M, et al. **Gastrointest Endosc** 1996 Mar;43(3):247-50 (10 ref.)

Progressive systemic sclerosis associated with primary small cell carcinoma of the stomach. Shikuwa S, et al. **J Gastroenterol** 1997 Aug;32(4):538-42 (14 ref.)

[Unusual cause of gastric bleeding: leiomyoma] Alberti P, et al. **Minerva Chir** 1996 Oct;51(10):779-83 (22 ref.) (Eng. Abstr.) **(Ita)**

[Gastric ulcer and cancer] Matsukura N, et al. **Nippon Ika Daigaku Zasshi** 1997 Jun;64(3):207-10 (19 ref.) **(Jpn)**

[A case of ulcerative colitis with minute gastric cancer and intraductal papillary adenoma of the pancreas] Yamamoto T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Aug; 94(8):532-7 (12 ref.) **(Jpn)**

DIAGNOSIS

Meningeal carcinomatosis as the presenting manifestation of gastric adenocarcinoma. Deeb LS, et al. **Am J Gastroenterol** 1997 Feb;92(2):329-31 (22 ref.)

Screening for gastric cancer. Pisani P, et al. **Cancer Treat Res** 1996;86:113-9 (35 ref.)

A comparison of imaging techniques for the localisation of gastro-enteropancreatic neuroendocrine tumours. Chayvialle JA. **Digestion** 1996;57 Suppl 1:54-6 (12 ref.)

The ultimate biochemical diagnosis of neuroendocrine gastro-enteropancreatic tumours. Faiss S, et al. **Digestion** 1996;57 Suppl 1:48-9 (12 ref.)

The ultimate biochemical diagnosis of gastro-enteropancreatic tumours. Oberg K. **Digestion** 1996; 57 Suppl 1:45-7 (5 ref.)

Sectional imaging of the gastroesophageal junction. van Overhagen H. **Eur J Radiol** 1996 May;22(2):86-94 (34 ref.)

Progressive systemic sclerosis associated with primary small cell carcinoma of the stomach. Shikuwa S, et al. **J Gastroenterol** 1997 Aug;32(4):538-42 (14 ref.)

Gastrobronchial fistula in untreated lymphoma. Cameron EW, et al. **J Thorac Imaging** 1996 Spring;11(2):150-2 (15 ref.)

Esophageal carcinoma: current controversies. DeMeester TR. **Semin Surg Oncol** 1997 Jul-Aug;13(4):217-33 (93 ref.)

Diagnosis and management of gastroduodenal polyps. Burke CA, et al. **Surg Oncol Clin N Am** 1996 Jul;5(3):589-607 (69 ref.)

[Gastric lesion revealed by a persistent hiccup] Hoang C, et al. **Ann Pathol** 1996 Sep;16(4):303-4 (6 ref.) **(Fre)**

[Gastric neoplasms: their characterization, assessment of the degree of parietal infiltration and check on recurrence. The potentials and limits of CT, endoscopic US and MR] Gualdi GF, et al. **Clin Ter** 1996 Nov;147(11):585-94 (20 ref.) (Eng. Abstr.) **(Ita)**

[Primary gastrointestinal localization of N-H lymphoma: authors' experience] Versaci A, et al. **G Chir** 1997 Jun-Jul; 18(6-7):340-3 (40 ref.) (Eng. Abstr.) **(Ita)**

[A large symptomatic gastric leiomyoma. A case report and considerations of the treatment possibilities] Falsitta M, et al. **Minerva Chir** 1997 Apr;52(4):461-4 (7 ref.) (Eng. Abstr.) **(Ita)**

[Current topics and endoscopic characteristics of the diagnosis how to detect in early gastric or colon cancer] Hanai H, et al. **Nippon Rinsho** 1996 May;54(5):1224-9 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Early gastric cancer] Tada M, et al. **Nippon Rinsho** 1996 May;54(5):1371-4 (3 ref.) (Eng. Abstr.) **(Jpn)**

[Diagnosis of Epstein-Barr virus-associated gastric carcinoma and its background gastric mucosa] Yanai H, et al. **Nippon Rinsho** 1997 Feb;55(2):374-80 (31 ref.) (Eng. Abstr.) **(Jpn)**

[A case of primary gastric T-cell malignant lymphoma] Ozaki M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jul; 93(7):470-4 (10 ref.) **(Jpn)**

[Fluorescent endoscopy in diagnosis of stomach neoplasm] Kuzin NM, et al. **Khirurgiia (Mosk)** 1997;(6):70-2 (21 ref.) **(Rus)**

[A giant ulcer of the stomach with perforation into the liver simulating cancer] Kovalenko VL, et al. **Vestn Khir Im I I Grek** 1996;155(6):82-3 (7 ref.) **(Rus)**

DRUG THERAPY

Chemotherapy of gastric cancer. Schipper DL, et al. **Anticancer Drugs** 1996 Feb;7(2):137-49 (165 ref.)

Control of growth in neuroendocrine gastro-enteropancreatic tumours. Arnold R, et al. **Digestion** 1996;57 Suppl 1:69-71 (19 ref.)

The role of somatostatin analogues in the treatment of gastro-enteropancreatic endocrine tumours. Bajetta E, et al. **Digestion** 1996;57 Suppl 1:72-6 (11 ref.)

Chemotherapy for gastric cancer in Japan. Furue H. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:120-5 (13 ref.)

Selection of adjuvant chemotherapy for gastric cancer using objective criteria. Nishiyama M, et al. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:232-8 (10 ref.)

Mitomycin-C induced hemolytic uremic syndrome: a case report and literature review. Wu DC, et al. **Jpn J Clin Oncol** 1997 Apr;27(2):115-8 (27 ref.)

Preoperative chemotherapy in gastric cancer. Wilke H, et al. **Recent Results Cancer Res** 1996;142:237-48 (20 ref.)

[The value of adjuvant and neoadjuvant chemotherapy in treatment of stomach carcinoma] Ausch C, et al. **Wien Klin Wochenschr** 1996;108(16):496-504 (50 ref.) (Eng. Abstr.) **(Ger)**

[Chemosensitivity test for gastric carcinoma] Kubota T. **Gan To Kagaku Ryoho** 1997 Feb;24(4):495-500 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Optimal administration in combination chemotherapy with 5-fluorouracil and cisplatin for gastric cancer] Maeda Y, et al. **Gan To Kagaku Ryoho** 1996 Nov;23(13):1763-9 (35 ref.) (Eng. Abstr.) **(Jpn)**

[Sequential methotrexate and 5-fluorouracil] Sasaki T. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1907-10 (16 ref.) (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

[Prognostic role of cisteine and serin proteases in gastriC cancer] Herszényi L, et al. **Orv Hetil** 1996 Jul 28; 137(30):1637-41 (47 ref.) (Eng. Abstr.) **(Hun)**

EPIDEMIOLOGY

Epidemiology of gastric cancer. Palli D. **Ann Ist Super Sanita** 1996;32(1):85-99 (128 ref.)

Nutrition and stomach cancer. Kono S, et al. **Cancer Causes Control** 1996 Jan;7(1):41-55 (108 ref.)

Early gastric cancer in Europe. Everett SM, et al. **Gut** 1997 Aug;41(2):142-50 (88 ref.)

Tea and cancer prevention: an evaluation of the epidemiologic literature. Kohlmeier L, et al. **Nutr Cancer** 1997;27(1):1-13 (30 ref.)

ETIOLOGY

Gastric Crohn's disease complicated by adenocarcinoma of the stomach: case report and review of the literature. Patel M, et al. **Am J Gastroenterol** 1997 Aug;92(8):1368-71 (19 ref.)

Pernicious anemia and gastric carcinoid tumor: case report and review. Sculco D, et al. **Am J Gastroenterol** 1997 Aug; 92(8):1378-80 (57 ref.)

Occupational risk factors for gastric cancer: an overview. Cocco P, et al. **Epidemiol Rev** 1996;18(2):218-34 (231 ref.)

Studies of stable N-nitroso compounds in human gastric juice--a review. Reed PI. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:75-82 (36 ref.)

Future directions in research of endogenous production on N-nitroso compounds. Stockbrügger RW. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:67-9 (21 ref.)

Gastric lymphoma and Helicobacter pylori. Isaacson PG, et al. **Important Adv Oncol** 1996;:111-21 (58 ref.)

Molecular pathogenesis of adenoma and differentiated adenocarcinoma of the stomach. Tamura G. **Pathol Int** 1996 Nov;46(11):834-41 (69 ref.)

[Etiology of stomach carcinoma--opinions and facts--yesterday and today] Schramm T, et al. **Z Arztl Fortbild Qualitatssich** 1997 Mar;91(2):111-5 (28 ref.) (Eng. Abstr.) **(Ger)**

[Helicobacter pylori and malignant stomach neoplasms] Asaka M. **Nippon Naika Gakkai Zasshi** 1996 May 10; 85(5):767-71 (18 ref.) **(Jpn)**

[Helicobacter pylori infection--from gastritis to stomach cancer] Asaka M. **Nippon Naika Gakkai Zasshi** 1996 Sep 10;85(9):1540-5 (12 ref.) **(Jpn)**

[Etiology and pathogenesis of stomach cancer] Iushkov PV. **Arkh Patol** 1997 Jan-Feb;59(1):69-73 (53 ref.) (Eng. Abstr.) **(Rus)**

[Cancer from an ulcer or ulcerative stomach cancer? (a review of the literature and the authors' own observations)] Sadchikov VD, et al. **Lik Sprava** 1997 Mar-Apr;(2):137-41 (38 ref.) (Eng. Abstr.) **(Rus)**

[Malignant stomach tumors in patients who have had a vagotomy for duodenal ulcers] Zuev VK, et al. **Vestn Khir Im I I Grek** 1996;155(4):97-100 (48 ref.) **(Rus)**

[Risk factors in stomach diseases] Bézayová T, et al. **Bratisl Lek Listy** 1996 Dec;97(12):705-11 (78 ref.) (Eng. Abstr.) **(Slo)**

[Risk factors for gastric cancer] González CA, et al. **Gastroenterol Hepatol** 1997 May;20(5):239-47 (114 ref.) **(Spa)**

GENETICS

Genetic alterations in gastric cancer. Ranzani GN. **Ann Ist Super Sanita** 1996;32(1):101–10 (75 ref.)

[Analyses of mutator gene mutations in familial gastric cancers] Akiyama Y, et al. **Nippon Rinsho** 1996 Apr; 54(4):1019–24 (29 ref.) (Eng. Abstr.) **(Jpn)**

[Mutation frequency of the p16/CDKN2 gene and amplification of the cyclin E gene in human primary gastric carcinomas] Sasaki H, et al. **Nippon Rinsho** 1996 Apr; 54(4):1049–53 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Allelic chromosomal deletion using microsatellite polymorphism—the clue to the positional cloning of the tumor suppressor genes responsible for gastric carcinoma] Sato J, et al. **Nippon Rinsho** 1996 Apr;54(4):992–5 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Multistep stomach carcinogenesis] Yokozaki H, et al. **Nippon Rinsho** 1996 Apr;54(4):1066–71 (31 ref.) (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

Helicobacter pylori and the risk and management of associated diseases: gastritis, ulcer disease, atrophic gastritis and gastric cancer. Kuipers EJ. **Aliment Pharmacol Ther** 1997 Apr;11 Suppl 1:71–88 (193 ref.)

Is the study of human cancer-associated factors, the best or the only model for human carcinogenesis research? I. The question of Helicobacter pylori infection as an accused human gastric carcinogen (editorial). Mathé G. **Biomed Pharmacother** 1997;51(1):1–4 (36 ref.)

Detection of Helicobacter pylori in biopsy of patients with gastric carcinoma. Shibata T, et al. **Biomed Pharmacother** 1997;51(1):22–8 (40 ref.)

Helicobacter pylori and gastric cancer. McFarlane GA, et al. **Br J Surg** 1997 Sep;84(9):1190–9 (163 ref.)

Helicobacter pylori, gastric cancer and gastric MALT lymphoma. Williams CN. **Can J Gastroenterol** 1996 Oct; 10(6):359–60 (13 ref.)

Gastric cancer and Helicobacter pylori. Muñoz N. **Eur J Cancer Prev** 1996 Oct;5(5):405–8 (33 ref.)

Significance of Helicobacter pylori infection and gastric cancer: implications for screening. Moayyedi P, et al. **Gastrointest Endosc Clin N Am** 1997 Jan;7(1):47–64 (141 ref.)

Pathogenesis and prevention of stomach cancer. Youn HS, et al. **J Korean Med Sci** 1996 Oct;11(5):373–85 (96 ref.)

Helicobacter pylori: the cancer link [see comments] O'Connor F, et al. **J R Soc Med** 1996 Dec;89(12):674–8 (53 ref.) Comment in: J R Soc Med 1997 Mar;90(3):180. Comment in: J R Soc Med 1997 Jun;90(6):359.

Helicobacter pylori and gastric cancer: an overrated risk? Crespi M, et al. **Scand J Gastroenterol** 1996 Nov; 31(11):1041–6 (69 ref.)

Helicobacter pylori and gastric cancer. Forman D. **Scand J Gastroenterol Suppl** 1996;215:48–51 (19 ref.)

Helicobacter pylori and gastric cancer. Forman D. **Scand J Gastroenterol Suppl** 1996;220:23–6 (17 ref.)

Helicobacter pylori and disturbance of gastric function associated with duodenal ulcer disease and gastric cancer. McColl KE, et al. **Scand J Gastroenterol Suppl** 1996; 215:32–7 (40 ref.)

Helicobacter pylori and gastric neoplasia. Sharma BC, et al. **Trop Gastroenterol** 1996 Oct–Dec;17(4):236–7 (23 ref.)

Gastric MALT lymphoma and Helicobacter pylori. Wotherspoon AC. **Yale J Biol Med** 1996 Jan–Feb; 69(1):61–8 (32 ref.)

[Gastric lymphomas: role of Helicobacter pylori] Ruskoné-Fourmestraux A. **Presse Med** 1997 Feb 15; 26(4):184–9 (26 ref.) **(Fre)**

[Helicobacter pylori and MALT gastric lymphomas] Belaiche J. **Rev Med Liege** 1997 May;52(5):352–4 (12 ref.) **(Fre)**

[Stomach cancer and MALT lymphoma: prevention with Helicobacter pylori eradication] Fischbach W. **Dtsch Med Wochenschr** 1997 Aug 1;122(31–32):983–7 (67 ref.) **(Ger)**

[Gastric MALT lymphoma and Helicobacter pylori infection] Chiba T. **Nippon Shokakibyo Gakkai Zasshi** 1997 Apr;94(4):233–40 (57 ref.) **(Jpn)**

[Helicobacter pylori infection is carcinogenic for humans] Aruin LI. **Arkh Patol** 1997 May–Jun;59(3):74–8 (53 ref.) (Eng. Abstr.) **(Rus)**

[Is gastric cancer an infectious disease?] Gisbert JP, et al. **Rev Esp Enferm Dig** 1996 Aug;88(8):555–62 (91 ref.) **(Spa)**

[Helicobacter pylori may cause stomach cancer. The connection is not yet completely surveyed] Wadström T, et al. **Lakartidningen** 1997 Aug 27;94(35):2947–50 (15 ref.) **(Swe)**

MORTALITY

[Prognosis factors in stomach carcinoma] Sendler A, et al. **Dtsch Med Wochenschr** 1997 Jun 13;122(24):794–800 (40 ref.) **(Ger)**

PATHOLOGY

Early gastric cancer and gastric dysplasia. Pascal RR, et al. **Ann Ital Chir** 1996 May–Jun;67(3):391–7; discussion 397–8 (51 ref.)

Laparoscopy in the management of gastric adenocarcinoma. Burke EC, et al. **Ann Surg** 1997 Mar;225(3):262–7 (9 ref.)

Gastric cancer and flow cytometry: the beginning of a promising match. Melato M. **Anticancer Res** 1997 May–Jun; 17(3C):2279–84 (73 ref.)

Cutaneous metastases from gastric adenocarcinoma. Report of two cases and review of the literature. Boscaino A, et al. **Arch Anat Cytol Pathol** 1996;44(1):60–4 (8 ref.)

Recent progress in researches on precancerous lesions of gastric cancer in China. Li C, et al. **Chin Med J (Engl)** 1996 May;109(5):407–10 (14 ref.)

Somatostatin receptor regulation of gastric carcinoid tumours. Tang LH, et al. **Digestion** 1996;57 Suppl 1:11–4 (30 ref.)

Arterial infusion chemotherapy for peritoneal and liver metastasis in gastric cancer. Kitamura M, et al. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:45–51 (14 ref.)

Endoscopic evaluation of the postoperative stomach. Mellinger JD, et al. **Gastrointest Endosc Clin N Am** 1996 Jul;6(3):621–39 (59 ref.)

Gastric polyps as precancerous lesions. Schmitz JM, et al. **Gastrointest Endosc Clin N Am** 1997 Jan;7(1):29–46 (32 ref.)

Precursor lesions for cancer of the cardia. Weinstein WM. **Gastrointest Endosc Clin N Am** 1997 Jan;7(1):19–28 (24 ref.)

Gastric stromal tumor with peritoneal nodules in pregnancy: tumor spread or rare variant of diffuse leiomyomatosis. Valente PT, et al. **Gynecol Oncol** 1996 Dec;63(3):392–7 (29 ref.)

Multiple leiomyosarcoma of the stomach. Colovic RB, et al. **Hepatogastroenterology** 1997 Mar–Apr;44(14):610–2 (4 ref.)

Portal tumor thrombi due to gastric cancer. Sugawara Y, et al. **Hepatogastroenterology** 1996 Jul–Aug;43(10):1000–5 (25 ref.)

Gastrointestinal hepatoid adenocarcinoma: venous permeation and mimicry of hepatocellular carcinoma, a report of four cases. Ishikura H, et al. **Histopathology** 1997 Jul;31(1):47–54 (28 ref.)

Gastric epithelial dysplasia and adenoma: historical review and histological criteria for grading. Goldstein NS, et al. **Hum Pathol** 1997 Feb;28(2):127–33 (100 ref.)

Biology of colorectal and gastric cancer cell lines. Park JG, et al. **J Cell Biochem Suppl** 1996;24:131–41 (26 ref.)

Gastrointestinal autonomic nerve tumor with giant abscess. A case report and literature review. Honda K, et al. **J Clin Gastroenterol** 1997 Jun;24(4):280–5 (12 ref.)

Adenosquamous carcinoma of the stomach associated with separate early gastric cancer (type IIc). Toyota N, et al. **J Gastroenterol** 1996 Feb;31(1):105–8 (18 ref.)

Gastric ganglioneuroblastoma: a rare finding in an infant with multifocal ganglioneuroblastoma. Sandoval C, et al. **J Pediatr Hematol Oncol** 1996 Nov;18(4):409–12 (19 ref.)

Clinicopathological studies on coexisting gastric malignant lymphoma and gastric adenocarcinoma: report of four cases and review of the Japanese literature. Ishihama T, et al. **Jpn J Clin Oncol** 1997 Apr;27(2):101–6 (24 ref.)

Cancer–stromal interaction through growth factor/cytokine networks implicated in growth of stomach cancer. Tahara E. **Princess Takamatsu Symp** 1994;24:187–94 (19 ref.)

Gastric cancer. Clinical and pathologic features. Gore RM. **Radiol Clin North Am** 1997 Mar;35(2):295–310 (92 ref.)

Gastric cancer. Radiologic staging. Miller FH, et al. **Radiol Clin North Am** 1997 Mar;35(2):331–49 (84 ref.)

Pathology neoplastic and non-neoplastic. Graeme-Cook F. **Surg Oncol Clin N Am** 1996 Jul;5(3):487–512 (31 ref.)

Prognostic indicators for cancer. Gastric cancer. Kirkwood KS, et al. **Surg Oncol Clin N Am** 1997 Jul;6(3):495–514 (78 ref.)

Resection of liver metastasis from alpha-fetoprotein-producing early gastric cancer: report of a case. Tsurumachi T, et al. **Surg Today** 1997;27(6):563–6 (11 ref.)

Gastric MALT lymphoma and Helicobacter pylori. Wotherspoon AC. **Yale J Biol Med** 1996 Jan–Feb; 69(1):61–8 (32 ref.)

[Association of a low-grade MALT lymphoma and a slightly differentiated adenocarcinoma of the stomach] Brochériou I, et al. **Ann Pathol** 1997 Apr;17(2):109–12 (12 ref.) (Eng. Abstr.) **(Fre)**

[Antitumor effect and mechanism of a novel multifunctional nucleoside, 3'-ethynylnucleoside, on human cancers] Tanaka M, et al. **Gan To Kagaku Ryoho** 1997 Feb; 24(4):476–82 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Clinicopathology of Epstein–Barr virus-related gastric carcinoma] Itoh T, et al. **Nippon Rinsho** 1997 Feb; 55(2):363–7 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Expression of Bcl-2 and Bax in human gastric cancer tissue] Komatsu K, et al. **Nippon Rinsho** 1996 Jul;54(7):1929–34 (20 ref.) (Eng. Abstr.) **(Jpn)**

[A case of gastric lipoma prolapsed into the duodenal bulb, which caused ball valve syndrome] Machishi H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Aug;93(8):560–4 (12 ref.) **(Jpn)**

[A case of extramedullary plasmacytoma of the stomach] Takehara Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Feb;94(2):111–6 (8 ref.) **(Jpn)**

[A case of liver metastasis from so-called hepatoid adenocarcinoma of stomach with lipiodol accumulation] Ueda H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Feb; 93(2):120–5 (14 ref.) **(Jpn)**

[A case of synchronous triple early cancer occurring in the stomach, colon and gallbladder] Yazawa K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Jun;94(6):440–4 (12 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Biological aspects of neuroendocrine gastro-enteropancreatic tumours. Oberg K. **Digestion** 1996;57 Suppl 1:42–4 (5 ref.)

The role of Helicobacter pylori in the pathophysiology of duodenal ulcer disease and gastric cancer. McColl KE, et al. **Semin Gastrointest Dis** 1997 Jul;8(3):142–55 (88 ref.)

PREVENTION & CONTROL

Inhibition by vitamins C and E of in vivo nitrosation and vitamin C occurrence in the stomach. Mirvish SS. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:131–6 (37 ref.)

Vitamin C and gastric cancer: supplements for some or fruit for all? O'Toole P, et al. **Gut** 1996 Sep;39(3):345–7 (54 ref.)

Chemoprevention of stomach cancer. Buiatti E, et al. **IARC Sci Publ** 1996;(136):35–9 (18 ref.)

Tea and cancer prevention: an evaluation of the epidemiologic literature. Kohlmeier L, et al. **Nutr Cancer** 1997;27(1):1–13 (30 ref.)

[Stomach cancer and MALT lymphoma: prevention with Helicobacter pylori eradication] Fischbach W. **Dtsch Med Wochenschr** 1997 Aug 1;122(31–32):983–7 (67 ref.) **(Ger)**

[Prevention of cancer of the upper gastrointestinal tract] Lersch C, et al. **Dtsch Med Wochenschr** 1997 Feb 7; 122(6):169–73 (38 ref.) **(Ger)**

[Detection of early esophageal and gastric cancers by mass screening] Mitsunaga N, et al. **Nippon Rinsho** 1996 May; 54(5):1415–20 (20 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Computed tomography of the gastro-duodenal region. Small JH, et al. **Eur J Radiol** 1996 May;22(2):95–103 (39 ref.)

CT of the stomach: spectrum of disease. Fishman EK, et al. **Radiographics** 1996 Sep;16(5):1035–54 (57 ref.)

Gastric cancer. Radiologic diagnosis. Gore RM, et al. **Radiol Clin North Am** 1997 Mar;35(2):311–29 (88 ref.)

Gastric cancer. Radiologic staging. Miller FH, et al. **Radiol Clin North Am** 1997 Mar;35(2):331–49 (84 ref.)

[Potentialities of present day computed tomography in diagnosis of stomach cancer] Portnoi LM, et al. **Vestn Rentgenol Radiol** 1997 May–Jun;(3):7–14 (23 ref.) (Eng. Abstr.) **(Rus)**

SECONDARY

Metastatic head and neck cancer to the percutaneous endoscopic gastrostomy exit site: a case report and review of the literature. Schneider AM, et al. **Am Surg** 1997 Jun; 63(6):481–6 (11 ref.)

[Metastatic linitis plastica of the bladder] Signori GB, et al. **Arch Ital Urol Androl** 1997 Feb;69(1):69–72 (18 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

The future of oesophageal and gastric surgery. Siewert JR. **Ann Chir Gynaecol** 1996;85(3):196–200 (1 ref.)

Primary liposarcoma of the stomach resected endoscopically. Yamamoto K, et al. **Endoscopy** 1995 Nov;27(9):711 (5 ref.)

Therapeutic strategies for early gastric cancer. Sowa M, et al. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:18–28 (10 ref.)

Gastric stump carcinoma: a surgical challenge. Looi KP, et al. **Singapore Med J** 1996 Apr;37(2):184–5 (15 ref.)

Gastric cancer nodal metastases: biologic significance and therapeutic considerations. Hundahl SA. **Surg Oncol Clin N Am** 1996 Jan;5(1):129–44 (72 ref.)

Management of carcinoid tumors of the stomach, duodenum, and pancreas. Akerström G. **World J Surg** 1996 Feb; 20(2):173–82 (128 ref.)

[Stomach carcinoma—the current trends in its surgical treatment] Damianov N. **Khirurgiia (Sofiia)** 1996;49(2):51–6 (0 ref.) **(Bul)**

[Lymphadenectomy in tumors of the upper gastrointestinal tract] Siewert JR, et al. **Chirurg** 1996 Sep;67(9):877–88 (29 ref.) (Eng. Abstr.) **(Ger)**

[Surgical relevance of preoperative diagnosis of tumors of the gastrointestinal tract—decision making in esophageal, stomach, colon and rectal carcinoma] Siewert JR, et al. **Chirurg** 1997 Apr;68(4):317–24 (29 ref.) (Eng. Abstr.) **(Ger)**

[Small-cell sarcoma of the esophagus as a fourth malignancy. Its palliative therapy with argon gas coagulation] Glaser J, et al. **Dtsch Med Wochenschr** 1997 Aug 22; 122(34–35):1037–40 (8 ref.) (Eng. Abstr.) **(Ger)**

[Therapy of carcinoids of the stomach] Becker HD, et al. **Langenbecks Arch Chir** 1996;381(1):18–22 (34 ref.) (Eng. Abstr.) **(Ger)**

[MALT-lymphoma—surgical therapy] Verreet PR. **Schweiz Rundsch Med Prax** 1996 Nov 5;85(45):1451–4 (53 ref.) (Eng. Abstr.) **(Ger)**

[Consensus of the CAO, AIO and ARO in diagnosis and therapy of primary stomach lymphoma] **Zentralbl Chir** 1996;121(7):599–602 (4 ref.) **(Ger)**

[Gastric lymphomas in old age] Pannella A, et al. **Minerva Chir** 1996 Jul–Aug;51(7–8):527–31 (10 ref.) (Eng. Abstr.) **(Ita)**

[Laparoscopic surgery for early gastric cancer—its advantage and pitfall] Ohgami M, et al. **Gan To Kagaku Ryoho** 1997 Mar;24(5):532–7 (9 ref.) (Eng. Abstr.) **(Jpn)**

STOMACH NEOPLASMS

[Lymph node excision in stomach cancer and clinical comparative tests] Sakamoto J, et al. **Nippon Geka Gakkai Zasshi** 1996 Oct;97(10):926–31 (18 ref.) **(Jpn)**

[Endoscopic mucosal resection for early gastric cancer] Hamada T, et al. **Nippon Rinsho** 1996 May;54(5):1292–7 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Laparoscopic curative surgery for early gastric cancer] Ohgami M, et al. **Nippon Rinsho** 1996 May;54(5):1307–11 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Endoscopic treatment of early gastric cancer with heat probe method] Otsuka S. **Nippon Rinsho** 1996 May; 54(5):1351–3 (11 ref.) (Eng. Abstr.) **(Jpn)**

[A case of synchronous triple cancers with curative resection] Matsuoka M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Oct;93(10):732–7 (11 ref.) **(Jpn)**

THERAPY

Eradication of Helicobacter pylori and regression of B-cell lymphoma. Vanagunas A. **Biomed Pharmacother** 1997; 51(4):156–60 (32 ref.)

Self-expanding metal stents for palliation of stenosing tumors of the esophagus and cardia: a critical review. Ell C, et al. **Endoscopy** 1997 Jun;29(5):392–8 (40 ref.)

Pre- and/or post-operative immunochemotherapy for advanced digestive cancer. Saji S, et al. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:239–49 (14 ref.)

[Cancer vaccine therapy using peptides derived from tumor-rejection antigens] Akiyoshi T. **Gan To Kagaku Ryoho** 1997 Mar;24(5):511–9 (38 ref.) (Eng. Abstr.) **(Jpn)**

[Endoscopic treatment of early gastric cancer with laser and laserthermia using Nd : YAG laser] Otsuka S. **Nippon Rinsho** 1996 May;54(5):1326–31 (17 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Endoscopic ultrasonography for esophageal and gastric mass lesions. Catalano MF. **Gastroenterologist** 1997 Mar;5(1):3–9 (46 ref.)

[Endosonography of tumors of the upper gastrointestinal tract: is routine use justified?] Zoller WG, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:747–52 (0 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Tumours of the oral cavity, buccal pouch, oesophagus, forestomach and salivary glands. Takahashi M, et al. **IARC Sci Publ** 1996;(126):59–77 (60 ref.)

Tumours of the glandular stomach. Takahashi M, et al. **IARC Sci Publ** 1996;(126):127–35 (29 ref.)

VIROLOGY

Epstein-Barr virus-associated gastric carcinoma. Adachi Y, et al. **J Clin Gastroenterol** 1996 Oct;23(3):207–10 (24 ref.)

Epstein-Barr virus and gastric carcinoma. Osato T, et al. **Semin Cancer Biol** 1996 Aug;7(4):175–82 (41 ref.)

Detection of Epstein-Barr virus DNA in gastric carcinoma with lymphoid stroma. Jing X, et al. **Viral Immunol** 1997; 10(1):49–58 (23 ref.)

[EBV-related stomach cancer and HLA] Akiba S, et al. **Nippon Rinsho** 1997 Feb;55(2):386–90 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Epstein-Barr virus associated gastric carcinoma: the genetic alteration and the expression of CD44 variant] Chong JM, et al. **Nippon Rinsho** 1997 Feb;55(2):381–5 (12 ref.) (Eng. Abstr.) **(Jpn)**

[State of art: Epstein Barr virus-associated gastric carcinoma] Fukayama M, et al. **Nippon Rinsho** 1997 Feb;55(2):357–62 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Virological studies on Epstein-Barr virus-positive gastric carcinoma] Imai S. **Nippon Rinsho** 1997 Feb;55(2):368–73 (29 ref.) (Eng. Abstr.) **(Jpn)**

[Clinicopathology of Epstein-Barr virus-related gastric carcinoma] Itoh T, et al. **Nippon Rinsho** 1997 Feb; 55(2):363–7 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Critical review on the WHO/IARC report regarding carcinogenicity of Helicobacter pylori] Tanida N, et al. **Nippon Rinsho** 1997 Apr;55(4):995–1002 (20 ref.) (Eng. Abstr.) **(Jpn)**

STOMACH, RUMINANT

PHYSIOLOGY

[Motor, digestive and secretory processes of the forestomach and the abomasum--a short review] Wolffram S. **Schweiz Arch Tierheilkd** 1996;138(7):343–50 (6 ref.) (Eng. Abstr.) **(Ger)**

STOMACH ULCER

Endoscopy and gastric ulcers. Moayyedi P, et al. **Endoscopy** 1995 Nov;27(9):689–93 (73 ref.)

CHEMICALLY INDUCED

Non-nonsteroidal anti-inflammatory drug, nonmalignant gastric ulcers. Bjorkman DJ, et al. **Gastrointest Endosc Clin N Am** 1996 Jul;6(3):527–44 (102 ref.)

Nonsteroidal anti-inflammatory drug gastropathy. Laine L. **Gastrointest Endosc Clin N Am** 1996 Jul;6(3):489–504 (76 ref.)

Prevention of NSAID-gastropathy. Ardizzone S, et al. **Ital J Gastroenterol** 1996 Dec;28 Suppl 4:33–6 (19 ref.)

Ultrastructural damage of gastric epithelium in patients taking NSAIDs. Caselli M, et al. **Ital J Gastroenterol** 1996 Dec;28 Suppl 4:16–8 (12 ref.)

Therapy of NSAIDs-induced gastropathy. La Corte R, et al. **Ital J Gastroenterol** 1996 Dec;28 Suppl 4:37–41 (34 ref.)

The gastroenterologist's caseload: contribution of the rheumatologist. Hawkey CJ. **Semin Arthritis Rheum** 1997 Jun;26(6 Suppl 1):11–5 (13 ref.)

[The epidemiology of the gastroduodenal damage induced by aspirin and other nonsteroidal anti-inflammatory drugs] Dobrilla G, et al. **Recenti Prog Med** 1997 May;88(5):202–11 (78 ref.) (Eng. Abstr.) **(Ita)**

[Pathogenesis and therapy of non-steroidal anti-inflammatory drug (NSAID)-induced gastric mucosal injury] Yoshikawa T, et al. **Nippon Seikeigeka Gakkai Zasshi** 1996 May;70(5):269–73 (20 ref.) **(Jpn)**

COMPLICATIONS

Gastric tuberculosis presenting with hematemesis. Rathnaraj S, et al. **Indian J Gastroenterol** 1997 Jul;16(3):110–1 (3 ref.)

Ulcer bleeding and perforation: non-steroidal anti-inflammatory drugs or Helicobacter pylori. Svanes C, et al. **Scand J Gastroenterol Suppl** 1996;220:128–31 (43 ref.)

[Gastric ulcer and cancer] Matsukura N, et al. **Nippon Ika Daigaku Zasshi** 1997 Jun;64(3):207–10 (19 ref.) **(Jpn)**

[Changes in the body of patients with peptic ulcer after acute hemorrhage] Desiaterik VI. **Klin Khir** 1996;(10):47–50 (24 ref.) **(Rus)**

[Cancer from an ulcer or ulcerative stomach cancer? (a review of the literature and the authors' own observations)] Sadchikov VD, et al. **Lik Sprava** 1997 Mar-Apr;(2):137–41 (38 ref.) (Eng. Abstr.) **(Rus)**

[A giant ulcer of the stomach with perforation into the liver simulating cancer] Kovalenko VL, et al. **Vestn Khir Im I I Grek** 1996;155(6):82–3 (7 ref.) **(Rus)**

DRUG THERAPY

Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders [published errata appear in Drugs 1996 Jun;51(6):1074 and 1996 Jul;52(1):92] Fitton A, et al. **Drugs** 1996 Mar;51(3):460–82 (132 ref.)

Therapy of NSAIDs-induced gastropathy. La Corte R, et al. **Ital J Gastroenterol** 1996 Dec;28 Suppl 4:37–41 (34 ref.)

Arachidonic acid cascade and gastric mucosal injury, protection, and healing: topics of this decade. Kobayashi K, et al. **J Clin Gastroenterol** 1995;21 Suppl 1:S12–7 (35 ref.)

[Current developments in Helicobacter pylori therapy] Labenz J. **Leber Magen Darm** 1996 Jul;26(4):223–6 (0 ref.) **(Ger)**

EPIDEMIOLOGY

[The epidemiology of the gastroduodenal damage induced by aspirin and other nonsteroidal anti-inflammatory drugs] Dobrilla G, et al. **Recenti Prog Med** 1997 May;88(5):202–11 (78 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Giant antral ulcer: a rare presentation of eosinophilic gastroenteritis--case report and review of the literature. Kristopaitis T, et al. **Am J Gastroenterol** 1997 Jul; 92(7):1205–8 (21 ref.)

Guilty as charged: bugs and drugs in gastric ulcer. Sontag SJ. **Am J Gastroenterol** 1997 Aug;92(8):1255–61 (76 ref.)

[Pathophysiology of the harmful influence of smoking on the course of gastric and duodenal ulcer diseases] Budzyński J, et al. **Przegl Lek** 1996;53(11):811–5 (26 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

[The antioxidant allowance of the body and lipid peroxidation in patients with gastric and duodenal peptic ulcers] Petrov EE. **Lik Sprava** 1996 Jul-Sep;(7–9):13–8 (50 ref.) **(Rus)**

MICROBIOLOGY

[Ulcer--an infection?] Eissele R, et al. **Chirurg** 1996 Jan; 67(1):1–6 (35 ref.) (Eng. Abstr.) **(Ger)**

[Helicobacter pylori: role in the onset of chronic gastritis and ulcer] Tsimmerman IS, et al. **Klin Med (Mosk)** 1997; 75(4):8–13 (60 ref.) **(Rus)**

[Why, when and how to treat Helicobacter pylori infection in gastroduodenal ulcer disease?] Gisbert JP, et al. **Rev Clin Esp** 1996 Sep;196(9):610–21 (248 ref.) **(Spa)**

PATHOLOGY

Non-nonsteroidal anti-inflammatory drug, nonmalignant gastric ulcers. Bjorkman DJ, et al. **Gastrointest Endosc Clin N Am** 1996 Jul;6(3):527–44 (102 ref.)

Gastric malignancy. Ellis KK, et al. **Gastrointest Endosc Clin N Am** 1996 Jul;6(3):545–63 (111 ref.)

Cellular mechanisms, interactions, and dynamics of gastric ulcer healing. Tarnawski A, et al. **J Clin Gastroenterol** 1995; 21 Suppl 1:S93–7 (31 ref.)

A new model to study repair of gastric mucosa using primary cultured rabbit gastric epithelial cells. Watanabe S, et al. **J Clin Gastroenterol** 1995;21 Suppl 1:S40–4 (11 ref.)

Migration of the ductular elements of gut-associated glands gives clues to the histogenesis of structures associated with responses to acid hypersecretory state: the origins of "gastric metaplasia" in the duodenum of the specialized mucosa of barrett's esophagus and of pseudopyloric metaplasia. Wright NA. **Yale J Biol Med** 1996 Mar-Apr; 69(2):147–53 (24 ref.)

[Morphologic and morphogenetic features of stomach ulcer] Dmitriev IV, et al. **Arkh Patol** 1996 Sep-Oct;58(5):74–8 (55 ref.) (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Chilli, capsaicin and the stomach. Kang JY. **Clin Sci (Colch)** 1996 Sep;91(3):252–4 (25 ref.)

Prevention of NSAID-gastropathy. Ardizzone S, et al. **Ital J Gastroenterol** 1996 Dec;28 Suppl 4:33–6 (19 ref.)

Therapy and prevention of gastric ulcer. Lamers CB, et al. **Yale J Biol Med** 1996 May-Jun;69(3):265–70 (34 ref.)

SURGERY

Direct button percutaneous endoscopic jejunostomy: successful placement in a patient with severe malnutrition and previous gastric resection. Dumot JA, et al. **Gastrointest Endosc** 1997 Jan;45(1):92–4 (14 ref.)

[Advantages and disadvantages of stomach resection with PU anastomosis in treatment of gastric and duodenal peptic ulcers] Maiorova IV, et al. **Khirurgiia (Mosk)** 1996;(5):61–6 (120 ref.) **(Rus)**

[The modern surgical problems of gastric peptic ulcer] Gurin NN, et al. **Vestn Khir Im I I Grek** 1997;156(3):101–5 (46 ref.) **(Rus)**

THERAPY

Recurrent peptic ulceration. Howden CW. **Dig Dis** 1997 Jan-Apr;15(1–2):92–9 (45 ref.)

Gastric malignancy. Ellis KK, et al. **Gastrointest Endosc Clin N Am** 1996 Jul;6(3):545–63 (111 ref.)

Therapy and prevention of gastric ulcer. Lamers CB, et al. **Yale J Biol Med** 1996 May-Jun;69(3):265–70 (34 ref.)

VETERINARY

Suppression of gastric acidity in horses. Murray MJ. **J Am Vet Med Assoc** 1997 Jul 1;211(1):37–40 (33 ref.)

STOMACH VOLVULUS

Gastric volvulus: a report of four cases. Adebamowo CA, et al. **West Afr J Med** 1996 Apr-Jun;15(2):126–31 (19 ref.)

CONGENITAL

[Volvulus in childhood] Peitz HG. **Radiologe** 1997 Jun; 37(6):439–45 (30 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

[Acute intra-abdominal gastric volvulus in adults. Defect of dorsal mesogastrium fusion] Benoit L, et al. **Ann Chir** 1997; 51(4):379–81 (18 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

[Endoscopic repositioning of the upside-down stomach and its fixation by percutaneous endoscopic gastrostomy] Januschowski R. **Dtsch Med Wochenschr** 1996 Oct 11; 121(41):1261–4 (19 ref.) (Eng. Abstr.) **(Ger)**

STOMATITIS

CHEMICALLY INDUCED

Assessment and management of chemotherapy-induced mucositis in children. Kennedy L, et al. **J Pediatr Oncol Nurs** 1997 Jul;14(3):164–74; quiz 175–7 (19 ref.)

ETIOLOGY

Manifestations and treatment of xerostomia and associated oral effects secondary to head and neck radiation therapy. Garg AK, et al. **J Am Dent Assoc** 1997 Aug;128(8):1128–33 (40 ref.)

[Dental materials--problem substances in allergologic diagnosis? II: Patch test diagnosis and relevance evaluation of selected dental material groups] Richter G. **Hautarzt** 1996 Nov;47(11):844–9 (50 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Severe erosive stomatitis: association with immunological diseases? Reynaers A, et al. **Dermatology** 1997;194(4):411–5 (24 ref.)

NURSING

Assessment and management of chemotherapy-induced

mucositis in children. Kennedy L, et al. **J Pediatr Oncol Nurs** 1997 Jul;14(3):164–74; quiz 175–7 (19 ref.)

PATHOLOGY

Oral mucositis with features of psoriasis: report of a case and review of the literature. Younai FS, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jul;84(1):61–7 (58 ref.)

PREVENTION & CONTROL

[The therapeutic management of radiogenic oral mucositis] Dörr W, et al. **Strahlenther Onkol** 1997 Apr;173(4):183–92 (81 ref.) (Eng. Abstr.) **(Ger)**

STOMATITIS, APHTHOUS

DRUG THERAPY

[Sucralfate in odontostomatology. Clinical experience] Campisi G, et al. **Minerva Stomatol** 1997 Jun;46(6):297–305 (42 ref.) (Eng. Abstr.) **(Ita)**

[Aphthosis of the oral cavity: therapeutic prospectives] Colella G, et al. **Minerva Stomatol** 1996 Jun;45(6):295–303 (40 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Recurrent scarring ulcers of the oral mucosa. Sutton disease (periadenitis mucosa necrotica recurrens. Chung JY, et al. **Arch Dermatol** 1997 Sep;133(9):1162–3, 1165–6 (6 ref.)

STOMATITIS, DENTURE

PREVENTION & CONTROL

Complete dentures—the soft option. An update for general dental practice. Jagger DC, et al. **Br Dent J** 1997 Apr 26; 182(8):313–7 (25 ref.)

STOMATITIS, GANGRENOUS see **NOMA**

STOMATOLOGY see **ORAL MEDICINE**

STOMOXYS CALCITRANS see **MUSCIDAE**

STOREROOM see **MATERIALS MANAGEMENT, HOSPITAL**

STOREROOMS see **MATERIALS MANAGEMENT, HOSPITAL**

STOVE-IN CHEST see **FLAIL CHEST**

STRABISMUS

COMPLICATIONS

The relationship between infantile strabismus and latent nystagmus. Kommerell G. **Eye** 1996;10 (Pt 2):274–81 (74 ref.)

The neural basis of suppression and amblyopia in strabismus. Sengpiel F, et al. **Eye** 1996;10 (Pt 2):250–8 (80 ref.)

CONGENITAL

Aplasia of the inferior rectus muscle. A case report and review of the literature. Taylor RH, et al. **Ophthalmology** 1997 Mar;104(3):415–8 (15 ref.)

DIAGNOSIS

Practical approach to diagnosis of strabismus. Thomas R, et al. **Indian J Ophthalmol** 1996 Jun;44(2):103–12 (3 ref.)

Reliability of and comparisons among methods of measuring dissociated phoria. Schroeder TL, et al. **Optom Vis Sci** 1996 Jun;73(6):389–97 (31 ref.)

Preschool vision screening: rationale, methodology and outcome. Simons K. **Surv Ophthalmol** 1996 Jul–Aug; 41(1):3–30 (366 ref.)

DRUG THERAPY

[Use of botulinum toxin in ophthalmology] Huber A. **Klin Monatsbl Augenheilkd** 1997 May;210(5):289–92 (28 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Surgical management of strabismus associated with chronic progressive external ophthalmoplegia. Wallace DK, et al. **Ophthalmology** 1997 Apr;104(4):695–700 (40 ref.)

HISTORY

Lincoln's vertical strabismus. Goldstein JH. **J Pediatr Ophthalmol Strabismus** 1997 Mar–Apr; 34(2):118–20 (10 ref.)

PATHOLOGY

Binocularity in prism-reared monkeys. Crawford ML, et al. **Eye** 1996;10 (Pt 2):161–6 (26 ref.)

PHYSIOPATHOLOGY

Where is the naso-temporal asymmetry? Motion processing. Braddick O. **Curr Biol** 1996 Mar 1;6(3):250–3 (17 ref.)

What happens to binocularity in primate strabismus? Boothe RG, et al. **Eye** 1996;10 (Pt 2):199–208 (47 ref.)

Psychophysics of suppression. Harrad R. **Eye** 1996;10 (Pt 2):270–3 (28 ref.)

How useful is anomalous correspondence? Herzau V. **Eye** 1996;10 (Pt 2):266–9 (16 ref.)

The neural basis of suppression and amblyopia in strabismus. Sengpiel F, et al. **Eye** 1996;10 (Pt 2):250–8 (80 ref.)

Unifying concepts in mechanism of amblyopia. Tong LM. **Med Hypotheses** 1997 Feb;48(2):97–102 (31 ref.)

Clinical findings before the onset of myopia in youth: 3. Heterophoria. Goss DA, et al. **Optom Vis Sci** 1996 Apr; 73(4):269–78 (73 ref.)

SURGERY

Aplasia of the inferior rectus muscle. A case report and review of the literature. Taylor RH, et al. **Ophthalmology** 1997 Mar;104(3):415–8 (15 ref.)

Surgical management of strabismus associated with chronic progressive external ophthalmoplegia. Wallace DK, et al. **Ophthalmology** 1997 Apr;104(4):695–700 (40 ref.)

VETERINARY

What happens to binocularity in primate strabismus? Boothe RG, et al. **Eye** 1996;10 (Pt 2):199–208 (47 ref.)

STRABISMUS, CONVERGENT see **ESOTROPIA**

STRAMONIUM

The dangers of jimson weed and its abuse by teenagers in the Kanawha Valley of West Virginia. Dewitt MS, et al. **W V Med J** 1997 Jul–Aug;93(4):182–5 (9 ref.)

STREET CHILDREN see **HOMELESS YOUTH**

STREET DRUG TESTING see **SUBSTANCE ABUSE DETECTION**

STREET DRUGS

Alcohol and drug abuse in patients with physical disabilities. Hubbard JR, et al. **Am J Drug Alcohol Abuse** 1996 May; 22(2):215–31 (41 ref.)

Familial factors in illicit drug abuse: an interdisciplinary perspective. Ripple CH, et al. **Am J Drug Alcohol Abuse** 1996 May;22(2):147–72 (54 ref.)

Cannabis. Robson P. **Arch Dis Child** 1997 Aug;77(2):164–6 (30 ref.)

What is the psychiatrist's role in drugs and alcohol? Pols RG, et al. **Aust N Z J Psychiatry** 1996 Aug;30(4):540–8; discussion 548–9 (99 ref.)

Psychobiology of novelty seeking and drug seeking behavior. Bardo MT, et al. **Behav Brain Res** 1996 May;77(1–2):23–43 (205 ref.)

ABC of mental health. Addiction and dependence—I: Illicit drugs. Gerada C, et al. **BMJ** 1997 Aug 2;315(7103):297–300 (0 ref.)

The costs of drug abuse consequences: a summary of research findings. French MT, et al. **J Subst Abuse Treat** 1996 Nov–Dec;13(6):453–66 (56 ref.)

The validity of self-reported drug use in survey research: an overview and critique of research methods. Harrison L. **NIDA Res Monogr** 1997;167:17–36 (41 ref.)

MDMA (ecstasy) and the rave: a review. Schwartz RH, et al. **Pediatrics** 1997 Oct;100(4):705–8 (5 ref.)

Role of oxytocin in the neuroadaptation to drugs of abuse. Sarnyai Z, et al. **Psychoneuroendocrinology** 1994; 19(1):85–117 (100 ref.)

The consequences of knowing: ethical and legal liabilities in illicit drug research. Fitzgerald J, et al. **Soc Sci Med** 1996 Dec;43(11):1591–600 (35 ref.)

The role of ethnic versus nonethnic sociocultural factors in substance use and misuse. Collins RL. **Subst Use Misuse** 1996 Jan;31(1):95–101 (27 ref.)

Southeast Asians: Asian-Pacific Americans at risk for substance misuse. D'Avanzo CE. **Subst Use Misuse** 1997 Jun;32(7–8):829–48 (65 ref.)

Problems among youths entering the juvenile justice system, their service needs and innovative approaches to address them. Dembo R. **Subst Use Misuse** 1996 Jan;31(1):81–94 (100 ref.)

Drug problems among immigrants and refugees in The Netherlands and the Dutch health care and treatment system. van de Wijngaart GF. **Subst Use Misuse** 1997 Jun; 32(7–8):909–38 (60 ref.)

[Ambulatory medical treatment of drug dependent patients] Gölz J. **Z Arztl Fortbild (Jena)** 1996 Jun;90(4):271–8 (5 ref.) (Eng. Abstr.) **(Ger)**

[Substance dependence. Information, diagnosis and therapy—encouragement for pragmatic treatment] Salloch-Vogel RR, et al. **Z Arztl Fortbild (Jena)** 1996 Jun; 90(4):279–94 (0 ref.) (Eng. Abstr.) **(Ger)**

[Drug dependence among physicians] Schifferdecker M, et al. **Z Arztl Fortbild (Jena)** 1996 Jun;90(4):295–300 (39 ref.) (Eng. Abstr.) **(Ger)**

[Are there new methods in therapy of drug dependence?] Täschner KL. **Z Arztl Fortbild (Jena)** 1996 Jun; 90(4):315–20 (18 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Drug induced psychosis [editorial] [see comments] Poole R, et al. **Br J Psychiatry** 1996 Feb;168(2):135–8 (34 ref.) Comment in: Br J Psychiatry 1996 May;168(5):651. Comment in: Br J Psychiatry 1996 May;168(5):651–2. Comment in: Br J Psychiatry 1996 Jul;169(1):114–5.

Adverse consequences of prenatal illicit drug exposure. Woods JR Jr. **Curr Opin Obstet Gynecol** 1996 Dec; 8(6):403–11 (71 ref.)

Pregnancy outcome and neurodevelopment of children exposed in utero to psychoactive drugs: the Motherisk experience. Loebstein R, et al. **J Psychiatry Neurosci** 1997 May;22(3):192–6 (21 ref.)

ANALYSIS

[Dependence producing substances in the practice of the Insitute of Forensic Experts in Krakow] Kala M. **Przegl Lek** 1997;54(6):430–7 (28 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

New developments in biological measures of drug prevalence. Cone EJ. **NIDA Res Monogr** 1997;167:108–29 (21 ref.)

The forensic application of testing hair for drugs of abuse. Miller ML, et al. **NIDA Res Monogr** 1997;167:146–60 (12 ref.)

PHARMACOKINETICS

Biocatalysts in detoxication of drugs of abuse. Cashman JR. **NIDA Res Monogr** 1997;173:225–58 (95 ref.)

PHARMACOLOGY

Habitual, toxic, and lethal concentrations of 103 drugs of abuse in humans. Repetto MR, et al. **J Toxicol Clin Toxicol** 1997;35(1):1–9 (20 ref.)

Molecular and cellular basis of addiction. Nestler EJ, et al. **Science** 1997 Oct 3;278(5335):58–63 (63 ref.)

TOXICITY

Immunotoxicology of opioids, inhalants, and other drugs of abuse. House RV, et al. **NIDA Res Monogr** 1997; 173:175–200 (51 ref.)

Inhalation studies with drugs of abuse. Meng Y, et al. **NIDA Res Monogr** 1997;173:201–24 (30 ref.)

STREET PEOPLE see **HOMELESS PERSONS**

STREET YOUTH see **HOMELESS YOUTH**

STREETER SYNDROME see **AMNIOTIC BAND SYNDROME**

STREPSIRHINI

PSYCHOLOGY

Determinants of primate social organization: comparative evidence and new insights from Malagasy lemurs. Kappeler PM. **Biol Rev Camb Philos Soc** 1997 Feb;72(1):111–51 (248 ref.)

STREPTOCOCCACEAE

CLASSIFICATION

Lactic acid bacteria of foods and their current taxonomy. Stiles ME, et al. **Int J Food Microbiol** 1997 Apr 29; 36(1):1–29 (167 ref.)

GENETICS

Genomic organization of lactic acid bacteria. Davidson BE, et al. **Antonie Van Leeuwenhoek** 1996 Oct;70(2–4):161–83 (153 ref.)

Barriers to application of genetically modified lactic acid bacteria. Verrips CT, et al. **Antonie Van Leeuwenhoek** 1996 Oct;70(2–4):299–316 (44 ref.)

METABOLISM

Metabolic engineering of sugar catabolism in lactic acid bacteria. de Vos WM. **Antonie Van Leeuwenhoek** 1996 Oct; 70(2–4):223–42 (132 ref.)

Biosynthesis of bacteriocins in lactic acid bacteria. Nes IF, et al. **Antonie Van Leeuwenhoek** 1996 Oct;70(2–4):113–28 (82 ref.)

Biopreservation by lactic acid bacteria. Stiles ME. **Antonie Van Leeuwenhoek** 1996 Oct;70(2–4):331–45 (132 ref.)

Casein and peptide degradation in lactic acid bacteria. Mierau I, et al. **Biotechnol Genet Eng Rev** 1997;14:279–301 (125 ref.)

PHYSIOLOGY

Lytic systems in lactic acid bacteria and their bacteriophages. Gasson MJ. **Antonie Van Leeuwenhoek** 1996 Oct; 70(2–4):147–59 (63 ref.)

Geographical spread of bacterial and fungal diseases of

STREPTOCOCCACEAE

crustaceans. Alderman DJ. **Rev Sci Tech** 1996 Jun; 15(2):603–32 (59 ref.)

[The biological properties of Aerococcus antagonists, representatives of human microbiocenoses] Kremenchutskii GN, et al. **Mikrobiol Z** 1994 Jul–Sep;56(4):36–42 (61 ref.) (Eng. Abstr.) **(Rus)**

VIROLOGY

Biotechnology of lactic acid bacteria with special reference to bacteriophage resistance. Daly C, et al. **Antonie Van Leeuwenhoek** 1996 Oct;70(2–4):99–110 (118 ref.)

STREPTOCOCCAL INFECTIONS

Group B streptococcal infections. Baker CJ. **Clin Perinatol** 1997 Mar;24(1):59–70 (47 ref.)

Management of staphylococcal and streptococcal infections. Tan JS, et al. **Clin Podiatr Med Surg** 1996 Oct;13(4):793–816 (56 ref.)

Update on complications of group A streptococcal infections. Ayoub EM, et al. **Curr Probl Pediatr** 1997 Mar;27(3):90–101 (87 ref.)

Invasive group A streptococcal disease. Stevens DL. **Infect Agents Dis** 1996 Jun;5(3):157–66 (48 ref.)

Vancomycin-resistant enterococci: clinical, microbiologic, and epidemiologic features. Noskin GA. **J Lab Clin Med** 1997 Jul;130(1):14–20 (40 ref.)

[Streptococcal perianal disease] García Puga JM, et al. **An Esp Pediatr** 1996 Dec;45(6):647–8 (19 ref.) **(Spa)**

[Endocarditis caused by group B streptococci in adults] Marron A, et al. **Enferm Infecc Microbiol Clin** 1997 Mar; 15(3):147–50 (25 ref.) (Eng. Abstr.) **(Spa)**

[Streptococcal pharyngitis] Romero J, et al. **Enferm Infecc Microbiol Clin** 1995 Dec;13(10):611–27 (204 ref.) **(Spa)**

COMPLICATIONS

Streptococcus sanguis bacteremia associated with cecal carcinoma: case report and review of the literature. Marinella MA. **Am J Gastroenterol** 1997 Sep;92(9):1541–2 (12 ref.)

Recurrent brain abscesses in an HIV-positive patient with hereditary hemorrhagic telangiectasia and arteriovenous malformations of the lung. Thurnheer R, et al. **Eur J Clin Microbiol Infect Dis** 1996 May;15(5):407–10 (20 ref.)

Periurethral abscess: complication of UTI. Mylonakis E, et al. **Geriatrics** 1997 Aug;52(8):86–8 (18 ref.)

Cervical cellulitis with mediastinitis from an odontogenic infection complicated by diabetes mellitus: report of a case. Sugata T, et al. **J Oral Maxillofac Surg** 1997 Aug; 55(8):864–9 (14 ref.)

Group A streptococcal bacteremia. A 10-year prospective study. Bernaldo de Quirós JC, et al. **Medicine (Baltimore)** 1997 Jul;76(4):238–48 (94 ref.)

Group B streptococcal sepsis and meningitis complicated with severe sensorineural hearing loss in a fourteen-year-old boy. Likitnukul S, et al. **Pediatr Infect Dis J** 1996 May;15(5):468–70 (15 ref.)

[Aortic valve perforation] Shu T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):415–20 (16 ref.) **(Jpn)**

CONGENITAL

Neonatal group B streptococcal disease. Mitchell A, et al. **MCN Am J Matern Child Nurs** 1997 Sep–Oct;22(5):249–53 (11 ref.)

DIAGNOSIS

Neonatal pleural empyema with group A Streptococcus. Thaarup J, et al. **Acta Paediatr** 1997 Jul;86(7):769–71 (17 ref.)

Necrotizing fasciitis: a diagnostic challenge. Meltzer DL, et al. **Am Fam Physician** 1997 Jul;56(1):145–9 (14 ref.)

Prosthetic valve endocarditis due to Streptococcus pneumoniae [letter] Collazos J, et al. **Arch Intern Med** 1996 Oct 14;156(18):2141, 2146, 2148 (10 ref.)

Reconsidering sore throats. Part I: Problems with current clinical practice [see comments] McIsaac WJ, et al. **Can Fam Physician** 1997 Mar;43:485–93 (62 ref.) Comment in: Can Fam Physician 1997 May;43:843, 845. Comment in: Can Fam Physician 1997 Jul;43:1207–8.

Reconsidering sore throats. Part 2: Alternative approach and practical office tool [see comments] McIsaac WJ, et al. **Can Fam Physician** 1997 Mar;43:495–500 (40 ref.) Comment in: Can Fam Physician 1997 May;43:843, 845. Comment in: Can Fam Physician 1997 Jul;43:1207–8.

Pyogenic arthritis caused by streptococcus equisimilis (group-C streptococcus) in a patient with AIDS. Steinfeld S, et al. **Clin Rheumatol** 1997 May;16(3):314–6 (20 ref.)

A case of bacteremia caused by Streptococcus dysgalactiae [letter] Bert F, et al. **Eur J Clin Microbiol Infect Dis** 1997 Apr;16(4):324–6 (10 ref.)

Infective endocarditis due to Streptococcus suis serotype 2 [letter] Tayoro J, et al. **Eur J Clin Microbiol Infect Dis** 1996 Sep;15(9):765–6 (10 ref.)

Management of a deep space infection of the neck in a patient with Glanzmann's thrombasthenia. Kirita T, et al. **J Oral Maxillofac Surg** 1997 Aug;55(8):882–5 (9 ref.)

Group C streptococcal infection in a term newborn infant. Faix RG, et al. **J Perinatol** 1997 Jan–Feb;17(1):79–82 (35 ref.)

Management of group A streptococcus pharyngitis with a second-generation rapid strep screen: Strep A OIA. Badgett JT, et al. **Microb Drug Resist** 1996 Fall;2(3):371–6 (54 ref.)

Group B streptococcal endocarditis in children beyond the neonatal period. Alsoub H, et al. **Pediatr Infect Dis J** 1997 Apr;16(4):418–20 (11 ref.)

Balanitis caused by group A beta-hemolytic streptococci. Orden B, et al. **Pediatr Infect Dis J** 1996 Oct;15(10):920–1 (10 ref.)

Tropical pyomyositis: imaging findings and a review of the literature. Pretorius ES, et al. **Skeletal Radiol** 1996 Aug; 25(6):576–9 (15 ref.)

Spontaneous group B streptococcal meningitis in a patient with cirrhosis. Tung BY, et al. **West J Med** 1996 Oct; 165(4):229–30 (13 ref.)

[How to recognize streptococcal pharyngitis? (editorial)] Ghanassia JP, et al. **Arch Pediatr** 1996 Aug;3(8):749–51 (17 ref.) **(Fre)**

DRUG THERAPY

Reconsidering sore throats. Part 2: Alternative approach and practical office tool [see comments] McIsaac WJ, et al. **Can Fam Physician** 1997 Mar;43:495–500 (40 ref.) Comment in: Can Fam Physician 1997 May;43:843, 845. Comment in: Can Fam Physician 1997 Jul;43:1207–8.

Reconsidering sore throats. Part I: Problems with current clinical practice [see comments] McIsaac WJ, et al. **Can Fam Physician** 1997 Mar;43:485–93 (62 ref.) Comment in: Can Fam Physician 1997 May;43:843, 845. Comment in: Can Fam Physician 1997 Jul;43:1207–8.

The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: current antibiotic therapy in the 1990s. Bradley JS, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S213–21 (58 ref.)

Recent evaluation of antimicrobial resistance in beta-hemolytic streptococci. Kaplan EL. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S89–92 (15 ref.)

Streptococcal pharyngitis: is penicillin still the right choice? Pichichero ME. **Compr Ther** 1996 Dec;22(12):782–7 (37 ref.)

Current concepts in the management of pharyngitis. Smith DS. **Compr Ther** 1996 Dec;22(12):806–9 (3 ref.)

Optimum treatment of streptococcal pharyngitis. Scaglione F, et al. **Drugs** 1997 Jan;53(1):86–97 (106 ref.)

The role of macrolides in Streptococcus pyogenes pharyngitis. Schito GC, et al. **J Antimicrob Chemother** 1997 May;39(5):562–5 (34 ref.)

Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media. Block SL. **Pediatr Infect Dis J** 1997 Apr;16(4):449–56 (39 ref.)

Macrolides in the management of streptococcal pharyngitis/tonsillitis. Tarlow MJ. **Pediatr Infect Dis J** 1997 Apr;16(4):444–8 (24 ref.)

[A case of liver abscess caused by Streptococcus milleri] Nagata S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Apr;94(4):290–4 (10 ref.) **(Jpn)**

ECONOMICS

The pediatric costs of strategies for minimizing the risk of early-onset group B streptococcal disease. Fargason CA Jr, et al. **Obstet Gynecol** 1997 Sep;90(3):347–52 (24 ref.)

EPIDEMIOLOGY

Horizontal gene transfer among group A streptococci: implications for pathogenesis and epidemiology. Kehoe MA, et al. **Trends Microbiol** 1996 Nov;4(11):436–43 (50 ref.)

ETIOLOGY

Peritoneal and pleural infection following placement of an internal biliary stent for a large bile leak. Weiss K, et al. **Am J Gastroenterol** 1997 Feb;92(2):347–8 (9 ref.)

Group G streptococcal arthritis: case report and review of the literature. Bronze MS, et al. **Am J Med Sci** 1997 Apr; 313(4):239–43 (33 ref.)

Group A beta-hemolytic streptococcal epiglottitis as a complication of varicella infection. Belfer RA. **Pediatr Emerg Care** 1996 Jun;12(3):203–4 (11 ref.)

Sore throat after sore throat after sore throat. Are you asking the critical questions? Pichich ro ME. **Postgrad Med** 1997 Jan;101(1):205–6, 209–12, 215–8, passim (22 ref.)

Horizontal gene transfer among group A streptococci: implications for pathogenesis and epidemiology. Kehoe MA, et al. **Trends Microbiol** 1996 Nov;4(11):436–43 (50 ref.)

[Invasive streptococcal group A infection] Riapis LA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Jan–Feb; (1):96–100 (18 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Psoriasis vulgaris, streptococci and the immune system: a riddle to be solved soon? Prinz JC. **Scand J Immunol** 1997 Jun;45(6):583–6 (30 ref.)

MICROBIOLOGY

AAP issues revised guidelines for the prevention of early-onset group B streptococcal infection. Rose VL. **Am Fam Physician** 1997 Sep 1;56(3):961, 965 (02 ref.)

Polymicrobial brain abscess in a patient infected with human immunodeficiency virus. Maniglia RJ, et al. **Clin Infect Dis** 1997 Mar;24(3):449–51 (12 ref.)

Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Stevens DL. **Emerg Infect Dis** 1995 Jul–Sep;1(3):69–78 (80 ref.)

Fatal Streptococcus viridans descending mediastinitis: case report and review of the literature. Berlot G, et al. **Eur J Emerg Med** 1997 Jun;4(2):111–4 (10 ref.)

The toxins of group A streptococcus, the flesh eating bacteria. Stevens DL. **Immunol Invest** 1997 Jan–Feb; 26(1–2):129–50 (74 ref.)

Streptococcal toxic shock syndrome in a postpartum woman. Case report and review of the literature. Jorup-Rönström C, et al. **Infection** 1996 Mar–Apr;24(2):164–7 (68 ref.)

Alpha-hemolytic streptococci: a major pathogen of iatrogenic meningitis following lumbar puncture. Case reports and a review of the literature. Schneeberger PM, et al. **Infection** 1996 Jan–Feb;24(1):29–33 (38 ref.)

Streptococcus B meningitis in post-partum. Guerin JM, et al. **J Infect** 1997 Mar;34(2):151–3 (14 ref.)

Group B streptococcal sepsis and meningitis complicated with severe sensorineural hearing loss in a fourteen-year-old boy. Likitnukul S, et al. **Pediatr Infect Dis J** 1996 May;15(5):468–70 (15 ref.)

Acute otitis media. Maxson S, et al. **Pediatr Rev** 1996 Jun; 17(6):191–5; quiz 196 (18 ref.)

[Skin infections due to Staphylococcus aureus and Streptococcus pyogenes] Arata J. **Nippon Rai Gakkai Zasshi** 1996 Jul;65(2):83–7 (10 ref.) **(Jpn)**

[Streptococcus equisimilis as the etiologic agent of endocarditis (letter)] Prada JL, et al. **Enferm Infecc Microbiol Clin** 1996 Apr;14(4):274–6 (10 ref.) **(Spa)**

PATHOLOGY

Platelet-streptococcal interactions in endocarditis. Herzberg MC. **Crit Rev Oral Biol Med** 1996;7(3):222–36 (117 ref.)

PREVENTION & CONTROL

AAP issues revised guidelines for the prevention of early-onset group B streptococcal infection. Rose VL. **Am Fam Physician** 1997 Sep 1;56(3):961, 965 (02 ref.)

Prevention of group B Streptococcus infection in neonates. Logsdon BA, et al. **Ann Pharmacother** 1997 Jul–Aug; 31(7–8):897–906 (68 ref.)

Management of healthcare workers with pharyngitis or suspected streptococcal infections. Weber DJ, et al. **Infect Control Hosp Epidemiol** 1996 Nov;17(11):753–61 (95 ref.)

Group B streptococcus in the perinatal period. A review. Clay LS. **J Nurse Midwifery** 1996 Sep–Oct;41(5):355–63 (69 ref.)

Prevention of early onset group B streptococcal sepsis in the newborn. Vigneswaran R, et al. **J Paediatr Child Health** 1995 Dec;31(6):493–4 (13 ref.)

Group B streptococcus and pregnancy: update and recommendations. Mitchell A, et al. **MCN Am J Matern Child Nurs** 1997 Sep–Oct;22(5):242–8 (16 ref.)

The pediatric costs of strategies for minimizing the risk of early-onset group B streptococcal disease. Fargason CA Jr, et al. **Obstet Gynecol** 1997 Sep;90(3):347–52 (24 ref.)

SURGERY

Treatment of brain abscess associated with ventricular rupture--three case reports. Isono M, et al. **Neurol Med Chir (Tokyo)** 1997 Aug;37(8):630–6 (23 ref.)

THERAPY

Adjunctive treatment of streptococcal toxic shock syndrome using intravenous immunoglobulin: case report and review. Perez CM, et al. **Am J Med** 1997 Jan;102(1):111–3 (15 ref.)

Group A Streptococcus invasive infections: a review. Weiss KA, et al. **Can J Surg** 1997 Feb;40(1):18–25 (44 ref.)

Management of neonates born to mothers with group B streptococcus colonization [published erratum appears in J Perinatol 1997 Mar–Apr;17(2):106] Alkalay AL, et al. **J Perinatol** 1996 Nov–Dec;16(6):470–7 (54 ref.)

TRANSMISSION

A household cluster of fulminant group A streptococcus pneumonia associated with toxic shock syndrome–Quebec. **Can Commun Dis Rep** 1996 Mar 15;22(6):41–3 (6 ref.)

ACOG committee opinion. Prevention of early-onset group B streptococcal disease in newborns. Number 173--June 1996. Committee on Obstetric Practice. American College of Obstetrics and Gynecologists. **Int J Gynaecol Obstet** 1996 Aug;54(2):197–205 (47 ref.)

The surgical team as a source of postoperative wound infections caused by Streptococcus pyogenes. Kolmos HJ, et al. **J Hosp Infect** 1997 Mar;35(3):207–14 (19 ref.)

Management of neonates born to mothers with group B streptococcus colonization [published erratum appears in

J Perinatol 1997 Mar-Apr;17(2):106] Alkalay AL, et al. **J Perinatol** 1996 Nov-Dec;16(6):470-7 (54 ref.)
Neonatal group B streptococcal disease. Mitchell A, et al. **MCN Am J Matern Child Nurs** 1997 Sep-Oct;22(5):249-53 (11 ref.)
Group B streptococcus and pregnancy. Mercer BM, et al. **Pediatr Ann** 1996 Apr;25(4):206-14 (93 ref.)

VETERINARY

Streptococcus agalactiae mastitis: a review. Keefe GP. **Can Vet J** 1997 Jul;38(7):429-37 (94 ref.)
Immunization with bacterial antigens: infections with streptococci and related organisms. Bercovier H, et al. **Dev Biol Stand** 1997;90:153-60 (25 ref.)
Streptococcus suis: past and present. Staats JJ, et al. **Vet Res Commun** 1997 Aug;21(6):381-407 (220 ref.)

STREPTOCOCCAL OK-432 see **PICIBANIL**

STREPTOCOCCAL PHAGES see **STREPTOCOCCUS PHAGES**

STREPTOCOCCAL PREPARATION OK-432 see **PICIBANIL**

STREPTOCOCCUS

Emerging resistance to antimicrobial agents in gram-positive bacteria. Enterococci, staphylococci and nonpneumococcal streptococci. Cormican MG, et al. **Drugs** 1996;51 Suppl 1:6-12 (38 ref.)

CHEMISTRY

The staphylococcal and streptococcal pyrogenic toxin family. Bohach GA, et al. **Adv Exp Med Biol** 1996;391:131-54 (116 ref.)

CLASSIFICATION

Taxonomical changes in intestinal (faecal) enterococci and streptococci: consequences on their use as indicators of faecal contamination in drinking water. Leclerc H, et al. **J Appl Bacteriol** 1996 Nov;81(5):459-66 (97 ref.)

DRUG EFFECTS

Recent evaluation of antimicrobial resistance in beta-hemolytic streptococci. Kaplan EL. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S89-92 (15 ref.)

ENZYMOLOGY

The phosphoenolpyruvate:sugar phosphotransferase system of oral streptococci and its role in the control of sugar metabolism. Vadeboncoeur C, et al. **FEMS Microbiol Rev** 1997 Feb;19(3):187-207 (107 ref.)

GENETICS

Streptococcal competence for genetic transformation: regulation by peptide pheromones. Morrison DA. **Microb Drug Resist** 1997 Spring;3(1):27-37 (86 ref.)
Structure, function and immunogenicity of streptococcal antigen I/II polypeptides. Jenkinson HF, et al. **Mol Microbiol** 1997 Jan;23(2):183-90 (33 ref.)

IMMUNOLOGY

Is psoriasis induced by streptococcal superantigens and maintained by M-protein-specific T cells that cross-react with keratin? Valdimarsson H, et al. **Clin Exp Immunol** 1997 Jan;107 Suppl 1:21-4 (28 ref.)
Immunization with bacterial antigens: infections with streptococci and related organisms. Bercovier H, et al. **Dev Biol Stand** 1997;90:153-60 (25 ref.)
Structure, function and immunogenicity of streptococcal antigen I/II polypeptides. Jenkinson HF, et al. **Mol Microbiol** 1997 Jan;23(2):183-90 (33 ref.)

ISOLATION & PURIFICATION

Deep neck infections. Marra S, et al. **Am J Otolaryngol** 1996 Sep-Oct;17(5):287-98 (15 ref.)
A case of bacteremia caused by Streptococcus dysgalactiae [letter] Bert F, et al. **Eur J Clin Microbiol Infect Dis** 1997 Apr;16(4):324-6 (10 ref.)
Alpha-hemolytic streptococci: a major pathogen of iatrogenic meningitis following lumbar puncture. Case reports and a review of the literature. Schneeberger PM, et al. **Infection** 1996 Jan-Feb;24(1):29-33 (38 ref.)

METABOLISM

[Streptococcal cytolysins] Nagamune H. **Seikagaku** 1997 May;69(5):343-8 (15 ref.) **(Jpn)**

PATHOGENICITY

[Streptococcus equisimilis as the etiologic agent of endocarditis (letter)] Prada JL, et al. **Enferm Infecc Microbiol Clin** 1996 Apr;14(4):274-6 (10 ref.) **(Spa)**

PHYSIOLOGY

Platelet-streptococcal interactions in endocarditis. Herzberg MC. **Crit Rev Oral Biol Med** 1996;7(3):222-36 (117 ref.)
Streptococcal adhesion and colonization. Jenkinson HF, et al. **Crit Rev Oral Biol Med** 1997;8(2):175-200 (189 ref.)

STREPTOCOCCUS AGALACTIAE

AAP issues revised guidelines for the prevention of early-onset group B streptococcal infection. Rose VL. **Am Fam Physician** 1997 Sep 1;56(3):961, 965 (02 ref.)
Prevention of group B Streptococcus infection in neonates. Logsdon BA, et al. **Ann Pharmacother** 1997 Jul-Aug; 31(7-8):897-906 (68 ref.)
Streptococcus agalactiae mastitis: a review. Keefe GP. **Can Vet J** 1997 Jul;38(7):429-37 (94 ref.)
Group B streptococcal infections. Baker CJ. **Clin Perinatol** 1997 Mar;24(1):59-70 (47 ref.)
Streptococcus B meningitis in post-partum. Guerin JM, et al. **J Infect** 1997 Mar;34(2):151-3 (14 ref.)
Group B streptococcus in the perinatal period. A review. Clay LS. **J Nurse Midwifery** 1996 Sep-Oct;41(5):355-63 (69 ref.)
Prevention of early onset group B streptococcal sepsis in the newborn. Vigneswaran R, et al. **J Paediatr Child Health** 1995 Dec;31(6):493-4 (13 ref.)
Management of neonates born to mothers with group B streptococcus colonization [published erratum appears in J Perinatol 1997 Mar-Apr;17(2):106] Alkalay AL, et al. **J Perinatol** 1996 Nov-Dec;16(6):470-7 (54 ref.)
Neonatal group B streptococcal disease. Mitchell A, et al. **MCN Am J Matern Child Nurs** 1997 Sep-Oct;22(5):249-53 (11 ref.)
Group B streptococcus and pregnancy: update and recommendations. Mitchell A, et al. **MCN Am J Matern Child Nurs** 1997 Sep-Oct;22(5):242-8 (16 ref.)
The pediatric costs of strategies for minimizing the risk of early-onset group B streptococcal disease. Fargason CA Jr, et al. **Obstet Gynecol** 1997 Sep;90(3):347-52 (24 ref.)
Group B streptococcus and pregnancy. Mercer BM, et al. **Pediatr Ann** 1996 Apr;25(4):206-14 (93 ref.)
Group B streptococcal endocarditis in children beyond the neonatal period. Alsoub H, et al. **Pediatr Infect Dis J** 1997 Apr;16(4):418-20 (11 ref.)
Group B streptococcal sepsis and meningitis complicated with severe sensorineural hearing loss in a fourteen-year-old boy. Likitnukul S, et al. **Pediatr Infect Dis J** 1996 May;15(5):468-70 (15 ref.)

ISOLATION & PURIFICATION

Septic sternoclavicular arthritis caused by group B Streptococcus: case report and review. Carrascosa M, et al. **Clin Infect Dis** 1996 Mar;22(3):579-80 (9 ref.)
ACOG committee opinion. Prevention of early-onset group B streptococcal disease in newborns. Number 173—June 1996. Committee on Obstetric Practice. American College of Obstetrics and Gynecologists. **Int J Gynaecol Obstet** 1996 Aug;54(2):197-205 (47 ref.)
Spontaneous group B streptococcal meningitis in a patient with cirrhosis. Tung BY, et al. **West J Med** 1996 Oct; 165(4):229-30 (13 ref.)
[Endocarditis caused by group B streptococci in adults] Marron A, et al. **Enferm Infecc Microbiol Clin** 1997 Mar; 15(3):147-50 (25 ref.) (Eng. Abstr.) **(Spa)**

STREPTOCOCCUS EQUI

ISOLATION & PURIFICATION

Pyogenic arthritis caused by streptococcus equisimilis (group-C streptococcus) in a patient with AIDS. Steinfeld S, et al. **Clin Rheumatol** 1997 May;16(3):314-6 (20 ref.)
Group C streptococcal infection in a term newborn infant. Faix RG, et al. **J Perinatol** 1997 Jan-Feb;17(1):79-82 (35 ref.)

STREPTOCOCCUS FAECALIS see **ENTEROCOCCUS FAECALIS**

STREPTOCOCCUS FAECIUM see **ENTEROCOCCUS FAECIUM**

STREPTOCOCCUS GROUP A see **STREPTOCOCCUS PYOGENES**

STREPTOCOCCUS GROUP B see **STREPTOCOCCUS AGALACTIAE**

STREPTOCOCCUS LACTIS see **LACTOCOCCUS LACTIS**

STREPTOCOCCUS MUTANS

A Streptococcus mutans Safari! Bratthall D. **J Dent Res** 1997 Jul;76(7):1332-6 (21 ref.)

DRUG EFFECTS

Mutans streptococci caries and chlorhexidine. Bowden GH. **J Can Dent Assoc** 1996 Sep;62(9):700, 703-7 (40 ref.)

PATHOGENICITY

[Characterization of virulence factors of mutans streptococci and specific inhibition of these factors] Hamada S. **Nippon Saikingaku Zasshi** 1996 Oct;51(4):931-51 (106 ref.) **(Jpn)**

STREPTOCOCCUS PHAGES

GENETICS

Bacteriophages of Streptococcus pneumoniae: a molecular approach. García P, et al. **Microb Drug Resist** 1997 Summer;3(2):165-76 (69 ref.)

STREPTOCOCCUS PNEUMONIAE

see related
PNEUMOCOCCAL INFECTIONS

Prosthetic valve endocarditis due to Streptococcus pneumoniae [letter] Collazos J, et al. **Arch Intern Med** 1996 Oct 14;156(18):2141, 2146, 2148 (10 ref.)
The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: current antibiotic therapy in the 1990s. Bradley JS, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S213-21 (58 ref.)
Genetics and molecular biology of beta-lactam-resistant pneumococci. Coffey TJ, et al. **Microb Drug Resist** 1995 Spring;1(1):29-34 (39 ref.)
Antibiotic-resistant pneumococci in pediatric disease. Klugman KP, et al. **Microb Drug Resist** 1995 Spring; 1(1):5-8 (31 ref.)
[Pneumococcal endocarditis of the tricuspid valve. A case report with review of the literature] Holm M, et al. **Tidsskr Nor Laegeforen** 1997 Feb 28;117(6):815-7 (8 ref.) (Eng. Abstr.) **(Nor)**

CLASSIFICATION

Pan American Health Organization epidemiological surveillance network for Streptococcus pneumoniae. di Fabio JL, et al. **Microb Drug Resist** 1997 Summer; 3(2):131-3 (4 ref.)
[Purulent meningitis in an adult patient caused by multi-drug resistant Streptococcus pneumoniae 19A] Vukmirovits G, et al. **Orv Hetil** 1996 Jul 21;137(29):1587-90 (28 ref.) (Eng. Abstr.) **(Hun)**

DRUG EFFECTS

Antibiotic-resistance in Streptococcus pneumoniae. Krisher K. **Adv Exp Med Biol** 1995;390:123-40 (102 ref.)
Resistant pneumococci: protecting patients through judicious use of antibiotics [see comments] Dowell SF, et al. **Am Fam Physician** 1997 Apr;55(5):1647-54, 1657-8 (33 ref.)
Comment in: Am Fam Physician 1997 Apr;55(5):1535-6.
The antibiotic selective process: concentration-specific amplification of low-level resistant populations. Baquero F, et al. **Ciba Found Symp** 1997;207:93-105; discussion 105-11 (27 ref.)
Antibiotic resistance in Streptococcus pneumoniae. Tomasz A. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S85-8 (22 ref.)
The emerging role of multi-drug-resistant Streptococcus pneumoniae--a cause for concern [editorial] Koay B, et al. **Clin Otolaryngol** 1996 Aug;21(4):289-91 (36 ref.)
Streptococcus pneumoniae: impact of antibiotic resistance in pediatrics. Kaplan SL. **Curr Probl Pediatr** 1997 May-Jun; 27(5):187-95 (74 ref.)
Emerging resistance to antimicrobial agents in gram-positive bacteria. Pneumococci. Appelbaum PC. **Drugs** 1996;51 Suppl 1:1-5 (17 ref.)
New prospects for antibacterial agents against multidrug-resistant pneumococci. Appelbaum PC. **Microb Drug Resist** 1995 Spring;1(1):43-8 (42 ref.)
Pneumococcal resistance to beta-lactam antibiotics: a global geographic overview. Baquero F. **Microb Drug Resist** 1995 Summer;1(2):115-20 (16 ref.)
Effect of antimicrobial use and other risk factors on antimicrobial resistance in pneumococci. Kristinsson KG. **Microb Drug Resist** 1997 Summer;3(2):117-23 (70 ref.)
Antimicrobial-drug resistance. Gold HS, et al. **N Engl J Med** 1996 Nov 7;335(19):1445-53 (104 ref.)
Epidemiology and in vitro susceptibility of drug-resistant Streptococcus pneumoniae. Appelbaum PC. **Pediatr Infect Dis J** 1996 Oct;15(10):932-4 (65 ref.)
Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media. Block SL. **Pediatr Infect Dis J** 1997 Apr;16(4):449-56 (39 ref.)
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Craig WA, et al. **Pediatr Infect Dis J** 1996 Mar;15(3):255-9 (30 ref.)
Antibiotic resistant Streptococcus pneumoniae. Minton EJ, et al. **Thorax** 1996 Aug;51 Suppl 2:S45-50 (57 ref.)
[Macrolide antibiotics: Streptococcus pneumoniae and Haemophilus influenzae] Soriano F, et al. **Enferm Infecc Microbiol Clin** 1996 Oct;14(8):503-4 (7 ref.) **(Spa)**

GENETICS

Immunologic epitope, gene, and immunity involved in pneumococcal glycoconjugate. Lee CJ, et al. **Crit Rev Microbiol** 1997;23(2):121-42 (131 ref.)
Molecular biology of the capsular genes of Streptococcus pneumoniae. García E, et al. **FEMS Microbiol Lett** 1997 Apr 1;149(1):1-10 (39 ref.)
A functional analysis of the Streptococcus pneumoniae genes involved in the synthesis of type 1 and type 3 capsular

STREPTOCOCCUS PNEUMONIAE

polysaccharides. García E, et al. **Microb Drug Resist** 1997 Spring;3(1):73–88 (112 ref.)

Control of recombination rate during transformation of Streptococcus pneumoniae: an overview. Mortier-Barriere I, et al. **Microb Drug Resist** 1997 Fall;3(3):233–42 (53 ref.)

Characterization of the capsular polysaccharide biosynthesis locus of Streptococcus pneumoniae type 19F. Paton JC, et al. **Microb Drug Resist** 1997 Spring;3(1):89–99 (40 ref.)

[Penicillin-resistant mechanisms of Streptococcus pneumoniae] Ubukata K, et al. **Nippon Rinsho** 1997 May; 55(5):1213–8 (6 ref.) **(Jpn)**

IMMUNOLOGY

Belgian consensus on pneumococcal vaccine.Working Party on Pneumococcal Vaccine. **Acta Clin Belg** 1996;51(5):350–6 (18 ref.)

Systemic and mucosal protective immunity to pneumococcal surface protein A. Briles DE, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:118–26 (42 ref.)

Immunologic epitope, gene, and immunity involved in pneumococcal glycoconjugate. Lee CJ, et al. **Crit Rev Microbiol** 1997;23(2):121–42 (131 ref.)

New vaccines for the prevention of pneumococcal infections. Käyhty H, et al. **Emerg Infect Dis** 1996 Oct-Dec; 2(4):289–98 (74 ref.)

Autosplenectomy in systemic lupus erythematosus. Uthman I, et al. **J Rheumatol** 1996 Oct;23(10):1806–10 (18 ref.)

ISOLATION & PURIFICATION

Microbiology and management of sinusitis. Brook I. **J Otolaryngol** 1996 Aug;25(4):249–56 (44 ref.)

METABOLISM

A functional analysis of the Streptococcus pneumoniae genes involved in the synthesis of type 1 and type 3 capsular polysaccharides. García E, et al. **Microb Drug Resist** 1997 Spring;3(1):73–88 (112 ref.)

The pneumococcal cell wall degrading enzymes: a modular design to create new lysins? López R, et al. **Microb Drug Resist** 1997 Summer;3(2):199–111 (73 ref.)

Characterization of the capsular polysaccharide biosynthesis locus of Streptococcus pneumoniae type 19F. Paton JC, et al. **Microb Drug Resist** 1997 Spring;3(1):89–99 (40 ref.)

PATHOGENICITY

Molecular and cellular mechanisms of pneumococcal meningitis. Tuomanen EI. **Ann N Y Acad Sci** 1996 Oct 25;797:42–52 (66 ref.)

The contribution of pneumolysin to the pathogenicity of Streptococcus pneumoniae. Paton JC. **Trends Microbiol** 1996 Mar;4(3):103–6 (32 ref.)

PHYSIOLOGY

PAf receptor anchors Streptococcus pneumoniae to activated human endothelial cells. Cundell DR, et al. **Adv Exp Med Biol** 1996;416:89–94 (15 ref.)

The enduring pneumococcus: unfinished business and opportunities for the future. Austrian R. **Microb Drug Resist** 1997 Summer;3(2):111–5 (50 ref.)

STREPTOCOCCUS PNEUMONIAE INFECTIONS see **PNEUMOCOCCAL INFECTIONS**

STREPTOCOCCUS PYOGENES

Necrotizing fasciitis: a diagnostic challenge. Meltzer DL, et al. **Am Fam Physician** 1997 Jul;56(1):145–9 (14 ref.)

Adjunctive treatment of streptococcal toxic shock syndrome using intravenous immunoglobulin: case report and review. Perez CM, et al. **Am J Med** 1997 Jan;102(1):111–3 (15 ref.)

Reconsidering sore throats. Part 2: Alternative approach and practical office tool [see comments] McIsaac WJ, et al. **Can Fam Physician** 1997 Mar;43:495–500 (40 ref.) Comment in: Can Fam Physician 1997 May;43:843, 845. Comment in: Can Fam Physician 1997 Jul;43:1207–8.

Reconsidering sore throats. Part I: Problems with current clinical practice [see comments] McIsaac WJ, et al. **Can Fam Physician** 1997 Mar;43:485–93 (62 ref.) Comment in: Can Fam Physician 1997 May;43:843, 845. Comment in: Can Fam Physician 1997 Jul;43:1207–8.

Streptococcal pharyngitis: is penicillin still the right choice? Pichichero ME. **Compr Ther** 1996 Dec;22(12):782–7 (37 ref.)

Update on complications of group A streptococcal infections. Ayoub EM, et al. **Curr Probl Pediatr** 1997 Mar;27(3):90–101 (87 ref.)

Invasive group A streptococcal disease. Stevens DL. **Infect Agents Dis** 1996 Jun;5(3):157–66 (48 ref.)

Management of healthcare workers with pharyngitis or suspected streptococcal infections. Weber DJ, et al. **Infect Control Hosp Epidemiol** 1996 Nov;17(11):753–61 (95 ref.)

Streptococcal toxic shock syndrome in a postpartum woman. Case report and review of the literature. Jorup-Rönström C, et al. **Infection** 1996 Mar-Apr;24(2):164–7 (68 ref.)

The role of macrolides in Streptococcus pyogenes pharyngitis. Schito GC, et al. **J Antimicrob Chemother** 1997 May;39(5):562–5 (34 ref.)

The surgical team as a source of postoperative wound infections caused by Streptococcus pyogenes. Kolmos HJ, et al. **J Hosp Infect** 1997 Mar;35(3):207–14 (19 ref.)

Management of group A streptococcus pharyngitis with a second-generation rapid strep screen: Strep A OIA. Badgett JT, et al. **Microb Drug Resist** 1996 Fall;2(3):371–6 (54 ref.)

Group A beta-hemolytic streptococcal epiglottitis as a complication of varicella infection. Belfer RA. **Pediatr Emerg Care** 1996 Jun;12(3):203–4 (11 ref.)

Balanitis caused by group A beta-hemolytic streptococci. Orden B, et al. **Pediatr Infect Dis J** 1996 Oct;15(10):920–1 (10 ref.)

Sore throat after sore throat after sore throat. Are you asking the critical questions? Pichichero ME. **Postgrad Med** 1997 Jan;101(1):205–6, 209–12, 215–8, passim (22 ref.)

[How to recognize streptococcal pharyngitis? (editorial)] Ghanassia JP, et al. **Arch Pediatr** 1996 Aug;3(8):749–51 (17 ref.) **(Fre)**

[Invasive streptococcal group A infection] Riapis LA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Jan-Feb; (1):96–100 (18 ref.) (Eng. Abstr.) **(Rus)**

[Streptococcal perianal disease] García Puga JM, et al. **An Esp Pediatr** 1996 Dec;45(6):647–8 (19 ref.) **(Spa)**

[Streptococcal pharyngitis] Romero J, et al. **Enferm Infecc Microbiol Clin** 1995 Dec;13(10):611–27 (204 ref.) **(Spa)**

DRUG EFFECTS

Streptococcus pyogenes: resistant, tolerant, neither or both? Mortensen JE, et al. **Adv Exp Med Biol** 1995;390:109–17 (63 ref.)

GENETICS

Streptococcus pyogenes: resistant, tolerant, neither or both? Mortensen JE, et al. **Adv Exp Med Biol** 1995;390:109–17 (63 ref.)

Streptococcal superantigen, mitogenic factor, and pyrogenic exotoxin B expressed by Streptococcus pyogenes. Structure and function. Musser JM. **Prep Biochem Biotechnol** 1997 May-Aug;27(2–3):143–72 (141 ref.)

Horizontal gene transfer among group A streptococci: implications for pathogenesis and epidemiology. Kehoe MA, et al. **Trends Microbiol** 1996 Nov;4(11):436–43 (50 ref.)

IMMUNOLOGY

Group A streptococcal adhesion. All of the theories are correct. Hasty DL, et al. **Adv Exp Med Biol** 1996;408:81–94 (75 ref.)

Changing streptococci and prospects for the global eradication of rheumatic fever. Stollerman GH. **Perspect Biol Med** 1997 Winter;40(2):165–89 (113 ref.)

Psoriasis vulgaris, streptococci and the immune system: a riddle to be solved soon? Prinz JC. **Scand J Immunol** 1997 Jun;45(6):583–6 (30 ref.)

[Group A Streptococcus and autoimmune] Ohkuni H. **Ryumachi** 1996 Dec;36(6):874–83 (36 ref.) **(Jpn)**

ISOLATION & PURIFICATION

Neonatal pleural empyema with group A Streptococcus. Thaarup J, et al. **Acta Paediatr** 1997 Jul;86(7):769–71 (17 ref.)

A household cluster of fulminant group A streptococcus pneumonia associated with toxic shock syndrome-Quebec. **Can Commun Dis Rep** 1996 Mar 15;22(6):41–3 (6 ref.)

Group A Streptococcus invasive infections: a review. Weiss KA, et al. **Can J Surg** 1997 Feb;40(1):18–25 (44 ref.)

Bacterial L-forms research in China. Huang G, et al. **Chin Med J (Engl)** 1996 Jan;109(1):18–20 (0 ref.)

Group A streptococcal bacteremia. A 10-year prospective study. Bernaldo de Quirós JC, et al. **Medicine (Baltimore)** 1997 Jul;76(4):238–48 (94 ref.)

METABOLISM

Proteins F1 and F2 of Streptococcus pyogenes. Properties of fibronectin binding. Hanski E, et al. **Adv Exp Med Biol** 1996;408:141–50 (23 ref.)

PATHOGENICITY

Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Stevens DL. **Emerg Infect Dis** 1995 Jul-Sep;1(3):69–78 (80 ref.)

The toxins of group A streptococcus, the flesh eating bacteria. Stevens DL. **Immunol Invest** 1997 Jan-Feb; 26(1–2):129–50 (74 ref.)

Streptococcal superantigen, mitogenic factor, and pyrogenic exotoxin B expressed by Streptococcus pyogenes. Structure and function. Musser JM. **Prep Biochem Biotechnol** 1997 May-Aug;27(2–3):143–72 (141 ref.)

[Role of the M protein of Streptococcus pyogenes and its regulation] Okada N. **Nippon Saikingaku Zasshi** 1996 Feb; 51(2):571–81 (44 ref.) **(Jpn)**

STREPTOCOCCUS SANGUIS

Streptococcus sanguis bacteremia associated with cecal carcinoma: case report and review of the literature. Marinella MA. **Am J Gastroenterol** 1997 Sep;92(9):1541–2 (12 ref.)

[Aortic valve perforation] Shu T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):415–20 (16 ref.) **(Jpn)**

IMMUNOLOGY

[Behçet's disease and streptococcal antigens] Yoshikawa K, et al. **Nippon Ganka Gakkai Zasshi** 1996 Mar;100(3):173–80 (47 ref.) (Eng. Abstr.) **(Jpn)**

STREPTOCOCCUS SOBRINUS

IMMUNOLOGY

Anti-adhesins of Streptococcus sobrinus. Wang Q, et al. **Adv Exp Med Biol** 1996;408:249–62 (48 ref.)

STREPTOCOCCUS SUIS

Streptococcus suis: past and present. Staats JJ, et al. **Vet Res Commun** 1997 Aug;21(6):381–407 (220 ref.)

IMMUNOLOGY

The Gal alpha 1–4 Gal-binding adhesin of Streptococcus suis, a gram-positive meningitis-associated bacterium. Haataja S, et al. **Adv Exp Med Biol** 1996;408:25–34 (21 ref.)

ISOLATION & PURIFICATION

Infective endocarditis due to Streptococcus suis serotype 2 [letter] Tayoro J, et al. **Eur J Clin Microbiol Infect Dis** 1996 Sep;15(9):765–6 (10 ref.)

STREPTOCOCCUS ZOOEPIDEMICUS see **STREPTOCOCCUS EQUI**

STREPTODORNASE see **DEOXYRIBONUCLEASE I**

STREPTOGRAMIN see **VIRGINIAMYCIN**

STREPTOKINASE

ADVERSE EFFECTS

[Spontaneous liver rupture after thrombolytic therapy with streptokinase] Hinterthaner M, et al. **Zentralbl Chir** 1997; 122(1):49–51 (20 ref.) (Eng. Abstr.) **(Ger)**

[Pulmonary hemorrhage after thrombolysis in acute myocardial infarct (letter) (corrected and republished letter originally printed in An Med Interna 1996 Oct;13(10):514–5)] Rodríguez Blanco VM, et al. **An Med Interna** 1997 Apr;14(4):209 (7 ref.) **(Spa)**

THERAPEUTIC USE

Report of two cases of children with Budd-Chiari syndrome successfully treated with streptokinase. Sawamura R, et al. **Arq Gastroenterol** 1996 Jul-Sep;33(3):179–81 (31 ref.)

Heparin and streptokinase [editorial; comment] Sobel BE. **Cardiovasc Drugs Ther** 1997 Apr;11(2):97–100 (31 ref.) Comment on: Cardiovasc Drugs Ther 1997 Apr;11(2):101–9. Comment on: Cardiovasc Drugs Ther 1997 Apr;11(2):111–9.

Thrombolysis after acute myocardial infarction. Nee PA. **J Accid Emerg Med** 1997 Jan;14(1):2–9 (49 ref.)

Comparison of streptokinase and urokinase in local thrombolysis of peripheral arterial occlusions for lower limb salvage. Dubé M, et al. **J Vasc Interv Radiol** 1996 Jul-Aug;7(4):587–93 (25 ref.)

Thrombolytic therapy in acute ischaemic stroke: the jury needs more evidence. Hankey GJ. **Med J Aust** 1997 Apr 21;166(8):419–22 (27 ref.)

Controlled trials comparing reteplase with alteplase and streptokinase in patients with acute myocardial infarction. Amsterdam EA. **Pharmacotherapy** 1996 Sep-Oct;16(5 Pt 2):137S–140S (9 ref.)

Superior vena cava thrombosis secondary to hickman catheter and complete resolution after fibrinolytic therapy. Morales M, et al. **Support Care Cancer** 1997 Jan;5(1):67–9 (8 ref.)

[Bolus thrombolysis in pulmonary embolism. Review of experimental and clinical data] Zonzin P, et al. **Ann Ital Med Int** 1996 Apr-Jun;11(2):132–7 (35 ref.) (Eng. Abstr.) **(Ita)**

[Thrombolysis in acute ischemic attack] Dávalos A. **Rev Neurol** 1997 Feb;25(138):281–2 (9 ref.) **(Spa)**

STREPTOLYSINS

[Streptococcal cytolysins] Nagamune H. **Seikagaku** 1997 May;69(5):343–8 (15 ref.) **(Jpn)**

PHYSIOLOGY

Relationship of structure of function in pneumolysin. Andrew PW, et al. **Microb Drug Resist** 1997 Spring;3(1):11–7 (49 ref.)

Biological properties of pneumolysin. Mitchell TJ, et al. **Microb Drug Resist** 1997 Spring;3(1):19–26 (56 ref.)

The contribution of pneumolysin to the pathogenicity of Streptococcus pneumoniae. Paton JC. **Trends Microbiol** 1996 Mar;4(3):103–6 (32 ref.)

STREPTOMYCES

ENZYMOLOGY

Bacterial signalling involving eukaryotic-type protein

kinases. Zhang CC. **Mol Microbiol** 1996 Apr;20(1):9–15 (32 ref.)

GENETICS

Applications of transposition mutagenesis in antibiotic producing streptomycetes. Baltz RH, et al. **Antonie Van Leeuwenhoek** 1997 Feb;71(1-2):179–87 (39 ref.)

METABOLISM

Applications of transposition mutagenesis in antibiotic producing streptomycetes. Baltz RH, et al. **Antonie Van Leeuwenhoek** 1997 Feb;71(1-2):179–87 (39 ref.)

Carbon metabolism and its regulation in Streptomyces and other high GC gram-positive bacteria. Paulsen IT. **Res Microbiol** 1996 Jul-Sep;147(6-7):535–41 (42 ref.)

[Biosynthesis of avermectins: physiological and technological aspects] Mironov VA, et al. **Antibiot Khimioter** 1997; 42(3):31–6 (24 ref.) **(Rus)**

PHYSIOLOGY

Constitution of the metabolic type of streptomycetes during the first hours of cultivation. Janeček J, et al. **Folia Microbiol (Praha)** 1997;42(2):75–96 (120 ref.)

STREPTOMYCETACEAE

CHEMISTRY

Protein secretion in streptomycetes. Morosoli R, et al. **FEMS Microbiol Lett** 1997 Jan 15;146(2):167–74 (35 ref.)

GENETICS

[Streptomycete genetics, basis for the production of new antibiotics] Bechtold A. **Pharm Unserer Zeit** 1997 Jan; 26(1):12–6 (22 ref.) **(Ger)**

METABOLISM

[Streptomycete genetics, basis for the production of new antibiotics] Bechtold A. **Pharm Unserer Zeit** 1997 Jan; 26(1):12–6 (22 ref.) **(Ger)**

STREPTOMYCIN

ADMINISTRATION & DOSAGE

Use of streptomycin-lidocaine injections in the treatment of the cluster-tic syndrome. Clinical perspectives and a case report. Kreiner M. **J Craniomaxillofac Surg** 1996 Oct; 24(5):289–92 (48 ref.)

BIOSYNTHESIS

Constitution of the metabolic type of streptomycetes during the first hours of cultivation. Janeček J, et al. **Folia Microbiol (Praha)** 1997;42(2):75–96 (120 ref.)

PHARMACOLOGY

Dissemination of the strA-strB streptomycin-resistance genes among commensal and pathogenic bacteria from humans, animals, and plants. Sundin GW, et al. **Mol Ecol** 1996 Feb; 5(1):133–43 (100 ref.)

THERAPEUTIC USE

Very high-dose streptomycin labyrinthectomy. Sataloff RT, et al. **Ear Nose Throat J** 1996 Apr;75(4):239–43 (20 ref.)

STREPTOZOCIN DIABETES see **DIABETES MELLITUS, EXPERIMENTAL**

STREPTOZOTOCIN DIABETES see **DIABETES MELLITUS, EXPERIMENTAL**

STRESS

see related
GENERAL ADAPTATION SYNDROME

Culture as a stressor: a revised model of biocultural interaction. Schell LM. **Am J Phys Anthropol** 1997 Jan; 102(1):67–77 (49 ref.)

The stress activated protein kinase pathway. Woodgett JR, et al. **Cancer Surv** 1996;27:127–38 (41 ref.)

Neuronal circuit regulation of the hypothalamo-pituitary-adrenocortical stress axis. Herman JP, et al. **Crit Rev Neurobiol** 1996;10(3-4):371–94 (206 ref.)

Apoptosis: does stress kill? Cosulich S, et al. **Curr Biol** 1996 Dec 1;6(12):1586–8 (18 ref.)

Heat-shock induced protein modifications and modulation of enzyme activities. Bensaude O, et al. **EXS** 1996; 77:199–219 (151 ref.)

Viral infection. Santoro MG. **EXS** 1996;77:337–57 (103 ref.)

Sensing stress and responding to stress. Voellmy R. **EXS** 1996;77:121–37 (73 ref.)

Stress-inducible cellular responses. Introduction. Yahara I. **EXS** 1996;77:XI–XII (0 ref.)

Cultural discourse and the myth of stress in nursing and medicine. Mulhall A. **Int J Nurs Stud** 1996 Oct; 33(5):455–68 (75 ref.)

Romanian contribution to stress research. Derevenco P. **Rom J Physiol** 1996 Jan-Dec;33(1-4):101–12 (60 ref.)

[Stress and skin: experimental approach] Gauthier Y. **Pathol Biol (Paris)** 1996 Dec;44(10):882–7 (30 ref.) (Eng. Abstr.) **(Fre)**

[Merit of surgical stress suppression--special reference to epidural and intravenous anesthesia in view of endocrine systems] Ishihara H. **Masui** 1996 Dec;45 Suppl:S51–5 (13 ref.) **(Jpn)**

[How does Staphylococcus aureus adapt to environmental stresses?] Ohta T. **Nippon Saikingaku Zasshi** 1996 Feb; 51(2):627–33 (14 ref.) **(Jpn)**

[Stress response of pathogenic bacteria--are stress proteins virulence factors?] Yamamoto T. **Nippon Saikingaku Zasshi** 1996 Oct;51(4):1025–36 (15 ref.) **(Jpn)**

[Regulation of plant MAP kinase cascade by environmental stresses and plant hormones] Ichimura K, et al. **Tanpakushitsu Kakusan Koso** 1997 Apr;42(5):706–16 (53 ref.) **(Jpn)**

[Tobacco PMSAP kinase is transiently activated by wounding] Usami S, et al. **Tanpakushitsu Kakusan Koso** 1997 Apr;42(5):717–26 (28 ref.) **(Jpn)**

[Morphology of myocardial adaptive responses to extreme environmental factors] Nepomniashchikh LM. **Vestn Ross Akad Med Nauk** 1997;(3):49–54 (42 ref.) (Eng. Abstr.) **(Rus)**

COMPLICATIONS

Current management of patients with stress ulceration. O'Keefe G, et al. **Adv Surg** 1996;30:155–77 (95 ref.)

The role of early adverse life events in the etiology of depression and posttraumatic stress disorder. Focus on corticotropin-releasing factor. Heim C, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:194–207 (92 ref.)

Chronic fatigue syndrome: a stress disorder? Cleare AJ, et al. **Br J Hosp Med** 1996 May 1-14;55(9):571–4 (26 ref.)

Potential role of stress and sensitization in the development and expression of multiple chemical sensitivity. Sorg BA, et al. **Environ Health Perspect** 1997 Mar;105 Suppl 2:467–71 (46 ref.)

Multiple sclerosis: an altered immune response or an altered stress response? van Noort JM. **J Mol Med** 1996 Jun; 74(6):285–96 (49 ref.)

Stress, stress reduction, and hypertension in African Americans: an updated review. Barnes V, et al. **J Natl Med Assoc** 1997 Jul;89(7):464–76 (139 ref.)

A review of stress ulcer prophylaxis in the neurosurgical intensive care unit. Lu WY, et al. **Neurosurgery** 1997 Aug; 41(2):416–25; discussion 425–6 (150 ref.)

Catecholamines, stress, and disease: a psychobiological perspective. McCarty R, et al. **Psychosom Med** 1996 Nov-Dec;58(6):590–7 (79 ref.)

[Stress research between molecular and supra-molecular observations] Oehme P, et al. **Med Monatsschr Pharm** 1996 Sep;19(9):270–4 (7 ref.) **(Ger)**

[Stress and cognition] Spitzer M. **Med Monatsschr Pharm** 1996 Oct;19(10):295–308 (64 ref.) **(Ger)**

DIAGNOSIS

[Measurement of stress response during surgery and anesthesia] Ninomiya S, et al. **Masui** 1996 Dec;45 Suppl:S38–43 (4 ref.) **(Jpn)**

ENZYMOLOGY

Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion. Bogoyevitch MA, et al. **Circ Res** 1996 Aug;79(2):162–73 (108 ref.)

Sounding the alarm: protein kinase cascades activated by stress and inflammation. Kyriakis JM, et al. **J Biol Chem** 1996 Oct 4;271(40):24313–6 (78 ref.)

ETIOLOGY

Passenger safety, health, and comfort: a review. Rayman RB. **Aviat Space Environ Med** 1997 May;68(5):432–40 (43 ref.)

Unrelieved job stress can lead to burnout. Clarke S, et al. **Radiol Technol** 1996 Nov-Dec;68(2):159–60 (9 ref.)

[Adaptation to weightlessness and stress] Grigor'ev AI, et al. **Aviakosm Ekolog Med** 1996;30(3):4–8 (53 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

The stress gene response in brain. Massa SM, et al. **Cerebrovasc Brain Metab Rev** 1996 Summer;8(2):95–158 (402 ref.)

Genetic analyses of emotionality. Eley TC, et al. **Curr Opin Neurobiol** 1997 Apr;7(2):279–84 (38 ref.)

The limit to human longevity: an approach through a stress theory of ageing. Parsons PA. **Mech Ageing Dev** 1996 Jun 25;87(3):211–8 (46 ref.)

Regulation of translational initiation during cellular responses to stress. Brostrom CO, et al. **Prog Nucleic Acid Res Mol Biol** 1998;58:79–125 (203 ref.)

IMMUNOLOGY

A suppressive protein generated in peripheral lymph tissue induced by restraint stress. Fan SG, et al. **Adv Neuroimmunol** 1996;6(3):279–88 (44 ref.)

Pro-opiomelanocortin-derived peptides, cytokines, and nitric oxide in immune responses and stress: an evolutionary approach. Ottaviani E, et al. **Int Rev Cytol** 1997;170:79–141 (400 ref.)

The neuroimmunology of stress from invertebrates to man [published erratum appears in Prog Neurobiol 1996 Jun;49(3):285] Ottaviani E, et al. **Prog Neurobiol** 1996 Mar-Apr;48(4-5):421–40 (103 ref.)

Psychoneuroimmunology: animal models of disease. Moynihan JA, et al. **Psychosom Med** 1996 Nov-Dec; 58(6):546–58 (114 ref.)

[Local immune response to surgical stress] Hosokawa T. **Masui** 1996 Dec;45 Suppl:S31–7 (27 ref.) **(Jpn)**

METABOLISM

Stress hormones, genotype, and brain organization. Implications for aggression. De Kloet ER, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:179–91 (65 ref.)

Early environmental regulation of forebrain glucocorticoid receptor gene expression: implications for adrenocortical responses to stress. Meaney MJ, et al. **Dev Neurosci** 1996; 18(1-2):49–72 (138 ref.)

The cellular stress response to exercise: role of stress proteins. Locke M. **Exerc Sport Sci Rev** 1997;25:105–36 (192 ref.)

Acid stress responses in enterobacteria. Bearson S, et al. **FEMS Microbiol Lett** 1997 Feb 15;147(2):173–80 (39 ref.)

Simulated weightlessness to induce chronic hypoactivity of brain norepinephrine for exercise and stress studies. Sothmann M, et al. **Med Sci Sports Exerc** 1997 Jan; 29(1):39–44 (42 ref.)

Corticotropin-releasing factor (CRF) and endocrine responses to stress: CRF receptors, binding protein, and related peptides. Turnbull AV, et al. **Proc Soc Exp Biol Med** 1997 May;215(1):1–10 (114 ref.)

Regulation of lipid biosynthesis by the AMP-activated protein kinase and its role in the hepatocellular response to stress. Corton JM, et al. **Prog Liver Dis** 1996;14:69–99 (133 ref.)

The heat shock stress response after brain lesions: induction of 72 kDa heat shock protein (cell types involved, axonal transport, transcriptional regulation) and protein synthesis inhibition. Planas AM, et al. **Prog Neurobiol** 1997 Apr; 51(6):607–36 (256 ref.)

Stress versus depression. Lechin F, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Aug; 20(6):899–950 (215 ref.)

Regulation of translational initiation during cellular responses to stress. Brostrom CO, et al. **Prog Nucleic Acid Res Mol Biol** 1998;58:79–125 (203 ref.)

[Energy substrate metabolism during stress] Sugimoto H. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):726–32 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Free radicals and surgical stress] Yukioka T, et al. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):716–20 (11 ref.) (Eng. Abstr.) **(Jpn)**

PARASITOLOGY

Effects of osmotic stress on metabolism, shape, and amino acid content of Leishmania. Blum JJ. **Biol Cell** 1996; 87(1-2):9–16 (63 ref.)

PATHOLOGY

Stress-induced apoptosis and the sphingomyelin pathway. Peña LA, et al. **Biochem Pharmacol** 1997 Mar 7; 53(5):615–21 (63 ref.)

PHYSIOPATHOLOGY

Neuroendocrine response during stress with relation to gender differences. Ježová D, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(3):779–85 (44 ref.)

Stress and nutritional influences on GnRH and somatostatin neuronal systems in the ewe. Polkowska J. **Acta Neurobiol Exp (Warsz)** 1996;56(3):797–806 (38 ref.)

The stress response and its role in cellular defense mechanisms after ischemia. Abe H, et al. **Adv Neurol** 1996; 71:451–66; discussion 466–7 (141 ref.)

The stress response and the lung. Wong HR, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):L1–9 (94 ref.)

Decreasing the burden of trauma for victims of violence. Kaufmann MC. **Ann Emerg Med** 1997 Aug;30(2):199–203 (31 ref.)

Microneurography as a tool to investigate sympathetic nerve responses to environmental stress. Mano T. **Aviakosm Ekolog Med** 1997;31(1):8–14 (48 ref.)

Resilience in highly stressed urban children: concepts and findings. Cowen EL, et al. **Bull N Y Acad Med** 1996 Winter; 73(2):267–84 (46 ref.)

Novel estrogen feedback sites associated with stress-induced suppression of luteinizing hormone secretion in female rats. Maeda K, et al. **Cell Mol Neurobiol** 1996 Jun;16(3):311–24 (32 ref.)

Peripheral benzodiazepine receptors: molecular pharmacology to possible physiological significance in stress-induced hypertension. Drugan RC. **Clin Neuropharmacol** 1996 Dec;19(6):475–96 (157 ref.)

Nutritional modulation of somatotropic axis-cytokine relationships in cattle: a brief review. Elsasser TH, et al. **Comp Biochem Physiol A Physiol** 1997 Mar;116(3):209–21 (88 ref.)

The amygdala: corticotropin-releasing factor, steroids, and

stress. Gray TS, et al. **Crit Rev Neurobiol** 1996;10(2):155–68 (109 ref.)

The role of mesoprefrontal dopamine neurons in stress. Horger BA, et al. **Crit Rev Neurobiol** 1996;10(3–4):395–418 (232 ref.)

Stress activated cytokines and the heart. Mann DL. **Cytokine Growth Factor Rev** 1996 Dec;7(4):341–54 (126 ref.)

Noise stress and airway toxicity: a prospect for experimental analysis. Van Raaij MT, et al. **Food Chem Toxicol** 1996 Nov–Dec;34(11–12):1159–61 (15 ref.)

The role of cytokines in cardiac surgery. Tønnesen E, et al. **Int J Cardiol** 1996 Apr 26;53 Suppl:S1–10 (77 ref.)

Role of prostaglandins in the stimulation of the hypothalamic–pituitary–adrenal axis by adrenergic and neurohormone systems. Bugajski J. **J Physiol Pharmacol** 1996 Dec;47(4):559–75 (78 ref.)

Modifications of arterial baroreflexes: obligatory roles in cardiovascular regulation in stress and poststress recovery. Nosaka S. **Jpn J Physiol** 1996 Aug;46(4):271–88 (198 ref.)

Morphological and functional studies of the paracrine interaction between cortex and medulla in the adrenal gland. Bornstein SR, et al. **Microsc Res Tech** 1997 Mar 15;36(6):520–33 (123 ref.)

Does prenatal stress impair coping and regulation of hypothalamic–pituitary–adrenal axis? Weinstock M. **Neurosci Biobehav Rev** 1997 Jan;21(1):1–10 (128 ref.)

Stress, social support and pregnancy outcome: a reassessment based on recent research. Hoffman S, et al. **Paediatr Perinat Epidemiol** 1996 Oct;10(4):380–405 (144 ref.)

Behavioral sensitization to ethanol: genetics and the effects of stress. Phillips TJ, et al. **Pharmacol Biochem Behav** 1997 Jul;57(3):487–93 (120 ref.)

Intestinal adaptation to nutritional stress. Raul F, et al. **Proc Nutr Soc** 1996 Mar;55(1B):279–89 (74 ref.)

The paraventricular nucleus of the hypothalamus and the functional neuroanatomy of visceromotor responses to stress. Sawchenko PE, et al. **Prog Brain Res** 1996; 107:201–22 (104 ref.)

The neuroimmunology of stress from invertebrates to man [published erratum appears in Prog Neurobiol 1996 Jun;49(3):285] Ottaviani E, et al. **Prog Neurobiol** 1996 Mar–Apr;48(4–5):421–40 (103 ref.)

Persistent changes in corticotropin-releasing factor systems due to early life stress: relationship to the pathophysiology of major depression and post-traumatic stress disorder. Heim C, et al. **Psychopharmacol Bull** 1997;33(2):185–92 (63 ref.)

Stress, depression and the mesolimbic dopamine system. Cabib S, et al. **Psychopharmacology (Berl)** 1996 Dec; 128(4):331–42 (100 ref.)

Use of animal models in peptic ulcer disease. Weiner H. **Psychosom Med** 1996 Nov–Dec;58(6):524–45 (259 ref.)

The pediatric physiologic stress response: a concept analysis. Rosenthal–Dichter CH. **Sch Inq Nurs Pract** 1996 Fall; 10(3):211–34 (58 ref.)

The emerging role of glutamine as an indicator of exercise stress and overtraining. Rowbottom DG, et al. **Sports Med** 1996 Feb;21(2):80–97 (124 ref.)

Neurocircuitry of stress: central control of the hypothalamo–pituitary–adrenocortical axis. Herman JP, et al. **Trends Neurosci** 1997 Feb;20(2):78–84 (81 ref.)

Stress, hormonal changes, alcohol, food constituents and drugs: factors that advance the incidence of tobacco smoke-related cancer? Maser E. **Trends Pharmacol Sci** 1997 Aug;18(8):270–5 (95 ref.)

[Surgical stress and nervous systems] Komatsu T, et al. **Masui** 1996 Dec;45 Suppl:S16–24 (36 ref.) **(Jpn)**

[Biological response to surgical stress—endocrine response] Sakai T. **Masui** 1996 Dec;45 Suppl:S25–30 (14 ref.) **(Jpn)**

[Result of biological response to surgical stress] Yuge T. **Masui** 1996 Dec;45 Suppl:S44–8 (14 ref.) **(Jpn)**

[Cytokine storm in the pathogenesis of multiple organ dysfunction syndrome associated with surgical insults] Aikawa N. **Nippon Geka Gakkai Zasshi** 1996 Sep; 97(9):771–7 (31 ref.) (Eng. Abstr.) **(Jpn)**

[The significance of neurological manifestations from the aspect of aggressology] Aruga T. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):733–8 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Cytokines in surgical stress] Endo S, et al. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):708–15 (34 ref.) (Eng. Abstr.) **(Jpn)**

[Acute renal failure following surgical insult] Hirasawa H, et al. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):765–70 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Immune response induced by surgical trauma] Hirota M, et al. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):721–5 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Surgical stress and organ dysfunction: liver] Nakatani T, et al. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):752–8 (47 ref.) (Eng. Abstr.) **(Jpn)**

[Endocrine response to surgical stress] Saito H. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):701–7 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Cardiac contractile dysfunction in response to surgical stress including trauma, hemorrhage, and infection] Suzuki K, et al. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):745–51 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Surgical stress and acute lung injury] Takezawa J. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):739–44 (33 ref.) (Eng. Abstr.) **(Jpn)**

[Microcirculatory disturbances after surgical insults—important role of inflammatory cytokines] Wakabayashi G, et al. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):759–64 (14 ref.) (Eng. Abstr.) **(Jpn)**

[The functional swings in the neuroendocrine regulation of stress] Shaliapina VG. **Fiziol Zh Im I M Sechenova** 1996 Apr;82(4):9–14 (31 ref.) **(Rus)**

[The role of the opioid system in body adaptation and protection of the heart in stress] Lishmanov IuB, et al. **Usp Fiziol Nauk** 1997 Jan–Mar;28(1):75–96 (120 ref.) (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Multimodal approach to control postoperative pathophysiology and rehabilitation. Kehlet H. **Br J Anaesth** 1997 May;78(5):606–17 (117 ref.)

Psychiatric interventions for prevention of mental disorders. A psychosocial perspective. Dalgard OS, et al. **Int J Technol Assess Health Care** 1996 Fall;12(4):604–17 (24 ref.)

[Preventive effect of anesthesia to surgical stress] Fujita T. **Masui** 1996 Dec;45 Suppl:S49–50 (4 ref.) **(Jpn)**

[Protective effect of intravenous anesthesia using propofol from surgical stress] Kazama T. **Masui** 1996 Dec;45 Suppl:S68–72 (4 ref.) **(Jpn)**

[Surgical stress suppressive effect of epidural anesthesia and the limitation] Takasaki M, et al. **Masui** 1996 Dec;45 Suppl:S73–8 (20 ref.) **(Jpn)**

[The participation of the epiphysis in the anti-stress protection of the brain] Arushanian EB. **Usp Fiziol Nauk** 1996 Jul–Sep;27(3):31–50 (153 ref.) (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

Decreasing the burden of trauma for victims of violence. Kaufmann MC. **Ann Emerg Med** 1997 Aug;30(2):199–203 (31 ref.)

The role of early environmental events in regulating neuroendocrine development. Moms, pups, stress, and glucocorticoid receptors. Francis D, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:136–52 (81 ref.)

Performance tests. Wetherell A. **Environ Health Perspect** 1996 Apr;104 Suppl 2:247–73 (418 ref.)

Theoretical perspectives concerning positive aspects of caring for elderly persons with dementia: stress/adaptation and existentialism. Farran CJ. **Gerontologist** 1997 Apr; 37(2):250–6 (51 ref.)

The concept of hardiness: a brief but critical commentary. Low J. **J Adv Nurs** 1996 Sep;24(3):588–90 (15 ref.)

Stress versus depression. Lechin F, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Aug; 20(6):899–950 (215 ref.)

Successful coping, adaptation and resilience in the elderly: an interpretation of epidemiologic data. Foster JR. **Psychiatr Q** 1997 Fall;68(3):189–219 (96 ref.)

Animal models provide insight into psychosomatic factors in diabetes. Surwit RS, et al. **Psychosom Med** 1996 Nov–Dec;58(6):582–9 (65 ref.)

THERAPY

Effect of pain relief on the surgical stress response. Kehlet H. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):35–7 (3 ref.)

VETERINARY

Extraction of the upper cuspid, without stress. Legendre L. **Can Vet J** 1996 Nov;37(11):692–4 (4 ref.)

Winter stress syndrome: an important consideration for hazard assessment of aquatic pollutants. Lemly AD. **Ecotoxicol Environ Saf** 1996 Aug;34(3):223–7 (22 ref.)

Using aversion learning techniques to assess the mental state, suffering, and welfare of farm animals. Rushen J. **J Anim Sci** 1996 Aug;74(8):1990–5 (35 ref.)

The stress response in fish. Wendelaar Bonga SE. **Physiol Rev** 1997 Jul;77(3):591–625 (285 ref.)

[Physiology and physiopathology of ryanodine receptors in swine. Significance of sensitivity to stress, stress myopathies, malignant hyperthermia and meat quality] Martens H. **Tierarztl Prax** 1997 Jan;25(1):41–51 (62 ref.) (Eng. Abstr.) **(Ger)**

STRESS DISORDERS, POST-TRAUMATIC

Traumatic stress—an overview of diagnostic evolution and clinical treatment. Wong JC, et al. **Ann Acad Med Singapore** 1997 Jan;26(1):76–87 (65 ref.)

Animal models of relevance to PTSD. Rasmusson AM, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:332–51 (148 ref.)

Post-traumatic stress disorder. Medley I. **Br J Hosp Med** 1996 May 1–14;55(9):567–70 (35 ref.)

Post-traumatic stress disorder: the importance of clinical objectivity and systematic research. McFarlane AC. **Med J Aust** 1997 Jan 20;166(2):88–90 (19 ref.)

Occupational stress in contemporary fire service. Gist R, et al. **Occup Med** 1995 Oct–Dec;10(4):763–87 (53 ref.)

Torture and war trauma survivors in primary care practice. Weinstein HM, et al. **West J Med** 1996 Sep;165(3):112–8 (30 ref.)

CLASSIFICATION

Should there be a clinical typology of posttraumatic stress disorder? Alarcon RD, et al. **Aust N Z J Psychiatry** 1997 Apr;31(2):159–67; discussion 168–71 (90 ref.)

COMPLICATIONS

Self-injury in trauma survivors: 1. functions and meanings. Connors R. **Am J Orthopsychiatry** 1996 Apr;66(2):197–206 (50 ref.)

Self-injury in trauma survivors: 2. levels of clinical response. Connors R. **Am J Orthopsychiatry** 1996 Apr;66(2):207–16 (34 ref.)

Trauma and the gut: interactions between stressful experience and intestinal function. Stam R, et al. **Gut** 1997 Jun; 40(6):704–9 (110 ref.)

DIAGNOSIS

Traumatic stress—an overview of diagnostic evolution and clinical treatment. Wong JC, et al. **Ann Acad Med Singapore** 1997 Jan;26(1):76–87 (65 ref.)

Courts and torts: the psychiatrist preparing for trial. Hoffman BF. **Can J Psychiatry** 1997 Jun;42(5):497–501 (11 ref.)

Posttraumatic stress disorder. Friedman MJ. **J Clin Psychiatry** 1997;58 Suppl 9:33–6 (21 ref.)

Trauma research: a new era [editorial] Alexander DA. **J Psychosom Res** 1996 Jul;41(1):1–5 (20 ref.)

Mental defenses and posttraumatic stress disorder: assessment of criminal intent. Sparr LF. **J Trauma Stress** 1996 Jul; 9(3):405–25 (100 ref.)

[Trauma diagnosis: difficulty in differentiating between recall and fantasy] Person ES, et al. **Psychother Psychosom Med Psychol** 1997 Mar–Apr; 47(3–4):97–107 (31 ref.) (Eng. Abstr.) **(Ger)**

[Post-traumatic stress disorders in childhood—diagnosis, prognostic predictors and therapeutic strategies] Schepker R. **Z Kinder Jugenpsychiatr** 1997 Mar;25(1):46–56 (65 ref.) **(Ger)**

[PTSD—diagnostic criteria, clinical and certification application] Heitzman J. **Psychiatr Pol** 1995 Nov–Dec; 29(6):751–66 (31 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Drug treatment for PTSD. Answers and questions. Friedman MJ. **Ann N Y Acad Sci** 1997 Jun 21;821:359–71 (50 ref.)

A review of the psychobiology and pharmacotherapy of posttraumatic stress disorder. Katz L, et al. **Can J Psychiatry** 1996 May;41(4):233–8 (46 ref.)

Current status of pharmacotherapy for PTSD: an effect size analysis of controlled studies. Penava SJ, et al. **Depress Anxiety** 1996–97;4(5):240–2 (22 ref.)

Biological therapies for posttraumatic stress disorder: an overview. Davidson JR. **J Clin Psychiatry** 1997;58 Suppl 9:29–32 (20 ref.)

EPIDEMIOLOGY

Comorbid psychiatric disorders in PTSD. Implications for research. Keane TM, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:24–34 (30 ref.)

Posttraumatic stress disorder and comorbidity: recognizing the many faces of PTSD. Brady KT. **J Clin Psychiatry** 1997;58 Suppl 9:12–5 (23 ref.)

Trauma and women: course, predictors, and treatment. Foa EB. **J Clin Psychiatry** 1997;58 Suppl 9:25–8 (11 ref.)

Trauma: prevalence, impairment, service use, and cost. Solomon SD, et al. **J Clin Psychiatry** 1997;58 Suppl 9:5–11 (30 ref.)

The epidemic of post-traumatic stress disorder: a passing phase? Ellard JH. **Med J Aust** 1997 Jan 20;166(2):84–7 (13 ref.)

ETIOLOGY

The role of early adverse life events in the etiology of depression and posttraumatic stress disorder. Focus on corticotropin-releasing factor. Heim C, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:194–207 (92 ref.)

Post-traumatic stress disorder after childbirth: the phenomenon of traumatic birth. Reynolds JL. **Can Med Assoc J** 1997 Mar 15;156(6):831–5 (32 ref.)

The sequelae of childhood sexual abuse: a primary care focus for adult female survivors. Roberts SJ. **Nurse Pract** 1996 Dec;21(12 Pt 1):42, 45, 49–52 (26 ref.)

GENETICS

Familial risk factors in posttraumatic stress disorder. Connor KM, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:35–51 (64 ref.)

METABOLISM

Stressor-induced oscillation. A possible model of the bidirectional symptoms in PTSD. Antelman SM, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:296–304 (21 ref.)

The role of early adverse life events in the etiology of depression and posttraumatic stress disorder. Focus on corticotropin-releasing factor. Heim C, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:194–207 (92 ref.)

Functional neuroimaging studies in posttraumatic stress disorder. Rauch SL, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:83–98 (49 ref.)

NURSING

Posttraumatic stress disorder: how to support healing. Clark CC. **Am J Nurs** 1997 Aug;97(8):26–32; quiz 33 (10 ref.)
Critical incident stress debriefing and the community health nurse. Hollister R. **J Community Health Nurs** 1996; 13(1):43–9 (11 ref.)

PATHOLOGY

Structural brain changes in PTSD. Does trauma alter neuroanatomy? Stein MB, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:76–82 (59 ref.)

PHYSIOPATHOLOGY

How the brain processes emotional information. Armony JL, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:259–70 (87 ref.)
The neurobiology of emotionally influenced memory. Implications for understanding traumatic memory. Cahill L. **Ann N Y Acad Sci** 1997 Jun 21;821:238–46 (41 ref.)
Roles of the amygdala and bed nucleus of the stria terminalis in fear and anxiety measured with the acoustic startle reflex. Possible relevance to PTSD. Davis M, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:305–31 (76 ref.)
Psychological processes related to recovery from a trauma and an effective treatment for PTSD. Foa EB. **Ann N Y Acad Sci** 1997 Jun 21;821:410–24 (41 ref.)
The prevalence and longitudinal course of PTSD. Implications for the neurobiological models of PTSD. McFarlane AC. **Ann N Y Acad Sci** 1997 Jun 21;821:10–23 (49 ref.)
Psychobiology of sleep disturbances in posttraumatic stress disorder. Mellman TA. **Ann N Y Acad Sci** 1997 Jun 21; 821:142–9 (44 ref.)
The psychobiology of posttraumatic stress disorder: an overview. Murburg MM. **Ann N Y Acad Sci** 1997 Jun 21; 821:352–8 (34 ref.)
Psychophysiologic reactivity to trauma-related imagery in PTSD. Diagnostic and theoretical implications of recent findings. Orr SP. **Ann N Y Acad Sci** 1997 Jun 21;821:114–24 (31 ref.)
Overview of biological themes in PTSD. Pitman RK. **Ann N Y Acad Sci** 1997 Jun 21;821:1–9 (27 ref.)
Kindling versus quenching. Implications for the evolution and treatment of posttraumatic stress disorder. Post RM, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:285–95 (50 ref.)
Issues in the developmental neurobiology of traumatic stress. Pynoos RS, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:176–93 (52 ref.)
Noradrenergic alterations in posttraumatic stress disorder. Southwick SM, et al. **Ann N Y Acad Sci** 1997 Jun 21; 821:125–41 (115 ref.)
The psychobiology of traumatic memory. Clinical implications of neuroimaging studies. Van Der Kolk BA, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:99–113 (58 ref.)
Sensitization of the hypothalamic-pituitary-adrenal axis in posttraumatic stress disorder. Yehuda R. **Ann N Y Acad Sci** 1997 Jun 21;821:57–75 (83 ref.)
The psychobiology of posttraumatic stress disorder. van der Kolk BA. **J Clin Psychiatry** 1997;58 Suppl 9:16–24 (75 ref.)
The psychobiological basis of posttraumatic stress disorder. Grillon C, et al. **Mol Psychiatry** 1996 Sep;1(4):278–97 (258 ref.)
Persistent changes in corticotropin-releasing factor systems due to early life stress: relationship to the pathophysiology of major depression and post-traumatic stress disorder. Heim C, et al. **Psychopharmacol Bull** 1997;33(2):185–92 (63 ref.)
[Complex memory function for mental trauma. Memory and forgetting ae necessary for the emotional adaptation process] Christianson SA, et al. **Lakartidningen** 1997 Apr 30;94(18):1721–4 (20 ref.) **(Swe)**

PREVENTION & CONTROL

Preventing post-traumatic stress disorders in military medical personnel. Baker MS, et al. **Mil Med** 1996 May;161(5):262–4 (16 ref.)
[Sensitivity training for debriefing in the school context] Leuenberger JF. **Rev Med Suisse Romande** 1997 May; 117(5):413–8 (0 ref.) **(Fre)**
[In times of survival, the right of silence] Métraux JC. **Rev Med Suisse Romande** 1997 May;117(5):419–23 (7 ref.) **(Fre)**
[Prevention and therapy of post-traumatic disorders from a biopsychosocial viewpoint] Schnyder U. **Schweiz Rundsch Med Prax** 1996 Dec 10;85(50):1603–8 (43 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Self-injury in trauma survivors: 1. functions and meanings. Connors R. **Am J Orthopsychiatry** 1996 Apr;66(2):197–206 (50 ref.)
Self-injury in trauma survivors: 2. levels of clinical response. Connors R. **Am J Orthopsychiatry** 1996 Apr;66(2):207–16 (34 ref.)
Neglected victims of homicide: the needs of young siblings of murder victims. Freeman LN, et al. **Am J Orthopsychiatry** 1996 Jul;66(3):337–45 (30 ref.)
Trauma and its sequelae in male prisoners: effects of confinement, overcrowding, and diminished services. Kupers TA. **Am J Orthopsychiatry** 1996 Apr;66(2):189–96 (65 ref.)
Stressor-induced oscillation. A possible model of the bidirectional symptoms in PTSD. Antelman SM, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:296–304 (21 ref.)
How the brain processes emotional information. Armony JL, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:259–70 (87 ref.)
The neurobiology of emotionally influenced memory. Implications for understanding traumatic memory. Cahill L. **Ann N Y Acad Sci** 1997 Jun 21;821:238–46 (41 ref.)
Familial risk factors in posttraumatic stress disorder. Connor KM, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:35–51 (64 ref.)
Roles of the amygdala and bed nucleus of the stria terminalis in fear and anxiety measured with the acoustic startle reflex. Possible relevance to PTSD. Davis M, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:305–31 (76 ref.)
Psychological processes related to recovery from a trauma and an effective treatment for PTSD. Foa EB. **Ann N Y Acad Sci** 1997 Jun 21;821:410–24 (41 ref.)
The prevalence and longitudinal course of PTSD. Implications for the neurobiological models of PTSD. McFarlane AC. **Ann N Y Acad Sci** 1997 Jun 21;821:10–23 (49 ref.)
Implicit and explicit memory for trauma-related information in PTSD. McNally RJ. **Ann N Y Acad Sci** 1997 Jun 21; 821:219–24 (23 ref.)
Psychobiology of sleep disturbances in posttraumatic stress disorder. Mellman TA. **Ann N Y Acad Sci** 1997 Jun 21; 821:142–9 (44 ref.)
The psychobiology of posttraumatic stress disorder: an overview. Murburg MM. **Ann N Y Acad Sci** 1997 Jun 21; 821:352–8 (34 ref.)
Psychophysiologic reactivity to trauma-related imagery in PTSD. Diagnostic and theoretical implications of recent findings. Orr SP. **Ann N Y Acad Sci** 1997 Jun 21;821:114–24 (31 ref.)
Kindling versus quenching. Implications for the evolution and treatment of posttraumatic stress disorder. Post RM, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:285–95 (50 ref.)
Functional neuroimaging studies in posttraumatic stress disorder. Rauch SL, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:83–98 (49 ref.)
Noradrenergic alterations in posttraumatic stress disorder. Southwick SM, et al. **Ann N Y Acad Sci** 1997 Jun 21; 821:125–41 (115 ref.)
Trauma, dissociation, and memory. Spiegel D. **Ann N Y Acad Sci** 1997 Jun 21;821:225–37 (86 ref.)
The psychobiology of traumatic memory. Clinical implications of neuroimaging studies. Van Der Kolk BA, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:99–113 (58 ref.)
Performance of PTSD patients on standard tests of memory. Implications for trauma. Wolfe J, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:208–18 (52 ref.)
Oklahoma City bombing: exacerbation of symptoms in veterans with PTSD. Moyers F. **Arch Psychiatr Nurs** 1996 Feb;10(1):55–9 (19 ref.)
A review of the psychobiology and pharmacotherapy of posttraumatic stress disorder. Katz L, et al. **Can J Psychiatry** 1996 May;41(4):233–8 (46 ref.)
Posttraumatic stress disorder and motor vehicle accidents: a multidisciplinary overview [see comments] Kuch K, et al. **Can J Psychiatry** 1996 Sep;41(7):429–34 (69 ref.) Comment in: Can J Psychiatry 1997 Mar;42(2):210.
Posttraumatic stress symptoms and medical procedures in children. Wintgens A, et al. **Can J Psychiatry** 1997 Aug; 42(6):611–6 (44 ref.)
Traumatic intrusive imagery as an emotional memory phenomenon: a review of research and explanatory information processing theories. vanOyen Witvliet C. **Clin Psychol Rev** 1997;17(5):509–36 (150 ref.)
Posttraumatic stress disorder: a sensitization reaction. Dykman RA, et al. **Integr Physiol Behav Sci** 1997 Jan–Mar; 32(1):9–18 (0 ref.)
Current perspectives on posttraumatic stress disorder: from the clinic and the laboratory. Paige SR. **Integr Physiol Behav Sci** 1997 Jan–Mar;32(1):5–8 (0 ref.)
Understanding vicarious traumatization. Blair DT, et al. **J Psychosoc Nurs Ment Health Serv** 1996 Nov;34(11):24–30 (54 ref.)
Personal space intrusion and PTSD. Brown P, et al. **J Psychosoc Nurs Ment Health Serv** 1996 Jul;34(7):23–8 (44 ref.)
Miscarriage as a traumatic event: a review of the literature and new implications for intervention. Lee C, et al. **J Psychosom Res** 1996 Mar;40(3):235–44 (60 ref.)
Whiplash neck injury. Mayou R, et al. **J Psychosom Res** 1996 May;40(5):461–74 (60 ref.)
The epidemic of post-traumatic stress disorder: a passing phase? Ellard JH. **Med J Aust** 1997 Jan 20;166(2):84–7 (13 ref.)
The psychobiological basis of posttraumatic stress disorder. Grillon C, et al. **Mol Psychiatry** 1996 Sep;1(4):278–97 (258 ref.)
Histories of childhood trauma and complex post-traumatic sequelae in women with eating disorders. Rorty M, et al. **Psychiatr Clin North Am** 1996 Dec;19(4):773–91 (145 ref.)
A dual representation theory of posttraumatic stress disorder. Brewin CR, et al. **Psychol Rev** 1996 Oct;103(4):670–86 (190 ref.)

REHABILITATION

A critical review of recovered memories in psychotherapy: Part II—Trauma and therapy. Paris J. **Can J Psychiatry** 1996 May;41(4):206–10 (35 ref.)
New directions for treatment research on sequelae of sexual abuse in persons with severe mental illness. Rosenberg SD, et al. **Community Ment Health J** 1996 Aug;32(4):387–400 (75 ref.)
Posttraumatic stress, mental health professionals, and the clergy: a need for collaboration, training, and research. Weaver AJ, et al. **J Trauma Stress** 1996 Oct;9(4):847–56 (54 ref.)

THERAPY

Management of post traumatic stress disorder using combat stress treatment principles—a case report. Lee JT. **Ann Acad Med Singapore** 1997 Jan;26(1):113–7 (24 ref.)
Traumatic stress—an overview of diagnostic evolution and clinical treatment. Wong JC, et al. **Ann Acad Med Singapore** 1997 Jan;26(1):76–87 (65 ref.)
Psychological processes related to recovery from a trauma and an effective treatment for PTSD. Foa EB. **Ann N Y Acad Sci** 1997 Jun 21;821:410–24 (41 ref.)
Treatment failure in acute PTSD. Lessons learned about the complexity of the disorder. Shalev AY. **Ann N Y Acad Sci** 1997 Jun 21;821:372–87 (52 ref.)
Psychosocial treatments for posttraumatic stress disorder: a critical review. Foa EB, et al. **Annu Rev Psychol** 1997; 48:449–80 (105 ref.)
Post-traumatic stress counselling: benefit or indulgence? [editorial] [see comments] Cramer D. **Br J Hosp Med** 1996 Dec 11–1997 Jan 14;56(11):567–8 (9 ref.) Comment in: Br J Hosp Med 1997 Feb 5–18;57(3):111–2. Comment in: Br J Hosp Med 1997 Feb 5–18;57(3):112.
Eye movement desensitisation treatment utilises the positive visceral element of the investigatory reflex to inhibit the memories of post-traumatic stress disorder: a theoretical analysis. MacCulloch MJ, et al. **Br J Psychiatry** 1996 Nov; 169(5):571–9 (37 ref.)
A critical review of recovered memories in psychotherapy: Part I—Trauma and memory. Paris J. **Can J Psychiatry** 1996 May;41(4):201–5 (52 ref.)
Eye movement desensitization and reprocessing (EMDR): evaluation of controlled PTSD research. Shapiro F. **J Behav Ther Exp Psychiatry** 1996 Sep;27(3):209–18 (36 ref.)
Posttraumatic stress disorder. Friedman MJ. **J Clin Psychiatry** 1997;58 Suppl 9:33–6 (21 ref.)
[Post-traumatic stress disorder. New research findings] Bronisch T. **Fortschr Neurol Psychiatr** 1997 May; 65(5):195–207 (108 ref.) (Eng. Abstr.) **(Ger)**
[Treatment of post-traumatic stress disorder] Ebbinghaus R, et al. **Fortschr Neurol Psychiatr** 1996 Nov;64(11):433–43 (140 ref.) (Eng. Abstr.) **(Ger)**

STRESS FRACTURES see **FRACTURES, STRESS**

STRESS, MECHANICAL

Stress and insufficiency fractures. Buckwalter JA, et al. **Am Fam Physician** 1997 Jul;56(1):175–82 (15 ref.)
Regulation of extracellular matrix synthesis by mechanical stress. Chiquet M, et al. **Biochem Cell Biol** 1996; 74(6):737–44 (55 ref.)
Gene regulation by mechanical forces. Oluwole BO, et al. **Endothelium** 1997;5(2):85–93 (29 ref.)
Investigation of spectral content from discrete plantar areas during adult gait: an expansion of rehabilitation technology. Harris GF, et al. **IEEE Trans Rehabil Eng** 1996 Dec; 4(4):360–74 (20 ref.)
Stress corrosion cracking in Björk-Shiley convexo-concave prosthetic heart valves due to random in vivo electrochemical pulsing [see comments] Xiao K, et al. **Int J Artif Organs** 1996 Aug;19(8):477–86 (33 ref.) Comment in: Int J Artif Organs 1997 Mar;20(3):186–7.
The role of mechanical stresses in microvascular remodeling. Skalak TC, et al. **Microcirculation** 1996 Jun;3(2):143–65 (198 ref.)
Force: a new structural control parameter? Bensimon D. **Structure** 1996 Aug 15;4(8):885–9 (36 ref.)

STRESS, OXIDATIVE see **OXIDATIVE STRESS**

STRESS PROTEINS see **HEAT-SHOCK PROTEINS**

STRESS, PSYCHOLOGICAL

see related
CROWDING
LIFE CHANGE EVENTS

Stress and burnout in HIV/AIDS carers. Miller D. **AIDS** 1996;10 Suppl A:S213–9 (59 ref.)
Brain systems for the mediation of social separation-distress and social-reward. Evolutionary antecedents and neuropeptide intermediaries. Panksepp J, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:78–100 (63 ref.)
Animal models of relevance to PTSD. Rasmusson AM, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:332–51 (148 ref.)
Compensatory control in the regulation of human performance under stress and high workload; a cognitive-energetical framework. Hockey GR. **Biol Psychol** 1997 Mar 21;45(1–3):73–93 (48 ref.)
ABC of work related disorders. Stress at work. von Onciul J. **BMJ** 1996 Sep 21;313(7059):745–8 (0 ref.)
Occupational stress and the law: some current issues for

employers. Howard GS. **Br J Hosp Med** 1996 May 1–14; 55(9):563–6 (9 ref.)

Stress, coping, lifestyle and hypertension: a paradigm for research, prevention and non-pharmacological management of hypertension. Beilin LJ. **Clin Exp Hypertens** 1997 Jul–Aug;19(5–6):739–52 (24 ref.)

The influence of ethnicity and culture on the caregiver stress and coping process: a sociocultural review and analysis. Aranda MP, et al. **Gerontologist** 1997 Jun;37(3):342–54 (92 ref.)

Stress and the life course: a paradigmatic alliance. Pearlin LI, et al. **Gerontologist** 1996 Apr;36(2):239–47 (69 ref.)

Nurses and physicians evaluate their intensive care experiences. Laubach W, et al. **Heart Lung** 1996 Nov–Dec; 25(6):475–82 (32 ref.)

Models of shiftwork and health: an examination of the influence of stress on shiftwork theory. Taylor E, et al. **Hum Factors** 1997 Mar;39(1):67–82 (58 ref.)

Stress experiences of occupational therapists in mental health practice arenas: a review of the literature. Sweeney G, et al. **Int J Soc Psychiatry** 1996 Summer;42(2):132–40 (35 ref.)

A conceptual foundation for human suffering in nursing care and research. Rodgers BL, et al. **J Adv Nurs** 1997 May; 25(5):1048–53 (47 ref.)

Occupational stress in contemporary fire service. Gist R, et al. **Occup Med** 1995 Oct–Dec;10(4):763–87 (53 ref.)

Psychophysiological interactions in esophageal diseases. Richter JE, et al. **Semin Gastrointest Dis** 1996 Oct; 7(4):169–84 (98 ref.)

Psychosocial work environment in human service organizations: a conceptual analysis and development of the demand–control model. Söderfeldt B, et al. **Soc Sci Med** 1996 May;42(9):1217–26 (50 ref.)

[Skin and stress] Consoli S. **Pathol Biol (Paris)** 1996 Dec; 44(10):875–81 (28 ref.) (Eng. Abstr.) **(Fre)**

[Physiopathological analysis of stress reaction and drug design] Takahashi M, et al. **Nippon Yakurigaku Zasshi** 1996 Sep;108(3):163–5 (5 ref.) **(Jpn)**

[The role of psycho-oncology in the treatment of cancer patients] Blinov NN, et al. **Vopr Onkol** 1996;42(5):86–9 (16 ref.) (Eng. Abstr.) **(Rus)**

[Burnout and reaction to stress] De las Cuevas C, et al. **Rev Med Univ Navarra** 1997 Apr–Jun;41(2):10–8 (36 ref.) (Eng. Abstr.) **(Spa)**

[Complex memory function for mental trauma. Memory and forgetting ae necessary for the emotional adaptation process] Christianson SA, et al. **Lakartidningen** 1997 Apr 30;94(18):1721–4 (20 ref.) **(Swe)**

COMPLICATIONS

Fortnighly review. Stress, the brain, and mental illness. Herbert J. **BMJ** 1997 Aug 30;315(7107):530–5 (47 ref.)

Delayed traumatic recall in adults: a synthesis with legal, clinical, and forensic recommendations. Beahrs JO, et al. **Bull Am Acad Psychiatry Law** 1996;24(1):45–55 (63 ref.)

Psychological factors affecting health after toxicological disasters. Havenaar JM, et al. **Clin Psychol Rev** 1997; 17(4):359–74 (90 ref.)

Psychophysiology of stress in dermatology. The psychobiologic pattern of psychosomatics. Panconesi E, et al. **Dermatol Clin** 1996 Jul;14(3):399–421 (117 ref.)

Looking beyond age and race: the structure of networks, functions of support, and chronic stress [editorial; comment] Berkman LF. **Epidemiology** 1997 Sep;8(5):469–70 (9 ref.) Comment on: Epidemiology 1997 Sep;8(5):475–81. Comment on: Epidemiology 1997 Sep;8(5):482–7.

Stressful life events and Graves' disease. Chiovato L, et al. **Eur J Endocrinol** 1996 Jun;134(6):680–2 (12 ref.)

Stress-related mucosal damage. What to do or not to do. Goldin GF, et al. **Gastrointest Endosc Clin N Am** 1996 Jul;6(3):505–26 (106 ref.)

Stress in clinical psychologists. Cushway D, et al. **Int J Soc Psychiatry** 1996 Summer;42(2):141–9 (39 ref.)

Stress in mental health professionals: a theoretical overview. Moore KA, et al. **Int J Soc Psychiatry** 1996 Summer; 42(2):82–9 (28 ref.)

Stress experiences of occupational therapists in mental health practice arenas: a review of the literature. Sweeney G, et al. **Int J Soc Psychiatry** 1996 Summer;42(2):132–40 (35 ref.)

Stress, stress reduction, and hypertension in African Americans: an updated review. Barnes V, et al. **J Natl Med Assoc** 1997 Jul;89(7):464–76 (139 ref.)

Additive effects, but no synergistic interaction of stressful life-events and genetic loading in affective disorders. Fritze J, et al. **J Neural Transm** 1996;103(10):1221–9 (24 ref.)

The role of stress and dopamine-GABA interactions in the vulnerability for schizophrenia. Benes FM. **J Psychiatr Res** 1997 Mar–Apr;31(2):257–75 (105 ref.)

Physiological stress reactivity and recovery: conceptual siblings separated at birth? Linden W, et al. **J Psychosom Res** 1997 Feb;42(2):117–35 (59 ref.)

Hypertension and objective and self-reported stressor exposure: a review. Nyklíček I, et al. **J Psychosom Res** 1996 Jun;40(6):585–601 (76 ref.)

Experimental stress and cardiac function [editorial] Tennant C. **J Psychosom Res** 1996 Jun;40(6):569–83 (125 ref.)

Coronary heart disease: a review of the role of psychosocial stress and social support. Greenwood DC, et al. **J Public Health Med** 1996 Jun;18(2):221–31 (52 ref.)

A stitch in time: self-regulation and proactive coping. Aspinwall LG, et al. **Psychol Bull** 1997 May;121(3):417–36 (175 ref.)

Psychosocial factors, sex differences, and atherosclerosis: lessons from animal models. Kaplan JR, et al. **Psychosom Med** 1996 Nov–Dec;58(6):598–611 (126 ref.)

Psychological stress, neuroimmunomodulation, and susceptibility to infectious diseases in animals and man: a review. Biondi M, et al. **Psychother Psychosom** 1997; 66(1):3–26 (271 ref.)

Sick building syndrome, work factors and occupational stress. Crawford JO, et al. **Scand J Work Environ Health** 1996 Aug;22(4):243–50 (71 ref.)

[Stress theories and the somatization process] Dantzer R. **Encephale** 1995 Dec;21 Spec No 7:3–9 (21 ref.) (Eng. Abstr.) **(Fre)**

[Is drug dependence an occupational risk for physicians?] Schifferdecker M, et al. **Fortschr Med** 1996 Oct 20; 114(29):372–3, 376 (20 ref.) (Eng. Abstr.) **(Ger)**

[Psychosocial factors in Crohn disease--an overview] Enck P, et al. **Z Gastroenterol** 1996 Oct;34(10):708–13 (62 ref.) (Eng. Abstr.) **(Ger)**

[Hazards to workers' health caused by work-related psychosocial factors--a challenge to occupational health services] Dudek B, et al. **Med Pr** 1996;47(1):63–72 (12 ref.) (Eng. Abstr.) **(Pol)**

ETHNOLOGY

Searching for resilience among African-American youth exposed to community violence: theoretical issues. Howard DE. **J Adolesc Health** 1996 Apr;18(4):254–62 (66 ref.)

ETIOLOGY

Opportunistic infections and psychosocial stress in HIV [see comments] Montauk SL, et al. **Am Fam Physician** 1997 Jul;56(1):87–96 (24 ref.) Comment in: Am Fam Physician 1997 Jul;56(1):37, 40–2.

Stress and the biology of inequality. Brunner E. **BMJ** 1997 May 17;314(7092):1472–6 (45 ref.)

Stress in the workplace. Cooper CL. **Br J Hosp Med** 1996 May 1–14;55(9):559–63 (22 ref.)

The impact of the symptoms of dementia on caregivers. Donaldson C, et al. **Br J Psychiatry** 1997 Jan;170:62–8 (34 ref.)

Symptom distress in adult patients with cancer. McClement SE, et al. **Cancer Nurs** 1997 Aug;20(4):236–43 (44 ref.)

Psychological factors affecting health after toxicological disasters. Havenaar JM, et al. **Clin Psychol Rev** 1997; 17(4):359–74 (90 ref.)

Cardiovascular reactivity during verbal communication: an emerging risk factor. Thomas SA, et al. **J Cardiovasc Nurs** 1995 Jan;9(2):1–11 (42 ref.)

Stress and quality of life following cervical cancer. Andersen BL. **J Natl Cancer Inst Monogr** 1996;(21):65–70 (54 ref.)

Is caffeine involved in the pathogenesis of combat-stress reaction? Iancu I, et al. **Mil Med** 1996 Apr;161(4):230–32 (14 ref.)

Emotional disturbances and their interaction with neuropsychological deficits. Reitan RM, et al. **Neuropsychol Rev** 1997 Mar;7(1):3–19 (67 ref.)

IMMUNOLOGY

How psychological states affect the immune system: implications for interventions in the context of HIV. Littrell J. **Health Soc Work** 1996 Nov;21(4):287–95 (83 ref.)

Psychological stress, exercise and immunity. Perna FM, et al. **Int J Sports Med** 1997 Mar;18 Suppl 1:S78–83 (68 ref.)

[Psychoneuroimmunology and breast cancer] van der Pompe G. **Ned Tijdschr Geneeskd** 1996 Dec 28;140(52):2614–7 (33 ref.) **(Dut)**

METABOLISM

The neuroendocrinology of depression and chronic stress. Checkley S. **Br Med Bull** 1996 Jul;52(3):597–617 (122 ref.)

Tryptophan availability and the susceptibility to stress in multiple sclerosis: a hypothesis. Sandyk R. **Int J Neurosci** 1996 Jul;86(1–2):47–53 (85 ref.)

Brain monoamines, exercise, and behavioral stress: animal models. Dishman RK. **Med Sci Sports Exerc** 1997 Jan; 29(1):63–74 (76 ref.)

[Stress, neuroendocrine regulation and diabetes] Nilsson P. **Lakartidningen** 1997 Jan 15;94(3):145–7 (32 ref.) **(Swe)**

NURSING

The middle-range theory of unpleasant symptoms: an update. Lenz ER, et al. **ANS Adv Nurs Sci** 1997 Mar;19(3):14–27 (53 ref.)

Managing spiritual distress in patients with advanced cancer pain. Georgesen J, et al. **Cancer Nurs** 1996 Oct;19(5):376–83 (20 ref.)

PATHOLOGY

Stress effects on morphology and function of the hippocampus. McEwen BS, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:271–84 (70 ref.)

Hippocampal vulnerability to stress and aging: possible role of neurotrophic factors. Smith MA. **Behav Brain Res** 1996 Jun;78(1):25–36 (116 ref.)

PHYSIOPATHOLOGY

Overview of dietary sodium effects on and interactions with cardiovascular and neuroendocrine functions. Ely DL. **Am J Clin Nutr** 1997 Feb;65(2 Suppl):594S–605S (163 ref.)

Stress-related disturbances of the menstrual cycle. Xiao E, et al. **Ann Med** 1997 Jun;29(3):215–9 (38 ref.)

Stress effects on morphology and function of the hippocampus. McEwen BS, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:271–84 (70 ref.)

Stress-activated hormonal systems and the regulation of memory storage. Roozendaal B, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:247–58 (81 ref.)

Searching for the biological pathways between stress and health. Kelly S, et al. **Annu Rev Public Health** 1997; 18:437–62 (177 ref.)

Catecholamine-induced leukocytosis: early observations, current research, and future directions. Benschop RJ, et al. **Brain Behav Immun** 1996 Jun;10(2):77–91 (103 ref.)

Resilience in highly stressed urban children: concepts and findings. Cowen EL, et al. **Bull N Y Acad Med** 1996 Winter; 73(2):267–84 (46 ref.)

Brain-corticosteroid hormone dialogue: slow and persistent. de Kloet ER, et al. **Cell Mol Neurobiol** 1996 Jun; 16(3):345–56 (52 ref.)

Oxidative stress associated with exercise, psychological stress and life-style factors. Møller P, et al. **Chem Biol Interact** 1996 Sep 27;102(1):17–36 (171 ref.)

Physiological consequences of everyday psychosocial stress. Pollard TM. **Coll Antropol** 1997 Jun;21(1):17–28 (71 ref.)

Emotional stress effects on immunity, gingivitis and periodontitis. Breivik T, et al. **Eur J Oral Sci** 1996 Aug; 104(4 (Pt 1)):327–34 (74 ref.)

Assessment of stress during handling and transport. Grandin T. **J Anim Sci** 1997 Jan;75(1):249–57 (93 ref.)

Environmental influences on blood pressure and the role of job strain. Pickering TG, et al. **J Hypertens Suppl** 1996 Dec;14(5):S179–85 (67 ref.)

Patterns of ACTH secretagog secretion in response to psychological stimuli. Romero LM, et al. **J Neuroendocrinol** 1996 Apr;8(4):243–58 (193 ref.)

Physiological, immunohistochemical and molecular aspects of gastric adaptation to stress, aspirin and to H. pylori-derived gastrotoxins. Konturek PC. **J Physiol Pharmacol** 1997 Mar;48(1):3–42 (89 ref.)

Stress, glucocorticoids, and mesencephalic dopaminergic neurons: a pathophysiological chain determining vulnerability to psychostimulant abuse. Piazza PV, et al. **NIDA Res Monogr** 1996;163:277–99 (91 ref.)

Assessment of the effects of developmental toxicants: pharmacological and stress vulnerability of offspring. Spear LP. **NIDA Res Monogr** 1996;164:125–45 (42 ref.)

Stress, social support and pregnancy outcome: a reassessment based on recent research. Hoffman S, et al. **Paediatr Perinat Epidemiol** 1996 Oct;10(4):380–405 (144 ref.)

The central adaptation syndrome: psychosocial stress as a trigger for adaptive modifications of brain structure and brain function. Huether G. **Prog Neurobiol** 1996 Apr; 48(6):569–612 (455 ref.)

Benzodiazepines: tolerability in elderly patients. Lechin F, et al. **Psychother Psychosom** 1996;65(4):171–82 (202 ref.)

Psychosocial factors and their role in symptomatic gastroesophageal reflux disease and functional dyspepsia. Wiklund I, et al. **Scand J Gastroenterol Suppl** 1996; 220:94–100 (68 ref.)

Stress and behaviorally induced reproductive dysfunction in primates. Cameron JL. **Semin Reprod Endocrinol** 1997 Feb; 15(1):37–45 (56 ref.)

The neurobiology of stress: understanding regulation of affect during female biological transitions. Dorn LD, et al. **Semin Reprod Endocrinol** 1997 Feb;15(1):19–35 (162 ref.)

Noradrenergic mechanisms in stress and anxiety: II. Clinical studies. Bremner JD, et al. **Synapse** 1996 May;23(1):39–51 (118 ref.)

Noradrenergic mechanisms in stress and anxiety: I. Preclinical studies. Bremner JD, et al. **Synapse** 1996 May; 23(1):28–38 (138 ref.)

[Changes in cAMP signal transduction function and gene expression related to the onset of affective disturbance--the relationship between stress, antidepressants and expression of BDNF mRNA] Morinobu S, et al. **Seishin Shinkeigaku Zasshi** 1996;98(11):937–42; discussion 942–6 (7 ref.) **(Jpn)**

[Stress] Manso CF. **Acta Med Port** 1997 Apr;10(4):307–10 (18 ref.) (Eng. Abstr.) **(Por)**

[New accents of the classical concept of stress] Sudakov KV. **Biull Eksp Biol Med** 1997 Feb;123(2):124–30 (58 ref.) **(Rus)**

PREVENTION & CONTROL

Integrative functions of lactational hormones in social behavior and stress management. Carter CS, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:164–74 (78 ref.)

Toward a middle-range theory of resilience. Polk LV. **ANS Adv Nurs Sci** 1997 Mar;19(3):1–13 (42 ref.)

Toward a definition of family resilience: integrating life-span and family perspectives. Hawley DR, et al. **Fam Process** 1996 Sep;35(3):283–98 (66 ref.)

The concept of family resilience: crisis and challenge. Walsh F. **Fam Process** 1996 Sep;35(3):261–81 (112 ref.)

Interventions for caregivers of patients with Alzheimer's disease: a review and analysis of content, process, and outcomes. Bourgeois MS, et al. **Int J Aging Hum Dev** 1996; 43(1):35–92 (117 ref.)

Writing as a therapeutic modality. McGihon NN.

J Psychosoc Nurs Ment Health Serv 1996 Jun;34(6):31–5 (8 ref.)
Occupational stress management programmes: a practical overview of published effect studies. van der Hek H, et al. **Occup Med (Oxf)** 1997 Apr;47(3):133–41 (53 ref.)
Some conceptual considerations on the sense of coherence. Geyer S. **Soc Sci Med** 1997 Jun;44(12):1771–9 (59 ref.)
[Psychoemotional stress: its prevention and rehabilitation] Sudakov KV. **Ter Arkh** 1997;69(1):70–4 (46 ref.) **(Rus)**

PSYCHOLOGY

Stress-activated hormonal systems and the regulation of memory storage. Roozendaal B, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:247–58 (81 ref.)
Uncertainty in acute illness. Mishel MH. **Annu Rev Nurs Res** 1997;15:57–80 (76 ref.)
Searching for the biological pathways between stress and health. Kelly S, et al. **Annu Rev Public Health** 1997; 18:437–62 (177 ref.)
Managing spiritual distress in patients with advanced cancer pain. Georgesen J, et al. **Cancer Nurs** 1996 Oct;19(5):376–83 (20 ref.)
Fundamental analysis in research on well-being: distress and the sense of control. Mirowsky J, et al. **Gerontologist** 1996 Oct;36(5):584–94 (26 ref.)
Review: pathways to morbidity in carers of dementia sufferers. Wijeratne C. **Int Psychogeriatr** 1997 Mar; 9(1):69–79 (74 ref.)
Militarism: a psychosocial disease. Coulter NA. **Med War** 1992 Jan–Mar;8(1):7–17 (15 ref.)
Long lasting blindness, availability of resources, and early aging. Bachar E, et al. **Percept Mot Skills** 1997 Apr; 84(2):675–88 (77 ref.)
Beyond stress and arousal: a reconceptualization of alcohol-emotion relations with reference to psychophysiological methods. Stritzke WG, et al. **Psychol Bull** 1996 Nov;120(3):376–95 (183 ref.)
Parenting a technology assisted infant: coping with occupational stress. Murphy KE. **Soc Work Health Care** 1997;24(3–4):113–26 (32 ref.)
[Stress, depression and anxiety in patients with headache. Considerations of literature and experimental data] Fulcheri M, et al. **Minerva Psichiatr** 1995 Dec;36(4):179–85 (48 ref.) (Eng. Abstr.) **(Ita)**

REHABILITATION

[Psychoemotional stress: its prevention and rehabilitation] Sudakov KV. **Ter Arkh** 1997;69(1):70–4 (46 ref.) **(Rus)**

THERAPY

The use of electrolyte solutions for reducing transport stress. Schaefer AL, et al. **J Anim Sci** 1997 Jan;75(1):258–65 (97 ref.)

STRESS TEST see **EXERCISE TEST**

STRESSFUL EVENTS see **LIFE CHANGE EVENTS**

STRETCH RECEPTORS see **MECHANORECEPTORS**

STRETCH RECEPTORS, ARTERIAL see **PRESSORECEPTORS**

STRETCH RECEPTORS, MUSCLE see **MUSCLE SPINDLES**

STRETCH RECEPTORS, PULMONARY see **PULMONARY STRETCH RECEPTORS**

STRETCH RECEPTORS, VASCULAR see **PRESSORECEPTORS**

STRIA VASCULARIS

CYTOLOGY

Comparison of ion transport mechanisms between vestibular dark cells and strial marginal cells. Wangemann P. **Hear Res** 1995 Oct;90(1–2):149–57 (50 ref.)

PHYSIOLOGY

[Potassium ion secretion and generation of the endocochlear potential in the stria vascularis] Wangemann P. **HNO** 1997 Apr;45(4):205–9 (31 ref.) (Eng. Abstr.) **(Ger)**

STRIATE CORTEX see **VISUAL CORTEX**

STRIATED BORDER see **MICROVILLI**

STRIDOR see **RESPIRATORY SOUNDS**

STROKE see **CEREBROVASCULAR DISORDERS**

STROKE VOLUME

Importance of the right ventricle in valvular heart disease. Nagel E, et al. **Eur Heart J** 1996 Jun;17(6):829–36 (75 ref.)
The arrhythmogenic right ventricle. Dysplasia versus cardiomyopathy. Fontaine G, et al. **Heart Vessels** 1995; 10(5):227–35 (37 ref.)
Determination of ventricular ejection fraction: a comparison of available imaging methods. The Cardiovascular Imaging Working Group. Rumberger JA, et al. **Mayo Clin Proc** 1997 Sep;72(9):860–70 (54 ref.)
[Coronary bypass in patients with severe left ventricular dysfunction (EF < or = 25%). Apropos of 111 patients] Bouchart F, et al. **Arch Mal Coeur Vaiss** 1997 Apr; 90(4):441–8 (33 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

[Frank–Starling mechanism and the 1st temporal derivative of ventricular pressure] Okoshi K, et al. **Arq Bras Cardiol** 1996 Apr;66(4):233–7 (41 ref.) **(Por)**

STROMAL CELLS

Significance of bone marrow stromal cells in hematopoiesis and hematological disorders. Nagao T. **Tokai J Exp Clin Med** 1995 Jul;20(2):121–30 (83 ref.)

CYTOLOGY

A new role for the stromal cells in kidney development. Bard J. **Bioessays** 1996 Sep;18(9):705–7 (15 ref.)
Long-term B-lymphoid cultures from murine bone marrow establishment and cloning by using stromal cell line AC 6.21. Whitlock CA, et al. **Methods Mol Biol** 1997;75:231–48 (13 ref.)
Marrow stromal cells as stem cells for nonhematopoietic tissues. Prockop DJ. **Science** 1997 Apr 4;276(5309):71–4 (32 ref.)

ENZYMOLOGY

Stromal cell expression of components of matrix-degrading protease systems in human cancer. Hewitt R, et al. **Enzyme Protein** 1996;49(1–3):163–73 (89 ref.)
The role of stromelysin-1 in stromal-epithelial interactions and cancer. Wiesen JF, et al. **Enzyme Protein** 1996; 49(1–3):174–81 (53 ref.)

PATHOLOGY

Stromal-epithelial cell interactions in breast cancer. Heber D, et al. **Adv Exp Med Biol** 1996;399:41–51 (69 ref.)
Role of stromal myofibroblasts infiltrating colon cancer in tumor invasion. Martin M, et al. **Pathol Res Pract** 1996 Jul;192(7):712–7 (47 ref.)
Gastrointestinal stromal tumors. Suster S. **Semin Diagn Pathol** 1996 Nov;13(4):297–313 (65 ref.)

PHYSIOLOGY

Extracellular matrix remodeling and the regulation of epithelial-stromal interactions during differentiation and involution. Werb Z, et al. **Kidney Int Suppl** 1996 May; 54:S68–74 (46 ref.)
The multiple roles of tumour stroma. Wernert N. **Virchows Arch** 1997 Jun;430(6):433–43 (161 ref.)
[The role of bone marrow stromal cells in apoptosis in myelodysplastic syndrome] Yaguchi M, et al. **Rinsho Ketsueki** 1996 Jul;37(7):542–6 (10 ref.) **(Jpn)**

STROMAL DYSTROPHIES, CORNEAL see **CORNEAL DYSTROPHIES, HEREDITARY**

STROMELYSIN 1

BIOSYNTHESIS

Cytokines secreted by glial cells infected with HTLV-I modulate the expression of matrix metalloproteinases (MMPs) and their natural inhibitor (TIMPs): possible involvement in neurodegenerative processes. Giraudon P, et al. **Mol Psychiatry** 1997 Mar;2(2):107–10, 84 (23 ref.)

PHYSIOLOGY

Stromelysin-3 and other stromelysins in breast cancer: importance of epithelial-stromal interactions during tumor progression. Basset P, et al. **Cancer Treat Res** 1996; 83:353–67 (69 ref.)
The role of stromelysin-1 in stromal-epithelial interactions and cancer. Wiesen JF, et al. **Enzyme Protein** 1996; 49(1–3):174–81 (53 ref.)

STRONGYLIDA

DRUG EFFECTS

[Structural changes in the genital system of nematodes of the suborder Strongylata after exposure to anthelmintics] Bogoiavlenskii IuK. **Med Parazitol (Mosk)** 1997 Jan–Mar; (1):58–61 (4 ref.) **(Rus)**

STRONGYLIDA INFECTIONS

COMPLICATIONS

Eosinophilic ileitis with perforation caused by Angiostrongylus (Parastrongylus) costaricensis. A case study and review. Wu SS, et al. **Arch Pathol Lab Med** 1997 Sep;121(9):989–91 (15 ref.)

STRONGYLOIDES STERCORALIS

Strongyloidiasis. Mahmoud AA. **Clin Infect Dis** 1996 Nov; 23(5):949–52; quiz 953 (11 ref.)
Pulmonary manifestations of strongyloidiasis. Wehner JH, et al. **Semin Respir Infect** 1997 Jun;12(2):122–9 (79 ref.)

ISOLATION & PURIFICATION

Reactive arthritis induced by Strongyloides stercoralis. Brocq O, et al. **Rev Rhum Engl Ed** 1996 Mar;63(3):217–9 (12 ref.)

STRONGYLOIDIASIS

Strongyloidiasis. Mahmoud AA. **Clin Infect Dis** 1996 Nov; 23(5):949–52; quiz 953 (11 ref.)
Strongyloidiasis. The protean parasitic infection. Schneider JH, et al. **Postgrad Med** 1997 Sep;102(3):177–84 (24 ref.)
Pulmonary manifestations of strongyloidiasis. Wehner JH, et al. **Semin Respir Infect** 1997 Jun;12(2):122–9 (79 ref.)

COMPLICATIONS

Reactive arthritis induced by Strongyloides stercoralis. Brocq O, et al. **Rev Rhum Engl Ed** 1996 Mar;63(3):217–9 (12 ref.)

DIAGNOSIS

[Strongyloidosis. II. Clinical manifestations] Soroczan W. **Wiad Parazytol** 1996;42(3):291–312 (101 ref.) (Eng. Abstr.) **(Pol)**
[Strongyloidosis. IV. Immunodiagnosis] Soroczan W. **Wiad Parazytol** 1996;42(4):381–94 (46 ref.) (Eng. Abstr.) **(Pol)**

PARASITOLOGY

Parasitic diseases in immunocompromised hosts. Cryptosporidiosis, isosporiasis, and strongyloidiasis. Heyworth MF. **Gastroenterol Clin North Am** 1996 Sep; 25(3):691–707 (116 ref.)

STRONTIUM RADIOISOTOPES

ADMINISTRATION & DOSAGE

The treatment of osseous metastases of hormone-refractory prostate cancer with external beam radiotherapy and Strontium-89. De Ruysscher D, et al. **Acta Urol Belg** 1996 Sep;64(3):13–9 (44 ref.)

G-STROPHANTHIN see **OUABAIN**

STRUCTURAL GENES see **GENES, STRUCTURAL**

STRUCTURE-ACTIVITY RELATIONSHIP

Structure-function analysis of the cloned opiate receptors: peptide and small molecule interactions. Blake AD, et al. **Chem Biol** 1996 Dec;3(12):967–72 (28 ref.)
QSAR predictive of contact allergy: scope and limitations. Hostýnek JJ, et al. **Curr Probl Dermatol** 1996;25:18–27 (34 ref.)
Quantitative structure-activity relationships in substrates, inducers, and inhibitors of cytochrome P4501 (CYP1). Lewis DF. **Drug Metab Rev** 1997 Aug;29(3):589–650 (64 ref.)
Serendipity meets precision: the integration of structure-based drug design and combinatorial chemistry for efficient drug discovery. Salemme FR, et al. **Structure** 1997 Mar 15;5(3):319–24 (28 ref.)

STRUCTURE, MOLECULAR see **MOLECULAR STRUCTURE**

STRUMA OVARII

DIAGNOSIS

Malignant struma ovarii. A case report and review of the literature. Berghella V, et al. **Gynecol Obstet Invest** 1997; 43(1):68–72 (20 ref.)

PATHOLOGY

[Struma ovarii—a rare tumor in gynecological practice] Popov I, et al. **Akush Ginekol (Sofiia)** 1996;35(4):41–5 (26 ref.) (Eng. Abstr.) **(Bul)**
[Struma ovarii or malignant ovarian goiter. A case] Barrande G, et al. **Presse Med** 1997 Jun 7;26(19):900–2 (21 ref.) (Eng. Abstr.) **(Fre)**

STUART FACTOR see **FACTOR X**

STUART-PROWER FACTOR see **FACTOR X**

STUDENT SELECTION see **SCHOOL ADMISSION CRITERIA**

STUDENTS

Essential practices as adults read to meet the needs of deaf or hard of hearing students. Luetke-Stahlman B, et al. **Am Ann Deaf** 1996 Oct;141(4):309–20 (176 ref.)

STUDENTS

Health problems of college students. Grace TW. **J Am Coll Health** 1997 May;45(6):243–50 (79 ref.)

The importance of healthy communities of higher education. Jackson ML, et al. **J Am Coll Health** 1997 May; 45(6):237–41 (24 ref.)

HIV/AIDS risk in heterosexual college students. A review of a decade of literature. Lewis JE, et al. **J Am Coll Health** 1997 Jan;45(4):147–58 (76 ref.)

A 33-yr follow-up of peak oxygen uptake and related variables of former physical education students. Astrand PO, et al. **J Appl Physiol** 1997 Jun;82(6):1844–52 (28 ref.)

Bridging student health risks and academic achievement through comprehensive school health programs. Symons CW, et al. **J Sch Health** 1997 Aug;67(6):220–7 (73 ref.)

School age outcome in low birth weight preterm infants. Leonard CH, et al. **Semin Perinatol** 1997 Jun;21(3):240–53 (52 ref.)

[Illegal drug use by secondary school children in Belgium: north-south differences] Navarro FJ, et al. **Rev Epidemiol Sante Publique** 1996 Oct;44(5):395–406 (41 ref.) (Eng. Abstr.) **(Fre)**

LEGISLATION & JURISPRUDENCE

Disciplining children with disabilities under the Individuals with Disabilities Education Act. Ramsingh OM. **J Contemp Health Law Policy** 1995 Fall;12(1):155–81 (211 ref.)

PSYCHOLOGY

The multiple functions of the supervisor: a summary of the seventh IPA conference of training analysis. Vollmer Filho G, et al. **Int J Psychoanal** 1996 Aug;77 (Pt 4):813–8 (0 ref.)

[Sensitivity training for debriefing in the school context] Leuenberger JF. **Rev Med Suisse Romande** 1997 May; 117(5):413–8 (0 ref.) **(Fre)**

STATISTICS & NUMERICAL DATA

Criterion variability in problem-drinking research on college students. Heck EJ, et al. **J Subst Abuse** 1995;7(4):437–47 (43 ref.)

STUDENTS, HEALTH OCCUPATIONS

Students' expectations of clinical teachers. Daniels M, et al. **Radiol Technol** 1996 Sep–Oct;68(1):89–93 (10 ref.)

Distance learning for health care students. Tanenbaum BG, et al. **Radiol Technol** 1996 Nov–Dec;68(2):157–8 (4 ref.)

PSYCHOLOGY

Process over person?: occupational therapy students' fieldwork experiences of people in psychiatric settings. Lyons M. **Disabil Rehabil** 1996 Apr;18(4):197–204 (51 ref.)

STUDENTS, MEDICAL

Being female in medical school. Observations of a counselor. Wright BV. **J Fla Med Assoc** 1996 Aug–Sep;83(7):498–501 (9 ref.)

Medical students' specialty choice and the need for primary care. Our future. Rosenthal MP, et al. **Prim Care** 1996 Mar; 23(1):155–67 (79 ref.)

The Objective Structured Clinical Examination (OSCE) in the clinical clerkship: an overview. Tervo RC, et al. **S D J Med** 1997 May;50(5):153–6 (11 ref.)

[Thoracic surgery that is attractive to medical students] Osada H. **Kyobu Geka** 1997 Jan;50(1):26–9 (1 ref.) **(Jpn)**

PSYCHOLOGY

Enhancing clinical teaching with information technologies: what can we do right now? Sandroni S. **Acad Med** 1997 Sep;72(9):770–4 (17 ref.)

Use of effective feedback to facilitate adult learning. Sachdeva AK. **J Cancer Educ** 1996 Summer;11(2):106–18 (53 ref.)

[Questions on organ donation. An exploratory study of medical students and overview of the literature] Strenge H. **Psychother Psychosom Med Psychol** 1996 Sep–Oct; 46(9–10):327–32 (45 ref.) (Eng. Abstr.) **(Ger)**

STUDENTS, NURSING

Faculty commitment: retaining minority nursing students in majority institutions. Campbell AR, et al. **J Nurs Educ** 1996 Oct;35(7):298–303 (28 ref.)

An issue of conflicting rights: nursing student charged with drug trafficking. Cullen P, et al. **J Prof Nurs** 1997 May–Jun; 13(3):186–92 (23 ref.)

PSYCHOLOGY

Constructing meaning in the learning experience: the role of alternative theoretical frameworks. Lauder W. **J Adv Nurs** 1996 Jul;24(1):91–7 (50 ref.)

Issues in recruitment and retention of minority nursing students. Dowell MA. **J Nurs Educ** 1996 Oct;35(7):293–7 (43 ref.)

Guiding dialogue in the transformation of teacher-student relationships. Gaines S, et al. **Nurs Outlook** 1996 May–Jun; 44(3):124–8 (14 ref.)

STUNNED MYOCARDIUM see **MYOCARDIAL STUNNING**

STURGE-WEBER SYNDROME

COMPLICATIONS

[Sturge-Weber angiomatosis responsible for hemiplegia without cerebral infarction in term pregnancy] Chabriat H, et al. **Rev Neurol (Paris)** 1996 Aug–Sep;152(8–9):536–41 (56 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Sturge-Weber syndrome revisited: the role of neuroradiology. Griffiths PD. **Neuropediatrics** 1996 Dec; 27(6):284–94 (44 ref.)

[Bilateral Sturge-Weber-Krabbe syndrome. Apropos of a case] Hamdani M, et al. **J Fr Ophtalmol** 1997;20(3):213–6 (11 ref.) (Eng. Abstr.) **(Fre)**

STUTTERING

GENETICS

Genetics of stuttering: a critical review. Yairi E, et al. **J Speech Hear Res** 1996 Aug;39(4):771–84 (84 ref.)

SUBACROMIAL IMPINGEMENT SYNDROME see **SHOULDER IMPINGEMENT SYNDROME**

SUBACUTE SCLEROSING PANENCEPHALITIS

Fulminating subacute sclerosing panencephalitis: case report and literature review. PeBenito R, et al. **Clin Pediatr (Phila)** 1997 Mar;36(3):149–54 (31 ref.)

[Subacute sclerosing panencephalitis (SSPE)] Nihei K. **Nippon Rinsho** 1997 Apr;55(4):908–15 (25 ref.) (Eng. Abstr.) **(Jpn)**

[Slow virus infection] Yamanouchi K. **Nippon Rinsho** 1997 Apr;55(4):795–9 (15 ref.) (Eng. Abstr.) **(Jpn)**

CEREBROSPINAL FLUID

[Subacute sclerosing panencephalitis (SSPE) as differential diagnosis in severe personality changes and ataxia--case report and literature review] Wölfle J, et al. **Klin Padiatr** 1997 May–Jun;209(3):111–5 (19 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Subacute sclerosing panencephalitis presenting as acute disseminated encephalomyelitis: a case report. Arora SC, et al. **J Neurol Sci** 1997 Feb 27;146(1):13–8 (28 ref.)

Subacute sclerosing panencephalitis. Gascon GG. **Semin Pediatr Neurol** 1996 Dec;3(4):260–9 (78 ref.)

[Subacute sclerosing panencephalitis (SSPE) as differential diagnosis in severe personality changes and ataxia--case report and literature review] Wölfle J, et al. **Klin Padiatr** 1997 May–Jun;209(3):111–5 (19 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

[Sclerotic subacute panencephalitis: data on 1997] Gascón GG. **Rev Neurol** 1997 Jun;25(142):945–53 (85 ref.) **(Spa)**

PATHOLOGY

Adult-onset subacute sclerosing panencephalitis: case reports and review of the literature. Singer C, et al. **Mov Disord** 1997 May;12(3):342–53 (24 ref.)

SUBARACHNOID HEMORRHAGE

Review on traumatic subarachnoid hemorrhage. Kakarieka A. **Neurol Res** 1997 Jun;19(3):230–2 (47 ref.)

COMPLICATIONS

Giant cerebral arterial aneurysm in an infant: report of a case and review of 42 previous cases in infants with cerebral arterial aneurysm. Kasahara E, et al. **Acta Paediatr Jpn** 1996 Dec;38(6):684–8 (15 ref.)

Hypertensive, hypervolemic, hemodilutional therapy for aneurysmal subarachnoid hemorrhage. Is it efficacious? No. Oropello JM, et al. **Crit Care Clin** 1996 Jul;12(3):709–30 (79 ref.)

Hypertensive, hypervolemic, hemodilutional therapy for aneurysmal subarachnoid hemorrhage. Is it efficacious? Yes. Ullman JS, et al. **Crit Care Clin** 1996 Jul;12(3):697–707 (70 ref.)

[Cardiovascular abnormalities in subarachnoidal hemorrhage] Kubo S, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (15):422–4 (14 ref.) **(Jpn)**

DIAGNOSIS

Diagnosis of spontaneous subarachnoid hemorrhage. Sawin PD, et al. **Am Fam Physician** 1997 Jan;55(1):145–56 (21 ref.)

Predictive value of signs and symptoms in the diagnosis of subarachnoid hemorrhage among stroke patients. Talavera JO, et al. **Arch Med Res** 1996 Autumn;27(3):353–7 (28 ref.)

Subarachnoid haemorrhage. diPierro CG, et al. **Baillieres Clin Neurol** 1996 Oct;5(3):543–63 (37 ref.)

Traumatic spinal subarachnoid hematoma: report of a case with MRI. Gupta SK, et al. **Surg Neurol** 1997 Aug; 48(2):189–92 (36 ref.)

DRUG THERAPY

Efficacy and mechanisms of action of the cytoprotective lipid peroxidation inhibitor tirilazad mesylate in subarachnoid haemorrhage. Hall ED. **Eur J Anaesthesiol** 1996 May; 13(3):279–89 (55 ref.)

Technical considerations on intra-arterial papaverine hydrochloride for cerebral vasospasm. Mathis JM, et al. **Neuroradiology** 1997 Feb;39(2):90–8 (31 ref.)

ETIOLOGY

Management of nontraumatic subarachnoid hemorrhage in a patient with sickle-cell disease: a case report. Rinnert S, et al. **Acad Emerg Med** 1996 Sep;3(9):859–63 (37 ref.)

Traumatic tear of the basilar artery associated with vertebral column injuries. Sato Y, et al. **Am J Forensic Med Pathol** 1997 Jun;18(2):129–34 (21 ref.)

A patient with Wegener's granulomatosis presenting with a subarachnoid hemorrhage: case report and review of CNS disease associated with Wegener's granulomatosis. Cruz DN, et al. **Am J Nephrol** 1997;17(2):181–6 (19 ref.)

Arteriovenous malformations of the posterior fossa: a report on 28 cases and review of the literature. Symon L, et al. **Br J Neurosurg** 1995;9(6):721–32 (48 ref.)

Aneurysmal subarachnoid hemorrhage associated with weight training: three case reports. Haykowsky MJ, et al. **Clin J Sport Med** 1996 Jan;6(1):52–5 (21 ref.)

Subarachnoid hemorrhage and aneurysms. Young BJ, et al. **Semin Ultrasound CT MR** 1996 Jun;17(3):265–77 (83 ref.)

Circadian fluctuations in onset of subarachnoid hemorrhage. New data on aneurysmal and perimesencephalic hemorrhage and a systematic review. Vermeer SE, et al. **Stroke** 1997 Apr;28(4):805–8 (29 ref.)

[Posterior cerebral aneurysm associated with complete occlusion of the middle cerebral artery caused subarachnoid hemorrhage: a case report] Kawamura A, et al. **No Shinkei Geka** 1996 Dec;24(12):1107–11 (17 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Multiple cerebral aneurysms in identical twins. Hagen T, et al. **AJNR Am J Neuroradiol** 1997 May;18(5):973–6 (34 ref.)

MORTALITY

Case-fatality rates and functional outcome after subarachnoid hemorrhage: a systematic review. Hop JW, et al. **Stroke** 1997 Mar;28(3):660–4 (44 ref.)

PATHOLOGY

Subarachnoid haemorrhage: diagnosis and treatment. Vermeulen M. **J Neurol** 1996 Jul;243(7):496–501 (19 ref.)

PHYSIOPATHOLOGY

Arteriovenous malformations of the posterior fossa: a report on 28 cases and review of the literature. Symon L, et al. **Br J Neurosurg** 1995;9(6):721–32 (48 ref.)

SURGERY

Management of nontraumatic subarachnoid hemorrhage in a patient with sickle-cell disease: a case report. Rinnert S, et al. **Acad Emerg Med** 1996 Sep;3(9):859–63 (37 ref.)

Treatment of dissecting basilar artery aneurysm by flow reversal. Amin-Hanjani S, et al. **Acta Neurochir (Wien)** 1997;139(1):44–51 (38 ref.)

Aneurysm of the internal auditory artery: our experience and review of the literature. Banczerowski P, et al. **Acta Neurochir (Wien)** 1996;138(10):1157–62 (39 ref.)

Vascular neurosurgery: aneurysms, arteriovenous malformations, subarachnoid hemorrhage, and intracranial hemorrhage. Guterman LR, et al. **Curr Opin Neurol** 1996 Feb;9(1):57–61 (34 ref.)

Subarachnoid haemorrhage: diagnosis and treatment. Vermeulen M. **J Neurol** 1996 Jul;243(7):496–501 (19 ref.)

Aneurysm of an azygos anterior cerebral artery: report of two cases and review of the literature. Baykal S, et al. **Neurosurg Rev** 1996;19(1):57–9 (10 ref.)

Perimesencephalic nonaneurysmal subarachnoid hemorrhage: review of the literature [see comments] Schwartz TH, et al. **Neurosurgery** 1996 Sep;39(3):433–40; discussion 440 (58 ref.) Comment in: Neurosurgery 1997 Apr;40(4):885.

[Indications for surgical therapy of aneurysmic subarachnoid hemorrhage--current status] Pietilä TA, et al. **Wien Med Wochenschr** 1997;147(7–8):149–51 (21 ref.) (Eng. Abstr.) **(Ger)**

[Neurosurgical therapy of subarachnoid hemorrhage] Seifert V. **Wien Med Wochenschr** 1997;147(7–8):152–8 (20 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Subarachnoid haemorrhage. diPierro CG, et al. **Baillieres Clin Neurol** 1996 Oct;5(3):543–63 (37 ref.)

Case-fatality rates and functional outcome after subarachnoid hemorrhage: a systematic review. Hop JW, et al. **Stroke** 1997 Mar;28(3):660–4 (44 ref.)

Intra-aneurysmal GDC embolization followed by intrathecal tPA administration for poor-grade basilar tip aneurysm. Ezura M, et al. **Surg Neurol** 1997 Feb;47(2):144-7; discussion 147-8 (20 ref.)
[Forum: Clips and coils in aneurysm treatment] Spetzger U, et al. **Wien Med Wochenschr** 1997;147(7-8):172-7 (62 ref.) (Eng. Abstr.) **(Ger)**

SUBARACHNOID PRESSURE see **INTRACRANIAL PRESSURE**

SUBARACHNOID SPACE

Traumatic subarachnoid-pleural fistula [see comments] Sarwal V, et al. **Ann Thorac Surg** 1996 Dec;62(6):1622-6 (26 ref.) Comment in: Ann Thorac Surg 1997 May;63(5):1511.
Inadvertent intrathecal use of ionic contrast agents: treatment with immediate ventriculolumbar lavage [letter] Schwab S, et al. **J Neurol** 1996 Sep;243(9):671-3 (9 ref.)

SUBCELLULAR FRACTIONS

CHEMISTRY

Intracellular factor XIII: cellular distribution of factor XIII subunit a in humans. Adány R. **Semin Thromb Hemost** 1996; 22(5):399-408 (92 ref.)

ENZYMOLOGY

Influence of cell differentiation and protein kinase C activation on sub-cellular distribution of beta-N-acetylhexosaminidases of HL 60 cells. Emiliani C, et al. **Physiol Chem Phys Med NMR** 1995;27(4):369-76 (26 ref.)
Anchoring and scaffold proteins for kinases and phosphatases. Lester LB, et al. **Recent Prog Horm Res** 1997; 52:409-29; discussion 429-30 (98 ref.)
[Proteolytic enzymes: subcellular localization, properties and participation in neuropeptide metabolism] Vernigora AN, et al. **Biokhimiia** 1996 May;61(5):771-85 (151 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Cardiac alpha(1)-adrenoceptors that regulate contractile function: subtypes and subcellular signal transduction mechanisms. Endoh M. **Neurochem Res** 1996 Feb; 21(2):217-29 (100 ref.)

SUBCHONDRAL CYSTS see **BONE CYSTS**

SUBCLAVIAN ARTERY

Spontaneous arterial thrombosis with an advanced ovarian malignancy. Minjarez DA, et al. **Gynecol Oncol** 1997 Jan; 64(1):176-9 (18 ref.)
[Left subclavian artery total occlusion] Anzai T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):479-80 (7 ref.) **(Jpn)**
[Subclavian artery aneurysm] Ito M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):476-8 (14 ref.) **(Jpn)**

ABNORMALITIES

Aberrant right subclavian artery aneurysm--a surgical review. Jebara VA, et al. **J Med Liban** 1995;43(3):157-61 (32 ref.)
[Dissecting aneurysm of an aberrant right subclavian artery: diagnosis with ultrafast-CT] Reittner P, et al. **Aktuelle Radiol** 1996 Jan;6(1):38-40 (8 ref.) (Eng. Abstr.) **(Ger)**
[Aberrant subclavian artery] Takahashi M. **Ryoikibetsu Shokogun Shirizu** 1996;(13):98-100 (7 ref.) **(Jpn)**

INJURIES

Penetrating injuries to the thoracic great vessels. Demetriades D. **J Card Surg** 1997 Mar-Apr;12(2 Suppl):173-9; discussion 179-80 (15 ref.)

RADIOGRAPHY

Expanding aneurysm of aberrant right subclavian artery. Case report and imaging evaluation. Hogg JP, et al. **Clin Imaging** 1997 May-Jun;21(3):195-9 (8 ref.)

ULTRASONOGRAPHY

Doppler sonography of vertebral-subclavian system. Rabbia C. **Rays** 1995 Oct-Dec;20(4):426-53 (16 ref.)

SUBCLAVIAN STEAL SYNDROME

[The subclavian steal syndrome] Takaba T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):473-5 (21 ref.) **(Jpn)**

SURGERY

Subclavian carotid transposition: an analysis of a clinical series and a review of the literature. Schardey HM, et al. **Eur J Vasc Endovasc Surg** 1996 Nov;12(4):431-6 (27 ref.)
[Aorto-bi-subclavian bypass in the treatment of left subclavian steal syndrome and stenosis of the innominate artery] Balogh A, et al. **Orv Hetil** 1997 Jul 13; 138(28):1797-800 (27 ref.) (Eng. Abstr.) **(Hun)**

THERAPY

Percutaneous transluminal angioplasty in coronary-internal thoracic-subclavian steal syndrome. Nguyen NH, et al. **Can J Cardiol** 1997 Mar;13(3):285-9 (34 ref.)

ULTRASONOGRAPHY

Doppler sonography of vertebral-subclavian system. Rabbia C. **Rays** 1995 Oct-Dec;20(4):426-53 (16 ref.)

SUBCLAVIAN VEIN

Pulmonary embolism from axillosubclavian thrombosis on a rehabilitation unit: case report. Kissel DJ. **Arch Phys Med Rehabil** 1997 Mar;78(3):319-23 (44 ref.)
Primary subclavian-axillary vein thrombosis: consensus and commentary. Rutherford RB, et al. **Cardiovasc Surg** 1996 Aug;4(4):420-3 (15 ref.)
You are asked to place a dialysis access catheter in a patient. What is your preferred access site, and why? Trerotola SO. **J Vasc Interv Radiol** 1997 Jan-Feb;8(1 Pt 1):75-6 (10 ref.)
[Primary subclavian vein thrombosis (Paget-Schroetter syndrome)] Nakashima K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):462-5 (19 ref.) **(Jpn)**

INJURIES

Penetrating injuries to the thoracic great vessels. Demetriades D. **J Card Surg** 1997 Mar-Apr;12(2 Suppl):173-9; discussion 179-80 (15 ref.)

PATHOLOGY

Stenting of central venous stenoses in hemodialysis patients: long-term results. Mickley V, et al. **Kidney Int** 1997 Jan; 51(1):277-80 (31 ref.)

SUBCOMMISSURAL ORGAN

The subcommissural organ and Reissner's fiber complex. An enigma in the central nervous system? Meiniel A, et al. **Prog Histochem Cytochem** 1996;30(2):1-66 (179 ref.)

SUBCONSCIOUS see **UNCONSCIOUS (PSYCHOLOGY)**

SUBCORNEAL PUSTULAR DERMATOSIS see **SKIN DISEASES, VESICULOBULLOUS**

SUBCUTANEOUS EMPHYSEMA

[Nontraumatic subcutaneous emphysema. Diagnostic and therapeutic problems] Subotić D, et al. **Srp Arh Celok Lek** 1997 Jul-Aug;125(7-8):228-33 (9 ref.) (Eng. Abstr.) **(Scc)**

SUBDURAL EMPYEMA see **EMPYEMA, SUBDURAL**

SUBFORNICAL ORGAN

PHYSIOLOGY

Actions of angiotensin in the subfornical organ and area postrema: implications for long term control of autonomic output. Ferguson AV, et al. **Clin Exp Pharmacol Physiol** 1997 Jan;24(1):96-101 (46 ref.)

SUBICULUM see **HIPPOCAMPUS**

SUBLIMINAL PERCEPTION see **SUBLIMINAL STIMULATION**

SUBLIMINAL STIMULATION

Subliminal manipulation of smoking. Frydman M. **J Environ Pathol Toxicol Oncol** 1996;15(2-4):173-6 (8 ref.)

SUBLINGUAL GLAND NEOPLASMS

PATHOLOGY

Adenoid cystic carcinoma of the sublingual salivary gland in a 16-year-old female--report of a case and review of the literature. McFall MR, et al. **J Laryngol Otol** 1997 May; 111(5):485-8 (20 ref.)

SUBMANDIBULAR GLAND

ABNORMALITIES

Atypically located submandibular gland diagnosed by Doppler ultrasound. Carney AS, et al. **J Laryngol Otol** 1996 Dec;110(12):1171-2 (6 ref.)

CYTOLOGY

The rodent granular convoluted tubule cell--an update. Gresik EW, et al. **Eur J Morphol** 1996 Aug;34(3):221-4 (55 ref.)
Immunocytochemical studies of cell differentiation during rat salivary gland development. Hand AR, et al. **Eur J Morphol** 1996 Aug;34(3):149-54 (25 ref.)

EMBRYOLOGY

Epithelial morphogenesis in mouse embryonic submandibular gland: its relationships to the tissue organization of epithelium and mesenchyme. Hieda Y, et al. **Dev Growth Differ** 1997 Feb;39(1):1-8 (52 ref.)
Immunocytochemical studies of cell differentiation during rat salivary gland development. Hand AR, et al. **Eur J Morphol** 1996 Aug;34(3):149-54 (25 ref.)
Contemporary approaches to the study of salivary gland morphogenesis. Kashimata M, et al. **Eur J Morphol** 1996 Aug;34(3):143-7 (45 ref.)

IMMUNOLOGY

The submandibular gland: a key organ in the neuro-immuno-regulatory network? Sabbadini E, et al. **Neuroimmunomodulation** 1995 Jul-Aug;2(4):184-202 (205 ref.)

SURGERY

Nerve paralysis after surgery in the submandibular triangle: review of University of Tokyo Hospital experience. Ichimura K, et al. **Head Neck** 1997 Jan;19(1):48-53 (19 ref.)

ULTRASTRUCTURE

The rodent granular convoluted tubule cell--an update. Gresik EW, et al. **Eur J Morphol** 1996 Aug;34(3):221-4 (55 ref.)
X-ray microanalysis applied to the study of salivary glands. Roomans GM, et al. **Eur J Morphol** 1996 Aug;34(3):203-8 (30 ref.)

SUBMANDIBULAR GLAND DISEASES

PATHOLOGY

Submandibular salivary gland fibrosis. Ficarra BJ. **J Med** 1996;27(3-4):103-13 (9 ref.)
Oral inflammatory pseudotumour: immunohistochemical investigation of a case involving the submandibular gland and review of the literature. Monteil RA, et al. **Oral Oncol** 1997 May;33(3):215-9 (42 ref.)

SUBMANDIBULAR GLAND NEOPLASMS

PATHOLOGY

Basal cell adenocarcinoma of the salivary glands. Report of seven cases and review of the literature. Muller S, et al. **Cancer** 1996 Dec 15;78(12):2471-7 (26 ref.)
Oncocytomas of the submandibular gland. A series of 22 cases and a review of the literature. Thompson LD, et al. **Cancer** 1996 Dec 1;78(11):2281-7 (55 ref.)
Lymphoepithelioma-like salivary gland carcinoma in Taiwan: a clinicopathological study of nine cases demonstrating a strong association with Epstein-Barr virus. Kuo T, et al. **Histopathology** 1997 Jul;31(1):75-82 (22 ref.)
A massive pleomorphic adenoma of the submandibular salivary gland. Erol B, et al. **J Oral Maxillofac Surg** 1997 Sep;55(9):1011-4 (22 ref.)
[Effects of TNM extension and histopathological type of the tumor on long-term survival rates of parotid and submandibular gland cancer] Konno A, et al. **Gan To Kagaku Ryoho** 1997 Aug;24(10):1347-53 (10 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Salivary duct carcinoma: clinical characteristics and treatment strategies. Guzzo M, et al. **Head Neck** 1997 Mar; 19(2):126-33 (29 ref.)

VIROLOGY

Lymphoepithelioma-like salivary gland carcinoma in Taiwan: a clinicopathological study of nine cases demonstrating a strong association with Epstein-Barr virus. Kuo T, et al. **Histopathology** 1997 Jul;31(1):75-82 (22 ref.)

SUBMARINE MEDICINE

see related
ECOLOGICAL SYSTEMS, CLOSED

SUBMAXILLARY GLAND see **SUBMANDIBULAR GLAND**

SUBMUCOSAL PLEXUS see **SUBMUCOUS PLEXUS**

SUBMUCOUS PLEXUS

PHYSIOLOGY

Neural reflexes controlling intestinal microcirculation. Vanner S, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):G223-30 (66 ref.)

SUBSIDIES, GOVERNMENT see **FINANCING,**

SUBSIDIES, GOVERNMENT

GOVERNMENT

SUBSIDIES, RESEARCH see RESEARCH SUPPORT

SUBSTANCE ABUSE

see related
DESIGNER DRUGS
DRUG AND NARCOTIC CONTROL
STREET DRUGS

Synaptic regulation of mesocorticolimbic dopamine neurons. White FJ. **Annu Rev Neurosci** 1996;19:405–36 (191 ref.)
Burns following petrol sniffing. Janežič TF. **Burns** 1997 Feb; 23(1):78–80 (18 ref.)
Leaded gasoline abuse: the role of tetraethyl lead. Tenenbein M. **Hum Exp Toxicol** 1997 Apr;16(4):217–22 (44 ref.)
Alcohol and drug misuse in the nursing home. Joseph CL. **Int J Addict** 1995 Nov–Dec;30(13–14):1953–84 (100 ref.)
Abuse liability of flunitrazepam. Woods JH, et al. **J Clin Psychopharmacol** 1997 Jun;17(3 Suppl 2):1S–57S (232 ref.)
Zopiclone: is there any dependence and abuse potential? Lader M. **J Neurol** 1997 Apr;244(4 Suppl 1):S18–22 (31 ref.)
Managed care of substance abuse disorders. Implications for generalist physicians. Larson MJ, et al. **Med Clin North Am** 1997 Jul;81(4):1053–69 (58 ref.)
The role of the generalist in the care of the substance-abusing patient. Lewis DC. **Med Clin North Am** 1997 Jul; 81(4):831–43 (71 ref.)
Physician impairment by substance abuse. O'Connor PG, et al. **Med Clin North Am** 1997 Jul;81(4):1037–52 (49 ref.)
Prescription drug abuse. A question of balance. Parran T Jr. **Med Clin North Am** 1997 Jul;81(4):967–78 (16 ref.)
Women and substance abuse. Stein MD, et al. **Med Clin North Am** 1997 Jul;81(4):979–98 (125 ref.)
Barbiturates. Coupey SM. **Pediatr Rev** 1997 Aug;18(8):260–4; quiz 265 (13 ref.)
The influence of alternative reinforcers on cocaine use and abuse: a brief review. Higgins ST. **Pharmacol Biochem Behav** 1997 Jul;57(3):419–27 (24 ref.)
Substance abuse in pregnancy. A bigger problem than you think. King JC. **Postgrad Med** 1997 Sep;102(3):135–7, 140–5, 149–50 (42 ref.)
Managing drug misusers—a guide. Kemp K, et al. **Practitioner** 1996 May;240(1562):326–8, 330, 333–4 (8 ref.)
Teratogenic potential of cocaine. Buehler BA, et al. **Semin Perinatol** 1996 Apr;20(2):93–8 (38 ref.)
Cardiovascular effects of cocaine during pregnancy. Chao CR. **Semin Perinatol** 1996 Apr;20(2):107–14 (48 ref.)
The impact of prenatal cocaine exposure: studies of the developing infant. Landry SH, et al. **Semin Perinatol** 1996 Apr;20(2):99–106 (39 ref.)
Placental transfer of selected substances of abuse. Little BB, et al. **Semin Perinatol** 1996 Apr;20(2):147–53 (52 ref.)
The effect of cocaine on myometrial contractile activity: basic mechanisms. Monga M. **Semin Perinatol** 1996 Apr; 20(2):140–6 (45 ref.)
Gender differences in attitudes toward alcohol, tobacco, and other drugs. Kauffman SE, et al. **Soc Work** 1997 May; 42(3):231–41 (67 ref.)
Drug use amongst young athletes. Do any of us really know what we're talking about? Albrecht RR. **Sports Med** 1996 Dec;22(6):351–4 (17 ref.)
[Drug addiction—origin, development and pharmacological intervention] Qu B, et al. **Ther Umsch** 1997 May; 54(5):263–71 (11 ref.) (Eng. Abstr.) **(Ger)**
["Acid parties" and the return of LSD to Israel] Winkler E, et al. **Harefuah** 1996 Sep;131(5–6):176–8 (14 ref.) **(Heb)**
[Context-dependent sensitization: reconsideration and a hypothesis] Ohmori T, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1997 Apr; 17(2):61–8 (66 ref.) (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

DSM-IV: was it worth all the fuss? Schuckit MA. **Alcohol Alcohol Suppl** 1994;2:459–69 (52 ref.)

COMPLICATIONS

The clinical management of co-morbidity. Pols RG. **Alcohol Alcohol Suppl** 1994;2:485–90 (35 ref.)
Initial description of gastric melanosis in a laxative-abusing patient. Mitty RD, et al. **Am J Gastroenterol** 1997 Apr; 92(4):707–8 (4 ref.)
Mesenteric ischemia secondary to cocaine abuse: case reports and literature review. Sudhakar CB, et al. **Am J Gastroenterol** 1997 Jun;92(6):1053–4 (12 ref.)
Pneumothorax in pregnancy associated with cocaine use. Chan L, et al. **Am J Perinatol** 1997 Aug;14(7):385–8 (22 ref.)
Management of substance misusers on the general hospital ward. Williams H, et al. **Br J Clin Pract** 1996 Mar; 50(2):94–8 (23 ref.)
Burns with inhalation injury and petrol aspiration in adolescents seeking euphoria through hydrocarbon inhalation. Sheridan RL. **Burns** 1996 Nov;22(7):566–7 (18 ref.)
Acute complications of cocaine intoxication. Zafar H, et al. **Hosp Pract (Off Ed)** 1997 Feb 15;32(2):167–70, 175–7, 181 (12 ref.)
Reproductive risks of cocaine. Rizk B, et al. **Hum Reprod Update** 1996 Jan–Feb;2(1):43–55 (119 ref.)
New dimensions in toxicology: hyperthermic syndrome following amphetamine derivatives [editorial; comment] Bodenham AR, et al. **Intensive Care Med** 1996 Jul; 22(7):622–4 (15 ref.) Comment on: Intensive Care Med 1996 Jul;22(7):670–1.
Cocaine-induced ischemic colitis with small-vessel thrombosis of colon and gallbladder. Boutros HH, et al. **J Clin Gastroenterol** 1997 Jan;24(1):49–53 (27 ref.)
Ethical and legal issues associated with substance abuse by pregnant and parenting women. Garcia S. **J Psychoactive Drugs** 1997 Jan–Mar;29(1):101–11 (37 ref.)
Effects of alcohol and other drugs on children. Young NK. **J Psychoactive Drugs** 1997 Jan–Mar;29(1):23–42 (145 ref.)
Health consequences of rural illicit drug use: questions without answers. Fisher DG, et al. **NIDA Res Monogr** 1997; 168:175–95 (60 ref.)
Prenatal exposure to drugs of abuse: methodological considerations and effects on sexual differentiation. McGivern RF, et al. **NIDA Res Monogr** 1996;164:78–124 (219 ref.)
Treatment of depression in drug-dependent patients: effects on mood and drug use. Nunes EV, et al. **NIDA Res Monogr** 1997;172:61–85 (98 ref.)
Movement disorders and substance abuse. Lopez W, et al. **Psychiatr Serv** 1997 May;48(5):634–6 (23 ref.)
[The induction of psychopathology by somatic disorders, medications, toxins and drugs after systemic disorders] García Toro M, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1997 Jan–Feb;25(1):50–60 (93 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

DSM-IV: was it worth all the fuss? Schuckit MA. **Alcohol Alcohol Suppl** 1994;2:459–69 (52 ref.)
Drug induced psychosis [editorial] [see comments] Poole R, et al. **Br J Psychiatry** 1996 Feb;168(2):135–8 (34 ref.) Comment in: Br J Psychiatry 1996 May;168(5):651. Comment in: Br J Psychiatry 1996 May;168(5):651–2. Comment in: Br J Psychiatry 1996 Jul;169(1):114–5.
Screening for alcohol and drug abuse. Schorling JB, et al. **Med Clin North Am** 1997 Jul;81(4):845–65 (97 ref.)
The forensic application of testing hair for drugs of abuse. Miller ML, et al. **NIDA Res Monogr** 1997;167:146–60 (12 ref.)
[MDMA ("Ecstasy") use—an overview of psychiatric and medical sequelae] Thomasius R, et al. **Fortschr Neurol Psychiatr** 1997 Feb;65(2):49–61 (125 ref.) (Eng. Abstr.) **(Ger)**
[Ecstasy, a new designer drug in the techno-scene] Kuhlmann T. **Psychiatr Prax** 1996 Nov;23(6):266–9 (10 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Mainstreaming methadone maintenance treatment: the role of the family physician [editorial] Latowsky M, et al. **CMAJ** 1997 Aug 15;157(4):395–8 (31 ref.)
Recent developments in the pharmacotherapy of substance abuse. O'Brien CP. **J Consult Clin Psychol** 1996 Aug; 64(4):677–86 (57 ref.)
Pharmacotherapy for opioid and cocaine abuse. Warner EA, et al. **Med Clin North Am** 1997 Jul;81(4):909–25 (115 ref.)
Treatment of depression in drug-dependent patients: effects on mood and drug use. Nunes EV, et al. **NIDA Res Monogr** 1997;172:61–85 (98 ref.)

ECONOMICS

The costs of drug abuse consequences: a summary of research findings. French MT, et al. **J Subst Abuse Treat** 1996 Nov–Dec;13(6):453–66 (56 ref.)
The economic and social costs of drug abuse among the rural population. Donnermeyer JF. **NIDA Res Monogr** 1997; 168:220–45 (61 ref.)

EPIDEMIOLOGY

A substance abuse consultation service. Enhancing the care of hospitalized substance abusers and providing training in addiction psychiatry. McDuff DR, et al. **Am J Addict** 1997 Summer;6(3):256–65 (43 ref.)
Alcohol and drug abuse in patients with physical disabilities. Hubbard JR, et al. **Am J Drug Alcohol Abuse** 1996 May; 22(2):215–31 (41 ref.)
Drugs in East Germany. Dressler J, et al. **Am J Forensic Med Pathol** 1997 Sep;18(3):303–5 (14 ref.)
Adolescent substance use and abuse. Blum RW. **Arch Pediatr Adolesc Med** 1997 Aug;151(8):805–8 (21 ref.)
Why? Who? How? Estimating numbers of illicit drug users: lessons from a case study from the Australian Capital Territory. Larson A, et al. **Aust N Z J Public Health** 1996 Oct;20(5):493–9 (26 ref.)
Steroid abuse in female athletes. Honour JW. **Curr Opin Obstet Gynecol** 1997 Jun;9(3):181–6 (29 ref.)
Comorbidity and social phobia: clinical and epidemiological issues. Lépine JP, et al. **Int Clin Psychopharmacol** 1996 Jun; 11 Suppl 3:35–41 (39 ref.)
Alcohol and substance abuse in panic disorder. Marshall JR. **J Clin Psychiatry** 1997;58 Suppl 2:46–9; discussion 49–50 (38 ref.)
Psychosocial and pharmacologic explanations of nicotine's "gateway drug" function. Lindsay GB, et al. **J Sch Health** 1997 Apr;67(4):123–6 (27 ref.)
Prevalence of human immunodeficiency virus infection and drug use in pregnant women: a critical review of the literature. Abercrombie PD, et al. **J Womens Health** 1997 Apr;6(2):163–87 (108 ref.)
Anxiety disorders, comorbid substance abuse, and benzodiazepine discontinuation: implications for treatment. Barlow DH. **NIDA Res Monogr** 1997;172:33–51 (48 ref.)
New developments in biological measures of drug prevalence. Cone EJ. **NIDA Res Monogr** 1997;167:108–29 (21 ref.)
Substance use and HIV risk among people with severe mental illness. Cournos F, et al. **NIDA Res Monogr** 1997; 172:110–29 (47 ref.)
Drug and alcohol use among youth in rural communities. Edwards RW. **NIDA Res Monogr** 1997;168:53–78 (14 ref.)
Studies of nonresponse and measurement error in the national household survey on drug abuse. Gfroerer J, et al. **NIDA Res Monogr** 1997;167:273–95 (15 ref.)
The validity of self-reported drug use in survey research: an overview and critique of research methods. Harrison L. **NIDA Res Monogr** 1997;167:17–36 (41 ref.)
Self-reported drug use: results of selected empirical investigations of validity. Hser YI. **NIDA Res Monogr** 1997; 167:320–43 (27 ref.)
Depression, substance use, and sexual orientation as cofactors in HIV-1 infected men: cross-cultural comparisons. Satz P, et al. **NIDA Res Monogr** 1997;172:130–55 (44 ref.)
Time series models of individual substance abusers. Velicer WF. **NIDA Res Monogr** 1994;142:264–301 (72 ref.)
Alcohol and drug abuse by migrant farmworkers: past research and future priorities. Watson JM. **NIDA Res Monogr** 1997;168:443–58 (22 ref.)
The use of external data sources and ratio estimation to improve estimates of hardcore drug use from the NHSDA. Wright D, et al. **NIDA Res Monogr** 1997;167:477–97 (22 ref.)

ETHNOLOGY

Drug and alcohol use among rural Mexican-Americans. Castro FG, et al. **NIDA Res Monogr** 1997;168:498–530 (90 ref.)
Substance abuse in rural African-American populations. Dawkins MP, et al. **NIDA Res Monogr** 1997;168:484–97 (72 ref.)
The consequences of knowing: ethical and legal liabilities in illicit drug research. Fitzgerald J, et al. **Soc Sci Med** 1996 Dec;43(11):1591–600 (35 ref.)
The role of ethnic versus nonethnic sociocultural factors in substance use and misuse. Collins RL. **Subst Use Misuse** 1996 Jan;31(1):95–101 (27 ref.)
[Illegal drug use by secondary school children in Belgium: north-south differences] Navarro FJ, et al. **Rev Epidemiol Sante Publique** 1996 Oct;44(5):395–406 (41 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Pharmacokinetic changes in the elderly. Do they contribute to drug abuse and dependence? Ozdemir V, et al. **Clin Pharmacokinet** 1996 Nov;31(5):372–85 (144 ref.)
The special nature of rural America. Conger RD. **NIDA Res Monogr** 1997;168:37–52 (16 ref.)
The social context of substance abuse: a developmental perspective. Conger RD. **NIDA Res Monogr** 1997;168:6–36 (64 ref.)
Risk and protective factors for drug use among rural American youth. Oetting ER, et al. **NIDA Res Monogr** 1997;168:90–130 (102 ref.)
The dangers of jimson weed and its abuse by teenagers in the Kanawha Valley of West Virginia. Dewitt MS, et al. **W V Med J** 1997 Jul–Aug;93(4):182–5 (9 ref.)

GENETICS

Polymorphisms of the D2 dopamine receptor gene and alcoholism and other substance use disorders. Noble EP. **Alcohol Alcohol Suppl** 1994;2:35–43 (61 ref.)
Familial factors in illicit drug abuse: an interdisciplinary perspective. Ripple CH, et al. **Am J Drug Alcohol Abuse** 1996 May;22(2):147–72 (54 ref.)
Psychobiology of novelty seeking and drug seeking behavior. Bardo MT, et al. **Behav Brain Res** 1996 May;77(1–2):23–43 (205 ref.)
Behavior genetics of drug sensitization. Phillips TJ. **Crit Rev Neurobiol** 1997;11(1):21–33 (90 ref.)
Mating assortment and the liability to substance abuse. Vanyukov MM, et al. **Drug Alcohol Depend** 1996 Sep; 42(1):1–10 (100 ref.)
Strategies for identifying genes underlying drug abuse susceptibility. Crabbe JC, et al. **NIDA Res Monogr** 1996; 161:201–19 (40 ref.)
The potential role of the cytochrome P-450 2D6 pharmacogenetic polymorphism in drug abuse. Sellers EM, et al. **NIDA Res Monogr** 1997;173:6–26 (58 ref.)
Behavioral sensitization to ethanol: genetics and the effects of stress. Phillips TJ, et al. **Pharmacol Biochem Behav** 1997 Jul;57(3):487–93 (120 ref.)

METABOLISM

Role of metabolites in aviation forensic toxicology. Chaturvedi AK, et al. **Aviat Space Environ Med** 1997 Mar;

68(3):230–3 (30 ref.)
Acute complications of cocaine intoxication. Zafar H, et al. **Hosp Pract (Off Ed)** 1997 Feb 15;32(2):167–70, 175–7, 181 (12 ref.)
Cocaine addiction: hypothesis derived from imaging studies with PET. Volkow ND, et al. **J Addict Dis** 1996; 15(4):55–71 (49 ref.)

MORTALITY

Involvement of codeine in drug-related deaths. Gerostamoulos J, et al. **Am J Forensic Med Pathol** 1996 Dec;17(4):327–35 (26 ref.)

PATHOLOGY

Solvent abuse: a case report and a review. Sarvesvaran R, et al. **Malays J Pathol** 1994 Dec;16(2):167–71 (22 ref.)
[The pathomorphological aspects of drug abuse and addiction] Gerasimenko AI, et al. **Lik Sprava** 1997 Jan–Feb; (1):28–33 (41 ref.) **(Rus)**

PHYSIOPATHOLOGY

Cocaine, dopamine and the endogenous opioid system. Kreek MJ. **J Addict Dis** 1996;15(4):73–96 (84 ref.)
Feeding, drug abuse, and the sensitization of reward by metabolic need. Carr KD. **Neurochem Res** 1996 Nov; 21(11):1455–67 (107 ref.)
Opioid receptors: some perspectives from early studies of their role in normal physiology, stress responsivity, and in specific addictive diseases. Kreek MJ. **Neurochem Res** 1996 Nov;21(11):1469–88 (139 ref.)
Stress, glucocorticoids, and mesencephalic dopaminergic neurons: a pathophysiological chain determining vulnerability to psychostimulant abuse. Piazza PV, et al. **NIDA Res Monogr** 1996;163:277–99 (91 ref.)

PREVENTION & CONTROL

Drug-abuse prevention efforts for young children: a review and critique of existing programs. Hall NW, et al. **Am J Orthopsychiatry** 1997 Jan;67(1):134–43 (62 ref.)
What is the psychiatrist's role in drugs and alcohol? Pols RG, et al. **Aust N Z J Psychiatry** 1996 Aug;30(4):540–8; discussion 548–9 (99 ref.)
Role of metabolites in aviation forensic toxicology. Chaturvedi AK, et al. **Aviat Space Environ Med** 1997 Mar; 68(3):230–3 (30 ref.)
The challenge for women with a drug-abusing family member: the Jamaican perspective. Boyce-Reid K. **Bull Narc** 1995;47(1–2):23–30 (11 ref.)
Curricula, competition and conventional bonds: the educational role in drug control. Norland S, et al. **J Drug Educ** 1996;26(3):231–42 (28 ref.)
A review of the evaluation of 47 drug abuse prevention curricula available nationally. Dusenbury L, et al. **J Sch Health** 1997 Apr;67(4):127–32 (38 ref.)
Use and misuse of repeated measures designs. Barcikowski RS, et al. **NIDA Res Monogr** 1994;142:302–41 (44 ref.)
A drug abuse prevention strategy for rural America. Biglan A, et al. **NIDA Res Monogr** 1997;168:364–97 (112 ref.)
New statistical methods for substance use prevention research. Collins LM, et al. **NIDA Res Monogr** 1994; 142:1–12 (10 ref.)
Analysis with missing data in drug prevention research. Graham JW, et al. **NIDA Res Monogr** 1994;142:13–63 (27 ref.)
Seven ways to increase power without increasing N. Hansen WB, et al. **NIDA Res Monogr** 1994;142:184–95 (19 ref.)
In living context: an interdisciplinary approach to rethinking rural prevention. Karim G. **NIDA Res Monogr** 1997; 168:398–412 (35 ref.)
Dynamic systems-modeling as a means to estimate community-based prevention effects. Kibel BM, et al. **NIDA Res Monogr** 1994;142:404–46 (91 ref.)
Multilevel models for hierarchically nested data: potential applications in substance abuse prevention research. Kreft IG. **NIDA Res Monogr** 1994;142:140–83 (39 ref.)
Designing and analyzing studies of onset, cessation, and relapse: using survival analysis in drug abuse prevention research. Singer JD, et al. **NIDA Res Monogr** 1994; 142:196–263 (123 ref.)
Culturally competent substance abuse prevention research among rural Native American communities. Stubben J. **NIDA Res Monogr** 1997;168:459–83 (59 ref.)
Meta-analytical issues for prevention intervention research. Tobler N. **NIDA Res Monogr** 1994;142:342–403 (63 ref.)
Latent class analysis of substance abuse patterns. Uebersax JS. **NIDA Res Monogr** 1994;142:64–80 (22 ref.)

PSYCHOLOGY

On the importance of peer influence for adolescent drug use: commonly neglected considerations. Bauman KE, et al. **Addiction** 1996 Feb;91(2):185–98 (116 ref.)
Sex, drugs and escape: a psychological model of HIV-risk sexual behaviours. McKirnan DJ, et al. **AIDS Care** 1996 Dec;8(6):655–69 (93 ref.)
Characteristics and putative mechanisms in boys at risk for drug abuse and aggression. Pihl RO, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:238–52 (81 ref.)
Substance use and abuse in adolescence: an overview. Segal BM, et al. **Child Psychiatry Hum Dev** 1996 Summer; 26(4):193 (108 ref.)
Mainstreaming methadone maintenance treatment: the role of the family physician [editorial] Latowsky M, et al. **CMAJ** 1997 Aug 15;157(4):395–8 (31 ref.)
Curricula, competition and conventional bonds: the educational role in drug control. Norland S, et al. **J Drug Educ** 1996;26(3):231–42 (28 ref.)
Alcohol and other drugs: the scope of the problem among pregnant and parenting women in California. Young N. **J Psychoactive Drugs** 1997 Jan–Mar;29(1):3–22 (122 ref.)
Psychosocial and pharmacologic explanations of nicotine's "gateway drug" function. Lindsay GB, et al. **J Sch Health** 1997 Apr;67(4):123–6 (27 ref.)
Gender roles and interactions in drinking and drug use. Room R. **J Subst Abuse** 1996;8(2):227–39 (46 ref.)
Nonpharmacologic approaches to substance abuse treatment. Carroll KM, et al. **Med Clin North Am** 1997 Jul; 81(4):927–44 (88 ref.)
Treatment matching. Theoretic basis and practical implications. Gastfriend DR, et al. **Med Clin North Am** 1997 Jul;81(4):945–66 (134 ref.)
Feeding, drug abuse, and the sensitization of reward by metabolic need. Carr KD. **Neurochem Res** 1996 Nov; 21(11):1455–67 (107 ref.)
Locating reward cue at response manipulandum (CAM) induces symptoms of drug abuse. Tomie A. **Neurosci Biobehav Rev** 1996 Autumn;20(3):505–35 (576 ref.)
Prenatal drug exposure: behavioral functioning in late childhood and adolescence. Hans SL. **NIDA Res Monogr** 1996;164:261–76 (30 ref.)
Help-seeking by substance abusers: the role of harm reduction and behavioral-economic approaches to facilitate treatment entry and retention. Marlatt GA, et al. **NIDA Res Monogr** 1997;165:44–84 (147 ref.)
Drug effects: a search for outcomes. Zuckerman B. **NIDA Res Monogr** 1996;164:277–87 (29 ref.)
The role of the social worker in perinatal substance-abuse. Cook C. **Soc Work Health Care** 1997;24(3–4):65–83 (46 ref.)
Chronic cocaine use as a neuropsychiatric syndrome: a model for debate. Cadet JL, et al. **Synapse** 1996 Jan;22(1):28–34 (77 ref.)
[Entactogenic drugs "ecstasy" (MDMA), "eve" (MDE) and other ring-substituted methamphetamine derivatives. A new class of substances among illegal designer drugs?] Gouzoulis-Mayfrank E, et al. **Nervenarzt** 1996 May; 67(5):369–80 (98 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Assessment of neurotoxicity from potential medications for drug abuse: ibogaine testing and brain imaging. Vocci FJ, et al. **Ann N Y Acad Sci** 1997 May 30;820:29–39; discussion 39–40 (42 ref.)

RADIONUCLIDE IMAGING

Cocaine addiction: hypothesis derived from imaging studies with PET. Volkow ND, et al. **J Addict Dis** 1996; 15(4):55–71 (49 ref.)

REHABILITATION

Helping patients who misuse drugs. **Drug Ther Bull** 1997 Mar; 35(3):18–22 (25 ref.)
Social interventions for homeless substance abusers: evaluating treatment outcomes [editorial] Stahler GJ. **J Addict Dis** 1995;14(4):xv–xxvi (41 ref.)
California's approach to perinatal substance abuse: toward a model of comprehensive care. Brindis CD, et al. **J Psychoactive Drugs** 1997 Jan–Mar;29(1):113–22 (52 ref.)
The role of case management in substance abuse treatment services for women and their children. Brindis CD, et al. **J Psychoactive Drugs** 1997 Jan–Mar;29(1):79–88 (66 ref.)
An existential model for promoting life change. Confronting the disease concept. Ford GG. **J Subst Abuse Treat** 1996 Mar–Apr;13(2):151–8 (35 ref.)
Sexual partners of substance abuse clients: strategies for HIV/AIDS prevention. Wermuth L. **J Subst Abuse Treat** 1996 Nov–Dec;13(6):505–9 (16 ref.)
Problems among youths entering the juvenile justice system, their service needs and innovative approaches to address them. Dembo R. **Subst Use Misuse** 1996 Jan;31(1):81–94 (100 ref.)

THERAPY

Treatment of substance abusers: single or mixed gender programs? Hodgins DC, et al. **Addiction** 1997 Jul; 92(7):805–12 (60 ref.)
The clinical management of co-morbidity. Pols RG. **Alcohol Alcohol Suppl** 1994;2:485–90 (35 ref.)
Drug abuse and addiction treatment research. The next generation [comment] Leshner AI. **Arch Gen Psychiatry** 1997 Aug;54(8):691–4 (20 ref.) Comment on: Arch Gen Psychiatry 1997 Aug;54(8):696–9. Comment on: Arch Gen Psychiatry 1997 Aug;54(8):700–5. Comment on: Arch Gen Psychiatry 1997 Aug;54(8):706–12. Comment on: Arch Gen Psychiatry 1997 Aug;54(8):713–20. Comment on: Arch Gen Psychiatry 1997 Aug;54(8):721–6. Comment on: Arch Gen Psychiatry 1997 Aug;54(8):730–5. Comment on: Arch Gen Psychiatry 1997 Aug;54(8):737–42.
Management of substance misusers on the general hospital ward. Williams H, et al. **Br J Clin Pract** 1996 Mar; 50(2):94–8 (23 ref.)
Services for perinatal women with substance abuse and mental health disorders: the unmet need. Grella CE. **J Psychoactive Drugs** 1997 Jan–Mar;29(1):67–78 (53 ref.)
Background and overview of mental health and substance abuse treatment systems: meeting the needs of women who are pregnant or parenting. Grella CE. **J Psychoactive Drugs** 1996 Oct–Dec;28(4):319–43 (236 ref.)
Consensus conference on HIV/AIDS and drug abuse treatment. Maryland, March 14–15, 1995. **J Subst Abuse Treat** 1996 Sep–Oct;13(5):373–443 (0 ref.)
Brief interventions with substance-abusing patients. Barnes HN, et al. **Med Clin North Am** 1997 Jul;81(4):867–79 (32 ref.)
Nonpharmacologic approaches to substance abuse treatment. Carroll KM, et al. **Med Clin North Am** 1997 Jul; 81(4):927–44 (88 ref.)
Treatment matching. Theoretic basis and practical implications. Gastfriend DR, et al. **Med Clin North Am** 1997 Jul;81(4):945–66 (134 ref.)
Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Mello NK, et al. **Neuropsychopharmacology** 1996 Jun;14(6):375–424 (288 ref.)
Treatment of comorbid schizophrenia and substance abuse disorders. Hansell S. **New Dir Ment Health Serv** 1997 Spring;(73):65–73 (47 ref.)
Anxiety disorders, comorbid substance abuse, and benzodiazepine discontinuation: implications for treatment. Barlow DH. **NIDA Res Monogr** 1997;172:33–51 (48 ref.)
Tailoring interventions to clients: effects on engagement and retention. Beutler LE, et al. **NIDA Res Monogr** 1997; 165:85–109 (104 ref.)
Enhancing retention in clinical trials of psychosocial treatments: practical strategies. Carroll KM. **NIDA Res Monogr** 1997;165:4–24 (52 ref.)
Stages of change: interactions with treatment compliance and involvement. DiClemente CC, et al. **NIDA Res Monogr** 1997;165:131–56 (71 ref.)
From the initial clinic contact to aftercare: a brief review of effective strategies for retaining cocaine abusers in treatment. Higgins ST, et al. **NIDA Res Monogr** 1997; 165:25–43 (35 ref.)
Establishing a therapeutic alliance with substance abusers. Luborsky L, et al. **NIDA Res Monogr** 1997;165:233–44 (37 ref.)
Help-seeking by substance abusers: the role of harm reduction and behavioral-economic approaches to facilitate treatment entry and retention. Marlatt GA, et al. **NIDA Res Monogr** 1997;165:44–84 (147 ref.)
Establishing and maintaining a therapeutic alliance with substance abuse patients: a cognitive therapy approach. Newman CF. **NIDA Res Monogr** 1997;165:181–206 (38 ref.)
Antibodies as pharmacokinetic and metabolic modifiers of neurotoxicity. Owens SM. **NIDA Res Monogr** 1997; 173:259–72 (34 ref.)
Mental health service delivery in rural areas: organizational and clinical issues. Wagenfeld MO, et al. **NIDA Res Monogr** 1997;168:418–37 (59 ref.)
Psychostimulant abuse: the case for combined behavioral and pharmacological treatments. Stitzer ML, et al. **Pharmacol Biochem Behav** 1997 Jul;57(3):457–70 (96 ref.)
[Drug withdrawal therapy] Heinälä P. **Duodecim** 1995; 111(12):1113–6 (28 ref.) **(Fin)**

URINE

Clinical issues associated with urine testing of substances of abuse. Eskridge KD, et al. **Pharmacotherapy** 1997 May–Jun; 17(3):497–510 (89 ref.)

SUBSTANCE ABUSE DETECTION

Beyond CAGE. A brief clinical approach after detection of substance abuse. Samet JH, et al. **Arch Intern Med** 1996 Nov 11;156(20):2287–93 (39 ref.)
Issues in detecting abuse of xenobiotic anabolic steroids and testosterone by analysis of athletes' urine. Catlin DH, et al. **Clin Chem** 1997 Jul;43(7):1280–8 (56 ref.)
Stimulants, narcotics and beta-blockers: 25 years of development in analytical techniques for doping control. Hemmersbach P, et al. **J Chromatogr B Biomed Appl** 1996 Dec 6;687(1):221–38 (107 ref.)
Chromatographic techniques—the basis of doping control. Mueller RK, et al. **J Chromatogr B Biomed Appl** 1995 Dec 1;674(1):1–11 (16 ref.)
Detection of diuretic agents in doping control. Ventura R, et al. **J Chromatogr B Biomed Appl** 1996 Dec 6; 687(1):127–44 (116 ref.)

LEGISLATION & JURISPRUDENCE

Drug testing programs in government agencies and private workplaces. The legal challenge continues. Snyder JW, et al. **Occup Med** 1996 Jan–Mar;11(1):87–100 (52 ref.)

METHODS

Screening for drugs of abuse (II): Cannabinoids, lysergic acid diethylamide, buprenorphine, methadone, barbiturates, benzodiazepines and other drugs. Simpson D, et al. **Ann Clin Biochem** 1997 Sep;34 (Pt 5):460–510 (408 ref.)
Role of metabolites in aviation forensic toxicology. Chaturvedi AK, et al. **Aviat Space Environ Med** 1997 Mar; 68(3):230–3 (30 ref.)
Detection of misreported drug use in forensic populations:

SUBSTANCE ABUSE DETECTION

an overview of hair analysis. Kelly KS, et al. **Bull Am Acad Psychiatry Law** 1996;24(1):85–94 (45 ref.)

Analytical advances in detection of performance-enhancing compounds. Bowers LD. **Clin Chem** 1997 Jul; 43(7):1299–304 (22 ref.)

Doping in sport: misuse, analytical tests, and legal aspects [editorial] Cowan DA, et al. **Clin Chem** 1997 Jul; 43(7):1110–3 (32 ref.)

Clinical issues associated with urine testing of substances of abuse. Eskridge KD, et al. **Pharmacotherapy** 1997 May–Jun; 17(3):497–510 (89 ref.)

[Dependence producing substances in the practice of the Insitute of Forensic Experts in Krakow] Kala M. **Przegl Lek** 1997;54(6):430–7 (28 ref.) (Eng. Abstr.) **(Pol)**

STANDARDS

Quality control by the Society of Hair Testing. Sachs H. **Forensic Sci Int** 1997 Jan 17;84(1–3):145–50 (4 ref.)

TRENDS

Supercritical fluid extraction and hair analysis: the situation in 1996. Staub C. **Forensic Sci Int** 1997 Jan 17; 84(1–3):295–304 (10 ref.)

SUBSTANCE ABUSE, INTRAVENOUS

see related
NEEDLE SHARING

Interventions among injecting drug users: do they work? van Ameijden EJ, et al. **AIDS** 1995;9 Suppl A:S75–84 (117 ref.)

HIV in illicit drug users. O'Donnell AE. **Clin Chest Med** 1996 Dec;17(4):797–807 (90 ref.)

COMPLICATIONS

Once more unto the breach: controlling hepatitis C in injecting drug users. Wodak A, et al. **Addiction** 1996 Feb; 91(2):181–4 (33 ref.)

Vascular complications of injecting drug misuse [see comments] Woodburn KR, et al. **Br J Surg** 1996 Oct; 83(10):1329–34 (40 ref.) Comment in: Br J Surg 1997 Apr;84(4):582–3.

Diagnosis and management of complications of self-injection injuries of the neck. Kay DJ, et al. **Ear Nose Throat J** 1996 Oct;75(10):670–6 (27 ref.)

Mathematical modelling of the spread of HIV/AIDS amongst injecting drug users. Greenhalgh D, et al. **IMA J Math Appl Med Biol** 1997 Mar;14(1):11–38 (42 ref.)

Clinical features of drug use and drug use related HIV [editorial] Brettle RP. **Int J STD AIDS** 1996 May–Jun; 7(3):151–65 (114 ref.)

HIV epidemiology and interventions among injecting drug users. Des Jarlais DC, et al. **Int J STD AIDS** 1996;7 Suppl 2:57–61 (35 ref.)

Interventions with drug injectors in the UK: trends in risk behaviour and HIV prevalence. Stimson GV, et al. **Int J STD AIDS** 1996;7 Suppl 2:52–6 (46 ref.)

Acute hematogenous osteomyelitis in intravenous drug users. Fox IM, et al. **J Foot Ankle Surg** 1997 Jul–Aug;36(4):301–5 (13 ref.)

Effects of heterogeneity on the spread of HIV/AIDS among intravenous drug users in shooting galleries. Greenhalgh D. **Math Biosci** 1996 Sep;136(2):141–86 (42 ref.)

[Peripheral nerve and spinal cord complication in intravenous heroin addiction] Bernasconi A, et al. **Rev Neurol (Paris)** 1996 Nov;152(11):688–94 (53 ref.) (Eng. Abstr.) **(Fre)**

[Ischemic complications of accidental intra-arterial injection in drug addicts] Haj-Yahia S, et al. **Harefuah** 1996 Sep; 131(5–6):178–80 (33 ref.) **(Heb)**

[Infection with hepatitis GB virus C in intravenous drug abusers with type C chronic liver diseases] Kojima M, et al. **Nippon Rinsho** 1997 Mar;55(3):549–53 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Polymicrobial endocarditis in an intravenous drug addict with isolation of Eikenella corrodens (letter)] Saavedra J, et al. **Enferm Infecc Microbiol Clin** 1996 Aug–Sep; 14(7):454–6 (10 ref.) **(Spa)**

EPIDEMIOLOGY

Infectious endocarditis and sudden unexpected death: incidence and morphology of lesions in intravenous addicts and non-drug abusers. Burke AP, et al. **J Heart Valve Dis** 1997 Mar;6(2):198–203 (13 ref.)

The impact of HIV infection on medical services in drug abuse treatment programs. Selwyn PA. **J Subst Abuse Treat** 1996 Sep–Oct;13(5):397–410; discussion 439 (85 ref.)

Sex, drugs, intervention, and research: from the individual to the social. Rhodes T, et al. **Subst Use Misuse** 1996 Feb; 31(3):375–407 (130 ref.)

PSYCHOLOGY

Psychosocial risk factors for HIV transmission in female drug abusers. Brook DW, et al. **Am J Addict** 1997 Spring; 6(2):124–34 (35 ref.)

REHABILITATION

Consensus statements from conference on AIDS/HIV infection and drug abuse treatment. **J Subst Abuse Treat** 1996 Sep–Oct;13(5):441 (0 ref.)

Therapeutic communities: AIDS/HIV risk and harm reduction. De Leon G. **J Subst Abuse Treat** 1996 Sep–Oct; 13(5):411–20; discussion 439 (40 ref.)

HIV risk reduction and service delivery strategies in criminal justice settings. Inciardi JA. **J Subst Abuse Treat** 1996 Sep–Oct;13(5):421–8; discussion 439 (52 ref.)

Impact of HIV risk and infection on delivery of psychosocial treatment services in outpatient programs. Sorensen JL, et al. **J Subst Abuse Treat** 1996 Sep–Oct;13(5):387–95; discussion 439 (80 ref.)

Impact of HIV risk and infection and the role of prevention services. Watters JK. **J Subst Abuse Treat** 1996 Sep–Oct; 13(5):375–85; discussion 439 (60 ref.)

SUBSTANCE ABUSE TESTING see **SUBSTANCE ABUSE DETECTION**

SUBSTANCE ABUSE TREATMENT CENTERS

The role of case management in substance abuse treatment services for women and their children. Brindis CD, et al. **J Psychoactive Drugs** 1997 Jan–Mar;29(1):79–88 (66 ref.)

METHODS

Opiate-dependent patients receiving methadone. How physicians should manage therapy. Kahan M, et al. **Can Fam Physician** 1996 Sep;42:1769–78 (47 ref.)

Withdrawal strategies for outpatients. Alcohol, benzodiazepine, barbiturate, and opiate addictions. Mezciems PE. **Can Fam Physician** 1996 Sep;42:1745–52 (27 ref.)

ORGANIZATION & ADMINISTRATION

Background and overview of mental health and substance abuse treatment systems: meeting the needs of women who are pregnant or parenting. Grella CE. **J Psychoactive Drugs** 1996 Oct–Dec;28(4):319–43 (236 ref.)

Can psychiatric and chemical dependency treatment units be smoke free? Patten CA, et al. **J Subst Abuse Treat** 1996 Mar–Apr;13(2):107–18 (77 ref.)

Alcoholism—treating the disease. Lee A. **Singapore Med J** 1997 May;38(5):214–6 (11 ref.)

STANDARDS

Consensus conference on HIV/AIDS and drug abuse treatment. Maryland, March 14–15, 1995. **J Subst Abuse Treat** 1996 Sep–Oct;13(5):373–443 (0 ref.)

SUBSTANCE DEPENDENCE

see related
DESIGNER DRUGS
STREET DRUGS

Tolerance and dependence to opiates. Jasinski DR. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 2):184–6 (16 ref.)

Endorphins and experimental addiction. Van Ree JM. **Alcohol** 1996 Jan–Feb;13(1):25–30 (37 ref.)

Synaptic regulation of mesocorticolimbic dopamine neurons. White FJ. **Annu Rev Neurosci** 1996;19:405–36 (191 ref.)

ABC of mental health. Addiction and dependence—I: Illicit drugs. Gerada C, et al. **BMJ** 1997 Aug 2;315(7103):297–300 (0 ref.)

Addiction. Sell L, et al. **Br J Hosp Med** 1996 Aug 21–Sep 3;56(4):136–40 (20 ref.)

Opioid and benzodiazepine tolerance and dependence: application of theory to critical care practice. Puntillo K, et al. **Heart Lung** 1997 Jul–Aug;26(4):317–24 (32 ref.)

Misuse of prescription drugs. Finlayson RE. **Int J Addict** 1995 Nov–Dec;30(13–14):1871–901 (88 ref.)

Nicotine addiction. Johnson CR, et al. **J Fla Med Assoc** 1996 Feb;83(2):102–7 (56 ref.)

Zopiclone: is there any dependence and abuse potential? Lader M. **J Neurol** 1997 Apr;244(4 Suppl 1):S18–22 (31 ref.)

Clinical realities and economic considerations: special therapeutic issues in intrathecal therapy—tolerance and addiction. Portenoy RK, et al. **J Pain Symptom Manage** 1997 Sep;14(3 Suppl):S27–35 (19 ref.)

Melanocortins and opiate addiction. Alvaro JD, et al. **Life Sci** 1997;61(1):1–9 (73 ref.)

Dual diagnosis in primary care. Detecting and treating both the addiction and mental illness. Ziedonis D, et al. **Med Clin North Am** 1997 Jul;81(4):1017–36 (53 ref.)

Opiates, opioids and addiction. Kreek MJ. **Mol Psychiatry** 1996 Jul;1(3):232–54 (158 ref.)

Molecular mechanisms of drug addiction: adaptations in signal transduction pathways. Nestler EJ, et al. **Mol Psychiatry** 1996 Jul;1(3):190–9 (65 ref.)

Immunological approaches to nicotine receptors. Patrick JW, et al. **NIDA Res Monogr** 1996;161:3–19 (70 ref.)

Transcription factors: potential roles in drug-induced neuroplasticity. Persico AM, et al. **Rev Neurosci** 1996 Oct–Dec;7(4):233–75 (330 ref.)

Alcohol and drug use among displaced persons: an overview. Johnson TP. **Subst Use Misuse** 1996 Nov;31(13):1853–89 (80 ref.)

The long-term effects of cocaine use during pregnancy—reasons for hope. Kane DJ, et al. **Wis Med J** 1997 Feb;96(2):37–40 (43 ref.)

[Drug addiction—origin, development and pharmacological intervention] Qu B, et al. **Ther Umsch** 1997 May; 54(5):263–71 (11 ref.) (Eng. Abstr.) **(Ger)**

[Clinical dose dependence of anti-anxiety agents] Murasaki M. **Seishin Shinkeigaku Zasshi** 1996;98(9):612–21 (38 ref.) **(Jpn)**

[The problem of opioid tolerance and dependence during clinical use thereof] Osipova NA. **Anesteziol Reanimatol** 1996 Jul–Aug;(4):17–21 (26 ref.) (Eng. Abstr.) **(Rus)**

COMPLICATIONS

Treatment of depressive syndromes in detoxified drug addicts: use of methadone. Laqueille X, et al. **Biomed Pharmacother** 1996;50(6–7):279–82 (20 ref.)

The effects of dual diagnosis on pregnancy and parenting. Mallouh C. **J Psychoactive Drugs** 1996 Oct–Dec; 28(4):367–80 (98 ref.)

Psychiatric problems among alcohol and other drug dependent women. Zweben JE. **J Psychoactive Drugs** 1996 Oct–Dec;28(4):345–66 (69 ref.)

Primary care of the HIV-seropositive chemically dependent patient. O'Neill JF. **Prim Care** 1997 Sep;24(3):667–76 (19 ref.)

Prenatal diagnosis of amniotic band syndrome in a methadone user: review of the literature and a case report. Daly CA, et al. **Ultrasound Obstet Gynecol** 1996 Aug;8(2):123–5 (12 ref.)

[Consequences of cocaine addiction during pregnancy on the development in the child] Ferraro F, et al. **Arch Pediatr** 1997 Jul;4(7):677–82 (42 ref.) (Eng. Abstr.) **(Fre)**

[Management of drug addict pregnant women and their children] Lejeune C, et al. **Arch Pediatr** 1997 Mar; 4(3):263–70 (71 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Beyond CAGE. A brief clinical approach after detection of substance abuse. Samet JH, et al. **Arch Intern Med** 1996 Nov 11;156(20):2287–93 (39 ref.)

Drug induced psychosis [editorial] [see comments] Poole R, et al. **Br J Psychiatry** 1996 Feb;168(2):135–8 (34 ref.) Comment in: Br J Psychiatry 1996 May;168(5):651. Comment in: Br J Psychiatry 1996 May;168(5):651–2. Comment in: Br J Psychiatry 1996 Jul;169(1):114–5.

[Ecstasy, a new designer drug in the techno-scene] Kuhlmann T. **Psychiatr Prax** 1996 Nov;23(6):266–9 (10 ref.) (Eng. Abstr.) **(Ger)**

[Dependence producing substances in the practice of the Insitute of Forensic Experts in Krakow] Kala M. **Przegl Lek** 1997;54(6):430–7 (28 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

A risk-benefit assessment of naltrexone in the treatment of alcohol dependence. Berg BJ, et al. **Drug Saf** 1996 Oct; 15(4):274–82 (44 ref.)

Recent developments in the pharmacotherapy of alcohol dependence. Schuckit MA. **J Consult Clin Psychol** 1996 Aug;64(4):669–76 (82 ref.)

Cyclazocine revisited. Archer S, et al. **Neurochem Res** 1996 Nov;21(11):1369–73 (22 ref.)

Association of enkephalin catabolism inhibitors and CCK-B antagonists: a potential use in the management of pain and opioid addiction. Roques BP, et al. **Neurochem Res** 1996 Nov;21(11):1397–410 (116 ref.)

A range of research-based pharmacotherapies for addiction. O'Brien CP. **Science** 1997 Oct 3;278(5335):66–70 (54 ref.)

ECONOMICS

The costs of drug abuse consequences: a summary of research findings. French MT, et al. **J Subst Abuse Treat** 1996 Nov–Dec;13(6):453–66 (56 ref.)

EPIDEMIOLOGY

Alcohol and drug abuse in patients with physical disabilities. Hubbard JR, et al. **Am J Drug Alcohol Abuse** 1996 May; 22(2):215–31 (41 ref.)

Adolescent substance use and abuse. Blum RW. **Arch Pediatr Adolesc Med** 1997 Aug;151(8):805–8 (21 ref.)

The Nathan B. Eddy Lecture: challenging conventional wisdom about drug abuse. Robins LN. **NIDA Res Monogr** 1994;140:30–45 (5 ref.)

[Physicians as patients—on the problem of the mentally ill physician] Loevenich A, et al. **Fortschr Neurol Psychiatr** 1996 Sep;64(9):344–52 (47 ref.) (Eng. Abstr.) **(Ger)**

ETHNOLOGY

Racism and perinatal addiction. Neuspiel DR. **Ethn Dis** 1996 Winter–Spring;6(1–2):47–55 (45 ref.)

Substance use and multiculturalism. Adrian M. **Subst Use Misuse** 1996 Sep–Oct;31(11–12):1459–501 (68 ref.)

The role of ethnic versus nonethnic sociocultural factors in substance use and misuse. Collins RL. **Subst Use Misuse** 1996 Jan;31(1):95–101 (27 ref.)

Prevention issues in a multicultural developing country: the Mexican case. Rosovsky H, et al. **Subst Use Misuse** 1996 Sep–Oct;31(11–12):1657–88 (84 ref.)

ETIOLOGY

Pharmacokinetic changes in the elderly. Do they contribute to drug abuse and dependence? Ozdemir V, et al. **Clin Pharmacokinet** 1996 Nov;31(5):372–85 (144 ref.)

Addiction in women: prevalence, profiles, and meaning. Jessup M. **J Obstet Gynecol Neonatal Nurs** 1997 Jul–Aug; 26(4):449–58 (52 ref.)

Opioids in headache treatment. Is there a role? Ziegler DK. **Neurol Clin** 1997 Feb;15(1):199–207 (53 ref.)

The Sonda Project: prevention, prediction, and psychological disorder. Buscema M. **Subst Use Misuse** 1997 Jul; 32(9):1053–153 (315 ref.)

[New aspects of learning addictive effects of narcotic analgesics] Zvartau EE, et al. **Anesteziol Reanimatol** 1996 Jul–Aug;(4):13–6 (20 ref.) **(Rus)**

GENETICS

Familial factors in illicit drug abuse: an interdisciplinary perspective. Ripple CH, et al. **Am J Drug Alcohol Abuse** 1996 May;22(2):147–72 (54 ref.)

Psychobiology of novelty seeking and drug seeking behavior. Bardo MT, et al. **Behav Brain Res** 1996 May;77(1–2):23–43 (205 ref.)

Mating assortment and the liability to substance abuse. Vanyukov MM, et al. **Drug Alcohol Depend** 1996 Sep; 42(1):1–10 (100 ref.)

IMMUNOLOGY

Anti–cocaine catalytic antibodies—a novel approach to the problem of addiction. Landry DW, et al. **J Addict Dis** 1997; 16(3):1–17 (53 ref.)

METABOLISM

The neurobiology of drug addiction. Koob GF, et al. **J Neuropsychiatry Clin Neurosci** 1997 Summer;9(3):482–97 (169 ref.)

Molecular and cellular basis of addiction. Nestler EJ, et al. **Science** 1997 Oct 3;278(5335):58–63 (63 ref.)

NURSING

Toward an understanding of addiction. Flagler S, et al. **J Obstet Gynecol Neonatal Nurs** 1997 Jul–Aug;26(4):441–8 (16 ref.)

Addiction in women: prevalence, profiles, and meaning. Jessup M. **J Obstet Gynecol Neonatal Nurs** 1997 Jul–Aug; 26(4):449–58 (52 ref.)

Drug treatment for women: traditional models and new directions. Kearney MH. **J Obstet Gynecol Neonatal Nurs** 1997 Jul–Aug;26(4):459–68 (52 ref.)

PATHOLOGY

A novel view of opiate tolerance. Stefano GB, et al. **Adv Neuroimmunol** 1996;6(3):265–77 (46 ref.)

[The pathomorphological aspects of drug abuse and addiction] Gerasimenko AI, et al. **Lik Sprava** 1997 Jan–Feb; (1):28–33 (41 ref.) **(Rus)**

PHYSIOPATHOLOGY

Addictive drugs and brain stimulation reward. Wise RA. **Annu Rev Neurosci** 1996;19:319–40 (202 ref.)

The drug addicted patient. Cheng DC. **Can J Anaesth** 1997 May;44(5 Pt 2):R101–11 (46 ref.) **(Eng, Fre)**

Neurobiology of addiction. Wise RA. **Curr Opin Neurobiol** 1996 Apr;6(2):243–51 (96 ref.)

The neurobiology of drug addiction. Koob GF, et al. **J Neuropsychiatry Clin Neurosci** 1997 Summer;9(3):482–97 (169 ref.)

Modulatory effects of Gs–coupled excitatory opioid receptor functions on opioid analgesia, tolerance, and dependence. Crain SM, et al. **Neurochem Res** 1996 Nov;21(11):1347–51 (59 ref.)

Opioid receptors: some perspectives from early studies of their role in normal physiology, stress responsivity, and in specific addictive diseases. Kreek MJ. **Neurochem Res** 1996 Nov;21(11):1469–88 (139 ref.)

Modeling drug dependence behaviors for animal and human studies. Hughes JR, et al. **Pharmacol Biochem Behav** 1997 Jul;57(3):413–7 (43 ref.)

Biological consequences of drug administration: implications for acute and chronic tolerance. Ramsay DS, et al. **Psychol Rev** 1997 Jan;104(1):170–93 (180 ref.)

A neuroendocrine role in cocaine reinforcement. Goeders NE. **Psychoneuroendocrinology** 1997 May;22(4):237–59 (180 ref.)

Role of oxytocin in the neuroadaptation to drugs of abuse. Sarnyai Z, et al. **Psychoneuroendocrinology** 1994; 19(1):85–117 (100 ref.)

PREVENTION & CONTROL

What is the psychiatrist's role in drugs and alcohol? Pols RG, et al. **Aust N Z J Psychiatry** 1996 Aug;30(4):540–8; discussion 548–9 (99 ref.)

Prevention issues in a multicultural developing country: the Mexican case. Rosovsky H, et al. **Subst Use Misuse** 1996 Sep–Oct;31(11–12):1657–88 (84 ref.)

[State and local administration, alcoholism and narcotic addiction] Lach U, et al. **Przegl Lek** 1997;54(6):456–8 (12 ref.) (Eng. Abstr.) **(Pol)**

[Prevention of narcotic dependence in Polish legal regulations] Morawska J. **Przegl Lek** 1997;54(6):452–5 (17 ref.) (Eng. Abstr.) **(Pol)**

PSYCHOLOGY

The cultural and social consequences and effect on families of women's involvement in drug trafficking in Cameroon: crime and imprisonment. Nouthe–Djubgang J, et al. **Bull Narc** 1995;47(1–2):31–7 (5 ref.)

Toward an understanding of addiction. Flagler S, et al. **J Obstet Gynecol Neonatal Nurs** 1997 Jul–Aug;26(4):441–8 (16 ref.)

All my buddies was male: relationship issues of women with addictions. Henderson D, et al. **J Obstet Gynecol Neonatal Nurs** 1997 Jul–Aug;26(4):469–76 (41 ref.)

Motivational factors in cocaine pharmacotherapy trials with methadone–maintained patients: problems and paradoxes. Margolin A, et al. **J Psychoactive Drugs** 1997 Apr–Jun; 29(2):205–12 (50 ref.)

The semantics of addiction: moving beyond expert models to lay understandings. Quintero G, et al. **J Psychoactive Drugs** 1996 Jul–Sep;28(3):219–28 (66 ref.)

Cloninger's tridimensional theory of personality and psychopathology: applications to substance use disorders. Howard MO, et al. **J Stud Alcohol** 1997 Jan;58(1):48–66 (55 ref.)

Gender roles and interactions in drinking and drug use. Room R. **J Subst Abuse** 1996;8(2):227–39 (46 ref.)

Personal construct psychotherapy of addictions. Klion RE, et al. **J Subst Abuse Treat** 1997 Jan–Feb;14(1):37–43 (26 ref.)

Reinforcement processes in opiate addiction: a homeostatic model. Schulteis G, et al. **Neurochem Res** 1996 Nov; 21(11):1437–54 (133 ref.)

Alcohol, drugs, and violence in children's lives. Miller BA, et al. **Recent Dev Alcohol** 1997;13:357–85 (120 ref.)

Paths to recovery from substance misuse: change of lifestyle and the role of treatment. Biomqvist J. **Subst Use Misuse** 1996 Nov;31(13):1807–52 (109 ref.)

[Management of drug addict pregnant women and their children] Lejeune C, et al. **Arch Pediatr** 1997 Mar; 4(3):263–70 (71 ref.) (Eng. Abstr.) **(Fre)**

[Entactogenic drugs "ecstasy" (MDMA), "eve" (MDE) and other ring–substituted methamphetamine derivatives. A new class of substances among illegal designer drugs?] Gouzoulis–Mayfrank E, et al. **Nervenarzt** 1996 May; 67(5):369–80 (98 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

Integrating psychotherapy and pharmacotherapy to improve drug abuse outcomes. Carroll KM. **Addict Behav** 1997 Mar–Apr;22(2):233–45 (70 ref.)

Harm reduction: come as you are. Marlatt GA. **Addict Behav** 1996 Nov–Dec;21(6):779–88 (18 ref.)

Motivational interviewing: research, practice, and puzzles. Miller WR. **Addict Behav** 1996 Nov–Dec;21(6):835–42 (35 ref.)

Treatment of maternal addiction to prevent child abuse and neglect. Peterson L, et al. **Addict Behav** 1996 Nov–Dec; 21(6):789–801 (62 ref.)

Relapse revisited: a critique of current concepts and clinical practice in the management of alcohol problems. Saunders B, et al. **Addict Behav** 1996 Nov–Dec;21(6):843–55 (45 ref.)

Conceptualizations of relapse: a summary of psychological and psychobiological models. Connors GJ, et al. **Addiction** 1996 Dec;91 Suppl:S5–13 (28 ref.)

Assessment issues and domains in the prediction of relapse. Donovan DM. **Addiction** 1996 Dec;91 Suppl:S29–36 (22 ref.)

What is a relapse? Fifty ways to leave the wagon. Miller WR. **Addiction** 1996 Dec;91 Suppl:S15–27 (33 ref.)

Treatment of depressive syndromes in detoxified drug addicts: use of methadone. Laqueille X, et al. **Biomed Pharmacother** 1996;50(6–7):279–82 (20 ref.)

The cultural and social consequences and effect on families of women's involvement in drug trafficking in Cameroon: crime and imprisonment. Nouthe–Djubgang J, et al. **Bull Narc** 1995;47(1–2):31–7 (5 ref.)

Treatment of the mentally ill physician. Myers MF. **Can J Psychiatry** 1997 Aug;42(6):12 p. (43 ref.) **(Eng, Fre)**

New directions for treatment research on sequelae of sexual abuse in persons with severe mental illness. Rosenberg SD, et al. **Community Ment Health J** 1996 Aug;32(4):387–400 (75 ref.)

Social interventions for homeless substance abusers: evaluating treatment outcomes [editorial] Stahler GJ. **J Addict Dis** 1995;14(4):xv–xxvi (41 ref.)

Social model of recovery: origin, early features, changes, and future. Dodd MH. **J Psychoactive Drugs** 1997 Apr–Jun; 29(2):133–9 (16 ref.)

Motivational factors in cocaine pharmacotherapy trials with methadone–maintained patients: problems and paradoxes. Margolin A, et al. **J Psychoactive Drugs** 1997 Apr–Jun; 29(2):205–12 (50 ref.)

The impact of intensive case–managed intervention on substance–using pregnant and postpartum women. Lanehart RE, et al. **J Subst Abuse** 1996;8(4):487–95 (18 ref.)

Integrating substance abuse treatment for the seriously mentally ill into inpatient psychiatric treatment. Bradizza CM, et al. **J Subst Abuse Treat** 1997 Mar–Apr;14(2):103–11 (34 ref.)

Attachment transition, addiction and therapeutic bonding—an integrative approach. Höfler DZ, et al. **J Subst Abuse Treat** 1996 Nov–Dec;13(6):511–9 (56 ref.)

Rethinking patient placement: the human service matrix model for matching services to needs. McGee MD, et al. **J Subst Abuse Treat** 1997 Mar–Apr;14(2):141–8 (75 ref.)

Sexual partners of substance abuse clients: strategies for HIV/AIDS prevention. Wermuth L. **J Subst Abuse Treat** 1996 Nov–Dec;13(6):505–9 (16 ref.)

Issues in the linkage of alcohol and domestic violence services. Collins JJ, et al. **Recent Dev Alcohol** 1997; 13:387–405 (91 ref.)

Radicalizing recovery: addiction, spirituality, and politics. Morell C. **Soc Work** 1996 May;41(3):306–12 (34 ref.)

Problems among youths entering the juvenile justice system, their service needs and innovative approaches to address them. Dembo R. **Subst Use Misuse** 1996 Jan;31(1):81–94 (100 ref.)

[Ambulatory medical treatment of drug dependent patients] Gölz J. **Z Arztl Fortbild (Jena)** 1996 Jun;90(4):271–8 (5 ref.) (Eng. Abstr.) **(Ger)**

[Substance dependence. Information, diagnosis and therapy—encouragement for pragmatic treatment] Salloch–Vogel RR, et al. **Z Arztl Fortbild (Jena)** 1996 Jun; 90(4):279–94 (0 ref.) (Eng. Abstr.) **(Ger)**

[Drug dependence among physicians] Schifferdecker M, et al. **Z Arztl Fortbild (Jena)** 1996 Jun;90(4):295–300 (39 ref.) (Eng. Abstr.) **(Ger)**

[Are there new methods in therapy of drug dependence?] Täschner KL. **Z Arztl Fortbild (Jena)** 1996 Jun; 90(4):315–20 (18 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Drug abuse and addiction treatment research. The next generation [comment] Leshner AI. **Arch Gen Psychiatry** 1997 Aug;54(8):691–4 (20 ref.) Comment on: Arch Gen Psychiatry 1997 Aug;54(8):696–9. Comment on: Arch Gen Psychiatry 1997 Aug;54(8):700–5. Comment on: Arch Gen Psychiatry 1997 Aug;54(8):706–12. Comment on: Arch Gen Psychiatry 1997 Aug;54(8):713–20. Comment on: Arch Gen Psychiatry 1997 Aug;54(8):721–6. Comment on: Arch Gen Psychiatry 1997 Aug;54(8):730–5. Comment on: Arch Gen Psychiatry 1997 Aug;54(8):737–42.

Beyond CAGE. A brief clinical approach after detection of substance abuse. Samet JH, et al. **Arch Intern Med** 1996 Nov 11;156(20):2287–93 (39 ref.)

Acupuncture and addiction treatment. Moner SE. **J Addict Dis** 1996;15(3):79–100 (49 ref.)

Factors associated with treatment continuation: implications for the treatment of drug dependence. Kolden GG, et al. **NIDA Res Monogr** 1997;165:110–30 (47 ref.)

Back to basics: fundamental cognitive therapy skills for keeping drug–dependent individuals in treatment. Liese BS, et al. **NIDA Res Monogr** 1997;165:207–32 (39 ref.)

The role of family and significant others in the engagement and retention of drug–dependent individuals. Stanton MD. **NIDA Res Monogr** 1997;165:157–80 (89 ref.)

Paths to recovery from substance misuse: change of lifestyle and the role of treatment. Biomqvist J. **Subst Use Misuse** 1996 Nov;31(13):1807–52 (109 ref.)

SUBSTANCE K see **NEUROKININ A**

SUBSTANCE K RECEPTORS see **RECEPTORS, NEUROKININ–2**

SUBSTANCE P

see related
RECEPTORS, NEUROKININ–1

BLOOD

[Tension–type headache: 5–hydroxytryptamine and related substances] Shimomura T. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1342–4 (8 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Direct neural regulation of the mammalian anterior pituitary. Ju G. **Chin Med J (Engl)** 1996 Jan;109(1):44–6 (8 ref.)

Tachykinins in the gut. Part I. Expression, release and motor function. Holzer P, et al. **Pharmacol Ther** 1997; 73(3):173–217 (504 ref.)

[Substance P and human skin] Staniek V, et al. **Pathol Biol (Paris)** 1996 Dec;44(10):860–6 (63 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Role of free radicals and substance P in magnesium deficiency [see comments] Weglicki WB, et al. **Cardiovasc Res** 1996 May;31(5):677–82 (51 ref.) Comment in: Cardiovasc Res 1996 May;31(5):675.

Beta–blocker induced asthma: a role for sensory nerve hyperresponsiveness? [editorial; comment] Belvisi M. **Clin Exp Allergy** 1996 Dec;26(12):1343–6 (29 ref.) Comment on: Clin Exp Allergy 1996 Dec;26(12):1428–35.

Pulmonary inflammation—a balancing act. Colten HR, et al. **N Engl J Med** 1997 Apr 10;336(15):1094–6 (3 ref.)

SUBSTANCE P

Tachykinins in the gut. Part II. Roles in neural excitation, secretion and inflammation. Holzer P, et al. **Pharmacol Ther** 1997;73(3):219–63 (539 ref.)
The possible role of substance P in eliciting and modulating deep somatic pain. Mense S, et al. **Prog Brain Res** 1996; 110:125–35 (55 ref.)
Sensory mechanisms. Widdicombe J. **Pulm Pharmacol** 1996 Oct–Dec;9(5–6):383–7 (77 ref.)

SECRETION

Neurogenic inflammation. A model for studying efferent actions of sensory nerves. McDonald DM, et al. **Adv Exp Med Biol** 1996;410:453–62 (68 ref.)

SUBSTANCE P RECEPTORS see **RECEPTORS, NEUROKININ-1**

SUBSTANCE USE DISORDERS

Science, medicine, and the future. Substance use disorders. Schuckit MA. **BMJ** 1997 May 31;314(7094):1605–8 (36 ref.)
Child maltreatment and substance use: a review of the literature. Arellano CM. **Subst Use Misuse** 1996 May; 31(7):927–35 (59 ref.)

COMPLICATIONS

Diagnosing addictive disease in chronic pain patients [see comments] Miotto K, et al. **Psychosomatics** 1996 May–Jun; 37(3):223–35 (66 ref.) Comment in: Psychosomatics 1997 Mar–Apr;38(2):158–9.

DIAGNOSIS

Diagnosing addictive disease in chronic pain patients [see comments] Miotto K, et al. **Psychosomatics** 1996 May–Jun; 37(3):223–35 (66 ref.) Comment in: Psychosomatics 1997 Mar–Apr;38(2):158–9.

EPIDEMIOLOGY

Inhalant abuse in Bolivia. Baldivieso LE. **NIDA Res Monogr** 1995;148:50–63 (23 ref.)
Inhalant use among Brazilian youths. Carlini–Cotrim B. **NIDA Res Monogr** 1995;148:64–78 (20 ref.)
Inhalant use in the United States. Edwards RW, et al. **NIDA Res Monogr** 1995;148:8–28 (15 ref.)
Gathering epidemiologic information on inhalant abuse: some methodological issues. Frank B. **NIDA Res Monogr** 1995; 148:260–73 (12 ref.)
Inhalant abuse: a Hungarian review. Katona E. **NIDA Res Monogr** 1995;148:100–20 (24 ref.)
An overview of inhalant abuse in selected countries of Asia and the Pacific Regio.. Kin F, et al. **NIDA Res Monogr** 1995;148:29–49 (11 ref.)
Inhalants in Peru. Lerner R, et al. **NIDA Res Monogr** 1995; 148:191–204 (29 ref.)
Epidemiology of inhalant abuse in Mexico. Medina–Mora ME, et al. **NIDA Res Monogr** 1995;148:136–74 (35 ref.)
The course and treatment of substance use disorder in persons with severe mental illness. Mueser KT, et al. **NIDA Res Monogr** 1997;172:86–109 (76 ref.)
Epidemiology of inhalant abuse in Nigeria. Obot IS. **NIDA Res Monogr** 1995;148:175–89 (17 ref.)
Volatile substance abuse in the United Kingdom. Ramsey J, et al. **NIDA Res Monogr** 1995;148:205–49 (94 ref.)
Solvent abuse trends in Japan. Suwaki H. **NIDA Res Monogr** 1995;148:121–35 (7 ref.)
Southeast Asians: Asian–Pacific Americans at risk for substance misuse. D'Avanzo CE. **Subst Use Misuse** 1997 Jun;32(7–8):829–48 (65 ref.)

ETHNOLOGY

Drug problems among immigrants and refugees in The Netherlands and the Dutch health care and treatment system. van de Wijngaart GF. **Subst Use Misuse** 1997 Jun; 32(7–8):909–38 (60 ref.)

PREVENTION & CONTROL

Inhalants: a policy analysis of the problem in the United States. Harwood HJ. **NIDA Res Monogr** 1995;148:274–303 (20 ref.)

PSYCHOLOGY

Substance use and abuse in adolescence: an overview. Segal BM, et al. **Child Psychiatry Hum Dev** 1996 Summer; 26(4):193 (108 ref.)
Androgenic--anabolic steroids and body dysmorphia in young men. Wroblewska AM. **J Psychosom Res** 1997 Mar; 42(3):225–34 (75 ref.)
Risk appraisal and management of violent behavior. Harris GT, et al. **Psychiatr Serv** 1997 Sep;48(9):1168–76 (132 ref.)
[Value priorities and drug addiction] Tamayo A, et al. **Acta Psiquiatr Psicol Am Lat** 1995 Dec;41(4):300–7 (31 ref.) (Eng. Abstr.) **(Spa)**

REHABILITATION

Counseling Latino alcohol and other substance users/abusers. Cultural considerations for counselors. Gloria AM, et al. **J Subst Abuse Treat** 1996 Mar–Apr;13(2):119–26 (80 ref.)
Involuntary treatment of substance abuse disorders. Galon PA, et al. **New Dir Ment Health Serv** 1997 Fall;(75):35–45 (16 ref.)
Principles for assessment of patient outcomes in mental health care. Smith GR Jr, et al. **Psychiatr Serv** 1997 Aug; 48(8):1033–6 (14 ref.)

THERAPY

Treatment strategies for volatile solvent abusers in the United States. Jumper–Thurman P, et al. **NIDA Res Monogr** 1995; 148:250–9 (10 ref.)
The course and treatment of substance use disorder in persons with severe mental illness. Mueser KT, et al. **NIDA Res Monogr** 1997;172:86–109 (76 ref.)

SUBSTANCE WITHDRAWAL, NEONATAL see **NEONATAL ABSTINENCE SYNDROME**

SUBSTANCE WITHDRAWAL SYNDROME

Antidepressant withdrawal reactions. Wolfe RM. **Am Fam Physician** 1997 Aug;56(2):455–62 (50 ref.)
The alcohol withdrawal syndrome. Hall W, et al. **Lancet** 1997 Jun 28;349(9069):1897–900 (53 ref.)
Modeling drug dependence behaviors for animal and human studies. Hughes JR, et al. **Pharmacol Biochem Behav** 1997 Jul;57(3):413–7 (43 ref.)

DIAGNOSIS

Movement disorders associated with withdrawal from high–dose intravenous haloperidol therapy in delirious ICU patients. Riker RR, et al. **Chest** 1997 Jun;111(6):1778–81 (29 ref.)
Antidepressant discontinuation: a review of the literature. Lejoyeux M, et al. **J Clin Psychiatry** 1997;58 Suppl 7:11–5; discussion 16 (39 ref.)
Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus panel. Schatzberg AF, et al. **J Clin Psychiatry** 1997;58 Suppl 7:5–10 (32 ref.)
Measuring tobacco withdrawal: a review of self–report questionnaires. Patten CA, et al. **J Subst Abuse** 1996; 8(1):93–113 (75 ref.)
Pharmacotherapies for alcohol abuse. Withdrawal and treatment. Saitz R, et al. **Med Clin North Am** 1997 Jul; 81(4):881–907 (176 ref.)

DRUG THERAPY

Alcohol and the brain. Scheepers BD. **Br J Hosp Med** 1997 Jun 4–17;57(11):548–51 (16 ref.)
Role of dopamine mesolimbic system in opioid action of psychotropic analgesic nitrous oxide in alcohol and drug withdrawal. Lichtigfeld FJ, et al. **Clin Neuropharmacol** 1996 Jun;19(3):246–51 (43 ref.)
Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Wilde MI, et al. **Drugs** 1997 Jun; 53(6):1038–53 (62 ref.)
Pharmacotherapies for alcohol abuse. Withdrawal and treatment. Saitz R, et al. **Med Clin North Am** 1997 Jul; 81(4):881–907 (176 ref.)
[Drug withdrawal therapy] Heinälä P. **Duodecim** 1995; 111(12):1113–6 (28 ref.) **(Fin)**
[The effective therapy of the hot flashes during hormone withdrawal treatment in patients with advanced prostatic carcinoma] Kliesch S, et al. **Dtsch Med Wochenschr** 1997 Jul 25;122(30):940–5 (64 ref.) **(Ger)**

EPIDEMIOLOGY

Newer antidepressants and the discontinuation syndrome. Haddad P. **J Clin Psychiatry** 1997;58 Suppl 7:17–21; discussion 22 (367 ref.)
Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. Zajecka J, et al. **J Clin Psychiatry** 1997 Jul;58(7):291–7 (36 ref.)

ETIOLOGY

Withdrawal of antihypertensive medications [see comments] Froom J, et al. **J Am Board Fam Pract** 1997 Jul–Aug; 10(4):249–58 (53 ref.) Comment in: J Am Board Fam Pract 1997 Jul–Aug;10(4):305–7.
Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. Discontinuation Consensus Panel. Schatzberg AF, et al. **J Clin Psychiatry** 1997;58 Suppl 7:23–7 (29 ref.)
Clozapine withdrawal resulting in delirium with psychosis: a report of three cases. Stanilla JK, et al. **J Clin Psychiatry** 1997 Jun;58(6):252–5 (26 ref.)
Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. Zajecka J, et al. **J Clin Psychiatry** 1997 Jul;58(7):291–7 (36 ref.)
The risk of medication–free research. Carpenter WT Jr. **Schizophr Bull** 1997;23(1):11–8 (84 ref.)
Research in schizophrenia and the discontinuation of antipsychotic medications. Wyatt RJ. **Schizophr Bull** 1997; 23(1):3–9 (40 ref.)

GENETICS

Use of recombinant inbred strains for studying genetic determinants of responses to alcohol. Crabbe JC, et al. **Alcohol Alcohol Suppl** 1994;2:67–71 (22 ref.)

METABOLISM

Cocaine withdrawal alters regulatory elements of dopamine neurons. Pilotte NS, et al. **NIDA Res Monogr** 1996; 163:193–202 (34 ref.)
Neurochemical changes in cocaine withdrawal. Kuhar MJ, et al. **Trends Pharmacol Sci** 1996 Jul;17(7):260–4 (53 ref.)

PHYSIOPATHOLOGY

Synaptic regulation of mesocorticolimbic dopamine neurons. White FJ. **Annu Rev Neurosci** 1996;19:405–36 (191 ref.)
Corticosteroid therapy, nonendocrine disease, and corticosteroid withdrawal. Magiakou MA, et al. **Curr Ther Endocrinol Metab** 1997;6:138–42 (8 ref.)
Cocaine, Neuroleptics, and tardive dyskinesia as paleocortical escape. Howard JS 3rd. **Integr Physiol Behav Sci** 1996 Oct–Dec;31(4):306–14 (33 ref.)
Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence. Maldonado R. **Neurosci Biobehav Rev** 1997 Jan; 21(1):91–104 (137 ref.)
Where is the locus in opioid withdrawal? Christie MJ, et al. **Trends Pharmacol Sci** 1997 Apr;18(4):134–40 (73 ref.)
Alcohol withdrawal. Murray TD, et al. **Va Med Q** 1997 Summer;124(3):184–7, 189 (35 ref.)
[Withdrawal syndrome] Ando K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):622–5 (15 ref.) **(Jpn)**

PREVENTION & CONTROL

Safely withdrawing patients from chronic glucocorticoid therapy. Kountz DS, et al. **Am Fam Physician** 1997 Feb 1;55(2):521–5, 529–30 (10 ref.)
Withdrawal strategies for outpatients. Alcohol, benzodiazepine, barbiturate, and opiate addictions. Mezciems PE. **Can Fam Physician** 1996 Sep;42:1745–52 (27 ref.)
Clinical management of antidepressant discontinuation. Rosenbaum JF, et al. **J Clin Psychiatry** 1997;58 Suppl 7:37–40 (13 ref.)
Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Sulak PJ, et al. **Obstet Gynecol** 1997 Feb;89(2):179–83 (7 ref.)

PSYCHOLOGY

Improving detoxification outcomes from methadone maintenance treatment: the interrelationship of affective states and protracted withdrawal. Latowsky M. **J Psychoactive Drugs** 1996 Jul–Sep;28(3):251–7 (58 ref.)

THERAPY

Management of substance misusers on the general hospital ward. Williams H, et al. **Br J Clin Pract** 1996 Mar; 50(2):94–8 (23 ref.)
Emergency management of acute alcohol problems. Part 1: Uncomplicated withdrawal [see comments] Etherington JM. **Can Fam Physician** 1996 Nov;42:2186–90 (14 ref.) Comment in: Can Fam Physician 1997 Mar;43:420–1. Comment in: Can Fam Physician 1997 Mar;43:421–4.
Withdrawal from anabolic steroids. Brower KJ. **Curr Ther Endocrinol Metab** 1997;6:338–43 (8 ref.)

SUBSTANTIA INNOMINATA

ANATOMY & HISTOLOGY

Substantia innominata: a notion which impedes clinical–anatomical correlations in neuropsychiatric disorders. Heimer L, et al. **Neuroscience** 1997 Feb; 76(4):957–1006 (562 ref.)

PHYSIOLOGY

Suppression of the magnocellular pathway during saccades. Ross J, et al. **Behav Brain Res** 1996 Oct;80(1–2):1–8 (63 ref.)
The nucleus basalis magnocellularis cholinergic system: one hundred years of progress. Wenk GL. **Neurobiol Learn Mem** 1997 Mar;67(2):85–95 (119 ref.)
Substantia innominata: a notion which impedes clinical–anatomical correlations in neuropsychiatric disorders. Heimer L, et al. **Neuroscience** 1997 Feb; 76(4):957–1006 (562 ref.)

SUBSTANTIA NIGRA

DRUG EFFECTS

Cocaine, Neuroleptics, and tardive dyskinesia as paleocortical escape. Howard JS 3rd. **Integr Physiol Behav Sci** 1996 Oct–Dec;31(4):306–14 (33 ref.)

EMBRYOLOGY

The time course of loss of dopaminergic neurons and the gliotic reaction surrounding grafts of embryonic mesencephalon to the striatum. Barker RA, et al. **Exp Neurol** 1996 Sep;141(1):79–93 (95 ref.)

PATHOLOGY

Nigral and extranigral pathology in Parkinson's disease. Braak H, et al. **J Neural Transm Suppl** 1995;46:15–31 (87 ref.)
Neuronal vulnerability in Parkinson's disease. Hirsch EC, et al. **J Neural Transm Suppl** 1997;50:79–88 (36 ref.)
Nigrostriatal neuronal death in Parkinson's disease—a passive or an active genetically-controlled process? Ziv I, et al. **J Neural Transm Suppl** 1997;49:69–76 (26 ref.)
Modulation of control mechanisms of dopamine-induced apoptosis—a future approach to the treatment of Parkinson's disease? Ziv I, et al. **J Neural Transm Suppl** 1997;49:195–202 (21 ref.)
[Striatonigral degeneration] Mochizuki A, et al. **Nippon Rinsho** 1997 Jan;55(1):123–6 (15 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Regulation of substantia nigra dopamine neurons. Pucak ML, et al. **Crit Rev Neurobiol** 1994;9(1):67–89 (178 ref.)
Nigrostriatal dopamine system may contribute to behavioral learning through providing reinforcement signals to the striatum. Kimura M, et al. **Eur Neurol** 1997;38 Suppl 1:11–7 (33 ref.)

PHYSIOPATHOLOGY

Bipolar disorders, dystonia, and compulsion after dysfunction of the cerebellum, dentatorubrothalamic tract, and substantia nigra. Lauterbach EC. **Biol Psychiatry** 1996 Oct 15;40(8):726–30 (65 ref.)
Ontogeny and topography of seizure regulation by the substantia nigra. Moshé SL, et al. **Brain Dev** 1995;17 Suppl:61–72 (113 ref.)
Dopa-responsive dystonia: a syndrome of selective nigrostriatal dopaminergic deficiency. Jeon BS. **J Korean Med Sci** 1997 Aug;12(4):269–79 (78 ref.)

TRANSPLANTATION

Fetal nigral transplantation as a therapy for Parkinson's disease. Olanow CW, et al. **Trends Neurosci** 1996 Mar; 19(3):102–9 (81 ref.)

SUBTALAR JOINT

INJURIES

Occult fractures following subtalar joint injuries. Bohay DR, et al. **Foot Ankle Int** 1996 Mar;17(3):164–9 (11 ref.)
The use of a calcaneal reconstruction plate in intra-articular calcaneal fractures. Frankel JP, et al. **J Foot Ankle Surg** 1996 Jul–Aug;35(4):318–30; discussion 370 (38 ref.)
Open medial subtalar dislocation associated with fracture of the posterior process of the talus [see comments] Naranja RJ Jr, et al. **J Orthop Trauma** 1996;10(2):142–4 (5 ref.) Comment in: J Orthop Trauma 1997 Apr;11(3):238.
Posterior subtalar dislocation. Inokuchi S, et al. **J Trauma** 1997 Feb;42(2):310–3 (14 ref.)

PATHOLOGY

Extra-articular localized nodular synovitis (giant cell tumor of tendon sheath origin) attached to the subtalar joint. Villani C, et al. **Foot Ankle Int** 1996 Jul;17(7):413–6 (30 ref.)

SURGERY

Triple arthrodesis. Schramm CA, et al. **AORN J** 1996 Jul; 64(1):31–52; quiz 54–61 (22 ref.)
Use of demineralized bone matrix in hindfoot arthrodesis. Michelson JD, et al. **Clin Orthop** 1996 Apr;(325):203–8 (24 ref.)
[Surgical fusion of the subtalar joint—changing concepts in changing times] Fellmann J, et al. **Z Orthop Ihre Grenzgeb** 1996 Jul–Aug;134(4):341–5 (35 ref.) (Eng. Abstr.) **(Ger)**

SUBTILISINS

CHEMISTRY

Structure and function of subtilisin BPN' as studied through crystallographic studies on a series of its complexes with genetically engineered proteinaceous inhibitor SSI. Nonaka T, et al. **Adv Exp Med Biol** 1996;379:21–7 (24 ref.)
Propeptide-mediated folding in subtilisin: the intramolecular chaperone concept. Shinde U, et al. **Adv Exp Med Biol** 1996;379:147–54 (35 ref.)

GENETICS

Novel members of mammalian kexin family proteases, pace 4C, pace 4D, PC 7A and PC 7B. Matsuda Y, et al. **Adv Exp Med Biol** 1996;389:63–71 (15 ref.)

SUBTRACTION ANGIOGRAPHY, DIGITAL see **ANGIOGRAPHY, DIGITAL SUBTRACTION**

SUBTRACTION TECHNIQUE

Subtractive hybridization, a technique for extraction of DNA sequences distinguishing two closely related genomes: critical analysis. Ermolaeva OD, et al. **Genet Anal** 1996 Jul;13(2):49–58 (35 ref.)
Molecular dissection of corticosteroid action in the rat hippocampus. Application of the differential display techniques. Vreugdenhil E, et al. **J Mol Neurosci** 1996 Summer;7(2):135–46 (40 ref.)

SUBTROCHANTERIC FRACTURES see **HIP FRACTURES**

SUBVALVULAR STENOSIS, IDIOPATHIC HYPERTROPHIC see **CARDIOMYOPATHY, HYPERTROPHIC**

SUCCIMER

DIAGNOSTIC USE

The evaluation of acute pyelonephritis and renal scarring with technetium 99m-dimercaptosuccinic acid renal scintigraphy: evolving concepts and future directions. Rushton HG. **Pediatr Nephrol** 1997 Feb;11(1):108–20 (102 ref.)
[99m technetium-dimercaptosuccinic acid renal scan in urinary tract infection in infancy and childhood] Aladjem M, et al. **Harefuah** 1997 Jun 1;132(11):796–8 (25 ref.) **(Heb)**

SUCCINATE DEHYDROGENASE

DEFICIENCY

Inborn errors of the Krebs cycle: a group of unusual mitochondrial diseases in human. Rustin P, et al. **Biochim Biophys Acta** 1997 Aug 22;1361(2):185–97 (35 ref.)

PHYSIOLOGY

Succinate: quinone oxidoreductases. Variations on a conserved theme. Hägerhäll C. **Biochim Biophys Acta** 1997 Jun 13;1320(2):107–41 (188 ref.)

SUCCINIC OXIDASE see **SUCCINATE DEHYDROGENASE**

SUCCINYLCHOLINE

ADVERSE EFFECTS

Rhabdomyolysis and anesthesia: a report of two cases and review of the literature. Pedrozzi NE, et al. **Pediatr Neurol** 1996 Oct;15(3):254–7 (52 ref.)
[Myoglobinuria following anesthesia with enflurane and succinylcholine in an asthmatic child on theophylline] Shono S, et al. **Masui** 1996 Jan;45(1):91–5 (12 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Action of cholinesters on sensory nerve endings in skin and muscle. Carr RW, et al. **Clin Exp Pharmacol Physiol** 1996 May;23(5):355–62 (81 ref.)
Neuromuscular blocking drugs: onset and intubation. Bevan DR. **J Clin Anesth** 1997 Sep;9(6 Suppl):36S–39S (19 ref.)
Neuromuscular transmission and its pharmacological blockade. Part 2: Pharmacology of neuromuscular blocking agents. Booij LH. **Pharm World Sci** 1997 Feb;19(1):13–34 (301 ref.)

SUCCINYLDICHOLINE see **SUCCINYLCHOLINE**

SUCKING BEHAVIOR

Sucking habits in Saudi children: prevalence, contributing factors and effects on the primary dentition. Farsi NM, et al. **Pediatr Dent** 1997 Jan–Feb;19(1):28–33 (37 ref.)

PHYSIOLOGY

Nutritive and nonnutritive sucking habits: a review. Turgeon-O'Brien H, et al. **ASDC J Dent Child** 1996 Sep–Oct;63(5):321–7 (50 ref.)
Mothers and their infants: peptide-mediated physiological, behavioral and affective changes during suckling. Blass EM. **Regul Pept** 1996 Oct 8;66(1–2):109–12 (28 ref.)

SUCRALFATE

THERAPEUTIC USE

Sucralfate and Helicobacter pylori. Terano A, et al. **J Gastroenterol** 1996 Nov;31 Suppl 9:63–5 (10 ref.)
Helicobacter pylori eradication: therapy other than with bismuth or proton-pump inhibitors. Korman MG. **Scand J Gastroenterol Suppl** 1996;220:41–3 (25 ref.)
[The use of sucralfate in radiation oncology] Belka C, et al. **Strahlenther Onkol** 1997 May;173(5):247–52 (25 ref.) (Eng. Abstr.) **(Ger)**
[Sucralfate in odontostomatology. Clinical experience] Campisi G, et al. **Minerva Stomatol** 1997 Jun;46(6):297–305 (42 ref.) (Eng. Abstr.) **(Ita)**

SUCROSE

ANALOGS & DERIVATIVES

Olestra: assessing its potential to interact with drugs in the gastrointestinal tract. Goldman P. **Clin Pharmacol Ther** 1997 Jun;61(6):613–8 (39 ref.)
Olestra, a nonabsorbed, noncaloric replacement for dietary fat: a review. Lawson KD, et al. **Drug Metab Rev** 1997 Aug;29(3):651–703 (144 ref.)

SUCTION

METHODS

Bimanual irrigation/aspiration. Brauweiler P. **J Cataract Refract Surg** 1996 Oct;22(8):1013–6 (7 ref.)

VETERINARY

Transvaginal aspiration. Squires EL, et al. **Vet Clin North Am Equine Pract** 1996 Apr;12(1):13–29 (42 ref.)

SUCTION LIPECTOMY see **LIPECTOMY**

SUDDEN CARDIAC DEATH see **DEATH, SUDDEN, CARDIAC**

SUDDEN DEAFNESS see **DEAFNESS, SUDDEN**

SUDDEN INFANT DEATH

Supporting relatives following a cot death. Phillips BM. **Postgrad Med J** 1996 Nov;72(853):648–52 (13 ref.)
[Sudden infant death syndrome] Mizuta R. **Ryoikibetsu Shokogun Shirizu** 1996;(15):591–4 (8 ref.) **(Jpn)**

EPIDEMIOLOGY

Can risk factors for over-heating explain epidemiological features of sudden infant death syndrome? Wells JC. **Med Hypotheses** 1997 Feb;48(2):103–6 (42 ref.)
Sudden infant death syndrome and parental smoking—a literature review. Golding J. **Paediatr Perinat Epidemiol** 1997 Jan;11(1):67–77 (29 ref.)
[Sudden infant death] Pavesio D, et al. **Minerva Pediatr** 1996 Jul–Aug;48(7–8):291–6 (30 ref.) **(Ita)**

ETIOLOGY

Sudden infant death syndrome. Byard RW. **Aust Fam Physician** 1996 Feb;25(2):210–1, 213, 215 (10 ref.)
Clostridium perfringens type A enterotoxin (CPE): more than just explosive diarrhea. Lindsay JA. **Crit Rev Microbiol** 1996;22(4):257–77 (112 ref.)
Autism, child abuse, and sudden infant death syndrome. Church C, et al. **Curr Opin Pediatr** 1997 Apr;9(2):189–94 (35 ref.)
Sudden infant death syndrome: a hypothesis. David CM. **Med Hypotheses** 1997 Jul;49(1):61–7 (73 ref.)
Sudden infant death syndrome and placental disorders: the thyroid-selenium link. Reid GM, et al. **Med Hypotheses** 1997 Apr;48(4):317–24 (66 ref.)
Sudden infant death syndrome: near-weightlessness and delayed neural transformation. Reid GM, et al. **Med Hypotheses** 1996 Apr;46(4):383–7 (32 ref.)
Are bedding and rebreathing suffocation a cause of SIDS? Guntheroth WG, et al. **Pediatr Pulmonol** 1996 Dec; 22(6):335–41 (68 ref.)
Thermal stress, sleeping position, and the sudden infant death syndrome. Sawczenko A, et al. **Sleep** 1996 Dec;19(10 Suppl):S267–70 (36 ref.)

IMMUNOLOGY

Adhesins of Staphylococcus aureus that bind Lewis(a) antigen. Relationship to sudden infant death syndrome. Blackwell CC, et al. **Adv Exp Med Biol** 1996;408:95–105 (55 ref.)

PATHOLOGY

Simultaneous death of twins. An environmental hazard or SIDS? Ramos V, et al. **Am J Forensic Med Pathol** 1997 Mar;18(1):75–8 (22 ref.)
Intra-alveolar pulmonary siderophages in sudden infant death: a marker for previous imposed suffocation. Becroft DM, et al. **Pathology** 1997 Feb;29(1):60–3 (19 ref.)

PREVENTION & CONTROL

Is prevention of sudden infant death syndrome now a reality? Hein H. **Iowa Med** 1997 Jul–Aug;87(6):243–4 (0 ref.)
[Management in subsequent children in families where crib death occurred: management or home monitoring?] Hoir MP, et al. **Ned Tijdschr Geneeskd** 1996 Sep 21; 140(38):1888–90 (20 ref.) **(Dut)**
[Sleeping position, prevention of sudden death syndrome and gastroesophageal reflux] Faure C, et al. **Arch Pediatr** 1996 Jun;3(6):598–601 (16 ref.) (Eng. Abstr.) **(Fre)**
[Infant care practices and sudden infant death: a transcultural comparison (editorial)] Messer J, et al. **Arch Pediatr** 1997 Jan;4(1):3–7 (27 ref.) **(Fre)**
[Prevention of sudden death in Luxembourg] Caeymaex L,

et al. **Bull Soc Sci Med Grand Duche Luxemb** 1996; 133(2):5–12 (38 ref.) **(Fre)**

SUDECK'S ATROPHY see **REFLEX SYMPATHETIC DYSTROPHY**

SUFENTANIL

ADMINISTRATION & DOSAGE

Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update. Scholz J, et al. **Clin Pharmacokinet** 1996 Oct;31(4):275–92 (136 ref.)

PHARMACOKINETICS

Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update. Scholz J, et al. **Clin Pharmacokinet** 1996 Oct;31(4):275–92 (136 ref.)

SUFFOCATION see **ASPHYXIA**

SUGAR ACIDS

[Recent advances in glycobiology on KDN-containing glycoconjugates] Kitajima K, et al. **Seikagaku** 1997 Jan; 69(1):44–51 (33 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

[1,2:3,4:5,6-tri-O-isopropylidene-D-gluconolactone as a substrate in models synthesis of Kdo] Jarosz S, et al. **Postepy Hig Med Dosw** 1996;50(5):473–82 (15 ref.) (Eng. Abstr.) **(Pol)**

SUGAR ALCOHOL DEHYDROGENASES

GENETICS

Expression of recombinant L-gulono-gamma-lactone oxidase. Yagi K, et al. **Methods Enzymol** 1997;279:24–9 (16 ref.)

SUGAR ALCOHOL OXIDOREDUCTASES see **SUGAR ALCOHOL DEHYDROGENASES**

SUGAR ALCOHOLS

BLOOD

[Immunodiagnosis and blood biochemical diagnosis of visceral candidiasis and the cutoff limits of positive] Kume H, et al. **Rinsho Byori** 1996 Jun;44(6):505–11 (21 ref.) (Eng. Abstr.) **(Jpn)**

SUGAR SUBSTITUTES see **SWEETENING AGENTS**

SUGARS see **CARBOHYDRATES**

SUGGESTION

see related

PERSUASIVE COMMUNICATION

The state of the "state" debate in hypnosis: a view from the cognitive-behavioral perspective. Chaves JF. **Int J Clin Exp Hypn** 1997 Jul;45(3):251–65 (70 ref.)

Context and consistency: the Canadian connection. Council JR. **Int J Clin Exp Hypn** 1997 Jul;45(3):204–11 (28 ref.)

Convergence in understanding hypnosis? Perhaps, but perhaps not quite so fast. Kihlstrom JF. **Int J Clin Exp Hypn** 1997 Jul;45(3):324–32 (28 ref.)

Suggestibility or hypnosis: what do our scales really measure? Kirsch I. **Int J Clin Exp Hypn** 1997 Jul;45(3):212–25 (36 ref.)

Automaticity and hypnosis: a sociocognitive account. Lynn SJ. **Int J Clin Exp Hypn** 1997 Jul;45(3):239–50 (33 ref.)

What this field needs is a good nomological network. Nadon R. **Int J Clin Exp Hypn** 1997 Jul;45(3):314–23 (24 ref.)

EEG concomitants of hypnotic susceptibility. Ray WJ. **Int J Clin Exp Hypn** 1997 Jul;45(3):301–13 (53 ref.)

Have the hypnotic susceptibility scales outlived their usefulness? Woody EZ. **Int J Clin Exp Hypn** 1997 Jul; 45(3):226–38 (24 ref.)

"Indirect" suggestion in hypnosis: theoretical and experimental issues. Fourie DP. **Psychol Rep** 1997 Jun;80(3 Pt 2):1255–66 (50 ref.)

[Quantitative psychopathology of affect and emotion. Review of evaluation scales and emotion induction methods] Garcia C, et al. **Encephale** 1997 Mar-Apr;23(2):119–30 (129 ref.) (Eng. Abstr.) **(Fre)**

SUICIDE

Suicide by jumping. Gunnell D, et al. **Acta Psychiatr Scand** 1997 Jul;96(1):1–6 (64 ref.)

Suicide by gunshot while driving a motor vehicle. Two additional cases. Murphy GK. **Am J Forensic Med Pathol** 1997 Sep;18(3):295–8 (8 ref.)

Depression and suicide in children and adolescents. Besseghini VH. **Ann N Y Acad Sci** 1997 Jun 17;816:94–8 (05 ref.)

Suicide: how to survive as a survivor? Grad OT. **Crisis** 1996; 17(3):136–42 (38 ref.)

Epidemiology and relative toxicity of antidepressant drugs in overdose. Henry JA. **Drug Saf** 1997 Jun;16(6):374–90 (92 ref.)

Lethal suicidal intoxication with propafenone, after a history of self-inflicted injuries. Maxeiner H, et al. **Forensic Sci Int** 1997 Sep 19;89(1–2):27–32 (12 ref.)

Suicide risk factors among veterans: risk management in the changing culture of the Department of Veterans Affairs. Lambert MT, et al. **J Ment Health Adm** 1997 Summer; 24(3):350–8 (50 ref.)

[Fluoxetine, akathisia and suicide] Lançon C, et al. **Encephale** 1997 May-Jun;23(3):218–23 (46 ref.) (Eng. Abstr.) **(Fre)**

LEGISLATION & JURISPRUDENCE

Suicide as a crime in the UK: legal history, international comparisons and present implications. Neeleman J. **Acta Psychiatr Scand** 1996 Oct;94(4):252–7 (35 ref.)

Multiple gunshot suicides: potential for physical activity and medico-legal aspects. Karger B, et al. **Int J Legal Med** 1997;110(4):188–92 (34 ref.)

[Retained capacity for action in brain gunshot injury. Case report and systematic examination] Karger B, et al. **Arch Kriminol** 1997 May-Jun;199(5–6):159–66 (18 ref.) (Eng. Abstr.) **(Ger)**

[Differentiation of hunting accident and suicide with rifles] Karger B. **Versicherungsmedizin** 1996 Feb 1;48(1):11–5 (24 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

How are nations trying to prevent suicide? An analysis of national suicide prevention strategies. Taylor SJ, et al. **Acta Psychiatr Scand** 1997 Jun;95(6):457–63 (29 ref.)

Arguments for and against teaching suicide prevention in schools. Hazell P, et al. **Aust N Z J Psychiatry** 1996 Oct; 30(5):633–42 (59 ref.)

Management of suicidal risk. Hughes T, et al. **Br J Hosp Med** 1996 Aug 21-Sep 3;56(4):151–4 (24 ref.)

A systematic overview of adolescent suicide prevention programs. Ploeg J, et al. **Can J Public Health** 1996 Sep-Oct; 87(5):319–24 (33 ref.)

Preventing suicide in young people: what is known and what is needed. Williams K. **Child Care Health Dev** 1997 Mar; 23(2):173–85 (51 ref.)

Management of the suicidal child or adolescent in the emergency department. Press BR, et al. **Curr Opin Pediatr** 1997 Jun;9(3):237–41 (24 ref.)

Suicide and violence assessment in psychiatry. Hughes DH. **Gen Hosp Psychiatry** 1996 Nov;18(6):416–21 (37 ref.)

Risk of suicide in depression and its implication for psychopharmacological treatment. Kasper S, et al. **Int Clin Psychopharmacol** 1996 Jun;11(2):71–9 (100 ref.)

Strategies of suicide prevention: focus on health care. Rihmer Z. **J Affect Disord** 1996 Jul 8;39(2):83–91 (63 ref.)

Strategies for managing depression complicated by bipolar disorder, suicidal ideation, or psychotic features. Hartmann PM. **J Am Board Fam Pract** 1996 Jul-Aug;9(4):261–9 (69 ref.)

The aftercare of adolescents with deliberate self-harm. Brent DA. **J Child Psychol Psychiatry** 1997 Mar;38(3):277–86 (100 ref.)

The prevention of suicide: some practical steps. Whitfield W, et al. **J R Soc Health** 1996 Oct;116(5):295–8 (40 ref.)

Assessment and treatment of suicidal patients. Hirschfeld RM, et al. **N Engl J Med** 1997 Sep 25;337(13):910–5 (41 ref.)

Prevention of late life suicide: when, where, why and how. Conwell Y, et al. **Psychiatry Clin Neurosci** 1995 May;49 Suppl 1:S79–83 (34 ref.)

Mental disorders and suicide prevention. Lönnqvist JK, et al. **Psychiatry Clin Neurosci** 1995 May;49 Suppl 1:S111–6 (37 ref.)

The challenge and the promise of clinical suicidology. Jobes DA. **Suicide Life Threat Behav** 1995 Winter;25(4):437–49 (43 ref.)

[Suicide prevention--recognizing and treating acute suicidal behavior] Wolfersdorf M. **Fortschr Med** 1997 Apr 20; 115(11):38–40, 43–4 (12 ref.) (Eng. Abstr.) **(Ger)**

[Are preventive measures against suicide efficient? A literature review] Bilsbak US, et al. **Tidsskr Nor Laegeforen** 1997 May 10;117(12):1746–50 (27 ref.) (Eng. Abstr.) **(Nor)**

[Increased use of antidepressive agents. A correctly aimed development] Isacsson G, et al. **Lakartidningen** 1997 Apr 16;94(16):1484–6 (46 ref.) **(Swe)**

PSYCHOLOGY

Research in psychopathology in patients with HIV/AIDS and psychiatric services in Spain. Ayuso Mateos JL, et al. **AIDS Care** 1996 Apr;8(2):233–9 (22 ref.)

Adolescent/adult differences in suicidal behavior and outcome. Safer DJ. **Ann Clin Psychiatry** 1997 Mar;9(1):61–6 (68 ref.)

Children's understanding of death in relation to child suicidality and homicidality. Cuddy-Casey M, et al. **Clin Psychol Rev** 1997;17(1):33–45 (46 ref.)

Suicide and anomie. Spencer DJ. **J R Soc Med** 1997 Feb; 90(2):86–7 (6 ref.)

Suicide and mental disorders. Asukai N. **Psychiatry Clin Neurosci** 1995 May;49 Suppl 1:S91–7 (42 ref.)

Clinical evaluation of suicide risk. Leenaars AA. **Psychiatry Clin Neurosci** 1995 May;49 Suppl 1:S61–8 (52 ref.)

Recent trends in suicidal behavior in Japan. Takahashi Y. **Psychiatry Clin Neurosci** 1995 May;49 Suppl 1:S105–9 (23 ref.)

Family risk factors for child and adolescent suicidal behavior. Wagner BM. **Psychol Bull** 1997 Mar;121(2):246–98 (250 ref.)

[Epidemiologic and molecular genetic of suicidal behavior] Abbar M, et al. **Encephale** 1996 Dec;22 Spec No 4:19–24 (31 ref.) (Eng. Abstr.) **(Fre)**

[Psychological autopsies in the study of suicide] Bourgeois ML. **Encephale** 1996 Dec;22 Spec No 4:46–51 (38 ref.) (Eng. Abstr.) **(Fre)**

[Evaluation of suicidal risk in emergency service] König F, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Dec;31(10):615–20 (35 ref.) (Eng. Abstr.) **(Ger)**

[Anger and risk of suicide. Study of elderly psychiatric patients] Hodapp V, et al. **Nervenarzt** 1997 Jan;68(1):55–61 (35 ref.) (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

Understanding suicide among indigenous adolescents: a review using the PRECEDE model [see comments] Clarke VA, et al. **Inj Prev** 1997 Jun;3(2):126–34 (126 ref.) Comment in: Inj Prev 1997 Jun;3(2):74–5.

Suicide risk in the general hospital. Berger D. **Psychiatry Clin Neurosci** 1995 May;49 Suppl 1:S85–9 (20 ref.)

[Suicidal risk in bipolar disorders] Bourgeois ML, et al. **Encephale** 1997 Jan;23 Spec No 1:35–41 (30 ref.) (Eng. Abstr.) **(Fre)**

[Suicide in adolescence] Bouvard MP, et al. **Encephale** 1996 Dec;22 Spec No 4:35–9 (8 ref.) (Eng. Abstr.) **(Fre)**

[Suicide in Portugal] de Sousa MP. **Encephale** 1996 Dec;22 Spec No 4:28–34 (66 ref.) (Eng. Abstr.) **(Fre)**

[Suicide and psychotropic drugs] Lejoyeux M, et al. **Encephale** 1996 Dec;22 Spec No 4:40–5 (34 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

Violence in America: a survey of suicide linked to homicides. Aderibigbe YA. **J Forensic Sci** 1997 Jul;42(4):662–5 (21 ref.)

Recent trends in suicidal behavior in Japan. Takahashi Y. **Psychiatry Clin Neurosci** 1995 May;49 Suppl 1:S105–9 (23 ref.)

[The Hungarian suicide enigma] Arató M. **Encephale** 1996 Dec;22 Spec No 4:25–7 (18 ref.) (Eng. Abstr.) **(Fre)**

SUICIDE, ASSISTED

Euthanasia and assisted suicide: a family practice perspective. Gates TJ. **Am Fam Physician** 1997 May 15;55(7):2437–41, 2444 (33 ref.)

The end-of-life sequence. Waisel DB, et al. **Anesthesiology** 1997 Sep;87(3):676–86 (68 ref.)

Practical issues in physician-assisted suicide [see comments] Drickamer MA, et al. **Ann Intern Med** 1997 Jan 15; 126(2):146–51 (38 ref.) Comment in: Ann Intern Med 1997 Jul 15;127(2):174.

IASP task force on euthanasia and assisted suicide. Kelleher M, et al. **Crisis** 1995;16(3):111–5, 120 (00 ref.)

Is there a role for physician-assisted suicide in cancer? Yes. McKhann CF. **Important Adv Oncol** 1996;:267–79 (20 ref.)

Is there a role for physician-assisted suicide in cancer? No. Siegler M. **Important Adv Oncol** 1996;:281–91 (72 ref.)

Can suicide intervention in hospice be ethical? McGee EM. **J Palliat Care** 1997 Spring;13(1):27–33 (50 ref.)

Death with dignity. End-of-life issues for the HIV/AIDS patient. Evangelisto M. **J Psychosoc Nurs Ment Health Serv** 1996 Jun;34(6):45–7 (4 ref.)

When patients ask about assisted suicide. A viewpoint from Oregon. Lee MA, et al. **West J Med** 1996 Oct;165(4):205–8 (23 ref.)

LEGISLATION & JURISPRUDENCE

Constitutional aspects of physician-assisted suicide after Lee v. Oregon. Canick SM. **Am J Law Med** 1997;23(1):69–96 (251 ref.)

Physician-assisted suicide and the Dutch courts. Gevers JK. **Camb Q Healthc Ethics** 1996 Winter;5(1):93–9 (4 ref.)

Physician-assisted suicide in psychiatry: developments in The Netherlands. Legemaate J, et al. **Camb Q Healthc Ethics** 1997 Spring;6(2):175–88 (45 ref.)

An analysis of arguments for and against euthanasia and assisted suicide: Part one. Thomasma DC. **Camb Q Healthc Ethics** 1996 Winter;5(1):62–76 (62 ref.)

Physician-assisted suicide: a tragic view. Arras JD. **J Contemp Health Law Policy** 1997 Spring;13(2):361–89 (94 ref.)

It's my body and I'll die if I want to: a property-based argument in support of assisted suicide. Friedman RF. **J Contemp Health Law Policy** 1995 Fall;12(1):183–213 (210 ref.)

Physician-assisted suicide: landmark Supreme Court decisions and a summary of state law. Wolfson LA. **J Ky Med Assoc** 1997 Aug;95(8):311–2 (0 ref.)

Assisted suicide: nurse practitioners as providers? [see comments] Hall JK. **Nurse Pract** 1996 Oct;21(10):63–6, 71 (43 ref.) Comment in: Nurse Pract 1997 Jan;22(1):13.

PSYCHOLOGY

Normatology: a review and commentary with reference to abortion and physician-assisted suicide. Brodie HK, et al. **Am J Psychiatry** 1997 Jun;154(6 Suppl):13–9 (42 ref.)
Assisted suicide and euthanasia: what about the clinical issues? [see comments] Kelly BJ, et al. **Aust N Z J Psychiatry** 1996 Feb;30(1):3–8 (34 ref.) Comment in: Aust N Z J Psychiatry 1996 Aug;30(4):557–8.
Psychiatry and physician-assisted suicide. Zaubler TS, et al. **Psychiatr Clin North Am** 1996 Sep;19(3):413–27 (59 ref.)

SUICIDE, ATTEMPTED

Airway and respiratory management following non-lethal hanging. Kaki A, et al. **Can J Anaesth** 1997 Apr; 44(4):445–50 (15 ref.)
The use of air weapons in attempted suicide. Campbell-Hewson G, et al. **Injury** 1997 Mar;28(2):153–8 (31 ref.)
Spontaneous pneumothoraces, pneumomediastinum, and pneumoperitoneum: consequences of smoking crack cocaine. Uva JL. **Pediatr Emerg Care** 1997 Feb;13(1):24–6 (29 ref.)
Unusual complications of paracetamol poisoning. Jones AL, et al. **QJM** 1997 Mar;90(3):161–8 (148 ref.)
Intentional overdosage with isoniazid: case report and review of literature. Tai DY, et al. **Singapore Med J** 1996 Apr; 37(2):222–5 (44 ref.)
Campho-Phenique ingestion: an intentional overdose. Lahoud CA, et al. **South Med J** 1997 Jun;90(6):647–8 (11 ref.)

PREVENTION & CONTROL

Is psychotherapy helpful for adolescent suicide attempters? Spirito A. **Crisis** 1997;18(1):3–4 (4 ref.)
The aftercare of adolescents with deliberate self-harm. Brent DA. **J Child Psychol Psychiatry** 1997 Mar;38(3):277–86 (100 ref.)
Attempted suicide: efficacy of treatment programs. Kurz A, et al. **Psychiatry Clin Neurosci** 1995 May;49 Suppl 1:S99–103 (20 ref.)
[Are preventive measures against suicide efficient? A literature review] Bilsbak US, et al. **Tidsskr Nor Laegeforen** 1997 May 10;117(12):1746–50 (27 ref.) (Eng. Abstr.) **(Nor)**

PSYCHOLOGY

Psychosocial intervention following suicide attempt: a systematic review of treatment interventions. van der Sande R, et al. **Acta Psychiatr Scand** 1997 Jul;96(1):43–50 (33 ref.)
Adolescent/adult differences in suicidal behavior and outcome. Safer DJ. **Ann Clin Psychiatry** 1997 Mar;9(1):61–6 (68 ref.)
Individual therapy techniques with adolescent suicide attempters. Spirito A. **Crisis** 1997;18(2):62–4 (6 ref.)
Improving treatment compliance among adolescent suicide attempters. Spirito A. **Crisis** 1996;17(4):152–4 (18 ref.)
HIV infection and suicidality. Bellini M, et al. **J Affect Disord** 1996 Jun 5;38(2–3):153–64 (57 ref.)
Attempted suicide: efficacy of treatment programs. Kurz A, et al. **Psychiatry Clin Neurosci** 1995 May;49 Suppl 1:S99–103 (20 ref.)
[Epidemiologic and molecular genetic of suicidal behavior] Abbar M, et al. **Encephale** 1996 Dec;22 Spec No 4:19–24 (31 ref.) (Eng. Abstr.) **(Fre)**
[Evaluation of suicidal risk in emergency service] König F, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Dec;31(10):615–20 (35 ref.) (Eng. Abstr.) **(Ger)**
[Anger and risk of suicide. Study of elderly psychiatric patients] Hodapp V, et al. **Nervenarzt** 1997 Jan;68(1):55–61 (35 ref.) (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

A comparison of studies from the United States and western Europe on psychiatric hospitalization referrals for youths exhibiting suicidal behavior. Safer DJ. **Ann Clin Psychiatry** 1996 Sep;8(3):161–8 (142 ref.)
Classification of attempted suicide: a review of empirical studies, 1963–1993. Arensman E, et al. **Suicide Life Threat Behav** 1996 Spring;26(1):46–67 (82 ref.)
[Suicide in adolescence] Bouvard MP, et al. **Encephale** 1996 Dec;22 Spec No 4:35–9 (8 ref.) (Eng. Abstr.) **(Fre)**
[Suicide in Portugal] de Sousa MP. **Encephale** 1996 Dec;22 Spec No 4:28–34 (66 ref.) (Eng. Abstr.) **(Fre)**
[Alcohol and suicide attempts] Kolaciński Z, et al. **Przegl Lek** 1997;54(6):438–40 (11 ref.) (Eng. Abstr.) **(Pol)**

TRENDS

[The Hungarian suicide enigma] Arató M. **Encephale** 1996 Dec;22 Spec No 4:25–7 (18 ref.) (Eng. Abstr.) **(Fre)**

SULBACTAM

PHARMACOLOGY

beta-Lactamase inhibition and in vitro activity of sulbactam and sulbactam/cefoperazone. Williams JD. **Clin Infect Dis** 1997 Mar;24(3):494–7 (7 ref.)

SULFAMETHOXAZOLE-TRIMETHOPRIM COMBINATION see **TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION**

SULFAMYL DIURETICS see **DIURETICS, SULFAMYL**

SULFANILIC ACIDS

see related
INDICATORS AND REAGENTS

SULFASALAZINE

ADVERSE EFFECTS

[Pericarditis in chronic inflammatory bowel disease: underlying disease or side effects of therapy? Clinical problem solving] Kupferschmidt H, et al. **Schweiz Med Wochenschr** 1996 Dec 14;126(50):2184–90 (74 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

[Salazopyrine and male fertility] Marmor D. **Ann Gastroenterol Hepatol (Paris)** 1996 Nov–Dec; 31(6):349–53 (59 ref.) **(Fre)**

THERAPEUTIC USE

Sulphasalazine in the treatment of rheumatoid arthritis. Box SA, et al. **Br J Rheumatol** 1997 Mar;36(3):382–6 (64 ref.)
Combination sulfasalazine and methotrexate in the management of rheumatoid arthritis. Shiroky JB. **J Rheumatol Suppl** 1996 Mar;44:69–71 (31 ref.)
[Sulphasalazine: a promising drug in rheumatology] Nasonov EL. **Klin Med (Mosk)** 1997;75(6):39–44 (71 ref.) **(Rus)**

SULFATASES

GENETICS

The sulfatase gene family. Parenti G, et al. **Curr Opin Genet Dev** 1997 Jun;7(3):386–91 (35 ref.)

METABOLISM

Control and expression of oestrone sulphatase activities in human breast cancer. Pasqualini JR, et al. **J Endocrinol** 1996 Sep;150 Suppl:S99–105 (28 ref.)

SULFATES

The osmium ammine-SO2 staining method for studying the in situ configuration of viral genomes in ultrathin sections of DNA virus infected cells. Puvion-Dutilleul F, et al. **Biol Cell** 1996;87(3):133–41 (33 ref.)

ANALYSIS

Sulfate concentrations as an indicator of ambient particulate matter air pollution for health risk evaluations. Lippmann M, et al. **J Expo Anal Environ Epidemiol** 1996 Apr–Jun; 6(2):123–46 (51 ref.)

METABOLISM

Basic helix-loop-helix transcription factors and the cross-regulation of sulphate and phosphate metabolism in yeast. Crowther DJ, et al. **Biochem Soc Trans** 1996 May; 24(2):354–9 (53 ref.)
Two selectins converge on sulphate. Leukocyte adhesion. Rosen SD, et al. **Curr Biol** 1996 Mar 1;6(3):261–4 (21 ref.)
Sulfation and sulfotransferases. Introduction: changing view of sulfation and the cytosolic sulfotransferases. Falany CN. **FASEB J** 1997 Jan;11(1):1–2 (11 ref.)
Sulfation and sulfotransferases 5: the importance of 3'-phosphoadenosine 5'-phosphosulfate (PAPS) in the regulation of sulfation. Klaassen CD, et al. **FASEB J** 1997 May;11(6):404–18 (116 ref.)
Organization of glycosaminoglycan sulfation in the biosynthesis of proteochondroitin sulfate and proteodermatan sulfate. Silbert JE. **Glycoconj J** 1996 Dec; 13(6):907–12 (65 ref.)
Sulphation catalysed by the human cytosolic sulphotransferases--chemical defence or molecular terrorism? Coughtrie MW. **Hum Exp Toxicol** 1996 Jul; 15(7):547–55 (62 ref.)
Antiport-driven sulfate secretion in an invertebrate epithelium. Gerencser GA, et al. **J Exp Zool** 1996 Jul 1; 275(4):269–76 (58 ref.)
Cellular mechanisms in renal tubular transport of divalent inorganic anions. Murer H, et al. **Nephrologie** 1996; 17(7):365–9 (33 ref.)
Regulation of sulphation and glutathion conjugation of acetaminophen in isolated rat hepatocytes. Dalhoff K. **Pharmacol Toxicol** 1996;78 Suppl 1:1–24 (173 ref.)

URINE

A review of methods for the determination of sulphate in urine. Belcher R, et al. **Mikrochim Acta** 1977;(1–2 Pt 2):81–90 (44 ref.)

SULFATES, INORGANIC see **SULFATES**

SULFATIDATE SULFATASE see **CEREBROSIDE-SULFATASE**

SULFATIDOSIS see **LEUKODYSTROPHY, METACHROMATIC**

SULFATION FACTOR see **SOMATOMEDINS**

SULFHYDRASES

THERAPEUTIC USE

Methioninase: a therapeutic for diseases related to altered methionine metabolism and transmethylation: cancer, heart disease, obesity, aging, and Parkinson's disease. Hoffman RM. **Hum Cell** 1997 Mar;10(1):69–80 (117 ref.)

SULFHYDRYL COMPOUNDS

Gaining more insight into the pathomechanisms of thiol-induced acantholysis. Wolf R, et al. **Med Hypotheses** 1997 Feb;48(2):107–10 (23 ref.)

CHEMISTRY

Using self-assembled monolayers to understand the interactions of man-made surfaces with proteins and cells. Mrksich M, et al. **Annu Rev Biophys Biomol Struct** 1996; 25:55–78 (87 ref.)
Thioredoxins: universal, yet specific thiol-disulfide redox cofactors. Follmann H, et al. **Biofactors** 1995–96; 5(3):147–56 (128 ref.)

METABOLISM

Thiol template peptide synthesis systems in bacteria and fungi. Zocher R, et al. **Adv Microb Physiol** 1997;38:85–131 (120 ref.)
Regulation of cellular thiol redox status by nitric oxide. Padgett CM, et al. **Cell Biochem Biophys** 1995;27(3):157–77 (72 ref.)
The internal thioester and the covalent binding properties of the complement proteins C3 and C4. Law SK, et al. **Protein Sci** 1997 Feb;6(2):263–74 (95 ref.)
[Regulation of the stage of oxidoreduction in thiol groups of animal cells] Lenartowicz E, et al. **Postepy Biochem** 1996;42(2):154–61 (68 ref.) **(Pol)**

PHYSIOLOGY

Chemistry, analysis, and biological roles of S-nitrosothiols. Butler AR, et al. **Anal Biochem** 1997 Jun 15;249(1):1–9 (89 ref.)
Biological chemistry of thiols in the vasculature and in vascular-related disease. Stamler JS, et al. **Nutr Rev** 1996 Jan;54(1 Pt 1):1–30 (268 ref.)

SULFHYDRYL REAGENTS

see related
ENZYME INHIBITORS

SULFIDES

CHEMICAL SYNTHESIS

[Some recent advances in Pummerer-type reactions] Kita Y. **Yakugaku Zasshi** 1997 May;117(5):282–97 (23 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Colonic sulfide in pathogenesis and treatment of ulcerative colitis. Roediger WE, et al. **Dig Dis Sci** 1997 Aug; 42(8):1571–9 (116 ref.)

THERAPEUTIC USE

Organosulfur compounds and cancer. Lea MA. **Adv Exp Med Biol** 1996;401:147–54 (60 ref.)

SULFITE REDUCTASES

CHEMISTRY

The relationship between structure and function for the sulfite reductases. Crane BR, et al. **Curr Opin Struct Biol** 1996 Dec;6(6):744–56 (93 ref.)

METABOLISM

The relationship between structure and function for the sulfite reductases. Crane BR, et al. **Curr Opin Struct Biol** 1996 Dec;6(6):744–56 (93 ref.)

SULFITES

ADVERSE EFFECTS

[Clinical aspects and diagnosis of sulfite intolerance. Apropos of 9 patients] Miltgen J, et al. **Rev Pneumol Clin** 1996; 52(6):363–71 (41 ref.) (Eng. Abstr.) **(Fre)**

SULFITES, INORGANIC see **SULFITES**

SULFOBROMOPHTHALEIN

DIAGNOSTIC USE

[Indocyanine green and sulfobromophthalein tests] Sato T. **Nippon Rinsho** 1997 Apr;55 Suppl 2:177–9 (0 ref.) **(Jpn)**

METABOLISM

Characterization of membrane transport processes: lessons from the study of BSP, bilirubin, and fatty acid uptake. Berk PD, et al. **Semin Liver Dis** 1996 May;16(2):107–20 (69 ref.)

SULFOLOBUS

METABOLISM

Bioenergetics of the archaebacterium Sulfolobus. Schäfer G. **Biochim Biophys Acta** 1996 Dec 18;1277(3):163–200 (275 ref.)

SULFOLOBUS ACIDOCALDARIUS

GENETICS

Preribosomal RNA processing in archaea: characterization of the RNP endonuclease mediated processing of precursor 16S rRNA in the thermoacidophile Sulfolobus acidocaldarius. Potter S, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):813–23 (31 ref.)

SULFONAMIDES

Ibutilide. A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation. Foster RH, et al. **Drugs** 1997 Aug; 54(2):312–30 (58 ref.)

Nimesulide. Rajeshwari K, et al. **Indian Pediatr** 1997 Feb; 34(2):119–22 (22 ref.)

ADMINISTRATION & DOSAGE

[Local carbonic anhydrase inhibitor dorzolamide: development and properties] Pfeiffer N. **Ophthalmologe** 1996 Feb;93(1):103–18 (9 ref.) **(Ger)**

ADVERSE EFFECTS

Adverse reactions to sulphonamide and sulphonamide–trimethoprim antimicrobials: clinical syndromes and pathogenesis. Cribb AE, et al. **Adverse Drug React Toxicol Rev** 1996 Mar;15(1):9–50 (219 ref.)

Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter. Kowey PR, et al. **Am J Cardiol** 1996 Oct 17;78(8A):46–52 (15 ref.)

Antibiotic–associated hepatitis: update from 1990. Vial T, et al. **Ann Pharmacother** 1997 Feb;31(2):204–20 (162 ref.)

Benefits and risks of torasemide in congestive heart failure and essential hypertension. Brater DC. **Drug Saf** 1996 Feb; 14(2):104–20 (77 ref.)

Mechanisms of drug reactions: the metabolic track. Shapiro LE, et al. **Semin Cutan Med Surg** 1996 Dec;15(4):217–27 (66 ref.)

[Sulfonamide nephropathy] Shibasaki T. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):550–2 (4 ref.) **(Jpn)**

PHARMACOKINETICS

Electrophysiology and pharmacology of ibutilide. Naccarelli GV, et al. **Am J Cardiol** 1996 Oct 17;78(8A):12–6 (16 ref.)

PHARMACOLOGY

Electrophysiology and pharmacology of ibutilide. Naccarelli GV, et al. **Am J Cardiol** 1996 Oct 17;78(8A):12–6 (16 ref.)

Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. Balfour JA, et al. **Drugs Aging** 1997 May; 10(5):384–403 (81 ref.)

Development of new anticancer drugs in Japan—tubulin–interacting agents. Tsukagoshi S. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:94–9 (5 ref.)

Dofetilide versus quinidine for atrial flutter: viva la difference!? [editorial; comment] Olshansky B. **J Cardiovasc Electrophysiol** 1996 Sep;7(9):828–32 (18 ref.) Comment on: J Cardiovasc Electrophysiol 1996 Sep;7(9):809–27.

The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor. Sugrue MF. **J Ocul Pharmacol Ther** 1996 Fall;12(3):363–76 (41 ref.)

Outcome of specific COX–2 inhibition in rheumatoid arthritis. Lipsky PE, et al. **J Rheumatol** 1997 Jul;24 Suppl 49:9–14 (21 ref.)

[Endothelial receptor antagonists] Bornkessel B. **Med Monatsschr Pharm** 1997 Jul;20(7):174–6 (3 ref.) **(Ger)**

THERAPEUTIC USE

Efficacy of ibutilide for termination of atrial fibrillation and flutter. Ellenbogen KA, et al. **Am J Cardiol** 1996 Oct 17; 78(8A):42–5 (18 ref.)

Increases in rates of resistance to trimethoprim. Huovinen P. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S63–6 (37 ref.)

Benefits and risks of torasemide in congestive heart failure and essential hypertension. Brater DC. **Drug Saf** 1996 Feb; 14(2):104–20 (77 ref.)

Nimesulide in the treatment of patients intolerant of aspirin and other NSAIDs. Senna GE, et al. **Drug Saf** 1996 Feb; 14(2):94–103 (73 ref.)

Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia. Wilde MI, et al. **Drugs** 1996 Dec;52(6):883–98 (73 ref.)

New medical therapies for glaucoma. Drake MV. **Int Ophthalmol Clin** 1996 Spring;36(2):53–60 (29 ref.)

Antibiotic use in the emergency department. II The aminoglycosides, macrolides, tetracyclines, sulfa drugs, and urinary antiseptics. Graeme KA, et al. **J Emerg Med** 1996 May–Jun;14(3):361–71 (90 ref.)

Trusopt, a topical carbonic anhydrase inhibitor. Donohue EK, et al. **J Glaucoma** 1996 Feb;5(1):68–74 (79 ref.)

Ibutilide: a new class III antiarrhythmic agent. Cropp JS, et al. **Pharmacotherapy** 1997 Jan–Feb;17(1):1–9 (45 ref.)

Ibutilide—a new drug for the rapid termination of atrial fibrillation and atrial flutter [news] Kayser SR. **Prog Cardiovasc Nurs** 1997 Winter;12(1):39–43 (10 ref.)

[Thromboxane A2 receptor antagonist in asthma therapy] Endo S, et al. **Nippon Rinsho** 1996 Nov;54(11):3045–8 (15 ref.) (Eng. Abstr.) **(Jpn)**

SULFONIC ACIDS

METABOLISM

Enzymology of human cytosolic sulfotransferases. Falany CN. **FASEB J** 1997 Mar;11(4):206–16 (106 ref.)

PHARMACOLOGY

Nelfinavir. Perry CM, et al. **Drugs** 1997 Jul;54(1):81–7; discussion 88 (30 ref.)

SULFONYLDIANILINE see **DAPSONE**

SULFONYLUREA COMPOUNDS

ADMINISTRATION & DOSAGE

Combinations sulfonylurea and insulin therapy in diabetes mellitus. Kabadi UM, et al. **Compr Ther** 1995 Dec; 21(12):731–6 (51 ref.)

ADVERSE EFFECTS

Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients. Rosenkranz B. **Horm Metab Res** 1996 Sep;28(9):434–9 (23 ref.)

An overview of the safety and tolerance of glimepiride. Schneider J. **Horm Metab Res** 1996 Sep;28(9):413–8 (3 ref.)

PHARMACOKINETICS

Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients. Rosenkranz B. **Horm Metab Res** 1996 Sep;28(9):434–9 (23 ref.)

PHARMACOLOGY

Insulin secretion and its modulation by antiarrhythmic and sulfonylurea drugs. Horie M, et al. **Cardiovasc Res** 1997 Apr;34(1):69–72 (42 ref.)

Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients. Schotborgh CE, et al. **Cardiovasc Res** 1997 Apr;34(1):73–80 (88 ref.)

Influence of hypoglycaemic sulphonylureas on the electrophysiological parameters of the heart. Koltai MZ. **Diabetes Res Clin Pract** 1996 Jul;31 Suppl:S15–20 (31 ref.)

Haemodynamic and other effects of sulphonylurea drugs on the heart. Végh A, et al. **Diabetes Res Clin Pract** 1996 Jul;31 Suppl:S43–53 (75 ref.)

Mechanisms of the glycaemic effects of sulfonylureas. Ashcroft FM. **Horm Metab Res** 1996 Sep;28(9):456–63 (59 ref.)

Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta–cells. Kramer W, et al. **Horm Metab Res** 1996 Sep;28(9):464–8 (36 ref.)

Ion channel effects of antidiabetic sulfonylureas. Lazdunski M. **Horm Metab Res** 1996 Sep;28(9):488–95 (95 ref.)

Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at adipocytes. Müller G, et al. **Horm Metab Res** 1996 Sep;28(9):469–87 (111 ref.)

THERAPEUTIC USE

Cardiovascular effects of oral hypoglycaemic drugs. Howes LG, et al. **Clin Exp Pharmacol Physiol** 1996 Mar; 23(3):201–6 (54 ref.)

Oral antidiabetic drugs: an overview. Melander A. **Diabet Med** 1996 Sep;13(9 Suppl 6):S143–7 (28 ref.)

What kind of cardiovascular alterations could be influenced positively by oral antidiabetic agents? Pogátsa G. **Diabetes Res Clin Pract** 1996 Jul;31 Suppl:S27–31 (18 ref.)

Cardiovascular effects of sulphonylurea derivatives. Smits P, et al. **Diabetes Res Clin Pract** 1996 Jul;31 Suppl:S55–9 (24 ref.)

Oral antihyperglycaemics. Considerations in older patients with non–insulin–dependent diabetes mellitus. Jennings PE. **Drugs Aging** 1997 May;10(5):323–31 (27 ref.)

Role of sulfonylureas in non–insulin–dependent diabetes mellitus: Part II—"The cons". Heine RJ. **Horm Metab Res** 1996 Sep;28(9):522–6 (32 ref.)

Combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routine. Riddle MC. **Horm Metab Res** 1996 Sep;28(9):430–3 (30 ref.)

An overview of the safety and tolerance of glimepiride. Schneider J. **Horm Metab Res** 1996 Sep;28(9):413–8 (3 ref.)

Role of sulfonylureas in non–insulin–dependent diabetes mellitus: Part I—"The pros". Waldhäusl W. **Horm Metab Res** 1996 Sep;28(9):517–21 (42 ref.)

Antitumor diarylsulfonylureas: novel agents with unfulfilled promise. Houghton PJ, et al. **Invest New Drugs** 1996; 14(3):271–80 (34 ref.)

Non–insulin–dependent diabetes mellitus—current practice and future trends. Ponte CD. **J Am Pharm Assoc (Wash)** 1996 Jan;NS36(1):50–8; quiz 58–9 (37 ref.)

New treatments for patients with type 2 diabetes mellitus. Wolffenbuttel BH, et al. **Postgrad Med J** 1996 Nov; 72(853):657–62 (44 ref.)

SULFOTRANSFERASES

Steroid sulfotransferases. Strott CA. **Endocr Rev** 1996 Dec; 17(6):670–97 (229 ref.)

Sulfation and sulfotransferases 6: Biochemistry and molecular biology of plant sulfotransferases. Varin L, et al. **FASEB J** 1997 Jun;11(7):517–25 (44 ref.)

GENETICS

Genetic and environmental factors associated with variation of human xenobiotic glucuronidation and sulfation. Burchell B, et al. **Environ Health Perspect** 1997 Jun;105 Suppl 4:739–47 (95 ref.)

Regulation of expression of the rodent cytosolic sulfotransferases. Runge–Morris MA. **FASEB J** 1997 Feb; 11(2):109–17 (73 ref.)

Sulfation and sulfotransferases 1: Sulfotransferase molecular biology: cDNAs and genes. Weinshilboum RM, et al. **FASEB J** 1997 Jan;11(1):3–14 (99 ref.)

METABOLISM

Sulfotransferase–mediated activation of some benzylic and allylic alcohols. Surh YJ. **Adv Exp Med Biol** 1996; 387:339–45 (31 ref.)

Enzymology of human cytosolic sulfotransferases. Falany CN. **FASEB J** 1997 Mar;11(4):206–16 (106 ref.)

Sulfation and sulfotransferases 4: bioactivation of mutagens via sulfation. Glatt H. **FASEB J** 1997 Apr;11(5):314–21 (41 ref.)

Sulfation and sulfotransferases 5: the importance of 3'–phosphoadenosine 5'–phosphosulfate (PAPS) in the regulation of sulfation. Klaassen CD, et al. **FASEB J** 1997 May;11(6):404–18 (116 ref.)

Sulphation catalysed by the human cytosolic sulphotransferases—chemical defence or molecular terrorism? Coughtrie MW. **Hum Exp Toxicol** 1996 Jul; 15(7):547–55 (62 ref.)

Activation and detoxication of carcinogenic arylamines by sulfation. Yamazoe Y, et al. **Princess Takamatsu Symp** 1995; 23:154–62 (47 ref.)

PHYSIOLOGY

Sulfation and sulfotransferases. Introduction: changing view of sulfation and the cytosolic sulfotransferases. Falany CN. **FASEB J** 1997 Jan;11(1):1–2 (11 ref.)

SULFOXIDES

ADVERSE EFFECTS

Lack of pantoprazole drug interactions in man: an updated review. Steinijans VW, et al. **Int J Clin Pharmacol Ther** 1996 Jun;34(6):243–62 (125 ref.)

METABOLISM

Drug interactions with proton pump inhibitors. Unge P, et al. **Drug Saf** 1997 Mar;16(3):171–9 (115 ref.)

PHARMACOKINETICS

Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Andersson T. **Clin Pharmacokinet** 1996 Jul; 31(1):9–28 (170 ref.)

Pharmacokinetics of pantoprazole in man. Huber R, et al. **Int J Clin Pharmacol Ther** 1996 May;34(1 Suppl):S7–16 (61 ref.)

Pharmacokinetics and drug interactions—relevant factors for the choice of a drug. Zech K, et al.

Int J Clin Pharmacol Ther 1996 May;34(1 Suppl):S3–6 (32 ref.)

PHARMACOLOGY

Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders [published errata appear in Drugs 1996 Jun;51(6):1074 and 1996 Jul;52(1):92] Fitton A, et al. **Drugs** 1996 Mar;51(3):460–82 (132 ref.)

Lack of pantoprazole drug interactions in man: an updated review. Steinijans VW, et al. **Int J Clin Pharmacol Ther** 1996 May;34(1 Suppl):S31–50 (121 ref.)

THERAPEUTIC USE

Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders [published errata appear in Drugs 1996 Jun;51(6):1074 and 1996 Jul;52(1):92] Fitton A, et al. **Drugs** 1996 Mar;51(3):460–82 (132 ref.)

Pantoprazole, a new proton-pump inhibitor, has a precise and predictable profile of activity. Parsons ME. **Eur J Gastroenterol Hepatol** 1996 Oct;8 Suppl 1:S15–20 (45 ref.)

SULFUR

METABOLISM

Investigation of the carbon- and sulfur-oxidizing capabilities of microorganisms by active-site modeling. Holland HL. **Adv Appl Microbiol** 1997;44:125–65 (90 ref.)

Oxidative metabolism of inorganic sulfur compounds by bacteria. Kelly DP, et al. **Antonie Van Leeuwenhoek** 1997 Feb;71(1–2):95–107 (51 ref.)

The neurotransmitter candidature of sulphur-containing excitatory amino acids in the mammalian central nervous system. Thompson GA, et al. **Pharmacol Ther** 1996; 72(1):25–36 (109 ref.)

Iron-sulfur clusters: nature's modular, multipurpose structures. Beinert H, et al. **Science** 1997 Aug 1; 277(5326):653–9 (78 ref.)

PHARMACOLOGY

Recent results in the organosulfur and organoselenium chemistry of genus Allium and Brassica plants. Relevance for cancer prevention. Block E. **Adv Exp Med Biol** 1996; 401:155–69 (75 ref.)

THERAPEUTIC USE

Therapeutic values of onion (Allium cepa L.) and garlic (Allium sativum L.). Augusti KT. **Indian J Exp Biol** 1996 Jul;34(7):634–40 (77 ref.)

SULFUR AMINO ACIDS see **AMINO ACIDS, SULFUR**

SULFUR DIOXIDE

TOXICITY

Sulfur dioxide. Von Burg R. **J Appl Toxicol** 1996 Jul–Aug; 16(4):365–71 (96 ref.)

SULFUR HEXAFLUORIDE

ADMINISTRATION & DOSAGE

The Silicone Study. A small piece of the PVR puzzle is put into place [editorial; comment] Campochiaro PA. **Arch Ophthalmol** 1997 Mar;115(3):407–8 (6 ref.) Comment on: Arch Ophthalmol 1997 Mar;115(3):335–44.

SULFUR MUSTARD see **MUSTARD GAS**

SULFUR OXIDES

METABOLISM

Soil microorganisms as controllers of atmospheric trace gases (H2, CO, CH4, OCS, N2O, and NO). Conrad R. **Microbiol Rev** 1996 Dec;60(4):609–40 (602 ref.)

SULFURIC ACIDS

ADVERSE EFFECTS

Epidemiologic evidence on the relationship between mists containing sulfuric acid and respiratory tract cancer. Sathiakumar N, et al. **Crit Rev Toxicol** 1997 May; 27(3):233–51 (36 ref.)

TOXICITY

A review of the chronic toxicity, carcinogenicity, and possible mechanisms of action of inorganic acid mists in animals. Swenberg JA, et al. **Crit Rev Toxicol** 1997 May; 27(3):253–9 (28 ref.)

SULFURTRANSFERASES

ANALYSIS

Biotin synthase of Bacillus sphaericus. Bui BT, et al. **Methods Enzymol** 1997;279:356–62 (16 ref.)

ISOLATION & PURIFICATION

Purification and characterization of biotin synthases. Flint DH, et al. **Methods Enzymol** 1997;279:349–56 (21 ref.)

SULINDAC

PHARMACOKINETICS

Clinical pharmacokinetics of sulindac. A dynamic old drug. Davies NM, et al. **Clin Pharmacokinet** 1997 Jun; 32(6):437–59 (158 ref.)

SULPIRIDE

[Sulpiride: an atypical neuroleptic with a wide spectrum of therapeutic claims] Wasieczko A, et al. **Psychiatr Pol** 1996 Nov-Dec;30(6):1009–16 (23 ref.) **(Pol)**

ADVERSE EFFECTS

A risk-benefit assessment of sulpiride in the treatment of schizophrenia. Mauri MC, et al. **Drug Saf** 1996 May; 14(5):288–98 (73 ref.)

ANALOGS & DERIVATIVES

Concepts, properties, and applications of linear systems to describe distribution, identify input, and control endogenous substances and drugs in biological systems. Verotta D. **Crit Rev Biomed Eng** 1996;24(2–3):73–139 (119 ref.)

Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies. Freeman HL. **Int Clin Psychopharmacol** 1997 May;12 Suppl 2:S11–7 (22 ref.)

Clinical update on amisulpride in deficit schizophrenia. Rein W, et al. **Int Clin Psychopharmacol** 1997 May;12 Suppl 2:S19–27 (27 ref.)

Amisulpride: from animal pharmacology to therapeutic action. Scatton B, et al. **Int Clin Psychopharmacol** 1997 May;12 Suppl 2:S29–36 (45 ref.)

DIAGNOSTIC USE

[Metoclopramide, sulpiride, and chlorpromazine loading test] Azuma K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:249–51 (9 ref.) **(Jpn)**

THERAPEUTIC USE

A risk-benefit assessment of sulpiride in the treatment of schizophrenia. Mauri MC, et al. **Drug Saf** 1996 May; 14(5):288–98 (73 ref.)

SUMATRIPTAN

THERAPEUTIC USE

Clinical presentation and treatment of migraine. Skaer TL. **Clin Ther** 1996 Mar–Apr;18(2):229–45; discussion 228 (71 ref.)

Acute migraine therapy: the newer drugs. Schoenen J. **Curr Opin Neurol** 1997 Jun;10(3):237–43 (38 ref.)

Drug treatment of migraine: acute treatment and migraine prophylaxis. Tfelt-Hansen P. **Curr Opin Neurol** 1996 Jun; 9(3):211–3 (14 ref.)

Sumatriptan relieves migrainelike headaches associated with carbon monoxide exposure. Lipton RB, et al. **Headache** 1997 Jun;37(6):392–5 (39 ref.)

SUN see **SOLAR SYSTEM**

SUNBURN

see related
SUNSCREENING AGENTS

COMPLICATIONS

Sunburn, sunscreen, and melanoma. Donawho C, et al. **Curr Opin Oncol** 1996 Mar;8(2):159–66 (57 ref.)

PREVENTION & CONTROL

The case for sunscreens. A review of their use in preventing actinic damage and neoplasia. Naylor MF, et al. **Arch Dermatol** 1997 Sep;133(9):1146–54 (50 ref.)

The skin cancer cascade: from ozone depletion to melanoma--some definitions and some new interpretation, 1996. Fitzpatrick TB. **J Dermatol** 1996 Nov;23(11):816–20 (11 ref.)

Sunscreens: progress and perspectives on photoprotection of human skin against UVB and UVA radiation. Pathak MA. **J Dermatol** 1996 Nov;23(11):783–800 (25 ref.)

SUNLIGHT

[Cutaneous photoprotection. Suntan or no suntan? This is the question (editorial)] Casado Jiménez M, et al. **Rev Clin Esp** 1996 Jul;196(7):417–20 (38 ref.) **(Spa)**

ADVERSE EFFECTS

Genetic alterations in skin cancer. D'errico M, et al. **Ann Ist Super Sanita** 1996;32(1):53–63 (75 ref.)

Molecular epidemiology of skin cancers: DNA repair and non-melanocytic skin cancer. Hall J, et al. **Ann Ist Super Sanita** 1996;32(1):43–51 (56 ref.)

Sun exposure, sunscreens, and skin cancer prevention: a year-round concern. Farmer KC, et al. **Ann Pharmacother** 1996 Jun;30(6):662–73 (87 ref.)

Sun and skin cancer. Whittaker S. **Br J Hosp Med** 1996 Nov 20–Dec 10;56(10):515–8 (13 ref.)

Epidemiology of sun exposure and skin cancer. Armstrong BK, et al. **Cancer Surv** 1996;26:133–53 (46 ref.)

The effect of photodamage on dermal extracellular matrix. Bernstein EF, et al. **Clin Dermatol** 1996 Mar–Apr; 14(2):143–51 (72 ref.)

The aging skin. Bergfeld WF. **Int J Fertil Womens Med** 1997 Mar–Apr;42(2):57–66 (20 ref.)

UV radiation from sunlight: summary, conclusions and recommendations. van der Leun JC. **J Photochem Photobiol B** 1996 Sep;35(3):237–44 (0 ref.)

Immunogenetics of sunlight-induced skin cancer. Streilein JW. **Photochem Photobiol** 1996 Apr;63(4):422–4 (21 ref.)

Controversies in the role of sunlight in the pathogenesis of cutaneous melanoma. Weinstock MA. **Photochem Photobiol** 1996 Apr;63(4):406–10 (33 ref.)

Sunlight and skin cancer: another link revealed [comment] Kraemer KH. **Proc Natl Acad Sci U S A** 1997 Jan 7; 94(1):11–4 (56 ref.) Comment on: Proc Natl Acad Sci U S A 1996 Nov 26;93(24):14025–9.

Melanoma and sun exposure. Elwood JM. **Semin Oncol** 1996 Dec;23(6):650–66 (69 ref.)

SUNSCREENING AGENTS

Drug photosensitivity, idiopathic photodermatoses, and sunscreens. González E, et al. **J Am Acad Dermatol** 1996 Dec;35(6):871–85; quiz 886–7 (139 ref.)

PHARMACOLOGY

The skin cancer cascade: from ozone depletion to melanoma--some definitions and some new interpretation, 1996. Fitzpatrick TB. **J Dermatol** 1996 Nov;23(11):816–20 (11 ref.)

Sunscreens and photocarcinogenesis: an objective assessment. Elmets CA, et al. **Photochem Photobiol** 1996 Apr; 63(4):435–40 (46 ref.)

THERAPEUTIC USE

Sun exposure, sunscreens, and skin cancer prevention: a year-round concern. Farmer KC, et al. **Ann Pharmacother** 1996 Jun;30(6):662–73 (87 ref.)

The case for sunscreens. A review of their use in preventing actinic damage and neoplasia. Naylor MF, et al. **Arch Dermatol** 1997 Sep;133(9):1146–54 (50 ref.)

A review of skin ageing and its medical therapy. Gilchrest BA. **Br J Dermatol** 1996 Dec;135(6):867–75 (50 ref.)

Management of skin disease in lupus. Callen JP. **Bull Rheum Dis** 1997 Apr;46(2):4–7 (11 ref.)

Sunburn, sunscreen, and melanoma. Donawho C, et al. **Curr Opin Oncol** 1996 Mar;8(2):159–66 (57 ref.)

Linear atrophoderma of Moulin: treatment with Potaba. Artola Igarza JL, et al. **Dermatology** 1996;193(4):345–7 (7 ref.)

Sunscreens: progress and perspectives on photoprotection of human skin against UVB and UVA radiation. Pathak MA. **J Dermatol** 1996 Nov;23(11):783–800 (25 ref.)

SUPERANTIGENS

see related
APOPTOSIS
CLONAL ANERGY
RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA

B cell superantigens in HIV-1 infection. Müller S, et al. **Int Rev Immunol** 1997;14(4):339–49 (52 ref.)

B-cell superantigens: molecular and cellular implications. Silverman GJ, et al. **Int Rev Immunol** 1997;14(4):259–90 (108 ref.)

HIV-1 gp120: a novel viral B cell superantigen. Townsley-Fuchs J, et al. **Int Rev Immunol** 1997; 14(4):325–38 (59 ref.)

Superantigens as virulence factors in autoimmunity and immunodeficiency diseases. Soos JM, et al. **Med Hypotheses** 1997 Mar;48(3):253–9 (52 ref.)

Superantigen related to rabies. Lafon M, et al. **Springer Semin Immunopathol** 1996;17(4):307–18 (60 ref.)

[The role of superantigens in rheumatic disease] Miyata M, et al. **Ryumachi** 1996 Jun;36(3):598–604 (57 ref.) **(Jpn)**

[Superantigens: concept and applications in the pathogenesis and treatment of infectious and autoimmune diseases] Quirós E, et al. **An Med Interna** 1996 Jul;13(7):347–52 (72 ref.) (Eng. Abstr.) **(Spa)**

CHEMISTRY

Superantigens as immunomodulators: recent structural insights. Papageorgiou AC, et al. **Structure** 1997 Aug 15; 5(8):991–6 (37 ref.)

GENETICS

Streptococcal superantigen, mitogenic factor, and pyrogenic exotoxin B expressed by Streptococcus pyogenes. Structure and function. Musser JM. **Prep Biochem Biotechnol** 1997 May-Aug;27(2-3):143–72 (141 ref.)

SUPERANTIGENS

Genetically engineered superantigens in experimental tumor therapy. Antonsson P, et al. **Springer Semin Immunopathol** 1996;17(4):397–410 (34 ref.)

IMMUNOLOGY

Mouse mammary tumor virus and the immune system. Ross SR. **Adv Pharmacol** 1997;39:21–46 (95 ref.)

Is psoriasis induced by streptococcal superantigens and maintained by M-protein-specific T cells that cross-react with keratin? Valdimarsson H, et al. **Clin Exp Immunol** 1997 Jan;107 Suppl 1:21–4 (28 ref.)

Superantigens of mouse mammary tumour virus: implications for diabetes? Acha-Orbea H. **Diabetes Metab Rev** 1996 Jul; 12(2):111–9 (59 ref.)

MHC class II-dependent peptide antigen versus superantigen presentation to T cells. Shoukry NH, et al. **Hum Immunol** 1997 May;54(2):194–201 (60 ref.)

Role of the T cell receptor alpha-chain in superantigen recognition. Blackman MA, et al. **Immunol Res** 1996; 15(2):98–113 (84 ref.)

Superantigens in autoimmune diseases: still more shades of gray. Renno T, et al. **Immunol Rev** 1996 Dec;154:175–91 (103 ref.)

Virus-encoded superantigens. Huber BT, et al. **Microbiol Rev** 1996 Sep;60(3):473–82 (91 ref.)

Superantigens in demyelinating disease. Brocke S, et al. **Springer Semin Immunopathol** 1996;18(1):51–6 (25 ref.)

Superantigens in insulin-dependent diabetes mellitus. Luppi P, et al. **Springer Semin Immunopathol** 1996;17(4):333–62 (196 ref.)

Psoriasis and bacterial superantigens—formal or causal correlation? Boehncke WH. **Trends Microbiol** 1996 Dec; 4(12):485–9 (39 ref.)

[Superantigens and glomerulonephritis] Koyama T, et al. **Nippon Naika Gakkai Zasshi** 1997 Apr 10;86(4):695–701 (14 ref.) **(Jpn)**

[Superantigens and autoimmune diseases] Kaneoka H, et al. **Nippon Rinsho** 1997 Jun;55(6):1363–9 (34 ref.) (Eng. Abstr.) **(Jpn)**

[Superantigen-related nephritis(SARN)] Kobayashi M, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):167–70 (14 ref.) **(Jpn)**

[Superantigens and their behavior in the immune response] López H, et al. **Rev Alerg Mex** 1996 Jan-Feb;43(1):13–7 (40 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

B-cell superantigens. Silverman GJ. **Immunol Today** 1997 Aug;18(8):379–86 (59 ref.)

Why do superantigens care about peptides? Woodland DL, et al. **Immunol Today** 1997 Jan;18(1):18–22 (52 ref.)

B cell superantigens: potential modifiers of the normal human B cell repertoire. Domiati-Saad R, et al. **Int Rev Immunol** 1997;14(4):309–24 (62 ref.)

Superantigen and class II MHC molecules. Kim J. **J Korean Med Sci** 1995 Dec;10(6):393–8 (34 ref.)

Characterization of a superantigen produced by Yersinia pseudotuberculosis. Abe J, et al. **Prep Biochem Biotechnol** 1997 May-Aug;27(2-3):173–208 (159 ref.)

"Bazinc" instinct: how SEA attracts MHC class II molecules. Thibodeau J, et al. **Res Immunol** 1997 May;148(4):217–29 (72 ref.)

PHYSIOLOGY

Searching for superantigens. Schlievert PM. **Immunol Invest** 1997 Jan-Feb;26(1-2):283–90 (20 ref.)

Superantigens: their role in infectious diseases. Stevens DL. **Immunol Invest** 1997 Jan-Feb;26(1-2):275–81 (33 ref.)

Do superantigens play a role in lymphoproliferation? Amariglio N, et al. **Leuk Lymphoma** 1996 Jul; 22(3-4):237–43 (44 ref.)

Role of superantigens in experimental arthritis. Abdelnour A, et al. **Springer Semin Immunopathol** 1996;17(4):363–73 (69 ref.)

Superantigens related to Kawasaki syndrome. Leung DY. **Springer Semin Immunopathol** 1996;17(4):385–96 (47 ref.)

Evidence for a superantigen in the pathogenesis of tuberculosis. Ohmen JD, et al. **Springer Semin Immunopathol** 1996;17(4):375–84 (45 ref.)

Superantigens related to B cell hyperplasia. Ponzio NM, et al. **Springer Semin Immunopathol** 1996;17(4):285–306 (159 ref.)

THERAPEUTIC USE

Genetically engineered superantigens in experimental tumor therapy. Antonsson P, et al. **Springer Semin Immunopathol** 1996;17(4):397–410 (34 ref.)

SUPEREGO

Superego aspects of intellectual achievement. Gray SH. **J Am Acad Psychoanal** 1996 Spring;24(1):15–27 (46 ref.)

SUPERIOR CERVICAL GANGLION

[Can superior cervical ganglionectomy be an experimental model of stellate ganglion block?] Iwama H. **Masui** 1997 Apr;46(4):565–7 (4 ref.) **(Jpn)**

METABOLISM

Heterologous expression of receptors and signaling proteins in adult mammalian sympathetic neurons by microinjection. Ikeda SR. **Methods Mol Biol** 1997;83:191–202 (15 ref.)

SUPERIOR COLLICULUS

ANATOMY & HISTOLOGY

On the structure and function of the tectofugal visual pathway in laterally eyed birds. Bischof HJ, et al. **Eur J Morphol** 1997 Oct;35(4):246–54 (72 ref.)

CYTOLOGY

Unilateral containment of retinal axons by tectal glia: a possible role for sulfated proteoglycans. Jhaveri S, et al. **Prog Brain Res** 1996;108:135–48 (104 ref.)

METABOLISM

Pre- and postnatal expression of amino acid neurotransmitters, calcium binding proteins, and nitric oxide synthase in the developing superior colliculus. Mize RR, et al. **Prog Brain Res** 1996;108:313–32 (85 ref.)

PHYSIOLOGY

The superior colliculus and eye movement control. Moschovakis AK. **Curr Opin Neurobiol** 1996 Dec; 6(6):811–6 (55 ref.)

On the structure and function of the tectofugal visual pathway in laterally eyed birds. Bischof HJ, et al. **Eur J Morphol** 1997 Oct;35(4):246–54 (72 ref.)

The contribution of protein kinases to plastic events in the superior colliculus [see comments] McCrossan D, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Apr; 21(3):487–505 (49 ref.) Comment in: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):373–8.

PHYSIOPATHOLOGY

Functional anatomy of nociceptive neurones in rat superior colliculus. Redgrave P, et al. **Prog Brain Res** 1996; 107:403–15 (64 ref.)

ULTRASTRUCTURE

Control of retinotectal axon arbor growth by postsynaptic CaMKII. Zou DJ, et al. **Prog Brain Res** 1996;108:303–12 (44 ref.)

SUPERIOR MESENTERIC ARTERY SYNDROME

Recurrent superior mesenteric artery (Wilkie's) syndrome: a case report. Raissi B, et al. **Can J Surg** 1996 Oct; 39(5):410–6 (39 ref.)

DIAGNOSIS

The superior mesenteric artery syndrome and acute gastric dilatation in eating disorders: a report of two cases and a review of the literature. Adson DE, et al. **Int J Eat Disord** 1997 Mar;21(2):103–14 (59 ref.)

SUPERIOR VENA CAVA OBSTRUCTION see **SUPERIOR VENA CAVA SYNDROME**

SUPERIOR VENA CAVA SYNDROME

Superior vena cava obstruction: a modern management strategy. Ostler PJ, et al. **Clin Oncol (R Coll Radiol)** 1997; 9(2):83–9 (43 ref.)

[Superior vena cava syndromes of benign etiology (see comments)] Marlier S, et al. **Presse Med** 1996 Sep 14; 25(26):1203–7 (25 ref.) (Eng. Abstr.) Comment in: Presse Med 1997 Feb 1;26(2):83. **(Fre)**

[Superior vena cava syndrome] Sihmada T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):497–501 (14 ref.) **(Jpn)**

[Syndrome of the superior vena cava. (Compilation of the cases of the San Carlos University Clinical Hospital in Madrid in the last 5 years and review of the literature) (see comments)] Pérez-Segura P, et al. **An Med Interna** 1995 Nov;12(11):560–4 (56 ref.) (Eng. Abstr.) Comment in: An Med Interna 1997 Jan;14(1):50–1. **(Spa)**

DIAGNOSIS

[Superior vena cava syndrome. Description of 3 cases and review of the literature] Goerdt S, et al. **Hautarzt** 1997 Feb;48(2):122–6 (27 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Superior vena cava syndrome: an oncologic complication. Stewart IE. **Semin Oncol Nurs** 1996 Nov;12(4):312–7 (21 ref.)

Superior vena cava thrombosis secondary to hickman catheter and complete resolution after fibrinolytic therapy. Morales M, et al. **Support Care Cancer** 1997 Jan;5(1):67–9 (8 ref.)

Mediastinal compression syndromes due to idiopathic fibrosing mediastinitis--report of three cases and review of the literature. Kalweit G, et al. **Thorac Cardiovasc Surg** 1996 Apr;44(2):105–9 (34 ref.)

[Interventional pneumology: procedures for pulmonary hemorrhage and tumor-induced superior vena cava syndrome] Witt C, et al. **Pneumologie** 1996 Feb;50(2):202–8 (51 ref.) (Eng. Abstr.) **(Ger)**

[The superior vena cava occlusion syndrome. A case of neoplastic thrombosis due to hepatocarcinoma and cirrhosis] Zanetti PP, et al. **Minerva Chir** 1997 Apr; 52(4):455–9 (20 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Use of intravascular stents for superior vena caval obstruction after the Mustard operation. MacLellan-Tobert SG, et al. **Mayo Clin Proc** 1996 Nov;71(11):1071–6 (23 ref.)

SUPERIOR VENA CAVA THROMBOSIS see **SUPERIOR VENA CAVA SYNDROME**

SUPEROVULATION

DRUG EFFECTS

Role of different GnRH agonist regimens in pituitary suppression and the outcome of controlled ovarian hyperstimulation. Filicori M, et al. **Hum Reprod** 1996 Nov; 11 Suppl 3:123–32 (52 ref.)

Roles of follicle stimulating hormone and luteinizing hormone in controlled ovarian hyperstimulation. Hillier SG. **Hum Reprod** 1996 Nov;11 Suppl 3:113–21 (28 ref.)

PHYSIOLOGY

Superovulation. McCue PM. **Vet Clin North Am Equine Pract** 1996 Apr;12(1):1–11 (59 ref.)

SUPEROXIDE DISMUTASE

ANALYSIS

Chromatographic and electrophoretic methods for analysis of superoxide dismutases. Michalski WP. **J Chromatogr B Biomed Appl** 1996 Sep 20;684(1-2):59–75 (159 ref.)

BIOSYNTHESIS

Regulation of the oxidative stress protective enzymes, catalase and superoxide dismutase in Xanthomonas--a review. Loprasert S, et al. **Gene** 1996 Nov 7;179(1):33–7 (25 ref.)

GENETICS

Familial amyotrophic lateral sclerosis with a mutation in exon 4 of the Cu/Zn superoxide dismutase gene: pathological and immunocytochemical changes. Ince PG, et al. **Acta Neuropathol (Berl)** 1996 Oct;92(4):395–403 (28 ref.)

Do posttranslational modifications of CuZnSOD lead to sporadic amyotrophic lateral sclerosis? Bredesen DE, et al. **Ann Neurol** 1997 Aug;42(2):135–7 (25 ref.)

Cu,Zn-superoxide dismutase gene dosage and cell resistance to oxidative stress: a review. Peskin AV. **Biosci Rep** 1997 Feb;17(1):85–9 (54 ref.)

Superoxide dismutase and oxygen radical neurotoxicity. Hosler BA, et al. **Curr Opin Neurol** 1996 Dec;9(6):486–91 (49 ref.)

Genetics of amyotrophic lateral sclerosis. Siddique T, et al. **Hum Mol Genet** 1996;5 Spec No:1465–70 (68 ref.)

The roles of free radicals in amyotrophic lateral sclerosis. Liu D. **J Mol Neurosci** 1996 Fall;7(3):159–67 (100 ref.)

Familial amyotrophic lateral sclerosis. Siddique T, et al. **J Neural Transm Suppl** 1997;49:219–33 (66 ref.)

Cu/Zn superoxide dismutase gene mutations in amyotrophic lateral sclerosis: correlation between genotype and clinical features. Radunovíc A, et al. **J Neurol Neurosurg Psychiatry** 1996 Dec;61(6):565–72 (82 ref.)

An update on superoxide dismutase 1 in familial amyotrophic lateral sclerosis. Cudkowicz ME, et al. **J Neurol Sci** 1996 Aug;139 Suppl:10–5 (60 ref.)

Oxidative stress, mutant SOD1, and neurofilament pathology in transgenic mouse models of human motor neuron disease. Tu PH, et al. **Lab Invest** 1997 Apr;76(4):441–56 (144 ref.)

Pathogenic mechanisms in familial amyotrophic lateral sclerosis due to mutation of Cu, Zn superoxide dismutase. Gurney ME, et al. **Pathol Biol (Paris)** 1996 Jan;44(1):51–6 (38 ref.)

Therapeutic advances in amyotrophic lateral sclerosis. Louvel E, et al. **Trends Pharmacol Sci** 1997 Jun; 18(6):196–203 (84 ref.)

[Familial amyotrophic lateral sclerosis and mutations in the Cu/Zn superoxide dismutase gene] Nakano R. **Rinsho Shinkeigaku** 1995 Dec;35(12):1546–8 (10 ref.) (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

Extracellular superoxide dismutase: a regulator of nitric oxide bioavailability. Oury TD, et al. **Lab Invest** 1996 Nov; 75(5):617–36 (144 ref.)

METABOLISM

Salen-manganese complexes: combined superoxide dismutase/catalase mimics with broad pharmacological efficacy. Doctrow SR, et al. **Adv Pharmacol** 1997;38:247–69 (86 ref.)

Do posttranslational modifications of CuZnSOD lead to sporadic amyotrophic lateral sclerosis? Bredesen DE, et al. **Ann Neurol** 1997 Aug;42(2):135–7 (25 ref.)

Peroxisomes as a source of superoxide and hydrogen peroxide in stressed plants. del Rio LA, et al. **Biochem Soc Trans** 1996 May;24(2):434–8 (43 ref.)

Metal-independent putative superoxide dismutase mimics in chemistry, biology, and medicine. Ahmad N, et al. **Ecotoxicol Environ Saf** 1996 Jul;34(2):141–4 (37 ref.)

Tumor necrosis factor and lymphotoxin: protection against oxidative stress through induction of MnSOD. Wong GH, et al. **EXS** 1996;77:321–33 (77 ref.)

Use of transgenic plants to study antioxidant defenses. Allen RD, et al. **Free Radic Biol Med** 1997;23(3):473–9 (39 ref.)

How does superoxide dismutase protect against tumor necrosis factor: a hypothesis informed by effect of superoxide on "free" iron. Liochev SI, et al. **Free Radic Biol Med** 1997;23(4):668–71 (46 ref.)

The regulation and function of tobacco superoxide dismutases. Van Camp W, et al. **Free Radic Biol Med** 1997; 23(3):515–20 (44 ref.)

Superoxide anion radical (O2-.), superoxide dismutases, and related matters. Fridovich I. **J Biol Chem** 1997 Jul 25; 272(30):18515–7 (76 ref.)

Peroxynitrite-dependent tyrosine nitration catalyzed by superoxide dismutase, myeloperoxidase, and horseradish peroxidase. Sampson JB, et al. **Methods Enzymol** 1996; 269:210–18 (23 ref.)

Oxidative stress caused by glycation of Cu,Zn-superoxide dismutase and its effects on intracellular components. Fujii J, et al. **Nephrol Dial Transplant** 1996;11 Suppl 5:34–40 (36 ref.)

Newer findings on a unified perspective of copper restriction and cardiomyopathy. Medeiros DM, et al. **Proc Soc Exp Biol Med** 1997 Sep;215(4):299–313 (156 ref.)

Prevention of reperfusion-induced, free radical-mediated acute endothelial injury by superoxide dismutase as an effective tool to delay/prevent chronic renal allograft failure: a review. Land W, et al. **Transplant Proc** 1997 Sep; 29(6):2567–8 (7 ref.)

[Amyotrophic lateral sclerosis and superoxide dismutase--a review (see comments)] Binzer MN, et al. **Ugeskr Laeger** 1997 Mar 10;159(11):1593–6 (17 ref.) (Eng. Abstr.) Comment in: Ugeskr Laeger 1997 Jun 2;159(23):3619. **(Dan)**

PHYSIOLOGY

Superoxide dismutase and pulmonary oxygen toxicity. Tsan MF. **Proc Soc Exp Biol Med** 1997 Feb;214(2):107–13 (82 ref.)

THERAPEUTIC USE

[Superoxide dismutase and the eye] Turetz J, et al. **Harefuah** 1997 Jan 1;132(1):51–5 (36 ref.) **(Heb)**

SUPEROXIDES

see related
RESPIRATORY BURST

Biochemistry and pathology of radical-mediated protein oxidation. Dean RT, et al. **Biochem J** 1997 May 15;324 (Pt 1):1–18 (312 ref.)

Two-stage gene regulation of the superoxide stress response soxRS system in Escherichia coli. Nunoshiba T. **Crit Rev Eukaryot Gene Expr** 1996;6(4):377–89 (92 ref.)

ANALYSIS

Measuring nitric oxide and superoxide: rate constants for aconitase reactivity. Hausladen A, et al. **Methods Enzymol** 1996;269:37–41 (19 ref.)

[A method for the study of eosinophil oxidative metabolism] Tsuda A, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:216–8 (3 ref.) **(Jpn)**

METABOLISM

The importance of superoxide in nitric oxide-dependent toxicity: evidence for peroxynitrite-mediated injury. Crow JP, et al. **Adv Exp Med Biol** 1996;387:147–61 (78 ref.)

Utilization of superoxide anion by indoleamine oxygenase-catalyzed tryptophan and indoleamine oxidation. Hayaishi O. **Adv Exp Med Biol** 1996;398:285–9 (4 ref.)

Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Beckman JS, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):C1424–37 (109 ref.)

Peroxisomes as a source of superoxide and hydrogen peroxide in stressed plants. del Río LA, et al. **Biochem Soc Trans** 1996 May;24(2):434–8 (43 ref.)

Superoxide generation in relation to dehydration and rehydration. Navari-Izzo F, et al. **Biochem Soc Trans** 1996 May;24(2):447–51 (47 ref.)

Superoxide-driven aconitase FE-S center cycling. Gardner PR. **Biosci Rep** 1997 Feb;17(1):33–42 (65 ref.)

Superoxide production by the mitochondrial respiratory chain. Turrens JF. **Biosci Rep** 1997 Feb;17(1):3–8 (38 ref.)

Superoxide, hydrogen peroxide and nitric oxide as signalling molecules: their production and role in disease. Hancock JT. **Br J Biomed Sci** 1997 Mar;54(1):38–46 (110 ref.)

Interrelationship between cellular calcium homeostasis and free radical generation in myocardial reperfusion injury. Bagchi D, et al. **Chem Biol Interact** 1997 May 2; 104(2–3):65–85 (99 ref.)

Role of oxidants in microbial pathophysiology. Miller RA, et al. **Clin Microbiol Rev** 1997 Jan;10(1):1–18 (334 ref.)

Direct measurement of free radicals in ischemic/reperfused diabetic rat retina. Szabo ME, et al. **Clin Neurosci** 1997; 4(5):240–5 (40 ref.)

Disruption of vascular signalling by the reaction of nitric oxide with superoxide: implications for cardiovascular disease. Darley-Usmar V, et al. **Exp Physiol** 1997 Mar; 82(2):305–16 (85 ref.)

Superoxide anions, free-radical scavengers, and nitrergic neurotransmission. Gibson A, et al. **Gen Pharmacol** 1997 Apr;28(4):489–93 (37 ref.)

The physiology and pathophysiology of the nitric oxide/superoxide system. Münzel T, et al. **Herz** 1997 Jun; 22(3):158–72 (89 ref.)

Superoxide anion radical (O2-.), superoxide dismutases, and related matters. Fridovich I. **J Biol Chem** 1997 Jul 25; 272(30):18515–7 (76 ref.)

Role of nitric oxide and superoxide balance in hypoxia-reoxygenation proximal tubular injury. Yaqoob M, et al. **Nephrol Dial Transplant** 1996 Sep;11(9):1738–42 (34 ref.)

Role of nitric oxide and superoxide balance in hypoxia-reoxygenation proximal tubular injury. Yaqoob M, et al. **Nephrol Dial Transplant** 1996 Sep;11(9):1743–6 (34 ref.)

Reactive oxygen intermediates as second messengers of a general pathogen response. Baeuerle PA, et al. **Pathol Biol (Paris)** 1996 Jan;44(1):29–35 (50 ref.)

Mechanisms involved in the generation of free radicals. Halliwell B. **Pathol Biol (Paris)** 1996 Jan;44(1):6–13 (68 ref.)

Superoxide radical generation from heterocyclic amines. Maeda H, et al. **Princess Takamatsu Symp** 1995;23:103–12 (27 ref.)

[Active forms of oxygen: cytotoxic effects and methodological approaches to laboratory control of liver lesions (literature review)] Matiushin BN, et al. **Klin Lab Diagn** 1996 Jul-Aug;(4):51–3 (17 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

How does superoxide dismutase protect against tumor necrosis factor: a hypothesis informed by effect of superoxide on "free" iron. Liochev SI, et al. **Free Radic Biol Med** 1997;23(4):668–71 (46 ref.)

Role of cross talk between superoxide and NO in the energy metabolism and pathogenesis of vasogenic tissue injury. Inoue M. **J Toxicol Sci** 1996 Dec;21(5):289 (0 ref.)

TOXICITY

Role of oxidants in microbial pathophysiology. Miller RA, et al. **Clin Microbiol Rev** 1997 Jan;10(1):1–18 (334 ref.)

SUPINE POSITION

Compartment syndrome as a complication of the prolonged use of the Lloyd-Davies position. Goldsmith AL, et al. **Anaesthesia** 1996 Nov;51(11):1048–52 (26 ref.)

SUPPORT GROUPS see **SELF-HELP GROUPS**

SUPPORTED EMPLOYMENT see **EMPLOYMENT, SUPPORTED**

SUPPRESSION, GENETIC

Nonsense suppression in mammalian cells. Kuchino Y, et al. **Biochimie** 1996;78(11–12):1007–15 (32 ref.)

Cosuppression comes to the animals [comment] Bingham PM. **Cell** 1997 Aug 8;90(3):385–7 (20 ref.) Comment on: Cell 1997 Aug 8;90(3):479–90.

Analysis of point mutations by use of amber stop codon suppression. Lesley SA. **Methods Mol Biol** 1996;57:65–73 (6 ref.)

SUPPRESSOR CELLS see **T-LYMPHOCYTES, SUPPRESSOR-EFFECTOR**

SUPPRESSOR-EFFECTOR T-LYMPHOCYTES see **T-LYMPHOCYTES, SUPPRESSOR-EFFECTOR**

SUPPRESSOR FACTOR, T-CELL, GLIOBLASTOMA-DERIVED see **TRANSFORMING GROWTH FACTOR BETA**

SUPPRESSOR FACTORS, IMMUNOLOGIC

Antigen-specific suppressor factor: missing pieces in the puzzle. O'Hara RM Jr. **Immunol Res** 1995;14(4):252–62 (59 ref.)

BIOSYNTHESIS

A suppressive protein generated in peripheral lymph tissue induced by restraint stress. Fan SG, et al. **Adv Neuroimmunol** 1996;6(3):279–88 (44 ref.)

CHEMISTRY

TJ6: the pregnancy-associated cytokine. Beaman K, et al. **Am J Reprod Immunol** 1996 Apr;35(4):338–41 (21 ref.)

IMMUNOLOGY

Controversial issues and possible answers on the antigen-specific regulation of the IgE antibody response. Ishizaka K, et al. **Adv Exp Med Biol** 1996;409:317–25 (23 ref.)

PHYSIOLOGY

TJ6: the pregnancy-associated cytokine. Beaman K, et al. **Am J Reprod Immunol** 1996 Apr;35(4):338–41 (21 ref.)

Arousal and inhibition of human NK cells. Lanier LL, et al. **Immunol Rev** 1997 Feb;155:145–54 (98 ref.)

SUPPRESSOR MUTATION see **SUPPRESSION, GENETIC**

SUPPRESSOR T-CELL FACTORS see **SUPPRESSOR FACTORS, IMMUNOLOGIC**

SUPPRESSOR TRANSFER RNA see **RNA, TRANSFER**

SUPRACHIASMATIC NUCLEUS

ANATOMY & HISTOLOGY

The anatomical basis for the expression of circadian rhythms: the efferent projections of the suprachiasmatic nucleus. Buijs RM. **Prog Brain Res** 1996;111:229–40 (67 ref.)

DRUG EFFECTS

Excitatory and inhibitory amino acids and synaptic transmission in the suprachiasmatic nucleus. van den Pol AN, et al. **Prog Brain Res** 1996;111:41–56 (76 ref.)

METABOLISM

Melatonin receptors in the mammalian suprachiasmatic nucleus. Dubocovich ML, et al. **Behav Brain Res** 1996; 73(1–2):141–7 (79 ref.)

The role of glutamate in the photic regulation of the suprachiasmatic nucleus. Ebling FJ. **Prog Neurobiol** 1996 Oct;50(2–3):109–32 (209 ref.)

PHYSIOLOGY

Peptidergic mechanisms of action in the suprachiasmatic nucleus. Huhman KL, et al. **Ann N Y Acad Sci** 1997 Apr 24;814:300–4 (40 ref.)

Circadian actions of melatonin at the suprachiasmatic nucleus. Gillette MU, et al. **Behav Brain Res** 1996; 73(1–2):135–9 (41 ref.)

Let there be light: signal transduction in a mammalian circadian system. Golombek DA, et al. **Braz J Med Biol Res** 1996 Jan;29(1):131–40 (77 ref.)

Pacemaker interactions in the mammalian circadian system. Ralph MR, et al. **Braz J Med Biol Res** 1996 Jan;29(1):77–85 (34 ref.)

Components and connections of the circadian timing system in mammals. Reuss S. **Cell Tissue Res** 1996 Sep; 285(3):353–78 (280 ref.)

Influences of melatonin on human circadian rhythms. Cagnacci A. **Chronobiol Int** 1997 Mar;14(2):205–20 (138 ref.)

Developing circadian rhythmicity. Basic and clinical aspects. Rivkees SA. **Pediatr Clin North Am** 1997 Apr;44(2):467–87 (139 ref.)

Regulation of entrainment pathways by the suprachiasmatic circadian clock: sensitivities to second messengers. Gillette MU. **Prog Brain Res** 1996;111:121–32 (50 ref.)

Entrainment of the circadian clock. Hastings MH, et al. **Prog Brain Res** 1996;111:147–74 (114 ref.)

Electrophysiology of suprachiasmatic nucleus projections to hypothalamic paraventricular nucleus neurons. Hermes ML, et al. **Prog Brain Res** 1996;111:241–52 (46 ref.)

Circadian rhythms of neuropeptides in the suprachiasmatic nucleus. Inouye ST. **Prog Brain Res** 1996;111:75–90 (45 ref.)

Light entrainment and activation of signal transduction pathways in the SCN. Kornhauser JM, et al. **Prog Brain Res** 1996;111:133–46 (80 ref.)

Entrainment pathways and the functional organization of the circadian system. Moore RY. **Prog Brain Res** 1996; 111:103–19 (65 ref.)

SCN output drives the autonomic nervous system: with special reference to the autonomic function related to the regulation of glucose metabolism. Nagai K, et al. **Prog Brain Res** 1996;111:253–72 (91 ref.)

The suprachiasmastic nucleus: the biological clock of all seasons. Pevet P, et al. **Prog Brain Res** 1996;111:369–84 (68 ref.)

Biological rhythms in the human life cycle and their relationship to functional changes in the suprachiasmatic nucleus. Swaab DF, et al. **Prog Brain Res** 1996;111:349–68 (118 ref.)

[The suprachiasmatic nucleus: cellular approach to clock functioning] Servière J, et al. **Pathol Biol (Paris)** 1996 Jun;

44(6):497–508 (71 ref.) (Eng. Abstr.) **(Fre)**

SUPRANUCLEAR PALSY, PROGRESSIVE

[Progressive supranuclear palsy] Nakamura T, et al. **Nippon Rinsho** 1997 Jan;55(1):127–30 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Progressive supranuclear palsy] Imai H. **Rinsho Shinkeigaku** 1995 Dec;35(12):1452–4 (8 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Spectrum of memory dysfunction in degenerative disease. Perry RJ, et al. **Curr Opin Neurol** 1996 Aug;9(4):281–5 (60 ref.)

[MRI of degenerative extrapyramidal syndromes. Parkinson disease, progressive supranuclear palsy and multiple system atrophy] Elkeslassy A, et al. **J Neuroradiol** 1996 Dec; 23(3):157–63 (14 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

The clinical and pathologic hallmarks of progressive supranuclear palsy. Litvan I. **Curr Opin Neurol** 1997 Aug; 10(4):346–50 (23 ref.)

[Characterization of glial fibrillary tangles in progressive supranuclear palsy and Alzheimer's disease] Nishimura M. **No To Shinkei** 1996 Oct;48(10):895–903 (32 ref.) **(Jpn)**

SUPRAOPTIC NUCLEUS

CYTOLOGY

Morphological and electrophysiological classification of hypothalamic supraoptic neurons. Armstrong WE. **Prog Neurobiol** 1995 Nov–Dec;47(4–5):291–339 (388 ref.)

PHYSIOLOGY

Morphological and electrophysiological classification of hypothalamic supraoptic neurons. Armstrong WE. **Prog Neurobiol** 1995 Nov–Dec;47(4–5):291–339 (388 ref.)

SUPRASELLAR CYST see **CRANIOPHARYNGIOMA**

SUPRATENTORIAL NEOPLASMS

COMPLICATIONS

[Familial astrocytoma associated with von Recklinghausen's disease: report of two cases] Ito Y, et al. **No Shinkei Geka** 1997 Mar;25(3):283–8 (20 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

The expanding role of chemotherapy for pediatric supratentorial malignant gliomas. Lyden DC, et al. **J Neurooncol** 1996 May–Jun;28(2–3):185–91 (65 ref.)

GENETICS

[Familial astrocytoma associated with von Recklinghausen's disease: report of two cases] Ito Y, et al. **No Shinkei Geka** 1997 Mar;25(3):283–8 (20 ref.) (Eng. Abstr.) **(Jpn)**

MORTALITY

Prognostic value of complete response after the initial treatment for malignant astrocytoma. Kayama T, et al. **Neurol Res** 1996 Aug;18(4):321–4 (16 ref.)

PATHOLOGY

Malignant supratentorial glial–neuronal neoplasms: report of two cases and review of the literature. McLendon RE, et al. **Arch Pathol Lab Med** 1997 May;121(5):485–92 (45 ref.)

RADIOTHERAPY

Supratentorial low-grade glioma: is there a role for radiation therapy? Trautmann TG, et al. **Ann Acad Med Singapore** 1996 May;25(3):392–6 (36 ref.)

SURAL NERVE

PATHOLOGY

Ultrastructural morphometric analysis of human sural nerve biopsies. Giannini C. **Diabet Med** 1996 Jul;13(7):675–6 (10 ref.)

Nerve biopsy [editorial; comment] Thomas PK. **Diabet Med** 1997 May;14(5):345–6 (16 ref.) Comment on: Diabet Med 1997 May;14(5):353–6.

SURAMIN

ADMINISTRATION & DOSAGE

Other chemotherapy regimens including mitoxantrone and suramin. Siu LL, et al. **Semin Urol Oncol** 1997 Feb; 15(1):20–7 (38 ref.)

[Filtering glaucoma operations. Can growth factor blockers replace antimetabolites?] Mietz H. **Ophthalmologe** 1997 Mar;94(3):242–7 (64 ref.) **(Ger)**

THERAPEUTIC USE

Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder. Walther MM, et al. **World J Urol** 1996;14 Suppl 1:S8–11 (31 ref.)

SURFACE-ACTIVE AGENTS

see related
PULMONARY SURFACTANTS

Detergent and skin irritation. Effendy I, et al. **Clin Dermatol** 1996 Jan–Feb;14(1):15–21 (82 ref.)

Methods for measuring the skin-cleansing effect of surfactants in comparison with skin roughness and compatibility. Schrader K, et al. **Clin Dermatol** 1996 Jan–Feb;14(1):57–65 (15 ref.)

The effects of detergents on hydration and skin surface lipids. Thune P. **Clin Dermatol** 1996 Jan–Feb;14(1):29–33 (33 ref.)

Significance of bacterial surface-active compounds in interaction of bacteria with interfaces. Neu TR. **Microbiol Rev** 1996 Mar;60(1):151–66 (212 ref.)

ADMINISTRATION & DOSAGE

Soaps and detergents in children. Yamamoto K. **Clin Dermatol** 1996 Jan–Feb;14(1):81–4 (8 ref.)

ADVERSE EFFECTS

Allergic contact dermatitis and photoallergic contact dermatitis due to soaps and detergents. Dooms-Goossens A, et al. **Clin Dermatol** 1996 Jan–Feb;14(1):67–76 (115 ref.)

Prevention of surfactant-induced irritant contact dermatitis. Wilhelm KP. **Curr Probl Dermatol** 1996;25:78–85 (21 ref.)

[Protection of water supply sources from synthetic surface-active agents (review)] Mudryĭ IV. **Gig Sanit** 1996 Jul–Aug;(4):6–8 (33 ref.) **(Rus)**

CHEMICAL SYNTHESIS

Microbial production of surfactants and their commercial potential. Desai JD, et al. **Microbiol Mol Biol Rev** 1997 Mar;61(1):47–64 (271 ref.)

CHEMISTRY

Chiral micelle polymers for chiral separations in capillary electrophoresis. Williams CC, et al. **Adv Chromatogr** 1997; 37:363–423 (94 ref.)

On the importance of hydroxyl groups in the polar head-group of nonionic surfactants and membrane lipids. Shinoda K, et al. **Adv Colloid Interface Sci** 1996 Feb 8; 64:253–71 (25 ref.)

Monomeric and polymeric chiral surfactants as pseudo-stationary phases for chiral separations. Shamsi SA, et al. **Electrophoresis** 1997 Jun;18(6):853–72 (76 ref.)

METABOLISM

Microbial production of surfactants and their commercial potential. Desai JD, et al. **Microbiol Mol Biol Rev** 1997 Mar;61(1):47–64 (271 ref.)

The surfactant system of the lung modulates pathological processes. von Wichert P. **Pol Arch Med Wewn** 1997;97 Spec No:69–71 (24 ref.)

The composition and function of reptilian pulmonary surfactant. Daniels CB, et al. **Respir Physiol** 1995 Dec; 102(2–3):121–35 (50 ref.)

PHARMACOLOGY

Cut-off effects in biological activities of surfactants. Balgavý P, et al. **Adv Colloid Interface Sci** 1996 Aug 12;66:23–63 (101 ref.)

THERAPEUTIC USE

High frequency oscillation and exogenous surfactant in the treatment of neonatal respiratory distress syndrome. Claris O, et al. **Acta Paediatr** 1997 Apr;86(4):339–41 (18 ref.)

Surfactant for acute respiratory distress syndrome. Jobe AH, et al. **Adv Intern Med** 1997;42:203–30 (70 ref.)

Soaps and detergents in skin diseases. Hannuksela A, et al. **Clin Dermatol** 1996 Jan–Feb;14(1):77–80 (37 ref.)

[Surface-active substances in the arsenal of agents against AIDS] Krivoshein IuS, et al. **Mikrobiol Z** 1997 Jan–Feb; 59(1):87–97 (69 ref.) (Eng. Abstr.) **(Rus)**

TOXICITY

Regulations for combined effects of pollutants: consequences from risk assessment in aquatic toxicology. Altenburger R, et al. **Food Chem Toxicol** 1996 Nov–Dec; 34(11–12):1155–7 (19 ref.)

Cationic amphiphilic drug-induced phospholipidosis. Halliwell WH. **Toxicol Pathol** 1997 Jan–Feb;25(1):53–60 (87 ref.)

SURFACE ANTIGENS see **ANTIGENS, SURFACE**

SURFACE GLYCOPROTEINS see **MEMBRANE GLYCOPROTEINS**

SURFACE MARKERS, IMMUNOLOGICAL see **ANTIGENS, SURFACE**

SURFACE PROPERTIES

Using self-assembled monolayers to understand the interactions of man-made surfaces with proteins and cells. Mrksich M, et al. **Annu Rev Biophys Biomol Struct** 1996; 25:55–78 (87 ref.)

SURFACE PROTEINS see **MEMBRANE PROTEINS**

SURFACE VARIANT GLYCOPROTEINS, TRYPANOSOMA see **VARIANT SURFACE GLYCOPROTEINS, TRYPANOSOMA**

SURFACTANTS see **SURFACE-ACTIVE AGENTS**

SURFACTANTS, PULMONARY see **PULMONARY SURFACTANTS**

SURGERY

Training in laparoscopic surgery--have we got it right yet? Ooi LL. **Ann Acad Med Singapore** 1996 Sep;25(5):732–6 (34 ref.)

Occupational hazards of operating: opportunities for improvement. Davis MS. **Infect Control Hosp Epidemiol** 1996 Oct;17(10):691–3 (16 ref.)

A reader's guide to surgical decision analysis. Birkmeyer JD, et al. **J Am Coll Surg** 1997 Jun;184(6):589–95 (26 ref.)

The surgeon's database for AIDS: a collective review. Flum DR, et al. **J Am Coll Surg** 1997 Apr;184(4):403–12 (64 ref.)

The application of ergonomics in the work environment of general surgeons. Berguer R. **Rev Environ Health** 1997 Apr–Jun;12(2):99–106 (56 ref.)

Gene therapy in pediatric surgery. Brandt ML. **Semin Pediatr Surg** 1996 Aug;5(3):197–205 (78 ref.)

EDUCATION

Training and accreditation in endoscopic surgery. Cooper MJ, et al. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):278–80 (10 ref.)

Surgery and training in surgery in remote rural hospitals. Steiner AK. **East Afr Med J** 1996 Dec;73(12):830–1 (10 ref.)

Oral presentations for surgical meetings. Edwards MJ, et al. **J Surg Res** 1997 Feb 15;68(1):87–90 (4 ref.)

Surgery. Training or derailment? Livingstone JI, et al. **Lancet** 1996 Dec 21–28;348 Suppl 2:sII25 (5 ref.)

[Surgical school--an anachronism?] Borst HG. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:723–6 (11 ref.) **(Ger)**

HISTORY

Surgery in Egypt. el-Zawahry MD, et al. **Arch Surg** 1997 Jul;132(7):698–702 (05 ref.)

Historical evolution of inguinal hernia repair. Sachs M, et al. **World J Surg** 1997 Feb;21(2):218–23 (28 ref.)

LEGISLATION & JURISPRUDENCE

The case for patenting medical procedures. Garris JJ. **Am J Law Med** 1996;22(1):85–108 (235 ref.)

[The surgeon, the expert, the judge] Vayre P. **Bull Acad Natl Med** 1996 Dec;180(9):2149–58; discussion 2158–61 (11 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

Advances in molecular genetics. Lairmore TC, et al. **Am J Surg** 1997 Jan;173(1):37–41; discussion 42–3 (15 ref.)

Surgery. Training or derailment? Livingstone JI, et al. **Lancet** 1996 Dec 21–28;348 Suppl 2:sII25 (5 ref.)

SURGERY, COSMETIC see **SURGERY, PLASTIC**

SURGERY DEPARTMENT, HOSPITAL

[Acute pancreatitis treated in a surgery ward. Apropos of 57 cases] Benchimol D, et al. **J Chir (Paris)** 1996 Jul; 133(5):208–13 (43 ref.) (Eng. Abstr.) **(Fre)**

ORGANIZATION & ADMINISTRATION

Surgical process scheduling: a structured review. Blake JT, et al. **J Soc Health Syst** 1997;5(3):17–30 (39 ref.)

SURGERY, ELECTIVE

Elective surgery for gastrointestinal tumours in the elderly. Audisio RA, et al. **Ann Oncol** 1997 Apr;8(4):317–26 (112 ref.)

Theoretical and empirical arguments in relation to elective lymph node dissection for melanoma. Piepkorn M, et al. **Arch Dermatol** 1997 Aug;133(8):995–1002 (110 ref.)

The clinically N(0) neck: investigation and treatment [editorial] Watkinson J. **Clin Otolaryngol** 1993 Dec; 18(6):443–5 (39 ref.)

Psoriasis and elective foot surgery [see comments] Cheleuitte E, et al. **J Foot Ankle Surg** 1996 Jul–Aug;35(4):297–302; discussion 371 (25 ref.) Comment in: J Foot Ankle Surg 1997 Jan–Feb;36(1):77–8.

Diagnosis and indications for elective spinal surgery. McGuire RA Jr. **J South Orthop Assoc** 1996 Fall; 5(3):213–20 (20 ref.)

Management of anticoagulation before and after elective surgery. Kearon C, et al. **N Engl J Med** 1997 May 22; 336(21):1506–11 (66 ref.)

Consensus statement: using epoetin alfa to decrease the risk of allogeneic blood transfusion in the surgical setting. Roundtable of Experts in Surgery Blood Management. Messmer K. **Semin Hematol** 1997 Apr;33(2 Suppl 2):78–80 (0 ref.)

[Surgery in patients treated with anticoagulation during emergency and elective interventions] Encke A. **Chirurg** 1997 Jul;68(7):670–4 (11 ref.) (Eng. Abstr.) **(Ger)**

[Surgery in immunosuppressed patients with emergency or elective indications] Lang H, et al. **Chirurg** 1997 Jul; 68(7):675–80 (26 ref.) (Eng. Abstr.) **(Ger)**

[Pros and cons of elective appendectomy in gynecologic laparotomy] Grys E, et al. **Ginekol Pol** 1996 Jul;67(7):361–5 (30 ref.) (Eng. Abstr.) **(Pol)**

[New discoveries on metabolic preparation prior to surgery: carbohydrate loading is better than fasting] Ljungqvist O, et al. **Lakartidningen** 1997 Apr 9;94(15):1372–6 (37 ref.) **(Swe)**

STANDARDS

Proceedings of the roundtable of experts in surgery blood management. Vienna, Austria, April 7–9, 1995. **Semin Hematol** 1996 Apr;33(2 Suppl 2):1–80 (0 ref.)

SURGERY, ENDOSCOPIC

Endoscopical management of ureteral trauma. Billiet I. **Acta Urol Belg** 1997 Jun;65(2):35–41 (42 ref.)

Microendoscopic transoral CO2–laser resection of an extensive nasopharyngeal and oral teratoma. Gunkel AR, et al. **Am J Otolaryngol** 1997 Mar–Apr;18(2):140–4 (14 ref.)

Minimally invasive surgery of the esophagus and stomach. Trus TL, et al. **Am J Surg** 1997 Mar;173(3):242–55 (90 ref.)

Endoscopic banding ligation treatment for bleeding oesophageal varices. Sutedja DS, et al. **Ann Acad Med Singapore** 1996 Sep;25(5):708–11 (33 ref.)

The future of shoulder arthroscopy. Ellman H. **Ann Chir Gynaecol** 1996;85(2):150–5 (5 ref.)

Current state of antenatal in utero surgical interventions. Kimber C, et al. **Arch Dis Child Fetal Neonatal Ed** 1997 Mar;76(2):F134–9 (75 ref.)

Thoracoscopic sympathectomy in the treatment of palmar hyperhidrosis: anaesthetic implications. Fredman B, et al. **Br J Anaesth** 1997 Jul;79(1):113–9 (55 ref.)

Functional endoscopic sinus surgery. Swift AC. **Br J Hosp Med** 1996 May 1–14;55(9):554–8 (24 ref.)

Irrigating fluids in endoscopic surgery. Hahn RG. **Br J Urol** 1997 May;79(5):669–80 (130 ref.)

Endoscopic carpal tunnel release. In favor. Nagle DJ. **Clin Plast Surg** 1996 Jul;23(3):477–86 (36 ref.)

Complications of arthroscopic meniscal repair. Austin KS. **Clin Sports Med** 1996 Jul;15(3):613–9 (45 ref.)

Shoulder arthroscopy. New concepts. Burkhart SS. **Clin Sports Med** 1996 Oct;15(4):635–53 (106 ref.)

Rehabilitation of the athlete after shoulder arthroscopy. Buuck DA, et al. **Clin Sports Med** 1996 Oct;15(4):655–72 (29 ref.)

Introduction to the basics of arthroscopy of the knee. Cautilli R Jr. **Clin Sports Med** 1997 Jan;16(1):1–16 (23 ref.)

Arthroscopy of the foot and ankle in the athlete. Cooper PS, et al. **Clin Sports Med** 1996 Oct;15(4):805–24 (68 ref.)

Elbow arthroscopy in the athlete. Day B. **Clin Sports Med** 1996 Oct;15(4):785–97 (21 ref.)

Arthroscopy of the wrist in athletes. Ekman EF, et al. **Clin Sports Med** 1996 Oct;15(4):753–68 (40 ref.)

Open or arthroscopic lateral release. Indications, techniques, and rehabilitation. Ford DH, et al. **Clin Sports Med** 1997 Jan;16(1):29–49 (55 ref.)

Arthroscopic decompression of the shoulder in athletes. Kolowich PA. **Clin Sports Med** 1996 Oct;15(4):701–13 (44 ref.)

Arthroscopic treatment of rotator cuff disorders. Peterson CA 2nd, et al. **Clin Sports Med** 1996 Oct;15(4):715–36 (78 ref.)

Arthroscopy of the patellofemoral joint. Pidoriano AJ, et al. **Clin Sports Med** 1997 Jan;16(1):17–28 (30 ref.)

Arthroscopic posterior cruciate ligament reconstruction. Schulte KR, et al. **Clin Sports Med** 1997 Jan;16(1):145–56 (22 ref.)

Arthroscopic Bankart repair. Shea KP. **Clin Sports Med** 1996 Oct;15(4):737–51 (37 ref.)

Rehabilitation after meniscal repair. Shelbourne KD, et al. **Clin Sports Med** 1996 Jul;15(3):595–612 (36 ref.)

Arthroscopic anterior cruciate ligament reconstruction. Veltri DM. **Clin Sports Med** 1997 Jan;16(1):123–44 (56 ref.)

Endoscopic polypectomy under laparotomy throughout the alimentary tract for a patient with blue rubber bleb nevus syndrome. Shimada S, et al. **Gastrointest Endosc** 1997 May; 45(5):423–7 (25 ref.)

Endoscopic management of an intraluminal duodenal diverticulum. Van Os EC, et al. **Gastrointest Endosc** 1996 Oct;44(4):494–7 (16 ref.)

Percutaneous treatment of transitional cell carcinoma of the upper urinary tract. Okada H, et al. **Int J Urol** 1997 Mar; 4(2):130–3 (15 ref.)

Thoracoscopy in the management of spontaneous pneumothorax. Janssen JP. **Int Surg** 1996 Oct–Dec; 81(4):339–42 (63 ref.)

Endoscopic mucosal resection. Shim CS. **J Korean Med Sci** 1996 Dec;11(6):457–66 (33 ref.)

Hernia of the lung repaired by VATS: a case report. Brown WT, et al. **J Laparoendosc Surg** 1996 Dec;6(6):427–30 (5 ref.)

Visual evoked potentials in endoscopic and anterior skull base surgery: a review. Jones NS. **J Laryngol Otol** 1997 Jun; 111(6):513–6 (33 ref.)

Extended applications of endoscopic sinus surgery—the territorial imperative [editorial] Lund VJ. **J Laryngol Otol** 1997 Apr;111(4):313–5 (13 ref.)

Endoscopic management of traumatic posterior urethral stricture: early results and followup [see comments] Goel MC, et al. **J Urol** 1997 Jan;157(1):95–7 (23 ref.) Comment in: J Urol 1997 Jan;157(1):102.

Endoscopic management of ureteral strictures [see comments] Goldfischer ER, et al. **J Urol** 1997 Mar;157(3):770–5 (84 ref.) Comment in: J Urol 1997 Mar;157(3):817.

Diagnostic and therapeutic spinal arthroscopy. Kambin P. **Neurosurg Clin N Am** 1996 Jan;7(1):65–76 (49 ref.)

Transforaminal endoscopic microdiscectomy. Mathews HH. **Neurosurg Clin N Am** 1996 Jan;7(1):59–63 (23 ref.)

Percutaneous endoscopic thoracic discectomy. Regan JJ. **Neurosurg Clin N Am** 1996 Jan;7(1):87–98 (43 ref.)

Computer–assisted endoscopic sinus surgery. An international review. Anon JB, et al. **Otolaryngol Clin North Am** 1997 Jun;30(3):389–401 (23 ref.)

Technical considerations in powered instrumentation. Becker DG. **Otolaryngol Clin North Am** 1997 Jun;30(3):421–34 (15 ref.)

Endoscopic surgical management of glottic laryngeal cancer. Davis RK. **Otolaryngol Clin North Am** 1997 Feb; 30(1):79–86 (16 ref.)

Current concepts in the surgical management of chronic frontal sinusitis. Nguyen QA, et al. **Otolaryngol Clin North Am** 1997 Jun;30(3):355–70 (80 ref.)

Chronic sinusitis: a medical or surgical disease? Parsons DS. **Otolaryngol Clin North Am** 1996 Feb;29(1):1–9 (19 ref.)

Pediatric ethmoidectomy. Pransky SM, et al. **Otolaryngol Clin North Am** 1996 Feb;29(1):131–42 (38 ref.)

Endoscopic otologic surgery. Rosenberg SI. **Otolaryngol Clin North Am** 1996 Apr;29(2):291–300 (20 ref.)

Transanal endoscopic microsurgery. Saclarides TJ. **Surg Clin North Am** 1997 Feb;77(1):229–39 (10 ref.)

Minimal access vascular surgery, endovascular surgery, traditional surgeryTime for reflection, evaluation, and decision. Dion Y, et al. **Surg Endosc** 1996 Dec; 10(12):1125–9 (67 ref.)

Endoscopic management of malignant colorectal polyps. Kafka NJ, et al. **Surg Oncol Clin N Am** 1996 Jul;5(3):633–61 (158 ref.)

[Role of endoscopy in surgery for urinary incontinence] Grossmann T, et al. **Ann Chir** 1996;50(10):896–905 (34 ref.) (Eng. Abstr.) **(Fre)**

[Results of treatment of hemifacial spasm by surgical and endoscopic neurovascular decompression. Analysis of 60 records] Cacès F, et al. **Ann Otolaryngol Chir Cervicofac** 1996;113(3):119–31 (39 ref.) (Eng. Abstr.) **(Fre)**

[Use of CO2 laser in endoscopic treatment of Zenker's pharyngo–esophageal diverticula. Experience apropos of 33 cases] Hamoir M, et al. **Ann Otolaryngol Chir Cervicofac** 1997;114(1–2):7–12 (30 ref.) (Eng. Abstr.) **(Fre)**

[What role should hysterectomy play in benign uterine lesions?] Cosson M, et al. **Contracept Fertil Sex** 1997 Feb; 25(2):112–9 (42 ref.) (Eng. Abstr.) **(Fre)**

[Thoracoscopic methods in treatment of pulmonary emphysema] Klepetko W, et al. **Chirurg** 1996 Dec; 67(12):1215–21 (26 ref.) (Eng. Abstr.) **(Ger)**

[Inguinal hernia—which method leads to the goal? Endoscopic and open surgical procedures are available] Waninger J. **Fortschr Med** 1997 Mar 20;115(8):26, 29–32 (31 ref.) (Eng. Abstr.) **(Ger)**

[Endoscopic therapy of incidentaloma] Heintz A, et al. **Zentralbl Chir** 1997;122(6):477–80 (15 ref.) (Eng. Abstr.) **(Ger)**

[Video–assisted esophagectomy for carcinoma of the esophagus, using thoracoscopy or mediastinoscopy] Mafune K, et al. **Gan To Kagaku Ryoho** 1997 Mar; 24(5):525–31 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Video–assisted thoracic surgery for lung cancer] Shirakusa T, et al. **Gan To Kagaku Ryoho** 1997 Mar;24(5):520–4 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Endoscopic cancer surgery—uterine and ovarian cancer] Tsubata K, et al. **Gan To Kagaku Ryoho** 1997 Mar; 24(5):551–5 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Thoracoscopic surgery for diagnosis and treatment of pleural and mediastinal disease] Ando A. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:155–8 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Relief of dyspnea after lung volume reduction in patients with pulmonary emphysema] Hida W, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:169–71 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Endoscopic treatment of digestive system diseases. 6. Application and limitation of endoscopic treatment in early colonic cancer] Tada M, et al. **Nippon Naika Gakkai Zasshi** 1996 Sep 10;85(9):1454–7 (5 ref.) **(Jpn)**

[Endoscopic mucosal resection for early gastric cancer] Hamada T, et al. **Nippon Rinsho** 1996 May;54(5):1292–7 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Endoscopic mucosal resection for early esophageal cancer] Inoue M, et al. **Nippon Rinsho** 1996 May;54(5):1286–91 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Thoracoscopic surgery] Inui K, et al. **Nippon Rinsho** 1996 May;54(5):1322–5 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Endoscopic treatment in colorectal lesions—especially on endoscopic mucosal resection] Kudo S, et al. **Nippon Rinsho** 1996 May;54(5):1298–306 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Percutaneous microwave coagulation therapy and endoscopic microwave coagulo–necrotic therapy for small hepatocellular carcinoma] Otsuka S. **Nippon Rinsho** 1996 May;54(5):1343–6 (8 ref.) (Eng. Abstr.) **(Jpn)**

[A case of massive bleeding from rectal varices treated with endoscopic variceal ligation (EVL)] Kojima T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Feb;93(2):114–9 (16 ref.) **(Jpn)**

[The role of endoscopic surgery in the treatment of chronic inflammation of paranasal sinuses] Krzeski A, et al. **Otolaryngol Pol** 1996;50(1):37–45 (15 ref.) (Eng. Abstr.) **(Pol)**

[The endoscopic treatment of urethral strictures and stones by using the Ho:YAG laser] Dondukov TsV, et al. **Urol Nefrol (Mosk)** 1997 Jan–Feb;(1):44–8 (109 ref.) **(Rus)**

[Anatomic orientation in paranasal endoscopic surgery] Bernal Sprekelsen M. **Acta Otorrinolaringol Esp** 1996 Sep–Oct;47(5):337–41 (7 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Emphysematous cholecystitis after endoscopic wallstent placement complicated by distal migration of the stent. Takasaki M, et al. **Endoscopy** 1995 Nov;27(9):704–6 (10 ref.)

Complications of hysteroscopy–their cause, prevention, and correction [see comments] Loffer FD. **J Am Assoc Gynecol Laparosc** 1995 Nov;3(1):11–26 (139 ref.) Comment in: J Am Assoc Gynecol Laparosc 1995 Nov;3(1):1–2.

Complications and medicolegal aspects of endoscopic sinus surgery. Lund VJ, et al. **J R Soc Med** 1997 Aug;90(8):422–8 (41 ref.)

Trigonal splitting is a major complication of endoscopic trigonoplasty at 1–year followup. Okamura K, et al. **J Urol** 1997 Apr;157(4):1423–5 (13 ref.)

One–stage operation for treatment after delayed diagnosis of thoracic esophageal perforation. Balkan ME, et al. **Scand Cardiovasc J** 1997;31(2):111–5 (40 ref.)

Complications of endoscopic polypectomy. Vernava AM 3rd, et al. **Surg Oncol Clin N Am** 1996 Jul;5(3):663–73 (50 ref.)

INSTRUMENTATION

Self–expandable nitinol coil stent for management of colonic obstruction due to a malignant anastomotic stricture. Bashir RM, et al. **Gastrointest Endosc** 1996 Oct;44(4):497–501 (44 ref.)

Endoscopic stenting of minor papilla for symptomatic pancreas divisum. Bhasin DK, et al. **Indian J Gastroenterol** 1997 Jan;16(1):30–1 (7 ref.)

Possibilities and limits of operative hysteroscopy: an update on transcervical resectoscopic uterine surgery. Brandner P, et al. **Int Surg** 1996 Jul–Sep;81(3):259–65 (66 ref.)

Technology and principles of tomographic image–guided interventions and surgery. Melzer A, et al. **Surg Endosc** 1997 Sep;11(9):946–56 (25 ref.)

Endoscopic instruments. Misra M, et al. **Surg Neurol** 1997 Aug;48(2):140–2 (13 ref.)

Arthroscopic synovectomy. When, which diseases and which joints. Paus AC. **Z Rheumatol** 1996 Nov–Dec;55(6):394–400 (63 ref.)

[Technique and indications for sphincter–saving transanal resection in rectal carcinoma] Buess G, et al. **Chirurg** 1996 Feb;67(2):121–8 (22 ref.) (Eng. Abstr.) **(Ger)**

[Endonasal surgery of the paranasal sinuses—concepts, techniques, results, complications and revision interventions] Hosemann W. **Eur Arch Otorhinolaryngol Suppl** 1996;1:155–269 (894 ref.) **(Ger)**

[Minimally invasive ENT surgery. Progress due to modern technology] Plinkert PK, et al. **HNO** 1996 Jun; 44(6):288–301 (64 ref.) (Eng. Abstr.) **(Ger)**

[Minimal invasive surgery—impact on conventional surgery] Schumpelick V, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:528–32 (8 ref.) (Eng. Abstr.) **(Ger)**

[Neuroendoscopy and endoscopic neurosurgery] Gaab MR, et al. **Nervenarzt** 1997 Jun;68(6):459–65 (34 ref.) (Eng. Abstr.) **(Ger)**

[Minimally invasive approach and surgical procedures in the lumbar spine] Ogon M, et al. **Orthopade** 1997 Jun; 26(6):553–61 (49 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Thoracoscopic sympathicolysis for essential hyperhidrosis: immediate and one year follow–up results in 35 patients and review of the literature. Noppen M, et al. **Acta Clin Belg** 1996;51(4):244–53 (54 ref.)

Dacryocystocele in an adult: endoscopic management. Bhaya

M, et al. **Am J Otolaryngol** 1997 Mar–Apr;18(2):131–4 (24 ref.)

Advanced interventional endoscopy. Vitale GC.
Am J Surg 1997 Jan;173(1):21–5; discussion 26 (16 ref.)

Video-assisted thoracoscopic closure of PDA—a case report and literature review. Vanamo K, et al.
Ann Chir Gynaecol 1996;85(3):272–5 (33 ref.)

Out-patient arthroscopy. Pellacci F, et al.
Chir Organi Mov 1996 Apr–Jun;81(2):165–72 (22 ref.) **(Eng, Ita)**

Endoscopic techniques in spinal surgery. Regan JJ, et al. **Clin Orthop** 1997 Feb;(335):122–39 (45 ref.)

Endoscopic carpal tunnel release. The voice of polite dissent. Deune EG, et al. **Clin Plast Surg** 1996 Jul;23(3):487–505 (90 ref.)

Arthroscopic stabilization of the ankle. Kashuk KB, et al. **Clin Podiatr Med Surg** 1997 Jul;14(3):459–78 (38 ref.)

Endoscopic carpal tunnel release. Chow JC.
Clin Sports Med 1996 Oct;15(4):769–84 (38 ref.)

Arthroscopic all-inside meniscus repair. Reigel CA, et al. **Clin Sports Med** 1996 Jul;15(3):483–98 (22 ref.)

Meniscal repair using the outside-to-inside technique. Rodeo SA, et al. **Clin Sports Med** 1996 Jul;15(3):469–81 (44 ref.)

Primary liposarcoma of the stomach resected endoscopically. Yamamoto K, et al. **Endoscopy** 1995 Nov;27(9):711 (5 ref.)

Endoscopic management of pancreatic pseudocysts. Lo SK, et al. **Gastroenterologist** 1997 Mar;5(1):10–25 (76 ref.)

Endoscopic resection of heterotopic pancreas of the minor duodenal papilla: case report and review of the literature. Lucena JF, et al. **Gastrointest Endosc** 1997 Jul;46(1):69–72 (25 ref.)

Combined percutaneous-endoscopic therapy for recurrent pancreatitis and pancreas divisum. Spiess SE, et al.
Gastrointest Endosc 1997 Feb;45(2):188–91 (14 ref.)

Minimally invasive approaches to the spine. Regan JJ, et al. **Instr Course Lect** 1997;46:127–41 (44 ref.)

Transnasal endoscopic management of choanal atresia. Deutsch E, et al. **Int J Pediatr Otorhinolaryngol** 1997 May 4;40(1):19–26 (13 ref.)

Emergency management of bilateral choanal atresia in the newborn by the endoscopic endonasal approach: a clinical record and review of literature. Reddy TN, et al.
Int J Pediatr Otorhinolaryngol 1996 Dec 5;38(1):21–30 (27 ref.)

Video-assisted thoracic surgery in trauma patients [see comments] Carrillo EH, et al. **J Am Coll Surg** 1997 Mar; 184(3):316–24 (31 ref.) Comment in: J Am Coll Surg 1997 Aug;185(2):197–8.

Obscure gastrointestinal bleeding: role of small bowel enteroscopy. Portwood GL, et al. **J S C Med Assoc** 1997 Feb;93(2):51–6 (49 ref.)

Endoscopic carpal tunnel release. Innis PC.
J South Orthop Assoc 1996 Winter;5(4):281–91 (62 ref.)

Video-assisted thoracic surgery in treatment of chest trauma. Liu DW, et al. **J Trauma** 1997 Apr;42(4):670–4 (20 ref.)

Percutaneous endoscopic lumbar spine fusion. Leu HF, et al. **Neurosurg Clin N Am** 1996 Jan;7(1):107–17 (20 ref.)

In minimal access surgery. Lobe TE. **Pediatr Rev** 1996 Dec; 17(12):441–7 (25 ref.)

Successful treatment of a rectal anastomotic stenosis by transanal endoscopic microsurgery (TEM) using the contact Nd:YAG laser. Kato K, et al. **Surg Endosc** 1997 May;11(5):485–7 (11 ref.)

Endoscopic ligation of perforating veins using a mediastinoscope. Pierik RG, et al.
Surg Laparosc Endosc 1997 Feb;7(1):25–8 (28 ref.)

Carcinoma of the oesophagus: the time for a multidiciplinary approach? Clark GW, et al. **Surg Oncol** 1996 Aug; 5(4):149–64 (118 ref.)

[Endoscopic repositioning of the upside-down stomach and its fixation by percutaneous endoscopic gastrostomy] Januschowski R. **Dtsch Med Wochenschr** 1996 Oct 11; 121(41):1261–4 (19 ref.) (Eng. Abstr.) **(Ger)**

[Surgery in malignant obstructive jaundice: laparoscopic surgery—the future?] Schlumpf R, et al.
Schweiz Med Wochenschr 1997 May 10;127(19):834–8 (21 ref.) (Eng. Abstr.) **(Ger)**

[Pharmacological preparation of the endometrium in surgical hysteroscopy] Primiero FM, et al. **Clin Ter** 1996 May; 147(5):245–51 (43 ref.) (Eng. Abstr.) **(Ita)**

[Video-assisted thoracoscopic surgery for a 89-year-old patient with primary lung cancer—report of a case] Kamiyoshihara M, et al.
Nippon Kyobu Geka Gakkai Zasshi 1997 Apr;45(4):628–31 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Endoscope assisted transsphenoidal approach for pituitary adenomas] Kitano M, et al. **No Shinkei Geka** 1997 Mar; 25(3):197–203 (14 ref.) **(Jpn)**

[Neuroendoscopy: diagnosis and therapeutic uses] Jiménez-León JC. **Rev Neurol** 1997 Jun;25(142):941–5 (27 ref.) (Eng. Abstr.) **(Spa)**

REHABILITATION

Rehabilitation programmes following arthroscopic meniscectomy in athletes. Wheatley WB, et al.
Sports Med 1996 Jun;21(6):447–56 (22 ref.)

STANDARDS

Training and accreditation in endoscopic surgery. Cooper MJ, et al. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):278–80 (10 ref.)

Randomized studies in endoscopic surgery—where is the proof? [see comments] Nagele F, et al.
Curr Opin Obstet Gynecol 1996 Aug;8(4):281–9 (158 ref.)
Comment in: Curr Opin Obstet Gynecol 1996 Aug;8(4):243–5.

SURGERY, ESTHETIC see **SURGERY, PLASTIC**

SURGERY, FILTRATION see **FILTERING SURGERY**

SURGERY, LAPAROSCOPIC

Laparoscopic appendicectomy: pros & cons—literature review of 4190 cases. Hermans BP, et al.
Acta Chir Belg 1997 Jun;97(3):110–7 (29 ref.)

Immunological response in laparoscopic surgery. Smit MJ, et al. **Acta Gastroenterol Belg** 1996 Oct–Dec;59(4):245–7 (14 ref.)

Prospective comparison of laparoscopic and traditional colposuspensions in the treatment of genuine stress incontinence. Su TH, et al. **Acta Obstet Gynecol Scand** 1997 Jul;76(6):576–82 (25 ref.)

Review article: controversy in the therapy of gastro-oesophageal reflux disease—long-term proton pump inhibition or laparoscopic anti-reflux surgery? Walker SJ, et al. **Aliment Pharmacol Ther** 1997 Apr; 11(2):249–60 (133 ref.)

Sclerosing lipogranuloma of the scrotum following a laparoscopic herniorraphy and varicocelectomy—a case report. Baladas HG, et al. **Ann Acad Med Singapore** 1997 Mar;26(2):238–40 (4 ref.)

Laparoscopic exploration of the common bile duct–report on two cases and literature review. Kum CK, et al.
Ann Acad Med Singapore 1996 Sep;25(5):720–3 (17 ref.)

An overview of laparoscopic and thoracoscopic vagotomy. Lam YH, et al. **Ann Acad Med Singapore** 1996 Sep; 25(5):699–702 (18 ref.)

Laparoscopic hernia repair—what are the results? Misra MC, et al. **Ann Acad Med Singapore** 1996 Sep;25(5):737–41 (26 ref.)

Training in laparoscopic surgery—have we got it right yet? Ooi LL. **Ann Acad Med Singapore** 1996 Sep;25(5):732–6 (34 ref.)

Emergency laparoscopic procedures. Ravintharan T.
Ann Acad Med Singapore 1996 Sep;25(5):687–93 (65 ref.)

Video-assisted thoracoscopic management of primary spontaneous pneumothorax. Yim AP.
Ann Acad Med Singapore 1996 Sep;25(5):668–72 (28 ref.)

Preoperative screening for common bile duct stones with infusion cholangiography: review of 1000 patients. Lindsey I, et al. **Ann Surg** 1997 Aug;226(2):174–8 (23 ref.)

Mechanisms of hernia recurrence after preperitoneal mesh repair. Traditional and laparoscopic. Lowham AS, et al. **Ann Surg** 1997 Apr;225(4):422–31 (49 ref.)

Laparoscopic surgical treatment of ectopic pregnancy: salpingectomy or salpingostomy? Parker J, et al.
Aust N Z J Obstet Gynaecol 1997 Feb;37(1):115–7 (21 ref.)

Advanced laparoscopic procedures for pelvic pain and dysmenorrhoea. Daniell JF, et al.
Baillieres Clin Obstet Gynaecol 1995 Dec;9(4):795–808 (42 ref.)

The role of laparoscopic surgery in gynaecological oncology. Monaghan JM. **Baillieres Clin Obstet Gynaecol** 1995 Dec; 9(4):639–49 (16 ref.)

Impact of minimally invasive surgery in children. Lugo-Vicente HL. **Bol Asoc Med P R** 1997 Jan–Mar; 89(1–3):25–30 (43 ref.)

Open versus closed establishment of pneumoperitoneum in laparoscopic surgery. Bonjer HJ, et al. **Br J Surg** 1997 May; 84(5):599–602 (27 ref.)

Treatment of hepatic cysts in the era of laparoscopic surgery. Klingler PJ, et al. **Br J Surg** 1997 Apr;84(4):438–44 (60 ref.)

Systematic review of randomized controlled trials comparing laparoscopic with open appendicectomy. McCall JL, et al. **Br J Surg** 1997 Aug;84(8):1045–50 (39 ref.)

Analysis of randomized controlled trials in laparoscopic surgery. Slim K, et al. **Br J Surg** 1997 May;84(5):610–4 (36 ref.)

Laparoscopic appendicectomy [see comments] Tate JJ.
Br J Surg 1996 Sep;83(9):1169–70 (9 ref.) Comment in: Br J Surg 1997 May;84(5):726–7.

Laparoscopic staging of endometrial cancer. Fowler JM.
Clin Obstet Gynecol 1996 Sep;39(3):669–85 (54 ref.)

Outpatient laparoscopic interval female sterilization Intraprasert S, et al. **Contraception** 1997 May;55(5):283–6 (17 ref.)

Fluid balance during hysteroscopic surgery. Istre O.
Curr Opin Obstet Gynecol 1997 Aug;9(4):219–25 (68 ref.)

Indications, benefits and outcome of laparoscopic Nissen fundoplication [see comments] Peters JH, et al. **Dig Dis** 1996 May–Jun;14(3):169–79 (35 ref.) Comment in: Dig Dis 1996 May–Jun;14(3):129–31.

Recent publications in laparoscopic surgery: an overview. Mellinger JD, et al. **Endoscopy** 1996 Jun;28(5):441–51 (87 ref.)

Therapeutic strategies for early gastric cancer. Sowa M, et al. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:18–28 (10 ref.)

Laparoscopic colectomy. Prospects and problems. Holzman MD, et al. **Gastrointest Endosc Clin N Am** 1997 Jul; 7(3):525–39 (89 ref.)

Laparoscopic surgery of the bile ducts. Strasberg SM, et al. **Gastrointest Endosc Clin N Am** 1996 Jan;6(1):81–105 (72 ref.)

Laparoscopic treatment of symptomatic endometriosis. Pouly JL, et al. **Hum Reprod** 1996 Nov;11 Suppl 3:67–88 (88 ref.)

Laparoscopic procedures for treatment of infertility related to polycystic ovarian syndrome. Cohen J.
Hum Reprod Update 1996 Jul–Aug;2(4):337–44 (55 ref.)

Laparoscopic resection for colon cancer: a favorable view. Ota DM. **Important Adv Oncol** 1996;:227–9 (20 ref.)

Laparoscopic treatment is better than medical treatment for minimal or mild endometriosis. Adamson GD.
Int J Fertil Menopausal Stud 1996 Jul–Aug;41(4):396–9 (9 ref.)

The role of laparoscopy in myomectomy. Hasson HM.
Int J Fertil Menopausal Stud 1996 May–Jun;41(3):276–9 (21 ref.)

The potential for improved abdominal procedures and approaches for tubal occlusion. Steele SJ.
Int J Gynaecol Obstet 1995 Dec;51 Suppl 1:S17–22 (18 ref.)

Laparoscopic removal of gonads containing on occult seminoma in a woman with complete androgen resistance. Chantilis SJ, et al. **J Am Assoc Gynecol Laparosc** 1994 May; 1(3):277–82 (35 ref.)

Preoperative sonographic evaluation and laparoscopic management of persistent adnexal masses: a 1994 review. Hulka JF, et al. **J Am Assoc Gynecol Laparosc** 1994 May; 1(3):197–205 (67 ref.)

Bilateral atresia of the proximal ampullary segment of the fallopian tubes. Kozlowski D, et al.
J Am Assoc Gynecol Laparosc 1995 Nov;3(1):99–101 (7 ref.)

The impact of omeprazole and laparoscopy upon hiatal hernia and reflux esophagitis. McKenzie D, et al.
J Am Coll Surg 1996 Oct;183(4):413–8 (46 ref.)

Laparoscopic herniorrhaphy. Memon MA, et al.
J Am Coll Surg 1997 Mar;184(3):325–35 (80 ref.)

Laparoscopic adrenalectomy for solitary metachronous contralateral adrenal metastasis from renal cell carcinoma. Elashry OM, et al. **J Urol** 1997 Apr;157(4):1217–22 (37 ref.)

Laparoscopic ablation of peripelvic renal cysts. Hoenig DM, et al. **J Urol** 1997 Oct;158(4):1345–8 (16 ref.)

A retroperitoneal bronchogenic cyst treated with laparoscopic surgery. Tokuda N, et al. **J Urol** 1997 Feb; 157(2):619 (3 ref.)

Laparoscopic surgery [see comments] Johnson A. **Lancet** 1997 Mar 1;349(9052):631–5 (38 ref.) Comment in: Lancet 1997 May 3;349(9061):1323. Comment in: Lancet 1997 May 3;349(9061):1323–4. Comment in: Lancet 1997 May 3;349(9061):1324.

Laparoscopic hysterectomy [editorial; comment] [see comments] Hall BA. **Med J Aust** 1997 Feb 17;166(4):172–3 (13 ref.) Comment on: Med J Aust 1997 Feb 17;166(4):205–7. Comment in: Med J Aust 1997 Aug 4;167(3):171.

Ambulatory surgery. Laparoscopic surgery. Ferrara-Love R. **Nurs Clin North Am** 1997 Jun;32(2):429–40 (23 ref.)

Complications and recovery from laparoscopy-assisted vaginal hysterectomy compared with abdominal and vaginal hysterectomy [see comments] Meikle SF, et al.
Obstet Gynecol 1997 Feb;89(2):304–11 (39 ref.) Comment in: Obstet Gynecol 1997 Jun;89(6):1050–1.

Surgical treatment of endometriosis. Adamson GD, et al.
Obstet Gynecol Clin North Am 1997 Jun;24(2):375–409 (122 ref.)

Early complications of laparoscopic hysterectomy. Harris WJ, et al. **Obstet Gynecol Surv** 1996 Sep;51(9):559–67 (62 ref.)

Current status in laparoscopic colorectal surgery. Milsom JW, et al. **Rev Gastroenterol Mex** 1996 Apr–Jun;61(2):113–8 (51 ref.)

Laparoscopic surgery. Bornman PC.
Scand J Gastroenterol Suppl 1996;220:66–70 (28 ref.)

Laparoscopic antireflux surgery. Richardson WS, et al.
Semin Gastrointest Dis 1997 Apr;8(2):100–10 (83 ref.)

Laparoscopic antireflux surgery. Rice TW, et al.
Semin Thorac Cardiovasc Surg 1997 Apr;9(2):173–87 (40 ref.)

Laparoscopic antireflux surgery for gastroesophageal reflux disease (GERD). Results of a Consensus Development Conference. Held at the Fourth International Congress of the European Association for Endoscopic Surgery (E.A.E.S.), Trondheim, Norway, June 21–24, 1996.
Surg Endosc 1997 May;11(5):413–26 (284 ref.)

Laparoscopic surgery for cure of colorectal cancer [editorial] Bergamaschi R, et al. **Surg Endosc** 1997 Aug;11(8):797–9 (28 ref.)

Laparoscopic management of a noncommunicating uterine horn in a patient with an acute abdomen. Amara DP, et al. **Surg Laparosc Endosc** 1997 Feb;7(1):56–9 (12 ref.)

Laparoscopic accessory splenectomy for recurrent idiopathic thrombocytopenic purpura. Amaral JF, et al.
Surg Laparosc Endosc 1997 Aug;7(4):340–4 (15 ref.)

The role of laparoscopic colectomy and laparotomy with resection in the management of complex polyps of the colon. Sands LR, et al. **Surg Oncol Clin N Am** 1996 Jul; 5(3):713–21 (39 ref.)

Laparoscopic complications in markedly obese urologic patients (a multi-institutional review). Mendoza D, et al.
Urology 1996 Oct;48(4):562–7 (30 ref.)

Laparoscopic fundoplication: the alternative to long-term

medical therapy for severe gastroesophageal reflux disease. Perdikis G, et al. **Yale J Biol Med** 1996 May–Jun; 69(3):283–8 (29 ref.)

[Laparoscopic surgery in benign ovarian cysts] Feng F, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Jun;31(6):375–7 (20 ref.) **(Chi)**

[Laparoscopic excision of the rectum. An advanced technique or true clinical progress?] Bardram L, et al. **Ugeskr Laeger** 1996 Oct 14;158(42):5911–4 (32 ref.) (Eng. Abstr.) **(Dan)**

[Laparoscopy-assisted colonic surgery. Initial experience. Apropos of 49 cases] Bouillot JL, et al. **Ann Chir** 1996; 50(7):542–7 (47 ref.) (Eng. Abstr.) **(Fre)**

[Results and indications of laparoscopic distal tuboplasty] Lavergne N, et al. **Contracept Fertil Sex** 1996 Jan; 24(1):41–8 (29 ref.) (Eng. Abstr.) **(Fre)**

[Role of surgery in the treatment of infertility due to polycystic ovaries] Pauthier S, et al. **Contracept Fertil Sex** 1996 Nov;24(11):825–9 (31 ref.) (Eng. Abstr.) **(Fre)**

[Laparoscopic colectomy. Techniques and indications] Champault G, et al. **J Chir (Paris)** 1996 Sep;133(6):247–61 (69 ref.) (Eng. Abstr.) **(Fre)**

[Distal tubal surgery: a critical review of 104 laparoscopic distal tuboplasties] Filippini F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(5):471–8 (31 ref.) (Eng. Abstr.) **(Fre)**

[Topographic-anatomic aspects of laparoscopic management of inguinal hernia] Kunz R, et al. **Chirurg** 1996 Aug; 67(8):807–13 (31 ref.) (Eng. Abstr.) **(Ger)**

[Are high risk patients candidates for minimally invasive surgery with CO2 pneumoperitoneum? Viewpoint from anesthesiology] Schulte-Steinberg H, et al. **Chirurg** 1996 Jan;67(1):72–6 (33 ref.) (Eng. Abstr.) **(Ger)**

[A preoperative diagnostic concept for determining the extent of laparoscopic surgery of the adnexa] Hesseling M, et al. **Gynakol Geburtshilfliche Rundsch** 1997;37(1):5–13 (49 ref.) (Eng. Abstr.) **(Ger)**

[Endoscopic therapy of incidentaloma] Heintz A, et al. **Zentralbl Chir** 1997;122(6):477–80 (15 ref.) (Eng. Abstr.) **(Ger)**

[Laparoscopic splenic surgery--report of 17 personal cases] Schwetling R, et al. **Zentralbl Chir** 1997;122(4):291–4 (15 ref.) (Eng. Abstr.) **(Ger)**

[Conventional operation for therapy of incidentaloma] Simon D, et al. **Zentralbl Chir** 1997;122(6):473–6 (29 ref.) (Eng. Abstr.) **(Ger)**

[New directions in the surgical treatment of gastroesophageal reflux. Review of the literature] Bresadola V, et al. **Ann Ital Chir** 1997 Mar–Apr;68(2):213–8 (42 ref.) (Eng. Abstr.) **(Ita)**

[Laparoscopic surgery of stress urinary incontinence in women] Breda G, et al. **Chir Ital** 1996;48(5):35–40 (29 ref.) (Eng. Abstr.) **(Ita)**

[Current indications for video-laparoscopic surgery of adrenal gland neoplasms] Angrisani L, et al. **G Chir** 1996 Aug–Sep;17(8–9):453–7 (28 ref.) (Eng. Abstr.) **(Ita)**

[Video-laparoscopic colorectal surgery: critical review of our experience with mixed gasless pneumo-peritoneal method (editorial)] Tenchini P, et al. **G Chir** 1997 Jun–Jul; 18(6–7):325–30 (12 ref.) **(Ita)**

[Laparoscopic second-look in acute intestinal ischemia] Tola M, et al. **Minerva Chir** 1997 May;52(5):527–30 (11 ref.) (Eng. Abstr.) **(Ita)**

[Laparoscopic management of extrauterine pregnancy] Borsellino G, et al. **Minerva Ginecol** 1995 Nov;47(11):471–6 (23 ref.) (Eng. Abstr.) **(Ita)**

[Recent advance in laparoscopic-assisted colectomy for colon cancer] Konishi F, et al. **Gan To Kagaku Ryoho** 1997 Mar;24(5):538–43 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Laparoscopic surgery for early gastric cancer--its advantage and pitfall] Ohgami M, et al. **Gan To Kagaku Ryoho** 1997 Mar;24(5):532–7 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Laparoscopic surgery for renal carcinomas] Suzuki K, et al. **Gan To Kagaku Ryoho** 1997 Mar;24(5):544–50 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Laparoscopic surgery: its value and limits. Is the conversion a failure?] Duca S. **Chirurgia (Bucur)** 1997 May–Jun; 92(3):139–43 (13 ref.) **(Rum)**

[Laparoscopic adrenalectomy] Ippolitov LI, et al. **Khirurgiia (Mosk)** 1997;(3):70–4 (55 ref.) **(Rus)**

[Urological laparoscopic surgery] Kadyrov ZA. **Urol Nefrol (Mosk)** 1997 Jan–Feb;(1):40–4 (122 ref.) **(Rus)**

[Lymphocele after renal transplantation: therapeutic controversies in the age of laparoscopy] Lledó García E, et al. **Actas Urol Esp** 1996 Jul–Aug;20(7):648–54 (36 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Hernias in trocar ports following abdominal laparoscopy. A review. Lajer H, et al. **Acta Obstet Gynecol Scand** 1997 May;76(5):389–93 (33 ref.)

Laparoscopic port site recurrences in oncologic surgery--a review. Weiss EG, et al. **Ann Acad Med Singapore** 1996 Sep;25(5):694–8 (68 ref.)

Endoscopic surgery: yes, but ... [editorial; comment] Magos AL. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):243–5 (19 ref.) Comment on: Curr Opin Obstet Gynecol 1996 Aug;8(4):281–9.

How can we avoid adhesions after laparoscopic surgery? Tulandi T. **Curr Opin Obstet Gynecol** 1997 Aug;9(4):239–43 (37 ref.)

Laparoscopic resection for colon cancer: cause for pause. Berman IR. **Important Adv Oncol** 1996;:231–43 (51 ref.)

The "cons" of laparoscopic myomectomy in women who may reproduce in the future. Nezhat C. **Int J Fertil Menopausal Stud** 1996 May–Jun;41(3):280–3 (15 ref.)

Adhesion prevention in laparoscopic surgery. Tulandi T. **Int J Fertil Menopausal Stud** 1996 Sep–Oct;41(5):452–7 (42 ref.)

Venous air embolism during operative hysteroscopy [see comments] Brooks PG. **J Am Assoc Gynecol Laparosc** 1997 May;4(3):399–402 (10 ref.) Comment in: J Am Assoc Gynecol Laparosc 1997 May;4(3):291–2.

Evisceration after laparoscopic sterilization. Lopez A, et al. **J Am Assoc Gynecol Laparosc** 1995 Nov;3(1):109–11 (11 ref.)

Omental herniation through a 5-mm laparoscopic cannula site. Toub DB, et al. **J Am Assoc Gynecol Laparosc** 1994 Aug;1(4 Pt 1):413–4 (4 ref.)

Complications of endopyelotomy. Bellman GC. **J Endourol** 1996 Apr;10(2):177–81 (18 ref.)

Complications of major operative laparoscopy. A review of 452 cases. Saidi MH, et al. **J Reprod Med** 1996 Jul; 41(7):471–6 (29 ref.)

Ventricular laceration and cardiac tamponade during laparoscopic Nissen fundoplication. Firoozmand E, et al. **Surg Laparosc Endosc** 1996 Oct;6(5):394–7 (10 ref.)

[Esophageal and cardial risk of treating gastroesophageal reflux by laparoscopic surgery] Vayre P. **Chirurgie** 1997 Jan;121(9–10):636–41; discussion 641–2 (16 ref.) (Eng. Abstr.) **(Fre)**

[Incisional hernia after surgical laparoscopy: a case of hepatic ligament incarceration and review of the literature] Deval B, et al. **Contracept Fertil Sex** 1997 Jan;25(1):66–8 (14 ref.) (Eng. Abstr.) **(Fre)**

[Incarcerated hernia following laparoscopic surgery. A complication to be avoided. Case presentation and literature review] Esteve C, et al. **Rev Med Suisse Romande** 1997 Jan;117(1):25–8 (23 ref.) (Eng. Abstr.) **(Fre)**

[Sources of hazards in laparoscopic colon surgery and how to avoid them] Christen D, et al. **Swiss Surg** 1996;2(5):203–7 (11 ref.) (Eng. Abstr.) **(Ger)**

[Laparocele after laparoscopic surgery] Di Vita G, et al. **Minerva Chir** 1997 May;52(5):523–6 (28 ref.) (Eng. Abstr.) **(Ita)**

ECONOMICS

Laparoscopic and abdominal hysterectomy: a cost comparison [see comments] Tsaltas J, et al. **Med J Aust** 1997 Feb 17;166(4):205–7 (23 ref.) Comment in: Med J Aust 1997 Feb 17;166(4):172–3. Comment in: Med J Aust 1997 Aug 4;167(3):170; discussion 170–1.

[Laparoscopic surgery in gynecology. Surgical reform of mere luxury? (Physiologic and economic effects of laparoscopic surgery)] Hercz P. **Orv Hetil** 1997 Feb 2; 138(5):271–4 (31 ref.) (Eng. Abstr.) **(Hun)**

INSTRUMENTATION

Hernias in trocar ports following abdominal laparoscopy. A review. Lajer H, et al. **Acta Obstet Gynecol Scand** 1997 May;76(5):389–93 (33 ref.)

Laparoscopic adjustable silicone gastric banding in the treatment of super obesity in the Jeddah area, Saudi Arabia. A preliminary report. Ashy AA, et al. **Int Surg** 1996 Jul–Sep;81(3):289–91 (16 ref.)

Laparoscopy in pediatric urology: too much of a good thing? Colodny AH. **Semin Pediatr Surg** 1996 Feb;5(1):23–9 (61 ref.)

Laparoscopy in pediatric urology: challenge and opportunity. Peters CA. **Semin Pediatr Surg** 1996 Feb;5(1):16–22 (39 ref.)

[Appendectomy 1997--open or closed?] Becker H, et al. **Chirurg** 1997 Jan;68(1):17–29 (65 ref.) (Eng. Abstr.) **(Ger)**

[Staging laparoscopy] Feussner H, et al. **Chirurg** 1997 Mar; 68(3):201–9 (41 ref.) (Eng. Abstr.) **(Ger)**

[Errors and risks in oncologic laparoscopic surgery] Köckerling F, et al. **Chirurg** 1997 Mar;68(3):215–24 (39 ref.) (Eng. Abstr.) **(Ger)**

[Laparoscopic adrenal gland surgery] Nies C, et al. **Chirurg** 1997 Feb;68(2):99–106 (47 ref.) (Eng. Abstr.) **(Ger)**

[Laparoscopic resections of malignant diseases of the gastrointestinal tract] Rosenthal J, et al. **Chirurg** 1997 Mar; 68(3):210–4 (16 ref.) (Eng. Abstr.) **(Ger)**

[Minimally invasive surgery and tumor surgery--palliative laparoscopic techniques] Saeger HD, et al. **Chirurg** 1997 Mar;68(3):225–30 (25 ref.) (Eng. Abstr.) **(Ger)**

[Pathogenesis of puncture-site metastases after laparoscopy] Reymond MA, et al. **Zentralbl Chir** 1997;122(5):387–94 (75 ref.) (Eng. Abstr.) **(Ger)**

[Micro-endoscopy, minimal access endoscopy--an overview of current status and future possibilities] Wallwiener D, et al. **Zentralbl Gynakol** 1996;118(2):83–6 (11 ref.) (Eng. Abstr.) **(Ger)**

[Abdominal colposuspension: a synopsis of various approaches and techniques including endoscopic modifications] Wallwiener D, et al. **Zentralbl Gynakol** 1996; 118(2):98–106 (25 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Advanced laparoscopic surgery. Hunter JG. **Am J Surg** 1997 Jan;173(1):14–8; discussion 19–20 (16 ref.)

Surgical ovulation induction: the role of ovarian diathermy in polycystic ovary syndrome. Donesky BW, et al. **Baillieres Clin Endocrinol Metab** 1996 Apr;10(2):293–309 (83 ref.)

Laparoscopic radical hysterectomy for cervical cancer. Canis M, et al. **Baillieres Clin Obstet Gynaecol** 1995 Dec; 9(4):675–89 (20 ref.)

Comparison of hysterectomy techniques and cost-benefit analysis. Garry R. **Baillieres Clin Obstet Gynaecol** 1997 Mar;11(1):137–48 (13 ref.)

Laparoscopic anatomy and dissection of the pelvis. Kadar N. **Baillieres Clin Obstet Gynaecol** 1997 Mar;11(1):37–60 (8 ref.)

Laparoscopic hysterectomy. Wood C, et al. **Baillieres Clin Obstet Gynaecol** 1997 Mar;11(1):111–36 (62 ref.)

Laparoscopic inguinal hernia repair [see comments] Liem MS, et al. **Br J Surg** 1996 Sep;83(9):1197–1204 (96 ref.) Comment in: Br J Surg 1996 Dec;83(12):1795. Comment in: Br J Surg 1997 Apr;84(4):579–80.

Laparoscopy in children. Sharp HT. **Clin Obstet Gynecol** 1997 Mar;40(1):210–8 (20 ref.)

Laparoscopic surgery for ovarian cysts. Audebert AJ. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):261–5 (20 ref.)

Endometriosis: medical and surgical intervention. Falcone T, et al. **Curr Opin Obstet Gynecol** 1996 Jun;8(3):178–83 (40 ref.)

Myomectomies by endo-uterine resection. Hallez JP. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):250–6 (33 ref.)

Surgical anatomy and dissection techniques for laparoscopic surgery. Kadar N. **Curr Opin Obstet Gynecol** 1996 Aug; 8(4):266–77 (9 ref.)

Laparoscopic management of gynecological malignancies. Kadar N. **Curr Opin Obstet Gynecol** 1997 Aug;9(4):247–55 (52 ref.)

How can we avoid adhesions after laparoscopic surgery? Tulandi T. **Curr Opin Obstet Gynecol** 1997 Aug;9(4):239–43 (37 ref.)

Laparoscopic colposuspension and pelvic floor repair. Vancaillie TG. **Curr Opin Obstet Gynecol** 1997 Aug; 9(4):244–6 (19 ref.)

Laparoscopic adrenalectomy: history, indications, and current techniques for a minimally invasive approach to adrenal pathology. Hansen P, et al. **Endoscopy** 1997 May; 29(4):309–14 (20 ref.)

Laparoscopic Nissen fundoplication for severe gastroesophageal reflux disease: pros and cons. DeMaria EJ, et al. **Gastroenterologist** 1997 Mar;5(1):85–93 (27 ref.)

Management of common bile duct stones. Marks JM, et al. **Gastroenterologist** 1996 Sep;4(3):155–62 (31 ref.)

Fertility after hysteroscopic myomectomy. Ubaldi F, et al. **Hum Reprod Update** 1995 Jan;1(1):81–90 (77 ref.)

Minimally invasive arthroscopic spinal surgery. Kambin P, et al. **Instr Course Lect** 1997;46:143–61 (79 ref.)

Laparoscopic management of ovarian ectopic pregnancy. Hage PS, et al. **J Am Assoc Gynecol Laparosc** 1994 May; 1(3):283–5 (10 ref.)

Laparoscopic suturing and ligation techniques. Pasic R, et al. **J Am Assoc Gynecol Laparosc** 1995 Nov;3(1):67–79 (25 ref.)

Ovarian drilling in infertile women with polycystic ovary syndrome. Rose BI. **J Am Assoc Gynecol Laparosc** 1996 May;3(3):461–8 (44 ref.)

Crossing vessels at the ureteropelvic junction: do they influence endopyelotomy outcome? Gupta M, et al. **J Endourol** 1996 Apr;10(2):183–7 (39 ref.)

Laparoscopic transabdominal preperitoneal hernioplasty: results of 1000 consecutive cases. Birth M, et al. **J Laparoendosc Surg** 1996 Oct;6(5):293–300 (52 ref.)

Laparascopic excision of pelvic kidney with single vaginal ectopic ureter. Moores D, et al. **J Pediatr Surg** 1997 Apr; 32(4):634–5 (12 ref.)

Minimally invasive endoscopic surgery of the spine. Goldstein JA, et al. **J South Orthop Assoc** 1996 Winter; 5(4):251–62 (34 ref.)

Port-access coronary artery bypass graft (CABG): an emerging approach to revascularization. Shinn JA. **Prog Cardiovasc Nurs** 1996 Summer;11(3):46, 48 (4 ref.)

Laparoscopic colectomy. Paik PS, et al. **Surg Clin North Am** 1997 Feb;77(1):1–13 (44 ref.)

Laparoscopic closure of esophageal perforation following pneumatic dilatation for achalasia. Report of two cases. Bell RC. **Surg Endosc** 1997 May;11(5):476–8 (10 ref.)

Laparoscopic anatomy of the region of the esophageal hiatus. Kuster GG, et al. **Surg Endosc** 1997 Sep;11(9):883–93 (54 ref.)

Endoluminal surgery. Spivak H, et al. **Surg Endosc** 1997 Apr; 11(4):321–5 (19 ref.)

Laparoscopic removal of a swallowed toothbrush. Wishner JD, et al. **Surg Endosc** 1997 May;11(5):472–3 (7 ref.)

Laparoscopic closure for perforation of the sigmoid colon by endoscopic linear stapler. Hayashi K, et al. **Surg Laparosc Endosc** 1996 Oct;6(5):411–3 (13 ref.)

Laparoscopic resection of a pelvic schwannoma. Melvin WS. **Surg Laparosc Endosc** 1996 Dec;6(6):489–91 (12 ref.)

[Surgical treatment of inguinal hernia. Which criteria to be used for assessment?] Fingerhut A, et al. **Ann Chir** 1996; 50(9):832–7 (62 ref.) **(Fre)**

[Inguinal hernia: contribution of randomized studies over the

last 10 years] Parc Y, et al. **Ann Chir** 1996;50(9):827–31 (18 ref.) (Eng. Abstr.) **(Fre)**

[Axillary node removal prepared by liposuction and assisted by endoscopy in the surgical treatment of breast cancers] Brun JL, et al. **Contracept Fertil Sex** 1997 Mar; 25(3):XIV–XVIII (9 ref.) **(Fre)**

[Laparoscopic surgery without insufflation in gynecology] d'Ercole C, et al. **Contracept Fertil Sex** 1996 Oct; 24(10):723–6 (22 ref.) **(Fre)**

[Laparoscopic surgery of benign tumors of the liver. Apropos of 5 cases] Laporte J, et al. **J Chir (Paris)** 1996; 133(9–10):432–6 (15 ref.) (Eng. Abstr.) **(Fre)**

[Limitations of laparoscopic management of pelvic static disorders in gynecology] Mage G, et al. **Presse Med** 1996 Dec 21;25(40):2037–41 (30 ref.) (Eng. Abstr.) **(Fre)**

[Sources of hazards in laparoscopic colon surgery and how to avoid them] Christen D, et al. **Swiss Surg** 1996;2(5):203–7 (11 ref.) (Eng. Abstr.) **(Ger)**

[Technical aspects of minimally-invasive cancer surgery of the colon: the complete laparoscopic procedure] Schöb O, et al. **Swiss Surg** 1996;Suppl 4:50–3 (24 ref.) (Eng. Abstr.) **(Ger)**

[Laparoscopic colo-rectal surgery] Hayashi K, et al. **Nippon Rinsho** 1996 May;54(5):1312–21 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Laparoscopic curative surgery for early gastric cancer] Ohgami M, et al. **Nippon Rinsho** 1996 May;54(5):1307–11 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Colectomy and anterior resection with a video-laparoscopic approach. Initial experience-results] Habr-Gama A, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Nov–Dec; 50(6):299–304 (26 ref.) (Eng. Abstr.) **(Por)**

[Laparoscopic esophagomyotomy in cardial achalasia] Târcoveanu E, et al. **Chirurgia (Bucur)** 1996 Mar–Apr; 45(2):71–5 (4 ref.) (Eng. Abstr.) **(Rum)**

[Choice of method for laparoscopic hernioplasty] Timoshin AD, et al. **Khirurgiia (Mosk)** 1997;(2):84–7 (41 ref.) **(Rus)**

[The laparoscopic removal of an adrenal tumor] Maĭstrenko NA, et al. **Vestn Khir Im I I Grek** 1997;156(1):106–7 (14 ref.) **(Rus)**

STANDARDS

Current status and trends in laparoscopic antireflux surgery: results of a consensus meeting. The European Study Group for Antireflux Surgery (ESGARS). Fuchs KH, et al. **Endoscopy** 1997 May;29(4):298–308 (77 ref.)

Laparoscopically assisted vaginal hysterectomy. A review of current issues. Young W, et al. **Int J Technol Assess Health Care** 1997 Spring;13(2):368–79 (77 ref.)

TRENDS

Endoscopic surgery [editorial] Magos A. **Curr Opin Obstet Gynecol** 1997 Aug;9(4):217–8 (6 ref.)

Laparoscopic myomectomy today. Fibroids: management and treatment: the state of the art. Donnez J, et al. **Hum Reprod** 1996 Sep;11(9):1837–40 (38 ref.)

Laparoscopic surgery: time for re-evaluation [editorial] Johnson WR. **Med J Aust** 1996 Oct 7;165(7):355–6 (14 ref.)

Future endoscopic trends in gynecological oncology. Bruhat MA, et al. **Zentralbl Gynakol** 1996;118(2):49–52 (29 ref.)

UTILIZATION

Gynecologic laparoscopy and hysteroscopy in a day clinic: trends and perspectives. Gallinat A, et al. **J Am Assoc Gynecol Laparosc** 1994 Feb;1(2):103–10 (25 ref.)

SURGERY, LASER see **LASER SURGERY**

SURGERY, MAXILLOFACIAL see **SURGERY, ORAL**

SURGERY, MINIMALLY INVASIVE

see related
SURGERY, LAPAROSCOPIC

Current state of antenatal in utero surgical interventions. Kimber C, et al. **Arch Dis Child Fetal Neonatal Ed** 1997 Mar;76(2):F134–9 (75 ref.)

Less invasive surgery for gynecologic tumors. Monaghan JM. **Curr Opin Oncol** 1996 Sep;8(5):402–7 (32 ref.)

Interventional MR imaging. Hagspiel KD, et al. **J Vasc Interv Radiol** 1997 Sep–Oct;8(5):745–58 (107 ref.)

Extracorporeal circulation for port-access cardiac surgery. Toomasian JM, et al. **Perfusion** 1997 Mar;12(2):83–91 (20 ref.)

Laparoscopic surgery. Bornman PC. **Scand J Gastroenterol Suppl** 1996;220:66–70 (28 ref.)

Minimal access vascular surgery, endovascular surgery, traditional surgeryTime for reflection, evaluation, and decision. Dion Y, et al. **Surg Endosc** 1996 Dec; 10(12):1125–9 (67 ref.)

[Minimally invasive coronary surgery] Calafiore AM, et al. **Cardiologia** 1997 Apr;42(4):343–6 (12 ref.) **(Ita)**

INSTRUMENTATION

Technological aspects of minimal access surgery. Frank TG, et al. **Proc Inst Mech Eng [H]** 1997;211(2):129–44 (24 ref.)

[Minimal invasive surgery—impact on conventional surgery] Schumpelick V, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:528–32 (8 ref.) (Eng. Abstr.) **(Ger)**

[Minimally invasive approach and surgical procedures in the lumbar spine] Ogon M, et al. **Orthopade** 1997 Jun; 26(6):553–61 (49 ref.) (Eng. Abstr.) **(Ger)**

[Micro-endoscopy, minimal access endoscopy—an overview of current status and future possibilities] Wallwiener D, et al. **Zentralbl Gynakol** 1996;118(2):83–6 (11 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Minimally invasive coronary artery bypass grafting [see comments] Calafiore AM, et al. **Ann Thorac Surg** 1996 Nov; 62(5):1545–8 (29 ref.) Comment in: Ann Thorac Surg 1997 Jul;64(1):285–6.

Retroperitoneal lymphadenectomy in staging and treatment of clinical stage I and II nonseminomatous testis cancer (NSGCT): the development of nerve-sparing techniques. Donohue JP. **Cancer Treat Res** 1996;88:105–19 (20 ref.)

Innovations in minimalism: intraoperative MRI. Alexander E 3rd, et al. **Clin Neurosurg** 1996;43:338–52 (34 ref.)

Innovation through minimalism: assessing emerging technology in neurosurgery. Awad IA. **Clin Neurosurg** 1996;43:303–16 (35 ref.)

Minimalism through intraoperative functional mapping. Berger MS. **Clin Neurosurg** 1996;43:324–37 (17 ref.)

Minimalism through stereotactic technique. Ross DA. **Clin Neurosurg** 1996;43:317–23 (33 ref.)

In minimal access surgery. Lobe TE. **Pediatr Rev** 1996 Dec; 17(12):441–7 (25 ref.)

Image-guided minimally invasive therapy. Seibel RM. **Surg Endosc** 1997 Feb;11(2):154–62 (38 ref.)

Video assisted thoracic surgery for spontaneous pneumothorax. Berrisford RG, et al. **Thorax** 1996 Aug;51 Suppl 2:S23–8 (42 ref.)

TRENDS

Future perspectives of minimal invasive surgery. Fuchs KH, et al. **Digestion** 1997;58 Suppl 1:104–6 (6 ref.)

VETERINARY

[Endoscopy of body cavities and minimally invasive surgery in small animals—review] Thiele S, et al. **Berl Munch Tierarztl Wochenschr** 1996 Aug;109(8):288–91 (25 ref.) (Eng. Abstr.) **(Ger)**

SURGERY, OFFICE see **AMBULATORY SURGERY**

SURGERY, OPERATIVE

see related
INTRAOPERATIVE COMPLICATIONS
OPERATING ROOMS
POSTOPERATIVE COMPLICATIONS
REOPERATION

Autologous blood transfusion: preoperative blood collection and blood salvage techniques. Bengtsson A, et al. **Acta Anaesthesiol Scand** 1996 Sep;40(8 Pt 2):1041–56 (120 ref.)

The benefits of enteric feeding. Moore FA, et al. **Adv Surg** 1996;30:141–54 (47 ref.)

Surgical patients with heart disease: summary of the ACC/AHA guidelines. American College of Cardiology/American Heart Association. Eagle KA. **Am Fam Physician** 1997 Sep 1;56(3):811–8 (08 ref.)

Evolving concepts in autologous blood procurement and transfusion: case reports of perisurgical anemia complicated by myocardial infarction. Goodnough LT, et al. **Am J Med** 1996 Aug 26;101(2A):33S–37S (30 ref.)

New insights into the management of anemia in the surgical patient. Klein HG. **Am J Med** 1996 Aug 26; 101(2A):12S–15S (23 ref.)

Let us shorten antibiotic prophylaxis and therapy in surgery. Wittmann DH, et al. **Am J Surg** 1996 Dec;172(6A):26S–32S (46 ref.)

General surgical clinical pathways: an introduction. Gadacz TR, et al. **Am Surg** 1997 Jan;63(1):107–10 (06 ref.)

Effect of chronic and acute thyroid hormone reduction on perioperative outcome. Bennett-Guerrero E, et al. **Anesth Analg** 1997 Jul;85(1):30–6 (68 ref.)

Perioperative assessment and management of risk from coronary artery disease. Palda VA, et al. **Ann Intern Med** 1997 Aug 15;127(4):313–28 (187 ref.)

Perioperative thermoregulation and heat balance. Sessler DI. **Ann N Y Acad Sci** 1997 Mar 15;813:757–77 (56 ref.)

Nitric oxide and the surgical patient. Identifying therapeutic targets. Tzeng E, et al. **Arch Surg** 1997 Sep;132(9):977–82 (42 ref.)

Cytokines in anaesthesia. Sheeran P, et al. **Br J Anaesth** 1997 Feb;78(2):201–19 (148 ref.)

Peri-operative haemoglobin: an overview of current opinion regarding the acceptable level of haemoglobin in the peri-operative period. Wedgwood JJ, et al. **Eur J Anaesthesiol** 1996 Jul;13(4):316–24 (58 ref.)

Surgical risk assessment and management in patients with HIV disease. Harris HW, et al. **Gastroenterol Clin North Am** 1997 Jun;26(2):377–91 (38 ref.)

AIDS, emergency operations, and infection control. Wittmann MM, et al. **Infect Control Hosp Epidemiol** 1996 Aug;17(8):532–8 (23 ref.)

What's new in critical care and metabolism. Bessey PQ. **J Am Coll Surg** 1997 Feb;184(2):115–25 (72 ref.)

The role of the pulmonary circulation in the regulation of coagulation and fibrinolysis in relation to major surgery. Dahl OE. **J Cardiothorac Vasc Anesth** 1997 May; 11(3):322–8 (42 ref.)

Enhancement of perioperative tissue perfusion as a therapeutic strategy for major surgery. Boyd O, et al. **New Horiz** 1996 Nov;4(4):453–65 (59 ref.)

Invasive and noninvasive oxygen consumption and hemodynamic monitoring in elderly surgical patients. Yu M. **New Horiz** 1996 Nov;4(4):443–52 (111 ref.)

Effect of glutamine on immune function in the surgical patient. O'Riordain MG, et al. **Nutrition** 1996 Nov–Dec; 12(11–12 Suppl):S82–4 (14 ref.)

How do geriatric patients recover from surgery? Nusbaum NJ. **South Med J** 1996 Oct;89(10):950–7 (28 ref.)

The addition of antibiotics to fibrin glue. Thompson DF, et al. **South Med J** 1997 Jul;90(7):681–4 (15 ref.)

Hemodilution in clinical surgery: state of the art 1996. Kreimeier U, et al. **World J Surg** 1996 Nov–Dec; 20(9):1208–17 (95 ref.)

[The significance of nutrition for muscular function after surgery] Jensen MB. **Ugeskr Laeger** 1997 Feb 10; 159(7):923–6 (40 ref.) (Eng. Abstr.) **(Dan)**

[Caudal and spinal anesthesia in sub-umbilical surgery in children. Apropos of 1875 cases] Aguemon AR, et al. **Cah Anesthesiol** 1996;44(5):455–63 (22 ref.) (Eng. Abstr.) **(Fre)**

[Quality assurance in surgery—more than documentation of postoperative complications] Grundmann RT. **Zentralbl Chir** 1996;121(3):157–66 (65 ref.) (Eng. Abstr.) **(Ger)**

[Measuring quality of life as an integral component of quality management in surgical medicine] Lorenz W, et al. **Zentralbl Chir** 1996;121(7):545–51 (26 ref.) (Eng. Abstr.) **(Ger)**

[Anesthesia and postoperative management management of patients with Duchenne's dystrophy] Ben Abraham R, et al. **Harefuah** 1996 Nov 15;131(10):435–7 (20 ref.) **(Heb)**

[Cytokine storm in the pathogenesis of multiple organ dysfunction syndrome associated with surgical insults] Aikawa N. **Nippon Geka Gakkai Zasshi** 1996 Sep; 97(9):771–7 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Cytokine-mediated biological response to severe infections in surgical patients] Aikawa N, et al. **Nippon Geka Gakkai Zasshi** 1996 Dec;97(12):1054–9 (36 ref.) (Eng. Abstr.) **(Jpn)**

[The significance of neurological manifestations from the aspect of aggressology] Aruga T. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):733–8 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Cytokines in surgical stress] Endo S, et al. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):708–15 (34 ref.) (Eng. Abstr.) **(Jpn)**

[Acute renal failure following surgical insult] Hirasawa H, et al. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):765–70 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Immune response induced by surgical trauma] Hirota M, et al. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):721–5 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Surgical stress and organ dysfunction: liver] Nakatani T, et al. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):752–8 (47 ref.) (Eng. Abstr.) **(Jpn)**

[Endocrine response to surgical stress] Saito H. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):701–7 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Energy substrate metabolism during stress] Sugimoto H. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):726–32 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Cardiac contractile dysfunction in response to surgical stress including trauma, hemorrhage, and infection] Suzuki K, et al. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):745–51 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Surgical stress and acute lung injury] Takezawa J. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):739–44 (33 ref.) (Eng. Abstr.) **(Jpn)**

[Microcirculatory disturbances after surgical insults—important role of inflammatory cytokines] Wakabayashi G, et al. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):759–64 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Free radicals and surgical stress] Yukioka T, et al. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):716–20 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Hypertension in general anesthesia] Koyama T. **Ryoikibetsu Shokogun Shirizu** 1996;(12):114–7 (20 ref.) **(Jpn)**

[Surgical risk factors: cardiovascular diseases] Kuznetsov NA. **Khirurgiia (Mosk)** 1996;(6):93–8 (49 ref.) **(Rus)**

[Surgical risk factors: age?] Kuznetsov NA. **Khirurgiia (Mosk)** 1996;(5):74–80 (76 ref.) **(Rus)**

ADVERSE EFFECTS

Pharmacological stress testing with technetium-99m single-photon emission computerized tomography imaging in the preoperative assessment of patients undergoing noncardiac surgery [see comments] Heller GV, et al. **Am J Card Imaging** 1996 Apr;10(2):120–7 (45 ref.) Comment in: Am J Card Imaging 1996 Apr;10(2):117–9.

Use of dobutamine stress echocardiography for risk assessment before noncardiac surgery [see comments] Tawam MN, et al. **Am J Card Imaging** 1996 Apr;

10(2):128–32 (49 ref.) Comment in: **Am J Card Imaging** 1996 Apr;10(2):117–9.

Use of adhesion prevention barriers in ovarian surgery, tubalplasty, ectopic pregnancy, endometriosis, adhesiolysis, and myomectomy. diZerega GS.
Curr Opin Obstet Gynecol 1996 Jun;8(3):230–7 (32 ref.)

[Forensic medical implications of vascular injuries in orthopedic surgery] Natali J. **J Mal Vasc** 1996 Nov; 21(4):206–15 (9 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Are you ready for bloodless surgery? Vernon S, et al. **Am J Nurs** 1997 Sep;97(9):40–6; quiz 47 (12 ref.)

Surgical implications of vascular endothelial physiology. Cain BS, et al. **Surgery** 1997 Sep;122(3):516–26 (140 ref.)

Sonographic evaluation of ovarian masses and its therapeutical implications [editorial] Osmers R. **Ultrasound Obstet Gynecol** 1996 Oct;8(4):217–22 (60 ref.)

[Treatment of the patient with a coagulation defect in oral and maxillofacial surgery. III. The management of patients in a hypocoagulative state because of a hemophilic-type primary pathology] Chiarini L, et al. **Minerva Stomatol** 1997 Mar;46(3):115–31 (18 ref.) (Eng. Abstr.) **(Ita)**

MORTALITY

[High-risk surgical patients. Who are they and how should they be treated?] Martin C, et al. **Presse Med** 1996 Oct 19;25(31):1419–24 (58 ref.) (Eng. Abstr.) **(Fre)**

NURSING

Are you ready for bloodless surgery? Vernon S, et al. **Am J Nurs** 1997 Sep;97(9):40–6; quiz 47 (12 ref.)

PSYCHOLOGY

[Limits of geriatric surgery--where are they, can they be defined?] Schreiber HW. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:457–66 (74 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

Multimodal approach to control postoperative pathophysiology and rehabilitation. Kehlet H. **Br J Anaesth** 1997 May;78(5):606–17 (117 ref.)

STANDARDS

Clinical practice guidelines. Hoyt DB. **Am J Surg** 1997 Jan; 173(1):32–4; discussion 35–6 (20 ref.)

Local antibiotic prophylaxis in surgery. Martin C, et al. **Infect Control Hosp Epidemiol** 1996 Aug;17(8):539–44 (64 ref.)

TRENDS

Advanced interventional endoscopy. Vitale GC. **Am J Surg** 1997 Jan;173(1):21–5; discussion 26 (16 ref.)

Recent advances. General surgery. Corvera CU, et al. **BMJ** 1997 Sep 6;315(7108):586–9 (19 ref.)

SURGERY, ORAL

see related
DENTISTRY, OPERATIVE

[The prevention of infection in oral medicine] Vassal S, et al. **Rev Stomatol Chir Maxillofac** 1997 Sep;98(3):216–9 (19 ref.) **(Fre)**

[The treatment of the cardiac patient in dentistry and oromaxillofacial surgery. II. The practical management of patients with hemodynamic pathologies] Chiarini L, et al. **Minerva Stomatol** 1997 Apr;46(4):183–90 (15 ref.) (Eng. Abstr.) **(Ita)**

[The treatment of the cardiac patient in dentistry and oromaxillofacial surgery. I. The practical management of patients with arrhythmias] Chiarini L, et al. **Minerva Stomatol** 1997 Apr;46(4):175–82 (11 ref.) (Eng. Abstr.) **(Ita)**

INSTRUMENTATION

Use of the laryngeal mask airway in oral and maxillofacial surgery. Bennett J, et al. **J Oral Maxillofac Surg** 1996 Nov; 54(11):1346–51 (38 ref.)

METHODS

[Treatment of the patient with a coagulation defect in oral and maxillofacial surgery. III. The management of patients in a hypocoagulative state because of a hemophilic-type primary pathology] Chiarini L, et al. **Minerva Stomatol** 1997 Mar;46(3):115–31 (18 ref.) (Eng. Abstr.) **(Ita)**

SURGERY, ORTHOPEDIC see **ORTHOPEDICS**

SURGERY, OUTPATIENT see **AMBULATORY SURGERY**

SURGERY, PLASTIC

The aging upper and middle face: an overview for the aesthetic surgeon. Heinz GW, et al. **Int Ophthalmol Clin** 1997 Summer;37(3):1–10 (8 ref.)

Oculoplastic surgery in patients receiving warfarin: suggestions for management. Bartley GB. **Ophthal Plast Reconstr Surg** 1996 Dec;12(4):229–30 (5 ref.)

Post-burn reconstruction during growth and development. Germann G, et al. **Pediatr Surg Int** 1997 Jul;12(5–6):321–6 (22 ref.)

Lasers in plastic surgery: current practice. Achauer BM. **Plast Reconstr Surg** 1997 Apr;99(5):1442–50 (43 ref.)

The role of plastic surgery in the treatment of malignant melanoma. Eshima I. **Surg Clin North Am** 1996 Dec; 76(6):1331–42 (37 ref.)

Cranioplasty: cosmetic or therapeutic? Dujovny M, et al. **Surg Neurol** 1997 Mar;47(3):238–41 (23 ref.)

[Plastic surgery in the treatment of the outcome of intestinal bypass for obesity: a clinical case report] Bernardi C, et al. **G Chir** 1996 Nov–Dec;17(11–12):602–6 (15 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

Avoiding pitfalls and managing complications of aesthetic contouring of the craniofacial skeleton. Bucky LP, et al. **Clin Plast Surg** 1997 Jul;24(3):613–22 (18 ref.)

Secondary cleft deformities. Folk SN, et al. **Clin Plast Surg** 1997 Jul;24(3):599–611 (32 ref.)

Problems following genioplasty. Diagnosis and treatment. Guyuron B, et al. **Clin Plast Surg** 1997 Jul;24(3):507–14 (4 ref.)

Secondary deformities following mandibular reconstruction. Miller MJ, et al. **Clin Plast Surg** 1997 Jul;24(3):551–63 (14 ref.)

Adverse outcomes in orthognathic surgery and management of residual problems. Schendel SA, et al. **Clin Plast Surg** 1997 Jul;24(3):489–505 (63 ref.)

Management of complications of blepharoplasty. Lyon DB, et al. **Int Ophthalmol Clin** 1997 Summer;37(3):205–16 (20 ref.)

METHODS

Clinical use of leeches in reconstructive surgery. Daane S, et al. **Am J Orthop** 1997 Aug;26(8):528–32 (36 ref.)

Neovaginoplasty in male transsexuals: review of surgical techniques and recommendations regarding eligibility. Karim RB, et al. **Ann Plast Surg** 1996 Dec;37(6):669–75 (60 ref.)

Tessier 30 median mandibular cleft: case report and literature review. Armstrong AP, et al. **Br J Plast Surg** 1996 Dec; 49(8):536–8 (11 ref.)

Pneumosinus dilatans of the maxillary sinus: a report of two cases. Breidahl AF, et al. **Br J Plast Surg** 1997 Jan; 50(1):33–9 (22 ref.)

Principles of reconstruction following excision of nonmelanoma skin cancer. Fazio MJ, et al. **Clin Dermatol** 1995 Nov–Dec;13(6):601–16 (29 ref.)

Secondary management of congenital and acquired craniomaxillofacial deformities. Individualized treatment planning. Cohen SR, et al. **Clin Plast Surg** 1997 Jul; 24(3):475–88 (13 ref.)

Strategies for the treatment of enophthalmos. Grant MP, et al. **Clin Plast Surg** 1997 Jul;24(3):539–50 (17 ref.)

Enophthalmos revisited. Longaker MT, et al. **Clin Plast Surg** 1997 Jul;24(3):531–7 (11 ref.)

Craniofacial microsomia. A primary or secondary surgical treatment program. McCarthy JG. **Clin Plast Surg** 1997 Jul;24(3):459–74 (16 ref.)

The craniofacial dysostosis syndromes. Staging of reconstruction and management of secondary deformities. Posnick JC. **Clin Plast Surg** 1997 Jul;24(3):429–46 (43 ref.)

Secondary craniofacial management following initial correction of nonsyndromic craniosynostosis. Shin JH, et al. **Clin Plast Surg** 1997 Jul;24(3):415–28 (26 ref.)

Aesthetic skin resurfacing with the high-energy ultrapulsed CO2 laser. Weinstein C, et al. **Clin Plast Surg** 1997 Apr; 24(2):379–405 (157 ref.)

Lip augmentation with preserved fascia lata. Burres SA. **Dermatol Surg** 1997 Jun;23(6):459–62 (13 ref.)

Eyebrow ptosis. Green JP, et al. **Int Ophthalmol Clin** 1997 Summer;37(3):97–122 (30 ref.)

The suborbicularis oculi fat in aesthetic and reconstructive surgery. Hoenig JA, et al. **Int Ophthalmol Clin** 1997 Summer;37(3):179–91 (20 ref.)

Asian blepharoplasty. Kikkawa DO, et al. **Int Ophthalmol Clin** 1997 Summer;37(3):193–204 (27 ref.)

Lower-eyelid blepharoplasty. Kikkawa DO, et al. **Int Ophthalmol Clin** 1997 Summer;37(3):163–78 (40 ref.)

The aponeurotic approach for the correction of blepharoptosis. Shovlin JP. **Int Ophthalmol Clin** 1997 Summer;37(3):133–50 (30 ref.)

Upper-eyelid blepharoplasty. Stephenson CB. **Int Ophthalmol Clin** 1997 Summer;37(3):123–32 (17 ref.)

What's new in plastic surgery. Phillips LG. **J Am Coll Surg** 1997 Feb;184(2):187–95 (91 ref.)

Cartilage-sparing otoplasty: a review with long-term results. Vuyk HD. **J Laryngol Otol** 1997 May;111(5):424–30 (30 ref.)

Surgery and laser therapy. Lawrence CM. **J R Coll Physicians Lond** 1997 Jul–Aug;31(4):369–73 (25 ref.)

Concepts in orbital reconstruction. Howard G, et al. **Otolaryngol Clin North Am** 1997 Aug;30(4):541–62 (44 ref.)

Concepts in midface reconstruction. Tatum SA. **Otolaryngol Clin North Am** 1997 Aug;30(4):563–92 (48 ref.)

Chest wall reconstruction. Arnold PG, et al. **Surg Oncol Clin N Am** 1997 Jan;6(1):91–114 (14 ref.)

Reconstruction of the abdomen and perineum in cancer surgery. Fix RJ, et al. **Surg Oncol Clin N Am** 1997 Jan; 6(1):115–32 (11 ref.)

Reconstruction of the perineum after tumor surgery. McCraw JB, et al. **Surg Oncol Clin N Am** 1997 Jan; 6(1):177–89 (17 ref.)

Reconstruction of the orbit. Spinelli HM, et al. **Surg Oncol Clin N Am** 1997 Jan;6(1):45–69 (68 ref.)

Reconstruction following resection of malignancies of the upper extremity. Upton J, et al. **Surg Oncol Clin N Am** 1996 Oct;5(4):847–92 (99 ref.)

Reconstruction of the lower extremity after ablative resection for cancer. Walton RL, et al. **Surg Oncol Clin N Am** 1997 Jan;6(1):133–76 (102 ref.)

[Techniques of total reconstruction of the pinna] Boudard P. **Rev Laryngol Otol Rhinol (Bord)** 1997;118(1):17–23 (21 ref.) (Eng. Abstr.) **(Fre)**

[Inferior blepharoplasty: the transconjunctival approach] Mahé E. **Rev Laryngol Otol Rhinol (Bord)** 1997; 118(1):47–52 (16 ref.) (Eng. Abstr.) **(Fre)**

[Surgical treatment of lipodystrophies] De Mey A. **Rev Med Brux** 1996 Sep;17(4):240–3 (17 ref.) (Eng. Abstr.) **(Fre)**

ORGANIZATION & ADMINISTRATION

Managed care in reconstructive pelvic surgery and urogynecology. Strohbehn K. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):319–24 (27 ref.)

PSYCHOLOGY

Dysmorphophobia: recent developments of interest to the maxillofacial surgeon. Cunningham SJ, et al. **Br J Oral Maxillofac Surg** 1996 Oct;34(5):368–74 (26 ref.)

TRENDS

Future prospects for reconstructive surgery in breast cancer. Gabka CJ, et al. **Semin Surg Oncol** 1996 Jan–Feb; 12(1):67–75 (24 ref.)

SURGERY, REPEAT see **REOPERATION**

SURGERY, UNNECESSARY see **UNNECESSARY PROCEDURES**

SURGERY, VETERINARY

METHODS

Medical care of the neurosurgical patient. Longshore RC, et al. **Semin Vet Med Surg (Small Anim)** 1996 Nov; 11(4):208–17 (36 ref.)

Instrumentation and techniques in equine fracture fixation. Auer JA, et al. **Vet Clin North Am Equine Pract** 1996 Aug; 12(2):283–302 (40 ref.)

Instrumentation and techniques for treating orthopedic infections in horses. Baxter GM. **Vet Clin North Am Equine Pract** 1996 Aug;12(2):303–35 (70 ref.)

Instrumentation and techniques for laparoscopic and thoracoscopic surgery in the horse. Hendrickson DA, et al. **Vet Clin North Am Equine Pract** 1996 Aug;12(2):235–59 (27 ref.)

Instrumentation and techniques for carbon dioxide lasers in equine general surgery. Palmer SE. **Vet Clin North Am Equine Pract** 1996 Aug;12(2):397–414 (14 ref.)

Instrumentation and techniques in respiratory surgery. Stick JA. **Vet Clin North Am Equine Pract** 1996 Aug;12(2):351–72 (31 ref.)

Instrumentation and techniques in transendoscopic upper respiratory tract laser surgery. Tulleners E. **Vet Clin North Am Equine Pract** 1996 Aug;12(2):373–95 (19 ref.)

TRENDS

Instrumentation and techniques in equine gastrointestinal surgery. Mueller PO, et al. **Vet Clin North Am Equine Pract** 1996 Aug;12(2):207–33 (72 ref.)

Advances in equine arthroscopy. Trotter GW, et al. **Vet Clin North Am Equine Pract** 1996 Aug;12(2):261–81 (34 ref.)

SURGICAL ANASTOMOSIS see **ANASTOMOSIS, SURGICAL**

SURGICAL BLOOD LOSS see **BLOOD LOSS, SURGICAL**

SURGICAL DIATHERMY see **ELECTROCOAGULATION**

SURGICAL EQUIPMENT

Review of shape memory alloys medical applications in Russia. Brailovski V, et al. **Biomed Mater Eng** 1996; 6(4):291–8 (25 ref.)

The utility of superelasticity in medicine. Duerig TW, et al. **Biomed Mater Eng** 1996;6(4):255–66 (4 ref.)

On the nature of the biocompatibility and on medical applications of NiTi shape memory and superelastic alloys. Shabalovskaya SA. **Biomed Mater Eng** 1996;6(4):267–89 (39

ref.)
Technical considerations in powered instrumentation. Becker DG. **Otolaryngol Clin North Am** 1997 Jun;30(3):421–34 (15 ref.)
Powered instrumentation in orbital and optic nerve decompression. Chow JM, et al.
Otolaryngol Clin North Am 1997 Jun;30(3):467–78 (24 ref.)
Advanced drill technology in treatment of congenital choanal atresia. Vickery CL, et al. **Otolaryngol Clin North Am** 1997 Jun;30(3):457–65 (25 ref.)
[New developments in surgery of the injured spine] Blauth M, et al. **Orthopade** 1997 May;26(5):437–49 (49 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Surgical materials and wound closure techniques. Kawcak CE, et al. **Vet Clin North Am Equine Pract** 1996 Aug; 12(2):195–205 (44 ref.)

SURGICAL ERRORS see **MEDICAL ERRORS**

SURGICAL FLAPS

Mandibular reconstruction by vascularized free tissue transfer. Genden E, et al. **Am J Otolaryngol** 1996 Jul–Aug; 17(4):219–27 (50 ref.)
The superficial brachial flap. Iwahira Y, et al.
Ann Plast Surg 1996 Jul;37(1):48–54 (8 ref.)
Treatment of thromboembolic complications of fulminant meningococcal septic shock. Mele JA 3rd, et al.
Ann Plast Surg 1997 Mar;38(3):283–90 (29 ref.)
Chest wall resection and reconstruction. Sabanathan S, et al. **Br J Hosp Med** 1997 Mar 19–Apr 1;57(6):255–9 (21 ref.)
Thumb reconstruction. Brunelli GA, et al.
Bull Hosp Jt Dis 1996;54(4):245–8 (21 ref.)
Free flap coverage of the hand. Brown DM, et al.
Clin Plast Surg 1997 Jan;24(1):57–62 (22 ref.)
New reconstructive procedure for brachial plexus injury. Doi K. **Clin Plast Surg** 1997 Jan;24(1):75–85 (17 ref.)
Anatomy of upper extremity skin flaps. Birkbeck DP, et al. **Hand Clin** 1997 May;13(2):175–87 (71 ref.)
Treatment of chronic pain by "wrapping" intact nerves with pedicle and free flaps. Jones NF. **Hand Clin** 1996 Nov; 12(4):765–72 (23 ref.)
Oral rehabilitation with endosteal implants and free flaps. Hayter JP, et al. **Int J Oral Maxillofac Surg** 1996 Feb; 25(1):3–12 (59 ref.)
Resuturing the scleral flap leads to resolution of hypotony maculopathy. Schwartz GF, et al. **J Glaucoma** 1996 Aug; 5(4):246–51 (50 ref.)
Anteriorly based palatal flap for closure of large oroantral fistula. Salins PC, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Sep;82(3):253–6 (11 ref.)
[Treatment of cutaneous loss of substance of the dorsal surface of the proximal interphalangeal joints of fingers. A general review] Dap F, et al. **Ann Chir Plast Esthet** 1996 Jun;41(3):240–50 (27 ref.) (Eng. Abstr.) **(Fre)**
[Infrahyoid musculocutaneous flaps: anatomical bases and indications in cervicofacial oncologic surgery] Faucher A, et al. **Rev Laryngol Otol Rhinol (Bord)** 1997;118(1):43–6 (7 ref.) (Eng. Abstr.) **(Fre)**
[Plastic soft tissue coverage in defect fractures of the tibia] Steinau HU, et al. **Chirurg** 1996 Nov;67(11):1080–6 (30 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Clinical use of leeches in reconstructive surgery. Daane S, et al. **Am J Orthop** 1997 Aug;26(8):528–32 (36 ref.)

METHODS

The role of pedicled or free fibular grafts in knee arthrodesis. Hallock GG. **Ann Plast Surg** 1997 Jul;39(1):60–3 (14 ref.)
A case of double fingernail and ectopic fingernail. Muraoka M, et al. **Ann Plast Surg** 1996 Feb;36(2):201–5 (17 ref.)
The lower trapezius island myocutaneous flap for reconstruction of soft tissue of the lateral skullbase and neck. Cole I. **Aust N Z J Surg** 1997 Jul;67(7):452–6 (21 ref.)
L-shaped scalp flap for moustache reconstruction in a patient with an acid burn of the face. Kumar P. **Burns** 1996 Aug; 22(5):413–6 (4 ref.)
Intrathoracic muscle transposition. Surgical anatomy and techniques of harvest. Harris SU, et al.
Chest Surg Clin N Am 1996 Aug;6(3):501–18 (11 ref.)
Operative repair of pressure ulcers. Niazi ZB, et al.
Clin Geriatr Med 1997 Aug;13(3):587–97 (35 ref.)
Digital reconstruction with island flaps. Foucher G, et al.
Clin Plast Surg 1997 Jan;24(1):1–32 (80 ref.)
Microvascular reconstruction of the distal digits by partial toe transfer. el-Gammal TA, et al. **Clin Plast Surg** 1997 Jan;24(1):49–55 (36 ref.)
Reconstruction of the hand with forearm island flaps. Martin D, et al. **Clin Plast Surg** 1997 Jan;24(1):33–48 (27 ref.)
Secondary craniofacial management following skeletal correction in facial asymmetry. Application of microsurgical techniques. Siebert JW, et al.
Clin Plast Surg 1997 Jul;24(3):447–58 (26 ref.)
Lower eyelid reconstruction using pedicled skin flap and palatal mucoperiosteum. Perry MJ, et al. **Dermatol Surg** 1997 May;23(5):395–7; discussion 397–8 (10 ref.)
Distally based flaps for skin coverage of the foot and ankle. Hallock GG. **Foot Ankle Int** 1996 Jun;17(6):343–8 (25 ref.)
Use of the omental J-flap for prevention of postoperative complications following radical abdominal hysterectomy: report of 140 cases and literature review. Patsner B, et al. **Gynecol Oncol** 1997 Jun;65(3):405–7 (16 ref.)
Complex injuries of the forearm. Coverage considerations. Bray PW, et al. **Hand Clin** 1997 May;13(2):263–78 (90 ref.)
Soft-tissue defects of the digits. Coverage considerations. Goitz RJ, et al. **Hand Clin** 1997 May;13(2):189–205 (50 ref.)
Neurosensory free flaps. Digits and hand. Halbert CF, et al. **Hand Clin** 1997 May;13(2):251–62 (58 ref.)
Neurovascular pedicle and advancement flaps for palmar thumb defects. Hynes DE. **Hand Clin** 1997 May; 13(2):207–16 (40 ref.)
Pedicle flaps for coverage of the wrist and hand. Mih AD. **Hand Clin** 1997 May;13(2):217–29 (46 ref.)
Soft-tissue coverage for the elbow. Sherman R.
Hand Clin 1997 May;13(2):291–302 (20 ref.)
Composite free flaps to the hand. Wood MB. **Hand Clin** 1997 May;13(2):231–8 (26 ref.)
Salvaging the "unsalvageable" digit. Zachary SV, et al.
Hand Clin 1997 May;13(2):239–49 (59 ref.)
Free gastro-omental flap reconstruction of the complex, irradiated pharyngeal wound. Carlson GW, et al.
Head Neck 1997 Jan;19(1):68–71 (11 ref.)
Preservation of the larynx after resection of a carcinoma of the posterior wall of the hypopharynx: versatility of a free flap patch graft. Nakatsuka T, et al. **Head Neck** 1997 Mar; 19(2):137–42 (18 ref.)
Free tissue transplantation in the 90's. Yim KK, et al.
Int Angiol 1995 Sep;14(3):327–31 (36 ref.)
Use of the expanded skin flap in esthetic reconstruction of postburn deformity. Yamamoto Y, et al.
J Burn Care Rehabil 1996 Sep–Oct;17(5):397–401 (19 ref.)
Subaponeurotic connective tissue: a safe way to reconstruct facial and oropharyngeal defects. Ristić J, et al.
J Craniomaxillofac Surg 1996 Oct;24(5):276–80 (6 ref.)
Laplace's law and the risks and prevention of bladder rupture after enterocystoplasty and bladder autoaugmentation. Chancellor MB, et al. **Neurourol Urodyn** 1996;15(3):223–33 (19 ref.)
Current concepts in oromandibular reconstruction. Burkey BB, et al. **Otolaryngol Clin North Am** 1997 Aug; 30(4):607–30 (47 ref.)
Conceptual considerations in head & neck reconstruction. Defect analysis and options for reconstruction. Clevens RA, et al. **Otolaryngol Clin North Am** 1997 Aug; 30(4):495–517 (17 ref.)
Concepts in pharyngoesophageal reconstruction. Haller JR. **Otolaryngol Clin North Am** 1997 Aug;30(4):655–61 (14 ref.)
Concepts in lip reconstruction. Hamilton MM, et al.
Otolaryngol Clin North Am 1997 Aug;30(4):593–606 (10 ref.)
Concepts in neck reconstruction. Shindo ML.
Otolaryngol Clin North Am 1997 Aug;30(4):647–53 (14 ref.)
Concepts in scalp and forehead reconstruction. TerKonda RP, et al. **Otolaryngol Clin North Am** 1997 Aug; 30(4):519–39 (23 ref.)
The distally based medial gastrocnemius flap: case report and anatomic study. Atchabahian A, et al.
Plast Reconstr Surg 1996 Dec;98(7):1253–7 (10 ref.)
Reconstructive surgery in melanoma patients. Ariyan S.
Surg Oncol Clin N Am 1996 Oct;5(4):785–807 (09 ref.)
Reconstruction of the head and neck. Ariyan S, et al.
Surg Oncol Clin N Am 1997 Jan;6(1):1–43 (67 ref.)
Oncologic and reconstructive considerations in nonmelanotic skin and lip cancers. Luce EA, et al.
Surg Oncol Clin N Am 1996 Oct;5(4):751–84 (60 ref.)
Soft-tissue reconstruction following extravasation of chemotherapeutic agents. Shenaq SM, et al.
Surg Oncol Clin N Am 1996 Oct;5(4):825–45 (35 ref.)
[Radical surgical treatment of Peironie disease by excision of the plaque and dermal graft allowing conservation of erection] Austoni E, et al. **Ann Urol (Paris)** 1996; 30(4):204–12 (19 ref.) (Eng. Abstr.) **(Fre)**
[The Martius flap in vaginal surgery: technic and indications] Chassagne S, et al. **Prog Urol** 1997 Feb;7(1):120–5 (17 ref.) (Eng. Abstr.) **(Fre)**
[Plastic surgery concepts for coverage of extremity defects within the scope of general surgery] Erdmann D, et al. **Chirurg** 1997 May;68(5):454–60 (32 ref.) (Eng. Abstr.) **(Ger)**
[Plastic surgery defect coverage in the area of the pelvis and trunk] Germann G, et al. **Chirurg** 1997 May; 68(5):469–76 (26 ref.) (Eng. Abstr.) **(Ger)**
[Dynamic and functional abdominal wall stabilization, reconstruction of extensive abdominal wall defects] Harpf C, et al. **Chirurg** 1997 May;68(5):488–92 (10 ref.) (Eng. Abstr.) **(Ger)**
[Perforation of the cervical esophagus after ventral fusion of the cervical spine. Defect coverage by muscle-plasty with the sternocleidomastoid muscle: case report and review of the literature] Lamesch P, et al. **Chirurg** 1997 May;68(5):543–7 (30 ref.) (Eng. Abstr.) **(Ger)**
[Reconstructive plastic surgery of thoracic wall defects] Steinau HU, et al. **Chirurg** 1997 May;68(5):461–8 (23 ref.) (Eng. Abstr.) **(Ger)**
[New developments in covering post-traumatic soft tissue defects] Berger A, et al. **Orthopade** 1997 May;26(5):470–80 (34 ref.) (Eng. Abstr.) **(Ger)**
[Covering soft tissue defects] Kinzl L, et al. **Unfallchirurg** 1996 Oct;99(10):714–26 (29 ref.) (Eng. Abstr.) **(Ger)**
[Utilization of forearm island flaps in reconstructive surgery of the hand. Which one is the best option?] Amarante J, et al. **Acta Med Port** 1996 Jul–Sep;9(7–9):211–8 (59 ref.) (Eng. Abstr.) **(Por)**

PHYSIOLOGY

Approaches to postoperative blood flow monitoring after free tissue transfer. Which is the best? Berger A, et al.
Int Angiol 1995 Sep;14(3):288–96 (92 ref.)

REHABILITATION

Physical therapy implications following the TRAM procedure. Monteiro M. **Phys Ther** 1997 Jul;77(7):765–70 (20 ref.)

SURGICAL GLOVES see **GLOVES, SURGICAL**

SURGICAL INJURIES see **INTRAOPERATIVE COMPLICATIONS**

SURGICAL INSTRUMENTS

[Reuse of disposable equipment. Medicolegal viewpoint] Fallani M, et al. **Minerva Cardioangiol** 1996 May; 44(5):263–73 (40 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

Laparoscopic closure for perforation of the sigmoid colon by endoscopic linear stapler. Hayashi K, et al.
Surg Laparosc Endosc 1996 Oct;6(5):411–3 (13 ref.)

STANDARDS

Instrument sterilization, skin preparation, and wound management. Southwood LL, et al.
Vet Clin North Am Equine Pract 1996 Aug;12(2):173–94 (79 ref.)

VETERINARY

Instrumentation and techniques for laparoscopic and thoracoscopic surgery in the horse. Hendrickson DA, et al. **Vet Clin North Am Equine Pract** 1996 Aug;12(2):235–59 (27 ref.)
Instrumentation and techniques in equine gastrointestinal surgery. Mueller PO, et al.
Vet Clin North Am Equine Pract 1996 Aug;12(2):207–33 (72 ref.)
Instrumentation and techniques for carbon dioxide lasers in equine general surgery. Palmer SE.
Vet Clin North Am Equine Pract 1996 Aug;12(2):397–414 (14 ref.)
Instrumentation and techniques in respiratory surgery. Stick JA. **Vet Clin North Am Equine Pract** 1996 Aug;12(2):351–72 (31 ref.)
Instrumentation and techniques in transendoscopic upper respiratory tract laser surgery. Tulleners E.
Vet Clin North Am Equine Pract 1996 Aug;12(2):373–95 (19 ref.)

SURGICAL MESH

Mechanisms of hernia recurrence after preperitoneal mesh repair. Traditional and laparoscopic. Lowham AS, et al. **Ann Surg** 1997 Apr;225(4):422–31 (49 ref.)
The use of mesh in gynecologic surgery. Iglesia CB, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1997;8(2):105–15 (76 ref.)
Laparoscopic transabdominal preperitoneal hernioplasty: results of 1000 consecutive cases. Birth M, et al.
J Laparoendosc Surg 1996 Oct;6(5):293–300 (52 ref.)
[Repair of inguinal hernias without tension and without suture using a large dacron mesh prosthesis and by pre-peritoneal approach. A method of reference for selective indication] Stoppa R, et al. **Ann Chir** 1996; 50(9):808–13 (20 ref.) (Eng. Abstr.) **(Fre)**
[Inguinal hernia--which method leads to the goal? Endoscopic and open surgical procedures are available] Waninger J. **Fortschr Med** 1997 Mar 20;115(8):26, 29–32 (31 ref.) (Eng. Abstr.) **(Ger)**

SURGICAL NURSING see **PERIOPERATIVE NURSING**

SURGICAL REPLANTATION see **REPLANTATION**

SURGICAL REVISION see **REOPERATION**

SURGICAL STAPLERS

Oesophagogastrectomy with an anastomosis using linear staplers. Bird P, et al. **Aust N Z J Surg** 1996 Nov; 66(11):757–63 (17 ref.)
Surgical staplers: a review. McGuire J, et al.
J R Coll Surg Edinb 1997 Feb;42(1):1–9 (50 ref.)

SURGICAL STAPLING

[The use of the mechanical suture in surgery on the stomach and intestines] Mel'nik VM, et al. **Klin Khir** 1996;(9):37–40 (65 ref.) **(Rus)**

METHODS

Morbidity and mortality after single- and double-stapled colorectal anastomoses in patients with carcinoma of the rectum. Moore JW, et al. **Aust N Z J Surg** 1996 Dec; 66(12):820–3 (22 ref.)

Stapled anastomoses in colorectal surgery: a prospective study. Memon AA, et al. **Eur J Surg** 1996 Oct; 162(10):805–10 (40 ref.)

Stapler technique for extrahepatic vascular control during hepatic resection. Scudamore CH, et al. **J Invest Surg** 1997 Jan–Apr;10(1–2):59–61 (7 ref.)

SURGICAL WOUND DEHISCENCE

Acute wound failure. Carlson MA. **Surg Clin North Am** 1997 Jun;77(3):607–36 (200 ref.)

DRUG THERAPY

[Clinical evaluation of factor XIII for postoperative stomal leakage and fistulae after gastrointestinal surgery] Ishibiki K. **Rinsho Byori** 1997 Feb;Suppl 104:17–24 (7 ref.) **(Jpn)**

ETIOLOGY

Hernias in trocar ports following abdominal laparoscopy. A review. Lajer H, et al. **Acta Obstet Gynecol Scand** 1997 May;76(5):389–93 (33 ref.)

Recurrent aortic valve prosthesis dehiscence secondary to aortoarteritis: three case reports and literature review. Chau EM, et al. **Int J Cardiol** 1996 Oct 11;56(2):113–8 (12 ref.)

[Wound rupture—incisional hernia] Hohlbach G, et al. **Zentralbl Chir** 1997;122(3):190–2 (22 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

[Perioperative standards for prevention of anastomotic insufficiency] Waldner H, et al. **Zentralbl Chir** 1997; 122(1):25–8 (25 ref.) (Eng. Abstr.) **(Ger)**

[Concepts for recognition and securing anastomotic wound dehiscence of the gastrointestinal tract] Zirngibl H, et al. **Zentralbl Chir** 1997;122(1):20–4 (21 ref.) (Eng. Abstr.) **(Ger)**

[The techniques to protect the anastomotic leakage of esophagogastrostomy at the neck] Watanabe H. **Nippon Geka Gakkai Zasshi** 1996 Jun;97(6):432–6 (3 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

[Surgical management of leak in an esophageal anastomosis] Uchida Y, et al. **Nippon Geka Gakkai Zasshi** 1996 Jun; 97(6):449–54 (14 ref.) (Eng. Abstr.) **(Jpn)**

SURGICAL WOUND INFECTION

Epidemiology, diagnosis, and therapy of fungal infections in surgery. Giamarellou H, et al. **Infect Control Hosp Epidemiol** 1996 Aug;17(8):558–64 (64 ref.)

[Postoperative suppurative complications in intracranial interventions] Nurzhikov SR, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1996 Apr–Jun; (2):28–30 (74 ref.) **(Rus)**

DIAGNOSIS

Mycobacterium smegmatis infection in a healthy woman following a facelift: case report and review of the literature. Pennekamp A, et al. **Ann Plast Surg** 1997 Jul;39(1):80–3 (12 ref.)

[Soft tissue infection] Schneider U, et al. **Unfallchirurg** 1997 Feb;100(2):146–53 (8 ref.) **(Ger)**

DRUG THERAPY

Antibiotic-impregnated cement and beads for orthopedic infections. Wininger DA, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2675–9 (49 ref.)

Duration of Antibiotic Treatment in Surgical Infections of the Abdomen. Discussion forum for attaining consensus. **Eur J Surg Suppl** 1996;(576):1–75 (184 ref.)

Partial Achilles tendon ruptures associated with fluoroquinolone antibiotics: a case report and literature review. McGarvey WC, et al. **Foot Ankle Int** 1996 Aug; 17(8):496–8 (25 ref.)

Cefotaxime in the treatment of prophylaxis of surgical infections. Wittmann DH, et al. **J Chemother** 1997 May;9 Suppl 2:19–33 (70 ref.)

[Adjuvant therapy of peritonitis with taurolidine. Modulation of mediator liberation] Staubach KH. **Langenbecks Arch Chir** 1997;382(4 Suppl 1):S26–30 (17 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Surgical infection: current concerns. Taylor EW. **Eur J Surg Suppl** 1997;(578):5–9 (33 ref.)

[Rate of infection in trauma surgery. An overview based on recent German language literature] Hansis M, et al. **Unfallchirurg** 1997 Jun;100(6):457–64 (78 ref.) (Eng. Abstr.) **(Ger)**

[Current problems in the epidemiology and prevention of postoperative infections] Ianov IuK, et al. **Vestn Khir Im I I Grek** 1997;156(3):106–9 (38 ref.) **(Rus)**

ETIOLOGY

Fatal fungemia resulting from an infected transjugular intrahepatic portosystemic shunt stent. Schiano TD, et al. **Am J Gastroenterol** 1997 Apr;92(4):709–10 (9 ref.)

Peritoneal and pleural infection following placement of an internal biliary stent for a large bile leak. Weiss K, et al. **Am J Gastroenterol** 1997 Feb;92(2):347–8 (9 ref.)

Infection after open reduction and internal fixation with dynamic compression plates—clinical and experimental data. Arens S, et al. **Injury** 1996;27 Suppl 3:SC27–33 (29 ref.)

The influence of the chemical composition and surface of the implant on infection. Cordero J, et al. **Injury** 1996;27 Suppl 3:SC34–7 (28 ref.)

Pathophysiology of infection—a theoretical approach. Hansis M. **Injury** 1996;27 Suppl 3:SC5–8 (22 ref.)

Relevance, pathogenicity and virulence of microorganisms in implant related infections. Printzen G. **Injury** 1996;27 Suppl 3:SC9–15 (37 ref.)

Implantable materials and infection. Williams DF. **Injury** 1996;27 Suppl 3:SC1–4 (9 ref.)

Wound complications in total knee arthroplasty. Dennis DA. **Instr Course Lect** 1997;46:165–9 (69 ref.)

Shunt infections in children: presentation and management. Williams DG, et al. **J Neurosci Nurs** 1996 Jun;28(3):155–62 (18 ref.)

Toxic shock syndrome after explantation of breast implants: a case report and review of the literature. Walker LE, et al. **Plast Reconstr Surg** 1997 Mar;99(3):875–9 (19 ref.)

[Risk factors of surgical wound infection] Bay-Nielsen M. **Ugeskr Laeger** 1996 Oct 7;158(41):5749–53 (40 ref.) (Eng. Abstr.) **(Dan)**

[Infectious complications of cardioverter/defibrillators—case report and review of the literature] Hollenstein U, et al. **Acta Med Austriaca** 1996;23(5):164–7 (20 ref.) (Eng. Abstr.) **(Ger)**

[Nosocomial infections in head and neck surgery. 1] Vössing M, et al. **HNO** 1996 Feb;44(2):61–7 (58 ref.) (Eng. Abstr.) **(Ger)**

[The role of Pseudomonas aeruginosa and Proteus in the etiology of suppurative surgical infection] Nazarchuk LV. **Lik Sprava** 1996 Oct–Dec;(10–12):31–5 (22 ref.) **(Rus)**

[Risk factors for the occurrence of postoperative suppurative-septic complications in abdominal surgery] Ohonovs'kyĭ VK. **Klin Khir** 1995;(1):33–5 (44 ref.) **(Ukr)**

MICROBIOLOGY

Mycobacterium fortuitum infection of the sternum. Review of the literature and case illustration. Samuels LE, et al. **Arch Surg** 1996 Dec;131(12):1344–6 (7 ref.)

Tubercular sternal osteomyelitis and mediastinitis after open heart surgery. Aggarwal B, et al. **Indian Heart J** 1997 May–Jun;49(3):313–4 (4 ref.)

Sternotomy infection with Mycoplasma hominis: a cause of "culture negative" wound infection. Mossad SB, et al. **J Cardiovasc Surg (Torino)** 1996 Oct;37(5):505–9 (29 ref.)

Wound infection. A failure of wound healing caused by an imbalance of bacteria. Robson MC. **Surg Clin North Am** 1997 Jun;77(3):637–50 (44 ref.)

[Importance of mycoses in intra-abdominal infections] Blinzler L, et al. **Langenbecks Arch Chir** 1997;382(4 Suppl 1):S5–8 (16 ref.) (Eng. Abstr.) **(Ger)**

[Intraabdominal polymicrobial infection due to antimicrobial resistant anaerobes] Watanabe K, et al. **Nippon Geka Gakkai Zasshi** 1996 Dec;97(12):1036–41 (7 ref.) (Eng. Abstr.) **(Jpn)**

NURSING

Shunt infections in children: presentation and management. Williams DG, et al. **J Neurosci Nurs** 1996 Jun;28(3):155–62 (18 ref.)

PREVENTION & CONTROL

Surveillance of surgical site infections in alternative settings: exploring the current options. Manian FA. **Am J Infect Control** 1997 Apr;25(2):102–5 (20 ref.)

Timing of perioperative antibiotic administration [see comments] Butts JD, et al. **AORN J** 1997 Jan;65(1):109–15 (22 ref.) Comment in: AORN J 1997 May;65(5):888.

Applications of local antibiotic therapy. Rushton N. **Eur J Surg Suppl** 1997;(578):27–30 (19 ref.)

Pharmacotherapy—the facts and fantasies of prophylaxis and combined therapies. Scaglione F. **Eur J Surg Suppl** 1997; (578):11–5 (20 ref.)

Local treatment of bone and soft tissue infections with the collagen-gentamicin sponge. Stemberger A, et al. **Eur J Surg Suppl** 1997;(578):17–26 (80 ref.)

Surgical infection: current concerns. Taylor EW. **Eur J Surg Suppl** 1997;(578):5–9 (33 ref.)

The challenge of postoperative infections: does the surgeon make a difference? Holzheimer RG, et al. **Infect Control Hosp Epidemiol** 1997 Jun;18(6):449–56 (97 ref.)

Local antibiotic prophylaxis in surgery. Martin C, et al. **Infect Control Hosp Epidemiol** 1996 Aug;17(8):539–44 (64 ref.)

Wound complications in total knee arthroplasty. Dennis DA. **Instr Course Lect** 1997;46:165–9 (69 ref.)

Cefotaxime in the treatment of prophylaxis of surgical infections. Wittmann DH, et al. **J Chemother** 1997 May;9 Suppl 2:19–33 (70 ref.)

Psoriasis and elective foot surgery [see comments] Cheleuitte E, et al. **J Foot Ankle Surg** 1996 Jul–Aug;35(4):297–302; discussion 371 (25 ref.) Comment in: J Foot Ankle Surg 1997 Jan–Feb;36(1):77–8.

Antibiotic prophylaxis and tourniquet application in podiatric surgery. Deacon JS, et al. **J Foot Ankle Surg** 1996 Jul–Aug; 35(4):344–9 (31 ref.)

Continuing search for solutions to trauma associated infections. Polk HC Jr. **J R Coll Surg Edinb** 1996 Feb; 41(1):1–6 (29 ref.)

Prophylactic antibiotics in cataract operations. Liesegang TJ. **Mayo Clin Proc** 1997 Feb;72(2):149–59 (99 ref.)

Wound healing and wound infection. What surgeons and anesthesiologists can do. Hunt TK, et al. **Surg Clin North Am** 1997 Jun;77(3):587–606 (69 ref.)

[Surgical wound infections—have we achieved all that is possible?] Poulsen KB. **Ugeskr Laeger** 1997 May 5; 159(19):2841–5 (40 ref.) (Eng. Abstr.) **(Dan)**

[The current status of vaccination and antibiotic prophylaxis in splenectomy. I: Adults] Funk EM, et al. **Chirurg** 1997 Jun;68(6):586–90 (25 ref.) (Eng. Abstr.) **(Ger)**

[Current status of vaccination and antibiotic prophylaxis in splenectomy. II: Children] Funk EM, et al. **Chirurg** 1997 Jun;68(6):591–5 (28 ref.) (Eng. Abstr.) **(Ger)**

[What is prevention of perioperative infection? Overview exemplified by trauma surgery] Hansis M. **Chirurg** 1996 Nov;67(11):1123–8 (18 ref.) (Eng. Abstr.) **(Ger)**

[Disinfection of human donor corneas during preparation and preservation] Hagenah M, et al. **Klin Monatsbl Augenheilkd** 1996 Jul;209(1):1–6; discussion 1 (58 ref.) (Eng. Abstr.) **(Ger)**

[When is antibiotic prophylaxis required?] Hansis M. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:708–12 (16 ref.) (Eng. Abstr.) **(Ger)**

[Perioperative hygiene in trauma surgery] Kasperczyk WJ, et al. **Unfallchirurg** 1996 Jul;99(7):460–5 (22 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Approaches to sternal wound infections. Gottlieb LJ, et al. **Adv Card Surg** 1996;7:147–62 (44 ref.)

[Therapy of peritonitis today. Surgical management and adjuvant therapy strategies] Reith HB. **Langenbecks Arch Chir** 1997;382(4 Suppl 1):S14–7 (23 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[Changes in nosocomial infections and progress in their treatment] Rudolph H. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:694–7 (13 ref.) **(Ger)**

TRANSMISSION

The surgical team as a source of postoperative wound infections caused by Streptococcus pyogenes. Kolmos HJ, et al. **J Hosp Infect** 1997 Mar;35(3):207–14 (19 ref.)

VETERINARY

Instrument sterilization, skin preparation, and wound management. Southwood LL, et al. **Vet Clin North Am Equine Pract** 1996 Aug;12(2):173–94 (79 ref.)

SURGICENTERS

ORGANIZATION & ADMINISTRATION

Hospital and ambulatory surgery center syndications: selling interests to physicians. Becker S. **J Health Care Finance** 1997 Summer;23(4):60–70 (0 ref.)

SURROGATE MARKERS see **BIOLOGICAL MARKERS**

SURVEILLANCE, IMMUNOLOGIC see **IMMUNOLOGIC SURVEILLANCE**

SURVEY METHODS see **DATA COLLECTION**

SURVEYS see **DATA COLLECTION**

SURVIVAL

Behavioural impairment in smoke environments. Purser D. **Toxicology** 1996 Dec 31;115(1–3):25–40 (17 ref.)

Fractional effective dose model for post-crash aircraft survivability. Speitel LC. **Toxicology** 1996 Dec 31; 115(1–3):167–77 (30 ref.)

PHYSIOLOGY

Survival at high altitudes: wheel-well passengers. Veronneau SJ, et al. **Aviat Space Environ Med** 1996 Aug;67(8):784–6 (6 ref.)

Application of full-scale fire tests to characterize and improve the aircraft postcrash fire environment. Sarkos CP.

SURVIVAL

Toxicology 1996 Dec 31;115(1-3):79-87 (16 ref.)
The management of aircraft passenger survival in fire. Trimble EJ. **Toxicology** 1996 Dec 31;115(1-3):41-61 (25 ref.)

PSYCHOLOGY

Psychological factors affecting health after toxicological disasters. Havenaar JM, et al. **Clin Psychol Rev** 1997; 17(4):359-74 (90 ref.)
Ageing Jewish Holocaust survivors: anxieties in dealing with health professionals. Joffe HI, et al. **Med J Aust** 1996 Nov 4;165(9):517-20 (38 ref.)
Children of Holocaust survivors: separation obstacles, attachments, and anxiety. Zilberfein F. **Soc Work Health Care** 1996;23(3):35-55 (30 ref.)

SURVIVAL ANALYSIS

see related
PROPORTIONAL HAZARDS MODELS

Multivariate statistical analysis for anatomic pathology. Part II: failure time analysis. Vollmer RT. **Am J Clin Pathol** 1996 Oct;106(4):522-34 (16 ref.)
Survival analysis in public health research. Lee ET, et al. **Annu Rev Public Health** 1997;18:105-34 (62 ref.)
Censoring issues in survival analysis. Leung KM, et al. **Annu Rev Public Health** 1997;18:83-104 (36 ref.)
A user's review of commercial sample size software for design of biomedical studies using survival data. Iwane M, et al. **Control Clin Trials** 1997 Feb;18(1):65-83 (18 ref.)
How frailty models can be used for evaluating longevity limits: taking advantage of an interdisciplinary approach. Yashin AI, et al. **Demography** 1997 Feb;34(1):31-48 (105 ref.)
Prognoses of seriously ill hospitalized patients on the days before death: implications for patient care and public policy. Lynn J, et al. **New Horiz** 1997 Feb;5(1):56-61 (10 ref.)
Designing and analyzing studies of onset, cessation, and relapse: using survival analysis in drug abuse prevention research. Singer JD, et al. **NIDA Res Monogr** 1994; 142:196-263 (123 ref.)
Alternative statistical methods to use with survival data. Holt F, et al. **Nurs Res** 1996 Nov-Dec;45(6):345-9 (23 ref.)
Survival analysis in observational studies. Bull K, et al. **Stat Med** 1997 May 15;16(9):1041-74 (31 ref.)
Frailty modelling for the excess hazard. Zahl PH. **Stat Med** 1997 Jul 30;16(14):1573-85 (24 ref.)

SURVIVAL RATE

Cardiopulmonary resuscitation: what cost to cheat death? Lee KH, et al. **Crit Care Med** 1996 Dec;24(12):2046-52 (51 ref.)
Intersections of mortality-rate and survival functions: model-independent considerations. Hirsch HR. **Exp Gerontol** 1997 May-Jun;32(3):287-96 (24 ref.)

TRENDS

Interpreting survival differences and trends. Berrino F, et al. **Tumori** 1997 Jan-Feb;83(1):9-16 (34 ref.)

SURVIVORS

Childbearing issues in breast carcinoma survivors. Surbone A, et al. **Cancer** 1997 Apr 1;79(7):1271-8 (62 ref.)
Survival after cardiac arrest and severe acidosis (pH = 6.54) [letter] Fumeaux T, et al. **Intensive Care Med** 1997 May; 23(5):594 (4 ref.)
Long-term survivors of childhood cancer. The medical consequences of cure. Marina N. **Pediatr Clin North Am** 1997 Aug;44(4):1021-42 (143 ref.)
Legal and societal issues facing survivors of childhood cancer. Monaco GP, et al. **Pediatr Clin North Am** 1997 Aug;44(4):1043-58 (27 ref.)
Torture and war trauma survivors in primary care practice. Weinstein HM, et al. **West J Med** 1996 Sep;165(3):112-8 (30 ref.)

PSYCHOLOGY

Assisting sexually abused adults. Practical guide to interviewing patients. Leach MM, et al. **Can Fam Physician** 1996 Jan;42:82-6 (22 ref.)
Evaluation of brain injury related behavioral disturbances in community mental health centers. McAllister TW. **Community Ment Health J** 1997 Aug;33(4):341-58; discussion 359-64 (96 ref.)
Sense of self in children with cancer and in childhood cancer survivors: a critical review. Woodgate R, et al. **J Pediatr Oncol Nurs** 1997 Jul;14(3):137-55 (62 ref.)
The impact of child sexual abuse on the children of survivors. Implications for forensic nursing. Palmer L. **J Psychosoc Nurs Ment Health Serv** 1996 Oct;34(10):42-6 (19 ref.)
Attitude and disposition: do they make a difference in cancer survival? Creagan ET. **Mayo Clin Proc** 1997 Feb; 72(2):160-4 (24 ref.)
The sequelae of childhood sexual abuse: a primary care focus for adult female survivors. Roberts SJ. **Nurse Pract** 1996 Dec;21(12 Pt 1):42, 45, 49-52 (26 ref.)
Services for adults who have experienced child sexual assault: improving agency response. Gibbons J. **Soc Sci Med** 1996 Dec;43(12):1755-63 (48 ref.)
Studying the quality of life after organ transplantation: research problems and solutions. Joralemon D, et al. **Soc Sci Med** 1997 May;44(9):1259-69 (100 ref.)
[In times of survival, the right of silence] Métraux JC. **Rev Med Suisse Romande** 1997 May;117(5):419-23 (7 ref.) **(Fre)**

STATISTICS & NUMERICAL DATA

The long-term survivors. Hawkins MM, et al. **Br Med Bull** 1996 Oct;52(4):898-923 (68 ref.)

SURVIVORSHIP see **SURVIVAL RATE**

SUSLIKS see **SCIURIDAE**

SUSPENDING AGENTS see **EXCIPIENTS**

SUSTAINED-RELEASE PREPARATIONS see **DELAYED-ACTION PREPARATIONS**

SUTURE TECHNIQUES

Arthroscopic all-inside meniscus repair. Reigel CA, et al. **Clin Sports Med** 1996 Jul;15(3):483-98 (22 ref.)
Meniscal repair using the outside-to-inside technique. Rodeo SA, et al. **Clin Sports Med** 1996 Jul;15(3):469-81 (44 ref.)
Long-term, indwelling setons for low transsphincteric and intersphincteric anal fistulas. Experience with 108 cases. Lentner A, et al. **Dis Colon Rectum** 1996 Oct; 39(10):1097-101 (15 ref.)
Corneal coupling principles. Rowsey JJ, et al. **Int Ophthalmol Clin** 1996 Fall;36(4):29-38 (26 ref.)
Laparoscopic suturing and ligation techniques. Pasic R, et al. **J Am Assoc Gynecol Laparosc** 1995 Nov;3(1):67-79 (25 ref.)
Search for a scientific basis for continuous suture closure: a 30-yr odyssey. Drake DB, et al. **J Emerg Med** 1997 Jul-Aug;15(4):495-504 (18 ref.)
[Personal technique for suturing the flexor tendons of the fingers with immediate mobilization] Brunelli G, et al. **Ann Chir Main** 1982;1(1):92-6 (11 ref.) (Eng. Abstr.) **(Fre)**
[Tension-free suture of incisional hernia] Farthmann EH, et al. **Chirurg** 1997 Apr;68(4):310-6 (28 ref.) (Eng. Abstr.) **(Ger)**
[Concepts for recognition and securing anastomotic wound dehiscence of the gastrointestinal tract] Zirngibl H, et al. **Zentralbl Chir** 1997;122(1):20-4 (21 ref.) (Eng. Abstr.) **(Ger)**
[A case of ventricular septal perforation treated surgically with an infarction exclusion technique] Kawase Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):582-8 (24 ref.) (Eng. Abstr.) **(Jpn)**
[Meniscal repair] Kimura M. **Nippon Seikeigeka Gakkai Zasshi** 1996 May;70(5):274-84 (26 ref.) **(Jpn)**
[Characteristics of several types of manual intestinal sutures] Mel'nik VM, et al. **Klin Khir** 1996;(8):34-7 (71 ref.) **(Rus)**

VETERINARY

Surgical materials and wound closure techniques. Kawcak CE, et al. **Vet Clin North Am Equine Pract** 1996 Aug; 12(2):195-205 (44 ref.)

SUTURES

Resuturing the scleral flap leads to resolution of hypotony maculopathy. Schwartz GF, et al. **J Glaucoma** 1996 Aug; 5(4):246-51 (50 ref.)
The role of sutures and fibrin sealant in wound healing. Spotnitz WD, et al. **Surg Clin North Am** 1997 Jun; 77(3):651-69 (61 ref.)
[Medical applications of special fibers] Schnegelsberg G. **Zentralbl Chir** 1997;122(5):383-5; discussion 386 (18 ref.) **(Ger)**
[Characteristics of several types of manual intestinal sutures] Mel'nik VM, et al. **Klin Khir** 1996;(8):34-7 (71 ref.) **(Rus)**

VETERINARY

Surgical materials and wound closure techniques. Kawcak CE, et al. **Vet Clin North Am Equine Pract** 1996 Aug; 12(2):195-205 (44 ref.)

SUXAMETHONIUM see **SUCCINYLCHOLINE**

SV40 VIRUS see **POLYOMAVIRUS MACACAE**

SWALLOWING see **DEGLUTITION**

SWAMP FEVER see **EQUINE INFECTIOUS ANEMIA**

SWAMP FEVER VIRUS see **INFECTIOUS ANEMIA VIRUS, EQUINE**

SWAN-GANZ CATHETERIZATION see **CATHETERIZATION, SWAN-GANZ**

SWEAT

CHEMISTRY

Diagnosing cystic fibrosis: blood, sweat, and tears. Wallis C. **Arch Dis Child** 1997 Feb;76(2):85-8 (38 ref.)

SWEAT GLAND DISEASES

PHYSIOPATHOLOGY

Blood, sweat and fear. "A classification of hematidrosis". Holoubek JE, et al. **J Med** 1996;27(3-4):115-33 (53 ref.)

SURGERY

Excision of subcutaneous tissue for the treatment of axillary osmidrosis. Tung TC, et al. **Br J Plast Surg** 1997 Jan; 50(1):61-6 (15 ref.)

SWEAT GLAND NEOPLASMS

Malignant metastatic eccrine poroma. Proposal for a new therapeutic protocol. Barzi AS, et al. **Dermatol Surg** 1997 Apr;23(4):267-72 (30 ref.)
Clear cell hidradenoma of the second digit: a review of the literature with case presentation. Feldman AH, et al. **J Foot Ankle Surg** 1997 Jan-Feb;36(1):21-3 (7 ref.)
Eccrine carcinoma of the hand: a case report. Katzman BM, et al. **J Hand Surg [Am]** 1997 Jul;22(4):737-9 (12 ref.)

COMPLICATIONS

Extramammary Paget's disease of the axilla with an underlying apocrine carcinoma [letter] [see comments] Morgan JM, et al. **Acta Derm Venereol** 1996 Mar; 76(2):173-4 (8 ref.) Comment in: Acta Derm Venereol 1997 Jan;77(1):78.
Multiple eccrine hidrocystomas associated with Graves' disease. Nagai Y, et al. **J Dermatol** 1996 Sep;23(9):652-4 (9 ref.)

DIAGNOSIS

Localized vulvar syringomas [letter] Di Lernia V, et al. **Pediatr Dermatol** 1996 Jan-Feb;13(1):80-1 (15 ref.)

DRUG THERAPY

[Chemotherapy for advanced adenocarcinoma of the skin: experience with combination chemotherapy and a review of the literature] Yamazaki N. **Gan To Kagaku Ryoho** 1997 Jan;24(1):30-6 (15 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Periorbital solitary nodule and multiple small papules in a 63-year-old women. Primary mucinous carcinoma (nodule) and syringom (papules). Friednash M, et al. **Arch Dermatol** 1997 Sep;133(9):1161, 1164 (18 ref.)
Acrospiroma: a case report and review. Laws RA, et al. **Cutis** 1996 Nov;58(5):349-51 (6 ref.)
Solitary eccrine syringofibroadenoma (or eccrine syringofibroadenomatous hyperplasia?) and diabetic polyneuropathy. Gambini C, et al. **Dermatology** 1996; 193(1):68-9 (13 ref.)
Metastasizing eccrine porocarcinoma: report of a case and review of the literature. Huet P, et al. **J Am Acad Dermatol** 1996 Nov;35(5 Pt 2):860-4 (55 ref.)
Eccrine syringofibroadenoma: multiple lesions representing a new cutaneous marker of the Schöpf syndrome, and solitary nonhereditary tumors. Starink TM. **J Am Acad Dermatol** 1997 Apr;36(4):569-76 (38 ref.)
Signet ring cell carcinoma of the eccrine sweat glands in the eyelid. Wollensak G, et al. **Ophthalmology** 1996 Nov; 103(11):1788-93 (34 ref.)
Malignant eccrine spiradenoma with smooth muscle cell differentiation: histological and immunohistochemical study. Itoh T, et al. **Pathol Int** 1996 Nov;46(11):887-93 (23 ref.)

SWEAT GLANDS

PATHOLOGY

Eccrine or apocrine poroma? Six poromas with divergent adnexal differentiation. Harvell JD, et al. **Am J Dermatopathol** 1996 Feb;18(1):1-9 (30 ref.)

SWEATING

see related
CYSTIC FIBROSIS
HYPERHIDROSIS
HYPOHIDROSIS

Maximal sweating rate in humans. Torii M. **J Hum Ergol (Tokyo)** 1995 Dec;24(2):137-52 (85 ref.)

PHYSIOLOGY

Factors influencing the restoration of fluid and electrolyte balance after exercise in the heat. Maughan RJ, et al. **Br J Sports Med** 1997 Sep;31(3):175-82 (26 ref.)
The perimenopausal hot flash: epidemiology, physiology, and treatment. Shaw CR. **Nurse Pract** 1997 Mar;22(3):55-6, 61-6 (52 ref.)

SWEATING, GUSTATORY

DIAGNOSIS

Localized facial flushing in infancy. Auriculotemporal nerve (Frey) syndrome. Dizon MV, et al. **Arch Dermatol** 1997 Sep;133(9):1143–5 (28 ref.)

SWEETENING AGENTS

ADMINISTRATION & DOSAGE

Sugar, alternative sweeteners and meal frequency in relation to caries prevention: new perspectives. Kandelman D. **Br J Nutr** 1997 Apr;77 Suppl 1:S121–8 (48 ref.)

ADVERSE EFFECTS

Sweeteners, dyes, and other excipients in vitamin and mineral preparations. Kumar A, et al. **Clin Pediatr (Phila)** 1996 Sep; 35(9):443–50 (28 ref.)

METABOLISM

Saccharin mechanistic data and risk assessment: urine composition, enhanced cell proliferation, and tumor promotion. Whysner J, et al. **Pharmacol Ther** 1996; 71(1–2):225–52 (172 ref.)

PHARMACOLOGY

Erythritol: a review of biological and toxicological studies. Bernt WO, et al. **Regul Toxicol Pharmacol** 1996 Oct;24(2 Pt 2):S191–7 (85 ref.)

TOXICITY

Saccharin mechanistic data and risk assessment: urine composition, enhanced cell proliferation, and tumor promotion. Whysner J, et al. **Pharmacol Ther** 1996; 71(1–2):225–52 (172 ref.)

Erythritol: a review of biological and toxicological studies. Bernt WO, et al. **Regul Toxicol Pharmacol** 1996 Oct;24(2 Pt 2):S191–7 (85 ref.)

Low digestible carbohydrates (polyols and lactose): significance of adrenal medullary proliferative lesions in the rat. Lynch BS, et al. **Regul Toxicol Pharmacol** 1996 Jun;23(3):256–97 (279 ref.)

SWEET'S SYNDROME

Neutrophilic dermatoses: pyoderma gangrenosum and Sweet's syndrome. Lear JT, et al. **Postgrad Med J** 1997 Feb;73(856):65–8 (27 ref.)

[Sweet's syndrome] Mizoguchi M. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Jun; 19(3):169–178 (34 ref.) **(Jpn)**

[Sweet's syndrome. Presentation of six cases and review of the literature] Mendoza H, et al. **An Med Interna** 1997 May; 14(5):244–6 (21 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

A case of Sjögren's syndrome associated with Sweet's syndrome. Osawa H, et al. **Clin Rheumatol** 1997 Jan; 16(1):101–5 (16 ref.)

Concurrent Sweet's syndrome and Löfgren's syndrome. Cuende Quintana E, et al. **J Rheumatol** 1996 Nov; 23(11):1995–8 (13 ref.)

[Sweet's syndrome and aseptic abscess of the spleen] Quilichini R, et al. **Rev Med Interne** 1996;17(12):1029–31 (15 ref.) (Eng. Abstr.) **(Fre)**

[Sweet syndrome associated with essential thrombocytopenia (letter)] Camafort Babkowski M, et al. **Med Clin (Barc)** 1997 Mar 22;108(11):439 (8 ref.) **(Spa)**

PATHOLOGY

Sweet's syndrome. Fitzgerald RL, et al. **Int J Dermatol** 1996 Jan;35(1):9–15 (96 ref.)

SWIMMING

Nontraumatic glenohumeral instability and coracoacromial impingement in swimmers. Bak K. **Scand J Med Sci Sports** 1996 Jun;6(3):132–44 (76 ref.)

Effects of wetsuit use in swimming events. Practical recommendations. Chatard JC, et al. **Sports Med** 1996 Aug; 22(2):70–5 (26 ref.)

INJURIES

Rehabilitation of injuries in competitive swimmers. Kenal KA, et al. **Sports Med** 1996 Nov;22(5):337–47 (28 ref.)

Swimming injuries. An overview. McMaster WC. **Sports Med** 1996 Nov;22(5):332–6 (26 ref.)

PHYSIOLOGY

Lamprey spinal interneurons and their roles in swimming activity. Buchanan JT. **Brain Behav Evol** 1996;48(5):287–96 (49 ref.)

Key factors in success of altitude training for swimming. Miyashita M. **Res Q Exerc Sport** 1996 Sep;67(3 Suppl):S76–8 (10 ref.)

SWINE

Thromboembolic phenomena and the use of the pig as an appropriate animal model for research on cardiovascular devices. Gross DR. **Int J Artif Organs** 1997 Apr; 20(4):195–203 (89 ref.)

Swine manure cleanup criteria calculation for odor causing volatile organic compounds based on manure–to–ventilation air exposure pathway. Liao CM, et al. **J Environ Sci Health B** 1997 Jul;32(4):449–68 (33 ref.)

Considerations of specific pathogen–free swine (SPF) in xenotransplantation. Swindle MM. **J Invest Surg** 1996 Jul–Aug;9(4):267–71 (17 ref.)

Beyond hyperacute rejection: strategies for development of pig––>primate xenotransplantation. Hancock WW. **Kidney Int Suppl** 1997 Mar;58:S36–40 (31 ref.)

Aetiology of intersexuality in female (XX) pigs, with novel molecular interpretations. Hunter RH. **Mol Reprod Dev** 1996 Nov;45(3):392–402 (74 ref.)

Research applications using pigs. Almond GW. **Vet Clin North Am Food Anim Pract** 1996 Nov;12(3):707–16 (36 ref.)

The pig as a model in liver xenotransplantation. Wolf P, et al. **Vet Res** 1997 May–Jun;28(3):217–22 (14 ref.)

EMBRYOLOGY

[In vitro production of swine embryos] Rath D, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Aug–Sep; 103(8–9):331–6 (89 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

A comprehensive map of the porcine genome. Rohrer GA, et al. **Genome Res** 1996 May;6(5):371–91 (112 ref.)

Technical note: optimization of breed composition to maximize net merit of synthetic populations. Lin CY. **J Anim Sci** 1996 Jul;74(7):1477–80 (12 ref.)

GROWTH & DEVELOPMENT

Intestinal effects of milkborne growth factors in neonates of agricultural importance. Odle J, et al. **J Anim Sci** 1996 Oct;74(10):2509–22 (120 ref.)

Characterization of growth parameters needed as inputs for pig growth models. Schinckel AP, et al. **J Anim Sci** 1996 Aug;74(8):2021–36 (132 ref.)

Molecular mechanisms involved in the nutritional and hormonal regulation of growth in pigs. Brameld JM. **Proc Nutr Soc** 1997 Jul;56(2):607–19 (71 ref.)

IMMUNOLOGY

The respiratory immune system of pigs. Pabst R. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):191–5 (35 ref.)

METABOLISM

Mechanisms of intestinal calcium absorption and availability of dietary calcium in pigs. Kaune R. **DTW Dtsch Tierarztl Wochenschr** 1996 Jun;103(6):215–8 (28 ref.)

Mechanisms of intestinal phosphorus absorption and availability of dietary phosphorus in pigs. Schröder B, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Jun; 103(6):209–14 (87 ref.)

The regulation of intestinal metabolism and its impact on whole animal energetics. Cant JP, et al. **J Anim Sci** 1996 Oct;74(10):2541–53 (98 ref.)

Structure and function of the N–linked carbohydrate chains of pig zona pellucida glycoproteins. Nakano M, et al. **J Reprod Fertil Suppl** 1996;50:25–34 (40 ref.)

Sperm–associated protein candidates for primary zona pellucida–binding molecules: structure–function correlations of boar spermadhesins. Töpfer–Petersen E, et al. **J Reprod Fertil Suppl** 1996;50:55–61 (44 ref.)

Mathematical modelling of nitrogen flow in growing pigs and lactating sows. Pettigrew JE. **Proc Nutr Soc** 1997 Jul; 56(2):645–56 (27 ref.)

Nitrogen metabolism in gastrointestinal tissue of the pig. van der Meulen J, et al. **Proc Nutr Soc** 1997 Jul;56(2):535–45 (71 ref.)

MICROBIOLOGY

Hazard identification in swine slaughter with respect to foodborne bacteria. Borch E, et al. **Int J Food Microbiol** 1996 Jun;30(1–2):9–25 (56 ref.)

PHYSIOLOGY

Mathematical modeling of digestion and nutrient absorption in pigs. Bastianelli D, et al. **J Anim Sci** 1996 Aug; 74(8):1873–87 (86 ref.)

Sustainability issues of U.S. swine production. Honeyman MS. **J Anim Sci** 1996 Jun;74(6):1410–7 (36 ref.)

Intestinal effects of milkborne growth factors in neonates of agricultural importance. Odle J, et al. **J Anim Sci** 1996 Oct;74(10):2509–22 (120 ref.)

Ketamine and its use in the pig. Recommendations of the Consensus meeting on Ketamine Anaesthesia in Pigs, Bergen 1994. Ketamine Consensus Working Group. Boschert K, et al. **Lab Anim** 1996 Jul;30(3):209–19 (28 ref.)

Nutrient–hormone signals regulating muscle protein turnover in pigs. Sève B, et al. **Proc Nutr Soc** 1997 Jul;56(2):565–80 (62 ref.)

Nutritional control of amino acid supply to the mammary gland during lactation in the pig. Trottier NL. **Proc Nutr Soc** 1997 Jul;56(2):581–91 (39 ref.)

PSYCHOLOGY

Behavior problems of pet pigs. Tynes VV. **Vet Clin North Am Small Anim Pract** 1997 May; 27(3):667–90 (35 ref.)

[Social dominance and rank relationships in domestic pigs: a critical review] Puppe B. **Berl Munch Tierarztl Wochenschr** 1996 Nov–Dec; 109(11–12):457–64 (91 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Physiologic and pathophysiologic considerations for ruminant and swine anesthesia. Jorgensen JS, et al. **Vet Clin North Am Food Anim Pract** 1996 Nov; 12(3):481–500 (64 ref.)

Management and emergency intervention during anesthesia. Kruse–Elliott KT. **Vet Clin North Am Food Anim Pract** 1996 Nov;12(3):563–78 (29 ref.)

General anesthetic techniques in swine. Moon PF, et al. **Vet Clin North Am Food Anim Pract** 1996 Nov;12(3):663–91 (61 ref.)

Local and regional anesthesia in ruminants and swine. Skarda RT. **Vet Clin North Am Food Anim Pract** 1996 Nov; 12(3):579–626 (140 ref.)

Supplies and technical considerations for ruminant and swine anesthesia. Tobin E, et al. **Vet Clin North Am Food Anim Pract** 1996 Nov;12(3):531–62 (24 ref.)

SWINE DISEASES

Streptococcus suis: past and present. Staats JJ, et al. **Vet Res Commun** 1997 Aug;21(6):381–407 (220 ref.)

[Physiology and physiopathology of ryanodine receptors in swine. Significance of sensitivity to stress, stress myopathies, malignant hyperthermia and meat quality] Martens H. **Tierarztl Prax** 1997 Jan;25(1):41–51 (62 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

An overview of immunological and genetic methods for detecting swine coronaviruses, transmissible gastroenteritis virus, and porcine respiratory coronavirus in tissues. Sirinarumitr T, et al. **Adv Exp Med Biol** 1997;412:37–46 (46 ref.)

EPIDEMIOLOGY

Agricultural policy and social returns to eradication programs: the case of Aujeszky's disease in Sweden. Andersson H, et al. **Prev Vet Med** 1997 Feb;29(4):311–28 (30 ref.)

An overview of techniques for dealing with large numbers of independent variables in epidemiologic studies. Dohoo IR, et al. **Prev Vet Med** 1997 Jan;29(3):221–39 (24 ref.)

Husbandry and diseases of captive wild swine and peccaries. Fowler ME. **Rev Sci Tech** 1996 Mar;15(1):141–54 (14 ref.)

Enzootic pneumonia in pigs. Maes D, et al. **Vet Q** 1996 Sep; 18(3):104–9 (52 ref.)

MICROBIOLOGY

Virulence factors of the swine pathogen Actinobacillus pleuropneumoniae. Tascón RI, et al. **Microbiologia** 1996 Jun;12(2):171–84 (101 ref.)

[Swine erysipelas and Erysipelothrix] Takahashi T. **Nippon Saikingaku Zasshi** 1996 Aug;51(3):707–15 (32 ref.) **(Jpn)**

PREVENTION & CONTROL

Role of the Danish pig production system in the success of infectious disease control: a review. Medveczky I. **Acta Vet Hung** 1997;45(1):45–51 (10 ref.)

Agricultural policy and social returns to eradication programs: the case of Aujeszky's disease in Sweden. Andersson H, et al. **Prev Vet Med** 1997 Feb;29(4):311–28 (30 ref.)

Enzootic pneumonia in pigs. Maes D, et al. **Vet Q** 1996 Sep; 18(3):104–9 (52 ref.)

VIROLOGY

Pseudorabies virus infections in pigs. Role of viral proteins in virulence, pathogenesis and transmission. Mulder WA, et al. **Vet Res** 1997;28(1):1–17 (142 ref.)

SWINE FEVER VIRUS see **HOG CHOLERA VIRUS**

SWINE HERPESVIRUS 1 see **HERPESVIRUS 1, SUID**

SWINE INFERTILITY AND RESPIRATORY SYNDROME VIRUS

General overview of PRRSV: a perspective from the United States. Zimmerman JJ, et al. **Vet Microbiol** 1997 Apr; 55(1–4):187–96 (43 ref.)

SWINE INFERTILITY AND RESPIRATORY SYNDROME VIRUS

CLASSIFICATION

Molecular characterization of positive-strand RNA viruses: pestiviruses and the porcine reproductive and respiratory syndrome virus (PRRSV). Thiel HJ, et al. **Arch Virol Suppl** 1993;7:41-52 (33 ref.)

Epidemiology of porcine reproductive and respiratory syndrome (PRRS): an overview. Albina E. **Vet Microbiol** 1997 Apr;55(1-4):309-16 (42 ref.)

[Porcine reproductive and respiratory syndrome: ten years of experience (1986-1996) with this undesirable viral infection] Albina E. **Vet Res** 1997 Jul-Aug;28(4):305-52 (241 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Molecular characterization of Lelystad virus. Meulenberg JJ, et al. **Vet Microbiol** 1997 Apr;55(1-4):197-202 (20 ref.)

IMMUNOLOGY

Immunity to PRRSV: double-edged sword. Molitor TW, et al. **Vet Microbiol** 1997 Apr;55(1-4):265-76 (33 ref.)

ISOLATION & PURIFICATION

Diagnosis of PRRS. Bøtner A. **Vet Microbiol** 1997 Apr; 55(1-4):295-301 (25 ref.)

PHYSIOLOGY

Pathogenesis and clinical aspects of a respiratory porcine reproductive and respiratory syndrome virus infection. Van Reeth K. **Vet Microbiol** 1997 Apr;55(1-4):223-30 (29 ref.)

SWINE INFERTILITY & RESPIRATORY SYNDROME see **PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME**

SWINE, MINIATURE

PHYSIOLOGY

The Göttingen minipig in pharmacology and toxicology. Bollen P, et al. **Pharmacol Toxicol** 1997;80 Suppl 2:3-4 (14 ref.)

Health status of experimental pigs. Hansen AK. **Pharmacol Toxicol** 1997;80 Suppl 2:10-5 (19 ref.)

Nutrition of (Göttingen) minipigs: facts, assumptions and mysteries. Ritskes-Hoitinga J, et al. **Pharmacol Toxicol** 1997;80 Suppl 2:5-9 (19 ref.)

PSYCHOLOGY

Behavior problems of pet pigs. Tynes VV. **Vet Clin North Am Small Anim Pract** 1997 May; 27(3):667-90 (35 ref.)

SWINE TRANSMISSIBLE GASTROENTERITIS see **GASTROENTERITIS, TRANSMISSIBLE, OF SWINE**

SWINE VESICULAR DISEASE

VIROLOGY

Coxsackievirus B5 and the relationship to swine vesicular disease virus. Knowles NJ, et al. **Curr Top Microbiol Immunol** 1997;223:153-67 (50 ref.)

SWISS BLUE see **METHYLENE BLUE**

SWISS MICE see **MICE**

SWITCH GENES see **GENES, SWITCH**

SWITCH REGION GENES see **IMMUNOGLOBULIN SWITCH REGION**

SWITCH REGION, IMMUNOGLOBULIN see **IMMUNOGLOBULIN SWITCH REGION**

SWITCHBOARD SERVICE see **TELEPHONE**

SWITCHING COMPLEX see **GENES, SWITCH**

SYCOSIS see **FOLLICULITIS**

SYLVIAN VEIN see **CEREBRAL VEINS**

SYMBIOSIS

Non-cultivable microorganisms from symbiotic associations of insects and other hosts. Baumann P, et al. **Antonie Van Leeuwenhoek** 1997 Jul;72(1):39-48 (68 ref.)

Endosymbiotic interactions in anaerobic protozoa. Hackstein JH, et al. **Antonie Van Leeuwenhoek** 1997 Feb;71(1-2):151-8 (52 ref.)

Epibiotic microorganisms on copepods and other marine crustaceans. Carman KR, et al. **Microsc Res Tech** 1997 Apr 15;37(2):116-35 (137 ref.)

Rhizobium symbiosis: nod factors in perspective. Long SR. **Plant Cell** 1996 Oct;8(10):1885-98 (140 ref.)

Environmental regulation of rhizobial symbiotic nitrogen fixation genes. Fischer HM. **Trends Microbiol** 1996 Aug; 4(8):317-20 (27 ref.)

GENETICS

Nodulation genes in the Rhizobium--plant signal exchange. Lorkiewicz Z. **Acta Biochim Pol** 1997;44(1):1-12 (94 ref.)

PHYSIOLOGY

Lessons from a cooperative, bacterial-animal association: the Vibrio fischeri-Euprymna scolopes light organ symbiosis. Ruby EG. **Annu Rev Microbiol** 1996;50:591-624 (138 ref.)

The evolution of the Calvin cycle from prokaryotic to eukaryotic chromosomes: a case study of functional redundancy in ancient pathways through endosymbiosis. Martin W, et al. **Curr Genet** 1997 Jul;32(1):1-18 (158 ref.)

Rhizobium meliloti exopolysaccharides: synthesis and symbiotic function. González JE, et al. **Gene** 1996 Nov 7;179(1):141-6 (50 ref.)

Energetics of syntrophic cooperation in methanogenic degradation. Schink B. **Microbiol Mol Biol Rev** 1997 Jun; 61(2):262-80 (149 ref.)

Signal transduction in Rhizobium-induced nodule formation. Geurts R, et al. **Plant Physiol** 1996 Oct;112(2):447-53 (42 ref.)

SYMBIOTIC RELATIONS (PSYCHOLOGY) see **OBJECT ATTACHMENT**

SYMBOLISM

Symbolic aspects of confabulation following brain injury: influence of premorbid personality. Weinstein EA. **Bull Menninger Clin** 1996 Summer;60(3):331-50 (39 ref.)

Believing in make-believe: looking at theater as a metaphor for psychotherapy. MacCormack T. **Fam Process** 1997 Jun; 36(2):151-69 (81 ref.)

Walking a mile in their shoes... Symbolic interactionism for families living with severe mental illness. Saunders J. **J Psychosoc Nurs Ment Health Serv** 1997 Jun;35(6):8-13 (24 ref.)

White, red and black: colour classification and illness management in Northern Ghana. Kirby JP. **Soc Sci Med** 1997 Jan;44(2):215-30 (38 ref.)

About signs and symptoms: can semiotics expand the view of clinical medicine? Nessa J. **Theor Med** 1996 Dec; 17(4):363-77 (54 ref.)

SYMPATHECTOMY

Thorascopic sympathectomy in the treatment of palmar hyperhidrosis: anaesthetic implications. Fredman B, et al. **Br J Anaesth** 1997 Jul;79(1):113-9 (55 ref.)

Post-sympathectomy neuralgia: hypotheses on peripheral and central neuronal mechanisms [see comments] Kramis RC, et al. **Pain** 1996 Jan;64(1):1-9 (66 ref.) Comment in: Pain 1996 Sep;67(1):218-20. Comment in: Pain 1997 Apr;70(2-3):290-1.

INSTRUMENTATION

[CT-guided neurolysis. Status of the technique and current results] Schneider B, et al. **Radiologe** 1996 Sep;36(9):692-9 (24 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Thoracoscopic sympathicolysis for essential hyperhidrosis: immediate and one year follow-up results in 35 patients and review of the literature. Noppen M, et al. **Acta Clin Belg** 1996;51(4):244-53 (54 ref.)

Reflex sympathetic dystrophy. The controversy continues. Nath RK, et al. **Clin Plast Surg** 1996 Jul;23(3):435-46 (86 ref.)

Image-guided minimally invasive therapy. Seibel RM. **Surg Endosc** 1997 Feb;11(2):154-62 (38 ref.)

[Treatment of essential hyperhidrosis using thoracoscopic high dorsal sympathectomy] Noppen M. **Ned Tijdschr Geneeskd** 1997 Apr 5;141(14):671-5 (25 ref.) (Eng. Abstr.) **(Dut)**

SYMPATHECTOMY, CHEMICAL

INSTRUMENTATION

[CT-guided neurolysis. Status of the technique and current results] Schneider B, et al. **Radiologe** 1996 Sep;36(9):692-9 (24 ref.) (Eng. Abstr.) **(Ger)**

SYMPATHETIC-BLOCKING AGENTS see **SYMPATHOLYTICS**

SYMPATHETIC DENERVATION see **SYMPATHECTOMY**

SYMPATHETIC FIBERS see **ADRENERGIC FIBERS**

SYMPATHETIC FIBERS, POSTGANGLIONIC

METABOLISM

P2-purinoceptors on postganglionic sympathetic neurones. von Kügelgen I, et al. **J Auton Pharmacol** 1996 Dec; 16(6):413-6 (28 ref.)

SYMPATHETIC GANGLIA see **GANGLIA, SYMPATHETIC**

SYMPATHETIC NERVE BLOCK see **AUTONOMIC NERVE BLOCK**

SYMPATHETIC NERVOUS SYSTEM

see related
SYMPATHECTOMY
SYMPATHOLYTICS
SYMPATHOMIMETICS

The sympathetic nervous system in hypertension and renal disease. Saruta T, et al. **Curr Opin Nephrol Hypertens** 1996 Jan;5(1):72-9 (45 ref.)

CHEMISTRY

Membrane composition of adrenergic large and small dense cored vesicles and of synaptic vesicles: consequences for their biogenesis. Winkler H. **Neurochem Res** 1997 Aug; 22(8):921-32 (143 ref.)

CYTOLOGY

Programmed cell death in neurons: focus on the pathway of nerve growth factor deprivation-induced death of sympathetic neurons. Deshmukh M, et al. **Mol Pharmacol** 1997 Jun;51(6):897-906 (126 ref.)

DRUG EFFECTS

A comparative study of the effects of alpha 1-adrenoceptor antagonists on sympathetic function in rats. Saito H, et al. **Am J Hypertens** 1996 Nov;9(11):160S-169S (55 ref.)

The crosstalk between insulin and the sympathetic nervous system: possible implications in the pathogenesis of essential hypertension. Lembo G, et al. **Blood Press Suppl** 1996; 1:38-42 (43 ref.)

Nicotine and sympathetic neurotransmission. Haass M, et al. **Cardiovasc Drugs Ther** 1997 Jan;10(6):657-65 (55 ref.)

Modulation of sympathetic outflow by centrally acting antihypertensive drugs. van Zwieten PA. **Cardiovasc Drugs Ther** 1996 Jun;10 Suppl 1:283-9 (37 ref.)

Anti-adrenergic effects of angiotensin converting enzyme inhibitors. Bristow MR, et al. **Eur Heart J** 1995 Nov;16 Suppl K:37-41 (42 ref.)

Sympathetic and cardiorenal actions of leptin. Haynes WG, et al. **Hypertension** 1997 Sep;30(3 Pt 2):619-23 (45 ref.)

IMMUNOLOGY

Immune cytokine regulation of sympathetic ganglion response to injury. Jonakait GM, et al. **Neuroimmunomodulation** 1995 Jul-Aug;2(4):236-40 (37 ref.)

METABOLISM

Regulation of neuropeptide expression in sympathetic neurons. Paracrine and retrograde influences. Zigmond RE, et al. **Ann N Y Acad Sci** 1997 Apr 24;814:181-97 (90 ref.)

Functional roles of neurotrophin 3 in the developing and mature sympathetic nervous system. Zhou XF, et al. **Mol Neurobiol** 1996 Dec;13(3):185-97 (76 ref.)

PHYSIOLOGY

Neuropeptide Y Y1 receptor mechanisms in sympathetic vascular control. Malmström RE. **Acta Physiol Scand Suppl** 1997;636:1-55 (229 ref.)

Autonomic neural control of cardiac function: modulation by adenosine and adenosine 5'-triphosphate. Pelleg A, et al. **Am J Cardiol** 1997 Jun 19;79(12A):11-4 (72 ref.)

Introduction to the symposium: the sympathetic nervous system really is a key element in hypertension, with treatment implications. Tobian L. **Am J Hypertens** 1996 Nov;9(11):111S-112S (4 ref.)

Pituitary adenylate cyclase-activating polypeptides, PACAP-38 and PACAP-27, regulation of sympathetic neuron catecholamine, and neuropeptide Y expression through activation of type I PACAP/VIP receptor isoforms. Braas KM, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:204-16; discussion 217-8 (47 ref.)

Low and high frequency components of blood pressure variability. Pagani M, et al. **Ann N Y Acad Sci** 1996 Aug 15;783:10-23 (36 ref.)

Respiratory inputs to central cardiovascular neurons. Pilowsky P, et al. **Ann N Y Acad Sci** 1996 Aug 15;783:64-70 (36 ref.)

Obesity and the sympathetic nervous system. Grassi G, et al. **Blood Press Suppl** 1996;1:43-6 (24 ref.)

Insulin and the sympathetic nervous system in the pathophysiology of hypertension. Landsberg L. **Blood Press Suppl** 1996;1:25-9 (46 ref.)

Activation of the neuroendocrine response in heart failure: adaptive or maladaptive process? Ferrari R, et al. **Cardiovasc Drugs Ther** 1996 Nov;10 Suppl 2:623-9 (68 ref.)

Body fat and sympathetic nerve activity. Scherrer U, et al. **Cardiovasc Drugs Ther** 1996 Jun;10 Suppl 1:215-22 (55 ref.)

The supply of vasomotor drive to individual classes of sympathetic neuron. McAllen RM, et al. **Clin Exp Hypertens** 1997 Jul-Aug;19(5-6):607-18 (22 ref.)

Interactions between angiotensin II and the sympathetic nervous system in the the long-term control of arterial

pressure. Brooks VL. **Clin Exp Pharmacol Physiol** 1997 Jan;24(1):83–90 (86 ref.)
Interactions between vasopressin and baroreflex control of the sympathetic nervous system. Hasser EM, et al. **Clin Exp Pharmacol Physiol** 1997 Jan;24(1):102–8 (53 ref.)
Long-term increases in renal sympathetic nerve activity and hypertension. Osborn JL, et al. **Clin Exp Pharmacol Physiol** 1997 Jan;24(1):72–6 (30 ref.)
Hormones as long-term error signals for the sympathetic nervous system: importance of a new perspective. Osborn JW. **Clin Exp Pharmacol Physiol** 1997 Jan;24(1):109–15 (38 ref.)
The sympathetic nervous system and long-term regulation of arterial pressure: what are the critical questions? Osborn JW. **Clin Exp Pharmacol Physiol** 1997 Jan;24(1):68–71 (15 ref.)
Neural control of muscle blood flow: importance during dynamic exercise. Rowell LB. **Clin Exp Pharmacol Physiol** 1997 Feb;24(2):117–25 (71 ref.)
Neurotrophic factors are required by mature sympathetic neurons for survival, transmission and connectivity. Rush RA, et al. **Clin Exp Pharmacol Physiol** 1997 Aug; 24(8):549–55 (31 ref.)
Neurophysiology and neuropsychiatry of the IBS. Dapoigny M, et al. **Digestion** 1997;58(1):1–9 (38 ref.)
Calcium antagonist treatment, sympathetic activity and platelet function. Hjemdahl P, et al. **Eur Heart J** 1997 Jan; 18 Suppl A:A36–50 (105 ref.)
Sympathoadrenal system and immune system in the regulation of adrenocortical function. Ehrhart-Bornstein M, et al. **Eur J Endocrinol** 1996 Jul;135(1):19–26 (133 ref.)
The sympathetic skin response: a neurological perspective. Marchello L, et al. **Funct Neurol** 1996 Nov-Dec; 11(6):283–99 (104 ref.)
The cardiac beta-adrenoceptor-mediated signaling pathway and its alterations in hypertensive heart disease. Castellano M, et al. **Hypertension** 1997 Mar;29(3):715–22 (52 ref.)
The sympathetic nervous system as a target for intervention in obesity. Astrup A. **Int J Obes Relat Metab Disord** 1995 Dec;19 Suppl 7:S24–S28 (24 ref.)
Advances in our understanding of the role of the sympathetic nervous system in obesity. Macdonald IA. **Int J Obes Relat Metab Disord** 1995 Dec;19 Suppl 7:S2–S7 (31 ref.)
Low resting metabolic rate as a risk factor for weight gain: role of the sympathetic nervous system. Ravussin E. **Int J Obes Relat Metab Disord** 1995 Dec;19 Suppl 7:S8–S9 (16 ref.)
Effects of energy restriction and exercise on the sympathetic nervous system. Saris WH. **Int J Obes Relat Metab Disord** 1995 Dec;19 Suppl 7:S17–S23 (35 ref.)
Antiarrhythmic mechanisms during exercise. Paterson DJ. **J Appl Physiol** 1996 Jun;80(6):1853–62 (100 ref.)
Methods of sympathetic degeneration and alteration. Picklo MJ. **J Auton Nerv Syst** 1997 Feb 17;62(3):111–25 (158 ref.)
Changes in renal sympathetic nerve activities in the regulation of body fluid balance with special reference to central neuropeptides in conscious rats. Kannan H. **Jpn J Physiol** 1996 Apr;46(2):111–22 (107 ref.)
Neural control of the cardiovascular system: insights from muscle sympathetic nerve recordings in humans. Mitchell JH, et al. **Med Sci Sports Exerc** 1996 Oct;28(10 Suppl):S60–9 (48 ref.)
Noradrenaline storing vesicles in sympathetic neurons and their role in neurotransmitter release: an historical overview of controversial issues. De Potter WP, et al. **Neurochem Res** 1997 Aug;22(8):911–9 (74 ref.)
The development of cholinergic sympathetic neurons: a role for neuropoietic cytokines? Landis SC. **Perspect Dev Neurobiol** 1996;4(1):53–63 (105 ref.)
Changes in neuropeptide phenotype after axotomy of adult peripheral neurons and the role of leukemia inhibitory factor. Zigmond RE, et al. **Perspect Dev Neurobiol** 1996; 4(1):75–90 (146 ref.)
Interaction of nitric oxide with myogenic and adrenergic vasoconstrictor processes in the control of microcirculatory blood flow. Pohl U, et al. **Pflugers Arch** 1996;432(3 Suppl):R107–10 (46 ref.)
Adrenergic regulation of haematopoiesis. Maestroni GJ. **Pharmacol Res** 1995 Nov;32(5):249–53 (36 ref.)
Neural control of renal function. DiBona GF, et al. **Physiol Rev** 1997 Jan;77(1):75–197 (1736 ref.)
The role of altered sympathetic nervous system activity in the pathogenesis of obesity. Ravussin E, et al. **Proc Nutr Soc** 1996 Nov;55(3):793–802 (61 ref.)
Some principles of the spinal organization of the sympathetic preganglionic outflow. Cabot JB. **Prog Brain Res** 1996; 107:29–42 (81 ref.)
Role of medulla oblongata in generation of sympathetic and vagal outflows. Guyenet PG, et al. **Prog Brain Res** 1996; 107:127–44 (142 ref.)
Spinal cord reflex organization of sympathetic systems. Jänig W. **Prog Brain Res** 1996;107:43–77 (131 ref.)
Interactions of sympathetic and primary afferent neurons following nerve injury and tissue trauma. Jänig W, et al. **Prog Brain Res** 1996;113:161–84 (93 ref.)
Sympathetic modulation of cutaneous polymodal receptors in chronically inflamed and diabetic rats. Sato J, et al. **Prog Brain Res** 1996;113:153–9 (41 ref.)
Receptors controlling transmitter release from sympathetic neurons in vitro. Boehm S, et al. **Prog Neurobiol** 1997 Feb; 51(3):225–42 (94 ref.)
Impact of social environment characteristics on neuroendocrine regulation. Seeman TE, et al. **Psychosom Med** 1996 Sep-Oct;58(5):459–71 (159 ref.)
Regulation of net hepatic glucose uptake: interaction of neural and pancreatic mechanisms. Moore MC, et al. **Reprod Nutr Dev** 1996;36(4):399–406 (30 ref.)
Thermic effect of food and sympathetic nervous system activity in humans. Tappy L. **Reprod Nutr Dev** 1996; 36(4):391–7 (39 ref.)
Evidence that abnormalities of central neurohormonal systems are key to understanding fibromyalgia and chronic fatigue syndrome. Crofford LJ, et al. **Rheum Dis Clin North Am** 1996 May;22(2):267–84 (86 ref.)
[Interactions of adenosine with sympathetic neurotransmission in the heart] Ungerer M, et al. **Z Kardiol** 1996;85 Suppl 6:171–5 (33 ref.) (Eng. Abstr.) **(Ger)**
[Sympathetic–vagal euqilibrium and physical exercise] Pagani M. **Cardiologia** 1997 Jul;42(7):669–80 (46 ref.) **(Ita)**
[Sympathetic skin response (SSR)] Deguchi K, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:494–7 (12 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Sympathetic overactivity in hypertension. A moving target. Julius S, et al. **Am J Hypertens** 1996 Nov;9(11):113S–120S (64 ref.)
Relevance of 24 H blood pressure profile and sympathetic activity for outcome on short- versus long-acting 1,4-dihydropyridines. Ruzicka M, et al. **Am J Hypertens** 1996 Jan;9(1):86–94 (73 ref.)
Sympathetic neural mechanisms of cyclosporine-induced hypertension. Sander M, et al. **Am J Hypertens** 1996 Nov; 9(11):121S–138S (197 ref.)
Microneurography as a tool to investigate sympathetic nerve responses to environmental stress. Mano T. **Aviakosm Ekolog Med** 1997;31(1):8–14 (48 ref.)
Heart rate variability and its sympatho-vagal modulation. Lombardi F, et al. **Cardiovasc Res** 1996 Aug;32(2):208–16 (66 ref.)
Role of the sympathetic nervous system in the ischemic and reperfused heart. Hara A, et al. **EXS** 1996;76:285–97 (60 ref.)
The sympathetic nervous system in hypertension: a potential long-term regulator of arterial pressure. Mark AL. **J Hypertens Suppl** 1996 Dec;14(5):S159–65 (37 ref.)
Human polymodal receptors in pathological conditions. Ochoa J. **Prog Brain Res** 1996;113:185–97 (107 ref.)
[Hypertension and alcohol: central and peripheral mechanisms] Rupp H, et al. **Herz** 1996 Aug;21(4):258–64 (41 ref.) (Eng. Abstr.) **(Ger)**
[What is the role of the sympathetic nervous system in digital vasospasms?] Gasser P. **Schweiz Rundsch Med Prax** 1996 Oct 15;85(42):1320–3 (31 ref.) (Eng. Abstr.) **(Ger)**
[Sympathetic nervous system in heart failure: effect of catecholamines and nitric oxide] Drexler H. **Z Kardiol** 1996; 85 Suppl 6:247–52 (30 ref.) (Eng. Abstr.) **(Ger)**
[Neurogenic hypertension] Sasaki S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):87–90 (10 ref.) **(Jpn)**

RADIONUCLIDE IMAGING

Mechanism-based strategies for mapping heart sympathetic nerve function. Raffel DM, et al. **Nucl Med Biol** 1995 Nov; 22(8):1019–26 (45 ref.)
[Metabolic, adrenergic, and systolic function assessed by cardiac SPECT] Hattori N, et al. **Nippon Rinsho** 1997 Mar; 55 Suppl 1:656–61 (8 ref.) **(Jpn)**

SYMPATHETIC TRANSMITTER RELEASERS see **ADRENERGIC AGENTS**

SYMPATHINS see **CATECHOLAMINES**

SYMPATHOLYTICS

see related
ADRENERGIC AGENTS
ADRENERGIC ANTAGONISTS

Treatment of algodystrophy using intravenous guanethidine regional block. Jacquemoud G, et al. **Ann Chir Main** 1982; 1(1):57–64 (16 ref.) **(Eng, Fre)**

ADMINISTRATION & DOSAGE

Deep chemical peeling. Matarasso SL, et al. **Semin Cutan Med Surg** 1996 Sep;15(3):155–61 (33 ref.)

ADVERSE EFFECTS

Self-induced overdose of ADHD medication. Pearson CC. **J Paediatr Child Health** 1996 Jun;32(3):267 (4 ref.)

THERAPEUTIC USE

Vasodepressor syncope. Diagnosis and management. Barbey JT. **Cardiol Clin** 1997 May;15(2):251–6 (41 ref.)
Considerations in the treatment of insulin resistance and related disorders with a new sympatholytic agent. Lithell HO. **J Hypertens Suppl** 1997 Jan;15(1):S39–42 (30 ref.)

SYMPATHOMIMETICS

see related
ADRENERGIC / GONISTS
ADRENERGIC UPTAKE INHIBITORS
CARDIOTONIC AGENTS
CARDIOVASCULAR AGENTS
MONOAMINE OXIDASE INHIBITORS
RECEPTORS, ADRENERGIC

ADVERSE EFFECTS

Anomalous effects of albuterol and other sympathomimetics in the guinea pig. Morley J. **Clin Rev Allergy Immunol** 1996 Spring;14(1):65–89 (57 ref.)

PHARMACOLOGY

Anomalous effects of albuterol and other sympathomimetics in the guinea pig. Morley J. **Clin Rev Allergy Immunol** 1996 Spring;14(1):65–89 (57 ref.)
Cisapride. Drug interactions of clinical significance. Bedford TA, et al. **Drug Saf** 1996 Sep;15(3):167–75 (31 ref.)

POISONING

Eye drops—the hidden poison. Jones AL, et al. **Scott Med J** 1996 Aug;41(4):110–2 (32 ref.)

THERAPEUTIC USE

Pharmacologic intervention for acute low cardiac output. Marchetti A, et al. **Adv Card Surg** 1996;7:31–64 (91 ref.)
[Treatments of stress urinary incontinence (SUI) in women] Benizri EJ. **J Urol (Paris)** 1996;102(3):117–22 (68 ref.) **(Fre)**
[An approach to the pharmacological treatment of autism] Ruggieri VL. **Rev Neurol** 1996 Nov;24(135):1451–5 (58 ref.) (Eng. Abstr.) **(Spa)**

SYMPORT see **ION TRANSPORT**

SYNAPSES

see related
GAP JUNCTIONS
SYNAPTIC TRANSMISSION
SYNAPTOSOMES

Hypothetical mechanisms for the cellular and neurophysiologic basis of secondary epileptogenesis: proposed role of synaptic reorganization. Dudek FE, et al. **J Clin Neurophysiol** 1997 Mar;14(2):90–101 (67 ref.)
Axonal sprouting and synaptogenesis in temporal lobe epilepsy: possible pathogenetic and therapeutic roles of neurite growth inhibitory factors. Larner AJ. **Seizure** 1995 Dec;4(4):249–58 (68 ref.)
[The retrograde messengers in hippocampal long-term potentiation] Hu ZA, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan;27(1):82–4 (7 ref.) **(Chi)**

CHEMISTRY

Presynaptic mechanisms in central synaptic transmission: 'biochemistry' of an intact glutamatergic synapse. Shupliakov O, et al. **Acta Physiol Scand** 1996 Jul; 157(3):369–79 (60 ref.)
Cytoskeletal interactions with glutamate receptors at central synapses. Westbrook GL, et al. **Soc Gen Physiol Ser** 1997; 52:163–75 (76 ref.)
An old friend in a new home: cadherins at the synapse. Serafini T. **Trends Neurosci** 1997 Aug;20(8):322–3 (24 ref.)

DRUG EFFECTS

Synaptic effects of antidepressants. Richelson E. **J Clin Psychopharmacol** 1996 Jun;16(3 Suppl 2):1S–7S; discussion 7S–9S (9 ref.)

ENZYMOLOGY

Nip and tuck at the neuromuscular junction: a role for proteases in developmental synapse elimination. Chang Q, et al. **Bioessays** 1997 Apr;19(4):271–5 (33 ref.)

GENETICS

Genetic analysis of postsynaptic differentiation at the vertebrate neuromuscular junction. Sanes JR. **Curr Opin Neurobiol** 1997 Feb;7(1):93–100 (69 ref.)
Messengers from the synapses to the nucleus (MSNs) that establish late phase of long-term potentiation (LTP) and long-term memory. Suzuki T. **Neurosci Res** 1996 May; 25(1):1–6 (75 ref.)

METABOLISM

The pressor reflex evoked by static contraction: neurochemistry at the site of the first synapse. Wilson LB, et al. **Brain Res Brain Res Rev** 1997 Apr;23(3):196–209 (120 ref.)
Features of P2X receptor-mediated synapses in the rat brain: why doesn't ATP kill the postsynaptic cell? Edwards FA. **Ciba Found Symp** 1996;198:278–86; discussion 286–9 (15 ref.)
Synaptic plasticity: A molecular mechanism for metaplasticity. Deisseroth K, et al. **Curr Biol** 1995 Dec

1;5(12):1334–8 (30 ref.)
Synaptic structural dynamics and aging. Bertoni-Freddari C, et al. **Gerontology** 1996;42(3):170–80 (51 ref.)
Intersynaptic diffusion of neurotransmitter. Barbour B, et al. **Trends Neurosci** 1997 Sep;20(9):377–84 (58 ref.)

PATHOLOGY

Synaptic dysplasia in sympathetic autonomic ganglia. Schmidt RE. **J Neurocytol** 1996 Dec;25(12):777–91 (88 ref.)

PHYSIOLOGY

Synaptogenesis, heterochrony and epigenesis in the mammalian neocortex. Bourgeois JP. **Acta Paediatr Suppl** 1997 Jul;422:27–33 (62 ref.)
The development of nerve connections in the peripheral nervous system. Cullheim S. **Acta Paediatr Suppl** 1996 Oct; 416:3–7 (24 ref.)
Transmission and processing of synaptic information in single neurones: an introduction. Kiehn O, et al. **Acta Physiol Scand** 1996 Jul;157(3):367–8 (4 ref.)
Axonal growth and neosynaptogenesis in human and experimental hippocampal epilepsy. Babb TL. **Adv Neurol** 1997;72:45–51 (18 ref.)
Molecular and cellular cascades in seizure-induced neosynapse formation. Represa A, et al. **Adv Neurol** 1997; 72:25–34 (60 ref.)
Modifiable neuronal connections: an overview for psychiatrists. Jeffery KJ, et al. **Am J Psychiatry** 1997 Feb; 154(2):156–64 (35 ref.)
Long-term depression in hippocampus. Bear MF, et al. **Annu Rev Neurosci** 1996;19:437–62 (113 ref.)
Mechanisms and molecules that control growth cone guidance. Goodman CS. **Annu Rev Neurosci** 1996; 19:341–77 (178 ref.)
The drosophila neuromuscular junction: a model system for studying synaptic development and function. Keshishian H, et al. **Annu Rev Neurosci** 1996;19:545–75 (133 ref.)
Synaptic regulation of mesocorticolimbic dopamine neurons. White FJ. **Annu Rev Neurosci** 1996;19:405–36 (191 ref.)
Synaptic dysfunction in Alzheimer's disease: clinical assessment using quantitative EEG. Cook IA, et al. **Behav Brain Res** 1996 Jun;78(1):15–23 (42 ref.)
Modulation of cognitive processes by transsynaptic activation of the basal forebrain. Givens B, et al. **Behav Brain Res** 1997 Mar;84(1–2):1–22 (217 ref.)
Patterns of synaptic and nerve cell pathology in Alzheimer's disease. Lassmann H. **Behav Brain Res** 1996 Jun;78(1):9–14 (61 ref.)
Trans-synaptic stimulation of cortical acetylcholine and enhancement of attentional functions: a rational approach for the development of cognition enhancers. Sarter M, et al. **Behav Brain Res** 1997 Feb;83(1–2):7–14 (100 ref.)
Sleep states, memory processes and synaptic plasticity. Smith C. **Behav Brain Res** 1996 Jun;78(1):49–56 (71 ref.)
Signaling mechanisms mediating synapse formation. Wallace BG. **Bioessays** 1996 Oct;18(10):777–80 (27 ref.)
Potential neuronal mechanisms of estrogen actions in synaptogenesis and synaptic plasticity. Naftolin F, et al. **Cell Mol Neurobiol** 1996 Apr;16(2):213–23 (30 ref.)
Synaptic interactions in neocortical local circuits: dual intracellular recordings in vitro. Thomson AM, et al. **Cereb Cortex** 1997 Sep;7(6):510–22 (114 ref.)
A systematic approach to studying synaptic function in vertebrates. Janz R, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:309–14 (17 ref.)
Drosophila genetics and the functions of synaptic proteins. Parfitt K, et al. **Cold Spring Harb Symp Quant Biol** 1995; 60:371–7 (46 ref.)
Neurotrophic factors in brain synaptic plasticity. Nawa H, et al. **Crit Rev Neurobiol** 1997;11(1):91–100 (86 ref.)
Perceptual learning: insight in sight. Walsh V, et al. **Curr Biol** 1997 Apr 1;7(4):R249–51 (11 ref.)
Calcium regulation of neurotransmitter release: reliably unreliable? Goda Y, et al. **Curr Opin Cell Biol** 1997 Aug; 9(4):513–8 (40 ref.)
Neurotrophins and activity-dependent development of the neocortex. Bonhoeffer T. **Curr Opin Neurobiol** 1996 Feb; 6(1):119–26 (56 ref.)
Synapse maturation and structural plasticity at Drosophila neuromuscular junctions. Budnik V. **Curr Opin Neurobiol** 1996 Dec;6(6):858–67 (80 ref.)
Synaptic mechanisms in invertebrate pattern generation. Cropper EC, et al. **Curr Opin Neurobiol** 1996 Dec; 6(6):833–41 (48 ref.)
Saturation of postsynaptic receptors at central synapses? Frerking M, et al. **Curr Opin Neurobiol** 1996 Jun; 6(3):395–403 (66 ref.)
Role of neurotrophic factors in neuronal development. Henderson CE. **Curr Opin Neurobiol** 1996 Feb;6(1):64–70 (61 ref.)
Synaptic exocytosis and endocytosis: capacitance measurements. Matthews G. **Curr Opin Neurobiol** 1996 Jun; 6(3):358–64 (43 ref.)
Mechanism of synapse disassembly at the developing neuromuscular junction. Nguyen QT, et al. **Curr Opin Neurobiol** 1996 Feb;6(1):104–12 (68 ref.)
New views on synapse-glia interactions. Pfrieger FW, et al. **Curr Opin Neurobiol** 1996 Oct;6(5):615–21 (79 ref.)
Genetic analysis of postsynaptic differentiation at the vertebrate neuromuscular junction. Sanes JR. **Curr Opin Neurobiol** 1997 Feb;7(1):93–100 (69 ref.)
Intracellular and molecular aspects of Ca(2+)-mediated signal transduction in neuronal cells. Račay P, et al. **Gen Physiol Biophys** 1996 Aug;15(4):273–89 (89 ref.)
Intracellular studies of heterosynaptic long-term depression (LTD) in CA1 of hippocampal slices. Barry MF, et al. **Hippocampus** 1996;6(1):3–8 (24 ref.)
Ovarian steroidal control of connectivity in the female hippocampus: an overview of recent experimental findings and speculations on its functional consequences. Desmond NL, et al. **Hippocampus** 1997;7(2):239–45 (85 ref.)
LTD: many means to how many ends? Kerr DS, et al. **Hippocampus** 1996;6(1):30–4 (41 ref.)
LTD, LTP, and the sliding threshold for long-term synaptic plasticity. Stanton PK. **Hippocampus** 1996;6(1):35–42 (69 ref.)
Homosynaptic LTD and depotentiation: do they differ in name only? Wagner JJ, et al. **Hippocampus** 1996;6(1):24–9 (37 ref.)
The receptor mosaic hypothesis of the engram: possible relevance of Boolean network modeling. Zoli M, et al. **Int J Neural Syst** 1996 Sep;7(4):363–8 (40 ref.)
Developmental and genetic regulation of programmed neuronal death. Weller M, et al. **J Neural Transm Suppl** 1997;50:115–23 (29 ref.)
Multiple factors shape development of olfactory glomeruli: insights from an insect model system. Oland LA, et al. **J Neurobiol** 1996 May;30(1):92–109 (136 ref.)
Functional role of receptor neurons in encoding olfactory information. Trotier D, et al. **J Neurobiol** 1996 May; 30(1):58–66 (40 ref.)
Genetic analysis of cholinergic nerve terminal function in invertebrates. Baylis HA, et al. **J Neurocytol** 1996 Dec; 25(12):747–62 (100 ref.)
Gap junctions as electrical synapses. Bennett MV. **J Neurocytol** 1997 Jun;26(6):349–66 (98 ref.)
The role of synapses in cortical computation. Douglas RJ, et al. **J Neurocytol** 1996 Dec;25(12):893–911 (104 ref.)
Synaptic dysplasia in sympathetic autonomic ganglia. Schmidt RE. **J Neurocytol** 1996 Dec;25(12):777–91 (88 ref.)
Ultrastructural basis for gene expression at the synapse: synapse-associated polyribosome complexes. Steward O, et al. **J Neurocytol** 1996 Dec;25(12):717–34 (51 ref.)
Induction of heterosynaptic and homosynaptic LTD in hippocampal sub-regions in vivo. Abraham WC. **J Physiol Paris** 1996;90(5–6):305–6 (13 ref.)
Progress in understanding NMDA-receptor-dependent synaptic plasticity in the visual cortex. Bear MF. **J Physiol Paris** 1996;90(3–4):223–7 (39 ref.)
A discussion of activity-dependent forms of synaptic weakening and their possible role in ocular dominance plasticity. Dudek SM. **J Physiol Paris** 1996;90(3–4):167–70 (38 ref.)
Does Hebbian synaptic plasticity explain learning-induced sensory plasticity in adult mammals? Edeline JM. **J Physiol Paris** 1996;90(3–4):271–6 (52 ref.)
Expression mechanisms of long-term potentiation in the hippocampus. Isaac JT, et al. **J Physiol Paris** 1996; 90(5–6):299–303 (12 ref.)
Plasticity of the hippocampal-prefrontal cortex synapses. Jay TM, et al. **J Physiol Paris** 1996;90(5–6):361–6 (19 ref.)
Postsynaptic calcium and calcium-dependent processes in synaptic plasticity in the developing visual cortex. Tsumoto T, et al. **J Physiol Paris** 1996;90(3–4):151–6 (21 ref.)
Synaptic targeting of ionotropic neurotransmitter receptors. Kirsch J, et al. **Mol Cell Neurosci** 1996;8(2–3):93–8 (50 ref.)
Are neurotrophins synaptotrophins? Snider WD, et al. **Mol Cell Neurosci** 1996 Jun;7(6):433–42 (39 ref.)
Intercellular communication that mediates formation of the neuromuscular junction. Daniels MP. **Mol Neurobiol** 1997 Jun;14(3):143–70 (225 ref.)
Repetitive CMAPs: mechanisms of neural and synaptic genesis. van Dijk JG, et al. **Muscle Nerve** 1996 Sep; 19(9):1127–33 (51 ref.)
Nitric oxide precursor arginine and S-nitrosoglutathione in synaptic and glial function. Do KQ, et al. **Neurochem Int** 1996 Sep;29(3):213–24 (94 ref.)
CaM kinase II in long-term potentiation. Fukunaga K, et al. **Neurochem Int** 1996 Apr;28(4):343–58 (151 ref.)
Cell adhesion molecules, CREB, and the formation of new synaptic connections [comment] Martin KC, et al. **Neuron** 1996 Oct;17(4):567–70 (17 ref.) Comment on: Neuron 1996 Oct;17(4):641–54. Comment on: Neuron 1996 Oct;17(4):655–67. Comment on: Neuron 1996 Oct;17(4):669–76.
Synaptic economics: competition and cooperation in synaptic plasticity. Miller KD. **Neuron** 1996 Sep;17(3):371–4 (24 ref.)
Pre- and postfusion regulation of transmitter release. Rahamimoff R, et al. **Neuron** 1997 Jan;18(1):17–27 (128 ref.)
Synapse specificity and long-term information storage. Schuman EM. **Neuron** 1997 Mar;18(3):339–42 (22 ref.)
PDZs and receptor/channel clustering: rounding up the latest suspects [comment] Sheng M. **Neuron** 1996 Oct;17(4):575–8 (19 ref.) Comment on: Neuron 1996 Oct;17(4):759–67.
Dynamic synapses in the cortex. Zador AM, et al. **Neuron** 1997 Jul;19(1):1–4 (16 ref.)
Synaptic plasticity and physiological interactions between dopamine and glutamate in the striatum. Calabresi P, et al. **Neurosci Biobehav Rev** 1997 Jul;21(4):519–23 (60 ref.)
Memory, sleep and the evolution of mechanisms of synaptic efficacy maintenance. Kavanau JL. **Neuroscience** 1997 Jul; 79(1):7–44 (347 ref.)
Agrin: an extracellular matrix heparan sulfate proteoglycan involved in cell interactions and synaptogenesis. Cole GJ, et al. **Perspect Dev Neurobiol** 1996;3(4):359–71 (86 ref.)
Synaptic development in macaque monkey retina and its implications for other developmental sequences. Hendrickson AE. **Perspect Dev Neurobiol** 1996; 3(3):195–201 (58 ref.)
Toward a molecular definition of long-term memory storage. Bailey CH, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13445–52 (69 ref.)
A synaptic basis for memory storage in the cerebral cortex. Bear MF. **Proc Natl Acad Sci U S A** 1996 Nov 26; 93(24):13453–9 (59 ref.)
Memory from the dynamics of intrinsic membrane currents. Marder E, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26; 93(24):13481–6 (42 ref.)
Nicotinic acetylcholine receptors on hippocampal neurons: cell compartment-specific expression and modulatory control of channel activity. Albuquerque EX, et al. **Prog Brain Res** 1996;109:111–24 (88 ref.)
NMDA-receptor-dependent synaptic plasticity in the visual cortex. Bear MF. **Prog Brain Res** 1996;108:205–18 (78 ref.)
Cellular mechanisms underlying the formation of orderly connections in developing sensory pathways. Erzurumlu RS, et al. **Prog Brain Res** 1996;108:287–301 (85 ref.)
Developmental mechanisms for regulating signal amplification at excitatory synapses in the neocortex. Friedlander MJ, et al. **Prog Brain Res** 1996;108:245–62 (99 ref.)
Molecular organization of cerebellar glutamate synapses. Ottersen OP, et al. **Prog Brain Res** 1997;114:97–107 (45 ref.)
Purinergic regulation of acetylcholine release. Ribeiro JA, et al. **Prog Brain Res** 1996;109:231–41 (41 ref.)
Physiology of transmission at a giant glutamatergic synapse in cerebellum. Slater NT, et al. **Prog Brain Res** 1997; 114:151–63 (47 ref.)
Synaptic modulation by neurotrophic factors. Stoop R, et al. **Prog Brain Res** 1996;109:359–64 (37 ref.)
Reciprocal trophic interactions between climbing fibres and Purkinje cells in the rat cerebellum. Strata P, et al. **Prog Brain Res** 1997;114:263–82 (91 ref.)
Molecular properties and cellular distribution of cholinergic synaptic proteins. Zimmermann H, et al. **Prog Brain Res** 1996;109:31–40 (53 ref.)
Control of retinotectal axon arbor growth by postsynaptic CaMKII. Zou DJ, et al. **Prog Brain Res** 1996;108:303–12 (44 ref.)
Metaplasticity: a new vista across the field of synaptic plasticity. Abraham WC, et al. **Prog Neurobiol** 1997 Jul; 52(4):303–23 (138 ref.)
Autonomic neuromuscular transmission at a varicosity. Bennett MR. **Prog Neurobiol** 1996 Dec;50(5–6):505–32 (123 ref.)
Thalamocortical synapses. Castro-Alamancos MA, et al. **Prog Neurobiol** 1997 Apr;51(6):581–606 (205 ref.)
Glia-neuron intercommunications and synaptic plasticity. Vernadakis A. **Prog Neurobiol** 1996 Jun;49(3):185–214 (292 ref.)
Wiring and volume transmission in the central nervous system: the concept of closed and open synapses. Zoli M, et al. **Prog Neurobiol** 1996 Jul;49(4):363–80 (156 ref.)
Protein kinase C in synaptic plasticity: changes in the in situ phosphorylation state of identified pre- and postsynaptic substrates [see comments] Ramakers GM, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Apr; 21(3):455–86 (193 ref.) Comment in: Prog Neuropsychopharmacol Biol Psychiatry 1997 Apr;21(3):373–8.
Associative synaptic plasticity in hippocampus and visual cortex: cellular mechanisms and functional implications. Debanne D. **Rev Neurosci** 1996 Jan–Mar;7(1):29–46 (160 ref.)
Synapse elimination in the central nervous system: functional significance and cellular mechanisms. Lohof AM, et al. **Rev Neurosci** 1996 Apr–Jun;7(2):85–101 (138 ref.)
Synaptic activity and the construction of cortical circuits. Katz LC, et al. **Science** 1996 Nov 15;274(5290):1133–8 (86 ref.)
Growth factors sculpt the synapse [comment] Schuman E. **Science** 1997 Feb 28;275(5304):1277–8 (16 ref.) Comment on: Science 1997 Feb 28;275(5304):1318–20.
Nitric oxide, the enigmatic neuronal messenger: its role in synaptic plasticity. Hölscher C. **Trends Neurosci** 1997 Jul; 20(7):298–303 (93 ref.)
Information processing by graded-potential transmission through tonically active synapses. Juusola M, et al. **Trends Neurosci** 1996 Jul;19(7):292–7 (56 ref.)
Bursts as a unit of neural information: making unreliable synapses reliable [see comments] Lisman JE. **Trends Neurosci** 1997 Jan;20(1):38–43 (74 ref.) Comment in: Trends Neurosci 1997 Jun;20(6):244.
Centenary of the synapse: from Sherrington to the molecular biology of the synapse and beyond. Shepherd GM, et al. **Trends Neurosci** 1997 Sep;20(9):385–92 (72 ref.)
[Synaptogenesis and synaptic pruning: role in triggering schizophrenia] Granger B. **Presse Med** 1996 Nov 2; 25(33):1595–8 (25 ref.) (Eng. Abstr.) **(Fre)**
[Reversible changes of the neural pathways and receptor functions associated with development and regeneration following nerve injuries] Nabekura J. **Fukuoka Igaku Zasshi** 1997 Jul;88(7):267–73 (7 ref.) **(Jpn)**

[Dynamic regulation of the NMDA receptor channel subunits in the central nervous system and their involvement in synaptic plasticity and development] Watanabe M. **Kaibogaku Zasshi** 1996 Oct;71(5):517–22 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Postsynaptic density proteins related to the expression and modulation of synaptic plasticity] Suzuki T. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Apr; 16(2):53–8 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Ca2+ channels in the central nervous system] Murakoshi T, et al. **Nippon Yakurigaku Zasshi** 1997 May;109(5):213–22 (56 ref.) (Eng. Abstr.) **(Jpn)**

[Neurotrophic factors and synaptic plasticity in the central nervous system] Nawa H, et al. **Tanpakushitsu Kakusan Koso** 1996 Dec;41(16):2513–21 (86 ref.) **(Jpn)**

[Neurotrophin and synaptic plasticity] Takei N, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):481–8 (47 ref.) **(Jpn)**

[Role of cadherin adhesion systems in selective synapse formation] Uchida N, et al. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):525–34 (58 ref.) **(Jpn)**

[The system of subsynaptic units as an universal system–organizing and regulating factor of brain synapses] Semchenko VV, et al. **Biull Eksp Biol Med** 1997 Jul; 124(7):4–12 (82 ref.) **(Rus)**

[The morphofunctional characteristics of the neurons and their connections in the neocortex of man and animals] Okhotin VE, et al. **Usp Fiziol Nauk** 1997 Apr–Jun; 28(2):40–56 (131 ref.) (Eng. Abstr.) **(Rus)**

[The general principles of synaptic plasticity in the neocortex, hippocampus and cerebellum] Sil'skiĭ IG. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 Mar–Apr; 47(2):374–92 (73 ref.) (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

Presynaptic bodies ("ribbons"): from ultrastructural observations to molecular perspectives. Wagner HJ. **Cell Tissue Res** 1997 Mar;287(3):435–46 (110 ref.)

How to count synapses unbiasedly and efficiently at the ultrastructural level: proposal for a standard sampling and counting protocol. Mayhew TM. **J Neurocytol** 1996 Dec; 25(12):793–804 (84 ref.)

The morphology of synapses. Peters A, et al. **J Neurocytol** 1996 Dec;25(12):687–700 (64 ref.)

Ultrastructural basis for gene expression at the synapse: synapse-associated polyribosome complexes. Steward O, et al. **J Neurocytol** 1996 Dec;25(12):717–34 (51 ref.)

Ultrastructure of synapses in the first-evolved nervous systems. Westfall IA. **J Neurocytol** 1996 Dec;25(12):735–46 (53 ref.)

Plasticity of retinal ribbon synapses. Vollrath L, et al. **Microsc Res Tech** 1996 Dec 15;35(6):472–87 (151 ref.)

Structural correlates of cognition in dementia: quantification and assessment of synapse change. DeKosky ST, et al. **Neurodegeneration** 1996 Dec;5(4):417–21 (32 ref.)

[The morphofunctional characteristics of the neurons and their connections in the neocortex of man and animals] Okhotin VE, et al. **Usp Fiziol Nauk** 1997 Apr–Jun; 28(2):40–56 (131 ref.) (Eng. Abstr.) **(Rus)**

SYNAPTIC BOUTONS see **PRESYNAPTIC TERMINALS**

SYNAPTIC MEMBRANES

see related
SYNAPTOSOMES

METABOLISM

Binding proteins on synaptic membranes for certain phospholipases A2 with presynaptic toxicity. Tzeng MC, et al. **Adv Exp Med Biol** 1996;391:271–8 (46 ref.)

SYNAPTIC POTENTIALS see **SYNAPTIC TRANSMISSION**

SYNAPTIC RECEPTORS see **RECEPTORS, NEUROTRANSMITTER**

SYNAPTIC TERMINALS see **PRESYNAPTIC TERMINALS**

SYNAPTIC TRANSMISSION

see related
GAP JUNCTIONS
NEUROTRANSMITTERS
SYNAPSES

Exercise pressor reflex: studies on the effect of skeletal muscle fiber type and spinal cord transmission. Wilson LB, et al. **Adv Exp Med Biol** 1995;381:187–97 (34 ref.)

Purinergic receptors: their role in nociception and primary afferent neurotransmission. Burnstock G, et al. **Curr Opin Neurobiol** 1996 Aug;6(4):526–32 (63 ref.)

Synaptic transmission at vertebrate hair cells. Fuchs PA. **Curr Opin Neurobiol** 1996 Aug;6(4):514–9 (54 ref.)

ATP as a cotransmitter in perivascular sympathetic nerves. Kennedy C. **J Auton Pharmacol** 1996 Dec;16(6):337–40 (11 ref.)

Interactions of adenosine with sympathetic neurotransmission: protective effect in myocardial ischemia. Richardt G, et al. **J Auton Pharmacol** 1996 Dec; 16(6):333–5 (18 ref.)

Neuromuscular transmission at an active zone: the secretosome hypothesis. Bennett MR. **J Neurocytol** 1996 Dec;25(12):869–91 (116 ref.)

Ultrastructural view of central catecholaminergic transmission: immunocytochemical localization of synthesizing enzymes, transporters and receptors. Pickel VM, et al. **J Neurocytol** 1996 Dec;25(12):843–56 (141 ref.)

Anatomic organization of the basilar pontine projections from prefrontal cortices in rhesus monkey. Schmahmann JD, et al. **J Neurosci** 1997 Jan 1;17(1):438–58 (96 ref.)

Pre- and postfusion regulation of transmitter release. Rahamimoff R, et al. **Neuron** 1997 Jan;18(1):17–27 (128 ref.)

The Otto Loewi Lecture. Loewi's discovery and the XXI century. Karczmar AG. **Prog Brain Res** 1996;109:1–27, xvii (108 ref.)

Non-adrenergic non-cholinergic (NANC) transmission to smooth muscle: 35 years on. Bennett MR. **Prog Neurobiol** 1997 Jun;52(3):159–95 (261 ref.)

Biochemistry, localization and functional roles of ecto-nucleotidases in the nervous system. Zimmermann H. **Prog Neurobiol** 1996 Aug;49(6):589–618 (340 ref.)

Growth factors sculpt the synapse [comment] Schuman E. **Science** 1997 Feb 28;275(5304):1277–8 (16 ref.) Comment on: Science 1997 Feb 28;275(5304):1318–20.

[Neurochemical aspect of brain aging—neuronal death and decreased synaptic functions] Nomura Y. **Hokkaido Igaku Zasshi** 1996 May;71(3):309–14 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Dynamic analysis of neuronal responses by video microscopy: direct visualization of release and acceptance of neuronal signals] Terakawa S. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Apr; 16(2):59–64 (11 ref.) **(Jpn)**

[Impulse conduction and synaptic transmission] Haga T. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):203–7 (7 ref.) **(Jpn)**

DRUG EFFECTS

Domperidone as a tool to assess the role of dopamine within carotid body chemoreception. Zapata P, et al. **Adv Exp Med Biol** 1996;410:291–7 (36 ref.)

Pharmacological effects of oximes: how relevant are they? van Helden HP, et al. **Arch Toxicol** 1996;70(12):779–86 (44 ref.)

Neuroprotection by the pyridoindole stobadine: a minireview. Stolc S, et al. **Brain Res Bull** 1997;42(5):335–40 (55 ref.)

Nicotine and sympathetic neurotransmission. Haass M, et al. **Cardiovasc Drugs Ther** 1997 Jan;10(6):657–65 (55 ref.)

Phosphodiesterase inhibitors and endothelin as modulators of respiratory neurotransmission. Fernandes LB. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov;23(10–11):980–2 (35 ref.)

Synaptic signaling by nitric oxide. Brenman JE, et al. **Curr Opin Neurobiol** 1997 Jun;7(3):374–8 (43 ref.)

Monitoring of neuromuscular transmission by electromyography during anaesthesia. A comparison with mechanomyography in cat and man. Engbaek J. **Dan Med Bull** 1996 Sep;43(4):301–16 (188 ref.)

Modulation of neurotransmission by cannabinoids in the basal ganglia. Glass M, et al. **Eur J Neurosci** 1997 Feb; 9(2):199–203 (75 ref.)

Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine [published erratum appears in Int Clin Psychopharmacol 1996 Jun;11(2):153] Haddjeri N, et al. **Int Clin Psychopharmacol** 1995 Dec;10 Suppl 4:11–7 (30 ref.)

Synaptic effects of antidepressants. Richelson E. **J Clin Psychopharmacol** 1996 Jun;16(3 Suppl 2):1S–7S; discussion 7S–9S (9 ref.)

Noradrenergic mechanisms in the prefrontal cortex. Nutt DJ, et al. **J Psychopharmacol (Oxf)** 1997;11(2):163–8 (45 ref.)

On the role of c-fos expression in striatal transmission. The antisense oligonucleotide approach. Sommer W, et al. **Neurochem Int** 1997 Sep;31(3):425–36 (50 ref.)

Neuromuscular transmission and its pharmacological blockade. Part 3: Continuous infusion of relaxants and reversal and monitoring of relaxation. Booij LH. **Pharm World Sci** 1997 Feb;19(1):35–44 (152 ref.)

Neuromuscular transmission and its pharmacological blockade. Part 1: Neuromuscular transmission and general aspects of its blockade. Booij LH. **Pharm World Sci** 1997 Feb;19(1):1–12 (159 ref.)

Potassium channel activation: a potential therapeutic approach? Lawson K. **Pharmacol Ther** 1996;70(1):39–63 (301 ref.)

Excitatory and inhibitory amino acids and synaptic transmission in the suprachiasmatic nucleus. van den Pol AN, et al. **Prog Brain Res** 1996;111:41–56 (76 ref.)

The effects of methylenedioxymethamphetamine (MDMA, "Ecstasy") on monoaminergic neurotransmission in the central nervous system. White SR, et al. **Prog Neurobiol** 1996 Aug;49(5):455–79 (136 ref.)

Presynaptic inhibition by serotonin: a possible mechanism for switching motor output of the hypoglossal nucleus. Singer JH, et al. **Sleep** 1996 Dec;19(10 Suppl):S146–9 (28 ref.)

The stimulatory effects of opioids and their possible role in the development of tolerance. Smart D, et al. **Trends Pharmacol Sci** 1996 Jul;17(7):264–9 (58 ref.)

[Schizophrenia and neural transmission: an excess of analogical treatment?] Tassin JP. **Encephale** 1996 Oct;22 Spec No 3:91–8 (55 ref.) **(Fre)**

[The pharmacodynamics of general anesthetics. The neurological and cardiovascular aspects] Vale FM. **Rev Port Cardiol** 1997 Jan;16(1):41–50, 8 (34 ref.) (Eng. Abstr.) **(Por)**

GENETICS

Seizure-induced molecular changes, sprouting and synaptogenesis of hippocampal mossy fibers. Pollard H, et al. **Epilepsy Res Suppl** 1996;12:355–63 (32 ref.)

PHYSIOLOGY

Excitatory synaptic transmission in the rat medical vestibular nucleus. Takahashi Y, et al. **Acta Otolaryngol Suppl (Stockh)** 1997;528:56–8 (21 ref.)

Transmission and processing of synaptic information in single neurones: an introduction. Kiehn O, et al. **Acta Physiol Scand** 1996 Jul;157(3):367–8 (4 ref.)

Active membrane properties and spatiotemporal synaptic integration in dendrites of vertebrate neurones. Midtgaard J. **Acta Physiol Scand** 1996 Jul;157(3):395–401 (50 ref.)

Presynaptic mechanisms in central synaptic transmission: 'biochemistry' of an intact glutamatergic synapse. Shupliakov O, et al. **Acta Physiol Scand** 1996 Jul; 157(3):369–79 (60 ref.)

Role of adenosine as a modulator of synaptic activity in the central nervous system. Brundege JM, et al. **Adv Pharmacol** 1997;39:353–91 (200 ref.)

The role of vesicular transport proteins in synaptic transmission and neural degeneration. Liu Y, et al. **Annu Rev Neurosci** 1997;20:125–56 (178 ref.)

Neuroendocrine responses to serotonergic agonists as indices of the functional status of central serotonin neurotransmission in humans: a preliminary comparative analysis of neuroendocrine endpoints versus other endpoint measures. Murphy DL, et al. **Behav Brain Res** 1996; 73(1–2):209–14 (51 ref.)

Interactions of descending serotonergic systems with other neurotransmitters in the modulation of nociception. Sawynok J, et al. **Behav Brain Res** 1996;73(1–2):63–8 (42 ref.)

Olfaction, GABAergic neurotransmission in the olfactory bulb, and intermale aggression in mice: modulation by steroids. Guillot PV, et al. **Behav Genet** 1996 Sep; 26(5):497–504 (65 ref.)

SNAP-25, enSNAREd in neurotransmission and regulation of behaviour. Wilson MC, et al. **Biochem Soc Trans** 1996 Aug;24(3):670–76 (49 ref.)

Elementary forms of synaptic plasticity in the visual cortex. Kirkwood A, et al. **Biol Res** 1995;28(1):73–80 (23 ref.)

Resonant cell assemblies: a new approach to cognitive functions and neuronal synchrony. Varela FJ. **Biol Res** 1995;28(1):81–95 (69 ref.)

Glutamate: a role in normal brain function, anaesthesia, analgesia and CNS injury. Hudspith MJ. **Br J Anaesth** 1997 Jun;78(6):731–47 (232 ref.)

Evidence for the Hebbian hypothesis in experience-dependent physiological plasticity of neocortex: a critical review. Cruikshank SJ, et al. **Brain Res Brain Res Rev** 1996 Oct;22(3):191–228 (171 ref.)

Morphological adaptations of neuromuscular junctions depend on fiber type. Sieck GC, et al. **Can J Appl Physiol** 1997 Jun;22(3):197–230 (156 ref.)

Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Fink G, et al. **Cell Mol Neurobiol** 1996 Jun;16(3):325–44 (87 ref.)

Sensory afferent neurotransmission in caudal nucleus tractus solitarius—common denominators. Andresen MC, et al. **Chem Senses** 1996 Jun;21(3):387–95 (68 ref.)

Dipole theory and electroencephalography. Niedermeyer E. **Clin Electroencephalogr** 1996 Jul;27(3):121–31 (78 ref.)

Neurotrophic factors are required by mature sympathetic neurons for survival, transmission and connectivity. Rush RA, et al. **Clin Exp Pharmacol Physiol** 1997 Aug; 24(8):549–55 (31 ref.)

Functions and roles of glutamate receptors in synaptic transmission and plasticity. Nakanishi S, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:67–75 (39 ref.)

Synaptic transmission: well-placed modulators. Forsythe ID, et al. **Curr Biol** 1997 Jun 1;7(6):R362–5 (21 ref.)

Synaptic transmission: noisy synapses and noisy neurons. Smetters DK, et al. **Curr Biol** 1996 Oct 1;6(10):1217–8 (11 ref.)

Monitoring of neuromuscular transmission by electromyography during anaesthesia. A comparison with mechanomyography in cat and man. Engbaek J. **Dan Med Bull** 1996 Sep;43(4):301–16 (188 ref.)

Myasthenia gravis. Somnier FE. **Dan Med Bull** 1996 Feb; 43(1):1–10 (126 ref.)

Long-term enhancement of excitability and the regulation of glutamate receptors by protein kinases. MacDonald JF, et al. **Epilepsy Res Suppl** 1996;12:275–82 (38 ref.)

Dopamine neurotransmission and treatments for Parkinson's disease in the molecular biology era. Ogawa N. **Eur Neurol** 1997;38 Suppl 1:2–5 (39 ref.)

Basic aspects of GABA-transmission in alcoholism, with particular reference to GABA-transaminase. Sherif FM,

et al. **Eur Neuropsychopharmacol** 1997 Feb;7(1):1–7 (61 ref.)
Relevance of Na,K–ATPase to local extracellular potassium homeostasis and modulation of synaptic transmission. Gloor SM. **FEBS Lett** 1997 Jul 21;412(1):1–4 (46 ref.)
Synaptic structural dynamics and aging. Bertoni–Freddari C, et al. **Gerontology** 1996;42(3):170–80 (51 ref.)
Control of gonadotropin feedback: the possible role of estrogen–induced hypothalamic synaptic plasticity. Horvath TL, et al. **Gynecol Endocrinol** 1997 Apr; 11(2):139–43 (12 ref.)
Ammonia and GABA–ergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy. Basile AS, et al. **Hepatology** 1997 Jun;25(6):1303–5 (43 ref.)
Can quantum processes control synaptic emission? Beck F. **Int J Neural Syst** 1996 Sep;7(4):343–53 (24 ref.)
Synaptic transmission and modulation in the neostriatum. Lovinger DM, et al. **Int Rev Neurobiol** 1996;39:77–111 (151 ref.)
Synthesis of models for excitable membranes, synaptic transmission and neuromodulation using a common kinetic formalism. Destexhe A, et al. **J Comput Neurosci** 1994 Aug; 1(3):195–230 (119 ref.)
Homeostasis of energy conduction, neurotransmitters, cytotoxic compounds and metal ions. Nelson N. **J Exp Biol** 1997 Jan;200 (Pt 2):331–3 (21 ref.)
Retrograde messengers and long–term potentiation: a progress report. Williams JH. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):331–9 (55 ref.)
The Sec1 family: a novel family of proteins involved in synaptic transmission and general secretion. Halachmi N, et al. **J Neurochem** 1996 Mar;66(3):889–97 (51 ref.)
Estimating post–synaptic potentials in tonically discharging human motoneurons. Miles TS. **J Neurosci Methods** 1997 Jun 27;74(2):167–74 (32 ref.)
Assessing changes in presynaptic inhibition of Ia afferents during movement in humans. Pierrot–Deseilligny E. **J Neurosci Methods** 1997 Jun 27;74(2):189–99 (46 ref.)
Propagation of synchronous spiking activity in feedforward neural networks. Aertsen A, et al. **J Physiol Paris** 1996; 90(3–4):243–7 (19 ref.)
Redistribution of synaptic efficacy: a mechanism to generate infinite synaptic input diversity from a homogeneous population of neurons without changing absolute synaptic efficacies. Markram H, et al. **J Physiol Paris** 1996; 90(3–4):229–32 (12 ref.)
The nature of interactions involving prefrontal and striatal dopamine systems. Wilkinson LS. **J Psychopharmacol (Oxf)** 1997;11(2):143–50 (75 ref.)
Neural signals for command control and feedback in functional neuromuscular stimulation: a review. Hoffer JA, et al. **J Rehabil Res Dev** 1996 Apr;33(2):145–57 (48 ref.)
Innervation of the adrenal cortex, its physiological relevance, with primary focus on the noradrenergic transmission. Tóth IE, et al. **Microsc Res Tech** 1997 Mar 15;36(6):534–45 (93 ref.)
Synaptic targeting of ionotropic neurotransmitter receptors. Kirsch J, et al. **Mol Cell Neurosci** 1996;8(2–3):93–8 (50 ref.)
Synaptic transmission and plasticity in the amygdala. An emerging physiology of fear conditioning circuits. Maren S. **Mol Neurobiol** 1996 Aug;13(1):1–22 (140 ref.)
Molecular biology of glycinergic neurotransmission. Zafra F, et al. **Mol Neurobiol** 1997 Jun;14(3):117–42 (187 ref.)
Nitric oxide: a spatial second messenger. Schulman H. **Mol Psychiatry** 1997 Jul;2(4):296–9 (24 ref.)
Genetically engineered neural transmission. Son JH, et al. **Mol Psychiatry** 1997 Jan;2(1):26–31 (44 ref.)
Bioactive lipids in excitatory neurotransmission and neuronal plasticity. Bazan NG, et al. **Neurochem Int** 1997 Feb; 30(2):225–31 (59 ref.)
Cholinergic neurotransmission and synaptic plasticity concerning memory processing. Jerusalinsky D, et al. **Neurochem Res** 1997 Apr;22(4):507–15 (91 ref.)
Transmission by post–ganglionic axons of the autonomic nervous system: the importance of the specialized neuroeffector junction. Hirst GD, et al. **Neuroscience** 1996 Jul;73(1):7–23 (144 ref.)
Neurotransmission by neurons that use serotonin, noradrenaline, glutamate, glycine, and gamma–aminobutyric acid in the normal and injured spinal cord. Shapiro S. **Neurosurgery** 1997 Jan;40(1):168–76; discussion 177 (109 ref.)
Some new methods for the synthesis of cardiac neurotransmission PET radiotracers. Någren K, et al. **Nucl Med Biol** 1995 Nov;22(8):1037–43 (21 ref.)
Relevance of PET/SPET tracers for cardiac neurotransmission. Voipio–Pulkki LM. **Nucl Med Biol** 1995 Nov;22(8):1027–35 (68 ref.)
The medullary subnucleus reticularis dorsalis (SRD) as a key link in both the transmission and modulation of pain signals. Villanueva L, et al. **Pain** 1996 Oct;67(2–3):231–40 (109 ref.)
Activity–related modulation of cholinergic transmission. Collier B. **Prog Brain Res** 1996;109:243–9 (41 ref.)
The role of excitatory amino acid transmission in development and plasticity of SI barrel cortex. Fox K. **Prog Brain Res** 1996;108:219–34 (56 ref.)
Plasticity of excitatory synaptic transmission in the spinal cord dorsal horn. Randić M. **Prog Brain Res** 1996; 113:463–506 (338 ref.)
Physiology of transmission at a giant glutamatergic synapse in cerebellum. Slater NT, et al. **Prog Brain Res** 1997; 114:151–63 (47 ref.)
Involvement of glutamatergic neurotransmission and protein kinase C in spinal plasticity and the development of chronic pain. Tölle TR, et al. **Prog Brain Res** 1996;110:193–206 (54 ref.)
Slow synaptic transmission in the spinal dorsal horn. Yoshimura M. **Prog Brain Res** 1996;113:443–62 (149 ref.)
Autonomic neuromuscular transmission at a varicosity. Bennett MR. **Prog Neurobiol** 1996 Dec;50(5–6):505–32 (123 ref.)
Transmission of the cortical command for human voluntary movement through cervical propriospinal premotoneurons. Pierrot–Deseilligny E. **Prog Neurobiol** 1996 Mar–Apr; 48(4–5):489–517 (60 ref.)
Wiring and volume transmission in the central nervous system: the concept of closed and open synapses. Zoli M, et al. **Prog Neurobiol** 1996 Jul;49(4):363–80 (156 ref.)
Influence of the postsynaptic target on the functional properties of neurons in the adult mammalian central nervous system. de la Cruz RR, et al. **Rev Neurosci** 1996 Apr–Jun;7(2):115–49 (183 ref.)
The impact of receptor desensitization on fast synaptic transmission. Jones MV, et al. **Trends Neurosci** 1996 Mar; 19(3):96–101 (84 ref.)
Information processing by graded–potential transmission through tonically active synapses. Juusola M, et al. **Trends Neurosci** 1996 Jul;19(7):292–7 (56 ref.)
Glutamate receptors of the kainate type and synaptic transmission. Lerma J, et al. **Trends Neurosci** 1997 Jan; 20(1):9–12 (45 ref.)
Calcineurin regulation of synaptic function: from ion channels to transmitter release and gene transcription. Yakel JL. **Trends Pharmacol Sci** 1997 Apr;18(4):124–34 (63 ref.)
[Reflections on the psychobiology of depression] Aldenhoff J. **Nervenarzt** 1997 May;68(5):379–89 (93 ref.) (Eng. Abstr.) **(Ger)**
[Neurotransmitters and ontogenesis of the central nervous system in the human] Retz W, et al. **Z Kinder Jugenpsychiatr** 1996 Mar;24(1):34–43 (60 ref.) **(Ger)**
[Volume transmission as a means of interneuronal interaction in the striatum] Saul'skaia NB. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 Mar–Apr; 47(2):362–73 (52 ref.) (Eng. Abstr.) **(Rus)**

SYNAPTIC VESICLES

CHEMISTRY

Membrane composition of adrenergic large and small dense cored vesicles and of synaptic vesicles: consequences for their biogenesis. Winkler H. **Neurochem Res** 1997 Aug; 22(8):921–32 (143 ref.)
How does a vesicle know it is full? [comment] Williams J. **Neuron** 1997 May;18(5):683–6 (15 ref.) Comment on: Neuron 1997 May;18(5):815–26.

DRUG EFFECTS

Drug interactions with vesicular amine transport. Peter D, et al. **NIDA Res Monogr** 1996;161:176–200 (64 ref.)

METABOLISM

The role of vesicular transport proteins in synaptic transmission and neural degeneration. Liu Y, et al. **Annu Rev Neurosci** 1997;20:125–56 (178 ref.)
A molecular analysis of vesicular amine transport. Liu Y, et al. **Behav Brain Res** 1996;73(1–2):51–8 (76 ref.)
Molecular analysis of neurotransmitter transport into secretory vesicles. Liu Y, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:747–58 (113 ref.)
Amino acid neurotransmission: dynamics of vesicular uptake. Fykse EM, et al. **Neurochem Res** 1996 Sep;21(9):1053–60 (68 ref.)
SV2proteoglycan: a potential synaptic vesicle transporter and nerve terminal extracellular matrix receptor. Carlson SS. **Perspect Dev Neurobiol** 1996;3(4):373–86 (79 ref.)
Can Ca2+ be released from secretory granules or synaptic vesicles? Petersen OH. **Trends Neurosci** 1996 Oct; 19(10):411–3 (24 ref.)

PHYSIOLOGY

Neurotransmitter release. Matthews G. **Annu Rev Neurosci** 1996;19:219–33 (71 ref.)
Molecular mechanisms in synaptic vesicle endocytosis. Bauerfeind R, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:397–404 (88 ref.)
Insight into the molecular mechanisms of synaptic vesicle docking and fusion. Ting AE, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:361–9 (75 ref.)
Synaptic vesicle endocytosis. Cremona O, et al. **Curr Opin Neurobiol** 1997 Jun;7(3):323–30 (76 ref.)
Molecular mechanisms in synaptic vesicle recycling. Bauerfeind R, et al. **J Neurocytol** 1996 Dec;25(12):701–15 (139 ref.)
The role of Sec1p–related proteins in vesicle trafficking in the nerve terminal. Pevsner J. **J Neurosci Res** 1996 Jul 15;45(2):89–95 (45 ref.)
Noradrenaline storing vesicles in sympathetic neurons and their role in neurotransmitter release: an historical overview of controversial issues. De Potter WP, et al. **Neurochem Res** 1997 Aug;22(8):911–9 (74 ref.)
How does a vesicle know it is full? [comment] Williams J. **Neuron** 1997 May;18(5):683–6 (15 ref.) Comment on: Neuron 1997 May;18(5):815–26.
The heterogeneity of vesicular acetylcholine storage in cholinergic nerve terminals. Prior C, et al. **Pharmacol Res** 1995 Dec;32(6):345–53 (46 ref.)
SNAREs and regulated vesicle exocytosis [comment] Goda Y. **Proc Natl Acad Sci U S A** 1997 Feb 4;94(3):769–72 (23 ref.) Comment on: Proc Natl Acad Sci U S A 1997 Feb 4;94(3):997–1001.
Molecular properties and cellular distribution of cholinergic synaptic proteins. Zimmermann H, et al. **Prog Brain Res** 1996;109:31–40 (53 ref.)

SECRETION

Regulation of the synaptic vesicle cycle in Drosophila. Broadie KS. **Biochem Soc Trans** 1996 Aug;24(3):639–45 (48 ref.)

ULTRASTRUCTURE

Properties of biomolecules measured from atomic force microscope images: a review. Hansma HG, et al. **J Struct Biol** 1997 Jul;119(2):99–108 (59 ref.)

SYNAPTONEMAL COMPLEX

GENETICS

[Cytogenetic patterns in synapsis of meiotic chromosomes in animals and plants] Bogdanov IuF, et al. **Genetika** 1996 Nov;32(11):1474–93 (95 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Synaptonemal complexes: structure and function. Heyting C. **Curr Opin Cell Biol** 1996 Jun;8(3):389–96 (64 ref.)

SYNAPTOPHYSIN

ANALYSIS

Accumulation of synaptic vesicle proteins and cytoskeletal specializations at the peripheral node of Ranvier. Zimmermann H. **Microsc Res Tech** 1996 Aug 1; 34(5):462–73 (70 ref.)

BLOOD

The use of chromogranin, synaptophysin and islet amyloid polypeptide as markers for neuroendocrine tumours. Stridsberg M. **Ups J Med Sci** 1995;100(3):169–99 (186 ref.)

SYNAPTOSOMES

METABOLISM

Metabolic and energetic properties of isolated nerve ending particles (synaptosomes). Erecińska M, et al. **Biochim Biophys Acta** 1996 Nov 12;1277(1–2):13–34 (162 ref.)

PHYSIOLOGY

Presynaptic interactions between acetylcholine and glycine in the human brain. Marchi M, et al. **Prog Brain Res** 1996; 109:225–9 (35 ref.)

SYNCHROTRONS

Synchrotron in cancer medicine. Cartei F. **Eur J Cancer Prev** 1996 Oct;5(5):419–20 (7 ref.)
Synchrotron radiation sources. Fonda L. **Eur J Cancer Prev** 1996 Oct;5(5):417–9 (0 ref.)
Medical applications of synchrotron radiation x–rays. Lewis R. **Phys Med Biol** 1997 Jul;42(7):1213–43 (89 ref.)
X–ray computed microtomography (microCT) using synchrotron radiation (SR). Bonse U, et al. **Prog Biophys Mol Biol** 1996;65(1–2):133–69 (122 ref.)

SYNCOPE

Syncope in the elderly. Forman DE, et al. **Cardiol Clin** 1997 May;15(2):295–311 (153 ref.)
Syncope. A neurologist's viewpoint. Kaufmann H. **Cardiol Clin** 1997 May;15(2):177–94 (92 ref.)
Syncope in the pediatric patient. Tanel RE, et al. **Cardiol Clin** 1997 May;15(2):277–94 (96 ref.)
Unexplained syncope: diagnosis, mechanisms and treatment. Sra JS, et al. **Indian Heart J** 1995 Sep–Oct;47(5):461–5 (33 ref.)
The diagnosis and management of syncope in children and adolescents. Braden DS, et al. **Pediatr Ann** 1997 Jul; 26(7):422–6 (16 ref.)

COMPLICATIONS

Psychiatric illness and syncope. Oh JH, et al. **Cardiol Clin** 1997 May;15(2):269–75 (31 ref.)

DIAGNOSIS

Recurrent unexplained syncope: diagnostic and therapeutic approach. Krahn AD, et al. **Can J Cardiol** 1996 Oct; 12(10):989–94 (27 ref.)
Clinical approach to diagnosis of syncope. An Overview.

Benditt DG, et al. **Cardiol Clin** 1997 May;15(2):165–76 (50 ref.)
Value and limitations of noninvasive assessment of syncope. Hammill SC. **Cardiol Clin** 1997 May;15(2):195–218 (68 ref.)
Syncope: current diagnosis and treatment. Henderson MC, et al. **Curr Probl Cardiol** 1997 May;22(5):242–96 (240 ref.)
Spells. Differential diagnosis and management strategies. Preblick-Salib C, et al. **Emerg Med Clin North Am** 1997 Aug;15(3):637–48 (30 ref.)
Electroencephalography in syncope. Brenner RP. **J Clin Neurophysiol** 1997 May;14(3):197–209 (57 ref.)
[Recurrent losses of consciousness in anaphylactic reactions] Woltsche-Kahr I, et al. **Dtsch Med Wochenschr** 1997 Jun 6;122(23):747–50 (30 ref.) (Eng. Abstr.) **(Ger)**
[Syncopal pathology in childhood (I)] Castelli S, et al. **Pediatr Med Chir** 1997 May-Jun;19(3):165–73 (60 ref.) (Eng. Abstr.) **(Ita)**
[Syncope: neurological differential diagnosis] Benarroch EE. **Rev Neurol** 1997 Jan;25(137):100–5 (43 ref.) **(Spa)**

ETIOLOGY

Neurocardiogenic syncope. Somers VK, et al. **Adv Intern Med** 1996;41:399–435 (109 ref.)
Diagnosing syncope. Part 1: Value of history, physical examination, and electrocardiography. Clinical Efficacy Assessment Project of the American College of Physicians. Linzer M, et al. **Ann Intern Med** 1997 Jun 15;126(12):989–96 (34 ref.)
Diagnosing syncope. Part 2: Unexplained syncope. Clinical Efficacy Assessment Project of the American College of Physicians. Linzer M, et al. **Ann Intern Med** 1997 Jul 1; 127(1):76–86 (110 ref.)
Driving issues related to arrhythmic syncope. Miles WM. **Cardiol Clin** 1997 May;15(2):327–39 (58 ref.)
Syncope and the autonomic nervous system. Lurie KG, et al. **J Cardiovasc Electrophysiol** 1996 Aug;7(8):760–76 (123 ref.)
Neurally mediated syncope and syncope due to autonomic failure: differences and similarities. Kaufmann H. **J Clin Neurophysiol** 1997 May;14(3):183–96 (73 ref.)
When a syncopal event is more than a faint, Part I. Sharp KT. **MCN Am J Matern Child Nurs** 1997 Jan–Feb; 22(1):26–30 (17 ref.)
[Complete atrioventricular block disclosing Fabry's disease] Elhadad S, et al. **Arch Mal Coeur Vaiss** 1997 Mar; 90(3):393–7 (10 ref.) (Eng. Abstr.) **(Fre)**
[Anxiety disorders and unexplained syncopes of presumed vaso-vagal origin] Kouakam C, et al. **Arch Mal Coeur Vaiss** 1996 Oct;89(10):1247–54 (31 ref.) (Eng. Abstr.) **(Fre)**
[Comparative data of tilt test with or without isoproterenol in investigation of unexplained unconsciousness and syncope] Raybaud F, et al. **Arch Mal Coeur Vaiss** 1996 Sep;89(9):1145–51 (32 ref.) (Eng. Abstr.) **(Fre)**
[Sudden loss of consciousness in childhood] Bauersfeld U, et al. **Ther Umsch** 1997 Mar;54(3):156–60 (21 ref.) (Eng. Abstr.) **(Ger)**
[Tachycardia-induced syncopes] Koerfer J, et al. **Ther Umsch** 1997 Mar;54(3):151–5 (14 ref.) (Eng. Abstr.) **(Ger)**
[Sudden loss of consciousness: clinical presentation and pathophysiologic mechanisms] Osswald S. **Ther Umsch** 1997 Mar;54(3):114–9 (19 ref.) (Eng. Abstr.) **(Ger)**
[Syncopes from the neurologic viewpoint] Scollo-Lavizzari G, et al. **Ther Umsch** 1997 Mar;54(3):135–43 (9 ref.) (Eng. Abstr.) **(Ger)**
[Bradycardia-induced syncope] Wyss E, et al. **Ther Umsch** 1997 Mar;54(3):144–50 (19 ref.) (Eng. Abstr.) **(Ger)**
[Glossopharyngeal neuralgia with syncope] Mód G, et al. **Orv Hetil** 1996 Jun 2;137(22):1199–203 (31 ref.) (Eng. Abstr.) **(Hun)**
[Syncopal pathology in childhood (II)] Castelli S, et al. **Pediatr Med Chir** 1997 May-Jun;19(3):175–82 (40 ref.) **(Ita)**
[Hypersensitive carotid sinus syndrome] Sagara K. **Ryoikibetsu Shokogun Shirizu** 1996;(12):271–3 (6 ref.) **(Jpn)**
[Syncope as a cardiologic problem] Bacior B, et al. **Przegl Lek** 1996;53(6):509–13 (23 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

Postural syncope and autoregulation of cerebral blood flow. Mathew RJ. **Biol Psychiatry** 1996 Nov 1;40(9):923–6 (34 ref.)
Value and limitations of electrophysical testing for syncope. DiMarco JP. **Cardiol Clin** 1997 May;15(2):219–32 (46 ref.)
Recurrent syncope. Experience with an implantable loop recorder. Krahn AD, et al. **Cardiol Clin** 1997 May; 15(2):313–26 (22 ref.)
Neurally mediated syncope: a review of cardiac and arterial receptors. Grimm DR. **J Clin Neurophysiol** 1997 May; 14(3):170–82 (142 ref.)
[Hemodynamically-induced syncope] Brunner-La Rocca HP, et al. **Ther Umsch** 1997 Mar;54(3):127–34 (20 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Syncope: current diagnosis and treatment. Henderson MC, et al. **Curr Probl Cardiol** 1997 May;22(5):242–96 (240 ref.)

SYNCOPE, NEUROCARDIOGENIC see **SYNCOPE, VASOVAGAL**

SYNCOPE, NEUROGENIC see **SYNCOPE, VASOVAGAL**

SYNCOPE, VASOVAGAL

DIAGNOSIS

Vasodepressor syncope. Diagnosis and management. Barbey JT. **Cardiol Clin** 1997 May;15(2):251–6 (41 ref.)
Neurally mediated syncopal syndromes: pathophysiological concepts and clinical evaluation. Benditt DG. **Pacing Clin Electrophysiol** 1997 Feb;20(2 Pt 2):572–84 (81 ref.)
Tilt table testing: concepts and limitations. Grubb BP, et al. **Pacing Clin Electrophysiol** 1997 Mar;20(3 Pt 2):781–7 (35 ref.)
[Vasovagal syncope] Cottier C. **Ther Umsch** 1997 Mar; 54(3):120–6 (13 ref.) (Eng. Abstr.) **(Ger)**
[The tilt-table test: is it essential for adequate treatment of vasovagal syncope? Arguments in favor] Moya i Mitjans A, et al. **Rev Esp Cardiol** 1997 Jun;50(6):368–73 (49 ref.) (Eng. Abstr.) **(Spa)**
[The tilt-table test: is it essential for adequate treatment of vasovagal syncope? Arguments against] Ruiz Granell R, et al. **Rev Esp Cardiol** 1997 Jun;50(6):374–82 (98 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Syncope: pathophysiology, diagnosis, and pharmacotherapy. Lazarus JC, et al. **Ann Pharmacother** 1996 Sep; 30(9):994–1005 (51 ref.)
Vasodepressor syncope. Diagnosis and management. Barbey JT. **Cardiol Clin** 1997 May;15(2):251–6 (41 ref.)

ETIOLOGY

Outcome of patients with neurally mediated syncope following tilt table testing. Sheldon RS. **Cardiologia** 1997 Aug;42(8):795–802 (40 ref.)

PHYSIOPATHOLOGY

Dysautonomic and reflex syncope syndromes. Grubb BP, et al. **Cardiol Clin** 1997 May;15(2):257–68 (49 ref.)
Pathophysiologic basis for vasodepressor syncope. Morillo CA, et al. **Cardiol Clin** 1997 May;15(2):233–49 (212 ref.)
Neurally mediated syncopal syndromes: pathophysiological concepts and clinical evaluation. Benditt DG. **Pacing Clin Electrophysiol** 1997 Feb;20(2 Pt 2):572–84 (81 ref.)
Vasovagal syncope and skeletal muscle vasodilatation: the continuing conundrum. Dietz NM, et al. **Pacing Clin Electrophysiol** 1997 Mar;20(3 Pt 2):775–80 (45 ref.)
Neural monitoring of vasovagal syncope. Ellenbogen KA, et al. **Pacing Clin Electrophysiol** 1997 Mar;20(3 Pt 2):788–94 (47 ref.)
Mechanisms of heart rate and arterial blood pressure control: implications for the pathophysiology of neurocardiogenic syncope. Quan KJ, et al. **Pacing Clin Electrophysiol** 1997 Mar;20(3 Pt 2):764–74 (37 ref.)
Neural circulatory control in vasovagal syncope. van Lieshout JJ, et al. **Pacing Clin Electrophysiol** 1997 Mar;20(3 Pt 2):753–63 (97 ref.)
Pathophysiological mechanisms underlying vasovagal syncope in young subjects. Wieling W, et al. **Pacing Clin Electrophysiol** 1997 Aug;20(8 Pt 2):2034–8 (35 ref.)

THERAPY

Cardiac pacing for vasovagal syncope: a reasonable therapeutic option? Petersen ME, et al. **Pacing Clin Electrophysiol** 1997 Mar;20(3 Pt 2):824–6 (12 ref.)
Unexplained syncope: clinical management. Wolff GS. **Pacing Clin Electrophysiol** 1997 Aug;20(8 Pt 2):2043–7 (36 ref.)
[Therapeutic possibilities for the management of vasovagal syncopes] Raybaud F, et al. **Presse Med** 1996 Dec 14; 25(39):1975–80 (26 ref.) (Eng. Abstr.) **(Fre)**

SYNCYTIUM see **GIANT CELLS**

SYNDACTYLY

COMPLICATIONS

Perioperative considerations in a newly described subtype of congenital long QT syndrome. Joseph-Reynolds AM, et al. **Paediatr Anaesth** 1997;7(3):237–41 (25 ref.)

GENETICS

Central nervous system abnormalities in oculodentodigital dysplasia [letter] Schrander-Stumpel CT, et al. **Genet Couns** 1996;7(3):233–5 (9 ref.)

SURGERY

The thumb in syndactyly. Verdan C. **Ann Chir Main** 1982; 1(1):29–39 (13 ref.) **(Eng, Fre)**
Perioperative considerations in a newly described subtype of congenital long QT syndrome. Joseph-Reynolds AM, et al. **Paediatr Anaesth** 1997;7(3):237–41 (25 ref.)

SYNDROME

[Medico-biological definition of major clinical phenomena: syndrome, nosological form, disease] Serov VV. **Biull Eksp Biol Med** 1997 Mar;123(3):244–7 (11 ref.) **(Rus)**

SYNDROME X

Angina with normal coronary arteries: diagnosis, pathophysiology and treatment. Chierchia SL, et al. **Eur Heart J** 1996 Dec;17 Suppl G:14–9 (42 ref.)
[Angina pectoris in normal coronary arteries (microvascular angina/syndrome X) (see comments)] Langes K, et al. **Dtsch Med Wochenschr** 1997 Jan 3;122(1–2):33–8 (81 ref.) Comment in: Dtsch Med Wochenschr 1997 May 16;122(20):666–7. **(Ger)**
[Microvascular angina] Katagiri T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):758–61 (8 ref.) **(Jpn)**
[Syndrome X] Onodera K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):557–60 (21 ref.) **(Jpn)**
[Syndrome X] Maĭchuk EI, et al. **Klin Med (Mosk)** 1997; 75(3):4–7 (45 ref.) **(Rus)**

COMPLICATIONS

Chest pain and the sensitive heart. Cannon RO 3rd. **Eur J Gastroenterol Hepatol** 1995 Dec;7(12):1161–71 (44 ref.)

DIET THERAPY

Do high carbohydrate diets prevent the development or attenuate the manifestations (or both) of syndrome X? A viewpoint strongly against. Reaven GM. **Curr Opin Lipidol** 1997 Feb;8(1):23–7 (42 ref.)

PHYSIOPATHOLOGY

Cardiovascular syndromes X, endothelial dysfunction and insulin resistance. Goodfellow J, et al. **Diabetes Res Clin Pract** 1996 Jul;31 Suppl:S163–71 (34 ref.)
[Insulin resistance--possible causes and effects] Bornkessel B. **Med Monatsschr Pharm** 1996 Mar;19(3):81–4 (2 ref.) **(Ger)**
[Angina pectoris with normal coronary arteries] Monteiro J. **Acta Med Port** 1997 Apr;10(4):283–5 (37 ref.) (Eng. Abstr.) **(Por)**

THERAPY

[Non-drug therapeutics of idiopathic hyperuricemia] Togashi R, et al. **Nippon Rinsho** 1996 Dec;54(12):3256–60 (22 ref.) (Eng. Abstr.) **(Jpn)**

SYNECHOCYSTIS GROUP

PHYSIOLOGY

Heat shock proteins and circadian rhythms. Rensing L, et al. **Chronobiol Int** 1996 Oct;13(4):239–50 (74 ref.)

SYNGAMIASIS see **STRONGYLIDA INFECTIONS**

SYNOSTOSIS

CLASSIFICATION

Congenital bony syngnathia: a proposed classification. Dawson KH, et al. **Cleft Palate Craniofac J** 1997 Mar; 34(2):141–6 (26 ref.)

DIAGNOSIS

[Congenital tarsal synostosis] Daumas L, et al. **Arch Pediatr** 1996 Sep;3(9):900–5 (20 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Antley-Bixler syndrome. Description of two new cases and a review of the literature. Bottero L, et al. **Childs Nerv Syst** 1997 May;13(5):275–80; discussion 281 (19 ref.)

SYNOVIA see **SYNOVIAL FLUID**

SYNOVIAL CHONDROMATOSIS see **CHONDROMATOSIS, SYNOVIAL**

SYNOVIAL CHONDROMETAPLASIA see **CHONDROMATOSIS, SYNOVIAL**

SYNOVIAL CYST

Hip ganglion: case report and review of the literature. Golledge J, et al. **J R Coll Surg Edinb** 1996 Dec;41(6):405–7 (6 ref.)

COMPLICATIONS

Synovial cyst and degeneration of the transverse ligament:

SYNOVIAL CYST

an unusual cause of high cervical myelopathy. Case report. **Fransen P**, et al. **J Neurosurg** 1997 Jun;86(6):1027–30 (17 ref.)

[Synovial cyst of the hip: a rare cause of iliac vein compression] De Smedt M, et al. **Acta Orthop Belg** 1996 Dec;62(4):238–40 (5 ref.) (Eng. Abstr.) **(Fre)**

[Compression of the peroneal nerve by a synovial cyst in a 7-year-oldchild] Gayet LE, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(8):762–6 (17 ref.) (Eng. Abstr.) **(Fre)**

[Synovial cyst of the supracapsular notch of the shoulder with supracapsular nerve compression in a sportsman. Apropos of a case. Review of the literature] Rochwerger A, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996; 82(4):344–7 (12 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Synovial cyst formation complicating total hip arthroplasty: a case report. DeFrang RD, et al. **Clin Orthop** 1996 Apr; (325):163–7 (23 ref.)

SYNOVIAL FLUID

Monarthritis: differential diagnosis. Sack K. **Am J Med** 1997 Jan 27;102(1A):30S–34S (24 ref.)

CYTOLOGY

Synovial fluid cell analysis. Dougados M. **Baillieres Clin Rheumatol** 1996 Aug;10(3):519–34 (29 ref.)

Synovial metastasis: diagnosis by fine-needle aspiration cytologic investigation. Thompson KS, et al. **Diagn Cytopathol** 1996 Nov;15(4):334–7 (18 ref.)

ENZYMOLOGY

[Prospects for determining the activity of adenosine deaminase in biological fluids in tuberculosis] Titarenko OT, et al. **Probl Tuberk** 1996;(5):52–4 (42 ref.) **(Rus)**

METABOLISM

Pharmacokinetic optimisation of the treatment of septic arthritis. Hamed KA, et al. **Clin Pharmacokinet** 1996 Aug; 31(2):156–63 (32 ref.)

Fibrin degradation in the synovial fluid of rheumatoid arthritis patients: a model for extravascular fibrinolysis. Carmassi F, et al. **Semin Thromb Hemost** 1996;22(6):489–96 (90 ref.)

SYNOVIAL MEMBRANE

Synovial plicae of the knee. Controversies and review. Dupont JY. **Clin Sports Med** 1997 Jan;16(1):87–122 (86 ref.)

ANATOMY & HISTOLOGY

Percutaneous needle biopsy and synovial histology. Saaibi DL, et al. **Baillieres Clin Rheumatol** 1996 Aug;10(3):535–54 (118 ref.)

CHEMISTRY

Somatic mutation and CDR3 length of immunoglobulin lambda variable region genes in the synovium of patients with rheumatoid arthritis. Mageed RA, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:319–23 (4 ref.)

CYTOLOGY

Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? Firestein GS. **Arthritis Rheum** 1996 Nov;39(11):1781–90 (85 ref.)

Molecular and cellular interactions in rheumatoid synovium. Müller-Ladner U. **Curr Opin Rheumatol** 1996 May; 8(3):210–20 (105 ref.)

[Expression of Fas/Fas ligand and proto-oncogenes in rheumatoid synovial tissues] Asahara H, et al. **Nippon Rinsho** 1996 Jul;54(7):1960–4 (21 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

A germinal center-like reaction in the nonlymphoid tissue of the synovial membrane. Berek C, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:211–7 (17 ref.)

[Intra-articular B-cells in the pathogenesis of rheumatoid arthritis] Krenn V, et al. **Verh Dtsch Ges Pathol** 1996; 80:58–66 (35 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Cytokine expression and cell activation in inflammatory arthritis. Ivashkiv LB. **Adv Immunol** 1996;63:337–76 (190 ref.)

MRI in the assessment of synovium and cartilage. Peterfy CG. **Br J Rheumatol** 1996 Dec;35 Suppl 3:3–5 (10 ref.)

Synovial metastasis: diagnosis by fine-needle aspiration cytologic investigation. Thompson KS, et al. **Diagn Cytopathol** 1996 Nov;15(4):334–7 (18 ref.)

Synovial hemangioma of the knee. Price NJ, et al. **J Pediatr Orthop** 1997 Jan-Feb;17(1):74–7 (21 ref.)

Molecular mechanisms to form leukocyte infiltration patterns distinct between synovial tissue and fluid of rheumatoid arthritis. Yamamoto T, et al. **Semin Thromb Hemost** 1996; 22(6):507–11 (34 ref.)

[Malignant synovial "chondromatosis" or chondrosarcomatous transformation of synovial chondromatosis of the knee?] Bascoulergue G, et al. **Bull Cancer** 1996 Nov;83(11):951–6 (11 ref.) (Eng. Abstr.) **(Fre)**

[Intra-articular B-cells in the pathogenesis of rheumatoid arthritis] Krenn V, et al. **Verh Dtsch Ges Pathol** 1996; 80:58–66 (35 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Molecular and cellular interactions in rheumatoid synovium. Müller-Ladner U. **Curr Opin Rheumatol** 1996 May; 8(3):210–20 (105 ref.)

SECRETION

Surfactant protein A and lamellar bodies: a homologous secretory function of peritoneum, synovium, and lung. Dobbie JW. **Perit Dial Int** 1996 Nov-Dec;16(6):574–81 (43 ref.)

SURGERY

Primary synovial osteochondromatosis of the hip: report of two cases with long-term follow-up after synovectomy and a review of the literature. Gilbert SR, et al. **Am J Orthop** 1997 Aug;26(8):555–60 (14 ref.)

Orthopaedic management of juvenile chronic arthritis (JCA). Pahle JA. **Z Rheumatol** 1996 Nov-Dec;55(6):376–87 (23 ref.)

Arthroscopic synovectomy. When, which diseases and which joints. Paus AC. **Z Rheumatol** 1996 Nov-Dec;55(6):394–400 (63 ref.)

[Is synovectomy in chronic polyarthritis justified ? (editorial)] Hagena FW. **Z Rheumatol** 1996 Nov-Dec;55(6):371–5 (22 ref.) **(Ger)**

SYNOVIAL OSTEOCHONDROMATOSIS see **CHONDROMATOSIS, SYNOVIAL**

SYNOVIOMA see **SARCOMA, SYNOVIAL**

SYNOVITIS

[SAPHO syndrome: common denominator for various bone and skin diseases] Jahangier ZN, et al. **Ned Tijdschr Geneeskd** 1997 Apr 19;141(16):764–9 (37 ref.) (Eng. Abstr.) **(Dut)**

DIAGNOSIS

Transient synovitis of the hip in children. Hart JJ. **Am Fam Physician** 1996 Oct;54(3):1587–91, 1595–6 (20 ref.)

Remitting distal extremity swelling with pitting edema: a distinct syndrome or a clinical feature of different inflammatory rheumatic diseases? [editorial; comment] Olivieri I, et al. **J Rheumatol** 1997 Feb;24(2):249–52 (30 ref.) Comment on: J Rheumatol 1997 Feb;24(2):333–6.

[The SAPHO syndrome and ulcerative colitis (letter)] Sanjuán Portugal F, et al. **An Med Interna** 1997 Apr; 14(4):210–1 (9 ref.) **(Spa)**

DRUG THERAPY

Photodynamic treatment of rheumatoid and inflammatory arthritis. Trauner KB, et al. **Photochem Photobiol** 1996 Nov;64(5):740–50 (124 ref.)

ETIOLOGY

The role of VCAM-1 molecule in the pathogenesis of rheumatoid synovitis. Matsuyama T, et al. **Hum Cell** 1996 Sep;9(3):187–92 (10 ref.)

Synovitis and silicone joint implants: a summary of reported cases. Foliart DE. **Plast Reconstr Surg** 1997 Jan; 99(1):245–52 (59 ref.)

IMMUNOLOGY

The Michael Mason Prize Essay 1996. Role of adhesion mechanisms in the pathogenesis of chronic synovitis. Pitzalis C. **Br J Rheumatol** 1996 Dec;35(12):1198–215 (108 ref.)

MICROBIOLOGY

Tuberculous infection of the hand and wrist. Visuthikosol V, et al. **Ann Plast Surg** 1996 Jul;37(1):55–9 (23 ref.)

PATHOLOGY

Chronic diffuse sclerosing osteomyelitis of the mandible or mandibular location of S.A.P.H.O. syndrome. García-Marín F, et al. **Acta Stomatol Belg** 1996 Jun; 93(2):65–71 (31 ref.)

RADIOTHERAPY

[Principles of radio-synoviorthesis] Kotzerke J. **Rontgenpraxis** 1997 Jun;50(6):150–4 (42 ref.) **(Ger)**

SYNOVITIS, PIGMENTED VILLONODULAR

Pigmented villonodular synovitis of the wrist in childhood. Hoeffel JC, et al. **Clin Pediatr (Phila)** 1997 Jul;36(7):423–6 (28 ref.)

COMPLICATIONS

Neuropathy secondary to pigmented villonodular synovitis of the hip. Aboulafia AJ, et al. **Clin Orthop** 1996 Apr; (325):174–80 (19 ref.)

DIAGNOSIS

Pigmented villonodular synovitis of the temporomandibular joint. Tanaka K, et al. **Arch Otolaryngol Head Neck Surg** 1997 May;123(5):536–9 (11 ref.)

Spinal pigmented villonodular synovitis: a case report. Gezen F, et al. **Spine** 1996 Mar 1;21(5):642–5 (20 ref.)

PATHOLOGY

Malignant giant cell tumor of the tendon sheaths and joints (malignant pigmented villonodular synovitis). Bertoni F, et al. **Am J Surg Pathol** 1997 Feb;21(2):153–63 (14 ref.)

SURGERY

Extraarticular pigmented villonodular synovitis of the shoulder: a case report. Sawmiller CJ, et al. **Clin Orthop** 1997 Feb;(335):262–7 (26 ref.)

ULTRASONOGRAPHY

[Localized pigmented villonodular synovitis of the biceps tendon: ultrasonographic study. Report of a case and review of the literature] Chiodi E, et al. **Radiol Med (Torino)** 1996 Jul-Aug;92(1-2):128–9 (10 ref.) **(Ita)**

SYNOVIUM see **SYNOVIAL MEMBRANE**

SYNTHETASES see **LIGASES**

SYNTHETIC VACCINES see **VACCINES, SYNTHETIC**

SYPHILIS

Syphilis in adults: from Christopher Columbus to Sir Alexander Fleming to AIDS. Tramont EC. **Clin Infect Dis** 1995 Dec;21(6):1361–9 (49 ref.)

Syphilis in pregnancy. Sánchez PJ, et al. **Clin Perinatol** 1997 Mar;24(1):71–90 (112 ref.)

COMPLICATIONS

Musculoskeletal disorders: genitourinary medicine perspective [editorial] Tayal SC, et al. **Int J STD AIDS** 1996 Oct;7(6):396–9 (38 ref.)

Infectious causes of hydrops fetalis. Barron SD, et al. **Semin Perinatol** 1995 Dec;19(6):493–501 (94 ref.)

HIV and syphilis seroprevalence among clients with sexually transmitted diseases attending a walk-in clinic at Cook County Hospital. Ansell DA, et al. **Sex Transm Dis** 1994 Mar-Apr;21(2):93–6 (9 ref.)

[Syphilis in HIV infected individuals] Frisoli Junior A, et al. **Rev Assoc Med Bras** 1996 Jan-Mar;42(1):46–50 (45 ref.) **(Por)**

DIAGNOSIS

Role of polymerase chain reaction in the diagnosis of gastric syphilis [editorial; comment] Norris SJ, et al. **Hum Pathol** 1996 Aug;27(8):749–50 (11 ref.) Comment on: Hum Pathol 1996 Aug;27(8):761–5.

Evaluation of syphilis testing of blood donors. Cable RG. **Transfus Med Rev** 1996 Oct;10(4):296–302 (34 ref.)

[Syphilis in an HIV-infected patient] Cunha HM, et al. **Acta Med Port** 1997 Jun-Jul;10(6-7):503–7 (12 ref.) (Eng. Abstr.) **(Por)**

EPIDEMIOLOGY

Syphilis and AIDS. Podwińska J. **Arch Immunol Ther Exp (Warsz)** 1996;44(5-6):329–33 (46 ref.)

PREVENTION & CONTROL

Approaches to screening and antibiotic use for syphilis prevention [editorial; comment] Farley TA. **Sex Transm Dis** 1997 Apr;24(4):227–8 (13 ref.) Comment on: Sex Transm Dis 1997 Apr;24(4):218–26.

VETERINARY

Syphilis in European brown hares (Lepus europaeus). Lumeij JT. **Vet Q** 1996;18 Suppl 3:S151–2 (8 ref.)

SYPHILIS, CARDIOVASCULAR

[Spirochaeta! myocarditis] Shimizu K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):158–60 (16 ref.) **(Jpn)**

[Spirochetal pericarditis] Ueyama C, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):582–4 (11 ref.) **(Jpn)**

[Syphilitic aortitis] Yasuda K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):408–10 (19 ref.) **(Jpn)**

SYRINGADENOMA see **ADENOMA, SWEAT GLAND**

SYRINGE SHARING see **NEEDLE SHARING**

SYRINGOMA

DIAGNOSIS

Localized vulvar syringomas [letter] Di Lernia V, et al. **Pediatr Dermatol** 1996 Jan–Feb;13(1):80–1 (15 ref.)

PATHOLOGY

Periorbital solitary nodule and multiple small papules in a 63–year–old women. Primary mucinous carcinoma (nodule) and syringom (papules). Friednash M, et al. **Arch Dermatol** 1997 Sep;133(9):1161, 1164 (18 ref.)

SYRINGOMA, CHONDROID see **ADENOMA, PLEOMORPHIC**

SYRINGOMYELIA

COMPLICATIONS

[Syringomyelia and pregnancy. Report of a clinical case and review of the literature] Castello C, et al. **Minerva Ginecol** 1996 Jun;48(6):253–7 (7 ref.) (Eng. Abstr.) **(Ita)**

[Syringomyelia associated with posterior fossa cyst: a case report] Wakamoto H, et al. **No Shinkei Geka** 1996 Oct; 24(10):939–43 (12 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Delayed post–traumatic syringohydromyelia after an uncomplicated fracture of the spine: case report and literature review. Güler–Uysal F, et al. **Spinal Cord** 1996 May;34(5):301–4 (14 ref.)

SURGERY

[Surgical treatment for syringomyelia] Iwasaki Y, et al. **No Shinkei Geka** 1996 Aug;24(8):709–16 (28 ref.) **(Jpn)**

[Current treatment of syringomyelia based on new physiopathological concepts] Pou–Serradell A, et al. **Rev Neurol** 1997 Feb;25(138):275–80 (13 ref.) **(Spa)**

SYSTEMATIC BIAS see **BIAS (EPIDEMIOLOGY)**

SYSTEMATICS see **CLASSIFICATION**

SYSTEMIC HEMIBODY IRRADIATION see **HEMIBODY IRRADIATION**

SYSTEMIC INFLAMMATORY RESPONSE SYNDROME see **SEPSIS SYNDROME**

SYSTEMS ANALYSIS

see related
TASK PERFORMANCE AND ANALYSIS

An industrial process view of information delivery to support clinical decision making: implications for systems design and process measures. Elson RB, et al. **J Am Med Inform Assoc** 1997 Jul–Aug;4(4):266–78 (95 ref.)

Clinical hematology. In–clinic analysis, quality control, reference values, and system selection. Knoll JS, et al. **Vet Clin North Am Small Anim Pract** 1996 Sep; 26(5):981–1002 (21 ref.)

[The interoceptive properties of the vestibular apparatus (a systems analysis of vestibular–oculomotor interaction)] Ianov IuK, et al. **Usp Fiziol Nauk** 1996 Oct–Dec; 27(4):63–72 (22 ref.) (Eng. Abstr.) **(Rus)**

SYSTEMS INTEGRATION

Database and knowledge base integration—a data mapping method for Arden Syntax knowledge modules. Johansson B, et al. **Methods Inf Med** 1996 Dec;35(4–5):302–8 (22 ref.)

[Experience with integration of research institutes if the Russian Academy of Medical Sciences with the departments if higher educational establishments of the IM Sechenov is an effective type of teaching and research intensification] Paltsev MA, et al. **Vestn Ross Akad Med Nauk** 1997;(3):54–8 (0 ref.) **(Rus)**

SYSTEMS THEORY

see related
MODELS, THEORETICAL
SYSTEMS ANALYSIS

Families as systems. Cox MJ, et al. **Annu Rev Psychol** 1997; 48:243–67 (150 ref.)

Biogerontologic theories. McClearn GE. **Exp Gerontol** 1997 Jan–Apr;32(1–2):3–10 (25 ref.)

A systems process of reinforcement. Sudakov KV. **Neurosci Behav Physiol** 1997 Jul–Aug;27(4):370–80 (60 ref.)

[The functional significance of the multiunit construction of the hypothalamo–hypophyseal neuroendocrine systems] Filaretov AA. **Usp Fiziol Nauk** 1996 Jul–Sep;27(3):3–11 (35 ref.) (Eng. Abstr.) **(Rus)**

[The systems process of reinforcement] Sudakov KV. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jul–Aug; 46(4):643–55 (60 ref.) (Eng. Abstr.) **(Rus)**

SYSTOLE

Management of systolic hypertension in the elderly. Hall WD. **Semin Nephrol** 1996 Jul;16(4):299–308 (108 ref.)

[Left ventricular systolic dysfunction in cardiomyopathies] Bouhour JB, et al. **Arch Mal Coeur Vaiss** 1996 Jul;89 Spec No 2:33–7 (27 ref.) (Eng. Abstr.) **(Fre)**

[Metabolic, adrenergic, and systolic function assessed by cardiac SPECT] Hattori N, et al. **Nippon Rinsho** 1997 Mar; 55 Suppl 1:656–61 (8 ref.) **(Jpn)**

[Evaluation of left ventricular systolic function using cine MRI—application to hypertrophic cardiomyopathy] Ishino Y, et al. **Nippon Rinsho** 1997 Jul;55(7):1805–10 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Mid–systolic click–late systolic murmur syndrome (MSC–LSMS)] Ohara M. **Ryoikibetsu Shokogun Shirizu** 1996;(13):378–80 (12 ref.) **(Jpn)**

PHYSIOLOGY

Assessment of systolic and diastolic LV function by MR myocardial tagging. Matter C, et al. **Basic Res Cardiol** 1996; 91 Suppl 2:23–8 (26 ref.)

SYSTOLIC CLICK–MURMUR SYNDROME see **MITRAL VALVE PROLAPSE**

SYSTOLIC TIME INTERVAL see **SYSTOLE**

2,4,5–T see **2,4,5–TRICHLOROPHENOXYACETIC ACID**

T3 ANTIGENS see **ANTIGENS, CD3**

T3 PHAGE see **BACTERIOPHAGE T3**

T3 RECEPTORS see **RECEPTORS, THYROID HORMONE**

T4 ANTIGENS, T–CELL see **ANTIGENS, CD4**

T4 CELLS see **CD4–POSITIVE T–LYMPHOCYTES**

T4 PHAGE see **BACTERIOPHAGE T4**

T4 RECEPTORS see **RECEPTORS, THYROID HORMONE**

T6 ANTIGENS see **ANTIGENS, DIFFERENTIATION, T–LYMPHOCYTE**

T8 ANTIGENS, T–CELL see **ANTIGENS, CD8**

T8 CELLS see **CD8–POSITIVE T–LYMPHOCYTES**

T11 ERYTHROCYTE–BINDING GLYCOPROTEIN see **ANTIGENS, CD2**

T–ALL see **LEUKEMIA, T–CELL, ACUTE**

T ANTIGENS see **ANTIGENS, VIRAL, TUMOR**

T–CELL ACTIVATION ANTIGEN see **ANTIGENS, CD27**

T–CELL ANTIGEN RECEPTOR–CD3 COMPLEX see **RECEPTOR–CD3 COMPLEX, ANTIGEN, T–CELL**

T–CELL ANTIGEN RECEPTOR GAMMA–CHAIN GENE REARRANGEMENT see **GENE REARRANGEMENT, GAMMA–CHAIN T–CELL ANTIGEN RECEPTOR**

T–CELL DIFFERENTIATION ANTIGENS see **ANTIGENS, DIFFERENTIATION, T–LYMPHOCYTE**

T–CELL EPITOPES see **EPITOPES, T–LYMPHOCYTE**

T–CELL GENE REARRANGEMENT see **GENE REARRANGEMENT, T–LYMPHOCYTE**

T–CELL GROWTH FACTOR see **INTERLEUKIN–2**

T–CELL GROWTH FACTOR P40 see **INTERLEUKIN–9**

T–CELL GROWTH FACTOR RECEPTORS see **RECEPTORS, INTERLEUKIN–2**

T–CELL LEUKEMIA see **LEUKEMIA, T–CELL**

T–CELL LEUKEMIA, ACUTE see **LEUKEMIA, T–CELL, ACUTE**

T–CELL LEUKEMIA, ADULT see **LEUKEMIA, T–CELL**

T–CELL LEUKEMIA, CHRONIC see **LEUKEMIA, T–CELL, CHRONIC**

T–CELL LEUKEMIA–LYMPHOMA, ADULT see **LEUKEMIA–LYMPHOMA, T–CELL, ACUTE, HTLV–I–ASSOCIATED**

T–CELL LEUKEMIA–LYMPHOMA, HTLV–I–ASSOCIATED see **LEUKEMIA–LYMPHOMA, T–CELL, ACUTE, HTLV–I–ASSOCIATED**

T–CELL LEUKEMIA–LYMPHOMA VIRUS ANTIBODIES, HUMAN see **HTLV–BLV ANTIBODIES**

T–CELL LEUKEMIA VIRUS I, HUMAN see **HTLV–I**

T–CELL LEUKEMIA VIRUS II, HUMAN see **HTLV–II**

T–CELL LEUKEMIA VIRUSES, HUMAN see **HTLV–BLV VIRUSES**

T–CELL LYMPHOMA see **LYMPHOMA, T–CELL**

T–CELL LYMPHOMA, CUTANEOUS see **LYMPHOMA, T–CELL, CUTANEOUS**

T–CELL LYMPHOMA, PERIPHERAL see **LYMPHOMA, T–CELL, PERIPHERAL**

T–CELL RECEPTORS see **RECEPTORS, ANTIGEN, T–CELL**

T–CELL RECEPTORS, ALPHA–BETA see **RECEPTORS, ANTIGEN, T–CELL, ALPHA–BETA**

T–CELL RECEPTORS ALPHA–CHAIN see **RECEPTORS, ANTIGEN, T–CELL, ALPHA–BETA**

T–CELL RECEPTORS BETA–CHAIN see **RECEPTORS, ANTIGEN, T–CELL, ALPHA–BETA**

T–CELL RECEPTORS DELTA–CHAIN see **RECEPTORS, ANTIGEN, T–CELL, GAMMA–DELTA**

T–CELL RECEPTORS GAMMA–CHAIN see **RECEPTORS, ANTIGEN, T–CELL, GAMMA–DELTA**

T–CELL RECEPTORS, GAMMA–DELTA see **RECEPTORS, ANTIGEN, T–CELL, GAMMA–DELTA**

T–CELL REPLACING FACTOR see **INTERLEUKIN–5**

T–CELL SUBSETS see **T–LYMPHOCYTE SUBSETS**

T–CELL SUPPRESSIVE FACTORS see **SUPPRESSOR FACTORS, IMMUNOLOGIC**

T–CELLS see **T–LYMPHOCYTES**

T–CELLS, HELPER–INDUCER see **T–LYMPHOCYTES, HELPER–INDUCER**

T–CELLS, SUPPRESSOR–EFFECTOR see **T–LYMPHOCYTES, SUPPRESSOR–EFFECTOR**

T–INDEPENDENT ANTIGENS see **ANTIGENS, T–INDEPENDENT**

T RNA METHYLTRANSFERASES see **RNA, TRANSFER, METHYLTRANSFERASES**

T–SUPPRESSOR FACTORS see **SUPPRESSOR FACTORS, IMMUNOLOGIC**

T VIRUS see **RETICULOENDOTHELIOSIS VIRUS, AVIAN**

TABLE SALT see **SODIUM CHLORIDE, DIETARY**

TABLETS

Mechanical properties of compacts and particles that control tableting success. Hiestand EN. **J Pharm Sci** 1997 Sep; 86(9):985–90 (50 ref.)

ANALYSIS

Analytical challenges in the development of modified–release oral solid dosage forms. A review. Bowker MJ. **Analyst** 1996 Oct;121(10):91R–100R (106 ref.)

TABOO

An additional facet of the incest taboo: a protection of the mating–strategy template. Immerman RS, et al. **J Genet Psychol** 1997 Jun;158(2):151–64 (100 ref.)

TAC PEPTIDE see **RECEPTORS, INTERLEUKIN–2**

TAC P55 PEPTIDE see **RECEPTORS, INTERLEUKIN–2**

TACHYARRHYTHMIA see **TACHYCARDIA**

TACHYCARDIA

[Tachyarrhythmias] Tanabe T, et al. **Nippon Rinsho** 1996 Aug;54(8):2177–84 (7 ref.) **(Jpn)**

[Multifocal atrial tachycardia (MAT), chaotic atrial tachycardia] Matsuoka Y. **Ryoikibetsu Shokogun Shirizu** 1996;(12):377–9 (8 ref.) **(Jpn)**

[Tachycardia and bradycardia dependent paroxysmal A–V block] Taguchi A, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (12):455–7 (16 ref.) **(Jpn)**

TACHYCARDIA

CLASSIFICATION

To fumble flutter or tackle "tach"? Toward updated classifiers for atrial tachyarrhythmias. Lesh MD, et al. **J Cardiovasc Electrophysiol** 1996 May;7(5):460–6 (23 ref.)

COMPLICATIONS

Repolarization and the genesis of cardiac arrhythmias. Role of body surface mapping [editorial; comment] Fontaine G, et al. **Circulation** 1997 Jun 17;95(12):2600–2 (20 ref.) Comment on: Circulation 1997 Jun 17;95(12):2668–76.

Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. Shinbane JS, et al. **J Am Coll Cardiol** 1997 Mar 15;29(4):709–15 (88 ref.)

Radiofrequency ablation of accessory pathways associated with congenital heart disease. van Hare GF. **Pacing Clin Electrophysiol** 1997 Aug;20(8 Pt 2):2077–81 (28 ref.)

[Tachycardia-induced cardiomyopathy] Takaoka H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):199–202 (14 ref.) **(Jpn)**

DIAGNOSIS

Sensing and tachyarrhythmia detection problems in implantable cardioverter defibrillators. Reiter MJ, et al. **J Cardiovasc Electrophysiol** 1996 Jun;7(6):542–58 (42 ref.)

Mechanism of tachycardia-dependent appearance of ventricular extrasystoles in concealed bigeminy. Kinoshita S, et al. **J Electrocardiol** 1996 Oct;29(4):341–5 (16 ref.)

[Identification of the patient at risk for arrhythmias. Noninvasive and invasive diagnosis] Trappe HJ, et al. **Internist (Berl)** 1996 Jan;37(1):34–44 (98 ref.) **(Ger)**

DRUG THERAPY

Adenosine in wide-complex tachycardia. Herbert ME, et al. **Ann Emerg Med** 1997 Jan;29(1):172–4 (15 ref.)

The role of intravenous amiodarone in the management of cardiac arrhythmias. Desai AD, et al. **Ann Intern Med** 1997 Aug 15;127(4):294–303 (71 ref.)

Atrial arrhythmias after cardiothoracic surgery [published erratum appears in N Engl J Med 1997 Jul 17;337(3):209] Ommen SR, et al. **N Engl J Med** 1997 May 15; 336(20):1429–34 (58 ref.)

ETIOLOGY

The dangers of jimson weed and its abuse by teenagers in the Kanawha Valley of West Virginia. Dewitt MS, et al. **W V Med J** 1997 Jul-Aug;93(4):182–5 (9 ref.)

[Endless loop tachycardia] Ohnishi S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):529–31 (12 ref.) **(Jpn)**

[Cardiac involvement in Reiter's disease] Dzhus MB, et al. **Lik Sprava** 1995 Sep-Dec;(9–12):168–9 (10 ref.) (Eng. Abstr.) **(Ukr)**

PHYSIOPATHOLOGY

Adenosine in wide-complex tachycardia. Herbert ME, et al. **Ann Emerg Med** 1997 Jan;29(1):172–4 (15 ref.)

Early electrocardiographic signs in acute massive pulmonary embolism. Hubloue I, et al. **Eur J Emerg Med** 1996 Sep; 3(3):199–204 (17 ref.)

Autonomic influences in atrial tachyarrhythmias. Coumel P. **J Cardiovasc Electrophysiol** 1996 Oct;7(10):999–1007 (22 ref.)

SURGERY

[Ablation of distinct accessory pathways with decremental conduction] Cruz Filho FE, et al. **Arq Bras Cardiol** 1996 Mar;66 Suppl 1:39–44 (19 ref.) **(Por)**

[Advances in the treatment of tachiarrhythmias: role of nonpharmacological methods] Asenjo RG, et al. **Rev Med Chil** 1995 Sep;123(9):1137–49 (39 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Pacing therapy for atrial tachyarrhythmias. Zhu DW, et al. **Clin Cardiol** 1996 Sep;19(9):737–42 (45 ref.)

Ongoing risk stratification trials: the primary prevention of sudden death. Buxton AE. **Control Clin Trials** 1996 Jun; 17(3 Suppl):47S–51S (3 ref.)

Anti-tachycardia device therapy. Sopher SM, et al. **Coron Artery Dis** 1996 Jan;7(1):20–8 (58 ref.)

Defibrillators are superior to antiarrhythmic drugs in the treatment of ventricular tachyarrhythmias. Böcker D, et al. **Eur Heart J** 1997 Jan;18(1):26–30 (28 ref.)

Implantable cardioverter-defibrillators in children. A perspective on current and future uses. Silka MJ. **J Electrocardiol** 1996;29 Suppl:223–5 (12 ref.)

Antitachycardia pacing. Gillette PC. **Pacing Clin Electrophysiol** 1997 Aug;20(8 Pt 2):2121–4 (15 ref.)

TACHYCARDIA, ATRIOVENTRICULAR NODAL REENTRY

[Atrioventricular reentrant tachycardia] Fujiki A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):513–6 (2 ref.) **(Jpn)**

[Atrioventricular nodal reentrant tachycardia (AVNRT), atrioventricular junctional reentrant tachycardia] Mizumaki K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):500–4 (12 ref.) **(Jpn)**

[Slow-fast type atrioventricular nodal reentrant tachycardia] Mizumaki K, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (12):215–8 (12 ref.) **(Jpn)**

[Reentrant tachycardia] Ohnishi S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):542–6 (8 ref.) **(Jpn)**

[Coumel's tachycardia (permanent form of junctional reciprocating tachycardia)] Yagi T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):184–7 (18 ref.) **(Jpn)**

CLASSIFICATION

[Classification of regular atrial tachycardia] Davy JM, et al. **Arch Mal Coeur Vaiss** 1997 Apr;90 Spec No 1:33–40 (29 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Manifest and concealed AV nodal reentry in Wenckebach type of AV conduction with AV junctional escape rhythm. Oreto G, et al. **J Electrocardiol** 1996 Oct;29(4):333–6 (11 ref.)

Atrioventricular node reentry: physiology and radiofrequency ablation. Prystowsky EN. **Pacing Clin Electrophysiol** 1997 Feb;20(2 Pt 2):552–71 (53 ref.)

DRUG THERAPY

[Drug therapy of tachycardic atrial arrhythmias] Wietholt D, et al. **Med Klin** 1997 Apr 15;92(4):197–201 (12 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Electrophysiology of "incisional" reentrant atrial tachycardia complicating surgery for congenital heart disease. Lesh MD, et al. **Pacing Clin Electrophysiol** 1997 Aug;20(8 Pt 2):2107–11 (10 ref.)

[Exercise-induced uncommon type atrioventricular nodal reentrant tachycardia] Komori S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):243–7 (4 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Electrophysiology of the A–V node in relation to A–V nodal reentry. Janse MJ, et al. **Jpn Heart J** 1996 Sep;37(5):785–91 (9 ref.)

[Long RP' tachycardia] Ohnishi S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):192–5 (16 ref.) **(Jpn)**

SURGERY

Catheter ablation of atrioventricular nodal reentrant tachycardia and bypass-tract mediated tachycardias. Orias DW, et al. **Coron Artery Dis** 1996 Jan;7(1):5–11 (44 ref.)

Radiofrequency catheter ablation of the anterosuperior and posteroinferior atrial approaches to the AV node for treatment of AV nodal reentrant tachycardia: techniques for selective ablation of "fast" and "slow" AV node pathways. Kottkamp H, et al. **J Cardiovasc Electrophysiol** 1997 Apr;8(4):451–68 (64 ref.)

Catheter ablation for the common type of atrioventricular nodal reentrant tachycardia. Sakurada H, et al. **Jpn Heart J** 1996 Sep;37(5):751–8 (17 ref.)

Atrioventricular node reentry: physiology and radiofrequency ablation. Prystowsky EN. **Pacing Clin Electrophysiol** 1997 Feb;20(2 Pt 2):552–71 (53 ref.)

Radiofrequency ablation of intraatrial reentrant tachycardia after surgery for congenital heart disease. Saul JP, et al. **Pacing Clin Electrophysiol** 1997 Aug;20(8 Pt 2):2112–7 (35 ref.)

[Catheter ablation for therapy of patients with arrhythmia] Aizawa Y, et al. **Nippon Rinsho** 1996 Aug;54(8):2159–64 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Management of atrioventricular tachycardia via left accessory pathway] Tsuchiya T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):292–5 (9 ref.) **(Jpn)**

[Catheter ablation of atrial tachyarrhythmias] Moreira D, et al. **Arq Bras Cardiol** 1996 Mar;66 Suppl 1:11–9 (63 ref.) **(Por)**

[Radiofrequency catheter ablation. Curative treatment of reentry nodal tachycardia] Rassi SG, et al. **Arq Bras Cardiol** 1996 Mar;66 Suppl 1:21–8 (22 ref.) **(Por)**

TACHYCARDIA, AV NODAL REENTRANT see **TACHYCARDIA, ATRIOVENTRICULAR NODAL REENTRY**

TACHYCARDIA, ECTOPIC ATRIAL

[Automatic atrial tachycardia] Fujiki A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):300–3 (6 ref.) **(Jpn)**

COMPLICATIONS

[Atrial tachycardia with block] Atarashi H. **Ryoikibetsu Shokogun Shirizu** 1996;(12):483–5 (5 ref.) **(Jpn)**

DIAGNOSIS

[Incessant atrial tachycardia and peripartum cardiomyopathy--a therapeutic challenge] Brito D, et al. **Rev Port Cardiol** 1997 Feb;16(2):157–63, 124 (19 ref.) (Eng. Abstr.) **(Por)**

PHYSIOPATHOLOGY

[Ectopic atria tachycardia, ectopic atrial rhythm] Aonuma K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):224–7 (12 ref.) **(Jpn)**

[Atrial tachycardia originating left atrium] Niki T. **Ryoikibetsu Shokogun Shirizu** 1996;(12):296–9 (15 ref.) **(Jpn)**

[Wandering atrial pacemaker] Sumida M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):228–30 (13 ref.) **(Jpn)**

SURGERY

Radiofrequency catheter ablation of atrial tachycardia and atrial flutter. Simons GR, et al. **Coron Artery Dis** 1996 Jan; 7(1):12–9 (48 ref.)

[Catheter ablation of atrial tachyarrhythmias] Moreira D, et al. **Arq Bras Cardiol** 1996 Mar;66 Suppl 1:11–9 (63 ref.) **(Por)**

TACHYCARDIA, ECTOPIC JUNCTIONAL

[Accelerated AV junctional rhythm] Enjoji Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):461–4 (13 ref.) **(Jpn)**

[Atrioventricular nodal reentrant tachycardia (AVNRT), atrioventricular junctional reentrant tachycardia] Mizumaki K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):500–4 (12 ref.) **(Jpn)**

DIAGNOSIS

Manifest and concealed AV nodal reentry in Wenckebach type of AV conduction with AV junctional escape rhythm. Oreto G, et al. **J Electrocardiol** 1996 Oct;29(4):333–6 (11 ref.)

TACHYCARDIA, PAROXYSMAL

[Paroxysmal supraventricular tachycardia (PSVT)] Kanae K. **Ryoikibetsu Shokogun Shirizu** 1996;(12):519–22 (9 ref.) **(Jpn)**

DRUG THERAPY

Adenosine: an effective and safe antiarrhythmic drug in pediatrics. Paul T, et al. **Pediatr Cardiol** 1997 Mar-Apr; 18(2):118–26 (82 ref.)

[Heart frequency control in chronic and paroxysmal atrial fibrillation. Critical evaluation of traditional therapy concepts] Ostermaier R, et al. **Fortschr Med** 1997 Jan 20; 115(1–2):26–8, 30, 32, passim (23 ref.) (Eng. Abstr.) **(Ger)**

[Digoxin. The drug of choice for the in-utero treatment of paroxysmal supraventricular tachycardia] Silva IS, et al. **Acta Med Port** 1997 Jan;10(1):95–8 (7 ref.) (Eng. Abstr.) **(Por)**

TACHYCARDIA, RECIPROCAL see **TACHYCARDIA, PAROXYSMAL**

TACHYCARDIA, SA NODAL REENTRANT see **TACHYCARDIA, SINOATRIAL NODAL REENTRY**

TACHYCARDIA, SINOATRIAL NODAL REENTRY

[Sinus node reentrant tachycardia] Odakura H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):388–90 (20 ref.) **(Jpn)**

TACHYCARDIA, SINUS

[Sinus bradycardia, sinus tachycardia] Nishikado A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):395–8 (9 ref.) **(Jpn)**

SURGERY

[Catheter ablation of atrial tachyarrhythmias] Moreira D, et al. **Arq Bras Cardiol** 1996 Mar;66 Suppl 1:11–9 (63 ref.) **(Por)**

TACHYCARDIA, SUPRAVENTRICULAR

Supraventricular tachycardia. Occasional nuisance or frequent threat? Campbell RW. **Eur Heart J** 1996 Jul;17 Suppl C:21–5 (33 ref.)

[Non reentrant supraventricular tachycardia] Enjoji Y, et al.

Ryoikibetsu Shokogun Shirizu 1996;(12):444–7 (13 ref.) **(Jpn)**

[Paroxysmal supraventricular tachycardia (PSVT)] Kanae K. **Ryoikibetsu Shokogun Shirizu** 1996;(12):519–22 (9 ref.) **(Jpn)**

[Chaotic heart action (chaotic atrial tachycardia, chaotic ventricular rhythm)] Kuroiwa A. **Ryoikibetsu Shokogun Shirizu** 1996;(12):532–4 (9 ref.) **(Jpn)**

[Intraatrial reentrant tachycardia (IART)] Miyazaki T. **Ryoikibetsu Shokogun Shirizu** 1996;(12):349–51 (6 ref.) **(Jpn)**

CLASSIFICATION

[Classification of regular atrial tachycardia] Davy JM, et al. **Arch Mal Coeur Vaiss** 1997 Apr;90 Spec No 1:33–40 (29 ref.) (Eng. Abstr.) **(Fre)**

CONGENITAL

[Congenital arrhythmia, atrial flutter, supraventricular tachycardia, ventricular tachycardia, congenital complete atrioventricular block] Ogawa K. **Ryoikibetsu Shokogun Shirizu** 1996;(12):360–3 (14 ref.) **(Jpn)**

DIAGNOSIS

Supraventricular tachycardia. ECG diagnosis and anatomy. Obel OA, et al. **Eur Heart J** 1997 May;18 Suppl C:C2–11 (51 ref.)

The value of the ECG in the diagnosis of supraventricular tachycardias. Wellens HJ. **Eur Heart J** 1996 Jul;17 Suppl C:10–20 (23 ref.)

[Regular wide QRS tachycardia] Ohnishi S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):208–10 (8 ref.) **(Jpn)**

DRUG THERAPY

Proarrhythmia during drug treatment of supraventricular tachycardia: paradoxical risk of sinus rhythm for sudden death. Prystowsky EN. **Am J Cardiol** 1996 Oct 17; 78(8A):35–41 (87 ref.)

Use of the newer antiarrhythmic drugs in patients with supraventricular tachyarrhythmias: let's not throw out the baby with the bath water. Mitchell LB. **Can J Cardiol** 1996 Oct;12(10):972–82 (60 ref.)

Using the right drug: a treatment algorithm for regular supraventricular tachycardias. Lévy S, et al. **Eur Heart J** 1997 May;18 Suppl C:C27–32 (19 ref.)

Avoiding drug problems. The safety of drugs for supraventricular tachycardia. Reimold SC. **Eur Heart J** 1997 May;18 Suppl C:C40–4 (8 ref.)

Treatment of supraventricular tachyarrhythmias with intravenous calcium channel blockers: are subtle differences worth the cost? Cheiman DM, et al. **Pharmacotherapy** 1996 Sep–Oct;16(5):861–8 (29 ref.)

[Clinico–electrophysiologic effects of magnesium, especially in supraventricular tachycardia] Vester EG. **Herz** 1997 Jun; 22 Suppl 1:40–50 (33 ref.) (Eng. Abstr.) **(Ger)**

[Drug therapy of supraventricular and ventricular tachyarrhythmias] Hohnloser SH. **Internist (Berl)** 1996 Jan; 37(1):45–52 (31 ref.) **(Ger)**

[Drug therapy of tachycardic atrial arrhythmias] Wietholt D, et al. **Med Klin** 1997 Apr 15;92(4):197–201 (12 ref.) (Eng. Abstr.) **(Ger)**

[Magnesium: current studies—critical evaluation—consequences] Meinertz T. **Z Kardiol** 1996;85 Suppl 6:147–51 (13 ref.) (Eng. Abstr.) **(Ger)**

[Exogenous adenosine as an anti–arrhythmia agent] Tebbenjohanns J, et al. **Z Kardiol** 1996;85 Suppl 6:191–9 (47 ref.) (Eng. Abstr.) **(Ger)**

[Magnesium as an anti–arrhythmic therapy principle in supraventricular and ventricular cardiac arrhythmias] Zehender M. **Z Kardiol** 1996;85 Suppl 6:135–45 (120 ref.) (Eng. Abstr.) **(Ger)**

[Digoxin. The drug of choice for the in–utero treatment of paroxysmal supraventricular tachycardia] Silva IS, et al. **Acta Med Port** 1997 Jan;10(1):95–8 (7 ref.) (Eng. Abstr.) **(Por)**

ETIOLOGY

[Cardiac arrhythmias of primary and secondary origin in cardiomyopathy] Klein RM, et al. **Internist (Berl)** 1996 Jan; 37(1):18–33 (99 ref.) **(Ger)**

[Genesis, pathophysiology and clinical aspects of cardiac arrhythmias. Characterization of the risk patient] Steinbeck G. **Med Klin** 1997 Apr 15;92(4):192–6 (11 ref.) (Eng. Abstr.) **(Ger)**

[Arrhythmogenic right ventricular dysplasia] Nagoshi H. **Ryoikibetsu Shokogun Shirizu** 1996;(13):94–7 (30 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Recognizing and managing permanent junctional reciprocating tachycardia in the catheter ablation era. Critelli G. **J Cardiovasc Electrophysiol** 1997 Feb; 8(2):226–36 (27 ref.)

PREVENTION & CONTROL

Pharmacologic prophylaxis of supraventricular tachyarrhythmias after coronary artery bypass. Dorovenis SA, et al. **Pharmacotherapy** 1996 Jul–Aug;16(4):615–8 (24 ref.)

SURGERY

Radiofrequency catheter ablation of atrial tachycardia and atrial flutter. Simons GR, et al. **Coron Artery Dis** 1996 Jan; 7(1):12–9 (48 ref.)

Insights into the electrophysiology of accessory pathway–mediated arrhythmias provided by the catheter ablation experience: "learning while burning, part III". Callans DJ, et al. **J Cardiovasc Electrophysiol** 1996 Sep; 7(9):877–904 (154 ref.)

Autonomic dysfunction after catheter ablation. Friedman PL, et al. **J Cardiovasc Electrophysiol** 1996 May;7(5):450–9 (41 ref.)

[Catheter ablation in supraventricular tachycardia] Pitschner HF, et al. **Z Kardiol** 1996;85 Suppl 6:45–60 (85 ref.) (Eng. Abstr.) **(Ger)**

[Catheter ablation of atrioventricular junction] Pachón Mateos JC, et al. **Arq Bras Cardiol** 1996 Mar;66 Suppl 1:3–10 (45 ref.) **(Por)**

[Radiofrequency ablation in the treatment of supraventricular tachyarrhythmia. Experience with 500 consecutive patients] Iturralde Torres P, et al. **Arch Inst Cardiol Mex** 1995 Nov–Dec;65(6):503–19 (80 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Management of supraventricular tachycardia in the emergency department. Connors S, et al. **Can J Cardiol** 1997 Mar;13 Suppl A:19A–24A (10 ref.)

Supraventricular tachycardia. Doing the right things. Campbell RW. **Eur Heart J** 1997 May;18 Suppl C:C50–3 (12 ref.)

Non–pharmacological treatment of supraventricular arrhythmias. Josephson ME, et al. **Eur Heart J** 1996 Jul; 17 Suppl C:26–34 (52 ref.)

[Invasive differential therapy of supraventricular and ventricular tachyarrhythmias] Perings C, et al. **Internist (Berl)** 1996 Jan;37(1):60–73 (79 ref.) **(Ger)**

[Catheter ablation and implantable atrial defibrillators in supraventricular cardiac arrhythmias] Jung W, et al. **Med Klin** 1997 Apr 15;92(4):202–7 (20 ref.) (Eng. Abstr.) **(Ger)**

[Treatment of supraventricular tachycardia in children] Norgård G, et al. **Tidsskr Nor Laegeforen** 1996 Oct 30; 116(26):3124–9 (37 ref.) (Eng. Abstr.) **(Nor)**

TACHYCARDIA, VENTRICULAR

[Idiopathic monomorphic ventricular tachycardia] Fauchier JP, et al. **Arch Mal Coeur Vaiss** 1996 Jul;89(7):897–906 (32 ref.) (Eng. Abstr.) **(Fre)**

[Dysrhythmias following cardiac surgery] Yamashiro T. **Nippon Rinsho** 1996 Aug;54(8):2227–32 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Left ventricular tachycardia] Kasai A. **Ryoikibetsu Shokogun Shirizu** 1996;(12):288–91 (9 ref.) **(Jpn)**

[Monomorphic ventricular tachycardia] Kishi F, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):380–3 (19 ref.) **(Jpn)**

[Idiopathic sustained ventricular tachycardia] Konishi T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):420–3 (10 ref.) **(Jpn)**

[Ventricular tachycardia] Miyazaki T. **Ryoikibetsu Shokogun Shirizu** 1996;(12):329–33 (8 ref.) **(Jpn)**

[Bundle branch reentrant tachycardia] Ohnishi S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):264–6 (20 ref.) **(Jpn)**

[Polymorphic ventricular tachycardia] Saito K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):373–6 (14 ref.) **(Jpn)**

CHEMICALLY INDUCED

Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy. Management with intravenous magnesium sulfate. Winters SL, et al. **Chest** 1997 May; 111(5):1454–7 (6 ref.)

CLASSIFICATION

Ventricular tachycardia in neonates. Perry JC. **Pacing Clin Electrophysiol** 1997 Aug;20(8 Pt 2):2061–4 (25 ref.)

COMPLICATIONS

Value and limitations of noninvasive assessment of syncope. Hammill SC. **Cardiol Clin** 1997 May;15(2):195–218 (68 ref.)

Ventricular tachycardia in Duchenne's muscular dystrophy. Muñoz J, et al. **Int J Cardiol** 1996 Jun;54(3):259–62 (7 ref.)

Therapy of ventricular tachycardia in patients with nonischemic cardiomyopathies. Blanck Z, et al. **J Cardiovasc Electrophysiol** 1996 Jul;7(7):671–83 (66 ref.)

Surgical therapy of ventricular tachyarrhythmias in patients with coronary artery disease. Hargrove WC 3rd, et al. **J Cardiovasc Electrophysiol** 1996 May;7(5):469–80 (59 ref.)

[Tachycardia–induced syncopes] Koerfer J, et al. **Ther Umsch** 1997 Mar;54(3):151–5 (14 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Idiopathic right ventricular outflow tract tachycardia: a clinical approach. Lerman BB, et al. **Pacing Clin Electrophysiol** 1996 Dec;19(12 Pt 1):2120–37 (59 ref.)

Intraventricular electrogram mapping and radiofrequency cardiac ablation for ventricular tachycardia. Panescu D. **Physiol Meas** 1997 Feb;18(1):1–38 (82 ref.)

DRUG THERAPY

Beta–blockers for ventricular arrhythmias: have we underestimated their value? Campbell TJ. **Aust N Z J Med** 1996 Oct;26(5):689–96 (59 ref.)

Clinical trials of antiarrhythmic drugs in patients with sustained ventricular tachyarrhythmias. Mitchell LB. **Curr Opin Cardiol** 1997 Jan;12(1):33–40 (45 ref.)

Intravenous amiodarone. Kowey PR, et al. **J Am Coll Cardiol** 1997 May;29(6):1190–8 (110 ref.)

Action of antiarrhythmic agents on the area of slow conduction in ventricular tachycardia. Aizawa Y, et al. **Jpn Heart J** 1996 Sep;37(5):773–84 (24 ref.)

The ESVEM trial: impact on treatment of ventricular tachyarrhythmias. Electrophysiologic Study Versus Electrocardiographic Monitoring. Reiter MJ. **Pacing Clin Electrophysiol** 1997 Feb;20(2 Pt 2):468–77 (59 ref.)

Beta adrenergic blockade in the treatment of sustained ventricular tachycardia or ventricular fibrillation. Wiesfeld AC, et al. **Pacing Clin Electrophysiol** 1996 Jul;19(7):1026–35 (77 ref.)

Advanced cardiac life support controversy: where do antiarrhythmic agents fit in? [published erratum appears in Pharmacotherapy 1997 May–Jun;17(3):634] Chow MS. **Pharmacotherapy** 1997 Mar–Apr;17(2 Pt 2):84S–88S; discussion 89S–91S (36 ref.)

Pharmacokinetics and pharmacodynamics of intravenous agents for ventricular arrhythmias. Nolan PE Jr. **Pharmacotherapy** 1997 Mar–Apr;17(2 Pt 2):65S–75S; discussion 89S–91S (107 ref.)

[Medicamentous anti–arrhythmia therapy. Is oral adjuvant therapy with electrolytes of value?] Haberl R. **Herz** 1997 Jun;22 Suppl 1:77–80 (20 ref.) (Eng. Abstr.) **(Ger)**

[Effect of magnesium on sustained ventricular tachycardia] Manz M, et al. **Herz** 1997 Jun;22 Suppl 1:51–5 (11 ref.) (Eng. Abstr.) **(Ger)**

[Magnesium deficiency and magnesium substitution. Effect on ventricular cardiac arrhythmias of various etiology] Zehender M, et al. **Herz** 1997 Jun;22 Suppl 1:56–62 (54 ref.) (Eng. Abstr.) **(Ger)**

[Drug therapy of supraventricular and ventricular tachyarrhythmias] Hohnloser SH. **Internist (Berl)** 1996 Jan; 37(1):45–52 (31 ref.) **(Ger)**

[Drug therapy of ventricular arrhythmias] Hohnloser SH. **Med Klin** 1997 Apr 15;92(4):208–10 (11 ref.) (Eng. Abstr.) **(Ger)**

[Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti–arrhythmia drugs] Haverkamp W, et al. **Z Kardiol** 1996;85 Suppl 6:97–106 (66 ref.) (Eng. Abstr.) **(Ger)**

[Anti–arrhythmia therapy after myocardial infarct: preliminary results of EMIAT and CAMIAT studies] Kuck KH. **Z Kardiol** 1996;85 Suppl 6:107–13 (11 ref.) (Eng. Abstr.) **(Ger)**

[Magnesium: current studies—critical evaluation—consequences] Meinertz T. **Z Kardiol** 1996;85 Suppl 6:147–51 (13 ref.) (Eng. Abstr.) **(Ger)**

[Ventricular cardiac arrhythmias. New anti–arrhythmia agents] Scholz H. **Z Kardiol** 1996;85 Suppl 6:91–6 (27 ref.) (Eng. Abstr.) **(Ger)**

[Exogenous adenosine as an anti–arrhythmia agent] Tebbenjohanns J, et al. **Z Kardiol** 1996;85 Suppl 6:191–9 (47 ref.) (Eng. Abstr.) **(Ger)**

[Magnesium as an anti–arrhythmic therapy principle in supraventricular and ventricular cardiac arrhythmias] Zehender M. **Z Kardiol** 1996;85 Suppl 6:135–45 (120 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Frequency of sudden cardiac death and profiles of risk [see comments] Myerburg RJ, et al. **Am J Cardiol** 1997 Sep 11;80(5B):10F–19F (87 ref.) Comment in: Am J Cardiol 1997 Sep 11;80(5B):1F–2F.

ETIOLOGY

The arrhythmogenic right ventricle. Dysplasia versus cardiomyopathy. Fontaine G, et al. **Heart Vessels** 1995; 10(5):227–35 (37 ref.)

Pathophysiologic substrate for ventricular tachycardia in coronary artery disease and non–ischemic heart disease. Josephson ME, et al. **Isr J Med Sci** 1996 Oct;32(10):875–9 (17 ref.)

[Cardiac arrhythmias of primary and secondary origin in cardiomyopathy] Klein RM, et al. **Internist (Berl)** 1996 Jan; 37(1):18–33 (99 ref.) **(Ger)**

[Genesis, pathophysiology and clinical aspects of cardiac arrhythmias. Characterization of the risk patient] Steinbeck G. **Med Klin** 1997 Apr 15;92(4):192–6 (11 ref.) (Eng. Abstr.)

(Ger)
[Prospectives in catheter ablation: treatment of atrial fibrillation and recurrent post-infarct ventricular tachycardia] Della Bella P, et al. **Cardiologia** 1996 Aug; 41(8):747–50 (28 ref.) **(Ita)**
[Mitral isthmus ventricular tachycardia] Miyazaki T. **Ryoikibetsu Shokogun Shirizu** 1996;(12):199–202 (5 ref.) **(Jpn)**
[Arrhythmogenic right ventricular dysplasia (ARVD)] Shimizu W. **Ryoikibetsu Shokogun Shirizu** 1996;(12):479–82 (10 ref.) **(Jpn)**

GENETICS

[Familial ventricular tachycardia] Yotsukura A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):252–5 (13 ref.) **(Jpn)**

MORTALITY

[New aspects of the epidemiology of sudden cardiac death] Willich SN. **Internist (Berl)** 1996 Jan;37(1):12–7 (36 ref.) **(Ger)**

PHYSIOPATHOLOGY

Electrophysiological mechanisms for ventricular arrhythmias in patients with myocardial ischemia: anesthesiologic considerations, Part I. Gallagher JD. **J Cardiothorac Vasc Anesth** 1997 Jun;11(4):495–505 (80 ref.)
Adenosine-sensitive ventricular tachycardia: a conceptual approach. Lerman BB, et al. **J Cardiovasc Electrophysiol** 1996 Jun;7(6):559–69 (54 ref.)
Mechanisms of idiopathic left ventricular tachycardia. Lerman BB, et al. **J Cardiovasc Electrophysiol** 1997 May; 8(5):571–83 (49 ref.)
Pericardial space exploration for ventricular tachycardia mapping: should the countdown begin? [comment] Strickberger SA. **J Cardiovasc Electrophysiol** 1996 Jun; 7(6):537–8 (4 ref.) Comment on: J Cardiovasc Electrophysiol 1996 Jun;7(6):531–6.
Time-domain signal-averaged electrocardiogram in nonischemic ventricular tachycardia. Fauchier JP, et al. **Pacing Clin Electrophysiol** 1996 Feb;19(2):231–44 (87 ref.)
The ESVEM trial: impact on treatment of ventricular tachyarrhythmias. Electrophysiologic Study Versus Electrocardiographic Monitoring. Reiter MJ. **Pacing Clin Electrophysiol** 1997 Feb;20(2 Pt 2):468–77 (59 ref.)
Ventricular tachycardia: pathophysiology and radiofrequency catheter ablation. Simons GR, et al. **Pacing Clin Electrophysiol** 1997 Feb;20(2 Pt 2):534–51 (126 ref.)
[Quinidine and high-amplification ECG] Brembilla-Perrot B, et al. **Ann Cardiol Angeiol (Paris)** 1997 Jan;46(1):15–20 (20 ref.) (Eng. Abstr.) **(Fre)**
[Pleomorphic ventricular tachycardia] Nomura M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):471–4 (17 ref.) **(Jpn)**
[Ventricular tachycardia with a QRS pattern of right bundle-branch block and left axis deviation] Satake S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):234–7 (19 ref.) **(Jpn)**
[Bidirectional ventricular tachycardia] Tomita Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):547–50 (21 ref.) **(Jpn)**
[Right ventricular outflow originated ventricular tachycardia] Tsuchihashi K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):238–42 (15 ref.) **(Jpn)**

PREVENTION & CONTROL

What can we expect from prophylactic implantable defibrillators? [see comments] Wilber DJ, et al. **Am J Cardiol** 1997 Sep 11;80(5B):20F–27F (54 ref.) Comment in: Am J Cardiol 1997 Sep 11;80(5B):1F–2F.
Major clinical trials assessing the prophylactic use of amiodarone in patients with ventricular tachyarrhythmias. Fogoros RN. **Control Clin Trials** 1996 Jun;17(3 Suppl):37S–46S (18 ref.)

SURGERY

Current role and future perspectives for radiofrequency catheter ablation of postmyocardial infarction ventricular tachycardia. Farré J, et al. **Am J Cardiol** 1996 Sep 12; 78(5A):76–88 (42 ref.)
Catheter mapping and ablation of ventricular tachycardia. Ganz LI, et al. **Coron Artery Dis** 1996 Jan;7(1):29–35 (30 ref.)
Catheter ablation of incessant ventricular tachycardia. Borggrefe M. **Isr J Med Sci** 1996 Oct;32(10):868–71 (15 ref.)
Surgical therapy of ventricular tachyarrhythmias in patients with coronary artery disease. Hargrove WC 3rd, et al. **J Cardiovasc Electrophysiol** 1996 May;7(5):469–80 (59 ref.)
Ventricular tachycardia: pathophysiology and radiofrequency catheter ablation. Simons GR, et al. **Pacing Clin Electrophysiol** 1997 Feb;20(2 Pt 2):534–51 (126 ref.)
Intraventricular electrogram mapping and radiofrequency cardiac ablation for ventricular tachycardia. Panescu D. **Physiol Meas** 1997 Feb;18(1):1–38 (82 ref.)
[An update of surgery for ventricular tachycardia] Lacroix D. **Arch Mal Coeur Vaiss** 1997 Apr;90 Spec No 1:19–26 (46 ref.) (Eng. Abstr.) **(Fre)**
[Methods of catheter ablation in ventricular tachycardic arrhythmias] Borggrefe M, et al. **Z Kardiol** 1996;85 Suppl 6:61–7 (36 ref.) (Eng. Abstr.) **(Ger)**
[Successful scartectomy and cryoablation for ventricular tachycardia occurring late after correction of tetralogy of Fallot] Hanada T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 May;44(5):664–7 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Radiofrequency ablation of the sustained ventricular tachycardia in patients with structural heart disease] de Paola AA, et al. **Arq Bras Cardiol** 1996 Mar;66 Suppl 1:51–8 (52 ref.) **(Por)**
[Radiofrequency catheter ablation of ventricular tachycardias in patients with postinfarction scars] Merino Lloréns JL, et al. **Rev Esp Cardiol** 1997 Mar;50(3):157–65 (20 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Drugs or implantable cardioverter-defibrillators in patients with poor left ventricular function? Block M, et al. **Am J Cardiol** 1996 Sep 12;78(5A):62–8 (67 ref.)
Antitachycardia pacing: which patients and which methods? Rosenqvist M. **Am J Cardiol** 1996 Sep 12;78(5A):92–7 (32 ref.)
An overview of the management of electrical storm. Dorian P, et al. **Can J Cardiol** 1997 Mar;13 Suppl A:13A–17A (19 ref.)
Evaluation and treatment strategies in patients at high risk of sudden death post myocardial infarction. Underwood RD, et al. **Clin Cardiol** 1997 Sep;20(9):753–8 (60 ref.)
Pharmacologic and nonpharmacologic treatment of ventricular arrhythmias in heart failure. Stevenson WG, et al. **Curr Opin Cardiol** 1997 May;12(3):242–50 (80 ref.)
Ventricular tachycardia in Duchenne's muscular dystrophy. Muñoz J, et al. **Int J Cardiol** 1996 Jun;54(3):259–62 (7 ref.)
Therapy of ventricular tachycardia in patients with nonischemic cardiomyopathies. Blanck Z, et al. **J Cardiovasc Electrophysiol** 1996 Jul;7(7):671–83 (66 ref.)
Therapy of "idiopathic" ventricular tachycardia. Varma N, et al. **J Cardiovasc Electrophysiol** 1997 Jan;8(1):104–16 (29 ref.)
Modification of ventricular tachycardia by carotid sinus massage. Kappos KG, et al. **J Electrocardiol** 1996 Oct; 29(4):327–32 (32 ref.)
Current concepts in electrical defibrillation. Truong JH, et al. **J Emerg Med** 1997 May-Jun;15(3):331–8 (68 ref.)
Acute management of ventricular arrhythmias: role of antiarrhythmic agents. Singh BN. **Pharmacotherapy** 1997 Mar-Apr;17(2 Pt 2):56S–64S; discussion 89S–91S (32 ref.)
[Infectious complications of cardioverter/defibrillators—case report and review of the literature] Hollenstein U, et al. **Acta Med Austriaca** 1996;23(5):164–7 (20 ref.) (Eng. Abstr.) **(Ger)**
[Invasive differential therapy of supraventricular and ventricular tachyarrhythmias] Perings C, et al. **Internist (Berl)** 1996 Jan;37(1):60–73 (79 ref.) **(Ger)**
[New aspects of defibrillator therapy] Brachmann J, et al. **Z Kardiol** 1996;85 Suppl 6:83–9 (22 ref.) (Eng. Abstr.) **(Ger)**
[Combined therapy with transvenous cardioverter/defibrillator and anti-bradycardia pacemaker systems] Sticherling C, et al. **Z Kardiol** 1997 Feb; 86(2):105–12 (23 ref.) (Eng. Abstr.) **(Ger)**
[Guided anti-arrhythmia therapy by programmed ventricular stimulation. A case of arrhythmogenic dysplasia of the right ventricle] Oliveira M, et al. **Rev Port Cardiol** 1997 Jan; 16(1):33–8, 8 (27 ref.) (Eng. Abstr.) **(Por)**

VETERINARY

Diagnosis of inherited ventricular tachycardia in German shepherd dogs. Moïse NS, et al. **J Am Vet Med Assoc** 1997 Feb 1;210(3):403–10 (37 ref.)

TACHYKININ RECEPTORS see **RECEPTORS, TACHYKININ**

TACHYKININS

see related
RECEPTORS, TACHYKININ

Tachykinins: receptor to effector. Khawaja AM, et al. **Int J Biochem Cell Biol** 1996 Jul;28(7):721–38 (152 ref.)

ANTAGONISTS & INHIBITORS

Nonpeptide tachykinin antagonists: medicinal chemistry and molecular biology. Lowe JA 3rd. **Med Res Rev** 1996 Nov; 16(6):527–45 (87 ref.)

GENETICS

The molecular biology of preprotachykinin-A gene expression. Fiskerstrand C, et al. **Neuropeptides** 1996 Dec; 30(6):602–10 (59 ref.)

METABOLISM

Potential role of tachykinins in inflammatory diseases. Canning BJ. **J Allergy Clin Immunol** 1997 May;99(5):579–82 (30 ref.)

PHARMACOLOGY

The effects of tachykinins on inflammatory and immune cells. Maggi CA. **Regul Pept** 1997 Jun 18;70(2-3):75–90 (198 ref.)

PHYSIOLOGY

Hematopoietic modulation by the tachykinins. Rameshwar P, et al. **Acta Haematol** 1997;98(2):59–64 (44 ref.)
Role of tachykinins in bronchial hyper-responsiveness. Reynolds PN, et al. **Clin Exp Pharmacol Physiol** 1997 Mar-Apr;24(3-4):273–80 (84 ref.)
Tachykinins in the autonomic nervous system. Maggi CA. **Pharmacol Res** 1996 Mar;33(3):161–70 (152 ref.)
On the role of tachykinins and calcitonin gene-related peptide in the spinal mechanisms of nociception and in the induction and maintenance of inflammation-evoked hyperexcitability in spinal cord neurons (with special reference to nociception in joints). Schaible HG. **Prog Brain Res** 1996;113:423–41 (152 ref.)
Sensory mechanisms. Widdicombe J. **Pulm Pharmacol** 1996 Oct-Dec;9(5-6):383–7 (77 ref.)
Tachykinins, neurotrophism and neurodegenerative diseases: a critical review on the possible role of tachykinins in the aetiology of CNS diseases. Barker R. **Rev Neurosci** 1996 Jul-Sep;7(3):187–214 (270 ref.)

TACHYPHYLAXIS

PHYSIOLOGY

Anomalous effects of albuterol and other sympathomimetics in the guinea pig. Morley J. **Clin Rev Allergy Immunol** 1996 Spring;14(1):65–89 (57 ref.)

TACHYPLEUS see **HORSESHOE CRABS**

TACRINE

ADMINISTRATION & DOSAGE

[Should Alzheimer disease be treated with tacrine? Review of the literature (see comments)] Arsland D, et al. **Tidsskr Nor Laegeforen** 1996 Sep 30;116(23):2791–4 (34 ref.) (Eng. Abstr.) Comment in: Tidsskr Nor Laegeforen 1997 Feb 20;117(5):726. **(Nor)**

PHARMACOLOGY

Nootropics: preclinical results in the light of clinical effects; comparison with tacrine. Mondadori C. **Crit Rev Neurobiol** 1996;10(3-4):357–70 (85 ref.)
[Tacrine in Alzheimer's disease] López de Munain A. **Rev Neurol** 1997 Jul;25 Suppl 1:S70–2 (23 ref.) **(Spa)**

THERAPEUTIC USE

Nootropics: preclinical results in the light of clinical effects; comparison with tacrine. Mondadori C. **Crit Rev Neurobiol** 1996;10(3-4):357–70 (85 ref.)
A risk-benefit assessment of tacrine in the treatment of Alzheimer's disease. Samuels SC, et al. **Drug Saf** 1997 Jan; 16(1):66–77 (55 ref.)
Advances in pharmacotherapy for decline of memory and cognition in patients with Alzheimer's disease. Kumar V, et al. **Psychiatr Serv** 1996 Mar;47(3):249–53 (28 ref.)
Alzheimer's disease. Hier DB. **Surg Neurol** 1997 Jan; 47(1):84–5 (10 ref.)
[Piracetam, nimodipine and tacrine in the pharmacologic treatment of dementia: bibliographic review] Ojer Tsakiridu D, et al. **Aten Primaria** 1996 Sep 30;18(5):257–60, 262–4 (31 ref.) **(Spa)**
[Tacrine in Alzheimer's disease] López de Munain A. **Rev Neurol** 1997 Jul;25 Suppl 1:S70–2 (23 ref.) **(Spa)**

TACROLIMUS

[Tacrolimus (FK506): clinical, pharmacological and analytical aspects] Brunet M. **Med Clin (Barc)** 1997 Jun 14;109(3):98–106 (121 ref.) **(Spa)**

ADVERSE EFFECTS

Clinically significant drug interactions with new immunosuppressive agents. Mignat C. **Drug Saf** 1997 Apr; 16(4):267–78 (62 ref.)

PHARMACOLOGY

Immunosuppressants, immunophilins, and the nervous system [editorial] Dawson TM. **Ann Neurol** 1996 Oct;40(4):559–60 (18 ref.)

THERAPEUTIC USE

Tacrolimus (FK506): the pros and cons of its use as an immunosuppressant in pediatric liver transplantation. Cox KL, et al. **Clin Invest Med** 1996 Oct;19(5):389–92 (15 ref.)
Experimental and clinical experience with the use of tacrolimus (FK506) in kidney transplantation. Wagner K, et al. **Clin Nephrol** 1996 May;45(5):332–5 (17 ref.)
The superiority of tacrolimus in renal transplant recipients — the Pittsburgh experience. Shapiro R, et al. **Clin Transpl** 1995;:199–205 (51 ref.)
The use of tacrolimus and mycophenolate mofetil after cardiac transplantation. Taylor DO. **Curr Opin Cardiol** 1997

Mar;12(2):161–5 (33 ref.)
FK506 in the treatment of inflammatory skin disease: promises and perspectives. Michel G, et al. **Immunol Today** 1996 Mar;17(3):106–8 (17 ref.)
Tacrolimus: immunosuppression following liver and kidney transplant. Clark W. **J Clin Pharm Ther** 1996 Jun; 21(3):135–41 (19 ref.)
A new immunosuppressant: tacrolimus. James DG. **Postgrad Med J** 1996 Oct;72(852):586 (3 ref.)
Cyclosporine and tacrolimus. Vaden SL. **Semin Vet Med Surg (Small Anim)** 1997 Aug;12(3):161–6 (26 ref.)
Tacrolimus (FK506) is superior to cyclosporine in liver transplantation. Busuttil RW, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):534–8 (12 ref.)
Tacrolimus (FK–506) in kidney transplantation. Shapiro R. **Transplant Proc** 1997 Feb–Mar;29(1–2):45–7 (46 ref.)
The use of tacrolimus in renal transplantation. Jordan ML, et al. **World J Urol** 1996;14(4):239–42 (12 ref.)
[Present status and problems in clinical application of tacrolimus(FK506)] Teraoka S, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):689 (0 ref.) **(Jpn)**

TAE KWON DO see **MARTIAL ARTS**

TAENIA

PHYSIOLOGY

Neurocysticercosis. Pittella JE. **Brain Pathol** 1997 Jan; 7(1):681–93 (95 ref.)
Echinococcosis. Taratuto AL, et al. **Brain Pathol** 1997 Jan; 7(1):673–9 (56 ref.)

TAENIA INFECTIONS see **TAENIASIS**

TAENIARHYNCHUS see **TAENIA**

TAENIASIS

see related
CYSTICERCOSIS

[Taeniasis and cysticercosis due to Taenia solium] Sarti E. **Salud Publica Mex** 1997 May–Jun;39(3):225–31 (81 ref.) **(Spa)**

DIAGNOSIS

Childhood neurocysticercosis: issues in diagnosis and management. Garg RK. **Indian Pediatr** 1995 Sep; 32(9):1023–9 (40 ref.)

THERAPY

Childhood neurocysticercosis: issues in diagnosis and management. Garg RK. **Indian Pediatr** 1995 Sep; 32(9):1023–9 (40 ref.)

TAHYNA VIRUS see **CALIFORNIA GROUP VIRUSES**

T'AI CHI see **MARTIAL ARTS**

TAI–JI see **MARTIAL ARTS**

TAIL

SURGERY

Cosmetic tail docking of dogs [see comments] Wansbrough RK. **Aust Vet J** 1996 Jul;74(1):59–63 (11 ref.) Comment in: Aust Vet J 1996 Dec;74(6):476–7.

TAKATSUKI'S SYNDROME see **POEMS SYNDROME**

TAKAYASU SYNDROME see **TAKAYASU'S ARTERITIS**

TAKAYASU'S ARTERITIS

Large vessel vasculitis (giant cell arteritis, Takayasu arteritis). Wilke WS. **Baillieres Clin Rheumatol** 1997 May; 11(2):285–313 (112 ref.)
Takayasu's disease and temporal arteritis. Giordano JM. **Semin Vasc Surg** 1995 Dec;8(4):335–41 (46 ref.)
[Pulseless disease, Takayasu' disease] Shimizu A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):415–6 (4 ref.) **(Jpn)**

COMPLICATIONS

Takayasu's arteritis associated with ulcerative colitis; genetic factors in this association [see comments] Morita Y, et al. **Intern Med** 1996 Jul;35(7):574–8 (22 ref.) Comment in: Intern Med 1996 Jul;35(7):521–2.
Ulcerative colitis, Takayasu arteritis and HLA [editorial; comment] Numano F, et al. **Intern Med** 1996 Jul; 35(7):521–2 (25 ref.) Comment on: Intern Med 1996 Jul;35(7):574–8.
[Association of Takayasu's disease and unclassified colitis (letter)] Vuillemin E, et al. **Gastroenterol Clin Biol** 1996; 20(11):1027–8 (7 ref.) **(Fre)**
[Takayasu's disease hypertension] Ishikawa K. **Ryoikibetsu Shokogun Shirizu** 1996;(12):118–21 (17 ref.) **(Jpn)**
[Inflammatory aortic aneurysm (non–mycotic)] Sasaki S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):318–21 (17 ref.) **(Jpn)**

DIAGNOSIS

Takayasu arteritis in Mexico: a 38–year clinical perspective through literature review. Dabague J, et al. **Int J Cardiol** 1997 Aug;54 Suppl:S103–9 (37 ref.)
Diagnostic criteria for Takayasu arteritis. Sharma BK, et al. **Int J Cardiol** 1997 Aug;54 Suppl:S141–7 (22 ref.)

GENETICS

Takayasu's arteritis associated with ulcerative colitis; genetic factors in this association [see comments] Morita Y, et al. **Intern Med** 1996 Jul;35(7):574–8 (22 ref.) Comment in: Intern Med 1996 Jul;35(7):521–2.

IMMUNOLOGY

Atheroarteritis: a combined immunological and lipid imbalance. Wissler RW, et al. **Int J Cardiol** 1997 Aug;54 Suppl:S37–49 (126 ref.)
Ulcerative colitis, Takayasu arteritis and HLA [editorial; comment] Numano F, et al. **Intern Med** 1996 Jul; 35(7):521–2 (25 ref.) Comment on: Intern Med 1996 Jul;35(7):574–8.
Absence of ANCA in Mexican patients with Takayasu's arteritis. García–Torres R, et al. **Scand J Rheumatol** 1997; 26(1):55–7 (17 ref.)

MORTALITY

Current status of large and small vessel vasculitis in Japan. Toshihiko N. **Int J Cardiol** 1997 Aug;54 Suppl:S91–8 (13 ref.)

PHYSIOPATHOLOGY

Differences in clinical presentation and outcome in different countries for Takayasu's arteritis. Numano F. **Curr Opin Rheumatol** 1997 Jan;9(1):12–5 (20 ref.)

RADIOGRAPHY

Conventional and CT angiographic diagnosis of Takayasu arteritis. Park JH. **Int J Cardiol** 1997 Aug;54 Suppl:S165–71 (11 ref.)

SURGERY

Takayasu's arteritis: management of a complex case and literature review Dabrowski GP, et al. **J La State Med Soc** 1997 Jul;149(6):250–3 (13 ref.)

TALC

ADVERSE EFFECTS

Atypical mycobacteriosis as a complication of talc pneumoconiosis. De Coster C, et al. **Eur Respir J** 1996 Aug;9(8):1757–9 (12 ref.)
Surgical glove lubricants: from toxicity to opportunity. Woods JA, et al. **J Emerg Med** 1997 Mar–Apr;15(2):209–20 (59 ref.)

TALENT see **APTITUDE**

TALFAN DISEASE VIRUS see **ENTEROVIRUSES, PORCINE**

TALIN

PHYSIOLOGY

Vinculin, talin and focal adhesions. Goldmann WH, et al. **J Muscle Res Cell Motil** 1996 Feb;17(1):1–5 (51 ref.)

TALIPES CAVUS see **FOOT DEFORMITIES**

TALIPES EQUINOVARUS see **CLUBFOOT**

TALOCALCANEAL JOINT see **SUBTALAR JOINT**

TALUS

INJURIES

Isolated talus fractures: description of a new clinical sign. Mayer D. **Am J Emerg Med** 1997 Jul;15(4):412–4 (19 ref.)
Fracture–dislocation of the neck of the talus in a ten–year–old child: a case report and review of the literature. Pereles TR, et al. **Bull Hosp Jt Dis** 1996;55(2):88–91 (13 ref.)
Occult fractures following subtalar joint injuries. Bohay DR, et al. **Foot Ankle Int** 1996 Mar;17(3):164–9 (11 ref.)
Closed complete rupture of the flexor hallucis longus tendon at the groove of the talus. Inokuchi S, et al. **Foot Ankle Int** 1997 Jan;18(1):47–9 (10 ref.)
Fracture of the medial tubercle of the posterior process of the talus: a case report and literature review. Kim DH, et al. **Foot Ankle Int** 1996 Mar;17(3):186–8 (2 ref.)
Repair of talar neck nonunion with indirect corticocancellous graft technique: a case report and review of the literature. Migues A, et al. **Foot Ankle Int** 1996 Nov;17(11):690–4 (28 ref.)
Complex fractures of the talus. Adelaar RS. **Instr Course Lect** 1997;46:323–38 (44 ref.)
Concomitant medial facet and dome fractures of the talus. Storm M, et al. **J Foot Ankle Surg** 1996 Jul–Aug; 35(4):331–4 (12 ref.)
Open medial subtalar dislocation associated with fracture of the posterior process of the talus [see comments] Naranja RJ Jr, et al. **J Orthop Trauma** 1996;10(2):142–4 (5 ref.) Comment in: J Orthop Trauma 1997 Apr;11(3):238.
Helical CT of talar fractures. Wechsler RJ, et al. **Skeletal Radiol** 1997 Mar;26(3):137–42 (13 ref.)
[Injuries of the talus and calcaneus] Brunner U, et al. **Unfallchirurg** 1996 Feb;99(2):136–51 (10 ref.) **(Ger)**

PATHOLOGY

Intraosseous gouty invasion of the talus. Raikin S, et al. **Foot Ankle Int** 1997 Jul;18(7):439–42 (18 ref.)

RADIOGRAPHY

Helical CT of talar fractures. Wechsler RJ, et al. **Skeletal Radiol** 1997 Mar;26(3):137–42 (13 ref.)

SURGERY

Podiatry Institute ankle fusion technique. Mahan KT, et al. **J Am Podiatr Med Assoc** 1997 Mar;87(3):101–16 (63 ref.)

TAMARINS see **SAGUINUS**

TAMIAS see **SCIURIDAE**

TAMOXIFEN

Tamoxifen. **IARC Monogr Eval Carcinog Risks Hum** 1996; 66:253–365 (408 ref.)
Molecular mechanisms and future uses of antiestrogens. Jordan VC, et al. **Mol Aspects Med** 1997 Jun;18(3):167–247 (295 ref.)

ADMINISTRATION & DOSAGE

Systemic adjuvant therapy of breast cancer. Garrett TJ, et al. **J Surg Oncol** 1997 Feb;64(2):167–72 (35 ref.)
[Adjuvant tamoxifen duration: more large–scale randomized evidence is needed] Davies C, et al. **Gan To Kagaku Ryoho** 1997 Aug;24(10):1203–9 (30 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Tamoxifen and endometrial neoplasia. Barakat RR. **Clin Obstet Gynecol** 1996 Sep;39(3):629–40 (36 ref.)
Endometrial changes with chronic tamoxifen use. Loret de Mola JR. **Curr Opin Obstet Gynecol** 1997 Jun;9(3):160–4 (43 ref.)
Tamoxifen and secondary tumours. An update. Wilking N, et al. **Drug Saf** 1997 Feb;16(2):104–17 (151 ref.)
Tamoxifen in postmenopausal women a safety perspective. Robinson E, et al. **Drugs Aging** 1996 May;8(5):329–37 (46 ref.)
A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Assikis VJ, et al. **Eur J Cancer** 1996 Aug; 32A(9):1464–76 (75 ref.)
Mullerian adenosarcoma of the uterine corpus associated with tamoxifen therapy: a report of six cases and a review of tamoxifen–associated endometrial lesions. Clement PB, et al. **Int J Gynecol Pathol** 1996 Jul;15(3):222–9 (59 ref.)
Granulosa cell tumor of the ovary associated with antecedent tamoxifen use. Gherman RB, et al. **Obstet Gynecol** 1994 Oct;84(4 Pt 2):717–9 (11 ref.)
The tamoxifen controversy. Crabbe WW. **Oncol Nurs Forum** 1996 Jun;23(5):761–6 (32 ref.)
Benign and hyperplastic endometrial changes associated with tamoxifen use. Barakat RR. **Oncology (Huntingt)** 1997 Feb; 11(2 Suppl 1):35–7 (9 ref.)
Risk of endometrial cancer after tamoxifen treatment. Morgan RW. **Oncology (Huntingt)** 1997 Feb;11(2 Suppl 1):25–33 (46 ref.)
Overview of studies on endometrial cancer and other types of cancer in humans: perspectives of an epidemiologist. MacMahon B. **Semin Oncol** 1997 Feb;24(1 Suppl 1):S1–122–S1–39 (39 ref.)
Tamoxifen and the uterus: an old drug tested by new modalities. Achiron R, et al. **Ultrasound Obstet Gynecol** 1996 May;7(5):374–8 (35 ref.)
[Endometrial cancer and tamoxifen. Discussion apropos of a series of cases] Sasco AJ, et al. **Bull Cancer** 1997 Jan; 84(1):51–60 (81 ref.) (Eng. Abstr.) **(Fre)**

ANALOGS & DERIVATIVES

Droloxifene. **IARC Monogr Eval Carcinog Risks Hum** 1996; 66:241–51 (33 ref.)
Clinical potential of new antiestrogens. Gradishar WJ, et al. **J Clin Oncol** 1997 Feb;15(2):840–52 (138 ref.)

METABOLISM

Comparative metabolism of tamoxifen and DNA adduct formation and in vitro studies on genotoxicity. Tannenbaum SR. **Semin Oncol** 1997 Feb;24(1 Suppl 1):S1–81–S1–6 (38 ref.)
[Molecular aspects of different mechanisms of tamoxifen resistance] Bachmann–Moisson N, et al. **Bull Cancer** 1997

Jan;84(1):69-75 (62 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer. Lykkesfeldt AE. **Acta Oncol** 1996; 35 Suppl 5:9-14 (60 ref.)

Genomic effects of tamoxifen. Kellen JA. **Anticancer Res** 1996 Nov-Dec;16(6B):3537-41 (52 ref.)

Enhancement of the anti-neoplastic effects of tamoxifen by somatostatin analogues. Pollak M. **Digestion** 1996;57 Suppl 1:29-33 (37 ref.)

Interaction of chemopreventive agents with hormone receptors. Wiseman H. **IARC Sci Publ** 1996;(139):159-64 (20 ref.)

Tamoxifen's impact on the management of breast cancer: the oncologist's perspective. Glick JH, et al. **Oncology (Huntingt)** 1997 Feb;11(2 Suppl 1):49-54 (5 ref.)

Interaction of tamoxifen's impact on overall net mortality and quality of life. Ragaz J. **Oncology (Huntingt)** 1997 Feb; 11(2 Suppl 1):45-8 (22 ref.)

Clinical relevance of laboratory and animal data on tamoxifen. Swenberg JA. **Oncology (Huntingt)** 1997 Feb; 11(2 Suppl 1):39-44 (43 ref.)

Safety assessment of tamoxifen and toremifene. Williams GM, et al. **Oncology (Huntingt)** 1997 May;11(5 Suppl 4):41-7 (81 ref.)

Tamoxifen and endometrial cancer: tamoxifen effects on the human female genital tract. Cohen CJ. **Semin Oncol** 1997 Feb;24(1 Suppl 1):S1-55-S1-64 (61 ref.)

Antagonistic and agonistic effects of tamoxifen: significance in human cancer. Gallo MA, et al. **Semin Oncol** 1997 Feb; 24(1 Suppl 1):S1-71-S1-80 (72 ref.)

[Mechanism of acquired antiestrogen resistance and its management in breast cancer] Iino Y, et al. **Nippon Rinsho** 1997 May;55(5):1149-54 (21 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Effects of hormones on the plasma levels of the atherogenic amino acid homocysteine. Lien EA, et al. **Biochem Soc Trans** 1997 Feb;25(1):33-5 (19 ref.)

The treatment of disseminated malignant melanoma with special reference to the role of interferons, vinca alkaloids and tamoxifen. Bezwoda WR. **Cancer Treat Rev** 1997 Jan; 23(1):17-34 (144 ref.)

Adjuvant therapy in breast cancer. Optimal use in the elderly. Plowman PN. **Drugs Aging** 1996 Sep;9(3):185-90 (20 ref.)

Tamoxifen in postmenopausal women a safety perspective. Robinson E, et al. **Drugs Aging** 1996 May;8(5):329-37 (46 ref.)

Chemoprevention of breast cancer with tamoxifen. Cuzick J. **IARC Sci Publ** 1996;(136):95-109 (83 ref.)

Mullerian adenosarcoma of the uterine corpus associated with tamoxifen therapy: a report of six cases and a review of tamoxifen-associated endometrial lesions. Clement PB, et al. **Int J Gynecol Pathol** 1996 Jul;15(3):222-9 (59 ref.)

Long-term tamoxifen therapy: can an antagonist become an agonist? [editorial] Santen RJ. **J Clin Endocrinol Metab** 1996 Jun;81(6):2027-9 (16 ref.)

The Breast Cancer Prevention Trial: evaluating tamoxifen's efficacy in preventing breast cancer. McKeon VA. **J Obstet Gynecol Neonatal Nurs** 1997 Jan-Feb;26(1):79-90 (62 ref.)

Design of an ideal hormone replacement therapy for women. Tonetti DA, et al. **Mol Carcinog** 1996 Nov;17(3):108-11 (21 ref.)

Systemic adjuvant therapy for breast cancer. Reed EC. **Nebr Med J** 1996 Mar;81(3):48-50 (17 ref.)

Tamoxifen, balancing risks and benefits. Bergman L, et al. **Neth J Med** 1996 Dec;49(6):228-34 (33 ref.)

Risks and benefits of tamoxifen therapy. Assikis VJ, et al. **Oncology (Huntingt)** 1997 Feb;11(2 Suppl 1):21-3 (13 ref.)

Phase III trials of toremifene vs tamoxifen. Gams R. **Oncology (Huntingt)** 1997 May;11(5 Suppl 4):23-8 (0 ref.)

Tamoxifen treatment for breast cancer: concept to gold standard. Jordan VC. **Oncology (Huntingt)** 1997 Feb;11(2 Suppl 1):7-13 (51 ref.)

Tamoxifen's impact on the management of breast cancer: patient perspectives. Reichman BS. **Oncology (Huntingt)** 1997 Feb;11(2 Suppl 1):55-8 (14 ref.)

Clinical efficacy of tamoxifen. Robert NJ. **Oncology (Huntingt)** 1997 Feb;11(2 Suppl 1):15-20 (41 ref.)

Tamoxifen: from breast cancer therapy to the design of a postmenopausal prevention maintenance therapy. Jordan VC, et al. **Osteoporos Int** 1997;7 Suppl 1:S52-7 (36 ref.)

Scientific review of tamoxifen. Overview from a medical oncologist. Carlson RW. **Semin Oncol** 1997 Feb;24(1 Suppl 1):S1-151-S1-7 (19 ref.)

The control of breast cancer: the role of tamoxifen. Forbes JF. **Semin Oncol** 1997 Feb;24(1 Suppl 1):S1-5-S1-19 (33 ref.)

Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Gelmann EP. **Semin Oncol** 1997 Feb;24(1 Suppl 1):S1-65-S1-70 (71 ref.)

Efficacy of tamoxifen as treatment of breast cancer. Powles TJ. **Semin Oncol** 1997 Feb;24(1 Suppl 1):S1-48-S1-54 (50 ref.)

Is it time to develop an optimal endocrine therapy for premenopausal patients with axillary node positive and negative breast cancer? Bilimoria MM, et al. **Semin Surg Oncol** 1996 Sep-Oct;12(5):339-45 (44 ref.)

Endocrinology of melanoma. Neifeld JP. **Semin Surg Oncol** 1996 Nov-Dec;12(6):402-6 (37 ref.)

[Tamoxifen: modern drug therapy of estrogen-dependent breast tumors] Jovanović-Mićić D, et al. **Med Pregl** 1996; 49(7-8):287-90 (20 ref.) (Eng. Abstr.) **(Scr)**

TOXICITY

The metabolism and genotoxicity of tamoxifen. White IN, et al. **Prog Clin Biol Res** 1997;396:257-70 (53 ref.)

Adducts and tamoxifen. Busch H. **Semin Oncol** 1997 Feb;24(1 Suppl 1):S1-98-S1-104 (37 ref.)

Relevance of rat liver tumors to human hepatic and endometrial cancer. Guzelian PS. **Semin Oncol** 1997 Feb; 24(1 Suppl 1):S1-105-S1-21 (130 ref.)

Review of the toxicology of tamoxifen. Wogan GN. **Semin Oncol** 1997 Feb;24(1 Suppl 1):S1-87-S1-97 (36 ref.)

[Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines] Bachmann-Moisson N, et al. **Bull Cancer** 1996 Oct;83(10):808-15 (37 ref.) (Eng. Abstr.) **(Fre)**

TANDEM REPEAT see **REPETITIVE SEQUENCES, NUCLEIC ACID**

TANGIER DISEASE

COMPLICATIONS

Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. Vega GL, et al. **Curr Opin Lipidol** 1996 Aug;7(4):209-16 (25 ref.)

TANNINS

METABOLISM

Production and application of tannin acyl hydrolase: state of the art. Lekha PK, et al. **Adv Appl Microbiol** 1997; 44:215-60 (150 ref.)

PHARMACOLOGY

Natural polyphenols (vegetable tannins) as drugs: possible modes of action. Haslam E. **J Nat Prod** 1996 Feb; 59(2):205-15 (60 ref.)

TANTALUM

CHEMISTRY

The suitability of Ta6Br12(2+) for phasing in protein crystallography. Neuefeind T, et al. **Biol Chem** 1997 Mar-Apr;378(3-4):219-21 (21 ref.)

TAPE RECORDING, VIDEO see **VIDEOTAPE RECORDING**

TAPETORETINAL DEGENERATION see **RETINITIS PIGMENTOSA**

TAPEWORM INFECTION see **CESTODE INFECTIONS**

TAPEWORMS see **CESTODA**

TARGETED RADIOTHERAPY see **RADIOTHERAPY**

TARGETED TOXINS see **IMMUNOTOXINS**

TARICHA see **SALAMANDRIDAE**

TARICHATOXIN see **TETRODOTOXIN**

TARS

ADVERSE EFFECTS

Adverse effects of colophony. Keira T, et al. **Ind Health** 1997;35(1):1-7 (63 ref.)

TARSAL BONES

Aneurysmal bone cyst of the navicular: a case report and review of the literature. Fraipont MJ, et al. **Foot Ankle Int** 1996 Nov;17(11):709-11 (30 ref.)

Solitary IgA myeloma of the foot. A case report and review of the literature. Khoddami M, et al. **J Am Podiatr Med Assoc** 1997 May;87(5):233-7 (24 ref.)

ABNORMALITIES

Accessory bone or unusual congenital anomaly. O'Rourke J, et al. **J Am Podiatr Med Assoc** 1997 Sep;87(9):407-13 (52 ref.)

[Congenital tarsal synostosis] Daumas L, et al. **Arch Pediatr** 1996 Sep;3(9):900-5 (20 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

AIDS-related Kaposi sarcoma involving the tarsal bones. Nguyen C, et al. **Skeletal Radiol** 1996 Jan;25(1):100-2 (9 ref.)

SURGERY

Current concepts of absorbable fixation in first ray surgery. Cicchinelli LD, et al. **Clin Podiatr Med Surg** 1996 Jul; 13(3):533-47 (45 ref.)

TARSAL JOINT

Management of the foot and ankle in rheumatoid arthritis. Mann RA, et al. **Rheum Dis Clin North Am** 1996 Aug; 22(3):457-76 (23 ref.)

INJURIES

Imaging of injuries to the tarsometatarsal joint complex. Fox IM, et al. **Clin Podiatr Med Surg** 1997 Apr;14(2):357-68 (16 ref.)

Traumatic dislocations of the lesser toes. Brunet JA, et al. **Foot Ankle Int** 1997 Jul;18(7):406-11 (17 ref.)

RADIOGRAPHY

Imaging of injuries to the tarsometatarsal joint complex. Fox IM, et al. **Clin Podiatr Med Surg** 1997 Apr;14(2):357-68 (16 ref.)

SURGERY

Fracture-dislocation of the neck of the talus in a ten-year-old child: a case report and review of the literature. Pereles TR, et al. **Bull Hosp Jt Dis** 1996;55(2):88-91 (13 ref.)

Graft-enhanced arthrodesis. Catanzariti AR. **J Foot Ankle Surg** 1996 Sep-Oct;35(5):463-73 (31 ref.)

Coralline hydroxyapatite bone graft substitutes. Elsinger EC, et al. **J Foot Ankle Surg** 1996 Sep-Oct;35(5):396-9 (17 ref.)

TARSUS

see related
TARSAL BONES

TARSUS OSSEUS see **TARSAL BONES**

TASK PERFORMANCE AND ANALYSIS

see related
WORKLOAD

Job analysis in occupational therapy: stepping into the complex world of business and industry. Lysaght R. **Am J Occup Ther** 1997 Jul-Aug;51(7):569-75 (31 ref.)

Design-oriented functional capacity evaluation: the available motions inventory--a review. Malzahn DE, et al. **Disabil Rehabil** 1996 Aug;18(8):382-95 (21 ref.)

Effects of physical exertion on task performance in modern manufacturing: a taxonomy, a review, and a model. Mozrall JR, et al. **Ergonomics** 1996 Oct;39(10):1179-213 (100 ref.)

Expert-novice knowledge of computer programming at different levels of abstraction. Ye N, et al. **Ergonomics** 1996 Mar;39(3):461-81 (28 ref.)

Combining time and intensity effects in assessing operator information-processing load. Hendy KC, et al. **Hum Factors** 1997 Mar;39(1):30-47 (56 ref.)

Effect of divergent self-monitoring strategies on motor performance and emotion as a function of alternating task complexity. Anshel MH, et al. **J Sports Sci** 1996 Jun; 14(3):233-42 (47 ref.)

How do the elderly negotiate stairs? Cavanagh PR, et al. **Muscle Nerve Suppl** 1997;5:S52-5 (20 ref.)

Quantifying physical functional performance in older adults. Cress ME. **Muscle Nerve Suppl** 1997;5:S17-20 (5 ref.)

Sarcopenia and physical performance in old age: overview. Dutta C, et al. **Muscle Nerve Suppl** 1997;5:S5-9 (15 ref.)

Sarcopenia and physical performance in old age: introduction. Schwartz RS. **Muscle Nerve Suppl** 1997; 5:S10-2 (3 ref.)

TASTE

Novel sweet-tasting saponins of the cycloartane, oleanane, secodammarane, and steroidal types. Kennelly EJ, et al. **Adv Exp Med Biol** 1996;405:13-24 (47 ref.)

DRUG EFFECTS

Disturbances of taste and smell induced by drugs. Ackerman BH, et al. **Pharmacotherapy** 1997 May-Jun;17(3):482-96 (126 ref.)

PHYSIOLOGY

The taste for salt in humans. Mattes RD. **Am J Clin Nutr** 1997 Feb;65(2 Suppl):692S-697S (73 ref.)

Mechanism of nonlinear responses of taste cells to mixed tastes. Kashimori Y, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):C405-22 (40 ref.)

New perspectives in a gustatory physiology: transduction, development, and plasticity. Stewart RE, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):C1-26 (203 ref.)

Taste preferences and food intake. Drewnowski A. **Annu Rev Nutr** 1997;17:237-53 (109 ref.)

Making sense of chemicals. Gilbertson TA, et al. **Chem Biol** 1996 Apr;3(4):233-7 (41 ref.)

Neurotransmitter and neuromodulator activity in the gustatory zone of the nucleus tractus solitarius. Bradley

RM, et al. **Chem Senses** 1996 Jun;21(3):377–85 (55 ref.)
Volatile flavor release from foods during eating. Taylor AJ. **Crit Rev Food Sci Nutr** 1996 Dec;36(8):765–84 (75 ref.)
Chemoreception: tasting the sweet and the bitter. Lindemann B. **Curr Biol** 1996 Oct 1;6(10):1234–7 (20 ref.)
Mechanisms of taste transduction. Kinnamon SC, et al. **Curr Opin Neurobiol** 1996 Aug;6(4):506–13 (76 ref.)
The orbitofrontal cortex. Rolls ET. **Philos Trans R Soc Lond B Biol Sci** 1996 Oct 29; 351(1346):1433–43; discussion 1443–4 (103 ref.)
Mothers and their infants: peptide–mediated physiological, behavioral and affective changes during suckling. Blass EM. **Regul Pept** 1996 Oct 8;66(1–2):109–12 (28 ref.)

TASTE BUDS

PHYSIOLOGY

Neuromodulation of transduction and signal processing in the end organs of taste. Nagai T, et al. **Chem Senses** 1996 Jun;21(3):353–65 (106 ref.)

TASTE DISORDERS

CHEMICALLY INDUCED

Disturbances of taste and smell induced by drugs. Ackerman BH, et al. **Pharmacotherapy** 1997 May–Jun;17(3):482–96 (126 ref.)

DRUG THERAPY

Zinc deficiency and taste disorders. Heyneman CA. **Ann Pharmacother** 1996 Feb;30(2):186–7 (15 ref.)

ETIOLOGY

Zinc deficiency and taste disorders. Heyneman CA. **Ann Pharmacother** 1996 Feb;30(2):186–7 (15 ref.)

TASTE THRESHOLD

PHYSIOLOGY

[Electrogustometry] Ueda T, et al. **Nippon Rinsho** 1997 Mar; 55 Suppl 1:480–3 (7 ref.) **(Jpn)**

TAT GENE PRODUCTS see **GENE PRODUCTS, TAT**

TAT GENES see **GENES, TAT**

TAT PROTEIN see **GENE PRODUCTS, TAT**

TATA BOX

Retinoid–dependent transcription: the RAR/RXR–TBP–EIA/EIA–LA connection. Meyer M, et al. **Biochem Soc Symp** 1996;62:97–109 (50 ref.)
Mechanisms of transcriptional activation in vivo: two steps forward. Stargell LA, et al. **Trends Genet** 1996 Aug; 12(8):311–5 (54 ref.)

TATTOOING

Laser treatment of tattoos. Kilmer SL. **Dermatol Clin** 1997 Jul;15(3):409–17 (50 ref.)
Marking and identifying colon lesions. Tattoos, clips, and radiology in imaging the colon. Ellis KK, et al. **Gastrointest Endosc Clin N Am** 1997 Jul;7(3):401–11 (48 ref.)
[Q–switched ruby laser in dermatologic therapy. Use and indications] Michel S, et al. **Hautarzt** 1997 Jul;48(7):462–70 (81 ref.) (Eng. Abstr.) **(Ger)**
[Uvulectomy and blue gingiva tattoo among Ethiopian immigrants in Israel] Menachem S, et al. **Harefuah** 1997 Jan 15;132(2):128–30 (22 ref.) **(Heb)**

TAU PROTEINS

ANALYSIS

The neurochemistry of Alzheimer's disease. Blennow K, et al. **Acta Neurol Scand Suppl** 1996;168:77–86 (129 ref.)

CEREBROSPINAL FLUID

Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer's disease. Arai H, et al. **Gerontology** 1997;43 Suppl 1:2–10 (35 ref.)

METABOLISM

Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Billingsley ML, et al. **Biochem J** 1997 May 1;323 (Pt 3):577–91 (216 ref.)
Neurobiology of Alzheimer's disease. Peskind ER. **J Clin Psychiatry** 1996;57 Suppl 14:5–8 (53 ref.)
The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Lovestone S, et al. **Neuroscience** 1997 May;78(2):309–24 (169 ref.)

PHYSIOLOGY

Interaction of aluminum with paired helical filament tau is involved in neurofibrillary pathology of Alzheimer's disease. Shin RW. **Gerontology** 1997;43 Suppl 1:16–23 (60 ref.)
Normal and pathological Tau proteins as factors for microtubule assembly. Delacourte A, et al. **Int Rev Cytol** 1997;171:167–224 (269 ref.)
[The role of tau in neural morphogenesis] Kanai T. **Kaibogaku Zasshi** 1996 Dec;71(6):604–10 (9 ref.) **(Jpn)**

TAURINE

ANALOGS & DERIVATIVES

Subtypes of alcoholism and their role in therapy. Lesch OM, et al. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:63–7 (20 ref.)
Pharmacotherapies for alcohol problems: a review of research with focus on developments since 1991 [see comments] Litten RZ, et al. **Alcohol Clin Exp Res** 1996 Aug;20(5):859–76 (247 ref.) Comment in: Alcohol Clin Exp Res 1997 Apr;21(2):380.
Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Wilde MI, et al. **Drugs** 1997 Jun; 53(6):1038–53 (62 ref.)
Recent developments in the pharmacotherapy of alcohol dependence. Schuckit MA. **J Consult Clin Psychol** 1996 Aug;64(4):669–76 (82 ref.)
Anti–craving compounds for ethanol: new pharmacological tools to study addictive processes. Spanagel R, et al. **Trends Pharmacol Sci** 1997 Feb;18(2):54–9 (76 ref.)
[Adjuvant therapy of peritonitis with taurolidine. Modulation of mediator liberation] Staubach KH. **Langenbecks Arch Chir** 1997;382(4 Suppl 1):S26–30 (17 ref.) (Eng. Abstr.) **(Ger)**
[Pharmacological treatment of alcohol dependence. Acamprosate and naltrexone offer new approach] Berglund M, et al. **Lakartidningen** 1997 Jul 23;94(30–31):2645–8 (19 ref.) **(Swe)**

BLOOD

Association of the band 3 protein with a volume–activated, anion and amino acid channel: a molecular approach. Motais R, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):361–7 (54 ref.)

DEFICIENCY

Taurine deficiency and neuronal migration. Morán J, et al. **Adv Exp Med Biol** 1996;403:519–26 (24 ref.)

METABOLISM

Taurine in hepatic encephalopathy. Butterworth RF. **Adv Exp Med Biol** 1996;403:601–6 (29 ref.)
Characterization of the volume–activated taurine pathway in cultured cerebellar granule neurons. Pasantes–Morales H, et al. **Adv Exp Med Biol** 1996;403:393–400 (27 ref.)
Sodium– and chloride–dependent transport of taurine at the blood–brain barrier. Tsuji A, et al. **Adv Exp Med Biol** 1996; 403:385–91 (12 ref.)
Is taurine a preventive nutritional factor of cardiovascular diseases or just a biological marker of nutrition? Yamori Y, et al. **Adv Exp Med Biol** 1996;403:623–9 (26 ref.)

PHARMACOLOGY

Taurine. Past, present, and future. Huxtable RJ. **Adv Exp Med Biol** 1996;403:641–50 (72 ref.)
Taurine deficiency and neuronal migration. Morán J, et al. **Adv Exp Med Biol** 1996;403:519–26 (24 ref.)
Some actions of taurine on ionic currents of myocardial cells and myometrial cells. Sperelakis N, et al. **Adv Exp Med Biol** 1996;403:275–84 (18 ref.)
Magnesium taurate and fish oil for prevention of migraine. McCarty MF. **Med Hypotheses** 1996 Dec;47(6):461–6 (94 ref.)

PHYSIOLOGY

Taurine. Past, present, and future. Huxtable RJ. **Adv Exp Med Biol** 1996;403:641–50 (72 ref.)
Taurine and inflammation—a new approach to an old problem? [letter] Stapleton PP, et al. **J Leukoc Biol** 1997 Feb;61(2):231–2 (19 ref.)

THERAPEUTIC USE

Is taurine a preventive nutritional factor of cardiovascular diseases or just a biological marker of nutrition? Yamori Y, et al. **Adv Exp Med Biol** 1996;403:623–9 (26 ref.)
[Pharmacological treatment of alcohol dependence. Acamprosate and naltrexone offer new approach] Berglund M, et al. **Lakartidningen** 1997 Jul 23;94(30–31):2645–8 (19 ref.) **(Swe)**

TAUSSIG–BING ANOMALY see **DOUBLE OUTLET RIGHT VENTRICLE**

TAX GENE PRODUCTS see **GENE PRODUCTS, TAX**

TAX GENES see **GENES, PX**

TAX PROTEIN see **GENE PRODUCTS, TAX**

TAXOL see **PACLITAXEL**

TAXONOMY see **CLASSIFICATION**

TAY–SACHS DISEASE

GENETICS

Heterozygote screening for Tay–Sachs disease: past successes and future challenges. Natowicz MR, et al. **Curr Opin Pediatr** 1996 Dec;8(6):625–9 (30 ref.)
Tay–Sachs disease–causing mutations and neutral polymorphisms in the Hex A gene. Myerowitz R. **Hum Mutat** 1997;9(3):195–208 (66 ref.)

TBARS see **THIOBARBITURIC ACID REACTIVE SUBSTANCES**

TC 99M–ALBUMIN see **TECHNETIUM TC 99M AGGREGATED ALBUMIN**

TC 99M–ALBUMIN COLLOID see **TECHNETIUM TC 99M AGGREGATED ALBUMIN**

TC–DTPA see **TECHNETIUM TC 99M PENTETATE**

TC 99M–DTPA see **TECHNETIUM TC 99M PENTETATE**

99MTC–HEXAMIBI see **TECHNETIUM TC 99M SESTAMIBI**

TC 99M–PERTECHNETATE see **SODIUM PERTECHNETATE TC 99M**

99MTC–SESTAMIBI see **TECHNETIUM TC 99M SESTAMIBI**

TCDD RECEPTORS see **RECEPTORS, ARYL HYDROCARBON**

TCGF see **INTERLEUKIN–2**

TCR ALPHA–BETA see **RECEPTORS, ANTIGEN, T–CELL, ALPHA–BETA**

TCR–CD3 COMPLEX see **RECEPTOR–CD3 COMPLEX, ANTIGEN, T–CELL**

TCR GAMMA–DELTA see **RECEPTORS, ANTIGEN, T–CELL, GAMMA–DELTA**

TEA

see related
THEOPHYLLINE

Japanese green tea as a cancer preventive in humans. Fujiki H, et al. **Nutr Rev** 1996 Nov;54(11 Pt 2):S67–70 (25 ref.)

ADVERSE EFFECTS

[Bradycardiac atrial fibrillation after consuming herbal tea] Brustbauer R, et al. **Dtsch Med Wochenschr** 1997 Jul 25; 122(30):930–2 (12 ref.) (Eng. Abstr.) **(Ger)**

CHEMISTRY

Cancer chemoprevention by polyphenols in green tea and artichoke. Agarwal R, et al. **Adv Exp Med Biol** 1996; 401:35–50 (107 ref.)
Effects of tea on carcinogenesis in animal models and humans. Yang CS, et al. **Adv Exp Med Biol** 1996;401:51–61 (82 ref.)
Chemoprotection: a review of the potential therapeutic antioxidant properties of green tea (Camellia sinensis) and certain of its constituents. Mitscher LA, et al. **Med Res Rev** 1997 Jul;17(4):327–65 (160 ref.)
Bioactive ingredients: antioxidants and polyphenols in tea. Dreosti IE. **Nutr Rev** 1996 Nov;54(11 Pt 2):S51–8 (62 ref.)

PHYSIOLOGY

Tea and cancer: a review of the epidemiological evidence. Blot WJ, et al. **Eur J Cancer Prev** 1996 Dec;5(6):425–38 (113 ref.)

STANDARDS

Tea and cancer prevention: an evaluation of the epidemiologic literature. Kohlmeier L, et al. **Nutr Cancer** 1997;27(1):1–13 (30 ref.)
Tea consumption and cancer. Katiyar SK, et al. **World Rev Nutr Diet** 1996;79:154–84 (141 ref.)

TEACHING

see related
FACULTY

Essential practices as adults read to meet the needs of deaf or hard of hearing students. Luetke–Stahlman B, et al. **Am Ann Deaf** 1996 Oct;141(4):309–20 (176 ref.)
Cognitive/concept mapping: a teaching strategy for nursing. All AC, et al. **J Adv Nurs** 1997 Jun;25(6):1210–9 (31 ref.)
Schools, families, and early adolescents: what are we doing

wrong and what can we do instead? Eccles JS, et al. **J Dev Behav Pediatr** 1996 Aug;17(4):267–76 (65 ref.)

Students' expectations of clinical teachers. Daniels M, et al. **Radiol Technol** 1996 Sep–Oct;68(1):89–93 (10 ref.)

[An attempt to identify an increased incidence of occupational laryngeal diseases in teachers] Wośkowiak G. **Med Pr** 1996;47(5):519–22 (14 ref.) (Eng. Abstr.) **(Pol)**

[Experience with integration of research institutes if the Russian Academy of Medical Sciences with the departments if higher educational establishments of the IM Sechenov is an effective type of teaching and research intensification] Paltsev MA, et al. **Vestn Ross Akad Med Nauk** 1997;(3):54–8 (0 ref.) **(Rus)**

ECONOMICS

What is the cost of ambulatory education? Adams M, et al. **J Gen Intern Med** 1997 Apr;12 Suppl 2:S104–10 (27 ref.)

METHODS

Early intervention for young children with developmental delay: the Portage approach. Cameron RJ. **Child Care Health Dev** 1997 Jan;23(1):11–27 (51 ref.)

Clinicians teaching orthopaedics: effective strategies. Meals RA, et al. **Instr Course Lect** 1997;46:583–94 (38 ref.)

The use of computer technology to improve the effectiveness of orthopaedic presentations. Russell JA, et al. **Instr Course Lect** 1997;46:595–610 (27 ref.)

Facilitation: a concept analysis. Burrows DE. **J Adv Nurs** 1997 Feb;25(2):396–404 (36 ref.)

Supportive learning in distance education. Lawton S. **J Adv Nurs** 1997 May;25(5):1076–83 (34 ref.)

Developing the reflective teacher. Scanlan JM, et al. **J Adv Nurs** 1997 Jun;25(6):1138–43 (14 ref.)

HIV education: a challenge to adult learning theory and practice. Gallagher DM. **J Assoc Nurses AIDS Care** 1996; 7 Suppl 1:5–14 (25 ref.)

Use of effective feedback to facilitate adult learning. Sachdeva AK. **J Cancer Educ** 1996 Summer;11(2):106–18 (53 ref.)

What if Osler were one of us? Inpatient teaching today. Ende J. **J Gen Intern Med** 1997 Apr;12 Suppl 2:S41–8 (38 ref.)

Teaching procedural skills. Norris TE, et al. **J Gen Intern Med** 1997 Apr;12 Suppl 2:S64–70 (27 ref.)

Developing an ethical basis for student–teacher interaction. Wehrwein T. **J Prof Nurs** 1996 Sep–Oct;12(5):297–302 (25 ref.)

Orienting medical education to community need: a review. Habbick BF, et al. **Med Educ** 1996 May;30(3):163–71 (52 ref.)

Persuasive communication: marketing health promotion. Stubblefield C. **Nurs Outlook** 1997 Jul–Aug;45(4):173–7 (25 ref.)

The clinical reasoning case study: a powerful teaching tool. Ryan–Wenger NA, et al. **Nurse Pract** 1997 May;22(5):66–7, 70, 76–9 passim (36 ref.)

Contract learning, clinical learning and clinicians. Parsell G, et al. **Postgrad Med J** 1996 May;72(847):284–9 (29 ref.)

[Psychological and moral aspects of physician's training at the phthisiopulmonological clinic of medical university] Khudzik LB, et al. **Probl Tuberk** 1997;(2):58–9 (0 ref.) **(Rus)**

[On teaching philosophy at medical higher educational establishments] Sarkisov DS, et al. **Vestn Ross Akad Med Nauk** 1997;(7):57–9 (0 ref.) **(Rus)**

ORGANIZATION & ADMINISTRATION

Career satisfaction and clinician–educators. The rewards and challenges of teaching. The Society of General Internal Medicine Career Satisfaction Study Group. Gerrity MS, et al. **J Gen Intern Med** 1997 Apr;12 Suppl 2:S90–7 (55 ref.)

Distance learning for health care students. Tanenbaum BG, et al. **Radiol Technol** 1996 Nov–Dec;68(2):157–8 (4 ref.)

STANDARDS

The multiple functions of the supervisor: a summary of the seventh IPA conference of training analysis. Vollmer Filho G, et al. **Int J Psychoanal** 1996 Aug;77 (Pt 4):813–8 (0 ref.)

Faculty development. A resource for clinical teachers. Skeff KM, et al. **J Gen Intern Med** 1997 Apr;12 Suppl 2:S56–63 (57 ref.)

TEACHING MATERIALS

see related
AUDIOVISUAL AIDS

STANDARDS

Strategies to improve cancer education materials. Doak LG, et al. **Oncol Nurs Forum** 1996 Sep;23(8):1305–12 (69 ref.)

TEAR GASES

ADVERSE EFFECTS

[Eye lesions from the contents of tear gas canisters and treatment methods] Gundorova RA, et al. **Vestn Oftalmol** 1996 Apr–Jun;112(2):55–6 (24 ref.) **(Rus)**

TEARS

METABOLISM

Tear film lipid layer formation: implications for contact lens wear. Korb DR, et al. **Optom Vis Sci** 1996 Mar;73(3):189–92 (38 ref.)

PHYSIOLOGY

Tearing: lacrimal obstructions. Sakol PJ. **Pa Med** 1996 Mar; 99 Suppl:99–104 (22 ref.)

SECRETION

[Evaluation of lacrimal function] Tamura N, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:462–5 (12 ref.) **(Jpn)**

TEARS, ARTIFICIAL see **OPHTHALMIC SOLUTIONS**

TEAS, HERBAL see **BEVERAGES**

TEAS, MEDICINAL see **BEVERAGES**

TECHNETIUM

see related
ORGANOTECHNETIUM COMPOUNDS

Radiopharmaceutical–related pitfalls and artifacts. Hung JC, et al. **Semin Nucl Med** 1996 Oct;26(4):208–55 (465 ref.)

DIAGNOSTIC USE

Cancer imaging with radiolabeled antibodies: new advances with technetium–99m–labeled monoclonal antibody Fab' fragments, especially CEA–Scan and prospects for therapy. Goldenberg DM, et al. **J Nucl Med Technol** 1997 Mar; 25(1):18–23; quiz 34 (46 ref.)

Cerebral blood flow imaging in paediatrics: a review. Gordon I. **Nucl Med Commun** 1996 Dec;17(12):1021–9 (28 ref.)

Small peptides radiolabeled with 99mTc. Lister–James J, et al. **Q J Nucl Med** 1996 Sep;40(3):221–33 (34 ref.)

[Diagnosis of hepatic angiomas and 99m–Tc labeled red cells scintigraphy] Zerbib E, et al. **J Radiol** 1996 Sep;77(9):683–5 (11 ref.) **(Fre)**

[Regional evaluation of ventilation by RI] Kawakami K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:42–4 (3 ref.) **(Jpn)**

[Ulcerative colitis and colonic angiodysplasia associated with a lower digestive hemorrhage. Their diagnosis by 99–technetium–labelled red blood cells] Martínez–Caballero A, et al. **Rev Esp Enferm Dig** 1997 Jan;89(1):51–4 (16 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOKINETICS

Pharmacokinetic modeling of multidrug resistance P–glycoprotein transport of gamma–emitting substrates. Bae KT, et al. **Q J Nucl Med** 1997 Jun;41(2):101–10 (53 ref.)

TECHNETIUM COMPOUNDS

DIAGNOSTIC USE

[Measurement of gastric emptying using radioisotope] Ishikawa H, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:139–42 (5 ref.) **(Jpn)**

TECHNETIUM–DTPA see **TECHNETIUM TC 99M PENTETATE**

TECHNETIUM TC 99M AGGREGATED ALBUMIN

DIAGNOSTIC USE

[Measurement of gastric emptying using radioisotope] Ishikawa H, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:139–42 (5 ref.) **(Jpn)**

TECHNETIUM TC 99M PENTETATE

DIAGNOSTIC USE

Pulmonary technetium–99m diethylene triamine penta–acetic acid aerosol clearance as an index of lung injury. O'Doherty MJ, et al. **Eur J Nucl Med** 1997 Jan;24(1):81–7 (48 ref.)

[Measurement of gastric emptying using radioisotope] Ishikawa H, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:139–42 (5 ref.) **(Jpn)**

TECHNETIUM TC 99M PERTECHNETATE see **SODIUM PERTECHNETATE TC 99M**

TECHNETIUM TC 99M SESTAMIBI

Exercise–induced left bundle branch block: a case report of false positive MIBI imaging and review of the literature. Munt B, et al. **Can J Cardiol** 1997 May;13(5):517–21 (14 ref.)

Unexpected keys in cell biochemistry imaging: some lessons from technetium–99m–sestamibi. Mariani G. **J Nucl Med** 1996 Mar;37(3):536–8 (35 ref.)

DIAGNOSTIC USE

Pharmacological stress testing with technetium–99m single–photon emission computerized tomography imaging in the preoperative assessment of patients undergoing noncardiac surgery [see comments] Heller GV, et al. **Am J Card Imaging** 1996 Apr;10(2):120–7 (45 ref.) Comment in: Am J Card Imaging 1996 Apr;10(2):117–9.

Sestamibi scan for preoperative localization in primary hyperparathyroidism. Shaha AR, et al. **Head Neck** 1997 Mar;19(2):87–91 (17 ref.)

Detection of hibernated myocardium using intracoronary technetium–99m–sestamibi. Giordano A, et al. **Q J Nucl Med** 1997 Mar;41(1):46–50 (30 ref.)

Scintimammography: the new role of technetium–99m Sestamibi imaging for the diagnosis of breast carcinoma. Khalkhali I, et al. **Q J Nucl Med** 1997 Sep;41(3):231–8 (42 ref.)

The role of (99m)Tc methoxyisobutylisonitrile in imaging breast cancer. Waxman AD. **Semin Nucl Med** 1997 Jan; 27(1):40–54 (75 ref.)

TECHNOLOGY

Contraceptive vaccines. Jones WR. **Baillieres Clin Obstet Gynaecol** 1996 Apr;10(1):69–86 (65 ref.)

Impact of technology on the emergence of infectious diseases. Breiman RF. **Epidemiol Rev** 1996;18(1):4–9 (49 ref.)

(Ir)reconcilable differences? The debate concerning nursing and technology. Sandelowski M. **Image J Nurs Sch** 1997; 29(2):169–74 (85 ref.)

The gastroenterologist and his endoscope: the embodiment of technology and the necessity for a medical ethics. Cooper MW. **Theor Med** 1996 Dec;17(4):379–98 (56 ref.)

[Aging and technology] Rudinger G. **Z Gerontol Geriatr** 1996 Jul–Aug;29(4):246–56 (49 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

Physical activity, sport, and health: toward the next century. Haskell WL. **Res Q Exerc Sport** 1996 Sep;67(3 Suppl):S37–47 (59 ref.)

TECHNOLOGY ASSESSMENT, BIOMEDICAL

Bioelectrical impedance analysis in body composition measurement: National Institutes of Health Technology Assessment Conference Statement. **Am J Clin Nutr** 1996 Sep;64(3 Suppl):524S–532S (0 ref.)

Automation of the Papanicolaou smear: a technology assessment perspective. Linder J. **Arch Pathol Lab Med** 1997 Mar;121(3):282–6 (30 ref.)

Technology and nursing: an anatomy of definition. Barnard A. **Int J Nurs Stud** 1996 Aug;33(4):433–41 (60 ref.)

Evaluating the impact of health care information systems. Anderson JG, et al. **Int J Technol Assess Health Care** 1997 Spring;13(2):380–93 (42 ref.)

The public's role in the evaluation of health care technology. The conflict over ECT. Heitman E. **Int J Technol Assess Health Care** 1996 Fall;12(4):657–72 (89 ref.)

Total joint replacement: on innovation, ambition, courage, irony and morsellized bone, of course. Huiskes R. **Iowa Orthop J** 1997;17:130–3 (0 ref.)

Diagnosis and risk stratification in coronary artery disease: nuclear cardiology versus stress echocardiography. Bonow RO. **J Nucl Cardiol** 1997 Mar–Apr;4(2 Pt 2):S172–8 (72 ref.)

National Institutes of Health Technology Assessment Conference on Management of Temporomandibular Disorders. Bethesda, Maryland, April 29–May 1, 1996. Proceedings. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jan;83(1):49–183 (0 ref.)

Medical and dental technology assessment. Ballard GT. **Technol Health Care** 1996 Sep;4(3):291–303 (56 ref.)

ECONOMICS

EUR–ASSESS Project Subgroup Report on Coverage. Cranovsky R, et al. **Int J Technol Assess Health Care** 1997 Spring;13(2):287–332 (69 ref.)

METHODS

Technology assessment. A framework for generating questions useful in evaluating nursing information systems. Manning J, et al. **Comput Nurs** 1997 May–Jun;15(3):141–6 (12 ref.)

EUR–ASSESS Project Subgroup report on Methodology. Methodological guidance for the conduct of health technology assessment. Liberati A, et al. **Int J Technol Assess Health Care** 1997 Spring;13(2):186–219 (55 ref.)

Laparoscopically assisted vaginal hysterectomy. A review of current issues. Young W, et al. **Int J Technol Assess Health Care** 1997 Spring;13(2):368–79 (77 ref.)

ORGANIZATION & ADMINISTRATION

EUR-ASSESS Project Subgroup Report on Dissemination and Impact. Granados A, et al. **Int J Technol Assess Health Care** 1997 Spring;13(2):220–86 (120 ref.)

Priority setting for health technology assessment. Theoretical considerations and practical approaches. Priority setting Subgroup of the EUR-ASSESS Project. Henshall C, et al. **Int J Technol Assess Health Care** 1997 Spring; 13(2):144–85 (43 ref.)

STANDARDS

EUR-ASSESS Project Subgroup report on Methodology. Methodological guidance for the conduct of health technology assessment. Liberati A, et al. **Int J Technol Assess Health Care** 1997 Spring;13(2):186–219 (55 ref.)

What you don't know can't hurt you? Statistical issues and standards for medical technology evaluation. Mullahy J. **Med Care** 1996 Dec;34(12 Suppl):DS124–35 (30 ref.)

TECHNOLOGY, DENTAL

Medical and dental technology assessment. Ballard GT. **Technol Health Care** 1996 Sep;4(3):291–303 (56 ref.)

TECHNOLOGY, EDUCATIONAL see **EDUCATIONAL TECHNOLOGY**

TECHNOLOGY, FOOD see **FOOD TECHNOLOGY**

TECHNOLOGY, HIGH-COST

High-technology medicine and the old: the dialysis example. Kjellstrand CM. **J Intern Med** 1996 Mar;239(3):195–210 (94 ref.)

TECHNOLOGY, MEDICAL

see related

DIAGNOSIS, LABORATORY

Using technology-based techniques to assess postural control and gait in older adults. Alexander NB. **Clin Geriatr Med** 1996 Nov;12(4):725–44 (135 ref.)

Invasive modalities for the diagnosis and treatment of pain in the elderly [published erratum appears in Clin Geriatr Med 1996 Nov;12(4):X] Prager JP. **Clin Geriatr Med** 1996 Aug;12(3):549–61 (18 ref.)

The safe introduction of new technologies into neonatal medicine. Clark RH. **Clin Perinatol** 1996 Sep;23(3):519–27 (28 ref.)

Technology and health system reform. Lang AC. **Int Anesthesiol Clin** 1995 Fall;33(4):119–32 (19 ref.)

A critical review of the belief that technology is a neutral object and nurses are its master. Barnard A. **J Adv Nurs** 1997 Jul;26(1):126–31 (57 ref.)

Reconfiguring nature and culture: intersections of medical anthropology and technoscience studies. Casper MJ, et al. **Med Anthropol Q** 1996 Dec;10(4):523–36 (64 ref.)

Technology and alternative cancer therapies: an analysis of heterodoxy and constructivism. Hess DJ. **Med Anthropol Q** 1996 Dec;10(4):657–74 (62 ref.)

Death in technological time: locating the end of meaningful life. Lock M. **Med Anthropol Q** 1996 Dec;10(4):575–600 (63 ref.)

An implicit world view in technology and its consequences for contemporary life. Ketner KL. **Nurs Outlook** 1996 Nov-Dec;44(6):280–3 (9 ref.)

Technological aspects of minimal access surgery. Frank TG, et al. **Proc Inst Mech Eng [H]** 1997;211(2):129–44 (24 ref.)

A change of heart and a change of mind? Technology and the redefinition of death in 1968. Giacomini M. **Soc Sci Med** 1997 May;44(10):1465–82 (63 ref.)

[New technologies in the treatment of benign prostatic hyperplasia] Trapeznikova MF, et al. **Urol Nefrol (Mosk)** 1996 Jul-Aug;(4):41–7 (73 ref.) **(Rus)**

EDUCATION

Teaching procedural skills. Norris TE, et al. **J Gen Intern Med** 1997 Apr;12 Suppl 2:S64–70 (27 ref.)

LEGISLATION & JURISPRUDENCE

The case for patenting medical procedures. Garris JJ. **Am J Law Med** 1996;22(1):85–108 (235 ref.)

Technology transfer of neuroprosthetic devices. Peckham PH, et al. **J Rehabil Res Dev** 1996 Apr;33(2):173–83 (13 ref.)

METHODS

The clinical usefulness of glucated haemoglobin in diabetes care evaluated by use of a medical technology assessment strategy. Larsen ML. **Dan Med Bull** 1997 Jun;44(3):303–15 (174 ref.)

ORGANIZATION & ADMINISTRATION

Technology and nursing: an anatomy of definition. Barnard A. **Int J Nurs Stud** 1996 Aug;33(4):433–41 (60 ref.)

TRENDS

Advances in HIV testing technology and their potential impact on prevention. Kassler WJ. **AIDS Educ Prev** 1997 Jun;9(3 Suppl):27–40 (40 ref.)

Capitation, advances in medical technology, and the advent of a new era in medical ethics. Malinowski MJ. **Am J Law Med** 1996;22(2–3):331–60 (0 ref.)

A theory of technophysio evolution, with some implications for forecasting population, health care costs, and pension costs [published erratum appears in Demography 1997 May;34(2):170] Fogel RW, et al. **Demography** 1997 Feb; 34(1):49–66 (119 ref.)

Advances in computer technology: impact on the practice of medicine. Groth-Vasselli B, et al. **J Med** 1995; 26(5–6):323–31 (18 ref.)

The migration offshore of U.S. medical technology innovation--what it means for U.S. physicians. Loarie TM. **J Refract Surg** 1997 Mar-Apr;13(2):176–84 (81 ref.)

TECHNOLOGY, MEDICAL LABORATORY

[Development of the clinical laboratory examination with a progress of high technology] Wakamatsu H. **Nippon Rinsho** 1997 Mar;55 Suppl 1:11–28 (6 ref.) **(Jpn)**

METHODS

Converging technologies and their impact on the clinical laboratory. Burtis CA. **Clin Chem** 1996 Nov;42(11):1735–49 (240 ref.)

TRENDS

Converging technologies and their impact on the clinical laboratory. Burtis CA. **Clin Chem** 1996 Nov;42(11):1735–49 (240 ref.)

Major technological advances affecting clinical and diagnostic immunology. Sever JL. **Clin Diagn Lab Immunol** 1997 Jan;4(1):1–3 (5 ref.)

TECHNOLOGY, PHARMACEUTICAL

Discovery, development, and clinical trial strategies for immunosuppressive agents. Kahan BD. **Adv Nephrol Necker Hosp** 1996;25:63–89 (98 ref.)

METHODS

New alcohol dehydrogenases for the synthesis of chiral compounds. Hummel W. **Adv Biochem Eng Biotechnol** 1997;58:145–84 (252 ref.)

Self-assembled monolayers for biosensors. Wink T, et al. **Analyst** 1997 Apr;122(4):43R–50R (102 ref.)

Evaluation of anti-viral filters. Hughes B, et al. **Dev Biol Stand** 1996;88:91–8 (3 ref.)

STANDARDS

Process simulation testing for aseptically filled products. Parenteral Drug Association. **PDA J Pharm Sci Technol** 1996;50 Suppl 1:S1–16 (13 ref.)

TRENDS

Professional prospects in clinical pharmacology. An experience within the pharmaceutical industry. Delgadillo J. **Methods Find Exp Clin Pharmacol** 1996;18 Suppl C:19–20 (2 ref.)

TECHNOLOGY, RADIOLOGIC

Dichotomous thinking in nuclear medicine technology. Dowd SB, et al. **J Nucl Med Technol** 1997 Jun;25(2):120–3 (22 ref.)

Imaging patients with chronic disabilities. Davidhizar R, et al. **Radiol Technol** 1997 Jul-Aug;68(6):520–2 (9 ref.)

Drug administration practices in medical imaging: a survey. Tortorici M, et al. **Radiol Technol** 1997 May-Jun; 68(5):379–85 (11 ref.)

[Diagnostic value of digital projection radiography in comparison with conventional roentgen technique] Krug B, et al. **Aktuelle Radiol** 1997 Mar;7(2):65–8 (33 ref.) (Eng. Abstr.) **(Ger)**

EDUCATION

Students' expectations of clinical teachers. Daniels M, et al. **Radiol Technol** 1996 Sep-Oct;68(1):89–93 (10 ref.)

TRENDS

Nuclear medicine at the crossroads. Strauss HW. **Eur J Nucl Med** 1996 Jun;23(6):697–704 (58 ref.)

New approaches in the use of radiation therapy in the treatment of infiltrative transitional-cell cancer of the bladder. Warde P, et al. **World J Urol** 1997;15(2):125–33 (61 ref.)

TECHNOLOGY TRANSFER

The migration offshore of U.S. medical technology innovation--what it means for U.S. physicians. Loarie TM. **J Refract Surg** 1997 Mar-Apr;13(2):176–84 (81 ref.)

Would it work for us? Learning from quality improvement in Europe and beyond. Ovretveit J. **Jt Comm J Qual Improv** 1997 Jan;23(1):7–22 (91 ref.)

Different approaches and cultural considerations in third world prosthetics. Meanley S. **Prosthet Orthot Int** 1995 Dec;19(3):176–80 (35 ref.)

Technology transfer at US universities: seeking public benefit from the results of basic research. Goodwin CD. **Technol Health Care** 1996 Sep;4(3):323–30 (6 ref.)

Technology transfer: incentives and disincentives. Rutherford RB. **Technol Health Care** 1996 Sep;4(3):347–51 (10 ref.)

TECTORIAL MEMBRANE

PHYSIOPATHOLOGY

Cochlear amplification and its pathology: emphasis on the role of the tectorial membrane. Gummer AW, et al. **Ear Nose Throat J** 1997 Mar;76(3):151–8, 160, 162–3 (95 ref.)

TECTUM MESENCEPHALI see **CORPORA QUADRIGEMINA**

TEDELPARIN

PHARMACOLOGY

Dalteparin: a low-molecular-weight heparin. Howard PA. **Ann Pharmacother** 1997 Feb;31(2):192–203 (80 ref.)

THERAPEUTIC USE

Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. Dunn CJ, et al. **Drugs** 1996 Aug;52(2):276–305 (118 ref.)

TEENAGE PREGNANCY see **PREGNANCY IN ADOLESCENCE**

TEFLON see **POLYTETRAFLUOROETHYLENE**

TEGAFUR

ADMINISTRATION & DOSAGE

[Moderately differentiated adenocarcinoma of the rectum: a case report of remarkable response to preoperative administration of FT suppository] Izumi M, et al. **Gan To Kagaku Ryoho** 1997 Aug;24(10):1321–5 (10 ref.) (Eng. Abstr.) **(Jpn)**

TEICHOIC ACIDS

BIOSYNTHESIS

Lipoteichoic acid as a target for antimicrobial action. Canepari P, et al. **Microb Drug Resist** 1996 Spring;2(1):85–9 (20 ref.)

The dlt operon in the biosynthesis of D-alanyl-lipoteichoic acid in Lactobacillus casei. Neuhaus FC, et al. **Microb Drug Resist** 1996 Spring;2(1):77–84 (44 ref.)

TEICHOMYCIN see **TEICOPLANIN**

TEICOPLANIN

[Vancomycin and teicoplanin: differential aspects] Cobo J. **Enferm Infecc Microbiol Clin** 1995 Dec;13(10):600–10 (112 ref.) **(Spa)**

THERAPEUTIC USE

Managing methicillin-resistant Staphylococcus aureus in hospital: the balance of risk. Stone SP. **Age Ageing** 1997 May;26(3):165–8 (45 ref.)

A review of teicoplanin in the treatment of serious neonatal infections. Fanos V, et al. **Eur J Pediatr** 1997 Jun; 156(6):423–7 (33 ref.)

[Glycopeptide resistant enterococci. Occurrence, distribution, resistance transmission, significance (editorial; comment)] Klare I, et al. **Wien Klin Wochenschr** 1997 May 9;109(9):293–300 (58 ref.) Comment on: Wien Klin Wochenschr 1997 May 9;109(9):312–20. **(Ger)**

TELANGIECTASIA, HEREDITARY HEMORRHAGIC

Hereditary hemorrhagic telangiectasia and other intestinal vascular anomalies. Korzenik JR. **Gastroenterologist** 1996 Sep;4(3):203–10 (75 ref.)

[Rendu-Osler-Weber syndrome] Tanabe S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):293–4 (12 ref.) **(Jpn)**

COMPLICATIONS

Pulmonary valve stenosis in a patient with ataxia telangiectasia [letter] Ruggieri M, et al. **Eur Heart J** 1996 Jun;17(6):968 (5 ref.)

Recurrent brain abscesses in an HIV-positive patient with hereditary hemorrhagic telangiectasia and arteriovenous malformations of the lung. Thurnheer R, et al. **Eur J Clin Microbiol Infect Dis** 1996 May;15(5):407–10 (20

ref.)
Hemangioma of the uterus associated with hereditary hemorrhagic telangiectasia. Shanberge JN.
Obstet Gynecol 1994 Oct;84(4 Pt 2):708–10 (13 ref.)
[Neurosurgical aspects of Rendu–Osler disease. Apropos of 6 recent cases and review of the literature] Emery E, et al. **Neurochirurgie** 1996;42(4–5):221–8 (25 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Generalized essential telangiectasia in the presence of gastrointestinal bleeding. Checketts SR, et al.
J Am Acad Dermatol 1997 Aug;37(2 Pt 2):321–5 (34 ref.)
Pulmonary arteriovenous malformations: diagnosis and transcatheter embolotherapy. White RI Jr, et al.
J Vasc Interv Radiol 1996 Nov–Dec;7(6):787–804 (56 ref.)
Lung–angiodysplasia and von Willebrand's disease in a family with Rendu–Osler disease. A case report. Girola SS, et al. **Recenti Prog Med** 1996 Dec;87(12):589–91 (9 ref.)

GENETICS

The molecular genetics of hereditary hemorrhagic telangiectasia. Marchuk DA. **Chest** 1997 Jun;111(6 Suppl):79S–82S (48 ref.)
Molecular defects in rare bleeding disorders: hereditary haemorrhagic telangiectasia. Shovlin CL.
Thromb Haemost 1997 Jul;78(1):145–50 (53 ref.)

THERAPY

Pulmonary arteriovenous malformations: diagnosis and transcatheter embolotherapy. White RI Jr, et al.
J Vasc Interv Radiol 1996 Nov–Dec;7(6):787–804 (56 ref.)

TELANGIECTASIS

COMPLICATIONS

Ovarian cancer and unilateral naevoid telangiectasia: a rare association. Pranteda G, et al. **J Exp Clin Cancer Res** 1997 Mar;16(1):71–3 (15 ref.)

CONGENITAL

[Cutis marmorata teleangiectatica congenita. Important aspects for dermatologic practice] Rupprecht R, et al. **Hautarzt** 1997 Jan;48(1):21–5 (30 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Unilateral naevoid telangiectasia syndrome in pregnancy. Woollons A, et al. **Clin Exp Dermatol** 1996 Nov; 21(6):459–60 (6 ref.)
Intracerebral capillary telangiectasia and venous malformation: a rare association. Van Roost D, et al.
Surg Neurol 1997 Aug;48(2):175–83 (58 ref.)

THERAPY

Sclerotherapy of telangiectases using sodium tetradecyl sulfate (Sotradecol) [see comments] Hren C, et al.
N C Med J 1996 Jan–Feb;57(1):42–6 (8 ref.) Comment in: N C Med J 1996 May–Jun;57(3):127–8.

TELECOMMUNICATION NETWORKS see **COMPUTER COMMUNICATION NETWORKS**

TELECOMMUNICATIONS

CDC and ATSDR electronic information resources for health officers [see comments] Friede A, et al.
Am J Infect Control 1996 Dec;24(6):440–54 (9 ref.) Comment in: Am J Infect Control 1996 Dec;24(6):417–20.
Telecommunications in healthcare: a primer.
Health Devices 1997 Jul;26(7):264–85 (13 ref.)
[Support by telecommunication of decisions in diagnostic pathology. Experience with the first telepathology system in Hungary] Gombás P, et al. **Orv Hetil** 1996 Oct 20; 137(42):2299–303 (50 ref.) (Eng. Abstr.) **(Hun)**

INSTRUMENTATION

Assessment of cellular telephone and other radio frequency exposure for epidemiologic research [see comments] Rothman KJ, et al. **Epidemiology** 1996 May;7(3):291–8 (43 ref.) Comment in: Epidemiology 1996 May;7(3):219. Comment in: Epidemiology 1997 Jul;8(4):466–7.

UTILIZATION

Electronic communication with patients. Evaluation of distance medicine technology. Balas EA, et al. **JAMA** 1997 Jul 9;278(2):152–9 (93 ref.)

TELECOMMUNICATIONS, SATELLITE see **SATELLITE COMMUNICATIONS**

TELECONFERENCE see **TELECOMMUNICATIONS**

TELECONSULTATION see **REMOTE CONSULTATION**

TELEFACSIMILE

ORGANIZATION & ADMINISTRATION

High touch meets high tech. Distance mental health screening for rural youth using Teleform. Puskar KR, et al. **Comput Nurs** 1996 Nov–Dec;14(6):323–9; quiz 330–2 (31 ref.)

TELEMEDICINE

see related
TELEMETRY

Teledermatology. Burdick AE, et al. **Adv Dermatol** 1997; 12:19–45; discussion 46 (110 ref.)
Telemedicine: a cautious welcome [see comments] Wootton R. **BMJ** 1996 Nov 30;313(7069):1375–7 (20 ref.) Comment in: BMJ 1997 Feb 15;314(7079):520–1. Comment in: BMJ 1997 Feb 15;314(7079):521.
Information technology for doctors. Kalra D.
Br J Hosp Med 1996 Feb 7–20;55(3):144–6 (12 ref.)
Telemedicine and telepathology. Balis UJ. **Clin Lab Med** 1997 Jun;17(2):245–61 (34 ref.)
An overview of telemedicine. Baquet CR.
J Assoc Acad Minor Phys 1997;8(1):2–10 (20 ref.)
Telemedicine—'toys for the boys' or an essential tool? Buxton PJ. **J R Nav Med Serv** 1997;83(1):16–8 (6 ref.)

METHODS

Telemedicine in northern Norway. Elford DR.
J Telemed Telecare 1997;3(1):1–22 (14 ref.)

ORGANIZATION & ADMINISTRATION

The possible use of telemedicine in developing countries. Wootton R. **J Telemed Telecare** 1997;3(1):23–6 (14 ref.)
Telemedicine; here to stay [see comments] Yellowlees PM, et al. **Med J Aust** 1997 Mar 3;166(5):262–5 (33 ref.) Comment in: Med J Aust 1997 Jun 2;166(11):616.

TRENDS

[Telemedicine—technical possibilities and practical applications] Feussner H, et al. **Chirurg** 1996 Oct; 67(10):984–8 (5 ref.) **(Ger)**
[Telemedicine] Kayser K. **Wien Klin Wochenschr** 1996; 108(17):532–40 (49 ref.) (Eng. Abstr.) **(Ger)**

TELEMETRY

see related
TELEMEDICINE

Urban teleradiology in Hong Kong. Sheng OR, et al.
J Telemed Telecare 1997;3(2):71–7 (8 ref.)

TELENCEPHALON

ANATOMY & HISTOLOGY

The telencephalon of tetrapods in evolution. Striedter GF.
Brain Behav Evol 1997;49(4):179–213 (160 ref.)
Functional anatomy of neural pathways contributing to the control of song production in birds. Wild JM.
Eur J Morphol 1997 Oct;35(4):303–25 (153 ref.)
Substantia innominata: a notion which impedes clinical–anatomical correlations in neuropsychiatric disorders. Heimer L, et al. **Neuroscience** 1997 Feb; 76(4):957–1006 (562 ref.)

CYTOLOGY

Functional anatomy of neural pathways contributing to the control of song production in birds. Wild JM.
Eur J Morphol 1997 Oct;35(4):303–25 (153 ref.)

EMBRYOLOGY

Regionalization in the mammalian telencephalon. Fishell G.
Curr Opin Neurobiol 1997 Feb;7(1):62–9 (72 ref.)

PHYSIOLOGY

Bird song: of tone and tempo in the telencephalon. Mooney R, et al. **Curr Biol** 1997 May 1;7(5):R289–91 (10 ref.)
Substantia innominata: a notion which impedes clinical–anatomical correlations in neuropsychiatric disorders. Heimer L, et al. **Neuroscience** 1997 Feb; 76(4):957–1006 (562 ref.)

TELEOLOGICAL ETHICS see **ETHICS**

TELEPATHINE see **HARMINE**

TELEPATHOLOGY

Telemedicine and telepathology. Balis UJ. **Clin Lab Med** 1997 Jun;17(2):245–61 (34 ref.)
[Support by telecommunication of decisions in diagnostic pathology. Experience with the first telepathology system in Hungary] Gombás P, et al. **Orv Hetil** 1996 Oct 20; 137(42):2299–303 (50 ref.) (Eng. Abstr.) **(Hun)**

METHODS

[Strategy for remote diagnosis and the image bank. A specific application for telepathology for hematology (editorial)] Flandrin G. **Ann Pathol** 1996;16(3):155–8 (14 ref.) **(Fre)**

TELEPHONE

Assessment of cellular telephone and other radio frequency exposure for epidemiologic research [see comments] Rothman KJ, et al. **Epidemiology** 1996 May;7(3):291–8 (43 ref.) Comment in: Epidemiology 1996 May;7(3):219. Comment in: Epidemiology 1997 Jul;8(4):466–7.
State of the science: pacemaker and defibrillator interference from wireless communication devices [see comments] Hayes DL, et al. **Pacing Clin Electrophysiol** 1996 Oct; 19(10):1419–30 (42 ref.) Comment in: Pacing Clin Electrophysiol 1996 Oct;19(10):1407–9.
The telephone in primary care. Studdiford JS III, et al.
Prim Care 1996 Mar;23(1):83–102 (76 ref.)

TELEPHONE HOTLINES see **HOTLINES**

TELERADIOISOTOPE THERAPY see **RADIOISOTOPE TELETHERAPY**

TELERADIOLOGY

Urban teleradiology in Hong Kong. Sheng OR, et al.
J Telemed Telecare 1997;3(2):71–7 (8 ref.)
[The digital image archive—its clinical applications and importance in cardiology consulting by telemedicine] Fiuza M, et al. **Rev Port Cardiol** 1997 Feb;16(2):127–39, 123 (44 ref.) (Eng. Abstr.) **(Por)**

STANDARDS

[Management and transmission of medical images. Main standards and norms] Chabriais J, et al. **J Radiol** 1996 Nov; 77(11):1105–20 (47 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

[Open questions on the topic of teleradiology from the current viewpoint] Stöger A, et al. **Aktuelle Radiol** 1997 Jul;7(4):228–9 (4 ref.) (Eng. Abstr.) **(Ger)**
[Goals, requirements and prerequisites of teleradiology. An assessment of current status] Walz M, et al. **Radiologe** 1997 Apr;37(4):260–8 (43 ref.) (Eng. Abstr.) **(Ger)**

TELEROBOTICS see **ROBOTICS**

TELEVISION

Television violence and its effect on children. Johnson MO.
J Pediatr Nurs 1996 Apr;11(2):94–9 (31 ref.)
Television viewing and adolescent sexuality [letter] Turner HA. **Nurse Pract** 1996 Nov;21(11):15, 18, 23 (11 ref.)

TELLURIUM

PHYSIOLOGY

Biochemistry of tellurium. Taylor A.
Biol Trace Elem Res 1996 Dec;55(3):231–9 (27 ref.)

TELOMERASE

Telomerase and telomere-binding proteins: controlling the endgame. Shore D. **Trends Biochem Sci** 1997 Jul; 22(7):233–5 (30 ref.)
[Role of free radicals, telomeres, and telomerases in aging and cancerogenesis] La Torre F, et al. **Minerva Med** 1997 May;88(5):205–14 (126 ref.) (Eng. Abstr.) **(Ita)**
[Human senescence, cancer and telomerase] Ide T, et al. **Tanpakushitsu Kakusan Koso** 1997 Jul;42(9):1351–74 (104 ref.) **(Jpn)**

ANALYSIS

Telomere dynamics and cytogenetic changes in human hematologic neoplasias: a working hypothesis. Ohyashiki K, et al. **Cancer Genet Cytogenet** 1997 Mar;94(1):67–72 (41 ref.)
Telomerase in hepatocellular carcinogenesis. Ide T, et al.
Hum Cell 1996 Dec;9(4):283–6 (2 ref.)
Technical improvement in determining telomerase activity in hematologic neoplasias: a possibility of single cell determination of telomerase activity. Ohyashiki K, et al.
Hum Cell 1996 Dec;9(4):295–300 (40 ref.)
Telomeres and telomerase in normal and malignant haematologic cells. Leber B, et al. **Leuk Lymphoma** 1996 Dec;24(1–2):1–9 (58 ref.)
Applications of telomerase in urologic oncology. Landman J, et al. **World J Urol** 1997;15(2):120–4 (39 ref.)
[Lung cancer: progress in diagnosis and treatment. IV. Related topics: 1. Telomere and telomerase, new targets for diagnosis and treatment of lung cancer] Hiyama K, et al. **Nippon Naika Gakkai Zasshi** 1997 Jan 10;86(1):95–9 (5 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Agents that target telomerase and telomeres. Raymond E, et al. **Curr Opin Biotechnol** 1996 Dec;7(6):583–91 (91 ref.)
Multiple pathways to cellular senescence: role of telomerase repressors. Oshimura M, et al. **Eur J Cancer** 1997 Apr; 33(5):710–5 (50 ref.)

[Telomerase inhibitor] Ide T. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1600–5 (24 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Structure and function of telomerase. Collins K. **Curr Opin Cell Biol** 1996 Jun;8(3):374–80 (59 ref.)

DEFICIENCY

Telomere maintenance without telomerase. Biessmann H, et al. **Chromosoma** 1997 Jul;106(2):63–9 (85 ref.)

GENETICS

A telomerase mutant defective in sister chromatid separation at mitosis. Nakaseko Y, et al. **Bioessays** 1997 Jul;19(7):557–9 (22 ref.)

Genetic regulation of telomerase in a multiple pathways model to cellular senescence. Oshimura M, et al. **Hum Cell** 1996 Dec;9(4):301–8 (44 ref.)

[A mammalian telomerase component gene TLP1] Ishikawa F, et al. **Tanpakushitsu Kakusan Koso** 1997 Jul; 42(9):1407–19 (21 ref.) **(Jpn)**

[Biochemistry of space and time (telomeres, telomerases, and longevity of cell populations and multicellular organisms] Golubev AG. **Biokhimiia** 1996 Nov;61(11):2045–59 (144 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Telomerase as a therapeutic target. Huminiecki L. **Acta Biochim Pol** 1996;43(3):531–8 (34 ref.)

Telomere crisis, the driving force in cancer cell evolution. Ishikawa F. **Biochem Biophys Res Commun** 1997 Jan 3; 230(1):1–6 (53 ref.)

Chromosome healing: spontaneous and programmed de novo telomere formation by telomerase. Melek M, et al. **Bioessays** 1996 Apr;18(4):301–8 (73 ref.)

Telomerase: anti-cancer target or just a fascinating enzyme? Hamilton SE, et al. **Chem Biol** 1996 Nov;3(11):863–7 (32 ref.)

Telomerase activity in human cancer. Shay JW, et al. **Curr Opin Oncol** 1996 Jan;8(1):66–71 (49 ref.)

Telomere dynamics and telomerase activity in in vitro immortalised human cells. Bryan TM, et al. **Eur J Cancer** 1997 Apr;33(5):767–73 (60 ref.)

Multiple pathways for the regulation of telomerase activity. Holt SE, et al. **Eur J Cancer** 1997 Apr;33(5):761–6 (52 ref.)

Telomere structure and telomerase expression during mouse development and tumorigenesis. Kipling D. **Eur J Cancer** 1997 Apr;33(5):792–800 (44 ref.)

The implications of telomerase biochemistry for human disease. Morin GB. **Eur J Cancer** 1997 Apr;33(5):750–60 (89 ref.)

Telomeres and telomerase in normal and malignant haematopoietic cells. Norrback KF, et al. **Eur J Cancer** 1997 Apr;33(5):774–80 (57 ref.)

The genetic basis of human keratinocyte immortalisation in squamous cell carcinoma development: the role of telomerase reactivation. Parkinson EK, et al. **Eur J Cancer** 1997 Apr;33(5):727–34 (81 ref.)

Telomere (telomerase) hypothesis of aging and immortalization. Rao KS. **Indian J Biochem Biophys** 1996 Apr;33(2):88–92 (47 ref.)

Telomerase in the early detection of cancer. Shay JW, et al. **J Clin Pathol** 1997 Feb;50(2):106–9 (57 ref.)

Telomerase activation and cancer. Klingelhutz AJ. **J Mol Med** 1997 Jan;75(1):45–9 (57 ref.)

Telomerase and early detection of cancer: a National Cancer Institute workshop. Breslow RA, et al. **J Natl Cancer Inst** 1997 May 7;89(9):618–23 (22 ref.)

Telomerase and cancer: revisiting the telomere hypothesis. Autexier C, et al. **Trends Biochem Sci** 1996 Oct; 21(10):387–91 (50 ref.)

Is telomerase activity in cancer due to selection of stem cells and differentiation arrest? Greaves M. **Trends Genet** 1996 Apr;12(4):127–8 (34 ref.)

The reactivation of telomerase activity in cancer progression. Shay JW, et al. **Trends Genet** 1996 Apr;12(4):129–31 (27 ref.)

[Telomere and telomerase] Ishikawa F. **Hum Cell** 1996 Dec; 9(4):287–94 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Telomere DNA and telomerase of lymphoma–derived cell lines—telomere hypothesis for cell growth control] Yanagi K, et al. **Nippon Rinsho** 1997 Feb;55(2):328–33 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Telomerase, aging, cancer] Egorov EE. **Mol Biol (Mosk)** 1997 Jan–Feb;31(1):16–24 (97 ref.) **(Rus)**

PHYSIOLOGY

Telomere maintenance in tumour cells. Bacchetti S. **Cancer Surv** 1996;28:197–216 (120 ref.)

Structure and function of telomerase. Collins K. **Curr Opin Cell Biol** 1996 Jun;8(3):374–80 (59 ref.)

Clinical implications of telomerase in cancer. Kim NW. **Eur J Cancer** 1997 Apr;33(5):781–6 (35 ref.)

A survey of telomerase activity in human cancer. Shay JW, et al. **Eur J Cancer** 1997 Apr;33(5):787–91 (51 ref.)

Telomerase and cancer. Harley CB, et al. **Important Adv Oncol** 1996;:57–67 (71 ref.)

The role of telomeres and telomerase in human cancer. Balasubramanian S, et al. **Indian J Physiol Pharmacol** 1996 Jul;40(3):199–204 (62 ref.)

Telomeres and telomerase in human hematologic neoplasia. Yamada O. **Int J Hematol** 1996 Aug;64(2):87–99 (72 ref.)

The roles of telomeres and telomerase in cell life span. Counter CM. **Mutat Res** 1996 Oct;366(1):45–63 (179 ref.)

Replicative senescence and cell immortality: the role of telomeres and telomerase. Chiu CP, et al. **Proc Soc Exp Biol Med** 1997 Feb;214(2):99–106 (81 ref.)

Telomeres, telomerase and chromosome stability. Preston RJ. **Radiat Res** 1997 May;147(5):529–34 (49 ref.)

TELOMERE

Telomere length regulation. Greider CW. **Annu Rev Biochem** 1996;65:337–65 (183 ref.)

Structure, function, and replication of Saccharomyces cerevisiae telomeres. Zakian VA. **Annu Rev Genet** 1996; 30:141–72 (147 ref.)

Telomere (telomerase) hypothesis of aging and immortalization. Rao KS. **Indian J Biochem Biophys** 1996 Apr;33(2):88–92 (47 ref.)

Telomeres and telomerase in human hematologic neoplasia. Yamada O. **Int J Hematol** 1996 Aug;64(2):87–99 (72 ref.)

[Role of free radicals, telomeres, and telomerases in aging and cancerogenesis] La Torre F, et al. **Minerva Med** 1997 May;88(5):205–14 (126 ref.) (Eng. Abstr.) **(Ita)**

[Lung cancer: progress in diagnosis and treatment. IV. Related topics: 1. Telomere and telomerase, new targets for diagnosis and treatment of lung cancer] Hiyama K, et al. **Nippon Naika Gakkai Zasshi** 1997 Jan 10;86(1):95–9 (5 ref.) **(Jpn)**

[A review of the structure and function of human telomere] Ishikawa F. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(15 Suppl):2241–53 (52 ref.) **(Jpn)**

CHEMISTRY

Telomerase and cancer: revisiting the telomere hypothesis. Autexier C, et al. **Trends Biochem Sci** 1996 Oct; 21(10):387–91 (50 ref.)

DRUG EFFECTS

Agents that target telomerase and telomeres. Raymond E, et al. **Curr Opin Biotechnol** 1996 Dec;7(6):583–91 (91 ref.)

ENZYMOLOGY

Telomere dynamics and telomerase activity in in vitro immortalised human cells. Bryan TM, et al. **Eur J Cancer** 1997 Apr;33(5):767–73 (60 ref.)

A survey of telomerase activity in human cancer. Shay JW, et al. **Eur J Cancer** 1997 Apr;33(5):787–91 (51 ref.)

Telomeres and telomerase in normal and malignant haematologic cells. Leber B, et al. **Leuk Lymphoma** 1996 Dec;24(1–2):1–9 (58 ref.)

GENETICS

Chromosomal instability and alteration of telomere repeat sequences. Pommier JP, et al. **Biochimie** 1995;77(10):817–25 (75 ref.)

The biology of replicative senescence. Campisi J. **Eur J Cancer** 1997 Apr;33(5):703–9 (79 ref.)

Telomere structure and telomerase expression during mouse development and tumorigenesis. Kipling D. **Eur J Cancer** 1997 Apr;33(5):792–800 (44 ref.)

The implications of telomerase biochemistry for human disease. Morin GB. **Eur J Cancer** 1997 Apr;33(5):750–60 (89 ref.)

Multiple pathways to cellular senescence: role of telomerase repressors. Oshimura M, et al. **Eur J Cancer** 1997 Apr; 33(5):710–5 (50 ref.)

The DNA structures at the ends of eukaryotic chromosomes. Wellinger RJ, et al. **Eur J Cancer** 1997 Apr;33(5):735–49 (244 ref.)

Reflections on telomeres, growth, aging, and essential hypertension. Aviv A, et al. **Hypertension** 1997 May; 29(5):1067–72 (69 ref.)

Telomere crisis in leukemia. Ishikawa F. **Int J Hematol** 1997 Jun;65(4):355–64 (46 ref.)

Telomeres and disease. Royle NJ. **J Pathol** 1996 Nov; 180(3):233–5 (26 ref.)

The involvement of telomeric sequences in chromosomal aberrations. Bouffler SD, et al. **Mutat Res** 1996 Nov; 366(2):129–35 (46 ref.)

Drosophila telomeres: new views on chromosome evolution. Pardue ML, et al. **Trends Genet** 1996 Feb;12(2):48–52 (19 ref.)

[Are the ends of chromosomes the beginning of tumor genesis? On the role of telomeres in cancer development] von Zglinicki T. **Fortschr Med** 1996 Nov 20;114(32):12–4 (12 ref.) **(Ger)**

[Linear prokaryotic chromosome; structure and synthesis of telomeres] Zarko-Postawka M, et al. **Postepy Biochem** 1997;43(1):12–7 (45 ref.) **(Pol)**

[Biochemistry of space and time (telomeres, telomerases, and longevity of cell populations and multicellular organisms] Golubev AG. **Biokhimiia** 1996 Nov;61(11):2045–59 (144 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Telomeres, not the end of the story. Gotta M, et al. **Bioessays** 1997 May;19(5):367–70 (34 ref.)

Chromosome healing: spontaneous and programmed de novo telomere formation by telomerase. Melek M, et al. **Bioessays** 1996 Apr;18(4):301–8 (73 ref.)

Telomere maintenance without telomerase. Biessmann H, et al. **Chromosoma** 1997 Jul;106(2):63–9 (85 ref.)

Recognition of telomeric DNA. König P, et al. **Trends Biochem Sci** 1997 Feb;22(2):43–7 (30 ref.)

PHYSIOLOGY

Telomere crisis, the driving force in cancer cell evolution. Ishikawa F. **Biochem Biophys Res Commun** 1997 Jan 3; 230(1):1–6 (53 ref.)

Telomere dynamics and cytogenetic changes in human hematologic neoplasias: a working hypothesis. Ohyashiki K, et al. **Cancer Genet Cytogenet** 1997 Mar;94(1):67–72 (41 ref.)

Telomere maintenance in tumour cells. Bacchetti S. **Cancer Surv** 1996;28:197–216 (120 ref.)

Telomeres, senescence and cellular radiation response. Crompton NE. **Cell Mol Life Sci** 1997 Jul;53(7):568–75 (104 ref.)

Telomeres and telomerase: biological and clinical importance. Dahse R, et al. **Clin Chem** 1997 May;43(5):708–14 (55 ref.)

Multiple pathways for the regulation of telomerase activity. Holt SE, et al. **Eur J Cancer** 1997 Apr;33(5):761–6 (52 ref.)

Clinical implications of telomerase in cancer. Kim NW. **Eur J Cancer** 1997 Apr;33(5):781–6 (35 ref.)

Telomeres and telomerase in normal and malignant haematopoietic cells. Norrback KF, et al. **Eur J Cancer** 1997 Apr;33(5):774–80 (57 ref.)

Telomerase and cancer. Harley CB, et al. **Important Adv Oncol** 1996;:57–67 (71 ref.)

The role of telomeres and telomerase in human cancer. Balasubramanian S, et al. **Indian J Physiol Pharmacol** 1996 Jul;40(3):199–204 (62 ref.)

The roles of telomeres and telomerase in cell life span. Counter CM. **Mutat Res** 1996 Oct;366(1):45–63 (179 ref.)

Telomeres, p53 and cellular senescence. Wynford-Thomas D. **Oncol Res** 1996;8(10–11):387–98 (95 ref.)

Replicative senescence and cell immortality: the role of telomeres and telomerase. Chiu CP, et al. **Proc Soc Exp Biol Med** 1997 Feb;214(2):99–106 (81 ref.)

Telomeres, telomerase and chromosome stability. Preston RJ. **Radiat Res** 1997 May;147(5):529–34 (49 ref.)

Unresolvable endings: defective telomeres and failed separation [comment] Hawley RS. **Science** 1997 Mar 7; 275(5305):1441–3 (9 ref.) Comment on: Science 1997 Mar 7;275(5305):1478–81.

[Telomere and telomerase] Ishikawa F. **Hum Cell** 1996 Dec; 9(4):287–94 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Chromosomal telomere and neoplastic transformation and aging of cells] Ishikawa F. **Nippon Naika Gakkai Zasshi** 1997 Jan 10;86(1):154–61 (10 ref.) **(Jpn)**

[Telomere DNA and telomerase of lymphoma–derived cell lines—telomere hypothesis for cell growth control] Yanagi K, et al. **Nippon Rinsho** 1997 Feb;55(2):328–33 (20 ref.) (Eng. Abstr.) **(Jpn)**

RADIATION EFFECTS

Telomeres, senescence and cellular radiation response. Crompton NE. **Cell Mol Life Sci** 1997 Jul;53(7):568–75 (104 ref.)

ULTRASTRUCTURE

Molecular model for telomeric heterochromatin in yeast. Grunstein M. **Curr Opin Cell Biol** 1997 Jun;9(3):383–7 (42 ref.)

TEMAZEPAM

Temazepam. **IARC Monogr Eval Carcinog Risks Hum** 1996; 66:161–73 (53 ref.)

TEMPERAMENT

Conceptualizing psychopathology: the importance of developmental profiles. Kagan J. **Dev Psychopathol** 1997 Spring;9(2):321–34 (27 ref.)

Integrating nature and nurture: implications of person–environment correlations and interactions for developmental psychopathology. Rutter M, et al. **Dev Psychopathol** 1997 Spring;9(2):335–64 (270 ref.)

Analysis of affiliation–related traits in terms of the PAD Temperament Model. Mehrabian A. **J Psychol** 1997 Jan; 131(1):101–17 (42 ref.)

Cloninger's tridimensional theory of personality and psychopathology: applications to substance use disorders. Howard MO, et al. **J Stud Alcohol** 1997 Jan;58(1):48–66 (55 ref.)

[Tools for clinical evaluation of affective temperaments] Hantouche EG, et al. **Encephale** 1997 Jan;23 Spec No 1:27–34 (16 ref.) (Eng. Abstr.) **(Fre)**

TEMPERANCE

PSYCHOLOGY

The role of coping in relapse crisis outcome: a prospective study of treated alcoholics. Moser AE, et al. **Addiction** 1996 Aug;91(8):1101–13 (32 ref.)

TEMPERATURE

see related
BODY TEMPERATURE
THERMOMETERS

Climate change and malaria transmission. Lindsay SW, et al. **Ann Trop Med Parasitol** 1996 Dec;90(6):573–88 (82 ref.)

Circadian pacemakers blowing hot and cold—but they're clocks, not thermometers. Hall JC. **Cell** 1997 Jul 11; 90(1):9–12 (22 ref.)

Fossilization processes in siliceous thermal springs: trends in preservation along thermal gradients. Cady SL, et al. **Ciba Found Symp** 1996;202:150–70; discussion 170–3 (23 ref.)

Conditionally immortalized cell lines with differentiated functions established from temperature-sensitive T-antigen transgenic mice. Obinata M. **Genes Cells** 1997 Apr; 2(4):235–44 (47 ref.)

Multinuclear MR frequency shifts of hydrated ions as a function of applied pressure and temperature. Sarkar SN, et al. **J Magn Reson B** 1996 Aug;112(2):197–9 (12 ref.)

Modeling incubation temperature: the effects of incubator design, embryonic development, and egg size. French NA. **Poult Sci** 1997 Jan;76(1):124–33 (52 ref.)

Thermal and biological treatments to control psychrotrophic pathogens. Sheldon BW, et al. **Poult Sci** 1996 Sep; 75(9):1126–32 (45 ref.)

[Anesthesia mechanisms: nerve excitation and temperature] Suzuki A, et al. **Masui** 1996 Jun;45(6):670–5 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Mechanism of action of temperature and chemical factors on the functioning of biological membranes] Vybornova II, et al. **Fiziol Cheloveka** 1997 Jan–Feb;23(1):70–80 (39 ref.) **(Rus)**

[Changes in the physiological functions, the mechanisms of their recovery and the temperature limits for life under hypothermia] Ivanov KP. **Usp Fiziol Nauk** 1996 Jul–Sep; 27(3):84–105 (66 ref.) (Eng. Abstr.) **(Rus)**

TEMPLATES

Site-directed mutagenesis using double-stranded plasmid DNA templates. Braman J, et al. **Methods Mol Biol** 1996; 57:31–44 (9 ref.)

Solid-phase in vitro mutagenesis using a plasmid DNA template. Edward R. **Methods Mol Biol** 1996;57:97–107 (12 ref.)

Site-directed mutagenesis using a uracil-containing phagemid template. Hagemeier C. **Methods Mol Biol** 1996; 57:45–54 (3 ref.)

Modification of the overlap extension method for extensive mutagenesis on the same template. Mikaelian I, et al. **Methods Mol Biol** 1996;57:193–202 (9 ref.)

A simple method for site-specific mutagenesis that leaves the rest of the template unaltered. Tomic-Canic M, et al. **Methods Mol Biol** 1996;57:259–67 (6 ref.)

[Molecular imprinting: tailor made synthetic receptors capable of molecular recognition] Takeuchi T. **Tanpakushitsu Kakusan Koso** 1997 Jun;42(8):1320–6 (13 ref.) **(Jpn)**

TEMPORAL ARTERIES

INJURIES

Pseudoaneurysm of the anterior superficial temporal artery. Han K, et al. **Ann Plast Surg** 1996 Dec;37(6):650–3 (19 ref.)

Pseudoaneurysm of the superficial temporal artery: report of a case. Webber CM, et al. **J Oral Maxillofac Surg** 1997 Feb;55(2):166–9 (22 ref.)

SURGERY

Pial synangiosis for treatment of Moyamoya syndrome in children. Hannon KE. **AORN J** 1996 Oct;64(4):540–54; quiz 557–60 (40 ref.)

TRANSPLANTATION

Revascularization of the anterior cerebral artery using a free superficial temporal artery graft: a case report. Terasaka S, et al. **Surg Neurol** 1997 Aug;48(2):164–9; discussion 169–70 (19 ref.)

TEMPORAL ARTERITIS

see related
POLYMYALGIA RHEUMATICA

Polymyalgia rheumatica and temporal arteritis: diagnosis and management. Swannell AJ. **BMJ** 1997 May 3; 314(7090):1329–32 (33 ref.)

Polymyalgia rheumatica and giant cell arteritis. Zilko PJ. **Med J Aust** 1996 Oct 21;165(8):438–42 (20 ref.)

Takayasu's disease and temporal arteritis. Giordano JM. **Semin Vasc Surg** 1995 Dec;8(4):335–41 (46 ref.)

[Temporal arteritis—old and new] Gur H, et al. **Harefuah** 1997 Mar 16;132(6):421–4 (51 ref.) **(Heb)**

[Horton's giant cell arteritis] Ponte E, et al. **Minerva Med** 1997 Jun;88(6):245–55 (85 ref.) (Eng. Abstr.) **(Ita)**

[Giant cell arteritis] Masuda Y. **Ryoikibetsu Shokogun Shirizu** 1996;(14):332–4 (10 ref.) **(Jpn)**

CLASSIFICATION

Temporal arteritis and polymyalgia rheumatica: nosographic and nosologic considerations. Turnbull J. **Neurology** 1996 Apr;46(4):901–6 (54 ref.)

COMPLICATIONS

Scalp necrosis in giant cell arteritis and review of the literature. Currey J. **Br J Rheumatol** 1997 Jul;36(7):814–6 (24 ref.)

Horton giant cell arteritis of the legs. Report of a case. Amatucci G, et al. **J Cardiovasc Surg (Torino)** 1997 Jun; 38(3):309–12 (14 ref.)

Temporal artery involvement revealing AL amyloidosis and IgD monoclonal gammopathy. Rodon P, et al. **J Rheumatol** 1996 Jan;23(1):189–90 (17 ref.)

Giant cell arteritis and polymyalgia rheumatica. Hunder GG. **Med Clin North Am** 1997 Jan;81(1):195–219 (93 ref.)

Progressive visual loss from giant cell arteritis despite high-dose intravenous methylprednisolone. Cornblath WT, et al. **Ophthalmology** 1997 May;104(5):854–8 (28 ref.)

[Aortitis in Horton disease. Review of the literature] Le Tourneau T, et al. **Ann Med Interne (Paris)** 1996; 147(5):361–8 (89 ref.) (Eng. Abstr.) **(Fre)**

[Unusual manifestation of Horton's disease: apropos of 2 case reports] Boschi A, et al. **Bull Soc Belge Ophtalmol** 1995; 259:189–95 (21 ref.) (Eng. Abstr.) **(Fre)**

[Early cerebral ischemic complication following corticotherapy for Horton disease (letter)] Peyrade F, et al. **Rev Med Interne** 1997 Jul;18(7):585–6 (7 ref.) **(Fre)**

[Chronic cor pulmonale after embolism, antiphospholipid syndrome, Horton disease: therapeutic approach apropos of a case] Beynel P, et al. **Rev Pneumol Clin** 1997; 53(3):162–6 (22 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Temporal arteritis: a review and case history. Moltyaner Y, et al. **J Fam Pract** 1996 Sep;43(3):294–300 (23 ref.)

Nonsteroidal antiinflammatory drug induced hypersensitivity vasculitis clinically mimicking temporal arteritis. Lie JT, et al. **J Rheumatol** 1996 Jan;23(1):183–5 (22 ref.)

ETIOLOGY

Giant cell arteritis: new concepts in pathogenesis and implications for management [editorial; comment] Weyand CM, et al. **Am J Ophthalmol** 1997 Mar;123(3):392–5 (16 ref.) Comment on: Am J Ophthalmol 1997 Mar;123(3):285–96.

The pathogenic role of T lymphocytes in vasculitis. Weyand CM, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct; 13(3):217–20 (9 ref.)

PATHOLOGY

Juvenile temporal arteritis with eosinophilia: a distinct clinicopathological entity. Fujimoto M, et al. **Dermatology** 1996;192(1):32–5 (16 ref.)

Giant cell arteritis of the uterus: case report and review. Ormsby AH, et al. **Pathology** 1997 May;29(2):227–30 (48 ref.)

PHYSIOPATHOLOGY

The implications of recognizing large-vessel involvement in elderly patients with giant cell arteritis. Evans J, et al. **Curr Opin Rheumatol** 1997 Jan;9(1):37–40 (18 ref.)

THERAPY

Giant cell arteritis: new concepts in pathogenesis and implications for management [editorial; comment] Weyand CM, et al. **Am J Ophthalmol** 1997 Mar;123(3):392–5 (16 ref.) Comment on: Am J Ophthalmol 1997 Mar;123(3):285–96.

TEMPORAL BONE

see related
LABYRINTH

Isolated facial nerve palsy from metastasis to the temporal bone: report of two cases and a review of the literature. Weiss MD, et al. **Am J Clin Oncol** 1997 Feb;20(1):19–23 (18 ref.)

Fibrous dysplasia of the temporal bone: reversal of sensorineural hearing loss after decompression of the internal auditory canal. Morrissey DD, et al. **Laryngoscope** 1997 Oct;107(10):1336–40 (18 ref.)

Chondromyxoid fibroma of the temporal bone. LeMay DR, et al. **Surg Neurol** 1997 Aug;48(2):148–52 (23 ref.)

[Temporo-sphenoidal giant cell tumors, apropos of a case] Barnabé D, et al. **Rev Laryngol Otol Rhinol (Bord)** 1997; 118(2):133–7 (30 ref.) (Eng. Abstr.) **(Fre)**

ABNORMALITIES

An anatomic variation of the stylomastoid foramen. Celik HH, et al. **Bull Assoc Anat (Nancy)** 1997 Mar;81(252):17–8 (3 ref.)

INJURIES

Management of complications from 820 temporal bone fractures. Brodie HA, et al. **Am J Otol** 1997 Mar; 18(2):188–97 (55 ref.)

Temporal bone fractures inducing facial nerve paralysis: a new classification and its clinical significance [see comments] Yanagihara N, et al. **Ear Nose Throat J** 1997 Feb;76(2):79–80, 83–6 (10 ref.) Comment in: Ear Nose Throat J 1997 Feb;76(2):64.

Trauma to the external auditory canal and temporal bone. Backous DD, et al. **Otolaryngol Clin North Am** 1996 Oct; 29(5):853–66 (43 ref.)

PATHOLOGY

Papillary adenoma of endolymphatic sac origin: a temporal bone tumor in von Hippel–Lindau disease. Case report. Ouallet JC, et al. **J Neurosurg** 1997 Sep;87(3):445–9 (11 ref.)

Cancer of the external auditory canal and temporal bone. Kuhel WI, et al. **Otolaryngol Clin North Am** 1996 Oct; 29(5):827–52 (88 ref.)

Eagle's syndrome (elongated styloid process). Balbuena L Jr, et al. **South Med J** 1997 Mar;90(3):331–4 (12 ref.)

Otitis media and interna and temporohyoid osteoarthropathy. Blythe LL. **Vet Clin North Am Equine Pract** 1997 Apr; 13(1):21–42 (24 ref.)

SURGERY

Primary intraosseous meningioma of the temporal bone in an infant. A case report. Kuzeyli K, et al. **Neurosurg Rev** 1996;19(3):197–9 (15 ref.)

TEMPORAL LOBE

Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Conference Participants. Foster NL, et al. **Ann Neurol** 1997 Jun; 41(6):706–15 (41 ref.)

Panic attacks caused by temporal tumors: an exemplary new case and a review. Kellner M, et al. **Depress Anxiety** 1996–97;4(5):243–5 (23 ref.)

[A case of the immediate efficacy of chemotherapy in a female patient with a glioblastoma] Kobiakov GL, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1996 Oct–Dec; (4):39–41 (22 ref.) **(Rus)**

ANATOMY & HISTOLOGY

Structure, functional and cerebral asymmetry: in vivo morphometry of the planum temporale. Steinmetz H. **Neurosci Biobehav Rev** 1996 Winter;20(4):587–91 (49 ref.)

BLOOD SUPPLY

Arteriovenous malformation associated with pleomorphic xanthoastrocytoma. Lee TT, et al. **Acta Neurochir (Wien)** 1996;138(5):590–1 (5 ref.)

INJURIES

Ventromedial temporal lobe anatomy, with comments on Alzheimer's disease and temporal injury. Van Hoesen GW. **J Neuropsychiatry Clin Neurosci** 1997 Summer;9(3):331–41 (55 ref.)

PATHOLOGY

A malignant astrocytoma in a patient with AIDS: a possible association between astrocytomas and HIV infection. Neal JW, et al. **J Infect** 1996 Nov;33(3):159–62 (24 ref.)

The medial temporal lobe in schizophrenia. Arnold SE. **J Neuropsychiatry Clin Neurosci** 1997 Summer;9(3):460–70 (137 ref.)

Ventromedial temporal lobe anatomy, with comments on Alzheimer's disease and temporal injury. Van Hoesen GW. **J Neuropsychiatry Clin Neurosci** 1997 Summer;9(3):331–41 (55 ref.)

PHYSIOLOGY

Inferotemporal cortex and object vision. Tanaka K. **Annu Rev Neurosci** 1996;19:109–39 (102 ref.)

The primate temporal pole: its putative role in object recognition and memory. Nakamura K, et al. **Behav Brain Res** 1996 May;77(1–2):53–77 (290 ref.)

Semantic category imprecision: a connectionist study of the boundaries of word meanings. Small SL. **Brain Lang** 1997 Apr;57(2):181–94 (31 ref.)

Perceptual and cognitive visual functions of parietal and temporal cortices in the cat. Lomber SG, et al. **Cereb Cortex** 1996 Sep–Oct;6(5):673–95 (86 ref.)

Memory beyond the hippocampus. Tulving E, et al. **Curr Opin Neurobiol** 1997 Apr;7(2):209–16 (103 ref.)

Ischemic brain damage and memory impairment: a commentary. Squire LR, et al. **Hippocampus** 1996; 6(5):546–52 (50 ref.)

High level object recognition without an anterior inferior temporal lobe. Biederman I, et al. **Neuropsychologia** 1997 Mar;35(3):271–87 (64 ref.)

PHYSIOPATHOLOGY

What have we learned from functional imaging studies in schizophrenia? The role of frontal, striatal and temporal areas. Velakoulis D, et al. **Aust N Z J Psychiatry** 1996 Apr;30(2):195–209 (111 ref.)

Fronto-temporal dementia: nosology, neuropsychology, and neuropathology. Neary D, et al. **Brain Cogn** 1996 Jul; 31(2):176–87 (41 ref.)

Memory, memory impairment, and the medial temporal lobe. Squire LR, et al. **Cold Spring Harb Symp Quant Biol** 1996; 61:185–95 (104 ref.)
Neuropsychological evaluation in epilepsy surgery. Loring DW. **Epilepsia** 1997;38 Suppl 4:S18–23 (35 ref.)
Auras and experiential responses arising in the temporal lobe. Fried I. **J Neuropsychiatry Clin Neurosci** 1997 Summer; 9(3):420–8 (45 ref.)
Neuropsychiatric symptoms from the temporolimbic lobes. Trimble MR, et al. **J Neuropsychiatry Clin Neurosci** 1997 Summer;9(3):429–38 (86 ref.)
[Progressive degenerative aphasia: clinical and neuroradiological observations in 18 cases] Robles A, et al. **Rev Neurol** 1997 Apr;25(140):505–12 (18 ref.) (Eng. Abstr.) **(Spa)**
[Mesial temporal sclerosis (I): histological data, physiopathological hypothesis and etiological factors] Serrano–Castro P, et al. **Rev Neurol** 1997 Apr;25(140):584–9 (41 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Neuropsychiatric complications after temporal lobe limbic system surgery. Gabriel EM, et al.
Neuroimaging Clin N Am 1997 Feb;7(1):155–64 (62 ref.)
Recent advancements in epilepsy. Wyler AR, et al.
Surg Neurol 1997 Aug;48(2):106–9 (06 ref.)
[Results of surgery treatment of epilepsy] Alvarez LA, et al. **Rev Neurol** 1996 Nov;24(135):1441–5 (21 ref.) (Eng. Abstr.) **(Spa)**

TEMPORAL MUSCLE

[Myositis ossificans of the pterygoid and temporal muscles with metachronous contralateral involvement] Salgarelli A, et al. **Minerva Stomatol** 1997 May;46(5):259–65 (23 ref.) (Eng. Abstr.) **(Ita)**

DRUG EFFECTS

Botulinum–A toxin in the treatment of craniocervical muscle spasms: short- and long–term, local and systemic effects. Dutton JJ. **Surv Ophthalmol** 1996 Jul–Aug;41(1):51–65 (145 ref.)

INNERVATION

[Exteroceptive suppression of activity of the temporal muscle. Principles and applications] Göbel H, et al.
Nervenarzt 1996 Oct;67(10):846–59 (102 ref.) (Eng. Abstr.) **(Ger)**

TEMPOROMANDIBULAR JOINT

see related

CENTRIC RELATION

Tumours and pseudotumorous lesions of the temporomandibular joint: a diagnostic challenge. Allias–Montmayeur F, et al. **J Laryngol Otol** 1997 Aug; 111(8):776–81 (27 ref.)
Temporomandibular pain and dysfunction syndrome. History, physical examination, and treatment. Marbach JJ. **Rheum Dis Clin North Am** 1996 Aug;22(3):477–98 (84 ref.)
Temporomandibular joint metastasis from rectal carcinoma: CT findings before and after radiotherapy. A case report. Balestreri L, et al. **Tumori** 1997 May–Jun;83(3):718–20 (6 ref.)
[Myoarthropathies of the chewing system—more than a problem of dental medicine] Türp JC.
Dtsch Med Wochenschr 1997 Apr 11;122(15):483–7 (40 ref.) **(Ger)**

ANATOMY & HISTOLOGY

Size and location of the human temporomandibular joint. Wish–Baratz S, et al. **Am J Phys Anthropol** 1996 Nov; 101(3):387–400 (39 ref.)

PHYSIOLOGY

A scientific basis for the biologic regeneration of synovial joints. Luyten FP.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jan;83(1):167–9 (169 ref.)
[The sound during mandibular joint kinematics. The diagnostic, epidemiologic and prognostic elements] Capurso U. **Minerva Stomatol** 1997 May;46(5):247–57 (79 ref.) (Eng. Abstr.) **(Ita)**

RADIOGRAPHY

Imaging of the temporomandibular joint: a position paper of the American Academy of Oral and Maxillofacial Radiology. Brooks SL, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 May;83(5):609–18 (92 ref.)

SURGERY

Combined middle cranial fossa and preauricular approach to the temporomandibular joint: report of a case. Li KK, et al. **J Oral Maxillofac Surg** 1997 Aug;55(8):851–2 (10 ref.)

TEMPOROMANDIBULAR JOINT DISK

PHYSIOPATHOLOGY

The "anchored disc phenomenon": a proposed etiology for sudden–onset, severe, and persistent closed lock of the temporomandibular joint. Nitzan DW, et al.
J Oral Maxillofac Surg 1997 Aug;55(8):797–802; discussion 802–3 (61 ref.)

SURGERY

Histologic and histochemical changes in failed auricular cartilage grafts used for a temporomandibular joint disc replacement: a report of three cases and review of the literature. Sandler NA, et al. **J Oral Maxillofac Surg** 1997 Sep;55(9):1014–9 (26 ref.)
The role of temporomandibular joint surgery in the treatment of patients with internal derangement. Dolwick MF.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jan;83(1):150–5 (60 ref.)

TEMPOROMANDIBULAR JOINT DISORDERS

Temporomandibular disorders in the medical practice. Okeson JP, et al. **J Fam Pract** 1996 Oct;43(4):347–56 (53 ref.)

CLASSIFICATION

Current terminology and diagnostic classification schemes. Okeson JP.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jan;83(1):61–4 (29 ref.)

COMPLICATIONS

Prosthetic rehabilitation in patients with temporomandibular disorders. Türp JC, et al. **J Prosthet Dent** 1996 Oct; 76(4):418–23 (53 ref.)

DIAGNOSIS

Pigmented villonodular synovitis of the temporomandibular joint. Tanaka K, et al.
Arch Otolaryngol Head Neck Surg 1997 May;123(5):536–9 (11 ref.)
Differentiation of orofacial pain related to Lyme disease from other dental and facial pain disorders. Heir GM.
Dent Clin North Am 1997 Apr;41(2):243–58 (32 ref.)
History and examination of the orofacial pain patient. Kaplan AS. **Dent Clin North Am** 1997 Apr;41(2):155–66 (42 ref.)
Management of temporomandibular disorders. National Institutes of Health Technology Assessment Conference Statement [see comments] **J Am Dent Assoc** 1996 Nov; 127(11):1595–606 (0 ref.) Comment in: J Am Dent Assoc 1997 Apr;128(4):402.
Imaging of the temporomandibular joint: a position paper of the American Academy of Oral and Maxillofacial Radiology. Brooks SL, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 May;83(5):609–18 (92 ref.)
The validity and utility of disease detection methods and of occlusal therapy for temporomandibular disorders. Clark GT, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jan;83(1):101–6 (44 ref.)
[The sound during mandibular joint kinematics. The diagnostic, epidemiologic and prognostic elements] Capurso U. **Minerva Stomatol** 1997 May;46(5):247–57 (79 ref.) (Eng. Abstr.) **(Ita)**

EPIDEMIOLOGY

Epidemiology of temporomandibular disorders: implications for the investigation of etiologic factors. LeResche L.
Crit Rev Oral Biol Med 1997;8(3):291–305 (78 ref.)
Epidemiology and natural progression of articular temporomandibular disorders. de Bont LG, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jan;83(1):72–6 (24 ref.)

ETIOLOGY

The aetiology of temporomandibular disorders: a philosophical overview. Mew JR. **Eur J Orthod** 1997 Jun; 19(3):249–58 (55 ref.)
The "anchored disc phenomenon": a proposed etiology for sudden–onset, severe, and persistent closed lock of the temporomandibular joint. Nitzan DW, et al.
J Oral Maxillofac Surg 1997 Aug;55(8):797–802; discussion 802–3 (61 ref.)
Orthodontic treatment and temporomandibular disorders: is there a relationship? Part 1: Clinical studies. McNamara JA Jr, et al. **J Orofac Orthop** 1997;58(2):74–89 (89 ref.) **(Eng, Ger)**
Orthodontic treatment and temporomandibular disorder: is there a relationship? Part 2: Clinical implications. Türp JC, et al. **J Orofac Orthop** 1997;58(3):136–43 (39 ref.) **(Eng, Ger)**
Orthodontic treatment and temporomandibular disorders. McNamara JA Jr.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jan;83(1):107–17 (90 ref.)

PATHOLOGY

Epidemiology and natural progression of articular temporomandibular disorders. de Bont LG, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jan;83(1):72–6 (24 ref.)
[Chondrosarcoma of the temporomandibular joint. Apropos of a case and review of the literature] Giraud O, et al.
Rev Stomatol Chir Maxillofac 1997 Jan;98(1):2–6 (21 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Assessment of physical and behavioral outcomes of treatment. LeResche L.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jan;83(1):82–6 (26 ref.)
Psychosocial and behavioral assessment of patients with temporomandibular disorders: diagnostic and treatment implications. Turk DC.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jan;83(1):65–71 (33 ref.)

SURGERY

The role of temporomandibular joint surgery in the treatment of patients with internal derangement. Dolwick MF.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jan;83(1):150–5 (60 ref.)
Failed implants and multiple operations. Milam SB.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jan;83(1):156–62 (103 ref.)
Temporomandibular joint devices: treatment factors and outcomes. Wolford LM.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jan;83(1):143–9 (149 ref.)

THERAPY

Intraoral orthotic therapy. Attanasio R.
Dent Clin North Am 1997 Apr;41(2):309–24 (105 ref.)
Management of temporomandibular disorders. National Institutes of Health Technology Assessment Conference Statement [see comments] **J Am Dent Assoc** 1996 Nov; 127(11):1595–606 (0 ref.) Comment in: J Am Dent Assoc 1997 Apr;128(4):402.
Evidence–based care of musculoskeletal facial pain: implications for the clinical science of dentistry [see comments] Raphael K, et al. **J Am Dent Assoc** 1997 Jan; 128(1):73–9 (47 ref.) Comment in: J Am Dent Assoc 1997 Apr;128(4):402. Comment in: J Am Dent Assoc 1997 Apr;128(4):402, 405. Comment in: J Am Dent Assoc 1997 Apr;128(4):405. Comment in: J Am Dent Assoc 1997 Apr;128(4):405–6.
Management of temporomandibular disorders: concepts and controversies. McNeill C. **J Prosthet Dent** 1997 May; 77(5):510–22 (106 ref.)
National Institutes of Health Technology Assessment Conference on Management of Temporomandibular Disorders. Bethesda, Maryland, April 29–May 1, 1996. Proceedings.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jan;83(1):49–183 (0 ref.)
The validity and utility of disease detection methods and of occlusal therapy for temporomandibular disorders. Clark GT, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jan;83(1):101–6 (44 ref.)
The role of occlusal adjustment in the management of temporomandibular disorders. Kirveskari P.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jan;83(1):87–90 (24 ref.)
Assessment of physical and behavioral outcomes of treatment. LeResche L.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jan;83(1):82–6 (26 ref.)

TEMPOROMANDIBULAR JOINT DYSFUNCTION SYNDROME

Phenomenology, epidemiology, and natural progression of the muscular temporomandibular disorders. Stohler CS.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jan;83(1):77–81 (25 ref.)
Temporomandibular pain and dysfunction syndrome. History, physical examination, and treatment. Marbach JJ.
Rheum Dis Clin North Am 1996 Aug;22(3):477–98 (84 ref.)

DIAGNOSIS

Psychoneuroimmunology and its relationship to the differential diagnosis of temporomandibular disorders. Auvenshine RC. **Dent Clin North Am** 1997 Apr; 41(2):279–96 (21 ref.)

DRUG THERAPY

Pharmacologic treatments for temporomandibular disorders. Dionne RA.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jan;83(1):134–42 (55 ref.)

TEMPOROMANDIBULAR JOINT DYSFUNCTION SYNDROME

PSYCHOLOGY

Behavioral and educational modalities. Dworkin SF. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jan;83(1):128–33 (24 ref.)

THERAPY

Special considerations in orofacial pain and headache. Austin DG. **Dent Clin North Am** 1997 Apr;41(2):325–39 (82 ref.)

Behavioral and educational modalities. Dworkin SF. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jan;83(1):128–33 (24 ref.)

Physical therapy: a critique [see comments] Feine JS, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jan;83(1):123–7 (38 ref.) Comment in: Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jul;84(1):3.

Future directions in the treatment of chronic musculoskeletal facial pain: the role of evidence–based care. Marbach JJ, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jan;83(1):170–6 (44 ref.)

Physical medicine modalities and trigger point injections in the management of temporomandibular disorders and assessing treatment outcome. Murphy GJ. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jan;83(1):118–22 (79 ref.)

[Role of the dentist in the treatment of cephalalgia and fascialgia] Kirveskari P. **Duodecim** 1995;111(14):1370–4 (15 ref.) **(Fin)**

[Critical review of the various treatments of temporomandibular joint pain–dysfunction syndrome. What will be the psychosomatic approach to these patients?] Fleury JE, et al. **Rev Stomatol Chir Maxillofac** 1997 Jan;98(1):50–4 (13 ref.) (Eng. Abstr.) **(Fre)**

TEMPOROMANDIBULAR JOINT SYNDROME see **TEMPOROMANDIBULAR JOINT DYSFUNCTION SYNDROME**

TENASCIN

CHEMISTRY

The extracellular matrix molecule tenascin–C: expression in vivo and functional characterization in vitro. Bartsch U. **Prog Neurobiol** 1996 Jun;49(2):145–68 (180 ref.)

GENETICS

The extracellular matrix molecule tenascin–C: expression in vivo and functional characterization in vitro. Bartsch U. **Prog Neurobiol** 1996 Jun;49(2):145–68 (180 ref.)

METABOLISM

[The role of syndecan and tenascine during tooth development. Review o the literature] Bucci P, et al. **Minerva Stomatol** 1996 Jun;45(6):259–66 (15 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

Tenascin: a multifunctional extracellular matrix protein with a restricted distribution in development and disease. Crossin KL. **J Cell Biochem** 1996 Jun 15;61(4):592–8 (47 ref.)

TENASCIN–C see **TENASCIN**

TENDINITIS

Calcifying tendinitis. Uhthoff HK. **Ann Chir Gynaecol** 1996; 85(2):111–5 (24 ref.)

Sports–related and other soft–tissue injuries, tendinitis, bursitis, and occupation–related syndromes [see comments] Biundo JJ Jr, et al. **Curr Opin Rheumatol** 1997 Mar; 9(2):151–4 (20 ref.) Comment in: Curr Opin Rheumatol 1997 Mar;9(2):133–43.

CHEMICALLY INDUCED

Partial Achilles tendon ruptures associated with fluoroquinolone antibiotics: a case report and literature review. McGarvey WC, et al. **Foot Ankle Int** 1996 Aug; 17(8):496–8 (25 ref.)

DIAGNOSIS

Simulators of hand infections. Kann SE, et al. **Instr Course Lect** 1997;46:69–82 (169 ref.)

Tendon problems in athletic individuals. Teitz CC, et al. **Instr Course Lect** 1997;46:569–82 (76 ref.)

DRUG THERAPY

Local corticosteroid injections in the treatment of rotator cuff tendinitis (except for frozen shoulder and calcific tendinitis). Groupe Rhumatologique Français de l'Epaule (G.R.E.P.). Goupille P, et al. **Clin Exp Rheumatol** 1996 Sep–Oct;14(5):561–6 (41 ref.)

ETIOLOGY

Tendinitis in golf. Clancy WG Jr, et al. **Clin Sports Med** 1996 Jan;15(1):27–35 (46 ref.)

[Epicondylitis and tenosynovitis or peritendinitis as an occupational disease] Kivi P, et al. **Duodecim** 1995; 111(17):1703–7 (8 ref.) **(Fin)**

THERAPY

General considerations for managing tendon injuries. Klaiman MD, et al. **Bull Rheum Dis** 1996 Feb;45(1):1–6 (25 ref.)

Use of extracorporeal shock waves in the treatment of pseudarthrosis, tendinopathy and other orthopedic diseases. Haupt G. **J Urol** 1997 Jul;158(1):4–11 (151 ref.)

ULTRASONOGRAPHY

[Ultrasound morphology of the Achilles tendon and differential diagnosis] Kainberger F, et al. **Ultraschall Med** 1996 Oct;17(5):212–7 (27 ref.) (Eng. Abstr.) **(Ger)**

TENDON INJURIES

Achilles and peroneal tendon injuries in the athlete. An expert's perspective. Subotnick SI. **Clin Podiatr Med Surg** 1997 Jul;14(3):447–58 (25 ref.)

Occupational soft–tissue and tendon disorders. Kasdan ML, et al. **Orthop Clin North Am** 1996 Oct;27(4):795–803 (20 ref.)

DIAGNOSIS

Late presentation of triceps rupture. A case report and review of the literature. Inhofe PD, et al. **Am J Orthop** 1996 Nov; 25(11):790–2 (10 ref.)

MR imaging of tendon injuries about the foot and ankle. Mammone JF. **Clin Podiatr Med Surg** 1997 Apr; 14(2):313–35 (48 ref.)

Surgically documented rupture of the plantaris muscle: a case report and literature review. Hamilton W, et al. **Foot Ankle Int** 1997 Aug;18(8):522–3 (9 ref.)

Magnetic resonance imaging studies of the shoulder: diagnosis of lesions of the rotator cuff. Recht MP, et al. **Instr Course Lect** 1994;43:483–92 (50 ref.)

MR imaging of tendon injuries in the elbow. Ho CP. **Magn Reson Imaging Clin N Am** 1997 Aug;5(3):529–43 (24 ref.)

Imaging of tendon injuries about the ankle. Clarke HD, et al. **Orthopedics** 1997 Jul;20(7):639–43; quiz 644–5 (39 ref.)

DRUG THERAPY

Local corticosteroid injection in sport: review of literature and guidelines for treatment. Fredberg U. **Scand J Med Sci Sports** 1997 Jun;7(3):131–9 (128 ref.)

ETIOLOGY

Spontaneous tendon ruptures in patients on chronic dialysis [see comments] Jones N, et al. **Am J Kidney Dis** 1996 Dec; 28(6):861–6 (29 ref.) Comment in: Am J Kidney Dis 1997 Jun;29(6):982.

Closed complete rupture of the flexor hallucis longus tendon at the groove of the talus. Inokuchi S, et al. **Foot Ankle Int** 1997 Jan;18(1):47–9 (10 ref.)

Flexor digitorum profundus rupture of the small finger secondary to nonunion of the hook of hamate: a case report. Hartford JM, et al. **J Hand Surg [Am]** 1996 Jul;21(4):621–3 (7 ref.)

Spontaneous avulsion injuries of tendons in patients with ankylosing spondylitis. Groupe de Recherche en Immuno–pathologie (GRIMP) [letter] Da Silva LF, et al. **Rev Rhum Engl Ed** 1996 Jul–Sep;63(7–8):504 (5 ref.)

REHABILITATION

Postoperative management of extensor tendon repairs in zones V, VI, and VII. Thomas D, et al. **J Hand Ther** 1996 Oct–Dec;9(4):309–14 (24 ref.)

[Possibilities and limits of functional conservative therapy of acute Achilles tendon ruptures] Richter J, et al. **Chirurg** 1997 May;68(5):517–24 (37 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Bilateral spontaneous patellar tendon rupture. Schwartzberg RS, et al. **Am J Orthop** 1996 May;25(5):369–72 (36 ref.)

Repair of rupture of the distal tendon of the biceps brachii. Review of the literature and report of three cases treated with a single anterior incision and suture anchors. Strauch RJ, et al. **Am J Orthop** 1997 Feb;26(2):151–6 (45 ref.)

Update on tendon repair. Ingari JV, et al. **Clin Plast Surg** 1997 Jan;24(1):161–73 (89 ref.)

Stapedius tendon reconstruction during stapedotomy: technique and results. Causse JB, et al. **Ear Nose Throat J** 1997 Apr;76(4):256–8, 260–9 (29 ref.)

Extensor hallucis longus tendon injury: an in–depth analysis and treatment protocol. Kass JC, et al. **J Foot Ankle Surg** 1997 Jan–Feb;36(1):24–7; discussion 80 (23 ref.)

Repair of neglected Achilles tendon ruptures with a triceps surae muscle tendon advancement. Mendicino SS, et al. **J Foot Ankle Surg** 1996 Jan–Feb;35(1):13–8 (21 ref.)

[Personal technique for suturing the flexor tendons of the fingers with immediate mobilization] Brunelli G, et al. **Ann Chir Main** 1982;1(1):92–6 (11 ref.) (Eng. Abstr.) **(Fre)**

[New developments in joint surgery] Lobenhoffer P, et al. **Orthopade** 1997 May;26(5):422–36 (76 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

General considerations for managing tendon injuries. Klaiman MD, et al. **Bull Rheum Dis** 1996 Feb;45(1):1–6 (25 ref.)

Adult acquired flatfoot deformity: treatment of dysfunction of the posterior tibial tendon. Myerson MS. **Instr Course Lect** 1997;46:393–405 (53 ref.)

Peroneal subluxation: a comprehensive review of the literature with case presentations. Niemi WJ, et al. **J Foot Ankle Surg** 1997 Mar–Apr;36(2):141–5 (47 ref.)

Irreducible dorsal dislocation of the distal interphalangeal joint: case report and literature review. Abouzahr MK, et al. **J Trauma** 1997 Apr;42(4):743–5 (9 ref.)

ULTRASONOGRAPHY

Sonography of tendons: patterns of disease. van Holsbeeck M, et al. **Instr Course Lect** 1994;43:475–81 (20 ref.)

[Ultrasound morphology of the Achilles tendon and differential diagnosis] Kainberger F, et al. **Ultraschall Med** 1996 Oct;17(5):212–7 (27 ref.) (Eng. Abstr.) **(Ger)**

TENDON TRANSFER

Failure of anterior cruciate ligament reconstruction: the biologic basis. Corsetti JR, et al. **Clin Orthop** 1996 Apr; (325):42–9 (39 ref.)

METHODS

Revision of failed prosthetic anterior cruciate ligament reconstruction. Greis PE, et al. **Clin Orthop** 1996 Apr; (325):78–90 (34 ref.)

Why grafts fail. Jaureguito JW, et al. **Clin Orthop** 1996 Apr; (325):25–41 (102 ref.)

Graft selection in anterior cruciate ligament revision surgery. Ritchie JR, et al. **Clin Orthop** 1996 Apr;(325):65–77 (58 ref.)

Clawfoot deformity: an analysis of the causes and surgical treatment using a modification of the Jones suspension procedure. Grumbine NA, et al. **Clin Podiatr Med Surg** 1996 Apr;13(2):221–38 (19 ref.)

Repair of neglected Achilles tendon ruptures with a triceps surae muscle tendon advancement. Mendicino SS, et al. **J Foot Ankle Surg** 1996 Jan–Feb;35(1):13–8 (21 ref.)

[Functional disorders of the foot after tenodeses: is the method still currently acceptable?] Becker HP, et al. **Sportverletz Sportschaden** 1996 Dec;10(4):94–9 (47 ref.) (Eng. Abstr.) **(Ger)**

[Development of replacement meniscus of autogenous tissue] Metak G, et al. **Unfallchirurg** 1996 Jul;99(7):477–86 (36 ref.) (Eng. Abstr.) **(Ger)**

TENDONS

see related
TENDON TRANSFER

Malignant giant cell tumor of the tendon sheaths and joints (malignant pigmented villonodular synovitis). Bertoni F, et al. **Am J Surg Pathol** 1997 Feb;21(2):153–63 (14 ref.)

Subungual giant cell tumor of the tendon sheath. Abimelec P, et al. **Cutis** 1996 Oct;58(4):273–5 (10 ref.)

ANATOMY & HISTOLOGY

Functional anatomy of the extensor tendons of the digits. von Schroeder HP, et al. **Hand Clin** 1997 Feb;13(1):51–62 (48 ref.)

PATHOLOGY

Extra–articular localized nodular synovitis (giant cell tumor of tendon sheath origin) attached to the subtalar joint. Villani C, et al. **Foot Ankle Int** 1996 Jul;17(7):413–6 (30 ref.)

PHYSIOLOGY

Force transmission in skeletal muscle: from actomyosin to external tendons. Patel TJ, et al. **Exerc Sport Sci Rev** 1997; 25:321–63 (121 ref.)

The aging tendon. Tuite DJ, et al. **Scand J Med Sci Sports** 1997 Apr;7(2):72–7 (56 ref.)

PHYSIOPATHOLOGY

Posterior tibial tendon dysfunction in the athlete. Ross JA. **Clin Podiatr Med Surg** 1997 Jul;14(3):479–88 (21 ref.)

Posterior tibial tendon dysfunction as a cause of acquired flatfoot in adults. Kupcha PC, et al. **Del Med J** 1997 May; 69(5):255–7 (5 ref.)

SURGERY

Update on tendon repair. Ingari JV, et al. **Clin Plast Surg** 1997 Jan;24(1):161–73 (89 ref.)

Extensor hallucis longus tendon injury: an in–depth analysis and treatment protocol. Kass JC, et al. **J Foot Ankle Surg** 1997 Jan–Feb;36(1):24–7; discussion 80 (23 ref.)

Compression of the lateral antebrachial cutaneous nerve by

the biceps tendon. Gillingham BL, et al. **J Shoulder Elbow Surg** 1996 Jul–Aug;5(4):330–2 (10 ref.)

TRANSPLANTATION

Graft selection in anterior cruciate ligament revision surgery. Ritchie JR, et al. **Clin Orthop** 1996 Apr;(325):65–77 (58 ref.)

Spontaneous avulsion injuries of tendons in patients with ankylosing spondylitis. Groupe de Recherche en Immuno–pathologie (GRIMP) [letter] Da Silva LF, et al. **Rev Rhum Engl Ed** 1996 Jul–Sep;63(7–8):504 (5 ref.)

ULTRASONOGRAPHY

[Sonography of the knee extensor system] Gruber G. **Ultraschall Med** 1996 Oct;17(5):206–11 (16 ref.) (Eng. Abstr.) **(Ger)**

TENDONS, PARA-ARTICULAR

INJURIES

Traumatic peroneal tendon instability [see comments] Mason RB, et al. **Am J Sports Med** 1996 Sep–Oct;24(5):652–8 (30 ref.) Comment in: Am J Sports Med 1997 Jul–Aug;25(4):587.

Spontaneous rupture of extensor hallucis longus tendon. Mulcahy DM, et al. **Foot Ankle Int** 1996 Mar;17(3):162–3 (10 ref.)

Extensor mechanism problems in total knee arthroplasty. Dennis DA. **Instr Course Lect** 1997;46:171–80 (119 ref.)

Tendon problems in athletic individuals. Teitz CC, et al. **Instr Course Lect** 1997;46:569–82 (76 ref.)

[Recent isolated lesions of the flexor tendon of the thumb (20 cases). A long–term review] Thomazeau H, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(7):590–7 (16 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Biomechanical studies of the remodeling of knee joint tendons and ligaments. Hayashi K. **J Biomech** 1996 Jun; 29(6):707–16 (55 ref.)

SURGERY

Postoperative management of extensor tendon repairs in zones V, VI, and VII. Thomas D, et al. **J Hand Ther** 1996 Oct–Dec;9(4):309–14 (24 ref.)

[Personal technique for suturing the flexor tendons of the fingers with immediate mobilization] Brunelli G, et al. **Ann Chir Main** 1982;1(1):92–6 (11 ref.) (Eng. Abstr.) **(Fre)**

TRANSPLANTATION

ACL reconstruction: semitendinosus tendon is the graft of choice. Rosenberg TD, et al. **Orthopedics** 1997 May; 20(5):396, 398 (14 ref.)

ULTRASONOGRAPHY

Sonography of tendons: patterns of disease. van Holsbeeck M, et al. **Instr Course Lect** 1994;43:475–81 (20 ref.)

TENIPOSIDE

PHARMACOLOGY

[DNA topoisomerases targeting anticancer agents and mechanism for acquirement of drug resistance] Furukawa M, et al. **Nippon Rinsho** 1997 May;55(5):1096–102 (20 ref.) (Eng. Abstr.) **(Jpn)**

TENNIS ELBOW

Tennis elbow. Current concepts of treatment and rehabilitation. Ollivierre CO, et al. **Sports Med** 1996 Aug; 22(2):133–9 (20 ref.)

ETIOLOGY

Cumulative trauma disorders. Higgs PE, et al. **Clin Plast Surg** 1996 Jul;23(3):421–33 (34 ref.)

[Epicondylitis and tenosynovitis or peritendinitis as an occupational disease] Kivi P, et al. **Duodecim** 1995; 111(17):1703–7 (8 ref.) **(Fin)**

THERAPY

[The treatment of therapy–resistant lateral epicondylitis] Nagy L. **Swiss Surg** 1997;3(2):76–9; discussion 80 (20 ref.) (Eng. Abstr.) **(Ger)**

TENOSYNOVITIS

DIAGNOSIS

Tendon problems in athletic individuals. Teitz CC, et al. **Instr Course Lect** 1997;46:569–82 (76 ref.)

ETIOLOGY

Cumulative trauma disorders. Higgs PE, et al. **Clin Plast Surg** 1996 Jul;23(3):421–33 (34 ref.)

Extensor tendon problems in rheumatoid arthritis. Wilson RL, et al. **Hand Clin** 1996 Aug;12(3):551–9 (30 ref.)

[Epicondylitis and tenosynovitis or peritendinitis as an occupational disease] Kivi P, et al. **Duodecim** 1995; 111(17):1703–7 (8 ref.) **(Fin)**

HISTORY

[100 years tendovaginitis stenosans de Quervain—review of the literature and personal results] Wetterkamp D, et al. **Handchir Mikrochir Plast Chir** 1997 Jul;29(4):214–7 (17 ref.) (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

Mycobacterium xenopi—an unusual presentation as tenosynovitis of the wrist in an immunocompetent patient. Coombes GM, et al. **Br J Rheumatol** 1996 Oct; 35(10):1008–10 (25 ref.)

SURGERY

Rheumatoid flexor tenosynovitis and rupture. Ferlic DC. **Hand Clin** 1996 Aug;12(3):561–72 (43 ref.)

TENS see **TRANSCUTANEOUS ELECTRIC NERVE STIMULATION**

TENSION HEADACHE

[Tension headache] Bendtsen L, et al. **Ugeskr Laeger** 1997 Aug 11;159(33):4965–8 (15 ref.) **(Dan)**

ETIOLOGY

[Tension type headache with special reference to muscle abnormality] Sakuta M. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1339–41 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Tension–type headache: 5–hydroxytryptamine and related substances] Shimomura T. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1342–4 (8 ref.) (Eng. Abstr.) **(Jpn)**

TENSION–TYPE HEADACHE see **TENSION HEADACHE**

TERATOGENS

see related

ABNORMALITIES, DRUG-INDUCED

Behavioral teratogenesis: an extension to the teratogenesis of functions [editorial] Auroux M. **Biol Neonate** 1997; 71(3):137–47 (92 ref.)

Oral retinoids—efficacy and toxicity in psoriasis. Gollnick HP. **Br J Dermatol** 1996 Oct;135 Suppl 49:6–17 (80 ref.)

How to ensure fetal safety when mothers use isotretinoin (Accutane). Koren G, et al. **Can Fam Physician** 1997 Feb; 43:216–9 (4 ref.)

Stillbirth after occupational exposure to N–methyl–2–pyrrolidone. A case report and review of the literature [see comments] Solomon GM, et al. **J Occup Environ Med** 1996 Jul;38(7):705–13 (58 ref.) Comment in: J Occup Environ Med 1997 May;39(5):393–4.

Mutagenicity, carcinogenicity and teratogenicity of antimony compounds. Léonard A, et al. **Mutat Res** 1996 Oct; 366(1):1–8 (61 ref.)

An assessment of boric acid and borax using the IEHR Evaluative Process for Assessing Human Developmental and Reproductive Toxicity of Agents. Expert Scientific Committee. Moore JA. **Reprod Toxicol** 1997 Jan–Feb; 11(1):123–60 (137 ref.)

The developmental toxicity of three antimicrobial agents observed only in nonroutine animal studies. Stahlmann R, et al. **Reprod Toxicol** 1997 Jan–Feb;11(1):1–7 (43 ref.)

Teratogen update: electromagnetic fields. Robert E. **Teratology** 1996 Dec;54(6):305–13 (83 ref.)

[Is lithium a teratogen?] Kučera V. **Cas Lek Cesk** 1996 Nov 20;135(22):726–8 (20 ref.) (Eng. Abstr.) **(Cze)**

[Toxic effects of fluorine compounds on the the fetus and their effect on the course of pregnancy] Chlubek D, et al. **Ginekol Pol** 1996 Aug;67(8):414–8 (21 ref.) (Eng. Abstr.) **(Pol)**

CLASSIFICATION

Drugs during pregnancy: an issue of risk classification and information to prescribers. Sannerstedt R, et al. **Drug Saf** 1996 Feb;14(2):69–77 (7 ref.)

PHARMACOKINETICS

Pharmacokinetics, pharmacodynamics, and prediction of developmental abnormalities. O'Flaherty EJ. **Reprod Toxicol** 1997 Mar–Jun;11(2–3):413–6 (28 ref.)

PHARMACOLOGY

Genetic determinants of teratogen–induced abnormal development in mouse and rat embryos in vitro. Kapron CM, et al. **Int J Dev Biol** 1997 Apr;41(2):337–44 (54 ref.)

TOXICITY

Fumonisin B1–immunological effects. The influence of FB1 on the early stage of immune response. Martinova EA. **Adv Exp Med Biol** 1996;391:331–42 (70 ref.)

Drug metabolic enzymes in developmental toxicology. Miller MS, et al. **Fundam Appl Toxicol** 1996 Dec;34(2):165–75 (67 ref.)

Mutagenicity, carcinogenicity and teratogenicity of thallium compounds. Léonard A, et al. **Mutat Res** 1997 Aug; 387(1):47–53 (56 ref.)

Assessment of the effects of developmental toxicants: pharmacological and stress vulnerability of offspring. Spear LP. **NIDA Res Monogr** 1996;164:125–45 (42 ref.)

Similarities in genetic mental retardation and neuroteratogenic syndromes. Adams J. **Pharmacol Biochem Behav** 1996 Dec;55(4):683–90 (75 ref.)

Teratogenic actions of ethanol in the mouse: a minireview. Becker HC, et al. **Pharmacol Biochem Behav** 1996 Dec; 55(4):501–13 (129 ref.)

Neurotoxicology and amino acid intake during development: the case of threonine. Castagne V, et al. **Pharmacol Biochem Behav** 1996 Dec;55(4):653–62 (138 ref.)

Paternal exposures: impact on reproductive and developmental outcome. An overview. Friedler G. **Pharmacol Biochem Behav** 1996 Dec;55(4):691–700 (135 ref.)

What research with animals is telling us about alcohol–related neurodevelopmental disorder. Hannigan JH. **Pharmacol Biochem Behav** 1996 Dec;55(4):489–99 (207 ref.)

Monoamine transporters and the neurobehavioral teratology of cocaine. Meyer JS, et al. **Pharmacol Biochem Behav** 1996 Dec;55(4):585–93 (108 ref.)

Methodological considerations in neurobehavioral teratology. Spear LP, et al. **Pharmacol Biochem Behav** 1996 Dec;55(4):455–7 (22 ref.)

Advances in understanding mechanisms of toxicity and implications for risk assessment. Daston GP. **Reprod Toxicol** 1997 Mar–Jun;11(2–3):389–96 (48 ref.)

New approaches for assessing the etiology and risks of developmental abnormalities from chemical exposure. Goldman LR. **Reprod Toxicol** 1997 Mar–Jun; 11(2–3):443–51 (62 ref.)

Recent advances in mathematical modeling of developmental abnormalities using mechanistic information. Kavlock RJ. **Reprod Toxicol** 1997 Mar–Jun;11(2–3):423–34 (86 ref.)

Pharmacokinetics, pharmacodynamics, and prediction of developmental abnormalities. O'Flaherty EJ. **Reprod Toxicol** 1997 Mar–Jun;11(2–3):413–6 (28 ref.)

Linking etiologies in humans and animal models: studies of autism. Rodier PM, et al. **Reprod Toxicol** 1997 Mar–Jun; 11(2–3):417–22 (24 ref.)

Never–ending tales of the mode of the teratogenic action of thalidomide [comment] Neubert D. **Teratog Carcinog Mutagen** 1997;17(1):i–ii (11 ref.) Comment on: Teratog Carcinog Mutagen 1997 ;17(1):1–5.

Teratogen update: polychlorinated biphenyls. Jacobson JL, et al. **Teratology** 1997 May;55(5):338–47 (91 ref.)

The safety of fluoxetine during pregnancy and lactation. Nulman I, et al. **Teratology** 1996 May;53(5):304–8 (33 ref.)

Teratogen update: smoking and reproductive outcomes. Werler MM. **Teratology** 1997 Jun;55(6):382–8 (101 ref.)

Teratogen update: toluene. Wilkins–Haug L. **Teratology** 1997 Feb;55(2):145–51 (45 ref.)

Review of the role of potential teratogens in the origin of human nonsyndromic oral clefts. Wyszynski DF, et al. **Teratology** 1996 May;53(5):309–17 (98 ref.)

TERATOID TUMOR see **TERATOMA**

TERATOLOGY

METHODS

Methodological considerations in neurobehavioral teratology. Spear LP, et al. **Pharmacol Biochem Behav** 1996 Dec;55(4):455–7 (22 ref.)

TRENDS

Immunoteratology: where we are and where to go. Toder V, et al. **Am J Reprod Immunol** 1996 Feb;35(2):114–7 (33 ref.)

TERATOMA

Teratomas in childhood. Azizkhan RG, et al. **Curr Opin Pediatr** 1996 Jun;8(3):287–92 (15 ref.)

Intramedullary teratoma: case report and review of the literature. Caruso R, et al. **Tumori** 1996 Nov–Dec; 82(6):616–20 (34 ref.)

[Benign pericardial tumor (angioma, lipoma, teratoma)] Natsume T. **Ryoikibetsu Shokogun Shirizu** 1996;(14):295–6 (5 ref.) **(Jpn)**

[Adenomatoid tumor of the epididymis. Report of a new case] Parra Muntaner L, et al. **Arch Esp Urol** 1996 Nov; 49(9):986–8 (8 ref.) (Eng. Abstr.) **(Spa)**

[Epididymal adenomatoid tumors. 2 new cases] Pellicé Vilalta C, et al. **Arch Esp Urol** 1997 Mar;50(2):127–30 (13 ref.) (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

Growing teratoma syndrome after chemotherapy for germ cell tumors of the ovary. Geisler JP, et al. **Obstet Gynecol** 1994 Oct;84(4 Pt 2):719–21 (9 ref.)

COMPLICATIONS

Mediastinal teratoma presenting as massive hemoptysis in an adult. Gunes S, et al. **J Emerg Med** 1997 May–Jun; 15(3):313–6 (14 ref.)

TERATOMA

CONGENITAL

Middle ear teratoma in a newborn. Navarro Cunchillos M, et al. **J Laryngol Otol** 1996 Sep;110(9):875–7 (14 ref.)
Congenital orbital teratoma: a clinicopathologic case report. Bilgiç S, et al. **Ophthal Plast Reconstr Surg** 1997 Jun; 13(2):142–6 (17 ref.)
Fetiform teratoma arising from a tubular intestinal duplication. A probable cause of ruptured exomphalos. Barker GM, et al. **Pediatr Surg Int** 1997 Feb;12(2–3):204–5 (7 ref.)

DIAGNOSIS

Malignant retroperitoneal teratoma: case report and literature review. Renato F, et al. **Acta Urol Belg** 1996 Sep; 64(3):49–54 (19 ref.)
Retrorectal tumors complicating pregnancy. Report of two cases. Sobrado CW, et al. **Dis Colon Rectum** 1996 Oct; 39(10):1176–9 (13 ref.)
Squamous cell carcinoma in mature cystic teratoma in a young woman: a diagnostic and management dilemma. Comerci JT Jr, et al. **Eur J Gynaecol Oncol** 1996; 17(6):501–3 (22 ref.)
A case of intrapulmonary teratoma presenting with hair expectoration. Üstün MO, et al. **Thorac Cardiovasc Surg** 1996 Oct;44(5):271–3 (9 ref.)
Neuroectodermal cyst may be a rare differential diagnosis of fetal sacrococcygeal teratoma: first case report of a prenatally observed neuroectodermal cyst. Bloechle M, et al. **Ultrasound Obstet Gynecol** 1996 Jan;7(1):64–7 (11 ref.)
[A case of mature retroperitoneal teratoma producing CEA] Iwai T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jul; 93(7):491–5 (16 ref.) **(Jpn)**

DRUG THERAPY

The management of poor prognosis teratoma. Welch RS, et al. **Br J Hosp Med** 1996 Sep 4–17;56(5):222–4 (14 ref.)

IMMUNOLOGY

Nonteratoid medulloepithelioma of the retina with electron microscopic and immunohistochemical characterization. Vadmal M, et al. **Pediatr Pathol Lab Med** 1996 Jul–Aug; 16(4):663–72 (17 ref.)

PATHOLOGY

The growing teratoma syndrome in a nongerminomatous germ cell tumor of the pineal gland: a case report and review. O'Callaghan AM, et al. **Cancer** 1997 Sep 1; 80(5):942–7 (32 ref.)
Malignant melanoma arising in mature ovarian cystic teratoma (dermoid cyst). Report of two cases and literature analysis. Davis GL. **Int J Gynecol Pathol** 1996 Oct; 15(4):356–62 (50 ref.)
Congenital orbital teratoma: a clinicopathologic case report. Bilgiç S, et al. **Ophthal Plast Reconstr Surg** 1997 Jun; 13(2):142–6 (17 ref.)
Placental teratoma. A case report and review of the literature. Wang L, et al. **Pathol Res Pract** 1995 Dec;191(12):1267–70; discussion 1270 (21 ref.)
Primary intracranial germ cell tumors: clinicopathologic review of 32 cases. Salzman KL, et al. **Pediatr Pathol Lab Med** 1997 Sep–Oct;17(5):713–27 (23 ref.)
Cervical teratomas [letter; comment] Vujanic GM. **Pediatr Pathol Lab Med** 1995 Jan–Feb;15(1):221–2 (12 ref.) Comment on: Pediatr Pathol 1993 Jan–Feb;13(1):21–7.
Intracranial adult teratoma—a case report. Ziółkowski P. **Pol J Pathol** 1996;47(2):95–6 (10 ref.)
Benign cervical teratoma in an adult: report of a case. Abe H, et al. **Surg Today** 1997;27(5):469–72 (21 ref.)
[Teratoma of the middle ear. Apropos of 4 new cases] Morisseau-Durand MP, et al. **Ann Otolaryngol Chir Cervicofac** 1996;113(6):362–6 (20 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Microendoscopic transoral CO2-laser resection of an extensive nasopharyngeal and oral teratoma. Gunkel AR, et al. **Am J Otolaryngol** 1997 Mar–Apr;18(2):140–4 (14 ref.)
Sacrococcygeal teratoma and anorectal malformation. Ng WT, et al. **Aust N Z J Surg** 1997 Apr;67(4):218–20 (28 ref.)
Before the horse is out of the barn: fetal surgery for hydrops. Bullard KM, et al. **Semin Perinatol** 1995 Dec;19(6):462–73 (84 ref.)

THERAPY

Modern management for testicular teratoma. Read G. **Br J Hosp Med** 1996 Sep 4–17;56(5):218–21 (19 ref.)

ULTRASTRUCTURE

Nonteratoid medulloepithelioma of the retina with electron microscopic and immunohistochemical characterization. Vadmal M, et al. **Pediatr Pathol Lab Med** 1996 Jul–Aug; 16(4):663–72 (17 ref.)
[Epidermoid carcinoma originating from a mature cystic ovarian teratoma. Report of two cases and review of the literature] Pérez Sanchez VM, et al. **Ginecol Obstet Mex** 1997 Jul;65:296–9 (11 ref.) (Eng. Abstr.) **(Spa)**

TERATOMA, CYSTIC see **TERATOMA**

TERATOMA, MATURE see **TERATOMA**

TERBUTALINE

ANALOGS & DERIVATIVES

Clinical pharmacokinetics of bambuterol. Sitar DS. **Clin Pharmacokinet** 1996 Oct;31(4):246–56 (48 ref.)

TERFENADINE

ADVERSE EFFECTS

Strategic proposals to avoid drug interactions during drug development: a lesson from a terfenadine–related drug interaction. Ishizaki T. **J Toxicol Sci** 1996 Dec;21(5):301–3 (15 ref.)

THERAPEUTIC USE

[Inhibitor of chemical mediator release] Fujimura M. **Nippon Rinsho** 1996 Nov;54(11):3029–33 (8 ref.) (Eng. Abstr.) **(Jpn)**

TERIPARATIDE

BLOOD

Secretion of parathyroid hormone–related peptide in patients with multiple myeloma. Beaudreuil J, et al. **Rev Rhum Engl Ed** 1996 Jul–Sep;63(7–8):502–3 (11 ref.)

TERMINAL ADDITION ENZYME see **DNA NUCLEOTIDYLEXOTRANSFERASE**

TERMINAL CARE

see related
HOSPICE CARE
LIFE SUPPORT CARE
PALLIATIVE CARE

Do dying patients really need i.v. fluids? [see comments] Zerwekh JV. **Am J Nurs** 1997 Mar;97(3):26–30; quiz 31 (9 ref.) Comment in: Am J Nurs 1997 May;97(5):16.
Can clinical interventions change care at the end of life? Hanson LC, et al. **Ann Intern Med** 1997 Mar 1;126(5):381–8 (65 ref.)
Consultation in palliative medicine. Weissman DE. **Arch Intern Med** 1997 Apr 14;157(7):733–7 (24 ref.)
Medical management of intestinal obstruction in terminal care. Frank C. **Can Fam Physician** 1997 Feb;43:259–65 (29 ref.)
Bioethics for clinicians: 11. Euthanasia and assisted suicide. Lavery JV, et al. **Can Med Assoc J** 1997 May 15; 156(10):1405–8 (43 ref.)
The family physician and end-of-life care. Schneiderman LJ. **J Fam Pract** 1997 Sep;45(3):259–62 (6 ref.)
How often can we justify parenteral nutrition in terminally ill cancer patients? Fainsinger RL, et al. **J Palliat Care** 1997 Spring;13(1):48–51 (21 ref.)
Palliative care in undergraduate medical education. Status report and future directions [see comments] Billings JA, et al. **JAMA** 1997 Sep 3;278(9):733–8 (95 ref.) Comment in: JAMA 1997 Sep 3;278(9):761–3.
Palliative care: an update on "terminal restlessness". Burke AL. **Med J Aust** 1997 Jan 6;166(1):39–42 (37 ref.)
Resolving conflicts surrounding end-of-life care. Prendergast TJ. **New Horiz** 1997 Feb;5(1):62–71 (33 ref.)
The spiritual dimension of hospice: the secularization of an ideal. Bradshaw A. **Soc Sci Med** 1996 Aug;43(3):409–19 (44 ref.)
Long-term subcutaneous infusion of midazolam for refractory delirium in terminal breast cancer. Ramani S, et al. **South Med J** 1996 Nov;89(11):1101–3 (12 ref.)
Medical futility and appropriate medical care in patients whose death is thought to be imminent. Escalante CP, et al. **Support Care Cancer** 1997 Jul;5(4):274–80 (36 ref.)
When to treat dehydration in a terminally ill patient? Fainsinger RL, et al. **Support Care Cancer** 1997 May; 5(3):205–11 (54 ref.)
[Terminal heart failure; therapeutic strategies. Drug therapy in cases of absence of possibility of heart transplantation: dobutamine therapy, aspects of compassion?] Roul G, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89 Spec No 6:27–32 (41 ref.) (Eng. Abstr.) **(Fre)**
[Palliative and supportive care: at the frontiers of medical omnipotence] Stiefel F, et al. **Rev Med Suisse Romande** 1997 Mar;117(3):191–5 (24 ref.) (Eng. Abstr.) **(Fre)**
[Dyspnea in terminal patients—opioid inhalation?] Lozober Z, et al. **Harefuah** 1997 Jan 15;132(2):120–4 (32 ref.) **(Heb)**
[Terminal care for the aged] Kashiwagi T. **Nippon Ronen Igakkai Zasshi** 1996 Jul;33(7):496–8 (5 ref.) **(Jpn)**
[Home care for the terminally ill HIV patient] Bascuñana Morejón de Girón J, et al. **An Med Interna** 1997 Feb; 14(2):93–7 (22 ref.) (Eng. Abstr.) **(Spa)**

CLASSIFICATION

Prognoses of seriously ill hospitalized patients on the days before death: implications for patient care and public policy. Lynn J, et al. **New Horiz** 1997 Feb;5(1):56–61 (10 ref.)

ECONOMICS

Futile care: confronting the high costs of dying [see comments] Coppa S. **J Nurs Adm** 1996 Dec;26(12):18–23 (30 ref.) Comment in: J Nurs Adm 1997 Jun;27(6):55.

LEGISLATION & JURISPRUDENCE

Deaths, dying and the euthanasia debate in Australia [editorial; comment] van der Weyden MB. **Med J Aust** 1997 Feb 17;166(4):173–4 (17 ref.) Comment on: Med J Aust 1997 Feb 17;166(4):191–6.

METHODS

Dehydration and provision of fluids in palliative care. What is the evidence? Burge FI. **Can Fam Physician** 1996 Dec; 42:2383–8 (14 ref.)
Symptomatic management of the older person with cancer. Sheehan DC, et al. **Clin Geriatr Med** 1997 Feb;13(1):203–19 (66 ref.)
Guidelines in the care of the dying cancer patient. Cherny NI, et al. **Hematol Oncol Clin North Am** 1996 Feb; 10(1):261–86 (109 ref.)
Psychiatric emergencies in terminally ill cancer patients. Roth AJ, et al. **Hematol Oncol Clin North Am** 1996 Feb; 10(1):235–59 (71 ref.)
Intractable pain in children with terminal cancer. Collins JJ. **J Palliat Care** 1996 Autumn;12(3):29–34 (43 ref.)
Refractory symptoms and terminal sedation of children: ethical issues and practical management. Kenny NP, et al. **J Palliat Care** 1996 Autumn;12(3):40–5 (22 ref.)
Caring for the terminally ill adolescent. Carr-Gregg MR, et al. **Med J Aust** 1997 Mar 3;166(5):255–8 (24 ref.)
Dehydration in the terminally ill—iatrogenic insult or natural process? Chadfield-Mohr SM, et al. **Postgrad Med J** 1997 Aug;73(862):476–80 (35 ref.)
[Terminal care medicine—basic principles and perspectives] Knupp B, et al. **Med Klin** 1997 Feb 15;92(2):106–11 (53 ref.) **(Ger)**

PSYCHOLOGY

Psychosocial and spiritual issues in terminal care. Kashiwagi T. **Psychiatry Clin Neurosci** 1995 May;49 Suppl 1:S123–7 (4 ref.)

STANDARDS

End-of-life care in The Netherlands and the United States: a comparison of values, justifications, and practices. Quill TE, et al. **Camb Q Healthc Ethics** 1997 Spring;6(2):189–204 (127 ref.)
Outcome measures in palliative care for advanced cancer patients: a review. Hearn J, et al. **J Public Health Med** 1997 Jun;19(2):193–9 (22 ref.)
The fallacies of death causation in palliative care [editorial; comment] Ashby M. **Med J Aust** 1997 Feb 17;166(4):176–7 (14 ref.) Comment on: Med J Aust 1997 Feb 17;166(4):191–6.
Environments that support ethical practice. Rushton CH, et al. **New Horiz** 1997 Feb;5(1):20–9 (55 ref.)

TERMINAL DEOXYRIBONUCLEOTIDYLTRANSFERASE see **DNA NUCLEOTIDYLEXOTRANSFERASE**

TERMINAL REPEAT see **REPETITIVE SEQUENCES, NUCLEIC ACID**

TERMINALLY ILL

Pain management at the end of life. Dickey NW. **J Orthop Sports Phys Ther** 1996 Oct;24(4):237–9 (11 ref.)
The ethics of death-hastening or death-causing palliative analgesic administration to the terminally ill [see comments] Cavanaugh TA. **J Pain Symptom Manage** 1996 Oct; 12(4):248–54 (18 ref.) Comment in: J Pain Symptom Manage 1997 Jul;14(1):2. Comment in: J Pain Symptom Manage 1997 Jul;14(1):2–4.

PSYCHOLOGY

Practical issues in physician-assisted suicide [see comments] Drickamer MA, et al. **Ann Intern Med** 1997 Jan 15; 126(2):146–51 (38 ref.) Comment in: Ann Intern Med 1997 Jul 15;127(2):174.
Psychoanalytic observations on the "gift" technique in the treatment of the dying patient: a case report. Garcia EE. **Psychoanal Rev** 1996 Jun;83(3):395–418 (39 ref.)

TERMINALS, COMPUTER see **COMPUTER TERMINALS**

TERMINATOR CODON see **CODON, TERMINATOR**

TERMINATOR REGIONS (GENETICS)

Control of transcription termination in prokaryotes. Henkin TM. **Annu Rev Genet** 1996;30:35–57 (87 ref.)
Analysis of point mutations by use of amber stop codon suppression. Lesley SA. **Methods Mol Biol** 1996;57:65–73 (6 ref.)

TERMINOLOGY see **NOMENCLATURE**

TERPENE PHOSPHATES see **POLYISOPRENYL PHOSPHATES**

TERPENES

CHEMICAL SYNTHESIS

Cytochrome P-450 in plant/insect interactions: geraniol 10-hydroxylase and the biosynthesis of iridoid monoterpenoids. Hallahan DL, et al. **Drug Metabol Drug Interact** 1995;12(3-4):369-82 (44 ref.)

METABOLISM

Metabolism of Eucalyptus terpenes by herbivorous marsupials. McLean S, et al. **Drug Metab Rev** 1997 Feb-May;29(1-2):213-8 (27 ref.)

The biosynthesis of C5-C25 terpenoid compounds. Dewick PM. **Nat Prod Rep** 1997 Apr;14(2):111-44 (260 ref.)

PHARMACOLOGY

Monoterpenes as regulators of malignant cell proliferation. Hohl RJ. **Adv Exp Med Biol** 1996;401:137-46 (43 ref.)

THERAPEUTIC USE

Antitumorigenic effects of limonene and perillyl alcohol against pancreatic and breast cancer. Crowell PL, et al. **Adv Exp Med Biol** 1996;401:131-6 (23 ref.)

Cancer chemoprevention and therapy by monoterpenes. Gould MN. **Environ Health Perspect** 1997 Jun;105 Suppl 4:977-9 (15 ref.)

TOXICITY

d-limonene mechanistic data and risk assessment: absolute species-specific cytotoxicity, enhanced cell proliferation, and tumor promotion. Whysner J, et al. **Pharmacol Ther** 1996;71(1-2):127-36 (44 ref.)

TERRORISM see **VIOLENCE**

TESCHEN DISEASE VIRUS see **ENTEROVIRUSES, PORCINE**

TEST-TUBE FERTILIZATION see **FERTILIZATION IN VITRO**

TESTICULAR DISEASES

Segmental hemorrhagic infarction of testicle. Baratelli GM, et al. **J Urol** 1996 Oct;156(4):1442 (3 ref.)

Bilateral intratesticular cysts--a specific entity. Lam KY. **Scand J Urol Nephrol** 1996 Aug;30(4):329-31 (11 ref.)

[Testicular varicocele in adolescence--a complicated and unsolved enigma] Bar-On E, et al. **Harefuah** 1996 Nov 1;131(9):327-31 (45 ref.) **(Heb)**

COMPLICATIONS

Cystic dysplasia of the rete testis: a benign congenital lesion associated with ipsilateral urological anomalies. Wojcik LJ, et al. **J Urol** 1997 Aug;158(2):600-4 (14 ref.)

[Testicular ectopy in children. Current practical attitude] Allouch G. **J Urol (Paris)** 1996;102(3):99-101 (6 ref.) (Eng. Abstr.) **(Fre)**

[Testicular microlithiasis associated with infertility] González Sánchez FJ, et al. **Arch Esp Urol** 1997 Jan-Feb;50(1):71-4 (12 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

MR imaging of scrotal, testicular, and penile diseases. Sica GT, et al. **Magn Reson Imaging Clin N Am** 1996 Aug; 4(3):545-63 (27 ref.)

DRUG THERAPY

Androgen replacement therapy. Wang C, et al. **Curr Ther Endocrinol Metab** 1997;6:331-7 (5 ref.)

PATHOLOGY

Cystic transformation of the rete testis. Nistal M, et al. **Am J Surg Pathol** 1996 Oct;20(10):1231-9 (27 ref.)

Multilocular renal cyst associated with testicular epidermoid cyst. Radhi JM, et al. **Histopathology** 1996 Oct;29(4):377-9 (4 ref.)

Intrascrotal sarcoidosis: case reports and review. Carmody JP, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Sep; 13(2):129-34 (73 ref.)

PHYSIOPATHOLOGY

[Morphofunctional changes in the testes in hemodynamic disorders] Astrakhantsev AF, et al. **Urol Nefrol (Mosk)** 1996 Sep-Oct;(5):50-1 (49 ref.) **(Rus)**

ULTRASONOGRAPHY

Scrotal ultrasound. Dewbury K. **Br J Hosp Med** 1997 Jan 15-Feb 5;57(1-2):10-4 (16 ref.)

Differential diagnosis of scrotal masses by ultrasound. Hamm B. **Eur Radiol** 1997;7(5):668-79 (51 ref.)

Scrotal imaging. Horstman WG. **Urol Clin North Am** 1997 Aug;24(3):653-71 (106 ref.)

TESTICULAR FEMINIZATION

COMPLICATIONS

Laparoscopic removal of gonads containing on occult seminoma in a woman with complete androgen resistance. Chantilis SJ, et al. **J Am Assoc Gynecol Laparosc** 1994 May; 1(3):277-82 (35 ref.)

DIAGNOSIS

Masculinizing and feminizing syndromes caused by functioning tumors. Masiakos PT, et al. **Semin Pediatr Surg** 1997 Aug;6(3):147-55 (64 ref.)

GENETICS

A clinician looks at androgen resistance. Balducci R, et al. **Steroids** 1996 Apr;61(4):205-11 (66 ref.)

Molecular basis of androgen insensitivity. Brinkmann A, et al. **Steroids** 1996 Apr;61(4):172-5 (30 ref.)

PHYSIOPATHOLOGY

A clinician looks at androgen resistance. Balducci R, et al. **Steroids** 1996 Apr;61(4):205-11 (66 ref.)

TESTICULAR HORMONES

BLOOD

Immunoreactive inhibin, müllerian inhibitory substance, and activin as biochemical markers for juvenile granulosa cell tumors. Silverman LA, et al. **J Pediatr** 1996 Dec; 129(6):918-21 (20 ref.)

GENETICS

Clinical aspects and molecular genetics of the persistent müllerian duct syndrome. Josso N, et al. **Clin Endocrinol (Oxf)** 1997 Aug;47(2):137-44 (44 ref.)

[Cloning of testican/SPOCK in man and mouse. Neuromuscular expression perspectives in pathology] Charbonnier F, et al. **C R Seances Soc Biol Fil** 1997; 191(1):127-33 (20 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

[The persistent müllerian duct syndrome with transverse testicular ectopia. A hypothesis on the role of müllerian inhibiting factor in the process of testicular migration] Asero L, et al. **Pediatr Med Chir** 1997 May-Jun;19(3):223-5 (14 ref.) (Eng. Abstr.) **(Ita)**

SECRETION

Regulation of testicular anti-M ullerian hormone secretion. Rey R, et al. **Eur J Endocrinol** 1996 Aug;135(2):144-52 (78 ref.)

TESTICULAR INTERSTITIAL CELLS see **LEYDIG CELLS**

TESTICULAR NEOPLASMS

Primary testicular non-Hodgkin's lymphoma: a clinical study and review of the literature. Sasai K, et al. **Am J Clin Oncol** 1997 Feb;20(1):59-62 (15 ref.)

Testicular cancer. Oliver RT. **Curr Opin Oncol** 1996 May; 8(3):252-8 (52 ref.)

Testicular cancer: a review. Hawkins C, et al. **Oncol Nurs Forum** 1996 Sep;23(8):1203-11; quiz 1212-3 (58 ref.)

How should a man with testicular cancer be counseled and what information is available to him? Reiker PP. **Semin Urol Oncol** 1996 Feb;14(1):17-22 (16 ref.)

Melanotic neuroectodermal tumor of infancy in the epididymis. Case report and literature review. Kobayashi T, et al. **Urol Int** 1996;57(4):262-5 (28 ref.)

[Vascular testicular tumors] Llarena Ibarguren R, et al. **Arch Esp Urol** 1996 Jun;49(5):474-8 (23 ref.) (Eng. Abstr.) **(Spa)**

[Adenomatoid tumor of the epididymis. Report of a new case] Parra Muntaner L, et al. **Arch Esp Urol** 1996 Nov; 49(9):986-8 (8 ref.) (Eng. Abstr.) **(Spa)**

[Epididymal adenomatoid tumors. 2 new cases] Pellicé Vilalta C, et al. **Arch Esp Urol** 1997 Mar;50(2):127-30 (13 ref.) (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

Leydig cell hyperplasia and adenoma formation: mechanisms and relevance to humans. Clegg ED, et al. **Reprod Toxicol** 1997 Jan-Feb;11(1):107-21 (170 ref.)

CHEMISTRY

Primary malignant mesothelioma of the tunica vaginalis of the testis. Immunohistochemistry and electron microscopy. Berti E, et al. **Pathology** 1997 Feb;29(1):96-9 (20 ref.)

COMPLICATIONS

Adenocarcinoma of the rete testis: report of a case with surgical history of adenomatous hyperplasia of the rete testis. Gruber H, et al. **J Urol** 1997 Oct;158(4):1525-6 (6 ref.)

Spinal cord compression from metastatic Leydig's cell tumor of the testis: case report. Sawin PD, et al. **Neurosurgery** 1996 Feb;38(2):407-11 (53 ref.)

[Gynecomastia and Leydig cell tumor] Catalá Bauset M, et al. **An Med Interna** 1997 Mar;14(3):131-4 (21 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

The role of tumour markers in the diagnosis and treatment of testicular germ cell cancers. Doherty AP, et al. **Br J Urol** 1997 Feb;79(2):247-52 (41 ref.)

Histologic diagnostics of early testicular germ-cell tumor. Holstein AF, et al. **Int J Urol** 1996 May;3(3):165-72 (38 ref.)

Malignant mesothelioma of the tunica vaginalis testis diagnosed by aspiration cytology--a case report with review of literature. Ahmed M, et al. **Int Urol Nephrol** 1996;28(6):793-6 (19 ref.)

Testicular carcinoma. O'Callaghan A, et al. **Postgrad Med J** 1997 Aug;73(862):481-6 (23 ref.)

[Upper gastrointestinal bleeding as the first manifestation of a nonseminomatous testicular carcinoma] Weidmann B, et al. **Dtsch Med Wochenschr** 1996 Nov 15;121(46):1428-32 (33 ref.) (Eng. Abstr.) **(Ger)**

[An interdisciplinary consensus conference on the diagnosis and therapy of testicular tumors] Bamberg M, et al. **Strahlenther Onkol** 1997 Aug;173(8):397-406 (28 ref.) (Eng. Abstr.) **(Ger)**

[Diagnosis and therapy of testicular tumors] Albers P. **Urologe A** 1997 Jul;36(4):387-96 (5 ref.) **(Ger)**

DRUG THERAPY

High-dose chemotherapy as salvage treatment for germ cell tumors. The ongoing IT94 study. Pico JL, et al. **Bone Marrow Transplant** 1996 Sep;18 Suppl 1:S63-6 (31 ref.)

The management of poor prognosis teratoma. Welch RS, et al. **Br J Hosp Med** 1996 Sep 4-17;56(5):222-4 (14 ref.)

Adjuvant therapy for stage I testicular cancer. Cullen M, et al. **Cancer Treat Rev** 1996 Jul;22(4):253-64 (38 ref.)

Future trials in germ cell malignancy (GCM) of the testis. Oliver RT. **Eur J Surg Oncol** 1997 Apr;23(2):117-22 (29 ref.)

Fertility after chemotherapy for testicular germ cell cancer. Pont J, et al. **Fertil Steril** 1997 Jul;68(1):1-5 (45 ref.)

Sexual dysfunction in nonseminoma testicular cancer patients is related to chemotherapy-induced angiopathy. van Basten JP, et al. **J Clin Oncol** 1997 Jun;15(6):2442-8 (55 ref.)

Residual masses after chemotherapy for metastatic testicular cancer: the clinical implications of the association between retroperitoneal and pulmonary histology. Re-analysis of Histology in Testicular Cancer (ReHiT) Study Group. Steyerberg EW, et al. **J Urol** 1997 Aug;158(2):474-8 (23 ref.)

Adjuvant chemotherapy for stage II nonseminomatous testicular cancer: what is its role? Motzer RJ. **Semin Urol Oncol** 1996 Feb;14(1):30-3 (28 ref.)

Late relapse of nonseminomatous germ cell tumor of the testis: successful treatment with salvage chemotherapy alone. Papadimitris C, et al. **Urology** 1997 Mar;49(3):469-70 (7 ref.)

The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tumors. Bokemeyer C, et al. **World J Urol** 1996;14(6):354-9 (37 ref.)

EPIDEMIOLOGY

Late relapse of germ cell tumors after cisplatin-based chemotherapy. Gerl A, et al. **Ann Oncol** 1997 Jan;8(1):41-7 (28 ref.)

Testis cancer. Oliver RT. **Curr Opin Oncol** 1997 May; 9(3):287-94 (52 ref.)

ETIOLOGY

[A case of testicular tumor in a patient with Down's syndrome: a case report] Nakamura K, et al. **Hinyokika Kiyo** 1996 Oct;42(10):747-9 (14 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

An excess of testicular germ cell tumors in Down's syndrome: three case reports and a review of the literature. Satgé D, et al. **Cancer** 1997 Sep 1;80(5):929-35 (56 ref.)

Use of fluorescence in situ hybridization and comparative genomic hybridization in the cytogenetic analysis of testicular germ cell tumors and uveal melanomas. Becher R, et al. **Cancer Genet Cytogenet** 1997 Jan;93(1):22-8 (70 ref.)

Molecular mechanisms of testicular carcinogenesis. Rukstalis DB. **World J Urol** 1996;14(5):347-52 (46 ref.)

PATHOLOGY

Metastatic testicular choriocarcinoma of the skin. Report and review of the literature. Shimizu S, et al. **Am J Dermatopathol** 1996 Dec;18(6):633-6 (9 ref.)

Primary mediastinal germ cell tumor with intratubular germ cell neoplasia of the testis--further support for germ cell origin of these tumors: a case report. Hailemariam S, et

al. **Cancer** 1997 Mar 1;79(5):1031–6 (43 ref.)

Prognostic risk factors in low stage testicular germ cell tumors: unanswered questions regarding clinically useful prognosticators for extratesticular disease [editorial; comment] Heidenreich A, et al. **Cancer** 1997 May 1; 79(9):1641–5; discussion 1646 (17 ref.) Comment on: Cancer 1997 May 1;79(9):1710–6.

Retroperitoneal lymphadenectomy in staging and treatment of clinical stage I and II nonseminomatous testis cancer (NSGCT): the development of nerve-sparing techniques. Donohue JP. **Cancer Treat Res** 1996;88:105–19 (20 ref.)

Primary treatment in stage II non-seminomatous germ cell tumours of the testis: a matter of scalpel or drug infusion? Culine S, et al. **Eur J Cancer** 1996 Sep;32A(10):1641–4 (31 ref.)

Malignant germ cell tumours in childhood. Pinkerton CR. **Eur J Cancer** 1997 May;33(6):895–901; discussion 901–2 (15 ref.)

Intracaval extension of germ cell carcinoma: diagnosis via endovascular biopsy and a review of the literature. Fidias P, et al. **Eur Urol** 1997;31(3):376–9 (32 ref.)

Metastatic carcinoma involving the testes. Sharma MC, et al. **Indian J Pathol Microbiol** 1996 Oct;39(4):293–6 (5 ref.)

Is biopsy of the contralateral testis necessary in patients with germ cell tumors? Herr HW, et al. **J Urol** 1997 Oct; 158(4):1331–4 (29 ref.)

Primary squamous cell carcinoma of the testis. Shih DF, et al. **J Urol** 1996 Nov;156(5):1772 (2 ref.)

Residual masses after chemotherapy for metastatic testicular cancer: the clinical implications of the association between retroperitoneal and pulmonary histology. Re-analysis of Histology in Testicular Cancer (ReHiT) Study Group. Steyerberg EW, et al. **J Urol** 1997 Aug;158(2):474–8 (23 ref.)

Malignant Sertoli cell tumor of the testicle in a black man. Zeitlin SI, et al. **J Urol** 1996 Dec;156(6):2006 (3 ref.)

Prognostic factors in low-stage nonseminomatous testicular cancer. Moul JW, et al. **Oncology (Huntingt)** 1996 Sep; 10(9):1359–68, 1374; discussion 1377–8 (65 ref.)

Testicular sex cord-stromal tumors in children: clinicopathologic study of sixteen children with review of the literature. Goswitz JJ, et al. **Pediatr Pathol Lab Med** 1996 May–Jun;16(3):451–70 (40 ref.)

Leydig cell hyperplasia and adenoma formation: mechanisms and relevance to humans. Clegg ED, et al. **Reprod Toxicol** 1997 Jan–Feb;11(1):107–21 (170 ref.)

Should the other testis be biopsied? Daugaard G, et al. **Semin Urol Oncol** 1996 Feb;14(1):8–12 (36 ref.)

Testicular cancer: what staging investigations are indicated? Richie JP. **Semin Urol Oncol** 1996 Feb;14(1):13–6 (20 ref.)

Proper staging techniques in testicular cancer patients. Moul JW. **Tech Urol** 1995 Fall;1(3):126–32 (35 ref.)

Primary plasmacytoma of the testis. Case report and review of the literature. Fischer C, et al. **Urol Int** 1996;56(4):263–5 (15 ref.)

Leiomyosarcoma with osteoclast-like giant cells of the spermatic cord. A case report and review of the literature. Konety BR, et al. **Urol Int** 1996;56(4):259–62 (14 ref.)

Biology of metastases and its clinical implications: testicular germ-cell tumors. Donohue JP, et al. **World J Urol** 1996; 14(3):197–203 (17 ref.)

Adenocarcinoma of the rete testis. Glazier DB, et al. **World J Urol** 1996;14(6):397–400 (25 ref.)

[Role of testicular biopsy in the investigation of a carcinoma in situ] de la Taille A, et al. **Prog Urol** 1997 Apr;7(2):209–14 (27 ref.) (Eng. Abstr.) **(Fre)**

[Bilateral malignant mesothelioma of the tunica vaginalis testis. Apropos of a case] Menut P, et al. **Prog Urol** 1996 Aug–Sep;6(4):587–9 (9 ref.) (Eng. Abstr.) **(Fre)**

[Follow-up of testicular tumors in the metastatic diffusion phase. Current orientation] Mirone V, et al. **Minerva Urol Nefrol** 1997 Jun;49(2):91–4 (13 ref.) (Eng. Abstr.) **(Ita)**

[Testicular lymphomas. A clinico-pathological study of 5 cases and a review of the literature] Zamagni MD, et al. **Recenti Prog Med** 1996 Jun;87(6):275–8 (18 ref.) (Eng. Abstr.) **(Ita)**

[Malignant mesothelioma of the tunica vaginalis: a case report] Machida T, et al. **Hinyokika Kiyo** 1997 Feb; 43(2):161–4 (9 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Sexual functioning after multimodality treatment for disseminated nonseminomatous testicular germ cell tumor. van Basten JP, et al. **J Urol** 1997 Oct;158(4):1411–6 (47 ref.)

[Cancer and male infertility] Botchan A, et al. **Harefuah** 1996 Jun 2;130(11):761–4 (45 ref.) **(Heb)**

PREVENTION & CONTROL

Laparoscopic removal of gonads containing on occult seminoma in a woman with complete androgen resistance. Chantilis SJ, et al. **J Am Assoc Gynecol Laparosc** 1994 May; 1(3):277–82 (35 ref.)

RADIONUCLIDE IMAGING

Possible role of FDG-PET in the evaluation of urologic malignancies. Bender H, et al. **Anticancer Res** 1997 May–Jun;17(3B):1655–60 (28 ref.)

RADIOTHERAPY

Postradiation lower motor neuron syndrome--a case report and brief literature review. Tallaksen CM, et al. **Acta Oncol** 1997;36(3):345–7 (40 ref.)

Management of seminoma of the testis: recommendations based on treatment results. Morgan G, et al. **Aust N Z J Surg** 1997 Jan;67(1):15–20 (26 ref.)

Radiotherapy in stage IIA and IIB testicular seminoma with reduced portals: a prospective multicenter study. Schmidberger H, et al. **Int J Radiat Oncol Biol Phys** 1997 Sep 1;39(2):321–6 (39 ref.)

Radiation-induced sarcoma following curative radiotherapy for testicular seminoma: case report and brief review of the literature. Stein ME, et al. **Tumori** 1997 May–Jun; 83(3):721–3 (14 ref.)

SECONDARY

Metastatic carcinoma involving the testes. Sharma MC, et al. **Indian J Pathol Microbiol** 1996 Oct;39(4):293–6 (5 ref.)

A case of testicular metastasis from carcinoma of the prostate. D'Amico A, et al. **Int Urol Nephrol** 1995;27(5):593–6 (23 ref.)

Spinal cord compression from metastatic Leydig's cell tumor of the testis: case report. Sawin PD, et al. **Neurosurgery** 1996 Feb;38(2):407–11 (53 ref.)

Carcinoma of the sigmoid colon presenting as a scrotal swelling. Bryan NP, et al. **Postgrad Med J** 1997 Jan; 73(855):47–8 (10 ref.)

SURGERY

Management of seminoma of the testis: recommendations based on treatment results. Morgan G, et al. **Aust N Z J Surg** 1997 Jan;67(1):15–20 (26 ref.)

Conservative surgery and quality of life in a young patient with synchronous bilateral embryonal carcinoma. Mearini E, et al. **Eur Urol** 1996;29(1):119–21 (16 ref.)

Surgery for a post-chemotherapy residual mass in seminoma. Herr HW, et al. **J Urol** 1997 Mar;157(3):860–2 (15 ref.)

Prognostic factors in low-stage nonseminomatous testicular cancer. Moul JW, et al. **Oncology (Huntingt)** 1996 Sep; 10(9):1359–68, 1374; discussion 1377–8 (65 ref.)

Current role of retroperitoneal lymph node dissection in testicular cancer. Steele GS, et al. **Oncology (Huntingt)** 1997 May;11(5):717–29; discussion 730–37 passim (56 ref.)

Germ cell tumors. Rescorla FJ. **Semin Pediatr Surg** 1997 Feb; 6(1):29–37 (95 ref.)

Retroperitoneal lymphadenectomy: the traditional treatment option. Jewett MA, et al. **Semin Urol Oncol** 1996 Feb; 14(1):24–9 (16 ref.)

[Orchidectomy in testicular cancer. Variant techniques and tactics] Houdelette P, et al. **Ann Urol (Paris)** 1996; 30(5):264–8 (19 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

High-dose chemotherapy as salvage treatment for germ cell tumors. The ongoing IT94 study. Pico JL, et al. **Bone Marrow Transplant** 1996 Sep;18 Suppl 1:S63–6 (31 ref.)

Modern management for testicular teratoma. Read G. **Br J Hosp Med** 1996 Sep 4–17;56(5):218–21 (19 ref.)

Germ cell tumors. Bajorin DF, et al. **Curr Ther Endocrinol Metab** 1997;6:387–92 (12 ref.)

Current concepts about testicular cancer. van Basten JP, et al. **Eur J Surg Oncol** 1997 Aug;23(4):354–60 (96 ref.)

Metastatic Sertoli cell carcinoma of the testis. Mene MP, et al. **J Am Osteopath Assoc** 1996 Oct;96(10):612–4 (7 ref.)

Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters. Bokemeyer C, et al. **J Cancer Res Clin Oncol** 1996;122(10):575–84 (85 ref.)

Sexual functioning after multimodality treatment for disseminated nonseminomatous testicular germ cell tumor. van Basten JP, et al. **J Urol** 1997 Oct;158(4):1411–6 (47 ref.)

Testicular germ-cell cancer. Bosl GJ, et al. **N Engl J Med** 1997 Jul 24;337(4):242–53 (122 ref.)

Testicular carcinoma. O'Callaghan A, et al. **Postgrad Med J** 1997 Aug;73(862):481–6 (23 ref.)

What are the chances of infertility and should sperm be banked? Ohl DA, et al. **Semin Urol Oncol** 1996 Feb; 14(1):36–44 (80 ref.)

What is the appropriate follow-up after treatment? Sharir S, et al. **Semin Urol Oncol** 1996 Feb;14(1):45–53 (31 ref.)

Secondary acute monocytic leukemia occurring during the treatment of a testicular germ cell tumor. A case report and review of the literature. Nonomura N, et al. **Urol Int** 1997;58(4):239–42 (26 ref.)

[Treatments of testicular cancer and protection of spermatogenesis] Bujan L, et al. **Contracept Fertil Sex** 1996 Jul–Aug;24(7–8):596–602 (34 ref.) (Eng. Abstr.) **(Fre)**

[Risk of secondary neoplasia after treatment of malignant germ cell tumors of the testis] Bokemeyer C, et al. **Med Klin** 1996 Nov 15;91(11):703–10 (51 ref.) **(Ger)**

[Effect of biological prognostic factors on therapy of non-seminomatous stage I testicular tumors--an assessment of the current status] Kuczyk MA, et al. **Urologe A** 1996 Jan;35(1):35–45 (94 ref.) (Eng. Abstr.) **(Ger)**

[Interdisciplinary consensus conference on "diagnosis and therapy of testicular tumors"] Weissbach L, et al. **Urologe A** 1997 Jul;36(4):362–8 (28 ref.) **(Ger)**

[Metallothionein expression as a marker of therapeutic sensitivity in the early stages of testicular cancer] Eid H, et al. **Orv Hetil** 1997 Jan 19;138(3):135–9 (28 ref.) (Eng. Abstr.) **(Hun)**

[Treatment of unusual testicular tumors] Motta M, et al. **Arch Ital Urol Androl** 1997 Feb;69 Suppl 1:3–7 (27 ref.) (Eng. Abstr.) **(Ita)**

ULTRASONOGRAPHY

Testicular ultrasound in Carney complex: report of three cases. Premkumar A, et al. **J Clin Ultrasound** 1997 May; 25(4):211–4 (7 ref.)

Ultrasound assessment of testicular and paratesticular masses. Tessler FN, et al. **J Clin Ultrasound** 1996 Oct;24(8):423–36 (31 ref.)

[Calcifying giant-cell Sertoli tumor: description of a case wtih atypical echographic presentation] Moro U, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):105–8 (19 ref.) (Eng. Abstr.) **(Ita)**

VETERINARY

Tumours of the testis and accessory male sex glands. Ribas JL, et al. **IARC Sci Publ** 1996;(126):261–80 (94 ref.)

TESTICULAR TORSION see **SPERMATIC CORD TORSION**

TESTING, BIOCOMPATIBLE MATERIALS see **MATERIALS TESTING**

TESTIS

see related
ORCHIECTOMY

Transplantation of the testis; from the past to the present. Barten EJ, et al. **Int J Androl** 1996 Aug;19(4):205–11 (72 ref.)

ABNORMALITIES

Severe mental retardation and macroorchidism without mutation in the FMR1 gene. Reyniers E, et al. **Am J Med Genet** 1996 Aug 9;64(2):408–12 (26 ref.)

Testicular exstrophy: bilateral presentation in a newborn. Gupta DK, et al. **J Urol** 1997 Aug;158(2):599 (3 ref.)

[Testicular ectopy in children. Current practical attitude] Allouch G. **J Urol (Paris)** 1996;102(3):99–101 (6 ref.) (Eng. Abstr.) **(Fre)**

[Polyorchidism: a case report and review of the literature] Kuratsukuri K, et al. **Hinyokika Kiyo** 1996 May; 42(5):389–92 (21 ref.) (Eng. Abstr.) **(Jpn)**

ANATOMY & HISTOLOGY

Diagnosing testicular function using 31P magnetic resonance spectroscopy: a current review. van der Grond J. **Hum Reprod Update** 1995 May;1(3):276–83 (57 ref.)

NMR spectroscopy in andrology: research uses and possible clinical applications. Rohr G, et al. **Int J Androl** 1995 Dec; 18 Suppl 2:12–9 (41 ref.)

BLOOD SUPPLY

Segmental hemorrhagic infarction of testicle. Baratelli GM, et al. **J Urol** 1996 Oct;156(4):1442 (3 ref.)

CYTOLOGY

Paracrine regulation of cellular interactions in the testis: factors in search of a function. Schlatt S, et al. **Eur J Endocrinol** 1997 Aug;137(2):107–17 (124 ref.)

Paracrine control of human Leydig cell and Sertoli cell functions. Carreau S. **Folia Histochem Cytobiol** 1996; 34(3–4):111–9 (90 ref.)

Transplantation of testis-derived Sertoli cells into the mammalian brain. Sanberg PR, et al. **Transplant Proc** 1997 Jun;29(4):1926–8 (42 ref.)

DRUG EFFECTS

Histopathology of chemically induced testicular atrophy in rats. Nolte T, et al. **Exp Toxicol Pathol** 1995 Sep; 47(4):267–86 (114 ref.)

Role of the cytokines in the hypothalamic-pituitary-adrenal and gonadal axes. Spangelo BL, et al. **Neuroimmunomodulation** 1995 Sep–Oct;2(5):299–312 (159 ref.)

Evaluation of testicular toxicity in safety evaluation studies: the appropriate use of spermatogenic staging. Creasy DM. **Toxicol Pathol** 1997 Mar–Apr;25(2):119–31 (61 ref.)

EMBRYOLOGY

Fetal testis formation: a critical event for sex determination and differentiation. Matsuo N. **Acta Paediatr Jpn** 1996 Aug; 38(4):377–9 (19 ref.)

The genitofemoral nerve may link testicular inguinoscrotal descent with congenital inguinal hernia. Clarnette TD, et al. **Aust N Z J Surg** 1996 Sep;66(9):612–7 (66 ref.)

Intersex disorders: shedding light on male sexual differentiation beyond SRY. MacLean HE, et al. **Clin Endocrinol (Oxf)** 1997 Jan;46(1):101–8 (62 ref.)

The hormonal control of testicular descent. Levy JB, et al. **J Androl** 1995 Nov–Dec;16(6):459–63 (16 ref.)

GROWTH & DEVELOPMENT

Anatomical and functional aspects of testicular descent and cryptorchidism. Hutson JM, et al. **Endocr Rev** 1997 Apr; 18(2):259–80 (237 ref.)

Expression of follicle stimulating hormone–receptor mRNA during gonadal development. O'Shaughnessy PJ, et al. **Mol Cell Endocrinol** 1996 Dec 20;125(1–2):169–75 (46 ref.)

INJURIES

Ultrasound in the assessment of the acute scrotum. Herbener TE. **J Clin Ultrasound** 1996 Oct;24(8):405–21 (52 ref.)

INNERVATION

The genitofemoral nerve may link testicular inguinoscrotal descent with congenital inguinal hernia. Clarnette TD, et al. **Aust N Z J Surg** 1996 Sep;66(9):612–7 (66 ref.)

Modification of nociceptor responses by inflammatory mediators and second messengers implicated in their action--a study in canine testicular polymodal receptors. Mizumura K, et al. **Prog Brain Res** 1996;113:115–41 (149 ref.)

METABOLISM

The role of cytochrome P450 17 alpha–hydroxylase and 3 beta–hydroxysteroid dehydrogenase in the integration of gonadal and adrenal steroidogenesis via the delta 5 and delta 4 pathways of steroidogenesis in mammals. Conley AJ, et al. **Biol Reprod** 1997 Apr;56(4):789–99 (147 ref.)

Regulation of transcription of the testis–specific histone H1t gene by multiple promoter elements. Grimes SR Jr, et al. **Mol Biol Rep** 1997 Aug;24(3):175–84 (70 ref.)

[Role of extragonadal estrogens and hormonal carcinogenesis] Bershteĭn LM. **Vestn Ross Akad Med Nauk** 1997;(8):54–8 (41 ref.) **(Rus)**

PATHOLOGY

New therapeutic possibilities handling residual azoospermia. Schoysman R, et al. **Acta Eur Fertil** 1995 Jul–Aug; 26(4):131–6 (21 ref.)

Histopathology of chemically induced testicular atrophy in rats. Nolte T, et al. **Exp Toxicol Pathol** 1995 Sep; 47(4):267–86 (114 ref.)

Gonadal cell apoptosis: hormone–regulated cell demise. Billig H, et al. **Hum Reprod Update** 1996 Mar–Apr;2(2):103–17 (167 ref.)

Adenocarcinoma of the rete testis: report of a case with surgical history of adenomatous hyperplasia of the rete testis. Gruber H, et al. **J Urol** 1997 Oct;158(4):1525–6 (6 ref.)

Is biopsy of the contralateral testis necessary in patients with germ cell tumors? Herr HW, et al. **J Urol** 1997 Oct; 158(4):1331–4 (29 ref.)

Should the other testis be biopsied? Daugaard G, et al. **Semin Urol Oncol** 1996 Feb;14(1):8–12 (36 ref.)

Testicular cancer: what staging investigations are indicated? Richie JP. **Semin Urol Oncol** 1996 Feb;14(1):13–6 (20 ref.)

Evaluation of testicular toxicity in safety evaluation studies: the appropriate use of spermatogenic staging. Creasy DM. **Toxicol Pathol** 1997 Mar–Apr;25(2):119–31 (61 ref.)

PHYSIOLOGY

The testis: the witness of the mating system, the site of mutation and the engine of desire. Short RV. **Acta Paediatr Suppl** 1997 Jul;422:3–7 (26 ref.)

Fantasies and facts of the testes. van Basten JP, et al. **Br J Urol** 1996 Nov;78(5):756–62 (63 ref.)

Age–related changes in male gonadal function. Implications for therapy. Maas D, et al. **Drugs Aging** 1997 Jul; 11(1):45–60 (128 ref.)

Gonadal peptides as mediators of development and functional control of the testis: an integrated system with hormones and local environment. Gnessi L, et al. **Endocr Rev** 1997 Aug;18(4):541–609 (844 ref.)

Dendritic cells and macrophages in the pituitary and the gonads. Evidence for their role in the fine regulation of the reproductive endocrine response. Hoek A, et al. **Eur J Endocrinol** 1997 Jan;136(1):8–24 (193 ref.)

Paracrine control of human Leydig cell and Sertoli cell functions. Carreau S. **Folia Histochem Cytobiol** 1996; 34(3–4):111–9 (90 ref.)

Diagnosing testicular function using 31P magnetic resonance spectroscopy: a current review. van der Grond J. **Hum Reprod Update** 1995 May;1(3):276–83 (57 ref.)

Stem cell factor and c–kit in the mammalian testis: lessons originating from Mother Nature's gene knockouts. Loveland KL, et al. **J Endocrinol** 1997 Jun;153(3):337–44 (71 ref.)

Patterns of translational regulation in the mammalian testis. Kleene KC. **Mol Reprod Dev** 1996 Feb;43(2):268–81 (127 ref.)

Growth factors and testicular function: relevance to disorders of spermatogenesis in humans. Smith EP, et al. **Semin Reprod Endocrinol** 1996 Aug;14(3):209–17 (114 ref.)

Scrotal/testicular thermoregulation and the effects of increased testicular temperature in the bull. Kastelic JP, et al. **Vet Clin North Am Food Anim Pract** 1997 Jul; 13(2):271–82 (36 ref.)

[Current views on the structural basis of repair regeneration of testis in mammals and humans] Kurnosova TR, et al. **Biull Eksp Biol Med** 1994 Apr;117(4):396–9 (50 ref.) **(Rus)**

PHYSIOPATHOLOGY

[Morphofunctional changes in the testes in hemodynamic disorders] Astrakhantsev AF, et al. **Urol Nefrol (Mosk)** 1996 Sep–Oct;(5):50–1 (49 ref.) **(Rus)**

SECRETION

Regulation of testicular anti–M ullerian hormone secretion. Rey R, et al. **Eur J Endocrinol** 1996 Aug;135(2):144–52 (78 ref.)

[Function tests for male gonads] Isurugi K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:380–4 (6 ref.) **(Jpn)**

SURGERY

Laparoscopic removal of gonads containing on occult seminoma in a woman with complete androgen resistance. Chantilis SJ, et al. **J Am Assoc Gynecol Laparosc** 1994 May; 1(3):277–82 (35 ref.)

TRANSPLANTATION

[Prospects for clinical transplantation of the testis as an organ and as a tissue] Bozhedomov VA, et al. **Biull Eksp Biol Med** 1994 Apr;117(4):400–4 (71 ref.) **(Rus)**

TESTIS, UNDESCENDED see **CRYPTORCHIDISM**

TESTOSTERONE

BLOOD

Decreased androgen levels and obesity in men. Vermeulen A. **Ann Med** 1996 Feb;28(1):13–5 (26 ref.)

The relationship of natural androgens to coronary heart disease in males: a review. Alexandersen P, et al. **Atherosclerosis** 1996 Aug 23;125(1):1–13 (85 ref.)

Effect of altered reproductive function and lowered testosterone levels on bone density in male endurance athletes. Bennell KL, et al. **Br J Sports Med** 1996 Sep; 30(3):205–8 (59 ref.)

Investigations in the assessment and management of patients with hirsutism. Barth JH. **Curr Opin Obstet Gynecol** 1997 Jun;9(3):187–92 (44 ref.)

DEFICIENCY

[Treatment of erectile disorders with androgens: When? How?] Tostain J, et al. **Prog Urol** 1997 Apr;7(2):314–9 (18 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Testosterone and progesterone metabolism in the central nervous system: cellular localization and mechanism of control of the enzymes involved. Martini L, et al. **Cell Mol Neurobiol** 1996 Jun;16(3):271–82 (60 ref.)

Novel modalities for appraising individual and coordinate pulsatile hormone secretion: the paradigm of luteinizing hormone and testosterone release in the aging male. Veldhuis JD. **Mol Psychiatry** 1997 Jan;2(1):70–80 (56 ref.)

PHARMACOKINETICS

[Finasteride: a new drug for the treatment of male hirsutism and androgenetic alopecia?] Spinucci G, et al. **Clin Ter** 1996 Jun;147(6):305–15 (41 ref.) (Eng. Abstr.) **(Ita)**

PHARMACOLOGY

Sex steroid effects on the development and functioning of the growth hormone axis. Chowen JA, et al. **Cell Mol Neurobiol** 1996 Jun;16(3):297–310 (31 ref.)

PHYSIOLOGY

Olfaction, GABAergic neurotransmission in the olfactory bulb, and intermale aggression in mice: modulation by steroids. Guillot PV, et al. **Behav Genet** 1996 Sep; 26(5):497–504 (65 ref.)

Sex hormones and vascular reactivity. Hutchison SJ, et al. **Herz** 1997 Jun;22(3):141–50 (106 ref.)

Testosterone and the aging male. Tenover JL. **J Androl** 1997 Mar–Apr;18(2):103–6 (14 ref.)

Physiological regulation of the human growth hormone (GH)–insulin–like growth factor type I (IGF–I) axis: predominant impact of age, obesity, gonadal function, and sleep. Veldhuis JD, et al. **Sleep** 1996 Dec;19(10 Suppl):S221–4 (17 ref.)

The effects of testosterone on the cavernous tissue and erectile function. Shabsigh R. **World J Urol** 1997;15(1):21–6 (62 ref.)

[Hormones and male sexual behavior: physiological and physiopathological data] Buvat J. **Contracept Fertil Sex** 1996 Oct;24(10):767–78 (93 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Overgrowth disorders. Sotos JF. **Clin Pediatr (Phila)** 1996 Oct;35(10):517–29 (66 ref.)

Use of androgens in postmenopausal women. Davis SR, et al. **Curr Opin Obstet Gynecol** 1997 Jun;9(3):177–80 (37 ref.)

Progestin–androgen combination regimens for male contraception. Meriggiola MC, et al. **J Androl** 1997 May–Jun;18(3):240–4 (41 ref.)

The use of anti–aging hormones. Melatonin, growth hormone, testosterone, and dehydroepiandrosterone: consumer enthusiasm for unproven therapies. Shomali ME. **Md Med J** 1997 Apr;46(4):181–6 (45 ref.)

[Treatment of erectile disorders with androgens: When? How?] Tostain J, et al. **Prog Urol** 1997 Apr;7(2):314–9 (18 ref.) (Eng. Abstr.) **(Fre)**

URINE

Issues in detecting abuse of xenobiotic anabolic steroids and testosterone by analysis of athletes' urine. Catlin DH, et al. **Clin Chem** 1997 Jul;43(7):1280–8 (56 ref.)

TESTOSTERONE 5–ALPHA–REDUCTASE

ANTAGONISTS & INHIBITORS

Prostate disease in older men: 1. Benign hyperplasia. Albertsen PC. **Hosp Pract (Off Ed)** 1997 May 15;32(5):61–4, 67–8, 77 passim (6 ref.)

5 alpha–reductase inhibitors--a new hope in dermatology? Amichai B, et al. **Int J Dermatol** 1997 Mar;36(3):182–4 (28 ref.)

Pharmacological options in the treatment of benign prostatic hyperplasia. Kenny B, et al. **J Med Chem** 1997 Apr 25; 40(9):1293–315 (146 ref.)

[Significance of 5–alpha–reductase inhibitors in therapy of benign prostatic hyperplasia with mild to modern symptoms] Wirth MP, et al. **Urologe A** 1997 Jan;36(1):35–9 (20 ref.) (Eng. Abstr.) **(Ger)**

DEFICIENCY

5 alpha–reductase–2 deficiency. Imperato–McGinley J. **Curr Ther Endocrinol Metab** 1997;6:384–7 (5 ref.)

METABOLISM

Increased scalp skin and serum 5 alpha–reductase reduced androgens in a man relevant to the acquired progressive kinky hair disorder and developing androgenetic alopecia. Boudou P, et al. **Arch Dermatol** 1997 Sep;133(9):1129–33 (44 ref.)

TESTOSTERONE DEHYDROGENASES see **17–HYDROXYSTEROID DEHYDROGENASES**

TESTOSTERONE DELTA–4–5–ALPHA–REDUCTASE see **TESTOSTERONE 5–ALPHA–REDUCTASE**

TESTOSTERONE–ESTRADIOL BINDING GLOBULIN see **SEX HORMONE–BINDING GLOBULIN**

TESTOSTERONE PROPIONATE see **TESTOSTERONE**

TETANUS

ETIOLOGY

Severe tetanus in a patient with ulcerating inflammatory breast carcinoma. A case report and review of management. Toh HC, et al. **Acta Oncol** 1997;36(1):94–6 (22 ref.)

PHYSIOPATHOLOGY

Unforgettable tetanus. Attygalle D, et al. **Eur J Anaesthesiol** 1997 Mar;14(2):122–33 (83 ref.)

PREVENTION & CONTROL

Performance and potency of tetanus toxoid: implications for eliminating neonatal tetanus. Dietz V, et al. **Bull World Health Organ** 1996;74(6):619–28 (34 ref.)

Factors affecting the immunogenicity and potency of tetanus toxoid: implications for the elimination of neonatal and non–neonatal tetanus as public health problems. Dietz V, et al. **Bull World Health Organ** 1997;75(1):81–93 (75 ref.)

Tetanus and diphtheria immunization/prophylaxis adults and older adults. **Nurse Pract** 1997 Mar;22(3):116, 119–20 (11 ref.)

THERAPY

The management of tetanus 1996. Sanders RK. **Trop Doct** 1996 Jul;26(3):107–15 (25 ref.)

TETANUS TOXIN

CHEMISTRY

Tetanus and botulism neurotoxins: a novel group of zinc–endopeptidases. Tonello F, et al. **Adv Exp Med Biol** 1996;389:251–60 (47 ref.)

Structure and function of tetanus and botulinum neurotoxins. Montecucco C, et al. **Q Rev Biophys** 1995 Nov;28(4):423–72 (335 ref.)

Botulinum versus tetanus neurotoxins: why is botulinum neurotoxin but not tetanus neurotoxin a food poison? Singh BR, et al. **Toxicon** 1995 Dec;33(12):1541–7 (48 ref.)

TETANUS TOXIN

PHARMACOLOGY

[Action mechanisms of botulinum neurotoxins and tetanus neurotoxins] Deloye F, et al. **C R Seances Soc Biol Fil** 1997;191(3):433–50 (85 ref.) (Eng. Abstr.) **(Fre)**

TOXICITY

Botulinum and tetanus neurotoxins: emerging tools for the study of membrane fusion. Jahn R, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:329–35 (66 ref.)

Structure and function of tetanus and botulinum neurotoxins. Montecucco C, et al. **Q Rev Biophys** 1995 Nov;28(4):423–72 (335 ref.)

TETANUS TOXOID

Performance and potency of tetanus toxoid: implications for eliminating neonatal tetanus. Dietz V, et al. **Bull World Health Organ** 1996;74(6):619–28 (34 ref.)

ADMINISTRATION & DOSAGE

[Pre- and postgestational vaccination] Figueroa-Damián R. **Ginecol Obstet Mex** 1996 Jul;64:310–5 (27 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Factors affecting the immunogenicity and potency of tetanus toxoid: implications for the elimination of neonatal and non-neonatal tetanus as public health problems. Dietz V, et al. **Bull World Health Organ** 1997;75(1):81–93 (75 ref.)

METABOLISM

Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model [published erratum appears in Vaccine 1996 Sep;14(13):1298] Devi SJ. **Vaccine** 1996 Jun;14(9):841–4 (29 ref.)

TETANUS VACCINE see **TETANUS TOXOID**

TETANY

CHEMICALLY INDUCED

Oral Fleet Phospho-Soda laxative-induced hyperphosphatemia and hypocalcemic tetany in an adult: report of a case. Vukasin P, et al. **Dis Colon Rectum** 1997 Apr;40(4):497–9 (11 ref.)

COMPLICATIONS

An incidental finding of Gitelman's syndrome. Leonard MB, et al. **Br J Clin Pract** 1997 Mar;51(2):121–4 (17 ref.)

TETHERED CORD SYNDROME see **SPINA BIFIDA OCCULTA**

TETRACEMATE see **EDETIC ACID**

TETRACHLORODIBENZODIOXIN

ANALOGS & DERIVATIVES

Food control surveys of polychlorinated dibenzo-p-dioxins and dibenzofurans and intake estimates. Hallikainen A, et al. **Food Addit Contam** 1997 May-Jun;14(4):355–66 (64 ref.)

Gas chromatographic analysis of polychlorinated dibenzo-p-dioxins and dibenzofurans. Singh SB, et al. **J Chromatogr A** 1997 Jul 11;774(1-2):97–109 (98 ref.)

Estimating relative potency for receptor-mediated toxicity: reevaluating the toxicity equivalence factor (TEF) model. Putzrath RM. **Regul Toxicol Pharmacol** 1997 Feb; 25(1):68–78 (45 ref.)

Breast-feeding exposure of infants to environmental contaminants—a public health risk assessment viewpoint: chlorinated dibenzodioxins and chlorinated dibenzofurans. Pohl HR, et al. **Toxicol Ind Health** 1996 Sep-Oct; 12(5):593–611 (98 ref.)

TOXICITY

Differential effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin, bis(tri-n-butyltin) oxide and cyclosporine on thymus histophysiology. De Waal EJ, et al. **Crit Rev Toxicol** 1997 Jul;27(4):381–430 (460 ref.)

Considerations on genetic and environmental factors that contribute to resistance or sensitivity of mammals including humans to toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds. Part 1: Genetic factors affecting the toxicity of TCDD. Geyer HJ, et al. **Ecotoxicol Environ Saf** 1997 Apr;36(3):213–30 (133 ref.)

The role of the aryl hydrocarbon receptor in animal development, physiological homeostasis and toxicity of TCDD. Gonzalez FJ, et al. **J Toxicol Sci** 1996 Dec; 21(5):273–7 (9 ref.)

2,3,7,8-Tetrachlorodibenzo-p-dioxin mechanistic data and risk assessment: gene regulation, cytotoxicity, enhanced cell proliferation, and tumor promotion. Whysner J, et al. **Pharmacol Ther** 1996;71(1-2):193–223 (167 ref.)

Latent effects of pesticides and toxic substances on sexual differentiation of rodents. Gray LE Jr, et al. **Toxicol Ind Health** 1996 May-Aug;12(3-4):515–31 (38 ref.)

Selected lesions of dioxin in laboratory rodents. Mann PC. **Toxicol Pathol** 1997 Jan-Feb;25(1):72–9 (25 ref.)

TETRACHLOROETHYLENE

Tetrachloroethylene. **IARC Monogr Eval Carcinog Risks Hum** 1995;63:159–221 (272 ref.)

Dry cleaning. **IARC Monogr Eval Carcinog Risks Hum** 1995; 63:33–71 (119 ref.)

ANALYSIS

[Total environmental exposure to chlorinated solvents: studies of exposure markers] Pregliasco F, et al. **Ann Ig** 1996 May-Jun;8(3):361–75 (56 ref.) (Eng. Abstr.) **(Ita)**

TOXICITY

Categorical regression analysis of acute exposure to tetrachloroethylene. Guth DJ, et al. **Risk Anal** 1997 Jun; 17(3):321–32 (36 ref.)

TETRACOSACTIDE see **COSYNTROPIN**

TETRACOSACTRIN see **COSYNTROPIN**

TETRACYCLINE

ADMINISTRATION & DOSAGE

Five-year results of the treatment of 23 patients with immunoproliferative small intestinal disease: a Turkish experience. Akbulut H, et al. **Cancer** 1997 Jul 1;80(1):8–14 (19 ref.)

TETRACYCLINE ANTIBIOTICS see **ANTIBIOTICS, TETRACYCLINE**

TETRACYCLINE RESISTANCE

Tetracycline resistance mediated by ribosomal protection. Taylor DE, et al. **Antimicrob Agents Chemother** 1996 Jan; 40(1):1–5 (41 ref.)

[Bacterial resistance mechanisms for tetracyclines] Yamaguchi A. **Nippon Rinsho** 1997 May;55(5):1245–51 (15 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Tetracycline resistance determinants: mechanisms of action, regulation of expression, genetic mobility, and distribution. Roberts MC. **FEMS Microbiol Rev** 1996 Oct;19(1):1–24 (131 ref.)

TETRACYCLINES

METABOLISM

[Bacterial resistance mechanisms for tetracyclines] Yamaguchi A. **Nippon Rinsho** 1997 May;55(5):1245–51 (15 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

[Tetracyclines as anti-inflammatory treatment in skin diseases] Autio P, et al. **Nord Med** 1996 Dec;111(10):348–51 (15 ref.) (Eng. Abstr.) **(Swe)**

TETRADECANOIC ACIDS see **MYRISTIC ACIDS**

TETRAETHYL LEAD

TOXICITY

Leaded gasoline abuse: the role of tetraethyl lead. Tenenbein M. **Hum Exp Toxicol** 1997 Apr;16(4):217–22 (44 ref.)

TETRAETHYLTHIURAM DISULFIDE see **DISULFIRAM**

TETRAGASTRIN

see related
GASTROINTESTINAL AGENTS

TETRAGASTRIN RECEPTORS see **RECEPTORS, CHOLECYSTOKININ**

TETRAHYDRO-1,4-OXAZINES see **MORPHOLINES**

TETRAHYDROAMINOACRIDINE see **TACRINE**

TETRAHYDROCANNABINOL

ADVERSE EFFECTS

Cannabinoids and immunity to Legionella pneumophila infection. Klein TW, et al. **Adv Exp Med Biol** 1996; 402:103–9 (20 ref.)

Cannabinoids and immunity to viruses. Specter S. **Adv Exp Med Biol** 1996;402:131–4 (11 ref.)

ANALOGS & DERIVATIVES

Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. Shohami E, et al. **J Neuroimmunol** 1997 Feb;72(2):169–77 (60 ref.)

THERAPEUTIC USE

Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. Voth EA, et al. **Ann Intern Med** 1997 May 15; 126(10):791–8 (92 ref.)

TETRAHYDROFOLATE DEHYDROGENASE

DRUG EFFECTS

Drug-resistant dihydrofolate reductases: generation, expression and therapeutic application. McIvor RS. **Bone Marrow Transplant** 1996 Dec;18 Suppl 3:S50–4 (19 ref.)

GENETICS

Molecular mechanisms of resistance to antifolates, a review. Banerjee D, et al. **Acta Biochim Pol** 1995;42(4):457–64 (56 ref.)

TETRAHYDRONAPHTHALENES

PHARMACOLOGY

Pharmacologic and pharmacokinetic profile of mibefradil, a T- and L-type calcium channel antagonist. Abernethy DR. **Am J Cardiol** 1997 Aug 21;80(4B):4C–11C (34 ref.)

Pharmacologic and therapeutic differences among calcium channel antagonists: profile of mibefradil, a new calcium antagonist. Triggle DJ. **Am J Cardiol** 1996 Nov 7; 78(9A):7–12 (41 ref.)

TETRAHYDROPTEROYLGLUTAMATE METHYLTRANSFERASE

CHEMISTRY

Structure-based perspectives on B12-dependent enzymes. Ludwig ML, et al. **Annu Rev Biochem** 1997;66:269–313 (155 ref.)

DEFICIENCY

Functional methionine synthase deficiency due to cblG disorder: a report of two patients and a review. Harding CO, et al. **Am J Med Genet** 1997 Sep 5;71(4):384–90 (22 ref.)

TETRAHYMENA

CYTOLOGY

[Molecular mechanism of cell division in tetrahymena] Numata O. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1883–90 (63 ref.) **(Jpn)**

ENZYMOLOGY

Adenylate and guanylate cyclases in Tetrahymena. Umeki S, et al. **Prog Mol Subcell Biol** 1996;17:40–60 (84 ref.)

[A mammalian telomerase component gene TLP1] Ishikawa F, et al. **Tanpakushitsu Kakusan Koso** 1997 Jul; 42(9):1407–19 (21 ref.) **(Jpn)**

GENETICS

Programmed DNA deletions in Tetrahymena: mechanisms and implications. Yao MC. **Trends Genet** 1996 Jan; 12(1):26–30 (28 ref.)

TETRAHYMENA THERMOPHILA

PHYSIOLOGY

Cell death, survival and proliferation in Tetrahymena thermophila. Effects of insulin, sodium nitroprusside, 8-Bromo cyclic GMP, NG-methyl-L-arginine and methylene blue. Christensen ST, et al. **Cell Biol Int** 1996 Oct;20(10):653–66 (78 ref.)

L-3,5,3',5'-TETRAIODOTHYRONINE see **LEVOTHYROXINE**

TETRALINS see **TETRAHYDRONAPHTHALENES**

TETRALOGY OF FALLOT

The floating harbor syndrome with cardiac septal defect. Lazebnik N, et al. **Am J Med Genet** 1996 Dec 18; 66(3):300–2 (23 ref.)

[Tetralogy of Fallot] Sekiguchi M. **Ryoikibetsu Shokogun Shirizu** 1996;(13):15–9 (19 ref.) **(Jpn)**

COMPLICATIONS

Tetralogy of Fallot, absent pulmonary valve and coarctation of the aorta [letter; comment] Momma K. **Int J Cardiol** 1996 Jun;54(3):287 (5 ref.) Comment on: Int J Cardiol 1995 Dec;52(3):203–6.

GENETICS

Facial asymmetry, cardio-vascular anomalies and adducted thumbs as unusual symptoms in Dubowitz syndrome? Vogels A, et al. **Ann Genet** 1996;39(1):31–4 (23 ref.)

SURGERY

[Successful scartectomy and cryoablation for ventricular tachycardia occurring late after correction of tetralogy of Fallot] Hanada T, et al.
Nippon Kyobu Geka Gakkai Zasshi 1996 May;44(5):664–7 (10 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

[Fallot's tetralogy: current status of its treatment] Herráiz Sarachaga JI, et al. **Rev Esp Cardiol** 1996 Feb;49(2):88–96 (72 ref.) (Eng. Abstr.) **(Spa)**

L-TETRAMISOLE see **LEVAMISOLE**

TETRANITROMETHANE

Tetranitromethane.
IARC Monogr Eval Carcinog Risks Hum 1996;65:437–48 (38 ref.)

TETRANUCLEOTIDE REPEATS see **MICROSATELLITE REPEATS**

TETRAPLEGIA see **QUADRIPLEGIA**

TETRAZOLES

The clinical pharmacology of losartan in Japanese subjects and patients. Nakashima M, et al. **Blood Press Suppl** 1996; 2:62–6 (13 ref.)

Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Markham A, et al. **Drugs** 1997 Aug;54(2):299–311 (50 ref.)

[Molecular biology of angiotensin II receptor and clinical application of the antagonist] Hiwada K.
Nippon Naika Gakkai Zasshi 1994 Jan 10;83(1):143–8 (15 ref.) **(Jpn)**

ADVERSE EFFECTS

Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension. Mallion JM, et al. **Blood Press Suppl** 1996; 2:82–6 (14 ref.)

Commentary: do angiotensin II receptor antagonists regress left ventricular hypertrophy? Lip GY.
J Hum Hypertens 1996 Nov;10(11):725–7 (28 ref.)

ECONOMICS

Medical and cost-economy aspects of modern antihypertensive therapy—with special reference to 2 years of clinical experience with losartan. Hansson L.
Blood Press Suppl 1997;1:52–5 (27 ref.)

HISTORY

Historical development of losartan (DuP 753) and angiotensin II receptor subtypes. Wong PC, et al.
Blood Press Suppl 1996;3:11–4 (29 ref.)

PHARMACOLOGY

Angiotensin II receptor antagonists: the prototype losartan. Schaefer KL, et al. **Ann Pharmacother** 1996 Jun; 30(6):625–36 (81 ref.)

The diversified pharmacology of angiotensin II–receptor blockade. Timmermans PB, et al. **Blood Press Suppl** 1996; 2:53–61 (112 ref.)

Pathologic consequences of increased angiotensin II activity. Ferrario CM, et al. **Cardiovasc Drugs Ther** 1996 Nov; 10(5):511–8 (100 ref.)

Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Goa KL, et al. **Drugs** 1996 May;51(5):820–45 (138 ref.)

THERAPEUTIC USE

Angiotensin II receptor inhibition. A new therapeutic principle. Messerli FH, et al. **Arch Intern Med** 1996 Sep 23;156(17):1957–65 (100 ref.)

Angiotensin II antagonism: a new avenue of hypertension management. Gavras H. **Blood Press Suppl** 1997;1:42–6 (24 ref.)

The clinical efficacy and tolerability of the angiotensin II–receptor antagonist losartan in Japanese patients with hypertension. Ogihara T, et al. **Blood Press Suppl** 1996; 2:78–81 (9 ref.)

The angiotensin II type 1 receptor blocker losartan in clinical practice: a review. Gavras HP, et al. **Clin Ther** 1996 Nov–Dec;18(6):1058–67; discussion 1057 (10 ref.)

A risk–benefit assessment of losartan potassium in the treatment of hypertension. Burrell LM. **Drug Saf** 1997 Jan; 16(1):56–65 (33 ref.)

Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Goa KL, et al. **Drugs** 1996 May;51(5):820–45 (138 ref.)

Losartan: first of a new class of angiotensin antagonists for the management of hypertension. Carr AA, et al.
J Clin Pharmacol 1996 Jan;36(1):3–12 (34 ref.)

The medicine of the month. Losartan (Cozaar)] Scheen AJ.
Rev Med Liege 1997 May;52(5):367–9 (8 ref.) **(Fre)**

[Peptidoleukotriene receptor antagonists in asthma therapy] Sakakibara H, et al. **Nippon Rinsho** 1996 Nov; 54(11):3049–55 (36 ref.) (Eng. Abstr.) **(Jpn)**

[Losartan, an angiotensin II receptor blocker: a new trend in cardiovascular chemotherapy] Krasnikova TL.
Klin Med (Mosk) 1996;74(3):17–21 (38 ref.) **(Rus)**

TETRODOTOXIN

METABOLISM

The guanidinium toxin binding site on the sodium channel. Fozzard HA, et al. **Jpn Heart J** 1996 Sep;37(5):683–92 (29 ref.)

PHYSIOLOGY

Mechanisms of paresthesiae, dysesthesiae, and hyperesthesiae: role of Na+ channel heterogeneity. Rizzo MA, et al.
Eur Neurol 1996;36(1):3–12 (44 ref.)

TEXTBOOKS

[What is psychiatry? Psychiatry in German language textbooks—I] Hoffmann-Richter U. **Psychiatr Prax** 1997 Mar;24(2):99–105 (0 ref.) **(Ger)**

TEXTILES

Contact dermatitis in the textile industry: a review of 72 patients. Soni BP, et al. **Am J Contact Dermat** 1996 Dec; 7(4):226–30 (21 ref.)

TFE see **POLYTETRAFLUOROETHYLENE**

TFII TRANSCRIPTION FACTORS see **TRANSCRIPTION FACTORS, TFII**

TGE VIRUS see **GASTROENTERITIS VIRUS, PORCINE TRANSMISSIBLE**

TGF-ALPHA see **TRANSFORMING GROWTH FACTOR ALPHA**

TGF-ALPHA RECEPTORS see **RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE**

TGF-BETA see **TRANSFORMING GROWTH FACTOR BETA**

TGF-BETA RECEPTORS see **RECEPTORS, TRANSFORMING GROWTH FACTOR BETA**

TH1 CELLS

[Cytokine gene expression in Th1 and Th2: its molecular mechanism and clinical implication] Naito Y, et al.
Nippon Rinsho 1997 Jun;55(6):1431–7 (19 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Markers of Th1 and Th2 cells. Almerigogna F, et al.
Chem Immunol 1996;63:30–50 (61 ref.)

CYTOLOGY

Role of cytokines in development of Th1 and Th2 cells. O'Garra A, et al. **Chem Immunol** 1996;63:1–13 (88 ref.)

The role of macrophage- and dendritic cell-derived IL12 in Th1 phenotype development. O'Garra A, et al.
Res Immunol 1995 Sep–Oct;146(7–8):466–72 (50 ref.)

Role of IL12 in the development of human Th1 type cells. Romagnani S, et al. **Res Immunol** 1995 Sep–Oct; 146(7–8):452–60 (22 ref.)

The role of IL12 in the regulation of Th1 and Th2 differentiation. Seder RA. **Res Immunol** 1995 Sep–Oct; 146(7–8):473–6 (31 ref.)

The role of type I interferons in the differentiation and function of Th1 and Th2 cells. de Waal Malefyt R.
Semin Oncol 1997 Jun;24(3 Suppl 9):S9–94–S9–98 (55 ref.)

Modulation of T-helper cell populations: potential mechanisms of respiratory hypersensitivity and immune suppression. Selgrade MK, et al.
Toxicol Appl Pharmacol 1997 Jul;145(1):218–29 (102 ref.)

IMMUNOLOGY

In vivo direction of CD4 T cells to Th1 and Th2–like patterns of cytokine synthesis. HayGlass KT, et al.
Adv Exp Med Biol 1996;409:309–16 (39 ref.)

TH1–TH2 cells in allergic responses: at the limits of a concept. Aebischer I, et al. **Adv Immunol** 1996;61:341–403 (491 ref.)

An Occam's razor approach to the immunopathogenesis of HIV infection. Clerici M, et al. **AIDS** 1995;9 Suppl A:S33–40 (97 ref.)

Immune suppression and Th1/Th2 balance in pregnancy revisited: a (very) personal tribute to Tom Wegmann. Chaouat G, et al. **Am J Reprod Immunol** 1997 Jun; 37(6):427–34 (23 ref.)

The role of IL-12 in the pathogenesis of Th1 cell–mediated autoimmune diseases. Adorini L, et al.
Ann N Y Acad Sci 1996 Oct 31;795:208–15 (46 ref.)

Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Constant SL, et al.
Annu Rev Immunol 1997;15:297–322 (99 ref.)

Manipulation of the Th1/Th2 cell balance: an approach to treat human autoimmune diseases? Adorini L, et al.
Autoimmunity 1996;23(1):53–68 (131 ref.)

Differential involvement of Th1 and Th2 cytokines in autoimmune diseases. Kroemer G, et al. **Autoimmunity** 1996;24(1):25–33 (68 ref.)

Immune deviation towards Th2 inhibits Th–1–mediated autoimmune diabetes. Adorini L, et al.
Biochem Soc Trans 1997 May;25(2):625–9 (58 ref.)

Th1 and Th2 cells in autoimmunity. Druet P, et al.
Chem Immunol 1996;63:138–70 (67 ref.)

Role of cytokines in development of Th1 and Th2 cells. O'Garra A, et al. **Chem Immunol** 1996;63:1–13 (88 ref.)

Role of Th1 and Th2 cells in human allergic disorders. Robinson DS, et al. **Chem Immunol** 1996;63:187–203 (113 ref.)

Role of interleukin–12 in human Th1 response. Trinchieri G. **Chem Immunol** 1996;63:14–29 (79 ref.)

Role of Th1 and Th2 cells in neurologic disorders. Windhagen A, et al. **Chem Immunol** 1996;63:171–86 (75 ref.)

The Th1/Th2 dichotomy, hsp60 autoimmunity, and type I diabetes. Cohen IR. **Clin Immunol Immunopathol** 1997 Aug; 84(2):103–6 (27 ref.)

T–cell subsets: recruiting the right kind of help. Lichtman AH, et al. **Curr Biol** 1997 Apr 1;7(4):R242–4 (10 ref.)

Function and clinical use of interleukin–12. Trinchieri G. **Curr Opin Hematol** 1997 Jan;4(1):59–66 (78 ref.)

Type 1 and type 2: a fundamental dichotomy for all T–cell subsets. Carter LL, et al. **Curr Opin Immunol** 1996 Jun; 8(3):336–42 (73 ref.)

Manipulation of the Th1/Th2 balance in autoimmune disease. Nicholson LB, et al. **Curr Opin Immunol** 1996 Dec; 8(6):837–42 (62 ref.)

The Th1/Th2 paradigm and the allograft response. Strom TB, et al. **Curr Opin Immunol** 1996 Oct;8(5):688–93 (38 ref.)

Immunoregulation of the allergic reaction in the respiratory tract. Holt PG. **Eur Respir J Suppl** 1996 Aug;22:85s–89s (35 ref.)

Genetic approaches to the study of cytokine regulation of mucosal immunity. Ramsay AJ. **Immunol Cell Biol** 1995 Dec;73(6):484–8 (42 ref.)

Th1–Th2: reliable paradigm or dangerous dogma? Allen JE, et al. **Immunol Today** 1997 Aug;18(8):387–92 (73 ref.)

The Th1/Th2 paradigm. Romagnani S. **Immunol Today** 1997 Jun;18(6):263–6 (27 ref.)

Development of Th 1– or Th 2–dominated immune responses: what about the polarizing signals? Romagnani S.
Int J Clin Lab Res 1996;26(2):83–98 (176 ref.)

TH1/TH2 cytokine profile in celiac disease. Karban A, et al. **Isr J Med Sci** 1997 Mar;33(3):209–14 (49 ref.)

TH1 and TH2 CD4+ cells in human allergic diseases. Umetsu DT, et al. **J Allergy Clin Immunol** 1997 Jul; 100(1):1–6 (18 ref.)

Th2 and Th1 autoreactive anti–class II cell lines in the rat suppress or induce autoimmunity. Druet P, et al.
J Autoimmun 1996 Apr;9(2):221–6 (44 ref.)

Differential roles for IL–12 in the maintenance of immune responses in infectious versus autoimmune disease. Seder RA, et al. **J Immunol** 1996 Oct 1;157(7):2745–8 (24 ref.)

Th1/Th2 changes in aging. Shearer GM.
Mech Ageing Dev 1997 Mar;94(1–3):1–5 (14 ref.)

Do holes in the T–cell repertoire have a center–surround regulatory structure? A rationale for the bifurcation of the Th1 and Th2 pathways of differentiation. Mannie MD.
Med Hypotheses 1997 Mar;48(3):261–5 (56 ref.)

Zinc–controlled Th1/Th2 switch significantly determines development of diseases. Sprietsma JE. **Med Hypotheses** 1997 Jul;49(1):1–14 (82 ref.)

T helper cell activation and human retroviral pathogenesis. Copeland KF, et al. **Microbiol Rev** 1996 Dec;60(4):722–42 (370 ref.)

Th1 and Th2 CD4+ cells in the pathogenesis of allergic diseases. Umetsu DT, et al. **Proc Soc Exp Biol Med** 1997 May;215(1):11–20 (72 ref.)

The role of endogenous IL12 in the induction of Th1–cell–mediated autoimmune diseases. Adorini L, et al.
Res Immunol 1995 Sep–Oct;146(7–8):645–51 (51 ref.)

The influence of IL12 on the development of Th1 and Th2 cells and its adjuvant effect for humoral immune responses. Germann T, et al. **Res Immunol** 1995 Sep–Oct; 146(7–8):481–6 (40 ref.)

The role of IL12 in helper T–cell differentiation. Perez VL, et al. **Res Immunol** 1995 Sep–Oct;146(7–8):477–80 (17 ref.)

Activity of IL12 as adjuvant in promoting Th1 and Th2 recall responses. Wolf SF, et al. **Res Immunol** 1995 Sep–Oct; 146(7–8):486–9 (26 ref.)

The role of HIV1 Nef in T–cell activation: Nef impairs induction of Th1 cytokines and interacts with the Src family tyrosine kinase Lck. Collette Y, et al. **Res Virol** 1997 Jan–Feb;148(1):52–8 (44 ref.)

Th1 and Th2 responses regulate experimental lung granuloma development. Kunkel SL, et al.
Sarcoidosis Vasc Diffuse Lung Dis 1996 Sep;13(2):120–8

TH1 CELLS

(86 ref.)
The transfusion immunomodulation theory: the Th1/Th2 paradigm and an analogy with pregnancy as a unifying mechanism. Blumberg N, et al. **Semin Hematol** 1996 Oct; 33(4):329–40 (66 ref.)
[Th1 cells, Th2 cells and atopic dermatitis] Böhm I, et al. **Hautarzt** 1997 Apr;48(4):223–7 (41 ref.) (Eng. Abstr.) **(Ger)**
[Th1/Th2 cells and autoimmunity] Amital H, et al. **Harefuah** 1996 Sep;131(5–6):189–92 (43 ref.) **(Heb)**
[An imbalance between Th1 and Th2-like cytokines in patients with autoimmune diseases—differential diagnosis between Th1 dominant autoimmune diseases and Th2 dominant autoimmune diseases] Ishida H, et al. **Nippon Rinsho** 1997 Jun;55(6):1438–43 (11 ref.) (Eng. Abstr.) **(Jpn)**
[T cell vaccination—induction of anti-idiotypic immune response against TCR and shift of Th1/Th2 balance] Kakimoto K, et al. **Nippon Rinsho** 1997 Jun;55(6):1512–8 (18 ref.) (Eng. Abstr.) **(Jpn)**
[The mechanisms of oral tolerance] Yamamoto M, et al. **Nippon Rinsho** 1997 Jun;55(6):1444–9 (23 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

There is a bias against type 1 (inflammatory) cytokine expression and function in pregnancy. Guilbert LJ. **J Reprod Immunol** 1996 Dec;32(2):105–10 (27 ref.)

MICROBIOLOGY

Role of Th1 and Th2 cells in bacterial infections. Daugelat S, et al. **Chem Immunol** 1996;63:66–97 (265 ref.)

PHYSIOLOGY

TH1 and TH2 lymphocytes in autoimmunity. Druet P, et al. **Adv Nephrol Necker Hosp** 1996;25:217–41 (143 ref.)
Type 1 and type 2: a fundamental dichotomy for all T-cell subsets. Carter LL, et al. **Curr Opin Immunol** 1996 Jun; 8(3):336–42 (73 ref.)
Regulation of fetal allograft survival by a hormone-controlled Th1- and Th2-type cytokines. Piccinni MP, et al. **Immunol Res** 1996;15(2):141–50 (54 ref.)
The expanding universe of T-cell subsets: Th1, Th2 and more. Mosmann TR, et al. **Immunol Today** 1996 Mar; 17(3):138–46 (94 ref.)
In vitro maturation of naive human CD4+ T lymphocytes into Th1, Th2 effectors. Delespesse G, et al. **Int Arch Allergy Immunol** 1997 May–Jul;113(1–3):157–9 (20 ref.)
An update on human Th1 and Th2 cells. Romagnani S, et al. **Int Arch Allergy Immunol** 1997 May–Jul;113(1–3):153–6 (30 ref.)

VIROLOGY

Th1 and Th2 cells in HIV infection. Manetti R, et al. **Chem Immunol** 1996;63:138–57 (83 ref.)
T helper cell activation and human retroviral pathogenesis. Copeland KF, et al. **Microbiol Rev** 1996 Dec;60(4):722–42 (370 ref.)

TH2 CELLS

[Cytokine gene expression in Th1 and Th2: its molecular mechanism and clinical implication] Naito Y, et al. **Nippon Rinsho** 1997 Jun;55(6):1431–7 (19 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Markers of Th1 and Th2 cells. Almerigogna F, et al. **Chem Immunol** 1996;63:30–50 (61 ref.)

CYTOLOGY

Role of cytokines in development of Th1 and Th2 cells. O'Garra A, et al. **Chem Immunol** 1996;63:1–13 (88 ref.)
The role of IL12 in the regulation of Th1 and Th2 differentiation. Seder RA. **Res Immunol** 1995 Sep–Oct; 146(7–8):473–6 (31 ref.)
The role of type I interferons in the differentiation and function of Th1 and Th2 cells. de Waal Malefyt R. **Semin Oncol** 1997 Jun;24(3 Suppl 9):S9-94–S9-98 (55 ref.)
Modulation of T-helper cell populations: potential mechanisms of respiratory hypersensitivity and immune suppression. Selgrade MK, et al. **Toxicol Appl Pharmacol** 1997 Jul;145(1):218–29 (102 ref.)

IMMUNOLOGY

In vivo direction of CD4 T cells to Th1 and Th2-like patterns of cytokine synthesis. HayGlass KT, et al. **Adv Exp Med Biol** 1996;409:309–16 (39 ref.)
Role of type 2 T helper cells (Th2) in allergic disorders. Parronchi P, et al. **Adv Exp Med Biol** 1996;409:359–63 (26 ref.)
TH1–TH2 cells in allergic responses: at the limits of a concept. Aebischer I, et al. **Adv Immunol** 1996;61:341–403 (491 ref.)
An Occam's razor approach to the immunopathogenesis of HIV infection. Clerici M, et al. **AIDS** 1995;9 Suppl A:S33–40 (97 ref.)
Th2-type cytokines, hypereosinophilia, and interleukin-5 in HIV disease. Paganelli R, et al. **Allergy** 1997 Jan; 52(1):110–1 (9 ref.)
Immune suppression and Th1/Th2 balance in pregnancy revisited: a (very) personal tribute to Tom Wegmann. Chaouat G, et al. **Am J Reprod Immunol** 1997 Jun; 37(6):427–34 (23 ref.)
Maternal anti-placental cell-mediated reactivity and spontaneous abortions. Raghupathy R. **Am J Reprod Immunol** 1997 Jun;37(6):478–84 (62 ref.)
Development of an antipathology vaccine for schistosomiasis. Wynn TA. **Ann N Y Acad Sci** 1996 Oct 25;797:191–5 (27 ref.)
Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Constant SL, et al. **Annu Rev Immunol** 1997;15:297–322 (99 ref.)
Manipulation of the Th1/Th2 cell balance: an approach to treat human autoimmune diseases? Adorini L, et al. **Autoimmunity** 1996;23(1):53–68 (131 ref.)
Differential involvement of Th1 and Th2 cytokines in autoimmune diseases. Kroemer G, et al. **Autoimmunity** 1996;24(1):25–33 (68 ref.)
Immune deviation towards Th2 inhibits Th-1-mediated autoimmune diabetes. Adorini L, et al. **Biochem Soc Trans** 1997 May;25(2):625–9 (58 ref.)
Th1 and Th2 cells in autoimmunity. Druet P, et al. **Chem Immunol** 1996;63:138–70 (67 ref.)
Role of cytokines in development of Th1 and Th2 cells. O'Garra A, et al. **Chem Immunol** 1996;63:1–13 (88 ref.)
Role of Th1 and Th2 cells in human allergic disorders. Robinson DS, et al. **Chem Immunol** 1996;63:187–203 (113 ref.)
Role of Th1 and Th2 cells in neurologic disorders. Windhagen A, et al. **Chem Immunol** 1996;63:171–86 (75 ref.)
The Th2 cell in asthma: initial expectations yet to be realised. Krug N, et al. **Clin Exp Allergy** 1997 Feb;27(2):142–50 (82 ref.)
Source of IL-4 able to induce the development of TH2-like cells. Ricci M, et al. **Clin Exp Allergy** 1997 May; 27(5):488–500 (118 ref.)
The Th1/Th2 dichotomy, hsp60 autoimmunity, and type I diabetes. Cohen IR. **Clin Immunol Immunopathol** 1997 Aug; 84(2):103–6 (27 ref.)
T-cell subsets: recruiting the right kind of help. Lichtman AH, et al. **Curr Biol** 1997 Apr 1;7(4):R242–4 (10 ref.)
Function and clinical use of interleukin-12. Trinchieri G. **Curr Opin Hematol** 1997 Jan;4(1):59–66 (78 ref.)
Type 1 and type 2: a fundamental dichotomy for all T-cell subsets. Carter LL, et al. **Curr Opin Immunol** 1996 Jun; 8(3):336–42 (73 ref.)
Manipulation of the Th1/Th2 balance in autoimmune disease. Nicholson LB, et al. **Curr Opin Immunol** 1996 Dec; 8(6):837–42 (62 ref.)
The Th1/Th2 paradigm and the allograft response. Strom TB, et al. **Curr Opin Immunol** 1996 Oct;8(5):688–93 (38 ref.)
Modulation of T-cell cytokine secretion by accessory cell-derived products. Hilkens CM, et al. **Eur Respir J Suppl** 1996 Aug;22:90s–94s (33 ref.)
Immunoregulation of the allergic reaction in the respiratory tract. Holt PG. **Eur Respir J Suppl** 1996 Aug;22:85s–89s (35 ref.)
The role of Th2 type CD4+ T cells and Th2 type CD8+ T cells in asthma. Erb KJ, et al. **Immunol Cell Biol** 1996 Apr;74(2):206–8 (16 ref.)
Genetic approaches to the study of cytokine regulation of mucosal immunity. Ramsay AJ. **Immunol Cell Biol** 1995 Dec;73(6):484–8 (42 ref.)
Induction of Th2 cell tolerance to a soluble antigen by blockade of the LFA-1-dependent pathway prevents allergic inflammation. Iwamoto I, et al. **Immunol Res** 1995; 14(4):263–70 (36 ref.)
Th1–Th2: reliable paradigm or dangerous dogma? Allen JE, et al. **Immunol Today** 1997 Aug;18(8):387–92 (73 ref.)
The Th1/Th2 paradigm. Romagnani S. **Immunol Today** 1997 Jun;18(6):263–6 (27 ref.)
Development of Th 1- or Th 2-dominated immune responses: what about the polarizing signals? Romagnani S. **Int J Clin Lab Res** 1996;26(2):83–98 (176 ref.)
TH1/TH2 cytokine profile in celiac disease. Karban A, et al. **Isr J Med Sci** 1997 Mar;33(3):209–14 (49 ref.)
TH1 and TH2 CD4+ cells in human allergic diseases. Umetsu DT, et al. **J Allergy Clin Immunol** 1997 Jul; 100(1):1–6 (18 ref.)
Th2 and Th1 autoreactive anti-class II cell lines in the rat suppress or induce autoimmunity. Druet P, et al. **J Autoimmun** 1996 Apr;9(2):221–6 (44 ref.)
IL-4 as a key factor influencing the development of allergen-specific Th2-like cells in atopic individuals. Ricci M, et al. **J Investig Allergol Clin Immunol** 1997 May–Jun; 7(3):144–50 (63 ref.)
A T-helper-2 bias in decidua: the prostaglandin contribution of the macrophage and trophoblast. Kelly RW, et al. **J Reprod Immunol** 1997 Jul;33(3):181–7 (48 ref.)
Is there a Th2 bias in human pregnancy? Vince GS, et al. **J Reprod Immunol** 1996 Dec;32(2):101–4 (22 ref.)
Th1/Th2 changes in aging. Shearer GM. **Mech Ageing Dev** 1997 Mar;94(1–3):1–5 (14 ref.)
Do holes in the T-cell repertoire have a center-surround regulatory structure? A rationale for the bifurcation of the Th1 and Th2 pathways of differentiation. Mannie MD. **Med Hypotheses** 1997 Mar;48(3):261–5 (56 ref.)
Zinc-controlled Th1/Th2 switch significantly determines development of diseases. Sprietsma JE. **Med Hypotheses** 1997 Jul;49(1):1–14 (82 ref.)
T helper cell activation and human retroviral pathogenesis. Copeland KF, et al. **Microbiol Rev** 1996 Dec;60(4):722–42 (370 ref.)
Th1 and Th2 CD4+ cells in the pathogenesis of allergic diseases. Umetsu DT, et al. **Proc Soc Exp Biol Med** 1997 May;215(1):11–20 (72 ref.)
The influence of IL12 on the development of Th1 and Th2 cells and its adjuvant effect for humoral immune responses. Germann T, et al. **Res Immunol** 1995 Sep–Oct; 146(7–8):481–6 (40 ref.)
The role of IL12 in modulating an established Th2 response in experimental leishmaniasis. Hondowicz B, et al. **Res Immunol** 1995 Sep–Oct;146(7–8):560–5 (21 ref.)
Activity of IL12 as adjuvant in promoting Th1 and Th2 recall responses. Wolf SF, et al. **Res Immunol** 1995 Sep–Oct; 146(7–8):486–9 (26 ref.)
Th1 and Th2 responses regulate experimental lung granuloma development. Kunkel SL, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Sep;13(2):120–8 (86 ref.)
The transfusion immunomodulation theory: the Th1/Th2 paradigm and an analogy with pregnancy as a unifying mechanism. Blumberg N, et al. **Semin Hematol** 1996 Oct; 33(4):329–40 (66 ref.)
[Th1 cells, Th2 cells and atopic dermatitis] Böhm I, et al. **Hautarzt** 1997 Apr;48(4):223–7 (41 ref.) (Eng. Abstr.) **(Ger)**
[Th1/Th2 cells and autoimmunity] Amital H, et al. **Harefuah** 1996 Sep;131(5–6):189–92 (43 ref.) **(Heb)**
[Immune mechanism of mucous membrane and mucous membrane vaccines: Expression of level 1 and 2 Th2-type cytokine and IgA immune response] Kiyono H. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):690 (0 ref.) **(Jpn)**
[An imbalance between Th1 and Th2-like cytokines in patients with autoimmune diseases—differential diagnosis between Th1 dominant autoimmune diseases and Th2 dominant autoimmune diseases] Ishida H, et al. **Nippon Rinsho** 1997 Jun;55(6):1438–43 (11 ref.) (Eng. Abstr.) **(Jpn)**
[T cell vaccination—induction of anti-idiotypic immune response against TCR and shift of Th1/Th2 balance] Kakimoto K, et al. **Nippon Rinsho** 1997 Jun;55(6):1512–8 (18 ref.) (Eng. Abstr.) **(Jpn)**
[The mechanisms of oral tolerance] Yamamoto M, et al. **Nippon Rinsho** 1997 Jun;55(6):1444–9 (23 ref.) (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

Role of Th1 and Th2 cells in bacterial infections. Daugelat S, et al. **Chem Immunol** 1996;63:66–97 (265 ref.)

PHYSIOLOGY

TH1 and TH2 lymphocytes in autoimmunity. Druet P, et al. **Adv Nephrol Necker Hosp** 1996;25:217–41 (143 ref.)
TH2-type cytokines in asthma. Kay AB. **Ann N Y Acad Sci** 1996 Oct 31;796:1–8 (45 ref.)
TH2 cells in allergic inflammation: a target of immunotherapy. Lord CJ, et al. **Clin Exp Allergy** 1996 Jul; 26(7):756–65 (105 ref.)
Type 1 and type 2: a fundamental dichotomy for all T-cell subsets. Carter LL, et al. **Curr Opin Immunol** 1996 Jun; 8(3):336–42 (73 ref.)
Regulation of fetal allograft survival by a hormone-controlled Th1- and Th2-type cytokines. Piccinni MP, et al. **Immunol Res** 1996;15(2):141–50 (54 ref.)
The expanding universe of T-cell subsets: Th1, Th2 and more. Mosmann TR, et al. **Immunol Today** 1996 Mar; 17(3):138–46 (94 ref.)
In vitro maturation of naive human CD4+ T lymphocytes into Th1, Th2 effectors. Delespesse G, et al. **Int Arch Allergy Immunol** 1997 May–Jul;113(1–3):157–9 (20 ref.)
An update on human Th1 and Th2 cells. Romagnani S, et al. **Int Arch Allergy Immunol** 1997 May–Jul;113(1–3):153–6 (30 ref.)
Are Th2 helper T lymphocytes beneficial, deleterious, or irrelevant in promoting allograft survival? Piccotti JR, et al. **Transplantation** 1997 Mar 15;63(5):619–24 (50 ref.)

VIROLOGY

Th1 and Th2 cells in HIV infection. Manetti R, et al. **Chem Immunol** 1996;63:138–57 (83 ref.)
T helper cell activation and human retroviral pathogenesis. Copeland KF, et al. **Microbiol Rev** 1996 Dec;60(4):722–42 (370 ref.)

THALAMIC DISEASES

DIAGNOSIS

Acute bilateral striatal necrosis associated with Mycoplasma pneumoniae infection. Larsen PD, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1124–6 (16 ref.)

THALAMIC NUCLEI

Deep brain stimulation for intractable pain: a 15-year

experience. Kumar K, et al. **Neurosurgery** 1997 Apr; 40(4):736–46; discussion 746–7 (64 ref.)

ANATOMY & HISTOLOGY

The primate motor thalamus. Percheron G, et al. **Brain Res Brain Res Rev** 1996 Aug;22(2):93–181 (388 ref.)

Toward an agreement on terminology of nuclear and subnuclear divisions of the motor thalamus. Macchi G, et al. **J Neurosurg** 1997 Apr;86(4):670–85 (93 ref.)

PATHOLOGY

A panencephalopathic type of Creutzfeldt–Jakob disease with selective lesions of the thalamic nuclei in 2 Swiss patients. Carota A, et al. **Clin Neuropathol** 1996 May–Jun; 15(3):125–34 (77 ref.)

PHYSIOLOGY

The connections of the primate subthalamic nucleus: indirect pathways and the open–interconnected scheme of basal ganglia–thalamocortical circuitry. Joel D, et al. **Brain Res Brain Res Rev** 1997 Feb;23(1–2):62–78 (115 ref.)

Attention, awareness, and the triangular circuit. LaBerge D. **Conscious Cogn** 1997 Jun–Sep;6(2–3):149–81 (120 ref.)

Toward an agreement on terminology of nuclear and subnuclear divisions of the motor thalamus. Macchi G, et al. **J Neurosurg** 1997 Apr;86(4):670–85 (93 ref.)

Frontal–subcortical circuits: the anatomic basis of executive, social and motivated behaviors. Masterman DL, et al. **J Psychopharmacol (Oxf)** 1997;11(2):107–14 (60 ref.)

Dual response modes in lateral geniculate neurons: mechanisms and functions. Sherman SM. **Vis Neurosci** 1996 Mar–Apr;13(2):205–13 (68 ref.)

PHYSIOPATHOLOGY

Bipolar disorders, dystonia, and compulsion after dysfunction of the cerebellum, dentatorubrothalamic tract, and substantia nigra. Lauterbach EC. **Biol Psychiatry** 1996 Oct 15;40(8):726–30 (65 ref.)

SURGERY

The thalamic commissure in generalized epilepsy. Heick A. **Br J Neurosurg** 1996 Jun;10(3):309–10 (24 ref.)

Treatment of Parkinson's disease. New surgical treatment strategies. Pollak P, et al. **Eur Neurol** 1996;36(6):400–4 (43 ref.)

THALAMOSTRIATE VEIN see **CEREBRAL VEINS**

THALAMUS

Current treatment of thalamic gliomas in children. Souweidane MM, et al. **J Neurooncol** 1996 May–Jun; 28(2–3):157–66 (58 ref.)

[Hallucinations and thalamic infarction] Tatu L, et al. **Rev Neurol (Paris)** 1996 Aug–Sep;152(8–9):557–9 (10 ref.) (Eng. Abstr.) **(Fre)**

ANATOMY & HISTOLOGY

The anatomy of manual dexterity. The new connectivity of the primate sensorimotor thalamus and cerebral cortex. Darian–Smith I, et al. **Adv Anat Embryol Cell Biol** 1996; 133:1–140 (400 ref.)

Trends in the anatomical organization and functional significance of the mammalian thalamus. Macchi G, et al. **Ital J Neurol Sci** 1996 Apr;17(2):105–29 (295 ref.)

Toward an agreement on terminology of nuclear and subnuclear divisions of the motor thalamus. Macchi G, et al. **J Neurosurg** 1997 Jan;86(1):77–92 (93 ref.)

Diencephalic asymmetries. Harris JA, et al. **Neurosci Biobehav Rev** 1996 Winter;20(4):637–43 (51 ref.)

[Serial anatomy and MRI of the basal ganglia and the thalamus] Francke JP, et al. **Neurochirurgie** 1997;43 Suppl 1:20–32 (0 ref.) **(Fre)**

BLOOD SUPPLY

Global aphasia due to thalamic hemorrhage: a case report and review of the literature. Kumar R, et al. **Arch Phys Med Rehabil** 1996 Dec;77(12):1312–5 (16 ref.)

[Blepharospasm caused by bilateral paramedian thalamic infarction] Awada A. **Rev Neurol (Paris)** 1997 Feb; 155(1):62–4 (11 ref.) (Eng. Abstr.) **(Fre)**

CYTOLOGY

The specificity of interactions between the cortex and the thalamus. Bolz J, et al. **Ciba Found Symp** 1995;193:173–91; discussion 192–9 (40 ref.)

Subplate neurons and the patterning of thalamocortial connections. Ghosh A. **Ciba Found Symp** 1995;193:150–72; discussion 192–9 (31 ref.)

Guidance of thalamocortical innervation. Molnár Z, et al. **Ciba Found Symp** 1995;193:127–49; discussion 192–9 (20 ref.)

EMBRYOLOGY

Subplate neurons and the patterning of thalamocortial connections. Ghosh A. **Ciba Found Symp** 1995;193:150–72; discussion 192–9 (31 ref.)

GROWTH & DEVELOPMENT

The specificity of interactions between the cortex and the thalamus. Bolz J, et al. **Ciba Found Symp** 1995;193:173–91; discussion 192–9 (40 ref.)

INJURIES

[Post-traumatic focal dystonia after contralateral thalamic lesion] Tränkle R, et al. **Nervenarzt** 1997 Jun;68(6):521–4 (17 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Short-term functional plasticity of cortical and thalamic sensory representations and its implication for information processing. Dinse HR, et al. **Adv Neurol** 1997;73:159–78 (78 ref.)

Sleep and arousal: thalamocortical mechanisms. McCormick DA, et al. **Annu Rev Neurosci** 1997;20:185–215 (122 ref.)

Physiological origins and functional correlates of EEG rhythmic activities: implications for self-regulation. Sterman MB. **Biofeedback Self Regul** 1996 Mar;21(1):3–33 (82 ref.)

Cortico–thalamic interplay and the security of operation of neural assemblies and temporal chains in the cerebral cortex. Miller R. **Biol Cybern** 1996 Sep;75(3):263–75 (78 ref.)

The connections of the primate subthalamic nucleus: indirect pathways and the open–interconnected scheme of basal ganglia–thalamocortical circuitry. Joel D, et al. **Brain Res Brain Res Rev** 1997 Feb;23(1–2):62–78 (115 ref.)

Synchronized activities of coupled oscillators in the cerebral cortex and thalamus at different levels of vigilance. Steriade M. **Cereb Cortex** 1997 Sep;7(6):583–604 (139 ref.)

Complexities in the thalamocortical and corticothalamic pathways. Adams NC, et al. **Eur J Neurosci** 1997 Feb; 9(2):204–9 (52 ref.)

Trends in the anatomical organization and functional significance of the mammalian thalamus. Macchi G, et al. **Ital J Neurol Sci** 1996 Apr;17(2):105–29 (295 ref.)

Functional organization of thalamocortical relays. Sherman SM, et al. **J Neurophysiol** 1996 Sep;76(3):1367–95 (310 ref.)

Do cortical and thalamic bioelectric oscillations have a functional role? A brief survey and discussion. Buser P, et al. **J Physiol Paris** 1995;89(4–6):249–54 (42 ref.)

Dynamical computational properties of local cortical networks for visual and motor processing: a bayesian framework. Koechlin E, et al. **J Physiol Paris** 1996; 90(3–4):257–62 (17 ref.)

Diencephalic asymmetries. Harris JA, et al. **Neurosci Biobehav Rev** 1996 Winter;20(4):637–43 (51 ref.)

Thalamocortical synapses. Castro–Alamancos MA, et al. **Prog Neurobiol** 1997 Apr;51(6):581–606 (205 ref.)

PHYSIOPATHOLOGY

The role of the thalamus in schizophrenia [see comments] Andreasen NC. **Can J Psychiatry** 1997 Feb;42(1):27–33 (48 ref.) Comment in: Can J Psychiatry 1997 Feb;42(1):19–20.

The thalamus and neuropsychiatric illness. Scheibel AB. **J Neuropsychiatry Clin Neurosci** 1997 Summer;9(3):342–53 (94 ref.)

SURGERY

Pallidal and thalamic surgery for Parkinson's disease. Tasker RR, et al. **Exp Neurol** 1997 Mar;144(1):35–40 (21 ref.)

[Surgical therapy of Parkinson's disease] Luquin MR. **Rev Neurol** 1997 Aug;25 Suppl 2:S180–4 (45 ref.) (Eng. Abstr.) **(Spa)**

THALASSEMIA

The thalassaemias. Weatherall DJ. **BMJ** 1997 Jun 7; 314(7095):1675–8 (26 ref.)

[Congenital hemolytic anemia—hemoglobin abnormality—thalassemia] Fujita S. **Nippon Rinsho** 1996 Sep;54(9):2454–9 (15 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Post transfusion purpura in a thalassemic child. Kashyap R, et al. **Indian Pediatr** 1997 Mar;34(3):246–7 (6 ref.)

THALASSEMIA-ALPHA see **ALPHA-THALASSEMIA**

THALASSEMIA MAJOR see **BETA-THALASSEMIA**

THALASSEMIA MINOR see **BETA-THALASSEMIA**

THALIDOMIDE

ADVERSE EFFECTS

Linking etiologies in humans and animal models: studies of autism. Rodier PM, et al. **Reprod Toxicol** 1997 Mar–Jun; 11(2–3):417–22 (24 ref.)

PHARMACOLOGY

Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use. Klausner JD, et al. **Clin Immunol Immunopathol** 1996 Dec;81(3):219–23 (35 ref.)

Immunomodulation by thalidomide: systematic review of the literature and of unpublished observations. Zwingenberger K, et al. **J Inflamm** 1995–96;46(4):177–211 (215 ref.)

Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis. McCarty MF. **Med Hypotheses** 1997 Aug; 49(2):123–31 (108 ref.)

[Novel biological response modifiers: phthalimides with TNF-alpha production regulating activity] Miyachi H, et al. **Yakugaku Zasshi** 1997 Feb;117(2):91–107 (49 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use. Klausner JD, et al. **Clin Immunol Immunopathol** 1996 Dec;81(3):219–23 (35 ref.)

Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. Tseng S, et al. **J Am Acad Dermatol** 1996 Dec;35(6):969–79 (101 ref.)

Thalidomide. A surprising recovery. Stirling D, et al. **J Am Pharm Assoc (Wash)** 1997 May–Jun;NS37(3):306–13 (38 ref.)

Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis. McCarty MF. **Med Hypotheses** 1997 Aug; 49(2):123–31 (108 ref.)

TOXICITY

Never-ending tales of the mode of the teratogenic action of thalidomide [comment] Neubert D. **Teratog Carcinog Mutagen** 1997;17(1):i–ii (11 ref.) Comment on: Teratog Carcinog Mutagen 1997 ;17(1):1–5.

Mechanism of teratogenic action of thalidomide [letter] Vaisman B. **Teratology** 1996 May;53(5):283–4 (17 ref.)

THALLIUM

PHARMACOLOGY

Mutagenicity, carcinogenicity and teratogenicity of thallium compounds. Léonard A, et al. **Mutat Res** 1997 Aug; 387(1):47–53 (56 ref.)

THALLIUM RADIOISOTOPES

DIAGNOSTIC USE

Myocardial viability. Stress echocardiography vs nuclear medicine. Piérard LA, et al. **Eur Heart J** 1997 Jun;18 Suppl D:D117–23 (43 ref.)

[Value of cardiac scintigraphy using thallium dipyridamole in the preoperative diagnosis of vascular diseases] Natale A, et al. **Minerva Cardioangiol** 1996 Jul–Aug; 44(7–8):337–42 (38 ref.) (Eng. Abstr.) **(Ita)**

METABOLISM

Twenty years of myocardial perfusion imaging 1976–1996: anything new for the clinical cardiologist? van der Wall EE, et al. **Eur Heart J** 1996 Jul;17(7):987–90 (25 ref.)

THANATOLOGY

see related
DEATH

THANATOPHORIC DWARFISM see **THANATOPHORIC DYSPLASIA**

THANATOPHORIC DYSPLASIA

DIAGNOSIS

Antenatal sonographic diagnosis of thanatophoric dysplasia: a report of three cases and a review of the literature with special emphasis on the differential diagnosis. Schild RL, et al. **Ultrasound Obstet Gynecol** 1996 Jul;8(1):62–7 (22 ref.)

GENETICS

Fibroblast growth factor receptor 3 and the human chondrodysplasias. Horton WA. **Curr Opin Pediatr** 1997 Aug;9(4):437–42 (49 ref.)

THAPSIGARGIN

CHEMISTRY

Sesquiterpenoids from Thapsia species and medicinal chemistry of the thapsigargins. Christensen SB, et al. **Fortschr Chem Org Naturst** 1997;71:129–67 (84 ref.)

PHARMACOLOGY

Use of thapsigargin to study Ca2+ homeostasis in cardiac cells. Rogers TB, et al. **Biosci Rep** 1995 Oct;15(5):341–9 (18 ref.)

THC see **TETRAHYDROCANNABINOL**

THEA

THEA see **TEA**

THEFT

PREVENTION & CONTROL

Policies for developing workplace violence prevention strategies. Cabral R. **Occup Med** 1996 Apr–Jun; 11(2):303–14 (32 ref.)

Retail employees as a group at risk for violence. Erickson RJ. **Occup Med** 1996 Apr–Jun;11(2):269–76 (21 ref.)

STATISTICS & NUMERICAL DATA

Epidemiology of violence and theft in the workplace. Bachman R. **Occup Med** 1996 Apr–Jun;11(2):237–41 (9 ref.)

THEILERIA

PATHOGENICITY

The same but different: the biology of Theileria sporozoite entry into bovine cells. Shaw MK. **Int J Parasitol** 1997 May;27(5):457–74 (121 ref.)

Theileria transformation of bovine leukocytes: a parasite model for the study of lymphoproliferation. Chaussepied M, et al. **Res Immunol** 1996 Mar–Apr;147(3):127–38 (64 ref.)

THEILERIA ANNULATA

IMMUNOLOGY

A general review on the prevention and treatment of Theileria annulata in China. Zhang ZH. **Vet Parasitol** 1997 Jun;70(1–3):77–81 (0 ref.)

THEILERIASIS

DRUG THERAPY

A general review on the prevention and treatment of Theileria annulata in China. Zhang ZH. **Vet Parasitol** 1997 Jun;70(1–3):77–81 (0 ref.)

PARASITOLOGY

The same but different: the biology of Theileria sporozoite entry into bovine cells. Shaw MK. **Int J Parasitol** 1997 May;27(5):457–74 (121 ref.)

PREVENTION & CONTROL

A general review on the prevention and treatment of Theileria annulata in China. Zhang ZH. **Vet Parasitol** 1997 Jun;70(1–3):77–81 (0 ref.)

THEILER'S MURINE ENCEPHALOMYELITIS VIRUS

GENETICS

Molecular determinants of Theiler's murine encephalomyelitis-induced disease. Jakob J, et al. **J Neurovirol** 1996 Apr;2(2):70–7 (25 ref.)

THELAZIA see **THELAZIOIDEA**

THELAZIOIDEA

ISOLATION & PURIFICATION

Eye infestation with Thelazia species. Mahanta J, et al. **Indian J Ophthalmol** 1996 Jun;44(2):99–101 (6 ref.)

THEOBROMA see **CACAO**

THEOLOGY see **RELIGION**

THEOPHYLLINE

[The development of slow-release theophylline products and revaluation of theophylline's role as a bronchodilator] Mano K. **Nippon Rinsho** 1996 Nov;54(11):3093–101 (33 ref.) (Eng. Abstr.) **(Jpn)**

[Inhaled beta agonists as a bronchodilator are a mainstay of asthma therapy: focusing on inhaled beta agonists and oral theophylline] Nishimura K, et al. **Nippon Rinsho** 1996 Nov; 54(11):3073–7 (14 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

[Chronopharmacology and chronotherapy for asthma by using PEF] Burioka N, et al. **Nippon Rinsho** 1996 Nov; 54(11):2956–61 (31 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Acute and chronic human toxicity of theophylline. Minton NA, et al. **Hum Exp Toxicol** 1996 Jun;15(6):471–81 (177 ref.)

PHARMACOKINETICS

[The effect of new quinolone antimicrobial agents and macrolide antibiotics on the clearance of theophylline] Honma M. **Nippon Rinsho** 1996 Nov;54(11):3125–9 (14 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Anti-inflammatory effects of theophylline and selective phosphodiesterase inhibitors. Banner KH, et al. **Clin Exp Allergy** 1996 Mar;26 Suppl 2:2–9 (99 ref.)

The role of theophylline in the management of chronic asthma in adults. McDonald CJ, et al. **Clin Exp Allergy** 1996 Mar;26 Suppl 2:42–6 (64 ref.)

POISONING

Treatment of theophylline overdose [see comments] Minton NA, et al. **Am J Emerg Med** 1996 Oct;14(6):606–12 (143 ref.) Comment in: Am J Emerg Med 1997 Sep;15(5):547.

Theophylline intoxication: clinical features and pharmacokinetics during treatment with charcoal hemoperfusion. Shechter P, et al. **Isr J Med Sci** 1996 Sep; 32(9):766–70 (18 ref.)

[Clinico-pharmacological case (4). Epileptic seizure as an unwanted drug effect on theophylline poisoning] Schlienger RG, et al. **Schweiz Rundsch Med Prax** 1996 Oct 29;85(44):1407–12 (39 ref.) (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Theophylline revisited. D'Alonzo GE. **Allergy Asthma Proc** 1996 Nov–Dec;17(6):335–9 (58 ref.)

Theophylline in chronic asthma—evidence for disease-modifying properties. Chung KF. **Clin Exp Allergy** 1996 Mar;26 Suppl 2:22–7 (59 ref.)

The role of theophylline in the management of chronic asthma in adults. McDonald CJ, et al. **Clin Exp Allergy** 1996 Mar;26 Suppl 2:42–6 (64 ref.)

Theophylline in the treatment of asthma. Makino S. **Clin Exp Allergy** 1996 Mar;26 Suppl 2:47–54 (57 ref.)

The use of theophylline in chronic obstructive pulmonary disease. Pauwels R. **Clin Exp Allergy** 1996 Mar;26 Suppl 2:55–9 (33 ref.)

Low-dose theophylline: a new anti-inflammatory role in asthma management? MacLeod D, et al. **Monaldi Arch Chest Dis** 1996 Feb;51(1):30–4 (49 ref.)

[Mucociliary clearance function and medicamentous modification] Konrad F. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Sep; 31(7):404–8 (38 ref.) (Eng. Abstr.) **(Ger)**

[Theophylline and selective phosphodiesterase inhibitor in therapy of obstructive respiratory tract diseases] Rabe KF, et al. **Pneumologie** 1997 Mar;51(3):303–16 (140 ref.) **(Ger)**

[Myoglobinuria following anesthesia with enflurane and succinylcholine in an asthmatic child on theophylline] Shono S, et al. **Masui** 1996 Jan;45(1):91–5 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Slow-release theophylline for the treatment of asthmatic children] Iwasaki E, et al. **Nippon Rinsho** 1996 Nov; 54(11):3102–7 (11 ref.) (Eng. Abstr.) **(Jpn)**

[The clinical application of long-acting preparations of theophylline] Tanaka K. **Nippon Rinsho** 1996 Nov; 54(11):3108–12 (8 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC COMMUNITY

Swimming against the tide? A review of the therapeutic community. Schimmel P. **Aust N Z J Psychiatry** 1997 Feb; 31(1):120–7 (31 ref.)

Therapeutic communities: AIDS/HIV risk and harm reduction. De Leon G. **J Subst Abuse Treat** 1996 Sep–Oct; 13(5):411–20; discussion 439 (40 ref.)

THERAPEUTIC CULTS see **ALTERNATIVE MEDICINE**

THERAPEUTIC EQUIVALENCY

Bioequivalence assessment: a pharmaceutical industry perspective. Godbillon J, et al. **Eur J Drug Metab Pharmacokinet** 1996 Apr–Jun; 21(2):153–8 (11 ref.)

Bioequivalence assessment of generic drugs: an American point of view. Patnaik R, et al. **Eur J Drug Metab Pharmacokinet** 1996 Apr–Jun; 21(2):159–64 (21 ref.)

Individual bioequivalence—a regulatory update [see comments] Chen ML. **J Biopharm Stat** 1997 Mar;7(1):5–11 (16 ref.) Comment in: J Biopharm Stat 1997 Mar;7(1):13–6.

Some issues for the consideration of individual bioequivalence. Endrenyi L. **J Biopharm Stat** 1997 Mar; 7(1):35–9 (18 ref.)

Discussion of individual bioequivalence by M.-L. Chen. Gould AL. **J Biopharm Stat** 1997 Mar;7(1):23–9 (22 ref.)

Commentary on individual bioequivalence by M.-L. Chen [comment] Hauck WW, et al. **J Biopharm Stat** 1997 Mar; 7(1):13–6 (12 ref.) Comment on: J Biopharm Stat 1997 Mar;7(1):5–11.

Some thoughts on individual bioequivalence. Liu J, et al. **J Biopharm Stat** 1997 Mar;7(1):41–8 (9 ref.)

Individual bioequivalence—a European perspective. Steinijans VW, et al. **J Biopharm Stat** 1997 Mar;7(1):31–4 (16 ref.)

A comment on so-called individual criteria of bioequivalence. Wellek S. **J Biopharm Stat** 1997 Mar; 7(1):17–21 (14 ref.)

[The concept of therapeutic equivalence] Lange S, et al. **Med Klin** 1997 Apr 15;92(4):215–20 (11 ref.) (Eng. Abstr.) **(Ger)**

[Assessment of bioequivalence] Aoyagi N. **Eisei Shikenjo Hokoku** 1996;(114):141–2 (0 ref.) (Eng. Abstr.) **(Jpn)**

[Theoretic prediction of drug safety and efficacy—drug efficacy] Ito T, et al. **Nippon Yakurigaku Zasshi** 1996 Sep; 108(3):175–7 (8 ref.) **(Jpn)**

THERAPEUTIC RADIOLOGY see **RADIATION ONCOLOGY**

THERAPEUTIC TOUCH

Therapeutic touch, nursing practice and contemporary cutaneous wound healing research. Daley B. **J Adv Nurs** 1997 Jun;25(6):1123–32 (44 ref.)

Therapeutic touch: a healing modality [see comments] Mulloney SS, et al. **J Cardiovasc Nurs** 1996 Apr;10(3):27–49 (93 ref.) Comment in: J Cardiovasc Nurs 1996 Apr;10(3):v–x.

THERAPEUTICS

Nutrition and therapeutics [editorial] Mamo J. **Curr Opin Lipidol** 1997 Apr;8(2):U15–7 (11 ref.)

Adjunctive therapies in nutritional support. Ziegler TR, et al. **Nutrition** 1997 Sep;13(9 Suppl):64S–72S (82 ref.)

[The relative effectiveness of setting goals as a chance for dealing with complex decision processes in medicine] Schüppel R. **Gesundheitswesen** 1996 Aug–Sep; 58(8–9):423–31 (58 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Pet Therapy Program. Proposal for the US Department of Health and Human Services. 1996 Secretary's Award. Teeter LM. **J Am Vet Med Assoc** 1997 May 15; 210(10):1435–8 (7 ref.)

Metabolic engineering and human disease. Yarmush ML, et al. **Nat Biotechnol** 1997 Jun;15(6):525–8 (32 ref.)

THERAPY, COMBINED MODALITY see **COMBINED MODALITY THERAPY**

THERAPY, COMPUTER-ASSISTED

Computer aids to treatment in psychiatry. Kirkby KC, et al. **Aust N Z J Psychiatry** 1996 Feb;30(1):142–5 (20 ref.)

Computer rehabilitation in aphasia. Weinrich M. **Clin Neurosci** 1997;4(2):103–7 (43 ref.)

Computer assisted knee surgery: diagnostics and planning of knee surgery. Sati M, et al. **Comput Aided Surg** 1997; 2(2):108–23 (49 ref.)

Computer assisted diabetes care: a 6-year retrospective. Lehmann ED, et al. **Comput Methods Programs Biomed** 1996 Aug;50(3):209–30 (67 ref.)

Computer-assisted endoscopic sinus surgery. An international review. Anon JB, et al. **Otolaryngol Clin North Am** 1997 Jun;30(3):389–401 (23 ref.)

A CT-aided PC-based physical treatment planning of TBI: a method for dose calculation. Sánchez-Nieto B, et al. **Radiother Oncol** 1997 Jan;42(1):77–85 (27 ref.)

INSTRUMENTATION

Interstitial laser thermotherapy in neurosurgery: a review. Menovsky T, et al. **Acta Neurochir (Wien)** 1996; 138(9):1019–26 (49 ref.)

Controlling blood glucose: insights from an engineering control systems perspective. Worthington DR. **Med Inf (Lond)** 1997 Jan–Mar;22(1):5–19 (28 ref.)

METHODS

[Validation of a new interactive software monitoring a controlled-flow infusion pump for cisplatin dosage regimen adjustment] Cupissol D, et al. **Bull Cancer** 1996 Aug; 83(8):664–76 (36 ref.) (Eng. Abstr.) **(Fre)**

THERAPY, HOME INFUSION see **HOME INFUSION THERAPY**

THERMAL WATER POLLUTION see **WATER POLLUTION**

THERMOCOAGULATION see **ELECTROCOAGULATION**

THERMODILUTION

METHODS

Continuous measurement of cardiac output by the Fick principle in infants and children: comparison with the thermodilution method. Wippermann CF, et al. **Intensive Care Med** 1996 May;22(5):467–71 (20 ref.)

THERMODYNAMICS

Solvation: how to obtain microscopic energies from partitioning and solvation experiments. Chan HS, et al.

Annu Rev Biophys Biomol Struct 1997;26:425–59 (119 ref.)
Definite answers from random events [comment] Briehl RW. **Biophys J** 1997 Jan;72(1):3–4 (12 ref.) Comment on: Biophys J 1997 Jan;72(1):343–52.
Biodynamics for the emergence of energy consumers. Matsuno K. **Biosystems** 1997;42(2–3):119–27 (26 ref.)
Sensing the heat: the application of isothermal titration calorimetry to thermodynamic studies of biomolecular interactions. Ladbury JE, et al. **Chem Biol** 1996 Oct; 3(10):791–801 (38 ref.)
Theoretical studies of protein–folding thermodynamics and kinetics. Shakhnovich EI. **Curr Opin Struct Biol** 1997 Feb; 7(1):29–40 (102 ref.)
Molecular interaction analysis in ligand design using mass transport, kinetic and thermodynamic methods. Doyle ML, et al. **J Mol Recognit** 1996 Mar–Apr;9(2):65–74 (33 ref.)
Network thermodynamics: analysis and synthesis of membrane transport system. Imai Y. **Jpn J Physiol** 1996 Jun;46(3):187–99 (19 ref.)
Angströms and calories. Janin J. **Structure** 1997 Apr 15; 5(4):473–9 (41 ref.)
[Hierarchical thermodynamics and gerontology] Gladyshev GP, et al. **Vestn Ross Akad Med Nauk** 1996;(6):31–8 (28 ref.) (Eng. Abstr.) **(Rus)**

THERMOELECTRIC POWER PLANTS see **POWER PLANTS**

THERMOGRAPHY

[Evaluation of arterial sclerosis by thermography] Iketani T, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:697–700 (9 ref.) **(Jpn)**

THERMOMETERS

Case report of metallic mercury injury. Smith SR, et al. **Pediatr Emerg Care** 1997 Apr;13(2):114–6 (14 ref.)

THERMOPLASMA

ENZYMOLOGY

Catalytic mechanism of the 20S proteasome of Thermoplasma acidophilum revealed by X–ray crystallography. Stock D, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:525–32 (54 ref.)

THERMORECEPTORS

see related
BODY TEMPERATURE REGULATION

THERMOREGULATION see **BODY TEMPERATURE REGULATION**

THERMOTHERAPY see **HYPERTHERMIA, INDUCED**

THESAURUS see **VOCABULARY, CONTROLLED**

THESES see **DISSERTATIONS, ACADEMIC**

THIADIAZINES

THERAPEUTIC USE

[Adjuvant therapy of peritonitis with taurolidine. Modulation of mediator liberation] Staubach KH. **Langenbecks Arch Chir** 1997;382(4 Suppl 1):S26–30 (17 ref.) (Eng. Abstr.) **(Ger)**

THIADIAZOLES

PHARMACOLOGY

In vivo pharmacology of butylthio[2.2.2] (LY297802 / NNC11–1053), an orally acting antinociceptive muscarinic agonist. Shannon HE, et al. **Life Sci** 1997;60(13–14):969–76 (24 ref.)

THIAMAZOLE see **METHIMAZOLE**

THIAMINE

ANALOGS & DERIVATIVES

Pharmacokinetics of thiamine derivatives especially of benfotiamine. Loew D. **Int J Clin Pharmacol Ther** 1996 Feb;34(2):47–50 (30 ref.)
Enzymatic preparation of derivatives of thiamin: O–beta–galactosylthiamin and O–alpha–glucosylthiamin. Suzuki Y, et al. **Methods Enzymol** 1997;279:146–55 (9 ref.)

ANALYSIS

High–performance liquid chromatography determination of total thiamin in biological and food products. Fayol V. **Methods Enzymol** 1997;279:57–66 (16 ref.)
Cyanogen bromide–based assay of thiamin. Wyatt DT, et al. **Methods Enzymol** 1997;279:91–7 (6 ref.)

BIOSYNTHESIS

Sugars and nucleotides and the biosynthesis of thiamine. David S, et al. **Adv Carbohydr Chem Biochem** 1997; 52:267–309 (84 ref.)
Isotopically labeled precursors and mass spectrometry in elucidating biosynthesis of pyrimidine moiety of thiamin in Saccharomyces cerevisiae. Tazuya K, et al. **Methods Enzymol** 1997;279:97–108 (9 ref.)

BLOOD

Determination of thiamin and thiamin phosphates in whole blood by reversed–phase liquid chromatography with precolumn derivatization. Gerrits J, et al. **Methods Enzymol** 1997;279:74–82 (12 ref.)
High–performance liquid chromatography determination of total thiamin in human plasma. Mascher HJ, et al. **Methods Enzymol** 1997;279:83–90 (5 ref.)
Determination of thiamin and its phosphate esters in human blood, plasma, and urine. Tallaksen CM, et al. **Methods Enzymol** 1997;279:67–74 (33 ref.)

METABOLISM

Thiamine utilization in the pathogenesis of alcohol–induced brain damage. Martin PR, et al. **Alcohol Alcohol Suppl** 1994; 2:273–9 (35 ref.)
Thiamin transporters in yeast. Iwashima A, et al. **Methods Enzymol** 1997;279:109–17 (15 ref.)
In vitro systems for studying thiamin transport in mammals. Rindi G, et al. **Methods Enzymol** 1997;279:118–31 (35 ref.)

PHARMACOKINETICS

Bioavailability of Thiamin. Gregory JF 3rd. **Eur J Clin Nutr** 1997 Jan;51 Suppl 1:S34–7 (28 ref.)

PHYSIOLOGY

A non–cofactor role of thiamine derivatives in excitable cells? Bettendorff L. **Arch Physiol Biochem** 1996 Oct; 104(6):745–51 (34 ref.)
[The neural activity of thiamine: facts and hypotheses] Parkhomenko IuM, et al. **Ukr Biokhim Zh** 1996 Mar–Apr; 68(2):3–14 (92 ref.) (Eng. Abstr.) **(Rus)**

URINE

Determination of thiamin and its phosphate esters in human blood, plasma, and urine. Tallaksen CM, et al. **Methods Enzymol** 1997;279:67–74 (33 ref.)

THIAMINE DEFICIENCY

see related
BERIBERI

THIAMINE DIPHOSPHATE see **THIAMINE PYROPHOSPHATE**

THIAMINE MONOPHOSPHATE

BLOOD

Determination of thiamin and thiamin phosphates in whole blood by reversed–phase liquid chromatography with precolumn derivatization. Gerrits J, et al. **Methods Enzymol** 1997;279:74–82 (12 ref.)

THIAMINE PYROPHOSPHATE

Cofactor designing in functional analysis of thiamin diphosphate enzymes. Schellenberger A, et al. **Methods Enzymol** 1997;279:131–46 (25 ref.)

THIAZIDE DIURETICS see **DIURETICS, THIAZIDE**

THIAZINES

THERAPEUTIC USE

Meloxicam. Noble S, et al. **Drugs** 1996 Mar;51(3):424–30; discussion 431–32 (43 ref.)
Meloxicam: selective COX–2 inhibition in clinical practice. Furst DE. **Semin Arthritis Rheum** 1997 Jun;26(6 Suppl 1):21–7 (24 ref.)
[Pharma–Clinics. The drug of the month. Meloxicam (Mobic)] Scheen AJ. **Rev Med Liege** 1997 Apr;52(4):309–11 (5 ref.) **(Fre)**
[New aspects of anti–inflammatory therapy of rheumatic diseases: preclinical validation and clinical trial of meloxicam] Nasonov EL, et al. **Klin Med (Mosk)** 1996; 74(4):4–8 (48 ref.) **(Rus)**
[The new nonsteroidal anti–inflammatory preparation meloxicam in the treatment of rheumatoid arthritis] Grishina EI. **Lik Sprava** 1997 Mar–Apr;(2):19–25 (27 ref.) **(Rus)**

THIAZOLES

Riluzole [see comments] Wokke J. **Lancet** 1996 Sep 21; 348(9030):795–9 (38 ref.) Comment in: Lancet 1996 Dec 14;348(9042):1660; discussion 1660–1. Comment in: Lancet 1996 Dec 14;348(9042):1661.

ADVERSE EFFECTS

1,2–Benzisothiazolin–3–one (Proxel): irritant or allergen? A clinical study and literature review. Chew AL, et al. **Contact Dermatitis** 1997 Mar;36(3):131–6 (26 ref.)

METABOLISM

Metabolism of ebrotidine. A review. Rozman E, et al. **Arzneimittelforschung** 1997 Apr;47(4A):486–9 (13 ref.)

PHARMACOLOGY

Studies on the cytoprotective and antisecretory activity of ebrotidine. A review. Konturek PC, et al. **Arzneimittelforschung** 1997 Apr;47(4A):578–89 (73 ref.)
Gastroprotective properties of ebrotidine. A review. Slomiany BL, et al. **Arzneimittelforschung** 1997 Apr; 47(4A):459–67 (49 ref.)
Anti–Helicobacter pylori activities of ebrotidine. A review of biochemical and animal experimental studies and data. Slomiany BL, et al. **Arzneimittelforschung** 1997 Apr; 47(4A):475–82 (64 ref.)
Troglitazone. Spencer CM, et al. **Drugs** 1997 Jul; 54(1):89–101; discussion 102 (71 ref.)
Troglitazone (CS–045): a new antidiabetic agent. Kaneko T. **Horm Metab Res** 1997 May;29(5):203–13 (81 ref.)
Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects. Auwerx J, et al. **J Atheroscler Thromb** 1996;3(2):81–9 (71 ref.)
Glutamate, excitotoxicity and amyotrophic lateral sclerosis. Shaw PJ, et al. **J Neurol** 1997 May;244 Suppl 2:S3–14 (130 ref.)
The pharmacology and mechanism of action of riluzole. Doble A. **Neurology** 1996 Dec;47(6 Suppl 4):S233–41 (30 ref.)
Trans–differentiation of myoblasts to adipoblasts: triggering effects of fatty acids and thiazolidinediones. Grimaldi PA, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Jul; 57(1):71–5 (22 ref.)

THERAPEUTIC USE

Riluzole: a new agent for amyotrophic lateral sclerosis [see comments] Wagner ML, et al. **Ann Pharmacother** 1997 Jun; 31(6):738–44 (51 ref.) Comment in: Ann Pharmacother 1997 Jun;31(6):779–81.
Troglitazone: a new antihyperglycemic agent. Vidt DG, et al. **Cleve Clin J Med** 1997 May;64(5):238–40 (8 ref.)
Troglitazone. Santiago JV. **Compr Ther** 1997 Aug;23(8):560–2 (6 ref.)
Effects of troglitazone on insulin sensitivity. Henry RR. **Diabet Med** 1996 Sep;13(9 Suppl 6):S148–50 (9 ref.)
Oral antidiabetic drugs: an overview. Melander A. **Diabet Med** 1996 Sep;13(9 Suppl 6):S143–7 (28 ref.)
Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Saltiel AR, et al. **Diabetes** 1996 Dec; 45(12):1661–9 (53 ref.)
Riluzole for amyotrophic lateral sclerosis. **Drug Ther Bull** 1997 Feb;35(2):11–2 (12 ref.)
Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. Bryson HM, et al. **Drugs** 1996 Oct;52(4):549–63 (60 ref.)
Meloxicam. Noble S, et al. **Drugs** 1996 Mar;51(3):424–30; discussion 431–32 (43 ref.)
Therapeutic advances: riluzole for the treatment of motor neurone disease. Clark W, et al. **J Clin Pharm Ther** 1996 Dec;21(6):373–6 (9 ref.)
Impact of riluzole on the relationship between patient and physician. Dengler R, et al. **J Neurol** 1997 May;244 Suppl 2:S30–2 (11 ref.)
Meloxicam: selective COX–2 inhibition in clinical practice. Furst DE. **Semin Arthritis Rheum** 1997 Jun;26(6 Suppl 1):21–7 (24 ref.)
Riluzole and ALS therapy. Hugon J. **Wien Med Wochenschr** 1996;146(9–10):185–7 (27 ref.)
[Pharma–Clinics. The drug of the month. Meloxicam (Mobic)] Scheen AJ. **Rev Med Liege** 1997 Apr;52(4):309–11 (5 ref.) **(Fre)**
[New aspects of anti–inflammatory therapy of rheumatic diseases: preclinical validation and clinical trial of meloxicam] Nasonov EL, et al. **Klin Med (Mosk)** 1996; 74(4):4–8 (48 ref.) **(Rus)**
[The new nonsteroidal anti–inflammatory preparation meloxicam in the treatment of rheumatoid arthritis] Grishina EI. **Lik Sprava** 1997 Mar–Apr;(2):19–25 (27 ref.) **(Rus)**
[Ebrotidine] Elizalde JI. **Gastroenterol Hepatol** 1997 Feb; 20(2):65–7 (30 ref.) **(Spa)**

THIENAMYCINS

Meropenem: a new, extremely broad spectrum beta–lactam antibiotic for serious infections in pediatrics. Bradley JS. **Pediatr Infect Dis J** 1997 Mar;16(3):263–8 (19 ref.)

PHARMACOKINETICS

Pharmacokinetics of meropenem in animals, healthy volunteers, and patients. Moon YS, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S249–55 (44 ref.)

PHARMACOLOGY

The pharmacology of meropenem, a new carbapenem antibiotic. Craig WA. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S266–75 (62 ref.)

THIENAMYCINS

THERAPEUTIC USE

Use of meropenem in the treatment of serious infections in children: review of the current literature. Arrieta A. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S207–12 (51 ref.)

Empirical treatment of febrile neutropenia: evolution of current therapeutic approaches. Hathorn JW, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S256–65 (72 ref.)

Meropenem—a new parenteral broad-spectrum antibiotic. **Med Lett Drugs Ther** 1996 Sep 27;38(984):88–90 (0 ref.)

Efficacy, safety and tolerability of meropenem as empiric antibiotic therapy in hospitalized pediatric patients. Bradley JS, et al. **Pediatr Infect Dis J** 1996 Aug;15(8):749–57 (20 ref.)

Meropenem, a new carbapenem antibiotic. Fish DN, et al. **Pharmacotherapy** 1997 Jul–Aug;17(4):644–69 (164 ref.)

[Meropenem] Shatunov SM, et al. **Antibiot Khimioter** 1996 Jun;41(6):49–61 (114 ref.) **(Rus)**

THIGH

see related

FEMUR

Gracilis muscle transposition in the treatment of faecal incontinence. Sielezneff I, et al. **Int J Colorectal Dis** 1996; 11(1):15–8 (36 ref.)

Perforated cecal adenocarcinoma presenting as a thigh abscess. Mann GN, et al. **South Med J** 1997 Sep; 90(9):949–51 (7 ref.)

[Extraosseus osteogenic sarcoma: report of a case with atypical secondary involvement of the lung] Pezzullo L, et al. **Radiol Med (Torino)** 1997 Mar;93(3):296–8 (16 ref.) **(Ita)**

[Muscle metastasis in a patient with epidermoid carcinoma of the lung] Romano L, et al. **Radiol Med (Torino)** 1997 Mar;93(3):294–5 (11 ref.) **(Ita)**

BLOOD SUPPLY

Anomaly of the femoral artery passage through the substance of sartorius muscle. Clinical consequences. Banjo AO. **Afr J Med Med Sci** 1995 Dec;24(4):343–6 (12 ref.)

INJURIES

Heterotopic bone formation within a missile track. Morasch MD, et al. **J Accid Emerg Med** 1996 May;13(3):227–9 (13 ref.)

PATHOLOGY

Symmetrical multifocal liposarcoma. Kulhavy M, et al. **S Afr J Surg** 1997 May;35(2):68–9 (14 ref.)

THIN SECTIONING see **MICROTOMY**

THINKING

Developing the reflective teacher. Scanlan JM, et al. **J Adv Nurs** 1997 Jun;25(6):1138–43 (14 ref.)

Reflective journal writing in nurse education: whose interests does it serve? Wellard SJ, et al. **J Adv Nurs** 1996 Nov; 24(5):1077–82 (34 ref.)

Reflective learning: a teaching strategy for critical thinking. Baker CR. **J Nurs Educ** 1996 Jan;35(1):19–22 (14 ref.)

Issues in measuring critical thinking: meeting the challenge. Rane-Szostak D, et al. **J Nurs Educ** 1996 Jan;35(1):5–11 (41 ref.)

Externalizing the critical thinking in knowledge development and clinical judgment. Facione NC, et al. **Nurs Outlook** 1996 May-Jun;44(3):129–36 (19 ref.)

An implicit world view in technology and its consequences for contemporary life. Ketner KL. **Nurs Outlook** 1996 Nov-Dec;44(6):280–3 (9 ref.)

Counterfactual thinking. Roese NJ. **Psychol Bull** 1997 Jan; 121(1):133–48 (165 ref.)

Perseveration in schizophrenia. Crider A. **Schizophr Bull** 1997;23(1):63–74 (100 ref.)

CLASSIFICATION

Dichotomous thinking in nuclear medicine technology. Dowd SB, et al. **J Nucl Med Technol** 1997 Jun;25(2):120–3 (22 ref.)

PHYSIOLOGY

A cognitive neuroscience view of schizophrenic thought disorder. Spitzer M. **Schizophr Bull** 1997;23(1):29–50 (110 ref.)

THINNESS

[Lean hypertension] Nakamura Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):175–7 (19 ref.) **(Jpn)**

MORTALITY

[Are small and thin people condemned to an early death? Scotland Yard inquiry (editorial)] Rey J. **Arch Pediatr** 1997 Apr;4(4):299–304 (48 ref.) **(Fre)**

THIOBACTERIACEAE see **GRAM-NEGATIVE CHEMOLITHOTROPHIC BACTERIA**

THIOBARBITURIC ACID REACTIVE SUBSTANCES

ANALYSIS

Estimation of peroxidative damage. A critical review. Esterbauer H. **Pathol Biol (Paris)** 1996 Jan;44(1):25–8 (20 ref.)

THIOCARBAMATES

METABOLISM

Dithiocarbamates and the redox regulation of cell death. Orrenius S, et al. **Biochem Soc Trans** 1996 Nov;24(4):1032–8 (43 ref.)

THIOCTIC ACID

[alpha-Lipoic acid—a natural disulfide cofactor and antioxidant with anticarcinogenic effects] Dovinová I. **Ceska Slov Farm** 1996 Sep;45(5):237–41 (49 ref.) (Eng. Abstr.) **(Slo)**

ANALOGS & DERIVATIVES

High-performance liquid chromatography methods for determination of lipoic and dihydrolipoic acid in human plasma. Teichert J, et al. **Methods Enzymol** 1997;279:159–66 (6 ref.)

ANALYSIS

Analysis of lipoic acid by gas chromatography with flame photometric detection. Kataoka H, et al. **Methods Enzymol** 1997;279:166–76 (37 ref.)

BIOSYNTHESIS

Biosynthesis of lipoic acid and posttranslational modification with lipoic acid in Escherichia coli. Jordan SW, et al. **Methods Enzymol** 1997;279:176–83 (19 ref.)

BLOOD

High-performance liquid chromatography methods for determination of lipoic and dihydrolipoic acid in human plasma. Teichert J, et al. **Methods Enzymol** 1997;279:159–66 (6 ref.)

CHEMISTRY

Lipoylation of acyltransferase components of 2-oxo acid dehydrogenase complexes. Quinn J. **Methods Enzymol** 1997;279:193–202 (25 ref.)

METABOLISM

Alpha-lipoic acid: a metabolic antioxidant and potential redox modulator of transcription. Packer L, et al. **Adv Pharmacol** 1997;38:79–101 (102 ref.)

Lipoate addition to acyltransferases of alpha-keto acid dehydrogenase complexes and H-protein of glycine cleavage system. Fujiwara K, et al. **Methods Enzymol** 1997; 279:184–93 (23 ref.)

PHARMACOLOGY

Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Packer L, et al. **Free Radic Biol Med** 1997; 22(1-2):359–78 (215 ref.)

THERAPEUTIC USE

Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Ziegler D, et al. **Diabetes** 1997 Sep;46 Suppl 2:S62–6 (38 ref.)

THIOCYANATES

DIAGNOSTIC USE

[In vivo test of thyroid radioactive iodide uptake, pertechnetate 99m uptake and thyroid scintigraphy] Ochi Y, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:317–20 (5 ref.) **(Jpn)**

THIOETHERS see **SULFIDES**

THIOGLYCOLATES

THERAPEUTIC USE

Erdosteine. Dechant KL, et al. **Drugs** 1996 Dec;52(6):875–81; discussion 882 (23 ref.)

THIOGLYCOSIDES

CHEMISTRY

Thioglycosides as glycosyl donors in oligosaccharide synthesis. Garegg PJ. **Adv Carbohydr Chem Biochem** 1997; 52:179–205 (189 ref.)

THIOL PROTEINASES see **CYSTEINE PROTEINASES**

THIOLESTER HYDROLASES

ANALYSIS

Ubiquitin C-terminal hydrolases in chick skeletal muscle. Chung CH, et al. **Adv Exp Med Biol** 1996;389:203–8 (19 ref.)

METABOLISM

Use of the two-hybrid system to identify cellular partners of the HIV1 Nef protein. Benichou S, et al. **Res Virol** 1997 Jan-Feb;148(1):71–3 (30 ref.)

THIOLS see **SULFHYDRYL COMPOUNDS**

THIONUCLEOTIDES

Oligonucleotide-directed mutagenesis using an improved phosphorothioate approach. Dale SJ, et al. **Methods Mol Biol** 1996;57:55–64 (8 ref.)

CHEMISTRY

Oligonucleotide-directed random mutagenesis using the phosphorothioate method. Dale SJ, et al. **Methods Mol Biol** 1996;57:369–74 (5 ref.)

PHARMACOKINETICS

Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Geary RS, et al. **Anticancer Drug Des** 1997 Jul;12(5):383–93 (23 ref.)

Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase. Henry SP, et al. **Anticancer Drug Des** 1997 Jul;12(5):409–20 (38 ref.)

Pharmacokinetics of antisense analogues in the central nervous system. Szklarczyk A, et al. **Neurochem Int** 1997 Sep;31(3):413–23 (43 ref.)

PHARMACOLOGY

Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Geary RS, et al. **Anticancer Drug Des** 1997 Jul;12(5):383–93 (23 ref.)

TOXICITY

Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides. Henry SP, et al. **Anticancer Drug Des** 1997 Jul;12(5):395–408 (37 ref.)

Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase. Henry SP, et al. **Anticancer Drug Des** 1997 Jul;12(5):409–20 (38 ref.)

THIOPHENES

ADMINISTRATION & DOSAGE

[Local carbonic anhydrase inhibitor dorzolamide: development and properties] Pfeiffer N. **Ophthalmologe** 1996 Feb;93(1):103–18 (9 ref.) **(Ger)**

METABOLISM

New biological reactive intermediates: metabolic activation of thiophene derivatives. Mansuy D, et al. **Adv Exp Med Biol** 1996;387:1–6 (15 ref.)

PHARMACOLOGY

Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. Balfour JA, et al. **Drugs Aging** 1997 May; 10(5):384–403 (81 ref.)

The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor. Sugrue MF. **J Ocul Pharmacol Ther** 1996 Fall;12(3):363–76 (41 ref.)

Efficacy and tolerability of a new inhibitor of thymidylate synthase: 'Tomudex' (raltitrexed). Cunningham D. **Tumori** 1997 Jan-Feb;83(1 Suppl):S70–1 (08 ref.)

THERAPEUTIC USE

Raltitrexed in colorectal cancer. **Drug Ther Bull** 1996 Oct; 34(10):78–80 (11 ref.)

Erdosteine. Dechant KL, et al. **Drugs** 1996 Dec;52(6):875–81; discussion 882 (23 ref.)

New medical therapies for glaucoma. Drake MV. **Int Ophthalmol Clin** 1996 Spring;36(2):53–60 (29 ref.)

Tomudex (ZD1694): from concept to care, a programme in rational drug discovery. Jackman AL, et al. **Invest New Drugs** 1996;14(3):305–16 (83 ref.)

Trusopt, a topical carbonic anhydrase inhibitor. Donohue EK, et al. **J Glaucoma** 1996 Feb;5(1):68–74 (79 ref.)

The potential role of Tomudex in the treatment of advanced colorectal cancer. Sobrero AF. **Tumori** 1997 Mar-Apr; 83(2):576–80 (42 ref.)

THIOREDOXIN

BLOOD

[EBV-related malignancies and thioredoxin] Noda N, et al. **Nippon Rinsho** 1997 Feb;55(2):461-6 (24 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Thioredoxins: universal, yet specific thiol-disulfide redox cofactors. Follmann H, et al. **Biofactors** 1995-96; 5(3):147-56 (128 ref.)

METABOLISM

Redox regulation of cellular activation. Nakamura H, et al. **Annu Rev Immunol** 1997;15:351-69 (93 ref.)

PHARMACOLOGY

Thioredoxin/adult T-cell leukemia-derived factor (ADF) and redox regulation. Sasada T, et al. **J Toxicol Sci** 1996 Dec;21(5):285-7 (0 ref.)

THIOREDOXIN REDUCTASE (NADPH)

CHEMISTRY

The mutual sparing effects of selenium and vitamin E in animal nutrition may be further explained by the discovery that mammalian thioredoxin reductase is a selenoenzyme. Tamura T, et al. **Biofactors** 1995-96;5(2):99-102 (42 ref.)

THIOSULFATE CYANIDE TRANSSULPHURASE see **THIOSULFATE SULFURTRANSFERASE**

THIOSULFATE SULFURTRANSFERASE

GENETICS

Cotranslational folding of nascent proteins on Escherichia coli ribosomes. Hardesty B, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11-12):1199-207 (22 ref.)

THIRD-NERVE PALSY see **OCULOMOTOR NERVE PARALYSIS**

THIRD-NERVE PARALYSIS see **OCULOMOTOR NERVE PARALYSIS**

THIRD-PARTY PAYMENTS see **INSURANCE, HEALTH, REIMBURSEMENT**

THIRD-WORLD COUNTRIES see **DEVELOPING COUNTRIES**

THIRST

see related
WATER DEPRIVATION

PHYSIOLOGY

The neuronal role of angiotensin II in thirst, sodium appetite, cognition and memory. Mosimann R, et al. **Biol Rev Camb Philos Soc** 1996 Nov;71(4):545-59 (117 ref.)

The neuroendocrinology of thirst and salt appetite: visceral sensory signals and mechanisms of central integration. Johnson AK, et al. **Front Neuroendocrinol** 1997 Jul; 18(3):292-353 (369 ref.)

Interaction of vasopressin and angiotensin II in central control of blood pressure and thirst. Szczepańska-Sadowska E. **Regul Pept** 1996 Oct 8; 66(1-2):65-71 (60 ref.)

The role of angiotensin II in ingestive behaviour: a brief review of angiotensin II, thirst and Na appetite. Weisinger RS, et al. **Regul Pept** 1996 Oct 8;66(1-2):73-81 (100 ref.)

THOMSEN'S DISEASE see **MYOTONIA CONGENITA**

THORACIC ARTERIES

[Communication between intercostal artery and pulmonary vein—report of a case] Oura S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 May;44(5):691-6 (32 ref.) (Eng. Abstr.) **(Jpn)**

THORACIC CYST see **MEDIASTINAL CYST**

THORACIC DISEASES

DIAGNOSIS

Pediatric chest MR imaging. Noncardiac clinical uses. Siegel MJ, et al. **Magn Reson Imaging Clin N Am** 1996 Nov; 4(4):599-613 (27 ref.)

Lesions and nodes of the thoracic inlet. Dalley RW. **Semin Ultrasound CT MR** 1996 Dec;17(6):576-604 (31 ref.)

[Imaging of osteoarticular diseases of the anterior chest wall] Grignon B, et al. **J Radiol** 1997 Feb;78(2):103-10 (31 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

[Computerized tomography of AIDS associated thoracic diseases] Bankier AA, et al. **Radiologe** 1996 Jul;36(7):543-9 (16 ref.) (Eng. Abstr.) **(Ger)**

[Thoracic actinomycosis] Besznyák G, et al. **Orv Hetil** 1996 Sep 15;137(37):2041-3 (29 ref.) (Eng. Abstr.) **(Hun)**

SURGERY

[The potentials for the surgical treatment of intrathoracic sarcoidosis complicated by chronic pleurisy] Duzhil ID, et al. **Lik Sprava** 1996 Jul-Sep;(7-9):168-70 (12 ref.) (Eng. Abstr.) **(Rus)**

ULTRASONOGRAPHY

Thoracic sonography for diagnosis and intervention. Sistrom CL, et al. **Curr Probl Diagn Radiol** 1997 Jan-Feb;26(1):1-49 (148 ref.)

THORACIC DUCT

[Mediastinal thoracic duct cyst—a case report] Nishizaki K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Oct; 44(10):1871-6 (29 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

Bilateral chylothorax following thoracic duct ligation: case report and review of the literature. Robinson K, et al. **Ann Vasc Surg** 1996 Jul;10(4):390-5 (32 ref.)

THORACIC INJURIES

The fractured rib in chest wall trauma. Mayberry JC, et al. **Chest Surg Clin N Am** 1997 May;7(2):239-61 (75 ref.)

COMPLICATIONS

Traumatic rupture of the thoracic aorta: the diagnostic challenge. Casselman F, et al. **Acta Chir Belg** 1996 Nov-Dec;96(6):291-4 (13 ref.)

Missile emboli to the pulmonary artery [letter] Gupta AK, et al. **Am J Emerg Med** 1997 Mar;15(2):213-4 (12 ref.)

Traumatic adult respiratory distress syndrome. Bass TL, et al. **Chest Surg Clin N Am** 1997 May;7(2):429-42 (71 ref.)

Traumatic thoracic fistulas. Sebastian MW, et al. **Chest Surg Clin N Am** 1997 May;7(2):385-400 (33 ref.)

Tracheal rupture after blunt chest trauma in a child. Mordehai J, et al. **J Pediatr Surg** 1997 Jan;32(1):104-5 (12 ref.)

Video-assisted thoracic surgery in treatment of chest trauma. Liu DW, et al. **J Trauma** 1997 Apr;42(4):670-4 (20 ref.)

Survival following traumatic rupture of the heart in a child. Michaels A, et al. **Pediatr Emerg Care** 1997 Feb;13(1):19-20 (16 ref.)

Ventricular fibrillation following blunt chest trauma from a baseball. van Amerongen R, et al. **Pediatr Emerg Care** 1997 Apr;13(2):107-10 (19 ref.)

Post-traumatic costochondritis caused by Candida albicans. Aetiology, diagnosis and treatment. Heckenkamp J, et al. **Scand Cardiovasc J** 1997;31(3):165-7 (12 ref.)

Traumatic asphyxia syndrome. Nunn CR, et al. **Tenn Med** 1997 Apr;90(4):144-6 (19 ref.)

[A case of myocardial rupture in closed thoracic injury] Demarche M, et al. **Rev Med Liege** 1997 Feb;52(2):105-9 (39 ref.) **(Fre)**

[Bacillus cereus pneumonia after thoracic trauma. Case report and review of the literature] Bastian L, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Feb; 32(2):124-9 (28 ref.) (Eng. Abstr.) **(Ger)**

[Ventricular septal rupture after blunt chest trauma] Roithinger FX, et al. **Dtsch Med Wochenschr** 1996 Nov 15;121(46):1424-7 (23 ref.) (Eng. Abstr.) **(Ger)**

[Coronary vascular damage in thoracic trauma] Schwaiblmair M, et al. **Dtsch Med Wochenschr** 1997 Aug 22; 122(34-35):1043-6 (34 ref.) **(Ger)**

[Hemolysis and multiple trauma. A clinical case report] Buzio M, et al. **Minerva Chir** 1997 Apr;52(4):485-7 (10 ref.) (Eng. Abstr.) **(Ita)**

[Acute myocardial infarction due to trauma] Takino T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):573-6 (20 ref.) **(Jpn)**

DIAGNOSIS

Homicidal tandem bullet wound of the chest. Bentley AJ, et al. **Am J Forensic Med Pathol** 1997 Mar;18(1):56-9 (13 ref.)

Newer diagnostic measures and emergency management. Mattox KL, et al. **Chest Surg Clin N Am** 1997 May; 7(2):213-26 (66 ref.)

Mitral valve disruption following blunt trauma: case report and review of the literature. Pathi V, et al. **Eur J Cardiothorac Surg** 1996;10(9):806-8 (20 ref.)

Trauma of the chest. Reuter M. **Eur Radiol** 1996;6(5):707-16 (34 ref.)

Laparoscopic transdiaphragmatic diagnostic pericardial window in the hemodynamically stable patient with penetrating chest trauma. A brief report. McMahon DJ, et al. **Surg Endosc** 1997 May;11(5):474-5 (9 ref.)

PATHOLOGY

Left ventricular aneurysm caused by blunt chest trauma. Arcudi G, et al. **Am J Forensic Med Pathol** 1996 Sep; 17(3):194-6 (11 ref.)

PHYSIOPATHOLOGY

Pathophysiology of chest trauma. Calhoon JH, et al. **Chest Surg Clin N Am** 1997 May;7(2):199-211 (30 ref.)

RADIOGRAPHY

Traumatic first rib fracture: is angiography necessary? A review of 730 cases. Gupta A, et al. **Cardiovasc Surg** 1997 Feb;5(1):48-53 (21 ref.)

Chest trauma. Chan O, et al. **Eur J Radiol** 1996 Aug; 23(1):23-34 (108 ref.)

SURGERY

Anesthetic considerations in chest trauma. Fouché Y, et al. **Chest Surg Clin N Am** 1997 May;7(2):227-38 (22 ref.)

Video-assisted thoracic surgery in trauma patients [see comments] Carrillo EH, et al. **J Am Coll Surg** 1997 Mar; 184(3):316-24 (31 ref.) Comment in: J Am Coll Surg 1997 Aug;185(2):197-8.

Damage control for thoracic injuries. Wall MJ Jr, et al. **Surg Clin North Am** 1997 Aug;77(4):863-78 (28 ref.)

[Diaphragmatic injuries—classification, diagnosis and therapy] Steinau G, et al. **Chirurg** 1997 May;68(5):509-12 (18 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Newer diagnostic measures and emergency management. Mattox KL, et al. **Chest Surg Clin N Am** 1997 May; 7(2):213-26 (66 ref.)

ULTRASONOGRAPHY

Chest trauma: the role of transesophageal echocardiography. O'Connor C. **J Clin Anesth** 1996 Nov;8(7):605-13 (53 ref.)

[Valvular lesions in the course of nonpenetrating thoracic trauma: their diagnosis by transesophageal echocardiography] Ussia GP, et al. **Cardiologia** 1996 Nov; 41(11):1107-11 (39 ref.) (Eng. Abstr.) **(Ita)**

THORACIC NEOPLASMS

Malignant peripheral nerve sheath tumor arising in a "de novo" ganglioneuroma: a case report and review of the literature. Drago G, et al. **Med Pediatr Oncol** 1997 Mar; 28(3):216-22 (21 ref.)

COMPLICATIONS

Malignant pericardial effusion [see comments] Shepherd FA. **Curr Opin Oncol** 1997 Mar;9(2):170-4 (28 ref.) Comment in: Curr Opin Oncol 1997 Mar;9(2):147-8.

[Surgical emergency induced by chest tumors] Yamaguchi Y, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(3):272-8 (7 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Hourglass thoracic lipoma of infancy: case report and review of the literature. Solsona-Norbón B, et al. **J Pediatr Surg** 1997 May;32(5):785-6 (9 ref.)

ETIOLOGY

[A case of T-cell malignant lymphoma developing in the chest wall of chronic pyothorax after artificial pneumothorax] Kamiya I. **Nippon Kyobu Geka Gakkai Zasshi** 1996 May;44(5):709-13 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Malignant lymphoma of the chest wall in a patient with chronic empyema] Nishiyama N, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 May; 34(5):579-85 (15 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Mesenchymal hamartoma of the chest wall in infancy—a case report of this rare entity with cytologic findings [see comments] Szadowska A, et al. **Cytopathology** 1996 Jun; 7(3):211-7 (28 ref.) Comment in: Cytopathology 1997 Jun;8(3):215-7.

Pitfalls in the diagnosis of ectopic hamartomatous thymoma. Michal M, et al. **Histopathology** 1996 Dec;29(6):549-55 (11 ref.)

A case of liposarcoma originating in the chest wall. Urabe M, et al. **Nippon Geka Hokan** 1995 Nov 1;64(6):131-8 (20 ref.)

RADIOGRAPHY

[Computerized tomography of AIDS associated thoracic diseases] Bankier AA, et al. **Radiologe** 1996 Jul;36(7):543-9 (16 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Chest wall resection and reconstruction. Sabanathan S, et al. **Br J Hosp Med** 1997 Mar 19-Apr 1;57(6):255-9 (21 ref.)

[Reconstructive plastic surgery of thoracic wall defects] Steinau HU, et al. **Chirurg** 1997 May;68(5):461-8 (23 ref.) (Eng. Abstr.) **(Ger)**

[A case report of malignant schwannoma of the chest wall]

THORACIC NEOPLASMS

Morita I, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jan;45(1):46–50 (14 ref.) (Eng. Abstr.) **(Jpn)**

THORACIC NERVES

INJURIES

Long thoracic nerve injury due to an electric burn. Still JM, et al. **J Burn Care Rehabil** 1996 Nov–Dec;17(6 Pt 1):562–4 (7 ref.)

THORACIC OUTLET SYNDROME

Thoracic outlet syndrome. Oates SD, et al. **Hand Clin** 1996 Nov;12(4):705–18 (43 ref.)

The thoracic outlet syndrome in athletes. Nichols AW. **J Am Board Fam Pract** 1996 Sep–Oct;9(5):346–55 (43 ref.)

Thoracic outlet syndrome. Novak CB, et al. **Orthop Clin North Am** 1996 Oct;27(4):747–62 (64 ref.)

[Primary subclavian vein thrombosis (Paget–Schroetter syndrome)] Nakashima K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):462–5 (19 ref.) **(Jpn)**

DIAGNOSIS

[Thoracic outlet syndrome––an interdisciplinary topic. Experience with diagnosis and therapy in a 15-year patient cohort (80 trans-axillary resections of the 1st rib in 67 patients) and a literature review] Wenz W, et al. **Z Orthop Ihre Grenzgeb** 1997 Jan–Feb;135(1):84–90 (32 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Thoracic outlet compression syndrome: clinical evaluation and surgical results of 94 cases. Turgut M, et al. **Acta Chir Belg** 1996 Sep–Oct;96(5):211–6 (41 ref.)

[Removal of the 1st rib in thoracic outlet syndrome. Is it helpful? Is it safe? (see comments)] Richter HP. **Nervenarzt** 1996 Dec;67(12):1034–7 (26 ref.) (Eng. Abstr.) Comment in: Nervenarzt 1996 Dec;67(12):1038–9. **(Ger)**

[Thoracic outlet syndrome––an interdisciplinary topic. Experience with diagnosis and therapy in a 15-year patient cohort (80 trans-axillary resections of the 1st rib in 67 patients) and a literature review] Wenz W, et al. **Z Orthop Ihre Grenzgeb** 1997 Jan–Feb;135(1):84–90 (32 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[Conservative therapy in thoracic outlet syndrome. Literature review and pathogenetic considerations] Beer S, et al. **Schweiz Med Wochenschr** 1997 Apr 12; 127(15):617–22 (50 ref.) (Eng. Abstr.) **(Ger)**

THORACIC RADIOGRAPHY

Radiologic issues in lung transplantation for end-stage pulmonary disease. Erasmus JJ, et al. **AJR Am J Roentgenol** 1997 Jul;169(1):69–78 (81 ref.)

Chest radiography in the ICU. Henschke CI, et al. **Clin Imaging** 1997 Mar–Apr;21(2):90–103 (51 ref.)

Computed tomography of malpositioned thoracostomy drains: a pictorial essay. Cameron EW, et al. **Clin Radiol** 1997 Mar;52(3):187–93 (9 ref.)

Imaging the neonatal chest. Gibson AT, et al. **Clin Radiol** 1997 Mar;52(3):172–86 (139 ref.)

Interventional chest radiology. Giron J, et al. **Eur J Radiol** 1996 Aug;23(1):58–78 (42 ref.)

Chest imaging in the intensive care unit. Tocino I. **Eur J Radiol** 1996 Aug;23(1):46–57 (50 ref.)

Chest imaging: indications and interpretation. Briggs GM. **Med J Aust** 1997 May 19;166(10):555–60 (11 ref.)

Chest radiography. Ravin CE, et al. **Radiology** 1997 Sep; 204(3):593–600 (61 ref.)

[Pulmonary actinomycosis––diagnosis and therapy based on past reports of actinomycosis] Tanaka S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec; 34(12):1380–4 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Lung cancer: Progress in diagnosis and treatment. II. Diagnostic imaging: 1. Basis of interpretation of plain thoracic X-ray photographs] Ikezoe J. **Nippon Naika Gakkai Zasshi** 1997 Jan 10;86(1):33–8 (4 ref.) **(Jpn)**

INSTRUMENTATION

Stimulable phosphor plates in chest radiology. Tylén U. **Eur Radiol** 1997;7 Suppl 3:S83–6 (16 ref.)

Technical trends in functional radiology of the lung. Meduri A, et al. **Rays** 1997 Jan–Mar;22(1):14–37 (8 ref.) **(Eng, Ita)**

METHODS

Helical/spiral computed body tomography. Brink JA, et al. **Clin Radiol** 1997 Jul;52(7):489–503 (102 ref.)

[Digital radiography of the thorax] Frija J, et al. **J Radiol** 1997 Mar;78(3):193–207 (81 ref.) (Eng. Abstr.) **(Fre)**

[X-ray diagnosis of pericarditis] Vishniakova MV, et al. **Vestn Rentgenol Radiol** 1997 Jan–Feb;(1):39–44 (16 ref.) **(Rus)**

THORACIC SURGERY

The complications of thoracic surgery: prophylaxis and treatment of arrhythmias. Van Mieghem W. **Acta Cardiol** 1995;50(5):381–6 (11 ref.)

Using titanium plate or meshplate for chest wall reconstruction: report of 6 cases and literature review. Luh SP, et al. **Artif Organs** 1996 Dec;20(12):1295–8 (13 ref.)

Controlled clinical studies of fibrin sealant in cardiothoracic surgery––a review. Kjaergard HK, et al. **Eur J Cardiothorac Surg** 1996;10(9):727–33 (30 ref.)

What's new in general thoracic surgery. Patterson GA. **J Am Coll Surg** 1997 Feb;184(2):196–203 (37 ref.)

[Progresses in thoracic surgery in China, 1996] Li Z. **Chung Hua I Hsueh Tsa Chih** 1996 Dec;76(12):903–5 (0 ref.) **(Chi)**

[Value of video-assisted thoracic surgery in internal medicine. Apropos of 7 cases] Coutant G, et al. **Rev Med Interne** 1996;17(7):579–85 (20 ref.) (Eng. Abstr.) **(Fre)**

[Ideal clinical care system in thoracic surgery] Kawashima Y. **Kyobu Geka** 1997 Jan;50(1):22–5 (7 ref.) **(Jpn)**

[Reality of thoracic surgery in Japan viewed from other countries] Nikaido H. **Kyobu Geka** 1997 Jan;50(1):48–50 (0 ref.) **(Jpn)**

[Asian educational exchange in thoracic surgery] Oishi K. **Kyobu Geka** 1997 Jan;50(1):45–7 (0 ref.) **(Jpn)**

[Thoracic surgery that is attractive to medical students] Osada H. **Kyobu Geka** 1997 Jan;50(1):26–9 (1 ref.) **(Jpn)**

[Thoracic surgery and certification of the specialty] Watanabe Y. **Kyobu Geka** 1997 Jan;50(1):46–4 (5 ref.) **(Jpn)**

[A case of asymptomatic posterior mediastinal pheochromocytoma diagnosed during the procedure of video-assisted thoracic surgery (VATS)] Yajima H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Feb;45(2):155–60 (18 ref.) (Eng. Abstr.) **(Jpn)**

EDUCATION

[Undergraduate and graduate education of thoracic surgery] Tanaka S. **Kyobu Geka** 1997 Jan;50(1):30–9 (18 ref.) **(Jpn)**

METHODS

Chest wall resection and reconstruction. Sabanathan S, et al. **Br J Hosp Med** 1997 Mar 19–Apr 1;57(6):255–9 (21 ref.)

Fibrin sealant in thoracic surgery. Pulmonary applications, including management of bronchopleural fistula. Bayfield MS, et al. **Chest Surg Clin N Am** 1996 Aug;6(3):567–83 (60 ref.)

Intrathoracic muscle transposition. Surgical anatomy and techniques of harvest. Harris SU, et al. **Chest Surg Clin N Am** 1996 Aug;6(3):501–18 (11 ref.)

Video assisted thoracic surgery for spontaneous pneumothorax. Berrisford RG, et al. **Thorax** 1996 Aug;51 Suppl 2:S23–8 (42 ref.)

Surgical indications for treatment of pulmonary tuberculosis. Freixinet J. **World J Surg** 1997 Jun;21(5):475–9 (40 ref.)

THORACIC VERTEBRAE

Spinal angiolipomas revisited: two case reports. Trabulo A, et al. **Acta Neurochir (Wien)** 1996;138(11):1311–9 (21 ref.)

Burkitt's lymphoma-leukemia in patients treated for Hodgkin's disease. Salloum E, et al. **Cancer Invest** 1996; 14(6):527–33 (47 ref.)

Three-level thoracic disc herniation: case report and review of the literature. Korovessis PG, et al. **Eur Spine J** 1997; 6(1):74–6 (22 ref.)

Osteoid osteoma of the vertebral body with extension across the intervertebral disc. Hurtgen KL, et al. **J Manipulative Physiol Ther** 1996 Feb;19(2):118–23 (31 ref.)

Treatment of coccidioidal spinal infection: experience in 16 cases. Herron LD, et al. **J Spinal Disord** 1997 Jun; 10(3):215–22 (11 ref.)

Radiotherapy in the treatment of symptomatic vertebral hemangiomas: technical case report. Bremnes RM, et al. **Neurosurgery** 1996 Nov;39(5):1054–8 (37 ref.)

Radiologic case study. Symptomatic, calcified extruded disk of the thoracic spine. Falbo SE, et al. **Orthopedics** 1997 Jan;20(1):84, 76 (8 ref.)

Chordoma: a case report. Jallo J, et al. **Surg Neurol** 1997 Jul;48(1):46–8 (14 ref.)

[Vertebral hemangioma symptomatic during pregnancy. A case report and review of the literature] Abi-Fadel W, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(1):90–4 (20 ref.) (Eng. Abstr.) **(Fre)**

[Thoracic spondylotic myelopathies. Apropos of 4 new cases] Stecken J, et al. **Neurochirurgie** 1996;42(3):147–52 (40 ref.) (Eng. Abstr.) **(Fre)**

ABNORMALITIES

[Severe congenital thoracic-lumbar scoliosis in pregnancy. A case report and review of the literature] Restaino A, et al. **Minerva Ginecol** 1996 Dec;48(12):565–71 (29 ref.) (Eng. Abstr.) **(Ita)**

[Straight back syndrome] Hase M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):342–4 (8 ref.) **(Jpn)**

INJURIES

Traumatic tear of the basilar artery associated with vertebral column injuries. Sato Y, et al. **Am J Forensic Med Pathol** 1997 Jun;18(2):129–34 (21 ref.)

Pneumocephalus associated with fracture of thoracic spine: case report. Uemura K, et al. **Br J Neurosurg** 1997 Jun; 11(3):253–6 (16 ref.)

Anterior instrumentation in the management of thoracolumbar burst fractures. Ghanayem AJ, et al. **Clin Orthop** 1997 Feb;(335):89–100 (38 ref.)

Posterior instrumentation for thoracolumbar trauma. Stambough JL. **Clin Orthop** 1997 Feb;(335):73–88 (131 ref.)

Emergency department approach to acute thoracolumbar spine injury. Savitsky E, et al. **J Emerg Med** 1997 Jan–Feb; 15(1):49–60 (72 ref.)

Thoracic and lumbar spine trauma. Brandser EA, et al. **Radiol Clin North Am** 1997 May;35(3):533–57 (77 ref.)

Osteoporotic vertebral fractures in a man under high-dose inhaled glucocorticoid therapy. A case-report with a review of the literature. Laroche M, et al. **Rev Rhum Engl Ed** 1997 Apr;64(4):267–70 (16 ref.)

The role of imaging in the diagnosis and management of thoracolumbar burst fractures: current concepts and a review of the literature. Saifuddin A, et al. **Skeletal Radiol** 1996 Oct;25(7):603–13 (49 ref.)

PATHOLOGY

Percutaneous biopsy of the thoracic spine [published erratum of serious dosage error appears in Neurosurg Clin N Am 1997 Jul;8(3):1] Donaldson WF 3rd, et al. **Neurosurg Clin N Am** 1996 Jan;7(1):135–44 (38 ref.)

Spinal pigmented villonodular synovitis: a case report. Gezen F, et al. **Spine** 1996 Mar 1;21(5):642–5 (20 ref.)

PHYSIOLOGY

The influence of the mobility in the cervicothoracic spine and the upper ribs (shoulder girdle) on the mobility of the scapulohumeral joint. Sobel JS, et al. **J Manipulative Physiol Ther** 1996 Sep;19(7):469–74 (16 ref.)

RADIOGRAPHY

Neonatal mucolipidosis II (I-cell disease) with dysharmonic epiphyseal ossification and butterfly vertebral body. Herman TE, et al. **J Perinatol** 1996 Sep–Oct;16(5):400–2 (16 ref.)

SURGERY

Minimally invasive arthroscopic spinal surgery. Kambin P, et al. **Instr Course Lect** 1997;46:143–61 (79 ref.)

Minimally invasive endoscopic surgery of the spine. Goldstein JA, et al. **J South Orthop Assoc** 1996 Winter; 5(4):251–62 (34 ref.)

Percutaneous endoscopic thoracic discectomy. Regan JJ. **Neurosurg Clin N Am** 1996 Jan;7(1):87–98 (43 ref.)

THORACOPLASTY

[Thoracoplasty in pulmonary tuberculosis] Kravchenko AF. **Probl Tuberk** 1997;(2):38–41 (43 ref.) **(Rus)**

THORACOSCOPY

Thoracoscopic excision of bronchogenic cyst of the oesophagus––a case report. Sim EW, et al. **Ann Acad Med Singapore** 1996 Sep;25(5):730–1 (8 ref.)

Thoracoscopy in the management of spontaneous pneumothorax. Janssen JP. **Int Surg** 1996 Oct–Dec; 81(4):339–42 (63 ref.)

Pediatric thoracoscopy: a new vista [see comments] Bullard KM, et al. **Pediatr Pulmonol** 1996 Aug;22(2):129–35 (34 ref.) Comment in: Pediatr Pulmonol 1996 Aug;22(2):79.

Pleuroscopy: therapeutic applications. Weissberg D, et al. **Scand J Thorac Cardiovasc Surg** 1996;30(1):1–10 (55 ref.)

[Value of video-assisted thoracic surgery in internal medicine. Apropos of 7 cases] Coutant G, et al. **Rev Med Interne** 1996;17(7):579–85 (20 ref.) (Eng. Abstr.) **(Fre)**

[Thoracoscopic methods in treatment of pulmonary emphysema] Klepetko W, et al. **Chirurg** 1996 Dec; 67(12):1215–21 (26 ref.) (Eng. Abstr.) **(Ger)**

[Thoracoscopy: current diagnostic and therapeutic indications] Loddenkemper R, et al. **Pneumologie** 1996 Feb; 50(2):189–201 (130 ref.) **(Ger)**

[Video-assisted esophagectomy for carcinoma of the esophagus, using thoracoscopy or mediastinoscopy] Mafune K, et al. **Gan To Kagaku Ryoho** 1997 Mar; 24(5):525–31 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Video-assisted thoracic surgery for lung cancer] Shirakusa T, et al. **Gan To Kagaku Ryoho** 1997 Mar;24(5):520–4 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical application of thoracoscopy] Kitamura S. **Nippon Naika Gakkai Zasshi** 1996 Dec 10;85(12):2091–5 (7 ref.) **(Jpn)**

[Thoracoscopic surgery] Inui K, et al. **Nippon Rinsho** 1996 May;54(5):1322–5 (17 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Video-assisted thoracic surgery (VATS) for cancer. Risk of parietal seeding and of early local recurrence. Collard JM, et al. **Int Surg** 1996 Oct–Dec;81(4):343–6 (70 ref.)

INSTRUMENTATION

Pleuropericardial cysts: treatment by videothoracoscopy. Mouroux J, et al. **Surg Laparosc Endosc** 1996 Oct;6(5):403–4 (5 ref.)

METHODS

Thoracoscopic sympathicolysis for essential hyperhidrosis: immediate and one year follow-up results in 35 patients and review of the literature. Noppen M, et al. **Acta Clin Belg** 1996;51(4):244–53 (54 ref.)

Video-assisted thoracoscopic closure of PDA—a case report and literature review. Vanamo K, et al. **Ann Chir Gynaecol** 1996;85(3):272–5 (33 ref.)

Thoracoscopic approach to the management of empyema thoracis. Indications and results. Silen ML, et al. **Chest Surg Clin N Am** 1996 Aug;6(3):491–9 (48 ref.)

Thoracoscopic spinal surgery. Dickman CA, et al. **Clin Neurosurg** 1996;43:392–422 (42 ref.)

Video-assisted thoracic surgery in trauma patients [see comments] Carrillo EH, et al. **J Am Coll Surg** 1997 Mar; 184(3):316–24 (31 ref.) Comment in: J Am Coll Surg 1997 Aug;185(2):197–8.

Minimally invasive endoscopic surgery of the spine. Goldstein JA, et al. **J South Orthop Assoc** 1996 Winter; 5(4):251–62 (34 ref.)

Video-assisted thoracic surgery in treatment of chest trauma. Liu DW, et al. **J Trauma** 1997 Apr;42(4):670–4 (20 ref.)

Role of thoracoscopic lymph node staging for lung and esophageal cancer. Krasna MJ. **Oncology (Huntingt)** 1996 Jun;10(6):793–802; discussion 804, 813–4 (31 ref.)

Video-assisted thoracoscopic truncal vagotomy. Palma P, et al. **Rev Esp Enferm Dig** 1997 Feb;89(2):86–93 (16 ref.) **(Eng, Spa)**

[Treatment of essential hyperhidrosis using thoracoscopic high dorsal sympathectomy] Noppen M. **Ned Tijdschr Geneeskd** 1997 Apr 5;141(14):671–5 (25 ref.) (Eng. Abstr.) **(Dut)**

[Minimally invasive coronary surgery. Thoracostomy-assisted thoracotomy. Apropos a case] Aramendi JI, et al. **Rev Esp Cardiol** 1996 Dec;49(12):925–7 (9 ref.) (Eng. Abstr.) **(Spa)**

VETERINARY

Instrumentation and techniques for laparoscopic and thoracoscopic surgery in the horse. Hendrickson DA, et al. **Vet Clin North Am Equine Pract** 1996 Aug;12(2):235–59 (27 ref.)

THORACOSTOMY

see related
CHEST TUBES

Management of a giant fluid-filled bulla by closed-chest thoracostomy tube drainage. Kirschner LS, et al. **Chest** 1997 Jun;111(6):1772–4 (7 ref.)

Computed tomography of malpositioned thoracostomy drains: a pictorial essay. Cameron EW, et al. **Clin Radiol** 1997 Mar;52(3):187–93 (9 ref.)

THORACOTOMY

Bilateral thoracotomy and inferior sternotomy for bypass grafting after esophagostomy. Smedira NG, et al. **Ann Thorac Surg** 1997 Mar;63(3):847–9 (4 ref.)

The clinical and pathologic manifestations of iatrogenically produced mesothelium-rich fragments of operative debris. Walley VM, et al. **Eur J Cardiothorac Surg** 1997 Feb; 11(2):328–32 (8 ref.)

Management of solitary pulmonary nodules. How to decide when resection is required. Lillington GA. **Postgrad Med** 1997 Mar;101(3):145–50 (10 ref.)

[Indications of rethoracotomy after esophagectomy for esophageal cancer] Koide Y, et al. **Nippon Geka Gakkai Zasshi** 1996 Jun;97(6):442–8 (27 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Hernia of the lung: a case report and review of literature. Minai OA, et al. **Conn Med** 1997 Feb;61(2):77–81 (22 ref.)

METHODS

New surgical techniques: implications for the cardiac anesthesiologist: mini-thoracotomy for coronary revascularization without cardiopulmonary bypass. Schaff HV. **J Cardiothorac Vasc Anesth** 1997 Apr;11(2 Suppl 1):6–9; discussion 24–5 (17 ref.)

Hernia of the lung repaired by VATS: a case report. Brown WT, et al. **J Laparoendosc Surg** 1996 Dec;6(6):427–30 (5 ref.)

Chest wall reconstruction. Arnold PG, et al. **Surg Oncol Clin N Am** 1997 Jan;6(1):91–114 (14 ref.)

[Minimally invasive coronary surgery. Thoracostomy-assisted thoracotomy. Apropos a case] Aramendi JI, et al. **Rev Esp Cardiol** 1996 Dec;49(12):925–7 (9 ref.) (Eng. Abstr.) **(Spa)**

THORAX

see related
THORACIC RADIOGRAPHY
THORACIC SURGERY
THORACOPLASTY
THORACOSCOPY
THORACOSTOMY
THORACOTOMY

Necrotizing soft tissue infections of the chest wall. Urschel JD, et al. **Ann Thorac Surg** 1997 Jul;64(1):276–9 (28 ref.)

ABNORMALITIES

Congenital thoracic masses: imaging features in the adult. Raymond GS, et al. **Crit Rev Diagn Imaging** 1997; 38(2):115–205 (68 ref.)

[Deformity of the thorax] Hashimoto A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):347–9 (16 ref.) **(Jpn)**

[Jeune syndrome] Shima M, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):343–6 (21 ref.) **(Jpn)**

ANATOMY & HISTOLOGY

The thoracic inlet: normal anatomy. Reede DL. **Semin Ultrasound CT MR** 1996 Dec;17(6):509–18 (8 ref.)

BLOOD SUPPLY

Magnetic resonance imaging of thoracic vascular disease (congenital diseases excluded). Croisille P, et al. **J Belge Radiol** 1997 Jun;80(3):136–8 (8 ref.)

MICROBIOLOGY

Space-occupying and life-threatening infections of the head, neck, and thorax. Gradon JD. **Infect Dis Clin North Am** 1996 Dec;10(4):857–78 (105 ref.)

PATHOLOGY

Chest wall reconstruction. Arnold PG, et al. **Surg Oncol Clin N Am** 1997 Jan;6(1):91–114 (14 ref.)

Invasive cytology of internal organs. Cytology of the thorax and abdomen. Burkhard MJ, et al. **Vet Clin North Am Small Anim Pract** 1996 Sep; 26(5):1203–22 (28 ref.)

PHYSIOPATHOLOGY

[A case of Pryce's type I pulmonary sequestration with hemoptysis and bruit] Tamaki T, et al. **Kyobu Geka** 1996 Nov;49(12):1040–3 (7 ref.) (Eng. Abstr.) **(Jpn)**

RADIATION EFFECTS

[Reconstructive plastic surgery of thoracic wall defects] Steinau HU, et al. **Chirurg** 1997 May;68(5):461–8 (23 ref.) (Eng. Abstr.) **(Ger)**

THORIUM DIOXIDE

ADVERSE EFFECTS

Long-term effects of internally deposited alpha-particle emitting radionuclides. Epidemiological, pathological and molecular-biological studies of Danish Thorotrast-administered patients and their offspring. Andersson M. **Dan Med Bull** 1997 Apr;44(2):169–90 (140 ref.)

Malignant hepatic tumours associated with previous exposure to Thorotrast: four cases. Lee FI, et al. **Eur J Gastroenterol Hepatol** 1996 Nov;8(11):1121–4 (22 ref.)

THORIUM OXIDE see **THORIUM DIOXIDE**

THORNAPPLE see **STRAMONIUM**

THREADWORMS see **ENTEROBIUS**

3TC see **LAMIVUDINE**

THREONINE

PEST sequences and regulation by proteolysis. Rechsteiner M, et al. **Trends Biochem Sci** 1996 Jul;21(7):267–71 (48 ref.)

BIOSYNTHESIS

Molecular control mechanisms of lysine and threonine biosynthesis in amino acid-producing corynebacteria: redirecting carbon flow. Malumbres M, et al. **FEMS Microbiol Lett** 1996 Oct 1;143(2–3):103–14 (43 ref.)

METABOLISM

The role of serine/threonine phosphorylation in hematopoietic cytokine receptor signal transduction. Mufson RA. **FASEB J** 1997 Jan;11(1):37–44 (56 ref.)

Molecular mechanisms of the protein serine/threonine phosphatases. Barford D. **Trends Biochem Sci** 1996 Nov; 21(11):407–12 (54 ref.)

TOXICITY

Neurotoxicology and amino acid intake during development: the case of threonine. Castagne V, et al. **Pharmacol Biochem Behav** 1996 Dec;55(4):653–62 (138 ref.)

THRESHOLD LIMIT VALUES see **MAXIMUM PERMISSIBLE EXPOSURE LEVEL**

THROAT see **PHARYNX**

THROMBASE see **THROMBIN**

THROMBASTHENIA

COMPLICATIONS

Management of a deep space infection of the neck in a patient with Glanzmann's thrombasthenia. Kirita T, et al. **J Oral Maxillofac Surg** 1997 Aug;55(8):882–5 (9 ref.)

PHYSIOPATHOLOGY

The biologic and clinical spectrum of Glanzmann's thrombasthenia: implications of integrin alpha IIb beta 3 for its pathogenesis. Kato A. **Crit Rev Oncol Hematol** 1997 May;26(1):1–23 (210 ref.)

THROMBECTOMY

see related
EMBOLECTOMY

METHODS

Interventional radiology in the treatment of pulmonary embolism. Cotroneo AR, et al. **Rays** 1996 Jul–Sep; 21(3):417–24 (16 ref.) **(Eng, Ita)**

THROMBELASTOGRAPHY

Thromboelastography for the assessment of hypercoagulability during general surgery. Arcelus JI, et al. **Semin Thromb Hemost** 1995;21 Suppl 4:21–6 (62 ref.)

Thromboelastography: measuring statistical probabilities. Caprini JA, et al. **Semin Thromb Hemost** 1995;21 Suppl 4:14–20 (8 ref.)

Perspectives on thromboelastography. Caprini JA, et al. **Semin Thromb Hemost** 1995;21 Suppl 4:91–3 (10 ref.)

The thromboelastography and the thromboelastograph technique. Chandler WL. **Semin Thromb Hemost** 1995;21 Suppl 4:1–6 (7 ref.)

Thromboelastography and liver transplantation. Gillies BS. **Semin Thromb Hemost** 1995;21 Suppl 4:45–9 (15 ref.)

Thromboelastography in liver transplantation. Kang Y. **Semin Thromb Hemost** 1995;21 Suppl 4:34–44 (46 ref.)

Thromboelastography and cardiopulmonary bypass. Spiess BD. **Semin Thromb Hemost** 1995;21 Suppl 4:27–33 (31 ref.)

Thromboelastographic study of fibrinolytic agents. Summaria L. **Semin Thromb Hemost** 1995;21 Suppl 4:63–71 (43 ref.)

Thromboelastographic modifications induced by intravenous and subcutaneous heparin administration. Traverso CI, et al. **Semin Thromb Hemost** 1995;21 Suppl 4:53–8 (47 ref.)

Role of thromboelastography in evaluating other anticoagulant agents: warfarin and heparin-dihydroergotamine. Traverso CI, et al. **Semin Thromb Hemost** 1995;21 Suppl 4:59–62 (12 ref.)

The normal thromboelastogram and its interpretation. Traverso CI, et al. **Semin Thromb Hemost** 1995;21 Suppl 4:7–13 (47 ref.)

Application of thromboelastography in other medical and surgical states. Traverso CI, et al. **Semin Thromb Hemost** 1995;21 Suppl 4:50–2 (25 ref.)

THROMBIN

see related
COAGULANTS
HEMOSTATICS

ANALYSIS

[Thrombin deposition in brains of patients with Alzheimer's disease—activation of the coagulation system in the central nervous system] Akiyama H. **Rinsho Byori** 1997 Feb;Suppl 104:117–23 (31 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Direct thrombin inhibitors in cardiovascular disease. Catella-Lawson F. **Coron Artery Dis** 1997 Feb;8(2):105–11 (34 ref.)

Clinical trials of conjunctive anticoagulant strategies in thrombolysis. Kleiman NS. **Coron Artery Dis** 1996 Jul; 7(7):508–15 (100 ref.)

Potential advantages of direct-acting thrombin inhibitors. Philippides GJ, et al. **Coron Artery Dis** 1996 Jul; 7(7):497–507 (100 ref.)

Antiplatelet and antithrombin therapies in the acute coronary syndromes. Alexander JH, et al. **Curr Opin Cardiol** 1997 Jul;12(4):427–37 (44 ref.)

Modulating platelet function with selective thrombin inhibitors. Verstraete M. **Haemostasis** 1996 Oct;26 Suppl 4:70–7 (28 ref.)

Leu271-Glu292 in kininogens blocks thrombin-induced aggregation. Colman RW, et al. **Immunopharmacology** 1996 May;32(1–3):80–1 (3 ref.)

Thrombin regulation by physiological inhibitors: the role of vitronectin. Preissner KT, et al. **Semin Thromb Hemost** 1996;22(2):165–72 (78 ref.)

Antithrombotic strategies targeting thrombin activities,

thrombin receptors and thrombin generation. Harker LA, et al. **Thromb Haemost** 1997 Jul;78(1):736–41 (55 ref.)
[Direct thrombin inhibitors] Bornkessel B.
Med Monatsschr Pharm 1997 Apr;20(4):86–9 (3 ref.) **(Ger)**

BIOSYNTHESIS

Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin? Dietrich W.
J Cardiovasc Pharmacol 1996;27 Suppl 1:S50–7 (53 ref.)
Physiopathological significance of catalytic phospholipids in the generation of thrombin. Dachary-Prigent J, et al.
Semin Thromb Hemost 1996;22(2):157–64 (58 ref.)

DRUG EFFECTS

Leu271-Glu292 in kininogens blocks thrombin-induced aggregation. Colman RW, et al. **Immunopharmacology** 1996 May;32(1–3):80–1 (3 ref.)

METABOLISM

Restenosis following percutaneous revascularization--the potential role of thrombin and the thrombin receptor. Stouffer GA, et al. **Ann Hematol** 1996;73 Suppl 1:S39–41 (14 ref.)
Haemostatic factors and atherogenesis. Smith EB.
Atherosclerosis 1996 Aug 2;124(2):137–43 (80 ref.)
Regulation of thrombin formation by activated protein C: effect of the factor V Leiden mutation. Tans G, et al.
Semin Hematol 1997 Jul;34(3):244–55 (92 ref.)
Thrombin interaction with platelet membrane glycoprotein Ib. Jandrot-Perrus M, et al. **Semin Thromb Hemost** 1996; 22(2):151–6 (61 ref.)
Thrombin and vascular smooth muscle cell proliferation: implications for atherosclerosis and restenosis. McNamara CA, et al. **Semin Thromb Hemost** 1996;22(2):139–44 (55 ref.)
Modulation of thrombin and heparin activities by fibrin. Hogg PJ, et al. **Thromb Haemost** 1997 Mar;77(3):424–33 (70 ref.)
Modulation of thrombin's procoagulant and anticoagulant properties. Leung LL, et al. **Thromb Haemost** 1997 Jul; 78(1):577–80 (16 ref.)
[Inducing conformational changes in thrombin by ligands as a way of regulating its activity] Gershkovich AA.
Biokhimiia 1996 Jul;61(7):1139–51 (91 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

[Adherent reaction among activated platelets, polymorphonuclear cells and vascular endothelial cells under thrombin stimulation or shear stress] Kageoka T, et al. **Rinsho Byori** 1996 Aug;44(8):757–63 (9 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

The role of thrombin in coronary artery thrombosis. Eisenberg PR. **Coron Artery Dis** 1996 Jun;7(6):400–8 (88 ref.)
Thrombin, its receptor and protease nexin I, its potent serpin, in the nervous system. Festoff BW, et al.
Semin Thromb Hemost 1996;22(3):267–71 (47 ref.)
Regulation of thrombin-mediated endothelial cell contraction and permeability. Garcia JG, et al.
Semin Thromb Hemost 1996;22(4):309–15 (50 ref.)
Control mechanisms in thrombin generation. Ofosu FA, et al. **Semin Thromb Hemost** 1996;22(4):303–8 (26 ref.)
Thrombin stimulation of renal cells. Rondeau E, et al.
Semin Thromb Hemost 1996;22(2):135–8 (25 ref.)
Molecular Interactions of Thrombin. Tulinsky A.
Semin Thromb Hemost 1996;22(2):117–24 (47 ref.)
Thrombin, fibrin and platelets: a resonance loop in which von Willebrand factor is a necessary link. Béguin S, et al.
Thromb Haemost 1997 Jul;78(1):590–4 (30 ref.)
Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Nesheim M, et al.
Thromb Haemost 1997 Jul;78(1):386–91 (50 ref.)

THERAPEUTIC USE

Phosphorylation and dephosphorylation mechanisms in platelet function: a tightly regulated balance.
Levy-Toledano S, et al. **Thromb Haemost** 1997 Jul; 78(1):226–33 (53 ref.)

THROMBIN RECEPTORS see **RECEPTORS, THROMBIN**

THROMBOANGIITIS OBLITERANS

[Thromboangiitis obliterans (Buerger's syndrome): clinical aspects, diagnosis and therapy] Diehm C, et al.
Dtsch Med Wochenschr 1996 Dec 6;121(49):1543–8 (21 ref.) **(Ger)**
[Systemic arteriovenous thrombosis] Hifumi S.
Ryoikibetsu Shokogun Shirizu 1996;(14):521–6 (14 ref.) **(Jpn)**
[Arteriosclerosis obliterans and Buerger's disease] Ishimaru S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):553–6 (3 ref.) **(Jpn)**

DIAGNOSIS

Thromboangiitis obliterans (Buerger's disease). Mishima Y.
Int J Cardiol 1997 Aug;54 Suppl:S185–7 (16 ref.)

THROMBOCYTES see **BLOOD PLATELETS**

THROMBOCYTHEMIA see **THROMBOCYTOSIS**

THROMBOCYTHEMIA, ESSENTIAL see **THROMBOCYTHEMIA, HEMORRHAGIC**

THROMBOCYTHEMIA, HEMORRHAGIC

Essential thrombocythemia and pregnancy. Griesshammer M, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:57–63 (64 ref.)
Essential thrombocythemia during pregnancy. Eliyahu S, et al. **Obstet Gynecol Surv** 1997 Apr;52(4):243–7 (32 ref.)
[Essential thrombocythemia, thrombocytopenia] Nomura S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):125–8 (15 ref.) **(Jpn)**

BLOOD

Bleeding time and platelet function in essential thrombocythemia and other myeloproliferative syndromes. Finazzi G, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:71–8 (88 ref.)

DIAGNOSIS

Diagnostic and differential criteria of essential thrombocythemia and reactive thrombocytosis. Kutti J, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:41–5 (42 ref.)
Essential thrombocythemia in childhood. Michiels JJ, et al.
Semin Thromb Hemost 1997;23(3):295–301 (42 ref.)
[Primary thrombocythemia in a female carrier of IgA deficiency] Guzzini F, et al. **Recenti Prog Med** 1996 Oct; 87(10):476–9 (20 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives. Landolfi R, et al.
Leuk Lymphoma 1996 Sep;22 Suppl 1:83–6 (22 ref.)

PATHOLOGY

Clonality assays and megakaryocyte culture techniques in essential thrombocythemia. Yan L, et al.
Leuk Lymphoma 1996 Sep;22 Suppl 1:31–40 (61 ref.)
Diagnostic criteria of the myeloproliferative disorders (MPD): essential thrombocythaemia, polycythaemia vera and chronic megakaryocytic granulocytic metaplasia. Michiels JJ. **Neth J Med** 1997 Aug;51(2):57–64 (45 ref.)

PHYSIOPATHOLOGY

Intracranial hemorrhage in chronic childhood ITP [editorial] Lilleyman JS. **Pediatr Hematol Oncol** 1997 Sep–Oct; 14(5):iii–v (5 ref.)

THERAPY

Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. Barbui T, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:149–60 (86 ref.)
Essential thrombocythemia in childhood. Michiels JJ, et al.
Semin Thromb Hemost 1997;23(3):295–301 (42 ref.)

THROMBOCYTHEMIA, IDIOPATHIC see **THROMBOCYTHEMIA, HEMORRHAGIC**

THROMBOCYTHEMIA, PRIMARY see **THROMBOCYTHEMIA, HEMORRHAGIC**

THROMBOCYTOPATHY see **BLOOD PLATELET DISORDERS**

THROMBOCYTOPENIA

Thrombocytopenia in pregnancy: diagnosis, pathogenesis and management. Crowther MA, et al. **Blood Rev** 1996 Mar; 10(1):8–16 (83 ref.)
Fetal alloimmune thrombocytopenia: consensus and controversy. Bussel JB, et al. **J Matern Fetal Med** 1996 Sep–Oct;5(5):281–92 (56 ref.)
Thrombocytopenia in pregnancy. Bell WR, et al.
Rheum Dis Clin North Am 1997 Feb;23(1):183–94 (77 ref.)
Assays for heparin-induced thrombocytopenia. Griffiths E, et al. **Transfus Med** 1997 Mar;7(1):1–11 (54 ref.)

BLOOD

The thrombocytopenic rabbit bleeding time model to evaluate the in vivo hemostatic efficacy of platelets and platelet substitutes. Blajchman MA, et al.
Transfus Med Rev 1997 Apr;11(2):95–105 (51 ref.)
[Pseudothrombocytopenia: case reports and review of the literature] Huss B, et al. **Infusionsther Transfusionsmed** 1995 Oct;22(5):303–9 (66 ref.) (Eng. Abstr.) **(Ger)**

CHEMICALLY INDUCED

Pseudopulmonary embolism: acute respiratory distress in the syndrome of heparin-induced thrombocytopenia. Popov D, et al. **Am J Kidney Dis** 1997 Mar;29(3):449–52 (12 ref.)
Heparin-associated thrombocytopenia and thrombosis: implications for perioperative management. Slaughter TF, et al. **Anesthesiology** 1997 Sep;87(3):667–75 (93 ref.)
Ancrod: the use of snake venom in the treatment of patients with heparin-induced thrombocytopenia and thrombosis undergoing coronary artery bypass grafting: nursing management. Lathan LO, et al. **Heart Lung** 1996 Nov–Dec; 25(6):451–60; quiz 461–2 (27 ref.)
Heparin-induced thrombocytopenia [see comments] Shorten GD, et al. **J Cardiothorac Vasc Anesth** 1996 Jun; 10(4):521–30 (167 ref.) Comment in: J Cardiothorac Vasc Anesth 1997 Apr;11(2):262–3. Comment in: J Cardiothorac Vasc Anesth 1997 Jun;11(4):538–9.
Thrombocytopenia after high-dose chemotherapy and autologous stem cell transplantation: an unresolved problem and possible approaches to resolve it. Hassan HT, et al. **J Hematother** 1996 Aug;5(4):407–14 (57 ref.)
Heparin-induced thrombocytopenia--background and implications for haemodialysis [editorial] Finazzi G, et al. **Nephrol Dial Transplant** 1996 Nov;11(11):2120–2 (15 ref.)
Precipitous fall in platelet count with anagrelide: case report and critique of dosing recommendations. McCune JS, et al. **Pharmacotherapy** 1997 Jul–Aug;17(4):822–6 (9 ref.)
Considerations regarding the less-than-expected thrombocytopenia encountered with combination paclitaxel/carboplatin chemotherapy. Kearns CM, et al.
Semin Oncol 1997 Feb;24(1 Suppl 2):S2-91–S2-96 (24 ref.)
Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Lewis BE, et al. **Semin Thromb Hemost** 1997;23(2):197–202 (35 ref.)
Treatment of heparin-induced thrombocytopenia and thrombosis. Green RM. **Semin Vasc Surg** 1996 Dec; 9(4):292–5 (15 ref.)
Heparin-induced thrombocytopenia: pathophysiology. Kibbe MR, et al. **Semin Vasc Surg** 1996 Dec;9(4):284–91 (58 ref.)
The pathogenesis of the antiphospholipid syndrome: a hypothesis based on parallelisms with heparin-induced thrombocytopenia [see comments] Arnout J.
Thromb Haemost 1996 Apr;75(4):536–41 (93 ref.) Comment in: Thromb Haemost 1996 Nov;76(5):817–8.
Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Warkentin TE.
Transfus Med Rev 1996 Oct;10(4):249–58 (41 ref.)
[Heparin-induced thrombocytopenia] Dulíček P, et al.
Vnitr Lek 1996 Oct;42(10):705–9 (36 ref.) (Eng. Abstr.) **(Cze)**
[Platelet factor 4, target of anti-heparin antibodies: application to biological diagnosis of heparin-induced thrombopenia] Amiral J. **Ann Med Interne (Paris)** 1997; 148(2):142–9 (32 ref.) (Eng. Abstr.) **(Fre)**
[Thrombopenia induced by heparin. From physiopathology to treatment] Gruel Y. **Ann Med Interne (Paris)** 1997; 148(2):136–41 (55 ref.) (Eng. Abstr.) **(Fre)**
[Heparin-induced thrombocytopenia] Greinacher A.
Internist (Berl) 1996 Nov;37(11):1172–8; discussion 1178 (18 ref.) **(Ger)**
[Digitoxin overdose with reversible thrombocytopenia] Dahmen KG, et al. **Med Klin** 1996 Dec 15;91(12):791–5 (35 ref.) **(Ger)**
[Heparin-induced thrombocytopenias, arterial and venous thromboses--complications of heparin therapy] Baluda MV. **Ter Arkh** 1996;68(12):19–22 (63 ref.) **(Rus)**
[Cerebral infarction as first manifestation of thrombocytopenia caused by pentosan polysulfate (letter)] Gironell A, et al. **Med Clin (Barc)** 1997 Apr 26;108(16):636 (10 ref.) **(Spa)**

COMPLICATIONS

[Successful lysis of iliofemoral and inferior vena cava thrombi in heparin-induced type-II thrombocytopenia] Emig U, et al. **Dtsch Med Wochenschr** 1997 Aug 1;122(31–32):965–8 (25 ref.) (Eng. Abstr.) **(Ger)**
[Sweet syndrome associated with essential thrombocytopenia (letter)] Camafort Babkowski M, et al. **Med Clin (Barc)** 1997 Mar 22;108(11):439 (8 ref.) **(Spa)**
[Thrombocytopenia associated with human immunodeficiency virus infection] Moreno García M.
Rev Clin Esp 1996 Dec;196(12):834–45 (220 ref.) **(Spa)**

DIAGNOSIS

Prenatal diagnosis and management of neonatal alloimmune thrombocytopenia. Johnson JA, et al. **Semin Perinatol** 1997 Feb;21(1):45–52 (32 ref.)
[Thrombocytopenia, arthritis and enteropathy: a casual association or the expression of a unique entity?] Alpigiani MG, et al. **Pediatr Med Chir** 1996 Nov–Dec;18(6):583–4 (10 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Lewis BE,

et al. **Semin Thromb Hemost** 1997;23(2):197–202 (35 ref.)

ETIOLOGY

Thrombocytopenia in association with a wandering spleen. Moll S, et al. **Am J Hematol** 1996 Dec;53(4):259–63 (17 ref.)

Thrombocytopenia in the antiphospholipid syndrome: pathophysiology, clinical relevance and treatment. Galli M, et al. **Ann Med Interne (Paris)** 1996 Sep;147 Suppl 1:24–7 (44 ref.)

Radiotherapy-associated neutropenia and thrombocytopenia: analysis of risk factors and development of a predictive model. Mac Manus M, et al. **Blood** 1997 Apr 1; 89(7):2303–10 (36 ref.)

Guillain-Barré syndrome and ethylene diamine tetraacetic acid-dependent pseudothrombocytopenia associated with mumps. Sawazaki A, et al. **Intern Med** 1996 Dec; 35(12):996–9 (34 ref.)

Severe abdominal pain and thrombocytopenia--typical symptoms of occult jejunal diverticulum perforation? Klee FE, et al. **J Gastroenterol** 1997 Apr;32(2):246–50 (62 ref.)

[Hemostasis anomalies and human immunodeficiency virus infection] Fezoui H, et al. **Rev Med Interne** 1996; 17(9):738–45 (62 ref.) (Eng. Abstr.) **(Fre)**

[A case of severe thrombocytopenia in infectious mononucleosis] Zipper FC, et al. **Clin Ter** 1996 Oct; 147(10):529–33 (18 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

Megakaryocytes and inherited thrombocytopenias. Bellucci S. **Baillieres Clin Haematol** 1997 Feb;10(1):149–62 (90 ref.)

[May-Heggelin anomaly and pregnancy. A case report, review of the literature] Tordjeman N, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(8):836–40 (16 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Antibody-mediated thrombosis. Vermylen J, et al. **Thromb Haemost** 1997 Jul;78(1):420–6 (73 ref.)

Management of fetal and neonatal alloimmune thrombocytopenia. Kaplan C, et al. **Transfus Med Rev** 1996 Jul;10(3):233–40 (63 ref.)

PATHOLOGY

[Dysmegakaryocytopoiesis and thrombopoiesis in autoimmune thrombocytopenias] Bellucci S. **C R Seances Soc Biol Fil** 1996;190(5–6):541–8 (25 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Clinical effects of amifostine (Ethyol) in patients treated with carboplatin. Budd GT, et al. **Eur J Cancer** 1996;32A Suppl 4:S43–5 (8 ref.)

THERAPY

Clinical update on the use of recombinant factor VII. Glazer S, et al. **Adv Exp Med Biol** 1995;386:163–74 (40 ref.)

Potential use of recombinant human interleukin-6 in clinical oncology. Veldhuis GJ, et al. **Leuk Lymphoma** 1996 Feb; 20(5–6):373–9 (61 ref.)

Treatment of heparin-induced thrombocytopenia and thrombosis. Green RM. **Semin Vasc Surg** 1996 Dec; 9(4):292–5 (15 ref.)

Management of fetal and neonatal alloimmune thrombocytopenia. Kaplan C, et al. **Transfus Med Rev** 1996 Jul;10(3):233–40 (63 ref.)

[Clinical application of platelet hematopoiesis factor, thrombopoietin(c-Mp1ligand)] Fujimoto K, et al. **Nippon Naika Gakkai Zasshi** 1996 Jun 10;85(6):850–6 (7 ref.) **(Jpn)**

VIROLOGY

Thrombocytopenia in human immune deficiency virus infection. Literature review, case report and future directions. Abayomi EA, et al. **Cent Afr J Med** 1996 Sep; 42(9):271–2 (7 ref.)

THROMBOCYTOSIS

ABC of clinical haematology. Polycythaemia, primary (essential) thrombocythaemia and myelofibrosis. Messinezy M, et al. **BMJ** 1997 Feb 22;314(7080):587–90 (0 ref.)

Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Murphy S, et al. **Semin Hematol** 1997 Jan;34(1):29–39 (35 ref.)

COMPLICATIONS

Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia. Michiels JJ, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:47–56 (56 ref.)

Atypical transient ischemic attacks in thrombocythemia of various myeloproliferative disorders. Michiels JJ, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:65–70 (32 ref.)

[Myocardial infarction caused by thrombosis of the left coronary artery in a patient with thrombocythemia] Joseph T, et al. **Ann Cardiol Angeiol (Paris)** 1996 Dec;45(10):581–4 (16 ref.) (Eng. Abstr.) **(Fre)**

[Portal vein thrombosis associated with essential thrombocytosis. Clinical cases and review of the literature] Carvajal S, et al. **Rev Med Chil** 1996 Mar;124(3):353–8 (26 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Diagnostic and differential criteria of essential thrombocythemia and reactive thrombocytosis. Kutti J, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:41–5 (42 ref.)

Diagnostic applications of haemopoietic progenitor culture techniques in polycythaemias and thrombocythaemias. Westwood NB, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:95–103 (91 ref.)

DRUG THERAPY

New drugs in essential thrombocythemia and polycythemia vera. Tefferi A, et al. **Blood Rev** 1997 Mar;11(1):1–7 (87 ref.)

Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Petitt RM, et al. **Semin Hematol** 1997 Jan;34(1):51–4 (5 ref.)

ETIOLOGY

Prolonged extreme thrombocytosis associated with neurofibromatosis type 1. Hasle H, et al. **J Pediatr** 1997 Feb;130(2):317–9 (14 ref.)

VETERINARY

Basophilic leukemia in a dog. Mears EA, et al. **J Vet Intern Med** 1997 Mar-Apr;11(2):92–4 (13 ref.)

THROMBOELASTOGRAPHY see **THROMBELASTOGRAPHY**

THROMBOEMBOLISM

CHEMICALLY INDUCED

A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy. Douketis JD, et al. **Arch Intern Med** 1997 Jul 28; 157(14):1522–30 (95 ref.)

Thrombogenic potential of non-ionic contrast media--fact or fiction? Schräder R. **Eur J Radiol** 1996 Nov;23 Suppl 1:S10–3 (24 ref.)

Comments on desogestrel and gestoden (3rd generation progestogens) and the incidence of thromboembolism. Lauritzen C. **Horm Metab Res** 1996 May;28(5):245–7 (11 ref.)

Increased risk from third-generation progestogens: fuzzy logic or fuzzy science? [editorial] Corson SL. **J Reprod Med** 1996 Sep;41(9):711–2 (10 ref.)

Oral contraceptives and thrombotic disease: risk of venous thromboembolism. Helmerhorst FM, et al. **Thromb Haemost** 1997 Jul;78(1):327–33 (58 ref.)

COMPLICATIONS

Thromboembolic risks and complications in nephrotic children. Schlegel N. **Semin Thromb Hemost** 1997; 23(3):271–80 (88 ref.)

Venous thromboembolism and cancer: a two-way clinical association. Agnelli G. **Thromb Haemost** 1997 Jul; 78(1):117–20 (42 ref.)

CONGENITAL

[Inherited thrombophilia] Jia X, et al. **Chung Hua Nei Ko Tsa Chih** 1996 Feb;35(2):133–6 (18 ref.) **(Chi)**

DIAGNOSIS

ACOG educational bulletin. Thromboembolism in pregnancy. Number 234, March 1997. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1997 May;57(2):209–18 (56 ref.)

What's new in the prevention, diagnosis and treatment of venous thromboembolic disease. Jones JS. **J Miss State Med Assoc** 1997 Apr;38(4):115–8 (12 ref.)

D-dimer testing in suspected venous thromboembolism: an update. Bounameaux H, et al. **QJM** 1997 Jul;90(7):437–42 (26 ref.)

Thromboembolic diseases: biochemical mechanisms and new possibilities of biological diagnosis. Amiral J, et al. **Semin Thromb Hemost** 1996;22 Suppl 1:41–8 (48 ref.)

Diagnosis of thromboembolic disease during infancy and childhood. Sutor AH, et al. **Semin Thromb Hemost** 1997; 23(3):237–46 (94 ref.)

DRUG THERAPY

Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. Dunn CJ, et al. **Drugs** 1996 Aug;52(2):276–305 (118 ref.)

Fibrin-selective thrombolytic therapy with recombinant staphylokinase. Collen D, et al. **Haemostasis** 1996 Oct;26 Suppl 4:294–300 (25 ref.)

Thromboembolic disease. Pellegrini VD Jr. **Instr Course Lect** 1997;46:185–9 (34 ref.)

ACOG educational bulletin. Thromboembolism in pregnancy. Number 234, March 1997. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1997 May;57(2):209–18 (56 ref.)

The prevention and treatment of thromboembolic disease in children: a need for Thrombophilia Programs. Andrew M, et al. **J Pediatr Hematol Oncol** 1997 Jan-Feb;19(1):7–22 (192 ref.)

Current concepts of anticoagulant therapy in pregnancy. Barbour LA. **Obstet Gynecol Clin North Am** 1997 Sep; 24(3):499–521 (113 ref.)

Benefits of regional anesthesia on thromboembolic complications following surgery. Rosenfeld BA. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):9–12 (40 ref.)

Anticoagulants and thrombolytics during pregnancy. Ramin SM, et al. **Semin Perinatol** 1997 Apr;21(2):149–53 (35 ref.)

Thromboelastographic study of fibrinolytic agents. Summaria L. **Semin Thromb Hemost** 1995;21 Suppl 4:63–71 (43 ref.)

Role of thromboelastography in evaluating other anticoagulant agents: warfarin and heparin-dihydroergotamine. Traverso CI, et al. **Semin Thromb Hemost** 1995;21 Suppl 4:59–62 (12 ref.)

Drug trials that have influenced our practice in the treatment of venous thromboembolism. Kearon C. **Thromb Haemost** 1997 Jul;78(1):553–7 (60 ref.)

Optimal duration of oral anticoagulant therapy in venous thromboembolism. Schulman S. **Thromb Haemost** 1997 Jul; 78(1):693–8 (33 ref.)

Indications and drugs for anticoagulation therapy in children. Andrew M. **Thromb Res** 1996;81(2 Suppl):S61–73 (106 ref.)

EPIDEMIOLOGY

Thromboembolic risks and complications in nephrotic children. Schlegel N. **Semin Thromb Hemost** 1997; 23(3):271–80 (88 ref.)

Incidence of thromboembolic complications after laparoscopic cholecystectomy: review of the literature. Lindberg F, et al. **Surg Laparosc Endosc** 1997 Aug; 7(4):324–31 (79 ref.)

The epidemiology of inherited thrombophilia: the VITA Project. Vicenza Thrombophilia and Atherosclerosis Project. Rodeghiero F, et al. **Thromb Haemost** 1997 Jul; 78(1):636–40 (33 ref.)

ETIOLOGY

Cancer and venous thromboembolism. Piccioli A, et al. **Am Heart J** 1996 Oct;132(4):850–5 (50 ref.)

Hyperhomocysteinemia. An emerging and important risk factor for thromboembolic and cardiovascular disease [see comments] [published erratum appears in Am J Clin Pathol 1997 May;107(5):621] Guba SC, et al. **Am J Clin Pathol** 1996 Dec;106(6):709–22 (94 ref.) Comment in: Am J Clin Pathol 1997 Jul;108(1):115.

Low thromboembolic risk without anticoagulation using advanced-design left ventricular assist devices. Slater JP, et al. **Ann Thorac Surg** 1996 Nov;62(5):1321–7; discussion 1328 (41 ref.)

Cardiopulmonary complications of esophageal surgery. Amar D. **Chest Surg Clin N Am** 1997 Aug;7(3):449–56 (23 ref.)

Thromboembolism in pregnancy: an overview. Girling JC, et al. **Curr Opin Obstet Gynecol** 1996 Dec;8(6):458–63 (48 ref.)

The venous thrombotic risk in nonsurgical patients. Bouthier J. **Drugs** 1996;52 Suppl 7:16–28; discussion 28–9 (42 ref.)

Molecular basis for protein C hereditary deficiency. Aiach M, et al. **Haemostasis** 1996 Oct;26 Suppl 4:9–19 (61 ref.)

Plaque rupture, thrombosis, and therapeutic implications. Fuster V, et al. **Haemostasis** 1996 Oct;26 Suppl 4:269–84 (53 ref.)

Thromboembolic disease. Pellegrini VD Jr. **Instr Course Lect** 1997;46:185–9 (34 ref.)

Thromboembolic phenomena and the use of the pig as an appropriate animal model for research on cardiovascular devices. Gross DR. **Int J Artif Organs** 1997 Apr; 20(4):195–203 (89 ref.)

Arterial thromboembolic complications in paediatric patients. Andrew M, et al. **Thromb Haemost** 1997 Jul;78(1):715–25 (179 ref.)

Newly diagnosed malignancy in patients with venous thromboembolism. Search or wait and see? Prins MH, et al. **Thromb Haemost** 1997 Jul;78(1):121–5 (21 ref.)

[Thromboembolic complications of central venous catheters (see comments)] Manten A, et al. **Ned Tijdschr Geneeskd** 1996 Sep 7;140(36):1797–800 (32 ref.) Comment in: Ned Tijdschr Geneeskd 1996 Nov 16;140(46):2302. **(Dut)**

[Prevention of thromboembolism in atrial fibrillation of non-valvular etiology] Cattaneo M. **Ann Ital Med Int** 1996 Oct;11 Suppl 2:15S–17S (10 ref.) (Eng. Abstr.) **(Ita)**

[Transesophageal echocardiography and risk factors for embolism] Jacopi F, et al. **Ann Ital Med Int** 1996 Oct;11 Suppl 2:11S–14S (32 ref.) (Eng. Abstr.) **(Ita)**

[Acute myocardial infarction and thromboembolic complications in the nephrotic syndrome] Harada A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):436–9 (24 ref.) **(Jpn)**

[Thromboembolic complications in inflammatory bowel disease] Suárez Crespo JF, et al. **Gastroenterol Hepatol** 1997 Apr;20(4):180–3 (30 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Inherited defects of the protein C anticoagulant system in childhood thrombo-embolism. Nowak-Göttl U, et al.

Eur J Pediatr 1996 Nov;155(11):921–7 (83 ref.)

Thrombomodulin gene variations and thromboembolic disease. Ohlin AK, et al. **Thromb Haemost** 1997 Jul; 78(1):396–400 (26 ref.)

[Resistance to activated protein C. The most common cause of familial thrombophilia] Larsen TB, et al. **Ugeskr Laeger** 1996 Nov 11;158(46):6584–8 (40 ref.) (Eng. Abstr.) **(Dan)**

METABOLISM

Warfarin withdrawal. Pharmacokinetic–pharmacodynamic considerations. Palareti G, et al. **Clin Pharmacokinet** 1996 Apr;30(4):300–13 (87 ref.)

[The significance of APC resistance (activated protein C) for clinical practice] Lämmle B, et al. **Schweiz Rundsch Med Prax** 1997 Jan 28;86(5):154–61 (51 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Resistance to activated protein C as pathogenic factor of venous thromboembolism. Chrobák L, et al. **Acta Medica (Hradec Kralove)** 1996;39(2):55–62 (104 ref.)

Pathophysiology of thromboembolism and its modulation by low-molecular-weight heparins. Breddin HK. **Semin Thromb Hemost** 1996;22 Suppl 1:25–7 (7 ref.)

APC resistance in childhood thromboembolism: diagnosis and clinical aspects. Nowak-Göttl U, et al. **Semin Thromb Hemost** 1997;23(3):253–8 (35 ref.)

Disorders of hemostasis in childhood: risk factors for venous thromboembolism. Manco-Johnson MJ. **Thromb Haemost** 1997 Jul;78(1):710–4 (34 ref.)

The Leiden Thrombophilia Study (LETS). van der Meer FJ, et al. **Thromb Haemost** 1997 Jul;78(1):631–5 (18 ref.)

PREVENTION & CONTROL

Anticoagulation with warfarin in infants and children. Buck ML. **Ann Pharmacother** 1996 Nov;30(11):1316–22 (56 ref.)

Danaparoid in the prevention of thromboembolic complications. Skoutakis VA. **Ann Pharmacother** 1997 Jul–Aug;31(7–8):876–87 (81 ref.)

Low-dose heparin thromboembolism prophylaxis. Owings JT, et al. **Arch Surg** 1996 Oct;131(10):1069–73 (46 ref.)

Prophylaxis of venous thromboembolism [see comments] Verstraete M. **BMJ** 1997 Jan 11;314(7074):123–5 (27 ref.) Comment in: BMJ 1997 Apr 26;314(7089):1281–2; discussion 1282–3. Comment in: BMJ 1997 Apr 26;314(7089):1282; discussion 1282–3.

Prevention of thromboembolism in patients with atrial fibrillation. Cohen IS, et al. **Cardiol Clin** 1996 Nov; 14(4):537–42 (30 ref.)

Which prophylactic aspirin? **Drug Ther Bull** 1997 Jan; 35(1):7–8 (19 ref.)

Unresolved issues in the prevention of venous thromboembolism. Baglin T. **Drugs** 1996;52 Suppl 7:1–6; discussion 6–7 (30 ref.)

The postdischarge risk of venous thromboembolism after hip replacement. The role of prolonged prophylaxis. Bergqvist D. **Drugs** 1996;52 Suppl 7:55–9 (47 ref.)

The risk of thromboembolism in patients undergoing colorectal surgery. McLeod RS. **Drugs** 1996;52 Suppl 7:38–41 (25 ref.)

Prevention and treatment of venous thromboembolism. Pineo GF, et al. **Drugs** 1996 Jul;52(1):71–92 (163 ref.)

Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. Davis R, et al. **Drugs Aging** 1997 Apr;10(4):299–322 (110 ref.)

Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of venous thrombosis. Hirsh J. **Haemostasis** 1996 Oct;26 Suppl 4:189–98 (20 ref.)

Prevention of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). **Int Angiol** 1997 Mar;16(1):3–38 (421 ref.)

The prevention and treatment of thromboembolic disease in children: a need for Thrombophilia Programs. Andrew M, et al. **J Pediatr Hematol Oncol** 1997 Jan–Feb;19(1):7–22 (192 ref.)

Management of anticoagulation before and after elective surgery. Kearon C, et al. **N Engl J Med** 1997 May 22; 336(21):1506–11 (66 ref.)

Low-molecular-weight heparins. Weitz JI. **N Engl J Med** 1997 Sep 4;337(10):688–98 (100 ref.)

Low-molecular-weight heparin: from the bench to the orthopedic patient. Turpie AG. **Orthopedics** 1997 Feb;20 Suppl:10–3 (12 ref.)

New approaches to prevention of deep vein thrombosis. Bergqvist D. **Thromb Haemost** 1997 Jul;78(1):684–8 (41 ref.)

Efficacy and safety of oral anticoagulation in patients with cancer. Bona RD, et al. **Thromb Haemost** 1997 Jul; 78(1):137–40 (31 ref.)

Prevention of thromboembolic events in atrial fibrillation. Koefoed BG, et al. **Thromb Haemost** 1997 Jul;78(1):377–81 (40 ref.)

[Prevention of thromboembolism in patients with atrial fibrillation] Veselka J, et al. **Vnitr Lek** 1996 Nov; 42(11):792–5 (29 ref.) (Eng. Abstr.) **(Cze)**

[Current indications of low-molecular-weight heparins] Vignes S, et al. **Ann Med Interne (Paris)** 1997;148(2):154–62 (64 ref.) (Eng. Abstr.) **(Fre)**

[Antithrombotic therapy in patients with mechanical valve prostheses] Roudaut R, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1543–50 (30 ref.) (Eng. Abstr.) **(Fre)**

[New antithrombotic drugs. What developments can be expected?] Greinacher A. **Internist (Berl)** 1997 Jul; 38(7):680–7 (41 ref.) **(Ger)**

[Indications and problems of long-term medicamentous inhibition of blood coagulation] Ostermann H. **Internist (Berl)** 1997 Jul;38(7):672–9 (63 ref.) **(Ger)**

[Prevention with low dosage heparin. Selective or general?] Schmitz-Huebner U. **Internist (Berl)** 1997 Jul;38(7):667–71 (41 ref.) **(Ger)**

[Thrombophilia and antithrombotic prevention in gynecology and obstetrics] Winkler UH. **Internist (Berl)** 1997 Jul;38(7):650–7 (57 ref.) **(Ger)**

[Thrombosis in trauma and orthopedic surgery. Prevention, diagnosis, therapy] Haas S. **Unfallchirurg** 1997 Apr; 100(4):307–19 (10 ref.) **(Ger)**

[Prevention of thromboembolism in atrial fibrillation of non-valvular etiology] Cattaneo M. **Ann Ital Med Int** 1996 Oct;11 Suppl 2:15S–17S (10 ref.) (Eng. Abstr.) **(Ita)**

[The use of the new anticoagulant Fraxiparin in preventing and treating thromboembolism] Saenko VF, et al. **Klin Khir** 1995;(3):39–41 (31 ref.) **(Rus)**

[Prophylaxis of venous thrombosis, yes but...] Korin JD, et al. **Medicina (B Aires)** 1996;56(3):299–307 (40 ref.) (Eng. Abstr.) **(Spa)**

[Low molecular weight heparins. Implications in anesthesia and resuscitation] Llau JV, et al. **Rev Esp Anestesiol Reanim** 1997 Feb;44(2):70–8 (142 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Treatment of thromboembolic complications of fulminant meningococcal septic shock. Mele JA 3rd, et al. **Ann Plast Surg** 1997 Mar;38(3):283–90 (29 ref.)

[Early therapeutic intervention: thromboendarterectomy and percutaneous transluminal angioplasty] Gil-Peralta A. **Neurologia** 1995 Dec;10 Suppl 2:55–61 (30 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Thromboembolic phenomena and the use of the pig as an appropriate animal model for research on cardiovascular devices. Gross DR. **Int J Artif Organs** 1997 Apr; 20(4):195–203 (89 ref.)

What's new in the prevention, diagnosis and treatment of venous thromboembolic disease. Jones JS. **J Miss State Med Assoc** 1997 Apr;38(4):115–8 (12 ref.)

What is new in the prophylaxis and treatment of venous thromboembolism? Bergentz SE. **World J Surg** 1996 Nov–Dec;20(9):1141–8 (72 ref.)

ULTRASONOGRAPHY

Spontaneous echo contrast and thromboembolism. Ansari A, et al. **Hosp Pract (Off Ed)** 1997 Jan 15;32(1):109–11, 115–6 (12 ref.)

[Transesophageal echocardiography and risk factors for embolism] Jacopi F, et al. **Ann Ital Med Int** 1996 Oct;11 Suppl 2:11S–14S (32 ref.) (Eng. Abstr.) **(Ita)**

THROMBOENDARTERECTOMY see **ENDARTERECTOMY**

THROMBOKINASE see **FACTOR XA**

THROMBOLYSIN see **PLASMIN**

THROMBOLYSIS, THERAPEUTIC see **THROMBOLYTIC THERAPY**

THROMBOLYTIC AGENTS see **FIBRINOLYTIC AGENTS**

THROMBOLYTIC THERAPY

Thrombolytic therapy for cerebral infarction [see comments] Kothari R, et al. **Acad Emerg Med** 1996 Sep;3(9):881–92 (116 ref.) Comment in: Acad Emerg Med 1996 Sep;3(9):825–6. Comment in: Acad Emerg Med 1997 Jul;4(7):753–4.

Thrombolysis acute ischemic stroke. Fieschi C, et al. **Acta Neurochir Suppl (Wien)** 1996;66:76–80 (39 ref.)

Brain attack: emergency treatment of ischemic stroke [see comments] Selman WR, et al. **Am Fam Physician** 1997 Jun; 55(8):2655–62, 2665–6 (21 ref.) Comment in: Am Fam Physician 1997 Jun;55(8):2590–1.

Treatment of acute myocardial infarction today. Maggioni AP, et al. **Am Heart J** 1997 Aug;134(2 Pt 2):S9–14 (29 ref.)

Hyperacute stroke therapy with tissue plasminogen activator. Alberts MJ. **Am J Cardiol** 1997 Aug 28;80(4C):29D–34D; discussion 35D–39D (14 ref.)

Patency trials with reteplase (r-PA): what do they tell us? Bode C, et al. **Am J Cardiol** 1996 Dec 19;78(12A):16–9 (26 ref.)

How much do we gain by reducing time to reperfusion therapy? Califf RM, et al. **Am J Cardiol** 1996 Dec 19; 78(12A):8–15 (27 ref.)

Reactivation of the coagulation system: rationale for long-term antithrombotic treatment. Kontny F. **Am J Cardiol** 1997 Sep 4;80(5A):55E–60E (63 ref.)

Prognostic markers in thrombolytic therapy: looking beyond mortality. Pepine CJ. **Am J Cardiol** 1996 Dec 19; 78(12A):24–7 (15 ref.)

Molecular biology of plasminogen activators: what are the clinical implications of drug design? Smalling RW. **Am J Cardiol** 1996 Dec 19;78(12A):2–7 (38 ref.)

Clinical trials in thrombolytic therapy: what do they tell us? INJECT 6-month outcomes data. Wilcox RG. **Am J Cardiol** 1996 Dec 19;78(12A):20–3 (8 ref.)

Early management of acute myocardial infarction: thrombolysis, angioplasty, and adjunctive therapies. Selig MB. **Am J Emerg Med** 1996 Mar;14(2):209–17 (103 ref.)

Report of two cases of children with Budd–Chiari syndrome successfully treated with streptokinase. Sawamura R, et al. **Arq Gastroenterol** 1996 Jul–Sep;33(3):179–81 (31 ref.)

Remodeling after myocardial infarction: an opportunity for early intervention. Amos DJ, et al. **Basic Res Cardiol** 1997 Apr;92(2):69–71 (10 ref.)

Heparin as an adjuvant to thrombolytic therapy in acute myocardial infarction. Metz BK, et al. **Biomed Pharmacother** 1996;50(6–7):243–53 (33 ref.)

Thrombolytic therapy in acute myocardial infarction. Hampton JR. **Cardiovasc Drugs Ther** 1997 May;11 Suppl 1:241–6 (25 ref.)

Pericardial involvement in acute myocardial infarction in the post-thrombolytic era: clinical meaning and value. Correale E, et al. **Clin Cardiol** 1997 Apr;20(4):327–31 (37 ref.)

Low-dose intermittent urokinase therapy in chronic symptomatic end-stage arterial disease—clinical relevance for patients with coronary artery disease or peripheral arterial occlusive disease. Leschke M, et al. **Clin Hemorheol Microcirc** 1997 Jan–Feb;17(1):59–66 (51 ref.)

Post-myocardial infarction trials: beta blockers, antiarrhythmics, thrombolytics. Anderson JL. **Control Clin Trials** 1996 Jun;17(3 Suppl):17S–27S (35 ref.)

Angiographic studies demonstrating the need for conjunctive anticoagulation. Bleich SD. **Coron Artery Dis** 1996 Jul; 7(7):516–21 (29 ref.)

Rationale for the use of conjunctive anticoagulation during thrombolysis. Jaffe AS. **Coron Artery Dis** 1996 Jul; 7(7):491–6 (46 ref.)

Acute myocardial infarction: role of medical therapy versus primary PTCA. Keeley EC, et al. **Coron Artery Dis** 1995 Oct;6(10):759–64 (30 ref.)

Clinical trials of conjunctive anticoagulant strategies in thrombolysis. Kleiman NS. **Coron Artery Dis** 1996 Jul; 7(7):508–15 (100 ref.)

The open infarct-related artery: theoretical and practical considerations. Nash JA. **Coron Artery Dis** 1995 Sep; 6(9):739–49 (63 ref.)

Potential advantages of direct-acting thrombin inhibitors. Philippides GJ, et al. **Coron Artery Dis** 1996 Jul; 7(7):497–507 (100 ref.)

Biological rationale for the therapeutic role of specific antithrombins. Weitz JI. **Coron Artery Dis** 1996 Jun; 7(6):409–19 (56 ref.)

Vertebrobasilar thrombosis: diagnosis, management, and the use of intra-arterial thrombolytics. Becker KJ, et al. **Crit Care Med** 1996 Oct;24(10):1729–42 (45 ref.)

New interventions in cerebrovascular disease: the role of thrombolytic therapy and balloon angioplasty. Balousek PA, et al. **Curr Opin Cardiol** 1996 Sep;11(5):550–7 (67 ref.)

Risk stratification after myocardial infarction in the thrombolytic era. Rutherford JD. **Curr Opin Cardiol** 1996 Jul;11(4):428–33 (23 ref.)

Endovascular treatment for acute and chronic brain ischemia. Clark WM, et al. **Curr Opin Neurol** 1996 Feb;9(1):62–7 (48 ref.)

Primary and secondary stroke prevention. Feinberg WM. **Curr Opin Neurol** 1996 Feb;9(1):46–52 (63 ref.)

Management of acute myocardial infarction in the elderly. Forman DE, et al. **Drugs Aging** 1996 May;8(5):358–77 (149 ref.)

Thrombolytic therapy for evolving myocardial infarction needs an approach that integrates benefit and risk. Arnold AE, et al. **Eur Heart J** 1995 Nov;16(11):1502–9 (37 ref.)

Predictors of outcome of reperfusion therapy. Califf RM, et al. **Eur Heart J** 1997 May;18(5):728–35 (75 ref.)

Impending paradoxical embolism and dynamic left ventricular outflow obstruction in a patient with recurrent pulmonary embolism and secondary pulmonary hypertension [letter] Kruzer J, et al. **Eur Heart J** 1996 Sep; 17(9):1448–9 (5 ref.)

What is the likely benefit of earlier thrombolysis? Rawles J. **Eur Heart J** 1996 Jul;17(7):991–5 (30 ref.)

Should patients with suspected acute myocardial infarction without ST elevation be given thrombolytic treatment? Rawles J. **Eur Heart J** 1997 Jun;18(6):899–906 (39 ref.)

Management of myocardial infarction: the proper priorities. Simoons ML, et al. **Eur Heart J** 1997 Jun;18(6):896–9 (31 ref.)

The role of thrombolytic drugs in the management of myocardial infarction. Comparative clinical trials. Weaver WD. **Eur Heart J** 1996 Dec;17 Suppl F:9–15 (36 ref.)

Treatment for acute myocardial infarction. Overview of randomized clinical trials. Yusuf S, et al. **Eur Heart J** 1996 Dec;17 Suppl F:16–29 (77 ref.)

Fibrin-selective thrombolytic therapy with recombinant staphylokinase. Collen D, et al. **Haemostasis** 1996 Oct;26 Suppl 4:294–300 (25 ref.)

Comparison of the relative efficacy and safety of low

molecular weight heparin and unfractionated heparin for the treatment of venous thrombosis. Hirsh J. **Haemostasis** 1996 Oct;26 Suppl 4:189–98 (20 ref.)

Management of venous thromboembolism: optimization by clinical trials. Turpie AG. **Haemostasis** 1996 Oct;26 Suppl 4:220–6 (20 ref.)

Antithrombotic treatment in stable coronary syndromes: long-term intermittent urokinase therapy in end-stage coronary artery disease and refractory angina pectoris. Schoebel FC, et al. **Heart** 1997 Jan;77(1):13–7 (53 ref.)

Thrombolytic therapy. From myocardial to cerebral infarction. The MAST-I Group. Multicentre Acute Stroke Trial. Candelise L, et al. **Ital J Neurol Sci** 1996 Feb; 17(1):5–21 (134 ref.)

Thrombolysis after acute myocardial infarction. Nee PA. **J Accid Emerg Med** 1997 Jan;14(1):2–9 (49 ref.)

Revisiting reperfusion therapy in inferior myocardial infarction. Bates ER. **J Am Coll Cardiol** 1997 Aug; 30(2):334–42 (102 ref.)

Treatment of acute ischemic stroke, Part 1. Fullerton T. **J Am Pharm Assoc (Wash)** 1996 Oct;NS36(10):571–2 (6 ref.)

Antithrombotic and thrombolytic therapies for acute myocardial infarction. Godfried SL, et al. **J Cardiovasc Risk** 1996 Oct;3(5):453–7 (29 ref.)

Thrombolytic therapy for treatment of pulmonary embolism in the postoperative period: case report and review of the literature. Hartmannsgruber MW, et al. **J Clin Anesth** 1996 Dec;8(8):669–74 (41 ref.)

The rationale for new therapies in acute ischaemic stroke. Dyker AG, et al. **J Clin Pharm Ther** 1996 Dec;21(6):377–91 (105 ref.)

Thrombolysis in the management of limb arterial occlusion. Towards a consensus interim report. Working Party on Thrombolysis in the Management of Limb Ischaemia. **J Intern Med** 1996 Dec;240(6):343–55 (70 ref.)

Risk assessment after myocardial infarction: have the rules changed with thrombolytic therapy?. Verani MS. **J Nucl Cardiol** 1996 Nov-Dec;3(6 Pt 2):S50–9 (20 ref.)

Comparison of streptokinase and urokinase in local thrombolysis of peripheral arterial occlusions for lower limb salvage. Dubé M, et al. **J Vasc Interv Radiol** 1996 Jul-Aug;7(4):587–93 (25 ref.)

Helping heart attack victims to save their own lives [editorial; comment] Langton PE, et al. **Med J Aust** 1997 Mar 3; 166(5):228–9 (9 ref.) Comment on: Med J Aust 1997 Mar 3;166(5):233–6.

Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. Collins R, et al. **N Engl J Med** 1997 Mar 20;336(12):847–60 (97 ref.)

Antithrombotic treatment in chronic non-rheumatic atrial fibrillation. ten Bokkel Huinink D, et al. **Neth J Med** 1997 Aug;51(2):51–6 (25 ref.)

Intravenous thrombolysis for acute stroke. Lyden PD, et al. **Neurology** 1997 Jul;49(1):14–20 (47 ref.)

Thrombolysis for acute ischemic stroke. Landis DM, et al. **Neurosurg Clin N Am** 1997 Apr;8(2):219–26 (31 ref.)

Current concepts of anticoagulant therapy in pregnancy. Barbour LA. **Obstet Gynecol Clin North Am** 1997 Sep; 24(3):499–521 (113 ref.)

Establishing a universal protocol for deep vein thrombosis following orthopedic surgery: total knee arthroplasty. Sculco TP. **Orthopedics** 1996 Aug;19 Suppl:6–8 (22 ref.)

Anti-thrombotic therapy for non-rheumatic atrial fibrillation [see comments] More RS, et al. **QJM** 1996 Jun;89(6):409–14 (34 ref.) Comment in: QJM 1996 Oct;89(10):799–800; discussion 801–2.

Brain single-photon emission CT with HMPAO and safety of thrombolytic therapy in acute ischemic stroke. Proceedings of the meeting of the SPECT Safe Thrombolysis Study Collaborators and the members of the Brain Imaging Council of the Society of Nuclear Medicine. Alexandrov AV, et al. **Stroke** 1997 Sep;28(9):1830–4 (32 ref.)

Superior vena cava thrombosis secondary to hickman catheter and complete resolution after fibrinolytic therapy. Morales M, et al. **Support Care Cancer** 1997 Jan;5(1):67–9 (8 ref.)

Intra-arterial thrombolysis in acute ischemic stroke. Callahan AS 3rd, et al. **Tenn Med** 1997 Feb;90(2):61–4 (14 ref.)

Acute stroke intervention. Gaines KJ. **Tenn Med** 1996 Dec; 89(12):451–6 (10 ref.)

Transport processes in fibrinolysis and fibrinolytic therapy. Blinc A, et al. **Thromb Haemost** 1996 Oct;76(4):481–91 (152 ref.)

Thrombolytic therapy. Collen D. **Thromb Haemost** 1997 Jul; 78(1):742–6 (23 ref.)

Thrombolytic therapy in pediatric patients: a comprehensive review of the literature. Leaker M, et al. **Thromb Haemost** 1996 Aug;76(2):132–4 (16 ref.)

Conjunctive use of platelet glycoprotein IIb/IIIa antagonists and thrombolytic therapy for acute myocardial infarction. Moliterno DJ, et al. **Thromb Haemost** 1997 Jul;78(1):214–9 (41 ref.)

Elevated fibrinopeptide A and B levels during thrombolytic therapy: real or artefactual? Weitz JI. **Thromb Haemost** 1996 Apr;75(4):529–35 (60 ref.)

[Use of antithrombotic agents in peripheral arterial diseases] Wütschert R, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1551–5 (23 ref.) (Eng. Abstr.) **(Fre)**

[Reperfusion therapy in acute myocardial infarct, Thrombolysis or balloon dilatation?] Zeymer U, et al. **Dtsch Med Wochenschr** 1997 Sep 5;122(36):1081–5 (30 ref.) **(Ger)**

[Spontaneous liver rupture after thrombolytic therapy with streptokinase] Hinterthaner M, et al. **Zentralbl Chir** 1997; 122(1):49–51 (20 ref.) (Eng. Abstr.) **(Ger)**

[Thrombolytic therapy in acute myocardial infarction--update] Jaffe R, et al. **Harefuah** 1996 Jun 2; 130(11):751–7 (46 ref.) **(Heb)**

[Bolus thrombolysis in pulmonary embolism. Review of experimental and clinical data] Zonzin P, et al. **Ann Ital Med Int** 1996 Apr-Jun;11(2):132–7 (35 ref.) (Eng. Abstr.) **(Ita)**

[Current applications and perspectives of thrombolytic therapy in peripheral arterial diseases and deep venous thrombosis] Agnelli G. **Cardiologia** 1995 Dec;40(12 Suppl 1):345–9 (27 ref.) **(Ita)**

[The choice between primary angioplasty and thrombolysis: is there any change after GUSTO-IIb?] Fazzini PF. **G Ital Cardiol** 1997 Jan;27(1):79–84 (39 ref.) **(Ita)**

[Atherosclerosis obliterance; thrombolytic therapy] Terada M, et al. **Nippon Geka Gakkai Zasshi** 1996 Jul;97(7):540–4 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Acute myocardial infarction and coronary thrombolysis] Kanmatsuse K. **Rinsho Ketsueki** 1996 Sep;37(9):813–6 (7 ref.) **(Jpn)**

[Thrombolysis versus angioplasty in acute myocardial infarction] Ferreira Leite P, et al. **Arq Bras Cardiol** 1995 Oct;65(4):349–52 (35 ref.) **(Por)**

[Antithrombotic therapy in the elderly patient] de Sousa JC, et al. **Rev Port Cardiol** 1997 Mar;16(3):273–80, 242 (12 ref.) (Eng. Abstr.) **(Por)**

[Thrombolysis in acute myocardial infarction] Gabriel HM, et al. **Rev Port Cardiol** 1996 Jun;15(6):507–21 (98 ref.) **(Por)**

[Direct angioplasty and thrombolysis in acute myocardial infarct] Gottschall CA. **Rev Port Cardiol** 1997 Feb; 16(2):165–74 (60 ref.) **(Por)**

[The electrocardiogram in acute myocardial infarct in the "thrombolytic era"] Kuchárová L, et al. **Bratisl Lek Listy** 1996 Jul;97(7):388–96 (65 ref.) (Eng. Abstr.) **(Slo)**

[Cardiovascular pharmacology (XIII). The efficacy of different thrombolytic drugs in the treatment of acute myocardial infarct] López-Sendón J, et al. **Rev Esp Cardiol** 1995 Jun;48(6):407–39 (184 ref.) (Eng. Abstr.) **(Spa)**

[Clinical characteristics and hospital mortality of acute myocardial infarction in elderly patients treated with thrombolytic agents] Pabón Osuna P, et al. **Rev Esp Cardiol** 1996 Jul;49(7):501–8 (28 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Problems of thrombolytic therapy. Neilson RF, et al. **Adverse Drug React Toxicol Rev** 1996 Mar;15(1):51–64 (55 ref.)

Hepatic bleeding and hemorrhagic shock following thrombolytic therapy in patients with acute myocardial infarction [letter] Gárcia-Jiménez A, et al. **Chest** 1997 Jun; 111(6):1787 (5 ref.)

Cholesterol embolisation after thrombolytic therapy. Blankenship JC. **Drug Saf** 1996 Feb;14(2):78–84 (68 ref.)

Anticoagulants and thrombolytics during pregnancy. Ramin SM, et al. **Semin Perinatol** 1997 Apr;21(2):149–53 (35 ref.)

Intracerebral hemorrhage during fibrinolytic therapy in children: a review of the literature of the last thirty years. Zenz W, et al. **Semin Thromb Hemost** 1997;23(3):321–32 (225 ref.)

[Side effects of thrombolytic therapy in patients with myocardial infarction] Agostoni A, et al. **Cardiologia** 1995 Dec;40(12):899–908 (103 ref.) **(Ita)**

[Pulmonary hemorrhage after thrombolysis in acute myocardial infarct (letter) (corrected and republished letter originally printed in An Med Interna 1996 Oct;13(10):514–5)] Rodríguez Blanco VM, et al. **An Med Interna** 1997 Apr;14(4):209 (7 ref.) **(Spa)**

ECONOMICS

Thrombolytic therapy in the elderly. Pharmacoeconomic considerations. Ramanathan K, et al. **Drugs Aging** 1996 Apr;8(4):237–44 (52 ref.)

INSTRUMENTATION

Site-specific intravascular administration of drugs: history of a method applicable in humans. Camenzind E, et al. **Cathet Cardiovasc Diagn** 1997 Jul;41(3):342–7 (39 ref.)

Pulse-spray thrombolysis in acutely obstructed coronary artery in critical situations. Saito T, et al. **Cathet Cardiovasc Diagn** 1997 Jan;40(1):101–8 (23 ref.)

[Interventional therapy in acute myocardial infarct] Heintzen MP, et al. **Internist (Berl)** 1997 Jan;38(1):44–52 (63 ref.) **(Ger)**

METHODS

Use of urokinase in unstable angina. Duvvuri S, et al. **Coron Artery Dis** 1996 Sep;7(9):630–6 (51 ref.)

Urokinase recanalization of chronically occluded aortocoronary vein grafts. Hartmann JR. **Coron Artery Dis** 1996 Sep;7(9):641–8 (32 ref.)

Treatment of peripheral arterial and venous diseases. Navarro F, et al. **Coron Artery Dis** 1996 Sep;7(9):649–55 (35 ref.)

Promising applications of thrombolytic agents from results in studies in laboratory animals. Prewitt RM. **Coron Artery Dis** 1996 Sep;7(9):625–9 (24 ref.)

Clot-selective compared with nonselective fibrinolytic drugs: déjà vu--all over again. Sobel BE, et al. **Coron Artery Dis** 1996 Sep;7(9):689–91 (13 ref.)

Intracoronary recombinant tissue-type plasminogen activator (rt-PA). Tiefenbrunn AJ. **Coron Artery Dis** 1996 Sep; 7(9):637–40 (27 ref.)

Changing paradigms in thrombolysis in acute myocardial infarction. Gotsman MS, et al. **Int J Cardiol** 1997 May 23;59(3):227–42 (101 ref.)

New developments in the treatment of deep venous thrombosis. Janssen MC, et al. **Neth J Med** 1997 Jan; 50(1):36–45 (88 ref.)

[Local intra-arterial thrombolysis in acute ischemia of an extremity] Enevoldsen MT, et al. **Ugeskr Laeger** 1996 Sep 2;158(36):5011–4 (29 ref.) (Eng. Abstr.) **(Dan)**

[Orientated management towards reperfusion in the acute phase of myocardial infarction. Results in a cohort of 700 consecutive patients] Juliard JM, et al. **Arch Mal Coeur Vaiss** 1997 Mar;90(3):337–43 (30 ref.) (Eng. Abstr.) **(Fre)**

[Coronary thrombolysis--current aspects] Legrand V. **Rev Med Liege** 1996 Sep;51(9):571–5 (28 ref.) **(Fre)**

[Successful lysis of iliofemoral and inferior vena cava thrombi in heparin-induced type-II thrombocytopenia] Emig U, et al. **Dtsch Med Wochenschr** 1997 Aug 1;122(31–32):965–8 (25 ref.) (Eng. Abstr.) **(Ger)**

[Ultrahigh-dosage urokinase lysis during pulmonary embolism prophylaxis by means of an extractable caval filter] Neuerburg J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Nov;165(5):510–3 (16 ref.) **(Ger)**

[Chronic intermittent urokinase therapy: anti-ischemic and hemodynamic effects] Leschke M, et al. **Z Kardiol** 1997; 86 Suppl 1:85–94 (45 ref.) (Eng. Abstr.) **(Ger)**

[Main antithrombotic drugs in the therapy and prevention of arterial and venous thrombosis] Ferlito S. **Minerva Cardioangiol** 1996 Jun;44(6):299–312 (132 ref.) (Eng. Abstr.) **(Ita)**

[Current status and problems of coronary thrombolysis] Kambara H. **Rinsho Byori** 1997 Feb;Suppl 104:179–85 (15 ref.) **(Jpn)**

[Treatment and prevention of thrombotic episodes with hereditary thrombophilia] Bauer KA. **Vestn Ross Akad Med Nauk** 1997;(1):32–7 (101 ref.) **(Rus)**

STANDARDS

Thrombolytic therapy in acute ischaemic stroke: the jury needs more evidence. Hankey GJ. **Med J Aust** 1997 Apr 21;166(8):419–22 (27 ref.)

UTILIZATION

Survey of use of thromboprophylaxis for routine total hip replacement by British orthopaedic surgeons. Francis RM, et al. **Br J Hosp Med** 1997 May 7–20;57(9):427–31 (36 ref.)

THROMBOMODULIN

Thrombomodulin: a new frontier in lupus research? [editorial] Cucurull E, et al. **Clin Exp Rheumatol** 1997 Jan-Feb; 15(1):1–4 (38 ref.)

ANALYSIS

Soluble markers of endothelial cell function. Blann A, et al. **Clin Hemorheol Microcire** 1997 Jan-Feb;17(1):3–11 (100 ref.)

Considering cellular thrombomodulin distribution and its modulating factors can facilitate the use of plasma thrombomodulin as a reliable endothelial marker? Boffa MC. **Haemostasis** 1996 Oct;26 Suppl 4:233–43 (79 ref.)

BLOOD

[Assay of plasma thrombomodulin in systemic diseases] Mercié P, et al. **Rev Med Interne** 1997;18(2):126–31 (35 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Thrombomodulin structure and function. Sadler JE. **Thromb Haemost** 1997 Jul;78(1):392–5 (37 ref.)

GENETICS

Thrombomodulin gene variations and thromboembolic disease. Ohlin AK, et al. **Thromb Haemost** 1997 Jul; 78(1):396–400 (26 ref.)

PHYSIOLOGY

Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Nesheim M, et al. **Thromb Haemost** 1997 Jul;78(1):386–91 (50 ref.)

[Thrombomodulin: physiology and clinical applications (excluding systemic diseases)] Karmochkine M, et al. **Rev Med Interne** 1997;18(2):119–25 (61 ref.) (Eng. Abstr.) **(Fre)**

THROMBOPENIA see **THROMBOCYTOPENIA**

THROMBOPHLEBITIS

see related
VENA CAVA FILTERS

Disorders of pulmonary circulation [editorial; comment] Pineo GF, et al. **Curr Opin Pulm Med** 1997 Jul;3(4):265–7 (20 ref.) Comment on: Curr Opin Pulm Med 1997 Jul;3(4):268–74. Comment on: Curr Opin Pulm Med 1997 Jul;3(4):275–9. Comment on: Curr Opin Pulm Med 1997 Jul;3(4):280–5. Comment on: Curr Opin Pulm Med 1997 Jul;3(4):286–90. Comment on: Curr Opin Pulm Med 1997 Jul;3(4):291–302.

Venous thromboembolism during pregnancy: a current review of diagnosis and management. Toglia MR, et al. **Obstet Gynecol Surv** 1997 Jan;52(1):60–72 (113 ref.)

Thromboembolism in trauma: the problem and its prevention. Geerts WH. **Semin Thromb Hemost** 1996;22 Suppl 2:19–24; discussion 29–30 (45 ref.)

Post discharge clinically overt venous thromboembolism in orthopaedic surgery patients with negative venography--an overview analysis. Ricotta S, et al. **Thromb Haemost** 1996 Dec;76(6):887–92 (56 ref.)

Venous thrombosis and the "Wessler test". Thomas DP. **Thromb Haemost** 1996 Jul;76(1):1–4 (52 ref.)

[Update on deep thrombophlebitis and pulmonary thromboembolism] Fiori E, et al. **Minerva Chir** 1996 Jun; 51(6):461–9 (76 ref.) (Eng. Abstr.) **(Ita)**

[Systemic arteriovenous thrombosis] Hifumi S. **Ryoikibetsu Shokogun Shirizu** 1996;(14):521–6 (14 ref.) **(Jpn)**

[Superficial thrombophlebitis] Kusaba A. **Ryoikibetsu Shokogun Shirizu** 1996;(14):545–6 (7 ref.) **(Jpn)**

[Deep vein thrombosis, deep vein thrombophlebitis] Kusaba A. **Ryoikibetsu Shokogun Shirizu** 1996;(14):512–6 (20 ref.) **(Jpn)**

[Mondor's disease] Shindo S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):429–31 (18 ref.) **(Jpn)**

BLOOD

Hypercoagulability in venous and arterial thrombosis. Thomas DP, et al. **Ann Intern Med** 1997 Apr 15; 126(8):638–44 (51 ref.)

Resistance to activated protein C and factor V Leiden. Perry DJ, et al. **QJM** 1997 Jun;90(6):379–85 (44 ref.)

Hyperhomocysteinemia as a risk factor for arterial and venous disease. A review of evidence and relevance. Boers GH. **Thromb Haemost** 1997 Jul;78(1):520–2 (25 ref.)

[Fibrinolysis and vascular diseases] Udvardy M, et al. **Orv Hetil** 1996 Aug 25;137(34):1851–5 (45 ref.) (Eng. Abstr.) **(Hun)**

CHEMICALLY INDUCED

Oral contraceptives and venous thromboembolism. Speroff L. **Int J Gynaecol Obstet** 1996 Jul;54(1):45–50 (22 ref.)

Oral contraceptives and the risk of DVT. Piegsa K, et al. **Practitioner** 1996 Sep;240(1566):544–51 (15 ref.)

CLASSIFICATION

Classification and grading of chronic venous disease in the lower limbs. A consensus statement. Beebe HG, et al. **Eur J Vasc Endovasc Surg** 1996 Nov;12(4):487–91; discussion 491–2 (44 ref.)

COMPLICATIONS

Ulnar neuropathy caused by a thrombosed ulnar vein. Case report and literature review. Grossman JA, et al. **Ann Chir Main Memb Super** 1996;15(4):244–7 (40 ref.)

Venous thromboembolism in the cancer patient. Durica SS. **Curr Opin Hematol** 1997 Sep;4(5):306–11 (62 ref.)

The assessment of acute calf pain. Banerjee A. **Postgrad Med J** 1997 Feb;73(856):86–8 (29 ref.)

[Venous thromboembolism: epidemiology and risk factors] Siragusa S, et al. **Minerva Cardioangiol** 1996 Nov; 44(11):581–9 (58 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Diagnostic imaging of lower limb deep venous thrombosis. Barloon TJ, et al. **Am Fam Physician** 1997 Sep 1; 56(3):791–801 (28 ref.)

Diagnosis of deep vein thrombosis. Haines ST, et al. **Am J Health Syst Pharm** 1997 Jan 1;54(1):66–74 (54 ref.)

Diagnosis of deep vein thrombosis. Wells PS, et al. **Biomed Pharmacother** 1996;50(6–7):235–42 (30 ref.)

The role of D-dimer in the diagnosis of venous thromboembolism [see comments] Lee AY, et al. **Curr Opin Pulm Med** 1997 Jul;3(4):275–9 (42 ref.) Comment in: Curr Opin Pulm Med 1997 Jul;3(4):265–7.

The utility and cost-effectiveness of D-dimer measurements in the diagnosis of deep vein thrombosis. Crippa L, et al. **Haematologica** 1997 Jul–Aug;82(4):446–51 (51 ref.)

Deep venous thrombosis. The dilemma of diagnosis. Servatjoo P. **J Am Podiatr Med Assoc** 1997 May; 87(5):224–32 (24 ref.)

What's new in the prevention, diagnosis and treatment of venous thromboembolic disease. Jones JS. **J Miss State Med Assoc** 1997 Apr;38(4):115–8 (12 ref.)

Diagnosis of deep vein thrombosis, an overview. Janssen MC, et al. **Neth J Med** 1996 Mar;48(3):109–21 (128 ref.)

Cerebral venous thrombosis. Martin PJ, et al. **Postgrad Med J** 1996 Feb;72(844):72–6 (30 ref.)

Multidisciplinary approach to venous thromboembolism. Marano P, et al. **Rays** 1996 Jul–Sep;21(3):481–99 (48 ref.) **(Eng, Ita)**

Diagnostic imaging in deep vein thrombosis of the limbs. Salcuni M, et al. **Rays** 1996 Jul–Sep;21(3):328–39 (19 ref.) **(Eng, Ita)**

Antiphospholipid antibodies: predictive value of laboratory tests. Galli M, et al. **Thromb Haemost** 1997 Jul;78(1):75–8 (28 ref.)

Prediction of postoperative deep-vein thrombosis. Lowe GD. **Thromb Haemost** 1997 Jul;78(1):47–52 (41 ref.)

[New diagnostic approaches to deep venous thrombosis] Rauh S, et al. **Bull Soc Sci Med Grand Duche Luxemb** 1997; 134(1):21–4 (7 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Low-molecular-weight heparin: prophylaxis and treatment of venous thromboembolism. Pineo GF, et al. **Annu Rev Med** 1997;48:79–91 (98 ref.)

Optimal duration of oral anticoagulant therapy following deep vein thrombosis of lower limbs. Bounameaux H, et al. **Blood Coagul Fibrinolysis** 1996 Jul;7(5):507–14 (37 ref.)

Pharmacokinetic optimisation of the treatment of deep vein thrombosis. Iorio A, et al. **Clin Pharmacokinet** 1997 Feb; 32(2):145–72 (265 ref.)

Duration of anticoagulant treatment for venous thrombosis [see comments] Raskob GE. **Curr Opin Pulm Med** 1997 Jul;3(4):286–90 (16 ref.) Comment in: Curr Opin Pulm Med 1997 Jul;3(4):265–7.

Current status on new anticoagulant and antithrombotic drugs and devices [see comments] Walenga JM, et al. **Curr Opin Pulm Med** 1997 Jul;3(4):291–302 (96 ref.) Comment in: Curr Opin Pulm Med 1997 Jul;3(4):265–7.

Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of venous thrombosis. Hirsh J. **Haemostasis** 1996 Oct;26 Suppl 4:189–98 (20 ref.)

Management of venous thromboembolism: optimization by clinical trials. Turpie AG. **Haemostasis** 1996 Oct;26 Suppl 4:220–6 (20 ref.)

Low-molecular-weight heparin for venous thromboembolism. Schafer AI. **Hosp Pract (Off Ed)** 1997 Jan 15;32(1):99–101, 105–6 (9 ref.)

Anticoagulation in venous thrombosis. Schulman S. **J R Soc Med** 1996 Nov;89(11):624–30 (45 ref.)

Management of venous thromboembolism [see comments] Ginsberg JS. **N Engl J Med** 1996 Dec 12;335(24):1816–28 (106 ref.) Comment in: N Engl J Med 1997 May 22;336(21):1528; discussion 1529. Comment in: N Engl J Med 1997 May 22;336(21):1528–9; discussion 1529.

New developments in the treatment of deep venous thrombosis. Janssen MC, et al. **Neth J Med** 1997 Jan; 50(1):36–45 (88 ref.)

Treatment of deep vein thrombosis. Cina G, et al. **Rays** 1996 Jul–Sep;21(3):397–416 (66 ref.) **(Eng, Ita)**

Treatment of deep vein thrombosis: is thrombosis regression a desirable endpoint? Breddin HK. **Semin Thromb Hemost** 1997;23(2):179–83 (47 ref.)

Low-molecular-weight heparin for the out-of-hospital treatment of venous thrombosis: rationale and clinical results. Crowther M, et al. **Semin Thromb Hemost** 1997; 23(1):77–81 (32 ref.)

Treatment of deep vein thrombosis with low-molecular-weight heparins: a consensus statement of the Gesellschaft für Thrombose-und Hämostaseforschung (GTH). Harenberg J, et al. **Semin Thromb Hemost** 1997; 23(1):91–6 (28 ref.)

Comparison of the relative efficacy and safety of low-molecular-weight heparin and unfractionated heparin for the treatment of venous thrombosis. Hirsh J. **Semin Thromb Hemost** 1996;22 Suppl 2:7–12; discussion 29–30 (20 ref.)

Heparin in patients with venous thromboembolism and contraindications to oral anticoagulant therapy. Monreal M. **Semin Thromb Hemost** 1997;23(1):69–75 (47 ref.)

Low-molecular-weight heparin therapy and mortality. Valentine KA, et al. **Semin Thromb Hemost** 1997; 23(2):173–8 (48 ref.)

Low molecular weight heparin for the out-of-hospital treatment of venous thrombosis: rationale and clinical results. Hirsh J, et al. **Thromb Haemost** 1997 Jul; 78(1):689–92 (33 ref.)

[Treatment of venous thrombosis with low molecular weight heparin. Progress and outlook] Fiessinger JN. **Bull Acad Natl Med** 1997 May;181(5):875–83; discussion 883–5 (27 ref.) (Eng. Abstr.) **(Fre)**

[Spontaneous liver rupture after thrombolytic therapy with streptokinase] Hinterthaner M, et al. **Zentralbl Chir** 1997; 122(1):49–51 (20 ref.) (Eng. Abstr.) **(Ger)**

[Current applications and perspectives of thrombolytic therapy in peripheral arterial diseases and deep venous thrombosis] Agnelli G. **Cardiologia** 1995 Dec;40(12 Suppl 1):345–9 (27 ref.) **(Ita)**

[Main antithrombotic drugs in the therapy and prevention of arterial and venous thrombosis] Ferlito S. **Minerva Cardioangiol** 1996 Jun;44(6):299–312 (132 ref.) (Eng. Abstr.) **(Ita)**

[Use of heparin and oral anticoagulants to prevent and treat deep venous thrombosis and pulmonary embolism] Hamerschlak N, et al. **Arq Bras Cardiol** 1996 Sep; 67(3):209–13 (20 ref.) **(Por)**

EPIDEMIOLOGY

Factor V Leiden and other coagulation factor mutations affecting thrombotic risk. Bertina RM. **Clin Chem** 1997 Sep; 43(9):1678–83 (42 ref.)

The changing pattern of venous thromboembolic disease. Cohen AT, et al. **Haemostasis** 1996 Mar–Apr;26(2):65–71 (14 ref.)

Epidemiological disasters. Cohen J. **Hum Reprod** 1996 Apr; 11(4):689–90 (9 ref.)

Epidemiology, pathophysiology and natural history of venous thromboembolism. Cina G, et al. **Rays** 1996 Jul–Sep;21(3):315–27 (95 ref.) **(Eng, Ita)**

Risk factors for venous thrombosis: prevalence, risk, and interaction. Rosendaal FR. **Semin Hematol** 1997 Jul; 34(3):171–87 (157 ref.)

ETIOLOGY

Thrombosis in pregnancy. Bates SM, et al. **Curr Opin Hematol** 1997 Sep;4(5):335–43 (96 ref.)

Hyperhomocysteinemia and venous thromboembolic disease. D'Angelo A, et al. **Haematologica** 1997 Mar–Apr; 82(2):211–9 (127 ref.)

Inherited resistance to activated protein C caused by presence of the FV:Q506 allele as a basis of venous thrombosis. Dahlbäck B, et al. **Haemostasis** 1996 Oct;26 Suppl 4:301–14 (101 ref.)

Diagnosis and clinical characteristics of inherited activated protein C resistance. Samama MM, et al. **Haemostasis** 1996 Oct;26 Suppl 4:315–30 (55 ref.)

Differences in venous thromboembolism-risk are related to causes other than product characteristics. Kaper RF. **Hum Reprod** 1996 Apr;11(4):690–1 (10 ref.)

Deep venous thrombosis and pulmonary embolism following cast immobilization of the lower extremity. Nesheiwat F, et al. **J Foot Ankle Surg** 1996 Nov–Dec;35(6):590–4; discussion 602 (24 ref.)

A deep vein thrombosis prevention program for patients undergoing long-term invasive epilepsy monitoring. Cysyk BJ, et al. **J Neurosci Nurs** 1996 Oct;28(5):298–304 (37 ref.)

Risk factors and prevention of venous thromboembolism. Storti S, et al. **Rays** 1996 Jul–Sep;21(3):439–60 (137 ref.) **(Eng, Ita)**

Deep venous thrombosis complicating a congenital absence of the inferior vena cava. Shah NL, et al. **Surgery** 1996 Nov;120(5):891–6 (53 ref.)

[Deep venous thromboses and occult cancers] Chraibi S, et al. **Ann Cardiol Angeiol (Paris)** 1997 Mar;46(3):145–9 (19 ref.) (Eng. Abstr.) **(Fre)**

[Venous thrombosis on central catheters in oncology] Devie-Hubert I, et al. **Rev Med Interne** 1996;17(10):821–5 (52 ref.) (Eng. Abstr.) **(Fre)**

[Venous catheterization can cause infusion thrombophlebitis. Study of the literature on its causes and occurrence] Adolfsson A, et al. **Lakartidningen** 1996 Nov 27; 93(48):4398, 4403–4 (17 ref.) **(Swe)**

[The pathogenesis of venous thromboses] Henyk SM, et al. **Lik Sprava** 1996 Oct–Dec;(10–12):9–14 (22 ref.) **(Ukr)**

GENETICS

Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis. Zöller B, et al. **Annu Rev Med** 1997;48:45–58 (102 ref.)

Familial thrombophilia: a complex genetic disorder. Koeleman BP, et al. **Semin Hematol** 1997 Jul;34(3):256–64 (100 ref.)

Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis. Dahlbäck B. **Thromb Haemost** 1997 Jul; 78(1):483–8 (69 ref.)

[Resistance to activated protein C by mutation of the factor V gene. Most frequent blood coagulation defect in venous thromboses] Peus D, et al. **Hautarzt** 1997 Feb;48(2):84–8 (41 ref.) (Eng. Abstr.) **(Ger)**

[Activated protein C resistance--an evaluation of current status (see comments)] Hopmeier P. **Wien Klin Wochenschr** 1996;108(19):599–606 (93 ref.) (Eng. Abstr.) Comment in: Wien Klin Wochenschr 1996;108(19):595–8. **(Ger)**

IMMUNOLOGY

Pathogenesis of venous thrombosis: a new insight. Wakefield TW, et al. **Cardiovasc Surg** 1997 Feb;5(1):6–15 (99 ref.)

[Thrombophlebitis in a patient with acute Q fever and anticardiolipin antibodies (letter)] Gálvez J, et al. **Med Clin (Barc)** 1997 Mar 15;108(10):396–7 (6 ref.) **(Spa)**

METABOLISM

Resistance to activated protein C: role in venous and arterial thrombosis. Emmerich J, et al. **Biomed Pharmacother** 1996; 50(6–7):254–60 (64 ref.)

MORTALITY

Low-molecular-weight heparin therapy and mortality. Valentine KA, et al. **Semin Thromb Hemost** 1997; 23(2):173–8 (48 ref.)

PHYSIOPATHOLOGY

Venous thrombosis revisited [editorial] Thomas DP. **Blood Coagul Fibrinolysis** 1996 Sep;7(6):583–5 (25 ref.)
Epidemiology, pathophysiology and natural history of venous thromboembolism. Cina G, et al. **Rays** 1996 Jul–Sep;21(3):315–27 (95 ref.) **(Eng, Ita)**
The natural history of deep-vein thrombosis. Prandoni P, et al. **Semin Thromb Hemost** 1997;23(2):185–8 (29 ref.)
Disorders of hemostasis in childhood: risk factors for venous thromboembolism. Manco-Johnson MJ. **Thromb Haemost** 1997 Jul;78(1):710–4 (34 ref.)
[Cerebral venous thrombosis] Beltrán-Blasco I. **Rev Neurol** 1997 Apr;25(140):569–75 (52 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Thromboprophylaxis, coagulation disorders, and regional anaesthesia. Haljamäe H. **Acta Anaesthesiol Scand** 1996 Sep; 40(8 Pt 2):1024–40 (94 ref.)
Prophylaxis of venous thromboembolism in surgery. Verhaeghe R, et al. **Acta Chir Belg** 1997 Jun;97(3):106–9 (20 ref.)
Low molecular weight heparin: biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for regional anesthetic management. Horlocker TT, et al. **Anesth Analg** 1997 Oct;85(4):874–85 (78 ref.)
Factor V Leiden: should we screen oral contraceptive users and pregnant women? [see comments] Vandenbroucke JP, et al. **BMJ** 1996 Nov 2;313(7065):1127–30 (34 ref.) Comment in: BMJ 1997 Jul 5;315(7099):60.
Prevention of venous thromboembolism in high risk patients. Agnelli G, et al. **Haematologica** 1997 Jul–Aug; 82(4):496–502 (56 ref.)
Prolonged prophylaxis against postoperative venous thromboembolism. Bergqvist D. **Haemostasis** 1996 Oct;26 Suppl 4:379–87 (57 ref.)
New antithrombotic agents for the prevention and treatment of deep vein thrombosis. Boneu B. **Haemostasis** 1996 Oct; 26 Suppl 4:368–78 (30 ref.)
Prevention of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). **Int Angiol** 1997 Mar;16(1):3–38 (421 ref.)
A deep vein thrombosis prevention program for patients undergoing long-term invasive epilepsy monitoring. Cysyk BJ, et al. **J Neurosci Nurs** 1996 Oct;28(5):298–304 (37 ref.)
Establishing a universal protocol for deep vein thrombosis following orthopedic surgery: total knee arthroplasty. Sculco TP. **Orthopedics** 1996 Aug;19 Suppl:6–8 (22 ref.)
Risk factors and prevention of venous thromboembolism. Storti S, et al. **Rays** 1996 Jul–Sep;21(3):439–60 (137 ref.) **(Eng, Ita)**
The cost and benefit of prophylaxis against deep vein thrombosis in elective hip replacement. DVT/PE Prophylaxis Consensus Forum. Abdool-Carrim T, et al. **S Afr Med J** 1997 May;87(5):594–600 (5 ref.)
Identification of candidates for prevention of venous thromboembolism. Gensini GF, et al. **Semin Thromb Hemost** 1997;23(1):55–67 (150 ref.)
Prevention of recurrences after deep venous thrombosis: role of low-molecular-weight heparins. Pini M. **Semin Thromb Hemost** 1997;23(1):51–4 (18 ref.)
New approaches to prevention of deep vein thrombosis. Bergqvist D. **Thromb Haemost** 1997 Jul;78(1):684–8 (41 ref.)
Prevention of post-operative deep leg vein thrombosis in patients with cancer. Gallus AS. **Thromb Haemost** 1997 Jul;78(1):126–32 (67 ref.)
Patients at risk of venous thromboembolism--clinical results with reviparin. Kakkar VV, et al. **Thromb Res** 1996;81(2 Suppl):S39–45 (11 ref.)
[Non-medical prevention of deep vein thrombosis] Boccalon H. **Presse Med** 1996 Oct 5;25(29):1341–6 (58 ref.) **(Fre)**
[Prevention of deep venous thrombosis in medical care] Couturaud F, et al. **Presse Med** 1996 Dec 14;25(39):1935–40 (39 ref.) (Eng. Abstr.) **(Fre)**
[Thrombosis in trauma and orthopedic surgery. Prevention, diagnosis, therapy] Haas S. **Unfallchirurg** 1997 Apr; 100(4):307–19 (10 ref.) **(Ger)**
[Criteria for utilization and indications for use of permanent and short- and medium term temporary endocaval filters. Personal experience and review of the literature] Fuochi C, et al. **Radiol Med (Torino)** 1996 Oct;92(4):431–7 (35 ref.) (Eng. Abstr.) **(Ita)**
[Deep venous thrombosis. Prophylaxis] Baruzzi AC, et al. **Arq Bras Cardiol** 1996 Sep;67(3):215–8 (22 ref.) **(Por)**
[The prevention and treatment of postoperative thrombosis of the deep veins of the lower extremities (I. Prevention)] Baeshko AA, et al. **Vestn Khir Im I I Grek** 1997; 156(1):116–21 (108 ref.) **(Rus)**

THERAPY

Dalteparin: a low-molecular-weight heparin. Howard PA. **Ann Pharmacother** 1997 Feb;31(2):192–203 (80 ref.)
Clinical results of Greenfield filter use in patients with cancer. Greenfield LJ, et al. **Cardiovasc Surg** 1997 Apr;5(2):145–9 (21 ref.)
Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Hirsh J, et al. **Circulation** 1996 Jun 15; 93(12):2212–45 (451 ref.)
The detection & management of deep venous thrombosis. Gage AM, et al. **Compr Ther** 1997 Jun;23(6):407–12 (15 ref.)
What's new in the prevention, diagnosis and treatment of venous thromboembolic disease. Jones JS. **J Miss State Med Assoc** 1997 Apr;38(4):115–8 (12 ref.)
Practical management of venous thromboembolism following pelvic fractures. Montgomery KD, et al. **Orthop Clin North Am** 1997 Jul;28(3):397–404 (56 ref.)
Multidisciplinary approach to venous thromboembolism. Marano P, et al. **Rays** 1996 Jul–Sep;21(3):481–99 (48 ref.) **(Eng, Ita)**
The treatment of deep vein thrombosis and pulmonary embolism. Turkstra F, et al. **Thromb Haemost** 1997 Jul; 78(1):489–96 (76 ref.)
[Treatment and prevention of acute embolic venous thrombosis] Genyk SN, et al. **Khirurgiia (Mosk)** 1996; (2):138–40 (31 ref.) **(Rus)**
[The prevention and treatment of postoperative thrombosis of the deep veins of the lower extremities (II. Treatment)] Baeshko AA, et al. **Vestn Khir Im I I Grek** 1997; 156(2):132–6 (87 ref.) **(Rus)**

ULTRASONOGRAPHY

The detection & management of deep venous thrombosis. Gage AM, et al. **Compr Ther** 1997 Jun;23(6):407–12 (15 ref.)
Diagnosis of acute lower limb deep venous thrombosis with ultrasound: trends and controversies. Dauzat M, et al. **J Clin Ultrasound** 1997 Sep;25(7):343–58 (137 ref.)
Controversies in venous ultrasound. Cronan JJ. **Semin Ultrasound CT MR** 1997 Feb;18(1):33–8 (35 ref.)

THROMBOPLASTIN

see related
COAGULANTS
HEMOSTATICS

ANALYSIS

[Clinical usefulness of the measurements of plasmin-alpha 2-plasmin inhibitor complex and plasma tissue factor activity in patients with disseminated intravascular coagulation] Fukuda C, et al. **Rinsho Byori** 1996 Aug; 44(8):750–6 (12 ref.) (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway. Harker LA, et al. **Haemostasis** 1996;26 Suppl 1:76–82 (25 ref.)

BIOSYNTHESIS

P-selectin induction of tissue factor biosynthesis and expression. Furie B, et al. **Haemostasis** 1996;26 Suppl 1:60–5 (40 ref.)

CHEMISTRY

The tissue factor-factor VII complex: recent advances towards elucidating the structure and function of the initiator of haemostasis. Tuddenham EG. **Haemostasis** 1996;26 Suppl 1:20–4 (12 ref.)
The factor VIIa/tissue factor complex. Banner DW. **Thromb Haemost** 1997 Jul;78(1):512–5 (45 ref.)

GENETICS

Regulation of tissue factor gene expression in human monocytic and endothelial cells. Mackman N. **Haemostasis** 1996;26 Suppl 1:17–9 (20 ref.)
Regulation of the tissue factor gene. Mackman N. **Thromb Haemost** 1997 Jul;78(1):747–54 (49 ref.)

METABOLISM

Tissue factor in crescentic glomerulonephritis [comment] McCluskey RT. **Am J Pathol** 1997 Mar;150(3):787–92 (64 ref.) Comment on: Am J Pathol 1997 Mar;150(3):873–80.
Factor VIIa-tissue factor interactions: an evaluation using factor VII-factor IX chimeras. Chang JY. **Haemostasis** 1996;26 Suppl 1:35–9 (22 ref.)
Inhibition of tissue factor and cytokine release. Gray E, et al. **Haemostasis** 1996;26 Suppl 1:92–5 (12 ref.)
Cells and the activation of factor VII. Rao LV, et al. **Haemostasis** 1996;26 Suppl 1:1–5 (20 ref.)

PHYSIOLOGY

Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system. Carmeliet P, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:191–206 (58 ref.)
Role of tissue factor and factor VIIa in the coagulant and inflammatory response to LD100 Escherichia coli in the baboon. Taylor FB Jr. **Haemostasis** 1996;26 Suppl 1:83–91 (12 ref.)
Activation of the factor VII-tissue factor pathway. Bauer KA. **Thromb Haemost** 1997 Jul;78(1):108–11 (19 ref.)
The structural basis of function of the TF. VIIa complex in the cellular initiation of coagulation. Edgington TS, et al. **Thromb Haemost** 1997 Jul;78(1):401–5 (30 ref.)
Factor VIIa-tissue factor: functional importance of protein-membrane interactions. Morrissey JH, et al. **Thromb Haemost** 1997 Jul;78(1):112–6 (47 ref.)
Tissue factor: a complex biological role. Osterud B. **Thromb Haemost** 1997 Jul;78(1):755–8 (39 ref.)
Tissue factor in health and disease. Semeraro N, et al. **Thromb Haemost** 1997 Jul;78(1):759–64 (77 ref.)
Tissue factor in the pathogenesis of atherosclerosis. Taubman MB, et al. **Thromb Haemost** 1997 Jul;78(1):200–4 (57 ref.)
[Vascular smooth muscle cell and extrinsic coagulation pathway] Nakahara Y, et al. **Rinsho Byori** 1997 Feb;Suppl 104:205–15 (39 ref.) **(Jpn)**
[Assay methods and their significance of factors involved in tissue factor-dependent coagulation reaction] Miyata T, et al. **Rinsho Ketsueki** 1997 Apr;38(4):319–22 (8 ref.) **(Jpn)**

THROMBOPLASTIN TIME, PARTIAL see **PARTIAL THROMBOPLASTIN TIME**

THROMBOPLASTINOGEN see **FACTOR VIII**

THROMBOPOIETIN

Thrombopoietin. A review. Baatout S. **Haemostasis** 1997 Jan–Feb;27(1):1–8 (40 ref.)
Thrombopoietin: biology, clinical applications, role in the donor setting. Kuter DJ. **J Clin Apheresis** 1996;11(3):149–59 (69 ref.)
[Mpl ligand (thrombopoietin) and platelet regulation] Wendling F, et al. **Ann Pharm Fr** 1996;54(4):177–82 (35 ref.) (Eng. Abstr.) **(Fre)**
[Thrombopoietin] Mizoguchi H. **Rinsho Ketsueki** 1996 Jun; 37(6):483–7 (13 ref.) **(Jpn)**

ISOLATION & PURIFICATION

[Purification and biochemical properties of thrombopoietin] Kato T. **Seikagaku** 1997 Jun;69(6):433–8 (20 ref.) **(Jpn)**

PHARMACOLOGY

Thrombopoietin (Mpl-ligand) and the regulation of platelet production. Cohen-Solal K, et al. **Thromb Haemost** 1997 Jul;78(1):37–41 (48 ref.)
Thrombopoietin and platelet development. Kaushansky K. **West J Med** 1996 Mar;164(3):209–11 (50 ref.)
[Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple angonists] Miyakawa Y, et al. **Rinsho Ketsueki** 1996 Sep;37(9):785–9 (7 ref.) **(Jpn)**

PHYSIOLOGY

Thrombopoietin: in vitro predictions, in vivo realities. Kaushansky K. **Am J Hematol** 1996 Nov;53(3):188–91 (31 ref.)
Thrombopoietin: understanding and manipulating platelet production. Kaushansky K. **Annu Rev Med** 1997;48:1–11 (82 ref.)
Positive and negative regulation of megakaryocytopoiesis. Wendling F, et al. **Baillieres Clin Haematol** 1997 Feb; 10(1):29–45 (85 ref.)
Thrombopoietin: the primary regulator of megakaryocytopoiesis and thrombopoiesis. Eaton DL, et al. **Exp Hematol** 1997 Jan;25(1):1–7 (74 ref.)
Use of human leukemia-lymphoma cell lines in hematological research: effects of thrombopoietin on human leukemia cell lines. Drexler HG, et al. **Hum Cell** 1996 Dec;9(4):309–16 (36 ref.)
The effects of thrombopoietin on the growth of acute myeloblastic leukemia cells. Matsumura I, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):533–8 (43 ref.)
[Basic and clinical aspects of thrombopoietin] Mizoguchi H. **Nippon Naika Gakkai Zasshi** 1996 Sep 10;85(9):1600–4 (14 ref.) **(Jpn)**
[Purification and biochemical properties of thrombopoietin] Kato T. **Seikagaku** 1997 Jun;69(6):433–8 (20 ref.) **(Jpn)**
[Biology of thrombopoietin and its receptors] Robak T. **Postepy Hig Med Dosw** 1996;50(6):649–63 (57 ref.) (Eng. Abstr.) **(Pol)**
[Thrombopoietic growth factor--thrombopoietin. Molecular and biological properties] Skotnicki AB, et al. **Przegl Lek** 1996;53(11):826–9 (23 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

In vivo effects of Mpl ligand administration and emerging clinical applications for the Mpl ligands. Kuter DJ. **Curr Opin Hematol** 1997 May;4(3):163–70 (53 ref.)
Mechanism of action and clinical trials of Mpl ligand. Sheridan WP, et al. **Curr Opin Hematol** 1997 Sep;4(5):312–6 (35 ref.)
Clinical studies with megakaryocyte growth and development factor (Mpl-ligand). Begley CG. **Thromb Haemost** 1997 Jul;78(1):42–6 (32 ref.)
[Clinical application of platelet hematopoiesis factor, thrombopoietin(c-Mpl ligand)] Fujimoto K, et al. **Nippon Naika Gakkai Zasshi** 1996 Jun 10;85(6):850–6 (7 ref.) **(Jpn)**

THROMBOSIS

see related
THROMBECTOMY

Deep venous thrombosis of the upper extremity [published erratum appears in Am Fam Physician 1997 Apr;55(5):1586] Stephens MB. **Am Fam Physician** 1997 Feb 1;55(2):533–9 (23 ref.)

ABC of clinical haematology. Bleeding disorders, thrombosis, and anticoagulation. Hampton KK, et al. **BMJ** 1997 Apr 5;314(7086):1026–9 (0 ref.)

Lupus anticoagulants and thrombosis: the role of phospholipids. Esmon NL, et al. **Haematologica** 1997 Jul–Aug;82(4):474–7 (32 ref.)

Thrombosis and hemorrhage in oncology patients. Bick RL, et al. **Hematol Oncol Clin North Am** 1996 Aug; 10(4):875–907 (207 ref.)

Antiphospholipid antibody associated thrombosis: a consensus for treatment? McCrae KR. **Lupus** 1996 Dec; 5(6):560–70 (39 ref.)

Postprandial lipid metabolism and thrombosis. Miller GJ. **Proc Nutr Soc** 1997 Jul;56(2):739–44 (38 ref.)

Mesenteric venous thrombosis. Rhee RY, et al. **Surg Clin North Am** 1997 Apr;77(2):327–38 (30 ref.)

Inherited thrombophilia: Part 2 [published erratum appears in Thromb Haemost 1997 May;77(5):1047] Lane DA, et al. **Thromb Haemost** 1996 Dec;76(6):824–34 (106 ref.)

Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Warkentin TE. **Transfus Med Rev** 1996 Oct;10(4):249–58 (41 ref.)

Renal artery thrombosis in the newborn infant. Kavaler E, et al. **Urology** 1997 Aug;50(2):282–4 (6 ref.)

[What are the criteria for choosing a model for evaluating arterial antithrombotic therapy?] André P, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1461–70 (59 ref.) (Eng. Abstr.) **(Fre)**

[Membranous obstruction of the inferior vena cava] Balian A, et al. **Gastroenterol Clin Biol** 1997;21(4):265–73 (67 ref.) **(Fre)**

[Systemic arteriovenous thrombosis] Hifumi S. **Ryoikibetsu Shokogun Shirizu** 1996;(14):521–6 (14 ref.) **(Jpn)**

[Aortic thrombosis] Kamiya K. **Ryoikibetsu Shokogun Shirizu** 1996;(14):370–4 (30 ref.) **(Jpn)**

[Renal vein thrombosis] Matsui N. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):312–5 (15 ref.) **(Jpn)**

[Thrombosed type aortic dissection] Matsuo H. **Ryoikibetsu Shokogun Shirizu** 1996;(14):341–4 (16 ref.) **(Jpn)**

[Primary subclavian vein thrombosis (Paget-Schroetter syndrome)] Nakashima K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):462–5 (19 ref.) **(Jpn)**

[Intracardiac thrombus] Sato Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):538–42 (27 ref.) **(Jpn)**

[Renal arterial thrombosis, renal arterial embolism, renal artery occlusion] Yoshimura M, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):330–3 (8 ref.) **(Jpn)**

[Hereditary thrombophilia in the developing countries: incidence, prevention and treatment of hereditary thrombophilic syndromes] Chandi M. **Vestn Ross Akad Med Nauk** 1997;(1):38–42 (32 ref.) **(Rus)**

[Hereditary thrombophilia: prospects] Lein DA. **Vestn Ross Akad Med Nauk** 1997;(1):47–50 (19 ref.) **(Rus)**

[Thrombophilia, prethrombotic conditions, hypercoagulability (editorial)] Rolović Z. **Srp Arh Celok Lek** 1997 Mar–Apr;125(3–4):69–74 (50 ref.) (Eng. Abstr.) **(Scc)**

BLOOD

Hypercoagulability in venous and arterial thrombosis. Thomas DP, et al. **Ann Intern Med** 1997 Apr 15; 126(8):638–44 (51 ref.)

Activated protein C resistance--a major risk factor for thrombosis. Rosén SB, et al. **Eur J Clin Chem Clin Biochem** 1997 Jul;35(7):501–16 (177 ref.)

Plasma factor VIIa: measurement and potential clinical significance. Morrissey JH. **Haemostasis** 1996;26 Suppl 1:66–71 (50 ref.)

Regulation of fibrinogen biosynthesis by cytokines, consequences on the vascular risk. Vasse M, et al. **Haemostasis** 1996 Oct;26 Suppl 4:331–9 (29 ref.)

von Willebrand factor [published erratum appears in J Clin Invest 1997 Jul 1;100(1):237] Ruggeri ZM. **J Clin Invest** 1997 Feb 15;99(4):559–64 (38 ref.)

Thrombin receptor antagonists. Seiler SM. **Semin Thromb Hemost** 1996;22(3):223–32 (118 ref.)

Markers of platelet activation and oxidant stress in atherothrombotic disease. FitzGerald GA, et al. **Thromb Haemost** 1997 Jul;78(1):280–4 (68 ref.)

Hyperhomocysteinemia and thrombosis: acquired conditions. Selhub J, et al. **Thromb Haemost** 1997 Jul;78(1):527–31 (24 ref.)

[Fibrinogen: a risk factor] Potron G, et al. **J Mal Vasc** 1996; 21(3):126–32 (97 ref.) (Eng. Abstr.) **(Fre)**

[The appropriate use of clinical biological tests in hypercoagulability] De Wind AR, et al. **Rev Med Brux** 1997 Jun;18(3):111–2 (2 ref.) (Eng. Abstr.) **(Fre)**

[Hypercoagulable states: definition and general mechanisms] Wettendorff P. **Rev Med Brux** 1997 Jun;18(3):95–6 (3 ref.) (Eng. Abstr.) **(Fre)**

[Ovarian hyper stimulation syndrome and thrombosis] Goto K, et al. **Rinsho Ketsueki** 1996 Sep;37(9):799–807 (27 ref.) **(Jpn)**

[Molecular basis of hereditary thrombophilia] Bertina RM. **Vestn Ross Akad Med Nauk** 1997;(1):15–23 (140 ref.) **(Rus)**

CHEMICALLY INDUCED

Heparin-associated thrombocytopenia and thrombosis: implications for perioperative management. Slaughter TF, et al. **Anesthesiology** 1997 Sep;87(3):667–75 (93 ref.)

Anticardiolipin (aCL) antibodies in a patient with Behçet's syndrome with vena cava inferior thrombosis. Ebo DG, et al. **Clin Rheumatol** 1997 Jan;16(1):96–8 (15 ref.)

Ancrod: the use of snake venom in the treatment of patients with heparin-induced thrombocytopenia and thrombosis undergoing coronary artery bypass grafting: nursing management. Lathan LO, et al. **Heart Lung** 1996 Nov–Dec; 25(6):451–60; quiz 461–2 (27 ref.)

Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Lewis BE, et al. **Semin Thromb Hemost** 1997;23(2):197–202 (35 ref.)

[Risk of thrombosis with oral contraceptives: value of a thrombophilia screening test] Bauersachs R, et al. **Vasa** 1996;25(3):209–20 (69 ref.) (Eng. Abstr.) **(Ger)**

[Heparin-induced thrombocytopenias, arterial and venous thromboses—complications of heparin therapy] Baluda MV. **Ter Arkh** 1996;68(12):19–22 (63 ref.) **(Rus)**

COMPLICATIONS

Pulmonary embolism from axillosubclavian thrombosis on a rehabilitation unit: case report. Kissel DJ. **Arch Phys Med Rehabil** 1997 Mar;78(3):319–23 (44 ref.)

Thrombophilia and fetal loss. Brenner B, et al. **Blood Rev** 1997 Jun;11(2):72–9 (82 ref.)

The role of granulomatous phlebitis and thrombosis in the pathogenesis of cirrhosis and portal hypertension in sarcoidosis. Moreno-Merlo F, et al. **Hepatology** 1997 Sep; 26(3):554–60 (29 ref.)

Floating thrombus in the ascending aorta: a rare cause of peripheral emboli. Kalangos A, et al. **J Vasc Surg** 1997 Jul;26(1):150–4 (22 ref.)

Appendicitis in an eleven-year-old boy complicated by thrombosis of the portal and superior mesenteric veins. van Spronsen FJ, et al. **Pediatr Infect Dis J** 1996 Oct; 15(10):910–2 (10 ref.)

Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD). Murphy S. **Thromb Haemost** 1997 Jul;78(1):622–6 (46 ref.)

[Splenic infarction in a HIV-infected patient. Apropos of a case and review of the literature] Aouad K, et al. **J Chir (Paris)** 1996;133(8):392–5 (19 ref.) (Eng. Abstr.) **(Fre)**

[Cardiogenic brain embolism] Akatsuka Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):547–50 (19 ref.) **(Jpn)**

[Renal thrombotic microangiopathy] Sakakibara K. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):316–9 (18 ref.) **(Jpn)**

DIAGNOSIS

Prolonged survival after massive pulmonary embolism in a patient with atrial septal defect and mass in the right ventricle. Tak T, et al. **Can J Cardiol** 1997 Feb; 13(2):199–202 (4 ref.)

Absence of flow in ovarian vein by time-of-flight magnetic resonance angiography without evidence of thrombosis. Rizk B, et al. **Clin Imaging** 1997 May–Jun;21(3):203–6 (11 ref.)

Mesenteric vein thrombosis. Four cases and review of the literature. Chen MC, et al. **Dig Dis** 1996 Nov–Dec; 14(6):382–9 (44 ref.)

Dynamic breath-hold 3D gadolinium-enhanced MRI of intraarterial masses: findings in two patients. Krinsky G, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):631–4 (9 ref.)

Renal MR angiography. Borrello JA. **Magn Reson Imaging Clin N Am** 1997 Feb;5(1):83–93 (49 ref.)

Vascular diseases and MR angiography of the liver. Spritzer CE. **Magn Reson Imaging Clin N Am** 1997 May;5(2):377–96 (66 ref.)

Diagnosis of thromboembolic disease during infancy and childhood. Sutor AH, et al. **Semin Thromb Hemost** 1997; 23(3):237–46 (94 ref.)

Antiphospholipid antibodies: predictive value of laboratory tests. Galli M, et al. **Thromb Haemost** 1997 Jul;78(1):75–8 (28 ref.)

Fibrinolytic and inflammatory markers for arterial occlusion: the evolving epidemiology of thrombosis and hemostasis. Ridker PM. **Thromb Haemost** 1997 Jul;78(1):53–9 (86 ref.)

[Activated protein C resistance in the Japanese] Ozawa T. **Rinsho Ketsueki** 1996 Sep;37(9):790–3 (9 ref.) **(Jpn)**

[Laboratory diagnosis of genetic risk factors of thromboses] Dal'bek B. **Vestn Ross Akad Med Nauk** 1997;(1):23–7 (41 ref.) **(Rus)**

[Control of hereditary thrombophilia through detection of carriage and prenatal diagnosis] Seligson U. **Vestn Ross Akad Med Nauk** 1997;(1):27–9 (25 ref.) **(Rus)**

[The current state of the diagnosis and treatment of acute mesenteric ischemia] Loba MM, et al. **Klin Khir** 1996; (7):40–3 (49 ref.) **(Ukr)**

DRUG THERAPY

Case report of acute splenic and superior mesenteric vein thrombosis and its successful medical management. Foo E, et al. **Ann Acad Med Singapore** 1996 Sep;25(5):755–8 (36 ref.)

New approaches in plasminogen activator therapy. Bode C, et al. **Ann Hematol** 1996;73 Suppl 1:S1–7 (44 ref.)

Which experimental model to choose to study arterial thrombosis and evaluate potentially useful therapeutics? Andre P, et al. **Haemostasis** 1996 Oct;26 Suppl 4:55–69 (58 ref.)

Left atrial thrombus in a 10-month-old boy--successful thrombolysis with recombinant tissue-type plasminogen activator after open-heart surgery: review of the literature. Kehl HG, et al. **Intensive Care Med** 1996 Sep;22(9):968–71 (11 ref.)

Fifty years of experience with antithrombotic therapy in cardiac disease. A 1996 approach based on pathogenesis and risk. Freudenrerger RS, et al. **Mt Sinai J Med** 1996 Oct–Nov;63(5–6):342–58 (69 ref.)

Low-molecular-weight heparins. Weitz JI. **N Engl J Med** 1997 Sep 4;337(10):688–98 (100 ref.)

Local thrombolytic therapy in deep cerebral venous thrombosis. Smith AG, et al. **Neurology** 1997 Jun; 48(6):1613–9 (37 ref.)

Current trends in antithrombotic drug and device development. Fareed J. **Semin Thromb Hemost** 1996;22 Suppl 1:3–8 (26 ref.)

Pharmacology of the low-molecular-weight heparins. Fareed J, et al. **Semin Thromb Hemost** 1996;22 Suppl 2:13–8 (34 ref.)

Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Lewis BE, et al. **Semin Thromb Hemost** 1997;23(2):197–202 (35 ref.)

Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents. Schafer AI. **Tex Heart Inst J** 1997;24(2):90–6 (9 ref.)

Transport processes in fibrinolysis and fibrinolytic therapy. Blinc A, et al. **Thromb Haemost** 1996 Oct;76(4):481–91 (152 ref.)

Thrombolytic therapy. Collen D. **Thromb Haemost** 1997 Jul; 78(1):742–6 (23 ref.)

Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation. Harker LA, et al. **Thromb Haemost** 1997 Jul;78(1):736–41 (55 ref.)

[Ilio-femoral vein thrombosis treated with tissue plasminogen activator in a pregnant woman] Grand A, et al. **Ann Cardiol Angeiol (Paris)** 1996 Nov;45(9):517–22 (14 ref.) (Eng. Abstr.) **(Fre)**

[Successful lysis of iliofemoral and inferior vena cava thrombi in heparin-induced type-II thrombocytopenia] Emig U, et al. **Dtsch Med Wochenschr** 1997 Aug 1;122(31–32):965–8 (25 ref.) (Eng. Abstr.) **(Ger)**

[New agents and challenges in the antithrombotic management of arterial diseases] Udvardy M, et al. **Orv Hetil** 1997 Jan 12;138(2):59–65 (44 ref.) (Eng. Abstr.) **(Hun)**

[Signal-transduction therapy] Hidaka H, et al. **Nippon Yakurigaku Zasshi** 1996 Sep;108(3):119–21 (0 ref.) **(Jpn)**

[Antithrombotic therapy in the elderly patient] de Sousa JC, et al. **Rev Port Cardiol** 1997 Mar;16(3):273–80, 242 (12 ref.) (Eng. Abstr.) **(Por)**

[Treatment and prevention of thrombotic episodes with hereditary thrombophilia] Bauer KA. **Vestn Ross Akad Med Nauk** 1997;(1):32–7 (101 ref.) **(Rus)**

EPIDEMIOLOGY

Epidemiology of thrombotic-hemostatic factors and their associations with cardiovascular disease. Pearson TA, et al. **Am J Clin Nutr** 1997 May;65(5 Suppl):1674S–1682S (104 ref.)

Factor V Leiden and other coagulation factor mutations affecting thrombotic risk. Bertina RM. **Clin Chem** 1997 Sep; 43(9):1678–83 (42 ref.)

Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management. Dahlbäck B. **Semin Hematol** 1997 Jul;34(3):217–34 (107 ref.)

The epidemiology of inherited thrombophilia: the VITA Project. Vicenza Thrombophilia and Atherosclerosis Project. Rodeghiero F, et al. **Thromb Haemost** 1997 Jul; 78(1):636–40 (33 ref.)

Thrombosis in the young: effect of atherosclerotic risk factors on the risk of myocardial infarction associated with

prothrombotic factors. Siscovick DS, et al. **Thromb Haemost** 1997 Jul;78(1):7–12 (46 ref.)

[Lipoprotein(a) as an athero–thrombotic risk factor: epidemiologic evidence and possible pathogenetic mechanisms] Lenzi S, et al. **G Ital Cardiol** 1996 Oct; 26(10):1203–25 (189 ref.) (Eng. Abstr.) **(Ita)**

[Epidemiology of hereditary thrombophilia] Rozendal FR. **Vestn Ross Akad Med Nauk** 1997;(1):5–9 (62 ref.) **(Rus)**

ETIOLOGY

Evaluation and management of the thrombosis–prone patient. Hoak JC. **Adv Intern Med** 1997;42:105–37 (123 ref.)

Dietary factors in thrombosis and hemostasis: summary and conclusions. FitzGerald GA, et al. **Am J Clin Nutr** 1997 May;65(5 Suppl):1699S–1701S (34 ref.)

Fatty acids in animals: thrombosis and hemostasis. Hoak JC. **Am J Clin Nutr** 1997 May;65(5 Suppl):1683S–1686S (16 ref.)

Dietary fatty acids in human thrombosis and hemostasis. Knapp HR. **Am J Clin Nutr** 1997 May;65(5 Suppl):1687S–1698S (221 ref.)

Thrombosis: theoretical considerations. Mann KG. **Am J Clin Nutr** 1997 May;65(5 Suppl):1657S–1664S (66 ref.)

Assays for thrombosis factors: relations to plasma lipids. Tracy RP. **Am J Clin Nutr** 1997 May;65(5 Suppl):1669S–1673S (43 ref.)

Activated protein C resistance as a basis for venous thrombosis. Hillarp A, et al. **Am J Med** 1996 Nov; 101(5):534–40 (12 ref.)

Endothelial cell injury in cardiovascular surgery: the procoagulant response. Boyle EM Jr, et al. **Ann Thorac Surg** 1996 Nov;62(5):1549–57 (54 ref.)

Prognostic relevance of intracaval neoplastic extension for patients with renal cell cancer. Kuczyk MA, et al. **Br J Urol** 1997 Jul;80(1):18–24 (27 ref.)

Reactive oxygen metabolites and arterial thrombosis. Ambrosio G, et al. **Cardiovasc Res** 1997 Jun;34(3):445–52 (58 ref.)

Left ventricular mural thrombus after acute myocardial infarction. Keeley EC, et al. **Clin Cardiol** 1996 Feb; 19(2):83–6 (26 ref.)

The "lupus" circulating anticoagulant, AKA the primary antiphospholipid syndrome. Rothschild BM. **Compr Ther** 1996 Jul;22(7):420–3 (14 ref.)

The role of platelets in arterial thrombosis and the rationale for blockade of platelet GPIIb/IIIa receptors as antithrombotic therapy. Coller BS. **Eur Heart J** 1995 Nov; 16 Suppl L:11–5 (29 ref.)

Stent thrombosis revisited. Gershlick AH, et al. **Eur Heart J** 1996 Nov;17(11):1623–8 (39 ref.)

Activated protein C resistance--a major risk factor for thrombosis. Rosén SB, et al. **Eur J Clin Chem Clin Biochem** 1997 Jul;35(7):501–16 (177 ref.)

Spontaneous arterial thrombosis with an advanced ovarian malignancy. Minjarez DA, et al. **Gynecol Oncol** 1997 Jan; 64(1):176–9 (18 ref.)

Venous and arterial thrombophilia. Girolami A, et al. **Haematologica** 1997 Jan–Feb;82(1):96–100 (25 ref.)

Dietary fatty acids in athero–thrombogenesis: influence of palm oil ingestion. de Bosch NB, et al. **Haemostasis** 1996 Oct;26 Suppl 4:46–54 (35 ref.)

Injury models of the vascular endothelium: apoptosis and loss of thromboresistance induced by a viral protein. Eldor A, et al. **Haemostasis** 1996 Oct;26 Suppl 4:37–45 (46 ref.)

Homocysteine, oxidative stress, and vascular disease [see comments] Welch GN, et al. **Hosp Pract (Off Ed)** 1997 Jun 15;32(6):81–2, 85, 88–92 (13 ref.) Comment in: Hosp Pract (Off Ed) 1997 Aug 15;32(8):44.

Fulminant acute Budd–Chiari syndrome stemming from an adrenal tumor. Moreira V, et al. **J Clin Gastroenterol** 1997 Mar;24(2):110–2 (14 ref.)

Neonatal antiphospholipid syndrome [letter] Navarro F, et al. **J Rheumatol** 1997 Jun;24(6):1240–1 (17 ref.)

Hypothenar hammer syndrome in sports. Müller LP, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;4(3):167–70 (23 ref.)

Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia. Michiels JJ, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:47–56 (56 ref.)

Protein C and other cofactors involved in the binding of antiphospholipid antibodies: relation to the pathogenesis of thrombosis. de Groot PG, et al. **Lupus** 1996 Oct; 5(5):488–93 (52 ref.)

Vasculopathy of the antiphospholipid syndromes revisited: thrombosis is the culprit and vasculitis the consort. Lie JT. **Lupus** 1996 Oct;5(5):368–71 (40 ref.)

In vivo models of thrombosis for the antiphospholipid syndrome. Pierangeli SS, et al. **Lupus** 1996 Oct;5(5):451–5 (48 ref.)

Vascular access thrombosis--what are the possibilities of intervention? [editorial] Mysliwiec M. **Nephrol Dial Transplant** 1997 May;12(5):876–8 (11 ref.)

Bleeding and thrombosis in chronic uremia [editorial] Sagripanti A, et al. **Nephron** 1997;75(2):125–39 (172 ref.)

Right atrial thrombus as a complication of total parenteral nutrition in pregnancy. Turrentine MA, et al. **Obstet Gynecol** 1994 Oct;84(4 Pt 2):675–7 (13 ref.)

The hypercoagulable state. Who, how, and when to test and treat. Brigden ML. **Postgrad Med** 1997 May;101(5):249–52, 254–6, 259–62 passim (24 ref.)

Lipids, thrombosis and cardiovascular disease in diabetes. Yudkin JS. **Proc Nutr Soc** 1997 Mar;56(1B):273–80 (45 ref.)

Thrombotic syndromes and autoimmune diseases. Fessler BJ. **Rheum Dis Clin North Am** 1997 May;23(2):461–79 (180 ref.)

Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective [editorial] Petri M. **Scand J Rheumatol** 1996;25(4):191–3 (16 ref.)

Combination of activated protein C resistance and antibodies to phospholipids in the development of thrombosis. Bokarewa MI, et al. **Semin Hematol** 1997 Jul;34(3):235–43 (74 ref.)

Antithrombin deficiency in special clinical syndromes--Part II: hematologic malignancies and bone marrow transplantation. Haire WD. **Semin Hematol** 1995 Oct;32(4 Suppl 2):56–60 (8 ref.)

Thrombophilia and complex acquired deficiencies of antithrombin, protein C, and protein S. Humphries JE. **Semin Hematol** 1995 Oct;32(4 Suppl 2):8–16; discussion 17–8 (16 ref.)

Clinical relevance of antithrombin deficiencies. Mammen EF. **Semin Hematol** 1995 Oct;32(4 Suppl 2):2–6; discussion 7 (29 ref.)

The etiology, diagnosis and treatment of thrombotic disorders in newborn infants: a call for international and multi–institutional studies. Schmidt B. **Semin Perinatol** 1997 Feb;21(1):86–9 (12 ref.)

The pathogenesis of the antiphospholipid syndrome: a hypothesis based on parallelisms with heparin–induced thrombocytopenia [see comments] Arnout J. **Thromb Haemost** 1996 Apr;75(4):536–41 (93 ref.) Comment in: Thromb Haemost 1996 Nov;76(5):817–8.

Failure patterns of cryopreserved vein grafts in liver transplantation. Kuang AA, et al. **Transplantation** 1996 Sep 27;62(6):742–7 (21 ref.)

Portal vein thrombosis and stenosis in pediatric liver transplantation. Millis JM, et al. **Transplantation** 1996 Sep 27;62(6):748–54 (24 ref.)

[Hyperhomocysteinemia, atherosclerosis and arterial and venous thrombosis] Cacoub P, et al. **Ann Med Interne (Paris)** 1996;147(5):352–60 (70 ref.) **(Fre)**

[Antiphospholipid antibodies, lupus anticoagulant and thrombosis] Capel P. **Rev Med Brux** 1997 Jun;18(3):108–10 (18 ref.) (Eng. Abstr.) **(Fre)**

[Preventive management of patients presenting with an increased tendency to venous thrombosis] Demulder A, et al. **Rev Med Brux** 1997 Jun;18(3):113–8 (19 ref.) (Eng. Abstr.) **(Fre)**

[The appropriate use of clinical biological tests in hypercoagulability] De Wind AR, et al. **Rev Med Brux** 1997 Jun;18(3):111–2 (2 ref.) (Eng. Abstr.) **(Fre)**

[Hypercoagulable states: definition and general mechanisms] Wettendorff P. **Rev Med Brux** 1997 Jun;18(3):95–6 (3 ref.) (Eng. Abstr.) **(Fre)**

[Early stent–induced thrombosis in the pelvic circulation: a complication in APC resistance] Lenglinger FX, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Mar;166(3):260–2 (11 ref.) **(Ger)**

[Clinical significance and predictive value of laboratory tests in thrombosis associated with antiphospolipid antibodies] Barbui T, et al. **Ann Ital Med Int** 1997 Apr–Jun;12(2):76–83 (60 ref.) (Eng. Abstr.) **(Ita)**

[The arterial prothrombotic state and the plurimetabolic syndrome (editorial)] De Sandre G, et al. **Recenti Prog Med** 1996 Oct;87(10):489–90 (18 ref.) **(Ita)**

[Coping with pathological changes in nerves and blood vessels in collagen disease--antiphospholipid syndrome and thrombosis] Ichikawa K, et al. **Nippon Naika Gakkai Zasshi** 1996 Nov 10;85(11):1828–32 (5 ref.) **(Jpn)**

[Prosthetic valve thrombosis in the aortic position] Morita K. **Ryoikibetsu Shokogun Shirizu** 1996;(13):411–4 (18 ref.) **(Jpn)**

[Intracardiac thrombosis in myocardial infarction] Sudo K. **Ryoikibetsu Shokogun Shirizu** 1996;(12):696–9 (11 ref.) **(Jpn)**

[Clinical manifestations of hereditary thrombophilia] Mannuchchi PM. **Vestn Ross Akad Med Nauk** 1997; (1):29–31 (36 ref.) **(Rus)**

[Pathophysiology of thrombophilia] Miletich DP. **Vestn Ross Akad Med Nauk** 1997;(1):9–14 (27 ref.) **(Rus)**

[Antithrombotic therapy in atrial fibrillation] Farré J, et al. **Rev Esp Cardiol** 1996;49 Suppl 2:42–9 (27 ref.) (Eng. Abstr.) **(Spa)**

[Portal vein thrombosis associated with essential thrombocytosis. Clinical cases and review of the literature] Carvajal S, et al. **Rev Med Chil** 1996 Mar;124(3):353–8 (26 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Inherited thrombotic disorders: an update. Florell SR, et al. **Am J Hematol** 1997 Jan;54(1):53–60 (53 ref.)

Factor VLeiden and thrombophilia. Kalafatis M, et al. **Arterioscler Thromb Vasc Biol** 1997 Apr;17(4):620–7 (88 ref.)

Inherited thrombophilia: memorandum from a joint WHO/International Society on Thrombosis and Haemostasis meeting. **Bull World Health Organ** 1997; 75(3):177–89 (69 ref.)

Thrombophilia: an expanding group of genetic defects that predispose to thrombosis. Laffan M, et al. **Mol Med Today** 1997 Jul;3(7):303–9 (44 ref.)

Familial thrombophilia: a complex genetic disorder. Koeleman BP, et al. **Semin Hematol** 1997 Jul;34(3):256–64 (100 ref.)

Clinical relevance of polymorphic markers of arterial thrombosis. Di Minno G, et al. **Thromb Haemost** 1997 Jul; 78(1):462–6 (65 ref.)

Gene–environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis. Humphries SE, et al. **Thromb Haemost** 1997 Jul;78(1):457–61 (35 ref.)

Inherited thrombophilia: Part 1. Lane DA, et al. **Thromb Haemost** 1996 Nov;76(5):651–62 (150 ref.)

Protein C deficiency: from gene defects to disease. Reitsma PH. **Thromb Haemost** 1997 Jul;78(1):344–50 (69 ref.)

Thrombophilia as a multigenic disorder. Seligsohn U, et al. **Thromb Haemost** 1997 Jul;78(1):297–301 (55 ref.)

[Factor V Leiden and activated protein C resistance] Cauchie P, et al. **Rev Med Brux** 1997 Jun;18(3):97–102 (26 ref.) (Eng. Abstr.) **(Fre)**

[Activated protein C resistance in the Japanese] Ozawa T. **Rinsho Ketsueki** 1996 Sep;37(9):790–3 (9 ref.) **(Jpn)**

[Genetics of thrombophilia] Ginter EK. **Vestn Ross Akad Med Nauk** 1997;(1):42–7 (50 ref.) **(Rus)**

[Activated protein C resistance as a cause of thrombophilia] Ruiz–Argüelles GJ. **Rev Invest Clin** 1996 May–Jun; 48(3):223–9 (48 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Pathogenic role of antiprotein–phospholipid antibodies. Carreras LO, et al. **Haemostasis** 1996 Oct;26 Suppl 4:340–57 (91 ref.)

Antiphospholipid–protein antibodies: clinical use of laboratory test results (identification, predictive value, treatment). Triplett DA. **Haemostasis** 1996 Oct;26 Suppl 4:358–67 (44 ref.)

Thrombogenic mechanisms of antiphospholipid antibodies. Esmon NL, et al. **Thromb Haemost** 1997 Jul;78(1):79–82 (26 ref.)

Antibody–mediated thrombosis. Vermylen J, et al. **Thromb Haemost** 1997 Jul;78(1):420–6 (73 ref.)

METABOLISM

Haemostatic factors and atherogenesis. Smith EB. **Atherosclerosis** 1996 Aug 2;124(2):137–43 (80 ref.)

Resistance to activated protein C: role in venous and arterial thrombosis. Emmerich J, et al. **Biomed Pharmacother** 1996; 50(6–7):254–60 (64 ref.)

Homocysteine and thrombotic disease. D'Angelo A, et al. **Blood** 1997 Jul 1;90(1):1–11 (147 ref.)

Endothelial prostaglandin and nitric oxide synthesis in atherogenesis and thrombosis. Wu KK. **J Formos Med Assoc** 1996 Sep;95(9):661–6 (41 ref.)

Antioxidants, atherosclerosis and thrombosis. Rao GH, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Mar; 54(3):155–66 (154 ref.)

Activation of endothelial cells in thrombosis and vasculitis. Cockwell P, et al. **Scand J Rheumatol** 1997;26(3):145–50 (58 ref.)

Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy? Andrassy K, et al. **Thromb Res** 1996;81(2 Suppl):S29–38 (25 ref.)

MICROBIOLOGY

Focal intracranial infections. Heilpern KL, et al. **Infect Dis Clin North Am** 1996 Dec;10(4):879–98 (77 ref.)

PHYSIOPATHOLOGY

Dietary factors in thrombosis and hemostasis: summary and conclusions. FitzGerald GA, et al. **Am J Clin Nutr** 1997 May;65(5 Suppl):1699S–1701S (34 ref.)

Fatty acids in animals: thrombosis and hemostasis. Hoak JC. **Am J Clin Nutr** 1997 May;65(5 Suppl):1683S–1686S (16 ref.)

Dietary fatty acids in human thrombosis and hemostasis. Knapp HR. **Am J Clin Nutr** 1997 May;65(5 Suppl):1687S–1698S (221 ref.)

Thrombosis: theoretical considerations. Mann KG. **Am J Clin Nutr** 1997 May;65(5 Suppl):1657S–1664S (66 ref.)

Epidemiology of thrombotic–hemostatic factors and their associations with cardiovascular disease. Pearson TA, et al. **Am J Clin Nutr** 1997 May;65(5 Suppl):1674S–1682S (104 ref.)

Assays for thrombosis factors: relations to plasma lipids. Tracy RP. **Am J Clin Nutr** 1997 May;65(5 Suppl):1669S–1673S (43 ref.)

Activated protein C resistance as a basis for venous thrombosis. Hillarp A, et al. **Am J Med** 1996 Nov; 101(5):534–40 (12 ref.)

Relationships of the circadian rhythms of thrombotic, ischemic, hemorrhagic, and arrhythmic events to blood pressure rhythms. Manfredini R, et al. **Ann N Y Acad Sci** 1996 Aug 15;783:141–58 (183 ref.)

Thrombotic risk factors for atherosclerosis. Dobroski DR, et al. **Coron Artery Dis** 1996 Dec;7(12):919–32 (100 ref.)

Models to study thrombotic disorders. Badimon L. **Thromb Haemost** 1997 Jul;78(1):667–71 (62 ref.)

Mechanisms of bleeding and thrombosis in myeloproliferative

disorders. Landolfi R, et al. **Thromb Haemost** 1997 Jul; 78(1):617–21 (25 ref.)
Mechanisms initiating platelet thrombus formation. Ruggeri ZM. **Thromb Haemost** 1997 Jul;78(1):611–6 (25 ref.)
Tissue factor pathway inhibitor: clinical deficiency states. Sandset PM, et al. **Thromb Haemost** 1997 Jul;78(1):467–70 (45 ref.)
Tissue factor in health and disease. Semeraro N, et al. **Thromb Haemost** 1997 Jul;78(1):759–64 (77 ref.)
Cytokines: triggers of clinical thrombotic disease. ten Cate JW, et al. **Thromb Haemost** 1997 Jul;78(1):415–9 (44 ref.)
The Leiden Thrombophilia Study (LETS). van der Meer FJ, et al. **Thromb Haemost** 1997 Jul;78(1):631–5 (18 ref.)
Fibrinogen and fibrin—proteins with complex roles in hemostasis and thrombosis. Blombäck B. **Thromb Res** 1996 Jul 1;83(1):1–75 (440 ref.)
[Lipoprotein(a) as an athero–thrombotic risk factor: epidemiologic evidence and possible pathogenetic mechanisms] Lenzi S, et al. **G Ital Cardiol** 1996 Oct; 26(10):1203–25 (189 ref.) (Eng. Abstr.) **(Ita)**
[Thrombosis and apoptosis] Takeya H, et al. **Rinsho Byori** 1997 Jul;45(7):614–20 (32 ref.) (Eng. Abstr.) **(Jpn)**
[Platelet adhesion receptors and thrombus formation] Tomiyama Y. **Rinsho Byori** 1996 Sep;Suppl 102:153–63 (19 ref.) **(Jpn)**
[Pathophysiology of thrombophilia] Miletich DP. **Vestn Ross Akad Med Nauk** 1997;(1):9–14 (27 ref.) **(Rus)**
[The vascular endothelium: physiopathology and participation in thrombogenesis] Chordá C, et al. **Sangre (Barc)** 1995 Dec;40(6):491–8 (107 ref.) **(Spa)**

PREVENTION & CONTROL

Evaluation and management of the thrombosis–prone patient. Hoak JC. **Adv Intern Med** 1997;42:105–37 (123 ref.)
Prostacyclin and nitric oxide–related gene transfer in preventing arterial thrombosis and restenosis. Wu KK. **Agents Actions Suppl** 1997;48:107–23 (35 ref.)
Design of nonthrombogenic polymer surfaces for blood–contacting medical devices. Kim SW, et al. **Blood Purif** 1996;14(5):357–72 (24 ref.)
Stent thrombosis. Closing in on the best preventive treatment [editorial; comment] Baim DS, et al. **Circulation** 1997 Mar 4;95(5):1098–100 (14 ref.) Comment on: Circulation 1997 Mar 4;95(5):1145–56.
Stent thrombosis revisited. Gershlick AH, et al. **Eur Heart J** 1996 Nov;17(11):1623–8 (39 ref.)
The anti–GPIIb–IIIa agents: fundamental and clinical aspects. Coller BS, et al. **Haemostasis** 1996 Oct;26 Suppl 4:285–93 (36 ref.)
New thoughts on strategies for modulating platelet function through the inhibition of surface receptors. Nurden AT. **Haemostasis** 1996 Oct;26 Suppl 4:78–88 (36 ref.)
Investigation in the use of topical solutions for management or prevention of thrombosis in traumatized vessels. Cooley BC, et al. **Int Angiol** 1995 Sep;14(3):297–302 (87 ref.)
Hemodynamic screening and early percutaneous intervention reduce hemodialysis access thrombosis and increase graft longevity. Sullivan KL, et al. **J Vasc Interv Radiol** 1997 Mar–Apr;8(2):163–70 (45 ref.)
Intracardiac thrombus formation in cardiac impairment: the role of anticoagulant therapy. Lip GY. **Postgrad Med J** 1996 Dec;72(854):731–8 (64 ref.)
Antithrombin deficiency in special clinical syndromes—Part II: cardiovascular surgery. Levy JH. **Semin Hematol** 1995 Oct;32(4 Suppl 2):49–55 (14 ref.)
Antithrombin deficiency in special clinical syndromes—Part I: neonatal and pediatric/physiologic deficiency: extracorporeal membrane oxygenation. Shapiro A. **Semin Hematol** 1995 Oct;32(4 Suppl 2):33–6 (10 ref.)
Are the available low–molecular–weight heparin preparations the same? Fareed J, et al. **Semin Thromb Hemost** 1996;22 Suppl 1:77–91 (34 ref.)
Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Levine MN. **Thromb Haemost** 1997 Jul;78(1):133–6 (22 ref.)
Antithrombotic strategies in patients with cancer. Prandoni P. **Thromb Haemost** 1997 Jul;78(1):141–4 (33 ref.)
Cost–effectiveness of the low molecular weight heparin reviparin sodium in thromboprophylaxis. Kakkar VV. **Thromb Res** 1996;81(2 Suppl):S75–7 (2 ref.)
[Research on plasma TXA2, PGI2 levels, blood stasis syndrome and promoting blood circulation] Li H. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Nov; 15(11):701–4 (30 ref.) **(Chi)**
[Medical treatment after implantation of intracoronary stents] Caussin C, et al. **Presse Med** 1997 Apr 5;26(11):532–5 (14 ref.) (Eng. Abstr.) **(Fre)**
[Preventive management of patients presenting with an increased tendency to venous thrombosis] Demulder A, et al. **Rev Med Brux** 1997 Jun;18(3):113–8 (19 ref.) (Eng. Abstr.) **(Fre)**
[Glycoprotein IIb/IIIa receptor inhibitors] Bornkessel B. **Med Monatsschr Pharm** 1996 Dec;19(12):356–8 (3 ref.) **(Ger)**
[Current approach in antithrombotic treatment during coronary interventions: specific thrombocyte aggregation inhibitors and direct thrombin antagonists in high–risk patients] Meyer BJ. **Schweiz Med Wochenschr** 1996 Nov 16;126(46):1961–9 (43 ref.) (Eng. Abstr.) **(Ger)**
[Anti–thrombosis therapy following coronary stent implantation] Schuiki E, et al. **Schweiz Rundsch Med Prax** 1996 Oct 15;85(42):1316–9 (28 ref.) (Eng. Abstr.) **(Ger)**
[Treatment and prevention of thrombotic episodes with hereditary thrombophilia] Bauer KA. **Vestn Ross Akad Med Nauk** 1997;(1):32–7 (101 ref.) **(Rus)**
[Prophylaxis of venous thromboembolic disease. SEPAR's Pulmonary Thromboembolism Group] Ruiz Manzano J, et al. **Arch Bronconeumol** 1996 Aug–Sep;32(7):348–56 (60 ref.) **(Spa)**
[Antithrombotic therapy in atrial fibrillation] Farré J, et al. **Rev Esp Cardiol** 1996;49 Suppl 2:42–9 (27 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

[TIPSS in the Budd–Chiari syndrome with portal vein thrombosis] Nolte W, et al. **Dtsch Med Wochenschr** 1997 Jan 31;122(5):116–21 (25 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Primary subclavian–axillary vein thrombosis: consensus and commentary. Rutherford RB, et al. **Cardiovasc Surg** 1996 Aug;4(4):420–3 (15 ref.)
Case report: successful treatment of bleeding jejunal varices using mesoportal recanalization and stent placement: report of a case and review of the literature. Stafford Johnson DB, et al. **Clin Radiol** 1997 Jul;52(7):562–5 (17 ref.)
Percutaneous intervention for permanent hemodialysis access: a review. Gray RJ. **J Vasc Interv Radiol** 1997 May–Jun;8(3):313–27 (105 ref.)
Management of thrombosis in the antiphospholipid syndrome. Khamashta MA. **Lupus** 1996 Oct;5(5):463–6 (43 ref.)
Heparin–induced thrombocytopenia—background and implications for haemodialysis [editorial] Finazzi G, et al. **Nephrol Dial Transplant** 1996 Nov;11(11):2120–2 (15 ref.)
1995 American College of Chest Physicians (ACCP) consensus guidelines on antithrombotic therapy. Davidson B. **Semin Thromb Hemost** 1996;22 Suppl 2:1–5; discussion 29–30 (34 ref.)
The unstable atherosclerotic plaque: clinical significance and therapeutic intervention. Fuster V, et al. **Thromb Haemost** 1997 Jul;78(1):247–55 (45 ref.)
[The successful percutaneous revascularization of a subacute renal artery obstruction] Weishaupt D, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Mar;166(3):269–72 (15 ref.) **(Ger)**

ULTRASONOGRAPHY

Role of transesophageal echocardiography in the management of thromboembolic stroke. Manning WJ. **Am J Cardiol** 1997 Aug 28;80(4C):19D–28D; discussion 35D–39D (78 ref.)

VETERINARY

Antithrombotic and fibrinolytic factors. A review. Welles EG. **Vet Clin North Am Small Anim Pract** 1996 Sep; 26(5):1111–27 (136 ref.)

VIROLOGY

Viral activation of coagulation: implications for thrombosis and atherosclerosis. Hajjar DP, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:155–65; discussion 165–7 (68 ref.)

THROMBOSIS, CORONARY see **CORONARY THROMBOSIS**

THROMBOSIS, RETINAL VEIN see **RETINAL VEIN OCCLUSION**

THROMBOSIS, VENOUS see **THROMBOPHLEBITIS**

THROMBOSPONDIN RECEPTORS see **ANTIGENS, CD36**

THROMBOTEST see **PROTHROMBIN TIME**

THROMBOXANE A SYNTHASE see **THROMBOXANE SYNTHETASE**

THROMBOXANE A2

METABOLISM

[Molecular pharmacology and application to the bronchial asthma of thromboxane A2 antagonists] Kohno S. **Nippon Rinsho** 1996 Feb;54(2):551–8 (25 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Role of thromboxane A2 in mitogenesis of vascular smooth muscle cells. Dorn GW 2nd. **Agents Actions Suppl** 1997; 48:42–62 (61 ref.)
Thromboxane A2 and related prostaglandins in airways. Devillier P, et al. **Fundam Clin Pharmacol** 1997;11(1):2–18 (186 ref.)

THROMBOXANE A2 RECEPTORS see **RECEPTORS, THROMBOXANE**

THROMBOXANE B2

BLOOD

[Research on plasma TXA2, PGI2 levels, blood stasis syndrome and promoting blood circulation] Li H. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Nov; 15(11):701–4 (30 ref.) **(Chi)**

THROMBOXANE RECEPTORS see **RECEPTORS, THROMBOXANE**

THROMBOXANE SYNTHETASE

ANTAGONISTS & INHIBITORS

[Thromboxane A2 synthetase inhibitor in asthma therapy] Machida K, et al. **Nippon Rinsho** 1996 Nov;54(11):3034–9 (17 ref.) (Eng. Abstr.) **(Jpn)**

THROMBOXANES

see related
RECEPTORS, THROMBOXANE

BIOSYNTHESIS

The case of low–dose aspirin for the prevention of myocardial infarction: but how low is low? Förster W, et al. **Cardiovasc Drugs Ther** 1997 Jan;10(6):727–34 (51 ref.)

PHARMACOLOGY

Effect of nitric oxide, prostacyclin, and thromboxane on the vasospastic action of hydrogen peroxide on human umbilical artery. Okatani Y, et al. **Acta Obstet Gynecol Scand** 1997 Jul;76(6):515–20 (24 ref.)

PHYSIOLOGY

[The role of thromboxane in the pathogenesis of nephropathies] Dzúrik R, et al. **Vnitr Lek** 1996 Nov; 42(11):784–8 (46 ref.) (Eng. Abstr.) **(Slo)**

THROMBUS see **THROMBOSIS**

THRUSH see **CANDIDIASIS, ORAL**

THUMB

Renal cell carcinoma metastatic to the thumb: a case report and review of subungual metastases from all primary sites. Vine JE, et al. **Clin Exp Dermatol** 1996 Sep;21(5):377–80 (11 ref.)
The rheumatoid thumb. Stein AB, et al. **Hand Clin** 1996 Aug; 12(3):541–50 (49 ref.)
Aneurysmal bone cyst involving the distal phalanx of a child. Katz MA, et al. **Orthopedics** 1997 May;20(5):463–6 (23 ref.)

ABNORMALITIES

Heterogeneity in adducted thumbs sequence. Moldavsky M, et al. **Am J Med Genet** 1997 May 16;70(2):114–7 (13 ref.)
Variation in severity of cardiac disease in Holt–Oram syndrome. Sletten LJ, et al. **Am J Med Genet** 1996 Oct 16;65(2):128–32 (66 ref.)
The thumb in syndactyly. Verdan C. **Ann Chir Main** 1982; 1(1):29–39 (13 ref.) **(Eng, Fre)**
Facial asymmetry, cardio–vascular anomalies and adducted thumbs as unusual symptoms in Dubowitz syndrome? Vogels A, et al. **Ann Genet** 1996;39(1):31–4 (23 ref.)
Transvaginal sonographic detection of adducted thumbs, hydrocephalus, and agenesis of the corpus callosum at 22 postmenstrual weeks: the masa spectrum or L1 spectrum. A case report and review of the literature. Timor–Tritsch IE, et al. **Prenat Diagn** 1996 Jun;16(6):543–8 (31 ref.)
[Townes–Brocks syndrome] Ishikiriyama S. **Ryoikibetsu Shokogun Shirizu** 1996;(15):305–6 (8 ref.) **(Jpn)**
[Aase syndrome] Kondoh T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):232–3 (13 ref.) **(Jpn)**

ANATOMY & HISTOLOGY

A variation in the organization of abductor pollicis longus. Fabrizio PA, et al. **Clin Anat** 1996;9(6):371–5 (20 ref.)
[Morphology of the Neanderthal thumb. Apropos of 6 cases and a review of the literature] Oberlin C, et al. **Ann Chir Main Memb Super** 1997;16(1):58–65 (11 ref.) **(Fre)**

INJURIES

Anatomy, physiology, and functional restoration of the thumb. Emerson ET, et al. **Ann Plast Surg** 1996 Feb; 36(2):180–91 (58 ref.)
Thumb reconstruction. Brunelli GA, et al. **Bull Hosp Jt Dis** 1996;54(4):245–8 (21 ref.)
Neurovascular pedicle and advancement flaps for palmar thumb defects. Hynes DE. **Hand Clin** 1997 May; 13(2):207–16 (40 ref.)
Simultaneous open dislocations of the interphalangeal and metacarpo–phalangeal joints in a thumb—a case report. Lee JC, et al. **Singapore Med J** 1996 Jun;37(3):318–9 (7 ref.)
[Recent isolated lesions of the flexor tendon of the thumb

(20 cases). A long-term review] Thomazeau H, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(7):590–7 (16 ref.) (Eng. Abstr.) **(Fre)**

INNERVATION

Patterns of median nerve sensory innervation to the thumb and index finger: an anatomic study. Jolley BJ, et al. **J Hand Surg [Am]** 1997 Mar;22(2):228–31 (30 ref.)

PATHOLOGY

[Metastasis of an adenocarcinoma of the colon to the 1st metacarpal bone] Méndez López JM, et al. **Ann Chir Main Memb Super** 1997;16(2):134–7 (8 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Thumb reconstruction. Brunelli GA, et al. **Bull Hosp Jt Dis** 1996;54(4):245–8 (21 ref.)

Giant cell reparative granuloma: presentation of one case and review of the literature. Poli G, et al. **Chir Organi Mov** 1996 Apr–Jun;81(2):217–21 (10 ref.) **(Eng, Ita)**

Current status of metacarpophalangeal arthroplasty and basilar joint arthroplasty of the thumb. Murray PM. **Clin Plast Surg** 1996 Jul;23(3):395–406 (73 ref.)

Neurovascular pedicle and advancement flaps for palmar thumb defects. Hynes DE. **Hand Clin** 1997 May; 13(2):207–16 (40 ref.)

THUMBSUCKING see **FINGERSUCKING**

THYME see **HERBS**

THYMECTOMY

Current and future therapies for myasthenia gravis. Yi Q, et al. **Drugs Aging** 1997 Aug;11(2):132–9 (61 ref.)

Stiff-persons' syndrome associated with thymoma and subsequent myasthenia gravis. Nicholas AP, et al. **Muscle Nerve** 1997 Apr;20(4):493–8 (49 ref.)

[Indications and value of thymectomy in myasthenia gravis] Nix WA. **Nervenarzt** 1997 Feb;68(2):85–93 (73 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Surgical therapy of malignant thymoma. Schmidt R, et al. **J Cardiovasc Surg (Torino)** 1997 Jun;38(3):317–22 (41 ref.)

THYMIC CYST see **MEDIASTINAL CYST**

THYMIC FACTOR, CIRCULATING

METABOLISM

Sex hormones and the thymus in relation to thymocyte proliferation and maturation. Seiki K, et al. **Arch Histol Cytol** 1997 Mar;60(1):29–38 (25 ref.)

THYMIC GROUP VIRUSES see **HERPESVIRIDAE**

THYMIC HORMONES see **THYMUS HORMONES**

THYMIDINE KINASE

BIOSYNTHESIS

Targeted gene therapy for cancer: herpes simplex virus thymidine kinase gene-mediated cell killing leads to anti-tumour immunity that can be augmented by co-expression of cytokines in the tumour cells. Vile RG, et al. **Biochem Soc Trans** 1997 May;25(2):717–22 (51 ref.)

BLOOD

Clinical and biological significance of serum tumor markers in adult T-cell leukemia. Sadamori N. **Leuk Lymphoma** 1996 Aug;22(5–6):415–9 (59 ref.)

CHEMISTRY

Regulation and biological function of thymidine kinase. Wintersberger E. **Biochem Soc Trans** 1997 Feb;25(1):303–8 (42 ref.)

Integrated homology modelling and X-ray study of herpes simplex virus I thymidine kinase: a case study. Folkers G, et al. **J Recept Signal Transduct Res** 1997 Jan–May; 17(1–3):475–94 (28 ref.)

DRUG EFFECTS

Herpesvirus-encoded thymidine kinase in chemotherapy. Ostrowski T, et al. **Postepy Biochem** 1995;41(5 Suppl):342–7 (67 ref.)

GENETICS

Alternate hypothesis for the bimodal size distribution of mutant colonies of L5178Y mouse lymphoma cells. Mitchell AD. **Environ Mol Mutagen** 1997;29(4):431–3 (15 ref.)

METABOLISM

Molecular mechanism of thymidylate synthase-catalyzed reaction and interaction of the enzyme with 2- and/or 4-substituted analogues of dUMP and 5-fluoro-dUMP. Rode W, et al. **Acta Biochim Pol** 1996;43(1):133–42 (33 ref.)

Regulation and biological function of thymidine kinase. Wintersberger E. **Biochem Soc Trans** 1997 Feb;25(1):303–8 (42 ref.)

THYMIDINE PHOSPHATASE see **5'-NUCLEOTIDASE**

THYMIDINE PHOSPHORYLASE

PHYSIOLOGY

Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy. Griffiths L, et al. **Br J Cancer** 1997;76(6):689–93 (55 ref.)

THYMIDYLATE SYNTHETASE

ANTAGONISTS & INHIBITORS

Folate-based thymidylate synthase inhibitors in cancer chemotherapy. Takemura Y, et al. **Anticancer Drugs** 1997 Jan;8(1):3–16 (115 ref.)

Tomudex (ZD1694): from concept to care, a programme in rational drug discovery. Jackman AL, et al. **Invest New Drugs** 1996;14(3):305–16 (83 ref.)

Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. Rustum YM, et al. **J Clin Oncol** 1997 Jan;15(1):389–400 (77 ref.)

New concepts for the development and use of antifolates. Chu E, et al. **Stem Cells** 1996 Jan;14(1):41–6 (20 ref.)

Efficacy and tolerability of a new inhibitor of thymidylate synthase: 'Tomudex' (raltitrexed). Cunningham D. **Tumori** 1997 Jan–Feb;83(1 Suppl):S70–1 (08 ref.)

Inhibition of thymidylate synthase: biochemical pharmacology of drugs with activity in colorectal cancer. Jackman AL. **Tumori** 1997 Jan–Feb;83(1 Suppl):S65–6 (11 ref.)

The potential role of Tomudex in the treatment of advanced colorectal cancer. Sobrero AF. **Tumori** 1997 Mar–Apr; 83(2):576–80 (42 ref.)

[Inhibition of thymidylate synthase in chemotherapy] Rode W. **Postepy Biochem** 1996;42(2):133–40 (75 ref.) **(Pol)**

METABOLISM

The role of thymidylate synthase as an RNA binding protein. Chu E, et al. **Bioessays** 1996 Mar;18(3):191–8 (66 ref.)

THYMINE DIMERS see **PYRIMIDINE DIMERS**

THYMOANALEPTICS see **ANTIDEPRESSIVE AGENTS**

THYMOLEPTICS see **ANTIDEPRESSIVE AGENTS**

THYMOMA

CLASSIFICATION

[Thymomas and carcinoma of the thymus. Which classification should be used] de Montpréville VT, et al. **Ann Pathol** 1996;16(3):159–66 (69 ref.) **(Fre)**

[Noninvasive and invasive thymoma probes into evaluating the value of prognostic factors] Jacek G, et al. **Pneumonol Alergol Pol** 1996;64(11–12):834–41 (40 ref.) **(Pol)**

COMPLICATIONS

Thymoma and agranulocytosis: two case reports and literature review. Yip D, et al. **Br J Haematol** 1996 Oct; 95(1):52–6 (10 ref.)

Steroid-resistant nephrotic syndrome associated with malignant thymoma. Ishida I, et al. **Clin Nephrol** 1996 Nov; 46(5):340–6 (25 ref.)

Polymyositis in a patient with thymoma and T cell lymphocytosis. Cranney A, et al. **J Rheumatol** 1997 Jul; 24(7):1413–6 (19 ref.)

Stiff-persons' syndrome associated with thymoma and subsequent myasthenia gravis. Nicholas AP, et al. **Muscle Nerve** 1997 Apr;20(4):493–8 (49 ref.)

A case of thymoma-associated autoimmune haemolytic anaemia. Rennenberg RJ, et al. **Neth J Med** 1997 Mar; 50(3):110–4 (23 ref.)

PATHOLOGY

Primary thymic epithelial neoplasms showing combined features of thymoma and thymic carcinoma. A clinicopathologic study of 22 cases. Suster S, et al. **Am J Surg Pathol** 1996 Dec;20(12):1469–80 (32 ref.)

Characterization of the human thymic microenvironment: lymphoepithelial interaction in normal thymus and thymoma. Müller-Hermelink HK, et al. **Arch Histol Cytol** 1997 Mar;60(1):9–28 (161 ref.)

Intrapericardial thymoma: report of two incidental autopsy cases and review of the literature. Mirra M, et al. **Arch Pathol Lab Med** 1997 Jan;121(1):59–63 (17 ref.)

Primary pleural thymoma. Shih DF, et al. **Arch Pathol Lab Med** 1997 Jan;121(1):79–82 (10 ref.)

Thymic neoplasms. Debono DJ, et al. **Curr Opin Oncol** 1996 Mar;8(2):112–9 (65 ref.)

Cytologic Diagnosis of "CASTLE" of thyroid gland: report of a case with histologic correlation. Ng WK, et al. **Diagn Cytopathol** 1996 Sep;15(3):224–7 (20 ref.)

Pitfalls in the diagnosis of ectopic hamartomatous thymoma. Michal M, et al. **Histopathology** 1996 Dec;29(6):549–55 (11 ref.)

Thymoma presenting as nephrotic syndrome--an unusual case report and review of literature. Sirpal YM. **Indian J Cancer** 1995 Jun;32(2):89–92 (12 ref.)

SURGERY

Surgical therapy of malignant thymoma. Schmidt R, et al. **J Cardiovasc Surg (Torino)** 1997 Jun;38(3):317–22 (41 ref.)

[Complete Pleuropneumonectomy] Morita T, et al. **Kyobu Geka** 1996 Jul;49(8 Suppl):697–705 (90 ref.) **(Jpn)**

[Recurrence of a stage I thymoma after resection] Nomori H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jul; 34(7):833–6 (10 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Thymic neoplasms [see comments] Komaki R, et al. **Curr Opin Oncol** 1997 Mar;9(2):156–60 (35 ref.) Comment in: Curr Opin Oncol 1997 Mar;9(2):147–8.

VETERINARY

Tumours of the haematopoietic system. Barthold SW. **IARC Sci Publ** 1996;(126):365–83 (74 ref.)

The role of radiotherapy in the treatment of lymphoma and thymoma. Meleo KA. **Vet Clin North Am Small Anim Pract** 1997 Jan;27(1):115–29 (36 ref.)

THYMOTAXIN see **BETA 2-MICROGLOBULIN**

THYMUS-DEPENDENT LYMPHOCYTES see **T-LYMPHOCYTES**

THYMUS EXTRACTS

THERAPEUTIC USE

Thymus therapy for cancer? A criteria-based, systematic review [see comments] Ernst E. **Eur J Cancer** 1997 Apr; 33(4):531–5 (29 ref.) Comment in: Eur J Cancer 1997 Apr;33(4):517–8.

THYMUS GLAND

see related
BURSA OF FABRICIUS
THYMECTOMY

Aberrant cervical thymus: a case report and review of literature. Baek CH, et al. **Int J Pediatr Otorhinolaryngol** 1997 Aug 20;41(2):215–22 (11 ref.)

Ectopic intrathyroidal thymus diagnosed as a solid thyroid lesion: case report and review of the literature. Gimm O, et al. **J Pediatr Surg** 1997 Aug;32(8):1241–3 (18 ref.)

[Thymus in systemic lupus erythematosus] Kartashova VI, et al. **Klin Med (Mosk)** 1997;75(1):24–6 (15 ref.) (Eng. Abstr.) **(Rus)**

ABNORMALITIES

Early spontaneous abortions and fetal thymic abnormalities in maternal-to-fetal HIV infection. Shearer WT, et al. **Acta Paediatr Suppl** 1997 Jun;421:60–4 (25 ref.)

[CATCH22 syndrome] Miyamoto T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):205–7 (9 ref.) **(Jpn)**

ANATOMY & HISTOLOGY

Precise analyses of the structure of the thymus for establishing details of the mechanisms underlying thymocyte proliferation and maturation. Fukumoto T. **Arch Histol Cytol** 1997 Mar;60(1):1–8 (41 ref.)

Characterization of the human thymic microenvironment: lymphoepithelial interaction in normal thymus and thymoma. Müller-Hermelink HK, et al. **Arch Histol Cytol** 1997 Mar;60(1):9–28 (161 ref.)

Neurotensin pathway in the chicken thymus. Atoji Y, et al. **Kaibogaku Zasshi** 1997 Jun;72(3):181–6 (33 ref.)

CYTOLOGY

Cellular interactions in thymocyte development. Anderson G, et al. **Annu Rev Immunol** 1996;14:73–99 (155 ref.)

Regulation of thymocyte development from immature progenitors. Zúñiga-Pflücker JC, et al. **Curr Opin Immunol** 1996 Apr;8(2):215–24 (96 ref.)

Thymic stromal cell specialization and the T-cell receptor repertoire. Lo D, et al. **Immunol Res** 1997 Feb;16(1):3–14 (46 ref.)

Thymic dendritic cells. Ardavín C. **Immunol Today** 1997 Jul; 18(7):350–61 (95 ref.)

Thymic and extrathymic T cell development. Leclercq G, et al. **Leukemia** 1996 Dec;10(12):1853–9 (59 ref.)

Heterogeneity of epithelial cells in the rat thymus. De Waal EJ, et al. **Microsc Res Tech** 1997 Aug 1;38(3):227–36 (122 ref.)

Functional histology of the neuroendocrine thymus. Moll UM. **Microsc Res Tech** 1997 Aug 1;38(3):300–10 (118 ref.)

Thymic epithelial cell culture. Röpke C.

Microsc Res Tech 1997 Aug 1;38(3):276–86 (90 ref.)

Control of the thymic microenvironment by growth hormone/insulin-like growth factor-I-mediated circuits. Savino W, et al. **Neuroimmunomodulation** 1995 Nov-Dec; 2(6):313–8 (38 ref.)

Origin and development of the gamma delta T-cell system in sheep: a critical role for the thymus in the generation of TcR diversity and tissue tropism. Cahill RN, et al. **Semin Immunol** 1996 Dec;8(6):351–60 (61 ref.)

The nature of the peptide/MHC ligand involved in positive selection. Hogquist KA, et al. **Semin Immunol** 1996 Apr; 8(2):63–8 (31 ref.)

Cross-talk between the T cell antigen receptor and the glucocorticoid receptor regulates thymocyte development. Ashwell JD, et al. **Stem Cells** 1996 Sep;14(5):490–500 (58 ref.)

[Regulation of thymocyte apoptosis and positive selection] Iwata M. **Nippon Rinsho** 1996 Jul;54(7):1753–9 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Programmed thymic T cell death and negative selection via Fas and TCR/CD3 complex] Kishi S. **Nippon Rinsho** 1996 Jul;54(7):1760–7 (17 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Multiple effects of cyclosporin A on the thymus in relation to T-cell development and autoimmunity. Damoiseaux JG, et al. **Clin Immunol Immunopathol** 1997 Mar;82(3):197–202 (41 ref.)

Differential effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin, bis(tri-n-butyltin) oxide and cyclosporine on thymus histophysiology. De Waal EJ, et al. **Crit Rev Toxicol** 1997 Jul;27(4):381–430 (460 ref.)

EMBRYOLOGY

Alterations in fetal thymic and liver hematopoietic cells as indicators of exposure to developmental immunotoxicants. Holladay SD, et al. **Environ Health Perspect** 1996 Aug;104 Suppl 4:809–13 (34 ref.)

Development of Hassall's bodies of the thymus in humans and other vertebrates (especially mammals) under physiological and pathological conditions: immunocytochemical, electronmicroscopic and in vitro observations. Bodey B, et al. **In Vivo** 1997 Jan-Feb; 11(1):61–85 (335 ref.)

Development of the thymus. Bockman DE. **Microsc Res Tech** 1997 Aug 1;38(3):209–15 (37 ref.)

GROWTH & DEVELOPMENT

Thymocyte development in vitro: implications for studies of ageing and thymic involution. Montecino-Rodriguez E, et al. **Mech Ageing Dev** 1997 Feb;93(1-3):47–57 (63 ref.)

IMMUNOLOGY

Early spontaneous abortions and fetal thymic abnormalities in maternal-to-fetal HIV infection. Shearer WT, et al. **Acta Paediatr Suppl** 1997 Jun;421:60–4 (25 ref.)

The thymus and T cell death. Sprent J, et al. **Adv Exp Med Biol** 1996;406:191–8 (35 ref.)

T-cell repertoire: political correctness in the immune system. Lucas B, et al. **Curr Biol** 1996 Jul 1;6(7):783–7 (12 ref.)

Induction of tolerance by intrathymic inoculation of alloantigen. Naji A. **Curr Opin Immunol** 1996 Oct; 8(5):704–9 (60 ref.)

In thymic selection, peptide diversity gives and takes away. Bevan MJ. **Immunity** 1997 Aug;7(2):175–8 (16 ref.)

Thymic stromal cell specialization and the T-cell receptor repertoire. Lo D, et al. **Immunol Res** 1997 Feb;16(1):3–14 (46 ref.)

Evidence for a thymus-dependent form of tolerance that is not based on elimination or anergy of reactive T cells. Le Douarin N, et al. **Immunol Rev** 1996 Feb;149:35–53 (67 ref.)

A model for developmentally acquired thymus-dependent tolerance to central and peripheral antigens. Modigliani Y, et al. **Immunol Rev** 1996 Feb;149:155–20 (58 ref.)

The shaping of the brain-specific T lymphocyte repertoire in the thymus. Wekerle H, et al. **Immunol Rev** 1996 Feb; 149:231–43 (35 ref.)

Piecing together the thymic puzzle. Anderson G, et al. **Immunol Today** 1997 Aug;18(8):363–4 (17 ref.)

Thymic involution with ageing: obsolescence or good housekeeping? [see comments] George AJ, et al. **Immunol Today** 1996 Jun;17(6):267–72 (60 ref.) Comment in: Immunol Today 1996 Oct;17(10):492–3.

The thymic repertoire of neuroendocrine self-antigens: physiological implications in T-cell life and death. Martens H, et al. **Immunol Today** 1996 Jul;17(7):312–7 (44 ref.)

The role of the thymus in the control of autoimmunity. Heath VL, et al. **J Autoimmun** 1996 Apr;9(2):241–6 (32 ref.)

The nature of the peptide/MHC ligand involved in positive selection. Hogquist KA, et al. **Semin Immunol** 1996 Apr; 8(2):63–8 (31 ref.)

Thymic development of V gamma 3 cells. Leclercq G, et al. **Semin Immunol** 1996 Dec;8(6):315–21 (63 ref.)

Cellular and biochemical requirements for thymocyte negative selection. Page DM, et al. **Semin Immunol** 1996 Apr;8(2):69–82 (140 ref.)

Genes involved in T-cell receptor-mediated apoptosis of thymocytes and T-cell hybridomas. Winoto A. **Semin Immunol** 1997 Feb;9(1):51–8 (79 ref.)

METABOLISM

Sex hormones and the thymus in relation to thymocyte proliferation and maturation. Seiki K, et al. **Arch Histol Cytol** 1997 Mar;60(1):29–38 (25 ref.)

Expression and function of Fc receptors in the thymus. Leclercq G, et al. **Crit Rev Immunol** 1995;15(3-4):215–33 (151 ref.)

In thymic selection, peptide diversity gives and takes away. Bevan MJ. **Immunity** 1997 Aug;7(2):175–8 (16 ref.)

PATHOLOGY

Thymoma presenting as nephrotic syndrome--an unusual case report and review of literature. Sirpal YM. **Indian J Cancer** 1995 Jun;32(2):89–92 (12 ref.)

Primary thymic carcinomas. Moran CA, et al. **Pathology (Phila)** 1996;4(1):141–53 (33 ref.)

Myasthenia gravis. Marx A, et al. **Verh Dtsch Ges Pathol** 1996;80:116–26 (63 ref.)

PHYSIOLOGY

Genetic regulation of apoptosis in the mouse thymus. Osborne BA, et al. **Adv Exp Med Biol** 1996;406:199–207 (41 ref.)

Thymus influences liver functions through hypothalamus-pituitary-gonad axis in rats. Li L, et al. **Adv Neuroimmunol** 1996;6(3):289–93 (19 ref.)

Regulation of thymocyte development by glucocorticoids. Vacchio MS, et al. **Behring Inst Mitt** 1996 Oct;(97):24–31 (21 ref.)

Plasticity of neuro-endocrine-thymus interactions during aging--a minireview. Fabris N, et al. **Cell Mol Biol (Noisy-le-grand)** 1997 Jun;43(4):529–41 (59 ref.)

Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. Mackall CL, et al. **Immunol Rev** 1997 Jun; 157:61–72 (68 ref.)

The physiological role of regulatory T cells in the prevention of autoimmunity: the function of the thymus in the generation of the regulatory T cell subset. Saoudi A, et al. **Immunol Rev** 1996 Feb;149:195–216 (94 ref.)

Thymic involution with ageing: obsolescence or good housekeeping? [see comments] George AJ, et al. **Immunol Today** 1996 Jun;17(6):267–72 (60 ref.) Comment in: Immunol Today 1996 Oct;17(10):492–3.

Control of the thymic microenvironment by growth hormone/insulin-like growth factor-I-mediated circuits. Savino W, et al. **Neuroimmunomodulation** 1995 Nov-Dec; 2(6):313–8 (38 ref.)

Origin and development of the gamma delta T-cell system in sheep: a critical role for the thymus in the generation of TcR diversity and tissue tropism. Cahill RN, et al. **Semin Immunol** 1996 Dec;8(6):351–60 (61 ref.)

TRANSPLANTATION

Perspective: research highlights at the Duke University center for AIDS research. Immunoreconstitution in HIV infection: the role of the thymus. Markert ML. **AIDS Res Hum Retroviruses** 1996 Jun 10;12(9):751–5 (28 ref.)

The SCID-hu mouse: an in vivo model for HIV-1 infection in humans. Bonyhadi ML, et al. **Mol Med Today** 1997 Jun; 3(6):246–53 (51 ref.)

ULTRASTRUCTURE

Development of Hassall's bodies of the thymus in humans and other vertebrates (especially mammals) under physiological and pathological conditions: immunocytochemical, electronmicroscopic and in vitro observations. Bodey B, et al. **In Vivo** 1997 Jan-Feb; 11(1):61–85 (335 ref.)

Genes that regulate apoptosis in the mouse thymus. Osborne BA, et al. **J Cell Biochem** 1996 Jan;60(1):18–22 (18 ref.)

Thymic nurse cells: their functional ultrastructure. Brelińska R, et al. **Microsc Res Tech** 1997 Aug 1;38(3):250–66 (56 ref.)

Human thymic dendritic cells. Lafontaine M, et al. **Microsc Res Tech** 1997 Aug 1;38(3):267–75 (51 ref.)

VIROLOGY

HIV-1 and the thymus [editorial] Gaulton GN, et al. **AIDS** 1997 Mar 15;11(4):403–14 (114 ref.)

THYMUS HORMONES

THERAPEUTIC USE

Thymus-derived peptides in the treatment of viral chronic hepatitis [see comments] Naylor PH, et al. **Dig Dis** 1996 Nov-Dec;14(6):362–70 (41 ref.) Comment in: Dig Dis 1996 Nov-Dec;14(6):331–3.

THYMUS HYPERPLASIA

DIAGNOSIS

Hyperplasia of thymic gland. Lee YM, et al. **Singapore Med J** 1996 Jun;37(3):288–90 (20 ref.)

THYMUS-INDEPENDENT ANTIGENS see **ANTIGENS, T-INDEPENDENT**

THYMUS NEOPLASMS

CLASSIFICATION

[Thymomas and carcinoma of the thymus. Which classification should be used] de Montpréville VT, et al. **Ann Pathol** 1996;16(3):159–66 (69 ref.) **(Fre)**

[Noninvasive and invasive thymoma probes into evaluating the value of prognostic factors] Jacek G, et al. **Pneumonol Alergol Pol** 1996;64(11-12):834–41 (40 ref.) **(Pol)**

COMPLICATIONS

Thymoma and agranulocytosis: two case reports and literature review. Yip D, et al. **Br J Haematol** 1996 Oct; 95(1):52–6 (10 ref.)

Steroid-resistant nephrotic syndrome associated with malignant thymoma. Ishida I, et al. **Clin Nephrol** 1996 Nov; 46(5):340–6 (25 ref.)

Stiff-persons' syndrome associated with thymoma and subsequent myasthenia gravis. Nicholas AP, et al. **Muscle Nerve** 1997 Apr;20(4):493–8 (49 ref.)

A case of thymoma-associated autoimmune haemolytic anaemia. Rennenberg RJ, et al. **Neth J Med** 1997 Mar; 50(3):110–4 (23 ref.)

DIAGNOSIS

Magnetic resonance imaging of thymic epithelial tumors. Kushihashi T, et al. **Crit Rev Diagn Imaging** 1996 Aug; 37(3):191–259 (76 ref.)

[Classification and differential diagnosis of primary thymic tumors] Otto Kh. **Patol Fiziol Eksp Ter** 1996 Jul-Sep; (3):34–41 (34 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Tlag1, a novel murine tumor susceptibility gene that regulates MNU-induced thymic lymphoma development. Richie ER, et al. **Prog Clin Biol Res** 1996;395:23–32 (17 ref.)

PATHOLOGY

Primary thymic epithelial neoplasms showing combined features of thymoma and thymic carcinoma. A clinicopathologic study of 22 cases. Suster S, et al. **Am J Surg Pathol** 1996 Dec;20(12):1469–80 (32 ref.)

Characterization of the human thymic microenvironment: lymphoepithelial interaction in normal thymus and thymoma. Müller-Hermelink HK, et al. **Arch Histol Cytol** 1997 Mar;60(1):9–28 (161 ref.)

Intrapericardial thymoma: report of two incidental autopsy cases and review of the literature. Mirra M, et al. **Arch Pathol Lab Med** 1997 Jan;121(1):59–63 (17 ref.)

Primary pleural thymoma. Shih DF, et al. **Arch Pathol Lab Med** 1997 Jan;121(1):79–82 (10 ref.)

Thymic neoplasms. Debono DJ, et al. **Curr Opin Oncol** 1996 Mar;8(2):112–9 (65 ref.)

Cytologic Diagnosis of "CASTLE" of thyroid gland: report of a case with histologic correlation. Ng WK, et al. **Diagn Cytopathol** 1996 Sep;15(3):224–7 (20 ref.)

Thymic basaloid carcinoma: a case report and review of the literature. Iezzoni JC, et al. **Mod Pathol** 1996 Jan;9(1):21–5 (10 ref.)

A case of sarcomatoid carcinoma of the thymus. Nishimura M, et al. **Pathol Int** 1997 Apr;47(4):260–3 (11 ref.)

Primary thymic carcinomas. Moran CA, et al. **Pathology (Phila)** 1996;4(1):141–53 (33 ref.)

Clear cell neoplasms of the endocrine system and thymus. Wick MR, et al. **Semin Diagn Pathol** 1997 Aug; 14(3):183–202 (84 ref.)

Pulmonary and thymic carcinoid tumors. Dusmet ME, et al. **World J Surg** 1996 Feb;20(2):189–95 (59 ref.)

SURGERY

Surgical therapy of malignant thymoma. Schmidt R, et al. **J Cardiovasc Surg (Torino)** 1997 Jun;38(3):317–22 (41 ref.)

[Complete Pleuropneumonectomy] Morita T, et al. **Kyobu Geka** 1996 Jul;49(8 Suppl):697–705 (90 ref.) **(Jpn)**

[Recurrence of a stage I thymoma after resection] Nomori H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jul; 34(7):833–6 (10 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Thymic neoplasms [see comments] Komaki R, et al. **Curr Opin Oncol** 1997 Mar;9(2):156–60 (35 ref.) Comment in: Curr Opin Oncol 1997 Mar;9(2):147–8.

VETERINARY

The role of radiotherapy in the treatment of lymphoma and thymoma. Meleo KA. **Vet Clin North Am Small Anim Pract** 1997 Jan;27(1):115–29 (36 ref.)

THYROCALCITONIN see **CALCITONIN**

THYROGLOBULIN

BLOOD

131I therapy for elevated thyroglobulin levels. Schlumberger M, et al. **Thyroid** 1997 Apr;7(2):273–6 (10 ref.)

IMMUNOLOGY

Anti-thyroglobulin autoantibodies in autoimmune thyroid diseases: cross-reactive or pathogenic? Tomer Y. **Clin Immunol Immunopathol** 1997 Jan;82(1):3–11 (89 ref.)

Searching for pathogenic epitopes in thyroglobulin: parameters and caveats. Carayanniotis G, et al. **Immunol Today** 1997 Feb;18(2):83–8 (56 ref.)

Development of primary hypothyroidism with antithyroglobulin, antiperoxidase, and blocking-type thyrotropin receptor antibodies after radiation therapy for neuroblastoma. Kikawa Y, et al. **J Pediatr** 1996 Dec; 129(6):909–12 (19 ref.)

Molecular analysis of the antibody response to thyroglobulin and thyroid peroxidase. McIntosh RS, et al. **Thyroid** 1997 Jun;7(3):471–87 (90 ref.)

THYROGLOSSAL CYST

Thyroid gland ectopias. Batsakis JG, et al. **Ann Otol Rhinol Laryngol** 1996 Dec;105(12):996–1000 (31 ref.)

COMPLICATIONS

Squamous cell carcinoma in a thyroglossal duct cyst (TGDC): clinical presentation, diagnosis, and management. Hanna E. **Am J Otolaryngol** 1996 Sep–Oct;17(5):353–7 (9 ref.)

Laryngeal obstruction caused by lingual thyroglossal duct cyst presenting at birth. Kuint J, et al. **Am J Perinatol** 1997 Jul;14(6):353–6 (11 ref.)

Presentation and management of a thyroglossal duct cyst with a papillary carcinoma. Walton BR, et al. **South Med J** 1997 Jul;90(7):758–61 (24 ref.)

DIAGNOSIS

Non-nodal neck masses. Woodruff WW, et al. **Semin Ultrasound CT MR** 1997 Jun;18(3):182–204 (40 ref.)

GENETICS

Hereditary thyroglossal duct cysts. Greinwald JH Jr, et al. **Arch Otolaryngol Head Neck Surg** 1996 Oct;122(10):1094–6 (19 ref.)

PATHOLOGY

Cytologic findings in thyroglossal duct carcinoma [see comments] Bardales RH, et al. **Am J Clin Pathol** 1996 Nov; 106(5):615–9 (20 ref.) Comment in: Am J Clin Pathol 1996 Nov;106(5):559–60.

Squamous cell carcinoma in a thyroglossal duct cyst (TGDC): clinical presentation, diagnosis, and management. Hanna E. **Am J Otolaryngol** 1996 Sep–Oct;17(5):353–7 (9 ref.)

THYROID ANTAGONISTS see **ANTITHYROID AGENTS**

THYROID-ASSOCIATED OPHTHALMOPATHY see **GRAVES' DISEASE**

THYROID CARTILAGE

SURGERY

Laryngeal framework surgery (thyroplasty) [editorial] Harries ML. **J Laryngol Otol** 1997 Feb;111(2):103–5 (14 ref.)

THYROID CRISIS

THERAPY

Thyroid storm. Dillmann WH. **Curr Ther Endocrinol Metab** 1997;6:81–5 (6 ref.)

THYROID DISEASES

Thyroid disease and pregnancy [published erratum appears in Br J Hosp Med 1997 Feb 19–Mar 4;57(4):172] Girling JC. **Br J Hosp Med** 1996 Oct 2–15;56(7):316–20 (20 ref.)

Postpartum thyroid dysfunction. Browne-Martin K, et al. **Clin Obstet Gynecol** 1997 Mar;40(1):90–101 (51 ref.)

What could mice tell us about goiter or other benign thyroid diseases? Denef JF, et al. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 3:48–51 (35 ref.)

BLOOD

Measurement of serum free thyroid hormone concentrations: an essential tool for the diagnosis of thyroid dysfunction. Bartalena L, et al. **Horm Res** 1996;45(3–5):142–7 (25 ref.)

Effects of thyroid hormone on erythrocyte carbonic anhydrase-I and zinc concentrations in vivo and in vitro: clinical usefulness of carbonic anhydrase-I and zinc concentrations in erythrocytes. Yoshida K. **Tohoku J Exp Med** 1996 Apr;178(4):345–56 (33 ref.)

CHEMICALLY INDUCED

Effects of amiodarone on thyroid function. Harjai KJ, et al. **Ann Intern Med** 1997 Jan 1;126(1):63–73 (109 ref.)

Amiodarone-induced dysthyroidism. Pitfalls and management. Leenhardt L. **J Med Liban** 1995;43(3):148–9 (14 ref.)

Taking a lead from wildlife. Colborn T, et al. **Neurotoxicol Teratol** 1996 May–Jun;18(3):235–7; discussion 271–6 (21 ref.)

COMPLICATIONS

Disturbances of menstruation in thyroid disease. Koutras DA. **Ann N Y Acad Sci** 1997 Jun 17;816:280–4 (35 ref.)

Mediastinal parathyroid cysts. Landau O, et al. **Ann Thorac Surg** 1997 Apr;63(4):951–3 (10 ref.)

Autoimmune thyroid disease in systemic lupus erythematosus and Sjögren's syndrome. Scofield RH. **Clin Exp Rheumatol** 1996 May–Jun;14(3):321–30 (100 ref.)

Thyroid ophthalmopathy: surgical management. Putterman AM. **Curr Ther Endocrinol Metab** 1997;6:85–90 (2 ref.)

Histomorphological aspects of the development of thyroid autoimmune diseases: consequences for our understanding of endocrine ophthalmopathy. Delemarre FG, et al. **Thyroid** 1996 Aug;6(4):369–77 (62 ref.)

DIAGNOSIS

Maternal thyroid function: interpretation of thyroid function tests in pregnancy. Brent GA. **Clin Obstet Gynecol** 1997 Mar;40(1):3–15 (20 ref.)

Fetal thyroid function: diagnosis and management of fetal thyroid disorders. Fisher DA. **Clin Obstet Gynecol** 1997 Mar;40(1):16–31 (48 ref.)

Theoretical basis and application of molecular diagnostics. Finke R. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 4:92–7 (17 ref.)

Measurement of serum free thyroid hormone concentrations: an essential tool for the diagnosis of thyroid dysfunction. Bartalena L, et al. **Horm Res** 1996;45(3–5):142–7 (25 ref.)

Actinomycosis of the thyroid gland masquerading as a neoplasm. Yiotakis J, et al. **J Laryngol Otol** 1997 Feb; 111(2):172–4 (11 ref.)

A rationale for case-finding for thyroid disease in a chiropractic setting with illustrations from the LACC experience. Curl DD, et al. **J Manipulative Physiol Ther** 1996 Jul–Aug;19(6):419–24 (32 ref.)

The clinical approach to thyroid disorders associated with childhood insulin dependent diabetes mellitus. Jefferson IG. **J Pediatr Endocrinol Metab** 1996 Mar;9 Suppl 1:95–100 (32 ref.)

IDDM and autoimmune thyroid disease in the pediatric age group. Lorini R, et al. **J Pediatr Endocrinol Metab** 1996 Mar;9 Suppl 1:89–94 (32 ref.)

Ectopic intrathyroidal thymus diagnosed as a solid thyroid lesion: case report and review of the literature. Gimm O, et al. **J Pediatr Surg** 1997 Aug;32(8):1241–3 (18 ref.)

The thyroid. Fine-needle biopsy and cytological diagnosis of thyroid lesions. Orell SR, et al. **Monogr Clin Cytol** 1997; 14:I–IX, 1–205 (246 ref.)

Problems and pitfalls in thyroid cytology. Goellner JR. **Monogr Pathol** 1997;(39):75–93 (24 ref.)

Diagnosis of thyroid dysfunction: present and future. Bartalena L, et al. **Nucl Med Biol** 1994 Apr;21(3):531–44 (35 ref.)

Laboratory tests for thyroid disorders. LoPresti JS. **Otolaryngol Clin North Am** 1996 Aug;29(4):557–75 (44 ref.)

Fine-needle aspiration cytology of the thyroid. Jeffrey PB, et al. **Pathology (Phila)** 1996;4(2):319–35 (31 ref.)

Imaging of the thyroid gland. Loevner LA. **Semin Ultrasound CT MR** 1996 Dec;17(6):539–62 (80 ref.)

[The diagnosis of different forms of thyroid pathology] Pogorelov AV. **Klin Khir** 1995;(1):36–9 (90 ref.) **(Rus)**

DRUG THERAPY

Fetal thyroid function: diagnosis and management of fetal thyroid disorders. Fisher DA. **Clin Obstet Gynecol** 1997 Mar;40(1):16–31 (48 ref.)

Percutaneous ethanol injection therapy in the treatment of thyroid and parathyroid diseases. Bennedbaek FN, et al. **Eur J Endocrinol** 1997 Mar;136(3):240–50 (71 ref.)

Treatment of thyroid disease in pregnancy. Ecker JL, et al. **Obstet Gynecol Clin North Am** 1997 Sep;24(3):575–89 (40 ref.)

EPIDEMIOLOGY

The epidemiology of thyroid disease and implications for screening. Wang C, et al. **Endocrinol Metab Clin North Am** 1997 Mar;26(1):189–218 (142 ref.)

GENETICS

Theoretical basis and application of molecular diagnostics. Finke R. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 4:92–7 (17 ref.)

Transgenic models for proliferative and hyperfunctional thyroid diseases. Ledent C, et al. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 3:43–6 (20 ref.)

Molecular insights into TSH receptor abnormality and thyroid disease. Russo D, et al. **J Endocrinol Invest** 1997 Jan;20(1):36–47 (74 ref.)

IMMUNOLOGY

The antibody response in human autoimmune thyroid disease [editorial] McIntosh RS, et al. **Clin Sci (Colch)** 1997 Jun; 92(6):529–41 (110 ref.)

Update on the thyroid sodium iodide symporter: a novel thyroid antigen emerging on the horizon. Spitzweg C, et al. **Eur J Endocrinol** 1997 Jul;137(1):22–3 (7 ref.)

Immunopathogenicity of thyrotropin receptor—ability to induce autoimmune thyroid disease in an experimental animal model. Banga JP. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 3:32–4 (21 ref.)

The SCID mouse model: a discussion. Weetman AP. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 3:40–2 (7 ref.)

Bacterial virulence antigens and the pathogenesis of autoimmune thyroid diseases (AITD). Wenzel BE, et al. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 4:75–8 (33 ref.)

[Morphology and clinical features of autoimmune thyroid diseases] Schröder S, et al. **Verh Dtsch Ges Pathol** 1996; 80:80–92 (50 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Reactive intermediates of xenobiotics in thyroid: formation and biological consequences. Andrae U. **Adv Exp Med Biol** 1996;387:213–9 (38 ref.)

MICROBIOLOGY

Bacterial virulence antigens and the pathogenesis of autoimmune thyroid diseases (AITD). Wenzel BE, et al. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 4:75–8 (33 ref.)

PATHOLOGY

Histomorphological aspects of the development of thyroid autoimmune diseases: consequences for our understanding of endocrine ophthalmopathy. Delemarre FG, et al. **Thyroid** 1996 Aug;6(4):369–77 (62 ref.)

[Morphology and clinical features of autoimmune thyroid diseases] Schröder S, et al. **Verh Dtsch Ges Pathol** 1996; 80:80–92 (50 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Depression and endocrine disorders: focus on the thyroid and adrenal system. Musselman DL, et al. **Br J Psychiatry Suppl** 1996 Jun;(30):123–8 (73 ref.)

Coagulation disorders in thyroid diseases. Hofbauer LC, et al. **Eur J Endocrinol** 1997 Jan;136(1):1–7 (71 ref.)

[Thyroid function and dysfunction in the elderly] Schlienger JL, et al. **Rev Med Interne** 1996;17(8):653–60 (41 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Screening for thyroid abnormalities among immigrants to Israel from the former USSR. Slater PE, et al. **Public Health Rev** 1997;25(1):43–7 (19 ref.)

SURGERY

[Role of total thyroidectomy in the treatment of benign thyroid diseases] Peix JL, et al. **Ann Endocrinol (Paris)** 1996;57(6):502–7 (30 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Evaluation and management of common thyroid disorders in women. Mazzaferri EL. **Am J Obstet Gynecol** 1997 Mar; 176(3):507–14 (38 ref.)

Postpartum thyroid disease. Amino N, et al. **Curr Ther Endocrinol Metab** 1997;6:327–30 (2 ref.)

Thyroid disease after the sixth decade. Barzel US. **Curr Ther Endocrinol Metab** 1997;6:134–7 (2 ref.)

Inappropriate secretion of thyroid-stimulating hormone. Kourides IA. **Curr Ther Endocrinol Metab** 1997;6:52–6 (10 ref.)

Management of the patient with thyroid disease. Streff MM, et al. **Nurs Clin North Am** 1996 Dec;31(4):779–96 (20 ref.)

[Current status of the treatment with thyroid hormones] Laudo Pardos C, et al. **An Med Interna** 1996 Nov; 13(11):555–61 (98 ref.) (Eng. Abstr.) **(Spa)**

THYROID FUNCTION TESTS

Maternal thyroid function: interpretation of thyroid function tests in pregnancy. Brent GA. **Clin Obstet Gynecol** 1997 Mar;40(1):3–15 (20 ref.)

METHODS

[TRH loading test] Bando H. **Nippon Rinsho** 1997 Apr;55 Suppl 2:283–7 (11 ref.) **(Jpn)**

[T3 (triiodo-thyronin) suppression test] Bando H. **Nippon Rinsho** 1997 Apr;55 Suppl 2:288–90 (2 ref.) **(Jpn)**

[TRH test] Ochi Y, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:313–6 (9 ref.) **(Jpn)**

TRENDS

Diagnosis of thyroid dysfunction: present and future.

Bartalena L, et al. **Nucl Med Biol** 1994 Apr;21(3):531–44 (35 ref.)

THYROID GLAND

see related
STRUMA OVARII
THYROIDECTOMY

Thyroid gland ectopias. Batsakis JG, et al.
Ann Otol Rhinol Laryngol 1996 Dec;105(12):996–1000 (31 ref.)

Intra-abdominal ectopic thyroid presenting as a pancreatic tumour. Seelig MH, et al. **Eur J Surg** 1997 Jul;163(7):549–51 (18 ref.)

Follicular carcinoma in lingual thyroid presenting as a latero-cervical mass. Case report and review of the literature. Bigotti G, et al. **J Oral Pathol Med** 1997 Mar; 26(3):142–6 (37 ref.)

Imaging of the thyroid gland. Loevner LA.
Semin Ultrasound CT MR 1996 Dec;17(6):539–62 (80 ref.)

ABNORMALITIES

Subisthmic accessory thyroid gland in man: a case report and a review of thyroid anomalies. Bhatnagar KP, et al. **Clin Anat** 1997;10(5):341–4 (13 ref.)

The gene for the thyrotropin receptor (TSHR) as a candidate gene for congenital hypothyroidism with thyroid dysgenesis. Krude H, et al.
Exp Clin Endocrinol Diabetes 1996;104 Suppl 4:117–20 (11 ref.)

ANATOMY & HISTOLOGY

Subisthmic accessory thyroid gland in man: a case report and a review of thyroid anomalies. Bhatnagar KP, et al. **Clin Anat** 1997;10(5):341–4 (13 ref.)

[Variations in the anatomy and physiology of the thyroid gland in old age] Messina G, et al. **Recenti Prog Med** 1997 Jun;88(6):281–6 (32 ref.) (Eng. Abstr.) **(Ita)**

CYTOLOGY

Growth factors in thyroid cells. Gärtner R.
Curr Top Pathol 1997;91:65–81 (158 ref.)

Human thyroid epithelial cells. Williams DW, et al.
Methods Mol Biol 1997;75:163–72 (21 ref.)

Thyroid parafollicular cells. An accessible model for the study of serotonergic neurons. Russo AF, et al.
Mol Neurobiol 1996 Dec;13(3):257–76 (132 ref.)

DRUG EFFECTS

Control of efficiency and results, and adverse effects of excess iodine administration on thyroid function. Koutras DA. **Ann Endocrinol (Paris)** 1996;57(6):463–9 (55 ref.)

Effects of amiodarone on thyroid function. Harjai KJ, et al. **Ann Intern Med** 1997 Jan 1;126(1):63–73 (109 ref.)

Iodine-induced thyroid inhibition and cell necrosis: two consequences of the same free-radical mediated mechanism? Denef JF, et al. **Mol Cell Endocrinol** 1996 Jul 23;121(1):101–3 (22 ref.)

Mechanistic data and risk assessment of selected toxic end points of the thyroid gland. Capen CC. **Toxicol Pathol** 1997 Jan–Feb;25(1):39–48 (35 ref.)

[Amiodarone and thyroid: pharmacologic and toxic effects] Unger J. **Rev Med Brux** 1996 Sep;17(4):203–5 (24 ref.) (Eng. Abstr.) **(Fre)**

[Organic chlorinated pollutants and the thyroid gland] Langer P, et al. **Vnitr Lek** 1996 Sep;42(9):615–9 (53 ref.) (Eng. Abstr.) **(Slo)**

EMBRYOLOGY

Development of the hypothalamic-pituitary-thyroid axis in humans. Fuse Y. **Reprod Fertil Dev** 1996;8(1):1–21 (177 ref.)

GROWTH & DEVELOPMENT

A new understanding of goitrogenesis: role of cytokines in the regulation of normal and aberrant thyroid growth. Dagogo-Jack S. **Afr J Med Med Sci** 1995 Sep;24(3):211–7 (62 ref.)

Autoimmunity and thyroid growth. Where do we stand? [comment] Drexhage HA. **Eur J Endocrinol** 1996 Jul; 135(1):39–45 (79 ref.) Comment on: Eur J Endocrinol 1996 Jul;135(1):60–8. Comment on: Eur J Endocrinol 1996 Jul;135(1):69–76.

IMMUNOLOGY

Cytokines and thyroid function. Ajjan RA, et al.
Adv Neuroimmunol 1996;6(4):359–86 (252 ref.)

Immunomodulation of peripheral lymphocytes by hormones of the hypothalamus-pituitary-thyroid axis. Kruger TE. **Adv Neuroimmunol** 1996;6(4):387–95 (63 ref.)

Dynamic regulation of intestinal immunity by hormones of the hypothalamus-pituitary-thyroid axis. Wang J.
Adv Neuroimmunol 1996;6(4):407–17 (51 ref.)

A new understanding of goitrogenesis: role of cytokines in the regulation of normal and aberrant thyroid growth. Dagogo-Jack S. **Afr J Med Med Sci** 1995 Sep;24(3):211–7 (62 ref.)

Experience with immunoglobulins in thyroid autoimmunity. Lecomte P, et al. **Clin Exp Rheumatol** 1996 May–Jun;14 Suppl 15:S103–7 (5 ref.)

Update on the thyroid sodium iodide symporter: a novel thyroid antigen emerging on the horizon. Spitzweg C, et al. **Eur J Endocrinol** 1997 Jul;137(1):22–3 (7 ref.)

METABOLISM

Reactive intermediates of xenobiotics in thyroid: formation and biological consequences. Andrae U.
Adv Exp Med Biol 1996;387:213–9 (38 ref.)

Maternal thyroid function: interpretation of thyroid function tests in pregnancy. Brent GA. **Clin Obstet Gynecol** 1997 Mar;40(1):3–15 (20 ref.)

Expression of cytokines in the thyroid: thyrocytes as potential cytokine producers. Aust G, et al.
Exp Clin Endocrinol Diabetes 1996;104 Suppl 4:64–7 (28 ref.)

Intracellular protein transport to the thyrocyte plasma membrane: potential implications for thyroid physiology. Arvan P, et al. **Thyroid** 1997 Feb;7(1):89–105 (293 ref.)

PATHOLOGY

Papillary carcinoma associated with black thyroid gland. Onyia JN, et al. **Am J Otolaryngol** 1996 Sep–Oct; 17(5):299–302 (20 ref.)

Clinical consequences of activating germline mutations of TSH receptor, the concept of toxic hyperplasia. Leclère J, et al. **Horm Res** 1997;47(4–6):158–62 (15 ref.)

Transfection and transformation of human thyroid epithelial cells. Lemoine NR, et al. **Methods Mol Biol** 1997;75:441–7 (13 ref.)

The thyroid. Fine-needle biopsy and cytological diagnosis of thyroid lesions. Orell SR, et al. **Monogr Clin Cytol** 1997; 14:I–IX, 1–205 (246 ref.)

Fine-needle aspiration cytology of the thyroid. Jeffrey PB, et al. **Pathology (Phila)** 1996;4(2):319–35 (31 ref.)

Thyroid gland. Ranchod M. **Pathology (Phila)** 1996; 3(2):389–403 (24 ref.)

Acute suppurative thyroiditis and necrosis of the thyroid gland: a rare endocrine manifestation of acquired immunodeficiency syndrome. Golshan MM, et al.
Surgery 1997 May;121(5):593–6 (12 ref.)

PHYSIOLOGY

Cytokines and thyroid function. Ajjan RA, et al.
Adv Neuroimmunol 1996;6(4):359–86 (252 ref.)

Thyroid gland as sentinel: interface between internal and external environment. Schmidt MA, et al.
Altern Ther Health Med 1997 Jan;3(1):78–81 (23 ref.)

Circannual changes in thyroid hormone physiology: the role of cold environmental temperatures. Reed HL.
Arctic Med Res 1995;54 Suppl 2:9–15 (55 ref.)

The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. Glinoer D. **Endocr Rev** 1997 Jun;18(3):404–33 (276 ref.)

Major human cancers are preventable: physiological stimuli induce a dopamine-thyroid-immune efficient mechanism. Gilbert C. **Eur J Cancer Prev** 1997 Jun;6(3):269–76 (60 ref.)

Iodolactones and iodoaldehydes--mediators of iodine in thyroid autoregulation. Dugrillon A.
Exp Clin Endocrinol Diabetes 1996;104 Suppl 4:41–5 (21 ref.)

Stimulation of thyroidal and extrathyroidal thyrotropin receptors. Hoermann R. **Exp Clin Endocrinol Diabetes** 1996; 104 Suppl 4:88–91 (13 ref.)

Clinical review 84: Thyroid autonomy: mechanism and clinical effects. Dremier S, et al.
J Clin Endocrinol Metab 1996 Dec;81(12):4187–93 (74 ref.)

Mutations in the c-erbA beta 1 gene: do they underlie euthyroid fibromyalgia? Lowe JC, et al.
Med Hypotheses 1997 Feb;48(2):125–35 (152 ref.)

Iodine metabolism and thyroid physiology: current concepts. Cavalieri RR. **Thyroid** 1997 Apr;7(2):177–81 (30 ref.)

[Gap junctions in the thyroid gland: distribution, regulation, function] Munari-Silem Y. **Ann Endocrinol (Paris)** 1996; 57(6):484–6 (8 ref.) (Eng. Abstr.) **(Fre)**

[Thyroid function and dysfunction in the elderly] Schlienger JL, et al. **Rev Med Interne** 1996;17(8):653–60 (41 ref.) (Eng. Abstr.) **(Fre)**

[Variations in the anatomy and physiology of the thyroid gland in old age] Messina G, et al. **Recenti Prog Med** 1997 Jun;88(6):281–6 (32 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Human immunodeficiency virus infection and the thyroid gland. Heufelder AE, et al. **Eur J Endocrinol** 1996 Jun; 134(6):669–74 (61 ref.)

The thyroid gland as an intrinsic biologic response-modifier in advanced neoplasia--a novel paradigm. Hercbergs A. **In Vivo** 1996 Mar–Apr;10(2):245–7 (31 ref.)

Thyroid function in children treated for acute lymphoblastic leukemia. Mohn A, et al. **J Endocrinol Invest** 1997 Apr; 20(4):215–9 (25 ref.)

Mutations in the c-erbA beta 1 gene: do they underlie euthyroid fibromyalgia? Lowe JC, et al.
Med Hypotheses 1997 Feb;48(2):125–35 (152 ref.)

Sudden infant death syndrome and placental disorders: the thyroid-selenium link. Reid GM, et al. **Med Hypotheses** 1997 Apr;48(4):317–24 (66 ref.)

The thyroid axis and mood disorders: overview and future prospects. Esposito S, et al. **Psychopharmacol Bull** 1997; 33(2):205–17 (186 ref.)

[Physiopathology of maternal and feto-neonatal thyroid in pregnant women with endemic goiter] Pepe F, et al.
Minerva Ginecol 1997 Apr;49(4):153–60 (15 ref.) (Eng. Abstr.) **(Ita)**

RADIOGRAPHY

CT demonstration of an unusual aspect of the thyroid gland. Sigal R, et al. **J Comput Assist Tomogr** 1997 Jul–Aug; 21(4):594 (5 ref.)

RADIONUCLIDE IMAGING

[In vivo test of thyroid radioactive iodide uptake, pertechnetate 99m uptake and thyroid scintigraphy] Ochi Y, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:317–20 (5 ref.) **(Jpn)**

SURGERY

Thyroid gland. Ranchod M. **Pathology (Phila)** 1996; 3(2):389–403 (24 ref.)

TRANSPLANTATION

Graves' disease: xenotransplantation model (athymic nude mice). Rippegather K, et al.
Exp Clin Endocrinol Diabetes 1996;104 Suppl 3:34–6; discussion 36–7 (15 ref.)

THYROID HORMONE RECEPTORS see **RECEPTORS, THYROID HORMONE**

THYROID HORMONE RESISTANCE SYNDROME

see related
EUTHYROID SICK SYNDROMES

DIAGNOSIS

[Syndromes of thyroid hormone resistance] Wis JM, et al. **Pol Merkuriusz Lek** 1996 Oct;1(4):280–3 (46 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

Effect of thyroid hormone on growth. Lessons from the syndrome of resistance to thyroid hormone. Weiss RE, et al. **Endocrinol Metab Clin North Am** 1996 Sep;25(3):719–30 (44 ref.)

THERAPY

Resistance to thyroid hormone. Refetoff S.
Curr Ther Endocrinol Metab 1997;6:132–4 (8 ref.)

THYROID HORMONES

see related
HYPERTHYROIDISM
HYPOTHYROIDISM
RECEPTORS, THYROID HORMONE
THYROGLOBULIN

ADVERSE EFFECTS

Adverse effects of thyroid hormone preparations and antithyroid drugs. Bartalena L, et al. **Drug Saf** 1996 Jul; 15(1):53–63 (98 ref.)

Impact on bone of thyroid hormone therapy. Lauwers A, et al. **Rev Rhum Engl Ed** 1997 Feb;64(2):112–9 (38 ref.)

ANALYSIS

[Changes in thyroid tests in non-thyroid diseases] Ghayad E, et al. **J Med Liban** 1996;44(1):31–5 (30 ref.) **(Fre)**

BLOOD

Measurement of serum free thyroid hormone concentrations: an essential tool for the diagnosis of thyroid dysfunction. Bartalena L, et al. **Horm Res** 1996;45(3–5):142–7 (25 ref.)

Familial dysalbuminemic hyperthyroxinemia and thyroid hormone autoantibodies: interference in current free thyroid hormone assays. Sapin R, et al. **Horm Res** 1996; 45(3–5):139–41 (8 ref.)

IMMUNOLOGY

Immunomodulation of peripheral lymphocytes by hormones of the hypothalamus-pituitary-thyroid axis. Kruger TE. **Adv Neuroimmunol** 1996;6(4):387–95 (63 ref.)

Dynamic regulation of intestinal immunity by hormones of the hypothalamus-pituitary-thyroid axis. Wang J.
Adv Neuroimmunol 1996;6(4):407–17 (51 ref.)

Familial dysalbuminemic hyperthyroxinemia and thyroid hormone autoantibodies: interference in current free thyroid hormone assays. Sapin R, et al. **Horm Res** 1996; 45(3–5):139–41 (8 ref.)

METABOLISM

Regulation of selenoprotein gene expression and thyroid hormone metabolism. Arthur JR, et al.
Biochem Soc Trans 1996 May;24(2):384–8 (50 ref.)

Update on the human iodothyronine selenodeiodinases, the enzymes regulating the activation and inactivation of

thyroid hormone. Larsen PR. **Biochem Soc Trans** 1997 May;25(2):588–92 (35 ref.)

Thyroid carcinoma: interrelationships between local thyroid hormone metabolism by the type I 5'-deiodinase and the expression of thyroid hormone receptors and other thyroid-specific (de-)differentiation markers. Köhrle J. **Curr Top Pathol** 1997;91:83–116 (230 ref.)

Different regulation of thyroid hormone transport in liver and pituitary: its possible role in the maintenance of low T3 production during nonthyroidal illness and fasting in man. Everts ME, et al. **Thyroid** 1996 Aug;6(4):359–68 (79 ref.)

Thyroid hormone abnormalities in heart failure: possibilities for therapy. Hamilton MA, et al. **Thyroid** 1996 Oct; 6(5):527–9 (22 ref.)

PHARMACOLOGY

Effect of thyroid hormone on growth. Lessons from the syndrome of resistance to thyroid hormone. Weiss RE, et al. **Endocrinol Metab Clin North Am** 1996 Sep;25(3):719–30 (44 ref.)

Hormonal interventions with psychopharmacological potential: an overview. Halbreich U. **Psychopharmacol Bull** 1997;33(2):281–6 (69 ref.)

Nongenomic actions of thyroid hormone. Davis PJ, et al. **Thyroid** 1996 Oct;6(5):497–504 (69 ref.)

Effects of thyroid hormone on erythrocyte carbonic anhydrase-I and zinc concentrations in vivo and in vitro: clinical usefulness of carbonic anhydrase-I and zinc concentrations in erythrocytes. Yoshida K. **Tohoku J Exp Med** 1996 Apr;178(4):345–56 (33 ref.)

PHYSIOLOGY

Transforming growth factor-beta system and its regulation by members of the steroid-thyroid hormone superfamily. Koli K, et al. **Adv Cancer Res** 1996;70:63–94 (133 ref.)

Dynamic regulation of intestinal immunity by hormones of the hypothalamus-pituitary-thyroid axis. Wang J. **Adv Neuroimmunol** 1996;6(4):407–17 (51 ref.)

Effect of chronic and acute thyroid hormone reduction on perioperative outcome. Bennett-Guerrero E, et al. **Anesth Analg** 1997 Jul;85(1):30–6 (68 ref.)

Maternal thyroid function: interpretation of thyroid function tests in pregnancy. Brent GA. **Clin Obstet Gynecol** 1997 Mar;40(1):3–15 (20 ref.)

Regulation of in vivo ketogenesis: role of free fatty acids and control by epinephrine, thyroid hormones, insulin and glucagon. Beylot M. **Diabetes Metab** 1996 Oct; 22(5):299–304 (44 ref.)

Molecular basis of thyroid hormone-dependent brain development. Oppenheimer JH, et al. **Endocr Rev** 1997 Aug;18(4):462–75 (158 ref.)

Thyroid hormone and gene expression in the regulation of mitochondrial respiratory function. Pillar TM, et al. **Eur J Endocrinol** 1997 Mar;136(3):231–9 (75 ref.)

Mutations in the c-erbA beta 1 gene: do they underlie euthyroid fibromyalgia? Lowe JC, et al. **Med Hypotheses** 1997 Feb;48(2):125–35 (152 ref.)

Influence of thyroid hormones and temperature on adipose tissue development and lung maturation. Symonds ME, et al. **Proc Nutr Soc** 1996 Mar;55(1B):561–9 (58 ref.)

Iodine metabolism and thyroid-related functions in organisms lacking thyroid follicles: are thyroid hormones also vitamins? Eales JG. **Proc Soc Exp Biol Med** 1997 Apr; 214(4):302–17 (195 ref.)

Thyroid hormones as neurotransmitters. Dratman MB, et al. **Thyroid** 1996 Dec;6(6):639–47 (35 ref.)

Thyroid hormone-regulated actin polymerization in brain. Leonard JL, et al. **Thyroid** 1997 Feb;7(1):147–51 (31 ref.)

[Cardiovascular effects of thyroid hormones] Mohr-Kahaly S, et al. **Z Kardiol** 1996;85 Suppl 6:219–31 (126 ref.) (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Primary hypothyroidism. Gaitan E, et al. **Curr Ther Endocrinol Metab** 1997;6:94–8 (6 ref.)

Endemic goiter. Trimarchi F, et al. **Curr Ther Endocrinol Metab** 1997;6:101–7 (9 ref.)

Thyroid hormone therapy in patients infected with human immunodeficiency virus: a clinical approach to treatment. Derry DM. **Med Hypotheses** 1996 Sep;47(3):227–33 (59 ref.)

Thyroid hormones and the treatment of depression: an examination of basic hormonal actions in the mature mammalian brain. Henley WN, et al. **Synapse** 1997 Sep; 27(1):36–44 (111 ref.)

Novel uses of thyroid hormones in patients with affective disorders. Prange AJ Jr. **Thyroid** 1996 Oct;6(5):537–43 (56 ref.)

[Principles and modalities of hormonal treatment in therapeutic management of differentiated thyroid cancers] Wemeau JL. **Ann Endocrinol (Paris)** 1997;58(3):204–10 (90 ref.) (Eng. Abstr.) **(Fre)**

THYROID NEOPLASMS

Advances and controversies in the diagnosis and management of medullary thyroid carcinoma. Heshmati HM, et al. **Am J Med** 1997 Jul;103(1):60–9 (75 ref.)

Papillary microcarcinoma of the thyroid gland. Bramley MD, et al. **Br J Surg** 1996 Dec;83(12):1674–83 (93 ref.)

Well differentiated thyroid carcinoma. LiVolsi VA. **Clin Oncol (R Coll Radiol)** 1996;8(5):281–8 (103 ref.)

Thyroid neoplasia in children [see comments] Zimmerman D. **Curr Opin Pediatr** 1997 Aug;9(4):413–8 (68 ref.) Comment in: Curr Opin Pediatr 1997 Aug;9(4):407–12.

Xenotransplantation of human thyroid carcinomas in athymic nude mice. Wenisch HJ. **Exp Clin Endocrinol Diabetes** 1996; 104 Suppl 3:61–3 (23 ref.)

[Hürthle cell thyroid carcinoma] Bourcigaux N, et al. **Ann Endocrinol (Paris)** 1997;58(3):257–62 (37 ref.) **(Fre)**

[Oncocytic tumors of the thyroid. Diagnostic and therapeutic problems. Report of 17 cases and review of the literature] Gaschignard N, et al. **J Chir (Paris)** 1996 Jul;133(5):201–7 (51 ref.) (Eng. Abstr.) **(Fre)**

BLOOD

Heterogeneity of circulating calcitonin levels: relations with calcitonin biosynthesis in medullary thyroid carcinomas. Guliana JM, et al. **Nucl Med Biol** 1994 Apr;21(3):359–68 (40 ref.)

CHEMISTRY

A case report and review: the gross, histological and immunohistochemical characteristics of a carcinoma of ectopic thyroid in a dog. Constantino-Casas P, et al. **Br Vet J** 1996 Nov;152(6):669–72 (10 ref.)

Advances in immunocytochemistry of thyroid tumours 1987–1994. Jasani B. **Curr Top Pathol** 1997;91:21–36 (55 ref.)

CLASSIFICATION

[Prognostic factors in differentiated thyroid cancers (medullary excluded)] Leclère J, et al. **Ann Endocrinol (Paris)** 1997;58(3):183–7 (17 ref.) **(Fre)**

COMPLICATIONS

Squamous cell carcinoma in a thyroglossal duct cyst (TGDC): clinical presentation, diagnosis, and management. Hanna E. **Am J Otolaryngol** 1996 Sep-Oct;17(5):353–7 (9 ref.)

Association of primary hyperparathyroidism and non-medullary thyroid cancer. Krause UC, et al. **Eur J Surg** 1996 Sep;162(9):685–9 (29 ref.)

[Thyroid nodule and cancer in pregnant women] Glinoer D. **Ann Endocrinol (Paris)** 1997;58(3):263–7 (11 ref.) (Eng. Abstr.) **(Fre)**

[Differentiated thyroid cancer revealed by cervical adenopathy] Rodier JF, et al. **Ann Endocrinol (Paris)** 1997; 58(3):268–71 (28 ref.) **(Fre)**

[Thyroid cancer and Hashimoto's thyroiditis] Reda G, et al. **Minerva Chir** 1997 Jan-Feb;52(1-2):139–41 (12 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Advances in the diagnosis and management of well-differentiated thyroid cancers [see comments] Weigel RJ. **Curr Opin Oncol** 1996 Jan;8(1):37–43 (35 ref.) Comment in: Curr Opin Oncol 1996 Jan;8(1):29.

Unusual types of thyroid neoplasms. Burman KD, et al. **Endocrinol Metab Clin North Am** 1996 Mar;25(1):49–68 (43 ref.)

Imaging in thyroid cancer. Galloway RJ, et al. **Endocrinol Metab Clin North Am** 1996 Mar;25(1):93–113 (69 ref.)

Thyroid cancer in children, pregnant women, and patients with Graves' disease. McClellan DR, et al. **Endocrinol Metab Clin North Am** 1996 Mar;25(1):27–48 (111 ref.)

Fine-needle aspiration and the diagnosis of thyroid cancer. Oertel YC. **Endocrinol Metab Clin North Am** 1996 Mar; 25(1):69–91 (19 ref.)

Ectopic intrathyroidal thymus diagnosed as a solid thyroid lesion: case report and review of the literature. Gimm O, et al. **J Pediatr Surg** 1997 Aug;32(8):1241–3 (18 ref.)

Thyroid carcinoma as first manifestation of familial adenomatous polyposis. Stigt JA, et al. **Neth J Med** 1996 Sep;49(3):116–8 (17 ref.)

Thyroid cancers. II. Medullary, anaplastic, lymphoma, sarcoma, squamous cell. Austin JR, et al. **Otolaryngol Clin North Am** 1996 Aug;29(4):611–27 (86 ref.)

Thyroid cancers. I. Papillary, follicular, and Hürthle cell. Goldman ND, et al. **Otolaryngol Clin North Am** 1996 Aug; 29(4):593–609 (41 ref.)

[The role of imaging diagnosis in the study of thyroid neoplasms] Giammanco M, et al. **Minerva Chir** 1997 Apr; 52(4):427–32 (27 ref.) (Eng. Abstr.) **(Ita)**

[Medullary carcinoma of the thyroid. A report of 4 clinical cases and a review of the literature] Russo F, et al. **Minerva Chir** 1997 Apr;52(4):475–84 (40 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

[Principles and modalities of hormonal treatment in therapeutic management of differentiated thyroid cancers] Wemeau JL. **Ann Endocrinol (Paris)** 1997;58(3):204–10 (90 ref.) (Eng. Abstr.) **(Fre)**

[Modulation of cisplatin cytotoxicity by amphotericin B in six human cell lines of medullary thyroid cancer] Massart C, et al. **Bull Cancer** 1996 Aug;83(8):619–25 (50 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Follicular cell-derived thyroid carcinomas. Grebe SK, et al. **Cancer Treat Res** 1997;89:91–140 (264 ref.)

Childhood cancer 10 years after the Chernobyl accident. Schwenn MR, et al. **Curr Opin Pediatr** 1997 Feb;9(1):51–4 (26 ref.)

Head and neck radiation carcinogenesis: epidemiologic evidence. Ron E, et al. **Otolaryngol Head Neck Surg** 1996 Nov;115(5):403–8 (38 ref.)

ETIOLOGY

Childhood thyroid cancer following the Chernobyl accident: a status report [published erratum appears in Endocrinol Metab Clin North Am 1996 Jun;25(2):xi] Becker DV, et al. **Endocrinol Metab Clin North Am** 1996 Mar; 25(1):197–211 (55 ref.)

External radiation and thyroid neoplasia. Sarne D, et al. **Endocrinol Metab Clin North Am** 1996 Mar;25(1):181–95 (48 ref.)

Head and neck radiation carcinogenesis: epidemiologic evidence. Ron E, et al. **Otolaryngol Head Neck Surg** 1996 Nov;115(5):403–8 (38 ref.)

Potassium iodide for thyroid blockade in a reactor accident: administrative policies that govern its use. Becker DV, et al. **Thyroid** 1997 Apr;7(2):193–7 (15 ref.)

[131 iodine: medical use. Carcinogenic and genetic effects] Schlumberger M, et al. **Ann Endocrinol (Paris)** 1996; 57(3):166–76 (48 ref.) (Eng. Abstr.) **(Fre)**

[Familial adenomatous polyposis and thyroid cancer] Paraf F, et al. **Gastroenterol Clin Biol** 1997;21(1):74–7 (20 ref.) (Eng. Abstr.) **(Fre)**

[Risk factors and prevention of thyroid carcinoma] Lupoli G, et al. **Minerva Endocrinol** 1996 Sep;21(3):93–100 (68 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

The MEN II syndromes and the role of the ret proto-oncogene. Ponder BA, et al. **Adv Cancer Res** 1996; 70:179–222 (194 ref.)

Genetic testing and early thyroidectomy for inherited medullary thyroid carcinoma. Lairmore TC, et al. **Ann Med** 1996 Oct;28(5):401–6 (39 ref.)

Multiple endocrine neoplasia type II and familial medullary thyroid carcinoma. Impact of genetic screening on management. Gagel RF. **Cancer Treat Res** 1997;89:421–41 (74 ref.)

Endocrine and metabolism [editorial; comment] Root AW. **Curr Opin Pediatr** 1997 Aug;9(4):407–12 (19 ref.) Comment on: Curr Opin Pediatr 1997 Aug;9(4):413–80. Comment on: Curr Opin Pediatr 1997 Aug;9(4):419–23. Comment on: Curr Opin Pediatr 1997 Aug;9(4):424–30.

Application of genetic screening information to the management of medullary thyroid carcinoma and multiple endocrine neoplasia type 2. Wohllk N, et al. **Endocrinol Metab Clin North Am** 1996 Mar;25(1):1–25 (101 ref.)

Molecular aspects of the pathogenesis of nodular goiters, thyroid nodules and adenomas. Derwahl M. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 4:32–5 (15 ref.)

Molecular pathogenesis of thyroid cancer: the significance of oncogenes, tumor suppressor genes, and genomic instability. Farid NR. **Exp Clin Endocrinol Diabetes** 1996; 104 Suppl 4:1–12 (111 ref.)

Constitutively activating TSH receptor mutations as the cause of toxic thyroid adenoma, multinodular toxic goiter and autosomal dominant non autoimmune hyperthyroidism. Paschke R. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 4:129–32 (18 ref.)

Cytogenetics and molecular genetics of carcinomas arising from thyroid epithelial follicular cells. Pierotti MA, et al. **Genes Chromosomes Cancer** 1996 May;16(1):1–14 (106 ref.)

Targeted oncogenesis in the thyroid of transgenic mice. Feunteun J, et al. **Horm Res** 1997;47(4–6):137–9 (30 ref.)

RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. Marsh DJ, et al. **Horm Res** 1997;47(4–6):168–78 (105 ref.)

Origin and progression of thyroid epithelial tumours: cellular and molecular mechanisms. Wynford-Thomas D. **Horm Res** 1997;47(4–6):145–57 (73 ref.)

TSH receptor and Gs-alpha gene mutations in the pathogenesis of toxic thyroid adenomas--a note of caution [editorial] Derwahl M. **J Clin Endocrinol Metab** 1996 Aug; 81(8):2783–5 (27 ref.)

Familial nonmedullary thyroid carcinoma--the case for genetic susceptibility [editorial] Fagin JA. **J Clin Endocrinol Metab** 1997 Feb;82(2):342–4 (35 ref.)

Medullary carcinoma of the thyroid gland and the MEN 2 syndromes. Skinner MA, et al. **Semin Pediatr Surg** 1997 Aug;6(3):134–40 (35 ref.)

The RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications. Komminoth P. **Virchows Arch** 1997 Jul;431(1):1–9 (109 ref.)

[Cellular oncogenes and antioncogenes in thyroid tumors] Abrosimov AIu. **Arkh Patol** 1997 Jan-Feb;59(1):64–9 (41 ref.) (Eng. Abstr.) **(Rus)**

THYROID NEOPLASMS

IMMUNOLOGY

A new understanding of goitrogenesis: role of cytokines in the regulation of normal and aberrant thyroid growth. Dagogo-Jack S. **Afr J Med Med Sci** 1995 Sep;24(3):211–7 (62 ref.)

The immunology of thyroid cancer. Boyd CM, et al. **Endocrinol Metab Clin North Am** 1996 Mar;25(1):159–79 (100 ref.)

METABOLISM

Thyroid carcinoma: interrelationships between local thyroid hormone metabolism by the type I 5'-deiodinase and the expression of thyroid hormone receptors and other thyroid-specific (de-)differentiation markers. Köhrle J. **Curr Top Pathol** 1997;91:83–116 (230 ref.)

Expression of the calcitonin gene family in medullary thyroid carcinoma. Schifter S. **Peptides** 1997;18(2):307–17 (151 ref.)

NURSING

Medullary thyroid carcinoma: one component of the inherited disorder multiple endocrine neoplasia type 2A. Giarelli E. **Oncol Nurs Forum** 1997 Jul;24(6):1007–20; quiz 1021–2 (48 ref.)

PATHOLOGY

Squamous cell carcinoma in a thyroglossal duct cyst (TGDC): clinical presentation, diagnosis, and management. Hanna E. **Am J Otolaryngol** 1996 Sep–Oct;17(5):353–7 (9 ref.)

Papillary carcinoma associated with black thyroid gland. Onyia JN, et al. **Am J Otolaryngol** 1996 Sep–Oct; 17(5):299–302 (20 ref.)

Thyroid paraganglioma: a clinicopathologic and immunohistochemical study of three cases. LaGuette J, et al. **Am J Surg Pathol** 1997 Jul;21(7):748–53 (36 ref.)

Anaplastic carcinoma of the thyroid. Sweeney PJ, et al. **Ann Oncol** 1996 Sep;7(7):739–44 (37 ref.)

Decision-making in surgery: the management of thyroid malignancies. Huang J, et al. **Br J Hosp Med** 1996 Nov 20–Dec 10;56(10):510–2 (7 ref.)

A case report and review: the gross, histological and immunohistochemical characteristics of a carcinoma of ectopic thyroid in a dog. Constantino-Casas P, et al. **Br Vet J** 1996 Nov;152(6):669–72 (10 ref.)

A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example. Brierley JD, et al. **Cancer** 1997 Jun 15;79(12):2414–23 (30 ref.)

Primary smooth muscle tumors of the thyroid gland. Thompson LD, et al. **Cancer** 1997 Feb 1;79(3):579–87 (60 ref.)

Thyroid cancer: differentiated carcinoma. Harmer CL, et al. **Cancer Treat Rev** 1996 May;22(3):161–77 (42 ref.)

Surgical management of thyroid cancer invading the trachea. Zannini P, et al. **Chest Surg Clin N Am** 1996 Nov; 6(4):777–90 (24 ref.)

Histogenesis of thyroid C-cell carcinoma. Harach HR. **Curr Top Pathol** 1997;91:15–20 (61 ref.)

Lymphoma of the thyroid gland. Isaacson PG. **Curr Top Pathol** 1997;91:1–14 (15 ref.)

Poorly differentiated carcinoma of the thyroid: an aggressive type of tumour arising from thyroid follicular epithelium. Sakamoto A. **Curr Top Pathol** 1997;91:45–50 (22 ref.)

Cytologic Diagnosis of "CASTLE" of thyroid gland: report of a case with histologic correlation. Ng WK, et al. **Diagn Cytopathol** 1996 Sep;15(3):224–7 (20 ref.)

Papillary carcinoma of the thyroid metastatic to the parapharyngeal space. Sirotnak JJ, et al. **Ear Nose Throat J** 1997 May;76(5):342–4 (9 ref.)

Enhanced bilateral somatostatin receptor expression in mediastinal lymph nodes ("chimney sign") in occult metastatic medullary thyroid cancer: a typical site of tumour manifestation? Behr TM, et al. **Eur J Nucl Med** 1997 Feb;24(2):184–91 (20 ref.)

The regulation of proliferation and invasion in differentiated thyroid cancer by growth factors. Hoelting T, et al. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 4:29–31 (9 ref.)

Malignant struma ovarii. A case report and review of the literature. Berghella V, et al. **Gynecol Obstet Invest** 1997; 43(1):68–72 (20 ref.)

Characterisation of thyroid medullary carcinoma TT cell line. Zabel M, et al. **Histol Histopathol** 1997 Jan;12(1):283–9 (63 ref.)

Columnar cell carcinoma of the thyroid: report of three additional cases. Ferreiro JA, et al. **Hum Pathol** 1996 Nov; 27(11):1156–60 (18 ref.)

Sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid: report of two patients, one with distant metastasis, and review of the literature. Sim SJ, et al. **Hum Pathol** 1997 Sep;28(9):1091–6 (15 ref.)

Thyroid carcinoma metastatic to the skin: a cutaneous manifestation of a widely disseminated malignancy. Dahl PR, et al. **J Am Acad Dermatol** 1997 Apr;36(4):531–7 (40 ref.)

Metastatic follicular thyroid carcinoma to the paranasal sinuses: a case report and review. Altman KW, et al. **J Laryngol Otol** 1997 Jul;111(7):647–51 (22 ref.)

Multiple endocrine neoplasia type 2B (mucosal neuroma syndrome, Wagenmann-Froboese syndrome). Morrison PJ, et al. **J Med Genet** 1996 Sep;33(9):779–82 (31 ref.)

Langerhans' cell histiocytosis with thyroid involvement masquerading as thyroid carcinoma. Wang WS, et al. **Jpn J Clin Oncol** 1997 Jun;27(3):180–4 (17 ref.)

Mixed medullary-follicular carcinoma of the thyroid gland: a clinicopathologic variant of medullary thyroid carcinoma. Mizukami Y, et al. **Mod Pathol** 1996 Jun;9(6):631–5 (28 ref.)

Thyroid nodules and the detection of thyroid cancer. Haber RS. **Mt Sinai J Med** 1996 Jan;63(1):10–5 (13 ref.)

Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Grebe SK, et al. **Surg Oncol Clin N Am** 1996 Jan;5(1):43–63 (114 ref.)

Prognostic factors in thyroid carcinoma. Treseler PA, et al. **Surg Oncol Clin N Am** 1997 Jul;6(3):555–98 (223 ref.)

Predictors of thyroid tumor aggressiveness [see comments] Clark OH. **West J Med** 1996 Sep;165(3):131–8 (77 ref.) Comment in: West J Med 1996 Sep;165(3):156–7.

[Role of nuclear medicine in the diagnosis and treatment of macroscopic metastases] Chatal LF. **Ann Endocrinol (Paris)** 1997;58(3):248–50 (6 ref.) (Eng. Abstr.) **(Fre)**

[Anatomo-pathology and histological prognosis of follicular thyroid carcinoma] de Micco C. **Ann Endocrinol (Paris)** 1997;58(3):172–82 (96 ref.) (Eng. Abstr.) **(Fre)**

[Papillary microcarcinoma] Latapie JL, et al. **Ann Endocrinol (Paris)** 1997;58(3):251–3 (39 ref.) (Eng. Abstr.) **(Fre)**

[Extemporaneous anatomo-pathological test in surgery of thyroid cancers. Values and limitations] Godey B, et al. **Ann Otolaryngol Chir Cervicofac** 1996;113(4):219–24 (13 ref.) (Eng. Abstr.) **(Fre)**

[Value of fine-needle aspiration and extemporaneous examination in thyroid surgery. A prospective study of 1235 fine-needle aspirations and extemporaneous examinations in 846 patients] Becouarn G, et al. **J Chir (Paris)** 1996 Jul;133(5):214–21 (53 ref.) (Eng. Abstr.) **(Fre)**

[Autonomy and malignancy of thyroid glad tumors. A critical analysis of the literature on the existence of hyperfunctioning follicular and papillary thyroid gland carcinomas] Schröder S, et al. **Pathologe** 1996 Sep; 17(5):349–57 (74 ref.) (Eng. Abstr.) **(Ger)**

[Study of silver binding nucleolar organizer regions (AgNORs) in proliferative lesions of bronchi, colon and thyroid--semiautomatic computer image analysis] Zaczek M. **Folia Med Cracov** 1996;37(1–2):67–88 (82 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

Enhanced functional activity in thyroid adenomas in vitro. Poertl S, et al. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 4:39–40 (9 ref.)

Unraveling the pathogenesis of thyroid tumors using transgenic mice [editorial; comment] Tallini G, et al. **Lab Invest** 1997 Mar;76(3):301–5 (34 ref.) Comment on: Lab Invest 1997 Mar;76(3):307–18.

PREVENTION & CONTROL

Potassium iodide for thyroid blockade in a reactor accident: administrative policies that govern its use. Becker DV, et al. **Thyroid** 1997 Apr;7(2):193–7 (15 ref.)

[Protection of the thyroid in children and fetuses in case of nuclear accident] Vernis M, et al. **Arch Pediatr** 1997 May; 4(5):473–9 (29 ref.) (Eng. Abstr.) **(Fre)**

[Risk factors and prevention of thyroid carcinoma] Lupoli G, et al. **Minerva Endocrinol** 1996 Sep;21(3):93–100 (68 ref.) (Eng. Abstr.) **(Ita)**

RADIONUCLIDE IMAGING

Nuclear imaging in the management of thyroid carcinoma. Cavalieri RR. **Thyroid** 1996 Oct;6(5):485–92 (55 ref.)

Percent 131I uptake and post-therapy 131I scans: their role in the management of thyroid cancer. Reynolds JC. **Thyroid** 1997 Apr;7(2):281–4 (13 ref.)

Selection of the optimal scanning agent for thyroid cancer. Sisson JC. **Thyroid** 1997 Apr;7(2):295–302 (74 ref.)

[131 iodine and differentiated thyroid cancers] Delisle MJ, et al. **Ann Endocrinol (Paris)** 1996;57(3):186–93 (30 ref.) (Eng. Abstr.) **(Fre)**

RADIOTHERAPY

Squamous cell carcinoma in a thyroglossal duct cyst (TGDC): clinical presentation, diagnosis, and management. Hanna E. **Am J Otolaryngol** 1996 Sep–Oct;17(5):353–7 (9 ref.)

Radiotherapy in the management of thyroid cancer. Harmer CL. **Ann Acad Med Singapore** 1996 May;25(3):413–9 (28 ref.)

External radiation therapy in the treatment of thyroid malignancy. Brierley JD, et al. **Endocrinol Metab Clin North Am** 1996 Mar;25(1):141–57 (48 ref.)

The changing role of radioiodine in the management of differentiated thyroid cancer. Reynolds JC, et al. **Semin Nucl Med** 1997 Apr;27(2):152–64 (67 ref.)

131I therapy for pediatric thyroid cancer. Yeh SD, et al. **Semin Pediatr Surg** 1997 Aug;6(3):128–33 (49 ref.)

Nuclear imaging in the management of thyroid carcinoma. Cavalieri RR. **Thyroid** 1996 Oct;6(5):485–92 (55 ref.)

Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Maxon HR, et al. **Thyroid** 1997 Apr; 7(2):183–7 (26 ref.)

Structure and function of the TSH receptor: its suitability as a target for radiotherapy. Morris JC. **Thyroid** 1997 Apr; 7(2):253–8 (50 ref.)

Percent 131I uptake and post-therapy 131I scans: their role in the management of thyroid cancer. Reynolds JC. **Thyroid** 1997 Apr;7(2):281–4 (13 ref.)

[131 iodine for the initial treatment of thyroid cancer] Delisle MJ, et al. **Ann Endocrinol (Paris)** 1997;58(3):197–203 (43 ref.) (Eng. Abstr.) **(Fre)**

[131 iodine and differentiated thyroid cancers] Delisle MJ, et al. **Ann Endocrinol (Paris)** 1996;57(3):186–93 (30 ref.) (Eng. Abstr.) **(Fre)**

[Radioiodine therapy and radioiodine after-care in differentiated thyroid gland carcinomas] Börner AR, et al. **Zentralbl Chir** 1997;122(4):274–85 (80 ref.) (Eng. Abstr.) **(Ger)**

[Radioiodine therapy in differentiated thyroid gland carcinoma] Schicha H, et al. **Zentralbl Chir** 1997; 122(4):266–73 (44 ref.) (Eng. Abstr.) **(Ger)**

[Is radioiodine ablation of residual thyroid tissue indicated after an operation for differentiated thyroid cancer?] Chebotareva ED, et al. **Lik Sprava** 1997 Jan–Feb;(1):118–22 (18 ref.) **(Rus)**

SECONDARY

Spontaneous metastasizing squamous cell carcinoma of the oesophagus in a Sprague Dawley rat. Deschl U, et al. **Exp Toxicol Pathol** 1997 Feb;49(1–2):123–7 (10 ref.)

[Primary cerebral T-cell lymphoma] Vajtai I, et al. **Orv Hetil** 1996 Mar 24;137(12):637–41 (32 ref.) (Eng. Abstr.) **(Hun)**

SURGERY

Decision-making in surgery: the management of thyroid malignancies. Huang J, et al. **Br J Hosp Med** 1996 Nov 20–Dec 10;56(10):510–2 (7 ref.)

Surgical considerations and approach to thyroid cancer. Soh EY, et al. **Endocrinol Metab Clin North Am** 1996 Mar; 25(1):115–39 (127 ref.)

Controversies in the surgical management of differentiated thyroid carcinoma. Noguchi M, et al. **Int Surg** 1996 Apr-Jun;81(2):163–7 (91 ref.)

The role of surgery in the management of differentiated thyroid cancer. Grebe SK, et al. **J Endocrinol Invest** 1997 Jan;20(1):32–5 (15 ref.)

Thyroid tumors in children. Geiger JD, et al. **Otolaryngol Clin North Am** 1996 Aug;29(4):711–9 (38 ref.)

Postsurgical management of differentiated thyroid carcinoma. Mazzaferri EL, et al. **Otolaryngol Clin North Am** 1996 Aug;29(4):637–62 (115 ref.)

Surgery for thyroid cancer. Lennard TW. **Surg Oncol** 1996 Jun;5(3):103–5 (24 ref.)

Primary leiomyosarcoma of the thyroid gland. Ozaki O, et al. **Surg Today** 1997;27(2):177–80 (13 ref.)

Management of thyroid carcinosarcoma. al-Sobhi SS, et al. **Surgery** 1997 Sep;122(3):548–52 (22 ref.)

[First-line surgical treatment of differentiated thyroid cancers] Peix IL. **Ann Endocrinol (Paris)** 1997;58(3):188–96 (47 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of differentiated thyroid cancer. Management of invasive cancer] Squifflet JP. **Ann Endocrinol (Paris)** 1997; 58(3):225–8 (12 ref.) **(Fre)**

[Management of differentiated thyroid cancer of nodular type] Visset J, et al. **Ann Endocrinol (Paris)** 1997; 58(3):216–24 (56 ref.) (Eng. Abstr.) **(Fre)**

[Value of fine-needle aspiration and extemporaneous examination in thyroid surgery. A prospective study of 1235 fine-needle aspirations and extemporaneous examinations in 846 patients] Becouarn G, et al. **J Chir (Paris)** 1996 Jul;133(5):214–21 (53 ref.) (Eng. Abstr.) **(Fre)**

[Lymph node excision in thyroid carcinoma] Dralle H, et al. **Chirurg** 1996 Aug;67(8):788–806 (108 ref.) (Eng. Abstr.) **(Ger)**

[Surgical therapy of differentiated thyroid gland carcinoma] Walgenbach S, et al. **Zentralbl Chir** 1997;122(4):252–8 (43 ref.) (Eng. Abstr.) **(Ger)**

[Thyroid microcarcinoma] Sugino K, et al. **Nippon Rinsho** 1996 May;54(5):1354–8 (15 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Anaplastic carcinoma of the thyroid. Sweeney PJ, et al. **Ann Oncol** 1996 Sep;7(7):739–44 (37 ref.)

Advances in the diagnosis and management of well-differentiated thyroid cancers [see comments] Weigel RJ. **Curr Opin Oncol** 1996 Jan;8(1):37–43 (35 ref.) Comment in: Curr Opin Oncol 1996 Jan;8(1):29.

Medullary thyroid carcinoma. Evans DB, et al. **Curr Ther Endocrinol Metab** 1997;6:127–32 (12 ref.)

Differentiated thyroid carcinoma. Hershman JM, et al. **Curr Ther Endocrinol Metab** 1997;6:122–6 (14 ref.)

[Invasive differentiated thyroid cancers: discussion of therapeutics, multidisciplinary approach] Andry G. **Ann Endocrinol (Paris)** 1997;58(3):229–32 (19 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of differentiated thyroid cancers of nodular type] Tourniaire J, et al. **Ann Endocrinol (Paris)** 1997;58(3):211–5 (40 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

[Echotomography and color–Doppler in the diagnosis of thyroid carcinoma] Messina G, et al. **Ann Ital Med Int** 1996 Oct–Dec;11(4):263–7 (38 ref.) (Eng. Abstr.) **(Ita)**

ULTRASTRUCTURE

Cell adhesion receptors and gap junctions in normal and neoplastic transformed thyrocytes. Pötter E, et al. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 4:24–8 (34 ref.)

VETERINARY

Tumours of the endocrine glands. Schmidt RE, et al. **IARC Sci Publ** 1996;(126):307–20 (50 ref.)

THYROID NODULE

see related
GOITER, NODULAR

Thyroid nodular disease in pregnancy: current diagnosis and management. Rosen IB, et al. **Clin Obstet Gynecol** 1997 Mar;40(1):81–9 (23 ref.)

COMPLICATIONS

[Thyroid nodule and cancer in pregnant women] Glinoer D. **Ann Endocrinol (Paris)** 1997;58(3):263–7 (11 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

[Suppressive hormonal therapy for thyroid nodule. Theoretical bases and practical modalities] Wemeau JL. **Ann Chir** 1997;51(4):368–74 (52 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Molecular aspects of the pathogenesis of nodular goiters, thyroid nodules and adenomas. Derwahl M. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 4:32–5 (15 ref.)

PATHOLOGY

Thyroid nodules and the detection of thyroid cancer. Haber RS. **Mt Sinai J Med** 1996 Jan;63(1):10–5 (13 ref.)

[Extemporaneous anatomo–pathological test in surgery of thyroid cancers. Values and limitations] Godey B, et al. **Ann Otolaryngol Chir Cervicofac** 1996;113(4):219–24 (13 ref.) (Eng. Abstr.) **(Fre)**

[Reliability of needle biopsy of solitary thyroid nodules in view of surgical indications] Moisson–Meer A, et al. **Rev Med Interne** 1996;17(9):732–7 (36 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Tan GH, et al. **Ann Intern Med** 1997 Feb 1; 126(3):226–31 (45 ref.)

Single thyroid nodule. Gharib H. **Curr Ther Endocrinol Metab** 1997;6:112–7 (7 ref.)

Treatment of the autonomous thyroid nodule: a review. Ferrari C, et al. **Eur J Endocrinol** 1996 Oct;135(4):383–90 (73 ref.)

[Choice of therapy in unifocal functional autonomy of the thyroid gland with hyperthyroidism] Als C, et al. **Schweiz Med Wochenschr** 1997 May 24;127(21):891–8 (45 ref.) (Eng. Abstr.) **(Ger)**

THYROID PEROXIDASE see **IODIDE PEROXIDASE**

THYROID–STIMULATING ANTIBODIES see **IMMUNOGLOBULINS, THYROID–STIMULATING**

THYROID–STIMULATING HORMONE see **THYROTROPIN**

THYROID–STIMULATING HORMONE, ALPHA SUBUNIT see **GLYCOPROTEIN HORMONES, ALPHA SUBUNIT**

THYROID STIMULATING HORMONE RECEPTORS see **RECEPTORS, THYROTROPIN**

THYROID–STIMULATING IMMUNOGLOBULINS see **IMMUNOGLOBULINS, THYROID–STIMULATING**

THYROID STORM see **THYROID CRISIS**

THYROIDECTOMY

Controversies in the surgical management of differentiated thyroid carcinoma. Noguchi M, et al. **Int Surg** 1996 Apr–Jun;81(2):163–7 (91 ref.)

Postsurgical management of differentiated thyroid carcinoma. Mazzaferri EL, et al. **Otolaryngol Clin North Am** 1996 Aug;29(4):637–62 (115 ref.)

Considerations in surgery of the thyroid gland. Shindo ML. **Otolaryngol Clin North Am** 1996 Aug;29(4):629–35 (29 ref.)

Controversies related to the medical and surgical management of hyperthyroidism in children. Waldhausen JH. **Semin Pediatr Surg** 1997 Aug;6(3):121–7 (37 ref.)

[Results of reoperations for goiter] Peix JL, et al. **Ann Chir** 1997;51(3):217–21 (17 ref.) (Eng. Abstr.) **(Fre)**

[Role of total thyroidectomy in the treatment of benign thyroid diseases] Peix JL, et al. **Ann Endocrinol (Paris)** 1996;57(6):502–7 (30 ref.) (Eng. Abstr.) **(Fre)**

[Pre–surgical medical therapy of hyperthyroidism] Cesareo R, et al. **Recenti Prog Med** 1997 Jun;88(6):277–80 (20 ref.) (Eng. Abstr.) **(Ita)**

METHODS

[Basedow's disease—thyroidectomy or subtotal resection?] Böttger T. **Zentralbl Chir** 1997;122(4):231–5 (15 ref.) (Eng. Abstr.) **(Ger)**

[The extent of the surgical intervention for different forms of goiter] Mamchich VI, et al. **Klin Khir** 1995;(3):42–4 (37 ref.) **(Rus)**

THYROIDITIS

Postpartum thyroiditis. Sharma S, et al. **J Indian Med Assoc** 1995 May;93(5):175, 172 (10 ref.)

DIAGNOSIS

Inflammatory thyroid disorders. Farwell AP, et al. **Otolaryngol Clin North Am** 1996 Aug;29(4):541–56 (112 ref.)

THERAPY

Thyroiditis. Walfish PG. **Curr Ther Endocrinol Metab** 1997; 6:117–22 (8 ref.)

THYROIDITIS, AUTOIMMUNE

The non–obese diabetic (NOD) mouse: an animal model for autoimmune thyroiditis. Many MC, et al. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 3:17–20 (39 ref.)

Autoimmune thyroiditis—spontaneous disease models—cat. Schumm–Draeger PM, et al. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 3:12–3; discussion 14–6 (3 ref.)

The obese strain chicken as a model for human Hashimoto's thyroiditis. Sundick RS, et al. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 3:4–6 (19 ref.)

The role of the target organ in the development of autoimmune diseases exemplified in the obese strain (OS) chicken model for human Hashimoto disease. Wick G. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 3:1–4 (27 ref.)

Hashimoto's myoclonic encephalopathy: an underdiagnosed treatable condition? [see comments] Ghika–Schmid F, et al. **Mov Disord** 1996 Sep;11(5):555–62 (30 ref.) Comment in: Mov Disord 1997 May;12(3):471–2.

CHEMICALLY INDUCED

Iodine–induced thyroiditis in the non–obese diabetic (NOD) mouse—more questions than answers. Scherbaum WA. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 3:20–3 (7 ref.)

COMPLICATIONS

Encephalopathy associated with Hashimoto thyroiditis: diagnosis and treatment. Kothbauer–Margreiter I, et al. **J Neurol** 1996 Aug;243(8):585–93 (28 ref.)

[Kikuchi syndrome, Hashimoto thyroiditis and lupus serology. Apropos of a case] Bousquet E, et al. **Rev Med Interne** 1996;17(10):836–8 (14 ref.) (Eng. Abstr.) **(Fre)**

[Thyroid cancer and Hashimoto's thyroiditis] Reda G, et al. **Minerva Chir** 1997 Jan–Feb;52(1–2):139–41 (12 ref.) (Eng. Abstr.) **(Ita)**

[Depression and autoimmune thyroiditis] Bunevičius R, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996; 96(6):90–2 (86 ref.) **(Rus)**

ETIOLOGY

Searching for pathogenic epitopes in thyroglobulin: parameters and caveats. Carayanniotis G, et al. **Immunol Today** 1997 Feb;18(2):83–8 (56 ref.)

IMMUNOLOGY

Anti–thyroglobulin autoantibodies in autoimmune thyroid diseases: cross–reactive or pathogenic? Tomer Y. **Clin Immunol Immunopathol** 1997 Jan;82(1):3–11 (89 ref.)

The BB rat as a model for autoimmune thyroiditis: relevance for the pathogenesis of human disease. Delemarre FG, et al. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 3:10–2 (26 ref.)

Induction models of autoimmune thyroid disease—critical comments. Wiersinga WM. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 3:25–7 (17 ref.)

[Morphology and clinical features of autoimmune thyroid diseases] Schröder S, et al. **Verh Dtsch Ges Pathol** 1996; 80:80–92 (50 ref.) (Eng. Abstr.) **(Ger)**

[Diagnostic value of thyroid antibodies] Toldy E, et al. **Orv Hetil** 1996 Sep 22;137(38):2075–80 (30 ref.) (Eng. Abstr.) **(Hun)**

PATHOLOGY

Autocrine/paracrine cell death in Hashimoto's thyroiditis. Berg JP. **Eur J Endocrinol** 1997 Aug;137(2):122–3 (10 ref.)

[Morphology and clinical aspects of immune thyroid diseases] Schröder S, et al. **Pathologe** 1996 Jul;17(4):276–88 (101 ref.) (Eng. Abstr.) **(Ger)**

[Morphology and clinical features of autoimmune thyroid diseases] Schröder S, et al. **Verh Dtsch Ges Pathol** 1996; 80:80–92 (50 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Autocrine/paracrine cell death in Hashimoto's thyroiditis. Berg JP. **Eur J Endocrinol** 1997 Aug;137(2):122–3 (10 ref.)

Autoimmune thyroid disease and pregnancy. Amino N, et al. **J Endocrinol Invest** 1996 Jan;19(1):59–70 (54 ref.)

THYROIDITIS, CHRONIC see **THYROIDITIS, AUTOIMMUNE**

THYROIDITIS, INFECTIOUS see **THYROIDITIS, SUPPURATIVE**

THYROIDITIS, LYMPHOCYTIC see **THYROIDITIS, AUTOIMMUNE**

THYROIDITIS, LYMPHOMATOUS see **THYROIDITIS, AUTOIMMUNE**

THYROIDITIS, SUBACUTE

COMPLICATIONS

Graves' disease occurring after subacute thyroiditis: report of a case and review of the literature. Bartalena L, et al. **Thyroid** 1996 Aug;6(4):345–8 (22 ref.)

THYROIDITIS, SUPPURATIVE

COMPLICATIONS

Acute suppurative thyroiditis and necrosis of the thyroid gland: a rare endocrine manifestation of acquired immunodeficiency syndrome. Golshan MM, et al. **Surgery** 1997 May;121(5):593–6 (12 ref.)

MICROBIOLOGY

[Acute suppurative thyroiditis. Report of a case and review of the literature] Moffa F, et al. **Minerva Chir** 1996 Sep; 51(9):745–9 (14 ref.) (Eng. Abstr.) **(Ita)**

THYROLIBERIN see **PROTIRELIN**

THYROTOXIC CRISIS see **THYROID CRISIS**

THYROTOXIC STORM see **THYROID CRISIS**

THYROTOXICOSIS

CHEMICALLY INDUCED

Amiodarone–induced thyrotoxicosis. Tavackoli S, et al. **Am J Med Sci** 1997 Aug;314(2):97–100 (29 ref.)

COMPLICATIONS

Hypokalaemic thyrotoxic periodic paralysis: case report and review of an Oriental syndrome. van Dam GM, et al. **Neth J Med** 1996 Aug;49(2):90–7 (76 ref.)

DIAGNOSIS

Thyrotoxicosis. Kannan CR, et al. **Dis Mon** 1997 Sep; 43(9):601–77 (144 ref.)

ETIOLOGY

Thyrotoxicosis in a patient with multiple trauma: value of "AMPLE" history taking [see comments] Fitz–Henry J, et al. **BMJ** 1996 Oct 19;313(7063):997–8 (6 ref.) Comment in: BMJ 1997 Mar 8;314(7082):752; discussion 753. Comment in: BMJ 1997 Mar 8;314(7082):752–3.

PHYSIOPATHOLOGY

Subclinical thyroid dysfunction. Woeber KA. **Arch Intern Med** 1997 May 26;157(10):1065–8 (38 ref.)

Thyrotoxicosis. Kannan CR, et al. **Dis Mon** 1997 Sep; 43(9):601–77 (144 ref.)

THERAPY

Thyrotoxicosis in childhood. Perrild H, et al. **Eur J Endocrinol** 1996 Jun;134(6):678–9 (16 ref.)

THYROTROPIN

see related
RECEPTORS, THYROTROPIN

BIOSYNTHESIS

Role of Pit–1 in the gene expression of growth hormone,

THYROTROPIN

prolactin, and thyrotropin. Cohen LE, et al. **Endocrinol Metab Clin North Am** 1996 Sep;25(3):523–40 (94 ref.)

BLOOD

Clinical use of sensitive assays for thyroid-stimulating hormone. Masters PA, et al. **J Gen Intern Med** 1996 Feb; 11(2):115–27 (102 ref.)

GENETICS

Thyrotropin (TSH) beta-subunit gene expression—an example for the complex regulation of pituitary hormone genes. Steinfelder HJ, et al. **Exp Clin Endocrinol Diabetes** 1997;105(4):196–203 (52 ref.)

METABOLISM

Epitope analysis of the thyrotropin receptor, 1997. Kosugi S, et al. **Mol Cell Endocrinol** 1997 Apr 4;128(1–2):11–8 (58 ref.)

A gut reaction: lymphoepithelial communication in the intestine [comment] [see comments] Shanahan F. **Science** 1997 Mar 28;275(5308):1897–8 (11 ref.) Comment on: Science 1997 Mar 28;275(5308):1937–9. Comment in: Science 1997 Mar 28;275(5308):1897–8.

Hyperthyroidism caused by an ectopic TSH-secreting pituitary tumor. Cooper DS, et al. **Thyroid** 1996 Aug; 6(4):337–43 (50 ref.)

PHYSIOLOGY

Inappropriate secretion of thyroid-stimulating hormone. Kourides IA. **Curr Ther Endocrinol Metab** 1997;6:52–6 (10 ref.)

Novel insights into the molecular mechanisms of human thyrotropin action: structural, physiological, and therapeutic implications for the glycoprotein hormone family. Grossmann M, et al. **Endocr Rev** 1997 Aug; 18(4):476–501 (236 ref.)

SECRETION

Thyrotropin-secreting pituitary tumors. Beck-Peccoz P, et al. **Endocr Rev** 1996 Dec;17(6):610–38 (377 ref.)

Thyrotropin-secreting pituitary adenomas. Beck-Peccoz P, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):75–9 (28 ref.)

[Thyreotropic adenoma: review of the literature. Apropos of 2 cases] Prévost G, et al. **Ann Endocrinol (Paris)** 1996; 57(3):194–202 (40 ref.) (Eng. Abstr.) **(Fre)**

[T3 (triiodo-thyronin) suppression test] Bando H. **Nippon Rinsho** 1997 Apr;55 Suppl 2:288–90 (2 ref.) **(Jpn)**

[TRH loading test] Bando H. **Nippon Rinsho** 1997 Apr;55 Suppl 2:283–7 (11 ref.) **(Jpn)**

THYROTROPIN ALPHA SUBUNIT see **GLYCOPROTEIN HORMONES, ALPHA SUBUNIT**

THYROTROPIN RECEPTORS see **RECEPTORS, THYROTROPIN**

THYROTROPIN-RELEASING HORMONE see **PROTIRELIN**

THYROXINE

see related
HYPERTHYROXINEMIA
RECEPTORS, THYROID HORMONE

BLOOD

Circannual changes in thyroid hormone physiology: the role of cold environmental temperatures. Reed HL. **Arctic Med Res** 1995;54 Suppl 2:9–15 (55 ref.)

The hypothyroxinemia [corrected] of prematurity [editorial; comment] [published erratum appears in J Clin Endocrinol Metab 1997Jul;82(7):2191] Fisher DA. **J Clin Endocrinol Metab** 1997 Jun;82(6):1701–3 (25 ref.) Comment on: J Clin Endocrinol Metab 1997 Jun;82(6):1704–12.

DEFICIENCY

[Low-T3/Low-T4 syndrome] Nishikawa M, et al. **Nippon Naika Gakkai Zasshi** 1996 May 10;85(5):772–6 (16 ref.) **(Jpn)**

METABOLISM

Membrane iodothyronine transporters, Part II: Review of protein biochemistry. Kragie L. **Endocr Res** 1996 May; 22(2):95–119 (119 ref.)

Thyroid hormone abnormalities in heart failure: possibilities for therapy. Hamilton MA, et al. **Thyroid** 1996 Oct; 6(5):527–9 (22 ref.)

PHYSIOLOGY

Thyroxine's evolutionary roots. Johnson LG. **Perspect Biol Med** 1997 Summer;40(4):529–35 (27 ref.)

THERAPEUTIC USE

[Suppressive hormonal therapy for thyroid nodule. Theoretical bases and practical modalities] Wemeau JL. **Ann Chir** 1997;51(4):368–74 (52 ref.) (Eng. Abstr.) **(Fre)**

L-THYROXINE see **LEVOTHYROXINE**

THYROXINE-BINDING GLOBULIN see **THYROXINE-BINDING PROTEINS**

THYROXINE-BINDING PREALBUMIN see **THYROXINE-BINDING PROTEINS**

THYROXINE-BINDING PROTEINS

GENETICS

Clinical aspects and diagnosis of thyroid hormone transport protein anomalies. Langsteger W. **Curr Top Pathol** 1997; 91:129–61 (197 ref.)

Thyroxine-binding globulin: organization of the gene and variants [published erratum appears in Horm Res 1996 Jul;46(1):37] Refetoff S, et al. **Horm Res** 1996; 45(3–5):128–38 (81 ref.)

Mutations of the thyroxine-binding globulin gene in Japanese [editorial] Seo H. **Intern Med** 1996 Apr;35(4):237 (13 ref.)

THYROXINE 5'-DEIODINASE see **IODIDE PEROXIDASE**

THYROXINE 5'-MONODEIODINASE see **IODIDE PEROXIDASE**

THYROXINE RECEPTORS see **RECEPTORS, THYROID HORMONE**

TIBIA

Osteosarcomatosis with Rothmund-Thomson syndrome. el-Khoury JM, et al. **Br J Radiol** 1997 Feb;70:215–8 (11 ref.)

Posterior tibial tendon dysfunction as a cause of acquired flatfoot in adults. Kupcha PC, et al. **Del Med J** 1997 May; 69(5):255–7 (5 ref.)

Rotational problems in children. Staheli LT. **Instr Course Lect** 1994;43:199–209 (91 ref.)

Osteoid osteoma with a multicentric nidus. Gonzalez G, et al. **Int Orthop** 1996;20(1):61–3 (7 ref.)

Bilateral osteofibrous dysplasia: a report of two cases and review of the literature. Sunkara UK, et al. **Iowa Orthop J** 1997;17:47–52 (23 ref.)

ABNORMALITIES

Tibioperoneal diaphyseal toxopachyosteosis or Weismann-Netter-Stuhl syndrome: difficulties encountered in classifying this syndrome and differentiation from rickets. Nores JM, et al. **Clin Exp Rheumatol** 1997 Jan–Feb; 15(1):105–9 (49 ref.)

Rotational deformities in the lower extremities. Karol LA. **Curr Opin Pediatr** 1997 Feb;9(1):77–80 (6 ref.)

Congenital pseudarthrosis of the tibia. Delgado-Martínez AD, et al. **Int Orthop** 1996;20(3):192–9 (61 ref.)

Femoral hypoplasia-unusual facies syndrome with bifid hallux, absent tibia, and macrophallus: a report of a Bedouin baby. Sabry MA, et al. **J Med Genet** 1996 Feb;33(2):165–7 (9 ref.)

[The FF complex: a rare congenital malformation] Smilari P, et al. **Pediatr Med Chir** 1997 May-Jun;19(3):215–7 (9 ref.) **(Ita)**

RADIOGRAPHY

Chondromyxoid fibroma. White PG, et al. **Skeletal Radiol** 1996 Jan;25(1):79–81 (11 ref.)

SURGERY

Callotasis lengthening: a review of some technical aspects. Maffulli N. **Bull Hosp Jt Dis** 1996;54(4):249–54 (85 ref.)

[Twenty-eight years' treatments using high tibial osteotomy with development of Y-blade plate and postoperative repair of degenerated cartilage in the osteoarthritic knee] Koshino T. **Nippon Seikeigeka Gakkai Zasshi** 1996 Dec; 70(12):817–25 (29 ref.) **(Jpn)**

TIBIAL ARTERIES

RADIOGRAPHY

Pedal arterial imaging. Alson MD, et al. **J Vasc Interv Radiol** 1997 Jan–Feb;8(1 Pt 1):9–18 (56 ref.)

SURGERY

[Distal popliteal bypass in the diabetic patient. Clinical case] Cavallini M, et al. **Minerva Chir** 1996 Jul–Aug; 51(7–8):589–95 (23 ref.) (Eng. Abstr.) **(Ita)**

TIBIAL COLLATERAL LIGAMENT see **MEDIAL COLLATERAL LIGAMENT, KNEE**

TIBIAL FRACTURES

COMPLICATIONS

Compartment syndrome associated with tibial fracture. Tornetta P 3rd, et al. **Instr Course Lect** 1997;46:303–8 (34 ref.)

DIAGNOSIS

Fractures of the tibial plateau. Perry CR. **Instr Course Lect** 1994;43:119–26 (7 ref.)

Fractures of the ankle and the distal part of the tibia. Vander Griend R, et al. **Instr Course Lect** 1997;46:311–21 (66 ref.)

ECONOMICS

The economics of treating tibia fractures. The cost of delayed unions. Heckman JD, et al. **Bull Hosp Jt Dis** 1997; 56(1):63–72 (26 ref.)

SURGERY

The role of pedicled or free fibular grafts in knee arthrodesis. Hallock GG. **Ann Plast Surg** 1997 Jul;39(1):60–3 (14 ref.)

Arthroscopy assisted operative management of tibial plateau fractures. Buchko GM, et al. **Clin Orthop** 1996 Nov; (332):29–36 (19 ref.)

Technical considerations in the surgical management of tibial fractures. Tornetta P 3rd. **Instr Course Lect** 1997;46:271–80 (42 ref.)

Avulsion of the patellar ligament with combined fracture luxation of the proximal tibial epiphysis: case report and review of the literature. Perez Carro L. **J Orthop Trauma** 1996;10(5):355–8 (8 ref.)

[Fractures of the anterior rim of the distal part of the tibia. Apropos of a series of 38 cases] Cesari B, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(5):417–27 (20 ref.) (Eng. Abstr.) **(Fre)**

[Callus distraction in tibial defect fractures] Giebel G. **Chirurg** 1996 Nov;67(11):1063–8 (8 ref.) (Eng. Abstr.) **(Ger)**

[Defect fractures of the tibia—various forms of bone replacement] Mittelmeier W, et al. **Chirurg** 1996 Nov; 67(11):1087–92 (30 ref.) (Eng. Abstr.) **(Ger)**

[Plastic soft tissue coverage in defect fractures of the tibia] Steinau HU, et al. **Chirurg** 1996 Nov;67(11):1080–6 (30 ref.) (Eng. Abstr.) **(Ger)**

[Tibial plateau fractures] Hertel P. **Unfallchirurg** 1997 Jul; 100(7):508–23 (28 ref.) (Eng. Abstr.) **(Ger)**

[Complex trauma of the knee joint. Diagnosis—management—therapeutic principles] Krettek C, et al. **Unfallchirurg** 1996 Sep;99(9):616–27 (56 ref.) (Eng. Abstr.) **(Ger)**

[Biological fixation of distal tibial fractures] Mosheiff R, et al. **Harefuah** 1997 May 15;132(10):727–30 (9 ref.) **(Heb)**

[Remodelling of residual deformities after fractures of long bones in children] Oran A, et al. **Harefuah** 1996 Aug; 131(3–4):130–4 (43 ref.) **(Heb)**

THERAPY

Delayed union and nonunion of tibial shaft fractures. Goulet JA, et al. **Instr Course Lect** 1997;46:281–91 (100 ref.)

Open fractures of the tibial shaft. Olson SA. **Instr Course Lect** 1997;46:293–302 (72 ref.)

Fractures of the tibial plateau. Perry CR. **Instr Course Lect** 1994;43:119–26 (7 ref.)

Fractures of the ankle and the distal part of the tibia. Vander Griend R, et al. **Instr Course Lect** 1997;46:311–21 (66 ref.)

Current treatment of tibial plateau fractures. Dirschl DR, et al. **J South Orthop Assoc** 1997 Spring;6(1):54–61 (24 ref.)

TIBIAL MENISCI see **MENISCI, TIBIAL**

TIBIAL NERVE

Idiopathic tibial mononeuropathy with conduction block: an unusual case and review of the literature. Roth LS, et al. **J Foot Ankle Surg** 1997 Mar-Apr;36(2):127–30 (23 ref.)

PHYSIOLOGY

Estimating post-synaptic potentials in tonically discharging human motoneurons. Miles TS. **J Neurosci Methods** 1997 Jun 27;74(2):167–74 (32 ref.)

TIC

CLASSIFICATION

Tourette syndrome. Phenomenology and classification of tics. Jankovic J. **Neurol Clin** 1997 May;15(2):267–75 (43 ref.)

DIAGNOSIS

Tourette syndrome. Clinical rating and quantitative assessment of tics. Kompoliti K, et al. **Neurol Clin** 1997 May;15(2):239–54 (49 ref.)

IMMUNOLOGY

Neuroimmunology of tics and other childhood hyperkinesias. Hallett JJ, et al. **Neurol Clin** 1997 May;15(2):333–44 (45 ref.)

TIC DOULOUREUX see **TRIGEMINAL NEURALGIA**

TICK-BORNE DISEASES

The cold zone: a curious convergence of tick-transmitted diseases. Persing DH. **Clin Infect Dis** 1997 Jul;25 Suppl

1:S35–42 (89 ref.)

DIAGNOSIS

Respiratory manifestations of tick-borne diseases in the Southeastern United States [see comments] Byrd RP Jr, et al. **South Med J** 1997 Jan;90(1):1–4 (33 ref.) Comment in: South Med J 1997 Jun;90(6):663.

Laboratory diagnosis of tick-borne diseases in Wisconsin. Reed KD, et al. **Wis Med J** 1996 Aug;95(8):557–63 (25 ref.)

VETERINARY

Prospects for subunit vaccines against tick-borne diseases [see comments] Musoke AJ, et al. **Br Vet J** 1996 Nov; 152(6):621–39 (125 ref.) Comment in: Br Vet J 1996 Nov;152(6):617–9.

The control of heartwater in west Africa—present and future. Sumption KJ. **Trop Anim Health Prod** 1996 May;28(2 Suppl):65S–73S (20 ref.)

Sustainable tick and tickborne disease control in livestock improvement in developing countries. de Castro JJ. **Vet Parasitol** 1997 Jul 31;71(2–3):77–97 (102 ref.)

Survey of tick related problems in roe deer (Capreolus capreolus) in The Netherlands. Dorrestein GM, et al. **Vet Q** 1996;18 Suppl 3:S148 (5 ref.)

Do roe deer (Capreolus capreolus) spread Borrelia-infected Ixodes ricinus ticks? Rijpkema SG. **Vet Q** 1996;18 Suppl 3:S146–7 (14 ref.)

TICK CONTROL

Can house dust mite-triggered atopic dermatitis be alleviated using acaricides? Cameron MM. **Br J Dermatol** 1997 Jul; 137(1):1–8 (93 ref.)

The history of the cattle tick Boophilus microplus in Australia and achievements in its control. Angus BM. **Int J Parasitol** 1996 Dec;26(12):1341–55 (163 ref.)

The control of heartwater in west Africa—present and future. Sumption KJ. **Trop Anim Health Prod** 1996 May;28(2 Suppl):65S–73S (20 ref.)

Sustainable tick and tickborne disease control in livestock improvement in developing countries. de Castro JJ. **Vet Parasitol** 1997 Jul 31;71(2–3):77–97 (102 ref.)

METHODS

Prevention and nonpharmacologic treatment of mite allergy. Wickman M. **Allergy** 1997 Apr;52(4):369–73 (43 ref.)

TICK INFESTATIONS

EPIDEMIOLOGY

[Distribution of dog ticks (Rhipicephalus sanguineus Latreille, 1806) in Italy: a public health problem] Maroli M, et al. **Ann Ist Super Sanita** 1996;32(3):387–97 (118 ref.) (Eng. Abstr.) **(Ita)**

IMMUNOLOGY

Tick modulation of host cytokines. Wikel SK. **Exp Parasitol** 1996 Nov;84(2):304–9 (23 ref.)

VETERINARY

The history of the cattle tick Boophilus microplus in Australia and achievements in its control. Angus BM. **Int J Parasitol** 1996 Dec;26(12):1341–55 (163 ref.)

The pathogenesis of dermatophilosis. Ambrose NC. **Trop Anim Health Prod** 1996 May;28(2 Suppl):29S–37S (24 ref.)

[Distribution of dog ticks (Rhipicephalus sanguineus Latreille, 1806) in Italy: a public health problem] Maroli M, et al. **Ann Ist Super Sanita** 1996;32(3):387–97 (118 ref.) (Eng. Abstr.) **(Ita)**

TICKS

[Distribution of dog ticks (Rhipicephalus sanguineus Latreille, 1806) in Italy: a public health problem] Maroli M, et al. **Ann Ist Super Sanita** 1996;32(3):387–97 (118 ref.) (Eng. Abstr.) **(Ita)**

[Allergy to synanthropic ticks] Mokronosova MA, et al. **Klin Med (Mosk)** 1997;75(1):19–21 (39 ref.) **(Rus)**

[Astrakhan fever—a rickettsiosis of the tick-borne spotted fevers caused by a new pathovar of rickettsiae, Rickettsia conorii] Lukin EP, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Sep–Oct;(5):96–9 (37 ref.) **(Rus)**

IMMUNOLOGY

Tick modulation of host cytokines. Wikel SK. **Exp Parasitol** 1996 Nov;84(2):304–9 (23 ref.)

Large-scale production in Pichia pastoris of the recombinant vaccine Gavac against cattle tick. Canales M, et al. **Vaccine** 1997 Mar;15(4):414–22 (27 ref.)

MICROBIOLOGY

Controversies in the use of antimicrobials for the prevention and treatment of Lyme disease. Wormser GP. **Infection** 1996 Mar–Apr;24(2):178–81 (38 ref.)

PARASITOLOGY

Ticks and Borrelia: model systems for investigating pathogen-arthropod interactions. Schwan TG. **Infect Agents Dis** 1996 Jun;5(3):167–81 (120 ref.)

[Use of indirect immunofluorescence and polymerase chain reaction (PCR) for detection of Borrelia burgdorferi in ticks] Tylewska-Wierzbanowska S, et al. **Przegl Epidemiol** 1996;50(3):239–44 (11 ref.) (Eng. Abstr.) **(Pol)**

VIROLOGY

[Argas and arbovirus update] Vermeil C, et al. **Bull Soc Pathol Exot** 1996;89(5):363–5 (16 ref.) (Eng. Abstr.) **(Fre)**

TICLOPIDINE

ADMINISTRATION & DOSAGE

Ticlopidine and aspirin therapy following implantation of coronary artery stents. Hobson AG, et al. **Ann Pharmacother** 1997 Jun;31(6):770–2 (16 ref.)

[Evolution in coronary stenting: use of ticlopidine with and without oral anticoagulants] Zanini R, et al. **Cardiologia** 1997 Aug;42(8):837–43 (32 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

Ticlopidine induced cholestatic jaundice. Yim HB, et al. **Singapore Med J** 1997 Mar;38(3):132–3 (7 ref.)

[Bone marrow aplasia related to ticlopidine] de Jaureguiberry JP, et al. **Rev Med Interne** 1996;17(12):1032–6 (30 ref.) (Eng. Abstr.) **(Fre)**

[A case report of drug induced hepatitis and pancreatitis] Shimizu A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 May;94(5):351–5 (19 ref.) **(Jpn)**

[Bone marrow aplasia and ticlopidine (letter)] Gaspar Alonso-Vega G, et al. **Med Clin (Barc)** 1997 Apr 19; 108(15):596–7 (10 ref.) **(Spa)**

ANALOGS & DERIVATIVES

Ticlopidine or clopidogrel as alternatives to aspirin in prevention of ischemic stroke. Bendixen BH, et al. **Eur Neurol** 1996;36(5):256–7 (11 ref.)

THERAPEUTIC USE

Stent thrombosis. Closing in on the best preventive treatment [editorial; comment] Baim DS, et al. **Circulation** 1997 Mar 4;95(5):1098–100 (14 ref.) Comment on: Circulation 1997 Mar 4;95(5):1145–56.

Ticlopidine or clopidogrel as alternatives to aspirin in prevention of ischemic stroke. Bendixen BH, et al. **Eur Neurol** 1996;36(5):256–7 (11 ref.)

[Antiplatelet therapy during coronary endoprosthesis placement] Barragan P, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1515–20 (42 ref.) (Eng. Abstr.) **(Fre)**

TICRYNAFEN

ADVERSE EFFECTS

Anti-cytochrome P450 autoantibodies in drug-induced disease. Beaune PH, et al. **Eur J Haematol Suppl** 1996; 60:89–92 (23 ref.)

TOXICITY

Molecular structure and hepatotoxicity: compared data about two closely related thiophene compounds. Mansuy D. **J Hepatol** 1997;26 Suppl 2:22–5 (11 ref.)

TIDAL VOLUME

How to use diagnostic test articles in the intensive care unit: diagnosing weanability using f/Vt. Jaeschke RZ, et al. **Crit Care Med** 1997 Sep;25(9):1514–21 (24 ref.)

TIENILIC ACID see **TICRYNAFEN**

TIETZE'S SYNDROME

ETIOLOGY

Post-traumatic costochondritis caused by Candida albicans. Aetiology, diagnosis and treatment. Heckenkamp J, et al. **Scand Cardiovasc J** 1997;31(3):165–7 (12 ref.)

TIGHT JUNCTIONS

[Molecular biology of cellular barrier, tight junction] Kokai Y, et al. **Tanpakushitsu Kakusan Koso** 1997 Mar; 42(4):643–51 (36 ref.) **(Jpn)**

CHEMISTRY

Molecular structure of the apical junction complex and its contribution to the paracellular barrier. Lutz KL, et al. **J Pharm Sci** 1997 Sep;86(9):977–84 (127 ref.)

Molecular architecture of tight junctions: occludin and ZO-1. Tsukita S, et al. **Soc Gen Physiol Ser** 1997;52:69–76 (27 ref.)

GENETICS

[Intestinal intercellular tight junctions. I. Structure and molecular mechanisms of regulation] Stein J, et al. **Z Gastroenterol** 1997 Mar;35(3):205–20 (117 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Specificity of desmosomal plaque protein interactions with intermediate filaments: keeping adhesive junctions segregated. Green KJ, et al. **Soc Gen Physiol Ser** 1997; 52:123–39 (84 ref.)

PHYSIOLOGY

Molecular dissection of tight junctions. Tsukita S, et al. **Cell Struct Funct** 1996 Oct;21(5):381–5 (35 ref.)

TILT-TABLE TEST

Tilt table testing: concepts and limitations. Grubb BP, et al. **Pacing Clin Electrophysiol** 1997 Mar;20(3 Pt 2):781–7 (35 ref.)

[Comparative data of tilt test with or without isoproterenol in investigation of unexplained unconsciousness and syncope] Raybaud F, et al. **Arch Mal Coeur Vaiss** 1996 Sep;89(9):1145–51 (32 ref.) (Eng. Abstr.) **(Fre)**

[The tilt-table test: is it essential for adequate treatment of vasovagal syncope? Arguments in favor] Moya i Mitjans A, et al. **Rev Esp Cardiol** 1997 Jun;50(6):368–73 (49 ref.) (Eng. Abstr.) **(Spa)**

[The tilt-table test: is it essential for adequate treatment of vasovagal syncope? Arguments against] Ruiz Granell R, et al. **Rev Esp Cardiol** 1997 Jun;50(6):374–82 (98 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Outcome of patients with neurally mediated syncope following tilt table testing. Sheldon RS. **Cardiologia** 1997 Aug;42(8):795–802 (40 ref.)

METHODS

Vasodepressor syncope. Diagnosis and management. Barbey JT. **Cardiol Clin** 1997 May;15(2):251–6 (41 ref.)

TIME

Finding one's self in time. Nelson K. **Ann N Y Acad Sci** 1997 Jun 18;818:102–16 (31 ref.)

Temporal diagnostic reasoning based on time-objects. Keravnou ET. **Artif Intell Med** 1996 Jul;8(3):235–65 (61 ref.)

Defusing the Cambrian 'explosion'? Morris SC. **Curr Biol** 1997 Feb 1;7(2):R71–4 (13 ref.)

Time series analysis and its relationship with longitudinal analysis. Molenaar PC. **Int J Sports Med** 1997 Jul;18 Suppl 3:S232–7 (25 ref.)

The early solar system. Gaffey MJ. **Orig Life Evol Biosph** 1997 Jun;27(1–3):185–203 (39 ref.)

The origin of low mass stars. Wilking BA. **Orig Life Evol Biosph** 1997 Jun;27(1–3):135–55 (70 ref.)

TIME FACTORS

[Liver transplantation: problem of timing and predictive factors] Pár A. **Orv Hetil** 1996 Oct 20;137(42 Suppl 1):2364–8 (27 ref.) (Eng. Abstr.) **(Hun)**

TIME MANAGEMENT

Time management: a review for physicians. Brunicardi FC, et al. **J Natl Med Assoc** 1996 Sep;88(9):581–7 (29 ref.)

TIME PERCEPTION

PHYSIOLOGY

The representation of temporal information in perception and motor control. Ivry RB. **Curr Opin Neurobiol** 1996 Dec; 6(6):851–7 (51 ref.)

TIMED-RELEASE PREPARATIONS see **DELAYED-ACTION PREPARATIONS**

TIMOLOL

PHARMACOLOGY

Timolol hemihydrate: a new formulation of timolol for the treatment of glaucoma. Stewart WC. **J Ocul Pharmacol Ther** 1996 Summer;12(2):225–37 (30 ref.)

THERAPEUTIC USE

The additive intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents. Hoyng PF, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S93–8 (43 ref.)

TIN

see related
ORGANOTIN COMPOUNDS

TIN

[Biological activity of tin and immunity] Arakawa Y. **Sangyo Eiseigaku Zasshi** 1997 Jan;39(1):1–20 (176 ref.) (Eng. Abstr.) **(Jpn)**

TOXICITY

Ecotoxicology of organotin compounds. Fent K. **Crit Rev Toxicol** 1996 Jan;26(1):1–117 (428 ref.)

TIN COMPOUNDS

DIAGNOSTIC USE

[Measurement of gastric emptying using radioisotope] Ishikawa H, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:139–42 (5 ref.) **(Jpn)**

TINEA

DIAGNOSIS

Bedside testing: the diagnostic cornerstone of dermatology. Brodell RT, et al. **Compr Ther** 1997 Mar;23(3):211–7 (25 ref.)

Superficial fungal infections. Errors to avoid in diagnosis and treatment. Brodell RT, et al. **Postgrad Med** 1997 Apr; 101(4):279–87 (29 ref.)

DRUG THERAPY

Oral terbinafine: a new antifungal agent. Abdel-Rahman SM, et al. **Ann Pharmacother** 1997 Apr;31(4):445–56 (117 ref.)

Treatment and prophylaxis of tinea infections. Piérard GE, et al. **Drugs** 1996 Aug;52(2):209–24 (188 ref.)

Superficial fungal infections. Errors to avoid in diagnosis and treatment. Brodell RT, et al. **Postgrad Med** 1997 Apr; 101(4):279–87 (29 ref.)

PREVENTION & CONTROL

Treatment and prophylaxis of tinea infections. Piérard GE, et al. **Drugs** 1996 Aug;52(2):209–24 (188 ref.)

TINEA CAPITIS

Tinea capitis. Elewski B. **Dermatol Clin** 1996 Jan;14(1):23–31 (44 ref.)

International summit on cutaneous antifungal therapy, focus on tinea capitis, Boston, Massachusetts, November 11–13, 1994. Elewski BE, et al. **Pediatr Dermatol** 1996 Jan–Feb; 13(1):69–77 (35 ref.)

DRUG THERAPY

Treatment of tinea capitis. Abdel-Rahman SM, et al. **Ann Pharmacother** 1997 Mar;31(3):338–48 (134 ref.)

Tinea capitis. Smith ML. **Pediatr Ann** 1996 Feb;25(2):101–5 (20 ref.)

ETHNOLOGY

Tinea due to Trichophyton violaceum in Victoria, Australia. Maslen MM, et al. **Australas J Dermatol** 1997 Aug; 38(3):124–8 (21 ref.)

PATHOLOGY

Hair loss in a 5-year-old boy. Tinea capitis caused by Microsporum gypseum. Burke EM, et al. **Arch Dermatol** 1997 Sep;133(9):1161–2, 1164–5 (9 ref.)

Tinea caput medusa: an unusual presentation of Trichophyton mentagrophytes on the scalp. Houck HE, et al. **Cutis** 1996 Jul;58(1):48–52 (13 ref.)

THERAPY

Tinea caput medusa: an unusual presentation of Trichophyton mentagrophytes on the scalp. Houck HE, et al. **Cutis** 1996 Jul;58(1):48–52 (13 ref.)

TINEA PEDIS

Dermatophytosis of the feet. Masri-Fridling GD. **Dermatol Clin** 1996 Jan;14(1):33–40 (16 ref.)

Chronic dermatophytosis syndrome due to Trichophyton rubrum. Zaias N, et al. **Int J Dermatol** 1996 Sep;35(9):614–7 (8 ref.)

DIAGNOSIS

Tinea pedis: diagnosis and treatment. Brooks KE, et al. **Clin Podiatr Med Surg** 1996 Jan;13(1):31–46 (20 ref.)

DRUG THERAPY

Tinea pedis: diagnosis and treatment. Brooks KE, et al. **Clin Podiatr Med Surg** 1996 Jan;13(1):31–46 (20 ref.)

Tinea pedis: clinical experience and efficacy of short treatment. Evans EG. **Dermatology** 1997;194 Suppl 1:3–6 (13 ref.)

Treatment of onychomycosis and tinea pedis with intermittent itraconazole therapy. Del Rosso JQ. **J Am Osteopath Assoc** 1996 Oct;96(10):607–9 (19 ref.)

Advances in the treatment of superficial fungal infections: focus on onychomycosis and dry tinea pedis. Del Rosso JQ. **J Am Osteopath Assoc** 1997 Jun;97(6):339–46 (48 ref.)

EPIDEMIOLOGY

The descriptive epidemiology of tinea pedis in the community. Rogers D, et al. **Australas J Dermatol** 1996 Nov;37(4):178–84 (34 ref.)

TINEA UNGUIUM see **ONYCHOMYCOSIS**

TINEA VERSICOLOR

The superficial mycoses. Assaf RR, et al. **Dermatol Clin** 1996 Jan;14(1):57–67 (67 ref.)

Yeast infections. Hay RJ. **Dermatol Clin** 1996 Jan; 14(1):113–24 (33 ref.)

TINNITUS

Tinnitus—investigation and management. Vesterager V. **BMJ** 1997 Mar 8;314(7082):728–31 (23 ref.)

CHEMICALLY INDUCED

Drug-induced tinnitus and other hearing disorders. Seligmann H, et al. **Drug Saf** 1996 Mar;14(3):198–212 (168 ref.)

ETIOLOGY

Medicolegal aspects of neurotology. Hart CW, et al. **Otolaryngol Clin North Am** 1996 Jun;29(3):503–20 (29 ref.)

Update on tinnitus. Seidman MD, et al. **Otolaryngol Clin North Am** 1996 Jun;29(3):455–65 (28 ref.)

PHYSIOPATHOLOGY

Central tinnitus and lateral inhibition: an auditory brainstem model. Gerken GM. **Hear Res** 1996 Aug;97(1–2):75–83 (57 ref.)

REHABILITATION

Acupuncture for tinnitus: time to stop? Andersson G, et al. **Scand Audiol** 1996;25(4):273–5 (13 ref.)

TIPSS see **PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC**

TISSUE ADHESIVES

see related
BONE CEMENTS

From sticky stuff to sweet receptors—achievements, limits and novel approaches to bioadhesion. Lehr CM. **Eur J Drug Metab Pharmacokinet** 1996 Apr–Jun; 21(2):139–48 (51 ref.)

The proper use of glue: a 20-year experience with the GRF glue in acute aortic dissection. Bachet J, et al. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):243–53; discussion 253–5 (30 ref.)

Fibrin sealant: scientific rationale, production methods, properties, and current clinical use. Radosevich M, et al. **Vox Sang** 1997;72(3):133–43 (71 ref.)

[Bioadhesives: rationale, state of the art and therapeutic potential] Martini A, et al. **Boll Chim Farm** 1995 Dec; 134(11):595–603 (47 ref.) (Eng. Abstr.) **(Ita)**

THERAPEUTIC USE

Controlled clinical studies of fibrin sealant in cardiothoracic surgery—a review. Kjaergard HK, et al. **Eur J Cardiothorac Surg** 1996;10(9):727–33 (30 ref.)

Fibrin tissue adhesives. Martinowitz U, et al. **Thromb Haemost** 1997 Jul;78(1):661–6 (70 ref.)

Therapeutic use of fibrin—a new class of fibrin sealant with minimal risks. Cederholm-Williams SA. **Ukr Biokhim Zh** 1996 Jul–Aug;68(4):34–6 (29 ref.)

[Surgical adhesives in ophthalmology] Werner LP, et al. **J Fr Ophtalmol** 1997;20(2):146–59 (97 ref.) **(Fre)**

[Biological glue in neurosurgery] Dzenis IuL, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1996 Jul–Sep;(3):35–6 (29 ref.) **(Rus)**

TISSUE BANKS

Development of oocyte banks and systems for the in-vitro development of oocytes: future directions for the treatment of infertility. Carroll J. **Hum Reprod** 1996 Sep;11 Suppl 1:159–68; discussion 169–71 (39 ref.)

Expanding the donor pool. First MR. **Semin Nephrol** 1997 Jul;17(4):373–80 (59 ref.)

[Transplantation in orthopedic surgery and traumatology] Cara JA, et al. **Rev Med Univ Navarra** 1994 Oct–Dec; 38(4):207–11 (15 ref.) (Eng. Abstr.) **(Spa)**

ORGANIZATION & ADMINISTRATION

Practical issues in tissue banking. Haimowitz MD. **Am J Clin Pathol** 1997 Apr;107(4 Suppl 1):S75–81 (11 ref.)

Brain tissue banks in psychiatric and neurological research [see comments] Cairns NJ, et al. **J Clin Pathol** 1996 Nov; 49(11):870–3 (29 ref.) Comment in: J Clin Pathol 1997 Apr;50(4):355.

Donor screening: an overview of current regulation and practices in Europe. Tjabbes H. **Transplant Proc** 1996 Oct; 28(5):2950–2 (0 ref.)

STANDARDS

Practical issues in tissue banking. Haimowitz MD. **Am J Clin Pathol** 1997 Apr;107(4 Suppl 1):S75–81 (11 ref.)

Retrovirus screening of vaccine cell substrates. Khan AS. **Dev Biol Stand** 1996;88:157–62 (24 ref.)

Role of the blood transfusion service in tissue banking. Warwick RM, et al. **Vox Sang** 1996;71(2):71–7 (42 ref.)

TISSUE COMPATIBILITY see **HISTOCOMPATIBILITY**

TISSUE CULTURE

see related
CELLS, CULTURED
CELLS, IMMOBILIZED
CLONE CELLS
TUMOR CELLS, CULTURED

Human cells and cell cultures: availability, authentication and future prospects. Hay RJ. **Hum Cell** 1996 Sep;9(3):143–52 (41 ref.)

Investigations into mechanisms of amino acid supply to the rat embryo using whole-embryo culture. Beckman DA, et al. **Int J Dev Biol** 1997 Apr;41(2):315–8 (23 ref.)

Effects of excess glucose on mammalian post-implantation embryos. Ellington SK. **Int J Dev Biol** 1997 Apr; 41(2):299–306 (55 ref.)

The use of whole rat embryo cultures to identify and characterize causes of reproductive failure. Klein NW. **Int J Dev Biol** 1997 Apr;41(2):267–73 (32 ref.)

Mouse embryos in culture: models for understanding diabetes-induced embryopathies and gene function. Sadler TW. **Int J Dev Biol** 1997 Apr;41(2):291–7 (65 ref.)

A review of the contribution of whole embryo culture to the determination of hazard and risk in teratogenicity testing. Webster WS, et al. **Int J Dev Biol** 1997 Apr; 41(2):329–35 (68 ref.)

METHODS

Tissue engineering and autologous transplant formation: practical approaches with resorbable biomaterials and new cell culture techniques. Sittinger M, et al. **Biomaterials** 1996 Feb;17(3):237–42 (41 ref.)

Whole hair follicle culture. Philpott MP, et al. **Dermatol Clin** 1996 Oct;14(4):595–607 (69 ref.)

Early chick embryos in vitro. Stern CD, et al. **Int J Dev Biol** 1997 Apr;41(2):379–87 (30 ref.)

Tissue culture of skeletal muscle. Partridge TA. **Methods Mol Biol** 1997;75:131–44 (17 ref.)

TISSUE DONORS

see related
LIVING DONORS

Bone marrow transplantation using unrelated and family related donors: the impact of HLA-C disparity. Nagler A, et al. **Bone Marrow Transplant** 1996 Nov;18(5):891–7 (48 ref.)

What is the better strategy in unrelated bone marrow donor search? Souillet G, et al. **Bone Marrow Transplant** 1996 Nov;18 Suppl 2:75–9 (8 ref.)

What is the merit of an alternative bone marrow transplant? Trigg ME. **Bone Marrow Transplant** 1996 Dec;18 Suppl 3:S28–32 (32 ref.)

Donor criteria and evaluation. Frost AE. **Clin Chest Med** 1997 Jun;18(2):231–7 (22 ref.)

Consensus statement on unrelated donor BMT, 29 & 30 October 1996. Its use in leukaemias and allied disorders. Consensus Panel. **Clin Oncol (R Coll Radiol)** 1997; 9(2):132–3 (0 ref.)

Review of transplantation—1996. Halloran PF, et al. **Clin Transpl** 1996;:291–319 (294 ref.)

Should hepatitis C positive donors be accepted for renal transplantation? Morales JM, et al. **Curr Opin Nephrol Hypertens** 1996 May;5(3):199–201 (40 ref.)

Bone marrow transplantation from unrelated donors. Gajewski J, et al. **Curr Opin Oncol** 1996 Mar;8(2):84–8 (35 ref.)

Allogeneic blood stem cell transplantation: the US experience. Körbling M. **Hematol Cell Ther** 1996 Oct; 38(5):456–7 (11 ref.)

Information access and donated gametes: how much do we know about who wants to know? Broderick P, et al. **Hum Reprod** 1995 Dec;10(12):3338–41 (40 ref.)

Donor corneal tissue evaluation. Saini JS, et al. **Indian J Ophthalmol** 1996 Mar;44(1):3–13 (73 ref.)

Unrelated donor bone marrow transplantation: its use in leukaemias and allied disorders. Consensus statement from the RCPE/Consensus Conference on Unrelated Donor BMT held on 29 and 30 October 1996 [editorial] **J Clin Pathol** 1997 Feb;50(2):91–2 (0 ref.)

Unrelated donor bone marrow transplantation for hematological malignancies-current status. Davies SM, et al. **Leuk Lymphoma** 1996 Oct;23(3–4):221–6 (19 ref.)

Consensus conference on unrelated donor bone marrow transplantation: its use in leukaemias and allied disorders. Royal College of Physicians of Edinburgh, 29 and 30 October 1996 [letter] **Leukemia** 1997 Mar;11(3):451–2 (0 ref.)

Surgical issues in lung transplantation: options, donor selection, graft preservation, and airway healing. Daly RC,

et al. **Mayo Clin Proc** 1997 Jan;72(1):79–84 (24 ref.)
Bone marrow transplantation using unrelated donors for haematological malignancies. Ringdén O. **Med Oncol** 1997 Mar;14(1):11–22 (116 ref.)
Minisymposium. Definition of death, organ donation and interruption of treatment of Islam. Hassaballah AM. **Nephrol Dial Transplant** 1996 Jun;11(6):964–5 (10 ref.)
Bone marrow transplantation from unrelated volunteer donors. An overview [editorial] Busca A, et al. **Panminerva Med** 1997 Jun;39(2):71–7 (26 ref.)
Acquisition and use of DNA-based HLA typing data in bone marrow registries. Hurley CK. **Tissue Antigens** 1997 Apr; 49(4):323–8 (18 ref.)
Changing patterns in organ donation in Eurotransplant, 1990–1994. Cohen B, et al. **Transpl Int** 1997;10(1):1–6 (9 ref.)
Liver graft-transmitted glioblastoma multiforme. A case report and experience with 13 multiorgan donors suffering from primary cerebral neoplasia [see comments] Jonas S, et al. **Transpl Int** 1996;9(4):426–9 (16 ref.) Comment in: Transpl Int 1997;10(1):83–4.
The Bellagio Task Force report on transplantation, bodily integrity, and the International Traffic in Organs. Rothman DJ, et al. **Transplant Proc** 1997 Sep;29(6):2739–45 (38 ref.)
Donor screening: an overview of current regulation and practices in Europe. Tjabbes H. **Transplant Proc** 1996 Oct; 28(5):2950–2 (0 ref.)
Consensus statement from the Consensus Conference on Unrelated-Donor Bone Marrow Transplants—29 and 30 October 1996. Their use in leukaemias and allied disorders. Franklin IM. **Vox Sang** 1997;73(1):52–3 (0 ref.)
Contemporary criteria for cadaveric organ donation in renal transplantation: the need for better selection parameters. Taylor RJ, et al. **World J Urol** 1996;14(4):225–9 (23 ref.)
[Oocyte donation: ethical aspects related to the donor] Englert Y, et al. **Contracept Fertil Sex** 1997 Mar;25(3):251–7 (34 ref.) (Eng. Abstr.) **(Fre)**
[Surgical aspects of chronic kidney failure and transplantation. The donor] **Prog Urol** 1996 Oct;6(5):713–52 (370 ref.) **(Fre)**
[Life support for homeostasis in organ donors] Stocker R, et al. **Schweiz Med Wochenschr** 1997 Jun 14; 127(24):1044–50 (30 ref.) (Eng. Abstr.) **(Ger)**
[Alternatives to liver transplantation] Kupcsulik P. **Orv Hetil** 1996 Oct 20;137(42 Suppl 1):2381–7 (41 ref.) (Eng. Abstr.) **(Hun)**
[Indication of unrelated donor bone marrow transplantation for refractory leukemia] Oh H. **Rinsho Ketsueki** 1996 Aug; 37(8):671–5 (7 ref.) **(Jpn)**
[Bone marrow transplants from unrelated donors] Okamoto S. **Rinsho Ketsueki** 1997 May;38(5):349–54 (19 ref.) **(Jpn)**
[Is there an age limit for cadaveric kidney donors currently?] Cofán Pujol F, et al. **Arch Esp Urol** 1996 Dec; 49(10):1013–20 (61 ref.) (Eng. Abstr.) **(Spa)**

LEGISLATION & JURISPRUDENCE

Conferring a federal property right in genetic material: stepping into the future with the Genetic Privacy Act. Lin MM. **Am J Law Med** 1996;22(1):109–34 (242 ref.)
Organ donation—the role of the media and of public opinion [editorial] Matesanz R, et al. **Nephrol Dial Transplant** 1996 Nov;11(11):2127–8 (10 ref.)
[Organ donation: legal principles, procedures, organization] Gubernatis G. **Internist (Berl)** 1996 Mar;37(3):217–28 (32 ref.) **(Ger)**

PSYCHOLOGY

Organ donors and nondonors. An American dilemma. Peters TG, et al. **Arch Intern Med** 1996 Nov 25;156(21):2419–24 (25 ref.)
Risks and benefits of pediatric bone marrow donation: a critical need for research. Weisz V, et al. **Behav Sci Law** 1996 Autumn;14(4):375–91 (57 ref.)
Psychological aspects of organ donation: a critical review and synthesis of individual and next-of-kin donation decisions. Radecki CM, et al. **Health Psychol** 1997 Mar; 16(2):183–95 (158 ref.)
[Questions on organ donation. An exploratory study of medical students and overview of the literature] Strenge H. **Psychother Psychosom Med Psychol** 1996 Sep–Oct; 46(9–10):327–32 (45 ref.) (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

Validation of large data sets, an essential prerequisite for data analysis: an analytical survey of the Bone Marrow Donors Worldwide. Schipper RF, et al. **Tissue Antigens** 1996 Mar; 47(3):169–78 (10 ref.)
The potential organ donor pool: international figures. Miranda B, et al. **Transplant Proc** 1997 Feb–Mar; 29(1–2):1604–6 (25 ref.)

SUPPLY & DISTRIBUTION

Selection and management of cardiac allograft donors. Novitzky D. **Curr Opin Cardiol** 1996 Mar;11(2):174–82 (51 ref.)
Children and organ donation in the United Kingdom: a literature review. Baxter RC. **J Pediatr Nurs** 1996 Apr; 11(2):136–41 (40 ref.)
Expanding the donor pool. First MR. **Semin Nephrol** 1997 Jul;17(4):373–80 (59 ref.)
The potential organ donor pool: international figures. Miranda B, et al. **Transplant Proc** 1997 Feb–Mar; 29(1–2):1604–6 (25 ref.)
Future trends in the transplantation of hematopoietic cells. Wiktor-Jedrzejczak W. **Transplant Proc** 1996 Dec; 28(6):3423–5 (24 ref.)
[Kidney donation by the elderly—an emergency solution?] Waleczek H, et al. **Chirurg** 1996 Sep;67(9):907–14 (48 ref.) (Eng. Abstr.) **(Ger)**
[Transplantation today] Mühlbacher F. **Radiologe** 1997 Mar; 37(3):191–6 (23 ref.) (Eng. Abstr.) **(Ger)**
[Problems related to organ transplantation as an allocation of scarce medical resources: a review] Hagihara A, et al. **Nippon Eiseigaku Zasshi** 1996 Oct;51(3):648–56 (45 ref.) (Eng. Abstr.) **(Jpn)**

TISSUE EXPANSION

Tissue expansion in the upper extremities. Meland NB, et al. **Hand Clin** 1997 May;13(2):303–14 (24 ref.)

INSTRUMENTATION

Graether pupil expander for managing the small pupil during surgery. Graether JM. **J Cataract Refract Surg** 1996 Jun; 22(5):530–5 (19 ref.)

METHODS

Tissue expansion as an adjunct to reconstruction of congenital and acquired auricular deformities. Chana JS, et al. **Br J Plast Surg** 1997 Sep;50(6):456–62 (11 ref.)
A case of popliteal pterygium treated along with nerve expansion. Maral T, et al. **Plast Reconstr Surg** 1997 Jul; 100(1):91–5 (15 ref.)

TISSUE EXTRACTS

[Transcription regulation by FTZ-F1] Ueda H, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1210–8 (40 ref.) **(Jpn)**

PHARMACOLOGY

[Probiotics and functional food] Shendereov BA, et al. **Antibiot Khimioter** 1997;42(7):30–4 (13 ref.) **(Rus)**

THERAPEUTIC USE

[Neytumorin as biomodular onco-therapy—allegations without documentation] Allewelt MC, et al. **Schweiz Rundsch Med Prax** 1997 Apr 30;86(18):750–61 (110 ref.) (Eng. Abstr.) **(Ger)**

TISSUE FACTOR see **THROMBOPLASTIN**

TISSUE FIXATION

see related
FIXATIVES

TISSUE POLYPEPTIDE ANTIGEN

see related
KERATIN

TISSUE PRESERVATION

METHODS

[Methods of preservation of the human corneas] Delbosc B, et al. **J Fr Ophtalmol** 1997;20(3):221–40 (202 ref.) **(Fre)**

TISSUE PROCUREMENT see **ORGAN PROCUREMENT**

TISSUE STAINS see **DYES**

TISSUE SURVIVAL

Noninvasive evaluation of coronary artery disease and myocardial viability through stress echocardiography and myocardial perfusion imaging. Beattie S, et al. **Nurse Pract** 1997 Aug;22(8):32, 34, 39–40 passim (18 ref.)
[Assessment of coronary artery lesions and myocardial viability by pharmacological stress echocardiography] Senda S, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:615–8 (9 ref.) **(Jpn)**

TISSUE THERAPY

Thymus therapy for cancer? A criteria-based, systematic review [see comments] Ernst E. **Eur J Cancer** 1997 Apr; 33(4):531–5 (29 ref.) Comment in: Eur J Cancer 1997 Apr;33(4):517–8.
Allogenic transplantation of mobilized peripheral blood progenitor cells: towards tailored cell therapy. Dreger P, et al. **Int J Hematol** 1997 Jul;66(1):1–11 (89 ref.)
Cell and gene therapy for inherited deficiency of bilirubin glucuronidation. Kim BH, et al. **J Perinatol** 1996 May–Jun; 16(3 Pt 2):S67–72 (39 ref.)
[Immunocytotherapy. A novel direction in fetal tissue transplantation] Kulakov VI, et al. **Biull Eksp Biol Med** 1994 Apr;117(4):412–5 (22 ref.) **(Rus)**

TISSUE THROMBOPLASTIN see **THROMBOPLASTIN**

TISSUE TRANSPLANTATION

see related
TISSUE DONORS
TISSUE PRESERVATION
TRANSPLANTATION IMMUNOLOGY

Bi-versus multichimerism in colonial urochordates: a hypothesis for links between natural tissue transplantation, allogenetics and evolutionary ecology. Rinkevich B. **Exp Clin Immunogenet** 1996;13(2):61–9 (41 ref.)
Oncological implications in the replacement of ovarian tissue [see comments] Shaw J, et al. **Hum Reprod** 1997 Mar; 12(3):403–5 (16 ref.) Comment in: Hum Reprod 1997 Mar;12(3):403.
Tissue engineering. Pollok JM, et al. **Semin Pediatr Surg** 1996 Aug;5(3):191–6 (34 ref.)
Transplantation of encapsulated cells and tissues. Lanza RP, et al. **Surgery** 1997 Jan;121(1):1–9 (61 ref.)
[Prospects for clinical transplantation of the testis as an organ and as a tissue] Bozhedomov VA, et al. **Biull Eksp Biol Med** 1994 Apr;117(4):400–4 (71 ref.) **(Rus)**

ADVERSE EFFECTS

Risks of transfusion and organ and tissue transplantation: practical concerns that drive practical policies. DeChristopher PJ, et al. **Am J Clin Pathol** 1997 Apr;107(4 Suppl 1):S2–11 (39 ref.)

METHODS

Producing prefabricated tissues and organs via tissue engineering. Martin I, et al. **IEEE Eng Med Biol Mag** 1997 Mar–Apr;16(2):73–80 (45 ref.)
Free tissue transplantation in the 90's. Yim KK, et al. **Int Angiol** 1995 Sep;14(3):327–31 (36 ref.)

PHYSIOLOGY

Approaches to postoperative blood flow monitoring after free tissue transfer. Which is the best? Berger A, et al. **Int Angiol** 1995 Sep;14(3):288–96 (92 ref.)

STANDARDS

Practical issues in tissue banking. Haimowitz MD. **Am J Clin Pathol** 1997 Apr;107(4 Suppl 1):S75–81 (11 ref.)

TISSUE-TYPE PLASMINOGEN ACTIVATOR see **ALTEPLASE**

TISSUE TYPING see **HISTOCOMPATIBILITY TESTING**

TITAN see **SATURN**

TITANIUM

Studies and applications of NiTi shape memory alloys in the medical field in China. Dai K, et al. **Biomed Mater Eng** 1996;6(4):233–40 (40 ref.)
On the nature of the biocompatibility and on medical applications of NiTi shape memory and superelastic alloys. Shabalovskaya SA. **Biomed Mater Eng** 1996;6(4):267–89 (39 ref.)
Titanium-anchored prostheses in otology. Burton MJ, et al. **Otolaryngol Clin North Am** 1996 Apr;29(2):301–10 (32 ref.)
[The value of an electromagnetically formed titanium denture base. The use of an industrial procedure for fabricating a base for a complete removable upper denture] Lemounier-van Hemert F, et al. **Schweiz Monatsschr Zahnmed** 1996;106(10):915–24 (19 ref.) **(Fre, Ger)**
[Elastic plate osteosynthesis, biomechanics, indications and technique in comparison with rigid osteosynthesis] Stürmer KM. **Unfallchirurg** 1996 Nov;99(11):816–29 (57 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Using titanium plate or meshplate for chest wall reconstruction: report of 6 cases and literature review. Luh SP, et al. **Artif Organs** 1996 Dec;20(12):1295–8 (13 ref.)

TLV see **MAXIMUM PERMISSIBLE EXPOSURE LEVEL**

TMJ DISORDERS see **TEMPOROMANDIBULAR JOINT DISORDERS**

TMJ SYNDROME see **TEMPOROMANDIBULAR JOINT DYSFUNCTION SYNDROME**

TN ELEMENTS see **DNA INSERTION ELEMENTS**

TNF-ALPHA see **TUMOR NECROSIS FACTOR**

TNF-BETA see **LYMPHOTOXIN**

TNF RECEPTORS see **RECEPTORS, TUMOR NECROSIS FACTOR**

TNT see **TRINITROTOLUENE**

TOAD, FIRE-BELLIED

TOAD, FIRE-BELLIED see **ANURA**

TOADS AND FROGS see **ANURA**

TOADS, TRUE see **BUFONIDAE**

TOBACCO

see related
NICOTINE
SMOKING
TOBACCO USE DISORDER

European Cancer Experts recommendations for tobacco control. Helsinki Tobacco Consensus Conference. Boyle P. **Ann Oncol** 1997 Jan;8(1):9–13 (18 ref.)

Breaking through the tobacco industry's smoke screen: state lawsuits for reimbursement of medical expenses. Meade KE. **J Leg Med** 1996 Mar;17(1):113–41 (311 ref.)

The merchants, not the customers: resisting the alcohol and tobacco industries' strategy to blame young people for illegal alcohol and tobacco sales. Mosher JF. **J Public Health Policy** 1995;16(4):412–32 (47 ref.)

Cancer risk in relation to radioactivity in tobacco. Kilthau GF. **Radiol Technol** 1996 Jan–Feb;67(3):217–22 (53 ref.)

Power of one: nurses and tobacco control. Gallagher J, et al. **Semin Oncol Nurs** 1996 Nov;12(4):270–5 (14 ref.)

Tobacco and aging: a call for papers for the global coordinated theme issues of 1997 [editorial] Davis RM. **Tob Control** 1996 Winter;5(4):257–8 (18 ref.)

[Alcohol and smoking. The risk factors for the oral cavity] Weinstein RL, et al. **Minerva Stomatol** 1996 Sep; 45(9):405–13 (100 ref.) (Eng. Abstr.) **(Ita)**

[Effects of tobacco advertising regulations in various countries] Sone T. **Nippon Koshu Eisei Zasshi** 1995 Dec; 42(12):1017–28 (56 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

The changing cigarette, 1950–1995. Hoffmann D, et al. **J Toxicol Environ Health** 1997 Mar;50(4):307–64 (176 ref.)

The changing cigarette. Hoffmann D, et al. **Prev Med** 1997 Jul–Aug;26(4):427–34 (57 ref.)

ENZYMOLOGY

The regulation and function of tobacco superoxide dismutases. Van Camp W, et al. **Free Radic Biol Med** 1997; 23(3):515–20 (44 ref.)

[Tobacco PMSAP kinase is transiently activated by wounding] Usami S, et al. **Tanpakushitsu Kakusan Koso** 1997 Apr;42(5):717–26 (28 ref.) **(Jpn)**

GENETICS

Pathogenesis-related functions of plant beta-1,3-glucanases investigated by antisense transformation—a review. Beffa R, et al. **Gene** 1996 Nov 7;179(1):97–103 (50 ref.)

TOBACCO DEPENDENCE see **TOBACCO USE DISORDER**

TOBACCO HORNWORM see **MANDUCA**

TOBACCO INDUSTRY

The tobacco industry's code of advertising in the United States: myth and reality. Richards JW Jr, et al. **Tob Control** 1996 Winter;5(4):295–311 (84 ref.)

LEGISLATION & JURISPRUDENCE

Children and tobacco: the FDA's final rule. Rheinstein PH, et al. **Am Fam Physician** 1997 Mar;55(4):1441–4 (12 ref.)

Controlling tobacco advertising: the FDA regulations and the First Amendment. Glantz LH. **Am J Public Health** 1997 Mar;87(3):446–51 (24 ref.)

TRENDS

Subliminal manipulation of smoking. Frydman M. **J Environ Pathol Toxicol Oncol** 1996;15(2–4):173–6 (8 ref.)

The changing cigarette. Hoffmann D, et al. **Prev Med** 1997 Jul–Aug;26(4):427–34 (57 ref.)

TOBACCO MOSAIC VIRUS

CHEMISTRY

The in vitro biosynthesis of an authentic protein. Zinder ND. **Trends Biochem Sci** 1997 Aug;22(8):318–20 (15 ref.)

TOBACCO SMOKE POLLUTION

Cardiovascular disease and occupational exposure to environmental tobacco smoke. Aviado DM. **Am Ind Hyg Assoc J** 1996 Mar;57(3):285–94 (75 ref.)

A critical examination of OSHA's assessment of risk associated with workplace exposure to environmental tobacco smoke. Rosenbaum WL, et al. **Regul Toxicol Pharmacol** 1996 Jun;23(3):233–40 (29 ref.)

[Passive smoking and lung cancer: a new report in perspective (see comments)] van Barneveld TA, et al. **Ned Tijdschr Geneeskd** 1997 Jan 18;141(3):132–6 (38 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1997 Mar 8;141(10):493–4. **(Dut)**

[Passive smoking and bronchial cancer: a difficult relation to establish] Charloux A, et al. **Rev Pneumol Clin** 1996; 52(4):227–34 (60 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Invited commentary: confounding, measurement error, and publication bias in studies of passive smoking. Kawachi I, et al. **Am J Epidemiol** 1996 Nov 15;144(10):909–15 (57 ref.)

Longitudinal studies of active and passive smoking. Samet JM, et al. **Am J Respir Crit Care Med** 1996 Dec;154(6 Pt 2):S257–65 (77 ref.)

The toxicology of environmental tobacco smoke. Witschi H, et al. **Annu Rev Pharmacol Toxicol** 1997;37:29–52 (107 ref.)

Environmental tobacco smoke and lung cancer: a reappraisal. Nilsson R. **Ecotoxicol Environ Saf** 1996 Jun;34(1):2–17 (115 ref.)

Unfriendly fumes. Clay R. **Environ Health Perspect** 1996 Nov;104(11):1152–7 (0 ref.)

Biomonitoring exposure to environmental tobacco smoke (ETS): a critical reappraisal. Scherer G, et al. **Hum Exp Toxicol** 1997 Aug;16(8):449–59 (119 ref.)

Sudden infant death syndrome and parental smoking—a literature review. Golding J. **Paediatr Perinat Epidemiol** 1997 Jan;11(1):67–77 (29 ref.)

Mortality from tobacco in developed countries: are indirect estimates reliable? Lee PN. **Regul Toxicol Pharmacol** 1996 Aug;24(1 Pt 1):60–8 (25 ref.)

Respiratory health effects of exposure to environmental tobacco smoke. Jinot J, et al. **Rev Environ Health** 1996 Jul–Sep;11(3):89–100 (63 ref.)

Passive smoking, platelet function and atherosclerosis. Kritz H, et al. **Wien Klin Wochenschr** 1996;108(18):582–8 (50 ref.)

["Active" and "passive" smoking of pregnant women and risks to the child] Kaminski M. **Bull Acad Natl Med** 1997 Apr; 181(4):754–63 (52 ref.) **(Fre)**

[Passive smoking and cardiovascular diseases] Thomas D. **Bull Acad Natl Med** 1997 Apr;181(4):743–53 (62 ref.) **(Fre)**

[Passive smoking and carcinogenic risk to the lung] Trédaniel J. **Bull Acad Natl Med** 1997 Apr;181(4):736–42 (18 ref.) **(Fre)**

[Passive smoking, a risk factor for lung carcinoma?] Jahn O. **Wien Klin Wochenschr** 1996;108(18):570–3 (16 ref.) (Eng. Abstr.) **(Ger)**

[Epidemiology of health problems caused by passive smoking] Schwarz B, et al. **Wien Klin Wochenschr** 1996; 108(18):565–9 (48 ref.) (Eng. Abstr.) **(Ger)**

[Molecular biology of tobacco smoke associated neoplasia] Zojer N, et al. **Wien Klin Wochenschr** 1996;108(18):574–81 (79 ref.) (Eng. Abstr.) **(Ger)**

ANALYSIS

Cotinine as a biomarker of environmental tobacco smoke exposure. Benowitz NL. **Epidemiol Rev** 1996;18(2):188–204 (94 ref.)

The changing cigarette, 1950–1995. Hoffmann D, et al. **J Toxicol Environ Health** 1997 Mar;50(4):307–64 (176 ref.)

PREVENTION & CONTROL

Environmental tobacco smoke: health effects and policies to reduce exposure. Brownson RC, et al. **Annu Rev Public Health** 1997;18:163–85 (117 ref.)

TOBACCO, SMOKELESS

ADVERSE EFFECTS

Carcinogenic and genotoxic effects of the tobacco substitute pan masala: present status and likely future impact on the Indian population. Trivedi AH, et al. **Cancer Treat Rev** 1996 Sep;22(5):345–54 (70 ref.)

TOBACCO USE DISORDER

see related
SMOKING CESSATION

Helping your patients to quit smoking. Danis PG, et al. **Am Fam Physician** 1997 Mar;55(4):1207–14, 1217–8 (35 ref.)

Nicotine dependence in women. Fant RV, et al. **J Am Med Womens Assoc** 1996 Jan–Apr;51(1–2):19–20, 22–4, 28 (74 ref.)

Nicotine addiction. Johnson CR, et al. **J Fla Med Assoc** 1996 Feb;83(2):102–7 (56 ref.)

DRUG THERAPY

Current approaches in smoking cessation. Skaar K, et al. **Curr Opin Oncol** 1996 Sep;8(5):434–40 (19 ref.)

ETIOLOGY

Smoking among adolescent girls: prevalence and etiology. French SA, et al. **J Am Med Womens Assoc** 1996 Jan–Apr; 51(1–2):25–8 (35 ref.)

PHYSIOPATHOLOGY

Tobacco addiction and hypertension. Pipe A. **J Hum Hypertens** 1996 Feb;10 Suppl 2:S13–6 (24 ref.)

PSYCHOLOGY

Attention deficit disorder in adults and nicotine dependence: psychobiological factors in resistance to recovery? Coger RW, et al. **J Psychoactive Drugs** 1996 Jul–Sep;28(3):229–40 (56 ref.)

REHABILITATION

Smoking cessation and gender: the influence of physiological, psychological, and behavioral factors. Gritz ER, et al. **J Am Med Womens Assoc** 1996 Jan–Apr;51(1–2):35–42 (86 ref.)

TOBRAMYCIN

ADMINISTRATION & DOSAGE

[Inhalational antibiotic therapy in patients with cystic fibrosis and Pseudomonas infection] Mordasini C, et al. **Schweiz Med Wochenschr** 1997 May 24;127(21):905–10 (46 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

[Tobramycin—clinical pharmacology and chemotherapy] Periti P. **J Chemother** 1996 Jan;8 Suppl 1:3–30 (171 ref.) (Eng. Abstr.) **(Ita)**

THERAPEUTIC USE

[Tobramycin—clinical pharmacology and chemotherapy] Periti P. **J Chemother** 1996 Jan;8 Suppl 1:3–30 (171 ref.) (Eng. Abstr.) **(Ita)**

TOCODYNAMOMETRY see **UTERINE MONITORING**

TOCOGRAPHY see **UTERINE MONITORING**

TOCOLYSIS

Selected issues in premature rupture of the membranes: herpes, cerclage, twins, tocolysis, and hospitalization. Lewis R, et al. **Semin Perinatol** 1996 Oct;20(5):451–61 (76 ref.)

TOCOLYTIC AGENTS

ADVERSE EFFECTS

Ritodrine-induced leukopenia: a case report and literature review. Wu CD, et al. **Chang Keng I Hsueh** 1996 Dec; 19(4):388–91 (7 ref.)

[Maternal complications from tocolytic treatment with beta-mimetics. Three cases of pulmonary edema] Hourdequin P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(5):528–32 (21 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Mechanisms of drugs that affect uterine motility. Sultatos LG. **J Nurse Midwifery** 1997 Jul–Aug;42(4):367–70 (13 ref.)

THERAPEUTIC USE

[Magnesium sulfate in obstetrics: finally recognized! (editorial)] Treisser A. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(2):120–2 (8 ref.) **(Fre)**

[Calcium channel blockers in pregnancy] Tchobroutsky C. **Presse Med** 1996 Sep 28;25(28):1297–300 (28 ref.) (Eng. Abstr.) **(Fre)**

TOCOLYTIC THERAPY see **TOCOLYSIS**

TOCOPHEROL see **VITAMIN E**

TOE JOINT

BLOOD SUPPLY

Vascularized toe joint transfer to the hand. Chen SH, et al. **Plast Reconstr Surg** 1996 Dec;98(7):1275–84 (29 ref.)

INJURIES

Traumatic injuries of the first ray. Blakeslee TJ. **Clin Podiatr Med Surg** 1996 Jul;13(3):549–73 (22 ref.)

Fractures and dislocations of the digits. Daly N. **Clin Podiatr Med Surg** 1996 Apr;13(2):309–26 (29 ref.)

SURGERY

End-to-end arthrodesis with absorbable pin and suture fixation. Giovinco JD. **Clin Podiatr Med Surg** 1996 Apr; 13(2):251–4 (6 ref.)

Correction of crossover second toe deformity. Graziano TA. **Clin Podiatr Med Surg** 1996 Apr;13(2):269–78 (6 ref.)

Clawfoot deformity: an analysis of the causes and surgical treatment using a modification of the Jones suspension procedure. Grumbine NA, et al. **Clin Podiatr Med Surg** 1996 Apr;13(2):221–38 (19 ref.)

Operative procedures for the correction of hammertoe, claw toe, and mallet toe: a literature review. Harmonson JK, et al. **Clin Podiatr Med Surg** 1996 Apr;13(2):211–20 (47 ref.)

A comparison of end-to-end versus "V" arthrodesis procedures for the correction of digital deformities. Kimmel HM, et al. **Clin Podiatr Med Surg** 1996 Apr; 13(2):239-50 (17 ref.)
The combined hammer toe-mallet toe deformity with associated double corns: a retrospective review. Oliver TP, et al. **Clin Podiatr Med Surg** 1996 Apr;13(2):263-8 (9 ref.)
Digital implant arthroplasty. Sgarlato TE, et al. **Clin Podiatr Med Surg** 1996 Apr;13(2):255-62 (12 ref.)

TRANSPLANTATION

Vascularized toe joint transfer to the hand. Chen SH, et al. **Plast Reconstr Surg** 1996 Dec;98(7):1275-84 (29 ref.)

TOES

Metastatic endometrial adenocarcinoma to the skin of a toe. Giardina VN, et al. **Am J Dermatopathol** 1996 Feb; 18(1):94-8 (40 ref.)
Effect of persistent toe walking on ankle equinus. Analysis of 60 idiopathic toe walkers. Sobel E, et al. **J Am Podiatr Med Assoc** 1997 Jan;87(1):17-22 (33 ref.)
Idiopathic multicentric osteolysis principally affecting the phalanges of the hands and feet. Downing ND, et al. **J Hand Surg [Br]** 1996 Oct;21(5):656-9 (16 ref.)

ABNORMALITIES

Heterogeneity in adducted thumbs sequence. Moldavsky M, et al. **Am J Med Genet** 1997 May 16;70(2):114-7 (13 ref.)
Congenital digital deformities. McDaniel L, et al. **Clin Podiatr Med Surg** 1996 Apr;13(2):327-42 (49 ref.)
Hereditary painful callosities with associated features. Cambiaghi S, et al. **Dermatology** 1996;193(1):47-9 (15 ref.)
Femoral hypoplasia-unusual facies syndrome with bifid hallux, absent tibia, and macrophallus: a report of a Bedouin baby. Sabry MA, et al. **J Med Genet** 1996 Feb;33(2):165-7 (9 ref.)
Ectrodactyly, ectodermal dysplasia, and cleft lip syndrome. Case report. Seno H, et al. **Scand J Plast Reconstr Surg Hand Surg** 1996 Sep; 30(3):227-30 (22 ref.)
[Adams-Oliver syndrome] Ishikiriyama S. **Ryoikibetsu Shokogun Shirizu** 1996;(15):234-5 (10 ref.) **(Jpn)**
[The McKusick-Kaufman syndrome: a report of 5 new cases, including a male] Paredes Esteban RM, et al. **An Esp Pediatr** 1996 May;44(5):493-5 (17 ref.) **(Spa)**

INJURIES

Fractures and dislocations of the digits. Daly N. **Clin Podiatr Med Surg** 1996 Apr;13(2):309-26 (29 ref.)

MICROBIOLOGY

Cellulitis secondary to web space dermatophytosis. Day MR, et al. **Clin Podiatr Med Surg** 1996 Oct;13(4):759-66 (19 ref.)

PHYSIOPATHOLOGY

Anatomy, biomechanics, and pathomechanics of lesser digital deformities. Green DR, et al. **Clin Podiatr Med Surg** 1996 Apr;13(2):179-200 (14 ref.)

SURGERY

Laterally closing metatarsal head osteotomy in the correction of a medially overlapping digit. Berens TA. **Clin Podiatr Med Surg** 1996 Apr;13(2):293-307 (7 ref.)
End-to-end arthrodesis with absorbable pin and suture fixation. Giovinco JD. **Clin Podiatr Med Surg** 1996 Apr; 13(2):251-4 (6 ref.)
Displacement osteotomy for the treatment of digital transverse plane deformities. Goforth WP, et al. **Clin Podiatr Med Surg** 1996 Apr;13(2):279-92 (16 ref.)
Correction of crossover second toe deformity. Graziano TA. **Clin Podiatr Med Surg** 1996 Apr;13(2):269-78 (6 ref.)
Clawfoot deformity: an analysis of the causes and surgical treatment using a modification of the Jones suspension procedure. Grumbine NA, et al. **Clin Podiatr Med Surg** 1996 Apr;13(2):221-38 (19 ref.)
Operative procedures for the correction of hammertoe, claw toe, and mallet toe: a literature review. Harmonson JK, et al. **Clin Podiatr Med Surg** 1996 Apr;13(2):211-20 (47 ref.)
Congenital digital deformities. McDaniel L, et al. **Clin Podiatr Med Surg** 1996 Apr;13(2):327-42 (49 ref.)
Digital implant arthroplasty. Sgarlato TE, et al. **Clin Podiatr Med Surg** 1996 Apr;13(2):255-62 (12 ref.)

TRANSPLANTATION

Microvascular reconstruction of the distal digits by partial toe transfer. el-Gammal TA, et al. **Clin Plast Surg** 1997 Jan;24(1):49-55 (36 ref.)

TOLBUTAMIDE

DIAGNOSTIC USE

[Tolbutamide, glucagon, leucine and arginine tolerance test] Hosaka T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:423-7 (10 ref.) **(Jpn)**

TOLMETIN

ANALOGS & DERIVATIVES

Side effects of NSAIDs and dosing recommendations for ketorolac. Camu F, et al. **Acta Anaesthesiol Belg** 1996; 47(3):143-9 (29 ref.)
Analgesic efficacy of ketorolac. Wheatley RG. **Acta Anaesthesiol Belg** 1996;47(3):135-42 (38 ref.)
Transient paraparesis after postdural puncture spinal hematoma in a patient receiving ketorolac. Gerancher JC, et al. **Anesthesiology** 1997 Feb;86(2):490-4 (26 ref.)
Ketorolac for postoperative pain management in children. Forrest JB, et al. **Drug Saf** 1997 May;16(5):309-29 (113 ref.)
Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Gillis JC, et al. **Drugs** 1997 Jan;53(1):139-88 (293 ref.)
Ketorolac continuous infusion: a case report and review of the literature [see comments] Middleton RK, et al. **J Pain Symptom Manage** 1996 Sep;12(3):190-4 (15 ref.) Comment in: J Pain Symptom Manage 1997 Jun;13(6):315-6.
Ketorolac: an alternative for the management of acute pain. Burke SM. **MCN Am J Matern Child Nurs** 1997 Jan-Feb; 22(1):56 (6 ref.)

TOLOSA-HUNT SYNDROME see **OPHTHALMOPLEGIA**

TOLUENE

2-Nitrotoluene, 3-nitrotoluene and 4-nitrotoluene. **IARC Monogr Eval Carcinog Risks Hum** 1996;65:409-35 (68 ref.)
Solvent abuse: a case report and a review. Sarvesvaran R, et al. **Malays J Pathol** 1994 Dec;16(2):167-71 (22 ref.)

ADVERSE EFFECTS

The central nervous system and exposure to toluene: a risk characterization. Greenberg MM. **Environ Res** 1997 Jan; 72(1):1-7 (57 ref.)

BLOOD

Occupational chronic exposure to organic solvents. XVI. Ambient and biological monitoring of workers exposed to toluene. Angerer J, et al. **Int Arch Occup Environ Health** 1997;69(2):91-6 (38 ref.)

POISONING

Myocardial infarction after toluene inhalation. Carder JR, et al. **Pediatr Emerg Care** 1997 Apr;13(2):117-9 (7 ref.)

TOXICITY

Teratogen update: toluene. Wilkins-Haug L. **Teratology** 1997 Feb;55(2):145-51 (45 ref.)

TOLUENESULFONYL COMPOUNDS see **TOSYL COMPOUNDS**

TOLUIDINES

POISONING

Four cases of amitraz poisoning in humans. Kennel O, et al. **Vet Hum Toxicol** 1996 Feb;38(1):28-30 (26 ref.)

TOMATOES

GENETICS

Manipulation of host gene expression by root-knot nematodes. Bird DM. **J Parasitol** 1996 Dec;82(6):881-8 (56 ref.)

MICROBIOLOGY

Molecular and biochemical basis of the interaction between tomato and its fungal pathogen Cladosporium fulvum. de Wit PJ, et al. **Antonie Van Leeuwenhoek** 1997 Feb; 71(1-2):137-41 (27 ref.)

TOMODENSITOMETRY see **TOMOGRAPHY, X-RAY COMPUTED**

TOMOGRAPHY

INSTRUMENTATION

Current approaches to analogue instrumentation design in electrical impedance tomography. Boone KG, et al. **Physiol Meas** 1996 Nov;17(4):229-47 (47 ref.)

METHODS

Factors affecting electrode-gel-skin interface impedance in electrical impedance tomography. McAdams ET, et al. **Med Biol Eng Comput** 1996 Nov;34(6):397-408 (84 ref.)
Imaging of cerebral metastases. Schaefer PW, et al. **Neurosurg Clin N Am** 1996 Jul;7(3):393-423 (132 ref.)
[Gastric emptying study by electrical impedance tomography] Naruse S, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:143-5 (6 ref.) **(Jpn)**

TOMOGRAPHY, COMPUTED, SCANNERS see **TOMOGRAPHY SCANNERS, X-RAY COMPUTED**

TOMOGRAPHY, EMISSION-COMPUTED

see related
GAMMA CAMERAS

Application of PET in dementia disorders. Nordberg A. **Acta Neurol Scand Suppl** 1996;168:71-6 (50 ref.)
The use of positron emission tomography imaging in the management of patients with ischemic cardiomyopathy. Maddahi J, et al. **Adv Card Surg** 1996;7:163-88 (72 ref.)
Signal sources in PET. Herholz K. **Adv Exp Med Biol** 1997; 413:43-51 (44 ref.)
Functional neuroimaging studies in posttraumatic stress disorder. Rauch SL, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:83-98 (49 ref.)
Imaging studies of cocaine in the human brain and studies of the cocaine addict. Volkow ND, et al. **Ann N Y Acad Sci** 1997 May 30;820:41-54; discussion 54-5 (50 ref.)
Possible role of FDG-PET in the evaluation of urologic malignancies. Bender H, et al. **Anticancer Res** 1997 May-Jun;17(3B):1655-60 (28 ref.)
Crossed aphasia. Functional brain imaging with PET or SPECT. Bakar M, et al. **Arch Neurol** 1996 Oct; 53(10):1026-32 (36 ref.)
Positron emission tomography (PET) scanning in breast cancer. Powe JE. **Br J Radiol** 1997 Jul;70(835):668-70 (15 ref.)
A critical review of PET studies of phonological processing. Poeppel D. **Brain Lang** 1996 Dec;55(3):317-51; discussion 352-85 (66 ref.)
Positron emission tomography in cardiovascular disease. Beanlands R. **Can J Cardiol** 1996 Oct;12(10):875-83 (58 ref.)
A review of functional neuroimaging in mood disorders: positron emission tomography and depression. Kennedy SH, et al. **Can J Psychiatry** 1997 Jun;42(5):467-75 (82 ref.)
Positron emission tomography: new hope for early detection of recurrent brain tumors. Garner CM. **Cancer Nurs** 1997 Aug;20(4):277-84 (20 ref.)
PET imaging in soft tissue sarcomas. Miraldi F, et al. **Cancer Treat Res** 1997;91:51-64 (40 ref.)
PET activation and language. Chertkow H, et al. **Clin Neurosci** 1997;4(2):78-86 (69 ref.)
Functional anatomy of object recognition in humans: evidence from positron emission tomography and functional magnetic resonance imaging. Bly BM, et al. **Curr Opin Neurol** 1997 Feb;10(1):5-9 (27 ref.)
The anatomical localization of saccades using functional imaging studies and transcranial magnetic stimulation. Carter N, et al. **Curr Opin Neurol** 1997 Feb;10(1):10-7 (47 ref.)
New aspects of migraine pathophysiology: lessons learned from positron emission tomography [editorial] Diener HC, et al. **Curr Opin Neurol** 1996 Jun;9(3):199-201 (12 ref.)
Metabolic imaging in the diagnosis of brain tumors. Slosman DO, et al. **Curr Opin Neurol** 1996 Dec;9(6):429-35 (46 ref.)
Functional neuroimaging with positron emission tomography. Henry TR. **Epilepsia** 1996 Dec;37(12):1141-54 (124 ref.)
Myocardial viability. Stress echocardiography vs nuclear medicine. Piérard LA, et al. **Eur Heart J** 1997 Jun;18 Suppl D:D117-23 (43 ref.)
Quantification of regional myocardial perfusion by PET: rationale and first clinical results. Schwaiger M, et al. **Eur Heart J** 1995 Oct;16 Suppl J:84-91 (53 ref.)
Stroke: the role of functional imaging. Bakker D, et al. **Eur J Nucl Med** 1997 Jan;24(1):2-5 (42 ref.)
Nuclear medicine techniques for the study of breast cancer. Bombardieri E, et al. **Eur J Nucl Med** 1997 Jul;24(7):809-24 (142 ref.)
Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology? [see comments] Brock CS, et al. **Eur J Nucl Med** 1997 Jun;24(6):691-705 (136 ref.) Comment in: Eur J Nucl Med 1997 Jun;24(6):587-9.
The role of positron emission tomography within the spectrum of medical imaging. Jones T. **Eur J Nucl Med** 1996 Feb;23(2):207-11 (17 ref.)
Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Rigo P, et al. **Eur J Nucl Med** 1996 Dec;23(12):1641-74 (374 ref.)
Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Strauss LG. **Eur J Nucl Med** 1996 Oct;23(10):1409-15 (22 ref.)
Cerebral activity during visual stimulation: a positron emission tomography and functional magnetic resonance imaging study. Schiefer U, et al. **Ger J Ophthalmol** 1996 Mar;5(2):109-17 (63 ref.)
Metabolic imaging using F18-fluorodeoxyglucose to assess myocardial viability. Bax JJ, et al. **Int J Card Imaging** 1997 Apr;13(2):145-55; discussion 157-60 (87 ref.)
Neuroimaging of focal malformations of cortical development. Barkovich AJ, et al. **J Clin Neurophysiol** 1996 Nov;13(6):481-94 (103 ref.)
Neuroimaging and genetic assessment for early diagnosis of Alzheimer's disease. Small GW. **J Clin Psychiatry** 1996;57

Suppl 14:9–13 (41 ref.)
Contributions of positron emission tomography to elucidating the pathogenesis of idiopathic parkinsonism and dopa responsive dystonia. Calne DB, et al. **J Neural Transm Suppl** 1997;50:47–52 (21 ref.)
Positron emission tomography studies of sleep and sleep disorders. Maquet P. **J Neurol** 1997 Apr;244(4 Suppl 1):S23–8 (46 ref.)
Scintigraphic evaluation of cardiac autonomic innervation. Münch G, et al. **J Nucl Cardiol** 1996 May–Jun;3(3):265–77 (89 ref.)
PET evaluation of the dopamine system of the human brain. Volkow ND, et al. **J Nucl Med** 1996 Jul;37(7):1242–56 (254 ref.)
Radiation safety considerations for PET centers. Brown TF, et al. **J Nucl Med Technol** 1997 Jun;25(2):98–102; quiz 104–5 (16 ref.)
Neuropsychological and neuroimaging evidence for the involvement of the frontal lobes in depression. Goodwin GM. **J Psychopharmacol (Oxf)** 1997;11(2):115–22 (85 ref.)
Use of positron emission tomography to study tumors in vivo. Hamberg LM, et al. **Mol Med Today** 1996 Dec;2(12):528–34 (32 ref.)
Clinical use of positron emission tomography in cerebrovascular diseases. Baron JC. **Neurosurg Clin N Am** 1996 Oct;7(4):653–64 (116 ref.)
Basic principles and neurosurgical applications of positron emission tomography. Xiong J, et al. **Neurosurg Clin N Am** 1997 Jul;8(3):293–306 (95 ref.)
Some new methods for the synthesis of cardiac neurotransmission PET radiotracers. Någren K, et al. **Nucl Med Biol** 1995 Nov;22(8):1037–43 (21 ref.)
Radioligands for PET studies of central 5–HT receptors and re–uptake sites—current status. Pike VW. **Nucl Med Biol** 1995 Nov;22(8):1011–8 (38 ref.)
Relevance of PET/SPET tracers for cardiac neurotransmission. Voipio–Pulkki LM. **Nucl Med Biol** 1995 Nov;22(8):1027–35 (68 ref.)
Nuclear medicine imaging of breast cancer [editorial] Van Eijck CH, et al. **Nucl Med Commun** 1996 Nov;17(11):925–7 (17 ref.)
Imaging technologies for radionuclide dosimetry. Ott RJ. **Phys Med Biol** 1996 Oct;41(10):1885–94 (34 ref.)
The AAPM/RSNA physics tutorial for residents. Clinical aspects of emission tomography. Miller TR. **Radiographics** 1996 May;16(3):661–8 (14 ref.)
Advances in pulmonary nuclear medicine. Salvatori M. **Rays** 1997 Jan–Mar;22(1):51–72 (47 ref.) **(Eng, Ita)**
Cerebral blood flow activation and functional lesions in schizophrenia. Taylor SF. **Schizophr Res** 1996 May; 19(2–3):129–40 (42 ref.)
Normal physiological and benign pathological variants of 18–fluoro–2–deoxyglucose positron–emission tomography scanning: potential for error in interpretation. Cook GJ, et al. **Semin Nucl Med** 1996 Oct;26(4):308–14 (12 ref.)
Present assessment of myocardial viability by nuclear imaging. Saha GB, et al. **Semin Nucl Med** 1996 Oct; 26(4):315–35 (117 ref.)
Nuclear medicine techniques in breast imaging. Wahl RL. **Semin Ultrasound CT MR** 1996 Oct;17(5):494–505 (68 ref.)
18F–fluorodeoxyglucose PET scans in lung cancer. Hughes JM. **Thorax** 1996 Aug;51 Suppl 2:S16–22 (34 ref.)
Imaging of atherosclerosis (Part II). Kritz H, et al. **Wien Klin Wochenschr** 1996;108(5):123–32 (98 ref.)
[A study of 36 cases of mitral valve prolapse by isotopic ventricular tomography] Delhomme C, et al. **Arch Mal Coeur Vaiss** 1996 Sep;89(9):1127–35 (30 ref.) (Eng. Abstr.) **(Fre)**
[Contribution of positron emission tomography in the study of wakefulness and sleep. Status of the question] Maquet P. **Neurophysiol Clin** 1995;25(6):342–50 (35 ref.) (Eng. Abstr.) **(Fre)**
[Morphological and functional neuro–imaging of surgical partial epilepsies in adults] Mauguière F, et al. **Rev Neurol (Paris)** 1996 Aug–Sep;152(8–9):501–16 (121 ref.) (Eng. Abstr.) **(Fre)**
[Role of positron emission tomography in the evaluation of new treatments of Parkinson's disease] Remy P, et al. **Rev Neurol (Paris)** 1997 May;153(4):283–5 (17 ref.) **(Fre)**
[Possible uses of positron emission tomography in breast carcinoma] Römer W, et al. **Acta Med Austriaca** 1997; 24(2):60–2 (22 ref.) (Eng. Abstr.) **(Ger)**
[Examination of psychological functions by functional imaging with positron emission tomography and magnetic resonance imaging] Schneider F, et al. **Nervenarzt** 1996 Sep;67(9):721–9 (60 ref.) (Eng. Abstr.) **(Ger)**
[Clinical significance of nuclear medicine in the presurgical diagnosis of epilepsy (editorial)] Grünwald F, et al. **Nuklearmedizin** 1997 Mar;36(2):3–5 (21 ref.) **(Ger)**
[Clinical value of positron emission tomography (PET) in oncologic questions: results of an interdisciplinary consensus conference. Schirmerreschaft der Deutschen Gesellschaft for Nuklearmedizin] Reske SN, et al. **Nuklearmedizin** 1996 Apr;35(2):42–52 (98 ref.) (Eng. Abstr.) **(Ger)**
[Indications for clinical applications of positron emission tomography in cardiology. Position report of the PET Cardiology Study Group of the German Society of Nuclear Medicine and the Nuclear Cardiology Study Circle of the German Society of Cardiology] **Z Kardiol** 1996 Jul; 85(7):453–68 (141 ref.) (Eng. Abstr.) **(Ger)**
[Cerebral positron emission tomographic study in systemic lupus erythematosus] Csépány T, et al. **Orv Hetil** 1997 Aug 3;138(31):1947–52 (46 ref.) (Eng. Abstr.) **(Hun)**
[11C–methionine: an effective radio–tracer for PET scan in the detection of tumors of low proliferating capacity] Trón L, et al. **Orv Hetil** 1997 Aug 24;138(34):2107–12 (44 ref.) (Eng. Abstr.) **(Hun)**
[Positron emission tomography (PET): characteristics and potential applications in clinical oncology] Crippa F, et al. **Radiol Med (Torino)** 1996 Oct;92(4):453–60 (59 ref.) **(Ita)**
[Diagnosis of cancers by FDG–PET] Ichiya Y. **Fukuoka Igaku Zasshi** 1997 Jan;88(1):7–10 (2 ref.) **(Jpn)**
[18F–fluorodeoxyglucose positron emission tomography in Parkinson's disease] Arahata Y, et al. **Nippon Rinsho** 1997 Jan;55(1):222–6 (19 ref.) (Eng. Abstr.) **(Jpn)**
[Muscarinic cholinergic receptor imaging of parkinsonian brain using 11C–NMPB and PET] Asahina M, et al. **Nippon Rinsho** 1997 Jan;55(1):233–7 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Myocardial perfusion assessment with PET] Kinoshita S, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:641–3 (8 ref.) **(Jpn)**
[Assessment of myocardial energy metabolism with PET] Kinoshita S, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:644–7 (13 ref.) **(Jpn)**
[Diagnosis of early cancer with positron emission tomography] Kubota K. **Nippon Rinsho** 1996 May; 54(5):1263–7 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Evaluation of oxidative metabolism in the myocardium] Kudoh T. **Nippon Rinsho** 1997 Mar;55 Suppl 1:648–50 (9 ref.) **(Jpn)**
[Striatal dopamine D2 receptor in Parkinson disease and its related disorders assessed by C–11 NMSP and PET] Momose T, et al. **Nippon Rinsho** 1997 Jan;55(1):227–32 (4 ref.) (Eng. Abstr.) **(Jpn)**
[PET study using 6–[18F]–fluorodopa in Parkinson's disease] Nagasawa H, et al. **Nippon Rinsho** 1997 Jan;55(1):213–7 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Glucose metabolism and blood flow studies in 2 cases with juvenile Parkinson's disease] Shibasaki T. **Nippon Rinsho** 1997 Jan;55(1):95–100 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Evaluation of cerebral blood flow and metabolism using PET scan] Suzuki A. **Nippon Rinsho** 1997 Mar;55 Suppl 1:330–3 (1 ref.) **(Jpn)**
[Cerebral perfusion and oxygen metabolism in Parkinson's disease: positron emission tomographic study using oxygen–15–labeled CO2 and O2] Tanaka M, et al. **Nippon Rinsho** 1997 Jan;55(1):218–21 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Quantitative measurement of the blood flow in the pancreas] Taniguchi H, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:206–9 (14 ref.) **(Jpn)**
[PET study of dopamine metabolism and dopamine D2 receptor in juvenile parkinsonism] Tanji H, et al. **Nippon Rinsho** 1997 Jan;55(1):89–94 (25 ref.) (Eng. Abstr.) **(Jpn)**
[Neurotransmission in human brains measured by positron emission tomography (PET)] Yanai K. **Nippon Yakurigaku Zasshi** 1997 Jun;109(6):259–70 (33 ref.) (Eng. Abstr.) **(Jpn)**
[Clinical application of functional mapping: the present state of the art and its future prospects: (series 8) functional brain mapping using PET] Itoh M, et al. **No Shinkei Geka** 1996 Sep;24(9):779–83 (13 ref.) **(Jpn)**
[Positron emission tomography and single photon CT in the diagnosis of cerebrovascular disorders] Fukuyama H, et al. **Rinsho Shinkeigaku** 1995 Dec;35(12):1578–80 (7 ref.) (Eng. Abstr.) **(Jpn)**
[Neurotransmitter systems in the human brain studied by positron emission tomography] Shinotoh H. **Rinsho Shinkeigaku** 1996 Dec;36(12):1313–5 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Positron emission tomography for assessment of myocardial perfusion and metabolism] Chižyński K. **Pol Tyg Lek** 1996 Mar;51(10–13):182–3 (17 ref.) **(Pol)**
[PET and SPECT in Parkinson's disease] Blesa R. **Rev Neurol** 1997 Aug;25 Suppl 2:S147–50 (43 ref.) (Eng. Abstr.) **(Spa)**
[In vitro and in vivo techniques for the location of the receptors in human brain: methodological basis and general applications] Pazos A. **Rev Neurol** 1997 Jul;25 Suppl 1:S23–7 (16 ref.) **(Spa)**

ECONOMICS

Cost–effectiveness of cardiac positron emission tomography in the treatment of ischemic cardiomyopathy. Schelbert HR. **Am J Card Imaging** 1996 Jul;10(3):191–7 (28 ref.)
Cost–effectiveness of PET imaging in clinical oncology. Valk PE, et al. **Nucl Med Biol** 1996 Aug;23(6):737–43 (23 ref.)

INSTRUMENTATION

The value of quantitative myocardial perfusion imaging with positron emission tomography in coronary artery disease. Wijns W, et al. **Herz** 1997 Apr;22(2):87–95 (58 ref.)
PET imaging using gamma camera systems: a review. Jarritt PH, et al. **Nucl Med Commun** 1996 Sep;17(9):758–66 (13 ref.)
[Positron emission tomography] Haberkorn U, et al. **Med Monatsschr Pharm** 1997 May;20(5):117–25 (31 ref.) **(Ger)**

METHODS

Positron emission tomography and the lung. Hughes JM. **Br J Hosp Med** 1996 Jul 10–Aug 20;56(2–3):86–9 (11 ref.)
Clinical applications of myocardial perfusion assessments made with oxygen–15 water and positron emission tomography. Bergmann SR. **Cardiology** 1997 Jan–Feb; 88(1):71–9 (31 ref.)
Towards absolute quantitation of myocardial blood flow in patients. Bianco JA, et al. **Cardiology** 1997 Jan–Feb; 88(1):52–3 (25 ref.)
Quantitative evaluation of myocardial blood flow with [13N]ammonia. Hutchins GD. **Cardiology** 1997 Jan–Feb; 88(1):106–15 (50 ref.)
Imaging techniques for coronary artery disease: current status and future directions. Merz CN, et al. **Clin Cardiol** 1997 Jun;20(6):526–32 (41 ref.)
PET for diagnosis of malignant lymphoma of the scalp: comparison of [11C]methyl–L–methionine and [18F]fluoro–2–deoxyglucose. Tsuyuguchi N, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):590–3 (16 ref.)
Images of the working brain: understanding human brain function with positron emission tomography. Watson JD. **J Neurosci Methods** 1997 Jun 27;74(2):245–56 (68 ref.)
The contribution of astrocytes to the 18F–2–deoxyglucose signal in PET activation studies. Magistretti PJ, et al. **Mol Psychiatry** 1996 Dec;1(6):445–52 (92 ref.)
Looking into the black box: new directions in neuroimaging. Engel SA. **Neuron** 1996 Sep;17(3):375–8 (25 ref.)
Advances in positron tomography for oncology. Budinger TF, et al. **Nucl Med Biol** 1996 Aug;23(6):659–67 (25 ref.)
Clinical applications of fusion imaging in oncology. Scott AM, et al. **Nucl Med Biol** 1994 Jul;21(5):775–84 (46 ref.)
PET imaging using gamma camera systems: a review. Jarritt PH, et al. **Nucl Med Commun** 1996 Sep;17(9):758–66 (13 ref.)
Targeted radiotherapy using Auger electron emitters. O'Donoghue JA, et al. **Phys Med Biol** 1996 Oct; 41(10):1973–92 (81 ref.)
Interpretation of bone densitometry. Genant HK. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):20S–25S (81 ref.)
PET in oncology: will it replace the other modalities? Hoh CK, et al. **Semin Nucl Med** 1997 Apr;27(2):94–106 (85 ref.)
[Examination of myocardial perfusion with positron emission tomography: a clinically useful and valid method?] vom Dahl J. **Herz** 1997 Feb;22(1):1–15 (117 ref.) (Eng. Abstr.) **(Ger)**

TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON

Clinical nuclear cardiology: flow tracers and free fatty acid analogs to detect viable myocardium after infarction. Franken PR, et al. **Acta Cardiol** 1996;51(6):501–14 (20 ref.)
Risk stratification in coronary artery disease: implications for stabilization and prevention. Berman D, et al. **Am J Cardiol** 1997 Jun 26;79(12B):10–6 (27 ref.)
Myocardial perfusion imaging during adenosine–induced coronary hyperemia. Iskandrian AE, et al. **Am J Cardiol** 1997 Jun 19;79(12A):20–4 (37 ref.)
Role of nuclear cardiology in the evaluation of acute coronary syndromes. Kim SC, et al. **Ann Emerg Med** 1997 Aug;30(2):210–8 (38 ref.)
Functional neuroimaging studies in posttraumatic stress disorder. Rauch SL, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:83–98 (49 ref.)
Interventional brain SPECT—a review. Biersack HJ, et al. **Ann Nucl Med** 1996 Aug;10(3):277–80 (19 ref.)
Crossed aphasia. Functional brain imaging with PET or SPECT. Bakar M, et al. **Arch Neurol** 1996 Oct; 53(10):1026–32 (36 ref.)
Isotope imaging. Ryan PJ, et al. **Baillieres Clin Rheumatol** 1996 Nov;10(4):589–613 (54 ref.)
A review of functional neuroimaging in mood disorders: positron emission tomography and depression. Kennedy SH, et al. **Can J Psychiatry** 1997 Jun;42(5):467–75 (82 ref.)
Bone SPECT imaging of the painful back. Gates GF. **Clin Nucl Med** 1996 Jul;21(7):560–71 (33 ref.)
Metabolic imaging in the diagnosis of brain tumors. Slosman DO, et al. **Curr Opin Neurol** 1996 Dec;9(6):429–35 (46 ref.)
Musicogenic epilepsy: review of the literature and case report with ictal single photon emission computed tomography. Wieser HG, et al. **Epilepsia** 1997 Feb;38(2):200–7 (32 ref.)
Focal brain dysfunction in a 41–year old man with familial alternating hemiplegia. Dangond F, et al. **Eur Arch Psychiatry Clin Neurosci** 1997;247(1):35–41 (37 ref.)
Myocardial viability. Stress echocardiography vs nuclear medicine. Piérard LA, et al. **Eur Heart J** 1997 Jun;18 Suppl D:D117–23 (43 ref.)
Stroke: the role of functional imaging. Bakker D, et al. **Eur J Nucl Med** 1997 Jan;24(1):2–5 (42 ref.)
Nuclear medicine techniques for the study of breast cancer. Bombardieri E, et al. **Eur J Nucl Med** 1997 Jul;24(7):809–24 (142 ref.)
Iodine–123 labelled radiopharmaceuticals and single–photon emission tomography: a natural liaison. Bourguignon MH, et al. **Eur J Nucl Med** 1997 Mar;24(3):331–44 (106 ref.)
Slowly progressive limb–kinetic apraxia. Otsuki M, et al. **Eur Neurol** 1997;37(2):100–3 (17 ref.)

Brain SPECT and stroke prognosis. Alexandrov AV, et al. **Funct Neurol** 1996 Jul-Aug;11(4):167-71, 175-8 (55 ref.)
Metabolic imaging using F18-fluorodeoxyglucose to assess myocardial viability. Bax JJ, et al. **Int J Card Imaging** 1997 Apr;13(2):145-55; discussion 157-60 (87 ref.)
Low back pain and nuclear medicine. Everaert H, et al. **J Belge Radiol** 1997 Jun;80(3):124-7 (15 ref.)
Neuroimaging of focal malformations of cortical development. Barkovich AJ, et al. **J Clin Neurophysiol** 1996 Nov;13(6):481-94 (103 ref.)
rCBF SPECT in Parkinson's disease patients with mental dysfunction. Bissessur S, et al. **J Neural Transm Suppl** 1997; 50:25-30 (38 ref.)
Epidemiological, genetic, pharmacological, kinesiological, nuclear medical (IBZM-SPECT), standard and functional MRI studies on Parkinson's disease and related disorders and economic evaluation of Parkinson's disease therapy--clinical projects in the BMFT-research program Munich: "Parkinson's disease and other basal ganglia disorders". Oertel WH, et al. **J Neural Transm Suppl** 1995; 46:325-37 (40 ref.)
IBZM- and CIT-SPECT of the dopaminergic system in parkinsonism. Tissingh G, et al. **J Neural Transm Suppl** 1997;50:31-7 (38 ref.)
Risk assessment in patients with stable coronary artery disease: incremental value of nuclear imaging. Berman DS, et al. **J Nucl Cardiol** 1996 Nov-Dec;3(6 Pt 2):S41-9 (11 ref.)
Prognostic value of myocardial perfusion imaging: state of the art and new developments. Brown KA. **J Nucl Cardiol** 1996 Nov-Dec;3(6 Pt 1):516-37 (116 ref.)
Detection of coronary artery disease in women with use of stress single-photon emission computed tomography myocardial perfusion imaging. Iskandrian AE, et al. **J Nucl Cardiol** 1997 Jul-Aug;4(4):329-35 (71 ref.)
Absolute quantitation of myocardial blood flow: the technical and clinical prospects for single-photon emission computed tomography. Maddahi J, et al. **J Nucl Cardiol** 1996 Nov-Dec;3(6 Pt 2):S60-5 (36 ref.)
Scintigraphic evaluation of cardiac autonomic innervation. Münch G, et al. **J Nucl Cardiol** 1996 May-Jun;3(3):265-77 (89 ref.)
Fluorine 18-labeled fluorodeoxyglucose myocardial single-photon emission computed tomography: an alternative for determining myocardial viability. Sandler MP, et al. **J Nucl Cardiol** 1996 Jul-Aug;3(4):342-9 (48 ref.)
Understanding Fourier space and filter selection. Zubal IG, et al. **J Nucl Cardiol** 1997 May-Jun;4(3):234-43 (39 ref.)
Neuropsychological and neuroimaging evidence for the involvement of the frontal lobes in depression. Goodwin GM. **J Psychopharmacol (Oxf)** 1997;11(2):115-22 (85 ref.)
Functional brain imaging with cerebral perfusion SPECT in cerebrovascular disease, epilepsy, and trauma. Lewis DH. **Neurosurg Clin N Am** 1997 Jul;8(3):337-44 (72 ref.)
Single photon emission computed tomography brain imaging. Mullan BP, et al. **Neurosurg Clin N Am** 1996 Oct; 7(4):617-51 (214 ref.)
Neuropsychological abnormalities in cocaine abusers: possible correlates in SPECT neuroimaging. Kosten TR, et al. **NIDA Res Monogr** 1996;163:175-92 (40 ref.)
Relevance of PET/SPET tracers for cardiac neurotransmission. Voipio-Pulkki LM. **Nucl Med Biol** 1995 Nov;22(8):1027-35 (68 ref.)
Diagnostic imaging in neuro-oncology. Vezina LG. **Pediatr Clin North Am** 1997 Jun;44(3):701-19 (33 ref.)
Pharmacokinetics of SPECT radiopharmaceuticals for imaging hypoxic tissues. Wiebe LI, et al. **Q J Nucl Med** 1996 Sep;40(3):270-84 (43 ref.)
Cerebral blood flow activation and functional lesions in schizophrenia. Taylor SF. **Schizophr Res** 1996 May; 19(2-3):129-40 (42 ref.)
Technical pitfalls in image acquisition, processing, and display. Forstrom LA, et al. **Semin Nucl Med** 1996 Oct; 26(4):278-94 (44 ref.)
Patient-related pitfalls and artifacts in nuclear medicine imaging. Howarth DM, et al. **Semin Nucl Med** 1996 Oct; 26(4):295-307 (32 ref.)
Instrument- and computer-related problems and artifacts in nuclear medicine. O'Connor MK. **Semin Nucl Med** 1996 Oct;26(4):256-77 (21 ref.)
Present assessment of myocardial viability by nuclear imaging. Saha GB, et al. **Semin Nucl Med** 1996 Oct; 26(4):315-35 (117 ref.)
Nuclear medicine techniques in breast imaging. Wahl RL. **Semin Ultrasound CT MR** 1996 Oct;17(5):494-505 (68 ref.)
Brain single-photon emission CT with HMPAO and safety of thrombolytic therapy in acute ischemic stroke. Proceedings of the meeting of the SPECT Safe Thrombolysis Study Collaborators and the members of the Brain Imaging Council of the Society of Nuclear Medicine. Alexandrov AV, et al. **Stroke** 1997 Sep;28(9):1830-4 (32 ref.)
Imaging of atherosclerosis (Part II). Kritz H, et al. **Wien Klin Wochenschr** 1996;108(5):123-32 (98 ref.)
[Functional imaging] Rascol O, et al. **Neurochirurgie** 1997; 43 Suppl 1:41-51 (0 ref.) **(Fre)**
[Morphological and functional neuro-imaging of surgical partial epilepsies in adults] Mauguière F, et al. **Rev Neurol (Paris)** 1996 Aug-Sep;152(8-9):501-16 (121 ref.) (Eng. Abstr.) **(Fre)**
[Neuroradiologic activation studies of cerebral organization of language capacities. A review of the literature] Ackermann H, et al. **Fortschr Neurol Psychiatr** 1997 Apr; 65(4):182-94 (125 ref.) (Eng. Abstr.) **(Ger)**
[Clinical significance of nuclear medicine in the presurgical diagnosis of epilepsy (editorial)] Grünwald F, et al. **Nuklearmedizin** 1997 Mar;36(2):3-5 (21 ref.) **(Ger)**
[Functional brain imaging with SPECT] Hatazawa J. **Nippon Rinsho** 1997 Mar;55 Suppl 1:334-6 (10 ref.) **(Jpn)**
[Metabolic, adrenergic, and systolic function assessed by cardiac SPECT] Hattori N, et al. **Nippon Rinsho** 1997 Mar; 55 Suppl 1:656-61 (8 ref.) **(Jpn)**
[The use of magnetic resonance imaging (MRI) and single photon emission computing tomography (SPECT) for the differential diagnosis of Parkinson's disease and other neurodegenerative disorders presenting as parkinsonism] Kohira I. **Nippon Rinsho** 1997 Jan;55(1):39-42 (5 ref.) (Eng. Abstr.) **(Jpn)**
[Evaluation of renal function by SPECT] Nakagawa T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:638-41 (7 ref.) **(Jpn)**
[Functional mapping of the brain in a patient before neurological surgery by superposition of activation SPECT and MR images] Otsuki H, et al. **No Shinkei Geka** 1996 Jul;24(7):598-603 (26 ref.) **(Jpn)**
[Positron emission tomography and single photon CT in the diagnosis of cerebrovascular disorders] Fukuyama H, et al. **Rinsho Shinkeigaku** 1995 Dec;35(12):1578-80 (7 ref.) (Eng. Abstr.) **(Jpn)**
[Abnormally distributed regional cerebral blood flow in brain malformations detected by single photon emission computed tomography] Ueda M, et al. **Rinsho Shinkeigaku** 1997 Feb;37(2):99-105 (24 ref.) (Eng. Abstr.) **(Jpn)**
[Neuroimaging and fundamental symptoms in schizophrenia] Lopez-Ibor MI, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 Jan-Feb;24(1):25-8 (30 ref.) (Eng. Abstr.) **(Spa)**
[Single photon emission computer tomography in the differential diagnosis of the paroxysmal clinical events in newborns] Alfonso I, et al. **Rev Neurol** 1996 Nov; 24(135):1408-10 (20 ref.) (Eng. Abstr.) **(Spa)**
[PET and SPECT in Parkinson's disease] Blesa R. **Rev Neurol** 1997 Aug;25 Suppl 2:S147-50 (43 ref.) (Eng. Abstr.) **(Spa)**
[In vitro and in vivo techniques for the location of the receptors in human brain: methodological basis and general applications] Pazos A. **Rev Neurol** 1997 Jul;25 Suppl 1:S23-7 (16 ref.) **(Spa)**
[Intercritical SPECT in drug-resistant partial epilepsy with normal MRI: a study of 33 cases] Vidal JA, et al. **Rev Neurol** 1997 Jan;25(137):48-55 (33 ref.) (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

Physical and subjective evaluation of a three-detector (TRIAD 88) SPECT system. D'Souza MF, et al. **Australas Phys Eng Sci Med** 1995 Dec;18(4):185-96 (49 ref.)
[Tumor imaging in nuclear medicine] Uno K, et al. **Nippon Rinsho** 1996 May;54(5):1268-72 (14 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Pharmacological stress testing with technetium-99m single-photon emission computerized tomography imaging in the preoperative assessment of patients undergoing noncardiac surgery [see comments] Heller GV, et al. **Am J Card Imaging** 1996 Apr;10(2):120-7 (45 ref.) Comment in: Am J Card Imaging 1996 Apr;10(2):117-9.
Imaging of stress injuries to bone. Radiography, scintigraphy, and MR imaging. Deutsch AL, et al. **Clin Sports Med** 1997 Apr;16(2):275-90 (29 ref.)
Contemporary imaging of athletic injuries. Tung GA, et al. **Clin Sports Med** 1997 Jul;16(3):393-417 (46 ref.)
FDG SPECT in the assessment of myocardial viability. Comparison with dobutamine echo. Bax JJ, et al. **Eur Heart J** 1997 Jun;18 Suppl D:D124-9 (39 ref.)
Should the diagnosis of coronary artery disease be based on the evaluation of myocardial function or perfusion? Geleijnse ML, et al. **Eur Heart J** 1997 Jun;18 Suppl D:D68-77 (44 ref.)
Clinical applications of fusion imaging in oncology. Scott AM, et al. **Nucl Med Biol** 1994 Jul;21(5):775-84 (46 ref.)
Cerebral blood flow imaging in paediatrics: a review. Gordon I. **Nucl Med Commun** 1996 Dec;17(12):1021-9 (28 ref.)
Bland-White-Garland syndrome in an adult. Case report and review of diagnostic and predictive strategies. Gunaydin S, et al. **Scand Cardiovasc J** 1997;31(2):105-9 (15 ref.)

STANDARDS

Myocardial single-photon emission computed tomographic quality assurance. Baron JM, et al. **J Nucl Cardiol** 1996 Mar-Apr;3(2):157-66 (33 ref.)

STATISTICS & NUMERICAL DATA

Sensitivity, specificity, and positive predictive value of technetium 99-HMPAO SPECT in discriminating Alzheimer's disease from other dementias. Masterman DL, et al. **J Geriatr Psychiatry Neurol** 1997 Jan;10(1):15-21 (50 ref.)

TOMOGRAPHY, NMR see **MAGNETIC RESONANCE IMAGING**

TOMOGRAPHY, POSITRON-EMISSION see **TOMOGRAPHY, EMISSION-COMPUTED**

TOMOGRAPHY, PROTON SPIN see **MAGNETIC RESONANCE IMAGING**

TOMOGRAPHY, RADIONUCLIDE-COMPUTED see **TOMOGRAPHY, EMISSION-COMPUTED**

TOMOGRAPHY SCANNERS, X-RAY COMPUTED

see related
RADIOGRAPHIC IMAGE ENHANCEMENT

[Spiral X-ray computed tomography: a new modality of scanner imaging] Bonaldi VM, et al. **Presse Med** 1996 Jul 6-13;25(24):1109-14 (18 ref.) (Eng. Abstr.) **(Fre)**

TOMOGRAPHY, SINGLE-PHOTON, EMISSION-COMPUTED see **TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON**

TOMOGRAPHY, TRANSMISSION COMPUTED see **TOMOGRAPHY, X-RAY COMPUTED**

TOMOGRAPHY, ULTRASONIC see **ULTRASONOGRAPHY**

TOMOGRAPHY, X-RAY COMPUTED

Magnetic resonance imaging and computed tomography in Alzheimer's disease. Wahlund LO. **Acta Neurol Scand Suppl** 1996;168:50-3 (47 ref.)
Intracranial chondroma. Brownlee RD, et al. **AJNR Am J Neuroradiol** 1997 May;18(5):889-93 (17 ref.)
Ground-glass opacity at CT: the ABCs. Collins J, et al. **AJR Am J Roentgenol** 1997 Aug;169(2):355-67 (85 ref.)
Virtual colonoscopy: what will the issues be? Fenlon HM, et al. **AJR Am J Roentgenol** 1997 Aug;169(2):453-8 (14 ref.)
Laryngeal involvement in multiple symmetric lipomatosis: the role of computed tomography in diagnosis. Borges A, et al. **Am J Otolaryngol** 1997 Mar-Apr;18(2):127-30 (12 ref.)
Rapid prototyping techniques for anatomical modelling in medicine. McGurk M, et al. **Ann R Coll Surg Engl** 1997 May;79(3):169-74 (29 ref.)
Imaging findings in rabies. Sing TM, et al. **Australas Radiol** 1996 Aug;40(3):338-41 (14 ref.)
CT scans and arthro-CT scans. Drape JL, et al. **Baillieres Clin Rheumatol** 1996 Nov;10(4):615-34 (13 ref.)
Three-dimensional methods for quantification of cancellous bone architecture. Odgaard A. **Bone** 1997 Apr;20(4):315-28 (189 ref.)
Neural arch tuberculosis: radiological features and their correlation with surgical findings. Naim-Ur-Rahman, et al. **Br J Neurosurg** 1997 Feb;11(1):32-8 (7 ref.)
Review article: the quantification of renal function with enhanced computed tomography. Blomley MJ, et al. **Br J Radiol** 1996 Nov;69(827):989-95 (40 ref.)
Approach to the incidentally discovered pituitary mass. Molitch ME. **Cancer Treat Res** 1997;89:73-90 (83 ref.)
CT of pancreatitis with renal and juxtarenal manifestations. Farman J, et al. **Clin Imaging** 1997 May-Jun;21(3):183-8 (9 ref.)
Inter-hemispheric scissure, a rare location for a traumatic subdural hematoma, case report and review of the literature. Rapanà A, et al. **Clin Neurol Neurosurg** 1997 May;99(2):124-9 (65 ref.)
Imaging of calcaneal fractures. Born CT, et al. **Clin Podiatr Med Surg** 1997 Apr;14(2):337-56 (33 ref.)
Computed tomography of malpositioned thoracostomy drains: a pictorial essay. Cameron EW, et al. **Clin Radiol** 1997 Mar;52(3):187-93 (9 ref.)
Small airways disease: expiratory computed tomography comes of age. Desai SR, et al. **Clin Radiol** 1997 May; 52(5):332-7 (6 ref.)
The differential diagnosis of early inferior vena caval opacification on dynamic CT. Naik KS, et al. **Clin Radiol** 1997 Jul;52(7):504-9 (15 ref.)
Subjective pitfalls in HRCT interpretation. Gruden JF, et al. **Crit Rev Diagn Imaging** 1996 Oct;37(5):349-434 (32 ref.)
CT evaluation of the acute abdomen: bowel pathology spectrum of disease. Johnson GL, et al. **Crit Rev Diagn Imaging** 1996 Aug;37(3):163-90 (8 ref.)
Radiographic and computed tomography (CT) imaging of complex pleural disease. Knisely BL, et al. **Crit Rev Diagn Imaging** 1997;38(1):1-58 (122 ref.)
The leaking esophagus: CT patterns of esophageal rupture, perforation, and fistulization. Lee S, et al. **Crit Rev Diagn Imaging** 1996 Dec;37(6):461-90 (10 ref.)
Computed tomographic evaluation of laryngotracheal trauma. Lupetin AR. **Curr Probl Diagn Radiol** 1997 Jul-Aug;26(4):185-206 (38 ref.)
CT of pancreatic neoplasms. Part I: Adenocarcinoma. Stephens DH. **Curr Probl Diagn Radiol** 1997 Mar-Apr; 26(2):59-80 (45 ref.)
CT of pancreatic neoplasms. Part II: The unusual tumors. Stephens DH. **Curr Probl Diagn Radiol** 1997 Mar-Apr;

26(2):81–106 (113 ref.)
Ventilation–perfusion lung scanning and spiral computed tomography of the lungs: competing or complementary modalities? Robinson PJ. **Eur J Nucl Med** 1996 Nov; 23(11):1547–53 (55 ref.)
Lung cancer staging: the role of computed tomography and magnetic resonance imaging. Bonomo L, et al. **Eur J Radiol** 1996 Aug;23(1):35–45 (48 ref.)
Computed tomography of the rectosigmoid region. Dixon AK. **Eur J Radiol** 1996 May;22(2):107–15 (39 ref.)
Computed tomography of the gastro–duodenal region. Small JH, et al. **Eur J Radiol** 1996 May;22(2):95–103 (39 ref.)
Survey of CT and MR imaging of the orbit. Weber AL, et al. **Eur J Radiol** 1996 Mar;22(1):42–52 (28 ref.)
Imaging of primary small intestinal tumours by enteroclysis and CT with pathological correlation. Gourtsoyiannis N, et al. **Eur Radiol** 1997;7(5):625–42 (50 ref.)
Quantitative computed tomography at the axial and peripheral skeleton. Guglielmi G, et al. **Eur Radiol** 1997; 7 Suppl 2:S32–42 (91 ref.)
Spontaneous rupture of a hepatic angiomyolipoma: CT findings and literature review. Guidi G, et al. **Eur Radiol** 1997;7(3):335–7 (32 ref.)
High–resolution computed tomography in chronic infiltrative lung disease. Hansell DM. **Eur Radiol** 1996;6(6):796–800 (44 ref.)
Aneurysms of proximal pulmonary arteries: CT diagnosis and preoperative assessment. Iula G, et al. **Eur Radiol** 1996; 6(5):730–3 (16 ref.)
State–of–the–art CT and MRI of the adrenal gland. Peppercorn PD, et al. **Eur Radiol** 1997;7(6):822–36 (117 ref.)
Computed tomography of the airways. Worthy SA, et al. **Eur Radiol** 1996;6(5):717–29 (98 ref.)
Computed tomographic colography and virtual colonoscopy. Ahlquist DA, et al. **Gastrointest Endosc Clin N Am** 1997 Jul;7(3):439–52 (47 ref.)
Recent developments in biliary tract imaging. Gillams AR, et al. **Gastrointest Endosc Clin N Am** 1996 Jan;6(1):1–15 (37 ref.)
Conventional and CT angiographic diagnosis of Takayasu arteritis. Park JH. **Int J Cardiol** 1997 Aug;54 Suppl:S165–71 (11 ref.)
Clinical applications of fast CT scanning in cardiology. Shemesh J, et al. **Isr J Med Sci** 1997 Mar;33(3):214–21 (56 ref.)
Cerebral infarction as multifocal clonic seizures in a term neonate. Balcom TA, et al. **J Am Board Fam Pract** 1997 Jan–Feb;10(1):43–9 (42 ref.)
Adolescent schizophrenia: a methodologic review of the current neuroimaging and neuropsychologic literature. Findling RL, et al. **J Autism Dev Disord** 1995 Dec; 25(6):627–39 (39 ref.)
Nasal and paranasal sinus imaging. Benson ML, et al. **J Belge Radiol** 1997 Apr;80(2):89–91 (19 ref.)
Neuroimaging of focal malformations of cortical development. Barkovich AJ, et al. **J Clin Neurophysiol** 1996 Nov;13(6):481–94 (103 ref.)
Ossification of a rectal tumor: CT evaluation. Beauchamp NJ, et al. **J Comput Assist Tomogr** 1997 Jul–Aug; 21(4):671–3 (8 ref.)
Case report. Aortic pseudoaneurysm with aortobronchial fistula: diagnosis with CT angiography. Ferretti GR, et al. **J Comput Assist Tomogr** 1996 Nov–Dec;20(6):975–8 (8 ref.)
Case report. Pulmonary involvement in Niemann–Pick disease subtype B: CT findings. Ferretti GR, et al. **J Comput Assist Tomogr** 1996 Nov–Dec;20(6):990–2 (9 ref.)
Intracranial developmental venous anomalies: diagnosis using CT angiography. Peebles TR, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):582–6 (11 ref.)
CT patterns of nodular hepatic and splenic sarcoidosis: a review of the literature. Scott GC, et al. **J Comput Assist Tomogr** 1997 May–Jun;21(3):369–72 (11 ref.)
CT demonstration of an unusual aspect of the thyroid gland. Sigal R, et al. **J Comput Assist Tomogr** 1997 Jul–Aug; 21(4):594 (5 ref.)
Bone density measurement—a systematic review. A report from SBU, the Swedish Council on Technology Assessment in Health Care. **J Intern Med Suppl** 1997; 739:1–60 (148 ref.)
CT and MRI of stroke. Bahn MM, et al. **J Magn Reson Imaging** 1996 Sep–Oct;6(5):833–45 (88 ref.)
Imaging of pelvic trauma: the role of CT with multiplanar and three–dimensional reconstruction. Noh HM, et al. **J South Orthop Assoc** 1996 Summer;5(2):111–25 (38 ref.)
Rounded atelectasis. Batra P, et al. **J Thorac Imaging** 1996 Summer;11(3):187–97 (34 ref.)
CT evaluation of fibrosing alveolitis—applications and insights. Hansell DM, et al. **J Thorac Imaging** 1996 Fall; 11(4):231–49 (129 ref.)
Imaging evaluation of obstructive atelectasis. Molina PL, et al. **J Thorac Imaging** 1996 Summer;11(3):176–86 (49 ref.)
CT appearance of interstitial pulmonary emphysema. Satoh K, et al. **J Thorac Imaging** 1996 Spring;11(2):153–4 (8 ref.)
Detection and staging of renal cancer. Choyke PL. **Magn Reson Imaging Clin N Am** 1997 Feb;5(1):29–47 (50 ref.)
The kidney: radiologic–pathologic correlation. Wagner BJ. **Magn Reson Imaging Clin N Am** 1997 Feb;5(1):13–28 (42 ref.)
Assessment of the severity of pulmonary emphysema by computed tomography. Zompatori M, et al. **Monaldi Arch Chest Dis** 1997 Apr;52(2):147–54 (56 ref.)
Imaging of small airways disease, with emphasis on high resolution computed tomography. Zompatori M, et al. **Monaldi Arch Chest Dis** 1997 Jun;52(3):242–8 (47 ref.)
Pediatric orbital and visual pathway lesions. Barnes PD, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):179–98 (86 ref.)
Vascular lesions in the orbit. Forbes G. **Neuroimaging Clin N Am** 1996 Feb;6(1):113–22 (22 ref.)
Normal computed tomography and magnetic resonance imaging anatomy of the globe, orbit, and visual pathways. Hesselink JR, et al. **Neuroimaging Clin N Am** 1996 Feb; 6(1):15–27 (16 ref.)
Clinical signs and symptoms requiring computed tomography and magnetic resonance imaging evaluation. Levin LA. **Neuroimaging Clin N Am** 1996 Feb;6(1):1–14 (38 ref.)
Radiologic assessment of trauma and foreign bodies of the eye and orbit. Lustrin ES, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):219–37 (40 ref.)
Computed tomography angiography. Marks MP. **Neuroimaging Clin N Am** 1996 Nov;6(4):899–909 (22 ref.)
Surgical methods and approaches in the treatment of orbital disease. Rubin PA, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):239–55 (68 ref.)
The role of computed tomographic angiography in the assessment of intracranial vascular disease. Tampieri D, et al. **Neuroimaging Clin N Am** 1996 Aug;6(3):759–67 (14 ref.)
Benign and malignant tumors of the orbital cavity including the lacrimal gland. Warner MA, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):123–42 (109 ref.)
Imaging evaluation of the optic nerve and visual pathway including cranial nerves affecting the visual pathway. Weber AL, et al. **Neuroimaging Clin N Am** 1996 Feb; 6(1):143–77 (162 ref.)
Normal anatomy and lesions of the lacrimal sac and duct: evaluated by dacryocystography, computed tomography, and MR imaging. Weber AL, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):199–217 (122 ref.)
Graves' disease of the orbit. Weber AL, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):61–72 (34 ref.)
Pseudotumor of the orbit. Weber AL, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):73–92 (71 ref.)
Lymphoproliferative disease of the orbit. Weber AL, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):93–111 (51 ref.)
A false traumatic giant aneurysm of the supraclinoid carotid artery. A case report and review of the literature. Baskaya MK, et al. **Neurol Res** 1996 Apr;18(2):135–9 (29 ref.)
MR imaging and CT of pituitary abscess: case report and review. Kabuto M, et al. **Neurol Res** 1996 Dec;18(6):495–8 (22 ref.)
Prognostic value of complete response after the initial treatment for malignant astrocytoma. Kayama T, et al. **Neurol Res** 1996 Aug;18(4):321–4 (16 ref.)
Epidural lipomatosis: case report and literature review. Hierholzer J, et al. **Neuroradiology** 1996 May;38(4):343–8 (25 ref.)
Automated percutaneous nucleotomy: restricted indications based on CT scan appearance. Castro WH, et al. **Neurosurg Clin N Am** 1996 Jan;7(1):43–7 (24 ref.)
Occipital condyle fractures. Tuli S, et al. **Neurosurgery** 1997 Aug;41(2):368–76; discussion 376–7 (42 ref.)
A general concept of spiral volumetric CT and a newly developed, post–processing method designated as CT–endoscopy. Kobayashi H. **Nippon Ika Daigaku Zasshi** 1996 Feb;63(1):9–21 (23 ref.)
Anatomic variation in pediatric chronic sinusitis: a CT study. Lusk RP, et al. **Otolaryngol Clin North Am** 1996 Feb; 29(1):75–91 (25 ref.)
Imaging of laryngeal cancer. Williams DW 3rd. **Otolaryngol Clin North Am** 1997 Feb;30(1):35–58 (51 ref.)
Imaging of paranasal sinus disease. Bangert BA. **Pediatr Clin North Am** 1997 Jun;44(3):681–99 (55 ref.)
Bone marrow transplantation in children. Imaging assessment of complications. Benya EC, et al. **Pediatr Clin North Am** 1997 Jun;44(3):741–61 (30 ref.)
Imaging of developmental dysplasia of the hip. Donaldson JS, et al. **Pediatr Clin North Am** 1997 Jun;44(3):591–614 (35 ref.)
Diagnostic imaging in pediatric AIDS. Haller JO, et al. **Pediatr Clin North Am** 1997 Jun;44(3):721–40 (64 ref.)
Imaging the child with a limp. Myers MT, et al. **Pediatr Clin North Am** 1997 Jun;44(3):637–58 (30 ref.)
Imaging of child abuse. Nimkin K, et al. **Pediatr Clin North Am** 1997 Jun;44(3):615–35 (47 ref.)
Diagnostic imaging in neuro–oncology. Vezina LG. **Pediatr Clin North Am** 1997 Jun;44(3):701–19 (33 ref.)
A serial CT scan and MRI verification of diffuse cerebrospinal gliomatosis: a case report with stereotactic diagnosis and radiological confirmation. Onal C, et al. **Pediatr Neurosurg** 1996 Aug;25(2):94–9 (50 ref.)
Neuroimaging of pediatric brain stem diseases other than brain stem glioma. Zimmerman RA. **Pediatr Neurosurg** 1996 Aug;25(2):83–92 (11 ref.)
X–ray microtomography of bones and teeth. Davis GR, et al. **Physiol Meas** 1996 Aug;17(3):121–46 (59 ref.)
Germinoma arising in the basal ganglia in early stage: CT and MR findings. Yamana D, et al. **Radiat Med** 1995 Nov–Dec;13(6):305–8 (30 ref.)
CT of the stomach: spectrum of disease. Fishman EK, et al. **Radiographics** 1996 Sep;16(5):1035–54 (57 ref.)
Blood flow and liver imaging. Itai Y, et al. **Radiology** 1997 Feb;202(2):306–14 (80 ref.)
High resolution computed tomography (HRCT) and new perspectives in functional radiology of the lung. Sallustio G, et al. **Rays** 1997 Jan–Mar;22(1):157–82 (41 ref.) **(Eng, Ita)**
Incisional herniation of the bladder: CT findings. Catalano O. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Nov;165(5):508–9 (8 ref.)
CT findings in ischaemic hepatic failure due to intra–arterial embolisation: a case report. Catalano O. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Jan;166(1):81–3 (18 ref.)
Contralateral adrenal metastasis in renal cell cancer. Dieckmann KP, et al. **Scand J Urol Nephrol** 1996 Apr; 30(2):139–43 (34 ref.)
Incidentally detected renal angiomyolipoma with tumour thrombus into the inferior vena cava. Rubio–Briones J, et al. **Scand J Urol Nephrol** 1997 Apr;31(2):189–91 (14 ref.)
VBR in schizophrenia: relationship to family history of psychosis and season of birth [published erratum appears in Schizophr Res 1997 May 24;25(2):167] DeQuardo JR, et al. **Schizophr Res** 1996 Jul 5;20(3):275–85 (60 ref.)
Computed tomography of the bile ducts. Baron RL. **Semin Roentgenol** 1997 Jul;32(3):172–87 (33 ref.)
Spontaneous intracranial hemorrhage: which patients need diagnostic cerebral angiography? A prospective study of 206 cases and review of the literature. Zhu XL, et al. **Stroke** 1997 Jul;28(7):1406–9 (27 ref.)
Imaging approach to staging of renal cell carcinoma. Bechtold RE, et al. **Urol Clin North Am** 1997 Aug; 24(3):507–22 (60 ref.)
[Rhabdoid tumor of the central nervous system. Ultrasonographic, computed tomographic and MRI aspects apropos of a case in an infant] Guessoum M, et al. **J Neuroradiol** 1997 Jun;24(1):60–4 (16 ref.) (Eng. Abstr.) **(Fre)**
[Parameters influencing hepatic parenchyma enhancement in x–ray computed tomography after intravenous injection of iodinated contrast medium] Bonaldi VM, et al. **J Radiol** 1997 Apr;78(4):265–70 (39 ref.) (Eng. Abstr.) **(Fre)**
[Tomographic study of the intra–abdominal digestive tract. Contributions of percutaneous echography and scanner in daily practice] Coche G, et al. **J Radiol** 1996 Sep; 77(9):611–36 (45 ref.) (Eng. Abstr.) **(Fre)**
[Imaging of osteoarticular diseases of the anterior chest wall] Grignon B, et al. **J Radiol** 1997 Feb;78(2):103–10 (31 ref.) (Eng. Abstr.) **(Fre)**
[Digestive tract imaging: what's new in 1996?] Legmann P. **J Radiol** 1996 Sep;77(9):679–82 (30 ref.) **(Fre)**
[Renal varices. X–ray computed tomographic diagnosis and treatment by embolization] Lenoir S, et al. **J Radiol** 1997 Jan;78(1):69–72 (13 ref.) (Eng. Abstr.) **(Fre)**
[Imaging of peritoneal mesotheliomas] Lewin M, et al. **J Radiol** 1996 Sep;77(9):649–56 (39 ref.) (Eng. Abstr.) **(Fre)**
[Retroperitoneal leiomyosarcoma: case report and literature review] Baraké H, et al. **Rev Med Brux** 1996 Dec; 17(6):384–8 (19 ref.) (Eng. Abstr.) **(Fre)**
[Radiologic diagnosis of hypophyseal adenomas] Brechtelsbauer D, et al. **Aktuelle Radiol** 1996 Nov; 6(6):301–7 (38 ref.) (Eng. Abstr.) **(Ger)**
[Injuries of the spine: current concepts in radiologic diagnosis] du Mesnil de Rochemont R, et al. **Aktuelle Radiol** 1997 Jan;7(1):1–13 (51 ref.) (Eng. Abstr.) **(Ger)**
[Imaging methods in traumatology of the shoulder– and elbow joint] Heyer D. **Aktuelle Radiol** 1996 Sep;6(5):225–31 (50 ref.) (Eng. Abstr.) **(Ger)**
[Intravascular lymphomatosis of the nervous system—case report and review of the literature] Heesen C, et al. **Fortschr Neurol Psychiatr** 1996 Jun;64(6):234–41 (104 ref.) (Eng. Abstr.) **(Ger)**
[Rare differential diagnosis of free intra–abdominal air. Pneumatosis cystoides intestinalis] Scheulen B, et al. **Internist (Berl)** 1996 Dec;37(12):1260–4 (14 ref.) **(Ger)**
[Risks and therapy options in dural arteriovenous fistulas between branches of the external carotid artery and the cavernous sinus. A case report and review of the literature] Thumann G, et al. **Klin Monatsbl Augenheilkd** 1996 Dec; 209(6):aA10–3 (31 ref.) (Eng. Abstr.) **(Ger)**
[Imaging of the labyrinth and vestibular nerve. Clinical significance for differential diagnosis of vestibular diseases] Jäger L, et al. **Nervenarzt** 1997 Jun;68(6):443–58 (42 ref.) (Eng. Abstr.) **(Ger)**
[Value of computerized tomography and magnetic resonance tomography in psychiatric diagnosis] Schlegel S, et al. **Nervenarzt** 1997 Jan;68(1):1–10 (95 ref.) (Eng. Abstr.) **(Ger)**
[Tracheobronchomegaly—Mounier–Kuhn syndrome—case report and review of the literature] Wiesner B, et al. **Pneumologie** 1997 Mar;51(3):291–5 (31 ref.) (Eng. Abstr.) **(Ger)**
[Pleural and pulmonary changes within the scope of rheumatoid arthritis] Bankier AA, et al. **Radiologe** 1996 Aug;36(8):637–45 (61 ref.) (Eng. Abstr.) **(Ger)**
[Malignant lymphoma. Diagnosis and after–care in adults with special reference to cross–sectional imaging] Brado M, et al. **Radiologe** 1997 Jan;37(1):10–8 (42 ref.) (Eng. Abstr.) **(Ger)**
[Primary malignant lymphoma of the brain] Hartmann M, et al. **Radiologe** 1997 Jan;37(1):42–50 (26 ref.) (Eng. Abstr.)

(Ger)
[Calcium in the lung or: it might not always be tuberculosis] Henk CB, et al. **Radiologe** 1996 Jul;36(7):534–42 (37 ref.) (Eng. Abstr.) (Ger)
[Pericardium—radiologic diagnosis] Kopsa W, et al. **Radiologe** 1997 May;37(5):378–87 (28 ref.) (Eng. Abstr.) (Ger)
[Rare intracranial plasmacytoma manifestations. Case reports and review of the literature in diffuse plasmocytoma, in primary solitary extramedullary plasmacytoma in in primary solitary osseous plasmacytoma] Kujat C, et al. **Radiologe** 1996 Nov;36(11):914–20 (42 ref.) (Eng. Abstr.) (Ger)
[Roentgen diagnosis and computerized tomography in inflammatory rheumatic diseases. Methods with a future?] Lingg G. **Radiologe** 1996 Aug;36(8):600–8 (21 ref.) (Eng. Abstr.) (Ger)
[Radiologic diagnosis of primary extranodal lymphoma manifestations] Malms J, et al. **Radiologe** 1997 Jan; 37(1):27–34 (28 ref.) (Eng. Abstr.) (Ger)
[Lymphoma in childhood] Wunsch C, et al. **Radiologe** 1997 Jan;37(1):51–61 (48 ref.) (Eng. Abstr.) (Ger)
[Bronchogenic cyst. A rare benign esophageal tumor] Zaunbauer W, et al. **Radiologe** 1996 Dec;36(12):991–5 (13 ref.) (Eng. Abstr.) (Ger)
[The computed tomographic findings on the lumbar spine in systemic mastocytosis] Lugmayr H, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Feb;166(2):162–3 (7 ref.) (Ger)
[Traumatic paresis of the n. facialis and n. cochlearis: its comparative imaging in MRT and CT] Mack MG, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Feb;166(2):170–2 (7 ref.) (Ger)
[Metastatic pulmonary calcification as a rare complication of terminal kidney failure: the x-ray and CT findings] Reuter M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Nov;165(5):493–5 (13 ref.) (Ger)
[The computed tomographic picture of deep gallstone ileus] Rieger J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Feb;166(2):164–6 (10 ref.) (Ger)
[The algorithm of imaging diagnostics of pulmonary embolism: is it time for a new definition?] Roberts HC, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Jun;166(6):463–74 (84 ref.) (Eng. Abstr.) (Ger)
[The computed tomographic finding of sigmoid-rectal invagination and the radiological-macropathological correlation] Rodekohr S, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Jan;166(1):78–80 (10 ref.) (Ger)
[The computed tomographic demonstration of duodenal perforation caused by a fish bone] Völk M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Aug;167(2):198–200 (10 ref.) (Ger)
[Roentgen morphology of pulmonary sarcoidosis] Hald HJ. **Rontgenpraxis** 1996 Aug;49(8):201–6 (38 ref.) (Ger)
[Periarticular fractures—what should be observed?] Hald HJ. **Rontgenpraxis** 1997 Jun;50(6):158–67 (41 ref.) (Ger)
[Possibilities of abdominal tumor volumetry] Helmberger H, et al. **Rontgenpraxis** 1997 Jan;50(1):11–7 (55 ref.) (Ger)
[Modern imaging methods in diagnosis of tumors of the oropharynx and mouth cavity] Lenz M. **Rontgenpraxis** 1996 Nov;49(11):286–96 (28 ref.) (Ger)
[Clinical aspects and therapy of degenerative joint diseases] Puhl W, et al. **Rontgenpraxis** 1997 Jun;50(6):142–9 (87 ref.) (Ger)
[Radiology and geriatrics: limits between normal values and pathology exemplified by conventional thoracic roentgen image, cerebral CT and MRI and pelvic-leg angiography] Osterheider MA. **Z Gerontol Geriatr** 1997 May–Jun; 30(3):226–34 (17 ref.) (Eng. Abstr.) (Ger)
[Imaging of interstitial pulmonary diseases] Sato M. **Nippon Ika Daigaku Zasshi** 1996 Oct;63(5):400–3 (0 ref.) (Jpn)
[Lung cancer: Progress in diagnosis and treatment. II. Diagnostic imaging: 3. Thoracic CT and MRI] Kusumoto M, et al. **Nippon Naika Gakkai Zasshi** 1997 Jan 10; 86(1):51–7 (7 ref.) (Jpn)
[Obstructive jaundice: progress in instrument used for diagnosis. 5) CT and MRI] Moriyama N, et al. **Nippon Naika Gakkai Zasshi** 1997 Apr 10;86(4):608–14 (4 ref.) (Jpn)
[Cardiac function using ultrafast computed tomography] Aizawa N, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:623–6 (4 ref.) (Jpn)
[Evaluation of pulmonary function by expiratory CT using helical CT] Eda S, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:45–7 (6 ref.) (Jpn)
[Drip infusion cholangiography combined helical computed tomography] Ishihara K, et al. **Nippon Rinsho** 1997 Apr; 55 Suppl 2:180–2 (8 ref.) (Jpn)
[Estimation of cardiac function by helical CT] Itani Y, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:627–9 (7 ref.) (Jpn)
[Evaluation of adrenal medullary function with CT scanning] Nakai T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:376–9 (12 ref.) (Jpn)
[An evaluation of the heart by enhanced CT] Watanabe S, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:619–22 (3 ref.) (Jpn)
[Evaluation of hepatic hemodynamics on CT] Yoshie K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:169–72 (13 ref.) (Jpn)
[Natural course of non-operative cases of acute subdural hematoma: sequential computed tomographic study in the acute and subacute stages] Izumihara A, et al. **No Shinkei Geka** 1997 Apr;25(4):307–14 (21 ref.) (Eng. Abstr.) (Jpn)
[CT and MRI: what you see and don't see] Okuda S. **Rinsho Shinkeigaku** 1995 Dec;35(12):1564–6 (10 ref.) (Eng. Abstr.) (Jpn)
[Potentialities of present day computed tomography in diagnosis of stomach cancer] Portnoĭ LM, et al. **Vestn Rentgenol Radiol** 1997 May–Jun;(3):7–14 (23 ref.) (Eng. Abstr.) (Rus)
[Neuroimaging and fundamental symptoms in schizophrenia] Lopez-Ibor MI, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 Jan–Feb;24(1):25–8 (30 ref.) (Eng. Abstr.) (Spa)
[Computerized tomography in aortic pathology] Lecumberri Olaverri F, et al. **Rev Esp Cardiol** 1996;49 Suppl 4:27–36 (54 ref.) (Eng. Abstr.) (Spa)
[Single photon emission computer tomography in the differential diagnosis of the paroxysmal clinical events in newborns] Alfonso I, et al. **Rev Neurol** 1996 Nov; 24(135):1408–10 (20 ref.) (Eng. Abstr.) (Spa)
[Diagnosis by imaging of the brain affected by AIDS] Mercader-Sobrequés JM, et al. **Rev Neurol** 1996 Dec; 24(136):1577–89 (43 ref.) (Eng. Abstr.) (Spa)

INSTRUMENTATION

Spiral CT of pulmonary embolism: technical considerations and interpretive pitfalls. Remy-Jardin M, et al. **J Thorac Imaging** 1997 Apr;12(2):103–17 (41 ref.)
Spiral CT of pulmonary hypertension and chronic thromboembolism. Roberts HC, et al. **J Thorac Imaging** 1997 Apr;12(2):118–27 (69 ref.)
Helical CT angiography of the thoracic aorta. Rubin GD. **J Thorac Imaging** 1997 Apr;12(2):128–49 (38 ref.)
X-ray computed microtomography (microCT) using synchrotron radiation (SR). Bonse U, et al. **Prog Biophys Mol Biol** 1996;65(1–2):133–69 (122 ref.)
[Computer-assisted orthopedic surgery. From pedicle screw insertion to further applications] Berlemann U, et al. **Orthopade** 1997 May;26(5):463–9 (34 ref.) (Eng. Abstr.) (Ger)
[CT-guided puncture] Nöldge G, et al. **Radiologe** 1996 Sep; 36(9):683–91 (34 ref.) (Eng. Abstr.) (Ger)
[CT-guided neurolysis. Status of the technique and current results] Schneider B, et al. **Radiologe** 1996 Sep;36(9):692–9 (24 ref.) (Eng. Abstr.) (Ger)
[Spiral-CT in diagnosis of lung embolism] Kauczor HU, et al. **Rontgenpraxis** 1996 Aug;49(8):195–200 (25 ref.) (Ger)
[CT-angiography for diagnostic assessment of intracranial vascular aneurysms] Koch C, et al. **Wien Med Wochenschr** 1997;147(7–8):163–71 (59 ref.) (Eng. Abstr.) (Ger)
[Development of rotational digital angiography system and new cone-beam 3 D CT] Kumazaki T. **Nippon Ika Daigaku Zasshi** 1997 Feb;64(1):57–60 (6 ref.) (Jpn)

METHODS

Spiral CT angiography of the abdomen and pelvis: interventional applications. Brink JA. **Abdom Imaging** 1997 Jul–Aug;22(4):365–72 (26 ref.)
Contrast-enhanced lymphography. CT or MR imaging? Vogl TJ, et al. **Acta Radiol Suppl** 1997;412:47–50 (41 ref.)
Rhinopharyngoscopy, computed tomography and magnetic resonance imaging. Bonifazi F, et al. **Allergy** 1997;52(33 Suppl):28–31 (32 ref.)
Coronary artery scanning using electron beam computed tomography [editorial; comment] Detrano RC. **Am J Card Imaging** 1996 Apr;10(2):97–100 (35 ref.) Comment on: Am J Card Imaging 1996 Apr;10(2):91–6.
Spiral computed tomographic scanning and respiratory disease. Sawyer RH. **Br J Hosp Med** 1996 Jul 10–Aug 20; 56(2–3):94–8 (12 ref.)
Neuroimaging techniques for the ophthalmologist. Gans M. **Can J Ophthalmol** 1997 Jun;32(4):277–81 (11 ref.)
Imaging of articular pathology: MRI, CT, arthrography. Berquist TH. **Clin Anat** 1997;10(1):1–13 (35 ref.)
Spiral CT: clinical applications in the gastrointestinal tract. Fishman EK. **Clin Imaging** 1997 Mar–Apr;21(2):111–21 (8 ref.)
Expanding aneurysm of aberrant right subclavian artery. Case report and imaging evaluation. Hogg JP, et al. **Clin Imaging** 1997 May–Jun;21(3):195–9 (8 ref.)
Computed tomography in the management of chest infections: current status. Wheeler JH, et al. **Clin Infect Dis** 1996 Aug;23(2):232–40 (28 ref.)
Helical/spiral computed body tomography. Brink JA, et al. **Clin Radiol** 1997 Jul;52(7):489–503 (102 ref.)
Spiral computed tomography and pulmonary embolism: current state. Hansell DM. **Clin Radiol** 1997 Aug; 52(8):575–81 (36 ref.)
CT arterial portography: technique, indications and applications. Redvanly RD, et al. **Clin Radiol** 1997 Apr; 52(4):256–68 (67 ref.)
Contemporary imaging of athletic injuries. Tung GA, et al. **Clin Sports Med** 1997 Jul;16(3):393–417 (46 ref.)
Relation of electron beam computed tomography screening for coronary calcium to cardiovascular risk and disease: a review. Teng W, et al. **Coron Artery Dis** 1996 May; 7(5):383–9 (48 ref.)
Lung metastases. Herold CJ, et al. **Eur Radiol** 1996; 6(5):596–606 (72 ref.)
Quantitative evaluation of regional myocardial perfusion using fast X-ray computed tomography. Schmermund A, et al. **Herz** 1997 Feb;22(1):29–39 (30 ref.)
Learning-based ventricle detection from cardiac MR and CT images. Weng J, et al. **IEEE Trans Med Imaging** 1997 Aug; 16(4):378–91 (36 ref.)
High resolution computed tomography of the lungs. Shetty PG, et al. **J Assoc Physicians India** 1996 Sep;44(9):621–6, 631–6 (35 ref.)
Imaging of maxillo-facial trauma. Hermans R, et al. **J Belge Radiol** 1997 Feb;80(1):25–9 (8 ref.)
Swyer-James syndrome documented by spiral CT angiography and high resolution inspiratory and expiratory CT: an accurate single modality exploration. Ghossain MA, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):616–8 (9 ref.)
Proximal ureter obstruction caused by a lower polar renal artery: demonstration with spiral CT angiography. Lee JY, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):641–2 (7 ref.)
Intracranial aneurysm: inner view and neck identification with CT angiography virtual endoscopy. Marro B, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):587–9 (9 ref.)
Asymptomatic coronary artery disease detection: update 1996. A screening protocol using 16-lead high-resolution ECG, ultrafast CT, exercise testing, and radionuclear imaging. Selvester RH, et al. **J Electrocardiol** 1996;29 Suppl:135–44 (77 ref.)
Functional imaging of the airways. Goldin JG, et al. **J Thorac Imaging** 1997 Jan;12(1):29–37 (56 ref.)
Volumetric (helical/spiral) CT (VCT) of the airways. Naidich DP, et al. **J Thorac Imaging** 1997 Jan;12(1):11–28 (43 ref.)
Xenon/computed tomography cerebral blood flow and its use in clinical management. Yonas H, et al. **Neurosurg Clin N Am** 1996 Oct;7(4):605–16 (60 ref.)
Evidence of optic pathway gliomas after previously negative neuroimaging. Massry GG, et al. **Ophthalmology** 1997 Jun; 104(6):930–5 (35 ref.)
X-ray computed microtomography (microCT) using synchrotron radiation (SR). Bonse U, et al. **Prog Biophys Mol Biol** 1996;65(1–2):133–69 (122 ref.)
Use of maximum intensity projections in CT angiography: a basic review. Prokop M, et al. **Radiographics** 1997 Mar–Apr;17(2):433–51 (26 ref.)
Helical biphasic contrast-enhanced CT of the liver: technique, indications, interpretation, and pitfalls. Oliver JH 3rd, et al. **Radiology** 1996 Oct;201(1):1–14 (34 ref.)
A CT-aided PC-based physical treatment planning of TBI: a method for dose calculation. Sánchez-Nieto B, et al. **Radiother Oncol** 1997 Jan;42(1):77–85 (27 ref.)
Pulmonary embolism: the role of computed tomography and magnetic resonance imaging. Bonomo L, et al. **Rays** 1996 Jul–Sep;21(3):378–96 (73 ref.) (Eng, Ita)
Oncologic imaging: interactions of nuclear medicine with CT and MRI using the bone scan as a model. Tryciecky EW, et al. **Semin Nucl Med** 1997 Apr;27(2):142–51 (39 ref.)
Delayed CT in acute renal infection. Dalla-Palma L, et al. **Semin Ultrasound CT MR** 1997 Apr;18(2):122–8 (12 ref.)
Computed tomography of renal metastases. Ferrozzi F, et al. **Semin Ultrasound CT MR** 1997 Apr;18(2):115–21 (31 ref.)
Spiral CT angiography of the aorta. Kopecky KK, et al. **Semin Ultrasound CT MR** 1996 Aug;17(4):304–15 (15 ref.)
MRI and CT in blunt renal trauma: an update. Leppäniemi A, et al. **Semin Ultrasound CT MR** 1997 Apr;18(2):129–35 (25 ref.)
Spiral (helical) CT of the renal vasculature. Rubin GD. **Semin Ultrasound CT MR** 1996 Aug;17(4):374–97 (33 ref.)
Fast CT for pulmonary embolus. Sheedy PF 2nd, et al. **Semin Ultrasound CT MR** 1996 Aug;17(4):324–38 (16 ref.)
CT angiography of the visceral vessels. Winter TC 3rd, et al. **Semin Ultrasound CT MR** 1996 Aug;17(4):339–51 (27 ref.)
Helical CT for detection and characterization of renal masses. Yuh BI, et al. **Semin Ultrasound CT MR** 1997 Apr; 18(2):82–90 (20 ref.)
Helical CT of talar fractures. Wechsler RJ, et al. **Skeletal Radiol** 1997 Mar;26(3):137–42 (13 ref.)
Urologic applications of multiplanar and three-dimensional computed tomography. Olson MC, et al. **Tech Urol** 1995 Fall;1(3):141–9 (8 ref.)
[Volume rendering technique in 3D vascular imaging] Marcus C, et al. **J Radiol** 1997 Jul;78(7):481–4 (11 ref.) (Eng. Abstr.) (Fre)
[Spiral X-ray computed tomography: a new modality of scanner imaging] Bonaldi VM, et al. **Presse Med** 1996 Jul 6–13;25(24):1109–14 (18 ref.) (Eng. Abstr.) (Fre)
[What's new in spiral tomodensitometry?] Rémy J, et al. **Rev Mal Respir** 1996;13(4):445–9 (11 ref.) (Fre)
[Dissecting aneurysm of an aberrant right subclavian artery: diagnosis with ultrafast-CT] Reittner P, et al. **Aktuelle Radiol** 1996 Jan;6(1):38–40 (8 ref.) (Eng. Abstr.) (Ger)
[Diagnostic imaging in bronchiectases. Value of CT and HRCT] Diederich S, et al. **Radiologe** 1996 Jul;36(7):550–9

TOMOGRAPHY, X-RAY COMPUTED

(39 ref.) (Eng. Abstr.) **(Ger)**

[HRCT of the lung in collagenoses] Diederich S, et al. **Radiologe** 1996 Jul;36(7):567–78 (37 ref.) (Eng. Abstr.) **(Ger)**

[Phenomenology of pulmonary HRCT. Definitions, differential diagnosis and clinical relevance] Roos N, et al. **Radiologe** 1996 Jul;36(7):521–33 (46 ref.) (Eng. Abstr.) **(Ger)**

[Differentiation of solitary pulmonary coin lesions by high-resolution computerized tomography] Seemann MD, et al. **Radiologe** 1996 Jul;36(7):579–85 (14 ref.) (Eng. Abstr.) **(Ger)**

[The Swyer-James syndrome: its imaging with high-resolution computed tomography] Hansen M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Nov;165(5):499–501 (12 ref.) **(Ger)**

[What is it called? A formulation and glossary for the finding and understanding of results in HRCT of the lung] Kauczor HU, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Nov;165(5):428–37 (88 ref.) (Eng. Abstr.) **(Ger)**

[Spiral computed tomography in the diagnosis and staging of bronchopulmonary carcinoma] Cittadini G Jr, et al. **Chir Ital** 1995;47(3):13–7 (24 ref.) (Eng. Abstr.) **(Ita)**

[Gastric emptying test using helical CT] Matsumoto K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:146–9 (7 ref.) **(Jpn)**

[Clinical application of helical CT and thin slice CT] Moriyama N. **Nippon Rinsho** 1996 May;54(5):1241–8 (4 ref.) (Eng. Abstr.) **(Jpn)**

[To radiation diagnosis of renal cancer with solitary metastasis into bone system] Chekunova EV, et al. **Vestn Rentgenol Radiol** 1997 Jan-Feb;(1):35–8 (18 ref.) **(Rus)**

[Present day radiation diagnosis of renal tumors and cysts] Vlasov PV, et al. **Vestn Rentgenol Radiol** 1997 May-Jun;(3):35–47 (62 ref.) (Eng. Abstr.) **(Rus)**

[Radiation diagnosis of spleen diseases] Vlasov PV, et al. **Vestn Rentgenol Radiol** 1997 May-Jun;(3):27–34 (28 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

Pulmonary arteries must be seen before they can be assessed [editorial; comment] Woodard PK. **Radiology** 1997 Jul; 204(1):11–2 (21 ref.) Comment on: Radiology 1997 Jul;204(1):157–63.

VETERINARY

Imaging of adrenal gland disorders. Tidwell AS, et al. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):237–54 (47 ref.)

Brain imaging. Tucker RL, et al. **Vet Clin North Am Small Anim Pract** 1996 Jul;26(4):735–58 (69 ref.)

Magnetic resonance imaging and computed tomography characteristics of intracranial intra-arachnoid cysts in 6 dogs. Vernau KM, et al. **Vet Radiol Ultrasound** 1997 May-Jun;38(3):171–6 (37 ref.)

TOMOGRAPHY, X-RAY COMPUTED, SCANNERS see **TOMOGRAPHY SCANNERS, X-RAY COMPUTED**

TONGUE

Episodic undulating hyperkinesias of the tongue associated with brainstem ischemia. Postert T, et al. **Mov Disord** 1997 Jul;12(4):619–21 (13 ref.)

ANATOMY & HISTOLOGY

Properties of tissues surrounding the upper airway. Schwab RJ. **Sleep** 1996 Dec;19(10 Suppl):S170–4 (25 ref.)

BLOOD SUPPLY

Pseudoaneurysm of the lingual artery: a case report. Salgarelli A, et al. **J Oral Maxillofac Surg** 1997 Aug;55(8):860–4 (11 ref.)

INNERVATION

Sources of afferent fibers from the tongue muscles. Woźniak W, et al. **Folia Morphol (Warsz)** 1996;55(3):129–32 (23 ref.)

PATHOLOGY

[Massive swelling of the tongue in two patients following the repair of cleft palate] Abe Y, et al. **Masui** 1996 Sep; 45(9):1145–8 (6 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Properties of tissues surrounding the upper airway. Schwab RJ. **Sleep** 1996 Dec;19(10 Suppl):S170–4 (25 ref.)

TONGUE DISEASES

Thyroid gland ectopias. Batsakis JG, et al. **Ann Otol Rhinol Laryngol** 1996 Dec;105(12):996–1000 (31 ref.)

CHEMICALLY INDUCED

Delayed onset of angioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature. O'Mara NB, et al. **Pharmacotherapy** 1996 Jul-Aug; 16(4):675–9 (40 ref.)

COMPLICATIONS

Laryngeal obstruction caused by lingual thyroglossal duct cyst presenting at birth. Kuint J, et al. **Am J Perinatol** 1997 Jul;14(6):353–6 (11 ref.)

DIAGNOSIS

Actinomycosis of the tongue associated with human immunodeficiency virus infection: case report. Vazquez AM, et al. **J Oral Maxillofac Surg** 1997 Aug;55(8):879–81 (18 ref.)

PATHOLOGY

Median lingual cyst: review of the literature and report of a case. Naidoo LC. **J Oral Maxillofac Surg** 1997 Feb; 55(2):172–5 (16 ref.)

Follicular carcinoma in lingual thyroid presenting as a latero-cervical mass. Case report and review of the literature. Bigotti G, et al. **J Oral Pathol Med** 1997 Mar; 26(3):142–6 (37 ref.)

TONGUE, FISSURED

see related
MELKERSSON-ROSENTHAL SYNDROME

TONGUE NEOPLASMS

DIAGNOSIS

[Extracranial schwannoma of the ENT region. Review of the literature with a case report of benign schwannoma of the base of the tongue] Dreher A, et al. **HNO** 1997 Jun;45(6):468–71 (20 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Spindle cell carcinoma of the tongue in a long-term survivor of childhood acute lymphoblastic leukemia. Shaw MP, et al. **Pediatr Hematol Oncol** 1997 Jan-Feb;14(1):79–83 (16 ref.)

GENETICS

RET protooncogene mutational analysis in multiple endocrine neoplasia syndrome type 2B: case report and review of the literature. Kahn MA, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Sep;82(3):288–94 (21 ref.)

PATHOLOGY

Depth of invasion as a predictive factor for cervical lymph node metastasis in tongue carcinoma. Fukano H, et al. **Head Neck** 1997 May;19(3):205–10 (14 ref.)

Epithelioid hemangiomas of the maxillofacial area. A report of three cases and a review of the literature. Martín-Granizo R, et al. **Int J Oral Maxillofac Surg** 1997 Jun;26(3):212–4 (10 ref.)

Multiple idiopathic mucosal neuromas: a minor form of multiple endocrine neoplasia type 2B or a new entity? Pujol RM, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):349–52 (22 ref.)

Follicular carcinoma in lingual thyroid presenting as a latero-cervical mass. Case report and review of the literature. Bigotti G, et al. **J Oral Pathol Med** 1997 Mar; 26(3):142–6 (37 ref.)

Granular cell myoblastoma. Review of the literature and report of a case. Zangari F, et al. **Minerva Stomatol** 1996 May;45(5):231–7 (51 ref.)

[Enormous lingual lymphangioma] Beziat JL, et al. **Rev Stomatol Chir Maxillofac** 1997 Aug;98(2):76–80 (19 ref.) (Eng. Abstr.) **(Fre)**

RADIOTHERAPY

Quality of life after radiation therapy for base of tongue cancer. Moore GJ. **Oncology (Huntingt)** 1996 Nov; 10(11):1643–8; discussion 1649–50, 1655 (20 ref.)

SURGERY

Synchronous lingual granular cell tumor and squamous carcinoma. A case report and review of the literature. Said-al-Naief N, et al. **Arch Otolaryngol Head Neck Surg** 1997 May;123(5):543–7 (48 ref.)

VETERINARY

Lingual hemangioma in a puppy: a case report and literature review. Schoofs SH. **J Am Anim Hosp Assoc** 1997 Mar-Apr;33(2):161–5 (23 ref.)

TONOFILAMENTS see **INTERMEDIATE FILAMENTS**

TONSIL

see related
TONSILLECTOMY

The palatine tonsil as an evolutionary novelty. Slipka J, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;523:8–11 (18 ref.)

CYTOLOGY

Phenotypic and functional characterization of human tonsillar subepithelial (SE) B cells. Dono M, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:171–81 (31 ref.)

IMMUNOLOGY

Significance of M-cells in the panautoprotection of the body. Karchev T. **Acta Otolaryngol Suppl (Stockh)** 1996;523:43–6 (18 ref.)

Subepithelial B cells of the human tonsil. Dono M, et al. **Chem Immunol** 1997;67:58–69 (28 ref.)

MICROBIOLOGY

[AIDS manifestations in otorhinolaryngology] Ciges M, et al. **Rev Neurol** 1996 Dec;24(136):1619–22 (24 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Torsion of the palatine tonsil. Prikas KG, et al. **J Laryngol Otol** 1996 Sep;110(9):891–2 (2 ref.)

PHYSIOPATHOLOGY

Relapsing infective-phlogistic pathology of Waldeyer's ring and its relationship with secretory otitis media. Passali D, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;523:138–41 (10 ref.)

VIROLOGY

[AIDS manifestations in otorhinolaryngology] Ciges M, et al. **Rev Neurol** 1996 Dec;24(136):1619–22 (24 ref.) (Eng. Abstr.) **(Spa)**

TONSIL, PALATINE see **TONSIL**

TONSILLAR NEOPLASMS

DIAGNOSIS

Cystic nodal metastasis in occult tonsil carcinoma--a case report. Soh KB, et al. **Ann Acad Med Singapore** 1996 Sep; 25(5):752–4 (16 ref.)

SECONDARY

Hepatocellular carcinomas diagnosed following metastasis to the oral cavity. Report of 2 cases. Llanes F, et al. **J Periodontol** 1996 Jul;67(7):717–9 (7 ref.)

TONSILLECTOMY

Tonsillectomy and adenoidectomy. Changing indications. Deutsch ES. **Pediatr Clin North Am** 1996 Dec; 43(6):1319–38 (102 ref.)

ADVERSE EFFECTS

Closed rhinolalia as a symptom of pneumomediastinum after tonsillectomy: a case report and literature review. Braverman I, et al. **Otolaryngol Head Neck Surg** 1997 Apr; 116(4):551–3 (14 ref.)

NURSING

Pediatric tonsillectomy and adenoidectomy procedures. Derkay CS, et al. **AORN J** 1995 Dec;62(6):887–904; quiz 906–10 (36 ref.)

PSYCHOLOGY

Perioperative psychosocial interventions for autistic children undergoing ENT surgery. Seid M, et al. **Int J Pediatr Otorhinolaryngol** 1997 Jun 20;40(2-3):107–13 (11 ref.)

TONSILLITIS

DRUG THERAPY

Shortened course of antibiotic therapy for acute otitis media, sinusitis and tonsillopharyngitis. Pichichero ME, et al. **Pediatr Infect Dis J** 1997 Jul;16(7):680–95 (144 ref.)

Macrolides in the management of streptococcal pharyngitis/tonsillitis. Tarlow MJ. **Pediatr Infect Dis J** 1997 Apr;16(4):444–8 (24 ref.)

ETIOLOGY

Sore throat after sore throat after sore throat. Are you asking the critical questions? Pichichero ME. **Postgrad Med** 1997 Jan;101(1):205–6, 209–12, 215–8, passim (22 ref.)

MICROBIOLOGY

[Streptococcal pharyngitis] Romero J, et al. **Enferm Infecc Microbiol Clin** 1995 Dec;13(10):611–27 (204 ref.) **(Spa)**

PATHOLOGY

[Current aspects of the problem of tonsillar disease] Bykov VP. **Arkh Patol** 1996 May-Jun;58(3):23–30 (37 ref.) (Eng. Abstr.) **(Rus)**

SURGERY

Tonsillectomy and adenoidectomy. Changing indications. Deutsch ES. **Pediatr Clin North Am** 1996 Dec; 43(6):1319–38 (102 ref.)

VIROLOGY

Human immunodeficiency virus-1 infection of the lymphoid tissues of Waldeyer's ring. Frankel SS, et al. **Ann Otol Rhinol Laryngol** 1997 Jul;106(7 Pt 1):611–8 (49 ref.)

TOOTH

see related
MALOCCLUSION
MASTICATION
ODONTOGENESIS

CHEMISTRY

Vertebrate mineralized matrix proteins: structure and function. Robey PG. **Connect Tissue Res** 1996; 35(1–4):131–6 (6 ref.)

CYTOLOGY

Tooth morphogenesis and cell differentiation. Thesleff I, et al. **Curr Opin Cell Biol** 1996 Dec;8(6):844–50 (53 ref.)

EMBRYOLOGY

Patterning of the mammalian dentition in development and evolution. Stock DW, et al. **Bioessays** 1997 Jun; 19(6):481–90 (90 ref.)

Tooth morphogenesis and cell differentiation. Thesleff I, et al. **Curr Opin Cell Biol** 1996 Dec;8(6):844–50 (53 ref.)

GROWTH & DEVELOPMENT

Weaning and dental health. Holt RD. **Proc Nutr Soc** 1997 Mar;56(1A):131–8 (35 ref.)

PHYSIOLOGY

Encoding of tooth loads by human periodontal afferents and their role in jaw motor control. Trulsson M, et al. **Prog Neurobiol** 1996 Jun;49(3):267–84 (89 ref.)

RADIATION EFFECTS

[Dental changes induced by radiotherapy: a study of subjects with retinoblastoma. I] Mascagni EE, et al. **Minerva Stomatol** 1997 Apr;46(4):191–200 (66 ref.) (Eng. Abstr.) **(Ita)**

RADIOGRAPHY

X-ray microtomography of bones and teeth. Davis GR, et al. **Physiol Meas** 1996 Aug;17(3):121–46 (59 ref.)

[Survey on oral health of university students: examination on tooth conditions using panoramic X-ray films] Susami T, et al. **Kokubyo Gakkai Zasshi** 1996 Sep;63(3):459–67 (31 ref.) (Eng. Abstr.) **(Jpn)**

TOOTH ABNORMALITIES

Clinical significance of tooth morphology correlated with periodontal disease–I. Hou GL, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1997 Apr; 13(4):200–12 (75 ref.)

A retrospective of personal craniofacidental research and clinical practice. Sarnat BG. **Plast Reconstr Surg** 1997 Jul; 100(1):132–53 (61 ref.)

COMPLICATIONS

Diseases with ocular and dental abnormalities. Regenbogen L, et al. **Metab Pediatr Syst Ophthalmol** 1995;18(1–4):5–14 (12 ref.)

DIAGNOSIS

CHARGE syndrome: review of literature and report of case. Coloboma, Heart disease, Atresia of choanae, Retarded mental development, Genital hypoplasia, Ear abnormalities–deafness. Grimm SE 3rd, et al. **ASDC J Dent Child** 1997 May–Jun;64(3):218–21, 228 (15 ref.)

GENETICS

Central nervous system abnormalities in oculodentodigital dysplasia [letter] Schrander-Stumpel CT, et al. **Genet Couns** 1996;7(3):233–5 (9 ref.)

TOOTH APEX

see related
APICOECTOMY

TOOTH, ARTIFICIAL

see related
ACRYLIC RESINS
DENTAL PORCELAIN

TOOTH AVULSION

COMPLICATIONS

Full intrusion of a tooth after facial trauma. Tung TC, et al. **J Trauma** 1997 Aug;43(2):357–9 (7 ref.)

TOOTH BLEACHING

Internal bleaching: long-term outcomes and complications. Friedman S. **J Am Dent Assoc** 1997 Apr;128 Suppl:51S–55S (34 ref.)

In-office bleaching: where we came from, where we are today. Goldstein RE. **J Am Dent Assoc** 1997 Apr;128 Suppl:11S–15S (13 ref.)

Nightguard vital bleaching: current concepts and research. Haywood VB. **J Am Dent Assoc** 1997 Apr;128 Suppl:19S–25S (31 ref.)

Toxicological considerations of tooth bleaching using peroxide-containing agents. Li Y. **J Am Dent Assoc** 1997 Apr;128 Suppl:31S–36S (58 ref.)

Restorative considerations with vital tooth bleaching. Swift EJ Jr. **J Am Dent Assoc** 1997 Apr;128 Suppl:60S–64S (43 ref.)

[The bleaching of stained anterior teeth] Glockner K, et al. **Schweiz Monatsschr Zahnmed** 1997;107(5):413–25 (40 ref.) **(Ger, Fre)**

ADVERSE EFFECTS

Vital tooth bleaching: sensitivity and pulpal considerations. Nathanson D. **J Am Dent Assoc** 1997 Apr;128 Suppl:41S–44S (13 ref.)

TOOTH CALCIFICATION

PHYSIOLOGY

Tuftelin: enamel mineralization and amelogenesis imperfecta. Deutsch D, et al. **Ciba Found Symp** 1997;205:135–47; discussion 147–155 (51 ref.)

Enamel maturation. Robinson C, et al. **Ciba Found Symp** 1997;205:156–70; discussion 170–4 (46 ref.)

Structure and function of secretory ameloblasts in enamel formation. Sasaki T, et al. **Ciba Found Symp** 1997;205:32–46; discussion 46–50 (41 ref.)

TOOTH CROWDING see **MALOCCLUSION**

TOOTH CROWN

ABNORMALITIES

Dens evaginatus: a review. Uyeno DS, et al. **ASDC J Dent Child** 1996 Sep–Oct;63(5):328–32 (40 ref.)

TOOTH, DECIDUOUS

ABNORMALITIES

Birooted primary canines: report of three cases. Ott NW, et al. **Pediatr Dent** 1996 Jul–Aug;18(4):328–30 (12 ref.)

PATHOLOGY

Pathohistology of undecalcified primary teeth in vitamin D–resistant rickets: review and report of two cases. Hillmann G, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Aug;82(2):218–24 (27 ref.)

SURGERY

Dentistry on deciduous teeth: what, when, and how. Legendre LF. **Can Vet J** 1994 Dec;35(12):793–4 (4 ref.)

TOOTH DEMINERALIZATION

see related
DENTAL CARIES

THERAPY

[Micro-abrasion of the enamel: an alternative to the removal of demineralization and superficial decalcification] Tudts M, et al. **Rev Belge Med Dent** 1996;51(1):54–71 (55 ref.) (Eng. Abstr.) **(Fre)**

TOOTH, DEVITALIZED see **TOOTH, NONVITAL**

TOOTH DISCOLORATION

see related
ENAMEL MICROABRASION
TOOTH BLEACHING

CLASSIFICATION

The chemistry and mechanisms of extrinsic and intrinsic discoloration. Nathoo SA. **J Am Dent Assoc** 1997 Apr;128 Suppl:6S–10S (34 ref.)

GENETICS

[Kohlschütter syndrome--an example of a rare progressive neuroectodermal disease. Case report and review of the literature] Wygold T, et al. **Klin Padiatr** 1996 Sep–Oct; 208(5):271–5 (4 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

The chemistry and mechanisms of extrinsic and intrinsic discoloration. Nathoo SA. **J Am Dent Assoc** 1997 Apr;128 Suppl:6S–10S (34 ref.)

THERAPY

Enamel microabrasion: observations after 10 years. Croll TP. **J Am Dent Assoc** 1997 Apr;128 Suppl:45S–50S (21 ref.)

Internal bleaching: long-term outcomes and complications. Friedman S. **J Am Dent Assoc** 1997 Apr;128 Suppl:51S–55S (34 ref.)

Restorative considerations with vital tooth bleaching. Swift EJ Jr. **J Am Dent Assoc** 1997 Apr;128 Suppl:60S–64S (43 ref.)

[Micro-abrasion of the enamel: an alternative to the removal of demineralization and superficial decalcification] Tudts M, et al. **Rev Belge Med Dent** 1996;51(1):54–71 (55 ref.) (Eng. Abstr.) **(Fre)**

[The bleaching of stained anterior teeth] Glockner K, et al. **Schweiz Monatsschr Zahnmed** 1997;107(5):413–25 (40 ref.) **(Ger, Fre)**

TOOTH DISEASES

DIAGNOSIS

A review of applications of recombinant DNA techniques in diagnosis and treatment of dental diseases. Kerns DG, et al. **Mil Med** 1996 Apr;161(4):236–8 (23 ref.)

DRUG THERAPY

Pharmacology of the gastrointestinal tract. Terezhalmy GT, et al. **Dent Clin North Am** 1996 Jul;40(3):493–520 (150 ref.)

A review of applications of recombinant DNA techniques in diagnosis and treatment of dental diseases. Kerns DG, et al. **Mil Med** 1996 Apr;161(4):236–8 (23 ref.)

ETIOLOGY

[Etiopathogenic hypotheses on dental ankylosis] Belcastro S, et al. **Minerva Stomatol** 1997 Mar;46(3):109–13 (9 ref.) (Eng. Abstr.) **(Ita)**

PSYCHOLOGY

[Psychiatric and psychologic aspects of stomatologic diseases, or stomatologic aspects of psychiatric diseases. Review of the literature] Hajnal A. **Fogorv Sz** 1997 Jun;90(6):163–76 (45 ref.) (Eng. Abstr.) **(Hun)**

RADIOGRAPHY

Panoramic radiography in dental diagnostics. Molander B. **Swed Dent J Suppl** 1996;119:1–26 (169 ref.)

THERAPY

Potential preventive and therapeutic hard-tissue applications of CO2, Nd:YAG and argon lasers in dentistry: a review. Gonzalez CD, et al. **ASDC J Dent Child** 1996 May–Jun; 63(3):196–207 (109 ref.)

VETERINARY

Dentistry on deciduous teeth: what, when, and how. Legendre LF. **Can Vet J** 1994 Dec;35(12):793–4 (4 ref.)

TOOTH, ENDODONTICALLY-TREATED see **TOOTH, NONVITAL**

TOOTH EROSION

CLASSIFICATION

Dental erosion. Definition, classification and links. Imfeld T. **Eur J Oral Sci** 1996 Apr;104(2 (Pt 2)):151–5 (59 ref.)

DIAGNOSIS

Methods of assessing erosion and erosive potential. Grenby TH. **Eur J Oral Sci** 1996 Apr;104(2 (Pt 2)):207–14 (43 ref.)

Dental erosion clinical diagnosis and case history taking. Lussi A. **Eur J Oral Sci** 1996 Apr;104(2 (Pt 2)):191–8 (43 ref.)

EPIDEMIOLOGY

Prevalence of dental erosion and the implications for oral health. Nunn JH. **Eur J Oral Sci** 1996 Apr;104(2 (Pt 2)):156–61 (36 ref.)

ETIOLOGY

Etiology of dental erosion--intrinsic factors. Scheutzel P. **Eur J Oral Sci** 1996 Apr;104(2 (Pt 2)):178–90 (76 ref.)

Etiology of dental erosion--extrinsic factors. Zero DT. **Eur J Oral Sci** 1996 Apr;104(2 (Pt 2)):162–77 (109 ref.)

PATHOLOGY

Pathogenesis and modifying factors of dental erosion. Meurman JH, et al. **Eur J Oral Sci** 1996 Apr;104(2 (Pt

TOOTH EROSION

2)):199–206 (71 ref.)

PREVENTION & CONTROL

Lessening dental erosive potential by product modification. Grenby TH. **Eur J Oral Sci** 1996 Apr;104(2 (Pt 2)):221–8 (36 ref.)

Prevention of progression of dental erosion by professional and individual prophylactic measures. Imfeld T. **Eur J Oral Sci** 1996 Apr;104(2 (Pt 2)):215–20 (46 ref.)

THERAPY

Restorative therapy for erosive lesions. Lambrechts P, et al. **Eur J Oral Sci** 1996 Apr;104(2 (Pt 2)):229–40 (95 ref.)

TOOTH ERUPTION, ECTOPIC

ETIOLOGY

Ectopic eruption of maxillary first permanent molars in children with cleft lip. da Silva Filho OG, et al. **Angle Orthod** 1996;66(5):373–80 (22 ref.)

THERAPY

The presentations and management of transposed teeth. Weeks EC, et al. **Br Dent J** 1996 Dec 7–21; 181(11–12):421–4 (13 ref.)

TOOTH EXFOLIATION

THERAPY

Preservation of permanent teeth in a patient with Papillon–Lefèvre syndrome by professional tooth–cleaning. Kim JB, et al. **ASDC J Dent Child** 1997 May–Jun; 64(3):222–6 (20 ref.)

TOOTH EXTRACTION

Prophylactic removal of impacted third molars: an assessment of published reviews. Song F, et al. **Br Dent J** 1997 May 10;182(9):339–46 (45 ref.)

[Benefits and risk of the extraction of wisdom teeth] Torres JH. **Rev Stomatol Chir Maxillofac** 1997 Sep;98(3):173–8 (33 ref.) **(Fre)**

VETERINARY

Extraction of the upper cuspid, without stress. Legendre L. **Can Vet J** 1996 Nov;37(11):692–4 (4 ref.)

TOOTH GERM

see related
ODONTOGENESIS

EMBRYOLOGY

The genetic control of early tooth development. Maas R, et al. **Crit Rev Oral Biol Med** 1997;8(1):4–39 (312 ref.)

TOOTH, IMPACTED

COMPLICATIONS

Metastasis of a malignant melanoma to the region of an impacted mandibular third molar: a case report. Santamaría J, et al. **J Oral Maxillofac Surg** 1997 Sep;55(9):1003–6 (15 ref.)

ETIOLOGY

The impacted maxillary canine. Further observations on aetiology, radiographic localization, prevention/interception of impaction, and when to suspect impaction. Jacobs SG. **Aust Dent J** 1996 Oct;41(5):310–6 (15 ref.)

SURGERY

Intentional partial odontectomy: review of cases. Freedman GL. **J Oral Maxillofac Surg** 1997 May;55(5):524–6 (2 ref.)

[Benefits and risk of the extraction of wisdom teeth] Torres JH. **Rev Stomatol Chir Maxillofac** 1997 Sep;98(3):173–8 (33 ref.) **(Fre)**

TOOTH INJURIES

ETIOLOGY

Dental injuries during general anaesthesia [see comments] Chadwick RG, et al. **Br Dent J** 1996 Apr 6;180(7):255–8 (21 ref.) Comment in: Br Dent J 1996 Jul 6;181(1):11.

PREVENTION & CONTROL

Athletic mouth guards prevent orofacial injuries. Woodmansey KF. **J Am Coll Health** 1997 Jan;45(4):179–82 (26 ref.)

THERAPY

Emergency management of oral trauma in children. Nelson LP, et al. **Curr Opin Pediatr** 1997 Jun;9(3):242–5 (15 ref.)

TOOTH LOSS

CLASSIFICATION

[Prosthetic indications of single-phase implants] Szöllösi K. **Fogorv Sz** 1997 Jul;90(7):195–200 (14 ref.) (Eng. Abstr.) **(Hun)**

REHABILITATION

[F habilitation of chewing function and after care in geriatrics] Müller N. **Fortschr Med** 1996 Aug 20; 114(22–23):270–2 (0 ref.) (Eng. Abstr.) **(Ger)**

TOOTH LUXATION see **TOOTH AVULSION**

TOOTH MIGRATION

THERAPY

The presentations and management of transposed teeth. Weeks EC, et al. **Br Dent J** 1996 Dec 7–21; 181(11–12):421–4 (13 ref.)

TOOTH MOBILITY

ETIOLOGY

Tooth intrusion in implant-assisted prostheses [published erratum appears in J Prosthet Dent 1997 Apr;77(4):453] Sheets CG, et al. **J Prosthet Dent** 1997 Jan;77(1):39–45 (30 ref.)

TOOTH MOVEMENT

Orthodontic management of root-filled teeth. Drysdale C, et al. **Br J Orthod** 1996 Aug;23(3):255–60 (28 ref.)

Orthodontic procedures improving periodontal prognosis. Diedrich PR. **Dent Clin North Am** 1996 Oct;40(4):875–87 (29 ref.)

Combined orthodontic and prosthetic therapy. Special considerations. Shroff B, et al. **Dent Clin North Am** 1996 Oct;40(4):911–43 (17 ref.)

INSTRUMENTATION

Correction of deep overbite in adults. Nanda R. **Dent Clin North Am** 1997 Jan;41(1):67–87 (14 ref.)

TOOTH MOVEMENT, MINOR see **TOOTH MOVEMENT**

TOOTH, NONVITAL

Internal bleaching: long-term outcomes and complications. Friedman S. **J Am Dent Assoc** 1997 Apr;128 Suppl:51S–55S (34 ref.)

TOOTH, PRIMARY see **TOOTH, DECIDUOUS**

TOOTH, PULPLESS see **TOOTH, NONVITAL**

TOOTH ROOT

see related
ROOT RESORPTION

ABNORMALITIES

Birooted primary canines: report of three cases. Ott NW, et al. **Pediatr Dent** 1996 Jul–Aug;18(4):328–30 (12 ref.)

ANATOMY & HISTOLOGY

Clinical significance of tooth morphology correlated with periodontal disease-I. Hou GL, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1997 Apr; 13(4):200–12 (75 ref.)

INJURIES

The influence of anatomic and iatrogenic root surface characteristics on bacterial colonization and periodontal destruction: a review. Leknes KN. **J Periodontol** 1997 Jun; 68(6):507–16 (106 ref.)

PATHOLOGY

The influence of anatomic and iatrogenic root surface characteristics on bacterial colonization and periodontal destruction: a review. Leknes KN. **J Periodontol** 1997 Jun; 68(6):507–16 (106 ref.)

SURGERY

A review of root resective therapy as a treatment option for maxillary molars. Hempton T, et al. **J Am Dent Assoc** 1997 Apr;128(4):449–55 (30 ref.)

[Intraoperative sonography. Intraoperative sonographic position finding for the surgical removal of a residual root from the sublingual space] Ludwig A, et al. **Schweiz Monatsschr Zahnmed** 1997;107(5):398–404 (6 ref.) **(Ger, Fre)**

ULTRASONOGRAPHY

[Intraoperative sonography. Intraoperative sonographic position finding for the surgical removal of a residual root from the sublingual space] Ludwig A, et al. **Schweiz Monatsschr Zahnmed** 1997;107(5):398–404 (6 ref.) **(Ger, Fre)**

ULTRASTRUCTURE

[Localization of the apical foramen using the newest electronic instruments: stereomicroscopy and SEM (scanning electron microscopy)] Pagavino G, et al. **Minerva Stomatol** 1995 Nov;44(11):499–506 (40 ref.) (Eng. Abstr.) **(Ita)**

TOOTH, SUPERNUMERARY

COMPLICATIONS

Cystic lesions of the nasal cavity and the paranasal sinuses: report of two unusual cases. Vele DD, et al. **J Laryngol Otol** 1996 Dec;110(12):1157–60 (7 ref.)

DIAGNOSIS

Supernumerary teeth: a review of the literature and four case reports. Scheiner MA, et al. **Aust Dent J** 1997 Jun; 42(3):160–5 (16 ref.)

PATHOLOGY

[Supernumerary molars. Apropos of 10 cases] Ntima-Nsiemi K, et al. **Rev Stomatol Chir Maxillofac** 1997 Aug;98(2):72–5 (20 ref.) (Eng. Abstr.) **(Fre)**

TOOTH SUPPORTING STRUCTURES see **PERIODONTIUM**

TOOTH, UNERUPTED

see related
TOOTH, IMPACTED

TOOTH, WISDOM see **MOLAR, THIRD**

TOOTHACHE

ETIOLOGY

Nonodontogenic toothache. Okeson JP, et al. **Dent Clin North Am** 1997 Apr;41(2):367–83 (28 ref.)

TOOTHBRUSHING

INSTRUMENTATION

The electric toothbrush: a review. Walmsley AD. **Br Dent J** 1997 Mar 22;182(6):209–18 (48 ref.)

Laparoscopic removal of a swallowed toothbrush. Wishner JD, et al. **Surg Endosc** 1997 May;11(5):472–3 (7 ref.)

TOOTHPASTE

Developments in fluoride toothpastes--an overview. Holt RD, et al. **Community Dent Health** 1997 Mar;14(1):4–10 (42 ref.)

ADVERSE EFFECTS

Biological properties of peroxide-containing tooth whiteners. Li Y. **Food Chem Toxicol** 1996 Sep;34(9):887–904 (212 ref.)

TOPECTOMY see **PSYCHOSURGERY**

TOPOGRAPHIC BRAIN MAPPING see **BRAIN MAPPING**

TOPOGRAPHY, MEDICAL

A short review of the previous and current epidemiological situation of schistosomiasis in China. Cen LP. **Rev Soc Bras Med Trop** 1996 Jan–Feb;30(1):57–60 (14 ref.)

Disease ecology and a reformist alternative: the case of infant mortality. Gesler WM, et al. **Soc Sci Med** 1997 Mar; 44(5):657–71 (106 ref.)

TOPOGRAPHY, MOIRE see **MOIRE TOPOGRAPHY**

TOREMIFENE

Toremifene. **IARC Monogr Eval Carcinog Risks Hum** 1996; 66:367–87 (68 ref.)

PHARMACOLOGY

Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer. Wiseman LR, et al. **Drugs** 1997 Jul;54(1):141–60 (117 ref.)

Safety assessment of tamoxifen and toremifene. Williams GM, et al. **Oncology (Huntingt)** 1997 May;11(5 Suppl 4):41–7 (81 ref.)

THERAPEUTIC USE

Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer. Wiseman LR, et al. **Drugs** 1997 Jul;54(1):141–60 (117 ref.)

Phase III trials of toremifene vs tamoxifen. Gams R. **Oncology (Huntingt)** 1997 May;11(5 Suppl 4):23–8 (0 ref.)
Phase I and II studies of toremifene. Hamm JT. **Oncology (Huntingt)** 1997 May;11(5 Suppl 4):19–22 (12 ref.)

TORNADOES see **NATURAL DISASTERS**

TOROVIRIDAE see **TOROVIRUS**

TOROVIRUS

CLASSIFICATION

Toroviruses--members of the coronavirus superfamily? Horzinek MC. **Arch Virol Suppl** 1993;7:75–80 (23 ref.)

TORP see **OSSICULAR REPLACEMENT PROSTHESIS**

TORQUE

Torque: an appraisal of misuse of terminology in chiropractic literature and technique. Harrison DD, et al. **J Manipulative Physiol Ther** 1996 Sep;19(7):454–62 (57 ref.)

TORSADES DE POINTES

A practical approach to torsade de pointes. Roden DM. **Clin Cardiol** 1997 Mar;20(3):285–90 (45 ref.)
[Torsades de pointes] Kishi F, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):391–4 (20 ref.) **(Jpn)**

CHEMICALLY INDUCED

Torsade de pointes and low-dose oral haloperidol. Jackson T, et al. **Arch Intern Med** 1997 Sep 22;157(17):2013–5 (7 ref.)
Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade. Skanes AC, et al. **Can J Cardiol** 1997 Apr;13(4):383–6 (36 ref.)
[Torsades de pointe with spiramycine and metiquazine therapy. Apropos of a case] Verdun F, et al. **Arch Mal Coeur Vaiss** 1997 Jan;90(1):103–6 (10 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Torsade de pointes in haemodialysis patients [editorial] [see comments] Bahrle S, et al. **Nephrol Dial Transplant** 1996 Jun;11(6):944–6 (7 ref.) Comment in: Nephrol Dial Transplant 1997 Feb;12(2):365.

ETIOLOGY

[Torsade de pointes in myxedema. Report of a case and review of the literature] Albrecht Aguilera G, et al. **Arch Inst Cardiol Mex** 1996 Sep–Oct;66(5):429–33 (11 ref.) (Eng. Abstr.) **(Spa)**

TORSION DYSTONIA see **DYSTONIA MUSCULORUM DEFORMANS**

TORTICOLLIS

DIAGNOSIS

[Sandifer's syndrome: a rare form of torticollis in childhood. A report of a patient] Greco F, et al. **Pediatr Med Chir** 1997 May–Jun;19(3):227–30 (24 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Treatment outcomes in cervical dystonia: a clinimetric study. Lindeboom R, et al. **Mov Disord** 1996 Jul;11(4):371–6 (48 ref.)
Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects. Dutton JJ. **Surv Ophthalmol** 1996 Jul–Aug;41(1):51–65 (145 ref.)
[Botulin toxins in the treatment of spasmodic torticollis] Teixeira SC, et al. **Rev Assoc Med Bras** 1995 Nov–Dec; 41(6):406–10 (21 ref.) **(Por)**

ETIOLOGY

Spontaneous torticollis in a breech-presenting fetus delivered by an atraumatic elective cesarean section: a case and review of the literature. Sherer DM. **Am J Perinatol** 1996 Jul;13(5):305–7 (17 ref.)

PHYSIOPATHOLOGY

Impairment of visuospatial function in idiopathic spasmodic torticollis. Hinse P, et al. **J Neurol** 1996 Jan;243(1):29–33 (39 ref.)

SURGERY

Surgical treatment of spasmodic torticollis: is there a role for microvascular decompression? With an illustrative case report. Brunori A, et al. **J Neurosurg Sci** 1996 Mar; 40(1):43–51 (41 ref.)

THERAPY

Spasmodic torticollis: a case report and review of therapies. Smith DL, et al. **J Am Board Fam Pract** 1996 Nov–Dec; 9(6):435–41 (39 ref.)

TORTURE

Torture and medical profession--an overview. Umesh MS. **J Indian Med Assoc** 1996 Jul;94(7):257–8, 261 (17 ref.)
Torture and war trauma survivors in primary care practice. Weinstein HM, et al. **West J Med** 1996 Sep;165(3):112–8 (30 ref.)

TORULOPSIS see **CANDIDA**

TORULOSIS see **CRYPTOCOCCOSIS**

TOSYL COMPOUNDS

PHARMACOLOGY

[Clinical pharmacology of leucotriene inhibitors] Paggiaro PL, et al. **Ann Ital Med Int** 1996 Oct;11 Suppl 2:85S–89S (39 ref.) (Eng. Abstr.) **(Ita)**

THERAPEUTIC USE

Zafirlukast for chronic asthma: convenient and generally safe, but is it effective? [comment] Hendeles L, et al. **Ann Pharmacother** 1997 Sep;31(9):1084–6 (21 ref.) Comment on: Ann Pharmacother 1997 Sep;31(9):1012–21.
Zafirlukast: the first leukotriene-receptor antagonist approved for the treatment of asthma [see comments] Kelloway JS. **Ann Pharmacother** 1997 Sep;31(9):1012–21 (43 ref.) Comment in: Ann Pharmacother 1997 Sep;31(9):1084–6.
Management of asthma with zafirlukast. Clinical experience and tolerability profile. Spector SL. **Drugs** 1996;52 Suppl 6:36–46 (46 ref.)
Zafirlukast: a new treatment for asthma [news] Kupecz D. **Nurse Pract** 1997 May;22(5):182, 185–6, 189–90 (41 ref.)
[Leukotriene receptor antagonists] Bornkessel B. **Med Monatsschr Pharm** 1996 Oct;19(10):284–6 (3 ref.) **(Ger)**
[Peptidoleukotriene receptor antagonists in asthma therapy] Sakakibara H, et al. **Nippon Rinsho** 1996 Nov; 54(11):3049–55 (36 ref.) (Eng. Abstr.) **(Jpn)**
[New drugs in asthma treatment. Leukotriene receptor blockers and leukotriene synthesis inhibitors] Männistö J, et al. **Nord Med** 1997 Apr;112(4):122–5 (15 ref.) (Eng. Abstr.) **(Swe)**

TOTAL BODY CLEARANCE RATE see **METABOLIC CLEARANCE RATE**

TOTAL BODY IRRADIATION see **WHOLE-BODY IRRADIATION**

TOTAL HEMOLYTIC COMPLEMENT see **COMPLEMENT HEMOLYTIC ACTIVITY ASSAY**

TOTAL LUNG CAPACITY

Pulmonary hyperinflation a clinical overview. Gibson GJ. **Eur Respir J** 1996 Dec;9(12):2640–9 (70 ref.)
[Measurements of residual volume and total lung capacity] Endo K. **Nippon Rinsho** 1997 Apr;55 Suppl 2:12–4 (2 ref.) **(Jpn)**

TOTAL LYMPHOCYTE COUNT see **LYMPHOCYTE COUNT**

TOTAL PARENTERAL NUTRITION see **PARENTERAL NUTRITION, TOTAL**

TOTAL QUALITY MANAGEMENT

see related
QUALITY CONTROL

Health care quality management: a status report. Vorhaus CB, et al. **Int Anesthesiol Clin** 1995 Fall;33(4):1–14 (17 ref.)
The evolving role of outcomes measurement and management in healthcare. Licciardone JC. **J Am Osteopath Assoc** 1997 May;97(5):290–2 (17 ref.)
Continuous quality improvement (CQI) in neuropathology. Pearl GS, et al. **J Neuropathol Exp Neurol** 1996 Aug; 55(8):875–9 (22 ref.)
Quality management for poison centers. McGuigan MA. **J Toxicol Clin Toxicol** 1997;35(3):283–93 (17 ref.)
Computer database for melanoma registry. A clinical management and research tool to monitor outcomes and ensure continuous quality improvement. Reintgen D, et al. **Surg Clin North Am** 1996 Dec;76(6):1273–85 (20 ref.)

METHODS

Strategies for reducing Papanicolaou smear screening errors: principles derived from data and experience with quality control. Krieger PA. **Arch Pathol Lab Med** 1997 Mar; 121(3):277–81 (5 ref.)
Integrated care pathways: effective tools for continuous evaluation of clinical practice. Kitchiner D, et al. **J Eval Clin Pract** 1996 Feb;2(1):65–9 (26 ref.)
Preparing for the coming consumer revolution in health care. Bartlett DF. **J Health Care Finance** 1997 Summer; 23(4):33–9 (2 ref.)
Healthcare outcomes management and quality improvement. al-Assaf AF. **J R Soc Health** 1996 Aug;116(4):245–52 (47 ref.)

ORGANIZATION & ADMINISTRATION

Collaborating across organizational boundaries to improve the quality of care. Plsek PE. **Am J Infect Control** 1997 Apr;25(2):85–95 (18 ref.)
Quality assurance programs for pressure ulcers. Xakellis GC Jr. **Clin Geriatr Med** 1997 Aug;13(3):599–606 (16 ref.)
Obstetrics/gynecology network development. Krieg KA. **Clin Obstet Gynecol** 1997 Jun;40(2):446–52 (5 ref.)
The contribution of epidemiology to CQI: a commentary. Kazandjian VA. **Int J Qual Health Care** 1996 Aug; 8(4):351–7 (14 ref.)
A model to create "organizational readiness" for the successful implementation of quality management systems. Penland T. **Int J Qual Health Care** 1997 Feb;9(1):69–72 (10 ref.)
HCFA's health care quality improvement program: the medical informatics challenge. Grant JB, et al. **J Am Med Inform Assoc** 1996 Jan–Feb;3(1):15–26 (47 ref.)
Local heroes beat national champions: quality improvement in Finnish health care. Brommels M, et al. **Jt Comm J Qual Improv** 1997 Jan;23(1):23–31 (6 ref.)
Quality management for health care in the Middle East and north Africa: professional cooperation as part of the peace process. Habib J, et al. **Jt Comm J Qual Improv** 1997 Jan; 23(1):65–8 (0 ref.)
The CQI/TQM journey in France. Maguerez G. **Jt Comm J Qual Improv** 1997 Jan;23(1):33–7 (20 ref.)
Quality improvement issues in Brazil. Malik AM. **Jt Comm J Qual Improv** 1997 Jan;23(1):55–9 (19 ref.)
Would it work for us? Learning from quality improvement in Europe and beyond. Ovretveit J. **Jt Comm J Qual Improv** 1997 Jan;23(1):7–22 (91 ref.)
Quality improvement in Germany. Paeger A. **Jt Comm J Qual Improv** 1997 Jan;23(1):38–46 (13 ref.)
Quality improvement in Swedish health care. Palmberg M. **Jt Comm J Qual Improv** 1997 Jan;23(1):47–54 (1 ref.)
The paradox of Japan: what about CQI in health care? Takahashi T. **Jt Comm J Qual Improv** 1997 Jan;23(1):60–4 (3 ref.)
The benefits of continuous performance measurement. Nadzam DM, et al. **Nurs Clin North Am** 1997 Sep; 32(3):543–59 (13 ref.)
Measuring nursing. Nielsen GH. **WHO Reg Publ Eur Ser** 1997;74:241–55 (14 ref.)

STANDARDS

[Development of standards for quality management in interventional cardiology] Brennecke R. **Herz** 1996 Oct; 21(5):304–13 (45 ref.) (Eng. Abstr.) **(Ger)**

TOUCH

Dynamic touch. Turvey MT. **Am Psychol** 1996 Nov; 51(11):1134–52 (50 ref.)
[Vulvodynia--sensitivity to touch of the vulva] Paavonen J. **Duodecim** 1995;111(13):1237–41 (21 ref.) **(Fin)**

PHYSIOLOGY

Parallel organization of somatosensory cortical areas I and II for tactile processing. Rowe MJ, et al. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov;23(10–11):931–8 (30 ref.)
Automatic visual to tactile translation--Part I: Human factors, access methods, and image manipulation. Way TP, et al. **IEEE Trans Rehabil Eng** 1997 Mar;5(1):81–94 (90 ref.)
Mechanisms of touch-evoked pain (allodynia): a new model. Cervero F, et al. **Pain** 1996 Nov;68(1):13–23 (85 ref.)
A supramolecular complex underlying touch sensitivity. Hamill OP, et al. **Trends Neurosci** 1996 Jul;19(7):258–61 (39 ref.)

TOURETTE SYNDROME

Neuropsychiatric disorders of childhood: Tourette's syndrome as a model. Cohen DJ, et al. **Acta Paediatr Suppl** 1997 Jul;422:106–11 (28 ref.)
[Tics and Tourette's syndrome] Jankovic J, et al. **Cas Lek Cesk** 1997 Jun 26;136(13):399–404 (24 ref.) (Eng. Abstr.) **(Cze)**

COMPLICATIONS

Hypothesis III. Tourette syndrome is only one of several causes of a developmental basal ganglia syndrome. Palumbo D, et al. **Arch Neurol** 1997 Apr;54(4):475–83 (142 ref.)
Tics, Tourette's, and attention deficit hyperactivity disorders: connections and treatment. Mitchell A, et al. **MCN Am J Matern Child Nurs** 1996 Nov–Dec; 21(6):294–300 (44 ref.)
Vomiting and retching in Gilles de la Tourette syndrome: a report of ten cases and a review of the literature. Rickards H, et al. **Mov Disord** 1997 Jul;12(4):531–5 (35 ref.)
Behavioral and emotional aspects of Tourette syndrome. Coffey BJ, et al. **Neurol Clin** 1997 May;15(2):277–89 (84 ref.)
Attention deficit hyperactivity disorder in the presence of Tourette syndrome. Freeman RD. **Neurol Clin** 1997 May;

15(2):411–20 (98 ref.)
Tourette syndrome. Coprolalia and other coprophenomena. Singer C. **Neurol Clin** 1997 May;15(2):299–308 (49 ref.)
Tics associated with autistic and pervasive developmental disorders. Stern JS, et al. **Neurol Clin** 1997 May; 15(2):345–55 (54 ref.)
Tics and fits. The current status of Gilles de la Tourette syndrome and its relationship with epilepsy. Rickards H. **Seizure** 1995 Dec;4(4):259–66 (77 ref.)

DIAGNOSIS

Tourette syndrome. Dure LS, et al. **Curr Opin Neurol** 1997 Apr;10(2):153–9 (56 ref.)
The course and prognosis of Tourette syndrome. Bruun RD, et al. **Neurol Clin** 1997 May;15(2):291–8 (38 ref.)
Tourette syndrome. Phenomenology and classification of tics. Jankovic J. **Neurol Clin** 1997 May;15(2):267–75 (43 ref.)
Tourette syndrome. Clinical rating and quantitative assessment of tics. Kompoliti K, et al. **Neurol Clin** 1997 May;15(2):239–54 (49 ref.)
Tourette syndrome. Secondary tic disorders. Kumar R, et al. **Neurol Clin** 1997 May;15(2):309–31 (207 ref.)
Social and educational resources for patients with Tourette syndrome. Packer LE. **Neurol Clin** 1997 May;15(2):457–73 (51 ref.)

DRUG THERAPY

Future therapies of Tourette syndrome. Chappell PB, et al. **Neurol Clin** 1997 May;15(2):429–50 (102 ref.)
Tourette syndrome. Treatment of tics. Kurlan R. **Neurol Clin** 1997 May;15(2):403–9 (53 ref.)
[Nicotine in neuropsychiatric movement disorders] Erdmann R. **Fortschr Neurol Psychiatr** 1996 Sep;64(9):362–6 (42 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

The Gilles de la Tourette syndrome. Robertson MM, et al. **Crit Rev Neurobiol** 1997;11(1):1–19 (207 ref.)
Epidemiology of Tourette syndrome. Tanner CM, et al. **Neurol Clin** 1997 May;15(2):395–402 (51 ref.)

ETHNOLOGY

Tourette disorder: a cross–cultural review. Staley D, et al. **Compr Psychiatry** 1997 Jan–Feb;38(1):6–16 (48 ref.)

ETIOLOGY

Three cases of symptom change in Tourette's syndrome and obsessive–compulsive disorder associated with paediatric cerebral malignancies. Peterson BS, et al. **J Neurol Neurosurg Psychiatry** 1996 Nov;61(5):497–505 (48 ref.)
Future direction of research in Tourette syndrome. Kurlan R. **Neurol Clin** 1997 May;15(2):451–6 (49 ref.)

GENETICS

Quest for the elusive genetic basis of Tourette syndrome [editorial] Patel PI. **Am J Hum Genet** 1996 Nov;59(5):980–2 (14 ref.)
Tourette's syndrome in the year 2000. Robertson MM, et al. **Aust N Z J Psychiatry** 1996 Dec;30(6):749–59 (136 ref.)
The genetics of Tourette syndrome. Alsobrook JP 2nd, et al. **Neurol Clin** 1997 May;15(2):381–93 (83 ref.)

PHYSIOPATHOLOGY

Pathogenesis of Tourette's syndrome. Leckman JF, et al. **J Child Psychol Psychiatry** 1997 Jan;38(1):119–42 (225 ref.)
Neurobiology of Tourette syndrome. Singer HS. **Neurol Clin** 1997 May;15(2):357–79 (137 ref.)
Tourette's syndrome: a disorder of cingulate and orbitofrontal function? Weeks RA, et al. **QJM** 1996 Jun; 89(6):401–8 (90 ref.)

PSYCHOLOGY

Neurobiology of Tourette syndrome. Singer HS. **Neurol Clin** 1997 May;15(2):357–79 (137 ref.)

THERAPY

Tics, Tourette's, and attention deficit hyperactivity disorders: connections and treatment. Mitchell A, et al. **MCN Am J Matern Child Nurs** 1996 Nov–Dec; 21(6):294–300 (44 ref.)
[Gilles de la Tourette's disease. Symptoms, etiopathogenesis and therapeutic approaches] Knecht T. **Schweiz Rundsch Med Prax** 1997 May 14;86(20):844–9 (47 ref.) (Eng. Abstr.) **(Ger)**

TOURETTE'S DISORDER see **TOURETTE SYNDROME**

TOURNIQUET PAIN TEST see **PAIN MEASUREMENT**

TOURNIQUETS

[Tourniquet pain: anatomic–physiological notes and clinical aspects] Ramaioli F, et al. **Minerva Anestesiol** 1996 Jul–Aug;62(7–8):265–70 (36 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

[Pneumatic tourniquets in orthopedics] Estebe JP, et al. **Ann Fr Anesth Reanim** 1996;15(2):162–78 (211 ref.) (Eng. Abstr.) **(Fre)**

TOXIC SHOCK SYNDROME see **SHOCK, SEPTIC**

TOXIC SUBSTANCES, ENVIRONMENTAL see **HAZARDOUS SUBSTANCES**

TOXICITY TESTS

Preclinical development of antiviral drugs. Szczech GM. **Clin Infect Dis** 1996 Feb;22(2):355–60 (25 ref.)
Clinicoepidemiological, toxicological, and safety evaluation studies on argemone oil. Das M, et al. **Crit Rev Toxicol** 1997 May;27(3):273–97 (137 ref.)
EEC/COLIPA in vitro photoirritancy program: results of the first stage of validation. Spielmann H, et al. **Curr Probl Dermatol** 1995;23:256–64 (9 ref.)
Safety evaluation of lipase derived from Rhizopus oryzae: summary of toxicological data. Coenen TM, et al. **Food Chem Toxicol** 1997 Mar–Apr;35(3–4):315–22 (24 ref.)
Assessment of cassia gum. Hallagan JB, et al. **Food Chem Toxicol** 1997 Jun;35(6):625–32 (35 ref.)
Case studies for statistical analysis of toxicokinetic data. Igarashi T, et al. **Regul Toxicol Pharmacol** 1996 Jun; 23(3):193–208 (11 ref.)

ECONOMICS

Economical test methods for developmental neurobehavioral toxicity. Bignami G. **Environ Health Perspect** 1996 Apr;104 Suppl 2:285–98 (12 ref.)

METHODS

Acute inhalation toxicity testing: considerations of technical and regulatory aspects. Pauluhn J, et al. **Arch Toxicol** 1996; 71(1–2):1–10 (37 ref.)
Validation of in vitro methods to single out photoirritants using mechanistically based tests. Pape WJ. **Arch Toxicol Suppl** 1997;19:239–47 (13 ref.)
Transcutaneous electrical resistance: application in predicting skin corrosives. Lewis RW, et al. **Curr Probl Dermatol** 1995; 23:243–55 (15 ref.)
Ethological and experimental approaches to behavior analysis: implications for ecotoxicology. Cohn J, et al. **Environ Health Perspect** 1996 Apr;104 Suppl 2:299–305 (55 ref.)
Mammary gland neoplasia [comment] Neumann DA, et al. **Environ Health Perspect** 1996 Sep;104(9):912–4 (13 ref.) Comment on: Environ Health Perspect 1996 Sep;104(9):938–67.
Mammary gland neoplasia in long–term rodent studies [see comments] Russo IH, et al. **Environ Health Perspect** 1996 Sep;104(9):938–67 (266 ref.) Comment in: Environ Health Perspect 1996 Sep;104(9):912–4.
Neurobehavioral aspects of developmental toxicity testing. Ulbrich B, et al. **Environ Health Perspect** 1996 Apr;104 Suppl 2:407–12 (16 ref.)
Ophthalmologic examination in systemic toxicity studies: an overview. Kuiper B, et al. **Lab Anim** 1997 Apr;31(2):177–83 (31 ref.)
The Göttingen minipig in pharmacology and toxicology. Bollen P, et al. **Pharmacol Toxicol** 1997;80 Suppl 2:3–4 (14 ref.)
In vitro toxicological methods for environmental health testing. Hasspieler BM, et al. **Rev Environ Health** 1996 Oct–Dec;11(4):213–27 (51 ref.)
Computational predictive programs (expert systems) in toxicology. Benfenati E, et al. **Toxicology** 1997 May 16; 119(3):213–25 (41 ref.)
Immunohistochemistry for light microscopy in safety evaluation of therapeutic agents: an overview. Burnett R, et al. **Toxicology** 1997 Apr 11;119(1):83–93 (38 ref.)
Situational smoke toxicity testing: hazard assessment as the 'front end' of a smoke toxicity test. Clarke FB, et al. **Toxicology** 1996 Dec 31;115(1–3):179–84 (7 ref.)
An overview of the development, validation, and application of neurobehavioral and neuromolecular toxicity assessment batteries: potential applications to combustion toxicology. Rossi J 3rd, et al. **Toxicology** 1996 Dec 31;115(1–3):107–17 (18 ref.)
Epitope mapping: a new method for biological evaluation and immunotoxicology. Saint–Remy JM. **Toxicology** 1997 Apr 11;119(1):77–81 (24 ref.)
Autoantibodies in conventional toxicity testing. Verdier F, et al. **Toxicology** 1997 Apr 11;119(1):51–8 (33 ref.)

STANDARDS

Validation of alternative tests in the European Union. Balls M. **Curr Probl Dermatol** 1995;23:265–74 (15 ref.)
Expanding the RfD concept to incorporate and optimize beneficial effects while preventing toxic responses from nonessential toxicants. Calabrese EJ. **Ecotoxicol Environ Saf** 1996 Jun;34(1):94–101 (45 ref.)
Setting exposure standards: a decision process. Tilson HA, et al. **Environ Health Perspect** 1996 Apr;104 Suppl 2:401–5 (23 ref.)
Statistical planning and analysis considerations in the evaluation of in vitro alternatives to whole animal use for eye irritation testing. Feder P, et al. **Food Chem Toxicol** 1997 Jan;35(1):167–74 (6 ref.)
FIFRA Subdivision F testing Guidelines: are these tests adequate to detect potential hormonal activity for crop protection chemicals? Federal Insecticide, Fungicide, and Rodenticide Act. Stevens JT, et al. **J Toxicol Environ Health** 1997 Apr 11;50(5):415–31 (35 ref.)
Toxicity testing of pesticides sold in the United States. Keifer MC, et al. **Occup Med** 1997 Apr–Jun;12(2):365–70 (4 ref.)
Setting occupational exposure limits for pharmaceuticals. Naumann BD, et al. **Occup Med** 1997 Jan–Mar;12(1):67–80 (62 ref.)
New guidelines for preclinical testing of novel medicines for their effects on reproduction: clarity or confusion? Sutherland MF. **Regul Toxicol Pharmacol** 1996 Jun; 23(3):300–3 (19 ref.)

TRENDS

Future prospects for toxicokinetics: its ability to predict drug adverse events in humans. Sugiyama Y, et al. **J Toxicol Sci** 1996 Dec;21(5):511–6 (12 ref.)
The popliteal lymph node assay in 1996. Descotes J, et al. **Toxicology** 1997 Apr 11;119(1):45–9 (21 ref.)
Epitope mapping: a new method for biological evaluation and immunotoxicology. Saint–Remy JM. **Toxicology** 1997 Apr 11;119(1):77–81 (24 ref.)

TOXICODENDRON

see related
DERMATITIS, TOXICODENDRON

TOXICODENDRON DERMATITIS see **DERMATITIS, TOXICODENDRON**

TOXICOKINETICS see **PHARMACOKINETICS**

TOXICOLOGY

see related
POISONS

CDC and ATSDR electronic information resources for health officers [see comments] Friede A, et al. **Am J Infect Control** 1996 Dec;24(6):440–54 (9 ref.) Comment in: Am J Infect Control 1996 Dec;24(6):417–20.
An overview of the risk assessment of hazardous materials and the role of toxicology. Mattie DR. **Ann Clin Lab Sci** 1997 May–Jun;27(3):173–8 (3 ref.)
Toxicokinetics of endogenous substances: a neglected issue. Marzo A. **Arzneimittelforschung** 1996 Jan;46(1):1–10 (79 ref.)
Bias against the null hypothesis in maternal–fetal pharmacology and toxicology. Koren G. **Clin Pharmacol Ther** 1997 Jul;62(1):1–5 (21 ref.)
Pearls, pitfalls, and updates in toxicology. Kirk M, et al. **Emerg Med Clin North Am** 1997 May;15(2):427–49 (109 ref.)
Aquatic ecotoxicology: from the ecosystem to the cellular and molecular levels. Boudou A, et al. **Environ Health Perspect** 1997 Feb;105 Suppl 1:21–35 (95 ref.)
Confusion of concepts in mixture toxicology. Könemann WH, et al. **Food Chem Toxicol** 1996 Nov–Dec; 34(11–12):1025–31 (27 ref.)
Perturbation of the mitosis/apoptosis balance: a fundamental mechanism in toxicology. Roberts RA, et al. **Fundam Appl Toxicol** 1997 Aug;38(2):107–15 (44 ref.)
The effects of diet, overfeeding and moderate dietary restriction on Sprague–Dawley rat survival, disease and toxicology. Keenan KP, et al. **J Nutr** 1997 May;127(5 Suppl):851S–856S (43 ref.)
New nonpurified diet (NTP–2000) for rodents in the National Toxicology Program's toxicology and carcinogenesis studies. Rao GN. **J Nutr** 1997 May;127(5 Suppl):842S–846S (22 ref.)
Toxicokinetics in the National Toxicology Program. Goehl TJ. **NIDA Res Monogr** 1997;173:273–304 (20 ref.)
Overview of recent developments in ecotoxicological risk assessment. Solomon KR. **Risk Anal** 1996 Oct;16(5):627–33 (22 ref.)
Pharmacokinetics and pharmacodynamics in toxicology. Smith DA. **Xenobiotica** 1997 May;27(5):513–25 (46 ref.)
[The toxicological problems of disaster medicine in the Navy Fleet] Sharaevskii GIu, et al. **Voen Med Zh** 1996 Aug; 317(8):66–70, 80 (21 ref.) (Eng. Abstr.) **(Rus)**

EDUCATION

The National Poison Information Center in Poland. Jaraczewska W, et al. **J Toxicol Clin Toxicol** 1996; 34(6):669–72 (4 ref.)

HISTORY

Cognitive neurotoxicology: a luxury or necessity? Stollery BT. **Neurotoxicol Teratol** 1996 Jul–Aug;18(4):359–64 (32 ref.)

INSTRUMENTATION

Cognitive neurotoxicology: a luxury or necessity? Stollery BT. **Neurotoxicol Teratol** 1996 Jul–Aug;18(4):359–64 (32 ref.)

LEGISLATION & JURISPRUDENCE

Acute inhalation toxicity testing: considerations of technical

and regulatory aspects. Pauluhn J, et al. **Arch Toxicol** 1996; 71(1–2):1–10 (37 ref.)
Can we reverse the burden of proof? [see comments] Hansson SO. **Toxicol Lett** 1997 Feb 7;90(2–3):223–8 (15 ref.) Comment in: Toxicol Lett 1997 Feb 7;90(2–3):229–32. Comment in: Toxicol Lett 1997 Feb 7;90(2–3):233–4.
Environmental Protection Agency risk assessment—process and toxicologic pathology. Copley MP. **Toxicol Pathol** 1997 Jan–Feb;25(1):68–71 (3 ref.)
Food and Drug Administration risk assessment—process and toxicologic pathology. Moch RW, et al. **Toxicol Pathol** 1997 Jan–Feb;25(1):61–7 (12 ref.)

METHODS

Integrated approaches for the analysis of toxicologic interactions of chemical mixtures. el-Masri HA, et al. **Crit Rev Toxicol** 1997 Mar;27(2):175–97 (62 ref.)
Impact of knockout mice in toxicology. Ryffel B. **Crit Rev Toxicol** 1997 Mar;27(2):135–54 (120 ref.)
Prevention by exposure assessment. Flyvholm MA. **Curr Probl Dermatol** 1996;25:97–105 (29 ref.)
Immunotoxicology of T cell-dependent experimental liver injury. Tiegs G, et al. **Exp Toxicol Pathol** 1996 Jul; 48(5):471–6 (39 ref.)
Economical designs for detecting and characterizing departure from additivity in mixtures of many chemicals. Gennings C. **Food Chem Toxicol** 1996 Nov–Dec; 34(11–12):1053–8 (22 ref.)
Statistical designs in combination toxicology: a matter of choice. Schoen ED. **Food Chem Toxicol** 1996 Nov–Dec; 34(11–12):1059–65 (17 ref.)
Acute or grave accentuation. Farmer P. **Hum Exp Toxicol** 1996 Dec;15(12):984–5 (5 ref.)
Early indicators of immunotoxicity: development of molecular biological test batteries. Vandebriel RJ, et al. **Hum Exp Toxicol** 1996 Mar;15 Suppl 1:S1, S2–10 (10 ref.)
Transgenic rodents in toxicology. Dayan AD. **Int J Exp Pathol** 1996 Dec;77(6):251–6 (17 ref.)
Applications of liquid chromatography—mass spectrometry in analytical toxicology: a review. Hoja H, et al. **J Anal Toxicol** 1997 Mar–Apr;21(2):116–26 (119 ref.)
Drug screening in biological fluids. The need for a systematic approach. de Zeeuw RA. **J Chromatogr B Biomed Appl** 1997 Feb 7;689(1):71–9 (27 ref.)
Potential of high-performance liquid chromatography with photodiode array detection in forensic toxicology. Lambert WE, et al. **J Chromatogr B Biomed Appl** 1997 Feb 7; 689(1):45–53 (22 ref.)
Information technologies for clinical toxicology in Russia. Litvinov NN, et al. **J Toxicol Clin Toxicol** 1996;34(6):665–8 (6 ref.)
Current issues with regard to single dose toxicity studies. Hashimoto M. **J Toxicol Sci** 1996 Dec;21(5):417–20 (3 ref.)
Occupational toxicology: test methods and approaches for the pharmaceutical industry. Sprague G, et al. **Occup Med** 1997 Jan–Mar;12(1):119–29 (13 ref.)
Evolution of science-based uncertainty factors in noncancer risk assessment [see comments] Dourson ML, et al. **Regul Toxicol Pharmacol** 1996 Oct;24(2 Pt 1):108–20 (62 ref.) Comment in: Regul Toxicol Pharmacol 1996 Oct;24(2 Pt 1):107.
Testing and risk assessment strategies: international perspectives. Koëter HB. **Reprod Toxicol** 1997 Mar–Jun; 11(2–3):453–6 (4 ref.)
Selective protein covalent binding and target organ toxicity. Cohen SD, et al. **Toxicol Appl Pharmacol** 1997 Mar; 143(1):1–12 (99 ref.)
Risk assessment. Brecher RW. **Toxicol Pathol** 1997 Jan–Feb; 25(1):23–6 (6 ref.)
Mechanistic data and risk assessment of selected toxic end points of the thyroid gland. Capen CC. **Toxicol Pathol** 1997 Jan–Feb;25(1):39–48 (35 ref.)
Environmental Protection Agency risk assessment—process and toxicologic pathology. Copley MP. **Toxicol Pathol** 1997 Jan–Feb;25(1):68–71 (3 ref.)
Risk assessment of inhaled chloroform based on its mode of action. Wolf DC, et al. **Toxicol Pathol** 1997 Jan–Feb; 25(1):49–52 (36 ref.)
New research avenues in toxicology: 7-gas N-Gas Model, toxicant suppressants, and genetic toxicology. Levin BC. **Toxicology** 1996 Dec 31;115(1–3):89–106 (41 ref.)
Mutant and transgenic mice in immunotoxicology: an introduction. Løvik M. **Toxicology** 1997 Apr 11; 119(1):65–76 (64 ref.)
Diagnostic and forensic toxicology. Galey FD. **Vet Clin North Am Equine Pract** 1995 Dec;11(3):443–54 (8 ref.)

STANDARDS

Purpose and guidelines for toxicokinetic studies within the National Toxicology Program. Buchanan JR, et al. **Environ Health Perspect** 1997 May;105(5):468–71 (4 ref.)
Experimental designs, statistics and interpretation. Simmons JE, et al. **Food Chem Toxicol** 1996 Nov–Dec; 34(11–12):1169–71 (3 ref.)
Case studies defining non-toxic and toxic dose of pharmaceuticals. Naeshiro I. **J Toxicol Sci** 1996 Dec; 21(5):425–35 (6 ref.)
Diagnostic criteria for degenerative, inflammatory, proliferative nonneoplastic and neoplastic liver lesions in medaka (Oryzias latipes): consensus of a National Toxicology Program Pathology Working Group. Boorman GA, et al. **Toxicol Pathol** 1997 Mar–Apr;25(2):202–10 (32 ref.)

TRENDS

Application of physiologically based pharmacokinetic modelling to combination toxicology. Simmons JE. **Food Chem Toxicol** 1996 Nov–Dec;34(11–12):1067–73 (32 ref.)
Some current approaches for studying combination toxicology in chemical mixtures. Yang RS. **Food Chem Toxicol** 1996 Nov–Dec;34(11–12):1037–44 (56 ref.)
Current issues with regard to single dose toxicity studies. Hashimoto M. **J Toxicol Sci** 1996 Dec;21(5):417–20 (3 ref.)
Neurotoxicology: The Cinderella of neuroscience [see comments] Lotti M. **Neurotoxicology** 1996 Summer; 17(2):313–21 (71 ref.) Comment in: Neurotoxicology 1997;18(1):41–2.
Laboratory animal science, welfare and ethics in pharmacology and toxicology. Svendsen O, et al. **Pharmacol Toxicol** 1997 Jan;80(1):3–5 (14 ref.)
The need for policy and risk analysis—the Department of Energy experience. Henry CJ, et al. **Toxicol Pathol** 1997 Jan–Feb;25(1):27–31 (11 ref.)
Issues with introducing new immunotoxicology methods into the safety assessment of pharmaceuticals. Dean JH. **Toxicology** 1997 Apr 11;119(1):95–101 (4 ref.)
Mutant and transgenic mice in immunotoxicology: an introduction. Løvik M. **Toxicology** 1997 Apr 11; 119(1):65–76 (64 ref.)
Current trends in drug-induced autoimmunity. Uetrecht JP. **Toxicology** 1997 Apr 11;119(1):37–43 (41 ref.)
Is it safe? Doull J. **Vet Hum Toxicol** 1996 Dec;38(6):456–8 (5 ref.)

TOXIN-ANTIBODY CONJUGATES see **IMMUNOTOXINS**

TOXIN-ANTIBODY HYBRIDS see **IMMUNOTOXINS**

TOXIN CARRIERS see **IMMUNOTOXINS**

TOXIN CONJUGATES see **IMMUNOTOXINS**

TOXINS

see related
ANTITOXINS

Plant toxins. The essences of diversity and a challenge to research. Manners GD. **Adv Exp Med Biol** 1996;391:9–35 (137 ref.)
Modulation of cytotoxicity and enhancement of cytokine release induced by Viscum album L. extracts or mistletoe lectins. Ribéreau-Gayon G, et al. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S3–8 (20 ref.)

ADVERSE EFFECTS

Chemical- and toxin-induced hepatotoxicity. Zimmerman HJ, et al. **Gastroenterol Clin North Am** 1995 Dec; 24(4):1027–45 (107 ref.)
[The induction of psychopathology by somatic disorders, medications, toxins and drugs after systemic disorders] García Toro M, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1997 Jan–Feb;25(1):50–60 (93 ref.) (Eng. Abstr.) **(Spa)**

ANALYSIS

Mass spectrometric investigations on proteinaceous toxins and antibodies. Krishnamurthy T, et al. **Adv Exp Med Biol** 1996;391:439–63 (53 ref.)
Applications of liquid chromatography-mass spectrometry interfacing systems in food analysis: pesticide, drug and toxic substance residues. Careri M, et al. **J Chromatogr A** 1996 Mar 15;727(2):153–84 (162 ref.)
[Natural toxic substances in food] Pokorný J. **Cas Lek Cesk** 1997 May 7;136(9):267–70 (34 ref.) (Eng. Abstr.) **(Cze)**

BIOSYNTHESIS

Toxins produced by arthropod parasites: salivary gland proteins of human body lice and venom proteins of chelonine wasps. Jones D, et al. **Toxicon** 1996 Nov–Dec; 34(11–12):1421–9 (32 ref.)

BLOOD

Okadaic acid-like toxin in systemic lupus erythematosus patients: hypothesis for toxin-induced pathology, immune dysregulation, and transactivation of herpesviruses. Mitchell TM. **Med Hypotheses** 1996 Sep;47(3):217–25 (102 ref.)

CHEMISTRY

Membrane insertion: The strategies of toxins (review). Lesieur C, et al. **Mol Membr Biol** 1997 Apr–Jun;14(2):45–64 (152 ref.)
[Structures and functions of animal toxins] Guenneugues M, et al. **C R Seances Soc Biol Fil** 1997;191(3):329–44 (57 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

[Scorpion toxins] Legros C, et al. **C R Seances Soc Biol Fil** 1997;191(3):345–80 (126 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Induction of anti-mistletoe lectin antibodies in relation to different mistletoe-extracts. Stein GM, et al. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S57–9 (10 ref.)

ISOLATION & PURIFICATION

Toxins and genes isolated from scorpions of the genus Tityus. Becerril B, et al. **Toxicon** 1997 Jun;35(6):821–35 (81 ref.)

METABOLISM

Structure and experimental uses of arthropod venom proteins. Jones D. **Adv Exp Med Biol** 1996;391:379–86 (45 ref.)
Uremic toxins. Vanholder R. **Adv Nephrol Necker Hosp** 1997; 26:143–63 (124 ref.)
Membrane insertion: The strategies of toxins (review). Lesieur C, et al. **Mol Membr Biol** 1997 Apr–Jun;14(2):45–64 (152 ref.)

PHARMACOKINETICS

Elimination of drugs and toxins during cardiopulmonary bypass. Rosen DA, et al. **J Cardiothorac Vasc Anesth** 1997 May;11(3):337–40 (38 ref.)

PHARMACOLOGY

Clinical relevance of immunoactive mistletoe lectin-I. Beuth J. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S53–5 (19 ref.)
Differences in the apoptosis-inducing properties of Viscum album L. extracts. Büssing A, et al. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S9–14 (30 ref.)
Toxins affecting K+ channels. Rowan EG, et al. **Braz J Med Biol Res** 1996 Dec;29(12):1765–80 (186 ref.)
[Structures and functions of animal toxins] Guenneugues M, et al. **C R Seances Soc Biol Fil** 1997;191(3):329–44 (57 ref.) (Eng. Abstr.) **(Fre)**

TOXICITY

Expanding the RfD concept to incorporate and optimize beneficial effects while preventing toxic responses from nonessential toxicants. Calabrese EJ. **Ecotoxicol Environ Saf** 1996 Jun;34(1):94–101 (45 ref.)
Muscarinic receptor subtype selective toxins. Adem A, et al. **Life Sci** 1997;60(13–14):1069–76 (32 ref.)
Some aspects of the history of membrane-damaging toxins. Bernheimer AW. **Med Microbiol Immunol (Berl)** 1996 Sep; 185(2):59–63 (26 ref.)

TOXINS, CHIMERIC see **IMMUNOTOXINS**

TOXINS, DEACTIVATED see **TOXOIDS**

TOXINS, TARGETED see **IMMUNOTOXINS**

TOXOCARA CANIS

Human toxocariasis and the visceral larva migrans syndrome: correlative immunopathology. Kayes SG. **Chem Immunol** 1997;66:99–124 (140 ref.)
[Toxocara canis infection. 2 cases of peripheral granuloma in adults] Saint-Blancat P, et al. **J Fr Ophtalmol** 1997; 20(4):252–7 (19 ref.) (Eng. Abstr.) **(Fre)**
[Toxocariasis syndrome as a cause of hypereosinophilia] Dmoch A, et al. **Przegl Lek** 1995;52(12):610–1 (20 ref.) (Eng. Abstr.) **(Pol)**

PATHOGENICITY

[Toxocara canis (Nematoda) and toxocariasis of animals and humans] Okulewicz A, et al. **Wiad Parazytol** 1997; 43(1):3–25 (70 ref.) (Eng. Abstr.) **(Pol)**

TOXOCARIASIS

COMPLICATIONS

[Toxocariasis and functional intestinal disorders. Presentation of 4 cases] Konate A, et al. **Gastroenterol Clin Biol** 1996; 20(10):909–11 (16 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Toxocara canis infection. 2 cases of peripheral granuloma in adults] Saint-Blancat P, et al. **J Fr Ophtalmol** 1997; 20(4):252–7 (19 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

[Toxocara canis (Nematoda) and toxocariasis of animals and humans] Okulewicz A, et al. **Wiad Parazytol** 1997; 43(1):3–25 (70 ref.) (Eng. Abstr.) **(Pol)**

TOXOIDS

A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned [see comments] Schneerson R, et al. **Lancet** 1996 Nov 9;348(9037):1289–92 (38 ref.) Comment in: Lancet 1997 Jan 11;349(9045):136; discussion 137–8.

TOXOIDS

Comment in: Lancet 1997 Jan 11;349(9045):136-7; discussion 137-8. Comment in: Lancet 1997 Jan 11;349(9045):137; discussion 137-8.

IMMUNOLOGY

Examination of similarities between diphtheria and pertussis and their toxoids provide insight into vaccine-induced protection to Bordetella pertussis. Schneerson R, et al. **Dev Biol Stand** 1997;89:321-6 (35 ref.)

TOXOPLASMA

AIDS-associated cerebral toxoplasmosis: an update on diagnosis and treatment. Ammassari A, et al. **Curr Top Microbiol Immunol** 1996;219:209-22 (63 ref.)

Cytokine production by human cells after Toxoplasma gondii infection. Pelloux H, et al. **Curr Top Microbiol Immunol** 1996;219:155-63 (25 ref.)

Genetic basis of pathogenicity in toxoplasmosis. Sibley LD, et al. **Curr Top Microbiol Immunol** 1996;219:3-15 (55 ref.)

DRUG EFFECTS

Influence of antimicrobial agents on replication and stage conversion of Toxoplasma gondii. Gross U, et al. **Curr Top Microbiol Immunol** 1996;219:235-45 (39 ref.)

GENETICS

Bradyzoite-specific genes. Bohne W, et al. **Curr Top Microbiol Immunol** 1996;219:81-91 (33 ref.)

Biodiversity in Toxoplasma gondii. Dardé ML. **Curr Top Microbiol Immunol** 1996;219:27-41 (27 ref.)

DNA polymorphisms associated with murine virulence of Toxoplasma gondii identified by RAPD-PCR. Guo ZG, et al. **Curr Top Microbiol Immunol** 1996;219:17-26 (32 ref.)

Molecular genetic tools for the identification and analysis of drug targets in Toxoplasma gondii. Roos DS. **Curr Top Microbiol Immunol** 1996;219:247-59 (39 ref.)

Genomic drift of Toxoplasma gondii. Frenkel JK, et al. **Parasitol Res** 1997;83(1):1-5 (30 ref.)

GROWTH & DEVELOPMENT

[Structure and biology of Toxoplasma gondii bradyzoites] Fortier B, et al. **C R Seances Soc Biol Fil** 1996;190(4):385-94 (37 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Immunological control of Toxoplasma gondii and appropriate vaccine design. Alexander J, et al. **Curr Top Microbiol Immunol** 1996;219:183-95 (81 ref.)

Detection of IgA anti-P30 (SAG1) antibodies in acquired and congenital toxoplasmosis. Decoster A. **Curr Top Microbiol Immunol** 1996;219:199-207 (54 ref.)

Role of macrophage-derived cytokines in the induction and regulation of cell-mediated immunity to Toxoplasma gondii. Gazzinelli RT, et al. **Curr Top Microbiol Immunol** 1996;219:127-39 (46 ref.)

Cells and cytokines in resistance to Toxoplasma gondii. Hunter CA, et al. **Curr Top Microbiol Immunol** 1996; 219:113-25 (54 ref.)

Characterization of human T cell clones specific for Toxoplasma gondii. Pistoia V, et al. **Curr Top Microbiol Immunol** 1996;219:165-73 (29 ref.)

Serological recognition of Toxoplasma gondii cyst antigens. Smith JE, et al. **Curr Top Microbiol Immunol** 1996; 219:67-73 (27 ref.)

Contribution of 65-kDa heat shock protein induced by gamma and delta T cells to protection against Toxoplasma gondii infection. Himeno K, et al. **Immunol Res** 1996; 15(3):258-64 (25 ref.)

Role of IL12 in induction of cell-mediated immunity to Toxoplasma gondii [published erratum appears in Res Immunol 1996 Feb;147(2):121] Scharton-Kersten T, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):539-45 (29 ref.)

METABOLISM

Toxoplasma gondii microneme proteins: gene cloning and possible function. Fourmaux MN, et al. **Curr Top Microbiol Immunol** 1996;219:55-8 (16 ref.)

Toxoplasma gondii: kinetics of stage-specific protein expression during tachyzoite-bradyzoite conversion in vitro. Soête M, et al. **Curr Top Microbiol Immunol** 1996; 219:76-80 (16 ref.)

The major surface proteins of Toxoplasma gondii: structures and functions. Tomavo S. **Curr Top Microbiol Immunol** 1996;219:45-54 (38 ref.)

[Structure and biology of Toxoplasma gondii bradyzoites] Fortier B, et al. **C R Seances Soc Biol Fil** 1996;190(4):385-94 (37 ref.) (Eng. Abstr.) **(Fre)**

PATHOGENICITY

Toxoplasma gondii and ocular toxoplasmosis: pathogenesis. Pavesio CE, et al. **Br J Ophthalmol** 1996 Dec; 80(12):1099-107 (143 ref.)

Role of nitric oxide-induced immune suppression in toxoplasmosis during pregnancy and in infection by a virulent strain of Toxoplasma gondii. Candolfi E, et al. **Curr Top Microbiol Immunol** 1996;219:141-54 (61 ref.)

Co-infection of Toxoplasma gondii with other pathogens: pathogenicity and chemotherapy in animal models. Lacroix C, et al. **Curr Top Microbiol Immunol** 1996;219:223-33 (33 ref.)

PHYSIOLOGY

Structure and function of the Toxoplasma gondii vacuole. Joiner KA, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:1-7 (32 ref.)

Studies of the effect of various treatments on the viability of Toxoplasma gondii tissue cysts and oocysts. Kuticic V, et al. **Curr Top Microbiol Immunol** 1996;219:261-5 (15 ref.)

ULTRASTRUCTURE

Role of secretory dense granule organelles in the pathogenesis of toxoplasmosis. Cesbron-Delauw MF, et al. **Curr Top Microbiol Immunol** 1996;219:59-65 (31 ref.)

TOXOPLASMA GONDII see **TOXOPLASMA**

TOXOPLASMA GONDII INFECTION see **TOXOPLASMOSIS**

TOXOPLASMOSIS

Toxoplasmosis in kidney transplant recipients: report of six cases and review. Renoult E, et al. **Clin Infect Dis** 1997 Apr;24(4):625-34 (43 ref.)

Genetic basis of pathogenicity in toxoplasmosis. Sibley LD, et al. **Curr Top Microbiol Immunol** 1996;219:3-15 (55 ref.)

Toxoplasmosis. Lynfield R, et al. **Pediatr Rev** 1997 Mar; 18(3):75-83 (14 ref.)

Pulmonary toxoplasmosis. Campagna AC. **Semin Respir Infect** 1997 Jun;12(2):98-105 (47 ref.)

[Protozoal myocarditis] Kimura K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):79-82 (21 ref.) **(Jpn)**

[Protozoal pericarditis] Seto S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):508-10 (8 ref.) **(Jpn)**

[Toxoplasmosis in patients with AIDS] Zieliński A. **Przegl Epidemiol** 1995;49(4):343-52 (86 ref.) (Eng. Abstr.) **(Pol)**

COMPLICATIONS

Infectious causes of hydrops fetalis. Barron SD, et al. **Semin Perinatol** 1995 Dec;19(6):493-501 (94 ref.)

DIAGNOSIS

Serological recognition of Toxoplasma gondii cyst antigens. Smith JE, et al. **Curr Top Microbiol Immunol** 1996; 219:67-73 (27 ref.)

Screening for toxoplasmosis in pregnancy: what is the evidence of reducing a health problem? Eskild A, et al. **J Med Screen** 1996;3(4):188-94 (76 ref.)

[Value and limits of complementary investigations in cases of toxoplasmosis seroconversion during pregnancy. A case report and review of the literature] Therby D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(5):505-9 (14 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Influence of antimicrobial agents on replication and stage conversion of Toxoplasma gondii. Gross U, et al. **Curr Top Microbiol Immunol** 1996;219:235-45 (39 ref.)

Molecular genetic tools for the identification and analysis of drug targets in Toxoplasma gondii. Roos DS. **Curr Top Microbiol Immunol** 1996;219:247-59 (39 ref.)

Toxoplasmosis and parvovirus B19. Alger LS. **Infect Dis Clin North Am** 1997 Mar;11(1):55-75 (96 ref.)

EPIDEMIOLOGY

Gastric toxoplasmosis: case report and review of the literature. Kofman E, et al. **Am J Gastroenterol** 1996 Nov; 91(11):2436-8 (8 ref.)

ETIOLOGY

Toxoplasmosis: comparative species susceptibility and host immune response. Innes EA. **Comp Immunol Microbiol Infect Dis** 1997 Feb;20(2):131-8 (37 ref.)

[Inflammatory myopathies] Espinosa E. **Rev Neurol** 1996 Nov;24(135):1376-81 (33 ref.) **(Spa)**

IMMUNOLOGY

Mini review: protective immunity in toxoplasmosis. Nagasawa H, et al. **Appl Parasitol** 1996 Dec;37(4):284-92 (41 ref.)

Role of natural killer and NK1+ T-cells in regulating cell-mediated immunity during Toxoplasma gondii infection. Denkers EY, et al. **Biochem Soc Trans** 1997 May; 25(2):699-703 (43 ref.)

Toxoplasmosis: comparative species susceptibility and host immune response. Innes EA. **Comp Immunol Microbiol Infect Dis** 1997 Feb;20(2):131-8 (37 ref.)

Immunological control of Toxoplasma gondii and appropriate vaccine design. Alexander J, et al. **Curr Top Microbiol Immunol** 1996;219:183-95 (81 ref.)

Role of nitric oxide-induced immune suppression in toxoplasmosis during pregnancy and in infection by a virulent strain of Toxoplasma gondii. Candolfi E, et al. **Curr Top Microbiol Immunol** 1996;219:141-54 (61 ref.)

Detection of IgA anti-P30 (SAG1) antibodies in acquired and congenital toxoplasmosis. Decoster A. **Curr Top Microbiol Immunol** 1996;219:199-207 (54 ref.)

Role of macrophage-derived cytokines in the induction and regulation of cell-mediated immunity to Toxoplasma gondii. Gazzinelli RT, et al. **Curr Top Microbiol Immunol** 1996;219:127-39 (46 ref.)

Cells and cytokines in resistance to Toxoplasma gondii. Hunter CA, et al. **Curr Top Microbiol Immunol** 1996; 219:113-25 (54 ref.)

Cytokine production by human cells after Toxoplasma gondii infection. Pelloux H, et al. **Curr Top Microbiol Immunol** 1996;219:155-63 (25 ref.)

Characterization of human T cell clones specific for Toxoplasma gondii. Pistoia V, et al. **Curr Top Microbiol Immunol** 1996;219:165-73 (29 ref.)

Does human toxoplasmosis involve an imbalance in T1/T2 cytokines? Gómez Marín JE, et al. **Med Hypotheses** 1997 Feb;48(2):161-9 (72 ref.)

Role of IL12 in induction of cell-mediated immunity to Toxoplasma gondii [published erratum appears in Res Immunol 1996 Feb;147(2):121] Scharton-Kersten T, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):539-45 (29 ref.)

PARASITOLOGY

Bradyzoite-specific genes. Bohne W, et al. **Curr Top Microbiol Immunol** 1996;219:81-91 (33 ref.)

Role of secretory dense granule organelles in the pathogenesis of toxoplasmosis. Cesbron-Delauw MF, et al. **Curr Top Microbiol Immunol** 1996;219:59-65 (31 ref.)

Biodiversity in Toxoplasma gondii. Dardé ML. **Curr Top Microbiol Immunol** 1996;219:27-41 (27 ref.)

Toxoplasma gondii: kinetics of stage-specific protein expression during tachyzoite-bradyzoite conversion in vitro. Soête M, et al. **Curr Top Microbiol Immunol** 1996; 219:76-80 (16 ref.)

The major surface proteins of Toxoplasma gondii: structures and functions. Tomavo S. **Curr Top Microbiol Immunol** 1996;219:45-54 (38 ref.)

PATHOLOGY

Morphology and diagnostics of human toxoplasmosis. Röse I. **Gen Diagn Pathol** 1997 Jun;142(5-6):257-70 (88 ref.)

PHYSIOPATHOLOGY

Toxoplasmosis of the spinal cord in a patient with AIDS: case report and review. Vyas R, et al. **Clin Infect Dis** 1996 Nov;23(5):1061-5 (29 ref.)

PREVENTION & CONTROL

Strategies to reduce transmission of Toxoplasma gondii to animals and humans. Dubey JP. **Vet Parasitol** 1996 Aug; 64(1-2):65-70 (39 ref.)

[Prevention of toxoplasmosis in immunocompromised patients] Morlat P, et al. **Ann Med Interne (Paris)** 1997; 148(3):235-9 (32 ref.) (Eng. Abstr.) **(Fre)**

TRANSMISSION

Pulmonary toxoplasmosis after allogeneic bone marrow transplantation: case report and review. Saad R, et al. **Bone Marrow Transplant** 1996 Jul;18(1):211-2 (10 ref.)

Zoonotic protozoa. Trees AJ. **J Med Microbiol** 1997 Jan; 46(1):20-4, 28-33 (228 ref.)

TOXOPLASMOSIS, ANIMAL

Co-infection of Toxoplasma gondii with other pathogens: pathogenicity and chemotherapy in animal models. Lacroix C, et al. **Curr Top Microbiol Immunol** 1996;219:223-33 (33 ref.)

DIAGNOSIS

Feline toxoplasmosis: interpretation of diagnostic test results. Lappin MR. **Semin Vet Med Surg (Small Anim)** 1996 Aug; 11(3):154-60 (39 ref.)

ETIOLOGY

Toxoplasmosis: comparative species susceptibility and host immune response. Innes EA. **Comp Immunol Microbiol Infect Dis** 1997 Feb;20(2):131-8 (37 ref.)

GENETICS

DNA polymorphisms associated with murine virulence of Toxoplasma gondii identified by RAPD-PCR. Guo ZG, et al. **Curr Top Microbiol Immunol** 1996;219:17-26 (32 ref.)

IMMUNOLOGY

Toxoplasmosis: comparative species susceptibility and host immune response. Innes EA. **Comp Immunol Microbiol Infect Dis** 1997 Feb;20(2):131-8 (37 ref.)

Role of nitric oxide-induced immune suppression in toxoplasmosis during pregnancy and in infection by a virulent strain of Toxoplasma gondii. Candolfi E, et al. **Curr Top Microbiol Immunol** 1996;219:141-54 (61 ref.)

Contribution of 65-kDa heat shock protein induced by gamma and delta T cells to protection against Toxoplasma gondii infection. Himeno K, et al. **Immunol Res** 1996; 15(3):258–64 (25 ref.)
The role of IL12 in toxoplasmosis. Hunter CA, et al. **Res Immunol** 1995 Sep–Oct;146(7–8):546–52 (44 ref.)
Role of IL12 in induction of cell-mediated immunity to Toxoplasma gondii [published erratum appears in Res Immunol 1996 Feb;147(2):121] Scharton-Kersten T, et al. **Res Immunol** 1995 Sep–Oct;146(7–8):539–45 (29 ref.)

PARASITOLOGY

Role of secretory dense granule organelles in the pathogenesis of toxoplasmosis. Cesbron-Delauw MF, et al. **Curr Top Microbiol Immunol** 1996;219:59–65 (31 ref.)
Biodiversity in Toxoplasma gondii. Dardé ML. **Curr Top Microbiol Immunol** 1996;219:27–41 (27 ref.)
The major surface proteins of Toxoplasma gondii: structures and functions. Tomavo S. **Curr Top Microbiol Immunol** 1996;219:45–54 (38 ref.)

PREVENTION & CONTROL

Contribution of 65-kDa heat shock protein induced by gamma and delta T cells to protection against Toxoplasma gondii infection. Himeno K, et al. **Immunol Res** 1996; 15(3):258–64 (25 ref.)

TRANSMISSION

Strategies to reduce transmission of Toxoplasma gondii to animals and humans. Dubey JP. **Vet Parasitol** 1996 Aug; 64(1–2):65–70 (39 ref.)

TOXOPLASMOSIS, CEREBRAL

AIDS-associated cerebral toxoplasmosis: an update on diagnosis and treatment. Ammassari A, et al. **Curr Top Microbiol Immunol** 1996;219:209–22 (63 ref.)

DIAGNOSIS

Neuroimaging of AIDS. I. Central nervous system toxoplasmosis. Ramsey RG, et al. **Neuroimaging Clin N Am** 1997 May;7(2):171–86 (67 ref.)
[A solitary toxoplasmosis focus simulating a brain tumor as the first manifestation of AIDS] Röricht S, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Aug;167(2):201–3 (12 ref.) **(Ger)**

IMMUNOLOGY

Cellular immune reactions directed against Toxoplasma gondii with special emphasis on the central nervous system. Däubener W, et al. **Med Microbiol Immunol (Berl)** 1997 Mar;185(4):195–206 (133 ref.)

PREVENTION & CONTROL

[Risk factors of cerebral toxoplasmosis in patients with HIV infection. Definition of indications of primary prevention] Leport C, et al. **Ann Med Interne (Paris)** 1996;147(5):331–2 (8 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Treatment regimens for patients with toxoplasmic encephalitis. Fung HB, et al. **Clin Ther** 1996 Nov–Dec; 18(6):1037–56; discussion 1036 (67 ref.)
Toxoplasmosis of the central nervous system in non-human immunodeficiency virus-infected children: case report and review of the literature. Khan EA, et al. **Pediatr Infect Dis J** 1997 Jun;16(6):611–8 (60 ref.)

TOXOPLASMOSIS, CONGENITAL

Immunogenetics in pathogenesis of and protection against toxoplasmosis. McLeod R, et al. **Curr Top Microbiol Immunol** 1996;219:95–112 (67 ref.)

IMMUNOLOGY

Detection of IgA anti-P30 (SAG1) antibodies in acquired and congenital toxoplasmosis. Decoster A. **Curr Top Microbiol Immunol** 1996;219:199–207 (54 ref.)

PATHOLOGY

Morphology and diagnostics of human toxoplasmosis. Röse I. **Gen Diagn Pathol** 1997 Jun;142(5–6):257–70 (88 ref.)

PREVENTION & CONTROL

Screening for toxoplasmosis in pregnancy: what is the evidence of reducing a health problem? Eskild A, et al. **J Med Screen** 1996;3(4):188–94 (76 ref.)

TOXOPLASMOSIS, OCULAR

Toxoplasma gondii and ocular toxoplasmosis: pathogenesis. Pavesio CE, et al. **Br J Ophthalmol** 1996 Dec; 80(12):1099–107 (143 ref.)
Ocular toxoplasmosis in HIV infection [editorial] Rodgers CA, et al. **Int J STD AIDS** 1996 Aug–Sep;7(5):307–9 (21 ref.)

TOYS see **PLAY AND PLAYTHINGS**

TP53 GENES see **GENES, P53**

TP53 PROTEIN see **PROTEIN P53**

TP RECEPTORS see **RECEPTORS, THROMBOXANE**

TR ALPHA see **RECEPTORS, THYROID HORMONE**

TR BETA see **RECEPTORS, THYROID HORMONE**

TRABECULAR MESHWORK

ULTRASTRUCTURE

Pathological dilemmas in the outflow system in primary open-angle glaucoma. Grierson I, et al. **Acta Ophthalmol Scand Suppl** 1997;(220):7–12; discussion 13–4 (39 ref.)

TRABECULECTOMY

Mechanisms of failure in glaucoma filtering surgery: a consequence of antiglaucomatous drugs? Baudouin C. **Int J Clin Pharmacol Res** 1996;16(1):29–41 (39 ref.)
Outcomes of trabeculectomy for primary open-angle glaucoma. Nouri-Mahdavi K, et al. **Ophthalmology** 1995 Dec;102(12):1760–9 (46 ref.)

ADVERSE EFFECTS

Resuturing the scleral flap leads to resolution of hypotony maculopathy. Schwartz GF, et al. **J Glaucoma** 1996 Aug; 5(4):246–51 (50 ref.)
Bleb infections: clinically different courses of "blebitis" and endophthalmitis. Ayyala RS, et al. **Ophthalmic Surg Lasers** 1997 Jun;28(6):452–60 (24 ref.)

METHODS

Trabeculectomy with intraoperative sponge 5-fluorouracil in Afro-Caribbeans. Lachkar Y, et al. **Br J Ophthalmol** 1997 Jul;81(7):555–8 (28 ref.)

TRABECULOPLASTY see **TRABECULECTOMY**

TRACE ELEMENTS

see related
MICRONUTRIENTS

Functional changes appropriate for determining mineral element requirements. Lukaski HC, et al. **J Nutr** 1996 Sep; 126(9 Suppl):2354S–2364S (26 ref.)
How should dietary guidance be given for mineral elements with beneficial actions or suspected of being essential? Nielsen FH. **J Nutr** 1996 Sep;126(9 Suppl):2377S–2385S (25 ref.)
[Trace elements, human nutrition and health] Malbohan IM, et al. **Cas Lek Cesk** 1997 May 29;136(11):356–9 (35 ref.) (Eng. Abstr.) **(Cze)**
[Chromium—essential trace element for prevention and treatment of diabetes mellitus and cardiovascular diseases] Mirsky N. **Harefuah** 1997 Jan 15;132(2):133–6 (40 ref.) **(Heb)**

ADMINISTRATION & DOSAGE

Interactions related to trace elements in parenteral nutrition. Harraki B, et al. **Pharm Acta Helv** 1995 Dec;70(4):269–78 (71 ref.)
[Relationship of vitamins and microelements and their role in the prevention of iron deficiencies (review)] Nasolodin VV, et al. **Gig Sanit** 1996 Nov–Dec;(6):26–9 (41 ref.) **(Rus)**

ADVERSE EFFECTS

Trace elements and cardiovascular diseases. Houtman JP. **J Cardiovasc Risk** 1996 Feb;3(1):18–25 (96 ref.)

ANALYSIS

Standard reference materials and data quality assurance in the biomedical analysis of trace elements. Gallorini M, et al. **Biol Trace Elem Res** 1996 Jun;52(3):263–72 (18 ref.)
Nuclear microprobe: a microanalytical technique in biology. Moretto P. **Cell Mol Biol (Noisy-le-grand)** 1996 Feb; 42(1):1–16 (69 ref.)
Nuclear microscope analysis in Alzheimer's and Parkinson's disease: A review. Watt F. **Cell Mol Biol (Noisy-le-grand)** 1996 Feb;42(1):17–26 (34 ref.)
Concentrations of chlorinated hydrocarbons and trace elements in marine mammal tissues archived in the U.S. National Biomonitoring Specimen Bank. Becker PR, et al. **Chemosphere** 1997 May;34(9–10):2067–98 (38 ref.)
Sweeteners, dyes, and other excipients in vitamin and mineral preparations. Kumar A, et al. **Clin Pediatr (Phila)** 1996 Sep; 35(9):443–50 (28 ref.)
Adequacy of dialysis: trace elements in dialysis fluids. D'Haese PC, et al. **Nephrol Dial Transplant** 1996;11 Suppl 2:92–7 (34 ref.)

DEFICIENCY

Detection and monitoring of disorders of essential trace elements. Taylor A. **Ann Clin Biochem** 1996 Nov;33 (Pt 6):486–510 (199 ref.)
[General pathology of trace element deficiency] Zhavoronkov AA, et al. **Arkh Patol** 1997 Mar–Apr; 59(2):8–11 (24 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Trace elements and vitamins in immunomodulation in infancy and childhood. Zuin G, et al. **Eur J Cancer Prev** 1997 Mar; 6 Suppl 1:S69–77 (50 ref.)
[Trace elements and natural killer activity] Zhavoronkov AA, et al. **Arkh Patol** 1996 Nov–Dec;58(6):65–70 (59 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Trace mineral metabolism in the avian embryo. Richards MP. **Poult Sci** 1997 Jan;76(1):152–64 (112 ref.)
[The mineral requirements and mineral status in pregnancy] Ivanova L. **Akush Ginekol (Sofiia)** 1996;35(1–2):40–2 (23 ref.) (Eng. Abstr.) **(Bul)**

PHARMACOKINETICS

Bioavailability of oral vitamins, minerals, and trace elements in perspective. Schümann K, et al. **Arzneimittelforschung** 1997 Apr;47(4):369–80 (73 ref.)
Effects of milk and milk components on calcium, magnesium, and trace element absorption during infancy. Lönnerdal B. **Physiol Rev** 1997 Jul;77(3):643–69 (243 ref.)

PHYSIOLOGY

Trace elements in health and diseases. Xiu YM. **Biomed Environ Sci** 1996 Sep;9(2–3):130–6 (22 ref.)

THERAPEUTIC USE

[The pathogenetic use of trace elements in treating anemia] Popova IIu, et al. **Eksp Klin Farmakol** 1996 May–Jun; 59(3):72–7 (102 ref.) **(Rus)**

TRACHEA

see related
ANESTHESIA, INTRATRACHEAL
INTUBATION, INTRATRACHEAL
TRACHEOSTOMY
TRACHEOTOMY

ABNORMALITIES

Tracheal agenesis: a case report and review of the literature. Kerschner J, et al. **Otolaryngol Head Neck Surg** 1997 Jan; 116(1):123–8 (91 ref.)
Asynchronous pulmonary hyperplasia associated with tracheal atresia: pathologic and prenatal sonographic findings. Wright JR Jr, et al. **Pediatr Pathol Lab Med** 1995 Jan–Feb;15(1):81–97 (21 ref.)
Prenatal ultrasonographic detection of the tracheal atresia sequence. Kassanos D, et al. **Ultrasound Obstet Gynecol** 1997 Aug;10(2):133–6 (17 ref.)
[Variants and early symptoms of congenital diseases of larynx and trachea] Chireshkin DG, et al. **Vestn Otorinolaringol** 1996 Sep–Oct;(5):13–8 (28 ref.) (Eng. Abstr.) **(Rus)**

ANATOMY & HISTOLOGY

Surgical anatomy of the trachea. Allen MS. **Chest Surg Clin N Am** 1996 Nov;6(4):627–35 (8 ref.)

BLOOD SUPPLY

The tracheobronchial vasculature: a possible role in asthma. Widdicombe J. **Microcirculation** 1996 Jun;3(2):129–41 (68 ref.)
Extravasation, lamina propria flooding and lumenal entry of bulk plasma exudate in mucosal defence, inflammation and repair. Persson CG, et al. **Pulm Pharmacol** 1996 Jun; 9(3):129–39 (69 ref.)

EMBRYOLOGY

Cell-matrix interactions in gland development in the lung. Infeld MD. **Exp Lung Res** 1997 Mar–Apr;23(2):161–9 (24 ref.)

INJURIES

Lower airway injuries and anaesthesia [see comments] Devitt JH, et al. **Can J Anaesth** 1996 Feb;43(2):148–59 (63 ref.) Comment in: Can J Anaesth 1996 Nov;43(11):1181–2.
Laryngotracheal trauma. Chagnon FP, et al. **Chest Surg Clin N Am** 1996 Nov;6(4):733–48 (39 ref.)
Traumatic injury of the cervicothoracic trachea and major bronchi. Lee RB. **Chest Surg Clin N Am** 1997 May; 7(2):285–304 (78 ref.)
Computed tomographic evaluation of laryngotracheal trauma. Lupetin AR. **Curr Probl Diagn Radiol** 1997 Jul–Aug;26(4):185–206 (38 ref.)
Tracheal rupture after blunt chest trauma in a child. Mordehai J, et al. **J Pediatr Surg** 1997 Jan;32(1):104–5 (12 ref.)
[Two cases of tracheal injuries secondary to blunt trauma] Asakura S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):563–8 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Urgent thoracotomy for injuries to the tracheobronchial tree

due to blunt trauma--a seven cases report and a literature review of 32 cases in Japan] Tanaka H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jun;45(6):851–9 (46 ref.) (Eng. Abstr.) **(Jpn)**

[Conservative treatment of 2 tracheal lesions secondary to anesthetic intubation] Buitrago LJ, et al. **Arch Bronconeumol** 1997 Mar;33(3):151–3 (16 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Clinicopathological consultation. Lymphoepithelial carcinoma of the larynx hypopharynx, and trachea. Ferlito A, et al. **Ann Otol Rhinol Laryngol** 1997 May;106(5):437–44 (111 ref.)

Surgical management of thyroid cancer invading the trachea. Zannini P, et al. **Chest Surg Clin N Am** 1996 Nov; 6(4):777–90 (24 ref.)

Tracheoesophageal compression due to congenital vascular anomalies (vascular rings). Valletta EA, et al. **Pediatr Pulmonol** 1997 Aug;24(2):93–105 (82 ref.)

[Cell types of respiratory epithelium: morphology, molecular biology and clinical significance] Bals R. **Pneumologie** 1997 Feb;51(2):142–9 (79 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Epithelium, microcirculation, and eosinophils--new aspects of the allergic airway in vivo. Persson CG, et al. **Allergy** 1997 Mar;52(3):241–55 (98 ref.)

Muscarinic control of airway function. Zaagsma J, et al. **Life Sci** 1997;60(13–14):1061–8 (40 ref.)

RADIOGRAPHY

Radiologic evaluation of the trachea. Weber AL. **Chest Surg Clin N Am** 1996 Nov;6(4):637–73 (110 ref.)

Computed tomography of the airways. Worthy SA, et al. **Eur Radiol** 1996;6(5):717–29 (98 ref.)

SURGERY

Surgical management of congenital tracheal stenosis. Brown JW, et al. **Chest Surg Clin N Am** 1996 Nov;6(4):837–52 (13 ref.)

Laryngotracheal trauma. Chagnon FP, et al. **Chest Surg Clin N Am** 1996 Nov;6(4):733–48 (39 ref.)

Pediatric tracheal problems. Grillo HC. **Chest Surg Clin N Am** 1996 Nov;6(4):693–700 (29 ref.)

Postintubation tracheal stenosis. Grillo HC, et al. **Chest Surg Clin N Am** 1996 Nov;6(4):725–31 (14 ref.)

Tracheal release maneuvers. Heitmiller RF. **Chest Surg Clin N Am** 1996 Nov;6(4):675–82 (10 ref.)

Complications of tracheal surgery. Mathisen DJ. **Chest Surg Clin N Am** 1996 Nov;6(4):853–64 (9 ref.)

Tracheal tumors. Mathisen DJ. **Chest Surg Clin N Am** 1996 Nov;6(4):875–98 (16 ref.)

Surgical management of thyroid cancer invading the trachea. Zannini P, et al. **Chest Surg Clin N Am** 1996 Nov; 6(4):777–90 (24 ref.)

Type III–IV laryngotracheoesophageal cleft: report of a successfully treated case. Pinlong E, et al. **Int J Pediatr Otorhinolaryngol** 1996 Aug;36(3):253–62 (15 ref.)

Carinal resection for bronchogenic cancer. Dartevelle P, et al. **Semin Thorac Cardiovasc Surg** 1996 Oct;8(4):414–25 (28 ref.)

Carinal reconstruction: techniques and problems. Mathisen DJ. **Semin Thorac Cardiovasc Surg** 1996 Oct;8(4):403–13 (23 ref.)

Subglottic resection with primary tracheal anastomosis: including synchronous laryngotracheal reconstructions. Pearson FG, et al. **Semin Thorac Cardiovasc Surg** 1996 Oct; 8(4):381–91 (19 ref.)

[Two cases of tracheal injuries secondary to blunt trauma] Asakura S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):563–8 (14 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Asynchronous pulmonary hyperplasia associated with tracheal atresia: pathologic and prenatal sonographic findings. Wright JR Jr, et al. **Pediatr Pathol Lab Med** 1995 Jan–Feb;15(1):81–97 (21 ref.)

TRACHEAL CYST see **MEDIASTINAL CYST**

TRACHEAL DISEASES

COMPLICATIONS

Wegener's granulomatosis, acute laryngotracheal airway obstruction and death in a 17-year-old female: case report and review of the literature. Matt BH. **Int J Pediatr Otorhinolaryngol** 1996 Oct;37(2):163–72 (19 ref.)

CONGENITAL

[Variants and early symptoms of congenital diseases of larynx and trachea] Chireshkin DG, et al. **Vestn Otorinolaringol** 1996 Sep–Oct;(5):13–8 (28 ref.) (Eng. Abstr.) **(Rus)**

DIAGNOSIS

[Variants and early symptoms of congenital diseases of larynx and trachea] Chireshkin DG, et al. **Vestn Otorinolaringol** 1996 Sep–Oct;(5):13–8 (28 ref.) (Eng. Abstr.) **(Rus)**

SURGERY

Management of tracheoinnominate artery fistula. Wright CD. **Chest Surg Clin N Am** 1996 Nov;6(4):865–73 (17 ref.)

Laser applications in the tracheobronchial tree. Rebeiz EE, et al. **Otolaryngol Clin North Am** 1996 Dec;29(6):987–1003 (52 ref.)

ULTRASONOGRAPHY

Prenatal ultrasonographic detection of the tracheal atresia sequence. Kassanos D, et al. **Ultrasound Obstet Gynecol** 1997 Aug;10(2):133–6 (17 ref.)

TRACHEAL NEOPLASMS

Adenoid cystic carcinoma of the trachea. A report of 2 cases. Sur RK, et al. **S Afr J Surg** 1996 Nov;34(4):191–2 (8 ref.)

COMPLICATIONS

Malignant tracheo-esophageal fistula: use of esophageal endoprosthesis. Spivak F, et al. **J Surg Oncol** 1996 Sep; 63(1):65–70 (36 ref.)

PATHOLOGY

Clinicopathological consultation. Lymphoepithelial carcinoma of the larynx hypopharynx, and trachea. Ferlito A, et al. **Ann Otol Rhinol Laryngol** 1997 May;106(5):437–44 (111 ref.)

SURGERY

Chondrosarcoma originating from the trachea. Kiriyama M, et al. **Ann Thorac Surg** 1997 Jun;63(6):1772–3 (9 ref.)

Tracheal tumors. Mathisen DJ. **Chest Surg Clin N Am** 1996 Nov;6(4):875–98 (16 ref.)

Carinal reconstruction: techniques and problems. Mathisen DJ. **Semin Thorac Cardiovasc Surg** 1996 Oct;8(4):403–13 (23 ref.)

THERAPY

Management of malignant esophagorespiratory fistula. Burt M. **Chest Surg Clin N Am** 1996 Nov;6(4):765–76 (50 ref.)

TRACHEAL STENOSIS

CONGENITAL

Surgical management of congenital tracheal stenosis. Brown JW, et al. **Chest Surg Clin N Am** 1996 Nov;6(4):837–52 (13 ref.)

DIAGNOSIS

Assessment and management of laryngotracheal stenosis. Lesperance MM, et al. **Pediatr Clin North Am** 1996 Dec; 43(6):1413–27 (36 ref.)

ETIOLOGY

Postintubation tracheal stenosis. Grillo HC, et al. **Chest Surg Clin N Am** 1996 Nov;6(4):725–31 (14 ref.)

Tracheoesophageal compression due to congenital vascular anomalies (vascular rings). Valletta EA, et al. **Pediatr Pulmonol** 1997 Aug;24(2):93–105 (82 ref.)

Post intubation tracheal stenosis. Grillo HC, et al. **Semin Thorac Cardiovasc Surg** 1996 Oct;8(4):370–80 (16 ref.)

Mediastinal compression syndromes due to idiopathic fibrosing mediastinitis--report of three cases and review of the literature. Kalweit G, et al. **Thorac Cardiovasc Surg** 1996 Apr;44(2):105–9 (34 ref.)

RADIOGRAPHY

Radiologic evaluation of the trachea. Weber AL. **Chest Surg Clin N Am** 1996 Nov;6(4):637–73 (110 ref.)

SURGERY

Surgical management of congenital tracheal stenosis. Brown JW, et al. **Chest Surg Clin N Am** 1996 Nov;6(4):837–52 (13 ref.)

Management of idiopathic tracheal stenosis. Grillo HC. **Chest Surg Clin N Am** 1996 Nov;6(4):811–8 (5 ref.)

Pediatric tracheal problems. Grillo HC. **Chest Surg Clin N Am** 1996 Nov;6(4):693–700 (29 ref.)

Postintubation tracheal stenosis. Grillo HC, et al. **Chest Surg Clin N Am** 1996 Nov;6(4):725–31 (14 ref.)

Complications of tracheal surgery. Mathisen DJ. **Chest Surg Clin N Am** 1996 Nov;6(4):853–64 (9 ref.)

Assessment and management of laryngotracheal stenosis. Lesperance MM, et al. **Pediatr Clin North Am** 1996 Dec; 43(6):1413–27 (36 ref.)

Nonvascular stents. Vanderburgh L, et al. **Prog Cardiovasc Dis** 1996 Sep–Oct;39(2):187–200 (75 ref.)

[Surgical emergency induced by chest tumors] Yamaguchi Y, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(3):272–8 (7 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

[The use of endoprosthesis in treating tracheal and bronchial stenosis] Grubnik VV, et al. **Klin Khir** 1996;(11–12):38–41 (48 ref.) **(Rus)**

TRACHEITIS

BLOOD

Extravasation, lamina propria flooding and lumenal entry of bulk plasma exudate in mucosal defence, inflammation and repair. Persson CG, et al. **Pulm Pharmacol** 1996 Jun; 9(3):129–39 (69 ref.)

MICROBIOLOGY

Staphylococcal tracheitis, pneumonia, and adult respiratory distress syndrome. Horowitz IN. **Pediatr Emerg Care** 1996 Aug;12(4):288–90 (14 ref.)

PATHOLOGY

Airway inflammation and asthma. O'Byrne PM. **Aliment Pharmacol Ther** 1996;10 Suppl 2:18–24 (55 ref.)

TRACHEOBRONCHOMEGALY

DIAGNOSIS

[Tracheobronchomegaly--Mounier-Kuhn syndrome--case report and review of the literature] Wiesner B, et al. **Pneumologie** 1997 Mar;51(3):291–5 (31 ref.) (Eng. Abstr.) **(Ger)**

TRACHEOESOPHAGEAL FISTULA

CONGENITAL

Coexisting left congenital diaphragmatic hernia and esophageal atresia with tracheoesophageal fistula: successful management in a premature neonate. Sapin E, et al. **J Pediatr Surg** 1996 Jul;31(7):989–91 (20 ref.)

Esophageal duplication cyst with esophageal web and tracheoesophageal fistula. Snyder CL, et al. **J Pediatr Surg** 1996 Jul;31(7):968–9 (11 ref.)

ETIOLOGY

Acquired tracheoesophageal fistula and its management. Couraud L, et al. **Semin Thorac Cardiovasc Surg** 1996 Oct; 8(4):392–9 (12 ref.)

RADIOGRAPHY

The leaking esophagus: CT patterns of esophageal rupture, perforation, and fistulization. Lee S, et al. **Crit Rev Diagn Imaging** 1996 Dec;37(6):461–90 (10 ref.)

SURGERY

Management of acquired tracheoesophageal fistula. Dartevelle P, et al. **Chest Surg Clin N Am** 1996 Nov; 6(4):819–36 (30 ref.)

Malignant tracheo-esophageal fistula: use of esophageal endoprosthesis. Spivak F, et al. **J Surg Oncol** 1996 Sep; 63(1):65–70 (36 ref.)

Acquired tracheoesophageal fistula and its management. Couraud L, et al. **Semin Thorac Cardiovasc Surg** 1996 Oct; 8(4):392–9 (12 ref.)

THERAPY

Management of malignant esophagorespiratory fistula. Burt M. **Chest Surg Clin N Am** 1996 Nov;6(4):765–76 (50 ref.)

TRACHEOSTOMY

Tracheostomy. Wood DE. **Chest Surg Clin N Am** 1996 Nov; 6(4):749–64 (45 ref.)

Freeman Sheldon syndrome: severe upper airway obstruction requiring neonatal tracheostomy. Robinson PJ. **Pediatr Pulmonol** 1997 Jun;23(6):457–9 (5 ref.)

ADVERSE EFFECTS

Management of tracheoinnominate artery fistula. Wright CD. **Chest Surg Clin N Am** 1996 Nov;6(4):865–73 (17 ref.)

Free gastro-omental flap reconstruction of the complex, irradiated pharyngeal wound. Carlson GW, et al. **Head Neck** 1997 Jan;19(1):68–71 (11 ref.)

High tracheostomy and other errors--revisited. Bennett JD. **J Laryngol Otol** 1996 Nov;110(11):1003–7 (31 ref.)

Laryngeal foreign body: an unusual complication of percutaneous tracheostomy. Kumar BN, et al. **J Laryngol Otol** 1997 Jul;111(7):652–3 (13 ref.)

[Swallowing defects determined by tracheostomy (see comments)] Costa MM. **Arq Gastroenterol** 1996 Jul–Sep; 33(3):124–31 (20 ref.) (Eng. Abstr.) Comment in: Arq Gastroenterol 1996 Jul–Sep;33(3):122–3. **(Por)**

INSTRUMENTATION

Fractured tracheostomy tube: an overlooked foreign body. Gupta SC, et al. **J Laryngol Otol** 1996 Nov;110(11):1069–71 (14 ref.)

METHODS

Anterior mediastinal tracheostomy. Orringer MB.
Chest Surg Clin N Am 1996 Nov;6(4):701-24 (45 ref.)

TRACHEOTOMY

Nager acrofacial dysostosis: management of a difficult airway. Friedman RA, et al.
Int J Pediatr Otorhinolaryngol 1996 Mar;35(1):69-72 (14 ref.)

TRACHOMA

MICROBIOLOGY

[Isolation of Chlamydia trachomatis in trachomatous Moroccan patients] Takourt B, et al. **J Fr Ophtalmol** 1996; 19(8-9):527-32 (21 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Global trachoma control past, present and future approaches. Thylefors B.
Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique 1995;72:13-80 (85 ref.) **(Eng, Fre)**

TRACK AND FIELD

see related
RUNNING

PHYSIOLOGY

Nutritional practices of athletes: are they sub-optimal? Hawley JA, et al. **J Sports Sci** 1995 Summer;13 Spec No:S75-81 (73 ref.)
Biomechanical factors critical for performance in the men's javelin throw. Morriss C, et al. **Sports Med** 1996 Jun; 21(6):438-46 (22 ref.)

TRACTION

Traction in developmental dislocation of the hip. Is its use justified? Weinstein SL. **Clin Orthop** 1997 May;(338):79-85 (48 ref.)

HISTORY

The history of modern spinal traction with particular reference to neural disorders. Shterenshis MV.
Spinal Cord 1997 Mar;35(3):139-46 (46 ref.)

TRADE UNIONS see **LABOR UNIONS**

TRADEMARKS see **PATENTS**

TRADITIONAL BIRTH ATTENDANT see **MIDWIFERY**

TRADITIONAL MEDICINE, AFRICAN see **MEDICINE, AFRICAN TRADITIONAL**

TRADITIONAL MEDICINE, CHINESE see **MEDICINE, CHINESE TRADITIONAL**

TRADITIONAL MEDICINE, ORIENTAL see **MEDICINE, ORIENTAL TRADITIONAL**

TRAIL MAKING TEST

The geometric structure, construction, and interpretation of path-following (trail-making) tests. Vickers D, et al.
J Clin Psychol 1996 Nov;52(6):651-61 (50 ref.)

TRAINING PROGRAMS see **EDUCATION**

TRAMADOL

ADVERSE EFFECTS

[Tolerance and safety of tramadol use. Results of international studies and data from drug surveillance] Cossmann M, et al. **Drugs** 1997;53 Suppl 2:50-62 (68 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Pharmacology and clinical experience with tramadol in osteoarthritis. Katz WA. **Drugs** 1996;52 Suppl 3:39-47 (49 ref.)
[Pharmacology of tramadol] Dayer P, et al. **Drugs** 1997;53 Suppl 2:18-24 (39 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Nonsteroidal anti-inflammatory drugs, traditional opioids, and tramadol: contrasting therapies for the treatment of chronic pain. Aronson MD. **Clin Ther** 1997 May-Jun; 19(3):420-32; discussion 367-8 (38 ref.)
A risk-benefit assessment of tramadol in the management of pain. Radbruch L, et al. **Drug Saf** 1996 Jul;15(1):8-29 (128 ref.)
[Tramadol in acute pain] Lehmann KA. **Drugs** 1997;53 Suppl 2:25-33 (32 ref.) (Eng. Abstr.) **(Fre)**

TRANEXAMIC ACID

ADMINISTRATION & DOSAGE

Tranexamic acid in oncology. Seto AH, et al.
Ann Pharmacother 1996 Jul-Aug;30(7-8):868-70 (11 ref.)

TRANQUILIZING AGENTS

see related
HYPNOTICS AND SEDATIVES
Ripazepam. **IARC Monogr Eval Carcinog Risks Hum** 1996; 66:157-60 (3 ref.)

THERAPEUTIC USE

The diagnosis and treatment of mania in the elderly. McDonald WM, et al. **Bull Menninger Clin** 1996 Spring; 60(2):174-96 (136 ref.)
Acute disturbed or violent behaviour: principles of treatment. Kerr IB, et al. **J Psychopharmacol (Oxf)** 1997;11(3):271-7 (40 ref.)

TRANQUILIZING AGENTS, MAJOR see **ANTIPSYCHOTIC AGENTS**

TRANQUILIZING AGENTS, MINOR see **ANTI-ANXIETY AGENTS**

TRANS-ACTING FACTORS see **TRANS-ACTIVATORS**

TRANS-ACTING RESPONSIVE REGION, HIV see **HIV LONG TERMINAL REPEAT**

TRANS-ACTING TRANSCRIPTION FACTOR, HIV see **GENE PRODUCTS, TAT**

TRANS-ACTIVATION (GENETICS)

Trans-activation of cellular genes by hepatitis B virus proteins: a possible mechanism of hepatocarcinogenesis. Caselmann WH. **Adv Virus Res** 1996;47:253-302 (323 ref.)
Three steps in the regulation of transcription by the thyroid hormone receptor: establishment of a repressive chromatin structure, disruption of chromatin and transcriptional activation. Wolffe AP, et al. **Biochem Soc Trans** 1997 May; 25(2):612-5 (18 ref.)
Transcriptional control: how nuclear receptors get turned on. Schwabe JW. **Curr Biol** 1996 Apr 1;6(4):372-4 (13 ref.)
Mechanisms of transcriptional activation: differences and similarities between yeast, Drosophila, and man. Sauer F, et al. **Curr Opin Genet Dev** 1997 Apr;7(2):176-81 (40 ref.)
Interaction of steroid hormone receptors with the transcription initiation complex. Beato M, et al.
Endocr Rev 1996 Dec;17(6):587-609 (261 ref.)
Transcription factors and the cardiac gene programme. Doevendans PA, et al. **Int J Biochem Cell Biol** 1996 Apr; 28(4):387-403 (140 ref.)
Activation and regulation of human cytomegalovirus early genes. Spector DH. **Intervirology** 1996;39(5-6):361-77 (107 ref.)
GAS elements: a few nucleotides with a major impact on cytokine-induced gene expression. Decker T, et al.
J Interferon Cytokine Res 1997 Mar;17(3):121-34 (166 ref.)
Lipopolysaccharide dependent cellular activation. Tobias PS, et al. **J Periodontal Res** 1997 Jan;32(1 Pt 2):99-103 (40 ref.)
Genetic manipulations of cholinergic communication reveal trans-acting control mechanisms over acetylcholine receptors. Broide RS, et al.
J Recept Signal Transduct Res 1997 Jan-May; 17(1-3):279-91 (27 ref.)
Hepatitis B virus transcriptional activators: mechanisms and possible role in oncogenesis. Henkler F F, et al.
J Viral Hepat 1996 May;3(3):109-21 (129 ref.)
Howard Temin memorial lectureship. Molecular biology of HTLV-1: deregulation of host cell gene expression and cell cycle. Yoshida M. **Leukemia** 1997 Jan;11(1):14-5 (10 ref.)
Gene identification using the yeast two-hybrid system. Bai C, et al. **Methods Enzymol** 1996;273:331-47 (17 ref.)
Transcription activation at class II CAP-dependent promoters. Busby S, et al. **Mol Microbiol** 1997 Mar; 23(5):853-9 (31 ref.)
Transcriptional activation by recruitment. Ptashne M, et al. **Nature** 1997 Apr 10;386(6625):569-77 (101 ref.)
Mechanisms of transcriptional activation and repression can both involve TFIID. Manley JL, et al.
Philos Trans R Soc Lond B Biol Sci 1996 Apr 29; 351(1339):517-26 (60 ref.)
Protein-protein interactions during transcription activation: the case of the Escherichia coli cyclic AMP receptor protein. Savery N, et al.
Philos Trans R Soc Lond B Biol Sci 1996 Apr 29; 351(1339):543-50 (33 ref.)
The vitamin D receptor--structure and transcriptional activation. Strugnell SA, et al. **Proc Soc Exp Biol Med** 1997 Jul;215(3):223-8 (56 ref.)
STATs and gene regulation. Darnell JE Jr. **Science** 1997 Sep 12;277(5332):1630-5 (99 ref.)
Redox signal transduction via iron-sulfur clusters in the SoxR transcription activator. Hidalgo E, et al.
Trends Biochem Sci 1997 Jun;22(6):207-10 (37 ref.)
TAFs mediate transcriptional activation and promoter selectivity [see comments] Verrijzer CP, et al.
Trends Biochem Sci 1996 Sep;21(9):338-42 (50 ref.)
Comment in: Trends Biochem Sci 1996 Sep;21(9):325-6.
Mechanisms of transcriptional activation in vivo: two steps forward. Stargell LA, et al. **Trends Genet** 1996 Aug; 12(8):311-5 (54 ref.)
[Potential role of Epstein-Barr virus in Sjögren's syndrome] Saito I. **Nippon Rinsho** 1997 Jun;55(6):1505-11 (19 ref.) (Eng. Abstr.) **(Jpn)**
[A glucocorticoid-mediated transcriptional induction system in higher plants] Aoyama T.
Tanpakushitsu Kakusan Koso 1996 Dec;41(16):2559-63 (14 ref.) **(Jpn)**

DRUG EFFECTS

Control of transcriptional activation of the lipopolysaccharide binding protein (LBP) gene by proinflammatory cytokines. Kirchning C, et al.
Cytokines Cell Mol Ther 1997 Mar;3(1):59-62 (33 ref.)
Environmental endocrinology: hidden, but potent ways of activating the estrogen receptor. Heufelder AE, et al.
Eur J Endocrinol 1996 Dec;135(6):653-4 (7 ref.)

GENETICS

Transcriptional regulators of oxidative stress-inducible genes in prokaryotes and eukaryotes. Storz G, et al. **EXS** 1996; 77:239-54 (88 ref.)
Prerequisites for tissue specific and position independent expression of a gene locus in transgenic mice. Bonifer C, et al. **J Mol Med** 1996 Nov;74(11):663-71 (51 ref.)

PHYSIOLOGY

TFIIH: a key component in multiple DNA transactions. Hoeijmakers JH, et al. **Curr Opin Genet Dev** 1996 Feb; 6(1):26-33 (71 ref.)

TRANS-ACTIVATOR PROTEIN, HIV see **GENE PRODUCTS, REV**

TRANS-ACTIVATOR PROTEIN P40(TAX) see **GENE PRODUCTS, TAX**

TRANS-ACTIVATOR PROTEIN P40(X) see **GENE PRODUCTS, TAX**

TRANS-ACTIVATORS

Trans-acting factors in yeast pre-rRNA and pre-snoRNA processing. Lafontaine D, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11-12):803-12 (71 ref.)
[Transcription factors NF-IL6 and STAT3 involved in cytokine signal transductions] Akira S.
Tanpakushitsu Kakusan Koso 1996 Jun;41(8 Suppl):1237-48 (65 ref.) **(Jpn)**

CHEMISTRY

Eukaryotic transcription factor-DNA complexes. Patikoglou G, et al. **Annu Rev Biophys Biomol Struct** 1997;26:289-325 (156 ref.)
Reconstitution of TATA-binding protein-associated factor/TATA-binding protein complexes for in vitro transcription. Chen JL, et al. **Methods Enzymol** 1996; 273:208-17 (22 ref.)
Protein-protein interactions during transcription activation: the case of the Escherichia coli cyclic AMP receptor protein. Savery N, et al.
Philos Trans R Soc Lond B Biol Sci 1996 Apr 29; 351(1339):543-50 (33 ref.)

DEFICIENCY

Stat4- and Stat6-deficient mice as models for manipulating T helper cell responses. Grusby MJ.
Biochem Soc Trans 1997 May;25(2):359-60 (23 ref.)

GENETICS

Cancer gets Mad: DPC4 and other TGFbeta pathway genes in human cancer. Moskaluk CA, et al.
Biochim Biophys Acta 1996 Dec 9;1288(3):M31-3 (21 ref.)
Geminivirus replication: genetic and biochemical characterization of Rep protein function, a review. Laufs J, et al. **Biochimie** 1995;77(10):765-73 (85 ref.)
Forward genetic approach strikes gold: cloning of a mammalian clock gene. Reppert SM, et al. **Cell** 1997 May 16;89(4):487-90 (19 ref.)
Myb-induced transformation. Wolff L. **Crit Rev Oncog** 1996; 7(3-4):245-60 (126 ref.)
Cell cycle: on target with Myc. Zörnig M, et al.
Curr Biol 1996 Dec 1;6(12):1553-6 (22 ref.)
SRY and mammalian sex determination. Greenfield A, et al.
Curr Top Dev Biol 1996;34:1-23 (76 ref.)
Biology of EWS/FLI and related fusion genes in Ewing's sarcoma and primitive neuroectodermal tumor. May WA, et al. **Curr Top Microbiol Immunol** 1997;220:143-50 (35 ref.)
The regulation of p53-mediated transcription and the roles of hTAFII31 and mdm-2. Lu H, et al. **Harvey Lect** 1994-95;90:81-93 (32 ref.)
Hepatitis B virus transcriptional activators: mechanisms and possible role in oncogenesis. Henkler F F, et al.
J Viral Hepat 1996 May;3(3):109-21 (129 ref.)
Mutations of the X region of hepatitis B virus and their

clinical implications. Uchida T, et al. **Pathol Int** 1997 Apr; 47(4):183–93 (150 ref.)
The JAK–STAT pathway in Drosophila. Hou XS, et al. **Trends Genet** 1997 Mar;13(3):105–10 (34 ref.)
[Interaction between yeast transcription factor GAL11 and general transcription factors] Sakurai H, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1178–86 (70 ref.) **(Jpn)**

METABOLISM

Trans-activation of cellular genes by hepatitis B virus proteins: a possible mechanism of hepatocarcinogenesis. Caselmann WH. **Adv Virus Res** 1996;47:253–302 (323 ref.)
Stat4– and Stat6–deficient mice as models for manipulating T helper cell responses. Grusby MJ. **Biochem Soc Trans** 1997 May;25(2):359–60 (23 ref.)
Regulation of promoters by two transcription activators: evidence for a 'simultaneous touching' model. Savery N, et al. **Biochem Soc Trans** 1996 May;24(2):351–3 (9 ref.)
Geminivirus replication: genetic and biochemical characterization of Rep protein function, a review. Laufs J, et al. **Biochimie** 1995;77(10):765–73 (85 ref.)
Myb–induced transformation. Wolff L. **Crit Rev Oncog** 1996; 7(3–4):245–60 (126 ref.)
Drosophila development: homeodomains and translational control. Zamore PD, et al. **Curr Biol** 1996 Jul 1;6(7):773–5 (17 ref.)
The state of the STATs: recent developments in the study of signal transduction to the nucleus. Horvath CM, et al. **Curr Opin Cell Biol** 1997 Apr;9(2):233–9 (72 ref.)
Trans–acting factors in ribosome synthesis. Tollervey D. **Exp Cell Res** 1996 Dec 15;229(2):226–32 (74 ref.)
Regulation of STAT–dependent pathways by growth factors and cytokines. Leaman DW, et al. **FASEB J** 1996 Dec; 10(14):1578–88 (104 ref.)
Protein–protein interactions during transcription activation: the case of the Escherichia coli cyclic AMP receptor protein. Savery N, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Apr 29; 351(1339):543–50 (33 ref.)
STATs and gene regulation. Darnell JE Jr. **Science** 1997 Sep 12;277(5332):1630–5 (99 ref.)
The JAK–STAT pathway in Drosophila. Hou XS, et al. **Trends Genet** 1997 Mar;13(3):105–10 (34 ref.)
The chain of command in Pseudomonas quorum sensing. Pesci EC, et al. **Trends Microbiol** 1997 Apr;5(4):132–4; discussion 134–5 (18 ref.)

PHYSIOLOGY

Hepatitis B virus X antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma. Feitelson MA, et al. **Am J Pathol** 1997 Apr; 150(4):1141–57 (164 ref.)
Cytokine receptor signal transduction through Jak tyrosine kinases and Stat transcription factors. Silvennoinen O, et al. **APMIS** 1997 Jul;105(7):497–509 (67 ref.)
STATs and MAPKs: obligate or opportunistic partners in signaling. Ihle JN. **Bioessays** 1996 Feb;18(2):95–8 (13 ref.)
The JAK/STAT pathway. Wilks AF, et al. **Cancer Surv** 1996;27:139–63 (113 ref.)
The c–myb proto–oncogene: a novel target for human gene therapy. Gewirtz AM. **Cancer Treat Res** 1996;84:93–112 (58 ref.)
Translational activator proteins required for cytochrome b synthesis in Saccharomyces cerevisiae. Rödel G. **Curr Genet** 1997 May;31(5):375–9 (56 ref.)
NM23/Nucleoside diphosphate kinase as a transcriptional activator of c–myc. Postel EH. **Curr Top Microbiol Immunol** 1996;213 (Pt 2):233–52 (96 ref.)
Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet? O'Shea JJ. **Immunity** 1997 Jul;7(1):1–11 (126 ref.)
Signaling by IL–2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency. Johnston JA, et al. **J Leukoc Biol** 1996 Oct;60(4):441–52 (153 ref.)
STAT6: its role in interleukin 4–mediated biological functions. Takeda K, et al. **J Mol Med** 1997 May; 75(5):317–26 (120 ref.)
Hepatitis B virus transcriptional activators: mechanisms and possible role in oncogenesis. Henkler F F, et al. **J Viral Hepat** 1996 May;3(3):109–21 (129 ref.)
Regulation of virulence gene expression in pathogenic Listeria. Brehm K, et al. **Microbiologia** 1996 Jun; 12(2):219–36 (66 ref.)
Transcription factors as activators of gene transcription: AP–1 and NF–kappa B. Adcock IM. **Monaldi Arch Chest Dis** 1997 Apr;52(2):178–86 (49 ref.)
MYB transcription factors in plants. Martin C, et al. **Trends Genet** 1997 Feb;13(2):67–73 (55 ref.)
Hepatitis B virus–induced hepatocellular carcinoma: possible roles for HBx. Cromlish JA. **Trends Microbiol** 1996 Jul; 4(7):270–4 (61 ref.)
[Interaction between yeast transcription factor GAL11 and general transcription factors] Sakurai H, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1178–86 (70 ref.) **(Jpn)**

TRANS TEST see **GENETIC COMPLEMENTATION TEST**

TRANSACTIONAL ANALYSIS

A transactional analysis of biobehavioral systems. Germana J. **Integr Physiol Behav Sci** 1996 Jul–Sep;31(3):210–8 (35 ref.)

TRANSACTIVATION see **TRANS-ACTIVATION (GENETICS)**

TRANSAMIDINASES see **AMIDINOTRANSFERASES**

TRANSAMINASES see **AMINOTRANSFERASES**

TRANSCORTIN

METABOLISM

Determinants of steroid hormone bioavailability. Hammond GL. **Biochem Soc Trans** 1997 May;25(2):577–82 (51 ref.)

PHYSIOLOGY

Corticosteroid–binding globulin during inflammation and burn injury: nutritional modulation and clinical implications. Garrel DR. **Horm Res** 1996;45(3–5):245–51 (54 ref.)
Regulation factors of corticosteroid–binding globulin: lesson from ontogenesis. Séralini GE. **Horm Res** 1996; 45(3–5):192–6 (37 ref.)

TRANSCRIPTASES see **RNA POLYMERASES**

TRANSCRIPTION FACTOR AP-1

see related
PROTO–ONCOGENE PROTEINS C–FOS
PROTO–ONCOGENE PROTEINS C–JUN

METABOLISM

Redox regulation of AP–1: a link between transcription factor signaling and DNA repair. Xanthoudakis S, et al. **Adv Exp Med Biol** 1996;387:69–75 (45 ref.)
Regulation of the activity of the transcription factors AP–1 and NFAT during differentiation of precursor CD4+ T–cells into effector cells. Rincón M, et al. **Biochem Soc Trans** 1997 May;25(2):347–54 (42 ref.)
Regulation of gene expression by insulin: analysis in single living cells. Tavaré JM, et al. **Biochem Soc Trans** 1996 May; 24(2):378–84 (33 ref.)
Transcription factor AP–1 regulation by mitogen–activated protein kinase signal transduction pathways. Whitmarsh AJ, et al. **J Mol Med** 1996 Oct;74(10):589–607 (234 ref.)
The AP–1 site and MMP gene regulation: what is all the fuss about? Benbow U, et al. **Matrix Biol** 1997 Mar; 15(8–9):519–26 (60 ref.)
Study of gene regulation by NF–kappa B and AP–1 in response to reactive oxygen intermediates. Müller JM, et al. **Methods** 1997 Mar;11(3):301–12 (90 ref.)
[MAP kinases and their role in regulation of protein level, subunit composition and degree of phosphorylation of transcription factor AP–1] Biedermann IW. **Postepy Biochem** 1996;42(3):244–52 (57 ref.) **(Pol)**

PHYSIOLOGY

AP–1 function and regulation. Karin M, et al. **Curr Opin Cell Biol** 1997 Apr;9(2):240–6 (83 ref.)
Transcription factor AP–1, and the role of Fra–2. Foletta VC. **Immunol Cell Biol** 1996 Apr;74(2):121–33 (163 ref.)
Transcription factors as activators of gene transcription: AP–1 and NF–kappa B. Adcock IM. **Monaldi Arch Chest Dis** 1997 Apr;52(2):178–86 (49 ref.)
[Cross–talk between transcription factors AP–1 and NFAT in the regulation of gene expression] Kamińska B, et al. **Postepy Biochem** 1996;42(2):120–8 (51 ref.) **(Pol)**

TRANSCRIPTION FACTOR NF-KB see **NF-KAPPA B**

TRANSCRIPTION FACTOR, SP1

CHEMISTRY

Specific targeting of protein–DNA complexes by DNA–reactive drugs (+)–CC–1065 and pluramycins. Henderson D, et al. **J Mol Recognit** 1996 Mar–Apr; 9(2):75–87 (59 ref.)

METABOLISM

Specific targeting of protein–DNA complexes by DNA–reactive drugs (+)–CC–1065 and pluramycins. Henderson D, et al. **J Mol Recognit** 1996 Mar–Apr; 9(2):75–87 (59 ref.)

TRANSCRIPTION FACTORS

see related
TRANS–ACTIVATORS

Transcription factors and head formation in vertebrates. Bally–Cuif L, et al. **Bioessays** 1997 Feb;19(2):127–35 (86 ref.)
RelB, a member of the Rel/NF–kappa B family of transcription factors. Ryseck RP, et al. **Braz J Med Biol Res** 1996 Jul;29(7):895–903 (46 ref.)
The Hsf world: classification and properties of plant heat stress transcription factors. Nover L, et al. **Cell Stress Chaperones** 1996 Dec;1(4):215–23 (58 ref.)
A new transcription factor family associated with human leukemias. Speck NA, et al. **Crit Rev Eukaryot Gene Expr** 1995;5(3–4):337–64 (169 ref.)
Redox regulation of transcriptional activators. Sun Y, et al. **Free Radic Biol Med** 1996;21(3):335–48 (133 ref.)
Five years on the wings of fork head. Kaufmann E, et al. **Mech Dev** 1996 Jun;57(1):3–20 (137 ref.)
RNA polymerase III and class III transcription factors from Saccharomyces cerevisiae. Huet J, et al. **Methods Enzymol** 1996;273:249–67 (70 ref.)
[The pituitary specific transcription factor Pit–1/GHF–1 and PIT1 abnormality] Tatsumi K, et al. **Rinsho Byori** 1997 Jul;45(7):656–9 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Transcription factors NF–IL6 and STAT3 involved in cytokine signal transductions] Akira S. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1237–48 (65 ref.) **(Jpn)**
[Cross–point of cAMP and Ca2+ signals to the transcription factors] Hagiwara M, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1282–7 (18 ref.) **(Jpn)**
[The structure and function of general transcription factor TFIIA] Handa H. **Tanpakushitsu Kakusan Koso** 1996 Jun; 41(8 Suppl):1124–34 (48 ref.) **(Jpn)**
[Analysis of the mechanism of transcriptional regulation based on yeast system] Horikoshi M, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1148–61 (57 ref.) **(Jpn)**
[Mechanisms of eukaryotic transcription initiation and its regulation centered on general transcription factors] Horikoshi M. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):957–88 (169 ref.) **(Jpn)**
[Molecular communications in transcription: basic mechanisms of transcription regulation] Ishihama A. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1328–31 (0 ref.) **(Jpn)**
[Myb: structure and regulation of activity] Ishii S. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1320–7 (29 ref.) **(Jpn)**
[Transcription factors involved in histone gene regulation] Iwabuchi M. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1226–36 (35 ref.) **(Jpn)**
[Regulation of general transcription factors by phosphorylation] Kitajima S. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1162–9 (45 ref.) **(Jpn)**
[Detection of TBP–interacting proteins (TIPs) and demonstration of a novel complex containing TBP and ATPases] Makino Y, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1170–7 (16 ref.) **(Jpn)**
[Function of the PEBP2/CBF/AML1 genes] Satake M. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):997–1007 (35 ref.) **(Jpn)**
[Structure and DNA recognition of transcription factors] Shirakawa M. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1306–19 (79 ref.) **(Jpn)**
[Molecular analysis of MIDA1, which associates with Id1] Shoji W, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1219–25 (16 ref.) **(Jpn)**
[Structure and function of PAS proteins: Ah receptor, Arnt, and others] Sogawa K, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1288–96 (47 ref.) **(Jpn)**
[Interaction of HTLV–1 Tax with cellular factors] Suzuki T, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1249–57 (39 ref.) **(Jpn)**
[Transcription regulation by FTZ–F1] Ueda H, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1210–8 (40 ref.) **(Jpn)**
[Where transcriptional factor research in developmental biology should go] Ueno N. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1332–5 (6 ref.) **(Jpn)**
[In vitro studies of chromatin structure and transcriptional regulation] Ura K. **Tanpakushitsu Kakusan Koso** 1996 Jul; 41(9):1385–90 (23 ref.) **(Jpn)**

ANALYSIS

Gene targeting reveals a hierarchy of transcription factors regulating specification of lymphoid cell fates. Singh H. **Curr Opin Immunol** 1996 Apr;8(2):160–5 (40 ref.)

BIOSYNTHESIS

Bcl–6 protein expression in normal and neoplastic lymphoid tissues. Falini B, et al. **Ann Oncol** 1997;8 Suppl 2:101–4 (28 ref.)
Wilms tumor gene expression in acute myeloid leukemias. Bergmann L, et al. **Leuk Lymphoma** 1997 May; 25(5–6):435–43 (55 ref.)
Expression of erythroid–specific genes in megakaryoblastic disorders. Ito E, et al. **Leuk Lymphoma** 1996 Nov; 23(5–6):545–50 (55 ref.)
Pattern of expression and their clinical implications of the GATA family, stem cell leukemia gene, and EVI1 in leukemia and myelodysplastic syndromes. Ohyashiki K, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):431–6 (47 ref.)
Complex activation of inducible transcription factors in the brain of normotensive and spontaneously hypertensive rats

following central angiotensin II administration. Lebrun CJ, et al. **Regul Pept** 1996 Oct 8;66(1-2):19-23 (33 ref.)

CHEMISTRY

Eukaryotic transcription factor-DNA complexes. Patikoglou G, et al. **Annu Rev Biophys Biomol Struct** 1997;26:289-325 (156 ref.)

Chromatin structure and function: the heretical path to an RNA transcription factor. Krause MO. **Biochem Cell Biol** 1996;74(5):623-32 (91 ref.)

Chromatin architectural proteins and transcription factors: a structural connection. van Holde K, et al. **Bioessays** 1996 Sep;18(9):697-700 (34 ref.)

Architectural transcription factors: proteins that remodel DNA. Werner MH, et al. **Cell** 1997 Mar 21;88(6):733-6 (18 ref.)

Histone-like transcription factors in eukaryotes. Burley SK, et al. **Curr Opin Struct Biol** 1997 Feb;7(1):94-102 (47 ref.)

ISGF3 gamma p48, a specificity switch for interferon activated transcription factors. Bluyssen AR, et al. **Cytokine Growth Factor Rev** 1996 Jun;7(1):11-7 (54 ref.)

Alpha-helical protein assembly motifs. Kohn WD, et al. **J Biol Chem** 1997 Jan 31;272(5):2583-6 (121 ref.)

Structural relationships in the OmpR family of winged-helix transcription factors. Martinez-Hackert E, et al. **J Mol Biol** 1997 Jun 13;269(3):301-12 (65 ref.)

Reconstitution of TATA-binding protein-associated factor/TATA-binding protein complexes for in vitro transcription. Chen JL, et al. **Methods Enzymol** 1996; 273:208-17 (22 ref.)

GAGA over the nucleosome [news; comment] Read CM, et al. **Nat Struct Biol** 1997 Feb;4(2):87-9 (27 ref.) Comment on: Nat Struct Biol 1997 Feb;4(2):122-32.

X-ray crystallographic studies of eukaryotic transcription initiation factors. Burley SK. **Philos Trans R Soc Lond B Biol Sci** 1996 Apr 29; 351(1339):483-9 (35 ref.)

Towards an understanding of protein-DNA recognition. Rhodes D, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Apr 29;351(1339):501-9 (50 ref.)

The biochemistry of transcription in eukaryotes: a paradigm for multisubunit regulatory complexes. Tjian R. **Philos Trans R Soc Lond B Biol Sci** 1996 Apr 29; 351(1339):491-9 (47 ref.)

Do basic region-leucine zipper proteins bend their DNA targets ... does it matter? [comment] Hagerman PJ. **Proc Natl Acad Sci U S A** 1996 Sep 17;93(19):9993-6 (45 ref.) Comment on: Proc Natl Acad Sci U S A 1996 Sep 17;93(19):10117-22.

Pieces of the puzzle: assembling the preinitiation complex of Pol II. Ghosh G, et al. **Structure** 1996 Aug 15;4(8):891-5 (19 ref.)

The SANT domain: a putative DNA-binding domain in the SWI-SNF and ADA complexes, the transcriptional co-repressor N-CoR and TFIIIB. Aasland R, et al. **Trends Biochem Sci** 1996 Mar;21(3):87-8 (16 ref.)

Redox signal transduction via iron-sulfur clusters in the SoxR transcription activator. Hidalgo E, et al. **Trends Biochem Sci** 1997 Jun;22(6):207-10 (37 ref.)

DRUG EFFECTS

Transcription factors as drug targets in cancer. Hurst HC. **Eur J Cancer** 1996 Oct;32A(11):1857-63 (41 ref.)

Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects. Auwerx J, et al. **J Atheroscler Thromb** 1996;3(2):81-9 (71 ref.)

GENETICS

The mouse Xist gene: a model for studying the gametic imprinting phenomenon. Zuccotti M, et al. **Acta Genet Med Gemellol (Roma)** 1996;45(1-2):199-204 (23 ref.)

Mutations in SOX9 cause both autosomal sex reversal and campomelic dysplasia. Foster JW. **Acta Paediatr Jpn** 1996 Aug;38(4):405-11 (26 ref.)

SF-1: a key regulator of development and function in the mammalian reproductive system. Ikeda Y. **Acta Paediatr Jpn** 1996 Aug;38(4):412-9 (45 ref.)

Sex determining gene on the X chromosome short arm: dosage sensitive sex reversal. Ogata T, et al. **Acta Paediatr Jpn** 1996 Aug;38(4):390-8 (40 ref.)

Gene regulation of cell adhesion molecules in neural morphogenesis. Edelman GM, et al. **Acta Paediatr Suppl** 1997 Jul;422:12-9 (41 ref.)

XIST expression and X-chromosome inactivation in human preimplantation embryos [editorial; comment] Brown CJ, et al. **Am J Hum Genet** 1997 Jul;61(1):5-8 (28 ref.) Comment on: Am J Hum Genet 1997 Jul;61(1):33-9.

Molecular basis of cardiocyte cell specification. Goswami SK, et al. **Ann N Y Acad Sci** 1996 Sep 30;793:259-66 (33 ref.)

Novel transcription factors are induced by chronic cocaine treatment. Hope BT. **Ann N Y Acad Sci** 1996 Oct 31; 801:1-12 (29 ref.)

The role of the Ikaros gene in lymphocyte development and homeostasis. Georgopoulos K, et al. **Annu Rev Immunol** 1997;15:155-76 (51 ref.)

Structure-function relationships of the PEA3 group of Ets-related transcription factors. de Launoit Y, et al. **Biochem Mol Med** 1997 Aug;61(2):127-35 (47 ref.)

The PML nuclear compartment and cancer. Doucas V, et al. **Biochim Biophys Acta** 1996 Dec 9;1288(3):M25-9 (38 ref.)

Everything you have ever wanted to know about Yin Yang 1..... Shi Y, et al. **Biochim Biophys Acta** 1997 Apr 18; 1332(2):F49-66 (122 ref.)

Pax genes and organogenesis. Dahl E, et al. **Bioessays** 1997 Sep;19(9):755-65 (88 ref.)

Craniofacial defects in AP-2 null mutant mice. Morriss-Kay GM. **Bioessays** 1996 Oct;18(10):785-8 (22 ref.)

The hypoxic response: huffing and HIFing. Guillemin K, et al. **Cell** 1997 Apr 4;89(1):9-12 (21 ref.)

PAX: developmental control genes in cell growth and differentiation. Stuart ET, et al. **Cell Growth Differ** 1996 Mar;7(3):405-12 (80 ref.)

Indirect and direct disruption of transcriptional regulation in cancer: E2F and AML-1. Meyers S, et al. **Crit Rev Eukaryot Gene Expr** 1995;5(3-4):365-83 (161 ref.)

Two-stage gene regulation of the superoxide stress response soxRS system in Escherichia coli. Nunoshiba T. **Crit Rev Eukaryot Gene Expr** 1996;6(4):377-89 (92 ref.)

Cell division: why daughters cannot be like their mothers. Chang F, et al. **Curr Biol** 1996 Jun 1;6(6):651-4 (18 ref.)

Carcinogenesis: a balance between beta-catenin and APC. Gumbiner BM. **Curr Biol** 1997 Jul 1;7(7):R443-6 (26 ref.)

Pax genes and their roles in cell differentiation and development. Mansouri A, et al. **Curr Opin Cell Biol** 1996 Dec;8(6):851-7 (78 ref.)

Mechanisms of transcription complex assembly. Pugh BF. **Curr Opin Cell Biol** 1996 Jun;8(3):303-11 (69 ref.)

Dosage compensation and chromatin structure in Drosophila. Bashaw GJ, et al. **Curr Opin Genet Dev** 1996 Aug; 6(4):496-501 (41 ref.)

Transcription factors in disease. Engelkamp D, et al. **Curr Opin Genet Dev** 1996 Jun;6(3):334-42 (73 ref.)

Defining the regulatory networks for muscle development. Molkentin JD, et al. **Curr Opin Genet Dev** 1996 Aug; 6(4):445-53 (58 ref.)

Sox genes find their feet. Pevny LH, et al. **Curr Opin Genet Dev** 1997 Jun;7(3):338-44 (70 ref.)

Early steps in mammalian sex determination. Ramkissoon Y, et al. **Curr Opin Genet Dev** 1996 Jun;6(3):316-21 (58 ref.)

Brachyury and the T-box genes. Smith J. **Curr Opin Genet Dev** 1997 Aug;7(4):474-80 (67 ref.)

Hereditary predisposition to breast cancer. Stratton MR, et al. **Curr Opin Genet Dev** 1996 Feb;6(1):93-7 (29 ref.)

Gene targeting reveals a hierarchy of transcription factors regulating specification of lymphoid cell fates. Singh H. **Curr Opin Immunol** 1996 Apr;8(2):160-5 (40 ref.)

Regulation of vertebrate neural cell fate by transcription factors. Bang AG, et al. **Curr Opin Neurobiol** 1996 Feb; 6(1):25-32 (79 ref.)

Pax proteins and eye development. Macdonald R, et al. **Curr Opin Neurobiol** 1996 Feb;6(1):49-56 (56 ref.)

Recent advances in breast cancer biology. Blackwood MA, et al. **Curr Opin Oncol** 1996 Nov;8(6):449-54 (49 ref.)

Biology of EWS/FLI and related fusion genes in Ewing's sarcoma and primitive neuroectodermal tumor. May WA, et al. **Curr Top Microbiol Immunol** 1997;220:143-50 (35 ref.)

Chromosome translocation-mediated conversion of a tumor suppressor gene into a dominant oncogene: fusion of EWS1 to WT1 in desmoplastic small round cell tumors. Rauscher FJ 3rd. **Curr Top Microbiol Immunol** 1997;220:151-62 (47 ref.)

Disruption of a homolog of trithorax by 11q23 translocations: leukemogenic and transcriptional implications. Waring PM, et al. **Curr Top Microbiol Immunol** 1997;220:1-23 (135 ref.)

Chick ovalbumin upstream promoter-transcription factors (COUP-TFs): coming of age. Tsai SY, et al. **Endocr Rev** 1997 Apr;18(2):229-40 (94 ref.)

Role of the peroxisome proliferator-activated receptor in cytochrome P450 4A gene regulation. Johnson EF, et al. **FASEB J** 1996 Sep;10(11):1241-8 (67 ref.)

Ad4BP/SF-1, a transcription factor essential for the transcription of steroidogenic cytochrome P450 genes and for the establishment of the reproductive function. Morohashi KI, et al. **FASEB J** 1996 Dec;10(14):1569-77 (50 ref.)

Redox signaling and gene control in the Escherichia coli soxRS oxidative stress regulon--a review. Demple B. **Gene** 1996 Nov 7;179(1):53-7 (25 ref.)

The various strategies within the TyrR regulation of Escherichia coli to modulate gene expression. Pittard J. **Genes Cells** 1996 Aug;1(8):717-25 (48 ref.)

Upstream and downstream of erythroid transcription factor GATA-1. Yamamoto M, et al. **Genes Cells** 1997 Feb; 2(2):107-15 (49 ref.)

Ends Xist, but where are the beginnings? [comment] Solter D, et al. **Genes Dev** 1997 Jan 15;11(2):153-5 (17 ref.) Comment on: Genes Dev 1997 Jan 15;11(2):156-66.

PML, PLZF and NPM genes in the molecular pathogenesis of acute promyelocytic leukemia. Pandolfi PP. **Haematologica** 1996 Sep-Oct;81(5):472-82 (86 ref.)

Pit-1 gene expression in human pituitary adenomas. Pellegrini-Bouiller I, et al. **Horm Res** 1997;47(4-6):251-8 (43 ref.)

Transcription factor genes and the developing eye: a genetic perspective. Freund C, et al. **Hum Mol Genet** 1996;5 Spec No:1471-88 (234 ref.)

Recent advances in understanding of genetic susceptibility to breast cancer. Stratton MR. **Hum Mol Genet** 1996;5 Spec No:1515-9 (50 ref.)

Transcriptional control of lymphoid development: lessons from gene targeting. Clevers HC, et al. **Immunol Today** 1996 Jul;17(7):336-43 (59 ref.)

The Oct-2 transcription factor. Latchman DS. **Int J Biochem Cell Biol** 1996 Oct;28(10):1081-3 (10 ref.)

Regulation and function of the tissue-specific transcription factor HNF1 alpha (LFB1) during Xenopus development. Weber H, et al. **Int J Dev Biol** 1996 Feb;40(1):297-304 (25 ref.)

Pax and vertebrate development. Wehr R, et al. **Int J Dev Biol** 1996 Feb;40(1):369-77 (127 ref.)

Transcription factor IIIA (TFIIIA) in the second decade. Shastry BS. **J Cell Sci** 1996 Mar;109 (Pt 3):535-9 (39 ref.)

Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium [see comments] Burke W, et al. **JAMA** 1997 Mar 26;277(12):997-1003 (120 ref.) Comment in: JAMA 1997 Jul 23-30;278(4):289-90; discussion 290. Comment in: JAMA 1997 Jul 23-30;278(4):290.

Molecular basis governing primary sex in mammals. Nagai K. **Jpn J Hum Genet** 1996 Dec;41(4):363-79 (57 ref.)

Significance of quantitative analysis of AML1/ETO transcripts in peripheral blood stem cells from t(8;21) acute myelogenous leukemia. Miyamoto T, et al. **Leuk Lymphoma** 1997 Mar;25(1-2):69-75 (37 ref.)

ETV6 gene rearrangements in hematopoietic malignant disorders. Wlodarska I, et al. **Leuk Lymphoma** 1996 Oct; 23(3-4):287-95 (54 ref.)

Leukemogenesis by the chromosomal translocations. Mitani K. **Leukemia** 1997 Apr;11 Suppl 3:294-6 (32 ref.)

Functional relationships among ETS gene family members. Papas TS, et al. **Leukemia** 1997 Apr;11 Suppl 3:557-66 (49 ref.)

Patterning the expression of a tissue-specific transcription factor in embryogenesis: HNF1 alpha gene activation during Xenopus development. von Strandmann EP, et al. **Mech Dev** 1997 Jun;64(1-2):7-17 (66 ref.)

Fusion of the EWS1 and WT1 genes as a result of the t(11;22)(p13;q12) translocation in desmoplastic small round cell tumors. Benjamin LE, et al. **Med Pediatr Oncol** 1996 Nov;27(5):434-9 (34 ref.)

Pax-2, kidney development, and oncogenesis. Dressler GR. **Med Pediatr Oncol** 1996 Nov;27(5):440-4 (34 ref.)

Purification of the transcription/repair factor TFIIH and evaluation of its associated activities in vitro. Marinoni JC, et al. **Methods** 1997 Jul;12(3):235-53 (60 ref.)

Transcriptional regulation during myelopoiesis. Lenny N, et al. **Mol Biol Rep** 1997 Aug;24(3):157-68 (164 ref.)

POU domain transcription factors in embryonic development. Veenstra GJ, et al. **Mol Biol Rep** 1997 Aug; 24(3):139-55 (245 ref.)

SOX genes: architects of development. Prior HM, et al. **Mol Med** 1996 Jul;2(4):405-12 (57 ref.)

Double indemnity: p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in Brca1 and Brca2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair [news] Brugarolas J, et al. **Nat Med** 1997 Jul;3(7):721-2 (24 ref.)

Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families [see comments] Tonin P, et al. **Nat Med** 1996 Nov;2(11):1179-83 (25 ref.) Comment in: Nat Med 1995 Nov;2(11):1162.

Transcription factor access to chromatin. Beato M, et al. **Nucleic Acids Res** 1997 Sep 15;25(18):3559-63 (82 ref.)

Use of transcription factors as agents and targets for drug development. Smith LM, et al. **Oncology (Huntingt)** 1996 Oct;10(10):1532-8; discussion 1541-2 (47 ref.)

Induction and differentiation of extra-embryonic mesoderm in the mouse. Boucher DM, et al. **Reprod Fertil Dev** 1996; 8(4):765-77 (121 ref.)

Post-transcriptional regulation of bacterial carbohydrate metabolism: evidence that the gene product CsrA is a global mRNA decay factor. Romeo T. **Res Microbiol** 1996 Jul-Sep;147(6-7):505-12 (25 ref.)

The RNA polymerase II general elongation factors. Reines D, et al. **Trends Biochem Sci** 1996 Sep;21(9):351-5 (37 ref.)

The role of general initiation factors in transcription by RNA polymerase II. Roeder RG. **Trends Biochem Sci** 1996 Sep; 21(9):327-35 (65 ref.)

Extra specificity from extradenticle: the partnership between HOX and PBX/EXD homeodomain proteins [published erratum appears in Trends Genet 1996 Aug;12(8):328] Mann RS, et al. **Trends Genet** 1996 Jul;12(7):258-62 (52 ref.)

From gradients to stripes in Drosophila embryogenesis: filling in the gaps. Rivera-Pomar R, et al. **Trends Genet** 1996 Nov; 12(11):478-83 (48 ref.)

Cell-cycle regulation of gene expression by transcriptional repression. Zwicker J, et al. **Trends Genet** 1997 Jan; 13(1):3-6 (29 ref.)

Loss of oxyR in Mycobacterium tuberculosis. Deretic V, et al. **Trends Microbiol** 1997 Sep;5(9):367-72 (49 ref.)

POU-domain gene expression during spermatogenesis. Zini A, et al. **World J Urol** 1996;14(5):274-7 (20 ref.)

[Activation of transcription in eukaryotic cells: interactions between transcription factors and components of the basal transcriptional mechanism] Diagana TT. **C R Acad Sci III** 1997 Jul;320(7):509-21 (143 ref.) (Eng. Abstr.) **(Fre)**

[Role of the Krox-20 gene in the development of rhombencephalon] Schneider-Maunoury S, et al. **C R Seances Soc Biol Fil** 1997;191(1):91-4 (15 ref.) (Eng.

Abstr.) **(Fre)**

[Ad4BP/SF-1 and sex differentiation of the gonads] Morohashi K, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun; 41(8 Suppl):1033–41 (32 ref.) **(Jpn)**

[Involvement of maf gene family in crystallin gene regulation] Ogino H, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1050–7 (34 ref.) **(Jpn)**

[X chromosome inactivation and XIST] Sakai K. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(15 Suppl):2296–305 (70 ref.) **(Jpn)**

[Function of the PEBP2/CBF/AML1 genes] Satake M. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):997–1007 (35 ref.) **(Jpn)**

[Developmental expression patterns and target assignment of the bombyx fork head and POU-M1 genes] Suzuki Y, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1083–7 (25 ref.) **(Jpn)**

[ZFH/ATBF1 gene family: transcription factors containing both homeo- and zinc finger-domains] Tamaoki T, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(11):1550–9 (35 ref.) **(Jpn)**

IMMUNOLOGY

Autoimmunity due to defective Nur77, Fas, and TNF-RI apoptosis. Mountz JD, et al. **Adv Exp Med Biol** 1996; 406:241–62 (93 ref.)

The role of the Ikaros gene in lymphocyte development and homeostasis. Georgopoulos K, et al. **Annu Rev Immunol** 1997;15:155–76 (51 ref.)

ISOLATION & PURIFICATION

Purification of the transcription/repair factor TFIIH and evaluation of its associated activities in vitro. Marinoni JC, et al. **Methods** 1997 Jul;12(3):235–53 (60 ref.)

Purification of RNA polymerase II general transcription factors from rat liver. Conaway RC, et al. **Methods Enzymol** 1996;273:194–207 (18 ref.)

Purification of yeast RNA polymerase II holoenzymes. Koleske AJ, et al. **Methods Enzymol** 1996;273:176–84 (12 ref.)

Purification and analysis of functional preinitiation complexes. Roberts SG, et al. **Methods Enzymol** 1996; 273:110–8 (10 ref.)

Purification, assay, and properties of RNA polymerase I and class I-specific transcription factors in mouse. Schnapp A, et al. **Methods Enzymol** 1996;273:233–48 (16 ref.)

METABOLISM

Antioxidants, redox-regulated transcription factors, and inflammation. Winyard PG, et al. **Adv Pharmacol** 1997; 38:403–21 (103 ref.)

Alcohol and cytokine-inducible transcription factors. Zeldin G, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1639–45 (36 ref.)

Biochemistry and structural biology of transcription factor IID (TFIID). Burley SK, et al. **Annu Rev Biochem** 1996; 65:769–99 (150 ref.)

Census and consensus in bacterial ecosystems: the LuxR-LuxI family of quorum-sensing transcriptional regulators. Fuqua C, et al. **Annu Rev Microbiol** 1996; 50:727–51 (106 ref.)

Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Auwerx J, et al. **Atherosclerosis** 1996 Jul;124 Suppl:S29–37 (59 ref.)

The role of p53 as a transcription factor in the induction of apoptosis. Yonish-Rouach E, et al. **Behring Inst Mitt** 1996 Oct;(97):60–71 (104 ref.)

Regulation of transcription factor activity during cellular aging. Wheaton K, et al. **Biochem Cell Biol** 1996; 74(4):523–34 (110 ref.)

Retinoid-dependent transcription: the RAR/RXR-TBP-EIA/EIA-LA connection. Meyer M, et al. **Biochem Soc Symp** 1996;62:97–109 (50 ref.)

Basic helix-loop-helix transcription factors and the cross-regulation of sulphate and phosphate metabolism in yeast. Crowther DJ, et al. **Biochem Soc Trans** 1996 May; 24(2):354–9 (53 ref.)

Subnuclear trafficking of steroid receptors. DeFranco DB. **Biochem Soc Trans** 1997 May;25(2):592–7 (50 ref.)

Mechanisms of transcriptional activation by retinoic acid receptors. Glass CK, et al. **Biochem Soc Trans** 1997 May; 25(2):602–5 (20 ref.)

Regulation of transcription factor function by proteolysis. Goodbourn S, et al. **Biochem Soc Trans** 1997 May; 25(2):498–502 (49 ref.)

TIF1 alpha: a chromatin-specific mediator for the ligand-dependent activation function AF-2 of nuclear receptors? Le Douarin B, et al. **Biochem Soc Trans** 1997 May;25(2):605–12 (39 ref.)

Steroid-independent activation of steroid receptors in mammalian and yeast cells and in breast cancer. Picard D, et al. **Biochem Soc Trans** 1997 May;25(2):597–602 (50 ref.)

Regulation of the activity of the transcription factors AP-1 and NFAT during differentiation of precursor CD4+ T-cells into effector cells. Rincón M, et al. **Biochem Soc Trans** 1997 May;25(2):347–54 (42 ref.)

Three steps in the regulation of transcription by the thyroid hormone receptor: establishment of a repressive chromatin structure, disruption of chromatin and transcriptional activation. Wolffe AP, et al. **Biochem Soc Trans** 1997 May; 25(2):612–5 (18 ref.)

Regulation of gene expression and transcription factor binding activity during cellular aging. Meyyappan M, et al. **Biol Signals** 1996 May-Jun;5(3):130–8 (81 ref.)

Transcription factors, normal myeloid development, and leukemia. Tenen DG, et al. **Blood** 1997 Jul 15;90(2):489–519 (455 ref.)

The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Brown MS, et al. **Cell** 1997 May 2;89(3):331–40 (63 ref.)

Heat stress proteins and transcription factors. Nover L, et al. **Cell Mol Life Sci** 1997 Jan;53(1):80–103 (415 ref.)

Double agent: translational regulation by a transcription factor. Mayfield S. **Chem Biol** 1996 Jun;3(6):415–8 (13 ref.)

Gene regulation associated with apoptosis. Jehn BM, et al. **Crit Rev Eukaryot Gene Expr** 1997;7(1–2):179–93 (98 ref.)

Oncogene-initiated aberrant signaling engenders the metastatic phenotype: synergistic transcription factor interactions are targets for cancer therapy. Denhardt DT. **Crit Rev Oncog** 1996;7(3–4):261–91 (238 ref.)

EGR-1, the reluctant suppression factor: EGR-1 is known to function in the regulation of growth, differentiation, and also has significant tumor suppressor activity and a mechanism involving the induction of TGF-beta1 is postulated to account for this suppressor activity. Liu C, et al. **Crit Rev Oncog** 1996;7(1–2):101–25 (159 ref.)

Aryl hydrocarbon receptor-mediated signal transduction. Rowlands JC, et al. **Crit Rev Toxicol** 1997 Mar;27(2):109–34 (223 ref.)

Versatile molecular glue. Transcriptional control. Janknecht R, et al. **Curr Biol** 1996 Aug 1;6(8):951–4 (25 ref.)

Drosophila development: homeodomains and translational control. Zamore PD, et al. **Curr Biol** 1996 Jul 1;6(7):773–5 (17 ref.)

Transcription factors in immune-mediated disease. Peltz G. **Curr Opin Biotechnol** 1997 Aug;8(4):467–73 (60 ref.)

Nuclear receptor coactivators. Glass CK, et al. **Curr Opin Cell Biol** 1997 Apr;9(2):222–32 (50 ref.)

Armadillo and dTCF: a marriage made in the nucleus. Cavallo R, et al. **Curr Opin Genet Dev** 1997 Aug; 7(4):459–66 (68 ref.)

TFIIH: a key component in multiple DNA transactions. Hoeijmakers JH, et al. **Curr Opin Genet Dev** 1996 Feb; 6(1):26–33 (71 ref.)

Vertebrate heart development. Lyons GE. **Curr Opin Genet Dev** 1996 Aug;6(4):454–60 (63 ref.)

Peroxisome proliferator-activated receptor gamma and the control of adipogenesis. Brun RP, et al. **Curr Opin Lipidol** 1997 Aug;8(4):212–8 (55 ref.)

Getting hydrophilic compounds into cells: lessons from homeopeptides. Prochianty A. **Curr Opin Neurobiol** 1996 Oct;6(5):629–34 (31 ref.)

Interaction of steroid hormone receptors with the transcription initiation complex. Beato M, et al. **Endocr Rev** 1996 Dec;17(6):587–609 (261 ref.)

The shortest path from the surface to the nucleus: RBP-J kappa/Su(H) transcription factor. Honjo T. **Genes Cells** 1996 Jan;1(1):1–9 (49 ref.)

Differentiation of T-helper lymphocytes: selective regulation by members of the STAT family of transcription factors. Schindler U, et al. **Genes Cells** 1996 Jun;1(6):507–15 (64 ref.)

The general transcription factors of RNA polymerase II. Orphanides G, et al. **Genes Dev** 1996 Nov 1;10(21):2657–83 (281 ref.)

POU domain family values: flexibility, partnerships, and developmental codes. Ryan AK, et al. **Genes Dev** 1997 May 15;11(10):1207–25 (176 ref.)

Retinoic acid receptors and nuclear orphan receptors in the development of Xenopus laevis. Dreyer C, et al. **Int J Dev Biol** 1996 Feb;40(1):255–62 (55 ref.)

Transcriptional regulation of secretin gene expression. Nishitani J, et al. **J Clin Gastroenterol** 1995;21 Suppl 1:S50–55 (21 ref.)

Roles of gastric GATA DNA-binding proteins. Maeda M, et al. **J Exp Biol** 1996 Mar;199 (Pt 3):513–20 (54 ref.)

Tyrosines 113, 128, and 145 of SLP-76 are required for optimal augmentation of NFAT promoter activity. Fang N, et al. **J Immunol** 1996 Nov 1;157(9):3769–73 (16 ref.)

GAS elements: a few nucleotides with a major impact on cytokine-induced gene expression. Decker T, et al. **J Interferon Cytokine Res** 1997 Mar;17(3):121–34 (166 ref.)

Jun: transcription factor and oncoprotein. Rahmsdorf HJ. **J Mol Med** 1996 Dec;74(12):725–47 (276 ref.)

Specific targeting of protein-DNA complexes by DNA-reactive drugs (+)-CC-1065 and pluramycins. Henderson D, et al. **J Mol Recognit** 1996 Mar-Apr; 9(2):75–87 (59 ref.)

Neuroglial ATF/CREB factors interact with the human immunodeficiency virus type 1 long terminal repeat. Krebs FC, et al. **J Neurovirol** 1997 May;3 Suppl 1:S28–32 (28 ref.)

Erythropoietin gene regulation depends on heme-dependent oxygen sensing and assembly of interacting transcription factors. Huang LE, et al. **Kidney Int** 1997 Feb;51(2):548–52 (34 ref.)

Functional relationships among ETS gene family members. Papas TS, et al. **Leukemia** 1997 Apr;11 Suppl 3:557–66 (49 ref.)

Rigorous and quantitative assay of transcription in vitro. Zhang H, et al. **Methods Enzymol** 1996;273:86–99 (39 ref.)

DnaA initiator--also a transcription factor. Messer W, et al. **Mol Microbiol** 1997 Apr;24(1):1–6 (68 ref.)

Activation and repression of gene expression by POU family transcription factors. Latchman DS. **Philos Trans R Soc Lond B Biol Sci** 1996 Apr 29; 351(1339):511–5 (33 ref.)

Ligand-dependent interaction of nuclear receptors with potential transcriptional intermediary factors (mediators). Le Douarin B, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Apr 29; 351(1339):569–78 (45 ref.)

Mechanisms of transcriptional activation and repression can both involve TFIID. Manley JL, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Apr 29; 351(1339):517–26 (60 ref.)

Towards an understanding of protein-DNA recognition. Rhodes D, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Apr 29;351(1339):501–9 (50 ref.)

Gene regulation in the Drosophila embryo. Sauer F, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Apr 29; 351(1339):579–87 (44 ref.)

The biochemistry of transcription in eukaryotes: a paradigm for multisubunit regulatory complexes. Tjian R. **Philos Trans R Soc Lond B Biol Sci** 1996 Apr 29; 351(1339):491–9 (47 ref.)

Do basic region-leucine zipper proteins bend their DNA targets ... does it matter? [comment] Hagerman PJ. **Proc Natl Acad Sci U S A** 1996 Sep 17;93(19):9993–6 (45 ref.) Comment on: Proc Natl Acad Sci U S A 1996 Sep 17;93(19):10117–22.

Dexamethasone stimulation of rat insulin-like growth factor binding protein-1 (IGFBP-1) promoter activity involves the interaction of multiple transcription factors. Suh DS, et al. **Prog Growth Factor Res** 1995;6(2–4):131–40 (18 ref.)

A novel DNA/protein complex interacts with the insulin-like growth factor binding protein-1 (IGFBP-1) insulin response sequence and is required for maximal effects of insulin and glucocorticoids on promoter function. Unterman T, et al. **Prog Growth Factor Res** 1995; 6(2–4):119–29 (26 ref.)

Dietary polyunsaturated fatty acid regulation of gene transcription. Jump DB, et al. **Prog Lipid Res** 1996 Sep; 35(3):227–41 (142 ref.)

General transcription factors for RNA polymerase II. Conaway RC, et al. **Prog Nucleic Acid Res Mol Biol** 1997; 56:327–46 (170 ref.)

Transcriptional regulation by steroid hormones. Beato M, et al. **Steroids** 1996 Apr;61(4):240–51 (176 ref.)

Regulation of expression of the steroidogenic acute regulatory protein (StAR) gene: a central role for steroidogenic factor 1 [published erratum appears in Steroids 1997 Apr;62(4):395] Sugawara T, et al. **Steroids** 1997 Jan;62(1):5–9 (12 ref.)

Two's company, three's a crowd: the yeast two hybrid system for mapping molecular interactions. Warbrick E. **Structure** 1997 Jan 15;5(1):13–7 (29 ref.)

Redox signal transduction via iron-sulfur clusters in the SoxR transcription activator. Hidalgo E, et al. **Trends Biochem Sci** 1997 Jun;22(6):207–10 (37 ref.)

Silencers and locus control regions: opposite sides of the same coin. Kamakaka RT. **Trends Biochem Sci** 1997 Apr; 22(4):124–8 (42 ref.)

The RNA polymerase II general elongation factors. Reines D, et al. **Trends Biochem Sci** 1996 Sep;21(9):351–5 (37 ref.)

Transcription factors vs nucleosomes: regulation of the PHO5 promoter in yeast. Svaren J, et al. **Trends Biochem Sci** 1997 Mar;22(3):93–7 (50 ref.)

ERM proteins: head-to-tail regulation of actin-plasma membrane interaction. Tsukita S, et al. **Trends Biochem Sci** 1997 Feb;22(2):53–8 (37 ref.)

Regulation of transcription factor localization: fine-tuning of gene expression. Vandromme M, et al. **Trends Biochem Sci** 1996 Feb;21(2):59–64 (42 ref.)

TAFs mediate transcriptional activation and promoter selectivity [see comments] Verrijzer CP, et al. **Trends Biochem Sci** 1996 Sep;21(9):338–42 (50 ref.) Comment in: Trends Biochem Sci 1996 Sep;21(9):325–6.

Gene expression: increasing evidence for a transcriptosome. Halle JP, et al. **Trends Genet** 1996 May;12(5):161–3 (22 ref.)

Mechanisms of transcriptional activation in vivo: two steps forward. Stargell LA, et al. **Trends Genet** 1996 Aug; 12(8):311–5 (54 ref.)

[Intergenic interrelations in regulating the cell cycle: key role of E2F family transcription factors] Kel' OV, et al. **Mol Biol (Mosk)** 1997 Jul-Aug;31(4):656–70 (152 ref.) **(Rus)**

PHYSIOLOGY

The role of Ets transcription factors in the development and function of the mammalian immune system. Bassuk AG, et al. **Adv Immunol** 1997;64:65–104 (273 ref.)

The role of transcription factors in erythroid development. Bungert J, et al. **Ann Med** 1996 Feb;28(1):47–55 (60 ref.)

Transcription factors: regulators of gene expression in normal and pathological states [editorial] Wilson DB. **Ann Med** 1996 Feb;28(1):1–3 (15 ref.)

The peroxisome proliferator-activated receptors: ligands and activators. Forman BM, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:266–75 (42 ref.)

Peroxisome proliferator-activated receptors: a nuclear

receptor signaling pathway in lipid physiology. Lemberger T, et al. **Ann Rev Cell Dev Biol** 1996;12:335–63 (116 ref.)
Transcription factors of the NFAT family: regulation and function. Rao A, et al. **Annu Rev Immunol** 1997;15:707–47 (220 ref.)
PAX-6 in development and evolution. Callaerts P, et al. **Annu Rev Neurosci** 1997;20:483–532 (161 ref.)
Chromatin structure and function: the heretical path to an RNA transcription factor. Krause MO. **Biochem Cell Biol** 1996;74(5):623–32 (91 ref.)
IRF-1: the transcription factor linking the interferon response and oncogenesis. Taniguchi T, et al. **Biochim Biophys Acta** 1997 Aug 8;1333(1):M9–17 (58 ref.)
Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators of lipid metabolism. Latruffe N, et al. **Biochimie** 1997 Feb–Mar; 79(2–3):81–94 (162 ref.)
PPAR gamma and the control of adipogenesis. Spiegelman BM, et al. **Biochimie** 1997 Feb–Mar;79(2–3):111–2 (4 ref.)
The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs). Staels B, et al. **Biochimie** 1997 Feb–Mar;79(2–3):95–9 (39 ref.)
Illuminating flowers: CONSTANS induces LEAFY expression. Blázquez MA. **Bioessays** 1997 Apr;19(4):277–9 (21 ref.)
Craniofacial defects in AP-2 null mutant mice. Morriss-Kay GM. **Bioessays** 1996 Oct;18(10):785–8 (22 ref.)
The SCL/TAL1 gene: roles in normal and malignant haematopoiesis. Robb L, et al. **Bioessays** 1997 Jul; 19(7):607–13 (69 ref.)
p300 and CBP as transcriptional regulators and targets of oncogenic events. Eckner R. **Biol Chem** 1996 Nov; 377(11):685–8 (34 ref.)
Role of transcription factors in the age-dependent regulation of the androgen receptor gene in rat liver. Supakar PC, et al. **Biol Signals** 1996 May–Jun;5(3):170–9 (37 ref.)
SWI2/SNF2 and related proteins: ATP-driven motors that disrupt protein–DNA interactions? Pazin MJ, et al. **Cell** 1997 Mar 21;88(6):737–40 (20 ref.)
MyoD meets its maker. Rawls A, et al. **Cell** 1997 Apr 4; 89(1):5–8 (17 ref.)
Catching a Gli-mpse of Hedgehog. Ruiz i Altaba A. **Cell** 1997 Jul 25;90(2):193–6 (20 ref.)
Architectural transcription factors: proteins that remodel DNA. Werner MH, et al. **Cell** 1997 Mar 21;88(6):733–6 (18 ref.)
Transcription factors and induction in Xenopus laevis embryos. Knöchel W, et al. **Cell Mol Life Sci** 1997 Apr; 53(4):362–81 (233 ref.)
HSP gene expression and HSF2 in mouse development. Loones MT, et al. **Cell Mol Life Sci** 1997 Feb;53(2):179–90 (119 ref.)
Cholesterol homeostasis: clipping out a slippery regulator [published erratum appears in Curr Biol 1997 Apr 1;7(4):285] Osborne TF. **Curr Biol** 1997 Mar 1;7(3):R172–4 (11 ref.)
A new twist to the tale? Apoptosis. Warbrick E. **Curr Biol** 1996 Sep 1;6(9):1057–9 (10 ref.)
RNA polymerase II holoenzyme and transcriptional regulation. Greenblatt J. **Curr Opin Cell Biol** 1997 Jun; 9(3):310–9 (78 ref.)
Molecular model for telomeric heterochromatin in yeast. Grunstein M. **Curr Opin Cell Biol** 1997 Jun;9(3):383–7 (42 ref.)
Lipid metabolism [editorial] Poisson JP. **Curr Opin Lipidol** 1997 Apr;8(2):U20–1 (5 ref.)
Peroxisome proliferator-activated receptors, orphans with ligands and functions. Schoonjans K, et al. **Curr Opin Lipidol** 1997 Jun;8(3):159–66 (101 ref.)
The BRCA1 and BRCA2 breast cancer genes. Casey G. **Curr Opin Oncol** 1997 Jan;9(1):88–93 (84 ref.)
Transcription factors of the bHLH and LIM families: synergistic mediators of T cell acute leukemia? Baer R, et al. **Curr Top Microbiol Immunol** 1997;220:55–65 (58 ref.)
Fusions involving paired box and fork head family transcription factors in the pediatric cancer alveolar rhabdomyosarcoma. Barr FG. **Curr Top Microbiol Immunol** 1997;220:113–29 (68 ref.)
Differential gene expression in tumor metastasis: Nm23. Freije JM, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 2):215–32 (62 ref.)
The TEL gene contributes to the pathogenesis of myeloid and lymphoid leukemias by diverse molecular genetic mechanisms. Golub TR, et al. **Curr Top Microbiol Immunol** 1997;220:67–79 (15 ref.)
E2A–HLF chimeric transcription factors in pro-B cell acute lymphoblastic leukemia. Look AT. **Curr Top Microbiol Immunol** 1997;220:45–53 (54 ref.)
NM23/Nucleoside diphosphate kinase as a transcriptional activator of c-myc. Postel EH. **Curr Top Microbiol Immunol** 1996;213 (Pt 2):233–52 (96 ref.)
TLS–CHOP and the role of RNA-binding proteins in oncogenic transformation. Ron D. **Curr Top Microbiol Immunol** 1997;220:131–42 (53 ref.)
Steroidogenic factor 1: a key determinant of endocrine development and function. Parker KL, et al. **Endocr Rev** 1997 Jun;18(3):361–77 (123 ref.)
Role of Pit-1 in the gene expression of growth hormone, prolactin, and thyrotropin. Cohen LE, et al. **Endocrinol Metab Clin North Am** 1996 Sep;25(3):523–40 (94 ref.)
Transcription factors in the pathophysiology of diabetes mellitus. Hussain MA. **Eur J Endocrinol** 1997 May; 136(5):469–70 (15 ref.)
Role of the thyroid-specific enhancer-binding protein in transcription, development and differentiation. Kimura S. **Eur J Endocrinol** 1997 Feb;136(2):128–36 (81 ref.)
Heritable diseases of the skeleton. Part I: Molecular insights into skeletal development-transcription factors and signaling pathways. Mundlos S, et al. **FASEB J** 1997 Feb; 11(2):125–32 (60 ref.)
Activators and repressors: making use of chromatin to regulate transcription. Wolffe AP, et al. **Genes Cells** 1997 May;2(5):291–302 (103 ref.)
Transcription factors in eye development: a gorgeous mosaic? [comment] Kumar J, et al. **Genes Dev** 1997 Aug 15; 11(16):2023–8 (47 ref.) Comment on: Genes Dev 1997 Aug 15;11(16):2066–73.
The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias. Lo Coco F, et al. **Haematologica** 1997 May–Jun;82(3):364–70 (66 ref.)
Transcription factors contributing to the pancreatic beta-cell phenotype. Madsen OD, et al. **Horm Metab Res** 1997 Jun; 29(6):265–70 (60 ref.)
Pit-1: clinical aspects. Pfäffle R, et al. **Horm Res** 1996;45 Suppl 1:25–8 (10 ref.)
Transcription factor AP-1, and the role of Fra-2. Foletta VC. **Immunol Cell Biol** 1996 Apr;74(2):121–33 (163 ref.)
BCL-6 in diffuse large-cell lymphomas. Dalla-Favera R, et al. **Important Adv Oncol** 1996;:139–48 (49 ref.)
IRF-1 and IRF-2 as regulators of the interferon system and cell growth. Taniguchi T. **Indian J Biochem Biophys** 1995 Oct;32(5):235–9 (33 ref.)
Transcription factors and the cardiac gene programme. Doevendans PA, et al. **Int J Biochem Cell Biol** 1996 Apr; 28(4):387–403 (140 ref.)
Inhibitory transcription factors. Latchman DS. **Int J Biochem Cell Biol** 1996 Sep;28(9):965–74 (58 ref.)
Retinoid X receptors. Rowe A. **Int J Biochem Cell Biol** 1997 Feb;29(2):275–8 (11 ref.)
Regulation of hematopoietic cell proliferation and differentiation by the myb oncogene family of transcription factors. Golay J, et al. **Int J Clin Lab Res** 1996;26(1):24–32 (95 ref.)
Regulating adipogenesis. Mandrup S, et al. **J Biol Chem** 1997 Feb 28;272(9):5367–70 (56 ref.)
Regulation of nuclear oncogenes expressed in lung cancer cell lines. Sabichi AL, et al. **J Cell Biochem Suppl** 1996; 24:218–27 (31 ref.)
Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. Schoonjans K, et al. **J Lipid Res** 1996 May;37(5):907–25 (193 ref.)
The beta cell transcription factors and development of the pancreas. Sander M, et al. **J Mol Med** 1997 May; 75(5):327–40 (129 ref.)
Molecular dissection of corticosteroid action in the rat hippocampus. Application of the differential display techniques. Vreugdenhil E, et al. **J Mol Neurosci** 1996 Summer;7(2):135–46 (40 ref.)
The biologic function of PML and its role in acute promyelocytic leukemia. Mu ZM, et al. **Leuk Lymphoma** 1996 Oct;23(3–4):277–85 (55 ref.)
Nuclear RNA polymerases: role of general initiation factors and cofactors in eukaryotic transcription. Roeder RG. **Methods Enzymol** 1996;273:165–71 (30 ref.)
Transcription factors in early development of the central nervous system. Scotting PJ, et al. **Neuropathol Appl Neurobiol** 1996 Dec;22(6):469–81 (52 ref.)
Adipocyte differentiation is regulated by a prostaglandin liganded to the nuclear peroxisome proliferator-activated receptor. Wolf G. **Nutr Rev** 1996 Sep;54(9):290–2 (9 ref.)
Complex interplay among apoptosis factors: RB, p53, E2F, TGF-beta, cell cycle inhibitors and the bcl2 gene family. Chiarugi V, et al. **Pharmacol Res** 1997 Apr;35(4):257–61 (46 ref.)
Evidence to suggest that expression of MITF induces melanocyte differentiation and haploinsufficiency of MITF causes Waardenburg syndrome type 2A. Tachibana M. **Pigment Cell Res** 1997 Feb–Apr;10(1–2):25–33 (33 ref.)
Invasive carcinomas dismantle surrounding stroma induced to express the nuclear factor c-ets-1. Stehelin D. **Princess Takamatsu Symp** 1994;24:171–86 (48 ref.)
Regulatory factors in the control of muscle development. Dauncey MJ, et al. **Proc Nutr Soc** 1996 Mar;55(1B):543–59 (86 ref.)
The multifunctional role of the co-activator CBP in transcriptional regulation. Goldman PS, et al. **Recent Prog Horm Res** 1997;52:103–19; discussion 119–20 (83 ref.)
Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Shibata H, et al. **Recent Prog Horm Res** 1997;52:141–64; discussion 164–5 (119 ref.)
Steroidogenic factor 1 plays multiple roles in endocrine development and function. Wong M, et al. **Recent Prog Horm Res** 1997;52:167–82; discussion 182–4 (49 ref.)
Transcription factors: potential roles in drug-induced neuroplasticity. Persico AM, et al. **Rev Neurosci** 1996 Oct–Dec;7(4):233–75 (330 ref.)
Regulation of the tissue factor gene. Mackman N. **Thromb Haemost** 1997 Jul;78(1):747–54 (49 ref.)
The multiple roles of transcription/repair factor TFIIH. Svejstrup JQ, et al. **Trends Biochem Sci** 1996 Sep; 21(9):346–50 (49 ref.)
The roles of engrailed. Hidalgo A. **Trends Genet** 1996 Jan; 12(1):1–4 (25 ref.)
Extra specificity from extradenticle: the partnership between HOX and PBX/EXD homeodomain proteins [published erratum appears in Trends Genet 1996 Aug;12(8):328] Mann RS, et al. **Trends Genet** 1996 Jul;12(7):258–62 (52 ref.)
MYB transcription factors in plants. Martin C, et al. **Trends Genet** 1997 Feb;13(2):67–73 (55 ref.)
Engrailed and retinotectal topography. Rétaux S, et al. **Trends Neurosci** 1996 Dec;19(12):542–6 (56 ref.)
[Molecular mechanisms of cancer metastasis--ets-related nuclear transcription factor play an important role in cancer metastasis] Kaya M, et al. **Gan To Kagaku Ryoho** 1996 Sep; 23(10):1225–34 (52 ref.) (Eng. Abstr.) **(Jpn)**
[Transcriptional regulation of factor IX promoter by HNF 4, ARP 1 and COUP] Naka H. **Rinsho Byori** 1997 Feb; Suppl 104:107–16 (13 ref.) **(Jpn)**
[Mechanism of transcription activation by FTZ-F1] Ueda H. **Seikagaku** 1997 Apr;69(4):244–7 (14 ref.) **(Jpn)**
[Gene program regulating differentiation of embryonal carcinoma cells] Hamada H. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1018–21 (8 ref.) **(Jpn)**
[Helix-loop-helix transcription factor network regulating mammalian neurogenesis] Kageyama R, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):989–96 (25 ref.) **(Jpn)**
[Pax-5, a transcription factor controlling B cell differentiation] Kudo A. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1058–66 (25 ref.) **(Jpn)**
[Ad4BP/SF-1 and sex differentiation of the gonads] Morohashi K, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun; 41(8 Suppl):1033–41 (32 ref.) **(Jpn)**
[Multistep transcriptional regulation by the general transcription factor TFIIE and TFIIH] Ohkuma Y. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1135–47 (58 ref.) **(Jpn)**
[Regulation mechanism of specific transcription in erythroid differentiation] Takahashi S, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1042–9 (44 ref.) **(Jpn)**
[Cross-talk between transcription factors AP-1 and NFAT in the regulation of gene expression] Kamińska B, et al. **Postepy Biochem** 1996;42(2):120–8 (51 ref.) **(Pol)**

TRANSCRIPTION FACTORS, TFII

GENETICS

TAFs: guilt by association? Tansey WP, et al. **Cell** 1997 Mar 21;88(6):729–32 (22 ref.)
Considerations of transcriptional control mechanisms: do TFIID-core promoter complexes recapitulate nucleosome-like functions? Hoffmann A, et al. **Proc Natl Acad Sci U S A** 1997 Aug 19;94(17):8928–35 (127 ref.)

METABOLISM

Mechanisms of transcriptional activation and repression can both involve TFIID. Manley JL, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Apr 29; 351(1339):517–26 (60 ref.)

PHYSIOLOGY

[DNA repair and cell cycle regulation] Yokoi M, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1791–8 (36 ref.) **(Jpn)**

TRANSCRIPTION, GENETIC

see related
GENE PRODUCTS, REV
GENE PRODUCTS, TAT
GENE PRODUCTS, TAX
GENES, PX
GENES, REV
GENES, TAT
TRANS-ACTIVATORS
TRANSCRIPTION FACTORS

Alpha-lipoic acid: a metabolic antioxidant and potential redox modulator of transcription. Packer L, et al. **Adv Pharmacol** 1997;38:79–101 (102 ref.)
Relationships between DNA repair and transcription. Friedberg EC. **Annu Rev Biochem** 1996;65:15–42 (180 ref.)
Transcriptional regulation by cyclic AMP. Montminy M. **Annu Rev Biochem** 1997;66:807–22 (79 ref.)
Basic mechanisms of transcript elongation and its regulation. Uptain SM, et al. **Annu Rev Biochem** 1997;66:117–72 (422 ref.)
rRNA transcription and growth rate-dependent regulation of ribosome synthesis in Escherichia coli. Gourse RL, et al. **Annu Rev Microbiol** 1996;50:645–77 (157 ref.)
Processing of eukaryotic pre-rRNA: the role of the transcribed spacers. van Nues RW, et al. **Biochem Cell Biol** 1995 Nov–Dec;73(11–12):789–801 (65

ref.)
Retinoid-dependent transcription: the RAR/RXR-TBP-EIA/EIA-LA connection. Meyer M, et al. **Biochem Soc Symp** 1996;62:97-109 (50 ref.)
Interleukin 15. Cosman D, et al. **Biochem Soc Trans** 1997 May;25(2):371-4 (30 ref.)
Mechanisms of transcriptional activation by retinoic acid receptors. Glass CK, et al. **Biochem Soc Trans** 1997 May; 25(2):602-5 (20 ref.)
TIF1 alpha: a chromatin-specific mediator for the ligand-dependent activation function AF-2 of nuclear receptors? Le Douarin B, et al. **Biochem Soc Trans** 1997 May;25(2):605-12 (39 ref.)
Regulation of the activity of the transcription factors AP-1 and NFAT during differentiation of precursor CD4+ T-cells into effector cells. Rincón M, et al. **Biochem Soc Trans** 1997 May;25(2):347-54 (42 ref.)
Histones, nucleosomes and the roles of chromatin structure in transcriptional control. Wolffe AP. **Biochem Soc Trans** 1997 May;25(2):354-8 (22 ref.)
Three steps in the regulation of transcription by the thyroid hormone receptor: establishment of a repressive chromatin structure, disruption of chromatin and transcriptional activation. Wolffe AP, et al. **Biochem Soc Trans** 1997 May; 25(2):612-5 (18 ref.)
Transcriptional control of globin gene switching during vertebrate development. Baron MH. **Biochim Biophys Acta** 1997 Mar 20;1351(1-2):51-72 (175 ref.)
Transcription initiation from TATA-less promoters within eukaryotic protein-coding genes. Smale ST. **Biochim Biophys Acta** 1997 Mar 20;1351(1-2):73-88 (105 ref.)
A multi-functional enzyme with RNA polymerase and RNase activities: molecular anatomy of influenza virus RNA polymerase. Ishihama A. **Biochimie** 1996; 78(11-12):1097-102 (46 ref.)
Nonsense suppression in mammalian cells. Kuchino Y, et al. **Biochimie** 1996;78(11-12):1007-15 (32 ref.)
Structural and functional evidence that initiation and elongation of HIV-1 reverse transcription are distinct processes. Lanchy JM, et al. **Biochimie** 1996; 78(11-12):1087-96 (56 ref.)
Some novel transcription attenuation mechanisms used by bacteria. Yanofsky C, et al. **Biochimie** 1996; 78(11-12):1017-24 (35 ref.)
Cockayne syndrome--a primary defect in DNA repair, transcription, both or neither? Friedberg EC. **Bioessays** 1996 Sep;18(9):731-8 (55 ref.)
Remodeling chromatin structures for transcription: what happens to the histones? Steger DJ, et al. **Bioessays** 1996 Nov;18(11):875-84 (69 ref.)
News and views on the nucleolus in 1996. Report on the 'Colloquium on the nucleolus', a meeting at Paris-Grignon, July 18-20, 1996. Mosgoeller W, et al. **Biol Cell** 1996; 88(1-2):1-4 (12 ref.)
p300 and CBP as transcriptional regulators and targets of oncogenic events. Eckner R. **Biol Chem** 1996 Nov; 377(11):685-8 (34 ref.)
RNA-protein interactions in the regulation of coronavirus RNA replication and transcription. Lai MM. **Biol Chem** 1997 Jun;378(6):477-81 (32 ref.)
TP53 tumour suppressor gene: clues to molecular carcinogenesis and cancer therapy. Wang XW, et al. **Cancer Surv** 1996;28:169-96 (231 ref.)
Transcriptional checkpoints determining the fate of male germ cells. Sassone-Corsi P. **Cell** 1997 Jan 24;88(2):163-6 (22 ref.)
Transcriptional control in the developing lung. The Parker B. Francis lectureship. Korfhagen TR, et al. **Chest** 1997 Jun;111(6 Suppl):83S-88S (25 ref.)
Transcriptional regulation of the surfactant protein-A gene in fetal lung. Mendelson CR, et al. **Chest** 1997 Jun;111(6 Suppl):96S-104S (32 ref.)
Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases. Borden P, et al. **Crit Rev Eukaryot Gene Expr** 1997;7(1-2):159-78 (150 ref.)
Lessons in transcriptional regulation learned from studies on immunoglobulin genes. Henderson AJ, et al. **Crit Rev Eukaryot Gene Expr** 1995;5(3-4):255-80 (257 ref.)
Transcriptional control mechanisms in the regulation of cholesterol balance. Osborne TF. **Crit Rev Eukaryot Gene Expr** 1995;5(3-4):317-35 (96 ref.)
Myb-induced transformation. Wolff L. **Crit Rev Oncog** 1996; 7(3-4):245-60 (126 ref.)
Identification of a prime suspect. Buc H. **Curr Biol** 1997 Feb 1;7(2):R97-9 (13 ref.)
Transposition: mobile introns get into line. Grivell LA. **Curr Biol** 1996 Jan 1;6(1):48-51 (20 ref.)
Versatile molecular glue. Transcriptional control. Janknecht R, et al. **Curr Biol** 1996 Aug 1;6(8):951-4 (25 ref.)
Transcriptional elongation and cancer. Tumorigenesis. Li XY, et al. **Curr Biol** 1996 Aug 1;6(8):943-4 (24 ref.)
Transcription: building an initiation machine. Travers A. **Curr Biol** 1996 Apr 1;6(4):401-3 (22 ref.)
Histone acetyltransferases in control. Wade PA, et al. **Curr Biol** 1997 Feb 1;7(2):R82-4 (13 ref.)
RNA polymerase II holoenzyme and transcriptional regulation. Greenblatt J. **Curr Opin Cell Biol** 1997 Jun; 9(3):310-9 (78 ref.)
Common themes in the function of transcription and splicing enhancers. Hertel KJ, et al. **Curr Opin Cell Biol** 1997 Jun; 9(3):350-7 (68 ref.)
Nucleosomes and transcription: recent lessons from genetics. Hartzog GA, et al. **Curr Opin Genet Dev** 1997 Apr; 7(2):192-8 (60 ref.)
Transcriptional control of Hox genes in the vertebrate nervous system. Lufkin T. **Curr Opin Genet Dev** 1996 Oct; 6(5):575-80 (66 ref.)
Retinoid receptors in transcriptional regulation. Minucci S, et al. **Curr Opin Genet Dev** 1996 Oct;6(5):567-74 (67 ref.)
Chromatin remodeling and transcription. Tsukiyama T, et al. **Curr Opin Genet Dev** 1997 Apr;7(2):182-91 (140 ref.)
Transcriptional activation of plant defense genes. Zhu Q, et al. **Curr Opin Genet Dev** 1996 Oct;6(5):624-30 (76 ref.)
Disruption of a homolog of trithorax by 11q23 translocations: leukemogenic and transcriptional implications. Waring PM, et al. **Curr Top Microbiol Immunol** 1997;220:1-23 (135 ref.)
Regulation of neuronal nitric oxide synthase through alternative transcripts. Brenman JE, et al. **Dev Neurosci** 1997;19(3):224-31 (39 ref.)
Cockayne syndrome: defective repair of transcription? van Gool AJ, et al. **EMBO J** 1997 Jul 16;16(14):4155-62 (91 ref.)
Role of transcription-coupled DNA repair in susceptibility to environmental carcinogenesis. Hanawalt PC. **Environ Health Perspect** 1996 May;104 Suppl 3:547-51 (40 ref.)
Transcription and DNA damage: a link to a kink. Scicchitano DA, et al. **Environ Health Perspect** 1997 Feb;105 Suppl 1:145-53 (73 ref.)
Role of the thyroid-specific enhancer-binding protein in transcription, development and differentiation. Kimura S. **Eur J Endocrinol** 1997 Feb;136(2):128-36 (81 ref.)
Transcriptional regulation of MHC class I genes. Girdlestone J. **Eur J Immunogenet** 1996 Oct;23(5):395-413 (124 ref.)
The topology of transcription by immobilized polymerases. Iborra FJ, et al. **Exp Cell Res** 1996 Dec 15;229(2):167-73 (27 ref.)
Ultrastructure of the nucleus in relation to transcription and splicing: roles of perichromatin fibrils and interchromatin granules. Puvion E, et al. **Exp Cell Res** 1996 Dec 15; 229(2):217-25 (54 ref.)
Ad4BP/SF-1, a transcription factor essential for the transcription of steroidogenic cytochrome P450 genes and for the establishment of the reproductive function. Morohashi KI, et al. **FASEB J** 1996 Dec;10(14):1569-77 (50 ref.)
Cytochromes P450 12: diversity of ACTH (cAMP)-dependent transcription of bovine steroid hydroxylase genes. Waterman MR, et al. **FASEB J** 1997 May;11(6):419-27 (42 ref.)
Negative regulation of cytokine gene transcription. Ye J, et al. **FASEB J** 1997 Sep;11(11):825-33 (99 ref.)
Involvement of host factors in transcription from baculovirus very late promoters -- a review. Hasnain SE, et al. **Gene** 1997 Apr 29;190(1):113-8 (45 ref.)
How is osmotic regulation of transcription of the Escherichia coli proU operon achieved? A review and a model. Gowrishankar J, et al. **Genetica** 1996 May;97(3):363-78 (140 ref.)
The biochemistry of transcription and gene regulation. Tjian R. **Harvey Lect** 1994-95;90:19-39 (64 ref.)
Multiparameter microscopic analysis of nucleolar structure and ribosomal gene transcription. Trendelenburg MF, et al. **Histochem Cell Biol** 1996 Aug;106(2):167-92 (156 ref.)
Progress in transcriptionally targeted and regulatable vectors for genetic therapy. Miller N, et al. **Hum Gene Ther** 1997 May 1;8(7):803-15 (108 ref.)
Coupling transcription to translation: a novel site for the regulation of eukaryotic gene expression. Wolffe AP, et al. **Int J Biochem Cell Biol** 1996 Mar;28(3):247-57 (103 ref.)
Transcriptional regulation of chemokine gene expression in astrocytes. Majumder S, et al. **J Neurosci Res** 1996 Sep 15;45(6):758-69 (79 ref.)
Mutations in the c-erbA beta 1 gene: do they underlie euthyroid fibromyalgia? Lowe JC, et al. **Med Hypotheses** 1997 Feb;48(2):125-35 (152 ref.)
Analysis of open complex formation during RNA polymerase II transcription initiation using heteroduplex templates and potassium permanganate probing. Holstege FC, et al. **Methods** 1997 Jul;12(3):203-11 (46 ref.)
Assays for investigating transcription by RNA polymerase II in vitro. Reines D, et al. **Methods** 1997 Jul;12(3):192-202 (75 ref.)
Reconstitution of TATA-binding protein-associated factor/TATA-binding protein complexes for in vitro transcription. Chen JL, et al. **Methods Enzymol** 1996; 273:208-17 (22 ref.)
Basal and activated in vitro transcription in plants by RNA polymerase II and III. Fan H, et al. **Methods Enzymol** 1996; 273:268-77 (12 ref.)
Promoters and basal transcription machinery in eubacteria and eukaryotes: concepts, definitions, and analogies. Fassler JS, et al. **Methods Enzymol** 1996;273:3-29 (248 ref.)
Global steps during initiation by RNA polymerase II. Gralla JD. **Methods Enzymol** 1996;273:99-110 (30 ref.)
Analysis of two-component signal transduction systems involved in transcriptional regulation. Hakenbeck R, et al. **Methods Enzymol** 1996;273:281-300 (96 ref.)
Quantitative parameters for promoter clearance. Hsu LM. **Methods Enzymol** 1996;273:59-71 (30 ref.)
Purification, characterization, and role of CCAAT-binding factor in transcription. Maity SN, et al. **Methods Enzymol** 1996;273:217-32 (32 ref.)
In vitro assay for reiterative transcription during transcriptional initiation by Escherichia coli RNA polymerase. Qi F, et al. **Methods Enzymol** 1996;273:71-85 (18 ref.)
Purification and analysis of functional preinitiation complexes. Roberts SG, et al. **Methods Enzymol** 1996; 273:110-8 (10 ref.)
Nuclear RNA polymerases: role of general initiation factors and cofactors in eukaryotic transcription. Roeder RG. **Methods Enzymol** 1996;273:165-71 (30 ref.)
Rigorous and quantitative assay of transcription in vitro. Zhang H, et al. **Methods Enzymol** 1996;273:86-99 (39 ref.)
Stable DNA replication: interplay between DNA replication, homologous recombination, and transcription. Kogoma T. **Microbiol Mol Biol Rev** 1997 Jun;61(2):212-38 (266 ref.)
Nuclear matrix, dynamic histone acetylation and transcriptionally active chromatin. Davie JR. **Mol Biol Rep** 1997 Aug;24(3):197-207 (159 ref.)
Transfer RNA gene organization and RNase P. Green CJ. **Mol Biol Rep** 1995-96;22(2-3):181-5 (67 ref.)
Regulation of transcription of the testis-specific histone H1t gene by multiple promoter elements. Grimes SR Jr, et al. **Mol Biol Rep** 1997 Aug;24(3):175-84 (70 ref.)
tRNA processing in human mitochondrial disorders. Masucci JP, et al. **Mol Biol Rep** 1995-96;22(2-3):187-93 (78 ref.)
The osteocalcin gene: a model for multiple parameters of skeletal-specific transcriptional control. Stein GS, et al. **Mol Biol Rep** 1997 Aug;24(3):185-96 (102 ref.)
A flexible partnership: the CytR anti-activator and the cAMP-CRP activator protein, comrades in transcription control. Valentin-Hansen P, et al. **Mol Microbiol** 1996 May; 20(3):461-6 (26 ref.)
Transcriptional regulation of the mouse CSF-1 gene. Harrington M, et al. **Mol Reprod Dev** 1997 Jan;46(1):39-44; discussion 44-5 (16 ref.)
Regulation of transcription by proteins that control the cell cycle. Dynlacht BD. **Nature** 1997 Sep 11;389(6647):149-52 (70 ref.)
Histone acetylation in chromatin structure and transcription. Grunstein M. **Nature** 1997 Sep 25;389(6649):349-52 (75 ref.)
Signal transduction and protein kinases: the long way from the plasma membrane into the nucleus. Hucho F, et al. **Naturwissenschaften** 1997 Jul;84(7):281-90 (88 ref.)
Mechanisms of transcriptional regulation and neural gene expression. Tamura T, et al. **Neurochem Int** 1996 Dec; 29(6):573-81 (61 ref.)
Transcriptional regulation of axon pathfinding. Daston MM, et al. **Neuron** 1996 Jul;17(1):5-8 (14 ref.)
mRNA localization in neurons: a multipurpose mechanism? Steward O. **Neuron** 1997 Jan;18(1):9-12 (19 ref.)
Alterations in transcriptional regulation of proinflammatory and immunoregulatory cytokine expression by hemorrhage, injury, and critical illness. Abraham E. **New Horiz** 1996 May;4(2):184-93 (98 ref.)
Transcription factor access to chromatin. Beato M, et al. **Nucleic Acids Res** 1997 Sep 15;25(18):3559-63 (82 ref.)
CREM: a master-switch in the transcriptional response to cAMP. Lamas M, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Apr 29; 351(1339):561-7 (46 ref.)
Ligand-dependent interaction of nuclear receptors with potential transcriptional intermediary factors (mediators). Le Douarin B, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Apr 29; 351(1339):569-78 (45 ref.)
The biochemistry of transcription in eukaryotes: a paradigm for multisubunit regulatory complexes. Tjian R. **Philos Trans R Soc Lond B Biol Sci** 1996 Apr 29; 351(1339):491-9 (47 ref.)
Considerations of transcriptional control mechanisms: do TFIID-core promoter complexes recapitulate nucleosome-like functions? Hoffmann A, et al. **Proc Natl Acad Sci U S A** 1997 Aug 19;94(17):8928-35 (127 ref.)
Dietary polyunsaturated fatty acid regulation of gene transcription. Jump DB, et al. **Prog Lipid Res** 1996 Sep; 35(3):227-41 (142 ref.)
General transcription factors for RNA polymerase II. Conaway RC, et al. **Prog Nucleic Acid Res Mol Biol** 1997; 56:327-46 (170 ref.)
The multifunctional role of the co-activator CBP in transcriptional regulation. Goldman PS, et al. **Recent Prog Horm Res** 1997;52:103-19; discussion 119-20 (83 ref.)
Control of papillomavirus DNA replication and transcription. Desaintes C, et al. **Semin Cancer Biol** 1996 Dec;7(6):339-47 (76 ref.)
Transcriptional regulation by steroid hormones. Beato M, et al. **Steroids** 1996 Apr;61(4):240-51 (176 ref.)
Sigma domain structure: one down, one to go. Chan CL, et al. **Structure** 1996 Nov 15;4(11):1235-8 (34 ref.)
Pieces of the puzzle: assembling the preinitiation complex of Pol II. Ghosh G, et al. **Structure** 1996 Aug 15;4(8):891-5 (19 ref.)
Mediator of transcriptional regulation [see comments] Björklund S, et al. **Trends Biochem Sci** 1996 Sep;21(9):335-7 (25 ref.) Comment in: Trends Biochem Sci 1996 Sep;21(9):325-6.
Mitotic repression of the transcriptional machinery. Gottesfeld JM, et al. **Trends Biochem Sci** 1997 Jun;

22(6):197–202 (51 ref.)
Silencers and locus control regions: opposite sides of the same coin. Kamakaka RT. **Trends Biochem Sci** 1997 Apr; 22(4):124–8 (42 ref.)
The role of general initiation factors in transcription by RNA polymerase II. Roeder RG. **Trends Biochem Sci** 1996 Sep; 21(9):327–35 (65 ref.)
Common themes in translational and transcriptional regulation. Sachs AB, et al. **Trends Biochem Sci** 1997 Jun; 22(6):189–92 (20 ref.)
The multiple roles of transcription/repair factor TFIIH. Svejstrup JQ, et al. **Trends Biochem Sci** 1996 Sep; 21(9):346–50 (49 ref.)
Histone acetylation: chromatin in action. Wade PA, et al. **Trends Biochem Sci** 1997 Apr;22(4):128–32 (30 ref.)
Modular regulation of muscle gene transcription: a mechanism for muscle cell diversity. Firulli AB, et al. **Trends Genet** 1997 Sep;13(9):364–9 (51 ref.)
Strand asymmetries in DNA evolution. Francino MP, et al. **Trends Genet** 1997 Jun;13(6):240–5 (47 ref.)
Active repression mechanisms of eukaryotic transcription repressors. Hanna-Rose W, et al. **Trends Genet** 1996 Jun; 12(6):229–34 (46 ref.)
Core promoters and transcriptional control. Novina CD, et al. **Trends Genet** 1996 Sep;12(9):351–5 (49 ref.)
Cell-cycle regulation of gene expression by transcriptional repression. Zwicker J, et al. **Trends Genet** 1997 Jan; 13(1):3–6 (29 ref.)
A proposed mechanism of mRNA synthesis and capping by vesicular stomatitis virus. Shuman S. **Virology** 1997 Jan 6;227(1):1–6 (41 ref.)
[1997 Maurice Dérot. Transcriptional regulation of the insulin gene: a step toward gene therapy of diabetes] Cerasi E, et al. **Journ Annu Diabetol Hotel Dieu** 1997;:299–304 (15 ref.) **(Fre)**
[Functional screening of p53 status in tumor cells using Saccharomyces cerevisiae] Jia LQ, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(4):466–70 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Molecular mechanisms of cancer metastasis--ets-related nuclear transcription factor play an important role in cancer metastasis] Kaya M, et al. **Gan To Kagaku Ryoho** 1996 Sep; 23(10):1225–34 (52 ref.) (Eng. Abstr.) **(Jpn)**
[Structure of the histamine H1 receptor gene and transcriptional up-regulation of the H1 receptor] Fukui H. **Nippon Rinsho** 1996 Feb;54(2):389–95 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Gastric proton pump: genes and their expression] Futai M. **Nippon Rinsho** 1996 Apr;54(4):1138–43 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Transcriptional activity of EBNA2 through RBP-J] Sakai T, et al. **Nippon Rinsho** 1997 Feb;55(2):293–8 (22 ref.) (Eng. Abstr.) **(Jpn)**
[The transcriptional regulation of the human gastrin gene by EGF] Shiotani A. **Nippon Rinsho** 1996 Apr; 54(4):1087–91 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Mechanism of transcription activation by FTZ-F1] Ueda H. **Seikagaku** 1997 Apr;69(4):244–7 (14 ref.) **(Jpn)**
[HMG box proteins: general architectural elements in the assembly of active transcription complex] Yoshida M. **Seikagaku** 1996 Dec;68(12):1829–34 (14 ref.) **(Jpn)**
[Cancer and transcriptional regulation] Fujinaga K, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1336–41 (30 ref.) **(Jpn)**
[Cross-point of cAMP and Ca2+ signals to the transcription factors] Hagiwara M, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1282–7 (18 ref.) **(Jpn)**
[The structure and function of general transcription factor TFIIA] Handa H. **Tanpakushitsu Kakusan Koso** 1996 Jun; 41(8 Suppl):1124–34 (48 ref.) **(Jpn)**
[Role of yeast global repressors, Bel2 and Tup1, in chromatin-and nucleosome-mediated transcriptional regulation] Harashima S. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1187–97 (31 ref.) **(Jpn)**
[Transcriptional regulation through chromatin structure] Hirose S. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(15 Suppl):2393–6 (23 ref.) **(Jpn)**
[Analysis of the mechanism of transcriptional regulation based on yeast system] Horikoshi M, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1148–61 (57 ref.) **(Jpn)**
[Molecular communications in transcription: basic mechanisms of transcription regulation] Ishihama A. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1328–31 (0 ref.) **(Jpn)**
[Regulation of general transcription factors by phosphorylation] Kitajima S. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1162–9 (45 ref.) **(Jpn)**
[Detection of TBP-interacting proteins (TIPs) and demonstration of a novel complex containing TBP and ATPases] Makino Y, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1170–7 (16 ref.) **(Jpn)**
[Multistep transcriptional regulation by the general transcription factor TFIIE and TFIIH] Ohkuma Y. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1135–47 (58 ref.) **(Jpn)**
[Structure and function of PAS proteins: Ah receptor, Arnt, and others] Sogawa K, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1288–96 (47 ref.) **(Jpn)**
[Interaction of HTLV-1 Tax with cellular factors] Suzuki T, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1249–57 (39 ref.) **(Jpn)**
[Transcription regulation by FTZ-F1] Ueda H, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1210–8 (40 ref.) **(Jpn)**
[Signal transduction of steroids and vitamins mediated by nuclear receptor proteins] Umesono K. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1265–72 (37 ref.) **(Jpn)**
[In vitro studies of chromatin structure and transcriptional regulation] Ura K. **Tanpakushitsu Kakusan Koso** 1996 Jul; 41(9):1385–90 (23 ref.) **(Jpn)**
[Unique mechanism of coronavirus mRNA transcription] Tsukamoto K. **Uirusu** 1996 Dec;46(2):99–107 (41 ref.) **(Jpn)**
[Genes for gastric proton pump and their transcriptional regulation] Maeda M. **Yakugaku Zasshi** 1996 Feb; 116(2):91–105 (45 ref.) (Eng. Abstr.) **(Jpn)**
[Random necessity, transcription initiation, induction of differentiation and need for randomness] Golubev AG. **Biokhimiia** 1996 Jul;61(7):1303–19 (88 ref.) (Eng. Abstr.) **(Rus)**
[Mechanisms of transcriptional regulation of interferon-induced genes: description in the IIG-TRRD information system] Anan'ko EA, et al. **Mol Biol (Mosk)** 1997 Jul-Aug;31(4):701–13 (98 ref.) **(Rus)**
[Transcriptional regulation of lipid metabolism genes: description in the TRDD database] Ignat'eva EV, et al. **Mol Biol (Mosk)** 1997 Jul-Aug;31(4):684–700 (81 ref.) **(Rus)**
[Mechanisms of transcriptional regulation of erythroid specific genes] Podkolodnaia OA, et al. **Mol Biol (Mosk)** 1997 Jul-Aug;31(4):671–83 (127 ref.) **(Rus)**

DRUG EFFECTS

Immunobiology of picolinic acid. Melillo G, et al. **Adv Exp Med Biol** 1996;398:135–41 (43 ref.)
Effects of GnRH and PACAP on gonadotropin secretion and subunit messenger RNAs. Winters SJ, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:343–52; discussion 352–4 (30 ref.)
Genomic effects of tamoxifen. Kellen JA. **Anticancer Res** 1996 Nov-Dec;16(6B):3537–41 (52 ref.)
Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Arts EJ, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):527–40 (182 ref.)
Transcription-modulating drugs: mechanism and selectivity. Cai W, et al. **Curr Opin Biotechnol** 1996 Dec;7(6):608–15 (86 ref.)
Interactions of glucocorticoids and beta 2-agonists. Adcock IM, et al. **Eur Respir J** 1996 Jan;9(1):160–8 (82 ref.)
Apoptosis in neurodegenerative disorders: potential for therapy by modifying gene transcription. Tatton WG, et al. **J Neural Transm Suppl** 1997;49:245–68 (156 ref.)
Regulation of gene transcription by fatty acids, fibrates and prostaglandins: the phosphoenolpyruvate carboxykinase gene as a model. Forest C, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Jul; 57(1):47–56 (66 ref.)

GENETICS

Hepadnaviruses: current models of RNA encapsidation and reverse transcription. Fallows DA, et al. **Adv Virus Res** 1996;46:165–94 (138 ref.)
The Polycomb and trithorax group proteins of Drosophila: trans-regulators of homeotic gene function. Kennison JA. **Annu Rev Genet** 1995;29:289–303 (83 ref.)
Transcriptional repression in development. Gray S, et al. **Curr Opin Cell Biol** 1996 Jun;8(3):358–64 (37 ref.)
Nuclear organization and transcriptional silencing in yeast. Gotta M, et al. **Experientia** 1996 Dec 15;52(12):1136–47 (84 ref.)
Attenuated heat shock transcriptional response in aging: molecular mechanism and implication in the biology of aging. Liu AY, et al. **EXS** 1996;77:393–408 (74 ref.)
Toxic metal-responsive gene transcription. Zhu Z, et al. **EXS** 1996;77:307–20 (59 ref.)
Transcriptional control of lymphoid development: lessons from gene targeting. Clevers HC, et al. **Immunol Today** 1996 Jul;17(7):336–43 (59 ref.)
Functional interrelationships between nuclear structure and transcriptional control: contributions to regulation of cell cycle- and tissue-specific gene expression. Stein GS, et al. **J Cell Biochem** 1996 Aug;62(2):198–209 (102 ref.)
Circadian rhythms and autoregulatory transcription loops--going round in circles? Carter DA, et al. **Mol Cell Endocrinol** 1996 Nov 29;124(1-2):1–5 (43 ref.)
Antitermination of transcription of catabolic operons. Rutberg B. **Mol Microbiol** 1997 Feb;23(3):413–21 (71 ref.)
Neuronal-specific gene expression--the interaction of both positive and negative transcriptional regulators. Quinn JP. **Prog Neurobiol** 1996 Nov;50(4):363–79 (100 ref.)
Post-transcriptional regulation of bacterial carbohydrate metabolism: evidence that the gene product CsrA is a global mRNA decay factor. Romeo T. **Res Microbiol** 1996 Jul-Sep;147(6-7):505–12 (25 ref.)
Membrane-type matrix metalloproteinases (MT-MMPs) in cell invasion. Sato H, et al. **Thromb Haemost** 1997 Jul; 78(1):497–500 (37 ref.)
[Activation of transcription in eukaryotic cells: interactions between transcription factors and components of the basal transcriptional mechanism] Diagana TT. **C R Acad Sci III** 1997 Jul;320(7):509–21 (143 ref.) (Eng. Abstr.) **(Fre)**
[Transcriptional regulation of DNA replication-related genes during Drosophila melanogaster development] Hirose F, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1022–32 (29 ref.) **(Jpn)**
[Mechanisms of eukaryotic transcription initiation and its regulation centered on general transcription factors] Horikoshi M. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):957–88 (169 ref.) **(Jpn)**
[Involvement of SOX proteins in activation of crystallin genes and lens development] Kamachi Y. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1113–23 (32 ref.) **(Jpn)**
[Downstream of Hox genes] Kuroiwa A. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1075–82 (33 ref.) **(Jpn)**
[Interaction between yeast transcription factor GAL11 and general transcription factors] Sakurai H, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1178–86 (70 ref.) **(Jpn)**
[Transcriptional regulation by Hox gene products] Takahashi N. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1088–94 (46 ref.) **(Jpn)**
[Regulation mechanism of specific transcription in erythroid differentiation] Takahashi S, et al. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1042–9 (44 ref.) **(Jpn)**

IMMUNOLOGY

B lymphocyte development and transcription regulation in vivo. Opstelten D. **Adv Immunol** 1996;63:197–268 (308 ref.)
Accessibility control of antigen-receptor variable-region gene assembly: role of cis-acting elements. Sleckman BP, et al. **Annu Rev Immunol** 1996;14:459–81 (116 ref.)
Regulation of transcription of MHC class II genes. Boss JM. **Curr Opin Immunol** 1997 Feb;9(1):107–13 (57 ref.)
Transcriptional control of the expression of the c-fms gene encoding the receptor for macrophage colony-stimulating factor (CSF-1). Yue X, et al. **Immunobiology** 1996 Oct; 195(4-5):461–76 (59 ref.)

PHYSIOLOGY

Human immunodeficiency virus type 1 reverse transcriptase and early events in reverse transcription. Arts EJ, et al. **Adv Virus Res** 1996;46:97–163 (333 ref.)
Subtype 2 and atypical angiotensin receptors in the human heart. Regitz-Zagrosek V, et al. **Basic Res Cardiol** 1996; 91 Suppl 2:73–7 (18 ref.)
RNA polymerase slides home: pause and termination site recognition. Landick R. **Cell** 1997 Mar 21;88(6):741–4 (20 ref.)
A versatile transcriptional effector of Wingless signaling. Nusse R. **Cell** 1997 May 2;89(3):321–3 (21 ref.)
What's up and down with histone deacetylation and transcription? Pazin MJ, et al. **Cell** 1997 May 2;89(3):325–8 (20 ref.)
Archaeal histones, nucleosomes, and transcription initiation. Reeve JN, et al. **Cell** 1997 Jun 27;89(7):999–1002 (18 ref.)
TAFs: guilt by association? Tansey WP, et al. **Cell** 1997 Mar 21;88(6):729–32 (22 ref.)
Rhythmic transcription and autoregulatory loops: nuclear pacemaker CREM. Lamas M, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:285–94 (58 ref.)
Hanging on to histones. Chromatin. Wolffe AP, et al. **Curr Biol** 1996 Mar 1;6(3):234–7 (9 ref.)
Adipocyte differentiation: a transcriptional regulatory cascade. Brun RP, et al. **Curr Opin Cell Biol** 1996 Dec; 8(6):826–32 (68 ref.)
Influences of the cell cycle on silencing. Fox CA, et al. **Curr Opin Cell Biol** 1996 Jun;8(3):354–7 (27 ref.)
Cyclin-dependent kinase 7: at the cross-roads of transcription, DNA repair and cell cycle control? Nigg EA. **Curr Opin Cell Biol** 1996 Jun;8(3):312–7 (50 ref.)
Mechanisms of transcription complex assembly. Pugh BF. **Curr Opin Cell Biol** 1996 Jun;8(3):303–11 (69 ref.)
Transcriptional control of the cell cycle. Sánchez I, et al. **Curr Opin Cell Biol** 1996 Jun;8(3):318–24 (45 ref.)
Transcriptional regulatory strategies in male germ cells. Goldberg E. **J Androl** 1996 Nov-Dec;17(6):628–32 (27 ref.)
The transcriptional basis of chromosome pairing. Cook PR. **J Cell Sci** 1997 May;110 (Pt 9):1033–40 (75 ref.)
Transcriptional responses to tubule challenges. Gullans SR, et al. **Kidney Int** 1996 Jun;49(6):1678–81 (19 ref.)
Regulation of somatostatin gene transcription by cyclic adenosine monophosphate. Montminy M, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):4–7 (12 ref.)
Transcription factors as activators of gene transcription: AP-1 and NF-kappa B. Adcock IM. **Monaldi Arch Chest Dis** 1997 Apr;52(2):178–86 (49 ref.)
Invasive carcinomas dismantle surrounding stroma induced to express the nuclear factor c-ets-1. Stehelin D. **Princess Takamatsu Symp** 1994;24:171–86 (48 ref.)
Calcineurin regulation of synaptic function: from ion channels to transmitter release and gene transcription.

TRANSCRIPTION, GENETIC

Yakel JL. **Trends Pharmacol Sci** 1997 Apr;18(4):124–34 (63 ref.)

[Methods of studying transcriptional regulation of gene expression] Abe T. **Nippon Rinsho** 1996 Feb;54(2):316–21 (22 ref.) (Eng. Abstr.) **(Jpn)**

TRANSCRIPTIONAL ACTIVATION see **TRANS-ACTIVATION (GENETICS)**

TRANSCRIPTIONAL REGULATORY ELEMENTS see **GENES, REGULATOR**

TRANSCULTURAL NURSING

Haitian Americans: implications for nursing care. Holcomb LO, et al. **J Community Health Nurs** 1996;13(4):249–60 (32 ref.)

Cultural competence in the care of abused women. Campbell JC, et al. **J Nurse Midwifery** 1996 Nov–Dec;41(6):457–62 (22 ref.)

Family dynamics and family therapy with Mexican Americans. Grothaus KL.
J Psychosoc Nurs Ment Health Serv 1996 Feb;34(2):31–7 (9 ref.)

EDUCATION

Cultural safety in nursing: the New Zealand experience. Papps E, et al. **Int J Qual Health Care** 1996 Oct;8(5):491–7 (23 ref.)

Promoting cultural competence in HIV/AIDS care. O'Connor BB. **J Assoc Nurses AIDS Care** 1996;7 Suppl 1:41–53 (28 ref.)

STANDARDS

Promoting cultural competence in HIV/AIDS care. O'Connor BB. **J Assoc Nurses AIDS Care** 1996;7 Suppl 1:41–53 (28 ref.)

TRANSCULTURAL STUDIES see **CROSS-CULTURAL COMPARISON**

TRANSCUTANEOUS ADMINISTRATION see **ADMINISTRATION, CUTANEOUS**

TRANSCUTANEOUS BLOOD GAS MONITORING see **BLOOD GAS MONITORING, TRANSCUTANEOUS**

TRANSCUTANEOUS CAPNOMETRY see **BLOOD GAS MONITORING, TRANSCUTANEOUS**

TRANSCUTANEOUS ELECTRIC NERVE STIMULATION

Randomization is important in studies with pain outcomes: systematic review of transcutaneous electrical nerve stimulation in acute postoperative pain. Carroll D, et al. **Br J Anaesth** 1996 Dec;77(6):798–803 (52 ref.)

Angina pectoris refractory for conventional therapy—is neurostimulation a possible alternative treatment? Hautvast RW, et al. **Clin Cardiol** 1996 Jul;19(7):531–5 (68 ref.)

Transcutaneous electrical nerve stimulation for the control of pain in musculoskeletal disorders. Robinson AJ.
J Orthop Sports Phys Ther 1996 Oct;24(4):208–26 (83 ref.)

Spinal cord stimulation in severe angina pectoris—presentation of current studies, indications and clinical experience. Eliasson T, et al. **Pain** 1996 May–Jun; 65(2–3):169–79 (137 ref.)

[Epidural electric nerve stimulation] Brusin VI, et al.
Anesteziol Reanimatol 1995 Nov–Dec;(6):26–31 (67 ref.) **(Rus)**

METHODS

Transcutaneous electrical nerve stimulation in labour pain: a systematic review. Carroll D, et al.
Br J Obstet Gynaecol 1997 Feb;104(2):169–75 (20 ref.)

[Stimulation of the endorphin structures of the brain—a new nondrug treatment method] Aleksandrova VA, et al.
Zh Nevropatol Psikhiatr Im S S Korsakova 1996;96(2):101–4 (65 ref.) **(Rus)**

TRANSCUTANEOUS OXIMETRY see **BLOOD GAS MONITORING, TRANSCUTANEOUS**

TRANSDERMAL ADMINISTRATION see **ADMINISTRATION, CUTANEOUS**

TRANSDERMAL ELECTROSTIMULATION see **TRANSCUTANEOUS ELECTRIC NERVE STIMULATION**

TRANSDUCERS

An optoelectric plantar "shear" sensing transducer: design, validation, and preliminary subject tests. Lebar AM, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):310–9 (27 ref.)

TRANSDUCIN

PHYSIOLOGY

Chemoreception: tasting the sweet and the bitter. Lindemann B. **Curr Biol** 1996 Oct 1;6(10):1234–7 (20 ref.)

TRANSDUCTION, GENETIC

Cytokine gene transduction in the immunotherapy of cancer. Parmiani G, et al. **Adv Pharmacol** 1997;40:259–307 (235 ref.)

Selection of retrovirally transduced cells to enhance the efficiency of gene therapy. Medin JA, et al.
Proc Assoc Am Physicians 1997 Mar;109(2):111–9 (67 ref.)

[SLTR, a new family of retroviral vectors for gene transduction] Choulika A, et al.
C R Seances Soc Biol Fil 1996;190(1):153–8 (17 ref.) (Eng. Abstr.) **(Fre)**

[Role of prophages in the formation of antibiotic-resistant populations of Staphylococcus in the process of transformation, transduction and conjugation] Zueva VS, et al. **Antibiot Khimioter** 1996;41(10):35–42 (35 ref.) **(Rus)**

TRANSESOPHAGEAL ECHOCARDIOGRAPHY see **ECHOCARDIOGRAPHY, TRANSESOPHAGEAL**

TRANSFECTION

see related
ELECTROPORATION

Genetic transformation of parasitic protozoa. Kelly JM.
Adv Parasitol 1997;39:227–70 (110 ref.)

The physico-chemical factors that govern retrovirus-mediated gene transfer. Palsson B, et al.
Exp Hematol 1997 Feb;25(2):94–102 (94 ref.)

Transfectable and transplantable postmitotic human neurons: a potential "platform" for gene therapy of nervous system diseases. Trojanowski JQ, et al. **Exp Neurol** 1997 Mar; 144(1):92–7 (36 ref.)

Methods for transient expression of hetero-oligomeric ligand-gated ion channels. Lüddens H, et al.
Methods Mol Biol 1997;83:55–63 (25 ref.)

Approaches to the stable transfection of G protein-coupled receptors. Townsend-Nicholson A. **Methods Mol Biol** 1997;83:45–54 (7 ref.)

[Synthetic vectors for gene transfection] Emi N, et al.
Nippon Rinsho 1996 Jul;54(7):1997–2002 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Transfection] Ohta T. **Nippon Rinsho** 1996 Mar;54(3):757–64 (15 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Gene transfer to muscle. Dickson G. **Biochem Soc Trans** 1996 May;24(2):514–9 (48 ref.)

Viral vectors for modulating gene expression in neurons. Slack RS, et al. **Curr Opin Neurobiol** 1996 Oct;6(5):576–83 (53 ref.)

Gene delivery into the glomerulus via mesangial cell vectors. Kitamura M. **Exp Nephrol** 1997 Mar–Apr;5(2):118–25 (40 ref.)

Cationic liposome-mediated gene transfer. Gao X, et al.
Gene Ther 1995 Dec;2(10):710–22 (92 ref.)

Somatic gene transfer approaches to manipulate neural networks. Federoff HJ, et al. **J Neurosci Methods** 1997 Jan;71(1):133–42 (67 ref.)

Defective viral vectors as agents for gene transfer in the nervous system. Kaplitt MG, et al. **J Neurosci Methods** 1997 Jan;71(1):125–32 (87 ref.)

Adenovirus-mediated gene transfer to the brain: methodological assessment. Peltékian E, et al.
J Neurosci Methods 1997 Jan;71(1):77–84 (37 ref.)

Alphavirus-based expression vectors: strategies and applications. Frolov I, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11371–7 (72 ref.)

Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Moss B.
Proc Natl Acad Sci U S A 1996 Oct 15;93(21):11341–8 (180 ref.)

[Selective transfection of animal cells by non viral vectors: polylysine carrying recognition signals] Monsigny M, et al. **C R Seances Soc Biol Fil** 1996;190(1):39–43 (14 ref.) (Eng. Abstr.) **(Fre)**

TRANSFER FACTOR

CHEMISTRY

Transfer factor in the age of molecular biology: a review. Dwyer JM. **Biotherapy** 1996;9(1–3):7–11 (15 ref.)

IMMUNOLOGY

Transfer factor in the age of molecular biology: a review. Dwyer JM. **Biotherapy** 1996;9(1–3):7–11 (15 ref.)

PHYSIOLOGY

Transfer factor—current status and future prospects. Lawrence HS, et al. **Biotherapy** 1996;9(1–3):1–5 (16 ref.)

THERAPEUTIC USE

The use of transfer factors in chronic fatigue syndrome: prospects and problems. Levine PH. **Biotherapy** 1996; 9(1–3):77–9 (25 ref.)

AIDS and transfer factor: myths, certainties and realities. Viza D. **Biotherapy** 1996;9(1–3):17–26 (88 ref.)

[Use of transfer++factor in allergic bronchial asthma] Salazar Villa RM, et al. **Rev Alerg** 1993 Mar–Apr; 40(2):42–5 (41 ref.) (Eng. Abstr.) **(Spa)**

TRANSFER-GLUCOSIDASE see **GLYCOGEN DEBRANCHING ENZYME SYSTEM**

TRANSFER RNA see **RNA, TRANSFER**

TRANSFER RNA, AMINO ACID-SPECIFIC see **RNA, TRANSFER, AMINO ACID-SPECIFIC**

TRANSFER RNA, AMINO ACYL see **RNA, TRANSFER, AMINO ACYL**

TRANSFER RNA, ASP see **RNA, TRANSFER, ASP**

TRANSFER RNA, GLN see **RNA, TRANSFER, GLN**

TRANSFER RNA, LYS see **RNA, TRANSFER, LYS**

TRANSFER RNA, MET see **RNA, TRANSFER, MET**

TRANSFER RNA, PHE see **RNA, TRANSFER, PHE**

TRANSFER RNA, SER see **RNA, TRANSFER, SER**

TRANSFERASES

ANTAGONISTS & INHIBITORS

The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Gibbs JB, et al.
Annu Rev Pharmacol Toxicol 1997;37:143–66 (125 ref.)

Farnesyltransferase inhibitors: a new class of cancer chemotherapeutics. Koblan KS, et al.
Biochem Soc Trans 1996 Aug;24(3):688–92 (26 ref.)

Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Cox AD, et al. **Biochim Biophys Acta** 1997 Aug 8;1333(1):F51–71 (139 ref.)

Farnesyl: proteintransferase inhibitors as agents to inhibit tumor growth. Omer CA, et al. **Biofactors** 1997;6(3):359–66 (37 ref.)

Inhibitors of farnesyl:protein transferase—a possible cancer chemotherapeutic. Scholten JD, et al.
Bioorg Med Chem 1996 Sep;4(9):1537–43 (26 ref.)

Farnesyltransferase inhibitors and anti-Ras therapy. Gibbs JB, et al. **Breast Cancer Res Treat** 1996;38(1):75–83 (29 ref.)

Farnesyl protein transferase inhibitors as potential cancer chemopreventives. Kelloff GJ, et al.
Cancer Epidemiol Biomarkers Prev 1997 Apr;6(4):267–82 (187 ref.)

[Inhibitors of Ras farnesylation: tomorrow's anticancer agents?] Perrin D, et al. **Bull Cancer** 1997 Jun;84(6):635–42 (56 ref.) (Eng. Abstr.) **(Fre)**

[Growth inhibition of human pancreatic cancer by farnesyl transferase inhibitor] Kainuma O, et al.
Gan To Kagaku Ryoho 1996 Oct;23(12):1657–9 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Inhibitors of isoprenylation of ras p21] Yoshimatsu K.
Gan To Kagaku Ryoho 1997 Sep;24(11):1495–502 (30 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Farnesyltransferase as a target for anticancer drug design. Qian Y, et al. **Biopolymers** 1997;43(1):25–41 (122 ref.)

GENETICS

Molecular basis of polymorphic drug metabolism. Daly AK.
J Mol Med 1995 Nov;73(11):539–53 (210 ref.)

Apamin binding proteins and oligosaccharyltransferases [letter] Strong PN, et al. **Toxicon** 1996 May;34(5):507–9 (15 ref.)

[Bio-chemoprevention of cancer] Nishino H.
Gan To Kagaku Ryoho 1997 Jul;24(9):1047–52 (2 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Ras farnesyltransferase: a new therapeutic target. Leonard DM. **J Med Chem** 1997 Sep 12;40(19):2971–90 (187 ref.)

Polyprenyl diphosphate synthases. Ogura K, et al.
Subcell Biochem 1997;28:57–87 (88 ref.)

TRANSFERASES (OTHER SUBSTITUTED PHOSPHATE GROUPS)

Holo-[acyl-carrier-protein] synthase of Escherichia coli. Lambalot RH, et al. **Methods Enzymol** 1997;279:254–62 (14 ref.)

METABOLISM

beta-Catenin is a target for extracellular signals controlling cadherin function: the neurocan-GalNAcPTase connection. Lilien J, et al. **Curr Top Dev Biol** 1997; 35:161–89 (137 ref.)

TRANSFERENCE (PSYCHOLOGY)

Toward a conceptual alliance about therapeutic alliance: a

voyage through the Inferno. Szajnberg NM. **J Am Acad Psychoanal** 1996 Spring;24(1):95–113 (33 ref.)
The primal scene: variations on a theme. Knafo D, et al. **J Am Psychoanal Assoc** 1996;44(2):549–69 (41 ref.)
[Somatic gain, somatic transfer and somatic neurosis] Chemouni J. **Ann Med Psychol (Paris)** 1996 Jun; 154(3):174–83 (18 ref.) (Eng. Abstr.) **(Fre)**

TRANSFERRIN

see related
RECEPTORS, TRANSFERRIN

ANALOGS & DERIVATIVES

Treatment of alcohol dependence: experiences of using biological markers in monitoring and prevention of relapse. Borg S. **Alcohol Alcohol** 1996 Nov;31(6):621–4 (10 ref.)
New 'state' markers for the detection of alcoholism. Lesch OM, et al. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:59–62 (30 ref.)
Laboratory markers of alcohol abuse. Sillanaukee P. **Alcohol Alcohol** 1996 Nov;31(6):613–6 (29 ref.)

ANALYSIS

Fatty acid ethyl esters: short-term and long-term serum markers of ethanol intake. Laposata M. **Clin Chem** 1997 Aug;43(8 Pt 2):1527–34 (53 ref.)

METABOLISM

Alcohol and iron: one glass of red or more? Fletcher LM. **J Gastroenterol Hepatol** 1996 Nov;11(11):1039–41 (6 ref.)
Mixture models in haematology: a series of case studies [see comments] McLaren CE. **Stat Methods Med Res** 1996 Jun; 5(2):129–53 (83 ref.) Comment in: Stat Methods Med Res 1996 Jun;5(2):107–27.
[Advances in the study of mechanism of iron uptake and some related etiology] Qian Z, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Oct;76(10):792–4 (19 ref.) **(Chi)**
[Erythron transferrin uptake--a new refind parameter to assess erythropoietic activity] Takahashi Y, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:84–7 (5 ref.) **(Jpn)**

TRANSFERRIN RECEPTORS see **RECEPTORS, TRANSFERRIN**

TRANSFORMATION, BACTERIAL

Binding and transport of transforming DNA by Bacillus subtilis: the role of type-IV pilin-like proteins--a review. Dubnau D. **Gene** 1997 Jun 11;192(1):191–8 (56 ref.)
Transformation competence and type-4 pilus biogenesis in Neisseria gonorrhoeae--a review. Fussenegger M, et al. **Gene** 1997 Jun 11;192(1):125–34 (93 ref.)
Uptake and processing of DNA by Acinetobacter calcoaceticus--a review. Palmen R, et al. **Gene** 1997 Jun 11;192(1):179–90 (72 ref.)
Control of recombination rate during transformation of Streptococcus pneumoniae: an overview. Mortier-Barriere I, et al. **Microb Drug Resist** 1997 Fall;3(3):233–42 (53 ref.)

GENETICS

Streptococcal competence for genetic transformation: regulation by peptide pheromones. Morrison DA. **Microb Drug Resist** 1997 Spring;3(1):27–37 (86 ref.)

PHYSIOLOGY

Who's competent and when: regulation of natural genetic competence in bacteria. Solomon JM, et al. **Trends Genet** 1996 Apr;12(4):150–5 (59 ref.)

TRANSFORMATION, GENETIC

see related
DNA, RECOMBINANT

Genetic transformation of parasitic protozoa. Kelly JM. **Adv Parasitol** 1997;39:227–70 (110 ref.)
Plant transformation: a pilus in Agrobacterium T-DNA transfer. Baron C, et al. **Curr Biol** 1996 Dec 1;6(12):1567–9 (12 ref.)
Transforming sperm nuclei into male pronuclei in vivo and in vitro. Poccia D, et al. **Curr Top Dev Biol** 1996;34:25–88 (250 ref.)
Adeno-associated virus 2-mediated transduction and erythroid lineage-specific expression in human hematopoietic progenitor cells. Srivastava A, et al. **Curr Top Microbiol Immunol** 1996;218:93–117 (72 ref.)
Transposable elements and gene transformation in non-drosophilid insects. O'Brochta DA, et al. **Insect Biochem Mol Biol** 1996 Sep-Oct;26(8–9):739–53 (96 ref.)
Acute phase proteins and transformed cells. Mackiewicz A. **Int Rev Cytol** 1997;170:225–300 (500 ref.)
Biolistic transformation of yeasts. Johnston SA, et al. **Methods Mol Biol** 1996;53:147–53 (12 ref.)
Transformation of lithium-treated yeast cells and the selection of auxotrophic and dominant markers. Mount RC, et al. **Methods Mol Biol** 1996;53:139–45 (19 ref.)
Transformation of follicular lymphoma with both t(14;18) and t(8;22). Bisiau H, et al. **Nouv Rev Fr Hematol** 1995; 37(4):241–4 (12 ref.)
Rice transformation: bombardment. Christou P. **Plant Mol Biol** 1997 Sep;35(1–2):197–203 (29 ref.)
Transformation of rice mediated by Agrobacterium tumefaciens. Hiei Y, et al. **Plant Mol Biol** 1997 Sep; 35(1–2):205–18 (119 ref.)
Transformation of malaria parasites: the barriers come down. Hyde JE. **Trends Microbiol** 1996 Feb;4(2):43–5 (15 ref.)
[Role of prophages in the formation of antibiotic-resistant populations of Staphylococcus in the process of transformation, transduction and conjugation] Zueva VS, et al. **Antibiot Khimioter** 1996;41(10):35–42 (35 ref.) **(Rus)**
[Cell differentiation and its regulation during genetic transformation in bacteria] Prozorov AA. **Mikrobiologiia** 1997 Jan-Feb;66(1):5–13 (54 ref.) (Eng. Abstr.) **(Rus)**

TRANSFORMING GENES see **ONCOGENES**

TRANSFORMING GROWTH FACTOR ALPHA

CHEMISTRY

Biophysical characterization and formulation of TP40: A chimeric protein that requires a pH-dependent conformational change for its biological activity. Sanyal G, et al. **Pharm Biotechnol** 1996;9:365–92 (30 ref.)

IMMUNOLOGY

Transforming growth factor-alpha (TGF-alpha) and epidermal growth factor-receptor (EGF-R) immunoreactivity in normal and pathologic brain. Ferrer I, et al. **Prog Neurobiol** 1996 Jun;49(2):99–123 (110 ref.)

METABOLISM

Roles for transforming growth factor-alpha in the stomach. Coffey RJ, et al. **J Clin Gastroenterol** 1995;21 Suppl 1:S36–9 (29 ref.)

PHARMACOLOGY

Biophysical characterization and formulation of TP40: A chimeric protein that requires a pH-dependent conformational change for its biological activity. Sanyal G, et al. **Pharm Biotechnol** 1996;9:365–92 (30 ref.)

PHYSIOLOGY

Occupational lung disease and the role of peptide growth factors. Brody AR. **Curr Opin Pulm Med** 1997 May; 3(3):203–8 (37 ref.)
Insights into the physiology of TGF alpha and signaling through the EGF receptor revealed by gene targeting and acts of nature. Dunn AR, et al. **Princess Takamatsu Symp** 1994;24:276–89 (63 ref.)

TRANSFORMING GROWTH FACTOR ALPHA RECEPTORS see **RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE**

TRANSFORMING GROWTH FACTOR BETA

[Vg1, a possible natural mesoderm inducer derived from the study of the localized maternal mRNA in the Xenopus egg cytoplasm] Shiokawa K, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(11):1594–9 (18 ref.) **(Jpn)**

BIOSYNTHESIS

EGR-1, the reluctant suppression factor: EGR-1 is known to function in the regulation of growth, differentiation, and also has significant tumor suppressor activity and a mechanism involving the induction of TGF-beta1 is postulated to account for this suppressor activity. Liu C, et al. **Crit Rev Oncog** 1996;7(1–2):101–25 (159 ref.)
Embryonic asymmetry: left TGFbeta at the right time? King T, et al. **Curr Biol** 1997 Apr 1;7(4):R212–5 (25 ref.)
Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation. Strober W, et al. **Immunol Today** 1997 Feb;18(2):61–4 (11 ref.)
Development of mesencephalic dopaminergic neurons and the transforming growth factor-beta superfamily. Krieglstein K, et al. **J Neural Transm Suppl** 1995;46:209–16 (32 ref.)
Cartilage morphogenesis: role of bone and cartilage morphogenetic proteins, homeobox genes and extracellular matrix. Reddi AH. **Matrix Biol** 1995 Oct;14(8):599–606 (64 ref.)
[Control of growth and expression of protooncogenes in regenerating liver] Zou Y, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan;27(1):7–12 (17 ref.) (Eng. Abstr.) **(Chi)**

CHEMISTRY

Stability, characterization, formulation, and delivery system development for transforming growth factor-beta 1. Gombotz WR, et al. **Pharm Biotechnol** 1996;9:219–45 (78 ref.)
TGF-beta latency: biological significance and mechanisms of activation. Gleizes PE, et al. **Stem Cells** 1997;15(3):190–7 (70 ref.)

GENETICS

Cancer gets Mad: DPC4 and other TGFbeta pathway genes in human cancer. Moskaluk CA, et al. **Biochim Biophys Acta** 1996 Dec 9;1288(3):M31–3 (21 ref.)
The type II transforming growth factor-beta receptor as a tumor-suppressor gene. Brattain MG, et al. **Curr Opin Oncol** 1996 Jan;8(1):49–53 (26 ref.)
[Role of TGF-beta and PDGF on the pathogenesis of pulmonary fibrosis--analysis by in vivo gene transfer] Yoshida M, et al. **Nippon Rinsho** 1996 Feb;54(2):418–22 (13 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Weller M, et al. **Brain Res Brain Res Rev** 1995 Sep;21(2):128–51 (254 ref.)

METABOLISM

Bone morphogenetic proteins in development. Hogan BL. **Curr Opin Genet Dev** 1996 Aug;6(4):432–8 (57 ref.)
Alpha 2-macroglobulin: a binding protein for transforming growth factor-beta and various cytokines. Feige JJ, et al. **Horm Res** 1996;45(3–5):227–32 (36 ref.)
Growth factors and bone formation in osteoporosis: roles for IGF-I and TGF-beta. Marie P. **Rev Rhum Engl Ed** 1997 Jan;64(1):44–53 (95 ref.)
Cytokines and production of surfactant components. Bry K, et al. **Semin Perinatol** 1996 Jun;20(3):194–205 (137 ref.)
TGF-beta latency: biological significance and mechanisms of activation. Gleizes PE, et al. **Stem Cells** 1997;15(3):190–7 (70 ref.)
[Regulation of tissue-associated fibrinolysis by retinoids: mechanism and consequence of retinoid-PA-TGF-beta system] Kojima S. **Seikagaku** 1997 Feb;69(2):104–8 (14 ref.) **(Jpn)**

PHARMACOLOGY

Effect of neurotrophic factors on the inner ear: clinical implications. Kopke R, et al. **Acta Otolaryngol (Stockh)** 1996 Mar;116(2):248–52 (25 ref.)
Growth factor function in the development and maintenance of midbrain dopaminergic neurons: concepts, facts and prospects for TGF-beta. Unsicker K, et al. **Ciba Found Symp** 1996;196:70–80; discussion 80–4 (41 ref.)
Regulation and interactions of transforming growth factor-beta with cardiovascular cells: implications for development and disease. Saltis J, et al. **Clin Exp Pharmacol Physiol** 1996 Mar;23(3):193–200 (94 ref.)
p53-dependent repression of cdk4 synthesis in transforming growth factor-beta-induced G1 cell cycle arrest. Ewen ME. **J Lab Clin Med** 1996 Oct;128(4):355–60 (13 ref.)
Antiproliferative actions of insulin-like growth factor binding protein (IGFBP)-3 in human breast cancer cells. Oh Y, et al. **Prog Growth Factor Res** 1995;6(2–4):503–12 (42 ref.)

PHYSIOLOGY

Transforming growth factor-beta system and its regulation by members of the steroid-thyroid hormone superfamily. Koli K, et al. **Adv Cancer Res** 1996;70:63–94 (133 ref.)
Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-beta. Ravitz MJ, et al. **Adv Cancer Res** 1997;71:165–207 (248 ref.)
Transforming growth factor-beta: the breaking open of a black box. Alevizopoulos A, et al. **Bioessays** 1997 Jul; 19(7):581–91 (93 ref.)
Growth factors for bone growth and repair: IGF, TGF beta and BMP. Linkhart TA, et al. **Bone** 1996 Jul;19(1 Suppl):1S–12S (96 ref.)
Cellular signaling roles of TGF beta, TNF alpha and beta APP in brain injury responses and Alzheimer's disease. Mattson MP, et al. **Brain Res Brain Res Rev** 1997 Feb; 23(1–2):47–61 (119 ref.)
The multifunctional role of transforming growth factor (TGF)-beta's on mammary epithelial cell biology. Arteaga CL, et al. **Breast Cancer Res Treat** 1996;38(1):49–56 (51 ref.)
Serine/threonine kinase receptors: mediators of transforming growth factor beta family signals. Massagué J, et al. **Cancer Surv** 1996;27:41–64 (128 ref.)
Signalling to the nucleus by members of the transforming growth factor-beta (TGF-beta) superfamily. Hill CS. **Cell Signal** 1996 Dec;8(8):533–44 (125 ref.)
GDNF: a cytokine at the interface of TGF-betas and neurotrophins. Unsicker K. **Cell Tissue Res** 1996 Nov; 286(2):175–8 (30 ref.)
TGF-beta: a critical modulator of immune cell function. Letterio JJ, et al. **Clin Immunol Immunopathol** 1997 Sep; 84(3):244–50 (61 ref.)
Regulation of differentiation by TGF-beta. Moses HL, et al. **Curr Opin Genet Dev** 1996 Oct;6(5):581–6 (61 ref.)
Transforming growth factor-beta in human glomerular injury. Peters H, et al. **Curr Opin Nephrol Hypertens** 1997 Jul;6(4):389–93 (27 ref.)
Signal transduction by members of the transforming growth factor-beta superfamily. Attisano L, et al.

Cytokine Growth Factor Rev 1996 Dec;7(4):327–39 (127 ref.)
Tumor suppressor activity of the TGF-beta pathway in human cancers [see comments] Markowitz SD, et al. **Cytokine Growth Factor Rev** 1996 Jun;7(1):93–102 (123 ref.) Comment in: Cytokine Growth Factor Rev 1996 Dec;7(4):295.
Genetic and biochemical analysis of TGF beta signal transduction. Padgett RW, et al. **Cytokine Growth Factor Rev** 1997 Mar;8(1):1–9 (75 ref.)
Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Pepper MS. **Cytokine Growth Factor Rev** 1997 Mar;8(1):21–43 (242 ref.)
Central role of TGF-beta in the pathogenesis of diabetic nephropathy and macrovascular complications: a hypothesis. Yokoyama H, et al. **Diabet Med** 1996 Apr; 13(4):313–20 (89 ref.)
Transforming growth factor beta in diabetic nephropathy. Border WA, et al. **Diabetes Metab Rev** 1996 Dec; 12(4):309–39 (128 ref.)
Transforming growth factor-beta: a general review. Lawrence DA. **Eur Cytokine Netw** 1996 Sep;7(3):363–74 (121 ref.)
The role of growth factors in peritoneal healing: transforming growth factor beta (TGF-beta). Chegini N. **Eur J Surg Suppl** 1997;(577):17–23 (41 ref.)
Growth factors in mechanisms of malignancy: roles for TGF-beta and FGF. Wright JA, et al. **Histol Histopathol** 1996 Apr;11(2):521–36 (145 ref.)
Transforming growth factors-beta s: a multifunctional cytokine family. Implication in the regulation of adrenocortical cell endocrine functions. Chambaz EM, et al. **Horm Res** 1996;45(3–5):222–6 (21 ref.)
The endothelin-parathyroid hormone-related protein vasoactive peptide system in human endometrium: modulation by transforming growth factor-beta. Casey ML, et al. **Hum Reprod** 1996 Oct;11 Suppl 2:62–82 (116 ref.)
Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation. Strober W, et al. **Immunol Today** 1997 Feb;18(2):61–4 (11 ref.)
Transforming growth factor beta s and wound healing. O'Kane S, et al. **Int J Biochem Cell Biol** 1997 Jan; 29(1):63–78 (131 ref.)
TGF-beta receptors and signal transduction. Miyazono K. **Int J Hematol** 1997 Feb;65(2):97–104 (42 ref.)
Activation of latent TGF-beta at the vascular wall--roles of endothelial cells and mural pericytes or smooth muscle cells. Sato Y. **J Atheroscler Thromb** 1995;2(1):24–9 (38 ref.)
Transforming growth factor beta s and fibroblast growth factors and their receptors: role in sutural biology and craniosynostosis [editorial; comment] Cohen MM Jr. **J Bone Miner Res** 1997 Mar;12(3):322–31 (76 ref.) Comment on: J Bone Miner Res 1997 Mar;12(3):301–10. Comment on: J Bone Miner Res 1997 Mar;12(3):311–21.
TGF-beta in kidney fibrosis: a target for gene therapy. Border WA, et al. **Kidney Int** 1997 May;51(5):1388–96 (40 ref.)
Biology of TGF-beta in knockout and transgenic mouse models. Böttinger EP, et al. **Kidney Int** 1997 May; 51(5):1355–60 (69 ref.)
Latent transforming growth factor-beta: structural features and mechanisms of activation. Munger JS, et al. **Kidney Int** 1997 May;51(5):1376–82 (78 ref.)
TGF-beta and the endothelium during immune injury. Pintavorn P, et al. **Kidney Int** 1997 May;51(5):1401–12 (193 ref.)
Cytokine regulation of schistosome-induced granuloma and fibrosis. Wahl SM, et al. **Kidney Int** 1997 May;51(5):1370–5 (62 ref.)
Neuropathogenesis of HIV-1 infection: interactions between interleukin-1 and transforming growth factor-beta 1. Vitković L. **Mol Psychiatry** 1997 Mar;2(2):111–2 (16 ref.)
TGF-beta and glomerulonephritis: anti-inflammatory versus prosclerotic actions. Kitamura M, et al. **Nephrol Dial Transplant** 1997 Apr;12(4):669–79 (161 ref.)
Complex interplay among apoptosis factors: RB, p53, E2F, TGF-beta, cell cycle inhibitors and the bcl2 gene family. Chiarugi V, et al. **Pharmacol Res** 1997 Apr;35(4):257–61 (46 ref.)
An emerging complexity of receptors for transforming growth factor-beta. Derynck R, et al. **Princess Takamatsu Symp** 1994;24:264–75 (54 ref.)
TGF beta regulation of cell proliferation. Moses HL, et al. **Princess Takamatsu Symp** 1994;24:250–63 (73 ref.)
Role of transforming growth factor-beta in tissue injury and repair. Grande JP. **Proc Soc Exp Biol Med** 1997 Jan; 214(1):27–40 (246 ref.)
TGF beta in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Barrack ER. **Prostate** 1997 Apr 1;31(1):61–70 (100 ref.)
Growth factors sculpt the synapse [comment] Schuman E. **Science** 1997 Feb 28;275(5304):1277–8 (16 ref.) Comment on: Science 1997 Feb 28;275(5304):1318–20.
Transforming growth factor-beta and prostate cancer. Steiner MS. **World J Urol** 1995;13(6):329–36 (77 ref.)
[TGF-beta and its receptors] Yuasa Y. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1460–4 (19 ref.) (Eng. Abstr.) **(Jpn)**
[Role of TGF-beta and PDGF on the pathogenesis of pulmonary fibrosis--analysis by in vivo gene transfer] Yoshida M, et al. **Nippon Rinsho** 1996 Feb;54(2):418–22 (13 ref.) (Eng. Abstr.) **(Jpn)**
[MAP kinase cascade regulating TGF beta signaling pathway] Matsumoto K, et al. **Seikagaku** 1996 Dec; 68(12):1824–8 (8 ref.) **(Jpn)**
[TGF-beta signal transduction and Smad] Miyazono K, et al. **Seikagaku** 1997 Jun;69(6):424–8 (16 ref.) **(Jpn)**
[Transforming growth factor-beta: a new approach to the pathogenesis of glomerulonephritis and glomerulosclerosis] Witowski J, et al. **Przegl Lek** 1995;52(9):467–73 (49 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Vascular remodelling and molecular biology: new concepts and therapeutic possibilities. Agrotis A, et al. **Clin Exp Pharmacol Physiol** 1996 May;23(5):363–8 (57 ref.)

TRANSFORMING GROWTH FACTOR BETA RECEPTORS see **RECEPTORS, TRANSFORMING GROWTH FACTOR BETA**

TRANSFORMING GROWTH FACTORS

PHYSIOLOGY

Cytokines in neuronal development. Jonakait GM. **Adv Pharmacol** 1997;37:35–67 (369 ref.)
Use of transgenic mice to study autocrine-paracrine signaling in lung morphogenesis and differentiation. Whitsett JA, et al. **Clin Perinatol** 1996 Dec;23(4):753–69 (54 ref.)

TRANSFORMING REGION see **BASE SEQUENCE**

TRANSGENES

see related
ANIMALS, TRANSGENIC

The vagaries of variegating transgenes. Martin DI, et al. **Bioessays** 1996 Nov;18(11):919–23 (46 ref.)
Overexpression of growth-associated proteins in the neurons of adult transgenic mice. Caroni P. **J Neurosci Methods** 1997 Jan;71(1):3–9 (19 ref.)
Recent advances in transgenic technology. Cameron ER. **Mol Biotechnol** 1997 Jun;7(3):253–65 (113 ref.)
Transgene inheritance in plants genetically engineered by microprojectile bombardment. Pawlowski WP, et al. **Mol Biotechnol** 1996 Aug;6(1):17–30 (86 ref.)
Optimizing expression of transgenes with an emphasis on post-transcriptional events. Koziel MG, et al. **Plant Mol Biol** 1996 Oct;32(1–2):393–405 (80 ref.)
Do transgene arrays form heterochromatin in vertebrates? Dorer DR. **Transgenic Res** 1997 Jan;6(1):3–10 (60 ref.)
[Applications of transgenesis in xenotransplantation. Experimental results and clinical prospects] Malassagne B, et al. **Presse Med** 1996 Sep 21;25(27):1247–50 (24 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Production of pigs transgenic for human DAF to overcome complement-mediated hyperacute xenograft rejection in man. White DJ, et al. **Res Immunol** 1996 Feb;147(2):88–94 (28 ref.)

TRANSGENIC ANIMALS see **ANIMALS, TRANSGENIC**

TRANSGENIC MICE see **MICE, TRANSGENIC**

TRANSGENIC PLANTS see **PLANTS, TRANSGENIC**

TRANSGLUTAMINASE see **PROTEIN-GLUTAMINE GAMMA-GLUTAMYLTRANSFERASE**

TRANSIENT ISCHEMIC ATTACK see **CEREBRAL ISCHEMIA, TRANSIENT**

TRANSIENT SITUATIONAL DISTURBANCE see **ADJUSTMENT DISORDERS**

TRANSIENTS AND MIGRANTS

see related
HOMELESS PERSONS

Studies of cancer in migrants: rationale and methodology. Parkin DM, et al. **Eur J Cancer** 1996 May;32A(5):761–71 (70 ref.)
Sexually transmitted diseases in mobile populations. Mabey D, et al. **Genitourin Med** 1997 Feb;73(1):18–22 (33 ref.)
Alcohol and drug abuse by migrant farmworkers: past research and future priorities. Watson JM. **NIDA Res Monogr** 1997;168:443–58 (22 ref.)
Migrant studies in multiple sclerosis. Gale CR, et al. **Prog Neurobiol** 1995 Nov-Dec;47(4–5):425–48 (79 ref.)
[The impact of migratory processes on the epidemiology of tuberculosis in the Stavropol' territory] Odinets VS, et al. **Probl Tuberk** 1997;(1):33–4 (0 ref.) (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

Homesickness: a review of the literature. Van Tilburg MA, et al. **Psychol Med** 1996 Sep;26(5):899–912 (70 ref.)

TRANSIN see **STROMELYSIN 1**

TRANSLATING

Communication through interpreters in healthcare: ethical dilemmas arising from differences in class, culture, language, and power [see comments] Kaufert JM, et al. **J Clin Ethics** 1997 Spring;8(1):71–87 (47 ref.) Comment in: J Clin Ethics 1997 Spring;8(1):88–93.
From what's neutral to what's meaningful: reflections on a study of medical interpreters [see comments] Solomon MZ. **J Clin Ethics** 1997 Spring;8(1):88–93 (11 ref.) Comment in: J Clin Ethics 1997 Spring;8(1):71–87.
'Equivalence' and the translation and adaptation of health-related quality of life questionnaires. Herdman M, et al. **Qual Life Res** 1997 Apr;6(3):237–47 (42 ref.)

TRANSLATION, GENETIC

Recoding: dynamic reprogramming of translation. Gesteland RF, et al. **Annu Rev Biochem** 1996;65:741–68 (181 ref.)
Interrelationships of the pathways of mRNA decay and translation in eukaryotic cells. Jacobson A, et al. **Annu Rev Biochem** 1996;65:693–739 (400 ref.)
Programmed translational frameshifting. Farabaugh PJ. **Annu Rev Genet** 1996;30:507–28 (113 ref.)
Comparison of lantibiotic gene clusters and encoded proteins. Siezen RJ, et al. **Antonie Van Leeuwenhoek** 1996 Feb; 69(2):171–84 (73 ref.)
Genomic evolution drives the evolution of the translation system. Andersson SG, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11–12):775–87 (102 ref.)
A pseudoknot is required for efficient translational initiation and regulation of the Escherichia coli rpsO gene coding for ribosomal protein S15. Ehresmann C, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11–12):1131–40 (34 ref.)
A model of the translational apparatus based on a three-dimensional reconstruction of the Escherichia coli ribosome. Frank J, et al. **Biochem Cell Biol** 1995 Nov-Dec; 73(11–12):757–65 (38 ref.)
Cotranslational folding of nascent proteins on Escherichia coli ribosomes. Hardesty B, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11–12):1199–207 (22 ref.)
Termination of translation in eukaryotes. Kisselev LL, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11–12):1079–86 (34 ref.)
Cotranslational folding of proteins. Kolb VA, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11–12):1217–20 (38 ref.)
The accuracy center of a eukaryotic ribosome. Liebman SW, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11–12):1141–9 (49 ref.)
Escherichia coli initiator tRNA: structure-function relationships and interactions with the translational machinery. Mangroo D, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11–12):1023–31 (51 ref.)
Regulation of translation termination: conserved structural motifs in bacterial and eukaryotic polypeptide release factors. Nakamura Y, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11–12):1113–22 (38 ref.)
Translational regulation of infC operon in Bacillus stearothermophilus. Pediconi D, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11–12):1071–8 (25 ref.)
Translational termination efficiency in both bacteria and mammals is regulated by the base following the stop codon. Tate WP, et al. **Biochem Cell Biol** 1995 Nov-Dec; 73(11–12):1095–103 (42 ref.)
Comparison of functional peptide encoded in the Escherichia coli 23S rRNA with other peptides involved in cis-regulation of translation. Tenson T, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11–12):1061–70 (40 ref.)
Interleukin 15. Cosman D, et al. **Biochem Soc Trans** 1997 May;25(2):371–4 (30 ref.)
Targeting proteins to mitochondria: is there a role for mRNA localization? Lightowlers RN, et al. **Biochem Soc Trans** 1996 May;24(2):527–31 (41 ref.)
Intracellular signalling pathways regulating initiation factor eIF4E phosphorylation during the activation of cell growth. Morley SJ. **Biochem Soc Trans** 1997 May; 25(2):503–9 (65 ref.)
Dual functions of ribosome recycling factor in protein biosynthesis: disassembling the termination complex and preventing translational errors. Janosi L, et al. **Biochimie** 1996;78(11–12):959–69 (50 ref.)
Nonsense suppression in mammalian cells. Kuchino Y, et al. **Biochimie** 1996;78(11–12):1007–15 (32 ref.)
Structure and function of 10Sa RNA: trans-translation system. Muto A, et al. **Biochimie** 1996;78(11–12):985–91 (41 ref.)
Molecular recognition governing the initiation of translation in Escherichia coli. A review. Schmitt E, et al. **Biochimie** 1996;78(7):543–54 (141 ref.)
The translational stop signal: codon with a context, or extended factor recognition element? Tate WP, et al. **Biochimie** 1996;78(11–12):945–52 (32 ref.)
Strategies for in vitro and in vivo translation with non-natural amino acids. Ibba M. **Biotechnol Genet Eng Rev** 1996;13:197–216 (116 ref.)
Double agent: translational regulation by a transcription factor. Mayfield S. **Chem Biol** 1996 Jun;3(6):415–8 (13 ref.)
Translational control during early development. Stebbins-Boaz B, et al. **Crit Rev Eukaryot Gene Expr** 1997;

7(1-2):73-94 (159 ref.)
Ribosomes: protein synthesis in slow motion. Moore PB. **Curr Biol** 1997 Mar 1;7(3):R179-81 (10 ref.)
Drosophila development: homeodomains and translational control. Zamore PD, et al. **Curr Biol** 1996 Jul 1;6(7):773-5 (17 ref.)
Translational controls impinging on the 5'-untranslated region and initiation factor proteins. Jackson RJ, et al. **Curr Opin Genet Dev** 1997 Apr;7(2):233-41 (72 ref.)
Translational regulation of maternal mRNAs. Macdonald PM, et al. **Curr Opin Genet Dev** 1996 Aug;6(4):403-7 (46 ref.)
Mechanisms of translational control in early development. Seydoux G. **Curr Opin Genet Dev** 1996 Oct;6(5):555-61 (65 ref.)
The error catastrophe theory of aging. Point counterpoint [letter] Gallant J, et al. **Exp Gerontol** 1997 May-Jun; 32(3):333-46 (28 ref.)
Translation attenuation regulation of chloramphenicol resistance in bacteria--a review. Lovett PS. **Gene** 1996 Nov 7;179(1):157-62 (20 ref.)
Coupling transcription to translation: a novel site for the regulation of eukaryotic gene expression. Wolffe AP, et al. **Int J Biochem Cell Biol** 1996 Mar;28(3):247-57 (103 ref.)
In vitro translation analysis of integral membrane proteins. Bayle D, et al. **J Recept Signal Transduct Res** 1997 Jan-May;17(1-3):29-56 (70 ref.)
Preparation and use of yeast cell-free translation lysate. Hartley AD, et al. **Methods Mol Biol** 1996;53:249-57 (9 ref.)
Polysome analysis. Sagliocco FA, et al. **Methods Mol Biol** 1996;53:297-311 (13 ref.)
Post-transcriptional control of PARP gene expression. Clayton C, et al. **Mol Biochem Parasitol** 1996 Apr;77(1):1-6 (40 ref.)
Three, four or more: the translational stop signal at length. Tate WP, et al. **Mol Microbiol** 1996 Jul;21(2):213-9 (28 ref.)
Patterns of translational regulation in the mammalian testis. Kleene KC. **Mol Reprod Dev** 1996 Feb;43(2):268-81 (127 ref.)
The plant translational apparatus. Browning KS. **Plant Mol Biol** 1996 Oct;32(1-2):107-44 (352 ref.)
Translation in plants--rules and exceptions. Fütterer J, et al. **Plant Mol Biol** 1996 Oct;32(1-2):159-89 (375 ref.)
Translational control of cellular and viral mRNAs. Gallie DR. **Plant Mol Biol** 1996 Oct;32(1-2):145-58 (109 ref.)
Translation of hepatitis C virus genome. Ali N, et al. **Princess Takamatsu Symp** 1995;25:99-110 (48 ref.)
Mechanism of translation initiation on hepatitis C virus RNA. Nomoto A, et al. **Princess Takamatsu Symp** 1995;25:111-9 (30 ref.)
TOP genes: a translationally controlled class of genes including those coding for ribosomal proteins. Amaldi F, et al. **Prog Mol Subcell Biol** 1997;18:1-17 (70 ref.)
Translational control by polyadenylation during early development. Osborne HB, et al. **Prog Mol Subcell Biol** 1997;18:173-98 (100 ref.)
3' untranslated regions of c-myc and c-fos mRNAs: multifunctional elements regulating mRNA translation, degradation and subcellular localization. Veyrune JL, et al. **Prog Mol Subcell Biol** 1997;18:35-63 (160 ref.)
Structural and functional considerations of the aminoacylation reaction. Arnez JG, et al. **Trends Biochem Sci** 1997 Jun;22(6):211-6 (45 ref.)
Common themes in translational and transcriptional regulation. Sachs AB, et al. **Trends Biochem Sci** 1997 Jun; 22(6):189-92 (20 ref.)
[Translational control through nonsense suppression] Muramatsu T, et al. **Seikagaku** 1997 Jan;69(1):36-9 (8 ref.) **(Jpn)**
[Phosphate sites of RNA-ligands interacting with ribosome at different stages of translation. Thiophosphate method of analysis] Dabrowski M, et al. **Biokhimiia** 1996 Nov; 61(11):1971-83 (38 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Antisense-protein kinase A: a single-gene-based therapeutic approach. Cho-Chung YS, et al. **Antisense Nucleic Acid Drug Dev** 1997 Jun;7(3):217-23 (20 ref.)

GENETICS

Ancient ciphers: translation in Archaea. Dennis PP. **Cell** 1997 Jun 27;89(7):1007-10 (8 ref.)
Starting at the beginning, middle, and end: translation initiation in eukaryotes. Sachs AB, et al. **Cell** 1997 Jun 13; 89(6):831-8 (61 ref.)
Translational control of endogenous and recoded nuclear genes in yeast mitochondria: regulation and membrane targeting. Fox TD. **Experientia** 1996 Dec 15;52(12):1130-5 (63 ref.)
Throwing a spanner in the works: antibiotics and the translation apparatus. Spahn CM, et al. **J Mol Med** 1996 Aug;74(8):423-39 (150 ref.)

PHYSIOLOGY

Ribosomes and translation. Green R, et al. **Annu Rev Biochem** 1997;66:679-716 (198 ref.)
Translational regulation of maternal mRNA. Hake LE, et al. **Biochim Biophys Acta** 1997 Feb 22;1332(1):M31-8 (45 ref.)

TRANSLATIONS

Overcoming language barriers when teaching the Advanced Trauma Life Support course [editorial] Ali J, et al. **Eur J Surg** 1997 Jul;163(7):483-6 (14 ref.)
[Preparation of International Chemical Safety Cards (ICSC) and their translation into Japanese] Yamamoto M, et al. **Eisei Shikenjo Hokoku** 1994;(112):143-6 (3 ref.) (Eng. Abstr.) **(Jpn)**

TRANSLOCATION (GENETICS)

Monosomy 1p36.31-33-->pter due to a paternal reciprocal translocation: prognostic significance of FISH analysis. Blennow E, et al. **Am J Med Genet** 1996 Oct 2;65(1):60-7 (30 ref.)
Prenatal diagnosis of a fetus with two balanced de novo chromosome rearrangements. Cotter PD, et al. **Am J Med Genet** 1996 Dec 11;66(2):197-9 (12 ref.)
A case of presumptive monosomy 21 re-diagnosed as unbalanced t(5p;21q) by FISH and review of literature. Iqbal MA, et al. **Am J Med Genet** 1997 May 16;70(2):174-8 (21 ref.)
Partial trisomy 17q22-qter and partial monosomy Xq27-qter in a girl with a de novo unbalanced translocation due to a postzygotic error: case report and review of the literature on partial trisomy 17qter. Sarri C, et al. **Am J Med Genet** 1997 May 2;70(1):87-94 (46 ref.)
Translocation t(10;11) involving the MLL gene in acute myeloid leukemia. Importance of fluorescence in situ hybridization (FISH) analysis. Berger R, et al. **Ann Genet** 1996;39(3):147-51 (39 ref.)
Down syndrome with unusual chromosome translocation: case report and review. Bruni L, et al. **Ann Genet** 1996; 39(4):240-2 (19 ref.)
Characterization of a de novo t(Y;9) (q11.2;q22) by FISH technique. Conte RA, et al. **Ann Genet** 1996;39(1):10-5 (53 ref.)
Further delineation of 7p trisomy. Case report and review of literature. Pallotta R, et al. **Ann Genet** 1996;39(3):152-8 (26 ref.)
The elongating ribosome: structural and functional aspects. Nierhaus KH, et al. **Biochem Cell Biol** 1995 Nov-Dec; 73(11-12):1011-21 (24 ref.)
Robertsonian translocation as an acquired karyotypic abnormality in leukaemia. Ma SK, et al. **Br J Haematol** 1997 Jul;98(1):213-5 (12 ref.)
Characterization of a complex translocation [t(4;9;22)(p16;q34;q11)] in chronic myelogenous leukemia by fluorescence in situ hybridization technique. Gudi R, et al. **Cancer Genet Cytogenet** 1996 Sep;90(2):142-5 (17 ref.)
5q-, twenty-five years later: a synopsis. Van den Berghe H, et al. **Cancer Genet Cytogenet** 1997 Mar;94(1):1-7 (37 ref.)
Chromosome abnormalities in leukaemia: the 11q23 paradigm. Young BD, et al. **Cancer Surv** 1996;28:225-45 (135 ref.)
Blepharophimosis syndrome (BPES) and additional abnormalities in a female with a balanced X:3 translocation [letter] Karimi-Nejad A, et al. **Clin Dysmorphol** 1996 Jul; 5(3):259-61 (5 ref.)
De novo duplication of 12pter-->p12.1: clinical and cytogenetic diagnosis confirmed by chromosome painting. Back E, et al. **Clin Genet** 1997 Mar;51(3):205-10 (28 ref.)
Möbius-like syndrome associated with a 1;2 chromosome translocation. Nishikawa M, et al. **Clin Genet** 1997 Feb; 51(2):122-3 (7 ref.)
Cerebral defects confirm midline developmental field disturbances in supernumerary der(22), t(11;22) syndrome. Pallotta R, et al. **Clin Genet** 1996 Nov;50(5):411-6 (15 ref.)
Implication of cyclin D1 in malignant lymphoma. Callanan M, et al. **Crit Rev Oncog** 1996;7(3-4):191-203 (89 ref.)
Translocations in solid tumours. Cooper CS. **Curr Opin Genet Dev** 1996 Feb;6(1):71-5 (27 ref.)
Characterisation of the PML/RAR alpha rearrangement associated with t(15;17) acute promyelocytic leukaemia. Grimwade D, et al. **Curr Top Microbiol Immunol** 1997; 220:81-112 (153 ref.)
Chromosome translocation-mediated conversion of a tumor suppressor gene into a dominant oncogene: fusion of EWS1 to WT1 in desmoplastic small round cell tumors. Rauscher FJ 3rd. **Curr Top Microbiol Immunol** 1997;220:151-62 (47 ref.)
Disruption of a homolog of trithorax by 11q23 translocations: leukemogenic and transcriptional implications. Waring PM, et al. **Curr Top Microbiol Immunol** 1997;220:1-23 (135 ref.)
BCL3 rearrangements and t(14;19) in chronic lymphocytic leukemia and other B-cell malignancies: a molecular and cytogenetic study. McKeithan TW, et al. **Genes Chromosomes Cancer** 1997 Sep;20(1):64-72 (38 ref.)
Recombination in a balanced complex translocation of a mother leading to a balanced reciprocal translocation in the child. Review of 60 cases of balanced complex translocations. Madan K, et al. **Hum Genet** 1997 Jun; 99(6):806-15 (72 ref.)
Molecular cytogenetics of t(12;21) (p13;q22). Bernard OA, et al. **Leuk Lymphoma** 1996 Nov;23(5-6):459-65 (41 ref.)
Variant and masked translocations in acute promyelocytic leukemia. Brunel V, et al. **Leuk Lymphoma** 1996 Jul; 22(3-4):221-8 (68 ref.)
The clinicopathological features of anaplastic large cell lymphomas expressing p80NPM/ALK. Shiota M, et al. **Leuk Lymphoma** 1996 Sep;23(1-2):25-32 (25 ref.)
Translocation t(8;16)(p11;p13) in acute non-lymphocytic leukemia: report on two new cases and review of the literature. Velloso ER, et al. **Leuk Lymphoma** 1996 Mar; 21(1-2):137-42 (33 ref.)
Molecular diagnosis and monitoring of acute myeloid leukemia. Biondi A, et al. **Leuk Res** 1996 Oct;20(10):801-7 (47 ref.)
Leukemogenesis by the chromosomal translocations. Mitani K. **Leukemia** 1997 Apr;11 Suppl 3:294-6 (32 ref.)
Chronic granulocytic leukemia: recent information on pathogenesis, diagnosis, and disease monitoring. Tefferi A, et al. **Mayo Clin Proc** 1997 May;72(5):445-52 (76 ref.)
Transformation of follicular lymphoma with both t(14;18) and t(8;22). Bisiau H, et al. **Nouv Rev Fr Hematol** 1995; 37(4):241-4 (12 ref.)
Coexistent T-cell lymphoblastic lymphoma and an atypical myeloproliferative disorder associated with t(8;13)(p21;q14). Somers GR, et al. **Pediatr Pathol Lab Med** 1997 Jan-Feb;17(1):141-58 (58 ref.)
Genetic lesions in mantle cell lymphoma. Ott G, et al. **Recent Results Cancer Res** 1997;143:307-19 (26 ref.)
Induced mouse chromosomal rearrangements as tools for identifying critical developmental genes and pathways. Culiat CT, et al. **Reprod Toxicol** 1997 Mar-Jun; 11(2-3):345-51 (58 ref.)
Molecular biology of acute lymphocytic leukemia. Thandla S, et al. **Semin Oncol** 1997 Feb;24(1):45-56 (94 ref.)
[Werner's syndrome developing acute megakaryoblastic leukemia with der(1;7)] Yamada T, et al. **Rinsho Ketsueki** 1997 Jan;38(1):28-32 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Molecular biology in malignant blood diseases. Clinical applications. Study of immunoglobulin and T-cell receptor genes and molecular analysis of the translocations] González M, et al. **Sangre (Barc)** 1996 Aug;41(4):321-34 (95 ref.) **(Spa)**

GENETICS

Biologic implications of genetic changes in head and neck squamous cell carcinogenesis. Reid CB, et al. **Aust N Z J Surg** 1997 Jul;67(7):410-6 (72 ref.)
Dichotomy of hyperdiploid acute lymphoblastic leukemia on the basis of the distribution of gained chromosomes. Mertens F, et al. **Cancer Genet Cytogenet** 1996 Nov; 92(1):8-10 (10 ref.)
t(14;19)/BCL3 rearrangements in lymphoproliferative disorders: a review of 23 cases. Michaux L, et al. **Cancer Genet Cytogenet** 1997 Mar;94(1):36-43 (49 ref.)
Are Robertsonian translocations rare in cancers? [letter] Multani AS, et al. **Cancer Genet Cytogenet** 1997 Feb; 93(2):179-80 (21 ref.)
Fusion of the EWS1 and WT1 genes as a result of the t(11;22)(p13;q12) translocation in desmoplastic small round cell tumors. Benjamin LE, et al. **Med Pediatr Oncol** 1996 Nov;27(5):434-9 (34 ref.)
Molecular biology of acute myeloid leukemia. Caligiuri MA, et al. **Semin Oncol** 1997 Feb;24(1):32-44 (120 ref.)

TRANSLOCATION, BACTERIAL see **BACTERIAL TRANSLOCATION**

TRANSLOCATION, CHROMOSOMAL see **TRANSLOCATION (GENETICS)**

TRANSLUMINAL CORONARY BALLOON DILATATION see **ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY**

TRANSMEMBRANE POTENTIALS see **MEMBRANE POTENTIALS**

TRANSMISSIBLE DEMENTIAS see **PRION DISEASES**

TRANSMISSIBLE GASTROENTERITIS OF SWINE see **GASTROENTERITIS, TRANSMISSIBLE, OF SWINE**

TRANSMISSIBLE GASTROENTERITIS VIRUS, SWINE see **GASTROENTERITIS VIRUS, PORCINE TRANSMISSIBLE**

TRANSMISSION, DENTIST-PATIENT see **DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT**

TRANSMISSION ELECTRON MICROSCOPY see **MICROSCOPY, ELECTRON**

TRANSMISSION, HEALTH CARE WORKER-PATIENT see **DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT**

TRANSMISSION, HORIZONTAL see **DISEASE TRANSMISSION, HORIZONTAL**

TRANSMISSION, PATIENT-TO-PROFESSIONAL see **DISEASE TRANSMISSION, PATIENT-TO-PROFESSIONAL**

TRANSMISSION, PHYSICIAN-PATIENT see **DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT**

TRANSMISSION, PROFESSIONAL-TO-PATIENT see **DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT**

TRANSMISSION, VERTICAL see **DISEASE TRANSMISSION, VERTICAL**

TRANSMITTERS, BIOGENIC AMINE see **BIOGENIC AMINE NEUROTRANSMITTERS**

TRANSPEPTIDASES see **PEPTIDYL TRANSFERASES**

TRANSPHOSPHORIBOSIDASE see **ADENINE PHOSPHORIBOSYLTRANSFERASE**

TRANSPHOSPHORYLASES see **PHOSPHOTRANSFERASES**

TRANSPLACENTAL EXPOSURE see **MATERNAL-FETAL EXCHANGE**

TRANSPLANT REJECTION see **GRAFT REJECTION**

TRANSPLANTATION

see related
HISTOCOMPATIBILITY TESTING
LIVING DONORS
NEOPLASM TRANSPLANTATION
ORGAN TRANSPLANTATION
TISSUE DONORS
TISSUE TRANSPLANTATION
TRANSPLANTATION CHIMERA

Cytomegalovirus in transplantation: new developments. Lam KM, et al. **Coron Artery Dis** 1997 May;8(5):305–16 (134 ref.)
Transplantation and chimera as extended self. Chigira M. **Med Hypotheses** 1997 Jan;48(1):63–9 (90 ref.)
Human T–and B–cell functions in SCID–hu mice. Roncarolo MG, et al. **Semin Immunol** 1996 Aug;8(4):207–13 (38 ref.)
Gene therapy in transplantation. Knechtle SJ, et al. **Transpl Immunol** 1996 Dec;4(4):257–64 (47 ref.)
Creutzfeldt–Jakob disease and transplantation: facts and fables. Dormont D. **Transplant Proc** 1996 Oct;28(5):2931–3 (39 ref.)
Hemodilution, what is right? Koopman–van Gemert AW. **Transplant Proc** 1996 Oct;28(5):2934–6 (14 ref.)
Role of testing for antibody to hepatitis B core antigen to prevent transmission of hepatitis B virus in organ and tissue transplantation. Kroes AC. **Transplant Proc** 1996 Oct; 28(5):2937–8 (12 ref.)
[Present status and problems in clinical application of tacrolimus(FK506)] Teraoka S, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):689 (0 ref.) **(Jpn)**
[Tuberculosis and protozoan infections in patients undergoing transplantation] Aguado JM, et al. **Enferm Infecc Microbiol Clin** 1997 May;15 Suppl 2:57–68 (171 ref.) **(Spa)**
[Pre–transplant evaluation of the donor and recipient. Recommendations for surveillance and control of infection after transplantation] Cisneros JM, et al. **Enferm Infecc Microbiol Clin** 1997 May;15 Suppl 2:98–103 (68 ref.) **(Spa)**
[Risk factors and chronology of infection in solid organ transplantation] Gavaldà J, et al. **Enferm Infecc Microbiol Clin** 1997 May;15 Suppl 2:3–11 (123 ref.) **(Spa)**
[Bacterial infection in solid organ transplantation] Gavilán F, et al. **Enferm Infecc Microbiol Clin** 1997 May;15 Suppl 2:12–21 (61 ref.) **(Spa)**
[Prevention of infection in recipients of solid organ transplants] Lumbreras C, et al. **Enferm Infecc Microbiol Clin** 1997 May;15 Suppl 2:77–89 (155 ref.) **(Spa)**
[Viral infections in solid organ transplant recipients] Moreno MA. **Enferm Infecc Microbiol Clin** 1997 May;15 Suppl 2:22–33 (260 ref.) **(Spa)**
[Fungal infections in patients undergoing solid organ transplantation] Muñoz P, et al. **Enferm Infecc Microbiol Clin** 1997 May;15 Suppl 2:34–50 (241 ref.) **(Spa)**
[Transplantation ethics: review] Monge MA. **Rev Med Univ Navarra** 1994 Oct–Dec;38(4):226–30 (19 ref.) **(Spa)**

ADVERSE EFFECTS

Post–transplantation lymphoproliferative disease. Savage P, et al. **QJM** 1997 Aug;90(8):497–503 (57 ref.)

HISTORY

Is transplantation only 100 years old? Bhandari M, et al. **Br J Urol** 1997 Apr;79(4):495–8 (21 ref.)

METHODS

Chronic rejection: potential new sites of therapy. Häyry P, et al. **Transplant Proc** 1996 Dec;28(6):3225–6 (19 ref.)

PATHOLOGY

[Pathological anatomy of organ transplantation] Pardo FJ, et al. **Rev Med Univ Navarra** 1994 Oct–Dec;38(4):189–94 (39 ref.) (Eng. Abstr.) **(Spa)**

TRENDS

Transplantation of the testis; from the past to the present. Barten EJ, et al. **Int J Androl** 1996 Aug;19(4):205–11 (72 ref.)
The future of transplantation: with particular reference to chimerism and xenotransplantation. Starzl TE, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):19–27 (68 ref.)

TRANSPLANTATION, ALLOGENEIC see **TRANSPLANTATION, HOMOLOGOUS**

TRANSPLANTATION, AUTOLOGOUS

Mandibular reconstruction by vascularized free tissue transfer. Genden E, et al. **Am J Otolaryngol** 1996 Jul–Aug; 17(4):219–27 (50 ref.)
Tissue engineering and autologous transplant formation: practical approaches with resorbable biomaterials and new cell culture techniques. Sittinger M, et al. **Biomaterials** 1996 Feb;17(3):237–42 (41 ref.)
Autologous stem cell transplantation for solid tumors in children. Ladenstein R, et al. **Curr Opin Pediatr** 1997 Feb; 9(1):55–69 (130 ref.)
Autotransplanted jejunum in head and neck cancer. Kornfehl J. **Eur J Cancer B Oral Oncol** 1994 Jan;30B(1):16–22 (96 ref.)

METHODS

Rationalizing autotransplant strategies for chronic myeloid leukemia. Daley GQ. **Leuk Lymphoma** 1996 May; 21(5–6):353–8 (39 ref.)

TRANSPLANTATION, BONE see **BONE TRANSPLANTATION**

TRANSPLANTATION, BONE MARROW see **BONE MARROW TRANSPLANTATION**

TRANSPLANTATION, BRAIN TISSUE see **BRAIN TISSUE TRANSPLANTATION**

TRANSPLANTATION, CARDIAC see **HEART TRANSPLANTATION**

TRANSPLANTATION CHIMERA

see related
ANIMALS, TRANSGENIC

The hu–PBL–SCID mouse in human lymphocyte function and lymphomagenesis studies: achievements and caveats. Amadori A, et al. **Semin Immunol** 1996 Aug;8(4):249–54 (50 ref.)
SCID–hu mice: a model for studying disseminated HIV infection. Goldstein H, et al. **Semin Immunol** 1996 Aug; 8(4):223–31 (42 ref.)
The SCID–hu mouse: an in–vivo model for HIV–1 pathogenesis and stem cell gene therapy for AIDS. Jamieson BD, et al. **Semin Immunol** 1996 Aug;8(4):215–21 (43 ref.)
Development and applications of the SCID–hu mouse model. McCune JM. **Semin Immunol** 1996 Aug;8(4):187–96 (66 ref.)
Viral pathogenesis in hu–PBL–SCID mice [published erratum appears in Semin Immunol 1996 Oct;8(5):311] Mosier DE. **Semin Immunol** 1996 Aug;8(4):255–62 (87 ref.)
The huPBL–SCID mouse as a means to examine human immune function in vivo. Murphy WJ, et al. **Semin Immunol** 1996 Aug;8(4):233–41 (69 ref.)
Human T–and B–cell functions in SCID–hu mice. Roncarolo MG, et al. **Semin Immunol** 1996 Aug;8(4):207–13 (38 ref.)
The future of transplantation: with particular reference to chimerism and xenotransplantation. Starzl TE, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):19–27 (68 ref.)
[Mixed chimerism and immune tolerance induction by low–stress pretreatment before kidney transplantation in monkeys] Kawai T, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):670–4 (6 ref.) **(Jpn)**

IMMUNOLOGY

Microchimerism and graft tolerance: cause or effect? [comment] Adams DH, et al. **Lancet** 1997 May 10; 349(9062):1336–7 (10 ref.) Comment on: Lancet 1997 May 10;349(9062):1358–60.
Transplantation and chimera as extended self. Chigira M. **Med Hypotheses** 1997 Jan;48(1):63–9 (90 ref.)
SCID–hu–PBL: a model for making human antibodies? Ifversen P, et al. **Semin Immunol** 1996 Aug;8(4):243–8 (51 ref.)
Defining antibody protection against HIV–1 transmission in Hu–PBL–SCID mice. Koup RA, et al. **Semin Immunol** 1996 Aug;8(4):263–8 (52 ref.)

TRANSPLANTATION CONDITIONING

see related
TRANSPLANTATION

Stem cell manipulation: why and how performing peripheral blood progenitor cell purging. Rizzoli V, et al. **Crit Rev Oncol Hematol** 1997 Jul;26(2):101–15 (156 ref.)
Development of a protocol for allogeneic marrow transplantation for severe systemic sclerosis: paradigm for autoimmune disease. Nash RA, et al. **J Rheumatol Suppl** 1997 May;48:72–8 (51 ref.)
Osteochondroma after total body irradiation in bone marrow transplant recipients: report of two cases. Maeda G, et al. **Jpn J Clin Oncol** 1996 Dec;26(6):480–3 (14 ref.)
[Allogeneic peripheral blood stem cell transplantation] Harada M. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1877–85 (35 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Late onset bone marrow transplant nephropathy. Oyama Y, et al. **Intern Med** 1996 Jun;35(6):489–93 (23 ref.)
Inflammatory reactions induced by pretransplant conditioning--an alternative target for modulation of acute GvHD and complications following allogeneic bone marrow transplantation? Holler E, et al. **Leuk Lymphoma** 1997 Apr;25(3–4):217–24 (35 ref.)
Efficacy and toxicity of radiation in preparative regimens for pediatric stem cell transplantation. II: Deleterious consequences. Miale TD, et al. **Med Oncol** 1996 Mar; 13(1):43–61 (130 ref.)

TRENDS

[Blood stem–cell transplantation. Its current status and outlook] Lange W, et al. **Dtsch Med Wochenschr** 1997 Jan 31;122(5):129–31 (11 ref.) **(Ger)**

TRANSPLANTATION, CORNEAL see **CORNEAL TRANSPLANTATION**

TRANSPLANTATION, FETAL TISSUE see **FETAL TISSUE TRANSPLANTATION**

TRANSPLANTATION, HEART see **HEART TRANSPLANTATION**

TRANSPLANTATION, HEART–LUNG see **HEART–LUNG TRANSPLANTATION**

TRANSPLANTATION, HEMATOPOIETIC STEM CELL see **HEMATOPOIETIC STEM CELL TRANSPLANTATION**

TRANSPLANTATION, HEPATIC see **LIVER TRANSPLANTATION**

TRANSPLANTATION, HETEROLOGOUS

Tissue xenografts as a model system for study of the pathogenesis of papillomaviruses. Howett MK, et al. **Clin Dermatol** 1997 Mar–Apr;15(2):229–36 (53 ref.)
Hematopoietic cell transplantation for the induction of allo– and xenotolerance. Sykes M. **Clin Transplant** 1996 Aug; 10(4):357–63 (48 ref.)
Xenogeneic organ transplantation. Squinto SP. **Curr Opin Biotechnol** 1996 Dec;7(6):641–5 (26 ref.)
Cardiac xenotransplantation. Artrip JH, et al. **Curr Opin Cardiol** 1997 Mar;12(2):172–8 (47 ref.)
Xenotransplantation. Cozzi E, et al. **Curr Opin Nephrol Hypertens** 1996 Nov;5(6):514–8 (48 ref.)
Graves' disease: xenotransplantation model (athymic nude mice). Rippegather K, et al. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 3:34–6; discussion 36–7 (15 ref.)
Xenotransplantation of human thyroid carcinomas in athymic nude mice. Wenisch HJ. **Exp Clin Endocrinol Diabetes** 1996; 104 Suppl 3:61–3 (23 ref.)
Efficiency of orthotopic xenograft models for human colon cancers. Pocard M, et al. **In Vivo** 1996 Sep–Oct;10(5):463–9 (35 ref.)
The hybrid autograft/xenograft aortic valve [editorial; comment] Vesely I. **J Heart Valve Dis** 1997 May;6(3):292–5 (35 ref.) Comment on: J Heart Valve Dis 1997 May;6(3):296–306.
Human–mouse xenografts in stem cell research. Wermann K, et al. **J Hematother** 1996 Aug;5(4):379–90 (69 ref.)
Prospects for xenotransplantation of the liver. Harland RC, et al. **J Hepatol** 1996 Aug;25(2):248–58 (98 ref.)
Xenosis and xenotransplantation: addressing the infectious risks posed by an emerging technology. Fishman JA. **Kidney Int Suppl** 1997 Mar;58:S41–5 (45 ref.)
Clinical xenotransplantation of solid organs. Dorling A, et al. **Lancet** 1997 Mar 22;349(9055):867–71 (40 ref.)
The SCID–hu mouse: an in vivo model for HIV–1 infection in humans. Bonyhadi ML, et al. **Mol Med Today** 1997 Jun; 3(6):246–53 (51 ref.)
Benefits and risks of hosting animal cells in the human brain [see comments] Isacson O, et al. **Nat Med** 1997 Sep; 3(9):964–9 (77 ref.) Comment in: Nat Med 1997 Sep;3(9):935.
Xenotransplantation: problems and prospects. Perico N, et al. **Nephrol Dial Transplant** 1997;12 Suppl 1:59–64 (52 ref.)
The prospects for xenotransplantation. Warrens AN, et al. **QJM** 1996 Dec;89(12):885–91 (28 ref.)
Xenotransplantation: ethical acceptability. Kennedy I. **Transplant Proc** 1997 Sep;29(6):2729–30 (0 ref.)
The future of transplantation: with particular reference to

chimerism and xenotransplantation. Starzl TE, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):19-27 (68 ref.)
Xenotransplantation--scientific aspects. White DJ. **Transplant Proc** 1997 Sep;29(6):2727-8 (0 ref.)
Molecular barriers to xenotransplantation. Lawson JH, et al. **Transplantation** 1996 Aug 15;62(3):303-10 (61 ref.)
The pig as a model in liver xenotransplantation. Wolf P, et al. **Vet Res** 1997 May-Jun;28(3):217-22 (14 ref.)
[Xenotransplantation in man. 1: Immunology of xenogenic graft rejection] Borie DC, et al. **Gastroenterol Clin Biol** 1996;20(11):972-81 (95 ref.) **(Fre)**
[Xenotransplantation in man. 2: Control of rejection and application to xenotransplantation of the swine liver in man] Borie DC, et al. **Gastroenterol Clin Biol** 1996;20(11):982-90 (84 ref.) **(Fre)**
[Applications of transgenesis in xenotransplantation. Experimental results and clinical prospects] Malassagne B, et al. **Presse Med** 1996 Sep 21;25(27):1247-50 (24 ref.) (Eng. Abstr.) **(Fre)**
[Alternatives to liver transplantation] Kupcsulik P. **Orv Hetil** 1996 Oct 20;137(42 Suppl 1):2381-7 (41 ref.) (Eng. Abstr.) **(Hun)**
[Heterologous transplant of the cornea. Clinical contribution and considerations] Silletti L. **Minerva Oftalmol** 1967 Jul-Aug;9(4):139-46 (45 ref.) (Eng. Abstr.) **(Ita)**
[How far can heterologous transplantation progress?] Kawauchi M, et al. **Kyobu Geka** 1997 Jan;50(1):17-21 (28 ref.) **(Jpn)**
[Application of complement inactivator gene for control of heterograft rejection] Takeshita K, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):675-8 (8 ref.) **(Jpn)**
[Xenotransplantation] Itsuo Y, et al. **Nippon Geka Gakkai Zasshi** 1996 Nov;97(11):1010-7 (24 ref.) (Eng. Abstr.) **(Jpn)**
[Transplantation of animal organs (xenotransplantation). Status and future development] Fiane AE, et al. **Tidsskr Nor Laegeforen** 1997 Mar 20;117(8):1071-6 (65 ref.) (Eng. Abstr.) **(Nor)**

ADVERSE EFFECTS

Delayed xenograft rejection. Bach FH, et al. **Immunol Today** 1996 Aug;17(8):379-84 (62 ref.)
Transplantation of discordant xenografts: a challenge revisited. Parker W, et al. **Immunol Today** 1996 Aug; 17(8):373-8 (53 ref.)
Modification of vascular responses in xenotransplantation: inflammation and apoptosis [see comments] Bach FH, et al. **Nat Med** 1997 Sep;3(9):944-8 (32 ref.) Comment in: Nat Med 1997 Sep;3(9):935.

IMMUNOLOGY

The immunological barriers to xenotransplantation. Platt JL. **Crit Rev Immunol** 1996;16(4):331-58 (191 ref.)
Xenotransplantation of baboon bone marrow cells: a historical review of the protocols as a possible treatment modality for HIV/AIDS. Relf MV. **J Assoc Nurses AIDS Care** 1996 Sep-Oct;7(5):27-35 (38 ref.)
Immunologic barriers to xenotransplantation. Lin SS, et al. **J Heart Lung Transplant** 1996 Jun;15(6):547-55 (72 ref.)
Hyperacute xenograft rejection as an immunologic barrier to xenotransplantation. Daniels LJ, et al. **Kidney Int Suppl** 1997 Mar;58:S28-35 (72 ref.)
Xenotransplantation: from animal facility to the clinic? Rowe PM. **Mol Med Today** 1996 Jan;2(1):10-5 (17 ref.)
The use of tolerance for transplantation across xenogeneic barriers. Greenstein JL, et al. **Nat Biotechnol** 1997 Mar; 15(3):235-8 (57 ref.)
Immunosuppression in xenotransplantation. Hammer C. **Transplant Proc** 1996 Dec;28(6):3017-20 (71 ref.)
Aspects of immunoprotection of islets. van Schilfgaarde R, et al. **Transplant Proc** 1996 Dec;28(6):3516-7 (11 ref.)
[Xenotransplantation] Bueno V, et al. **Rev Assoc Med Bras** 1995 Jul-Aug;41(4):284-92 (51 ref.) **(Por)**
[Complement in organ xenotransplantation] Dalmasso AP. **Rev Clin Esp** 1996 Mar;196 Spec No:44-51 (50 ref.) **(Spa)**

METHODS

Considerations of specific pathogen-free swine (SPF) in xenotransplantation. Swindle MM. **J Invest Surg** 1996 Jul-Aug;9(4):267-71 (17 ref.)
Beyond hyperacute rejection: strategies for development of pig-->primate xenotransplantation. Hancock WW. **Kidney Int Suppl** 1997 Mar;58:S36-40 (31 ref.)
[Overview on heterologous transplantation] Takagi H. **Nippon Geka Gakkai Zasshi** 1997 Jun;98(6):571-5 (12 ref.) **(Jpn)**

PATHOLOGY

Modification of vascular responses in xenotransplantation: inflammation and apoptosis [see comments] Bach FH, et al. **Nat Med** 1997 Sep;3(9):944-8 (32 ref.) Comment in: Nat Med 1997 Sep;3(9):935.

PHYSIOLOGY

The importance of the kidney in primary hypertension: insights from cross-transplantation. Rettig R, et al. **J Hum Hypertens** 1996 Oct;10(10):641-4 (31 ref.)

TRENDS

Clinical xenotransplantation: past, present and future. Taniguchi S, et al. **Ann R Coll Surg Engl** 1997 Jan; 79(1):13-9 (64 ref.)
Xenotransplantation: recent progress and current perspectives. Platt JL. **Curr Opin Immunol** 1996 Oct; 8(5):721-8 (69 ref.)

TRANSPLANTATION, HETEROTOPIC

Transplantation of testis-derived Sertoli cells into the mammalian brain. Sanberg PR, et al. **Transplant Proc** 1997 Jun;29(4):1926-8 (42 ref.)
[Adrenal transplantation and Parkinson's disease] Luquin MR, et al. **Rev Med Univ Navarra** 1994 Oct-Dec; 38(4):174-80 (38 ref.) (Eng. Abstr.) **(Spa)**

TRANSPLANTATION, HOMOLOGOUS

Evolution of the fetal-maternal immunological relationship. Loke YW, et al. **Am J Reprod Immunol** 1996 Mar; 35(3):256-7 (1 ref.)
Review of transplantation--1996. Halloran PF, et al. **Clin Transpl** 1996;:291-319 (294 ref.)
Hematopoietic cell transplantation for the induction of allo- and xenotolerance. Sykes M. **Clin Transplant** 1996 Aug; 10(4):357-63 (48 ref.)
Allograft valves for aortic and mitral valve replacement. Reardon MJ, et al. **Curr Opin Cardiol** 1997 Mar; 12(2):114-22 (30 ref.)
Arterial homografts. Callow AD. **Eur J Vasc Endovasc Surg** 1996 Oct;12(3):272-81 (73 ref.)
Pancreatic islet allograft immunity and tolerance: the two-signal hypothesis revisited. Gill RG, et al. **Immunol Rev** 1996 Feb;149:75-96 (94 ref.)
Allogeneic peripheral blood progenitor cells: current status and future directions. Dreger P, et al. **J Hematother** 1996 Aug;5(4):331-7 (65 ref.)
The use of mobilized peripheral blood stem cells from normal donors for allografting. Anderlini P, et al. **Stem Cells** 1997; 15(1):9-17 (56 ref.)
Allotransplantation of cultured human parathyroid cells: present status and perspectives. Tołłoczko T, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):998-1000 (25 ref.)
[Use of aortic valve homografts in adults] Habib G, et al. **Ann Cardiol Angeiol (Paris)** 1997 Feb;46(2):99-105 (31 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Extracorporeal immunomodulation relevant to organ substitutions. Agishi T. **Artif Organs** 1996 Aug;20(8):917-21 (18 ref.)
[Cytomegalovirus infection and allograft rejection] Humbert M, et al. **Rev Mal Respir** 1996 Nov;13(5 Suppl):S85-91 (62 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Late onset haemolysis and red cell autoimmunisation after allogeneic bone marrow transplant. Chen FE, et al. **Bone Marrow Transplant** 1997 Mar;19(5):491-5 (23 ref.)
Role of the major histocompatibility complex class I regions in rat natural killer cell allograft responses in vivo and in vitro. Rolstad B. **Chem Immunol** 1996;64:59-76 (65 ref.)
The role of polymorphic donor peptides in allograft recognition and rejection. Fabre JW. **Immunol Rev** 1996 Dec;154:21-43 (79 ref.)
Indirect T-cell allorecognition: perspectives for peptide-based therapy in transplantation. Benichou G, et al. **Immunol Today** 1997 Feb;18(2):67-71 (34 ref.)
The lost chord: microchimerism and allograft survival. Starzl TE, et al. **Immunol Today** 1996 Dec;17(12):577-84; discussion 588 (78 ref.)
Chimerism and transplantation tolerance: cause and effect. Wood K, et al. **Immunol Today** 1996 Dec;17(12):584-7; discussion 588 (35 ref.)
The contribution of peptides to T cell allorecognition and allograft rejection. Benichou G, et al. **Int Rev Immunol** 1996;13(3):231-43 (60 ref.)
Indirect T cell recognition in allograft rejection. Bradley JA. **Int Rev Immunol** 1996;13(3):245-55 (85 ref.)
Role of indirect allorecognition in allograft rejection. Sayegh MH, et al. **Int Rev Immunol** 1996;13(3):221-9 (43 ref.)
Chronic allograft arteriosclerosis: contributing factors and molecular mechanisms in the light of experimental studies. Räisänen-Sokolowski A, et al. **Transpl Immunol** 1996 Jun; 4(2):91-8 (87 ref.)
Biological immunosuppressants: the way to clinical transplantation tolerance. Chatenoud L. **Transplant Proc** 1997 Feb-Mar;29(1-2):51-5 (44 ref.)
Molecular biology of the allograft response. Dallman MJ. **Transplant Proc** 1996 Dec;28(6 Suppl 1):2-6 (25 ref.)
Immunobiology and pathology of chronic rejection. Häyry P, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):77-8 (17 ref.)
Antirejection strategy in small bowel transplantation. Wood RF. **Transplant Proc** 1996 Oct;28(5):2491-3 (39 ref.)

METHODS

Experimental basis for intestinal transplantation. Sonnino RE. **Transplant Proc** 1997 May;29(3):1795-7 (53 ref.)

PHYSIOLOGY

Transplantation-induced injuries of the intestinal muscularis and its innervation: from preservation to chronic rejection. Bauer AJ. **Transplant Proc** 1996 Oct;28(5):2539-41 (11 ref.)
Motility and absorption in the transplanted gut. Sarr MG. **Transplant Proc** 1996 Oct;28(5):2535-8 (30 ref.)

TRENDS

A future for HLA matching in clinical transplantation. Dyer PA, et al. **Eur J Immunogenet** 1997 Feb;24(1):17-28 (54 ref.)

TRANSPLANTATION IMMUNOLOGY

see related
HISTOCOMPATIBILITY TESTING
IMMUNOSUPPRESSION

Immunosuppressive agents in clinical trials in transplantation. Halloran PF. **Am J Med Sci** 1997 May;313(5):283-8 (39 ref.)
Chronic allograft failure: the clinical problem. Nagano H, et al. **Am J Med Sci** 1997 May;313(5):305-9 (48 ref.)
Leflunomide and malononitrilamides. Silva Júnior HT, et al. **Am J Med Sci** 1997 May;313(5):289-301 (101 ref.)
Xenogeneic organ transplantation. Squinto SP. **Curr Opin Biotechnol** 1996 Dec;7(6):641-5 (26 ref.)
Antigen processing and presentation in transplantation. Auchincloss H Jr, et al. **Curr Opin Immunol** 1996 Oct; 8(5):681-7 (52 ref.)
Xenotransplantation: recent progress and current perspectives. Platt JL. **Curr Opin Immunol** 1996 Oct; 8(5):721-8 (69 ref.)
The Th1/Th2 paradigm and the allograft response. Strom TB, et al. **Curr Opin Immunol** 1996 Oct;8(5):688-93 (38 ref.)
Chimerism after organ transplantation. Starzl TE, et al. **Curr Opin Nephrol Hypertens** 1997 May;6(3):292-8 (52 ref.)
Flow cytometry cross-match. Brando B, et al. **Eur J Histochem** 1996;40 Suppl 1:53-62 (26 ref.)
Application of flow cytometry in transplantation medicine. Shanahan T. **Immunol Invest** 1997 Jan-Feb;26(1-2):91-101 (25 ref.)
From stem cells to lymphocytes: biology and transplantation. Aguila HL, et al. **Immunol Rev** 1997 Jun;157:13-40 (282 ref.)
Immunology of hematopoietic stem cell transplantation: a brief review of its history. Dupont B. **Immunol Rev** 1997 Jun;157:5-12 (44 ref.)
Immunoisolation: at a turning point. Lanza RP, et al. **Immunol Today** 1997 Mar;18(3):135-9 (30 ref.)
New approaches to specific immunomodulation in transplantation. Colovai AI, et al. **Int Rev Immunol** 1996; 13(3):161-72 (83 ref.)
In vivo immunosuppressive mechanisms. Halloran PF, et al. **J Heart Lung Transplant** 1996 Oct;15(10):959-71 (96 ref.)
Immunosuppression in organ transplantation. Oka T, et al. **Jpn J Pharmacol** 1996 Jun;71(2):89-100 (48 ref.)
Post-transplant EBV induced lymphoproliferative disorders. Lucas KG, et al. **Leuk Lymphoma** 1997 Mar;25(1-2):1-8 (68 ref.)
Transplantation and chimera as extended self. Chigira M. **Med Hypotheses** 1997 Jan;48(1):63-9 (90 ref.)
The role of cell migration and microchimerism in the induction of tolerance after solid organ transplantation. Jindal RM, et al. **Postgrad Med J** 1997 Mar;73(857):146-50 (39 ref.)
The use of leflunomide in transplantation immunology. Waer M. **Transpl Immunol** 1996 Sep;4(3):181-5 (49 ref.)
Biological immunosuppressants: the way to clinical transplantation tolerance. Chatenoud L. **Transplant Proc** 1997 Feb-Mar;29(1-2):51-5 (44 ref.)
Chronic rejection: potential new sites of therapy. Häyry P, et al. **Transplant Proc** 1996 Dec;28(6):3225-6 (19 ref.)
Cellular adhesion molecules in transplantation. Rodriguez-Iturbe B. **Transplant Proc** 1996 Dec; 28(6):3285-9 (53 ref.)
Current perspectives of transplantation immunology via the intestine. Starzl TE. **Transplant Proc** 1996 Oct;28(5):2430-2 (32 ref.)
Pharmacodynamic monitoring of immunosuppressive drugs. Yatscoff RW, et al. **Transplant Proc** 1996 Dec;28(6):3013-5 (16 ref.)
[The problem of viral hepatitis in transplantation medicine] Tillmann HL, et al. **Internist (Berl)** 1996 Mar;37(3):240-9 (149 ref.) **(Ger)**
[Immunosuppression and the problems in homologous bone marrow transplantation] Yabe H, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):681-2 (0 ref.) **(Jpn)**
[Transplantation immunology and immunosuppressive drug] Suzuki S. **Nippon Geka Gakkai Zasshi** 1996 Nov; 97(11):964-9 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Complement in organ xenotransplantation] Dalmasso AP. **Rev Clin Esp** 1996 Mar;196 Spec No:44-51 (50 ref.) **(Spa)**

DRUG EFFECTS

[Immunosuppression in organ transplantation. New substances and therapeutic approaches] Wonigeit K.

TRANSPLANTATION IMMUNOLOGY

Internist (Berl) 1996 Mar;37(3):229–39 (62 ref.) **(Ger)**

GENETICS

Studies of transplantation immunology with major histocompatibility complex knockout mice. Chitilian HV, et al. **J Heart Lung Transplant** 1997 Feb;16(2):153–9 (27 ref.)

Gene therapy and transplantation—a brief review. Knechtle SJ. **Transplant Proc** 1996 Dec;28(6 Suppl 1):19–23 (37 ref.)

IMMUNOLOGY

Will tolerance become a clinical reality? Aradhye S, et al. **Am J Med Sci** 1997 May;313(5):310–4 (40 ref.)

Recent advances and the potential for clinical use of xenotransplantation. Minanov OP, et al. **Curr Opin Cardiol** 1996 Mar;11(2):214–20 (40 ref.)

Induction of tolerance to cardiac allografts. Wood KJ. **Curr Opin Cardiol** 1996 Mar;11(2):208–13 (32 ref.)

The use of CD4 and CD8 knockout mice to study the role of T-cell subsets in allotransplant rejection. Krieger NR, et al. **J Heart Lung Transplant** 1997 Mar;16(3):263–7 (40 ref.)

Networked alloimmunity: a brief reexamination of some basic concepts in transplantation immunobiology. Orosz CG. **J Heart Lung Transplant** 1996 Nov;15(11):1063–8 (12 ref.)

Transplantation tolerance: fooling mother nature [comment] Suthanthiran M. **Proc Natl Acad Sci U S A** 1996 Oct 29; 93(22):12072–5 (56 ref.) Comment on: Proc Natl Acad Sci U S A 1996 Oct 29;93(22):12439–44.

[Xenotransplantation] Bueno V, et al. **Rev Assoc Med Bras** 1995 Jul–Aug;41(4):284–92 (51 ref.) **(Por)**

PHYSIOLOGY

Clonal deletion as a mechanism of transplantation tolerance. Nikolic B, et al. **J Heart Lung Transplant** 1996 Dec; 15(12):1171–8 (72 ref.)

TRANSPLANTATION, ISLETS OF LANGERHANS see **ISLETS OF LANGERHANS TRANSPLANTATION**

TRANSPLANTATION, ISOGENEIC

ADVERSE EFFECTS

Immunobiology and immunotherapeutic implications of syngeneic/autologous graft-versus-host disease. Hess AD, et al. **Immunol Rev** 1997 Jun;157:111–23 (102 ref.)

TRANSPLANTATION, KIDNEY see **KIDNEY TRANSPLANTATION**

TRANSPLANTATION, LIVER see **LIVER TRANSPLANTATION**

TRANSPLANTATION, LUNG see **LUNG TRANSPLANTATION**

TRANSPLANTATION, ORGAN see **ORGAN TRANSPLANTATION**

TRANSPLANTATION, PANCREAS see **PANCREAS TRANSPLANTATION**

TRANSPLANTATION, PANCREATIC ISLETS see **ISLETS OF LANGERHANS TRANSPLANTATION**

TRANSPLANTATION, RENAL see **KIDNEY TRANSPLANTATION**

TRANSPLANTATION, SKIN see **SKIN TRANSPLANTATION**

TRANSPLANTATION, SYNGENEIC see **TRANSPLANTATION, ISOGENEIC**

TRANSPLANTATION, TISSUE see **TISSUE TRANSPLANTATION**

TRANSPORT, BIOLOGICAL see **BIOLOGICAL TRANSPORT**

TRANSPORT OF WOUNDED AND SICK see **TRANSPORTATION OF PATIENTS**

TRANSPORT PROTEINS see **CARRIER PROTEINS**

TRANSPORTATION

Assessment of stress during handling and transport. Grandin T. **J Anim Sci** 1997 Jan;75(1):249–57 (93 ref.)

The use of electrolyte solutions for reducing transport stress. Schaefer AL, et al. **J Anim Sci** 1997 Jan;75(1):258–65 (97 ref.)

TRANSPORTATION OF PATIENTS

[Early care or quick transport? The effectiveness of preclinical treatment of emergency patients] Rossi R. **Anaesthesist** 1997 Feb;46(2):126–32 (36 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Emergency interhospital critical care transport for children. McCloskey KA. **Curr Opin Pediatr** 1996 Jun;8(3):236–8 (14 ref.)

Total facility evacuation at Helena Regional Medical Center. Vasudevan P, et al. **J Ark Med Soc** 1997 Jul;94(2):76–7 (0 ref.)

[Planning for evacuation of the severely traumatised patient in Africa] Thiery JF, et al. **Med Trop (Mars)** 1996; 56(4):341–4 (6 ref.) **(Fre)**

TRANSPOSABLE ELEMENTS see **DNA INSERTION ELEMENTS**

TRANSPOSITION OF GREAT VESSELS

[Transposition of the great arteries] Oka R, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):224–7 (19 ref.) **(Jpn)**

[Double outlet left ventricle] Uemura H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):348–51 (16 ref.) **(Jpn)**

[Complete transposition of the great arteries] Yagihara T. **Ryoikibetsu Shokogun Shirizu** 1996;(13):67–70 (13 ref.) **(Jpn)**

[Corrected transposition of the great arteries] Yamashita H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):122–5 (6 ref.) **(Jpn)**

COMPLICATIONS

Aneurysm of the membranous ventricular septum resulting in pulmonary outflow tract obstruction in congenitally corrected transposition of the great arteries. Reddy SC, et al. **Am Heart J** 1997 Jan;133(1):112–9 (35 ref.)

SURGERY

Aneurysm of the membranous ventricular septum resulting in pulmonary outflow tract obstruction in congenitally corrected transposition of the great arteries. Reddy SC, et al. **Am Heart J** 1997 Jan;133(1):112–9 (35 ref.)

Treatment of transposition of the great arteries [see comments] Losay J, et al. **Curr Opin Cardiol** 1997 Jan; 12(1):84–90 (35 ref.) Comment in: Curr Opin Cardiol 1997 Jan;12(1):41–3.

[Alteration of myocardial viability and systemic ventricular dysfunction after Senning procedure] Labbé L, et al. **Arch Mal Coeur Vaiss** 1997 May;90(5):631–7 (30 ref.) (Eng. Abstr.) **(Fre)**

[2D and Doppler echocardiography after atrial switch operation for transposition of great arteries; a review] Kaulitz R, et al. **Z Kardiol** 1996 Jan;85(1):35–44 (46 ref.) (Eng. Abstr.) **(Ger)**

[Rastelli's procedure] Okabe H, et al. **Rinsho Kyobu Geka** 1989 Apr;9(2):125–32 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Anatomic correction of transposition of the great arteries] Yasui H, et al. **Rinsho Kyobu Geka** 1989 Apr;9(2):142–7 (37 ref.) (Eng. Abstr.) **(Jpn)**

[Transposition of great arteries. The reality of its cure today (editorial)] Atik E, et al. **Arq Bras Cardiol** 1995 Nov; 65(5):395–7 (5 ref.) **(Por)**

TRANSPOSONS see **DNA INSERTION ELEMENTS**

TRANSSEXUALISM

PSYCHOLOGY

[Psychosocial and biological aspects of transsexualism] Radziwiłłowicz W, et al. **Psychiatr Pol** 1996 Nov–Dec; 30(6):953–62 (30 ref.) (Eng. Abstr.) **(Pol)**

SURGERY

Neovaginoplasty in male transsexuals: review of surgical techniques and recommendations regarding eligibility. Karim RB, et al. **Ann Plast Surg** 1996 Dec;37(6):669–75 (60 ref.)

THERAPY

Multistep treatment concept of transsexual patients. Schlatterer K, et al. **Exp Clin Endocrinol Diabetes** 1996; 104(6):413–9 (63 ref.)

TRANSTHYRETIN see **PREALBUMIN**

TRANSUDATES see **EXUDATES AND TRANSUDATES**

TRANYLCYPROMINE

METABOLISM

One fatal and one nonfatal intoxication with tranylcypromine. Absence of amphetamines as metabolites. Iwersen S, et al. **J Anal Toxicol** 1996 Sep;20(5):301–4 (21 ref.)

TRAUMA see **WOUNDS AND INJURIES**

TRAUMA CENTERS

[The trauma patient: open hospital choice? (editorial)] Leutenegger A, et al. **Swiss Surg** 1997;3(4):136–41 (27 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Toward effective regional trauma networks: management auditing initiatives in Ontario. Caro DH. **Health Care Manage Rev** 1997 Spring;22(2):21–32 (46 ref.)

STANDARDS

Preventable death studies: an inappropriate tool for evaluating trauma systems. Kelly AM, et al. **Aust N Z J Surg** 1997 Sep;67(9):591–2 (25 ref.)

TRAUMA DISORDERS, CUMULATIVE see **CUMULATIVE TRAUMA DISORDERS**

TRAUMA, MULTIPLE see **MULTIPLE TRAUMA**

TRAUMA SEVERITY INDICES

Severity of illness scoring systems to adjust nosocomial infection rates: a review and commentary. Keita-Perse O, et al. **Am J Infect Control** 1996 Dec;24(6):429–34 (20 ref.)

[Traumatology. Scoring systems and their use] Printzlau A, et al. **Ugeskr Laeger** 1996 Oct 21;158(43):6074–80 (35 ref.) (Eng. Abstr.) **(Dan)**

[Value of clinical scoring systems for evaluation of injury severity and as an instrument for quality management of severely injured patients] Bouillon B, et al. **Zentralbl Chir** 1996;121(11):914–23 (45 ref.) (Eng. Abstr.) **(Ger)**

[Methods for evaluating treatment and rehabilitation progress in patients with stroke] Brola W, et al. **Przegl Lek** 1996; 53(10):736–8 (20 ref.) (Eng. Abstr.) **(Pol)**

TRAUMA UNITS see **TRAUMA CENTERS**

TRAUMATOLOGY

see related
WOUNDS AND INJURIES

EDUCATION

Education in orthopaedic trauma. Chapman MW. **Clin Orthop** 1997 Jun;(339):7–19 (20 ref.)

Overcoming language barriers when teaching the Advanced Trauma Life Support course [editorial] Ali J, et al. **Eur J Surg** 1997 Jul;163(7):483–6 (14 ref.)

TRAVEL

Infections associated with international travel: recent developments and global trends. Tornieporth NG, et al. **Adv Intern Med** 1996;41:119–64 (162 ref.)

Imported malaria in children in the UK. Brabin BJ, et al. **Arch Dis Child** 1997 Jul;77(1):76–81 (23 ref.)

African tick-bite fever. An imported spotless rickettsiosis. Brouqui P, et al. **Arch Intern Med** 1997 Jan 13; 157(1):119–24 (40 ref.)

Cutaneous myiasis in a traveller returning from Africa. Ng SO, et al. **Australas J Dermatol** 1997 Feb;38(1):38–9 (16 ref.)

Medical guidelines for air travel. Aerospace Medical Association, Air Transport Medicine Committee, Alexandria, Va. **Aviat Space Environ Med** 1996 Oct;67(10 Suppl):B1–16 (62 ref.)

Passenger safety, health, and comfort: a review. Rayman RB. **Aviat Space Environ Med** 1997 May;68(5):432–40 (43 ref.)

Fever in the returning traveller. Felton JM, et al. **Br J Hosp Med** 1996 Jun 5–18;55(11):705–11 (20 ref.)

Health care work in developing countries. Redwood-Campbell L. **Can Fam Physician** 1997 Sep; 43:1599–602 (12 ref.)

Preliminary conjoint statement on oral cholera vaccination. **Can Med Assoc J** 1996 Oct 15;155(8):1087–90 (11 ref.) **(Eng, Fre)**

Interindividual differences in the flexibility of human temporal organization: pertinence to jet lag and shiftwork. Ashkenazi IE, et al. **Chronobiol Int** 1997 Mar;14(2):99–113 (35 ref.)

Bright light: a countermeasure for jet lag? Samel A, et al. **Chronobiol Int** 1997 Mar;14(2):173–83 (40 ref.)

Promoting sleep in shiftworkers and intercontinental travelers. Stone BM, et al. **Chronobiol Int** 1997 Mar; 14(2):133–43 (64 ref.)

Some comments on the measurement of circadian rhythms after time-zone transitions and during night work. Waterhouse J, et al. **Chronobiol Int** 1997 Mar;14(2):125–32 (45 ref.)

Persistent diarrhea in travelers. DuPont HL, et al. **Clin Infect Dis** 1996 Jan;22(1):124–8 (45 ref.)

Infectious considerations in the world traveler. Tornieporth NG, et al. **Dermatol Clin** 1997 Apr;15(2):285–93 (34 ref.)

Medical limitations to wilderness travel. Backer H. **Emerg Med Clin North Am** 1997 Feb;15(1):17–41 (73 ref.)

Travel with infants and children. Foster JA, et al. **Emerg Med Clin North Am** 1997 Feb;15(1):71–92 (31 ref.)

Medical emergencies in commercial air travel. Jagoda A, et al. **Emerg Med Clin North Am** 1997 Feb;15(1):251–60 (21 ref.)

Travel medicine problems encountered in emergency

departments. Jong EC, et al.
Emerg Med Clin North Am 1997 Feb;15(1):261–81 (30 ref.)
Traveler's diarrhea. Larson SC.
Emerg Med Clin North Am 1997 Feb;15(1):179–89 (15 ref.)
Poisonings: food, fish, shellfish. Mines D, et al.
Emerg Med Clin North Am 1997 Feb;15(1):157–77 (65 ref.)
General medical advice for travelers. Reyes I, et al.
Emerg Med Clin North Am 1997 Feb;15(1):1–16 (73 ref.)
Pregnancy and travel. Rose SR.
Emerg Med Clin North Am 1997 Feb;15(1):93–111 (45 ref.)
Maritime medicine. Scott J, et al.
Emerg Med Clin North Am 1997 Feb;15(1):241–9 (10 ref.)
Malaria. Stanley J. **Emerg Med Clin North Am** 1997 Feb; 15(1):113–55 (139 ref.)
Immunizations and travel. Thanassi WT, et al.
Emerg Med Clin North Am 1997 Feb;15(1):43–70 (30 ref.)
High-altitude medicine. Zafren K, et al.
Emerg Med Clin North Am 1997 Feb;15(1):191–222 (201 ref.)
Preparing the international traveler. Nettleman MD.
Gastroenterol Clin North Am 1996 Sep;25(3):451–69 (75 ref.)
Sexually transmitted diseases in mobile populations. Mabey D, et al. **Genitourin Med** 1997 Feb;73(1):18–22 (33 ref.)
Dermatology and the recently returned traveler: infectious diseases with dermatologic manifestations. Lucchina LC, et al. **Int J Dermatol** 1997 Mar;36(3):167–81 (55 ref.)
Furuncular cutaneous myiasis caused by Dermatobia hominis larvae following travel to Brazil. Tsuda S, et al.
Int J Dermatol 1996 Feb;35(2):121–3 (21 ref.)
Sex and travel: studies of sexual behaviour, disease and health promotion in international travellers—a global review [editorial] Mulhall BP. **Int J STD AIDS** 1996 Nov–Dec; 7(7):455–65 (108 ref.)
Emergencies in the air: problems, management, and prevention. Rosenberg CA, et al. **J Emerg Med** 1997 Mar–Apr;15(2):159–64 (31 ref.)
Melatonin and jet lag. Croughs RJ, et al. **Neth J Med** 1996 Oct;49(4):164–6 (12 ref.)
Protecting travelers against infections: immunizations and other preventive strategies. Blair JE. **Postgrad Med** 1996 Dec;100(6):159–62, 165–6, 169–72 (5 ref.)
Foodborne diseases. Lee CC, et al. **Singapore Med J** 1996 Apr;37(2):197–204 (55 ref.)
Foodborne diseases in travellers. Cartwright RY, et al.
World Health Stat Q 1997;50(1–2):102–10 (40 ref.)
[Human mobility and sexually transmitted diseases] Carosi G, et al. **Med Trop (Mars)** 1997;57(2):115–9 (28 ref.) **(Fre)**
[Jet lag or desynchronization syndrome] Martet G. **Med Trop (Mars)** 1996;56(2):129–30 (4 ref.) **(Fre)**
[The heart and travel] Touze JE, et al. **Med Trop (Mars)** 1996;56(3 Suppl):47–9 (12 ref.) **(Fre)**
[An acute septic course of melioidosis after a stay in Thailand] Koch FW, et al. **Dtsch Med Wochenschr** 1997 Jan 31; 122(5):122–6 (21 ref.) (Eng. Abstr.) **(Ger)**
[Bronchopneumonia caused by Neisseria meningitidis—probable transmission by a family member who had been in Hong Kong] Ohtaki M, et al.
Nippon Kyobu Shikkan Gakkai Zasshi 1997 Apr;35(4):461–5 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Prophylaxis of infectious intestinal diseases before leaving for underdeveloped countries] Sakaue Y. **Rinsho Byori** 1997 May;45(5):415–20 (0 ref.) (Eng. Abstr.) **(Jpn)**

PSYCHOLOGY

Homesickness: a review of the literature. Van Tilburg MA, et al. **Psychol Med** 1996 Sep;26(5):899–912 (70 ref.)

TRAZODONE

THERAPEUTIC USE

Trazodone for aggression in an adolescent with hydrocephalus. Mashiko H, et al.
Psychiatry Clin Neurosci 1996 Jun;50(3):133–6 (16 ref.)

TREACHER COLLINS SYNDROME see **MANDIBULOFACIAL DYSOSTOSIS**

TREADMILL TEST see **EXERCISE TEST**

TREATMENT COSTS see **HEALTH CARE COSTS**

TREATMENT EFFECTIVENESS see **TREATMENT OUTCOME**

TREATMENT FAILURE

The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Weller M, et al.
Brain Res Brain Res Rev 1995 Sep;21(2):128–51 (254 ref.)
Treatment failure in erythema migrans—a review. Weber K.
Infection 1996 Jan–Feb;24(1):73–5 (17 ref.)
The effect of diarrhea on oral poliovirus vaccine failure in Brazil. Posey DL, et al. **J Infect Dis** 1997 Feb;175 Suppl 1:S258–63 (57 ref.)
Why is the treatment of cancer more successful than that of obesity? Berry EM. **Public Health Rev** 1996;24(2):147–63 (29 ref.)
[Failures after tympanoplasty] Desaulty A, et al.
Rev Laryngol Otol Rhinol (Bord) 1996;117(5):357–61 (24 ref.) (Eng. Abstr.) **(Fre)**

TREATMENT FUTILITY see **MEDICAL FUTILITY**

TREATMENT OUTCOME

Antimicrobials for acute otitis media? A review from the International Primary Care Network. Froom J, et al.
BMJ 1997 Jul 12;315(7100):98–102 (58 ref.)
Cardiopulmonary resuscitation: what cost to cheat death? Lee KH, et al. **Crit Care Med** 1996 Dec;24(12):2046–52 (51 ref.)
Action research—a strategy for evaluation of medical interventions. Malterud K. **Fam Pract** 1995 Dec; 12(4):476–81 (25 ref.)
"Medical effectiveness" in Canadian and U.S. health policy: the comparative politics of inferential ambiguity. Tanenbaum SJ. **Health Serv Res** 1996 Dec;31(5):517–32 (42 ref.)
Evaluation of efficacy of antiviral therapy for chronic hepatitis C: a EUROHEP Consensus Report on response criteria. Craxì A, et al. **J Viral Hepat** 1996 Sep;3(5):273–6 (14 ref.)
Patient satisfaction and quality of care. Jackson JL, et al. **Mil Med** 1997 Apr;162(4):273–7 (79 ref.)

TREATMENT PROTOCOLS see **CLINICAL PROTOCOLS**

TREATMENT REFUSAL

see related
PATIENT DROPOUTS

The combat of non-compliance during prophylactic lithium treatment. Schou M. **Acta Psychiatr Scand** 1997 May; 95(5):361–3 (28 ref.)
Issues of medication compliance and the elderly. Atkin PA, et al. **Adverse Drug React Toxicol Rev** 1996 Jun; 15(2):109–18 (61 ref.)
Practical issues when confronting the patient who refuses blood transfusion therapy. Bennett DR, et al.
Am J Clin Pathol 1997 Apr;107(4 Suppl 1):S23–7 (17 ref.)
The end-of-life sequence. Waisel DB, et al.
Anesthesiology 1997 Sep;87(3):676–86 (68 ref.)
Impact of medication nonadherence on coronary heart disease outcomes. A critical review. McDermott MM, et al. **Arch Intern Med** 1997 Sep 22;157(17):1921–9 (34 ref.)
Parental discretion in refusal of treatment for newborns. A real but limited right. Paris JJ, et al. **Clin Perinatol** 1996 Sep;23(3):573–81 (21 ref.)
The implications of noncompliance with antihypertensive medication. Girvin B, et al. **Drugs** 1996 Aug;52(2):186–95 (72 ref.)
Ambivalence and dialysis discontinuation. Cohen LM, et al. **Gen Hosp Psychiatry** 1996 Nov;18(6):431–5 (42 ref.)
Letting the deaf be deaf. Reconsidering the use of cochlear implants in prelingually deaf children. Crouch RA.
Hastings Cent Rep 1997 Jul–Aug;27(4):14–21 (36 ref.)
Failure to comply: a therapeutic dilemma and the bane of clinical trials. Gibaldi M. **J Clin Pharmacol** 1996 Aug; 36(8):674–82 (49 ref.)
Drug compliance in pediatrics. Clinical and research issues. Matsui DM. **Pediatr Clin North Am** 1997 Feb;44(1):1–14 (71 ref.)
[Therapeutic non-compliance: hard truth to say or hard truth to hear? (editorial)] Alvin P. **Arch Pediatr** 1997 May; 4(5):395–7 (5 ref.) **(Fre)**
[Assuring normovolemia in extreme hemodilution] Adams HA. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Oct;31(8):494–6 (20 ref.) **(Ger)**
[Administration of erythropoietin in extreme anemia] von Bormann B, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Oct; 31(8):497–8 (18 ref.) **(Ger)**
[Oxygen supply and acid-base status in extreme anemia] Zander R.
Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Oct; 31(8):492–4 (30 ref.) **(Ger)**

ETHNOLOGY

Withdrawal from dialysis: a review with an emphasis on the black experience. Leggat JE Jr, et al.
Adv Ren Replace Ther 1997 Jan;4(1):22–9 (44 ref.)

LEGISLATION & JURISPRUDENCE

Capacity to decide about medical treatment. Feenan D.
Br J Hosp Med 1996 Sep 18–Oct 1;56(6):295–7 (20 ref.)
Managing self-harm: the legal issues. **Drug Ther Bull** 1997 Jun;35(6):41–3 (25 ref.)
[Are we legally allowed to administer blood for lifesaving to a patient who refuses it?] Shimasaki H, et al. **Masui** 1997 Apr;46(4):556–9 (24 ref.) (Eng. Abstr.) **(Jpn)**

PSYCHOLOGY

In their own hands: adolescents' refusals of medical treatment. Traugott I, et al. **Arch Pediatr Adolesc Med** 1997 Sep;151(9):922–7 (31 ref.)

TREES

Forest tree biotechnology. Dean JF, et al.
Adv Biochem Eng Biotechnol 1997;57:1–44 (352 ref.)
Triterpene saponins from maté, Ilex paraguariensis. Schenkel EP, et al. **Adv Exp Med Biol** 1996;405:47–56 (18 ref.)
Nutritional and economic benefits of Leucaena and Gliricidia as feed supplements for small ruminants in humid West Africa. Jabbar MA, et al. **Trop Anim Health Prod** 1997 Feb;29(1):35–47 (44 ref.)
[The place of ixodid ticks (Ixodidae) in forest ecosystems] Balashov IuS. **Parazitologiia** 1996 May–Jun;30(3):193–204 (50 ref.) (Eng. Abstr.) **(Rus)**

TREHALASE

METABOLISM

Trehalases and trehalose hydrolysis in fungi. Jorge JA, et al. **FEMS Microbiol Lett** 1997 Sep 15;154(2):165–71 (44 ref.)
Molecular biology of trehalose and the trehalases in the yeast Saccharomyces cerevisiae. Nwaka S, et al.
Prog Nucleic Acid Res Mol Biol 1998;58:197–237 (178 ref.)

TREHALOSE

BIOSYNTHESIS

[Novel enzymes catalyzing trehalose formation] Tsusaki K, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(6):834–41 (42 ref.) **(Jpn)**

METABOLISM

The role of trehalose in cell stress. de-Araujo PS.
Braz J Med Biol Res 1996 Jul;29(7):873–5 (40 ref.)
Trehalases and trehalose hydrolysis in fungi. Jorge JA, et al. **FEMS Microbiol Lett** 1997 Sep 15;154(2):165–71 (44 ref.)
Molecular biology of trehalose and the trehalases in the yeast Saccharomyces cerevisiae. Nwaka S, et al.
Prog Nucleic Acid Res Mol Biol 1998;58:197–237 (178 ref.)

PHYSIOLOGY

The role of trehalose in the physiology of nematodes. Behm CA. **Int J Parasitol** 1997 Feb;27(2):215–29 (119 ref.)

TREMATODA

see related
ANTIPLATYHELMINTIC AGENTS

CLASSIFICATION

How many parasite species are there: are we close to answers? Poulin R. **Int J Parasitol** 1996 Oct;26(10):1127–9 (7 ref.)

PATHOGENICITY

Benedeniine capsalid monogeneans from Australian fishes: pathogenic species, site-specificity and camouflage. Whittington ID. **J Helminthol** 1996 Sep;70(3):177–84 (46 ref.)

PHYSIOLOGY

Parasitic effects on host life-history traits: a review of recent studies. Michalakis Y, et al. **Parasite** 1994 Dec;1(4):291–4 (20 ref.)
Neuromuscular physiology and pharmacology of parasitic flatworms. Pax RA, et al. **Parasitology** 1996;113 Suppl:S83–96 (111 ref.)
[Fluke invasion and the immune system of the snail] Kofta W. **Wiad Parazytol** 1997;43(1):27–38 (40 ref.) (Eng. Abstr.) **(Pol)**

TREMATODE INFECTIONS

see related
ANTIPLATYHELMINTIC AGENTS

IMMUNOLOGY

Defence against the immune barrage: helminth survival strategies. Riffkin M, et al. **Immunol Cell Biol** 1996 Dec; 74(6):564–74 (118 ref.)

PARASITOLOGY

Liver and intestinal flukes. Liu LX, et al.
Gastroenterol Clin North Am 1996 Sep;25(3):627–36 (41 ref.)
Defence against the immune barrage: helminth survival strategies. Riffkin M, et al. **Immunol Cell Biol** 1996 Dec; 74(6):564–74 (118 ref.)

VETERINARY

Benedeniine capsalid monogeneans from Australian fishes: pathogenic species, site-specificity and camouflage. Whittington ID. **J Helminthol** 1996 Sep;70(3):177–84 (46 ref.)
[The etiology and diagnosis of "black spot disease" of fish] Kurochkin IuV, et al. **Parazitologiia** 1996 Mar–Apr; 30(2):117–25 (93 ref.) (Eng. Abstr.) **(Rus)**

TREMOR

[Clinicophysiological study of tremor in Parkinson's disease: quantitative tremor-based assessment of motor count using actigraphy] Mochio S, et al. **Nippon Rinsho** 1997 Jan; 55(1):158–62 (11 ref.) (Eng. Abstr.) **(Jpn)**

CHEMICALLY INDUCED

Tremors associated with trimethoprim–sulfamethoxazole therapy in a patient with AIDS: case report and review. Aboulafia DM. **Clin Infect Dis** 1996 Mar;22(3):598–600 (10 ref.)

Can tremor be used to measure the effect of chronic mercury exposure in human subjects? Beuter A, et al. **Neurotoxicology** 1996 Spring;17(1):213–27 (46 ref.)

DIAGNOSIS

Classification of tremors. Findley LJ. **J Clin Neurophysiol** 1996 Mar;13(2):122–32 (55 ref.)

PHYSIOPATHOLOGY

Clinical neurophysiology of tremor. Deuschl G, et al. **J Clin Neurophysiol** 1996 Mar;13(2):110–21 (79 ref.)

Central mechanisms of tremor. Elble RJ. **J Clin Neurophysiol** 1996 Mar;13(2):133–44 (156 ref.)

A framework for the analysis of mixed time series/point process data—theory and application to the study of physiological tremor, single motor unit discharges and electromyograms. Halliday DM, et al. **Prog Biophys Mol Biol** 1995;64(2–3):237–78 (41 ref.)

[Clinical features and current principles in medical treatment] Destée A. **Neurochirurgie** 1997;43 Suppl 1:52–8 (0 ref.) **(Fre)**

[Skeletal myoclonus and midbrain tremor] Nagaoka M. **No To Shinkei** 1996 Mar;48(3):209–16 (12 ref.) **(Jpn)**

[Action myoclonus, intention tremor and terminal oscillation] Ugawa Y. **No To Shinkei** 1996 Mar;48(3):203–8 (12 ref.) **(Jpn)**

THERAPY

[Clinical features and current principles in medical treatment] Destée A. **Neurochirurgie** 1997;43 Suppl 1:52–8 (0 ref.) **(Fre)**

TRENCH FEVER

The expanding spectrum of Bartonella infections: I. Bartonellosis and trench fever. Bass JW, et al. **Pediatr Infect Dis J** 1997 Jan;16(1):2–10 (80 ref.)

MICROBIOLOGY

Bartonella (Rochalimaea) quintana infections. Maurin M, et al. **Clin Microbiol Rev** 1996 Jul;9(3):273–92 (170 ref.)

TREPONEMA

Syphilis in European brown hares (Lepus europaeus). Lumeij JT. **Vet Q** 1996;18 Suppl 3:S151–2 (8 ref.)

TREPONEMA PALLIDUM

IMMUNOLOGY

Surface antigens of the syphilis spirochete and their potential as virulence determinants. Blanco DR, et al. **Emerg Infect Dis** 1997 Jan–Mar;3(1):11–20 (47 ref.)

PATHOGENICITY

Surface antigens of the syphilis spirochete and their potential as virulence determinants. Blanco DR, et al. **Emerg Infect Dis** 1997 Jan–Mar;3(1):11–20 (47 ref.)

TRETINOIN

see related
RECEPTORS, RETINOIC ACID

[All-trans retinoic acid (Tretinoin)] Ohno R. **Gan To Kagaku Ryoho** 1997 Apr;24(6):741–6 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Is retinoic acid essential for the development?] Kakizuka A. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1067–74 (74 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Injection of all-trans retinoic acid for treatment of thin wrinkles. Personelle J, et al. **Aesthetic Plast Surg** 1997 May–Jun;21(3):196–204 (49 ref.)

[Progress in the treatment of adult acute myeloid leukemia] Ohno R. **Gan To Kagaku Ryoho** 1997 Jul;24(9):1053–8 (20 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Rare but important adverse effects of all-trans retinoic acid in acute promyelocytic leukemia and their management. Hatake K, et al. **Int J Hematol** 1997 Jul;66(1):13–9 (46 ref.)

All-trans-retinoic acid and pseudotumor cerebri. Visani G, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):437–42 (96 ref.)

ANALOGS & DERIVATIVES

Tretinoin tocoferil as a possible differentiation-inducing agent against myelomonocytic leukemia. Makishima M, et al. **Leuk Lymphoma** 1997 Jun;26(1–2):43–8 (55 ref.)

Retinoyl beta-glucuronide: a biologically active form of vitamin A. Barua AB. **Nutr Rev** 1997 Jul;55(7):259–67 (76 ref.)

METABOLISM

Evidence that class IV alcohol dehydrogenase may function in embryonic retinoic acid synthesis. Duester G, et al. **Adv Exp Med Biol** 1997;414:357–64 (25 ref.)

Retinoylation of proteins in mammalian cells. Breitman TR, et al. **Biochem Soc Trans** 1996 Aug;24(3):723–7 (48 ref.)

Involvement of alcohol dehydrogenase, short-chain dehydrogenase/reductase, aldehyde dehydrogenase, and cytochrome P450 in the control of retinoid signaling by activation of retinoic acid synthesis. Duester G. **Biochemistry** 1996 Sep 24;35(38):12221–7 (79 ref.)

Is retinoic acid an endogenous ligand during urodele limb regeneration? Viviano CM, et al. **Int J Dev Biol** 1996 Aug; 40(4):817–22 (42 ref.)

The regulation of retinoic acid formation. Wolf G. **Nutr Rev** 1996 Jun;54(6):182–4 (13 ref.)

PHARMACOKINETICS

Clinical pharmacokinetics of tretinoin. Regazzi MB, et al. **Clin Pharmacokinet** 1997 May;32(5):382–402 (111 ref.)

Clinical relevance of all-trans retinoic acid pharmacokinetics and its modulation in acute promyelocytic leukemia. Lazzarino M, et al. **Leuk Lymphoma** 1996 Nov; 23(5–6):539–43 (45 ref.)

PHARMACOLOGY

Effects of retinoic acid on Xenopus embryos. Old RW, et al. **Biochem Soc Symp** 1996;62:157–74 (52 ref.)

Retinoid resistance in leukemic cells. Kizaki M, et al. **Leuk Lymphoma** 1997 May;25(5–6):427–34 (42 ref.)

Retinoic acid response elements as positive and negative regulators of the expression of the homeobox b–1 gene. De Luca LM, et al. **Nutr Rev** 1996 Feb;54(2 Pt 1):61–3 (17 ref.)

Retinoic acid, neoplasia, differentiation and development. Berry C. **Virchows Arch** 1997 Apr;430(4):267–70 (24 ref.)

[Mechanisms of retinoid resistance in leukemic cells] Kizaki M, et al. **Rinsho Ketsueki** 1996 Sep;37(9):766–9 (16 ref.) **(Jpn)**

PHYSIOLOGY

Regulation of metabolism by retinoic acid and its nuclear receptors. Pfahl M, et al. **Annu Rev Nutr** 1996;16:257–83 (157 ref.)

Retinoic acid. A key molecule for eye and photoreceptor development. Hyatt GA, et al. **Invest Ophthalmol Vis Sci** 1997 Jul;38(8):1471–5 (14 ref.)

[Genetic control of the development by retinoic acid] Mark M, et al. **C R Seances Soc Biol Fil** 1997;191(1):77–90 (27 ref.) (Eng. Abstr.) **(Fre)**

[Analyses of dominant mutations and their phenotypes: unraveling of physiological functions of retinoid and identification of the responsible gene for Machado-Joseph disease] Kakizuka A. **Seikagaku** 1997 Feb;69(2):87–103 (51 ref.) **(Jpn)**

[Regulation of tissue-associated fibrinolysis by retinoids: mechanism and consequence of retinoid-PA-TGF-beta system] Kojima S. **Seikagaku** 1997 Feb;69(2):104–8 (14 ref.) **(Jpn)**

THERAPEUTIC USE

The efficacy of 9-cis retinoic acid in experimental models of cancer. Gottardis MM, et al. **Breast Cancer Res Treat** 1996;38(1):85–96 (57 ref.)

Necrobiosis lipoidica treated with topical tretinoin. Heymann WR. **Cutis** 1996 Jul;58(1):53–4 (8 ref.)

Topical retinoic acid (tretinoin) for photoaging: conceptions and misperceptions. Kligman AM. **Cutis** 1996 Mar; 57(3):142–4 (11 ref.)

All-trans retinoic acid in hematological malignancies, an update. GER (Gruppo Ematologico Retinoidi). Sacchi S, et al. **Haematologica** 1997 Jan–Feb;82(1):106–21 (117 ref.)

Treatment of photodamage with topical tretinoin: an overview. Gilchrest BA. **J Am Acad Dermatol** 1997 Mar; 36(3 Pt 2):S27–36 (29 ref.)

Molecular genetics of acute leukaemia. Sawyers CL. **Lancet** 1997 Jan 18;349(9046):196–200 (40 ref.)

Acute promyelocytic leukaemia in the all trans retinoic acid era. DeLoughery TG, et al. **Med Oncol** 1996 Dec; 13(4):233–40 (107 ref.)

Retinoic acid as a therapy for emphysema? DeLuca LM, et al. **Nutr Rev** 1997 Aug;55(8):307–8 (14 ref.)

[All-trans retinoic acid therapy in acute promyelocytic leukemia—current status and prospect] Kitamura K, et al. **Rinsho Ketsueki** 1996 Sep;37(9):760–5 (15 ref.) **(Jpn)**

[Acute promyelocytic leukemia: model of differential therapy] Samochatova EV, et al. **Gematol Transfuziol** 1996 Mar–Apr;41(2):29–32 (40 ref.) **(Rus)**

TOXICITY

Tretinoin: a review of the nonclinical developmental toxicology experience. Kochhar DM, et al. **J Am Acad Dermatol** 1997 Mar;36(3 Pt 2):S47–59 (49 ref.)

TRIACETYLOLEANDOMYCIN see **TROLEANDOMYCIN**

TRIACYLGLYCEROL LIPASE see **LIPASE**

TRIACYLGLYCEROLS see **TRIGLYCERIDES**

TRIAGE

Priorities in assessment and intervention in trauma victim medical care. Cooper J, et al. **Eur J Emerg Med** 1996 Dec; 3(4):225–32 (18 ref.)

METHODS

Outpatient chemotherapy: telephone triage for symptom management. Anastasia PJ, et al. **Oncol Nurs Forum** 1997 Jan–Feb;24(1 Suppl):13–22 (42 ref.)

ORGANIZATION & ADMINISTRATION

Telephone advice: new solutions for old problems. Robinson DL, et al. **Nurse Pract** 1997 Mar;22(3):179–80, 183–6, 189 passim (18 ref.)

TRIAL OF LABOR

see related
CESAREAN SECTION
DELIVERY

The case for trial of labor in the patient with a prior low-segment vertical cesarean incision. Martin JN Jr, et al. **Am J Obstet Gynecol** 1997 Jul;177(1):144–8 (25 ref.)

Trial of scar. Chua S, et al. **Aust N Z J Obstet Gynaecol** 1997 Feb;37(1):6–11 (58 ref.)

[Amniotic fluid embolism in trial of labor. A case report] D'Addato F, et al. **Minerva Ginecol** 1997 May;49(5):217–20 (16 ref.) (Eng. Abstr.) **(Ita)**

TRIALKYLTIN COMPOUNDS

TOXICITY

Differential effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin, bis(tri-n-butyltin) oxide and cyclosporine on thymus histophysiology. De Waal EJ, et al. **Crit Rev Toxicol** 1997 Jul;27(4):381–430 (460 ref.)

TRIAMCINOLONE

ADMINISTRATION & DOSAGE

Aggressive giant keratoacanthoma of the face treated with intramuscular methotrexate and triamcinolone acetonide. Santoso-Pham JC, et al. **Cutis** 1997 Jun;59(6):329–32 (26 ref.)

TRIAMCINOLONE ACETONIDE

PHARMACOLOGY

Triamcinolone acetonide. A review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis. Jeal W, et al. **Drugs** 1997 Feb;53(2):257–80 (73 ref.)

THERAPEUTIC USE

Triamcinolone acetonide. A review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis. Jeal W, et al. **Drugs** 1997 Feb;53(2):257–80 (73 ref.)

TRIAMTERENE

ANALOGS & DERIVATIVES

Potassium and magnesium retaining triamterene derivatives. Priewer H, et al. **Pharmazie** 1997 Mar;52(3):179–81 (56 ref.)

PHARMACOLOGY

Potassium and magnesium retaining triamterene derivatives. Priewer H, et al. **Pharmazie** 1997 Mar;52(3):179–81 (56 ref.)

THERAPEUTIC USE

[Potassium-sparing diuretics (spironolactone, triamterene, amylorid)] Haris A, et al. **Orv Hetil** 1996 Sep 1; 137(35):1907–14 (72 ref.) (Eng. Abstr.) **(Hun)**

TRIATOMIDAE see **TRIATOMINAE**

TRIATOMINAE

GENETICS

Chromosome numbers in the Triatominae (Hemiptera-Reduviidae): a review. Panzera F, et al. **Mem Inst Oswaldo Cruz** 1996 Jul–Aug;91(4):515–8 (24 ref.)

TRIATRIAL HEART see **COR TRIATRIATUM**

TRIAZINES

ADVERSE EFFECTS

Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and immunosuppressive management. Sullivan JR, et al. **Australas J Dermatol** 1996 Nov;37(4):208–12 (32 ref.)

ECONOMICS

A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy [see comments] Hughes D, et al. **Seizure** 1996 Jun; 5(2):89–95 (38 ref.) Comment in: Seizure 1996 Sep;5(3):247–8.

PHARMACOLOGY

New drugs and vagal stimulation for treatment of epilepsy—the Israeli experience. Neufeld MY, et al. **Neurol Neurochir Pol** 1996;30 Suppl 2:113–20 (23 ref.)

[Effect of quinine on the multiple drug resistance and intracellular distribution of pirarubicin in LR73 tumor cells: a comparative study with verapamil and S9788 by confocal laser microspectrofluorometry] Belhoussine R, et al. **Bull Cancer** 1997 Apr;84(4):343–9 (39 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

A review of the newer antiepileptic drugs and the ketogenic diet. Barron TF, et al. **Clin Pediatr (Phila)** 1997 Sep; 36(9):513–21 (61 ref.)

N-(Hydroxymethyl) melamines. Coley HM. **Gen Pharmacol** 1997 Feb;28(2):177–82 (31 ref.)

Seizure control: how to use the new antiepileptic drugs in older patients. Haider A, et al. **Geriatrics** 1996 Sep; 51(9):42–5 (16 ref.)

New drugs and vagal stimulation for treatment of epilepsy—the Israeli experience. Neufeld MY, et al. **Neurol Neurochir Pol** 1996;30 Suppl 2:113–20 (23 ref.)

A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy [see comments] Hughes D, et al. **Seizure** 1996 Jun; 5(2):89–95 (38 ref.) Comment in: Seizure 1996 Sep;5(3):247–8.

Lamotrigine in childhood epilepsies. Dreifuss FE. **Semin Pediatr Neurol** 1997 Mar;4(1):19–23 (40 ref.)

TRIAZOLAM

THERAPEUTIC USE

Zolpidem: distinct from triazolam? Lobo BL, et al. **Ann Pharmacother** 1997 May;31(5):625–32 (52 ref.)

TRIAZOLES

Nefazodone: its place among antidepressants. Cyr M, et al. **Ann Pharmacother** 1996 Sep;30(9):1006–12 (39 ref.)

Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide. Goldberg RJ. **Drugs Aging** 1997 Aug;11(2):119–31 (86 ref.)

PHARMACOLOGY

Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression [see comments] Davis R, et al. **Drugs** 1997 Apr;53(4):608–36 (110 ref.) Comment in: Drugs 1997 Jul;54(1);186–7.

[Antifungal resistance in opportunistic pathogenic fungi (II). Imidazoles and triazoles] Martínez-Suárez JV, et al. **Enferm Infecc Microbiol Clin** 1996 Oct;14(8):490–8 (79 ref.) **(Spa)**

THERAPEUTIC USE

Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients. Trunet PF, et al. **Acta Oncol** 1996;35 Suppl 5:15–8 (27 ref.)

Use of azoles for systemic antifungal therapy. Kauffman CA, et al. **Adv Pharmacol** 1997;39:143–89 (340 ref.)

New aromatase inhibitors for breast cancer. **Drug Ther Bull** 1997 Jul;35(7):55–6 (11 ref.)

Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression [see comments] Davis R, et al. **Drugs** 1997 Apr;53(4):608–36 (110 ref.) Comment in: Drugs 1997 Jul;54(1);186–7.

Can a killer be arrested? Kierszenbaum F. **Nat Med** 1996 Oct;2(10):1071–2 (10 ref.)

Role of new selective aromatase inhibitor in therapy for metastatic breast cancer in postmenopausal women [news] Hannaford M. **Nurse Pract** 1997 Mar;22(3):195–6, 201–2 (21 ref.)

Venlafaxine and nefazodone, two pharmacologically distinct antidepressants. Augustin BG, et al. **Pharmacotherapy** 1997 May–Jun;17(3):511–30 (91 ref.)

[PAF receptor antagonist in asthma therapy] Sagara H, et al. **Nippon Rinsho** 1996 Nov;54(11):3056–61 (24 ref.) (Eng. Abstr.) **(Jpn)**

TRIBAVIRIN see **RIBAVIRIN**

TRIBUTYRINASE see **LIPASE**

TRICARBOXYLIC ACID CYCLE see **CITRIC ACID CYCLE**

TRICHINA see **TRICHINELLA**

TRICHINA SPIRALIS see **TRICHINELLA SPIRALIS**

TRICHINELLA

ISOLATION & PURIFICATION

Trichinella isolates: parasite variability and host responses. Wakelin D, et al. **Int J Parasitol** 1996 May;26(5):471–81 (82 ref.)

TRICHINELLA SPIRALIS

Trichinella infection and clinical disease. Clausen MR, et al. **QJM** 1996 Aug;89(8):631–6 (58 ref.)

IMMUNOLOGY

Workshop on a detailed characterization of Trichinella spiralis antigens: a platform for future studies on antigens and antibodies to this parasite. Ortega-Pierres MG, et al. **Parasite Immunol** 1996 Jun;18(6):273–84 (37 ref.)

TRICHINELLIASIS see **TRICHINOSIS**

TRICHINOSIS

[Parasitic myocarditis] Kimura K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):65–8 (14 ref.) **(Jpn)**

EPIDEMIOLOGY

Trichinella infection and clinical disease. Clausen MR, et al. **QJM** 1996 Aug;89(8):631–6 (58 ref.)

ETIOLOGY

[Inflammatory myopathies] Espinosa E. **Rev Neurol** 1996 Nov;24(135):1376–81 (33 ref.) **(Spa)**

VETERINARY

[Updates on equine trichinellosis] Arriaga-Díaz C, et al. **Rev Latinoam Microbiol** 1996 Apr–Jun;38(2):139–50 (31 ref.) (Eng. Abstr.) **(Spa)**

TRICHLOROACETIC ACID

Trichloroacetic acid. **IARC Monogr Eval Carcinog Risks Hum** 1995;63:291–314 (136 ref.)

ADMINISTRATION & DOSAGE

Medium-depth chemical peeling. Otley CC, et al. **Semin Cutan Med Surg** 1996 Sep;15(3):145–54 (23 ref.)

TRICHLOROETHYLENE

Trichloroethylene. **IARC Monogr Eval Carcinog Risks Hum** 1995;63:75–158 (374 ref.)

ADVERSE EFFECTS

Assessment of the health effects of trichloroethylene. Kaneko T, et al. **Ind Health** 1997 Jul;35(3):301–24 (97 ref.)

Bilateral optic neuritis in occupational exposure to trichloroethylene. Abecia E, et al. **Med Lav** 1996 Sep–Oct; 87(5):432–6 (25 ref.)

ANALYSIS

[Total environmental exposure to chlorinated solvents: studies of exposure markers] Pregliasco F, et al. **Ann Ig** 1996 May–Jun;8(3):361–75 (56 ref.) (Eng. Abstr.) **(Ita)**

TOXICITY

Trichloroethylene cancer risk: simplified calculation of PBPK-based MCLs for cytotoxic end points. Bogen KT, et al. **Regul Toxicol Pharmacol** 1997 Feb;25(1):26–42 (121 ref.)

2,4,5-TRICHLOROPHENOXYACETIC ACID

METABOLISM

Biodegradation of 2,4,5-trichlorophenoxyacetic acid by Burkholderia cepacia strain AC1100: evolutionary insight. Daubaras DL, et al. **Gene** 1996 Nov 7;179(1):1–8 (40 ref.)

TRICHOBEZOARS see **BEZOARS**

TRICHOCEPHALIASIS see **TRICHURIASIS**

TRICHODERMA

ISOLATION & PURIFICATION

Trichoderma longibrachiatum infection in a pediatric patient with aplastic anemia. Munoz FM, et al. **J Clin Microbiol** 1997 Feb;35(2):499–503 (24 ref.)

METABOLISM

The role of lectins in recognition and adhesion of the mycoparasitic fungus Trichoderma spp. to its host. Inbar J, et al. **Adv Exp Med Biol** 1996;408:229–31 (7 ref.)

TRICHOMONAS

see related
ANTITRICHOMONAL AGENTS

TRICHOMONAS INFECTIONS

see related
ANTITRICHOMONAL AGENTS

VETERINARY

Pathogenesis, diagnosis, and management of trichomoniasis in cattle. BonDurant RH. **Vet Clin North Am Food Anim Pract** 1997 Jul;13(2):345–61 (55 ref.)

TRICHOMONAS VAGINALIS

METABOLISM

Trichomonas vaginalis adhesin proteins display molecular mimicry to metabolic enzymes. Engbring JA, et al. **Adv Exp Med Biol** 1996;408:207–23 (86 ref.)

PHYSIOLOGY

Organelle origins: energy-producing symbionts in early eukaryotes?. Sogin ML. **Curr Biol** 1997 May 1;7(5):R315–7 (11 ref.)

TRICHOMONAS VAGINITIS

VETERINARY

Sustained estrogenization is insufficient to support long-term experimentally induced genital Trichomonas vaginalis infection in BALB/c mice. Van Andel RA, et al. **Lab Anim Sci** 1996 Dec;46(6):689–90 (11 ref.)

TRICHOPHYTON

Childhood white superficial onychomycosis caused by Trichophyton rubrum: report of seven cases and review of the literature. Ploysangam T, et al. **J Am Acad Dermatol** 1997 Jan;36(1):29–32 (23 ref.)

ISOLATION & PURIFICATION

Tinea due to Trichophyton violaceum in Victoria, Australia. Maslen MM, et al. **Australas J Dermatol** 1997 Aug; 38(3):124–8 (21 ref.)

Tinea caput medusa: an unusual presentation of Trichophyton mentagrophytes on the scalp. Houck HE, et al. **Cutis** 1996 Jul;58(1):48–52 (13 ref.)

Epidemiology and ecology of onychomycosis. Summerbell RC. **Dermatology** 1997;194 Suppl 1:32–6 (12 ref.)

Chronic dermatophytosis syndrome due to Trichophyton rubrum. Zaias N, et al. **Int J Dermatol** 1996 Sep;35(9):614–7 (8 ref.)

TRICHOPHYTOSIS see **TINEA**

TRICHOSPORON

[White genital piedra] Schwinn A, et al. **Hautarzt** 1996 Aug; 47(8):638–41 (32 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

[Summer-type hypersensitivity pneumonitis in a patient with a positive skin test (15 minutes) for Trichosporon mucoides and a high serum IgE level] Nakajima M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Oct; 34(10):1168–73 (20 ref.) (Eng. Abstr.) **(Jpn)**

TRICHOSTRONGYLOIDIASIS

EPIDEMIOLOGY

[Intestinal geohelminthosis in man and domestic animals in the riverside sections of the Valdivia River Basin, Chile] Torres P, et al. **Bol Chil Parasitol** 1995 Jul–Dec; 50(3-4):57–66 (82 ref.) (Eng. Abstr.) **(Spa)**

TRICHOSTRONGYLOSIS

GENETICS

Genetic control of resistance to helminths in sheep. Windon RG. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):245–54 (39 ref.)

TRICHOSTRONGYLOSIS

IMMUNOLOGY

Genetic control of resistance to helminths in sheep. Windon RG. **Vet Immunol Immunopathol** 1996 Nov;54(1-4):245-54 (39 ref.)

VETERINARY

The immunogenetics of resistance to Trichostrongylus colubriformis and Haemonchus contortus parasites in sheep [see comments] Hohenhaus MA, et al. **Br Vet J** 1995 Mar-Apr;151(2):119-40 (65 ref.) Comment in: Br Vet J 1995 Mar-Apr;151(2):111-3.

TRICHOSTRONGYLUS

IMMUNOLOGY

The immunogenetics of resistance to Trichostrongylus colubriformis and Haemonchus contortus parasites in sheep [see comments] Hohenhaus MA, et al. **Br Vet J** 1995 Mar-Apr;151(2):119-40 (65 ref.) Comment in: Br Vet J 1995 Mar-Apr;151(2):111-3.

TRICHOTILLOMANIA

DIAGNOSIS

Pediatric psychocutaneous disorders. Hansen RC. **Curr Opin Pediatr** 1997 Aug;9(4):367-71 (14 ref.)

The diagnosis and psychopharmacological treatment of trichotillomania: a review. Jaspers JP. **Pharmacopsychiatry** 1996 May;29(3):115-20 (39 ref.)

DRUG THERAPY

The diagnosis and psychopharmacological treatment of trichotillomania: a review. Jaspers JP. **Pharmacopsychiatry** 1996 May;29(3):115-20 (39 ref.)

ETIOLOGY

Trichotillomania and anorexia nervosa in an adolescent female: a case study of comorbidity [see comments] Pinhas L, et al. **J Adolesc Health** 1996 Aug;19(2):141-4 (27 ref.) Comment in: J Adolesc Health 1997 May;20(5):336.

PATHOLOGY

Trichotillomania in connection with alopecia areata. Trüeb RM, et al. **Cutis** 1996 Jul;58(1):67-70 (10 ref.)

PSYCHOLOGY

Trichotillomania: a comprehensive behavioral model. Mansueto CS, et al. **Clin Psychol Rev** 1997;17(5):567-77 (19 ref.)

THERAPY

Understanding trichotillomania. Warmbrodt L, et al. **J Psychosoc Nurs Ment Health Serv** 1996 Dec;34(12):11-5 (15 ref.)

TRICHURIASIS

EPIDEMIOLOGY

[Intestinal geohelminthosis in man and domestic animals in the riverside sections of the Valdivia River Basin, Chile] Torres P, et al. **Bol Chil Parasitol** 1995 Jul-Dec; 50(3-4):57-66 (82 ref.) (Eng. Abstr.) **(Spa)**

PARASITOLOGY

Enterobius, trichuris, capillaria, and hookworm including ancylostoma caninum. Grencis RK, et al. **Gastroenterol Clin North Am** 1996 Sep;25(3):579-97 (90 ref.)

TRICUSPID ATRESIA

see related
FONTAN PROCEDURE

[Tricuspid regurgitation, tricuspid stenosis, tricuspid atresia] Minagoe S. **Ryoikibetsu Shokogun Shirizu** 1996;(13):113-8 (7 ref.) **(Jpn)**

SURGERY

Fatal rupture of an acquired aneurysm of the pulmonary artery: rare complication after surgical palliation of tricuspid atresia. Boubaker A, et al. **Pediatr Cardiol** 1997 Sep-Oct;18(5):392-5 (9 ref.)

TRICUSPID INCOMPETENCE see **TRICUSPID VALVE INSUFFICIENCY**

TRICUSPID REGURGITATION see **TRICUSPID VALVE INSUFFICIENCY**

TRICUSPID VALVE

[Combined valvular heart disease] Ohashi H. **Ryoikibetsu Shokogun Shirizu** 1996;(13):448-50 (8 ref.) **(Jpn)**

[Ruptured chordae tendineae of the tricuspid valve] Okada M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):371-3 (14 ref.) **(Jpn)**

ABNORMALITIES

Unguarded tricuspid orifice: a rare malformation of tricuspid valve diagnosed by echocardiography. Report of two cases and review of the literature. Özkutlu S, et al. **Int J Cardiol** 1996 Oct 11;56(2):125-9 (9 ref.)

Isolated congenital tricuspid valve dysplasia: a rare condition mimicking persistent pulmonary hypertension of the newborn. Yam MC, et al. **J Paediatr Child Health** 1996 Dec;32(6):536-8 (7 ref.)

[Tricuspid pouch] Magara T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):119-21 (15 ref.) **(Jpn)**

MICROBIOLOGY

[Pneumococcal endocarditis of the tricuspid valve. A case report with review of the literature] Holm M, et al. **Tidsskr Nor Laegeforen** 1997 Feb 28;117(6):815-7 (8 ref.) (Eng. Abstr.) **(Nor)**

PATHOLOGY

Isolated tricuspid valve endocarditis in nonaddicted patients: a diagnostic challenge. Nandakumar R, et al. **Am J Med Sci** 1997 Sep;314(3):207-12 (41 ref.)

Primary lipomatous tumors of the cardiac valves. Benvenuti LA, et al. **South Med J** 1996 Oct;89(10):1018-20 (17 ref.)

[Edema caused by retroperitoneal and tricuspid fibrosis with sclerodermatous cutaneous involvement disclosing carcinoid tumor. Apropos of a case and review of the literature] Morand JJ, et al. **Rev Med Interne** 1997; 18(5):388-95 (61 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

[Is tricuspid valve necessary in patients with mitral stenosis undergoing mitral valve repair or replacement?] Sagie A, et al. **Harefuah** 1996 Oct;131(7-8):260-3 (22 ref.) **(Heb)**

SURGERY

Mitral, tricuspid, and aortic valve repair or reconstruction. Hammond GL, et al. **Curr Opin Cardiol** 1997 Mar; 12(2):100-7 (47 ref.)

Importance of the right ventricle in valvular heart disease. Nagel E, et al. **Eur Heart J** 1996 Jun;17(6):829-36 (75 ref.)

[Surgical treatment of tricuspid valve insufficiency. Carpentier's annuloplasty] Radermecker MA, et al. **Rev Med Liege** 1997 Mar;52(3):159-62 (11 ref.) **(Fre)**

[Tricuspid valvulectomy in antibiotic-refractory right-heart endocarditis] Hust MH, et al. **Dtsch Med Wochenschr** 1997 Jan 24;122(4):80-5 (36 ref.) (Eng. Abstr.) **(Ger)**

TRICUSPID VALVE ATRESIA see **TRICUSPID ATRESIA**

TRICUSPID VALVE INCOMPETENCE see **TRICUSPID VALVE INSUFFICIENCY**

TRICUSPID VALVE INSUFFICIENCY

[Idiopathic tricuspid regurgitation] Kubo S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):428-30 (12 ref.) **(Jpn)**

[Tricuspid regurgitation, tricuspid stenosis, tricuspid atresia] Minagoe S. **Ryoikibetsu Shokogun Shirizu** 1996;(13):113-8 (7 ref.) **(Jpn)**

[Tricuspid regurgitation] Okada M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):374-7 (19 ref.) **(Jpn)**

SURGERY

Successful tricuspid valve replacement and pulmonary valvulotomy for carcinoid heart disease. Defraigne JO, et al. **Acta Chir Belg** 1996 Jul-Aug;96(4):170-6 (46 ref.)

[Surgical treatment of tricuspid valve insufficiency. Carpentier's annuloplasty] Radermecker MA, et al. **Rev Med Liege** 1997 Mar;52(3):159-62 (11 ref.) **(Fre)**

[Tricuspid valvulectomy in antibiotic-refractory right-heart endocarditis] Hust MH, et al. **Dtsch Med Wochenschr** 1997 Jan 24;122(4):80-5 (36 ref.) (Eng. Abstr.) **(Ger)**

[A case of congenital tricuspid regurgitation associated with atrial septal defect and peripheral pulmonary stenosis] Tanji M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Dec; 44(12):2146-50 (16 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Echocardiographic evaluation of the severity of tricuspid valve regurgitation: 29 considerations useful in recognizing hemodynamically important lesions. Schiller NB. **Isr J Med Sci** 1996 Oct;32(10):853-67 (36 ref.)

Isolated congenital tricuspid valve dysplasia: a rare condition mimicking persistent pulmonary hypertension of the newborn. Yam MC, et al. **J Paediatr Child Health** 1996 Dec;32(6):536-8 (7 ref.)

TRICUSPID VALVE PROLAPSE

[Tricuspid valve prolapse] Okada M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):363-6 (22 ref.) **(Jpn)**

TRICUSPID VALVE STENOSIS

[Tricuspid regurgitation, tricuspid stenosis, tricuspid atresia] Minagoe S. **Ryoikibetsu Shokogun Shirizu** 1996;(13):113-8 (7 ref.) **(Jpn)**

[Tricuspid stenosis] Okada M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):367-70 (15 ref.) **(Jpn)**

TRICYCLIC ANTIDEPRESSIVE AGENTS see **ANTIDEPRESSIVE AGENTS, TRICYCLIC**

TRIFLUOPERAZINE

PHARMACOLOGY

The 1996 Lindberg Award. Calcium antagonists alter cell shape and induce procollagenase synthesis in keloid and normal human dermal fibroblasts. Doong H, et al. **J Burn Care Rehabil** 1996 Nov-Dec;17(6 Pt 1):497-514 (19 ref.)

TRIFLUOROPERAZINE see **TRIFLUOPERAZINE**

TRIFTAZIN see **TRIFLUOPERAZINE**

TRIGEMINAL GANGLION

BLOOD SUPPLY

Neurological episodes after minor head injury and trigeminovascular activation. Sakas DE, et al. **Med Hypotheses** 1997 May;48(5):431-5 (48 ref.)

TRIGEMINAL NERVE

see related
TRIGEMINAL NEURALGIA

[Mixed connective tissue disease: progress in diagnosis and treatment. III. Treatment. 3. Clinical aspects and treatment of specific conditions. 2) Disorders of the trigeminal nerve] Okada J. **Nippon Naika Gakkai Zasshi** 1996 Aug 10; 85(8):1244-7 (5 ref.) **(Jpn)**

ANATOMY & HISTOLOGY

The trigeminal complex. Anatomy and physiology. Brown JA. **Neurosurg Clin N Am** 1997 Jan;8(1):1-10 (52 ref.)

The trigeminal nerve. Nemzek WR. **Top Magn Reson Imaging** 1996 Jun;8(3):132-54 (60 ref.)

BLOOD SUPPLY

Bilateral persistent trigeminal arteries associated with cerebral aneurysms and aortic arch vessel anomaly. Alleyne CH Jr, et al. **South Med J** 1997 Apr;90(4):434-8 (49 ref.)

DRUG EFFECTS

Inhibition of the trigemino-vascular system with 5-HT1D agonist drugs: selectively targeting additional sites of action. Martin GR. **Eur Neurol** 1996;36 Suppl 2:13-8 (22 ref.)

INJURIES

Experimental trigeminal nerve injury. Holland GR. **Crit Rev Oral Biol Med** 1996;7(3):237-58 (148 ref.)

PHYSIOLOGY

Trigeminal neo-neurotization of the paralyzed face. Cheney ML, et al. **Ann Otol Rhinol Laryngol** 1997 Sep;106(9):733-8 (31 ref.)

Corneal nerve recovery after photorefractive keratectomy and laser in situ keratomileusis. Latvala T, et al. **Int Ophthalmol Clin** 1996 Fall;36(4):21-7 (38 ref.)

PHYSIOPATHOLOGY

[Exteroceptive suppression of activity of the temporal muscle. Principles and applications] Göbel H, et al. **Nervenarzt** 1996 Oct;67(10):846-59 (102 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Percutaneous balloon compression of the trigeminal nerve. Brown JA, et al. **Neurosurg Clin N Am** 1997 Jan;8(1):53-62 (10 ref.)

TRIGEMINAL NEURALGIA

COMPLICATIONS

Herpes zoster-associated trigeminal neurotrophic ulcer [letter] Nielsen NH, et al. **Acta Derm Venereol** 1996 Mar; 76(2):159-60 (8 ref.)

DIAGNOSIS

Atypical facial pain and other pain syndromes. Differential diagnosis and treatment. Gouda JJ, et al. **Neurosurg Clin N Am** 1997 Jan;8(1):87-100 (67 ref.)

DRUG THERAPY

Use of streptomycin-lidocaine injections in the treatment of

the cluster-tic syndrome. Clinical perspectives and a case report. Kreiner M. **J Craniomaxillofac Surg** 1996 Oct; 24(5):289-92 (48 ref.)

PHYSIOPATHOLOGY

SUNCT syndrome. A clinical review. Pareja JA, et al. **Headache** 1997 Apr;37(4):195-202 (23 ref.)

SURGERY

Trigeminal neuralgia: neurosurgical management options. Pannullo SC, et al. **J Am Dent Assoc** 1996 Nov; 127(11):1635-9; quiz 1666 (25 ref.)

Gamma knife radiosurgery for trigeminal neuralgia. Kondziolka D, et al. **Neurosurg Clin N Am** 1997 Jan; 8(1):79-85 (17 ref.)

Microvascular decompression for trigeminal neuralgia. Surgical technique and long-term results. Lovely TJ, et al. **Neurosurg Clin N Am** 1997 Jan;8(1):11-29 (54 ref.)

Radiofrequency treatment of trigeminal neuralgia using a cordotomy-type electrode. A method. Nugent GR. **Neurosurg Clin N Am** 1997 Jan;8(1):41-52 (26 ref.)

Treatment of trigeminal neuralgia by percutaneous radiofrequency rhizotomy. Taha JM, et al. **Neurosurg Clin N Am** 1997 Jan;8(1):31-9 (30 ref.)

[Management of trigeminal neuralgia by microvascular decompression] Kuncz A, et al. **Orv Hetil** 1997 Aug 17; 138(33):2051-5 (39 ref.) (Eng. Abstr.) **(Hun)**

THERAPY

Percutaneous balloon compression of the trigeminal nerve. Brown JA, et al. **Neurosurg Clin N Am** 1997 Jan;8(1):53-62 (10 ref.)

[Neurovascular compression syndrome--treatment of facial spasm, trigeminal neuralgia and disabling vertigo] Hashimoto T. **Ryoikibetsu Shokogun Shirizu** 1996; (14):540-4 (7 ref.) **(Jpn)**

TRIGEMINAL NUCLEI

The trigeminal system in man. Usunoff KG, et al. **Adv Anat Embryol Cell Biol** 1997;136:I-X, 1-126 (630 ref.)

ANATOMY & HISTOLOGY

The trigeminal complex. Anatomy and physiology. Brown JA. **Neurosurg Clin N Am** 1997 Jan;8(1):1-10 (52 ref.)

PHYSIOLOGY

Cellular mechanisms underlying the formation of orderly connections in developing sensory pathways. Erzurumlu RS, et al. **Prog Brain Res** 1996;108:287-301 (85 ref.)

TRIGGER POINTS, MYOFASCIAL see **MYOFASCIAL PAIN SYNDROMES**

TRIGLYCERIDE LIPASE see **LIPASE**

TRIGLYCERIDES

ADMINISTRATION & DOSAGE

The usefulness of dietary medium-chain triglycerides in body weight control: fact or fancy? Bach AC, et al. **J Lipid Res** 1996 Apr;37(4):708-26 (222 ref.)

Parenteral use of medium-chain triglycerides: a reappraisal. Ulrich H, et al. **Nutrition** 1996 Apr;12(4):231-8 (82 ref.)

ANALYSIS

Regulation of milk lipid secretion and composition. Neville MC, et al. **Annu Rev Nutr** 1997;17:159-83 (140 ref.)

BIOSYNTHESIS

Biosynthesis of triacylglycerols. Lehner R, et al. **Prog Lipid Res** 1996;35(2):169-201 (208 ref.)

BLOOD

Triglycerides and coronary risk in women and the elderly. LaRosa JC. **Arch Intern Med** 1997 May 12;157(9):961-8 (65 ref.)

The atherogenic role of triglycerides and small, dense low density lipoproteins: impact of ciprofibrate therapy. Chapman MJ, et al. **Atherosclerosis** 1996 Jul;124 Suppl:S21-8 (33 ref.)

The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs). Staels B, et al. **Biochimie** 1997 Feb-Mar;79(2-3):95-9 (39 ref.)

Assessment of postprandial lipemia: nutritional influences. Bergeron N, et al. **Curr Opin Lipidol** 1997 Feb;8(1):43-52 (59 ref.)

Triacylglycerol and coronary heart disease. Austin MA. **Proc Nutr Soc** 1997 Jul;56(2):667-70 (24 ref.)

[High triglyceride, low HDL-cholesterol and risk of coronary heart disease] Jeppesen J, et al. **Ugeskr Laeger** 1996 Nov 25;158(48):6896-901 (40 ref.) (Eng. Abstr.) **(Dan)**

GENETICS

Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Auwerx J, et al. **Atherosclerosis** 1996 Jul;124 Suppl:S29-37 (59 ref.)

METABOLISM

Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Auwerx J, et al. **Atherosclerosis** 1996 Jul;124 Suppl:S29-37 (59 ref.)

Microbial lipases: structures, function and industrial applications. Rogalska E, et al. **Biochem Soc Trans** 1997 Feb;25(1):161-4 (34 ref.)

The acylation stimulating protein pathway: clinical implications. Cianflone K. **Clin Biochem** 1997 Jun; 30(4):301-12 (125 ref.)

Recent advances in elucidating the role of the microsomal triglyceride transfer protein in apolipoprotein B lipoprotein assembly. Gordon DA. **Curr Opin Lipidol** 1997 Jun; 8(3):131-7 (41 ref.)

Triglyceride-rich lipoproteins in non-insulin-dependent diabetes mellitus: post-prandial metabolism and relation to premature atherosclerosis. De Man FH, et al. **Eur J Clin Invest** 1996 Feb;26(2):89-108 (264 ref.)

Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects. Auwerx J, et al. **J Atheroscler Thromb** 1996;3(2):81-9 (71 ref.)

New insights into the utilization of medium-chain triglycerides by the neonate: observations from a piglet model. Odle J. **J Nutr** 1997 Jun;127(6):1061-7 (55 ref.)

PHYSIOLOGY

Triglyceride is the major atherogenic lipid in NIDDM. Taskinen MR. **Diabetes Metab Rev** 1997 Jun;13(2):93-8 (31 ref.)

The role of medium-chain triglycerides in exercise. Berning JR. **Int J Sport Nutr** 1996 Jun;6(2):121-33 (53 ref.)

The new dietary fats in health and disease. Bell SJ, et al. **J Am Diet Assoc** 1997 Mar;97(3):280-6; quiz 287-8 (37 ref.)

SECRETION

Regulation of milk lipid secretion and composition. Neville MC, et al. **Annu Rev Nutr** 1997;17:159-83 (140 ref.)

THERAPEUTIC USE

The scientific rationale and clinical application of short-chain fatty acids and medium-chain triacylglycerols. Velázquez OC, et al. **Proc Nutr Soc** 1996 Mar;55(1B):49-78 (207 ref.)

TRIHEXOSYL CERAMIDES see **TRIHEXOSYLCERAMIDES**

TRIHEXOSYLCERAMIDES

THERAPEUTIC USE

[New approach for the absorbent therapy of verotoxin-producing Escherichia coli infection] Takeda T, et al. **Nippon Rinsho** 1997 Mar;55(3):751-7 (10 ref.) **(Jpn)**

TRIIODOBENZOIC ACIDS

Safety, tolerance, and pharmacokinetics of iodixanol injection, a nonionic, isosmolar, hexa-iodinated contrast agent. Fountaine H, et al. **Acad Radiol** 1996 Sep;3 Suppl 3:S475-84 (54 ref.)

DIAGNOSTIC USE

Iodinated contrast material in uroradiology. Choice of agent and management of complications. Cohan RH, et al. **Urol Clin North Am** 1997 Aug;24(3):471-91 (110 ref.)

PHARMACOLOGY

Iodixanol. A review of its pharmacodynamic and pharmacokinetic properties and diagnostic use as an x-ray contrast medium. Spencer CM, et al. **Drugs** 1996 Dec; 52(6):899-927 (107 ref.)

TRIIODOTHYRONINE

see related
RECEPTORS, THYROID HORMONE

ANALOGS & DERIVATIVES

Development of a thyroid hormone analogue for the treatment of congestive heart failure. Morkin E, et al. **Thyroid** 1996 Oct;6(5):521-6 (18 ref.)

BIOSYNTHESIS

Different regulation of thyroid hormone transport in liver and pituitary: its possible role in the maintenance of low T3 production during nonthyroidal illness and fasting in man. Everts ME, et al. **Thyroid** 1996 Aug;6(4):359-68 (79 ref.)

BLOOD

Circannual changes in thyroid hormone physiology: the role of cold environmental temperatures. Reed HL. **Arctic Med Res** 1995;54 Suppl 2:9-15 (55 ref.)

DEFICIENCY

[Low-T3/Low-T4 syndrome] Nishikawa M, et al. **Nippon Naika Gakkai Zasshi** 1996 May 10;85(5):772-6 (16 ref.) **(Jpn)**

DIAGNOSTIC USE

[T3 (triiodo-thyronin) suppression test] Bando H. **Nippon Rinsho** 1997 Apr;55 Suppl 2:288-90 (2 ref.) **(Jpn)**

METABOLISM

Membrane iodothyronine transporters, Part II: Review of protein biochemistry. Kragie L. **Endocr Res** 1996 May; 22(2):95-119 (119 ref.)

Thyroid hormone abnormalities in heart failure: possibilities for therapy. Hamilton MA, et al. **Thyroid** 1996 Oct; 6(5):527-9 (22 ref.)

PHYSIOLOGY

Novel actions of thyroid hormone: the role of triiodothyronine in cardiac transplantation. Novitzky D. **Thyroid** 1996 Oct;6(5):531-6 (32 ref.)

THERAPEUTIC USE

The use of thyroid hormone in cardiac surgery. Dyke C. **Curr Opin Cardiol** 1996 Nov;11(6):603-9 (51 ref.)

Use of thyroid hormone to diminish the cognitive side effects of psychiatric treatment. Tremont G, et al. **Psychopharmacol Bull** 1997;33(2):273-80 (68 ref.)

Triiodothyronine in cardiac surgery. Broderick TJ, et al. **Thyroid** 1997 Feb;7(1):133-7 (24 ref.)

Triiodothyronine: spectrum of use in heart transplantation. Jeevanandam V. **Thyroid** 1997 Feb;7(1):139-45 (11 ref.)

Novel actions of thyroid hormone: the role of triiodothyronine in cardiac transplantation. Novitzky D. **Thyroid** 1996 Oct;6(5):531-6 (32 ref.)

TRIIODOTHYRONINE RECEPTORS see **RECEPTORS, THYROID HORMONE**

TRIMEPRIMINE see **TRIMIPRAMINE**

TRIMERESURUS

Structure and functions of coagulation factor IX/factor X-binding protein isolated from the venom of Trimeresurus flavoviridis. Morita T, et al. **Adv Exp Med Biol** 1996; 391:187-96 (29 ref.)

TRIMESTER, FIRST see **PREGNANCY TRIMESTER, FIRST**

TRIMESTER, SECOND see **PREGNANCY TRIMESTER, SECOND**

TRIMETAZIDINE

THERAPEUTIC USE

[Trimetazidine (Preductal). A new approach in controlling myocardial ischemia] Eliseev OM. **Ter Arkh** 1996; 68(8):57-63 (78 ref.) **(Rus)**

TRIMETHOPRIM

THERAPEUTIC USE

Increases in rates of resistance to trimethoprim. Huovinen P. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S63-6 (37 ref.)

TRIMETHOPRIM RESISTANCE

Increases in rates of resistance to trimethoprim. Huovinen P. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S63-6 (37 ref.)

TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION

ADMINISTRATION & DOSAGE

[Value of desensitization for reintroducing trimethoprim-sulfamethoxazole in hypersensitive patients with HIV infection] Caumes E. **Ann Med Interne (Paris)** 1997;148(2):172-6 (21 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose. Perazella MA, et al. **Clin Nephrol** 1996 Sep;46(3):187-92 (32 ref.)

Hyperkalemia and trimethoprim-sulfamethoxazole: a new problem emerges 25 years later. Perazella MA. **Conn Med** 1997 Aug;61(8):451-8 (31 ref.)

TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION

Adverse reactions to co-trimoxazole in HIV infection: a reappraisal of the glutathione-hydroxylamine hypothesis. van der Ven AJ, et al. **J Antimicrob Chemother** 1996 May; 37 Suppl B:55-60 (22 ref.)

IMMUNOLOGY

Trimethoprim/sulfamethoxazole desensitization. Cortese LM, et al. **Ann Pharmacother** 1996 Feb;30(2):184-6 (10 ref.)

METABOLISM

Adverse reactions to co-trimoxazole in HIV infection: a reappraisal of the glutathione-hydroxylamine hypothesis. van der Ven AJ, et al. **J Antimicrob Chemother** 1996 May; 37 Suppl B:55-60 (22 ref.)

PHARMACOLOGY

Nocardial infections in bone marrow transplant recipients. Chouciño C, et al. **Clin Infect Dis** 1996 Nov;23(5):1012-9 (41 ref.)

THERAPEUTIC USE

Tremors associated with trimethoprim-sulfamethoxazole therapy in a patient with AIDS: case report and review. Aboulafia DM. **Clin Infect Dis** 1996 Mar;22(3):598-600 (10 ref.)

Endocarditis caused by Stenotrophomonas maltophilia: case report and review. Gutiérrez Rodero F, et al. **Clin Infect Dis** 1996 Dec;23(6):1261-5 (26 ref.)

Increases in rates of resistance to trimethoprim. Huovinen P. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S63-6 (37 ref.)

Primary and secondary prophylaxis for Pneumocystis carinii related complications in HIV patients [editorial] Held M, et al. **Eur Respir J** 1996 May;9(5):868-71 (47 ref.)

Co-trimoxazole and Wegener's granulomatosis: more than a coincidence? [editorial] Stegeman CA, et al. **Nephrol Dial Transplant** 1997 Apr;12(4):652-5 (20 ref.)

New uses for older antibiotics. The 'rediscovery' of four beneficial and cost-effective antimicrobials. Cunha BA. **Postgrad Med** 1997 Apr;101(4):68-70, 73-4, 79-80 passim (19 ref.)

Staphylococcus aureus, trimethoprim-sulfamethoxazole, and Wegener's granulomatosis. Kallenberg CG, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct;13(3):253-5 (19 ref.)

Treatment of Pneumocystis carinii pneumonia in adults with AIDS. Deresinski SC. **Semin Respir Infect** 1997 Jun; 12(2):79-97 (142 ref.)

TRIMETHYLTIN COMPOUNDS

PHARMACOLOGY

Repeated acquisition and the assessment of centrally acting compounds. Cohn J, et al. **Brain Res Cogn Brain Res** 1996 Jun;3(3-4):183-91 (60 ref.)

TRIMIPRAMINE

THERAPEUTIC USE

Trimipramine: a challenge to current concepts on antidepressives. Berger M, et al. **Eur Arch Psychiatry Clin Neurosci** 1996;246(5):235-9 (45 ref.)

TRINITROTOLUENE

METABOLISM

Contaminated environments in the subsurface and bioremediation: organic contaminants. Holliger C, et al. **FEMS Microbiol Rev** 1997 Jul;20(3-4):517-23 (63 ref.)

TRINUCLEOTIDE REPEATS

Fragile X syndrome in humans and mice. Oostra BA. **Acta Genet Med Gemellol (Roma)** 1996;45(1-2):93-108 (79 ref.)

Trinucleotide repeats in neurogenetic disorders. Paulson HL, et al. **Annu Rev Neurosci** 1996;19:79-107 (143 ref.)

CAC--the neglected repeat. Sertedaki A, et al. **Bioessays** 1996 Mar;18(3):237-42 (60 ref.)

Mouse models of human CAG repeat disorders. Burright EN, et al. **Brain Pathol** 1997 Jul;7(3):965-77 (79 ref.)

The CAG/polyglutamine tract diseases: gene products and molecular pathogenesis. Koshy BT, et al. **Brain Pathol** 1997 Jul;7(3):927-42 (157 ref.)

Trinucleotide repeat instability: genetic features and molecular mechanisms. La Spada AR. **Brain Pathol** 1997 Jul;7(3):943-63 (146 ref.)

Clinical aspects of CAG repeat diseases. Nance MA. **Brain Pathol** 1997 Jul;7(3):881-900 (188 ref.)

The neuropathology of CAG repeat diseases: review and update of genetic and molecular features. Robitaille Y, et al. **Brain Pathol** 1997 Jul;7(3):901-26 (237 ref.)

Toward understanding the molecular pathology of Huntington's disease. Wellington CL, et al. **Brain Pathol** 1997 Jul;7(3):979-1002 (188 ref.)

Trinucleotide-repeat expansions and neurodegenerative disease: a mechanism of pathogenesis. Hannan AJ. **Clin Exp Pharmacol Physiol** 1996 Dec;23(12):1015-20 (48 ref.)

The complex pathology of trinucleotide repeats. Reddy PS, et al. **Curr Opin Cell Biol** 1997 Jun;9(3):364-72 (65 ref.)

Transgenic models of neurodegenerative diseases. Lee MK, et al. **Curr Opin Neurobiol** 1996 Oct;6(5):651-60 (115 ref.)

Huntington's disease: translating a CAG repeat into a pathogenic mechanism. MacDonald ME, et al. **Curr Opin Neurobiol** 1996 Oct;6(5):638-43 (45 ref.)

Trinucleotide repeat disorders in pediatrics. O'Donnell DM, et al. **Curr Opin Pediatr** 1995 Dec;7(6):715-25 (54 ref.)

Trinucleotide repeat disorders in humans: discussions of mechanisms and medical issues. Timchenko LT, et al. **FASEB J** 1996 Dec;10(14):1589-97 (70 ref.)

Huntington disease: new insights into the relationship between CAG expansion and disease. Nasir J, et al. **Hum Mol Genet** 1996;5 Spec No:1431-5 (48 ref.)

Molecular genetics of triplet repeats: unstable expansion of triplet repeats as a new mechanism for neurodegenerative diseases. Tsuji S. **Intern Med** 1997 Jan;36(1):3-8 (36 ref.)

Myotonic dystrophy: molecular and cellular consequences of expanded DNA repeats are elusive. Strong PN, et al. **J Inherit Metab Dis** 1997 Jun;20(2):159-70 (57 ref.)

Unstable expansion of triplet repeats as a new disease mechanism for neurodegenerative diseases. Tsuji S. **Jpn J Hum Genet** 1996 Sep;41(3):279-90 (47 ref.)

Etiology of (CAG)n triplet repeat neurodegenerative diseases such as Huntington's disease is connected to stimulation of glutamate receptors. Fischer KM. **Med Hypotheses** 1997 May;48(5):393-8 (66 ref.)

Triplet repeats and human disease. Singer RH. **Mol Med Today** 1996 Feb;2(2):65-9 (36 ref.)

Trinucleotide repeats associated with human disease. Mitas M. **Nucleic Acids Res** 1997 Jun 15;25(12):2245-54 (93 ref.)

[Neurodegenerative disorders and the role of trinucleotide repeat expansion. II. Molecular genetics] Knoers NV, et al. **Ned Tijdschr Geneeskd** 1996 Nov 23;140(47):2329-33 (23 ref.) **(Dut)**

[Neurodegenerative disorders and the role of trinucleotide repeat expansion. I. The diseases (see comments)] Kremer HP, et al. **Ned Tijdschr Geneeskd** 1996 Nov 23; 140(47):2325-9 (33 ref.) Comment in: Ned Tijdschr Geneeskd 1997 Feb 22;141(8):400-1. **(Dut)**

[Huntington's disease: trinucleotide disease or polyglutamine disease?] Ide K, et al. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1540-1 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular genetics of myotonic dystrophy] Miki T, et al. **Rinsho Shinkeigaku** 1995 Dec;35(12):1479-81 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular basis of triplet repeat diseases: genetic instability and unusual DNA structure] Shimizu M. **Tanpakushitsu Kakusan Koso** 1997 Mar;42(4):619-31 (35 ref.) **(Jpn)**

[Trinucleotide repeats and neurologic diseases] Tsuji S. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(15 Suppl):2349-54 (29 ref.) **(Jpn)**

[Triplet repeat expansions in hereditary neurodegenerative diseases] Peñuelas I, et al. **Med Clin (Barc)** 1997 Apr 12; 108(14):542-8 (63 ref.) **(Spa)**

GENETICS

Trinucleotide repeat expansion and human disease. Ashley CT Jr, et al. **Annu Rev Genet** 1995;29:703-28 (206 ref.)

Protein: protein interactions in Alzheimer's disease and the CAG triplet repeat diseases. Strittmatter WJ, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:597-605 (73 ref.)

Trinucleotide repetition and fragile X syndrome. Warren ST. **Hosp Pract (Off Ed)** 1997 Apr 15;32(4):73-6, 81-5, 90-2 passim (0 ref.)

[X chromosomal bulbospinal neuropathy (X-BSN, Kennedy syndrome): an illness with repetitive triplet sequences. Case report, differential diagnosis and molecular genetics aspects] Abel A, et al. **Nervenarzt** 1996 Dec;67(12):1011-9 (44 ref.) (Eng. Abstr.) **(Ger)**

TRIOSEPHOSPHATE DEHYDROGENASE see **GLYCERALDEHYDEPHOSPHATE DEHYDROGENASE**

TRIPHOSPHOPYRIDINE NUCLEOTIDE see **NADP**

TRIPLE-SYMPTOM COMPLEX see **BEHCET'S SYNDROME**

TRIPLET REPEATS see **TRINUCLEOTIDE REPEATS**

TRIPLETS

[Should fetal reduction be used in triplet pregnancies?] Nisand I. **Contracept Fertil Sex** 1997 Jun;25(6):423-8 (41 ref.) **(Fre)**

[Obstetrical management of triplets. A series of forty five cases] Charasson T, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(7):737-45 (45 ref.) (Eng. Abstr.) **(Fre)**

TRIS BUFFER see **TROMETHAMINE**

TRISACCHARIDES

IMMUNOLOGY

Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. Galili U, et al. **Immunol Today** 1997 Jun;18(6):281-5 (58 ref.)

A possible role for the alpha 1-->3 galactosyl epitope and the natural anti-gal antibody in oncogenesis. Gollogly L, et al. **Neoplasma** 1996;43(5):285-9 (27 ref.)

PHARMACOKINETICS

Pharmacokinetic-pharmacodynamic relationships of Acarbose. Salvatore T, et al. **Clin Pharmacokinet** 1996 Feb; 30(2):94-106 (99 ref.)

PHARMACOLOGY

Acarbose: its role in the treatment of diabetes mellitus [see comments] Campbell LK, et al. **Ann Pharmacother** 1996 Nov;30(11):1255-62 (33 ref.) Comment in: Ann Pharmacother 1996 Nov;30(11):1333-5.

THERAPEUTIC USE

Acarbose: an alpha-glucosidase inhibitor. Martin AE, et al. **Am J Health Syst Pharm** 1996 Oct 1;53(19):2277-90; quiz 2336-7 (111 ref.)

Acarbose: a review of US clinical experience. Coniff R, et al. **Clin Ther** 1997 Jan-Feb;19(1):16-26; discussion 2-3 (17 ref.)

A review of the safety and efficacy of acarbose in diabetes mellitus. Yee HS, et al. **Pharmacotherapy** 1996 Sep-Oct; 16(5):792-805 (80 ref.)

TRISAMINE see **TROMETHAMINE**

TRISOMY

Mosaic trisomy 22: a case presentation and literature review of trisomy 22 phenotypes. Crowe CA, et al. **Am J Med Genet** 1997 Sep 5;71(4):406-13 (35 ref.)

Proximal partial 5p trisomy resulting from a maternal (19;5) insertion. Lorda-Sánchez I, et al. **Am J Med Genet** 1997 Feb 11;68(4):476-80 (28 ref.)

Trisomy 15 mosaic derived from trisomic conceptus: report of a case and a review. Markovic VD, et al. **Am J Med Genet** 1996 Feb 2;61(4):363-70 (46 ref.)

Partial trisomy 17q22-qter and partial monosomy Xq27-qter in a girl with a de novo unbalanced translocation due to a postzygotic error: case report and review of the literature on partial trisomy 17qter. Sarri C, et al. **Am J Med Genet** 1997 May 2;70(1):87-94 (46 ref.)

Trisomy X: ACLF (Association des Cytogénéticiens de Langue Française) retrospective study. Guichet A, et al. **Ann Genet** 1996;39(3):117-22 (20 ref.)

Further delineation of 7p trisomy. Case report and review of literature. Pallotta R, et al. **Ann Genet** 1996;39(3):152-8 (26 ref.)

De novo direct duplication 7p (p11.2-->pter) in an Arab child with MCA/MR syndrome: trisomy 7p a delineated syndrome? Redha MA, et al. **Ann Genet** 1996;39(1):5-9 (18 ref.)

Two different pregnancy outcomes of trisomic zygote rescue through postzygotic mitotic error. Kalousek DK. **Birth Defects Orig Artic Ser** 1996;30(1):295-9 (12 ref.)

Behçet's disease associated with myelodysplastic syndromes. A case report and a review of the literature. Ohno E, et al. **Cancer** 1997 Jan 15;79(2):262-8 (31 ref.)

c-myc amplification in a preleukemia patient with trisomy 4 and double minutes: review of the unique coexistence of these two chromosome abnormalities in acute myelogenous leukemia. Reddy KS, et al. **Cancer Genet Cytogenet** 1997 Jun;95(2):206-9 (10 ref.)

Clinical correlations of immunophenotypic variations and the presence of trisomy 12 in B-cell chronic lymphocytic leukemia. Tefferi A, et al. **Cancer Genet Cytogenet** 1997 Jun;95(2):173-7 (28 ref.)

Partial trisomy 10 mosaicism with cutaneous manifestations: report of a case and review of the literature. Boon C, et al. **Clin Genet** 1996 Nov;50(5):417-21 (16 ref.)

Three cases of trisomy 13 mosaicism and a review of the literature. Delatycki M, et al. **Clin Genet** 1997 Jun; 51(6):403-7 (29 ref.)

Prenatal diagnosis of a de novo trisomy 6q22.2-->6qter and monosomy 1pter-->1p36.3. Case report with a 2-year follow-up and a brief review of other prenatal cases of partial trisomy 6q. Kulharya AS, et al. **Clin Genet** 1997 Feb;51(2):115-7 (2 ref.)

A history of miscarriages and mild prognathism as possible mode of presentation of mosaic trisomy 18 in women. Satge D, et al. **Clin Genet** 1996 Dec;50(6):470-3 (22 ref.)

The sonographic detection of trisomies 13, 18, and 21. Hill LM. **Clin Obstet Gynecol** 1996 Dec;39(4):831-50 (65 ref.)

Behcet's disease complicated with myelodysplastic syndrome: a report of two cases and review of the literature. Yano K, et al. **Clin Rheumatol** 1996 Jan;15(1):91-3 (13 ref.)

Partial trisomy 15q: report of a patient and literature review. Chandler K, et al. **Genet Couns** 1997;8(2):91-7 (25 ref.)

Hyperdiploidy and trisomy 12 in the cystic partially differentiated nephroblastoma. de Chadarévian JP, et al. **Hum Pathol** 1996 Sep;27(9):980-1 (5 ref.)

Confined placental mosaicism for trisomies 2, 3, 7, 8, 9, 16,

and 22: their incidence, likely origins, and mechanisms for cell lineage compartmentalization. Wolstenholme J. **Prenat Diagn** 1996 Jun;16(6):511–24 (51 ref.)
[Trisomy 13 syndrome (Patau syndrome), trisomy 18 syndrome (Edwards syndrome), Down syndrome (trisomy 21 syndrome), Turner syndrome (XO gonadal dysgenesis)] Harada N, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (15):198–201 (8 ref.) **(Jpn)**

GENETICS

Management of fetal choroid plexus cysts. Gupta JK, et al. **Br J Obstet Gynaecol** 1997 Aug;104(8):881–6 (53 ref.)
Genetic abnormalities in chronic lymphocytic leukemia and their clinical and prognostic implications. Dierlamm J, et al. **Cancer Genet Cytogenet** 1997 Mar;94(1):27–35 (84 ref.)
Chromosomal differences in susceptibility to meiotic aneuploidy. Warburton D, et al. **Environ Mol Mutagen** 1996;28(3):237–47 (52 ref.)
Partial trisomy and partial monosomy of the distal long arm of chromosome 4: patient report and literature review. Frints SG, et al. **Genet Couns** 1996;7(2):135–42 (55 ref.)
Hepatoblastoma in a child with trisomy 18: cytogenetics, liver anomalies, and literature review. Bove KE, et al. **Pediatr Pathol Lab Med** 1996 Mar–Apr;16(2):253–62 (39 ref.)

TRISOMY 21 see **DOWN SYNDROME**

TRITERPENES

CHEMISTRY

Triterpene saponins from plants of the flora of Turkey. Calis I, et al. **Adv Exp Med Biol** 1996;404:485–500 (44 ref.)
Proton and carbon-13 NMR studies of steroids and triterpenes. Cordell GA, et al. **Adv Exp Med Biol** 1996; 405:281–97 (96 ref.)
Steroid and triterpenoid oligoglycosides of marine origin. Minale L, et al. **Adv Exp Med Biol** 1996;404:335–56 (63 ref.)
Triterpene saponins from maté, Ilex paraguariensis. Schenkel EP, et al. **Adv Exp Med Biol** 1996;405:47–56 (18 ref.)
Chemistry and biological activity of triterpenoid glycosides from Medicago sativa. Timbekova AE, et al. **Adv Exp Med Biol** 1996;405:171–82 (19 ref.)

ISOLATION & PURIFICATION

Triterpene and steroid saponins isolated from two Melilotus species. Khodakov GV, et al. **Adv Exp Med Biol** 1996; 405:211–22 (17 ref.)
Bioactive triterpenoid and steroid saponins from medicinal plants in southwest China. Yang CR, et al. **Adv Exp Med Biol** 1996;404:225–38 (20 ref.)

PHARMACOLOGY

New biologically active steroidal and triterpenoid glycosides from medicinal plants. Aquino R, et al. **Adv Exp Med Biol** 1996;404:401–14 (30 ref.)
Anti-tumor-promoting activities or triterpenoid glycosides; cancer chemoprevention by saponins. Konoshima T. **Adv Exp Med Biol** 1996;404:87–100 (11 ref.)
Chemistry and biological activity of triterpenoid glycosides from Medicago sativa. Timbekova AE, et al. **Adv Exp Med Biol** 1996;405:171–82 (19 ref.)
Inhibitory effect of oleanene-type triterpene oligoglycosides on ethanol absorption: the structure-activity relationships. Yoshikawa M, et al. **Adv Exp Med Biol** 1996;404:207–18 (40 ref.)
Saponins as antimycotic agents: glycosides of medicagenic acid. Zehavi U, et al. **Adv Exp Med Biol** 1996;404:535–46 (37 ref.)

TRITICUM see **WHEAT**

TRITONS see **POLYETHYLENE GLYCOLS**

TRNA see **RNA, TRANSFER**

TRNA-AMINO ACID see **RNA, TRANSFER, AMINO ACID-SPECIFIC**

TRNA-AMINO ACYL see **RNA, TRANSFER, AMINO ACYL**

TRNAASP see **RNA, TRANSFER, ASP**

TRNAGLN see **RNA, TRANSFER, GLN**

TRNALYS see **RNA, TRANSFER, LYS**

TRNAMET see **RNA, TRANSFER, MET**

TRNA(F)MET see **RNA, TRANSFER, MET**

TRNA(I)MET see **RNA, TRANSFER, MET**

TRNA(M)MET see **RNA, TRANSFER, MET**

TRNAPHE see **RNA, TRANSFER, PHE**

TRNASER see **RNA, TRANSFER, SER**

TROCHANTER see **FEMUR**

TROCHANTERIC FRACTURES see **HIP FRACTURES**

TROCHLEAR NERVE

Neurogenic diplopia: paralysis of cranial nerves III, IV, and VI. Sowka J. **Optom Clin** 1996;5(3–4):53–76 (46 ref.)

PATHOLOGY

The ocular motor nerves. Miller NR. **Curr Opin Neurol** 1996 Feb;9(1):21–5 (43 ref.)
Cranial nerves III, IV, and VI. Laine FJ. **Top Magn Reson Imaging** 1996 Apr;8(2):111–30 (61 ref.)

SURGERY

Trochlear nerve schwannomas occurring in patients without neurofibromatosis: case report and review of the literature. Santoreneos S, et al. **Neurosurgery** 1997 Jul;41(1):282–7 (21 ref.)

TROLEANDOMYCIN

THERAPEUTIC USE

Alternative treatments in the patient with intractable asthma. Spector SL. **Curr Opin Pulm Med** 1997 Jan;3(1):23–9 (64 ref.)

TROMETAMOL see **TROMETHAMINE**

TROMETHAMINE

ANALOGS & DERIVATIVES

Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Patel SS, et al. **Drugs** 1997 Apr;53(4):637–56 (106 ref.)

TROPANES

POISONING

Systemic toxicity from ocular homatropine. Reilly KM, et al. **Acad Emerg Med** 1996 Sep;3(9):868–71 (15 ref.)

TROPHIC FACTOR RECEPTORS see **RECEPTORS, GROWTH FACTOR**

TROPHOBLAST

CYTOLOGY

Culture of syncytiotrophoblast for the study of human placental transfer. Part II: Production, culture and use of syncytiotrophoblast. Bloxam DL, et al. **Placenta** 1997 Mar–Apr;18(2–3):99–108 (103 ref.)
Culture of syncytiotrophoblast for the study of human placental transfer. Part I: Isolation and purification of cytotrophoblast. Bloxam DL, et al. **Placenta** 1997 Mar–Apr;18(2–3):93–8 (61 ref.)
Differentiation of trophoblast endocrine cells. Soares MJ, et al. **Placenta** 1996 Jul–Aug;17(5–6):277–89 (143 ref.)

IMMUNOLOGY

Immunobiology of the trophoblast: mechanisms by which placental tissues evade maternal recognition and rejection. Torry DS, et al. **Curr Top Microbiol Immunol** 1997; 222:127–40 (78 ref.)
Human decidual leukocytes do not proliferate in response to either extravillous trophoblast or allogeneic peripheral blood lymphocytes. King A, et al. **J Reprod Immunol** 1996 Feb;30(1):67–74 (20 ref.)
Immunology of human placental implantation: clinical implications of our current understanding. Loke YW, et al. **Mol Med Today** 1997 Apr;3(4):153–9 (35 ref.)
[Immunology of early pregnancy. II. Decidua and trophoblast relationship] Krzysiek J, et al. **Ginekol Pol** 1996 Sep;67(9):472–7 (55 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

A T-helper-2 bias in decidua: the prostaglandin contribution of the macrophage and trophoblast. Kelly RW, et al. **J Reprod Immunol** 1997 Jul;33(3):181–7 (48 ref.)

PATHOLOGY

Implication of abnormal human trophoblast karyotype for the evidence-based approach to the understanding, investigation, and treatment of recurrent spontaneous abortion. The Recurrent Miscarriage Immunotherapy Trialists Group [editorial] Clark DA, et al. **Am J Reprod Immunol** 1996 May;35(5):495–8 (28 ref.)
[The early placental trophoblast. I. Normal development and endometrial and non-tumor-induced disorders] Horn LC, et al. **Zentralbl Gynakol** 1996;118(9):487–97 (65 ref.) (Eng. Abstr.) **(Ger)**
[A case report of germinoma with syncytiotrophoblastic giant cells (STGC) in the basal ganglia] Ueda A, et al. **No Shinkei Geka** 1996 Mar;24(3):267–71 (13 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Epithelial–mesenchymal transition during trophoblast differentiation. Vićovac L, et al. **Acta Anat (Basel)** 1996; 156(3):202–16 (157 ref.)
Trophoblast migration during human placental implantation. Burrows TD, et al. **Hum Reprod Update** 1996 Jul–Aug; 2(4):307–21 (128 ref.)
Origins of pluriblast and' trophoblast in the eutherian conceptus. Johnson MH. **Reprod Fertil Dev** 1996; 8(4):699–709 (86 ref.)

SECRETION

Secretion of chorionic gonadotropin from human trophoblasts. Muyan M, et al. **Placenta** 1997 May; 18(4):237–41 (57 ref.)

ULTRASTRUCTURE

Structure and function in the ruminant synepitheliochorial placenta: central role of the trophoblast binucleate cell in deer. Wooding FB, et al. **Microsc Res Tech** 1997 Jul 1–15; 38(1–2):88–99 (27 ref.)

TROPHOBLASTIC NEOPLASMS

Chorionic tumors. Berkowitz RS, et al. **N Engl J Med** 1996 Dec 5;335(23):1740–8 (100 ref.)

COMPLICATIONS

Hyperthyroidism due to inappropriate production of human chorionic gonadotropin. Goodwin TM, et al. **Clin Obstet Gynecol** 1997 Mar;40(1):32–44 (41 ref.)

DIAGNOSIS

[Kidney involvement in trophoblastic disease (chorionepithelioma)] Timoshenko NI, et al. **Ter Arkh** 1995; 67(12):59–61 (6 ref.) (Eng. Abstr.) **(Rus)**

DRUG THERAPY

[Methotrexate in gynecologic oncology] Isonishi S, et al. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1896–900 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Etoposide (VP-16) in gynecologic malignancy] Kanazawa K, et al. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1925–8 (11 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

A review of trophoblastic diseases at the medical school of Dicle University. Gül T, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Jul;74(1):37–40 (16 ref.)
Gestational trophoblastic disease. Freedman RS, et al. **Obstet Gynecol Clin North Am** 1996 Jun;23(2):545–71 (82 ref.)

PATHOLOGY

Gestational trophoblastic disease. Freedman RS, et al. **Obstet Gynecol Clin North Am** 1996 Jun;23(2):545–71 (82 ref.)
[Trophoblastic diseases. Pathological concepts and genuine neoplasias] Bergh C. **Lakartidningen** 1997 Apr 16; 94(16):1499–502 (6 ref.) **(Swe)**

THERAPY

Gestational trophoblastic diseases and their treatment. Fisher PM, et al. **Cancer Treat Rev** 1997 Jan;23(1):1–16 (53 ref.)
[Clinical use of human chorionic gonadotropin in the treatment of trophoblastic neoplasia] Cohen AD, et al. **Harefuah** 1996 Nov 1;131(9):348–52 (43 ref.) **(Heb)**

TROPHOBLASTIC TUMOR see **TROPHOBLASTIC NEOPLASMS**

TROPHOBLASTIC TUMOR, PLACENTAL SITE

PATHOLOGY

Metastasizing placental site trophoblastic tumor: immunohistochemical and DNA analysis. 2 case reports and a review of the literature. Remadi S, et al. **Arch Gynecol Obstet** 1997;259(2):97–103 (24 ref.)
Placental site trophoblastic tumour with brief review of literature placental site trophoblastic tumour. Pulimood A, et al. **Indian J Cancer** 1996 Mar;33(1):12–6 (22 ref.)
[The early placental trophoblast. II. Tumorous disorders of trophoblast development] Horn LC, et al. **Zentralbl Gynakol** 1996;118(11):591–7 (36 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Gestational trophoblastic disease. Hammond CB, et al. **Curr Ther Endocrinol Metab** 1997;6:603–6 (8 ref.)

TROPICAL CLIMATE

Overview and consensus statement on diabetes in tropical

TROPICAL CLIMATE

areas. Tripathy BB, et al. **Diabetes Metab Rev** 1997 Mar; 13(1):63–76 (76 ref.)
Malaria. Stanley J. **Emerg Med Clin North Am** 1997 Feb; 15(1):113–55 (139 ref.)
HTLV-I and cancers in tropical countries. Moreau JP, et al. **Eur J Cancer Prev** 1996 Oct;5(5):409–10 (8 ref.)
Instability of (methyl)ergometrine in tropical climates: an overview. Hogerzeil HV, et al.
Eur J Obstet Gynecol Reprod Biol 1996 Oct;69(1):25–9 (19 ref.)

TROPICAL MEDICINE

Tropical diseases and the gender approach. Dias JC.
Bull Pan Am Health Organ 1996 Sep;30(3):242–60 (94 ref.)
Rheumatic manifestations of tropical diseases. Adebajo AO.
Curr Opin Rheumatol 1996 Jan;8(1):85–9 (30 ref.)
Geographical information systems and tropical diseases. Openshaw S. **Trans R Soc Trop Med Hyg** 1996 Jul–Aug; 90(4):337–9 (14 ref.)
[Ivermectin and tropical dermatoses] Caumes E.
Bull Soc Pathol Exot 1997;90(1):37–8 (17 ref.) (Eng. Abstr.) **(Fre)**
[Human ecology and tropical medicine] Froment A.
Bull Soc Pathol Exot 1997;90(2):131–8 (101 ref.) (Eng. Abstr.) **(Fre)**
[Melioidosis: a tropical time bomb that is spreading] Perret JL. **Med Trop (Mars)** 1997;57(2):195–201 (64 ref.) (Eng. Abstr.) **(Fre)**
[Prevention and therapy of important imported tropical diseases (except malaria)] Weinke T, et al.
Dtsch Med Wochenschr 1997 Mar 7;122(10):299–301 (15 ref.) **(Ger)**

HISTORY

The place of "the tropics' in Western medical ideas since 1750. Arnold D. **Trop Med Int Health** 1997 Apr;2(4):303–13 (31 ref.)

TRENDS

Tropical medicine. Not a white elephant. Greenwood B, et al. **Lancet** 1996 Dec 21–28;348 Suppl 2:sII27 (5 ref.)
Prospects for plant anthelmintics in tropical veterinary medicine. Hammond JA, et al. **Vet Res Commun** 1997 Apr; 21(3):213–28 (40 ref.)

TROPICAL SPASTIC PARAPARESIS see **PARAPARESIS, TROPICAL SPASTIC**

TROPISM

Strategies to accomplish targeted gene delivery to muscle cells employing tropism-modified adenoviral vectors. Douglas JT, et al. **Neuromuscul Disord** 1997 Jul;7(5):284–98 (98 ref.)

PHYSIOLOGY

Tropism in bacterial infections: urinary tract infections. Roberts JA. **J Urol** 1996 Nov;156(5):1552–9 (84 ref.)

TROPOELASTIN

METABOLISM

Posttranscriptional regulation of lung elastin production [comment] Parks WC. **Am J Respir Cell Mol Biol** 1997 Jul;17(1):1–2 (13 ref.) Comment on: Am J Respir Cell Mol Biol 1997 Jul;17(1):10–6.

TROPOMYOSIN

CHEMISTRY

Tropomyosin isoforms in nonmuscle cells. Lin JJ, et al.
Int Rev Cytol 1997;170:1–38 (275 ref.)

GENETICS

Tissue-specific splicing of two mutually exclusive exons of the chicken beta-tropomyosin pre-mRNA: positive and negative regulations. Gallego ME, et al. **Biochimie** 1996; 78(6):457–65 (68 ref.)

METABOLISM

Actin and tropomyosin isoforms in morphogenesis. Gunning P, et al. **Anat Embryol (Berl)** 1997 Apr;195(4):311–5 (44 ref.)

TROPONIN

ANALYSIS

Cardiac troponin I and troponin T: are enzymes still relevant as cardiac markers? Mair J. **Clin Chim Acta** 1997 Jan 3; 257(1):99–115 (63 ref.)
Troponin T: a diagnostic marker for myocardial infarction and minor cardiac cell damage. Rottbauer W, et al.
Eur Heart J 1996 Dec;17 Suppl F:3–8 (40 ref.)

BIOSYNTHESIS

Hypertrophic cardiomyopathy: a case study in converging pathways [editorial; comment] Robbins J. **J Clin Invest** 1996 Dec 1;98(11):2433–4 (9 ref.) Comment on: J Clin Invest 1996 Dec 1;98(11):2456–61.

BLOOD

To T or not to T, that is the question [editorial; comment] Collinson PO. **Clin Chem** 1997 Mar;43(3):421–3 (37 ref.) Comment on: Clin Chem 1997 Mar;43(3):458–66. Comment on: Clin Chem 1997 Mar;43(3):476–84.
[Troponins—new markers for the detection of myocardial cell damage] Hamm CW. **Fortschr Med** 1996 Nov 20; 114(32):433–6 (20 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Hypertrophic cardiomyopathy: a case study in converging pathways [editorial; comment] Robbins J. **J Clin Invest** 1996 Dec 1;98(11):2433–4 (9 ref.) Comment on: J Clin Invest 1996 Dec 1;98(11):2456–61.

METABOLISM

Structural interactions responsible for the assembly of the troponin complex on the muscle thin filament. Reinach FC, et al. **Cell Struct Funct** 1997 Feb;22(1):219–23 (30 ref.)
Are cardiac troponins reliable serodiagnositic markers of cardiac ischaemia in end-stage renal disease? [editorial] Haller C, et al. **Nephrol Dial Transplant** 1996 Jun; 11(6):941–4 (16 ref.)

TROPONIN C

PHYSIOLOGY

Regulation of myocardial contractility. Opie LH.
J Cardiovasc Pharmacol 1995;26 Suppl 1:S1–9 (30 ref.)

TROPONIN I

ANALYSIS

Cardiac troponin I and troponin T: are enzymes still relevant as cardiac markers? Mair J. **Clin Chim Acta** 1997 Jan 3; 257(1):99–115 (63 ref.)

BLOOD

SGOT, LDH, HBD, CPK, CK-MB, MB1MB2, cTnT, cTnC, cTnI. Futterman LG, et al. **Am J Crit Care** 1997 Jul;6(4):333–8 (6 ref.)
[Troponins—new markers for the detection of myocardial cell damage] Hamm CW. **Fortschr Med** 1996 Nov 20; 114(32):433–6 (20 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Molecular evolution of the vertebrate troponin I gene family. Hastings KE. **Cell Struct Funct** 1997 Feb;22(1):205–11 (36 ref.)

TROUT

BLOOD

Regulation of Na+/H+ antiporter in trout red blood cells. Malapert M, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):353–60 (48 ref.)
Association of the band 3 protein with a volume-activated, anion and amino acid channel: a molecular approach. Motais R, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):361–7 (54 ref.)

TROUT, RAINBOW see **ONCORHYNCHUS MYKISS**

TROUT, REDBAND see **ONCORHYNCHUS MYKISS**

TRS-ART GENE PROTEIN, HIV see **GENE PRODUCTS, REV**

TRS-ART GENES see **GENES, REV**

TRUNCAL VAGOTOMY see **VAGOTOMY, TRUNCAL**

TRUNCUS ARTERIOSUS, PERSISTENT

[Pseudotruncus arteriosus] Ando M.
Ryoikibetsu Shokogun Shirizu 1996;(13):71–2 (6 ref.) **(Jpn)**
[Truncus arteriosus communis] Ando M.
Ryoikibetsu Shokogun Shirizu 1996;(13):212–4 (11 ref.) **(Jpn)**

TRUTH DISCLOSURE

Legal and ethical myths about informed consent. Meisel A, et al. **Arch Intern Med** 1996 Dec 9–23;156(22):2521–6 (18 ref.)
Report disclaimers and informed expectations about Papanicolaou smears: an Australian view. Mitchell H.
Arch Pathol Lab Med 1997 Mar;121(3):327–30 (8 ref.)
Politics and South African mental health: hope, truth, and reconciliation. Comas-Díaz L, et al.
Cult Divers Ment Health 1996;2(2):133–8 (14 ref.)
Lesbian coming out as a multidimensional process. Morris JF. **J Homosex** 1997;33(2):1–22 (42 ref.)
Unique issues of the adopted child: helping parents talk openly and honestly with their child and the community. Smit EM. **J Psychosoc Nurs Ment Health Serv** 1996 Jul; 34(7):29–36 (22 ref.)
Informed consent and disclosure in the physician-patient relationship: expanding obligations for physicians in the United States. LeBlang TR. **Med Law** 1995;14(5–6):429–44 (46 ref.)
Criminal Procedure and Investigations Act 1996.
Med Sci Law 1997 Apr;37(2):107–13 (5 ref.)
Disclosure: the defence perspective. Edwards A, et al.
Med Sci Law 1997 Apr;37(2):113–9 (23 ref.)
The Law Commission's previous misconduct and hearsay proposals—a practitioner's response. Fulford A.
Med Sci Law 1997 Apr;37(2):133–8 (13 ref.)
Third party disclosure: public interest immunity. Lawson E.
Med Sci Law 1997 Apr;37(2):120–5 (28 ref.)
The Law Commission's work on hearsay and previous misconduct. Silber S. **Med Sci Law** 1997 Apr;37(2):125–33 (35 ref.)
Disclosure practices and cultural narratives: understanding concealment and silence around cancer in Tuscany, Italy. Gordon DR, et al. **Soc Sci Med** 1997 May;44(10):1433–52 (80 ref.)

TRYPANOCIDAL AGENTS

CHEMISTRY

The rational design of trypanocidal drugs: selective inhibition of the glyceraldehyde-3-phosphate dehydrogenase in Trypanosomatidae. Callens M, et al.
Ann Trop Med Parasitol 1995 Dec;89 Suppl 1:23–30 (25 ref.)

PHARMACOLOGY

Drugs affecting trypanosome topoisomerases. Shapiro TA.
Adv Pharmacol 1994;29B:187–200 (40 ref.)

THERAPEUTIC USE

Can a killer be arrested? Kierszenbaum F. **Nat Med** 1996 Oct;2(10):1071–2 (10 ref.)

TRYPANOSOMA

see related
TRYPANOCIDAL AGENTS

DRUG EFFECTS

Drugs affecting trypanosome topoisomerases. Shapiro TA.
Adv Pharmacol 1994;29B:187–200 (40 ref.)

IMMUNOLOGY

Antigenic variation in trypanosomes. Borst P, et al.
Arch Med Res 1996 Autumn;27(3):379–88 (83 ref.)

ULTRASTRUCTURE

Cortical structure and function in euglenoids with reference to trypanosomes, ciliates, and dinoflagellates. Bouck GB, et al. **Int Rev Cytol** 1996;169:267–318 (193 ref.)

TRYPANOSOMA BRUCEI see **TRYPANOSOMA BRUCEI BRUCEI**

TRYPANOSOMA BRUCEI BRUCEI

ENZYMOLOGY

The rational design of trypanocidal drugs: selective inhibition of the glyceraldehyde-3-phosphate dehydrogenase in Trypanosomatidae. Callens M, et al.
Ann Trop Med Parasitol 1995 Dec;89 Suppl 1:23–30 (25 ref.)

GENETICS

Genome research and evolution in trypanosomes. Donelson JE. **Curr Opin Genet Dev** 1996 Dec;6(6):699–703 (39 ref.)
Implications of conserved structural motifs in disparate trypanosome surface proteins. Carrington M, et al.
Mol Biochem Parasitol 1996 Oct 30;81(2):119–26 (27 ref.)
Parasite genome analysis. Genome research in Trypanosoma brucei: chromosome size polymorphism and its relevance to genome mapping and analysis. Melville SE.
Trans R Soc Trop Med Hyg 1997 Mar–Apr;91(2):116–20 (27 ref.)

IMMUNOLOGY

Antigenic variation in trypanosomes: secrets surface slowly. Cross GA. **Bioessays** 1996 Apr;18(4):283–91 (77 ref.)

METABOLISM

Post-transcriptional control of PARP gene expression. Clayton C, et al. **Mol Biochem Parasitol** 1996 Apr;77(1):1–6 (40 ref.)
Glycosyl phosphatidylinositol myristoylation in African trypanosomes. Werbovetz KA, et al.
Mol Biochem Parasitol 1997 Mar;85(1):1–7 (34 ref.)

TRYPANOSOMA BRUCEI GAMBIENSE

[Human African trypanosomiasis] Dumas M, et al. **C R Seances Soc Biol Fil** 1996;190(4):395–408 (46 ref.) (Eng. Abstr.) **(Fre)**

TRYPANOSOMA BRUCEI RHODESIENSE

[Human African trypanosomiasis] Dumas M, et al. **C R Seances Soc Biol Fil** 1996;190(4):395–408 (46 ref.) (Eng. Abstr.) **(Fre)**

TRYPANOSOMA CRUZI

ENZYMOLOGY

Cruzipain, the major cysteine proteinase from the protozoan parasite Trypanosoma cruzi. Cazzulo JJ, et al. **Biol Chem** 1997 Jan;378(1):1–10 (73 ref.)

GENETICS

Genome research and evolution in trypanosomes. Donelson JE. **Curr Opin Genet Dev** 1996 Dec;6(6):699–703 (39 ref.)

IMMUNOLOGY

Seropositivity for anti-trypanosoma cruzi antibodies among blood donors of the "Hospital Universitário Regional do Norte do Paraná", Londrina, Brazil. Reiche EM, et al. **Rev Inst Med Trop Sao Paulo** 1996 May–Jun;38(3):233–40 (45 ref.)

ISOLATION & PURIFICATION

Detection of Trypanosoma cruzi with the polymerase chain reaction and in situ hybridization in infected murine cardiac tissue. Lane JE, et al. **Am J Trop Med Hyg** 1997 Jun; 56(6):588–95 (36 ref.)

PCR and sero-diagnosis of chronic Chagas' disease. Biotechnological advances. Gomes YM. **Appl Biochem Biotechnol** 1997 May;66(2):107–19 (44 ref.)

PHYSIOLOGY

Members of the Tc-85 protein family from Trypanosoma cruzi are adhesion proteins. Alves MJ. **Braz J Med Biol Res** 1996 Jul;29(7):831–3 (32 ref.)

TRYPANOSOMA GAMBIENSE see **TRYPANOSOMA BRUCEI GAMBIENSE**

TRYPANOSOMA RHODESIENSE see **TRYPANOSOMA BRUCEI RHODESIENSE**

TRYPANOSOMA VARIANT SURFACE COAT GLYCOPROTEINS see **VARIANT SURFACE GLYCOPROTEINS, TRYPANOSOMA**

TRYPANOSOMIASIS

see related
TRYPANOCIDAL AGENTS

EPIDEMIOLOGY

Sleeping sickness: perspectives in African trypanosomiasis. Mhlanga JD. **Sci Prog** 1996;79 (Pt 3):183–214 (57 ref.)

PREVENTION & CONTROL

New approaches to the integrated control of trypanosomosis. Holmes PH. **Vet Parasitol** 1997 Jul 31;71(2–3):121–35 (38 ref.)

VETERINARY

New approaches to the integrated control of trypanosomosis. Holmes PH. **Vet Parasitol** 1997 Jul 31;71(2–3):121–35 (38 ref.)

TRYPANOSOMIASIS, AFRICAN

PATHOLOGY

Trypanosomiasis. Chimelli L, et al. **Brain Pathol** 1997 Jan; 7(1):599–611 (115 ref.)

PHYSIOPATHOLOGY

[Human African trypanosomiasis] Dumas M, et al. **C R Seances Soc Biol Fil** 1996;190(4):395–408 (46 ref.) (Eng. Abstr.) **(Fre)**

TRYPANOSOMIASIS, BOVINE

PREVENTION & CONTROL

Ecological implications of control strategies: arthropods of domestic and production animals. Petney TN. **Int J Parasitol** 1997 Feb;27(2):155–65 (121 ref.)

TRYPANOSOMIASIS, CARDIOVASCULAR see **CHAGAS CARDIOMYOPATHY**

TRYPANOSOMIASIS, SOUTH AMERICAN see **CHAGAS DISEASE**

TRYPSIN

CHEMISTRY

Trypsin: a case study in the structural determinants of enzyme specificity. Hedstrom L. **Biol Chem** 1996 Jul–Aug; 377(7–8):465–70 (22 ref.)

METABOLISM

Trypsin: a case study in the structural determinants of enzyme specificity. Hedstrom L. **Biol Chem** 1996 Jul–Aug; 377(7–8):465–70 (22 ref.)

TRYPSIN INHIBITOR, ALPHA 1-ANTITRYPSIN see **ALPHA 1-ANTITRYPSIN**

TRYPSIN INHIBITOR, BASIC, PANCREATIC see **APROTININ**

TRYPSIN INHIBITOR, KUNITZ, PANCREATIC see **APROTININ**

TRYPTAMINE RECEPTORS see **RECEPTORS, SEROTONIN**

TRYPTAMINES

see related
RECEPTORS, SEROTONIN

TRYPTOPHAN

see related
EOSINOPHILIA-MYALGIA SYNDROME

Tryptophan and niacin nutrition--is there a problem? Bender DA. **Adv Exp Med Biol** 1996;398:565–9 (25 ref.)

The roles of tryptophan residues in the structure, function, and folding of the gramicidin transmembrane ion channel. Wallace BA. **Adv Exp Med Biol** 1996;398:607–14 (29 ref.)

ADVERSE EFFECTS

Pathogenesis of L-tryptophan eosinophilia myalgia syndrome. Sternberg EM. **Adv Exp Med Biol** 1996; 398:325–30 (25 ref.)

Animal models of the eosinophilia-myalgia syndrome. Clauw DJ. **J Rheumatol Suppl** 1996 Oct;46:93–7; discussion 92, 97–8 (20 ref.)

Tryptophan produced by Showa Denko and epidemic eosinophilia-myalgia syndrome [comment] Kilbourne EM, et al. **J Rheumatol Suppl** 1996 Oct;46:81–8; discussion 89–91 (22 ref.) Comment on: J Rheumatol Suppl 1996 Oct;46 :44–58; discussion 58–9. Comment on: J Rheumatol Suppl 1996 Oct;46 :60–72.

ANALOGS & DERIVATIVES

Animal models of the eosinophilia-myalgia syndrome. Clauw DJ. **J Rheumatol Suppl** 1996 Oct;46:93–7; discussion 92, 97–8 (20 ref.)

Time-resolved fluorescence of constrained tryptophan derivatives: implications for protein fluorescence. McLaughlin ML, et al. **Methods Enzymol** 1997;278:190–202 (22 ref.)

ANALYSIS

Advances in tryptophan analysis in peptides and proteins. Molnár-Perl I. **Adv Exp Med Biol** 1996;398:635–48 (88 ref.)

Time-resolved room temperature tryptophan phosphorescence in proteins. Schauerte JA, et al. **Methods Enzymol** 1997;278:49–71 (89 ref.)

CHEMISTRY

1La and 1Lb transitions of tryptophan: applications of theory and experimental observations to fluorescence of proteins. Callis PR. **Methods Enzymol** 1997;278:113–50 (86 ref.)

Enhancement of protein spectra with tryptophan analogs: fluorescence spectroscopy of protein-protein and protein-nucleic acid interactions. Ross JB, et al. **Methods Enzymol** 1997;278:151–90 (110 ref.)

[Chemistry of the cyclic tautomer of tryptophans] Hino T. **Yakugaku Zasshi** 1996 Jul;116(7):566–86 (39 ref.) (Eng. Abstr.) **(Jpn)**

DEFICIENCY

The effect of low brain serotonin on mood and aggression in humans. Influence of baseline mood and genetic factors. Young SN, et al. **Adv Exp Med Biol** 1996;398:45–50 (24 ref.)

[The tryptophan depletion test. Basic principles and clinical relevance] Neumeister A, et al. **Nervenarzt** 1997 Jul; 68(7):556–62 (45 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Tryptophan metabolism and disposition in relation to alcohol and alcoholism. Badawy AA. **Adv Exp Med Biol** 1996; 398:75–82 (28 ref.)

Neuropsychiatric implications of brain tryptophan perturbations appearing in hepatic encephalopathy. Bengtsson F, et al. **Adv Exp Med Biol** 1996;398:387–95 (73 ref.)

Brain tryptophan. Normal and disturbed control. Curzon G. **Adv Exp Med Biol** 1996;398:27–34 (84 ref.)

Tryptophan and secondary anorexia. Fanelli FR, et al. **Adv Exp Med Biol** 1996;398:545–9 (19 ref.)

Utilization of superoxide anion by indoleamine oxygenase-catalyzed tryptophan and indoleamine oxidation. Hayaishi O. **Adv Exp Med Biol** 1996;398:285–9 (4 ref.)

Antioxidant properties of indole-3-pyruvic acid. Politi V, et al. **Adv Exp Med Biol** 1996;398:291–8 (38 ref.)

Pathogenesis of L-tryptophan eosinophilia myalgia syndrome. Sternberg EM. **Adv Exp Med Biol** 1996; 398:325–30 (25 ref.)

Endogenous kynurenine derivatives and pain. Weil-Fugazza J. **Adv Exp Med Biol** 1996;398:83–7 (27 ref.)

Tryptophan availability and the susceptibility to stress in multiple sclerosis: a hypothesis. Sandyk R. **Int J Neurosci** 1996 Jul;86(1–2):47–53 (85 ref.)

The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Heninger GR, et al. **Pharmacopsychiatry** 1996 Jan;29(1):2–11 (53 ref.)

PHARMACOLOGY

Effects of tryptophan related compounds on nuclear regulatory control. Possible role in the eosinophilia-myalgia syndrome. Sidransky H, et al. **Adv Exp Med Biol** 1996;398:343–50 (47 ref.)

PHYSIOLOGY

Metabolism and biology of tryptophan. Some clinical implications. Brown RR. **Adv Exp Med Biol** 1996;398:15–25 (60 ref.)

POISONING

The eosinophilia-myalgia syndrome and the toxic oil syndrome. Pursuing parallels. Hertzman PA. **Adv Exp Med Biol** 1996;398:339–42 (8 ref.)

TRYPTOPHAN HYDROXYLASE

GENETICS

[Epidemiologic and molecular genetic of suicidal behavior] Abbar M, et al. **Encephale** 1996 Dec;22 Spec No 4:19–24 (31 ref.) (Eng. Abstr.) **(Fre)**

TRYPTOPHAN MONOOXYGENASE see **TRYPTOPHAN HYDROXYLASE**

TRYPTOPHAN OXYGENASE

BIOSYNTHESIS

Utilization of superoxide anion by indoleamine oxygenase-catalyzed tryptophan and indoleamine oxidation. Hayaishi O. **Adv Exp Med Biol** 1996;398:285–9 (4 ref.)

TRYPTOPHAN PYRROLASE see **TRYPTOPHAN OXYGENASE**

TRYPTOPHAN SYNTHASE

CHEMISTRY

Protein architecture, dynamics and allostery in tryptophan synthase channeling. Pan P, et al. **Trends Biochem Sci** 1997 Jan;22(1):22–7 (25 ref.)

TRYPTOPHAN SYNTHETASE see **TRYPTOPHAN SYNTHASE**

TSETSE FLIES

Predicting the distribution of tsetse flies in West Africa using temporal Fourier processed meteorological satellite data. Rogers DJ, et al. **Ann Trop Med Parasitol** 1996 Jun; 90(3):225–41 (39 ref.)

PHYSIOLOGY

The tsetse (Diptera: Glossinidae) story: implications for mosquitoes. Torr SJ. **J Am Mosq Control Assoc** 1994 Jun; 10(2 Pt 2):258–65 (63 ref.)

TSH see **THYROTROPIN**

TSH, ALPHA SUBUNIT see **GLYCOPROTEIN HORMONES, ALPHA SUBUNIT**

TSH RECEPTORS see **RECEPTORS, THYROTROPIN**

TUBAL EMBRYO TRANSFER see **EMBRYO TRANSFER**

TUBAL LIGATION see **STERILIZATION, TUBAL**

TUBE CECOSTOMY see **CECOSTOMY**

TUBE FEEDING

TUBE FEEDING see **ENTERAL NUTRITION**

TUBE ILEOSTOMY see **ILEOSTOMY**

TUBER CINEREUM

PATHOLOGY

Hypothalamic osteolipoma: a case report. Wittig H, et al. **Gen Diagn Pathol** 1997 Jun;142(5–6):361–4 (30 ref.)

TUBERCULIN TEST

[The interpretation of a negative intradermal reaction to tuberculin in a case of tuberculous lymphadenitis] Tucciarone L, et al. **Minerva Pediatr** 1996 Jan–Feb; 48(1–2):49–53 (10 ref.) (Eng. Abstr.) **(Ita)**

[Skin test for delayed type hypersensitivity] Haida M. **Nippon Rinsho** 1997 Mar;55 Suppl 1:222–5 (6 ref.) **(Jpn)**

ADVERSE EFFECTS

Cellulitis versus positive purified protein derivative? A case report and review of the literature. Popper SE, et al. **Mil Med** 1996 Jul;161(7):436–7 (11 ref.)

STANDARDS

Mantoux (tuberculosis) testing. Evaluation of guidelines for testing in Canadian institutions. Thomas RE. **Can Fam Physician** 1997 May;43:933–8 (40 ref.)

TUBERCULIN-TYPE HYPERSENSITIVITY see **HYPERSENSITIVITY, DELAYED**

TUBERCULOID BACILLUS see **MYCOBACTERIUM, ATYPICAL**

TUBERCULOID INFECTIONS see **MYCOBACTERIUM INFECTIONS, ATYPICAL**

TUBERCULOID LEPROSY see **LEPROSY, TUBERCULOID**

TUBERCULOMA

DRUG THERAPY

Multiple intracranial tuberculomas with atypical response to tuberculostatic chemotherapy. Review of the literature and own experience. Hejazi N, et al. **Acta Neurochir (Wien)** 1997;139(3):194–202 (29 ref.)

PATHOLOGY

[Cellular and subcellular morphology of the repair process in pulmonary tuberculosis] Erokhin VV. **Probl Tuberk** 1996;(6):10–4 (10 ref.) (Eng. Abstr.) **(Rus)**

SURGERY

Optochiasmatic tuberculoma—case report and review. Kadioglu HH, et al. **Zentralbl Neurochir** 1996;57(1):30–6 (25 ref.)

TUBERCULOSIS

see related
ANTITUBERCULAR AGENTS
TUBERCULIN TEST

Tuberculosis in the HIV-positive patient. Corbett EL, et al. **Br J Hosp Med** 1996 Sep 4–17;56(5):200–4 (24 ref.)

Unique aspects of tuberculosis in the pediatric population. Correa AG. **Clin Chest Med** 1997 Mar;18(1):89–98 (51 ref.)

The origin and erratic global spread of tuberculosis. How the past explains the present and is the key to the future. Stead WW. **Clin Chest Med** 1997 Mar;18(1):65–77 (60 ref.)

Tuberculosis. An old disease but a new threat to the mother, fetus, and neonate. Starke JR. **Clin Perinatol** 1997 Mar; 24(1):107–27 (101 ref.)

Tuberculosis: a primary care perspective. Maupin K, et al. **Compr Ther** 1996 Nov;22(11):744–9 (9 ref.)

Mycobacterial infections: new threats from old disease. Preheim LC, et al. **Compr Ther** 1997 May;23(5):310–8 (19 ref.)

Co-infection of Toxoplasma gondii with other pathogens: pathogenicity and chemotherapy in animal models. Lacroix C, et al. **Curr Top Microbiol Immunol** 1996;219:223–33 (33 ref.)

Tuberculosis. Part I. McDermott LJ, et al. **Dis Mon** 1997 Mar;43(3):113–80 (172 ref.)

Tuberculosis in children: an update. Inselman LS. **Pediatr Pulmonol** 1996 Feb;21(2):101–20 (147 ref.)

Tuberculosis: the case for vigilance. Ormerod P. **Practitioner** 1997 Jan;241(1570):16, 20–2, 25–6 (6 ref.)

A 1990s perspective of hepatitis C, human immunodeficiency virus, and tuberculosis infections in dialysis patients. Murthy BV, et al. **Semin Nephrol** 1997 Jul;17(4):346–63 (185 ref.)

Tuberculosis in pregnancy. Anderson GD. **Semin Perinatol** 1997 Aug;21(4):328–35 (28 ref.)

[Progresses in tuberculosis in China, 1996] Wang Z. **Chung Hua I Hsueh Tsa Chih** 1996 Dec;76(12):896–7 (0 ref.) **(Chi)**

[Analytical survey of dissertation studies in specialty 14.00.26 "Phthisiatry " approved by the Higher Certifying Committee of Russia in 1995] Khudushina TA. **Probl Tuberk** 1996;(5):55–6 (0 ref.) **(Rus)**

[Phthisiologist's qualification certification by using tests and personal computers] Kopylova IF, et al. **Probl Tuberk** 1997; (2):59–62 (4 ref.) **(Rus)**

[Extrapulmonary tuberculosis in patients without human immunodeficiency virus infection. Review of relevant clinical aspects] Ramos Rincón JM, et al. **Rev Clin Esp** 1996 Jan;196(1):39–48 (179 ref.) **(Spa)**

COMPLICATIONS

Tuberculous pseudoaneurysm of the thoracic aorta. Ohtsuka T, et al. **Ann Thorac Surg** 1996 Dec;62(6):1831–4 (8 ref.)

Recent advances. HIV infection–II. Beiser C. **BMJ** 1997 Feb 22;314(7080):579–83 (56 ref.)

[Tuberculosis and HIV infection: epidemiology (the first of three parts)] Martiñez Vázquez JM, et al. **An Med Interna** 1997 May;14(5):253–6 (41 ref.) **(Spa)**

DIAGNOSIS

Tuberculous brain abscess in a patient with HIV infection: case report and review. Farrar DJ, et al. **Am J Med** 1997 Mar;102(3):297–301 (49 ref.)

Nasal tuberculosis in the 20th century. Butt AA. **Am J Med Sci** 1997 Jun;313(6):332–5 (27 ref.)

Mantoux (tuberculosis) testing. Evaluation of guidelines for testing in Canadian institutions. Thomas RE. **Can Fam Physician** 1997 May;43:933–8 (40 ref.)

Molecular diagnosis of tuberculosis: current clinical validity and future perspectives. Roth A, et al. **Eur Respir J** 1997 Aug;10(8):1877–91 (107 ref.)

Tuberculosis: a strategy to detect and treat new and reactivated infections. Hocking TL, et al. **Geriatrics** 1997 Mar;52(3):52–4, 60–3 (22 ref.)

Critical assessment of gene amplification approaches on the diagnosis of tuberculosis. Forbes BA. **Immunol Invest** 1997 Jan–Feb;26(1–2):105–16 (44 ref.)

Diagnosis of tuberculosis and other diseases caused by mycobacteria. Salfinger M. **Infection** 1997 Jan–Feb; 25(1):60–2 (5 ref.)

Serodiagnosis of tuberculosis. Gupta S, et al. **J Commun Dis** 1995 Dec;27(4):208–14 (41 ref.)

Neuroimaging of central nervous system tuberculosis in HIV-infected patients. Whiteman ML. **Neuroimaging Clin N Am** 1997 May;7(2):199–214 (79 ref.)

The application of molecular techniques to the diagnosis and epidemiology of mycobacterial diseases. Butcher PD, et al. **Soc Appl Bacteriol Symp Ser** 1996;25:53S–71S (140 ref.)

[Modern diagnostic methods for tuberculosis] Krychniak-Soszka A. **Pol Tyg Lek** 1996 Jun; 51(23–26):347–9 (32 ref.) **(Pol)**

[New microbiological Techniques in diagnosis of tuberculosis] Golyshevskaia VI, et al. **Probl Tuberk** 1996; (6):22–5 (17 ref.) (Eng. Abstr.) **(Rus)**

[Tuberculosis diagnosis] Caminero Luna JA, et al. **Arch Bronconeumol** 1996 Feb;32(2):85–99 (71 ref.) **(Spa)**

DRUG THERAPY

Current issues in the pathogenesis and management of HIV-related tuberculosis. Daley CL. **AIDS Clin Rev** 1997–98;:289–321 (96 ref.)

The value of in vitro drug activity and pharmacokinetics in predicting the effectiveness of antimycobacterial therapy: a critical review. Burman WJ. **Am J Med Sci** 1997 Jun; 313(6):355–63 (100 ref.)

Corticosteroids in tuberculosis. Cisneros JR, et al. **Ann Pharmacother** 1996 Nov;30(11):1298–303 (25 ref.)

Adherence to therapy in tuberculosis. Cohen FL. **Annu Rev Nurs Res** 1997;15:153–84 (80 ref.)

Management guidelines for M. tuberculosis in pregnancy. Casper GR, et al. **Aust N Z J Obstet Gynaecol** 1995 Nov; 35(4):401–5 (22 ref.)

Mantoux (tuberculosis) testing. Evaluation of guidelines for testing in Canadian institutions. Thomas RE. **Can Fam Physician** 1997 May;43:933–8 (40 ref.)

Supervised therapy in San Francisco. Schecter GF. **Clin Chest Med** 1997 Mar;18(1):165–8 (10 ref.)

Universal directly observed therapy. A treatment strategy for tuberculosis. Weis SE. **Clin Chest Med** 1997 Mar; 18(1):155–63 (11 ref.)

Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status. Durand F, et al. **Drug Saf** 1996 Dec;15(6):394–405 (62 ref.)

Future directions in the development of new antitubercular drugs. Where do we go from here? Yew WW, et al. **Drugs Aging** 1997 Jun;10(6):405–10 (66 ref.)

Tuberculosis: a strategy to detect and treat new and reactivated infections. Hocking TL, et al. **Geriatrics** 1997 Mar;52(3):52–4, 60–3 (22 ref.)

Pneumonia and tuberculosis in pregnancy. Riley L. **Infect Dis Clin North Am** 1997 Mar;11(1):119–33 (64 ref.)

The maternal and fetal effects of tuberculosis therapy. Brost BC, et al. **Obstet Gynecol Clin North Am** 1997 Sep; 24(3):659–73 (80 ref.)

Tuberculosis in Africa: clinical presentation and management. Harries AD. **Pharmacol Ther** 1997;73(1):1–50 (455 ref.)

[Tuberculosis. Current therapeutics] Tattevin P, et al. **Presse Med** 1996 Dec 14;25(39):1909–15 (31 ref.) (Eng. Abstr.) **(Fre)**

[Treatment and retreatment of tuberculosis] Vidal R, et al. **Arch Bronconeumol** 1996 Nov;32(9):463–74 (60 ref.) **(Spa)**

ENZYMOLOGY

[Prospects for determining the activity of adenosine deaminase in biological fluids in tuberculosis] Titarenko OT, et al. **Probl Tuberk** 1996;(5):52–4 (42 ref.) **(Rus)**

EPIDEMIOLOGY

Current issues in the pathogenesis and management of HIV-related tuberculosis. Daley CL. **AIDS Clin Rev** 1997–98;:289–321 (96 ref.)

Nasal tuberculosis in the 20th century. Butt AA. **Am J Med Sci** 1997 Jun;313(6):332–5 (27 ref.)

Migration: public health issues (polio, hepatitis A, hepatitis B, tuberculosis, diphtheria). Schwanig M. **Biologicals** 1997 Jun;25(2):187–93 (16 ref.)

Molecular diagnosis, detection of drug resistance and epidemiology of tuberculosis. Drobniewski FA, et al. **Br J Hosp Med** 1996 Sep 4–17;56(5):204–8 (22 ref.)

Overseas screening for tuberculosis in immigrants and refugees to the United States: current status. Binkin NJ, et al. **Clin Infect Dis** 1996 Dec;23(6):1226–32 (21 ref.)

Tuberculosis—the continuing scourge of India. Prabhakar R. **Indian J Med Res** 1996 Jan;103:19–25 (20 ref.)

Tuberculosis in a health care setting. Malinin T. **Instr Course Lect** 1994;43:551–7 (36 ref.)

Resurgence of tuberculosis: the perspective a dozen years later. Kamholz SL. **J Assoc Acad Minor Phys** 1996; 7(3):83–6 (29 ref.)

The rising incidence of tuberculosis. Millard FJ. **J R Soc Med** 1996 Sep;89(9):497–500 (42 ref.)

Tuberculosis—the global challenge [editorial] Ebrahim GJ. **J Trop Pediatr** 1996 Aug;42(4):190–1 (17 ref.)

Tuberculosis in Africa: clinical presentation and management. Harries AD. **Pharmacol Ther** 1997;73(1):1–50 (455 ref.)

The application of molecular techniques to the diagnosis and epidemiology of mycobacterial diseases. Butcher PD, et al. **Soc Appl Bacteriol Symp Ser** 1996;25:53S–71S (140 ref.)

The resurgence of tuberculosis. Parry C, et al. **Soc Appl Bacteriol Symp Ser** 1996;25:23S–26S (30 ref.)

Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Aguado JM, et al. **Transplantation** 1997 May 15; 63(9):1278–86 (22 ref.)

Women and tuberculosis. Connolly M, et al. **World Health Stat Q** 1996;49(2):115–9 (41 ref.)

Surgery of tuberculosis: state of the art—introduction. Perelman MI. **World J Surg** 1997 Jun;21(5):455–6 (8 ref.)

[Tuberculosis and the HIV pandemic. Risk of nosocomial tuberculosis infection] Pedersen C, et al. **Ugeskr Laeger** 1997 Feb 24;159(9):1233–8 (40 ref.) (Eng. Abstr.) **(Dan)**

[The new face of tuberculosis—update for the practitioner (see comments)] Horn B. **Schweiz Rundsch Med Prax** 1996 Oct 29;85(44):1398–403 (27 ref.) (Eng. Abstr.) Comment in: Schweiz Rundsch Med Prax 1997 Jan 28;86(5):175. **(Ger)**

[BCG vaccination] Hutás I. **Orv Hetil** 1996 Mar 24; 137(12):619–22 (31 ref.) (Eng. Abstr.) **(Hun)**

[New findings in the field of pediatric tuberculosis] Castello D, et al. **Pediatr Med Chir** 1996 Jul–Aug;18(4):329–32 (17 ref.) (Eng. Abstr.) **(Ita)**

[Significance of expedition studies in epidemiology of tuberculosis in Iakutia (to 70 anniversary of the first expedition)] Anisimov IV. **Probl Tuberk** 1997;(2):8–9 (5 ref.) (Eng. Abstr.) **(Rus)**

[Epidemiologic situation of tuberculosis in the Republic of Kazakhstan] Dzhunusbekov AD, et al. **Probl Tuberk** 1997; (1):25–7 (0 ref.) (Eng. Abstr.) **(Rus)**

[Current trends in the epidemiology of tuberculosis and ways of reducing a reservoir of infection] Khomenko AG. **Probl Tuberk** 1997;(1):4–6 (0 ref.) **(Rus)**

[Time course of changes in tuberculosis epidemiological parameters in Iakutia over 12 years (1983–1994)] Kondrat'eva MN, et al. **Probl Tuberk** 1997;(2):4–5 (2 ref.) (Eng. Abstr.) **(Rus)**

[The epidemiologic situation of tuberculosis in West Siberia in 1991–1995] Krasnov VA, et al. **Probl Tuberk** 1997; (1):13–4 (0 ref.) (Eng. Abstr.) **(Rus)**

[The impact of migratory processes on the epidemiology of tuberculosis in the Stavropol' territory] Odinets VS, et al. **Probl Tuberk** 1997;(1):33–4 (0 ref.) (Eng. Abstr.) **(Rus)**

[Trends in tuberculosis epidemiology in the Ivanovo Region and its stabilizing measures] Punga VV, et al. **Probl Tuberk** 1997;(1):8–10 (0 ref.) (Eng. Abstr.) **(Rus)**

[Epidemiology of tuberculosis in the Amur region] Rozenfel'd NI. **Probl Tuberk** 1997;(1):31–3 (0 ref.) (Eng. Abstr.) **(Rus)**

[Epidemiologic situation of tuberculosis in Armenia under the present condition] Safrian MD, et al. **Probl Tuberk** 1997; (1):22–5 (7 ref.) (Eng. Abstr.) **(Rus)**

[The tuberculosis situation and urgent task to optimize antitubercular care for the population in the Ural and Volgo–Viatka regions] Sokolov VA, et al. **Probl Tuberk** 1997;(1):15–7 (2 ref.) (Eng. Abstr.) **(Rus)**

[The first results of the international project "Tuberculosis in the Tomsk region"] Strelis AK, et al. **Probl Tuberk** 1997; (1):10–2 (0 ref.) **(Rus)**

[The epidemiology of tuberculosis and organization of its control in Uzbekistan] Ubaidullaev AM, et al.

Probl Tuberk 1997;(1):20–2 (11 ref.) (Eng. Abstr.) **(Rus)**
[The impact of ecological pressing on tuberculosis and nonspecific lung diseases in the Astrakhan' region] Vinnik LA. **Probl Tuberk** 1997;(1):27–30 (6 ref.) (Eng. Abstr.) **(Rus)**
[Tuberculosis of the otorhinolaryngologic region: laryngeal and extra-laryngeal forms] Fortún J, et al. **Enferm Infecc Microbiol Clin** 1996 Jun-Jul;14(6):352–6 (41 ref.) (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Tuberculosis and immigration. Ormerod P. **Br J Hosp Med** 1996 Sep 4–17;56(5):209–12 (20 ref.)

ETIOLOGY

Evidence for a superantigen in the pathogenesis of tuberculosis. Ohmen JD, et al. **Springer Semin Immunopathol** 1996;17(4):375–84 (45 ref.)
Gender differentials in tuberculosis: the role of socio-economic and cultural factors. Hudelson P. **Tuber Lung Dis** 1996 Oct;77(5):391–400 (51 ref.)
[AIDS and tuberculosis] Tanaka K. **Nippon Naika Gakkai Zasshi** 1996 Jan 10;85(1):129–34 (8 ref.) **(Jpn)**
[Tuberculosis and protozoan infections in patients undergoing transplantation] Aguado JM, et al. **Enferm Infecc Microbiol Clin** 1997 May;15 Suppl 2:57–68 (171 ref.) **(Spa)**

GENETICS

Significance of the antimicrobial resistance gene, Nramp1, in resistance to virulent Mycobacterium tuberculosis infection. North RJ, et al. **Res Immunol** 1996 Oct–Dec; 147(8–9):493–9 (13 ref.)

IMMUNOLOGY

In vitro cellular and cytokine responses to mycobacterial antigens: application to diagnosis of tuberculosis infection and assessment of response to mycobacterial vaccines. Lein AD, et al. **Am J Med Sci** 1997 Jun;313(6):364–71 (66 ref.)
Immunobiology of childhood tuberculosis: a window on the ontogeny of cellular immunity. Smith S, et al. **J Pediatr** 1997 Jul;131(1 Pt 1):16–26 (132 ref.)
The role of cytokines in the immune response to tuberculosis. Kaplan G, et al. **Res Immunol** 1996 Oct–Dec; 147(8–9):565–72 (62 ref.)
Significance of the antimicrobial resistance gene, Nramp1, in resistance to virulent Mycobacterium tuberculosis infection. North RJ, et al. **Res Immunol** 1996 Oct–Dec; 147(8–9):493–9 (13 ref.)
Human gamma delta T cells in tuberculosis. Poquet Y, et al. **Res Immunol** 1996 Oct–Dec;147(8–9):542–9 (52 ref.)
The cellular and molecular basis of immunity against mycobacterial diseases. Colston MJ. **Soc Appl Bacteriol Symp Ser** 1996;25:33S–39S (56 ref.)
Evidence for a superantigen in the pathogenesis of tuberculosis. Ohmen JD, et al. **Springer Semin Immunopathol** 1996;17(4):375–84 (45 ref.)
[Attempts to elucidate reasons why mycobacterial infections are intractable, by using an experimental mouse infection model] Tomioka H. **Nihon Hansenbyo Gakkai Zasshi** 1996 Nov;65(3):155–65 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Progress and prospects of tuberculosis immunology and immunogenetics] Litvinov VI, et al. **Probl Tuberk** 1996; (6):14–8 (41 ref.) (Eng. Abstr.) **(Rus)**
[Impact of low-energy laser irradiation on the immunological nonspecific responsiveness in patients with tuberculosis] Litvinov VI, et al. **Probl Tuberk** 1997;(4):58–60 (75 ref.) **(Rus)**

MICROBIOLOGY

Molecular diagnosis, detection of drug resistance and epidemiology of tuberculosis. Drobniewski FA, et al. **Br J Hosp Med** 1996 Sep 4–17;56(5):204–8 (22 ref.)
Critical assessment of gene amplification approaches on the diagnosis of tuberculosis. Forbes BA. **Immunol Invest** 1997 Jan–Feb;26(1–2):105–16 (44 ref.)
The bovine tuberculosis cycle—an African perspective. Daborn CJ, et al. **Soc Appl Bacteriol Symp Ser** 1996; 25:27S–32S (23 ref.)
Mycobacterial virulence factors. Gordon S, et al. **Soc Appl Bacteriol Symp Ser** 1996;25:10S–22S (120 ref.)

PATHOLOGY

Primary nasopharyngeal tuberculosis: case report and review of the literature. al Serhani AM, et al. **Ear Nose Throat J** 1997 Jan;76(1):41–2 (8 ref.)
Correlation of granuloma structure with clinical outcome defines two types of idiopathic disseminated BCG infection. Emile JF, et al. **J Pathol** 1997 Jan;181(1):25–30 (35 ref.)

PREVENTION & CONTROL

Use of the bacille Calmette-Guérin vaccination for the prevention of tuberculosis: renewed interest in an old vaccine. Cohn DL. **Am J Med Sci** 1997 Jun;313(6):372–6 (56 ref.)
Tuberculosis and immigration. Ormerod P. **Br J Hosp Med** 1996 Sep 4–17;56(5):209–12 (20 ref.)
Tuberculosis control in health care. Pugliese G, et al. **Infect Control Hosp Epidemiol** 1996 Dec;17(12):819–27 (25 ref.)
Fighting tuberculosis in the 1990s: how effective is planning in policy making? Dievler A. **J Public Health Policy** 1997; 18(2):167–87 (90 ref.)
Tuberculosis—the global challenge [editorial] Ebrahim GJ. **J Trop Pediatr** 1996 Aug;42(4):190–1 (17 ref.)
Involuntary confinement for tuberculosis control: the Jewish view. Rosner F. **Mt Sinai J Med** 1996 Jan;63(1):44–8 (27 ref.)
Managed care and the public health challenge of TB. Halverson PK, et al. **Public Health Rep** 1997 Jan–Feb; 112(1):22–8 (14 ref.)
Host responses and antigens involved in protective immunity to Mycobacterium tuberculosis. Andersen P. **Scand J Immunol** 1997 Feb;45(2):115–31 (222 ref.)
European Commission COST/STD Initiative. Report of the expert panel IX. Vaccines against tuberculosis. Harboe M, et al. **Vaccine** 1996 May;14(7):701–16 (23 ref.)
[Prevention of tuberculosis in immunocompromised patients] Perronne C. **Ann Med Interne (Paris)** 1997;148(3):226–9 (15 ref.) (Eng. Abstr.) **(Fre)**
[Update on the BGC vaccine. Indications for use in Europe and in developing countries] Guerin N, et al. **Med Trop (Mars)** 1996;56(2):173–6 (18 ref.) (Eng. Abstr.) **(Fre)**
[Tuberculosis control in the Kaliningrad region] Gortsev VA, et al. **Probl Tuberk** 1997;(1):30–1 (0 ref.) (Eng. Abstr.) **(Rus)**
[A concept of control of antituberculous measures under new socioeconomic conditions in Russia] Karpov LP. **Probl Tuberk** 1997;(1):6–8 (6 ref.) **(Rus)**
[Trends in tuberculosis epidemiology in the Ivanovo Region and its stabilizing measures] Punga VV, et al. **Probl Tuberk** 1997;(1):8–10 (0 ref.) (Eng. Abstr.) **(Rus)**
[The first results of the international project "Tuberculosis in the Tomsk region"] Strelis AK, et al. **Probl Tuberk** 1997; (1):10–2 (0 ref.) **(Rus)**
[The epidemiology of tuberculosis and organization of its control in Uzbekistan] Ubaidullaev AM, et al. **Probl Tuberk** 1997;(1):20–2 (11 ref.) (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

[Imaging diagnosis in the study of pulmonary and extrapulmonary tuberculosis] Gualdi GF, et al. **Clin Ter** 1996 Oct;147(10):515–27 (17 ref.) (Eng. Abstr.) **(Ita)**

RADIOTHERAPY

[Impact of low-energy laser irradiation on the immunological nonspecific responsiveness in patients with tuberculosis] Litvinov VI, et al. **Probl Tuberk** 1997;(4):58–60 (75 ref.) **(Rus)**

SURGERY

Surgery for tuberculosis before and after human immunodeficiency virus infection: a tropical perspective. Watters DA. **Br J Surg** 1997 Jan;84(1):8–14 (94 ref.)
Tuberculosis of the ear and a Nepalese experience [letter] Friedman I, et al. **J Laryngol Otol** 1997 Apr;111(4):408 (9 ref.)
Surgery of tuberculosis: state of the art—introduction. Perelman MI. **World J Surg** 1997 Jun;21(5):455–6 (8 ref.)

THERAPY

Gender differentials in tuberculosis: the role of socio-economic and cultural factors. Hudelson P. **Tuber Lung Dis** 1996 Oct;77(5):391–400 (51 ref.)
[The tuberculosis situation and urgent task to optimize antitubercular care for the population in the Ural and Volgo-Viatka regions] Sokolov VA, et al. **Probl Tuberk** 1997;(1):15–7 (2 ref.) (Eng. Abstr.) **(Rus)**

TRANSMISSION

How contagious is tuberculosis? Sepkowitz KA. **Clin Infect Dis** 1996 Nov;23(5):954–62 (96 ref.)
The viability of Mycobacterium tuberculosis in formalin-fixed pulmonary autopsy tissue: review of the literature and brief report. Kappel TJ, et al. **Hum Pathol** 1996 Dec;27(12):1361–4 (34 ref.)
Prevention of nosocomial transmission of Mycobacterium tuberculosis. Cookson ST, et al. **Infect Dis Clin North Am** 1997 Jun;11(2):385–409 (119 ref.)
Hazards to the orthopaedic trauma surgeon: occupational exposure to tuberculosis. Risk reduction, testing, and treatment (a review article). Esterhai JL Jr, et al. **J Orthop Trauma** 1996;10(5):366–70 (24 ref.)

VETERINARY

Tuberculosis in free-ranging, semi free-ranging and captive cervids. Hunter DL. **Rev Sci Tech** 1996 Mar;15(1):171–81 (17 ref.)
Vaccination of the badger (Meles meles) against Mycobacterium bovis. Hughes MS, et al. **Vet Microbiol** 1996 Aug;51(3–4):363–79 (115 ref.)

TUBERCULOSIS, AVIAN

MICROBIOLOGY

Mycobacterial virulence factors. Gordon S, et al. **Soc Appl Bacteriol Symp Ser** 1996;25:10S–22S (120 ref.)

TUBERCULOSIS, BOVINE

ETIOLOGY

Mycobacterial sepsis following intravesical instillation of bacillus Calmette-Guérin. Garyfallou GT. **Acad Emerg Med** 1996 Feb;3(2):157–60 (12 ref.)

MICROBIOLOGY

Mycobacterial virulence factors. Gordon S, et al. **Soc Appl Bacteriol Symp Ser** 1996;25:10S–22S (120 ref.)

PREVENTION & CONTROL

Vaccination of the badger (Meles meles) against Mycobacterium bovis. Hughes MS, et al. **Vet Microbiol** 1996 Aug;51(3–4):363–79 (115 ref.)

TRANSMISSION

The bovine tuberculosis cycle—an African perspective. Daborn CJ, et al. **Soc Appl Bacteriol Symp Ser** 1996; 25:27S–32S (23 ref.)

TUBERCULOSIS, CARDIOVASCULAR

[Bacterial myocarditis] Hiramitsu S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):102–3 (9 ref.) **(Jpn)**
[Tuberculous aortitis] Yasuda K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):335–7 (16 ref.) **(Jpn)**

COMPLICATIONS

Tuberculous pseudoaneurysm of the descending thoracic aorta: a case report and literature review of surgically treated cases. Ikezawa T, et al. **J Vasc Surg** 1996 Oct; 24(4):693–7 (32 ref.)

TUBERCULOSIS, CUTANEOUS

COMPLICATIONS

Cutaneous miliary tuberculosis in the AIDS era: case report and review. Libraty DH, et al. **Clin Infect Dis** 1996 Oct; 23(4):706–10 (28 ref.)
Concomitant occurrence of leprosy, cutaneous tuberculosis and pulmonary tuberculosis—a case report [letter] Inamadar AC, et al. **Lepr Rev** 1994 Sep;65(3):282–4 (8 ref.)

DIAGNOSIS

Cutaneous miliary tuberculosis in the AIDS era: case report and review. Libraty DH, et al. **Clin Infect Dis** 1996 Oct; 23(4):706–10 (28 ref.)
[Diagnosis and therapy of skin tuberculosis] Weilbach C, et al. **Dtsch Med Wochenschr** 1996 Oct 4;121(40):1231–5 (29 ref.) **(Ger)**
[Skin infections caused by Mycobacterium gordonae. Case report and review of the literature] Weyers W, et al. **Hautarzt** 1996 Oct;47(10):771–5 (48 ref.) (Eng. Abstr.) **(Ger)**
[The Calmette-Guérin bacillus (BCG). An agent to consider in pediatric infection] Marcelino F, et al. **Acta Med Port** 1996 Oct–Dec;9(10–12):397–400 (12 ref.) (Eng. Abstr.) **(Por)**

DRUG THERAPY

[Diagnosis and therapy of skin tuberculosis] Weilbach C, et al. **Dtsch Med Wochenschr** 1996 Oct 4;121(40):1231–5 (29 ref.) **(Ger)**

PATHOLOGY

Simultaneous occurrence of papulonecrotic tuberculide and erythema induratum and the identification of Mycobacterium tuberculosis DNA by polymerase chain reaction. Chuang YH, et al. **Br J Dermatol** 1997 Aug; 137(2):276–81 (33 ref.)
Skin infection caused by Mycobacterium avium. Ichiki Y, et al. **Br J Dermatol** 1997 Feb;136(2):260–3 (19 ref.)

TUBERCULOSIS, DRUG-RESISTANT see **TUBERCULOSIS, MULTIDRUG-RESISTANT**

TUBERCULOSIS, FEMALE GENITAL

Overview of tuberculosis of the female genital tract. Chowdhury NN. **J Indian Med Assoc** 1996 Sep;94(9):345–6, 361 (10 ref.)

TUBERCULOSIS, GASTROINTESTINAL

[Gastrointestinal tuberculosis] Miagkova LP. **Klin Med (Mosk)** 1997;75(8):9–12 (15 ref.) **(Rus)**

COMPLICATIONS

Gastric tuberculosis presenting with hematemesis. Rathnaraj S, et al. **Indian J Gastroenterol** 1997 Jul;16(3):110–1 (3 ref.)
Coexistent tuberculosis and carcinoma of the colon. Sheikh

TUBERCULOSIS, GASTROINTESTINAL

MY, et al. **JPMA J Pak Med Assoc** 1995 Nov;45(11):305–6 (10 ref.)
[Complicated intestinal tuberculosis of the mesenteric root] Wagner JB, et al. **Dtsch Med Wochenschr** 1997 May 16; 122(20):643–7 (25 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Anal and perianal tuberculosis: a report of three cases in 10 years. Chung CC, et al. **J R Coll Surg Edinb** 1997 Jun; 42(3):189–90 (6 ref.)
Abdominal tuberculosis. Aston NO. **World J Surg** 1997 Jun; 21(5):492–9 (122 ref.)

THERAPY

Abdominal tuberculosis. Aston NO. **World J Surg** 1997 Jun; 21(5):492–9 (122 ref.)

TUBERCULOSIS, HEPATIC

DIAGNOSIS

[A diagnostically difficult case of a combination of extrapulmonary tuberculosis with a rheumatic heart defect] Sarkisova ND, et al. **Ter Arkh** 1996;68(4):24–7 (9 ref.) **(Rus)**

TUBERCULOSIS, LARYNGEAL

EPIDEMIOLOGY

[Tuberculosis of the otorhinolaryngologic region: laryngeal and extra-laryngeal forms] Fortún J, et al. **Enferm Infecc Microbiol Clin** 1996 Jun–Jul;14(6):352–6 (41 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Hospital infection control practices for tuberculosis. Davis YM, et al. **Clin Chest Med** 1997 Mar;18(1):19–33 (43 ref.)

TUBERCULOSIS, LYMPH NODE

Tuberculous lymphadenitis in the adult. Sewell CL, et al. **J Ky Med Assoc** 1997 May;95(5):197–9 (13 ref.)

DIAGNOSIS

Mycobacterial cervical lymphadenitis: a review. Fitzpatrick EL, et al. **J La State Med Soc** 1996 Nov;148(11):451–4 (12 ref.)
[Current aspects of lymph node tuberculosis of the neck] Lenci G, et al. **Pneumologie** 1996 Jul;50(7):462–8 (74 ref.) (Eng. Abstr.) **(Ger)**
[The interpretation of a negative intradermal reaction to tuberculin in a case of tuberculous lymphadenitis] Tucciarone L, et al. **Minerva Pediatr** 1996 Jan–Feb; 48(1–2):49–53 (10 ref.) (Eng. Abstr.) **(Ita)**

EPIDEMIOLOGY

[Tuberculosis of peripheral lymph nodes in Iakutia] Makarova UE. **Probl Tuberk** 1997;(2):28–30 (11 ref.) **(Rus)**

TUBERCULOSIS, MALE GENITAL

DIAGNOSIS

Tuberculosis of the prostate: MR appearance. Wang JH, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):639–40 (6 ref.)

PATHOLOGY

[Advanced tubercular disease of urogenital tract] Pereira Arias JG, et al. **Arch Esp Urol** 1997 May;50(4):396–9 (11 ref.) (Eng. Abstr.) **(Spa)**

TUBERCULOSIS, MENINGEAL

[Progress on diagnosis and therapy of fungal and tuberculous meningitis] Kuroiwa Y, et al. **Nippon Naika Gakkai Zasshi** 1996 May 10;85(5):705–10 (6 ref.) **(Jpn)**

COMPLICATIONS

[Fulminant hepatitis during the therapy for tuberculous meningitis] Garavelli PL. **Recenti Prog Med** 1996 Dec; 87(12):597 (8 ref.) **(Ita)**

DRUG THERAPY

Multiple intracranial tuberculomas with atypical response to tuberculostatic chemotherapy. Review of the literature and own experience. Hejazi N, et al. **Acta Neurochir (Wien)** 1997;139(3):194–202 (29 ref.)

ETIOLOGY

Tuberculosis in bone marrow transplant recipients: report of two cases and review of the literature. Martino R, et al. **Bone Marrow Transplant** 1996 Oct;18(4):809–12 (19 ref.)

TUBERCULOSIS, MILIARY

COMPLICATIONS

Cutaneous miliary tuberculosis in the AIDS era: case report and review. Libraty DH, et al. **Clin Infect Dis** 1996 Oct; 23(4):706–10 (28 ref.)
Acute respiratory distress syndrome (ARDS) in miliary tuberculosis: a twelve year experience. Mohan A, et al. **Indian J Chest Dis Allied Sci** 1996 Jul–Sep;38(3):157–62 (17 ref.)

DIAGNOSIS

Cutaneous miliary tuberculosis in the AIDS era: case report and review. Libraty DH, et al. **Clin Infect Dis** 1996 Oct; 23(4):706–10 (28 ref.)
[Tuberculosis: a forgotten challenge] Martins P, et al. **Acta Med Port** 1997 Jun–Jul;10(6–7):517–21 (18 ref.) (Eng. Abstr.) **(Por)**

TUBERCULOSIS, MULTIDRUG-RESISTANT

Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and Lung Disease. Cohn DL, et al. **Clin Infect Dis** 1997 Jan; 24 Suppl 1:S121–30 (97 ref.)
Tuberculosis. Part I. McDermott LJ, et al. **Dis Mon** 1997 Mar;43(3):113–80 (172 ref.)

DIAGNOSIS

Multidrug-resistant tuberculosis in children: two cases and a review of the literature. Schluger NW, et al. **Pediatr Pulmonol** 1996 Feb;21(2):138–42 (28 ref.)

DRUG THERAPY

Multiple intracranial tuberculomas with atypical response to tuberculostatic chemotherapy. Review of the literature and own experience. Hejazi N, et al. **Acta Neurochir (Wien)** 1997;139(3):194–202 (29 ref.)
Multidrug resistance in the world: the present situation. Reichman LB. **Chemotherapy** 1996;42 Suppl 3:2–9; discussion 30–3 (18 ref.)
Treatment of multidrug-resistant tuberculosis in China. Zhang LX. **Chemotherapy** 1996;42 Suppl 3:16–9; discussion 30–3 (8 ref.)
Tuberculosis. Part II. LoBue PA, et al. **Dis Mon** 1997 Apr; 43(4):181–274 (346 ref.)
Multidrug-resistant tuberculosis in children: two cases and a review of the literature. Schluger NW, et al. **Pediatr Pulmonol** 1996 Feb;21(2):138–42 (28 ref.)
[The re-emergence of tuberculosis: the endemia of multiple-antibiotic-resistant strains (editorial)] Rossi G. **Recenti Prog Med** 1996 Oct;87(10):487–8 (16 ref.) **(Ita)**

EPIDEMIOLOGY

Treatment of multidrug-resistant tuberculosis in Thailand. Maranetra KN. **Chemotherapy** 1996;42 Suppl 3:10–5; discussion 30–3 (11 ref.)
Multidrug resistance in the world: the present situation. Reichman LB. **Chemotherapy** 1996;42 Suppl 3:2–9; discussion 30–3 (18 ref.)
Treatment of multidrug-resistant tuberculosis in China. Zhang LX. **Chemotherapy** 1996;42 Suppl 3:16–9; discussion 30–3 (8 ref.)
Epidemiology, control and treatment of multidrug-resistant tuberculosis. Chaulet P, et al. **Drugs** 1996;52 Suppl 2:103–7; discussion 107–8 (17 ref.)
Tuberculosis control: the relevance of classic principles in an era of acquired immunodeficiency syndrome and multidrug resistance. Kaye K, et al. **Epidemiol Rev** 1996; 18(1):52–63 (94 ref.)
Nosocomial multidrug-resistant tuberculosis--global spread of the third epidemic [editorial; comment] Nolan CM. **J Infect Dis** 1997 Sep;176(3):748–51 (45 ref.) Comment on: J Infect Dis 1997 Sep;176(3):637–42.

PREVENTION & CONTROL

Tuberculosis control: the relevance of classic principles in an era of acquired immunodeficiency syndrome and multidrug resistance. Kaye K, et al. **Epidemiol Rev** 1996; 18(1):52–63 (94 ref.)

SURGERY

Surgery in the treatment of multidrug-resistant tuberculosis. Pomerantz M, et al. **Clin Chest Med** 1997 Mar;18(1):123–30 (3 ref.)

THERAPY

Treatment of multidrug-resistant tuberculosis in Thailand. Maranetra KN. **Chemotherapy** 1996;42 Suppl 3:10–5; discussion 30–3 (11 ref.)

TUBERCULOSIS, OCULAR

DIAGNOSIS

[Pseudotumoral tuberculous choroiditis] Stefan C, et al. **Oftalmologia** 1997;41(1):22–5 (9 ref.) (Eng. Abstr.) **(Rum)**

SURGERY

Optochiasmatic tuberculoma--case report and review. Kadioglu HH, et al. **Zentralbl Neurochir** 1996;57(1):30–6 (25 ref.)

TUBERCULOSIS, OSTEOARTICULAR

Rheumatologic manifestations of tuberculosis. Kramer N, et al. **Bull Rheum Dis** 1997 May;46(3):5–8 (13 ref.)
Osteoarticular tuberculosis. Kosinski MA, et al. **Clin Podiatr Med Surg** 1996 Oct;13(4):725–39 (55 ref.)

DIAGNOSIS

Radiologic case study. Tuberculous osteomyelitis and arthritis. Wright T, et al. **Orthopedics** 1996 Aug; 19(8):699–702 (16 ref.)
[MRT in tuberculous gonarthritis in childhood] Staatz G, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Aug;167(2):210–2 (10 ref.) **(Ger)**
[The Calmette-Guérin bacillus (BCG). An agent to consider in pediatric infection] Marcelino F, et al. **Acta Med Port** 1996 Oct–Dec;9(10–12):397–400 (12 ref.) (Eng. Abstr.) **(Por)**

EPIDEMIOLOGY

[Epidemiological aspects of osteoarticular tuberculosis in adults. Retrospective study of 206 cases diagnosed in the Paris area from 1980 to 1994] Pertuiset E, et al. **Presse Med** 1997 Mar 8;26(7):311–5 (16 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Tubercular sternal osteomyelitis and mediastinitis after open heart surgery. Aggarwal B, et al. **Indian Heart J** 1997 May–Jun;49(3):313–4 (4 ref.)

TUBERCULOSIS, PERITONEAL

[Peritoneal tuberculosis] Verspyck E, et al. **Ann Chir** 1997; 51(4):375–8 (14 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Peritoneal tuberculosis. Value of laparoscopy] Kasia JM, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997; 26(4):367–73 (26 ref.) (Eng. Abstr.) **(Fre)**

TUBERCULOSIS, PLEURAL

DIAGNOSIS

Pleural tuberculosis. Ferrer J. **Eur Respir J** 1997 Apr; 10(4):942–7 (60 ref.)

ETIOLOGY

[Tuberculous pleurisy followed by bronchial cancer in a patient with HIV infection] N'Gbesso RD, et al. **Rev Pneumol Clin** 1996;52(6):398–403 (35 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

[Commemorative lecture of receiving Imamura Memorial Prize. Analysis of cellular immunity against tuberculosis in man with special reference to tuberculous pleurisy and cytokines] Shimokata K. **Kekkaku** 1996 Oct;71(10):591–6 (7 ref.) (Eng. Abstr.) **(Jpn)**

TUBERCULOSIS, PULMONARY

see related
PNEUMONECTOMY
Mycobacterial complications of HIV infection. Chin DP, et al. **Clin Chest Med** 1996 Dec;17(4):697–711 (155 ref.)
Tuberculosis: a primary care perspective. Maupin K, et al. **Compr Ther** 1996 Nov;22(11):744–9 (9 ref.)
Tuberculosis update: will good news become bad news? Efferen LS. **Curr Opin Pulm Med** 1997 Mar;3(2):131–8 (66 ref.)
Nontuberculous mycobacteria. Griffith DE. **Curr Opin Pulm Med** 1997 Mar;3(2):139–45 (37 ref.)
Tuberculosis: an update. Abernathy RS. **Pediatr Rev** 1997 Feb;18(2):50–8 (21 ref.)
Intrathoracic tuberculosis in children. Vallejo JG, et al. **Semin Respir Infect** 1996 Sep;11(3):184–95 (45 ref.)
[Recurrence of pulmonary tuberculosis in adults in the areas of the Republic of Sakha (Iakutia)] Ivanov EA, et al. **Probl Tuberk** 1997;(2):5–7 (5 ref.) (Eng. Abstr.) **(Rus)**

BLOOD

[Intravascular activation of hemostatic system and DIC syndrome in pulmonary tuberculosis] Makinskii AI. **Probl Tuberk** 1997;(3):46–8 (8 ref.) (Eng. Abstr.) **(Rus)**

CHEMICALLY INDUCED

Risks of infection or reactivation of tuberculosis associated with chronic corticosteroid therapy. Cline JC, et al.

Ann Pharmacother 1997 Jun;31(6):775–6 (10 ref.)

COMPLICATIONS

Concomitant occurrence of leprosy, cutaneous tuberculosis and pulmonary tuberculosis--a case report [letter] Inamadar AC, et al. **Lepr Rev** 1994 Sep;65(3):282–4 (8 ref.)

[Spontaneous pneumomediastinum and cavitary pulmonary tuberculosis (letter)] Molina M, et al. **Enferm Infecc Microbiol Clin** 1997 Apr;15(4):230–1 (7 ref.) **(Spa)**

DIAGNOSIS

Tuberculosis: a growing problem [editorial] Cotton MM. **Br J Hosp Med** 1996 Sep 4–17;56(5):193–4 (3 ref.)

Tuberculosis bacteriology laboratory services and incremental protocols for developing countries. Laszlo A. **Clin Lab Med** 1996 Sep;16(3):697–716 (59 ref.)

Tuberculosis. Part II. LoBue PA, et al. **Dis Mon** 1997 Apr; 43(4):181–274 (346 ref.)

Diagnosis of tuberculosis in children: increased need for better methods. Kahn EA, et al. **Emerg Infect Dis** 1995 Oct–Dec;1(4):115–23 (52 ref.)

Diagnosing latent and active pulmonary tuberculosis: a review for clinicians. Leiner S, et al. **Nurse Pract** 1996 Feb;21(2):86, 88, 91–2 passim (62 ref.)

Tuberculosis in children. Starke JR. **Prim Care** 1996 Dec; 23(4):861–81 (64 ref.)

Surgical indications for treatment of pulmonary tuberculosis. Freixinet J. **World J Surg** 1997 Jun;21(5):475–9 (40 ref.)

[Molecular biology methods in detection of mycobacteria. Improved and newly developed test systems for the diagnosis of mycobacteria] Reischl U, et al. **Fortschr Med** 1996 Jul 1;114(18–19):237–41 (15 ref.) (Eng. Abstr.) **(Ger)**

[Tuberculosis] Kirsten D. **Pneumologie** 1996 Sep;50 Suppl 2:595–8 (13 ref.) **(Ger)**

DRUG THERAPY

The Baltimore City Health Department program of directly observed therapy for tuberculosis. Chaulk CP, et al. **Clin Chest Med** 1997 Mar;18(1):149–54 (5 ref.)

Directly observed therapy in New York City. History, implementation, results, and challenges. Fujiwara PI, et al. **Clin Chest Med** 1997 Mar;18(1):135–48 (29 ref.)

Directly observed therapy. Who is responsible? Sbarbaro JA. **Clin Chest Med** 1997 Mar;18(1):131–3 (4 ref.)

Tuberculosis. Part II. LoBue PA, et al. **Dis Mon** 1997 Apr; 43(4):181–274 (346 ref.)

Effect of treatment on contagiousness of patients with active pulmonary tuberculosis. Menzies D. **Infect Control Hosp Epidemiol** 1997 Aug;18(8):582–6 (54 ref.)

New antimycobacterial agents. Yew WW, et al. **Monaldi Arch Chest Dis** 1996 Oct;51(5):394–404 (143 ref.)

Tuberculosis in children. Starke JR. **Prim Care** 1996 Dec; 23(4):861–81 (64 ref.)

Modern methods for assessing the drugs used in the chemotherapy of mycobacterial disease. Mitchison DA. **Soc Appl Bacteriol Symp Ser** 1996;25:72S–80S (50 ref.)

Immunotherapy with Mycobacterium vaccae and the treatment of tuberculosis. Stanford JL, et al. **Soc Appl Bacteriol Symp Ser** 1996;25:81S–86S (30 ref.)

[Shortening of therapy duration in patients with pulmonary tuberculosis from 9 to 6 months only justifiable on the basis of published data] van Loenhout-Rooyackers JH, et al. **Ned Tijdschr Geneeskd** 1996 Nov 2;140(44):2181–7 (36 ref.) (Eng. Abstr.) **(Dut)**

[Shorter treatment of pulmonary tuberculosis is only acceptable with at least 4 drugs in the initial combination of tuberculostatic agents] Veen J. **Ned Tijdschr Geneeskd** 1996 Nov 2;140(44):2164–7 (25 ref.) **(Dut)**

[Problems in the treatment of patients with pulmonary tuberculosis] Chukanov VI. **Probl Tuberk** 1997;(4):17–9 (19 ref.) (Eng. Abstr.) **(Rus)**

[The treatment of tuberculosis. Yesterday, today...and tomorrow] García Rodríguez JF, et al. **Med Clin (Barc)** 1997 Mar 15;108(10):389–95 (135 ref.) **(Spa)**

EPIDEMIOLOGY

The epidemiology of tuberculosis in the United States. McCray E, et al. **Clin Chest Med** 1997 Mar;18(1):99–113 (79 ref.)

[Epidemiologic indicators of tuberculosis] Auregan G. **Sante** 1997 Mar–Apr;7(2):97–102 (26 ref.) (Eng. Abstr.) **(Fre)**

[HIV-associated tuberculosis in Africa exemplified by Zimbabwe] Schoch OD. **Schweiz Med Wochenschr** 1997 Jul 22;127(29–30):1223–8 (61 ref.) (Eng. Abstr.) **(Ger)**

[Pulmonary tuberculosis and acquired immunodeficiency syndrome in Ukraine (first communication)] Feshchenko II, et al. **Probl Tuberk** 1997;(4):55–7 (8 ref.) (Eng. Abstr.) **(Rus)**

[Tuberculosis in the elderly patient (editorial)] Caminero Luna JA. **An Med Interna** 1997 Apr;14(4):163–6 (62 ref.) **(Spa)**

[Tuberculosis outbreak at a public school] Navarro Gracia JF, et al. **Rev Clin Esp** 1997 Mar;197(3):152–7 (59 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

The pathogenesis of tuberculosis. Rook GA, et al. **Annu Rev Microbiol** 1996;50:259–84 (118 ref.)

Tuberculosis in bone marrow transplant recipients: report of two cases and review of the literature. Martino R, et al. **Bone Marrow Transplant** 1996 Oct;18(4):809–12 (19 ref.)

Tuberculosis and human immunodeficiency virus infection. Telzak EE. **Med Clin North Am** 1997 Mar;81(2):345–60 (109 ref.)

[Pulmonary complications in diabetes mellitus] Marvisi M, et al. **Recenti Prog Med** 1996 Dec;87(12):623–7 (52 ref.) (Eng. Abstr.) **(Ita)**

[The role of biochemical studies in shaping the modern concepts of the pathogenesis of tuberculosis] Kaminskaia GO. **Probl Tuberk** 1996;(1):59–62 (67 ref.) **(Rus)**

[Course of a specific process in high risk ecological areas] Khudzik LB, et al. **Probl Tuberk** 1997;(1):46–8 (0 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

The pathogenesis of tuberculosis. Rook GA, et al. **Annu Rev Microbiol** 1996;50:259–84 (118 ref.)

[Cellular immunity in tuberculosis particularly the role of gamma delta T lymphocytes] Mróz RM, et al. **Pneumonol Alergol Pol** 1996;64(11–12):815–20 (33 ref.) **(Pol)**

METABOLISM

[Molecular mechanisms of cell-to-cell interactions during the progress and healing of tuberculosis] Kaminskaia GO, et al. **Probl Tuberk** 1996;(6):19–22 (31 ref.) (Eng. Abstr.) **(Rus)**

[The role of biochemical studies in shaping the modern concepts of the pathogenesis of tuberculosis] Kaminskaia GO. **Probl Tuberk** 1996;(1):59–62 (67 ref.) **(Rus)**

MICROBIOLOGY

The bovine tuberculosis cycle--an African perspective. Daborn CJ, et al. **Soc Appl Bacteriol Symp Ser** 1996; 25:27S–32S (23 ref.)

MORTALITY

[Thanatogenesis of respiratory tuberculosis under the present conditions] Kobeleva GV, et al. **Probl Tuberk** 1997;(1):35–7 (5 ref.) (Eng. Abstr.) **(Rus)**

PATHOLOGY

[Bronchial involvement in tuberculosis in children] Dubus JC. **Rev Mal Respir** 1996 Dec;13(6):609–10 (18 ref.) **(Fre)**

[Cellular and subcellular morphology of the repair process in pulmonary tuberculosis] Erokhin VV. **Probl Tuberk** 1996;(6):10–4 (10 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

HIV and tuberculosis. Sahoo RC. **J Assoc Physicians India** 1995 Jan;43(1):49–53 (62 ref.)

PREVENTION & CONTROL

Unresolved issues in controlling the tuberculosis epidemic among the foreign-born in the United States. Weber GS. **Am J Law Med** 1996;22(4):503–36 (353 ref.)

Rational design of antituberculosis vaccines: impact of antigen display and vaccine localization. Kaufmann SH, et al. **Biologicals** 1997 Jun;25(2):169–73 (25 ref.)

Tuberculosis: a growing problem [editorial] Cotton MM. **Br J Hosp Med** 1996 Sep 4–17;56(5):193–4 (3 ref.)

Short-course chemoprophylaxis for tuberculosis. Bishai WR, et al. **Clin Chest Med** 1997 Mar;18(1):115–22 (56 ref.)

Hospital infection control practices for tuberculosis. Davis YM, et al. **Clin Chest Med** 1997 Mar;18(1):19–33 (43 ref.)

Personal respiratory protection against Mycobacterium tuberculosis. Fennelly KP. **Clin Chest Med** 1997 Mar; 18(1):1–17 (79 ref.)

Biosafety in the clinical mycobacteriology laboratory. Richmond JY, et al. **Clin Lab Med** 1996 Sep;16(3):527–50 (38 ref.)

Using a mathematical model to evaluate the efficacy of TB control measures. Gammaitoni L, et al. **Emerg Infect Dis** 1997 Jul–Sep;3(3):335–42 (37 ref.)

TB and dentistry. Younai FS, et al. **N Y State Dent J** 1997 Jan;63(1):49–53 (29 ref.)

Tuberculosis. Recommendations for screening, prevention, and treatment. Moffitt MP, et al. **Postgrad Med** 1996 Oct; 100(4):201–4, 209, 212 passim (17 ref.)

[Primary chemoprevention of tuberculosis in HIV-infected patients in non-industrialized countries] Anglaret X, et al. **Sante** 1997 Mar–Apr;7(2):89–94 (38 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Patients with an abnormal chest radiograph and latent tuberculosis. Ferguson JS, et al. **Am Fam Physician** 1996 Dec;54(8):2495–500 (14 ref.)

Radiology of pulmonary tuberculosis. Rottenberg GT, et al. **Br J Hosp Med** 1996 Sep 4–17;56(5):195–9 (18 ref.)

Tuberculin conversion and abnormal chest radiograph in an infant. Magdorf K, et al. **Eur Respir J** 1996 Aug;9(8):1763–5 (12 ref.)

Tuberculosis in children with acquired immunodeficiency syndrome. Haller JO, et al. **Pediatr Radiol** 1997 Feb; 27(2):186–8 (12 ref.)

[Bronchial tuberculosis in the elderly: apropos of 9 cases. Radioclinical, endoscopic and developmental aspects] Bour-Guichenez G, et al. **Rev Med Interne** 1997;18(1):26–9 (14 ref.) (Eng. Abstr.) **(Fre)**

[Calcium in the lung or: it might not always be tuberculosis] Henk CB, et al. **Radiologe** 1996 Jul;36(7):534–42 (37 ref.) (Eng. Abstr.) **(Ger)**

[Imaging diagnosis in the study of pulmonary and extrapulmonary tuberculosis] Gualdi GF, et al. **Clin Ter** 1996 Oct;147(10):515–27 (17 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Surgery in the treatment of multidrug-resistant tuberculosis. Pomerantz M, et al. **Clin Chest Med** 1997 Mar;18(1):123–30 (3 ref.)

Surgical indications for treatment of pulmonary tuberculosis. Freixinet J. **World J Surg** 1997 Jun;21(5):475–9 (40 ref.)

[Thoracoplasty in pulmonary tuberculosis] Kravchenko AF. **Probl Tuberk** 1997;(2):38–41 (43 ref.) **(Rus)**

THERAPY

[Current methods for treating pulmonary tuberculosis (review of 1994–1995 literature)] Koretskaia NM. **Probl Tuberk** 1997;(4):66–9 (68 ref.) **(Rus)**

[Organization of in- and outpatient treatment of new cases of destructive pulmonary tuberculosis] Ursov IG, et al. **Probl Tuberk** 1997;(4):4–5 (6 ref.) (Eng. Abstr.) **(Rus)**

TRANSMISSION

Occupational transmission of tuberculosis: implications for anesthesiologists. Tait AR. **Anesth Analg** 1997 Aug; 85(2):444–51 (74 ref.)

Issues in the management of contacts of patients with active pulmonary tuberculosis. Menzies D. **Can J Public Health** 1997 May–Jun;88(3):197–201 (65 ref.)

Personal respiratory protection against Mycobacterium tuberculosis. Fennelly KP. **Clin Chest Med** 1997 Mar; 18(1):1–17 (79 ref.)

Effect of treatment on contagiousness of patients with active pulmonary tuberculosis. Menzies D. **Infect Control Hosp Epidemiol** 1997 Aug;18(8):582–6 (54 ref.)

[Tuberculosis. An especially contagious disease (editorial; comment)] Mallolas J, et al. **Med Clin (Barc)** 1997 Mar 15;108(10):382–4 (23 ref.) Comment on: Med Clin (Barc) 1997 Mar 15;108(10):361–5. **(Spa)**

TUBERCULOSIS, RENAL

DIAGNOSIS

[Specific infections of the kidney] Hirose T. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):254–7 (6 ref.) **(Jpn)**

TUBERCULOSIS SOCIETIES

ORGANIZATION & ADMINISTRATION

[Phthisiobacteriological service in the Republic of Sakha] Alekseeva GI. **Probl Tuberk** 1997;(2):11–3 (1 ref.) (Eng. Abstr.) **(Rus)**

TUBERCULOSIS, SPINAL

Rheumatologic manifestations of tuberculosis. Kramer N, et al. **Bull Rheum Dis** 1997 May;46(3):5–8 (13 ref.)

Spinal tuberculosis: a report of five cases and a review. Alamé T, et al. **Monaldi Arch Chest Dis** 1996 Oct;51(5):362–8 (51 ref.)

Tuberculosis of the spine. Controversies and a new challenge. Moon MS. **Spine** 1997 Aug 1;22(15):1791–7 (30 ref.)

COMPLICATIONS

Retropharyngeal abscess associated with tuberculosis of the cervical spine. Al Soub H. **Tuber Lung Dis** 1996 Dec; 77(6):563–5 (17 ref.)

DIAGNOSIS

Neural arch tuberculosis: radiological features and their correlation with surgical findings. Naim-Ur-Rahman, et al. **Br J Neurosurg** 1997 Feb;11(1):32–8 (7 ref.)

SURGERY

[Role of surgery in the treatment of Pott's disease in adults. Apropos of 29 cases] Ghadouane M, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(7):620–8 (26 ref.) (Eng. Abstr.) **(Fre)**

[Tuberculosis of the spine--a retrospective review of the cases treated with surgery for the past 30-year in the National Murayama Hospital] Otani K. **Nippon Seikeigeka Gakkai Zasshi** 1997 May;71(5):153–60 (19 ref.) **(Jpn)**

TUBERCULOSIS, SPLENIC

DIAGNOSIS

[Clinical and radiological aspects of tuberculous splenic abscesses. Presentation of 3 cases] Abitbol V, et al. **Gastroenterol Clin Biol** 1996;20(6–7):597–600 (20 ref.) (Eng. Abstr.) **(Fre)**

[A diagnostically difficult case of a combination of extrapulmonary tuberculosis with a rheumatic heart defect] Sarkisova ND, et al. **Ter Arkh** 1996;68(4):24–7 (9 ref.) **(Rus)**

TUBERCULOSIS, UROGENITAL

COMPLICATIONS

[Transitional carcinoma of the ureter and urinary tuberculosis] Cardini S, et al. **Minerva Urol Nefrol** 1997 Mar;49(1):33–7 (24 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Indications for surgical management of genitourinary tuberculosis. Carl P, et al. **World J Surg** 1997 Jun; 21(5):505–10 (24 ref.)

TUBERCULOSIS VACCINES see **BCG VACCINE**

TUBERCULOSTATIC AGENTS see **ANTITUBERCULAR AGENTS**

TUBEROUS SCLEROSIS

[Tuberous sclerosis] Sasaki M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):320–2 (5 ref.) **(Jpn)**

COMPLICATIONS

Neurological manifestations of tuberous sclerosis complex. Curatolo P. **Childs Nerv Syst** 1996 Sep;12(9):515–21 (34 ref.)

Renal manifestations of tuberous sclerosis complex. O'Hagan AR, et al. **Clin Pediatr (Phila)** 1996 Oct;35(10):483–9 (71 ref.)

Cataract in tuberous sclerosis. Warner JE, et al. **J Neuroophthalmol** 1997 Mar;17(1):33–5 (9 ref.)

The kidney in tuberous sclerosis: manifestations and molecular genetic mechanisms. Sampson JR. **Nephrol Dial Transplant** 1996;11 Suppl 6:34–7 (40 ref.)

[Bourneville's tuberous sclerosis and autism] Reich M, et al. **Arch Pediatr** 1997 Feb;4(2):170–5 (24 ref.) (Eng. Abstr.) **(Fre)**

[Renal angiomyolipoma and renal cell carcinoma associated with tuberous sclerosis: a case report] Sugimoto M, et al. **Hinyokika Kiyo** 1997 Jan;43(1):33–5 (14 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Tuberous sclerosis: between genetic and physical analysis. Halley DJ. **Acta Genet Med Gemellol (Roma)** 1996; 45(1–2):63–75 (39 ref.)

The phakomatoses: recent advances in genetics. MacDonald IM, et al. **Can J Ophthalmol** 1997 Feb;32(1):4–11 (81 ref.)

Neurocutaneous syndromes: neurofibromatosis 1, neurofibromatosis 2, and tuberous sclerosis. Korf BR. **Curr Opin Neurol** 1997 Apr;10(2):131–6 (63 ref.)

PATHOLOGY

Tuberous sclerosis and guttate leukodermas. Jimbow K. **Semin Cutan Med Surg** 1997 Mar;16(1):30–5 (14 ref.)

TUBULIN

CHEMISTRY

Evolution of the multi-tubulin hypothesis. Wilson PG, et al. **Bioessays** 1997 Jun;19(6):451–4 (37 ref.)

Motile systems: Tubulin-based motility races ahead. Egelman EH. **Curr Biol** 1995 Dec 1;5(12):1354–6 (19 ref.)

Protofilaments and rings, two conformations of the tubulin family conserved from bacterial FtsZ to alpha/beta and gamma tubulin. Erickson HP, et al. **J Cell Biol** 1996 Oct; 135(1):5–8 (25 ref.)

Visualizing the secondary structure of tubulin: three-dimensional map at 4 A. Nogales E, et al. **J Struct Biol** 1997 Mar;118(2):119–27 (18 ref.)

GENETICS

Muscle development and attachment to the epidermis is accompanied by expression of beta 3 and beta 1 tubulin isotypes, respectively. Buttgereit D, et al. **Int J Dev Biol** 1996 Feb;40(1):189–96 (49 ref.)

[Microtubules: functional polymorphisms of tubulin and associated proteins (structural and motor MAP's)] Regnard C, et al. **C R Seances Soc Biol Fil** 1996;190(2–3):255–68 (61 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Cytoskeleton: microtubule nucleation takes shape. Murphy SM, et al. **Curr Biol** 1996 Jun 1;6(6):642–4 (16 ref.)

Tubulin post-translational modifications--enzymes and their mechanisms of action. MacRae TH. **Eur J Biochem** 1997 Mar 1;244(2):265–78 (172 ref.)

Centrosome-microtubule nucleation. Pereira G, et al. **J Cell Sci** 1997 Feb;110 (Pt 3):295–300 (69 ref.)

Inhibition of brain tubulin-guanosine 5'-triphosphate interactions by mercury: similarity to observations in Alzheimer's diseased brain. Pendergrass JC, et al. **Met Ions Biol Syst** 1997;34:461–78 (35 ref.)

PHARMACOLOGY

Development of new anticancer drugs in Japan--tubulin-interacting agents. Tsukagoshi S. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:94–9 (5 ref.)

PHYSIOLOGY

How tubulin subunits are lost from the shortening ends of microtubules. Tran PT, et al. **J Struct Biol** 1997 Mar; 118(2):107–18 (65 ref.)

TUBULOINTERSTITIAL NEPHRITIS see **NEPHRITIS, INTERSTITIAL**

TULAREMIA

Tularemia pneumonia. Gill V, et al. **Semin Respir Infect** 1997 Mar;12(1):61–7 (22 ref.)

DIAGNOSIS

Tularemia. Jacobs RF. **Adv Pediatr Infect Dis** 1996;12:55–69 (15 ref.)

ECONOMICS

The economic impact of a bioterrorist attack: are prevention and postattack intervention programs justifiable? Kaufmann AF, et al. **Emerg Infect Dis** 1997 Apr-Jun;3(2):83–94 (22 ref.)

EPIDEMIOLOGY

Tularemia. Jacobs RF. **Adv Pediatr Infect Dis** 1996;12:55–69 (15 ref.)

Epidemiological analysis of tularemia in Japan (yato-byo). Ohara Y, et al. **FEMS Immunol Med Microbiol** 1996 Mar; 13(3):185–9 (9 ref.)

PREVENTION & CONTROL

[Tularemia vaccine strain is a potential vector] Pavlov VM, et al. **Vestn Ross Akad Med Nauk** 1997;(6):30–2 (28 ref.) (Eng. Abstr.) **(Rus)**

TUMESCENCE, PENILE see **PENILE ERECTION**

TUMOR ANTIBODIES see **ANTIBODIES, NEOPLASM**

TUMOR ANTIGENS see **ANTIGENS, NEOPLASM**

TUMOR ANTIGENS, VIRAL see **ANTIGENS, VIRAL, TUMOR**

TUMOR-ASSOCIATED CARBOHYDRATE ANTIGENS see **ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE**

TUMOR AUTOCRINE MOTILITY FACTOR see **AUTOCRINE MOTILITY FACTOR**

TUMOR CELLS, CULTURED

see related
DRUG SCREENING ASSAYS, ANTITUMOR

Telomere dynamics and telomerase activity in in vitro immortalised human cells. Bryan TM, et al. **Eur J Cancer** 1997 Apr;33(5):767–73 (60 ref.)

Human factor-dependent leukemia cell lines. Tohyama K. **Int J Hematol** 1997 Jun;65(4):309–17 (70 ref.)

T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL). Bunn PA Jr, et al. **J Cell Biochem Suppl** 1996;24:12–23 (125 ref.)

Cell line banks and their role in cancer research. Hay RJ, et al. **J Cell Biochem Suppl** 1996;24:107–30 (29 ref.)

[Cell cultures in the study of malignant blood diseases] del Cañizo MC, et al. **Sangre (Barc)** 1996 Aug;41(4):297–303 (55 ref.) **(Spa)**

DRUG EFFECTS

The role of butyrate in human colonic epithelial cells: an energy source or inducer of differentiation and apoptosis? Hague A, et al. **Proc Nutr Soc** 1996 Nov;55(3):937–43 (42 ref.)

[Effect of quinine on the multiple drug resistance and intracellular distribution of pirarubicin in LR73 tumor cells: a comparative study with verapamil and S9788 by confocal laser microspectrofluorometry] Belhoussine R, et al. **Bull Cancer** 1997 Apr;84(4):343–9 (39 ref.) (Eng. Abstr.) **(Fre)**

[Reversal of drug resistance in human cancer cells by anti-oncogenes] Funato T. **Gan To Kagaku Ryoho** 1997 Feb;24(4):395–400 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Cell signaling and CDDP resistance] Masumoto N, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(4):424–30 (36 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

[Biological role and mechanisms of realization of the Crabtree effect in rapidly proliferating cells. The role of Ca2+ ions] Evtodienko IuV, et al. **Biokhimiia** 1996 Nov; 61(11):1995–2004 (65 ref.) (Eng. Abstr.) **(Rus)**

TUMOR CELLS, EMBOLIC see **NEOPLASM CIRCULATING CELLS**

TUMOR-DERIVED ACTIVATED CELLS see **LYMPHOCYTES, TUMOR-INFILTRATING**

TUMOR ESCAPE

see related
IMMUNE TOLERANCE

IMMUNOLOGY

The Fas counterattack: a molecular mechanism of tumor immune privilege. O'Connell J, et al. **Mol Med** 1997 May; 3(5):294–300 (75 ref.)

TUMOR-INFILTRATING LYMPHOCYTES see **LYMPHOCYTES, TUMOR-INFILTRATING**

TUMOR INITIATORS see **CARCINOGENS**

TUMOR LYSIS SYNDROME

see related
TUMOR NECROSIS FACTOR

ETIOLOGY

[Hyperuricemia in hematological disorders] Iwata J. **Nippon Rinsho** 1996 Dec;54(12):3349–53 (12 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Tumour lysis syndrome, case report and review of the literature. Lorigan PC, et al. **Ann Oncol** 1996 Aug; 7(6):631–6 (32 ref.)

THERAPY

Tumour lysis syndrome, case report and review of the literature. Lorigan PC, et al. **Ann Oncol** 1996 Aug; 7(6):631–6 (32 ref.)

TUMOR MARKERS, BIOCHEMICAL see **TUMOR MARKERS, BIOLOGICAL**

TUMOR MARKERS, BIOLOGICAL

Estrogen and progesterone receptors in endometrial cancer. Clinicopathological correlations and prognostic significance. Nyholm HC. **APMIS Suppl** 1996;65:5–33 (186 ref.)

Is the study of human cancer-associated factors, the best or the only model for human carcinogenesis research? I. The question of Helicobacter pylori infection as an accused human gastric carcinogen (editorial). Mathé G. **Biomed Pharmacother** 1997;51(1):1–4 (36 ref.)

Cell proliferation indexes: a biomarker in solid tumors. Elias JM. **Biotech Histochem** 1997 Mar;72(2):78–85 (59 ref.)

Cervical pathology. Herrington CS. **Curr Opin Obstet Gynecol** 1997 Feb;9(1):57–62 (54 ref.)

Biomarkers in head and neck carcinoma. Oh Y, et al. **Curr Opin Oncol** 1997 May;9(3):247–56 (109 ref.)

Molecular epidemiology in environmental carcinogenesis. Perera FP, et al. **Environ Health Perspect** 1996 May;104 Suppl 3:441–3 (14 ref.)

Molecular epidemiology of lung and breast cancer. Ambrosone CB, et al. **Eur J Cancer Prev** 1996 Oct; 5(5):391–2 (6 ref.)

Biomarkers for malignancy in the columnar-lined esophagus. Rustgi AK. **Gastroenterol Clin North Am** 1997 Sep; 26(3):599–606 (57 ref.)

Prognostic markers in resectable non-small cell lung cancer. Strauss GM. **Hematol Oncol Clin North Am** 1997 Jun; 11(3):409–34 (88 ref.)

Biomarkers of squamous cell carcinoma of the head and neck. Kim J, et al. **Histol Histopathol** 1997 Jan;12(1):205–18 (259 ref.)

Large bowel adenomas: markers of risk and endpoints. Baron JA. **J Cell Biochem Suppl** 1996;25:142–8 (34 ref.)

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers [see comments] Hayes DF, et al. **J Natl Cancer Inst** 1996 Oct 16; 88(20):1456–66 (65 ref.) Comment in: J Natl Cancer Inst 1996 Oct 16;88(20):1419–20.

Molecular epidemiology of hematological neoplasms--present status and future directions. Shpilberg O, et al. **Leuk Res** 1997 Apr;21(4):265–84 (167 ref.)

[Regulation mechanism of specific expression of tumor marker gene during carcinogenesis] Imagawa M.

Yakugaku Zasshi 1996 Jul;116(7):505–18 (29 ref.) (Eng. Abstr.) **(Jpn)**

[Diagnostic and prognostic significance of oncogenes in pulmonary carcinoma] Andelić G, et al. **Vojnosanit Pregl** 1996 Sep–Oct;53(5):393–7 (44 ref.) **(Scr)**

ANALYSIS

Predictive factors for response to cytotoxic treatment in advanced breast cancer: a review. Sjöström J, et al. **Acta Oncol** 1996;35 Suppl 5:84–90 (42 ref.)

Cathepsin B expression in human tumors. Berquin IM, et al. **Adv Exp Med Biol** 1996;389:281–94 (56 ref.)

Bcl–1/cyclin D1 in malignant lymphoma. de Boer CJ, et al. **Ann Oncol** 1997;8 Suppl 2:109–17 (145 ref.)

Comparison of the diagnostic and prognostic value of biological markers in neuroblastoma. Proposal for a common methodology of analysis. SENSE group. Favrot MC, et al. **Ann Oncol** 1996 Aug;7(6):607–11 (50 ref.)

Individualizing chemotherapy for solid tumors—is there any alternative? Cree IA, et al. **Anticancer Drugs** 1997 Jul; 8(6):541–8 (78 ref.)

The beta–core fragment of human chorionic gonadotropin: biochemical background and clinical application. Schutter EM, et al. **Anticancer Res** 1997 Mar–Apr;17(2B):1255–72 (118 ref.)

The use of biomarker expression to characterize neoplastic processes. Grizzle WE, et al. **Biotech Histochem** 1997 Mar; 72(2):96–104 (60 ref.)

Changes in biomarker expression in the development of prostatic adenocarcinoma. Myers RB, et al. **Biotech Histochem** 1997 Mar;72(2):86–95 (73 ref.)

Expression of bone matrix proteins in human breast cancer: potential roles in microcalcification formation and in the genesis of bone metastases. Bellahcène A, et al. **Bull Cancer** 1997 Jan;84(1):17–24 (60 ref.)

Surrogate end–point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials. Einspahr JG, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Jan;6(1):37–48 (194 ref.)

Molecular and cellular biomarkers for field cancerization and multistep process in head and neck tumorigenesis. Papadimitrakopoulou VA, et al. **Cancer Metastasis Rev** 1996 Mar;15(1):53–76 (237 ref.)

Circulating tumor markers in gynecological tumors. Rustin GJ. **Curr Opin Oncol** 1996 Sep;8(5):426–31 (51 ref.)

Histopathologic and immunohistochemical prognostic factors in malignant gliomas. Stemmer–Rachamimov AO, et al. **Curr Opin Oncol** 1997 May;9(3):230–4 (16 ref.)

CD44 as a marker in human cancers. Sy MS, et al. **Curr Opin Oncol** 1997 Jan;9(1):108–12 (57 ref.)

Oncogenes and growth factor receptors as diagnostic and prognostic markers in precancers and cancers of the oral mucosa. Burkhardt A. **Curr Top Pathol** 1996;90:223–39 (136 ref.)

Suppressor protein p53 and its occurrence in oral tumours. Slootweg PJ. **Curr Top Pathol** 1996;90:179–200 (119 ref.)

Importance of proliferation markers in oral pathology. Warnakulasuriya KA, et al. **Curr Top Pathol** 1996;90:147–77 (105 ref.)

Stool markers for colorectal cancer screening: future considerations. Ahlquist DA, et al. **Dig Dis** 1996 May–Jun; 14(3):132–44 (78 ref.)

Role of surveillance endoscopy, biopsy and biomarkers in early detection of Barrett's adenocarcinoma. Ellis FH Jr, et al. **Dis Esophagus** 1997 Jul;10(3):165–71 (85 ref.)

Future research directions in the use of biomarkers. Hemminki K, et al. **Environ Health Perspect** 1996 May;104 Suppl 3:459–64 (35 ref.)

Immunoassays (ELISA) of urokinase–type plasminogen activator (uPA): report of an EORTC/BIOMED–1 workshop. Benraad TJ, et al. **Eur J Cancer** 1996 Jul; 32A(8):1371–81 (28 ref.)

An improved statistical approach: can it clarify the role of new prognostic factors for breast cancer? Chapman JW, et al. **Eur J Cancer** 1996 Oct;32A(11):1949–56 (33 ref.)

Biomarkers and histology of premalignant and malignant lesions. Beltrami AC, et al. **Eur J Cancer Prev** 1996 Oct; 5(5):375–6 (18 ref.)

Haemoglobin adducts of N–nitroso compounds. Richter E. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:115–9 (32 ref.)

Why do immunoassays for tumour markers give differing results?—a view from the UK National External Quality Assessment Schemes. Sturgeon CM, et al. **Eur J Clin Chem Clin Biochem** 1996 Sep;34(9):755–9 (10 ref.)

Cathepsin D and prognosis in breast cancer: one piece of a larger puzzle? [editorial; comment] Emmert–Buck MR. **Hum Pathol** 1996 Sep;27(9):869–71 (23 ref.) Comment on: Hum Pathol 1996 Sep;27(9):890–5.

Molecular genetic biomarkers in hematological malignancies. Bagg A, et al. **J Cell Biochem Suppl** 1996;25:165–71 (33 ref.)

Cancer risk factors for selecting cohorts for large–scale chemoprevention trials. Greenwald P. **J Cell Biochem Suppl** 1996;25:29–36 (37 ref.)

G–actin as a risk factor and modulatable endpoint for cancer chemoprevention trials. Hemstreet GP 3rd, et al. **J Cell Biochem Suppl** 1996;25:197–204 (46 ref.)

Risk biomarkers and current strategies for cancer chemoprevention. Kelloff GJ, et al. **J Cell Biochem Suppl** 1996;25:1–14 (73 ref.)

Carcinogen–DNA and protein adducts: biomarkers for cohort selection and modifiable endpoints in chemoprevention trials. Kensler TW, et al. **J Cell Biochem Suppl** 1996;25:85–91 (30 ref.)

Genetic alterations as clonal markers for bladder cancer detection in urine. Mao L. **J Cell Biochem Suppl** 1996; 25:191–6 (39 ref.)

Defining and analyzing cohorts using molecular markers of cancer risk. Mark SD. **J Cell Biochem Suppl** 1996;25:69–79 (18 ref.)

Clinical detection of lung cancer progression markers. Tockman MS. **J Cell Biochem Suppl** 1996;25:177–84 (36 ref.)

Relevance of cyclin D1 and other molecular markers to cancer chemoprevention. Weinstein IB. **J Cell Biochem Suppl** 1996;25:23–8 (19 ref.)

Molecular oncology in pancreatic cancer. Gansauge S, et al. **J Mol Med** 1996 Jun;74(6):313–20 (97 ref.)

Coexpression of lymphoid and myeloid markers on cell surfaces. Lefterova P, et al. **Leuk Lymphoma** 1997 Jun; 26(1–2):27–33 (68 ref.)

Prognostic and predictive factors in breast cancer. Jansen RL, et al. **Neth J Med** 1997 Aug;51(2):65–77 (155 ref.)

Prognostic factors in low–stage nonseminomatous testicular cancer. Moul JW, et al. **Oncology (Huntingt)** 1996 Sep; 10(9):1359–68, 1374; discussion 1377–8 (65 ref.)

Prostate–specific antigen: what's new in 1997. Pannek J, et al. **Oncology (Huntingt)** 1997 Sep;11(9):1273–8; discussion 1279–82 (59 ref.)

Immunohistochemistry: a prognostic as well as diagnostic tool? Mehregan D, et al. **Semin Cutan Med Surg** 1996 Dec; 15(4):317–25 (85 ref.)

Bladder cancer: natural history, tumor markers, and early detection strategies. Foresman WH, et al. **Semin Surg Oncol** 1997 Sep–Oct;13(5):299–306 (45 ref.)

[Analytical problems in the determination of tumor markers] Bohuon C, et al. **Nucl Med Biol** 1994 Apr;21(3):477–82 (12 ref.) **(Fre)**

[Importance of early detection of metastases? Impact on survival and quality of life] Pujol H. **Nucl Med Biol** 1994 Apr;21(3):303–15 (16 ref.) (Eng. Abstr.) **(Fre)**

[What can the clinician expect today from PSA determination?] Teillac P. **Nucl Med Biol** 1994 Apr; 21(3):455–69 (43 ref.) (Eng. Abstr.) **(Fre)**

[Significance of adhesion molecules in oncology] Terpe HJ, et al. **Pathologe** 1997 Mar;18(2):117–23 (82 ref.) (Eng. Abstr.) **(Ger)**

[Effect of biological prognostic factors on therapy of non–seminomatous stage I testicular tumors—an assessment of the current status] Kuczyk MA, et al. **Urologe A** 1996 Jan;35(1):35–45 (94 ref.) (Eng. Abstr.) **(Ger)**

[Cathepsin D as a prognostic marker in breast cancer] Asculai E, et al. **Harefuah** 1996 Jun 2;130(11):787–90 (28 ref.) **(Heb)**

[Prognostic factors in breast cancer patients] Roisman I, et al. **Harefuah** 1996 May 15;130(10):693–9 (49 ref.) **(Heb)**

[Molecular biological prognostic markers in lung cancer] Abe S. **Nippon Geka Gakkai Zasshi** 1997 Jan;98(1):2–7 (35 ref.) (Eng. Abstr.) **(Jpn)**

[Lung cancer: progress in diagnosis and treatment. I. Diagnosis and physiopathology: 4. Progress in the study of tumor markers] Kuwabara M, et al. **Nippon Naika Gakkai Zasshi** 1997 Jan 10;86(1):20–6 (12 ref.) **(Jpn)**

[Tumor associated biomarker for early diagnosis of cancer] Ohkura H. **Nippon Rinsho** 1996 May;54(5):1281–5 (15 ref.) (Eng. Abstr.) **(Jpn)**

[A case of mature retroperitoneal teratoma producing CEA] Iwai T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jul; 93(7):491–5 (16 ref.) **(Jpn)**

[Tumor markers in gynecological cancer] Orbo A. **Tidsskr Nor Laegeforen** 1996 Oct 10;116(24):2886–8 (41 ref.) (Eng. Abstr.) **(Nor)**

[Minimal residual disease in acute leukemias. Optimal method of detection] Deptala A, et al. **Pol Arch Med Wewn** 1996 Jun;95(6):585–94 (35 ref.) **(Pol)**

[The role of cytokines as tumor markers] Mroczko B, et al. **Pol Arch Med Wewn** 1997 Feb;97(2):170–6 (55 ref.) **(Pol)**

[Sialosyl–Le(a) and Sialosyl–Le(x) antigens in adhesion of cancer cells and tumor progression] Ugorski M, et al. **Postepy Hig Med Dosw** 1996;50(3):209–31 (111 ref.) (Eng. Abstr.) **(Pol)**

[Carcinoembryonic antigen, CEA, in colorectal cancer. An insensitive marker which may be excluded from follow–ups] Wählby L. **Lakartidningen** 1997 Apr 30; 94(18):1716–8 (34 ref.) **(Swe)**

BIOSYNTHESIS

The role of Src family kinases in the normal and neoplastic gastrointestinal tract. Banker N, et al. **Surg Oncol** 1996 Oct–Dec;5(5–6):201–10 (92 ref.)

BLOOD

Contemporary non–imaging methods in diagnosis of bladder cancer: a review. De Graeve N, et al. **Acta Urol Belg** 1997 Mar;65(1):55–8 (22 ref.)

The role of tumour markers in the diagnosis and treatment of testicular germ cell cancers. Doherty AP, et al. **Br J Urol** 1997 Feb;79(2):247–52 (41 ref.)

Reverse transcriptase– polymerase chain reaction (RT–PCR) to detect prostate cancer micrometastasis in the blood. Yao KL, et al. **Cancer Treat Res** 1996;88:77–91 (35 ref.)

Individual prostate–specific antigen (PSA) forms as prostate tumor markers. Becker C, et al. **Clin Chim Acta** 1997 Jan 3;257(1):117–32 (87 ref.)

Utilization of nuclear matrix proteins for cancer diagnosis. Keesee SK, et al. **Crit Rev Eukaryot Gene Expr** 1996; 6(2–3):189–214 (197 ref.)

The value of markers for cell proliferation and cell loss in gynaecological cancer. Cheung AN. **Curr Opin Obstet Gynecol** 1997 Feb;9(1):32–6 (35 ref.)

The value of cancer antigen 125 (CA 125) during treatment and follow–up of patients with ovarian cancer. de Bruijn HW, et al. **Curr Opin Obstet Gynecol** 1997 Feb;9(1):8–13 (64 ref.)

The prognostic importance of tumor markers in adenocarcinomas of the gastrointestinal tract. Grem J. **Curr Opin Oncol** 1997 Jul;9(4):380–7 (38 ref.)

Circulating markers in squamous cell carcinoma of the head and neck: a review. Rassekh CH, et al. **Eur J Cancer B Oral Oncol** 1994 Jan;30B(1):23–8 (63 ref.)

Screening for hepatocellular carcinoma. Haydon GH, et al. **Eur J Gastroenterol Hepatol** 1996 Sep;8(9):856–60 (49 ref.)

Angiogenic factors as tumor markers. Nguyen M. **Invest New Drugs** 1997;15(1):29–37 (44 ref.)

Immunoreactive inhibin, müllerian inhibitory substance, and activin as biochemical markers for juvenile granulosa cell tumors. Silverman LA, et al. **J Pediatr** 1996 Dec; 129(6):918–21 (20 ref.)

Telomeres and telomerase in normal and malignant haematologic cells. Leber B, et al. **Leuk Lymphoma** 1996 Dec;24(1–2):1–9 (58 ref.)

Clinical and biological significance of serum tumor markers in adult T–cell leukemia. Sadamori N. **Leuk Lymphoma** 1996 Aug;22(5–6):415–9 (59 ref.)

Management of asymptomatic rising PSA after prostatectomy or radiation therapy. Waxman S, et al. **Oncology (Huntingt)** 1997 Apr;11(4):457–60, 465; discussion 465–6, 469 (48 ref.)

Adenosine deaminase in childhood malignancy: should there be a second look? [editorial; comment] Blatt J. **Pediatr Hematol Oncol** 1996 Jul–Aug;13(4):301–3 (8 ref.) Comment on: Pediatr Hematol Oncol 1996 Jul–Aug;13(4):339–47.

Diagnostic and prognostic markers for human prostate cancer. Gao X, et al. **Prostate** 1997 Jun 1;31(4):264–81 (185 ref.)

Clinical relevance of serological markers in the detection and follow–up of pancreatic adenocarcinoma. Audisio RA, et al. **Surg Oncol** 1996 Apr;5(2):49–63 (171 ref.)

Resection of liver metastasis from alpha–fetoprotein–producing early gastric cancer: report of a case. Tsurumachi T, et al. **Surg Today** 1997;27(6):563–6 (11 ref.)

131I therapy for elevated thyroglobulin levels. Schlumberger M, et al. **Thyroid** 1997 Apr;7(2):273–6 (10 ref.)

Mucinous markers in breast cancer. Seregni E, et al. **Tumori** 1997 Mar–Apr;83(2):550–1 (09 ref.)

Prostate–specific antigen and early detection of prostate cancer. Chu TM. **Tumour Biol** 1997;18(2):123–34 (53 ref.)

The use of chromogranin, synaptophysin and islet amyloid polypeptide as markers for neuroendocrine tumours. Stridsberg M. **Ups J Med Sci** 1995;100(3):169–99 (186 ref.)

Prostate–specific membrane antigen and other prostatic tumor markers on the horizon. Israeli RS, et al. **Urol Clin North Am** 1997 May;24(2):439–50 (79 ref.)

[Prostate specific antigen] Koutani A, et al. **Ann Urol (Paris)** 1996;30(5):257–61 (30 ref.) (Eng. Abstr.) **(Fre)**

[The incidence of the variability of the free PSA/total PSA ratio on the early diagnosis of prostate cancer] de La Taille A, et al. **Prog Urol** 1997 Jun;7(3):455–63 (35 ref.) (Eng. Abstr.) **(Fre)**

[Early detection and preoperative diagnosis of ovarian carcinoma] Kainz C. **Wien Med Wochenschr** 1996; 146(1–2):2–7 (30 ref.) (Eng. Abstr.) **(Ger)**

[Molecular diagnostic detection of circulating tumor cells and their prognostic implications] Nakanishi H, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(3):257–65 (33 ref.) (Eng. Abstr.) **(Jpn)**

[Oncoproteins and anti–oncoproteins in blood serum as biomarkers of early health effects induced by occupational and environmental carcinogens] Lutz W, et al. **Med Pr** 1996;47(5):511–8 (29 ref.) (Eng. Abstr.) **(Pol)**

[Tumor markers (advances and limits)] Gomes FR. **Acta Med Port** 1997 Jan;10(1):75–80 (22 ref.) (Eng. Abstr.) **(Por)**

CHEMISTRY

Advances in immunocytochemistry of thyroid tumours 1987–1994. Jasani B. **Curr Top Pathol** 1997;91:21–36 (55 ref.)

DIAGNOSTIC USE

Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer. Isaacs JT. **Am J Pathol** 1997 May;150(5):1511–21 (92 ref.)

Novel leukaemia markers. Micklem KJ. **Biosci Rep** 1995 Dec; 15(6):463–8 (12 ref.)

Prostate cancer: to screen or not to screen?

Oncology (Huntingt) 1997 Apr;11(4):447–8, 451–2 (9 ref.)
Age-specific reference ranges for PSA in the detection of prostate cancer. DeAntoni EP. **Oncology (Huntingt)** 1997 Apr;11(4):475–82, 485; discussion 485–6, 489 (57 ref.)
[Carcinoembryonic antigen] Blanchon F. **Rev Mal Respir** 1997 Apr;14 Suppl 3:S30–1 (6 ref.) **(Fre)**
[Value of tumor markers for screening and diagnosis (except prognostic and surveillance values) in primary bronchial cancers] Grivaux M. **Rev Mal Respir** 1997 Apr;14 Suppl 3:S15–9 (41 ref.) **(Fre)**
[Neuron specific enolase] Milleron B. **Rev Mal Respir** 1997 Apr;14 Suppl 3:S36–7 (12 ref.) **(Fre)**
[CYFRA 21–1] Pujol JL. **Rev Mal Respir** 1997 Apr;14 Suppl 3:S31–6 (32 ref.) **(Fre)**
[Value of serial tumor markers for the detection of recurrences] Quoix E. **Rev Mal Respir** 1997 Apr;14 Suppl 3:S27–9 (32 ref.) **(Fre)**
[Which tumor markers should be used in primary bronchial cancers?] Schuller MP, et al. **Rev Mal Respir** 1997 Apr; 14 Suppl 3:S9–14 (29 ref.) * **(Fre)**
[Value of tumor markers in surveillance of primary bronchial cancers and to evaluate therapy] Sculier JP. **Rev Mal Respir** 1997 Apr;14 Suppl 3:S23–6 (29 ref.) **(Fre)**
[Value of serial tumor markers for determining the prognosis and predicting treatment response and survival] Souquet PJ. **Rev Mal Respir** 1997 Apr;14 Suppl 3:S20–2 (23 ref.) **(Fre)**

GENETICS

Detection of melanoma cells in peripheral blood using reverse transcription polymerase chain reaction assay for tyrosinase mRNA. Jung FA, et al. **Cancer Surv** 1996;26:251–65 (38 ref.)
The molecular epidemiology of lung cancer. Spivack SD, et al. **Crit Rev Toxicol** 1997 Jul;27(4):319–65 (315 ref.)
Oestrogen receptor mutants and variants in breast cancer. Dowsett M, et al. **Eur J Cancer** 1997 Jul;33(8):1177–83 (67 ref.)
Genetic studies and molecular markers of bladder cancer. Cordon-Cardo C, et al. **Semin Surg Oncol** 1997 Sep–Oct; 13(5):319–27 (73 ref.)
Androgen-receptor gene structure and function in prostate cancer. Hakimi JM, et al. **World J Urol** 1996;14(5):329–37 (46 ref.)
[Molecular biology markers of neuroblastoma as the basis for a therapy concept] Girgert R, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:1053–5 (9 ref.) (Eng. Abstr.) **(Ger)**
[Clinical use of polymerase chain reaction in diagnosis and monitoring of malignant diseases] Jäger U, et al. **Wien Klin Wochenschr** 1996;108(20):634–9 (35 ref.) (Eng. Abstr.) **(Ger)**
[Molecular biology of incidentally diagnosed adrenal gland space-occupying lesion] Reincke M, et al. **Zentralbl Chir** 1997;122(6):430–7 (42 ref.) (Eng. Abstr.) **(Ger)**
[Cholecystokinin-B/gastrin receptor is a novel molecular probe for human small cell lung cancer] Matsumori Y, et al. **Nippon Rinsho** 1996 Feb;54(2):507–12 (14 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

[Ki-67, marker of proliferation] Guinebretière JM, et al. **Ann Pathol** 1997 Mar;17(1):25–30 (57 ref.) **(Fre)**

METABOLISM

The utilization of nuclear matrix proteins for cancer diagnosis. Replogle-Schwab R, et al. **Crit Rev Eukaryot Gene Expr** 1996;6(2–3):103–13 (77 ref.)
Prognostic factors in breast cancer: use of cytologic preparations. Masood S. **Diagn Cytopathol** 1995 Dec; 13(5):388–95 (46 ref.)
Marked increase in serum CA 19–9 level in patients with alcoholic cirrhosis: report of four cases. Mathurin P, et al. **Eur J Gastroenterol Hepatol** 1996 Nov;8(11):1129–31 (17 ref.)
p53 and CD44 as clinical markers of tumour progression in colorectal carcinogenesis. Mulder JW, et al. **Histochem J** 1997 Jun;29(6):439–52 (163 ref.)
Adducts to nuclear DNA and mitochondrial DNA as biomarkers in chemoprevention. De Flora S, et al. **IARC Sci Publ** 1996;(139):291–301 (35 ref.)
Use of carcinogen-DNA and carcinogen-protein adduct biomarkers for cohort selection and as modifiable end points in chemoprevention trials. Kensler TW, et al. **IARC Sci Publ** 1996;(139):237–48 (70 ref.)
Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy. Fox SB, et al. **Invest New Drugs** 1997;15(1):15–28 (174 ref.)
Telomerase in the early detection of cancer. Shay JW, et al. **J Clin Pathol** 1997 Feb;50(2):106–9 (57 ref.)
Mucinous biliary cystadenoma with mesenchymal stroma: expressions of CA 19–9 and carcinoembryonic antigen in serum and cystic fluid. Lee JH, et al. **J Gastroenterol** 1996 Oct;31(5):732–6 (22 ref.)
Telomerase and early detection of cancer: a National Cancer Institute workshop. Breslow RA, et al. **J Natl Cancer Inst** 1997 May 7;89(9):618–23 (22 ref.)
Cyclin D1 in mammary carcinoma. Barnes DM. **J Pathol** 1997 Mar;181(3):267–9 (31 ref.)
Cell surface carbohydrates as prognostic markers in human carcinomas. Dabelsteen E. **J Pathol** 1996 Aug; 179(4):358–69 (141 ref.)
Leukocyte alkaline phosphatase a specific marker for the post-mitotic neutrophilic granulocyte: regulation in acute promyelocytic leukemia. Garattini E, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):493–503 (73 ref.)
Molecular prognostic factor in renal cell carcinoma. Shimazui T, et al. **Semin Urol Oncol** 1996 Nov;14(4):250–5 (62 ref.)
[Double primary lung cancers producing alpha-fetoprotein] Bessho T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Dec;44(12):2216–20 (11 ref.) (Eng. Abstr.) **(Jpn)**

URINE

The role of nuclear matrix protein 22 in the detection of persistent or recurrent transitional-cell cancer of the bladder. Shelfo SW, et al. **World J Urol** 1997;15(2):107–11 (25 ref.)

TUMOR NECROSIS FACTOR

Tumor necrosis factor (TNF) in inflammatory bowel disease: gene polymorphisms, animal models, and potential for anti-TNF therapy. Stokkers PC, et al. **J Inflamm** 1995–96; 47(1–2):97–103 (54 ref.)
Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. Chandler S, et al. **J Neuroimmunol** 1997 Feb;72(2):155–61 (95 ref.)
[Tumor necrosis factor and clinical diseases] Su X, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Dec;34(12):842–5 (19 ref.) **(Chi)**
[TNF-alpha: molecular tie between obesity and insulin resistance] Peraldi P, et al. **Journ Annu Diabetol Hotel Dieu** 1997;:149–59 (52 ref.) **(Fre)**
[TNF] Yamauchi N, et al. **Gan To Kagaku Ryoho** 1997 Sep; 24(11):1486–94 (68 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Isolated limb perfusion for malignant melanoma. Alexander HR Jr, et al. **Semin Surg Oncol** 1996 Nov–Dec;12(6):416–28 (85 ref.)

ADVERSE EFFECTS

Tumour necrosis factor and inflammatory bowel disease. Armstrong AM, et al. **Br J Surg** 1997 Aug;84(8):1051–8 (89 ref.)
Inhibition of and sensitization to the lethal effects of tumor necrosis factor. Brouckaert P, et al. **J Inflamm** 1995–96; 47(1–2):18–26 (31 ref.)

ANALYSIS

Micronutrient and cytokine interaction in congenital pediatric HIV infection. Cunningham-Rundles S, et al. **J Nutr** 1996 Oct;126(10 Suppl):2674S–2679S (42 ref.)
[The evaluation of tumor necrosis factor-alpha concentration in body fluids in local and systemic endotoxin exposure (published erratum appears in Zentralbl Veterinarmed [B] 1997 Mar;44(1):64)] Kretzschmar C. **Zentralbl Veterinarmed [B]** 1996 Nov;43(9):525–38 (93 ref.) (Eng. Abstr.) **(Ger)**

ANTAGONISTS & INHIBITORS

TNF blockade in rheumatoid arthritis: implications for therapy and pathogenesis. Maini RN, et al. **APMIS** 1997 Apr;105(4):257–63 (34 ref.)
Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use. Klausner JD, et al. **Clin Immunol Immunopathol** 1996 Dec;81(3):219–23 (35 ref.)
The potential of combinatorial peptide libraries for the identification of inhibitors of TNF-alpha mediated cytotoxicity in vitro. Partidos CD, et al. **Immunol Lett** 1997 Jun 1;57(1–3):113–6 (16 ref.)
Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. Shohami E, et al. **J Neuroimmunol** 1997 Feb;72(2):169–77 (60 ref.)
The cytokine network in rheumatoid arthritis: definition of TNF alpha as a therapeutic target. Feldmann M. **J R Coll Physicians Lond** 1996 Nov–Dec;30(6):560–70 (86 ref.)

BIOSYNTHESIS

Pro-inflammatory cytokines in inflammatory bowel disease. McAlindon ME, et al. **Aliment Pharmacol Ther** 1996;10 Suppl 2:72–4 (28 ref.)
Bidirectional feedback regulation on 17 kD tumor necrosis factor (TNF) production by 26 kD membrane-bound TNF precursor. Soma IG, et al. **J Inflamm** 1995–96;47(1–2):52–60 (9 ref.)
Is endothelial cell autocrine production of tumor necrosis factor a mediator of lipid-induced endothelial dysfunction? Toborek M, et al. **Med Hypotheses** 1996 Nov;47(5):377–82 (49 ref.)

GENETICS

TNF-alpha and genetic susceptibility to parasitic disease. Goldfeld AE, et al. **Exp Parasitol** 1996 Nov;84(2):300–3 (17 ref.)
Apoptosis mediated by the TNF-related cytokine and receptor families. Ware CF, et al. **J Cell Biochem** 1996 Jan;60(1):47–55 (48 ref.)
Potential role of TNFalpha and lipoprotein lipase as candidate genes for obesity. Kern PA. **J Nutr** 1997 Sep; 127(9):1917S–1922S (43 ref.)
Polymorphism at the tumour necrosis factor locus and asthma. Campbell DA, et al. **Monogr Allergy** 1996; 33:125–37 (58 ref.)
[Idiopathic interstitial pneumonia and TNF gene restriction fragment length polymorphism] Ohe M, et al. **Nippon Rinsho** 1996 Feb;54(2):544–9 (16 ref.) (Eng. Abstr.) **(Jpn)**
[TNF/TNFR gene and apoptosis] Takeda Y, et al. **Nippon Rinsho** 1996 Jul;54(7):1888–94 (15 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Cytokine and drug modulation of TNF alpha in mast cells. Lin TJ, et al. **Adv Exp Med Biol** 1996;409:279–85 (45 ref.)
The role of FasL and TNF in the homeostatic regulation of immune responses. Lynch DH. **Adv Exp Med Biol** 1996; 406:135–8 (23 ref.)
Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. Feldmann M, et al. **Adv Immunol** 1997;64:283–350 (271 ref.)
Tumour necrosis factors in immune regulation: everything that's interesting is...new! Pasparakis M, et al. **Cytokine Growth Factor Rev** 1996 Oct;7(3):223–9 (55 ref.)
Tumour necrosis factor-alpha (TNF-alpha): the good, the bad and potentially very effective. Barbara JA, et al. **Immunol Cell Biol** 1996 Oct;74(5):434–43 (107 ref.)
Tumour necrosis factor and lymphotoxin: molecular aspects and role in tissue-specific autoimmunity. Körner H, et al. **Immunol Cell Biol** 1996 Oct;74(5):465–72 (88 ref.)
What is the mechanism of action of anti-tumour necrosis factor-alpha antibody in rheumatoid arthritis? Feldmann M. **Int Arch Allergy Immunol** 1996 Dec;111(4):362–5 (25 ref.)
Is there a role for tumor necrosis factor-alpha (TNF-alpha) in oral lichen planus? Sugermann PB, et al. **J Oral Pathol Med** 1996 May;25(5):219–24 (81 ref.)
Is the induction of apoptosis the mechanism of the protective effects of TNF alpha in helminth infection? Garside P, et al. **Parasite Immunol** 1996 Mar;18(3):111–3 (30 ref.)
New therapies for inflammatory bowel disease: an update on chimeric anti-TNF alpha antibodies and IL-10 therapy. van Hogezand RA, et al. **Scand J Gastroenterol Suppl** 1997; 223:105–7 (105 ref.)
[New therapeutic methods against rheumatoid arthritisp6. Antibodies against TNFalpha significant for the progress] Bondeson J. **Lakartidningen** 1997 Jan 8;94(1–2):42–5 (30 ref.) (Eng. Abstr.) **(Swe)**

METABOLISM

Transgenic models for arthritis: useful clues to be gained? [editorial] Brennan FM. **Ann Med** 1996 Aug;28(4):271–4 (23 ref.)
Structural and biological features of the TNF receptor and TNF ligand superfamilies: interactive signals in the pathobiology of Hodgkin's disease. Gruss HJ, et al. **Ann Oncol** 1996;7 Suppl 4:19–26 (66 ref.)
Circulating cytokine concentrations and outcome prediction in intensive care unit patients: still the tip of the iceberg? [editorial; comment] Matuschak GM. **Crit Care Med** 1996 Nov;24(11):1769–71 (33 ref.) Comment on: Crit Care Med 1996 Nov;24(11):1775–81.
Transducing signals of life and death. Yuan J. **Curr Opin Cell Biol** 1997 Apr;9(2):247–51 (31 ref.)
Inhibition of insulin receptor signaling by TNF: potential role in obesity and non-insulin-dependent diabetes mellitus. Skolnik EY, et al. **Cytokine Growth Factor Rev** 1996 Aug; 7(2):161–73 (111 ref.)
TSG-6: an IL-1/TNF-inducible protein with anti-inflammatory activity. Wisniewski HG, et al. **Cytokine Growth Factor Rev** 1997 Jun;8(2):143–56 (135 ref.)
Cytokine expression and networks in rheumatoid arthritis: rationale for anti-TNF alpha antibody therapy and its mechanism of action. Feldmann M, et al. **J Inflamm** 1995–96;47(1–2):90–6 (32 ref.)
Bidirectional feedback regulation on 17 kD tumor necrosis factor (TNF) production by 26 kD membrane-bound TNF precursor. Soma IG, et al. **J Inflamm** 1995–96;47(1–2):52–60 (9 ref.)
Structural features and biochemical properties of TNF-alpha converting enzyme (TACE). Moss ML, et al. **J Neuroimmunol** 1997 Feb;72(2):127–9 (18 ref.)
Inhibiting inflammatory cytokines. Kluth DC, et al. **Semin Nephrol** 1996 Nov;16(6):576–82 (60 ref.)
Mini-review: tumor necrosis factor (TNF) and TNF soluble receptors (TNF-sR) in liver disease and liver transplantation. Majno PE, et al. **Swiss Surg** 1995;(4):182–5 (27 ref.)
[Novel biological response modifiers: phthalimides with TNF-alpha production regulating activity] Miyachi H, et al. **Yakugaku Zasshi** 1997 Feb;117(2):91–107 (49 ref.) (Eng. Abstr.) **(Jpn)**
[Metabolic host-tumor relationships during perinatal phase] Argilés JM, et al. **Med Clin (Barc)** 1997 Jun 28; 109(5):186–94 (52 ref.) **(Spa)**

PHARMACOLOGY

Regulation of expression of the endothelial cell nitric oxide synthase. Harrison DG, et al. **Clin Exp Pharmacol Physiol** 1996 Mar;23(3):251–5 (36 ref.)

Tumor necrosis factor and lymphotoxin: protection against oxidative stress through induction of MnSOD. Wong GH, et al. **EXS** 1996;77:321–33 (77 ref.)

How does superoxide dismutase protect against tumor necrosis factor: a hypothesis informed by effect of superoxide on "free" iron. Liochev SI, et al. **Free Radic Biol Med** 1997;23(4):668–71 (46 ref.)

TNF-induced intracellular signaling leading to gene induction or to cytotoxicity by necrosis or by apoptosis. Fiers W, et al. **J Inflamm** 1995–96;47(1–2):67–75 (27 ref.)

Tumor necrosis factor–alpha and interleukin 4 in myeloma cell precursor differentiation. Sawamura M, et al. **Leuk Lymphoma** 1996 Mar;21(1–2):31–6 (45 ref.)

PHYSIOLOGY

GSH transport in mitochondria: defense against TNF-induced oxidative stress and alcohol-induced defect. Fernández-Checa JC, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):G7–17 (85 ref.)

Review: cytokine involvement in ovarian processes. Terranova PF, et al. **Am J Reprod Immunol** 1997 Jan; 37(1):50–63 (121 ref.)

FasL/Fas and TNF/TNFR interactions in the regulation of immune responses and disease. Lynch DH, et al. **Behring Inst Mitt** 1996 Oct;(97):175–84 (36 ref.)

Tumor necrosis factors: pivotal components of pregnancy? Hunt JS, et al. **Biol Reprod** 1996 Mar;54(3):554–62 (79 ref.)

Cellular signaling roles of TGF beta, TNF alpha and beta APP in brain injury responses and Alzheimer's disease. Mattson MP, et al. **Brain Res Brain Res Rev** 1997 Feb; 23(1–2):47–61 (119 ref.)

Is TNF really involved in cachexia? García-Martínez C, et al. **Cancer Invest** 1997;15(1):47–54 (81 ref.)

Metalloprotease-disintegrins: links to cell adhesion and cleavage of TNF alpha and Notch. Blobel CP. **Cell** 1997 Aug 22;90(4):589–92 (17 ref.)

Nutritional modulation of somatotropic axis-cytokine relationships in cattle: a brief review. Elsasser TH, et al. **Comp Biochem Physiol A Physiol** 1997 Mar;116(3):209–21 (88 ref.)

Tumor necrosis factor: function, release and clearance. Bemelmans MH, et al. **Crit Rev Immunol** 1996;16(1):1–11 (119 ref.)

Functions of CD40 and its ligand, gp39 (CD40L). Laman JD, et al. **Crit Rev Immunol** 1996;16(1):59–108 (220 ref.)

Suicide by order: some open questions about the cell-killing activities of the TNF ligand and receptor families. Wallach D. **Cytokine Growth Factor Rev** 1996 Oct;7(3):211–21 (133 ref.)

Potential roles of tumor necrosis factor–alpha in follicular development, ovulation, and the life span of the corpus luteum. Terranova PF. **Domest Anim Endocrinol** 1997 Jan; 14(1):1–15 (104 ref.)

Mitogenic actions of peroxidase proliferators: involvement of protein kinase C and tumor necrosis factor alpha. Bojes HK, et al. **Drug Metab Rev** 1997 Feb–May;29(1–2):235–60 (71 ref.)

From steroid signals to local regulatory factors involved in endometrial bleeding. Tabibzadeh S, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Dec;70(1):25–7 (34 ref.)

TNF-alpha and genetic susceptibility to parasitic disease. Goldfeld AE, et al. **Exp Parasitol** 1996 Nov;84(2):300–3 (17 ref.)

Journey from cachexia to obesity by TNF. Argilés JM, et al. **FASEB J** 1997 Aug;11(10):743–51 (107 ref.)

Tumour necrosis factor and Crohn's disease [see comments] Van Deventer SJ. **Gut** 1997 Apr;40(4):443–8 (76 ref.) Comment in: Gut 1997 Apr;40(4):559.

TNF-alpha-induced regulation and signalling in macrophages. Riches DW, et al. **Immunobiology** 1996 Oct; 195(4–5):477–90 (31 ref.)

Recent progress in the tumor necrosis factor–alpha field. Rink L, et al. **Int Arch Allergy Immunol** 1996 Nov; 111(3):199–209 (120 ref.)

The effect of tumor necrosis factor–alpha on cardiac structure and function: a tale of two cytokines. Mann DL. **J Card Fail** 1996 Dec;2(4 Suppl):S165–72 (60 ref.)

Review: regulation of liver regeneration by pro-inflammatory cytokines. Diehl AM, et al. **J Gastroenterol Hepatol** 1996 May;11(5):466–70 (36 ref.)

Transgenic and knockout analyses of the role of TNF in immune regulation and disease pathogenesis. Douni E, et al. **J Inflamm** 1995–96;47(1–2):27–38 (64 ref.)

Cellular and molecular mechanisms of TNF protection in septic peritonitis. Echtenacher B, et al. **J Inflamm** 1995–96; 47(1–2):85–9 (24 ref.)

Tumor necrosis factor (TNF) receptors in cellular signaling of soluble and membrane-expressed TNF. Grell M. **J Inflamm** 1995–96;47(1–2):8–17 (28 ref.)

Early events in TNF signaling: a story of associations and dissociations. Darnay BG, et al. **J Leukoc Biol** 1997 May; 61(5):559–66 (47 ref.)

TNF and related molecules: trends in neuroscience and clinical applications. Probert L, et al. **J Neuroimmunol** 1997 Feb;72(2):113–7 (25 ref.)

Potential role of TNFalpha and lipoprotein lipase as candidate genes for obesity. Kern PA. **J Nutr** 1997 Sep; 127(9):1917S–1922S (43 ref.)

The role of cytokines in rheumatoid arthritis. The Croonian Lecture 1995. Maini RN. **J R Coll Physicians Lond** 1996 Jul–Aug;30(4):344–51 (44 ref.)

Tumor necrosis factor–alpha and interleukin 4 in myeloma cell precursor differentiation. Sawamura M, et al. **Leuk Lymphoma** 1996 Mar;21(1–2):31–6 (45 ref.)

The role of tumor necrosis factor–alpha in the pathogenesis of anorexia and bulimia nervosa, cancer cachexia and obesity. Holden RJ, et al. **Med Hypotheses** 1996 Dec; 47(6):423–38 (148 ref.)

Both soluble and membrane-associated TNF activate brain microvascular endothelium: relevance to multiple sclerosis. Burger D, et al. **Mol Psychiatry** 1997 Mar;2(2):113–6 (31 ref.)

Critical protective role of mast cell–derived tumour necrosis factor in bacterial infection. Männel DN, et al. **Res Immunol** 1996 Oct–Dec;147(8–9):491–3 (14 ref.)

Circulating endotoxin, tumour necrosis factor–alpha, and their natural antagonists in the pathophysiology of acute pancreatitis. De Beaux AC, et al. **Scand J Gastroenterol Suppl** 1996;219:43–6 (18 ref.)

Cell death induction by TNF: a matter of self control. Wallach D. **Trends Biochem Sci** 1997 Apr;22(4):107–9 (29 ref.)

[Similarity and synergy of trauma and sepsis: role of tumor necrosis factor–alpha and interleukin-6 (see comments)] Tang GJ. **Acta Anaesthesiol Sin** 1996 Sep;34(3):141–9 (46 ref.) (Eng. Abstr.) Comment in: Acta Anaesthesiol Sin 1996 Sep;34(3):i. **(Chi)**

[Interaction between tumor necrosis factor–alpha and the smooth muscle cells of the airway: implication in the physiopathology of asthma] Amrani Y, et al. **Rev Mal Respir** 1996 Dec;13(6):539–46 (49 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

The success of TNF alpha in isolated limb perfusion for irresectable extremity soft tissue sarcomas, melanoma and carcinomas: observations in patients and preclinical perfusion models. Eggermont AM. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1357–70 (74 ref.)

Regional immunotherapy for liver metastases and the potential of TNF alpha in hepatic perfusion from laboratory to the clinic. Eggermont AM. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1371–8 (56 ref.)

Monocyte deactivation--rationale for a new therapeutic strategy in sepsis. Volk HD, et al. **Intensive Care Med** 1996 Oct;22 Suppl 4:S474–81 (24 ref.)

Strategies for manipulating apoptosis for cancer therapy with tumor necrosis factor and lymphotoxin. Wong GH, et al. **J Cell Biochem** 1996 Jan;60(1):56–60 (29 ref.)

Regional application of TNF alpha in the treatment of cancer: a preclinical–clinical interactive program. Eggermont AM, et al. **J Inflamm** 1995–96;47(1–2):104–13 (77 ref.)

Cachectin/tumor necrosis factor. Khan AS, et al. **JPMA J Pak Med Assoc** 1996 Jun;46(6):137–40 (32 ref.)

Cytokine gene-modified vaccines in the therapy of cancer. Bubenik J. **Pharmacol Ther** 1996;69(1):1–14 (208 ref.)

Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma. Walther MM, et al. **World J Urol** 1996;14 Suppl 1:S2–7 (49 ref.)

TUMOR NECROSIS FACTOR-ALPHA see **TUMOR NECROSIS FACTOR**

TUMOR NECROSIS FACTOR-BETA see **LYMPHOTOXIN**

TUMOR NECROSIS FACTOR RECEPTORS see **RECEPTORS, TUMOR NECROSIS FACTOR**

TUMOR PROMOTERS see **CARCINOGENS**

TUMOR SPHEROIDS see **SPHEROIDS**

TUMOR STAGING see **NEOPLASM STAGING**

TUMOR STEM CELL ASSAY

Metabolic and clonogenic consequences of ischaemia reperfusion insult in solid tumours. Parkins CS, et al. **Exp Physiol** 1997 Mar;82(2):361–8 (22 ref.)

TUMOR STEM CELLS

DRUG EFFECTS

Ex vivo bone marrow purging with oligonucleotides. Bergan RC. **Antisense Nucleic Acid Drug Dev** 1997 Jun;7(3):251–5 (21 ref.)

Modulation of apoptosis with cytokines in B-cell chronic lymphocytic leukaemia. Mainou-Fowler T, et al. **Leuk Lymphoma** 1996 May;21(5–6):369–77 (126 ref.)

METABOLISM

Beta-1-integrin expression in adult acute lymphoblastic leukemia: possible relationship with the stem cell antigen CD34. Cacciola RR, et al. **Acta Haematol** 1997; 97(1–2):63–6 (41 ref.)

PATHOLOGY

E2A-Pbx1 induces growth, blocks differentiation, and interacts with other homeodomain proteins regulating normal differentiation. Kamps MP. **Curr Top Microbiol Immunol** 1997;220:25–43 (68 ref.)

E2A-HLF chimeric transcription factors in pro-B cell acute lymphoblastic leukemia. Look AT. **Curr Top Microbiol Immunol** 1997;220:45–53 (54 ref.)

Regulation of autocrine motility factor receptor expression in tumor cell locomotion and metastasis. Silletti S, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 2):137–69 (153 ref.)

Myeloma stem cells in autografting in multiple myeloma. To LB, et al. **J Hematother** 1996 Oct;5(5):557–9 (14 ref.)

Tumor necrosis factor–alpha and interleukin 4 in myeloma cell precursor differentiation. Sawamura M, et al. **Leuk Lymphoma** 1996 Mar;21(1–2):31–6 (45 ref.)

TUMOR SUPPRESSOR GENES see **GENES, SUPPRESSOR, TUMOR**

TUMOR VACCINES see **CANCER VACCINES**

TUMOR VIRUS INFECTIONS

Issues in the management of human papillomavirus genital disease [see comments] Verdon ME. **Am Fam Physician** 1997 Apr;55(5):1813–6, 1819, 1822 (34 ref.) Comment in: Am Fam Physician 1997 Apr;55(5):1545–6, 1548.

Human papillomavirus and cancers of the upper aerodigestive tract: a review of epidemiological and experimental evidence. Franceschi S, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Jul;5(7):567–75 (104 ref.)

HPV infections and immunosuppression. Bouwes Bavinck JN, et al. **Clin Dermatol** 1997 May–Jun;15(3):427–37 (155 ref.)

HPV-associated diseases of oral mucosa. Praetorius F. **Clin Dermatol** 1997 May–Jun;15(3):399–413 (100 ref.)

Cervical and vaginal HPV infections. Schneider A. **Clin Dermatol** 1997 May–Jun;15(3):389–98 (120 ref.)

Epstein–Barr virus in tumours. Anagnostopoulos I, et al. **Histopathology** 1996 Oct;29(4):297–315 (182 ref.)

Anogenital warts in prepubertal children: pathogenesis, HPV typing and management [editorial] Armstrong DK, et al. **Int J STD AIDS** 1997 Feb;8(2):78–81 (34 ref.)

Human papillomavirus–associated tumors of the skin and mucosa. Majewski S, et al. **J Am Acad Dermatol** 1997 May; 36(5 Pt 1):659–85; quiz 686–8 (272 ref.)

Epstein–Barr virus–associated gastric carcinoma. Adachi Y, et al. **J Clin Gastroenterol** 1996 Oct;23(3):207–10 (24 ref.)

Human papillomatous virus infection update: impact on women's health. Carson S. **Nurse Pract** 1997 Apr; 22(4):24–5, 28–30, 35–7 (23 ref.)

Clinical manifestations and natural history of genital human papillomavirus infections. Campion MJ, et al. **Obstet Gynecol Clin North Am** 1996 Dec;23(4):783–809 (63 ref.)

HPV infection and disease in men. Palefsky JM, et al. **Obstet Gynecol Clin North Am** 1996 Dec;23(4):895–916 (43 ref.)

Epstein–Barr virus in Hodgkin's disease. Herbst H. **Semin Cancer Biol** 1996 Aug;7(4):183–9 (69 ref.)

EBV infection of T cells: potential role in malignant transformation. Kelleher CA, et al. **Semin Cancer Biol** 1996 Aug;7(4):197–207 (69 ref.)

Epstein–Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: viral gene expression, tumour cell phenotype, and the role of the lymphoid stroma. Niedobitek G, et al. **Semin Cancer Biol** 1996 Aug; 7(4):165–74 (92 ref.)

Epstein–Barr virus and gastric carcinoma. Osato T, et al. **Semin Cancer Biol** 1996 Aug;7(4):175–82 (41 ref.)

[Oncogenic mechanisms of Epstein–Barr virus] Herrero JA. **Enferm Infecc Microbiol Clin** 1996 Nov;14(9):551–60 (132 ref.) **(Spa)**

[Human JC and BK polyomavirus infection] Pérez Gracia MT, et al. **Med Clin (Barc)** 1996 Jan 20;106(2):69–75 (123 ref.) **(Spa)**

COMPLICATIONS

Polyomavirus-induced interstitial nephritis in two renal transplant recipients: case reports and review of the literature. Mathur VS, et al. **Am J Kidney Dis** 1997 May; 29(5):754–8 (9 ref.)

Papillomavirus infections—a major cause of human cancers. zur Hausen H. **Biochim Biophys Acta** 1996 Oct 9; 1288(2):F55–78 (415 ref.)

Cutaneous and genital HPV-associated lesions in HIV-infected patients. Palefsky JM. **Clin Dermatol** 1997 May–Jun;15(3):439–47 (75 ref.)

Role of HPV in cutaneous premalignant and malignant tumors. Pfister H, et al. **Clin Dermatol** 1997 May–Jun; 15(3):335–47 (101 ref.)

Role of human papillomaviruses in cancer of the respiratory and upper digestive tract. Snijders PJ, et al. **Clin Dermatol** 1997 May–Jun;15(3):415–25 (112 ref.)

Epstein–Barr virus and its possible role in the pathogenesis of B-cell lymphomas. Oudejans JJ, et al. **Crit Rev Oncol Hematol** 1997 Feb;25(2):127–38 (133 ref.)

HPV-11- and HPV-16-associated oral verrucous carcinoma.

TUMOR VIRUS INFECTIONS

Lübbe J, et al. **Dermatology** 1996;192(3):217–21 (35 ref.)
Survey of sinonasal inverted papillomata for Epstein–Barr virus. Dunn ST, et al. **Head Neck** 1997 Mar;19(2):98–106 (65 ref.)
Anal human papillomavirus and anal cancer. Tilston P. **J Clin Pathol** 1997 Aug;50(8):625–34 (108 ref.)
Considerations on a possible viral etiology for B–precursor acute lymphoblastic leukemia of childhood. Smith M. **J Immunother** 1997 Mar;20(2):89–100 (122 ref.)
Epstein–Barr virus in Hodgkin's disease: more than just an innocent bystander [editorial] Oudejans JJ, et al. **J Pathol** 1997 Apr;181(4):353–6 (42 ref.)
Human papillomavirus infection and invasive cervical neoplasia: a study of prevalence and morphology. Zehbe I, et al. **J Pathol** 1997 Mar;181(3):270–5 (44 ref.)
Human papillomavirus, integration and cervical carcinogenesis: a clinicopathological perspective. Cooper K, et al. **Mol Pathol** 1997 Feb;50(1):1–3 (37 ref.)
The role of human papillomavirus in anogenital cancer. Pfister H. **Obstet Gynecol Clin North Am** 1996 Sep; 23(3):579–95 (110 ref.)
Recurrent respiratory papillomatosis. Bauman NM, et al. **Pediatr Clin North Am** 1996 Dec;43(6):1385–401 (103 ref.)
[HIV, HPV and cervical pathology] Quéreux C, et al. **Contracept Fertil Sex** 1997 Feb;25(2):120–4 (29 ref.) **(Fre)**
[State of art: Epstein Barr virus–associated gastric carcinoma] Fukayama M, et al. **Nippon Rinsho** 1997 Feb;55(2):357–62 (22 ref.) (Eng. Abstr.) **(Jpn)**

CONGENITAL

Congenital papillomas and papillomatoses associated with the human papilloma virus (HPV)–report on 5 cases. Dias EP, et al. **Rev Paul Med** 1995 Jul–Aug;113(4):957–63 (63 ref.)

DIAGNOSIS

Cervical carcinoma: role of imaging. Yu KK, et al. **Abdom Imaging** 1997 Mar–Apr;22(2):208–15 (50 ref.)
Genital viral infections. Studies on human papillomavirus and Epstein–Barr virus. Voog E. **Acta Derm Venereol Suppl (Stockh)** 1996;198:1–55 (232 ref.)
Clinical presentation and natural course of anogenital warts. Handsfield HH. **Am J Med** 1997 May 5;102(5A):16–20 (13 ref.)
Diagnosis of human papillomavirus genital tract infection. Trofatter KF Jr. **Am J Med** 1997 May 5;102(5A):21–7 (25 ref.)
Human papillomavirus infection in women. Special aspects of infectious diseases in women. Jablonska S, et al. **Clin Dermatol** 1997 Jan–Feb;15(1):67–79 (109 ref.)
Virus–host interactions and diagnosis of human polyomavirus–associated disease. Dörries K. **Intervirology** 1996;39(3):165–75 (75 ref.)
Molecular diagnosis of persistent human papilloma virus infections. Wieland U, et al. **Intervirology** 1996;39(3):145–57 (96 ref.)
Case report. MRI findings of severe Epstein–Barr virus encephalomyelitis. Donovan WD, et al. **J Comput Assist Tomogr** 1996 Nov–Dec;20(6):1027–9 (8 ref.)
Clinical role of HPV testing. Cox JT. **Obstet Gynecol Clin North Am** 1996 Dec;23(4):811–51 (153 ref.)
Molecular methods for the detection of human papillomavirus infection. Lörincz AT. **Obstet Gynecol Clin North Am** 1996 Sep;23(3):707–30 (73 ref.)
Genital HPV infections in children and adolescents. Moscicki AB. **Obstet Gynecol Clin North Am** 1996 Sep;23(3):675–97 (84 ref.)
Clinical and immunological considerations in Epstein–Barr virus–associated diseases. Andersson J. **Scand J Infect Dis Suppl** 1996;100:72–82 (36 ref.)
Diagnosis of Epstein–Barr virus–related diseases. Linde A. **Scand J Infect Dis Suppl** 1996;100:83–8 (46 ref.)
[Genital infection with human papillomavirus (HPV): viral screening and typing, importance of in situ hybridization] Walker F, et al. **Ann Pathol** 1996 Nov;16(5):364–73 (76 ref.) **(Fre)**
[Current diagnosis and prognostic importance of EBV–associated neoplasms] Kawa K. **Nippon Rinsho** 1997 Feb;55(2):446–51 (12 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Epidemiology of genital human papillomavirus infection. Koutsky L. **Am J Med** 1997 May 5;102(5A):3–8 (40 ref.)
Epidemiology of EBV and Hodgkin's lymphoma. Jarrett AF, et al. **Ann Oncol** 1996;7 Suppl 4:5–10 (52 ref.)
The impact of the human immunodeficiency virus on the human papillomavirus epidemic. Chopra KF, et al. **Arch Dermatol** 1997 May;133(5):629–33 (50 ref.)
Epstein Barr virus in Argentine pediatric Hodgkin's disease. Preciado MV, et al. **Leuk Lymphoma** 1997 Jan; 24(3–4):283–90 (56 ref.)
Anogenital papillomavirus infection and neoplasia in immunodeficient women. Wright TC Jr, et al. **Obstet Gynecol Clin North Am** 1996 Dec;23(4):861–93 (79 ref.)

ETIOLOGY

Epstein–Barr virus. A serial killer or an innocent bystander? [editorial; comment] Sangüeza OP. **Arch Dermatol** 1997 Sep;133(9):1156–7 (17 ref.) Comment on: Arch Dermatol 1997 Sep;133(9):1081–6.
Tissue xenografts as a model system for study of the pathogenesis of papillomaviruses. Howett MK, et al. **Clin Dermatol** 1997 Mar–Apr;15(2):229–36 (53 ref.)
Oncogenic retroviruses of cattle, chickens and turkeys: potential infectivity and oncogenicity for humans. Johnson ES, et al. **Med Hypotheses** 1996 Apr;46(4):354–6 (19 ref.)
Mouse mammary tumor virus and mammary tumorigenesis in wild mice. Imai S. **Pathol Int** 1996 Dec;46(12):919–32 (136 ref.)
Leukemogenesis by Moloney murine leukemia virus: a multistep process. Fan H. **Trends Microbiol** 1997 Feb; 5(2):74–82 (48 ref.)
[Opportunistic lymphoma] Katano H, et al. **Nippon Rinsho** 1997 Feb;55(2):441–5 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Lymphoproliferative syndromes associated to the Epstein Barr virus in organ transplants] Hidalgo M, et al. **Med Clin (Barc)** 1996 Sep 14;107(8):310–6 (116 ref.) **(Spa)**

GENETICS

Oncogenes and antioncogenes in the development of HPV associated tumors. Crawford L, et al. **Clin Dermatol** 1997 Mar–Apr;15(2):207–15 (96 ref.)
Viral genetic variation, AIDS, and the multistep nature of carcinogenesis: the feline leukemia virus model. Rohn JL, et al. **Leukemia** 1996 Dec;10(12):1867–9 (31 ref.)
The genetic program of genital human papillomaviruses in infection and cancer. Turek LP, et al. **Obstet Gynecol Clin North Am** 1996 Dec;23(4):735–58 (151 ref.)
[Sequence analysis of the carboxy terminal of the Epstein–Barr virus LMP–1 oncogene in Epstein–Barr virus associated disorders] Itakura O, et al. **Nippon Rinsho** 1997 Feb;55(2):467–72 (15 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Mouse mammary tumor virus and the immune system. Ross SR. **Adv Pharmacol** 1997;39:21–46 (95 ref.)
Human cytotoxic T lymphocyte responses to Epstein–Barr virus infection. Rickinson AB, et al. **Annu Rev Immunol** 1997;15:405–31 (135 ref.)
The rabbit viral skin papillomas and carcinomas: a model for the immunogenetics of HPV–associated carcinogenesis. Breitburd F, et al. **Clin Dermatol** 1997 Mar–Apr; 15(2):237–47 (111 ref.)
Humoral immune response to human papillomavirus infection. Carter JJ, et al. **Clin Dermatol** 1997 Mar–Apr; 15(2):249–59 (89 ref.)
Cellular immunity in cutaneous and genital HPV infections. Malejczyk J, et al. **Clin Dermatol** 1997 Mar–Apr; 15(2):261–74 (131 ref.)
Immunology of papillomavirus infection. Frazer IH. **Curr Opin Immunol** 1996 Aug;8(4):484–91 (89 ref.)
Moloney leukemia virus–induced cell surface antigen mimicry by monoclonal antibodies. Baskin JG, et al. **Immunol Res** 1995;14(4):292–316 (96 ref.)
Analysis of cytokine profiles in patients with human papillomavirus–associated neoplasms [editorial; comment] Wu TC, et al. **J Natl Cancer Inst** 1997 Feb 5;89(3):185–7 (33 ref.) Comment on: J Natl Cancer Inst 1997 Feb 5;89(3):245–50.
Effects of CD40 stimulation in the prevention of human EBV–lymphomagenesis. Funakoshi S, et al. **Leuk Lymphoma** 1997 Jan;24(3–4):187–99 (32 ref.)
Adoptive immunotherapy for Epstein–Barr virus–related lymphoma. Smith CA, et al. **Leuk Lymphoma** 1996 Oct; 23(3–4):213–20 (31 ref.)
The role of the immune response in MULV–induced lymphomagenesis. Marshall DJ, et al. **Leukemia** 1996 Dec; 10(12):1860–6 (79 ref.)
Immunologic responses to human papillomavirus infection. Gissmann L. **Obstet Gynecol Clin North Am** 1996 Sep; 23(3):625–39 (108 ref.)
[Anti–papillomavirus immunologic response and natural history of cervical lesions] Vinatier D, et al. **Contracept Fertil Sex** 1997 May;25(5):339–47 (88 ref.) **(Fre)**
[Role of macrophages in papillomavirus infections] Bianchi A, et al. **Pathol Biol (Paris)** 1997 Feb;45(2):165–8 (25 ref.) (Eng. Abstr.) **(Fre)**
[Immunologic aspects of infections with papillomaviruses. Prospects for a vaccine] Höpfl R, et al. **Hautarzt** 1996 Oct; 47(10):739–43 (42 ref.) (Eng. Abstr.) **(Ger)**
[EB virus infection] Kawa K. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Dec;19(6):583–7 (4 ref.) **(Jpn)**

PATHOLOGY

Tissue effects and host response. The key to the rational triage of cervical neoplasia. Ferenczy A, et al. **Obstet Gynecol Clin North Am** 1996 Dec;23(4):759–82 (50 ref.)
Cytopathic feline leukemia viruses cause apoptosis in hemolymphatic cells. Rojko JL, et al. **Prog Mol Subcell Biol** 1996;16:13–43 (150 ref.)
Papillomaviruses and potential copathogens. DiPaolo JA, et al. **Toxicol Lett** 1996 Nov;88(1–3):1–7 (25 ref.)
[Primary carcinoma of Bartholin's glands with HPV 18 detection] Schwarzlos G, et al. **Zentralbl Gynakol** 1997; 119(3):133–5 (17 ref.) (Eng. Abstr.) **(Ger)**
[Diagnosis of Epstein–Barr virus–associated gastric carcinoma and its background gastric mucosa] Yanai H, et al. **Nippon Rinsho** 1997 Feb;55(2):374–80 (31 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

EBV–B cell interactions: immortalization, rescue from apoptosis, tumorigenicity (a short review). Klein G. **Acta Microbiol Immunol Hung** 1996;43(2–3):97–105 (37 ref.)

PREVENTION & CONTROL

Efficacy of an inactivated feline leukemia virus vaccine. Hoover EA, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):379–83 (53 ref.)
The relevance of feline retroviruses to the development of vaccines against HIV. Jarrett O. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):385–7 (23 ref.)
Efficacy of recombinant feline leukemia virus vaccines. Jarrett O. **AIDS Res Hum Retroviruses** 1996 Mar 20; 12(5):435–6 (14 ref.)
Correlates of immune protection after vaccination with attenuated live murine leukemia virus. Ruprecht RM, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):375–7 (14 ref.)
Vaccination against papillomavirus in cattle. Campo MS. **Clin Dermatol** 1997 Mar–Apr;15(2):275–83 (51 ref.)
Papillomavirus–like particles for serology and vaccine development. Kirnbauer R. **Intervirology** 1996; 39(1–2):54–61 (82 ref.)
Synthesis, properties and applications of papillomavirus–like particles. Sapp M, et al. **Intervirology** 1996;39(1–2):49–53 (30 ref.)
Issues related to development of Epstein–Barr virus vaccines. Spring SB, et al. **J Natl Cancer Inst** 1996 Oct 16; 88(20):1436–41 (66 ref.)

PSYCHOLOGY

Counseling patients with genital warts. Reitano M. **Am J Med** 1997 May 5;102(5A):38–43 (15 ref.)

THERAPY

Therapeutic approaches to genital warts. Beutner KR, et al. **Am J Med** 1997 May 5;102(5A):28–37 (63 ref.)
The current status of therapeutic HPV vaccine. van Driel WJ, et al. **Ann Med** 1996 Dec;28(6):471–7 (72 ref.)
Therapy of anogenital HPV–induced lesions. Gross G, et al. **Clin Dermatol** 1997 May–Jun;15(3):457–70 (127 ref.)
Therapeutic approaches to papillomavirus infections. Baker GE, et al. **Dermatol Clin** 1997 Apr;15(2):331–40 (71 ref.)
The role of vaccines in the control of STDs: HPV vaccines. Frazer IH. **Genitourin Med** 1996 Dec;72(6):398–403 (65 ref.)
Adoptive cell therapy with donor lymphocytes for EBV–associated lymphomas developing after allogeneic marrow transplants. O'Reilly RJ, et al. **Important Adv Oncol** 1996;:149–66 (172 ref.)
Adoptive immunotherapy for Epstein–Barr virus–related lymphoma. Smith CA, et al. **Leuk Lymphoma** 1996 Oct; 23(3–4):213–20 (31 ref.)
Control of virus–induced lymphoproliferation: Epstein–Barr virus–induced lymphoproliferation and host immunity. Rooney CM, et al. **Mol Med Today** 1997 Jan;3(1):24–30 (44 ref.)
Therapeutic approaches for severe Epstein–Barr virus infection. Okano M. **Pediatr Hematol Oncol** 1997 Mar–Apr; 14(2):109–19 (44 ref.)
Clinical and immunological considerations in Epstein–Barr virus–associated diseases. Andersson J. **Scand J Infect Dis Suppl** 1996;100:72–82 (36 ref.)
Epstein–Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma. Ambinder RF, et al. **Semin Cancer Biol** 1996 Aug;7(4):217–26 (69 ref.)
[Adoptive immune therapy using EBV–specific CTL] Kuzushima K, et al. **Nippon Rinsho** 1997 Feb;55(2):473–8 (17 ref.) (Eng. Abstr.) **(Jpn)**

TRANSMISSION

Role of cesarean section in prevention of recurrent respiratory papillomatosis—is there one? Kosko JR, et al. **Int J Pediatr Otorhinolaryngol** 1996 Mar;35(1):31–8 (26 ref.)

VETERINARY

Avian tumor viruses: persistent and evolving pathogens. Witter RL. **Acta Vet Hung** 1997;45(3):251–66 (37 ref.)
Feline leukaemia virus: a review of immunity and vaccination. Sparkes AH. **J Small Anim Pract** 1997 May; 38(5):187–94 (49 ref.)
Cooperating events in lymphomagenesis mediated by feline leukemia virus. Levy LS, et al. **Leukemia** 1997 Apr;11 Suppl 3:239–41 (16 ref.)
Avian retroviruses. Fadly AM. **Vet Clin North Am Food Anim Pract** 1997 Mar;13(1):71–85 (65 ref.)

VIROLOGY

New aspects in the pathogenesis of polyomavirus-induced disease. Dörries K. **Adv Virus Res** 1997;48:205-61 (204 ref.)
Human papillomavirus and human disease. Beutner KR, et al. **Am J Med** 1997 May 5;102(5A):9-15 (36 ref.)
The role of Epstein-Barr virus in the pathogenesis of Hodgkin's disease. Niedobitek G. **Ann Oncol** 1996;7 Suppl 4:11-7 (67 ref.)
In vitro experimental systems for HPV: epithelial raft cultures for investigations of viral reproduction and pathogenesis and for genetic analyses of viral proteins and regulatory sequences. Chow LT, et al. **Clin Dermatol** 1997 Mar-Apr; 15(2):217-27 (63 ref.)
Epstein-Barr virus oncogenesis. Knecht H, et al. **Crit Rev Oncol Hematol** 1997 Jul;26(2):117-35 (263 ref.)
The role of Epstein-Barr virus in lymphoid malignancies. Su IJ, et al. **Crit Rev Oncol Hematol** 1997 May;26(1):25-41 (148 ref.)
Pathobiology of vulvar squamous neoplasia. Crum CP, et al. **Curr Opin Obstet Gynecol** 1997 Feb;9(1):63-9 (50 ref.)
Cervical pathology. Herrington CS. **Curr Opin Obstet Gynecol** 1997 Feb;9(1):57-62 (54 ref.)
Cervical human papillomavirus infection and intraepithelial neoplasia: a review. Mitchell MF, et al. **J Natl Cancer Inst Monogr** 1996;(21):17-25 (84 ref.)
The role of the immune response in MULV-induced lymphomagenesis. Marshall DJ, et al. **Leukemia** 1996 Dec; 10(12):1860-6 (79 ref.)
Viral genetic variation, AIDS, and the multistep nature of carcinogenesis: the feline leukemia virus model. Rohn JL, et al. **Leukemia** 1996 Dec;10(12):1867-9 (31 ref.)
In situ PCR to cells and to wax sections. An alternative to in situ hybridization for the detection of low copies of human papillomavirus and cytomegalovirus DNA. Mougin C, et al. **Methods Mol Biol** 1997;71:77-97 (44 ref.)
Mouse Moloney leukemia virus infects microglia but not neurons even though it induces motor neuron disease. Zachary JF, et al. **Mol Psychiatry** 1997 Mar;2(2):104-6 (19 ref.)
Virus infection and cancer risk in transplant recipients. McGregor JM, et al. **Trends Microbiol** 1996 Jan;4(1):2-3 (14 ref.)
[Follow-up of high risk, human papillomavirus (HPV)-positive patients with cancer of the uterine cervix] Hernádi Z, et al. **Orv Hetil** 1997 May 18;138(20):1249-53 (29 ref.) (Eng. Abstr.) **(Hun)**

TUMOR VIRUSES see **ONCOGENIC VIRUSES**

TUMOR VIRUSES, MURINE

GENETICS

Improved retroviral vectors for hematopoietic stem cell protection and in vivo selection. Baum C, et al. **J Hematother** 1996 Aug;5(4):323-9 (40 ref.)

TUMORICIDAL ACTIVITY, IMMUNOLOGIC see **CYTOTOXICITY, IMMUNOLOGIC**

TUMORIGENICITY TESTS see **CARCINOGENICITY TESTS**

TUMORS see **NEOPLASMS**

TUNGSTEN COMPOUNDS

PHARMACOLOGY

[Mini review: a factor enhanced the antibacterial effect of beta-lactams on methicillin-resistant Staphylococcus aureus] Tajima Y. **Rinsho Byori** 1996 Nov;44(11):1093-9 (6 ref.) (Eng. Abstr.) **(Jpn)**

TUNICA INTIMA

DRUG EFFECTS

C-type natriuretic protein inhibits intimal thickening after vascular injury. Matsuo H, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:45-7 (10 ref.)
[Effect of vitamin E on the endothelial function of the regenerated aorta in rats following direct arterial injury] Cartier R, et al. **Ann Chir** 1996;50(8):673-81 (36 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis. Hurt-Camejo E, et al. **Arterioscler Thromb Vasc Biol** 1997 Jun;17(6):1011-7 (101 ref.)

PATHOLOGY

Wild-type p53 gene transfer: a novel therapeutic strategy for neointimal hyperplasia after arterial injury. Yonemitsu Y, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:395-400 (13 ref.)
Neo-intimal hyperplasia in vascular grafts and its implications for autologous arterial grafting. Purcell C, et al. **Ann R Coll Surg Engl** 1997 May;79(3):164-8 (43 ref.)
Endothelial cell injury in cardiovascular surgery: the intimal hyperplastic response. Allaire E, et al. **Ann Thorac Surg** 1997 Feb;63(2):582-91 (112 ref.)
The intima: development and monoclonal responses to injury. Schwartz SM, et al. **Atherosclerosis** 1995 Dec;118 Suppl:S125-40 (125 ref.)
[Atherosclerosis: a dynamic disease of the arterial intima with a chronic evolution in a predictable phase and an unpredictable phase] Vaquero M. **Med Clin (Barc)** 1997 Jul 5;109(6):229-35 (59 ref.) **(Spa)**

ULTRASONOGRAPHY

Non-invasive assessment of cardiovascular disease in diabetes mellitus. Lehmann ED, et al. **Lancet** 1997 Jul;350 Suppl 1:SI14-9 (59 ref.)
Reproducibility of in vivo carotid intima-media thickness measurements: a review. Kanters SD, et al. **Stroke** 1997 Mar;28(3):665-71 (48 ref.)

TUNICA INTIMA VASORUM see **TUNICA INTIMA**

TUNICA MEDIA

Ruptured inferior mesenteric artery aneurysm due to segmental mediolytic arteritis. Kato T, et al. **Cardiovasc Surg** 1996 Oct;4(5):644-6 (10 ref.)

PATHOLOGY

[Cystic medial necrosis] Imakita M. **Ryoikibetsu Shokogun Shirizu** 1996;(14):405-7 (18 ref.) **(Jpn)**

ULTRASONOGRAPHY

Reproducibility of in vivo carotid intima-media thickness measurements: a review. Kanters SD, et al. **Stroke** 1997 Mar;28(3):665-71 (48 ref.)

TUNICATA see **UROCHORDATA**

TURBELLARIA

PHYSIOLOGY

Nutritional and respiratory pathways to parasitism exemplified in the Turbellaria. Jennings JB. **Int J Parasitol** 1997 Jun;27(6):679-91 (77 ref.)

TURBINATES

Middle turbinate headache syndrome. Anselmo-Lima WT, et al. **Headache** 1997 Feb;37(2):102-6 (17 ref.)
Leiomyosarcoma of the nasal cavity. Case report and literature review. Lippert BM, et al. **ORL J Otorhinolaryngol Relat Spec** 1996 Mar-Apr; 58(2):115-20 (49 ref.)

PHYSIOPATHOLOGY

[Presumed physiopathology of the nasal wall surgery and contemporary techniques of the inferior turbinates surgery] Passàli D, et al. **Acta Otorhinolaryngol Ital** 1996 Jun; 16(3):202-10 (61 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

[Inferior turbinectomy in asthmatic children] Ducroz V, et al. **Ann Otolaryngol Chir Cervicofac** 1997;114(1-2):36-40 (14 ref.) (Eng. Abstr.) **(Fre)**
[Presumed physiopathology of the nasal wall surgery and contemporary techniques of the inferior turbinates surgery] Passàli D, et al. **Acta Otorhinolaryngol Ital** 1996 Jun; 16(3):202-10 (61 ref.) (Eng. Abstr.) **(Ita)**

TURKEYS

Towards the routine application of nucleic acid technology for avian disease diagnosis. Cavanagh D, et al. **Acta Vet Hung** 1997;45(3):281-98 (37 ref.)
Epidemiology of avian diseases. Kaleta EF. **Acta Vet Hung** 1997;45(3):267-80 (11 ref.)
DNA amplification methods for diagnosis and epidemiological investigations of avian mycoplasmosis. Kempf I. **Acta Vet Hung** 1997;45(3):373-86 (65 ref.)
Changing expectations in the control of Mycoplasma gallisepticum. Kleven SH. **Acta Vet Hung** 1997; 45(3):299-305 (38 ref.)
Avian tumor viruses: persistent and evolving pathogens. Witter RL. **Acta Vet Hung** 1997;45(3):251-66 (37 ref.)

EMBRYOLOGY

Comparative development of the turkey and chicken embryo from cleavage through hypoblast formation. Bakst MR, et al. **Poult Sci** 1997 Jan;76(1):83-90 (14 ref.)

GENETICS

Direct and correlated responses to long-term selection for increased body weight and egg production in turkeys. Nestor KE, et al. **Poult Sci** 1996 Oct;75(10):1180-91 (54 ref.)

GROWTH & DEVELOPMENT

Relevance of water quality to broiler and turkey performance. Barton TL. **Poult Sci** 1996 Jul;75(7):854-6 (1 ref.)

MICROBIOLOGY

Principles of ex ovo competitive exclusion and in ovo administration of Lactobacillus reuteri. Edens FW, et al. **Poult Sci** 1997 Jan;76(1):179-96 (120 ref.)

TURMERIC YELLOW see **CURCUMIN**

TURNER-KIESER SYNDROME see **NAIL-PATELLA SYNDROME**

TURNER'S SYNDROME

[Current aspects of Turner syndrome] Battin J. **Arch Pediatr** 1996 Jun;3(6):588-97 (45 ref.) (Eng. Abstr.) **(Fre)**
[Trisomy 13 syndrome (Patau syndrome), trisomy 18 syndrome (Edwards syndrome), Down syndrome (trisomy 21 syndrome), Turner syndrome (XO gonadal dysgenesis)] Harada N, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (15):198-201 (8 ref.) **(Jpn)**

DIAGNOSIS

[Gonadal dysgenesis: diagnosis and therapeutic perspectives] Youlton R. **Rev Med Chil** 1996 Jan;124(1):103-8 (34 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

[Possibilities to increase the efficacy of growth hormone therapy in Turner syndrome] Ságodi L, et al. **Orv Hetil** 1997 Jun 8;138(23):1501-5 (36 ref.) (Eng. Abstr.) **(Hun)**

ETIOLOGY

Decreased sensitivity to insulin-like growth factor I as a cause of growth failure in Turner's syndrome? [comment] Kiess W, et al. **Eur J Clin Invest** 1997 Jul;27(7):548-9 (14 ref.) Comment on: Eur J Clin Invest 1997 Jul;27(7):543-7.

GENETICS

Gonadal (ovarian) dysgenesis in 46,XX individuals: frequency of the autosomal recessive form. Meyers CM, et al. **Am J Med Genet** 1996 Jun 28;63(4):518-24 (17 ref.)
[Genetic basis of Turner syndrome (published erratum appears in Pol Arch Med Wewn 1995 Aug;94(2):183)] Ślęzak R, et al. **Pol Arch Med Wewn** 1995 Oct;94(4):358-63 (39 ref.) **(Pol)**

METABOLISM

[Pediatric diseases that affect bone metabolism] Burrows R. **Rev Med Chil** 1996 Aug;124(8 Suppl):86-91 (27 ref.) **(Spa)**

THERAPY

Turner's syndrome. Saenger P. **Curr Ther Endocrinol Metab** 1997;6:239-43 (3 ref.)
Turner's syndrome [see comments] Saenger P. **N Engl J Med** 1996 Dec 5;335(23):1749-54 (44 ref.) Comment in: N Engl J Med 1997 May 22;336(21):1526-7; discussion 1527-8. Comment in: N Engl J Med 1997 May 22;336(21):1527; discussion 1527-8.

TURNER'S SYNDROME, MALE see **NOONAN SYNDROME**

TURPENTINE

POISONING

Acute intoxication and recovery following massive turpentine ingestion: clinical and toxicological data. Troulakis G, et al. **Vet Hum Toxicol** 1997 Jun;39(3):155-7 (10 ref.)

TURTLES

METABOLISM

Metabolic adaptations supporting anoxia tolerance in reptiles: recent advances. Storey KB. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Jan; 113(1):23-35 (92 ref.)

PHYSIOLOGY

Anoxia tolerant animals from a neurobiological perspective. Lutz PL, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Jan; 113(1):3-13 (100 ref.)
Maintenance of cardiac function during anoxia in turtles: from cell to organism. Wasser JS. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Jan; 113(1):15-22 (39 ref.)
Contrasting strategies for anoxic brain survival--glycolysis up or down. Lutz PL, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):411-9 (59 ref.)
Scales of urine acidification: apical membrane-associated particles in turtle bladder. Steinmetz PR, et al.

TURTLES

Kidney Int 1996 Jun;49(6):1655–9 (15 ref.)

TWEENS see **POLYSORBATES**

TWENTY-FOUR HOUR RHYTHM see **CIRCADIAN RHYTHM**

TWIN STUDIES

Twin studies in diabetes mellitus. Hawkes CH. **Diabet Med** 1997 May;14(5):347–52 (30 ref.)

Genetic influences on the response of body fat and fat distribution to positive and negative energy balances in human identical twins. Bouchard C, et al. **J Nutr** 1997 May; 127(5 Suppl):943S–947S (18 ref.)

Twin studies in medicine—what do they tell us? Hawkes CH. **QJM** 1997 May;90(5):311–21 (45 ref.)

TWIN TRANSFUSION see **FETOFETAL TRANSFUSION**

TWIN TRANSFUSION SYNDROME see **FETOFETAL TRANSFUSION**

TWINS

see related
DISEASES IN TWINS

Simultaneous death of twins. An environmental hazard or SIDS? Ramos V, et al. **Am J Forensic Med Pathol** 1997 Mar;18(1):75–8 (22 ref.)

Cleft–twin sets in Finland 1948–1987 [see comments] Nordström RE, et al. **Cleft Palate Craniofac J** 1996 Jul; 33(4):340–7 (65 ref.) Comment in: Cleft Palate Craniofac J 1996 Nov;33(6):530.

Fetal testing in twins. Denbow ML, et al. **Curr Opin Obstet Gynecol** 1997 Apr;9(2):96–100 (21 ref.)

Congenital abnormalities in twins: selective termination. Stewart KS, et al. **Curr Opin Obstet Gynecol** 1997 Apr; 9(2):136–9 (13 ref.)

First trimester fetal reduction: its role in the management of twin and higher order multiple pregnancies. Brambati B, et al. **Hum Reprod Update** 1995 Jul;1(4):397–408 (47 ref.)

Rudimentary uterine horn pregnancy. A case report on surviving twins delivered eight days apart. Nahum GG. **J Reprod Med** 1997 Aug;42(8):525–32 (30 ref.)

The early parenting of twins. Thomas JG. **Mil Med** 1996 Apr;161(4):233–5 (18 ref.)

Sonographic examination does not predict twin growth discordance accurately. Caravello JW, et al. **Obstet Gynecol** 1997 Apr;89(4):529–33 (14 ref.)

Genetics of ageing. Macieira-Coelho A. **Pathol Biol (Paris)** 1997 Jun;45(6):500–5 (46 ref.)

Antenatal assessment of twin gestation. Devoe LD, et al. **Semin Perinatol** 1995 Oct;19(5):413–23 (54 ref.)

Ultrasound in twin pregnancy. Divon MY, et al. **Semin Perinatol** 1995 Oct;19(5):404–12 (57 ref.)

Selected issues in premature rupture of the membranes: herpes, cerclage, twins, tocolysis, and hospitalization. Lewis R, et al. **Semin Perinatol** 1996 Oct;20(5):451–61 (76 ref.)

Intrapartum management of multiple gestation. Udom-Rice I, et al. **Semin Perinatol** 1995 Oct;19(5):424–34 (94 ref.)

Genetic diagnosis in multiple pregnancies. Wapner RJ. **Semin Perinatol** 1995 Oct;19(5):351–62 (61 ref.)

Monochorionic twin pregnancies: 'les liaisons dangereuses' [comment] Ville Y. **Ultrasound Obstet Gynecol** 1997 Aug; 10(2):82–5 (45 ref.) Comment on: Ultrasound Obstet Gynecol 1997 Aug;10(2):86–9.

[Breech extraction of the second twin. 56 cases and review of the literature] Riethmuller D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(1):94–8 (23 ref.) (Eng. Abstr.) **(Fre)**

[Successful twin delivery following reduction of quadruplet pregnancy] Patkós P, et al. **Orv Hetil** 1996 Nov 3; 137(44):2458–63 (37 ref.) (Eng. Abstr.) **(Hun)**

STATISTICS & NUMERICAL DATA

Earnings and schooling: an overview of economic research based on the Australian Twin Register. Miller P, et al. **Acta Genet Med Gemellol (Roma)** 1996;45(4):417–29 (19 ref.)

TWINS, CONJOINED

An unusual case of monozygotic epigastric heteropagus twinning. Hwang EH, et al. **J Pediatr Surg** 1996 Oct; 31(10):1457–60 (19 ref.)

EMBRYOLOGY

Minimally united ischiopagus twins: infraumbilical union with cloacal anomalies. Spencer R. **J Pediatr Surg** 1996 Nov; 31(11):1538–45 (25 ref.)

PATHOLOGY

Minimally united ischiopagus twins: infraumbilical union with cloacal anomalies. Spencer R. **J Pediatr Surg** 1996 Nov; 31(11):1538–45 (25 ref.)

Anatomic description of conjoined twins: a plea for standardized terminology. Spencer R. **J Pediatr Surg** 1996 Jul;31(7):941–4 (6 ref.)

SURGERY

Successful early separation of a premature xipho-omphalopagus conjoined twins: a case report. Lai HS, et al. **Can J Surg** 1997 Apr;40(2):139, 141–2 (7 ref.)

TWINS, DIZYGOTIC

The biology of the twinning process: how placentation influences outcome. Benirschke K. **Semin Perinatol** 1995 Oct;19(5):342–50 (26 ref.)

GENETICS

[Laterality in twins] Reiss M. **Z Morphol Anthropol** 1996 Sep; 81(2):141–55 (79 ref.) (Eng. Abstr.) **(Ger)**

TWINS, FRATERNAL see **TWINS, DIZYGOTIC**

TWINS, IDENTICAL see **TWINS, MONOZYGOTIC**

TWINS, MONOZYGOTIC

Embryologic development and monozygotic twinning. Hall JG, et al. **Acta Genet Med Gemellol (Roma)** 1996; 45(1–2):53–7 (24 ref.)

Multiple cerebral aneurysms in identical twins. Hagen T, et al. **AJNR Am J Neuroradiol** 1997 May;18(5):973–6 (34 ref.)

Twin-reversed arterial perfusion (TRAP) sequence: case reports and review of literature. Hanafy A, et al. **Aust N Z J Obstet Gynaecol** 1997 May;37(2):187–91 (29 ref.)

Monoamniotic twin pregnancy and cord entanglement: a clinical dilemma. Ritossa M, et al. **Aust N Z J Obstet Gynaecol** 1996 Aug;36(3):309–12 (12 ref.)

Keratoconus in two pairs of identical twins. Bechara SJ, et al. **Cornea** 1996 Jan;15(1):90–3 (22 ref.)

A hypothesis for the aetiology of spastic cerebral palsy—the vanishing twin. Pharoah PO, et al. **Dev Med Child Neurol** 1997 May;39(5):292–6 (36 ref.)

The use of skin from a monozygotic twin combined with cultured epithelial autografts as coverage for a large surface area burn: a case report and review of the literature. Caruso DM, et al. **J Burn Care Rehabil** 1996 Sep–Oct;17(5):432–4 (18 ref.)

Genetic influences on the response of body fat and fat distribution to positive and negative energy balances in human identical twins. Bouchard C, et al. **J Nutr** 1997 May; 127(5 Suppl):943S–947S (18 ref.)

Systemic lupus erythematosus in childhood. Concordance in a pair of monozygotic twins for anti-dsDNA antibodies and discordance for disease expression [letter] Bustabad S, et al. **J Rheumatol** 1997 Jul;24(7):1450–1 (7 ref.)

Monoamniotic twins delivered liveborn with a forked umbilical cord. Fraser RB, et al. **Pediatr Pathol Lab Med** 1997 Jul–Aug;17(4):639–44 (9 ref.)

The sequential in utero death of heterokaryotic monozygotic twins. A case report and literature review. Weeks AD, et al. **Prenat Diagn** 1996 Jul;16(7):657–63 (31 ref.)

The biology of the twinning process: how placentation influences outcome. Benirschke K. **Semin Perinatol** 1995 Oct;19(5):342–50 (26 ref.)

[Production of monozygotic multiple offspring in agricultural domestic animals] Reichelt B, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Aug–Sep; 103(8–9):340–8 (72 ref.) (Eng. Abstr.) **(Ger)**

[Identical twin sisters with IgA nephropathy] Masuda J, et al. **Nippon Jinzo Gakkai Shi** 1996 Jan;38(1):52–6 (23 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Twinning: mechanisms and genetic implications. Hall JG. **Curr Opin Genet Dev** 1996 Jun;6(3):343–7 (39 ref.)

[Laterality in twins] Reiss M. **Z Morphol Anthropol** 1996 Sep; 81(2):141–55 (79 ref.) (Eng. Abstr.) **(Ger)**

TWO-PARAMETER MODELS see **MODELS, STATISTICAL**

TY1 TRANSPOSON see **DNA INSERTION ELEMENTS**

TYLENCHOIDEA

PHYSIOLOGY

Manipulation of host gene expression by root-knot nematodes. Bird DM. **J Parasitol** 1996 Dec;82(6):881–8 (56 ref.)

TYMPANIC CAVITY see **EAR, MIDDLE**

TYMPANIC MEMBRANE

see related
TYMPANOPLASTY

PATHOLOGY

Epithelial migration in keratosis obturans. Corbridge RJ, et al. **Am J Otolaryngol** 1996 Nov–Dec;17(6):411–4 (12 ref.)

PHYSIOPATHOLOGY

Tympanosclerosis. Wielinga EW, et al. **Clin Otolaryngol** 1993 Oct;18(5):341–9 (76 ref.)

[Pockets of tympanic membrane retraction] Ars B, et al. **Acta Otorrinolaringol Esp** 1996 Nov–Dec;47(6):417–24 (56 ref.) (Eng. Abstr.) **(Spa)**

TYMPANOMETRY see **ACOUSTIC IMPEDANCE TESTS**

TYMPANOPLASTY

ADVERSE EFFECTS

[Failures after tympanoplasty] Desaulty A, et al. **Rev Laryngol Otol Rhinol (Bord)** 1996;117(5):357–61 (24 ref.) (Eng. Abstr.) **(Fre)**

METHODS

[Using cartilage in middle ear surgery] Hildmann H, et al. **HNO** 1996 Oct;44(10):597–602 (10 ref.) **(Ger)**

TYMPANOSTOMY TUBE INSERTION see **MIDDLE EAR VENTILATION**

TYMPANUM see **EAR, MIDDLE**

TYPE C ONCOVIRUSES see **RETROVIRIDAE**

TYPE D RETROVIRUSES, SIMIAN see **RETROVIRUSES TYPE D, SIMIAN**

TYPE I HYPERSENSITIVITY see **HYPERSENSITIVITY, IMMEDIATE**

TYPE II RESTRICTION ENZYMES see **DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC**

TYPE III HYPERSENSITIVITY see **IMMUNE COMPLEX DISEASES**

TYPE IV HYPERSENSITIVITY see **HYPERSENSITIVITY, DELAYED**

TYPHOID

COMPLICATIONS

Unusual neurologic manifestation of enteric fever—case report and review of the literature. Liman AS. **Cent Afr J Med** 1996 Oct;42(10):301–2 (6 ref.)

DIAGNOSIS

Recent advances in the diagnosis of enteric fever. Chaudhry R, et al. **Trop Gastroenterol** 1995 Jul–Sep;16(3):8–12 (24 ref.)

DRUG THERAPY

Multidrug-resistant Salmonella typhi: a worldwide epidemic. Rowe B, et al. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S106–9 (30 ref.)

EPIDEMIOLOGY

[The molecular epidemiology of typhoid] Riapis LA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Jul–Aug;(4):96–9 (39 ref.) **(Rus)**

GENETICS

[The molecular epidemiology of typhoid] Riapis LA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Jul–Aug;(4):96–9 (39 ref.) **(Rus)**

PREVENTION & CONTROL

New and improved vaccines. Promising weapons against varicella, hepatitis A, and typhoid fever. Conrad DA, et al. **Postgrad Med** 1996 Oct;100(4):113–8, 121–5, 127 (20 ref.)

[Vaccination against typhoid fever: results and perspectives] Gremiakova TA, et al. **Vestn Ross Akad Med Nauk** 1997; (6):11–6 (62 ref.) (Eng. Abstr.) **(Rus)**

TYPHOID-PARATYPHOID VACCINES

New and improved vaccines. Promising weapons against varicella, hepatitis A, and typhoid fever. Conrad DA, et al. **Postgrad Med** 1996 Oct;100(4):113–8, 121–5, 127 (20 ref.)

ADMINISTRATION & DOSAGE

[Vaccination against typhoid fever: results and perspectives] Gremiakova TA, et al. **Vestn Ross Akad Med Nauk** 1997; (6):11–6 (62 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

[The problem of designing typhoid vaccines] Tymchuk SN, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Jul–Aug; (4):86–90 (50 ref.) **(Rus)**

TYPHUS, ABDOMINAL see **TYPHOID**

TYPHUS, SAO PAULO see **ROCKY MOUNTAIN SPOTTED FEVER**

TYPING, BACTERIAL see **BACTERIAL TYPING TECHNIQUES**

TYPING, BACTERIOPHAGE see **BACTERIOPHAGE TYPING**

TYPING, FUNGAL see **MYCOLOGICAL TYPING TECHNIQUES**

TYPOLOGY see **SOMATOTYPES**

TYROSINASE see **MONOPHENOL MONOOXYGENASE**

TYROSINE

Localization signals in proteins internalized from the cell surface. Banting G. **Biochem Soc Trans** 1996 May; 24(2):531–4 (29 ref.)

ANALOGS & DERIVATIVES

Pathways for oxidation of low density lipoprotein by myeloperoxidase: tyrosyl radical, reactive aldehydes, hypochlorous acid and molecular chlorine. Heinecke JW. **Biofactors** 1997;6(2):145–55 (44 ref.)

Detection and quantitation of nitrotyrosine residues in proteins: in vivo marker of peroxynitrite. Crow JP, et al. **Methods Enzymol** 1996;269:185–94 (26 ref.)

Nitrotyrosine as biomarker for reactive nitrogen species. van der Vliet A, et al. **Methods Enzymol** 1996;269:175–84 (50 ref.)

Antibodies that recognize nitrotyrosine. Ye YZ, et al. **Methods Enzymol** 1996;269:201–9 (11 ref.)

BIOSYNTHESIS

Microbial production of L-tyrosine: a review. Maiti TK, et al. **Hindustan Antibiot Bull** 1995 Feb–Nov;37(1–4):51–65 (88 ref.)

BLOOD

Tyrosinemia: the Quebec experience. Paradis K. **Clin Invest Med** 1996 Oct;19(5):311–6 (26 ref.)

Diagnosis and management of tyrosinemia type I. Holme E, et al. **Curr Opin Pediatr** 1995 Dec;7(6):726–32 (45 ref.)

CHEMISTRY

Oxidative damage and tyrosine nitration from peroxynitrite. Beckman JS. **Chem Res Toxicol** 1996 Jul–Aug;9(5):836–44 (79 ref.)

Can cysteine direct tyrosine in signal transduction for environment-oriented gene control? Nakashima I. **Nagoya J Med Sci** 1996 Mar;59(1–2):1–10 (72 ref.)

METABOLISM

Tyrosine and its catabolites: from disease to cancer. Tanguay RM, et al. **Acta Biochim Pol** 1996;43(1):209–16 (33 ref.)

Protein tyrosine phosphorylation and signal transduction during capacitation-acrosome reaction and zona pellucida binding in human sperm. Naz RK. **Arch Androl** 1996 Jul–Aug;37(1):47–55 (48 ref.)

Mesoprefrontal dopaminergic neurons: can tyrosine availability influence their functions? Tam SY, et al. **Biochem Pharmacol** 1997 Feb 21;53(4):441–53 (60 ref.)

Angiotensin II-induced tyrosine phosphorylation in mesangial and vascular smooth muscle cells. Marrero MB, et al. **Clin Exp Pharmacol Physiol** 1996 Jan;23(1):83–8 (46 ref.)

The nicotinic acetylcholine receptor at the neuromuscular junction: assembly and tyrosine phosphorylation. Wang ZZ, et al. **Cold Spring Harb Symp Quant Biol** 1996; 61:363–71 (51 ref.)

Tyrosine phosphorylation and axon guidance: of mice and flies. Desai CJ, et al. **Curr Opin Neurobiol** 1997 Feb; 7(1):70–4 (33 ref.)

Tyrosine phosphorylation and Fcgamma receptor-mediated phagocytosis. Strzelecka A, et al. **FEBS Lett** 1997 Jan 2; 400(1):11–4 (51 ref.)

Redox modulation of tyrosine phosphorylation-dependent signal transduction pathways. Monteiro HP, et al. **Free Radic Biol Med** 1996;21(3):323–33 (106 ref.)

Mutations in the fumarylacetoacetate hydrolase gene causing hereditary tyrosinemia type I: overview. St-Louis M, et al. **Hum Mutat** 1997;9(4):291–9 (44 ref.)

Peroxynitrite-dependent tyrosine nitration catalyzed by superoxide dismutase, myeloperoxidase, and horseradish peroxidase. Sampson JB, et al. **Methods Enzymol** 1996; 269:210–18 (23 ref.)

Tyrosine phosphorylation and protrusive structures of the growth cone. Goldberg DJ, et al. **Perspect Dev Neurobiol** 1996;4(2–3):183–92 (65 ref.)

PHYSIOLOGY

Immunoreceptor tyrosine-based inhibition motifs. Vivier E, et al. **Immunol Today** 1997 Jun;18(6):286–91 (52 ref.)

Tyrosines 113, 128, and 145 of SLP-76 are required for optimal augmentation of NFAT promoter activity. Fang N, et al. **J Immunol** 1996 Nov 1;157(9):3769–73 (16 ref.)

TYROSINE AMINOTRANSFERASE see **TYROSINE TRANSAMINASE**

TYROSINE HYDROXYLASE see **TYROSINE 3-MONOOXYGENASE**

TYROSINE 3-MONOOXYGENASE

BIOSYNTHESIS

Regulation of ionic conductances and gene expression by hypoxia in an oxygen sensitive cell line. Millhorn DE, et al. **Adv Exp Med Biol** 1996;410:135–42 (17 ref.)

CHEMISTRY

Tyrosine hydroxylase: human isoforms, structure and regulation in physiology and pathology. Nagatsu T. **Essays Biochem** 1995;30:15–35 (45 ref.)

GENETICS

Regulation of tyrosine hydroxylase mRNA stability by oxygen in PC12 cells. Czyzyk-Krzeska MF, et al. **Adv Exp Med Biol** 1996;410:143–50 (20 ref.)

GTP cyclohydrolase I gene, tetrahydrobiopterin, and tyrosine hydroxylase gene: their relations to dystonia and parkinsonism. Nagatsu T, et al. **Neurochem Res** 1996 Feb; 21(2):245–50 (47 ref.)

METABOLISM

Short- and long-term regulation of tyrosine hydroxylase in chromaffin cells by VIP and PACAP. Haycock JW. **Ann N Y Acad Sci** 1996 Dec 26;805:219–30; discussion 230–1 (34 ref.)

TYROSINE PHOSPHATASE see **PROTEIN-TYROSINE-PHOSPHATASE**

TYROSINE PROTEIN KINASE see **PROTEIN-TYROSINE KINASE**

TYROSINE-SPECIFIC PROTEIN KINASE see **PROTEIN-TYROSINE KINASE**

TYROSINE TRANSAMINASE

GENETICS

[Structure ond regulation of gene expression of tyrosine aminotransferase and proopiomelanocortin in mammals] Mertvetsov NP. **Vestn Ross Akad Med Nauk** 1997;(8):10–5 (50 ref.) **(Rus)**

TYROSYL PHOSPHOPROTEIN PHOSPHATASE see **PROTEIN-TYROSINE-PHOSPHATASE**

U1 SMALL NUCLEAR RIBONUCLEOPROTEINS see **RIBONUCLEOPROTEINS, SMALL, U1**

U1 SMALL NUCLEAR RNA see **RNA, SMALL NUCLEAR**

U2 SMALL NUCLEAR RNA see **RNA, SMALL NUCLEAR**

U3 SMALL NUCLEAR RIBONUCLEOPROTEINS see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

U3 SMALL NUCLEAR RNA see **RNA, SMALL NUCLEAR**

U4 SMALL NUCLEAR RNA see **RNA, SMALL NUCLEAR**

U5 SMALL NUCLEAR RNA see **RNA, SMALL NUCLEAR**

U6 SMALL NUCLEAR RNA see **RNA, SMALL NUCLEAR**

U7 SMALL NUCLEAR RIBONUCLEOPROTEINS see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

U7 SMALL NUCLEAR RNA see **RNA, SMALL NUCLEAR**

UBIQUINOL-CYTOCHROME-C REDUCTASE

METABOLISM

The role of the 'Rieske' iron sulfur protein in the hydroquinone oxidation (Q(P)) site of the cytochrome bc1 complex. The 'proton-gated affinity change' mechanism. Link TA. **FEBS Lett** 1997 Jul 28;412(2):257–64 (38 ref.)

UBIQUINONE

ANALOGS & DERIVATIVES

Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. Folkers K, et al. **Biochem Biophys Res Commun** 1997 May 19;234(2):296–9 (22 ref.)

METABOLISM

Function of coenzyme Q in the cell: some biochemical and physiological properties. Rauchová H, et al. **Physiol Res** 1995;44(4):209–16 (63 ref.)

PHYSIOLOGY

[Coenzyme Q--clinical significance] Jacheć W, et al. **Wiad Lek** 1994 Nov-Dec;47(21–24):850–3 (32 ref.) (Eng. Abstr.) **(Pol)**

UBIQUINONE REDUCTASE see **NAD(P)H DEHYDROGENASE (QUINONE)**

UBIQUITIN

ANALYSIS

Endosome-lysosomes, ubiquitin and neurodegeneration. Mayer RJ, et al. **Adv Exp Med Biol** 1996;389:261–9 (36 ref.)

BIOSYNTHESIS

Protein expression using ubiquitin fusion and cleavage. Baker RT. **Curr Opin Biotechnol** 1996 Oct;7(5):541–6 (42 ref.)

GENETICS

Protein expression using ubiquitin fusion and cleavage. Baker RT. **Curr Opin Biotechnol** 1996 Oct;7(5):541–6 (42 ref.)

METABOLISM

The ubiquitin-proteasome pathway: review of a novel intracellular mechanism of muscle protein breakdown during sepsis and other catabolic conditions. Hasselgren PO, et al. **Ann Surg** 1997 Mar;225(3):307–16 (59 ref.)

Ubiquitin-dependent protein degradation. Hochstrasser M. **Annu Rev Genet** 1996;30:405–39 (115 ref.)

Role of the ubiquitin/proteasome system in regulated protein degradation in Saccharomyces cerevisiae. Smith SE, et al. **Biol Chem** 1996 Jul–Aug;377(7–8):437–46 (107 ref.)

The DOA pathway: studies on the functions and mechanisms of ubiquitin-dependent protein degradation in the yeast Saccharomyces cerevisiae. Hochstrasser M, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:503–13 (36 ref.)

Protein degradation: de-ubiquitinate to decide your fate. Kalderon D. **Curr Biol** 1996 Jun 1;6(6):662–5 (12 ref.)

The N-end rule pathway of protein degradation. Varshavsky A. **Genes Cells** 1997 Jan;2(1):13–28 (75 ref.)

Regulating protein degradation by ubiquitination. Weissman AM. **Immunol Today** 1997 Apr;18(4):189–98 (119 ref.)

The ubiquitin-mediated proteolytic pathway as a therapeutic area. Rolfe M, et al. **J Mol Med** 1997 Jan;75(1):5–17 (139 ref.)

Effects of nucleotides on assembly of the 26S proteasome and degradation of ubiquitin conjugates. Hoffman L, et al. **Mol Biol Rep** 1997 Mar;24(1–2):13–6 (29 ref.)

Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. Mitch WE, et al. **N Engl J Med** 1996 Dec 19;335(25):1897–905 (70 ref.)

Selective proteolysis: 70-kDa heat-shock protein and ubiquitin-dependent mechanisms? Mayer RJ, et al. **Subcell Biochem** 1996;27:137–58 (77 ref.)

Lessons from the discovery of the ubiquitin system. Hershko A. **Trends Biochem Sci** 1996 Nov;21(11):445–9 (47 ref.)

[Ubiquitination and cell cycle] Utsugi T, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1826–32 (23 ref.) **(Jpn)**

PHYSIOLOGY

Mechanisms and regulation of ubiquitin-mediated cyclin degradation. Hershko A. **Adv Exp Med Biol** 1996;389:221–7 (40 ref.)

The ubiquitin system: a role in disease? Pallarés-Trujillo J, et al. **Med Res Rev** 1997 Mar;17(2):139–61 (144 ref.)

[Degradation mechanism of cell cycle factors by the proteasome] Tsurumi C, et al. **Nippon Rinsho** 1996 Mar; 54(3):861–9 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Proteolysis and cell cycle regulation] Tsurumi C, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1813–9 (19 ref.) **(Jpn)**

UDDER see **MAMMAE**

UDP GALACTOSE EPIMERASE see **URIDINE DIPHOSPHATE GLUCOSE EPIMERASE**

UDP GALACTOSE PYROPHOSPHORYLASE see **GALACTOSEPHOSPHATE URIDYLYLTRANSFERASE**

UDP GLUCOSE EPIMERASE see **URIDINE DIPHOSPHATE GLUCOSE EPIMERASE**

UDP GLUCURONOSYLTRANSFERASE see **GLUCURONOSYLTRANSFERASE**

ULCER

see related
CORNEAL ULCER
PEPTIC ULCER
SKIN ULCER

ULCER

CHEMICALLY INDUCED

Bleeding esophageal ulcers caused by NSAIDs. Sugawa C, et al. **Surg Endosc** 1997 Feb;11(2):143–6 (22 ref.)

DIAGNOSIS

Genital ulcer infections in the female patient and the vaginitides. Fiumara NJ. **Dermatol Clin** 1997 Apr; 15(2):233–45 (10 ref.)

DRUG THERAPY

Pharmacokinetics and pharmacodynamics of famotidine in paediatric patients. James LP, et al. **Clin Pharmacokinet** 1996 Aug;31(2):103–10 (21 ref.)

ETIOLOGY

Genital ulcer infections in the female patient and the vaginitides. Fiumara NJ. **Dermatol Clin** 1997 Apr; 15(2):233–45 (10 ref.)

Medical progress and ulcer disease: three key observations that changed the compass. Isenberg JI, et al. **Gastroenterology** 1997 Sep;113(3):1031–3 (21 ref.)

Idiopathic ulcerations of the oesophagus in HIV-infected patients: a review [editorial] Ehrenpreis ED, et al. **Int J STD AIDS** 1996 Mar–Apr;7(2):77–81 (32 ref.)

Idiopathic esophageal ulceration in patients infected with human immunodeficiency virus. Vega KJ, et al. **J Assoc Acad Minor Phys** 1996;7(4):93–8 (31 ref.)

A review of stress ulcer prophylaxis in the neurosurgical intensive care unit. Lu WY, et al. **Neurosurgery** 1997 Aug; 41(2):416–25; discussion 425–6 (150 ref.)

PATHOLOGY

Solitary "amyloid ulcer" localized in the sigmoid colon without evidence of systemic amyloidosis. Hirata K, et al. **Am J Gastroenterol** 1997 Feb;92(2):356–7 (11 ref.)

Hiatal hernia with cameron ulcers and erosions. Weston AP. **Gastrointest Endosc Clin N Am** 1996 Oct;6(4):671–9 (20 ref.)

PREVENTION & CONTROL

A review of stress ulcer prophylaxis in the neurosurgical intensive care unit. Lu WY, et al. **Neurosurgery** 1997 Aug; 41(2):416–25; discussion 425–6 (150 ref.)

THERAPY

Medical progress and ulcer disease: three key observations that changed the compass. Isenberg JI, et al. **Gastroenterology** 1997 Sep;113(3):1031–3 (21 ref.)

ULCER, APHTHOUS see **STOMATITIS, APHTHOUS**

ULNA

Ulnar drift [editorial] Flatt AE. **J Hand Ther** 1996 Oct–Dec; 9(4):282–92 (24 ref.)

The distal radioulnar joint: anatomy and management of disorders. Jaffe R, et al. **J Hand Ther** 1996 Apr–Jun; 9(2):129–38 (65 ref.)

ABNORMALITIES

Longitudinal failure of upper-limb formation. Manske PR. **Instr Course Lect** 1997;46:83–110 (95 ref.)

BLOOD SUPPLY

Ulnar neuropathy caused by a thrombosed ulnar vein. Case report and literature review. Grossman JA, et al. **Ann Chir Main Memb Super** 1996;15(4):244–7 (40 ref.)

INJURIES

Disorders of the distal radioulnar joint. Glowacki K, et al. **Am J Orthop** 1997 Mar;26(3):193–200 (51 ref.)

Isolated palmar radiocarpal dislocation and ulnar translocation: a case report and review of the literature. Howard RF, et al. **J Hand Surg [Am]** 1997 Jan;22(1):78–82 (10 ref.)

ULNA FRACTURES

COMPLICATIONS

Nonunion of distal radial fractures associated with distal ulnar shaft fractures: a report of four cases. McKee MD, et al. **J Orthop Trauma** 1997 Jan;11(1):49–53 (16 ref.)

Ulnar nerve laceration in a closed both bone forearm fracture. Torpey BM, et al. **J Orthop Trauma** 1996;10(2):131–4 (12 ref.)

Complications of type I coronoid fractures in competitive athletes: report of two cases and review of the literature. Liu SH, et al. **J Shoulder Elbow Surg** 1996 May–Jun; 5(3):223–7 (18 ref.)

DIAGNOSIS

Stress fracture of the ulnar diaphysis in a recreational golfer. Koskinen SK, et al. **Clin J Sport Med** 1997 Jan;7(1):63–5 (14 ref.)

ULNAR ARTERY

Spontaneous arterial thrombosis with an advanced ovarian malignancy. Minjarez DA, et al. **Gynecol Oncol** 1997 Jan; 64(1):176–9 (18 ref.)

INJURIES

Hypothenar hammer syndrome in sports. Müller LP, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;4(3):167–70 (23 ref.)

ULNAR NERVE

[Postoperative amyotrophic cubital neuralgia: 4 cases] Seror P, et al. **Rev Neurol (Paris)** 1997 Apr;153(3):201–4 (25 ref.) (Eng. Abstr.) **(Fre)**

INJURIES

Ulnar nerve laceration in a closed both bone forearm fracture. Torpey BM, et al. **J Orthop Trauma** 1996;10(2):131–4 (12 ref.)

PHYSIOPATHOLOGY

Pediatric ulnar mononeuropathy: report of 21 electromyography-documented cases and review of the literature. Felice KJ, et al. **J Child Neurol** 1996 Mar; 11(2):116–20 (21 ref.)

ULNAR NERVE COMPRESSION see **ULNAR NERVE COMPRESSION SYNDROME**

ULNAR NERVE COMPRESSION SYNDROME

DIAGNOSIS

Ulnar tunnel syndrome. Bednar MS. **Hand Clin** 1996 Nov; 12(4):657–64 (30 ref.)

Cubital tunnel syndrome and the painful upper extremity. Tetro AM, et al. **Hand Clin** 1996 Nov;12(4):665–77 (81 ref.)

[Ulnar neuropathy at the elbow. Diagnosis and therapeutic criteria] Montserrat L. **Neurologia** 1997 Mar;12(3):120–8 (59 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Ulnar neuropathy caused by a thrombosed ulnar vein. Case report and literature review. Grossman JA, et al. **Ann Chir Main Memb Super** 1996;15(4):244–7 (40 ref.)

SURGERY

Cubital tunnel syndrome and the painful upper extremity. Tetro AM, et al. **Hand Clin** 1996 Nov;12(4):665–77 (81 ref.)

ULNAR NERVE ENTRAPMENT see **ULNAR NERVE COMPRESSION SYNDROME**

ULTIMOBRANCHIAL BODY

see related
CALCITONIN

ULTRACENTRIFUGATION

METHODS

New revolutions in the evolution of analytical ultracentrifugation. Schuster TM, et al. **Curr Opin Struct Biol** 1996 Oct;6(5):650–8 (42 ref.)

Defining the structure and stability of macromolecular assemblies in solution: the re-emergence of analytical ultracentrifugation as a practical tool. Hensley P. **Structure** 1996 Apr 15;4(4):367–73 (59 ref.)

ULTRADIAN CYCLES see **ACTIVITY CYCLES**

ULTRAFILTRATION

see related
HEMOFILTRATION

Microdialysis and ultrafiltration. Janle EM, et al. **Adv Food Nutr Res** 1996;40:183–96 (16 ref.)

The hyperfiltration theory: a paradigm shift in nephrology. Brenner BM, et al. **Kidney Int** 1996 Jun;49(6):1774–7 (55 ref.)

METHODS

Measurement and analysis of unbound drug concentrations. Wright JD, et al. **Clin Pharmacokinet** 1996 Jun;30(6):445–62 (142 ref.)

Dye-affinity techniques for bioprocessing: recent developments. Garg N, et al. **J Mol Recognit** 1996 Jul–Aug; 9(4):259–74 (109 ref.)

ULTRAMICROTOMY see **MICROTOMY**

ULTRASONIC DIAGNOSIS see **ULTRASONOGRAPHY**

ULTRASONIC ENDOSCOPY see **ENDOSONOGRAPHY**

ULTRASONIC IMAGING see **ULTRASONOGRAPHY**

ULTRASONIC LITHOTRIPSY see **LITHOTRIPSY**

ULTRASONIC THERAPY

Physiotherapy for patients with soft tissue shoulder disorders: a systematic review of randomised clinical trials. van der Heijden GJ, et al. **BMJ** 1997 Jul 5;315(7099):25–30 (45 ref.)

Ultrasound focal beam surgery. ter Haar G. **Ultrasound Med Biol** 1995;21(9):1089–100 (78 ref.)

INSTRUMENTATION

[Therapeutic ultrasound in tumor therapy. Principles, applications and new developments] Huber P, et al. **Radiologe** 1996 Jan;36(1):64–71 (32 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Adjuvant therapy for ulcer care. Frantz RA. **Clin Geriatr Med** 1997 Aug;13(3):553–64 (50 ref.)

Ultrasonically assisted lipectomy in aesthetic breast surgery. Maillard GF, et al. **Plast Reconstr Surg** 1997 Jul; 100(1):238–41 (8 ref.)

ULTRASONICS

Ultrasonic characterization of foods and drinks: principles, methods, and applications. McClements DJ. **Crit Rev Food Sci Nutr** 1997 Feb;37(1):1–46 (180 ref.)

Application of focused ultrasound for research on pain. ab Ithel Davies I, et al. **Pain** 1996 Sep;67(1):17–27 (37 ref.)

ULTRASONOGRAPHY

Clinical and diagnostic utility of arbutamine for cardiovascular stress testing during echocardiographic monitoring. Armstrong WF, et al. **Eur Heart J** 1995 Nov; 16 Suppl M:24–7 (15 ref.)

Recent developments in biliary tract imaging. Gillams AR, et al. **Gastrointest Endosc Clin N Am** 1996 Jan;6(1):1–15 (37 ref.)

The role of ultrasonography in the evaluation of endometrial receptivity following assisted reproductive treatments: a critical review. Friedler S, et al. **Hum Reprod Update** 1996 Jul–Aug;2(4):323–35 (64 ref.)

The use of ultrasound as an adjunct to the performance of vascular procedures. Nemcek AA Jr. **J Vasc Interv Radiol** 1996 Nov–Dec;7(6):869–75 (23 ref.)

Bone marrow transplantation in children. Imaging assessment of complications. Benya EC, et al. **Pediatr Clin North Am** 1997 Jun;44(3):741–61 (30 ref.)

Imaging of developmental dysplasia of the hip. Donaldson JS, et al. **Pediatr Clin North Am** 1997 Jun;44(3):591–614 (35 ref.)

Diagnostic imaging in pediatric AIDS. Haller JO, et al. **Pediatr Clin North Am** 1997 Jun;44(3):721–40 (64 ref.)

Imaging the child with a limp. Myers MT, et al. **Pediatr Clin North Am** 1997 Jun;44(3):637–58 (30 ref.)

Clinical experience with sonographic contrast agents. Melany ML, et al. **Semin Ultrasound CT MR** 1997 Feb;18(1):3–12 (40 ref.)

[Modern imaging methods in diagnosis of tumors of the oropharynx and mouth cavity] Lenz M. **Rontgenpraxis** 1996 Nov;49(11):286–96 (28 ref.) **(Ger)**

[Diagnostic imaging and radiation protection in trauma surgery. 2] Wolf K, et al. **Unfallchirurg** 1996 Dec; 99(12):975–85 (23 ref.) **(Ger)**

[Early detection and preoperative diagnosis of ovarian carcinoma] Kainz C. **Wien Med Wochenschr** 1996; 146(1–2):2–7 (30 ref.) (Eng. Abstr.) **(Ger)**

[Assessment of myometrial invasion in endometrial cancer by transvaginal ultrasonography] Szabó I, et al. **Orv Hetil** 1997 May 25;138(21):1323–7 (23 ref.) (Eng. Abstr.) **(Hun)**

[Clinical application and merits of ultrasonography in orthopedic field] Semoto Y. **Nippon Seikeigeka Gakkai Zasshi** 1996 Jul;70(7):366–79 (19 ref.) **(Jpn)**

ADVERSE EFFECTS

A review of in vitro bioeffects of inertial ultrasonic cavitation from a mechanistic perspective. Miller MW, et al. **Ultrasound Med Biol** 1996;22(9):1131–54 (146 ref.)

INSTRUMENTATION

The expanding role of ultrasound [editorial] Cosgrove D. **Br J Hosp Med** 1997 Jan 15–Feb 5;57(1–2):7–9 (0 ref.)

Endoscopic ultrasonography and gallstone disease. Canto M. **Gastrointest Endosc** 1996 Feb;43(2 Pt 2):S37–43 (43 ref.)

Food and Drug Administration ultrasound device regulation: the output display standard, the "mechanical index," and ultrasound safety [editorial] Meltzer RS. **J Am Soc Echocardiogr** 1996 Mar–Apr;9(2):216–20 (35 ref.)

[MRI and ultrasound in rheumatology] Kainberger F, et al. **Radiologe** 1996 Aug;36(8):609–16 (38 ref.) (Eng. Abstr.) **(Ger)**

[Electronic documentation of findings and image in ultrasound diagnosis] Kuhn K. **Radiologe** 1996 Jan; 36(1):47–50 (15 ref.) (Eng. Abstr.) **(Ger)**

[New developments in ultrasound diagnosis. 3-dimensional ultrasound] Nitsch CD, et al. **Rontgenpraxis** 1997 Aug; 50(8):247–52 (9 ref.) **(Ger)**

[Sonography of the knee extensor system] Gruber G. **Ultraschall Med** 1996 Oct;17(5):206–11 (16 ref.) (Eng. Abstr.) **(Ger)**

[Standardized ultrasound study of the knee joint] Gruber G, et al. **Ultraschall Med** 1997 Apr;18(2):52–61 (6 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Ultrasound contrast agents. Examples of blood pool agents. Correas JM, et al. **Acta Radiol Suppl** 1997;412:101–12 (44 ref.)

Endoscopic ultrasonography: a new diagnostic imaging modality. Erickson RA. **Am Fam Physician** 1997 May 1; 55(6):2219–28 (31 ref.)

The interpretation and utility of ultrasound measurements of bone [editorial] Heaney RP, et al. **Bone** 1996 Jun; 18(6):491–2 (8 ref.)

The expanding role of ultrasound [editorial] Cosgrove D. **Br J Hosp Med** 1997 Jan 15–Feb 5;57(1–2):7–9 (0 ref.)

High-resolution sonography of breast carcinoma. Rizzatto G, et al. **Eur J Radiol** 1997 Jan;24(1):11–9 (21 ref.)

Ultrasound in gynecology: endometrium. Bourne T, et al. **Int J Gynaecol Obstet** 1997 Feb;56(2):115–27 (61 ref.)

Ultrasonic imaging of microscopic structures in living organs. Insana MF. **Int Rev Exp Pathol** 1996;36:73–92 (18 ref.)

Neurosonology in clinical practice. Beletsky VY, et al. **J La State Med Soc** 1996 Nov;148(11):467–73 (52 ref.)

Ultrasound velocity and broadband attenuation over a wide range of bone mineral density. Han S, et al. **Osteoporos Int** 1996;6(4):291–6 (31 ref.)

Finite amplitude distortion and its relationship to linear derating formulae for diagnostic ultrasound systems. Christopher T, et al. **Ultrasound Med Biol** 1996; 22(8):1103–16 (36 ref.)

Three-dimensional ultrasound is useful in diagnosing the fetus with abdominal wall defect [letter] Matsumi H, et al. **Ultrasound Obstet Gynecol** 1996 Nov;8(5):356–8 (13 ref.)

[Fundamentals, possibilities and limitations of sonography of osteofibrous tunnels in the shoulder area. 1] Moriggl B. **Anat Anz** 1997 Aug;179(4):355–73 (119 ref.) (Eng. Abstr.) **(Ger)**

[Ultrasound contrast media. New perspectives in ultrasound diagnosis] Schlief R, et al. **Radiologe** 1996 Jan;36(1):51–7 (22 ref.) (Eng. Abstr.) **(Ger)**

[Echography with contrast media. State of the art and future perspectives] Voci P, et al. **Cardiologia** 1996 Oct; 41(10):953–66 (171 ref.) **(Ita)**

[Evaluation of the degree of atherosclerosis by ultrasonic echo phase tracking system (Use-PT system)] Hasegawa M. **Nippon Rinsho** 1997 Mar;55 Suppl 1:691–3 (3 ref.) **(Jpn)**

[Record and preservation of ultrasound images and computer-assistant analysis--estimation of digital filing system and texture analysis] Taniguchi N, et al. **Rinsho Byori** 1997 May;45(5):442–6 (5 ref.) (Eng. Abstr.) **(Jpn)**

STANDARDS

EC Biomed1 Concerted Action "Assessment of Bone Quality in Osteoporosis": clinical ultrasound consensus workshop 5–6 October 1994, Hull, UK. Langton CM. **Clin Rheumatol** 1997 Jan;16(1):113–4 (0 ref.)

Definition consensus workshop for the ultrasonic assessment of bone 15th December 1995 (Paris). Langton CM, et al. **Clin Rheumatol** 1997 Jan;16(1):115–6 (0 ref.)

Food and Drug Administration ultrasound device regulation: the output display standard, the "mechanical index," and ultrasound safety [editorial] Meltzer RS. **J Am Soc Echocardiogr** 1996 Mar-Apr;9(2):216–20 (35 ref.)

Reproducibility of in vivo carotid intima-media thickness measurements: a review. Kanters SD, et al. **Stroke** 1997 Mar;28(3):665–71 (48 ref.)

UTILIZATION

Emergency department ultrasound services by emergency physicians: model for gaining hospital approval. Tandy TK 3rd, et al. **Ann Emerg Med** 1997 Mar;29(3):367–74 (60 ref.)

VETERINARY

Transvaginal aspiration. Squires EL, et al. **Vet Clin North Am Equine Pract** 1996 Apr;12(1):13–29 (42 ref.)

Imaging of adrenal gland disorders. Tidwell AS, et al. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):237–54 (47 ref.)

ULTRASONOGRAPHY, COLOR DOPPLER see **ULTRASONOGRAPHY, DOPPLER, COLOR**

ULTRASONOGRAPHY, DOPPLER

Doppler ultrasound in obstetric practice: 2. Beattie RB. **Br J Hosp Med** 1994 Jan 19–Feb 1;51(1–2):34–9 (27 ref.)

The extended role of carotid artery ultrasound. Sidhu PS, et al. **Clin Radiol** 1997 Sep;52(9):643–53 (150 ref.)

Ultrasound assessment of internal carotid artery stenosis. Sidhu PS, et al. **Clin Radiol** 1997 Sep;52(9):654–8 (54 ref.)

Methodological and clinical studies of Doppler ultrasound indices and their relation to fetal haemoglobin concentration, acid-base status, and blood gas values. Legarth J. **Dan Med Bull** 1996 Dec;43(5):419–28 (45 ref.)

Management of the menopause and HRT by ultrasound. Jakab A Jr. **Eur J Obstet Gynecol Reprod Biol** 1997 Feb; 71(2):155–62 (45 ref.)

Conservatively treated pelvic arteriovenous malformation: noninvasive sonographic monitoring during subsequent pregnancy. Zanetta G, et al. **J Clin Ultrasound** 1997 Sep; 25(7):401–4 (15 ref.)

Non-invasive evaluation of arterial abnormalities in hypertensive patients. Asmar RG, et al. **J Hypertens Suppl** 1997 Mar;15(2):S99–107 (57 ref.)

Prenatal ultrasonographic assessment of the ductus venosus: a review. Sherer DM, et al. **Obstet Gynecol** 1996 Oct;88(4 Pt 1):626–32 (32 ref.)

Ultrasound in twin pregnancy. Divon MY, et al. **Semin Perinatol** 1995 Oct;19(5):404–12 (57 ref.)

Doppler ultrasound of the kidney. Platt JF. **Semin Ultrasound CT MR** 1997 Feb;18(1):22–32 (81 ref.)

Assessment of the fetal circulatory state in uteroplacental insufficiency by Doppler ultrasound: which vessels are the most practicable? Gembruch U. **Ultrasound Obstet Gynecol** 1996 Aug;8(2):77–81 (56 ref.)

Pathology and clinical implications of abnormal umbilical artery Doppler waveforms. Kingdom JC, et al. **Ultrasound Obstet Gynecol** 1997 Apr;9(4):271–86 (173 ref.)

[Tumor vascularization: contribution of Doppler ultrasonography] Flais S, et al. **J Radiol** 1996 Dec; 77(12):1207–12 (27 ref.) (Eng. Abstr.) **(Fre)**

[Ultrasound Doppler blood flowmetry] Chihara K. **Nippon Rinsho** 1997 Mar;55 Suppl 1:59–64 (20 ref.) **(Jpn)**

INSTRUMENTATION

[Diagnosis of the female urethra and examination technique with Doppler balloon urethrography] Madeja C, et al. **Rontgenpraxis** 1997 Mar;50(3):51–4 (7 ref.) **(Ger)**

METHODS

Practical coronary physiology. Clinical application of the Doppler flow velocity guide wire. Bach RG, et al. **Cardiol Clin** 1997 Feb;15(1):77–99 (75 ref.)

Clinical application of coronary flow reserve using an intracoronary Doppler guide wire. Joye JD, et al. **Cardiol Clin** 1997 Feb;15(1):101–29 (111 ref.)

Advances in the use of ultrasound in infertility management. Zaidi J, et al. **Curr Opin Obstet Gynecol** 1996 Jun;8(3):161–5 (40 ref.)

Detection of embolic signals using Doppler ultrasound: a new approach to cardiac embolism. Pettelot G, et al. **Int J Cardiol** 1997 Jan 3;58(1):1–5 (27 ref.)

Overview of echo-enhanced vascular ultrasound imaging for clinical diagnosis in neurosonology. Burns PN. **J Neuroimaging** 1997 Apr;7 Suppl 1:S2–14 (35 ref.)

Power Doppler: it's a good thing. Murphy KJ, et al. **Semin Ultrasound CT MR** 1997 Feb;18(1):13–21 (33 ref.)

Tamoxifen and the uterus: an old drug tested by new modalities. Achiron R, et al. **Ultrasound Obstet Gynecol** 1996 May;7(5):374–8 (35 ref.)

STANDARDS

Duplex Doppler evaluation of acute renal obstruction. Platt JF. **Semin Ultrasound CT MR** 1997 Apr;18(2):147–53 (36 ref.)

VETERINARY

A review of sonographic identification of abdominal blood vessels and juxtavascular organs. Spaulding KA. **Vet Radiol Ultrasound** 1997 Jan-Feb;38(1):4–23 (18 ref.)

ULTRASONOGRAPHY, DOPPLER, COLOR

Portal vein aneurysm: report of six cases and review of the literature. Ohnami Y, et al. **Abdom Imaging** 1997 May-Jun; 22(3):281–6 (38 ref.)

Renal vein aneurysm: diagnosis with color Doppler sonography. Kabaalioğlu A, et al. **AJR Am J Roentgenol** 1997 Mar;168(3):645–6 (8 ref.)

Preoperative sonographic evaluation and laparoscopic management of persistent adnexal masses: a 1994 review. Hulka JF, et al. **J Am Assoc Gynecol Laparosc** 1994 May; 1(3):197–205 (67 ref.)

Atypically located submandibular gland diagnosed by Doppler ultrasound. Carney AS, et al. **J Laryngol Otol** 1996 Dec;110(12):1171–2 (6 ref.)

The first three weeks assessed by transvaginal color Doppler. Kupešić S. **J Perinat Med** 1996;24(4):301–17 (61 ref.)

Intraoperative color-flow duplex ultrasonography following carotid endarterectomy. Hallett JW Jr, et al. **Neurosurg Clin N Am** 1996 Oct;7(4):733–40 (11 ref.)

Doppler sonography of vertebral-subclavian system. Rabbia C. **Rays** 1995 Oct-Dec;20(4):426–53 (15 ref.)

Doppler US in interventional neuroradiology. Rollo M, et al. **Rays** 1995 Oct-Dec;20(4):454–66 (18 ref.)

Ultrasonic color flow mapping: the visualization of four-dimensional cardiac and vascular flow phenomena using two dimensions and "real time". Beach KW, et al. **Ultrasound Med Biol** 1997;23(3):347–63 (12 ref.)

The role of color Doppler and staging biopsies in prostate cancer detection. Bree RL. **Urology** 1997 Mar;49(3A Suppl):31–4 (28 ref.)

[Early ultrasonographic detection of endometrial cancer] Rudigoz RC, et al. **Contracept Fertil Sex** 1997 Jan; 25(1):21–6 (49 ref.) **(Fre)**

[Color-coded duplex ultrasonography of extracranial vascular lesions] Schuknecht BF, et al. **Radiologe** 1996 Jan; 36(1):1–11 (78 ref.) (Eng. Abstr.) **(Ger)**

[Ultrasound contrast media for neurovascular applications] Gahn G, et al. **Ultraschall Med** 1997 Jun;18(3):101–4 (13 ref.) (Eng. Abstr.) **(Ger)**

[Post-traumatic priapism in a 10-year-old boy] Sperling H, et al. **Urologe A** 1997 Mar;36(2):162–4 (11 ref.) (Eng. Abstr.) **(Ger)**

[Ultrasound in the study of gynecologic neoplasms] Pepe F, et al. **Minerva Ginecol** 1996 Jul-Aug;48(7–8):303–20 (82 ref.) (Eng. Abstr.) **(Ita)**

[The role of Doppler US in the study of carotid system] Salcuni M, et al. **Rays** 1995 Oct-Dec;20(4):406–25 (46 ref.) (Eng. Abstr.) **(Ita)**

[Color Doppler sonography of the liver] Konno K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:165–8 (0 ref.) **(Jpn)**

[Evaluation of gallbladder wall blood flow using color Doppler ultrasonography] Miyazaki E, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:190–3 (7 ref.) **(Jpn)**

[Cor triatriatum with interventricular communication: Doppler color ultrasonography and magnetic resonance diagnosis. Repair in the first months] Cabrera A, et al. **Rev Esp Cardiol** 1997 Apr;50(4):290–2 (8 ref.) (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

[Ultrasound diagnosis of the transplanted kidney] Mutze S, et al. **Radiologe** 1996 Jan;36(1):31–7 (49 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Ultrasound diagnosis of polycystic ovary syndrome. Kyei-Mensah A, et al. **Baillieres Clin Endocrinol Metab** 1996 Apr;10(2):249–62 (50 ref.)

Pregnancy hypertension and uterine artery Doppler ultrasound. Aquilina J, et al. **Curr Opin Obstet Gynecol** 1996 Dec;8(6):435–40 (31 ref.)

Diagnosis of acute lower limb deep venous thrombosis with ultrasound: trends and controversies. Dauzat M, et al. **J Clin Ultrasound** 1997 Sep;25(7):343–58 (137 ref.)

Ultrasound in the assessment of the acute scrotum. Herbener TE. **J Clin Ultrasound** 1996 Oct;24(8):405–21 (52 ref.)

Renovascular disease: Doppler ultrasound. Hélénon O, et al. **Semin Ultrasound CT MR** 1997 Apr;18(2):136–46 (27 ref.)

Color flow mapping. Ferrara K, et al. **Ultrasound Med Biol** 1997;23(3):321–45 (78 ref.)

Doppler indices in tumors--resolution of a dilemma? [comment] Cosgrove D, et al. **Ultrasound Obstet Gynecol** 1997 Jul;10(1):9–11 (13 ref.) Comment on: Ultrasound Obstet Gynecol 1997 Jul;10(1):41–7. Comment on: Ultrasound Obstet Gynecol 1997 Jul;10(1):48–53.

Intervillous circulation in the first trimester: the phantom of the color Doppler obstetric opera [editorial] Jauniaux E. **Ultrasound Obstet Gynecol** 1996 Aug;8(2):73–6 (21 ref.)

[Progress and clinical usefulness of color Doppler method in diagnosing abdominal diseases] Tomiyama T, et al. **Nippon Rinsho** 1996 Sep;54(9):2561–73 (29 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY, DOPPLER, DUPLEX

Blood flow measurements in lower limb arteries using duplex ultrasound. Hussain ST. **Ann R Coll Surg Engl** 1997 Sep; 79(5):323–30 (25 ref.)

The use of duplex sonography in the diagnosis of renal artery stenosis. Riehl J, et al. **Eur J Med Res** 1997 Jan;2(1):14–22 (62 ref.)

The impact of duplex scanning on vascular practice. Androulakis AE, et al. **Int Angiol** 1996 Dec;15(4):283–90 (109 ref.)

Duplex sonography of lower extremity arteries. Zierler RE, et al. **Semin Ultrasound CT MR** 1997 Feb;18(1):39–56 (67 ref.)

Duplex ultrasonography in evaluation of splanchnic artery stenosis. Nicoloff AD, et al. **Surg Clin North Am** 1997 Apr; 77(2):339–55 (18 ref.)

ULTRASONOGRAPHY, DOPPLER, PULSED

Doppler ultrasound simulation model for pulsatile flow with nonaxial components. Oung H, et al. **Ultrason Imaging** 1996 Jul;18(3):157–72 (31 ref.)

Deciphering the hieroglyphics of venous Doppler velocities [comment] Huhta JC. **Ultrasound Obstet Gynecol** 1997 May;9(5):300–1 (5 ref.) Comment on: Ultrasound Obstet Gynecol 1997 May;9(5):319–23.

METHODS

Ultrasound diagnosis of polycystic ovary syndrome. Kyei-Mensah A, et al. **Baillieres Clin Endocrinol Metab** 1996 Apr;10(2):249–62 (50 ref.)

ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL

Transcranial Doppler ultrasonography in the neurocritical care unit. Manno EM. **Crit Care Clin** 1997 Jan;13(1):79–104 (87 ref.)

Cerebral microembolism in atherosclerotic carotid artery disease: facts and perspectives. Sitzer M, et al. **Funct Neurol** 1995 Nov–Dec;10(6):251–8 (45 ref.)

The role of transcranial Doppler sonography in the identification of patients at risk of cerebral and brainstem ischemia. Terenzi TJ, et al. **J Manipulative Physiol Ther** 1996 Jul–Aug;19(6):406–14 (61 ref.)

Intraoperative use of transcranial Doppler ultrasonography. Lam AM, et al. **Neurosurg Clin N Am** 1996 Oct;7(4):709–22 (82 ref.)

Use of transcranial Doppler sonography to evaluate patients with cerebrovascular disease. Taormina MA, et al. **Neurosurg Clin N Am** 1996 Oct;7(4):589–603 (77 ref.)

Doppler sonography of vertebral–subclavian system. Rabbia C. **Rays** 1995 Oct–Dec;20(4):426–53 (16 ref.)

Doppler US in interventional neuroradiology. Rollo M, et al. **Rays** 1995 Oct–Dec;20(4):454–66 (18 ref.)

[Color–coded duplex ultrasonography of extracranial vascular lesions] Schuknecht BF, et al. **Radiologe** 1996 Jan; 36(1):1–11 (78 ref.) (Eng. Abstr.) **(Ger)**

[Ultrasound contrast media for neurovascular applications] Gahn G, et al. **Ultraschall Med** 1997 Jun;18(3):101–4 (13 ref.) (Eng. Abstr.) **(Ger)**

[Transcranial ultrasonography in neurosurgery] Limoni P. **Clin Ter** 1996 Nov;147(11):559–66 (30 ref.) (Eng. Abstr.) **(Ita)**

[Cerebral Doppler ultrasonography in newborn infants] Luciano R, et al. **Rays** 1995 Oct–Dec;20(4):377–405 (104 ref.) (Eng. Abstr.) **(Ita)**

[The role of Doppler US in the study of carotid system] Salcuni M, et al. **Rays** 1995 Oct–Dec;20(4):406–25 (46 ref.) (Eng. Abstr.) **(Ita)**

INSTRUMENTATION

[Doppler ultrasound imaging of cerebral arteries] Ranke C, et al. **HNO** 1996 Sep;44(9):533–47 (15 ref.) **(Ger)**

METHODS

Ultrasound of the neonatal brain. Ng VW, et al. **Br J Hosp Med** 1997 Jan 15–Feb 5;57(1–2):19–22 (24 ref.)

Clinical experience with echo–enhanced transcranial Doppler and duplex imaging. Ries F. **J Neuroimaging** 1997 Apr;7 Suppl 1:S15–21 (17 ref.)

ULTRASONOGRAPHY, DUPLEX DOPPLER see **ULTRASONOGRAPHY, DOPPLER, DUPLEX**

ULTRASONOGRAPHY, ENDOSCOPIC see **ENDOSONOGRAPHY**

ULTRASONOGRAPHY, FETAL see **ULTRASONOGRAPHY, PRENATAL**

ULTRASONOGRAPHY, INTERVENTIONAL

Volumetric intracoronary ultrasound: a new maximum confidence approach for the quantitative assessment of progression–regression of atherosclerosis? von Birgelen C, et al. **Atherosclerosis** 1995 Dec;118 Suppl:S103–13 (89 ref.)

Intravascular ultrasound: basic interpretation. Metz JA, et al. **Cardiol Clin** 1997 Feb;15(1):1–15 (35 ref.)

Incremental value of intravascular ultrasound during rotational coronary atherectomy. De Franco AC, et al. **Cathet Cardiovasc Diagn** 1996;Suppl 3:23–33 (26 ref.)

Use of intravascular ultrasound in evaluating repeated balloon rupture during coronary stenting. Zellner C, et al. **Cathet Cardiovasc Diagn** 1997 Jan;40(1):52–4 (10 ref.)

Intracoronary ultrasound: insights into mechanisms and results of coronary interventions. Schreiter SW, et al. **Clin Cardiol** 1996 Feb;19(2):86–92 (45 ref.)

Intravascular ultrasound, directional coronary atherectomy, and the Optimal Atherectomy Restenosis Study (OARS). Dussaillant GR, et al. **Coron Artery Dis** 1996 Apr; 7(4):294–8 (26 ref.)

Ultrasound–guided atherectomy: the vision for the future? Yock PG, et al. **Coron Artery Dis** 1996 Apr;7(4):299–303 (16 ref.)

Intravascular and intracardiac ultrasound: a tool of the future. Hoit BD. **Crit Care Clin** 1996 Apr;12(2):451–70 (70 ref.)

Coronary artery flow monitoring: the value of intravascular Doppler for detection of complications after interventions. Anderson HV, et al. **Eur Heart J** 1995 Nov;16 Suppl L:93–6 (20 ref.)

Intravascular ultrasound: a guide for management of complications during intervention? Görge G, et al. **Eur Heart J** 1995 Nov;16 Suppl L:86–92 (57 ref.)

Endoscopic ultrasound–guided fine–needle aspiration biopsy and interventional endoscopic ultrasonography. Emerging technologies. Chang KJ, et al. **Gastrointest Endosc Clin N Am** 1997 Apr;7(2):221–35 (62 ref.)

Intravascular ultrasound guidance for peripheral vascular interventions. Scoccianti M, et al. **J Endovasc Surg** 1994 Sep;1:71–80 (43 ref.)

Intravascular ultrasound: the ultimate tool for abdominal aortic aneurysm assessment and endovascular graft delivery. White RA, et al. **J Endovasc Surg** 1997 Feb; 4(1):45–55 (12 ref.)

Laparoscopic staging and intraoperative ultrasonography for liver tumor management. Ravikumar TS. **Surg Oncol Clin N Am** 1996 Apr;5(2):271–82 (36 ref.)

Intraoperative ultrasonography and other techniques for segmental resections. Takayama T, et al. **Surg Oncol Clin N Am** 1996 Apr;5(2):261–9 (16 ref.)

Time reversal focusing applied to lithotripsy. Thomas JL, et al. **Ultrason Imaging** 1996 Apr;18(2):106–21 (9 ref.)

Interventional ultrasound. Holm HH, et al. **Ultrasound Med Biol** 1996;22(7):773–89 (80 ref.)

Pathology and clinical implications of abnormal umbilical artery Doppler waveforms. Kingdom JC, et al. **Ultrasound Obstet Gynecol** 1997 Apr;9(4):271–86 (173 ref.)

[Progresses in ultrasonic medicine in China, 1996] Dong B. **Chung Hua I Hsueh Tsa Chih** 1996 Dec;76(12):936–8 (0 ref.) **(Chi)**

[The color Doppler–guided compression therapy of pseudoaneurysms. The authors' own experiences and a review of the literature] Oelerich M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Nov;165(5):484–90 (34 ref.) (Eng. Abstr.) **(Ger)**

[The coronary arteries—seen from the inside] Prati F. **Cardiologia** 1995 Dec;40(12):951–7 (40 ref.) **(Ita)**

[Progress in instrument used for diagnosis of obstructive jaundice. 2) Intraductal ultrasonography] Koito K, et al. **Nippon Naika Gakkai Zasshi** 1997 Apr 10;86(4):588–96 (8 ref.) **(Jpn)**

[Angina pectoris: progress in diagnosis and treatment. II. Progress in imaging diagnosis. 4. Current status of intravascular ultrasonography] Saito S, et al. **Nippon Naika Gakkai Zasshi** 1997 Feb 10;86(2):226–36 (12 ref.) **(Jpn)**

[Recent advance of endoscopic ultrasonography for evaluating gastroenterologic early cancer] Kida M, et al. **Nippon Rinsho** 1996 May;54(5):1230–5 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Measurement of coronary flow velocity by intravascular Doppler catheter] Nakatani S, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:599–602 (10 ref.) **(Jpn)**

[Evaluation of atherosclerosis by ultrasonography] Teranishi J, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:694–6 (7 ref.) **(Jpn)**

[The site and the method for the viewing inside a living body] Yamanaka R, et al. **Tanpakushitsu Kakusan Koso** 1997 May; 42(7 Suppl):924–31 (10 ref.) **(Jpn)**

[Intravascular ultrasound. Initial experience and review of the literature] Ledesma M, et al. **Arch Inst Cardiol Mex** 1996 Jul–Aug;66(4):313–21 (33 ref.) (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

[Intravascular ultrasound imaging in coronary angioplasty] Mudra H. **Internist (Berl)** 1997 Jan;38(1):56–63 (52 ref.) **(Ger)**

[The significance of intravascular ultrasound in differential diagnosis and therapy of coronary stenoses] Görge G, et al. **Z Kardiol** 1996;85 Suppl 1:73–80 (41 ref.) (Eng. Abstr.) **(Ger)**

[Applications and value of intravascular ultrasound imaging in coronary interventions] Mudra H, et al. **Z Kardiol** 1996; 85 Suppl 1:39–47 (33 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Clinical application of coronary flow reserve using an intracoronary Doppler guide wire. Joye JD, et al. **Cardiol Clin** 1997 Feb;15(1):101–29 (111 ref.)

Intravascular ultrasound. Three–dimensional applications and forward viewing. McPherson DD, et al. **Cardiol Clin** 1997 Feb;15(1):63–76 (20 ref.)

Intravascular ultrasound insights into mechanisms of stenosis formation and restenosis. Mintz GS, et al. **Cardiol Clin** 1997 Feb;15(1):17–29 (57 ref.)

Ultrasound–guided stent placement. Russo RJ. **Cardiol Clin** 1997 Feb;15(1):49–61 (64 ref.)

Intravascular ultrasound and balloon percutaneous transluminal coronary angioplasty. Tenaglia AN. **Cardiol Clin** 1997 Feb;15(1):31–8 (30 ref.)

Intravascular ultrasound in the setting of directional coronary atherectomy and percutaneous transluminal coronary rotational atherectomy. Timmis SB, et al. **Cardiol Clin** 1997 Feb;15(1):39–48 (63 ref.)

Reconstruction and quantification with three–dimensional intracoronary ultrasound. An update on techniques, challenges, and future directions. von Birgelen C, et al. **Eur Heart J** 1997 Jul;18(7):1056–67 (54 ref.)

The clinical value of three–dimensional intravascular ultrasound imaging. Reid DB, et al. **J Endovasc Surg** 1995 Nov;2(4):356–64 (16 ref.)

Overview of echo–enhanced vascular ultrasound imaging for clinical diagnosis in neurosonology. Burns PN. **J Neuroimaging** 1997 Apr;7 Suppl 1:S2–14 (35 ref.)

Contemporary stent designs: technical considerations, complications, role of intravascular ultrasound, and anticoagulation therapy. Popma JJ, et al. **Prog Cardiovasc Dis** 1996 Sep–Oct;39(2):111–28 (166 ref.)

Three–dimensional saline contrast hysterosonography and surface rendering of uterine cavity pathology. Weinraub Z, et al. **Ultrasound Obstet Gynecol** 1996 Oct;8(4):277–82 (16 ref.)

[Evaluation of pancreatic function with intraductal ultrasonography (IDUS)] Fujimoto M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:210–3 (9 ref.) **(Jpn)**

[A survey of early arteriosclerosis. New possibilities with angiography and ultrasound] Jogestrand T. **Lakartidningen** 1996 Oct 23;93(43):3783–4, 3787 (10 ref.) **(Swe)**

ULTRASONOGRAPHY, INTRAVASCULAR see **ULTRASONOGRAPHY, INTERVENTIONAL**

ULTRASONOGRAPHY, MAMMARY

Image–guided breast biopsy. Burns RP. **Am J Surg** 1997 Jan; 173(1):9–11; discussion 12–3 (16 ref.)

Sonography of the breast. Jackson VP, et al. **Semin Ultrasound CT MR** 1996 Oct;17(5):460–75 (91 ref.)

[Ultrasound mammography] Lesnik G, et al. **Acta Med Austriaca** 1997;24(2):33–8 (38 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY, PRENATAL

In utero management of hydrops fetalis caused by critical aortic stenosis. Bitar FF, et al. **Am J Perinatol** 1997 Aug; 14(7):389–91 (7 ref.)

Ultrasound detection of Apert syndrome: a case report and literature review. Kaufmann K, et al. **Am J Perinatol** 1997 Aug;14(7):427–30 (15 ref.)

Prenatal ultrasound diagnosis of seizures. Osiovich H, et al. **Am J Perinatol** 1996 Nov;13(8):499–501 (16 ref.)

Isolated persistent fetal bradycardia in complete A–V block: a conservative approach is appropriate. A case report and a review of the literature. Rabinerson D, et al. **Am J Perinatol** 1997 Jul;14(6):317–20 (17 ref.)

The use of ultrasound in pregnancy. Acton CM. **Aust Fam Physician** 1997 Mar;26(3):239–43 (10 ref.)

The sonographic detection of trisomies 13, 18, and 21. Hill LM. **Clin Obstet Gynecol** 1996 Dec;39(4):831–50 (65 ref.)

Oligohydramnios: sonographic diagnosis and clinical implications. Hill LM. **Clin Obstet Gynecol** 1997 Jun; 40(2):314–27 (55 ref.)

Ultrasound of the placenta. Kuhlmann RS, et al. **Clin Obstet Gynecol** 1996 Sep;39(3):519–34 (58 ref.)

The routine or screening obstetrical ultrasound examination. Seeds JW. **Clin Obstet Gynecol** 1996 Dec;39(4):814–30 (28 ref.)

New developments in fetal echocardiography [see comments] Spevak PJ. **Curr Opin Cardiol** 1997 Jan;12(1):78–83 (19 ref.) Comment in: Curr Opin Cardiol 1997 Jan;12(1):41–3.

Second trimester ultrasound markers for fetal aneuploidy. Bilardo C. **Early Hum Dev** 1996 Dec 30;47 Suppl:S31–3 (4 ref.)

Etiology, prognosis and management of nuchal cystic hygroma: 25 new cases and literature review. Descamps P, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Jan; 71(1):3–10 (112 ref.)

Early prenatal diagnosis of bladder exstrophy: case report and review of the literature. Khandelwal M, et al. **Fetal Diagn Ther** 1996 Mar–Apr;11(2):146–9 (13 ref.)

The antenatal diagnosis of fetal atrial septal aneurysm. Haddad S, et al. **Gynecol Obstet Invest** 1996;41(1):27–9 (14 ref.)

Antenatal diagnosis of Grebe syndrome in a twin pregnancy by ultrasound. Kulkarni ML, et al. **Indian Pediatr** 1995 Sep; 32(9):1007–11 (7 ref.)

First and second trimester sonography: an American perspective. Scorza WE, et al. **Int J Fertil Menopausal Stud** 1996 May–Jun;41(3):288–92 (11 ref.)

Cervical pregnancy—a forgotten entity in family practice. Acosta DA. **J Am Board Fam Pract** 1997 Jul–Aug; 10(4):290–5 (33 ref.)

Sonographic detection of lipomyelomeningocele: a retrospective documentation. Chreston J, et al. **J Clin Ultrasound** 1997 Jan;25(1):50–1 (5 ref.)

Rapid growth of a fetal abdominal mass: a case report of congenital neuroblastoma. Shen MR, et al. **J Clin Ultrasound** 1997 Jan;25(1):39–42 (11 ref.)

Prenatally diagnosed ureterocele presenting as fetal bladder outlet obstruction. Gloor JM, et al. **J Perinatol** 1996 Jul–Aug;16(4):285–7 (18 ref.)

Fetal ovarian torsion appearing as a solid abdominal mass. Katz VL, et al. **J Perinatol** 1996 Jul–Aug;16(4):302–4 (37 ref.)

Abdominal lymphangioma in a preterm infant. Salvador A, et al. **J Perinatol** 1996 Jul–Aug;16(4):305–8 (9 ref.)

Genetics casebook. Pallister–Killian sindrome. Smulian J, et al. **J Perinatol** 1996 Sep–Oct;16(5):406–12 (13 ref.)

Prenatal ultrasound characterization of the suprarenal mass: distinction between neuroblastoma and subdiaphragmatic extralobar pulmonary sequestration. Curtis MR, et al. **J Ultrasound Med** 1997 Feb;16(2):75–83 (69 ref.)

Successful thoracoamniotic shunting and review of the literature in unilateral pleural effusion with hydrops. Wilkins–Haug LE, et al. **J Ultrasound Med** 1997 Feb; 16(2):153–60 (20 ref.)

Prenatal ultrasonographic diagnosis of fetal heart echogenic foci: no correlation with Down syndrome. Achiron R, et

al. **Obstet Gynecol** 1997 Jun;89(6):945–8 (10 ref.)
Sonographic examination does not predict twin growth discordance accurately. Caravello JW, et al. **Obstet Gynecol** 1997 Apr;89(4):529–33 (14 ref.)
Sonographic screening to detect fetal cardiac anomalies: a 5-year experience with 111 abnormal cases. Kirk JS, et al. **Obstet Gynecol** 1997 Feb;89(2):227–32 (19 ref.)
Prenatal ultrasonographic assessment of the ductus venosus: a review. Sherer DM, et al. **Obstet Gynecol** 1996 Oct;88(4 Pt 1):626–32 (32 ref.)
Prenatal ultrasonographic assessment of the middle cerebral artery: a review. Sherer DM. **Obstet Gynecol Surv** 1997 Jul;52(7):444–55 (70 ref.)
Prenatal ultrasonographic morphologic assessment of the umbilical cord: a review. Part II. Sherer DM, et al. **Obstet Gynecol Surv** 1997 Aug;52(8):515–23 (150 ref.)
Ultrasound detection of fetal abnormalities. Abramowicz JS, et al. **Pediatr Ann** 1996 Apr;25(4):228–38 (29 ref.)
Osteogenesis imperfecta Type IIA and pulmonary hypoplasia with normal alveolar development. Thibeault DW, et al. **Pediatr Pulmonol** 1995 Nov;20(5):301–6 (23 ref.)
Prenatal diagnosis of diastematomyelia: case reports and review of the literature. Sepulveda W, et al. **Prenat Diagn** 1997 Feb;17(2):161–5 (11 ref.)
The sonographic finding of persistent umbilical cord cystic masses is associated with lethal aneuploidy and/or congenital anomalies. Smith GN, et al. **Prenat Diagn** 1996 Dec;16(12):1141–7 (17 ref.)
Transvaginal sonographic detection of adducted thumbs, hydrocephalus, and agenesis of the corpus callosum at 22 postmenstrual weeks: the masa spectrum or L1 spectrum. A case report and review of the literature. Timor-Tritsch IE, et al. **Prenat Diagn** 1996 Jun;16(6):543–8 (31 ref.)
Prenatal diagnosis of ring chromosome 6 in a fetus with hydrocephalus. Walker ME, et al. **Prenat Diagn** 1996 Sep; 16(9):857–61 (26 ref.)
The sequential in utero death of heterokaryotic monozygotic twins. A case report and literature review. Weeks AD, et al. **Prenat Diagn** 1996 Jul;16(7):657–63 (31 ref.)
Prenatal diagnosis and management of abdominal wall defects. Dykes EH. **Semin Pediatr Surg** 1996 May;5(2):90–4 (17 ref.)
Holoprosencephaly and chromosomal anomalies. Chow BH, et al. **Singapore Med J** 1996 Aug;37(4):394–7 (19 ref.)
Prenatal findings in chondrodysplasia punctata, tibia-metacarpal type. Argo KM, et al. **Ultrasound Obstet Gynecol** 1996 Nov;8(5):350–4 (14 ref.)
The second-trimester fetus with Down syndrome: detection using sonographic features. Benacerraf BR. **Ultrasound Obstet Gynecol** 1996 Feb;7(2):147–55 (80 ref.)
Neuroectodermal cyst may be a rare differential diagnosis of fetal sacrococcygeal teratoma: first case report of a prenatally observed neuroectodermal cyst. Bloechle M, et al. **Ultrasound Obstet Gynecol** 1996 Jan;7(1):64–7 (11 ref.)
The fetal 'heart-sparing effect' detected by the assessment of coronary blood flow: a further ominous sign of fetal compromise [see comments] Chaoui R. **Ultrasound Obstet Gynecol** 1996 Jan;7(1):5–9 (44 ref.) Comment in: Ultrasound Obstet Gynecol 1996 Jun;7(6):461–2.
Clinical and perinatal sonographic features of congenital adrenal cystic neuroblastoma: a case report with review of the literature. Chen CP, et al. **Ultrasound Obstet Gynecol** 1997 Jul;10(1):68–73 (31 ref.)
Prenatal diagnosis of amniotic band syndrome in a methadone user: review of the literature and a case report. Daly CA, et al. **Ultrasound Obstet Gynecol** 1996 Aug;8(2):123–5 (12 ref.)
Assessment of the fetal circulatory state in uteroplacental insufficiency by Doppler ultrasound: which vessels are the most practicable? Gembruch U. **Ultrasound Obstet Gynecol** 1996 Aug;8(2):77–81 (56 ref.)
Prenatal diagnosis of the split hand anomaly: how early is early? Haratz-Rubinstein N, et al. **Ultrasound Obstet Gynecol** 1996 Jul;8(1):57–61 (28 ref.)
Characteristics of fetal venous blood flow under normal circumstances and during fetal disease. Hecher K, et al. **Ultrasound Obstet Gynecol** 1996 Jan;7(1):68–83 (70 ref.)
Intervillous circulation in the first trimester: the phantom of the color Doppler obstetric opera [editorial] Jauniaux E. **Ultrasound Obstet Gynecol** 1996 Aug;8(2):73–6 (21 ref.)
Prenatal ultrasonographic detection of the tracheal atresia sequence. Kassanos D, et al. **Ultrasound Obstet Gynecol** 1997 Aug;10(2):133–6 (17 ref.)
Prenatal diagnosis of ectrodactyly: the 'lobster claw' anomaly. Leung KY, et al. **Ultrasound Obstet Gynecol** 1995 Dec;6(6):443–6 (16 ref.)
Prenatal diagnosis of ectopia cordis at 10 weeks of gestation using two-dimensional and three-dimensional ultrasonography. Liang RI, et al. **Ultrasound Obstet Gynecol** 1997 Aug;10(2):137–9 (10 ref.)
Three-dimensional ultrasound is useful in diagnosing the fetus with abdominal wall defect [letter] Matsumi H, et al. **Ultrasound Obstet Gynecol** 1996 Nov;8(5):356–8 (13 ref.)
Abnormalities of the intra-abdominal fetal umbilical vein: reports of four cases and a review of the literature. Moore L, et al. **Ultrasound Obstet Gynecol** 1996 Jan;7(1):21–5 (16 ref.)
Late prenatal ultrasound features of hydrometrocolpos secondary to cloacal anomaly: case reports and review of the literature. Odibo AO, et al. **Ultrasound Obstet Gynecol** 1997 Jun;9(6):419–21 (6 ref.)
Giant glioependymal cyst resembling holoprosencephaly on prenatal ultrasound: case report and review of the literature. Pelkey TJ, et al. **Ultrasound Obstet Gynecol** 1997 Mar;9(3):200–3 (34 ref.)
The prenatal sonographic appearance of enteric duplication cysts. Richards DS, et al. **Ultrasound Obstet Gynecol** 1996 Jan;7(1):17–20 (18 ref.)
Antenatal sonographic diagnosis of thanatophoric dysplasia: a report of three cases and a review of the literature with special emphasis on the differential diagnosis. Schild RL, et al. **Ultrasound Obstet Gynecol** 1996 Jul;8(1):62–7 (22 ref.)
Prenatal diagnosis of persistent right umbilical vein. Shen O, et al. **Ultrasound Obstet Gynecol** 1996 Jul;8(1):31–3 (20 ref.)
Monochorionic twin pregnancies: 'les liaisons dangereuses' [comment] Ville Y. **Ultrasound Obstet Gynecol** 1997 Aug; 10(2):82–5 (45 ref.) Comment on: Ultrasound Obstet Gynecol 1997 Aug;10(2):86–9.
Spontaneous resolution of an isolated unilateral fetal pleural effusion: a case report. Cordero DR, et al. **W V Med J** 1996 Jul–Aug;92(4):194–6 (14 ref.)
[Placenta praevia. A review of contradictory opinions on its incidence. The importance of ultrasonic study] Ruseva R, et al. **Akush Ginekol (Sofiia)** 1996;35(1–2):43–5 (12 ref.) (Eng. Abstr.) **(Bul)**
[Meckel syndrome. Update on a recurrent case] Calmelet P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997; 26(4):435–41 (35 ref.) (Eng. Abstr.) **(Fre)**
[Congenital adenomatoid cystic malformation of the lung and renal polycystosis. A fetal case report and review of the literature] Jamet F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(2):193–6 (11 ref.) (Eng. Abstr.) **(Fre)**
[Anomalies of umbilical vein in the fetus. A case report and review of the literature] Tordjeman N, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(5):495–9 (18 ref.) (Eng. Abstr.) **(Fre)**
[Is an ultrasound screening program in pregnancy justified?] Holzgreve W. **Arch Gynecol Obstet** 1996;259 Suppl 1:S118–27 (30 ref.) **(Ger)**
[Obstetric ultrasonic studies in clinical practice] Wisser J. **Schweiz Rundsch Med Prax** 1996 Sep 24;85(39):1217–20 (27 ref.) (Eng. Abstr.) **(Ger)**
[Biochemical and ultrasonic screening of chromosomal aneuploidies in the second trimester of pregnancy] Török O, et al. **Orv Hetil** 1997 Jan 19;138(3):123–7 (21 ref.) (Eng. Abstr.) **(Hun)**
[Relationship between prenatal and postnatal echographic diagnosis of uropathy: is mass screening useful?] Cacciari A, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):13–7 (27 ref.) (Eng. Abstr.) **(Ita)**
[Embryo-fetal ultrasonographic diagnosis in the early pregnancy using transvaginal echography] Guariglia L, et al. **Minerva Ginecol** 1997 Mar;49(3):95–108 (61 ref.) (Eng. Abstr.) **(Ita)**
[Fetal arrhythmia] Hirose O. **Ryoikibetsu Shokogun Shirizu** 1996;(12):370–2 (16 ref.) **(Jpn)**
[Anatomico-echocardiographic studies of the fetal and neonatal heart] Kosourov AK, et al. **Morfologiia** 1996; 109(3):89–92 (38 ref.) **(Rus)**
[Screening for fetal chromosome aberrations. Ultrasonic measurement of nuchal translucency thickness is most efficient] Valentin L. **Lakartidningen** 1997 Aug 20; 94(34):2810–2, 2815–6 (52 ref.) **(Swe)**

ECONOMICS

Financial implications of routine screening ultrasound [comment] DeVore GR. **Ultrasound Obstet Gynecol** 1996 May;7(5):307–8 (8 ref.) Comment on: Ultrasound Obstet Gynecol 1996 May;7(5):309–14.

METHODS

Doppler ultrasound in obstetric practice: 2. Beattie RB. **Br J Hosp Med** 1994 Jan 19–Feb 1;51(1–2):34–9 (27 ref.)
Ultrasound measurement of fetal urine flow. Hedriana HL. **Clin Obstet Gynecol** 1997 Jun;40(2):337–51 (28 ref.)
Diagnosis of congenital malformations using two-dimensional and three-dimensional ultrasonography. Chan L, et al. **Obstet Gynecol Clin North Am** 1997 Mar; 24(1):49–69 (25 ref.)
Prenatal ultrasonographic morphologic assessment of the umbilical cord: a review. Part I. Sherer DM, et al. **Obstet Gynecol Surv** 1997 Aug;52(8):506–14 (150 ref.)
Noninvasive first-trimester screening for fetal aneuploidy. Sherer DM, et al. **Obstet Gynecol Surv** 1997 Feb; 52(2):123–9 (89 ref.)
Office procedures. Obstetric ultrasonography. Deutchman ME, et al. **Prim Care** 1997 Jun;24(2):407–31 (35 ref.)
Ultrasound in twin pregnancy. Divon MY, et al. **Semin Perinatol** 1995 Oct;19(5):404–12 (57 ref.)
Assessing skeletal development [comment] Ashhurst DE. **Ultrasound Obstet Gynecol** 1997 Jun;9(6):373 (4 ref.) Comment on: Ultrasound Obstet Gynecol 1997 Jun;9(6):392–7.
Three-dimensional visualization of the human embryo: a potential revolution in prenatal diagnosis [editorial] Bonilla-Musoles F. **Ultrasound Obstet Gynecol** 1996 Jun; 7(6):393–7 (19 ref.)
Deciphering the hieroglyphics of venous Doppler velocities [comment] Huhta JC. **Ultrasound Obstet Gynecol** 1997 May;9(5):300–1 (5 ref.) Comment on: Ultrasound Obstet Gynecol 1997 May;9(5):319–23.
Pathology and clinical implications of abnormal umbilical artery Doppler waveforms. Kingdom JC, et al. **Ultrasound Obstet Gynecol** 1997 Apr;9(4):271–86 (173 ref.)
In a different vein: the ductus venosus could yield much valuable information. Kiserud T. **Ultrasound Obstet Gynecol** 1997 Jun;9(6):369–72 (50 ref.)
Isolated choroid plexus cysts: should we offer karyotyping? [comment] [see comments] Snijders RJ. **Ultrasound Obstet Gynecol** 1996 Oct;8(4):223–4 (17 ref.) Comment on: Ultrasound Obstet Gynecol 1996 Oct;8(4):232–5. Comment in: Ultrasound Obstet Gynecol 1997 Jan;9(1):67–8.

STANDARDS

[Value of the systematic uterine Doppler in the primiparous woman. A series of 315 cases] Soutif C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(8):819–23 (17 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Use of transvaginal ultrasound-guided puncture for elimination of equine pregnancies. Squires EL. **Vet Clin North Am Equine Pract** 1996 Apr;12(1):161–8 (19 ref.)

ULTRASONOGRAPHY, PULSED DOPPLER see **ULTRASONOGRAPHY, DOPPLER, PULSED**

ULTRASONOGRAPHY, TRANSCRANIAL DOPPLER see **ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL**

ULTRASOUND, INTERVENTIONAL see **ULTRASONOGRAPHY, INTERVENTIONAL**

ULTRAVIOLET RAYS

Photoaging of the connective tissue of skin: its prevention and therapy. Scharffetter-Kochanek K. **Adv Pharmacol** 1997;38:639–55 (116 ref.)
Purines as targets for DNA photodamage. Davies RJ. **Biochem Soc Trans** 1997 Feb;25(1):323–6 (25 ref.)
Activation of mammalian gene expression by the UV component of sunlight—from models to reality. Tyrrell RM. **Bioessays** 1996 Feb;18(2):139–48 (77 ref.)
UV-induced cutaneous photobiology. Beissert S, et al. **Crit Rev Biochem Mol Biol** 1996 Dec;31(5–6):381–404 (150 ref.)
Chemoprevention of ultraviolet radiation-induced skin cancer. Ley RD, et al. **Environ Health Perspect** 1997 Jun; 105 Suppl 4:981–4 (50 ref.)
UV activation of mammalian stress proteins. Tyrrell RM. **EXS** 1996;77:255–71 (89 ref.)
Ultraviolet light may contribute to geographic and racial blood pressure differences. Rostand SG. **Hypertension** 1997 Aug;30(2 Pt 1):150–6 (110 ref.)
UV-induced signal transduction. Bender K, et al. **J Photochem Photobiol B** 1997 Jan;37(1–2):1–17 (187 ref.)
Photocarcinogenesis: an overview. Black HS, et al. **J Photochem Photobiol B** 1997 Aug;40(1):29–47 (194 ref.)
Biological effects of narrow-band (311 nm TL01) UVB irradiation: a review. el-Ghorr AA, et al. **J Photochem Photobiol B** 1997 Apr;38(2–3):99–106 (45 ref.)
UV effects in "the real world": problems of UV dosimetry in complex organisms. Sutherland BM. **J Photochem Photobiol B** 1997 Aug;40(1):8–13 (9 ref.)
Stress proteins in the cellular response to ultraviolet radiation. Trautinger F, et al. **J Photochem Photobiol B** 1996 Sep; 35(3):141–8 (71 ref.)
Review of the impact on the activation of the human immunodeficiency virus type 1 of ultraviolet light. Duan Y, et al. **Med Hypotheses** 1996 Jul;47(1):11–4 (9 ref.)
Mutants of Arabidopsis as tools to understand the regulation of phenylpropanoid pathway and UVB protection mechanisms. Bharti AK, et al. **Photochem Photobiol** 1997 May;65(5):765–76 (104 ref.)
The influence of ultraviolet light on immunological cytotoxicity in the skin. Norris DA, et al. **Photochem Photobiol** 1997 Apr;65(4):636–46 (117 ref.)
Formation and processing of UV photoproducts: effects of DNA sequence and chromatin environment. Pfeifer GP. **Photochem Photobiol** 1997 Feb;65(2):270–83 (195 ref.)
Ultraviolet-induced photolesions: repair and mutagenesis. Mullenders LH, et al. **Recent Results Cancer Res** 1997; 143:89–99 (33 ref.)
[Ultraviolet light, skin urocanic acid and immune tolerance (editorial)] Laihia J, et al. **Duodecim** 1995;111(10):905–6 (17 ref.) **(Fin)**
[Photosensitized DNA damage: mechanisms and clinical use] Ito K, et al. **Nippon Rinsho** 1996 Nov;54(11):3131–42 (23 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Ultraviolet light and non-Hodgkin's lymphoma. Melbye M, et al. **Acta Oncol** 1996;35(6):655–7 (37 ref.)
The case for sunscreens. A review of their use in preventing actinic damage and neoplasia. Naylor MF, et al. **Arch Dermatol** 1997 Sep;133(9):1146–54 (50 ref.)
Molecular aspects of UVB-induced immunosuppression. Garssen J, et al. **Arch Toxicol Suppl** 1997;19:97–109 (60

ref.)
A review of skin ageing and its medical therapy. Gilchrest BA. **Br J Dermatol** 1996 Dec;135(6):867–75 (50 ref.)
Ultraviolet irradiation in systemic lupus erythematosus: friend or foe? Cohen MR, et al. **Br J Rheumatol** 1996 Oct; 35(10):1002–7 (68 ref.)
DNA damage and repair in melanoma and non-melanoma skin cancer. Camplejohn RS. **Cancer Surv** 1996;26:193–206 (46 ref.)
The role of UVA in the aetiology of non-melanoma skin cancer. de Laat JM, et al. **Cancer Surv** 1996;26:173–91 (109 ref.)
Relevance of in vitro melanocytic cell studies to the understanding of melanoma. Linge C. **Cancer Surv** 1996; 26:71–87 (49 ref.)
Photoimmunology of non-melanoma skin cancer. Streilein JW. **Cancer Surv** 1996;26:207–17 (40 ref.)
Second Symposium on Ultraviolet Radiation-related Diseases. Mills CJ, et al. **Chronic Dis Can** 1997;18(1):27–38 (51 ref.)
Ultraviolet radiation revisited. Bergmanson JP, et al. **CLAO J** 1997 Jul;23(3):196–204 (70 ref.)
Aspects of exposure to UVA tanning sources. Carcinogenic effect in mice and melanogenic effect in man and mice. Bech-Thomsen N. **Dan Med Bull** 1997 Jun;44(3):242–56 (116 ref.)
Fixed exanthema induced by ultraviolet radiation. del Río E, et al. **Dermatology** 1996;193(1):54–5 (3 ref.)
The role of cytokines in ultraviolet-B induced immunosuppression. Boonstra A, et al. **Eur Cytokine Netw** 1997 Jun;8(2):117–23 (60 ref.)
Cosmic radiation and ozone. Hack M. **Eur J Cancer Prev** 1996 Oct;5(5):378–9 (4 ref.)
Ultraviolet exposure and cancer. Wolf P. **Eur J Cancer Prev** 1996 Oct;5(5):381–3 (7 ref.)
The skin cancer cascade: from ozone depletion to melanoma--some definitions and some new interpretation, 1996. Fitzpatrick TB. **J Dermatol** 1996 Nov;23(11):816–20 (11 ref.)
Sunscreens: progress and perspectives on photoprotection of human skin against UVB and UVA radiation. Pathak MA. **J Dermatol** 1996 Nov;23(11):783–800 (25 ref.)
UV radiation from sunlight: summary, conclusions and recommendations. van der Leun JC. **J Photochem Photobiol B** 1996 Sep;35(3):237–44 (0 ref.)
Ultraviolet light modulation of autoantigens, epidermal cytokines and adhesion molecules as contributing factors of the pathogenesis of cutaneous LE. Bennion SD, et al. **Lupus** 1997;6(2):181–92 (116 ref.)
Ultraviolet light-induced keratinocyte apoptosis: a potential mechanism for the induction of skin lesions and autoantibody production in LE. Casciola-Rosen L, et al. **Lupus** 1997;6(2):175–80 (52 ref.)
Deleterious effects of ultraviolet A radiation in human cells. Stary A, et al. **Mutat Res** 1997 Jan 31;383(1):1–8 (50 ref.)
Protective effects of glutamine enriched diets on acute actinic enteritis. Campos FG, et al. **Nutr Hosp** 1996 May-Jun; 11(3):167–77 (140 ref.)
Oncogenes and tumor suppressor genes in photocarcinogenesis. Ananthaswamy HN, et al. **Photochem Photobiol** 1996 Apr;63(4):428–32 (36 ref.)
Cell-mediated immunosuppressive mechanisms induced by UV radiation. Cooper KD. **Photochem Photobiol** 1996 Apr; 63(4):400–6 (120 ref.)
Photobiology of photocarcinogenesis. de Gruijl FR. **Photochem Photobiol** 1996 Apr;63(4):372–5 (21 ref.)
Relevance of animal models of photocarcinogenesis to humans. Forbes PD. **Photochem Photobiol** 1996 Apr; 63(4):357–62 (39 ref.)
Cytokines and photocarcinogenesis. Granstein RD. **Photochem Photobiol** 1996 Apr;63(4):390–4 (54 ref.)
Analysis of rodent photo cocarcinogenicity models for hazard evaluation and risk assessment: industry viewpoint. Kraus AL. **Photochem Photobiol** 1996 Apr;63(4):365–9 (54 ref.)
The role of DNA damage and repair in ultraviolet B radiation-induced immunomodulation: relevance for human photocarcinogenesis. Krutmann J, et al. **Photochem Photobiol** 1996 Apr;63(4):394–6 (27 ref.)
Chromophore for UV-induced immunosuppression: urocanic acid. Norval M. **Photochem Photobiol** 1996 Apr; 63(4):386–90 (42 ref.)
Impact of UVB radiation on the epidermal cytokine network. Takashima A, et al. **Photochem Photobiol** 1996 Apr; 63(4):397–400 (80 ref.)
Chromophore for UV-induced immunosuppression: DNA. Vink AA, et al. **Photochem Photobiol** 1996 Apr;63(4):383–6 (27 ref.)
Optical radiation safety of medical light sources. Sliney DH. **Phys Med Biol** 1997 May;42(5):981–96 (50 ref.)
Risk assessment for the harmful effects of immunotoxic agents on the immunological resistance to infectious diseases: ultraviolet light as an example. Van Loveren H, et al. **Toxicology** 1997 Apr 11;119(1):59–64 (19 ref.)
[Ultraviolet irradiation devices. Risks related to their use] Doré JF, et al. **Presse Med** 1997 Jun 14;26(20):966–71 (39 ref.) **(Fre)**
[Contemporary views on the pathogenesis and possible prophylaxis of age related cataracts] Kałużny JJ, et al. **Pol Merkuriusz Lek** 1997 Jan;2(7):76–8 (19 ref.) (Eng. Abstr.) **(Pol)**
[A comparative analysis of the existing standards for exposure to ultraviolet radiation] Strzhizhovskiĭ AD. **Usp Fiziol Nauk** 1997 Apr-Jun;28(2):94–106 (40 ref.) (Eng. Abstr.) **(Rus)**
[Natural ultraviolet radiation: the nature of its behavior and human health] Strzhizhovskiĭ AD. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Jul-Aug; (4):49–53 (75 ref.) **(Rus)**
[Cutaneous photoprotection. Suntan or no suntan? This is the question (editorial)] Casado Jiménez M, et al. **Rev Clin Esp** 1996 Jul;196(7):417–20 (38 ref.) **(Spa)**

ULTRAVIOLET THERAPY

see related
PHOTOCHEMOTHERAPY

Ultraviolet irradiation in systemic lupus erythematosus: friend or foe? Cohen MR, et al. **Br J Rheumatol** 1996 Oct; 35(10):1002–7 (68 ref.)
Ultraviolet phototherapy. Farr PM. **J R Coll Physicians Lond** 1997 May-Jun;31(3):250–3 (25 ref.)
Prospects for UV-A1 therapy as a treatment modality in cutaneous and systemic LE. McGrath H Jr. **Lupus** 1997; 6(2):209–17 (81 ref.)
Phototherapy of eczema. Larkö O. **Photodermatol Photoimmunol Photomed** 1996 Jun; 12(3):91–4 (60 ref.)

INSTRUMENTATION

Biological effects of narrow-band (311 nm TL01) UVB irradiation: a review. el-Ghorr AA, et al. **J Photochem Photobiol B** 1997 Apr;38(2–3):99–106 (45 ref.)

STANDARDS

Immunomodulation in transplantation with photopheresis. Barr ML. **Artif Organs** 1996 Aug;20(8):971–3 (12 ref.)

UMBILICAL ARTERIES

ABNORMALITIES

Twin-reversed arterial perfusion (TRAP) sequence: case reports and review of literature. Hanafy A, et al. **Aust N Z J Obstet Gynaecol** 1997 May;37(2):187–91 (29 ref.)

DRUG EFFECTS

Effect of nitric oxide, prostacyclin, and thromboxane on the vasospastic action of hydrogen peroxide on human umbilical artery. Okatani Y, et al. **Acta Obstet Gynecol Scand** 1997 Jul;76(6):515–20 (24 ref.)

PATHOLOGY

Pathology and clinical implications of abnormal umbilical artery Doppler waveforms. Kingdom JC, et al. **Ultrasound Obstet Gynecol** 1997 Apr;9(4):271–86 (173 ref.)

UMBILICAL CORD

[Cord prolapse. Review of the literature. A series of 50 cases] Dufour P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(8):841–5 (20 ref.) (Eng. Abstr.) **(Fre)**

ABNORMALITIES

Prenatal ultrasonographic morphologic assessment of the umbilical cord: a review. Part I. Sherer DM, et al. **Obstet Gynecol Surv** 1997 Aug;52(8):506–14 (150 ref.)
Monoamniotic twins delivered liveborn with a forked umbilical cord. Fraser RB, et al. **Pediatr Pathol Lab Med** 1997 Jul-Aug;17(4):639–44 (9 ref.)

PATHOLOGY

Monoamniotic twin pregnancy and cord entanglement: a clinical dilemma. Ritossa M, et al. **Aust N Z J Obstet Gynaecol** 1996 Aug;36(3):309–12 (12 ref.)
The umbilical cord: obstetrically important lesions. Heifetz SA. **Clin Obstet Gynecol** 1996 Sep;39(3):571–87 (23 ref.)
Prenatal ultrasonographic morphologic assessment of the umbilical cord: a review. Part II. Sherer DM, et al. **Obstet Gynecol Surv** 1997 Aug;52(8):515–23 (150 ref.)
[Surviving mono-amniotic twins. Case report and review of the literature] Golaszewski T, et al. **Z Geburtshilfe Neonatol** 1997 Mar-Apr;201(2):62–4 (11 ref.) (Eng. Abstr.) **(Ger)**
[Primary nontrophoblastic tumors of the placenta] Fiutowski M, et al. **Ginekol Pol** 1996 Oct;67(10):515–9 (30 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

[Effects of hypoxemia and umbilical cord occlusion on fetal circulation in sheep] Kozuma S. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Aug;48(8):654–9 (0 ref.) **(Jpn)**

SURGERY

Surgery of the placenta and umbilical cord. De Lia JE. **Clin Obstet Gynecol** 1996 Sep;39(3):607–25 (64 ref.)

ULTRASONOGRAPHY

Prenatal ultrasonographic morphologic assessment of the umbilical cord: a review. Part I. Sherer DM, et al. **Obstet Gynecol Surv** 1997 Aug;52(8):506–14 (150 ref.)
Prenatal ultrasonographic morphologic assessment of the umbilical cord: a review. Part II. Sherer DM, et al. **Obstet Gynecol Surv** 1997 Aug;52(8):515–23 (150 ref.)

UMBILICAL CORD BLOOD see **FETAL BLOOD**

UMBILICAL CYST see **URACHAL CYST**

UMBILICAL HERNIA see **HERNIA, UMBILICAL**

UMBILICAL VEINS

An easy test for coeliac disease using human umbilical vein endothelial cells. Usselmann B, et al. **Eur J Gastroenterol Hepatol** 1996 Oct;8(10):947–50 (23 ref.)
Characteristics of fetal venous blood flow under normal circumstances and during fetal disease. Hecher K, et al. **Ultrasound Obstet Gynecol** 1996 Jan;7(1):68–83 (70 ref.)

ABNORMALITIES

Abnormalities of the intra-abdominal fetal umbilical vein: reports of four cases and a review of the literature. Moore L, et al. **Ultrasound Obstet Gynecol** 1996 Jan;7(1):21–5 (16 ref.)
Prenatal diagnosis of persistent right umbilical vein. Shen O, et al. **Ultrasound Obstet Gynecol** 1996 Jul;8(1):31–3 (20 ref.)
[Anomalies of umbilical vein in the fetus. A case report and review of the literature] Tordjeman N, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(5):495–9 (18 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Cell adhesion molecules in HTLV-I infection. Uchiyama T, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996; 13 Suppl 1:S114–8 (22 ref.)

ULTRASONOGRAPHY

Prenatal ultrasonographic assessment of the ductus venosus: a review. Sherer DM, et al. **Obstet Gynecol** 1996 Oct;88(4 Pt 1):626–32 (32 ref.)
Deciphering the hieroglyphics of venous Doppler velocities [comment] Huhta JC. **Ultrasound Obstet Gynecol** 1997 May;9(5):300–1 (5 ref.) Comment on: Ultrasound Obstet Gynecol 1997 May;9(5):319–23.

UMBILICUS

[Umbilical metastasis of an endometrial adenocarcinoma: "Sister (Mary) Joseph's nodule". Review of the literature] Poncelet C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(8):799–803 (13 ref.) (Eng. Abstr.) **(Fre)**

ABNORMALITIES

Successful early separation of a premature xipho-omphalopagus conjoined twins: a case report. Lai HS, et al. **Can J Surg** 1997 Apr;40(2):139, 141–2 (7 ref.)
Minimally united ischiopagus twins: infraumbilical union with cloacal anomalies. Spencer R. **J Pediatr Surg** 1996 Nov; 31(11):1538–45 (25 ref.)

UMBRELLA FILTERS see **VENA CAVA FILTERS**

UMP see **URIDINE MONOPHOSPHATE**

UNCOMPENSATED CARE

see related
MEDICALLY UNINSURED

TRENDS

The evolution of support for safety-net hospitals. Fishman LE, et al. **Health Aff (Millwood)** 1997 Jul-Aug;16(4):30–47 (30 ref.)

UNCONSCIOUS (PSYCHOLOGY)

Psychic reality and unconscious belief: a reconsideration. Gerard HB. **Int J Psychoanal** 1997 Apr;78 (Pt 2):327–33; discussion 335–40 (30 ref.)
[Factitious disorders: psychopathologic markers, biographic background and therapy follow-up] Lauer G. **Psychiatr Prax** 1996 Jan;23(1):37–9 (16 ref.) (Eng. Abstr.) **(Ger)**

UNCONSCIOUSNESS

see related
SYNCOPE

DIAGNOSIS

Postconcussional disorder and loss of consciousness. Anderson SD. **Bull Am Acad Psychiatry Law** 1996; 24(4):493–504 (35 ref.)

ETIOLOGY

[Comparative data of tilt test with or without isoproterenol in investigation of unexplained unconsciousness and syncope] Raybaud F, et al. **Arch Mal Coeur Vaiss** 1996 Sep;89(9):1145–51 (32 ref.) (Eng. Abstr.) **(Fre)**

UNCOUPLING AGENTS

see related
IONOPHORES

PHARMACOLOGY

A new uncoupling protein: a potential component of the human body weight regulation system. Wolf G. **Nutr Rev** 1997 May;55(5):178–9 (8 ref.)

UNDER-DEVELOPED COUNTRIES see **DEVELOPING COUNTRIES**

UNDERPOPULATION see **POPULATION DENSITY**

UNDULANT FEVER see **BRUCELLOSIS**

UNEMPLOYMENT

Is unemployment pathogenic? A review of current concepts with lessons for policy planners. Shortt SE. **Int J Health Serv** 1996;26(3):569–89 (115 ref.)

PSYCHOLOGY

Coping with job loss: an attributional model. Thomson NF. **J Psychol** 1997 Jan;131(1):73–80 (26 ref.)

[Cardiovascular diseases caused by unemployment? An analysis from the viewpoint of social medicine (see comments)] Weber A, et al. **Wien Klin Wochenschr** 1997 Mar 28;109(6):202–10 (50 ref.) (Eng. Abstr.) Comment in: Wien Klin Wochenschr 1997 Mar 28;109(6):177–9. **(Ger)**

UNESCO see **UNITED NATIONS**

UNICEF see **UNITED NATIONS**

UNIFIED MEDICAL LANGUAGE SYSTEM

see related
NOMENCLATURE

UNIPOLAR DEPRESSION see **DEPRESSIVE DISORDER**

UNIPORT see **ION TRANSPORT**

UNIT DOSE DRUG DISTRIBUTION SYSTEMS see **MEDICATION SYSTEMS**

UNITED NATIONS

The Food and Agriculture Organization food-composition initiative. Lupien JR. **Am J Clin Nutr** 1997 Apr;65(4 Suppl):1194S–1197S (6 ref.)

Market commodities and poor relief: the world bank proposal for health. Laurell AC, et al. **Int J Health Serv** 1996; 26(1):1–18 (42 ref.)

The rights of psychiatric patients in the light of the principles announced by the United Nations: a recognition of the right to consent to treatment? Gendreau C. **Int J Law Psychiatry** 1997 Spring;20(2):259–78 (77 ref.)

LEGISLATION & JURISPRUDENCE

The right to a family environment for children with disabilities. Weisz V, et al. **Am Psychol** 1996 Dec; 51(12):1239–45 (63 ref.)

UNITED STATES AGENCY FOR HEALTH CARE POLICY AND RESEARCH

Management of otitis media with effusion in young children. Paap CM. **Ann Pharmacother** 1996 Nov;30(11):1291–7 (19 ref.)

ORGANIZATION & ADMINISTRATION

The role of the Agency for Health Care Policy and Research (AHCPR) in improving outcomes of care. McCormick KA, et al. **Nurs Clin North Am** 1997 Sep;32(3):521–42 (14 ref.)

UNITED STATES CENTERS FOR DISEASE CONTROL AND PREVENTION see **CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.)**

UNITED STATES DEPARTMENT OF AGRICULTURE

Fumonisin toxicity and metabolism studies at the USDA. Fumonisin toxicity and metabolism. Norred WP, et al. **Adv Exp Med Biol** 1996;392:225–36 (73 ref.)

The USDA Forest Service pesticide spray behavior and application development program--an overview. Barry JW. **J Am Mosq Control Assoc** 1996 Jun;12(2 Pt 2):342–52 (88 ref.)

UNITED STATES ENVIRONMENTAL PROTECTION AGENCY

State pesticide regulatory programs: themes and variations. Arne KH. **Occup Med** 1997 Apr-Jun;12(2):371–85 (33 ref.)

LEGISLATION & JURISPRUDENCE

Partnerships to protect. VanderMeer D. **Environ Health Perspect** 1996 Nov;104(11):1158–60 (0 ref.)

STANDARDS

Technical basis for EPA's proposed regulation on the cleanup of sites contaminated with radioactivity. Wolbarst AB, et al. **Health Phys** 1996 Nov;71(5):644–60 (56 ref.)

UNITED STATES FEDERAL TRADE COMMISSION

LEGISLATION & JURISPRUDENCE

Release of spectacle prescriptions: an update. Classé JG. **J Am Optom Assoc** 1996 Oct;67(10):631–7 (11 ref.)

UNITED STATES FOOD AND DRUG ADMINISTRATION

Regulatory aspects of fumonisins in the United States. Troxell TC. **Adv Exp Med Biol** 1996;392:355–61 (4 ref.)

Some Food and Drug Administration perspectives of fat and fatty acids. Scarbrough FE. **Am J Clin Nutr** 1997 May;65(5 Suppl):1578S–1580S (6 ref.)

FDA regulatory reform. Beatrice M. **Curr Opin Biotechnol** 1997 Jun;8(3):370–8 (22 ref.)

Food and drug administration regulations and computer-controlled infusion pumps. Bazaral MG, et al. **Int Anesthesiol Clin** 1995 Summer;33(3):45–63 (42 ref.)

Characteristics of materials distributed by drug companies. An evaluation of appropriateness [see comments] Stryer D, et al. **J Gen Intern Med** 1996 Oct;11(10):575–83 (81 ref.) Comment in: J Gen Intern Med 1996 Oct;11(10):635–6. Comment in: J Gen Intern Med 1996 Oct;11(10):637–9. Comment in: J Gen Intern Med 1996 Oct;11(10):640–1. Comment in: J Gen Intern Med 1996 Oct;11(10):642–4.

Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? [see comments] Grossman E, et al. **JAMA** 1996 Oct 23–30;276(16):1328–31 (65 ref.) Comment in: JAMA 1996 Oct 23–30;276(16):1342–3. Comment in: JAMA 1997 Mar 12;277(10):787; discussion 790–1. Comment in: JAMA 1997 Mar 12;277(10):787–8; discussion 790–1. Comment in: JAMA 1997 Mar 12;277(10):788; discussion 790–1. Comment in: JAMA 1997 Mar 12;277(10):788–9; discussion 790–1. Comment in: JAMA 1997 Mar 12;277(10):789–90; discussion 790–1. Comment in: JAMA 1997 Mar 12;277(10):790; discussion 790–1.

Asymmetric assessments in valuing pharmaceutical risks. Viscusi WK, et al. **Med Care** 1996 Dec;34(12 Suppl):DS34–47 (26 ref.)

LEGISLATION & JURISPRUDENCE

Cosmetic industry. Year in review: 1995/1996. Barker MO. **Am J Contact Dermat** 1996 Dec;7(4):251–3 (0 ref.)

Food safety regulation: reforming the Delaney Clause. Merrill RA. **Annu Rev Public Health** 1997;18:313–40 (70 ref.)

'1996' starting the modern era of biologics regulation: FDA's elimination of establishment licensure and other changes. Gamerman GE, et al. **Biotechnol Appl Biochem** 1997 Jun; 25 (Pt 3):189–95 (31 ref.)

ORGANIZATION & ADMINISTRATION

The corporate assault on the Food and Drug Administration. Nixon R. **Int J Health Serv** 1996;26(3):561–8 (18 ref.)

UNITED STATES HEALTH CARE FINANCING ADMINISTRATION

STANDARDS

Health Care Financing Administration/American Society for Cytotechnology inspections: government assessment of cytology laboratory practice under the regulations of the Clinical Laboratory Improvement Amendments of 1988. Triol JH, et al. **Arch Pathol Lab Med** 1997 Mar; 121(3):264–6 (3 ref.)

HCFA's health care quality improvement program: the medical informatics challenge. Grant JB, et al. **J Am Med Inform Assoc** 1996 Jan-Feb;3(1):15–26 (47 ref.)

UNITED STATES NATIONAL HEALTH INSURANCE see **NATIONAL HEALTH INSURANCE, UNITED STATES**

UNITED STATES NATIONAL INSTITUTE OF MENTAL HEALTH see **NATIONAL INSTITUTE OF MENTAL HEALTH (U.S.)**

UNITED STATES NATIONAL INSTITUTES OF HEALTH see **NATIONAL INSTITUTES OF HEALTH (U.S.)**

UNITED STATES NATIONAL LIBRARY OF MEDICINE see **NATIONAL LIBRARY OF MEDICINE (U.S.)**

UNITED STATES OCCUPATIONAL SAFETY AND HEALTH ADMINISTRATION

LEGISLATION & JURISPRUDENCE

Occupational health services and OSHA compliance. Jones DL. **Occup Med** 1996 Jan-Mar;11(1):57–68 (9 ref.)

Control of biologic hazards. Stave GM. **Occup Med** 1996 Jan-Mar;11(1):79–85 (9 ref.)

Health hazard labeling for hazard communication in the pharmaceutical industry. Sussman RG, et al. **Occup Med** 1997 Jan-Mar;12(1):107–17 (12 ref.)

STANDARDS

Generic strategies for protecting worker health and safety. OSHA's general duty clause and hazard communications standard. Baram M. **Occup Med** 1996 Jan-Mar;11(1):69–77 (46 ref.)

UNIVERSAL COVERAGE

The German health system. Lessons for reform in the United States [see comments] Jackson JL. **Arch Intern Med** 1997 Jan 27;157(2):155–60 (31 ref.) Comment in: Arch Intern Med 1997 Aug 11–25;157(15):1773–4.

ORGANIZATION & ADMINISTRATION

Universal health care coverage in the United States: barriers, prospects, and implications. Gorin S. **Health Soc Work** 1997 Aug;22(3):223–30 (80 ref.)

UNIVERSITIES

Building community capacity to promote social and public health: challenges for universities [editorial] Poole DL. **Health Soc Work** 1997 Aug;22(3):163–70 (48 ref.)

Developing industrial-governmental-academic partnerships to address micronutrient malnutrition. Darnton-Hill I. **Nutr Rev** 1997 Mar;55(3):76–81 (24 ref.)

Technology transfer at US universities: seeking public benefit from the results of basic research. Goodwin CD. **Technol Health Care** 1996 Sep;4(3):323–30 (6 ref.)

STANDARDS

Academic research: policies and practice. Bertha SL. **J Ethnopharmacol** 1996 Apr;51(1–3):59–73 (7 ref.)

TRENDS

Global linkages in animal agriculture: new opportunities for United States agricultural universities. Johnson WL. **J Anim Sci** 1996 Jun;74(6):1386–94 (13 ref.)

UNIVERSITY MEDICAL CENTERS see **ACADEMIC MEDICAL CENTERS**

UNKNOWN PRIMARY TUMORS see **NEOPLASMS, UNKNOWN PRIMARY**

UNNECESSARY PROCEDURES

The cesarean birth epidemic: trends, causes, and solutions [see comments] Porreco RP, et al. **Am J Obstet Gynecol** 1996 Aug;175(2):369–74 (39 ref.) Comment in: Am J Obstet Gynecol 1997 Jul;177(1):249.

ECONOMICS

The role of medical necessity and cost-effectiveness in making medical decisions [see comments] Glassman PA, et al. **Ann Intern Med** 1997 Jan 15;126(2):152–6 (19 ref.) Comment in: Ann Intern Med 1997 Jul 15;127(2):165–6. Comment in: Ann Intern Med 1997 Jul 15;127(2):166.

UNNECESSARY SURGERY see **UNNECESSARY PROCEDURES**

UNSATURATED DIETARY FATS see **DIETARY FATS, UNSATURATED**

UP-REGULATION (PHYSIOLOGY)

see related
DOWN-REGULATION (PHYSIOLOGY)

Commentary on magnesium deficiency, substance P receptor up-regulation and NO overproduction. Weglicki WB, et al. **Magnes Res** 1996 Dec;9(4):331–2 (10 ref.)

[Structure of the histamine H1 receptor gene and transcriptional up-regulation of the H1 receptor] Fukui H. **Nippon Rinsho** 1996 Feb;54(2):389–95 (15 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Regulation of the invasion suppressor function of the

UP-REGULATION (PHYSIOLOGY)

cadherin/catenin complex. Vermeulen S, et al. **Pathol Res Pract** 1996 Jul;192(7):694–707 (97 ref.)

IMMUNOLOGY

Recognition events that inhibit and activate natural killer cells. Raulet DH. **Curr Opin Immunol** 1996 Jun;8(3):372–7 (55 ref.)

Flavivirus-induced up-regulation of MHC class I antigens; implications for the induction of CD8+ T-cell-mediated autoimmunity. Lobigs M, et al. **Immunol Rev** 1996 Aug; 152:5–19 (67 ref.)

PHYSIOLOGY

Upregulation of tachykinin receptors in chronic airway inflammation. McDonald DM. **Pulm Pharmacol** 1995 Aug–Oct;8(4–5):203–5 (15 ref.)

UPHILL TRANSPORT see **BIOLOGICAL TRANSPORT, ACTIVE**

UPPER EXTREMITY see **ARM**

UPPER RESPIRATORY INFECTIONS see **RESPIRATORY TRACT INFECTIONS**

UPREGULATION see **UP-REGULATION (PHYSIOLOGY)**

URACHAL CYST

GENETICS

The sonographic finding of persistent umbilical cord cystic masses is associated with lethal aneuploidy and/or congenital anomalies. Smith GN, et al. **Prenat Diagn** 1996 Dec;16(12):1141–7 (17 ref.)

ULTRASONOGRAPHY

The sonographic finding of persistent umbilical cord cystic masses is associated with lethal aneuploidy and/or congenital anomalies. Smith GN, et al. **Prenat Diagn** 1996 Dec;16(12):1141–7 (17 ref.)

URACHUS

Adenocarcinoma of the urachus: 3 case reports and a review of the literature. Mattelaer P, et al. **Acta Urol Belg** 1997 Mar;65(1):63–7 (18 ref.)

SURGERY

Is partial cystectomy the treatment of choice for mucinous adenocarcinoma of the urachus? Santucci RA, et al. **Urology** 1997 Apr;49(4):536–40 (26 ref.)

URACIL

Site-directed mutagenesis using a uracil-containing phagemid template. Hagemeier C. **Methods Mol Biol** 1996; 57:45–54 (3 ref.)

METABOLISM

Precluding uracil from DNA. Vassylyev DG, et al. **Structure** 1996 Dec 15;4(12):1381–5 (18 ref.)

URACIL ARABINOFURANOSIDE see **ARABINOFURANOSYLURACIL**

URACIL ARABINOSIDE see **ARABINOFURANOSYLURACIL**

URACIL NUCLEOTIDES

METABOLISM

Involvement of distinct receptors in the actions of extracellular uridine nucleotides. Boeynaems JM, et al. **Ciba Found Symp** 1996;198:266–74; discussion 274–7 (26 ref.)

Release, metabolism and interconversion of adenine and uridine nucleotides: implications for G protein-coupled P2 receptor agonist selectivity. Harden TK, et al. **Trends Pharmacol Sci** 1997 Feb;18(2):43–6 (15 ref.)

URALENIC ACID see **GLYCYRRHETINIC ACID**

URBAN HEALTH

Epidemiology of pollution-induced airway disease: urban/rural differences in East and West Germany. Nicolai T. **Allergy** 1997;52(38 Suppl):26–9; discussion 35–6 (18 ref.)

Culture as a stressor: a revised model of biocultural interaction. Schell LM. **Am J Phys Anthropol** 1997 Jan; 102(1):67–77 (49 ref.)

Blood lead levels in children in south central Los Angeles. Rothenberg SJ, et al. **Arch Environ Health** 1996 Sep–Oct; 51(5):383–8 (25 ref.)

Reason and protest in the new urban public health movement: an observation on the sociological analysis of political discourse in the 'healthy city'. Milewa T, et al. **Br J Sociol** 1996 Dec;47(4):657–70 (40 ref.)

Resilience in highly stressed urban children: concepts and findings. Cowen EL, et al. **Bull N Y Acad Med** 1996 Winter; 73(2):267–84 (46 ref.)

Segregation, discrimination and mortality in U.S. blacks. Polednak AP. **Ethn Dis** 1996 Winter–Spring;6(1–2):99–108 (67 ref.)

Risk assessment of complex mixtures: some considerations on polycyclic aromatic hydrocarbons in urban areas. Zapponi GA, et al. **J Environ Pathol Toxicol Oncol** 1997; 16(2–3):209–14 (29 ref.)

An effective model for reorganization of perinatal services in a metropolitan area: a descriptive analysis and historical perspective. Pollack LD. **J Perinatol** 1996 Jan–Feb; 16(1):3–8 (30 ref.)

The homeless. Abdul-Hamid W, et al. **Postgrad Med J** 1996 Nov;72(853):667–70 (49 ref.)

STDS in women attending family planning clinics: a case study in Addis Ababa. Duncan ME, et al. **Soc Sci Med** 1997 Feb;44(4):441–54 (101 ref.)

Urban violence and health--South Africa 1995. Gilbert L. **Soc Sci Med** 1996 Sep;43(5):873–86 (74 ref.)

Improving the safety of street-vended food. Moy G, et al. **World Health Stat Q** 1997;50(1–2):124–31 (8 ref.)

[Urban atmospheric pollution and public health: epidemiologic data] Aubier M. **Bull Acad Natl Med** 1997 Mar 18;181(3):489–97 (21 ref.) (Eng. Abstr.) **(Fre)**

[Urban atmospheric pollution: sources, pollutants and evolution] Festy B. **Bull Acad Natl Med** 1997 Mar 18; 181(3):461–74; discussion 474–6 (11 ref.) (Eng. Abstr.) **(Fre)**

[In Africa, urban malaria is the malaria of tomorrow] Baudon D, et al. **Med Trop (Mars)** 1996;56(4):323–5 (11 ref.) **(Fre)**

[Genotoxicity of urban air particulate matter] Clonfero E. **Med Lav** 1997 Jan–Feb;88(1):13–23 (81 ref.) (Eng. Abstr.) **(Ita)**

URBAN HEALTH SERVICES

Urban teleradiology in Hong Kong. Sheng OR, et al. **J Telemed Telecare** 1997;3(2):71–7 (8 ref.)

ORGANIZATION & ADMINISTRATION

Medicaid managed care and urban poor people: implications for social work. Perloff JD. **Health Soc Work** 1996 Aug; 21(3):189–95 (33 ref.)

STANDARDS

Reduction of maternal and perinatal mortality in rural and peri-urban settings: what works? Kwast BE. **Eur J Obstet Gynecol Reprod Biol** 1996 Oct;69(1):47–53 (22 ref.)

URBAN POPULATION

The impact of exposure to crime and violence on urban youth. Berman SL, et al. **Am J Orthopsychiatry** 1996 Jul; 66(3):329–36 (29 ref.)

[Primary angioplasty in acute myocardial infarction. A one-year experience in a small urban community] Moquet B, et al. **Arch Mal Coeur Vaiss** 1997 Jan;90(1):11–5 (30 ref.) (Eng. Abstr.) **(Fre)**

[The risk of urban yellow fever outbreaks in Brazil by dengue vectors. Aedes aegypti and Aedes albopictus] Mondet B, et al. **Bull Soc Pathol Exot** 1996;89(2):107–13; discussion 114 (11 ref.) (Eng. Abstr.) **(Fre)**

STATISTICS & NUMERICAL DATA

Lead poisoning: the implications of current biomedical knowledge for public policy. Silbergeld EK. **Md Med J** 1996 Mar;45(3):209–17 (38 ref.)

URBAN RENEWAL

see related
HOUSING

URBANIZATION

Biometeorological studies on urban climate. Fukuoka Y. **Int J Biometeorol** 1997 Feb;40(1):54–7 (15 ref.)

The last Ms for 40th anniversary issue. Aspects of urban human biometeorology. Jauregui E. **Int J Biometeorol** 1997 Feb;40(1):58–61 (32 ref.)

UREA

ADMINISTRATION & DOSAGE

Urea production in normal breast-fed infants measured with primed/intermittent oral doses of [15N, 15N]urea. Steinbrecher HA, et al. **Acta Paediatr** 1996 Jun; 85(6):656–62 (30 ref.)

ANALOGS & DERIVATIVES

Nightguard vital bleaching: current concepts and research. Haywood VB. **J Am Dent Assoc** 1997 Apr;128 Suppl:19S–25S (31 ref.)

Toxicological considerations of tooth bleaching using peroxide-containing agents. Li Y. **J Am Dent Assoc** 1997 Apr;128 Suppl:31S–36S (58 ref.)

BLOOD

Solute clearance approach to adequacy of peritoneal dialysis [see comments] Burkart JM, et al. **Perit Dial Int** 1996 Sep–Oct;16(5):457–70 (80 ref.) Comment in: Perit Dial Int 1996 Sep–Oct;16(5):432–3.

CHEMISTRY

HIV protease mutations leading to reduced inhibitor susceptibility. Korant B, et al. **Adv Exp Med Biol** 1996; 389:241–5 (11 ref.)

DIAGNOSTIC USE

Non-endoscopic tests in the diagnosis of Helicobacter pylori infection. Atherton JC. **Aliment Pharmacol Ther** 1997 Apr; 11 Suppl 1:11–20 (107 ref.)

METABOLISM

Urea production in normal breast-fed infants measured with primed/intermittent oral doses of [15N, 15N]urea. Steinbrecher HA, et al. **Acta Paediatr** 1996 Jun; 85(6):656–62 (30 ref.)

Urea transporters in kidney and erythrocytes. Sands JM, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):F321–39 (163 ref.)

Evolution and regulation of urea synthesis and ureotely in (batrachoidid) fishes. Walsh PJ. **Annu Rev Physiol** 1997; 59:299–323 (110 ref.)

Water channels and urea transporters. Wintour EM. **Clin Exp Pharmacol Physiol** 1997 Jan;24(1):1–9 (78 ref.)

Urea and amphibian water economy. Jørgensen CB. **Comp Biochem Physiol A Physiol** 1997 Jun;117(2):161–70 (87 ref.)

Regulation of urea synthesis by diet protein and carbohydrate in normal man and in patients with cirrhosis. Relationship to glucagon and insulin. Hamberg O. **Dan Med Bull** 1997 Jun;44(3):225–41 (220 ref.)

Urea volume estimates in peritoneal dialysis: pitfalls and corrections [editorial] Tzamaloukas AH, et al. **Int J Artif Organs** 1996 Jun;19(6):321–4 (25 ref.)

Direct and indirect cost of urea excretion. Bankir L, et al. **Kidney Int** 1996 Jun;49(6):1598–607 (68 ref.)

Structure, regulation and physiological roles of urea transporters. Hediger MA, et al. **Kidney Int** 1996 Jun; 49(6):1615–23 (48 ref.)

Active urea transport in the rat inner medullary collecting duct: functional characterization and initial expression cloning. Sands JM, et al. **Kidney Int** 1996 Jun;49(6):1611–4 (41 ref.)

Urea, sodium, and water changes in profiling dialysis. Mann H, et al. **Nephrol Dial Transplant** 1996;11 Suppl 8:10–5 (12 ref.)

The rationale and ultimate limitations of urea kinetic modelling in the estimation of nutritional status. Bargman JM. **Perit Dial Int** 1996 Jul–Aug;16(4):347–51 (24 ref.)

Urea cycle disorders: clinical paradigm of hyperammonemic encephalopathy. Brusilow SW. **Prog Liver Dis** 1995; 13:293–309 (52 ref.)

[Clinical and kinetic evaluation of continuous ambulatory peritoneal dialysis (CAPD)] Grzegorzewska A, et al. **Przegl Lek** 1996;53(8):619–22 (17 ref.) (Eng. Abstr.) **(Pol)**

UREAPLASMA INFECTIONS

Ureaplasma urealyticum infections in the perinatal period. Wang EE, et al. **Clin Perinatol** 1997 Mar;24(1):91–105 (97 ref.)

CLASSIFICATION

Infections due to species of Mycoplasma and Ureaplasma: an update. Taylor-Robinson D. **Clin Infect Dis** 1996 Oct; 23(4):671–82; quiz 683–4 (85 ref.)

EPIDEMIOLOGY

[The spread of Mycoplasma infections] Fovi G, et al. **Ann Ig** 1996 May–Jun;8(3):329–39 (61 ref.) **(Ita)**

MICROBIOLOGY

Ureaplasma urealyticum colonization, prematurity and bronchopulmonary dysplasia. van Waarde WM, et al. **Eur Respir J** 1997 Apr;10(4):886–90 (26 ref.)

Genital mycoplasma infections. Taylor-Robinson D, et al. **Wien Klin Wochenschr** 1997 Aug 8;109(14–15):578–83 (44 ref.)

UREAPLASMA UREALYTICUM

Ureaplasma urealyticum infections in the perinatal period. Wang EE, et al. **Clin Perinatol** 1997 Mar;24(1):91–105 (97 ref.)

[The spread of Mycoplasma infections] Fovi G, et al. **Ann Ig** 1996 May–Jun;8(3):329–39 (61 ref.) **(Ita)**

ISOLATION & PURIFICATION

Ureaplasma urealyticum colonization, prematurity and bronchopulmonary dysplasia. van Waarde WM, et al. **Eur Respir J** 1997 Apr;10(4):886–90 (26 ref.)

PATHOGENICITY

Infections due to species of Mycoplasma and Ureaplasma: an update. Taylor-Robinson D. **Clin Infect Dis** 1996 Oct; 23(4):671–82; quiz 683–4 (85 ref.)

UREMIA

The acute uraemic emergency. Tomson C.
J R Coll Physicians Lond 1997 Jan–Feb;31(1):10–5 (12 ref.)

[Metabolic pericarditis (uremia, myxedema)] Katoh S, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):585–8 (17 ref.) **(Jpn)**

COMPLICATIONS

Mechanisms causing loss of lean body mass in uremia. Mitch WE. **Adv Nephrol Necker Hosp** 1997;26:133–42 (52 ref.)

Cardiac disease in chronic uremia: clinical outcome and risk factors. Foley RN, et al. **Adv Ren Replace Ther** 1997 Jul; 4(3):234–48 (160 ref.)

Cardiac disease in chronic uremia: investigation. Nally JV Jr. **Adv Ren Replace Ther** 1997 Jul;4(3):225–33 (49 ref.)

Cardiac disease in chronic uremia: management. Venkatesan J, et al. **Adv Ren Replace Ther** 1997 Jul;4(3):249–66 (152 ref.)

Uremic pruritus [published erratum appears in Am J Health Syst Pharm 1996 Oct 15;53(20):2523] Robertson KE, et al. **Am J Health Syst Pharm** 1996 Sep 15;53(18):2159–70; quiz 2215–6 (127 ref.)

Ischemic heart disease in chronic uremia. Parfrey PS, et al. **Blood Purif** 1996;14(4):321–6 (32 ref.)

How to achieve optimal correction of acidosis in end-stage renal failure patients. Zucchelli P, et al. **Blood Purif** 1995 Nov-Dec;13(6):375–84 (34 ref.)

Acidosis in uremic patients. Bommer J, et al.
Clin Nephrol 1996 Oct;46(4):280–5 (43 ref.)

Thoracic complications in uremic patients and in patients undergoing dialytic treatment: state of the art. Gavelli G, et al. **Eur Radiol** 1997;7(5):708–17 (76 ref.)

De novo diabetes in dialysis patients: when diabetes is not diabetic nephropathy [editorial] Catalano C.
Nephrol Dial Transplant 1996 Jun;11(6):938–41 (21 ref.)

A clinical approach to the uraemic patient with extraskeletal calcifications. Drüeke TB. **Nephrol Dial Transplant** 1996; 11 Suppl 3:37–42 (52 ref.)

Percutaneous coronary angioplasty (PTCA) or coronary artery bypass grafting (CABG)--which is the appropriate therapy of coronary artery disease in uraemic patients? [editorial] Ivens K, et al. **Nephrol Dial Transplant** 1996 Oct; 11(10):1949–51 (23 ref.)

Bleeding and thrombosis in chronic uremia [editorial] Sagripanti A, et al. **Nephron** 1997;75(2):125–39 (172 ref.)

The search for the uremic toxin: the case for metabolic acidosis [see comments] Bailey JL, et al.
Wien Klin Wochenschr 1997 Jan 17;109(1):7–12 (50 ref.)
Comment in: Wien Klin Wochenschr 1997 Jan 17;109(1):1–2.

[Uremic myopathy] Arimura Y, et al.
Ryoikibetsu Shokogun Shirizu 1997;(16 Pt 1):72–5 (15 ref.) **(Jpn)**

[Uremic pleuritis] Gonda H, et al.
Ryoikibetsu Shokogun Shirizu 1997;(16 Pt 1):48–50 (17 ref.) **(Jpn)**

[Gastrointestinal complications of uremic syndrome] Hirakawa M, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):51–5 (24 ref.) **(Jpn)**

[Uremic lung] Joko T, et al.
Ryoikibetsu Shokogun Shirizu 1997;(16 Pt 1):69–71 (16 ref.) **(Jpn)**

[Uremic dyslipoproteinemia] Kimura H, et al.
Ryoikibetsu Shokogun Shirizu 1997;(16 Pt 1):76–9 (18 ref.) **(Jpn)**

[Uremic neuropathy] Maeda K.
Ryoikibetsu Shokogun Shirizu 1997;(16 Pt 1):63–5 (20 ref.) **(Jpn)**

[Uremic encephalopathy, uremic coma] Maeda K.
Ryoikibetsu Shokogun Shirizu 1997;(16 Pt 1):66–8 (13 ref.) **(Jpn)**

[Uremic cardiomyopathy] Tsuzuki K.
Ryoikibetsu Shokogun Shirizu 1997;(16 Pt 1):56–9 (6 ref.) **(Jpn)**

[Uremic pericarditis] Tsuzuki K, et al.
Ryoikibetsu Shokogun Shirizu 1997;(16 Pt 1):60–2 (3 ref.) **(Jpn)**

EPIDEMIOLOGY

Cardiac disease in chronic uremia: epidemiology. Bloembergen WE. **Adv Ren Replace Ther** 1997 Jul; 4(3):185–93 (30 ref.)

ETIOLOGY

How important is vitamin D deficiency in uraemia? [editorial] Cunningham J, et al. **Nephrol Dial Transplant** 1997 Jan; 12(1):16–8 (19 ref.)

The Maillard reaction--from food chemistry to uraemia research [editorial] Henle T, et al.
Nephrol Dial Transplant 1996 Sep;11(9):1718–22 (22 ref.)

A case of reflex anuria and uremia related to a unilateral ureteral stone. Hayashi K, et al.
Nippon Jinzo Gakkai Shi 1996 Oct;38(10):460–2 (5 ref.)

[Uremic syndrome] Shirasaki A, et al.
Ryoikibetsu Shokogun Shirizu 1997;(16 Pt 1):38–41 (6 ref.) **(Jpn)**

IMMUNOLOGY

New molecular aspects of chronic uraemia and dialysis-related immunocompetent cell activation. Descamps-Latscha B, et al. **Nephrol Dial Transplant** 1996; 11 Suppl 2:121–4 (23 ref.)

Are granulocyte inhibitory proteins contributing to enhanced susceptibility to infections in uraemia? Haag-Weber M, et al. **Nephrol Dial Transplant** 1996;11 Suppl 2:98–100 (20 ref.)

METABOLISM

Uremic toxins. Vanholder R. **Adv Nephrol Necker Hosp** 1997; 26:143–63 (124 ref.)

Peripheral metabolism of parathyroid hormone. Studies with isolated perfused kidneys and livers from normal and uremic rats. Daugaard H. **Dan Med Bull** 1996 Jun; 43(3):203–15 (143 ref.)

Sodium and water profiling in chronic uraemia. Churchill DN. **Nephrol Dial Transplant** 1996;11 Suppl 8:38–41 (15 ref.)

Abnormalities of the vitamin D receptor in uraemia. Kumar R. **Nephrol Dial Transplant** 1996;11 Suppl 3:6–10 (77 ref.)

PHYSIOPATHOLOGY

Cardiac disease in chronic uremia: pathophysiology. Amann K, et al. **Adv Ren Replace Ther** 1997 Jul;4(3):212–24 (125 ref.)

Cardiac disease in chronic uremia: pathogenesis. London GM, et al. **Adv Ren Replace Ther** 1997 Jul;4(3):194–211 (140 ref.)

Cardiac structure and function in renal disease. Amann K, et al. **Curr Opin Nephrol Hypertens** 1996 Jan;5(1):102–6 (62 ref.)

The parathyroid-bone axis in uremia: new insights into old questions. Hory B, et al. **Curr Opin Nephrol Hypertens** 1997 Jan;6(1):40–8 (94 ref.)

Effect of phosphate on the parathyroid gland: direct and indirect? Rodriguez M, et al.
Curr Opin Nephrol Hypertens 1996 Jul;5(4):321–8 (44 ref.)

Uremic pruritus [editorial] Hiroshige K, et al.
Int J Artif Organs 1996 May;19(5):265–7 (13 ref.)

Endocrine disturbances of calcium metabolism in uremia: renal causes and systemic consequences. Ritz E, et al.
Kidney Int 1996 Jun;49(6):1765–8 (39 ref.)

Growth hormone and insulin-like growth factor in non-uremic acidosis and uremic acidosis. Kuemmerle N, et al. **Kidney Int Suppl** 1997 Mar;58:S102–5 (39 ref.)

Parathyroid pathophysiology in uraemia. Cunningham J.
Nephrol Dial Transplant 1996;11 Suppl 3:106–10 (46 ref.)

New insights into mechanisms of blood pressure regulation in patients with uraemia. Ritz E, et al.
Nephrol Dial Transplant 1996;11 Suppl 2:52–9 (66 ref.)

Physical working capacity in uremic patients. Clyne N.
Scand J Urol Nephrol 1996 Aug;30(4):247–52 (31 ref.)

[Uremia: pathophysiologic sequelae and indications for kidney replacement therapy] Jakob SM, et al.
Schweiz Med Wochenschr 1997 Jun 21;127(25):1077–81 (20 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Long-term therapy for uremic bleeding [editorial] [see comments] Sloand JA. **Int J Artif Organs** 1996 Aug; 19(8):439–40 (15 ref.) Comment in: Int J Artif Organs 1997 Mar;20(3):184–5.

Limitations of peritoneal dialysis. Ronco C.
Kidney Int Suppl 1996 Nov;56:S69–74 (25 ref.)

De novo diabetes in dialysis patients: when diabetes is not diabetic nephropathy [editorial] Catalano C.
Nephrol Dial Transplant 1996 Jun;11(6):938–41 (21 ref.)

Sodium and water profiling in chronic uraemia. Churchill DN. **Nephrol Dial Transplant** 1996;11 Suppl 8:38–41 (15 ref.)

N-acetylglucosamine: a new osmotic solute in peritoneal dialysis solutions. Breborowicz A, et al. **Perit Dial Int** 1997; 17 Suppl 2:S80–3 (20 ref.)

Bicarbonate-buffered CAPD solutions: from clinical trials to clinical practice. Feriani M. **Perit Dial Int** 1997;17 Suppl 2:S51–5 (30 ref.)

Integration of peritoneal dialysis in active uremia treatment. Ronco C, et al. **Perit Dial Int** 1997;17 Suppl 2:S155–60 (9 ref.)

[Indications for and problems in active therapy of uremic patients (editorial)] Forsström J. **Duodecim** 1995; 111(15):1395–8 (8 ref.) **(Fin)**

VETERINARY

Managing gastrointestinal complications of uremia. Krawiec DR. **Vet Clin North Am Small Anim Pract** 1996 Nov; 26(6):1287–92 (11 ref.)

Management of postrenal azotemia. Polzin DJ, et al.
Vet Clin North Am Small Anim Pract 1996 May; 26(3):507–13 (4 ref.)

URETER

see related
URETEROSCOPY
URINARY DIVERSION

[Complications of double J ureteral stents] el Khader K.
J Urol (Paris) 1996;102(4):173–5 (25 ref.) (Eng. Abstr.) **(Fre)**

ABNORMALITIES

Pediatric gynecology urologic problems. Starr NT.
Clin Obstet Gynecol 1997 Mar;40(1):181–99 (55 ref.)

Giant hydronephrosis of bilateral duplex systems associated with ureteral ectopia: a case report. Tsuboniwa N, et al.
Hinyokika Kiyo 1996 Aug;42(8):587–90 (8 ref.)

Unilateral pulmonary hypoplasia with bifid ureter and pelvis. Prasad R, et al. **Indian J Chest Dis Allied Sci** 1996 Jul–Sep; 38(3):205–9 (9 ref.)

Congenital ectopic vas deferens inserting into the bladder with ipsilateral renal agenesis. Delakas D, et al.
Int Urol Nephrol 1996;28(5):701–7 (13 ref.)

Laparascopic excision of pelvic kidney with single vaginal ectopic ureter. Moores D, et al. **J Pediatr Surg** 1997 Apr; 32(4):634–5 (12 ref.)

Left retrocaval ureter associated with the Goldenhar syndrome (branchial arch syndrome). Ishitoya S, et al.
J Urol 1997 Aug;158(2):572–3 (5 ref.)

Management of ectopic ureters: experience with the upper tract approach. Plaire JC, et al. **J Urol** 1997 Sep;158(3 Pt 2):1245–7 (11 ref.)

Synchronous bilateral carcinoma of the ureter in association with unilateral incomplete duplication of the ureter. Tan LB, et al. **Urol Int** 1996;56(3):196–9 (22 ref.)

Type II ureteral triplication associated with ectopic ureter. Engelstein D, et al. **Urology** 1996 Nov;48(5):786–8 (9 ref.)

Ureteral duplication with lower pole ectopia to the vas: a case report of an exception to the Weigert-Meyer law. Slaughenhoupt BL, et al. **Urology** 1997 Feb;49(2):269–71 (3 ref.)

[Ureteral triplication and contralateral ureteral duplication. Apropos of a case] Cherasse A, et al. **Acta Urol Belg** 1997 Mar;65(1):35–41 (9 ref.) (Eng. Abstr.) **(Fre)**

[Renal angiolipoma associated with bilateral double ureter. A clinical case] Verna C, et al. **Minerva Urol Nefrol** 1997 Mar;49(1):39–44 (28 ref.) (Eng. Abstr.) **(Ita)**

[Diagnostic imaging of ectopic ureter. Report of 2 cases] Assante M, et al. **Radiol Med (Torino)** 1996 Dec;92(6):810–2 (13 ref.) **(Ita)**

[Ectopic ureter opening in the vestibulum without urinary incontinence: a case report] Matsumoto S, et al.
Hinyokika Kiyo 1996 Dec;42(12):965–8 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Retrocaval ureter: report of a case] Cabello Padial J, et al.
Arch Esp Urol 1996 Jul–Aug;49(6):642–4 (11 ref.) (Eng. Abstr.) **(Spa)**

INJURIES

Endoscopical management of ureteral trauma. Billiet I.
Acta Urol Belg 1997 Jun;65(2):35–41 (42 ref.)

Ureteric injury at Burch colposuspension. 4 case reports and literature review. Rosen DM, et al.
Aust N Z J Obstet Gynaecol 1996 Aug;36(3):354–8 (15 ref.)

Ureteral injuries during gynecologic procedures. Mariotti G, et al. **Minerva Urol Nefrol** 1997 Jun;49(2):95–8 (23 ref.)

SURGERY

Management of ectopic ureters: experience with the upper tract approach. Plaire JC, et al. **J Urol** 1997 Sep;158(3 Pt 2):1245–7 (11 ref.)

Acute glomerulonephritis with zoster [letter] Rossetti A, et al. **Pediatr Infect Dis J** 1996 Jul;15(7):643–4 (4 ref.)

Management of complete ureteral replacement. Experiences and review of the literature. Schoeneich G, et al.
Scand J Urol Nephrol 1997 Aug;31(4):383–8 (29 ref.)

URETERAL CALCULI

COMPLICATIONS

A case of reflex anuria and uremia related to a unilateral ureteral stone. Hayashi K, et al.
Nippon Jinzo Gakkai Shi 1996 Oct;38(10):460–2 (5 ref.)

DIAGNOSIS

Patient evaluation. Laboratory and imaging studies. Begun FP, et al. **Urol Clin North Am** 1997 Feb;24(1):97–116 (41 ref.)

ETIOLOGY

[Complications of double J ureteral stents] el Khader K.
J Urol (Paris) 1996;102(4):173–5 (25 ref.) (Eng. Abstr.) **(Fre)**

[Urinary lithiasis in transplanted kidney] Lancina Martín JA, et al. **Arch Esp Urol** 1997 Mar;50(2):141–50 (60 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Conservative management of ureteric stones. Simon J, et al.
Acta Urol Belg 1997 Jun;65(2):7–9 (6 ref.)

Treatment options for distal ureteral stones. Boulier JA, et al. **Arch Esp Urol** 1997 Mar;50(2):208–13 (37 ref.)

Contemporary management of ureteral stones. Singal RK, et al. **Urol Clin North Am** 1997 Feb;24(1):59–70 (78 ref.)

[Ureteroscopic lithotripsy using the laser] Usaï E, et al.
Ann Urol (Paris) 1997;31(1):49–53 (21 ref.) (Eng. Abstr.)

URETERAL CALCULI

(Fre)

[Ureteroscopy versus in situ extracorporeal shockwave lithotripsy in the treatment of calculi of the distal ureter] Leblanc B, et al. **Prog Urol** 1996 Aug-Sep;6(4):535-8 (22 ref.) (Eng. Abstr.) **(Fre)**

[Extracorporeal shockwave lithotripsy today--an assessment of current status] Chaussy C, et al. **Urologe A** 1997 May; 36(3):194-9 (82 ref.) (Eng. Abstr.) **(Ger)**

[Extracorporeal shockwave lithotripsy in childhood] Schultz-Lampel D, et al. **Urologe A** 1997 May;36(3):200-8 (81 ref.) (Eng. Abstr.) **(Ger)**

URETERAL DISEASES

COMPLICATIONS

[Transitional carcinoma of the ureter and urinary tuberculosis] Cardini S, et al. **Minerva Urol Nefrol** 1997 Mar;49(1):33-7 (24 ref.) (Eng. Abstr.) **(Ita)**

CONGENITAL

[Congenital diverticula of the ureter] Machmouchi M, et al. **J Med Liban** 1996;44(4):227-9 (8 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Inflammatory disease of the ureter. Wasserman NF. **Radiol Clin North Am** 1996 Nov;34(6):1131-56 (63 ref.)

[Idiopathic retroperitoneal fibrosis simulating pelvic tumor with distal ureter infiltration. Report of a case] Luján Galán M, et al. **Arch Esp Urol** 1997 Apr;50(3):299-302 (10 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

[A case of ureteral malacoplakia in a hemodialysis patient] Suzuki N, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Aug; 87(8):1056-9 (6 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Diagnosis and management of ureteroiliac artery fistula: value of provocative arteriography followed by common iliac artery embolization and extraanatomic arterial bypass grafting. Vandersteen DR, et al. **J Urol** 1997 Sep;158(3 Pt 1):754-8 (31 ref.)

SURGERY

Autologous vein-covered stent for the endovascular management of an iliac artery-ureteral fistula: case report and review of the literature. Kerns DB, et al. **J Vasc Surg** 1996 Oct;24(4):680-6 (46 ref.)

Management of complete ureteral replacement. Experiences and review of the literature. Schoeneich G, et al. **Scand J Urol Nephrol** 1997 Aug;31(4):383-8 (29 ref.)

[A case of uretero-aortic fistula] Awakura Y, et al. **Hinyokika Kiyo** 1997 Apr;43(4):299-301 (14 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Diagnosis and management of ureteroiliac artery fistula: value of provocative arteriography followed by common iliac artery embolization and extraanatomic arterial bypass grafting. Vandersteen DR, et al. **J Urol** 1997 Sep;158(3 Pt 1):754-8 (31 ref.)

Update on interventional uroradiology. Dyer RB, et al. **Urol Clin North Am** 1997 Aug;24(3):623-52 (128 ref.)

URETERAL NEOPLASMS

Extra-adrenal pheochromocytoma. Atiyeh BA, et al. **J Nephrol** 1997 Jan-Feb;10(1):25-9 (32 ref.)

COMPLICATIONS

Synchronous bilateral carcinoma of the ureter in association with unilateral incomplete duplication of the ureter. Tan LB, et al. **Urol Int** 1996;56(3):196-9 (22 ref.)

[Transitional carcinoma of the ureter and urinary tuberculosis] Cardini S, et al. **Minerva Urol Nefrol** 1997 Mar;49(1):33-7 (24 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Endoscopic brush cytology of the upper urinary tract. Evaluation of its efficacy and potential limitations in diagnosis. Dodd LG, et al. **Acta Cytol** 1997 Mar-Apr; 41(2):377-84 (45 ref.)

[A fibroepithelial polyp of the ureter. A report of 2 new cases] Tato Rodriguez J, et al. **Actas Urol Esp** 1997 Apr; 21(4):420-5 (23 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

A review of clinical studies of bropirimine immunotherapy of carcinoma in situ of the bladder and upper urinary tract. Sarosdy MF. **Eur Urol** 1997;31 Suppl 1:20-6 (36 ref.)

ETIOLOGY

Transitional cell carcinoma of the ureteral stump 13 years after nephrectomy for benign disease. Manganelli A, et al. **Urol Int** 1996;56(1):52-4 (17 ref.)

RADIOTHERAPY

[Value of postoperative radiotherapy in malignant tumors of the upper urinary tract. Apropos of a series of 26 patients] Maulard-Durdux C, et al. **Bull Cancer** 1996 Nov; 83(11):940-4 (23 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

Metastatic breast carcinoma presenting as urinoma. Zunarelli E, et al. **Pathologica** 1995 Dec;87(6):712-4 (8 ref.)

[Multiple metastases of malignant cutaneous melanoma into the upper urinary tract] Török P, et al. **Orv Hetil** 1997 Feb 2;138(5):285-7 (13 ref.) (Eng. Abstr.) **(Hun)**

VETERINARY

Tumours of the urinary bladder, renal pelvis, ureter and urethra. Fukushima S, et al. **IARC Sci Publ** 1996; (126):243-59 (39 ref.)

URETERAL OBSTRUCTION

CHEMICALLY INDUCED

Bilateral ureteric obstruction secondary to the prolonged use of tiaprofenic acid. Crew JP, et al. **Br J Clin Pract** 1997 Jan-Feb;51(1):59-60 (9 ref.)

COMPLICATIONS

[Tubulointerstitial kidney diseases in urinary tract infection, reflux and obstruction] Krautzig S, et al. **Internist (Berl)** 1996 Nov;37(11):1096-110 (61 ref.) **(Ger)**

CONGENITAL

Growth factors and apoptosis in neonatal ureteral obstruction. Chevalier RL. **J Am Soc Nephrol** 1996 Aug; 7(8):1098-105 (54 ref.)

DIAGNOSIS

Urinary tract obstruction during pregnancy: recent developments in imaging. Murthy LN. **Br J Urol** 1997 Jul; 80 Suppl 1:1-3 (25 ref.)

Resistive index in obstructive uropathy. Shokeir AA, et al. **Br J Urol** 1997 Aug;80(2):195-200 (35 ref.)

Imaging for ureteropelvic junction obstruction in adults. Wolf JS Jr, et al. **J Endourol** 1996 Apr;10(2):93-104 (88 ref.)

ETIOLOGY

Primary localised amyloidosis of the ureter. Van Cleynenbreugel B, et al. **Acta Urol Belg** 1996 Sep;64(3):43-5 (13 ref.)

Influence of urological complications on the prognosis of prostate cancer. Colombel M, et al. **Eur Urol** 1997;31 Suppl 3:21-4 (12 ref.)

Metastatic breast carcinoma presenting as urinoma. Zunarelli E, et al. **Pathologica** 1995 Dec;87(6):712-4 (8 ref.)

[An unusual complication of anterograde endopyelotomy: ureteral intussusception (a case report)] el Khader K, et al. **Prog Urol** 1997 Apr;7(2):273-6 (14 ref.) (Eng. Abstr.) **(Fre)**

[Urological emergency for cancer patients] Ozono S, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(3):292-6 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Surgical treatment of obstructive disease of the transplanted kidney] Montañés Medina P, et al. **Arch Esp Urol** 1996 Dec;49(10):1071-8 (28 ref.) (Eng. Abstr.) **(Spa)**

[Ureteral stenosis secondary to Churg-Strauss allergic granulomatous vasculitis] Tremps Velázquez E, et al. **Arch Esp Urol** 1997 Jan-Feb;50(1):82-4 (8 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

A new case of oculocerebral hypopigmentation syndrome (Cross syndrome) with additional findings. Tezcan I, et al. **Clin Genet** 1997 Feb;51(2):118-21 (13 ref.)

PHYSIOPATHOLOGY

Physiology and evaluation of ureteropelvic junction obstruction. Anderson KR, et al. **J Endourol** 1996 Apr; 10(2):87-91 (40 ref.)

RADIOGRAPHY

Proximal ureter obstruction caused by a lower polar renal artery: demonstration with spiral CT angiography. Lee JY, et al. **J Comput Assist Tomogr** 1997 Jul-Aug;21(4):641-2 (7 ref.)

SURGERY

The management of patients with advanced cancer (II). Heys SD, et al. **Eur J Surg Oncol** 1997 Jun;23(3):257-63 (69 ref.)

Complications of endopyelotomy. Bellman GC. **J Endourol** 1996 Apr;10(2):177-81 (18 ref.)

Crossing vessels at the ureteropelvic junction: do they influence endopyelotomy outcome? Gupta M, et al. **J Endourol** 1996 Apr;10(2):183-7 (39 ref.)

Acucise endopyelotomy: evolution of a less-invasive technology. Nakada SY, et al. **J Endourol** 1996 Apr; 10(2):133-9 (30 ref.)

Prenatal intervention for hydronephrosis. Coplen DE. **J Urol** 1997 Jun;157(6):2270-7 (63 ref.)

Endoscopic management of ureteral strictures [see comments] Goldfischer ER, et al. **J Urol** 1997 Mar;157(3):770-5 (84 ref.) Comment in: J Urol 1997 Mar;157(3):817.

[Surgical treatment of iatrogenic stenoses of the ureter. Apropos of 17 cases] Koutani A, et al. **J Urol (Paris)** 1996; 102(4):145-9 (41 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Treatment options for pelvi-ureteric junction obstruction: implications for practice and training. Eden CG. **Br J Urol** 1997 Sep;80(3):365-72 (71 ref.)

Integrating medical and surgical treatments in gastrointestinal, genitourinary, and biliary obstruction in patients with cancer. Fainsinger RL. **Hematol Oncol Clin North Am** 1996 Feb;10(1):173-88 (115 ref.)

Vesicoureteral reflux and ureteropelvic junction obstruction: association, treatment options and outcome. Bomalaski MD, et al. **J Urol** 1997 Mar;157(3):969-74 (21 ref.)

Long-term results of endoureterotomy for benign ureteral and ureteroenteric strictures. Wolf JS Jr, et al. **J Urol** 1997 Sep;158(3 Pt 1):759-64 (28 ref.)

ULTRASONOGRAPHY

Prenatal intervention for hydronephrosis. Coplen DE. **J Urol** 1997 Jun;157(6):2270-7 (63 ref.)

Duplex Doppler evaluation of acute renal obstruction. Platt JF. **Semin Ultrasound CT MR** 1997 Apr;18(2):147-53 (36 ref.)

Acute urinary tract obstruction. Imaging update. Koelliker SL, et al. **Urol Clin North Am** 1997 Aug;24(3):571-82 (28 ref.)

URETEROCELE

ULTRASONOGRAPHY

Prenatally diagnosed ureterocele presenting as fetal bladder outlet obstruction. Gloor JM, et al. **J Perinatol** 1996 Jul-Aug;16(4):285-7 (18 ref.)

URETEROLITHIASIS see **URETERAL CALCULI**

URETEROSCOPY

Long-term outcome of flexible ureterorenoscopy in the diagnosis and treatment of lateralizing essential hematuria. Nakada SY, et al. **J Urol** 1997 Mar;157(3):776-9 (10 ref.)

Long-term results of endoureterotomy for benign ureteral and ureteroenteric strictures. Wolf JS Jr, et al. **J Urol** 1997 Sep;158(3 Pt 1):759-64 (28 ref.)

[Ureteroscopic lithotripsy using the laser] Usaï E, et al. **Ann Urol (Paris)** 1997;31(1):49-53 (21 ref.) (Eng. Abstr.) **(Fre)**

[Ureteroscopy versus in situ extracorporeal shockwave lithotripsy in the treatment of calculi of the distal ureter] Leblanc B, et al. **Prog Urol** 1996 Aug-Sep;6(4):535-8 (22 ref.) (Eng. Abstr.) **(Fre)**

HISTORY

Ureteroscopy. Development and instrumentation. Conlin MJ, et al. **Urol Clin North Am** 1997 Feb;24(1):25-42 (44 ref.)

INSTRUMENTATION

Ureteroscopy. Development and instrumentation. Conlin MJ, et al. **Urol Clin North Am** 1997 Feb;24(1):25-42 (44 ref.)

METHODS

Endoscopic brush cytology of the upper urinary tract. Evaluation of its efficacy and potential limitations in diagnosis. Dodd LG, et al. **Acta Cytol** 1997 Mar-Apr; 41(2):377-84 (45 ref.)

[Endoscopic techniques in the treatment of calculi in the upper urinary tract] Hem E. **Tidsskr Nor Laegeforen** 1996 Oct 10;116(24):2893-6 (28 ref.) (Eng. Abstr.) **(Nor)**

URETHANE

see related
POLYURETHANES

URETHRA

ABNORMALITIES

Megalourethra: a report of four cases and review of the literature. Sharma AK, et al. **Pediatr Surg Int** 1997 Jul; 12(5-6):458-60 (29 ref.)

Distal urethral duplication--a case report and literature review. Singh G, et al. **Scand J Urol Nephrol** 1996 Apr; 30(2):149-51 (5 ref.)

[Posterior urethral valve, from the prenatal period to adulthood [editorial]] Cochat P, et al. **Arch Pediatr** 1996 Nov;3(11):1059-63 (39 ref.) **(Fre)**

[Posterior urethral valve: determining factors of long-term results] Mouriquand PD. **Arch Pediatr** 1997;4 Suppl 1:31s-36s (44 ref.) (Eng. Abstr.) **(Fre)**

ANATOMY & HISTOLOGY

Reliability and validity of stationary cystometry, stationary cysto-urethrometry and ambulatory cysto-urethro-vaginometry. Kulseng-Hanssen S. **Acta Obstet Gynecol Scand Suppl** 1997;166:33-8 (36 ref.)

INJURIES

Urethral injuries revisited. Boon TA, et al. **Injury** 1996 Oct; 27(8):533-8 (46 ref.)

Endoscopic management of traumatic posterior urethral stricture: early results and followup [see comments] Goel MC, et al. **J Urol** 1997 Jan;157(1):95-7 (23 ref.) Comment in: J Urol 1997 Jan;157(1):102.

Blunt urethral trauma: a unified, anatomical mechanical classification. Goldman SM, et al. **J Urol** 1997 Jan; 157(1):85-9 (19 ref.)

Pelvic fracture urethral injuries: evaluation of various methods of management [see comments] Koraitim MM. **J Urol** 1996 Oct;156(4):1288-91 (27 ref.) Comment in: J Urol 1997 Aug;158(2):550.

Management of pelvic fractures with concomitant urologic injuries. Taffet R. **Orthop Clin North Am** 1997 Jul; 28(3):389-96 (47 ref.)

Use and misuse of indwelling urethral catheters. Lees GF. **Vet Clin North Am Small Anim Pract** 1996 May; 26(3):499-505 (6 ref.)

[Therapeutic strategy apropos of 122 cases of early disclosed traumatic rupture of the urethra] Le Guillou M, et al. **Chirurgie** 1996;121(5):367-71 (10 ref.) (Eng. Abstr.) **(Fre)**

[Transvaginal closure of the bladder neck in women with a neurogenic bladder and destroyed urethra] Chassagne S, et al. **Prog Urol** 1997 Apr;7(2):286-92 (8 ref.) (Eng. Abstr.) **(Fre)**

[Surgical treatment of fracture of the corpus cavernosum and the urethra: review of the literature and report of 2 cases] Rubio Briones J, et al. **Arch Esp Urol** 1996 Jun; 49(5):499-506 (26 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Urethral pressure measurement. Lose G. **Acta Obstet Gynecol Scand Suppl** 1997;166:39-42 (31 ref.)

Urethral function. Griffiths DJ, et al. **Curr Opin Obstet Gynecol** 1996 Oct;8(5):372-5 (25 ref.)

The physiological mechanisms involved in bladder emptying. Morrison JF. **Scand J Urol Nephrol Suppl** 1997;184:15-8 (15 ref.)

Change in length of the detrusor muscle cells. Tammela T. **Scand J Urol Nephrol Suppl** 1997;184:19-24 (22 ref.)

PHYSIOPATHOLOGY

[Fluctuations in the maximal intraurethral pressure and urination disorders in women] Loran OB, et al. **Urol Nefrol (Mosk)** 1997 May-Jun;(3):44-8 (96 ref.) **(Rus)**

RADIOGRAPHY

Voiding cystourethrography after uncomplicated ureteral reimplantation in children: is it necessary? Bisignani G, et al. **J Urol** 1997 Sep;158(3 Pt 2):1229-31 (26 ref.)

SURGERY

Voiding cystourethrography after uncomplicated ureteral reimplantation in children: is it necessary? Bisignani G, et al. **J Urol** 1997 Sep;158(3 Pt 2):1229-31 (26 ref.)

Endoscopic management of traumatic posterior urethral stricture: early results and followup [see comments] Goel MC, et al. **J Urol** 1997 Jan;157(1):95-7 (23 ref.) Comment in: J Urol 1997 Jan;157(1):102.

Pelvic fracture urethral injuries: evaluation of various methods of management [see comments] Koraitim MM. **J Urol** 1996 Oct;156(4):1288-91 (27 ref.) Comment in: J Urol 1997 Aug;158(2):550.

Nephrogenic adenoma after urethral reconstruction using bladder mucosa: report of 6 cases and review of the literature. Weingärtner K, et al. **J Urol** 1997 Sep;158(3 Pt 2):1175-7 (20 ref.)

Comparison of the modified vest and the direct anastomosis for radical retropubic prostatectomy. Novicki DE, et al. **Urology** 1997 May;49(5):732-6 (9 ref.)

Feline perineal urethrostomy: a potential cause of feline lower urinary tract disease. Osborne CA, et al. **Vet Clin North Am Small Anim Pract** 1996 May; 26(3):535-49 (23 ref.)

Update of urethra-sparing approaches in cystectomy in women. Stenzl A, et al. **World J Urol** 1997;15(2):134-8 (16 ref.)

[Surgical treatment of fracture of the corpus cavernosum and the urethra: review of the literature and report of 2 cases] Rubio Briones J, et al. **Arch Esp Urol** 1996 Jun; 49(5):499-506 (26 ref.) (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Ultrasound evaluation of the male urethra for assessment of urethral stricture. Morey AF, et al. **J Clin Ultrasound** 1996 Oct;24(8):473-9 (6 ref.)

URETHRAL DISEASES

COMPLICATIONS

Urethral mucosa prolapse in young girls. Kisanga RE, et al. **Cent Afr J Med** 1996 Jan;42(1):31-3 (09 ref.)

CONGENITAL

Congenital posterior urethral diverticulum. Ng WT. **Aust N Z J Surg** 1996 Oct;66(10):717-9 (15 ref.)

DIAGNOSIS

Urethral prolapse in a premenarchal girl: case report and literature review. Desai SR, et al. **Aust N Z J Surg** 1997 Sep;67(9):660-2 (7 ref.)

[Skene's cyst in pregnancy. A clinical case] Ingrassia I, et al. **Minerva Ginecol** 1997 May;49(5):225-8 (13 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Pseudoneoplastic lesions of the urinary bladder and urethra: a selective review with emphasis on recent information. Young RH. **Semin Diagn Pathol** 1997 May;14(2):133-46 (83 ref.)

[Mesonephric adenocarcinoma arising in the female urethral diverticulum] Okubo Y, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Sep;87(9):1138-41 (11 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

Female urethral diverticula: a report of 5 cases. Pauwels M, et al. **Acta Urol Belg** 1996 Sep;64(3):27-31 (15 ref.)

Urethral prolapse in a premenarchal girl: case report and literature review. Desai SR, et al. **Aust N Z J Surg** 1997 Sep;67(9):660-2 (7 ref.)

[Diagnostic and therapeutic aspects of suburethral diverticuli. Apropos of 9 cases and review of the literature] el Khader K, et al. **J Urol (Paris)** 1996;102(3):107-10 (29 ref.) (Eng. Abstr.) **(Fre)**

[The endoscopic treatment of urethral strictures and stones by using the Ho:YAG laser] Dondukov TsV, et al. **Urol Nefrol (Mosk)** 1997 Jan-Feb;(1):44-8 (109 ref.) **(Rus)**

ULTRASONOGRAPHY

[Diagnosis of the female urethra and examination technique with Doppler balloon urethrography] Madeja C, et al. **Rontgenpraxis** 1997 Mar;50(3):51-4 (7 ref.) **(Ger)**

URETHRAL NEOPLASMS

Urethral hemangioma: case report. Hayashi T, et al. **J Urol** 1997 Aug;158(2):539-40 (3 ref.)

DIAGNOSIS

Leiomyoma of the female urethra and bladder: report of twenty-three patients and review of the literature. Cornella JL, et al. **Am J Obstet Gynecol** 1997 Jun;176(6):1278-85 (24 ref.)

A case of primary urethral lymphoma presenting as a huge mass surrounding the female urethra. Shimizu Y, et al. **Hinyokika Kiyo** 1997 Mar;43(3):229-32 (18 ref.)

EPIDEMIOLOGY

Risk of urethral, vaginal and cervical involvement in patients undergoing radical cystectomy for bladder cancer: results of a contemporary cystectomy series from M. D. Anderson Cancer Center. Chen ME, et al. **J Urol** 1997 Jun; 157(6):2120-3 (13 ref.)

ETIOLOGY

Nephrogenic adenoma after urethral reconstruction using bladder mucosa: report of 6 cases and review of the literature. Weingärtner K, et al. **J Urol** 1997 Sep;158(3 Pt 2):1175-7 (20 ref.)

PATHOLOGY

Urethral carcinoma metastatic to bone: a case report and literature review. Mirzayan R, et al. **Gynecol Oncol** 1996 Oct;63(1):127-32 (29 ref.)

Primary carcinomas of the urethra. Amin MB, et al. **Semin Diagn Pathol** 1997 May;14(2):147-60 (55 ref.)

[Inverted papilloma of the posterior urethra: a case report] Nozawa M, et al. **Hinyokika Kiyo** 1996 Jul;42(7):533-5 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Mesonephric adenocarcinoma arising in the female urethral diverticulum] Okubo Y, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Sep;87(9):1138-41 (11 ref.) (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY

Brachytherapy for cancer of the female urethra. Micaily B, et al. **Semin Surg Oncol** 1997 May-Jun;13(3):208-14 (29 ref.)

[Argon laser treatment of urethral angioma. Report of the first case] Borrego Hernando J, et al. **Arch Esp Urol** 1996 Oct;49(8):859-61 (12 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

[Primary transitional cell carcinoma of the prostatic urethra: a case report] Hashimoto K, et al. **Hinyokika Kiyo** 1996 May;42(5):385-7 (9 ref.) (Eng. Abstr.) **(Jpn)**

VETERINARY

Tumours of the urinary bladder, renal pelvis, ureter and urethra. Fukushima S, et al. **IARC Sci Publ** 1996; (126):243-59 (39 ref.)

URETHRAL OBSTRUCTION

COMPLICATIONS

Systemic lupus erythematosus with obstructive uropathy. Case report and review. Kim HJ, et al. **J Korean Med Sci** 1995 Dec;10(6):462-9 (31 ref.)

[Posterior urethral valve: determining factors of long-term results] Mouriquand PD. **Arch Pediatr** 1997;4 Suppl 1:31s-36s (44 ref.) (Eng. Abstr.) **(Fre)**

CONGENITAL

Distal urethral duplication--a case report and literature review. Singh G, et al. **Scand J Urol Nephrol** 1996 Apr; 30(2):149-51 (5 ref.)

ETIOLOGY

Nephrogenic adenoma in children. Case report and review of literature. Schumacher K, et al. **Eur J Pediatr Surg** 1997 Apr;7(2):115-7 (24 ref.)

Influence of urological complications on the prognosis of prostate cancer. Colombel M, et al. **Eur Urol** 1997;31 Suppl 3:21-4 (12 ref.)

PATHOLOGY

Systemic lupus erythematosus with obstructive uropathy. Case report and review. Kim HJ, et al. **J Korean Med Sci** 1995 Dec;10(6):462-9 (31 ref.)

[Posterior urethral valve, from the prenatal period to adulthood [editorial]] Cochat P, et al. **Arch Pediatr** 1996 Nov;3(11):1059-63 (39 ref.) **(Fre)**

ULTRASONOGRAPHY

Duplex Doppler evaluation of acute renal obstruction. Platt JF. **Semin Ultrasound CT MR** 1997 Apr;18(2):147-53 (36 ref.)

VETERINARY

Medical management of feline urethral obstruction. Osborne CA, et al. **Vet Clin North Am Small Anim Pract** 1996 May; 26(3):483-98 (2 ref.)

URETHRAL STENOSIS see **URETHRAL STRICTURE**

URETHRAL STRICTURE

SURGERY

Endoscopic management of traumatic posterior urethral stricture: early results and followup [see comments] Goel MC, et al. **J Urol** 1997 Jan;157(1):95-7 (23 ref.) Comment in: J Urol 1997 Jan;157(1):102.

[The endoscopic treatment of urethral strictures and stones by using the Ho:YAG laser] Dondukov TsV, et al. **Urol Nefrol (Mosk)** 1997 Jan-Feb;(1):44-8 (109 ref.) **(Rus)**

ULTRASONOGRAPHY

Ultrasound evaluation of the male urethra for assessment of urethral stricture. Morey AF, et al. **J Clin Ultrasound** 1996 Oct;24(8):473-9 (6 ref.)

URETHRITIS

ETIOLOGY

Periurethral abscess: complication of UTI. Mylonakis E, et al. **Geriatrics** 1997 Aug;52(8):86-8 (18 ref.)

MICROBIOLOGY

Do men become infertile after having sexually transmitted urethritis? An epidemiologic examination. Ness RB, et al. **Fertil Steril** 1997 Aug;68(2):205-13 (73 ref.)

URIC ACID

BLOOD

An expanded view of SIADH, hyponatremia and hypouricemia [editorial] Maesaka JK. **Clin Nephrol** 1996 Aug;46(2):79-83 (26 ref.)

Gout and hyperuricemia. Simkin PA. **Curr Opin Rheumatol** 1997 May;9(3):268-73 (64 ref.)

[Uric acid and tubulointerstitial kidney diseases] Wrenger E, et al. **Internist (Berl)** 1996 Nov;37(11):1137-42 (51 ref.) **(Ger)**

[Uric acid and pre-eclampsia] Garrone C, et al. **Minerva Ginecol** 1997 May;49(5):213-6 (19 ref.) (Eng. Abstr.) **(Ita)**

URIC ACID

[Gout and hyperuricemia] Nakamura T. **Nippon Naika Gakkai Zasshi** 1996 Sep 10;85(9):1520–7 (28 ref.) **(Jpn)**

[PRPP synthetase superactivity] Fujimori S. **Nippon Rinsho** 1996 Dec;54(12):3309–14 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Pharmacological agents affecting uric acid metabolism] Higashino K, et al. **Nippon Rinsho** 1996 Dec;54(12):3364–8 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Hypertension and hyperuricemia] Hirai A, et al. **Nippon Rinsho** 1996 Dec;54(12):3283–8 (25 ref.) (Eng. Abstr.) **(Jpn)**

[Metabolic disorder of purine nucleotide in patients with renal disease] Hosoya T, et al. **Nippon Rinsho** 1996 Dec; 54(12):3354–9 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Hyperuricemia and the kidney] Ichida K, et al. **Nippon Rinsho** 1996 Dec;54(12):3277–82 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Inherited disorders of uric acid metabolism—classification, enzymatic- and DNA-diagnosis] Iwahana H, et al. **Nippon Rinsho** 1996 Dec;54(12):3303–8 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Hyperuricemia in hematological disorders] Iwata J. **Nippon Rinsho** 1996 Dec;54(12):3349–53 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Association of hyperuricemia with hyperlipidemia and obesity] Nakamura H. **Nippon Rinsho** 1996 Dec; 54(12):3289–92 (4 ref.) (Eng. Abstr.) **(Jpn)**

[Non-drug therapeutics of idiopathic hyperuricemia] Togashi R, et al. **Nippon Rinsho** 1996 Dec;54(12):3256–60 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Gout and atherosclerosis] Tsutsumi Z, et al. **Nippon Rinsho** 1996 Dec;54(12):3297–302 (37 ref.) (Eng. Abstr.) **(Jpn)**

[Hyperuricemia and insulin resistance] Wasada T, et al. **Nippon Rinsho** 1996 Dec;54(12):3293–6 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Alcohol ingestion and hyperuricemia] Yamanaka H. **Nippon Rinsho** 1996 Dec;54(12):3369–73 (9 ref.) (Eng. Abstr.) **(Jpn)**

[How to select and use urate lowering agents for hyperuricemia] Yamanaka H. **Nippon Rinsho** 1996 Dec; 54(12):3261–5 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Myogenic hyperuricemia] Yamasaki T, et al. **Nippon Rinsho** 1996 Dec;54(12):3343–8 (29 ref.) (Eng. Abstr.) **(Jpn)**

[Abnormal serum uric acid level in endocrine disorders] Yokogoshi Y, et al. **Nippon Rinsho** 1996 Dec;54(12):3360–3 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Hyperuricemia] Takeda M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):39–42 (24 ref.) **(Jpn)**

METABOLISM

Gouty arthritis and uric acid metabolism [see comments] Wise CM, et al. **Curr Opin Rheumatol** 1996 May;8(3):248–54 (54 ref.) Comment in: Curr Opin Rheumatol 1996 May;8(3):235–7.

Comparative aspects of renal urate transport. Dantzler WH. **Kidney Int** 1996 Jun;49(6):1549–51 (15 ref.)

The importance of uric acid examination. Sebesta I, et al. **Sb Lek** 1994;95(4):383–9 (26 ref.)

Uric acid stones. Asplin JR. **Semin Nephrol** 1996 Sep; 16(5):412–24 (86 ref.)

Uric acid-related nephrolithiasis. Low RK, et al. **Urol Clin North Am** 1997 Feb;24(1):135–48 (69 ref.)

[Abnormalities in urate metabolism: concept and classification] Akaoka I, et al. **Nippon Rinsho** 1996 Dec; 54(12):3243–7 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Uric acid clearance] Hidaka Y. **Nippon Rinsho** 1997 Mar;55 Suppl 1:287–90 (3 ref.) **(Jpn)**

[Dynamics of uric acid metabolism in hyperuricemia] Nakamura T, et al. **Nippon Rinsho** 1996 Dec;54(12):3230–6 (18 ref.) (Eng. Abstr.) **(Jpn)**

[The mechanisms of urate transport in the kidney and the intestine] Sekine T, et al. **Nippon Rinsho** 1996 Dec; 54(12):3237–42 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Metabolism of purine nucleotides and the production of uric acid] Yamaoka T, et al. **Nippon Rinsho** 1996 Dec; 54(12):3188–94 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Renal hypouricemia (idiopathic, secondary)] Tofuku Y. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):660–2 (16 ref.) **(Jpn)**

URINE

[Renal hypouricemia] Hisatome I, et al. **Nippon Rinsho** 1996 Dec;54(12):3337–42 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Hyperuricosuria and urolithiasis] Koide T. **Nippon Rinsho** 1996 Dec;54(12):3273–6 (4 ref.) (Eng. Abstr.) **(Jpn)**

URICOSURIC AGENTS

ADMINISTRATION & DOSAGE

[How to select and use urate lowering agents for hyperuricemia] Yamanaka H. **Nippon Rinsho** 1996 Dec; 54(12):3261–5 (12 ref.) (Eng. Abstr.) **(Jpn)**

URIDINE

ANALOGS & DERIVATIVES

[Antitumor effect and mechanism of a novel multifunctional nucleoside, 3'-ethynylnucleoside, on human cancers] Tanaka M, et al. **Gan To Kagaku Ryoho** 1997 Feb; 24(4):476–82 (8 ref.) (Eng. Abstr.) **(Jpn)**

URIDINE DIPHOSPHATE GLUCOSE EPIMERASE

METABOLISM

Nicotinoprotein alcohol/aldehyde oxidoreductases. Enzymes with bound NAD(P) as cofactor. Piersma SR, et al. **Adv Exp Med Biol** 1997;414:425–34 (29 ref.)

URIDINE MONOPHOSPHATE

ANALOGS & DERIVATIVES

[Proteins in bone morphogenesis (BMP)] Lacombe D. **Arch Pediatr** 1997;4(2 Suppl 2):121s–124s (26 ref.) **(Fre)**

METABOLISM

RNA editing: getting U into RNA. Kable ML, et al. **Trends Biochem Sci** 1997 May;22(5):162–6 (27 ref.)

URIDINE PHOSPHATES see **URACIL NUCLEOTIDES**

URIDINE TRIPHOSPHATE

METABOLISM

P2 purinoceptors and pyrimidinoceptors of catecholamine-producing cells and immunocytes. Illes P, et al. **Ciba Found Symp** 1996;198:110–25; discussion 125–9 (59 ref.)

URIDYLATE 5'-NUCLEOTIDASE see **5'-NUCLEOTIDASE**

URIDYLIC ACID see **URIDINE MONOPHOSPHATE**

URINALYSIS

Habitual, toxic, and lethal concentrations of 103 drugs of abuse in humans. Repetto MR, et al. **J Toxicol Clin Toxicol** 1997;35(1):1–9 (20 ref.)

METHODS

Measurements of leukotrienes in the urine: strategies and applications. Kumlin M. **Allergy** 1997 Feb;52(2):124–35 (100 ref.)

URINARY CALCULI

Idiopathic calcium oxalate urolithiasis and endogenous oxalate production. Baker PW, et al. **Crit Rev Clin Lab Sci** 1996 Jan;33(1):39–82 (250 ref.)

Urinary stone disease: a practical guide to metabolic evaluation. McDonald MW, et al. **Geriatrics** 1997 May; 52(5):38–40, 49–52, 55–6 (17 ref.)

Urinary calculi during pregnancy. When are they cause for concern? Houshiar AM, et al. **Postgrad Med** 1996 Oct; 100(4):131–8 (29 ref.)

Genetic hypercalciuric stone forming rats. Bushinsky DA. **Semin Nephrol** 1996 Sep;16(5):448–57 (41 ref.)

Pathogenesis and treatment of calcium stones. Parks JH, et al. **Semin Nephrol** 1996 Sep;16(5):398–411 (89 ref.)

Clinical approach to children with urolithiasis. Stapleton FB. **Semin Nephrol** 1996 Sep;16(5):389–97 (65 ref.)

[Urolithiasis in clinical practice. Occurrence, etiology, investigation and preventive treatment] Laerum E. **Tidsskr Nor Laegeforen** 1996 Oct 10;116(24):2897–902 (33 ref.) (Eng. Abstr.) **(Nor)**

CHEMISTRY

Uric acid stones. Asplin JR. **Semin Nephrol** 1996 Sep; 16(5):412–24 (86 ref.)

Mechanism of stone formation. Mandel N. **Semin Nephrol** 1996 Sep;16(5):364–74 (105 ref.)

Inhibitors of stone formation. Worcester EM. **Semin Nephrol** 1996 Sep;16(5):474–86 (74 ref.)

DIAGNOSIS

Suspected urolithiasis in pregnant women: imaging algorithm and literature review. Boridy IC, et al. **AJR Am J Roentgenol** 1996 Oct;167(4):869–75 (62 ref.)

Cystine calculi. Diagnosis and management. Rutchik SD, et al. **Urol Clin North Am** 1997 Feb;24(1):163–71 (79 ref.)

EPIDEMIOLOGY

Epidemiology of urolithiasis. Trinchieri A. **Arch Ital Urol Androl** 1996 Sep;68(4):203–49 (457 ref.)

Urolithiasis in the exstrophy-epispadias complex. Silver RI, et al. **J Urol** 1997 Sep;158(3 Pt 2):1322–6 (20 ref.)

Current aspects of epidemiology and nutrition in urinary stone disease. Hesse A, et al. **World J Urol** 1997; 15(3):165–71 (45 ref.)

Risk formulas in calcium oxalate urolithiasis. Tiselius HG. **World J Urol** 1997;15(3):176–85 (50 ref.)

ETIOLOGY

Mechanism of stone formation. Balaji KC, et al. **Urol Clin North Am** 1997 Feb;24(1):1–11 (56 ref.)

Current aspects of epidemiology and nutrition in urinary stone disease. Hesse A, et al. **World J Urol** 1997; 15(3):165–71 (45 ref.)

Intratubular crystallization events. Kok DJ. **World J Urol** 1997;15(4):219–28 (89 ref.)

[Hyperuricosuria and urolithiasis] Koide T. **Nippon Rinsho** 1996 Dec;54(12):3273–6 (4 ref.) (Eng. Abstr.) **(Jpn)**

[Hypercalciuria and its consequences] Konopielko Z. **Pediatr Pol** 1996 Aug;71(8):695–700 (29 ref.) (Eng. Abstr.) **(Pol)**

[Etiology and pathogenesis of urolithiasis] Kmiecik J, et al. **Przegl Lek** 1997;54(3):173–9 (65 ref.) (Eng. Abstr.) **(Pol)**

[Surgical treatment of obstructive disease of the transplanted kidney] Montañés Medina P, et al. **Arch Esp Urol** 1996 Dec;49(10):1071–8 (28 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Genes in idiopathic calcium oxalate stone disease. Goodman HO, et al. **World J Urol** 1997;15(3):186–94 (51 ref.)

MICROBIOLOGY

Struvite calculi. Cohen TD, et al. **Semin Nephrol** 1996 Sep; 16(5):425–34 (71 ref.)

PHYSIOPATHOLOGY

Intratubular crystallization events. Kok DJ. **World J Urol** 1997;15(4):219–28 (89 ref.)

PREVENTION & CONTROL

Inhibitors of stone formation. Worcester EM. **Semin Nephrol** 1996 Sep;16(5):474–86 (74 ref.)

[Cost-effectiveness analysis of preventive treatment of urinary lithiasis recurrence using potassium citrate] Gisbert Gelonch R, et al. **Arch Esp Urol** 1997 May;50(4):373–80 (14 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

[The endoscopic treatment of urethral strictures and stones by using the Ho:YAG laser] Dondukov TsV, et al. **Urol Nefrol (Mosk)** 1997 Jan-Feb;(1):44–8 (109 ref.) **(Rus)**

THERAPY

Extracorporeal shock wave lithotripsy. Zanetti G, et al. **Arch Ital Urol Androl** 1996 Sep;68(4):263–76 (113 ref.)

Contemporary clinical practice of shock wave lithotripsy: a reevaluation of contraindications. Streem SB. **J Urol** 1997 Apr;157(4):1197–203 (66 ref.)

Advances in lithotripsy and stone disease treatment [published errata appear in Radiol Technol 1996 Sep-Oct;68(1):17 and 1997 Mar-Apr;68(4):285] Newman J. **Radiol Technol** 1996 Jul-Aug;67(6):479–96; quiz 497–500 (44 ref.)

Struvite calculi. Cohen TD, et al. **Semin Nephrol** 1996 Sep; 16(5):425–34 (71 ref.)

Lithotripsy and surgery. Lingeman JE. **Semin Nephrol** 1996 Sep;16(5):487–98 (56 ref.)

Pediatric urolithiasis. Kroovand RL. **Urol Clin North Am** 1997 Feb;24(1):173–84 (63 ref.)

Cystine calculi. Diagnosis and management. Rutchik SD, et al. **Urol Clin North Am** 1997 Feb;24(1):163–71 (79 ref.)

Glycosaminoglycans and semisynthetic sulfated polysaccharides: an overview of their potential application in treatment of patients with urolithiasis. Cao LC, et al. **Urology** 1997 Aug;50(2):173–83 (111 ref.)

Treatment update on pediatric urolithiasis. Esen T, et al. **World J Urol** 1997;15(3):195–202 (62 ref.)

[Endoscopic techniques in the treatment of calculi in the upper urinary tract] Hem E. **Tidsskr Nor Laegeforen** 1996 Oct 10;116(24):2893–6 (28 ref.) (Eng. Abstr.) **(Nor)**

[Extracorporeal shock wave lithotripsy in urolithiasis. An update] Karlsen SJ. **Tidsskr Nor Laegeforen** 1996 Oct 10; 116(24):2889–92 (25 ref.) (Eng. Abstr.) **(Nor)**

URINE

Urinary inhibitors of calcium oxalate crystallization and their potential role in stone formation. Ryall RL. **World J Urol** 1997;15(3):155–64 (141 ref.)

VETERINARY

Management of urocystoliths by voiding urohydropropulsion. Lulich JP, et al. **Vet Clin North Am Small Anim Pract** 1996 May; 26(3):629–37 (6 ref.)

Diagnosis, medical treatment, and prognosis of feline urolithiasis. Osborne CA, et al. **Vet Clin North Am Small Anim Pract** 1996 May; 26(3):589–627 (42 ref.)

URINARY CATHETERIZATION

Long-term urethral catheterization and the urine-biomaterial interface. Elves AW, et al. **Br J Urol** 1997 Jul;80(1):1-5 (39 ref.)

Surgical management. O'Riordain DS, et al. **Ir J Med Sci** 1996 Jul-Sep;165(3):219-20 (15 ref.)

ADVERSE EFFECTS

Standards to prevent complications of urinary catheterization in children: should and should-knots. Carlson D, et al. **J Soc Pediatr Nurs** 1997 Jan-Mar;2(1):37-41 (11 ref.)

[Complications of double J ureteral stents] el Khader K. **J Urol (Paris)** 1996;102(4):173-5 (25 ref.) (Eng. Abstr.) **(Fre)**

[Transvaginal closure of the bladder neck in women with a neurogenic bladder and destroyed urethra] Chassagne S, et al. **Prog Urol** 1997 Apr;7(2):286-92 (8 ref.) (Eng. Abstr.) **(Fre)**

[Renal hematoma as a result of internal ureteral catheterization] Lujan Galán M, et al. **Actas Urol Esp** 1997 Apr;21(4):427-9 (6 ref.) (Eng. Abstr.) **(Spa)**

[The proximal migration of a double-J catheter. A review of the predisposing factors. Apropos a case] Vallejo Herrádor J, et al. **Actas Urol Esp** 1997 Apr;21(4):430-3 (30 ref.) (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

Management of undeflatable Foley catheter balloons in women. Gülmez I, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1997;8(2):81-4 (25 ref.)

Acucise endopyelotomy: evolution of a less-invasive technology. Nakada SY, et al. **J Endourol** 1996 Apr; 10(2):133-9 (30 ref.)

Standards to prevent complications of urinary catheterization in children: should and should-knots. Carlson D, et al. **J Soc Pediatr Nurs** 1997 Jan-Mar;2(1):37-41 (11 ref.)

NURSING

Long-term indwelling urinary catheter care: conceptualizing the research base. Wilde MH. **J Adv Nurs** 1997 Jun; 25(6):1252-61 (61 ref.)

VETERINARY

Use and misuse of indwelling urethral catheters. Lees GF. **Vet Clin North Am Small Anim Pract** 1996 May; 26(3):499-505 (6 ref.)

URINARY DIVERSION

Recurrent transitional cell carcinoma arising within an ileal conduit following cystectomy. A case report and review of the literature. Carter A, et al. **Eur Urol** 1996;30(4):519-20 (11 ref.)

Cystectomy and urinary diversion. Turner WH, et al. **Semin Surg Oncol** 1997 Sep-Oct;13(5):350-8 (32 ref.)

[Urinary diversion 1996] Hautmann R. **Urologe A** 1996 Jul; 35(4):279-83 (11 ref.) **(Ger)**

ADVERSE EFFECTS

Metabolic complications of urinary diversions: an overview. Cruz DN, et al. **Am J Med** 1997 May;102(5):477-84 (73 ref.)

Synchronous signet ring cell carcinoma and squamous cell carcinoma arising in an augmented ileocystoplasty. Case report and review of the literature. Fernandez-Arjona M, et al. **Eur Urol** 1996;29(1):125-8 (14 ref.)

Early development of adenocarcinoma in a young woman following augmentation cystoplasty for undiversion. Carr LK, et al. **J Urol** 1997 Jun;157(6):2255-6 (3 ref.)

METHODS

Laplace's law and the risks and prevention of bladder rupture after enterocystoplasty and bladder autoaugmentation. Chancellor MB, et al. **Neurourol Urodyn** 1996;15(3):223-33 (19 ref.)

Current management of bladder exstrophy. Ben-Chaim J, et al. **Tech Urol** 1996 Spring;2(1):22-33 (66 ref.)

URINARY FISTULA

Urinary fistula. Menefee SA, et al. **Curr Opin Obstet Gynecol** 1996 Oct;8(5):380-3 (35 ref.)

ETIOLOGY

Colovesical fistula caused by chronic chicken bone perforation. Khan MS, et al. **Ir J Med Sci** 1996 Jan-Mar; 165(1):51-2 (19 ref.)

Renocolic fistula as a complication to xanthogranulomatous pyelonephritis. Majeed HA, et al. **Singapore Med J** 1997 Mar;38(3):116-9 (17 ref.)

RADIOGRAPHY

Diagnosis and management of ureteroiliac artery fistula: value of provocative arteriography followed by common iliac artery embolization and extraanatomic arterial bypass grafting. Vandersteen DR, et al. **J Urol** 1997 Sep;158(3 Pt 1):754-8 (31 ref.)

SURGERY

Debate: 'post-operative urinary fistulae should be managed by gynaecologists in specialist centres'. Hilton P. **Br J Urol** 1997 Jul;80 Suppl 1:35-42 (9 ref.)

Autologous vein-covered stent for the endovascular management of an iliac artery-ureteral fistula: case report and review of the literature. Kerns DB, et al. **J Vasc Surg** 1996 Oct;24(4):680-6 (46 ref.)

[A case of uretero-aortic fistula] Awakura Y, et al. **Hinyokika Kiyo** 1997 Apr;43(4):299-301 (14 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Diagnosis and management of ureteroiliac artery fistula: value of provocative arteriography followed by common iliac artery embolization and extraanatomic arterial bypass grafting. Vandersteen DR, et al. **J Urol** 1997 Sep;158(3 Pt 1):754-8 (31 ref.)

Update on interventional uroradiology. Dyer RB, et al. **Urol Clin North Am** 1997 Aug;24(3):623-52 (128 ref.)

URINARY INCONTINENCE

see related
URINARY SPHINCTER, ARTIFICIAL

Urinary incontinence. Nazir T, et al. **Clin Obstet Gynecol** 1996 Dec;39(4):906-11 (0 ref.)

Urinary incontinence in women: a review for the pharmacist. Beizer JL. **J Am Pharm Assoc (Wash)** 1996 Mar; NS36(3):196-202 (14 ref.)

COMPLICATIONS

[Urination disorders and neurological disease except for o obvious medullary pathology: perinatal brain lesions with mental handicap] Gautheron V. **Arch Pediatr** 1997;4 Suppl 1:37s-40s (13 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Patient history in the diagnosis of urinary incontinence and determining the quality of life. Kujansuu E. **Acta Obstet Gynecol Scand Suppl** 1997;166:15-8 (14 ref.)

Reliability and validity of stationary cystometry, stationary cysto-urethrometry and ambulatory cysto-urethro-vaginometry. Kulseng-Hanssen S. **Acta Obstet Gynecol Scand Suppl** 1997;166:33-8 (36 ref.)

Pad weighing tests: the best way to quantify urine loss in patients with incontinence. Siltberg H, et al. **Acta Obstet Gynecol Scand Suppl** 1997;166:28-32 (28 ref.)

Evaluation and medical management of female urinary incontinence. Rackley RR, et al. **Cleve Clin J Med** 1997 Feb;64(2):83-92 (7 ref.)

Urinary incontinence. Diokno AC, et al. **Compr Ther** 1996 Sep;22(9):592-7 (10 ref.)

Evaluation and medical management of female urinary incontinence. Rackley R, et al. **Compr Ther** 1996 Sep; 22(9):547-53 (6 ref.)

Measures of differential diagnostic value of diagnostic procedures. Brenner H. **J Clin Epidemiol** 1996 Dec; 49(12):1435-39 (13 ref.)

Urinary incontinence: steps to evaluation, diagnosis, and treatment. Gallo ML, et al. **Nurse Pract** 1997 Feb; 22(2):21-4, 26, 28 passim (26 ref.)

DRUG THERAPY

The role of estrogen replacement therapy in the management of urinary incontinence and urinary tract infection in postmenopausal women. Griebling TL, et al. **Endocrinol Metab Clin North Am** 1997 Jun;26(2):347-60 (76 ref.)

[Urinary incontinence. Various forms and therapeutic consequences] Löhmer H, et al. **Med Monatsschr Pharm** 1996 Nov;19(11):320-9 (11 ref.) **(Ger)**

EPIDEMIOLOGY

Risk factors for urinary incontinence after radical prostatectomy [see comments] Eastham JA, et al. **J Urol** 1996 Nov;156(5):1707-13 (32 ref.) Comment in: J Urol 1996 Nov;156(5):1724.

ETIOLOGY

Some reflections and hypotheses on the pathophysiology of female urinary incontinence. Ulmsten U. **Acta Obstet Gynecol Scand Suppl** 1997;166:3-8 (31 ref.)

Urogenital effects of the menopause. Schaffer J, et al. **Baillieres Clin Obstet Gynaecol** 1996 Sep;10(3):401-17 (69 ref.)

The pelvic floor sequelae of childbirth. Sultan AH, et al. **Br J Hosp Med** 1996 May 1-14;55(9):575-9 (45 ref.)

Voiding dysfunction in women. Stevenson KR. **Curr Opin Obstet Gynecol** 1996 Oct;8(5):343-6 (39 ref.)

Laparoscopic colposuspension and pelvic floor repair. Vancaillie TG. **Curr Opin Obstet Gynecol** 1997 Aug; 9(4):244-6 (19 ref.)

Leaky urothelium and/or vesical ischemia enable urinary potassium to cause idiopathic urgency/frequency syndrome and urge incontinence. Hohlbrugger G. **Int Urogynecol J Pelvic Floor Dysfunct** 1996;7(5):242-55 (94 ref.)

An unusual case of urinary incontinence, ataxia-telangiectasia, and metastatic dysgerminoma: case report and review of the literature. deVries CR, et al. **Urology** 1997 Sep;50(3):453-5 (15 ref.)

[Transvaginal closure of the bladder neck in women with a neurogenic bladder and destroyed urethra] Chassagne S, et al. **Prog Urol** 1997 Apr;7(2):286-92 (8 ref.) (Eng. Abstr.) **(Fre)**

["Enuresis diurna" is not a diagnosis--new results on classification, pathogenesis and therapy of functional urinary incontinence in childhood] von Gontard A, et al. **Prax Kinderpsychol Kinderpsychiatr** 1997 Feb;46(2):92-112 (55 ref.) (Eng. Abstr.) **(Ger)**

[Ectopic ureter opening in the vestibulum without urinary incontinence: a case report] Matsumoto S, et al. **Hinyokika Kiyo** 1996 Dec;42(12):965-8 (11 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

The pelvic floor muscles: muscle thickness in healthy and urinary-incontinent women measured by perineal ultrasonography with reference to the effect of pelvic floor training. Estrogen receptor studies. Bernstein IT. **Neurourol Urodyn** 1997;16(4):237-75 (145 ref.)

Etiology of incontinence: a review and hypothesis. Levin RM, et al. **Scand J Urol Nephrol Suppl** 1996;179:15-25 (71 ref.)

[Therapy relevant aspects of anatomy, pathophysiology and diagnosis of urinary incontinence in women] Uher EM, et al. **Acta Med Austriaca** 1996;23(5):152-5 (56 ref.) (Eng. Abstr.) **(Ger)**

[Urinary incontinence] Trinkler FB. **Ther Umsch** 1996 Sep; 53(9):687-96 (11 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

Nonoperative management of urinary incontinence. Nygaard IE. **Curr Opin Obstet Gynecol** 1996 Oct;8(5):347-50 (26 ref.)

Continence for women: evidence-based practice. Sampselle CM, et al. **J Obstet Gynecol Neonatal Nurs** 1997 Jul-Aug; 26(4):375-85 (29 ref.)

[Possibilities of therapy and rehabilitation of patients with urinary incontinence] Zermann DH, et al. **Z Arztl Fortbild (Jena)** 1996 Oct;90(6):533-7 (19 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Surgical treatment of urinary incontinence. Thomas DF. **Arch Dis Child** 1997 Apr;76(4):377-80 (11 ref.)

Managed care in reconstructive pelvic surgery and urogynecology. Strohbehn K. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):319-24 (27 ref.)

Laparoscopic colposuspension and pelvic floor repair. Vancaillie TG. **Curr Opin Obstet Gynecol** 1997 Aug; 9(4):244-6 (19 ref.)

Advances in the management of urinary incontinence in children. Van Savage J, et al. **J Ky Med Assoc** 1997 Jun; 95(6):226-34 (11 ref.)

Dynamic myoplasty: surgical transfer and stimulation of skeletal muscle for functional substitution or enhancement. Grandjean P, et al. **J Rehabil Res Dev** 1996 Apr; 33(2):133-44 (30 ref.)

Post-prostatectomy incontinence and the artificial urinary sphincter: a long-term study of patient satisfaction and criteria for success. Litwiller SE, et al. **J Urol** 1996 Dec; 156(6):1975-80 (21 ref.)

[Transvaginal closure of the bladder neck in women with a neurogenic bladder and destroyed urethra] Chassagne S, et al. **Prog Urol** 1997 Apr;7(2):286-92 (8 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Ethical and practice considerations for biofeedback therapists in the treatment of urinary incontinence. Paul P, et al. **Biofeedback Self Regul** 1996 Sep;21(3):229-40 (32 ref.)

Evaluation and medical management of female urinary incontinence. Rackley RR, et al. **Cleve Clin J Med** 1997 Feb;64(2):83-92 (7 ref.)

Urinary incontinence. Diokno AC, et al. **Compr Ther** 1996 Sep;22(9):592-7 (10 ref.)

Evaluation and medical management of female urinary incontinence. Rackley R, et al. **Compr Ther** 1996 Sep; 22(9):547-53 (6 ref.)

Management of urinary incontinence in the elderly. Iqbal P, et al. **Gerontology** 1997;43(3):151-7 (41 ref.)

Treating urinary incontinence in the elderly population: accepting the challenge. Bennett JK, et al. **J Med Assoc Ga** 1997 Apr;86(2):97-100 (13 ref.)

Urinary bladder control by electrical stimulation: review of electrical stimulation techniques in spinal cord injury. Rijkhoff NJ, et al. **Neurourol Urodyn** 1997;16(1):39-53 (82 ref.)

Urinary incontinence: steps to evaluation, diagnosis, and treatment. Gallo ML, et al. **Nurse Pract** 1997 Feb; 22(2):21-4, 26, 28 passim (26 ref.)

Transurethral collagen injection for treatment of postprostatectomy urinary incontinence in men. Griebling TL, et al. **Urology** 1997 Jun;49(6):907-12 (25 ref.)

[Physiotherapy in the treatment of urinary incontinence in elderly women] Bø K. **Tidsskr Nor Laegeforen** 1997 Aug

URINARY INCONTINENCE

10;117(18):2623–6 (43 ref.) (Eng. Abstr.) **(Nor)**

VETERINARY

[Urinary incontinence in castrated bitches. 2. Diagnosis and treatment] Arnold S. **Schweiz Arch Tierheilkd** 1997; 139(7):319–24 (27 ref.) (Eng. Abstr.) **(Ger)**

URINARY INCONTINENCE, STRESS

Followup of intraurethral collagen for female stress urinary incontinence. Herschorn S, et al. **J Urol** 1996 Oct; 156(4):1305–9 (24 ref.)

DIAGNOSIS

Patient history in the diagnosis of urinary incontinence and determining the quality of life. Kujansuu E. **Acta Obstet Gynecol Scand Suppl** 1997;166:15–8 (14 ref.)

Reliability and validity of stationary cystometry, stationary cysto-urethrometry and ambulatory cysto-urethro-vaginometry. Kulseng-Hanssen S. **Acta Obstet Gynecol Scand Suppl** 1997;166:33–8 (36 ref.)

Pad weighing tests: the best way to quantify urine loss in patients with incontinence. Siltberg H, et al. **Acta Obstet Gynecol Scand Suppl** 1997;166:28–32 (28 ref.)

DRUG THERAPY

[Treatments of stress urinary incontinence (SUI) in women] Benizri EJ. **J Urol (Paris)** 1996;102(3):117–22 (68 ref.) **(Fre)**

[Peri-ureteral injections for stress urinary incontinence] Haab F. **Prog Urol** 1997 Apr;7(2):293–6 (15 ref.) **(Fre)**

ETIOLOGY

Some reflections and hypotheses on the pathophysiology of female urinary incontinence. Ulmsten U. **Acta Obstet Gynecol Scand Suppl** 1997;166:3–8 (31 ref.)

PATHOLOGY

Morphology and neuropathology of the pelvic floor in patients with stress incontinence. Morley R, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1996;7(1):3–12 (63 ref.)

PHYSIOPATHOLOGY

Urethral pressure measurement. Lose G. **Acta Obstet Gynecol Scand Suppl** 1997;166:39–42 (31 ref.)

Stress urinary incontinence: where are we now, where should we go? DeLancey JO. **Am J Obstet Gynecol** 1996 Aug; 175(2):311–9 (26 ref.)

SURGERY

Prospective comparison of laparoscopic and traditional colposuspensions in the treatment of genuine stress incontinence. Su TH, et al. **Acta Obstet Gynecol Scand** 1997 Jul;76(6):576–82 (25 ref.)

Ureteric injury at Burch colposuspension. 4 case reports and literature review. Rosen DM, et al. **Aust N Z J Obstet Gynaecol** 1996 Aug;36(3):354–8 (15 ref.)

What is the right operation for stress incontinence? A urologist's view. Evans C. **Br J Urol** 1997 Jul;80 Suppl 1:88–90 (12 ref.)

What is the right operation for stress incontinence? A gynaecological view. Stanton SL. **Br J Urol** 1997 Jul;80 Suppl 1:84–7 (11 ref.)

[Role of endoscopy in surgery for urinary incontinence] Grossmann T, et al. **Ann Chir** 1996;50(10):896–905 (34 ref.) (Eng. Abstr.) **(Fre)**

[Limitations of laparoscopic management of pelvic static disorders in gynecology] Mage G, et al. **Presse Med** 1996 Dec 21;25(40):2037–41 (30 ref.) (Eng. Abstr.) **(Fre)**

[Abdominal colposuspension: a synopsis of various approaches and techniques including endoscopic modifications] Wallwiener D, et al. **Zentralbl Gynakol** 1996; 118(2):98–106 (25 ref.) (Eng. Abstr.) **(Ger)**

[Laparoscopic surgery of stress urinary incontinence in women] Breda G, et al. **Chir Ital** 1996;48(5):35–40 (29 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Stress urinary incontinence: where are we now, where should we go? DeLancey JO. **Am J Obstet Gynecol** 1996 Aug; 175(2):311–9 (26 ref.)

Collagen injection therapy for type III stress urinary incontinence. Bartholomew B, et al. **AORN J** 1996 Jul; 64(1):75–83, 85–6 (28 ref.)

Followup of intraurethral collagen for female stress urinary incontinence. Herschorn S, et al. **J Urol** 1996 Oct; 156(4):1305–9 (24 ref.)

Current approach to the management of urinary stress incontinence. Lim FK, et al. **Singapore Med J** 1995 Oct; 36(5):532–7 (62 ref.)

ULTRASONOGRAPHY

Ultrasonography in stress urinary incontinence. Demirci F, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1996; 7(3):125–32 (57 ref.)

URINARY RESERVOIRS, CONTINENT

Bladder replacement in women: a new experience. Racioppi M, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1997; 8(1):36–46 (141 ref.)

Continent urinary diversion: the Children's Hospital experience. Kaefer M, et al. **J Urol** 1997 Apr;157(4):1394–9 (43 ref.)

Standardization of terminology and assessment of functional characteristics of intestinal urinary reservoirs. Thüroff JW, et al. **Neurourol Urodyn** 1996;15(5):499–511 (6 ref.)

The standardization of terminology and assessment of functional characteristics of intestinal urinary reservoirs. Thüroff JW, et al. **Scand J Urol Nephrol** 1996 Oct; 30(5):349–56 (6 ref.)

Reconstruction of the urinary tract after radical cystectomy: the case for continent urinary diversion [editorial] Turner WH, et al. **Urology** 1997 May;49(5):663–7 (34 ref.)

[Urinary diversion 1996] Hautmann R. **Urologe A** 1996 Jul; 35(4):279–83 (11 ref.) **(Ger)**

ADVERSE EFFECTS

[Orthotopic bladder substitution: II. Types and complications] Huguet Pérez J, et al. **Arch Esp Urol** 1997 Apr;50(3):221–33 (51 ref.) (Eng. Abstr.) **(Spa)**

[Orthotopic bladder replacement: II. Functional results and complications in patients with Studer-type ileal neobladder] Regalado Pareja R, et al. **Arch Esp Urol** 1997 Apr;50(3):234–41 (26 ref.) (Eng. Abstr.) **(Spa)**

METHODS

Urinary reconstruction (rather than diversion) for continence in difficult pediatric urologic disorders. Sheldon CA. **Semin Pediatr Surg** 1996 Feb;5(1):8–15 (21 ref.)

Adaptations of the Mitrofanoff principle in adult continent urinary reservoirs. Bihrle R, et al. **Tech Urol** 1995 Summer; 1(2):94–101 (18 ref.)

[Orthotopic bladder replacement: I. Physiopathology of orthotopic bladder replacement with intestine] Errando Smet C, et al. **Arch Esp Urol** 1997 Mar;50(2):109–13 (24 ref.) (Eng. Abstr.) **(Spa)**

[Orthotopic bladder substitution: II. Types and complications] Huguet Pérez J, et al. **Arch Esp Urol** 1997 Apr;50(3):221–33 (51 ref.) (Eng. Abstr.) **(Spa)**

[Orthotopic bladder replacement: II. Functional results and complications in patients with Studer-type ileal neobladder] Regalado Pareja R, et al. **Arch Esp Urol** 1997 Apr;50(3):234–41 (26 ref.) (Eng. Abstr.) **(Spa)**

URINARY RETENTION

see related
URINARY CATHETERIZATION

[Urinary retension in women] Halachmi S, et al. **Harefuah** 1997 Feb 16;132(4):279–83 (25 ref.) **(Heb)**

PREVENTION & CONTROL

Surgical management. O'Riordain DS, et al. **Ir J Med Sci** 1996 Jul–Sep;165(3):219–20 (15 ref.)

URINARY SPHINCTER, ARTIFICIAL

Post-prostatectomy incontinence and the artificial urinary sphincter: a long-term study of patient satisfaction and criteria for success. Litwiller SE, et al. **J Urol** 1996 Dec; 156(6):1975–80 (21 ref.)

[Intravesical migration of an artificial urinary sphincter AMS-800: a rare complication] Asensio Egea L, et al. **Actas Urol Esp** 1996 Nov–Dec;20(10):915–8 (11 ref.) (Eng. Abstr.) **(Spa)**

URINARY TRACT

see related
UROGRAPHY

ABNORMALITIES

[Prognosis of prenatal uropathies: should fetal urine tests be continued?] Bensman A. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(5):510–4 (28 ref.) (Eng. Abstr.) **(Fre)**

[Relationship between prenatal and postnatal echographic diagnosis of uropathy: is mass screening useful?] Cacciari A, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):13–7 (27 ref.) (Eng. Abstr.) **(Ita)**

EMBRYOLOGY

[Fetal uropathies: anatomo-pathologic background] Caruso G, et al. **Arch Ital Urol Androl** 1997 Jun;69(3):201–8 (13 ref.) (Eng. Abstr.) **(Ita)**

[Functional aspects of the fetal urinary apparatus in relation to growth] Luzi G, et al. **Arch Ital Urol Androl** 1996 Dec; 68(5 Suppl):9–12 (15 ref.) (Eng. Abstr.) **(Ita)**

IMMUNOLOGY

Bacterial adherence and mucosal cytokine responses. Receptors and transmembrane signaling. Svanborg C, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:177–90 (49 ref.)

INJURIES

Trauma. Mirvis SE. **Radiol Clin North Am** 1996 Nov; 34(6):1225–57 (28 ref.)

INNERVATION

Clinical neurophysiological methods for investigating the lower urinary tract in patients with micturition disorders. Flink R. **Acta Obstet Gynecol Scand Suppl** 1997;166:50–8 (57 ref.)

Neurotransmitters and neuroreceptors in the lower urinary tract. Andersson KE. **Curr Opin Obstet Gynecol** 1996 Oct; 8(5):361–5 (49 ref.)

Neural control of the lower urinary tract. Yoshimura N, et al. **Int J Urol** 1997 Mar;4(2):111–25 (162 ref.)

Neurophysiology of micturition and continence in women. Chai TC, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1997;8(2):85–97 (150 ref.)

MICROBIOLOGY

Bacterial adherence and mucosal cytokine responses. Receptors and transmembrane signaling. Svanborg C, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:177–90 (49 ref.)

[Progress on study of urinary tract infections] Matsumoto T. **Fukuoka Igaku Zasshi** 1996 Dec;87(12):260–5 (7 ref.) **(Jpn)**

PATHOLOGY

Errors and pitfalls in cytology of the lower urinary tract. Koss LG. **Monogr Pathol** 1997;(39):60–74 (48 ref.)

Urinary tract and male genital system. Coulson WF. **Pathology (Phila)** 1996;3(2):493–502 (17 ref.)

Urethroscopy, cystoscopy, and biopsy of the feline lower urinary tract. Chew DJ, et al. **Vet Clin North Am Small Anim Pract** 1996 May; 26(3):441–62 (8 ref.)

Cystoscopy and biopsy of the feline lower urinary tract. McCarthy TC. **Vet Clin North Am Small Anim Pract** 1996 May;26(3):463–82 (16 ref.)

[Nephrogenic metaplasia of the urinary tract] Fournier G. **Prog Urol** 1996 Dec;6(6):861–8 (69 ref.) (Eng. Abstr.) **(Fre)**

[Fetal uropathies: anatomo-pathologic background] Caruso G, et al. **Arch Ital Urol Androl** 1997 Jun;69(3):201–8 (13 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

Progress in urodynamic research on the upper urinary tract: implications for practical urology [editorial] Kinn AC. **Urol Res** 1996;24(1):1–7 (39 ref.)

Feline urodynamic procedures. Lane IF. **Vet Clin North Am Small Anim Pract** 1996 May; 26(3):423–39 (34 ref.)

RADIATION EFFECTS

Radiation change in normal organs: an overview of body imaging. Libshitz HI, et al. **Eur Radiol** 1996;6(6):786–95 (82 ref.)

SURGERY

Urinary tract and male genital system. Coulson WF. **Pathology (Phila)** 1996;3(2):493–502 (17 ref.)

[Internal drainage of the upper urinary tract] Zenkov SS. **Urol Nefrol (Mosk)** 1996 May-Jun;(3):51–6 (133 ref.) **(Rus)**

URINARY TRACT DISEASES see **UROLOGIC DISEASES**

URINARY TRACT INFECTIONS

see related
ANTI-INFECTIVE AGENTS, URINARY

Urinary tract infection in pregnancy. MacLean AB. **Br J Urol** 1997 Jul;80 Suppl 1:10–3 (28 ref.)

Office laboratory procedures, office economics, patient and parent education, and urinary tract infection. Ey JL, et al. **Curr Opin Pediatr** 1996 Dec;8(6):639–49 (78 ref.)

Urinary tract infections--a fresh look. Singh NP, et al. **J Assoc Physicians India** 1996 Nov;44(11):809–14 (33 ref.)

Renal disease. II. Urinary tract infection in women [see comments] Cattell WR. **J R Coll Physicians Lond** 1997 Mar–Apr;31(2):130–3 (12 ref.) Comment in: J R Coll Physicians Lond 1997 May-Jun;31(3):341.

Pediatric urinary tract infections. Batisky D. **Pediatr Ann** 1996 May;25(5):266, 269–76 (33 ref.)

[Progress on study of urinary tract infections] Matsumoto T. **Fukuoka Igaku Zasshi** 1996 Dec;87(12):260–5 (7 ref.) **(Jpn)**

[Urosepsis] Moen H, et al. **Tidsskr Nor Laegeforen** 1997 Mar 10;117(7):959–62 (13 ref.) (Eng. Abstr.) **(Nor)**

[Urinary tract infection: up-date on concepts with therapy implications] Jiménez Cruz JF, et al. **Rev Clin Esp** 1997 Mar;197(3):180–5 (39 ref.) **(Spa)**

COMPLICATIONS

Periurethral abscess: complication of UTI. Mylonakis E, et al. **Geriatrics** 1997 Aug;52(8):86–8 (18 ref.)

Giant intra-adrenal myelolipoma associated with recurrent urinary tract infection. Houshiar AM, et al. **Int Urol Nephrol** 1997;29(2):130–6 (15 ref.)

Widespread cutaneous necrosis and antiphospholipid antibodies: two episodes related to surgical manipulation and urinary tract infection. Del Castillo LF, et al. **J Am Acad Dermatol** 1997 May;36(5 Pt 2):872–5 (15 ref.)
Renal abscess: an illustrative case and review of the literature. Rinder MR. **Md Med J** 1996 Oct;45(10):839–43 (27 ref.)
Struvite calculi. Cohen TD, et al. **Semin Nephrol** 1996 Sep; 16(5):425–34 (71 ref.)
[Parietal calcifications of the kidney pelvis in Corynebacterium urealyticum urinary infection] Maciejewski C, et al. **J Radiol** 1996 Aug;77(8):571–3 (12 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Pediatric uroradiology update. Auringer ST. **Urol Clin North Am** 1997 Aug;24(3):673–81 (28 ref.)
Imaging and radiologic management of upper urinary tract infections. Baumgarten DA, et al. **Urol Clin North Am** 1997 Aug;24(3):545–69 (74 ref.)
[Urinary tract infections in children: how should it be managed?] Panchard MA, et al. **Rev Med Suisse Romande** 1996 Oct;116(10):801–8 (15 ref.) **(Fre)**

DRUG THERAPY

Phenazopyridine in urinary tract infections. Zelenitsky SA, et al. **Ann Pharmacother** 1996 Jul–Aug;30(7–8):866–8 (10 ref.)
Fleroxacin in complicated urinary tract infections. Giamarellou H. **Chemotherapy** 1996 Mar;42 Suppl 1:17–27 (29 ref.)
Fluoroquinolones in urinary tract infections. Proper and improper use. Naber KG. **Drugs** 1996;52 Suppl 2:27–33 (40 ref.)
A practical guide to the management of complicated urinary tract infection. Nicolle LE. **Drugs** 1997 Apr;53(4):583–92 (39 ref.)
Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Patel SS, et al. **Drugs** 1997 Apr;53(4):637–56 (106 ref.)
Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections. Patel SS, et al. **Drugs** 1996 Jan;51(1):137–60 (201 ref.)
Optimal treatment of urinary tract infections in elderly patients [see comments] Wood CA, et al. **Drugs Aging** 1996 Nov;9(5):352–62 (64 ref.) Comment in: Drugs Aging 1997 Feb;10(2):167.
Nosocomial infection of the urinary tract: pattern of antibiotic use and drug resistance. Magoha GA. **East Afr Med J** 1997 Mar;74(3):190–2 (23 ref.)
Urinary tract infections complicating pregnancy. Millar LK, et al. **Infect Dis Clin North Am** 1997 Mar;11(1):13–26 (61 ref.)
Urinary tract infections. Bacheller CD, et al. **Med Clin North Am** 1997 May;81(3):719–30 (46 ref.)
Urinary tract infection. Current management strategies. Wisinger DB. **Postgrad Med** 1996 Nov;100(5):229–36, 239 (25 ref.)
[Urinary tract infections: risk factors and therapeutic trends] Margariti PA, et al. **Recenti Prog Med** 1997 Feb;88(2):65–8 (28 ref.) (Eng. Abstr.) **(Ita)**

EPIDEMIOLOGY

[Urinary tract infection caused by Haemophilus spp. in pediatrics: a rarely studied disease] Galán F, et al. **Enferm Infecc Microbiol Clin** 1996 Oct;14(8):483–5 (17 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Urogenital effects of the menopause. Schaffer J, et al. **Baillieres Clin Obstet Gynaecol** 1996 Sep;10(3):401–17 (69 ref.)
[Urinary tract infections in patients with diabetes mellitus] Geerlings SE, et al. **Ned Tijdschr Geneeskd** 1997 Feb 22; 141(8):372–5 (26 ref.) (Eng. Abstr.) **(Dut)**
[Recurrent urinary tract infections and their prevention in women] Ikäheimo R, et al. **Duodecim** 1995;111(15):1403–9 (37 ref.) **(Fin)**
[Morbidity of transperineal echo-guided prostatic biopsy, our experience] Zambolin T, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):217–9 (6 ref.) (Eng. Abstr.) **(Ita)**

MICROBIOLOGY

Pathogenetic aspects of uncomplicated urinary tract infection: recent advances. Fünfstück R, et al. **Clin Nephrol** 1997 Jan;47(1):13–8 (43 ref.)
Tropism in bacterial infections: urinary tract infections. Roberts JA. **J Urol** 1996 Nov;156(5):1552–9 (84 ref.)

PHYSIOPATHOLOGY

Factors predisposing to urinary tract infections in children. Roberts JA. **Pediatr Nephrol** 1996 Aug;10(4):517–22 (68 ref.)

PREVENTION & CONTROL

The role of estrogen replacement therapy in the management of urinary incontinence and urinary tract infection in postmenopausal women. Griebling TL, et al. **Endocrinol Metab Clin North Am** 1997 Jun;26(2):347–60 (76 ref.)
Long-term indwelling urinary catheter care: conceptualizing the research base. Wilde MH. **J Adv Nurs** 1997 Jun; 25(6):1252–61 (61 ref.)
Antibiotic prophylaxis in ultrasound guided transrectal prostate biopsy. Sieber PR, et al. **J Urol** 1997 Jun; 157(6):2199–200 (13 ref.)
Cranberry juice and urinary tract infections: is there a beneficial relationship? Kuzminski LN. **Nutr Rev** 1996 Nov; 54(11 Pt 2):S87–90 (27 ref.)
Prevention of urinary tract infection in patients with spinal cord injury—a microbiological review. Galloway A. **Spinal Cord** 1997 Apr;35(4):198–204 (87 ref.)
[Recurrent urinary tract infections and their prevention in women] Ikäheimo R, et al. **Duodecim** 1995;111(15):1403–9 (37 ref.) **(Fin)**
[Urinary infections in pregnant women] Mauroy B, et al. **Prog Urol** 1996 Aug–Sep;6(4):607–22 (38 ref.) (Eng. Abstr.) **(Fre)**
[Mass screening of urinary tract infection for elementary and junior high school children] Murakami M. **Nippon Ika Daigaku Zasshi** 1996 Dec;63(6):441–5 (9 ref.) **(Jpn)**

RADIOGRAPHY

The role of imaging in adult acute urinary tract infection. Webb JA. **Eur Radiol** 1997;7(6):837–43 (41 ref.)

RADIONUCLIDE IMAGING

Renal cortical scintigraphy: effect on medical decision making in childhood urinary tract infection [editorial; comment] Strife CF, et al. **J Pediatr** 1996 Dec;129(6):785–7 (18 ref.) Comment on: J Pediatr 1996 Dec;129(6):815–20.
[99m technetium-dimercaptosuccinic acid renal scan in urinary tract infection in infancy and childhood] Aladjem M, et al. **Harefuah** 1997 Jun 1;132(11):796–8 (25 ref.) **(Heb)**

THERAPY

[Urinary tract infections in children: how should it be managed?] Panchard MA, et al. **Rev Med Suisse Romande** 1996 Oct;116(10):801–8 (15 ref.) **(Fre)**
[New approaches to the treatment of urinary tract infection] Iris-de la Cruz S. **Ginecol Obstet Mex** 1996 Jul;64:319–24 (8 ref.) (Eng. Abstr.) **(Spa)**

VETERINARY

Antimicrobial therapy of urinary tract infections. Dowling PM. **Can Vet J** 1996 Jul;37(7):438–41 (6 ref.)
Pharmacologic management of feline lower urinary tract disorders. Lane IF. **Vet Clin North Am Small Anim Pract** 1996 May; 26(3):515–33 (64 ref.)

URINATION

PHYSIOLOGY

Neurophysiology of micturition and continence in women. Chai TC, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1997;8(2):85–97 (150 ref.)
The neuronal control of micturition and its relation to the emotional motor system. Blok BF, et al. **Prog Brain Res** 1996;107:113–26 (82 ref.)
Initiation of contraction in detrusor smooth muscle. Fry CH, et al. **Scand J Urol Nephrol Suppl** 1997;184:7–14 (26 ref.)
Cells and cell junctions in the muscle coat of the bladder. Gabella G. **Scand J Urol Nephrol Suppl** 1997;184:3–6 (11 ref.)
The collagens and their urologic significance. Macarak EJ, et al. **Scand J Urol Nephrol Suppl** 1997;184:25–33 (43 ref.)
The physiological mechanisms involved in bladder emptying. Morrison JF. **Scand J Urol Nephrol Suppl** 1997;184:15–8 (15 ref.)
Change in length of the detrusor muscle cells. Tammela T. **Scand J Urol Nephrol Suppl** 1997;184:19–24 (22 ref.)
Management of urocystoliths by voiding urohydropropulsion. Lulich JP, et al. **Vet Clin North Am Small Anim Pract** 1996 May; 26(3):629–37 (6 ref.)

URINATION DISORDERS

Pediatric gynecology urologic problems. Starr NT. **Clin Obstet Gynecol** 1997 Mar;40(1):181–99 (55 ref.)

COMPLICATIONS

The nonneurogenic neurogenic bladder of early infancy. Jayanthi VR, et al. **J Urol** 1997 Sep;158(3 Pt 2):1281–5 (18 ref.)

CONGENITAL

The nonneurogenic neurogenic bladder of early infancy. Jayanthi VR, et al. **J Urol** 1997 Sep;158(3 Pt 2):1281–5 (18 ref.)

DIAGNOSIS

Clinical neurophysiological methods for investigating the lower urinary tract in patients with micturition disorders. Flink R. **Acta Obstet Gynecol Scand Suppl** 1997;166:50–8 (57 ref.)
Urologic 'nuisances': how to work up and relieve men's symptoms. Albertsen PC. **Geriatrics** 1997 Feb;52(2):46–50, 53–4; quiz 55 (17 ref.)
Urodynamic tests: client preparation, assessment, and follow-up. Wozniak-Petrofsky J. **Nurse Pract** 1997 Mar; 22(3):70–1, 77–9, 83–4 passim; quiz 90–1 (8 ref.)

DRUG THERAPY

The role of estrogen replacement therapy in the management of urinary incontinence and urinary tract infection in postmenopausal women. Griebling TL, et al. **Endocrinol Metab Clin North Am** 1997 Jun;26(2):347–60 (76 ref.)

ETIOLOGY

Lower urinary tract symptoms in women: who to investigate and how. Abrams P. **Br J Urol** 1997 Jul;80 Suppl 1:43–8 (10 ref.)
Lower urinary tract symptoms in pregnancy. Cardozo L, et al. **Br J Urol** 1997 Jul;80 Suppl 1:14–23 (49 ref.)
Leaky urothelium and/or vesical ischemia enable urinary potassium to cause idiopathic urgency/frequency syndrome and urge incontinence. Hohlbrugger G. **Int Urogynecol J Pelvic Floor Dysfunct** 1996;7(5):242–55 (94 ref.)

GENETICS

EEC syndrome and genitourinary anomalies: an update. Maas SM, et al. **Am J Med Genet** 1996 Jun 14;63(3):472–8 (24 ref.)

NURSING

Urodynamic tests: client preparation, assessment, and follow-up. Wozniak-Petrofsky J. **Nurse Pract** 1997 Mar; 22(3):70–1, 77–9, 83–4 passim; quiz 90–1 (8 ref.)

PHYSIOPATHOLOGY

[Fluctuations in the maximal intraurethral pressure and urination disorders in women] Loran OB, et al. **Urol Nefrol (Mosk)** 1997 May–Jun;(3):44–8 (96 ref.) **(Rus)**

THERAPY

Urologic 'nuisances': how to work up and relieve men's symptoms. Albertsen PC. **Geriatrics** 1997 Feb;52(2):46–50, 53–4; quiz 55 (17 ref.)

VETERINARY

Behavioral and pharmacologic approaches to problem urination in cats. Hart BL. **Vet Clin North Am Small Anim Pract** 1996 May;26(3):651–8 (12 ref.)

URINE

see related
ALBUMINURIA
ALKAPTONURIA
AMINOACIDURIA, RENAL
ANURIA
BACTERIURIA
CYSTINURIA
GLYCOSURIA
HEMATURIA
HEMOGLOBINURIA
MAPLE SYRUP URINE DISEASE
PHENYLKETONURIA
POLYURIA
PROTEINURIA

Urotherapy for patients with cancer. Eldor J. **Med Hypotheses** 1997 Apr;48(4):309–15 (96 ref.)
Metastatic breast carcinoma presenting as urinoma. Zunarelli E, et al. **Pathologica** 1995 Dec;87(6):712–4 (8 ref.)

CHEMISTRY

Saccharin mechanistic data and risk assessment: urine composition, enhanced cell proliferation, and tumor promotion. Whysner J, et al. **Pharmacol Ther** 1996; 71(1–2):225–52 (172 ref.)
The urinary excretion of solvents and gases for the biological monitoring of occupational exposure: a review. Gobba F, et al. **Sci Total Environ** 1997 Jun 20;199(1–2):3–12 (46 ref.)
Urinary inhibitors of calcium oxalate crystallization and their potential role in stone formation. Ryall RL. **World J Urol** 1997;15(3):155–64 (141 ref.)

CYTOLOGY

Urine cytology: an underused method to diagnose acute renal allograft rejection. Corey HE. **Pediatr Nephrol** 1997 Apr; 11(2):226–30 (62 ref.)

URINE CONCENTRATING ABILITY see **KIDNEY CONCENTRATING ABILITY**

UROCANIC ACID

UROCANIC ACID

RADIATION EFFECTS

Chromophore for UV-induced immunosuppression: urocanic acid. Norval M. **Photochem Photobiol** 1996 Apr; 63(4):386-90 (42 ref.)

UROCHORDATA

ENZYMOLOGY

Physiological functions of proteasomes in ascidian fertilization and embryonic cell cycle. Sawada H, et al. **Adv Exp Med Biol** 1996;389:229-32 (12 ref.)

GENETICS

Bi-versus multichimerism in colonial urochordates: a hypothesis for links between natural tissue transplantation, allogenetics and evolutionary ecology. Rinkevich B. **Exp Clin Immunogenet** 1996;13(2):61-9 (41 ref.)

IMMUNOLOGY

Cytotoxic activity of tunicate hemocytes. Parrinello N. **Prog Mol Subcell Biol** 1996;15:190-217 (105 ref.)

Humoral factors in tunicates. Saito Y. **Prog Mol Subcell Biol** 1996;15:218-34 (73 ref.)

URODELA

ANATOMY & HISTOLOGY

Genome size, secondary simplification, and the evolution of the brain in salamanders. Roth G, et al. **Brain Behav Evol** 1997 Jul;50(1):50-9 (60 ref.)

EMBRYOLOGY

An essay on the similarities and differences between inductive interactions in anuran and urodele embryos. Malacinski GM, et al. **Cell Mol Life Sci** 1997 Apr;53(4):410-7 (30 ref.)

Evolutionary patterns in ontogenetic transformation: from laws to regularities. Alberch P, et al. **Int J Dev Biol** 1996 Aug;40(4):845-58 (78 ref.)

How did urodele embryos come into prominence as a model system? Beetschen JC. **Int J Dev Biol** 1996 Aug; 40(4):629-36 (97 ref.)

What mechanisms drive neural induction and neural determination in urodeles? Duprat AM. **Int J Dev Biol** 1996 Aug;40(4):745-54 (68 ref.)

Developmental neurobiology of the anterior areas in amphibians: urodele perspectives. Eagleson GW. **Int J Dev Biol** 1996 Aug;40(4):735-43 (46 ref.)

What insights into the phenomena of cell fate determination and cell migration has the study of the urodele neural crest provided? Epperlein HH, et al. **Int J Dev Biol** 1996 Aug; 40(4):695-707 (89 ref.)

Neural crest cell migration and pigment pattern formation in urodele amphibians. Epperlein HH, et al. **Int J Dev Biol** 1996 Feb;40(1):229-38 (78 ref.)

How does the urodele ear develop? Fritzsch B. **Int J Dev Biol** 1996 Aug;40(4):763-71 (62 ref.)

What are the key advantages and disadvantages of urodele species compared to anurans as a model system for experimental analysis of early development? Nieuwkoop PD. **Int J Dev Biol** 1996 Aug;40(4):617-9 (16 ref.)

A conceptual framework for analyzing axial patterning in regenerating urodele limbs. Stocum DL. **Int J Dev Biol** 1996 Aug;40(4):773-83 (108 ref.)

Primordial germ cell development: is the urodele pattern closer to mammals than to anurans? Wakahara M. **Int J Dev Biol** 1996 Aug;40(4):653-9 (55 ref.)

GROWTH & DEVELOPMENT

What insights into the developmental traits of urodeles does the study of interspecific hybrids provide? Voss SR, et al. **Int J Dev Biol** 1996 Aug;40(4):885-93 (70 ref.)

PHYSIOLOGY

Spinal cord regeneration: a phenomenon unique to urodeles? Chernoff EA. **Int J Dev Biol** 1996 Aug;40(4):823-31 (78 ref.)

Re-examining jaw regeneration in urodeles: what have we learnt? Ferretti P. **Int J Dev Biol** 1996 Aug;40(4):807-11 (30 ref.)

The cellular basis of limb regeneration in urodeles. Mescher AL. **Int J Dev Biol** 1996 Aug;40(4):785-95 (102 ref.)

Heart development and regeneration in urodeles. Neff AW, et al. **Int J Dev Biol** 1996 Aug;40(4):719-25 (76 ref.)

Can insights into urodele limb regeneration be achieved with cell cultures and retroviruses? Tsonis PA, et al. **Int J Dev Biol** 1996 Aug;40(4):813-6 (13 ref.)

Is retinoic acid an endogenous ligand during urodele limb regeneration? Viviano CM, et al. **Int J Dev Biol** 1996 Aug; 40(4):817-22 (42 ref.)

Amphibian limb regeneration: rebuilding a complex structure. Brockes JP. **Science** 1997 Apr 4;276(5309):81-7 (55 ref.)

URODYNAMICS

Reliability and validity of stationary cystometry, stationary cysto-urethrometry and ambulatory cysto-urethro-vaginometry. Kulseng-Hanssen S. **Acta Obstet Gynecol Scand Suppl** 1997;166:33-8 (36 ref.)

Urodynamic tests: client preparation, assessment, and follow-up. Wozniak-Petrofsky J. **Nurse Pract** 1997 Mar; 22(3):70-1, 77-9, 83-4 passim; quiz 90-1 (8 ref.)

Progress in urodynamic research on the upper urinary tract: implications for practical urology [editorial] Kinn AC. **Urol Res** 1996;24(1):1-7 (39 ref.)

The role of urodynamic study in the evaluation and management of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Gerber GS. **Urology** 1996 Nov;48(5):668-75 (88 ref.)

Urodynamic abnormalities in two brothers with adrenomyeloneuropathy. Walther MM, et al. **World J Urol** 1997;15(4):262-5 (11 ref.)

[Progresses in urology in China, 1996] Guo Y. **Chung Hua I Hsueh Tsa Chih** 1996 Dec;76(12):907-8 (0 ref.) **(Chi)**

PHYSIOLOGY

Ambulatory bladder monitoring: is it an advance? Heslington K. **Br J Urol** 1997 Jul;80 Suppl 1:49-53 (18 ref.)

Ultrasound measurement of fetal urine flow. Hedriana HL. **Clin Obstet Gynecol** 1997 Jun;40(2):337-51 (28 ref.)

The mechanism of urine concentration in the inner medulla. Oh MS, et al. **Nephron** 1997;75(4):384-93 (27 ref.)

Emptying against outflow obstruction--pharmacological aspects. Andersson KE. **Scand J Urol Nephrol Suppl** 1997; 184:77-84 (83 ref.)

Alterations in the physiological properties of urinary bladder smooth muscle caused by bladder emptying against an obstruction. Brading AF. **Scand J Urol Nephrol Suppl** 1997; 184:51-8 (46 ref.)

Contractile protein changes in urinary bladder smooth muscle during obstruction-induced hypertrophy. Chacko S, et al. **Scand J Urol Nephrol Suppl** 1997;184:67-76 (82 ref.)

Initiation of contraction in detrusor smooth muscle. Fry CH, et al. **Scand J Urol Nephrol Suppl** 1997;184:7-14 (26 ref.)

Cells and cell junctions in the muscle coat of the bladder. Gabella G. **Scand J Urol Nephrol Suppl** 1997;184:3-6 (11 ref.)

The collagens and their urologic significance. Macarak EJ, et al. **Scand J Urol Nephrol Suppl** 1997;184:25-33 (43 ref.)

The physiological mechanisms involved in bladder emptying. Morrison JF. **Scand J Urol Nephrol Suppl** 1997;184:15-8 (15 ref.)

Change in length of the detrusor muscle cells. Tammela T. **Scand J Urol Nephrol Suppl** 1997;184:19-24 (22 ref.)

Behçet's disease and the neuropathic bladder: urodynamic features: case report and a literature review. Porru D, et al. **Spinal Cord** 1996 May;34(5):305-7 (14 ref.)

Feline urodynamic procedures. Lane IF. **Vet Clin North Am Small Anim Pract** 1996 May; 26(3):423-39 (34 ref.)

[Therapy relevant aspects of anatomy, pathophysiology and diagnosis of urinary incontinence in women] Uher EM, et al. **Acta Med Austriaca** 1996;23(5):152-5 (56 ref.) (Eng. Abstr.) **(Ger)**

UROGASTRONE see **EPIDERMAL GROWTH FACTOR-UROGASTRONE**

UROGASTRONE RECEPTORS see **RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE**

UROGENITAL DISEASES

Diagnosing and managing genitourinary prolapse. Jackson S, et al. **BMJ** 1997 Mar 22;314(7084):875-80 (31 ref.)

Genitourinary medicine and The Internet No. 4. Lau RK. **Genitourin Med** 1997 Feb;73(1):73-4 (0 ref.)

[Genitourinary malacoplakia] Cambronero Santos J, et al. **Actas Urol Esp** 1997 Feb;21(2):140-9 (42 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Limitations of serodiagnosis in chlamydial genital tract infections. Ngeow YF. **Ann Acad Med Singapore** 1996 Mar; 25(2):300-4 (38 ref.)

Direct hybridization and amplification applications for the diagnosis of infectious diseases. Wagar EA. **J Clin Lab Anal** 1996;10(6):312-25 (72 ref.)

[MRI in urology] Kutschker C, et al. **Rontgenpraxis** 1997 May;50(5):110-4 (18 ref.) **(Ger)**

[Somatoform disorders in urology] Csef H. **Urologe A** 1997 Jan;36(1):87-99; quiz 97-8 (9 ref.) **(Ger)**

DRUG THERAPY

Rational prescribing for postmenopausal urogenital complaints. Milsom I. **Drugs Aging** 1996 Aug;9(2):78-86 (59 ref.)

ETIOLOGY

Two genitourinary manifestations of Wegener's granulomatosis. Stone JH, et al. **J Rheumatol** 1997 Sep; 24(9):1846-8 (9 ref.)

MICROBIOLOGY

Models of mycoplasma respiratory and genital tract infections. Brunner H. **Wien Klin Wochenschr** 1997 Aug 8;109(14-15):569-73 (30 ref.)

Genital mycoplasma infections. Taylor-Robinson D, et al. **Wien Klin Wochenschr** 1997 Aug 8;109(14-15):578-83 (44 ref.)

REHABILITATION

[Implants in urology] Huschke T, et al. **Z Arztl Fortbild (Jena)** 1997 Jan;90(8):725-31 (0 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Laparoscopy in pediatric urology: too much of a good thing? Colodny AH. **Semin Pediatr Surg** 1996 Feb;5(1):23-9 (61 ref.)

Laparoscopy in pediatric urology: challenge and opportunity. Peters CA. **Semin Pediatr Surg** 1996 Feb;5(1):16-22 (39 ref.)

Genitourinary reconstructive surgery utilizing laser tissue welding [published erratum appears in Tech Urol 1995 Winter;1(4):227] Uzzo RG, et al. **Tech Urol** 1995 Summer; 1(2):55-61 (41 ref.)

[Surgical treatment of genitourinary prolapse by the abdominal approach. Apropos of a series of 232 cases] Deval B, et al. **Ann Chir** 1997;51(3):256-65 (36 ref.) (Eng. Abstr.) **(Fre)**

[Limitations of laparoscopic management of pelvic static disorders in gynecology] Mage G, et al. **Presse Med** 1996 Dec 21;25(40):2037-41 (30 ref.) (Eng. Abstr.) **(Fre)**

[Anesthesiologic preparation for urologic operations. II: Procedure in concomitant diseases] Wilhelm W, et al. **Urologe A** 1996 Nov;35(6):497-510 (10 ref.) **(Ger)**

VIROLOGY

Cellular immunity in cutaneous and genital HPV infections. Malejczyk J, et al. **Clin Dermatol** 1997 Mar-Apr; 15(2):261-74 (131 ref.)

Viral genitourinary tract infections--distinctive features and clinical implications. Ohlemeyer CL, et al. **Pediatr Ann** 1996 Oct;25(10):561, 564-70 (26 ref.)

UROGENITAL NEOPLASMS

Pediatric genitourinary tumors. Angell SK, et al. **Curr Opin Oncol** 1996 May;8(3):240-6 (42 ref.)

Plexiform neurofibroma involving the genitourinary tract in children: case reports and review of the literature. Nguyen HT, et al. **Urology** 1997 Feb;49(2):257-60 (21 ref.)

[Significance of prognostic factors in urologic oncology] Radošević-Jelić L, et al. **Vojnosanit Pregl** 1997 May-Jun; 54(3):233-6 (25 ref.) **(Scr)**

BLOOD SUPPLY

Intratumoral vascularity as a prognostic factor in cancers of the urogenital tract. Weidner N. **Eur J Cancer** 1996 Dec; 32A(14):2506-12 (34 ref.)

DIAGNOSIS

[MRI in urology] Kutschker C, et al. **Rontgenpraxis** 1997 May;50(5):110-4 (18 ref.) **(Ger)**

GENETICS

[Familial forms of cancer of the urogenital tract: clinical and genetic features] Fournier G, et al. **Prog Urol** 1996 Jun; 6(3):343-55 (120 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

New pathologic techniques for diagnosing genitourinary malignancies. Wojno KJ. **Cancer Treat Res** 1996;88:41-75 (173 ref.)

Adult genitourinary sarcomas: a report of seventeen cases and review of the literature. Berkmen F, et al. **J Exp Clin Cancer Res** 1997 Mar;16(1):45-8 (20 ref.)

Urogenital involvement by desmoplastic small round-cell tumor. Furman J, et al. **J Urol** 1997 Oct;158(4):1506-9 (19 ref.)

PHYSIOPATHOLOGY

Cellular adhesion molecules in urologic malignancies. Cohen MB, et al. **Am J Clin Pathol** 1997 Jan;107(1):56-63 (107 ref.)

The role of the cell cycle in genitourinary carcinoma. McGarvey TW, et al. **World J Urol** 1996;14(5):310-7 (101 ref.)

SURGERY

Genitourinary tract cancer in childhood. La Quaglia MP. **Semin Pediatr Surg** 1996 Feb;5(1):49-65 (79 ref.)

THERAPY

Assessing health-related quality of life in patients with genitourinary malignancies. Litwin MS. **Cancer Treat Res** 1996;88:249-64 (94 ref.)

Pediatric genitourinary tumors. Agarwal SK, et al. **Curr Opin Oncol** 1997 May;9(3):307-12 (46 ref.)

UROGENITAL SYSTEM

see related
UROGRAPHY

ABNORMALITIES

Further arguments for non-fortuitous association of Potter sequence with XYY males. Rudnik-Schöneborn S, et al. **Ann Genet** 1996;39(1):43-6 (12 ref.)

INJURIES

Damage control for urologic injuries. Coburn M. **Surg Clin North Am** 1997 Aug;77(4):821-34 (16 ref.)

[Genito-urinary injuries. Sequelae. Medico-legal aspects] Aubert J, et al. **Chirurgie** 1996;121(5):377-80 (36 ref.) (Eng. Abstr.) **(Fre)**

[Perineal injuries in complicated pelvic trauma] David A, et al. **Swiss Surg** 1996;(1):4-9 (35 ref.) (Eng. Abstr.) **(Ger)**

INNERVATION

Electromyogram, evoked sensory and motor potentials in neurourology. Vodušek DB. **Neurophysiol Clin** 1997 Jun; 27(3):204-10 (22 ref.)

MICROBIOLOGY

[The interrelations of mucosal epithelial cells with microbes--intracellular parasites] Domaradskiĭ IV, et al. **Med Parazitol (Mosk)** 1996 Oct-Dec;(4):3-8 (53 ref.) (Eng. Abstr.) **(Rus)**

PATHOLOGY

Percutaneous biopsy. Cronan JJ. **Radiol Clin North Am** 1996 Nov;34(6):1207-23 (43 ref.)

PHYSIOLOGY

Urogenital effects of the menopause. Schaffer J, et al. **Baillieres Clin Obstet Gynaecol** 1996 Sep;10(3):401-17 (69 ref.)

UROGRAPHY

MR urography. Hussain S, et al. **Magn Reson Imaging Clin N Am** 1997 Feb;5(1):95-106 (22 ref.)

Urography into the 21st century: new contrast media, renal handling, imaging characteristics, and nephrotoxicity. Katzberg RW. **Radiology** 1997 Aug;204(2):297-312 (163 ref.)

Pediatric uroradiology update. Auringer ST. **Urol Clin North Am** 1997 Aug;24(3):673-81 (28 ref.)

Iodinated contrast material in uroradiology. Choice of agent and management of complications. Cohan RH, et al. **Urol Clin North Am** 1997 Aug;24(3):471-91 (110 ref.)

METHODS

Urologic applications of multiplanar and three-dimensional computed tomography. Olson MC, et al. **Tech Urol** 1995 Fall;1(3):141-9 (8 ref.)

[Present day radiation diagnosis of renal tumors and cysts] Vlasov PV, et al. **Vestn Rentgenol Radiol** 1997 May-Jun; (3):35-47 (62 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

Excretory urography before prostatectomy. Ntia IO, et al. **Afr J Med Med Sci** 1996 Mar;25(1):75-9 (11 ref.)

UROKINASE

ADMINISTRATION & DOSAGE

[Ultrahigh-dosage urokinase lysis during pulmonary embolism prophylaxis by means of an extractable caval filter] Neuerburg J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Nov;165(5):510-3 (16 ref.) **(Ger)**

[Chronic intermittent urokinase therapy: anti-ischemic and hemodynamic effects] Leschke M, et al. **Z Kardiol** 1997; 86 Suppl 1:85-94 (45 ref.) (Eng. Abstr.) **(Ger)**

[Atherosclerosis obliterance; thrombolytic therapy] Terada M, et al. **Nippon Geka Gakkai Zasshi** 1996 Jul;97(7):540-4 (14 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop. Benraad TJ, et al. **Eur J Cancer** 1996 Jul; 32A(8):1371-81 (28 ref.)

The plasminogen activation system in tumour invasion and metastasis. de Vries TJ, et al. **Pathol Res Pract** 1996 Jul; 192(7):718-33 (242 ref.)

METABOLISM

Tumor-associated urokinase-type plasminogen activator: significance in breast cancer. Torre EA, et al. **Eur J Gynaecol Oncol** 1996;17(4):315-8 (63 ref.)

Urokinase-type plasminogen activator and its receptor in bladder cancer [editorial; comment] Hasui Y, et al. **J Natl Cancer Inst** 1997 May 21;89(10):678-9 (19 ref.) Comment on: J Natl Cancer Inst 1997 May 21;89(10):709-17.

The urokinase receptor and cell migration. Blasi F. **Semin Thromb Hemost** 1996;22(6):513-6 (36 ref.)

Endocrine and paracrine regulation of cumulus expansion. Salustri A, et al. **Zygote** 1996 Nov;4(4):313-5 (13 ref.)

[Autocrine-generated matrix metalloproteinases of tumor cells and the cascade network of protease activation mediated by membrane associated urokinase-type plasminogen activator: involvement in the degradation of extracellular matrices] Takahashi K. **Rinsho Byori** 1997 Feb;Suppl 104:159-69 (28 ref.) **(Jpn)**

PHYSIOLOGY

Regulation and role of urokinase plasminogen activator in vascular remodelling. Tkachuk V, et al. **Clin Exp Pharmacol Physiol** 1996 Sep;23(9):759-65 (75 ref.)

uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Blasi F. **Immunol Today** 1997 Sep;18(9):415-7 (24 ref.)

The urokinase-type plasminogen activator system in cancer metastasis: a review. Andreasen PA, et al. **Int J Cancer** 1997 Jul 3;72(1):1-22 (325 ref.)

Endothelium in hemostasis and thrombosis. Lijnen HR, et al. **Prog Cardiovasc Dis** 1997 Jan-Feb;39(4):343-50 (54 ref.)

The urokinase receptor and cell migration. Blasi F. **Semin Thromb Hemost** 1996;22(6):513-6 (36 ref.)

[Regulation of tissue-associated fibrinolysis by retinoids: mechanism and consequence of retinoid-PA-TGF-beta system] Kojima S. **Seikagaku** 1997 Feb;69(2):104-8 (14 ref.) **(Jpn)**

THERAPEUTIC USE

Low-dose intermittent urokinase therapy in chronic symptomatic end-stage arterial disease--clinical relevance for patients with coronary artery disease or peripheral arterial occlusive disease. Leschke M, et al. **Clin Hemorheol Microcirc** 1997 Jan-Feb;17(1):59-66 (51 ref.)

Use of urokinase in unstable angina. Duvvuri S, et al. **Coron Artery Dis** 1996 Sep;7(9):630-6 (51 ref.)

Urokinase recanalization of chronically occluded aortocoronary vein grafts. Hartmann JR. **Coron Artery Dis** 1996 Sep;7(9):641-8 (32 ref.)

Antithrombotic treatment in stable coronary syndromes: long-term intermittent urokinase therapy in end-stage coronary artery disease and refractory angina pectoris. Schoebel FC, et al. **Heart** 1997 Jan;77(1):13-7 (53 ref.)

Thrombolytic therapy for treatment of pulmonary embolism in the postoperative period: case report and review of the literature. Hartmannsgruber MW, et al. **J Clin Anesth** 1996 Dec;8(8):669-74 (41 ref.)

Comparison of streptokinase and urokinase in local thrombolysis of peripheral arterial occlusions for lower limb salvage. Dubé M, et al. **J Vasc Interv Radiol** 1996 Jul-Aug;7(4):587-93 (25 ref.)

Local thrombolytic therapy in deep cerebral venous thrombosis. Smith AG, et al. **Neurology** 1997 Jun; 48(6):1613-9 (37 ref.)

[Bolus thrombolysis in pulmonary embolism. Review of experimental and clinical data] Zonzin P, et al. **Ann Ital Med Int** 1996 Apr-Jun;11(2):132-7 (35 ref.) (Eng. Abstr.) **(Ita)**

UROKINASE-TYPE PLASMINOGEN ACTIVATOR see **UROKINASE**

UROLITHIASIS see **URINARY CALCULI**

UROLOGIC DISEASES

Quality of life and its assessment in urology. Macdonagh R. **Br J Urol** 1996 Oct;78(4):485-96 (87 ref.)

Urogynaecology [editorial] Stanton SL. **Curr Opin Obstet Gynecol** 1996 Oct;8(5):355-6 (11 ref.)

Urologic emergencies. Conditions affecting the kidney, ureter, bladder, prostate, and urethra. Samm BJ, et al. **Postgrad Med** 1996 Oct;100(4):177-80, 183-4 (5 ref.)

[Obstructive uropathy] Kurachi M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):472-9 (29 ref.) **(Jpn)**

[Urologic irrigation solutions are not safe. Serious adverse effects are documented] Hahn R. **Lakartidningen** 1997 Feb 5;94(6):437-8 (32 ref.) **(Swe)**

COMPLICATIONS

[Obstructive pyelonephritis] Orikasa S, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):272-4 (17 ref.) **(Jpn)**

[The disseminated intravascular coagulation syndrome in urological diseases] Lopatkin NA, et al. **Urol Nefrol (Mosk)** 1997 May-Jun;(3):3-8 (49 ref.) (Eng. Abstr.) **(Rus)**

DIAGNOSIS

Imaging in urogynaecology. Khullar V, et al. **Br J Obstet Gynaecol** 1996 Nov;103(11):1061-7 (71 ref.)

MR urography. Hussain S, et al. **Magn Reson Imaging Clin N Am** 1997 Feb;5(1):95-106 (22 ref.)

Urinary obstruction. Platt JF. **Radiol Clin North Am** 1996 Nov;34(6):1113-29 (91 ref.)

Uroradiologic emergencies in infants and children. Zerin JM. **Radiol Clin North Am** 1997 Jul;35(4):897-919 (66 ref.)

ETIOLOGY

Pregnancy and intercurrent diseases of the urogenital tract. Tomezsko JE, et al. **Clin Perinatol** 1997 Jun;24(2):343-68 (67 ref.)

Urological complications of pancreatic transplantation. Hickey DP, et al. **J Urol** 1997 Jun;157(6):2042-8 (81 ref.)

Spine update. Urological management in patients with spinal cord injuries. Nygaard IE, et al. **Spine** 1996 Jan 1; 21(1):128-32 (18 ref.)

MORTALITY

[Prognosis in gynecologic diseases] Kremling H. **Versicherungsmedizin** 1996 Feb 1;48(1):25-7 (29 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

[Nephrogenic metaplasia of the urinary tract] Fournier G. **Prog Urol** 1996 Dec;6(6):861-8 (69 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Corino-Andrade disease (familial amyloidotic polineuropathy type I) in Spain: urological and andrological disorders. Hita Villaplana G, et al. **Neurourol Urodyn** 1997;16(1):55-61 (17 ref.)

RADIOGRAPHY

[Uroangiographic contrast media, today. Elements of interest for the urologist] Alberti C. **Minerva Urol Nefrol** 1997 Mar; 49(1):9-20 (30 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Female adult reconstructive urology. N'Dow J, et al. **Br J Urol** 1997 Jul;80 Suppl 1:69-78 (84 ref.)

Nonvascular stents. Vanderburgh L, et al. **Prog Cardiovasc Dis** 1996 Sep-Oct;39(2):187-200 (75 ref.)

Laparoscopic complications in markedly obese urologic patients (a multi-institutional review). Mendoza D, et al. **Urology** 1996 Oct;48(4):562-7 (30 ref.)

[Pre-anesthesiologic preparation for urologic operations. I: Screening for anesthesia] Wilhelm W, et al. **Urologe A** 1996 Sep;35(5):W427-36 (0 ref.) **(Ger)**

[Urological laparoscopic surgery] Kadyrov ZA. **Urol Nefrol (Mosk)** 1997 Jan-Feb;(1):40-4 (122 ref.) **(Rus)**

THERAPY

Common urologic disorders. When to treat and when to refer. Gottesman J, et al. **Postgrad Med** 1997 Aug; 102(2):235-40, 243, 246 (18 ref.)

Spine update. Urological management in patients with spinal cord injuries. Nygaard IE, et al. **Spine** 1996 Jan 1; 21(1):128-32 (18 ref.)

[Hyperbaric oxygenation in uronephrology] Zadoev SA, et al. **Urol Nefrol (Mosk)** 1997 May-Jun;(3):52-5 (70 ref.) **(Rus)**

ULTRASONOGRAPHY

[Relationship between prenatal and postnatal echographic diagnosis of uropathy: is mass screening useful?] Cacciari A, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):13-7 (27 ref.) (Eng. Abstr.) **(Ita)**

URINE

Use of urinary beta-2-microglobulin to predict severe renal damage in fetal obstructive uropathy. Freedman AL, et al. **Fetal Diagn Ther** 1997 Jan-Feb;12(1):1-6 (29 ref.)

VETERINARY

Management of nonobstructive idiopathic feline lower urinary tract disease. Kruger JM, et al. **Vet Clin North Am Small Anim Pract** 1996 May; 26(3):571-88 (65 ref.)

Pharmacologic management of feline lower urinary tract disorders. Lane IF. **Vet Clin North Am Small Anim Pract** 1996 May; 26(3):515-33 (64 ref.)

Feline perineal urethrostomy: a potential cause of feline lower urinary tract disease. Osborne CA, et al. **Vet Clin North Am Small Anim Pract** 1996 May; 26(3):535-49 (23 ref.)

Treatment of feline lower urinary tract disease by debriding the bladder mucosa: first do no harm. Osborne CA, et al. **Vet Clin North Am Small Anim Pract** 1996 May; 26(3):639-42 (6 ref.)

Management of feline lower urinary tract disease by homeopathy. Osborne CA. **Vet Clin North Am Small Anim Pract** 1996 May; 26(3):643-50 (10 ref.)

UROLOGIC NEOPLASMS

Management of urological tumours in pregnancy. Hendry WF. **Br J Urol** 1997 Jul;80 Suppl 1:24–8 (40 ref.)

BLOOD SUPPLY

[Angiogenesis--principles and significance in urologic tumors] Strohmeyer D, et al. **Urologe A** 1996 Sep; 35(5):357–62 (54 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

[Multidrug resistance] Mickisch GH. **Urologe A** 1996 Sep; 35(5):370–7 (8 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

Economics of urinary tract cancers: state of the art. Neymark N, et al. **Eur Urol** 1997;31 Suppl 1:72–81 (13 ref.)

GENETICS

The relevance of p53 mutation in urological malignancies: possible clinical implications for bladder cancer. Nouri AM, et al. **Br J Urol** 1996 Sep;78(3):337–44 (53 ref.)

[Multidrug resistance] Mickisch GH. **Urologe A** 1996 Sep; 35(5):370–7 (8 ref.) (Eng. Abstr.) **(Ger)**

[Basic principles of gene therapy] Vieweg J. **Urologe A** 1996 Sep;35(5):378–89 (64 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

The prognostic value of a primary inverted papilloma of the urinary tract. Witjes JA, et al. **J Urol** 1997 Oct; 158(4):1500–5 (84 ref.)

PHYSIOPATHOLOGY

The E-cadherin cell-cell adhesion pathway in urologic malignancies. Morton RA Jr, et al. **World J Urol** 1995; 13(6):364–8 (52 ref.)

[Adhesion molecules in urologic tumors] Heicappell R. **Urologe A** 1996 Sep;35(5):363–9 (75 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Quality of life as an outcome measure in cancer clinical trials. Kiebert GM. **Eur Urol** 1997;31 Suppl 1:56–64 (21 ref.)

RADIONUCLIDE IMAGING

Possible role of FDG-PET in the evaluation of urologic malignancies. Bender H, et al. **Anticancer Res** 1997 May-Jun;17(3B):1655–60 (28 ref.)

SURGERY

Surgical palliation of incurable urologic cancer. Alagiri M, et al. **Curr Probl Cancer** 1995 Nov-Dec;19(6):360–71 (55 ref.)

Percutaneous treatment of transitional cell carcinoma of the upper urinary tract. Okada H, et al. **Int J Urol** 1997 Mar; 4(2):130–3 (15 ref.)

THERAPY

The role of immunotherapy for urological tumours. Hrouda D, et al. **Br J Urol** 1997 Mar;79(3):307–16 (100 ref.)

The role of immunotherapy in urologic malignancies. Abubakr YA, et al. **Cancer Treat Res** 1996;88:235–48 (86 ref.)

[Basic principles of gene therapy] Vieweg J. **Urologe A** 1996 Sep;35(5):378–89 (64 ref.) (Eng. Abstr.) **(Ger)**

[Intrarenal bacillus Calmette-Guerin therapy for carcinoma in situ of the upper urinary tract] Okubo K, et al. **Nippon Hinyokika Gakkai Zasshi** 1997 Mar;88(3):386–90 (12 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

[Echographic diagnosis of nephro-urological neoplasia in a pediatric nephrology center] Giordano M, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):133–7 (7 ref.) (Eng. Abstr.) **(Ita)**

UROLOGY

see related

UROLOGIC DISEASES

What is the right operation for stress incontinence? A urologist's view. Evans C. **Br J Urol** 1997 Jul;80 Suppl 1:88–90 (12 ref.)

The Internet for British urologists? [see comments] Lyth DR, et al. **Br J Urol** 1996 Nov;78(5):677–9; discussion 679–80 (10 ref.) Comment in: Br J Urol 1997 Jul;80(1):191–2.

METHODS

Cellular and molecular biology in urogynaecology. Blakeman P, et al. **Curr Opin Obstet Gynecol** 1996 Oct;8(5):357–60 (37 ref.)

Urogynaecology [editorial] Stanton SL. **Curr Opin Obstet Gynecol** 1996 Oct;8(5):355–6 (11 ref.)

Consensus workshop on advanced diagnostic andrology techniques. ESHRE (European Society of Human Reproduction and Embryology) Andrology Special Interest Group. **Hum Reprod** 1996 Jul;11(7):1463–79 (117 ref.)

Consensus workshop on advanced diagnostic andrology techniques [letter] Comhaire F. **Hum Reprod** 1997 Apr; 12(4):872 (2 ref.)

New approaches in the treatment of metastatic transitional-cell cancer of the bladder. Corral DA, et al. **World J Urol** 1997;15(2):139–43 (28 ref.)

Applications of telomerase in urologic oncology. Landman J, et al. **World J Urol** 1997;15(2):120–4 (39 ref.)

ORGANIZATION & ADMINISTRATION

Managed care in reconstructive pelvic surgery and urogynecology. Strohbehn K. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):319–24 (27 ref.)

TRENDS

Approaching the next millennium: how should we manage andrology diagnosis in the intracytoplasmic sperm injection era? [editorial] Oehninger S, et al. **Fertil Steril** 1997 Mar; 67(3):434–6 (15 ref.)

Recent concepts in the management of male infertility. Namiki M. **Int J Urol** 1996 Jul;3(4):249–55 (104 ref.)

Computational tools for the modern andrologist. Niederberger C. **J Androl** 1996 Sep-Oct;17(5):462–6 (16 ref.)

Progress in urodynamic research on the upper urinary tract: implications for practical urology [editorial] Kinn AC. **Urol Res** 1996;24(1):1–7 (39 ref.)

Current concepts in the role of intravesical instillations in the therapy and prophylaxis of superficial transitional-cell cancer of the bladder. The Finnbladder Research Group. Alfthan O, et al. **World J Urol** 1997;15(2):89–95 (64 ref.)

UROTHELIUM

Human papillomavirus and bladder cancer. Lopez-Beltran A, et al. **Biomed Pharmacother** 1997;51(6-7):252–7 (34 ref.)

CYTOLOGY

Formation of asymmetric unit membrane during urothelial differentiation. Sun TT, et al. **Mol Biol Rep** 1996;23(1):3–11 (43 ref.)

PATHOLOGY

Pathologic prognostic parameters in bladder urothelial biopsy, transurethral resection, and cystectomy specimens. Lapham RL, et al. **Semin Diagn Pathol** 1997 May; 14(2):109–22 (110 ref.)

PHYSIOPATHOLOGY

The role of the epithelial cell in Escherichia coli induced neutrophil migration into the urinary tract. Agace WW. **Eur Respir J** 1996 Aug;9(8):1713–28 (161 ref.)

URSODEOXYCHOLIC ACID

ADMINISTRATION & DOSAGE

[New gastroenterological prospects of ursodeoxycholic acid] Sheptulin AA. **Klin Med (Mosk)** 1996;74(4):8–10 (38 ref.) **(Rus)**

PHARMACOLOGY

[Mechanism of action of ursodeoxycholic acid in cholestatic liver diseases] Lévy S, et al. **Gastroenterol Clin Biol** 1996; 20(6-7):549–59 (130 ref.) **(Fre)**

[Bile acids and immune regulation] Tanaka H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Oct;93(10):693–9 (49 ref.) **(Jpn)**

THERAPEUTIC USE

Ursodeoxycholic acid therapy in primary biliary cirrhosis. Podda M, et al. **Ital J Gastroenterol** 1996 Feb-Mar; 28(2):114–7 (21 ref.)

Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid. Balistreri WF. **J Pediatr Gastroenterol Nutr** 1997 May;24(5):573–89 (184 ref.)

Ursodeoxycholic acid in cystic fibrosis-related liver disease: a systematic review. Cheng K, et al. **J R Soc Med** 1997; 90 Suppl 31:6–12 (32 ref.)

Pharmacological treatment of cholestasis. Alvaro D. **Methods Find Exp Clin Pharmacol** 1996;18 Suppl B:47–51 (42 ref.)

Ursodeoxycholic acid in the treatment of liver diseases. Saksena S, et al. **Postgrad Med J** 1997 Feb;73(856):75–80 (78 ref.)

The use of methotrexate, colchicine, and other immunomodulatory drugs in the treatment of primary biliary cirrhosis. Kaplan MM. **Semin Liver Dis** 1997 May; 17(2):129–36 (57 ref.)

[Use of ursodeoxycholic acid in treatment of chronic hepatitis C] Warunek W, et al. **Folia Med Cracov** 1996; 37(1-2):97–100 (17 ref.) (Eng. Abstr.) **(Pol)**

URTICARIA

Urticaria and angioedema. Beltrani VS. **Dermatol Clin** 1996 Jan;14(1):171–198 (148 ref.)

Histamine: the quintessential mediator. Greaves MW, et al. **J Dermatol** 1996 Nov;23(11):735–40 (43 ref.)

Physical urticaria: a common misdiagnosis [see comments] Scott CB, et al. **Nurse Pract** 1996 Nov;21(11):42–6, 49–54 passim; quiz 59–61 (42 ref.) Comment in: Nurse Pract 1997 Mar;22(3):11; discussion 11, 14.

[Urticaria] Guerrero Núñez GB. **Rev Alerg Mex** 1997 Jan-Feb;44(1):17–22 (25 ref.) (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

Contact urticaria syndrome: 1997. Amin S, et al. **Am J Contact Dermat** 1997 Mar;8(1):15–9 (17 ref.)

Sensitivity reaction to parenteral vitamin B12: recurrence of symptoms after Marmite ingestion [letter] Denis R, et al. **Clin Lab Haematol** 1996 Jun;18(2):129–31 (11 ref.)

Angiooedema and urticaria with angiotensin converting enzyme inhibitors. Pillans PI, et al. **Eur J Clin Pharmacol** 1996;51(2):123–6 (14 ref.)

CLASSIFICATION

Urticaria. Evaluation and treatment. Condemi JJ. **Pol Arch Med Wewn** 1997;97 Spec No:3–6 (12 ref.)

Urticaria, angioedema, and rheumatologic disease. Kulp-Shorten CL, et al. **Rheum Dis Clin North Am** 1996 Feb;22(1):95–115 (74 ref.)

COMPLICATIONS

Schnitzler's syndrome: report of a new case and a review of the literature. Puddu P, et al. **Clin Exp Rheumatol** 1997 Jan-Feb;15(1):91–5 (32 ref.)

Urticaria, angioedema, and rheumatologic disease. Kulp-Shorten CL, et al. **Rheum Dis Clin North Am** 1996 Feb;22(1):95–115 (74 ref.)

DIAGNOSIS

Consensus meeting on the definition of physical urticarias and urticarial vasculitis. Black AK, et al. **Clin Exp Dermatol** 1996 Nov;21(6):424–6 (16 ref.)

DRUG THERAPY

Pharmacologic therapy for urticaria. Negro-Alvarez JM, et al. **Allergol Immunopathol (Madr)** 1997 Jan-Feb;25(1):36–51 (220 ref.)

Loratadine in the treatment of urticaria. Monroe EW. **Clin Ther** 1997 Mar-Apr;19(2):232–42 (60 ref.)

Safety and efficacy of loratadine in urticaria. Monroe EW. **Int J Dermatol** 1996 Dec;35(12):837–41 (35 ref.)

Chronic urticaria: pathophysiology and treatment approaches. Tharp MD. **J Allergy Clin Immunol** 1996 Dec; 98(6 Pt 3):S325–30 (45 ref.)

ETIOLOGY

Coincident cold urticaria in a married couple: case report and a literature review. Leong KP, et al. **Ann Acad Med Singapore** 1997 Mar;26(2):221–4 (27 ref.)

Update in allergy and immunology. Condemi JJ. **Ann Intern Med** 1996 Nov 1;125(9):744–50 (2 ref.)

The pathogenesis of chronic idiopathic urticaria. Sabroe RA, et al. **Arch Dermatol** 1997 Aug;133(8):1003–8 (107 ref.)

Agents causing contact urticaria. Warner MR, et al. **Clin Dermatol** 1997 Jul-Aug;15(4):623–35 (82 ref.)

The pathogenesis of urticaria. Black AK. **Keio J Med** 1997 Mar;46(1):37–9 (14 ref.)

Exercise-induced urticaria and anaphylaxis. Volcheck GW, et al. **Mayo Clin Proc** 1997 Feb;72(2):140–7 (32 ref.)

Papular urticaria in children. Howard R, et al. **Pediatr Dermatol** 1996 May-Jun;13(3):246–9 (15 ref.)

PHYSIOPATHOLOGY

Chronic urticaria: pathophysiology and treatment approaches. Tharp MD. **J Allergy Clin Immunol** 1996 Dec; 98(6 Pt 3):S325–30 (45 ref.)

THERAPY

Urticaria. Evaluation and treatment. Condemi JJ. **Pol Arch Med Wewn** 1997;97 Spec No:3–6 (12 ref.)

Urticaria: a rational GP approach. Blow C. **Practitioner** 1997 Feb;241(1571):80–2, 85 (0 ref.)

URTICARIA, GIANT see **ANGIONEUROTIC EDEMA**

URTICARIA PIGMENTOSA

COMPLICATIONS

Urticaria pigmentosa and juvenile xanthogranuloma: case report and brief review of the literature. Mann RE, et al. **Pediatr Dermatol** 1996 Mar-Apr;13(2):122–6 (32 ref.)

PATHOLOGY

Urticaria pigmentosa. Allison MA, et al. **Int J Dermatol** 1997 May;36(5):321–5 (27 ref.)

THERAPY

Urticaria pigmentosa. Allison MA, et al. **Int J Dermatol** 1997 May;36(5):321–5 (27 ref.)

USER-COMPUTER INTERFACE

Virtual reality, disability and rehabilitation. Wilson PN, et al. **Disabil Rehabil** 1997 Jun;19(6):213–20 (58 ref.)

A review of the technical and clinical aspects of virtual endoscopy. Kay CL, et al. **Endoscopy** 1996 Nov; 28(9):768–75 (25 ref.)

Computed tomographic colography and virtual colonoscopy. Ahlquist DA, et al. **Gastrointest Endosc Clin N Am** 1997 Jul;7(3):439–52 (47 ref.)

Automatic visual to tactile translation—Part I: Human factors, access methods, and image manipulation. Way TP, et al. **IEEE Trans Rehabil Eng** 1997 Mar;5(1):81–94 (90 ref.)

The World Wide Web: a review of an emerging internet-based technology for the distribution of biomedical information. Lowe HJ, et al.
J Am Med Inform Assoc 1996 Jan–Feb;3(1):1–14 (82 ref.)

The barriers to electronic medical record systems and how to overcome them. McDonald CJ.
J Am Med Inform Assoc 1997 May–Jun;4(3):213–21 (32 ref.)

Intracranial aneurysm: inner view and neck identification with CT angiography virtual endoscopy. Marro B, et al.
J Comput Assist Tomogr 1997 Jul–Aug;21(4):587–9 (9 ref.)

USTILAGO

GENETICS

Genetics of Ustilago maydis, a fungal pathogen that induces tumors in maize. Banuett F. **Annu Rev Genet** 1995; 29:179–208 (111 ref.)

UTERINE CONTRACTION

see related
CARDIOTOCOGRAPHY
LABOR, PREMATURE
OXYTOCICS
TOCOLYTIC AGENTS
UTERINE MONITORING

ACOG committee opinion. Home uterine activity monitoring. Number 172, May 1996 (replaces number 115, September 1992). Committee on Obstetric Practice. American College of Obstetricians and Gynecologists.
Int J Gynaecol Obstet 1996 Jul;54(1):71–7 (32 ref.)

DRUG EFFECTS

Mechanisms of drugs that affect uterine motility. Sultatos LG. **J Nurse Midwifery** 1997 Jul–Aug;42(4):367–70 (13 ref.)

Oxytocin and its receptor in pregnancy and parturition: current concepts and clinical implications. Zeeman GG, et al. **Obstet Gynecol** 1997 May;89(5 Pt 2):873–83 (107 ref.)

Nitric oxide and the myometrium. Norman J.
Pharmacol Ther 1996;70(2):91–100 (70 ref.)

The effect of cocaine on myometrial contractile activity: basic mechanisms. Monga M. **Semin Perinatol** 1996 Apr; 20(2):140–6 (45 ref.)

PHYSIOLOGY

Intrapartum assessment of uterine activity. Vanner T, et al. **Baillieres Clin Obstet Gynaecol** 1996 Jun;10(2):243–57 (52 ref.)

[Uterine activity and premature delivery. Review of the literature] Vercoustre L.
J Gynecol Obstet Biol Reprod (Paris) 1997;26(2):131–6 (30 ref.) (Eng. Abstr.) **(Fre)**

UTERINE DISEASES

CHEMICALLY INDUCED

Tamoxifen and the uterus: an old drug tested by new modalities. Achiron R, et al. **Ultrasound Obstet Gynecol** 1996 May;7(5):374–8 (35 ref.)

COMPLICATIONS

[Uterine adenomyosis. Renaissance of a disease] Mergui JL, et al. **Contracept Fertil Sex** 1997 Feb;25(2):105–11 (69 ref.) **(Fre)**

DIAGNOSIS

Uterine sacculation: myth, reality or rarity—a case report. Adu SA. **Cent Afr J Med** 1996 Jul;42(7):211–5 (16 ref.)

Hysteroscopy or ultrasound? al-Azzawi F.
Curr Opin Obstet Gynecol 1996 Aug;8(4):246–9 (21 ref.)

Spontaneous perforated pyometra presenting as pneumoperitoneum. Ikematsu Y, et al.
Gynecol Obstet Invest 1996;42(4):274–6 (11 ref.)

[Uterine and tubal-peritoneal factors in infertility: comparison of radiologic and endoscopic techniques] Valentini AL, et al. **Radiol Med (Torino)** 1996 Nov; 92(5):514–9 (43 ref.) **(Ita)**

EPIDEMIOLOGY

Puerperal inversion of the uterus in Nepal: case reports and review of literature. Dali SM, et al.
J Obstet Gynaecol Res 1997 Jun;23(3):319–25 (44 ref.)

ETIOLOGY

'Menouria'—a presentation of vesicouterine fistula. Bhutta SZ. **JPMA J Pak Med Assoc** 1996 Jul;46(7):159–61 (20 ref.)

[Uterine arteriovenous malformations, Review of the literature] Noguera-Sánchez MF, et al.
Ginecol Obstet Mex 1997 Jun;65:258–61 (25 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Endometrial biopsy. Shelly MS. **Am Fam Physician** 1997 Apr; 55(5):1731–6 (38 ref.)

Giant cell arteritis of the uterus: case report and review. Ormsby AH, et al. **Pathology** 1997 May;29(2):227–30 (48 ref.)

Office procedures. Endometrial biopsy. Apgar BS, et al.
Prim Care 1997 Jun;24(2):303–26 (61 ref.)

SURGERY

Hysterectomy: indications, alternatives and predictors [see comments] [published erratum appears in Am Fam Physician 1997 Apr;55(5):1586] Kramer MG, et al.
Am Fam Physician 1997 Feb 15;55(3):827–34 (33 ref.)
Comment in: Am Fam Physician 1997 Feb 15;55(3):774–6.

Indications and alternatives to hysterectomy. Davies A, et al. **Baillieres Clin Obstet Gynaecol** 1997 Mar;11(1):61–75 (96 ref.)

Use of adhesion prevention barriers in ovarian surgery, tubalplasty, ectopic pregnancy, endometriosis, adhesiolysis, and myomectomy. diZerega GS.
Curr Opin Obstet Gynecol 1996 Jun;8(3):230–7 (32 ref.)

Possibilities and limits of operative hysteroscopy: an update on transcervical resectoscopic uterine surgery. Brandner P, et al. **Int Surg** 1996 Jul–Sep;81(3):259–65 (66 ref.)

Which route for hysterectomy? Evidence-based outcomes guide selection. Kovac SR. **Postgrad Med** 1997 Sep; 102(3):153–8 (16 ref.)

[Hysteroscopic treatment of uterine synechias. A report of 102 cases] Rogé P, et al.
J Gynecol Obstet Biol Reprod (Paris) 1996;25(1):33–40 (22 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Endometriosis: medical and surgical intervention. Falcone T, et al. **Curr Opin Obstet Gynecol** 1996 Jun;8(3):178–83 (40 ref.)

[Uterine adenomyosis. The death of a disease!] Belaisch J, et al. **Contracept Fertil Sex** 1997 Feb;25(2):101–5 (19 ref.) **(Fre)**

ULTRASONOGRAPHY

Hysteroscopy or ultrasound? al-Azzawi F.
Curr Opin Obstet Gynecol 1996 Aug;8(4):246–9 (21 ref.)

Ultrasound in gynecology: endometrium. Bourne T, et al.
Int J Gynaecol Obstet 1997 Feb;56(2):115–27 (61 ref.)

Late prenatal ultrasound features of hydrometrocolpos secondary to cloacal anomaly: case reports and review of the literature. Odibo AO, et al.
Ultrasound Obstet Gynecol 1997 Jun;9(6):419–21 (6 ref.)

Three-dimensional saline contrast hysterosonography and surface rendering of uterine cavity pathology. Weinraub Z, et al. **Ultrasound Obstet Gynecol** 1996 Oct;8(4):277–82 (16 ref.)

VETERINARY

Uterine health and disorders. Lewis GS. **J Dairy Sci** 1997 May;80(5):984–94 (67 ref.)

UTERINE ENDOSCOPY see **HYSTEROSCOPY**

UTERINE HEMORRHAGE

see related
MENORRHAGIA
METRORRHAGIA

Dysfunctional uterine bleeding. Deligeoroglou E.
Ann N Y Acad Sci 1997 Jun 17;816:158–64 (28 ref.)

Dysfunctional uterine bleeding in adolescents. Lavin C.
Curr Opin Pediatr 1996 Aug;8(4):328–32 (26 ref.)

Future directions for research on endometrial bleeding. Findlay JK. **Hum Reprod** 1996 Oct;11 Suppl 2:179–83 (6 ref.)

CHEMICALLY INDUCED

The uterus and the menopause. Rees MC.
Baillieres Clin Obstet Gynaecol 1996 Sep;10(3):419–32 (69 ref.)

Progestogen-only pills and bleeding disturbances. Kovacs G. **Hum Reprod** 1996 Oct;11 Suppl 2:20–3 (22 ref.)

DIAGNOSIS

Unraveling bleeding problems in midlife women. Dean CL.
Hosp Pract (Off Ed) 1996 Sep 15;31(9):155–60 (7 ref.)

ETIOLOGY

The pathophysiology of bleeding disorders presenting as abnormal uterine bleeding. Ewenstein BM.
Am J Obstet Gynecol 1996 Sep;175(3 Pt 2):770–7 (50 ref.)

Transcatheter arterial embolization for the control of life-threatening pelvic hemorrhage in a patient with locally advanced cervix carcinoma. Lin YC, et al.
Eur J Gynaecol Oncol 1996;17(6):480–3 (12 ref.)

From steroid signals to local regulatory factors involved in endometrial bleeding. Tabibzadeh S, et al.
Eur J Obstet Gynecol Reprod Biol 1996 Dec;70(1):25–7 (34 ref.)

Benign papilloma of the cervix in childhood: immunohistochemical findings and review of the literature. Schmedding A, et al. **Eur J Pediatr** 1997 Apr;156(4):320–2 (18 ref.)

Unraveling bleeding problems in midlife women. Dean CL.
Hosp Pract (Off Ed) 1996 Sep 15;31(9):155–60 (7 ref.)

A comparison of mechanisms underlying disturbances of bleeding caused by spontaneous dysfunctional uterine bleeding or hormonal contraception. Fraser IS, et al.
Hum Reprod 1996 Oct;11 Suppl 2:165–78 (82 ref.)

Leiomyoma-related bleeding: a classic hypothesis updated for the molecular era. Stewart EA, et al.
Hum Reprod Update 1996 Jul–Aug;2(4):295–306 (94 ref.)

Diagnostic options for assessment of postmenopausal bleeding. Good AE. **Mayo Clin Proc** 1997 Apr;72(4):345–9 (13 ref.)

[What role should hysterectomy play in benign uterine lesions?] Cosson M, et al. **Contracept Fertil Sex** 1997 Feb; 25(2):112–9 (42 ref.) (Eng. Abstr.) **(Fre)**

[Ultrasonic diagnosis of placenta percreta. Apropos of a case with hemorrhagic complication] Durand-Réville M, et al.
J Radiol 1997 Apr;78(4):313–6 (10 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

[Dysfunctional endometrial hemorrhage. Contribution of biopsy and curettage] Vacher-Lavenu MC. **Ann Pathol** 1996 Nov;16(5):381–90 (40 ref.) **(Fre)**

PHYSIOPATHOLOGY

Dysmenorrhea and dysfunctional uterine bleeding. Apgar BS.
Prim Care 1997 Mar;24(1):161–78 (69 ref.)

PREVENTION & CONTROL

Management of abnormal bleeding in women receiving hormone replacement therapy. Spencer CP, et al. **BMJ** 1997 Jul 5;315(7099):37–42 (39 ref.)

THERAPY

Management of abnormal uterine bleeding. Chuong CJ, et al. **Am J Obstet Gynecol** 1996 Sep;175(3 Pt 2):787–92 (35 ref.)

Uterine artery embolization: an underused method of controlling pelvic hemorrhage. Vedantham S, et al.
Am J Obstet Gynecol 1997 Apr;176(4):938–48 (49 ref.)

Transcatheter arterial embolization for the control of life-threatening pelvic hemorrhage in a patient with locally advanced cervix carcinoma. Lin YC, et al.
Eur J Gynaecol Oncol 1996;17(6):480–3 (12 ref.)

Endometrial ablation by hysteroscopic instillation of hot saline sclution. Goldrath MH, et al.
J Am Assoc Gynecol Laparosc 1997 Feb;4(2):235–40 (13 ref.)

UTERINE INVERSION see **UTERINE DISEASES**

UTERINE MONITORING

ACOG committee opinion. Home uterine activity monitoring. Number 172, May 1996 (replaces number 115, September 1992). Committee on Obstetric Practice. American College of Obstetricians and Gynecologists.
Int J Gynaecol Obstet 1996 Jul;54(1):71–7 (32 ref.)

UTERINE MUSCLE see **MYOMETRIUM**

UTERINE NEOPLASMS

Malignant rhabdoid tumor of the uterine corpus [letter; comment] Niemann T. **Gynecol Oncol** 1997 Jan;64(1):181–2 (5 ref.) Comment on: Gynecol Oncol 1996 Apr;61(1):142–6.

Chorionic tumors. Berkowitz RS, et al. **N Engl J Med** 1996 Dec 5;335(23):1740–8 (100 ref.)

[Primary malignart lymphoma of corpus uteri] Wu X, et al.
Chung Hua Fu Chan Ko Tsa Chih 1996 Feb;31(2):122–4 (8 ref.) **(Chi)**

[Müllerian mixed tumors. Experience of the Rennes Regional University Hospital] Leveque J, et al. **Chirurgie** 1996; 121(3):198–202 (20 ref.) (Eng. Abstr.) **(Fre)**

BLOOD

Pure alveolar rhabdomyosarcoma of the corpus uteri: description of a case with increased serum level of CA-125. Chiarle R, et al. **Gynecol Oncol** 1997 Aug;66(2):320–3 (19 ref.)

CHEMICALLY INDUCED

Mullerian adenosarcoma of the uterine corpus associated with tamoxifen therapy: a report of six cases and a review of tamoxifen-associated endometrial lesions. Clement PB, et al. **Int J Gynecol Pathol** 1996 Jul;15(3):222–9 (59 ref.)

UTERINE NEOPLASMS

Ovulation induction for infertility is it safe or not? Anderson SM, et al. **S D J Med** 1996 Nov;49(11):419–21 (14 ref.)

CHEMISTRY

Immunohistological detection of estrogen and progesterone receptors in multiple and well differentiated leiomyomatous lung tumors in women with uterine leiomyomas (so–called benign metastasizing leiomyomas). A report on 5 cases. Jautzke G, et al. **Pathol Res Pract** 1996 Mar;192(3):215–23 (77 ref.)

COMPLICATIONS

Leiomyoma–related bleeding: a classic hypothesis updated for the molecular era. Stewart EA, et al.
Hum Reprod Update 1996 Jul–Aug;2(4):295–306 (94 ref.)

Diagnostic options for assessment of postmenopausal bleeding. Good AE. **Mayo Clin Proc** 1997 Apr;72(4):345–9 (13 ref.)

Giant uterine fibromyoma producing secondary polycythemia. Clark CL, et al. **Obstet Gynecol** 1994 Oct; 84(4 Pt 2):722–4 (10 ref.)

Hemangioma of the uterus associated with hereditary hemorrhagic telangiectasia. Shanberge JN.
Obstet Gynecol 1994 Oct;84(4 Pt 2):708–10 (13 ref.)

[Microangiopathic hemolytic anemia associated with uterine sarcoma: report of a case. Review of the literature] Tsatsaris V, et al. **Rev Med Interne** 1996;17(9):749–53 (23 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Female genital tract malignancies during puberty. Uterine and cervical malignancies. Tscherne G.
Ann N Y Acad Sci 1997 Jun 17;816:331–7 (09 ref.)

Uterine myomas in adolescents: case reports and a review of the literature. Fields KR, et al.
J Pediatr Adolesc Gynecol 1996 Nov;9(4):195–8 (14 ref.)

Diagnostic options for assessment of postmenopausal bleeding. Good AE. **Mayo Clin Proc** 1997 Apr;72(4):345–9 (13 ref.)

Complete hydatidiform mole and surviving coexistent twin. Bristow RE, et al. **Obstet Gynecol Surv** 1996 Dec; 51(12):705–9 (33 ref.)

[Determination of cellular DNA content in the diagnosis and prognosis of mesenchymal tumors] Tóth E, et al.
Orv Hetil 1996 Nov 10;137(45):2511–5 (27 ref.) (Eng. Abstr.) **(Hun)**

[Early cancer in the uterus and ovaries] Fujimura M, et al. **Nippon Rinsho** 1996 May;54(5):1400–4 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Kidney involvement in trophoblastic disease (chorionepithelioma)] Timoshenko NI, et al. **Ter Arkh** 1995; 67(12):59–61 (6 ref.) (Eng. Abstr.) **(Rus)**

DRUG THERAPY

GnRH agonists and uterine leiomyomas. Broekmans FJ.
Hum Reprod 1996 Nov;11 Suppl 3:3–25 (145 ref.)

GnRH analogues in the treatment of uterine fibroids. Golan A. **Hum Reprod** 1996 Nov;11 Suppl 3:33–41 (31 ref.)

Blood flow changes in the uterus induced by treatment with GnRH analogues. Shaw RW. **Hum Reprod** 1996 Nov;11 Suppl 3:27–32 (10 ref.)

GnRH agonists before surgery for uterine leiomyomas. A review [see comments] Crosignani PG, et al.
J Reprod Med 1996 Jun;41(6):415–21 (38 ref.) Comment in: J Reprod Med 1997 Apr;42(4):253.

[Methotrexate in gynecologic oncology] Isonishi S, et al. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1896–900 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Etoposide (VP–16) in gynecologic malignancy] Kanazawa K, et al. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1925–8 (11 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

A review of trophoblastic diseases at the medical school of Dicle University. Gül T, et al.
Eur J Obstet Gynecol Reprod Biol 1997 Jul;74(1):37–40 (16 ref.)

Gestational trophoblastic disease. Freedman RS, et al.
Obstet Gynecol Clin North Am 1996 Jun;23(2):545–71 (82 ref.)

ETIOLOGY

[Endocrinological contribution for invasion and metastasis in gynecological cancers] Fujimoto J.
Nippon Sanka Fujinka Gakkai Zasshi 1996 Aug; 48(8):633–43 (30 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Leiomyoma of uterus in a patient with ring chromosome 12: case presentation and literature review. Hajianpour MJ, et al. **Am J Med Genet** 1996 May 17;63(2):335–9 (12 ref.)

Smooth muscle neoplasms of the uterus. Tiltman AJ.
Curr Opin Obstet Gynecol 1997 Feb;9(1):48–51 (26 ref.)

Hydatidiform moles: DNA flow cytometry, image analysis and selected topics in molecular biology. Lage JM, et al. **Histopathology** 1996 Apr;28(4):379–82 (20 ref.)

METABOLISM

[Uterine fibromas and the hormonal pattern: the therapeutic considerations] De Leo V, et al. **Minerva Ginecol** 1996 Dec; 48(12):533–8 (35 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Metastasizing placental site trophoblastic tumor: immunohistochemical and DNA analysis. 2 case reports and a review of the literature. Remadi S, et al.
Arch Gynecol Obstet 1997;259(2):97–103 (24 ref.)

Pure alveolar rhabdomyosarcoma of the corpus uteri: description of a case with increased serum level of CA–125. Chiarle R, et al. **Gynecol Oncol** 1997 Aug;66(2):320–3 (19 ref.)

Lymphangioleiomyomatosis of the uterus simulating high–stage endometrial stromal sarcoma. Longacre TA, et al. **Gynecol Oncol** 1996 Dec;63(3):404–10 (39 ref.)

Hydatidiform moles: DNA flow cytometry, image analysis and selected topics in molecular biology. Lage JM, et al. **Histopathology** 1996 Apr;28(4):379–82 (20 ref.)

Placental site trophoblastic tumour with brief review of literature placental site trophoblastic tumour. Pulimood A, et al. **Indian J Cancer** 1996 Mar;33(1):12–6 (22 ref.)

Malignant müllerian mixed tumor of the uterus with a prominent alpha–fetoprotein–producing component of yolk sac tumor. Shokeir MO, et al. **Mod Pathol** 1996 Jun; 9(6):647–51 (22 ref.)

Regression of uterine low–grade smooth–muscle tumors metastatic to the lung after oophorectomy. Abu–Rustum NR, et al. **Obstet Gynecol** 1997 May;89(5 Pt 2):850–2 (13 ref.)

Gestational trophoblastic disease. Freedman RS, et al.
Obstet Gynecol Clin North Am 1996 Jun;23(2):545–71 (82 ref.)

Uterine sarcoma. Levenback CF, et al.
Obstet Gynecol Clin North Am 1996 Jun;23(2):457–73 (37 ref.)

Immunohistological detection of estrogen and progesterone receptors in multiple and well differentiated leiomyomatous lung tumors in women with uterine leiomyomas (so–called benign metastasizing leiomyomas). A report on 5 cases. Jautzke G, et al. **Pathol Res Pract** 1996 Mar;192(3):215–23 (77 ref.)

Placental teratoma. A case report and review of the literature. Wang L, et al. **Pathol Res Pract** 1995 Dec;191(12):1267–70; discussion 1270 (21 ref.)

A case of female adnexal tumor of probable Wolffian origin: histologically, tumor cells showed three different patterns. Wagatsuma S, et al. **Tohoku J Exp Med** 1997 Mar; 181(3):371–7 (11 ref.)

[Uterine leiomyosarcomas: a surprising pathology. Review of the literature. Six case reports] Durand–Réville M, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(7):710–5 (19 ref.) (Eng. Abstr.) **(Fre)**

[Intravenous leiomyomatosis of uterine origin with cardiac extension. A case report and review of the literature] Tribondeau P, et al.
J Gynecol Obstet Biol Reprod (Paris) 1997;26(2):187–92 (33 ref.) (Eng. Abstr.) **(Fre)**

[The early placental trophoblast. II. Tumorous disorders of trophoblast development] Horn LC, et al.
Zentralbl Gynakol 1996;118(11):591–7 (36 ref.) (Eng. Abstr.) **(Ger)**

[Assessment of myometrial invasion in endometrial cancer by transvaginal ultrasonography] Szabó I, et al.
Orv Hetil 1997 May 25;138(21):1323–7 (23 ref.) (Eng. Abstr.) **(Hun)**

[Endocrinological contribution for invasion and metastasis in gynecological cancers] Fujimoto J.
Nippon Sanka Fujinka Gakkai Zasshi 1996 Aug; 48(8):633–43 (30 ref.) (Eng. Abstr.) **(Jpn)**

[Trophoblastic diseases. Pathological concepts and genuine neoplasias] Bergh C. **Lakartidningen** 1997 Apr 16; 94(16):1499–502 (6 ref.) **(Swe)**

PHYSIOPATHOLOGY

Growth factors and cytokines in uterine leiomyomas. Andersen J. **Semin Reprod Endocrinol** 1996 Aug; 14(3):269–82 (123 ref.)

PREVENTION & CONTROL

[The efficacy of mass screening for uterine cancer] Kuzuya K, et al. **Nippon Rinsho** 1996 May;54(5):1441–6 (20 ref.) (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY

The role of whole–pelvic irradiation in the treatment of early–stage uterine carcinosarcoma. Chi DS, et al.
Gynecol Oncol 1997 Jun;65(3):493–8 (21 ref.)

[Uterine sarcoma treated by surgery and postoperative radiation therapy. Patterns of relapse, prognostic factors and role of radiation therapy] Coquard R, et al.
Bull Cancer 1997 Jun;84(6):625–9 (29 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

Breast cancer metastatic to uterine leiomyoma: a case report. Sugiyama T, et al. **J Obstet Gynaecol** 1995 Aug; 21(4):349–55 (21 ref.)

SURGERY

Myomectomies by endo–uterine resection. Hallez JP.
Curr Opin Obstet Gynecol 1996 Aug;8(4):250–6 (33 ref.)

Endoscopic surgery: yes, but ... [editorial; comment] Magos AL. **Curr Opin Obstet Gynecol** 1996 Aug;8(4):243–5 (19 ref.) Comment on: Curr Opin Obstet Gynecol 1996 Aug;8(4):281–9.

Laparoscopic myomectomy today. Fibroids: management and treatment: the state of the art. Donnez J, et al.
Hum Reprod 1996 Sep;11(9):1837–40 (38 ref.)

The role of laparoscopy in myomectomy. Hasson HM.
Int J Fertil Menopausal Stud 1996 May–Jun;41(3):276–9 (21 ref.)

The "cons" of laparoscopic myomectomy in women who may reproduce in the future. Nezhat C.
Int J Fertil Menopausal Stud 1996 May–Jun;41(3):280–3 (15 ref.)

[Uterine sarcoma treated by surgery and postoperative radiation therapy. Patterns of relapse, prognostic factors and role of radiation therapy] Coquard R, et al.
Bull Cancer 1997 Jun;84(6):625–9 (29 ref.) (Eng. Abstr.) **(Fre)**

[Infertility and small myoma: role of myomectomy] Fernandez H. **Contracept Fertil Sex** 1997 May;25(5):348–9 (12 ref.) **(Fre)**

[A case of myomectomy for infertility and a following twin pregnancy associated with hyperthyroidism] Berlingieri D, et al. **Minerva Ginecol** 1996 Dec;48(12):545–52 (20 ref.) (Eng. Abstr.) **(Ita)**

[Endoscopic cancer surgery—uterine and ovarian cancer] Tsubata K, et al. **Gan To Kagaku Ryoho** 1997 Mar; 24(5):551–5 (7 ref.) (Eng. Abstr.) **(Jpn)**

[In an infertile woman, does the presence of one or several myomas of less than three cm in diameter justify a myomectomy?] Lopes P. **Contracept Fertil Sex** 1997 May; 25(5):350–1 (6 ref.) **(Spa)**

THERAPY

Female genital tract malignancies during puberty. Uterine and cervical malignancies. Tscherne G.
Ann N Y Acad Sci 1997 Jun 17;816:331–7 (09 ref.)

The levonorgestrel–releasing intrauterine device: a wider role than contraception. Coleman M, et al.
Aust N Z J Obstet Gynaecol 1997 May;37(2):195–201 (68 ref.)

Gestational trophoblastic diseases and their treatment. Fisher PM, et al. **Cancer Treat Rev** 1997 Jan;23(1):1–16 (53 ref.)

Uterine myomas in adolescents: case reports and a review of the literature. Fields KR, et al.
J Pediatr Adolesc Gynecol 1996 Nov;9(4):195–8 (14 ref.)

Rodent model of reproductive tract leiomyomata: characterization and use in preclinical therapeutic studies. Howe SR, et al. **Prog Clin Biol Res** 1997;396:205–15 (29 ref.)

[The development of conservative treatment in uterine myoma] Nikolov A, et al. **Akush Ginekol (Sofiia)** 1996; 35(1–2):51–3 (14 ref.) **(Bul)**

[Clinical use of human chorionic gonadotropin in the treatment of trophoblastic neoplasia] Cohen AD, et al.
Harefuah 1996 Nov 1;131(9):348–52 (43 ref.) **(Heb)**

[A case of the invasive mole in an elderly aged (54–year old) woman] Kakimoto K, et al.
Nippon Sanka Fujinka Gakkai Zasshi 1996 Sep;48(9):849–52 (10 ref.) **(Jpn)**

ULTRASTRUCTURE

Adenosarcoma of the uterus with extensive smooth muscle differentiation: ultrastructural study and review of the literature. Fehmian C, et al. **Ultrastruct Pathol** 1997 Jan–Feb;21(1):73–9 (15 ref.)

VIROLOGY

Papillary squamous cell carcinoma of the uterine cervix: report of a case with HPV 16 DNA and brief review. Ollayos CW, et al. **Gynecol Oncol** 1996 Dec;63(3):388–91 (20 ref.)

The genetic program of genital human papillomaviruses in infection and cancer. Turek LP, et al.
Obstet Gynecol Clin North Am 1996 Dec;23(4):735–58 (151 ref.)

UTERINE PERFORATION

DIAGNOSIS

Spontaneous perforated pyometra presenting as pneumoperitoneum. Ikematsu Y, et al.
Gynecol Obstet Invest 1996;42(4):274–6 (11 ref.)

UTERINE PROLAPSE

DIAGNOSIS

[Preoperative examinations: the essential and the superfluous] Zafiropulo M, et al. **Contracept Fertil Sex** 1997 Jun; 25(6):434–7 (5 ref.) **(Fre)**

ETIOLOGY

The pelvic floor sequelae of childbirth. Sultan AH, et al.
Br J Hosp Med 1996 May 1–14;55(9):575–9 (45 ref.)

SURGERY

Sacrospinous vault fixation. Hogston P. **Br J Hosp Med** 1997 Jan 15–Feb 5;57(1–2):39–40 (4 ref.)
Managed care in reconstructive pelvic surgery and urogynecology. Strohbehn K.
Curr Opin Obstet Gynecol 1996 Aug;8(4):319–24 (27 ref.)
Evisceration after enterocele repair: a rare complication of vaginal surgery. Virtanen HS, et al.
Int Urogynecol J Pelvic Floor Dysfunct 1996;7(6):344–7 (27 ref.)
Transvaginal repair of vault prolapse: a review. Sze EH, et al. **Obstet Gynecol** 1997 Mar;89(3):466–75 (50 ref.)
Anterior vaginal prolapse: review of anatomy and techniques of surgical repair. Weber AM, et al. **Obstet Gynecol** 1997 Feb;89(2):311–8 (90 ref.)
[Preoperative examinations: the essential and the superfluous] Zafiropulo M, et al. **Contracept Fertil Sex** 1997 Jun; 25(6):434–7 (5 ref.) **(Fre)**
[Abdominal colposuspension: a synopsis of various approaches and techniques including endoscopic modifications] Wallwiener D, et al. **Zentralbl Gynakol** 1996; 118(2):98–106 (25 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Treatment of uterine and vaginal prolapse. Morley GW. **Clin Obstet Gynecol** 1996 Dec;39(4):959–69 (14 ref.)

UTERINE RUPTURE

COMPLICATIONS

[Uterine rupture and placenta percreta in the second trimester. Presentation of a case] Bernal-Martínez S, et al. **Ginecol Obstet Mex** 1996 Oct;64:482–3 (24 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

[Uterine rupture. A case of spontaneous rupture in a thirty week primiparous gestation] Bretones S, et al.
J Gynecol Obstet Biol Reprod (Paris) 1997;26(3):324–7 (19 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Intrapartum rupture of the unscarred uterus. Miller DA, et al. **Obstet Gynecol** 1997 May;89(5 Pt 1):671–3 (18 ref.)

SURGERY

[Uterine rupture. A case of spontaneous rupture in a thirty week primiparous gestation] Bretones S, et al.
J Gynecol Obstet Biol Reprod (Paris) 1997;26(3):324–7 (19 ref.) (Eng. Abstr.) **(Fre)**

UTERINE STIMULANTS see **OXYTOCICS**

UTEROGLOBIN

CHEMISTRY

Antiflammins: endogenous nonapeptides with regulatory effect on inflammation. Moreno JJ. **Gen Pharmacol** 1997 Jan;28(1):23–6 (41 ref.)

UTEROPLACENTAL CIRCULATION

Maternal circulation in the first-trimester human placenta--myth or reality? Jaffe R, et al.
Am J Obstet Gynecol 1997 Mar;176(3):695–705 (53 ref.)

UTERUS

see related
HYSTERECTOMY
HYSTEROSALPINGOGRAPHY
HYSTEROSCOPY

ABNORMALITIES

Clinical aspects and molecular genetics of the persistent müllerian duct syndrome. Josso N, et al.
Clin Endocrinol (Oxf) 1997 Aug;47(2):137–44 (44 ref.)
Uterine surgery by operative hysteroscopy. Bacskó G.
Eur J Obstet Gynecol Reprod Biol 1997 Feb;71(2):219–22 (21 ref.)
Rudimentary uterine horn pregnancy. A case report on surviving twins delivered eight days apart. Nahum GG.
J Reprod Med 1997 Aug;42(8):525–32 (30 ref.)
Laparoscopic management of a noncommunicating uterine horn in a patient with an acute abdomen. Amara DP, et al. **Surg Laparosc Endosc** 1997 Feb;7(1):56–9 (12 ref.)
[The McKusick-Kaufman syndrome: a report of 5 new cases, including a male] Paredes Esteban RM, et al.
An Esp Pediatr 1996 May;44(5):493–5 (17 ref.) **(Spa)**

BLOOD SUPPLY

Spontaneous rupture of the uterine vessels in a pregnancy complicated by endometriosis. Mizumoto Y, et al.
Acta Obstet Gynecol Scand 1996 Oct;75(9):860–2 (7 ref.)
Uterine artery embolization: an underused method of controlling pelvic hemorrhage. Vedantham S, et al.
Am J Obstet Gynecol 1997 Apr;176(4):938–48 (49 ref.)
Radiologic diagnosis and management of uterine artery pseudoaneurysm: case report. Bromley PJ, et al.
Can Assoc Radiol J 1997 Apr;48(2):119–22 (17 ref.)
Pregnancy hypertension and uterine artery Doppler ultrasound. Aquilina J, et al. **Curr Opin Obstet Gynecol** 1996 Dec;8(6):435–40 (31 ref.)
Blood flow changes in the uterus induced by treatment with GnRH analogues. Shaw RW. **Hum Reprod** 1996 Nov;11 Suppl 3:27–32 (10 ref.)
The first three weeks assessed by transvaginal color Doppler. Kupešić S. **J Perinat Med** 1996;24(4):301–17 (61 ref.)
Conflicting data on intervillous circulation in early pregnancy. Kurjak A, et al. **J Perinat Med** 1997; 25(3):225–36 (40 ref.)
Diagnosis of uterine arteriovenous malformation by color and pulsed Doppler ultrasonography [letter] Sugiyama T, et al. **Ultrasound Obstet Gynecol** 1996 Nov;8(5):359–60 (12 ref.)
[Value of the systematic uterine Doppler in the primiparous woman. A series of 315 cases] Soutif C, et al.
J Gynecol Obstet Biol Reprod (Paris) 1996;25(8):819–23 (17 ref.) (Eng. Abstr.) **(Fre)**

CYTOLOGY

[Regulation of uterine cellular proliferation with estrogens and growth factors] Alvarez-Rodríguez C, et al.
Ginecol Obstet Mex 1996 Sep;64:406–10 (35 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Analogies between oxytocin systems of the uterus and brain. Caldwell JD, et al. **Horm Metab Res** 1996 Feb;28(2):65–74 (100 ref.)

ENZYMOLOGY

Regulation of matrilysin in the rat uterus. Woessner JF Jr. **Biochem Cell Biol** 1996;74(6):777–84 (62 ref.)

IMMUNOLOGY

Uterine macrophages and environmental programming for pregnancy success. Hunt JS, et al. **J Reprod Immunol** 1996 Nov;32(1):1–25 (120 ref.)
Uterine natural killer cells: insights into lineage relationships and functions from studies of pregnancies in mutant and transgenic mice. Croy BA, et al. **Nat Immun** 1996–97; 15(1):22–33 (69 ref.)
Uterine natural killer cells in species with epitheliochorial placentation. Engelhardt H, et al. **Nat Immun** 1996–97; 15(1):53–69 (95 ref.)
Uterine natural killer cells during pregnancy in rodents. Head JR. **Nat Immun** 1996–97;15(1):7–21 (79 ref.)
Human uterine natural killer cells. King A, et al.
Nat Immun 1996–97;15(1):41–52 (60 ref.)
Natural killer cells in the nonpregnant murine uterus. Pollack SB, et al. **Nat Immun** 1996–97;15(1):34–40 (33 ref.)
Granulated lymphocytes of pregnancy. Whitelaw PF, et al. **Placenta** 1996 Nov;17(8):533–43 (112 ref.)

METABOLISM

Regulation of IGFBP-3 expression in breast cancer cells and uterus by estradiol and antiestrogens: correlations with effects on proliferation: a review. Hung H, et al.
Prog Growth Factor Res 1995;6(2–4):495–501 (33 ref.)

PATHOLOGY

Apoptosis: a programmed cell death involved in ovarian and uterine physiology. Vinatier D, et al.
Eur J Obstet Gynecol Reprod Biol 1996 Aug;67(2):85–102 (282 ref.)
The progestogen challenge test in postmenopausal women: clinical and morphologic aspects. Bortoletto C de C, et al. **Rev Paul Med** 1996 May-Jun;114(3):1166–72 (28 ref.)

PHYSIOLOGY

Intrauterine signaling and embryonic implantation. Barkai U, et al. **Biol Signals** 1996 Mar-Apr;5(2):111–21 (134 ref.)
The cytoskeleton of uterine epithelial cells: a new player in uterine receptivity and the plasma membrane transformation. Murphy CR. **Hum Reprod Update** 1995 Nov;1(6):567–80 (171 ref.)
Assessment of uterine receptivity prior to embryo transfer: a review of currently available imaging modalities. Turnbull LW, et al. **Hum Reprod Update** 1995 Sep; 1(5):505–14 (38 ref.)
The uterine environment in early pregnancy in the tammar wallaby. Shaw G. **Reprod Fertil Dev** 1996;8(4):811–8 (66 ref.)

PHYSIOPATHOLOGY

Apoptosis: a programmed cell death involved in ovarian and uterine physiology. Vinatier D, et al.
Eur J Obstet Gynecol Reprod Biol 1996 Aug;67(2):85–102 (282 ref.)

ULTRASONOGRAPHY

Three-dimensional saline contrast hysterosonography and surface rendering of uterine cavity pathology. Weinraub Z, et al. **Ultrasound Obstet Gynecol** 1996 Oct;8(4):277–82 (16 ref.)

UTILITARIANISM see **ETHICS**

UTILIZATION AND QUALITY CONTROL PEER REVIEW ORGANIZATIONS see **PROFESSIONAL REVIEW ORGANIZATIONS**

UTILIZATION REVIEW

see related
INSURANCE CLAIM REVIEW

LEGISLATION & JURISPRUDENCE

Refusing to pay for health care--Part III (of III): Avoiding third-party payer liability. Ross EJ.
Prog Cardiovasc Nurs 1996 Summer;11(3):41–5 (35 ref.)
Refusing to pay for health care--Part II (of III): Emerging trends in third-party payer liability. Ross EJ.
Prog Cardiovasc Nurs 1996 Spring;11(2):40–5 (57 ref.)

UTILIZATION REVIEW, DRUG see **DRUG UTILIZATION REVIEW**

UTP see **URIDINE TRIPHOSPHATE**

UTRICLE see **SACCULE AND UTRICLE**

UVEA

METABOLISM

Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: implications for uveoscleral outflow. Lindsey JD, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S53–9 (53 ref.)

PATHOLOGY

Ring melanoma of the anterior uvea presenting as unilateral neovascular glaucoma. Allaire GS, et al.
Can J Ophthalmol 1997 Aug;32(5):338–41 (14 ref.)

PHYSIOLOGY

[Equine recurrent uveitis] Spiess BM.
Schweiz Arch Tierheilkd 1997;139(3):126–33 (30 ref.) (Eng. Abstr.) **(Ger)**

UVEAL NEOPLASMS

CLASSIFICATION

Prognostic value of morphometric features and the callender classification in uveal melanomas. Coleman K, et al.
Ophthalmology 1996 Oct;103(10):1634–41 (23 ref.)

DIAGNOSIS

Posterior uveal melanoma. The Swedish perspective [see comments] Seregard S. **Acta Ophthalmol Scand** 1996 Aug; 74(4):315–29 (158 ref.) Comment in: Acta Ophthalmol Scand 1996 Aug;74(4):313.
Ring melanoma of the anterior uvea presenting as unilateral neovascular glaucoma. Allaire GS, et al.
Can J Ophthalmol 1997 Aug;32(5):338–41 (14 ref.)
Hemangioma of the ciliary body: a case report and review of the literature. Isola VM. **Ophthalmologica** 1996; 210(4):239–43 (14 ref.)
Diagnosis and treatment of uveal melanoma. Shields JA, et al. **Semin Oncol** 1996 Dec;23(6):763–7 (23 ref.)

GENETICS

Use of fluorescence in situ hybridization and comparative genomic hybridization in the cytogenetic analysis of testicular germ cell tumors and uveal melanomas. Becher R, et al. **Cancer Genet Cytogenet** 1997 Jan;93(1):22–8 (70 ref.)
Genetic aspects of uveal melanoma: a brief review. Singh AD, et al. **Semin Oncol** 1996 Dec;23(6):768–72 (45 ref.)

PATHOLOGY

Cutaneous metastasis of ocular malignant melanoma. An unusual presentation simulating blue nevi. Wieselthier JS, et al. **Am J Dermatopathol** 1996 Jun;18(3):289–95 (17 ref.)
Primary choroidal melanoma in a patient with previous cutaneous melanoma. Scull JJ, et al. **Arch Ophthalmol** 1997 Jun;115(6):796–8 (16 ref.)
Prognostic value of morphometric features and the callender classification in uveal melanomas. Coleman K, et al.
Ophthalmology 1996 Oct;103(10):1634–41 (23 ref.)
Prognostic parameters in uveal melanoma: a review. Mooy CM, et al. **Surv Ophthalmol** 1996 Nov-Dec;41(3):215–28 (137 ref.)

THERAPY

Posterior uveal melanoma. The Swedish perspective [see comments] Seregard S. **Acta Ophthalmol Scand** 1996 Aug; 74(4):315–29 (158 ref.) Comment in: Acta Ophthalmol Scand 1996 Aug;74(4):313.
Uveal melanoma: updated considerations on current management modalities. Manschot WA, et al.

UVEAL NEOPLASMS

Int Ophthalmol 1995-96;19(4):203-9 (46 ref.)
Diagnosis and treatment of uveal melanoma. Shields JA, et al. **Semin Oncol** 1996 Dec;23(6):763-7 (23 ref.)

UVEITIS

CHEMICALLY INDUCED

Experimental autoimmune uveitis: molecular mimicry and oral tolerance. Singh VK, et al. **Immunol Res** 1996; 15(4):323-46 (179 ref.)

COMPLICATIONS

The possible impact of uveitis in blindness: a literature survey. Suttorp-Schulten MS, et al. **Br J Ophthalmol** 1996 Sep; 80(9):844-8 (78 ref.)
Glaucoma associated with uveitis. Moorthy RS, et al. **Surv Ophthalmol** 1997 Mar-Apr;41(5):361-94 (368 ref.)
[Acute interstitial nephritis with bone marrow granulomas and uveitis] Akioka Y, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):270-1 (8 ref.) **(Jpn)**

DIAGNOSIS

[Uveitis. An eye disease with many faces] Bodanowitz S, et al. **Med Monatsschr Pharm** 1996 Feb;19(2):38-41 (0 ref.) **(Ger)**

DRUG THERAPY

Immunologic mechanisms of uveitis. New targets for immunomodulation. Whitcup SM, et al. **Arch Ophthalmol** 1997 Apr;115(4):520-5 (49 ref.)

ETIOLOGY

Uveitis in Behçet's disease. Nussenblatt RB. **Int Rev Immunol** 1997;14(1):67-79 (27 ref.)
Experimental autoimmune uveitis and its relationship to clinical ocular inflammatory disease. Nussenblatt RB, et al. **J Autoimmun** 1996 Oct;9(5):575-85 (131 ref.)
Case reports and mini review of bee stings of the cornea. Chuah G, et al. **Singapore Med J** 1996 Aug;37(4):389-91 (12 ref.)

IMMUNOLOGY

Immunologic mechanisms of uveitis. New targets for immunomodulation. Whitcup SM, et al. **Arch Ophthalmol** 1997 Apr;115(4):520-5 (49 ref.)
Experimental autoimmune uveitis: molecular mimicry and oral tolerance. Singh VK, et al. **Immunol Res** 1996; 15(4):323-46 (179 ref.)

PATHOLOGY

Antiendothelial cell antibodies (AECA) in patients with uveoretinitis. Edelsten C, et al. **Clin Rev Allergy Immunol** 1997 Spring;15(1):41-52 (40 ref.)

PHYSIOPATHOLOGY

The pathophysiology of uveitis. Hoang-Xuan T. **Rev Rhum Engl Ed** 1997 Apr;64(4):255-8 (24 ref.)
[Physiopathology of uveitic glaucoma] Mermoud A. **Klin Monatsbl Augenheilkd** 1997 May;210(5):269-73 (66 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Tolerance and uveitis [editorial; comment] Bach JF. **Am J Ophthalmol** 1997 May;123(5):684-7 (22 ref.) Comment on: Am J Ophthalmol 1997 May;123(5):583-92.

VETERINARY

[Equine recurrent uveitis] Spiess BM. **Schweiz Arch Tierheilkd** 1997;139(3):126-33 (30 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

HTLV-I uveitis. Mochizuki M, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S50-6 (22 ref.)

UVEITIS, ANTERIOR

CHEMICALLY INDUCED

Uveitis associated with rifabutin therapy: a clinical alert. Petrowski JT 3rd. **J Am Optom Assoc** 1996 Nov; 67(11):693-6 (17 ref.)

DIAGNOSIS

[Anterior uveitis as the form of presentation of orbital pseudotumor in a child (letter)] Matesanz JL, et al. **Rev Clin Esp** 1997 Jan;197(1):69-70 (6 ref.) **(Spa)**

DRUG THERAPY

Systemic toxicity from ocular homatropine. Reilly KM, et al. **Acad Emerg Med** 1996 Sep;3(9):868-71 (15 ref.)

ETIOLOGY

[2 cases of anterior uveitis in multiple sclerosis patients] Karlova IZ, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1997;97(5):57-8 (6 ref.) **(Rus)**

UVEITIS, INTERMEDIATE

[Intermediate uveitis] Havlíková M, et al. **Cesk Slov Oftalmol** 1996 Nov;52(6):403-6 (22 ref.) **(Cze)**

UVEITIS, POSTERIOR

DIAGNOSIS

Diagnostic molecular microbiology in posterior uveitis: principles and applications. Adra CN, et al. **Int Ophthalmol Clin** 1995 Summer;35(3):75-92 (40 ref.)
Laboratory investigations in posterior uveitis. Rahi AH, et al. **Int Ophthalmol Clin** 1995 Summer;35(3):59-74 (44 ref.)
Clinical diagnosis of posterior uveitis. Tabbara KF. **Int Ophthalmol Clin** 1995 Summer;35(3):1-19 (30 ref.)

GENETICS

Molecular genetics of posterior uveitis. Ohno S, et al. **Int Ophthalmol Clin** 1995 Summer;35(3):21-32 (69 ref.)

PATHOLOGY

Fluorescein angiography in posterior uveitis. De Laey JJ. **Int Ophthalmol Clin** 1995 Summer;35(3):33-58 (41 ref.)

THERAPY

Systemic immunosuppression in the treatment of posterior uveitis. Wakefield D, et al. **Int Ophthalmol Clin** 1995 Summer;35(3):107-22 (23 ref.)

UVEOMENINGOENCEPHALITIC SYNDROME

ETHNOLOGY

Vogt-Koyanagi-Harada syndrome in patients of Vietnamese ancestry. Riddington L, et al. **Aust N Z J Ophthalmol** 1996 May;24(2):147-9 (7 ref.)

GENETICS

Pathogenesis of idiopathic uveoencephalitis. The association of HLA-DR4 gene subtypes with Vogt-Koyanaki-Harada syndrome. Jiang Y. **Chin Med J (Engl)** 1996 Jan;109(1):67-9 (0 ref.)

UVOMORULIN see **CADHERINS**

UVULA

PHYSIOLOGY

Control of the three-dimensional dynamic characteristics of the angular vestibulo-ocular reflex by the nodulus and uvula. Wearne S, et al. **Prog Brain Res** 1997;114:321-34 (104 ref.)

SURGERY

An unusual appearance of velopharyngeal closure in a post-uvulopalatopharyngoplasty patient. Yanagisawa E, et al. **Ear Nose Throat J** 1997 Jan;76(1):14-5 (5 ref.)
The surgical treatment of snoring [see comments] Harries PG, et al. **J Laryngol Otol** 1996 Dec;110(12):1103-4 (9 ref.) Comment in: J Laryngol Otol 1997 Jun;111(6):598.
Critical analysis of the results of surgery in the treatment of snoring, upper airway resistance syndrome (UARS), and obstructive sleep apnea (OSA). Pépin JL, et al. **Sleep** 1996 Nov;19(9 Suppl):S90-100 (92 ref.)
[Uvulectomy and blue gingiva tattoo among Ethiopian immigrants in Israel] Menachem S, et al. **Harefuah** 1997 Jan 15;132(2):128-30 (22 ref.) **(Heb)**

V1 RECEPTORS see **RECEPTORS, VASOPRESSIN**

V2 RECEPTORS see **RECEPTORS, VASOPRESSIN**

V-ABL GENES see **GENES, ABL**

V-FMS GENES see **GENES, FMS**

V-FOS GENES see **GENES, FOS**

V-HA-RAS GENES see **GENES, RAS**

V-JUN GENES see **GENES, JUN**

V-KI-RAS GENES see **GENES, RAS**

V-MYC GENES see **GENES, MYC**

V-ONC PROTEINS see **ONCOGENE PROTEINS, VIRAL**

V-SRC PROTEIN PP60 see **ONCOGENE PROTEIN PP60(V-SRC)**

VACCINATION

"HIV-peplotion vaccine"--a novel approach to protection against AIDS by transepithelial transport of viral peptides to Langerhans cells for long-term antiviral CTL response. (A review). Becker Y. **Acta Microbiol Immunol Hung** 1996; 43(1):1-17 (83 ref.)
Is vaccination against IgE possible? Hellman L. **Adv Exp Med Biol** 1996;409:337-42 (18 ref.)
Staphylococcus aureus vaccination for dialysis patients--an update. Fattom AI, et al. **Adv Ren Replace Ther** 1996 Oct; 3(4):302-8 (57 ref.)
Live attenuated varicella vaccine. Arvin AM, et al. **Annu Rev Microbiol** 1996;50:59-100 (261 ref.)
Pneumococcal vaccination: four issues for western Europe. Fedson DS. **Biologicals** 1997 Jun;25(2):215-9 (15 ref.)
Adult pertussis: a salesman's dream--and an epidemiologist's nightmare. Fine PE. **Biologicals** 1997 Jun;25(2):195-8 (22 ref.)
Live attenuated varicella vaccine for prevention of herpes zoster. Gershon A, et al. **Biologicals** 1997 Jun;25(2):227-30 (24 ref.)
Influenza immunization. Glück R. **Biologicals** 1997 Jun; 25(2):221-5 (22 ref.)
Vaccination of the immunocompromised patient. Loutan L. **Biologicals** 1997 Jun;25(2):231-6 (29 ref.)
Immune recognition, control of infections and vaccination strategies. **Ciba Found Symp** 1997;204:142-7 (4 ref.)
Vaccination against papillomavirus in cattle. Campo MS. **Clin Dermatol** 1997 Mar-Apr;15(2):275-83 (51 ref.)
Prospects for vaccines during pregnancy and in the newborn period. Fischer GW, et al. **Clin Perinatol** 1997 Mar; 24(1):231-49 (81 ref.)
Adult immunizations. Gardner P, et al. **Compr Ther** 1996 Jul;22(7):440-8 (62 ref.)
Animal-induced injuries and disease, neonatal jaundice, immunizations, and viral infections. Gerson WT. **Curr Opin Pediatr** 1996 Aug;8(4):417-25 (69 ref.)
Neonatal immunization [editorial] Isaacs D. **Curr Opin Pediatr** 1997 Feb;9(1):5-8 (24 ref.)
New vaccines for the prevention of pneumococcal infections. Käyhty H, et al. **Emerg Infect Dis** 1996 Oct-Dec; 2(4):289-98 (74 ref.)
Immunization: protecting older patients from infectious disease [see comments] Plichta AM. **Geriatrics** 1996 Sep; 51(9):47-52; quiz 53 (22 ref.) Comment in: Geriatrics 1996 Dec;51(12): 12, 14.
Immunisation against hepatitis A--active or passive? Iwarson S. **Infection** 1996 Jan-Feb;24(1):2-4 (15 ref.)
Vaccination against cestode parasites. Lightowlers MW. **Int J Parasitol** 1996 Aug-Sep;26(8-9):819-24 (27 ref.)
Tumor immunotherapy by vaccination with cytokine gene transfected cells. Viret C, et al. **Int Rev Immunol** 1997; 14(2-3):193-212 (88 ref.)
Appropriate season for measles immunisation campaign in India. Singh J, et al. **J Commun Dis** 1995 Sep;27(3):164-9 (44 ref.)
Perspective: prospects for development of vaccines against human helminth infections [published erratum appears in J Infect Dis 1997 Mar;175(3):742] McCarthy JS, et al. **J Infect Dis** 1996 Dec;174(6):1384-90 (89 ref.)
Nonresponse to hepatitis B vaccines and the kinetics of anti-HBs production. Zuckerman JN. **J Med Virol** 1996 Dec;50(4):283-8 (62 ref.)
Vaccination with autoreactive T cell clones in multiple sclerosis: overview of immunological and clinical data. Stinissen P, et al. **J Neurosci Res** 1996 Aug 15;45(4):500-11 (75 ref.)
"Love's labours lost": failure to implement mass vaccination against group A meningococcal meningitis in sub-Saharan Africa. Robbins JB, et al. **Lancet** 1997 Sep 20; 350(9081):880-2 (41 ref.)
Epidemiology of pertussis. Black S. **Pediatr Infect Dis J** 1997 Apr;16(4 Suppl):S85-9 (36 ref.)
Combination vaccines consisting of acellular pertussis vaccines. Edwards KM, et al. **Pediatr Infect Dis J** 1997 Apr;16(4 Suppl):S97-102 (24 ref.)
Pertussis: current concepts of pathogenesis and prevention. Hewlett EL. **Pediatr Infect Dis J** 1997 Apr;16(4 Suppl):S78-84 (72 ref.)
Active immunization in HIV-infected patients. Pau AK, et al. **Pharmacotherapy** 1996 Mar-Apr;16(2):163-70 (60 ref.)
Protecting travelers against infections: immunizations and other preventive strategies. Blair JE. **Postgrad Med** 1996 Dec;100(6):159-62, 165-6, 169-72 (5 ref.)
Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Moss B. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11341-8 (180 ref.)
Community-acquired pneumonia. Ong KC, et al. **Singapore Med J** 1995 Oct;36(5):539-44 (30 ref.)
European Commission COST/STD Initiative. Report of the expert panel III. European surveillance system for infectious disease. & Report of the expert panel V. Harmonisation of European vaccination programmes. Miller L, et al. **Vaccine** 1996 May;14(7):611-23 (9 ref.)
[Vaccination of premature infants] Kristensen K, et al. **Ugeskr Laeger** 1996 Nov 4;158(45):6421-3 (20 ref.) (Eng. Abstr.) **(Dan)**
[Vaccinations in immunosuppressed patients] Bouchaud O. **Ann Med Interne (Paris)** 1997;148(3):272-9 (41 ref.) (Eng. Abstr.) **(Fre)**

[New strategies of vaccination in France in 1995] Aubertin J, et al. **Rev Med Interne** 1996;17(8):684–8 (18 ref.) (Eng. Abstr.) **(Fre)**

[Anti-pneumococcal vaccine: justifications and results] Bacle A, et al. **Rev Pneumol Clin** 1997;53(3):128–37 (82 ref.) (Eng. Abstr.) **(Fre)**

[The current status of vaccination and antibiotic prophylaxis in splenectomy. I: Adults] Funk EM, et al. **Chirurg** 1997 Jun;68(6):586–90 (25 ref.) (Eng. Abstr.) **(Ger)**

[Current status of vaccination and antibiotic prophylaxis in splenectomy. II: Children] Funk EM, et al. **Chirurg** 1997 Jun;68(6):591–5 (28 ref.) (Eng. Abstr.) **(Ger)**

[Vaccination of chronically ill children] Zielen S, et al. **Z Arztl Fortbild Qualitatssich** 1997 Jun;91(3):213–7 (23 ref.) (Eng. Abstr.) **(Ger)**

[BCG vaccination] Hutás I. **Orv Hetil** 1996 Mar 24; 137(12):619–22 (31 ref.) (Eng. Abstr.) **(Hun)**

[The "rapidity" factor in the specific immunity response after oral vaccination] Negretti F. **Minerva Med** 1997 Apr; 88(4):127–41 (82 ref.) (Eng. Abstr.) **(Ita)**

[Mercury as an allergic factor] Kieć-Swierczyńska M. **Med Pr** 1996;47(1):77–81 (33 ref.) (Eng. Abstr.) **(Pol)**

[Vaccination against typhoid fever: results and perspectives] Gremiakova TA, et al. **Vestn Ross Akad Med Nauk** 1997; (6):11–6 (62 ref.) (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

ACIP issues update on potential adverse events from vaccines. Advisory Committee on Immunizations Practices. **Am Fam Physician** 1997 Feb 1;55(2):702–4 (04 ref.)

Disseminated bacille Calmette–Guérin disease after vaccination: case report and review. Talbot EA, et al. **Clin Infect Dis** 1997 Jun;24(6):1139–46 (85 ref.)

Does influenza immunisation cause exacerbations of chronic airflow obstruction or asthma? Watson JM, et al. **Thorax** 1997 Feb;52(2):190–4 (51 ref.)

ECONOMICS

Clinical and economic considerations of vaccination against varicella. Strassels SA, et al. **Pharmacotherapy** 1997 Jan–Feb;17(1):133–9 (24 ref.)

LEGISLATION & JURISPRUDENCE

Good performance of vaccination by education. Peltola H. **Biologicals** 1997 Jun;25(2):237–9 (9 ref.)

METHODS

Lactic acid bacteria as vaccine delivery vehicles. Wells JM, et al. **Antonie Van Leeuwenhoek** 1996 Oct;70(2–4):317–30 (51 ref.)

Rotavirus vaccines: an overview. Midthun K, et al. **Clin Microbiol Rev** 1996 Jul;9(3):423–34 (153 ref.)

Influenza vaccination for all elderly. Wijma G, et al. **Gerontology** 1996;42(5):270–3 (18 ref.)

An HTLV-I/II vaccine: from animal models to clinical trials? de Thé G, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S191–8 (48 ref.)

T cell vaccination: clinical application in autoimmune diseases. Zhang J, et al. **J Mol Med** 1996 Nov;74(11):653–62 (43 ref.)

Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. Rosenberg SA. **J Natl Cancer Inst** 1996 Nov 20; 88(22):1635–44 (61 ref.)

Treatment of food allergy with low-dose vaccination. Ansotegui IJ, et al. **Monogr Allergy** 1996;32:241–5 (20 ref.)

Vaccination in pulses: a strategy for global eradication of measles and polio? Nokes DJ, et al. **Trends Microbiol** 1997 Jan;5(1):14–9 (37 ref.)

PSYCHOLOGY

Acceptability of bio-engineered vaccines. Danner K. **Comp Immunol Microbiol Infect Dis** 1997 Jan;20(1):3–12 (27 ref.)

STANDARDS

Potency control of modified live viral vaccines for veterinary use. Terpstra C, et al. **Vaccine** 1996 Apr;14(6):570–5 (13 ref.)

TRENDS

What to expect of future vaccines? Morein B, et al. **Acta Vet Scand Suppl** 1996;90:101–6 (14 ref.)

Current developments in new vaccines for adolescents. Rappuoli R. **Biologicals** 1997 Jun;25(2):159–63 (36 ref.)

Developments in childhood immunization. Reuman PD, et al. **Curr Probl Pediatr** 1996 Apr;26(4):107–37 (322 ref.)

Progress and challenges toward an AIDS vaccine: Brother, can you spare a paradigm? Koff WC, et al. **J Clin Immunol** 1996 May;16(3):127–33 (63 ref.)

[New vaccines in medicine: the outlook] Navarro Alonso JA. **Aten Primaria** 1997 May 15;19(8):431–40 (73 ref.) **(Spa)**

VETERINARY

Vaccination strategies in freshwater salmonid aquaculture. Larsen JL, et al. **Dev Biol Stand** 1997;90:391–400 (30 ref.)

Vaccination strategies in seawater cage culture of salmonids. Lillehaug A. **Dev Biol Stand** 1997;90:401–8 (23 ref.)

Vaccinated fish welfare: protection versus side-effects. Midtlyng PJ. **Dev Biol Stand** 1997;90:371–9 (28 ref.)

Antigen uptake and immune responses after immersion vaccination. Nakanishi T, et al. **Dev Biol Stand** 1997; 90:59–68 (61 ref.)

Antigen uptake and immune responses after oral vaccination. Quentel C, et al. **Dev Biol Stand** 1997;90:69–78 (75 ref.)

Immune responses after injection vaccination of fish. van Muiswinkel WB, et al. **Dev Biol Stand** 1997;90:55–7 (10 ref.)

Antigen delivery strategies for mucosal vaccines. Husband AJ, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):825–34 (86 ref.)

Cytokines as adjuvants for ruminant vaccines. Lofthouse SA, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):835–42 (57 ref.)

Feline leukaemia virus: a review of immunity and vaccination. Sparkes AH. **J Small Anim Pract** 1997 May; 38(5):187–94 (49 ref.)

Potency control of modified live viral vaccines for veterinary use. Terpstra C, et al. **Vaccine** 1996 Apr;14(6):570–5 (13 ref.)

The design of veterinary vaccination programmes [see comments] Woolhouse ME, et al. **Vet J** 1997 Jan; 153(1):41–7 (18 ref.) Comment in: Vet J 1997 Jan;153(1):7–8.

Vaccination of the badger (Meles meles) against Mycobacterium bovis. Hughes MS, et al. **Vet Microbiol** 1996 Aug;51(3–4):363–79 (115 ref.)

Vaccination against worm parasites of animals. Emery DL. **Vet Parasitol** 1996 Aug;64(1–2):31–45 (93 ref.)

VACCINATION ENCEPHALITIS see ENCEPHALOMYELITIS, ACUTE DISSEMINATED

VACCINE THERAPY see IMMUNOTHERAPY, ACTIVE

VACCINES

The role of adjuvants and delivery systems in modulation of immune response to vaccines. Gupta RK, et al. **Adv Exp Med Biol** 1996;397:105–13 (44 ref.)

Therapeutic vaccines. A pandoric prospect. Spier RE. **Adv Exp Med Biol** 1996;397:183–9 (7 ref.)

Progress in the development of human chorionic gonadotropin antifertility vaccines. Stevens VC. **Am J Reprod Immunol** 1996 Mar;35(3):148–55 (19 ref.)

Poultry vaccine laboratories in the United States: a historical perspective. Hitchner SB. **Avian Dis** 1996 Apr–Jun; 40(2):255–65 (10 ref.)

Saponins as vaccine adjuvants. Kensil CR. **Crit Rev Ther Drug Carrier Syst** 1996;13(1–2):1–55 (178 ref.)

Developments in childhood immunization. Reuman PD, et al. **Curr Probl Pediatr** 1996 Apr;26(4):107–37 (322 ref.)

Progress on vaccines against parasites. Engers HD, et al. **Dev Biol Stand** 1996;87:73–84 (30 ref.)

Vaccine stability in the context of vaccine delivery in a developing country: India. John TJ. **Dev Biol Stand** 1996; 87:19–25 (5 ref.)

Research priorities for the WHO Global Programme for Vaccines and Immunization. Lambert PH. **Dev Biol Stand** 1996;87:45–9 (0 ref.)

Experience with veterinary vaccines in warm climates. Tulasne JJ, et al. **Dev Biol Stand** 1996;87:33–42 (20 ref.)

Analysis of vaccine stability. Volkin DB, et al. **Dev Biol Stand** 1996;87:135–42 (23 ref.)

Vaccine transport and storage: environmental challenges. Zaffran M. **Dev Biol Stand** 1996;87:9–17 (14 ref.)

Multivalent vaccines: prospects and challenges. Spier RE. **Folia Microbiol (Praha)** 1997;42(2):105–12 (17 ref.)

Vaccination against cestode parasites. Lightowlers MW. **Int J Parasitol** 1996 Aug–Sep;26(8–9):819–24 (27 ref.)

Cytokines as adjuvants for ruminant vaccines. Lofthouse SA, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):835–42 (57 ref.)

Rational design of nematode vaccines; natural antigens. Meeusen EN. **Int J Parasitol** 1996 Aug–Sep;26(8–9):813–8 (35 ref.)

Purification of heat shock protein-peptide complexes for use in vaccination against cancers and intracellular pathogens. Srivastava PK. **Methods** 1997 Jun;12(2):165–71 (24 ref.)

Childhood immunizations—1996. Hodes DS. **Mt Sinai J Med** 1996 Oct–Nov;63(5–6):413–9 (48 ref.)

Progress toward the development of vaccines against parasitic diseases: a review based on studies performed by participants of the Laveran seminar. Liance M. **Parasite** 1994 Sep;1(3):197–203 (38 ref.)

Pneumococcal vaccine [published erratum appears in Pediatr Rev 1996 Dec;17(12):425] Peter G, et al. **Pediatr Rev** 1996 Oct;17(10):335–41; quiz 342 (12 ref.)

A bait-delivered immunocontraceptive vaccine for the European red fox (Vulpes vulpes) by the year 2002? Bradley MP, et al. **Reprod Fertil Dev** 1997;9(1):111–6 (20 ref.)

Immunocontraception in rodents: a review of the development of a sperm-based immunocontraceptive vaccine for the grey squirrel (Sciurus carolinensis). Moore HD, et al. **Reprod Fertil Dev** 1997;9(1):125–9 (33 ref.)

Plant-derived immunocontraceptive vaccines. Smith G, et al. **Reprod Fertil Dev** 1997;9(1):85–9 (31 ref.)

Zoonoses and fertility control in wildlife—requirements for vaccines. Stöhr K, et al. **Reprod Fertil Dev** 1997;9(1):149–55 (59 ref.)

Prophylactic use of antibiotics and vaccines in patients with rheumatologic disorders. Mounzer KC, et al. **Rheum Dis Clin North Am** 1997 May;23(2):259–75 (83 ref.)

Novel vaccines for ectoparasites. Willadsen P. **Vet Parasitol** 1997 Jul 31;71(2–3):209–22 (47 ref.)

[Vaccines against parasitic diseases of domestic animals] Eckert J, et al. **Tierarztl Prax** 1996 Aug;24(4):322–9 (50 ref.) (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

Immunization of adolescents [see comments] Averhoff FM, et al. **Am Fam Physician** 1997 Jan;55(1):159–67 (30 ref.) Comment in: Am Fam Physician 1997 Jan;55(1):31, 35–6.

Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases. Lin R, et al. **Clin Infect Dis** 1995 Dec;21(6):1439–49 (134 ref.)

Gram-positive commensal bacteria for mucosal vaccine delivery. Fischetti VA, et al. **Curr Opin Biotechnol** 1996 Dec;7(6):659–66 (95 ref.)

Adjuvants and immunostimulants for enhancing vaccine potency in fish. Anderson DP. **Dev Biol Stand** 1997; 90:257–65 (41 ref.)

Adult immunizations: how are we doing? Eickhoff TC. **Hosp Pract (Off Ed)** 1996 Nov 15;31(11):107–8, 111–2, 115–7, passim (12 ref.)

Antigen delivery strategies for mucosal vaccines. Husband AJ, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):825–34 (86 ref.)

Nanoparticles and microparticles for drug and vaccine delivery. Kreuter J. **J Anat** 1996 Dec;189 (Pt 3):503–5 (24 ref.)

The intestinal uptake of particles and the implications for drug and antigen delivery. O'Hagan DT. **J Anat** 1996 Dec; 189 (Pt 3):477–82 (38 ref.)

Nasal delivery of vaccines. Almeida AJ, et al. **J Drug Target** 1996;3(6):455–67 (125 ref.)

Controlled delivery of antigens and adjuvants in vaccine development. Zhao Z, et al. **J Pharm Sci** 1996 Dec; 85(12):1261–70 (185 ref.)

Drug delivery issues in vaccine development. Powell MF. **Pharm Res** 1996 Dec;13(12):1777–85 (132 ref.)

Prophylactic use of antibiotics and vaccines in patients with rheumatologic disorders. Mounzer KC, et al. **Rheum Dis Clin North Am** 1997 May;23(2):259–75 (83 ref.)

European Commission COST/STD Initiative. Report of the expert panel VII. Vaccine delivery systems. Cryz S Jr, et al. **Vaccine** 1996 May;14(7):665–90 (16 ref.)

[Anti-inflammatory and anti-allergic oral vaccines?] Lomholt HB, et al. **Ugeskr Laeger** 1996 Sep 16; 158(38):5273–6 (40 ref.) (Eng. Abstr.) **(Dan)**

[Mucosal immune system and mucosal vaccine] Yanagita M, et al. **Nippon Rinsho** 1997 Feb;55(2):492–501 (38 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Vaccine-induced autoimmunity. Cohen AD, et al. **J Autoimmun** 1996 Dec;9(6):699–703 (63 ref.)

The complicated task of monitoring vaccine safety. Ellenberg SS, et al. **Public Health Rep** 1997 Jan–Feb;112(1):10–20; discussion 21 (51 ref.)

Drug-induced rheumatic disorders. Bannwarth B. **Rev Rhum Engl Ed** 1996 Nov;63(10):639–47 (125 ref.)

BIOSYNTHESIS

Chimeric potyvirus-like particles as vaccine carriers. Jagadish MN, et al. **Intervirology** 1996;39(1–2):85–92 (27 ref.)

CHEMISTRY

What's going on in vaccine technology? Russo S, et al. **Med Res Rev** 1997 May;17(3):277–301 (165 ref.)

ECONOMICS

European Commission COST/STD Initiative. Report of the expert panel I. Models for scientific and economic interaction in vaccines R & D. Schwanig M, et al. **Vaccine** 1996 May;14(7):582–610 (0 ref.)

IMMUNOLOGY

Vaccination against echinococcus in perspective. Heath DD, et al. **Acta Trop** 1997 Sep 15;67(1–2):37–41 (21 ref.)

Immunocontraception becomes a reality: the Talwar HCG vaccine [editorial] Coulam CB. **Am J Reprod Immunol** 1997 Feb;37(2):151–2 (15 ref.)

Development of an antipathology vaccine for schistosomiasis. Wynn TA. **Ann N Y Acad Sci** 1996 Oct 25;797:191–5 (27 ref.)

ELISPOT for detecting antibody-secreting cells in response to infections and vaccination. Arvilommi H. **APMIS** 1996 Jun;104(6):401–10 (70 ref.)

Vaccines for bluetongue. Murray PK, et al. **Aust Vet J** 1996 Jun;73(6):207–10 (33 ref.)

Heat shock proteins as immunological carriers and vaccines. Suzue K, et al. **EXS** 1996;77:451–65 (100 ref.)

Development of contraceptive vaccines for humans using antigens derived from gametes (spermatozoa and zona pellucida) and hormones (human chorionic gonadotrophin): current status. Naz RK, et al. **Hum Reprod Update** 1995

Jan;1(1):1–18 (133 ref.)
Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system. Wu HY, et al. **Immunol Res** 1997;16(2):187–201 (88 ref.)
Rational design of nematode vaccines: hidden antigens. Munn EA. **Int J Parasitol** 1997 Apr;27(4):359–66 (30 ref.)
Can epitope-focused vaccines select advantageous immune responses? Delves PJ, et al. **Mol Med Today** 1997 Feb; 3(2):55–60 (14 ref.)
Vaccine adjuvants. Macy DW. **Semin Vet Med Surg (Small Anim)** 1997 Aug;12(3):206–11 (42 ref.)
[New vaccines in medicine: the outlook] Navarro Alonso JA. **Aten Primaria** 1997 May 15;19(8):431–40 (73 ref.) **(Spa)**
[New vaccines and the immune response (I). Immunologic memory. Humoral response versus cellular response] Villarrubia VG, et al. **Med Clin (Barc)** 1996 Jun 22; 107(4):146–54 (93 ref.) **(Spa)**
[The new vaccines and immunologic response (and II). The antigenic presentation. Adjuvants as inducers of inducer T-lymphocyte cell-mediated response] Villarrubia VG, et al. **Med Clin (Barc)** 1996 Jun 29;107(5):185–96 (162 ref.) **(Spa)**

ISOLATION & PURIFICATION

Schistosomiasis vaccine development—the current picture. Waine GJ, et al. **Bioessays** 1997 May;19(5):435–43 (76 ref.)

PHARMACOLOGY

In vitro methods for vaccine evaluation. Reitan LJ, et al. **Dev Biol Stand** 1997;90:293–301 (24 ref.)
Vaccination against leprosy—the view from 1996 [editorial] Fine PE, et al. **Lepr Rev** 1996 Dec;67(4):249–52 (18 ref.)
What's going on in vaccine technology? Russo S, et al. **Med Res Rev** 1997 May;17(3):277–301 (165 ref.)
Can epitope-focused vaccines select advantageous immune responses? Delves PJ, et al. **Mol Med Today** 1997 Feb; 3(2):55–60 (14 ref.)
European Commission COST/STD Initiative. Report of the expert panel X. Animals models for vaccines to prevent infectious diseases. Mäkelä H, et al. **Vaccine** 1996 May; 14(7):717–31 (8 ref.)

STANDARDS

Hypothesis: how licensed vaccines confer protective immunity. Robbins JB, et al. **Adv Exp Med Biol** 1996; 397:169–82 (115 ref.)
Vaccines: current regulatory issues. Kenimer JG. **Curr Opin Biotechnol** 1997 Jun;8(3):357–60 (15 ref.)
Regulatory requirements for veterinary vaccine stability in the European Community. Fawthrop D. **Dev Biol Stand** 1996;87:319–27 (9 ref.)
Regulatory practices and problems with vaccine stability studies and the establishment of shelf lives. Fenyves A. **Dev Biol Stand** 1996;87:329–33 (7 ref.)

VACCINES, ATTENUATED

Bacterial outer membrane protein vaccines. The meningococcal example. Poolman JT. **Adv Exp Med Biol** 1996;397:73–7 (39 ref.)
The radiation-attenuated vaccine against schistosomes in animal models: paradigm for a human vaccine? Coulson PS. **Adv Parasitol** 1997;39:271–336 (210 ref.)
Correlates of immune protection after vaccination with attenuated live murine leukemia virus. Ruprecht RM, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):375–7 (14 ref.)
The role of biotechnologically engineered vaccines and diagnostics in pseudorabies (Aujeszky's disease) eradication strategies. Mengeling WL, et al. **Vet Microbiol** 1997 Apr; 55(1–4):49–60 (70 ref.)

ADMINISTRATION & DOSAGE

[Varicella zoster virus vaccine—a review] Petersen CS, et al. **Ugeskr Laeger** 1997 Feb 17;159(8):1081–5 (40 ref.) (Eng. Abstr.) **(Dan)**

IMMUNOLOGY

Attenuated poxvirus vectors as carriers in vaccines against human T cell leukemia-lymphoma virus type I. Franchini G, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20; 12(5):407–8 (21 ref.)
Replication in goats in vivo of caprine arthritis-encephalitis virus deleted in vif or tat genes: possible use of these deletion mutants as live vaccines. Harmache A, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):409–11 (9 ref.)
Potency control of modified live viral vaccines for veterinary use. Terpstra C, et al. **Vaccine** 1996 Jan;14(1):13–8 (13 ref.)

VACCINES, CANCER see **CANCER VACCINES**

VACCINES, COMBINED

Challenges in the development of combination vaccines. Ellis RW. **Adv Exp Med Biol** 1996;397:127–32 (14 ref.)
Developments in immunization practices and strategies: implications for vaccine stability. Plotkin SA, et al. **Dev Biol Stand** 1996;87:85–94 (18 ref.)
European Commission COST/STD Initiative. Report of the expert panel VIII. New vaccines, especially new combined vaccines. Rappuoli R, et al. **Vaccine** 1996 May; 14(7):691–700 (19 ref.)

ADMINISTRATION & DOSAGE

Combination vaccines and immunization visits. Plotkin SA, et al. **Pediatr Infect Dis J** 1996 Feb;15(2):103–5 (33 ref.)

IMMUNOLOGY

[Immune mechanism of mucous membrane and mucous membrane vaccines: Expression of level 1 and 2 Th2-type cytokine and IgA immune response] Kiyono H. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):690 (0 ref.) **(Jpn)**

PHARMACOLOGY

Polyvalent vaccines in fish: the interactive effects of multiple antigens. Busch RA. **Dev Biol Stand** 1997;90:245–56 (25 ref.)

VACCINES, CONJUGATE

Clinical trials of Shigella vaccines in Israel. Cohen D, et al. **Adv Exp Med Biol** 1996;397:159–67 (27 ref.)
Polysaccharide conjugate vaccines for the prevention of gram-positive bacterial infections. Naso R, et al. **Adv Exp Med Biol** 1996;397:133–40 (17 ref.)
New mechanisms for developing vaccines [editorial] Corbel MJ. **Br J Hosp Med** 1996 Jun 19–Jul 9;56(1):4–6 (5 ref.)
Glycoconjugate vaccines: future combinations. Paradiso PR, et al. **Dev Biol Stand** 1996;87:269–75 (12 ref.)
Pneumococcal conjugate vaccines: review and update. Klein DL. **Microb Drug Resist** 1995 Spring;1(1):49–58 (66 ref.)

VACCINES, DNA

Exploring the potential of DNA vaccination. Cohen IR, et al. **Hosp Pract (Off Ed)** 1997 May 15;32(5):169–71, 176–8 (7 ref.)
DNA vaccines for malaria: the past, the present, & the future. Doolan DL, et al. **Indian J Med Res** 1997 Aug;106:109–19 (77 ref.)
Recombinant viral vector vaccines for the veterinary use. Yokoyama N, et al. **J Vet Med Sci** 1997 May;59(5):311–22 (135 ref.)
DNA vaccines. Donnelly JJ, et al. **Life Sci** 1997;60(3):163–72 (69 ref.)

ADMINISTRATION & DOSAGE

"Naked" DNA transfer technology for genetic vaccination against infectious disease. Fazio VM. **Res Virol** 1997 Mar–Apr;148(2):101–8 (49 ref.)
[DNA vaccination and gene therapy based on transient expression of nucleic acids in human and animal somatic cells] Debabov VG. **Mol Biol (Mosk)** 1997 Mar–Apr; 31(2):209–15 (72 ref.) **(Rus)**

ADVERSE EFFECTS

Nonhuman primate models to evaluate vaccine safety and immunogenicity. Kennedy RC, et al. **Vaccine** 1997 Jun; 15(8):903–8 (42 ref.)
[Polynucleotide (DNA) viral vaccines and their safety problems] Gendon IuZ. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Jan–Feb; (1):78–81 (27 ref.) **(Rus)**

IMMUNOLOGY

Nucleic acid-based immunization against HIV-I: induction of protective in vivo immune responses. Wang B, et al. **AIDS** 1995;9 Suppl A:S159–70 (66 ref.)
DNA vaccines — a modern gimmick or a boon to vaccinology? Manickan E, et al. **Crit Rev Immunol** 1997; 17(2):139–54 (70 ref.)
DNA vaccines for emerging infectious diseases: what if? Whalen RG. **Emerg Infect Dis** 1996 Jul–Sep;2(3):168–75 (53 ref.)
Chimaera and its modern virus-like descendants. Ulrich R, et al. **Intervirology** 1996;39(1–2):126–32 (107 ref.)
DNA vaccines, cyberspace and self-help programs. Whalen RG. **Intervirology** 1996;39(1–2):120–5 (21 ref.)
DNA vaccines against malaria: immunogenicity and protection in a rodent model. Gardner MJ, et al. **J Pharm Sci** 1996 Dec;85(12):1294–300 (56 ref.)
Nucleic acid vaccines. Cernescu C. **Rom J Virol** 1995 Jan–Jun;46(1–2):69–73 (13 ref.)
DNA immunization. Hassett DE, et al. **Trends Microbiol** 1996 Aug;4(8):307–12 (43 ref.)
Biological features of genetic immunization. Barry MA, et al. **Vaccine** 1997 Jun;15(8):788–91 (10 ref.)
Nonhuman primate models to evaluate vaccine safety and immunogenicity. Kennedy RC, et al. **Vaccine** 1997 Jun; 15(8):903–8 (42 ref.)
Nucleic acid vaccines: an overview. Robinson HL. **Vaccine** 1997 Jun;15(8):785–7 (15 ref.)
Potential advantages and risks of nucleic acid vaccines for infant immunization. Siegrist CA. **Vaccine** 1997 Jun; 15(8):798–800 (7 ref.)

PHARMACOLOGY

DNA vaccines. Donnelly JJ, et al. **Annu Rev Immunol** 1997; 15:617–48 (122 ref.)
DNA for genetic vaccination and therapy. Moelling K. **Cytokines Cell Mol Ther** 1997 Jun;3(2):127–35 (42 ref.)

THERAPEUTIC USE

DNA for genetic vaccination and therapy. Moelling K. **Cytokines Cell Mol Ther** 1997 Jun;3(2):127–35 (42 ref.)
DNA vaccines for emerging infectious diseases: what if? Whalen RG. **Emerg Infect Dis** 1996 Jul–Sep;2(3):168–75 (53 ref.)
Genetic immunization: a new era in vaccines and immune therapeutics. Chattergoon M, et al. **FASEB J** 1997 Aug; 11(10):753–63 (42 ref.)
Naked DNA for vaccine or therapy [editorial] Mölling K. **J Mol Med** 1997 Apr;75(4):242–6 (21 ref.)
New peptide and protein drugs. Vermeij P, et al. **Pharm World Sci** 1996 Jun;18(3):87–93 (81 ref.)

VACCINES, INACTIVATED

Efficacy of an inactivated feline leukemia virus vaccine. Hoover EA, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):379–83 (53 ref.)
New mechanisms for developing vaccines [editorial] Corbel MJ. **Br J Hosp Med** 1996 Jun 19–Jul 9;56(1):4–6 (5 ref.)
Anti-hepatitis A virus (HAV) vaccination: guidelines for an immunization strategy in Italy. Workshop Consensus Conference—Rome, May 2–3, 1995 [published erratum appears in Ital J Gastroenterol 1996 Jul–Aug;28(6):368] **Ital J Gastroenterol** 1996 Apr;28(3):181–4 (0 ref.)
Inactivated poliovirus vaccine: past and present experience. Murdin AD, et al. **Vaccine** 1996 Jun;14(8):735–46 (118 ref.)

ADMINISTRATION & DOSAGE

The acellular pertussis vaccine trials: an interpretation. Plotkin SA, et al. **Pediatr Infect Dis J** 1997 May; 16(5):508–17; discussion 517–9 (46 ref.)

ADVERSE EFFECTS

The potential role of inflammation in the development of postvaccinal sarcomas in cats. Macy DW, et al. **Vet Clin North Am Small Anim Pract** 1996 Jan;26(1):103–9 (36 ref.)

IMMUNOLOGY

Acellular pertussis vaccine composed of genetically inactivated pertussis toxin. Peppoloni S, et al. **Physiol Chem Phys Med NMR** 1995;27(4):355–61 (21 ref.)

VACCINES, KILLED see **VACCINES, INACTIVATED**

VACCINES, NEOPLASM see **CANCER VACCINES**

VACCINES, RECOMBINANT see **VACCINES, SYNTHETIC**

VACCINES, RECOMBINANT DNA see **VACCINES, DNA**

VACCINES, SYNTHETIC

Synthetic recombinant vaccine induces anti-influenza long-term immunity and cross-strain protection. Arnon R, et al. **Adv Exp Med Biol** 1996;397:23–9 (15 ref.)
Parameters for the rational design of genetic toxoid vaccines. Burnette WN. **Adv Exp Med Biol** 1996;397:61–7 (27 ref.)
Unique immunomodulating properties of dimethyl dioctadecyl ammonium bromide (DDA) in experimental viral vaccines. Katz D, et al. **Adv Exp Med Biol** 1996; 397:115–25 (22 ref.)
Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Moss B, et al. **Adv Exp Med Biol** 1996;397:7–13 (35 ref.)
Bacterial outer membrane protein vaccines. The meningococcal example. Poolman JT. **Adv Exp Med Biol** 1996;397:73–7 (39 ref.)
Alphavirus-based expression systems. Rice CM. **Adv Exp Med Biol** 1996;397:31–40 (38 ref.)
Hybrid hepatitis B virus core antigen as a vaccine carrier moiety. II. Expression in avirulent Salmonella spp. for mucosal immunization. Schödel F, et al. **Adv Exp Med Biol** 1996;397:15–21 (18 ref.)
Synthetic vaccines for infectious and autoimmune diseases. Sela M. **Adv Exp Med Biol** 1996;397:1–5 (22 ref.)
A recombinant HIV-1 virus-like particle vaccine: from concepts to a field study. Wagner R, et al. **Antibiot Chemother** 1996;48:68–83 (42 ref.)
New mechanisms for developing vaccines [editorial] Corbel MJ. **Br J Hosp Med** 1996 Jun 19–Jul 9;56(1):4–6 (5 ref.)
Acceptability of bio-engineered vaccines. Danner K. **Comp Immunol Microbiol Infect Dis** 1997 Jan;20(1):3–12 (27 ref.)
Design of peptide and polypeptide vaccines. Ben-Yedidia T, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):442–8 (66 ref.)
Recent developments in the design of viral vaccines. Minor PD. **Dev Biol Stand** 1996;87:51–7 (11 ref.)
Genetically modified tumour vaccines carrying inserted genes for immunoregulatory molecules. Bubeník J. **Folia Biol (Praha)** 1996;42(6):295–304 (114 ref.)

Cytokine-based gene therapy of human tumors. An overview. Parmiani G, et al. **Folia Biol (Praha)** 1996; 42(6):305–9 (21 ref.)
Experimental immunization against Lyme borreliosis with recombinant Osp proteins: an overview. Sadziene A, et al. **Infection** 1996 Mar–Apr;24(2):195–202 (89 ref.)
Lyme disease vaccine. Wormser GP. **Infection** 1996 Mar–Apr;24(2):203–7 (54 ref.)
Malaria vaccines. Amador R, et al. **J Clin Immunol** 1996 Jul;16(4):183–9 (51 ref.)
New developments in adjuvants. Donnelly JJ. **Mech Ageing Dev** 1997 Feb;93(1–3):171–7 (17 ref.)
Molecular approaches to vaccinating against hookworm disease. Hotez PJ, et al. **Pediatr Res** 1996 Oct;40(4):515–21 (82 ref.)
Negative-strand RNA viruses: genetic engineering and applications. Palese P, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11354–8 (46 ref.)
Applications of pox virus vectors to vaccination: an update. Paoletti E. **Proc Natl Acad Sci U S A** 1996 Oct 15; 93(21):11349–53 (34 ref.)
Selection of antigens for use in a virus-vectored immunocontraceptive vaccine: PH–20 as a case study. Holland MK, et al. **Reprod Fertil Dev** 1997;9(1):117–24 (22 ref.)
Tumor antigens and tumor vaccines: peptides as immunogens. Slingluff CL Jr. **Semin Surg Oncol** 1996 Nov–Dec; 12(6):446–53 (89 ref.)
The role of biotechnologically engineered vaccines and diagnostics in pseudorabies (Aujeszky's disease) eradication strategies. Mengeling WL, et al. **Vet Microbiol** 1997 Apr; 55(1–4):49–60 (70 ref.)
[Advances in the study on human chorionic gonadotropin based birth-control vaccines] Cao Z, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Sep;31(9):569–70 (15 ref.) **(Chi)**
[Use of Salmonellas as a vector in the designing of recombinant vaccines] Boichenko MN, et al. **Vestn Ross Akad Med Nauk** 1997;(3):43–6 (28 ref.) **(Rus)**

ADMINISTRATION & DOSAGE

Lactic acid bacteria as vaccine delivery vehicles. Wells JM, et al. **Antonie Van Leeuwenhoek** 1996 Oct;70(2–4):317–30 (51 ref.)
Progress in the development of Lactococcus lactis as a recombinant mucosal vaccine delivery system. Norton PM, et al. **Folia Microbiol (Praha)** 1995;40(3):225–30 (10 ref.)

ANALYSIS

Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model [published erratum appears in Vaccine 1996 Sep;14(13):1298] Devi SJ. **Vaccine** 1996 Jun;14(9):841–4 (29 ref.)

BIOSYNTHESIS

Fish vaccine antigens produced or delivered by recombinant DNA technologies. Leong JC, et al. **Dev Biol Stand** 1997; 90:267–77 (47 ref.)
Chimeric potyvirus-like particles as vaccine carriers. Jagadish MN, et al. **Intervirology** 1996;39(1–2):85–92 (27 ref.)
The development of cowpea mosaic virus as a potential source of novel vaccines. Porta C, et al. **Intervirology** 1996; 39(1–2):79–84 (24 ref.)
Genetically engineered particulate virus-like structures and their use as vaccine delivery systems. Roy P. **Intervirology** 1996;39(1–2):62–71 (25 ref.)
Large-scale production in Pichia pastoris of the recombinant vaccine Gavac against cattle tick. Canales M, et al. **Vaccine** 1997 Mar;15(4):414–22 (27 ref.)

CHEMISTRY

Peptide secondary structure mimetics: applications to vaccines and pharmaceuticals. Qabar M, et al. **Farmaco** 1996 Feb;51(2):87–96 (77 ref.)
Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. O'Hagan DT, et al. **Mol Med Today** 1997 Feb;3(2):69–75 (47 ref.)
Epitope selection and development of peptide based vaccines to treat cancer. Celis E, et al. **Semin Cancer Biol** 1995 Dec; 6(6):329–36 (52 ref.)
Definition of tumor antigens suitable for vaccine construction. Lewis JJ, et al. **Semin Cancer Biol** 1995 Dec; 6(6):321–7 (47 ref.)
Selection of potent immunological adjuvants for vaccine construction. McElrath MJ. **Semin Cancer Biol** 1995 Dec; 6(6):375–85 (74 ref.)

GENETICS

The new generation of recombinant viral subunit vaccines. Ellis RW. **Curr Opin Biotechnol** 1996 Dec;7(6):646–52 (52 ref.)
Toward the development of DNA vaccines. Ulmer JB, et al. **Curr Opin Biotechnol** 1996 Dec;7(6):653–8 (51 ref.)
Alphavirus expression vectors and their use as recombinant vaccines: a minireview. Tubulekas I, et al. **Gene** 1997 Apr 29;190(1):191–5 (32 ref.)
Display of heterologous proteins on the surface of microorganisms: from the screening of combinatorial libraries to live recombinant vaccines. Georgiou G, et al. **Nat Biotechnol** 1997 Jan;15(1):29–34 (90 ref.)

IMMUNOLOGY

Novel approaches to peptide and engineered protein vaccines for HIV using defined epitopes: advances in 1994–1995. Berzofsky JA, et al. **AIDS** 1995;9 Suppl A:S143–57 (178 ref.)
Zona pellucida antigens: targets for contraceptive vaccines. Skinner SM, et al. **Am J Reprod Immunol** 1996 Mar; 35(3):163–74 (112 ref.)
WC3 reassortant vaccines in children. Clark HF, et al. **Arch Virol Suppl** 1996;12:187–98 (25 ref.)
Jennerian and modified Jennerian approach to vaccination against rotavirus diarrhea using a quadrivalent rhesus rotavirus (RRV) and human-RRV reassortant vaccine. Kapikian AZ, et al. **Arch Virol Suppl** 1996;12:163–75 (30 ref.)
Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer. Schlom J, et al. **Breast Cancer Res Treat** 1996;38(1):27–39 (36 ref.)
The new generation of recombinant viral subunit vaccines. Ellis RW. **Curr Opin Biotechnol** 1996 Dec;7(6):646–52 (52 ref.)
Toward the development of DNA vaccines. Ulmer JB, et al. **Curr Opin Biotechnol** 1996 Dec;7(6):653–8 (51 ref.)
DNA vaccines. Ulmer JB, et al. **Curr Opin Immunol** 1996 Aug;8(4):531–6 (36 ref.)
ISCOMs (immunostimulating complexes): the first decade. Barr IG, et al. **Immunol Cell Biol** 1996 Feb;74(1):8–25 (152 ref.)
Malaria vaccine trials: the missing qualitative data. Ferreira M. **Immunol Cell Biol** 1996 Aug;74(4):301–5 (20 ref.)
The recombinant outer surface protein A (lipOspA) of Borrelia burgdorferi: a Lyme disease vaccine. Wallich R, et al. **Infection** 1996 Sep–Oct;24(5):396–7 (12 ref.)
Chimeric rhinoviruses as tools for vaccine development and characterization of protein epitopes. Arnold GF, et al. **Intervirology** 1996;39(1–2):72–8 (38 ref.)
Papillomavirus-like particles for serology and vaccine development. Kirnbauer R. **Intervirology** 1996; 39(1–2):54–61 (82 ref.)
Synthesis, properties and applications of papillomavirus-like particles. Sapp M, et al. **Intervirology** 1996;39(1–2):49–53 (30 ref.)
Chimaera and its modern virus-like descendants. Ulrich R, et al. **Intervirology** 1996;39(1–2):126–32 (107 ref.)
Development of novel influenza virus vaccines and vectors. Palese P, et al. **J Infect Dis** 1997 Aug;176 Suppl 1:S45–9 (16 ref.)
Host responses and antigens involved in protective immunity to Mycobacterium tuberculosis. Andersen P. **Scand J Immunol** 1997 Feb;45(2):115–31 (222 ref.)
Anti-idiotypic monoclonal antibody cancer vaccines. Chapman PB. **Semin Cancer Biol** 1995 Dec;6(6):367–74 (53 ref.)
The next wave of recombinant and synthetic anticancer vaccines. Irvine KR, et al. **Semin Cancer Biol** 1995 Dec; 6(6):337–47 (121 ref.)
Large-scale production in Pichia pastoris of the recombinant vaccine Gavac against cattle tick. Canales M, et al. **Vaccine** 1997 Mar;15(4):414–22 (27 ref.)
Nonrecombinant and recombinant avirulent Salmonella vaccines for poultry. Curtiss R 3rd, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):365–72 (40 ref.)
[Tularemia vaccine strain is a potential vector] Pavlov VM, et al. **Vestn Ross Akad Med Nauk** 1997;(6):30–2 (28 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Cytokine-containing liposomes as vaccine adjuvants. Lachman LB, et al. **Eur Cytokine Netw** 1996 Dec;7(4):693–8 (30 ref.)
Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. O'Hagan DT, et al. **Mol Med Today** 1997 Feb;3(2):69–75 (47 ref.)
Heat shock protein-based cancer vaccines and related thoughts on immunogenicity of human tumors. Blachere NE, et al. **Semin Cancer Biol** 1995 Dec;6(6):349–55 (56 ref.)
The next wave of recombinant and synthetic anticancer vaccines. Irvine KR, et al. **Semin Cancer Biol** 1995 Dec; 6(6):337–47 (121 ref.)
Definition of tumor antigens suitable for vaccine construction. Lewis JJ, et al. **Semin Cancer Biol** 1995 Dec; 6(6):321–7 (47 ref.)

THERAPEUTIC USE

Update on the Center for Recombinant Gamete Contraceptive Vaccinogens. Herr JC. **Am J Reprod Immunol** 1996 Mar;35(3):184–9 (31 ref.)
The development of therapeutic vaccines of the management of malignant melanoma. Dalgleish AG, et al. **Cancer Surv** 1996;26:289–319 (158 ref.)
Genetic immunization: a new era in vaccines and immune therapeutics. Chattergoon M, et al. **FASEB J** 1997 Aug; 11(10):753–63 (42 ref.)
Epitope selection and development of peptide based vaccines to treat cancer. Celis E, et al. **Semin Cancer Biol** 1995 Dec; 6(6):329–36 (52 ref.)
Anti-idiotypic monoclonal antibody cancer vaccines. Chapman PB. **Semin Cancer Biol** 1995 Dec;6(6):367–74 (53 ref.)
Augmenting the immunogenicity of carbohydrate tumor antigens. Livingston PO. **Semin Cancer Biol** 1995 Dec; 6(6):357–66 (56 ref.)
Selection of potent immunological adjuvants for vaccine construction. McElrath MJ. **Semin Cancer Biol** 1995 Dec; 6(6):375–85 (74 ref.)

VACCINES, TUMOR see **CANCER VACCINES**

VACCINIA VIRUS

Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Moss B, et al. **Adv Exp Med Biol** 1996;397:7–13 (35 ref.)
Applications of pox virus vectors to vaccination: an update. Paoletti E. **Proc Natl Acad Sci U S A** 1996 Oct 15; 93(21):11349–53 (34 ref.)

GENETICS

Vaccinia virus DNA replication: a short review. Beaud G. **Biochimie** 1995;77(10):774–9 (67 ref.)
Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Moss B. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11341–8 (180 ref.)

IMMUNOLOGY

Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Moss B. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11341–8 (180 ref.)
[Jenner's cowpox vaccine in light of current vaccinology] Huygelen C. **Verh K Acad Geneeskd Belg** 1996; 58(5):479–536; discussion 537–8 (144 ref.) (Eng. Abstr.) **(Dut)**

PHYSIOLOGY

A virus joins the movement. Intracellular pathogens. Strauss EJ. **Curr Biol** 1996 May 1;6(5):504–7 (20 ref.)

VACUOLATING AGENT see **POLYOMAVIRUS MACACAE**

VACUOLES

ENZYMOLOGY

The vacuolar H+-ATPase: a universal proton pump of eukaryotes. Finbow ME, et al. **Biochem J** 1997 Jun 15;324 (Pt 3):697–712 (227 ref.)

METABOLISM

Structural aspects of autophagy. Seglen PO, et al. **Adv Exp Med Biol** 1996;389:103–11 (19 ref.)
Protein transport from the cytoplasm into the vacuole. Klionsky DJ. **J Membr Biol** 1997 May 15;157(2):105–15 (65 ref.)

MICROBIOLOGY

Presentation of antigens derived from microorganisms residing in host-cell vacuoles. Ojcius DM, et al. **Trends Microbiol** 1996 Feb;4(2):53–9 (53 ref.)

PATHOLOGY

[Cytoplasmic inclusion bodies: a study in several diseases and a review of the literature] Scola RH, et al. **Arq Neuropsiquiatr** 1996 Jun;54(2):245–59 (62 ref.) (Eng. Abstr.) **(Por)**

PHYSIOLOGY

Structure and function of the Toxoplasma gondii vacuole. Joiner KA, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:1–7 (32 ref.)
Regulation of vacuolar acidification. Forgac M. **Soc Gen Physiol Ser** 1996;51:121–32 (51 ref.)
[Cytotoxin vacuolization of Helicobacter pylori] Przondo-Mordarska A, et al. **Postepy Hig Med Dosw** 1996; 50(4):309–20 (38 ref.) (Eng. Abstr.) **(Pol)**
[The vacuolar apparatus and membrane fusion in the cell] Bulychev AG, et al. **Tsitologiia** 1996;38(10):1001–35 (280 ref.) (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

Structure and function of the Toxoplasma gondii vacuole. Joiner KA, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:1–7 (32 ref.)
Mammalian oocyte organelles with special reference to pleomorphic mitochondria and vacuole formation in marsupials. Ullmann SL, et al. **Reprod Fertil Dev** 1996; 8(4):491–508 (117 ref.)

VACUUM

Vacuum-assisted vaginal delivery. Paluska SA. **Am Fam Physician** 1997 May 1;55(6):2197–203 (24 ref.)

VACUUM EXTRACTION, OBSTETRICAL

Failed trial of vacuum or forceps--maternal and fetal outcome. Revah A, et al. **Am J Obstet Gynecol** 1997 Jan; 176(1 Pt 1):200–4 (11 ref.)

ADVERSE EFFECTS

Forceps and vacuum injuries to the cornea: histopathologic features of twelve cases and review of the literature. Honig MA, et al. **Cornea** 1996 Sep;15(5):463–72 (27 ref.)

VAGAL BODY see AORTIC BODIES

VAGINA

see related
COLPOSCOPY

"Fearing our mothers": an overview of the psychoanalytic theories concerning the vagina dentata motif F547.1.1. Otero S. **Am J Psychoanal** 1996 Sep;56(3):269–88 (81 ref.)

ABNORMALITIES

Congenital anomalies of the vagina and their reconstruction. Meyers RL. **Clin Obstet Gynecol** 1997 Mar;40(1):168–80 (41 ref.)

Laparascopic excision of pelvic kidney with single vaginal ectopic ureter. Moores D, et al. **J Pediatr Surg** 1997 Apr; 32(4):634–5 (12 ref.)

Müllerian agenesis: an update. Lindenman E, et al. **Obstet Gynecol** 1997 Aug;90(2):307–12 (21 ref.)

[Ectopic ureter opening in the vestibulum without urinary incontinence: a case report] Matsumoto S, et al. **Hinyokika Kiyo** 1996 Dec;42(12):965–8 (11 ref.) (Eng. Abstr.) **(Jpn)**

[The McKusick–Kaufman syndrome: a report of 5 new cases, including a male] Paredes Esteban RM, et al. **An Esp Pediatr** 1996 May;44(5):493–5 (17 ref.) **(Spa)**

CHEMISTRY

The diagnostic accuracy of cervico-vaginal fetal fibronectin in predicting preterm delivery: an overview. Chien PF, et al. **Br J Obstet Gynaecol** 1997 Apr;104(4):436–44 (54 ref.)

DRUG EFFECTS

Estrogens--pharmacokinetics and pharmacodynamics with special reference to vaginal administration and the new estradiol formulation--Estring. Johnston A. **Acta Obstet Gynecol Scand Suppl** 1996;163:16–25 (41 ref.)

IMMUNOLOGY

Immunopathogenesis of recurrent vulvovaginal candidiasis. Fidel PL Jr, et al. **Clin Microbiol Rev** 1996 Jul;9(3):335–48 (117 ref.)

INJURIES

Coital injury requiring internal iliac artery ligation. Sivalingam N, et al. **Singapore Med J** 1996 Oct;37(5):547–8 (7 ref.)

METABOLISM

Vaginal epithelial models. Wu SJ, et al. **Pharm Biotechnol** 1996;8:409–24 (39 ref.)

MICROBIOLOGY

Puberal hormonal status and vaginal microbiology. Tolino A, et al. **Acta Eur Fertil** 1994 Nov–Dec;25(6):343–6 (10 ref.)

Menopausal hormonal status and vaginal microbiology. Tolino A, et al. **Acta Eur Fertil** 1994 Nov–Dec;25(6):339–41 (10 ref.)

[Vagina--an ecological entity] Sjöberg I. **Lakartidningen** 1996 Oct 23;93(43):3796–8 (31 ref.) **(Swe)**

PHYSIOLOGY

A morphologist's approach to the vagina. Forsberg JG. **Acta Obstet Gynecol Scand Suppl** 1996;163:3–10 (70 ref.)

SURGERY

Neovaginoplasty in male transsexuals: review of surgical techniques and recommendations regarding eligibility. Karim RB, et al. **Ann Plast Surg** 1996 Dec;37(6):669–75 (60 ref.)

The treatment of vesicovaginal fistulae [see comments] Woo HH, et al. **Eur Urol** 1996;29(1):1–9 (41 ref.) Comment in: Eur Urol 1997;31(1):126.

Evisceration after enterocele repair: a rare complication of vaginal surgery. Virtanen HS, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1996;7(6):344–7 (27 ref.)

Rectovaginal fistulas. Therapeutic options. Tsang CB, et al. **Surg Clin North Am** 1997 Feb;77(1):95–114 (59 ref.)

[The Martius flap in vaginal surgery: technic and indications] Chassagne S, et al. **Prog Urol** 1997 Feb;7(1):120–5 (17 ref.) (Eng. Abstr.) **(Fre)**

VIROLOGY

Detection of human immunodeficiency virus type 1 and type 2 in the female genital tract: implications for the understanding of virus transmission. Critchlow CW, et al. **Obstet Gynecol Surv** 1997 May;52(5):315–24 (73 ref.)

VAGINAL BIRTH AFTER CESAREAN

Trial of scar. Chua S, et al. **Aust N Z J Obstet Gynaecol** 1997 Feb;37(1):6–11 (58 ref.)

Once a cesarean, always a controversy. Flamm BL. **Obstet Gynecol** 1997 Aug;90(2):312–5 (19 ref.)

STANDARDS

The case for trial of labor in the patient with a prior low-segment vertical cesarean incision. Martin JN Jr, et al. **Am J Obstet Gynecol** 1997 Jul;177(1):144–8 (25 ref.)

VAGINAL CREAMS, FOAMS AND JELLIES

see related
SPERMATOCIDAL AGENTS

VAGINAL DISCHARGE

DRUG THERAPY

[Treatment of vaginal discharge] Hirsch HA. **Dtsch Med Wochenschr** 1997 Apr 18;122(16):513–6 (29 ref.) **(Ger)**

ETIOLOGY

[Rational diagnosis of vaginal discharge] Hirsch HA. **Dtsch Med Wochenschr** 1997 Apr 11;122(15):477–80 (21 ref.) **(Ger)**

MICROBIOLOGY

[Treatment of vaginal discharge] Hirsch HA. **Dtsch Med Wochenschr** 1997 Apr 18;122(16):513–6 (29 ref.) **(Ger)**

VAGINAL DISEASES

Cervical and vaginal HPV infections. Schneider A. **Clin Dermatol** 1997 May–Jun;15(3):389–98 (120 ref.)

Vulvovaginal disorders in the elderly woman. Nathan L. **Clin Obstet Gynecol** 1996 Dec;39(4):933–45 (36 ref.)

Abnormal vaginal bleeding in young women. Kenney A. **Int J STD AIDS** 1997 Feb;8(2):82–6; quiz 86–7 (10 ref.)

DIAGNOSIS

Vaginal endometriosis. Two case reports and review of the literature on rare urogenital sites. Azzena A, et al. **Clin Exp Obstet Gynecol** 1996;23(2):94–8 (26 ref.)

[Genital infection with human papillomavirus (HPV): viral screening and typing, importance of in situ hybridization] Walker F, et al. **Ann Pathol** 1996 Nov;16(5):364–73 (76 ref.) **(Fre)**

DRUG THERAPY

Pharmacologic management of sexually transmitted diseases. Roe VA, et al. **J Nurse Midwifery** 1997 May–Jun; 42(3):275–89 (110 ref.)

[Local vaginal therapies] Cohen J. **Contracept Fertil Sex** 1997 Mar;25(3):196–201 (0 ref.) **(Fre)**

ETIOLOGY

Coital injury requiring internal iliac artery ligation. Sivalingam N, et al. **Singapore Med J** 1996 Oct;37(5):547–8 (7 ref.)

PATHOLOGY

Ectopic vaginal decidualization. An unusual finding that presents problems of differential diagnosis with carcinoma. Castellví Vives J, et al. **Eur J Gynaecol Oncol** 1997; 18(3):183–4 (23 ref.)

SURGERY

[Treatment of rectovaginal endometriosis] Querleu D. **Presse Med** 1997 May 17;26(16):774–7 (10 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Late prenatal ultrasound features of hydrometrocolpos secondary to cloacal anomaly: case reports and review of the literature. Odibo AO, et al. **Ultrasound Obstet Gynecol** 1997 Jun;9(6):419–21 (6 ref.)

VAGINAL NEOPLASMS

Melanomas of the vulva and vagina. Trimble EL. **Oncology (Huntingt)** 1996 Jul;10(7):1017–23; discussion 1024 (37 ref.)

COMPLICATIONS

High grade non-Hodgkins stage IEB primary malignant lymphoma of the cervix and upper vagina. A case report. Papadopoulos AJ, et al. **Eur J Gynaecol Oncol** 1996; 17(6):484–6 (11 ref.)

Pre leukemic granulocytic sarcoma of vagina. A case report with review of literature. Lakshminarasimhan S, et al. **Indian J Cancer** 1996 Sep;33(3):145–8 (13 ref.)

DIAGNOSIS

Two cases of benign vaginal rhabdomyoma. Case reports. Iversen UM. **APMIS** 1996 Jul–Aug;104(7–8):575–8 (18 ref.)

Ectopic vaginal decidualization. An unusual finding that presents problems of differential diagnosis with carcinoma. Castellví Vives J, et al. **Eur J Gynaecol Oncol** 1997; 18(3):183–4 (23 ref.)

EPIDEMIOLOGY

Risk of urethral, vaginal and cervical involvement in patients undergoing radical cystectomy for bladder cancer: results of a contemporary cystectomy series from M. D. Anderson Cancer Center. Chen ME, et al. **J Urol** 1997 Jun; 157(6):2120–3 (13 ref.)

ETIOLOGY

Neovaginal malignant melanoma following surgery and radiation for vulvar squamous cell carcinoma. Lara PN Jr, et al. **Gynecol Oncol** 1997 Jun;65(3):520–2 (18 ref.)

PATHOLOGY

Vaginal leiomyoma--a case report with review of the literature. Sharma D, et al. **Cent Afr J Med** 1995 Dec; 41(12):403–5 (10 ref.)

Vaginal intraepithelial neoplasia and vaginal cancer. Wharton JT, et al. **Obstet Gynecol Clin North Am** 1996 Jun; 23(2):325–45 (32 ref.)

SECONDARY

Isolated vaginal recurrences in endometrial carcinoma: treatment results using high-dose-rate intracavitary brachytherapy and external beam radiotherapy. Pai HH, et al. **Gynecol Oncol** 1997 Aug;66(2):300–7 (27 ref.)

SURGERY

[Leiomyosarcoma of the vagina: a rare case] Hachi H, et al. **Bull Cancer** 1997 Feb;84(2):215–7 (11 ref.) (Eng. Abstr.) **(Fre)**

VAGINAL PROLAPSE see UTERINE PROLAPSE

VAGINAL SMEARS

Shedding of HIV-1 in the genital tract [editorial] Mostad SB, et al. **AIDS** 1996 Oct;10(12):1305–15 (74 ref.)

Controversies in women's health maintenance [see comments] Morrison EH. **Am Fam Physician** 1997 Mar;55(4):1283–90 (50 ref.) Comment in: Am Fam Physician 1997 Mar;55(4):1039, 1042, 1047–8.

"Litigation cells" in the Papanicolaou smear: extramural review of smears by "experts". Frable WJ. **Arch Pathol Lab Med** 1997 Mar;121(3):292–5 (9 ref.)

Report disclaimers and informed expectations about Papanicolaou smears: an Australian view. Mitchell H. **Arch Pathol Lab Med** 1997 Mar;121(3):327–30 (8 ref.)

Liability issues with the Papanicolaou smear: an insurance industry perspective. Scott MD. **Arch Pathol Lab Med** 1997 Mar;121(3):239–40 (0 ref.)

Pap smear risk management by process control. Gill GW. **Cancer** 1997 Aug 25;81(4):198–211 (52 ref.)

Integration of surgical and cytopathology: a historical perspective. Frable WJ. **Diagn Cytopathol** 1995 Dec; 13(5):375–8 (32 ref.)

Pregnancy-related changes: a retrospective review of 278 cervical smears. Michael CW, et al. **Diagn Cytopathol** 1997 Aug;17(2):99–107 (28 ref.)

Is cervical screening working? A cytopathologist's view from the United Kingdom [see comments] Herbert A. **Hum Pathol** 1997 Feb;28(2):120–6 (64 ref.) Comment in: Hum Pathol 1997 Feb;28(2):117–9.

Management of patients with atypical squamous cells of undetermined significance (ASCUS) on Papanicolaou smears. Terry RR. **J Am Osteopath Assoc** 1996 Aug; 96(8):465–8 (17 ref.)

Errors in cervical smears: minimizing the risk of medicolegal consequences. Greening SE. **Monogr Pathol** 1997; (39):16–39 (52 ref.)

Pitfalls in diagnostic cervicovaginal cytology. Sidawy MK, et al. **Monogr Pathol** 1997;(39):1–15 (45 ref.)

A clinician's guide to Pap smear interpretation. Mashburn J, et al. **Nurse Pract** 1997 Apr;22(4):115–8, 124–7, 130 passim (32 ref.)

The role of exfoliative cytology and histopathology in screening and triage. Sherman ME, et al. **Obstet Gynecol Clin North Am** 1996 Sep;23(3):641–55 (37 ref.)

Use of fetal fibronectin in clinical practice. Ascarelli MH, et al. **Obstet Gynecol Surv** 1997 Apr;52(4 Suppl):S1–12 (32 ref.)

Pap smears. Still a reliable screening tool for cervical cancer. Stack PS. **Postgrad Med** 1997 Apr;101(4):207–8, 211–4 (8 ref.)

INSTRUMENTATION

The AcCell series 2000 as a support system for training and evaluation in educational and clinical settings. Greening SE, et al. **Acta Cytol** 1997 Jan-Feb;41(1):153-9 (10 ref.)

Utility of the TracCell system in mapping Papanicolaou-stained cytologic material. Grohs DH, et al. **Acta Cytol** 1997 Jan-Feb;41(1):144-52 (20 ref.)

Automated rescreening in cervical cytology. Mathematical models for evaluating overall process sensitivity, specificity and cost. Kaminsky FC, et al. **Acta Cytol** 1997 Jan-Feb; 41(1):209-23 (35 ref.)

The ThinPrep Pap test. A review of clinical studies. Linder J, et al. **Acta Cytol** 1997 Jan-Feb;41(1):30-8 (22 ref.)

Computerized scanning devices for Pap smear screening: current status and critical review. Rosenthal DL. **Clin Lab Med** 1997 Jun;17(2):263-84 (28 ref.)

METHODS

Automation of the Papanicolaou smear: a technology assessment perspective. Linder J. **Arch Pathol Lab Med** 1997 Mar;121(3):282-6 (30 ref.)

Binary (Bethesda) system for cervical precursor lesions: a histologic perspective. Crum CP. **Diagn Cytopathol** 1995 Dec;13(5):379-85 (50 ref.)

The Bethesda System, the pathology of preinvasive lesions, and screening technology. The Bethesda System (TBS) of nomenclature for cervical smears. Henry M. **J Natl Cancer Inst Monogr** 1996;(21):13-6 (22 ref.)

[Cervical smears. Contribution of automated screening] Ziol M, et al. **Ann Pathol** 1996 Nov;16(5):351-5 (26 ref.) **(Fre)**

PSYCHOLOGY

Attitudes to Papanicolaou smears. Conway K. **J Psychosom Obstet Gynaecol** 1996 Dec;17(4):189-94 (45 ref.)

STANDARDS

Results of blinded rescreening of Papanicolaou smears versus biased retrospective review. Austin RM. **Arch Pathol Lab Med** 1997 Mar;121(3):311-4 (18 ref.)

College of American Pathologists Conference XXX on quality and liability issues with the Papanicolaou smear: summation. Austin RM. **Arch Pathol Lab Med** 1997 Mar; 121(3):341-2 (21 ref.)

Papanicolaou smear 5-year retrospective review: what is required by the Clinical Laboratory Improvement Amendments of 1988? Davey DD. **Arch Pathol Lab Med** 1997 Mar;121(3):296-8 (11 ref.)

Quality and liability issues with the Papanicolaou smear: the problem of definition of errors and false-negative smears. Davey DD. **Arch Pathol Lab Med** 1997 Mar;121(3):267-9 (26 ref.)

Common problems in Papanicolaou smear interpretation. DeMay RM. **Arch Pathol Lab Med** 1997 Mar;121(3):229-38 (173 ref.)

Quality and liability issues with the Papanicolaou smear: lessons from the science of error prevention. Derman H. **Arch Pathol Lab Med** 1997 Mar;121(3):287-91 (16 ref.)

Does a zero error standard exist for the Papanicolaou smear? A pathologist's perspective. Frable WJ. **Arch Pathol Lab Med** 1997 Mar;121(3):301-10 (42 ref.)

Guidelines for experts reviewing Papanicolaou smear litigation cases. Frable WJ. **Arch Pathol Lab Med** 1997 Mar; 121(3):331-4 (12 ref.)

Implications of mandating amended reports following retrospective review of Papanicolaou smears. Freedman LF. **Arch Pathol Lab Med** 1997 Mar;121(3):299-300 (0 ref.)

The gynecologist's perspective of liability and quality issues with the Papanicolaou smear. Greer BE. **Arch Pathol Lab Med** 1997 Mar;121(3):246-9 (30 ref.)

American Society of Cytopathology Laboratory Accreditation Program. Gupta PK, et al. **Arch Pathol Lab Med** 1997 Mar;121(3):260-3 (25 ref.)

Liability issues with the Papanicolaou smear: general legal background. Kline TJ. **Arch Pathol Lab Med** 1997 Mar; 121(3):250-2 (14 ref.)

The challenge of quality improvement with the Papanicolaou smear. Kline TS. **Arch Pathol Lab Med** 1997 Mar; 121(3):253-5 (20 ref.)

Strategies for reducing Papanicolaou smear screening errors: principles derived from data and experience with quality control. Krieger PA. **Arch Pathol Lab Med** 1997 Mar; 121(3):277-81 (5 ref.)

The false-negative fraction for Papanicolaou smears: how often are "abnormal" smears not detected by a "standard" screening cytologist? Naryshkin S. **Arch Pathol Lab Med** 1997 Mar;121(3):270-2 (10 ref.)

Cytopathology laboratory improvement programs of the College of American Pathologists: Laboratory Accreditation Program (CAP LAP) and Performance Improvement Program in Cervicovaginal Cytology (CAP PAP). Nielsen ML. **Arch Pathol Lab Med** 1997 Mar; 121(3):256-9 (26 ref.)

Liability issues with the Papanicolaou smear: the view of a hospital administrator at Newport Hospital, Newport, Rhode Island. Sampson AJ. **Arch Pathol Lab Med** 1997 Mar;121(3):241-5 (2 ref.)

Quality and liability issues with the Papanicolaou smear: the role of professional organizations in reform initiatives. Stanley MW. **Arch Pathol Lab Med** 1997 Mar;121(3):321-6 (10 ref.)

Liability issues with the Papanicolaou smear: a defense lawyer's perspective. Varner CD. **Arch Pathol Lab Med** 1997 Mar;121(3):315-20 (50 ref.)

False negatives in focused rescreening of Papanicolaou smears: how frequently are 'abnormal' cells detected in retrospective review of smears preceding cancer or high-grade intraepithelial neoplasia? Wilbur DC. **Arch Pathol Lab Med** 1997 Mar;121(3):273-6 (12 ref.)

Liability issues with the Papanicolaou smear: the expert witness database. Wood WS. **Arch Pathol Lab Med** 1997 Mar;121(3):335-40 (58 ref.)

Internal quality control for cervical cytopathology laboratories [editorial; comment] [see comments] Coleman DV. **Cytopathology** 1996 Feb;7(1):1-3 (7 ref.) Comment on: Cytopathology 1996 Feb;7(1):4-9. Comment in: Cytopathology 1996 Aug;7(4):296-7.

Malpractice protection: communication of diagnostic uncertainty. Skoumal SM, et al. **Diagn Cytopathol** 1996 Jun; 14(4):385-9 (51 ref.)

Update on the Papanicolaou smear: new issues for the 1990s. Ollayos CW. **Mil Med** 1997 Aug;162(8):521-3 (30 ref.)

[Cervical smears and evaluation of quality] Marsan C. **Ann Pathol** 1996 Nov;16(5):344-9 (41 ref.) **(Fre)**

[Cervical cancer screening. False negative smears] Vassilakos P, et al. **Rev Med Suisse Romande** 1997 Aug;117(8):597-601 (7 ref.) **(Fre)**

TRENDS

Quality assurance in cervical cytopathology—time for a more evidence-based approach [editorial; comment] Slater DN. **Cytopathology** 1997 Apr;8(2):75-8 (12 ref.) Comment on: Cytopathology 1997 Apr;8(2):96-102. Comment on: Cytopathology 1997 Apr;8(2):79-84. Comment on: Cytopathology 1997 Apr;8(2):85-95. Comment on: Cytopathology 1997 Apr;8(2):103-7.

UTILIZATION

A neglected lesbian health concern: cervical neoplasia. Ferris DG, et al. **J Fam Pract** 1996 Dec;43(6):581-4 (16 ref.)

VAGINITIS

DIAGNOSIS

Vaginitis/cervicitis: diagnosis and treatment options in a limited resource environment. Landers DV. **Womens Health Issues** 1996 Nov-Dec;6(6):342-8 (32 ref.)

VAGINITIS, BACTERIAL see **VAGINOSIS, BACTERIAL**

VAGINITIS, NONSPECIFIC see **VAGINOSIS, BACTERIAL**

VAGINOSIS, BACTERIAL

The relationship between bacterial vaginosis and preterm birth. A review. Chaim W, et al. **Arch Gynecol Obstet** 1997; 259(2):51-8 (44 ref.)

Bacterial vaginosis. Priestley CJ, et al. **Br J Clin Pract** 1996 Sep;50(6):331-4 (26 ref.)

COMPLICATIONS

[Bacterial vaginosis and preterm labor] Bar-David J, et al. **Harefuah** 1997 Jun 15;132(12):871-5 (50 ref.) **(Heb)**

DIAGNOSIS

Defining bacterial vaginosis: to BV or not to BV, that is the question [editorial] Hay PE, et al. **Int J STD AIDS** 1996 Jul;7(4):233-5 (14 ref.)

[The bacterial vaginosis problem] Borisov I, et al. **Akush Ginekol (Sofiia)** 1996;35(1-2):48-51 (12 ref.) (Eng. Abstr.) **(Bul)**

DRUG THERAPY

Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. Steele RW. **Clin Pediatr (Phila)** 1996 Jul;35(7):378-9 (0 ref.)

MICROBIOLOGY

[The bacterial vaginosis problem. II. The microbiology of bacterial vaginosis] Shopova E, et al. **Akush Ginekol (Sofiia)** 1996;35(3):37-9 (14 ref.) (Eng. Abstr.) **(Bul)**

VAGOTOMY

[Malignant stomach tumors in patients who have had a vagotomy for duodenal ulcers] Zuev VK, et al. **Vestn Khir Im I I Grek** 1996;155(4):97-100 (48 ref.) **(Rus)**

VAGOTOMY, TRUNCAL

An overview of laparoscopic and thoracoscopic vagotomy. Lam YH, et al. **Ann Acad Med Singapore** 1996 Sep; 25(5):699-702 (18 ref.)

METHODS

Video-assisted thoracoscopic truncal vagotomy. Palma P, et al. **Rev Esp Enferm Dig** 1997 Feb;89(2):86-93 (16 ref.) **(Eng, Spa)**

VAGUS NERVE

see related **VAGOTOMY**

Modern management of epilepsy: Vagus nerve stimulation. Ben-Menachem E. **Baillieres Clin Neurol** 1996 Dec; 5(4):841-8 (29 ref.)

ANATOMY & HISTOLOGY

[The dorsal motor nucleus of the vagus nerve and its role in innervating the digestive tract] Bagaev VA, et al. **Morfologiia** 1997;111(1):7-14 (47 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

New drugs and vagal stimulation for treatment of epilepsy—the Israeli experience. Neufeld MY, et al. **Neurol Neurochir Pol** 1996;30 Suppl 2:113-20 (23 ref.)

PHYSIOLOGY

Role of selected peptides in the vagal regulation of gastric motor and endocrine pancreatic function. Krowicki ZK. **J Physiol Pharmacol** 1996 Sep;47(3):399-409 (55 ref.)

Assessment of vagus nerve stimulation for epilepsy: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Fisher RS, et al. **Neurology** 1997 Jul;49(1):293-7 (38 ref.)

Neural monitoring system for circulating somatostatin in the hepatoportal area. Nakabayashi H. **Nutrition** 1997 Mar; 13(3):225-9 (17 ref.)

Role of medulla oblongata in generation of sympathetic and vagal outflows. Guyenet PG, et al. **Prog Brain Res** 1996; 107:127-44 (142 ref.)

Vagal efferent projections: viscerotopy, neurochemistry and effects of vagotomy. Hopkins DA, et al. **Prog Brain Res** 1996;107:79-96 (85 ref.)

Cellular mechanisms of inflammatory mediators acting on vagal sensory nerve excitability. Weinreich D. **Pulm Pharmacol** 1995 Aug-Oct;8(4-5):173-9 (5 ref.)

Vagal regulation of the gastrointestinal neuroendocrine system. Qian B, et al. **Scand J Gastroenterol** 1996 Jun; 31(6):529-40 (146 ref.)

[Progress in the study of the dorsal motor nucleus of the vagus nerve] Cheng SB, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan;27(1):13-8 (17 ref.) (Eng. Abstr.) **(Chi)**

[Pulmonary vagal afferents in man] Paleček F. **Cesk Fysiol** 1997 Jun;46(2):57-63 (90 ref.) (Eng. Abstr.) **(Cze)**

[Sympathetic-vagal euqilibrium and physical exercise] Pagani M. **Cardiologia** 1997 Jul;42(7):669-80 (46 ref.) **(Ita)**

PHYSIOPATHOLOGY

Pathophysiologic basis for vasodepressor syncope. Morillo CA, et al. **Cardiol Clin** 1997 May;15(2):233-49 (212 ref.)

Heart rate variability and its sympatho-vagal modulation. Lombardi F, et al. **Cardiovasc Res** 1996 Aug;32(2):208-16 (66 ref.)

Autonomic influences in atrial tachyarrhythmias. Coumel P. **J Cardiovasc Electrophysiol** 1996 Oct;7(10):999-1007 (22 ref.)

Enhancement of afferent nerve excitability in the airways by allergic inflammation. Riccio MM, et al. **Pulm Pharmacol** 1995 Aug-Oct;8(4-5):181-5 (16 ref.)

VALIDITY OF RESULTS see **REPRODUCIBILITY OF RESULTS**

VALINE

ANALOGS & DERIVATIVES

Valacyclovir. Acosta EP, et al. **Ann Pharmacother** 1997 Feb; 31(2):185-91 (36 ref.)

Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Markham A, et al. **Drugs** 1997 Aug;54(2):299-311 (50 ref.)

Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Perry CM, et al. **Drugs** 1996 Nov; 52(5):754-72 (70 ref.)

Treatment of herpes simplex & varicella zoster infection [editorial] Barrg C, et al. **Ir Med J** 1996 Jul-Aug; 89(4):132-4 (8 ref.)

Pharmacology of new antiherpes agents: famciclovir and valacyclovir. Stein GE. **J Am Pharm Assoc (Wash)** 1997 Mar-Apr;NS37(2):157-63 (39 ref.)

[Future prospects of valacyclovir in treating and preventing herpesviridae infections in immunosuppressed patients] Raffi F. **Presse Med** 1997 Jan;26 Suppl 1:19-21 (13 ref.) **(Fre)**

VALPROIC ACID

ADMINISTRATION & DOSAGE

Dosing strategies and time course of response to antimanic drugs. Bowden CL. **J Clin Psychiatry** 1996;57 Suppl 13:4–9; discussion 10–2 (44 ref.)

ADVERSE EFFECTS

Alopecia and mood stabilizer therapy. McKinney PA, et al. **Ann Clin Psychiatry** 1996 Sep;8(3):183–5 (12 ref.)

Altered cognitive functioning in children with idiopathic epilepsy receiving valproate monotherapy. Legarda SB, et al. **J Child Neurol** 1996 Jul;11(4):321–30 (81 ref.)

Perioperative blood loss: the effect of valproate. Winter SL, et al. **Pediatr Neurol** 1996 Jul;15(1):19–22 (10 ref.)

METABOLISM

Effect of valproate on the metabolism of the central nervous system. Bolaños JP, et al. **Life Sci** 1997;60(22):1933–42 (126 ref.)

PHARMACOKINETICS

Erythrocytes and the transport of drugs and endogenous compounds. Highley MS, et al. **Pharm Res** 1996 Feb; 13(2):186–95 (50 ref.)

PHARMACOLOGY

Possible mechanisms of valproate in migraine prophylaxis. Cutrer FM, et al. **Cephalalgia** 1997 Apr;17(2):93–100 (84 ref.)

Regulation of signal transduction pathways by mood-stabilizing agents: implications for the delayed onset of therapeutic efficacy. Manji HK, et al. **J Clin Psychiatry** 1996;57 Suppl 13:34–46; discussion 47–8 (109 ref.)

G protein-mediated signal transduction as a target of antidepressant and antibipolar drug action: evidence from model systems. Rasenick MM, et al. **J Clin Psychiatry** 1996; 57 Suppl 13:49–55; discussion 56–8 (38 ref.)

Mechanisms of action of antiepileptic drugs. Davies JA. **Seizure** 1995 Dec;4(4):267–71 (28 ref.)

THERAPEUTIC USE

Criteria for use of valproate in adult psychiatric inpatients and outpatients. Puzantian T. **Am J Health Syst Pharm** 1996 May 15;53(10):1187–8 (24 ref.)

Valproic acid: a migraine prophylaxis alternative. Shelton CE, et al. **Ann Pharmacother** 1996 Jul–Aug;30(7–8):865–6 (9 ref.)

Lithium therapy in the treatment of manic–depressive illness. Present status and future perspectives. A critical review. Emilien G, et al. **Arch Int Pharmacodyn Ther** 1995 Nov–Dec;330(3):251–78 (137 ref.)

The diagnosis and treatment of mania in the elderly. McDonald WM, et al. **Bull Menninger Clin** 1996 Spring; 60(2):174–96 (136 ref.)

Clinical studies of valproate for migraine prophylaxis. Rothrock JF. **Cephalalgia** 1997 Apr;17(2):81–3 (14 ref.)

Divalproex sodium in headache: literature review and clinical guidelines. Silberstein SD. **Headache** 1996 Oct;36(9):547–55 (66 ref.)

Health-economic implications of the onset of action of antimanic agents. Keck PE Jr, et al. **J Clin Psychiatry** 1996; 57 Suppl 13:13–8; discussion 19–22 (53 ref.)

Polypharmacy in bipolar I disorder. Solomon DA, et al. **Psychopharmacol Bull** 1996;32(4):579–87 (45 ref.)

The place of anticonvulsant therapy in bipolar illness. Post RM, et al. **Psychopharmacology (Berl)** 1996 Nov; 128(2):115–29 (160 ref.)

Mechanisms of action of antiepileptic drugs. Davies JA. **Seizure** 1995 Dec;4(4):267–71 (28 ref.)

[The diagnosis and treatment of partial epilepsy in childhood and adolescence] Martínez Bermejo Z, et al. **Neurologia** 1996 Dec;11 Suppl 4:58–71 (178 ref.) (Eng. Abstr.) **(Spa)**

[Infantile spasms (West's syndrome): characteristics and therapeutic options] Prats-Viñas JM, et al. **Rev Neurol** 1996 Nov;24(135):1411–4 (65 ref.) **(Spa)**

TOXICITY

Linking etiologies in humans and animal models: studies of autism. Rodier PM, et al. **Reprod Toxicol** 1997 Mar–Jun; 11(2–3):417–22 (24 ref.)

VAN BOGAERT-SCHERER-EPSTEIN DISEASE see **XANTHOMATOSIS, CEREBROTENDINOUS**

VAN BOGAERT'S LEUKOENCEPHALITIS see **SUBACUTE SCLEROSING PANENCEPHALITIS**

VANADATES

ADMINISTRATION & DOSAGE

Long-term antidiabetic activity of vanadyl after treatment withdrawal: restoration of insulin secretion? Cros GH, et al. **Mol Cell Biochem** 1995 Dec 6–20;153(1–2):191–5 (13 ref.)

PHARMACOLOGY

Effects of vanadate on the expression of genes involved in fuel homeostasis in animal models of Type I and Type II diabetes. Brichard SM. **Mol Cell Biochem** 1995 Dec 6–20; 153(1–2):121–4 (33 ref.)

Modulation of insulin action by vanadate: evidence of a role for phosphotyrosine phosphatase activity to alter cellular signaling. Fantus IG, et al. **Mol Cell Biochem** 1995 Dec 6–20;153(1–2):103–12 (76 ref.)

Unique and selective mitogenic effects of vanadate on SV40-transformed cells. Wang H, et al. **Mol Cell Biochem** 1995 Dec 6–20;153(1–2):59–67 (73 ref.)

THERAPEUTIC USE

In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus. Goldfine AB, et al. **Mol Cell Biochem** 1995 Dec 6–20;153(1–2):217–31 (77 ref.)

VANADIUM

METABOLISM

Membrane--vanadium interaction: a toxicokinetic evaluation. Upreti RK. **Mol Cell Biochem** 1995 Dec 6–20; 153(1–2):167–71 (26 ref.)

VANADIUM COMPOUNDS

CHEMICAL SYNTHESIS

Increased potency of vanadium using organic ligands. McNeill JH, et al. **Mol Cell Biochem** 1995 Dec 6–20; 153(1–2):175–80 (46 ref.)

CHEMISTRY

The chemistry of peroxovanadium compounds relevant to insulin mimesis. Shaver A, et al. **Mol Cell Biochem** 1995 Dec 6–20;153(1–2):5–15 (84 ref.)

PHARMACOLOGY

Peroxovanadium compounds: biological actions and mechanism of insulin-mimesis. Bevan AP, et al. **Mol Cell Biochem** 1995 Dec 6–20;153(1–2):49–58 (52 ref.)

THERAPEUTIC USE

Vanadium salts as insulin substitutes: mechanisms of action, a scientific and therapeutic tool in diabetes mellitus research. Sekar N, et al. **Crit Rev Biochem Mol Biol** 1996 Dec;31(5–6):339–59 (134 ref.)

Antihypertensive effects of vanadium compounds in hyperinsulinemic, hypertensive rats. Bhanot S, et al. **Mol Cell Biochem** 1995 Dec 6–20;153(1–2):205–9 (36 ref.)

Increased potency of vanadium using organic ligands. McNeill JH, et al. **Mol Cell Biochem** 1995 Dec 6–20; 153(1–2):175–80 (46 ref.)

TOXICITY

Toxicology of vanadium compounds in diabetic rats: the action of chelating agents on vanadium accumulation. Domingo JL, et al. **Mol Cell Biochem** 1995 Dec 6–20; 153(1–2):233–40 (75 ref.)

VANADYL see **VANADATES**

VANCOMYCIN

Role of environmental contamination in the transmission of vancomycin-resistant enterococci [editorial; comment] Weber DJ, et al. **Infect Control Hosp Epidemiol** 1997 May; 18(5):306–9 (33 ref.) Comment on: Infect Control Hosp Epidemiol 1997 May;18(5):345–7.

[Vancomycin and teicoplanin: differential aspects] Cobo J. **Enferm Infecc Microbiol Clin** 1995 Dec;13(10):600–10 (112 ref.) **(Spa)**

ADMINISTRATION & DOSAGE

Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children. Rodvold KA, et al. **Clin Pharmacokinet** 1997 Jul;33(1):32–51 (89 ref.)

ANTAGONISTS & INHIBITORS

Vancomycin-resistant enterococci. Murray BE. **Am J Med** 1997 Mar;102(3):284–93 (37 ref.)

PHARMACOKINETICS

Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children. Rodvold KA, et al. **Clin Pharmacokinet** 1997 Jul;33(1):32–51 (89 ref.)

Vancomycin cerebrospinal fluid concentrations after intravenous administration in premature infants. Reiter PD, et al. **J Perinatol** 1996 Sep–Oct;16(5):331–5 (14 ref.)

PHARMACOLOGY

Glycopeptide resistance in gram-positive pathogens. Fraimow HS, et al. **Adv Exp Med Biol** 1995;390:81–95 (51 ref.)

Vancomycin-resistant enterococci [see comments] Gin AS, et al. **Ann Pharmacother** 1996 Jun;30(6):615–24 (82 ref.) Comment in: Ann Pharmacother 1996 Dec;30(12):1500.

Bacterial resistance to vancomycin: five genes and one missing hydrogen bond tell the story. Walsh CT, et al. **Chem Biol** 1996 Jan;3(1):21–8 (32 ref.)

Resistance to glycopeptides in enterococci. Leclercq R, et al. **Clin Infect Dis** 1997 Apr;24(4):545–54; quiz 555–6 (92 ref.)

Vancomycin-resistant enterococci. Thakor K, et al. **Clin Podiatr Med Surg** 1996 Oct;13(4):661–9 (43 ref.)

Vancomycin-resistant enterococci outside the health-care setting: prevalence, sources, and public health implications. McDonald LC, et al. **Emerg Infect Dis** 1997 Jul–Sep; 3(3):311–7 (52 ref.)

Vancomycin-resistant enterococcus. Detection, epidemiology, and control measures. Boyce JM. **Infect Dis Clin North Am** 1997 Jun;11(2):367–84 (95 ref.)

Mechanisms of glycopeptide resistance in enterococci. Arthur M, et al. **J Infect** 1996 Jan;32(1):11–6 (20 ref.)

Vancomycin-resistant enterococci: clinical, microbiologic, and epidemiologic features. Noskin GA. **J Lab Clin Med** 1997 Jul;130(1):14–20 (40 ref.)

Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities. Michel M, et al. **Lancet** 1997 Jun 28; 349(9069):1901–6 (63 ref.)

Vancomycin resistant enterococci--a threat to the nephrologist on the horizon? Glycopeptide-resistant enterococci and ICDC-recommendations for a limited use of glycopeptides. Lameire N, et al. **Nephrol Dial Transplant** 1996 Dec;11(12):2402–6 (32 ref.)

Vancomycin-resistant enterococci. Palmer SM, et al. **Pharmacotherapy** 1996 Sep–Oct;16(5):819–29 (72 ref.)

Glycopeptide resistance in enterococci. Arthur M, et al. **Trends Microbiol** 1996 Oct;4(10):401–7 (41 ref.)

[Regulation mechanism of glycopeptide resistance expression] Ohno A, et al. **Nippon Rinsho** 1997 May; 55(5):1206–12 (14 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: current antibiotic therapy in the 1990s. Bradley JS, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S213–21 (58 ref.)

Vancomycin-resistant Enterococcus faecium infections in the ICU and quinupristin/dalfopristin. Zervos M. **New Horiz** 1996 Aug;4(3):385–92 (38 ref.)

First documented isolation of vancomycin-resistant Enterococcus faecium in Sweden. Melhus A, et al. **Scand J Infect Dis** 1996;28(2):191–3 (23 ref.)

[Glycopeptide resistant enterococci. Occurrence, distribution, resistance transmission, significance (editorial; comment)] Klare I, et al. **Wien Klin Wochenschr** 1997 May 9;109(9):293–300 (58 ref.) Comment on: Wien Klin Wochenschr 1997 May 9;109(9):312–20. **(Ger)**

VAPORIZATION, LASER see **LASER SURGERY**

VAPORIZERS see **NEBULIZERS AND VAPORIZERS**

VARIABLE NUMBER OF TANDEM REPEATS see **MINISATELLITE REPEATS**

VARIABLE REGION, IG see **IMMUNOGLOBULIN VARIABLE REGION**

VARIANT SURFACE GLYCOPROTEINS, TRYPANOSOMA

GENETICS

Antigenic variation in trypanosomes. Borst P, et al. **Arch Med Res** 1996 Autumn;27(3):379–88 (83 ref.)

Antigenic variation in trypanosomes: secrets surface slowly. Cross GA. **Bioessays** 1996 Apr;18(4):283–91 (77 ref.)

Implications of conserved structural motifs in disparate trypanosome surface proteins. Carrington M, et al. **Mol Biochem Parasitol** 1996 Oct 30;81(2):119–26 (27 ref.)

METABOLISM

Glycosyl phosphatidylinositol myristoylation in African trypanosomes. Werbovetz KA, et al. **Mol Biochem Parasitol** 1997 Mar;85(1):1–7 (34 ref.)

VARIATION, ANTIGENIC see **ANTIGENIC VARIATION**

VARIATION (GENETICS)

Implications of HIV variability for transmission: scientific and policy issues. Expert Group of the Joint United Nations Programme on HIV/AIDS. **AIDS** 1997 Mar 15; 11(4):UNAIDS1–15 (126 ref.)

Genetic variability of HIV-1. Subbarao S, et al. **AIDS** 1996; 10 Suppl A:S13–23 (124 ref.)

Species diversity and the evolution of behavioral controlling mechanisms. Crews D. **Ann N Y Acad Sci** 1997 Jan 15; 807:1–21 (64 ref.)

What size should a bacterium be? A question of scale. Koch AL. **Annu Rev Microbiol** 1996;50:317–48 (111 ref.)

Genetic and antigenic diversity of human caliciviruses (HuCVs) using RT-PCR and new EIAs. Jiang X, et al. **Arch Virol Suppl** 1996;12:251–62 (36 ref.)

Conservation and diversity in the structure of translation initiation factor EIF3 from humans and yeast. Hershey JW, et al. **Biochimie** 1996;78(11-12):903-7 (24 ref.)
The nature of quantitative genetic variation revisited: lessons from Drosophila bristles. Mackay TF. **Bioessays** 1996 Feb; 18(2):113-21 (68 ref.)
Genetic variation and nutrition. Simopoulos AP. **Biomed Environ Sci** 1996 Sep;9(2-3):124-9 (22 ref.)
Harvesting molecular diversity--biology's new commodity. Smith JW, et al. **Biotechnol Genet Eng Rev** 1997;14:51-65 (45 ref.)
Hypertensive cardiac hypertrophy--is genetic variance the missing link? Nunez DJ, et al. **Br J Clin Pharmacol** 1996 Jul;42(1):107-17 (128 ref.)
Structure-function relationships of band 3 variants. Bruce LJ, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 Nov; 42(7):953-73 (137 ref.)
Genetic and geographical variability in cystic fibrosis: evolutionary considerations. Bertranpetit J, et al. **Ciba Found Symp** 1996;197:97-114; discussion 114-8 (41 ref.)
Interpreting genetic variability: the effects of shared evolutionary history. Donnelly P. **Ciba Found Symp** 1996; 197:25-40; discussion 40-50 (42 ref.)
Quantitative phenotype analysis for localization and identification of disease-related genes in a complex genetic background. Lathrop GM. **Ciba Found Symp** 1996; 197:284-93; discussion 293-9 (40 ref.)
The phenylalanine hydroxylase locus: a marker for the history of phenylketonuria and human genetic diversity. PAH Mutation Analysis Consortium. Scriver CR, et al. **Ciba Found Symp** 1996;197:73-90; discussion 90-6 (60 ref.)
Cladistic approaches to identifying determinants of variability in multifactorial phenotypes and the evolutionary significance of variation in the human genome. Templeton AR. **Ciba Found Symp** 1996;197:259-77; discussion 277-83 (51 ref.)
Phylogeographic variability in traditional societies. Ward RH, et al. **Ciba Found Symp** 1996;197:6-19; discussion 19-24 (39 ref.)
The genetics of common diseases: the implications of population variability. Weatherall DJ. **Ciba Found Symp** 1996;197:300-8; discussion 308-11 (30 ref.)
Molecular variants of hepatitis B virus. Carman WF. **Clin Lab Med** 1996 Jun;16(2):407-28 (97 ref.)
Genetic variation in arthropod vectors of disease-causing organisms: obstacles and opportunities. Gooding RH. **Clin Microbiol Rev** 1996 Jul;9(3):301-20 (196 ref.)
Behavior genetics of drug sensitization. Phillips TJ. **Crit Rev Neurobiol** 1997;11(1):21-33 (90 ref.)
Defusing the Cambrian 'explosion'? Morris SC. **Curr Biol** 1997 Feb 1;7(2):R71-4 (13 ref.)
Vitamin D receptor gene variants: implications for therapy. Eisman JA. **Curr Opin Genet Dev** 1996 Jun;6(3):361-5 (53 ref.)
Apolipoprotein C-III gene variation and dyslipidaemia. Talmud PJ, et al. **Curr Opin Lipidol** 1997 Jun;8(3):154-8 (24 ref.)
Biodiversity in Toxoplasma gondii. Dardé ML. **Curr Top Microbiol Immunol** 1996;219:27-41 (27 ref.)
Clinical aspects and diagnosis of thyroid hormone transport protein anomalies. Langsteger W. **Curr Top Pathol** 1997; 91:129-61 (197 ref.)
Hepatitis C virus: molecular biology and genetic variability. Bréchot C. **Dig Dis Sci** 1996 Dec;41(12 Suppl):6S-21S (162 ref.)
The role of genetic variants in angiotensin I converting enzyme, angiotensinogen and the angiotensin II type-1 receptor in the pathophysiology of heart muscle disease. Raynolds MV, et al. **Eur Heart J** 1995 Nov;16 Suppl K:23-30 (85 ref.)
Salivary glands, cellular evolution, and adaptive radiation in mammals. Phillips CJ, et al. **Eur J Morphol** 1996 Aug; 34(3):155-61 (30 ref.)
Issues in the choice of genetic configuration for animal aging models. Austad SN. **Exp Gerontol** 1997 Jan-Apr; 32(1-2):55-63 (25 ref.)
Chromosomal and molecular divergence in the Indian pygmy field mice Mus booduga-terricolor lineage of the subgenus Mus. Sharma T. **Genetica** 1996 May;97(3):331-8 (34 ref.)
Comparing mutational variabilities. Houle D, et al. **Genetics** 1996 Jul;143(3):1467-83 (130 ref.)
Molecular dissection of quantitative traits: progress and prospects. Paterson AH. **Genome Res** 1995 Nov;5(4):321-33 (145 ref.)
Modulation of the phenotypic diversity of sickle cell anemia. Steinberg MH. **Hemoglobin** 1996 Feb;20(1):1-19 (88 ref.)
Thyroxine-binding globulin: organization of the gene and variants [published erratum appears in Horm Res 1996 Jul;46(1):37] Refetoff S, et al. **Horm Res** 1996; 45(3-5):128-38 (81 ref.)
Genetic variation in India. Papiha SS. **Hum Biol** 1996 Oct; 68(5):607-28 (65 ref.)
Identical mutations and phenotypic variation. Wolf U. **Hum Genet** 1997 Sep;100(3-4):305-21 (99 ref.)
Phenotype variation and newcomers in ion channel disorders. Bulman DE. **Hum Mol Genet** 1997;6(10):1679-85 (84 ref.)
Dynamics of HIV variants and specific cytotoxic T-cell recognition in nonprogressors and progressors. Haas G, et al. **Immunol Lett** 1997 Jun 1;57(1-3):63-8 (48 ref.)
Genetic diversity of HLA-A2: evolutionary and functional significance. Browning M, et al. **Immunol Today** 1996 Apr; 17(4):165-70 (43 ref.)
Superciliary upsweep or tented eyebrows. A distinct mendelian trait. Itin PH, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):295-7 (7 ref.)
Diet-gene interactions in human lipoprotein metabolism. Dreon DM, et al. **J Am Coll Nutr** 1997 Aug;16(4):313-24 (146 ref.)
Riboprinting: a tool for the study of genetic diversity in microorganisms. Clark CG. **J Eukaryot Microbiol** 1997 Jul-Aug;44(4):277-83 (52 ref.)
The effects of habitat fragmentation on the genetic structure of small mammal populations. Gaines MS, et al. **J Hered** 1997 Jul-Aug;88(4):294-304 (48 ref.)
Gene flow and genetic diversity in naturally fragmented metapopulations of deep-sea hydrothermal vent animals. Vrijenhoek RC. **J Hered** 1997 Jul-Aug;88(4):285-93 (67 ref.)
DNA diagnosis of human genetic individuality. Pena SD, et al. **J Mol Med** 1995 Nov;73(11):555-64 (100 ref.)
Clinical relevance of hepatitis C virus quasispecies. Enomoto N, et al. **J Viral Hepat** 1995;2(6):267-72 (27 ref.)
Investigation of the pattern of diversity of hepatitis C virus in relation to times of transmission. Simmonds P, et al. **J Viral Hepat** 1997;4 Suppl 1:69-74 (13 ref.)
Limited diversity in the major histocompatibility complex class II loci of Syrian hamster DNA. Hixon ML, et al. **Lab Anim Sci** 1996 Dec;46(6):679-81 (15 ref.)
Alternative splice variants of cytokines: making a list. Atamas SP. **Life Sci** 1997;61(12):1105-12 (53 ref.)
Biological variation in Anopheles darlingi Root. Charlwood JD. **Mem Inst Oswaldo Cruz** 1996 Jul-Aug;91(4):391-8 (80 ref.)
Evolutionary divergence and salinity-mediated selection in halophilic archaea. Dennis PP, et al. **Microbiol Mol Biol Rev** 1997 Mar;61(1):90-104 (33 ref.)
neurogenins, a novel family of atonal-related bHLH transcription factors, are putative mammalian neuronal determination genes that reveal progenitor cell heterogeneity in the developing CNS and PNS. Sommer L, et al. **Mol Cell Neurosci** 1996;8(4):221-41 (51 ref.)
To what extent is strain variation evidence for an independent genome in the agent of the transmissible spongiform encephalopathies? Ridley RM, et al. **Neurodegeneration** 1996 Sep;5(3):219-31 (89 ref.)
Rare variant of total anomalous pulmonary venous connection: intrapulmonary drainage of one lung by the other--a case report and review of the literature. Chung JH, et al. **Pediatr Pathol Lab Med** 1997 Jan-Feb; 17(1):133-40 (15 ref.)
Alien introgression in rice. Brar DS, et al. **Plant Mol Biol** 1997 Sep;35(1-2):35-47 (45 ref.)
Rice genetic resources: history, conservation, investigative characterization and use in Japan. Nakagahra M, et al. **Plant Mol Biol** 1997 Sep;35(1-2):69-77 (45 ref.)
Genetic and molecular dissection of quantitative traits in rice. Yano M, et al. **Plant Mol Biol** 1997 Sep;35(1-2):145-53 (61 ref.)
Genetic variation in susceptibility as a key parameter in risk assessment and risk communication: policy aspects. Omenn GS. **Prog Clin Biol Res** 1996;395:235-47 (37 ref.)
Seed banks and molecular maps: unlocking genetic potential from the wild. Tanksley SD, et al. **Science** 1997 Aug 22; 277(5329):1063-6 (22 ref.)
Inherited factor VII deficiency: molecular genetics and pathophysiology. Cooper DN, et al. **Thromb Haemost** 1997 Jul;78(1):151-60 (104 ref.)
Gene-environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis. Humphries SE, et al. **Thromb Haemost** 1997 Jul;78(1):457-61 (35 ref.)
Thrombomodulin gene variations and thromboembolic disease. Ohlin AK, et al. **Thromb Haemost** 1997 Jul; 78(1):396-400 (26 ref.)
Simple sequence repeats as a source of quantitative genetic variation. Kashi Y, et al. **Trends Genet** 1997 Feb;13(2):74-8 (82 ref.)
Retrovirus variation: a finger on the pulse [comment] Meyerhans A. **Trends Microbiol** 1996 Jun;4(6):218-9 (15 ref.) Comment on: Trends Microbiol 1996 Apr;4(4):135-41.
Variation and selection in neural function [letter; comment] Changeux JP. **Trends Neurosci** 1997 Jul;20(7):291-3 (20 ref.) Comment on: Trends Neurosci 1996 Nov;19(11):460-4.
Variation and selection in neural function [letter; comment] Sporns O. **Trends Neurosci** 1997 Jul;20(7):291; discussion 293 (20 ref.) Comment on: Trends Neurosci 1996 Nov;19(11):460-4.
Genetic diversity of Borrelia of Lyme borreliosis. Postic D, et al. **Wien Klin Wochenschr** 1996 Dec 13;108(23):748-51 (33 ref.)
[Hepatitis C virus. Structure and genetic variability] Bréchot C. **Bull Acad Natl Med** 1996 Jun-Jul;180(6):1219-39; discussion 1239-40 (92 ref.) (Eng. Abstr.) **(Fre)**
[Preservation of genetic variation in domestic animals using biotechnical methods] Falge R, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Aug-Sep; 103(8-9):336-40 (42 ref.) (Eng. Abstr.) **(Ger)**
[Diversity of DNA sequences among enterohemorrhagic Escherichia coli O157:H7 detected by PCR-based DNA fingerprinting] Kurazono T, et al. **Nippon Rinsho** 1997 Mar; 55(3):671-4 (7 ref.) (Eng. Abstr.) **(Jpn)**
[Hereditary biochemical diversity in the processes of evolution and individual development] Altukhov IuP, et al. **Genetika** 1996 Nov;32(11):1450-73 (199 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Genetic variation and aging. Curtsinger JW, et al. **Annu Rev Genet** 1995;29:553-75 (156 ref.)
Cystic fibrosis: genotypic and phenotypic variations. Zielenski J, et al. **Annu Rev Genet** 1995;29:777-807 (214 ref.)
Aggression in wild house mice: current state of affairs. Sluyter F, et al. **Behav Genet** 1996 Sep;26(5):489-96 (55 ref.)
The genetical archaeology of the human genome. von Haeseler A, et al. **Nat Genet** 1996 Oct;14(2):135-40 (58 ref.)

IMMUNOLOGY

Partitioning of genetic variation between regulatory and coding gene segments: the predominance of software variation in genes encoding introvert proteins. Mitchison A. **Immunogenetics** 1997;46(1):46-52 (48 ref.)

VARICELLA see **CHICKENPOX**

VARICELLA VACCINE see **CHICKENPOX VACCINE**

VARICELLA-ZOSTER VIRUS see **HERPESVIRUS 3, HUMAN**

VARICES see **VARICOSE VEINS**

VARICOCELE

The adolescent varicocele: what's new with an old problem in young patients? Skoog SJ, et al. **Pediatrics** 1997 Jul; 100(1):112-21 (14 ref.)
[Testicular varicocele in adolescence--a complicated and unsolved enigma] Bar-On E, et al. **Harefuah** 1996 Nov 1;131(9):327-31 (45 ref.) **(Heb)**
[Testicular varicocele in adolescents] Tal O, et al. **Harefuah** 1997 Jun 1;132(11):802-6 (43 ref.) **(Heb)**
[Primary varicocele: a substimated pathology in pediatrico-adolescent age] D'Agostino S, et al. **Pediatr Med Chir** 1996 Sep-Oct;18(5 Suppl):21-6 (32 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

Sclerosing lipogranuloma of the scrotum following a laparoscopic herniorraphy and varicocelectomy--a case report. Baladas HG, et al. **Ann Acad Med Singapore** 1997 Mar;26(2):238-40 (4 ref.)
Is assisted reproduction the optimal treatment for varicocele-associated male infertility? A cost-effectiveness analysis. Schlegel PN. **Urology** 1997 Jan;49(1):83-90 (52 ref.)

SURGERY

The influence of surgical approach and intraoperative venography on successful varicocelectomy in adolescents. Palmer LS, et al. **J Urol** 1997 Sep;158(3 Pt 2):1201-4 (22 ref.)
Varicocelectomy. Mellinger BC. **Tech Urol** 1995 Winter; 1(4):188-96 (49 ref.)

THERAPY

Varicocele. Girardi SK, et al. **Curr Ther Endocrinol Metab** 1997;6:355-8 (7 ref.)
Varicocele: indications for treatment. Comhaire F, et al. **Int J Androl** 1995 Dec;18 Suppl 2:67-71 (36 ref.)

VARICOSE ULCER

Chronic venous ulcer [see comments] Angle N, et al. **BMJ** 1997 Apr 5;314(7086):1019-23 (34 ref.) Comment in: BMJ 1997 Jul 19;315(7101):188; discussion 189. Comment in: BMJ 1997 Jul 19;315(7101):188-9; discussion 189. Comment in: BMJ 1997 Jul 19;315(7101):189.
[Venous leg ulcer] Hamilton Jakobsen B, et al. **Ugeskr Laeger** 1997 May 5;159(19):2836-40 (40 ref.) (Eng. Abstr.) **(Dan)**
[Venous ulcer] Esato K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):506-8 (8 ref.) **(Jpn)**

IMMUNOLOGY

The microcirculation in venous hypertension. Smith PD. **Cardiovasc Res** 1996 Oct;32(4):789-95 (59 ref.)

PHYSIOPATHOLOGY

Chronic venous insufficiency and venous ulceration. Alguire PC, et al. **J Gen Intern Med** 1997 Jun;12(6):374-83 (112 ref.)

SURGERY

Endoscopic ligation of perforating veins using a mediastinoscope. Pierik RG, et al. **Surg Laparosc Endosc** 1997 Feb;7(1):25-8 (28 ref.)

VARICOSE ULCER

THERAPY

Chronic venous insufficiency and venous ulceration. Alguire PC, et al. **J Gen Intern Med** 1997 Jun;12(6):374–83 (112 ref.)

The Unna's boot as a treatment for venous ulcers. Barr DM. **Nurse Pract** 1996 Jul;21(7):55–6, 61–4, 71–2 passim; quiz 76–7 (53 ref.)

[Chronic venous insufficiency—from pathophysiology to therapy. 4: Treatment of ulcus cruris—therapy guidelines] Peschen M, et al. **Fortschr Med** 1996 Oct 30;114(30):395–7 (8 ref.) (Eng. Abstr.) **(Ger)**

VARICOSE VEINS

see related
ESOPHAGEAL AND GASTRIC VARICES
SCLEROSING SOLUTIONS
SCLEROTHERAPY

[Visceral varix] Sakurai T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):547–9 (9 ref.) **(Jpn)**

COMPLICATIONS

Aberrant external jugular vein phlebectasia with tongue pain. Stofman GM, et al. **Am J Otolaryngol** 1997 Mar–Apr; 18(2):148–50 (8 ref.)

Colonic variceal bleeding in a patient with mesenteric venous obstruction due to an ileal carcinoid tumour. Miao YM, et al. **Eur J Gastroenterol Hepatol** 1996 Nov;8(11):1133–5 (13 ref.)

Enteroscopic diagnosis of bleeding jejunal phlebectasia: a case report and review of literature. Kumar P, et al. **Gastrointest Endosc** 1997 Aug;46(2):185–7 (13 ref.)

Bleeding from bile duct varices: an unexpected hazard during therapeutic ERCP. Tighe M, et al. **Gastrointest Endosc** 1996 Mar;43(3):250–2 (7 ref.)

Duodenal varices: a case report and review of the literature. McChesney L, et al. **HPB Surg** 1995;9(1):31–5 (25 ref.)

DIAGNOSIS

Endoscopy. Dillon JF, et al. **Baillieres Clin Gastroenterol** 1995 Dec;9(4):745–58 (54 ref.)

DRUG THERAPY

Consensus Conference on Sclerotherapy. Padua, 24 September 1994. Baccaglini U. **Int Angiol** 1995 Sep; 14(3):239–40 (0 ref.)

Vessel wall modification in venous pathology. Application to the study of phlebotonic drugs. Niebes P. **Int Angiol** 1996 Jun;15(2):88–92 (37 ref.)

ETIOLOGY

Interactions between endothelial cells and smooth muscle cells after their activation by hypoxia. A possible etiology for venous disease. Michiels C, et al. **Int Angiol** 1996 Jun; 15(2):124–30 (31 ref.)

The role of radial reflux in the genesis of varicose veins. Crotty TP. **Med Hypotheses** 1996 Dec;47(6):449–54 (32 ref.)

PATHOLOGY

Vessel wall modification in venous pathology. Application to the study of phlebotonic drugs. Niebes P. **Int Angiol** 1996 Jun;15(2):88–92 (37 ref.)

PHYSIOPATHOLOGY

The venous wall and valvular function in chronic venous insufficiency. Thulesius O. **Int Angiol** 1996 Jun;15(2):114–8 (15 ref.)

Pathophysiology and treatment of variceal hemorrhage. Roberts LR, et al. **Mayo Clin Proc** 1996 Oct;71(10):973–83 (63 ref.)

RADIOGRAPHY

Symptomatic lumbar foraminal epidural varix. Case report and review of the literature. Pekindil G, et al. **Br J Neurosurg** 1997 Apr;11(2):159–60 (11 ref.)

[Renal varices. X-ray computed tomographic diagnosis and treatment by embolization] Lenoir S, et al. **J Radiol** 1997 Jan;78(1):69–72 (13 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Idiopathic non-familial rectal and colonic varices requiring sigmoidorectal resection and coloanal anastomosis. Detry RJ, et al. **Eur J Gastroenterol Hepatol** 1996 Oct; 8(10):1023–6 (32 ref.)

[A case of massive bleeding from rectal varices treated with endoscopic variceal ligation (EVL)] Kojima T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Feb;93(2):114–9 (16 ref.) **(Jpn)**

THERAPY

A novel therapeutic approach for rectal varices: a case report of rectal varices treated with double balloon-occluded embolotherapy. Kimura T, et al. **Am J Gastroenterol** 1997 May;92(5):883–6 (14 ref.)

Case report: successful treatment of bleeding jejunal varices using mesoportal recanalization and stent placement: report of a case and review of the literature. Stafford Johnson DB, et al. **Clin Radiol** 1997 Jul;52(7):562–5 (17 ref.)

Sclerotherapy of varicose veins of the lower limbs. Consensus paper. North American Society of Phlebology. Baccaglini U, et al. **Dermatol Surg** 1996 Oct;22(10):883–9 (15 ref.)

Pathophysiology and treatment of variceal hemorrhage. Roberts LR, et al. **Mayo Clin Proc** 1996 Oct;71(10):973–83 (63 ref.)

[Treatment of a hemorrhagic duodenal varice by endoscopic sclerotherapy] Paupard T, et al. **Gastroenterol Clin Biol** 1995 Dec;19(12):1051–4 (18 ref.) (Eng. Abstr.) **(Fre)**

[A case of rectal varices treated with endoscopic injection sclerotherapy] Zeniya A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Jan;94(1):38–43 (19 ref.) **(Jpn)**

ULTRASONOGRAPHY

Practical management of primary varicose veins. Houghton AD, et al. **Br J Clin Pract** 1996 Mar;50(2):103–5 (9 ref.)

VARIOLA see **SMALLPOX**

VARIOLA MINOR see **SMALLPOX**

VARNISH see **PAINT**

VAS DEFERENS

see related
VASECTOMY
VASOVASOSTOMY

Vasectomy review: sequelae in the human epididymis and ductus deferens. McDonald SW. **Clin Anat** 1996; 9(5):337–42 (57 ref.)

ABNORMALITIES

Cystic fibrosis and infertility caused by congenital bilateral absence of the vas deferens and related clinical entities. Lissens W, et al. **Hum Reprod** 1996 Dec;11 Suppl 4:55–78; discussion 79–80 (89 ref.)

Congenital ectopic vas deferens inserting into the bladder with ipsilateral renal agenesis. Delakas D, et al. **Int Urol Nephrol** 1996;28(5):701–7 (13 ref.)

Mutations in the cystic fibrosis gene in men with congenital bilateral absence of the vas deferens. De Braekeleer M, et al. **Mol Hum Reprod** 1996 Sep;2(9):669–77 (124 ref.)

Congenital absence of the vas deferens: a mild form of cystic fibrosis. Patrizio P, et al. **Mol Med Today** 1996 Jan; 2(1):24–31 (40 ref.)

Ureteral duplication with lower pole ectopia to the vas: a case report of an exception to the Weigert-Meyer law. Slaughenhoupt BL, et al. **Urology** 1997 Feb;49(2):269–71 (3 ref.)

Congenital anomalies of the vas deferens, epididymis, and seminal vesicles. Vohra S, et al. **Urology** 1997 Mar; 49(3):313–21 (42 ref.)

SURGERY

[Surgical therapy of obstructive azoospermia: microsurgery] Fenice O, et al. **Arch Ital Urol Androl** 1996 Dec; 68(5):379–88 (29 ref.) (Eng. Abstr.) **(Ita)**

VASA VASORUM

ANATOMY & HISTOLOGY

[The vasa vasorum of the arteries] Williams JK, et al. **J Mal Vasc** 1996;21 Suppl C:266–9 (25 ref.) (Eng. Abstr.) **(Fre)**

VASCULAR ACCESS PORTS see **CATHETERS, INDWELLING**

VASCULAR-ASSIST DEVICES see **HEART-ASSIST DEVICES**

VASCULAR CAPACITANCE

see related
VASCULAR RESISTANCE

PHYSIOLOGY

Neuroendocrine regulation of vascular capacitance. Karim F. **Adv Exp Med Biol** 1995;381:81–94 (53 ref.)

Ventricular interaction and venous capacitance modulate left ventricular preload. Tyberg JV, et al. **Can J Cardiol** 1996 Oct;12(10):1058–64 (45 ref.)

VASCULAR CELL ADHESION MOLECULE-1

Basic research in antioxidant inhibition of steps in atherogenesis. Gokce N, et al. **J Cardiovasc Risk** 1996 Aug; 3(4):352–7 (65 ref.)

BIOSYNTHESIS

The significance of adhesion molecules in nephrology. Burkhardt K, et al. **Artif Organs** 1996 May;20(5):433–6 (27 ref.)

GENETICS

Genetic manipulation of vascular adhesion molecules in mice. Hynes RO, et al. **J Clin Invest** 1996 Nov 15;98(10):2193–5 (7 ref.)

Molecular defects in rare bleeding disorders: hereditary haemorrhagic telangiectasia. Shovlin CL. **Thromb Haemost** 1997 Jul;78(1):145–50 (53 ref.)

METABOLISM

VCAM-1/alpha 4-integrin adhesion pathway: therapeutic target for allergic inflammatory disorders. Foster CA. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 2):S270–7 (86 ref.)

PHYSIOLOGY

Homing and trafficking of hemopoietic progenitor cells. Papayannopoulou T, et al. **Acta Haematol** 1997; 97(1–2):97–104 (73 ref.)

The role of VCAM-1 molecule in the pathogenesis of rheumatoid synovitis. Matsuyama T, et al. **Hum Cell** 1996 Sep;9(3):187–92 (10 ref.)

VASCULAR DEMENTIA see **DEMENTIA, VASCULAR**

VASCULAR DISEASES

Liver transplantation: review of the literature. Part 2: Vascular and biliary complications. Patenaude YG, et al. **Can Assoc Radiol J** 1997 Aug;48(4):231–42 (63 ref.)

Watermelon stomach. Abedi M, et al. **Gastroenterologist** 1997 Sep;5(3):179–84 (32 ref.)

Vascular emergencies. Semashko DC. **Mt Sinai J Med** 1997 Sep–Oct;64(4–5):316–22 (24 ref.)

[Progress and view of the studies on intravascular malignant lymphomatosis] Mannen T. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1476–7 (10 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

Platelet size: measurement, physiology and vascular disease. Bath PM, et al. **Blood Coagul Fibrinolysis** 1996 Mar; 7(2):157–61 (41 ref.)

von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Lip GY, et al. **Cardiovasc Res** 1997 May;34(2):255–65 (119 ref.)

Flow cytometry assessment of leukocyte functions in vascular pathologies. Freyburger G, et al. **Hematol Cell Ther** 1996 Dec;38(6):513–26 (102 ref.)

Hyperhomocysteinemia as a risk factor for arterial and venous disease. A review of evidence and relevance. Boers GH. **Thromb Haemost** 1997 Jul;78(1):520–2 (25 ref.)

[Hyperhomocysteinemia: a new independent vascular risk factor?] Cafagna D, et al. **Minerva Cardioangiol** 1997 Jan–Feb;45(1–2):49–55 (40 ref.) (Eng. Abstr.) **(Ita)**

CHEMICALLY INDUCED

The estrogen component of OCs: cardiovascular benefits and risks. Burkman RT. **Int J Fertil Womens Med** 1997;Suppl 1:145–57 (52 ref.)

[Cyclosporine nephrotoxicity (chronic arteriolopathy, glomerulopathy)] Matsushima H, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):553–5 (20 ref.) **(Jpn)**

[Lead—an etiologic factor in vascular disease: main evidence (lecture)] Zerbino DD, et al. **Arkh Patol** 1997 Jan–Feb; 59(1):9–12 (49 ref.) (Eng. Abstr.) **(Rus)**

COMPLICATIONS

The hazy vitreous in vasoproliferative diseases. Dralands L. **Bull Soc Belge Ophtalmol** 1995;258:113–63 (279 ref.)

Vascular homeostasis, adhesion molecules, and macrovascular disease in non-insulin-dependent diabetes mellitus. Carter AM, et al. **Diabet Med** 1997 Jun; 14(6):423–32 (104 ref.)

DIAGNOSIS

Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Weitz JI, et al. **Circulation** 1996 Dec 1;94(11):3026–49 (294 ref.)

Phase-derivative analysis in MR angiography: reduced Venc dependency and improved vessel wall detection in laminar and disturbed flow. Hoogeveen RM, et al. **J Magn Reson Imaging** 1997 Mar–Apr;7(2):321–30 (32 ref.)

Contrast-enhanced MR angiography. Bosmans H, et al. **Radiologe** 1996 Feb;36(2):115–23 (42 ref.)

Gadolinium-enhanced three-dimensional MR angiography of the thoracoabdominal aorta. Krinsky G, et al. **Semin Ultrasound CT MR** 1996 Aug;17(4):280–303 (19 ref.)

[MR angiography: abdominal veins] Arlart IP. **Radiologe** 1997 Jul;37(7):554–65 (48 ref.) (Eng. Abstr.) **(Ger)**

[Standardization of nailfold capillary microscopy in routine diagnosis] Schmidt JA, et al. **Vasa** 1997;26(1):5–10 (12 ref.) (Eng. Abstr.) **(Ger)**

[Development of instrumental and technical measurement aspects for clinical capillary microscopy] Gasser P, et al. **Z Rheumatol** 1996 Jul–Aug;55(4):260–6 (30 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

EDTA chelation therapy in the treatment of vascular disease

[see comments] Chappell LT, et al. **J Cardiovasc Nurs** 1996 Apr;10(3):78–86 (49 ref.) Comment in: J Cardiovasc Nurs 1996 Apr;10(3):v–x.

Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis. McCarty MF. **Med Hypotheses** 1997 Aug; 49(2):123–31 (108 ref.)

Clinical trials with defibrotide in vascular disorders. Cimminiello C. **Semin Thromb Hemost** 1996;22 Suppl 1:29–34 (42 ref.)

EPIDEMIOLOGY

Genetic and nongenetic factors for moderate hyperhomocyst(e)inemia. Kang SS, et al. **Atherosclerosis** 1996 Jan 26;119(2):135–8 (21 ref.)

ETIOLOGY

The surgical complications of Ehlers-Danlos syndrome. Freeman RK, et al. **Am Surg** 1996 Oct;62(10):869–73 (50 ref.)

Cardiac, cerebral, and vascular complications of infective endocarditis. Harris PS, et al. **Cardiol Clin** 1996 Aug; 14(3):437–50 (98 ref.)

Cardiac allograft vasculopathy: a review. Weis M, et al. **Circulation** 1997 Sep 16;96(6):2069–77 (115 ref.)

Vascular disease of the lower extremities in diabetes mellitus. LoGerfo FW, et al. **Endocrinol Metab Clin North Am** 1996 Jun;25(2):439–45 (27 ref.)

Role of catecholamines in platelet function: pathophysiological and clinical significance. Anfossi G, et al. **Eur J Clin Invest** 1996 May;26(5):353–70 (362 ref.)

Advanced glycation end products, oxidant stress and vascular lesions. Chappey O, et al. **Eur J Clin Invest** 1997 Feb; 27(2):97–108 (107 ref.)

Vascular complications of coronary interventions. Davis C, et al. **Heart Lung** 1997 Mar-Apr;26(2):118–27 (21 ref.)

Putative mechanisms for vascular damage by homocysteine. Bellamy MF, et al. **J Inherit Metab Dis** 1997 Jun; 20(2):307–15 (37 ref.)

Hypertension, the endothelium and the pathogenesis of chronic vascular disease. Haller H. **Kidney Blood Press Res** 1996;19(3–4):166–71 (60 ref.)

Vascular dysfunction in diabetes mellitus. Feener EP, et al. **Lancet** 1997 Jul;350 Suppl 1:SI9–13 (35 ref.)

[Vascular complications during surgery of lumbar disk herniation. Apropos of 3 personal cases and 37 cases from a national investigation] Mercier P, et al. **Neurochirurgie** 1996;42(4–5):202–8 (16 ref.) (Eng. Abstr.) **(Fre)**

[Venous compression syndrome: etiology, diagnosis and therapy from the radiologic viewpoint] Alfke H, et al. **Aktuelle Radiol** 1997 May;7(3):123–9 (23 ref.) (Eng. Abstr.) **(Ger)**

["Saint Anthony's fire:" ergotamine-induced vascular spasms as the cause of acute ischemic syndrome] Rosenkranz S, et al. **Dtsch Med Wochenschr** 1997 Apr 4;122(14):450–4 (51 ref.) **(Ger)**

GENETICS

Four sibs with arterial tortuosity: description and review of the literature. Pletcher BA, et al. **Am J Med Genet** 1996 Dec 11;66(2):121–8 (06 ref.)

Genes and the development of vascular disease. Foy CA, et al. **Postgrad Med J** 1997 May;73(859):271–8 (32 ref.)

METABOLISM

Considering cellular thrombomodulin distribution and its modulating factors can facilitate the use of plasma thrombomodulin as a reliable endothelial marker? Boffa MC. **Haemostasis** 1996 Oct;26 Suppl 4:233–43 (79 ref.)

Expression of receptors for advanced glycation end-products in occlusive vascular and renal disease. Bierhaus A, et al. **Nephrol Dial Transplant** 1996;11 Suppl 5:87–90 (32 ref.)

MICROBIOLOGY

Fungal infections of the cardiovascular system--a review. Kuttin ES. **Mycoses** 1997 Jan-Feb;40(1–2):3–24 (324 ref.)

PATHOLOGY

Elastase and cell matrix interactions in the pathobiology of vascular disease. Rabinovitch M. **Acta Paediatr Jpn** 1995 Dec;37(6):657–66 (45 ref.)

Significance of vascular natriuretic peptide system in vascular remodeling in humans and its application to gene therapy. Itoh H, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:533–41 (32 ref.)

Myosin gene expression and cell phenotypes in vascular smooth muscle during development, in experimental models, and in vascular disease. Sartore S, et al. **Arterioscler Thromb Vasc Biol** 1997 Jul;17(7):1210–5 (42 ref.)

Megakaryocytes and platelets in vascular disease. van der Loo B, et al. **Baillieres Clin Haematol** 1997 Feb; 10(1):109–23 (102 ref.)

Endothelial cells in culture: an experimental model for the study of vascular dysfunctions. Chappey O, et al. **Cell Biol Toxicol** 1996 Dec;12(4–6):199–205 (17 ref.)

[The vasa vasorum of the arteries] Williams JK, et al. **J Mal Vasc** 1996;21 Suppl C:266–9 (25 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Elastase and cell matrix interactions in the pathobiology of vascular disease. Rabinovitch M. **Acta Paediatr Jpn** 1995 Dec;37(6):657–66 (45 ref.)

The role of nitric oxide in vascular biology and pathobiology. Dattilo JB, et al. **Ann Vasc Surg** 1997 May;11(3):307–14 (55 ref.)

Endothelial barrier dysfunction and oxidative stress: roles for nitric oxide? McQuaid KE, et al. **Exp Physiol** 1997 Mar; 82(2):369–76 (30 ref.)

Genetic manipulation of vascular adhesion molecules in mice. Hynes RO, et al. **J Clin Invest** 1996 Nov 15;98(10):2193–5 (7 ref.)

Systemic sclerosis. A vascular perspective. LeRoy EC. **Rheum Dis Clin North Am** 1996 Nov;22(4):675–94 (52 ref.)

[Vascular "remodeling"] Ponte E, et al. **Minerva Med** 1997 Apr;88(4):143–9 (64 ref.) (Eng. Abstr.) **(Ita)**

[Homocysteine as a risk factor for vascular changes] Nowakowski P, et al. **Pol Arch Med Wewn** 1997 Mar; 97(3):281–6 (38 ref.) **(Pol)**

[Interaction of monocytes and blood platelets in vascular wall diseases] Giedrojć J. **Postepy Hig Med Dosw** 1996; 50(3):265–76 (69 ref.) (Eng. Abstr.) **(Pol)**

SURGERY

Quality of life assessment in vascular disease: towards a consensus. Beattie DK, et al. **Eur J Vasc Endovasc Surg** 1997 Jan;13(1):9–13 (49 ref.)

What's new in vascular surgery. Perry MO. **J Am Coll Surg** 1997 Feb;184(2):223–32 (43 ref.)

A primer on common technical problems in endovascular surgery: know them to avoid them. Criado FJ, et al. **J Endovasc Surg** 1997 Feb;4(1):95–9 (6 ref.)

Noncoronary vascular stenting. Sniderman KW. **Prog Cardiovasc Dis** 1996 Sep-Oct;39(2):141–64 (134 ref.)

Evaluation of patients with suspected hypercoagulability: what tests to order. Donaldson MC. **Semin Vasc Surg** 1996 Dec;9(4):277–83 (33 ref.)

THERAPY

Endovascular stenting. Sullivan TM. **Am J Surg** 1997 Jan; 173(1):27–9; discussion 30–1 (17 ref.)

Gene therapy for vascular diseases. Nabel EG. **Atherosclerosis** 1995 Dec;118 Suppl:S51–6 (41 ref.)

Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Weitz JI, et al. **Circulation** 1996 Dec 1;94(11):3026–49 (294 ref.)

Management of vasospastic disorders of the hand. Troum SJ, et al. **Clin Plast Surg** 1997 Jan;24(1):121–32 (50 ref.)

Gene therapy and vascular disease: potential applications in vascular surgery. Hedin U, et al. **Eur J Vasc Endovasc Surg** 1997 Feb;13(2):101–11 (112 ref.)

Gene and other biological therapies for vascular diseases. Stephan D, et al. **Fundam Clin Pharmacol** 1997;11(2):97–110 (85 ref.)

Current aspects of gene therapy: implications for vascular interventions. Reifers F, et al. **J Mol Med** 1995 Dec; 73(12):595–602 (74 ref.)

The use of ultrasound as an adjunct to the performance of vascular procedures. Nemcek AA Jr. **J Vasc Interv Radiol** 1996 Nov-Dec;7(6):869–75 (23 ref.)

Vascular gene therapy in the 21st century. Clowes AW. **Thromb Haemost** 1997 Jul;78(1):605–10 (70 ref.)

ULTRASONOGRAPHY

The impact of duplex scanning on vascular practice. Androulakis AE, et al. **Int Angiol** 1996 Dec;15(4):283–90 (109 ref.)

Renovascular disease: Doppler ultrasound. Hélénon O, et al. **Semin Ultrasound CT MR** 1997 Apr;18(2):136–46 (27 ref.)

Duplex sonography of lower extremity arteries. Zierler RE, et al. **Semin Ultrasound CT MR** 1997 Feb;18(1):39–56 (67 ref.)

VASCULAR DISEASES, PERIPHERAL see **PERIPHERAL VASCULAR DISEASES**

VASCULAR ENDOTHELIUM see **ENDOTHELIUM, VASCULAR**

VASCULAR GRAFT OCCLUSION see **GRAFT OCCLUSION, VASCULAR**

VASCULAR INTIMA see **TUNICA INTIMA**

VASCULAR MEDIA see **TUNICA MEDIA**

VASCULAR NEOPLASMS

Leiomyosarcoma of the renal vein. Brandes SB, et al. **J Surg Oncol** 1996 Nov;63(3):195–200 (26 ref.)

[Vascular tumor] Nihei Z, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):458–61 (20 ref.) **(Jpn)**

COMPLICATIONS

Death due to a leiomyosarcoma of the pulmonary artery. Marchetti D, et al. **Am J Forensic Med Pathol** 1996 Dec; 17(4):315–8 (21 ref.)

DIAGNOSIS

Malignant hemangioendothelioma of the aorta. Shijubo N, et al. **Intern Med** 1995 Nov;34(11):1126–9 (14 ref.)

Pulmonary artery sarcomas: a review of clinical and radiologic features. Cox JE, et al. **J Comput Assist Tomogr** 1997 Sep-Oct;21(5):750–5 (30 ref.)

Dynamic breath-hold 3D gadolinium-enhanced MRI of intraarterial masses: findings in two patients. Krinsky G, et al. **J Comput Assist Tomogr** 1997 Jul-Aug;21(4):631–4 (9 ref.)

[Rare etiology of multiple pulmonary lacunae] Nourdine K, et al. **Rev Pneumol Clin** 1996;52(6):391–7 (32 ref.) (Eng. Abstr.) **(Fre)**

[Intravascular lymphomatosis of the nervous system--case report and review of the literature] Heesen C, et al. **Fortschr Neurol Psychiatr** 1996 Jun;64(6):234–41 (104 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Spindle cell hemangioendothelioma. An analysis of 78 cases with reassessment of its pathogenesis and biologic behavior. Perkins P, et al. **Am J Surg Pathol** 1996 Oct; 20(10):1196–204 (16 ref.)

Malignant endovascular papillary angioendothelioma (Dabska tumor) arising within a deep intramuscular hemangioma. Argani P, et al. **Arch Pathol Lab Med** 1997 Sep;121(9):992–5 (13 ref.)

Malignant peripheral nerve sheath tumour with vascular differentiation: a report of four cases. Morphopoulos GD, et al. **Histopathology** 1996 May;28(5):401–10 (41 ref.)

Giant intravenous glomus tumor. Acebo E, et al. **J Cutan Pathol** 1997 Jul;24(6):384–9 (31 ref.)

Leiomyosarcoma of the inferior vena cava: a clinicopathologic review and report of three cases. Kulaylat MN, et al. **J Surg Oncol** 1997 Jul;65(3):205–17 (95 ref.)

[Aortic tumors (neoplasms of the aortal)] Iwabuchi K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):383–6 (15 ref.) **(Jpn)**

RADIOTHERAPY

[Branchial paraganglioma. A case of carotid paraganglioma and review of the literature] Haddad Z, et al. **J Mal Vasc** 1996;21(5):315–9 (23 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

Inferior vena cava involvement by a left side adrenocortical carcinoma: operative and prognostic considerations. Mingoli A, et al. **Anticancer Res** 1996 Sep-Oct; 16(5B):3197–200 (20 ref.)

Prognostic relevance of intracaval neoplastic extension for patients with renal cell cancer. Kuczyk MA, et al. **Br J Urol** 1997 Jul;80(1):18–24 (27 ref.)

Intracaval extension of germ cell carcinoma: diagnosis via endovascular biopsy and a review of the literature. Fidias P, et al. **Eur Urol** 1997;31(3):376–9 (32 ref.)

[Intravenous leiomyomatosis of uterine origin with cardiac extension. A case report and review of the literature] Tribondeau P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(2):187–92 (33 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Treatment of haemorrhage following rupture of aortic leiomyosarcoma. Survival for 4.2 years. Testini M, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6):593–6 (16 ref.)

[Therapy of renovascular hypertension in neurofibromatosis: surgical revascularization versus percutaneous transluminal angioplasty] Türler A, et al. **Vasa** 1996;25(4):368–72 (34 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Primary sarcoma of pulmonary artery and valve: multimodality treatment by chemotherapy and homograft replacement. Zerkowski HR, et al. **J Thorac Cardiovasc Surg** 1996 Oct;112(4):1122–4 (12 ref.)

VASCULAR PATENCY

see related
GRAFT OCCLUSION, VASCULAR

The "open artery hypothesis" in survivors of myocardial infarction. Pitts WR, et al. **Clin Cardiol** 1997 Jun; 20(6):522–4 (12 ref.)

The open infarct-related artery: theoretical and practical considerations. Nash JA. **Coron Artery Dis** 1995 Sep; 6(9):739–49 (63 ref.)

Problems related to the definition of "distal" bypass and "secondary" patency rates. A paper for debate. Panayiotopoulos YP, et al. **Eur J Vasc Endovasc Surg** 1996 Nov;12(4):464–70 (37 ref.)

Recurrent myocardial infarction with patent coronary arteries. Haywood LJ, et al. **J Natl Med Assoc** 1997 Jun; 89(6):415–20 (20 ref.)

[Late reperfusion in acute myocardial infarct. The importance

VASCULAR PATENCY

of the open infarct vessel] Michel CJ, et al. **Dtsch Med Wochenschr** 1997 Mar 27;122(13):415–21 (64 ref.) **(Ger)**

VASCULAR PERMEABILITY see **CAPILLARY PERMEABILITY**

VASCULAR PROSTHESIS see **BLOOD VESSEL PROSTHESIS**

VASCULAR RESISTANCE

see related
VASCULAR CAPACITANCE

Calculating vascular resistances. Skimming JW, et al. **Clin Cardiol** 1997 Sep;20(9):805–8 (12 ref.)

[Measurement of vascular resistance] Itoh Y, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:511–3 (5 ref.) **(Jpn)**

DRUG EFFECTS

Effect of nitric oxide, prostacyclin, and thromboxane on the vasospastic action of hydrogen peroxide on human umbilical artery. Okatani Y, et al. **Acta Obstet Gynecol Scand** 1997 Jul;76(6):515–20 (24 ref.)

Effects of intra-arterial infusion of insulin on control of forearm vascular resistance in normotensive and hypertensive subjects. Imaizumi T. **Hypertens Res** 1996 Jun;19 Suppl 1:S47–50 (19 ref.)

[Effect of cyclosporin A on the reactivity of the pulmonary vascular network in dogs] Mathieu P, et al. **Ann Chir** 1996; 50(8):682–8 (25 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

The Seventh Heymans Memorial Lecture Ghent, February 18, 1995. Physiological aspects of small arteries. Mulvany MJ. **Arch Int Pharmacodyn Ther** 1996 Jan–Feb;331(1):1–31 (141 ref.)

Serotonergic vasomotor control in fish gills. Sundin L. **Braz J Med Biol Res** 1995 Nov–Dec;28(11–12):1217–21 (34 ref.)

Integrated regulation of pressure and flow in the coronary microcirculation. Muller JM, et al. **Cardiovasc Res** 1996 Oct;32(4):668–78 (59 ref.)

Neural regulation of coronary vascular resistance: role of nitric oxide in reflex cholinergic coronary vasodilation in normal and pathophysiologic states. Zhao G, et al. **EXS** 1996;76:1–19 (94 ref.)

Resistive vessel function in coronary artery disease. Uren NG, et al. **Heart** 1996 Oct;76(4):299–304 (50 ref.)

Effects of pH on vascular tension: which are the important mechanisms? Aalkjaer C, et al. **J Vasc Res** 1996 Sep–Oct; 33(5):347–59 (109 ref.)

[Endothelium as secretory organ. Possibilities for therapeutic intervention] Pfaffendorf M. **Med Monatsschr Pharm** 1996 Feb;19(2):42–53 (70 ref.) **(Ger)**

VASCULAR SMOOTH MUSCLE see **MUSCLE, SMOOTH, VASCULAR**

VASCULAR SURGERY

Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response. Boyle EM Jr, et al. **Ann Thorac Surg** 1997 Jan;63(1):277–84 (62 ref.)

Endothelial cell injury in cardiovascular surgery: the pathophysiology of vasomotor dysfunction. Sellke FW, et al. **Ann Thorac Surg** 1996 Oct;62(4):1222–8 (59 ref.)

Preoperative evaluation before noncardiac vascular surgery. Eagle KA, et al. **Cleve Clin J Med** 1996 Oct;63(6):325–30 (15 ref.)

Gene therapy and vascular disease: potential applications in vascular surgery. Hedin U, et al. **Eur J Vasc Endovasc Surg** 1997 Feb;13(2):101–11 (112 ref.)

Vascular surgery for impotence: a review. DePalma RG. **Int J Impot Res** 1997 Jun;9(2):61–7 (76 ref.)

Management of renal artery aneurysms. Cinat M, et al. **Semin Vasc Surg** 1996 Sep;9(3):236–44 (50 ref.)

Desmopressin, hemostasis, and vascular surgery. Clagett GP. **Semin Vasc Surg** 1996 Dec;9(4):340–6 (30 ref.)

Evaluation of patients with suspected hypercoagulability: what tests to order. Donaldson MC. **Semin Vasc Surg** 1996 Dec;9(4):277–83 (33 ref.)

Preoperative evaluation and intraoperative management of patients with chronic renal failure undergoing vascular procedures. Morrison DE. **Semin Vasc Surg** 1996 Sep; 9(3):166–71 (16 ref.)

[Retroperitoneal tumors and surgery of the great vessels] Barret A, et al. **Chirurgie** 1997;122(1):25–30 (18 ref.) (Eng. Abstr.) **(Fre)**

[Contribution of molecular biology to cardiovascular surgery] Sawa Y, et al. **Kyobu Geka** 1997 Jan;50(1):9–12 (11 ref.) **(Jpn)**

ADVERSE EFFECTS

Prognostic value of dobutamine-atropine stress echocardiography for peri-operative and late cardiac events in patients scheduled for vascular surgery. Poldermans D, et al. **Eur Heart J** 1997 Jun;18 Suppl D:D86–96 (56 ref.)

Crossing vessels at the ureteropelvic junction: do they influence endopyelotomy outcome? Gupta M, et al. **J Endourol** 1996 Apr;10(2):183–7 (39 ref.)

HISTORY

Carotid surgery: the past is prologue. The John Homans lecture. Thompson JE. **J Vasc Surg** 1997 Jan;25(1):131–40 (68 ref.)

METHODS

Abdominal aortic aneurysms. The old and the new. Myers K, et al. **Aust Fam Physician** 1997 Apr;26(4):418–21, 423, 425 (16 ref.)

Aortic reconstruction in patients with horseshoe or ectopic kidneys. de Virgilio C, et al. **Semin Vasc Surg** 1996 Sep; 9(3):245–52 (12 ref.)

Results of revascularization for peripheral arterial insufficiency in chronic renal failure patients. Donayre CE. **Semin Vasc Surg** 1996 Sep;9(3):253–61 (34 ref.)

Surgical methods for renal revascularization. Fujitani RM, et al. **Semin Vasc Surg** 1996 Sep;9(3):198–217 (58 ref.)

Damage control for vascular injuries. Aucar JA, et al. **Surg Clin North Am** 1997 Aug;77(4):853–62 (27 ref.)

Minimal access vascular surgery, endovascular surgery, traditional surgeryTime for reflection, evaluation, and decision. Dion Y, et al. **Surg Endosc** 1996 Dec; 10(12):1125–9 (67 ref.)

Stereotactic transsylvian, transinsular approach for deep-seated lesions. Heffez DS. **Surg Neurol** 1997 Aug; 48(2):113–24 (16 ref.)

STANDARDS

Reporting guidelines: another perspective. Bray A. **J Endovasc Surg** 1995 Nov;2(4):334–40 (8 ref.)

Revising the reporting guidelines: how far do we need to go? Rutherford RB. **J Endovasc Surg** 1995 Nov;2(4):329–31 (3 ref.)

Can there really be "uniform" reporting guidelines? Veith FJ, et al. **J Endovasc Surg** 1995 Nov;2(4):332–3 (1 ref.)

Operative repair for aortic aneurysms: the gold standard. Zarins CK, et al. **J Endovasc Surg** 1997 Aug;4(3):232–41 (57 ref.)

TRENDS

[Restenosis—elusive shadow of vascular biology. New discoveries set hopes about future therapy] Hedin U. **Lakartidningen** 1997 Jun 25;94(26–27):2481–4 (20 ref.) **(Swe)**

VASCULITIS

Vasculitis in the central nervous system. Calabrese LH, et al. **Arthritis Rheum** 1997 Jul;40(7):1189–201 (80 ref.)

Vasculitis and the kidney. Rees AJ. **Curr Opin Nephrol Hypertens** 1996 May;5(3):273–81 (122 ref.)

Vasculitis in children. Athreya BH. **Curr Opin Rheumatol** 1996 Sep;8(5):477–84 (56 ref.)

Vasculitis, Kawasaki disease, and pseudovasculitis. Cuttica RJ. **Curr Opin Rheumatol** 1997 Sep;9(5):448–57 (52 ref.)

Cutaneous necrotizing vasculitis. Lotti T, et al. **Int J Dermatol** 1996 Jul;35(7):457–74 (242 ref.)

Primary systemic vasculitis [see comments] Savage CO, et al. **Lancet** 1997 Feb 22;349(9051):553–8 (45 ref.) Comment in: Lancet 1997 Apr 5;349(9057):1029–30.

Classification, pathogenesis, and treatment of systemic vasculitis. Griffith ME, et al. **Ren Fail** 1996 Sep; 18(5):785–802 (119 ref.)

[Vasculitis: classification, mechanisms, animal, models and treatment] Sherer Y, et al. **Harefuah** 1997 Apr 15; 132(8):567–72 (46 ref.) **(Heb)**

[Vasculitic syndrome] Suzuki S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):451–4 (4 ref.) **(Jpn)**

[Vasculites—a hetergenous disease group] Palmblad J. **Lakartidningen** 1997 Feb 26;94(9):714–5 (8 ref.) **(Swe)**

BLOOD

New developments in the pathogenesis of systemic vasculitis. Cid MC. **Curr Opin Rheumatol** 1996 Jan;8(1):1–11 (114 ref.)

CHEMICALLY INDUCED

A case of eosinophilic pneumonia and vasculitis induced by diflunisal. Rich MW, et al. **Chest** 1997 Jun;111(6):1767–9 (7 ref.)

Case of propylthiouracil-induced vasculitis associated with anti-neutrophil cytoplasmic antibody (ANCA); review of literature. Kitahara T, et al. **Clin Nephrol** 1997 May; 47(5):336–40 (20 ref.)

ANCA-associated diseases and silica exposure. Gregorini G, et al. **Clin Rev Allergy Immunol** 1997 Spring;15(1):21–40 (80 ref.)

Drug-induced vasculitis. Calabrese LH, et al. **Curr Opin Rheumatol** 1996 Jan;8(1):34–40 (86 ref.)

CLASSIFICATION

Vasculitis by organ systems. Chakravarty K. **Baillieres Clin Rheumatol** 1997 May;11(2):357–93 (69 ref.)

Other forms of vasculitis and pseudovasculitis. Hamuryudan V, et al. **Baillieres Clin Rheumatol** 1997 May;11(2):335–55 (57 ref.)

Classification and epidemiology of the vasculitides. Watts RA, et al. **Baillieres Clin Rheumatol** 1997 May; 11(2):191–217 (98 ref.)

Pulmonary vasculitis: classification, clinical features, and management. Ciaccia A, et al. **Clin Rev Allergy Immunol** 1997 Spring;15(1):73–95 (249 ref.)

Classification and management of necrotising vasculitides. Guillevin L, et al. **Drugs** 1997 May;53(5):805–16 (43 ref.)

Cutaneous lymphocytic vasculitis: a definition, a review, and a proposed classification. Carlson JA, et al. **Semin Diagn Pathol** 1996 Feb;13(1):72–90 (57 ref.)

COMPLICATIONS

Neurological manifestation of vasculitis: update on immunopathogenic mechanisms and clinical features. Moore PM. **Ann Neurol** 1995 May;37 Suppl 1:S131–41 (118 ref.)

Systemic vasculitis and myelodysplastic syndromes. A report of two cases. Philippe B, et al. **Arthritis Rheum** 1997 Jan; 40(1):179–82 (16 ref.)

Idiopathic eosinophilic myositis associated with vasculitis and symmetrical polyneuropathy. Espino-Montoro A, et al. **Br J Rheumatol** 1997 Feb;36(2):276–9 (18 ref.)

The potential of bronchoalveolar lavage in the prognosis and treatment of connective-vascular diseases. Spertini F, et al. **Clin Exp Rheumatol** 1996 Nov–Dec;14(6):681–8 (47 ref.)

Mixed cryoglobulinemia as a model of systemic vasculitis. Dammacco F, et al. **Clin Rev Allergy Immunol** 1997 Spring; 15(1):97–119 (92 ref.)

Rheumatologic manifestations of HIV infections. Kaye BR. **Clin Rev Allergy Immunol** 1996–97 Winter;14(4):385–416 (274 ref.)

Vasculitides associated with malignancy. Fortin PR. **Curr Opin Rheumatol** 1996 Jan;8(1):30–3 (27 ref.)

Vasculitis in Behçet's disease. Ehrlich GE. **Int Rev Immunol** 1997;14(1):81–8 (33 ref.)

Inflammation as an early component of atherosclerosis and vascular damage—a role for P-selectin and platelet-activating factor. Prescott SM, et al. **Jpn Circ J** 1996 Mar;60(3):137–41 (26 ref.)

Association of vasculitic glomerulonephritis with membranous nephropathy: a report of 10 cases. Tse WY, et al. **Nephrol Dial Transplant** 1997 May;12(5):1017–27 (39 ref.)

Orchitis due to vasculitis in autoimmune diseases. Pannek J, et al. **Scand J Rheumatol** 1997;26(3):151–4 (40 ref.)

[Vasculitis attacking the kidneys] Grönhagen-Riska C, et al. **Duodecim** 1995;111(15):1442–51 (54 ref.) **(Fin)**

[Vasculitis in infectious diseases] Somer T, et al. **Duodecim** 1995;111(10):964–70 (34 ref.) **(Fin)**

[Pleuropulmonary manifestations of systemic vasculitis] Huong DL, et al. **Rev Med Interne** 1996;17(8):640–52 (129 ref.) (Eng. Abstr.) **(Fre)**

[Hypertension associated with systemic vasculitis] Nagasawa T. **Ryoikibetsu Shokogun Shirizu** 1996;(12):33–5 (5 ref.) **(Jpn)**

[Vasculitis and malignant diseases] Gran JT. **Tidsskr Nor Laegeforen** 1997 Apr 30;117(11):1627–9 (47 ref.) (Eng. Abstr.) **(Nor)**

[Vasculitis associated with HIV infection] Fernández-Miranda Parra C, et al. **Rev Clin Esp** 1996 Oct; 196(10):714–20 (98 ref.) **(Spa)**

DIAGNOSIS

Laboratory findings in the vasculitides. Kallenberg CG. **Baillieres Clin Rheumatol** 1997 May;11(2):395–421 (89 ref.)

Biopsy diagnosis of systemic vasculitis. Lie JT. **Baillieres Clin Rheumatol** 1997 May;11(2):219–36 (42 ref.)

Disease assessment and management of the vasculitides. Luqmani RA, et al. **Baillieres Clin Rheumatol** 1997 May; 11(2):423–46 (43 ref.)

Pulmonary capillaritis and alveolar hemorrhage. Update on diagnosis and management [published erratum appears in Chest 1997 Jul;112(1):300] Green RJ, et al. **Chest** 1996 Nov; 110(5):1305–16 (69 ref.)

Consensus meeting on the definition of physical urticarias and urticarial vasculitis. Black AK, et al. **Clin Exp Dermatol** 1996 Nov;21(6):424–6 (16 ref.)

Pulmonary vasculitis: classification, clinical features, and management. Ciaccia A, et al. **Clin Rev Allergy Immunol** 1997 Spring;15(1):73–95 (249 ref.)

Retinal vasculitis: pathogenesis and laboratory investigations. Rahi AH, et al. **Int Ophthalmol Clin** 1995 Summer; 35(3):93–105 (62 ref.)

Vasculitis and the kidney. Kallenberg CG. **Kidney Blood Press Res** 1997;20(3):194–7 (15 ref.)

Diagnosis and treatment of the systemic and cutaneous necrotizing vasculitis syndromes. Allen NB, et al. **Med Clin North Am** 1997 Jan;81(1):243–59 (39 ref.)

Atrophie blanche—a special form of vasculopathy. Kwok CY, et al. **Singapore Med J** 1997 Mar;38(3):123–4 (12 ref.)

[Basic principles in the diagnosis of vasculitis] Somer T, et al. **Duodecim** 1995;111(10):954–63 (38 ref.) **(Fin)**

[Antineutrophil cytoplasmic antibody (ANCA) and vasculitis] Yoshida M. **Ryumachi** 1995 Dec;35(6):934–42 (30 ref.) **(Jpn)**

[Systemic vasculitis as the initial presentation of a left atrial myxoma] Macedo ME, et al. **Rev Port Cardiol** 1997 May; 16(5):463–6, 441 (14 ref.) (Eng. Abstr.) **(Por)**

[Antigens and antibodies in circulating immune complex. Intensive diagnosis of symptoms difficult to interpret] Lefvert AK. **Lakartidningen** 1997 Feb 26;94(9):719–20 (4 ref.) **(Swe)**

[Renal vasculitis. Early discovery is significant for prognosis] Westberg G. **Lakartidningen** 1997 Mar 5;94(10):857–60 (11 ref.) **(Swe)**

DRUG THERAPY

Chronic immunosuppressive therapy for systemic vasculitis. Langford CA. **Curr Opin Rheumatol** 1997 Jan;9(1):41–7 (52 ref.)

Classification and management of necrotising vasculitides. Guillevin L, et al. **Drugs** 1997 May;53(5):805–16 (43 ref.)

Side-effects of intravenous cyclophosphamide pulse therapy. Martin F, et al. **Lupus** 1997;6(3):254–7 (16 ref.)

Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Jayne DR, et al. **Mayo Clin Proc** 1997 Aug;72(8):737–47 (63 ref.)

ANCA-associated vasculitis: diagnosis and treatment in the elderly. Parry R, et al. **Postgrad Med J** 1996 Jul; 72(849):423–6 (16 ref.)

[Conventional immunosuppression of chronic inflammatory systemic diseases] Gross WL, et al. **Internist (Berl)** 1997 Jun;38(6):520–31 (62 ref.) **(Ger)**

EPIDEMIOLOGY

Classification and epidemiology of the vasculitides. Watts RA, et al. **Baillieres Clin Rheumatol** 1997 May; 11(2):191–217 (98 ref.)

New insights into the epidemiology of systemic vasculitis. Cotch MF, et al. **Curr Opin Rheumatol** 1996 Jan;8(1):19–25 (55 ref.)

ETIOLOGY

Crohn's disease and gastrocnemius vasculitis: two new cases. Disdier P, et al. **Am J Gastroenterol** 1997 May;92(5):880–2 (10 ref.)

Vasculitis associated with connective tissue disease. Breedveld FC. **Baillieres Clin Rheumatol** 1997 May; 11(2):315–34 (105 ref.)

Retinal vasculitis in Lyme borreliosis. Leys AM, et al. **Bull Soc Belge Ophtalmol** 1995;259:205–14 (64 ref.)

Renal involvement in primary vasculitides. Sinico RA, et al. **Clin Rev Allergy Immunol** 1997 Spring;15(1):65–72 (28 ref.)

Multisystem interactions in the pathogenesis of vasculitis. Weyand CM, et al. **Curr Opin Rheumatol** 1997 Jan;9(1):3–11 (36 ref.)

Retinal vasculitis: pathogenesis and laboratory investigations. Rahi AH, et al. **Int Ophthalmol Clin** 1995 Summer; 35(3):93–105 (62 ref.)

Vasculitis in systemic lupus erythematosus. Drenkard C, et al. **Lupus** 1997;6(3):235–42 (41 ref.)

Vasculopathy of the antiphospholipid syndromes revisited: thrombosis is the culprit and vasculitis the consort. Lie JT. **Lupus** 1996 Oct;5(5):368–71 (40 ref.)

Pathogenesis of vasculitis syndromes. Sneller MC, et al. **Med Clin North Am** 1997 Jan;81(1):221–42 (106 ref.)

Vasculitis and lymphoproliferative diseases. Wooten MD, et al. **Semin Arthritis Rheum** 1996 Oct;26(2):564–74 (125 ref.)

[Cutaneous vasculitis disclosing parvovirus B19 infection (letter)] Andrès E, et al. **Ann Med Interne (Paris)** 1997; 148(1):107–8 (9 ref.) **(Fre)**

[Hepatitis C-associated vasculitic mononeuritis multiplex] Heckmann JG, et al. **Dtsch Med Wochenschr** 1997 Feb 28; 122(9):259–62 (22 ref.) (Eng. Abstr.) **(Ger)**

[Pulmonary vasculitis: systematic aspects, pathogenesis and therapy] Kummer F, et al. **Pneumologie** 1997 Mar; 51(3):279–85 (24 ref.) **(Ger)**

[Infections and vasculitis] Glück T, et al. **Z Rheumatol** 1997 May-Jun;56(3):105–13 (80 ref.) (Eng. Abstr.) **(Ger)**

[Renal necrotizing vasculitis] Hiromura K. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):301–4 (18 ref.) **(Jpn)**

IMMUNOLOGY

Autoantibodies to neutrophil granule proteins: pathogenic potential in vasculitis? Locke IC, et al. **Br J Biomed Sci** 1996 Dec;53(4):302–16 (133 ref.)

ANCA-associated diseases and silica exposure. Gregorini G, et al. **Clin Rev Allergy Immunol** 1997 Spring;15(1):21–40 (80 ref.)

ANCA small-vessel vasculitis. Falk RJ, et al. **J Am Soc Nephrol** 1997 Feb;8(2):314–22 (31 ref.)

Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Jayne DR, et al. **Mayo Clin Proc** 1997 Aug;72(8):737–47 (63 ref.)

The spectrum of pulmonary vasculitis. DeRemee RA. **Monaldi Arch Chest Dis** 1996 Feb;51(1):35–8 (21 ref.)

ANCA defines the clinical disease manifestations of vasculitis. The "con" side of the issue. Colby TV. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct;13(3):227–9 (22 ref.)

A lung biopsy is unnecessary in the management of ANCA-positive patients with chest-roentgenographic abnormalities. Cordier JF. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct;13(3):235–7 (17 ref.)

Serial ANCA testing has limited value during the follow-up of disease activity in patients with ANCA-associated vasculitis. Lesavre P, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct;13(3):246–8 (11 ref.)

The interaction of endothelial cells with inflammatory cells in vasculitis. Savage CO. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct;13(3):214–6 (19 ref.)

Serial ANCA testing is useful in monitoring disease activity of patients with ANCA-associated vasculitides. Tervaert JW, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct; 13(3):241–5 (40 ref.)

ANCA defines the clinical disease manifestations of vasculitis. Zhao MH, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct;13(3):221–6 (59 ref.)

[The role of perinuclear antineutrophil granulocytes cytoplasmic antibodies in the diagnosis of vasculitis and chronic inflammatory diseases (see comments)] Franssen CF, et al. **Ned Tijdschr Geneeskd** 1996 Oct 19; 140(42):2076–82 (66 ref.) Comment in: Ned Tijdschr Geneeskd 1997 Jan 4;141(1):63–4. **(Dut)**

[Antineutrophilic cytoplasmic antibodies (ANCA) in respiratory pathology] Lauque D. **Rev Mal Respir** 1996 Oct;13(5):534–6 (22 ref.) **(Fre)**

METABOLISM

Activation of endothelial cells in thrombosis and vasculitis. Cockwell P, et al. **Scand J Rheumatol** 1997;26(3):145–50 (58 ref.)

MICROBIOLOGY

Vasculitis associated with infectious agents. Lie JT. **Curr Opin Rheumatol** 1996 Jan;8(1):26–9 (40 ref.)

MORTALITY

Current status of large and small vessel vasculitis in Japan. Toshihiko N. **Int J Cardiol** 1997 Aug;54 Suppl:S91–8 (13 ref.)

PATHOLOGY

Systemic necrotizing vasculitis. Gross WL. **Baillieres Clin Rheumatol** 1997 May;11(2):259–84 (89 ref.)

Laboratory findings in the vasculitides. Kallenberg CG. **Baillieres Clin Rheumatol** 1997 May;11(2):395–421 (89 ref.)

Biopsy diagnosis of systemic vasculitis. Lie JT. **Baillieres Clin Rheumatol** 1997 May;11(2):219–36 (42 ref.)

Small vessel vasculitis and vasculitis confined to skin. Mat C, et al. **Baillieres Clin Rheumatol** 1997 May;11(2):237–57 (52 ref.)

Mixed cryoglobulinemia as a model of systemic vasculitis. Dammacco F, et al. **Clin Rev Allergy Immunol** 1997 Spring; 15(1):97–119 (92 ref.)

The spectrum of pulmonary vasculitis. DeRemee RA. **Monaldi Arch Chest Dis** 1996 Feb;51(1):35–8 (21 ref.)

Vasculitis of the lung. Travis WD, et al. **Pathology (Phila)** 1996;4(1):23–41 (98 ref.)

Neonatal acute hemorrhagic edema of childhood: case report and review of the English-language literature. Cunningham BB, et al. **Pediatr Dermatol** 1996 Jan-Feb;13(1):39–44 (10 ref.)

Cutaneous lymphocytic vasculitis: a definition, a review, and a proposed classification. Carlson JA, et al. **Semin Diagn Pathol** 1996 Feb;13(1):72–90 (57 ref.)

[ANCA-associated forms of vasculitis] Helmchen U, et al. **Verh Dtsch Ges Pathol** 1996;80:38–45 (30 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Clinical disease activity in systemic vasculitis. Exley AR, et al. **Curr Opin Rheumatol** 1996 Jan;8(1):12–8 (55 ref.)

Cell adhesion molecules in vasculitis. Tervaert JW, et al. **Curr Opin Rheumatol** 1997 Jan;9(1):16–25 (79 ref.)

THERAPY

Disease assessment and management of the vasculitides. Luqmani RA, et al. **Baillieres Clin Rheumatol** 1997 May; 11(2):423–46 (43 ref.)

The spectrum and treatment of virus-associated vasculitides. Guillevin L, et al. **Curr Opin Rheumatol** 1997 Jan;9(1):31–6 (20 ref.)

New developments in the treatment of Wegener's granulomatosis, polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome. Langford CA, et al. **Curr Opin Rheumatol** 1997 Jan;9(1):26–30 (35 ref.)

Vasculitis and the kidney. Kallenberg CG. **Kidney Blood Press Res** 1997;20(3):194–7 (15 ref.)

[Treatment of vasculitis] Friman C. **Duodecim** 1995; 111(10):978–89 (64 ref.) **(Fin)**

VIROLOGY

The spectrum and treatment of virus-associated vasculitides. Guillevin L, et al. **Curr Opin Rheumatol** 1997 Jan;9(1):31–6 (20 ref.)

VASCULITIS, ALLERGIC CUTANEOUS

DIAGNOSIS

Ciprofloxacin-induced cutaneous vasculitis. Lieu PK, et al. **Allergy** 1997 May;52(5):593–4 (5 ref.)

[Microscopic polyangiitis with eosinophilia--an overlap syndrome or separate disease entity? A case report and review of the literature] Weninger W, et al. **Hautarzt** 1997 May;48(5):332–8 (48 ref.) (Eng. Abstr.) **(Ger)**

VASCULITIS, CHURG-STRAUSS see **CHURG-STRAUSS SYNDROME**

VASCULITIS, HEMORRHAGIC see **PURPURA, SCHOENLEIN-HENOCH**

VASCULITIS, HYPERSENSITIVITY

Autoimmune vasculitis: a good clinical and basic exercise. Meroni PL, et al. **Clin Rev Allergy Immunol** 1997 Spring; 15(1):1–3 (0 ref.)

[Systemic necrotizing angitis, hypersensitivity vasculitis] Aizawa O, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (15):179–84 (10 ref.) **(Jpn)**

CHEMICALLY INDUCED

Methotrexate related cutaneous vasculitis [letter] Torner O, et al. **Clin Rheumatol** 1997 Jan;16(1):108–9 (7 ref.)

Nonsteroidal antiinflammatory drug induced hypersensitivity vasculitis clinically mimicking temporal arteritis. Lie JT, et al. **J Rheumatol** 1996 Jan;23(1):183–5 (22 ref.)

Leucocytoclastic vasculitis in a patient with azathioprine hypersensitivity. Beckett CG, et al. **Postgrad Med J** 1996 Jul;72(849):437–8 (6 ref.)

[Leukocytoclastic vasculitis associated with naproxen] Lossos IS, et al. **Harefuah** 1996 May 1;130(9):600–1, 655 (9 ref.) (Eng. Abstr.) **(Heb)**

COMPLICATIONS

Erythema elevatum diutinum in human immunodeficiency virus-infected patients--report of a case and review of the literature. Dronda F, et al. **Clin Exp Dermatol** 1996 May; 21(3):222–5 (14 ref.)

Leukocytoclastic vasculitis in subacute cutaneous lupus erythematosus: clinicopathologic study of three cases and review of the literature. Sánchez-Pérez J, et al. **Dermatology** 1996;193(3):230–5 (22 ref.)

DIAGNOSIS

Nonsteroidal antiinflammatory drug induced hypersensitivity vasculitis clinically mimicking temporal arteritis. Lie JT, et al. **J Rheumatol** 1996 Jan;23(1):183–5 (22 ref.)

ETIOLOGY

Crohn's disease and acute leukocytoclastic vasculitis of skin. Zlatanic J, et al. **Am J Gastroenterol** 1996 Nov; 91(11):2410–3 (27 ref.)

Non-infective mucocutaneous presentations of human immunodeficiency virus infection. Hamann ID, et al. **Australas J Dermatol** 1997 Aug;38(3):105–12; quiz 113–4 (43 ref.)

Microscopic polyangiitis after influenza vaccination. Kelsall JT, et al. **J Rheumatol** 1997 Jun;24(6):1198–202 (15 ref.)

IMMUNOLOGY

Cutaneous manifestations in systemic vasculitis. Decleva I, et al. **Clin Rev Allergy Immunol** 1997 Spring;15(1):5–20 (84 ref.)

PATHOLOGY

Cutaneous manifestations in systemic vasculitis. Decleva I, et al. **Clin Rev Allergy Immunol** 1997 Spring;15(1):5–20 (84 ref.)

VASCULITIS, LEUKOCYTOCLASTIC see **VASCULITIS, HYPERSENSITIVITY**

VASECTOMY

see related
STERILIZATION REVERSAL

Vasectomy and vasectomy reversal. Goldstein M, et al. **Curr Ther Endocrinol Metab** 1997;6:371–80 (6 ref.)

ADVERSE EFFECTS

Is vasectomy harmful to health? McDonald SW. **Br J Gen Pract** 1997 Jun;47(419):381–6 (113 ref.)

Vasectomy review: sequelae in the human epididymis and ductus deferens. McDonald SW. **Clin Anat** 1996; 9(5):337–42 (57 ref.)

METHODS

Sterilization. Wilson EW. **Baillieres Clin Obstet Gynaecol** 1996 Apr;10(1):103–19 (96 ref.)

Male contraception. Wu FC. **Baillieres Clin Obstet Gynaecol** 1996 Apr;10(1):1–23 (99 ref.)

Office procedures. No-scalpel vasectomy. Davis LE, et al.

VASECTOMY

Prim Care 1997 Jun;24(2):433–61 (29 ref.)

NURSING

A comprehensive and efficient process for counseling patients desiring sterilization. Haws JM, et al. **Nurse Pract** 1997 Jun;22(6):52, 55–6, 59–61 passim (40 ref.)

VASECTOMY REVERSAL see **VASOVASOSTOMY**

VASOACTIVE AGONISTS see **VASOCONSTRICTOR AGENTS**

VASOACTIVE ANTAGONISTS see **VASODILATOR AGENTS**

VASOACTIVE INTESTINAL PEPTIDE

see related
GASTROINTESTINAL AGENTS
RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE
VASODILATOR AGENTS

AGONISTS

Development of VIP agonists and antagonists with tissue and receptor specificity: effects on behavioral maturation, sexual function, and the biologic clock. Gozes I, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:159–69; discussion 169–71 (60 ref.)

ANTAGONISTS & INHIBITORS

Development of VIP agonists and antagonists with tissue and receptor specificity: effects on behavioral maturation, sexual function, and the biologic clock. Gozes I, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:159–69; discussion 169–71 (60 ref.)

BIOSYNTHESIS

Expression of vasoactive intestinal peptide in lymphocytes: a possible endogenous role in the regulation of the immune system. Leceta J, et al. **Adv Neuroimmunol** 1996;6(1):29–36 (35 ref.)

Enhancement of glucose-induced insulin secretion in transgenic mice overexpressing human VIP gene in pancreatic beta cells. Kato I, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:232–42; discussion 242–3 (28 ref.)

Regulation of VIP gene expression in general. Human lung cancer cells in particular. Davidson A, et al. **J Mol Neurosci** 1996 Summer;7(2):99–110 (77 ref.)

CHEMISTRY

Structural simplification of potent growth hormone-releasing hormone analogs: implications for other members of the VIP/GHRH/PACAP family. Coy DH, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:149–58 (15 ref.)

Speculations on the mechanism of hormone-receptor interactions of the secretin/glucagon family of polypeptide hormones derived from computational structural studies. Momany FA, et al. **Ann N Y Acad Sci** 1996 Dec 26; 805:172–81; discussion 181–3 (18 ref.)

METABOLISM

Target regulation of VIP expression in sympathetic neurons. Habecker BA, et al. **Ann N Y Acad Sci** 1997 Apr 24; 814:198–208 (47 ref.)

PHARMACOLOGY

VIP modulation of immune cell functions. De la Fuente M, et al. **Adv Neuroimmunol** 1996;6(1):75–91 (132 ref.)

Regulatory effects of vasoactive intestinal peptide on cytokine production in central and peripheral lymphoid organs. Ganea D. **Adv Neuroimmunol** 1996;6(1):61–74 (143 ref.)

Vasoactive intestinal peptide differentially modulates human immunoglobulin production. Kimata H. **Adv Neuroimmunol** 1996;6(1):107–15 (28 ref.)

Vasoactive intestinal peptide regulation of granulomatous inflammation in murine Schistosomiasis mansoni. Weinstock JV. **Adv Neuroimmunol** 1996;6(1):95–105 (51 ref.)

Identity of neurotrophic molecules released from astroglia by vasoactive intestinal peptide. Brenneman DE, et al. **Ann N Y Acad Sci** 1997 Apr 24;814:167–73 (30 ref.)

VIP and PACAP receptor-mediated actions on cell proliferation and survival. Waschek JA. **Ann N Y Acad Sci** 1996 Dec 26;805:290–300; discussion 300–1 (71 ref.)

PHYSIOLOGY

The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation. Bellinger DL, et al. **Adv Neuroimmunol** 1996;6(1):5–27 (171 ref.)

Expression of vasoactive intestinal peptide in lymphocytes: a possible endogenous role in the regulation of the immune system. Leceta J, et al. **Adv Neuroimmunol** 1996;6(1):29–36 (35 ref.)

Structural simplification of potent growth hormone-releasing hormone analogs: implications for other members of the VIP/GHRH/PACAP family. Coy DH, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:149–58 (15 ref.)

Region-specific regulation of neurogenesis by VIP and PACAP: direct and indirect modes of action. DiCicco-Bloom E. **Ann N Y Acad Sci** 1996 Dec 26; 805:244–56; discussion 256–8 (30 ref.)

Short- and long-term regulation of tyrosine hydroxylase in chromaffin cells by VIP and PACAP. Haycock JW. **Ann N Y Acad Sci** 1996 Dec 26;805:219–30; discussion 230–1 (34 ref.)

PACAP/VIP receptor subtypes, signal transducers, and effectors in pituitary cells. Hezareh M, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:315–27; discussion 327–8 (41 ref.)

VIP regulation of embryonic growth. Hill JM, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:259–68; discussion 268–9 (23 ref.)

The control of fluid-secreting epithelia by VIP. Martin SC, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:133–47; discussion 147–8 (64 ref.)

Interplay of VIP and nitric oxide in the regulation of neuromuscular function in the gut. Murthy KS, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:355–62; discussion 362–3 (27 ref.)

Vasoactive intestinal peptide and nitric oxide: divergent roles in relation to tissue injury. Said SI. **Ann N Y Acad Sci** 1996 Dec 26;805:379–87; discussion 387–8 (60 ref.)

THERAPEUTIC USE

Basic aspects of vasorelaxant and bronchodilating peptides in clinical use: urodilatin (INN: Ularitide), VIP, and PACAP. Meyer M, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:443–61; discussion 461–3 (104 ref.)

VASOACTIVE INTESTINAL PEPTIDE RECEPTORS see **RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE**

VASOCONSTRICTION

see related
VASOCONSTRICTOR AGENTS

The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Rockey D. **Hepatology** 1997 Jan;25(1):2–5 (43 ref.)

[Changed views on vasoconstriction of coronary vessels and angina pectoris] Spáčil J. **Vnitr Lek** 1996 Aug;42(8):564–7 (21 ref.) (Eng. Abstr.) **(Cze)**

DRUG EFFECTS

Angiotensin II-receptor (AT1) blockade in the human forearm. Ritter JM, et al. **Blood Press Suppl** 1996;2:67–70 (31 ref.)

PHYSIOLOGY

Cyclic phenomena in early myocardial infarction. Gasser R, et al. **Acta Med Austriaca** 1995;22(4):69–72 (22 ref.)

Interactions of neurotransmitters and endothelial cells in determining vascular tone. Shepherd JT. **Adv Exp Med Biol** 1995;381:1–13 (94 ref.)

Endothelial cell injury in cardiovascular surgery: the pathophysiology of vasomotor dysfunction. Sellke FW, et al. **Ann Thorac Surg** 1996 Oct;62(4):1222–8 (59 ref.)

Use of isolated ocular arteries in vitro to define the pathology of vascular changes in glaucoma. Buckley CH, et al. **Br J Ophthalmol** 1997 Jul;81(7):599–607 (112 ref.)

Serotonergic vasomotor control in fish gills. Sundin L. **Braz J Med Biol Res** 1995 Nov-Dec;28(11–12):1217–21 (34 ref.)

Venous tone regulatory mechanisms: what's new? Comerota AJ, et al. **Int Angiol** 1995 Sep;14(3 Suppl 1):1–7 (23 ref.)

Factors important in arterial narrowing. Schwartz SM, et al. **J Hypertens Suppl** 1996 Dec;14(5):S71–81 (119 ref.)

Interaction of nitric oxide with myogenic and adrenergic vasoconstrictor processes in the control of microcirculatory blood flow. Pohl U, et al. **Pflugers Arch** 1996;432(3 Suppl):R107–10 (46 ref.)

Acute hypoxic pulmonary vasoconstriction: a model of oxygen sensing. Michelakis ED, et al. **Physiol Res** 1995; 44(6):361–7 (45 ref.)

[Cell membrane receptors and intracellular signalling. Characterization in cultivated, contractile and endothelial cells] Briner V. **Fortschr Med** 1996 Oct 20;114(29):384–6 (18 ref.) (Eng. Abstr.) **(Ger)**

[Isoprostanes, a new substance group in angiology--of future significance?] Aghajanian AA, et al. **Vasa** 1997 May; 26(2):65–9 (24 ref.) (Eng. Abstr.) **(Ger)**

[Patchy renal vasoconstriction] Ishikawa I. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):293–6 (20 ref.) **(Jpn)**

VASOCONSTRICTOR AGENTS

Biosynthesis, metabolization and biological importance of the primary 15-lipoxygenase metabolites 15-hydro(pero)XY-5Z,8Z,11Z,13E-eicosatetraenoic acid and 13-hydro(pero)XY-9Z,11E-octadecadienoic acid. Kühn H. **Prog Lipid Res** 1996 Sep;35(3):203–26 (251 ref.)

ADVERSE EFFECTS

Cocaine-induced myocardial ischemia and infarction: pathophysiology, recognition, and management. Pitts WR, et al. **Prog Cardiovasc Dis** 1997 Jul-Aug;40(1):65–76 (88 ref.)

[Local anesthesia in operations of the head-neck area] Grevers G, et al. **Laryngorhinootologie** 1996 Jul;75(7):433–6 (10 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSTIC USE

[Pitressin test and DDAVP test] Ohta M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:303–6 (6 ref.) **(Jpn)**

METABOLISM

Molecular determinants of peptide and non-peptide binding to the AT1 receptor. Karnik SS, et al. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S58–66 (35 ref.)

PHARMACOLOGY

Use of isolated ocular arteries in vitro to define the pathology of vascular changes in glaucoma. Buckley CH, et al. **Br J Ophthalmol** 1997 Jul;81(7):599–607 (112 ref.)

Angiotensin II and the adrenal. Giacchetti G, et al. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S119–24 (49 ref.)

Regulation of renal tubular sodium transport by angiotensin II and atrial natriuretic factor. Harris PJ, et al. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S112–8 (74 ref.)

Cytokine production and its manipulation by vasoactive drugs. Pastores SM, et al. **New Horiz** 1996 May;4(2):252–64 (104 ref.)

Vascular endothelium: vasoactive mediators. Vanhoutte PM, et al. **Prog Cardiovasc Dis** 1996 Nov-Dec;39(3):229–38 (109 ref.)

[Effect of cyclosporin A on the reactivity of the pulmonary vascular network in dogs] Mathieu P, et al. **Ann Chir** 1996; 50(8):682–8 (25 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Hemodynamic support during sepsis. Ognibene FP. **Clin Chest Med** 1996 Jun;17(2):279–87 (22 ref.)

Pharmacological treatment of portal hypertension. Groszmann RJ. **Digestion** 1996;57 Suppl 1:103–6 (30 ref.)

TOXICITY

Physiological actions of angiotensin II mediated by AT1 and AT2 receptors in the brain. McKinley MJ, et al. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S99–104 (69 ref.)

VASODILATION

see related
VASODILATOR AGENTS

Aspects of coronary vasomotor regulation. Hoffman JI, et al. **Adv Exp Med Biol** 1995;381:135–46 (104 ref.)

Endothelial control of vasomotion and nitric oxide production: a potential target for risk factor management. Harrison DG. **Cardiol Clin** 1996 Feb;14(1):1–15 (68 ref.)

Role of vasopressin deficiency in the vasodilation of septic shock [editorial; comment] Reid IA. **Circulation** 1997 Mar 4;95(5):1108–10 (21 ref.) Comment on: Circulation 1997 Mar 4;95(5):1122–5.

Pharmacology of coronary vasodilation: a brief review. Orlandi C. **J Nucl Cardiol** 1996 Nov-Dec;3(6 Pt 2):S27–30 (26 ref.)

DRUG EFFECTS

Lipid-lowering treatment: effects on endothelial dysfunction. Rubba P, et al. **Curr Opin Lipidol** 1995 Dec;6(6):348–53 (61 ref.)

The niacin challenge test in schizophrenia: past, present and future. Lin A, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Aug; 55(1–2):17–9 (15 ref.)

PHYSIOLOGY

Endothelial cell injury in cardiovascular surgery: the pathophysiology of vasomotor dysfunction. Sellke FW, et al. **Ann Thorac Surg** 1996 Oct;62(4):1222–8 (59 ref.)

Aging of the vascular wall and atherogenesis: role of the elastin-laminin receptor [published erratum appears in Atherosclerosis 1996 Sep 27;126(1):173] Robert L. **Atherosclerosis** 1996 Jun;123(1–2):169–79 (56 ref.)

Insulin and the sympathetic nervous system in the pathophysiology of hypertension. Landsberg L. **Blood Press Suppl** 1996;1:25–9 (46 ref.)

Serotonergic vasomotor control in fish gills. Sundin L. **Braz J Med Biol Res** 1995 Nov-Dec;28(11–12):1217–21 (34 ref.)

Nitric oxide and shock. Kilbourn RG, et al. **Dis Mon** 1997 May;43(5):277–348 (317 ref.)

Sex hormones and vascular reactivity. Hutchison SJ, et al. **Herz** 1997 Jun;22(3):141–50 (106 ref.)

Endothelium-derived hyperpolarizing factor: a key mediator of the vasodilator action of bradykinin. Mombouli JV, et al. **Immunopharmacology** 1996 Jun;33(1–3):46–50 (25 ref.)

Neurogenic nitric oxide (NO) in the regulation of cerebroarterial tone. Toda N, et al. **J Chem Neuroanat** 1996 Jun;10(3–4):259–65 (40 ref.)

G proteins and endothelium-dependent relaxations. Boulanger CM, et al. **J Vasc Res** 1997 May-Jun; 34(3):175–85 (101 ref.)

Is nitric oxide really important for regulation of the cerebral circulation? Yes or no? Tanaka K. **Keio J Med** 1996 Mar;

45(1):14–27 (154 ref.)
Nitric oxide– and nitric oxide donor–induced relaxation. Ku DD. **Methods Enzymol** 1996;269:107–19 (20 ref.)
Endothelial vasoregulation and mechanosensitive ion channels in hypertension [editorial] Hoyer J. **Nephrol Dial Transplant** 1997 Jan;12(1):6–8 (24 ref.)
Vasovagal syncope and skeletal muscle vasodilatation: the continuing conundrum. Dietz NM, et al. **Pacing Clin Electrophysiol** 1997 Mar;20(3 Pt 2):775–80 (45 ref.)
Control of skeletal muscle blood flow during dynamic exercise: contribution of endothelium–derived nitric oxide. Green DJ, et al. **Sports Med** 1996 Feb;21(2):119–46 (265 ref.)
[Nitric oxide—a basic mediator of vasodilation and septic shock] Vasilev D, et al. **Khirurgiia (Sofiia)** 1996;49(4):14–6 (35 ref.) (Eng. Abstr.) **(Bul)**
[Vasodilation in cirrhosis: is CGRP (calcitonin gene–related peptide) also among the possible mediators?] Paoletti V, et al. **Clin Ter** 1996 Oct;147(10):505–14 (34 ref.) (Eng. Abstr.) **(Ita)**

VASODILATOR AGENTS

Adrenomedullin: view on a novel vasodilatory peptide with natriuretic properties. Massart PE, et al. **Acta Cardiol** 1996; 51(3):259–69 (53 ref.)
Adrenomedullin: a new modulator of vascular tone. Kangawa K, et al. **J Card Fail** 1996 Dec;2(4 Suppl):S135–40 (28 ref.)
Adrenomedullin: a novel cardiovascular regulatory peptide. Hanna FW, et al. **QJM** 1996 Dec;89(12):881–4 (26 ref.)

ADMINISTRATION & DOSAGE

Pharmacological treatment of ischaemic heart disease. Monotherapy vs combination therapy. Cohn PF. **Eur Heart J** 1997 May;18 Suppl B:B27–34 (43 ref.)
Advances in the treatment of organic erectile dysfunction. Kim ED, et al. **Hosp Pract (Off Ed)** 1997 Apr 15; 32(4):101–4, 107–8, 113–4 passim (0 ref.)
Technical considerations on intra–arterial papaverine hydrochloride for cerebral vasospasm. Mathis JM, et al. **Neuroradiology** 1997 Feb;39(2):90–8 (31 ref.)
[Drug treatment of sexual disorders in men (see comments)] Slob AK, et al. **Ned Tijdschr Geneeskd** 1996 Oct 12; 140(41):2029–32 (33 ref.) Comment in: Ned Tijdschr Geneeskd 1996 Dec 14;140(50):2528. **(Dut)**
[Limitations of inhaled vasodilators] Booke M, et al. **Anaesthesist** 1996 Nov;45(11):1097–107 (139 ref.) (Eng. Abstr.) **(Ger)**
[NO and alternative inhalational therapy approaches in pulmonary hypertension] Walmrath D, et al. **Internist (Berl)** 1997 May;38(5):453–60 (55 ref.) **(Ger)**
[Nitric oxide via inhalation in the newborn infant and the child with acute hypoxemic respiratory failure] Biban P, et al. **Pediatr Med Chir** 1996 May–Jun;18(3):245–51 (44 ref.) (Eng. Abstr.) **(Ita)**
[Oral vasodilators in the treatment of congestive heart failure] Pérez–Olea J. **Rev Med Chil** 1996 Oct;124(10):1256–60 (16 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Asystole during dipyridamole infusion in patients without coronary artery disease or beta–blocker therapy. Frossard M, et al. **Clin Nucl Med** 1997 Feb;22(2):97–100 (16 ref.)
Verapamil deleterious effects in chronic renal failure. Váquez C, et al. **Nephron** 1996;72(3):461–4 (11 ref.)

CHEMISTRY

The discovery of a new organic nitrate: an overview. Benedini F, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 4:S1–5 (27 ref.)

DIAGNOSTIC USE

Adenosine stress echocardiography. Chaudhry FA. **Am J Cardiol** 1997 Jun 19;79(12A):25–9 (43 ref.)
Myocardial perfusion imaging during adenosine–induced coronary hyperemia. Iskandrian AE, et al. **Am J Cardiol** 1997 Jun 19;79(12A):20–4 (37 ref.)
Role of adenosine in the cardiac catheterization laboratory. Ogilby JD. **Am J Cardiol** 1997 Jun 19;79(12A):15–9 (19 ref.)
Coronary vein flow velocity changes during transluminal balloon angioplasty: a study using the Doppler guide wire. Manginas A, et al. **Cathet Cardiovasc Diagn** 1997 Jan; 40(1):85–91 (23 ref.)
Prognostic value of stress echocardiography in stable angina or after myocardial infarction [see comments] Nagueh SF, et al. **Curr Opin Cardiol** 1996 Nov;11(6):627–34 (28 ref.) Comment in: Curr Opin Cardiol 1996 Nov;11(6):611–2.
Adenosine echocardiography in the diagnosis of coronary artery disease. Marwick TH. **Eur Heart J** 1997 Jun;18 Suppl D:D31–6 (26 ref.)
Use of stress echocardiography for the prognostic assessment of patients with stable chronic coronary artery disease. Marwick TH. **Eur Heart J** 1997 Jun;18 Suppl D:D97–101 (13 ref.)
Dipyridamole and dobutamine: competitors or allies in pharmacological stress echocardiography? Ostojic M, et al. **Eur Heart J** 1995 Oct;16 Suppl J:26–30 (31 ref.)
Dipyridamole stress echocardiography: state of the art 1996. EPIC (Echo Persantin International Cooperative) Study Group. Picano E, et al. **Eur Heart J** 1997 Jun;18 Suppl D:D16–23 (104 ref.)
Pharmacologic stress versus maximal–exercise stress for perfusion imaging: which, when, and why? Cerqueira MD. **J Nucl Cardiol** 1996 Nov–Dec;3(6 Pt 2):S10–4 (13 ref.)
Comparison of pharmacologic stress agents. Leppo JA. **J Nucl Cardiol** 1996 Nov–Dec;3(6 Pt 2):S22–6 (32 ref.)
Are separate normal data files required for quantitative pharmacologic stress radionuclide myocardial perfusion imaging? Wackers FJ. **J Nucl Cardiol** 1996 Nov–Dec;3(6 Pt 2):S31–40 (18 ref.)

ECONOMICS

Is medical treatment for angina the most cost–effective option? Cleland JG, et al. **Eur Heart J** 1997 May;18 Suppl B:B35–42 (25 ref.)

METABOLISM

Adrenomedullin: a new peptide involved in cardiorenal homeostasis? Edwards RM, et al. **Exp Nephrol** 1997 Jan–Feb;5(1):18–22 (25 ref.)
[Roles of vasoactive factors synthetized by endothelium in pulmonary arterial hypertension] Lévy M, et al. **Arch Pediatr** 1997 Mar;4(3):271–7 (32 ref.) (Eng. Abstr.) **(Fre)**
[Insulin as vasoactive hormone. Significance for diabetes, obesity and hypertension] Lind L, et al. **Lakartidningen** 1997 Aug 6;94(32–33):2730–2 (47 ref.) **(Swe)**

PHARMACOLOGY

The regulation of pulmonary vascular tone. Wilkins MR, et al. **Br J Clin Pharmacol** 1996 Jul;42(1):127–31 (39 ref.)
Use of isolated ocular arteries in vitro to define the pathology of vascular changes in glaucoma. Buckley CH, et al. **Br J Ophthalmol** 1997 Jul;81(7):599–607 (112 ref.)
Nitric oxide and related vasodilators. Young JD. **Can J Anaesth** 1997 May;44(5 Pt 2):R23–33 (46 ref.) **(Eng, Fre)**
Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. Ruffolo RR Jr, et al. **Cardiovasc Drugs Ther** 1997 May;11 Suppl 1:247–56 (77 ref.)
Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease. Brogden RN, et al. **Drugs** 1996 May;51(5):792–819 (194 ref.)
Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease. Barradell LB, et al. **Drugs Aging** 1996 Apr; 8(4):299–322 (136 ref.)
Calcitonin gene–related peptide: vasoactive effects and potential therapeutic role. Brain SD, et al. **Gen Pharmacol** 1996 Jun;27(4):607–11 (36 ref.)
The pulmonary vasodilator properties of potassium channel opening drugs. Wanstall JC. **Gen Pharmacol** 1996 Jun; 27(4):599–605 (91 ref.)
Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Windmeier C, et al. **Gen Pharmacol** 1997 Aug;29(2):181–96 (195 ref.)
K+ channel opening: a new drug principle in cardiovascular medicine [see comments] Nielsen–Kudsk JE, et al. **Heart** 1996 Aug;76(2):109–16 (51 ref.) Comment in: Heart 1997 May;77(5):487.
Nitric oxide donor, linsidomine chlorhydrate (SIN–1), in the diagnosis and treatment of erectile dysfunction: critical appraisal and review of the literature. Wegner HE, et al. **Int Urol Nephrol** 1995;27(5):621–8 (29 ref.)
Nicorandil: a potassium channel opening drug for treatment of ischemic heart disease. Goldschmidt M, et al. **J Clin Pharmacol** 1996 Jul;36(7):559–72 (83 ref.)
Pharmacology of coronary vasodilation: a brief review. Orlandi C. **J Nucl Cardiol** 1996 Nov–Dec;3(6 Pt 2):S27–30 (26 ref.)
Cytokine production and its manipulation by vasoactive drugs. Pastores SM, et al. **New Horiz** 1996 May;4(2):252–64 (104 ref.)
Vascular endothelium: vasoactive mediators. Vanhoutte PM, et al. **Prog Cardiovasc Dis** 1996 Nov–Dec;39(3):229–38 (109 ref.)
Nitric oxide supplementation or synthesis block—which is the better approach to treatment of heart disease? Curtis MJ, et al. **Trends Pharmacol Sci** 1997 Jul;18(7):239–44 (63 ref.)
Intracavernous pharmacotherapy. Truss MC, et al. **World J Urol** 1997;15(1):71–7 (109 ref.)
[Physiopathologic and pharmacodynamic rationale for the use of nitrate compounds in cardiac decompensation] Geraci E. **G Ital Cardiol** 1996 Sep;26(9):1073–7 (25 ref.) **(Ita)**
[Endothelial function, nitrate derivatives and cardiac insufficiency] Ledda F. **G Ital Cardiol** 1996 Sep; 26(9):1067–72 (22 ref.) **(Ita)**
[The effect of vasoactive preparations on kidney functional status in patients with chronic glomerulonephritis and kidney failure] Kolesnyk MO, et al. **Lik Sprava** 1996 Jul–Sep;(7–9):18–21 (30 ref.) **(Ukr)**

THERAPEUTIC USE

Adenosine for myocardial protection in acute myocardial infarction. Granger CB. **Am J Cardiol** 1997 Jun 19; 79(12A):44–8 (55 ref.)
Achieving sustained improvement in myocardial perfusion: role of isosorbide mononitrate. Lewin HC, et al. **Am J Cardiol** 1997 Jun 26;79(12B):31–5 (50 ref.)
Basic aspects of vasorelaxant and bronchodilating peptides in clinical use: urodilatin (INN: Ularitide), VIP, and PACAP. Meyer M, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:443–61; discussion 461–3 (104 ref.)
Clinical experience with pentoxifylline. Labs KH, et al. **Atherosclerosis** 1997 Jun;131 Suppl:S37–9 (15 ref.)
Remodeling after myocardial infarction: an opportunity for early intervention. Amos DJ, et al. **Basic Res Cardiol** 1997 Apr;92(2):69–71 (10 ref.)
Combination drug therapy in chronic heart failure: is treatment part of the problem in heart failure? Cleland JG. **Cardiovasc Drugs Ther** 1997 May;11 Suppl 1:297–303 (47 ref.)
Oral nitrates: more than symptomatic therapy in coronary artery disease? Thadani U. **Cardiovasc Drugs Ther** 1997 May;11 Suppl 1:213–8 (76 ref.)
Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure. Thadani U. **Cardiovasc Drugs Ther** 1997 Jan;10(6):735–42 (65 ref.)
Systemic lupus erythematosus with ischemic peripheral neuropathy and lupus anticoagulant: response to intravenous prostaglandin E1. Yoshikawa Y, et al. **Cutis** 1996 Dec;58(6):393–6 (8 ref.)
Pharmacological treatment of portal hypertension. Groszmann RJ. **Digestion** 1996;57 Suppl 1:103–6 (30 ref.)
Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease. Brogden RN, et al. **Drugs** 1996 May;51(5):792–819 (194 ref.)
Recognition and treatment of unstable angina. Brunelli C, et al. **Drugs** 1996 Aug;52(2):196–208 (80 ref.)
Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease. Barradell LB, et al. **Drugs Aging** 1996 Apr; 8(4):299–322 (136 ref.)
Optimal treatment of angina in older patients. Doughty RN, et al. **Drugs Aging** 1996 May;8(5):349–57 (39 ref.)
Stable angina: drugs, angioplasty or surgery? Jackson G. **Eur Heart J** 1997 May;18 Suppl B:B2–10 (20 ref.)
Medical management of primary pulmonary hypertension. Kneussl MP, et al. **Eur Respir J** 1996 Nov;9(11):2401–9 (104 ref.)
A nonsurgical approach to chronic anal fissure. Scholefield JH, et al. **Hosp Pract (Off Ed)** 1997 Sep 15;32(9):181–6, 188 (10 ref.)
Vasoactive drugs in chronic regurgitant lesions of the mitral and aortic valves. Levine HJ, et al. **J Am Coll Cardiol** 1996 Nov 1;28(5):1083–91 (53 ref.)
Pentoxifylline: brief review and rationale for its possible use in the treatment of autism. Gupta S, et al. **J Child Neurol** 1996 Nov;11(6):501–4 (44 ref.)
NO–donors and angina pectoris: more than just symptomatic treatment? Cleophas TJ, et al. **Neth J Med** 1997 Apr; 50(4):180–3 (24 ref.)
Potassium channel activation: a potential therapeutic approach? Lawson K. **Pharmacol Ther** 1996;70(1):39–63 (301 ref.)
Amiodarone therapy in chronic heart failure and myocardial infarction: a review of the mortality trials with special attention to STAT–CHF and the GESICA trials. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina. Pinto JV Jr, et al. **Prog Cardiovasc Dis** 1997 Jul–Aug;40(1):85–93 (34 ref.)
[Methyl thionine (methylene blue) in the treatment of sepsis] Bindels AJ, et al. **Ned Tijdschr Geneeskd** 1996 Dec 7; 140(49):2447–50 (20 ref.) **(Dut)**
[Limitations of inhaled vasodilators] Booke M, et al. **Anaesthesist** 1996 Nov;45(11):1097–107 (139 ref.) (Eng. Abstr.) **(Ger)**
[Nitric oxide donors in therapy of chronic heart failure] Blasini R, et al. **Internist (Berl)** 1997 May;38(5):448–52 (48 ref.) **(Ger)**
[Nitric oxide in therapy of angina pectoris: nitrates or molsidomine?] Schächinger V, et al. **Internist (Berl)** 1997 May;38(5):438–47 (49 ref.) **(Ger)**
[Pharmacotherapy of severe heart failure with inodilators—new approaches] Baumann G, et al. **Z Kardiol** 1996;85 Suppl 4:9–19 (49 ref.) (Eng. Abstr.) **(Ger)**
[Clinical and diagnostic indications for the use of nitrates in dynamic heart defects (decompensation, left ventricular dysfunction without decompensation, etc.] Branzi A. **G Ital Cardiol** 1996 Sep;26(9):1079–84 (19 ref.) **(Ita)**
[Pharmacologic interactions with nitrates in patients with, or at risk of, cardiac decompensation] Filardi PP, et al. **G Ital Cardiol** 1996 Sep;26(9):1085–8 (09 ref.) **(Ita)**
[The role of nitrates in left ventricular insufficiency in patients with acute myocardial infarction] Maggioni AP. **G Ital Cardiol** 1996 Sep;26(9):1095–8 (04 ref.) **(Ita)**
[Effectiveness, tolerance, adverse effects of prolonged therapy with nitrate compounds] Mazzotta G. **G Ital Cardiol** 1996 Sep;26(9):1099–106 (56 ref.) **(Ita)**
[Medical treatment of arteriosclerosis obliterans (ASO)] Matsuo H. **Nippon Geka Gakkai Zasshi** 1996 Jul;97(7):520–5 (23 ref.) (Eng. Abstr.) **(Jpn)**
[Vasodilators: treatment of heart failure] Kumada T. **Nippon Naika Gakkai Zasshi** 1994 Jan 10;83(1):64–9 (2 ref.)

VASODILATOR AGENTS

(Jpn)
[Trimetazidine (Preductal). A new approach in controlling myocardial ischemia] Eliseev OM. **Ter Arkh** 1996; 68(8):57–63 (78 ref.) (Rus)

VASOMOTOR RHINITIS see **RHINITIS, VASOMOTOR**

VASOMOTOR SYSTEM

see related
BAROREFLEX
MUSCLE, SMOOTH, VASCULAR
VASOCONSTRICTOR AGENTS
VASODILATOR AGENTS

Gap junctions in vascular tissues. Evaluating the role of intercellular communication in the modulation of vasomotor tone. Christ GJ, et al. **Circ Res** 1996 Oct; 79(4):631–46 (154 ref.)

DRUG EFFECTS

Vasomotor reactions with gold*[editorial] Ho M, et al. **Br J Rheumatol** 1997 Feb;36(2):154–6 (15 ref.)
Pharmacology of reticulospinal vasomotor neurons in cardiovascular regulation. Sun MK. **Pharmacol Rev** 1996 Dec;48(4):465–94 (408 ref.)

PHYSIOLOGY

The supply of vasomotor drive to individual classes of sympathetic neuron. McAllen RM, et al. **Clin Exp Hypertens** 1997 Jul–Aug;19(5–6):607–18 (22 ref.)
Pharmacology of reticulospinal vasomotor neurons in cardiovascular regulation. Sun MK. **Pharmacol Rev** 1996 Dec;48(4):465–94 (408 ref.)

PHYSIOPATHOLOGY

Role of coronary vasomotor tone in patients with stable angina pectoris. Kaufmann P, et al. **Cardiologia** 1996 Oct; 41(10):945–51 (63 ref.)
Vibration syndrome and autonomic nervous system. Sakakibara H, et al. **Cent Eur J Public Health** 1995;3 Suppl:11–4 (56 ref.)
Vasoactive hormones and renal sclerosis. Egido J. **Kidney Int** 1996 Feb;49(2):578–97 (229 ref.)
[The significance of endothelin for physiologic and pathophysiologic processes of the lung (see comments)] Schmeck J, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jul; 32(7):401–8 (123 ref.) (Eng. Abstr.) Comment in: Anasthesiol Intensivmed Notfallmed Schmer 1997 Jul;32(7):397–8. (Ger)
[Coronary vasomotion in coronary heart disease—significance of epicardial and microcirculatory vessels for myocardial perfusion] Kelm M, et al. **Z Kardiol** 1997;86 Suppl 1:33–41 (73 ref.) (Eng. Abstr.) (Ger)

VASOPRESSIN, ARGININE see **ARGIPRESSIN**

VASOPRESSIN, DEAMINO ARGININE see **DESMOPRESSIN**

VASOPRESSIN RECEPTORS see **RECEPTORS, VASOPRESSIN**

VASOPRESSINS

see related
INAPPROPRIATE ADH SYNDROME
RECEPTORS, VASOPRESSIN

CHEMISTRY

Cellular and molecular events in the action of antidiuretic hormone. Hays RM. **Kidney Int** 1996 Jun;49(6):1700–5 (30 ref.)

DEFICIENCY

Role of vasopressin deficiency in the vasodilation of septic shock [editorial; comment] Reid IA. **Circulation** 1997 Mar 4;95(5):1108–10 (21 ref.) Comment on: Circulation 1997 Mar 4;95(5):1122–5.

DIAGNOSTIC USE

[Lysine-vasopressin test] Horiba N, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:272–4 (5 ref.) (Jpn)
[Pitressin test and DDAVP test] Ohta M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:303–6 (6 ref.) (Jpn)

METABOLISM

Regulation of the hypothalmic–pituitary–adrenal axis and vasopressin secretion. Role of angiotensin II. Aguilera G, et al. **Adv Exp Med Biol** 1996;396:105–12 (29 ref.)

PHARMACOLOGY

Role of prostaglandins in the stimulation of the hypothalamic–pituitary–adrenal axis by adrenergic and neurohormone systems. Bugajski J. **J Physiol Pharmacol** 1996 Dec;47(4):559–75 (78 ref.)
[Hormone-mediated calcium responses of rat and human hepatocytes. Study of multicellular systems by videomicroscopy] Tordjmann T, et al. **Gastroenterol Clin Biol** 1995 Dec;19(12):980–90 (24 ref.) (Eng. Abstr.) (Fre)

PHYSIOLOGY

Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin. Knepper MA. **Am J Physiol** 1997 Jan;272(1 Pt 2):F3–12 (59 ref.)
A neurobiological basis of social attachment. Insel TR. **Am J Psychiatry** 1997 Jun;154(6):726–35 (84 ref.)
Peptides, steroids, and pair bonding. Carter CS, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:260–72 (33 ref.)
Interactions between vasopressin and baroreflex control of the sympathetic nervous system. Hasser EM, et al. **Clin Exp Pharmacol Physiol** 1997 Jan;24(1):102–8 (53 ref.)
Regulation of aquaporin-2 water channel trafficking by vasopressin. Knepper MA, et al. **Curr Opin Cell Biol** 1997 Aug;9(4):560–4 (46 ref.)
Oxytocin and vasopressin neurones: vive la différence! Hatton GI. **J Physiol (Lond)** 1997 Apr 15;500 (Pt 2):284 (5 ref.)
Cellular and molecular events in the action of antidiuretic hormone. Hays RM. **Kidney Int** 1996 Jun;49(6):1700–5 (30 ref.)
Sodium and water retention in heart failure: pathogenesis and treatment. Martin PY, et al. **Kidney Int Suppl** 1997 Jun;59:S57–61 (39 ref.)
Behavioral consequences of intracerebral vasopressin and oxytocin: focus on learning and memory. Engelmann M, et al. **Neurosci Biobehav Rev** 1996 Autumn;20(3):341–58 (219 ref.)
Central behavioral effects of vasopressin: point and perspectives. Alescio-Lautier B, et al. **Rev Neurosci** 1993 Jul–Sep;4(3):239–66 (167 ref.)
Do aquaporins have a role in nocturnal enuresis? Frøkiaer J, et al. **Scand J Urol Nephrol Suppl** 1997;183:31–2 (10 ref.)
[Heart failure and circulatory control peptides] Takeshita A. **Nippon Naika Gakkai Zasshi** 1994 Jan 10;83(1):138–42 (10 ref.) (Jpn)
[The role of oxytocin and vasopressin in the regulation of mammalian reproduction] Grinevich VV, et al. **Morfologiia** 1997;111(2):17–27 (96 ref.) (Eng. Abstr.) (Rus)
[Aquaretic agents] Bosch-Marcé M, et al. **Gastroenterol Hepatol** 1996 Nov;19(9):472–7 (55 ref.) (Spa)

SECRETION

Evidence for a renomedullary vasodepressor hormone. Thomas CJ, et al. **Clin Exp Pharmacol Physiol** 1996 Sep; 23(9):777–85 (69 ref.)
[Endocrine theory of idiopathic nocturnal enuresis] Guignard JP. **Arch Pediatr** 1997;4 Suppl 1:3s–6s (21 ref.) (Eng. Abstr.) (Fre)
[Carter-Robbins test] Kimura T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:291–4 (5 ref.) (Jpn)
[Clinical studies in antidiuretic hormone secretion] Shoji M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:299–302 (3 ref.) (Jpn)

THERAPEUTIC USE

Octreotide or vasopressin for bleeding esophageal varices. Law AW, et al. **Ann Pharmacother** 1997 Feb;31(2):237–8 (15 ref.)

VASOPRESSOR AGENTS see **VASOCONSTRICTOR AGENTS**

VASOSTOMY see **VASOVASOSTOMY**

VASOVASOSTOMY

[Surgical therapy of obstructive azoospermia: microsurgery] Fenice O, et al. **Arch Ital Urol Androl** 1996 Dec; 68(5):379–88 (29 ref.) (Eng. Abstr.) (Ita)

VATER'S AMPULLA

see related
CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE
SPHINCTEROTOMY, ENDOSCOPIC

An impacted metallic clip at the ampulla causing ascending cholangitis. Venu RP, et al. **Gastrointest Endosc** 1997 May; 45(5):435–6 (12 ref.)
Villous adenocarcinoma of the duodenum invading the ampulla of Vater case report and review of literature. Catania G, et al. **HPB Surg** 1996;10(2):105–9 (23 ref.)
Surgical approaches to benign and malignant tumors of the ampulla of vater. Rivera JA, et al. **Surg Oncol Clin N Am** 1996 Jul;5(3):689–711 (80 ref.)
Ampullary carcinoma in familial adenomatous polyposis: report of a case. Tomita H, et al. **Surg Today** 1996; 26(7):522–6 (16 ref.)
[Malignant bile duct diseases and jaundice] Mukai H, et al. **Nippon Naika Gakkai Zasshi** 1997 Apr 10;86(4):620–8 (5 ref.) (Jpn)
[A case of von Recklinghausen's disease complicated by adenocarcinoma of the papilla of Vater] Nagayama K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Feb;94(2):123–8 (16 ref.) (Jpn)
[Neuroendocrine carcinoma of the ampullar region with oat-cell histological features and adenocarcinoma] Fresno MF, et al. **Rev Esp Enferm Dig** 1997 Jan;89(1):60–4 (24 ref.) (Eng. Abstr.) (Spa)

ABNORMALITIES

[Congenital duodenal diaphragm in an adult associated with an abnormal location of Vater's ampulla: a case report and review of the literature] Lapointe R, et al. **Can J Surg** 1997 Jun;40(3):231–5 (39 ref.) (Eng. Abstr.) (Fre)

SURGERY

Transduodenal excision of tumours of the ampulla of Vater. Alstrup N, et al. **Eur J Surg** 1996 Dec;162(12):961–7 (22 ref.)
[Tumors of the papilla of Vater—diagnostic and therapeutic dilemmas] Balgha V, et al. **Orv Hetil** 1997 Jun 1; 138(22):1387–91 (42 ref.) (Eng. Abstr.) (Hun)
[Pancreatoduodenectomy in the treatment of carcinoma of Vater's ampulla] Morales-Linares JC, et al. **Rev Invest Clin** 1996 May–Jun;48(3):185–9 (25 ref.) (Eng. Abstr.) (Spa)

VCAM-1 see **VASCULAR CELL ADHESION MOLECULE-1**

VECTORCARDIOGRAPHY

[Vectorcardiography] Yotsukura M, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:547–51 (4 ref.) (Jpn)

VECTORS, GENETIC see **GENETIC VECTORS**

VEGETABLE OILS see **PLANT OILS**

VEGETABLE PROTEINS

BIOSYNTHESIS

Engineering nutritious proteins. Hefford MA. **Biotechnol Genet Eng Rev** 1997;14:191–210 (108 ref.)

VEGETABLES

The National 5 A Day for Better Health Program. Heimendinger J, et al. **Adv Exp Med Biol** 1996;401:199–206 (29 ref.)
Colon cancer: the evolution of causal concepts [editorial] McMichael AJ. **Cancer Causes Control** 1997 Jul;8(4):541–3 (24 ref.)
Cancer prevention: epidemiology and experiment. Potter JD. **Cancer Lett** 1997 Mar 19;114(1–2):7–9 (5 ref.)
Combined effects of complex mixtures of potentially anti-carcinogenic compounds on antioxidant enzymes and carcinogen metabolizing enzymes in the rat. Vang O, et al. **Cancer Lett** 1997 Mar 19;114(1–2):283–6 (12 ref.)
Vegetables, fruit and phytoestrogens as preventive agents. Potter JD, et al. **IARC Sci Publ** 1996;(139):61–90 (205 ref.)
Fruit and vegetables, and cardiovascular disease: a review. Ness AR, et al. **Int J Epidemiol** 1997 Feb;26(1):1–13 (63 ref.)
Vegetables, fruit, and cancer prevention: a review. Steinmetz KA, et al. **J Am Diet Assoc** 1996 Oct;96(10):1027–39 (262 ref.)
Plant foods in the management of diabetes mellitus: vegetables as potential hypoglycaemic agents. Platel K, et al. **Nahrung** 1997 Apr;41(2):68–74 (53 ref.)
Fruits and vegetables: protective or just fellow travelers? Nestle M. **Nutr Rev** 1996 Aug;54(8):255–7 (22 ref.)
An approach to functional food: cancer preventive potential of vegetables and fruits and their active constituents. Ohigashi H, et al. **Nutr Rev** 1996 Nov;54(11 Pt 2):S24–8 (26 ref.)
[The Mediterranean diet in Spain. Legend or reality? (II). Other elements in the Mediterranean diet: vegetables and fruits, fish. Evolution of the diet and cardiovascular diseases in Spain in the last decades] Alvarez-Sala Walther LA, et al. **Rev Clin Esp** 1996 Sep;196(9):636–46 (161 ref.) (Spa)

ADVERSE EFFECTS

1,2,3-Trithiane-5-carboxylic acid, a first contact allergen from Asparagus officinalis (Liliaceae). Hausen BM, et al. **Am J Contact Dermat** 1996 Mar;7(1):41–6 (32 ref.)

CHEMISTRY

Squash inhibitor family of serine proteinases. Otlewski J, et al. **Acta Biochim Pol** 1996;43(3):431–44 (81 ref.)
Cancer chemoprevention by polyphenols in green tea and artichoke. Agarwal R, et al. **Adv Exp Med Biol** 1996; 401:35–50 (107 ref.)
Official multiresidue methods of pesticide analysis in vegetables, fruits and soil. Motohashi N, et al. **J Chromatogr A** 1996 Nov 22;754(1–2):333–46 (64 ref.)
Determination of pesticide residues in fruit and vegetables. Torres CM, et al. **J Chromatogr A** 1996 Nov 22; 754(1–2):301–31 (185 ref.)
Natural polyphenols (vegetable tannins) as drugs: possible modes of action. Haslam E. **J Nat Prod** 1996 Feb; 59(2):205–15 (60 ref.)

IMMUNOLOGY

Identification of allergens in apple, pear, celery, carrot and potato: cross-reactivity with pollen allergens. Ebner C, et al. **Monogr Allergy** 1996;32:73-7 (21 ref.)

PHYSIOLOGY

Review on tropical root and tuber crops. II. Physiological disorders in freshly stored roots and tubers. Ravi V, et al. **Crit Rev Food Sci Nutr** 1996 Oct;36(7):711-31 (170 ref.)

STANDARDS

Review on tropical root and tuber crops. I. Storage methods and quality changes. Ravi V, et al.
Crit Rev Food Sci Nutr 1996 Oct;36(7):661-709 (374 ref.)

VEGETARIANISM

Effects of vegetarian diets on aging and longevity. Walter P. **Nutr Rev** 1997 Jan;55(1 Pt 2):S61-5; discussion S65-8 (49 ref.)

ADVERSE EFFECTS

Persistence of neurological damage induced by dietary vitamin B-12 deficiency in infancy. von Schenck U, et al. **Arch Dis Child** 1997 Aug;77(2):137-9 (20 ref.)

PSYCHOLOGY

Meat avoidance and body weight concerns: nutritional implications for teenage girls. Ryan YM. **Proc Nutr Soc** 1997 Mar;56(1B):519-24 (19 ref.)

VEGETATIVE STATE, PERSISTENT see **PERSISTENT VEGETATIVE STATE**

VEHICLE EMISSIONS

ADVERSE EFFECTS

Global increases in allergic respiratory disease: the possible role of diesel exhaust particles. Peterson B, et al.
Ann Allergy Asthma Immunol 1996 Oct;77(4):263-8; quiz 269-70 (45 ref.)
[Vehicular traffic pollution and risks to health] De Luca d'Alessandro E, et al. **Ann Ig** 1996 Nov-Dec;8(6):675-80 (29 ref.) **(Ita)**

ANALYSIS

Long-term trends in United States highway emissions, ambient concentrations, and in-vehicle exposure to carbon monoxide in traffic. Flachsbart PG.
J Expo Anal Environ Epidemiol 1995 Oct-Dec;5(4):473-95 (51 ref.)
Recent advances in the estimation of population exposure to mobile source pollutants. Johnson TR.
J Expo Anal Environ Epidemiol 1995 Oct-Dec;5(4):551-71 (39 ref.)

TOXICITY

The role of diesel exhaust particles and their associated polyaromatic hydrocarbons in the induction of allergic airway disease. Diaz-Sanchez D. **Allergy** 1997;52(38 Suppl):52-6; discussion 57-8 (16 ref.)
Analysis of diesel-exhaust unit-risk estimates derived from animal bioassays. Valberg PA, et al.
Regul Toxicol Pharmacol 1996 Aug;24(1 Pt 1):30-44 (58 ref.)

VEHICLES

Escherichia coli serotype O157:H7: novel vehicles of infection and emergence of phenotypic variants. Feng P. **Emerg Infect Dis** 1995 Apr-Jun;1(2):47-52 (44 ref.)

VEILED CELLS see **DENDRITIC CELLS**

VEIN OF GALEN see **CEREBRAL VEINS**

VEINS

[Venous compression syndrome: etiology, diagnosis and therapy from the radiologic viewpoint] Alfke H, et al.
Aktuelle Radiol 1997 May;7(3):123-9 (23 ref.) (Eng. Abstr.) **(Ger)**

ABNORMALITIES

Blood vessel formation: what is its molecular basis? [comment] Folkman J, et al. **Cell** 1996 Dec 27;87(7):1153-5 (20 ref.) Comment on: Cell 1996 Dec 27;87(7):1161-9. Comment on: Cell 1996 Dec 27;87(7):1171-80. Comment on: Cell 1996 Dec 27;87(7):1181-90.

ANATOMY & HISTOLOGY

Stratified multiphase model for blood flow in a venular bifurcation. Das B, et al. **Ann Biomed Eng** 1997 Jan-Feb; 25(1):135-53 (32 ref.)

INJURIES

Peripheral venous injuries: a collective review. Ierardi RP, et al. **J Am Coll Surg** 1996 Nov;183(5):531-40 (84 ref.)

PATHOLOGY

Absence of flow in ovarian vein by time-of-flight magnetic resonance angiography without evidence of thrombosis. Rizk B, et al. **Clin Imaging** 1997 May-Jun;21(3):203-6 (11 ref.)

PHYSIOLOGY

[Evaluation of the venous network before arterial revascularization surgery] Puppinck P, et al.
J Mal Vasc 1997 Jul;22(3):162-7 (25 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Venous tone regulatory mechanisms: what's new? Comerota AJ, et al. **Int Angiol** 1995 Sep;14(3 Suppl 1):1-7 (23 ref.)

TRANSPLANTATION

Problems related to the definition of "distal" bypass and "secondary" patency rates. A paper for debate. Panayiotopoulos YP, et al. **Eur J Vasc Endovasc Surg** 1996 Nov;12(4):464-70 (37 ref.)
The treatment of epineural scarring with allograft vein wrapping. Masear VR, et al. **Hand Clin** 1996 Nov; 12(4):773-9 (28 ref.)
Autologous vein-covered stent for the endovascular management of an iliac artery-ureteral fistula: case report and review of the literature. Kerns DB, et al.
J Vasc Surg 1996 Oct;24(4):680-6 (46 ref.)
[Therapy of renovascular hypertension in neurofibromatosis: surgical revascularization versus percutaneous transluminal angioplasty] Türler A, et al. **Vasa** 1996;25(4):368-72 (34 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

In a different vein: the ductus venosus could yield much valuable information. Kiserud T.
Ultrasound Obstet Gynecol 1997 Jun;9(6):369-72 (50 ref.)

VELOCIMETRY see **RHEOLOGY**

VELOCIMETRY, LASER-DOPPLER see **LASER-DOPPLER FLOWMETRY**

VELOPHARYNGEAL INSUFFICIENCY

see related
SPEECH DISORDERS
Identification and assessment of velopharyngeal inadequacy. Conley SF, et al. **Am J Otolaryngol** 1997 Jan-Feb; 18(1):38-46 (85 ref.)

ETIOLOGY

An unusual appearance of velopharyngeal closure in a post-uvulopalatopharyngoplasty patient. Yanagisawa E, et al. **Ear Nose Throat J** 1997 Jan;76(1):14-5 (5 ref.)

SURGERY

Recent progress in treating patients with cleft palate. Kawano M, et al. **Folia Phoniatr Logop** 1997;49(3-4):117-38 (17 ref.)

VELUM PALATINUM see **PALATE, SOFT**

VENA CAVA FILTERS

Clinical results of Greenfield filter use in patients with cancer. Greenfield LJ, et al. **Cardiovasc Surg** 1997 Apr;5(2):145-9 (21 ref.)
Multidisciplinary approach to venous thromboembolism. Marano P, et al. **Rays** 1996 Jul-Sep;21(3):481-99 (48 ref.) **(Eng, Ita)**
[Ultrahigh-dosage urokinase lysis during pulmonary embolism prophylaxis by means of an extractable caval filter] Neuerburg J, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996 Nov;165(5):510-3 (16 ref.) **(Ger)**
[Criteria for utilization and indications for use of permanent and short- and medium term temporary endocaval filters. Personal experience and review of the literature] Fuochi C, et al. **Radiol Med (Torino)** 1996 Oct;92(4):431-7 (35 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

Duodenal perforation by a Greenfield filter: endoscopic diagnosis. Bianchini AU, et al. **Am J Gastroenterol** 1997 Apr;92(4):686-7 (26 ref.)

VENA CAVA, INFERIOR

Inferior vena cava involvement by a left side adrenocortical carcinoma: operative and prognostic considerations. Mingoli A, et al. **Anticancer Res** 1996 Sep-Oct; 16(5B):3197-200 (20 ref.)
Prognostic relevance of intracaval neoplastic extension for patients with renal cell cancer. Kuczyk MA, et al.
Br J Urol 1997 Jul;80(1):18-24 (27 ref.)
Anticardiolipin (aCL) antibodies in a patient with Behçet's syndrome with vena cava inferior thrombosis. Ebo DG, et al. **Clin Rheumatol** 1997 Jan;16(1):96-8 (15 ref.)
Intracaval extension of germ cell carcinoma: diagnosis via endovascular biopsy and a review of the literature. Fidias P, et al. **Eur Urol** 1997;31(3):376-9 (32 ref.)
Aortocaval fistula in ruptured inflammatory abdominal aortic aneurysm. A report of two cases and literature review. Farid A, et al. **J Cardiovasc Surg (Torino)** 1996 Dec; 37(6):561-5 (24 ref.)
Fulminant acute Budd-Chiari syndrome stemming from an adrenal tumor. Moreira V, et al. **J Clin Gastroenterol** 1997 Mar;24(2):110-2 (14 ref.)
Leiomyosarcoma of the inferior vena cava: a clinicopathologic review and report of three cases. Kulaylat MN, et al. **J Surg Oncol** 1997 Jul;65(3):205-17 (95 ref.)
Survival of patients with renal cell carcinoma invading the inferior vena cava. Mattos RM, et al.
Semin Urol Oncol 1996 Nov;14(4):223-6 (15 ref.)
Local recurrence of renal cell carcinoma causing duodenal-inferior vena caval fistula: case report and review of the literature. Benjamin DS, et al. **Urology** 1996 Oct; 48(4):636-8 (16 ref.)
Transitional cell carcinoma of the kidney with tumor thrombus into the vena cava. Williams JH, et al.
Urology 1996 Dec;48(6):932-5 (14 ref.)
[Membranous obstruction of the inferior vena cava] Balian A, et al. **Gastroenterol Clin Biol** 1997;21(4):265-73 (67 ref.) **(Fre)**
[Intravenous leiomyomatosis of uterine origin with cardiac extension. A case report and review of the literature] Tribondeau P, et al.
J Gynecol Obstet Biol Reprod (Paris) 1997;26(2):187-92 (33 ref.) (Eng. Abstr.) **(Fre)**
[Successful lysis of iliofemoral and inferior vena cava thrombi in heparin-induced type-II thrombocytopenia] Emig U, et al. **Dtsch Med Wochenschr** 1997 Aug 1;122(31-32):965-8 (25 ref.) (Eng. Abstr.) **(Ger)**
[Rational diagnosis and surgical therapy of renal cell carcinoma with tumor thrombosis in the vena cava] Piechota HJ, et al. **Urologe A** 1997 Jan;36(1):54-63 (47 ref.) (Eng. Abstr.) **(Ger)**

ABNORMALITIES

A rare intrahepatic portacaval tubular shunt in a patient with spastic paraparesis. Ardic S, et al. **Australas Radiol** 1997 May;41(2):181-4 (17 ref.)
Congenital extrahepatic portocaval shunts--the Abernethy malformation. Howard ER, et al. **J Pediatr Surg** 1997 Mar; 32(3):494-7 (24 ref.)
Agenesis of the ductus venosus and its correlation to hydrops fetalis and the fetal hepatic circulation: case reports and review of the literature [see comments] Sivén M, et al. **Pediatr Pathol Lab Med** 1995 Jan-Feb;15(1):39-50 (24 ref.)
Comment in: Pediatr Pathol Lab Med 1997 Mar-Apr;17(2):331-2.
Deep venous thrombosis complicating a congenital absence of the inferior vena cava. Shah NL, et al. **Surgery** 1996 Nov;120(5):891-6 (53 ref.)
[Anomalies of umbilical vein in the fetus. A case report and review of the literature] Tordjeman N, et al.
J Gynecol Obstet Biol Reprod (Paris) 1996;25(5):495-9 (18 ref.) (Eng. Abstr.) **(Fre)**
[Abdominothoracic large-caliber skin vein--a symptom of vena cava discontinuity] Wildberger JE, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1997 Jul;167(1):101-2 (9 ref.) **(Ger)**
[Anomalous drainage of superior and inferior vena cava into left atrium] Miyamura H. **Ryoikibetsu Shokogun Shirizu** 1996;(13):140-1 (7 ref.) **(Jpn)**
[Anomalies of the systemic veins and anomalous systemic venous return] Miyamura H.
Ryoikibetsu Shokogun Shirizu 1996;(13):236-8 (9 ref.) **(Jpn)**
[Double inferior vena cava] Ohta H.
Ryoikibetsu Shokogun Shirizu 1996;(13):126-8 (7 ref.) **(Jpn)**
[Azygos continuation of the inferior vena cava] Takayama S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):59-62 (9 ref.) **(Jpn)**
[Interruption of inferior vena cava] Takayama S, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):63-6 (12 ref.) **(Jpn)**
[Technical options of renal transplant in the absence of a viable ilio-caval venous circuit. Presentation of a case and review of the literature] Lledo García E, et al.
Actas Urol Esp 1996 Jun;20(6):577-81 (22 ref.) (Eng. Abstr.) **(Spa)**

INJURIES

Management of retrohepatic venous injuries with atrial caval shunts. Weber S, et al. **AORN J** 1996 Sep;64(3):376-7, 380-2 (14 ref.)

PATHOLOGY

Venous aneurysms: MR diagnosis with the "layered gadolinium" sign. Krinsky G, et al.
J Comput Assist Tomogr 1997 Jul-Aug;21(4):623-7 (12 ref.)
[Bilateral renal cell carcinoma with extension into the vena cava associated with von Hippel-Lindau disease: a case report and review of the literature] Minamide M, et al.
Hinyokika Kiyo 1996 May;42(5):361-4 (8 ref.) (Eng. Abstr.)

VENA CAVA, INFERIOR

(Jpn)
[Obstruction of inferior vena cava (vena cava inferior syndrome)] Kuramochi M.
Ryoikibetsu Shokogun Shirizu 1996;(14):438–9 (4 ref.)
(Jpn)

RADIOGRAPHY

The differential diagnosis of early inferior vena caval opacification on dynamic CT. Naik KS, et al.
Clin Radiol 1997 Jul;52(7):504–9 (15 ref.)
Incidentally detected renal angiomyolipoma with tumour thrombus into the inferior vena cava. Rubio-Briones J, et al. **Scand J Urol Nephrol** 1997 Apr;31(2):189–91 (14 ref.)

SURGERY

Management of retrohepatic venous injuries with atrial caval shunts. Weber S, et al. **AORN J** 1996 Sep;64(3):376–7, 380–2 (14 ref.)

ULTRASONOGRAPHY

Transesophageal echocardiographic diagnosis of eustachian valve endocarditis. Georgeson R, et al.
J Am Soc Echocardiogr 1996 Mar–Apr;9(2):206–8 (14 ref.)
Prenatal ultrasonographic assessment of the ductus venosus: a review. Sherer DM, et al. **Obstet Gynecol** 1996 Oct;88(4 Pt 1):626–32 (32 ref.)

VENA CAVA, SUPERIOR

see related
SUPERIOR VENA CAVA SYNDROME
[Thromboembolic complications of central venous catheters (see comments)] Manten A, et al.
Ned Tijdschr Geneeskd 1996 Sep 7;140(36):1797–800 (32 ref.) Comment in: Ned Tijdschr Geneeskd 1996 Nov 16;140(46):2302. (Dut)

ABNORMALITIES

Persistent left superior vena cava: transoesophageal echocardiographic findings and surgical strategies. Broka SM, et al. **Acta Chir Belg** 1997 Apr;97(2):86–9 (20 ref.)
Absent right superior vena cava in visceroatrial situs solitus. Bartram U, et al. **Am J Cardiol** 1997 Jul 15;80(2):175–83 (95 ref.)
[Persistent left superior vena cava] Hoshino S, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):327–9 (15 ref.)
(Jpn)
[Anomalies of the systemic veins and anomalous systemic venous return] Miyamura H.
Ryoikibetsu Shokogun Shirizu 1996;(13):236–8 (9 ref.)
(Jpn)
[Anomalous drainage of superior and inferior vena cava into left atrium] Miyamura H. **Ryoikibetsu Shokogun Shirizu** 1996;(13):140–1 (7 ref.) (Jpn)

PATHOLOGY

[The superior vena cava occlusion syndrome. A case of neoplastic thrombosis due to hepatocarcinoma and cirrhosis] Zanetti PP, et al. **Minerva Chir** 1997 Apr; 52(4):455–9 (20 ref.) (Eng. Abstr.) (Ita)

VENAE CAVAE

ABNORMALITIES

Intraatrial baffle repair of isolated ventricular inversion with left atrial isomerism. McElhinney DB, et al.
Ann Thorac Surg 1996 Nov;62(5):1529–32 (12 ref.)
[Cogenital anomalies of the vena cava] Sakamoto S, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):193–8 (14 ref.)
(Jpn)

VENEREAL DISEASES see **SEXUALLY TRANSMITTED DISEASES**

VENEREAL DISEASES, BACTERIAL see **SEXUALLY TRANSMITTED DISEASES, BACTERIAL**

VENEREAL DISEASES, VIRAL see **SEXUALLY TRANSMITTED DISEASES, VIRAL**

VENEREAL WARTS see **CONDYLOMATA ACUMINATA**

VENEREOLOGY

see related
SEXUALLY TRANSMITTED DISEASES
Genitourinary medicine and the Internet No 5. Lau RK.
Genitourin Med 1997 Apr;73(2):144–5 (0 ref.)

VENESECTION see **PHLEBOTOMY**

VENIPUNCTURE see **PHLEBOTOMY**

VENO-OCCLUSIVE DISEASE, HEPATIC see **HEPATIC VENO-OCCLUSIVE DISEASE**

VENO-OCCLUSIVE DISEASE, PULMONARY see **PULMONARY VENO-OCCLUSIVE DISEASE**

VENOMS

see related
ANTIVENINS

CHEMISTRY

Pharmacological action of Australian animal venoms. Hodgson WC. **Clin Exp Pharmacol Physiol** 1997 Jan; 24(1):10–7 (74 ref.)
[Structures and functions of animal toxins] Guenneugues M, et al. **C R Seances Soc Biol Fil** 1997;191(3):329–44 (57 ref.) (Eng. Abstr.) (Fre)

PHARMACOLOGY

Pharmacological action of Australian animal venoms. Hodgson WC. **Clin Exp Pharmacol Physiol** 1997 Jan; 24(1):10–7 (74 ref.)
[Structures and functions of animal toxins] Guenneugues M, et al. **C R Seances Soc Biol Fil** 1997;191(3):329–44 (57 ref.) (Eng. Abstr.) (Fre)

VENOUS CATHETERIZATION, CENTRAL see **CATHETERIZATION, CENTRAL VENOUS**

VENOUS CATHETERIZATION, PERIPHERAL see **CATHETERIZATION, PERIPHERAL**

VENOUS INSUFFICIENCY

Chronic venous insufficiency: mechanisms and management. Ibrahim S, et al. **Am Heart J** 1996 Oct;132(4):856–60 (34 ref.)
[Chronic venous insufficiency] Sakurai T, et al.
Ryoikibetsu Shokogun Shirizu 1996;(14):550–2 (9 ref.)
(Jpn)

EPIDEMIOLOGY

Venous insufficiency at work. Hobson J. **Angiology** 1997 Jul; 48(7):577–82 (19 ref.)

ETIOLOGY

Pelvic lipoma causing venous obstruction syndrome. Acheson A, et al. **Eur J Vasc Endovasc Surg** 1997 Aug; 14(2):149–50 (6 ref.)
Interactions between endothelial cells and smooth muscle cells after their activation by hypoxia. A possible etiology for venous disease. Michiels C, et al. **Int Angiol** 1996 Jun; 15(2):124–30 (31 ref.)

PHYSIOPATHOLOGY

Venous disease: from pathophysiology to quality of life. Vanhoutte PM, et al. **Angiology** 1997 Jul;48(7):559–67 (29 ref.)
The venous wall and valvular function in chronic venous insufficiency. Thulesius O. **Int Angiol** 1996 Jun;15(2):114–8 (15 ref.)
Chronic venous insufficiency and venous ulceration. Alguire PC, et al. **J Gen Intern Med** 1997 Jun;12(6):374–83 (112 ref.)
[Heavy legs, venular microangiopathy and stasis acrodermatitis] Piérard GE. **Rev Med Liege** 1996 Aug; 51(8):510–3 (22 ref.) (Fre)

SURGERY

Minimally invasive surgery for perforator vein incompetence. Saharay M, et al. **Cardiovasc Surg** 1996 Dec;4(6):701–5 (58 ref.)

THERAPY

Chronic venous insufficiency and venous ulceration. Alguire PC, et al. **J Gen Intern Med** 1997 Jun;12(6):374–83 (112 ref.)
[Chronic venous insufficiency--from pathophysiology to therapy. 4: Treatment of ulcus cruris--therapy guidelines] Peschen M, et al. **Fortschr Med** 1996 Oct 30;114(30):395–7 (8 ref.) (Eng. Abstr.) (Ger)
[Chronic venous insufficiency--from pathophysiology to therapy. 1: Pathophysiology--compression treatment--systemic pharmacotherapy] Peschen M, et al. **Fortschr Med** 1996 Sep 20;114(26):315–8 (0 ref.) (Eng. Abstr.) (Ger)

VENOUS LEAKAGE, PENILE see **IMPOTENCE, VASCULOGENIC**

VENOUS PRESSURE

Hepatic venous pressure measurement: an old test as a new prognostic marker in cirrhosis? Armonis A, et al.
Hepatology 1997 Jan;25(1):245–8 (52 ref.)
Variceal and portal pressure measurement: techniques and applications. Armonis A, et al. **Ital J Gastroenterol** 1996 Jun;28(5):272–9 (62 ref.)

VENOUS THROMBOSIS see **THROMBOPHLEBITIS**

VENOUS ULCER see **VARICOSE ULCER**

VENOVENOUS HEMOFILTRATION see **HEMOFILTRATION**

VENTILATION

Ventilation effects on combustion products. Tewarson A.
Toxicology 1996 Dec 31;115(1–3):145–56 (9 ref.)

STANDARDS

Evaluation of indoor air quality using the decibel concept. Part II–ventilation for acceptable indoor air quality. Jokl MV. **Cent Eur J Public Health** 1997 Mar;5(1):9–12 (7 ref.)

VENTILATION, HIGH-FREQUENCY see **HIGH-FREQUENCY VENTILATION**

VENTILATION, INTERMITTENT POSITIVE-PRESSURE see **INTERMITTENT POSITIVE-PRESSURE VENTILATION**

VENTILATION, MECHANICAL see **RESPIRATION, ARTIFICIAL**

VENTILATION, MIDDLE EAR see **MIDDLE EAR VENTILATION**

VENTILATION-PERFUSION RATIO

Gas exchange, expiratory flow obstruction and the clinical spectrum of asthma. Wagner PD, et al. **Eur Respir J** 1996 Jun;9(6):1278–82 (17 ref.)
Lung mechanics and gas exchange in pulmonary embolism. D'Angelo E. **Haematologica** 1997 May–Jun;82(3):371–4 (34 ref.)

VENTILATION, PULMONARY see **PULMONARY VENTILATION**

VENTILATION TESTS see **PULMONARY VENTILATION**

VENTILATOR WEANING

Weaning from ventilatory support. Lessard MR, et al.
Clin Chest Med 1996 Sep;17(3):475–89 (96 ref.)
Weaning from mechanical ventilation. Mancebo J.
Eur Respir J 1996 Sep;9(9):1923–31 (71 ref.)
Respiratory muscles and weaning failure. Vassilakopoulos T, et al. **Eur Respir J** 1996 Nov;9(11):2383–400 (114 ref.)
Weaning from mechanical ventilation. Ketzler JT, et al.
Int Anesthesiol Clin 1997 Winter;35(1):29–44 (72 ref.)
How to wean from mechanical ventilation [editorial] Benito S. **Monaldi Arch Chest Dis** 1996 Aug;51(4):267–9 (9 ref.)
[Experience of an intermediate respiratory intensive therapy in the treatment of prolonged weaning from mechanical ventilation] Vitacca M, et al. **Minerva Anestesiol** 1996 Mar; 62(3):57–64 (23 ref.) (Eng. Abstr.) (Ita)

METHODS

How to use diagnostic test articles in the intensive care unit: diagnosing weanability using f/Vt. Jaeschke RZ, et al.
Crit Care Med 1997 Sep;25(9):1514–21 (24 ref.)
Postnatal steroid therapy in neonates. Young TE.
Curr Opin Pediatr 1997 Apr;9(2):184–8 (32 ref.)
Weaning from mechanical ventilation. Dries DJ.
J Trauma 1997 Aug;43(2):372–84 (113 ref.)
[Termination of long-term artificial pulmonary ventilation ("weaning from an APV apparatus"). Functional criteria and methodological principles] Gologorskii VA, et al.
Anesteziol Reanimatol 1995 Nov–Dec;(6):64–71 (197 ref.)
(Rus)

STANDARDS

Weaning from mechanical ventilation. Dries DJ.
J Trauma 1997 Aug;43(2):372–84 (113 ref.)

VENTILATORS, MECHANICAL

Pulmonary hyperinflation and ventilator-dependent patients. Rossi A, et al. **Eur Respir J** 1997 Jul;10(7):1663–74 (90 ref.)
Ventilators in the operating room. Eisenkraft JB, et al.
Int Anesthesiol Clin 1997 Winter;35(1):87–108 (25 ref.)
Building intelligent alarm systems by combining mathematical models and inductive machine learning techniques. Müller B, et al. **Int J Biomed Comput** 1996 Apr; 41(2):107–24 (18 ref.)
Patient ventilator interfaces: practical aspects in the chronic situation. Clini E. **Monaldi Arch Chest Dis** 1997 Feb; 52(1):76–9 (27 ref.)
Home mechanical ventilation in children: techniques, outcomes and ethics. Shneerson JM.
Monaldi Arch Chest Dis 1996 Oct;51(5):426–30 (23 ref.)
[Sedation and analgesia in ventilator-treated children] Hansen TG, et al. **Ugeskr Laeger** 1996 Dec 30;159(1):31–6 (40 ref.) (Eng. Abstr.) (Dan)
[Artificial ventilation in children during anesthesia] Marraro G, et al. **Minerva Anestesiol** 1996 Apr;62(4):131–6 (12 ref.) (Eng. Abstr.) (Ita)

ADVERSE EFFECTS

Role of colonization of the upper intestinal tract in the

pathogenesis of ventilator-associated pneumonia [see comments] Bonten MJ, et al. **Clin Infect Dis** 1997 Mar; 24(3):309–19 (80 ref.) Comment in: Clin Infect Dis 1997 Mar;24(3):320–3.

TRENDS

Advances in neonatal conventional ventilation. Sinha SK, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 Sep; 75(2):F135–40 (25 ref.)

Lungs at home. Petty TL. **Monaldi Arch Chest Dis** 1996 Feb; 51(1):60–3 (20 ref.)

VENTILATORS, NEGATIVE-PRESSURE

Negative pressure ventilation in the treatment of acute respiratory failure: an old noninvasive technique reconsidered. Corrado A, et al. **Eur Respir J** 1996 Jul; 9(7):1531–44 (113 ref.)

Negative pressure ventilation in COPD patients with acute on chronic respiratory failure. Corrado A, et al. **Monaldi Arch Chest Dis** 1997 Feb;52(1):60–3 (44 ref.)

VENTILATORS, PULMONARY see **VENTILATORS, MECHANICAL**

VENTILATORS, PULMONARY, NEGATIVE-PRESSURE see **VENTILATORS, NEGATIVE-PRESSURE**

VENTILATORY MUSCLES see **RESPIRATORY MUSCLES**

VENTRAL HERNIA see **HERNIA, VENTRAL**

VENTRAL ROOTS see **SPINAL NERVE ROOTS**

VENTRAL TEGMENTAL AREA

METABOLISM

Ventral tegmental area 5-HT receptors: mesolimbic dopamine release and behavioural studies. Mylecharane EJ. **Behav Brain Res** 1996;73(1–2):1–5 (37 ref.)

VENTRICLE-ASSIST DEVICE see **HEART-ASSIST DEVICES**

VENTRICULAR DYSFUNCTION

COMPLICATIONS

Arrhythmias and sudden death in heart failure. Stevenson WG, et al. **Jpn Circ J** 1997 Sep;61(9):727–40 (115 ref.)

Anemia, hypertension, and myocardial dysfunction in end-stage renal disease. Venkatesan J, et al. **Semin Nephrol** 1997 Jul;17(4):257–69 (125 ref.)

DRUG THERAPY

Antiarrhythmic drug therapy for ventricular arrhythmias: current perspectives. Link MS, et al. **J Cardiovasc Electrophysiol** 1996 Jul;7(7):653–70 (156 ref.)

[Propafenone and flecainide in the therapy of ventricular arrhythmias] Paperini L, et al. **Minerva Cardioangiol** 1995 Oct;43(10):449–57 (32 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Regional dysfunction and ventricular remodeling in the infarcted patient. Marino P, et al. **Basic Res Cardiol** 1997 Apr;92(2):72–4 (10 ref.)

PATHOLOGY

Cellular mechanisms of cardiac failure in the infarcted heart. Anversa P, et al. **Cardiologia** 1995 Dec;40(12):909–20 (89 ref.)

PHYSIOPATHOLOGY

Regional dysfunction and ventricular remodeling in the infarcted patient. Marino P, et al. **Basic Res Cardiol** 1997 Apr;92(2):72–4 (10 ref.)

Cellular mechanisms of cardiac failure in the infarcted heart. Anversa P, et al. **Cardiologia** 1995 Dec;40(12):909–20 (89 ref.)

SURGERY

Prognosis determination in patients with advanced heart failure. Kao W, et al. **J Heart Lung Transplant** 1997 Jun; 16(6):S2–6 (29 ref.)

VENTRICULAR DYSFUNCTION, LEFT

COMPLICATIONS

Drugs or implantable cardioverter-defibrillators in patients with poor left ventricular function? Block M, et al. **Am J Cardiol** 1996 Sep 12;78(5A):62–8 (67 ref.)

From left ventricular dysfunction to heart failure. Cleland JG. **Arch Mal Coeur Vaiss** 1996 Nov;89(11):1397–402 (20 ref.)

Angina and left ventricular dysfunction. Dargie HJ. **Eur Heart J** 1996 Dec;17 Suppl G:2–7 (25 ref.)

Exercise testing and training of patients with heart failure due to left ventricular systolic dysfunction. Keteyian SJ, et al. **J Cardiopulm Rehabil** 1997 Jan–Feb;17(1):19–28 (58 ref.)

Heart failure secondary to left ventricular systolic dysfunction. Therapeutic advances and treatment recommendations. Dracup K. **Nurse Pract** 1996 Sep; 21(9):56–8, 61, 65–8 (30 ref.)

[Myocardial viability in patients with chronic ischemic heart disease and left ventricular dysfunction. Diagnostic methods and clinical significance] Perrone Filardi P, et al. **Cardiologia** 1996 Aug;41(8):707–26 (111 ref.) **(Ita)**

DIAGNOSIS

Outer limits of the athlete's heart, the effect of gender, and relevance to the differential diagnosis with primary cardiac diseases. Pelliccia A, et al. **Cardiol Clin** 1997 Aug; 15(3):381–96 (88 ref.)

Abnormalities of the S-T segment--Part II. Hurst JW. **Clin Cardiol** 1997 Jul;20(7):595–600 (10 ref.)

Determination of left ventricular mass in clinical practice. Boudoulas H. **J Heart Valve Dis** 1997 May;6(3):222–7 (31 ref.)

DRUG THERAPY

ASHP therapeutic guidelines on angiotensin-converting-enzyme inhibitors in patients with left ventricular dysfunction. This official ASHP practice standard was developed through the ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 16, 1996 [see comments] **Am J Health Syst Pharm** 1997 Feb 1;54(3):299–313 (109 ref.) Comment in: Am J Health Syst Pharm 1997 Feb 1;54(3):264.

ACE inhibitor use in elderly patients with systolic left ventricular dysfunction: problems and opportunities. Pitt B. **Br J Clin Pract Symp Suppl** 1996 Jul;84:11–6 (36 ref.)

Anticoagulation trials. Grahame-Clarke C, et al. **Br J Hosp Med** 1996 Jun 19–Jul 9;56(1):25–8 (25 ref.)

Medical treatment of heart failure: the Canadian Cardiovascular Society's Consensus Conference revisited. Vantrimpont P, et al. **Cardiovasc Drugs Ther** 1997 Jan; 10(6):711–6 (27 ref.)

Angina and left ventricular dysfunction. Dargie HJ. **Eur Heart J** 1996 Dec;17 Suppl G:2–7 (25 ref.)

How European cardiologists perceive the role of calcium antagonists in the treatment of heart failure and left ventricular dysfunction. Iliceto S, et al. **Eur Heart J** 1997 Jan;18 Suppl A:A125–33 (2 ref.)

Left ventricular dysfunction: which role for calcium antagonists? Iliceto S. **Eur Heart J** 1997 Jan;18 Suppl A:A87–91 (25 ref.)

The value of angiotensin converting enzyme inhibitors for the treatment of patients with left ventricular dysfunction, heart failure or after acute myocardial infarction. Swedberg K, et al. **Eur Heart J** 1996 Sep;17(9):1306–11 (31 ref.)

What have the ACE-inhibitor trials in postmyocardial patients with left ventricular dysfunction taught us? Reynolds G, et al. **Eur J Clin Pharmacol** 1996;49 Suppl 1:S35–9 (19 ref.)

Calcium antagonists in patients with left ventricular dysfunction: back on the bridge? Lewis BS. **J Card Fail** 1996 Dec;2(4 Suppl):S259–65 (52 ref.)

[Diastolic dysfunction of the left ventricle: from physiopathology to treatment] Karpuz H, et al. **Schweiz Rundsch Med Prax** 1997 Feb 11;86(7):246–50 (34 ref.) (Eng. Abstr.) **(Fre)**

[Clinical and diagnostic indications for the use of nitrates in dynamic heart defects (decompensation, left ventricular dysfunction without decompensation, etc.] Branzi A. **G Ital Cardiol** 1996 Sep;26(9):1079–84 (19 ref.) **(Ita)**

[The role of nitrates in left ventricular insufficiency in patients with acute myocardial infarction] Maggioni AP. **G Ital Cardiol** 1996 Sep;26(9):1095–8 (04 ref.) **(Ita)**

EPIDEMIOLOGY

The decreasing incidence of left ventricular remodeling following myocardial infarction. Solomon SD, et al. **Basic Res Cardiol** 1997 Apr;92(2):61–5 (10 ref.)

ETIOLOGY

Amniotic fluid embolism causing severe left ventricular dysfunction and death: case report and review of the literature. Dib N, et al. **Cathet Cardiovasc Diagn** 1996 Oct; 39(2):177–80 (9 ref.)

Ventricular dysfunction in the pediatric population: evaluation and intervention. Hanna BD. **J Heart Lung Transplant** 1997 Jun;16(6):S16–8 (22 ref.)

Reversible causes of severe myocardial dysfunction. Hollenberg SM, et al. **J Heart Lung Transplant** 1997 Jun; 16(6):S7–12 (28 ref.)

Small aortic root: specific problems in the child. Vouhé PR. **J Heart Valve Dis** 1996 Nov;5 Suppl 3:S269–71 (9 ref.)

Minimal operative mortality in patients undergoing coronary artery bypass with significant left ventricular dysfunction by maximization of metabolic and mechanical support. Cimochowski GE, et al. **J Thorac Cardiovasc Surg** 1997 Apr;113(4):655–64; discussion 664–6 (36 ref.)

[Diastolic dysfunction in chronic renal failure patients under hemodialysis] Douchet MP, et al. **Ann Cardiol Angeiol (Paris)** 1996 Dec;45(10):589–92 (15 ref.) (Eng. Abstr.) **(Fre)**

[Left ventricular systolic dysfunction in cardiomyopathies] Bouhour JB, et al. **Arch Mal Coeur Vaiss** 1996 Jul;89 Spec No 2:33–7 (27 ref.) (Eng. Abstr.) **(Fre)**

[The role of nitrates in left ventricular insufficiency in patients with acute myocardial infarction] Maggioni AP. **G Ital Cardiol** 1996 Sep;26(9):1095–8 (04 ref.) **(Ita)**

[Exertion-induced myocardial ischemia has little influence on ventricular remodeling in post-infarction patients with preserved systolic function] Temporelli PL, et al. **G Ital Cardiol** 1996 Jul;26(7):729–37 (37 ref.) (Eng. Abstr.) **(Ita)**

[The mechanisms of diastolic dysfunction and their assessment by a Doppler method] Zharinov OI, et al. **Fiziol Zh** 1997;43(3–4):130–3 (24 ref.) (Eng. Abstr.) **(Ukr)**

PATHOLOGY

Mechanisms and management of heart failure due to diastolic dysfunction. Ruzumna P, et al. **Curr Opin Cardiol** 1996 May;11(3):269–75 (54 ref.)

PHYSIOPATHOLOGY

Assessment of systolic and diastolic LV function by MR myocardial tagging. Matter C, et al. **Basic Res Cardiol** 1996; 91 Suppl 2:23–8 (26 ref.)

Left ventricular remodeling: clinical significance and therapy. Rosado A, et al. **Basic Res Cardiol** 1997 Apr;92(2):66–8 (18 ref.)

Cardiac dysfunction during septic shock. Bunnell E, et al. **Clin Chest Med** 1996 Jun;17(2):237–48 (40 ref.)

Myocardial stunning and hibernation. Rinaldi CA, et al. **Indian Heart J** 1996 Nov-Dec;48(6):721–5 (42 ref.)

Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's Rosetta Stone. Nishimura RA, et al. **J Am Coll Cardiol** 1997 Jul;30(1):8–18 (93 ref.)

Mechanisms of idiopathic left ventricular tachycardia. Lerman BB, et al. **J Cardiovasc Electrophysiol** 1997 May; 8(5):571–83 (49 ref.)

The multifarious spectrum of ischemic left ventricular dysfunction: relevance of new ischemic syndromes. Opie LH. **J Mol Cell Cardiol** 1996 Dec;28(12):2403–14 (89 ref.)

Myocardial viability [see comments] Birnbaum Y, et al. **West J Med** 1996 Dec;165(6):364–71 (62 ref.) Comment in: West J Med 1996 Dec;165(6):393–6.

[Diastolic dysfunction of the left ventricle: from physiopathology to treatment] Karpuz H, et al. **Schweiz Rundsch Med Prax** 1997 Feb 11;86(7):246–50 (34 ref.) (Eng. Abstr.) **(Fre)**

[Hypertrophy due to left cardiac insufficiency: role of the neurohumoral system] Lerch R, et al. **Schweiz Rundsch Med Prax** 1997 Feb 11;86(7):238–41 (32 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Remodeling after myocardial infarction: an opportunity for early intervention. Amos DJ, et al. **Basic Res Cardiol** 1997 Apr;92(2):69–71 (10 ref.)

[Acute myocardial infarct and left ventricular dysfunction. Morphologic bases, clinical aspects and pharmacologic prevention] Perdigão C. **Acta Med Port** 1996 Feb-Mar; 9(2–3):113–9 (46 ref.) (Eng. Abstr.) **(Por)**

RADIOGRAPHY

How well can the chest radiograph diagnose left ventricular dysfunction? [see comments] Badgett RG, et al. **J Gen Intern Med** 1996 Oct;11(10):625–34 (93 ref.) Comment in: ACP J Club 1997 May-Jun;126(3):77.

SURGERY

Myocardial viability in patients with coronary artery disease and left ventricular dysfunction: transplantation or revascularization? DeNofrio D, et al. **Curr Opin Cardiol** 1996 Jul;11(4):394–402 (54 ref.)

Mechanical circulatory assistance: changing indications and options. Piccione W Jr. **J Heart Lung Transplant** 1997 Jun; 16(6):S25–8 (12 ref.)

Coronary artery bypass surgery in patients with left ventricular dysfunction: candidate selection and perioperative care. Winkel E, et al. **J Heart Lung Transplant** 1997 Jun;16(6):S19–24 (19 ref.)

Small aortic root in neonates. Frescura C, et al. **J Heart Valve Dis** 1996 Nov;5 Suppl 3:S272–5 (10 ref.)

Small aortic root: specific problems in the child. Vouhé PR. **J Heart Valve Dis** 1996 Nov;5 Suppl 3:S269–71 (9 ref.)

[Coronary bypass in patients with severe left ventricular dysfunction (EF < or = 25%). Apropos of 111 patients] Bouchart F, et al. **Arch Mal Coeur Vaiss** 1997 Apr; 90(4):441–8 (33 ref.) (Eng. Abstr.) **(Fre)**

[Operations in limited left ventricular pump function] Scheld HH, et al. **Z Kardiol** 1996;85 Suppl 6:287–301 (82 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Left ventricular remodeling: clinical significance and therapy. Rosado A, et al. **Basic Res Cardiol** 1997 Apr;92(2):66–8 (18 ref.)

VENTRICULAR DYSFUNCTION, LEFT

[Value of echocardiography-dobutamine in the study of reserve myocardial contractility in aortic stenosis with alteration of left ventricular function. Apropos of a case] Deluche L, et al. **Ann Cardiol Angeiol (Paris)** 1996 Nov; 45(9):523–6 (10 ref.) (Eng. Abstr.) **(Fre)**

[Mechanical myocardial support systems 1997: an overview of inta-aortic balloon counterpulsation to implantable left ventricular support systems] Hammel D, et al. **Anaesthesist** 1997 May;46(5):408–18 (66 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Assessment of myocardial viability by dobutamine stress echocardiography [see comments] Cornel JH, et al. **Curr Opin Cardiol** 1996 Nov;11(6):621–6 (29 ref.) Comment in: Curr Opin Cardiol 1996 Nov;11(6):611–2.

Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's Rosetta Stone. Nishimura RA, et al. **J Am Coll Cardiol** 1997 Jul;30(1):8–18 (93 ref.)

[The mechanisms of diastolic dysfunction and their assessment by a Doppler method] Zharinov OI, et al. **Fiziol Zh** 1997;43(3–4):130–3 (24 ref.) (Eng. Abstr.) **(Ukr)**

VENTRICULAR DYSFUNCTION, RIGHT

COMPLICATIONS

Idiopathic ventricular fibrillation of the Brugada type: an atypical form of arrhythmogenic right ventricular cardiomyopathy? [editorial; comment] Ohe T. **Intern Med** 1996 Aug;35(8):595 (5 ref.) Comment on: Intern Med 1996 Aug;35(8):637–40.

[Arrhythmogenic right ventricular dysplasia (ARVD)] Shimizu W. **Ryoikibetsu Shokogun Shirizu** 1996;(12):479–82 (10 ref.) **(Jpn)**

DIAGNOSIS

Abnormalities of the S-T segment—Part II. Hurst JW. **Clin Cardiol** 1997 Jul;20(7):595–600 (10 ref.)

[Alteration of myocardial viability and systemic ventricular dysfunction after Senning procedure] Labbé L, et al. **Arch Mal Coeur Vaiss** 1997 May;90(5):631–7 (30 ref.) (Eng. Abstr.) **(Fre)**

[Arrhythmogenic dysplasia of the right heart ventricle] Kalarus Z, et al. **Przegl Lek** 1997;54(1):43–5 (18 ref.) (Eng. Abstr.) **(Pol)**

ETIOLOGY

[Clinical, echocardiographic and Doppler outcome in ischemic right ventricular dysfunction associated with inferior wall infarction] Logeart D, et al. **Arch Mal Coeur Vaiss** 1997 Mar;90(3):363–9 (22 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

The arrhythmogenic right ventricle. Dysplasia versus cardiomyopathy. Fontaine G, et al. **Heart Vessels** 1995; 10(5):227–35 (37 ref.)

PHYSIOPATHOLOGY

Cardiac dysfunction during septic shock. Bunnell E, et al. **Clin Chest Med** 1996 Jun;17(2):237–48 (40 ref.)

[Arrhythmogenic dysplasia of the right ventricle] Brugada J, et al. **Rev Esp Cardiol** 1997 Aug;50(8):541–7 (29 ref.) (Eng. Abstr.) **(Spa)**

RADIONUCLIDE IMAGING

Assessment of the right ventricle with radionuclide techniques. Schulman DS. **J Nucl Cardiol** 1996 May-Jun; 3(3):253–64 (75 ref.)

THERAPY

[Arrhythmogenic dysplasia of the right heart ventricle] Kalarus Z, et al. **Przegl Lek** 1997;54(1):43–5 (18 ref.) (Eng. Abstr.) **(Pol)**

[Guided anti-arrhythmia therapy by programmed ventricular stimulation. A case of arrhythmogenic dysplasia of the right ventricle] Oliveira M, et al. **Rev Port Cardiol** 1997 Jan; 16(1):33–8, 8 (27 ref.) (Eng. Abstr.) **(Por)**

ULTRASONOGRAPHY

Echocardiographic detection of reversible right ventricular strain in patients with acute pulmonary embolism: report of 2 cases. Fang BR, et al. **Cardiology** 1996 Jul-Aug; 87(4):279–82 (12 ref.)

VENTRICULAR ECTOPIC BEATS see **VENTRICULAR PREMATURE COMPLEXES**

VENTRICULAR EJECTION FRACTION see **STROKE VOLUME**

VENTRICULAR END-DIASTOLIC VOLUME see **STROKE VOLUME**

VENTRICULAR END-SYSTOLIC VOLUME see **STROKE VOLUME**

VENTRICULAR FIBRILLATION

[Brugada syndrome] Nomura M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):181–3 (13 ref.) **(Jpn)**

[Idiopathic ventricular fibrillation] Saito K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):424–7 (14 ref.) **(Jpn)**

DIAGNOSIS

Survivors of out-of-hospital cardiac arrest with apparently normal heart. Need for definition and standardized clinical evaluation. Consensus Statement of the Joint Steering Committees of the Unexplained Cardiac Arrest Registry of Europe and of the Idiopathic Ventricular Fibrillation Registry of the United States. **Circulation** 1997 Jan 7; 95(1):265–72 (100 ref.)

[Ventricular fibrillation, ventricular flutter] Saito J, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):311–4 (22 ref.) **(Jpn)**

DRUG THERAPY

Clinical trials of antiarrhythmic drugs in patients with sustained ventricular tachyarrhythmias. Mitchell LB. **Curr Opin Cardiol** 1997 Jan;12(1):33–40 (45 ref.)

Intravenous amiodarone. Kowey PR, et al. **J Am Coll Cardiol** 1997 May;29(6):1190–8 (110 ref.)

Beta adrenergic blockade in the treatment of sustained ventricular tachycardia or ventricular fibrillation. Wiesfeld AC, et al. **Pacing Clin Electrophysiol** 1996 Jul;19(7):1026–35 (77 ref.)

Class III antiarrhythmic agents: the next wave. Bauman JL. **Pharmacotherapy** 1997 Mar-Apr;17(2 Pt 2):76S–83S; discussion 89S–91S (28 ref.)

Advanced cardiac life support controversy: where do antiarrhythmic agents fit in? [published erratum appears in Pharmacotherapy 1997 May-Jun;17(3):634] Chow MS. **Pharmacotherapy** 1997 Mar-Apr;17(2 Pt 2):84S–88S; discussion 89S–91S (36 ref.)

Pharmacokinetics and pharmacodynamics of intravenous agents for ventricular arrhythmias. Nolan PE Jr. **Pharmacotherapy** 1997 Mar-Apr;17(2 Pt 2):65S–75S; discussion 89S–91S (107 ref.)

[Medicamentous anti-arrhythmia therapy. Is oral adjuvant therapy with electrolytes of value?] Haberl R. **Herz** 1997 Jun;22 Suppl 1:77–80 (20 ref.) (Eng. Abstr.) **(Ger)**

[Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs] Haverkamp W, et al. **Z Kardiol** 1996;85 Suppl 6:97–106 (66 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Idiopathic ventricular fibrillation of the Brugada type: an atypical form of arrhythmogenic right ventricular cardiomyopathy? [editorial; comment] Ohe T. **Intern Med** 1996 Aug;35(8):595 (5 ref.) Comment on: Intern Med 1996 Aug;35(8):637–40.

Ventricular fibrillation following blunt chest trauma from a baseball. van Amerongen R, et al. **Pediatr Emerg Care** 1997 Apr;13(2):107–10 (19 ref.)

PHYSIOPATHOLOGY

Protection by preconditioning and cardiac pacing against ventricular arrhythmias resulting from ischemia and reperfusion. Parratt JR, et al. **Ann N Y Acad Sci** 1996 Sep 30;793:98–107 (42 ref.)

The ESVEM trial: impact on treatment of ventricular tachyarrhythmias. Electrophysiologic Study Versus Electrocardiographic Monitoring. Reiter MJ. **Pacing Clin Electrophysiol** 1997 Feb;20(2 Pt 2):468–77 (59 ref.)

On the mechanism of ventricular defibrillation. Walcott GP, et al. **Pacing Clin Electrophysiol** 1997 Feb;20(2 Pt 2):422–31 (62 ref.)

Ventricular fibrillation in the neonate: elusive or illusive? Kralios FA, et al. **Reprod Fertil Dev** 1996;8(1):49–60 (61 ref.)

PREVENTION & CONTROL

Can catheter ablation in cardiac arrest survivors prevent ventricular fibrillation recurrence? Reek S, et al. **Pacing Clin Electrophysiol** 1997 Jul;20(7):1840–59 (167 ref.)

Which cardiac potassium channel subtype is the preferable target for suppression of ventricular arrhythmias? Rees S, et al. **Pharmacol Ther** 1996;69(3):199–217 (272 ref.)

THERAPY

An overview of the management of electrical storm. Dorian P, et al. **Can J Cardiol** 1997 Mar;13 Suppl A:13A–17A (19 ref.)

Transvenous defibrillation lead systems. Gold MR, et al. **J Cardiovasc Electrophysiol** 1996 Jun;7(6):570–80 (82 ref.)

Current concepts in electrical defibrillation. Truong JH, et al. **J Emerg Med** 1997 May-Jun;15(3):331–8 (68 ref.)

Optimal access to- and response by-public and voluntary services, including the role of bystanders and family members, in cardiopulmonary resuscitation. White RD. **New Horiz** 1997 May;5(2):153–7 (29 ref.)

Acute management of ventricular arrhythmias: role of antiarrhythmic agents. Singh BN. **Pharmacotherapy** 1997 Mar-Apr;17(2 Pt 2):56S–64S; discussion 89S–91S (32 ref.)

VENTRICULAR FUNCTION

see related
HEART FUNCTION TESTS

Ca transport during contraction and relaxation in mammalian ventricular muscle. Bers DM. **Basic Res Cardiol** 1997;92 Suppl 1:1–10 (42 ref.)

Regional dysfunction and ventricular remodeling in the infarcted patient. Marino P, et al. **Basic Res Cardiol** 1997 Apr;92(2):72–4 (10 ref.)

The heart muscle's putative "secondary structure'. Functional implications of a band-like anisotropy. Lunkenheimer PP, et al. **Technol Health Care** 1997 Apr;5(1–2):53–64 (53 ref.)

PHYSIOLOGY

Collagen and ventricular remodeling after acute myocardial infarction: concepts and hypotheses. Whittaker P. **Basic Res Cardiol** 1997 Apr;92(2):79–81 (10 ref.)

Myocyte cell death and ventricular remodeling [see comments] Anversa P, et al. **Curr Opin Nephrol Hypertens** 1997 Mar;6(2):169–76 (68 ref.) Comment in: Curr Opin Nephrol Hypertens 1997 Mar;6(2):167–8.

[Diastolic filling and the law of Frank-Starling] Gioffrè PA, et al. **Cardiologia** 1995 Dec;40(12 Suppl 1):359–64 (34 ref.) **(Ita)**

[Exertion-induced myocardial ischemia has little influence on ventricular remodeling in post-infarction patients with preserved systolic function] Temporelli PL, et al. **G Ital Cardiol** 1996 Jul;26(7):729–37 (37 ref.) (Eng. Abstr.) **(Ita)**

VENTRICULAR FUNCTION, LEFT

Infarct-related artery patency and long-term effects on left ventricular remodelling. Visser CA. **Cardiology** 1997;88 Suppl 1:26–35; discussion 36 (86 ref.)

Relaxation-systolic pressure relation. A load-independent assessment of left ventricular contractility. Gillebert TC, et al. **Circulation** 1997 Feb 4;95(3):745–52 (43 ref.)

Assessment of left ventricular function and hemodynamics with transesophageal echocardiography. Troianos CA, et al. **Crit Care Clin** 1996 Apr;12(2):253–72 (65 ref.)

Echocardiographic assessment of diastolic function. Zimpfer M, et al. **Eur J Anaesthesiol** 1996 Sep;13(5):436–44 (32 ref.)

Assessment of left ventricular dimensions and functions in athletes and sedentary subjects at rest and during exercise using echocardiography, Doppler sonography and radionuclide ventriculography. Huonker M, et al. **Int J Sports Med** 1996 Nov;17 Suppl 3:S173–9 (64 ref.)

Left ventricular dysfunction due to the new ischemic outcomes: stunning and hibernation. Ferrari R, et al. **J Cardiovasc Pharmacol** 1996;28 Suppl 1:S18–26 (50 ref.)

Echocardiography and the small aortic root. Chambers J. **J Heart Valve Dis** 1996 Nov;5 Suppl 3:S264–8 (35 ref.)

[Evaluation of left ventricular systolic function using cine MRI—application to hypertrophic cardiomyopathy] Ishino Y, et al. **Nippon Rinsho** 1997 Jul;55(7):1805–10 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Estimation of left ventricular wall motion and viability by SPAMM tagging cine MRI] Miura T, et al. **Nippon Rinsho** 1997 Jul;55(7):1811–5 (4 ref.) (Eng. Abstr.) **(Jpn)**

[Assessment of ventricular wall motion and volume by fast cine MRI using Fastcard sequence] Nakanishi T, et al. **Nippon Rinsho** 1997 Jul;55(7):1800–4 (13 ref.) (Eng. Abstr.) **(Jpn)**

[The evaluation of left ventricular wall motion with MRI tagging method] Saito I, et al. **Nippon Rinsho** 1997 Mar; 55 Suppl 1:634–7 (6 ref.) **(Jpn)**

[An analysis of left ventricular function by left ventriculography] Sakai Y, et al. **Nippon Rinsho** 1997 Mar; 55 Suppl 1:666–71 (9 ref.) **(Jpn)**

[Evaluation of left ventricular function by M-mode and two-dimensional echocardiography] Tomochika Y, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:581–7 (3 ref.) **(Jpn)**

[Doppler echocardiography in the assessment of left ventricular diastolic function] Alekhin MN, et al. **Ter Arkh** 1996;68(12):84–8 (59 ref.) **(Rus)**

[Impact of electric cardiac stimulation on ventricular function and the natural history of patients with myocardiopathy] Tascón JC, et al. **Rev Esp Cardiol** 1996 Aug;49(8):598–608 (72 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Role of angiotensin converting enzyme inhibitors in preventing left ventricular remodelling following myocardial infarction. Konstam MA. **Eur Heart J** 1995 Nov;16 Suppl K:42–8 (57 ref.)

PHYSIOLOGY

Ventricular interaction and venous capacitance modulate left ventricular preload. Tyberg JV, et al. **Can J Cardiol** 1996 Oct;12(10):1058–64 (45 ref.)

Mechanics of left ventricular systolic and diastolic function in physiologic hypertrophy of the athlete's heart. Colan

SD. **Cardiol Clin** 1997 Aug;15(3):355–72 (112 ref.)
The morphologic consequences of systemic training. Shapiro LM. **Cardiol Clin** 1997 Aug;15(3):373–9 (34 ref.)
Quantitative analysis of cardiovascular MR images. van der Geest RJ, et al. **Int J Card Imaging** 1997 Jun;13(3):247–58 (39 ref.)
The hemodynamic consequences of mechanical ventilation: an evolving story. Pinsky MR. **Intensive Care Med** 1997 May;23(5):493–503 (93 ref.)
Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's Rosetta Stone. Nishimura RA, et al. **J Am Coll Cardiol** 1997 Jul;30(1):8–18 (93 ref.)
Paracrine coronary endothelial modulation of diastolic left ventricular function in man: implications for diastolic heart failure. Paulus WJ. **J Card Fail** 1996 Dec;2(4 Suppl):S155–64 (80 ref.)
Nuclear and echocardiographic imaging for prediction of reversible left ventricular ischemic dysfunction after coronary revascularization: current status and future directions. Vanoverschelde JL, et al. **J Cardiovasc Pharmacol** 1996;28 Suppl 1:S27–36 (56 ref.)
Review of tests for monitoring doxorubicin-induced cardiomyopathy. Ganz WI, et al. **Oncology** 1996 Nov–Dec; 53(6):461–70 (62 ref.)
[Structure and function of the left ventricle as a prognostic factor in patients after myocardial infarction] Witkowska M. **Pol Arch Med Wewn** 1996 Sep;96(3):268–74 (42 ref.) **(Pol)**
[Frank–Starling mechanism and the 1st temporal derivative of ventricular pressure] Okoshi K, et al. **Arq Bras Cardiol** 1996 Apr;66(4):233–7 (41 ref.) **(Por)**

VENTRICULAR FUNCTION, RIGHT

Repolarization and the genesis of cardiac arrhythmias. Role of body surface mapping [editorial; comment] Fontaine G, et al. **Circulation** 1997 Jun 17;95(12):2600–2 (20 ref.)
Comment on: Circulation 1997 Jun 17;95(12):2668–76.
[Right ventricular function in intensive care patients] Bakker J, et al. **Ned Tijdschr Geneeskd** 1996 Dec 14; 140(50):2498–502 (34 ref.) **(Dut)**

PHYSIOLOGY

The new pulmonary arterial catheters. Right ventricular ejection fraction and continuous cardiac output. Nelson LD. **Crit Care Clin** 1996 Oct;12(4):795–818 (82 ref.)
Importance of the right ventricle in valvular heart disease. Nagel E, et al. **Eur Heart J** 1996 Jun;17(6):829–36 (75 ref.)
Assessment of the right ventricle with radionuclide techniques. Schulman DS. **J Nucl Cardiol** 1996 May–Jun; 3(3):253–64 (75 ref.)

VENTRICULAR HYPERTROPHY, LEFT see **HYPERTROPHY, LEFT VENTRICULAR**

VENTRICULAR HYPERTROPHY, RIGHT see **HYPERTROPHY, RIGHT VENTRICULAR**

VENTRICULAR INFLOW OBSTRUCTION see **VENTRICULAR OUTFLOW OBSTRUCTION**

VENTRICULAR OUTFLOW OBSTRUCTION

ETIOLOGY

Aneurysm of the membranous ventricular septum resulting in pulmonary outflow tract obstruction in congenitally corrected transposition of the great arteries. Reddy SC, et al. **Am Heart J** 1997 Jan;133(1):112–9 (35 ref.)
Right outflow tract obstruction by a pedunculated neurofibroma: case report and literature review. Henderson W, et al. **Can J Cardiol** 1997 Apr;13(4):387–90 (17 ref.)

VENTRICULAR OUTFLOW OBSTRUCTION, LEFT see **VENTRICULAR OUTFLOW OBSTRUCTION**

VENTRICULAR OUTFLOW OBSTRUCTION, RIGHT see **VENTRICULAR OUTFLOW OBSTRUCTION**

VENTRICULAR PREMATURE COMPLEXES

DIAGNOSIS

Mechanism of tachycardia-dependent appearance of ventricular extrasystoles in concealed bigeminy. Kinoshita S, et al. **J Electrocardiol** 1996 Oct;29(4):341–5 (16 ref.)

ETIOLOGY

[Congenital cystic adenomatoid degeneration of the lung and ventricular trigeminism at adult age. Is there a cause–effect relation?] Salmon JP, et al. **Rev Pneumol Clin** 1997; 53(1):33–6 (18 ref.) (Eng. Abstr.) **(Fre)**

VENTRICULAR PRESSURE

[Pressure measurement systems in cardiac chambers and pulmonary artery] Shigematsu Y, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:501–3 (2 ref.) **(Jpn)**

VENTRICULAR SEPTAL DEFECTS see **HEART SEPTAL DEFECTS, VENTRICULAR**

VENTRICULAR SEPTAL PERFORATION see **VENTRICULAR SEPTAL RUPTURE**

VENTRICULAR SEPTAL RUPTURE

DIAGNOSIS

Management of postinfarction ventricular septal defect. Caputo M, et al. **Br J Hosp Med** 1995 Dec 13–1996 Jan 16;54(11):562–6 (17 ref.)

SURGERY

Management of postinfarction ventricular septal defect. Caputo M, et al. **Br J Hosp Med** 1995 Dec 13–1996 Jan 16;54(11):562–6 (17 ref.)
[Survival of a patient with postinfarction ventricular septal defect following venoarterial bypass with centrifugal pump and reoperation for residual shunt] Ohuchi H, et al. **Kyobu Geka** 1996 Sep;49(10):838–41 (6 ref.) (Eng. Abstr.) **(Jpn)**
[A case of report of surgical repair of ventricular septal perforation with left ventricular free wall rupture following acute myocardial infarction in an 86-year-old woman] Akimoto T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Oct;44(10):1891–5 (20 ref.) (Eng. Abstr.) **(Jpn)**
[A case of ventricular septal perforation treated surgically with an infarction exclusion technique] Kawase Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):582–8 (24 ref.) (Eng. Abstr.) **(Jpn)**

VENTRICULOCISTERNOSTOMY see **VENTRICULOSTOMY**

VENTRICULOGRAPHY, EQUILIBRIUM RADIONUCLIDE see **GATED BLOOD-POOL IMAGING**

VENTRICULOGRAPHY, FIRST-PASS

see related
GATED BLOOD-POOL IMAGING
[Imaging of cardiac blood pool] Machida K, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:662–5 (8 ref.) **(Jpn)**

INSTRUMENTATION

First-pass radionuclide angiocardiography with single-crystal gamma cameras. Nichols K, et al. **J Nucl Cardiol** 1997 Jan–Feb;4(1 Pt 1):61–73 (99 ref.)

VENTRICULOGRAPHY, GATED RADIONUCLIDE see **GATED BLOOD-POOL IMAGING**

VENTRICULOGRAPHY, RADIONUCLIDE see **RADIONUCLIDE VENTRICULOGRAPHY**

VENTRICULOPERITONEAL SHUNT

Endocarditis caused by Stenotrophomonas maltophilia: case report and review. Gutiérrez Rodero F, et al. **Clin Infect Dis** 1996 Dec;23(6):1261–5 (26 ref.)
Idiopathic normal-pressure hydrocephalus in adults: result of shunting correlated with clinical findings in 18 patients and review of the literature. Caruso R, et al. **Neurosurg Rev** 1997;20(2):104–7 (30 ref.)

ADVERSE EFFECTS

Pseudomyopia in a patient with blocked ventriculo-peritoneal shunt—a case report. Voon LW, et al. **Ann Acad Med Singapore** 1997 Mar;26(2):229–31 (15 ref.)
Intracranial germinoma metastasizing via a ventriculo-peritoneal shunt. Wong KT, et al. **Singapore Med J** 1996 Aug;37(4):441–2 (13 ref.)
[Perforation of the intestine by a peritoneal tube 10 years after a ventriculo-peritoneal shunt] Kin S, et al. **No Shinkei Geka** 1997 Jun;25(6):573–5 (14 ref.) (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

Propionebacterium acnes in cultures from ventriculo-peritoneal shunts: infection or contamination? Westergren H, et al. **Acta Neurochir (Wien)** 1997; 139(1):33–6 (24 ref.)
[Laparoscopic retrieval of a dislocated ventriculoperitoneal shunt catheter: report of three cases and a review of the literature] Hirano Y, et al. **No Shinkei Geka** 1997 Jul; 25(7):629–33 (19 ref.) (Eng. Abstr.) **(Jpn)**

VENTRICULOSTOMY

Secondary amenorrhea due to hydrocephalus treated with endoscopic ventriculocisternostomy. Case report. Lowry DW, et al. **J Neurosurg** 1996 Dec;85(6):1148–52 (37 ref.)
Third ventriculostomy: a review. Grant JA, et al. **Surg Neurol** 1997 Mar;47(3):210–2 (11 ref.)

VENTROMEDIAL HYPOTHALAMIC NUCLEUS

DRUG EFFECTS

Functions of angiotensin peptides in the rostral ventrolateral medulla. Dampney RA, et al. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S105–11 (65 ref.)

VENULES

PHYSIOLOGY

Regulation of lymphocyte migration into lymph nodes by high endothelial venules. Ager A. **Biochem Soc Trans** 1997 May;25(2):421–8 (46 ref.)
The role of mechanical stresses in microvascular remodeling. Skalak TC, et al. **Microcirculation** 1996 Jun;3(2):143–65 (198 ref.)

PHYSIOPATHOLOGY

Ischemia/reperfusion-induced leukocyte–endothelial interactions in postcapillary venules. Eppihimer MJ, et al. **Shock** 1997 Jul;8(1):16–25 (85 ref.)

VERAPAMIL

ADVERSE EFFECTS

Calcium channel blockers for hypertension: dissecting the evidence for adverse effects. Opie LH. **Am J Hypertens** 1997 May;10(5 Pt 1):565–77 (84 ref.)
Safety profile of the combination of verapamil and trandolapril. Holzgreve H. **J Hypertens Suppl** 1997 Mar; 15(2):S51–3 (4 ref.)
Verapamil deleterious effects in chronic renal failure. Váquez C, et al. **Nephron** 1996;72(3):461–4 (11 ref.)

PHARMACOLOGY

Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease. Brogden RN, et al. **Drugs** 1996 May;51(5):792–819 (194 ref.)
The 1996 Lindberg Award. Calcium antagonists alter cell shape and induce procollagenase synthesis in keloid and normal human dermal fibroblasts. Doong H, et al. **J Burn Care Rehabil** 1996 Nov–Dec;17(6 Pt 1):497–514 (19 ref.)
[Effect of quinine on the multiple drug resistance and intracellular distribution of pirarubicin in LR73 tumor cells: a comparative study with verapamil and S9788 by confocal laser microspectrofluorometry] Belhoussine R, et al. **Bull Cancer** 1997 Apr;84(4):343–9 (39 ref.) (Eng. Abstr.) **(Fre)**
[Intracellular signal transmission of low density lipoprotein receptors in human monocytes] Balogh Z, et al. **Orv Hetil** 1997 Sep 7;138(36 Suppl 2):2318–21 (30 ref.) (Eng. Abstr.) **(Hun)**

THERAPEUTIC USE

Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease. Brogden RN, et al. **Drugs** 1996 May;51(5):792–819 (194 ref.)
Treatment with verapamil and trandolapril in patients with congestive heart failure and myocardial infarction. The Danish Verapamil Infarction Trial (DAVIT Study Group). Hansen JF, et al. **J Hypertens Suppl** 1997 Mar; 15(2):S119–22 (32 ref.)
Preclinical considerations and results with the combination of verapamil and trandolapril: blood pressure reduction and beyond. Kirchengast M. **J Hypertens Suppl** 1997 Mar; 15(2):S27–33 (41 ref.)
Treatment of supraventricular tachyarrhythmias with intravenous calcium channel blockers: are subtle differences worth the cost? Cheiman DM, et al. **Pharmacotherapy** 1996 Sep–Oct;16(5):861–8 (29 ref.)
Clinical reversal of multidrug resistance. Bates SE, et al. **Stem Cells** 1996 Jan;14(1):56–63 (31 ref.)
[Comparative study of verapamil and bisoprolol in the secondary prevention of myocardial infarction] Sárosi I, et al. **Orv Hetil** 1997 Aug 3;138(31):1939–45 (40 ref.) (Eng. Abstr.) **(Hun)**

VERBAL BEHAVIOR

see related
LANGUAGE DISORDERS
SPEECH DISORDERS
Stimulability: a useful clinical tool. Powell TW, et al. **J Commun Disord** 1996 Jul–Aug;29(4):237–53 (56 ref.)
Stroop theory, memory, and prefrontal cortical functioning: reply to Cohen et al. (1997) [comment] Schooler C, et al. **J Exp Psychol Gen** 1997 Mar;126(1):42–4 (18 ref.)
Comment on: J Exp Psychol Gen 1997 Mar;126(1):37–41.
Managing threatening behavior. The role of talk down and talk up. Maier GJ. **J Psychosoc Nurs Ment Health Serv** 1996 Jun;34(6):25–30 (17 ref.)
Confabulation and the control of recollection. Burgess PW, et al. **Memory** 1996 Jul;4(4):359–411 (115 ref.)
Naturalistic observation of children with autism: evidence for intersubjectivity. Toomey J, et al. **New Dir Child Dev** 1995 Fall;(69):75–89 (28 ref.)

VERBAL BEHAVIOR

De-escalating verbal aggression in primary care settings. Anderson LN, et al. **Nurse Pract** 1996 Oct;21(10):95, 98, 101-2, passim (30 ref.)
Discourse behaviors in older adults. Shadden BB. **Semin Speech Lang** 1997 May;18(2):143-56; quiz 156-7 (90 ref.)

PHYSIOLOGY

Cardiovascular reactivity during verbal communication: an emerging risk factor. Thomas SA, et al. **J Cardiovasc Nurs** 1995 Jan;9(2):1-11 (42 ref.)
Hemispheric specialization for emotions, affective aspects of language and communication and the cognitive control of display behaviors in humans. Ross ED. **Prog Brain Res** 1996;107:583-94 (131 ref.)
[Neuroradiologic activation studies of cerebral organization of language capacities. A review of the literature] Ackermann H, et al. **Fortschr Neurol Psychiatr** 1997 Apr; 65(4):182-94 (125 ref.) (Eng. Abstr.) **(Ger)**

VERBAL LEARNING

see related
LANGUAGE DISORDERS

Input and learning processes in first language acquisition. Moerk EL. **Adv Child Dev Behav** 1996;26:181-228 (275 ref.)
[Combined verbal and sign language for promoting communication development in non-verbal or or pre-verbal children and adolescents with mental retardation] Wilken E. **Rehabilitation (Stuttg)** 1996 Nov; 35(4):228-32 (11 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Connectionism and developmental psychology. Plunkett K, et al. **J Child Psychol Psychiatry** 1997 Jan;38(1):53-80 (60 ref.)
[Neuroradiologic activation studies of cerebral organization of language capacities. A review of the literature] Ackermann H, et al. **Fortschr Neurol Psychiatr** 1997 Apr; 65(4):182-94 (125 ref.) (Eng. Abstr.) **(Ger)**

VERMIFUGES see **ANTHELMINTICS**

VERNER-MORRISON SYNDROME see **VIPOMA**

VERRUCA see **WARTS**

VERRUGA PERUANA see **BARTONELLA INFECTIONS**

VERSION, FETAL

METHODS

Pregnancy outcome after successful external cephalic version for breech presentation at term. Lau TK, et al. **Am J Obstet Gynecol** 1997 Jan;176(1 Pt 1):218-23 (24 ref.)

VERTEBRAE see **SPINE**

VERTEBRAL ANKYLOSING HYPEROSTOSIS see **HYPEROSTOSIS, DIFFUSE IDIOPATHIC SKELETAL**

VERTEBRAL ARTERY

Ectasia of the vertebral artery as a cause of isolated pyramidal tract signs: case report and a review of the literature. Moss MS, et al. **Br J Neurosurg** 1996 Oct;10(5):497-9 (13 ref.)
Carotid and vertebral artery dissections. Stahmer SA, et al. **Emerg Med Clin North Am** 1997 Aug;15(3):677-98 (99 ref.)
Rotational vertebral artery occlusion: a mechanism of vertebrobasilar insufficiency. Kuether TA, et al. **Neurosurgery** 1997 Aug;41(2):427-32; discussion 432-3 (26 ref.)
Coil embolization of ruptured vertebral dissection in acute stage with interlocking detachable coils. Manabe H, et al. **Surg Neurol** 1997 May;47(5):476-80 (25 ref.)

ABNORMALITIES

Combined endovascular and surgical treatment in vertebral arteriovenous fistula. A case report. Nakstad PH, et al. **Acta Radiol** 1997 Jan;38(1):25-9 (19 ref.)
Cervical myelopathy caused by the anomalous vertebral artery. A case report. Furumoto T, et al. **Spine** 1996 Oct 1;21(19):2280-3 (7 ref.)
Cervical vertebral arteriovenous fistula balloon embolization in a patient with neurofibromatosis type 1. Koenigsberg RA, et al. **Surg Neurol** 1997 Mar;47(3):265-73 (21 ref.)

INJURIES

Injury of the cervical spine associated with carotid and vertebral artery occlusion: case report and literature review. Schippinger G, et al. **Injury** 1997 May;28(4):315-8 (24 ref.)
Bilateral vertebral artery lesion after dislocating cervical spine trauma. A case report. Wirbel R, et al. **Spine** 1996 Jun 1;21(11):1375-9; discussion 1380 (22 ref.)

PATHOLOGY

Unruptured intracranial vertebral artery dissection. Clinical course and serial radiographic imagings. Yoshimoto Y, et al. **Stroke** 1997 Feb;28(2):370-4 (30 ref.)
De novo vertebral artery-posterior inferior cerebellar artery aneurysm: a case report. Kanemoto Y, et al. **Surg Neurol** 1997 May;47(5):473-5 (12 ref.)

RADIOGRAPHY

Giant pseudoaneurysm of the extracranial vertebral artery: case report. Gallo P, et al. **Arq Neuropsiquiatr** 1996 Jun; 54(2):297-303 (53 ref.)

SURGERY

Transfacial transclival approach for midline posterior circulation aneurysms. Ogilvy CS, et al. **Neurosurgery** 1996 Oct;39(4):736-41; discussion 742 (31 ref.)

ULTRASONOGRAPHY

Doppler sonography of vertebral-subclavian system. Rabbia C. **Rays** 1995 Oct-Dec;20(4):426-53 (16 ref.)

VERTEBRAL ARTERY INSUFFICIENCY see **VERTEBROBASILAR INSUFFICIENCY**

VERTEBRATES

ABNORMALITIES

Multiple vertebral segmentation defects: analysis of 26 new patients and review of the literature [see comments] Mortier GR, et al. **Am J Med Genet** 1996 Feb 2;61(4):310-9 (52 ref.) Comment in: Am J Med Genet 1996 Dec 2;66(1):91.

ANATOMY & HISTOLOGY

[The motor innervation of the axial skeletal musculature in vertebrates] Balezina OP. **Usp Fiziol Nauk** 1997 Apr-Jun; 28(2):57-78 (99 ref.) (Eng. Abstr.) **(Rus)**

BLOOD

Volume-sensitive transport systems and volume homeostasis in vertebrate red blood cells. Cossins AR, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):343-52 (97 ref.)
Oxygen and carbon dioxide transport in vertebrate erythrocytes: an evolutionary change in the role of membrane transport. Nikinmaa M. **J Exp Biol** 1997 Jan;200 (Pt 2):369-80 (118 ref.)

EMBRYOLOGY

Spatial distribution of postotic crest cells defines the head/trunk interface of the vertebrate body: embryological interpretation of peripheral nerve morphology and evolution of the vertebrate head. Kuratani S. **Anat Embryol (Berl)** 1997 Jan;195(1):1-13 (104 ref.)
There is no highly conserved embryonic stage in the vertebrates: implications for current theories of evolution and development. Richardson MK, et al. **Anat Embryol (Berl)** 1997 Aug;196(2):91-106 (81 ref.)
Left-right asymmetry in vertebrate embryogenesis. Levin M. **Bioessays** 1997 Apr;19(4):287-96 (94 ref.)
Receptor tyrosine kinase-dependent neural crest migration in response to differentially localized growth factors. Wehrle-Haller B, et al. **Bioessays** 1997 Apr;19(4):337-45 (73 ref.)
Recent molecular advances in understanding vertebrate limb development. Robertson KE, et al. **Br J Plast Surg** 1997 Feb;50(2):109-15 (59 ref.)
Phenotypic specification of hindbrain rhombomeres and the origins of rhythmic circuits in vertebrates. Bass AH, et al. **Brain Behav Evol** 1997;50 Suppl 1:3-16 (120 ref.)
Embryonic asymmetry: left TGFbeta at the right time? King T, et al. **Curr Biol** 1997 Apr 1;7(4):R212-5 (25 ref.)
Vertebrate heart development. Lyons GE. **Curr Opin Genet Dev** 1996 Aug;6(4):454-60 (63 ref.)
Notch in vertebrates. Robey E. **Curr Opin Genet Dev** 1997 Aug;7(4):551-7 (71 ref.)
Left-right asymmetry in vertebrates. Varlet I, et al. **Curr Opin Genet Dev** 1997 Aug;7(4):519-23 (40 ref.)
The patterning and onset of opsin expression in vertebrate retinae. Cepko CL. **Curr Opin Neurobiol** 1996 Aug; 6(4):542-6 (32 ref.)
Ectodermal patterning in vertebrate embryos. Sasai Y, et al. **Dev Biol** 1997 Feb 1;182(1):5-20 (167 ref.)
Genetics and limb development. Tickle C. **Dev Genet** 1996; 19(1):1-8 (80 ref.)
Fashioning the vertebrate heart: earliest embryonic decisions. Fishman MC, et al. **Development** 1997 Jun;124(11):2099-117 (208 ref.)
Neural crest apoptosis and the establishment of craniofacial pattern: an honorable death. Graham A, et al. **Mol Cell Neurosci** 1996;8(2-3):76-83 (26 ref.)
Antagonism within and around the organizer: BMP inhibitors in vertebrate body patterning. Thomsen GH. **Trends Genet** 1997 Jun;13(6):209-11 (25 ref.)
[Control of limb morphogenesis by the Hox genes] Hérault Y, et al. **C R Seances Soc Biol Fil** 1997;191(1):21-7 (16 ref.) (Eng. Abstr.) **(Fre)**
[Cells of the neural crest and their derivatives in vertebrates: the mechanisms of migration and its role in tissue formation] Mglinets VA. **Ontogenez** 1997 Jan-Feb; 28(1):18-30 (70 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Mitochondrial DNA maintenance in vertebrates. Shadel GS, et al. **Annu Rev Biochem** 1997;66:409-35 (207 ref.)
The human genome: organization and evolutionary history. Bernardi G. **Annu Rev Genet** 1995;29:445-76 (126 ref.)
Genetic depletion reveals an essential role for an SR protein splicing factor in vertebrate cells. Mount SM. **Bioessays** 1997 Mar;19(3):189-92 (30 ref.)
Gen(om)e duplications in the evolution of early vertebrates. Sidow A. **Curr Opin Genet Dev** 1996 Dec;6(6):715-22 (39 ref.)
Neurogenic genes and vertebrate neurogenesis. Lewis J. **Curr Opin Neurobiol** 1996 Feb;6(1):3-10 (75 ref.)
Genetic analysis of postsynaptic differentiation at the vertebrate neuromuscular junction. Sanes JR. **Curr Opin Neurobiol** 1997 Feb;7(1):93-100 (69 ref.)
Emergence of the immunoglobulin family: conservation in protein sequence and plasticity in gene organization. Marchalonis JJ, et al. **Glycobiology** 1996 Oct;6(7):657-63 (60 ref.)
Computational methods for the identification of genes in vertebrate genomic sequences. Claverie JM. **Hum Mol Genet** 1997;6(10):1735-44 (100 ref.)
Zebrafish genetics and its implications for understanding vertebrate development. Ingham PW. **Hum Mol Genet** 1997;6(10):1755-60 (41 ref.)
Do transgene arrays form heterochromatin in vertebrates? Dorer DR. **Transgenic Res** 1997 Jan;6(1):3-10 (60 ref.)
Evolutionary origins and maintenance of redundant gene expression during metazoan development. Cooke J, et al. **Trends Genet** 1997 Sep;13(9):360-4 (44 ref.)
The vertebrate organizer: structure and molecules. Lemaire P, et al. **Trends Genet** 1996 Dec;12(12):525-31 (60 ref.)
[Hox genes and genetic control of limb development] Hérault Y, et al. **Arch Pediatr** 1997;4(2 Suppl 2):107s-111s (17 ref.) **(Fre)**
[Control of limb morphogenesis by the Hox genes] Hérault Y, et al. **C R Seances Soc Biol Fil** 1997;191(1):21-7 (16 ref.) (Eng. Abstr.) **(Fre)**
[Hox genes, developmental evolution and the origin of vertebrates] Holland RW, et al. **Ontogenez** 1996 Jul-Aug; 27(4):273-9 (22 ref.) (Eng. Abstr.) **(Rus)**
[The role of conserved sequences in the regulatory elements of the Antp-like homeobox-containing genes of vertebrates] Spirov AV. **Zh Evol Biokhim Fiziol** 1996 Sep-Oct;32(5):556-68 (32 ref.) (Eng. Abstr.) **(Rus)**

GROWTH & DEVELOPMENT

Vertebrate neural induction. Hemmati-Brivanlou A, et al. **Annu Rev Neurosci** 1997;20:43-60 (70 ref.)
New insights into segmentation and patterning during vertebrate somitogenesis. Yamaguchi TP. **Curr Opin Genet Dev** 1997 Aug;7(4):513-8 (50 ref.)
Regulation of vertebrate neural cell fate by transcription factors. Bang AG, et al. **Curr Opin Neurobiol** 1996 Feb; 6(1):25-32 (79 ref.)
The patterning and onset of opsin expression in vertebrate retinae. Cepko CL. **Curr Opin Neurobiol** 1996 Aug; 6(4):542-6 (32 ref.)
The role of positive and negative signals in somite patterning. Lassar AB, et al. **Curr Opin Neurobiol** 1996 Feb;6(1):57-63 (64 ref.)
Tripartite signaling of pattern: interactions between Hedgehogs, BMPs and Wnts in the control of vertebrate development. Roelink H. **Curr Opin Neurobiol** 1996 Feb; 6(1):33-40 (78 ref.)
Genetic analysis of postsynaptic differentiation at the vertebrate neuromuscular junction. Sanes JR. **Curr Opin Neurobiol** 1997 Feb;7(1):93-100 (69 ref.)
Vertebrate neural progenitor cells: subtypes and regulation. Temple S, et al. **Curr Opin Neurobiol** 1996 Feb;6(1):11-7 (65 ref.)
Notch signaling in vertebrate development and disease. Gridley T. **Mol Cell Neurosci** 1997;9(2):103-8 (43 ref.)

IMMUNOLOGY

Jaw, adaptive immunity and phylogeny of vertebrate antibody VH gene family. Andersson E, et al. **Res Immunol** 1996 May;147(4):233-40 (65 ref.)
The immune system of ectothermic vertebrates. Flajnik MF. **Vet Immunol Immunopathol** 1996 Nov;54(1-4):145-50 (33 ref.)

METABOLISM

Intracellular fatty acid-binding proteins: putting lower vertebrates in perspective. Londraville RL. **Braz J Med Biol Res** 1996 Jun;29(6):707-20 (109 ref.)
Structure and function of eukaryotic mono-ADP-ribosyltransferases. Okazaki IJ, et al. **Rev Physiol Biochem Pharmacol** 1996;129:51-104 (268 ref.)

PHYSIOLOGY

Serotonergic modulation of behaviour: a phylogenetic overview. Weiger WA. **Biol Rev Camb Philos Soc** 1997 Feb;72(1):61-95 (172 ref.)
The ascending neuromodulatory systems in learning by reinforcement: comparing computational conjectures with experimental findings. Pennartz CM. **Brain Res Brain Res Rev** 1995 Nov;21(3):219-45 (235 ref.)
Cellular signalling in vertebrate pigment cells. deOliveira

AR, et al. **Braz J Med Biol Res** 1996 Dec;29(12):1743–9 (51 ref.)

A list of vertebrate cardiac ionic currents nomenclature, properties, function and cloned equivalents. Boyett MR, et al. **Cardiovasc Res** 1996 Sep;32(3):455–81 (259 ref.)

A systematic approach to studying synaptic function in vertebrates. Janz R, et al.
Cold Spring Harb Symp Quant Biol 1995;60:309–14 (17 ref.)

The mechanisms of vertebrate light adaptation: speeded recovery versus slowed activation. Detwiler PB, et al.
Curr Opin Neurobiol 1996 Aug;6(4):440–4 (41 ref.)

Synaptic transmission at vertebrate hair cells. Fuchs PA.
Curr Opin Neurobiol 1996 Aug;6(4):514–9 (54 ref.)

Thermoregulatory spectrum in vertebrates. Varghese E, et al. **Indian J Exp Biol** 1996 Nov;34(11):1053–70 (164 ref.)

Particle uptake and translocation across epithelial membranes. Thomas NW, et al. **J Anat** 1996 Dec;189 (Pt 3):487–90 (17 ref.)

Gaseous second messengers in vertebrate olfaction. Broillet MC, et al. **J Neurobiol** 1996 May;30(1):49–57 (65 ref.)

Olfactory information processing in the brain: encoding chemical and temporal features of odors. Christensen TA, et al. **J Neurobiol** 1996 May;30(1):82–91 (68 ref.)

Perireceptor events in olfaction. Pelosi P. **J Neurobiol** 1996 May;30(1):3–19 (99 ref.)

Comparative aspects of the pineal/melatonin system of poikilothermic vertebrates. Filadelfi AM, et al.
J Pineal Res 1996 May;20(4):175–86 (161 ref.)

Notch signaling in vertebrate development and disease. Gridley T. **Mol Cell Neurosci** 1997;9(2):103–8 (43 ref.)

Signal transduction in vertebrate growth cones navigating in vivo. Chien CB, et al. **Perspect Dev Neurobiol** 1996; 4(2–3):253–66 (77 ref.)

The role of ryanodine receptor isoforms in the structure and function of the vertebrate triad. Block BA, et al.
Soc Gen Physiol Ser 1996;51:47–65 (56 ref.)

Was Urbilateria segmented? Kimmel CB. **Trends Genet** 1996 Sep;12(9):329–31 (27 ref.)

Antagonism within and around the organizer: BMP inhibitors in vertebrate body patterning. Thomsen GH.
Trends Genet 1997 Jun;13(6):209–11 (25 ref.)

Regulation of sensitivity in vertebrate rod photoreceptors by calcium. Koutalos Y, et al. **Trends Neurosci** 1996 Feb; 19(2):73–81 (80 ref.)

Modelling the spatio-temporal modulation response of ganglion cells with difference-of-Gaussians receptive fields: relation to photoreceptor response kinetics. Donner K, et al. **Vis Neurosci** 1996 Jan–Feb;13(1):173–86 (67 ref.)

[The formation of cardiac-electric-field potentials on the surface of the heart and torso in vertebrate animals] Shmakov DN, et al. **Fiziol Zh Im I M Sechenova** 1995 Oct;81(10):51–8 (29 ref.) (Eng. Abstr.) **(Rus)**

VIROLOGY

Present status of classification of viruses of vertebrates. Malicki K, et al. **Arch Immunol Ther Exp (Warsz)** 1996; 44(5–6):283–9 (20 ref.)

VERTEBROBASILAR INSUFFICIENCY

[Intermittent vertebral artery compression] Ishimaru S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):440–3 (10 ref.) **(Jpn)**

DIAGNOSIS

Vertebrobasilar thrombosis: diagnosis, management, and the use of intra-arterial thrombolytics. Becker KJ, et al.
Crit Care Med 1996 Oct;24(10):1729–42 (45 ref.)

[A quickly reversible occlusion in the vertebrobasilar circulatory bed: often unrecognized?] Stangel M, et al. **Dtsch Med Wochenschr** 1996 Sep 13;121(37):1123–6 (10 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Vertebrobasilar thrombosis: diagnosis, management, and the use of intra-arterial thrombolytics. Becker KJ, et al.
Crit Care Med 1996 Oct;24(10):1729–42 (45 ref.)

ETIOLOGY

Cervical artery dissections. Leys D, et al. **Eur Neurol** 1997; 37(1):3–12 (134 ref.)

Rotational vertebral artery occlusion: a mechanism of vertebrobasilar insufficiency. Kuether TA, et al.
Neurosurgery 1997 Aug;41(2):427–32; discussion 432–3 (26 ref.)

ULTRASONOGRAPHY

Doppler sonography of vertebral-subclavian system. Rabbia C. **Rays** 1995 Oct–Dec;20(4):426–53 (16 ref.)

[Color-coded duplex ultrasonography of extracranial vascular lesions] Schuknecht BF, et al. **Radiologe** 1996 Jan; 36(1):1–11 (78 ref.) (Eng. Abstr.) **(Ger)**

VERTICAL DIMENSION

Correction of deep overbite in adults. Nanda R.
Dent Clin North Am 1997 Jan;41(1):67–87 (14 ref.)

Open bite: a review of etiology and management. Ngan P, et al. **Pediatr Dent** 1997 Mar–Apr;19(2):91–8 (76 ref.)

VERTICAL TRANSMISSION see **DISEASE TRANSMISSION, VERTICAL**

VERTICILLIUM see **HYPHOMYCETES**

VERTIGO

Recent advances of otology in China. Wang L, et al.
Chin Med J (Engl) 1996 Oct;109(10):743–6 (12 ref.)

[Progress concerning vertigo and dizziness. Now most patients can receive symptomatic relief] Bergenius J, et al. **Lakartidningen** 1997 Jul 23;94(30–31):2639–42 (20 ref.) **(Swe)**

COMPLICATIONS

[Equilibrium and auditory disorders in patients affected by HIV-1] Domènech J, et al. **Rev Neurol** 1996 Dec; 24(136):1623–6 (22 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Vertigo: new approaches to diagnosis and management. Luxon LM. **Br J Hosp Med** 1996 Nov 20–Dec 10; 56(10):519–20, 537–41 (22 ref.)

Persistent trigeminal artery as a cause of dizziness. Battista RA, et al. **Ear Nose Throat J** 1997 Jan;76(1):43–5 (18 ref.)

MRI evidence of labyrinthine and eighth-nerve bundle involvement in mumps virus sudden deafness and vertigo. Comacchio F, et al.
ORL J Otorhinolaryngol Relat Spec 1996 Nov–Dec; 58(6):295–7 (18 ref.)

DRUG THERAPY

Very high-dose streptomycin labyrinthectomy. Sataloff RT, et al. **Ear Nose Throat J** 1996 Apr;75(4):239–43 (20 ref.)

ETIOLOGY

Whiplash injury. A clinical review with emphasis on neuro-otological aspects. Fischer AJ, et al.
Clin Otolaryngol 1997 Jun;22(3):192–201 (134 ref.)

Deafness and vertigo. Gresty M, et al. **Curr Opin Neurol** 1997 Feb;10(1):36–42 (70 ref.)

Vertigo: some uncommon causes of a common problem. Lewis RF. **Semin Neurol** 1996 Mar;16(1):55–62 (49 ref.)

[Acute vertigo caused by ischemia of the postero-inferior cerebellar artery or PICA. Apropos of 2 cases] Duclos JY, et al. **Rev Laryngol Otol Rhinol (Bord)** 1997; 118(2):119–24 (18 ref.) (Eng. Abstr.) **(Fre)**

[Image diagnosis and functional tests--vertigo due to cerebellar and brain stem disorders] Kitamura T.
Nippon Jibiinkoka Gakkai Kaiho 1996 Jul;99(7):1036–9 (9 ref.) **(Jpn)**

[Clinical study in vertiginuous patients suspected of having neurovascular compression syndrome of the eighth cranial nerve] Noguchi Y, et al.
Nippon Jibiinkoka Gakkai Kaiho 1997 May;100(5):492–8 (28 ref.) (Eng. Abstr.) **(Jpn)**

REHABILITATION

A review of management of benign paroxysmal positional vertigo by exercise therapy and by repositioning manoeuvres. Beynon GJ. **Br J Audiol** 1997 Feb;31(1):11–26 (56 ref.)

Repositioning maneuver for benign paroxysmal positional vertigo (BPPV). Brooks JG, et al.
J Am Osteopath Assoc 1997 May;97(5):277–9 (10 ref.)

Update on vestibular rehabilitation therapy. Telian SA, et al. **Otolaryngol Clin North Am** 1996 Apr;29(2):359–71 (25 ref.)

SURGERY

Update on posterior canal occlusion for benign paroxysmal positional vertigo. Parnes LS.
Otolaryngol Clin North Am 1996 Apr;29(2):333–42 (28 ref.)

THERAPY

Vertigo: new approaches to diagnosis and management. Luxon LM. **Br J Hosp Med** 1996 Nov 20–Dec 10; 56(10):519–20, 537–41 (22 ref.)

Vestibular and auditory disorders. Baloh RW.
Curr Opin Neurol 1996 Feb;9(1):32–6 (24 ref.)

Particle repositioning for benign paroxysmal positional vertigo. Epley JM. **Otolaryngol Clin North Am** 1996 Apr; 29(2):323–31 (16 ref.)

[Neurovascular compression syndrome--treatment of facial spasm, trigeminal neuralgia and disabling vertigo] Hashimoto T. **Ryoikibetsu Shokogun Shirizu** 1996; (14):540–4 (7 ref.) **(Jpn)**

VERTIGO, AURAL see **MENIERE'S DISEASE**

VERY-LOW-DENSITY LIPOPROTEINS see **LIPOPROTEINS, VLDL**

VESICAL FISTULA see **BLADDER FISTULA**

VESICANTS see **IRRITANTS**

VESICATION see **BLISTER**

VESICO-URETERAL REFLUX

COMPLICATIONS

Vesicoureteric reflux and reflux nephropathy: the Christchurch contribution. Bailey RR, et al.
N Z Med J 1997 Jul 25;110(1048):266–9 (53 ref.)

[Tubulointerstitial kidney diseases in urinary tract infection, reflux and obstruction] Krautzig S, et al.
Internist (Berl) 1996 Nov;37(11):1096–110 (61 ref.) **(Ger)**

[Reflux nephropathy in vesico-ureteral reflux (VUR)] Shigematsu H. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):275–7 (19 ref.) **(Jpn)**

DIAGNOSIS

Vesicoureteral reflux: practical aspects of evaluation and management [see comments] Greenfield SP, et al.
Pediatr Nephrol 1996 Dec;10(6):789–94 (53 ref.) Comment in: Pediatr Nephrol 1996 Dec;10(6):795–7.

[Vesico-renal reflux] Steffens J, et al. **Urologe A** 1997 Mar; 36(2):w187–92 (16 ref.) **(Ger)**

ETIOLOGY

[Complications of double J ureteral stents] el Khader K. **J Urol (Paris)** 1996;102(4):173–5 (25 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Unravelling the genetics of vesicoureteric reflux: a common familial disorder. Eccles MR, et al. **Hum Mol Genet** 1996; 5 Spec No:1425–9 (65 ref.)

SURGERY

Voiding cystourethrography after uncomplicated ureteral reimplantation in children: is it necessary? Bisignani G, et al. **J Urol** 1997 Sep;158(3 Pt 2):1229–31 (26 ref.)

Trigonal splitting is a major complication of endoscopic trigonoplasty at 1-year followup. Okamura K, et al.
J Urol 1997 Apr;157(4):1423–5 (13 ref.)

THERAPY

Polytetrafluoroethylene giant granuloma and adenopathy: long-term complications following subureteral polytetrafluoroethylene injection for the treatment of vesicoureteral reflux in children. Aragona F, et al.
J Urol 1997 Oct;158(4):1539–42 (41 ref.)

Vesicoureteral reflux and ureteropelvic junction obstruction: association, treatment options and outcome. Bomalaski MD, et al. **J Urol** 1997 Mar;157(3):969–74 (21 ref.)

Vesicoureteral reflux: practical aspects of evaluation and management [see comments] Greenfield SP, et al.
Pediatr Nephrol 1996 Dec;10(6):789–94 (53 ref.) Comment in: Pediatr Nephrol 1996 Dec;10(6):795–7.

[Endoscopic treatment of vesico-renal reflux with teflon: personal experience among adults and neurologic patients] Giannotti P, et al. **Arch Ital Urol Androl** 1997 Feb;69 Suppl 1:47–53 (46 ref.) (Eng. Abstr.) **(Ita)**

[Endoscopic treatment of vesico-ureteral reflux in the neurogenic bladder. Presentation of 2 cases and review of the literature] Casals Armada J, et al. **Arch Esp Urol** 1997 May;50(4):381–7 (34 ref.) (Eng. Abstr.) **(Spa)**

VESICOVAGINAL FISTULA

COMPLICATIONS

Obstructed labor injury complex: obstetric fistula formation and the multifaceted morbidity of maternal birth trauma in the developing world. Arrowsmith S, et al.
Obstet Gynecol Surv 1996 Sep;51(9):568–74 (15 ref.)

PREVENTION & CONTROL

The problem of post-partum fistulas in developing countries. Steiner AK. **Acta Trop** 1996 Dec 30;62(4):217–23 (10 ref.)

SURGERY

The problem of post-partum fistulas in developing countries. Steiner AK. **Acta Trop** 1996 Dec 30;62(4):217–23 (10 ref.)

The treatment of vesicovaginal fistulae [see comments] Woo HH, et al. **Eur Urol** 1996;29(1):1–9 (41 ref.) Comment in: Eur Urol 1997;31(1):126.

[Surgical repair of vesico-vaginal fistulae with abdominal-transvesical approach. Comments on this technique and long-term results] Diaz Calleja E, et al.
Arch Esp Urol 1997 Jan–Feb;50(1):55–60 (22 ref.) (Eng. Abstr.) **(Spa)**

VESICULAR SKIN DISEASES see **SKIN DISEASES, VESICULOBULLOUS**

VESICULAR STOMATITIS–INDIANA VIRUS

GENETICS

A proposed mechanism of mRNA synthesis and capping by vesicular stomatitis virus. Shuman S. **Virology** 1997 Jan 6;227(1):1–6 (41 ref.)

VESICULAR STOMATITIS VIRUS

VESICULAR STOMATITIS VIRUS see **VESICULAR STOMATITIS-INDIANA VIRUS**

VESICULOBULLOUS SKIN DISEASES see **SKIN DISEASES, VESICULOBULLOUS**

VESPID VENOMS see **WASP VENOMS**

VESTIBULAR APPARATUS see **VESTIBULE**

VESTIBULAR DISEASES

Time-varying characteristics of visually induced postural sway. Loughlin PJ, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):416-24 (36 ref.)

DIAGNOSIS

Hearing, speech, language, and vestibular disorders in the fetal alcohol syndrome: a literature review. Church MW, et al. **Alcohol Clin Exp Res** 1997 May;21(3):495-512 (163 ref.)

Aggressive papillary adenoma of the cerebellopontine angle: case report of an endolymphatic sac tumor. Folker RJ, et al. **Am J Otolaryngol** 1997 Mar-Apr;18(2):135-9 (9 ref.)

Schwannoma in the vestibule and cochlea. Susilawati S, et al. **Australas Radiol** 1997 May;41(2):109-11 (8 ref.)

[Imaging of the labyrinth and vestibular nerve. Clinical significance for differential diagnosis of vestibular diseases] Jäger L, et al. **Nervenarzt** 1997 Jun;68(6):443-58 (42 ref.) (Eng. Abstr.) **(Ger)**

[Posturography: efficacy and prospects in Otorhinolaryngology] Luchikhin LA. **Vestn Otorinolaringol** 1997;(1):19-23 (34 ref.) (Eng. Abstr.) **(Rus)**

ETIOLOGY

Whiplash injury. A clinical review with emphasis on neuro-otological aspects. Fischer AJ, et al. **Clin Otolaryngol** 1997 Jun;22(3):192-201 (134 ref.)

[Dysfunctions of the vestibulocochlear system of vascular origin (a review of the literature)] Troshin OV. **Lik Sprava** 1995 Mar-Apr;(3-4):47-51 (51 ref.) **(Rus)**

GENETICS

Should endolymphatic sac tumors be considered part of the von Hippel-Lindau complex? Pathology case report. Tibbs RE Jr, et al. **Neurosurgery** 1997 Apr;40(4):848-55; discussion 855 (29 ref.)

PHYSIOPATHOLOGY

Plasticity of the vestibular system: central compensation and sensory substitution for vestibular deficits. Brandt T, et al. **Adv Neurol** 1997;73:297-309 (51 ref.)

REHABILITATION

Update on vestibular rehabilitation therapy. Telian SA, et al. **Otolaryngol Clin North Am** 1996 Apr;29(2):359-71 (25 ref.)

Advances in the treatment of vestibular disorders. Herdman SJ. **Phys Ther** 1997 Jun;77(6):602-18 (96 ref.)

THERAPY

Vestibular and auditory disorders. Baloh RW. **Curr Opin Neurol** 1996 Feb;9(1):32-6 (24 ref.)

VESTIBULAR FUNCTION TESTS

Testing the vestibulo-ocular reflex. Halmagyi GM, et al. **Adv Otorhinolaryngol** 1997;53:132-54 (24 ref.)

[Equilibrium test] Yabe T, et al. **Nippon Rinsho** 1997 Mar; 55 Suppl 1:473-9 (3 ref.) **(Jpn)**

METHODS

[Posturography: efficacy and prospects in Otorhinolaryngology] Luchikhin LA. **Vestn Otorinolaringol** 1997;(1):19-23 (34 ref.) (Eng. Abstr.) **(Rus)**

VESTIBULAR NERVE

PHYSIOLOGY

The recovery of static vestibular function following peripheral vestibular lesions in mammals: the intrinsic mechanism hypothesis. Darlington CL, et al. **J Vestib Res** 1996 May-Jun;6(3):185-201 (161 ref.)

PHYSIOPATHOLOGY

Balance and equilibrium, II: The retrovestibular neural pathway. Swartz JD, et al. **AJNR Am J Neuroradiol** 1996 Jun-Jul;17(6):1187-90 (9 ref.)

SURGERY

Selective vestibular neurectomy in Menière's disease: a review. Van de Heyning PH, et al. **Acta Otolaryngol Suppl (Stockh)** 1997;526:58-66 (47 ref.)

VESTIBULAR NUCLEI

Periodic vestibulocerebellar ataxia, an autosomal dominant ataxia with defective smooth pursuit, is genetically distinct from other autosomal dominant ataxias. Damji KF, et al. **Arch Neurol** 1996 Apr;53(4):338-44 (42 ref.)

PHYSIOLOGY

Excitatory synaptic transmission in the rat medical vestibular nucleus. Takahashi Y, et al. **Acta Otolaryngol Suppl (Stockh)** 1997;528:56-8 (21 ref.)

Plasticity of the vestibular system: central compensation and sensory substitution for vestibular deficits. Brandt T, et al. **Adv Neurol** 1997;73:297-309 (51 ref.)

Spatial orientation perception and reflexive eye movements--a perspective, an overview, and some clinical implications. Guedry FE. **Brain Res Bull** 1996; 40(5-6):505-12 (77 ref.)

Processing the head direction cell signal: a review and commentary. Taube JS, et al. **Brain Res Bull** 1996; 40(5-6):477-84; discussion 484-6 (58 ref.)

The recovery of static vestibular function following peripheral vestibular lesions in mammals: the intrinsic mechanism hypothesis. Darlington CL, et al. **J Vestib Res** 1996 May-Jun;6(3):185-201 (161 ref.)

VESTIBULE

BLOOD SUPPLY

[Dysfunctions of the vestibulocochlear system of vascular origin (a review of the literature)] Troshin OV. **Lik Sprava** 1995 Mar-Apr;(3-4):47-51 (51 ref.) **(Rus)**

CYTOLOGY

Comparison of ion transport mechanisms between vestibular dark cells and strial marginal cells. Wangemann P. **Hear Res** 1995 Oct;90(1-2):149-57 (50 ref.)

DRUG EFFECTS

Recent advances in the pharmacology of the vestibulo-ocular reflex system. Smith PF, et al. **Trends Pharmacol Sci** 1996 Nov;17(11):421-7 (60 ref.)

PHYSIOLOGY

Physiopathology of H3-receptors and pharmacology of betahistine. Van Cauwenberge PB, et al. **Acta Otolaryngol Suppl (Stockh)** 1997;526:43-6 (23 ref.)

Vestibular evoked potentials. Trinus KF. **Adv Otorhinolaryngol** 1997;53:155-81 (25 ref.)

Vestibular function and sensory interaction in altered gravity. Kornilova LN. **Adv Space Biol Med** 1997;6:275-313 (73 ref.)

Visuo-vestibular integration in the development of posture and gait. Amblard B. **Arch Ital Biol** 1996 Jul;134(3):249-77 (104 ref.)

The vestibular system as a model of sensorimotor transformations. A combined in vivo and in vitro approach to study the cellular mechanisms of gaze and posture stabilization in mammals. Vibert N, et al. **Prog Neurobiol** 1997 Feb;51(3):243-86 (269 ref.)

Recent advances in the pharmacology of the vestibulo-ocular reflex system. Smith PF, et al. **Trends Pharmacol Sci** 1996 Nov;17(11):421-7 (60 ref.)

[The interoceptive properties of the vestibular apparatus (a systems analysis of vestibular-oculomotor interaction)] Ianov IuK, et al. **Usp Fiziol Nauk** 1996 Oct-Dec; 27(4):63-72 (22 ref.) (Eng. Abstr.) **(Rus)**

[Vestibulology of 20th century: methodology of reflex or methodology of functional systems?] Ianov IK, et al. **Vestn Otorinolaringol** 1997;(1):13-8 (44 ref.) (Eng. Abstr.) **(Rus)**

[Methodological bases of studying vestibular reactions] Gerasimov KV, et al. **Vestn Ross Akad Med Nauk** 1996; (5):54-60 (50 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Vestibular findings and brainstem pathology in two siblings with Cockayne's syndrome. Iwasaki S, et al. **ORL J Otorhinolaryngol Relat Spec** 1996 Nov-Dec; 58(6):343-6 (17 ref.)

SURGERY

The best treatment for vestibular schwannoma (acoustic neuroma): microsurgery or radiosurgery? Sekhar LN, et al. **Am J Otol** 1996 Jul;17(4):676-82; discussion 683-9 (34 ref.)

VESTIBULO-OCULAR REFLEX see **REFLEX, VESTIBULO-OCULAR**

VESTIBULOCOCHLEAR NERVE see **ACOUSTIC NERVE**

VETERANS

PSYCHOLOGY

Oklahoma City bombing: exacerbation of symptoms in veterans with PTSD. Moyers F. **Arch Psychiatr Nurs** 1996 Feb;10(1):55-9 (19 ref.)

Stages of decompensation in combat-related posttraumatic stress disorder: a new conceptual model. Wang S, et al. **Integr Physiol Behav Sci** 1996 Jul-Sep;31(3):237-53 (42 ref.)

Anger regulation deficits in combat-related posttraumatic stress disorder. Chemtob CM, et al. **J Trauma Stress** 1997 Jan;10(1):17-36 (28 ref.)

STATISTICS & NUMERICAL DATA

Suicide risk factors among veterans: risk management in the changing culture of the Department of Veterans Affairs. Lambert MT, et al. **J Ment Health Adm** 1997 Summer; 24(3):350-8 (50 ref.)

VETERANS DISABILITY CLAIMS

LEGISLATION & JURISPRUDENCE

Veterans affairs disability compensation: a case study in countertherapeutic jurisprudence. Mossman D. **Bull Am Acad Psychiatry Law** 1996;24(1):27-44 (100 ref.)

VETERANS HOSPITALS see **HOSPITALS, VETERANS**

VETERINARIANS

Veterinarians serving US animal care and control facilities. Yoffe-Sharp B, et al. **J Am Vet Med Assoc** 1996 Nov 15; 209(10):1692-6 (20 ref.)

ORGANIZATION & ADMINISTRATION

Integration of veterinarians into the official response to disasters. Heath SE, et al. **J Am Vet Med Assoc** 1997 Feb 1;210(3):349-52 (17 ref.)

VETERINARY DRUGS

ADVERSE EFFECTS

Suspected adverse drug reactions in the Hungarian veterinary practice between 1982 and 1992. Bernáth S, et al. **Acta Vet Hung** 1996;44(4):451-6 (12 ref.)

CHEMISTRY

Enantioselective behaviour of drugs used in domestic animals: a review. Landoni MF, et al. **J Vet Pharmacol Ther** 1997 Feb;20(1):1-16 (114 ref.)

METABOLISM

The safety assessment of drug residues at injection sites. Galer DM, et al. **J Vet Pharmacol Ther** 1996 Aug;19(4):312 (5 ref.)

Evaluation of certain veterinary drug residues in food. Forty-fifth report of the Joint FAO/WHO Expert Committee on Food Additives. **World Health Organ Tech Rep Ser** 1996;864:1-62 (118 ref.)

PHARMACOKINETICS

Residue avoidance after topical application of veterinary drugs and parasiticides. Baynes RE, et al. **J Am Vet Med Assoc** 1997 May 1;210(9):1288-9 (2 ref.)

Veterinary drug bioequivalence determination. Toutain PL, et al. **J Vet Pharmacol Ther** 1997 Apr;20(2):79-90 (65 ref.)

THERAPEUTIC USE

Interpreting published results of extra-label drug use with special reference to reports of drugs used to correct problem behavior in animals. Hart BL, et al. **J Am Vet Med Assoc** 1996 Oct 15;209(8):1382-5 (32 ref.)

VETERINARY EDUCATION see **EDUCATION, VETERINARY**

VETERINARY MEDICINE

see related
ANIMAL DISEASES
LABORATORY ANIMAL SCIENCE

Equine clinical neonatology in the USA: past, present and future. Koterba AM, et al. **Equine Vet J Suppl** 1988 Sep; (5):6-10 (22 ref.)

Perinatology: an end and a beginning. Rossdale PD. **Equine Vet J Suppl** 1988 Sep;(5):19-24 (61 ref.)

Newborn intensive care--success, failure and opportunities. Stahlman MT. **Equine Vet J Suppl** 1988 Sep;(5):1-4; discussion 5 (39 ref.)

An overview of disaster preparedness for veterinarians [comment] Heath SE, et al. **J Am Vet Med Assoc** 1997 Feb 1;210(3):345-8 (19 ref.) Comment on: J Am Vet Med Assoc 1997 Feb 1;210(3):325-8.

Nuclear war, disaster medicine, and the veterinary profession. Stalheim OH. **J Am Vet Med Assoc** 1997 Apr 15; 210(8):1102-5 (20 ref.)

Wherefore complementary medicine? Wynn SG. **J Am Vet Med Assoc** 1996 Oct 1;209(7):1228-33 (46 ref.)

Basic principles and techniques of pharmacokinetic modeling. Riviere JE. **J Zoo Wildl Med** 1997 Mar;28(1):3-19 (20 ref.)

Managing problem wildlife in the 'Old World': a veterinary perspective. Artois M. **Reprod Fertil Dev** 1997;9(1):17-25 (98 ref.)

What is computer-aided diagnosis? Steward D.

Semin Vet Med Surg (Small Anim) 1996 May;11(2):74–84 (21 ref.)
WAAP and Pfizer Award for excellence in veterinary parasitology research. Pursuing life cycles and transmission of cyst-forming coccidia of animals and humans. Dubey JP. **Vet Parasitol** 1996 Aug;64(1–2):13–20 (41 ref.)
Veterinary cancer epidemiology. Misdorp W. **Vet Q** 1996 Mar;18(1):32–6 (53 ref.)
[Recombinant probiotics: problems and prospects of their use for medicine and veterinary practice] Sorokulova IB, et al. **Vestn Ross Akad Med Nauk** 1997;(3):46–9 (15 ref.) (Eng. Abstr.) **(Rus)**

METHODS

Modes of treatment. Rijnberk A. **Aust Vet J** 1997 Apr; 75(4):260–1 (6 ref.)
Composting alternative for animal carcass disposal. Glanville TD, et al. **J Am Vet Med Assoc** 1997 Apr 15;210(8):1116–20 (23 ref.)
Biotechnological advances in goat reproduction. Amoah EA, et al. **J Anim Sci** 1997 Feb;75(2):578–85 (74 ref.)
Does the use of antimicrobial agents in veterinary medicine and animal husbandry select antibiotic-resistant bacteria that infect man and compromise antimicrobial chemotherapy? [see comments] Piddock LJ. **J Antimicrob Chemother** 1996 Jul;38(1):1–3 (23 ref.) Comment in: J Antimicrob Chemother 1997 Feb;39(2):285–6. Comment in: J Antimicrob Chemother 1997 Mar;39(3):435.
The use of laboratory tests in equine practice. Messer NT IV. **Vet Clin North Am Equine Pract** 1995 Dec;11(3):345–50 (0 ref.)
Application of molecular biology in veterinary parasitology. Prichard R. **Vet Parasitol** 1997 Jul 31;71(2–3):155–75 (102 ref.)
[Application possibilities of laser surgery in veterinary medicine. 3: Literature review and some case reports] Weigand K, et al. **Tierarztl Prax** 1997 Jul;25(4):289–302 (73 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Use of veterinary clinic records for evaluating possible risk factors for disease. Morton JM. **Aust Vet J** 1996 Nov; 74(5):365–6 (9 ref.)
The design of veterinary vaccination programmes [see comments] Woolhouse ME, et al. **Vet J** 1997 Jan; 153(1):41–7 (18 ref.) Comment in: Vet J 1997 Jan;153(1):7–8.

TRENDS

Modes of treatment. Rijnberk A. **Aust Vet J** 1997 Apr; 75(4):260–1 (6 ref.)
Emerging diseases—what veterinarians need to know. Brown C. **J Vet Diagn Invest** 1997 Apr;9(2):113–7 (58 ref.)
Chirality: a major issue in veterinary pharmacology. Landoni MF, et al. **J Vet Pharmacol Ther** 1996 Feb;19(1):82–4 (17 ref.)
Future of veterinary radiation oncology. Gavin PR. **Vet Clin North Am Small Anim Pract** 1997 Jan;27(1):157–65 (24 ref.)
An update on chemistry analyzers. Vap LM, et al. **Vet Clin North Am Small Anim Pract** 1996 Sep; 26(5):1129–54 (41 ref.)
Prospects for plant anthelmintics in tropical veterinary medicine. Hammond JA, et al. **Vet Res Commun** 1997 Apr; 21(3):213–28 (40 ref.)
[Significance of biotechnology in reproductive biology and veterinary medicine] Glatzel PS. **Berl Munch Tierarztl Wochenschr** 1997 May;110(5):166–70 (14 ref.) (Eng. Abstr.) **(Ger)**
[Experiences in the changes of biotechnology in veterinary practice] Görlach A. **DTW Dtsch Tierarztl Wochenschr** 1996 Aug–Sep;103(8–9):312–5 (11 ref.) (Eng. Abstr.) **(Ger)**
[The zoo veterinarian in changing times] Hatt JM, et al. **Schweiz Arch Tierheilkd** 1996;138(12):573–8 (21 ref.) (Eng. Abstr.) **(Ger)**

VIBRATION

Vibration effects on setting pregnant women—subjects of various masses. Qassem W, et al. **J Biomech** 1996 Apr; 29(4):493–501 (28 ref.)
Vibration of the abdominal segment in pregnant sheep. Abrams RM, et al. **Semin Perinatol** 1996 Feb;20(1):30–7 (27 ref.)
Low back pain disorders and exposure to whole-body vibration in the workplace. Bovenzi M. **Semin Perinatol** 1996 Feb;20(1):38–53 (61 ref.)
Practical approach to measurement and evaluation of exposure to whole-body vibration in the workplace. Thalheimer E. **Semin Perinatol** 1996 Feb;20(1):77–89 (21 ref.)
Mechanical stress reduction during seated jolt/vibration exposure. Wilder DG, et al. **Semin Perinatol** 1996 Feb; 20(1):54–60 (85 ref.)
[Central motor conduction time using magnetic and vibratory stimulation in Parkinson's disease, especially in patients with rigidity] Mochio S, et al. **Nippon Rinsho** 1997 Jan; 55(1):173–8 (17 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Evaluation of the white finger risk prediction model in ISO 5349 suggests need for prospective studies. Gemne G, et al. **Cent Eur J Public Health** 1996 May;4(2):137–9 (23 ref.)
Vibration syndrome and autonomic nervous system. Sakakibara H, et al. **Cent Eur J Public Health** 1995;3 Suppl:11–4 (56 ref.)
Proposal for hand-arm vibration exposure limits adopted for Japanese workers operating hand-held vibration tools. Mirbod SM, et al. **Int Arch Occup Environ Health** 1997; 69(6):418–22 (25 ref.)
Whole-body vibration exposure and occupational work-hardening [editorial] Wasserman DE, et al. **J Occup Environ Med** 1997 May;39(5):403–7 (56 ref.)
Diagnostics of hand-arm system disorders in workers who use vibrating tools. Gemne G. **Occup Environ Med** 1997 Feb;54(2):90–5 (95 ref.)
[The influence of chemical and physical factors in the work environment on the amount of risk for abnormal pregnancy outcome] Makowiec-Dąbrowska T, et al. **Med Pr** 1997; 48(3):239–59 (84 ref.) (Eng. Abstr.) **(Pol)**

VIBRIO

Vibrio vulnificus, an emerging human pathogen. Horré R, et al. **Zentralbl Bakteriol** 1996 Jul;284(2–3):273–84 (82 ref.)

PATHOGENICITY

Pathogenic vibrios in the natural aquatic environment. Chakraborty S, et al. **Rev Environ Health** 1997 Apr–Jun; 12(2):63–80 (173 ref.)
[Recent knowledge on fish pathogenic bacteria Aeromonas salmonicida, Listonella anguillara and Cytophaga columnaris, and their virulence factors] Nomura S. **Nippon Saikingaku Zasshi** 1997 Apr;52(2):393–416 (193 ref.) **(Jpn)**

PHYSIOLOGY

Census and consensus in bacterial ecosystems: the LuxR-LuxI family of quorum-sensing transcriptional regulators. Fuqua C, et al. **Annu Rev Microbiol** 1996; 50:727–51 (106 ref.)
Lessons from a cooperative, bacterial-animal association: the Vibrio fischeri-Euprymna scolopes light organ symbiosis. Ruby EG. **Annu Rev Microbiol** 1996;50:591–624 (138 ref.)
Global analysis of physiological responses in marine bacteria. Ostling J, et al. **Electrophoresis** 1997 Aug;18(8):1441–50 (54 ref.)

VIBRIO CHOLERAE

see related
CHOLERA TOXIN
[Origin of the pathogenic vibrios in the environment: inference from the studies on the molecular genetics of Vibrio cholerae and Vibrio parahaemolyticus] Nishibuchi M. **Nippon Saikingaku Zasshi** 1996 Aug;51(3):823–32 (15 ref.) **(Jpn)**

DRUG EFFECTS

Antibiotic resistance pattern of Vibrio cholerae and Shigella causing diarrhoea outbreaks in the eastern Africa region: 1994–1996 [see comments] Materu SF, et al. **East Afr Med J** 1997 Mar;74(3):193–7 (18 ref.) Comment in: East Afr Med J 1997 Mar;74(3):121–3.

GENETICS

Cholera: nice bacteria and bad viruses. Levin BR, et al. **Curr Biol** 1996 Nov 1;6(11):1389–91 (23 ref.)
The evolution of epidemic Vibrio cholerae strains [see comments] Mooi FR, et al. **Trends Microbiol** 1997 Apr; 5(4):161–5 (38 ref.) Comment in: Trends Microbiol 1997 May;5(5):178–80.
[Origin of the pathogenic vibrios in the environment: inference from the studies on the molecular genetics of Vibrio cholerae and Vibrio parahaemolyticus] Nishibuchi M. **Nippon Saikingaku Zasshi** 1996 Aug;51(3):823–32 (15 ref.) **(Jpn)**

IMMUNOLOGY

Mucosal immune responses to intestinal bacterial pathogens. Bloom PD, et al. **Semin Gastrointest Dis** 1996 Jul; 7(3):151–66 (125 ref.)

PATHOGENICITY

Global climate and infectious disease: the cholera paradigm. Colwell RR. **Science** 1996 Dec 20;274(5295):2025–31 (89 ref.)
[Origin of the pathogenic vibrios in the environment: inference from the studies on the molecular genetics of Vibrio cholerae and Vibrio parahaemolyticus] Nishibuchi M. **Nippon Saikingaku Zasshi** 1996 Aug;51(3):823–32 (15 ref.) **(Jpn)**

PHYSIOLOGY

Survival in a cruel world: how Vibrio cholerae and Salmonella respond to an unwilling host. Slauch J, et al. **Genes Dev** 1997 Jul 15;11(14):1761–74 (125 ref.)

VIBRIO COMMA see **VIBRIO CHOLERAE**

VIBRIO FETUS see **CAMPYLOBACTER FETUS**

VIBRIO INFECTIONS

Vibrio vulnificus, an emerging human pathogen. Horré R, et al. **Zentralbl Bakteriol** 1996 Jul;284(2–3):273–84 (82 ref.)

EPIDEMIOLOGY

Pathogenic vibrios in the natural aquatic environment. Chakraborty S, et al. **Rev Environ Health** 1997 Apr–Jun; 12(2):63–80 (173 ref.)

ETIOLOGY

First European case of gastroenteritis and bacteremia due to Vibrio hollisae. Gras-Rouzet S, et al. **Eur J Clin Microbiol Infect Dis** 1996 Nov;15(11):864–6 (13 ref.)

VETERINARY

Immunization with bacterial antigens: Vibrio infections. Toranzo AE, et al. **Dev Biol Stand** 1997;90:93–105 (40 ref.)

VIBRIO PARAHAEMOLYTICUS

GENETICS

[Origin of the pathogenic vibrios in the environment: inference from the studies on the molecular genetics of Vibrio cholerae and Vibrio parahaemolyticus] Nishibuchi M. **Nippon Saikingaku Zasshi** 1996 Aug;51(3):823–32 (15 ref.) **(Jpn)**

METABOLISM

[Characteristics of energy transducing systems in membrane of Vibrio parahaemolyticus] Kuroda T, et al. **Nippon Saikingaku Zasshi** 1996 Aug;51(3):697–705 (31 ref.) **(Jpn)**

PATHOGENICITY

[Origin of the pathogenic vibrios in the environment: inference from the studies on the molecular genetics of Vibrio cholerae and Vibrio parahaemolyticus] Nishibuchi M. **Nippon Saikingaku Zasshi** 1996 Aug;51(3):823–32 (15 ref.) **(Jpn)**

VIBRIONACEAE

PATHOGENICITY

[The pathogenicity factors of opportunistic bacteria in the family Vibrionaceae (II)] Caplan D. **Bacteriol Virusol Parazitol Epidemiol** 1997 Jan–Jun; 42(1–2):3–10 (51 ref.) **(Rum)**
[The pathogenicity factors of opportunistic bacteria in the family Vibrionaceae (I)] Caplan D. **Bacteriol Virusol Parazitol Epidemiol** 1996 Jul–Dec; 41(3–4):99–105 (39 ref.) **(Rum)**

VIBRISSAE

INNERVATION

Is the cerebellum sensory for motor's sake, or motor for sensory's sake: the view from the whiskers of a rat? Bower JM. **Prog Brain Res** 1997;114:463–96 (193 ref.)

VICTIMIZATION see **CRIME VICTIMS**

VIDARABINE

ANALOGS & DERIVATIVES

Purine analogues in the management of lymphoproliferative diseases. Johnson SA. **Clin Oncol (R Coll Radiol)** 1996; 8(5):289–96 (107 ref.)
Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Adkins JC, et al. **Drugs** 1997 Jun;53(6):1005–37 (259 ref.)
Perspectives on purine analogues. Cheson BD. **Hematol Cell Ther** 1996 Dec;38 Suppl 2:S109–16 (104 ref.)
Adverse and beneficial immunological effects of purine nucleoside analogues. Dighiero G. **Hematol Cell Ther** 1996 Dec;38 Suppl 2:S75–81 (98 ref.)
Clinical experience with fludarabine in hemato-oncology. Keating MJ, et al. **Hematol Cell Ther** 1996 Dec;38 Suppl 2:S83–91 (61 ref.)
Pharmacology of purine nucleoside analogues. Plunkett W, et al. **Hematol Cell Ther** 1996 Dec;38 Suppl 2:S67–74 (77 ref.)
Present status of purine analogs in the therapy of chronic lymphocytic leukemias. Bergmann L. **Leukemia** 1997 Apr; 11 Suppl 2:S29–34 (77 ref.)
Purine analogs in the treatment of chronic lymphocytic leukemia. Pott C, et al. **Leukemia** 1997 Apr;11 Suppl 2:S25–8 (52 ref.)
Prophylactic strategies to meet infectious complications in fludarabine-treated CLL. Südhoff T, et al. **Leukemia** 1997 Apr;11 Suppl 2:S38–41 (38 ref.)
[A new purine analog in the treatment of hematologic

VIDARABINE

malignancy. I. Fludarabine] Vášová I, et al. **Vnitr Lek** 1997 Jan;43(1):45–50 (41 ref.) (Eng. Abstr.) **(Cze)**
[Antileukemic agents--new drugs and attempts of rational administration] Ueda T. **Rinsho Ketsueki** 1996 Aug; 37(8):635–9 (16 ref.) **(Jpn)**

VIDARABINE MONOPHOSPHATE see **VIDARABINE PHOSPHATE**

VIDARABINE PHOSPHATE

ANALOGS & DERIVATIVES

Fludarabine phosphate in lymphoma: an important new therapeutic agent. McLaughlin P, et al. **Cancer Treat Res** 1996;85:3–14 (56 ref.)
Why do drugs work in CLL? Plunkett W, et al. **Leuk Lymphoma** 1996 Oct;22 Suppl 2:1–11 (75 ref.)

VIDEO DISPLAY TERMINALS see **COMPUTER TERMINALS**

VIDEO GAMES

Is Mr Pac Man eating our children? A review of the effect of video games on children. Emes CE. **Can J Psychiatry** 1997 May;42(4):409–14 (38 ref.)
Video and computer games: effect on children and implications for health education. Dorman SM. **J Sch Health** 1997 Apr;67(4):133–8 (36 ref.)

VIDEO MICROSCOPY see **MICROSCOPY, VIDEO**

VIDEO RECORDING

Video-assisted thoracoscopic management of primary spontaneous pneumothorax. Yim AP. **Ann Acad Med Singapore** 1996 Sep;25(5):668–72 (28 ref.)
Video-assisted thoracic surgery in treatment of chest trauma. Liu DW, et al. **J Trauma** 1997 Apr;42(4):670–4 (20 ref.)
Pleuropericardial cysts: treatment by videothoracoscopy. Mouroux J, et al. **Surg Laparosc Endosc** 1996 Oct;6(5):403–4 (5 ref.)
Lobectomy by video-assisted thoracic surgery for a hilar bronchial carcinoid tumor. Watanabe M, et al. **Surg Laparosc Endosc** 1996 Dec;6(6):476–9 (6 ref.)
Video assisted thoracic surgery for spontaneous pneumothorax. Berrisford RG, et al. **Thorax** 1996 Aug;51 Suppl 2:S23–8 (42 ref.)
[A case of asymptomatic posterior mediastinal pheochromocytoma diagnosed during the procedure of video-assisted thoracic surgery (VATS)] Yajima H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Feb;45(2):155–60 (18 ref.) (Eng. Abstr.) **(Jpn)**
[Colectomy and anterior resection with a video-laparoscopic approach. Initial experience-results] Habr-Gama A, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Nov-Dec; 50(6):299–304 (26 ref.) (Eng. Abstr.) **(Por)**

INSTRUMENTATION

[New techniques in gastroenterologic endoscopy] Hagenmüller F, et al. **Internist (Berl)** 1996 Aug; 37(8):775–84 (37 ref.) **(Ger)**

VIDEOMICROSCOPY see **MICROSCOPY, VIDEO**

VIDEOTAPE RECORDING

Video-assisted thoracoscopic closure of PDA--a case report and literature review. Vanamo K, et al. **Ann Chir Gynaecol** 1996;85(3):272–5 (33 ref.)
What can EEG-video monitoring do for you and your patients? Benbadis SR. **J Fla Med Assoc** 1997 Jun-Jul; 84(5):320–2 (21 ref.)
Safety in long-term EEG/video monitoring. Sanders PT, et al. **J Neurosci Nurs** 1996 Oct;28(5):305–13 (14 ref.)

VIDINE see **CHOLINE**

VIF GENES see **GENES, VIF**

VIGILANCE, CORTICAL see **AROUSAL**

VILLAGE HEALTH WORKER see **COMMUNITY HEALTH AIDES**

VIMENTIN

METABOLISM

Visualization of protein kinase activities in single cells by antibodies against phosphorylated vimentin and GFAP. Inagaki N, et al. **Neurochem Res** 1996 Jul;21(7):795–800 (30 ref.)
The roles of calmodulin, actin, and vimentin in steroid synthesis by adrenal cells. Hall PF. **Steroids** 1997 Jan; 62(1):185–9 (34 ref.)

VINBLASTINE

ADVERSE EFFECTS

Mediastinitis related to probable central vinblastine extravasation in a woman undergoing adjuvant chemotherapy for early breast cancer. Anderson CM, et al. **Am J Clin Oncol** 1996 Dec;19(6):566–8 (6 ref.)

ANALOGS & DERIVATIVES

Vinorelbine (Navelbine): a third-generation vinca alkaloid. Budman DR. **Cancer Invest** 1997;15(5):475–90 (140 ref.)
Vinorelbine: an update and review of activity. Johnson SA. **Clin Oncol (R Coll Radiol)** 1996;8(6):353–7 (60 ref.)
Clinical pharmacokinetics of vinorelbine [published erratum appears in Clin Pharmacokinet 1997 Apr;32(4):323] Levêque D, et al. **Clin Pharmacokinet** 1996 Sep; 31(3):184–97 (89 ref.)
Vinorelbine: a new promising drug in Hodgkin's disease. Devizzi L, et al. **Leuk Lymphoma** 1996 Aug;22(5–6):409–14 (47 ref.)
Integration of vinorelbine into chemotherapy strategies for non-small-cell lung cancer. Vokes EE. **Oncology (Huntingt)** 1995 Jun;9(6):565–74, 577; discussion 577–8, 581– (106 ref.)

VINCA ALKALOIDS

THERAPEUTIC USE

The treatment of disseminated malignant melanoma with special reference to the role of interferons, vinca alkaloids and tamoxifen. Bezwoda WR. **Cancer Treat Rev** 1997 Jan; 23(1):17–34 (144 ref.)

VINCALEUKOBLASTINE see **VINBLASTINE**

VINCRISTINE

ADVERSE EFFECTS

Acute mesenteric ischaemia associated with 5-FU, cisplatin and vincristine chemotherapy. Allerton R. **Clin Oncol (R Coll Radiol)** 1996;8(2):116–7 (15 ref.)

VINCULIN

PHYSIOLOGY

Vinculin, talin and focal adhesions. Goldmann WH, et al. **J Muscle Res Cell Motil** 1996 Feb;17(1):1–5 (51 ref.)

VINEGAR see **ACETIC ACID**

VINYL CHLORIDE

ANALOGS & DERIVATIVES

1-Chloro-2-methylpropene. **IARC Monogr Eval Carcinog Risks Hum** 1995;63:315–24 (27 ref.)

TOXICITY

Vinyl chloride mechanistic data and risk assessment: DNA reactivity and cross-species quantitative risk extrapolation. Whysner J, et al. **Pharmacol Ther** 1996;71(1–2):7–28 (135 ref.)

VINYL COMPOUNDS

Vinyl acetate. **IARC Monogr Eval Carcinog Risks Hum** 1995; 63:443–65 (85 ref.)
Vinyl fluoride. **IARC Monogr Eval Carcinog Risks Hum** 1995; 63:467–75 (37 ref.)

METABOLISM

The versatility of phosphoenolpyruvate and its vinyl ether products in biosynthesis. Walsh CT, et al. **Chem Biol** 1996 Feb;3(2):83–91 (38 ref.)

PHARMACOKINETICS

Vinylcyclohexene dioxide. Dhillon S, et al. **J Appl Toxicol** 1996 Sep-Oct;16(5):465–8 (34 ref.)

TOXICITY

Vinylcyclohexene dioxide. Dhillon S, et al. **J Appl Toxicol** 1996 Sep-Oct;16(5):465–8 (34 ref.)

VINYLIDENE CHLORIDES see **DICHLOROETHYLENES**

VIOLENCE

see related
BATTERED CHILD SYNDROME
BATTERED WOMEN

The impact of exposure to crime and violence on urban youth. Berman SL, et al. **Am J Orthopsychiatry** 1996 Jul; 66(3):329–36 (29 ref.)
Media violence, gun control, and public policy. Zuckerman DM. **Am J Orthopsychiatry** 1996 Jul;66(3):378–89 (32 ref.)
Improving the clinical practice of violence risk assessment. Technology, guidelines, and training. Borum R. **Am Psychol** 1996 Sep;51(9):945–56 (112 ref.)
Memory, abuse, and science. Questioning claims about the false memory syndrome epidemic. Pope KS. **Am Psychol** 1996 Sep;51(9):957–74 (140 ref.)
Disordered views of aggressive children. A late twentieth century perspective. Richters JE. **Ann N Y Acad Sci** 1996 Sep 20;794:208–23 (65 ref.)
ABC of mental health. Mental health emergencies. Atakan Z, et al. **BMJ** 1997 Jun 14;314(7096):1740–2 (0 ref.)
Treating mass burns in warfare, disaster or terrorist strikes. Sparkes BG. **Burns** 1997 May;23(3):238–47 (101 ref.)
Chronic problems in understanding tribal violence and warfare. Chagnon NA. **Ciba Found Symp** 1996;194:202–32; discussion 232–6 (68 ref.)
The implications for responsibility of possible genetic factors in the explanation of violence. Glover J. **Ciba Found Symp** 1996;194:237–47 (6 ref.)
Serotonin in alcoholic violent offenders. Virkkunen M, et al. **Ciba Found Symp** 1996;194:168–77; discussion 177–82 (47 ref.)
Violence of psychotic patients: how much responsibility can be attributed? Nedopil N. **Int J Law Psychiatry** 1997 Spring;20(2):243–7 (15 ref.)
A personality disorder of excessive power strivings. Charny IW. **Isr J Psychiatry Relat Sci** 1997;34(1):3–15; discussion 16–7 (38 ref.)
Sarin: guidelines on the management of victims of a nerve gas attack [see comments] Volans AP. **J Accid Emerg Med** 1996 May;13(3):202–6 (16 ref.) Comment in: J Accid Emerg Med 1996 Nov;13(6):431–2.
Acute disturbed or violent behaviour: principles of treatment. Kerr IB, et al. **J Psychopharmacol (Oxf)** 1997;11(3):271–7 (40 ref.)
Violence and public health. Golding A. **J R Soc Med** 1996 Sep;89(9):501–5 (35 ref.)
Public mental health. II: The psychological dimension. Curle A. **Med Confl Surviv** 1997 Jan-Mar;13(1):26–36 (3 ref.)
Public employees as a group at risk for violence. Barab J. **Occup Med** 1996 Apr-Jun;11(2):257–67 (34 ref.)
Violence against women. Burge SK. **Prim Care** 1997 Mar; 24(1):67–81 (53 ref.)
Psychopharmacologic violence associated with cocaine abuse: kindling of a limbic dyscontrol syndrome? Davis WM. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Nov;20(8):1273–300 (143 ref.)
Psychotherapeutic approaches to aggressive and violent patients. Alpert JE, et al. **Psychiatr Clin North Am** 1997 Jun;20(2):453–72 (122 ref.)
The developmental course of violence and aggression. Mechanisms of family and peer influence. Pettit GS. **Psychiatr Clin North Am** 1997 Jun;20(2):283–99 (47 ref.)
Legal issues in treating perpetrators and victims of violence. Resnick PJ, et al. **Psychiatr Clin North Am** 1997 Jun; 20(2):473–87 (74 ref.)
Psychophysiology of anger and violent behavior. Scarpa A, et al. **Psychiatr Clin North Am** 1997 Jun;20(2):375–94 (96 ref.)
[Violence and aggression in adolescents and young adults. Review of the recent literature] Sand EA, et al. **Rev Epidemiol Sante Publique** 1996 Aug;44(4):301–45 (134 ref.) (Eng. Abstr.) **(Fre)**
[When does alcohol trigger violence? "Emotional blindness" and impulsiveness are important links] Heilig M. **Lakartidningen** 1997 Mar 5;94(10):841–4 (37 ref.) **(Swe)**

ETHNOLOGY

Searching for resilience among African-American youth exposed to community violence: theoretical issues. Howard DE. **J Adolesc Health** 1996 Apr;18(4):254–62 (66 ref.)

LEGISLATION & JURISPRUDENCE

Violent offender research and implications for the criminal justice system. Rice ME. **Am Psychol** 1997 Apr; 52(4):414–23 (70 ref.)
The law of workplace violence. Mathiason GG, et al. **Occup Med** 1996 Apr-Jun;11(2):315–34 (96 ref.)

PREVENTION & CONTROL

Violence in the workplace. Hewitt JB, et al. **Annu Rev Nurs Res** 1997;15:81–99 (72 ref.)
Schizophrenia, violence, clozapine and risperidone: a review. The Special Hospitals Treatment Resistant Schizophrenia Research Group. **Br J Psychiatry Suppl** 1996 Dec; (31):21–30 (60 ref.)
Suicide and violence assessment in psychiatry. Hughes DH. **Gen Hosp Psychiatry** 1996 Nov;18(6):416–21 (37 ref.)
Preventing firearm violence: a physician's guide. Hunt DK. **J Gen Intern Med** 1996 Nov;11(11):694–701 (94 ref.)
Workplace violence: preventive and interventive strategies. Warshaw LJ, et al. **J Occup Environ Med** 1996 Oct; 38(10):993–1006 (53 ref.)
Preventing violence, preventing war. Ashford MW. **Med Confl Surviv** 1997 Jan-Mar;13(1):57–62 (7 ref.)
The prevention of delinquency, with particular reference to violent crime. Shepherd JP, et al. **Med Sci Law** 1996 Oct; 36(4):331–6 (69 ref.)
De-escalating verbal aggression in primary care settings. Anderson LN, et al. **Nurse Pract** 1996 Oct;21(10):95, 98, 101–2, passim (30 ref.)

Tools for developing a workplace violence prevention program. Askari E. **Occup Med** 1996 Apr-Jun;11(2):363-74 (5 ref.)
Organizational factors in workplace violence: developing effective programs to reduce workplace violence. Baron SA. **Occup Med** 1996 Apr-Jun;11(2):335-48 (11 ref.)
Policies for developing workplace violence prevention strategies. Cabral R. **Occup Med** 1996 Apr-Jun; 11(2):303-14 (32 ref.)
Improving workplace security. D'Addario FJ. **Occup Med** 1996 Apr-Jun;11(2):349-61 (15 ref.)
Retail employees as a group at risk for violence. Erickson RJ. **Occup Med** 1996 Apr-Jun;11(2):269-76 (21 ref.)
State and local regulatory approaches to preventing workplace violence. Howard J. **Occup Med** 1996 Apr-Jun; 11(2):293-301 (20 ref.)
Health care workers and workplace violence. Simonowitz JA. **Occup Med** 1996 Apr-Jun;11(2):277-91 (43 ref.)
Risk appraisal and management of violent behavior. Harris GT, et al. **Psychiatr Serv** 1997 Sep;48(9):1168-76 (132 ref.)
[Violence in the school--analysis of the problem and possible interventions] Meier U. **Prax Kinderpsychol Kinderpsychiatr** 1997 Mar;46(3):169-81 (31 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Decreasing the burden of trauma for victims of violence. Kaufmann MC. **Ann Emerg Med** 1997 Aug;30(2):199-203 (31 ref.)
Autonomic nervous system factors underlying disinhibited, antisocial, and violent behavior. Biosocial perspectives and treatment implications. Raine A. **Ann N Y Acad Sci** 1996 Sep 20;794:46-59 (53 ref.)
Key issues in the development of aggression and violence from childhood to early adulthood. Loeber R, et al. **Annu Rev Psychol** 1997;48:371-410 (240 ref.)
A clinical and interactionist perspective on the bully-victim-bystander relationship. Twemlow SW, et al. **Bull Menninger Clin** 1996 Summer;60(3):296-313 (40 ref.)
The social context of mental illness and violence. Hiday VA. **J Health Soc Behav** 1995 Jun;36(2):122-37 (143 ref.)
Television violence and its effect on children. Johnson MO. **J Pediatr Nurs** 1996 Apr;11(2):94-9 (31 ref.)
The effects of violence on health and adjustment of Southeast Asian refugee children: an integrative review. Fox PG, et al. **Public Health Nurs** 1994 Jun;11(3):195-201 (28 ref.)
When women are under the influence. Does drinking or drug use by women provoke beatings by men? Kantor GK, et al. **Recent Dev Alcohol** 1997;13:315-36 (91 ref.)
Alcohol, drugs, and violence in children's lives. Miller BA, et al. **Recent Dev Alcohol** 1997;13:357-85 (120 ref.)
[Reflections on the cause and consequences of exposure to violent presentations in children] Rauchfleisch U. **Prax Kinderpsychol Kinderpsychiatr** 1997 Jul-Aug; 46(6):435-44 (27 ref.) (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

A reassessment of the link between mental disorder and violent behaviour, and its implications for clinical practice. Mullen PE. **Aust N Z J Psychiatry** 1997 Feb;31(1):3-11 (54 ref.)
Violence in medical facilities: a review of 40 incidents. Feldmann TB, et al. **J Ky Med Assoc** 1997 May;95(5):183-9 (21 ref.)
Epidemiology of violence and theft in the workplace. Bachman R. **Occup Med** 1996 Apr-Jun;11(2):237-41 (9 ref.)
Workplace homicide: industries and occupations at high risk. Jenkins EL. **Occup Med** 1996 Apr-Jun;11(2):219-25 (15 ref.)
Epidemiology of violent injury in the workplace. Kraus JF, et al. **Occup Med** 1996 Apr-Jun;11(2):201-17 (42 ref.)
Alcohol and violence-related injuries in the emergency room. Cherpitel CJ. **Recent Dev Alcohol** 1997;13:105-18 (51 ref.)
Alcohol and cocaine interactions and aggressive behaviors. Denison ME, et al. **Recent Dev Alcohol** 1997;13:283-303 (31 ref.)
Is there a causal relationship between alcohol use and violence? A synthesis of evidence. Lipsey MW, et al. **Recent Dev Alcohol** 1997;13:245-82 (84 ref.)
Epidemiological issues in alcohol-related violence. Roizen J. **Recent Dev Alcohol** 1997;13:7-40 (60 ref.)
Longitudinal perspective on alcohol use and aggression during adolescence. White HR. **Recent Dev Alcohol** 1997; 13:81-103 (82 ref.)
Urban violence and health--South Africa 1995. Gilbert L. **Soc Sci Med** 1996 Sep;43(5):873-86 (74 ref.)

VIP see **VASOACTIVE INTESTINAL PEPTIDE**

VIP RECEPTORS see **RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE**

VIPER VENOMS

ENZYMOLOGY

Insights into the mechanism of haemorrhage caused by snake venom metalloproteinases. Kamiguti AS, et al. **Toxicon** 1996 Jun;34(6):627-42 (96 ref.)
Cross-reactivities of polyclonal antibodies against lebetase, fibrinolytic enzyme of Levantine viper (Vipera lebetina) venom. Siigur J, et al. **Toxicon** 1996 May;34(5):608-13 (17 ref.)

TOXICITY

The Gaboon viper, Bitis gabonica: hemorrhagic, metabolic, cardiovascular and clinical effects of the venom. Marsh N, et al. **Life Sci** 1997;61(8):763-9 (35 ref.)

VIPERIDAE

see related
VIPER VENOMS

Incidence, pathology, and treatment of adder (Vipera berus L.) bites in man. Reading CJ. **J Accid Emerg Med** 1996 Sep;13(5):346-51 (32 ref.)
Snakebite by the bushmaster (Lachesis muta) in Brazil: case report and review of the literature. Jorge MT, et al. **Toxicon** 1997 Apr;35(4):545-54 (33 ref.)

VIPERINAE see **VIPERIDAE**

VIPOMA

[Treatment of liver metastasis of endocrine tumors of the pancreas] Orozco Zepeda H. **Rev Gastroenterol Mex** 1997 Jan-Mar;62(1):50-6 (28 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Vasoactive intestinal polypeptide-secreting tumours: biology and therapy. Park SK, et al. **Baillieres Clin Gastroenterol** 1996 Dec;10(4):673-96 (130 ref.)

PHYSIOPATHOLOGY

Pathophysiology and management of VIPoma: a case study. Meriney DK. **Oncol Nurs Forum** 1996 Jul;23(6):941-8; quiz 949-50 (36 ref.)

THERAPY

Pathophysiology and management of VIPoma: a case study. Meriney DK. **Oncol Nurs Forum** 1996 Jul;23(6):941-8; quiz 949-50 (36 ref.)

VIRAL ANTIBODIES see **ANTIBODIES, VIRAL**

VIRAL ANTIGENS see **ANTIGENS, VIRAL**

VIRAL BURDEN see **VIRAL LOAD**

VIRAL COAT PROTEINS see **CAPSID**

VIRAL CONJUNCTIVITIS see **CONJUNCTIVITIS, VIRAL**

VIRAL CORE PROTEINS

[Expression and characterization of hepatitis C virus proteins] Matsuura Y. **Uirusu** 1995 Dec;45(2):105-15 (56 ref.) **(Jpn)**

CHEMISTRY

Influence of core protein sequence on glycosaminoglycan assembly. Esko JD, et al. **Curr Opin Struct Biol** 1996 Oct; 6(5):663-70 (37 ref.)

METABOLISM

Molecular basis of subcellular localization of HCV core protein. Suzuki T, et al. **Liver** 1996 Aug;16(4):221-4 (35 ref.)

VIRAL DNA see **DNA, VIRAL**

VIRAL ENCEPHALITIS see **ENCEPHALITIS, VIRAL**

VIRAL ENVELOPE PROTEINS

[Expression and characterization of hepatitis C virus proteins] Matsuura Y. **Uirusu** 1995 Dec;45(2):105-15 (56 ref.) **(Jpn)**

ANALYSIS

Antigenic differences between HSV-1 and HSV-2 glycoproteins and their importance for type-specific serology. Bergström T, et al. **Intervirology** 1996; 39(3):176-84 (79 ref.)

BIOSYNTHESIS

Structural and functional analysis of bovine herpesvirus 1 minor glycoproteins. Baranowski E, et al. **Vet Microbiol** 1996 Nov;53(1-2):91-101 (73 ref.)

CHEMISTRY

The HTLV-I envelope glycoproteins: structure and functions. Delamarre L, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S85-91 (54 ref.)
[Structure and biological functions of the spike protein of mouse hepatitis virus] Taguchi F. **Uirusu** 1996 Dec; 46(2):109-17 (52 ref.) **(Jpn)**

GENETICS

Molecular studies of visna virus gene expression: analysis of envelope gene expression in transgenic sheep. Clements JE, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):421-3 (65 ref.)
Investigation of the pattern of diversity of hepatitis C virus in relation to times of transmission. Simmonds P, et al. **J Viral Hepat** 1997;4 Suppl 1:69-74 (13 ref.)

PHARMACOLOGY

Injury models of the vascular endothelium: apoptosis and loss of thromboresistance induced by a viral protein. Eldor A, et al. **Haemostasis** 1996 Oct;26 Suppl 4:37-45 (46 ref.)

PHYSIOLOGY

Maturation and assembly of retroviral glycoproteins. Einfeld D. **Curr Top Microbiol Immunol** 1996;214:133-76 (285 ref.)
Functions of the large hepatitis B virus surface protein in viral particle morphogenesis. Bruss V, et al. **Intervirology** 1996;39(1-2):23-31 (50 ref.)
The HTLV-I envelope glycoproteins: structure and functions. Delamarre L, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S85-91 (54 ref.)
Functional aspects of Aujeszky's disease (pseudorabies) viral proteins with relation to invasion, virulence and immunogenicity. Nauwynck HJ. **Vet Microbiol** 1997 Apr; 55(1-4):3-11 (48 ref.)
[Structure and biological functions of the spike protein of mouse hepatitis virus] Taguchi F. **Uirusu** 1996 Dec; 46(2):109-17 (52 ref.) **(Jpn)**

TOXICITY

Identification of cytotoxic peptide as possible mechanism for neurotoxicity of HIV viral envelope and AIDS pathogenesis. Sangster B. **Med Hypotheses** 1997 Jun; 48(6):463-8 (25 ref.)

ULTRASTRUCTURE

[Morphology of micro-organism--development of my electron microscopical study] Hosaka Y. **Nippon Saikingaku Zasshi** 1996 Oct;51(4):1003-13 (15 ref.) **(Jpn)**

VIRAL EYE INFECTIONS see **EYE INFECTIONS, VIRAL**

VIRAL FUSION GLYCOPROTEINS see **VIRAL FUSION PROTEINS**

VIRAL FUSION PROTEINS

Virus-cell and cell-cell fusion. Hernandez LD, et al. **Ann Rev Cell Dev Biol** 1996;12:627-61 (176 ref.)

CHEMISTRY

Low-pH induced conformational changes in viral fusion proteins: implications for the fusion mechanism. Gaudin Y, et al. **J Gen Virol** 1995 Jul;76 (Pt 7):1541-56 (128 ref.)

PHYSIOLOGY

Low-pH induced conformational changes in viral fusion proteins: implications for the fusion mechanism. Gaudin Y, et al. **J Gen Virol** 1995 Jul;76 (Pt 7):1541-56 (128 ref.)

VIRAL GAG PROTEINS see **GENE PRODUCTS, GAG**

VIRAL GENE EXPRESSION REGULATION see **GENE EXPRESSION REGULATION, VIRAL**

VIRAL GENE PRODUCTS see **VIRAL PROTEINS**

VIRAL GENE PROTEINS see **VIRAL PROTEINS**

VIRAL GENES see **GENES, VIRAL**

VIRAL GENOME see **GENOME, VIRAL**

VIRAL HEPATITIS VACCINES

Hepatitis vaccines. Petruff CA, et al. **Dig Dis** 1997 Jan-Apr; 15(1-2):1-22 (115 ref.)
Hepatitis A: epidemiology and prevention. Feinstone SM. **Eur J Gastroenterol Hepatol** 1996 Apr;8(4):300-5 (67 ref.)
Anti-hepatitis A virus (HAV) vaccination: guidelines for an immunization strategy in Italy. Workshop Consensus Conference--Rome, May 2-3, 1995 [published erratum appears in Ital J Gastroenterol 1996 Jul-Aug;28(6):368] **Ital J Gastroenterol** 1996 Apr;28(3):181-4 (0 ref.)
Vaccines to prevent viral hepatitis. Lemon SM, et al. **N Engl J Med** 1997 Jan 16;336(3):196-204 (117 ref.)
New and improved vaccines. Promising weapons against varicella, hepatitis A, and typhoid fever. Conrad DA, et al. **Postgrad Med** 1996 Oct;100(4):113-8, 121-5, 127 (20 ref.)

ADMINISTRATION & DOSAGE

Occupational medicine forum [see comments]

VIRAL HEPATITIS VACCINES

J Occup Environ Med 1996 Apr;38(4):339–41 (16 ref.) Comment in: J Occup Environ Med 1996 Dec;38(12):1200–1.

[Preventive vaccination for viral hepatitis] Jilg W. **Z Gastroenterol** 1997 Jul;35(7):585–90 (18 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

New hepatitis A vaccines and their role in prevention [published erratum appears in Drugs 1996 Sep;52(3):449] Strader DB, et al. **Drugs** 1996 Mar;51(3):359–66 (25 ref.)

IMMUNOLOGY

Immunisation against hepatitis A--active or passive? Iwarson S. **Infection** 1996 Jan–Feb;24(1):2–4 (15 ref.)

Clinical development of a new inactivated hepatitis A vaccine. Vidor E, et al. **Infection** 1996 Nov–Dec; 24(6):447–58 (153 ref.)

Hepatitis A vaccines. Bittar Z. **J Med Liban** 1996;44(2):90–5 (29 ref.)

[Vaccination against hepatitis A] Balli F, et al. **Pediatr Med Chir** 1996 May–Jun;18(3):259–62 (19 ref.) (Eng. Abstr.) **(Ita)**

THERAPEUTIC USE

Prevention of hepatitis A infections: guidelines for use of hepatitis A vaccine and immune globulin. American Academy of Pediatrics Committee on Infectious Diseases. **Pediatrics** 1996 Dec;98(6 Pt 1):1207–15 (50 ref.)

[Perspectives of developing a vaccine against hepatitis C virus] Skarpetowski AC, et al. **Pediatr Pol** 1996 Apr; 71(4):295–300 (25 ref.) (Eng. Abstr.) **(Pol)**

VIRAL INSERTIONAL MUTAGENESIS see **MUTAGENESIS, INSERTIONAL**

VIRAL INTERFERENCE

see related
INTERFERONS

VIRAL LOAD

HIV viral dynamics. Coffin JM. **AIDS** 1996 Dec;10 Suppl 3:S75–84 (19 ref.)

Advances in antiretroviral therapy and viral load monitoring. Hammer SM. **AIDS** 1996 Dec;10 Suppl 3:S1–11 (84 ref.)

Will killing the last HIV1 particle cure AIDS patients? II: Second Part. Decrease of viral load and of T-suppressor cells, and increase of the cytotoxic cells, without effect on CD4, after the use of 10 virostatics applied in 3 or 4 drug combinations of different sequences. The time for CD4 immunotherapy? [editorial] Mathé G, et al. **Biomed Pharmacother** 1996;50(10):473–9 (41 ref.)

Applying viral load measurements to HIV care. Klaus BD. **Nurse Pract** 1996 Aug;21(8):102–4 (8 ref.)

[The HIV viral load: new aspects and limits of its clinical use] Mühlhöfer A, et al. **Dtsch Med Wochenschr** 1996 Oct 18;121(42):1303–8 (32 ref.) **(Ger)**

[Viral load and monitoring of antiretroviral treatment] Soriano V, et al. **Rev Clin Esp** 1996 Dec;196(12):872–7 (53 ref.) **(Spa)**

METHODS

HIV-1 viral dynamics and viral load measurement: implications for therapy. Riddler SA, et al. **AIDS Clin Rev** 1997–98;:47–65 (53 ref.)

Branched DNA for quantification of viral load. Wilber JC. **Immunol Invest** 1997 Jan–Feb;26(1–2):9–13 (12 ref.)

VIRAL M PROTEINS see **VIRAL MATRIX PROTEINS**

VIRAL MARKERS see **BIOLOGICAL MARKERS**

VIRAL MATRIX PROTEINS

[Anti-apoptotic function of the Epstein-Barr virus LMP1 and BHRF1 proteins] Kawanishi M. **Nippon Rinsho** 1996 Jul;54(7):1848–54 (19 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Mutations in the hemagglutinin and matrix genes of a virulent influenza virus variant, A/FM/1/47-MA, control different stages in pathogenesis. Smeenk CA, et al. **Virus Res** 1996 Oct;44(2):79–95 (44 ref.)

[Sequence analysis of the carboxy terminal of the Epstein-Barr virus LMP-1 oncogene in Epstein-Barr virus associated disorders] Itakura O, et al. **Nippon Rinsho** 1997 Feb;55(2):467–72 (15 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Regulation of Epstein-Barr virus latency by latent membrane protein 2. Longnecker R, et al. **Trends Microbiol** 1996 Jan; 4(1):38–42 (59 ref.)

[The TRAF family protein-mediated B cell proliferation signal and the mechanism of LMP1-induced B cell transformation] Inoue J. **Nippon Rinsho** 1997 Feb; 55(2):299–304 (18 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Epstein-Barr virus oncogenesis. Knecht H, et al. **Crit Rev Oncol Hematol** 1997 Jul;26(2):117–35 (263 ref.)

Are particular Epstein-Barr virus strains linked to disease? Jenkins PJ, et al. **Semin Cancer Biol** 1996 Aug;7(4):209–15 (52 ref.)

[Regulation of apoptosis by the latent infection membrane protein 1 of Epstein-Barr virus] Kawanishi M. **Nippon Rinsho** 1997 Feb;55(2):305–10 (20 ref.) (Eng. Abstr.) **(Jpn)**

VIRAL NONSTRUCTURAL PROTEINS

[Expression and characterization of hepatitis C virus proteins] Matsuura Y. **Uirusu** 1995 Dec;45(2):105–15 (56 ref.) **(Jpn)**

CHEMISTRY

Structure and function of rotavirus NSP1. Taniguchi K, et al. **Arch Virol Suppl** 1996;12:53–8 (22 ref.)

The nonstructural proteins of the hepatitis C virus: structure and functions. Neddermann P, et al. **Biol Chem** 1997 Jun; 378(6):469–76 (84 ref.)

Targeting the Achilles' heel of hepatitis C virus. Lemon SM. **Hepatology** 1997 Apr;25(4):1035–7 (10 ref.)

GENETICS

Investigation of the pattern of diversity of hepatitis C virus in relation to times of transmission. Simmonds P, et al. **J Viral Hepat** 1997;4 Suppl 1:69–74 (13 ref.)

METABOLISM

A hypothesis about the mechanism of assembly of double-shelled rotavirus particles. Suzuki H. **Arch Virol Suppl** 1996;12:79–85 (30 ref.)

Structure and function of rotavirus NSP1. Taniguchi K, et al. **Arch Virol Suppl** 1996;12:53–8 (22 ref.)

Rotavirus protein expression is important for virus assembly and pathogenesis. Tian P, et al. **Arch Virol Suppl** 1996; 12:69–77 (26 ref.)

Processing pathways of the hepatitis C virus proteins. Lohmann V, et al. **J Hepatol** 1996;24(2 Suppl):11–9 (63 ref.)

PHYSIOLOGY

The nonstructural proteins of the hepatitis C virus: structure and functions. Neddermann P, et al. **Biol Chem** 1997 Jun; 378(6):469–76 (84 ref.)

VIRAL ONCOGENE PROTEINS see **ONCOGENE PROTEINS, VIRAL**

VIRAL PACKAGING see **VIRUS ASSEMBLY**

VIRAL PROTEINS

The human cytomegalovirus genes and proteins required for DNA synthesis. Anders DG, et al. **Intervirology** 1996; 39(5–6):378–88 (115 ref.)

Human cytomegalovirus glycoproteins. Britt WJ, et al. **Intervirology** 1996;39(5–6):401–12 (97 ref.)

Myxoma T2 protein as a model for poxvirus TNF receptor homologs. McFadden G, et al. **J Neuroimmunol** 1997 Feb; 72(2):119–26 (47 ref.)

[Inhibition of apoptosis by a baculovirus p35 gene] Ohtsubo T, et al. **Nippon Rinsho** 1996 Jul;54(7):1907–11 (19 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

Bovine viral diarrhea virus proteins and their antigenic analyses. Donis RO, et al. **Arch Virol Suppl** 1991;3:29–40 (47 ref.)

ANTAGONISTS & INHIBITORS

Stabilising oral poliovaccine at high ambient temperatures. Newman JF, et al. **Dev Biol Stand** 1996;87:103–11 (15 ref.)

BIOSYNTHESIS

The regulation of gene expression in neurotrophic viruses. Roos RP. **J Neurovirol** 1997 May;3 Suppl 1:S25–7 (15 ref.)

The murine coronavirus as a model of trafficking and assembly of viral proteins in neural tissue. Kalicharran K, et al. **Trends Microbiol** 1996 Jul;4(7):264–9 (58 ref.)

CHEMISTRY

Metabolism and biology of tryptophan. Some clinical implications. Brown RR. **Adv Exp Med Biol** 1996;398:15–25 (60 ref.)

The baculovirus 10-kDa protein. Van Oers MM, et al. **J Invertebr Pathol** 1997 Jul;70(1):1–17 (152 ref.)

CLASSIFICATION

The influence of virus structure on antibody responses and virus serotype formation. Bachmann MF, et al. **Immunol Today** 1996 Dec;17(12):553–8 (48 ref.)

GENETICS

In vitro experimental systems for HPV: epithelial raft cultures for investigations of viral reproduction and pathogenesis and for genetic analyses of viral proteins and regulatory sequences. Chow LT, et al. **Clin Dermatol** 1997 Mar–Apr; 15(2):217–27 (63 ref.)

Functional roles of immediate early proteins encoded by the human cytomegalovirus UL36–38, UL115–119, TRS1/IRS1 and US3 loci. Colberg-Poley AM. **Intervirology** 1996;39(5–6):350–60 (78 ref.)

Bacteriophage lambda lysis gene product modified and inserted into Escherichia coli outer membrane: Rz1 lipoprotein. Taylor A, et al. **Microb Drug Resist** 1996 Spring;2(1):147–53 (36 ref.)

Selection of proteins and peptides from libraries displayed on filamentous bacteriophage. McGregor D. **Mol Biotechnol** 1996 Oct;6(2):155–62 (54 ref.)

Receptors for gamma-interferon encoded by poxviruses: implications for the unknown origin of vaccinia virus. Alcamí A, et al. **Trends Microbiol** 1996 Aug;4(8):321–6 (38 ref.)

Evolution of viral DNA-dependent RNA polymerases. Sonntag KC, et al. **Virus Genes** 1995;11(2–3):271–84 (81 ref.)

["X"--the last unknown of hepatitis B virus? Gene X and products of its expression] Sidorkiewicz M. **Postepy Biochem** 1997;43(1):25–30 (51 ref.) **(Pol)**

IMMUNOLOGY

One step ahead of the game: viral immunomodulatory molecules. Spriggs MK. **Annu Rev Immunol** 1996;14:101–30 (207 ref.)

Cytomegaloviruses use multiple mechanisms to elude the host immune response. Wiertz E, et al. **Immunol Lett** 1997 Jun 1;57(1–3):213–6 (24 ref.)

The influence of virus structure on antibody responses and virus serotype formation. Bachmann MF, et al. **Immunol Today** 1996 Dec;17(12):553–8 (48 ref.)

Inhibition of MHC class I antigen presentation by viral proteins. Früh K, et al. **J Mol Med** 1997 Jan;75(1):18–27 (110 ref.)

METABOLISM

Inhibition of cysteine and serine proteinases by the cowpox virus serpin CRMA. Komiyama T, et al. **Adv Exp Med Biol** 1996;389:173–6 (39 ref.)

RNA-protein interactions in the regulation of coronavirus RNA replication and transcription. Lai MM. **Biol Chem** 1997 Jun;378(6):477–81 (32 ref.)

Virus proteins that bind cytokines, chemokines or interferons. Smith GL. **Curr Opin Immunol** 1996 Aug;8(4):467–71 (47 ref.)

Involvement of host factors in transcription from baculovirus very late promoters — a review. Hasnain SE, et al. **Gene** 1997 Apr 29;190(1):113–8 (45 ref.)

Filamentous phage assembly: variation on a protein export theme. Russel M, et al. **Gene** 1997 Jun 11;192(1):23–32 (62 ref.)

Cellular and viral protein interactions regulating I kappa B alpha activity during human retrovirus infection. Hiscott J, et al. **J Leukoc Biol** 1997 Jul;62(1):82–92 (80 ref.)

Processing of hepatitis C virus precursor polyprotein. Shimotohno K, et al. **Princess Takamatsu Symp** 1995; 25:121–8 (21 ref.)

Nuclear export and its significance in retroviral infection. Yoneda Y. **Trends Microbiol** 1996 Jan;4(1):1–2 (15 ref.)

[Fibrillary proteins from bacteriophage T4 as a model for studying folding] Mesianzhinov VV. **Mol Biol (Mosk)** 1997 May–Jun;31(3):389–97 (53 ref.) **(Rus)**

PHYSIOLOGY

One step ahead of the game: viral immunomodulatory molecules. Spriggs MK. **Annu Rev Immunol** 1996;14:101–30 (207 ref.)

Mechanism of formation of post Golgi vesicles from TGN membranes: Arf-dependent coat assembly and PKC-regulated vesicle scission. Sabatini DD, et al. **Biocell** 1996 Dec;20(3):287–300 (104 ref.)

Virocrine transformation. Drummond-Barbosa D, et al. **Biochim Biophys Acta** 1997 Feb 22;1332(1):M1–17 (148 ref.)

Computational genomic analysis of hemorrhagic fever viruses. Viral selenoproteins as a potential factor in pathogenesis. Ramanathan CS, et al. **Biol Trace Elem Res** 1997 Jan;56(1):93–106 (46 ref.)

The roles of AAV Rep proteins in gene expression and targeted integration. Chiorini JA, et al. **Curr Top Microbiol Immunol** 1996;218:25–33 (43 ref.)

M-T2: a poxvirus TNF receptor homologue with dual activities. Sedger L, et al. **Immunol Cell Biol** 1996 Dec; 74(6):538–45 (77 ref.)

The baculovirus 10-kDa protein. Van Oers MM, et al. **J Invertebr Pathol** 1997 Jul;70(1):1–17 (152 ref.)

Regulation of apoptosis by viral gene products. Teodoro JG, et al. **J Virol** 1997 Mar;71(3):1739–46 (103 ref.)

Two beginnings for a single purpose: the dual-start holins in the regulation of phage lysis. Bläsi U, et al. **Mol Microbiol** 1996 Aug;21(4):675–82 (39 ref.)

Plant virus proteins involved in natural vector transmission. Gray SM. **Trends Microbiol** 1996 Jul;4(7):259–64 (55 ref.)

Pseudorabies virus infections in pigs. Role of viral proteins in virulence, pathogenesis and transmission. Mulder WA, et al. **Vet Res** 1997;28(1):1–17 (142 ref.)

Do Vpu and Vpr of human immunodeficiency virus type

1 and NB of influenza B virus have ion channel activities in the viral life cycles? Lamb RA, et al. **Virology** 1997 Mar 3;229(1):1–11 (127 ref.)

[Anti-apoptotic function of the Epstein–Barr virus LMP1 and BHRF1 proteins] Kawanishi M. **Nippon Rinsho** 1996 Jul;54(7):1848–54 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Cooperation of phage and bacterial proteins in bacteriophage lambda DNA replication] Marszałek J. **Postepy Biochem** 1997;43(1):5–12 (58 ref.) **(Pol)**

VIRAL REGULATORY PROTEINS

METABOLISM

HIV accessory proteins as therapeutic targets. Miller RH, et al. **Nat Med** 1997 Apr;3(4):389–94 (49 ref.)

VIRAL RNA see **RNA, VIRAL**

VIRAL SHEDDING see **VIRUS SHEDDING**

VIRAL STRUCTURAL PROTEINS

BIOSYNTHESIS

A role for Rev in the association of HIV-1 gag mRNA with cytoskeletal beta-actin and viral protein expression. Kimura T, et al. **Biochimie** 1996;78(11–12):1075–80 (48 ref.)

CHEMISTRY

Structural features unique to enteric adenoviruses. Brown M, et al. **Arch Virol Suppl** 1996;12:301–7 (46 ref.)

METABOLISM

Processing pathways of the hepatitis C virus proteins. Lohmann V, et al. **J Hepatol** 1996;24(2 Suppl):11–9 (63 ref.)

VIRAL TRANSFORMING PROTEINS see **ONCOGENE PROTEINS, VIRAL**

VIRAL TUMOR ANTIGENS see **ANTIGENS, VIRAL, TUMOR**

VIRAL VACCINES

Viral diseases of the immune system and strategies to control infectious bursal disease by vaccination. Lütticken D. **Acta Vet Hung** 1997;45(3):239–49 (37 ref.)

Advantages and disadvantages of using live vaccines risks and control measures. Alexandersen S. **Acta Vet Scand Suppl** 1996;90:89–100 (27 ref.)

Unique immunomodulating properties of dimethyl dioctadecyl ammonium bromide (DDA) in experimental viral vaccines. Katz D, et al. **Adv Exp Med Biol** 1996; 397:115–25 (22 ref.)

Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Moss B, et al. **Adv Exp Med Biol** 1996;397:7–13 (35 ref.)

Alphavirus-based expression systems. Rice CM. **Adv Exp Med Biol** 1996;397:31–40 (38 ref.)

DNA vaccines for bacteria and viruses. Ulmer JB, et al. **Adv Exp Med Biol** 1996;397:49–53 (15 ref.)

Comparative approach to retroviral vaccines. Burny A. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):389–92 (6 ref.)

Efficacy of an inactivated feline leukemia virus vaccine. Hoover EA, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):379–83 (53 ref.)

The relevance of feline retroviruses to the development of vaccines against HIV. Jarrett O. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):385–7 (23 ref.)

Correlates of immune protection after vaccination with attenuated live murine leukemia virus. Ruprecht RM, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):375–7 (14 ref.)

Perspectives on retroviral pathogenesis and vaccines. Weiss RA. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):465–7 (3 ref.)

Viral vaccines: selected topics. Kańtoch M. **Arch Immunol Ther Exp (Warsz)** 1996;44(5–6):367–71 (40 ref.)

Controlling orthopoxvirus infections--200 years after Jenner's revolutionary immunization. Niemialtowski MG, et al. **Arch Immunol Ther Exp (Warsz)** 1996;44(5–6):373–8 (36 ref.)

Yellow fever vaccines. Barrett AD. **Biologicals** 1997 Mar; 25(1):17–25 (67 ref.)

Japanese encephalitis and dengue vaccines. Barrett AD. **Biologicals** 1997 Mar;25(1):27–34 (62 ref.)

Current developments in new vaccines for adolescents. Rappuoli R. **Biologicals** 1997 Jun;25(2):159–63 (36 ref.)

Vaccination against papillomavirus in cattle. Campo MS. **Clin Dermatol** 1997 Mar–Apr;15(2):275–83 (51 ref.)

Prevention of liver cancer and cirrhosis by vaccines. Prince AM. **Clin Lab Med** 1996 Jun;16(2):493–505 (80 ref.)

Recent developments in the design of viral vaccines. Minor PD. **Dev Biol Stand** 1996;87:51–7 (11 ref.)

Stability of yellow fever vaccine. Monath TP. **Dev Biol Stand** 1996;87:219–25 (21 ref.)

Factors affecting the stability of viral vaccines. Peetermans J. **Dev Biol Stand** 1996;87:97–101 (4 ref.)

Human papillomavirus vaccines. Vonka V. **Folia Biol (Praha)** 1996;42(3):73–8 (50 ref.)

The role of vaccines in the control of STDs: HPV vaccines. Frazer IH. **Genitourin Med** 1996 Dec;72(6):398–403 (65 ref.)

Issues related to development of Epstein-Barr virus vaccines. Spring SB, et al. **J Natl Cancer Inst** 1996 Oct 16; 88(20):1436–41 (66 ref.)

Feline leukaemia virus: a review of immunity and vaccination. Sparkes AH. **J Small Anim Pract** 1997 May; 38(5):187–94 (49 ref.)

Recombinant viral vector vaccines for the veterinary use. Yokoyama N, et al. **J Vet Med Sci** 1997 May;59(5):311–22 (135 ref.)

Rotavirus vaccines: a perspective. Nakagomi O, et al. **Microbiol Immunol** 1996;40(10):701–9 (61 ref.)

Manipulation of the Semliki Forest virus genome and its potential for vaccine construction. Atkins GJ, et al. **Mol Biotechnol** 1996 Feb;5(1):33–8 (29 ref.)

Negative-strand RNA viruses: genetic engineering and applications. Palese P, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11354–8 (46 ref.)

Applications of pox virus vectors to vaccination: an update. Paoletti E. **Proc Natl Acad Sci U S A** 1996 Oct 15; 93(21):11349–53 (34 ref.)

The role of biotechnologically engineered vaccines and diagnostics in pseudorabies (Aujeszky's disease) eradication strategies. Mengeling WL, et al. **Vet Microbiol** 1997 Apr; 55(1–4):49–60 (70 ref.)

Advances in the development and evaluation of bovine herpesvirus 1 vaccines. van Oirschot JT, et al. **Vet Microbiol** 1996 Nov;53(1–2):43–54 (60 ref.)

Vaccination strategies for improving the efficacy of programs to eradicate Aujeszky's disease virus. Visser N. **Vet Microbiol** 1997 Apr;55(1–4):61–74 (38 ref.)

[Prevention of virus-related neurological diseases by vaccines] Takahashi M. **Nippon Rinsho** 1997 Apr; 55(4):954–8 (17 ref.) (Eng. Abstr.) **(Jpn)**

[New vaccines for wide usage] Mravunac B, et al. **Lijec Vjesn** 1997 Feb;119(2):72–6 (65 ref.) (Eng. Abstr.) **(Scr)**

ADMINISTRATION & DOSAGE

Combination vaccines. Ellis RW, et al. **Adv Pharmacol** 1997; 39:393–423 (60 ref.)

The current status of therapeutic HPV vaccine. van Driel WJ, et al. **Ann Med** 1996 Dec;28(6):471–7 (72 ref.)

New Australian immunisation guidelines. **Commun Dis Intell** 1997 Mar 20;21(6):78–9 (0 ref.)

Enteric immunization: promises and challenges. Brown WR. **Dig Dis** 1996 May–Jun;14(3):192–200 (41 ref.)

Yellow fever: a decade of reemergence. Robertson SE, et al. **JAMA** 1996 Oct 9;276(14):1157–62 (62 ref.)

[Varicella zoster virus vaccine—a review] Petersen CS, et al. **Ugeskr Laeger** 1997 Feb 17;159(8):1081–5 (40 ref.) (Eng. Abstr.) **(Dan)**

[Virology. The art of controlling the geniality which even the smallest contagions show] Norrby E. **Lakartidningen** 1997 Jun 18;94(25):2357–8, 2362–4 (0 ref.) **(Swe)**

ADVERSE EFFECTS

Characterization of protective and enhancing immune responses to equine infectious anemia virus resulting from experimental vaccines. Montelaro RC, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):413–5 (22 ref.)

The potential role and mechanisms of FeLV vaccine-induced neoplasms. Macy DW. **Semin Vet Med Surg (Small Anim)** 1995 Nov;10(4):234–7 (36 ref.)

Immunological determinants of disease caused by respiratory syncytial virus [see comments] Graham BS. **Trends Microbiol** 1996 Jul;4(7):290–3 (39 ref.) Comment in: Trends Microbiol 1996 Aug;4(8):299–300.

[Polynucleotide (DNA) viral vaccines and their safety problems] Gendon IuZ. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Jan–Feb; (1):78–81 (27 ref.) **(Rus)**

BIOSYNTHESIS

Fish vaccine antigens produced or delivered by recombinant DNA technologies. Leong JC, et al. **Dev Biol Stand** 1997; 90:267–77 (47 ref.)

The development of cowpea mosaic virus as a potential source of novel vaccines. Porta C, et al. **Intervirology** 1996; 39(1–2):79–84 (24 ref.)

Genetically engineered particulate virus-like structures and their use as vaccine delivery systems. Roy P. **Intervirology** 1996;39(1–2):62–71 (25 ref.)

CHEMISTRY

Stabilization of rinderpest vaccine by modification of the lyophilization process. House JA, et al. **Dev Biol Stand** 1996;87:235–44 (23 ref.)

GENETICS

The new generation of recombinant viral subunit vaccines. Ellis RW. **Curr Opin Biotechnol** 1996 Dec;7(6):646–52 (52 ref.)

HISTORY

Safety of biopharmaceuticals: a current perspective. Parkman PD. **Dev Biol Stand** 1996;88:5–7 (9 ref.)

IMMUNOLOGY

Varicella-zoster virus: aspects of pathogenesis and host response to natural infection and varicella vaccine. Arvin AM, et al. **Adv Virus Res** 1996;46:263–309 (75 ref.)

Vaccine against human T cell leukemia-lymphoma virus type I: progress and prospects. Bomford R, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):403–5 (34 ref.)

Attenuated poxvirus vectors as carriers in vaccines against human T cell leukemia-lymphoma virus type I. Franchini G, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20; 12(5):407–8 (21 ref.)

Simian retrovirus vaccines: simian retrovirus and simian immunodeficiency lentivirus. Gardner MB, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):399–401 (20 ref.)

Replication in goats in vivo of caprine arthritis-encephalitis virus deleted in vif or tat genes: possible use of these deletion mutants as live vaccines. Harmache A, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):409–11 (9 ref.)

Efficacy of recombinant feline leukemia virus vaccines. Jarrett O. **AIDS Res Hum Retroviruses** 1996 Mar 20; 12(5):435–6 (14 ref.)

Vaccination of cats with recombinant envelope glycoprotein of feline immunodeficiency virus: decreased viral load after challenge infection. Lutz H, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):431–3 (17 ref.)

Characterization of protective and enhancing immune responses to equine infectious anemia virus resulting from experimental vaccines. Montelaro RC, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):413–5 (22 ref.)

T cell-mediated destruction of bovine leukemia virus-infected peripheral lymphocytes by bovine leukemia virus env-vaccinia recombinant vaccine. Ohishi K, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):393–8 (18 ref.)

Evaluation of vaccines for ovine lentivirus infection. Perk K, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20; 12(5):425–6 (19 ref.)

DNA vaccines. Robinson HL, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):455–7 (27 ref.)

WC3 reassortant vaccines in children. Clark HF, et al. **Arch Virol Suppl** 1996;12:187–98 (25 ref.)

Jennerian and modified Jennerian approach to vaccination against rotavirus diarrhea using a quadrivalent rhesus rotavirus (RRV) and human-RRV reassortant vaccine. Kapikian AZ, et al. **Arch Virol Suppl** 1996;12:163–75 (30 ref.)

The new generation of recombinant viral subunit vaccines. Ellis RW. **Curr Opin Biotechnol** 1996 Dec;7(6):646–52 (52 ref.)

Chimeric rhinoviruses as tools for vaccine development and characterization of protein epitopes. Arnold GF, et al. **Intervirology** 1996;39(1–2):72–8 (38 ref.)

Papillomavirus-like particles for serology and vaccine development. Kirnbauer R. **Intervirology** 1996; 39(1–2):54–61 (82 ref.)

Synthesis, properties and applications of papillomavirus-like particles. Sapp M, et al. **Intervirology** 1996;39(1–2):49–53 (30 ref.)

Human papillomavirus immunology and vaccine prospects. Steller MA, et al. **J Natl Cancer Inst Monogr** 1996; (21):145–8 (28 ref.)

Prospects for prophylactic and therapeutic hepatitis C virus vaccines. Houghton M, et al. **Princess Takamatsu Symp** 1995;25:237–43 (33 ref.)

Papillomavirus-like particles and HPV vaccine development. Schiller JT, et al. **Semin Cancer Biol** 1996 Dec;7(6):373–82 (65 ref.)

Vaccines against human cytomegalovirus: time to test. Britt WJ. **Trends Microbiol** 1996 Jan;4(1):34–8 (47 ref.)

Biological features of genetic immunization. Barry MA, et al. **Vaccine** 1997 Jun;15(8):788–91 (10 ref.)

Perspectives on FIV vaccine development. Elyar JS, et al. **Vaccine** 1997 Aug–Sep;15(12–13):1437–44 (59 ref.)

Potency control of modified live viral vaccines for veterinary use. Terpstra C, et al. **Vaccine** 1996 Jan;14(1):13–8 (13 ref.)

Novel viral vaccines for livestock. Babiuk LA, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):355–63 (49 ref.)

[Immunologic aspects of infections with papillomaviruses. Prospects for a vaccine] Höpfl R, et al. **Hautarzt** 1996 Oct; 47(10):739–43 (42 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Human papillomavirus vaccines for cervical cancer. Tindle RW. **Curr Opin Immunol** 1996 Oct;8(5):643–50 (63 ref.)

Rotavirus vaccines [editorial] Ebrahim GJ. **J Trop Pediatr** 1996 Oct;42(5):254–5 (18 ref.)

The immunologic aspects of human immunodeficiency virus infection in the gastrointestinal tract. Schneider T, et al. **Semin Gastrointest Dis** 1996 Jan;7(1):19–29 (108 ref.)

VIRAL VACCINES

STANDARDS

Feline calicivirus: a need for vaccine modification? Baulch-Brown C, et al. **Aust Vet J** 1997 Mar;75(3):209–13 (67 ref.)
Retrovirus screening of vaccine cell substrates. Khan AS. **Dev Biol Stand** 1996;88:157–62 (24 ref.)
Issues of biological assays for viral vaccines. Lee CK. **Dev Biol Stand** 1996;88:41–7 (11 ref.)
Mammalian cells and their contaminants. Minor PD. **Dev Biol Stand** 1996;88:25–9 (6 ref.)
Potency control of modified live viral vaccines for veterinary use. Terpstra C, et al. **Vaccine** 1996 Apr;14(6):570–5 (13 ref.)

THERAPEUTIC USE

Varicella vaccine in immunocompromised patients. Cat LK, et al. **Ann Pharmacother** 1996 Feb;30(2):181–4 (16 ref.)
The development of therapeutic vaccines of the management of malignant melanoma. Dalgleish AG, et al. **Cancer Surv** 1996;26:289–319 (158 ref.)
Immunization strategy for prevention of congenital cytomegalovirus infection. Pass RF. **Infect Agents Dis** 1996 Oct;5(4):240–4 (44 ref.)
Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Barrow PA, et al. **Trends Microbiol** 1997 Jul;5(7):268–71 (21 ref.)

VIREMIA

Diagnosis and treatment of infectious diseases in HIV-infected hosts. Castano-Molina C, et al. **Dermatol Clin** 1997 Apr;15(2):267–83 (197 ref.)

DIAGNOSIS

Measuring hepatitis C viremia in clinical samples: can we trust the assays? Pawlotsky JM. **Hepatology** 1997 Jul; 26(1):1–4 (26 ref.)
Diffuse arthralgia and myalgia as the first manifestation of benign myeloradiculopathy due to cytomegalovirus infection in an immunocompetent patient. Etaouil N, et al. **Rev Rhum Engl Ed** 1997 Jan;64(1):57–8 (7 ref.)

EPIDEMIOLOGY

Occupationally acquired infections in health care workers. Part II [published erratum appears in Ann Intern Med 1997 Apr 1;126(7):588] Sepkowitz KA. **Ann Intern Med** 1996 Dec 1;125(11):917–28 (279 ref.)

VIROLOGY

HIV-1 viral dynamics and viral load measurement: implications for therapy. Riddler SA, et al. **AIDS Clin Rev** 1997–98;:47–65 (53 ref.)

VIRGINIAMYCIN

CHEMISTRY

Streptogramins. A unique class of antibiotics. Pechère JC. **Drugs** 1996;51 Suppl 1:13–9 (21 ref.)

PHARMACOLOGY

Quinupristin–dalfopristin [see comments] Bryson HM, et al. **Drugs** 1996 Sep;52(3):406–15 (62 ref.) Comment in: Drugs 1996 Nov;52(5):795.
Quinupristin/dalfopristin: spectrum of activity, pharmacokinetics, and initial clinical experience. Low DE. **Microb Drug Resist** 1995 Fall;1(3):223–34 (74 ref.)
Treatment of vancomycin-resistant enterococci, with a focus on quinupristin–dalfopristin. Fuller RE, et al. **Pharmacotherapy** 1996 Jul–Aug;16(4):584–92 (87 ref.)

THERAPEUTIC USE

The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: current antibiotic therapy in the 1990s. Bradley JS, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S213–21 (58 ref.)
Quinupristin–dalfopristin [see comments] Bryson HM, et al. **Drugs** 1996 Sep;52(3):406–15 (62 ref.) Comment in: Drugs 1996 Nov;52(5):795.
Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use. Finch RG. **Drugs** 1996;51 Suppl 1:31–7 (41 ref.)
Future prospects and therapeutic potential of streptogramins. Rubinstein E, et al. **Drugs** 1996;51 Suppl 1:38–42 (30 ref.)
Quinupristin/dalfopristin: spectrum of activity, pharmacokinetics, and initial clinical experience. Low DE. **Microb Drug Resist** 1995 Fall;1(3):223–34 (74 ref.)
Vancomycin-resistant Enterococcus faecium infections in the ICU and quinupristin/dalfopristin. Zervos M. **New Horiz** 1996 Aug;4(3):385–92 (38 ref.)

VIRGINIAMYCIN FACTOR M1 see **VIRGINIAMYCIN**

VIRGINIAMYCIN FACTOR S1 see **VIRGINIAMYCIN**

VIRILISM

DIAGNOSIS

Masculinizing and feminizing syndromes caused by functioning tumors. Masiakos PT, et al. **Semin Pediatr Surg** 1997 Aug;6(3):147–55 (64 ref.)

ETIOLOGY

[Pathogenesis and diagnosis of androgenetic manifestations] Imthurn B. **Schweiz Rundsch Med Prax** 1997 Jun 4; 86(23):993–5 (7 ref.) (Eng. Abstr.) **(Ger)**

VIRION

IMMUNOLOGY

Papillomavirus-like particles and HPV vaccine development. Schiller JT, et al. **Semin Cancer Biol** 1996 Dec;7(6):373–82 (65 ref.)

PHYSIOLOGY

Proteolytic processing and particle maturation. Vogt VM. **Curr Top Microbiol Immunol** 1996;214:95–131 (154 ref.)

ULTRASTRUCTURE

[Visualization of virus particles] Yazaki K, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1065–8 (10 ref.) **(Jpn)**

VIROIDS

GENETICS

Origin and evolution of viroids and viroid-like satellite RNAs. Diener TO. **Virus Genes** 1995;11(2–3):119–31 (61 ref.)

VIROLOGY

Mathematical and computational challenges in population biology and ecosystems science. Levin SA, et al. **Science** 1997 Jan 17;275(5298):334–43 (108 ref.)

METHODS

Amplification and subtraction methods and their application to the discovery of novel human viruses. Muerhoff AS, et al. **J Med Virol** 1997 Sep;53(1):96–103 (63 ref.)
[Molecular biology at the service of the daily medical virology. 1. Methodological principles] Wattré P. **Ann Biol Clin (Paris)** 1997 Jan–Feb;55(1):25–31 (8 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

Advances in dengue diagnosis. Guzmán MG, et al. **Clin Diagn Lab Immunol** 1996 Nov;3(6):621–7 (136 ref.)
[Virology. The art of controlling the geniality which even the smallest contagions show] Norrby E. **Lakartidningen** 1997 Jun 18;94(25):2357–8, 2362–4 (0 ref.) **(Swe)**

VIRTUAL SYSTEMS see **USER-COMPUTER INTERFACE**

VIRULENCE

Genetic and tissue culture systems for the study of bacterial pathogenesis. Quinn FD, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:19–25 (27 ref.)
Virulence factors of medically important fungi. Hogan LH, et al. **Clin Microbiol Rev** 1996 Oct;9(4):469–88 (326 ref.)
The evolution and maintenance of virulence in microparasites. Levin BR. **Emerg Infect Dis** 1996 Apr–Jun; 2(2):93–102 (62 ref.)
Iron depletion and virulence in Staphylococcus aureus. Trivier D, et al. **FEMS Microbiol Lett** 1996 Aug 1; 141(2–3):117–27 (51 ref.)
Mycobacterial virulence factors. Gordon S, et al. **Soc Appl Bacteriol Symp Ser** 1996;25:10S–22S (120 ref.)
[A modern view of the evolution of virulence] Giorgio S. **Rev Saude Publica** 1995 Oct;29(5):398–402 (19 ref.) (Eng. Abstr.) **(Por)**

GENETICS

Genetics of coxsackievirus virulence. Chapman NM, et al. **Curr Top Microbiol Immunol** 1997;223:227–58 (175 ref.)
Microbial pathogenesis: genomics and beyond. Strauss EJ, et al. **Science** 1997 May 2;276(5313):707–12 (29 ref.)
Did the inheritance of a pathogenicity island modify the virulence of Helicobacter pylori? [see comments] Covacci A, et al. **Trends Microbiol** 1997 May;5(5):205–8 (25 ref.) Comment in: Trends Microbiol 1997 Jul;5(7):264–5.
How Salmonella became a pathogen. Groisman EA, et al. **Trends Microbiol** 1997 Sep;5(9):343–9 (74 ref.)
[Genes involved in the virulence of enterohemorrhagic Escherichia coli] Izumiya H, et al. **Nippon Rinsho** 1997 Mar;55(3):641–5 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Yersinia outer membrane proteins coded for by the virulence plasmid] Mikerov AN, et al. **Mol Gen Mikrobiol Virusol** 1997;(3):3–10 (131 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Shared themes of antigenic variation and virulence in bacterial, protozoal, and fungal infections. Deitsch KW, et al. **Microbiol Mol Biol Rev** 1997 Sep;61(3):281–93 (192 ref.)

VIRUS ACTIVATION

The Viral Activation Transfusion Study (VATS): rationale, objectives, and design overview. Busch MP, et al. **Transfusion** 1996 Oct;36(10):854–9 (65 ref.)

GENETICS

Latency and reactivation of varicella zoster virus infections. Dueland AN. **Scand J Infect Dis Suppl** 1996;100:46–50 (34 ref.)

PHYSIOLOGY

[The mechanisms of Epstein-Barr virus activation in B cells] Sairenji T. **Nippon Rinsho** 1997 Feb;55(2):316–20 (12 ref.) (Eng. Abstr.) **(Jpn)**

RADIATION EFFECTS

Review of the impact on the activation of the human immunodeficiency virus type 1 of ultraviolet light. Duan Y, et al. **Med Hypotheses** 1996 Jul;47(1):11–4 (9 ref.)

VIRUS ASSEMBLY

Hepadnaviruses: current models of RNA encapsidation and reverse transcription. Fallows DA, et al. **Adv Virus Res** 1996;46:165–94 (138 ref.)
A hypothesis about the mechanism of assembly of double-shelled rotavirus particles. Suzuki H. **Arch Virol Suppl** 1996;12:79–85 (30 ref.)
Rotavirus protein expression is important for virus assembly and pathogenesis. Tian P, et al. **Arch Virol Suppl** 1996; 12:69–77 (26 ref.)
Use of heterologous expression systems to study retroviral morphogenesis. Boulanger P, et al. **Curr Top Microbiol Immunol** 1996;214:237–60 (112 ref.)
Dynamic interactions of the Gag polyprotein. Craven RC, et al. **Curr Top Microbiol Immunol** 1996;214:65–94 (113 ref.)
Packaging systems for adeno-associated virus vectors. Trempe JP. **Curr Top Microbiol Immunol** 1996;218:35–50 (68 ref.)
Structure and assembly of the virion. Gibson W. **Intervirology** 1996;39(5–6):389–400 (130 ref.)
The HTLV-I envelope glycoproteins: structure and functions. Delamarre L, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S85–91 (54 ref.)

PHYSIOLOGY

Poliovirus assembly and encapsidation of genomic RNA. Ansardi DC, et al. **Adv Virus Res** 1996;46:1–68 (232 ref.)
Role of auxiliary proteins in retroviral morphogenesis. Cohen EA, et al. **Curr Top Microbiol Immunol** 1996;214:219–35 (102 ref.)
Functions of the large hepatitis B virus surface protein in viral particle morphogenesis. Bruss V, et al. **Intervirology** 1996;39(1–2):23–31 (50 ref.)
Defined amino acids in the gag proteins of human immunodeficiency virus type 1 are functionally active during virus assembly. Kattenbeck B, et al. **Intervirology** 1996;39(1–2):32–9 (55 ref.)
Synthesis and assembly of chimeric human immunodeficiency virus gag pseudovirions [published erratum appears in Intervirology 1996;39(4):258] Tobin GJ, et al. **Intervirology** 1996;39(1–2):40–8 (43 ref.)

VIRUS DISEASES

see related

ANTIVIRAL AGENTS

Other viral agents of perinatal importance. Varicella, parvovirus, respiratory syncytial virus, and enterovirus. Keyserling HL. **Clin Perinatol** 1997 Mar;24(1):193–211 (91 ref.)
The spectrum and treatment of virus-associated vasculitides. Guillevin L, et al. **Curr Opin Rheumatol** 1997 Jan;9(1):31–6 (20 ref.)
Nutrition and newly emerging viral diseases: an overview. Levander OA. **J Nutr** 1997 May;127(5 Suppl):948S–950S (18 ref.)
Infectious causes of acute pancreatitis. Parenti DM, et al. **Pancreas** 1996 Nov;13(4):356–71 (238 ref.)
Viral genitourinary tract infections--distinctive features and clinical implications. Ohlemeyer CL, et al. **Pediatr Ann** 1996 Oct;25(10):561, 564–70 (26 ref.)
Infections of the oral cavity. Peter JR, et al. **Pediatr Ann** 1996 Oct;25(10):572–6 (11 ref.)
Major medical complications of lung transplantation: a pediatric perspective. Mallory GB Jr. **Semin Thorac Cardiovasc Surg** 1996 Jul;8(3):305–12 (58 ref.)
[Infectious complications of lung and heart-lung transplantation] Nicod LP. **Rev Mal Respir** 1996 Nov;13(5 Suppl):S41–7 (58 ref.) (Eng. Abstr.) **(Fre)**
[Microbes that invade nervous system] Shimada K. **Nippon Naika Gakkai Zasshi** 1996 May 10;85(5):655–8 (12

ref.) **(Jpn)**
[Acute viral infection] Yasui K. **Nippon Rinsho** 1997 Apr; 55(4):787–94 (35 ref.) (Eng. Abstr.) **(Jpn)**
[Infective myocarditis] Hiramitsu S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):61–4 (20 ref.) **(Jpn)**
[Viral myocarditis] Inoue K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):29–35 (20 ref.) **(Jpn)**
[Viral pericarditis] Suzuki S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):491–4 (12 ref.) **(Jpn)**
[Occupational dangers to health of nursing staffs in hemodialysis units] Washio M, et al. **Sangyo Ika Daigaku Zasshi** 1996 Sep 1;18(3):239–45 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Acute infectious diarrhea in children] de Sousa JS. **Acta Med Port** 1996 Oct–Dec;9(10–12):347–52 (68 ref.) (Eng. Abstr.) **(Por)**

CLASSIFICATION

[A classification of virus–related neurological disease] Takasu T. **Nippon Rinsho** 1997 Apr;55(4):783–6 (5 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Viral myocarditis: balance between viral infection and immune response. Liu P, et al. **Can J Cardiol** 1996 Oct; 12(10):935–43 (85 ref.)
Infections in solid–organ transplant recipients. Patel R, et al. **Clin Microbiol Rev** 1997 Jan;10(1):86–124 (800 ref.)
What is new in clinical research of viral diseases of the skin. Walther RR. **Dermatol Clin** 1997 Jan;15(1):189–96 (65 ref.)
Infection and coronary heart disease. Ellis RW. **J Med Microbiol** 1997 Jul;46(7):535–9 (44 ref.)
Selected reviews common childhood and adolescent infections and multiple sclerosis. Granieri E, et al. **Neurology** 1997 Aug;49(2 Suppl 2):S42–54 (73 ref.)
The elusive search for fetal infection. Changing the gold standards. Weiner CP. **Obstet Gynecol Clin North Am** 1997 Mar;24(1):19–32 (67 ref.)
Impact of viral infection on bronchial hyperresponsiveness. Wennergren G. **Pediatr Allergy Immunol** 1996;7(9 Suppl):10–3 (30 ref.)
Hematologic manifestations of viral infections. Friedman AD. **Pediatr Ann** 1996 Oct;25(10):555–60 (24 ref.)
Infectious causes of hydrops fetalis. Barron SD, et al. **Semin Perinatol** 1995 Dec;19(6):493–501 (94 ref.)
[Relationship between virus and bacterial infections––with special reference to respiratory tract infections] Nagatake T, et al. **Nippon Naika Gakkai Zasshi** 1997 Mar 10; 86(3):491–5 (10 ref.) **(Jpn)**
[Acute disseminated encephalomyelitis] Hirano Y. **Nippon Rinsho** 1997 Apr;55(4):934–9 (23 ref.) (Eng. Abstr.) **(Jpn)**
[The pathogenesis of postinfectious encephalomyelitis and polyradiculoneuritis] Ohara Y. **Nippon Rinsho** 1997 Apr; 55(4):800–4 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Viruses and malignant diseases] Jovanović J, et al. **Med Pregl** 1997 Jan–Feb;50(1–2):23–6 (23 ref.) (Eng. Abstr.) **(Scr)**
[Virus in hemophilia: current status and future perspectives] Aguilar C, et al. **Sangre (Barc)** 1996 Apr;41(2):141–5 (73 ref.) **(Spa)**

CONGENITAL

Congenital viral infections: a reappraisal. Barton LL, et al. **Compr Ther** 1996 Oct;22(10):665–72 (23 ref.)

DIAGNOSIS

Viruses and multiple sclerosis. Dalgleish AG. **Acta Neurol Scand Suppl** 1997;169:8–15 (98 ref.)
PCR diagnosis of viral pneumonitis from fixed–lung tissue in children. Akhtar N, et al. **Biochem Mol Med** 1996 Jun; 58(1):66–76 (35 ref.)
Molecular diagnosis of microbial infections. Blum HE. **Biologicals** 1996 Sep;24(3):193–5 (10 ref.)
New aspects of oral viral diseases. Scully C. **Curr Top Pathol** 1996;90:29–96 (648 ref.)
Viral lesions of the mouth in HIV–infected patients. Itin PH, et al. **Dermatology** 1997;194(1):1–7 (85 ref.)
Detection of viral infections by in situ PCR: theoretical considerations and possible value in diagnostic pathology. Nuovo GJ. **J Clin Lab Anal** 1996;10(6):335–49 (30 ref.)
Viral gastroenteritis: small round structured viruses, caliciviruses and astroviruses. Part I. The clinical and diagnostic perspective. Caul EO. **J Clin Pathol** 1996 Nov; 49(11):874–80 (58 ref.)
Neuroimaging of AIDS. I. Viral infections. Lizerbram EK, et al. **Neuroimaging Clin N Am** 1997 May;7(2):261–80 (74 ref.)
The elusive search for fetal infection. Changing the gold standards. Weiner CP. **Obstet Gynecol Clin North Am** 1997 Mar;24(1):19–32 (67 ref.)
[Molecular biology at the service of the daily medical virology. 2. Applications to virological diagnosis] Wattré P. **Ann Biol Clin (Paris)** 1997 Mar–Apr;55(2):81–91 (58 ref.) (Eng. Abstr.) **(Fre)**
[Renal manifestations of viral diseases] Péchère–Bertschi A, et al. **Schweiz Rundsch Med Prax** 1997 Jul 30; 86(31–32):1204–8 (15 ref.) (Eng. Abstr.) **(Fre)**
[Immunologic diagnosis of central nervous system viral infection] Arasaki K. **Nippon Rinsho** 1997 Apr;55(4):828–32 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Genetic diagnosis of viral diseases in nervous system] Nakamura S, et al. **Nippon Rinsho** 1997 Apr;55(4):833–8 (5 ref.) (Eng. Abstr.) **(Jpn)**
[Diagnosis of obstetrical–gynecological infectious diseases using PCR] Fujita Y, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Aug; 48(8):769–80 (29 ref.) **(Jpn)**
[Application of in situ PCR to clinical pathology––detection of viral infection] Aoyagi K. **Rinsho Byori** 1997 Mar; 45(3):229–33 (23 ref.) (Eng. Abstr.) **(Jpn)**
[PCR––a new era in clinical microbiologic diagnosis and epidemiologic studies? (Part II)] Kur J, et al. **Przegl Epidemiol** 1996;50(3):227–37 (124 ref.) (Eng. Abstr.) **(Pol)**
[Molecular diagnosis of infectious and parasitic diseases] Said–Fernández S, et al. **Gac Med Mex** 1996 May–Jun; 132(3):295–318 (135 ref.) **(Spa)**
[Infections with cutaneous and nervous system alterations] Losada–Campa A, et al. **Rev Neurol** 1997 Sep;25 Suppl 3:S281–93 (76 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Antisense inhibition of virus infections. Kilkuskie RE, et al. **Adv Pharmacol** 1997;40:437–83 (181 ref.)
Treatment of viral infections during pregnancy and the neonatal period. Whitley RJ, et al. **Clin Perinatol** 1997 Mar; 24(1):267–83 (51 ref.)
Chelators in biomedical research: a review. Mbati PA. **East Afr Med J** 1996 Jun;73(6):350–6 (51 ref.)
Antisense technology and prospects for therapy of viral infections and cancer. Wagner RW, et al. **Mol Med Today** 1997 Jan;3(1):31–8 (36 ref.)
Wheel keeps turning for antiviral combination chemotherapy. Coen DM. **Trends Microbiol** 1996 Feb;4(2):51–2 (14 ref.)
[ORL infections. 10th consensus conference on anti–infectious therapeutics. Under the collaboration of the French Societies of Infectious Diseases, of ORL and of Pediatrics] **Arch Pediatr** 1997 Feb;4(2):188–94 (0 ref.) **(Fre)**
[Virology. The art of controlling the geniality which even the smallest contagions show] Norrby E. **Lakartidningen** 1997 Jun 18;94(25):2357–8, 2362–4 (0 ref.) **(Swe)**

EPIDEMIOLOGY

Communicable diseases surveillance. **Commun Dis Intell** 1997 Aug 7;21(16):222–30 (0 ref.)
Emerging viral infections with special reference to India. Banerjee K. **Indian J Med Res** 1996 Apr;103:177–200 (112 ref.)
Sensitive populations: who is at the greatest risk? Gerba CP, et al. **Int J Food Microbiol** 1996 Jun;30(1–2):113–23 (59 ref.)
The public health threat of emerging viral disease. Morse SS. **J Nutr** 1997 May;127(5 Suppl):951S–957S (60 ref.)
Annual report on findings of infectious agents in Japan 1993. **Jpn J Med Sci Biol** 1994;47 Suppl:1–164 (0 ref.)
Xenosis and xenotransplantation: addressing the infectious risks posed by an emerging technology. Fishman JA. **Kidney Int Suppl** 1997 Mar;58:S41–5 (45 ref.)
[Illness rate with viral infections in the Russian Federation] Onishchenko GG. **Vopr Virusol** 1997 Jul–Aug;42(4):148–52 (0 ref.) (Eng. Abstr.) **(Rus)**

ETIOLOGY

Molecular mechanisms of lymphocyte–mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Kägi D, et al. **Annu Rev Immunol** 1996;14:207–32 (157 ref.)
Reactive oxygen species and nitric oxide in viral diseases. Peterhans E. **Biol Trace Elem Res** 1997 Jan;56(1):107–16 (75 ref.)
Viral safety of blood derivatives: an overview. Horaud F. **Clin Ther** 1996;18 Suppl B:37–42 (14 ref.)
Immunopathogenesis of virus diseases affecting the central nervous system. Bilzer T, et al. **Crit Rev Immunol** 1996; 16(2):145–222 (890 ref.)
Oxidative stress during viral infection: a review. Schwarz KB. **Free Radic Biol Med** 1996;21(5):641–9 (76 ref.)
Risk of fetal infection from invasive procedures. Workman MR, et al. **J Hosp Infect** 1997 Mar;35(3):169–74 (20 ref.)
Infections in neutropenic patients I: aetiology. Engervall P, et al. **Med Oncol** 1995 Dec;12(4):251–6 (65 ref.)
[Virus–related neurological disorders complicating in compromised hosts] Kimura S. **Nippon Rinsho** 1997 Apr; 55(4):949–53 (24 ref.) (Eng. Abstr.) **(Jpn)**
[Pulmonary complications during HIV infection in children] Murgoci G, et al. **Paeumoftiziologia** 1997 Jan–Mar; 46(1):39–44 (12 ref.) **(Rum)**
[Viral infections in solid organ transplant recipients] Moreno MA. **Enferm Infecc Microbiol Clin** 1997 May;15 Suppl 2:22–33 (260 ref.) **(Spa)**
[Characteristics of non–bacterial infections in solid organ transplantation] Cisterna Cancer R, et al. **Rev Clin Esp** 1995 Oct;195 Spec No:37–43 (57 ref.) **(Spa)**

IMMUNOLOGY

Anatomy of viral persistence: mechanisms of persistence and associated disease. de la Torre JC, et al. **Adv Virus Res** 1996;46:311–43 (187 ref.)
Virus–induced immunopathology. Rouse BT. **Adv Virus Res** 1996;47:353–76 (121 ref.)
Natural killer cell regulation during viral infection. Biron CA. **Biochem Soc Trans** 1997 May;25(2):687–90 (33 ref.)
Viral myocarditis: balance between viral infection and immune response. Liu P, et al. **Can J Cardiol** 1996 Oct; 12(10):935–43 (85 ref.)
The immunopharmacology of the opsoclonus–myoclonus syndrome. Pranzatelli MR. **Clin Neuropharmacol** 1996 Feb; 19(1):1–47 (285 ref.)
Viral immunity: interferons jog old T–cell memories. Gray D. **Curr Biol** 1996 Oct 1;6(10):1254–5 (9 ref.)
Activation and function of natural killer cell responses during viral infections. Biron CA. **Curr Opin Immunol** 1997 Feb; 9(1):24–34 (91 ref.)
To kill or to cure: options in host defense against viral infection. Guidotti LG, et al. **Curr Opin Immunol** 1996 Aug; 8(4):478–83 (58 ref.)
Different roles for cytotoxic T cells in the control of infections with cytopathic versus noncytopathic viruses. Kägi D, et al. **Curr Opin Immunol** 1996 Aug;8(4):472–7 (49 ref.)
Modulation of antigen processing and presentation by persistent virus infections and in tumors. Ehrlich R. **Hum Immunol** 1997 May;54(2):104–16 (126 ref.)
Immunopathology or organ–specific autoimmunity as a consequence of virus infection. Aichele P, et al. **Immunol Rev** 1996 Aug;152:21–45 (149 ref.)
B–cell activation by superstimulatory influenza virus hemagglutinin: a pathogenesis for autoimmunity? Cash E, et al. **Immunol Rev** 1996 Aug;152:67–88 (116 ref.)
Autism and the immune system. van Gent T, et al. **J Child Psychol Psychiatry** 1997 Mar;38(3):337–49 (115 ref.)
Zoonoses: a personal perspective on the Jennerian principle of cross–protective immunity. Nelson GS. **J Med Microbiol** 1997 Jan;46(1):6–11, 28–33 (228 ref.)
Chemokines in viral disease. Friedland JS. **Res Virol** 1996 Mar–Jun;147(2–3):131–8 (50 ref.)
Viruses as pacemakers in the evolution of defence mechanisms against cancer. Eick D, et al. **Trends Genet** 1996 Jan;12(1):4–6 (22 ref.)
Long–term humoral immunity against viruses: revisiting the issue of plasma cell longevity [see comments] Slifka MK, et al. **Trends Microbiol** 1996 Oct;4(10):394–400 (63 ref.) Comment in: Trends Microbiol 1997 May;5(5):180–1.
Novel viral vaccines for livestock. Babiuk LA, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):355–63 (49 ref.)
How viruses escape from cytotoxic T lymphocytes: molecular parameters and players. Oldstone MB. **Virology** 1997 Aug 4;234(2):179–85 (67 ref.)
[Clinical significance and interpretation of immunological tests for nervous system infections] Arasaki K. **Nippon Naika Gakkai Zasshi** 1996 May 10;85(5):682–6 (11 ref.) **(Jpn)**
[The importance of endothelium as a target for virus infection] Błach–Olszewska Z, et al. **Postepy Hig Med Dosw** 1996;50(3):233–43 (57 ref.) (Eng. Abstr.) **(Pol)**
[Mechanisms of immune response in acute viral respiratory infections] Zheleznikova GF. **Vopr Virusol** 1997 Jul–Aug; 42(4):153–7 (60 ref.) **(Rus)**
[Interaction of microorganisms with the host immune system] Bojić I. **Vojnosanit Pregl** 1996 Jul–Aug;53(4):325–30 (46 ref.) **(Scr)**

METABOLISM

Reactive oxygen species and nitric oxide in viral diseases. Peterhans E. **Biol Trace Elem Res** 1997 Jan;56(1):107–16 (75 ref.)
Role of oxidants in microbial pathophysiology. Miller RA, et al. **Clin Microbiol Rev** 1997 Jan;10(1):1–18 (334 ref.)
Oxidative stress during viral infection: a review. Schwarz KB. **Free Radic Biol Med** 1996;21(5):641–9 (76 ref.)
Oxidants and antioxidants in viral diseases: disease mechanisms and metabolic regulation. Peterhans E. **J Nutr** 1997 May;127(5 Suppl):962S–965S (41 ref.)

PATHOLOGY

Virus–induced immunopathology. Rouse BT. **Adv Virus Res** 1996;47:353–76 (121 ref.)
Viruses and rickettsiae. Esiri MM. **Brain Pathol** 1997 Jan; 7(1):695–709 (107 ref.)
Apoptosis II: Apoptosis in the pathogenesis and treatment of diseases. Moldoveanu E, et al. **Rom J Morphol Embryol** 1996 Jan–Jun;42(1–2):41–51 (37 ref.)
[Apoptosis and human viral infections] Wattre P, et al. **Ann Biol Clin (Paris)** 1996;54(5):189–97 (51 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Chemokine receptors: structure, function and role in microbial pathogenesis. Murphy PM. **Cytokine Growth Factor Rev** 1996 Jun;7(1):47–64 (174 ref.)
Role of viral infections in the induction of adverse drug

reactions. Levy M. **Drug Saf** 1997 Jan;16(1):1–8 (77 ref.)
The antiviral role of nitric oxide. Mannick JB. **Res Immunol** 1995 Nov–Dec;146(9):693–7 (41 ref.)
The role of natural killer cells in viral infections. See DM, et al. **Scand J Immunol** 1997 Sep;46(3):217–24 (98 ref.)
[Neurologic signs and symptoms in viral infections—disease involving meninges, central nervous system or peripheral nerve system] Araga S, et al. **Nippon Rinsho** 1997 Apr; 55(4):805–8 (24 ref.) (Eng. Abstr.) **(Jpn)**
[Virus-induced apoptosis as a host defence mechanism] Koyama AH. **Tanpakushitsu Kakusan Koso** 1996 Jul; 41(9):1363–71; discussion 1396–7 (36 ref.) **(Jpn)**

PREVENTION & CONTROL

Combination vaccines. Ellis RW, et al. **Adv Pharmacol** 1997; 39:393–423 (60 ref.)
Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Kägi D, et al. **Annu Rev Immunol** 1996;14:207–32 (157 ref.)
Viral vaccines: selected topics. Kańtoch M. **Arch Immunol Ther Exp (Warsz)** 1996;44(5–6):367–71 (40 ref.)
Iron withholding: a defense against viral infections. Weinberg ED. **Biometals** 1996 Oct;9(4):393–9 (46 ref.)
Animal-induced injuries and disease, neonatal jaundice, immunizations, and viral infections. Gerson WT. **Curr Opin Pediatr** 1996 Aug;8(4):417–25 (69 ref.)
Enteric immunization: promises and challenges. Brown WR. **Dig Dis** 1996 May–Jun;14(3):192–200 (41 ref.)
Postexposure prophylaxis. Lutwick LI. **Infect Dis Clin North Am** 1996 Dec;10(4):899–915 (85 ref.)
Drinking water and microbiological pathogens—issues and challenges for the year 2000. Hellard ME, et al. **J Public Health Med** 1997 Jun;19(2):129–31 (31 ref.)
Occupational health issues in the pharmaceutical research and development process. Klees JE, et al. **Occup Med** 1997 Jan–Mar;12(1):5–27 (155 ref.)
Clinical studies with solvent detergent-treated products. Pehta JC. **Transfus Med Rev** 1996 Oct;10(4):303–11 (39 ref.)
Potency control of modified live viral vaccines for veterinary use. Terpstra C, et al. **Vaccine** 1996 Jan;14(1):13–8 (13 ref.)
Novel viral vaccines for livestock. Babiuk LA, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):355–63 (49 ref.)
[Prevention of opportunistic infections in HIV seropositive patients. Prevention of viral infections and mycoses] Casassus P, et al. **Presse Med** 1997 Mar 8;26(7):344–7 (25 ref.) (Eng. Abstr.) **(Fre)**
[Prevention of virus-related neurological diseases by vaccines] Takahashi M. **Nippon Rinsho** 1997 Apr; 55(4):954–8 (17 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Ex vivo manipulation of cell subsets for cell therapies. Nordon RE, et al. **Artif Organs** 1996 May;20(5):396–402 (56 ref.)
Interferon antibodies in patients with infectious diseases. Anti-interferon antibodies. Antonelli G, et al. **Biotherapy** 1997;10(1):7–14 (50 ref.)
To kill or to cure: options in host defense against viral infection. Guidotti LG, et al. **Curr Opin Immunol** 1996 Aug; 8(4):478–83 (58 ref.)
Combination therapy with BRMs in cancer and infectious diseases. Garaci E, et al. **Mech Ageing Dev** 1997 Jun; 96(1–3):103–16 (57 ref.)
[Progress of the therapy for virus related neurological disorders] Harukawa H, et al. **Nippon Rinsho** 1997 Apr; 55(4):959–66 (26 ref.) (Eng. Abstr.) **(Jpn)**
[The significance of specific oligonucleotides in clinical medicine and their use in the treatment of patients with infective diseases] Bojić I. **Vojnosanit Pregl** 1996 Sep–Oct; 53(5):399–408 (94 ref.) **(Scr)**

TRANSMISSION

Transfusion-transmitted disease. Lee CA. **Baillieres Clin Haematol** 1996 Jun;9(2):369–94 (107 ref.)
Overview: diagnostic tests for viral infections transmitted by blood. Holland PV. **Nucl Med Biol** 1994 Apr;21(3):407–17 (26 ref.)
Viral infectivity of albumin and plasma protein fraction. Erstad BL. **Pharmacotherapy** 1996 Nov–Dec; 16(6):996–1001 (47 ref.)
Clinical studies with solvent detergent-treated products. Pehta JC. **Transfus Med Rev** 1996 Oct;10(4):303–11 (39 ref.)
Virulence and transmissibility of pathogens: what is the relationship? Lipsitch M, et al. **Trends Microbiol** 1997 Jan; 5(1):31–7 (69 ref.)
Virus transmission via food. Cliver DO. **World Health Stat Q** 1997;50(1–2):90–101 (53 ref.)

VETERINARY

Viral diseases of the immune system and strategies to control infectious bursal disease by vaccination. Lütticken D. **Acta Vet Hung** 1997;45(3):239–49 (37 ref.)
Advantages and disadvantages of using live vaccines risks and control measures. Alexandersen S. **Acta Vet Scand Suppl** 1996;90:89–100 (27 ref.)
Viral pathogens of the penaeid shrimp. Loh PC, et al. **Adv Virus Res** 1997;48:263–312 (150 ref.)
Phosprenyl: a novel drug with antiviral and immunomodulatory activity. Danilov LL, et al. **Arch Immunol Ther Exp (Warsz)** 1996;44(5–6):395–400 (13 ref.)
Gordon Memorial Lecture. Chicken anaemia virus—a glimpse of the future? McNulty MS. **Br Poult Sci** 1997 Mar;38(1):7–13 (31 ref.)
Virus zoonoses—a long-term overview. Bennett M, et al. **Comp Immunol Microbiol Infect Dis** 1997 Feb;20(2):101–9 (42 ref.)
Immunization with viral antigens: viral diseases of carp and catfish. Dixon P. **Dev Biol Stand** 1997;90:221–32 (31 ref.)
Recombinant viral vector vaccines for the veterinary use. Yokoyama N, et al. **J Vet Med Sci** 1997 May;59(5):311–22 (135 ref.)
Viral diseases of livestock in Zambia. Mweene AS, et al. **Jpn J Vet Res** 1996 Aug;44(2):89–105 (77 ref.)
Major viral diseases affecting fish aquaculture in Spain. Pérez SI, et al. **Microbiologia** 1997 Jun;13(2):149–60 (43 ref.)
Special challenges of maintaining wild animals in captivity in Australia and New Zealand: prevention of infectious and parasitic diseases. Schultz DJ, et al. **Rev Sci Tech** 1996 Mar;15(1):289–308 (53 ref.)
Infectious and parasitic diseases of captive carnivores, with special emphasis on the black-footed ferret (Mustela nigripes). Williams ES, et al. **Rev Sci Tech** 1996 Mar; 15(1):91–114 (154 ref.)
Potency control of modified live viral vaccines for veterinary use. Terpstra C, et al. **Vaccine** 1996 Jan;14(1):13–8 (13 ref.)
Detection of animal pathogens by using the polymerase chain reaction (PCR). Rodriguez JM. **Vet J** 1997 May; 153(3):287–305 (232 ref.)
Diseases of freshwater fish. Haenen OL. **Vet Q** 1996;18 Suppl 3:S132–3 (24 ref.)
Molecular epidemiology of animal virus diseases. Haas L. **Zentralbl Veterinarmed [B]** 1997 Jul;44(5):257–72 (78 ref.)

VIROLOGY

Transgenic cell lines for detection of animal viruses. Olivo PD. **Clin Microbiol Rev** 1996 Jul;9(3):321–34 (91 ref.)
Viral infections in human immunodeficiency virus disease. Cavert W. **Med Clin North Am** 1997 Mar;81(2):411–26 (85 ref.)
Negative-strand RNA viruses: genetic engineering and applications. Palese P, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11354–8 (46 ref.)
Infectious complications of patients undergoing therapy for acute leukemia: current status and future prospects. Chanock SJ, et al. **Semin Oncol** 1997 Feb;24(1):132–40 (65 ref.)
[Virus and gastrointestinal infections] Denis F, et al. **Ann Biol Clin (Paris)** 1997 Jul–Aug;55(4):275–87 (13 ref.) (Eng. Abstr.) **(Fre)**

VIRUS INDUCTION see **VIRUS ACTIVATION**

VIRUS INTEGRATION

see related
INTEGRASE
PROVIRUSES

HIV cDNA integration: molecular biology and inhibitor development. Farnet CM, et al. **AIDS** 1996;10 Suppl A:S3–11 (140 ref.)
A new concept in (adenoviral) oncogenesis: integration of foreign DNA and its consequences. Doerfler W. **Biochim Biophys Acta** 1996 Oct 9;1288(2):F79–99 (111 ref.)
The roles of AAV Rep proteins in gene expression and targeted integration. Chiorini JA, et al. **Curr Top Microbiol Immunol** 1996;218:25–33 (43 ref.)
Fre2, a proviral integration site of Friend murine leukemia virus that is closely linked to Fv2. Friedrich RW, et al. **Leukemia** 1997 May;11(5):619–23 (31 ref.)
Site-specific integration by adeno-associated virus. Linden RM, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15; 93(21):11288–94 (37 ref.)

GENETICS

Tying together integration and chromatin. Curcio MJ, et al. **Trends Genet** 1996 Nov;12(11):436–8 (25 ref.)
[Endogenous retroviral sequences as a factor in the pathogenesis of systemic lupus erythematosus] Walchner M, et al. **Hautarzt** 1996 Jul;47(7):502–9 (55 ref.) (Eng. Abstr.) **(Ger)**

VIRUS LATENCY

see related
VIRUS ACTIVATION

Latent and persistent infections of monocytes and macrophages. Sinclair J, et al. **Intervirology** 1996; 39(5–6):293–301 (71 ref.)
Herpes simplex virus latent infection in the nervous system. Steiner I, et al. **J Neurovirol** 1995 Mar;1(1):19–29 (100 ref.)
Recent developments in latency and recombination of Aujeszky's disease (pseudorabies) virus. Maes RK, et al. **Vet Microbiol** 1997 Apr;55(1–4):13–27 (48 ref.)
[HIV infection and long-term non progressor] Suzuki Y, et al. **Nippon Rinsho** 1997 Jun;55(6):1563–71 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Beta-herpesvirus (human cytomegalovirus and human herpesvirus 6) latent infection] Kondo K. **Uirusu** 1996 Dec; 46(2):161–8 (13 ref.) **(Jpn)**

GENETICS

Experimental investigation of herpes simplex virus latency. Wagner EK, et al. **Clin Microbiol Rev** 1997 Jul;10(3):419–43 (332 ref.)
The molecular genetics of herpes simplex virus latency and pathogenesis: a puzzle with many pieces still missing [editorial; comment] Bennett JL, et al. **J Neurovirol** 1996 Aug;2(4):225–9 (51 ref.) Comment on: J Neurovirol 1996 Aug;2(4):268–78. Comment on: J Neurovirol 1996 Aug;2(4):279–88. Comment on: J Neurovirol 1996 Aug;2(4):289–95.
Latency and reactivation of varicella zoster virus infections. Dueland AN. **Scand J Infect Dis Suppl** 1996;100:46–50 (34 ref.)

IMMUNOLOGY

To kill or to cure: options in host defense against viral infection. Guidotti LG, et al. **Curr Opin Immunol** 1996 Aug; 8(4):478–83 (58 ref.)
Modulation of antigen processing and presentation by persistent virus infections and in tumors. Ehrlich R. **Hum Immunol** 1997 May;54(2):104–16 (126 ref.)
Human herpes viruses latent infection in the nervous system. Steiner I. **Immunol Rev** 1996 Aug;152:157–73 (110 ref.)

PHYSIOLOGY

Regulation of Epstein–Barr virus latency by latent membrane protein 2. Longnecker R, et al. **Trends Microbiol** 1996 Jan; 4(1):38–42 (59 ref.)

VIRUS PARTICLE see **VIRION**

VIRUS PEPLOMER PROTEINS see **VIRAL ENVELOPE PROTEINS**

VIRUS RECEPTORS see **RECEPTORS, VIRUS**

VIRUS REPLICATION

Comparison of the replication of positive-stranded RNA viruses of plants and animals. Buck KW. **Adv Virus Res** 1996;47:159–251 (543 ref.)
HIV viral dynamics. Coffin JM. **AIDS** 1996 Dec;10 Suppl 3:S75–84 (19 ref.)
Molecular biology and the development of AIDS therapeutics. Trono D. **AIDS** 1996 Dec;10 Suppl 3:S53–9 (23 ref.)
Virus-host interactions in African swine fever: the attachment to cellular receptors. Angulo A, et al. **Arch Virol Suppl** 1993;7:169–83 (48 ref.)
Molecular organization and replication of hepatitis E virus (HEV). Reyes GR, et al. **Arch Virol Suppl** 1993;7:15–25 (35 ref.)
In vitro experimental systems for HPV: epithelial raft cultures for investigations of viral reproduction and pathogenesis and for genetic analyses of viral proteins and regulatory sequences. Chow LT, et al. **Clin Dermatol** 1997 Mar–Apr; 15(2):217–27 (63 ref.)
Recombinant cytomegaloviruses for study of replication and pathogenesis. Mocarski ES Jr, et al. **Intervirology** 1996; 39(5–6):320–30 (124 ref.)
Perspectives series: host/pathogen interactions. Dynamics of HIV-1 replication in vivo. Ho DD. **J Clin Invest** 1997 Jun 1;99(11):2565–7 (14 ref.)
HIV-1 viral protein R (Vpr) regulates viral replication and cellular proliferation in T cells and monocytoid cells in vitro. Ayyavoo V, et al. **J Leukoc Biol** 1997 Jul;62(1):93–9 (42 ref.)
Cellular and viral protein interactions regulating I kappa B alpha activity during human retrovirus infection. Hiscott J, et al. **J Leukoc Biol** 1997 Jul;62(1):82–92 (80 ref.)
Cellular aspects of HIV-1 infection of macrophages leading to neuronal dysfunction in in vitro models for HIV-1 encephalitis. Nottet HS, et al. **J Leukoc Biol** 1997 Jul; 62(1):107–16 (112 ref.)
Immune stimulation and HIV-1 viral replication. Wahl SM, et al. **J Leukoc Biol** 1997 Jul;62(1):67–71 (60 ref.)
Replication of hepatitis delta virus. Monjardino J. **J Viral Hepat** 1996 Jul;3(4):163–6 (24 ref.)
New insight on the role of extrachromosomal retroviral DNA. Cara A, et al. **Leukemia** 1997 Sep;11(9):1395–9 (48 ref.)
Replication-competent retroviral vectors for expressing genes in avian cells in vitro and in vivo. Bell EJ, et al. **Mol Biotechnol** 1997 Jun;7(3):289–98 (45 ref.)
Replicating viruses as selective cancer therapeutics. Kirn DH, et al. **Mol Med Today** 1996 Dec;2(12):519–27 (28 ref.)
Alphavirus-based expression vectors: strategies and applications. Frolov I, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11371–7 (72 ref.)
Site-specific integration by adeno-associated virus. Linden RM, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15; 93(21):11288–94 (37 ref.)
Virus-lymphoid cell interactions [comment] Oldstone MB. **Proc Natl Acad Sci U S A** 1996 Nov 12;93(23):12756–8 (48 ref.) Comment on: Proc Natl Acad Sci U S A 1996 Nov 12;93(23):13125–30. Comment on: Proc Natl Acad Sci U S A 1996 Nov 12;93(23):13194–9.

[Replication of human immunodeficiency virus in the cells] Yamamoto N. **Rinsho Ketsueki** 1996 Jun;37(6):464–6 (0 ref.) **(Jpn)**

[Mechanism of HIV replication] Adachi A, et al. **Uirusu** 1996 Dec;46(2):145–54 (56 ref.) **(Jpn)**

DRUG EFFECTS

Chemotherapy of human immunodeficiency virus (HIV) infection: anti-HIV agents targeted at early stages in the virus replicative cycle. De Clercq E. **Biomed Pharmacother** 1996;50(5):207–15 (76 ref.)

Human immunodeficiency virus replication in the presence of antiretroviral drugs: analogies to antineoplastic drug resistance. Strair RK, et al. **Cancer Treat Res** 1996; 87:225–39 (63 ref.)

Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes. Aquaro S, et al. **J Leukoc Biol** 1997 Jul;62(1):138–43 (39 ref.)

GM-CSF and its effects on replication of HIV-1 in cells of macrophage lineage. Crowe SM, et al. **J Leukoc Biol** 1997 Jul;62(1):41–8 (100 ref.)

Targeting antiviral nucleotide analogues to macrophages. Magnani M, et al. **J Leukoc Biol** 1997 Jul;62(1):133–7 (32 ref.)

Inhibition of HIV-1 replication by targeting the Rev protein. Nakaya T, et al. **Leukemia** 1997 Apr;11 Suppl 3:134–7 (24 ref.)

The human immunodeficiency virus. Hardy WD Jr. **Med Clin North Am** 1996 Nov;80(6):1239–61 (131 ref.)

Chemotherapy of human immunodeficiency virus (HIV) infection based on chemotherapeutic intervention with early steps of the virus replicative cycle. De Clercq E. **Postepy Biochem** 1995;41(5 Suppl):338–42 (50 ref.)

GENETICS

HIV-1 biological phenotype varies with severity of infection across HIV-1 genetic subtypes. Fenyö EM. **Antibiot Chemother** 1996;48:49–55 (19 ref.)

Herpes simplex virus type 1 replication and recombination. Bataille D, et al. **Biochimie** 1995;77(10):787–95 (110 ref.)

Vaccinia virus DNA replication: a short review. Beaud G. **Biochimie** 1995;77(10):774–9 (67 ref.)

Role of mouse polyomavirus late region in the control of viral DNA replication: a review. Iacoangeli A, et al. **Biochimie** 1995;77(10):780–6 (50 ref.)

The potential of extrachromosomal replicating vectors for gene therapy. Calos MP. **Trends Genet** 1996 Nov; 12(11):463–6 (32 ref.)

[Flavivirus RNA replication and involvement of host factors] Takegami T. **Uirusu** 1996 Dec;46(2):91–7 (35 ref.) **(Jpn)**

IMMUNOLOGY

Role of pro-inflammatory cytokines and beta-chemokines in controlling HIV replication. Vicenzi E, et al. **J Leukoc Biol** 1997 Jul;62(1):34–40 (88 ref.)

PHYSIOLOGY

Cell types involved in replication and distribution of human cytomegalovirus. Plachter B, et al. **Adv Virus Res** 1996; 46:195–261 (384 ref.)

Virocrine transformation. Drummond-Barbosa D, et al. **Biochim Biophys Acta** 1997 Feb 22;1332(1):M1–17 (148 ref.)

Controlling elements in replication of the human immunodeficiency virus type 1. Li X, et al. **Cell Mol Biol (Noisy-le-grand)** 1997 May;43(3):443–54 (85 ref.)

Reflections on the years in interferon research. Pitha PM. **J Interferon Cytokine Res** 1997 Apr;17(4):181–4 (27 ref.)

Replication of hepatitis C virus. Yoshikura H, et al. **J Viral Hepat** 1996 Jan;3(1):3–10 (50 ref.)

Structure, genomic organization, replication and variability of hepatitis C virus. Pozzetto B, et al. **Nephrol Dial Transplant** 1996;11 Suppl 4:2–5 (11 ref.)

Interaction of retroviral reverse transcriptase with template-primer duplexes during replication. Arts EJ, et al. **Prog Nucleic Acid Res Mol Biol** 1998;58:339–93 (215 ref.)

[Molecular mechanism of lytic phase of Epstein-Barr virus DNA replication] Tsurumi T. **Nippon Rinsho** 1997 Feb; 55(2):321–7 (19 ref.) (Eng. Abstr.) **(Jpn)**

VIRUS SHEDDING

Shedding of HIV-1 in the genital tract [editorial] Mostad SB, et al. **AIDS** 1996 Oct;10(12):1305–15 (74 ref.)

Genital herpes infection: a review. Brugha R, et al. **Int J Epidemiol** 1997 Aug;26(4):698–709 (127 ref.)

Asymptomatic shedding of herpes simplex virus from the genital tract: uncertainty and its consequences for patient management. The Herpes Simplex Virus Advisory Panel [editorial] Barton SE, et al. **Int J STD AIDS** 1996 Jul; 7(4):229–32 (13 ref.)

VIRUS TRANSFORMING ANTIGENS see **ANTIGENS, VIRAL, TUMOR**

VIRUSES

see related
ANTIVIRAL AGENTS
RECEPTORS, VIRUS

Anaesthetic machine and breathing system contamination and the efficacy of bacterial/viral filters. Hogarth I. **Anaesth Intensive Care** 1996 Apr;24(2):154–63 (74 ref.)

Virus-cell and cell-cell fusion. Hernandez LD, et al. **Ann Rev Cell Dev Biol** 1996;12:627–61 (176 ref.)

Viral vectors for modulating gene expression in neurons. Slack RS, et al. **Curr Opin Neurobiol** 1996 Oct;6(5):576–83 (53 ref.)

Viral inhibitors of apoptosis. Uren AG, et al. **Vitam Horm** 1997;53:175–93 (105 ref.)

CLASSIFICATION

Present status of classification of viruses of vertebrates. Malicki K, et al. **Arch Immunol Ther Exp (Warsz)** 1996; 44(5–6):283–9 (20 ref.)

DRUG EFFECTS

[Antiviral agents that act in the early phases of the viral cycle] Damonte EB. **Rev Argent Microbiol** 1996 Oct–Dec; 28(4):204–16 (67 ref.) (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

Purification of viral polymerases: general considerations. Sardana V, et al. **Methods Enzymol** 1996;275:3–16 (47 ref.)

GENETICS

Comparison of the replication of positive-stranded RNA viruses of plants and animals. Buck KW. **Adv Virus Res** 1996;47:159–251 (543 ref.)

The cat and mouse games that genes, viruses, and cells play. Weinberg RA. **Cell** 1997 Mar 7;88(5):573–5 (20 ref.)

Virus 'quasispecies': making a mountain out of a molehill? Smith DB, et al. **J Gen Virol** 1997 Jul;78 (Pt 7):1511–9 (49 ref.)

Amplification and subtraction methods and their application to the discovery of novel human viruses. Muerhoff AS, et al. **J Med Virol** 1997 Sep;53(1):96–103 (63 ref.)

Development and use of virus-vectored immunocontraception. Williams CK. **Reprod Fertil Dev** 1997;9(1):169–78 (23 ref.)

The role of cytotoxic T lymphocytes in the evolution of genetically stable viruses. Khanna R, et al. **Trends Microbiol** 1997 Feb;5(2):64–9 (64 ref.)

A short introduction to the origin and molecular evolution of viruses. Becker Y. **Virus Genes** 1995;11(2–3):73–7 (21 ref.)

[Nuclear targeting of viral genome] Nakanishi A, et al. **Tanpakushitsu Kakusan Koso** 1997 Jan;42(1):12–21 (81 ref.) **(Jpn)**

GROWTH & DEVELOPMENT

Transgenic cell lines for detection of animal viruses. Olivo PD. **Clin Microbiol Rev** 1996 Jul;9(3):321–34 (91 ref.)

Viral inhibition of apoptosis. Gillet G, et al. **Trends Microbiol** 1996 Aug;4(8):312–7 (50 ref.)

[Antiviral agents that act in the early phases of the viral cycle] Damonte EB. **Rev Argent Microbiol** 1996 Oct–Dec; 28(4):204–16 (67 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Virus-induced apoptosis. Hardwick JM. **Adv Pharmacol** 1997;41:295–336 (337 ref.)

Anatomy of viral persistence: mechanisms of persistence and associated disease. de la Torre JC, et al. **Adv Virus Res** 1996;46:311–43 (187 ref.)

Virus-induced immunopathology. Rouse BT. **Adv Virus Res** 1996;47:353–76 (121 ref.)

Immunology and immunity studied with viruses. Zinkernagel RM. **Ciba Found Symp** 1997;204:105–25; discussion 125–9 (168 ref.)

Trafficking and assembly of MHC molecules: how viruses elude the immune system. Ploegh HL. **Cold Spring Harb Symp Quant Biol** 1995;60:263–6 (8 ref.)

To kill or to cure: options in host defense against viral infection. Guidotti LG, et al. **Curr Opin Immunol** 1996 Aug; 8(4):478–83 (58 ref.)

Different roles for cytotoxic T cells in the control of infections with cytopathic versus noncytopathic viruses. Kägi D, et al. **Curr Opin Immunol** 1996 Aug;8(4):472–7 (49 ref.)

The new vaccines: building viruses that elicit antitumor immunity. Restifo NP. **Curr Opin Immunol** 1996 Oct; 8(5):658–63 (54 ref.)

Immunopathology or organ-specific autoimmunity as a consequence of virus infection. Aichele P, et al. **Immunol Rev** 1996 Aug;152:21–45 (149 ref.)

Viruses, hidden self-epitopes and autoimmunity. Barnaba V. **Immunol Rev** 1996 Aug;152:47–66 (115 ref.)

A novel mechanism for virus-induced autoimmunity in humans. Nauclér CS, et al. **Immunol Rev** 1996 Aug; 152:175–92 (65 ref.)

Viruses use stealth technology to escape from the host immune system. Wiertz EJ, et al. **Mol Med Today** 1997 Mar;3(3):116–23 (52 ref.)

Cytokines and viral anti-immune genes. Evans CH. **Stem Cells** 1996 Mar;14(2):177–84 (72 ref.)

The role of cytotoxic T lymphocytes in the evolution of genetically stable viruses. Khanna R, et al. **Trends Microbiol** 1997 Feb;5(2):64–9 (64 ref.)

ISOLATION & PURIFICATION

Advances in immunochemical detection of microorganisms. Hock B. **Ann Biol Clin (Paris)** 1996;54(6):243–52 (24 ref.)

Relationship between nature and source of risk and process validation. Berthold W, et al. **Dev Biol Stand** 1996;88:59–71 (1 ref.)

Strategies for viral removal and inactivation. Burstyn DG, et al. **Dev Biol Stand** 1996;88:73–9 (2 ref.)

Viral safety of biological products and the concept of validation. Horaud F. **Dev Biol Stand** 1996;88:19–24 (12 ref.)

Evaluation of anti-viral filters. Hughes B, et al. **Dev Biol Stand** 1996;88:91–8 (3 ref.)

Process changes and their effect on process evaluation for viral clearance. Marcus-Sekura C. **Dev Biol Stand** 1996; 88:125–30 (10 ref.)

Mammalian cells and their contaminants. Minor PD. **Dev Biol Stand** 1996;88:25–9 (6 ref.)

Strategy for adventitious agent assays. Robertson JS. **Dev Biol Stand** 1996;88:37–40 (3 ref.)

Process scale considerations in evaluation studies and scale-up. Walter JK, et al. **Dev Biol Stand** 1996;88:99–108 (6 ref.)

Amplification and subtraction methods and their application to the discovery of novel human viruses. Muerhoff AS, et al. **J Med Virol** 1997 Sep;53(1):96–103 (63 ref.)

METABOLISM

Microbial/host interactions in health and disease: who controls the cytokine network? Henderson B, et al. **Immunopharmacology** 1996 Oct;35(1):1–21 (126 ref.)

Viral and cellular enzymes involved in synthesis of mRNA cap structure. Bisaillon M, et al. **Virology** 1997 Sep 15; 236(1):1–7 (65 ref.)

PATHOGENICITY

Principles of viral pathogenesis. Oldstone MB. **Cell** 1996 Nov 29;87(5):799–801 (15 ref.)

How pathogens exploit interactions mediated by SH3 domains. Bliska J. **Chem Biol** 1996 Jan;3(1):7–11 (23 ref.)

Different roles for cytotoxic T cells in the control of infections with cytopathic versus noncytopathic viruses. Kägi D, et al. **Curr Opin Immunol** 1996 Aug;8(4):472–7 (49 ref.)

The evolution and maintenance of virulence in microparasites. Levin BR. **Emerg Infect Dis** 1996 Apr–Jun; 2(2):93–102 (62 ref.)

Non-receptor protein tyrosine kinases as immune targets of viruses. Collette Y, et al. **Immunol Today** 1997 Aug; 18(8):393–400 (86 ref.)

Microbial adherence to and invasion through proteoglycans. Rostand KS, et al. **Infect Immun** 1997 Jan;65(1):1–8 (114 ref.)

Transgenic mice to study viral pathogenesis and autoimmunity. Hengartner H. **Int J Exp Pathol** 1996 Dec; 77(6):279–82 (25 ref.)

Virulence and transmissibility of pathogens: what is the relationship? Lipsitch M, et al. **Trends Microbiol** 1997 Jan; 5(1):31–7 (69 ref.)

PHYSIOLOGY

Viral activation of coagulation: implications for thrombosis and atherosclerosis. Hajjar DP, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:155–65; discussion 165–7 (68 ref.)

Microbial laser light scattering. Harding SE. **Biotechnol Genet Eng Rev** 1997;14:145–64 (93 ref.)

Microbial utilization of human signalling molecules. Virji M. **Microbiology** 1996 Dec;142 (Pt 12):3319–36 (107 ref.)

Replicating viruses as selective cancer therapeutics. Kirn DH, et al. **Mol Med Today** 1996 Dec;2(12):519–27 (28 ref.)

Viruses—a conundrum. Pandit HM. **Physiol Chem Phys Med NMR** 1996;28(1):29–33 (34 ref.)

Viruses and behavioural changes: a review of clinical and experimental findings. Mohammed AH, et al. **Rev Neurosci** 1993 Jul–Sep;4(3):267–86 (164 ref.)

Viral manipulations of the actin cytoskeleton. Cudmore S, et al. **Trends Microbiol** 1997 Apr;5(4):142–8 (71 ref.)

Tails from the hall of infection: actin-based motility of pathogens. Sanders MC, et al. **Trends Microbiol** 1996 Jun; 4(6):211–3 (18 ref.)

How viruses escape from cytotoxic T lymphocytes: molecular parameters and players. Oldstone MB. **Virology** 1997 Aug 4;234(2):179–85 (67 ref.)

[Viral evolution: the development of the ecological trend in research] Izmailova ES. **Izv Akad Nauk Ser Biol** 1996 Sep–Oct;(5):598–608 (77 ref.) (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

The making and breaking of symmetry in virus capsid assembly: glimpses of capsid biology from cryoelectron microscopy. Steven AC, et al. **FASEB J** 1997 Aug; 11(10):733–42 (75 ref.)

Advances in the study of marine viruses. Proctor LM.

VIRUSES

Microsc Res Tech 1997 Apr 15;37(2):136–61 (137 ref.)

VIRUSES, SMALL ROUND-STRUCTURED see **NORWALK VIRUS**

VISCERA

BLOOD SUPPLY

Aneurysms of the visceral and renal arteries. Panayiotopoulos YP, et al. **Ann R Coll Surg Engl** 1996 Sep;78(5):412–9 (85 ref.)

The diagnosis and management of splanchnic artery aneurysms. Røkke O, et al. **Scand J Gastroenterol** 1996 Aug; 31(8):737–43 (89 ref.)

CT angiography of the visceral vessels. Winter TC 3rd, et al. **Semin Ultrasound CT MR** 1996 Aug;17(4):339–51 (27 ref.)

INNERVATION

Neural regulation of viscera elicited by individual interpretations of life experiences. Wolf S. **Integr Physiol Behav Sci** 1997 Apr–Jun;32(2):109–12 (14 ref.)

Somatosensory and visceral input to the hypothalamus and limbic system. Burstein R. **Prog Brain Res** 1996;107:257–67 (92 ref.)

Visceral polymodal receptors. Gebhart GF. **Prog Brain Res** 1996;113:101–12 (31 ref.)

Vagal efferent projections: viscerotopy, neurochemistry and effects of vagotomy. Hopkins DA, et al. **Prog Brain Res** 1996;107:79–96 (85 ref.)

The paraventricular nucleus of the hypothalamus and the functional neuroanatomy of visceromotor responses to stress. Sawchenko PE, et al. **Prog Brain Res** 1996; 107:201–22 (104 ref.)

PHYSIOLOGY

[The neuronal organization of the amygdala–visceral reflex arch] Baklavadzhian OG, et al. **Usp Fiziol Nauk** 1996 Jul–Sep;27(3):51–77 (193 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Bueno L, et al. **Gastroenterology** 1997 May;112(5):1714–43 (329 ref.)

On the dorsal columns: translating basic research hypotheses to the clinic [editorial] Berkley KJ. **Pain** 1997 Apr; 70(2–3):103–7 (35 ref.)

VISCERAL MYOPATHY see **INTESTINAL PSEUDO-OBSTRUCTION**

VISCOSITY

see related
BLOOD VISCOSITY

Viscous effects in capillary electrophoresis: theory and experiment. Schure MR, et al. **Electrophoresis** 1995 Nov; 16(11):2074–85 (26 ref.)

VISCUM

Clinical relevance of immunoactive mistletoe lectin-I. Beuth J. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S53–5 (19 ref.)

Differences in the apoptosis-inducing properties of Viscum album L. extracts. Büssing A, et al. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S9–14 (30 ref.)

Stimulation of the specific immune system by mistletoe extracts. Fischer S, et al. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S33–7 (32 ref.)

Modulation of cytotoxicity and enhancement of cytokine release induced by Viscum album L. extracts or mistletoe lectins. Ribéreau-Gayon G, et al. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S3–8 (20 ref.)

Mistletoe therapy for human cancer: the role of the natural killer cells. Schink M. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S47–51 (50 ref.)

IMMUNOLOGY

Induction of anti-mistletoe lectin antibodies in relation to different mistletoe-extracts. Stein GM, et al. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S57–9 (10 ref.)

VISION

see related
VISUAL PERCEPTION

A comparison of the self-awareness and kinesthetic-visual matching theories of self-recognition: autistic children and others. Mitchell RW. **Ann N Y Acad Sci** 1997 Jun 18; 818:38–62 (111 ref.)

Inferotemporal cortex and object vision. Tanaka K. **Annu Rev Neurosci** 1996;19:109–39 (102 ref.)

Vision standards in the Royal Canadian Mounted Police: are they reasonable and fair? [see comments] Easterbrook M, et al. **Can J Ophthalmol** 1997 Apr;32(3):153–7 (23 ref.) Comment in: Can J Ophthalmol 1997 Apr;32(3):145–7.

Physics of mosquito vision—an overview. Allan SA. **J Am Mosq Control Assoc** 1994 Jun;10(2 Pt 2):266–71 (37 ref.)

How mosquitoes see traps: role of visual responses. Bidlingmayer WL. **J Am Mosq Control Assoc** 1994 Jun;10(2 Pt 2):272–9 (45 ref.)

Impairment of visuospatial function in idiopathic spasmodic torticollis. Hinse P, et al. **J Neurol** 1996 Jan;243(1):29–33 (39 ref.)

Long lasting blindness, availability of resources, and early aging. Bachar E, et al. **Percept Mot Skills** 1997 Apr; 84(2):675–88 (77 ref.)

PHYSIOLOGY

Recovery of vision after partial visual system injury as a model of postlesion neuroplasticity. Sabel BA, et al. **Adv Neurol** 1997;73:251–76 (123 ref.)

Visuo-vestibular integration in the development of posture and gait. Amblard B. **Arch Ital Biol** 1996 Jul;134(3):249–77 (104 ref.)

Origin and evolution of sleep: roles of vision and endothermy. Kavanau JL. **Brain Res Bull** 1997;42(4):245–64 (239 ref.)

Polyenes and vision. Rando RR. **Chem Biol** 1996 Apr; 3(4):255–62 (20 ref.)

What fMRI has taught us about human vision. Courtney SM, et al. **Curr Opin Neurobiol** 1997 Aug;7(4):554–61 (90 ref.)

Processing and encoding of visual information in the retina. Masland RH. **Curr Opin Neurobiol** 1996 Aug;6(4):467–74 (47 ref.)

Parietal cortex: from sight to action. Rizzolatti G, et al. **Curr Opin Neurobiol** 1997 Aug;7(4):562–7 (51 ref.)

Vision, learning and dyslexia. A joint organizational policy statement of the American Academy of Optometry and the American Optometric Association. **J Am Optom Assoc** 1997 May;68(5):284–6 (29 ref.)

Neuro-ophthalmology of the pregeniculate afferent visual system. Developments in 1996 (Part II). Balcer LJ, et al. **J Neuroophthalmol** 1997 Jun;17(2):127–42 (217 ref.)

Similarity, connectionism, and the problem of representation in vision. Edelman S, et al. **Neural Comput** 1997 May 15; 9(4):701–20 (48 ref.)

Models of orientation and ocular dominance columns in the visual cortex: a critical comparison. Erwin E, et al. **Neural Comput** 1995 May;7(3):425–68 (83 ref.)

Dynamics of the impulse activity of neurons of the neocortex of monkeys in a visual recognition task after brief oxygen deprivation. Breslav IS. **Neurosci Behav Physiol** 1996 Mar–Apr;26(2):143–52 (69 ref.)

Effect of oculomotor and other visual skills on reading performance: a literature review. Kulp MT, et al. **Optom Vis Sci** 1996 Apr;73(4):283–92 (122 ref.)

Spherical aberration of the reduced schematic eye with elliptical refracting surface. Thibos LN, et al. **Optom Vis Sci** 1997 Jul;74(7):548–56 (26 ref.)

Retinoids and the visual process. Crouch RK, et al. **Photochem Photobiol** 1996 Oct;64(4):613–21 (113 ref.)

The role of vision and spatial orientation in the maintenance of posture. Wade MG, et al. **Phys Ther** 1997 Jun; 77(6):619–28 (58 ref.)

When neurobiology and genetics meet: the study of visual system development in Drosophila melanogaster. Ramos RG. **Rev Bras Biol** 1995 Dec;55 Suppl 1:11–24 (90 ref.)

Mach bands: how many models are possible? Recent experimental findings and modeling attempts. Pessoa L. **Vision Res** 1996 Oct;36(19):3205–27 (115 ref.)

VISION, BINOCULAR

Binocularity in prism-reared monkeys. Crawford ML, et al. **Eye** 1996;10 (Pt 2):161–6 (26 ref.)

Clinical tests for binocular vision. Lee J, et al. **Eye** 1996;10 (Pt 2):282–5 (0 ref.)

Accommodative and binocular vision disorders associated with video display terminals: diagnosis and management issues. Scheiman M. **J Am Optom Assoc** 1996 Sep; 67(9):531–9 (20 ref.)

PHYSIOLOGY

Chiasmal crossing defects in disorders of binocular vision. Apkarian P. **Eye** 1996;10 (Pt 2):222–32 (73 ref.)

What happens to binocularity in primate strabismus? Boothe RG, et al. **Eye** 1996;10 (Pt 2):199–208 (47 ref.)

Binocularity in infancy. Braddick O. **Eye** 1996;10 (Pt 2):182–8 (41 ref.)

The neural architecture of binocular vision. Casagrande VA, et al. **Eye** 1996;10 (Pt 2):153–60 (64 ref.)

Does stereopsis matter in humans? Fielder AR, et al. **Eye** 1996;10 (Pt 2):233–8 (45 ref.)

Why do albinos and other hypopigmented mutants lack normal binocular vision, and what else is abnormal in their central visual pathways? Guillery RW. **Eye** 1996;10 (Pt 2):217–21 (46 ref.)

Psychophysics of suppression. Harrad R. **Eye** 1996;10 (Pt 2):270–3 (28 ref.)

Motor and sensory fusion in monkeys: psychophysical measurements. Harwerth RS, et al. **Eye** 1996;10 (Pt 2):209–16 (59 ref.)

How useful is anomalous correspondence? Herzau V. **Eye** 1996;10 (Pt 2):266–9 (16 ref.)

How is binocularity maintained during convergence and divergence? Judge SJ. **Eye** 1996;10 (Pt 2):172–6 (43 ref.)

Abnormal motion processing and binocularity: infantile esotropia as a model system for effects of early interruptions of binocularity. Norcia AM. **Eye** 1996;10 (Pt 2):259–65 (49 ref.)

Binocular correspondence in stereoscopic vision. Parker AJ, et al. **Eye** 1996;10 (Pt 2):177–81 (25 ref.)

The neural basis of suppression and amblyopia in strabismus. Sengpiel F, et al. **Eye** 1996;10 (Pt 2):250–8 (80 ref.)

Binocular disparity and the perception of depth. Qian N. **Neuron** 1997 Mar;18(3):359–68 (55 ref.)

[Binocular function clarified] Pigassou-Albouy R. **Oftalmologia** 1996 Jul–Sep;40(3):274–8 (36 ref.) (Eng. Abstr.) **(Fre)**

[Binocular vision and its role in car driving] Chernysheva SG, et al. **Vestn Oftalmol** 1997 Mar–Apr;113(2):40–2 (23 ref.) **(Rus)**

VISION DISORDERS

Keeping an eye on vision: primary care of age-related ocular disease. Part 1. Butler RN, et al. **Geriatrics** 1997 Aug; 52(8):30–41 (0 ref.)

Eyeing up Graves' ophthalmopathy. Weetman AP. **Mol Cell Endocrinol** 1997 Feb 7;126(2):113–6 (21 ref.)

CHEMICALLY INDUCED

Interferon alfa-associated retinopathy. Chambers RB, et al. **J Am Osteopath Assoc** 1997 Jan;97(1):43–5 (12 ref.)

Ophthalmological monitoring of patients taking antimalarials: preferred practice patterns. Easterbrook M, et al. **J Rheumatol** 1997 Jul;24(7):1390–2 (21 ref.)

COMPLICATIONS

Monocular vision loss can cause bilateral nystagmus in young children. Good WV, et al. **Dev Med Child Neurol** 1997 Jun;39(6):421–4 (30 ref.)

Loss of vision alone may result in seesaw nystagmus. May EF, et al. **J Neuroophthalmol** 1997 Jun;17(2):84–5 (8 ref.)

DIAGNOSIS

Multiple evanescent white dot syndrome—an uncommon cause for an enlarged blind spot. Fong KS, et al. **Ann Acad Med Singapore** 1996 Nov;25(6):866–8 (13 ref.)

Early diagnosis of functional damage in patients with glaucoma [editorial; comment] Caprioli J. **Arch Ophthalmol** 1997 Jan;115(1):113–4 (31 ref.) Comment on: Arch Ophthalmol 1997 Jan;115(1):26–33.

Glaucomatous visual field defects: their characteristics and how to detect them. Kitazawa Y, et al. **Clin Neurosci** 1997; 4(5):279–83 (29 ref.)

Clinical tests for binocular vision. Lee J, et al. **Eye** 1996;10 (Pt 2):282–5 (0 ref.)

Accommodative and binocular vision disorders associated with video display terminals: diagnosis and management issues. Scheiman M. **J Am Optom Assoc** 1996 Sep; 67(9):531–9 (20 ref.)

ETIOLOGY

Visual system dysfunction in migraine: a review of clinical and psychophysical findings. Chronicle EP, et al. **Cephalalgia** 1996 Dec;16(8):525–35; discussion 523 (136 ref.)

Why do albinos and other hypopigmented mutants lack normal binocular vision, and what else is abnormal in their central visual pathways? Guillery RW. **Eye** 1996;10 (Pt 2):217–21 (46 ref.)

Migraine-related visual-field loss with prolonged recovery. Sullivan-Mee M, et al. **J Am Optom Assoc** 1997 Jun; 68(6):377–88 (29 ref.)

Pediatric orbital and visual pathway lesions. Barnes PD, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):179–98 (86 ref.)

Clinical signs and symptoms requiring computed tomography and magnetic resonance imaging evaluation. Levin LA. **Neuroimaging Clin N Am** 1996 Feb;6(1):1–14 (38 ref.)

Chewing-induced visual impairment from a dumbbell dermoid cyst. Emerick GT, et al. **Ophthal Plast Reconstr Surg** 1997 Mar;13(1):57–61 (11 ref.)

Etiology of an unusual visual field deficit associated with a craniopharyngioma: case report. Huang PP, et al. **Ophthalmologica** 1997;211(4):256–62 (24 ref.)

Progressive visual loss from giant cell arteritis despite high-dose intravenous methylprednisolone. Cornblath WT, et al. **Ophthalmology** 1997 May;104(5):854–8 (28 ref.)

Visual phenomena, disturbances, and hallucinations. Adamczyk DT. **Optom Clin** 1996;5(3–4):33–52 (3 ref.)

Intracranial hypertension. Kabat AG. **Optom Clin** 1996; 5(3–4):153–79 (51 ref.)

Biosocial consequences of poverty: associated visual problems. Solan HA, et al. **Optom Vis Sci** 1997 Apr; 74(4):185–9 (44 ref.)

Optic neuritis in a child. Williams JR. **Pediatr Emerg Care** 1996 Jun;12(3):210–2 (11 ref.)

[Vision in Alzheimer's disease] Ceccaldi M. **Rev Neurol (Paris)** 1996 Jun–Jul;152(6–7):441–6 (57 ref.) (Eng. Abstr.) **(Fre)**

[Idiopathic hypertrophic cranial pachymeningitis associated with Horner's syndrome. A case report] Shindo K, et al. **Rinsho Shinkeigaku** 1997 Apr;37(4):300–3 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Disordered visual functions in patients with a traumatic carotid-cavernous fistula] Ryzhova IP. **Lik Sprava** 1997 Mar–Apr;(2):25–31 (44 ref.) **(Rus)**

PHYSIOPATHOLOGY

Acute ocular methanol toxicity: clinical and electrophysiological features. McKellar MJ, et al. **Aust N Z J Ophthalmol** 1997 Aug;25(3):225–30 (22 ref.)
Visual deficits and mobility. Evaluation and management. Maino JH. **Clin Geriatr Med** 1996 Nov;12(4):803–23 (50 ref.)
Chiasmal crossing defects in disorders of binocular vision. Apkarian P. **Eye** 1996;10 (Pt 2):222–32 (73 ref.)
Visual function in multiple personality disorder. Birnbaum MH, et al. **J Am Optom Assoc** 1996 Jun;67(6):327–34 (35 ref.)

PREVENTION & CONTROL

Visual deficits and mobility. Evaluation and management. Maino JH. **Clin Geriatr Med** 1996 Nov;12(4):803–23 (50 ref.)
Reflections on antireflection films. McQuaid RD. **J Am Optom Assoc** 1997 Mar;68(3):191–201 (116 ref.)
Preventative ophthalmology. Age-related macular degeneration. Bressler NM, et al. **Ophthalmology** 1995 Aug; 102(8):1206–11 (46 ref.)

REHABILITATION

[Contact lenses--an overview] Azem H. **Wien Med Wochenschr** 1997;147(12–13):293–4 (0 ref.) (Eng. Abstr.) **(Ger)**
[Disposable contact lenses and their complications] Egger SF. **Wien Med Wochenschr** 1997;147(12–13):295–7 (11 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Report of the Visual Handicap Group. Kohner E, et al. **Diabet Med** 1996 Sep;13(9 Suppl 4):S13–26 (48 ref.)
Optometric management of patients with Alzheimer's disease. Baker DR, et al. **J Am Optom Assoc** 1997 Aug;68(8):483–94 (59 ref.)
Accommodative and binocular vision disorders associated with video display terminals: diagnosis and management issues. Scheiman M. **J Am Optom Assoc** 1996 Sep; 67(9):531–9 (20 ref.)
The bottom line on fixing computer-related vision and eye problems [editorial] Sheedy JE. **J Am Optom Assoc** 1996 Sep;67(9):512–7 (20 ref.)
International Symposium for Therapy of Ocular Motility and Related Visual Disturbances. Kaminski HJ, et al. **Neurology** 1997 May;48(5):1178–84 (72 ref.)

VISION DISPARITY

Pulfrich revisited. Diaper CJ. **Surv Ophthalmol** 1997 May–Jun;41(6):493–9 (64 ref.)

PHYSIOLOGY

Binocular rivalry: ambiguities resolved. Sengpiel F. **Curr Biol** 1997 Jul 1;7(7):R447–50 (15 ref.)
A discussion of activity-dependent forms of synaptic weakening and their possible role in ocular dominance plasticity. Dudek SM. **J Physiol Paris** 1996;90(3–4):167–70 (38 ref.)

VISION, ENTOPTIC

PHYSIOLOGY

Visual phenomena, disturbances, and hallucinations. Adamczyk DT. **Optom Clin** 1996;5(3–4):33–52 (3 ref.)

VISION, LOW see **VISION, SUBNORMAL**

VISION, MONOCULAR

Monocular vision loss can cause bilateral nystagmus in young children. Good WV, et al. **Dev Med Child Neurol** 1997 Jun;39(6):421–4 (30 ref.)

PHYSIOLOGY

A discussion of activity-dependent forms of synaptic weakening and their possible role in ocular dominance plasticity. Dudek SM. **J Physiol Paris** 1996;90(3–4):167–70 (38 ref.)
Neuronal plasticity induced by neonatal monocular (and binocular) enucleation. Toldi J, et al. **Prog Neurobiol** 1996 Feb;48(3):191–218 (200 ref.)

VISION SCREENING

Visual predictors of reading performance in kindergarten and first grade children. Kulp MT, et al. **Optom Vis Sci** 1996 Apr;73(4):255–62 (99 ref.)
Preschool vision screening: rationale, methodology and outcome. Simons K. **Surv Ophthalmol** 1996 Jul–Aug; 41(1):3–30 (366 ref.)

STANDARDS

Vision standards in the Royal Canadian Mounted Police: are they reasonable and fair? [see comments] Easterbrook M, et al. **Can J Ophthalmol** 1997 Apr;32(3):153–7 (23 ref.) Comment in: Can J Ophthalmol 1997 Apr;32(3):145–7.

VISION, SUBNORMAL

REHABILITATION

Reading with magnifiers. Den Brinker BP, et al. **Ergonomics** 1996 Oct;39(10):1231–48 (90 ref.)
Evaluating the value of low-vision services. Raasch TW, et al. **J Am Optom Assoc** 1997 May;68(5):287–95 (58 ref.)
[Recent progress in psychosensory rehabilitation of low vision. The third method for the prevention of blindness] Langlois J. **Bull Acad Natl Med** 1997 Apr;181(4):699–707; discussion 708–12 (16 ref.) (Eng. Abstr.) **(Fre)**

VISION TESTS

[Visual acuity, visual field] Kubota N. **Nippon Rinsho** 1997 Mar;55 Suppl 1:430–1 (8 ref.) **(Jpn)**

INSTRUMENTATION

[Merits and demerits of automation ophthalmic instruments (editorial)] Otori T. **Nippon Ganka Gakkai Zasshi** 1997 May;101(5):369–70 (4 ref.) **(Jpn)**

METHODS

Clinical tests for binocular vision. Lee J, et al. **Eye** 1996;10 (Pt 2):282–5 (0 ref.)
Practical approach to diagnosis of strabismus. Thomas R, et al. **Indian J Ophthalmol** 1996 Jun;44(2):103–12 (3 ref.)
Case history: cornerstone in the neuro-ophthalmic examination. Carr L. **Optom Clin** 1996;5(3–4):17–32 (26 ref.)
Afferent pupillary defects and the swinging flashlight test. What you thought you already knew. Modica PA. **Optom Clin** 1996;5(3–4):1–15 (24 ref.)
Pediatric primary care vision examination. Ryan JB. **Optom Clin** 1996;5(2):1–34 (64 ref.)
Preschool vision screening: rationale, methodology and outcome. Simons K. **Surv Ophthalmol** 1996 Jul–Aug; 41(1):3–30 (366 ref.)
[Informative value of psychophysical examinations aside from conventional white-white perimetry] Lachenmayr B. **Ophthalmologe** 1996 Aug;93(4):389–95 (81 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

New standardized visual acuity charts in Hindi and Gujarati. Khamar BM, et al. **Indian J Ophthalmol** 1996 Sep; 44(3):161–4 (4 ref.)

VISITING NURSES see **COMMUNITY HEALTH NURSING**

VISITORS TO PATIENTS

The experiences of families with a relative in the intensive care unit. Jamerson PA, et al. **Heart Lung** 1996 Nov–Dec; 25(6):467–74 (36 ref.)
Opening the doors: family presence during resuscitation. Eichhorn DJ, et al. **J Cardiovasc Nurs** 1996 Jul;10(4):59–70 (26 ref.)

VISNA

Maedi-Visna and ovine progressive pneumonia. de la Concha-Bermejillo A. **Vet Clin North Am Food Anim Pract** 1997 Mar;13(1):13–33 (125 ref.)

IMMUNOLOGY

Lentivirus replication in lymphoid tissue: use of lymphatic cannulation to study the initial stages of infection and immunity. McConnell I, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):417–20 (18 ref.)

VIROLOGY

Molecular studies of visna virus gene expression: analysis of envelope gene expression in transgenic sheep. Clements JE, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):421–3 (65 ref.)

VISNA-MAEDI VIRUS

Histogenesis of the pulmonary lesions in the course of visna maedi virus-induced pneumonia. Cadoré JL, et al. **Vet Res** 1996;27(4–5):419–26 (46 ref.)

GENETICS

Molecular studies of visna virus gene expression: analysis of envelope gene expression in transgenic sheep. Clements JE, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):421–3 (65 ref.)

IMMUNOLOGY

Lentivirus replication in lymphoid tissue: use of lymphatic cannulation to study the initial stages of infection and immunity. McConnell I, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):417–20 (18 ref.)

VISNA VIRUS see **VISNA-MAEDI VIRUS**

VISUAL ACUITY

see related
FORM PERCEPTION
REFRACTION, OCULAR
REFRACTIVE ERRORS

New standardized visual acuity charts in Hindi and Gujarati. Khamar BM, et al. **Indian J Ophthalmol** 1996 Sep; 44(3):161–4 (4 ref.)
Improvement in Vernier acuity in adults with amblyopia. Practice makes better. Levi DM, et al. **Invest Ophthalmol Vis Sci** 1997 Jul;38(8):1493–510 (58 ref.)
Refractive surgery, optical aberrations, and visual performance [see comments] Applegate RA, et al. **J Refract Surg** 1997 May–Jun;13(3):295–9 (17 ref.) Comment in: J Refract Surg 1997 May–Jun;13(3):213–5.
20/20--how close must we get? [see comments] Werblin TP. **J Refract Surg** 1997 May–Jun;13(3):300–1 (3 ref.) Comment in: J Refract Surg 1997 May–Jun;13(3):213–5.
Extradural optic nerve decompression for fibrous dysplasia with a favorable visual outcome. Kurimoto M, et al. **Neurol Med Chir (Tokyo)** 1996 Feb;36(2):102–5 (19 ref.)
Invariance of ophthalmic properties under spherocylindrical transposition. Harris WF. **Optom Vis Sci** 1997 Jun; 74(6):459–62 (9 ref.)
[Visual acuity, visual field] Kubota N. **Nippon Rinsho** 1997 Mar;55 Suppl 1:430–1 (8 ref.) **(Jpn)**

PHYSIOLOGY

The hand and the eye. Filan SL, et al. **J Hand Surg [Br]** 1997 Jun;22(3):293–8 (48 ref.)
Varieties of vision: from blind responses to conscious recognition [see comments] Stoerig P. **Trends Neurosci** 1996 Sep;19(9):401–6 (52 ref.) Comment in: Trends Neurosci 1997 Jan;20(1):22–3.

VISUAL AIDS see **AUDIOVISUAL AIDS**

VISUAL ANALOGUE PAIN SCALE see **PAIN MEASUREMENT**

VISUAL CONTRAST SENSITIVITY see **CONTRAST SENSITIVITY**

VISUAL CORTEX

ANATOMY & HISTOLOGY

Cortical dynamics. Gilbert CD. **Acta Paediatr Suppl** 1997 Jul;422:34–7 (33 ref.)
Cytochrome oxidase 'blobs' and other characteristics of primary visual cortex in a lemuroid primate, Cheirogaleus medius. Preuss TM, et al. **Brain Behav Evol** 1996; 47(2):103–12 (49 ref.)
Limits of parallel processing: excitatory convergence of different information channels on single neurons in striate and extrastriate visual cortices. Dreher B, et al. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov; 23(10–11):913–25 (81 ref.)
The functional anatomy of visual awareness. Koch C, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:49–57 (59 ref.)
Theories of visual cortex organization in primates: areas of the third level. Kaas JH. **Prog Brain Res** 1996;112:213–21 (53 ref.)
New images from human visual cortex. Tootell RB, et al. **Trends Neurosci** 1996 Nov;19(11):481–9 (99 ref.)
[Simulation of the structure and function of the lateral geniculate bodies and visual analyzer system] Radchenko AN. **Fiziol Cheloveka** 1997 Jul–Aug;23(4):28–35 (14 ref.) **(Rus)**

CYTOLOGY

Multiple mechanisms underlying the orientation selectivity of visual cortical neurones. Vidyasagar TR, et al. **Trends Neurosci** 1996 Jul;19(7):272–7 (61 ref.)

DRUG EFFECTS

Cortical blindness secondary to cyclosporine after orthotopic heart transplantation: a case report and review of the literature. Drachman BM, et al. **J Heart Lung Transplant** 1996 Nov;15(11):1158–64 (38 ref.)

EMBRYOLOGY

Prenatal development of axon outgrowth and connectivity. Casagrande VA, et al. **Prog Brain Res** 1996;108:83–93 (71 ref.)

GROWTH & DEVELOPMENT

Factors that are critical for plasticity in the visual cortex. Daw NW, et al. **Ciba Found Symp** 1995; 193:258–76;discussion 322–4 (35 ref.)
Binocularity in infancy. Braddick O. **Eye** 1996;10 (Pt 2):182–8 (41 ref.)
Evidence for greater sight in blindsight following damage of primary visual cortex early in life. Payne BR, et al. **Neuropsychologia** 1996 Aug;34(8):741–74 (331 ref.)
Behavioral, structural and neurochemical asymmetries in the avian brain: a model system for studying visual development and processing. Rogers L. **Neurosci Biobehav Rev** 1996 Autumn;20(3):487–503 (149

ref.)
The action of neurotrophins in the development and plasticity of the visual cortex [published erratum appears in Prog Neurobiol 1996 Oct;50(2–3):333] Cellerino A, et al. **Prog Neurobiol** 1996 May;49(1):53–71 (180 ref.)

INJURIES

Evidence for greater sight in blindsight following damage of primary visual cortex early in life. Payne BR, et al. **Neuropsychologia** 1996 Aug;34(8):741–74 (331 ref.)

PATHOLOGY

Binocularity in prism-reared monkeys. Crawford ML, et al. **Eye** 1996;10 (Pt 2):161–6 (26 ref.)

PHYSIOLOGY

Cortical dynamics. Gilbert CD. **Acta Paediatr Suppl** 1997 Jul;422:34–7 (33 ref.)
Perilesional cortical dysfunction and reorganization. Eysel UT. **Adv Neurol** 1997;73:195–206 (38 ref.)
Strategies of visual perception suggested by optically imaged patterns of functional architecture in monkey visual cortex. Blasdel G. **Ann N Y Acad Sci** 1997 May 30;820:170–95 (44 ref.)
Inferotemporal cortex and object vision. Tanaka K. **Annu Rev Neurosci** 1996;19:109–39 (102 ref.)
Elementary forms of synaptic plasticity in the visual cortex. Kirkwood A, et al. **Biol Res** 1995;28(1):73–80 (23 ref.)
Sensory regulation of immediate-early gene expression in mammalian visual cortex: implications for functional mapping and neural plasticity. Kaczmarek L, et al. **Brain Res Brain Res Rev** 1997 Apr;23(3):237–56 (169 ref.)
Role of the temporal domain for response selection and perceptual binding. Engel AK, et al. **Cereb Cortex** 1997 Sep;7(6):571–82 (119 ref.)
A model of color vision based on cortical reentry. Wray J, et al. **Cereb Cortex** 1996 Sep–Oct;6(5):701–16 (81 ref.)
Factors that are critical for plasticity in the visual cortex. Daw NW, et al. **Ciba Found Symp** 1995; 193:258–76;discussion 322–4 (35 ref.)
Limits of parallel processing: excitatory convergence of different information channels on single neurons in striate and extrastriate visual cortices. Dreher B, et al. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov; 23(10–11):913–25 (81 ref.)
Functional imaging studies of human visual cortex. Watson JD. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov; 23(10–11):926–30 (27 ref.)
Cortical dynamics and visual perception. Gilbert CD, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:105–13 (44 ref.)
A solution to the binding problem? Information processing. Golledge HDR, et al. **Curr Biol** 1996 Sep 1;6(9):1092–5 (24 ref.)
Where is the mind's eye? Visual perception. Mitchison G. **Curr Biol** 1996 May 1;6(5):508–10 (15 ref.)
Visual cortex: a cat's-eye view of the visual system. Swindale NV. **Curr Biol** 1997 Jun 1;7(6):R387–9 (12 ref.)
Visual cortex: looking into a Klein bottle. Swindale NV. **Curr Biol** 1996 Jul 1;6(7):776–9 (11 ref.)
Cortical development: a role for spontaneous activity? Thompson I. **Curr Biol** 1997 May 1;7(5):R324–6 (25 ref.)
Perception: the seeing ear. Walsh V. **Curr Biol** 1996 Apr 1;6(4):389–91 (15 ref.)
What fMRI has taught us about human vision. Courtney SM, et al. **Curr Opin Neurobiol** 1997 Aug;7(4):554–61 (90 ref.)
The processing and encoding of information in the visual cortex. Reid RC, et al. **Curr Opin Neurobiol** 1996 Aug; 6(4):475–80 (60 ref.)
The neural architecture of binocular vision. Casagrande VA, et al. **Eye** 1996;10 (Pt 2):153–60 (64 ref.)
Low-frequency oscillations of visual, auditory and somatosensory cortical neurons evoked by sensory stimulation. Dinse HR, et al. **Int J Psychophysiol** 1997 Jun; 26(1–3):205–27 (31 ref.)
Phase correlation among rhythms present at different frequencies: spectral methods, application to microelectrode recordings from visual cortex and functional implications. Schanze T, et al. **Int J Psychophysiol** 1997 Jun;26(1–3):171–89 (33 ref.)
Synchronous oscillations in neuronal systems: mechanisms and functions. Gray CM. **J Comput Neurosci** 1994 Jun; 1(1–2):11–38 (164 ref.)
The role of synapses in cortical computation. Douglas RJ, et al. **J Neurocytol** 1996 Dec;25(12):893–911 (104 ref.)
Postgeniculate afferent visual system and visual higher cortical function, 1994. Wall M. **J Neuroophthalmol** 1996 Mar;16(1):23–32 (52 ref.)
Postgeniculate afferent visual system and visual higher cortical function, 1995–1996. Wall M. **J Neuroophthalmol** 1997 Sep;17(3):209–17 (67 ref.)
Progress in understanding NMDA-receptor-dependent synaptic plasticity in the visual cortex. Bear MF. **J Physiol Paris** 1996;90(3–4):223–7 (39 ref.)
An intracellular study of space and time representation in primary visual cortical receptive fields. Frégnac Y, et al. **J Physiol Paris** 1996;90(3–4):189–97 (57 ref.)
Dynamics of functional connectivity in visual cortical networks: an overview. Frégnac Y. **J Physiol Paris** 1996; 90(3–4):113–39 (185 ref.)
Postsynaptic calcium and calcium-dependent processes in synaptic plasticity in the developing visual cortex. Tsumoto T, et al. **J Physiol Paris** 1996;90(3–4):151–6 (21 ref.)
Models of orientation and ocular dominance columns in the visual cortex: a critical comparison. Erwin E, et al. **Neural Comput** 1995 May;7(3):425–68 (83 ref.)
The neural coding of stereoscopic depth. Ohzawa I, et al. **Neuroreport** 1997 Feb 10;8(3):iii–xii (36 ref.)
Cortical dynamics of boundary segmentation and reset: persistence, afterimages, and residual traces. Francis G, et al. **Perception** 1996;25(5):543–67 (60 ref.)
Some reflections on (or by?) grandmother cells [editorial] Rose D. **Perception** 1996;25(8):881–6 (26 ref.)
NMDA-receptor-dependent synaptic plasticity in the visual cortex. Bear MF. **Prog Brain Res** 1996;108:205–18 (78 ref.)
Afferent and developmentally inherent mechanisms of form and motion processing in cat extrastriate cortex. Spear PD. **Prog Brain Res** 1996;112:223–30 (41 ref.)
The action of neurotrophins in the development and plasticity of the visual cortex [published erratum appears in Prog Neurobiol 1996 Oct;50(2–3):333] Cellerino A, et al. **Prog Neurobiol** 1996 May;49(1):53–71 (180 ref.)
Invariant face and object recognition in the visual system. Wallis G, et al. **Prog Neurobiol** 1997 Feb;51(2):167–94 (113 ref.)
Associative synaptic plasticity in hippocampus and visual cortex: cellular mechanisms and functional implications. Debanne D. **Rev Neurosci** 1996 Jan–Mar;7(1):29–46 (160 ref.)
Synaptic activity and the construction of cortical circuits. Katz LC, et al. **Science** 1996 Nov 15;274(5290):1133–8 (86 ref.)
Visual brain and visual perception: how does the cortex do perceptual grouping? Grossberg S, et al. **Trends Neurosci** 1997 Mar;20(3):106–11 (72 ref.)
Multiple mechanisms underlying the orientation selectivity of visual cortical neurones. Vidyasagar TR, et al. **Trends Neurosci** 1996 Jul;19(7):272–7 (61 ref.)
[Brain functional MRI of the visual cortex with echo planar imaging] Yamada H. **Nippon Rinsho** 1997 Jul;55(7):1684–7 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Clinical application of functional mapping; the present state of the art and its future prospects: (series 2) Identification of motor, sensory, visual and speech cortex by functional MRI] Ito T, et al. **No Shinkei Geka** 1996 Feb;24(2):109–18 (23 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Blindsight in man and monkey. Stoerig P, et al. **Brain** 1997 Mar;120 (Pt 3):535–59 (173 ref.)
The neural basis of suppression and amblyopia in strabismus. Sengpiel F, et al. **Eye** 1996;10 (Pt 2):250–8 (80 ref.)

RADIONUCLIDE IMAGING

Functional imaging studies of human visual cortex. Watson JD. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov; 23(10–11):926–30 (27 ref.)

VISUAL EVOKED RESPONSE see **EVOKED POTENTIALS, VISUAL**

VISUAL FATIGUE see **ASTHENOPIA**

VISUAL FIELDS

see related
PERIMETRY

Glaucomatous visual field defects: their characteristics and how to detect them. Kitazawa Y, et al. **Clin Neurosci** 1997; 4(5):279–83 (29 ref.)
Altitudinal visual stimuli and the cruciform model of evoked potentials. Onofrj M, et al. **Electroencephalogr Clin Neurophysiol Suppl** 1996;46:147–59 (36 ref.)
Migraine-related visual-field loss with prolonged recovery. Sullivan-Mee M, et al. **J Am Optom Assoc** 1997 Jun; 68(6):377–88 (29 ref.)
Etiology of an unusual visual field deficit associated with a craniopharyngioma: case report. Huang PP, et al. **Ophthalmologica** 1997;211(4):256–62 (24 ref.)
Evidence of a global oblique effect in human extrafoveal vision. Pointer JS. **Perception** 1996;25(5):523–30 (20 ref.)
[Visual acuity, visual field] Kubota N. **Nippon Rinsho** 1997 Mar;55 Suppl 1:430–1 (8 ref.) **(Jpn)**
[Objective measurement of visual field by using visual evoked potentials] Tobimatsu S. **Nippon Rinsho** 1997 Mar;55 Suppl 1:450–3 (6 ref.) **(Jpn)**

PHYSIOLOGY

Representation of object-centered space in the primate frontal lobe. Olson CR, et al. **Brain Res Cogn Brain Res** 1996 Dec;5(1–2):147–56 (32 ref.)
Visual sensation during pecking in pigeons. Ostheim J. **Eur J Morphol** 1997 Oct;35(4):269–76 (36 ref.)
An intracellular study of space and time representation in primary visual cortical receptive fields. Frégnac Y, et al. **J Physiol Paris** 1996;90(3–4):189–97 (57 ref.)
Location and function of the human frontal eye-field: a selective review. Paus T. **Neuropsychologia** 1996 Jun; 34(6):475–83 (36 ref.)
Displacement field estimation and image segmentation using block matching enhanced by a neural network. Chen YS, et al. **Spat Vis** 1996;10(1):31–50 (19 ref.)
Long-range interactions in visual perception. Spillmann L, et al. **Trends Neurosci** 1996 Oct;19(10):428–34 (89 ref.)
Modelling the spatio-temporal modulation response of ganglion cells with difference-of-Gaussians receptive fields: relation to photoreceptor response kinetics. Donner K, et al. **Vis Neurosci** 1996 Jan–Feb;13(1):173–86 (67 ref.)

VISUAL MOTOR COORDINATION see **PSYCHOMOTOR PERFORMANCE**

VISUAL PATHWAYS

The anterior visual pathways. Sadun AA, et al. **J Neuroophthalmol** 1996 Jun;16(2):137–51 (199 ref.)
Clinical signs and symptoms requiring computed tomography and magnetic resonance imaging evaluation. Levin LA. **Neuroimaging Clin N Am** 1996 Feb;6(1):1–14 (38 ref.)

ANATOMY & HISTOLOGY

Retinopetal projections in lampreys. Vesselkin NP, et al. **Brain Behav Evol** 1996;48(5):277–86 (96 ref.)
Limits of parallel processing: excitatory convergence of different information channels on single neurons in striate and extrastriate visual cortices. Dreher B, et al. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov; 23(10–11):913–25 (81 ref.)
Aligning maps of visual and auditory space. Sensory maps. Rees A. **Curr Biol** 1996 Aug 1;6(8):955–8 (14 ref.)
On the structure and function of the tectofugal visual pathway in laterally eyed birds. Bischof HJ, et al. **Eur J Morphol** 1997 Oct;35(4):246–54 (72 ref.)
Separate channels for visuomotor transformations in the pigeon. Jäger R. **Eur J Morphol** 1997 Oct;35(4):277–89 (70 ref.)
Normal computed tomography and magnetic resonance imaging anatomy of the globe, orbit, and visual pathways. Hesselink JR, et al. **Neuroimaging Clin N Am** 1996 Feb; 6(1):15–27 (16 ref.)

EMBRYOLOGY

The genetics of visual system development in Drosophila: specification, connectivity and asymmetry. Cutforth T, et al. **Curr Opin Neurobiol** 1997 Feb;7(1):48–54 (55 ref.)

GROWTH & DEVELOPMENT

Emergence of order in visual system development. Shatz CJ. **J Physiol Paris** 1996;90(3–4):141–50 (55 ref.)
What do developmental mapping rules optimize? Xiong M, et al. **Prog Brain Res** 1996;112:351–61 (43 ref.)

INJURIES

Recovery of vision after partial visual system injury as a model of postlesion neuroplasticity. Sabel BA, et al. **Adv Neurol** 1997;73:251–76 (123 ref.)

PATHOLOGY

The cellular mechanism underlying neuronal degeneration in glaucoma: parallels with Alzheimer's disease. Vickers JC. **Aust N Z J Ophthalmol** 1997 May;25(2):105–9 (47 ref.)
Neuro-ophthalmology of the pregeniculate afferent visual system. Developments in 1996 (Part I). Balcer LJ, et al. **J Neuroophthalmol** 1997 Mar;17(1):60–71 (87 ref.)
Pediatric orbital and visual pathway lesions. Barnes PD, et al. **Neuroimaging Clin N Am** 1996 Feb;6(1):179–98 (86 ref.)
Imaging evaluation of the optic nerve and visual pathway including cranial nerves affecting the visual pathway. Weber AL, et al. **Neuroimaging Clin N Am** 1996 Feb; 6(1):143–77 (162 ref.)
Evidence of optic pathway gliomas after previously negative neuroimaging. Massry GG, et al. **Ophthalmology** 1997 Jun; 104(6):930–5 (35 ref.)

PHYSIOLOGY

Visual perceptual learning: a sign of neural plasticity at early stages of visual processing. Fiorentini A, et al. **Arch Ital Biol** 1997 Mar;135(2):157–67 (37 ref.)
Suppression of the magnocellular pathway during saccades. Ross J, et al. **Behav Brain Res** 1996 Oct;80(1–2):1–8 (63 ref.)
Spatial representations for action in parietal cortex. Colby CL, et al. **Brain Res Cogn Brain Res** 1996 Dec; 5(1–2):105–15 (34 ref.)
Stimulus-driven facilitation and inhibition of visual information processing in environmental and retinotopic representations of space. Shimojo S, et al. **Brain Res Cogn Brain Res** 1996 Dec;5(1–2):11–21 (14 ref.)
Visual system dysfunction in migraine: a review of clinical and psychophysical findings. Chronicle EP, et al. **Cephalalgia** 1996 Dec;16(8):525–35; discussion 523 (136 ref.)
Limits of parallel processing: excitatory convergence of different information channels on single neurons in striate and extrastriate visual cortices. Dreher B, et al. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov; 23(10–11):913–25 (81 ref.)
The Eph family in retinal axon guidance. Drescher U, et al. **Curr Opin Neurobiol** 1997 Feb;7(1):75–80 (54 ref.)
Activation and inactivation steps in the visual transduction pathway. Palczewski K, et al. **Curr Opin Neurobiol** 1997 Aug;7(4):500–4 (40 ref.)
On the structure and function of the tectofugal visual

pathway in laterally eyed birds. Bischof HJ, et al. **Eur J Morphol** 1997 Oct;35(4):246–54 (72 ref.)
Visual lateralization in birds: from neurotrophins to cognition? Güntürkün O. **Eur J Morphol** 1997 Oct; 35(4):290–302 (69 ref.)
Separate channels for visuomotor transformations in the pigeon. Jäger R. **Eur J Morphol** 1997 Oct;35(4):277–89 (70 ref.)
Neuronal coupling in rod–signal pathways of the retina. Vaney DI. **Invest Ophthalmol Vis Sci** 1997 Feb; 38(2):267–73 (24 ref.)
Neuro–ophthalmology of the pregeniculate afferent visual system. Developments in 1996 (Part II). Balcer LJ, et al. **J Neuroophthalmol** 1997 Jun;17(2):127–42 (217 ref.)
Postgeniculate afferent visual system and visual higher cortical function, 1995–1996. Wall M. **J Neuroophthalmol** 1997 Sep;17(3):209–17 (67 ref.)
Postgeniculate afferent visual system and visual higher cortical function, 1994. Wall M. **J Neuroophthalmol** 1996 Mar;16(1):23–32 (52 ref.)
License to see: for one eye only? Treue S. **Neuron** 1997 Aug; 19(2):223–5 (11 ref.)
Avian visual lateralization: a review. Güntürkün O. **Neuroreport** 1997 Apr 14;8(6):iii–xi (93 ref.)
The neural coding of stereoscopic depth. Ohzawa I, et al. **Neuroreport** 1997 Feb 10;8(3):iii–xii (36 ref.)
Behavioral, structural and neurochemical asymmetries in the avian brain: a model system for studying visual development and processing. Rogers L. **Neurosci Biobehav Rev** 1996 Autumn;20(3):487–503 (149 ref.)
The orbitofrontal cortex. Rolls ET. **Philos Trans R Soc Lond B Biol Sci** 1996 Oct 29; 351(1346):1433–43; discussion 1443–4 (103 ref.)
The role of NMDA receptors and nitric oxide in retinogeniculate development. Cramer KS, et al. **Prog Brain Res** 1996;108:235–44 (84 ref.)
Cellular mechanisms underlying the formation of orderly connections in developing sensory pathways. Erzurumlu RS, et al. **Prog Brain Res** 1996;108:287–301 (85 ref.)
Synaptic activity and the construction of cortical circuits. Katz LC, et al. **Science** 1996 Nov 15;274(5290):1133–8 (86 ref.)
Interaction of motion and color in the visual pathways. Gegenfurtner KR, et al. **Trends Neurosci** 1996 Sep; 19(9):394–401 (67 ref.)
Varieties of vision: from blind responses to conscious recognition [see comments] Stoerig P. **Trends Neurosci** 1996 Sep;19(9):401–6 (52 ref.) Comment in: Trends Neurosci 1997 Jan;20(1):22–3.
[The pupil and retrogeniculate visual pathway. Overview] Wilhelm H. **Ophthalmologe** 1996 Aug;93(4):319–24 (24 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Interocular interactions in esotropia. Di Stefano M, et al. **Arch Ital Biol** 1997 Mar;135(2):145–56 (45 ref.)
The anterior visual pathways—Part II. Sadun AA, et al. **J Neuroophthalmol** 1996 Sep;16(3):212–22 (340 ref.)
Varieties of vision: from blind responses to conscious recognition [see comments] Stoerig P. **Trends Neurosci** 1996 Sep;19(9):401–6 (52 ref.) Comment in: Trends Neurosci 1997 Jan;20(1):22–3.

VISUAL PERCEPTION

Strategies of visual perception suggested by optically imaged patterns of functional architecture in monkey visual cortex. Blasdel G. **Ann N Y Acad Sci** 1997 May 30;820:170–95 (44 ref.)
Visual object recognition. Legothetis NK, et al. **Annu Rev Neurosci** 1996;19:577–621 (228 ref.)
Inferotemporal cortex and object vision. Tanaka K. **Annu Rev Neurosci** 1996;19:109–39 (102 ref.)
Visual attention: control, representation, and time course. Egeth HE, et al. **Annu Rev Psychol** 1997;48:269–97 (110 ref.)
Blindsight in man and monkey. Stoerig P, et al. **Brain** 1997 Mar;120 (Pt 3):535–59 (173 ref.)
The bailiwick of visuo–spatial working memory: evidence from unilateral spatial neglect. Ellis AX, et al. **Brain Res Cogn Brain Res** 1996 Mar;3(2):71–8 (39 ref.)
Understanding diverse effects of visual attention with the VAP–filters metaphor. Cheal M. **Conscious Cogn** 1997 Jun–Sep;6(2–3):348–62 (76 ref.)
Where is the mind's eye? Visual perception. Mitchison G. **Curr Biol** 1996 May 1;6(5):508–10 (15 ref.)
Perceptual learning: insight in sight. Walsh V, et al. **Curr Biol** 1997 Apr 1;7(4):R249–51 (11 ref.)
Reflections on mirror images. Neuropsychology. Walsh V. **Curr Biol** 1996 Sep 1;6(9):1079–81 (16 ref.)
Blindsight revisited. Weiskrantz L. **Curr Opin Neurobiol** 1996 Apr;6(2):215–20 (50 ref.)
The Charles Bonnet syndrome: a review. Fernandez A, et al. **J Nerv Ment Dis** 1997 Mar;185(3):195–200 (60 ref.)
Neural mechanisms for visual memory and their role in attention. Desimone R. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13494–9 (66 ref.)
The vestibular system as a model of sensorimotor transformations. A combined in vivo and in vitro approach to study the cellular mechanisms of gaze and posture stabilization in mammals. Vibert N, et al. **Prog Neurobiol** 1997 Feb;51(3):243–86 (269 ref.)
[Vision in Alzheimer's disease] Ceccaldi M. **Rev Neurol (Paris)** 1996 Jun–Jul;152(6–7):441–6 (57 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Cortical dynamics. Gilbert CD. **Acta Paediatr Suppl** 1997 Jul;422:34–7 (33 ref.)
Flexibility in the structure of human information processing. Heinze HJ, et al. **Adv Neurol** 1997;73:359–75 (64 ref.)
Blindsight and consciousness. Natsoulas T. **Am J Psychol** 1997 Spring;110(1):1–33 (75 ref.)
Visual perceptual learning: a sign of neural plasticity at early stages of visual processing. Fiorentini A, et al. **Arch Ital Biol** 1997 Mar;135(2):157–67 (37 ref.)
Gestalten of today: early processing of visual contours and surfaces. Kovács I. **Behav Brain Res** 1996 Dec;82(1):1–11 (93 ref.)
Functional imagining of human visual recognition. Kanwisher N, et al. **Brain Res Cogn Brain Res** 1996 Dec; 5(1–2):55–67 (39 ref.)
Role of the motor cortex in the control of visually triggered gait modifications. Drew T, et al. **Can J Physiol Pharmacol** 1996 Apr;74(4):426–42 (85 ref.)
Role of the temporal domain for response selection and perceptual binding. Engel AK, et al. **Cereb Cortex** 1997 Sep;7(6):571–82 (119 ref.)
Perceptual and cognitive visual functions of parietal and temporal cortices in the cat. Lomber SG, et al. **Cereb Cortex** 1996 Sep–Oct;6(5):673–95 (86 ref.)
Cortical dynamics and visual perception. Gilbert CD, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:105–13 (44 ref.)
The functional anatomy of visual awareness. Koch C, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:49–57 (59 ref.)
Visual awareness: still at sea with seeing? Cowey A. **Curr Biol** 1996 Jan 1;6(1):45–7 (12 ref.)
Object recognition: the man who mistook his dog for a cat. Humphreys GW. **Curr Biol** 1996 Jul 1;6(7):821–4 (20 ref.)
Visual cortex: a cat's–eye view of the visual system. Swindale NV. **Curr Biol** 1997 Jun 1;7(6):R387–9 (12 ref.)
Cortical development: a role for spontaneous activity? Thompson I. **Curr Biol** 1997 May 1;7(5):R324–6 (25 ref.)
Competitive brain activity in visual attention. Duncan J, et al. **Curr Opin Neurobiol** 1997 Apr;7(2):255–61 (76 ref.)
Plasticity in visual perception and physiology. Gilbert CD. **Curr Opin Neurobiol** 1996 Apr;6(2):269–74 (44 ref.)
Insect visual perception: complex abilities of simple nervous systems. Giurfa M, et al. **Curr Opin Neurobiol** 1997 Aug; 7(4):505–13 (46 ref.)
Towards the neuronal correlate of visual awareness. Koch C, et al. **Curr Opin Neurobiol** 1996 Apr;6(2):158–64 (56 ref.)
Time–varying characteristics of visually induced postural sway. Loughlin PJ, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):416–24 (36 ref.)
Automatic visual to tactile translation—Part I: Human factors, access methods, and image manipulation. Way TP, et al. **IEEE Trans Rehabil Eng** 1997 Mar;5(1):81–94 (90 ref.)
A new case of atypical cerebral dominance. Posteraro L, et al. **Ital J Neurol Sci** 1996 Jun;17(3):237–40 (19 ref.)
The hand and the eye. Filan SL, et al. **J Hand Surg [Br]** 1997 Jun;22(3):293–8 (48 ref.)
Postgeniculate afferent visual system and visual higher cortical function, 1994. Wall M. **J Neuroophthalmol** 1996 Mar;16(1):23–32 (52 ref.)
Are there sex differences in hemispatial visual neglect after unilateral stroke? McGlone J, et al. **Neuropsychiatry Neuropsychol Behav Neurol** 1997 Apr; 10(2):125–34 (57 ref.)
Evidence for greater sight in blindsight following damage of primary visual cortex early in life. Payne BR, et al. **Neuropsychologia** 1996 Aug;34(8):741–74 (331 ref.)
Afferent and developmentally inherent mechanisms of form and motion processing in cat extrastriate cortex. Spear PD. **Prog Brain Res** 1996;112:223–30 (41 ref.)
Cortical dynamics of lateral inhibition: metacontrast masking. Francis G. **Psychol Rev** 1997 Jul;104(3):572–94 (45 ref.)
Consciousness of perception after brain damage. Farah MJ, et al. **Semin Neurol** 1997 Jun;17(2):145–52 (45 ref.)
Consciousness and the neurobiology of perceptual binding. Hardcastle VG. **Semin Neurol** 1997 Jun;17(2):163–70 (132 ref.)
Visual learning in the perception of texture: simple and contingent aftereffects of texture density. Durgin FH, et al. **Spat Vis** 1996;9(4):423–74 (127 ref.)
An integrated computational model of three–dimensional vision. Uttal WR, et al. **Spat Vis** 1996;9(4):393–422 (46 ref.)
Neural correlates of key stimulus and releasing mechanism: a case study and two concepts. Ewert JP. **Trends Neurosci** 1997 Aug;20(8):332–9 (71 ref.)
Interaction of motion and color in the visual pathways. Gegenfurtner KR, et al. **Trends Neurosci** 1996 Sep; 19(9):394–401 (67 ref.)
Visual brain and visual perception: how does the cortex do perceptual grouping? Grossberg S, et al. **Trends Neurosci** 1997 Mar;20(3):106–11 (72 ref.)
Long–range interactions in visual perception. Spillmann L, et al. **Trends Neurosci** 1996 Oct;19(10):428–34 (89 ref.)
[Non–invasive analysis of visual information processing] Tobimatsu S. **Fukuoka Igaku Zasshi** 1997 Jun;88(6):241–6 (5 ref.) **(Jpn)**
[Masking as a result of matched filtration in the human visual system] Krasil'nikov NN, et al. **Fiziol Cheloveka** 1996 Sep–Oct;22(5):99–103 (10 ref.) **(Rus)**
[Frequency–contrast characteristics of visual system in the presence of noise] Krasil'nikov NN, et al. **Fiziol Cheloveka** 1996 Jul–Aug;22(4):33–8 (15 ref.) **(Rus)**

VISUAL PURPLE see **RHODOPSIN**

VISUAL STIMULATION see **PHOTIC STIMULATION**

VISUAL TRANSDUCTION see **PHOTOTRANSDUCTION**

VITAL STATISTICS

Annual summary of vital statistics—1995. Guyer B, et al. **Pediatrics** 1996 Dec;98(6 Pt 1):1007–19 (43 ref.)
Population review: (7). Review of children. Botting B. **Popul Trends** 1996 Autumn;(85):25–33 (30 ref.)
Population review: (6). Families and households in Great Britain. Haskey J. **Popul Trends** 1996 Autumn;(85):7–24 (32 ref.)

VITAMIN A

ADMINISTRATION & DOSAGE

Safety aspects of vitamin A administration. Chytil F. **Eur J Clin Nutr** 1996 Jul;50 Suppl 3:S21–3 (20 ref.)
Vitamin A intake and status. van den Berg H. **Eur J Clin Nutr** 1996 Jul;50 Suppl 3:S7–12 (43 ref.)

ADVERSE EFFECTS

Safety aspects of vitamin A administration. Chytil F. **Eur J Clin Nutr** 1996 Jul;50 Suppl 3:S21–3 (20 ref.)
The impact of disease states as a modifying factor for nutrition toxicity. Russell RM. **Nutr Rev** 1997 Feb; 55(2):50–3 (18 ref.)
Vitamin A and its congeners. Monga M. **Semin Perinatol** 1997 Apr;21(2):135–42 (64 ref.)

ANALOGS & DERIVATIVES

A new metabolite of retinol: all–trans–4–oxo–retinol as a receptor activator and differentiation agent. Ross SA, et al. **Nutr Rev** 1996 Nov;54(11 Pt 1):355–6 (10 ref.)

ANALYSIS

Plant sources of vitamin A and human nutrition: renewed strategies. **Nutr Rev** 1996 Mar;54(3):89–91 (15 ref.)

BLOOD

Importance of adequate vitamin A status during iron supplementation. Ribaya–Mercado JD. **Nutr Rev** 1997 Aug; 55(8):306–7 (13 ref.)

IMMUNOLOGY

Vitamin A and human immunodeficiency virus infection. Semba RD. **Proc Nutr Soc** 1997 Mar;56(1B):459–69 (57 ref.)

METABOLISM

Quantitative and conceptual contributions of mathematical modeling to current views on vitamin A metabolism, biochemistry, and nutrition. Green MH, et al. **Adv Food Nutr Res** 1996;40:3–24 (29 ref.)
The molecular basis of signaling by vitamin A and its metabolites. Evans RM. **Harvey Lect** 1994–95;90:105–17 (42 ref.)
Retinoyl beta–glucuronide: a biologically active form of vitamin A. Barua AB. **Nutr Rev** 1997 Jul;55(7):259–67 (76 ref.)

PHARMACOKINETICS

Bioavailability of vitamin A. Biesalski HK. **Eur J Clin Nutr** 1997 Jan;51 Suppl 1:S71–5 (40 ref.)
Plant sources of vitamin A and human nutrition: renewed strategies. **Nutr Rev** 1996 Mar;54(3):89–91 (15 ref.)

PHARMACOLOGY

Retinol (vitamin A) supplements in the elderly. Ward BJ. **Drugs Aging** 1996 Jul;9(1):48–59 (151 ref.)

PHYSIOLOGY

Vitamin A—functions, dietary requirements and safety in humans. Gerster H. **Int J Vitam Nutr Res** 1997;67(2):71–90 (142 ref.)
Vitamin A, visual pigments, and visual receptors in Drosophila. Lee RD, et al. **Microsc Res Tech** 1996 Dec 15;35(6):418–30 (96 ref.)
Retinoids and the visual process. Crouch RK, et al. **Photochem Photobiol** 1996 Oct;64(4):613–21 (113 ref.)

THERAPEUTIC USE

Overview of the potential role of vitamin A in mother–to–child transmission of HIV–1. Semba RD. **Acta Paediatr Suppl** 1997 Jun;421:107–12 (29 ref.)
Clinical problems in measles case management. Hussey GD, et al. **Ann Trop Paediatr** 1996 Dec;16(4):307–17 (69 ref.)

VITAMIN A ACID

VITAMIN A ACID see **TRETINOIN**

VITAMIN A ALDEHYDE see **RETINALDEHYDE**

VITAMIN A DEFICIENCY

COMPLICATIONS

Overview of the potential role of vitamin A in mother-to-child transmission of HIV-1. Semba RD. **Acta Paediatr Suppl** 1997 Jun;421:107-12 (29 ref.)

Vitamin A and human immunodeficiency virus infection. Semba RD. **Proc Nutr Soc** 1997 Mar;56(1B):459-69 (57 ref.)

DIAGNOSIS

Vitamin A intake and status. van den Berg H. **Eur J Clin Nutr** 1996 Jul;50 Suppl 3:S7-12 (43 ref.)

DRUG THERAPY

Safety aspects of vitamin A administration. Chytil F. **Eur J Clin Nutr** 1996 Jul;50 Suppl 3:S21-3 (20 ref.)

METABOLISM

Interaction of iron with other nutrients. Lynch SR. **Nutr Rev** 1997 Apr;55(4):102-10 (92 ref.)

PREVENTION & CONTROL

Dietary carotenoids and their role in combating vitamin A deficiency: a review of the literature. de Pee S, et al. **Eur J Clin Nutr** 1996 Jul;50 Suppl 3:S38-53 (99 ref.)

Meta-analyses/meta-projects: a small but relevant contribution by Sight and Life to the prevention of vitamin A deficiency. Frigg M. **Eur J Clin Nutr** 1996 Jul;50 Suppl 3:S68-9 (7 ref.)

VITAMIN B 1 see **THIAMINE**

VITAMIN B 2 see **RIBOFLAVIN**

VITAMIN B 6 see **PYRIDOXINE**

VITAMIN B 12

see related
SCHILLING TEST

ADVERSE EFFECTS

Sensitivity reaction to parenteral vitamin B12: recurrence of symptoms after Marmite ingestion [letter] Denis R, et al. **Clin Lab Haematol** 1996 Jun;18(2):129-31 (11 ref.)

ANALOGS & DERIVATIVES

The reactivity of B12 cofactors: the proteins make a difference. Ludwig ML, et al. **Structure** 1996 May 15; 4(5).505-12 (42 ref.)

BIOSYNTHESIS

Cobalamin (coenzyme B12): synthesis and biological significance. Roth JR, et al. **Annu Rev Microbiol** 1996; 50:137-81 (175 ref.)

Biochemistry and molecular genetics of cobalamin biosynthesis. Rondon MR, et al. **Prog Nucleic Acid Res Mol Biol** 1997;56:347-84 (193 ref.)

CHEMISTRY

Structure-based perspectives on B12-dependent enzymes. Ludwig ML, et al. **Annu Rev Biochem** 1997;66:269-313 (155 ref.)

GENETICS

Biochemistry and molecular genetics of cobalamin biosynthesis. Rondon MR, et al. **Prog Nucleic Acid Res Mol Biol** 1997;56:347-84 (193 ref.)

METABOLISM

The Yin-Yang of cobalamin biochemistry. Banerjee R. **Chem Biol** 1997 Mar;4(3):175-86 (90 ref.)

Cobalamin. Markle HV. **Crit Rev Clin Lab Sci** 1996; 33(4):247-356 (327 ref.)

[Absorption test of vitamin] Nakamura T. **Nippon Rinsho** 1997 Apr;55 Suppl 2:113-4 (7 ref.) **(Jpn)**

PHARMACOKINETICS

Bioavailability of vitamin B12. Scott JM. **Eur J Clin Nutr** 1997 Jan;51 Suppl 1:S49-53 (41 ref.)

THERAPEUTIC USE

Vitamin B12 replacement. To B12 or not to B12? Delva MD. **Can Fam Physician** 1997 May;43:917-22 (25 ref.)

VITAMIN B 12 COENZYMES see **COBAMIDES**

VITAMIN B 12 DEFICIENCY

BLOOD

[Blood and urinary level of methylmalonic acid: an important index in evaluating cobalamin deficiency] Sela BA, et al. **Harefuah** 1997 Jun 15;132(12):866-71 (30 ref.) **(Heb)**

COMPLICATIONS

Persistence of neurological damage induced by dietary vitamin B-12 deficiency in infancy. von Schenck U, et al. **Arch Dis Child** 1997 Aug;77(2):137-9 (20 ref.)

Anemia secondary to combined deficiencies of iron and cobalamin. Hash RB, et al. **Arch Fam Med** 1996 Nov-Dec; 5(10):585-8 (25 ref.)

Folate, vitamin B12, and neuropsychiatric disorders. Bottiglieri T. **Nutr Rev** 1996 Dec;54(12):382-90 (59 ref.)

[Atrophy of the oro-pharyngeal mucosa caused by vitamin B12 and folic acid deficiency. Etiopathologic aspects and clinico-therapeutic problems] Bottero A, et al. **Minerva Stomatol** 1997 Jul-Aug;46(7-8):359-74 (99 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Anemia secondary to combined deficiencies of iron and cobalamin. Hash RB, et al. **Arch Fam Med** 1996 Nov-Dec; 5(10):585-8 (25 ref.)

Vitamin B12 replacement. To B12 or not to B12? Delva MD. **Can Fam Physician** 1997 May;43:917-22 (25 ref.)

[Blood and urinary level of methylmalonic acid: an important index in evaluating cobalamin deficiency] Sela BA, et al. **Harefuah** 1997 Jun 15;132(12):866-71 (30 ref.) **(Heb)**

DRUG THERAPY

Vitamin B12 replacement. To B12 or not to B12? Delva MD. **Can Fam Physician** 1997 May;43:917-22 (25 ref.)

Sensitivity reaction to parenteral vitamin B12: recurrence of symptoms after Marmite ingestion [letter] Denis R, et al. **Clin Lab Haematol** 1996 Jun;18(2):129-31 (11 ref.)

PHYSIOPATHOLOGY

Cobalamin. Markle HV. **Crit Rev Clin Lab Sci** 1996; 33(4):247-356 (327 ref.)

VITAMIN B COMPLEX

THERAPEUTIC USE

B-complex vitamins in the prophylaxis and treatment of Wernicke-Korsakoff syndrome. Cook CC, et al. **Br J Hosp Med** 1997 May 7-20;57(9):461-5 (45 ref.)

VITAMIN B T see **CARNITINE**

VITAMIN C see **ASCORBIC ACID**

VITAMIN C DEFICIENCY see **ASCORBIC ACID DEFICIENCY**

VITAMIN D

see related
RECEPTORS, CALCITRIOL

Nutritional aspects of calcium and vitamin D from infancy to adolescence. Saggese G, et al. **Ann Ist Super Sanita** 1995; 31(4):461-79 (116 ref.)

Diagnostic and therapeutic aspects of calciotropic hormones. Cormier C, et al. **Curr Opin Rheumatol** 1997 Jul;9(4):370-6 (40 ref.)

[Nutritional and biochemical studies on vitamin D and its active derivatives] Kobayashi T. **Yakugaku Zasshi** 1996 Jun;116(6):457-72 (29 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Calcium and vitamin D in the prevention and treatment of osteoporosis. Orcel P. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):70S-74S (50 ref.)

ANALOGS & DERIVATIVES

Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 8. Vitamin D metabolites and analogs in the treatment of osteoporosis. Jones G, et al. **Can Med Assoc J** 1996 Oct 1;155(7):955-61 (47 ref.)

Vitamin D analogues in insulin-dependent diabetes mellitus and other autoimmune diseases: a therapeutic perspective. Mauricio D, et al. **Diabetes Metab Rev** 1996 Apr; 12(1):57-68 (87 ref.)

Nonhypercalcemic vitamin D analogs: interactions with the vitamin D-binding protein. Bouillon R, et al. **Horm Res** 1996;45(3-5):117-21 (20 ref.)

Vitamin D analogues and psoriasis. Stewart DG, et al. **J Clin Pharm Ther** 1996 Jun;21(3):143-8 (53 ref.)

New vitamin D analogues. Posner GH. **Nephrol Dial Transplant** 1996;11 Suppl 3:32-6 (37 ref.)

[Basic aspects of osteoporosis therapy with active vitamin D metabolites] Schacht E. **Med Klin** 1996 Feb 15;91 Suppl 1:34-7 (17 ref.) **(Ger)**

BLOOD

Measurement of vitamin D and its metabolites (calcidiol and calcitriol) and their clinical significance. Schmidt-Gayk H, et al. **Scand J Clin Lab Invest Suppl** 1997;227:35-45 (36 ref.)

IMMUNOLOGY

Interactions between magnesium and vitamin D: possible implications in the immune system. McCoy H, et al. **Magnes Res** 1996 Oct;9(3):185-203 (196 ref.)

METABOLISM

Osteomalacia. Francis RM, et al. **Baillieres Clin Endocrinol Metab** 1997 Apr;11(1):145-63 (70 ref.)

Control of nuclear transcription of vitamin D-dependent genes by vitamin D. Perret C, et al. **Curr Opin Nephrol Hypertens** 1997 Jul;6(4):314-20 (65 ref.)

Interactions between magnesium and vitamin D: possible implications in the immune system. McCoy H, et al. **Magnes Res** 1996 Oct;9(3):185-203 (196 ref.)

Vitamin D metabolite-mediated hypercalcemia in Wegener's granulomatosis. Bosch X, et al. **Mayo Clin Proc** 1997 May; 72(5):440-4 (21 ref.)

PHARMACOKINETICS

Bioavailability of vitamin D. van den Berg H. **Eur J Clin Nutr** 1997 Jan;51 Suppl 1:S76-9 (40 ref.)

Vitamin D insufficiency as a determinant of hip fractures. Quesada-Gómez JM, et al. **Osteoporos Int** 1996;6 Suppl 3:42-7 (75 ref.)

PHARMACOLOGY

Control of nuclear transcription of vitamin D-dependent genes by vitamin D. Perret C, et al. **Curr Opin Nephrol Hypertens** 1997 Jul;6(4):314-20 (65 ref.)

Toward therapeutic intervention of cancer by vitamin D compounds [editorial; comment] Campbell MJ, et al. **J Natl Cancer Inst** 1997 Feb 5;89(3):182-5 (50 ref.) Comment on: J Natl Cancer Inst 1997 Feb 5;89(3):212-8.

PHYSIOLOGY

Alcohol, osteoporosis, and bone regulating hormones. Sampson HW. **Alcohol Clin Exp Res** 1997 May;21(3):400-3 (45 ref.)

The role of vitamin D in the pathogenesis and treatment of osteoporosis. Gallagher JC. **J Rheumatol Suppl** 1996 Aug;45:15-8 (25 ref.)

Calcium, phosphate, vitamin D, and the parathyroid. Marks KH, et al. **Pediatr Nephrol** 1996 Jun;10(3):364-7 (32 ref.)

THERAPEUTIC USE

Therapy of osteoporosis: calcium, vitamin D, and exercise. Reid IR. **Am J Med Sci** 1996 Dec;312(6):278-86 (74 ref.)

Metabolic bone disease of prematurity. Backström MC, et al. **Ann Med** 1996 Aug;28(4):275-82 (73 ref.)

Is there a differential response to alfacalcidol and vitamin D in the treatment of osteoporosis? Francis RM. **Calcif Tissue Int** 1997 Jan;60(1):111-4 (43 ref.)

Vitamin D analogs: from renal bone disease to osteoporosis. Kanis JA. **Calcif Tissue Int** 1997 Jan;60(1):106-10 (42 ref.)

The importance of genetic and nutritional factors in responses to vitamin D and its analogs in osteoporotic patients. Nakamura T. **Calcif Tissue Int** 1997 Jan;60(1):119-23 (38 ref.)

The potential use of vitamin D analogs in the treatment of cancer. Ogata E. **Calcif Tissue Int** 1997 Jan;60(1):130-3 (9 ref.)

Active vitamin D metabolites in glucocorticoid-induced osteoporosis. Ringe JD. **Calcif Tissue Int** 1997 Jan; 60(1):124-7 (47 ref.)

Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 8. Vitamin D metabolites and analogs in the treatment of osteoporosis. Jones G, et al. **Can Med Assoc J** 1996 Oct 1;155(7):955-61 (47 ref.)

Vitamin D analogues in insulin-dependent diabetes mellitus and other autoimmune diseases: a therapeutic perspective. Mauricio D, et al. **Diabetes Metab Rev** 1996 Apr; 12(1):57-68 (87 ref.)

Vitamin D deficiency and osteoporosis: the role of vitamin D deficiency and treatment with vitamin D and analogues in the prevention of osteoporosis-related fractures. Lips P. **Eur J Clin Invest** 1996 Jun;26(6):436-42 (50 ref.)

Vitamin-D dependent rickets type II. Mishra S, et al. **Indian Pediatr** 1996 Apr;33(4):334-6 (15 ref.)

Vitamin D analogues and psoriasis. Stewart DG, et al. **J Clin Pharm Ther** 1996 Jun;21(3):143-8 (53 ref.)

VITAMIN D 2 see **ERGOCALCIFEROLS**

VITAMIN D 3 see **CHOLECALCIFEROL**

VITAMIN D 3 RECEPTORS see **RECEPTORS, CALCITRIOL**

VITAMIN D-BINDING GLOBULIN see **VITAMIN D-BINDING PROTEIN**

VITAMIN D-BINDING PROTEIN

METABOLISM

Nonhypercalcemic vitamin D analogs: interactions with the vitamin D-binding protein. Bouillon R, et al. **Horm Res** 1996;45(3-5):117-21 (20 ref.)

VITAMIN D DEFICIENCY

see related
RICKETS

COMPLICATIONS

Osteomalacia. Francis RM, et al.
Baillieres Clin Endocrinol Metab 1997 Apr;11(1):145–63 (70 ref.)
Vitamin D deficiency and osteoporosis: the role of vitamin D deficiency and treatment with vitamin D and analogues in the prevention of osteoporosis–related fractures. Lips P. **Eur J Clin Invest** 1996 Jun;26(6):436–42 (50 ref.)
How important is vitamin D deficiency in uraemia? [editorial] Cunningham J, et al. **Nephrol Dial Transplant** 1997 Jan; 12(1):16–8 (19 ref.)
Vitamin D insufficiency as a determinant of hip fractures. Quesada–Gómez JM, et al. **Osteoporos Int** 1996;6 Suppl 3:42–7 (75 ref.)

VITAMIN D–DEPENDENT CALCIUM–BINDING PROTEIN see **CALCIUM–BINDING PROTEIN, VITAMIN D–DEPENDENT**

VITAMIN D RECEPTORS see **RECEPTORS, CALCITRIOL**

VITAMIN DEFICIENCY see **AVITAMINOSIS**

VITAMIN E

Beta–carotene, vitamin C, and vitamin E: the protective micronutrients. Charleux JL. **Nutr Rev** 1996 Nov;54(11 Pt 2):S109–14 (28 ref.)
Vitamins C and E and LDL oxidation. Frei B, et al. **Vitam Horm** 1996;52:1–34 (122 ref.)

ADMINISTRATION & DOSAGE

Vitamin E in humans: demand and delivery. Traber MG, et al. **Annu Rev Nutr** 1996;16:321–47 (158 ref.)
Rationale for the introduction of long chain polyunsaturated fatty acids and for concomitant increase in the level of vitamin E in infant formulas. Bendich A, et al. **Int J Vitam Nutr Res** 1997;67(4):213–31 (98 ref.)
Vitamin E and human health: rationale for determining recommended intake levels. Weber P, et al. **Nutrition** 1997 May;13(5):450–60 (104 ref.)
[Is supplemental vitamin E for prevention of coronary heart disease ov value?] Thiery J, et al. **Internist (Berl)** 1997 Feb; 38(2):168–76; discussion 176 (39 ref.) **(Ger)**

ANALOGS & DERIVATIVES

Tretinoin tocoferil as a possible differentiation–inducing agent against myelomonocytic leukemia. Makishima M, et al. **Leuk Lymphoma** 1997 Jun;26(1–2):43–8 (55 ref.)

BLOOD

Regulation of human plasma vitamin E. Traber MG. **Adv Pharmacol** 1997;38:49–63 (81 ref.)

CHEMISTRY

The chemistry and antioxidant properties of tocopherols and tocotrienols. Kamal–Eldin A, et al. **Lipids** 1996 Jul; 31(7):671–701 (324 ref.)

METABOLISM

[Nutritional biochemical aspects of the significance, of the utilization, of metabolism and of the administration of vitamin E and of selenium in sheep (review)] Kolb E, et al. **Berl Munch Tierarztl Wochenschr** 1997 May; 110(5):178–84 (48 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOKINETICS

Bioavailability of vitamin E. Cohn W. **Eur J Clin Nutr** 1997 Jan;51 Suppl 1:S80–5 (61 ref.)

PHARMACOLOGY

The mutual sparing effects of selenium and vitamin E in animal nutrition may be further explained by the discovery that mammalian thioredoxin reductase is a selenoenzyme. Tamura T, et al. **Biofactors** 1995–96;5(2):99–102 (42 ref.)
Inhibition by vitamins C and E of in vivo nitrosation and vitamin C occurrence in the stomach. Mirvish SS. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:131–6 (37 ref.)
Dietary vitamin E and selenium affect mastitis and milk quality. Smith KL, et al. **J Anim Sci** 1997 Jun;75(6):1659–65 (54 ref.)
Tocopherols and the etiology of colon cancer. Stone WL, et al. **J Natl Cancer Inst** 1997 Jul 16;89(14):1006–14 (95 ref.)
Importance of dietary fat in modulating PGE2 responses and influence of vitamin E on bone morphometry. Watkins BA, et al. **World Rev Nutr Diet** 1997;82:250–9 (30 ref.)
[Effect of vitamin E on the endothelial function of the regenerated aorta in rats following direct arterial injury] Cartier R, et al. **Ann Chir** 1996;50(8):673–81 (36 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Microcirculation, vitamin E and omega 3 fatty acids: an overview. Bruckner G. **Adv Exp Med Biol** 1997; 415:195–208 (104 ref.)
Will the 'good fairies' please prove to us that vitamin E lessens human degenerative disease? Diplock AT. **Free Radic Res** 1997 Jun;26(6):565–83 (85 ref.)

THERAPEUTIC USE

Is it time to say yes to antioxidants? Kuritzky L. **Hosp Pract (Off Ed)** 1996 Sep 15;31(9):96, 99–100 (12 ref.)
Vitamin E and breast cancer: a review. Kimmick GG, et al. **Nutr Cancer** 1997;27(2):109–17 (60 ref.)
Antioxidant vitamins and cardiovascular disease. Buring JE, et al. **Nutr Rev** 1997 Jan;55(1 Pt 2):S53–8; discussion S58–60 (42 ref.)
Update on dietary antioxidants and cancer. Gaziano JM, et al. **Pathol Biol (Paris)** 1996 Jan;44(1):42–5 (15 ref.)
A closer look at vitamin E. Can this antioxidant prevent chronic diseases? Meydani M, et al. **Postgrad Med** 1997 Aug;102(2):199–201, 206–7 (22 ref.)
[Neuroprotective and neurorestorative therapy in Parkinson's disease] Jiménez–Jiménez FJ, et al. **Rev Neurol** 1997 Aug; 25 Suppl 2:S185–93 (207 ref.) (Eng. Abstr.) **(Spa)**

VITAMIN E DEFICIENCY

COMPLICATIONS

Neurologic findings in vitamin E deficiency. Tanyel MC, et al. **Am Fam Physician** 1997 Jan;55(1):197–201 (15 ref.)
Interacting nutritional and infectious etiologies of Keshan disease. Insights from coxsackie virus B–induced myocarditis in mice deficient in selenium or vitamin E. Levander OA, et al. **Biol Trace Elem Res** 1997 Jan; 56(1):5–21 (75 ref.)

VIROLOGY

Increased virulence of coxsackievirus B3 in mice due to vitamin E or selenium deficiency. Beck MA. **J Nutr** 1997 May;127(5 Suppl):966S–970S (12 ref.)

VITAMIN G see **RIBOFLAVIN**

VITAMIN H see **BIOTIN**

VITAMIN K

ANTAGONISTS & INHIBITORS

[Antithrombotic therapy of atrial fibrillation] Chalon S, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1533–42 (47 ref.) (Eng. Abstr.) **(Fre)**
[Antithrombotic therapy in patients with mechanical valve prostheses] Roudaut R, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1543–50 (30 ref.) (Eng. Abstr.) **(Fre)**
[Biological monitoring and prevention of complications from antithrombotic agents] Samama MM, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1569–77 (28 ref.) (Eng. Abstr.) **(Fre)**
[Anticoagulants and platelet aggregation inhibitors in urology] Verdy E. **Prog Urol** 1997 Apr;7(2):326–32 (4 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Vitamin K–dependent protein production in transgenic animals. Luboń H, et al. **Thromb Haemost** 1997 Jul; 78(1):532–6 (65 ref.)

PHYSIOLOGY

Skeletal functions of vitamin K–dependent proteins: not just for clotting anymore. Booth SL. **Nutr Rev** 1997 Jul; 55(7):282–4 (15 ref.)

VITAMIN K 1 see **PHYTONADIONE**

VITAMIN K–DEPENDENT BONE PROTEIN see **OSTEOCALCIN**

VITAMIN K–DEPENDENT PROTEIN S see **PROTEIN S**

VITAMIN K REDUCTASE see **NAD(P)H DEHYDROGENASE (QUINONE)**

VITAMIN M see **FOLIC ACID**

VITAMIN P COMPLEX see **BIOFLAVONOIDS**

VITAMIN PP see **NIACINAMIDE**

VITAMINS

Vitamins and immunomodulation in AIDS. Liang B, et al. **Nutrition** 1996 Jan;12(1):1–7 (91 ref.)
Antioxidant vitamins and human immune responses. Bendich A. **Vitam Horm** 1996;52:35–62 (104 ref.)

ADMINISTRATION & DOSAGE

Antioxidant vitamins in the prevention of cardiovascular disease. The epidemiological evidence. Price JE, et al. **Eur Heart J** 1997 May;18(5):719–27 (59 ref.)
Vitamin requirements: present recommendations and future prospects. Giacosa A, et al. **Eur J Cancer Prev** 1997 Mar; 6 Suppl 1:S79–81 (10 ref.)
Vitamin supplementation in the elderly: a critical evaluation. Buchman AL. **Gastroenterologist** 1996 Dec;4(4):262–75 (181 ref.)
Antioxidants in health and disease [see comments] Cheraskin E. **J Am Optom Assoc** 1996 Jan;67(1):50–7 (50 ref.) Comment in: J Am Optom Assoc 1996 Jan;67(1):6–10.
Vitamin and mineral supplement prior to and during pregnancy. Menard MK. **Obstet Gynecol Clin North Am** 1997 Sep;24(3):479–98 (21 ref.)
[Periconceptional multivitamin administration result in reduction of congenital abnormalities: adequate evidence for formulating national recommendations for Germany?] Hort A, et al. **Gesundheitswesen** 1997 Apr;59(4):248–51 (20 ref.) (Eng. Abstr.) **(Ger)**
[Relationship of vitamins and microelements and their role in the prevention of iron deficiencies (review)] Nasolodin VV, et al. **Gig Sanit** 1996 Nov–Dec;(6):26–9 (41 ref.) **(Rus)**

ADVERSE EFFECTS

Nutritional supplements and surgical patients. Petry JJ. **AORN J** 1997 Jun;65(6):1117–21 (20 ref.)

ANALYSIS

Sweeteners, dyes, and other excipients in vitamin and mineral preparations. Kumar A, et al. **Clin Pediatr (Phila)** 1996 Sep; 35(9):443–50 (28 ref.)
Vitamin nutritional status in Italy. Maiani G, et al. **Eur J Cancer Prev** 1997 Mar;6 Suppl 1:S3–9 (56 ref.)

BIOSYNTHESIS

Intestinal flora and endogenous vitamin synthesis. Hill MJ. **Eur J Cancer Prev** 1997 Mar;6 Suppl 1:S43–5 (10 ref.)

IMMUNOLOGY

Trace elements and vitamins in immunomodulation in infancy and childhood. Zuin G, et al. **Eur J Cancer Prev** 1997 Mar; 6 Suppl 1:S69–77 (50 ref.)

METABOLISM

Olestra: assessing its potential to interact with drugs in the gastrointestinal tract. Goldman P. **Clin Pharmacol Ther** 1997 Jun;61(6):613–8 (39 ref.)
Hormone, growth factor, and vitamin handling by proximal tubule cells. Christensen EI, et al. **Curr Opin Nephrol Hypertens** 1997 Jan;6(1):20–7 (134 ref.)
Exercise, free radical generation and vitamins. Giuliani A, et al. **Eur J Cancer Prev** 1997 Mar;6 Suppl 1:S55–67 (163 ref.)
Vitamins as antimutagens: advantages and some possible mechanisms of antimutagenic action. Odin AP. **Mutat Res** 1997 Mar;386(1):39–67 (180 ref.)
Impact of disease on markers of micronutrient status. Thurnham DI. **Proc Nutr Soc** 1997 Mar;56(1B):421–31 (66 ref.)
[Absorptive mechanism of vitamins, lipids and bile acid] Miura S, et al. **Nippon Naika Gakkai Zasshi** 1996 Jul 10; 85(7):1042–7 (5 ref.) **(Jpn)**
[Signal transduction of steroids and vitamins mediated by nuclear receptor proteins] Umesono K. **Tanpakushitsu Kakusan Koso** 1996 Jun;41(8 Suppl):1265–72 (37 ref.) **(Jpn)**
[Vitamin disturbances in chronic renal insufficiency. I. Water soluble vitamins] Pietrzak I. **Przegl Lek** 1995;52(10):522–5 (20 ref.) (Eng. Abstr.) **(Pol)**

PHARMACOKINETICS

Bioavailability of oral vitamins, minerals, and trace elements in perspective. Schümann K, et al. **Arzneimittelforschung** 1997 Apr;47(4):369–80 (73 ref.)

PHARMACOLOGY

Vitamins and cancer. van Poppel G, et al. **Cancer Lett** 1997 Mar 19;114(1–2):195–202 (49 ref.)
The role of vitamins in the pathogenesis and treatment of hyperhomocyst(e)inaemia. Ubbink JB. **J Inherit Metab Dis** 1997 Jun;20(2):316–25 (48 ref.)
Vitamins as antimutagens: advantages and some possible mechanisms of antimutagenic action. Odin AP. **Mutat Res** 1997 Mar;386(1):39–67 (180 ref.)

PHYSIOLOGY

The role of hormones, growth factors and vitamins in carcinogenesis. Lupulescu A. **Crit Rev Oncol Hematol** 1996 Jun;23(2):95–130 (355 ref.)
Iodine metabolism and thyroid–related functions in organisms lacking thyroid follicles: are thyroid hormones also vitamins? Eales JG. **Proc Soc Exp Biol Med** 1997 Apr; 214(4):302–17 (195 ref.)

THERAPEUTIC USE

Vitamins and minerals: efficacy and safety. Hathcock JN. **Am J Clin Nutr** 1997 Aug;66(2):427–37 (152 ref.)

VITAMINS

Hormones, vitamins, and growth factors in cancer treatment and prevention. A critical appraisal. Lupulescu AP. **Cancer** 1996 Dec 1;78(11):2264–80 (131 ref.)
Vitamins and cancer. van Poppel G, et al. **Cancer Lett** 1997 Mar 19;114(1–2):195–202 (49 ref.)
Vitamins and cancer chemoprevention. Giacosa A, et al. **Eur J Cancer Prev** 1997 Mar;6 Suppl 1:S47–54 (68 ref.)
Micronutrients (vitamins and minerals) as cancer–preventive agents. Omenn GS. **IARC Sci Publ** 1996;(139):33–45 (55 ref.)
Antioxidant vitamins and health. Gibaldi M. **J Clin Pharmacol** 1996 Dec;36(12):1093–9 (36 ref.)
Antioxidants in cardiovascular disease: randomized trials. Gaziano JM. **Nutrition** 1996 Sep;12(9):583–8 (59 ref.)
The effects of oral vitamin supplementation on cardiovascular risk factors. Woodside JV, et al. **Proc Nutr Soc** 1997 Mar; 56(1B):479–88 (77 ref.)
Novel therapies for advanced prostate cancer. Konety BR, et al. **Semin Urol Oncol** 1997 Feb;15(1):33–42 (80 ref.)
The role of antioxidant vitamins and enzymes in the prevention of exercise–induced muscle damage. Dekkers JC, et al. **Sports Med** 1996 Mar;21(3):213–38 (62 ref.)
[Value of antioxidants and vitamins in cardiovascular prevention and therapy] Wascher TC. **Wien Klin Wochenschr Suppl** 1997;2:33–7 (26 ref.) (Eng. Abstr.) **(Ger)**

VITELLINE DUCT

ABNORMALITIES

Omphalomesenteric duct malformations. Moore TC. **Semin Pediatr Surg** 1996 May;5(2):116–23 (27 ref.)

VITILIGO

Vitiligo. Le Poole C, et al. **Semin Cutan Med Surg** 1997 Mar; 16(1):3–14 (86 ref.)

CHEMICALLY INDUCED

Chloroquine–induced vitiligo. A case report and review of the literature [letter] Selvaag E. **Acta Derm Venereol** 1996 Mar;76(2):166–7 (6 ref.)
Interferon–induced vitiligo in a patient with chronic viral hepatitis C infection. Simsek H, et al. **Dermatology** 1996; 193(1):65–6 (11 ref.)

COMPLICATIONS

Vitiligo coexistent with nevus depigmentosus. Kang IK, et al. **J Dermatol** 1996 Mar;23(3):187–90 (18 ref.)

DRUG THERAPY

Vitiligo, psoralen, and melanogenesis: some observations and understanding. Chakraborty DP, et al. **Pigment Cell Res** 1996 Jun;9(3):107–16 (90 ref.)

ETIOLOGY

Recent investigations on vitiligo vulgaris. Nordlund JJ, et al. **Dermatol Clin** 1997 Jan;15(1):69–78 (106 ref.)
Vitiligo following the resolution of psoriatic plaques during PUVA therapy. Halcin C, et al. **Int J Dermatol** 1997 Jul; 36(7):534–6 (11 ref.)
[Vitiligo] Njoo MD, et al. **Ned Tijdschr Geneeskd** 1997 Apr 19;141(16):759–64 (19 ref.) (Eng. Abstr.) **(Dut)**

PATHOLOGY

Vitiligo coexistent with nevus depigmentosus. Kang IK, et al. **J Dermatol** 1996 Mar;23(3):187–90 (18 ref.)

THERAPY

Recent investigations on vitiligo vulgaris. Nordlund JJ, et al. **Dermatol Clin** 1997 Jan;15(1):69–78 (106 ref.)

VITRECTOMY

The Silicone Study. A small piece of the PVR puzzle is put into place [editorial; comment] Campochiaro PA. **Arch Ophthalmol** 1997 Mar;115(3):407–8 (6 ref.) Comment on: Arch Ophthalmol 1997 Mar;115(3):335–44.
Management of idiopathic macular holes. Saxena S, et al. **Ophthalmic Surg Lasers** 1996 Jul;27(7):618–27 (71 ref.)
[Role of vitrectomy and intra–vitreous injections in the treatment of traumtic and iatrogenic endophthalmitis] Gribomont AC. **Bull Soc Belge Ophtalmol** 1996;260:93–9 (33 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Vitrectomy in ocular trauma. Claes C, et al. **Bull Soc Belge Ophtalmol** 1995;258:169–88 (59 ref.)
Surgery for idiopathic full–thickness macular holes. Gregor ZJ. **Eye** 1996;10 (Pt 6):685–90 (37 ref.)

VITREORETINOPATHY, PROLIFERATIVE

ETIOLOGY

Pathogenic mechanisms in proliferative vitreoretinopathy. Campochiaro PA. **Arch Ophthalmol** 1997 Feb; 115(2):237–41 (49 ref.)
Vitrectomy in ocular trauma. Claes C, et al. **Bull Soc Belge Ophtalmol** 1995;258:169–88 (59 ref.)
[Modern data on etiology and pathogenesis of posttraumatic proliferative vitreoretinopathy] Chichua GA, et al. **Vestn Oftalmol** 1997 May–Jun;113(3):43–4 (41 ref.) (Eng. Abstr.) **(Rus)**

SURGERY

The Silicone Study. A small piece of the PVR puzzle is put into place [editorial; comment] Campochiaro PA. **Arch Ophthalmol** 1997 Mar;115(3):407–8 (6 ref.) Comment on: Arch Ophthalmol 1997 Mar;115(3):335–44.
Vitrectomy in ocular trauma. Claes C, et al. **Bull Soc Belge Ophtalmol** 1995;258:169–88 (59 ref.)

VITREOUS BODY

see related
VITRECTOMY

The hazy vitreous in vasoproliferative diseases. Dralands L. **Bull Soc Belge Ophtalmol** 1995;258:113–63 (279 ref.)
Hereditary vitreopathy [see comments] Snead MP. **Eye** 1996; 10 (Pt 6):653–63 (102 ref.) Comment in: Eye 1996 ;10 (Pt 6):651–2.
Fluid vitreous substitutes in vitreo retinal surgery. Saxena S, et al. **Indian J Ophthalmol** 1996 Dec;44(4):191–206 (142 ref.)

ANATOMY & HISTOLOGY

Embryology—anatomy—developments and aging of the vitreous. Comhaire–Poutchinian Y. **Bull Soc Belge Ophtalmol** 1995;258:11–30 (94 ref.)

CHEMISTRY

The biochemical structure of mammalian vitreous [see comments] Bishop P. **Eye** 1996;10 (Pt 6):664–70 (48 ref.) Comment in: Eye 1996 ;10 (Pt 6):651–2.

PATHOLOGY

Idiopathic peripheral vitreous membranes. Marren SE. **Optom Vis Sci** 1996 Aug;73(8):562–8 (53 ref.)
Postsurgical hypotony: relationship to fistulization, inflammation, chorioretinal lesions, and the vitreous. Schubert HD. **Surv Ophthalmol** 1996 Sep–Oct;41(2):97–125 (331 ref.)
Optical explanation of the gradual disappearance of flying dots in posterior vitreous detachment. Serpetopoulos C. **Surv Ophthalmol** 1997 Jul–Aug;42(1):92–4 (5 ref.)

PHYSIOLOGY

[Aging of the vitreous body. Role of glycation and free radicals] Deguine V, et al. **Pathol Biol (Paris)** 1997 Apr; 45(4):321–30 (69 ref.) (Eng. Abstr.) **(Fre)**

VITREOUS HEMORRHAGE

Vitreous Hemorrhage. Spraul CW, et al. **Surv Ophthalmol** 1997 Jul–Aug;42(1):3–39 (420 ref.)

ETIOLOGY

Non traumatic and non vasoproliferative vitreous hemorrhages. Gribomont AC, et al. **Bull Soc Belge Ophtalmol** 1995;258:91–109 (100 ref.)
Hemorrhages in the vitreo–retinal interface: premacular hemorrhages. Tassignon MJ, et al. **Bull Soc Belge Ophtalmol** 1995;258:71–81 (50 ref.)
Vitreous hemorrhage as an ophthalmic complication of galactosemia. Levy HL, et al. **J Pediatr** 1996 Dec; 129(6):922–5 (15 ref.)
[Terson's syndrome which arose from ruptured right superior cerebellar artery aneurysm: a case report and 32 series investigations] Takeuchi T, et al. **No Shinkei Geka** 1997 Mar;25(3):259–64 (32 ref.) (Eng. Abstr.) **(Jpn)**

VITRONECTIN

METABOLISM

Constitutive and regulated expression of vitronectin. Seiffert D. **Histol Histopathol** 1997 Jul;12(3):787–97 (144 ref.)

PHYSIOLOGY

Thrombin regulation by physiological inhibitors: the role of vitronectin. Preissner KT, et al. **Semin Thromb Hemost** 1996;22(2):165–72 (78 ref.)

VIVISECTION

see related
ANIMAL WELFARE

VLA PROTEIN COMPLEX see **RECEPTORS, VERY LATE ANTIGEN**

VM–26 see **TENIPOSIDE**

VNTR see **MINISATELLITE REPEATS**

VNTR LOCI see **MINISATELLITE REPEATS**

VNTR REGION see **MINISATELLITE REPEATS**

VNTR SEQUENCES see **MINISATELLITE REPEATS**

VOCABULARY

Introduction. The investigation of lexical semantic representation in Alzheimer's disease. Henderson VW. **Brain Lang** 1996 Aug;54(2):179–83 (13 ref.)
Semantic category imprecision: a connectionist study of the boundaries of word meanings. Small SL. **Brain Lang** 1997 Apr;57(2):181–94 (31 ref.)

VOCABULARY, CONTROLLED

Nursing classification systems: necessary but not sufficient for representing "what nurses do" for inclusion in computer–based patient record systems [see comments] Henry SB, et al. **J Am Med Inform Assoc** 1997 May–Jun; 4(3):222–32 (48 ref.) Comment in: J Am Med Inform Assoc 1997 May–Jun;4(3):254–5.
How NIC describes MCH nursing. Eganhouse DJ, et al. **MCN Am J Matern Child Nurs** 1996 Sep–Oct;21(5):247–52 (22 ref.)
Review paper: coding systems in health care. Cimino JJ. **Methods Inf Med** 1996 Dec;35(4–5):273–84 (73 ref.)

VOCABULARY TESTS see **LANGUAGE TESTS**

VOCAL CORD PARALYSIS

Vocal cord dysfunction. Wood RP 2nd, et al. **J Allergy Clin Immunol** 1996 Sep;98(3):481–5 (26 ref.)
Labor analgesia and anesthesia in a patient with spinal muscular atrophy and vocal cord paralysis. A rare and unusual case report. Weston LA, et al. **Reg Anesth** 1996 Jul–Aug;21(4):350–4 (11 ref.)

ETIOLOGY

[A case of X–linked bulbospinal muscular atrophy with bilateral abductor vocal cord paralysis] Tomiyasu K, et al. **Rinsho Shinkeigaku** 1996 May;36(5):683–6 (20 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Congenital vocal cord paralysis with possible autosomal recessive inheritance: case report and review of the literature. Koppel R, et al. **Am J Med Genet** 1996 Aug 23;64(3):485–7 (14 ref.)

PHYSIOPATHOLOGY

Electromyographic evaluation of vocal cord disorders. Pototschnig C, et al. **Acta Otorhinolaryngol Belg** 1997; 51(2):99–104 (17 ref.)

SURGERY

Laryngeal framework surgery (thyroplasty) [editorial] Harries ML. **J Laryngol Otol** 1997 Feb;111(2):103–5 (14 ref.)

VOCAL CORDS

Neck failure in T2N0 squamous cell carcinoma of the true vocal cords: the Fox Chase experience and review of the literature. Fein DA, et al. **Am J Clin Oncol** 1997 Apr; 20(2):154–7 (17 ref.)
A rare case of laryngeal myxoma. Tsunoda K, et al. **J Laryngol Otol** 1997 Mar;111(3):271–3 (6 ref.)
[Photochemotherapy in the treatment of carcinoma of the vocal cords of early stage (Tis, T1)] Delbove H, et al. **Ann Otolaryngol Chir Cervicofac** 1996;113(3):155–61 (29 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Electromyographic evaluation of vocal cord disorders. Pototschnig C, et al. **Acta Otorhinolaryngol Belg** 1997; 51(2):99–104 (17 ref.)
Vocal cord dysfunction. Wood RP 2nd, et al. **J Allergy Clin Immunol** 1996 Sep;98(3):481–5 (26 ref.)
Vocal cord dysfunction presenting as acute asthma in a pediatric patient. Poirier MP, et al. **Pediatr Emerg Care** 1996 Jun;12(3):213–4 (14 ref.)

SURGERY

Speech outcomes after laryngeal cancer management. Simpson CB, et al. **Otolaryngol Clin North Am** 1997 Apr; 30(2):189–205 (71 ref.)
[A review of phonosurgery of voice and speech disorders. I. Surgery of the vocal cords] Milutinović Z. **Srp Arh Celok Lek** 1996 Jul–Aug;124(7–8):201–5 (59 ref.) (Eng. Abstr.) **(Scc)**

VOCAL FOLD see **VOCAL CORDS**

VOCALIZATION, ANIMAL

Functional anatomy of forebrain vocal control pathways in the budgerigar (Melopsittacus undulatus). Brauth SE, et

al. **Ann N Y Acad Sci** 1997 Jan 15;807:368–85 (32 ref.)
Audio-vocal learning in budgerigars. Hall WS, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:352–67 (58 ref.)
Neural correlates of sensitive periods in avian song learning. Nordeen KW. **Ann N Y Acad Sci** 1997 Jan 15;807:386–400 (109 ref.)
Affiliative processes and vocal development. Snowdon CT. **Ann N Y Acad Sci** 1997 Jan 15;807:340–51 (36 ref.)
The influence of surface atmospheric conditions on the range and area reached by animal vocalizations. Larom D, et al. **J Exp Biol** 1997 Feb;200 (Pt 3):421–31 (31 ref.)

DRUG EFFECTS

Assessment and treatment of excessive barking in the domestic dog. Juarbe-Díaz SV. **Vet Clin North Am Small Anim Pract** 1997 May; 27(3):515–32 (26 ref.)

PHYSIOLOGY

Bird song: of tone and tempo in the telencephalon. Mooney R, et al. **Curr Biol** 1997 May 1;7(5):R289–91 (10 ref.)
Functional anatomy of neural pathways contributing to the control of song production in birds. Wild JM. **Eur J Morphol** 1997 Oct;35(4):303–25 (153 ref.)
Midbrain and medullary regulation of respiration and vocalization. Davis PJ, et al. **Prog Brain Res** 1996; 107:315–25 (61 ref.)
A concept for the final common pathway of vocalization and lordosis behavior in the cat. VanderHorst VG, et al. **Prog Brain Res** 1996;107:327–42 (83 ref.)
Multiple regulators of ultrasonic vocalization in the infant rat [published erratum appears in Psychoneuroendocrinology 1996 Jul;21(5):501] Hofer MA. **Psychoneuroendocrinology** 1996 Feb;21(2):203–17 (72 ref.)
Assessment and treatment of excessive barking in the domestic dog. Juarbe-Díaz SV. **Vet Clin North Am Small Anim Pract** 1997 May; 27(3):515–32 (26 ref.)

VOCATIONAL EDUCATION

Competency beliefs and occupational role behavior among adolescents: explication of the personal causation construct. Henry AD, et al. **Am J Occup Ther** 1997 Apr;51(4):267–76 (80 ref.)

ECONOMICS

Two-generation programs: design, cost, and short-term effectiveness. St. Pierre RG, et al. **Future Child** 1995 Winter;5(3):76–93 (35 ref.)

ORGANIZATION & ADMINISTRATION

Turning job finders into job keepers. Hershey AM, et al. **Future Child** 1997 Spring;7(1):74–86 (39 ref.)
Alternative strategies for increasing employment. Nightingale DS, et al. **Future Child** 1997 Spring;7(1):52–64 (30 ref.)

VOCATIONAL REHABILITATION see **REHABILITATION, VOCATIONAL**

VOCATIONS see **OCCUPATIONS**

VOGT-KOYANAGI-HARADA SYNDROME see **UVEOMENINGOENCEPHALITIC SYNDROME**

VOICE

Behavioral and electrophysiological indices of voicing-cue discrimination: laterality patterns and development. Simos PG, et al. **Brain Lang** 1997 Mar;57(1):122–50 (84 ref.)
Speaker identification using time-delay HMEs. Chen K, et al. **Int J Neural Syst** 1996 Mar;7(1):29–43 (38 ref.)
CNN: a speaker recognition system using a cascaded neural network [letter] Zaki M, et al. **Int J Neural Syst** 1996 May; 7(2):203–12 (29 ref.)

PHYSIOLOGY

Aerodynamic measurements of voice production. Raes JP, et al. **Acta Otorhinolaryngol Belg** 1996;50(4):293–8 (22 ref.)
ALBERT: a real-time visual feedback computer tool for professional vocal development. Rossiter D, et al. **J Voice** 1996 Dec;10(4):321–36 (79 ref.)

VOICE DISORDERS

Care of the professional voice. Irving RM, et al. **Clin Otolaryngol** 1997 Jun;22(3):202–5 (23 ref.)
Voice disorders in children. Gray SD, et al. **Pediatr Clin North Am** 1996 Dec;43(6):1357–84 (147 ref.)

CLASSIFICATION

Classification of voice pathology. Milutinović Z. **Folia Phoniatr Logop** 1996;48(6):301–8 (12 ref.)

DIAGNOSIS

The perceptual evaluation of voice disorders. De Bodt MS, et al. **Acta Otorhinolaryngol Belg** 1996;50(4):283–91 (40 ref.)
Ventricular dysphonia: a case of false vocal fold mucosal traveling wave. Nasri S, et al. **Am J Otolaryngol** 1996 Nov-Dec;17(6):427–31 (12 ref.)

ETIOLOGY

High tracheostomy and other errors—revisited. Bennett JD. **J Laryngol Otol** 1996 Nov;110(11):1003–7 (31 ref.)
Closed rhinolalia as a symptom of pneumomediastinum after tonsillectomy: a case report and literature review. Braverman I, et al. **Otolaryngol Head Neck Surg** 1997 Apr; 116(4):551–3 (14 ref.)
[Quality assurance in phoniatrics. Recommendation for standardization of clinical voice evaluation (see comments)] Friedrich G. **HNO** 1996 Jul;44(7):401–16 (65 ref.) Comment in: HNO 1996 Aug;44(8):423. **(Ger)**

PHYSIOPATHOLOGY

Phonetography in voice diagnoses. Heylen LG, et al. **Acta Otorhinolaryngol Belg** 1996;50(4):299–308 (54 ref.)
[Phoniatric aspects of oropharyngeal dysphagia in diagnosis and therapy] Denk DM. **HNO** 1996 Jun;44(6):339–53 (87 ref.) **(Ger)**

PSYCHOLOGY

[Psychogenic dysphonia] Urrutikoetxea Sarriegui A, et al. **An Otorrinolaringol Ibero Am** 1996;23(4):401–14 (24 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

[A review of phonosurgery of voice and speech disorders. I. Surgery of the vocal cords] Milutinović Z. **Srp Arh Celok Lek** 1996 Jul-Aug;124(7–8):201–5 (59 ref.) (Eng. Abstr.) **(Scc)**
[A review of phonosurgery of voice and speech disorders. II. Surgery other than on the vocal cords] Milutinović Z. **Srp Arh Celok Lek** 1996 Jul-Aug;124(7–8):206–9 (52 ref.) (Eng. Abstr.) **(Scc)**

VOICE PROSTHESIS see **LARYNX, ARTIFICIAL**

VOICE QUALITY

The perceptual evaluation of voice disorders. De Bodt MS, et al. **Acta Otorhinolaryngol Belg** 1996;50(4):283–91 (40 ref.)
Classification of voice pathology. Milutinović Z. **Folia Phoniatr Logop** 1996;48(6):301–8 (12 ref.)
[Familial vocal patrimony] Dalléas B. **Rev Laryngol Otol Rhinol (Bord)** 1996;117(4):319–22 (37 ref.) (Eng. Abstr.) **(Fre)**
[The voice of the child, morphological evolution of the larynx and its acoustic consequences] Woisard V, et al. **Rev Laryngol Otol Rhinol (Bord)** 1996;117(4):313–7 (18 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

The aging voice. Mueller PB. **Semin Speech Lang** 1997 May; 18(2):159–68; quiz 168–9 (50 ref.)

VOICE TRAINING

The role of the speech and language therapist in voice restoration after laryngectomy [editorial] Perry A. **J Laryngol Otol** 1997 Jan;111(1):4–7 (33 ref.)

VOLCANIC ASH see **VOLCANIC ERUPTION**

VOLCANIC ERUPTION

Chemical and physical context for life in terrestrial hydrothermal systems: chemical reactors for the early development of life and hydrothermal ecosystems. Henley RW. **Ciba Found Symp** 1996;202:61–76; discussion 76–82 (40 ref.)

VOLCANIC GASES see **VOLCANIC ERUPTION**

VOLITION

Planning, preparation, execution, and imagery of volitional action. Deecke L. **Brain Res Cogn Brain Res** 1996 Mar; 3(2):59–64 (51 ref.)

PHYSIOLOGY

Orienting a spatial attention—its reflexive, compensatory, and voluntary mechanisms. Hikosaka O, et al. **Brain Res Cogn Brain Res** 1996 Dec;5(1–2):1–9 (32 ref.)

VOLKMANN CONTRACTURE see **COMPARTMENT SYNDROMES**

VOLTAGE-CLAMP TECHNIQUES see **PATCH-CLAMP TECHNIQUES**

VOLUNTARY HEALTH AGENCIES

Community care: the independent sector. Barodawala S. **BMJ** 1996 Sep 21;313(7059):740–3 (2 ref.)

VOLUNTARY STERILIZATION see **STERILIZATION, SEXUAL**

VOLUNTARY WORKERS

Optimal access to- and response by-public and voluntary services, including the role of bystanders and family members, in cardiopulmonary resuscitation. White RD. **New Horiz** 1997 May;5(2):153–7 (29 ref.)

STATISTICS & NUMERICAL DATA

Thanksgiving day for the gift of life [editorial] Whyte GS, et al. **Med J Aust** 1997 Jul 7;167(1):7–8 (15 ref.)

VOLUNTEERS see **VOLUNTARY WORKERS**

VOLVULUS see **INTESTINAL OBSTRUCTION**

VOLVULUS, STOMACH see **STOMACH VOLVULUS**

VOMER see **NASAL SEPTUM**

VOMERONASAL NERVE see **VOMERONASAL ORGAN**

VOMERONASAL ORGAN

[The mammalian pheromone receptors] Nagawa F, et al. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(14):2101–6 (24 ref.) **(Jpn)**
[The vomeronasal system] Osada T. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(14):2059–61 (0 ref.) **(Jpn)**
[Do humans possess the vomeronasal sensory system?] Takami S. **Tanpakushitsu Kakusan Koso** 1996 Nov; 41(14):2093–100 (35 ref.) **(Jpn)**

ANATOMY & HISTOLOGY

[Structure and plasticity in the vomeronasal system] Ichikawa M. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(14):2062–9 (15 ref.) **(Jpn)**

CYTOLOGY

[Neurogenesis in the vomeronasal organ] Osada T, et al. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(14):2070–6 (15 ref.) **(Jpn)**

PHYSIOLOGY

Olfactory receptors, vomeronasal receptors, and the organization of olfactory information. Bargmann CI. **Cell** 1997 Aug 22;90(4):585–7 (17 ref.)
Signal processing in the vomeronasal system: modulation of sexual behavior in the female rat. Dudley CA, et al. **Crit Rev Neurobiol** 1996;10(3–4):265–90 (158 ref.)
[An olfactory memory formed in the vomeronasal system] Kaba H. **Tanpakushitsu Kakusan Koso** 1996 Nov; 41(14):2077–83 (29 ref.) **(Jpn)**
[Neuroethological approach to the vomeronasal function] Mori Y, et al. **Tanpakushitsu Kakusan Koso** 1996 Nov; 41(14):2084–92 (15 ref.) **(Jpn)**

VOMERONASAL SYSTEM see **VOMERONASAL ORGAN**

VOMITING

see related
ANTIEMETICS

[Chemotherapy-induced nausea and vomiting: from experimentation to experience] Marty M. **Bull Cancer** 1996 Dec;83(12):1014–8 (22 ref.) (Eng. Abstr.) **(Fre)**

CHEMICALLY INDUCED

Nausea and vomiting in the postoperative patient-controlled analgesia environment. Woodhouse A, et al. **Anaesthesia** 1997 Aug;52(8):770–5 (46 ref.)
Physiology of chemotherapy-induced emesis and antiemetic therapy. Predictive models for evaluation of new compounds. Veyrat-Follet C, et al. **Drugs** 1997 Feb; 53(2):206–34 (141 ref.)
Proposal for classifying the acute emetogenicity of cancer chemotherapy. Hesketh PJ, et al. **J Clin Oncol** 1997 Jan; 15(1):103–9 (69 ref.)
Risk factors and antiemetic management of chemotherapy-induced nausea and vomiting. Goodman M. **Oncol Nurs Forum** 1997 Aug;24(7 Suppl):20–32 (39 ref.)
[Postoperative nausea and vomiting (see comments)] Jensen LB, et al. **Ugeskr Laeger** 1997 Jan 13;159(3):269–74 (40 ref.) (Eng. Abstr.) Comment in: Ugeskr Laeger 1997 May 19;159(21):3191–2. **(Dan)**
[Role of serotonin in emesis] Minami M, et al. **Nippon Yakurigaku Zasshi** 1996 Nov;108(5):233–42 (50 ref.) (Eng. Abstr.) **(Jpn)**
[Mechanisms of cytotoxic drug-induced emesis and its prevention] Matsuki N. **Yakugaku Zasshi** 1996 Sep; 116(9):710–8 (32 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Etiology of dental erosion—intrinsic factors. Scheutzel P. **Eur J Oral Sci** 1996 Apr;104(2 (Pt 2)):178–90 (76 ref.)

DRUG THERAPY

Antiemetic therapy. Axelrod RS. **Compr Ther** 1997 Aug; 23(8):539–45 (24 ref.)

Risks and benefits of drugs used in the management of postoperative nausea and vomiting. Sung YF. **Drug Saf** 1996 Mar;14(3):181–97 (140 ref.)
Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. Balfour JA, et al. **Drugs** 1997 Aug;54(2):273–98 (86 ref.)
Drug treatment of chemotherapy-induced delayed emesis. Tavorath R, et al. **Drugs** 1996 Nov;52(5):639–48 (43 ref.)
Postoperative nausea and vomiting—its pathophysiology and management. Dabbous A. **Middle East J Anesthesiol** 1996 Jun;13(5):495–512 (5 ref.)
5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy. Cunningham RS. **Oncol Nurs Forum** 1997 Aug;24(7 Suppl):33–40 (54 ref.)
Innovative approaches in the treatment of emesis [see comments] Grunberg SM. **Support Care Cancer** 1997 Jan; 5(1):9–11 (22 ref.) Comment in: Support Care Cancer 1997 Jan;5(1):1–2.
New perspectives in antiemetic treatment. Herrstedt J. **Support Care Cancer** 1996 Nov;4(6):416–9 (41 ref.)
Standard treatment of chemotherapy-induced emesis [see comments] Warr D. **Support Care Cancer** 1997 Jan; 5(1):12–6 (24 ref.) Comment in: Support Care Cancer 1997 Jan;5(1):1–2.
[Clinical use of antiemetic drugs for prevention and therapy of postoperative nausea and vomiting] Saur P, et al. **Anaesthesiol Reanim** 1996;21(6):153–8 (67 ref.) (Eng. Abstr.) **(Ger)**
[Vomiting: causes and therapy] Neiger R. **Schweiz Arch Tierheilkd** 1996;138(9):421–8 (42 ref.) (Eng. Abstr.) **(Ger)**
[Recent improvements in antiemetic therapy] Roila F, et al. **Tumori** 1997;83(2 Suppl):S3–14 (63 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Nausea and vomiting in patients with cancer. Lichter I. **Hematol Oncol Clin North Am** 1996 Feb;10(1):207–220 (54 ref.)
Vomiting and retching in Gilles de la Tourette syndrome: a report of ten cases and a review of the literature. Rickards H, et al. **Mov Disord** 1997 Jul;12(4):531–5 (35 ref.)
Managing the multiple causes of nausea and vomiting in the patient with cancer. Fessele KS. **Oncol Nurs Forum** 1996 Oct;23(9):1409–15; quiz 1416–7 (39 ref.)
Postoperative nausea and vomiting in children. Baines D. **Paediatr Anaesth** 1996;6(1):7–14 (52 ref.)
Postoperative nausea and vomiting: review and clinical approaches. Haynes GR, et al. **South Med J** 1996 Oct; 89(10):940–9 (118 ref.)
[Vomiting: causes and therapy] Neiger R. **Schweiz Arch Tierheilkd** 1996;138(9):421–8 (42 ref.) (Eng. Abstr.) **(Ger)**

NURSING

Criteria for assessment of nausea, vomiting, and retching. Rhodes VA. **Oncol Nurs Forum** 1997 Aug;24(7 Suppl):13–9 (42 ref.)

PHYSIOPATHOLOGY

Physiology of chemotherapy-induced emesis and antiemetic therapy. Predictive models for evaluation of new compounds. Veyrat-Follet C, et al. **Drugs** 1997 Feb; 53(2):206–34 (141 ref.)
Postoperative nausea and vomiting—its pathophysiology and management. Dabbous A. **Middle East J Anesthesiol** 1996 Jun;13(5):495–512 (5 ref.)
Physiologic mechanisms of nausea and vomiting in patients with cancer. Hogan CM, et al. **Oncol Nurs Forum** 1997 Aug;24(7 Suppl):8–12 (19 ref.)
[Nausea and vomiting. Pathophysiology and new therapeutic methods] Schwörer H, et al. **Dtsch Med Wochenschr** 1997 Aug 15;122(33):1014–9 (49 ref.) **(Ger)**

PREVENTION & CONTROL

Propofol in chemotherapy-associated nausea and vomiting. Phelps KC, et al. **Ann Pharmacother** 1996 Mar;30(3):290–2 (22 ref.)
Antiemetics revisited. Roila F, et al. **Curr Opin Oncol** 1997 Jul;9(4):321–6 (31 ref.)
Comparative studies of various antiemetic regimens. Roila F, et al. **Support Care Cancer** 1996 Jul;4(4):270–80 (57 ref.)
[Prevention of postoperative nausea and vomiting with single and repeat administration of ondansetron—review of the literature on different administration forms] Saur P, et al. **Anaesthesiol Reanim** 1996;21(5):131–5 (30 ref.) (Eng. Abstr.) **(Ger)**
[Mechanisms of cytotoxic drug-induced emesis and its prevention] Matsuki N. **Yakugaku Zasshi** 1996 Sep; 116(9):710–8 (32 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Nonpharmacologic management of chemotherapy-induced nausea and vomiting. King CR. **Oncol Nurs Forum** 1997 Aug;24(7 Suppl):41–8 (59 ref.)
[Nausea and vomiting. Pathophysiology and new therapeutic methods] Schwörer H, et al. **Dtsch Med Wochenschr** 1997 Aug 15;122(33):1014–9 (49 ref.) **(Ger)**

VON GIERKE'S DISEASE see **GLYCOGEN STORAGE DISEASE TYPE I**

VON HIPPEL-LINDAU DISEASE see **HIPPEL-LINDAU DISEASE**

VON WILLEBRAND FACTOR

see related
COAGULANTS
The revised classification of von Willebrand disease including the previously masqueraded female hemophilia A (type 2N). Nishino M, et al. **Int J Hematol** 1997 Jul;66(1):21–30 (64 ref.)

ANALYSIS

Soluble markers of endothelial cell function. Blann A, et al. **Clin Hemorheol Microcirc** 1997 Jan–Feb;17(1):3–11 (100 ref.)

CHEMISTRY

Von Willebrand factor: molecular size and functional activity. Furlan M. **Ann Hematol** 1996 Jun;72(6):341–8 (52 ref.)
von Willebrand disease: from the bedside to therapy. Aledort LM. **Thromb Haemost** 1997 Jul;78(1):562–5 (36 ref.)

DRUG EFFECTS

Snake venom proteins modulating the interaction between von Willebrand factor and platelet glycoprotein Ib. Fujimura Y, et al. **Thromb Haemost** 1996 Nov;76(5):633–9 (62 ref.)

GENETICS

Molecular basis of von Willebrand disease. Mazurier C, et al. **Baillieres Clin Haematol** 1996 Jun;9(2):229–41 (58 ref.)
Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: from the patient to the gene. INSERM Network on Molecular Abnormalities in von Willebrand Disease. Meyer D, et al. **Thromb Haemost** 1997 Jul; 78(1):451–6 (30 ref.)
[The application of molecular biology to thrombosis and hemostasis] Niiya K, et al. **Rinsho Byori** 1997 Apr; 45(4):305–9 (15 ref.) **(Jpn)**

IMMUNOLOGY

Antibodies to von Willebrand factor in von Willebrand disease. Mannucci PM, et al. **Adv Exp Med Biol** 1995; 386:87–92 (23 ref.)

METABOLISM

von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Lip GY, et al. **Cardiovasc Res** 1997 May;34(2):255–65 (119 ref.)
Structure and function of the glycoprotein Ib–IX–V complex. López JA, et al. **Curr Opin Hematol** 1997 Sep;4(5):323–9 (67 ref.)
A mathematical model of coagulation factor VIII kinetics. Noe DA. **Haemostasis** 1996 Nov–Dec;26(6):289–303 (31 ref.)

PHYSIOLOGY

Von Willebrand factor: molecular size and functional activity. Furlan M. **Ann Hematol** 1996 Jun;72(6):341–8 (52 ref.)
Von Willebrand factor-dependent shear-induced platelet aggregation: basic mechanisms and clinical implications. Ikeda Y, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:325–36 (29 ref.)
von Willebrand factor [published erratum appears in J Clin Invest 1997 Jul 1;100(1):237] Ruggeri ZM. **J Clin Invest** 1997 Feb 15;99(4):559–64 (38 ref.)
Thrombin, fibrin and platelets: a resonance loop in which von Willebrand factor is a necessary link. Béguin S, et al. **Thromb Haemost** 1997 Jul;78(1):590–4 (30 ref.)
The significance of subendothelial von Willebrand factor. Rand JH, et al. **Thromb Haemost** 1997 Jul;78(1):445–50 (40 ref.)
Mechanisms initiating platelet thrombus formation. Ruggeri ZM. **Thromb Haemost** 1997 Jul;78(1):611–6 (25 ref.)

THERAPEUTIC USE

New treatments of von Willebrand disease: plasma derived von Willebrand factor concentrates. Menache D, et al. **Thromb Haemost** 1997 Jul;78(1):566–70 (37 ref.)
Recombinant von Willebrand factor. Schwarz HP, et al. **Thromb Haemost** 1997 Jul;78(1):571–6 (29 ref.)

VON WILLEBRAND'S DISEASE

Acquired von Willebrand's disease: a concise review. Rinder MR, et al. **Am J Hematol** 1997 Feb;54(2):139–45 (60 ref.)

CLASSIFICATION

The revised classification of von Willebrand disease including the previously masqueraded female hemophilia A (type 2N). Nishino M, et al. **Int J Hematol** 1997 Jul;66(1):21–30 (64 ref.)

DIAGNOSIS

Von Willebrand's disease. Ewenstein BM. **Annu Rev Med** 1997;48:525–42 (118 ref.)
Lung-angiodysplasia and von Willebrand's disease in a family with Rendu-Osler disease. A case report. Girola SS, et al. **Recenti Prog Med** 1996 Dec;87(12):589–91 (9 ref.)

DRUG THERAPY

New treatments of von Willebrand disease: plasma derived von Willebrand factor concentrates. Menache D, et al. **Thromb Haemost** 1997 Jul;78(1):566–70 (37 ref.)
Recombinant von Willebrand factor. Schwarz HP, et al. **Thromb Haemost** 1997 Jul;78(1):571–6 (29 ref.)

ETIOLOGY

Acquired von Willebrand disease in myeloproliferative disorders. van Genderen PJ, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:79–82 (24 ref.)
von Willebrand disease: pathogenesis, classification, and management. Murray EW, et al. **Transfus Med Rev** 1996 Apr;10(2):93–110 (197 ref.)

GENETICS

Molecular basis of von Willebrand disease. Mazurier C, et al. **Baillieres Clin Haematol** 1996 Jun;9(2):229–41 (58 ref.)
von Willebrand disease. Nichols WC, et al. **Medicine (Baltimore)** 1997 Jan;76(1):1–20 (265 ref.)
Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: from the patient to the gene. INSERM Network on Molecular Abnormalities in von Willebrand Disease. Meyer D, et al. **Thromb Haemost** 1997 Jul; 78(1):451–6 (30 ref.)

IMMUNOLOGY

Antibodies to von Willebrand factor in von Willebrand disease. Mannucci PM, et al. **Adv Exp Med Biol** 1995; 386:87–92 (23 ref.)

NURSING

Von Willebrand disease: a nursing perspective. Kleinert D, et al. **J Obstet Gynecol Neonatal Nurs** 1997 May–Jun; 26(3):271–6 (14 ref.)

PHYSIOPATHOLOGY

Platelet-type von Willebrand disease. Miller JL. **Thromb Haemost** 1996 Jun;75(6):865–9 (42 ref.)

THERAPY

von Willebrand disease: from the bedside to therapy. Aledort LM. **Thromb Haemost** 1997 Jul;78(1):562–5 (36 ref.)

VETERINARY

von Willebrand's disease in the dog and cat. Thomas JS. **Vet Clin North Am Small Anim Pract** 1996 Sep; 26(5):1089–110 (86 ref.)

VP-16 see **ETOPOSIDE**

VP 16-213 see **ETOPOSIDE**

VPR GENE PRODUCTS see **GENE PRODUCTS, VPR**

VPR PROTEIN see **GENE PRODUCTS, VPR**

VPU GENE PRODUCTS see **GENE PRODUCTS, VPU**

VPU PROTEIN see **GENE PRODUCTS, VPU**

VS-I VIRUS see **VESICULAR STOMATITIS-INDIANA VIRUS**

VULVA

Localized vulvar syringomas [letter] Di Lernia V, et al. **Pediatr Dermatol** 1996 Jan–Feb;13(1):80–1 (15 ref.)

VULVAR DISEASES

The commonest causes of symptomatic vulvar disease: a dermatologist's perspective. Fischer GO. **Australas J Dermatol** 1996 Feb;37(1):12–8 (43 ref.)
Vulval skin disease and the gynaecologist. Evans S. **Br J Hosp Med** 1997 Jun 4–17;57(11):579–81 (3 ref.)
Vulvar disorders of the infant and young child. Dodds ML. **Clin Obstet Gynecol** 1997 Mar;40(1):141–52 (14 ref.)
Vulvovaginal disorders in the elderly woman. Nathan L. **Clin Obstet Gynecol** 1996 Dec;39(4):933–45 (36 ref.)
Vulvar problems in elderly women. Don't assume that menopause is the culprit. Barhan S, et al. **Postgrad Med** 1997 Sep;102(3):121–5, 131–2 (18 ref.)

CONGENITAL

Congenital papillomas and papillomatoses associated with the human papilloma virus (HPV)-report on 5 cases. Dias EP, et al. **Rev Paul Med** 1995 Jul–Aug;113(4):957–63 (63 ref.)

DIAGNOSIS

Nodular fasciitis of the vulva: a study of six cases and

literature review. O'Connell JX, et al.
Int J Gynecol Pathol 1997 Apr;16(2):117–23 (17 ref.)
Localized bullous pemphigoid of the vulva. Urano S.
J Dermatol 1996 Aug;23(8):580–2 (11 ref.)
[Genital infection with human papillomavirus (HPV): viral screening and typing, importance of in situ hybridization] Walker F, et al. **Ann Pathol** 1996 Nov;16(5):364–73 (76 ref.) **(Fre)**
[Principles of the clinical evaluation of the vulvar region] Cattaneo A, et al. **Minerva Ginecol** 1996 Oct;48(10):429–33 (6 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Acquired clitoral enlargement. Diagnosis and treatment. Hořejší J. **Ann N Y Acad Sci** 1997 Jun 17;816:369–72 (23 ref.)

PATHOLOGY

Latent and subclinical HPV external anogenital infection. Barrasso R. **Clin Dermatol** 1997 May–Jun;15(3):349–53 (22 ref.)
Dermatologic diseases of the vulva. Kamarashev JA, et al. **Clin Dermatol** 1997 Jan–Feb;15(1):53–65 (158 ref.)
Nodular fasciitis of the vulva: a study of six cases and literature review. O'Connell JX, et al.
Int J Gynecol Pathol 1997 Apr;16(2):117–23 (17 ref.)
[Vulvar dermatoses and intra-epithelial neoplasia. Classification, criticism and suggestions] Leibowitch M, et al. **Ann Pathol** 1996 Nov;16(5):334–42 (18 ref.) **(Fre)**

PHYSIOPATHOLOGY

Vulvar vestibulitis syndrome: a critical review. Bergeron S, et al. **Clin J Pain** 1997 Mar;13(1):27–42 (80 ref.)
[Vulvodynia—sensitivity to touch of the vulva] Paavonen J. **Duodecim** 1995;111(13):1237–41 (21 ref.) **(Fin)**

THERAPY

Acquired clitoral enlargement. Diagnosis and treatment. Hořejší J. **Ann N Y Acad Sci** 1997 Jun 17;816:369–72 (23 ref.)
The management of genital condylomas, intraepithelial neoplasia, and vulvodynia. Reid R.
Obstet Gynecol Clin North Am 1996 Dec;23(4):917–91 (136 ref.)

VIROLOGY

Human papillomavirus infection in women. Special aspects of infectious diseases in women. Jablonska S, et al.
Clin Dermatol 1997 Jan–Feb;15(1):67–79 (109 ref.)

VULVAR NEOPLASMS

Vulvar cancer–continuing evolution in management. Cavanagh D. **Gynecol Oncol** 1997 Sep;66(3):362–7 (28 ref.)
Primary endodermal sinus tumor of the vulva: a case report and review of the literature. Flanagan CW, et al.
Gynecol Oncol 1997 Sep;66(3):515–8 (11 ref.)
Merkel cell carcinoma of the vulva. Gil-Moreno A, et al. **Gynecol Oncol** 1997 Mar;64(3):526–32 (40 ref.)
Melanomas of the vulva and vagina. Trimble EL.
Oncology (Huntingt) 1996 Jul;10(7):1017–23; discussion 1024 (37 ref.)

CONGENITAL

Congenital neoplasm of the clitoris. Levard G, et al.
J Urol 1997 Feb;157(2):649 (3 ref.)

DIAGNOSIS

Amelanotic malignant melanoma of the vulva. Case report and review of the literature. Ulmer A, et al.
Arch Gynecol Obstet 1996;259(1):45–50 (30 ref.)
Vulvar eccrine porocarcinoma. Katsanis WA, et al.
Gynecol Oncol 1996 Sep;62(3):396–9 (21 ref.)
Granular cell tumor of the vulva: literature review and case report. Simone J, et al. **J La State Med Soc** 1996 Dec; 148(12):539–41 (18 ref.)

DRUG THERAPY

Primary radiation, cisplatin, and 5-fluorouracil for advanced squamous carcinoma of the vulva. Cunningham MJ, et al. **Gynecol Oncol** 1997 Aug;66(2):258–61 (19 ref.)

EPIDEMIOLOGY

Vulvar intraepithelial neoplasia and vulvar cancer. Edwards CL, et al. **Obstet Gynecol Clin North Am** 1996 Jun; 23(2):295–324 (81 ref.)

ETIOLOGY

Pathobiology of vulvar squamous neoplasia. Crum CP, et al. **Curr Opin Obstet Gynecol** 1997 Feb;9(1):63–9 (50 ref.)

PATHOLOGY

Extramammary Paget's disease of the vulva: metastases to the bone marrow in the absence of an underlying adenocarcinoma—case report and literature review. Cappuccini F, et al. **Gynecol Oncol** 1997 Jul;66(1):146–50 (14 ref.)
Sebaceous carcinoma of the vulva: a case report and review of the literature. Carlson JW, et al. **Gynecol Oncol** 1996 Mar;60(3):489–91 (8 ref.)
Purely epithelioid malignant peripheral nerve sheath tumor of the vulva. Lee YS, et al. **J Korean Med Sci** 1997 Feb; 12(1):78–81 (10 ref.)
Vulvar intraepithelial neoplasia and vulvar cancer. Edwards CL, et al. **Obstet Gynecol Clin North Am** 1996 Jun; 23(2):295–324 (81 ref.)
Desmoplastic melanoma of the vulva. Mulvany NJ, et al. **Pathology** 1997 May;29(2):241–5 (33 ref.)
[Vulvar dermatoses and intra-epithelial neoplasia. Classification, criticism and suggestions] Leibowitch M, et al. **Ann Pathol** 1996 Nov;16(5):334–42 (18 ref.) **(Fre)**
[Primary carcinoma of Bartholin's glands with HPV 18 detection] Schwarzlos G, et al. **Zentralbl Gynakol** 1997; 119(3):133–5 (17 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Neovaginal malignant melanoma following surgery and radiation for vulvar squamous cell carcinoma. Lara PN Jr, et al. **Gynecol Oncol** 1997 Jun;65(3):520–2 (18 ref.)

RADIOTHERAPY

Primary radiation, cisplatin, and 5-fluorouracil for advanced squamous carcinoma of the vulva. Cunningham MJ, et al. **Gynecol Oncol** 1997 Aug;66(2):258–61 (19 ref.)

SURGERY

The effect of sartorius transposition on wound morbidity following inguinal-femoral lymphadenectomy. Paley PJ, et al. **Gynecol Oncol** 1997 Feb;64(2):237–41 (20 ref.)
A trend toward more conservative surgery in gynecologic oncology. Menczer J. **Obstet Gynecol Surv** 1996 Oct; 51(10):628–36 (143 ref.)

VIROLOGY

Human papillomavirus-associated tumors of the skin and mucosa. Majewski S, et al. **J Am Acad Dermatol** 1997 May; 36(5 Pt 1):659–85; quiz 686–8 (272 ref.)

VULVITIS

COMPLICATIONS

[Treatment of vulvar vestibulitis by posterior vestibulectomy. Twelve case reports] Berville S, et al.
J Gynecol Obstet Biol Reprod (Paris) 1997;26(1):71–5 (22 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

[Treatment of vulvar vestibulitis by posterior vestibulectomy. Twelve case reports] Berville S, et al.
J Gynecol Obstet Biol Reprod (Paris) 1997;26(1):71–5 (22 ref.) (Eng. Abstr.) **(Fre)**

VULVOVAGINITIS

Pediatric vulvo-vaginitis. Farrington PF.
Clin Obstet Gynecol 1997 Mar;40(1):135–40 (13 ref.)

VVEDENSKII INHIBITION see **NEURAL CONDUCTION**

VZ VIRUS see **HERPESVIRUS 3, HUMAN**

WAARDENBURG'S SYNDROME

DIAGNOSIS

[A case of Waardenburg-Klein syndrome observed at the Cotonou NUHC] Bassabi SK, et al. **J Fr Ophtalmol** 1997; 20(5):387–90 (8 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

[The main etiopathogenic mechanisms of neurocutaneous diseases] Vicente FJ, et al. **Rev Neurol** 1997 Sep;25 Suppl 3:S214–21 (63 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Waardenburg-Hirschsprung disease in two sisters: a possible clue to the genetics of this association? Bonnet JP, et al. **Eur J Pediatr Surg** 1996 Aug;6(4):245–8 (21 ref.)
The incidence of deafness is non-randomly distributed among families segregating for Waardenburg syndrome type 1 (WS1). Morell R, et al. **J Med Genet** 1997 Jun;34(6):447–52 (49 ref.)
Evidence to suggest that expression of MITF induces melanocyte differentiation and haploinsufficiency of MITF causes Waardenburg syndrome type 2A. Tachibana M.
Pigment Cell Res 1997 Feb–Apr;10(1–2):25–33 (33 ref.)
[The main etiopathogenic mechanisms of neurocutaneous diseases] Vicente FJ, et al. **Rev Neurol** 1997 Sep;25 Suppl 3:S214–21 (63 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Waardenburg syndrome. Read AP, et al. **J Med Genet** 1997 Aug;34(8):656–65 (76 ref.)
Piebaldism, Waardenburg syndrome, and related disorders of melanocyte development. Spritz RA.
Semin Cutan Med Surg 1997 Mar;16(1):15–23 (59 ref.)

WAGR SYNDROME

GENETICS

A clinical overview of WT1 gene mutations. Little M, et al. **Hum Mutat** 1997;9(3):209–25 (118 ref.)

WAIST-HIP RATIO see **BODY CONSTITUTION**

WAKEFULNESS

see related
INSOMNIA
The relationship between sleep and cognitive functions during wakefulness: an introduction. Schulz H, et al.
Acta Neurol Belg 1997 Jun;97(2):93–5 (8 ref.)
Behavioral intervention strategies for sleep-activity disruption. Dowling GA. **Int Psychogeriatr** 1996;8 Suppl 1:77–86 (34 ref.)

DRUG EFFECTS

Alertness-enhancing drugs as a countermeasure to fatigue in irregular work hours. Akerstedt T, et al.
Chronobiol Int 1997 Mar;14(2):145–58 (81 ref.)

PHYSIOLOGY

Human sleep/wake regulation. Gillberg M.
Acta Anaesthesiol Scand Suppl 1997;110:8–10 (11 ref.)
Circadian rhythms: basic neurobiology and clinical applications. Moore RY. **Annu Rev Med** 1997;48:253–66 (59 ref.)
Some measures to reduce effects of prolonged sleep deprivation. Lagarde D, et al. **Neurophysiol Clin** 1995; 25(6):376–85 (28 ref.) (Eng. Abstr.)
c-Fos expression during wakefulness and sleep. Pompeiano M, et al. **Neurophysiol Clin** 1995;25(6):329–41 (56 ref.)
Consciousness in waking and dreaming: the roles of neuronal oscillation and neuromodulation in determining similarities and differences. Kahn D, et al. **Neuroscience** 1997 May; 78(1):13–38 (265 ref.)
Sleep regulation: relation to photoperiod, sleep duration, waking activity, and torpor. Borbély AA, et al.
Prog Brain Res 1996;111:343–8 (29 ref.)
[Waking mechanisms: multiple networks in the mesencephalic reticular formation] Jouvet M. **Arch Physiol Biochem** 1996 Oct;104(6):762–9 (26 ref.) (Eng. Abstr.) **(Fre)**
[Contribution of positron emission tomography in the study of wakefulness and sleep. Status of the question] Maquet P. **Neurophysiol Clin** 1995;25(6):342–50 (35 ref.) (Eng. Abstr.) **(Fre)**
[Effect of biological rhythm on sleep-wakefulness regulation] Zulley J. **Internist (Berl)** 1996 May;37(5):463–9 (12 ref.) **(Ger)**
[Sleep fragmentation as the cause of daytime sleepiness and reduced performance] Bonnet MH.
Wien Med Wochenschr 1996;146(13–14):332–4 (14 ref.) (Eng. Abstr.) **(Ger)**
[New data on the characteristics of sleep and the organization of the wakefulness-sleep cycle in cold-blooded vertebrates] Karmanova IG. **Zh Evol Biokhim Fiziol** 1996 Jul–Aug; 32(4):511–35 (10 ref.) **(Rus)**

WALDENSTROM'S MACROGLOBULINEMIA

COMPLICATIONS

Waldenström's macroglobulinemia associated with glioblastoma. A case report. Lamaida E, et al.
Rev Neurol (Paris) 1996 Oct;152(10):637–9 (10 ref.)

DIAGNOSIS

Autoimmune hemolytic anemia with warm antibodies complicated with an intercurrent attack of hemolysis with cold agglutinins in a case of Waldenström disease. Gologan R, et al. **Rom J Intern Med** 1996 Jan–Jun;34(1–2):149–54 (30 ref.)

DRUG THERAPY

Purine analogs in chronic lymphocytic leukemia and Waldenström's macroglobulinemia. O'Brien S, et al.
Ann Oncol 1996;7 Suppl 6:S27–33 (53 ref.)

WALKERS

The potential for ambulation by severely handicapped cerebral palsy patients. Stallard J, et al.
Prosthet Orthot Int 1996 Aug;20(2):122–8 (28 ref.)

WALKING

Recovery of walking after spinal cord injury. Ladouceur M, et al. **Adv Neurol** 1997;72:249–55 (33 ref.)
Serum ferritin and heart disease: the effect of moderate exercise on stored iron levels in postmenopausal women. Naimark BJ, et al. **Can J Cardiol** 1996 Dec;12(12):1253–7 (30 ref.)
Effect of persistent toe walking on ankle equinus. Analysis

WALKING

of 60 idiopathic toe walkers. Sobel E, et al. **J Am Podiatr Med Assoc** 1997 Jan;87(1):17–22 (33 ref.)

Timed walking tests of exercise capacity in chronic cardiopulmonary illness. Steele B. **J Cardiopulm Rehabil** 1996 Jan–Feb;16(1):25–33 (49 ref.)

Transcutaneous functional neuromuscular stimulation of certain traumatic complete thoracic paraplegics for independent short–distance ambulation. Graupe D, et al. **Neurol Res** 1997 Jun;19(3):323–33 (16 ref.)

Imaging the child with a limp. Myers MT, et al. **Pediatr Clin North Am** 1997 Jun;44(3):637–58 (30 ref.)

The potential for ambulation by severely handicapped cerebral palsy patients. Stallard J, et al. **Prosthet Orthot Int** 1996 Aug;20(2):122–8 (28 ref.)

Exercise for osteoporosis—is walking enough? The case for site specificity and resistive exercise. Swezey RL. **Spine** 1996 Dec 1;21(23):2809–13 (27 ref.)

Walking to health. Morris JN, et al. **Sports Med** 1997 May; 23(5):306–32 (196 ref.)

PHYSIOLOGY

Balance control during walking in the older adult: research and its implications. Woollacott MH, et al. **Phys Ther** 1997 Jun;77(6):646–60 (67 ref.)

WALLABIES see **KANGAROOS**

WALLENBERG'S SYNDROME

[History of Wallenberg's syndrome] Roig C, et al. **Rev Neurol** 1996 Jan;24(125):96–100 (46 ref.) **(Spa)**

WALLERIAN DEGENERATION

PHYSIOLOGY

The role of macrophages in Wallerian degeneration. Brück W. **Brain Pathol** 1997 Apr;7(2):741–52 (124 ref.)

WANGIELLA see **EXOPHIALA**

WAR

see related
COMBAT DISORDERS

Hypertonic saline dextran (HSD) and intraosseous vascular access for the treatment of haemorrhagic hypotension in the far–forward combat arena. Dubick MA, et al. **Ann Acad Med Singapore** 1997 Jan;26(1):64–9 (48 ref.)

Effects of sleep deprivation with reference to military operations. Giam GC. **Ann Acad Med Singapore** 1997 Jan; 26(1):88–93 (20 ref.)

Pharmacology and toxicology of chemical warfare agents. Lee EJ. **Ann Acad Med Singapore** 1997 Jan;26(1):104–7 (18 ref.)

An overview of recent developments in the management and research of trauma. Wang ZG. **Ann Acad Med Singapore** 1997 Jan;26(1):54–9 (47 ref.)

Management of small fragment wounds in modern warfare: a return to Hunterian principles? Bowyer GW. **Ann R Coll Surg Engl** 1997 May;79(3):175–82 (20 ref.)

Colostomy in conflict: military colonic surgery. Edwards DP, et al. **Ann R Coll Surg Engl** 1997 Jul;79(4):243–4 (13 ref.)

Abdominal wounds in war. Coupland R. **Br J Surg** 1996 Nov;83(11):1505–11 (57 ref.)

Treating mass burns in warfare, disaster or terrorist strikes. Sparkes BG. **Burns** 1997 May;23(3):238–47 (101 ref.)

The symphony of the damned: racial discourse, complex political emergencies and humanitarian aid. Duffield M. **Disasters** 1996 Sep;20(3):173–93 (45 ref.)

Conflict, the continuum and chronic emergencies: a critical analysis of the scope for linking relief, rehabilitation and development planning in Sudan. Macrae J, et al. **Disasters** 1997 Sep;21(3):223–43 (23 ref.)

Cruel wars and safe havens: humanitarian aid in Liberia 1989–1996. Outram Q. **Disasters** 1997 Sep;21(3):189–205 (60 ref.)

Research in the war zones of Eritrea and northern Ethiopia. Silkin T, et al. **Disasters** 1997 Jun;21(2):166–76 (15 ref.)

Doing the right thing: relief agencies, moral dilemmas and responsibility in political emergencies and war. Slim H. **Disasters** 1997 Sep;21(3):244–57 (15 ref.)

Management of war–related neck injuries during the war in Croatia, 1991–1992. Prgomet D, et al. **Eur Arch Otorhinolaryngol** 1996;253(4–5):294–6 (28 ref.)

Very late outcome after focal wartime brain wounds. Newcombe F. **J Clin Exp Neuropsychol** 1996 Feb; 18(1):1–23 (93 ref.)

The surgical management in war of penetrating wounds contaminated with chemical warfare agents. Cooper GJ, et al. **J R Army Med Corps** 1994 Oct;140(3):113–8 (15 ref.)

Trauma management on the battlefield: a modern approach. Hawley A. **J R Army Med Corps** 1996 Oct;142(3):120–5 (33 ref.)

Public mental health. III: Hatred and reconciliation. Curle A. **Med Confl Surviv** 1997 Jan–Mar;13(1):37–47 (2 ref.)

The social, cultural and political dimensions of contemporary war. Summerfield D. **Med Confl Surviv** 1997 Jan–Mar; 13(1):3–25 (39 ref.)

Militarism: a psychosocial disease. Coulter NA. **Med War** 1992 Jan–Mar;8(1):7–17 (15 ref.)

The anti–personnel land mine epidemic: a case report and review of the literature [see comments] Gondring WH. **Mil Med** 1996 Dec;161(12):760–2 (6 ref.) Comment in: Mil Med 1997 Apr;162(4):i.

Al Eskan disease: Persian Gulf syndrome [see comments] Korényi–Both AL, et al. **Mil Med** 1997 Jan;162(1):1–13 (75 ref.) Comment in: Mil Med 1997 Mar;162(3):ii.

Possibilities for unexplained chronic illnesses among reserve units deployed in Operation Desert Shield/Desert Storm. Malone JD, et al. **South Med J** 1996 Dec;89(12):1147–55 (38 ref.)

Torture and war trauma survivors in primary care practice. Weinstein HM, et al. **West J Med** 1996 Sep;165(3):112–8 (30 ref.)

[Gulf War syndrome—more than meets the eye] Vidan A, et al. **Harefuah** 1996 Jul;131(1–2):27–30 (22 ref.) **(Heb)**

HISTORY

Nursing at war: catalyst for change. Brunk Q. **Annu Rev Nurs Res** 1997;15:217–36 (53 ref.)

WAR NEUROSES see **COMBAT DISORDERS**

WARDS, GENERAL see **PATIENTS' ROOMS**

WARFARIN

ADMINISTRATION & DOSAGE

Evolving models of warfarin management: anticoagulation clinics, patient self–monitoring, and patient self–management [editorial] Ansell JE, et al. **Am Heart J** 1996 Nov;132(5):1095–100 (42 ref.)

Treating the non–electrical risks of atrial fibrillation. Gershlick AH. **Eur Heart J** 1997 May;18 Suppl C:C19–26 (39 ref.)

ADVERSE EFFECTS

Warfarin and heparin–induced skin necrosis and the purple toe syndrome: infrequent complications of anticoagulant treatment. Sallah S, et al. **Thromb Haemost** 1997 Aug; 78(2):785–90 (96 ref.)

METABOLISM

Human P450 metabolism of warfarin. Kaminsky LS, et al. **Pharmacol Ther** 1997;73(1):67–74 (60 ref.)

PHARMACOKINETICS

Warfarin withdrawal. Pharmacokinetic–pharmacodynamic considerations. Palareti G, et al. **Clin Pharmacokinet** 1996 Apr;30(4):300–13 (87 ref.)

Inability to attain oral anticoagulation: warfarin–rifampin interaction revisited. Casner PR. **South Med J** 1996 Dec; 89(12):1200–3 (21 ref.)

PHARMACOLOGY

Anticoagulation with warfarin in infants and children. Buck ML. **Ann Pharmacother** 1996 Nov;30(11):1316–22 (56 ref.)

Role of thromboelastography in evaluating other anticoagulant agents: warfarin and heparin–dihydroergotamine. Traverso CI, et al. **Semin Thromb Hemost** 1995;21 Suppl 4:59–62 (12 ref.)

THERAPEUTIC USE

Antithrombotic therapy for patients with stroke symptoms. Guidelines for family physicians. Brown J, et al. **Can Fam Physician** 1996 Sep;42:1724–30 (27 ref.)

Prevention and treatment of venous thromboembolism. Pineo GF, et al. **Drugs** 1996 Jul;52(1):71–92 (163 ref.)

Should all patients with atrial fibrillation receive warfarin? Evidence from randomized clinical trials. Cleland JG, et al. **Eur Heart J** 1996 May;17(5):674–81 (56 ref.)

Management of anticoagulation before and after elective surgery. Kearon C, et al. **N Engl J Med** 1997 May 22; 336(21):1506–11 (66 ref.)

Oculoplastic surgery in patients receiving warfarin: suggestions for management. Bartley GB. **Ophthal Plast Reconstr Surg** 1996 Dec;12(4):229–30 (5 ref.)

Warfarin resistance: diagnosis and therapeutic alternatives. Hulse ML. **Pharmacotherapy** 1996 Nov–Dec;16(6):1009–17 (31 ref.)

Coumadin: principles of use. Liem TK, et al. **Semin Vasc Surg** 1996 Dec;9(4):354–61 (51 ref.)

WART–HOG DISEASE VIRUS see **AFRICAN SWINE FEVER VIRUS**

WARTHIN TUMOR see **ADENOLYMPHOMA**

WARTS

Primary care treatment approach to nongenital verruca. Kimble–Haas S. **Nurse Pract** 1996 Oct;21(10):29–33, 36 (24 ref.)

DIAGNOSIS

Localized vulvar syringomas [letter] Di Lernia V, et al. **Pediatr Dermatol** 1996 Jan–Feb;13(1):80–1 (15 ref.)

PATHOLOGY

Benign persistent papular acantholytic and dyskeratotic eruption with features of warty dyskeratoma [letter] Urbani CE, et al. **Australas J Dermatol** 1996 Nov;37(4):225–6 (13 ref.)

SURGERY

Laser treatment of warts and other epidermal and dermal lesions. Hruza GJ. **Dermatol Clin** 1997 Jul;15(3):487–506 (129 ref.)

THERAPY

Therapy of cutaneous warts. Benton EC. **Clin Dermatol** 1997 May–Jun;15(3):449–55 (49 ref.)

Diagnosis, pathophysiology, and treatment of plantar verruca. Landsman MJ, et al. **Clin Podiatr Med Surg** 1996 Jan;13(1):55–71 (39 ref.)

Warts on children: an approach to therapy. Siegfried EC. **Pediatr Ann** 1996 Feb;25(2):79–90 (27 ref.)

Warts and molluscum contagiosum: beware of treatments worse than the disease. Ordoukhanian E, et al. **Postgrad Med** 1997 Feb;101(2):223–6, 229–32, 235 (31 ref.)

VIROLOGY

Cutaneous warts. Jabłońska S, et al. **Clin Dermatol** 1997 May–Jun;15(3):309–19 (65 ref.)

WARTS, GENITAL see **CONDYLOMATA ACUMINATA**

WARTS, VENEREAL see **CONDYLOMATA ACUMINATA**

WASP VENOMS

BIOSYNTHESIS

Toxins produced by arthropod parasites: salivary gland proteins of human body lice and venom proteins of chelonine wasps. Jones D, et al. **Toxicon** 1996 Nov–Dec; 34(11–12):1421–9 (32 ref.)

TOXICITY

Toxins produced by arthropod parasites: salivary gland proteins of human body lice and venom proteins of chelonine wasps. Jones D, et al. **Toxicon** 1996 Nov–Dec; 34(11–12):1421–9 (32 ref.)

WASPS

CLASSIFICATION

[Claves ilustradas para las subfamilias, tribus y géneros de esfécidos neotropicales (Apoidea: Sphecidae) [Illustrated clues for subfamilies, tribes, and genera of neotropical Spheciade (Apoidea:Sphecidae)] Menke AS, et al. **Rev Biol Trop** 1996 Aug;44 Suppl 2:1–68 (106 ref.) **(Eng, Spa)**

METABOLISM

Toxins produced by arthropod parasites: salivary gland proteins of human body lice and venom proteins of chelonine wasps. Jones D, et al. **Toxicon** 1996 Nov–Dec; 34(11–12):1421–9 (32 ref.)

WASTE DISPOSAL, FLUID

Understanding and advancing wastewater treatment. Stams AJ, et al. **Curr Opin Biotechnol** 1997 Jun;8(3):328–34 (58 ref.)

WASTE DISPOSAL, MEDICAL see **MEDICAL WASTE DISPOSAL**

WASTE DISPOSAL, SOLID see **REFUSE DISPOSAL**

WASTE MANAGEMENT

Swine manure cleanup criteria calculation for odor causing volatile organic compounds based on manure–to–ventilation air exposure pathway. Liao CM, et al. **J Environ Sci Health B** 1997 Jul;32(4):449–68 (33 ref.)

[Effects of residues of anti–infective agents in animal excretions on slurry treatment and the soil] Böhm R. **DTW Dtsch Tierarztl Wochenschr** 1996 Jul;103(7):264–8 (12 ref.) (Eng. Abstr.) **(Ger)**

METHODS

A conceptual framework for implementation of bioavailability of metals for environmental management purposes. Peijnenburg WJ, et al. **Ecotoxicol Environ Saf** 1997 Jul;37(2):163–72 (48 ref.)

Microbial studies in the Canadian nuclear fuel waste management program. Stroes–Gascoyne S, et al. **FEMS Microbiol Rev** 1997 Jul;20(3–4):573–90 (74 ref.)

Composting alternative for animal carcass disposal. Glanville TD, et al. **J Am Vet Med Assoc** 1997 Apr 15;210(8):1116–20 (23 ref.)

Land application of sewage sludge in China. Wang MJ. **Sci Total Environ** 1997 Apr 30;197(1–3):149–60 (47 ref.)

STANDARDS

Soil and solid poultry waste nutrient management and water quality. Chapman SL. **Poult Sci** 1996 Jul;75(7):862–6 (26 ref.)
Worldwide overview of hazardous wastes. Cortinas de Nava C. **Toxicol Ind Health** 1996 Mar–Apr;12(2):127–38 (18 ref.)

WASTE PRODUCTS

The complexation of Cu(II) by anthropogenic fulvic acids extracted from composted urban and livestock wastes. Esteves da Silva JC, et al. **J Environ Sci Health B** 1997 Jul;32(4):469–82 (32 ref.)

WASTING DISEASE see **WASTING SYNDROME**

WASTING DISEASE, HIV see **HIV WASTING SYNDROME**

WASTING SYNDROME

PHYSIOPATHOLOGY

Wasting illness as a disorder of body weight regulation. Schwartz MW, et al. **Proc Nutr Soc** 1997 Jul;56(2):785–91 (45 ref.)

THERAPY

The 1995 John M. Kinney International Award for Nutrition and Metabolism. Effect of passive stretching on the wasting of muscle in the critically ill: background. Griffiths RD. **Nutrition** 1997 Jan;13(1):70–4 (24 ref.)

WASTING SYNDROME, HIV see **HIV WASTING SYNDROME**

WATER

see related
BODY WATER
FRESH WATER
MINERAL WATERS
SEAWATER

Total energy expenditure of free-living humans can be estimated with the doubly labeled water method. Wong WW. **Adv Food Nutr Res** 1996;40:171–80 (23 ref.)
Water on early Mars. Carr MH. **Ciba Found Symp** 1996; 202:249–65; discussion 265–7 (36 ref.)
Hydrothermal systems on Mars: an assessment of present evidence. Farmer JD. **Ciba Found Symp** 1996;202:273–95; discussion 295–9 (51 ref.)
Physical activity levels from a meta-analysis of doubly labeled water studies for validating energy intake as measured by dietary assessment. Black AE. **Nutr Rev** 1996 Jun;54(6):170–4 (28 ref.)
Water exercise in pregnancy. Katz VL. **Semin Perinatol** 1996 Aug;20(4):285–91 (47 ref.)

ANALYSIS

Determination of coal tar and creosote constituents in the aquatic environment. Hale RC, et al. **J Chromatogr A** 1997 Jul 11;774(1–2):79–95 (154 ref.)
NMR relaxation data of water proton in normal tissues. Akber SF. **Physiol Chem Phys Med NMR** 1996; 28(4):205–38 (234 ref.)

CHEMISTRY

Chloramine removal from water used in hemodialysis. Ward DM. **Adv Ren Replace Ther** 1996 Oct;3(4):337–47 (55 ref.)
Fossilization processes in siliceous thermal springs: trends in preservation along thermal gradients. Cady SL, et al. **Ciba Found Symp** 1996;202:150–70; discussion 170–3 (23 ref.)
The role of water in protein–DNA interactions. Schwabe JW. **Curr Opin Struct Biol** 1997 Feb;7(1):126–34 (70 ref.)
Liquid water and biological systems: the most important problem in science that hardly anyone wants to see solved. Cho CH, et al. **Faraday Discuss** 1996;(103):19–27 (43 ref.)
Theory of phase formation in aqueous two-phase systems. Cabezas H Jr. **J Chromatogr B Biomed Appl** 1996 May 17;680(1–2):3–30 (98 ref.)
The manipulation of water relaxation and water suppression in biological systems using the water-PRESS pulse sequence. Price WS, et al. **J Magn Reson B** 1996 Aug; 112(2):190–2 (20 ref.)

DIAGNOSTIC USE

[Water deprivation and water load test] Ota K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:295–8 (4 ref.) **(Jpn)**

METABOLISM

Aquaporins: from physiology to nephrogenic diabetes insipidus. Knoers N, et al. **Adv Nephrol Necker Hosp** 1996; 25:257–73 (73 ref.)
Salt and water transport across alveolar and distal airway epithelia in the adult lung. Matthay MA, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):L487–503 (145 ref.)
Water transport across mammalian cell membranes. Verkman AS, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):C12–30 (156 ref.)
Low permeabilities of apical membranes of barrier epithelia: what makes watertight membranes watertight? Zeidel ML. **Am J Physiol** 1996 Aug;271(2 Pt 2):F243–5 (29 ref.)
The dynamics of water–protein interactions. Bryant RG. **Annu Rev Biophys Biomol Struct** 1996;25:29–53 (129 ref.)
Aquaporins and water transfer across epithelial barriers. Parisi M, et al. **Braz J Med Biol Res** 1996 Aug;29(8):933–9 (63 ref.)
High and low density water and resting, active and transformed cells. Wiggins PM. **Cell Biol Int** 1996 Jun; 20(6):429–35 (28 ref.)
The effects of detergents on hydration and skin surface lipids. Thune P. **Clin Dermatol** 1996 Jan–Feb;14(1):29–33 (33 ref.)
The aquaporin family of water channels in kidney: an update on physiology and pathophysiology of aquaporin-2. Nielsen S, et al. **Kidney Int** 1996 Jun;49(6):1718–23 (43 ref.)
The aquaporin family of water channel proteins in clinical medicine. Lee MD, et al. **Medicine (Baltimore)** 1997 May; 76(3):141–56 (186 ref.)
Sodium and water profiling in chronic uraemia. Churchill DN. **Nephrol Dial Transplant** 1996;11 Suppl 8:38–41 (15 ref.)
Urea, sodium, and water changes in profiling dialysis. Mann H, et al. **Nephrol Dial Transplant** 1996;11 Suppl 8:10–5 (12 ref.)
The mechanisms of renal tubule electrolyte and water absorption, 100 years after Carl Ludwig. Greger R. **Pflugers Arch** 1996;432(3 Suppl):R82–6 (31 ref.)
Erythrocytes and the transport of drugs and endogenous compounds. Highley MS, et al. **Pharm Res** 1996 Feb; 13(2):186–95 (50 ref.)
Placental transfer of inorganic ions and water. Stulc J. **Physiol Rev** 1997 Jul;77(3):805–36 (297 ref.)
How does photosystem 2 split water? The structural basis of efficient energy conversion. Rögner M, et al. **Trends Biochem Sci** 1996 Feb;21(2):44–9 (41 ref.)
[Absorption and secretion mechanism of water and electrolytes in intestines] Hanai H, et al. **Nippon Naika Gakkai Zasshi** 1996 Jul 10;85(7):1034–41 (7 ref.) **(Jpn)**
[Aquaporin water channels] Ishibashi K. **Nippon Rinsho** 1996 Mar;54(3):685–91 (6 ref.) (Eng. Abstr.) **(Jpn)**

PARASITOLOGY

Environmental ecology of Cryptosporidium and public health implications. Rose JB. **Annu Rev Public Health** 1997; 18:135–61 (109 ref.)
Epidemiologic aspects of human cryptosporidiosis and the role of waterborne transmission. Meinhardt PL, et al. **Epidemiol Rev** 1996;18(2):118–36 (146 ref.)
Protistan communities in aquifers: a review. Novarino G, et al. **FEMS Microbiol Rev** 1997 Jul;20(3–4):261–75 (95 ref.)
Drinking water and microbiological pathogens—issues and challenges for the year 2000. Hellard ME, et al. **J Public Health Med** 1997 Jun;19(2):129–31 (31 ref.)

PHARMACOLOGY

Just add water! The effect of water on the specificity of protein–ligand binding sites and its potential application to drug design. Ladbury JE. **Chem Biol** 1996 Dec; 3(12):973–80 (39 ref.)
Inhalation cough challenge in the investigation of the cough reflex and antitussives. Morice AH. **Pulm Pharmacol** 1996 Oct–Dec;9(5–6):281–4 (25 ref.)

PHYSIOLOGY

Introduction to medical physiology: cellular membranes and transmembrane transport of solutes and water [published erratum appears in Am J Physiol 1997 Jun;272(6 Pt 3):following table of contents] Benos DJ. **Am J Physiol** 1996 Dec;271(6 Pt 3):S2–9 (27 ref.)
Anhydrobiosis in yeast: activation effect. Rapoport AI, et al. **Braz J Med Biol Res** 1997 Jan;30(1):9–13 (15 ref.)

WATER BUFFALOES see **BUFFALOES**

WATER CONSUMPTION see **DRINKING**

WATER DEPRIVATION

see related
THIRST

Pharmacokinetic considerations in the camel (Camelus dromedarius): a review. Ali BH, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Sep;115(1):1–9 (61 ref.)
[Water deprivation and water load test] Ota K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:295–8 (4 ref.) **(Jpn)**
[Clinical studies in antidiuretic hormone secretion] Shoji M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:299–302 (3 ref.) **(Jpn)**

WATER-ELECTROLYTE BALANCE

see related
FLUID THERAPY
OSMOLAR CONCENTRATION
REHYDRATION SOLUTIONS
WATER-ELECTROLYTE IMBALANCE

Osmoreceptors in the central nervous system. Bourque CW, et al. **Annu Rev Physiol** 1997;59:601–19 (98 ref.)
200 years of amphibian water economy: from Robert Townson to the present. Jørgensen CB. **Biol Rev Camb Philos Soc** 1997 May;72(2):153–237 (390 ref.)
Volume reflex in diabetes. Patel KP. **Cardiovasc Res** 1997 Apr;34(1):81–90 (78 ref.)
Assessing fluid and electrolyte status in the newborn. National Academy of Clinical Biochemistry. Lorenz JM. **Clin Chem** 1997 Jan;43(1):205–10 (51 ref.)
Osmotic regulation of gene expression. Burg MB, et al. **FASEB J** 1996 Dec;10(14):1598–606 (39 ref.)
Nephrology. The year of the pores. Schieppati A, et al. **Lancet** 1996 Dec 21–28;348 Suppl 2:sII13 (5 ref.)
Experimental studies of intestinal ion and water transport. Holtug K, et al. **Scand J Gastroenterol Suppl** 1996; 216:95–110 (176 ref.)
Solute and water transport pathways in cholangiocytes. Marinelli RA, et al. **Semin Liver Dis** 1996 May;16(2):221–9 (90 ref.)
[Aquaretic agents] Bosch-Marcé M, et al. **Gastroenterol Hepatol** 1996 Nov;19(9):472–7 (55 ref.) **(Spa)**

DRUG EFFECTS

[Effects of diuretic therapy on electrolyte and acid–base homeostasis] Mayer G. **Wien Med Wochenschr** 1996; 146(16):436–8 (8 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Mitogen-activated protein kinase cascades and the signaling of hyperosmotic stress to immediate early genes. Cohen DM. **Comp Biochem Physiol A Physiol** 1997 Jul; 117(3):291–9 (79 ref.)

PHYSIOLOGY

Regulation of body fluid volume and electrolyte concentrations in spaceflight. Smith SM, et al. **Adv Space Biol Med** 1997;6:123–65 (87 ref.)
Water balance and physical performance in cold. Rintamäki H, et al. **Arctic Med Res** 1995;54 Suppl 2:32–6 (26 ref.)
Factors influencing the restoration of fluid and electrolyte balance after exercise in the heat. Maughan RJ, et al. **Br J Sports Med** 1997 Sep;31(3):175–82 (26 ref.)
Physiology of amniotic fluid volume regulation. Brace RA. **Clin Obstet Gynecol** 1997 Jun;40(2):280–9 (20 ref.)
Fetal swallowing: relation to amniotic fluid regulation. Ross MG, et al. **Clin Obstet Gynecol** 1997 Jun;40(2):352–65 (56 ref.)
Mitogen-activated protein kinase cascades and the signaling of hyperosmotic stress to immediate early genes. Cohen DM. **Comp Biochem Physiol A Physiol** 1997 Jul; 117(3):291–9 (79 ref.)
Mechanisms and management of renal dysfunction in heart failure. Anand IS, et al. **Curr Opin Cardiol** 1997 May; 12(3):251–8 (93 ref.)
The key role of the H+ V-ATPase in acid–base balance and Na+ transport processes in frog skin. Ehrenfeld J, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):247–56 (78 ref.)
Association of the band 3 protein with a volume-activated, anion and amino acid channel: a molecular approach. Motais R, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):361–7 (54 ref.)
Mechanism of fluid secretion common to aglomerular and glomerular kidneys. Beyenbach KW, et al. **Kidney Int** 1996 Jun;19(6):1543–8 (9 ref.)
Coordinate regulation of organic osmolytes in renal cells. Burg MB. **Kidney Int** 1996 Jun;49(6):1684–5 (20 ref.)
Organic osmolyte channels: transport characteristics and regulation. Goldstein L, et al. **Kidney Int** 1996 Jun; 49(6):1690–4 (24 ref.)
Osmoregulation in the renal papilla: membranes, messengers and molecules. Kinne RK, et al. **Kidney Int** 1996 Jun; 49(6):1686–9 (29 ref.)
Mechanisms of fluid secretion by polycystic epithelia. Sullivan LP, et al. **Kidney Int** 1996 Jun;49(6):1586–91 (26 ref.)
Neural control of atrial natriuretic peptide actions on fluid intake and excretion. McCann SM, et al. **Proc Soc Exp Biol Med** 1996 Nov;213(2):117–27 (53 ref.)
Tubule electrophysiology: from single channels back to the renal epithelium. Boulpaep EL. **Wien Klin Wochenschr** 1997 Jun 27;109(12–13):489–92 (18 ref.)
Cystic fibrosis transmembrane conductance regulator (CFTR) and renal function. Stanton BA. **Wien Klin Wochenschr** 1997 Jun 27;109(12–13):457–64 (83 ref.)
[Hydroelectrolytic requirements during the first week of life in premature infants weighing less than 1000 g. Physiopathology and recommendations] Yaseen H, et al. **Arch Pediatr** 1997 Jun;4(6):555–60 (43 ref.) (Eng. Abstr.) **(Fre)**
[Pathogenesis of sodium and water retention in cirrhosis of the liver] Martin PY. **Schweiz Rundsch Med Prax** 1997 Jul 30;86(31–32):1194–7 (15 ref.) (Eng. Abstr.) **(Fre)**
[Osmolytes and osmoregulation in renal cells] Więckowski MR, et al. **Postepy Biochem** 1996;42(2):167–77 (76 ref.) **(Pol)**

WATER-ELECTROLYTE IMBALANCE

see related
FLUID THERAPY
REHYDRATION SOLUTIONS

General management of gastrointestinal fistulas. Recognition, stabilization, and correction of fluid and electrolyte imbalances. Foster CE 3rd, et al. **Surg Clin North Am** 1996 Oct;76(5):1019–33 (60 ref.)

[Disorders of electrolytes] Hashizume Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):52–5 (10 ref.) **(Jpn)**

CHEMICALLY INDUCED

[Disturbances of water–electrolyte and acid–base balance due to pharmacologic treatment of hypertension] Kokot F, et al. **Przegl Lek** 1996;53(9):693–6 (7 ref.) (Eng. Abstr.) **(Pol)**

COMPLICATIONS

[Cardiac arrhythmias caused by electrolyte imbalance] Nishimura M, et al. **Nippon Rinsho** 1996 Aug;54(8):2207–12 (8 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Problems and progress in the diagnosis and treatment of polydipsia and hyponatremia. Verghese C, et al. **Schizophr Bull** 1996;22(3):455–64 (65 ref.)

ETIOLOGY

Fluid balance during hysteroscopic surgery. Istre O. **Curr Opin Obstet Gynecol** 1997 Aug;9(4):219–25 (68 ref.)

Fluid and electrolyte management in the neurologically-impaired patient. Parobek V, et al. **J Neurosci Nurs** 1996 Oct;28(5):322–8 (12 ref.)

[Severe and unexpected occurrence of water–electrolyte disorders in the postoperative period] Nesa S, et al. **Acta Urol Belg** 1997 Jun;65(2):71–5 (11 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Clinical indications for the use of urinary steroid profiles in neonates and children. Honour JW, et al. **Ann Clin Biochem** 1997 Jan;34 (Pt 1):45–54 (37 ref.)

PHYSIOPATHOLOGY

Water, electrolyte and acid base disturbances in renal insufficiency. Physiological and pathophysiological significance of cell volume. Busch GL, et al. **Clin Nephrol** 1996 Oct;46(4):270–3 (50 ref.)

Role of aquaporins in water balance disorders. Knepper MA, et al. **Curr Opin Nephrol Hypertens** 1997 Jul;6(4):367–71 (31 ref.)

THERAPY

Some sodium, potassium and water changes in the elderly and their treatment. Andreucci VE, et al. **Nephrol Dial Transplant** 1996;11 Suppl 9:9–17 (113 ref.)

Fluids and electrolytes--clinical aspects. Jospe N, et al. **Pediatr Rev** 1996 Nov;17(11):395–403; quiz 404 (3 ref.)

Fluid and electrolyte therapy in West African adults. Badoe EA. **West Afr J Med** 1997 May–Jun;16(2):64–70 (14 ref.)

VETERINARY

Electrolyte and acid–base disturbances in the horse. Johnson PJ. **Vet Clin North Am Equine Pract** 1995 Dec; 11(3):491–514 (58 ref.)

WATER INTAKE see **DRINKING**

WATER INTOXICATION

see related
WATER-ELECTROLYTE IMBALANCE

WATER MICROBIOLOGY

Marine microorganisms as a source of new natural products. Bernan VS, et al. **Adv Appl Microbiol** 1997;43:57–90 (74 ref.)

Protozoal agents: what are the dangers for the public water supply? Steiner TS, et al. **Annu Rev Med** 1997;48:329–40 (50 ref.)

Decontamination of dental unit water systems: a review of current recommendations. Fayle SA, et al. **Br Dent J** 1996 Nov 23;181(10):369–72 (26 ref.)

Summary of the National Consensus Conference on Foodborne, Waterborne and Enteric Disease Surveillance. **Can Commun Dis Rep** 1996 Jun 1;22(11):81–4 (0 ref.) **(Eng, Fre)**

Microbiology and biodegradation of resin acids in pulp mill effluents: a minireview. Liss SN, et al. **Can J Microbiol** 1997 Jul;43(7):599–611 (100 ref.)

Hyperthermophiles in the history of life. Stetter KO. **Ciba Found Symp** 1996;202:1–10; discussion 11–8 (19 ref.)

Lipid biomarkers for bacterial ecosystems: studies of cultured organisms, hydrothermal environments and ancient sediments. Summons RE, et al. **Ciba Found Symp** 1996; 202:174–93; discussion 193–4 (33 ref.)

Ancient hydrothermal ecosystems on earth: a new palaeobiological frontier. Walter MR. **Ciba Found Symp** 1996;202:112–27; discussion 127–30 (78 ref.)

Waterborne protozoan pathogens. Marshall MM, et al. **Clin Microbiol Rev** 1997 Jan;10(1):67–85 (206 ref.)

Natural protection of spring and well drinking water against surface microbial contamination. II. Indicators and monitoring parameters for parasites. Edberg SC, et al. **Crit Rev Microbiol** 1997;23(2):179–206 (81 ref.)

Pseudomonas aeruginosa: assessment of risk from drinking water. Hardalo C, et al. **Crit Rev Microbiol** 1997; 23(1):47–75 (179 ref.)

Natural protection of spring and well drinking water against surface microbial contamination. I. Hydrogeological parameters. Robertson JB, et al. **Crit Rev Microbiol** 1997; 23(2):143–78 (32 ref.)

Microorganisms as tracers in groundwater injection and recovery experiments: a review. Harvey RW. **FEMS Microbiol Rev** 1997 Jul;20(3–4):461–72 (46 ref.)

In situ microcosms in aquifer bioremediation studies. Mandelbaum RT, et al. **FEMS Microbiol Rev** 1997 Jul; 20(3–4):489–502 (40 ref.)

Sensitive populations: who is at the greatest risk? Gerba CP, et al. **Int J Food Microbiol** 1996 Jun;30(1–2):113–23 (59 ref.)

Developments in microbiological risk assessment models for drinking water--a short review. Gale P. **J Appl Bacteriol** 1996 Oct;81(4):403–10 (27 ref.)

Taxonomical changes in intestinal (faecal) enterococci and streptococci: consequences on their use as indicators of faecal contamination in drinking water. Leclerc H, et al. **J Appl Bacteriol** 1996 Nov;81(5):459–66 (97 ref.)

Trophic controls on stage transformations of a toxic ambush-predator dinoflagellate. Burkholder JM, et al. **J Eukaryot Microbiol** 1997 May–Jun;44(3):200–5 (29 ref.)

Drinking water and microbiological pathogens--issues and challenges for the year 2000. Hellard ME, et al. **J Public Health Med** 1997 Jun;19(2):129–31 (31 ref.)

Marine hitch hikers--the transport of pathogens in ballast water. Murrison AW. **J R Nav Med Serv** 1996 Spring; 82(1):40–3 (34 ref.)

Isolation and identification of yeasts from natural habitats. Spencer JF, et al. **Methods Mol Biol** 1996;53:1–4 (8 ref.)

Advances in the study of marine viruses. Proctor LM. **Microsc Res Tech** 1997 Apr 15;37(2):136–61 (137 ref.)

New indicators to evaluate bacteriological quality of the dialysis fluid and the associated inflammatory response in ESRD patients. Krautzig S, et al. **Nephrol Dial Transplant** 1996;11 Suppl 2:87–91 (29 ref.)

Pathogenic vibrios in the natural aquatic environment. Chakraborty S, et al. **Rev Environ Health** 1997 Apr–Jun; 12(2):63–80 (173 ref.)

Biology of the Humber rivers. Whitton BA, et al. **Sci Total Environ** 1997 Feb 24;194–195:247–62 (145 ref.)

The role of food in the epidemiology of cholera. Albert MJ, et al. **World Health Stat Q** 1997;50(1–2):111–8 (59 ref.)

WATER POLLUTANTS

Water-borne pollutants. Johansson N. **Arctic Med Res** 1996; 55 Suppl 1:6–12 (13 ref.)

ANALYSIS

The calibration of an artificial stream system used to investigate the tolerances of South African riverine invertebrates to selected water quality variables. Palmer CG, et al. **Arch Environ Contam Toxicol** 1997 Jan; 32(1):22–31 (25 ref.)

Specimen banking of marine organisms in the United States: current status and long-term prospective. Becker PR, et al. **Chemosphere** 1997 May;34(9–10):1889–906 (33 ref.)

Risk assessment in the regulatory process for wetlands. Lemly AD. **Ecotoxicol Environ Saf** 1996 Oct;35(1):41–56 (39 ref.)

Determination of coal tar and creosote constituents in the aquatic environment. Hale RC, et al. **J Chromatogr A** 1997 Jul 11;774(1–2):79–95 (154 ref.)

POISONING

Perspectives on Canadian field studies examining the potential of pulp and paper mill effluent to affect fish reproduction. Kovacs TG, et al. **J Toxicol Environ Health** 1997 Jul;51(4):305–52 (77 ref.)

TOXICITY

Aquatic risk assessment of a polycarboxylate dispersant polymer used in laundry detergents. Hamilton JD, et al. **J Toxicol Environ Health** 1996 Sep;49(1):67–82 (36 ref.)

Rubber tire leachates in the aquatic environment. Evans JJ. **Rev Environ Contam Toxicol** 1997;151:67–115 (125 ref.)

WATER POLLUTANTS, CHEMICAL

Bioaccumulation of mercury in the aquatic food chain in newly flooded areas. Bodaly RA, et al. **Met Ions Biol Syst** 1997;34:259–87 (93 ref.)

[New regulation of tap water quality and exposure assessment] Ando M. **Eisei Shikenjo Hokoku** 1994; (112):1–16 (37 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Multiple myeloma: clusters, clues, and dioxins. Schwartz GG. **Cancer Epidemiol Biomarkers Prev** 1997 Jan;6(1):49–56 (84 ref.)

Guideline values for sediments contaminated with dioxins and furans. Comber SD, et al. **Ecotoxicol Environ Saf** 1996 Nov;35(2):102–8 (41 ref.)

The genesis, status and future of environmental toxicology. Bhattacharya S. **Indian J Exp Biol** 1996 Jun;34(6):491–5 (110 ref.)

ANALYSIS

Annual variation of insecticides in precipitation in rural Japan. Kawata K, et al. **Bull Environ Contam Toxicol** 1996 Dec;57(6):853–8 (15 ref.)

Concentrations of chlorinated hydrocarbons and trace elements in marine mammal tissues archived in the U.S. National Biomonitoring Specimen Bank. Becker PR, et al. **Chemosphere** 1997 May;34(9–10):2067–98 (38 ref.)

Behaviour and ecotoxicology of aluminium in soil and water--review of the scientific literature. Klöppel H, et al. **Chemosphere** 1997 Jul;35(1–2):353–63 (33 ref.)

Calculation of soil–water and benthic sediment partition coefficients for mercury. Lyon BF, et al. **Chemosphere** 1997 Aug;35(4):791–808 (30 ref.)

Literature review and analysis of biological complexity in model stream ecosystems: influence of size and experimental design. Belanger SE. **Ecotoxicol Environ Saf** 1997 Feb;36(1):1–16 (187 ref.)

A protocol for aquatic hazard assessment of selenium. Lemly AD. **Ecotoxicol Environ Saf** 1995 Dec;32(3):280–8 (149 ref.)

Strategies for chromatographic analysis of pesticide residues in water. Balinova A. **J Chromatogr A** 1996 Nov 22; 754(1–2):125–35 (125 ref.)

Occurrence and determination of pesticides in natural and treated waters. Biziuk M, et al. **J Chromatogr A** 1996 Nov 22;754(1–2):103–23 (431 ref.)

Screening and analysis of polar pesticides in environmental monitoring programmes by coupled-column liquid chromatography and gas chromatography–mass spectrometry. Hogendoorn EA, et al. **J Chromatogr A** 1996 Nov 22;754(1–2):49–60 (37 ref.)

The longevity of minewater pollution: a basis for decision-making. Younger PL. **Sci Total Environ** 1997 Feb 24;194–195:457–66 (26 ref.)

METABOLISM

Metabolism of micro-organisms responsible for enhanced biological phosphorus removal from wastewater. Use of dynamic enrichment cultures. van Loosdrecht MC, et al. **Antonie Van Leeuwenhoek** 1997 Feb;71(1–2):109–16 (34 ref.)

Microbiology and biodegradation of resin acids in pulp mill effluents: a minireview. Liss SN, et al. **Can J Microbiol** 1997 Jul;43(7):599–611 (100 ref.)

In situ microcosms in aquifer bioremediation studies. Mandelbaum RT, et al. **FEMS Microbiol Rev** 1997 Jul; 20(3–4):489–502 (40 ref.)

TOXICITY

Ecotoxicology of organisms adapted to life in temporary freshwater ponds in arid and semi-arid regions. Lahr J. **Arch Environ Contam Toxicol** 1997 Jan;32(1):50–7 (74 ref.)

Behaviour and ecotoxicology of aluminium in soil and water--review of the scientific literature. Klöppel H, et al. **Chemosphere** 1997 Jul;35(1–2):353–63 (33 ref.)

Ecotoxicology of organotin compounds. Fent K. **Crit Rev Toxicol** 1996 Jan;26(1):1–117 (428 ref.)

Influence of the energy relationships of organic compounds on toxicity to the cladoceran Daphnia magna and the fish Pimephales promelas. Genoni GP. **Ecotoxicol Environ Saf** 1997 Feb;36(1):27–37 (95 ref.)

Environmental quality objectives for 10 polycyclic aromatic hydrocarbons (PAHs). Kalf DF, et al. **Ecotoxicol Environ Saf** 1997 Feb;36(1):89–97 (46 ref.)

Winter stress syndrome: an important consideration for hazard assessment of aquatic pollutants. Lemly AD. **Ecotoxicol Environ Saf** 1996 Aug;34(3):223–7 (22 ref.)

The ecotoxicity of chlorate to aquatic organisms: a critical review. van Wijk DJ, et al. **Ecotoxicol Environ Saf** 1995 Dec;32(3):244–53 (54 ref.)

Evaluation of health risks for contaminated aquifers. Piver WT, et al. **Environ Health Perspect** 1997 Feb;105 Suppl 1:127–43 (156 ref.)

Regulations for combined effects of pollutants: consequences from risk assessment in aquatic toxicology. Altenburger R, et al. **Food Chem Toxicol** 1996 Nov–Dec; 34(11–12):1155–7 (19 ref.)

The Great Lakes: a historical overview. Hicks HE. **Toxicol Ind Health** 1996 May–Aug;12(3–4):303–13 (30 ref.)

WATER POLLUTION

Concepts of marine specimen banking. Rossbach M, et al. **Chemosphere** 1997 May;34(9–10):1997–2010 (39 ref.)

LEGISLATION & JURISPRUDENCE

Impacts of water and air quality legislation on the poultry industry. Morse D. **Poult Sci** 1996 Jul;75(7):857–61 (6 ref.)

PREVENTION & CONTROL

Natural protection of spring and well drinking water against surface microbial contamination. II. Indicators and monitoring parameters for parasites. Edberg SC, et al. **Crit Rev Microbiol** 1997;23(2):179–206 (81 ref.)

Natural protection of spring and well drinking water against surface microbial contamination. I. Hydrogeological parameters. Robertson JB, et al. **Crit Rev Microbiol** 1997; 23(2):143–78 (32 ref.)

The chlorine controversy. Cap AP. **Int Arch Occup Environ Health** 1996;68(6):455–8 (19 ref.)

STATISTICS & NUMERICAL DATA

Research and the problems of litter and medical wastes on the UK coastline. Philipp R, et al. **Br J Clin Pract** 1997 Apr–May;51(3):164–8 (54 ref.)

WATER POLLUTION, CHEMICAL

Microbial transformation of mercury species and their importance in the biogeochemical cycle of mercury. Baldi F. **Met Ions Biol Syst** 1997;34:213–57 (187 ref.)

Impaired immunity in harbour seals [Phoca vitulina] fed environmentally contaminated herring. de Swart RL, et al. **Vet Q** 1996;18 Suppl 3:S127–8 (12 ref.)

PREVENTION & CONTROL

[Protection of water supply sources from synthetic surface-active agents (review)] Mudryĭ IV. **Gig Sanit** 1996 Jul–Aug;(4):6–8 (33 ref.) **(Rus)**

WATER POLLUTION, THERMAL see **WATER POLLUTION**

WATER PURIFICATION

Chloramine removal from water used in hemodialysis. Ward DM. **Adv Ren Replace Ther** 1996 Oct;3(4):337–47 (55 ref.)

Reproductive and developmental effects of disinfection by-products in drinking water. Reif JS, et al. **Environ Health Perspect** 1996 Oct;104(10):1056–61 (26 ref.)

Drinking water chlorination by-products and cancer. Koivusalo M, et al. **Rev Environ Health** 1997 Apr–Jun; 12(2):81–90 (63 ref.)

METHODS

Public health benefits of using algae for simultaneous multiple metal extraction from waters. Pascucci PR, et al. **Rev Environ Health** 1996 Oct–Dec;11(4):205–11 (16 ref.)

WATER SUPPLY

see related
WATER PURIFICATION

Decontamination of dental unit water systems: a review of current recommendations. Fayle SA, et al. **Br Dent J** 1996 Nov 23;181(10):369–72 (26 ref.)

Pseudomonas aeruginosa: assessment of risk from drinking water. Hardalo C, et al. **Crit Rev Microbiol** 1997; 23(1):47–75 (179 ref.)

Epidemiologic aspects of human cryptosporidiosis and the role of waterborne transmission. Meinhardt PL, et al. **Epidemiol Rev** 1996;18(2):118–36 (146 ref.)

Copper tubings, home wells and early childhood cirrhosis. Mühlendahl KE. **Eur J Pediatr** 1996 Dec;155(12):1061–2 (21 ref.)

Microorganisms as tracers in groundwater injection and recovery experiments: a review. Harvey RW. **FEMS Microbiol Rev** 1997 Jul;20(3–4):461–72 (46 ref.)

Taxonomical changes in intestinal (faecal) enterococci and streptococci: consequences on their use as indicators of faecal contamination in drinking water. Leclerc H, et al. **J Appl Bacteriol** 1996 Nov;81(5):459–66 (97 ref.)

Public health benefits of using algae for simultaneous multiple metal extraction from waters. Pascucci PR, et al. **Rev Environ Health** 1996 Oct–Dec;11(4):205–11 (16 ref.)

[Protection of water supply sources from synthetic surface-active agents (review)] Mudryĭ IV. **Gig Sanit** 1996 Jul–Aug;(4):6–8 (33 ref.) **(Rus)**

ANALYSIS

[Copper in the drinking water—cause of gastrointestinal symptoms?] Andersen V, et al. **Nord Med** 1996 Sep; 111(7):230–2 (15 ref.) (Eng. Abstr.) **(Dan)**

STANDARDS

Natural protection of spring and well drinking water against surface microbial contamination. II. Indicators and monitoring parameters for parasites. Edberg SC, et al. **Crit Rev Microbiol** 1997;23(2):179–206 (81 ref.)

Natural protection of spring and well drinking water against surface microbial contamination. I. Hydrogeological parameters. Robertson JB, et al. **Crit Rev Microbiol** 1997; 23(2):143–78 (32 ref.)

Reproductive and developmental effects of disinfection by-products in drinking water. Reif JS, et al. **Environ Health Perspect** 1996 Oct;104(10):1056–61 (26 ref.)

Position of the American Dietetic Association: food and water safety. **J Am Diet Assoc** 1997 Feb;97(2):184–9 (44 ref.)

Drinking water and microbiological pathogens—issues and challenges for the year 2000. Hellard ME, et al. **J Public Health Med** 1997 Jun;19(2):129–31 (31 ref.)

Relevance of water quality to broiler and turkey performance. Barton TL. **Poult Sci** 1996 Jul;75(7):854–6 (1 ref.)

Soil and solid poultry waste nutrient management and water quality. Chapman SL. **Poult Sci** 1996 Jul;75(7):862–6 (26 ref.)

Water quality and poultry production. King AJ. **Poult Sci** 1996 Jul;75(7):852–3 (16 ref.)

[New regulation of tap water quality and exposure assessment] Ando M. **Eisei Shikenjo Hokoku** 1994; (112):1–16 (37 ref.) (Eng. Abstr.) **(Jpn)**

WATERHOUSE-FRIDERICHSEN SYNDROME

SURGERY

Treatment of thromboembolic complications of fulminant meningococcal septic shock. Mele JA 3rd, et al. **Ann Plast Surg** 1997 Mar;38(3):283–90 (29 ref.)

WATERY DIARRHEA SYNDROME see **VIPOMA**

WATERY DIARRHEA WITH HYPOKALEMIC ALKALOSIS see **VIPOMA**

WAXES

see related
CERUMEN
INLAY CASTING WAX

CHEMISTRY

Pattern waxes and inaccuracies in fixed and removable partial denture castings. Diwan R, et al. **J Prosthet Dent** 1997 May;77(5):553–5 (20 ref.)

WDHA see **VIPOMA**

WDHH see **VIPOMA**

WEANING

Weaning: current status and practical recommendations. Maggioni G. **Ann Ist Super Sanita** 1995;31(4):419–25 (50 ref.)

Weaning and dental health. Holt RD. **Proc Nutr Soc** 1997 Mar;56(1A):131–8 (35 ref.)

Ethnic influences on weaning diet in the UK. James J, et al. **Proc Nutr Soc** 1997 Mar;56(1A):121–30 (43 ref.)

Weaning in Britain: practice, policy and problems. Wharton BA. **Proc Nutr Soc** 1997 Mar;56(1A):105–19 (48 ref.)

WEATHER

The association between external weather conditions and pain and stiffness in women with rheumatoid arthritis. Drane D, et al. **J Rheumatol** 1997 Jul;24(7):1309–16 (23 ref.)

Joint pain and weather. A critical review of the literature. Quick DC. **Minn Med** 1997 Mar;80(3):25–9 (24 ref.)

[The influence of biometeorologic conditions on morbidity] Kochmański M, et al. **Pol Merkuriusz Lek** 1996 Aug; 1(2):147–9 (40 ref.) (Eng. Abstr.) **(Pol)**

WEAVER MICE see **MICE, NEUROLOGIC MUTANTS**

WEBER-CHRISTIAN DISEASE see **PANNICULITIS, NODULAR NONSUPPURATIVE**

WEDENSKY INHIBITION see **NEURAL CONDUCTION**

WEGENER'S GRANULOMATOSIS

Specificity of cANCA for Wegener's granulomatosis [letter] Nolan P, et al. **Aust N Z J Med** 1996 Oct;26(5):720–1 (4 ref.)

Wegener's granulomatosis complicating pregnancy: presentation of two patients and review of the literature. Habib A, et al. **Clin Nephrol** 1996 Nov;46(5):332–6 (29 ref.)

The clinical spectrum of Wegener's granulomatosis in the elderly: case study and review of the literature. al-Bilbeisi F, et al. **Med Health R I** 1996 Nov;79(11):392–5 (18 ref.)

[Wegener's granulomatosis] Yoshida M. **Ryoikibetsu Shokogun Shirizu** 1996;(15):168–72 (17 ref.) **(Jpn)**

COMPLICATIONS

A patient with Wegener's granulomatosis presenting with a subarachnoid hemorrhage: case report and review of CNS disease associated with Wegener's granulomatosis. Cruz DN, et al. **Am J Nephrol** 1997;17(2):181–6 (19 ref.)

Chronic meningitis with cranial neuropathies in Wegener's granulomatosis. Case report and review of the literature. Jinnah HA, et al. **Arthritis Rheum** 1997 Mar;40(3):573–7 (17 ref.)

Cerebral involvement in two patients with Wegener's granulomatosis. Bajema IM, et al. **Clin Nephrol** 1997 Jun; 47(6):401–6 (38 ref.)

Subglottic stenosis in Wegener's granulomatosis limited to the head and neck region. Yumoto E, et al. **Ear Nose Throat J** 1997 Aug;76(8):571–4 (15 ref.)

Wegener's granulomatosis, acute laryngotracheal airway obstruction and death in a 17-year-old female: case report and review of the literature. Matt BH. **Int J Pediatr Otorhinolaryngol** 1996 Oct;37(2):163–72 (19 ref.)

Cardiac valve disease in Wegener's granulomatosis [letter] Greidinger EL, et al. **J Rheumatol** 1996 Aug;23(8):1485–7 (11 ref.)

Two genitourinary manifestations of Wegener's granulomatosis. Stone JH, et al. **J Rheumatol** 1997 Sep; 24(9):1846–8 (9 ref.)

Vitamin D metabolite-mediated hypercalcemia in Wegener's granulomatosis. Bosch X, et al. **Mayo Clin Proc** 1997 May; 72(5):440–4 (21 ref.)

Still another case of Wegener's granulomatosis with a digital gangrene [letter; comment] Karjalainen A, et al. **Scand J Rheumatol** 1996;25(5):339 (3 ref.) Comment on: Scand J Rheumatol 1996;25(2):103–4.

[Unilateral peripheral pulmonary nodules: initial symptoms of a limited form of Wegener's disease] Dechambre S, et al. **J Belge Radiol** 1996 Aug;79(4):162–4 (9 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Wegener's granulomatosis. Apropos of a case] el Amine el Alami N, et al. **Rev Stomatol Chir Maxillofac** 1997 Jan; 98(1):12–5 (12 ref.) (Eng. Abstr.) **(Fre)**

[Microscopic polyangiitis with eosinophilia—an overlap syndrome or separate disease entity? A case report and review of the literature] Weninger W, et al. **Hautarzt** 1997 May;48(5):332–8 (48 ref.) (Eng. Abstr.) **(Ger)**

[The diagnosis of Wegener's granulomatosis in a young woman] Il'chenko VP, et al. **Lik Sprava** 1996 Jul–Sep; (7–9):163–5 (8 ref.) **(Rus)**

[Renal vasculitis. Early discovery is significant for prognosis] Westberg G. **Lakartidningen** 1997 Mar 5;94(10):857–60 (11 ref.) **(Swe)**

DRUG THERAPY

Wegener's granulomatosis in pregnancy. Luisiri P, et al. **Arthritis Rheum** 1997 Jul;40(7):1354–60 (21 ref.)

Co-trimoxazole and Wegener's granulomatosis: more than a coincidence? [editorial] Stegeman CA, et al. **Nephrol Dial Transplant** 1997 Apr;12(4):652–5 (20 ref.)

Immunosuppressive therapy is always required for the treatment of limited Wegener's granulomatosis. Hoffman GS. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct; 13(3):249–52 (35 ref.)

IMMUNOLOGY

Infections and Wegener's granulomatosis—a cause and effect relationship? George J, et al. **QJM** 1997 May;90(5):367–73 (63 ref.)

Gene structure of ANCA target antigens: implications for the pathogenesis of vasculitis. Jenne DE. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct;13(3):209–13 (49 ref.)

A lung biopsy is necessary in the management of ANCA-positive patients with chest roentgenographic abnormalities. King TE Jr. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct;13(3):238–40 (10 ref.)

METABOLISM

Vitamin D metabolite-mediated hypercalcemia in Wegener's granulomatosis. Bosch X, et al. **Mayo Clin Proc** 1997 May; 72(5):440–4 (21 ref.)

MICROBIOLOGY

Staphylococcus aureus, trimethoprim-sulfamethoxazole, and Wegener's granulomatosis. Kallenberg CG, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct;13(3):253–5 (19 ref.)

PATHOLOGY

Update in ophthalmic and general pathology: Wegener's granulomatosis—a review of the ophthalmic manifestations. Heathcote JG. **Can J Ophthalmol** 1997 Apr;32(3):149–52 (30 ref.)

Pathology of pulmonary granulomatous vasculitis [see comments] Travis WD. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Mar;13(1):14–27 (107 ref.) Comment in: Sarcoidosis Vasc Diffuse Lung Dis 1996 Mar;13(1):13.

[Microscopic polyarteritis] de Ancos Aracil C, et al. **An Med Interna** 1995 Sep;12(9):456–60 (36 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Wegener's granulomatosis in pregnancy. Luisiri P, et al. **Arthritis Rheum** 1997 Jul;40(7):1354–60 (21 ref.)

THERAPY

New developments in the treatment of Wegener's granulomatosis, polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome. Langford CA,

WEGENER'S GRANULOMATOSIS

et al. **Curr Opin Rheumatol** 1997 Jan;9(1):26–30 (35 ref.)
Renal vasculitis. D'Amico G, et al.
Nephrol Dial Transplant 1996;11 Suppl 9:69–74 (47 ref.)

WEIGHT-BEARING

Osteoarthrosis of the knee and physical load from occupation. Vingård E. **Ann Rheum Dis** 1996 Sep;55(9):677–9 (23 ref.)

PHYSIOLOGY

Force and the motor cortex. Ashe J. **Behav Brain Res** 1997 Jun;86(1):1–15 (75 ref.)
The biomechanics of cartilage load–carriage. Oloyede A, et al. **Connect Tissue Res** 1996;34(2):119–43 (96 ref.)
Evaluation of a rehabilitative pedorthic: plantar pressure alterations with scaphoid pad application. Abu-Faraj ZO, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):328–36 (36 ref.)

WEIGHT GAIN

see related
OBESITY

Gestational weight gain as a predictor of birth and placenta weight according to pre–pregnancy body mass index. Zhou W, et al. **Acta Obstet Gynecol Scand** 1997 Apr;76(4):300–7 (36 ref.)
The concept of "dry weight" in maintenance hemodialysis: flaws in clinical application [editorial] Ifudu O.
Int J Artif Organs 1996 Jul;19(7):384–6 (22 ref.)
Weight gain in women diagnosed with breast cancer. Demark-Wahnefried W, et al. **J Am Diet Assoc** 1997 May; 97(5):519–26, 529; quiz 527–8 (83 ref.)
Addressing women's concerns about weight gain due to smoking cessation. Perkins KA, et al.
J Subst Abuse Treat 1997 Mar–Apr;14(2):173–82 (65 ref.)
A critical review of the relationship between gestational weight gain and preterm delivery. Carmichael SL, et al. **Obstet Gynecol** 1997 May;89(5 Pt 2):865–73 (64 ref.)

DRUG EFFECTS

[Body weight changes under psychotropic treatment] Bernard D, et al. **Presse Med** 1996 Sep 28;25(28):1292–6 (38 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Energy cost of growth in infants. Jéquier E.
Bibl Nutr Dieta 1996;(53):129–34 (18 ref.)
Overconsumption as a cause of weight gain: behavioural–physiological interactions in the control of food intake (appetite). Blundell JE, et al.
Ciba Found Symp 1996;201:138–54; discussion 154–8, 188–93 (69 ref.)
Low resting metabolic rate as a risk factor for weight gain: role of the sympathetic nervous system. Ravussin E.
Int J Obes Relat Metab Disord 1995 Dec;19 Suppl 7:S8–S9 (16 ref.)
Human pattern of food intake and fuel–partitioning during weight recovery after starvation: a theory of autoregulation of body composition. Dulloo AG. **Proc Nutr Soc** 1997 Mar; 56(1A):25–40 (43 ref.)

WEIGHT LIFTING

Spontaneous rupture of the anterior cruciate ligament after anabolic steroids. Freeman BJ, et al. **Br J Sports Med** 1995 Dec;29(4):274–5 (8 ref.)
Cardiovascular complications and anabolic steroids [letter] Dickerman RD, et al. **Eur Heart J** 1996 Dec;17(12):1912 (6 ref.)

INJURIES

Aneurysmal subarachnoid hemorrhage associated with weight training: three case reports. Haykowsky MJ, et al. **Clin J Sport Med** 1996 Jan;6(1):52–5 (21 ref.)

WEIGHT LOSS

see related
THINNESS

Mechanisms causing loss of lean body mass in uremia. Mitch WE. **Adv Nephrol Necker Hosp** 1997;26:133–42 (52 ref.)
Standardization of nomenclature of body composition in weight loss. Roubenoff R, et al. **Am J Clin Nutr** 1997 Jul; 66(1):192–6 (36 ref.)
A review of long–term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity. Pi-Sunyer FX. **Clin Ther** 1996 Nov–Dec; 18(6):1006–35; discussion 1005 (76 ref.)
Dementia is not necessarily a cause of undernutrition [editorial; comment] Morley JE. **J Am Geriatr Soc** 1996 Nov;44(11):1403–4 (34 ref.) Comment on: J Am Geriatr Soc 1996 Nov;44(11):1366–70.
American College of Sports Medicine position stand. Weight loss in wrestlers. Oppliger RA, et al.
Med Sci Sports Exerc 1996 Jun;28(6):ix–xii (72 ref.)
A new uncoupling protein: a potential component of the human body weight regulation system. Wolf G.
Nutr Rev 1997 May;55(5):178–9 (8 ref.)
Methods for voluntary weight loss and control. **Nutrition** 1996 Oct;12(10):663–71 (0 ref.)
Recent implications of weight loss in lung cancer management. Chlebowski RT, et al. **Nutrition** 1996 Jan;12(1 Suppl):S43–7 (61 ref.)
Methods for voluntary weight loss and control: update 1996. Goodrick GK, et al. **Nutrition** 1996 Oct;12(10):672–6 (40 ref.)
Obesity and weight loss in obstructive sleep apnea: a critical review. Strobel RJ, et al. **Sleep** 1996 Feb;19(2):104–15 (82 ref.)
The importance of fat free mass maintenance in weight loss programmes. Marks BL, et al. **Sports Med** 1996 Nov; 22(5):273–81 (45 ref.)
[Significance of intentional weight loss on health] Heitmann BL, et al. **Ugeskr Laeger** 1997 Jun 23;159(26):4099–104 (38 ref.) (Eng. Abstr.) **(Dan)**

DRUG EFFECTS

The effect of megestrol acetate on anorexia, weight loss and cachexia in cancer and AIDS patients (review). Strang P.
Anticancer Res 1997 Jan–Feb;17(1B):657–62 (36 ref.)
Sibutramine: a review of the pharmacology of a novel anti–obesity agent. Stock MJ.
Int J Obes Relat Metab Disord 1997 Mar;21 Suppl 1:S25–9 (29 ref.)
The usefulness of dietary medium–chain triglycerides in body weight control: fact or fancy? Bach AC, et al.
J Lipid Res 1996 Apr;37(4):708–26 (222 ref.)
The fenfluramine/phentermine combination for weight loss [letter] Garrett SD, et al. **Nurse Pract** 1997 Aug;22(8):166, 168, 170 (13 ref.)

PHYSIOLOGY

Mechanisms of loss of lean body mass in patients on chronic dialysis. Dinarello CA, et al. **Blood Purif** 1996;14(5):388–94 (27 ref.)
The benefits of modest weight loss in type II diabetes. Bosello O, et al. **Int J Obes Relat Metab Disord** 1997 Mar;21 Suppl 1:S10–3 (44 ref.)
Defining success in obesity management. Rössner S.
Int J Obes Relat Metab Disord 1997 Mar;21 Suppl 1:S2–4 (15 ref.)
Long–term intervention strategies in obesity treatment. Rössner S. **Int J Obes Relat Metab Disord** 1995 Dec;19 Suppl 7:S29–S33 discussion S34–S35 (26 ref.)
The beneficial effects of modest weight loss on cardiovascular risk factors. Van Gaal LF, et al.
Int J Obes Relat Metab Disord 1997 Mar;21 Suppl 1:S5–9 (28 ref.)
Intentional weight loss: patterns in the general population and its association with morbidity and mortality. Williamson DF. **Int J Obes Relat Metab Disord** 1997 Mar; 21 Suppl 1:S14–9; discussion S20–1 (21 ref.)
The role of low–fat diets and fat substitutes in body weight management: what have we learned from clinical studies? Astrup A, et al. **J Am Diet Assoc** 1997 Jul;97(7 Suppl):S82–7 (33 ref.)
Seminars in medicine of the Beth Israel Deaconess Medical Center. Neuroendocrine responses to starvation and weight loss. Schwartz MW, et al. **N Engl J Med** 1997 Jun 19; 336(25):1802–11 (87 ref.)
Leptin: the weight–reducing plasma protein encoded by the obese gene. **Nutr Rev** 1996 Mar;54(3):91–3 (12 ref.)

WEIGHT-LOSS AGENTS see **ANTI-OBESITY AGENTS**

WEIGHT REDUCTION see **WEIGHT LOSS**

WEIGHTLESSNESS

see related
HYPOGRAVITY

Human physiology in space. Vernikos J. **Bioessays** 1996 Dec; 18(12):1029–37 (50 ref.)
Biology of plant cells in microgravity and under clinostating. Kordyum EL. **Int Rev Cytol** 1997;171:1–78 (299 ref.)
Blunt trauma and operative care in microgravity: a review of microgravity physiology and surgical investigations with implications for critical care and operative treatment in space. Kirkpatrick AW, et al. **J Am Coll Surg** 1997 May; 184(5):441–53 (120 ref.)
Regulation of the systemic circulation at microgravity and during readaptation to 1G. Blomqvist GC.
Med Sci Sports Exerc 1996 Oct;28(10 Suppl):S9–13 (24 ref.)
Clinical aspects of the control of plasma volume at microgravity and during return to one gravity. Convertino VA. **Med Sci Sports Exerc** 1996 Oct;28(10 Suppl):S45–52 (44 ref.)
Space research activities during missions of the past. Frey MA. **Med Sci Sports Exerc** 1996 Oct;28(10 Suppl):S3–8 (28 ref.)
Cardiovascular adaptation to spaceflight. Hargens AR, et al.
Med Sci Sports Exerc 1996 Aug;28(8):977–82 (57 ref.)
Pulmonary function and cardiopulmonary interactions at microgravity. Linnarsson D. **Med Sci Sports Exerc** 1996 Oct;28(10 Suppl):S14–7 (21 ref.)
Role of arginine vasopressin in the regulation of extracellular fluid volume. Norsk P. **Med Sci Sports Exerc** 1996 Oct; 28(10 Suppl):S36–41 (25 ref.)
Clinical models of cardiovascular regulation after weightlessness. Robertson D, et al.
Med Sci Sports Exerc 1996 Oct;28(10 Suppl):S80–4 (28 ref.)
Simulated weightlessness to induce chronic hypoactivity of brain norepinephrine for exercise and stress studies. Sothmann M, et al. **Med Sci Sports Exerc** 1997 Jan; 29(1):39–44 (42 ref.)
[Adaptive potentials of mammals under conditions of weightlessness] Serova LV. **Aviakosm Ekolog Med** 1996; 30(2):5–11 (69 ref.) (Eng. Abstr.) **(Rus)**
[Physiologic effects of weightlessness on man under spaceflight conditions] Gazenko OG, et al.
Fiziol Cheloveka 1997 Mar–Apr;23(2):138–46 (29 ref.) **(Rus)**

ADVERSE EFFECTS

Activation and proliferation of lymphocytes and other mammalian cells in microgravity. Cogoli A, et al.
Adv Space Biol Med 1997;6:33–79 (76 ref.)
Vestibular function and sensory interaction in altered gravity. Kornilova LN. **Adv Space Biol Med** 1997;6:275–313 (73 ref.)
Pharmacology in space: pharmacokinetics. Saivin S, et al.
Adv Space Biol Med 1997;6:107–21 (26 ref.)
Motor function in microgravity: movement in weightlessness. Lackner JR, et al. **Curr Opin Neurobiol** 1996 Dec; 6(6):744–50 (48 ref.)
Life sciences space missions. Overview. Sulzman FM.
J Appl Physiol 1996 Jul;81(1):3–6 (26 ref.)
Exercise as a countermeasure for physiological adaptation to prolonged spaceflight. Convertino VA.
Med Sci Sports Exerc 1996 Aug;28(8):999–1014 (99 ref.)
[Adaptation to weightlessness and stress] Grigor'ev AI, et al. **Aviakosm Ekolog Med** 1996;30(3):4–8 (53 ref.) (Eng. Abstr.) **(Rus)**

WEIGHTLESSNESS SIMULATION

Cerebellar afferents to neuroendocrine cells: implications for adaptive responses to simulated weightlessness. Katafuchi T, et al. **Endocr J** 1995 Dec;42(6):729–37 (42 ref.)

ADVERSE EFFECTS

Activation and proliferation of lymphocytes and other mammalian cells in microgravity. Cogoli A, et al.
Adv Space Biol Med 1997;6:33–79 (76 ref.)

WEIGHTS AND MEASURES

Current methods of measuring ulcers. A review. Houghton E, et al. **J Am Podiatr Med Assoc** 1997 Aug;87(8):358–9 (5 ref.)

WEIL'S DISEASE

[Spirochaetal myocarditis] Shimizu K, et al.
Ryoikibetsu Shokogun Shirizu 1996;(14):158–60 (16 ref.) **(Jpn)**
[Spirochetal pericarditis] Ueyama C, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):582–4 (11 ref.) **(Jpn)**

WELLNESS PROGRAMS see **HEALTH PROMOTION**

WERDNIG–HOFFMANN DISEASE

GENETICS

Spinal muscular atrophy of childhood: genetics. Raymond FL. **Dev Med Child Neurol** 1997 Jun;39(6):419–20 (10 ref.)
The neurobiology of childhood spinal muscular atrophy. Crawford TO, et al. **Neurobiol Dis** 1996 Apr;3(2):97–110 (120 ref.)
Spinal muscular atrophy in childhood. Fidziańska A.
Semin Pediatr Neurol 1996 Jun;3(2):53–8 (31 ref.)
[Childhood spinal muscular atrophies] Colomer J.
Neurologia 1996 Dec;11 Suppl 5:29–42 (29 ref.) (Eng. Abstr.) **(Spa)**
[Genetic diagnosis of the hypotonic newborn] Bauer MS.
Rev Neurol 1997 May;25(141):703–6 (21 ref.) (Eng. Abstr.) **(Spa)**

WERLHOF'S DISEASE see **PURPURA, THROMBOCYTOPENIC, IDIOPATHIC**

WERMER SYNDROME see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 1**

WERNER'S SYNDROME

COMPLICATIONS

[Neurologic complications in a case of Werner syndrome] Just A, et al. **Rev Neurol (Paris)** 1996 Oct;152(10):634–6 (11 ref.) (Eng. Abstr.) **(Fre)**
[Myelodysplastic syndrome with multiple chromosome aberrations in a patient with Werner's syndrome] Mita M, et al. **Rinsho Ketsueki** 1996 Aug;37(8):725–30 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Werner's syndrome developing acute megakaryoblastic leukemia with der(1;7)] Yamada T, et al.
Rinsho Ketsueki 1997 Jan;38(1):28–32 (15 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Werner syndrome: entering the helicase era. Epstein CJ, et al. **Bioessays** 1996 Dec;18(12):1025–7 (23 ref.)
The genetics of aging. Martin GM. **Hosp Pract (Off Ed)** 1997 Feb 15;32(2):47–50, 55–6, 59–61 passim (8 ref.)
The Werner mutation: does it lead to a "public" or "private" mechanism of aging? Martin GM. **Mol Med** 1997 Jun; 3(6):356–8 (20 ref.)
Cloning the gene for Werner syndrome: a disease with many symptoms of premature aging. Lombard DB, et al. **Trends Genet** 1996 Aug;12(8):283–6 (39 ref.)
[Molecular genetic approach to geriatric diseases] Kumahara Y. **Nippon Ronen Igakkai Zasshi** 1996 Jul;33(7):489–94 (20 ref.) **(Jpn)**

WERNICKE AREA see **TEMPORAL LOBE**

WERNICKE'S ENCEPHALOPATHY

DRUG THERAPY

B-complex vitamins in the prophylaxis and treatment of Wernicke–Korsakoff syndrome. Cook CC, et al. **Br J Hosp Med** 1997 May 7–20;57(9):461–5 (45 ref.)

EPIDEMIOLOGY

Wernicke's disease and schizophrenia: a case report and review of the literature. Casanova MF. **Int J Psychiatry Med** 1996;26(3):319–28 (50 ref.)

PHYSIOPATHOLOGY

Wernicke–Korsakoff syndrome. Zubaran C, et al. **Postgrad Med J** 1997 Jan;73(855):27–31 (55 ref.)

WEST SYNDROME see **SPASMS, INFANTILE**

WESTERN WORLD

The importance of intelligence in western societies. Brand CR. **J Biosoc Sci** 1996 Oct;28(4):387–404 (85 ref.)

WET LUNG see **PULMONARY EDEMA**

WHALES

VIROLOGY

[Viruses of whales and dolphins] Birkun AA Jr. **Mikrobiol Z** 1996 Sep–Oct;58(5):100–6 (52 ref.) (Eng. Abstr.) **(Rus)**

WHEAT

ADVERSE EFFECTS

Relation between gliadin structure and coeliac toxicity. Wieser H. **Acta Paediatr Suppl** 1996 May;412:3–9 (39 ref.)

CHEMISTRY

Relation between gliadin structure and coeliac toxicity. Wieser H. **Acta Paediatr Suppl** 1996 May;412:3–9 (39 ref.)
Wheat bran, colon cancer, and breast cancer. What do we have? What do we need? Black RM. **Adv Exp Med Biol** 1996;401:221–9 (37 ref.)

ENZYMOLOGY

Wheat microsomal cytochrome P450 monooxygenases: characterization and importance in the metabolic detoxification and selectivity of wheat herbicides. Frear DS. **Drug Metabol Drug Interact** 1995;12(3–4):329–57 (77 ref.)

GENETICS

QTL analysis to study the association between leaf size and abscisic acid accumulation in droughted rice leaves and comparisons across cereals. Quarrie SA, et al. **Plant Mol Biol** 1997 Sep;35(1–2):155–65 (45 ref.)

HISTORY

From the neolithic revolution to gluten intolerance: benefits and problems associated with the cultivation of wheat. Greco L. **J Pediatr Gastroenterol Nutr** 1997 May; 24(5):S14–6; discussion S16–7 (10 ref.)

IMMUNOLOGY

Allergies to wheat, yeast and royal jelly: a connection between ingestion and inhalation? Baldo BA. **Monogr Allergy** 1996;32:84–91 (12 ref.)

WHEELCHAIRS

Electrodiagnostic study of carpal tunnel syndrome in wheelchair basketball players. Jackson DL, et al. **Clin J Sport Med** 1996 Jan;6(1):27–31 (21 ref.)
Seat cushion design for elderly wheelchair users based on minimization of soft tissue deformation using stiffness and pressure measurements. Brienza DM, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):320–7 (27 ref.)

WHEEZING see **RESPIRATORY SOUNDS**

WHIPLASH INJURIES

Whiplash injury. A clinical review with emphasis on neuro-otological aspects. Fischer AJ, et al. **Clin Otolaryngol** 1997 Jun;22(3):192–201 (134 ref.)
Hyperextension soft tissue injuries of the cervical spine--a review. Johnson G. **J Accid Emerg Med** 1996 Jan;13(1):3–8 (76 ref.)

DIAGNOSIS

Acute neck sprain: "whiplash" reappraised. Hammacher ER, et al. **Injury** 1996 Sep;27(7):463–6 (57 ref.)

EPIDEMIOLOGY

The nosologic status of the whiplash syndrome: a critical review based on a methodological approach. Stovner LJ. **Spine** 1996 Dec 1;21(23):2735–46 (106 ref.)

PHYSIOPATHOLOGY

The whiplash (hyperextension–flexion) syndrome: a disorder of dorsal root ganglion neurons? [editorial] Waxman SG, et al. **J Neurotrauma** 1996 Dec;13(12):735–9 (60 ref.)

PSYCHOLOGY

Whiplash neck injury. Mayou R, et al. **J Psychosom Res** 1996 May;40(5):461–74 (60 ref.)

SURGERY

Odontoid fractures in the child with neurological injury. Direct anterior osteosynthesis with a cortico-spongious screw and literature review. Godard J, et al. **Childs Nerv Syst** 1997 Feb;13(2):105–7 (14 ref.)

WHIPPLE'S DISEASE

[Whipple's disease] Bamba T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):383–6 (17 ref.) **(Jpn)**

COMPLICATIONS

Long-term follow-up in cerebral Whipple's disease. Schnider PJ, et al. **Eur J Gastroenterol Hepatol** 1996 Sep; 8(9):899–903 (37 ref.)
[Neurologic disorders in Whipple's disease] Jović NS, et al. **Srp Arh Celok Lek** 1996 Mar–Apr;124(3–4):98–102 (33 ref.) (Eng. Abstr.) **(Scc)**

DIAGNOSIS

Whipple's disease and the central nervous system. A case report and a review of the literature. Verhagen WI, et al. **Clin Neurol Neurosurg** 1996 Nov;98(4):299–304 (57 ref.)
Whipple disease. Clinical review of 52 cases. The SNFMI Research Group on Whipple Disease. Société Nationale Française de Médecine Interne. Durand DV, et al. **Medicine (Baltimore)** 1997 May;76(3):170–84 (186 ref.)
Whipple's disease: a difficult diagnosis? Peters FP, et al. **Neth J Med** 1996 Sep;49(3):106–11 (18 ref.)
[Whipple disease] Kaufmann M, et al. **Internist (Berl)** 1996 Sep;37(9):895–902 (49 ref.) **(Ger)**
[Whipple's disease: molecular biology—clinical aspects—therapy] Blum HE. **Schweiz Rundsch Med Prax** 1997 Jul 16;86(29–30):1143–6 (13 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Whipple's disease. Marth T, et al. **Semin Gastrointest Dis** 1996 Jan;7(1):41–8 (42 ref.)
[Whipple's disease (editorial)] Ronchetto F, et al. **Recenti Prog Med** 1996 Dec;87(12):609–11 (16 ref.) **(Ita)**

PATHOLOGY

Whipple's disease. Marth T, et al. **Semin Gastrointest Dis** 1996 Jan;7(1):41–8 (42 ref.)

PHYSIOPATHOLOGY

Whipple disease. Clinical review of 52 cases. The SNFMI Research Group on Whipple Disease. Société Nationale Française de Médecine Interne. Durand DV, et al. **Medicine (Baltimore)** 1997 May;76(3):170–84 (186 ref.)

WHIRLPOOL BATHS see **HYDROTHERAPY**

WHISKERS see **VIBRISSAE**

WHISTLEBLOWING see **TRUTH DISCLOSURE**

WHITE BLOOD CELL COUNT see **LEUKOCYTE COUNT**

WHITE BLOOD CELL TRANSFUSION see **LEUKOCYTE TRANSFUSION**

WHITE BLOOD CELLS see **LEUKOCYTES**

WHITE HEIFER DISEASE see **FREEMARTINISM**

WHITE MUSCLE DISEASE

White muscle disease of foals. Löfstedt J. **Vet Clin North Am Equine Pract** 1997 Apr;13(1):169–85 (30 ref.)

WHITE SPOTS see **DENTAL CARIES**

WHITEFISH see **SALMONIDAE**

WHITES

see related
CAUCASOID RACE

Race and child welfare services: past research and future directions. Courtney ME, et al. **Child Welfare** 1996 Mar–Apr;75(2):99–137 (68 ref.)
Religion and subjective health among black and white elders. Musick MA. **J Health Soc Behav** 1996 Sep;37(3):221–37 (60 ref.)
Geographic variation in stroke mortality in blacks and whites in the United States. Pickle LW, et al. **Stroke** 1997 Aug; 28(8):1639–47 (41 ref.)

WHOLE BLOOD COAGULATION TIME

[Whole blood clotting time] Matsuno K. **Nippon Rinsho** 1997 Mar;55 Suppl 1:135–8 (3 ref.) **(Jpn)**

WHOLE-BODY IRRADIATION

see related
HEMIBODY IRRADIATION
LYMPHATIC IRRADIATION

A new immunobiological view of radiation-promoted lymphomagenesis. Coggin JH Jr, et al. **Int J Radiat Biol** 1997 Jan;71(1):81–94 (14 ref.)

ADVERSE EFFECTS

Late onset bone marrow transplant nephropathy. Oyama Y, et al. **Intern Med** 1996 Jun;35(6):489–93 (23 ref.)
Osteochondroma after total body irradiation in bone marrow transplant recipients: report of two cases. Maeda G, et al. **Jpn J Clin Oncol** 1996 Dec;26(6):480–3 (14 ref.)
Efficacy and toxicity of radiation in preparative regimens for pediatric stem cell transplantation. II: Deleterious consequences. Miale TD, et al. **Med Oncol** 1996 Mar; 13(1):43–61 (130 ref.)
Efficacy and toxicity of radiation in preparative regimens for pediatric stem cell transplantation. I: Clinical applications and therapeutic effects. Miale TD, et al. **Med Oncol** 1995 Dec;12(4):231–49 (162 ref.)

METHODS

Efficacy and toxicity of radiation in preparative regimens for pediatric stem cell transplantation. I: Clinical applications and therapeutic effects. Miale TD, et al. **Med Oncol** 1995 Dec;12(4):231–49 (162 ref.)
A CT-aided PC-based physical treatment planning of TBI: a method for dose calculation. Sánchez-Nieto B, et al. **Radiother Oncol** 1997 Jan;42(1):77–85 (27 ref.)
[Technological approaches to total body radiotherapy of cancer patients] Korytova LI, et al. **Vestn Rentgenol Radiol** 1997 Jul–Aug;(4):38–40 (3 ref.) **(Rus)**

WHOLE-CELL RECORDING see **PATCH-CLAMP TECHNIQUES**

WHOLE COMPLEMENT TITER see **COMPLEMENT HEMOLYTIC ACTIVITY ASSAY**

WHOOPING COUGH

see related
PERTUSSIS VACCINE

Pertussis in the 1990s: diagnosis, treatment, and prevention. Pasternack MS. **Curr Clin Top Infect Dis** 1997;17:24–36 (38 ref.)

COMPLICATIONS

A 6-week-old girl with persistent apnea and worsening pulmonary disease. Vernacchio L, et al. **Curr Opin Pediatr** 1996 Oct;8(5):459–66 (67 ref.)

DIAGNOSIS

Diagnostic polymerase chain reaction. Reizenstein E. **Dev Biol Stand** 1997;89:247–54 (26 ref.)
Differences by antigen in seroconversion: sensitivity, specificity and bias in the serological confirmation of pertussis. Wassilak SG, et al. **Dev Biol Stand** 1997;89:221–8 (10 ref.)
Pertussis in primary care practice. Recent advances in diagnosis, treatment, and prevention. Waggoner-Fountain L, et al. **Prim Care** 1996 Dec;23(4):793–804 (45 ref.)

DRUG THERAPY

Pertussis in primary care practice. Recent advances in diagnosis, treatment, and prevention. Waggoner-Fountain

L, et al. **Prim Care** 1996 Dec;23(4):793–804 (45 ref.)

EPIDEMIOLOGY

Pertussis: an update on primary prevention and outbreak control. Scott PT, et al. **Am Fam Physician** 1997 Sep 15; 56(4):1121–8 (31 ref.)

Adult pertussis: a salesman's dream—and an epidemiologist's nightmare. Fine PE. **Biologicals** 1997 Jun;25(2):195–8 (22 ref.)

Epidemiology and prevention of pertussis. He Q, et al. **Curr Opin Pediatr** 1997 Feb;9(1):14–8 (24 ref.)

The role of Bordetella pertussis infections in adults in the epidemiology of pertussis. Cherry JD. **Dev Biol Stand** 1997; 89:181–6 (12 ref.)

Pertussis: a worldwide problem. Ivanoff B, et al. **Dev Biol Stand** 1997;89:3–13 (36 ref.)

Epidemiological determinants of pertussis. Miller E, et al. **Dev Biol Stand** 1997;89:15–23 (16 ref.)

Pertussis vaccination in the United States—new developments and recommendations. Guris D, et al. **Pediatr Ann** 1997 Jun;26(6):372–7 (23 ref.)

Epidemiology of pertussis. Black S. **Pediatr Infect Dis J** 1997 Apr;16(4 Suppl):S85–9 (36 ref.)

IMMUNOLOGY

The acellular pertussis vaccine trials: an interpretation. Plotkin SA, et al. **Pediatr Infect Dis J** 1997 May; 16(5):508–17; discussion 517–9 (46 ref.)

MICROBIOLOGY

Signal transduction and virulence regulation in Bordetella pertussis. Beier D, et al. **Microbiologia** 1996 Jun; 12(2):185–96 (60 ref.)

PHYSIOPATHOLOGY

Autotoxicity of nitric oxide in airway disease. Flak TA, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 2):S202–6 (46 ref.)

PREVENTION & CONTROL

Pertussis: an update on primary prevention and outbreak control. Scott PT, et al. **Am Fam Physician** 1997 Sep 15; 56(4):1121–8 (31 ref.)

Adult pertussis: a salesman's dream—and an epidemiologist's nightmare. Fine PE. **Biologicals** 1997 Jun;25(2):195–8 (22 ref.)

Epidemiology and prevention of pertussis. He Q, et al. **Curr Opin Pediatr** 1997 Feb;9(1):14–8 (24 ref.)

Safety of acellular pertussis vaccine: follow-up studies. Chen RT. **Dev Biol Stand** 1997;89:373–5 (5 ref.)

A consideration of control requirements for acellular pertussis vaccines. Corbel MJ, et al. **Dev Biol Stand** 1997; 89:343–7 (20 ref.)

Implications of different study designs for the evaluation of acellular pertussis vaccines. Fine PE. **Dev Biol Stand** 1997; 89:123–33 (5 ref.)

Are serological responses to acellular pertussis antigens sufficient criteria to ensure that new combination vaccines are effective for prevention of disease? Granoff DM, et al. **Dev Biol Stand** 1997;89:379–89 (39 ref.)

Public health application of acellular pertussis vaccines. Hadler SC, et al. **Dev Biol Stand** 1997;89:355–61 (8 ref.)

Acellular pertussis vaccines: the next step. Halperin SA. **Dev Biol Stand** 1997;89:363–5 (0 ref.)

Absolute and relative efficacy of whole-cell vaccines. Jafari HS. **Dev Biol Stand** 1997;89:167–70 (9 ref.)

The United States research strategy on pertussis. La Montagne JR. **Dev Biol Stand** 1997;89:25–8 (6 ref.)

The effectiveness of whole-cell pertussis vaccines. Plotkin SA. **Dev Biol Stand** 1997;89:171–4 (7 ref.)

Examination of similarities between diphtheria and pertussis and their toxoids provide insight into vaccine-induced protection to Bordetella pertussis. Schneerson R, et al. **Dev Biol Stand** 1997;89:321–6 (35 ref.)

A cellular pertussis vaccine (Infanrix-DTPa; SB-3). A review of its immunogenicity, protective efficacy and tolerability in the prevention of Bordetella pertussis infection. Patel SS, et al. **Drugs** 1996 Aug;52(2):254–75 (136 ref.)

Pertussis, pertussis vaccine, and care of exposed persons. Zimmerman RK, et al. **J Am Board Fam Pract** 1996 Nov-Dec;9(6):422–34 (47 ref.)

Acellular pertussis vaccines developed in Japan and their application for disease control. Aoyama T. **J Infect Dis** 1996 Nov;174 Suppl 3:S264–9 (13 ref.)

Historical review of pertussis and the classical vaccine. Cherry JD. **J Infect Dis** 1996 Nov;174 Suppl 3:S259–63 (35 ref.)

Strategy for pertussis prevention in the World Health Organization's European Region. Dittmann S. **J Infect Dis** 1996 Nov;174 Suppl 3:S291–4 (10 ref.)

Acellular pertussis vaccines: the rationale for an efficacy trial in Germany. Schmitt HJ, et al. **J Infect Dis** 1996 Nov;174 Suppl 3:S287–90 (20 ref.)

A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned [see comments] Schneerson R, et al. **Lancet** 1996 Nov 9;348(9037):1289–92 (38 ref.) Comment in: Lancet 1997 Jan 11;349(9045):136; discussion 137–8. Comment in: Lancet 1997 Jan 11;349(9045):136–7; discussion 137–8. Comment in: Lancet 1997 Jan 11;349(9045);137; discussion 137–8.

Pertussis vaccination in the United States—new developments and recommendations. Guris D, et al. **Pediatr Ann** 1997 Jun;26(6):372–7 (23 ref.)

Epidemiology of pertussis. Black S. **Pediatr Infect Dis J** 1997 Apr;16(4 Suppl):S85–9 (36 ref.)

Combination vaccines consisting of acellular pertussis vaccines. Edwards KM, et al. **Pediatr Infect Dis J** 1997 Apr;16(4 Suppl):S97–102 (24 ref.)

Pertussis: current concepts of pathogenesis and prevention. Hewlett EL. **Pediatr Infect Dis J** 1997 Apr;16(4 Suppl):S78–84 (72 ref.)

The acellular pertussis vaccine trials: an interpretation. Plotkin SA, et al. **Pediatr Infect Dis J** 1997 May; 16(5):508–17; discussion 517–9 (46 ref.)

Acellular pertussis vaccine composed of genetically inactivated pertussis toxin. Peppoloni S, et al. **Physiol Chem Phys Med NMR** 1995;27(4):355–61 (21 ref.)

TRANSMISSION

[Whooping cough in pregnant patients and newborn infants] Hoppe JE. **Z Geburtshilfe Neonatol** 1996 Nov-Dec; 200(6):241–4 (29 ref.) (Eng. Abstr.) **(Ger)**

WIDOWERS see **WIDOWHOOD**

WIDOWHOOD

PSYCHOLOGY

Bereavement and late-life depression: grief and its complications in the elderly. Rozenzweig A, et al. **Annu Rev Med** 1997;48:421–8 (43 ref.)

WIDOWS see **WIDOWHOOD**

WIFE ABUSE see **SPOUSE ABUSE**

WILCOX TEST see **STATISTICS, NONPARAMETRIC**

WILCOXON RANK TEST see **STATISTICS, NONPARAMETRIC**

WILL see **VOLITION**

WILLIAMS-BEUREN SYNDROME see **WILLIAMS SYNDROME**

WILLIAMS SYNDROME

[Williams syndrome] Momma K. **Ryoikibetsu Shokogun Shirizu** 1996;(15):229–31 (17 ref.) **(Jpn)**

GENETICS

Williams syndrome starts making sense [editorial] Ashkenas J. **Am J Hum Genet** 1996 Oct;59(4):756–61 (37 ref.)

Human genetics: dissecting Williams syndrome. Monaco AP. **Curr Biol** 1996 Nov 1;6(11):1396–8 (14 ref.)

Elastin gene deletions in Williams syndrome. Smoot LB. **Curr Opin Pediatr** 1995 Dec;7(6):698–701 (21 ref.)

[Genetic diagnosis of Williams syndrome] Urbán Z, et al. **Orv Hetil** 1997 Jul 6;138(27):1749–52 (27 ref.) (Eng. Abstr.) **(Hun)**

PATHOLOGY

Sudden death in Williams syndrome: report of ten cases. Bird LM, et al. **J Pediatr** 1996 Dec;129(6):926–31 (36 ref.)

WILLIS' CIRCLE see **CIRCLE OF WILLIS**

WILLS

LEGISLATION & JURISPRUDENCE

[Mental competence of dementia patients to execute a will] Wetterling T, et al. **Psychiatr Prax** 1996 Sep;23(5):213–8 (61 ref.) (Eng. Abstr.) **(Ger)**

WILMS' TUMOR see **NEPHROBLASTOMA**

WILMS' TUMOR GENES see **GENES, WILMS' TUMOR**

WILSON'S DISEASE see **HEPATOLENTICULAR DEGENERATION**

WINE

[Cardio-protective effect of red wine as reflected in the literature] Lugasi A, et al. **Orv Hetil** 1997 Mar 16; 138(11):673–8 (50 ref.) (Eng. Abstr.) **(Hun)**

[Mediterranean diet in Spain. Legend or reality? (I). Study of 7 countries. Various elements of the Mediterranean diet: olive oil and red wine] Alvarez-Sala Walther LA, et al. **Rev Clin Esp** 1996 Aug;196(8):548–56 (106 ref.) **(Spa)**

ANALYSIS

Resveratrol: a molecule whose time has come? And gone? Soleas GJ, et al. **Clin Biochem** 1997 Mar;30(2):91–113 (183 ref.)

WING

EMBRYOLOGY

Insect evolution: how did insect wings originate? Jockusch EL, et al. **Curr Biol** 1997 Jun 1;7(6):R358–61 (11 ref.)

GROWTH & DEVELOPMENT

Controlling growth of the wing: vestigial integrates signals from the compartment boundaries. Cohen SM. **Bioessays** 1996 Nov;18(11):855–8 (42 ref.)

Pattern formation in colour on butterfly wings. French V. **Curr Opin Genet Dev** 1997 Aug;7(4):524–9 (30 ref.)

INNERVATION

The evolution of insect wings and their sensory apparatus. Dickinson MH, et al. **Brain Behav Evol** 1997 Jul;50(1):13–24 (70 ref.)

WIRSUNG'S DUCT see **PANCREATIC DUCTS**

WISKOTT-ALDRICH SYNDROME

METABOLISM

The identification of Bruton's tyrosine kinase and Wiskott-Aldrich syndrome protein associated proteins and signalling pathways. Kinnon C, et al. **Biochem Soc Trans** 1997 May;25(2):648–50 (27 ref.)

Disease mechanism: unravelling Wiskott-Aldrich syndrome. Kirchhausen T, et al. **Curr Biol** 1996 Jun 1;6(6):676–8 (19 ref.)

PHYSIOPATHOLOGY

Genetic and clinical advances in Wiskott-Aldrich syndrome. Sullivan KE. **Curr Opin Pediatr** 1995 Dec;7(6):683–7 (34 ref.)

THERAPY

Preclinical investigations that subserve efforts to employ bone marrow transplantation for rheumatoid or autoimmune diseases. Good RA, et al. **J Rheumatol Suppl** 1997 May; 48:5–12 (73 ref.)

WIT AND HUMOR

Humor in the emergency room: a social work perspective. van Wormer K, et al. **Health Soc Work** 1997 May; 22(2):87–92 (17 ref.)

Humor and laughter in palliative care. Dean RA. **J Palliat Care** 1997 Spring;13(1):34–9 (29 ref.)

The power of humor and play as nursing interventions for a child with cancer: a case report. Frankenfield PK. **J Pediatr Oncol Nurs** 1996 Jan;13(1):15–20 (21 ref.)

Humor in medicine. Wender RC. **Prim Care** 1996 Mar; 23(1):141–54 (23 ref.)

WITHDRAWAL SYMPTOMS see **SUBSTANCE WITHDRAWAL SYNDROME**

WITTENBORN SCALES see **PSYCHIATRIC STATUS RATING SCALES**

WIVES see **SPOUSES**

WOLFF-PARKINSON-WHITE SYNDROME

[Wolff-Parkinson-White syndrome] Kitaoka S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):219–23 (19 ref.) **(Jpn)**

[Concealed WPW syndrome] Kitaoka S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):352–5 (17 ref.) **(Jpn)**

[Radiofrequency ablation in patients with Wolff-Parkinson-White syndrome and other accessory pathways] Atié J, et al. **Arq Bras Cardiol** 1996 Mar;66 Suppl 1:29–37 (48 ref.) **(Por)**

PHYSIOPATHOLOGY

The asymptomatic patient with the Wolff-Parkinson-White electrocardiogram. Wellens HJ, et al. **Pacing Clin Electrophysiol** 1997 Aug;20(8 Pt 2):2082–6 (21 ref.)

SURGERY

Catheter ablation of atrioventricular nodal reentrant tachycardia and bypass-tract mediated tachycardias. Orias DW, et al. **Coron Artery Dis** 1996 Jan;7(1):5–11 (44 ref.)

Wolff-Parkinson-White syndrome: surgery to radiofrequency catheter ablation. Gallagher JJ. **Pacing Clin Electrophysiol** 1997 Feb;20(2 Pt 2):512–33 (80 ref.)

[Catheter ablation for therapy of patients with arrhythmia] Aizawa Y, et al. **Nippon Rinsho** 1996 Aug;54(8):2159–64 (17 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Therapy of Wolff-Parkinson-White syndrome and concealed

bypass tracts: part II. Miller JM.
J Cardiovasc Electrophysiol 1996 Feb;7(2):178–187 (36 ref.)
Wolff–Parkinson–White syndrome: surgery to radiofrequency catheter ablation. Gallagher JJ.
Pacing Clin Electrophysiol 1997 Feb;20(2 Pt 2):512–33 (80 ref.)

WOLFFIAN BODY see **MESONEPHROS**

WOLFFIAN DUCT

[Malformations of male internal genitalia originating from the Wolffian duct] Mure PY, et al. **Arch Pediatr** 1997 Feb; 4(2):163–9 (34 ref.) (Eng. Abstr.) **(Fre)**

ABNORMALITIES

[Bilateral persistence of the common mesonephric duct in children. Apropos of a case. Review of the literature] Merrot T, et al. **Prog Urol** 1996 Aug–Sep;6(4):582–6 (12 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

A case of female adnexal tumor of probable Wolffian origin: histologically, tumor cells showed three different patterns. Wagatsuma S, et al. **Tohoku J Exp Med** 1997 Mar; 181(3):371–7 (11 ref.)

WOLFRAM SYNDROME

DIAGNOSIS

[The Wolfram syndrome: diabetes mellitus, hypacusis, optic atrophy and short stature in STH deficiency] Hofmann M, et al. **Dtsch Med Wochenschr** 1997 Jan 24;122(4):86–90 (13 ref.) (Eng. Abstr.) **(Ger)**

WOMEN

Women and diabetes. Lunt H. **Diabet Med** 1996 Dec; 13(12):1009–16 (109 ref.)
Being female in medical school. Observations of a counselor. Wright BV. **J F a Med Assoc** 1996 Aug–Sep;83(7):498–501 (9 ref.)
Women, food, and mood. Kurzer MS. **Nutr Rev** 1997 Jul; 55(7):268–76 (96 ref.)
Poverty among single elderly women under different systems of old-age security: a comparative review. Siegenthaler JK. **Soc Secur Bull** 1996 Fall;59(3):31–44 (59 ref.)

PSYCHOLOGY

Sources of stigma associated with women with HIV. Bunting SM. **ANS Adv Nurs Sci** 1996 Dec;19(2):64–73 (41 ref.)
Psychological well-being of Cambodian women in resettlement. Catolico O. **ANS Adv Nurs Sci** 1997 Jun; 19(4):75–84 (52 ref.)
The challenge for women with a drug-abusing family member: the Jamaican perspective. Boyce–Reid K.
Bull Narc 1995;47(1–2):23–30 (11 ref.)
All my buddies was male: relationship issues of women with addictions. Henderson D, et al.
J Obstet Gynecol Neonatal Nurs 1997 Jul–Aug;26(4):469–76 (41 ref.)
Addiction in women: prevalence, profiles, and meaning. Jessup M. **J Obstet Gynecol Neonatal Nurs** 1997 Jul–Aug; 26(4):449–58 (52 ref.)
Blood and nerves revisited: menopause and the privatization of the body in a Newfoundland postindustrial fishery. Davis DL. **Med Anthropol Q** 1997 Mar;11(1):3–20; discussion 21–5 (44 ref.)
Violence against women. Burge SK. **Prim Care** 1997 Mar; 24(1):67–81 (53 ref.)
Unilateral interventions for women living with heavy drinkers. Barber JG, et al. **Soc Work** 1997 Jan;42(1):69–78 (38 ref.)
Genetic counseling and women. Fine BA.
Womens Health Issues 1997 Jul–Aug;7(4):220–4 (15 ref.)
Defining and measuring unintended pregnancy: issues and concerns. Petersen R, et al. **Womens Health Issues** 1997 Jul–Aug;7(4):234–40 (18 ref.)
Genetic accountability and pregnant women. Rothenberg KH. **Womens Health Issues** 1997 Jul–Aug;7(4):215–9 (12 ref.)

WOMEN, ABUSED see **BATTERED WOMEN**

WOMEN, BATTERED see **BATTERED WOMEN**

WOMEN PHYSICIANS see **PHYSICIANS, WOMEN**

WOMEN, WORKING

Reproductive hazards of the American lifestyle: work during pregnancy. Gabbe SG, et al. **Am J Obstet Gynecol** 1997 Apr;176(4):826–32 (40 ref.)
Welfare recipients' job skills and employment prospects. Burtless GT. **Future Child** 1997 Spring;7(1):39–51 (20 ref.)
Arranging child care. Kisker EE, et al. **Future Child** 1997 Spring;7(1):99–109 (39 ref.)
Effects of low-wage employment on family well-being [comment] Parcel TL, et al. **Future Child** 1997 Spring; 7(1):116–21 (16 ref.) Comment on: Future Child 1997 Spring;7(1):110–5.
When low-income mothers go to work: implications for children [see comments] Zaslow MJ, et al. **Future Child** 1997 Spring;7(1):110–5 (30 ref.) Comment in: Future Child 1997 Spring;7(1):116–21. Comment in: Future Child 1997 Spring;7(1):122–7.
The role of mentors for women in animal science: perspectives from government. Glenn BP. **J Anim Sci** 1996 Nov;74(11):2855–9 (15 ref.)
Assessment and treatment of low back pain in working pregnant women. Ostgaard HC. **Semin Perinatol** 1996 Feb; 20(1):61–9 (25 ref.)
Sociodemographic perspectives on pregnant women at work. Shehan CL. **Semin Perinatol** 1996 Feb;20(1):3–10 (15 ref.)
[Professional work of woman as a risk factor for circulation disorders] Makowiec-Dąbrowska T. **Med Pr** 1996; 47(5):485–500 (45 ref.) (Eng. Abstr.) **(Pol)**

EDUCATION

Turning job finders into job keepers. Hershey AM, et al. **Future Child** 1997 Spring;7(1):74–86 (39 ref.)
Alternative strategies for increasing employment. Nightingale DS, et al. **Future Child** 1997 Spring;7(1):52–64 (30 ref.)

PSYCHOLOGY

Women and career development: a decade of research. Phillips SD, et al. **Annu Rev Psychol** 1997;48:31–59 (255 ref.)
Labouring the emotions: expanding the remit of nursing work? Phillips S. **J Adv Nurs** 1996 Jul;24(1):139–43 (16 ref.)
Women, alcohol and work: interactions of gender, ethnicity and occupational culture. Ames GM, et al.
Soc Sci Med 1996 Dec;43(11):1649–63 (100 ref.)

STATISTICS & NUMERICAL DATA

Breaking through the glass ceiling: an industrial perspective. Harlander SK. **J Anim Sci** 1996 Nov;74(11):2849–54 (10 ref.)
Fixing the leaky pipeline: women scientists in academia. Pell AN. **J Anim Sci** 1996 Nov;74(11):2843–8 (30 ref.)

WOMEN'S HEALTH

Integration or evolution: women's health as a model for interdisciplinary change in medical education. Nelson M, et al. **Acad Med** 1997 Sep;72(9):737–40 (14 ref.)
Do young women in tropical regions constitute a recognized social category? Ahlberg BM. **Acta Trop** 1996 Dec 30; 62(4):201–7 (15 ref.)
A woman-centered agenda for the twenty-first century. Fathalla MF. **Adv Contracept** 1996 Dec;12(4):331–4 (0 ref.)
Women's health in Europe. Landgren BM.
Adv Contracept 1996 Dec;12(4):309–13 (0 ref.)
Oral contraceptives and breast cancer risk. Van Os WA, et al. **Adv Contracept** 1997 Mar;13(1):63–9 (13 ref.)
Controversies in women's health maintenance [see comments] Morrison EH. **Am Fam Physician** 1997 Mar;55(4):1283–90 (50 ref.) Comment in: Am Fam Physician 1997 Mar;55(4):1039, 1042, 1047–8.
Correcting misconceptions about women and heart disease [see comments] Moser DK. **Am J Nurs** 1997 Apr; 97(4):26–33 (20 ref.) Comment in: Am J Nurs 1997 Aug;97(8):17.
How to provide better care for the postmenopausal woman [see comments] Scura KW, et al. **Am J Nurs** 1997 Apr; 97(4):36–43 (9 ref.) Comment in: Am J Nurs 1997 May;97(5):16.
The patient advocate. Jennings RH Jr.
Am J Obstet Gynecol 1997 Aug;177(2):251–5 (15 ref.)
Women and smoking: an update for the 1990s. Kendrick JS, et al. **Am J Obstet Gynecol** 1996 Sep;175(3 Pt 1):528–35 (62 ref.)
Arthritis and women's health: prevalence, impact, and prevention. Callahan LF, et al. **Am J Prev Med** 1996 Sep–Oct;12(5):401–9 (122 ref.)
Reframing women's risk: social inequalities and HIV infection. Zierler S, et al. **Annu Rev Public Health** 1997; 18:401–36 (168 ref.)
Sources of stigma associated with women with HIV. Bunting SM. **ANS Adv Nurs Sci** 1996 Dec;19(2):64–73 (41 ref.)
The epidemic of dieting women: the need for a sociological approach to food and nutrition. Germov J, et al.
Appetite 1996 Oct;27(2):97–108 (60 ref.)
ABC of work related disorders. Women at work. Kapadia LH. **BMJ** 1996 Oct 26;313(7064):1073–6 (0 ref.)
How does hormone replacement therapy affect the longevity of women with different risk profiles? Frank J, et al.
Can Fam Physician 1997 Aug;43:1371–3 (5 ref.)
Preoperative and postoperative care of the elderly woman. Barber HR. **Clin Obstet Gynecol** 1996 Dec;39(4):902–5 (7 ref.)
Risk factors for cardiovascular disease among women. Kuller LH, et al. **Curr Opin Lipidol** 1996 Aug;7(4):203–8 (81 ref.)
Don't test, do sell: legal implications of inclusion and exclusion of women in clinical drug trials. Herz SE.
Epilepsia 1997;38 Suppl 4:S42–9 (21 ref.)
Maximizing the health of women with epilepsy: science and ethics in new drug development. Morrell MJ. **Epilepsia** 1997;38 Suppl 4:S32–41 (119 ref.)
The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and fetal outcome. Morrell MJ. **Epilepsia** 1996;37 Suppl 6:S34–44 (107 ref.)
Clinical decision-making with the woman after menopause. Bidikov I, et al. **Geriatrics** 1997 Mar;52(3):28–35; quiz 36 (22 ref.)
A postmodern perspective on feminist gerontology. Ray RE. **Gerontologist** 1996 Oct;36(5):674–80 (64 ref.)
Women as dental patients: are there any gender differences? Zakrzewska JM. **Int Dent J** 1996 Dec;46(6):548–57 (82 ref.)
Diagnosis and treatment of viral STDs in women. Baker DA.
Int J Fertil Womens Med 1997 Mar–Apr;42(2):107–14 (38 ref.)
Gender-specific physiology: how real is it? How important is it? Legato MJ. **Int J Fertil Womens Med** 1997 Jan–Feb; 42(1):19–29 (90 ref.)
Mood disorders in the female patient. Redmond G.
Int J Fertil Womens Med 1997 Mar–Apr;42(2):67–72 (5 ref.)
Palpitations: what is the mechanism, and when should we treat them? Rosano GM, et al.
Int J Fertil Womens Med 1997 Mar–Apr;42(2):94–100 (23 ref.)
The politics of sex research and constructions of female sexuality: what relevance to sexual health work with young women? Few C. **J Adv Nurs** 1997 Mar;25(3):615–25 (95 ref.)
The concept of hardiness: a brief but critical commentary. Low J. **J Adv Nurs** 1996 Sep;24(3):588–90 (15 ref.)
Women in the new world order: where old values command new respect. Finn SC. **J Am Diet Assoc** 1997 May; 97(5):475–80 (43 ref.)
How clinicians can affect patient smoking behavior through community involvement and clinical practice. Epps RP, et al. **J Am Med Womens Assoc** 1996 Jan–Apr;51(1–2):43–7 (8 ref.)
Nicotine dependence in women. Fant RV, et al.
J Am Med Womens Assoc 1996 Jan–Apr;51(1–2):19–20, 22–4, 28 (74 ref.)
Smoking among adolescent girls: prevalence and etiology. French SA, et al. **J Am Med Womens Assoc** 1996 Jan–Apr; 51(1–2):25–8 (35 ref.)
Smoking cessation and gender: the influence of physiological, psychological, and behavioral factors. Gritz ER, et al.
J Am Med Womens Assoc 1996 Jan–Apr;51(1–2):35–42 (86 ref.)
The impact of managed mental health care on women. Newell AR, et al. **J Am Med Womens Assoc** 1997 Spring; 52(2):69–74 (58 ref.)
A two way view of gender bias in medicine [editorial] Ruiz MT, et al. **J Epidemiol Community Health** 1997 Apr; 51(2):106–9 (45 ref.)
A neglected lesbian health concern: cervical neoplasia. Ferris DG, et al. **J Fam Pract** 1996 Dec;43(6):581–4 (16 ref.)
Women's use of complementary medicine. Combining mainstream medicine with alternative practices. Burg MA.
J Fla Med Assoc 1996 Aug–Sep;83(7):482–8 (21 ref.)
African American women. Disparities in health care. Gary F, et al. **J Fla Med Assoc** 1996 Aug–Sep;83(7):489–93 (26 ref.)
Coronary heart disease in women. Past gaps, present state and future promises. Limacher MC. **J Fla Med Assoc** 1996 Aug–Sep;83(7):455–8 (25 ref.)
Breast health. Challenges and promises. Masood S, et al.
J Fla Med Assoc 1996 Aug–Sep;83(7):459–65 (0 ref.)
Health care of Latina women. Sociocultural factors. Vera MI. **J Fla Med Assoc** 1996 Aug–Sep;83(7):494–7 (15 ref.)
Some contributions from the social system to gender inequalities in heart disease [published erratum appears in J Health Soc Behav 1996 Jun;37(2):preceding 121] McKinlay JB. **J Health Soc Behav** 1996 Mar;37(1):1–26 (102 ref.)
Sequelae of abuse. Health effects of childhood sexual abuse, domestic battering, and rape. Bohn DK, et al.
J Nurse Midwifery 1996 Nov–Dec;41(6):442–56 (106 ref.)
Pharmacologic management of common gastrointestinal health problems in women. Brucker MC, et al.
J Nurse Midwifery 1997 May–Jun;42(3):145–62 (95 ref.)
Sources of information on women's and infants' health. Lee MA. **J Nurse Midwifery** 1996 Sep–Oct;41(5):393–400 (63 ref.)
Toward an understanding of addiction. Flagler S, et al.
J Obstet Gynecol Neonatal Nurs 1997 Jul–Aug;26(4):441–8 (16 ref.)
All my buddies was male: relationship issues of women with addictions. Henderson D, et al.
J Obstet Gynecol Neonatal Nurs 1997 Jul–Aug;26(4):469–76 (41 ref.)
Addiction in women: prevalence, profiles, and meaning. Jessup M. **J Obstet Gynecol Neonatal Nurs** 1997 Jul–Aug; 26(4):449–58 (52 ref.)
Drug treatment for women: traditional models and new directions. Kearney MH.
J Obstet Gynecol Neonatal Nurs 1997 Jul–Aug;26(4):459–68 (52 ref.)
Cervical cancer: a developmental perspective. Klemm PR, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Sep; 25(7):629–34 (42 ref.)
Developmental care: the key to the emergence of the vital older woman. Pulliam LW, et al.
J Obstet Gynecol Neonatal Nurs 1996 Sep;25(7):623–8 (30 ref.)
In harm's way: childbearing women and nicotine. Scheibmeir

M, et al. **J Obstet Gynecol Neonatal Nurs** 1997 Jul–Aug; 26(4):477–84 (49 ref.)

Issues in sexuality and gynecologic care of women with developmental disabilities. Sulpizi LK. **J Obstet Gynecol Neonatal Nurs** 1996 Sep;25(7):609–14 (24 ref.)

Changing women's health, changing nursing practice [see comments] Taylor DL, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Nov–Dec; 25(9):791–802 (55 ref.) Comment in: J Obstet Gynecol Neonatal Nurs 1997 Jul–Aug;26(4):373.

The middle years: women, sexuality, and the self. Wilmoth MC. **J Obstet Gynecol Neonatal Nurs** 1996 Sep; 25(7):615–21 (34 ref.)

Forensic nursing in Pakistan. Bridging the gap between victimized women and health care delivery systems. Carbonu DM, et al. **J Psychosoc Nurs Ment Health Serv** 1997 Jun;35(6):19–27 (41 ref.)

Menopause and osteoporosis: theoretical aspects. Effects of pluriform practices for present day health care and for women. Klinge I. **J Psychosom Obstet Gynaecol** 1997 Jun; 18(2):105–12 (26 ref.)

Medicalization of menopause and public health. Rueda Martinez de Santos JR. **J Psychosom Obstet Gynaecol** 1997 Jun;18(2):175–80 (20 ref.)

The National Women's Tobacco Control Plan. McLellan DL, et al. **J Public Health Policy** 1996;17(1):47–58 (02 ref.)

Female genital mutilation: balancing intolerance of the practice with tolerance of culture. Bashir LM. **J Womens Health** 1997 Feb;6(1):11–4 (12 ref.)

Coronary heart disease. Women's hearts are hard to break. Newnham HH, et al. **Lancet** 1997 Mar;349 Suppl 1:sI3–6 (40 ref.)

Human immunodeficiency virus infection in women. Anastos K, et al. **Med Clin North Am** 1997 Mar;81(2):533–53 (100 ref.)

Women and substance abuse. Stein MD, et al. **Med Clin North Am** 1997 Jul;81(4):979–98 (125 ref.)

Domestic violence: the new standard of care. Holtz HA. **N J Med** 1996 Aug;93(8):33–6 (10 ref.)

Women's health and women's health care: recommendations of the 1996 AAN Expert Panel on Women's Health. **Nurs Outlook** 1997 Jan–Feb;45(1):7–15 (27 ref.)

Human papillomatous virus infection update: impact on women's health. Carson S. **Nurse Pract** 1997 Apr; 22(4):24–5, 28–30, 35–7 (23 ref.)

Women's issues in epilepsy. Menses, childbearing, and more. Liporace JD. **Postgrad Med** 1997 Jul;102(1):123–4, 127–9, 133–5 passim (32 ref.)

Alcoholism in women. More common—and serious—than you might think. North CS. **Postgrad Med** 1996 Oct; 100(4):221–4, 230, 232–3 (25 ref.)

Methodological issues of randomized controlled trials for the evaluation of reproductive health interventions. Villar J, et al. **Prev Med** 1996 May–Jun;25(3):365–75 (53 ref.)

Folate requirements for health in women. McNulty H. **Proc Nutr Soc** 1997 Mar;56(1B):291–303 (86 ref.)

Nutritional issues for women in developing countries. Walker SP. **Proc Nutr Soc** 1997 Mar;56(1B):345–56 (66 ref.)

Where women stand today in primary prevention of coronary heart disease. Drown DJ. **Prog Cardiovasc Nurs** 1997 Spring;12(2):34–6 (15 ref.)

Psychosocial issues and lung cancer: a behavioral approach. Ryan LS. **Semin Oncol Nurs** 1996 Nov;12(4):318–23 (80 ref.)

Lymphatic filariasis and the women of India. Bandyopadhyay L. **Soc Sci Med** 1996 May;42(10):1401–10 (33 ref.)

Psychosocial factors of coronary heart disease in women: a review. Brezinka V, et al. **Soc Sci Med** 1996 May; 42(10):1351–65 (187 ref.)

Women, health and the environment. Kettel B. **Soc Sci Med** 1996 May;42(10):1367–79 (47 ref.)

Gender perspectives and quality of care in underdeveloped countries: disease, gender and contextuality. Zaidi SA. **Soc Sci Med** 1996 Sep;43(5):721–30 (52 ref.)

The profile of HIV infection in women: a challenge to the profession. Katz DA. **Soc Work Health Care** 1997; 24(3–4):127–34 (18 ref.)

Women's HIV risk reduction efforts and traditional models of health behavior: a review and critique. Gillespie CC. **Womens Health** 1997 Spring;3(1):1–30 (123 ref.)

Policy implications of the Human Genome Project for women. Cassel CK. **Womens Health Issues** 1997 Jul–Aug; 7(4):225–9 (10 ref.)

Reproductive health and blurred professional boundaries. Chavkin W, et al. **Womens Health Issues** 1996 Mar–Apr; 6(2):89–96 (46 ref.)

Genetic counseling and women. Fine BA. **Womens Health Issues** 1997 Jul–Aug;7(4):220–4 (15 ref.)

The women's health specialty: curriculum implications. Hunt L. **Womens Health Issues** 1997 Mar–Apr;7(2):116–20 (14 ref.)

An overview of the Human Genome Project and its implications for women. Mahowald MB. **Womens Health Issues** 1997 Jul–Aug;7(4):206–8 (5 ref.)

[Increased concentration on research of women's health] Schei B, et al. **Tidsskr Nor Laegeforen** 1997 Apr 30; 117(11):1634–6 (42 ref.) **(Nor)**

[Professional work of woman as a risk factor for circulation disorders] Makowiec-Dąbrowska T. **Med Pr** 1996; 47(5):485–500 (45 ref.) (Eng. Abstr.) **(Pol)**

WOMEN'S HEALTH SERVICES

The politics of women's health: setting a global agenda. Doyal L. **Int J Health Serv** 1996;26(1):47–65 (73 ref.)

[Female Medicine in the Elderly] Sugawa T. **Nippon Ronen Igakkai Zasshi** 1996 Jan;33(1):4–6 (7 ref.) **(Jpn)**

LEGISLATION & JURISPRUDENCE

Empowering battered women transnationally: the case for postmodern interventions. Mills L. **Soc Work** 1996 May; 41(3):261–8 (38 ref.)

ORGANIZATION & ADMINISTRATION

The cultural and social consequences and effect on families of women's involvement in drug trafficking in Cameroon: crime and imprisonment. Nouthe-Djubgang J, et al. **Bull Narc** 1995;47(1–2):31–7 (5 ref.)

Women's health education: an opportunity for community pharmacy. Knowlton CH, et al. **J Am Pharm Assoc (Wash)** 1997 Jan–Feb;NS37(1):109–20; quiz 121–2 (11 ref.)

Outcomes management in women's health. Houston S, et al. **J Obstet Gynecol Neonatal Nurs** 1997 May–Jun; 26(3):342–50 (19 ref.)

Toward an integrative science of women's health. Walker LO, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Jun; 25(5):379–82 (33 ref.)

Background and overview of mental health and substance abuse treatment systems: meeting the needs of women who are pregnant or parenting. Grella CE. **J Psychoactive Drugs** 1996 Oct–Dec;28(4):319–43 (236 ref.)

Disease management initiatives in women's health. Moore DL. **J Womens Health** 1997 Feb;6(1):23–9 (9 ref.)

Women's access to appropriate providers within managed care: implications for the quality of primary care. Bartman BA. **Womens Health Issues** 1996 Jan–Feb;6(1):45–50 (21 ref.)

Women's health in HMOs: what we know and what we need to find out. Bernstein AB. **Womens Health Issues** 1996 Jan–Feb;6(1):51–9 (26 ref.)

Delivering breast and cervical cancer screening services to underserved women: Part I. Literature review and telephone survey. Vellozzi CJ, et al. **Womens Health Issues** 1996 Mar–Apr;6(2):65–73 (34 ref.)

Planning for women's health care services. Warner CK. **Womens Health Issues** 1996 Jan–Feb;6(1):60–3 (4 ref.)

STANDARDS

Women's health and women's health care: recommendations of the 1996 AAN Expert Panel on Women's Health. **Nurs Outlook** 1997 Jan–Feb;45(1):7–15 (27 ref.)

Gender perspectives and quality of care: towards appropriate and adequate health care for women. Gijsbers van Wijk CM, et al. **Soc Sci Med** 1996 Sep;43(5):707–20 (75 ref.)

TRENDS

Women's health initiative. Why now? What is it? What's new? Matthews KA, et al. **Am Psychol** 1997 Feb;52(2):101–16 (100 ref.)

Changing women's health, changing nursing practice [see comments] Taylor DL, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Nov–Dec; 25(9):791–802 (55 ref.) Comment in: J Obstet Gynecol Neonatal Nurs 1997 Jul–Aug;26(4):373.

WOMEN'S LIBERATION see **WOMEN'S RIGHTS**

WOMEN'S RIGHTS

see related
FEMINISM

Reframing women's risk: social inequalities and HIV infection. Zierler S, et al. **Annu Rev Public Health** 1997; 18:401–36 (168 ref.)

The politics of women's health: setting a global agenda. Doyal L. **Int J Health Serv** 1996;26(1):47–65 (73 ref.)

Legislating to preserve women's autonomy during pregnancy. Feitshans IL. **Med Law** 1995;14(5–6):397–412 (40 ref.)

Gender justice in genetics. Mahowald MB. **Womens Health Issues** 1997 Jul–Aug;7(4):230–3 (4 ref.)

In quest of the perfect analogy for using in vitro fertilization patients as oocyte donors. Nisker JA. **Womens Health Issues** 1997 Jul–Aug;7(4):241–7 (31 ref.)

LEGISLATION & JURISPRUDENCE

Empowering battered women transnationally: the case for postmodern interventions. Mills L. **Soc Work** 1996 May; 41(3):261–8 (38 ref.)

WOOD

Microorganisms and enzymes involved in the degradation of plant fiber cell walls. Kuhad RC, et al. **Adv Biochem Eng Biotechnol** 1997;57:45–125 (676 ref.)

Hemicellulases in the bleaching of chemical pulps. Suurnäkki A, et al. **Adv Biochem Eng Biotechnol** 1997;57:261–87 (140 ref.)

What to do about softwood? A review of respiratory effects and recommendations regarding exposure limits. Demers PA, et al. **Am J Ind Med** 1997 Apr;31(4):385–98 (72 ref.)

Wood dust and nasal cancer risk. A review of the evidence from North America. Blot WJ, et al. **J Occup Environ Med** 1997 Feb;39(2):148–56 (51 ref.)

WOOLLY MONKEY see **CEBIDAE**

WORK

see related
EFFICIENCY
EMPLOYMENT

Work and leisure: transcending the dichotomy. Primeau LA. **Am J Occup Ther** 1996 Jul–Aug;50(7):569–77 (61 ref.)

Nearwork-induced transient myopia: a critical review. Ong E, et al. **Doc Ophthalmol** 1995;91(1):57–85 (64 ref.)

Environmental influences on blood pressure and the role of job strain. Pickering TG, et al. **J Hypertens Suppl** 1996 Dec;14(5):S179–85 (67 ref.)

[Adaptational autoregulation of humans during work activities (literature review)] Akhlakov MK, et al. **Med Tr Prom Ekol** 1997;(5):21–4 (21 ref.) **(Rus)**

PHYSIOLOGY

Ergonomics. Scheer SJ, et al. **Arch Phys Med Rehabil** 1997 Mar;78(3 Suppl):S36–45 (66 ref.)

The hand in the cold, performance and risk. Havenith G, et al. **Arctic Med Res** 1995;54 Suppl 2:37–47 (48 ref.)

Prediction of responses to cold. Holmér I. **Arctic Med Res** 1995;54 Suppl 2:48–54 (34 ref.)

Dynamic work in cold. Oksa J, et al. **Arctic Med Res** 1995; 54 Suppl 2:29–31 (15 ref.)

Water balance and physical performance in cold. Rintamäki H, et al. **Arctic Med Res** 1995;54 Suppl 2:32–6 (26 ref.)

PSYCHOLOGY

Labouring the emotions: expanding the remit of nursing work? Phillips S. **J Adv Nurs** 1996 Jul;24(1):139–43 (16 ref.)

WORK CAPACITY EVALUATION

Job analysis in occupational therapy: stepping into the complex world of business and industry. Lysaght R. **Am J Occup Ther** 1997 Jul–Aug;51(7):569–75 (31 ref.)

Incorporating occupational medicine methodology into military fitness for duty and readiness issues. Popper SE. **Aviat Space Environ Med** 1997 Aug;68(8):740–5 (28 ref.)

Design-oriented functional capacity evaluation: the available motions inventory—a review. Malzahn DE, et al. **Disabil Rehabil** 1996 Aug;18(8):382–95 (21 ref.)

Finnish research project on aging workers in 1981–1992. Tuomi K, et al. **Scand J Work Environ Health** 1997;23 Suppl 1:7–11 (33 ref.)

[The role of health care in occupationally disability (see comments)] ten Hove-Edens M, et al. **Ned Tijdschr Geneeskd** 1996 Oct 5;140(40):1982–6 (46 ref.) Comment in: Ned Tijdschr Geneeskd 1996 Dec 7;140(49):2477. **(Dut)**

[Glaucoma and aircraft pilot fitness] Schwartz R, et al. **Ophthalmologe** 1996 Feb;93(1):76–9 (18 ref.) (Eng. Abstr.) **(Ger)**

[Performance capacity of elderly workers—internal and external influencing factors] Dittmann-Kohli F, et al. **Z Gerontol Geriatr** 1996 Sep–Oct;29(5):323–7 (47 ref.) (Eng. Abstr.) **(Ger)**

[On work capacity certification among persons with nervous system dysfunction] Polakowska B. **Med Pr** 1996;47(1):73–6 (11 ref.) (Eng. Abstr.) **(Pol)**

WORK SATISFACTION see **JOB SATISFACTION**

WORK SCHEDULE TOLERANCE

Air traffic controller shiftwork: what are the implications for aviation safety? A review. Luna TD. **Aviat Space Environ Med** 1997 Jan;68(1):69–79 (142 ref.)

Alertness-enhancing drugs as a countermeasure to fatigue in irregular work hours. Akerstedt T, et al. **Chronobiol Int** 1997 Mar;14(2):145–58 (81 ref.)

Interindividual differences in the flexibility of human temporal organization: pertinence to jet lag and shiftwork. Ashkenazi IE, et al. **Chronobiol Int** 1997 Mar;14(2):99–113 (35 ref.)

Changing schedules: shiftwork. Knauth P. **Chronobiol Int** 1997 Mar;14(2):159–71 (24 ref.)

Promoting sleep in shiftworkers and intercontinental travelers. Stone BM, et al. **Chronobiol Int** 1997 Mar; 14(2):133–43 (64 ref.)

Models of shiftwork and health: an examination of the influence of stress on shiftwork theory. Taylor E, et al. **Hum Factors** 1997 Mar;39(1):67–82 (58 ref.)

Health and safety problems associated with long working hours: a review of the current position. Spurgeon A, et al. **Occup Environ Med** 1997 Jun;54(6):367–75 (76 ref.)

PHYSIOLOGY

The problem: shiftwork. Costa G. **Chronobiol Int** 1997 Mar; 14(2):89–98 (42 ref.)

Some comments on the measurement of circadian rhythms

after time-zone transitions and during night work. Waterhouse J, et al. **Chronobiol Int** 1997 Mar;14(2):125–32 (45 ref.)
Work hours and sleepiness. Akerstedt T. **Neurophysiol Clin** 1995;25(6):367–75 (68 ref.) (Eng. Abstr.)
Some measures to reduce effects of prolonged sleep deprivation. Lagarde D, et al. **Neurophysiol Clin** 1995; 25(6):376–85 (28 ref.) (Eng. Abstr.)

WORKERS' COMPENSATION

see related
DISABILITY EVALUATION

ECONOMICS

Compensation for hearing loss. Dobie RA. **Audiology** 1996 Jan–Feb;35(1):1–7 (20 ref.)
Prevention of low back disability. Waddell G. **Bull Hosp Jt Dis** 1996;55(4):221–4 (28 ref.)

LEGISLATION & JURISPRUDENCE

Occupationally acquired HIV: the vulnerability of health care workers under workers' compensation laws. Tereskerz PM, et al. **Am J Public Health** 1997 Sep;87(9):1558–62 (36 ref.)
Medicolegal aspects of neurotology. Hart CW, et al. **Otolaryngol Clin North Am** 1996 Jun;29(3):503–20 (29 ref.)
Policy development for compensating workers exposed to crystalline silica in Ontario, Canada. Elinson L, et al. **Scand J Work Environ Health** 1995;21 Suppl 2:111–4 (14 ref.)
[Epicondylitis and tenosynovitis or peritendinitis as an occupational disease] Kivi P, et al. **Duodecim** 1995; 111(17):1703–7 (8 ref.) **(Fin)**
[Significance of isthmic spondylolisthesis in expert assessment of occupational disease of the lumbar spine] Grosser V, et al. **Unfallchirurg** 1996 Jul;99(7):470–6 (16 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

The future role of managed care and capitation in worker's compensation. Hashimoto DM. **Am J Law Med** 1996; 22(2–3):233–61 (0 ref.)

STATISTICS & NUMERICAL DATA

Workplace organizational correlates of lost-time accident rates in manufacturing. Shannon HS, et al. **Am J Ind Med** 1996 Mar;29(3):258–68 (17 ref.)

WORKING WOMEN see **WOMEN, WORKING**

WORKLOAD

Managing fatigue in operational settings 2: An integrated approach. Rosekind MR, et al. **Behav Med** 1996 Winter; 21(4):166–70 (7 ref.)
Compensatory control in the regulation of human performance under stress and high workload; a cognitive-energetical framework. Hockey GR. **Biol Psychol** 1997 Mar 21;45(1–3):73–93 (48 ref.)
Combining time and intensity effects in assessing operator information-processing load. Hendy KC, et al. **Hum Factors** 1997 Mar;39(1):30–47 (56 ref.)
The role of production control in the development of burnout. Houben GJ, et al. **Int J Health Serv** 1996; 26(2):331–53 (97 ref.)

LEGISLATION & JURISPRUDENCE

Health and safety problems associated with long working hours: a review of the current position. Spurgeon A, et al. **Occup Environ Med** 1997 Jun;54(6):367–75 (76 ref.)

PSYCHOLOGY

On the current status of rated perceived exertion. Russell WD. **Percept Mot Skills** 1997 Jun;84(3 Pt 1):799–808 (52 ref.)
Psychosocial work environment in human service organizations: a conceptual analysis and development of the demand-control model. Söderfeldt B, et al. **Soc Sci Med** 1996 May;42(9):1217–26 (50 ref.)

WORKMEN'S COMPENSATION see **WORKERS' COMPENSATION**

WORKPLACE

Violence in the workplace. Hewitt JB, et al. **Annu Rev Nurs Res** 1997;15:81–99 (72 ref.)
Sexual harassment and hostile environments in the perioperative area. Kaye J. **AORN J** 1996 Feb;63(2):443–6, 448–9 (51 ref.)
Managing fatigue in operational settings. 1: Physiological considerations and countermeasures. Rosekind MR, et al. **Behav Med** 1996 Winter;21(4):157–65 (41 ref.)
Stress in the workplace. Cooper CL. **Br J Hosp Med** 1996 May 1–14;55(9):559–63 (22 ref.)
Multiple exposure to solvents in the workplace. Alessio L. **Int Arch Occup Environ Health** 1996;69(1):1–4 (29 ref.)
Workplace violence: preventive and interventive strategies. Warshaw LJ, et al. **J Occup Environ Med** 1996 Oct; 38(10):993–1006 (53 ref.)
Sexual orientation: a cultural diversity issue for nursing. Misener TR, et al. **Nurs Outlook** 1997 Jul–Aug;45(4):178–81 (42 ref.)
Legal and ethical aspects of medical screening. Rothstein MA. **Occup Med** 1996 Jan–Mar;11(1):31–9 (27 ref.)
Drug testing programs in government agencies and private workplaces. The legal challenge continues. Snyder JW, et al. **Occup Med** 1996 Jan–Mar;11(1):87–100 (52 ref.)

LEGISLATION & JURISPRUDENCE

Title I of the Americans with disabilities act. Langer CS. **Occup Med** 1996 Jan–Mar;11(1):5–16 (5 ref.)

ORGANIZATION & ADMINISTRATION

Workplace organizational correlates of lost-time accident rates in manufacturing. Shannon HS, et al. **Am J Ind Med** 1996 Mar;29(3):258–68 (17 ref.)

WORLD HEALTH

Antimicrobial resistance: a global perspective. Levy SB. **Adv Exp Med Biol** 1995;390:1–13 (42 ref.)
International Federation of Infection Control: the first 10 years. Hambraeus A, et al. **Am J Infect Control** 1997 Aug; 25(4):297–302 (16 ref.)
A global perspective on the past, present, and future of nosocomial infection prevention and control [editorial] Soule BM, et al. **Am J Infect Control** 1997 Aug;25(4):289–93 (25 ref.)
Malaria in the 1990s: plus ça change, plus ça même chose [editorial] Walker J. **Aust N Z J Public Health** 1997 Jun; 21(3):244–6 (11 ref.)
The origin and erratic global spread of tuberculosis. How the past explains the present and is the key to the future. Stead WW. **Clin Chest Med** 1997 Mar;18(1):65–77 (60 ref.)
Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and Lung Disease. Cohn DL, et al. **Clin Infect Dis** 1997 Jan; 24 Suppl 1:S121–30 (97 ref.)
Approaches to limiting emergence of antimicrobial resistance in bacteria in human populations. Hughes JM, et al. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S131–5 (43 ref.)
The global epidemic nature of antimicrobial resistance and the need to monitor and manage it locally. O'Brien TF. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S2–8 (35 ref.)
The global impact of neonatal infection. Stoll BJ. **Clin Perinatol** 1997 Mar;24(1):1–21 (175 ref.)
International perspectives on ethics in critical care. Nyman DJ, et al. **Crit Care Clin** 1997 Apr;13(2):409–15 (36 ref.)
The age of extremes: concentrated affluence and poverty in the twenty-first century [see comments] Massey DS. **Demography** 1996 Nov;33(4):395–412; discussion 413–6 (100 ref.) Comment in: Demography 1996 Nov;33(4):417–20; discussion 427–8. Comment in: Demography 1996 Nov;33(4):421–5; discussion 427–8.
Ethics, values, and world culture: the impact on rehabilitation. Banja JD. **Disabil Rehabil** 1996 Jun; 18(6):279–84 (7 ref.)
The health effects of earthquakes in the mid-1990s. Alexander D. **Disasters** 1996 Sep;20(3):231–47 (34 ref.)
Global warming and health: a review. Amofah GK. **East Afr Med J** 1996 Aug;73(8):560–2 (30 ref.)
Epidemiological aspects of antimicrobial drug resistance. Kariuki SM, et al. **East Afr Med J** 1997 Mar;74(3):124–8 (50 ref.)
Globalization, international law, and emerging infectious diseases [see comments] Fidler DP. **Emerg Infect Dis** 1996 Apr–Jun;2(2):77–84 (33 ref.) Comment in: Emerg Infect Dis 1996 Apr–Jun;2(2):151.
Designing an international policy and legal framework for the control of emerging infectious diseases: first steps. Plotkin BJ, et al. **Emerg Infect Dis** 1997 Jan–Mar;3(1):1–9 (38 ref.)
Emerging infections: pandemic influenza. Glezen WP. **Epidemiol Rev** 1996;18(1):64–76 (83 ref.)
Hepatitis C virus and hepatocellular carcinoma [editorial] Giacosa A, et al. **Eur J Cancer Prev** 1996 Dec;5(6):423–4 (5 ref.)
The politics of women's health: setting a global agenda. Doyal L. **Int J Health Serv** 1996;26(1):47–65 (73 ref.)
Japan/United States collaboration in international HIV prevention and care. Brown T, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 2:S68–80 (18 ref.)
Interrelationships of food, nutrition, diet and health: the National Association of State Universities and Land Grant Colleges White Paper. Bidlack WR. **J Am Coll Nutr** 1996 Oct;15(5):422–33 (52 ref.)
Hypertension control in the world: an agenda for the coming decade (the 1995 WHL Ottawa Declaration). **J Hum Hypertens** 1996 Feb;10 Suppl 1:S1–3 (20 ref.)
National immunization days: state of the art. Birmingham ME, et al. **J Infect Dis** 1997 Feb;175 Suppl 1:S183–8 (39 ref.)
The biologic principles of poliovirus eradication. Dowdle WR, et al. **J Infect Dis** 1997 Feb;175 Suppl 1:S286–92 (74 ref.)
International perspectives on individual and community approaches to the prevention of sexually transmitted disease and human immunodeficiency virus infection. O'Reilly KR, et al. **J Infect Dis** 1996 Oct;174 Suppl 2:S214–22 (51 ref.)
Outbreaks of paralytic poliomyelitis, 1976–1995. Patriarca PA, et al. **J Infect Dis** 1997 Feb;175 Suppl 1:S165–72 (114 ref.)
The story of nutrition [editorial] Hashim SA. **J Med Liban** 1997;45(2):68–72 (0 ref.)
Overview of perinatal HIV infection. Fowler MG, et al. **J Nutr** 1996 Oct;126(10 Suppl):2602S–2607S (51 ref.)
An international perspective on palliative care for children. Martinson I. **J Palliat Care** 1996 Autumn;12(3):13–5 (15 ref.)
The state of world health, 1995. **J Public Health Policy** 1995; 16(4):440–51 (0 ref.)
Tuberculosis—the global challenge [editorial] Ebrahim GJ. **J Trop Pediatr** 1996 Aug;42(4):190–1 (17 ref.)
Negotiating relevance: belief, knowledge, and practice in international health projects [see comments] Yoder PS. **Med Anthropol Q** 1997 Jun;11(2):131–46 (54 ref.) Comment in: Med Anthropol Q 1997 Jun;11(2):252–5.
The consumption bomb. Butler CD. **Med Confl Surviv** 1997 Jul–Sep;13(3):209–18 (50 ref.)
Living conditions, inequalities in health, human rights and security: a European perspective in a global context. Middleton J. **Med Confl Surviv** 1996 Jul–Sep;12(3):240–53 (76 ref.)
The social, cultural and political dimensions of contemporary war. Summerfield D. **Med Confl Surviv** 1997 Jan–Mar; 13(1):3–25 (39 ref.)
The nutrition transition: new trends in the global diet. Drewnowski A, et al. **Nutr Rev** 1997 Feb;55(2):31–43 (57 ref.)
Worldwide prevention of vertical human immunodeficiency virus (HIV) transmission. van Vliet A, et al. **Obstet Gynecol Surv** 1997 May;52(5):301–9 (87 ref.)
A review of perinatal autopsy rates worldwide, 1960s to 1990s [see comments] Khong TY. **Paediatr Perinat Epidemiol** 1996 Jan;10(1):97–105; discussion 106–9 (67 ref.) Comment in: Paediatr Perinat Epidemiol 1996 Jul;10(3):363–4.
Re-assessing the global prevalence and distribution of lymphatic filariasis. Michael E, et al. **Parasitology** 1996 Apr; 112 (Pt 4):409–28 (200 ref.)
Annual summary of vital statistics—1995. Guyer B, et al. **Pediatrics** 1996 Dec;98(6 Pt 1):1007–19 (43 ref.)
Reproduction: a global nutritional challenge. Goldberg GR. **Proc Nutr Soc** 1997 Mar;56(1B):319–33 (58 ref.)
Demographic yearbook 1992: the disease picture of the developed and developing worlds compared [see comments] Brockington CF. **Public Health** 1997 May; 111(3):129–33 (6 ref.) Comment in: Public Health 1997 May;111(3):123.
Macrosocial transition and health hazards. Schröder H, et al. **Rev Environ Health** 1996 Jan–Jun;11(1–2):1–5 (9 ref.)
The World Trade Organisation agreement on the application of sanitary and phytosanitary measures. Chillaud T. **Rev Sci Tech** 1996 Jun;15(2):733–51 (6 ref.) **(Eng, Fre)**
Global climate and infectious disease: the cholera paradigm. Colwell RR. **Science** 1996 Dec 20;274(5295):2025–31 (89 ref.)
International efforts in cancer pain relief. Coyne PJ. **Semin Oncol Nurs** 1997 Feb;13(1):57–62 (29 ref.)
Epidemiology of lung cancer: a worldwide epidemic. Valanis BG. **Semin Oncol Nurs** 1996 Nov;12(4):251–9 (51 ref.)
The impact of globalization on the determination and management of ethical choices in the health arena. Kalekin-Fishman D. **Soc Sci Med** 1996 Sep;43(5):809–22 (126 ref.)
Market-oriented health care reforms: trends and future options. van de Ven WP. **Soc Sci Med** 1996 Sep; 43(5):655–66 (40 ref.)
Empowering battered women transnationally: the case for postmodern interventions. Mills L. **Soc Work** 1996 May; 41(3):261–8 (38 ref.)
Couples and reproductive health: a review of couple studies. Becker S. **Stud Fam Plann** 1996 Nov–Dec;27(6):291–306 (116 ref.)
Substance use and multiculturalism. Adrian M. **Subst Use Misuse** 1996 Sep–Oct;31(11–12):1459–501 (68 ref.)
Vaccination in pulses: a strategy for global eradication of measles and polio? Nokes DJ, et al. **Trends Microbiol** 1997 Jan;5(1):14–9 (37 ref.)
Emerging diseases with a worldwide impact and the consequences for veterinary curricula. Osburn BI. **Vet Q** 1996;18 Suppl 3:S124–6 (0 ref.)
Health dilemmas at the borders—a global challenge. Kamel WW. **World Health Forum** 1997;18(1):9–16 (22 ref.)
Monitoring and assessment of dietary exposure to chemical contaminants. Baht RV, et al. **World Health Stat Q** 1997; 50(1–2):132–49 (82 ref.)
Foodborne salmonellosis. Gomez TM, et al. **World Health Stat Q** 1997;50(1–2):81–9 (35 ref.)
Global estimation of foodborne diseases. Motarjemi Y, et al. **World Health Stat Q** 1997;50(1–2):5–11 (7 ref.)
Enterohaemorrhagic Escherichia coli. Takeda Y. **World Health Stat Q** 1997;50(1–2):74–80 (57 ref.)
Epidemiology of foodborne diseases: a worldwide review. Todd EC. **World Health Stat Q** 1997;50(1–2):30–50 (133 ref.)
[Tuberculosis and the HIV pandemic. Risk of nosocomial tuberculosis infection] Pedersen C, et al. **Ugeskr Laeger**

WORLD HEALTH

1997 Feb 24;159(9):1233–8 (40 ref.) (Eng. Abstr.) **(Dan)**

[Melioidosis: a tropical time bomb that is spreading] Perret JL. **Med Trop (Mars)** 1997;57(2):195–201 (64 ref.) (Eng. Abstr.) **(Fre)**

[Update on the dracunculosis eradication program] Ranque P, et al. **Med Trop (Mars)** 1996;56(3):289–96 (20 ref.) (Eng. Abstr.) **(Fre)**

[Hepatitis C epidemiology in the world] Richard V. **Med Trop (Mars)** 1996;56(4):393–9 (102 ref.) (Eng. Abstr.) **(Fre)**

[Rotaviruses in human and veterinary medicine] Dodet B, et al. **Sante** 1997 May–Jun;7(3):195–9 (7 ref.) (Eng. Abstr.) **(Fre)**

[A new generation of infections in a changing world. Infectious diseases at the end of the twentieth century] Berger SA, et al. **Harefuah** 1997 May 1;132(9):669–72 (21 ref.) **(Heb)**

[Increased concentration on research of women's health] Schei B, et al. **Tidsskr Nor Laegeforen** 1997 Apr 30; 117(11):1634–6 (42 ref.) **(Nor)**

WORLD HEALTH ORGANIZATION

The WHO Research and Training Centre in Human Reproduction at the Karolinska Institute between 1970 and 1995. Bygdeman M. **Adv Contracept** 1996 Dec;12(4):319–24 (12 ref.)

The WHO growth chart: historical considerations and current scientific issues. de Onis M, et al. **Bibl Nutr Dieta** 1996;(53):74–89 (39 ref.)

Research priorities for the WHO Global Programme for Vaccines and Immunization. Lambert PH. **Dev Biol Stand** 1996;87:45–9 (0 ref.)

WHO and its role in the prevention of deafness and hearing impairment [editorial] Hinchcliffe R. **J Laryngol Otol** 1997 Aug;111(8):699–701 (14 ref.)

The World Health Organization's global initiative on neurology and public health. Janca A, et al. **J Neurol Sci** 1997 Jan;145(1):1–2 (4 ref.)

Dysthymia in neurological disorders. Akiskal HS, et al. **Mol Psychiatry** 1996 Dec;1(6):478–91 (77 ref.)

Strategies of the Pan American Health Organization/World Health Organization for the control of iron deficiency in Latin America. Freire WB. **Nutr Rev** 1997 Jun;55(6):183–8 (15 ref.)

Psychiatric assessment instruments developed by the World Health Organization. Sartorius N, et al. **Soc Psychiatry Psychiatr Epidemiol** 1996 Mar;31(2):55–69 (59 ref.)

Nursing up to and beyond the year 2000. Robinson J, et al. **WHO Reg Publ Eur Ser** 1997;74:127–44 (22 ref.)

Nursing and midwifery in Europe. Salvage J, et al. **WHO Reg Publ Eur Ser** 1997;74:21–123 (32 ref.)

Surgery of tuberculosis: state of the art—introduction. Perelman MI. **World J Surg** 1997 Jun;21(5):455–6 (8 ref.)

[WHO and hereditary blood diseases. Human genetics programme] Bulyzhenkov VE. **Vestn Ross Akad Med Nauk** 1997;(1):3–4 (16 ref.) **(Rus)**

[Management of viral hepatitis in patients with HIV infection] Soriano V, et al. **Rev Clin Esp** 1996 Jul;196(7):479–87 (183 ref.) **(Spa)**

ORGANIZATION & ADMINISTRATION

WHO/ILAR Taskforce on quality of life. Strand CV, et al. **J Rheumatol** 1997 Aug;24(8):1630–3 (1 ref.)

"It ain't what you do; it's the way that you do it". Beerling A. **WHO Reg Publ Eur Ser** 1997;74:191–206 (7 ref.)

WOUND HEALING

see related
CICATRIX

Cartilage repair. A critical review [see comments] Messner K, et al. **Acta Orthop Scand** 1996 Oct;67(5):523–9 (58 ref.) Comment in: Acta Orthop Scand 1997 Apr;68(2):186–91.

Cigarette smoking and its orthopedic consequences. Kwiatkowski TC, et al. **Am J Orthop** 1996 Sep;25(9):590–7 (112 ref.)

Vascular myofibroblasts. Lessons from coronary repair and remodeling. Zalewski A, et al. **Arterioscler Thromb Vasc Biol** 1997 Mar;17(3):417–22 (46 ref.)

Tissue repair and angiotensin II generated at sites of healing. Weber KT, et al. **Basic Res Cardiol** 1997 Apr;92(2):75–8 (10 ref.)

Collagen and ventricular remodeling after acute myocardial infarction: concepts and hypotheses. Whittaker P. **Basic Res Cardiol** 1997 Apr;92(2):79–81 (10 ref.)

Towards a molecular definition of keratinocyte activation after acute injury to stratified epithelia. Coulombe PA. **Biochem Biophys Res Commun** 1997 Jul 18;236(2):231–8 (96 ref.)

Peripheral blood fibrocytes: novel fibroblast-like cells that present antigen and mediate tissue repair. Chesney J, et al. **Biochem Soc Trans** 1997 May;25(2):520–4 (30 ref.)

Recent advances in tissue synthesis in vivo by use of collagen-glycosaminoglycan copolymers. Ellis DL, et al. **Biomaterials** 1996 Feb;17(3):291–9 (70 ref.)

Wound healing following myocardial infarction. Weber KT, et al. **Clin Cardiol** 1996 Jun;19(6):447–55 (68 ref.)

Pressure ulcers. Assessment of healing. Ferrell BA. **Clin Geriatr Med** 1997 Aug;13(3):575–86 (24 ref.)

The role of nutrition in prevention and healing of pressure ulcers. Thomas DR. **Clin Geriatr Med** 1997 Aug; 13(3):497–511 (75 ref.)

Epithelial migration in the colon: filling in the gaps [editorial] Wilson AJ, et al. **Clin Sci (Colch)** 1997 Aug;93(2):97–108 (103 ref.)

Regulation of eukaryotic abasic endonucleases and their role in genetic stability. Demple B, et al. **Environ Health Perspect** 1997 Jun;105 Suppl 4:931–4 (25 ref.)

Role of the macrophage in angiogenesis-dependent diseases. Polverini PJ. **EXS** 1997;79:11–28 (111 ref.)

Corneal wound healing in laser in situ keratomileusis. Rocha G, et al. **Int Ophthalmol Clin** 1996 Fall;36(4):9–20 (41 ref.)

Therapeutic touch, nursing practice and contemporary cutaneous wound healing research. Daley B. **J Adv Nurs** 1997 Jun;25(6):1123–32 (44 ref.)

Biomechanics of knee ligament healing, repair and reconstruction. Woo SL, et al. **J Biomech** 1997 May; 30(5):431–9 (68 ref.)

A review of wound healing and wound dressing products. Hanna JR, et al. **J Foot Ankle Surg** 1997 Jan–Feb; 36(1):2–14; discussion 79 (39 ref.)

Wound healing—aiming for perfect skin regeneration. Martin P. **Science** 1997 Apr 4;276(5309):75–81 (92 ref.)

Spine update. The use of adjunctive electrical stimulation to enhance the healing of spine fusions. Kahanovitz N. **Spine** 1996 Nov 1;21(21):2523–5 (16 ref.)

The difficult perineal wound. Del Pino A, et al. **Surg Clin North Am** 1997 Feb;77(1):155–74 (110 ref.)

Wound infection. A failure of wound healing caused by an imbalance of bacteria. Robson MC. **Surg Clin North Am** 1997 Jun;77(3):637–50 (44 ref.)

DRUG EFFECTS

Phenytoin in wound healing. Anstead GM, et al. **Ann Pharmacother** 1996 Jul–Aug;30(7–8):768–75 (71 ref.)

Nutritional supplements and surgical patients. Petry JJ. **AORN J** 1997 Jun;65(6):1117–21 (20 ref.)

Effects of postoperative intraperitoneal chemotherapy on peritoneal wound healing and adhesion formation. Jacquet P, et al. **Cancer Treat Res** 1996;82:327–35 (39 ref.)

Wound cleansers. Witkowski JA, et al. **Clin Dermatol** 1996 Jan–Feb;14(1):89–93 (51 ref.)

New developments in the immunology of asthma, with a focus on mechanisms and treatment. Bousquet J, et al. **Curr Opin Pulm Med** 1997 Jan;3(1):42–50 (119 ref.)

Pharmacological intervention in post-infarction wound healing. Jugdutt BI. **EXS** 1996;76:501–12 (60 ref.)

DNA antisense strategies in the study of receptors for vasoactive peptides, and of growth and wound-healing factors. D'Orléans-Juste P, et al. **Mol Cell Biochem** 1997 Jul;172(1–2):199–211 (77 ref.)

[Cutaneous wound healing: clinical evaluation of locally active growth factors—an overview] Coerper S, et al. **Zentralbl Chir** 1996;121 Suppl:49–51 (21 ref.) **(Ger)**

[Current perspective on the clinical use of fibrinogen] Yamazumi K, et al. **Rinsho Byori** 1997 Feb;Suppl 104:37–40 (10 ref.) **(Jpn)**

IMMUNOLOGY

T-lymphocyte-fibroblast interactions. Crowston JG, et al. **Biochem Soc Trans** 1997 May;25(2):529–31 (14 ref.)

PHYSIOLOGY

Bombesin-like peptides and airway repair: a recapitulation of lung development? Spurzem JR, et al. **Am J Respir Cell Mol Biol** 1997 Mar;16(3):209–11 (44 ref.)

Wound healing in embryos: a review. Nodder S, et al. **Anat Embryol (Berl)** 1997 Mar;195(3):215–28 (87 ref.)

Techniques of cartilage growth enhancement: a review of the literature. Wirth CJ, et al. **Arthroscopy** 1996 Jun; 12(3):300–8 (96 ref.)

Periodontal tissue engineering by growth factors. Giannobile WV. **Bone** 1996 Jul;19(1 Suppl):23S–37S (117 ref.)

From wound to scar. Linares HA. **Burns** 1996 Aug; 22(5):339–52 (122 ref.)

In vitro models to study wound healing fibroblasts. Moulin V, et al. **Burns** 1996 Aug;22(5):359–62 (22 ref.)

Mechanisms of wound healing in the embryo and fetus. Martin P. **Curr Top Dev Biol** 1996;32:175–203 (95 ref.)

What is new in clinical research in wound healing. Choucair MM, et al. **Dermatol Clin** 1997 Jan;15(1):45–58 (135 ref.)

The role of growth factors in peritoneal healing: transforming growth factor beta (TGF-beta). Chegini N. **Eur J Surg Suppl** 1997;(577):17–23 (41 ref.)

Biochemical events in peritoneal tissue repair. diZerega GS. **Eur J Surg Suppl** 1997;(577):10–6 (44 ref.)

Cyclooxygenase 2 and wound healing in the stomach [editorial; comment] Stenson WF. **Gastroenterology** 1997 Feb;112(2):645–8 (32 ref.) Comment on: Gastroenterology 1997 Feb;112(2):387–97.

Effects of growth factors on cartilage repair. Coutts RD, et al. **Instr Course Lect** 1997;46:487–94 (95 ref.)

Wound complications in total knee arthroplasty. Dennis DA. **Instr Course Lect** 1997;46:165–9 (69 ref.)

Apoptosis during wound healing, fibrocontractive diseases and vascular wall injury. Desmoulière A, et al. **Int J Biochem Cell Biol** 1997 Jan;29(1):19–30 (78 ref.)

Mechanisms of tissue repair: from wound healing to fibrosis. Mutsaers SE, et al. **Int J Biochem Cell Biol** 1997 Jan; 29(1):5–17 (96 ref.)

Transforming growth factor beta s and wound healing. O'Kane S, et al. **Int J Biochem Cell Biol** 1997 Jan; 29(1):63–78 (131 ref.)

Cell biology of wound healing. Schaffer CJ, et al. **Int Rev Cytol** 1996;169:151–81 (105 ref.)

Repair mechanisms in asthma. Rennard SI. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 2):S278–86 (85 ref.)

Collagen-based devices for soft tissue repair. Pachence JM. **J Biomed Mater Res** 1996 Spring;33(1):35–40 (65 ref.)

The use of skin from a monozygotic twin combined with cultured epithelial autografts as coverage for a large surface area burn: a case report and review of the literature. Caruso DM, et al. **J Burn Care Rehabil** 1996 Sep–Oct;17(5):432–4 (18 ref.)

Essential microminerals and their response to burn injury. Gamliel Z, et al. **J Burn Care Rehabil** 1996 May–Jun; 17(3):264–72 (108 ref.)

The influence of endodontic treatment upon periodontal wound healing. Chen SY, et al. **J Clin Periodontol** 1997 Jul;24(7):449–56 (98 ref.)

Earliest phases in the evolution of sickness and healing. Fabrega H Jr. **Med Anthropol Q** 1997 Mar;11(1):26–55 (62 ref.)

Neurotrophins and their receptors in nerve injury and repair. Ebadi M, et al. **Neurochem Int** 1997 Apr–May; 30(4–5):347–74 (240 ref.)

Integrated processes responsible for soft tissue healing. Wong ME, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Nov;82(5):475–92 (109 ref.)

Scar wars: implications of fetal wound healing for the pediatric burn patient. Cass DL, et al. **Pediatr Surg Int** 1997 Sep;12(7):484–9 (38 ref.)

Molecular and cellular control points in pediatric liver injury and repair. Tracy TF Jr, et al. **Semin Pediatr Surg** 1996 Aug;5(3):175–81 (24 ref.)

Wound healing and wound infection. What surgeons and anesthesiologists can do. Hunt TK, et al. **Surg Clin North Am** 1997 Jun;77(3):587–606 (69 ref.)

Healing in other tissues. Mast BA. **Surg Clin North Am** 1997 Jun;77(3):529–47 (50 ref.)

The role of sutures and fibrin sealant in wound healing. Spotnitz WD, et al. **Surg Clin North Am** 1997 Jun; 77(3):651–69 (61 ref.)

The role of growth factors in wound healing. Steed DL. **Surg Clin North Am** 1997 Jun;77(3):575–86 (38 ref.)

Healing in the gastrointestinal tract. Thornton FJ, et al. **Surg Clin North Am** 1997 Jun;77(3):549–73 (186 ref.)

General principles of wound healing. Witte MB, et al. **Surg Clin North Am** 1997 Jun;77(3):509–28 (144 ref.)

Global curriculum for wound management. Ryan TJ. **Trop Doct** 1997;27 Suppl 1:31–5 (20 ref.)

[Cell growth factors and tissue repair] Vaillant P. **Rev Mal Respir** 1996 Dec;13(6):555–8 (15 ref.) **(Fre)**

[Some aspects of wound scarring] Bluth F, et al. **Rev Med Liege** 1997;52(7):469–77 (29 ref.) **(Fre)**

[Use of cell and molecular biology in a model and the clinic] Vogt PM. **Zentralbl Chir** 1996;121 Suppl:25–8 (43 ref.) **(Ger)**

[The utilization of nutrient substances during wound healing] Mayer NA, et al. **Anesteziol Reanimatol** 1996 Sep–Oct; (5):29–39 (167 ref.) (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Biostimulation of wound healing by low-energy laser irradiation. A review. Conlan MJ, et al. **J Clin Periodontol** 1996 May;23(5):492–6 (36 ref.)

WOUND INFECTION

COMPLICATIONS

[Pyogenic osteomyelitis after a plantar puncture wound: analysis of a series of 8 cases] Morales M, et al. **Enferm Infecc Microbiol Clin** 1996 Oct;14(8):479–82 (17 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

[Soft tissue infection] Schneider U, et al. **Unfallchirurg** 1997 Feb;100(2):146–53 (8 ref.) **(Ger)**

ETIOLOGY

Aeromonas bacteraemia in burn patients. Barillo DJ, et al. **Burns** 1996 Feb;22(1):48–52 (33 ref.)

Central venous catheter replacement strategies: a systematic review of the literature. Cook D, et al. **Crit Care Med** 1997 Aug;25(8):1417–24 (35 ref.)

Overview of the etiology of wound infections with particular emphasis on community-acquired illnesses. Janda JM, et al. **Eur J Clin Microbiol Infect Dis** 1997 Mar;16(3):189–201 (71 ref.)

MICROBIOLOGY

Leclercia adecarboxylata infections: case report and review. Temesgen Z, et al. **Clin Infect Dis** 1997 Jul;25(1):79–81 (11 ref.)

Escherichia vulneris in a Danish soccer wound. Jepsen CF, et al. **Scand J Infect Dis** 1997;29(3):313–4 (6 ref.)

PREVENTION & CONTROL

Prophylaxis in lower-extremity infectious diseases. Joseph WS, et al. **Clin Podiatr Med Surg** 1996 Oct;13(4):647–60 (41 ref.)

Continuing search for solutions to trauma associated infections. Polk HC Jr. **J R Coll Surg Edinb** 1996 Feb; 41(1):1–6 (29 ref.)

Infectious complications: prevention and strategies for their control. Greenfield E, et al. **Nurs Clin North Am** 1997 Jun; 32(2):297–309 (24 ref.)

SURGERY

[Bone and joint infections] Schneider U, et al. **Unfallchirurg** 1996 Oct;99(10):789–800 (8 ref.) **(Ger)**

THERAPY

Management of bite wounds and infection in primary care. Kelleher AT, et al. **Cleve Clin J Med** 1997 Mar;64(3):137–41 (15 ref.)

Pressure ulcers. Managing bacterial colonization and infection. Stotts NA, et al. **Clin Geriatr Med** 1997 Aug; 13(3):565–73 (45 ref.)

Infectious complications: prevention and strategies for their control. Greenfield E, et al. **Nurs Clin North Am** 1997 Jun; 32(2):297–309 (24 ref.)

[Wound sorption] Bondarchuk OI, et al. **Klin Khir** 1996; (9):41–4 (50 ref.) **(Rus)**

WOUNDS AND INJURIES

see related
FIRST AID
TRANSPORTATION OF PATIENTS

An overview of recent developments in the management and research of trauma. Wang ZG. **Ann Acad Med Singapore** 1997 Jan;26(1):54–9 (47 ref.)

The cytokine response to critical illness. Foëx BA, et al. **J Accid Emerg Med** 1996 May;13(3):154–62 (58 ref.)

Biogenesis of hepatic acute-phase response to trauma. Fouad FM, et al. **Med Hypotheses** 1996 Aug;47(2):157–77 (75 ref.)

Torture and war rauma survivors in primary care practice. Weinstein HM, et al. **West J Med** 1996 Sep;165(3):112–8 (30 ref.)

[Errors in trauma team work] Hirshberg A, et al. **Harefuah** 1996 Dec 1;131(11):506–7 (9 ref.) **(Heb)**

[The analysis of frequency, causes and consequences of accidents on children's playgrounds] Kosmala M. **Pediatr Pol** 1996 Feb;71(2):143–52 (44 ref.) (Eng. Abstr.) **(Pol)**

BLOOD

Activation of the clotting system and complement after trauma. Dries DJ. **New Horiz** 1996 May;4(2):276–88 (80 ref.)

Antithrombin deficiency in special clinical syndromes--Part II: trauma/burns. Penner J. **Semin Hematol** 1995 Oct;32(4 Suppl 2):42–7; discussion 48 (23 ref.)

[Non-enzyme cation proteins of peripheral blood leukocytes-factor of nonspecific reaction of body to injury] Priima OB. **Klin Med (Mosk)** 1997;75(2):4–6 (36 ref.) **(Rus)**

COMPLICATIONS

Infectious complications following trauma in children. Brook I. **Adv Pediatr** 1997;44:429–51 (46 ref.)

Traumatic tear of the basilar artery associated with vertebral column injuries. Sato Y, et al. **Am J Forensic Med Pathol** 1997 Jun;18(2):129–34 (21 ref.)

Acute pain management: operative or medical procedures and trauma. Follin SL, et al. **Ann Pharmacother** 1997 Sep; 31(9):1068–76 (63 ref.)

Thoracic infection after trauma. Richardson JD, et al. **Chest Surg Clin N Am** 1997 May;7(2):401–27 (64 ref.)

Prehospital management of the traumatized airway. Deakin CD. **Eur J Emerg Med** 1996 Dec;3(4):233–43 (62 ref.)

Isolated medial compartment syndrome of the foot: a case report. Myerson MS, et al. **Foot Ankle Int** 1996 Mar; 17(3):183–5 (9 ref.)

Pain after injury: some basic mechanisms. Yaksh TL. **J Fla Med Assoc** 1997 Jan;84(1):16–9 (19 ref.)

Psoriatic and seronegative inflammatory arthropathy associated with a traumatic onset: 4 cases and a review of the literature. Sandorfi N, et al. **J Rheumatol** 1997 Jan; 24(1):187–92 (23 ref.)

Alcohol and injury severity: reappraisal of the continuing controversy. Li G, et al. **J Trauma** 1997 Mar;42(3):562–9 (74 ref.)

Obtaining arterial access in trauma patients. Sclafani SJ. **J Vasc Interv Radiol** 1997 Jul-Aug;8(4):593–4 (0 ref.)

Thromboembolism in trauma: the problem and its prevention. Geerts WH. **Semin Thromb Hemost** 1996;22 Suppl 2:19–24; discussion 29–30 (45 ref.)

[Respiratory distress syndrome in adults with trauma or some other diseases] Gembitskiĭ EV, et al. **Klin Med (Mosk)** 1997; 75(6):8–12 (18 ref.) **(Rus)**

DIAGNOSIS

Physical abuse of children: an update. Sirotnak AP, et al. **Del Med J** 1997 Jul;69(7):335–43 (20 ref.)

Wound care. Howell JM, et al. **Emerg Med Clin North Am** 1997 May;15(2):417–25 (33 ref.)

[Severe trauma in children] Paut O, et al. **Arch Pediatr** 1997 May;4(5):443–59 (93 ref.) (Eng. Abstr.) **(Fre)**

[Diagnostic imaging and radiation protection in trauma surgery. 2] Wolf K, et al. **Unfallchirurg** 1996 Dec; 99(12):975–85 (23 ref.) **(Ger)**

DRUG THERAPY

Wound cleansers. Witkowski JA, et al. **Clin Dermatol** 1996 Jan-Feb;14(1):89–93 (51 ref.)

Clinical neuro-protection trials in severe traumatic brain injury: lessons from previous studies. Doppenberg EM, et al. **J Neurotrauma** 1997 Feb;14(2):71–80 (46 ref.)

New clinical applications of granulocyte-macrophage colony-stimulating factor. Masucci G. **Med Oncol** 1996 Sep;13(3):149–54 (19 ref.)

EPIDEMIOLOGY

Methodological challenges to the study of occupational injury--an international epidemiology workshop. Courtney TK, et al. **Am J Ind Med** 1997 Aug;32(2):103–5 (15 ref.)

Alternative approaches to analytical designs in occupational injury epidemiology. Mittleman MA, et al. **Am J Ind Med** 1997 Aug;32(2):129–41 (58 ref.)

The frequency of golf injuries. McCarroll JR. **Clin Sports Med** 1996 Jan;15(1):1–7 (15 ref.)

The health effects of earthquakes in the mid-1990s. Alexander D. **Disasters** 1996 Sep;20(3):231–47 (34 ref.)

School injuries in an occupational health perspective: what do we learn from community based epidemiological studies? Laflamme L, et al. **Inj Prev** 1997 Mar;3(1):50–6 (30 ref.)

Alcohol and violence-related injuries in the emergency room. Cherpitel CJ. **Recent Dev Alcohol** 1997;13:105–18 (51 ref.)

ETIOLOGY

Light vehicle occupant ejections--a comprehensive investigation. Malliaris AC, et al. **Accid Anal Prev** 1996 Jan;28(1):1–14 (9 ref.)

The pathogenesis of non-freezing cold nerve injury. Observations in the rat. Jia J, et al. **Brain** 1997 Apr;120 (Pt 4):631–46 (121 ref.)

A multifactorial approach to reducing injurious falls. King MB, et al. **Clin Geriatr Med** 1996 Nov;12(4):745–59 (67 ref.)

What is new in clinical research in wound healing. Choucair MM, et al. **Dermatol Clin** 1997 Jan;15(1):45–58 (135 ref.)

The safety of manipulative treatment: review of the literature from 1925 to 1993. Vick DA, et al. **J Am Osteopath Assoc** 1996 Feb;96(2):113–5 (7 ref.)

Biological response to blast overpressure: a summary of modeling. Stuhmiller JH. **Toxicology** 1997 Jul 25; 121(1):91–103 (45 ref.)

[Damage due to patient positioning in anesthesia and surgical medicine (1)] Ullrich W, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jan; 32(1):4–20 (0 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Interleukin-6 in the injured patient. Marker of injury or mediator of inflammation? Biffl WL, et al. **Ann Surg** 1996 Nov;224(5):647–64 (256 ref.)

Concept of autoimmunity following spinal cord injury: possible roles for T lymphocytes in the traumatized central nervous system. Popovich PG, et al. **J Neurosci Res** 1996 Aug 15;45(4):349–63 (120 ref.)

Activation of the clotting system and complement after trauma. Dries DJ. **New Horiz** 1996 May;4(2):276–88 (80 ref.)

Regional macrophage activation after injury and the compartmentalization of inflammation in trauma. Hauser CJ. **New Horiz** 1996 May;4(2):235–51 (129 ref.)

METABOLISM

Mechanisms of calpain proteolysis following traumatic brain injury: implications for pathology and therapy: implications for pathology and therapy: a review and update. Kampfl A, et al. **J Neurotrauma** 1997 Mar;14(3):121–34 (136 ref.)

Acute-phase protein synthesis in rats is influenced by alterations in plasma and muscle free amino acid pools related to lower plasma volume following trauma. Sevaljević LM, et al. **J Nutr** 1996 Dec;126(12):3136–42 (39 ref.)

Alterations in transcriptional regulation of proinflammatory and immunoregulatory cytokine expression by hemorrhage, injury, and critical illness. Abraham E. **New Horiz** 1996 May;4(2):184–93 (98 ref.)

Metabolic response to injury and sepsis: changes in protein metabolism. Biolo G, et al. **Nutrition** 1997 Sep;13(9 Suppl):52S–57S (52 ref.)

Energy metabolism in sepsis and injury. Chioléro R, et al. **Nutrition** 1997 Sep;13(9 Suppl):45S–51S (78 ref.)

MICROBIOLOGY

Infectious complications following trauma in children. Brook I. **Adv Pediatr** 1997;44:429–51 (46 ref.)

The pathogenesis of Staphylococcus aureus in the trauma patient and potential future therapies. Villavicencio RT, et al. **Am J Surg** 1996 Sep;172(3):291–6 (76 ref.)

Trauma, shock, and gut translocation. Deitch EA, et al. **New Horiz** 1996 May;4(2):289–99 (61 ref.)

MORTALITY

Preventable death studies: an inappropriate tool for evaluating trauma systems. Kelly AM, et al. **Aust N Z J Surg** 1997 Sep;67(9):591–2 (25 ref.)

The current situation of road traffic trauma. Wang Z. **Chin Med J (Engl)** 1996 Jan;109(1):24–7 (9 ref.)

PHYSIOPATHOLOGY

Vasoactive intestinal peptide and nitric oxide: divergent roles in relation to tissue injury. Said SI. **Ann N Y Acad Sci** 1996 Dec 26;805:379–87; discussion 387–8 (60 ref.)

Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part III. Proliferation in normal, injured and diseased tissue, growth factors, differentiation, DNA replication sites and in situ hybridization. Dolbeare F. **Histochem J** 1996 Aug;28(8):531–75 (539 ref.)

The kallikrein/kinin system and kinin antagonists in trauma. Rodell TC. **Immunopharmacology** 1996 Jun;33(1–3):279–83 (9 ref.)

Clinical implications of exercise: injury and performance. Kibler WB. **Instr Course Lect** 1994;43:17–24 (38 ref.)

The biomechanics of low back injury: implications on current practice in industry and the clinic. McGill SM. **J Biomech** 1997 May;30(5):465–75 (50 ref.)

A review of wound healing and wound dressing products. Hanna JR, et al. **J Foot Ankle Surg** 1997 Jan-Feb; 36(1):2–14; discussion 79 (39 ref.)

Platelet activating factor and its role in trauma, shock, and sepsis. Ayala A, et al. **New Horiz** 1996 May;4(2):265–75 (91 ref.)

MOF/MODS, SIRS: an update. Baue AE. **Shock** 1996;6 Suppl 1:S1–5 (45 ref.)

Sepsis and septic complications in the surgical patient: who is at risk? Cheadle WG, et al. **Shock** 1996;6 Suppl 1:S6–9 (42 ref.)

[Similarity and synergy of trauma and sepsis: role of tumor necrosis factor-alpha and interleukin-6 (see comments)] Tang GJ. **Acta Anaesthesiol Sin** 1996 Sep;34(3):141–9 (46 ref.) (Eng. Abstr.) Comment in: Acta Anaesthesiol Sin 1996 Sep;34(3):i. **(Chi)**

[Cardiac contractile dysfunction in response to surgical stress including trauma, hemorrhage, and infection] Suzuki K, et al. **Nippon Geka Gakkai Zasshi** 1996 Sep;97(9):745–51 (20 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Injury prevention: is there a role for out-of-hospital emergency medical services? Kinnane JM, et al. **Acad Emerg Med** 1997 Apr;4(4):306–12 (52 ref.)

Design and conduct of occupational injury intervention studies: a review of evaluation strategies. Zwerling C, et al. **Am J Ind Med** 1997 Aug;32(2):164–79 (105 ref.)

The role of emergency medical services in primary injury prevention. Consensus workshop. Arlington, Virginia, August 25-26, 1995. Garrison HG, et al. **Ann Emerg Med** 1997 Jul;30(1):84–91 (11 ref.)

Preventable death studies: an inappropriate tool for evaluating trauma systems. Kelly AM, et al. **Aust N Z J Surg** 1997 Sep;67(9):591–2 (25 ref.)

Family processes and child risk for injury. Peterson L, et al. **Behav Res Ther** 1997 Mar;35(3):179–90 (70 ref.)

A multifactorial approach to reducing injurious falls. King MB, et al. **Clin Geriatr Med** 1996 Nov;12(4):745–59 (67 ref.)

Prevention and treatment of elbow injuries in golf. Kohn HS. **Clin Sports Med** 1996 Jan;15(1):65–83 (14 ref.)

Preventative exercises in golf: arm, leg, and back. Pink MM, et al. **Clin Sports Med** 1996 Jan;15(1):147–62 (11 ref.)

Prevention of unintentional injuries in children. Szabo RM. **J South Orthop Assoc** 1997 Spring;6(1):17–24 (28 ref.)

Injury prevention. First of two parts. Rivara FP, et al. **N Engl J Med** 1997 Aug 21;337(8):543–8 (70 ref.)

Injury prevention. Second of two parts. Rivara FP, et al. **N Engl J Med** 1997 Aug 28;337(9):613–8 (145 ref.)

A review of successful transport and home injury interventions to guide developing countries. Forjuoh SN, et al. **Soc Sci Med** 1996 Dec;43(11):1551–60 (90 ref.)

Injuries in developing countries: policy response needed now. Zwi AB, et al. **Trans R Soc Trop Med Hyg** 1996 Nov-Dec; 90(6):593–5 (9 ref.)

[Positioning trauma in anesthesia and surgical intensive care medicine (2)] Kienzle F, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Feb; 32(2):72–86 (204 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Traumatic stress--an overview of diagnostic evolution and clinical treatment. Wong JC, et al. **Ann Acad Med Singapore** 1997 Jan;26(1):76–87 (65 ref.)

The neurobiology of emotionally influenced memory. Implications for understanding traumatic memory. Cahill L. **Ann N Y Acad Sci** 1997 Jun 21;821:238–46 (41 ref.)

Trauma, dissociation, and memory. Spiegel D. **Ann N Y Acad Sci** 1997 Jun 21;821:225–37 (86 ref.)

Are there injury-prone children? A critical review of the

literature. Wazana A. **Can J Psychiatry** 1997 Aug; 42(6):602–10 (40 ref.)

RADIOGRAPHY

[Imaging methods in trauma surgery. 1] Wolf K, et al. **Unfallchirurg** 1996 Nov;99(11):889–99; quiz 900 (23 ref.) **(Ger)**

REHABILITATION

Industrial rehabilitation medicine. 4. Strategies for disability management. Rondinelli RD, et al. **Arch Phys Med Rehabil** 1997 Mar;78(3 Suppl):S21–8 (54 ref.)

SURGERY

Pathophysiology of infection—a theoretical approach. Hansis M. **Injury** 1996;27 Suppl 3:SC5–8 (22 ref.)

Orthopaedic surgery on the HIV-positive patient: complications and outcome. Luck JV Jr. **Instr Course Lect** 1994;43:543–9 (36 ref.)

Sepsis and septic complications in the surgical patient: who is at risk? Cheadle WG, et al. **Shock** 1996;6 Suppl 1:S6–9 (42 ref.)

Physiologic rationale for abbreviated laparotomy. Burch JM, et al. **Surg Clin North Am** 1997 Aug;77(4):779–82 (11 ref.)

The logistics of damage control. Granchi TS, et al. **Surg Clin North Am** 1997 Aug;77(4):921–8 (13 ref.)

Anesthetic considerations in damage control surgery. Ham AA, et al. **Surg Clin North Am** 1997 Aug;77(4):909–20 (13 ref.)

Implications of new dry fibrin sealant technology for trauma surgery. Holcomb JB, et al. **Surg Clin North Am** 1997 Aug; 77(4):943–52 (35 ref.)

Postoperative care and complications of damage control surgery. Martin RR, et al. **Surg Clin North Am** 1997 Aug; 77(4):929–42 (16 ref.)

Damage control for the obstetric patient. Moise KJ Jr, et al. **Surg Clin North Am** 1997 Aug;77(4):835–52 (42 ref.)

[What is prevention of perioperative infection? Overview exemplified by trauma surgery] Hansis M. **Chirurg** 1996 Nov;67(11):1123–8 (18 ref.) (Eng. Abstr.) **(Ger)**

[Value of imaging methods in trauma surgery] Wolf K, et al. **Orthopade** 1997 May;26(5):481–8 (17 ref.) (Eng. Abstr.) **(Ger)**

[Thrombosis in trauma and orthopedic surgery. Prevention, diagnosis, therapy] Haas S. **Unfallchirurg** 1997 Apr; 100(4):307–19 (10 ref.) **(Ger)**

[Rate of infection in trauma surgery. An overview based on recent German language literature] Hansis M, et al. **Unfallchirurg** 1997 Jun;100(6):457–64 (78 ref.) (Eng. Abstr.) **(Ger)**

[Perioperative hygiene in trauma surgery] Kasperczyk WJ, et al. **Unfallchirurg** 1996 Jul;99(7):460–5 (22 ref.) (Eng. Abstr.) **(Ger)**

[Transplantation in orthopedic surgery and traumatology] Cara JA, et al. **Rev Med Univ Navarra** 1994 Oct–Dec; 38(4):207–11 (15 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

From laboratory to clinic: noradrenergic enhancement of physical therapy for stroke or trauma patients. Feeney DM. **Adv Neurol** 1997;73:383–94 (49 ref.)

Helicopter emergency medical services: their role in integrated trauma care. Zalstein S, et al. **Aust N Z J Surg** 1997 Sep;67(9):593–8 (56 ref.)

Recent advances in tissue synthesis in vivo by use of collagen-glycosaminoglycan copolymers. Ellis DL, et al. **Biomaterials** 1996 Feb;17(3):291–9 (70 ref.)

What is new in clinical research in wound healing. Choucair MM, et al. **Dermatol Clin** 1997 Jan;15(1):45–58 (135 ref.)

Wound care. Howell JM, et al. **Emerg Med Clin North Am** 1997 May;15(2):417–25 (33 ref.)

Advanced life support for acute toxic injury (TOXALS). Baker DJ. **Eur J Emerg Med** 1996 Dec;3(4):256–62 (12 ref.)

Priorities in assessment and intervention in trauma victim medical care. Cooper J, et al. **Eur J Emerg Med** 1996 Dec; 3(4):225–32 (18 ref.)

Entrapment, extrication and immobilization. Mahoney PF, et al. **Eur J Emerg Med** 1996 Dec;3(4):244–6 (16 ref.)

Major interventions in the field stabilization of trauma patients: what is possible? Schou J. **Eur J Emerg Med** 1996 Dec;3(4):221–4 (10 ref.)

Overcoming language barriers when teaching the Advanced Trauma Life Support course [editorial] Ali J, et al. **Eur J Surg** 1997 Jul;163(7):483–6 (14 ref.)

Orthopaedic challenges in the aging population: trauma treatment and related clinical issues. Koval KJ, et al. **Instr Course Lect** 1997;46:423–30 (39 ref.)

Should we use occlusive dressings in the treatment of acute wounds? Lotti T, et al. **Int J Dermatol** 1997 Feb;36(2):97–9 (10 ref.)

Therapeutic touch, nursing practice and contemporary cutaneous wound healing research. Daley B. **J Adv Nurs** 1997 Jun;25(6):1123–32 (44 ref.)

The biomechanics of low back injury: implications on current practice in industry and the clinic. McGill SM. **J Biomech** 1997 May;30(5):465–75 (50 ref.)

Trauma management in solid organ transplant recipients. Barone GW, et al. **J Emerg Med** 1997 Mar–Apr; 15(2):169–76 (12 ref.)

A review of wound healing and wound dressing products. Hanna JR, et al. **J Foot Ankle Surg** 1997 Jan–Feb; 36(1):2–14; discussion 79 (39 ref.)

Trauma management on the battlefield: a modern approach. Hawley A. **J R Army Med Corps** 1996 Oct;142(3):120–5 (33 ref.)

Irreversible shock revisited: mechanical support of the cardiovascular system: a case report and review. Lisagor P, et al. **J Trauma** 1997 Jun;42(6):1182–6 (28 ref.)

Pediatric trauma. Kapklein MJ, et al. **Mt Sinai J Med** 1997 Sep–Oct;64(4–5):302–10 (13 ref.)

Evaluation and management of traumatic lacerations. Singer AJ, et al. **N Engl J Med** 1997 Oct 16;337(16):1142–8 (57 ref.)

The trauma team—a system of initial trauma care [see comments] Adedeji OA, et al. **Postgrad Med J** 1996 Oct; 72(852):587–93 (72 ref.) Comment in: Postgrad Med J 1997 Mar;73(857):190.

Special situations for regional anesthesia: trauma. Brown DL. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):122–5 (28 ref.)

The damage control sequence and underlying logic. Rotondo MF, et al. **Surg Clin North Am** 1997 Aug;77(4):761–77 (80 ref.)

Global curriculum for wound management. Ryan TJ. **Trop Doct** 1997;27 Suppl 1:31–5 (20 ref.)

Comorbidity and the elderly trauma patient. McMahon DJ, et al. **World J Surg** 1996 Oct;20(8):1113–9; discussion 1119–20 (58 ref.)

[Progresses in emergency medicine in China, 1996] Wang Y. **Chung Hua I Hsueh Tsa Chih** 1996 Dec;76(12):925–6 (0 ref.) **(Chi)**

[Indications and role of albumin for vascular loading in trauma patients and during preoperative period] Sztark F. **Ann Fr Anesth Reanim** 1996;15(4):473–80 (34 ref.) (Eng. Abstr.) **(Fre)**

[Severe trauma in children] Paut O, et al. **Arch Pediatr** 1997 May;4(5):443–59 (93 ref.) (Eng. Abstr.) **(Fre)**

[Prehospital fluid resuscitation] Kreimeier U, et al. **Anaesthesist** 1996 Oct;45(10):884–99 (104 ref.) (Eng. Abstr.) **(Ger)**

[Early care or quick transport? The effectiveness of preclinical treatment of emergency patients] Rossi R. **Anaesthesist** 1997 Feb;46(2):126–32 (36 ref.) (Eng. Abstr.) **(Ger)**

[The trauma patient: open hospital choice? (editorial)] Leutenegger A, et al. **Swiss Surg** 1997;3(4):136–41 (27 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Ultrasound in the diagnosis of injury. Bode PJ, et al. **Injury** 1996 Jul;27(6):379–83 (38 ref.)

VETERINARY

[Suffering and misfortune—the beginning of comprehension] Winckler C, et al. **DTW Dtsch Tierarztl Wochenschr** 1997 Feb;104(2):43–6 (25 ref.) (Eng. Abstr.) **(Ger)**

WOUNDS, GUNSHOT

Missiles in the cardiovascular system. Symbas PN, et al. **Chest Surg Clin N Am** 1997 May;7(2):343–56 (28 ref.)

On the physics of momentum in ballistics: can the human body be displaced or knocked down by a small arms projectile? Karger B, et al. **Int J Legal Med** 1996; 109(3):147–9 (9 ref.)

[Treatment of facial gunshot injuries] Høgevold HE, et al. **Tidsskr Nor Laegeforen** 1997 Jan 20;117(2):240–5 (29 ref.) (Eng. Abstr.) **(Nor)**

COMPLICATIONS

Missile emboli to the pulmonary artery [letter] Gupta AK, et al. **Am J Emerg Med** 1997 Mar;15(2):213–4 (12 ref.)

Heterotopic bone formation within a missile track. Morasch MD, et al. **J Accid Emerg Med** 1996 May;13(3):227–9 (13 ref.)

Traumatic carotid cavernous sinus fistula following a gunshot wound to the face. Wallick K 4th, et al. **J Emerg Med** 1997 Jan–Feb;15(1):23–9 (17 ref.)

Intrahepatic arterioportal fistula after hepatic gunshot wound: a case report and review of the literature. Eastridge BJ, et al. **J Trauma** 1997 Sep;43(3):523–6 (29 ref.)

DIAGNOSIS

Homicidal tandem bullet wound of the chest. Bentley AJ, et al. **Am J Forensic Med Pathol** 1997 Mar;18(1):56–9 (13 ref.)

Carotid arterial trauma: assessment with the Glasgow Coma Scale (GCS) as a guide to surgical management. Teehan EP, et al. **Cardiovasc Surg** 1997 Apr;5(2):196–200 (27 ref.)

[Retained capacity for action in brain gunshot injury. Case report and systematic examination] Karger B, et al. **Arch Kriminol** 1997 May–Jun;199(5–6):159–66 (18 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Outpatient antibiotic treatment of uncomplicated gunshot wounds: ramifications for military use [see comments] Brouker ME. **Mil Med** 1997 Apr;162(4):266–7 (6 ref.) Comment in: Mil Med 1997 Jul;162(7):ii.

MORTALITY

Multiple gunshot suicides: potential for physical activity and medico-legal aspects. Karger B, et al. **Int J Legal Med** 1997;110(4):188–92 (34 ref.)

PATHOLOGY

The relationship between cortical injury and brain tumour. Report of two cases and review of the literature. Stendel R, et al. **Acta Neurochir (Wien)** 1997;139(3):208–14 (52 ref.)

Suicide by gunshot while driving a motor vehicle. Two additional cases. Murphy GK. **Am J Forensic Med Pathol** 1997 Sep;18(3):295–8 (8 ref.)

Findings in gunshot wounds from tandem projectiles. Simmons GT. **J Forensic Sci** 1997 Jul;42(4):678–81 (5 ref.)

[Differentiation of hunting accident and suicide with rifles] Karger B. **Versicherungsmedizin** 1996 Feb 1;48(1):11–5 (24 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Penetrating BB shot head wound in an asymptomatic 9-year-old girl: the ultimate teaching moment. Johnson NA. **J Am Board Fam Pract** 1997 Mar–Apr;10(2):125–30 (14 ref.)

RADIOGRAPHY

The use of air weapons in attempted suicide. Campbell-Hewson G, et al. **Injury** 1997 Mar;28(2):153–8 (31 ref.)

Gunshot wounds of the internal carotid artery at the skull base: management with vein bypass grafts and a review of the literature. Rostomily RC, et al. **J Trauma** 1997 Jan; 42(1):123–32 (60 ref.)

SURGERY

Management of war-related neck injuries during the war in Croatia, 1991–1992. Prgomet D, et al. **Eur Arch Otorhinolaryngol** 1996;253(4–5):294–6 (28 ref.)

THERAPY

Management of small fragment wounds in modern warfare: a return to Hunterian principles? Bowyer GW. **Ann R Coll Surg Engl** 1997 May;79(3):175–82 (20 ref.)

VETERINARY

Traumatic head injury in ruminant livestock. Finnie IW. **Aust Vet J** 1997 Mar;75(3):204–8 (29 ref.)

WOUNDS, MULTIPLE see MULTIPLE TRAUMA

WOUNDS, NONPENETRATING

Cardiac trauma. Diagnosis, management, and current therapy. Olsovsky MR, et al. **Angiology** 1997 May; 48(5):423–32 (60 ref.)

Blunt injury to the supra-aortic arteries. Prêtre R, et al. **Br J Surg** 1997 May;84(5):603–9 (65 ref.)

Esophageal injuries. Bastos RB, et al. **Chest Surg Clin N Am** 1997 May;7(2):357–71 (57 ref.)

Trauma to the heart. Brown J, et al. **Chest Surg Clin N Am** 1997 May;7(2):325–41 (44 ref.)

Traumatic injury of the cervicothoracic trachea and major bronchi. Lee RB. **Chest Surg Clin N Am** 1997 May; 7(2):285–304 (78 ref.)

Trauma to the diaphragm. Mansour KA. **Chest Surg Clin N Am** 1997 May;7(2):373–83 (36 ref.)

Blunt injury of the abdominal aorta: a review. Roth SM, et al. **J Trauma** 1997 Apr;42(4):748–55 (63 ref.)

Blunt trauma to the heart and great vessels. Prêtre R, et al. **N Engl J Med** 1997 Feb 27;336(9):626–32 (49 ref.)

MRI and CT in blunt renal trauma: an update. Leppäniemi A, et al. **Semin Ultrasound CT MR** 1997 Apr;18(2):129–35 (25 ref.)

Diagnosis and treatment of blunt cardiac rupture. Powell MA, et al. **W V Med J** 1997 Mar–Apr;93(2):64–7 (10 ref.)

[Renal traumatism: diagnostic protocol and therapeutic indications] Monserrat Monfort JJ, et al. **Actas Urol Esp** 1996 Jun;20(6):534–43 (18 ref.) (Eng. Abstr.) **(Spa)**

CLASSIFICATION

Blunt urethral trauma: a unified, anatomical mechanical classification. Goldman SM, et al. **J Urol** 1997 Jan; 157(1):85–9 (19 ref.)

COMPLICATIONS

Traumatic retinopathy resembling acute macular neuroretinopathy. Gillies M, et al. **Aust N Z J Ophthalmol** 1997 Aug;25(3):207–10 (11 ref.)

Traumatic adult respiratory distress syndrome. Bass TL, et al. **Chest Surg Clin N Am** 1997 May;7(2):429–42 (71 ref.)

Trauma to the lung. Boyd AD, et al. **Chest Surg Clin N Am** 1997 May;7(2):263–84 (70 ref.)

Appendicitis after blunt abdominal trauma: cause or coincidence? Ciftci AO, et al. **Eur J Pediatr Surg** 1996 Dec;6(6):350–3 (26 ref.)

Injury of the cervical spine associated with carotid and vertebral artery occlusion: case report and literature review. Schippinger G, et al. **Injury** 1997 May;28(4):315–8

(24 ref.)
Diagnosis and management of blunt great vessel trauma. von Segesser LK, et al. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):181–6; discussion 186–92 (27 ref.)
Traumatic rupture of hepatic hemangioma. Hotokezaka M, et al. **J Clin Gastroenterol** 1996 Jul;23(1):69–71 (20 ref.)
Traumatic popliteal artery thrombosis and compartment syndrome of the leg following blunt trauma to the knee: a discussion of treatment and complications. Seybold EA, et al. **J Orthop Trauma** 1996;10(2):138–41 (21 ref.)
Tracheal rupture after blunt chest trauma in a child. Mordehai J, et al. **J Pediatr Surg** 1997 Jan;32(1):104–5 (12 ref.)
Delayed presentation and rupture of a posttraumatic innominate artery aneurysm: case report and review of the literature. Hirose H, et al. **J Trauma** 1997 Jun;42(6):1187–95 (30 ref.)
Aortic dissection after trauma: case report and review of the literature. Rogers FB, et al. **J Trauma** 1996 Nov; 41(5):906–8 (16 ref.)
Survival following traumatic rupture of the heart in a child. Michaels A, et al. **Pedistr Emerg Care** 1997 Feb;13(1):19–20 (16 ref.)
Ventricular fibrillation following blunt chest trauma from a baseball. van Amerongen R, et al.
Pediatr Emerg Care 1997 Apr;13(2):107–10 (19 ref.)
Traumatic spinal subarachnoid hematoma: report of a case with MRI. Gupta SK, et al. **Surg Neurol** 1997 Aug; 48(2):189–92 (36 ref.)
Traumatic asphyxia syndrome. Nunn CR, et al.
Tenn Med 1997 Apr;90(4):144–6 (19 ref.)
Post-traumatic priapism treated with selective cavernosal artery ligation. Shapiro RH, et al. **Urology** 1997 Apr; 49(4):638–43 (15 ref.)
[A case of myocardial rupture in closed thoracic injury] Demarche M, et al. **Rev Med Liege** 1997 Feb;52(2):105–9 (39 ref.) **(Fre)**
[Bacillus cereus pneumonia after thoracic trauma. Case report and review of the literature] Bastian L, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1997 Feb; 32(2):124–9 (28 ref.) (Eng. Abstr.) **(Ger)**
[Ventricular septal rupture after blunt chest trauma] Roithinger FX, et al. **Dtsch Med Wochenschr** 1996 Nov 15;121(46):1424–7 (23 ref.) (Eng. Abstr.) **(Ger)**
[Hemolysis and multiple trauma. A clinical case report] Buzio M, et al. **Minerva Chir** 1997 Apr;52(4):485–7 (10 ref.) (Eng. Abstr.) **(Ita)**
[Two cases of tracheal injuries secondary to blunt trauma] Asakura S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):563–8 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Surgical treatment of aortic valve regurgitation due to nonpenetrating trauma of the chest—a case report and review of the literature in Japan] Ashida Y, et al.
Nippon Kyobu Geka Gakkai Zasshi 1997 Feb;45(2):207–12 (24 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

The role of laparoscopy in blunt abdominal trauma. Leppäniemi AK, et al. **Ann Med** 1996 Dec;28(6):483–9 (52 ref.)
Newer diagnostic measures and emergency management. Mattox KL, et al. **Chest Surg Clin N Am** 1997 May; 7(2):213–26 (66 ref.)
Magnetic resonance angiography in trauma. James CA.
Clin Neurosci 1997;4(3):137–45 (19 ref.)
Delayed diagnosis and repair of total bronchial rupture: a report of two cases. Frimpong-Boateng K, et al.
East Afr Med J 1997 Feb;74(2):114–5 (23 ref.)
Mitral valve disruption following blunt trauma: case report and review of the literature. Pathi V, et al.
Eur J Cardiothorac Surg 1996;10(9):806–8 (20 ref.)
Urethral injuries revisited. Boon TA, et al. **Injury** 1996 Oct; 27(8):533–8 (46 ref.)
Traumatic disruption of the thoracic aorta: a rational approach to imaging. Driscoll PA, et al. **Injury** 1996 Dec; 27(10):679–85 (43 ref.)
Assessment of blunt aortic-brachiocephalic trauma: should angiography be supplanted by transesophageal echocardiography? [comment] Ben-Menachem Y.
J Trauma 1997 May;42(5):969–72 (42 ref.) Comment on: J Trauma 1996 Mar;40(3):422–7. Comment on: J Trauma 1997 May;42(5):960–3.
Blunt popliteal artery injury: is physical examination alone enough for evaluation? Gable DR, et al. **J Trauma** 1997 Sep;43(3):541–4 (21 ref.)
Isolated common iliac artery occlusion secondary to atherosclerotic plaque rupture from blunt abdominal trauma: case report and review of the literature. Tsai FC, et al. **J Trauma** 1997 Jan;42(1):133–6 (18 ref.)
Blunt disruption of the abdominal aorta: report of a case and review of the literature. Naude GP, et al. **J Vasc Surg** 1997 May;25(5):931–5 (21 ref.)
[Aortic trauma] Ando M. **Ryoikibetsu Shokogun Shirizu** 1996; (14):356–9 (6 ref.) **(Jpn)**

ETIOLOGY

Tendinitis in golf. Clancy WG Jr, et al. **Clin Sports Med** 1996 Jan;15(1):27–35 (46 ref.)
Back pain in golf. Hosea TM, et al. **Clin Sports Med** 1996 Jan;15(1):37–53 (37 ref.)
Shoulder pain in golf. Jobe FW, et al. **Clin Sports Med** 1996 Jan;15(1):55–63 (15 ref.)
Golf-induced injuries of the wrist. Murray PM, et al.
Clin Sports Med 1996 Jan;15(1):85–109 (45 ref.)

PHYSIOPATHOLOGY

Pathophysiology of chest trauma. Calhoon JH, et al.
Chest Surg Clin N Am 1997 May;7(2):199–211 (30 ref.)
[Biomechanical characteristics of interactions between the drainage and accommodation regulatory systems of the eye in health and in contusion sens subluxation] Volkov VV, et al. **Vestn Oftalmol** 1997 May–Jun;113(3):5–7 (21 ref.) (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

[Determination of the trauma severity level] Gennari TD, et al. **Rev Saude Publica** 1995 Oct;29(5):333–41 (32 ref.) (Eng. Abstr.) **(Por)**

RADIOGRAPHY

Traumatic blunt carotid injury: clinical experience and review of the literature. Berlot G, et al.
Eur J Emerg Med 1996 Mar;3(1):36–42 (24 ref.)
Traumatic transection of the intrapancreatic common bile duct due to blunt injury: a case report and literature review. Soffer D, et al. **Injury** 1996 Nov;27(9):672–4 (15 ref.)
Trauma. Mirvis SE. **Radiol Clin North Am** 1996 Nov; 34(6):1225–57 (28 ref.)
Choledochal cyst misinterpreted as a biloma after a blunt abdominal trauma. Vanlangenhove P, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996 Nov;165(5):496–8 (10 ref.)

SURGERY

Laryngotracheal trauma. Chagnon FP, et al.
Chest Surg Clin N Am 1996 Nov;6(4):733–48 (39 ref.)
Pediatric depressed skull fractures: analysis of 530 cases. Erşahin Y, et al. **Childs Nerv Syst** 1996 Jun;12(6):323–31 (15 ref.)
Delayed diagnosis and repair of total bronchial rupture: a report of two cases. Frimpong-Boateng K, et al.
East Afr Med J 1997 Feb;74(2):114–5 (23 ref.)
Blunt trauma and operative care in microgravity: a review of microgravity physiology and surgical investigations with implications for critical care and operative treatment in space. Kirkpatrick AW, et al. **J Am Coll Surg** 1997 May; 184(5):441–53 (120 ref.)
Isolated common iliac artery occlusion secondary to atherosclerotic plaque rupture from blunt abdominal trauma: case report and review of the literature. Tsai FC, et al. **J Trauma** 1997 Jan;42(1):133–6 (18 ref.)
Damage control for urologic injuries. Coburn M.
Surg Clin North Am 1997 Aug;77(4):821–34 (16 ref.)
Damage control for devastating pelvic and extremity injuries. Henry SM, et al. **Surg Clin North Am** 1997 Aug; 77(4):879–95 (47 ref.)
Damage control for the obstetric patient. Moise KJ Jr, et al. **Surg Clin North Am** 1997 Aug;77(4):835–52 (42 ref.)
[Diaphragmatic injuries—classification, diagnosis and therapy] Steinau G, et al. **Chirurg** 1997 May;68(5):509–12 (18 ref.) (Eng. Abstr.) **(Ger)**
[Results of surgical treatment of acute traumatic aortic rupture] Charpentier A, et al. **Zentralbl Chir** 1996; 121(9):744–9 (26 ref.) (Eng. Abstr.) **(Ger)**
[Surgical treatment of traumatic rupture of the aortic valve] Imamaki M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Nov;44(11):2050–3 (18 ref.) (Eng. Abstr.) **(Jpn)**
[Urgent thoracotomy for injuries to the tracheobronchial tree due to blunt trauma—a seven cases report and a literature review of 32 cases in Japan] Tanaka H, et al.
Nippon Kyobu Geka Gakkai Zasshi 1997 Jun;45(6):851–9 (46 ref.) (Eng. Abstr.) **(Jpn)**
[Emergency pancreaticoduodenal resection in closed abdominal trauma] Dolgushin NE, et al.
Vestn Khir Im I I Grek 1996;155(2):58–9 (17 ref.) **(Rus)**

THERAPY

The increasing frequency of nonoperative management of patients with liver and spleen injury. Rutledge R.
Adv Surg 1996;30:385–415 (72 ref.)
Newer diagnostic measures and emergency management. Mattox KL, et al. **Chest Surg Clin N Am** 1997 May; 7(2):213–26 (66 ref.)
The management of fractures with soft-tissue disruptions. Sanders R, et al. **Instr Course Lect** 1994;43:559–70 (87 ref.)

ULTRASONOGRAPHY

Ultrasound in the evaluation and management of blunt abdominal trauma. Nordenholz KE, et al.
Ann Emerg Med 1997 Mar;29(3):357–66 (51 ref.)
Role of ultrasonography in blunt abdominal trauma: a prospective study. Abu-Zidan FM, et al. **Eur J Surg** 1996 May;162(5):361–5 (19 ref.)
The evaluation of blunt abdominal trauma: the evolving role of ultrasound. Givre S, et al. **Mt Sinai J Med** 1997 Sep–Oct; 64(4–5):311–5 (23 ref.)
[Post-traumatic priapism in a 10-year-old boy] Sperling H, et al. **Urologe A** 1997 Mar;36(2):162–4 (11 ref.) (Eng. Abstr.) **(Ger)**
[Valvular lesions in the course of nonpenetrating thoracic trauma: their diagnosis by transesophageal echocardiography] Ussia GP, et al. **Cardiologia** 1996 Nov; 41(11):1107–11 (39 ref.) (Eng. Abstr.) **(Ita)**

WOUNDS, PENETRATING

Cardiac trauma. Diagnosis, management, and current therapy. Olsovsky MR, et al. **Angiology** 1997 May; 48(5):423–32 (60 ref.)
Esophageal injuries. Bastos RB, et al.
Chest Surg Clin N Am 1997 May;7(2):357–71 (57 ref.)
Trauma to the heart. Brown J, et al.
Chest Surg Clin N Am 1997 May;7(2):325–41 (44 ref.)
Traumatic injury of the cervicothoracic trachea and major bronchi. Lee RB. **Chest Surg Clin N Am** 1997 May; 7(2):285–304 (78 ref.)
Trauma to the diaphragm. Mansour KA.
Chest Surg Clin N Am 1997 May;7(2):373–83 (36 ref.)
Penetrating cranio-cerebral injuries. Buxton N.
J R Army Med Corps 1997 Jun;143(2):112–4 (34 ref.)
[Impalement injuries. A clinical case] De Rosa G, et al.
Minerva Chir 1997 Jan–Feb;52(1–2):143–8 (19 ref.) (Eng. Abstr.) **(Ita)**
[Renal traumatism: diagnostic protocol and therapeutic indications] Monserrat Monfort JJ, et al.
Actas Urol Esp 1996 Jun;20(6):534–43 (18 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Pseudoaneurysms of the radial artery. Importance of microsurgery. Apropos of a case. Moufarrège R, et al.
Ann Chir Main 1982;1(1):40–4 (13 ref.) **(Eng, Fre)**
Vitrectomy in ocular trauma. Claes C, et al.
Bull Soc Belge Ophtalmol 1995;258:169–88 (59 ref.)
Traumatic adult respiratory distress syndrome. Bass TL, et al. **Chest Surg Clin N Am** 1997 May;7(2):429–42 (71 ref.)
Trauma to the lung. Boyd AD, et al.
Chest Surg Clin N Am 1997 May;7(2):263–84 (70 ref.)
Traumatic thoracic fistulas. Sebastian MW, et al.
Chest Surg Clin N Am 1997 May;7(2):385–400 (33 ref.)
Cost effectiveness of magnetic resonance imaging in diagnosing Pseudomonas aeruginosa infection after puncture wound. Lau LS, et al. **J Foot Ankle Surg** 1997 Jan–Feb;36(1):36–43 (23 ref.)

DIAGNOSIS

Newer diagnostic measures and emergency management. Mattox KL, et al. **Chest Surg Clin N Am** 1997 May; 7(2):213–26 (66 ref.)
Magnetic resonance angiography in trauma. James CA.
Clin Neurosci 1997;4(3):137–45 (19 ref.)

ETIOLOGY

Evisceration after laparoscopic sterilization. Lopez A, et al.
J Am Assoc Gynecol Laparosc 1995 Nov;3(1):109–11 (11 ref.)
Ax injuries of the hand. Muir L, et al. **J Trauma** 1997 May; 42(5):927–32 (9 ref.)
Bilateral vertebral artery lesion after dislocating cervical spine trauma. A case report. Wirbel R, et al. **Spine** 1996 Jun 1;21(11):1375–9; discussion 1380 (22 ref.)

PHYSIOPATHOLOGY

Pathophysiology of chest trauma. Calhoon JH, et al.
Chest Surg Clin N Am 1997 May;7(2):199–211 (30 ref.)

PREVENTION & CONTROL

[Determination of the trauma severity level] Gennari TD, et al. **Rev Saude Publica** 1995 Oct;29(5):333–41 (32 ref.) (Eng. Abstr.) **(Por)**

RADIOGRAPHY

Trauma. Mirvis SE. **Radiol Clin North Am** 1996 Nov; 34(6):1225–57 (28 ref.)

SURGERY

Abdominal wounds in war. Coupland R. **Br J Surg** 1996 Nov;83(11):1505–11 (57 ref.)
Laryngotracheal trauma. Chagnon FP, et al.
Chest Surg Clin N Am 1996 Nov;6(4):733–48 (39 ref.)
Pediatric depressed skull fractures: analysis of 530 cases. Erşahin Y, et al. **Childs Nerv Syst** 1996 Jun;12(6):323–31 (15 ref.)
Penetrating cardiac injuries. Karmy-Jones R, et al. **Injury** 1997 Jan;28(1):57–61 (29 ref.)
The surgical management in war of penetrating wounds contaminated with chemical warfare agents. Cooper GJ, et al. **J R Army Med Corps** 1994 Oct;140(3):113–8 (15 ref.)
Damage control for urologic injuries. Coburn M.
Surg Clin North Am 1997 Aug;77(4):821–34 (16 ref.)
Damage control for devastating pelvic and extremity injuries. Henry SM, et al. **Surg Clin North Am** 1997 Aug; 77(4):879–95 (47 ref.)
Damage control for the obstetric patient. Moise KJ Jr, et al. **Surg Clin North Am** 1997 Aug;77(4):835–52 (42 ref.)
[Perforating injuries: management of the repair of scleral and corneal injuries] Comhaire-Poutchinian Y.
Bull Soc Belge Ophtalmol 1996;260:81–8 (12 ref.) (Eng. Abstr.) **(Fre)**

WOUNDS, PENETRATING

[Impalement injury of the colon, iliac vein and sacrum--a rare combination in penetrating abdominal trauma. A case report] Funke M, et al. **Chirurg** 1996 Nov;67(11):1184–7 (27 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Newer diagnostic measures and emergency management. Mattox KL, et al. **Chest Surg Clin N Am** 1997 May; 7(2):213–26 (66 ref.)

The management of fractures with soft-tissue disruptions. Sanders R, et al. **Instr Course Lect** 1994;43:559–70 (87 ref.)

Penetrating injuries to the thoracic great vessels. Demetriades D. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):173–9; discussion 179–80 (15 ref.)

WOUNDS, STAB

COMPLICATIONS

Exogenous lumbar spondylodiscitis following a stabwound injury and vertebral fracture. A case report and review of the literature. Schulze CJ, et al. **Eur Spine J** 1995; 4(6):357–9 (16 ref.)

Isolated stab wound to the artery of Adamkiewicz: case report and review of the literature. Rogers FB, et al. **J Trauma** 1997 Sep;43(3):549–51 (18 ref.)

Pneumomediastinum following penetrating oral trauma. McHugh TP. **Pediatr Emerg Care** 1997 Jun;13(3):211–3 (20 ref.)

Post-traumatic costochondritis caused by Candida albicans. Aetiology, diagnosis and treatment. Heckenkamp J, et al. **Scand Cardiovasc J** 1997;31(3):165–7 (12 ref.)

[Pyogenic osteomyelitis after a plantar puncture wound: analysis of a series of 8 cases] Morales M, et al. **Enferm Infecc Microbiol Clin** 1996 Oct;14(8):479–82 (17 ref.) (Eng. Abstr.) **(Spa)**

[Intestinal obstruction as late presentation of traumatic diaphragmatic hernia: report of a case and review of the literature] Vásquez JC, et al. **Rev Gastroenterol Peru** 1996 May–Aug;16(2):158–61 (21 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Carotid arterial trauma: assessment with the Glasgow Coma Scale (GCS) as a guide to surgical management. Teehan EP, et al. **Cardiovasc Surg** 1997 Apr;5(2):196–200 (27 ref.)

Laparoscopic transdiaphragmatic diagnostic pericardial window in the hemodynamically stable patient with penetrating chest trauma. A brief report. McMahon DJ, et al. **Surg Endosc** 1997 May;11(5):474–5 (9 ref.)

ETIOLOGY

Case report of metallic mercury injury. Smith SR, et al. **Pediatr Emerg Care** 1997 Apr;13(2):114–6 (14 ref.)

WPW SYNDROME see **WOLFF-PARKINSON-WHITE SYNDROME**

WR-2721 see **AMIFOSTINE**

WRESTLING

INJURIES

Humeral shaft fracture sustained during arm wrestling: report on 30 cases and review of the literature. Ogawa K, et al. **J Trauma** 1997 Feb;42(2):243–6 (30 ref.)

PHYSIOLOGY

American College of Sports Medicine position stand. Weight loss in wrestlers. Oppliger RA, et al. **Med Sci Sports Exerc** 1996 Jun;28(6):ix–xii (72 ref.)

WRIST

Pigmented villonodular synovitis of the wrist in childhood. Hoeffel JC, et al. **Clin Pediatr (Phila)** 1997 Jul;36(7):423–6 (28 ref.)

Cumulative trauma disorders. Higgs PE, et al. **Clin Plast Surg** 1996 Jul;23(3):421–33 (34 ref.)

Update on imaging techniques of the wrist and hand. Metz VM, et al. **Clin Plast Surg** 1996 Jul;23(3):369–84 (60 ref.)

Acquired dermal melanocytosis on the wrist. Kuniyuki S. **J Dermatol** 1997 Feb;24(2):120–4 (18 ref.)

ABNORMALITIES

Freeman Sheldon syndrome: severe upper airway obstruction requiring neonatal tracheostomy. Robinson PJ. **Pediatr Pulmonol** 1997 Jun;23(6):457–9 (5 ref.)

ANATOMY & HISTOLOGY

Magnetic resonance imaging of the musculoskeletal system. Part 5. The wrist. Siegel S, et al. **Clin Orthop** 1996 Nov; (332):281–300 (35 ref.)

BLOOD SUPPLY

Upper extremity arterial bypass distal to the wrist. Dalman RL. **Ann Vasc Surg** 1997 Sep;11(5):550–7 (55 ref.)

MICROBIOLOGY

Tuberculous infection of the hand and wrist. Visuthikosol V, et al. **Ann Plast Surg** 1996 Jul;37(1):55–9 (23 ref.)

PATHOLOGY

Kienböck's disease. I. Anatomy and Etiology. Fredericks TK, et al. **Int J Occup Med Environ Health** 1997;10(1):11–7 (21 ref.)

Dupuytren's disease may extend beyond the wrist crease in continuity. Sinha A. **J Bone Joint Surg Br** 1997 Mar; 79(2):211–2 (12 ref.)

PHYSIOPATHOLOGY

Impaired limb position sense after stroke: a quantitative test for clinical use. Carey LM, et al. **Arch Phys Med Rehabil** 1996 Dec;77(12):1271–8 (70 ref.)

Chronic wrist pain [see comments] Ko EH, et al. **Curr Opin Rheumatol** 1997 Mar;9(2):155–8 (24 ref.) Comment in: Curr Opin Rheumatol 1997 Mar;9(2):133–43.

RADIOGRAPHY

Radiology of the hand and wrist [see comments] Weisman TL, et al. **Orthopedics** 1996 Nov;19(11):957–64; quiz 965–6 (20 ref.) Comment in: Orthopedics 1997 Apr;20(4):300.

SURGERY

Arthroscopy in hand surgery. Jones KJ. **Clin Plast Surg** 1996 Jul;23(3):463–76 (30 ref.)

Surgical principles and planning for the rheumatoid hand and wrist. O'Brien ET. **Clin Plast Surg** 1996 Jul; 23(3):407–20 (43 ref.)

WRIST INJURIES

Common wrist injuries. Morgan RL, et al. **Am Fam Physician** 1997 Feb 15;55(3):857–68 (15 ref.)

The natural progression of scaphoid instability. Watson HK, et al. **Hand Clin** 1997 Feb;13(1):39–49 (16 ref.)

Distal radius fractures: concepts and complications. Glowacki KA, et al. **Orthopedics** 1996 Jul;19(7):601–8 (49 ref.)

DIAGNOSIS

Stress fracture of the ulnar diaphysis in a recreational golfer. Koskinen SK, et al. **Clin J Sport Med** 1997 Jan;7(1):63–5 (14 ref.)

Magnetic resonance imaging of the musculoskeletal system. Part 5. The wrist. Siegel S, et al. **Clin Orthop** 1996 Nov; (332):281–300 (35 ref.)

Additional thoughts on the physical examination of the wrist. Nelson DL. **Hand Clin** 1997 Feb;13(1):35–7 (6 ref.)

Physical examination of the wrist. Watson HK, et al. **Hand Clin** 1997 Feb;13(1):17–34 (6 ref.)

Clinical examination of the wrist. Skirven T. **J Hand Ther** 1996 Apr–Jun;9(2):96–107 (47 ref.)

[Radiologic skeletal diagnosis: traumatology of the distal forearm, the wrists and the hand] Neumann K, et al. **Aktuelle Radiol** 1996 Jul;6(4):171–5 (15 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Sports injuries of the hand and wrist. Barton N. **Br J Sports Med** 1997 Sep;31(3):191–6 (50 ref.)

Golf-induced injuries of the wrist. Murray PM, et al. **Clin Sports Med** 1996 Jan;15(1):85–109 (45 ref.)

PHYSIOPATHOLOGY

Overuse syndromes of the hand and wrist. Verdon ME. **Prim Care** 1996 Jun;23(2):305–19 (44 ref.)

RADIOGRAPHY

Disorders of the distal radioulnar joint. Glowacki K, et al. **Am J Orthop** 1997 Mar;26(3):193–200 (51 ref.)

Occult scaphoid fracture: need to avoid complacency--case report and literature review. Ohiorenoya D, et al. **J Trauma** 1996 Dec;41(6):1054–5 (14 ref.)

Imaging of acute injuries to the wrist and hand. Gilbert TJ, et al. **Radiol Clin North Am** 1997 May;35(3):701–25 (58 ref.)

SURGERY

Arthroscopic repairs of triangular fibrocartilage complex tears. Baehser-Griffith P, et al. **AORN J** 1997 Jul; 66(1):101–2, 105–11, quiz 112, 115, 117–8 (23 ref.)

Fractures of the hand. Corley FG Jr, et al. **Clin Plast Surg** 1996 Jul;23(3):447–62 (63 ref.)

Arthroscopy of the wrist in athletes. Ekman EF, et al. **Clin Sports Med** 1996 Oct;15(4):753–68 (40 ref.)

Pedicle flaps for coverage of the wrist and hand. Mih AD. **Hand Clin** 1997 May;13(2):217–29 (46 ref.)

The Galeazzi-equivalent lesion in children revisited. Imatani J, et al. **J Hand Surg [Br]** 1996 Aug;21(4):455–7 (11 ref.)

Nonunion of distal radial fractures associated with distal ulnar shaft fractures: a report of four cases. McKee MD, et al. **J Orthop Trauma** 1997 Jan;11(1):49–53 (16 ref.)

[Scapho-capitate fracture. Apropos of a case, review of the literature] Boisgard S, et al. **Ann Chir Main Memb Super** 1996;15(3):181–8 (21 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Disorders of the distal radioulnar joint. Glowacki K, et al. **Am J Orthop** 1997 Mar;26(3):193–200 (51 ref.)

The management of carpal fractures and dislocations. Prosser R, et al. **J Hand Ther** 1996 Apr–Jun;9(2):139–47 (30 ref.)

Splinting the wrist: mobilization and protection. Schultz-Johnson K. **J Hand Ther** 1996 Apr–Jun; 9(2):165–77 (54 ref.)

WRIST JOINT

Disorders of the distal radioulnar joint. Glowacki K, et al. **Am J Orthop** 1997 Mar;26(3):193–200 (51 ref.)

Evaluation of the painful wrist. Kuschner SH, et al. **Am J Orthop** 1997 Feb;26(2):95–102 (66 ref.)

Arthroscopic repairs of triangular fibrocartilage complex tears. Baehser-Griffith P, et al. **AORN J** 1997 Jul; 66(1):101–2, 105–11, quiz 112, 115, 117–8 (23 ref.)

An approach to complex rheumatoid hand and wrist problems. Blair WF. **Hand Clin** 1996 Aug;12(3):615–28 (16 ref.)

The distal radioulnar joint in rheumatoid arthritis. Blank JE, et al. **Hand Clin** 1996 Aug;12(3):499–513 (87 ref.)

Rheumatoid flexor tenosynovitis and rupture. Ferlic DC. **Hand Clin** 1996 Aug;12(3):561–72 (43 ref.)

Additional thoughts on the physical examination of the wrist. Nelson DL. **Hand Clin** 1997 Feb;13(1):35–7 (6 ref.)

The wrist in rheumatoid arthritis. Shapiro JS. **Hand Clin** 1996 Aug;12(3):477–98 (80 ref.)

The natural progression of scaphoid instability. Watson HK, et al. **Hand Clin** 1997 Feb;13(1):39–49 (16 ref.)

Physical examination of the wrist. Watson HK, et al. **Hand Clin** 1997 Feb;13(1):17–34 (6 ref.)

The treatment of wrist instability. Garcia-Elias M. **J Bone Joint Surg Br** 1997 Jul;79(4):684–90 (51 ref.)

Congenital absence of the scaphoid without other congenital abnormality: a case report. Kuz JE, et al. **J Hand Surg [Am]** 1997 May;22(3):489–91 (7 ref.)

Management of rheumatoid arthritis of the wrist. Dell PC, et al. **J Hand Ther** 1996 Apr–Jun;9(2):157–64 (22 ref.)

The distal radioulnar joint: anatomy and management of disorders. Jaffe R, et al. **J Hand Ther** 1996 Apr–Jun; 9(2):129–38 (65 ref.)

Development of a scale for patient rating of wrist pain and disability. MacDermid JC. **J Hand Ther** 1996 Apr–Jun; 9(2):178–83 (37 ref.)

Splinting the wrist: mobilization and protection. Schultz-Johnson K. **J Hand Ther** 1996 Apr–Jun; 9(2):165–77 (54 ref.)

Clinical examination of the wrist. Skirven T. **J Hand Ther** 1996 Apr–Jun;9(2):96–107 (47 ref.)

Management of carpal instabilities. Wright TW, et al. **J Hand Ther** 1996 Apr–Jun;9(2):148–56 (37 ref.)

Tumoral calcinosis in hemodialysis patients. A review of three cases. Franco M, et al. **Rev Rhum Engl Ed** 1997 Jan; 64(1):59–62 (19 ref.)

ANATOMY & HISTOLOGY

The ligaments of the wrist. A current overview of anatomy with considerations of their potential functions. Berger RA. **Hand Clin** 1997 Feb;13(1):63–82 (25 ref.)

The anatomy and basic biomechanics of the wrist joint. Berger RA. **J Hand Ther** 1996 Apr–Jun;9(2):84–93 (26 ref.)

MICROBIOLOGY

[A case of arthritis of the wrist caused by Mycobacterium marinum. Review of the literature] Flisch CW, et al. **Ann Chir Main Memb Super** 1996;15(4):238–43 (15 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Magnetic resonance imaging of the musculoskeletal system. Part 5. The wrist. Siegel S, et al. **Clin Orthop** 1996 Nov; (332):281–300 (35 ref.)

Evaluation of the patient presenting with a painful wrist. Young VL, et al. **Clin Plast Surg** 1996 Jul;23(3):361–8 (12 ref.)

Wrist disorders: what should we be looking for with imaging techniques? Berquist TH. **J Hand Ther** 1996 Apr–Jun; 9(2):108–13 (22 ref.)

MR imaging of the wrist. Pretorius ES, et al. **Radiol Clin North Am** 1997 Jan;35(1):145–61 (54 ref.)

PHYSIOLOGY

Kinetic analysis of carpal stability during grip. Garcia-Elias M. **Hand Clin** 1997 Feb;13(1):151–8 (36 ref.)

Functional wrist motion. Nelson DL. **Hand Clin** 1997 Feb; 13(1):83–92 (19 ref.)

Load mechanics of the wrist. Viegas SF, et al. **Hand Clin** 1997 Feb;13(1):109–28 (16 ref.)

The anatomy and basic biomechanics of the wrist joint. Berger RA. **J Hand Ther** 1996 Apr–Jun;9(2):84–93 (26 ref.)

PHYSIOPATHOLOGY

[Impaired associated movement in Parkinson's disease] Kawakami O, et al. **Nippon Rinsho** 1997 Jan;55(1):179–84 (15 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Definitions of osteoarthritis in the knee and hand. Jacobson LT. **Ann Rheum Dis** 1996 Sep;55(9):656–8 (23 ref.)
Update on imaging techniques of the wrist and hand. Metz VM, et al. **Clin Plast Surg** 1996 Jul;23(3):369–84 (60 ref.)

SURGERY

Proximal row carpectomy: an alternative to wrist fusion? Steenwerckx A, et al. **Acta Orthop Belg** 1997 Mar;63(1):1–7 (23 ref.)
Current status of wrist arthrodesis and wrist arthroplasty. Murray PM. **Clin Plast Surg** 1996 Jul;23(3):385–94 (63 ref.)

WRITING

"While you're up, get me a grant": a guide to grant writing. Streiner DL. **Can J Psychiatry** 1996 Apr;41(3):137–43 (2 ref.)
Managing and communicating information in a new era. Crandall S, et al. **Fam Med** 1997 Apr;29(4):270–4 (46 ref.)
How to write a paper. Driscoll P. **J Accid Emerg Med** 1997 Mar;14(2):65–9 (20 ref.)
Reflective journal writing in nurse education: whose interests does it serve? Wellard SJ, et al. **J Adv Nurs** 1996 Nov; 24(5):1077–82 (34 ref.)
Writing across the curriculum: putting theory into practice in animal science courses. Aaron DK. **J Anim Sci** 1996 Nov;74(11):2810–27 (18 ref.)
Writing as a therapeutic modality. McGihon NN. **J Psychosoc Nurs Ment Health Serv** 1996 Jun;34(6):31–5 (8 ref.)
Medical records and other stories: a narratological framework [see comments] Kay S, et al. **Methods Inf Med** 1996 Jun;35(2):72–87 (119 ref.) Comment in: Methods Inf Med 1996 Jun;35(2):88–92. Comment in: Methods Inf Med 1996 Jun;35(2):93–7. Comment in: Methods Inf Med 1996 Jun;35(2):98–100. Comment in: Methods Inf Med 1996 Jun;35(2):101–3.

STANDARDS

How to read a paper. Papers that report diagnostic or screening tests. Greenhalgh T. **BMJ** 1997 Aug 30; 315(7107):540–3 (15 ref.)
How to read a paper. Papers that tell you what things cost (economic analyses). Greenhalgh T. **BMJ** 1997 Sep 6; 315(7108):596–9 (18 ref.)
How to incorporate and evaluate writing skills in animal science and dairy science courses. Haug M. **J Anim Sci** 1996 Nov;74(11):2835–42 (7 ref.)

WRYNECK see **TORTICOLLIS**

WUCHERERIA

ISOLATION & PURIFICATION

Tropical pulmonary eosinophilia. Vijayan VK. **Indian J Chest Dis Allied Sci** 1996 Jul–Sep;38(3):169–80 (101 ref.)

WUCHERERIA BANCROFTI

Lymphatic filariasis. Rajan TV, et al. **Chem Immunol** 1997; 66:125–58 (127 ref.)
Lymphatic filariasis and the women of India. Bandyopadhyay L. **Soc Sci Med** 1996 May;42(10):1401–10 (33 ref.)
[Diethylcarbamazine in the treatment of Bancroft's filariasis] Dreyer G, et al. **Rev Soc Bras Med Trop** 1997 May–Jun; 30(3):229–40 (93 ref.) (Eng. Abstr.) **(Por)**

X CHROMOSOME

XIST expression and X-chromosome inactivation in human preimplantation embryos [editorial; comment] Brown CJ, et al. **Am J Hum Genet** 1997 Jul;61(1):5–8 (28 ref.) Comment on: Am J Hum Genet 1997 Jul;61(1):33–9.
The great escape [editorial; comment] Disteche CM. **Am J Hum Genet** 1997 Jun;60(6):1312–5 (40 ref.) Comment on: Am J Hum Genet 1997 Jun;60(6):1333–43.
How many X-linked genes for non-specific mental retardation (MRX) are there? [letter] Gedeon AK, et al. **Am J Med Genet** 1996 Jul 12;64(1):158–62 (40 ref.)
XLMR genes: update 1996. Lubs HA, et al. **Am J Med Genet** 1996 Jul 12;64(1):147–57 (105 ref.)
Study of X-linked mental retardation (XLMR): summary of 61 families in the Miami/Greenwood Study. Lubs HA, et al. **Am J Med Genet** 1996 Jul 12;64(1):169–75 (34 ref.)
Ring chromosome X in a child with manifestations of Kabuki syndrome. McGinniss MJ, et al. **Am J Med Genet** 1997 May 2;70(1):37–42 (34 ref.)
Severe mental retardation and macroorchidism without mutation in the FMR1 gene. Reyniers E, et al. **Am J Med Genet** 1996 Aug 9;64(2):408–12 (26 ref.)
Partial trisomy 17q22–qter and partial monosomy Xq27–qter in a girl with a de novo unbalanced translocation due to a postzygotic error: case report and review of the literature on partial trisomy 17qter. Sarri C, et al. **Am J Med Genet** 1997 May 2;70(1):87–94 (46 ref.)
Mapping of the loci for mental retardation syndromes in the distal Xq [letter] Schmidt M. **Am J Med Genet** 1996 Jul 12;64(1):163–5 (41 ref.)
X chromosome inactivation and X-linked mental retardation. Willard HF. **Am J Med Genet** 1996 Jul 12;64(1):21–6 (53 ref.)
Molecular cytogenetic identification of four X chromosome duplications. Zhang A, et al. **Am J Med Genet** 1997 Jan 10;68(1):29–38 (38 ref.)
Trisomy X: ACLF (Association des Cytogénéticiens de Langue Française) retrospective study. Guichet A, et al. **Ann Genet** 1996;39(3):117–22 (20 ref.)
Sex determination in humans. Schafer AJ, et al. **Bioessays** 1996 Dec;18(12):955–63 (80 ref.)
XYY male and hematologic malignancy. Oguma N, et al. **Cancer Genet Cytogenet** 1996 Sep;90(2):179–81 (22 ref.)
Dystrophinopathy, the expanding phenotype. Dystrophin abnormalities in X-linked dilated cardiomyopathy [editorial; comment] Beggs AH. **Circulation** 1997 May 20; 95(10):2344–7 (24 ref.) Comment on: Circulation 1997 May 20;95(10):2434–40.
Blepharophimosis syndrome (BPES) and additional abnormalities in a female with a balanced X:3 translocation [letter] Karimi-Nejad A, et al. **Clin Dysmorphol** 1996 Jul; 5(3):259–61 (5 ref.)
Multiple congenital malformations in an infant prenatally diagnosed with mosaicism for dup(1q) and del(Xq). Wells SR, et al. **Clin Genet** 1996 Apr;49(4):216–9 (10 ref.)
Dosage compensation: X-repress yourself. Wood WB, et al. **Curr Biol** 1997 Apr 1;7(4):R227–30 (18 ref.)
The (epi)genetic control of mammalian X-chromosome inactivation. Lee JT, et al. **Curr Opin Genet Dev** 1997 Apr; 7(2):274–80 (42 ref.)
Molecular analysis of X-linked nephrogenic diabetes insipidus. Fujiwara TM, et al. **Eur J Endocrinol** 1996 Jun; 134(6):675–7 (12 ref.)
New mutations in the X-linked form of Charcot-Marie-Tooth disease. Latour P, et al. **Eur Neurol** 1997;37(1):38–42 (23 ref.)
Kabuki syndrome in son and low grade mosaic 45,X/46,XX in mother. Van Hagen JM, et al. **Genet Couns** 1996; 7(3):201–6 (16 ref.)
The mappers' torch song. Yu J, et al. **Genome Res** 1997 Jul; 7(7):666–8 (22 ref.)
L1-associated diseases: clinical geneticists divide, molecular geneticists unite. Fransen E, et al. **Hum Mol Genet** 1997; 6(10):1625–32 (103 ref.)
The predetermination of embryonic sex using flow cytometrically separated X and Y spermatozoa. Cran DG, et al. **Hum Reprod Update** 1996 Jul–Aug;2(4):355–63 (48 ref.)
X-chromosome activity: impact of imprinting and chromatin structure. Jamieson RV, et al. **Int J Dev Biol** 1996 Dec; 40(6):1065–80 (170 ref.)
DNA diagnosis of X-linked adrenoleukodystrophy. Seneca S, et al. **J Inherit Metab Dis** 1995;18 Suppl 1:34–44 (60 ref.)
The recognition and investigation of X-linked learning disability syndromes. Feldman EJ. **J Intellect Disabil Res** 1996 Oct;40 (Pt 5):400–11 (77 ref.)
Molecular genetics of familial spastic paraplegia: a multitude of responsible genes. Kobayashi H, et al. **J Neurol Sci** 1996 May;137(2):131–8 (40 ref.)
Craniosynostosis in X-linked hypophosphataemic rickets. Willis FR, et al. **J Paediatr Child Health** 1997 Feb; 33(1):78–9 (12 ref.)
X-linked agammaglobulinemia. A clinical and molecular analysis. Ochs HD, et al. **Medicine (Baltimore)** 1996 Nov; 75(6):287–99 (134 ref.)
X-linked malformations of neuronal migration. Dobyns WB, et al. **Neurology** 1996 Aug;47(2):331–9 (65 ref.)
X-linked myotubular myopathy: refinement of the critical gene region. Smolenicka Z, et al. **Neuromuscul Disord** 1996 Aug;6(4):275–81 (33 ref.)
Hybrid sterility in the mouse [published erratum appears in Trends Genet 1997 Jan;13(1):42] Forejt J. **Trends Genet** 1996 Oct;12(10):412–7 (51 ref.)
[Dyskeratosis congenita. Genetic hematologic-immunologic systemic disease with pancytopenia] Sölder B, et al. **Klin Padiatr** 1996 Nov–Dec;208(6):344–9 (50 ref.) (Eng. Abstr.) **(Ger)**
[X chromosomal bulbospinal neuropathy (X-BSN, Kennedy syndrome): an illness with repetitive triplet sequences. Case report, differential diagnosis and molecular genetics aspects] Abel A, et al. **Nervenarzt** 1996 Dec;67(12):1011–9 (44 ref.) (Eng. Abstr.) **(Ger)**
[Albinism. Current clinical and molecular genetic aspects of an important differential congenital nystagmus diagnosis] Lorenz B. **Ophthalmologe** 1997 Jul;94(7):534–44 (46 ref.) **(Ger)**
[Molecular genetics of X-linked primary immunodeficiencies: advances in diagnosis and prevention] Carbonara A, et al. **Ann Ital Med Int** 1996 Jul–Sep;11(3):180–6 (55 ref.) (Eng. Abstr.) **(Ita)**
[Cousins with X-linked recessive myotubular myopathy] Mori Y, et al. **No To Hattatsu** 1997 Jul;29(4):310–4 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Inactivation of X-chromosome and Xist gene] Takagi N. **Tanpakushitsu Kakusan Koso** 1996 Jul;41(9):1391–5 (23 ref.) **(Jpn)**
[Mutation "outbursts" of various genes in natural populations of Drosophila melanogaster] Gershenzon SM. **Genetika** 1997 Apr;33(4):421–30 (86 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Sex determining gene on the X chromosome short arm: dosage sensitive sex reversal. Ogata T, et al. **Acta Paediatr Jpn** 1996 Aug;38(4):390–8 (40 ref.)
Karyotype-phenotype correlation in females with X chromosome abnormalities. Kosmaidou-Aravidou Z. **Ann N Y Acad Sci** 1997 Jun 17;816:373–7 (27 ref.)
Monosomy X as a recurring sole cytogenetic abnormality associated with myelodysplastic diseases. Abruzzese E, et al. **Cancer Genet Cytogenet** 1997 Feb;93(2):140–6 (41 ref.)
Molecular biology of hereditary enamel defects. Aldred MJ, et al. **Ciba Found Symp** 1997;205:200–5; discussion 205–9 (29 ref.)
Inherited enamel defects. Bäckman B. **Ciba Found Symp** 1997; 205:175–82; discussion 183–6 (37 ref.)
Nonsyndromic X-linked mental retardation: review and mapping of MRX29 to Xp21. Häne B, et al. **Clin Genet** 1996 Oct;50(4):176–83 (49 ref.)
X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy. van Geel BM, et al. **J Neurol Neurosurg Psychiatry** 1997 Jul;63(1):4–14 (139 ref.)
Mutation watch: PEX PLUS? Gene(s) for X-linked hypophosphatemia and deafness. Meisler M. **Mamm Genome** 1997 Aug;8(8):543–4 (8 ref.)
[X chromosome inactivation and XIST] Sakai K. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(15 Suppl):2296–305 (70 ref.) **(Jpn)**
[Genetic basis of Turner syndrome (published erratum appears in Pol Arch Med Wewn 1995 Aug;94(2):183)] Slezak R, et al. **Pol Arch Med Wewn** 1995 Oct;94(4):358–63 (39 ref.) **(Pol)**

IMMUNOLOGY

The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. Sugamura K, et al. **Annu Rev Immunol** 1996;14:179–205 (120 ref.)

PHYSIOLOGY

New insights into X-linked hypophosphatemia. Grieff M. **Curr Opin Nephrol Hypertens** 1997 Jan;6(1):15–9 (37 ref.)

ULTRASTRUCTURE

The license to pair: identification of meiotic pairing sites in Drosophila. McKee BD. **Chromosoma** 1996 Sep; 105(3):135–41 (34 ref.)
Two brothers with multiple congenital anomalies and mental retardation due to disomy (X)(q12-->q13.3) inherited from the mother. Apacik C, et al. **Clin Genet** 1996 Aug; 50(2):63–73 (23 ref.)

X INACTIVATION see **DOSAGE COMPENSATION (GENETICS)**

X-LINKED LYMPHOPROLIFERATIVE SYNDROME see **LYMPHOPROLIFERATIVE DISORDERS**

X-RAY ABSORPTIOMETRY, DUAL-ENERGY see **DENSITOMETRY, X-RAY**

X-RAY CRYSTALLOGRAPHY see **CRYSTALLOGRAPHY, X-RAY**

X-RAY, DIAGNOSTIC see **RADIOGRAPHY**

X-RAY DIFFRACTION

Intermediate trapping and laue X-ray diffraction: potential for enzyme mechanism, dynamics, and inhibitor screening. Stoddard BL. **Pharmacol Ther** 1996;70(3):215–56 (95 ref.)

METHODS

As MAD as can be. Read RJ. **Structure** 1996 Jan 15;4(1):11–4 (19 ref.)

X-RAY EMISSION SPECTROMETRY see **SPECTROMETRY, X-RAY EMISSION**

X-RAY EMISSION SPECTROMETRY, ELECTRON MICROSCOPIC see **ELECTRON PROBE MICROANALYSIS**

X-RAY EMISSION SPECTROMETRY, ELECTRON PROBE see **ELECTRON PROBE MICROANALYSIS**

X-RAY EMISSION SPECTROSCOPY see **SPECTROMETRY, X-RAY EMISSION**

X-RAY FILM

Base and fog densities of fresh Ektaspeed Plus dental X-ray films. Sewerin IP. **Acta Odontol Scand** 1997 Apr; 55(2):79–83 (20 ref.)
[Survey on oral health of university students: examination on tooth conditions using panoramic X-ray films] Susami T, et al. **Kokubyo Gakkai Zasshi** 1996 Sep;63(3):459–67 (31 ref.) (Eng. Abstr.) **(Jpn)**
[Current methods for processing of radiographic medical films] Koveshnikov AI. **Vestn Rentgenol Radiol** 1997

X-RAY FILM

Jul-Aug;(4):44-9 (3 ref.) **(Rus)**

X-RAY FILM-SCREEN SYSTEMS see **X-RAY INTENSIFYING SCREENS**

X-RAY FLUORESCENCE SPECTROMETRY see **SPECTROMETRY, X-RAY EMISSION**

X-RAY INFORMATION SYSTEMS see **RADIOLOGY INFORMATION SYSTEMS**

X-RAY INTENSIFYING SCREENS

Stimulable phosphor plates in chest radiology. Tylén U. **Eur Radiol** 1997;7 Suppl 3:S83-6 (16 ref.)

X-RAY MICROANALYSIS, ELECTRON MICROSCOPIC see **ELECTRON PROBE MICROANALYSIS**

X-RAY MICROANALYSIS, ELECTRON PROBE see **ELECTRON PROBE MICROANALYSIS**

X-RAY THERAPY

STANDARDS

Equivalent half-value layers. Burns JE. **Br J Radiol** 1996; Suppl 25:158-61 (7 ref.)

X-rays: half-value layers 0.01-8.0 mm Al (approx. 6-150 kV peak potential difference). Harrison RM. **Br J Radiol** 1996; Suppl 25:1-23 (47 ref.)

Megavoltage X-ray beams: 2-50 MV. Jordan TJ. **Br J Radiol** 1996;Suppl 25:62-109 (92 ref.)

The variation of percentage depth dose and scatter factor with beam quality. Pitchford WG. **Br J Radiol** 1996;Suppl 25:162-7 (3 ref.)

Orthovoltage X-ray beams (0.5 mm-4.0 mm Cu HVL). Smith CW. **Br J Radiol** 1996;Suppl 25:24-38 (21 ref.)

X-RAY TOMOGRAPHY, COMPUTED see **TOMOGRAPHY, X-RAY COMPUTED**

X-RAYS

Exploring the gene with X-rays. Manchester KL. **Trends Genet** 1996 Dec;12(12):515-8 (19 ref.)

X SYNDROME see **SYNDROME X**

XANTHENES

[Development of calcium fluorescent probes and their application in life sciences] Zhang CL, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan;27(1):37-42 (19 ref.) (Eng. Abstr.) **(Chi)**

XANTHINE DEHYDROGENASE

[Xanthine oxidase (xanthine dehydrogenase)] Sumi S, et al. **Nippon Rinsho** 1996 Dec;54(12):3226-9 (14 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Xanthine oxidoreductase. Biochemical, biological and pathogenic functions. Stipek S, et al. **Sb Lek** 1994; 95(4):289-95 (48 ref.)

XANTHINE OXIDASE

[Xanthine oxidase (xanthine dehydrogenase)] Sumi S, et al. **Nippon Rinsho** 1996 Dec;54(12):3226-9 (14 ref.) (Eng. Abstr.) **(Jpn)**

DEFICIENCY

[Xanthine oxidase deficiency (hereditary xanthinuria), molybdenum cofactor deficiency] Sumi S, et al. **Nippon Rinsho** 1996 Dec;54(12):3333-6 (11 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

The use of caffeine as a metabolic probe for human drug metabolizing enzymes. Miners JO, et al. **Gen Pharmacol** 1996 Mar;27(2):245-9 (34 ref.)

Xanthine oxidoreductase. Biochemical, biological and pathogenic functions. Stipek S, et al. **Sb Lek** 1994; 95(4):289-95 (48 ref.)

XANTHINES

PHARMACOLOGY

Modulation of glial cell signaling by adenosine and pharmacological reinforcement. A neuroprotective strategy? Schubert P, et al. **Mol Chem Neuropathol** 1996 May-Aug;28(1-3):185-90 (19 ref.)

Behavioral and physiological effects of xanthines in nonhuman primates. Howell LL, et al. **Psychopharmacology (Berl)** 1997 Jan;129(1):1-14 (143 ref.)

THERAPEUTIC USE

Orally active NGF synthesis stimulators: potential therapeutic agents in Alzheimer's disease. Yamada K, et al. **Behav Brain Res** 1997 Feb;83(1-2):117-22 (32 ref.)

URINE

[Xanthine oxidase deficiency (hereditary xanthinuria), molybdenum cofactor deficiency] Sumi S, et al. **Nippon Rinsho** 1996 Dec;54(12):3333-6 (11 ref.) (Eng. Abstr.) **(Jpn)**

XANTHOGRANULOMA, JUVENILE

Juvenile xanthogranuloma. Hernandez-Martin A, et al. **J Am Acad Dermatol** 1997 Mar;36(3 Pt 1):355-67; quiz 368-9 (123 ref.)

COMPLICATIONS

Urticaria pigmentosa and juvenile xanthogranuloma: case report and brief review of the literature. Mann RE, et al. **Pediatr Dermatol** 1996 Mar-Apr;13(2):122-6 (32 ref.)

DIAGNOSIS

Juvenile xanthogranuloma beneath a fingernail. Chang P, et al. **Cutis** 1996 Aug;58(2):173-4 (14 ref.)

[Juvenile xanthogranuloma. A deep macronodular form] Marco Macián A, et al. **An Esp Pediatr** 1996 May; 44(5):501-3 (10 ref.) **(Spa)**

PATHOLOGY

Palatal juvenile xanthogranuloma. A case report. Tagawa T, et al. **Int J Oral Maxillofac Surg** 1996 Dec;25(6):453-4 (10 ref.)

Juvenile xanthogranuloma on the palm. Shin HM, et al. **Pediatr Dermatol** 1996 Mar-Apr;13(2):146-7 (7 ref.)

[Juvenile xanthogranuloma localized in the parotid gland] Moukassa D, et al. **Ann Pathol** 1997 Apr;17(2):113-5 (14 ref.) (Eng. Abstr.) **(Fre)**

XANTHOGRANULOMATOUS PYELONEPHRITIS see **PYELONEPHRITIS, XANTHOGRANULOMATOUS**

XANTHOMA DISSEMINATUM see **HISTIOCYTOSIS, NON-LANGERHANS-CELL**

XANTHOMA, JUVENILE see **XANTHOGRANULOMA, JUVENILE**

XANTHOMATOSIS

COMPLICATIONS

Segmental xanthomatosis of the ileocecal valve with anatomic and functional obstruction. Goodman MD. **Arch Pathol Lab Med** 1997 Jan;121(1):75-8 (22 ref.)

DIAGNOSIS

Xanthogranulomatous cholecystitis: a radiological study of 12 cases and a review of the literature. Casas D, et al. **Abdom Imaging** 1996 Sep-Oct;21(5):456-60 (25 ref.)

ETIOLOGY

'Normolipidemic' tendinous and tuberous xanthomatosis. Mancuso G, et al. **Dermatology** 1996;193(1):27-32 (25 ref.)

THERAPY

Treatment of hypercholesterolemia with heparin-induced extracorporeal low-density lipoprotein precipitation (HELP). Lees RS, et al. **J Clin Apheresis** 1996;11(3):132-7 (37 ref.)

XANTHOMATOSIS, CEREBROTENDINOUS

DIAGNOSIS

Aspects of cerebrotendinous xanthomatosis (CTX). Berginer VM. **Neurol Neurochir Pol** 1996;30 Suppl 2:121-6 (44 ref.)

XANTHOMONAS

Stenotrophomonas maltophilia meningitis. Report of two cases and review of the literature. Papadakis KA, et al. **J Neurosurg** 1997 Jul;87(1):106-8 (14 ref.)

CLASSIFICATION

Epidemiological typing of Stenotrophomonas maltophilia. Marty N. **J Hosp Infect** 1997 Aug;36(4):261-6 (29 ref.)

DRUG EFFECTS

Stenotrophomonas (Xanthomonas) maltophilia: a multidrug-resistant nosocomial pathogen. Penzak SR, et al. **Pharmacotherapy** 1997 Mar-Apr;17(2):293-301 (88 ref.)

ENZYMOLOGY

A low-copy number plasmid mediating beta-lactamase production by Xanthomonas maltophilia. Kelly MD, et al. **Adv Exp Med Biol** 1995;390:71-80 (18 ref.)

Microbial dehalogenation of halogenated alkanoic acids, alcohols and alkanes. Slater JH, et al. **Adv Microb Physiol** 1997;38:133-76 (170 ref.)

GENETICS

Regulation of the oxidative stress protective enzymes, catalase and superoxide dismutase in Xanthomonas--a review. Loprasert S, et al. **Gene** 1996 Nov 7;179(1):33-7 (25 ref.)

ISOLATION & PURIFICATION

Endocarditis caused by Stenotrophomonas maltophilia: case report and review. Gutiérrez Rodero F, et al. **Clin Infect Dis** 1996 Dec;23(6):1261-5 (26 ref.)

METABOLISM

Microbial dehalogenation of halogenated alkanoic acids, alcohols and alkanes. Slater JH, et al. **Adv Microb Physiol** 1997;38:133-76 (170 ref.)

XANTHOMONAS CAMPESTRIS

PATHOGENICITY

The type III (Hrp) secretion pathway of plant pathogenic bacteria: trafficking harpins, Avr proteins, and death. Alfano JR, et al. **J Bacteriol** 1997 Sep;179(18):5655-62 (89 ref.)

XANTHOTOXIN see **METHOXSALEN**

XENOBIOTICS

Natural sex steroids and their xenobiotic analogs in animal production: growth, carcass quality, pharmacokinetics, metabolism, mode of action, residues, methods, and epidemiology. Lone KP. **Crit Rev Food Sci Nutr** 1997 Mar; 37(2):93-209 (1177 ref.)

ADVERSE EFFECTS

Xenobiotic-induced hepatotoxicity: mechanisms of liver injury and methods of monitoring hepatic function. Sturgill MG, et al. **Clin Chem** 1997 Aug;43(8 Pt 2):1512-26 (201 ref.)

Oestrogens and the environment. Olea N, et al. **Eur J Cancer Prev** 1996 Dec;5(6):491-6 (30 ref.)

Occupational exposure. Sterzl-Eckert H, et al. **Food Chem Toxicol** 1996 Nov-Dec;34(11-12):1177-8 (1 ref.)

Exposure to mixtures of chemical substances: is there a need for regulations? Van Zorge JA. **Food Chem Toxicol** 1996 Nov-Dec;34(11-12):1033-6 (5 ref.)

Drinking habits and occupational exposure to xenobiotics: a review. Bisio S, et al. **G Ital Med Lav** 1995 Jan-Nov; 17(1-6):37-40 (32 ref.)

The pharmacology of ryanodine and related compounds. Sutko JL, et al. **Pharmacol Rev** 1997 Mar;49(1):53-98 (196 ref.)

A perspective on the risk assessment process for endocrine-disruptive effects on wildlife and human health. Kavlock RJ, et al. **Risk Anal** 1996 Dec;16(6):731-9 (65 ref.)

Autoimmunity caused by xenobiotics. Bigazzi PE. **Toxicology** 1997 Apr 11;119(1):1-21 (85 ref.)

ANALYSIS

Liquid chromatographic determination using lanthanides as time-resolved luminescence probes for drugs and xenobiotics: advantages and limitations. Rieutord A, et al. **Analyst** 1997 May;122(5):59R-66R (44 ref.)

CHEMISTRY

Application of computational chemistry in the study of biologically reactive intermediates. Anders MW, et al. **Adv Exp Med Biol** 1996;387:347-53 (13 ref.)

METABOLISM

Reactive intermediates of xenobiotics in thyroid: formation and biological consequences. Andrae U. **Adv Exp Med Biol** 1996;387:213-9 (38 ref.)

Biosynthesis and cellular effects of toxic glutathione S-conjugates. Dekant W. **Adv Exp Med Biol** 1996; 387:297-312 (115 ref.)

The kidney as a target for biological reactive metabolites: linking metabolism to toxicity. Monks TJ, et al. **Adv Exp Med Biol** 1996;387:203-12 (72 ref.)

Acyl glucuronides: covalent binding and its potential relevance. Spahn-Langguth H, et al. **Adv Exp Med Biol** 1996;387:313-28 (61 ref.)

Mechanisms of cytochrome P450-mediated formation of pneumotoxic electrophiles. Yost GS. **Adv Exp Med Biol** 1996;387:221-9 (40 ref.)

Past, present, and future applications of precision-cut liver slices for in vitro xenobiotic metabolism. Ekins S. **Drug Metab Rev** 1996 Nov;28(4):591-623 (151 ref.)

Covalent binding of xenobiotics to specific proteins in the liver. Pumford NR, et al. **Drug Metab Rev** 1997 Feb-May; 29(1-2):39-57 (67 ref.)

Genetic and environmental factors associated with variation of human xenobiotic glucuronidation and sulfation. Burchell B, et al. **Environ Health Perspect** 1997 Jun;105 Suppl 4:739-47 (95 ref.)

The role of human glutathione transferases and epoxide hydrolases in the metabolism of xenobiotics. Seidegård J, et al. **Environ Health Perspect** 1997 Jun;105 Suppl 4:791–9 (102 ref.)

Stress proteins as molecular biomarkers for environmental toxicology. Ryan JA, et al. **EXS** 1996;77:411–24 (29 ref.)

Enzymology of human cytosolic sulfotransferases. Falany CN. **FASEB J** 1997 Mar;11(4):206–16 (106 ref.)

Influence of solubility and permeant size on absorption and metabolism of xenobiotics in rabbit skin. Bast GE. **Hum Exp Toxicol** 1997 Aug;16(8):435–40 (20 ref.)

Investigation of xenobiotic metabolism by CYP2D6 and CYP2C19: importance of enantioselective analytical methods. Marzo A, et al. **J Chromatogr B Biomed Appl** 1996 Mar 29;678(1):73–92 (105 ref.)

Simulation of human xenobiotic metabolism in microorganisms. Yeast a good compromise between E. coli and human cells. Pompon D, et al. **J Hepatol** 1997;26 Suppl 2:81–5 (19 ref.)

The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies. Windmill KF, et al. **Mutat Res** 1997 May 12; 376(1–2):153–60 (44 ref.)

Glutathione-dependent bioactivation and renal toxicity of xenobiotics. Dekant W. **Recent Results Cancer Res** 1997; 143:77–87 (83 ref.)

Selective protein covalent binding and target organ toxicity. Cohen SD, et al. **Toxicol Appl Pharmacol** 1997 Mar; 143(1):1–12 (99 ref.)

Time for a consistent approach to preparing and culturing hepatocytes? Skett P, et al. **Xenobiotica** 1996 Jan;26(1):1–7 (23 ref.)

[Cytochrome P450--its significance in the biotransformation of xenobiotics and interspecies comparisons] Hrubý K, et al. **Cesk Fysiol** 1997 Mar;46(1):34–9 (24 ref.) (Eng. Abstr.) **(Cze)**

[The metabolism of foreign substances in the horse with reference to other animal species] Schmid A, et al. **Zentralbl Veterinarmed A** 1994 Sep;41(7):493–508 (72 ref.) (Eng. Abstr.) **(Ger)**

[Genetic significance of determined oxidation of drugs and xenobiotics in the pathogenesis of neoplastic diseases] Niewiński P, et al. **Pol Merkuriusz Lek** 1997 Jan;2(7):71–5 (79 ref.) **(Pol)**

[The role of genetically determined oxidation of drugs and xenobiotics in pathogenesis of neoplastic diseases] Niewiński P, et al. **Postepy Hig Med Dosw** 1996; 50(4):321–32 (55 ref.) (Eng. Abstr.) **(Pol)**

PHARMACOKINETICS

Biokinetics and biokinetic models in risk assessment. van Vliet PW, et al. **Hum Exp Toxicol** 1996 Oct;15(10):799–809 (72 ref.)

Topics in xenobiochemistry--application of microdialysis techniques in pharmacokinetic studies. Fettweis G, et al. **Xenobiotica** 1996 May;26(5):473–85 (34 ref.)

PHARMACOLOGY

Molecular mechanisms regulating nitric oxide biosynthesis: role of xenobiotics in epithelial inflammation. Heck DE. **Adv Exp Med Biol** 1996;387:171–6 (40 ref.)

Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Brazelton TR, et al. **Curr Opin Immunol** 1996 Oct; 8(5):710–20 (74 ref.)

Male reproductive health and environmental xenoestrogens [see comments] Toppari J, et al. **Environ Health Perspect** 1996 Aug;104 Suppl 4:741–803 (323 ref.) Comment in: Environ Health Perspect 1997 Feb;105(2):162–3.

TOXICITY

Reactive intermediates of xenobiotics in thyroid: formation and biological consequences. Andrae U. **Adv Exp Med Biol** 1996;387:213–9 (38 ref.)

Biosynthesis and cellular effects of toxic glutathione S-conjugates. Dekant W. **Adv Exp Med Biol** 1996; 387:297–312 (115 ref.)

The kidney as a target for biological reactive metabolites: linking metabolism to toxicity. Monks TJ, et al. **Adv Exp Med Biol** 1996;387:203–12 (72 ref.)

Mechanisms of cytochrome P450-mediated formation of pneumotoxic electrophiles. Yost GS. **Adv Exp Med Biol** 1996;387:221–9 (40 ref.)

Impact of the hypothermic response in inhalation toxicology studies. Watkinson WP, et al. **Ann N Y Acad Sci** 1997 Mar 15;813:849–63 (12 ref.)

Protein targets of xenobiotic reactive intermediates. Pumford NR, et al. **Annu Rev Pharmacol Toxicol** 1997;37:91–117 (168 ref.)

Ecotoxicology for risk assessment in arid zones: some key issues. Everts JW. **Arch Environ Contam Toxicol** 1997 Jan; 32(1):1–10 (123 ref.)

The Gerhard Zbinden Memorial Lecture. Genetic polymorphism of drug metabolizing enzymes. Implications for toxicity of drugs and other xenobiotics. Ingelman-Sundberg M. **Arch Toxicol Suppl** 1997;19:3–13 (26 ref.)

Xenobiotic-induced hepatotoxicity: mechanisms of liver injury and methods of monitoring hepatic function. Sturgill MG, et al. **Clin Chem** 1997 Aug;43(8 Pt 2):1512–26 (201 ref.)

Integrated approaches for the analysis of toxicologic interactions of chemical mixtures. el-Masri HA, et al. **Crit Rev Toxicol** 1997 Mar;27(2):175–97 (62 ref.)

Laboratory probing of oncogenes from human liquid and solid specimens as markers of exposure to toxicants. Nelson E. **Crit Rev Toxicol** 1996 Sep;26(5):483–549 (397 ref.)

A new type of hazardous chemical: the chemosensitizers of multixenobiotic resistance. Kurelec B. **Environ Health Perspect** 1997 Jun;105 Suppl 4:855–60 (74 ref.)

Some current approaches for studying combination toxicology in chemical mixtures. Yang RS. **Food Chem Toxicol** 1996 Nov-Dec;34(11–12):1037–44 (56 ref.)

Localization of cytochromes P450 in human tissues: implications for chemical toxicity. McKinnon RA, et al. **Pathology** 1996 May;28(2):148–55 (78 ref.)

Glutathione-dependent bioactivation and renal toxicity of xenobiotics. Dekant W. **Recent Results Cancer Res** 1997; 143:77–87 (83 ref.)

Selective protein covalent binding and target organ toxicity. Cohen SD, et al. **Toxicol Appl Pharmacol** 1997 Mar; 143(1):1–12 (99 ref.)

Modulation of T-helper cell populations: potential mechanisms of respiratory hypersensitivity and immune suppression. Selgrade MK, et al. **Toxicol Appl Pharmacol** 1997 Jul;145(1):218–29 (102 ref.)

Mechanistic data and risk assessment of selected toxic end points of the thyroid gland. Capen CC. **Toxicol Pathol** 1997 Jan-Feb;25(1):39–48 (35 ref.)

Is it safe? Doull J. **Vet Hum Toxicol** 1996 Dec;38(6):456–8 (5 ref.)

[Chronotoxicology, a relatively unknown approach in toxicology] Pons M, et al. **Pathol Biol (Paris)** 1996 Jun; 44(6):555–63 (43 ref.) (Eng. Abstr.) **(Fre)**

XENOGRAFT see **TRANSPLANTATION, HETEROLOGOUS**

XENOGRAFT BIOPROSTHESIS see **BIOPROSTHESIS**

XENOGRAFT DRESSINGS see **BIOLOGICAL DRESSINGS**

XENON

[Xenon as inhalation anesthetic] Fröba G. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jan; 32(1):48–51 (40 ref.) **(Ger)**

XENON RADIOISOTOPES

DIAGNOSTIC USE

Diagnosis of dementia by regional cerebral blood flow measurements using 133Xe and stationary detectors. Risberg J. **Acta Neurol Scand Suppl** 1996;168:59–62 (42 ref.)

Cerebral blood flow xenon-133. Anderson RE. **Neurosurg Clin N Am** 1996 Oct;7(4):703–8 (24 ref.)

[Regional evaluation of ventilation by RI] Kawakami K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:42–4 (3 ref.) **(Jpn)**

XENOPUS

EMBRYOLOGY

Regulation of dorsal-ventral axis formation in Xenopus by intercellular and intracellular signalling. Kimelman D, et al. **Biochem Soc Symp** 1996;62:13–23 (57 ref.)

The role of fibroblast growth factors in early Xenopus development. Slack JM, et al. **Biochem Soc Symp** 1996; 62:1–12 (25 ref.)

Getting a head in frog development. Elinson RP. **Biol Bull** 1997 Feb;192(1):172–4 (19 ref.)

Anti-neural-inhibition: a conserved mechanism for neural induction. Bier E. **Cell** 1997 May 30;89(5):681–4 (21 ref.)

Conservation of dorsal-ventral patterning in arthropods and chordates. Ferguson EL. **Curr Opin Genet Dev** 1996 Aug; 6(4):424–31 (72 ref.)

Regulation and function of the tissue-specific transcription factor HNF1 alpha (LFB1) during Xenopus development. Weber H, et al. **Int J Dev Biol** 1996 Feb;40(1):297–304 (25 ref.)

Mesoderm migration in the Xenopus gastrula. Winklbauer R, et al. **Int J Dev Biol** 1996 Feb;40(1):305–11 (31 ref.)

Patterning the expression of a tissue-specific transcription factor in embryogenesis: HNF1 alpha gene activation during Xenopus development. von Strandmann EP, et al. **Mech Dev** 1997 Jun;64(1–2):7–17 (66 ref.)

[Vg1, a possible natural mesoderm inducer derived from the study of the localized maternal mRNA in the Xenopus egg cytoplasm] Shiokawa K, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(11):1594–9 (18 ref.) **(Jpn)**

GENETICS

The coming of age of ventralising homeobox genes in amphibian development. Lemaire P. **Bioessays** 1996 Sep; 18(9):701–4 (23 ref.)

Conservation of dorsal-ventral patterning in arthropods and chordates. Ferguson EL. **Curr Opin Genet Dev** 1996 Aug; 6(4):424–31 (72 ref.)

Determination of Xenopus cell lineage by maternal factors and cell interactions. Moody SA, et al. **Curr Top Dev Biol** 1996;32:103–38 (160 ref.)

Regulation and function of the tissue-specific transcription factor HNF1 alpha (LFB1) during Xenopus development. Weber H, et al. **Int J Dev Biol** 1996 Feb;40(1):297–304 (25 ref.)

Patterning the expression of a tissue-specific transcription factor in embryogenesis: HNF1 alpha gene activation during Xenopus development. von Strandmann EP, et al. **Mech Dev** 1997 Jun;64(1–2):7–17 (66 ref.)

Transgenic frogs and FGF signalling in early development. Smith JC. **Trends Genet** 1996 Nov;12(11):439–40 (35 ref.)

[Chromosome condensation in cell-free system of xenopus eggs] Ohsumi K, et al. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(15 Suppl):2202–9 (18 ref.) **(Jpn)**

GROWTH & DEVELOPMENT

A sticky problem: the Xenopus cement gland as a paradigm for anteroposterior patterning. Sive H, et al. **Dev Dyn** 1996 Mar;205(3):265–80 (97 ref.)

IMMUNOLOGY

The immune system of ectothermic vertebrates. Flajnik MF. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):145–50 (33 ref.)

METABOLISM

Xenopus cadherins: sorting out types and functions in embryogenesis. Kühl M, et al. **Dev Dyn** 1996 Oct; 207(2):121–34 (104 ref.)

PHYSIOLOGY

Overview of the regulation of S-phase in Xenopus egg extracts. Chevalier S, et al. **Biochimie** 1995;77(10):808–16 (103 ref.)

Cell-cell signalling: frog frizbees. Zorn AM. **Curr Biol** 1997 Aug 1;7(8):R501–4 (18 ref.)

XENOPUS LAEVIS

EMBRYOLOGY

Effects of retinoic acid on Xenopus embryos. Old RW, et al. **Biochem Soc Symp** 1996;62:157–74 (52 ref.)

Fish are like flies are like frogs: conservation of dorsal-ventral patterning mechanisms. Holley SA, et al. **Bioessays** 1997 Apr;19(4):281–4 (30 ref.)

Retinoid signalling and axial patterning during early vertebrate embryogenesis. Durston AJ, et al. **Cell Mol Life Sci** 1997 Apr;53(4):339–49 (136 ref.)

New perspectives on the role of the fibroblast growth factor family in amphibian development. Isaacs HV. **Cell Mol Life Sci** 1997 Apr;53(4):350–61 (81 ref.)

Transcription factors and induction in Xenopus laevis embryos. Knöchel W, et al. **Cell Mol Life Sci** 1997 Apr; 53(4):362–81 (233 ref.)

Establishment of polarities in the oocyte of Xenopus laevis: the provisional axial symmetry of the full-grown oocyte of Xenopus laevis. Ubbels GA. **Cell Mol Life Sci** 1997 Apr; 53(4):382–409 (186 ref.)

Neural induction in Xenopus laevis: evidence for the default model. Weinstein DC, et al. **Curr Opin Neurobiol** 1997 Feb; 7(1):7–12 (51 ref.)

Retinoic acid receptors and nuclear orphan receptors in the development of Xenopus laevis. Dreyer C, et al. **Int J Dev Biol** 1996 Feb;40(1):255–62 (55 ref.)

Zinc finger proteins in early Xenopus development. Hollemann T, et al. **Int J Dev Biol** 1996 Feb;40(1):291–5 (26 ref.)

Lens induction in axolotls: comparison with inductive signaling mechanisms in Xenopus laevis. Servetnick MD, et al. **Int J Dev Biol** 1996 Aug;40(4):755–61 (36 ref.)

Origin and morphogenesis of neurons in the frog cardiac ganglion. Heathcote RD. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1997 Jan; 13(1):36–41 (21 ref.)

GENETICS

Structure and expression of ribosomal protein genes in Xenopus laevis. Amaldi F, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11–12):969–77 (60 ref.)

Homologous genetic recombination in Xenopus: mechanism and implications for gene manipulation. Carroll D. **Prog Nucleic Acid Res Mol Biol** 1996;54:101–25 (79 ref.)

METABOLISM

Retinoic acid receptors and nuclear orphan receptors in the development of Xenopus laevis. Dreyer C, et al. **Int J Dev Biol** 1996 Feb;40(1):255–62 (55 ref.)

Zinc finger proteins in early Xenopus development. Hollemann T, et al. **Int J Dev Biol** 1996 Feb;40(1):291–5 (26 ref.)

XENOTRANSPLANTATION see **TRANSPLANTATION, HETEROLOGOUS**

XERODERMA

XERODERMA see **ICHTHYOSIS**

XERODERMA PIGMENTOSUM

COMPLICATIONS

Lessons learned from xeroderma pigmentosum. Kraemer KH. **Photochem Photobiol** 1996 Apr;63(4):420–2 (19 ref.)

GENETICS

The genetic basis of xeroderma pigmentosum and trichothiodystrophy syndromes. Stary A, et al. **Cancer Surv** 1996;26:155–71 (54 ref.)

Role of DNA excision repair gene defects in the etiology of cancer. Ford JM, et al. **Curr Top Microbiol Immunol** 1997;221:47–70 (104 ref.)

The molecular basis of xeroderma pigmentosum. Copeland NE, et al. **Dermatol Surg** 1997 Jun;23(6):447–55 (52 ref.)

Xeroderma pigmentosum knockout mice: an immunologic tale [editorial] Kraemer KH. **J Invest Dermatol** 1996 Sep; 107(3):291–2 (18 ref.)

DNA repair genes, enzymes, patients, and mouse models. Jaspers NG. **Recent Results Cancer Res** 1997;143:329–35 (0 ref.)

Xpa knockout mice. de Vries A, et al. **Semin Cancer Biol** 1996 Oct;7(5):229–40 (59 ref.)

Xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy: do the genes explain the diseases? Chu G, et al. **Trends Genet** 1996 May;12(5):187–92 (46 ref.)

IMMUNOLOGY

Xeroderma pigmentosum knockout mice: an immunologic tale [editorial] Kraemer KH. **J Invest Dermatol** 1996 Sep; 107(3):291–2 (18 ref.)

RADIOTHERAPY

Radiation therapy for patients with xeroderma pigmentosum. Sakata K, et al. **Radiat Med** 1996 Mar–Apr;14(2):87–90 (16 ref.)

XEROSTOMIA

[Xerostomia: a simple undesired effect?] Pujol T, et al. **Aten Primaria** 1997 Feb 28;19(3):142–7 (85 ref.) **(Spa)**

ETIOLOGY

Review: xerostomia: a symptom which acts like a disease [see comments] Ettinger RL. **Age Ageing** 1996 Sep; 25(5):409–12 (46 ref.) Comment in: Age Ageing 1997 May;26(3):239.

Manifestations and treatment of xerostomia and associated oral effects secondary to head and neck radiation therapy. Garg AK, et al. **J Am Dent Assoc** 1997 Aug;128(8):1128–33 (40 ref.)

Radiation-induced xerostomia: pathophysiology, clinical course and supportive treatment [see comments] Guchelaar HJ, et al. **Support Care Cancer** 1997 Jul;5(4):281–8 (57 ref.) Comment in: Support Care Cancer 1997 Jul;5(4):261–2.

PHYSIOPATHOLOGY

[Buccal dryness, xerostomia and measurement of salivary secretory activity] Jehl-Pietri C, et al. **Ann Med Interne (Paris)** 1997;148(3):209–16 (54 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Xerostomia—a review [see comments] Cooke C, et al. **Palliat Med** 1996 Oct;10(4):284–92 (33 ref.) Comment in: Palliat Med 1997 May;11(3):254–5.

XIPHOID BONE

ABNORMALITIES

Successful early separation of a premature xipho-omphalopagus conjoined twins: a case report. Lai HS, et al. **Can J Surg** 1997 Apr;40(2):139, 141–2 (7 ref.)

XIPHOPHORUS see **CYPRINODONTIFORMES**

XIPHOSURA see **HORSESHOE CRABS**

XYLANS

METABOLISM

Microbial xylanolytic enzyme system: properties and applications. Bajpai P. **Adv Appl Microbiol** 1997;43:141–94 (266 ref.)

Xylanolytic enzymes from fungi and bacteria. Sunna A, et al. **Crit Rev Biotechnol** 1997;17(1):39–67 (187 ref.)

XYLENES

Musk ambrette and musk xylene. **IARC Monogr Eval Carcinog Risks Hum** 1996;65:477–95 (68 ref.)

XYLOBIASES see **XYLOSIDASES**

XYLOSE

DIAGNOSTIC USE

[d-xylose absorption test] Nakamura T. **Nippon Rinsho** 1997 Apr;55 Suppl 2:115–6 (8 ref.) **(Jpn)**

XYLOSIDASES

METABOLISM

Xylanases: from biology to biotechnology. Prade RA. **Biotechnol Genet Eng Rev** 1996;13:101–31 (207 ref.)

XYY KARYOTYPE

Further arguments for non-fortuitous association of Potter sequence with XYY males. Rudnik-Schöneborn S, et al. **Ann Genet** 1996;39(1):43–6 (12 ref.)

DIAGNOSIS

[A case of 47XYY syndrome presenting with male infertility] Murakami J, et al. **Hinyokika Kiyo** 1997 Jun;43(6):433–6 (13 ref.) (Eng. Abstr.) **(Jpn)**

Y CHROMOSOME

Characterization of a de novo t(Y;9) (q11.2;q22) by FISH technique. Conte RA, et al. **Ann Genet** 1996;39(1):10–5 (53 ref.)

Oncogenic role of the Y chromosome. McDonough PG. **Ann N Y Acad Sci** 1997 Jun 17;816:356–61 (17 ref.)

Sex determination in humans. Schafer AJ, et al. **Bioessays** 1996 Dec;18(12):955–63 (80 ref.)

XYY male and hematologic malignancy. Oguma N, et al. **Cancer Genet Cytogenet** 1996 Sep;90(2):179–81 (22 ref.)

Detection of SRY in 45,X/47,XYY mosaicism leading to phenotypic female. Imai A, et al. **Clin Genet** 1997 Feb; 51(2):124–6 (15 ref.)

Human evolution and the Y chromosome. Mitchell RJ, et al. **Curr Opin Genet Dev** 1996 Dec;6(6):737–42 (52 ref.)

The predetermination of embryonic sex using flow cytometrically separated X and Y spermatozoa. Cran DG, et al. **Hum Reprod Update** 1996 Jul–Aug;2(4):355–63 (48 ref.)

The Y chromosome in forensic analysis and paternity testing. Jobling MA, et al. **Int J Legal Med** 1997;110(3):118–24 (32 ref.)

Why do some females reject males? The molecular basis for male-specific graft rejection. Scott DM, et al. **J Mol Med** 1997 Feb;75(2):103–14 (130 ref.)

[The Y chromosome—structure, function and evolution] Nakahori Y. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(15 Suppl):2306–14 (25 ref.) **(Jpn)**

GENETICS

The role of SRY in mammalian sex determination. Fechner PY. **Acta Paediatr Jpn** 1996 Aug;38(4):380–9 (112 ref.)

The azoospermic factor on the Y chromosome. Shinka T, et al. **Acta Paediatr Jpn** 1996 Aug;38(4):399–404 (34 ref.)

Human chromosome Y and SRY. Shah VC, et al. **Cell Biol Int** 1996 Jan;20(1):3–6 (14 ref.)

Progress in the genetic analysis of fetal cells circulating in maternal blood. Bianchi DW. **Curr Opin Obstet Gynecol** 1997 Apr;9(2):121–5 (33 ref.)

Cytogenetics of infertile men. Van Assche E, et al. **Hum Reprod** 1996 Dec;11 Suppl 4:1–24; discussion 25–6 (114 ref.)

[Azoospermia and genetic mutations: implications for the methods of in vitro fertilization] Rocchietti March M, et al. **Minerva Endocrinol** 1996 Dec;21(4):123–31 (19 ref.) (Eng. Abstr.) **(Ita)**

ULTRASTRUCTURE

The license to pair: identification of meiotic pairing sites in Drosophila. McKee BD. **Chromosoma** 1996 Sep; 105(3):135–41 (34 ref.)

YAC see **CHROMOSOMES, YEAST ARTIFICIAL**

YAGEINE see **HARMINE**

YEAST ARTIFICIAL CHROMOSOMES see **CHROMOSOMES, YEAST ARTIFICIAL**

YEAST, BAKER'S see **SACCHAROMYCES CEREVISIAE**

YEAST, BREWER'S see **SACCHAROMYCES CEREVISIAE**

YEAST, DRIED

ADVERSE EFFECTS

Sensitivity reaction to parenteral vitamin B12: recurrence of symptoms after Marmite ingestion [letter] Denis R, et al. **Clin Lab Haematol** 1996 Jun;18(2):129–31 (11 ref.)

YEAST, FISSION see **SCHIZOSACCHAROMYCES**

YEASTS

[Probiotics and their future] Pardio Sedas VT, et al. **Arch Latinoam Nutr** 1996 Mar;46(1):6–10 (44 ref.) (Eng. Abstr.) **(Spa)**

CHEMISTRY

Myosins in yeast. Brown SS. **Curr Opin Cell Biol** 1997 Feb; 9(1):44–8 (29 ref.)

Preparation of total RNA. Brown AJ. **Methods Mol Biol** 1996;53:269–76 (9 ref.)

The extraction and analysis of sterols from yeast. Quail MA, et al. **Methods Mol Biol** 1996;53:123–31 (7 ref.)

CLASSIFICATION

Yeast infections. Hay RJ. **Dermatol Clin** 1996 Jan; 14(1):113–24 (33 ref.)

Isolation, purification, and analysis of nuclear DNA in yeast taxonomy. Vaughan-Martini A, et al. **Methods Mol Biol** 1996;53:89–102 (14 ref.)

CYTOLOGY

The GS-X pump in plant, yeast, and animal cells: structure, function, and gene expression. Ishikawa T, et al. **Biosci Rep** 1997 Apr;17(2):189–207 (100 ref.)

Maintenance and culture of yeasts. Spencer JF, et al. **Methods Mol Biol** 1996;53:5–15 (6 ref.)

The secretory pathway of protists: spatial and functional organization and evolution. Becker B, et al. **Microbiol Rev** 1996 Dec;60(4):697–721 (337 ref.)

DRUG EFFECTS

Yeast as a genetic model system for studying topoisomerase inhibitors. Nitiss JL. **Adv Pharmacol** 1994;29B:201–26 (90 ref.)

The molecular defences against reactive oxygen species in yeast. Moradas-Ferreira P, et al. **Mol Microbiol** 1996 Feb; 19(4):651–8 (50 ref.)

[Fluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility of yeasts] Wildfeuer A, et al. **Mycoses** 1996;39 Suppl 2:51–7 (42 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Biotransformation for L-ephedrine production. Rogers PL, et al. **Adv Biochem Eng Biotechnol** 1997;56:33–59 (53 ref.)

Meiotic recombination in yeast: coronation of the double-strand-break repair model. Stahl F. **Cell** 1996 Dec 13;87(6):965–8 (10 ref.)

Genetic redundancy: screening for selection in yeast. Brookfield JFY. **Curr Biol** 1997 Jun 1;7(6):R366–8 (6 ref.)

Quality and authenticity of heterologous proteins synthesized in yeast. Eckart MR, et al. **Curr Opin Biotechnol** 1996 Oct; 7(5):525–30 (47 ref.)

The expression of recombinant proteins in yeasts. Sudbery PE. **Curr Opin Biotechnol** 1996 Oct;7(5):517–24 (33 ref.)

Therapeutic proteins and enzymes from genetically engineered yeasts. Wiseman A. **Endeavour** 1996;20(3):130–2 (15 ref.)

Yeasties and beasties: 7 years of genome sequencing. Thomas K. **FEBS Lett** 1996 Oct 28;396(1):1–6 (36 ref.)

Isolation of mitochondrial DNA. Bignell GR, et al. **Methods Mol Biol** 1996;53:109–16 (11 ref.)

Genomic yeast DNA clone banks. Construction and gene isolation. Bignell GR, et al. **Methods Mol Biol** 1996; 53:155–87 (21 ref.)

Biolistic transformation of yeasts. Johnston SA, et al. **Methods Mol Biol** 1996;53:147–53 (12 ref.)

Isolation of yeast DNA. Piper P. **Methods Mol Biol** 1996; 53:103–7 (6 ref.)

Induction of heat shock proteins and thermotolerance. Piper P. **Methods Mol Biol** 1996;53:313–7 (15 ref.)

Mad cows meet mad yeast: the prion hypothesis [see comments] Lindquist S. **Mol Psychiatry** 1996 Nov; 1(5):376–9 (29 ref.) Comment in: Mol Psychiatry 1996 Nov;1(5):347–8.

A quantitative model for the cdc2 control of S phase and mitosis in fission yeast. Stern B, et al. **Trends Genet** 1996 Sep;12(9):345–50 (36 ref.)

Maintenance and inheritance of yeast prions. Tuite MF, et al. **Trends Genet** 1996 Nov;12(11):467–71 (41 ref.)

GROWTH & DEVELOPMENT

[Effect of orally administered polyene antimycotics on the intestinal colonization with yeasts: possibilities and limitations] Blaschke-Hellmessen R, et al. **Mycoses** 1996; 39 Suppl 1:33–9 (17 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Allergies to wheat, yeast and royal jelly: a connection between ingestion and inhalation? Baldo BA. **Monogr Allergy** 1996;32:84–91 (12 ref.)

[Yeast allergy—does it exist?] Savolainen J, et al. **Duodecim** 1995;111(16):1592–3 (17 ref.) **(Fin)**

ISOLATION & PURIFICATION

Specific spoilage organisms in breweries and laboratory media for their detection. Jespersen L, et al. **Int J Food Microbiol** 1996 Nov;33(1):139–55 (75 ref.)

Isolation and identification of yeasts from natural habitats. Spencer JF, et al. **Methods Mol Biol** 1996;53:1–4 (8 ref.)
Review of the literature and investigations on the prevalence and consequences of yeasts in reptiles. Kostka VM, et al. **Vet Rec** 1997 Mar 15;140(11):282–7 (36 ref.)

METABOLISM

Biotransformation for L-ephedrine production. Rogers PL, et al. **Adv Biochem Eng Biotechnol** 1997;56:33–59 (53 ref.)
Prions of yeast, [PSI] and [URE3], as models for neurodegenerative diseases. Wickner RB, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:541–50 (57 ref.)
Production of lactones and peroxisomal beta-oxidation in yeasts. Endrizzi A, et al. **Crit Rev Biotechnol** 1996; 16(4):301–29 (195 ref.)
Quality and authenticity of heterologous proteins synthesized in yeast. Eckart MR, et al. **Curr Opin Biotechnol** 1996 Oct; 7(5):525–30 (47 ref.)
The molecular genetics of hexose transport in yeasts. Boles E, et al. **FEMS Microbiol Rev** 1997 Aug;21(1):85–111 (177 ref.)
Simulation of human xenobiotic metabolism in microorganisms. Yeast a good compromise between E. coli and human cells. Pompon D, et al. **J Hepatol** 1997;26 Suppl 2:81–5 (19 ref.)
Calorimetry of whole yeast cells. Ashby LJ, et al. **Methods Mol Biol** 1996;53:367–82 (14 ref.)
Some puzzles about carbon catabolite repression in yeast. Wills C. **Res Microbiol** 1996 Jul–Sep;147(6–7):566–72 (39 ref.)
Mitochondrial inner membrane channels in yeast and mammals. Ballarin C, et al. **Soc Gen Physiol Ser** 1996; 51:155–71 (51 ref.)
Structure and function of the yeast outer mitochondrial membrane channel, VDAC. Forte M, et al. **Soc Gen Physiol Ser** 1996;51:145–54 (19 ref.)

PHYSIOLOGY

Anhydrobiosis in yeast: activation effect. Rapoport AI, et al. **Braz J Med Biol Res** 1997 Jan;30(1):9–13 (15 ref.)
Yeast killer systems. Magliani W, et al. **Clin Microbiol Rev** 1997 Jul;10(3):369–400 (461 ref.)
From DNA damage to cell cycle arrest and suicide: a budding yeast perspective. Lydall D, et al. **Curr Opin Genet Dev** 1996 Feb;6(1):4–11 (62 ref.)
Physiology and genetics of the dimorphic fungus Yarrowia lipolytica. Barth G, et al. **FEMS Microbiol Rev** 1997 Apr; 19(4):219–37 (169 ref.)
The secretory pathway of protists: spatial and functional organization and evolution. Becker B, et al. **Microbiol Rev** 1996 Dec;60(4):697–721 (337 ref.)

ULTRASTRUCTURE

Organelle structure, function, and inheritance in yeast: a role for fatty acid synthesis? Schneiter R, et al. **Cell** 1997 Feb 21;88(4):431–4 (13 ref.)
Fluorescence microscopy methods. Hašek J, et al. **Methods Mol Biol** 1996;53:391–405 (14 ref.)
Isolation of yeast plasma membranes. Panaretou B, et al. **Methods Mol Biol** 1996;53:117–21 (9 ref.)
Light microscopy methods. Streiblová E, et al. **Methods Mol Biol** 1996;53:383–90 (5 ref.)
Immunoelectron microscopy. van Tuinen EJ. **Methods Mol Biol** 1996;53:407–22 (24 ref.)

YELLOW FEVER

Yellow fever: a decade of reemergence. Robertson SE, et al. **JAMA** 1996 Oct 9;276(14):1157–62 (62 ref.)

EPIDEMIOLOGY

[The risk of urban yellow fever outbreaks in Brazil by dengue vectors. Aedes aegypti and Aedes albopictus] Mondet B, et al. **Bull Soc Pathol Exot** 1996;89(2):107–13; discussion 114 (11 ref.) (Eng. Abstr.) **(Fre)**

TRANSMISSION

[The risk of urban yellow fever outbreaks in Brazil by dengue vectors. Aedes aegypti and Aedes albopictus] Mondet B, et al. **Bull Soc Pathol Exot** 1996;89(2):107–13; discussion 114 (11 ref.) (Eng. Abstr.) **(Fre)**

YELLOW FEVER VIRUS

IMMUNOLOGY

Yellow fever vaccines. Barrett AD. **Biologicals** 1997 Mar; 25(1):17–25 (67 ref.)
Stability of yellow fever vaccine. Monath TP. **Dev Biol Stand** 1996;87:219–25 (21 ref.)
Yellow fever: a decade of reemergence. Robertson SE, et al. **JAMA** 1996 Oct 9;276(14):1157–62 (62 ref.)

YELLOW JACKETS see **WASPS**

YELLOW MARROW see **BONE MARROW**

YERSINIA

Molecular genetics and biochemistry of Yersinia lipopolysaccharide. Skurnik M, et al. **APMIS** 1996 Dec; 104(12):849–72 (100 ref.)

GENETICS

Chromosomal virulence factors of Yersinia: an update. Carniel E. **Contrib Microbiol Immunol** 1995;13:218–24 (17 ref.)
The Yersinia Yop virulon: a bacterial system for subverting eukaryotic cells. Cornelis GR, et al. **Mol Microbiol** 1997 Mar;23(5):861–7 (33 ref.)
[Yersinia outer membrane proteins coded for by the virulence plasmid] Mikerov AN, et al. **Mol Gen Mikrobiol Virusol** 1997;(3):3–10 (131 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Customized secretion chaperones in pathogenic bacteria. Wattiau P, et al. **Mol Microbiol** 1996 Apr;20(2):255–62 (59 ref.)

PATHOGENICITY

Chromosomal virulence factors of Yersinia: an update. Carniel E. **Contrib Microbiol Immunol** 1995;13:218–24 (17 ref.)
Uptake of enteropathogenic Yersinia by mammalian cells. Isberg RR. **Curr Top Microbiol Immunol** 1996;209:1–24 (123 ref.)
Yersinia proteins that target host cell signaling pathways. Fällman M, et al. **J Clin Invest** 1997 Mar 15;99(6):1153–7 (35 ref.)
Molecular determinants of Yersinia pathogenesis. Iriarte M, et al. **Microbiologia** 1996 Jun;12(2):267–80 (97 ref.)

YERSINIA ENTEROCOLITICA

Clinical features and antibiotic treatment of septic arthritis and osteomyelitis due to Yersinia enterocolitica. Crowe M, et al. **J Med Microbiol** 1996 Oct;45(4):302–9 (55 ref.)

GROWTH & DEVELOPMENT

Factors affecting growth of Yersinia enterocolitica in cellular blood products. Högman CF, et al. **Transfus Med Rev** 1996 Oct;10(4):259–75 (81 ref.)

IMMUNOLOGY

Bacterial virulence antigens and the pathogenesis of autoimmune thyroid diseases (AITD). Wenzel BE, et al. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 4:75–8 (33 ref.)

ISOLATION & PURIFICATION

[Aortic aneurysms due to Yersinia enterocolitica: three new cases and a review of the literature] Mercié P, et al. **J Mal Vasc** 1996;21(2):68–71 (21 ref.) (Eng. Abstr.) **(Fre)**

PATHOGENICITY

Yersinia enterocolitica: the charisma continues. Bottone EJ. **Clin Microbiol Rev** 1997 Apr;10(2):257–76 (258 ref.)

YERSINIA INFECTIONS

see related
ARTHRITIS, REACTIVE

COMPLICATIONS

Infectious ileocecitis caused by Yersinia, Campylobacter, and Salmonella: clinical, radiological and US findings. Puylaert JB, et al. **Eur Radiol** 1997;7(1):3–9 (42 ref.)

DRUG THERAPY

Clinical features and antibiotic treatment of septic arthritis and osteomyelitis due to Yersinia enterocolitica. Crowe M, et al. **J Med Microbiol** 1996 Oct;45(4):302–9 (55 ref.)

EPIDEMIOLOGY

Yersinia as an emerging infection: epidemiologic aspects of Yersiniosis. Ostroff S. **Contrib Microbiol Immunol** 1995; 13:5–10 (33 ref.)

GENETICS

The Yersinia Yop virulon: a bacterial system for subverting eukaryotic cells. Cornelis GR, et al. **Mol Microbiol** 1997 Mar;23(5):861–7 (33 ref.)

IMMUNOLOGY

Bacterial virulence antigens and the pathogenesis of autoimmune thyroid diseases (AITD). Wenzel BE, et al. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 4:75–8 (33 ref.)

MICROBIOLOGY

Yersinia enterocolitica: the charisma continues. Bottone EJ. **Clin Microbiol Rev** 1997 Apr;10(2):257–76 (258 ref.)
Uptake of enteropathogenic Yersinia by mammalian cells. Isberg RR. **Curr Top Microbiol Immunol** 1996;209:1–24 (123 ref.)
Yersinia proteins that target host cell signaling pathways. Fällman M, et al. **J Clin Invest** 1997 Mar 15;99(6):1153–7 (35 ref.)
Molecular determinants of Yersinia pathogenesis. Iriarte M, et al. **Microbiologia** 1996 Jun;12(2):267–80 (97 ref.)

TRANSMISSION

Factors affecting growth of Yersinia enterocolitica in cellular blood products. Högman CF, et al. **Transfus Med Rev** 1996 Oct;10(4):259–75 (81 ref.)

VETERINARY

Immunization with bacterial antigens: yersiniosis. Stevenson RM. **Dev Biol Stand** 1997;90:117–24 (41 ref.)

YERSINIA PESTIS

GENETICS

[Genetic research on plague pathogen in plague control] Anisimov PI, et al. **Genetika** 1996 Jun;32(6):725–9 (36 ref.) (Eng. Abstr.) **(Rus)**
[Molecular genetic methods for detecting and identifying the plague microbe] Popov IuA, et al. **Med Parazitol (Mosk)** 1997 Apr–Jun;(2):21–4 (31 ref.) (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

[Molecular genetic methods for detecting and identifying the plague microbe] Popov IuA, et al. **Med Parazitol (Mosk)** 1997 Apr–Jun;(2):21–4 (31 ref.) (Eng. Abstr.) **(Rus)**

PATHOGENICITY

Yersinia pestis--etiologic agent of plague. Perry RD, et al. **Clin Microbiol Rev** 1997 Jan;10(1):35–66 (315 ref.)
[The mechanism of the existence of Yersinia pestis in nature] Nersesov V, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Jan–Feb;(1):102–6 (25 ref.) **(Rus)**

PHYSIOLOGY

[The mechanisms of the stable preservation of the causative agent of plague in the environment (new facts and hypotheses)] Litvin VIu. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Jul–Aug; (4):26–31 (32 ref.) **(Rus)**

YERSINIA PSEUDOTUBERCULOSIS

ENZYMOLOGY

Bacterial signalling involving eukaryotic-type protein kinases. Zhang CC. **Mol Microbiol** 1996 Apr;20(1):9–15 (32 ref.)

PATHOGENICITY

Characterization of a superantigen produced by Yersinia pseudotuberculosis. Abe J, et al. **Prep Biochem Biotechnol** 1997 May–Aug;27(2–3):173–208 (159 ref.)

YERSINIA PSEUDOTUBERCULOSIS INFECTIONS

COMPLICATIONS

Intussusception associated with Yersinia pseudotuberculosis infection. Koo JW, et al. **Acta Paediatr** 1996 Oct; 85(10):1253–5 (12 ref.)

MICROBIOLOGY

Characterization of a superantigen produced by Yersinia pseudotuberculosis. Abe J, et al. **Prep Biochem Biotechnol** 1997 May–Aug;27(2–3):173–208 (159 ref.)

YOGA

A therapy to live by: public health, the self and nationalism in the practice of a north Indian yoga society. Alter JS. **Med Anthropol** 1997 Jun;17(4):309–35 (83 ref.)

PSYCHOLOGY

Seminal truth: a modern science of male celibacy in north India. Alter JS. **Med Anthropol Q** 1997 Sep;11(3):275–98; discussion 299–301 (110 ref.)

YOLK PROTEINS see **EGG PROTEINS**

YOLK PROTEINS, DIETARY see **EGG PROTEINS, DIETARY**

YOLK SAC

CYTOLOGY

Hematopoietic stem cells in the mouse embryonic yolk sac. Auerbach R, et al. **Stem Cells** 1996 May;14(3):269–80 (65 ref.)

YOLK SAC TUMOR

YOLK SAC TUMOR see ENDODERMAL SINUS TUMOR

YOUTH see ADOLESCENCE

Z-DNA see DNA

ZALCITABINE

PHARMACOLOGY

Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection. Adkins JC, et al. **Drugs** 1997 Jun;53(6):1054–80 (178 ref.)

THERAPEUTIC USE

The development of resistance of HIV-1 to zalcitabine [editorial] Craig C, et al. **AIDS** 1997 Mar;11(3):271–9 (88 ref.)

[Antiretroviral treatment. Present and future of the combinations] Gatell-Artigas JM. **Rev Neurol** 1996 Dec; 24(136):1627–31 (16 ref.) (Eng. Abstr.) **(Spa)**

ZEA see CORN

ZEBRAFISH

EMBRYOLOGY

Fish are like flies are like frogs: conservation of dorsal-ventral patterning mechanisms. Holley SA, et al. **Bioessays** 1997 Apr;19(4):281–4 (30 ref.)

Fishing for genes controlling development. Granato M, et al. **Curr Opin Genet Dev** 1996 Aug;6(4):461–8 (88 ref.)

Genetics of neural development in zebrafish. Schier AF. **Curr Opin Neurobiol** 1997 Feb;7(1):119–26 (71 ref.)

Large scale genetics in a small vertebrate, the zebrafish. Haffter P, et al. **Int J Dev Biol** 1996 Feb;40(1):221–7 (32 ref.)

GENETICS

Zebrafish make a big splash. Eisen JS. **Cell** 1996 Dec 13; 87(6):969–77 (100 ref.)

Zebrafish genetics: mutant cornucopia. Currie PD. **Curr Biol** 1996 Dec 1;6(12):1548–52 (47 ref.)

Zebrafish: tools for investigating cellular differentiation. Stemple DL, et al. **Curr Opin Cell Biol** 1996 Dec; 8(6):858–64 (70 ref.)

Fishing for genes controlling development. Granato M, et al. **Curr Opin Genet Dev** 1996 Aug;6(4):461–8 (88 ref.)

Genetics of neural development in zebrafish. Schier AF. **Curr Opin Neurobiol** 1997 Feb;7(1):119–26 (71 ref.)

Zebrafish genetics and its implications for understanding vertebrate development. Ingham PW. **Hum Mol Genet** 1997;6(10):1755–60 (41 ref.)

Large scale genetics in a small vertebrate, the zebrafish. Haffter P, et al. **Int J Dev Biol** 1996 Feb;40(1):221–7 (32 ref.)

The zebrafish: heritable disorders in transparent embryos. Driever W, et al. **J Clin Invest** 1996;98(11 Suppl):S41–6 (67 ref.)

Defining the boundaries of zebrafish developmental genetics. Felsenfeld AL. **Nat Genet** 1996 Nov;14(3):258–63 (48 ref.)

Zebrafish genomics: from mutants to genes. Postlethwait JH, et al. **Trends Genet** 1997 May;13(5):183–90 (63 ref.)

Genetic analysis of axon guidance and mapping in the zebrafish. Karlstrom RO, et al. **Trends Neurosci** 1997 Jan; 20(1):3–8 (48 ref.)

GROWTH & DEVELOPMENT

Defining the boundaries of zebrafish developmental genetics. Felsenfeld AL. **Nat Genet** 1996 Nov;14(3):258–63 (48 ref.)

ZELLWEGER SYNDROME

GENETICS

Molecular basis of Zellweger syndrome, beta-ketothiolase deficiency and mucopolysaccharidoses. Orii T. **Jpn J Hum Genet** 1997 Mar;42(1):1–11 (63 ref.)

METABOLISM

On the molecular etiology of decreased arachidonic (20:4n-6), docosapentaenoic (22:5n-6) and docosahexaenoic (22:6n-3) acids in Zellweger syndrome and other peroxisomal disorders. Infante JP, et al. **Mol Cell Biochem** 1997 Mar;168(1-2):101–15 (167 ref.)

PHYSIOPATHOLOGY

Zellweger syndrome and associated phenotypes. FitzPatrick DR. **J Med Genet** 1996 Oct;33(10):863–8 (61 ref.)

ZENKER'S DIVERTICULUM

PHYSIOPATHOLOGY

Zenker's diverticulum—a historical review and trends in therapy. Westrin KM, et al. **Acta Otolaryngol (Stockh)** 1996 May;116(3):351–60 (51 ref.)

ZEOLITES

CHEMISTRY

Multinuclear solid-state NMR studies of acidic and non-acidic hydroxyl protons in zeolites. Hunger M. **Solid State Nucl Magn Reson** 1996 Feb;6(1):1–29 (151 ref.)

ZERO GRAVITY see WEIGHTLESSNESS

ZHONG YI XUE see MEDICINE, CHINESE TRADITIONAL

ZIDOVUDINE

ADMINISTRATION & DOSAGE

[HIV and pregnancy: risks of transmission and therapeutic possibilities] Ibe M, et al. **Gynakol Geburtshilfliche Rundsch** 1996;36(4):188–93 (36 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature. Sundar K, et al. **Crit Care Med** 1997 Aug;25(8):1425–30 (26 ref.)

PHARMACOKINETICS

Clinical pharmacokinetics of zidovudine. An update. Acosta EP, et al. **Clin Pharmacokinet** 1996 Apr;30(4):251–62 (56 ref.)

Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic-pharmacodynamic relationships. Hoetelmans RM, et al. **Clin Pharmacokinet** 1996 Apr;30(4):314–27 (98 ref.)

THERAPEUTIC USE

Reducing the risk of perinatal HIV-1 transmission with zidovudine: results and implications of AIDS Clinical Trials Group protocol 076. Mofenson LM. **Acta Paediatr Suppl** 1997 Jun;421:89–96 (44 ref.)

Use of floxuridine to modulate the antiviral activity of zidovudine. Medina DJ, et al. **AIDS Res Hum Retroviruses** 1996 Jul 20;12(11):965–8 (7 ref.)

Preventing perinatal HIV transmission: zidovudine use during pregnancy. Carmichael C. **Am Fam Physician** 1997 Jan;55(1):171–4, 177–8 (16 ref.)

Prevention of perinatal transmission of human immunodeficiency virus: a progress report 2 years after completion of AIDS Clinical Trials Group trial 076. Wilfert CM. **Clin Infect Dis** 1996 Sep;23(3):438–41 (19 ref.)

Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients. Bazarbachi A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S186–90 (16 ref.)

Use of observational data, including surveillance studies, for evaluating AIDS therapies. Gail MH. **Stat Med** 1996 Nov 15-30;15(21-22):2273–88 (39 ref.)

Wheel keeps turning for antiviral combination chemotherapy. Coen DM. **Trends Microbiol** 1996 Feb;4(2):51–2 (14 ref.)

[Antiretroviral treatment. Present and future of the combinations] Gatell-Artigas JM. **Rev Neurol** 1996 Dec; 24(136):1627–31 (16 ref.) (Eng. Abstr.) **(Spa)**

ZINC

ADVERSE EFFECTS

Trace elements, atherosclerosis, and abdominal aneurysms. Klevay LM. **Ann N Y Acad Sci** 1996 Nov 18;800:239–42 (31 ref.)

BLOOD

Measurement of zinc in clinical samples. Taylor A. **Ann Clin Biochem** 1997 Mar;34 (Pt 2):142–50 (55 ref.)

Effects of thyroid hormone on erythrocyte carbonic anhydrase-I and zinc concentrations in vivo and in vitro: clinical usefulness of carbonic anhydrase-I and zinc concentrations in erythrocytes. Yoshida K. **Tohoku J Exp Med** 1996 Apr;178(4):345–56 (33 ref.)

DEFICIENCY

Zinc deficiency and taste disorders. Heyneman CA. **Ann Pharmacother** 1996 Feb;30(2):186–7 (15 ref.)

Detecting subclinical deficiency of essential trace elements in children with special reference to zinc and selenium. Salmenperä L. **Clin Biochem** 1997 Mar;30(2):115–20 (49 ref.)

Zinc and diarrhea in infants. Folwaczny C. **J Trace Elem Med Biol** 1997 Jun;11(2):116–22 (60 ref.)

Effect of marginal zinc deficiency on human growth and development. Ploysangam A, et al. **J Trop Pediatr** 1997 Aug;43(4):192–8 (55 ref.)

Zinc-controlled Th1/Th2 switch significantly determines development of diseases. Sprietsma JE. **Med Hypotheses** 1997 Jul;49(1):1–14 (82 ref.)

[Benefits and dangers connected with clinical use of microelements] Martyka Z, et al. **Przegl Lek** 1995; 52(12):599–602 (25 ref.) (Eng. Abstr.) **(Pol)**

[Zinc, pregnancy and the fetus] Solé D, et al. **Rev Assoc Med Bras** 1996 Jan-Mar;42(1):31–8 (106 ref.) **(Por)**

IMMUNOLOGY

Zinc-controlled Th1/Th2 switch significantly determines development of diseases. Sprietsma JE. **Med Hypotheses** 1997 Jul;49(1):1–14 (82 ref.)

METABOLISM

Zinc transport in mammalian cells. Reyes JG. **Am J Physiol** 1996 Feb;270(2 Pt 1):C401–10 (75 ref.)

Zinc and Alzheimer's disease: is there a direct link? Cuajungco MP, et al. **Brain Res Brain Res Rev** 1997 Apr; 23(3):219–36 (249 ref.)

Molecular biology of iron and zinc uptake in eukaryotes. Eide D. **Curr Opin Cell Biol** 1997 Aug;9(4):573–7 (28 ref.)

Using models to explore whole-body metabolism and accessing models through a model library. Wastney ME, et al. **Metabolism** 1997 Mar;46(3):330–2 (18 ref.)

Mercurial-induced alterations in neuronal divalent cation homeostasis. Denny MF, et al. **Neurotoxicology** 1996 Spring;17(1):47–61 (90 ref.)

Zinc in pigmented cells and structures, interactions and possible roles. Borovanský J. **Sb Lek** 1994;95(4):309–320 (102 ref.)

PHARMACOKINETICS

Bioavailability of zinc. Sandström B. **Eur J Clin Nutr** 1997 Jan;51 Suppl 1:S17–9 (25 ref.)

Iron, copper, and zinc absorption and turnover; the use of stable isotopes. Aggett PJ. **Eur J Pediatr** 1997 Aug;156 Suppl 1:S29–34 (27 ref.)

PHYSIOLOGY

Calcium- and zinc-binding proteins in intracellular transport. Aballay A, et al. **Biocell** 1996 Dec;20(3):339–42 (28 ref.)

Zinc and growth. Nishi Y. **J Am Coll Nutr** 1996 Aug; 15(4):340–4 (47 ref.)

Function of metal-ion homeostasis in the cell division cycle, mitochondrial protein processing, sensitivity to mycobacterial infection and brain function. Supek F, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):321–30 (73 ref.)

Zinc modulation of immune function: specificity and mechanism of interaction [editorial; comment] Cunningham-Rundles S. **J Lab Clin Med** 1996 Jul; 128(1):9–11 (31 ref.) Comment on: J Lab Clin Med 1996 Jul;128(1):51–60.

The role of zinc in health and disease: relevance to child health in developing countries. Bhutta ZA. **JPMA J Pak Med Assoc** 1997 Feb;47(2):68–73 (139 ref.)

Antiatherogenic properties of zinc: implications in endothelial cell metabolism. Hennig B, et al. **Nutrition** 1996 Oct; 12(10):711–7 (90 ref.)

A reappraisal of the role of zinc in life and death decisions of cells. Fraker PJ, et al. **Proc Soc Exp Biol Med** 1997 Jul;215(3):229–36 (34 ref.)

POISONING

Lead and zinc intoxication in zoological medicine: a review. Mautino M. **J Zoo Wildl Med** 1997 Mar;28(1):28–35 (73 ref.)

THERAPEUTIC USE

Review article: management of patients with non-responsive coeliac disease. O'Mahony S, et al. **Aliment Pharmacol Ther** 1996 Oct;10(5):671–80 (96 ref.)

Zinc deficiency and taste disorders. Heyneman CA. **Ann Pharmacother** 1996 Feb;30(2):186–7 (15 ref.)

URINE

Measurement of zinc in clinical samples. Taylor A. **Ann Clin Biochem** 1997 Mar;34 (Pt 2):142–50 (55 ref.)

ZINC FINGERS

Bcl-6 protein expression in normal and neoplastic lymphoid tissues. Falini B, et al. **Ann Oncol** 1997;8 Suppl 2:101–4 (28 ref.)

Lessons from zinc-binding peptides. Berg JM, et al. **Annu Rev Biophys Biomol Struct** 1997;26:357–71 (48 ref.)

MLL fusion genes in the 11q23 acute leukemias. Downing JR, et al. **Cancer Treat Res** 1996;84:73–92 (81 ref.)

Human genetics: dissecting Williams syndrome. Monaco AP. **Curr Biol** 1996 Nov 1;6(11):1396–8 (14 ref.)

Early steps in mammalian sex determination. Ramkissoon Y, et al. **Curr Opin Genet Dev** 1996 Jun;6(3):316–21 (58 ref.)

The RING finger domain: a recent example of a sequence-structure family. Borden KL, et al. **Curr Opin Struct Biol** 1996 Jun;6(3):395–401 (46 ref.)

Transcription factor IIIA (TFIIIA) in the second decade. Shastry BS. **J Cell Sci** 1996 Mar;109 (Pt 3):535–9 (39 ref.)

Fluorescence studies of zinc finger peptides and proteins. Eis PS. **Methods Enzymol** 1997;278:330–43 (32 ref.)

Detection of nitric oxide interaction with zinc finger proteins. Kröncke KD, et al. **Methods Enzymol** 1996;269:279–84 (26 ref.)

[ZFH/ATBF1 gene family: transcription factors containing both homeo- and zinc finger-domains] Tamaoki T, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(11):1550-9 (35 ref.) **(Jpn)**

GENETICS

Dosage compensation and chromatin structure in Drosophila. Bashaw GJ, et al. **Curr Opin Genet Dev** 1996 Aug; 6(4):496-501 (41 ref.)

Fusion of the EWS1 and WT1 genes as a result of the t(11;22)(p13;q12) translocation in desmoplastic small round cell tumors. Benjamin LE, et al. **Med Pediatr Oncol** 1996 Nov;27(5):434-9 (34 ref.)

Numb diverts notch pathway off the tramtrack. Campos-Ortega JA. **Neuron** 1996 Jul;17(1):1-4 (18 ref.)

PHYSIOLOGY

End of the line? Tramtrack and cell fate determination in Drosophila. Badenhorst P, et al. **Genes Cells** 1996 Aug; 1(8):707-16 (64 ref.)

Zinc finger proteins in early Xenopus development. Hollemann T, et al. **Int J Dev Biol** 1996 Feb;40(1):291-5 (26 ref.)

ZOLLINGER-ELLISON SYNDROME

see related
MULTIPLE ENDOCRINE NEOPLASIA TYPE 1

Zollinger-Ellison syndrome: pathogenesis, diagnosis, and management. Hirschowitz BI. **Am J Gastroenterol** 1997 Apr;92(4 Suppl):44S-48S; discussion 49S-50S (31 ref.)

DIAGNOSIS

[Zollinger-Ellison syndrome] Bulgakov GA. **Khirurgiia (Mosk)** 1997;(6):72-7 (80 ref.) **(Rus)**

DRUG THERAPY

Lansoprazole: a proton pump inhibitor. Garnett WR. **Ann Pharmacother** 1996 Dec;30(12):1425-36 (108 ref.)

HISTORY

Gastrinoma before Zollinger and Ellison. Stabile BE. **Am J Surg** 1997 Sep;174(3):232-6 (21 ref.)

THERAPY

Zollinger-Ellison syndrome. Recognition and management of acid hypersecretion. Maton PN. **Drugs** 1996 Jul; 52(1):33-44 (59 ref.)

Is gastrinoma a medical disease? Mignon M, et al. **Yale J Biol Med** 1996 May-Jun;69(3):289-300 (45 ref.)

ZONA see **HERPES ZOSTER**

ZONA PELLUCIDA

[Physiology of human gamete interaction] Wolf JP, et al. **Contracept Fertil Sex** 1997 Jan;25(1):69-78 (20 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

The role of carbohydrate residues in mammalian fertilization. Shalgi R, et al. **Histol Histopathol** 1997 Jul;12(3):813-22 (105 ref.)

IMMUNOLOGY

Zona pellucida antigens: targets for contraceptive vaccines. Skinner SM, et al. **Am J Reprod Immunol** 1996 Mar; 35(3):163-74 (112 ref.)

Development of contraceptive vaccines for humans using antigens derived from gametes (spermatozoa and zona pellucida) and hormones (human chorionic gonadotrophin): current status. Naz RK, et al. **Hum Reprod Update** 1995 Jan;1(1):1-18 (133 ref.)

METABOLISM

Protein tyrosine phosphorylation and signal transduction during capacitation-acrosome reaction and zona pellucida binding in human sperm. Naz RK. **Arch Androl** 1996 Jul-Aug;37(1):47-55 (48 ref.)

Molecular mechanisms of the interaction between sperm and the zona pellucida in mammals: studies on the pig. Töpfer-Petersen E, et al. **Int J Androl** 1995 Dec;18 Suppl 2:20-6 (56 ref.)

Sperm-associated protein candidates for primary zona pellucida-binding molecules: structure-function correlations of boar spermadhesins. Töpfer-Petersen E, et al. **J Reprod Fertil Suppl** 1996;50:55-61 (44 ref.)

PHYSIOLOGY

The role of carbohydrate residues in mammalian fertilization. Shalgi R, et al. **Histol Histopathol** 1997 Jul;12(3):813-22 (105 ref.)

Molecular genetics of the zona pellucida: implications for immunocontraceptive strategies. Castle PE, et al. **J Reprod Fertil Suppl** 1996;50:1-8 (39 ref.)

Comparative structural and antigenic properties of zona pellucida glycoproteins. Hedrick JL. **J Reprod Fertil Suppl** 1996;50:9-17 (32 ref.)

Structure and function of the N-linked carbohydrate chains of pig zona pellucida glycoproteins. Nakano M, et al. **J Reprod Fertil Suppl** 1996;50:25-34 (40 ref.)

The molecular genetics of the zona pellucida: mouse mutations and infertility. Rankin T, et al. **Mol Hum Reprod** 1996 Nov;2(11):889-94 (56 ref.)

ULTRASTRUCTURE

Constructing the mammalian egg zona pellucida: some new pieces of an old puzzle. Wassarman PM, et al. **J Cell Sci** 1996 Aug;109 (Pt 8):2001-4 (36 ref.)

ZONE THERAPY see **MASSAGE**

ZOOLOGY

see related
ANIMALS

ZOOMASTIGOPHORA

CLASSIFICATION

Zooflagellate phylogeny and classification. Cavalier-Smith T. **Tsitologiia** 1995;37(11):1010-29 (95 ref.)

ZOONOSES

see related
DISEASE RESERVOIRS

Virus zoonoses--a long-term overview. Bennett M, et al. **Comp Immunol Microbiol Infect Dis** 1997 Feb;20(2):101-9 (42 ref.)

Immunology and genetics of zoonotic infections involving parasites. Wakelin D. **Comp Immunol Microbiol Infect Dis** 1996 Sep;19(4):255-65 (41 ref.)

Human babesiosis. Dao AH. **Compr Ther** 1996 Nov; 22(11):713-8 (40 ref.)

Animal-induced injuries and disease, neonatal jaundice, immunizations, and viral infections. Gerson WT. **Curr Opin Pediatr** 1996 Aug;8(4):417-25 (69 ref.)

Poxvirus zoonoses. Baxby D, et al. **J Med Microbiol** 1997 Jan;46(1):17-20, 28-33 (228 ref.)

Hydatid disease. Clarkson MJ. **J Med Microbiol** 1997 Jan; 46(1):24-6, 28-33 (228 ref.)

Hantavirus infections. Hart CA. **J Med Microbiol** 1997 Jan; 46(1):13-7, 28-33 (228 ref.)

Zoonoses. Introduction. Hart CA, et al. **J Med Microbiol** 1997 Jan;46(1):4-6 (228 ref.)

Food- and milk-borne zoonotic infections. Humphrey TJ. **J Med Microbiol** 1997 Jan;46(1):11-3, 28-33 (228 ref.)

Zoonoses: a personal perspective on the Jennerian principle of cross-protective immunity. Nelson GS. **J Med Microbiol** 1997 Jan;46(1):6-11, 28-33 (228 ref.)

Zoonotic protozoa. Trees AJ. **J Med Microbiol** 1997 Jan; 46(1):20-4, 28-33 (228 ref.)

Zoonoses and fertility control in wildlife--requirements for vaccines. Stöhr K, et al. **Reprod Fertil Dev** 1997;9(1):149-55 (59 ref.)

The World Trade Organisation agreement on the application of sanitary and phytosanitary measures. Chillaud T. **Rev Sci Tech** 1996 Jun;15(2):733-51 (6 ref.) **(Eng, Fre)**

Q fever pneumonia. Antony SJ, et al. **Semin Respir Infect** 1997 Mar;12(1):2-6 (22 ref.)

Plague pneumonia disease caused by Yersinia pestis. Cleri DJ, et al. **Semin Respir Infect** 1997 Mar;12(1):12-23 (65 ref.)

Tularemia pneumonia. Gill V, et al. **Semin Respir Infect** 1997 Mar;12(1):61-7 (22 ref.)

Psittacosis. Gregory DW, et al. **Semin Respir Infect** 1997 Mar;12(1):7-11 (10 ref.)

Leptospiral pneumonia. Hill MK, et al. **Semin Respir Infect** 1997 Mar;12(1):44-9 (42 ref.)

Rhodococcus equi pneumonia. Johnson DH, et al. **Semin Respir Infect** 1997 Mar;12(1):57-60 (23 ref.)

Pasteurella multocida pneumonia. Klein NC, et al. **Semin Respir Infect** 1997 Mar;12(1):54-6 (19 ref.)

Hantavirus pulmonary syndrome. Moolenaar RL, et al. **Semin Respir Infect** 1997 Mar;12(1):31-9 (41 ref.)

Cryptococcal pneumonia. Sarosi GA. **Semin Respir Infect** 1997 Mar;12(1):50-3 (26 ref.)

Paratuberculosis: a potential zoonosis? Chiodini RJ, et al. **Vet Clin North Am Food Anim Pract** 1996 Jul;12(2):457-67 (25 ref.)

[Sarcocystosis] Lian Z. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(4):295-9 (34 ref.) **(Chi)**

[Influenza, a special form of zoonosis] Rott R. **Berl Munch Tierarztl Wochenschr** 1997 Jul-Aug; 110(7-8):241-6 (19 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Xenosis and xenotransplantation: addressing the infectious risks posed by an emerging technology. Fishman JA. **Kidney Int Suppl** 1997 Mar;58:S41-5 (45 ref.)

Parasitic zoonoses in wildlife. van Knapen F. **Vet Q** 1996; 18 Suppl 3:S141-2 (0 ref.)

MICROBIOLOGY

The expanding genus of Helicobacter: pathogenic and zoonotic potential. Fox JG. **Semin Gastrointest Dis** 1997 Jul;8(3):124-41 (165 ref.)

PARASITOLOGY

[Animal mite-induced epizoonoses and their significance in dermatology] Beck W. **Hautarzt** 1996 Oct;47(10):744-8 (32 ref.) (Eng. Abstr.) **(Ger)**

TRANSMISSION

Human zoonotic infections transmitted by dogs and cats. Tan JS. **Arch Intern Med** 1997 Sep 22;157(17):1933-43 (62 ref.)

ZOOPHAGINAE see **VIRUSES**

ZOSTER see **HERPES ZOSTER**

ZUCKER RATS see **RATS, ZUCKER**

ZUCLOMIFENE see **CLOMIPHENE**

ZYGOMA

Zygomatic leiomyoma. Case report. Robiony M, et al. **Minerva Stomatol** 1996 Dec;45(12):593-7 (17 ref.)

SURGERY

Use of hydroxyapatite for reconstruction after surgical removal of intraosseous hemangioma in the zygomatic bone. Hirano S, et al. **Plast Reconstr Surg** 1997 Jul; 100(1):86-90 (18 ref.)

ZYGOMATIC ARCH see **ZYGOMA**

ZYGOMYCOSIS see **MUCORMYCOSIS**

ZYGOTE

ENZYMOLOGY


PKC--a pivotal regulator of early development. Gallicano GI, et al. **Bioessays** 1997 Jan;19(1):29-36 (69 ref.)

GROWTH & DEVELOPMENT

[Status of development and areas of employment of in vitro production of cattle embryos] Lucas-Hahn A, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Aug-Sep; 103(8-9):306-11 (26 ref.) (Eng. Abstr.) **(Ger)**

ZYMOGENS see **ENZYME PRECURSORS**




1.0
1.1
1.25
1.4
1.6
2.8
3.2
3.6
4.0
2.5
2.2
2.0
1.8